data_2m4j_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2m4j _Structure_validation_residue.Date_analyzed 2016-10-08 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 22.6 m-85 . . . . . 0 N--CA 1.473 0.705 0 N-CA-C 109.589 -0.523 . . . . 0.0 109.589 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 87.5 mtt180 -68.87 133.01 47.67 Favored 'General case' 0 N--CA 1.473 0.698 0 CA-C-N 116.612 -0.267 . . . . 0.0 111.101 -178.211 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 6.9 t-160 -98.71 127.77 44.75 Favored 'General case' 0 N--CA 1.474 0.732 0 N-CA-C 109.351 -0.611 . . . . 0.0 109.351 179.347 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' ASP . . . . . 0.447 ' O ' ' OG ' ' D' ' 8' ' ' SER . 4.1 m-20 -72.68 139.89 47.54 Favored 'General case' 0 CA--C 1.538 0.487 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.406 178.545 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 28.0 p -163.24 -168.91 1.84 Allowed 'General case' 0 N--CA 1.481 1.102 0 C-N-CA 122.508 0.323 . . . . 0.0 110.694 179.37 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 105.03 44.39 1.51 Allowed Glycine 0 N--CA 1.483 1.798 0 N-CA-C 111.764 -0.534 . . . . 0.0 111.764 -179.475 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 49.0 p90 -64.11 132.79 51.53 Favored 'General case' 0 N--CA 1.472 0.65 0 O-C-N 122.641 -0.329 . . . . 0.0 111.698 -179.899 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 48.7 mt-10 -90.98 152.34 20.72 Favored 'General case' 0 N--CA 1.477 0.907 0 N-CA-C 109.705 -0.48 . . . . 0.0 109.705 178.37 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -152.98 128.07 1.52 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.655 0 N-CA-C 107.805 -1.183 . . . . 0.0 107.805 178.268 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 46.1 m-70 -135.25 147.4 49.26 Favored 'General case' 0 N--CA 1.492 1.672 0 CA-C-N 119.083 0.856 . . . . 0.0 111.388 -178.965 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 6.5 t60 -164.53 97.39 0.78 Allowed 'General case' 0 N--CA 1.481 1.102 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.733 179.191 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 3.9 pt20 -102.15 -174.12 2.5 Favored 'General case' 0 CA--C 1.509 -0.634 0 N-CA-C 108.654 -0.869 . . . . 0.0 108.654 -179.755 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -169.77 95.68 0.29 Allowed 'General case' 0 N--CA 1.47 0.542 0 CA-C-N 114.565 -1.198 . . . . 0.0 108.345 178.351 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 6.3 mp -123.69 157.04 34.79 Favored 'General case' 0 N--CA 1.498 1.94 0 CA-C-O 121.882 0.848 . . . . 0.0 111.122 -178.151 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 60.2 t -111.92 127.11 69.3 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.099 0 CA-C-O 117.886 -1.054 . . . . 0.0 108.266 177.575 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 26.9 m-85 -126.91 123.05 36.33 Favored 'General case' 0 N--CA 1.497 1.903 0 CA-C-N 120.15 1.341 . . . . 0.0 110.418 179.559 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 66.0 m-85 53.45 74.83 0.29 Allowed 'General case' 0 N--CA 1.469 0.496 0 CA-C-O 121.483 0.659 . . . . 0.0 111.78 178.43 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -79.94 -77.77 0.18 Allowed 'General case' 0 C--N 1.352 0.703 0 CA-C-N 115.044 -0.98 . . . . 0.0 110.319 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 40.8 tt0 -113.96 100.79 8.68 Favored 'General case' 0 N--CA 1.47 0.527 0 N-CA-C 108.247 -1.02 . . . . 0.0 108.247 179.614 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 4.4 p30 -158.53 140.26 13.65 Favored 'General case' 0 N--CA 1.485 1.283 0 O-C-N 122.245 -0.284 . . . . 0.0 111.142 179.079 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 60.4 t -59.72 163.58 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.865 0 N-CA-C 108.042 -1.096 . . . . 0.0 108.042 177.108 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.443 ' H ' ' HB ' ' D' ' 24' ' ' VAL . . . -117.87 47.52 1.02 Allowed Glycine 0 N--CA 1.475 1.299 0 N-CA-C 111.776 -0.53 . . . . 0.0 111.776 -179.372 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -61.19 -168.01 0.01 OUTLIER 'General case' 0 N--CA 1.469 0.479 0 O-C-N 123.762 0.331 . . . . 0.0 110.337 179.529 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 26.6 t-20 -70.59 80.7 0.59 Allowed 'General case' 0 N--CA 1.465 0.277 0 CA-C-N 116.401 -0.363 . . . . 0.0 110.17 179.596 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 97.9 mttt -78.03 143.91 37.09 Favored 'General case' 0 N--CA 1.472 0.642 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 179.216 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.81 -167.27 1.07 Allowed Glycine 0 CA--C 1.524 0.625 0 N-CA-C 109.872 -1.291 . . . . 0.0 109.872 178.737 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.83 114.68 28.03 Favored 'General case' 0 N--CA 1.478 0.971 0 N-CA-C 109.67 -0.493 . . . . 0.0 109.67 179.691 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 66.2 mt -98.45 135.83 31.72 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.608 0 N-CA-C 106.883 -1.525 . . . . 0.0 106.883 179.067 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . 0.412 ' C ' ' H ' ' A' ' 34' ' ' LEU . 40.0 pt -152.44 -176.53 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.354 0.763 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.141 -178.765 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.35 4.85 9.61 Favored Glycine 0 CA--C 1.525 0.694 0 N-CA-C 110.861 -0.896 . . . . 0.0 110.861 179.956 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . 0.412 ' H ' ' C ' ' A' ' 32' ' ' ILE . 1.6 tt -75.07 126.58 31.32 Favored 'General case' 0 CA--C 1.544 0.731 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 -179.614 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 28.0 ttt -163.05 150.33 13.05 Favored 'General case' 0 C--O 1.224 -0.253 0 N-CA-C 109.002 -0.74 . . . . 0.0 109.002 178.73 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 27.9 m -155.78 165.58 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.346 0.447 0 N-CA-C 108.193 -1.04 . . . . 0.0 108.193 179.587 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.92 66.9 2.51 Favored Glycine 0 C--N 1.306 -1.105 0 CA-C-N 115.714 -0.675 . . . . 0.0 112.145 178.693 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.78 -173.12 24.77 Favored Glycine 0 N--CA 1.475 1.276 0 N-CA-C 110.817 -0.913 . . . . 0.0 110.817 179.052 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . 0.403 ' H ' HG11 ' D' ' 39' ' ' VAL . 35.3 m -125.55 157.51 34.83 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.819 0 C-N-CA 123.436 0.694 . . . . 0.0 110.419 -179.863 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 26.2 t . . . . . 0 C--O 1.218 -0.568 0 CA-C-O 118.451 -0.785 . . . . 0.0 110.758 179.775 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 24.4 m-85 . . . . . 0 N--CA 1.474 0.737 0 N-CA-C 109.699 -0.482 . . . . 0.0 109.699 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 87.9 mtt180 -69.06 132.16 46.17 Favored 'General case' 0 N--CA 1.474 0.767 0 CA-C-O 120.631 0.253 . . . . 0.0 110.995 -178.225 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 6.8 t-160 -97.95 127.68 44.05 Favored 'General case' 0 N--CA 1.474 0.751 0 N-CA-C 109.298 -0.631 . . . . 0.0 109.298 179.312 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 7' ' ' ASP . . . . . 0.445 ' O ' ' OG ' ' E' ' 8' ' ' SER . 4.1 m-20 -72.93 139.53 46.84 Favored 'General case' 0 CA--C 1.539 0.544 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.446 178.526 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 8' ' ' SER . . . . . . . . . . . . . 29.2 p -162.56 -168.51 1.84 Allowed 'General case' 0 N--CA 1.481 1.076 0 C-N-CA 122.52 0.328 . . . . 0.0 110.705 179.225 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.63 45.06 1.46 Allowed Glycine 0 N--CA 1.483 1.773 0 N-CA-C 111.732 -0.547 . . . . 0.0 111.732 -179.48 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 49.0 p90 -64.79 132.95 50.94 Favored 'General case' 0 N--CA 1.471 0.607 0 O-C-N 122.662 -0.316 . . . . 0.0 111.684 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 48.7 mt-10 -91.07 152.39 20.65 Favored 'General case' 0 N--CA 1.476 0.873 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 178.293 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -153.06 128.32 1.55 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.638 0 N-CA-C 107.734 -1.21 . . . . 0.0 107.734 178.335 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 45.6 m-70 -135.71 147.42 48.47 Favored 'General case' 0 N--CA 1.493 1.698 0 CA-C-N 118.917 0.78 . . . . 0.0 111.33 -178.958 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 6.5 t60 -164.65 97.33 0.76 Allowed 'General case' 0 N--CA 1.481 1.078 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.586 179.302 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . 0.405 HE22 ' CG2' ' B' ' 36' ' ' VAL . 3.9 pt20 -101.87 -173.68 2.41 Favored 'General case' 0 CA--C 1.51 -0.568 0 N-CA-C 108.639 -0.875 . . . . 0.0 108.639 -179.804 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -170.22 95.63 0.25 Allowed 'General case' 0 N--CA 1.471 0.591 0 CA-C-N 114.63 -1.168 . . . . 0.0 108.259 178.415 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 6.3 mp -123.71 157.05 34.79 Favored 'General case' 0 N--CA 1.497 1.896 0 CA-C-O 121.826 0.822 . . . . 0.0 111.123 -178.113 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 61.8 t -112.31 127.29 69.59 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.074 0 N-CA-C 108.016 -1.105 . . . . 0.0 108.016 177.501 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 27.0 m-85 -127.33 122.86 34.91 Favored 'General case' 0 N--CA 1.495 1.797 0 CA-C-N 119.667 1.121 . . . . 0.0 110.314 179.779 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 66.3 m-85 53.1 74.79 0.28 Allowed 'General case' 0 CA--C 1.539 0.547 0 CA-C-O 121.545 0.688 . . . . 0.0 111.859 178.397 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -79.98 -78.01 0.17 Allowed 'General case' 0 C--N 1.351 0.657 0 CA-C-N 115.016 -0.993 . . . . 0.0 110.278 179.966 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 40.5 tt0 -113.66 100.88 8.81 Favored 'General case' 0 N--CA 1.471 0.594 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 179.569 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 4.4 p30 -158.55 140.88 14.16 Favored 'General case' 0 N--CA 1.484 1.272 0 CA-C-O 119.494 -0.289 . . . . 0.0 111.151 179.021 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 59.0 t -60.13 163.81 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.91 0 N-CA-C 108.116 -1.068 . . . . 0.0 108.116 177.199 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 25' ' ' GLY . . . . . 0.449 ' H ' ' HB ' ' E' ' 24' ' ' VAL . . . -117.9 47.53 1.02 Allowed Glycine 0 N--CA 1.475 1.276 0 N-CA-C 111.739 -0.544 . . . . 0.0 111.739 -179.397 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -61.18 -167.74 0.01 OUTLIER 'General case' 0 N--CA 1.47 0.545 0 O-C-N 123.651 0.265 . . . . 0.0 110.379 179.396 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 26.9 t-20 -71.1 80.73 0.69 Allowed 'General case' 0 N--CA 1.466 0.348 0 N-CA-C 110.091 -0.337 . . . . 0.0 110.091 179.673 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -78.01 143.92 37.11 Favored 'General case' 0 N--CA 1.472 0.666 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 179.267 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.71 -166.7 0.94 Allowed Glycine 0 CA--C 1.524 0.628 0 N-CA-C 109.895 -1.282 . . . . 0.0 109.895 178.752 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -100.4 114.55 28.2 Favored 'General case' 0 N--CA 1.478 0.958 0 N-CA-C 109.668 -0.493 . . . . 0.0 109.668 179.628 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 65.5 mt -98.26 135.39 33.14 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.556 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 178.965 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . 0.404 ' C ' ' H ' ' B' ' 34' ' ' LEU . 38.1 pt -151.73 -176.51 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.353 0.733 0 CA-C-N 115.962 -0.563 . . . . 0.0 111.151 -178.789 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.37 4.73 9.45 Favored Glycine 0 CA--C 1.525 0.703 0 N-CA-C 110.947 -0.861 . . . . 0.0 110.947 179.833 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 34' ' ' LEU . . . . . 0.404 ' H ' ' C ' ' B' ' 32' ' ' ILE . 1.6 tt -74.95 126.69 31.53 Favored 'General case' 0 CA--C 1.544 0.744 0 N-CA-C 109.37 -0.604 . . . . 0.0 109.37 -179.617 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 27.4 ttt -163.04 150.17 12.96 Favored 'General case' 0 N--CA 1.467 0.378 0 N-CA-C 108.915 -0.772 . . . . 0.0 108.915 178.672 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 36' ' ' VAL . . . . . 0.405 ' CG2' HE22 ' B' ' 15' ' ' GLN . 27.8 m -155.8 165.26 1.15 Allowed 'Isoleucine or valine' 0 C--N 1.347 0.495 0 N-CA-C 108.155 -1.054 . . . . 0.0 108.155 179.6 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.09 67.16 2.36 Favored Glycine 0 C--N 1.307 -1.059 0 CA-C-N 115.674 -0.694 . . . . 0.0 112.098 178.649 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.54 -172.57 24.83 Favored Glycine 0 N--CA 1.476 1.318 0 N-CA-C 110.806 -0.917 . . . . 0.0 110.806 179.046 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 39' ' ' VAL . . . . . 0.422 ' H ' HG11 ' E' ' 39' ' ' VAL . 35.5 m -126.12 157.42 36.27 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.98 0 C-N-CA 123.448 0.699 . . . . 0.0 110.454 -179.651 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 26.0 t . . . . . 0 C--O 1.219 -0.509 0 CA-C-O 118.429 -0.796 . . . . 0.0 110.602 179.664 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 23.9 m-85 . . . . . 0 N--CA 1.475 0.794 0 N-CA-C 109.683 -0.488 . . . . 0.0 109.683 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 87.4 mtt180 -69.28 131.91 45.62 Favored 'General case' 0 N--CA 1.477 0.904 0 CA-C-O 120.714 0.292 . . . . 0.0 110.955 -178.236 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 6.8 t-160 -97.79 128.16 44.23 Favored 'General case' 0 N--CA 1.473 0.689 0 N-CA-C 109.262 -0.644 . . . . 0.0 109.262 179.215 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 7' ' ' ASP . . . . . 0.443 ' O ' ' OG ' ' F' ' 8' ' ' SER . 4.1 m-20 -73.33 139.77 46.26 Favored 'General case' 0 CA--C 1.538 0.49 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.428 178.583 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' C' C ' 8' ' ' SER . . . . . . . . . . . . . 29.8 p -162.99 -168.71 1.83 Allowed 'General case' 0 N--CA 1.481 1.092 0 CA-C-O 120.828 0.347 . . . . 0.0 110.671 179.249 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.92 44.25 1.54 Allowed Glycine 0 N--CA 1.483 1.798 0 N-CA-C 111.759 -0.537 . . . . 0.0 111.759 -179.498 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 49.3 p90 -64.21 133.29 52.56 Favored 'General case' 0 N--CA 1.472 0.667 0 O-C-N 122.672 -0.311 . . . . 0.0 111.687 -179.935 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 48.3 mt-10 -91.4 152.28 20.47 Favored 'General case' 0 N--CA 1.476 0.858 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 178.356 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -152.83 128.15 1.59 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.598 0 N-CA-C 107.814 -1.18 . . . . 0.0 107.814 178.327 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 45.4 m-70 -135.43 147.69 49.05 Favored 'General case' 0 N--CA 1.493 1.695 0 CA-C-N 118.948 0.794 . . . . 0.0 111.306 -178.969 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 6.5 t60 -164.85 97.31 0.74 Allowed 'General case' 0 N--CA 1.481 1.101 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.646 179.293 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 3.9 pt20 -102.05 -173.85 2.44 Favored 'General case' 0 CA--C 1.508 -0.645 0 N-CA-C 108.606 -0.887 . . . . 0.0 108.606 -179.735 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -170.06 95.81 0.27 Allowed 'General case' 0 N--CA 1.468 0.47 0 CA-C-N 114.623 -1.171 . . . . 0.0 108.292 178.298 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 6.4 mp -123.73 157.17 34.58 Favored 'General case' 0 N--CA 1.497 1.899 0 CA-C-O 121.808 0.813 . . . . 0.0 111.189 -178.194 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 61.7 t -112.32 127.63 69.41 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.057 0 N-CA-C 108.111 -1.07 . . . . 0.0 108.111 177.516 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 27.4 m-85 -127.58 122.77 34.09 Favored 'General case' 0 N--CA 1.493 1.723 0 CA-C-N 119.688 1.131 . . . . 0.0 110.305 179.861 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 66.6 m-85 53.28 74.77 0.28 Allowed 'General case' 0 CA--C 1.538 0.492 0 CA-C-O 121.488 0.661 . . . . 0.0 111.851 178.304 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -79.96 -78.23 0.17 Allowed 'General case' 0 C--N 1.35 0.621 0 CA-C-N 115.008 -0.996 . . . . 0.0 110.291 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 40.1 tt0 -113.58 100.66 8.67 Favored 'General case' 0 N--CA 1.471 0.591 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 179.629 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 4.4 p30 -158.29 140.41 14.09 Favored 'General case' 0 N--CA 1.484 1.229 0 O-C-N 122.264 -0.272 . . . . 0.0 111.117 179.183 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 59.4 t -59.88 163.51 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.868 0 N-CA-C 108.072 -1.084 . . . . 0.0 108.072 177.096 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 25' ' ' GLY . . . . . 0.426 ' H ' ' HB ' ' F' ' 24' ' ' VAL . . . -117.79 47.94 0.99 Allowed Glycine 0 N--CA 1.478 1.492 0 N-CA-C 111.597 -0.601 . . . . 0.0 111.597 -179.314 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -61.59 -168.18 0.01 OUTLIER 'General case' 0 N--CA 1.469 0.487 0 N-CA-C 110.268 -0.271 . . . . 0.0 110.268 179.447 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 26.7 t-20 -70.51 80.99 0.57 Allowed 'General case' 0 N--CA 1.466 0.332 0 N-CA-C 110.026 -0.361 . . . . 0.0 110.026 179.595 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -78.3 143.76 36.7 Favored 'General case' 0 N--CA 1.472 0.66 0 N-CA-C 109.089 -0.708 . . . . 0.0 109.089 179.312 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.45 -167.34 0.95 Allowed Glycine 0 CA--C 1.525 0.672 0 N-CA-C 109.937 -1.265 . . . . 0.0 109.937 178.689 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.86 113.97 26.86 Favored 'General case' 0 N--CA 1.48 1.028 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 179.657 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 66.0 mt -97.88 135.57 31.92 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.557 0 N-CA-C 106.942 -1.503 . . . . 0.0 106.942 178.992 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 32' ' ' ILE . . . . . 0.414 ' C ' ' H ' ' C' ' 34' ' ' LEU . 38.8 pt -152.01 -176.42 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.354 0.768 0 CA-C-N 115.902 -0.59 . . . . 0.0 111.122 -178.791 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.45 4.52 9.36 Favored Glycine 0 CA--C 1.525 0.717 0 N-CA-C 110.907 -0.877 . . . . 0.0 110.907 179.882 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 34' ' ' LEU . . . . . 0.414 ' H ' ' C ' ' C' ' 32' ' ' ILE . 1.6 tt -74.75 126.34 30.68 Favored 'General case' 0 CA--C 1.543 0.692 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 -179.619 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 27.5 ttt -162.57 150.36 13.97 Favored 'General case' 0 N--CA 1.466 0.349 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 178.763 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 27.6 m -156.09 165.22 1.12 Allowed 'Isoleucine or valine' 0 C--N 1.347 0.48 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 179.543 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.14 66.74 2.63 Favored Glycine 0 C--N 1.306 -1.106 0 CA-C-N 115.721 -0.672 . . . . 0.0 112.072 178.548 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.84 -172.47 25.06 Favored Glycine 0 N--CA 1.476 1.308 0 N-CA-C 110.813 -0.915 . . . . 0.0 110.813 178.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 39' ' ' VAL . . . . . 0.411 ' H ' HG11 ' F' ' 39' ' ' VAL . 35.6 m -126.21 157.66 36.36 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.892 0 C-N-CA 123.429 0.692 . . . . 0.0 110.421 -179.667 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 27.2 t . . . . . 0 C--O 1.219 -0.512 0 CA-C-O 118.43 -0.795 . . . . 0.0 110.526 179.722 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 26.7 m-85 . . . . . 0 N--CA 1.485 1.276 0 N-CA-C 108.304 -0.998 . . . . 0.0 108.304 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' D' D ' 5' ' ' ARG . . . . . . . . . . . . 0.314 94.1 mtt180 -77.63 134.01 38.29 Favored 'General case' 0 N--CA 1.483 1.179 0 CA-C-O 123.01 1.386 . . . . 0.0 107.946 -169.394 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 6.2 t-160 -95.14 130.81 41.71 Favored 'General case' 0 C--N 1.364 1.231 0 CA-C-N 113.53 -1.668 . . . . 0.0 108.662 -177.259 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 7' ' ' ASP . . . . . 0.502 ' O ' ' OG ' ' G' ' 8' ' ' SER . 2.8 m-20 -66.29 125.44 25.59 Favored 'General case' 0 C--N 1.309 -1.161 0 C-N-CA 126.841 2.056 . . . . 0.0 114.989 173.304 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' D' D ' 8' ' ' SER . . . . . 0.447 ' OG ' ' O ' ' A' ' 7' ' ' ASP . 27.6 p -153.35 -167.15 2.62 Favored 'General case' 0 N--CA 1.488 1.458 0 CA-C-N 120.187 1.358 . . . . 0.0 110.962 176.868 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.78 47.15 1.2 Allowed Glycine 0 N--CA 1.484 1.897 0 C-N-CA 124.797 1.189 . . . . 0.0 110.741 176.961 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 51.0 p90 -60.79 131.66 51.41 Favored 'General case' 0 N--CA 1.47 0.553 0 N-CA-C 112.838 0.681 . . . . 0.0 112.838 177.657 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 48.5 mt-10 -88.6 150.95 22.78 Favored 'General case' 0 N--CA 1.48 1.067 0 CA-C-N 117.862 0.301 . . . . 0.0 110.591 175.553 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -149.5 129.9 4.3 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.609 0 N-CA-C 107.377 -1.342 . . . . 0.0 107.377 173.464 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 42.4 m-70 -129.96 150.69 51.13 Favored 'General case' 0 N--CA 1.483 1.176 0 N-CA-C 112.05 0.389 . . . . 0.0 112.05 176.757 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 6.6 t60 -165.04 104.37 0.77 Allowed 'General case' 0 N--CA 1.483 1.194 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 172.32 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 3.9 pt20 -105.48 -176.17 3.0 Favored 'General case' 0 CA--C 1.501 -0.908 0 N-CA-C 108.491 -0.929 . . . . 0.0 108.491 179.243 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -166.03 104.59 0.67 Allowed 'General case' 0 N--CA 1.466 0.327 0 N-CA-C 106.064 -1.828 . . . . 0.0 106.064 174.26 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 5.4 mp -130.87 153.86 48.68 Favored 'General case' 0 N--CA 1.499 1.988 0 CA-C-O 122.188 0.994 . . . . 0.0 110.604 179.563 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 35.8 t -101.29 131.79 48.35 Favored 'Isoleucine or valine' 0 C--O 1.259 1.57 0 CA-C-O 116.884 -1.531 . . . . 0.0 109.563 174.11 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 25.0 m-85 -130.45 126.3 36.62 Favored 'General case' 0 N--CA 1.49 1.544 0 CA-C-N 120.063 1.302 . . . . 0.0 109.591 173.9 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 66.3 m-85 55.65 71.69 0.53 Allowed 'General case' 0 C--N 1.348 0.535 0 CA-C-N 115.618 -0.719 . . . . 0.0 111.521 175.989 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -81.92 -73.03 0.41 Allowed 'General case' 0 C--N 1.35 0.607 0 CA-C-O 118.478 -0.772 . . . . 0.0 110.988 -177.647 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 40.9 tt0 -117.0 104.62 11.45 Favored 'General case' 0 N--CA 1.482 1.14 0 N-CA-C 106.404 -1.702 . . . . 0.0 106.404 176.32 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -152.06 140.43 20.51 Favored 'General case' 0 N--CA 1.476 0.865 0 CA-C-O 116.797 -1.573 . . . . 0.0 113.494 177.995 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 24' ' ' VAL . . . . . 0.443 ' HB ' ' H ' ' A' ' 25' ' ' GLY . 79.3 t -62.53 165.93 1.01 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.282 0 CA-C-N 121.063 1.756 . . . . 0.0 108.013 175.027 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' D' D ' 25' ' ' GLY . . . . . 0.465 ' H ' ' HB ' ' G' ' 24' ' ' VAL . . . -116.92 51.15 0.74 Allowed Glycine 0 N--CA 1.479 1.508 0 CA-C-O 119.003 -0.887 . . . . 0.0 111.78 178.196 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -57.72 -170.71 0.01 OUTLIER 'General case' 0 C--N 1.32 -0.689 0 C-N-CA 123.563 0.745 . . . . 0.0 111.643 176.042 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 28.2 t-20 -72.73 86.62 1.24 Allowed 'General case' 0 C--N 1.346 0.435 0 N-CA-C 108.421 -0.955 . . . . 0.0 108.421 177.952 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 97.4 mttt -83.27 146.21 28.67 Favored 'General case' 0 C--N 1.352 0.708 0 N-CA-C 108.063 -1.088 . . . . 0.0 108.063 179.138 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -62.8 -164.98 0.5 Allowed Glycine 0 C--N 1.337 0.592 0 N-CA-C 110.626 -0.99 . . . . 0.0 110.626 179.1 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -102.38 116.13 32.0 Favored 'General case' 0 N--CA 1.47 0.533 0 N-CA-C 109.155 -0.683 . . . . 0.0 109.155 179.394 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 73.9 mt -102.68 142.59 16.5 Favored 'Isoleucine or valine' 0 C--N 1.356 0.867 0 N-CA-C 104.505 -2.406 . . . . 0.0 104.505 -179.917 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 39.4 pt -158.25 -177.39 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.126 0 CA-C-O 120.939 0.4 . . . . 0.0 110.186 -177.075 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 64.32 4.64 13.06 Favored Glycine 0 C--O 1.241 0.562 0 N-CA-C 110.132 -1.187 . . . . 0.0 110.132 -178.828 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 2.1 tt -77.52 133.39 38.55 Favored 'General case' 0 C--N 1.369 1.438 0 C-N-CA 117.944 -1.502 . . . . 0.0 107.155 -177.801 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 27.9 ttt -158.3 161.48 37.67 Favored 'General case' 0 CA--C 1.509 -0.62 0 CA-C-O 118.213 -0.899 . . . . 0.0 108.858 173.574 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 27.7 m -164.63 164.36 0.66 Allowed 'Isoleucine or valine' 0 CA--C 1.517 -0.319 0 N-CA-C 108.064 -1.088 . . . . 0.0 108.064 175.62 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 60.18 64.05 4.5 Favored Glycine 0 C--N 1.313 -0.706 0 C-N-CA 119.759 -1.21 . . . . 0.0 112.883 178.318 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 140.68 -171.27 24.12 Favored Glycine 0 N--CA 1.48 1.581 0 CA-C-N 117.319 0.559 . . . . 0.0 111.769 -179.221 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 39' ' ' VAL . . . . . 0.413 ' H ' HG11 ' G' ' 39' ' ' VAL . 34.9 m -128.37 154.81 39.6 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.851 0 C-N-CA 122.716 0.406 . . . . 0.0 110.146 -176.877 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 25.3 t . . . . . 0 C--N 1.332 -0.16 0 CA-C-O 116.657 -1.64 . . . . 0.0 110.051 178.19 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 24.0 m-85 . . . . . 0 N--CA 1.475 0.794 0 N-CA-C 109.962 -0.384 . . . . 0.0 109.962 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' E' E ' 5' ' ' ARG . . . . . . . . . . . . . 86.2 mtt180 -68.94 131.89 45.82 Favored 'General case' 0 N--CA 1.475 0.804 0 CA-C-N 116.423 -0.353 . . . . 0.0 111.153 -178.36 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 6.5 t-160 -97.66 129.03 44.77 Favored 'General case' 0 N--CA 1.475 0.789 0 N-CA-C 109.194 -0.669 . . . . 0.0 109.194 179.08 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' E' E ' 7' ' ' ASP . . . . . 0.44 ' O ' ' OG ' ' H' ' 8' ' ' SER . 4.2 m-20 -74.42 139.91 44.33 Favored 'General case' 0 N--CA 1.468 0.445 0 CA-C-N 116.513 -0.312 . . . . 0.0 110.531 178.725 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' E' E ' 8' ' ' SER . . . . . 0.445 ' OG ' ' O ' ' B' ' 7' ' ' ASP . 24.8 p -163.68 -168.25 1.6 Allowed 'General case' 0 N--CA 1.485 1.301 0 CA-C-O 120.888 0.375 . . . . 0.0 110.886 178.922 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 105.57 44.84 1.39 Allowed Glycine 0 N--CA 1.482 1.732 0 N-CA-C 111.485 -0.646 . . . . 0.0 111.485 -179.682 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 47.0 p90 -63.84 133.45 53.4 Favored 'General case' 0 N--CA 1.475 0.783 0 N-CA-C 112.02 0.378 . . . . 0.0 112.02 -179.806 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 47.2 mt-10 -90.73 152.39 20.84 Favored 'General case' 0 N--CA 1.48 1.036 0 CA-C-O 121.111 0.481 . . . . 0.0 109.747 177.777 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -154.09 127.44 1.19 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.574 0 N-CA-C 107.795 -1.187 . . . . 0.0 107.795 178.003 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 45.0 m-70 -135.74 146.38 47.61 Favored 'General case' 0 N--CA 1.483 1.215 0 CA-C-O 120.869 0.366 . . . . 0.0 111.542 -178.025 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 6.5 t60 -164.32 97.15 0.79 Allowed 'General case' 0 N--CA 1.486 1.344 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.592 179.459 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' E' E ' 15' ' ' GLN . . . . . 0.421 HE22 ' CG2' ' E' ' 36' ' ' VAL . 3.9 pt20 -101.4 -173.83 2.46 Favored 'General case' 0 CA--C 1.51 -0.588 0 N-CA-C 108.924 -0.769 . . . . 0.0 108.924 -179.728 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -169.77 94.67 0.27 Allowed 'General case' 0 N--CA 1.472 0.647 0 CA-C-N 114.774 -1.103 . . . . 0.0 108.464 178.347 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 6.2 mp -122.4 156.72 33.41 Favored 'General case' 0 N--CA 1.495 1.787 0 CA-C-O 121.698 0.761 . . . . 0.0 111.641 -177.546 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 48.3 t -113.88 124.36 70.46 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.232 0 N-CA-C 108.212 -1.033 . . . . 0.0 108.212 177.245 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 29.8 m-85 -124.83 121.97 36.07 Favored 'General case' 0 N--CA 1.489 1.524 0 CA-C-O 120.907 0.384 . . . . 0.0 110.974 -179.563 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 67.2 m-85 54.47 73.57 0.39 Allowed 'General case' 0 N--CA 1.469 0.476 0 CA-C-N 115.892 -0.594 . . . . 0.0 111.53 177.931 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -78.27 -78.46 0.14 Allowed 'General case' 0 CA--C 1.535 0.377 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.258 -179.711 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 40.9 tt0 -113.02 101.56 9.58 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 108.319 -0.993 . . . . 0.0 108.319 179.683 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -158.15 140.58 14.41 Favored 'General case' 0 C--O 1.205 -1.285 0 CA-C-O 119.488 -0.292 . . . . 0.0 111.481 179.17 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' E' E ' 24' ' ' VAL . . . . . 0.449 ' HB ' ' H ' ' B' ' 25' ' ' GLY . 63.3 t -58.7 168.46 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.973 0 N-CA-C 107.629 -1.248 . . . . 0.0 107.629 177.034 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' E' E ' 25' ' ' GLY . . . . . 0.406 ' H ' ' HB ' ' H' ' 24' ' ' VAL . . . -122.57 47.68 1.0 Allowed Glycine 0 N--CA 1.475 1.264 0 N-CA-C 110.931 -0.867 . . . . 0.0 110.931 -179.347 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -61.81 -167.48 0.01 OUTLIER 'General case' 0 N--CA 1.47 0.548 0 CA-C-O 120.704 0.288 . . . . 0.0 110.469 179.808 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 27.2 t-20 -70.68 77.85 0.6 Allowed 'General case' 0 N--CA 1.467 0.377 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.393 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -75.48 144.56 42.0 Favored 'General case' 0 N--CA 1.475 0.817 0 N-CA-C 109.567 -0.531 . . . . 0.0 109.567 179.331 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.46 -166.4 1.14 Allowed Glycine 0 CA--C 1.522 0.474 0 N-CA-C 110.421 -1.072 . . . . 0.0 110.421 178.629 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -100.08 113.36 25.92 Favored 'General case' 0 N--CA 1.468 0.443 0 N-CA-C 109.961 -0.385 . . . . 0.0 109.961 179.659 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 66.3 mt -97.36 135.28 32.2 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.443 0 N-CA-C 106.752 -1.573 . . . . 0.0 106.752 179.146 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' E' E ' 32' ' ' ILE . . . . . 0.402 ' C ' ' H ' ' E' ' 34' ' ' LEU . 39.2 pt -151.74 -174.73 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.123 0 CA-C-O 121.165 0.507 . . . . 0.0 110.682 -179.072 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.5 5.66 6.97 Favored Glycine 0 CA--C 1.53 1.03 0 CA-C-N 115.504 -0.771 . . . . 0.0 111.34 -179.674 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' E' E ' 34' ' ' LEU . . . . . 0.402 ' H ' ' C ' ' E' ' 32' ' ' ILE . 1.7 tt -74.86 126.62 31.34 Favored 'General case' 0 CA--C 1.545 0.787 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 -179.613 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 28.2 ttt -162.14 151.11 15.41 Favored 'General case' 0 C--O 1.203 -1.348 0 N-CA-C 108.972 -0.751 . . . . 0.0 108.972 178.776 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' E' E ' 36' ' ' VAL . . . . . 0.421 ' CG2' HE22 ' E' ' 15' ' ' GLN . 32.9 m -157.04 165.22 1.01 Allowed 'Isoleucine or valine' 0 C--N 1.343 0.287 0 N-CA-C 108.434 -0.95 . . . . 0.0 108.434 179.596 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.61 67.08 2.39 Favored Glycine 0 C--N 1.306 -1.096 0 CA-C-N 115.762 -0.654 . . . . 0.0 111.95 178.774 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.88 -172.48 25.08 Favored Glycine 0 N--CA 1.476 1.362 0 N-CA-C 111.16 -0.776 . . . . 0.0 111.16 179.034 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' E' E ' 39' ' ' VAL . . . . . 0.438 ' H ' HG11 ' H' ' 39' ' ' VAL . 33.4 m -126.29 156.78 36.86 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.703 0 C-N-CA 123.452 0.701 . . . . 0.0 110.682 -179.402 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 26.1 t . . . . . 0 C--O 1.218 -0.56 0 CA-C-O 118.451 -0.785 . . . . 0.0 110.701 179.525 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 24.0 m-85 . . . . . 0 N--CA 1.474 0.754 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' F' F ' 5' ' ' ARG . . . . . . . . . . . . . 87.2 mtt180 -69.0 132.66 47.02 Favored 'General case' 0 C--O 1.217 -0.634 0 CA-C-N 116.419 -0.355 . . . . 0.0 111.289 -178.244 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 6.6 t-160 -98.31 128.69 44.86 Favored 'General case' 0 N--CA 1.477 0.889 0 N-CA-C 109.323 -0.621 . . . . 0.0 109.323 179.31 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' F' F ' 7' ' ' ASP . . . . . 0.43 ' O ' ' OG ' ' I' ' 8' ' ' SER . 4.3 m-20 -74.1 139.54 44.66 Favored 'General case' 0 N--CA 1.467 0.42 0 CA-C-N 116.542 -0.299 . . . . 0.0 110.662 178.678 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' F' F ' 8' ' ' SER . . . . . 0.443 ' OG ' ' O ' ' C' ' 7' ' ' ASP . 24.7 p -163.6 -168.33 1.63 Allowed 'General case' 0 N--CA 1.486 1.327 0 CA-C-O 120.963 0.411 . . . . 0.0 110.945 178.905 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 105.7 44.84 1.37 Allowed Glycine 0 N--CA 1.482 1.745 0 N-CA-C 111.459 -0.656 . . . . 0.0 111.459 -179.729 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 46.2 p90 -63.67 133.72 54.13 Favored 'General case' 0 CA--C 1.543 0.707 0 N-CA-C 112.094 0.405 . . . . 0.0 112.094 -179.639 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 47.2 mt-10 -90.89 152.24 20.82 Favored 'General case' 0 N--CA 1.481 1.085 0 CA-C-O 121.172 0.51 . . . . 0.0 109.74 177.794 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -153.92 127.19 1.18 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.601 0 N-CA-C 107.776 -1.194 . . . . 0.0 107.776 178.034 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 44.3 m-70 -135.53 145.93 47.54 Favored 'General case' 0 N--CA 1.484 1.232 0 CA-C-O 120.796 0.331 . . . . 0.0 111.635 -177.959 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 6.6 t60 -163.94 97.26 0.83 Allowed 'General case' 0 N--CA 1.486 1.335 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.697 179.442 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' F' F ' 15' ' ' GLN . . . . . 0.415 HE22 ' CG2' ' F' ' 36' ' ' VAL . 3.9 pt20 -101.68 -173.96 2.48 Favored 'General case' 0 CA--C 1.507 -0.698 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 -179.711 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -169.5 94.71 0.29 Allowed 'General case' 0 N--CA 1.471 0.597 0 CA-C-N 114.633 -1.167 . . . . 0.0 108.424 178.357 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 6.3 mp -122.16 156.84 32.83 Favored 'General case' 0 N--CA 1.495 1.817 0 CA-C-O 121.628 0.728 . . . . 0.0 111.623 -177.687 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 48.6 t -113.94 124.35 70.51 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.181 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 177.185 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 29.8 m-85 -124.72 121.69 35.37 Favored 'General case' 0 N--CA 1.489 1.49 0 CA-C-O 120.888 0.375 . . . . 0.0 110.984 -179.57 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 67.3 m-85 54.41 74.08 0.36 Allowed 'General case' 0 C--N 1.344 0.353 0 CA-C-N 115.917 -0.583 . . . . 0.0 111.68 178.032 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -78.4 -78.42 0.14 Allowed 'General case' 0 CA--C 1.535 0.375 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.282 -179.707 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 40.8 tt0 -113.19 101.39 9.38 Favored 'General case' 0 C--N 1.325 -0.477 0 N-CA-C 108.312 -0.996 . . . . 0.0 108.312 179.777 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -158.08 140.52 14.45 Favored 'General case' 0 C--O 1.204 -1.308 0 CA-C-O 119.537 -0.268 . . . . 0.0 111.419 179.045 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' F' F ' 24' ' ' VAL . . . . . 0.426 ' HB ' ' H ' ' C' ' 25' ' ' GLY . 60.6 t -58.61 168.61 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.962 0 N-CA-C 107.644 -1.243 . . . . 0.0 107.644 177.047 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' F' F ' 25' ' ' GLY . . . . . 0.409 ' H ' ' HB ' ' I' ' 24' ' ' VAL . . . -122.71 48.07 0.98 Allowed Glycine 0 N--CA 1.477 1.381 0 N-CA-C 110.822 -0.911 . . . . 0.0 110.822 -179.398 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -62.24 -167.63 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.559 0 CA-C-O 120.75 0.309 . . . . 0.0 110.417 179.807 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 27.2 t-20 -70.16 77.54 0.51 Allowed 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.432 -179.936 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -75.49 144.18 42.17 Favored 'General case' 0 N--CA 1.475 0.814 0 N-CA-C 109.551 -0.537 . . . . 0.0 109.551 179.489 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.14 -166.58 1.07 Allowed Glycine 0 CA--C 1.522 0.512 0 N-CA-C 110.55 -1.02 . . . . 0.0 110.55 178.596 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.72 113.69 26.33 Favored 'General case' 0 N--CA 1.471 0.589 0 N-CA-C 109.879 -0.415 . . . . 0.0 109.879 179.649 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 66.2 mt -97.85 135.22 33.15 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.43 0 N-CA-C 106.796 -1.557 . . . . 0.0 106.796 179.058 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' F' F ' 32' ' ' ILE . . . . . 0.409 ' C ' ' H ' ' F' ' 34' ' ' LEU . 39.7 pt -151.65 -174.43 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.136 0 CA-C-O 121.208 0.527 . . . . 0.0 110.64 -179.049 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.11 6.0 6.59 Favored Glycine 0 CA--C 1.53 0.97 0 CA-C-N 115.426 -0.806 . . . . 0.0 111.345 -179.778 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' F' F ' 34' ' ' LEU . . . . . 0.409 ' H ' ' C ' ' F' ' 32' ' ' ILE . 1.7 tt -75.43 127.28 32.76 Favored 'General case' 0 N--CA 1.475 0.783 0 N-CA-C 109.31 -0.626 . . . . 0.0 109.31 -179.5 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 28.2 ttt -163.18 152.02 14.45 Favored 'General case' 0 C--O 1.204 -1.306 0 N-CA-C 109.203 -0.665 . . . . 0.0 109.203 178.437 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' F' F ' 36' ' ' VAL . . . . . 0.415 ' CG2' HE22 ' F' ' 15' ' ' GLN . 32.6 m -157.21 165.69 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.342 0.26 0 N-CA-C 108.408 -0.96 . . . . 0.0 108.408 179.897 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.34 67.41 2.22 Favored Glycine 0 C--N 1.307 -1.081 0 CA-C-N 115.717 -0.674 . . . . 0.0 111.979 178.56 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.33 -172.33 24.78 Favored Glycine 0 N--CA 1.477 1.378 0 N-CA-C 111.084 -0.807 . . . . 0.0 111.084 178.992 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' F' F ' 39' ' ' VAL . . . . . 0.437 ' H ' HG11 ' I' ' 39' ' ' VAL . 33.3 m -126.39 157.01 37.17 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.685 0 C-N-CA 123.425 0.69 . . . . 0.0 110.688 -179.285 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 26.0 t . . . . . 0 C--O 1.22 -0.496 0 O-C-N 124.017 0.823 . . . . 0.0 110.599 179.358 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 29.4 m-85 . . . . . 0 N--CA 1.476 0.851 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' G' G ' 5' ' ' ARG . . . . . . . . . . . . . 86.5 mtt180 -67.53 132.18 47.07 Favored 'General case' 0 N--CA 1.473 0.723 0 CA-C-N 116.33 -0.396 . . . . 0.0 110.846 -178.615 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 6.4 t-160 -98.27 129.92 44.98 Favored 'General case' 0 N--CA 1.474 0.761 0 N-CA-C 109.415 -0.587 . . . . 0.0 109.415 179.108 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -75.92 135.73 40.09 Favored 'General case' 0 N--CA 1.47 0.554 0 C-N-CA 122.714 0.406 . . . . 0.0 111.097 179.006 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' G' G ' 8' ' ' SER . . . . . 0.502 ' OG ' ' O ' ' D' ' 7' ' ' ASP . 24.7 p -160.11 -166.23 1.65 Allowed 'General case' 0 N--CA 1.477 0.903 0 CA-C-O 120.971 0.415 . . . . 0.0 110.512 178.73 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.42 45.51 1.43 Allowed Glycine 0 N--CA 1.481 1.684 0 N-CA-C 111.211 -0.756 . . . . 0.0 111.211 179.866 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 48.9 p90 -64.59 133.43 52.28 Favored 'General case' 0 CA--C 1.542 0.641 0 N-CA-C 111.91 0.337 . . . . 0.0 111.91 -179.562 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 49.4 mt-10 -90.97 151.76 20.96 Favored 'General case' 0 N--CA 1.479 1.018 0 CA-C-O 121.006 0.432 . . . . 0.0 110.036 178.41 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -154.82 127.53 1.08 Allowed 'Isoleucine or valine' 0 CA--C 1.553 1.088 0 N-CA-C 107.845 -1.169 . . . . 0.0 107.845 178.359 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 46.0 m-70 -135.23 147.11 49.21 Favored 'General case' 0 N--CA 1.478 0.934 0 CA-C-N 115.433 -0.803 . . . . 0.0 111.471 -178.135 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 6.6 t60 -165.22 97.63 0.71 Allowed 'General case' 0 N--CA 1.483 1.22 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.214 178.82 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 3.9 pt20 -102.06 -173.81 2.43 Favored 'General case' 0 CA--C 1.507 -0.678 0 N-CA-C 108.688 -0.856 . . . . 0.0 108.688 -179.595 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -170.32 94.37 0.23 Allowed 'General case' 0 N--CA 1.471 0.624 0 CA-C-N 114.663 -1.153 . . . . 0.0 108.224 178.54 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 6.3 mp -121.86 155.94 34.32 Favored 'General case' 0 N--CA 1.498 1.935 0 CA-C-O 121.298 0.571 . . . . 0.0 111.881 -177.812 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 43.2 t -113.63 124.53 70.36 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.013 0 CA-C-N 114.746 -1.115 . . . . 0.0 108.156 176.617 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 31.5 m-85 -125.13 121.76 35.16 Favored 'General case' 0 C--N 1.366 1.314 0 C-N-CA 123.358 0.663 . . . . 0.0 111.01 -179.324 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 66.7 m-85 54.4 73.43 0.4 Allowed 'General case' 0 N--CA 1.467 0.407 0 CA-C-N 115.865 -0.607 . . . . 0.0 111.532 177.898 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.49 -77.86 0.14 Allowed 'General case' 0 N--CA 1.473 0.682 0 O-C-N 122.296 -0.252 . . . . 0.0 110.451 -179.426 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 40.9 tt0 -113.59 101.61 9.49 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 108.048 -1.093 . . . . 0.0 108.048 179.806 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -158.25 141.65 15.18 Favored 'General case' 0 N--CA 1.478 0.964 0 O-C-N 122.368 -0.207 . . . . 0.0 111.438 179.067 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' G' G ' 24' ' ' VAL . . . . . 0.465 ' HB ' ' H ' ' D' ' 25' ' ' GLY . 58.8 t -60.23 167.12 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.637 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 177.338 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -120.71 48.51 0.94 Allowed Glycine 0 N--CA 1.481 1.662 0 N-CA-C 110.548 -1.021 . . . . 0.0 110.548 -179.499 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -62.93 -167.73 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.648 0 CA-C-N 117.03 0.415 . . . . 0.0 109.943 179.825 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 27.6 t-20 -70.28 77.2 0.54 Allowed 'General case' 0 CA--C 1.536 0.413 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.456 -179.979 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 97.9 mttt -74.29 144.23 44.66 Favored 'General case' 0 N--CA 1.475 0.807 0 N-CA-C 109.642 -0.503 . . . . 0.0 109.642 179.292 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.56 -164.98 0.92 Allowed Glycine 0 C--N 1.337 0.609 0 N-CA-C 110.061 -1.216 . . . . 0.0 110.061 178.623 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -100.03 113.48 26.11 Favored 'General case' 0 N--CA 1.469 0.52 0 C-N-CA 122.737 0.415 . . . . 0.0 110.577 179.865 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 67.6 mt -98.33 135.51 32.81 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.838 0 N-CA-C 106.827 -1.546 . . . . 0.0 106.827 179.062 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' G' G ' 32' ' ' ILE . . . . . 0.413 ' C ' ' H ' ' G' ' 34' ' ' LEU . 39.6 pt -152.27 -174.32 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.725 0 CA-C-N 119.784 1.174 . . . . 0.0 109.897 -179.473 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.06 5.63 8.14 Favored Glycine 0 CA--C 1.527 0.789 0 N-CA-C 111.03 -0.828 . . . . 0.0 111.03 -179.928 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' G' G ' 34' ' ' LEU . . . . . 0.413 ' H ' ' C ' ' G' ' 32' ' ' ILE . 1.6 tt -75.71 125.46 29.09 Favored 'General case' 0 CA--C 1.544 0.733 0 N-CA-C 109.561 -0.533 . . . . 0.0 109.561 -179.574 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 28.1 ttt -161.04 152.91 19.67 Favored 'General case' 0 C--O 1.206 -1.194 0 N-CA-C 108.861 -0.792 . . . . 0.0 108.861 178.712 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 30.4 m -157.8 164.28 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.343 0.293 0 N-CA-C 108.471 -0.937 . . . . 0.0 108.471 -179.836 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.42 67.63 2.11 Favored Glycine 0 C--N 1.309 -0.955 0 CA-C-N 115.602 -0.726 . . . . 0.0 112.207 178.457 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.89 -171.64 25.39 Favored Glycine 0 N--CA 1.478 1.438 0 N-CA-C 110.6 -1.0 . . . . 0.0 110.6 178.981 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' G' G ' 39' ' ' VAL . . . . . 0.413 HG11 ' H ' ' D' ' 39' ' ' VAL . 33.9 m -127.04 157.22 38.59 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.763 0 C-N-CA 123.138 0.575 . . . . 0.0 110.807 -179.43 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 28.0 t . . . . . 0 C--O 1.219 -0.51 0 O-C-N 123.976 0.797 . . . . 0.0 110.85 179.364 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 29.7 m-85 . . . . . 0 N--CA 1.476 0.833 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' H' H ' 5' ' ' ARG . . . . . . . . . . . . . 86.4 mtt180 -67.7 131.72 46.11 Favored 'General case' 0 N--CA 1.475 0.782 0 CA-C-N 116.421 -0.354 . . . . 0.0 110.798 -178.603 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 6.3 t-160 -98.09 129.5 44.91 Favored 'General case' 0 N--CA 1.475 0.78 0 N-CA-C 109.253 -0.647 . . . . 0.0 109.253 179.114 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -75.42 136.18 40.73 Favored 'General case' 0 N--CA 1.47 0.551 0 C-N-CA 122.666 0.386 . . . . 0.0 111.049 178.936 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' H' H ' 8' ' ' SER . . . . . 0.44 ' OG ' ' O ' ' E' ' 7' ' ' ASP . 27.2 p -160.39 -166.52 1.68 Allowed 'General case' 0 N--CA 1.475 0.794 0 CA-C-O 120.85 0.357 . . . . 0.0 110.476 178.786 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.27 46.16 1.37 Allowed Glycine 0 N--CA 1.481 1.674 0 N-CA-C 111.292 -0.723 . . . . 0.0 111.292 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 48.6 p90 -65.46 133.73 51.92 Favored 'General case' 0 CA--C 1.542 0.665 0 N-CA-C 111.894 0.331 . . . . 0.0 111.894 -179.635 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 48.8 mt-10 -91.2 151.63 20.87 Favored 'General case' 0 N--CA 1.479 0.98 0 CA-C-O 121.0 0.429 . . . . 0.0 110.154 178.481 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -154.52 127.66 1.16 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.057 0 N-CA-C 107.874 -1.158 . . . . 0.0 107.874 178.267 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 45.9 m-70 -135.25 147.0 49.14 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.438 -0.801 . . . . 0.0 111.408 -178.073 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 6.5 t60 -165.22 97.33 0.71 Allowed 'General case' 0 N--CA 1.483 1.192 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.264 178.837 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 3.9 pt20 -101.64 -173.77 2.43 Favored 'General case' 0 CA--C 1.511 -0.555 0 N-CA-C 108.637 -0.875 . . . . 0.0 108.637 -179.592 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -170.31 94.22 0.23 Allowed 'General case' 0 N--CA 1.472 0.652 0 CA-C-N 114.664 -1.153 . . . . 0.0 108.116 178.503 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 6.3 mp -121.81 155.66 34.86 Favored 'General case' 0 N--CA 1.498 1.964 0 CA-C-O 121.29 0.567 . . . . 0.0 111.96 -177.778 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 42.2 t -113.33 124.74 70.27 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.044 0 CA-C-N 114.766 -1.106 . . . . 0.0 108.159 176.521 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 30.9 m-85 -125.4 121.06 32.78 Favored 'General case' 0 C--N 1.368 1.401 0 CA-C-N 115.524 -0.762 . . . . 0.0 110.904 -179.082 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 67.2 m-85 54.55 73.63 0.39 Allowed 'General case' 0 C--O 1.236 0.389 0 CA-C-N 115.815 -0.63 . . . . 0.0 111.535 177.9 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.33 -77.98 0.14 Allowed 'General case' 0 N--CA 1.472 0.634 0 O-C-N 122.248 -0.283 . . . . 0.0 110.611 -179.526 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 41.0 tt0 -113.4 101.34 9.29 Favored 'General case' 0 C--N 1.323 -0.578 0 N-CA-C 108.1 -1.074 . . . . 0.0 108.1 179.731 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -157.7 141.87 16.07 Favored 'General case' 0 N--CA 1.478 0.971 0 O-C-N 122.453 -0.155 . . . . 0.0 111.371 179.095 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' H' H ' 24' ' ' VAL . . . . . 0.406 ' HB ' ' H ' ' E' ' 25' ' ' GLY . 57.4 t -60.45 166.92 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.617 0 N-CA-C 107.632 -1.247 . . . . 0.0 107.632 177.246 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . -120.6 49.36 0.88 Allowed Glycine 0 N--CA 1.48 1.603 0 N-CA-C 110.528 -1.029 . . . . 0.0 110.528 -179.592 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -63.77 -167.63 0.02 OUTLIER 'General case' 0 N--CA 1.473 0.697 0 CA-C-N 116.99 0.395 . . . . 0.0 110.028 179.812 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 27.4 t-20 -70.2 77.38 0.52 Allowed 'General case' 0 CA--C 1.536 0.41 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.445 179.883 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -74.8 144.21 43.62 Favored 'General case' 0 N--CA 1.474 0.754 0 N-CA-C 109.626 -0.509 . . . . 0.0 109.626 179.366 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.83 -165.42 1.08 Allowed Glycine 0 C--N 1.337 0.607 0 N-CA-C 109.978 -1.249 . . . . 0.0 109.978 178.731 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.66 113.57 26.1 Favored 'General case' 0 N--CA 1.468 0.431 0 C-N-CA 122.632 0.373 . . . . 0.0 110.593 179.902 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 66.6 mt -98.06 135.65 31.88 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.803 0 N-CA-C 106.81 -1.552 . . . . 0.0 106.81 178.964 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' H' H ' 32' ' ' ILE . . . . . 0.404 ' C ' ' H ' ' H' ' 34' ' ' LEU . 39.1 pt -152.38 -174.31 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 CA-C-N 119.838 1.199 . . . . 0.0 109.832 -179.637 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.05 5.92 8.75 Favored Glycine 0 CA--C 1.528 0.86 0 N-CA-C 110.974 -0.85 . . . . 0.0 110.974 -179.929 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' H' H ' 34' ' ' LEU . . . . . 0.404 ' H ' ' C ' ' H' ' 32' ' ' ILE . 1.6 tt -75.84 125.19 28.6 Favored 'General case' 0 CA--C 1.545 0.761 0 N-CA-C 109.512 -0.551 . . . . 0.0 109.512 -179.602 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 28.3 ttt -160.76 152.79 20.03 Favored 'General case' 0 C--O 1.207 -1.144 0 N-CA-C 108.925 -0.768 . . . . 0.0 108.925 178.595 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 28.4 m -157.8 164.17 1.14 Allowed 'Isoleucine or valine' 0 C--N 1.343 0.294 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 -179.81 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.54 67.81 2.01 Favored Glycine 0 C--N 1.309 -0.964 0 CA-C-N 115.559 -0.746 . . . . 0.0 112.168 178.542 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.55 -171.59 25.2 Favored Glycine 0 N--CA 1.478 1.475 0 N-CA-C 110.621 -0.992 . . . . 0.0 110.621 179.05 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' H' H ' 39' ' ' VAL . . . . . 0.438 HG11 ' H ' ' E' ' 39' ' ' VAL . 33.8 m -126.99 157.71 38.23 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.82 0 C-N-CA 123.168 0.587 . . . . 0.0 110.795 -179.456 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 29.7 t . . . . . 0 N--CA 1.469 0.506 0 O-C-N 123.985 0.803 . . . . 0.0 110.745 179.281 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 29.3 m-85 . . . . . 0 N--CA 1.476 0.868 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' I' I ' 5' ' ' ARG . . . . . . . . . . . . . 86.5 mtt180 -68.18 131.72 45.9 Favored 'General case' 0 N--CA 1.476 0.837 0 CA-C-N 116.435 -0.348 . . . . 0.0 110.719 -178.569 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 6.4 t-160 -97.89 129.56 44.83 Favored 'General case' 0 N--CA 1.473 0.718 0 N-CA-C 109.333 -0.617 . . . . 0.0 109.333 179.051 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -75.48 135.98 40.66 Favored 'General case' 0 CA--C 1.539 0.533 0 C-N-CA 122.707 0.403 . . . . 0.0 111.003 178.955 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' I' I ' 8' ' ' SER . . . . . 0.43 ' OG ' ' O ' ' F' ' 7' ' ' ASP . 25.0 p -160.41 -166.63 1.7 Allowed 'General case' 0 N--CA 1.476 0.833 0 CA-C-O 120.936 0.398 . . . . 0.0 110.494 178.841 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.37 45.97 1.38 Allowed Glycine 0 N--CA 1.481 1.693 0 N-CA-C 111.29 -0.724 . . . . 0.0 111.29 179.942 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 49.3 p90 -65.28 133.48 51.55 Favored 'General case' 0 N--CA 1.473 0.681 0 N-CA-C 111.942 0.349 . . . . 0.0 111.942 -179.599 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 49.1 mt-10 -90.93 151.71 21.0 Favored 'General case' 0 N--CA 1.478 0.949 0 CA-C-O 121.077 0.465 . . . . 0.0 110.165 178.463 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -154.72 127.55 1.1 Allowed 'Isoleucine or valine' 0 CA--C 1.553 1.073 0 N-CA-C 107.91 -1.144 . . . . 0.0 107.91 178.248 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 47.0 m-70 -135.22 146.84 49.04 Favored 'General case' 0 N--CA 1.477 0.915 0 CA-C-N 115.45 -0.796 . . . . 0.0 111.404 -178.002 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 6.5 t60 -165.05 97.41 0.73 Allowed 'General case' 0 N--CA 1.483 1.207 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.27 178.884 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 3.9 pt20 -101.82 -173.71 2.42 Favored 'General case' 0 CA--C 1.509 -0.627 0 N-CA-C 108.681 -0.859 . . . . 0.0 108.681 -179.612 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -170.36 94.02 0.22 Allowed 'General case' 0 N--CA 1.472 0.638 0 CA-C-N 114.628 -1.169 . . . . 0.0 108.128 178.607 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 6.3 mp -121.62 155.86 34.18 Favored 'General case' 0 N--CA 1.497 1.904 0 CA-C-O 121.257 0.551 . . . . 0.0 111.92 -177.751 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 42.1 t -113.53 125.09 70.75 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.997 0 CA-C-N 114.789 -1.096 . . . . 0.0 108.1 176.54 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 31.2 m-85 -125.73 121.41 33.31 Favored 'General case' 0 C--N 1.366 1.325 0 CA-C-N 115.61 -0.723 . . . . 0.0 110.945 -179.229 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 67.1 m-85 54.46 73.3 0.41 Allowed 'General case' 0 C--O 1.237 0.429 0 CA-C-N 115.911 -0.586 . . . . 0.0 111.482 177.885 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.15 -77.92 0.14 Allowed 'General case' 0 N--CA 1.473 0.702 0 O-C-N 122.272 -0.268 . . . . 0.0 110.5 -179.55 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 40.8 tt0 -113.4 101.54 9.48 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 108.069 -1.086 . . . . 0.0 108.069 179.692 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -157.91 141.59 15.56 Favored 'General case' 0 N--CA 1.479 1.004 0 O-C-N 122.42 -0.175 . . . . 0.0 111.361 179.087 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' I' I ' 24' ' ' VAL . . . . . 0.409 ' HB ' ' H ' ' F' ' 25' ' ' GLY . 59.0 t -60.26 167.27 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.631 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 177.22 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . -120.89 49.3 0.89 Allowed Glycine 0 N--CA 1.481 1.683 0 N-CA-C 110.523 -1.031 . . . . 0.0 110.523 -179.572 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -63.75 -167.65 0.02 OUTLIER 'General case' 0 N--CA 1.473 0.682 0 CA-C-N 117.002 0.401 . . . . 0.0 109.949 179.768 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 27.6 t-20 -70.21 77.27 0.52 Allowed 'General case' 0 CA--C 1.535 0.401 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.411 179.913 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -74.66 143.92 44.04 Favored 'General case' 0 N--CA 1.475 0.8 0 N-CA-C 109.617 -0.512 . . . . 0.0 109.617 179.424 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.44 -165.8 1.03 Allowed Glycine 0 C--N 1.337 0.601 0 N-CA-C 110.009 -1.236 . . . . 0.0 110.009 178.653 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.26 113.7 26.13 Favored 'General case' 0 N--CA 1.468 0.471 0 C-N-CA 122.729 0.412 . . . . 0.0 110.583 179.991 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 66.9 mt -98.5 135.49 33.12 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.842 0 N-CA-C 106.833 -1.543 . . . . 0.0 106.833 178.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' I' I ' 32' ' ' ILE . . . . . 0.41 ' C ' ' H ' ' I' ' 34' ' ' LEU . 39.2 pt -152.36 -174.3 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.725 0 CA-C-N 119.8 1.182 . . . . 0.0 109.84 -179.567 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.04 5.84 8.56 Favored Glycine 0 CA--C 1.527 0.819 0 N-CA-C 110.999 -0.84 . . . . 0.0 110.999 -179.874 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' I' I ' 34' ' ' LEU . . . . . 0.41 ' H ' ' C ' ' I' ' 32' ' ' ILE . 1.6 tt -75.82 125.42 29.05 Favored 'General case' 0 CA--C 1.545 0.753 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 -179.644 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 28.3 ttt -160.88 152.59 19.57 Favored 'General case' 0 C--O 1.206 -1.186 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 178.723 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 26.7 m -157.59 164.1 1.17 Allowed 'Isoleucine or valine' 0 C--N 1.342 0.262 0 N-CA-C 108.448 -0.945 . . . . 0.0 108.448 -179.988 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.57 67.91 1.96 Allowed Glycine 0 C--N 1.309 -0.951 0 CA-C-N 115.602 -0.727 . . . . 0.0 112.122 178.571 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.58 -171.86 25.11 Favored Glycine 0 N--CA 1.478 1.445 0 N-CA-C 110.644 -0.982 . . . . 0.0 110.644 178.97 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' I' I ' 39' ' ' VAL . . . . . 0.437 HG11 ' H ' ' F' ' 39' ' ' VAL . 33.9 m -126.82 157.26 38.07 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.792 0 C-N-CA 123.181 0.592 . . . . 0.0 110.832 -179.452 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 26.0 t . . . . . 0 C--O 1.22 -0.5 0 O-C-N 123.964 0.79 . . . . 0.0 110.825 179.347 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 63.1 m-85 . . . . . 0 N--CA 1.474 0.769 0 N-CA-C 110.309 -0.256 . . . . 0.0 110.309 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -144.45 142.51 30.34 Favored 'General case' 0 N--CA 1.483 1.221 0 N-CA-C 109.958 -0.386 . . . . 0.0 109.958 179.721 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 45.1 t-80 -152.61 118.77 5.51 Favored 'General case' 0 N--CA 1.469 0.524 0 N-CA-C 109.26 -0.645 . . . . 0.0 109.26 178.967 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' ASP . . . . . 0.515 ' O ' ' OG ' ' D' ' 8' ' ' SER . 4.0 m-20 -69.52 149.62 48.03 Favored 'General case' 0 CA--C 1.538 0.49 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.468 179.898 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 52.1 p -168.07 -173.24 2.0 Allowed 'General case' 0 N--CA 1.484 1.249 0 CA-C-O 121.075 0.464 . . . . 0.0 110.706 179.461 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.77 46.85 1.44 Allowed Glycine 0 N--CA 1.483 1.802 0 CA-C-N 115.962 -0.563 . . . . 0.0 111.941 179.808 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 47.8 p90 -65.27 132.56 49.37 Favored 'General case' 0 N--CA 1.471 0.616 0 CA-C-N 116.71 0.255 . . . . 0.0 111.62 179.764 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 48.1 mt-10 -91.87 151.77 20.4 Favored 'General case' 0 N--CA 1.478 0.935 0 N-CA-C 109.692 -0.484 . . . . 0.0 109.692 178.437 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.0 p -152.79 128.19 1.61 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.61 0 N-CA-C 107.894 -1.15 . . . . 0.0 107.894 178.239 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 45.3 m-70 -135.46 146.31 48.06 Favored 'General case' 0 N--CA 1.493 1.687 0 CA-C-N 118.993 0.815 . . . . 0.0 111.253 -178.916 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 6.0 t60 -165.8 96.78 0.64 Allowed 'General case' 0 N--CA 1.478 0.958 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.941 179.398 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . 0.667 HE22 ' H ' ' A' ' 37' ' ' GLY . 5.9 pt20 -108.27 -174.39 2.51 Favored 'General case' 0 CA--C 1.508 -0.645 0 N-CA-C 108.293 -1.003 . . . . 0.0 108.293 -179.781 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -164.22 98.79 0.83 Allowed 'General case' 0 N--CA 1.472 0.626 0 CA-C-N 114.477 -1.238 . . . . 0.0 108.285 178.38 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 6.5 mp -122.04 155.76 34.94 Favored 'General case' 0 N--CA 1.499 2.002 0 CA-C-O 121.837 0.827 . . . . 0.0 110.926 -178.341 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 60.2 t -111.55 126.73 68.97 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.093 0 CA-C-O 117.908 -1.044 . . . . 0.0 108.235 177.737 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 28.1 m-85 -126.43 122.99 36.87 Favored 'General case' 0 N--CA 1.497 1.902 0 CA-C-N 120.08 1.309 . . . . 0.0 110.477 179.203 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 67.0 m-85 54.08 73.79 0.37 Allowed 'General case' 0 N--CA 1.469 0.493 0 CA-C-O 121.306 0.574 . . . . 0.0 111.828 178.757 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -79.99 -77.97 0.18 Allowed 'General case' 0 C--N 1.351 0.665 0 CA-C-N 115.193 -0.912 . . . . 0.0 110.203 -179.752 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 40.6 tt0 -113.53 99.6 7.87 Favored 'General case' 0 N--CA 1.468 0.461 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 179.855 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -158.41 138.84 12.59 Favored 'General case' 0 C--O 1.206 -1.22 0 O-C-N 122.231 -0.293 . . . . 0.0 111.249 179.098 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 59.8 t -59.53 163.37 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.921 0 N-CA-C 107.941 -1.133 . . . . 0.0 107.941 177.071 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -116.88 47.61 1.02 Allowed Glycine 0 N--CA 1.476 1.359 0 N-CA-C 111.834 -0.506 . . . . 0.0 111.834 -179.417 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -60.61 -167.5 0.01 OUTLIER 'General case' 0 N--CA 1.469 0.478 0 O-C-N 123.786 0.345 . . . . 0.0 110.305 179.56 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 25.4 t-20 -71.02 80.46 0.66 Allowed 'General case' 0 N--CA 1.465 0.29 0 CA-C-N 116.45 -0.341 . . . . 0.0 110.246 179.539 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 97.7 mttt -77.45 142.95 38.92 Favored 'General case' 0 N--CA 1.474 0.744 0 N-CA-C 109.183 -0.673 . . . . 0.0 109.183 179.283 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.66 -167.89 1.12 Allowed Glycine 0 C--N 1.338 0.648 0 N-CA-C 109.957 -1.257 . . . . 0.0 109.957 178.757 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.44 115.12 28.54 Favored 'General case' 0 N--CA 1.478 0.951 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 179.727 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 71.0 mt -98.58 134.71 36.23 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.576 0 N-CA-C 107.202 -1.407 . . . . 0.0 107.202 178.722 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . 0.402 ' C ' ' H ' ' A' ' 34' ' ' LEU . 31.1 pt -150.63 -171.43 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.352 0.696 0 CA-C-O 121.168 0.508 . . . . 0.0 111.122 -179.259 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.39 4.95 9.96 Favored Glycine 0 N--CA 1.466 0.636 0 N-CA-C 110.735 -0.946 . . . . 0.0 110.735 179.843 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . 0.402 ' H ' ' C ' ' A' ' 32' ' ' ILE . 1.1 tt -75.38 135.21 40.81 Favored 'General case' 0 CA--C 1.545 0.77 0 N-CA-C 109.395 -0.594 . . . . 0.0 109.395 -179.727 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 27.1 ttt -158.82 146.46 17.79 Favored 'General case' 0 N--CA 1.467 0.418 0 N-CA-C 108.619 -0.882 . . . . 0.0 108.619 178.608 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 1.9 m -148.9 165.65 4.01 Favored 'Isoleucine or valine' 0 C--N 1.348 0.517 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 -179.625 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . 0.667 ' H ' HE22 ' A' ' 15' ' ' GLN . . . 54.87 68.44 1.68 Allowed Glycine 0 C--N 1.306 -1.118 0 CA-C-N 115.49 -0.777 . . . . 0.0 112.32 177.518 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.53 176.59 21.3 Favored Glycine 0 N--CA 1.472 1.072 0 N-CA-C 111.11 -0.796 . . . . 0.0 111.11 178.7 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 34.3 m -109.31 156.28 10.08 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.658 0 C-N-CA 123.385 0.674 . . . . 0.0 110.201 -179.689 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 24.4 t . . . . . 0 C--O 1.219 -0.55 0 CA-C-O 118.42 -0.8 . . . . 0.0 110.492 179.397 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 63.8 m-85 . . . . . 0 N--CA 1.473 0.678 0 N-CA-C 110.264 -0.272 . . . . 0.0 110.264 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -144.2 142.42 30.51 Favored 'General case' 0 N--CA 1.483 1.186 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 179.682 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 44.8 t-80 -152.45 118.63 5.53 Favored 'General case' 0 N--CA 1.471 0.582 0 N-CA-C 109.395 -0.594 . . . . 0.0 109.395 178.829 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 7' ' ' ASP . . . . . 0.502 ' O ' ' OG ' ' E' ' 8' ' ' SER . 3.8 m-20 -69.36 149.18 48.69 Favored 'General case' 0 CA--C 1.539 0.546 0 CA-C-N 116.4 -0.364 . . . . 0.0 110.622 179.896 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 8' ' ' SER . . . . . . . . . . . . . 52.7 p -167.52 -173.26 2.15 Favored 'General case' 0 N--CA 1.484 1.235 0 CA-C-O 121.033 0.444 . . . . 0.0 110.818 179.381 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.89 46.95 1.41 Allowed Glycine 0 N--CA 1.481 1.674 0 CA-C-N 115.966 -0.561 . . . . 0.0 112.015 179.661 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 47.7 p90 -65.79 132.53 48.94 Favored 'General case' 0 N--CA 1.472 0.652 0 CA-C-O 120.719 0.295 . . . . 0.0 111.649 179.837 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 47.9 mt-10 -91.65 151.86 20.49 Favored 'General case' 0 N--CA 1.477 0.894 0 N-CA-C 109.655 -0.498 . . . . 0.0 109.655 178.436 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -152.92 127.95 1.51 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.47 0 N-CA-C 107.972 -1.121 . . . . 0.0 107.972 178.13 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 43.5 m-70 -135.18 146.42 48.69 Favored 'General case' 0 N--CA 1.493 1.686 0 CA-C-N 118.869 0.759 . . . . 0.0 111.345 -178.93 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 6.1 t60 -165.79 97.02 0.65 Allowed 'General case' 0 N--CA 1.48 1.041 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.768 179.378 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . 0.665 HE22 ' H ' ' B' ' 37' ' ' GLY . 5.9 pt20 -108.37 -174.18 2.46 Favored 'General case' 0 CA--C 1.509 -0.603 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 -179.772 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -164.63 98.88 0.79 Allowed 'General case' 0 N--CA 1.474 0.755 0 CA-C-N 114.683 -1.144 . . . . 0.0 108.195 178.363 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 6.6 mp -122.04 156.04 34.35 Favored 'General case' 0 N--CA 1.497 1.925 0 CA-C-O 121.727 0.775 . . . . 0.0 111.012 -178.27 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 61.8 t -112.03 127.63 69.1 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.075 0 N-CA-C 108.028 -1.101 . . . . 0.0 108.028 177.605 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 28.2 m-85 -127.56 122.48 33.36 Favored 'General case' 0 N--CA 1.495 1.781 0 CA-C-N 119.678 1.126 . . . . 0.0 110.307 179.565 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 67.4 m-85 53.71 74.21 0.33 Allowed 'General case' 0 CA--C 1.538 0.504 0 CA-C-O 121.491 0.662 . . . . 0.0 111.846 178.792 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -80.55 -78.03 0.18 Allowed 'General case' 0 C--N 1.35 0.628 0 CA-C-N 115.065 -0.97 . . . . 0.0 110.116 -179.573 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 40.4 tt0 -113.15 99.57 7.93 Favored 'General case' 0 N--CA 1.47 0.543 0 N-CA-C 108.236 -1.024 . . . . 0.0 108.236 179.812 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -158.6 138.79 12.31 Favored 'General case' 0 C--O 1.205 -1.272 0 CA-C-O 119.524 -0.275 . . . . 0.0 111.236 179.1 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 57.1 t -59.41 163.8 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.857 0 N-CA-C 108.012 -1.107 . . . . 0.0 108.012 177.191 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 25' ' ' GLY . . . . . 0.402 ' H ' ' HB ' ' E' ' 24' ' ' VAL . . . -117.18 47.64 1.02 Allowed Glycine 0 N--CA 1.475 1.244 0 N-CA-C 111.773 -0.531 . . . . 0.0 111.773 -179.465 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -60.67 -167.62 0.01 OUTLIER 'General case' 0 N--CA 1.469 0.52 0 O-C-N 123.708 0.299 . . . . 0.0 110.202 179.457 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 25.4 t-20 -71.1 81.12 0.69 Allowed 'General case' 0 N--CA 1.465 0.29 0 CA-C-N 116.481 -0.327 . . . . 0.0 110.186 179.548 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 97.8 mttt -78.07 142.55 38.08 Favored 'General case' 0 N--CA 1.474 0.762 0 N-CA-C 109.015 -0.735 . . . . 0.0 109.015 179.418 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.22 -167.76 0.92 Allowed Glycine 0 C--N 1.336 0.557 0 N-CA-C 109.917 -1.273 . . . . 0.0 109.917 178.659 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.54 115.53 29.56 Favored 'General case' 0 N--CA 1.478 0.959 0 N-CA-C 109.599 -0.519 . . . . 0.0 109.599 179.77 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 70.9 mt -98.96 134.68 36.96 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.505 0 N-CA-C 107.107 -1.442 . . . . 0.0 107.107 178.6 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . 0.407 ' C ' ' H ' ' B' ' 34' ' ' LEU . 29.7 pt -150.77 -171.85 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.724 0 CA-C-O 121.141 0.496 . . . . 0.0 111.17 -179.022 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.76 4.58 10.68 Favored Glycine 0 C--N 1.337 0.595 0 N-CA-C 110.915 -0.874 . . . . 0.0 110.915 179.935 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 34' ' ' LEU . . . . . 0.407 ' H ' ' C ' ' B' ' 32' ' ' ILE . 1.1 tt -75.07 135.07 41.23 Favored 'General case' 0 CA--C 1.545 0.767 0 N-CA-C 109.497 -0.557 . . . . 0.0 109.497 -179.689 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 27.0 ttt -158.54 146.42 18.18 Favored 'General case' 0 N--CA 1.471 0.582 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 178.64 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 1.9 m -149.08 165.54 3.83 Favored 'Isoleucine or valine' 0 C--N 1.347 0.48 0 N-CA-C 108.094 -1.076 . . . . 0.0 108.094 -179.642 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . 0.665 ' H ' HE22 ' B' ' 15' ' ' GLN . . . 55.19 68.21 1.81 Allowed Glycine 0 C--N 1.306 -1.097 0 CA-C-N 115.469 -0.787 . . . . 0.0 112.367 177.54 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.24 176.75 21.21 Favored Glycine 0 N--CA 1.473 1.105 0 N-CA-C 111.113 -0.795 . . . . 0.0 111.113 178.674 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 39' ' ' VAL . . . . . 0.401 ' H ' HG11 ' E' ' 39' ' ' VAL . 34.4 m -109.35 155.81 10.31 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.655 0 C-N-CA 123.376 0.67 . . . . 0.0 110.299 -179.546 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 25.1 t . . . . . 0 C--O 1.22 -0.497 0 O-C-N 123.99 0.806 . . . . 0.0 110.407 179.317 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 64.8 m-85 . . . . . 0 N--CA 1.474 0.767 0 N-CA-C 110.25 -0.278 . . . . 0.0 110.25 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -144.22 142.4 30.48 Favored 'General case' 0 N--CA 1.484 1.244 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 179.769 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 45.2 t-80 -152.47 119.05 5.66 Favored 'General case' 0 N--CA 1.471 0.586 0 N-CA-C 109.397 -0.594 . . . . 0.0 109.397 179.013 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 7' ' ' ASP . . . . . 0.495 ' O ' ' OG ' ' F' ' 8' ' ' SER . 4.1 m-20 -70.1 149.03 48.04 Favored 'General case' 0 CA--C 1.538 0.493 0 CA-C-N 116.376 -0.375 . . . . 0.0 110.647 -179.983 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 8' ' ' SER . . . . . . . . . . . . . 54.0 p -167.28 -172.97 2.13 Favored 'General case' 0 N--CA 1.484 1.235 0 CA-C-O 121.061 0.457 . . . . 0.0 110.744 179.566 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.48 46.9 1.47 Allowed Glycine 0 N--CA 1.482 1.715 0 CA-C-N 115.945 -0.57 . . . . 0.0 112.035 179.688 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 47.7 p90 -65.78 132.35 48.51 Favored 'General case' 0 N--CA 1.471 0.591 0 O-C-N 122.745 -0.268 . . . . 0.0 111.686 179.826 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 47.7 mt-10 -91.41 151.82 20.66 Favored 'General case' 0 N--CA 1.475 0.782 0 N-CA-C 109.713 -0.477 . . . . 0.0 109.713 178.432 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -152.77 128.17 1.61 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.515 0 N-CA-C 107.833 -1.173 . . . . 0.0 107.833 177.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 41.7 m-70 -135.27 146.5 48.61 Favored 'General case' 0 N--CA 1.492 1.65 0 CA-C-N 118.916 0.78 . . . . 0.0 111.272 -179.056 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 6.0 t60 -165.88 96.84 0.63 Allowed 'General case' 0 N--CA 1.481 1.111 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.719 179.459 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 15' ' ' GLN . . . . . 0.666 HE22 ' H ' ' C' ' 37' ' ' GLY . 5.9 pt20 -108.39 -173.98 2.41 Favored 'General case' 0 CA--C 1.505 -0.77 0 N-CA-C 108.396 -0.965 . . . . 0.0 108.396 -179.898 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -164.63 98.85 0.79 Allowed 'General case' 0 N--CA 1.473 0.678 0 CA-C-N 114.617 -1.174 . . . . 0.0 108.223 178.502 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 6.6 mp -121.9 155.77 34.74 Favored 'General case' 0 N--CA 1.497 1.901 0 CA-C-O 121.84 0.828 . . . . 0.0 110.927 -178.35 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 61.2 t -111.68 127.55 68.77 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.117 0 N-CA-C 107.932 -1.136 . . . . 0.0 107.932 177.511 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 28.1 m-85 -127.51 123.06 35.0 Favored 'General case' 0 N--CA 1.495 1.782 0 CA-C-N 119.606 1.094 . . . . 0.0 110.272 179.395 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 67.0 m-85 53.08 74.12 0.32 Allowed 'General case' 0 N--CA 1.468 0.449 0 CA-C-O 121.558 0.694 . . . . 0.0 111.919 178.851 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -80.22 -78.29 0.17 Allowed 'General case' 0 C--N 1.35 0.62 0 CA-C-N 115.012 -0.994 . . . . 0.0 110.065 -179.595 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 40.4 tt0 -113.03 99.69 8.05 Favored 'General case' 0 N--CA 1.471 0.62 0 N-CA-C 108.153 -1.055 . . . . 0.0 108.153 179.899 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -158.45 139.15 12.8 Favored 'General case' 0 C--O 1.205 -1.246 0 O-C-N 122.309 -0.245 . . . . 0.0 111.203 179.131 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 60.7 t -59.94 163.3 0.96 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.878 0 N-CA-C 108.075 -1.083 . . . . 0.0 108.075 177.051 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 25' ' ' GLY . . . . . 0.402 ' H ' ' HB ' ' F' ' 24' ' ' VAL . . . -116.64 47.3 1.05 Allowed Glycine 0 N--CA 1.477 1.387 0 N-CA-C 111.722 -0.551 . . . . 0.0 111.722 -179.29 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -60.43 -167.38 0.01 OUTLIER 'General case' 0 N--CA 1.468 0.462 0 O-C-N 123.658 0.269 . . . . 0.0 110.284 179.539 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 25.5 t-20 -71.29 80.69 0.74 Allowed 'General case' 0 N--CA 1.466 0.333 0 CA-C-N 116.442 -0.344 . . . . 0.0 110.132 179.495 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 97.7 mttt -77.53 143.06 38.69 Favored 'General case' 0 N--CA 1.474 0.741 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 179.253 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.83 -167.68 1.15 Allowed Glycine 0 CA--C 1.524 0.617 0 N-CA-C 109.994 -1.242 . . . . 0.0 109.994 178.705 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.49 115.11 28.55 Favored 'General case' 0 N--CA 1.482 1.144 0 N-CA-C 109.677 -0.49 . . . . 0.0 109.677 179.879 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 71.1 mt -98.78 134.21 38.45 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.48 0 N-CA-C 107.296 -1.372 . . . . 0.0 107.296 178.591 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 29.7 pt -150.3 -171.49 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.724 0 CA-C-O 121.227 0.537 . . . . 0.0 111.173 -179.107 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.31 5.11 10.05 Favored Glycine 0 CA--C 1.524 0.62 0 N-CA-C 110.838 -0.905 . . . . 0.0 110.838 179.881 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 1.1 tt -75.46 134.77 40.77 Favored 'General case' 0 CA--C 1.546 0.813 0 N-CA-C 109.38 -0.6 . . . . 0.0 109.38 -179.703 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 27.1 ttt -158.19 146.57 18.79 Favored 'General case' 0 N--CA 1.47 0.531 0 N-CA-C 108.426 -0.953 . . . . 0.0 108.426 178.686 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 1.7 m -149.33 165.28 3.72 Favored 'Isoleucine or valine' 0 C--N 1.348 0.532 0 N-CA-C 108.142 -1.059 . . . . 0.0 108.142 -179.556 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 37' ' ' GLY . . . . . 0.666 ' H ' HE22 ' C' ' 15' ' ' GLN . . . 54.77 68.7 1.55 Allowed Glycine 0 C--N 1.306 -1.096 0 CA-C-N 115.413 -0.812 . . . . 0.0 112.317 177.782 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.26 176.42 20.94 Favored Glycine 0 N--CA 1.473 1.101 0 N-CA-C 111.078 -0.809 . . . . 0.0 111.078 178.698 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 34.4 m -109.38 155.73 10.38 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.624 0 C-N-CA 123.328 0.651 . . . . 0.0 110.443 -179.641 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 25.1 t . . . . . 0 C--O 1.219 -0.538 0 O-C-N 124.009 0.818 . . . . 0.0 110.491 179.386 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 72.3 m-85 . . . . . 0 N--CA 1.471 0.599 0 N-CA-C 108.948 -0.76 . . . . 0.0 108.948 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' D' D ' 5' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -146.87 140.99 26.12 Favored 'General case' 0 N--CA 1.476 0.86 0 N-CA-C 110.059 -0.348 . . . . 0.0 110.059 179.764 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 41.6 t-80 -149.75 123.52 9.26 Favored 'General case' 0 CA--C 1.545 0.774 0 N-CA-C 108.499 -0.926 . . . . 0.0 108.499 174.468 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 7' ' ' ASP . . . . . 0.598 ' O ' ' OG ' ' G' ' 8' ' ' SER . 2.8 m-20 -63.81 133.32 53.2 Favored 'General case' 0 C--N 1.32 -0.688 0 C-N-CA 126.61 1.964 . . . . 0.0 114.339 174.029 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' D' D ' 8' ' ' SER . . . . . 0.515 ' OG ' ' O ' ' A' ' 7' ' ' ASP . 52.3 p -154.04 -170.53 3.59 Favored 'General case' 0 N--CA 1.488 1.438 0 CA-C-N 119.649 1.113 . . . . 0.0 111.131 175.534 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.43 48.05 1.16 Allowed Glycine 0 N--CA 1.484 1.88 0 N-CA-C 109.941 -1.264 . . . . 0.0 109.941 173.365 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 50.9 p90 -60.66 131.01 49.35 Favored 'General case' 0 N--CA 1.468 0.434 0 N-CA-C 113.155 0.798 . . . . 0.0 113.155 177.697 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 47.8 mt-10 -88.84 150.65 22.8 Favored 'General case' 0 N--CA 1.481 1.084 0 CA-C-N 118.175 0.443 . . . . 0.0 110.946 174.98 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.0 p -149.49 130.03 4.41 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.594 0 N-CA-C 107.423 -1.325 . . . . 0.0 107.423 173.128 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 40.9 m-70 -130.03 149.25 51.83 Favored 'General case' 0 N--CA 1.484 1.232 0 CA-C-N 118.03 0.377 . . . . 0.0 111.907 176.41 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 6.1 t60 -164.99 104.38 0.78 Allowed 'General case' 0 N--CA 1.48 1.035 0 N-CA-C 109.175 -0.676 . . . . 0.0 109.175 172.13 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 15' ' ' GLN . . . . . 0.642 HE22 ' H ' ' D' ' 37' ' ' GLY . 5.9 pt20 -111.97 -176.05 2.84 Favored 'General case' 0 CA--C 1.499 -1.002 0 N-CA-C 108.228 -1.027 . . . . 0.0 108.228 178.911 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -161.04 105.96 1.36 Allowed 'General case' 0 N--CA 1.468 0.433 0 N-CA-C 106.634 -1.617 . . . . 0.0 106.634 175.151 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 5.5 mp -128.38 153.22 47.3 Favored 'General case' 0 N--CA 1.498 1.945 0 CA-C-O 122.06 0.934 . . . . 0.0 110.582 179.662 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 35.8 t -100.97 131.82 47.88 Favored 'Isoleucine or valine' 0 C--O 1.262 1.761 0 CA-C-O 116.723 -1.608 . . . . 0.0 109.546 174.2 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 25.7 m-85 -130.49 126.35 36.66 Favored 'General case' 0 N--CA 1.491 1.583 0 CA-C-N 120.149 1.34 . . . . 0.0 109.528 173.366 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 68.2 m-85 55.85 71.53 0.55 Allowed 'General case' 0 C--O 1.241 0.651 0 CA-C-N 115.493 -0.776 . . . . 0.0 111.258 176.357 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -82.43 -73.18 0.41 Allowed 'General case' 0 N--CA 1.475 0.794 0 CA-C-O 118.52 -0.752 . . . . 0.0 111.106 -177.507 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 40.8 tt0 -116.52 103.81 10.79 Favored 'General case' 0 N--CA 1.482 1.174 0 N-CA-C 106.195 -1.78 . . . . 0.0 106.195 176.217 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -151.9 138.79 18.98 Favored 'General case' 0 N--CA 1.474 0.752 0 CA-C-O 116.686 -1.626 . . . . 0.0 113.738 177.697 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 24' ' ' VAL . . . . . . . . . . . . . 64.1 t -62.27 166.23 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.206 0 CA-C-N 121.101 1.773 . . . . 0.0 107.834 175.184 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 25' ' ' GLY . . . . . 0.434 ' H ' ' HB ' ' G' ' 24' ' ' VAL . . . -116.79 51.14 0.74 Allowed Glycine 0 N--CA 1.478 1.46 0 CA-C-O 119.095 -0.836 . . . . 0.0 111.833 178.451 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -57.28 -170.42 0.01 OUTLIER 'General case' 0 C--N 1.322 -0.595 0 C-N-CA 123.706 0.802 . . . . 0.0 111.559 175.937 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 26.3 t-20 -72.89 86.69 1.29 Allowed 'General case' 0 C--N 1.347 0.466 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 177.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 97.2 mttt -82.87 145.56 29.38 Favored 'General case' 0 N--CA 1.476 0.84 0 N-CA-C 108.014 -1.106 . . . . 0.0 108.014 179.134 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.17 -165.34 0.61 Allowed Glycine 0 C--N 1.336 0.57 0 N-CA-C 110.45 -1.06 . . . . 0.0 110.45 179.171 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -102.35 116.11 31.95 Favored 'General case' 0 N--CA 1.476 0.851 0 N-CA-C 109.099 -0.704 . . . . 0.0 109.099 179.846 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 80.4 mt -102.52 142.24 17.07 Favored 'Isoleucine or valine' 0 C--N 1.358 0.941 0 N-CA-C 104.84 -2.281 . . . . 0.0 104.84 179.793 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 31.1 pt -157.43 -172.51 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.482 1.157 0 CA-C-O 120.84 0.353 . . . . 0.0 110.155 -177.332 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 64.27 4.55 12.59 Favored Glycine 0 N--CA 1.465 0.601 0 N-CA-C 110.387 -1.085 . . . . 0.0 110.387 -178.926 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 1.3 tt -76.52 140.47 41.17 Favored 'General case' 0 C--N 1.355 0.824 0 N-CA-C 107.787 -1.19 . . . . 0.0 107.787 -178.329 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 26.4 ttt -156.41 155.91 32.94 Favored 'General case' 0 C--O 1.247 0.955 0 N-CA-C 107.894 -1.15 . . . . 0.0 107.894 174.482 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 1.9 m -157.91 163.86 1.18 Allowed 'Isoleucine or valine' 0 CA--C 1.516 -0.334 0 N-CA-C 107.618 -1.252 . . . . 0.0 107.618 177.826 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 37' ' ' GLY . . . . . 0.642 ' H ' HE22 ' D' ' 15' ' ' GLN . . . 61.36 63.84 4.53 Favored Glycine 0 C--N 1.312 -0.76 0 C-N-CA 119.758 -1.211 . . . . 0.0 112.179 177.452 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 145.76 177.75 20.72 Favored Glycine 0 N--CA 1.476 1.365 0 CA-C-N 118.309 1.054 . . . . 0.0 111.776 179.756 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 35.2 m -112.5 152.76 14.24 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.895 0 N-CA-C 109.681 -0.489 . . . . 0.0 109.681 -176.824 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 25.2 t . . . . . 0 C--N 1.334 -0.066 0 CA-C-O 116.119 -1.896 . . . . 0.0 109.533 178.0 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 65.8 m-85 . . . . . 0 N--CA 1.474 0.756 0 N-CA-C 110.257 -0.275 . . . . 0.0 110.257 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' E' E ' 5' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -143.72 142.79 31.12 Favored 'General case' 0 N--CA 1.481 1.078 0 N-CA-C 110.113 -0.329 . . . . 0.0 110.113 179.458 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 45.1 t-80 -152.46 118.67 5.54 Favored 'General case' 0 N--CA 1.469 0.516 0 N-CA-C 109.294 -0.632 . . . . 0.0 109.294 178.86 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' E' E ' 7' ' ' ASP . . . . . 0.506 ' O ' ' OG ' ' H' ' 8' ' ' SER . 3.6 m-20 -70.14 149.14 47.87 Favored 'General case' 0 CA--C 1.535 0.391 0 CA-C-N 116.488 -0.324 . . . . 0.0 110.754 179.938 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' E' E ' 8' ' ' SER . . . . . 0.502 ' OG ' ' O ' ' B' ' 7' ' ' ASP . 43.7 p -168.26 -172.1 1.66 Allowed 'General case' 0 N--CA 1.486 1.33 0 CA-C-O 121.192 0.52 . . . . 0.0 110.854 179.18 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.24 47.7 1.3 Allowed Glycine 0 N--CA 1.478 1.485 0 CA-C-N 115.876 -0.602 . . . . 0.0 111.797 179.54 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 46.3 p90 -65.56 132.62 49.32 Favored 'General case' 0 N--CA 1.471 0.621 0 N-CA-C 112.064 0.394 . . . . 0.0 112.064 -179.891 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 49.0 mt-10 -90.98 152.29 20.74 Favored 'General case' 0 N--CA 1.481 1.123 0 CA-C-O 121.313 0.578 . . . . 0.0 109.575 177.954 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -154.65 127.07 1.04 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.588 0 N-CA-C 107.874 -1.158 . . . . 0.0 107.874 177.96 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 42.9 m-70 -135.42 144.4 46.49 Favored 'General case' 0 N--CA 1.482 1.149 0 CA-C-O 120.903 0.382 . . . . 0.0 111.478 -177.859 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 6.0 t60 -164.4 97.19 0.79 Allowed 'General case' 0 N--CA 1.484 1.237 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.694 179.419 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' E' E ' 15' ' ' GLN . . . . . 0.663 HE22 ' H ' ' E' ' 37' ' ' GLY . 6.0 pt20 -108.21 -174.33 2.49 Favored 'General case' 0 CA--C 1.507 -0.686 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 -179.924 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -164.18 97.73 0.82 Allowed 'General case' 0 N--CA 1.476 0.839 0 CA-C-N 114.698 -1.137 . . . . 0.0 108.436 178.563 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 6.5 mp -120.52 155.66 33.17 Favored 'General case' 0 N--CA 1.494 1.775 0 CA-C-O 121.533 0.682 . . . . 0.0 111.588 -177.867 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 48.8 t -113.44 124.66 70.3 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.254 0 N-CA-C 108.176 -1.046 . . . . 0.0 108.176 177.131 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 30.8 m-85 -124.94 121.8 35.51 Favored 'General case' 0 N--CA 1.489 1.495 0 CA-C-O 120.836 0.351 . . . . 0.0 110.934 -179.891 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 68.8 m-85 54.79 73.29 0.42 Allowed 'General case' 0 N--CA 1.468 0.429 0 CA-C-N 115.92 -0.582 . . . . 0.0 111.478 178.34 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -78.83 -79.03 0.14 Allowed 'General case' 0 CA--C 1.537 0.459 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.03 -179.378 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 40.5 tt0 -112.1 100.02 8.52 Favored 'General case' 0 C--N 1.323 -0.548 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 -179.987 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -157.89 138.84 13.22 Favored 'General case' 0 C--O 1.201 -1.458 0 N-CA-C 111.621 0.23 . . . . 0.0 111.621 179.029 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' E' E ' 24' ' ' VAL . . . . . 0.402 ' HB ' ' H ' ' B' ' 25' ' ' GLY . 59.0 t -58.15 168.28 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.927 0 N-CA-C 107.403 -1.332 . . . . 0.0 107.403 177.056 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . -122.0 48.63 0.94 Allowed Glycine 0 N--CA 1.473 1.157 0 N-CA-C 110.963 -0.855 . . . . 0.0 110.963 -179.38 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -62.12 -166.9 0.01 OUTLIER 'General case' 0 N--CA 1.47 0.541 0 CA-C-O 120.737 0.303 . . . . 0.0 110.482 179.892 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 26.0 t-20 -70.68 76.88 0.6 Allowed 'General case' 0 C--O 1.222 -0.362 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.481 -179.956 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 97.9 mttt -74.36 143.67 44.75 Favored 'General case' 0 N--CA 1.476 0.873 0 N-CA-C 109.554 -0.536 . . . . 0.0 109.554 179.403 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.68 -167.38 1.43 Allowed Glycine 0 C--N 1.333 0.414 0 N-CA-C 110.408 -1.077 . . . . 0.0 110.408 178.534 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.54 113.99 26.72 Favored 'General case' 0 N--CA 1.476 0.834 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 179.953 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 72.0 mt -97.8 134.48 35.86 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.265 0 N-CA-C 106.986 -1.487 . . . . 0.0 106.986 178.768 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' E' E ' 32' ' ' ILE . . . . . 0.41 ' C ' ' H ' ' E' ' 34' ' ' LEU . 31.4 pt -150.34 -169.7 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.174 0 CA-C-O 121.182 0.515 . . . . 0.0 110.753 -179.451 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.65 5.18 6.41 Favored Glycine 0 CA--C 1.527 0.834 0 CA-C-N 115.684 -0.689 . . . . 0.0 111.423 -179.796 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' E' E ' 34' ' ' LEU . . . . . 0.41 ' H ' ' C ' ' E' ' 32' ' ' ILE . 1.1 tt -74.75 135.26 41.77 Favored 'General case' 0 CA--C 1.549 0.941 0 N-CA-C 109.293 -0.632 . . . . 0.0 109.293 -179.616 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 26.3 ttt -158.37 145.78 17.98 Favored 'General case' 0 N--CA 1.473 0.724 0 N-CA-C 108.611 -0.885 . . . . 0.0 108.611 178.466 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 1.5 m -148.65 165.08 4.56 Favored 'Isoleucine or valine' 0 C--N 1.347 0.48 0 N-CA-C 108.5 -0.926 . . . . 0.0 108.5 -179.447 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' E' E ' 37' ' ' GLY . . . . . 0.663 ' H ' HE22 ' E' ' 15' ' ' GLN . . . 54.28 68.56 1.6 Allowed Glycine 0 C--N 1.308 -1.024 0 CA-C-N 115.324 -0.853 . . . . 0.0 112.231 177.888 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 146.65 173.76 18.16 Favored Glycine 0 N--CA 1.473 1.11 0 N-CA-C 111.41 -0.676 . . . . 0.0 111.41 178.734 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' E' E ' 39' ' ' VAL . . . . . 0.401 HG11 ' H ' ' B' ' 39' ' ' VAL . 32.7 m -107.0 155.69 7.59 Favored 'Isoleucine or valine' 0 C--N 1.352 0.702 0 C-N-CA 123.629 0.772 . . . . 0.0 110.645 -178.711 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 25.4 t . . . . . 0 C--O 1.218 -0.599 0 O-C-N 124.18 0.925 . . . . 0.0 110.25 179.615 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 65.1 m-85 . . . . . 0 N--CA 1.474 0.77 0 N-CA-C 110.235 -0.283 . . . . 0.0 110.235 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' F' F ' 5' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -143.56 142.66 31.19 Favored 'General case' 0 N--CA 1.478 0.97 0 CA-C-O 120.838 0.351 . . . . 0.0 110.091 179.657 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 45.0 t-80 -152.45 119.26 5.75 Favored 'General case' 0 N--CA 1.471 0.614 0 N-CA-C 109.429 -0.582 . . . . 0.0 109.429 178.783 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' F' F ' 7' ' ' ASP . . . . . 0.496 ' O ' ' OG ' ' I' ' 8' ' ' SER . 3.7 m-20 -70.76 149.33 47.01 Favored 'General case' 0 CA--C 1.535 0.382 0 CA-C-N 116.418 -0.356 . . . . 0.0 110.844 -179.929 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' F' F ' 8' ' ' SER . . . . . 0.495 ' OG ' ' O ' ' C' ' 7' ' ' ASP . 43.2 p -168.56 -171.63 1.48 Allowed 'General case' 0 N--CA 1.484 1.262 0 CA-C-O 121.236 0.541 . . . . 0.0 110.935 179.169 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.95 46.82 1.42 Allowed Glycine 0 N--CA 1.478 1.492 0 CA-C-N 115.855 -0.611 . . . . 0.0 111.761 179.551 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 46.6 p90 -64.64 132.42 49.69 Favored 'General case' 0 CA--C 1.542 0.642 0 N-CA-C 112.01 0.374 . . . . 0.0 112.01 -179.886 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 48.6 mt-10 -91.04 152.29 20.71 Favored 'General case' 0 N--CA 1.482 1.13 0 CA-C-O 121.266 0.555 . . . . 0.0 109.685 177.89 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -154.49 126.98 1.05 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.67 0 N-CA-C 107.855 -1.165 . . . . 0.0 107.855 178.058 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 42.5 m-70 -135.24 144.81 47.09 Favored 'General case' 0 N--CA 1.483 1.179 0 CA-C-O 120.847 0.356 . . . . 0.0 111.522 -177.919 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 6.0 t60 -164.88 96.91 0.74 Allowed 'General case' 0 N--CA 1.484 1.27 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.805 179.539 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' F' F ' 15' ' ' GLN . . . . . 0.667 HE22 ' H ' ' F' ' 37' ' ' GLY . 6.0 pt20 -108.02 -174.17 2.46 Favored 'General case' 0 CA--C 1.505 -0.751 0 N-CA-C 108.574 -0.899 . . . . 0.0 108.574 -179.875 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -164.17 97.79 0.82 Allowed 'General case' 0 N--CA 1.473 0.719 0 CA-C-N 114.578 -1.192 . . . . 0.0 108.397 178.561 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 6.4 mp -120.55 155.73 33.05 Favored 'General case' 0 N--CA 1.494 1.773 0 CA-C-O 121.667 0.746 . . . . 0.0 111.456 -177.727 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 48.4 t -113.64 124.38 70.23 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.25 0 N-CA-C 108.199 -1.037 . . . . 0.0 108.199 177.17 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 30.5 m-85 -124.7 121.19 33.97 Favored 'General case' 0 N--CA 1.488 1.439 0 CA-C-O 120.77 0.319 . . . . 0.0 111.015 -179.783 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 67.9 m-85 55.27 73.23 0.43 Allowed 'General case' 0 C--N 1.344 0.342 0 CA-C-N 115.953 -0.567 . . . . 0.0 111.733 178.322 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -78.92 -78.58 0.15 Allowed 'General case' 0 N--CA 1.467 0.419 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.147 -179.27 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 40.3 tt0 -112.66 99.99 8.36 Favored 'General case' 0 C--N 1.324 -0.524 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 -179.825 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -157.88 138.8 13.2 Favored 'General case' 0 C--O 1.203 -1.361 0 N-CA-C 111.681 0.252 . . . . 0.0 111.681 179.052 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' F' F ' 24' ' ' VAL . . . . . 0.402 ' HB ' ' H ' ' C' ' 25' ' ' GLY . 60.0 t -58.13 168.24 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.935 0 N-CA-C 107.398 -1.334 . . . . 0.0 107.398 177.116 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -121.92 48.53 0.94 Allowed Glycine 0 N--CA 1.476 1.35 0 N-CA-C 110.877 -0.889 . . . . 0.0 110.877 -179.394 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -62.11 -167.4 0.01 OUTLIER 'General case' 0 N--CA 1.47 0.565 0 CA-C-O 120.782 0.325 . . . . 0.0 110.285 179.895 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 25.8 t-20 -70.1 77.0 0.51 Allowed 'General case' 0 N--CA 1.466 0.338 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.589 179.979 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 97.8 mttt -74.57 143.81 44.28 Favored 'General case' 0 N--CA 1.478 0.957 0 N-CA-C 109.483 -0.562 . . . . 0.0 109.483 179.524 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.39 -167.11 1.25 Allowed Glycine 0 C--N 1.334 0.425 0 N-CA-C 110.486 -1.046 . . . . 0.0 110.486 178.539 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.69 113.65 26.25 Favored 'General case' 0 N--CA 1.477 0.917 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 179.752 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 72.0 mt -97.71 134.59 35.28 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.285 0 N-CA-C 106.981 -1.489 . . . . 0.0 106.981 178.717 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' F' F ' 32' ' ' ILE . . . . . 0.411 ' C ' ' H ' ' F' ' 34' ' ' LEU . 32.1 pt -150.74 -169.6 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.198 0 CA-C-O 121.126 0.489 . . . . 0.0 110.7 -179.476 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.64 5.12 6.29 Favored Glycine 0 CA--C 1.527 0.82 0 CA-C-N 115.688 -0.687 . . . . 0.0 111.407 -179.78 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' F' F ' 34' ' ' LEU . . . . . 0.411 ' H ' ' C ' ' F' ' 32' ' ' ILE . 1.1 tt -74.66 135.83 41.93 Favored 'General case' 0 CA--C 1.549 0.922 0 N-CA-C 109.18 -0.674 . . . . 0.0 109.18 -179.669 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 26.0 ttt -158.72 145.92 17.58 Favored 'General case' 0 N--CA 1.47 0.561 0 N-CA-C 108.66 -0.867 . . . . 0.0 108.66 178.446 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 1.5 m -148.78 165.14 4.35 Favored 'Isoleucine or valine' 0 C--N 1.349 0.547 0 N-CA-C 108.425 -0.954 . . . . 0.0 108.425 -179.495 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' F' F ' 37' ' ' GLY . . . . . 0.667 ' H ' HE22 ' F' ' 15' ' ' GLN . . . 54.33 68.37 1.7 Allowed Glycine 0 C--N 1.306 -1.108 0 CA-C-N 115.328 -0.851 . . . . 0.0 112.331 177.808 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 146.97 174.09 18.74 Favored Glycine 0 N--CA 1.472 1.097 0 N-CA-C 111.415 -0.674 . . . . 0.0 111.415 178.645 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' F' F ' 39' ' ' VAL . . . . . 0.408 ' H ' HG11 ' I' ' 39' ' ' VAL . 33.1 m -107.22 155.54 7.88 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.714 0 C-N-CA 123.471 0.708 . . . . 0.0 110.588 -178.803 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 26.8 t . . . . . 0 C--O 1.219 -0.55 0 O-C-N 124.286 0.991 . . . . 0.0 110.3 179.601 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 67.1 m-85 . . . . . 0 N--CA 1.473 0.692 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' G' G ' 5' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -143.91 142.77 30.95 Favored 'General case' 0 N--CA 1.483 1.189 0 CA-C-O 120.828 0.347 . . . . 0.0 110.162 179.983 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 45.8 t-80 -152.31 119.5 5.9 Favored 'General case' 0 N--CA 1.473 0.682 0 N-CA-C 109.574 -0.528 . . . . 0.0 109.574 178.794 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 4.0 m-20 -71.82 144.49 49.11 Favored 'General case' 0 CA--C 1.538 0.519 0 C-N-CA 122.716 0.406 . . . . 0.0 111.176 -179.938 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' G' G ' 8' ' ' SER . . . . . 0.598 ' OG ' ' O ' ' D' ' 7' ' ' ASP . 35.5 p -164.77 -169.62 1.76 Allowed 'General case' 0 N--CA 1.476 0.86 0 CA-C-O 121.178 0.513 . . . . 0.0 110.512 178.672 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.21 47.73 1.41 Allowed Glycine 0 N--CA 1.48 1.63 0 N-CA-C 111.344 -0.703 . . . . 0.0 111.344 179.291 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 48.0 p90 -65.69 133.16 50.51 Favored 'General case' 0 CA--C 1.542 0.636 0 N-CA-C 111.872 0.323 . . . . 0.0 111.872 -179.627 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 47.9 mt-10 -91.76 151.48 20.6 Favored 'General case' 0 N--CA 1.479 1.022 0 CA-C-O 121.162 0.506 . . . . 0.0 110.0 178.576 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -154.99 127.28 1.01 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.004 0 N-CA-C 107.851 -1.166 . . . . 0.0 107.851 178.196 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 44.2 m-70 -134.67 146.06 49.14 Favored 'General case' 0 N--CA 1.48 1.05 0 CA-C-N 115.667 -0.697 . . . . 0.0 111.45 -178.363 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 6.0 t60 -166.24 97.05 0.6 Allowed 'General case' 0 N--CA 1.481 1.115 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.385 178.946 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' G' G ' 15' ' ' GLN . . . . . 0.655 HE22 ' H ' ' G' ' 37' ' ' GLY . 6.0 pt20 -108.42 -174.51 2.54 Favored 'General case' 0 CA--C 1.508 -0.641 0 N-CA-C 108.31 -0.996 . . . . 0.0 108.31 -179.702 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -164.27 97.72 0.81 Allowed 'General case' 0 N--CA 1.475 0.802 0 CA-C-N 114.606 -1.179 . . . . 0.0 108.12 178.667 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 6.4 mp -120.4 154.8 34.64 Favored 'General case' 0 N--CA 1.498 1.934 0 CA-C-O 121.247 0.546 . . . . 0.0 111.774 -177.883 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 43.1 t -113.33 124.66 70.19 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.942 0 CA-C-N 114.777 -1.101 . . . . 0.0 108.186 176.55 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 32.1 m-85 -125.29 121.19 33.3 Favored 'General case' 0 C--N 1.367 1.349 0 C-N-CA 123.437 0.695 . . . . 0.0 110.979 -179.602 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 68.0 m-85 55.37 72.57 0.47 Allowed 'General case' 0 N--CA 1.467 0.393 0 CA-C-N 115.898 -0.592 . . . . 0.0 111.496 178.274 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.78 -77.99 0.14 Allowed 'General case' 0 N--CA 1.473 0.697 0 O-C-N 122.237 -0.289 . . . . 0.0 110.407 -178.932 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 41.1 tt0 -113.02 100.2 8.44 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 107.812 -1.181 . . . . 0.0 107.812 179.909 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -157.73 139.75 14.21 Favored 'General case' 0 N--CA 1.476 0.865 0 N-CA-C 111.649 0.24 . . . . 0.0 111.649 178.959 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' G' G ' 24' ' ' VAL . . . . . 0.434 ' HB ' ' H ' ' D' ' 25' ' ' GLY . 62.0 t -59.62 166.97 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.656 0 N-CA-C 107.564 -1.273 . . . . 0.0 107.564 177.353 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -120.13 49.32 0.88 Allowed Glycine 0 N--CA 1.479 1.538 0 N-CA-C 110.617 -0.993 . . . . 0.0 110.617 -179.507 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -63.45 -166.59 0.02 OUTLIER 'General case' 0 N--CA 1.471 0.62 0 N-CA-C 109.895 -0.409 . . . . 0.0 109.895 179.904 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 26.2 t-20 -70.99 76.96 0.65 Allowed 'General case' 0 CA--C 1.535 0.386 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.599 -179.89 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 97.9 mttt -73.95 143.14 45.81 Favored 'General case' 0 N--CA 1.475 0.808 0 N-CA-C 109.623 -0.51 . . . . 0.0 109.623 179.427 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.08 -166.17 0.98 Allowed Glycine 0 C--N 1.337 0.592 0 N-CA-C 110.019 -1.232 . . . . 0.0 110.019 178.642 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.57 114.28 27.2 Favored 'General case' 0 N--CA 1.472 0.659 0 C-N-CA 122.708 0.403 . . . . 0.0 110.138 -179.977 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 73.6 mt -98.51 135.02 34.97 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.649 0 N-CA-C 107.054 -1.461 . . . . 0.0 107.054 178.67 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' G' G ' 32' ' ' ILE . . . . . 0.419 ' C ' ' H ' ' G' ' 34' ' ' LEU . 34.3 pt -151.5 -169.28 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 CA-C-N 119.723 1.147 . . . . 0.0 109.916 -179.813 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.28 4.78 6.85 Favored Glycine 0 N--CA 1.468 0.774 0 N-CA-C 111.132 -0.787 . . . . 0.0 111.132 -179.864 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' G' G ' 34' ' ' LEU . . . . . 0.419 ' H ' ' C ' ' G' ' 32' ' ' ILE . 1.1 tt -74.95 135.12 41.41 Favored 'General case' 0 CA--C 1.545 0.775 0 N-CA-C 109.295 -0.631 . . . . 0.0 109.295 -179.757 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 25.0 ttt -158.28 146.06 18.31 Favored 'General case' 0 N--CA 1.47 0.566 0 N-CA-C 108.64 -0.874 . . . . 0.0 108.64 178.823 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 1.5 m -148.82 163.4 4.85 Favored 'Isoleucine or valine' 0 C--N 1.349 0.561 0 N-CA-C 108.587 -0.894 . . . . 0.0 108.587 -179.469 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' G' G ' 37' ' ' GLY . . . . . 0.655 ' H ' HE22 ' G' ' 15' ' ' GLN . . . 55.4 68.76 1.52 Allowed Glycine 0 C--N 1.308 -1.001 0 CA-C-N 115.226 -0.897 . . . . 0.0 112.293 177.596 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.39 172.35 17.46 Favored Glycine 0 N--CA 1.476 1.314 0 N-CA-C 110.569 -1.012 . . . . 0.0 110.569 178.892 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 33.9 m -106.01 155.64 6.92 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.923 0 C-N-CA 123.198 0.599 . . . . 0.0 110.452 -179.541 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 27.5 t . . . . . 0 C--O 1.22 -0.46 0 O-C-N 123.961 0.788 . . . . 0.0 110.563 179.371 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 68.8 m-85 . . . . . 0 N--CA 1.473 0.71 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' H' H ' 5' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -144.21 142.92 30.81 Favored 'General case' 0 N--CA 1.483 1.217 0 N-CA-C 110.046 -0.353 . . . . 0.0 110.046 -179.98 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 46.6 t-80 -152.65 119.69 5.82 Favored 'General case' 0 N--CA 1.472 0.636 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 178.812 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 3.9 m-20 -72.19 144.56 48.47 Favored 'General case' 0 N--CA 1.469 0.481 0 CA-C-N 116.319 -0.401 . . . . 0.0 111.222 -179.781 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' H' H ' 8' ' ' SER . . . . . 0.506 ' OG ' ' O ' ' E' ' 7' ' ' ASP . 52.2 p -164.72 -170.07 1.9 Allowed 'General case' 0 N--CA 1.475 0.776 0 CA-C-O 121.129 0.49 . . . . 0.0 110.492 178.912 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.48 47.63 1.39 Allowed Glycine 0 N--CA 1.478 1.499 0 N-CA-C 111.557 -0.617 . . . . 0.0 111.557 179.409 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 48.4 p90 -65.97 133.14 50.22 Favored 'General case' 0 CA--C 1.54 0.584 0 N-CA-C 111.861 0.319 . . . . 0.0 111.861 -179.587 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 47.8 mt-10 -91.67 151.44 20.67 Favored 'General case' 0 N--CA 1.477 0.921 0 CA-C-O 121.064 0.459 . . . . 0.0 110.065 178.583 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -154.98 127.35 1.03 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.004 0 N-CA-C 107.92 -1.141 . . . . 0.0 107.92 178.13 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 43.5 m-70 -134.67 146.36 49.43 Favored 'General case' 0 N--CA 1.479 0.98 0 CA-C-N 115.694 -0.685 . . . . 0.0 111.311 -178.321 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 6.1 t60 -166.43 96.71 0.57 Allowed 'General case' 0 N--CA 1.481 1.102 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.508 178.912 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' H' H ' 15' ' ' GLN . . . . . 0.65 HE22 ' H ' ' H' ' 37' ' ' GLY . 5.9 pt20 -107.97 -174.13 2.45 Favored 'General case' 0 CA--C 1.507 -0.681 0 N-CA-C 108.304 -0.999 . . . . 0.0 108.304 -179.624 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -164.68 97.5 0.76 Allowed 'General case' 0 N--CA 1.474 0.757 0 CA-C-N 114.584 -1.189 . . . . 0.0 108.127 178.61 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 6.4 mp -120.21 154.92 34.16 Favored 'General case' 0 N--CA 1.496 1.857 0 CA-C-O 121.265 0.555 . . . . 0.0 111.838 -177.939 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 43.2 t -113.4 124.65 70.25 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.079 0 CA-C-N 114.817 -1.083 . . . . 0.0 108.158 176.668 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 32.2 m-85 -125.22 121.28 33.65 Favored 'General case' 0 C--N 1.366 1.313 0 C-N-CA 123.471 0.708 . . . . 0.0 110.885 -179.443 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 68.3 m-85 54.72 72.92 0.43 Allowed 'General case' 0 C--O 1.238 0.455 0 CA-C-N 115.698 -0.683 . . . . 0.0 111.672 178.342 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.68 -78.31 0.14 Allowed 'General case' 0 N--CA 1.473 0.676 0 O-C-N 122.154 -0.341 . . . . 0.0 110.349 -178.914 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 40.8 tt0 -112.85 99.77 8.15 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 107.878 -1.156 . . . . 0.0 107.878 -179.946 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -157.24 139.96 15.02 Favored 'General case' 0 N--CA 1.477 0.887 0 O-C-N 122.346 -0.221 . . . . 0.0 111.471 178.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' H' H ' 24' ' ' VAL . . . . . . . . . . . . . 59.7 t -59.7 167.65 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.592 0 N-CA-C 107.458 -1.312 . . . . 0.0 107.458 177.313 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . -120.63 49.27 0.89 Allowed Glycine 0 N--CA 1.479 1.5 0 N-CA-C 110.622 -0.991 . . . . 0.0 110.622 -179.581 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -63.6 -167.33 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.643 0 CA-C-N 117.033 0.417 . . . . 0.0 110.036 179.766 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 26.2 t-20 -70.05 77.04 0.5 Allowed 'General case' 0 N--CA 1.465 0.318 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.587 -179.945 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 97.8 mttt -74.1 143.45 45.38 Favored 'General case' 0 N--CA 1.475 0.819 0 N-CA-C 109.5 -0.556 . . . . 0.0 109.5 179.41 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.67 -166.39 1.21 Allowed Glycine 0 C--N 1.338 0.669 0 N-CA-C 109.997 -1.241 . . . . 0.0 109.997 178.641 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.4 114.29 27.13 Favored 'General case' 0 N--CA 1.47 0.554 0 C-N-CA 122.683 0.393 . . . . 0.0 110.293 -179.995 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 74.0 mt -98.46 135.09 34.6 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.693 0 N-CA-C 106.992 -1.484 . . . . 0.0 106.992 178.672 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' H' H ' 32' ' ' ILE . . . . . 0.414 ' C ' ' H ' ' H' ' 34' ' ' LEU . 34.8 pt -151.51 -169.02 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.759 0 CA-C-N 119.667 1.121 . . . . 0.0 109.826 -179.929 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.08 5.28 7.42 Favored Glycine 0 N--CA 1.467 0.706 0 N-CA-C 111.055 -0.818 . . . . 0.0 111.055 -179.979 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' H' H ' 34' ' ' LEU . . . . . 0.414 ' H ' ' C ' ' H' ' 32' ' ' ILE . 1.1 tt -75.44 135.24 40.73 Favored 'General case' 0 CA--C 1.545 0.784 0 N-CA-C 109.4 -0.593 . . . . 0.0 109.4 -179.744 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 25.4 ttt -158.41 146.01 18.08 Favored 'General case' 0 N--CA 1.469 0.514 0 N-CA-C 108.698 -0.853 . . . . 0.0 108.698 178.882 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 1.5 m -148.91 163.83 4.57 Favored 'Isoleucine or valine' 0 C--N 1.35 0.594 0 N-CA-C 108.56 -0.904 . . . . 0.0 108.56 -179.467 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' H' H ' 37' ' ' GLY . . . . . 0.65 ' H ' HE22 ' H' ' 15' ' ' GLN . . . 55.29 68.29 1.76 Allowed Glycine 0 C--N 1.306 -1.087 0 CA-C-N 115.237 -0.892 . . . . 0.0 112.32 177.612 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.54 172.72 17.96 Favored Glycine 0 N--CA 1.475 1.24 0 N-CA-C 110.745 -0.942 . . . . 0.0 110.745 178.959 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 34.1 m -106.13 155.75 6.98 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.0 0 C-N-CA 123.32 0.648 . . . . 0.0 110.575 -179.497 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 25.9 t . . . . . 0 C--O 1.219 -0.533 0 O-C-N 123.991 0.807 . . . . 0.0 110.61 179.424 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 67.2 m-85 . . . . . 0 N--CA 1.475 0.788 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' I' I ' 5' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -144.12 142.48 30.61 Favored 'General case' 0 N--CA 1.482 1.153 0 N-CA-C 110.023 -0.362 . . . . 0.0 110.023 -179.931 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 45.1 t-80 -152.28 119.61 5.95 Favored 'General case' 0 N--CA 1.472 0.629 0 N-CA-C 109.503 -0.554 . . . . 0.0 109.503 178.824 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -71.96 144.81 48.77 Favored 'General case' 0 N--CA 1.469 0.481 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.105 -179.758 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' I' I ' 8' ' ' SER . . . . . 0.496 ' OG ' ' O ' ' F' ' 7' ' ' ASP . 51.7 p -164.95 -170.21 1.89 Allowed 'General case' 0 N--CA 1.474 0.742 0 CA-C-O 121.139 0.495 . . . . 0.0 110.547 178.956 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.27 47.72 1.4 Allowed Glycine 0 N--CA 1.479 1.518 0 N-CA-C 111.592 -0.603 . . . . 0.0 111.592 179.544 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 47.5 p90 -65.89 132.9 49.76 Favored 'General case' 0 N--CA 1.471 0.586 0 N-CA-C 111.883 0.327 . . . . 0.0 111.883 -179.789 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 48.4 mt-10 -91.57 151.13 20.87 Favored 'General case' 0 N--CA 1.478 0.936 0 CA-C-O 121.149 0.499 . . . . 0.0 110.013 178.654 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -154.75 127.32 1.06 Allowed 'Isoleucine or valine' 0 CA--C 1.551 0.983 0 N-CA-C 107.979 -1.119 . . . . 0.0 107.979 178.252 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 44.0 m-70 -134.83 146.2 49.06 Favored 'General case' 0 N--CA 1.479 0.993 0 CA-C-N 115.68 -0.691 . . . . 0.0 111.384 -178.149 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 6.0 t60 -166.31 96.87 0.59 Allowed 'General case' 0 N--CA 1.48 1.051 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.399 178.91 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' I' I ' 15' ' ' GLN . . . . . 0.662 HE22 ' H ' ' I' ' 37' ' ' GLY . 5.9 pt20 -108.17 -174.48 2.53 Favored 'General case' 0 CA--C 1.505 -0.762 0 N-CA-C 108.272 -1.01 . . . . 0.0 108.272 -179.731 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -164.3 97.84 0.81 Allowed 'General case' 0 N--CA 1.475 0.794 0 CA-C-N 114.58 -1.191 . . . . 0.0 108.043 178.698 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 6.4 mp -120.65 154.34 35.64 Favored 'General case' 0 N--CA 1.497 1.902 0 CA-C-O 121.215 0.531 . . . . 0.0 111.837 -177.938 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 42.9 t -112.72 125.16 69.95 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.949 0 N-CA-C 108.067 -1.086 . . . . 0.0 108.067 176.595 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 30.7 m-85 -125.71 121.37 33.24 Favored 'General case' 0 C--N 1.367 1.341 0 CA-C-N 115.585 -0.734 . . . . 0.0 110.815 -179.285 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 68.9 m-85 54.59 72.52 0.46 Allowed 'General case' 0 C--N 1.345 0.38 0 CA-C-N 115.916 -0.584 . . . . 0.0 111.49 178.27 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.33 -78.25 0.13 Allowed 'General case' 0 N--CA 1.473 0.72 0 N-CA-C 110.294 -0.262 . . . . 0.0 110.294 -178.971 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 40.9 tt0 -112.77 99.86 8.24 Favored 'General case' 0 C--N 1.323 -0.566 0 N-CA-C 107.978 -1.119 . . . . 0.0 107.978 -179.959 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 4.7 p30 -157.31 139.91 14.88 Favored 'General case' 0 N--CA 1.477 0.891 0 N-CA-C 111.487 0.18 . . . . 0.0 111.487 178.978 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' I' I ' 24' ' ' VAL . . . . . . . . . . . . . 61.2 t -59.76 167.26 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.56 0 N-CA-C 107.567 -1.271 . . . . 0.0 107.567 177.243 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . -120.34 49.62 0.87 Allowed Glycine 0 N--CA 1.479 1.516 0 N-CA-C 110.669 -0.972 . . . . 0.0 110.669 -179.494 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -63.73 -166.89 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.572 0 N-CA-C 110.036 -0.357 . . . . 0.0 110.036 179.881 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 26.4 t-20 -70.58 76.56 0.58 Allowed 'General case' 0 CA--C 1.533 0.294 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.584 179.983 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 97.9 mttt -73.65 143.63 46.2 Favored 'General case' 0 N--CA 1.475 0.816 0 N-CA-C 109.561 -0.533 . . . . 0.0 109.561 179.422 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.74 -166.31 1.22 Allowed Glycine 0 C--N 1.336 0.548 0 N-CA-C 110.016 -1.233 . . . . 0.0 110.016 178.647 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.24 114.11 26.74 Favored 'General case' 0 N--CA 1.473 0.721 0 C-N-CA 122.706 0.402 . . . . 0.0 110.315 179.937 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 75.1 mt -98.3 135.08 34.38 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.631 0 N-CA-C 106.94 -1.504 . . . . 0.0 106.94 178.695 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' I' I ' 32' ' ' ILE . . . . . 0.411 ' C ' ' H ' ' I' ' 34' ' ' LEU . 35.1 pt -151.5 -169.16 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.831 0 CA-C-N 119.62 1.1 . . . . 0.0 109.771 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.36 5.11 7.53 Favored Glycine 0 N--CA 1.466 0.686 0 N-CA-C 111.054 -0.818 . . . . 0.0 111.054 -179.893 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' I' I ' 34' ' ' LEU . . . . . 0.411 ' H ' ' C ' ' I' ' 32' ' ' ILE . 1.1 tt -75.21 134.92 41.07 Favored 'General case' 0 N--CA 1.474 0.77 0 N-CA-C 109.336 -0.616 . . . . 0.0 109.336 -179.646 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 24.7 ttt -158.06 145.97 18.55 Favored 'General case' 0 N--CA 1.47 0.555 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 178.906 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 1.5 m -149.08 163.67 4.41 Favored 'Isoleucine or valine' 0 C--N 1.35 0.616 0 N-CA-C 108.491 -0.929 . . . . 0.0 108.491 -179.455 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' I' I ' 37' ' ' GLY . . . . . 0.662 ' H ' HE22 ' I' ' 15' ' ' GLN . . . 55.25 68.58 1.61 Allowed Glycine 0 C--N 1.308 -1.015 0 CA-C-N 115.218 -0.901 . . . . 0.0 112.282 177.706 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.25 172.5 17.51 Favored Glycine 0 N--CA 1.475 1.234 0 N-CA-C 110.646 -0.982 . . . . 0.0 110.646 178.923 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' I' I ' 39' ' ' VAL . . . . . 0.408 HG11 ' H ' ' F' ' 39' ' ' VAL . 34.4 m -106.17 155.49 7.06 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.993 0 C-N-CA 123.185 0.594 . . . . 0.0 110.635 -179.382 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 25.9 t . . . . . 0 C--O 1.218 -0.559 0 O-C-N 123.955 0.784 . . . . 0.0 110.599 179.433 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 64.9 m-85 . . . . . 0 N--CA 1.474 0.77 0 N-CA-C 110.173 -0.306 . . . . 0.0 110.173 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -144.11 142.94 30.89 Favored 'General case' 0 N--CA 1.481 1.098 0 CA-C-O 120.925 0.393 . . . . 0.0 110.031 179.417 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 46.7 t-80 -152.83 118.99 5.49 Favored 'General case' 0 N--CA 1.472 0.654 0 N-CA-C 109.157 -0.683 . . . . 0.0 109.157 179.19 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' ASP . . . . . 0.512 ' O ' ' OG ' ' D' ' 8' ' ' SER . 4.3 m-20 -69.58 149.59 48.0 Favored 'General case' 0 N--CA 1.467 0.406 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.331 179.794 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 52.4 p -168.03 -173.27 2.02 Favored 'General case' 0 N--CA 1.484 1.243 0 CA-C-O 121.006 0.431 . . . . 0.0 110.698 179.107 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.79 46.49 1.49 Allowed Glycine 0 N--CA 1.481 1.686 0 CA-C-N 116.009 -0.541 . . . . 0.0 112.11 -179.941 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 49.1 p90 -65.12 132.43 49.14 Favored 'General case' 0 N--CA 1.473 0.685 0 O-C-N 122.687 -0.302 . . . . 0.0 111.561 179.631 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 49.2 mt-10 -91.83 152.13 20.26 Favored 'General case' 0 N--CA 1.477 0.889 0 N-CA-C 109.87 -0.419 . . . . 0.0 109.87 178.297 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -152.73 128.45 1.69 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.592 0 N-CA-C 107.849 -1.167 . . . . 0.0 107.849 178.248 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 44.5 m-70 -135.54 145.94 47.54 Favored 'General case' 0 N--CA 1.491 1.617 0 CA-C-N 119.011 0.823 . . . . 0.0 111.374 -179.107 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -166.9 97.25 0.53 Allowed 'General case' 0 N--CA 1.481 1.107 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.635 179.571 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 14.7 pt20 -109.69 -174.01 2.4 Favored 'General case' 0 CA--C 1.505 -0.788 0 N-CA-C 108.36 -0.978 . . . . 0.0 108.36 179.887 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -162.71 98.98 1.0 Allowed 'General case' 0 N--CA 1.472 0.669 0 CA-C-N 114.59 -1.186 . . . . 0.0 108.309 178.274 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 6.7 mp -121.45 155.55 34.64 Favored 'General case' 0 N--CA 1.497 1.901 0 CA-C-O 121.832 0.825 . . . . 0.0 110.938 -178.347 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 58.3 t -111.59 126.47 68.98 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.046 0 CA-C-O 117.894 -1.05 . . . . 0.0 108.344 177.742 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 29.2 m-85 -126.27 122.9 36.84 Favored 'General case' 0 N--CA 1.496 1.862 0 CA-C-N 120.147 1.34 . . . . 0.0 110.284 179.281 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 68.1 m-85 54.02 74.02 0.35 Allowed 'General case' 0 N--CA 1.47 0.538 0 CA-C-O 121.398 0.618 . . . . 0.0 111.66 178.729 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -79.77 -78.29 0.16 Allowed 'General case' 0 C--N 1.353 0.734 0 CA-C-N 115.175 -0.92 . . . . 0.0 110.442 -179.902 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 40.8 tt0 -113.15 100.19 8.4 Favored 'General case' 0 N--CA 1.47 0.565 0 N-CA-C 108.327 -0.99 . . . . 0.0 108.327 179.603 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 4.4 p30 -158.74 138.72 12.09 Favored 'General case' 0 N--CA 1.485 1.282 0 CA-C-O 119.403 -0.332 . . . . 0.0 111.226 179.271 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 57.4 t -59.83 163.9 0.87 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.783 0 N-CA-C 108.224 -1.028 . . . . 0.0 108.224 176.932 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -117.06 47.15 1.06 Allowed Glycine 0 N--CA 1.477 1.39 0 N-CA-C 111.753 -0.539 . . . . 0.0 111.753 -179.219 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -60.11 -167.79 0.01 OUTLIER 'General case' 0 N--CA 1.469 0.512 0 O-C-N 123.852 0.384 . . . . 0.0 110.405 179.272 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 26.1 t-20 -70.98 81.05 0.66 Allowed 'General case' 0 CA--C 1.531 0.219 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.212 179.6 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 97.7 mttt -77.93 143.16 37.9 Favored 'General case' 0 N--CA 1.471 0.582 0 N-CA-C 109.163 -0.68 . . . . 0.0 109.163 179.396 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.67 -167.51 1.06 Allowed Glycine 0 CA--C 1.525 0.707 0 N-CA-C 109.926 -1.269 . . . . 0.0 109.926 178.962 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.91 115.02 28.67 Favored 'General case' 0 N--CA 1.476 0.846 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 179.677 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 72.3 mt -98.68 134.46 37.34 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.518 0 N-CA-C 107.025 -1.472 . . . . 0.0 107.025 179.021 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 29.3 pt -150.68 -172.0 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.708 0 CA-C-O 121.209 0.528 . . . . 0.0 111.184 -179.14 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.63 4.73 10.5 Favored Glycine 0 CA--C 1.527 0.785 0 N-CA-C 110.699 -0.96 . . . . 0.0 110.699 179.882 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 1.1 tt -75.43 135.16 40.75 Favored 'General case' 0 CA--C 1.544 0.726 0 N-CA-C 109.405 -0.591 . . . . 0.0 109.405 -179.56 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 27.2 ttt -158.54 146.64 18.33 Favored 'General case' 0 N--CA 1.47 0.546 0 N-CA-C 108.557 -0.905 . . . . 0.0 108.557 178.705 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 1.7 m -149.16 165.49 3.78 Favored 'Isoleucine or valine' 0 C--N 1.349 0.579 0 N-CA-C 108.056 -1.09 . . . . 0.0 108.056 -179.584 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.19 68.36 1.73 Allowed Glycine 0 C--N 1.305 -1.158 0 CA-C-N 115.521 -0.763 . . . . 0.0 112.316 177.581 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.32 177.32 21.73 Favored Glycine 0 N--CA 1.474 1.192 0 N-CA-C 111.008 -0.837 . . . . 0.0 111.008 178.514 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 34.3 m -109.81 155.59 10.95 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.623 0 C-N-CA 123.432 0.693 . . . . 0.0 110.354 -179.643 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 23.4 t . . . . . 0 C--O 1.219 -0.501 0 O-C-N 124.031 0.832 . . . . 0.0 110.663 179.633 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 63.9 m-85 . . . . . 0 N--CA 1.475 0.804 0 N-CA-C 110.154 -0.313 . . . . 0.0 110.154 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -144.32 141.92 30.07 Favored 'General case' 0 N--CA 1.481 1.089 0 N-CA-C 109.881 -0.414 . . . . 0.0 109.881 179.513 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 47.2 t-80 -151.71 118.55 5.8 Favored 'General case' 0 N--CA 1.473 0.715 0 N-CA-C 109.319 -0.623 . . . . 0.0 109.319 178.989 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 7' ' ' ASP . . . . . 0.496 ' O ' ' OG ' ' E' ' 8' ' ' SER . 3.9 m-20 -69.2 148.9 49.21 Favored 'General case' 0 N--CA 1.469 0.485 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.525 179.761 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 8' ' ' SER . . . . . . . . . . . . . 49.4 p -167.52 -173.49 2.22 Favored 'General case' 0 N--CA 1.481 1.125 0 CA-C-O 120.974 0.416 . . . . 0.0 110.653 179.155 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.26 46.92 1.38 Allowed Glycine 0 N--CA 1.482 1.728 0 CA-C-N 116.007 -0.542 . . . . 0.0 112.158 179.987 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 48.7 p90 -65.74 132.33 48.48 Favored 'General case' 0 N--CA 1.472 0.668 0 O-C-N 122.733 -0.274 . . . . 0.0 111.618 179.663 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 48.6 mt-10 -91.52 152.32 20.37 Favored 'General case' 0 N--CA 1.475 0.819 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 178.167 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -153.05 128.25 1.54 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.581 0 N-CA-C 107.783 -1.191 . . . . 0.0 107.783 178.148 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 45.5 m-70 -135.4 145.86 47.72 Favored 'General case' 0 N--CA 1.493 1.692 0 CA-C-N 118.843 0.747 . . . . 0.0 111.37 -179.141 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -166.57 97.15 0.56 Allowed 'General case' 0 N--CA 1.48 1.05 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.651 179.485 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 14.9 pt20 -109.54 -173.62 2.3 Favored 'General case' 0 CA--C 1.507 -0.7 0 N-CA-C 108.324 -0.991 . . . . 0.0 108.324 179.854 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -163.2 98.82 0.94 Allowed 'General case' 0 N--CA 1.473 0.696 0 CA-C-N 114.699 -1.137 . . . . 0.0 108.279 178.357 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 6.6 mp -121.17 155.56 34.27 Favored 'General case' 0 N--CA 1.498 1.925 0 CA-C-O 121.894 0.854 . . . . 0.0 110.927 -178.298 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 60.4 t -111.77 127.69 68.78 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.082 0 N-CA-C 108.037 -1.097 . . . . 0.0 108.037 177.538 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 28.5 m-85 -127.66 122.34 32.78 Favored 'General case' 0 N--CA 1.495 1.821 0 CA-C-N 119.665 1.12 . . . . 0.0 110.161 179.566 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 67.4 m-85 53.96 73.65 0.37 Allowed 'General case' 0 CA--C 1.54 0.571 0 CA-C-O 121.505 0.669 . . . . 0.0 111.67 178.615 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -79.65 -78.0 0.17 Allowed 'General case' 0 C--N 1.351 0.649 0 CA-C-N 115.078 -0.965 . . . . 0.0 110.435 -179.917 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 41.0 tt0 -113.4 99.62 7.92 Favored 'General case' 0 N--CA 1.47 0.56 0 N-CA-C 108.499 -0.926 . . . . 0.0 108.499 179.624 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -157.99 139.15 13.35 Favored 'General case' 0 C--O 1.205 -1.266 0 CA-C-O 119.447 -0.311 . . . . 0.0 111.208 179.204 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 59.9 t -60.15 163.49 0.98 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.824 0 N-CA-C 108.212 -1.033 . . . . 0.0 108.212 176.976 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 25' ' ' GLY . . . . . 0.407 ' H ' ' HB ' ' E' ' 24' ' ' VAL . . . -116.42 47.63 1.02 Allowed Glycine 0 N--CA 1.476 1.357 0 N-CA-C 111.628 -0.589 . . . . 0.0 111.628 -179.167 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -60.69 -167.68 0.01 OUTLIER 'General case' 0 N--CA 1.468 0.46 0 O-C-N 123.782 0.342 . . . . 0.0 110.306 179.414 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 26.0 t-20 -71.17 81.01 0.71 Allowed 'General case' 0 CA--C 1.532 0.27 0 N-CA-C 110.074 -0.343 . . . . 0.0 110.074 179.616 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 97.7 mttt -77.9 143.1 38.01 Favored 'General case' 0 N--CA 1.472 0.638 0 N-CA-C 109.105 -0.702 . . . . 0.0 109.105 179.442 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.49 -167.42 0.97 Allowed Glycine 0 C--N 1.337 0.618 0 N-CA-C 109.92 -1.272 . . . . 0.0 109.92 178.894 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -100.25 114.78 28.49 Favored 'General case' 0 N--CA 1.475 0.786 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 179.757 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 71.5 mt -98.46 134.51 36.8 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.501 0 N-CA-C 107.105 -1.443 . . . . 0.0 107.105 178.889 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . 0.414 ' C ' ' H ' ' B' ' 34' ' ' LEU . 30.1 pt -150.31 -171.37 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.647 0 CA-C-O 121.115 0.484 . . . . 0.0 111.227 -179.166 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.1 4.57 8.11 Favored Glycine 0 CA--C 1.526 0.752 0 N-CA-C 110.835 -0.906 . . . . 0.0 110.835 179.748 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 34' ' ' LEU . . . . . 0.414 ' H ' ' C ' ' B' ' 32' ' ' ILE . 1.1 tt -75.11 135.08 41.18 Favored 'General case' 0 CA--C 1.544 0.726 0 N-CA-C 109.376 -0.601 . . . . 0.0 109.376 -179.554 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 27.1 ttt -158.24 146.63 18.77 Favored 'General case' 0 N--CA 1.472 0.628 0 N-CA-C 108.57 -0.9 . . . . 0.0 108.57 178.547 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 1.6 m -149.29 165.45 3.7 Favored 'Isoleucine or valine' 0 C--N 1.347 0.48 0 N-CA-C 108.018 -1.105 . . . . 0.0 108.018 -179.503 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 54.81 68.67 1.56 Allowed Glycine 0 C--N 1.305 -1.158 0 CA-C-N 115.354 -0.839 . . . . 0.0 112.23 177.654 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 146.95 176.89 21.09 Favored Glycine 0 N--CA 1.474 1.194 0 N-CA-C 111.106 -0.797 . . . . 0.0 111.106 178.612 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 39' ' ' VAL . . . . . 0.401 ' H ' HG11 ' E' ' 39' ' ' VAL . 34.1 m -109.68 155.22 10.92 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.698 0 C-N-CA 123.412 0.685 . . . . 0.0 110.415 -179.501 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 23.2 t . . . . . 0 C--O 1.218 -0.569 0 O-C-N 123.991 0.807 . . . . 0.0 110.331 179.552 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 62.0 m-85 . . . . . 0 N--CA 1.476 0.87 0 N-CA-C 110.179 -0.304 . . . . 0.0 110.179 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -144.38 142.27 30.24 Favored 'General case' 0 N--CA 1.482 1.139 0 N-CA-C 109.994 -0.373 . . . . 0.0 109.994 179.426 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 46.7 t-80 -152.19 118.97 5.74 Favored 'General case' 0 N--CA 1.472 0.673 0 N-CA-C 109.216 -0.661 . . . . 0.0 109.216 179.216 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 7' ' ' ASP . . . . . 0.493 ' O ' ' OG ' ' F' ' 8' ' ' SER . 4.1 m-20 -69.69 149.11 48.41 Favored 'General case' 0 N--CA 1.467 0.423 0 CA-C-N 116.356 -0.384 . . . . 0.0 110.485 179.793 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' C' C ' 8' ' ' SER . . . . . . . . . . . . . 52.3 p -167.7 -173.18 2.08 Favored 'General case' 0 N--CA 1.483 1.192 0 CA-C-O 121.018 0.437 . . . . 0.0 110.604 179.051 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.01 46.8 1.42 Allowed Glycine 0 N--CA 1.481 1.651 0 CA-C-N 115.898 -0.592 . . . . 0.0 112.201 -179.978 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 48.4 p90 -65.81 132.34 48.47 Favored 'General case' 0 N--CA 1.474 0.737 0 CA-C-O 120.699 0.285 . . . . 0.0 111.532 179.805 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 48.2 mt-10 -91.4 152.4 20.42 Favored 'General case' 0 N--CA 1.474 0.759 0 CA-C-O 121.001 0.429 . . . . 0.0 109.871 178.141 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -152.96 128.29 1.57 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.514 0 N-CA-C 107.81 -1.181 . . . . 0.0 107.81 178.193 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 42.8 m-70 -135.42 145.87 47.68 Favored 'General case' 0 N--CA 1.492 1.647 0 CA-C-N 118.939 0.79 . . . . 0.0 111.309 -179.141 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -166.74 97.19 0.55 Allowed 'General case' 0 N--CA 1.481 1.09 0 CA-C-N 116.414 -0.357 . . . . 0.0 110.571 179.481 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 14.8 pt20 -109.58 -173.68 2.32 Favored 'General case' 0 CA--C 1.504 -0.799 0 N-CA-C 108.381 -0.97 . . . . 0.0 108.381 179.884 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -163.19 98.91 0.94 Allowed 'General case' 0 N--CA 1.471 0.601 0 CA-C-N 114.695 -1.139 . . . . 0.0 108.304 178.332 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 6.6 mp -121.37 155.35 34.98 Favored 'General case' 0 N--CA 1.497 1.906 0 CA-C-O 121.846 0.832 . . . . 0.0 111.0 -178.32 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 61.0 t -111.43 127.45 68.57 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.065 0 N-CA-C 108.183 -1.043 . . . . 0.0 108.183 177.532 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 28.5 m-85 -127.28 122.52 34.07 Favored 'General case' 0 N--CA 1.494 1.747 0 CA-C-N 119.674 1.125 . . . . 0.0 110.152 179.527 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 68.0 m-85 53.57 73.98 0.34 Allowed 'General case' 0 CA--C 1.539 0.545 0 CA-C-O 121.502 0.668 . . . . 0.0 111.745 178.615 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -79.88 -78.12 0.17 Allowed 'General case' 0 C--N 1.351 0.644 0 CA-C-N 114.999 -1.001 . . . . 0.0 110.342 -179.864 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 40.9 tt0 -113.24 99.86 8.13 Favored 'General case' 0 N--CA 1.47 0.556 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 179.675 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 4.4 p30 -158.41 138.73 12.51 Favored 'General case' 0 N--CA 1.484 1.236 0 CA-C-O 119.46 -0.305 . . . . 0.0 111.23 179.112 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 62.1 t -59.55 164.23 0.8 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.87 0 N-CA-C 108.124 -1.065 . . . . 0.0 108.124 177.107 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -117.14 47.3 1.05 Allowed Glycine 0 N--CA 1.477 1.368 0 N-CA-C 111.553 -0.619 . . . . 0.0 111.553 -179.298 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -60.31 -168.11 0.01 OUTLIER 'General case' 0 N--CA 1.468 0.465 0 O-C-N 123.747 0.322 . . . . 0.0 110.335 179.301 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 25.9 t-20 -70.78 80.96 0.62 Allowed 'General case' 0 N--CA 1.465 0.317 0 N-CA-C 110.087 -0.338 . . . . 0.0 110.087 179.478 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 97.7 mttt -77.76 142.91 38.38 Favored 'General case' 0 N--CA 1.472 0.665 0 N-CA-C 109.151 -0.685 . . . . 0.0 109.151 179.32 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.51 -167.87 1.06 Allowed Glycine 0 CA--C 1.524 0.621 0 N-CA-C 109.938 -1.265 . . . . 0.0 109.938 178.826 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.5 114.84 28.06 Favored 'General case' 0 N--CA 1.477 0.894 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 179.708 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 71.5 mt -98.64 134.21 38.19 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.591 0 N-CA-C 106.98 -1.489 . . . . 0.0 106.98 178.85 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 32' ' ' ILE . . . . . 0.406 ' C ' ' H ' ' C' ' 34' ' ' LEU . 29.9 pt -150.18 -171.57 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.352 0.713 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.21 -179.217 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.2 4.81 8.86 Favored Glycine 0 CA--C 1.526 0.767 0 N-CA-C 110.795 -0.922 . . . . 0.0 110.795 179.815 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 34' ' ' LEU . . . . . 0.406 ' H ' ' C ' ' C' ' 32' ' ' ILE . 1.1 tt -75.32 135.15 40.9 Favored 'General case' 0 CA--C 1.545 0.759 0 N-CA-C 109.273 -0.639 . . . . 0.0 109.273 -179.579 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 27.3 ttt -158.41 146.4 18.35 Favored 'General case' 0 N--CA 1.471 0.585 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 178.734 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 1.6 m -149.25 165.44 3.73 Favored 'Isoleucine or valine' 0 C--N 1.348 0.506 0 N-CA-C 107.985 -1.117 . . . . 0.0 107.985 -179.476 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.08 68.56 1.62 Allowed Glycine 0 C--N 1.306 -1.13 0 CA-C-N 115.384 -0.825 . . . . 0.0 112.186 177.563 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.0 177.21 21.39 Favored Glycine 0 N--CA 1.473 1.132 0 N-CA-C 111.019 -0.832 . . . . 0.0 111.019 178.579 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 34.4 m -109.94 155.57 11.1 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.681 0 C-N-CA 123.401 0.68 . . . . 0.0 110.351 -179.523 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 23.6 t . . . . . 0 C--O 1.219 -0.514 0 O-C-N 124.021 0.826 . . . . 0.0 110.478 179.645 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 72.1 m-85 . . . . . 0 N--CA 1.474 0.748 0 N-CA-C 108.608 -0.886 . . . . 0.0 108.608 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' D' D ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -146.89 140.56 25.77 Favored 'General case' 0 N--CA 1.475 0.822 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.276 179.794 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 43.6 t-80 -149.78 123.69 9.33 Favored 'General case' 0 CA--C 1.545 0.78 0 N-CA-C 108.19 -1.041 . . . . 0.0 108.19 175.005 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 7' ' ' ASP . . . . . 0.598 ' O ' ' OG ' ' G' ' 8' ' ' SER . 2.9 m-20 -63.89 132.83 51.96 Favored 'General case' 0 C--N 1.321 -0.664 0 C-N-CA 127.068 2.147 . . . . 0.0 114.479 174.269 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' D' D ' 8' ' ' SER . . . . . 0.512 ' OG ' ' O ' ' A' ' 7' ' ' ASP . 51.9 p -154.8 -170.22 3.44 Favored 'General case' 0 N--CA 1.485 1.313 0 CA-C-N 120.046 1.294 . . . . 0.0 111.317 175.159 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.38 47.89 1.18 Allowed Glycine 0 N--CA 1.481 1.639 0 C-N-CA 124.553 1.073 . . . . 0.0 110.419 174.688 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 50.9 p90 -61.06 131.05 49.34 Favored 'General case' 0 N--CA 1.472 0.634 0 N-CA-C 112.725 0.639 . . . . 0.0 112.725 177.928 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 48.4 mt-10 -88.94 150.96 22.59 Favored 'General case' 0 N--CA 1.481 1.086 0 CA-C-N 117.961 0.346 . . . . 0.0 110.752 175.125 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -149.57 130.04 4.35 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.533 0 N-CA-C 107.518 -1.29 . . . . 0.0 107.518 173.119 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 40.9 m-70 -130.03 148.36 51.87 Favored 'General case' 0 N--CA 1.484 1.249 0 CA-C-N 118.098 0.408 . . . . 0.0 111.98 176.4 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -165.35 104.47 0.74 Allowed 'General case' 0 N--CA 1.481 1.098 0 N-CA-C 109.079 -0.711 . . . . 0.0 109.079 172.352 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 14.8 pt20 -113.36 -175.89 2.77 Favored 'General case' 0 CA--C 1.496 -1.127 0 N-CA-C 108.227 -1.027 . . . . 0.0 108.227 178.669 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -159.41 106.22 1.71 Allowed 'General case' 0 N--CA 1.468 0.444 0 N-CA-C 106.552 -1.648 . . . . 0.0 106.552 175.352 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 5.5 mp -128.01 152.87 47.4 Favored 'General case' 0 N--CA 1.499 2.008 0 CA-C-O 122.187 0.994 . . . . 0.0 110.396 179.795 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 38.4 t -101.01 131.66 48.24 Favored 'Isoleucine or valine' 0 C--O 1.258 1.518 0 CA-C-O 116.845 -1.55 . . . . 0.0 109.741 174.102 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 26.6 m-85 -130.27 126.39 37.15 Favored 'General case' 0 N--CA 1.491 1.617 0 CA-C-N 120.074 1.306 . . . . 0.0 109.417 173.61 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 68.5 m-85 55.27 71.67 0.53 Allowed 'General case' 0 C--N 1.35 0.597 0 CA-C-N 115.508 -0.769 . . . . 0.0 111.441 176.664 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -82.13 -73.21 0.4 Allowed 'General case' 0 C--N 1.353 0.721 0 CA-C-O 118.415 -0.803 . . . . 0.0 111.197 -177.693 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 41.1 tt0 -116.45 103.9 10.9 Favored 'General case' 0 N--CA 1.48 1.074 0 N-CA-C 106.434 -1.691 . . . . 0.0 106.434 176.124 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -151.82 138.5 18.79 Favored 'General case' 0 N--CA 1.477 0.896 0 CA-C-O 116.592 -1.671 . . . . 0.0 113.559 177.983 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 24' ' ' VAL . . . . . . . . . . . . . 63.5 t -62.26 166.41 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.267 0 CA-C-N 121.264 1.847 . . . . 0.0 107.964 174.961 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 25' ' ' GLY . . . . . 0.43 ' H ' ' HB ' ' G' ' 24' ' ' VAL . . . -116.78 51.04 0.75 Allowed Glycine 0 N--CA 1.479 1.556 0 CA-C-O 118.964 -0.909 . . . . 0.0 111.654 178.593 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -57.1 -170.91 0.01 OUTLIER 'General case' 0 C--N 1.322 -0.627 0 C-N-CA 123.688 0.795 . . . . 0.0 111.639 175.768 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 26.7 t-20 -72.54 86.81 1.19 Allowed 'General case' 0 C--N 1.347 0.475 0 C-N-CA 119.286 -0.965 . . . . 0.0 108.572 177.928 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 97.2 mttt -83.04 146.01 28.97 Favored 'General case' 0 N--CA 1.473 0.716 0 N-CA-C 107.948 -1.13 . . . . 0.0 107.948 179.281 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.45 -165.61 0.72 Allowed Glycine 0 C--N 1.337 0.609 0 N-CA-C 110.356 -1.098 . . . . 0.0 110.356 179.524 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -102.04 116.04 31.83 Favored 'General case' 0 N--CA 1.472 0.627 0 N-CA-C 109.36 -0.607 . . . . 0.0 109.36 179.594 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 80.8 mt -102.59 142.22 17.15 Favored 'Isoleucine or valine' 0 C--N 1.357 0.933 0 N-CA-C 104.568 -2.382 . . . . 0.0 104.568 179.979 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 30.0 pt -157.37 -172.59 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.482 1.148 0 CA-C-O 120.84 0.353 . . . . 0.0 110.189 -177.479 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 64.23 4.31 11.72 Favored Glycine 0 N--CA 1.466 0.668 0 N-CA-C 110.27 -1.132 . . . . 0.0 110.27 -178.917 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 1.3 tt -76.29 140.28 41.45 Favored 'General case' 0 CA--C 1.543 0.708 0 N-CA-C 107.797 -1.186 . . . . 0.0 107.797 -178.142 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 26.8 ttt -156.45 156.17 33.33 Favored 'General case' 0 C--O 1.244 0.782 0 N-CA-C 107.774 -1.195 . . . . 0.0 107.774 174.436 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 1.8 m -158.04 164.05 1.14 Allowed 'Isoleucine or valine' 0 CA--C 1.515 -0.399 0 N-CA-C 107.53 -1.285 . . . . 0.0 107.53 177.973 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 61.42 63.66 4.67 Favored Glycine 0 CA--C 1.526 0.742 0 C-N-CA 119.773 -1.203 . . . . 0.0 112.101 177.212 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 145.71 177.87 20.77 Favored Glycine 0 N--CA 1.478 1.469 0 CA-C-N 118.388 1.094 . . . . 0.0 111.665 179.885 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 35.2 m -112.64 152.36 14.43 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.881 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -176.89 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 23.5 t . . . . . 0 CA--C 1.522 -0.12 0 CA-C-O 116.166 -1.873 . . . . 0.0 109.597 178.315 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 63.2 m-85 . . . . . 0 N--CA 1.477 0.902 0 N-CA-C 110.27 -0.27 . . . . 0.0 110.27 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' E' E ' 5' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -143.6 142.69 31.17 Favored 'General case' 0 N--CA 1.48 1.039 0 CA-C-O 120.857 0.361 . . . . 0.0 110.163 179.356 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 45.7 t-80 -152.27 119.16 5.78 Favored 'General case' 0 N--CA 1.473 0.707 0 N-CA-C 109.194 -0.669 . . . . 0.0 109.194 179.027 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' E' E ' 7' ' ' ASP . . . . . 0.501 ' O ' ' OG ' ' H' ' 8' ' ' SER . 3.9 m-20 -70.23 149.26 47.66 Favored 'General case' 0 N--CA 1.469 0.501 0 CA-C-N 116.425 -0.352 . . . . 0.0 110.633 179.805 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' E' E ' 8' ' ' SER . . . . . 0.496 ' OG ' ' O ' ' B' ' 7' ' ' ASP . 44.5 p -168.68 -171.69 1.46 Allowed 'General case' 0 N--CA 1.484 1.234 0 CA-C-O 121.02 0.438 . . . . 0.0 110.842 178.591 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.05 47.02 1.38 Allowed Glycine 0 N--CA 1.478 1.476 0 CA-C-N 115.946 -0.57 . . . . 0.0 111.958 179.905 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 46.5 p90 -65.12 132.91 50.41 Favored 'General case' 0 N--CA 1.474 0.738 0 N-CA-C 111.881 0.326 . . . . 0.0 111.881 -179.873 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 48.9 mt-10 -91.45 152.71 20.26 Favored 'General case' 0 N--CA 1.479 0.989 0 CA-C-O 121.13 0.49 . . . . 0.0 109.75 177.885 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -154.58 127.59 1.13 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.538 0 N-CA-C 107.849 -1.167 . . . . 0.0 107.849 178.093 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 43.3 m-70 -135.89 143.97 45.3 Favored 'General case' 0 N--CA 1.482 1.135 0 CA-C-O 120.857 0.36 . . . . 0.0 111.609 -178.049 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -165.57 96.72 0.66 Allowed 'General case' 0 N--CA 1.484 1.256 0 CA-C-N 116.442 -0.345 . . . . 0.0 110.693 179.681 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 15.0 pt20 -108.71 -173.67 2.33 Favored 'General case' 0 CA--C 1.507 -0.688 0 N-CA-C 108.56 -0.904 . . . . 0.0 108.56 179.909 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -162.87 98.11 0.96 Allowed 'General case' 0 N--CA 1.477 0.903 0 CA-C-N 114.693 -1.139 . . . . 0.0 108.376 178.351 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 6.5 mp -120.07 155.48 32.87 Favored 'General case' 0 N--CA 1.495 1.78 0 CA-C-O 121.604 0.716 . . . . 0.0 111.5 -177.87 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 48.9 t -113.61 124.5 70.31 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.244 0 N-CA-C 108.249 -1.019 . . . . 0.0 108.249 177.167 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 31.3 m-85 -124.73 121.69 35.36 Favored 'General case' 0 N--CA 1.49 1.535 0 CA-C-O 120.921 0.391 . . . . 0.0 110.792 -179.769 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 70.0 m-85 54.75 73.21 0.42 Allowed 'General case' 0 N--CA 1.469 0.511 0 CA-C-N 115.969 -0.559 . . . . 0.0 111.281 178.219 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -78.39 -78.72 0.14 Allowed 'General case' 0 C--N 1.345 0.377 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.358 -179.594 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 40.4 tt0 -112.55 100.09 8.47 Favored 'General case' 0 C--N 1.325 -0.474 0 N-CA-C 108.467 -0.938 . . . . 0.0 108.467 179.758 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -157.31 138.5 13.6 Favored 'General case' 0 C--O 1.203 -1.369 0 CA-C-O 119.371 -0.347 . . . . 0.0 111.553 179.287 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' E' E ' 24' ' ' VAL . . . . . 0.407 ' HB ' ' H ' ' B' ' 25' ' ' GLY . 59.3 t -58.02 168.52 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.903 0 N-CA-C 107.663 -1.236 . . . . 0.0 107.663 176.615 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . -122.05 48.44 0.95 Allowed Glycine 0 N--CA 1.476 1.325 0 N-CA-C 110.735 -0.946 . . . . 0.0 110.735 -179.104 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -61.93 -167.41 0.01 OUTLIER 'General case' 0 N--CA 1.47 0.559 0 CA-C-O 120.729 0.3 . . . . 0.0 110.514 179.74 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 26.6 t-20 -70.34 77.33 0.55 Allowed 'General case' 0 N--CA 1.465 0.285 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.45 -179.939 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 97.8 mttt -74.69 143.55 44.16 Favored 'General case' 0 N--CA 1.474 0.765 0 N-CA-C 109.646 -0.502 . . . . 0.0 109.646 179.484 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.29 -167.44 1.29 Allowed Glycine 0 CA--C 1.522 0.496 0 N-CA-C 110.339 -1.105 . . . . 0.0 110.339 178.71 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.56 114.26 27.17 Favored 'General case' 0 N--CA 1.476 0.838 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 179.693 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 70.8 mt -98.32 134.23 37.64 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.35 0 N-CA-C 106.812 -1.551 . . . . 0.0 106.812 179.02 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' E' E ' 32' ' ' ILE . . . . . 0.411 ' C ' ' H ' ' E' ' 34' ' ' LEU . 30.9 pt -150.24 -169.8 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.149 0 CA-C-O 120.998 0.428 . . . . 0.0 110.785 -179.313 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.41 5.2 6.02 Favored Glycine 0 CA--C 1.531 1.056 0 N-CA-C 111.288 -0.725 . . . . 0.0 111.288 -179.781 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' E' E ' 34' ' ' LEU . . . . . 0.411 ' H ' ' C ' ' E' ' 32' ' ' ILE . 1.1 tt -74.88 135.64 41.52 Favored 'General case' 0 CA--C 1.547 0.86 0 N-CA-C 109.304 -0.628 . . . . 0.0 109.304 -179.597 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 26.6 ttt -158.82 145.57 17.22 Favored 'General case' 0 N--CA 1.474 0.734 0 N-CA-C 108.638 -0.875 . . . . 0.0 108.638 178.811 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 1.4 m -148.53 165.44 4.61 Favored 'Isoleucine or valine' 0 C--N 1.347 0.495 0 N-CA-C 108.388 -0.967 . . . . 0.0 108.388 -179.546 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 54.56 68.27 1.76 Allowed Glycine 0 C--N 1.308 -0.998 0 CA-C-N 115.266 -0.879 . . . . 0.0 112.1 177.573 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 146.81 174.28 18.77 Favored Glycine 0 N--CA 1.472 1.081 0 N-CA-C 111.381 -0.687 . . . . 0.0 111.381 178.685 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' E' E ' 39' ' ' VAL . . . . . 0.401 HG11 ' H ' ' B' ' 39' ' ' VAL . 33.1 m -107.58 154.97 8.47 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.768 0 C-N-CA 123.624 0.77 . . . . 0.0 110.568 -178.843 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 25.2 t . . . . . 0 C--O 1.219 -0.535 0 O-C-N 124.263 0.977 . . . . 0.0 110.263 179.802 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 63.8 m-85 . . . . . 0 N--CA 1.474 0.752 0 N-CA-C 110.199 -0.297 . . . . 0.0 110.199 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' F' F ' 5' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -143.51 143.26 31.48 Favored 'General case' 0 N--CA 1.477 0.908 0 CA-C-O 120.817 0.342 . . . . 0.0 110.195 179.318 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 46.1 t-80 -152.98 118.87 5.39 Favored 'General case' 0 N--CA 1.473 0.72 0 N-CA-C 109.275 -0.639 . . . . 0.0 109.275 179.055 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' F' F ' 7' ' ' ASP . . . . . 0.495 ' O ' ' OG ' ' I' ' 8' ' ' SER . 3.9 m-20 -70.2 149.03 47.92 Favored 'General case' 0 N--CA 1.468 0.447 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.68 179.981 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' F' F ' 8' ' ' SER . . . . . 0.493 ' OG ' ' O ' ' C' ' 7' ' ' ASP . 41.7 p -168.56 -171.74 1.5 Allowed 'General case' 0 N--CA 1.486 1.35 0 CA-C-O 121.039 0.447 . . . . 0.0 110.936 178.679 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.14 46.69 1.42 Allowed Glycine 0 N--CA 1.478 1.492 0 CA-C-N 115.951 -0.568 . . . . 0.0 111.984 179.955 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 46.3 p90 -64.65 132.74 50.57 Favored 'General case' 0 N--CA 1.474 0.734 0 O-C-N 122.623 -0.34 . . . . 0.0 111.913 -179.866 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 49.2 mt-10 -91.27 152.53 20.46 Favored 'General case' 0 N--CA 1.48 1.036 0 CA-C-O 121.158 0.504 . . . . 0.0 109.796 177.777 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -154.43 127.06 1.07 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.584 0 N-CA-C 107.828 -1.175 . . . . 0.0 107.828 178.13 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 42.0 m-70 -135.47 143.86 46.09 Favored 'General case' 0 N--CA 1.485 1.279 0 CA-C-O 120.849 0.357 . . . . 0.0 111.558 -178.045 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -165.32 97.11 0.69 Allowed 'General case' 0 N--CA 1.483 1.221 0 CA-C-N 116.43 -0.35 . . . . 0.0 110.771 179.754 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 15.0 pt20 -109.48 -174.17 2.44 Favored 'General case' 0 CA--C 1.503 -0.851 0 N-CA-C 108.629 -0.878 . . . . 0.0 108.629 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -162.22 98.46 1.04 Allowed 'General case' 0 N--CA 1.474 0.734 0 CA-C-N 114.694 -1.139 . . . . 0.0 108.401 178.384 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 6.4 mp -120.36 155.28 33.7 Favored 'General case' 0 N--CA 1.494 1.757 0 CA-C-O 121.532 0.682 . . . . 0.0 111.518 -177.854 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 50.2 t -113.41 124.2 69.81 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.246 0 N-CA-C 108.341 -0.985 . . . . 0.0 108.341 177.257 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 31.2 m-85 -124.56 121.58 35.18 Favored 'General case' 0 N--CA 1.489 1.49 0 CA-C-O 120.91 0.386 . . . . 0.0 110.796 -179.846 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 69.0 m-85 54.79 73.79 0.39 Allowed 'General case' 0 N--CA 1.468 0.437 0 CA-C-N 115.938 -0.574 . . . . 0.0 111.464 178.399 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -78.98 -78.31 0.15 Allowed 'General case' 0 C--N 1.344 0.359 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.537 -179.607 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 40.8 tt0 -112.76 100.09 8.42 Favored 'General case' 0 C--N 1.325 -0.471 0 N-CA-C 108.341 -0.985 . . . . 0.0 108.341 179.664 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -157.53 138.65 13.49 Favored 'General case' 0 C--O 1.205 -1.243 0 CA-C-O 119.422 -0.323 . . . . 0.0 111.532 179.282 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' F' F ' 24' ' ' VAL . . . . . . . . . . . . . 59.6 t -58.46 168.35 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.94 0 N-CA-C 107.646 -1.242 . . . . 0.0 107.646 176.757 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -121.73 48.07 0.98 Allowed Glycine 0 N--CA 1.477 1.418 0 N-CA-C 110.789 -0.924 . . . . 0.0 110.789 -179.163 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -61.62 -167.05 0.01 OUTLIER 'General case' 0 N--CA 1.469 0.481 0 CA-C-N 116.768 0.284 . . . . 0.0 110.453 179.771 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 26.7 t-20 -70.67 76.84 0.6 Allowed 'General case' 0 N--CA 1.466 0.367 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.441 -179.881 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -74.01 143.86 45.38 Favored 'General case' 0 N--CA 1.473 0.709 0 N-CA-C 109.691 -0.485 . . . . 0.0 109.691 179.242 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.57 -167.19 1.34 Allowed Glycine 0 CA--C 1.522 0.517 0 N-CA-C 110.426 -1.07 . . . . 0.0 110.426 178.712 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.6 113.81 26.47 Favored 'General case' 0 N--CA 1.472 0.662 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.837 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 72.0 mt -98.09 134.54 36.08 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.372 0 N-CA-C 106.84 -1.541 . . . . 0.0 106.84 179.038 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' F' F ' 32' ' ' ILE . . . . . 0.411 ' C ' ' H ' ' F' ' 34' ' ' LEU . 31.8 pt -150.47 -169.83 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.118 0 CA-C-O 121.052 0.453 . . . . 0.0 110.751 -179.409 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.64 4.9 5.95 Favored Glycine 0 CA--C 1.53 1.015 0 N-CA-C 111.261 -0.736 . . . . 0.0 111.261 -179.87 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' F' F ' 34' ' ' LEU . . . . . 0.411 ' H ' ' C ' ' F' ' 32' ' ' ILE . 1.1 tt -74.77 135.82 41.72 Favored 'General case' 0 CA--C 1.546 0.822 0 N-CA-C 109.241 -0.652 . . . . 0.0 109.241 -179.612 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 26.5 ttt -158.89 145.86 17.3 Favored 'General case' 0 N--CA 1.473 0.686 0 N-CA-C 108.494 -0.928 . . . . 0.0 108.494 178.804 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 1.5 m -148.72 165.33 4.38 Favored 'Isoleucine or valine' 0 C--N 1.348 0.537 0 N-CA-C 108.366 -0.976 . . . . 0.0 108.366 -179.449 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 54.33 68.61 1.58 Allowed Glycine 0 C--N 1.308 -1.021 0 CA-C-N 115.307 -0.861 . . . . 0.0 112.113 177.634 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 146.6 174.07 18.39 Favored Glycine 0 N--CA 1.473 1.118 0 N-CA-C 111.355 -0.698 . . . . 0.0 111.355 178.722 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 33.0 m -107.42 155.0 8.27 Favored 'Isoleucine or valine' 0 C--N 1.352 0.696 0 C-N-CA 123.528 0.731 . . . . 0.0 110.604 -178.773 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 25.9 t . . . . . 0 C--O 1.219 -0.543 0 O-C-N 124.365 1.041 . . . . 0.0 110.356 179.892 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 64.8 m-85 . . . . . 0 N--CA 1.475 0.785 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' G' G ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -144.09 142.09 30.42 Favored 'General case' 0 N--CA 1.481 1.091 0 CA-C-O 120.823 0.345 . . . . 0.0 110.205 179.726 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 46.8 t-80 -151.69 119.59 6.2 Favored 'General case' 0 N--CA 1.473 0.676 0 N-CA-C 109.46 -0.57 . . . . 0.0 109.46 179.016 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 4.1 m-20 -71.94 144.41 48.94 Favored 'General case' 0 N--CA 1.471 0.603 0 C-N-CA 122.763 0.425 . . . . 0.0 111.154 -179.833 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' G' G ' 8' ' ' SER . . . . . 0.598 ' OG ' ' O ' ' D' ' 7' ' ' ASP . 37.5 p -164.69 -169.24 1.68 Allowed 'General case' 0 N--CA 1.476 0.86 0 CA-C-O 121.049 0.452 . . . . 0.0 110.496 178.535 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 101.95 47.59 1.46 Allowed Glycine 0 N--CA 1.478 1.488 0 N-CA-C 111.529 -0.628 . . . . 0.0 111.529 179.553 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 48.6 p90 -65.93 132.71 49.27 Favored 'General case' 0 N--CA 1.473 0.692 0 N-CA-C 111.803 0.297 . . . . 0.0 111.803 -179.688 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 48.4 mt-10 -91.5 152.03 20.51 Favored 'General case' 0 N--CA 1.479 1.018 0 CA-C-O 121.043 0.449 . . . . 0.0 110.163 178.374 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -154.96 127.81 1.1 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.008 0 N-CA-C 107.864 -1.161 . . . . 0.0 107.864 178.221 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 44.9 m-70 -135.25 144.83 47.07 Favored 'General case' 0 N--CA 1.477 0.922 0 CA-C-N 115.702 -0.681 . . . . 0.0 111.407 -178.259 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -166.52 96.85 0.57 Allowed 'General case' 0 N--CA 1.483 1.181 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.288 179.132 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 15.0 pt20 -109.11 -173.75 2.34 Favored 'General case' 0 CA--C 1.503 -0.831 0 N-CA-C 108.391 -0.966 . . . . 0.0 108.391 179.88 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -163.15 98.03 0.93 Allowed 'General case' 0 N--CA 1.474 0.747 0 CA-C-N 114.701 -1.136 . . . . 0.0 108.132 178.558 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 6.4 mp -120.06 154.29 34.85 Favored 'General case' 0 N--CA 1.496 1.86 0 CA-C-O 121.204 0.526 . . . . 0.0 111.793 -177.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 44.5 t -112.83 125.39 70.09 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.968 0 CA-C-N 114.898 -1.046 . . . . 0.0 108.19 176.548 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 32.2 m-85 -125.88 121.15 32.38 Favored 'General case' 0 C--N 1.366 1.315 0 C-N-CA 123.39 0.676 . . . . 0.0 110.853 -179.532 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 69.3 m-85 55.13 72.76 0.45 Allowed 'General case' 0 N--CA 1.469 0.521 0 CA-C-N 115.882 -0.599 . . . . 0.0 111.292 178.24 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.67 -78.26 0.14 Allowed 'General case' 0 N--CA 1.471 0.583 0 O-C-N 122.244 -0.285 . . . . 0.0 110.55 -179.189 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 41.3 tt0 -112.57 100.43 8.73 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 108.124 -1.065 . . . . 0.0 108.124 179.646 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -157.86 139.78 14.08 Favored 'General case' 0 N--CA 1.478 0.949 0 N-CA-C 111.516 0.191 . . . . 0.0 111.516 179.153 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' G' G ' 24' ' ' VAL . . . . . 0.43 ' HB ' ' H ' ' D' ' 25' ' ' GLY . 61.4 t -59.96 167.25 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.624 0 N-CA-C 107.669 -1.234 . . . . 0.0 107.669 177.268 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -120.35 49.68 0.87 Allowed Glycine 0 N--CA 1.482 1.718 0 N-CA-C 110.313 -1.115 . . . . 0.0 110.313 -179.453 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -63.56 -167.51 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.658 0 CA-C-N 117.001 0.401 . . . . 0.0 109.953 179.484 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 26.6 t-20 -70.11 76.69 0.51 Allowed 'General case' 0 CA--C 1.535 0.386 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.478 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 97.9 mttt -73.36 143.92 46.66 Favored 'General case' 0 N--CA 1.474 0.77 0 N-CA-C 109.701 -0.481 . . . . 0.0 109.701 179.209 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.64 -166.08 1.14 Allowed Glycine 0 C--N 1.337 0.593 0 N-CA-C 110.069 -1.212 . . . . 0.0 110.069 178.723 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.82 113.93 26.76 Favored 'General case' 0 N--CA 1.47 0.541 0 C-N-CA 122.723 0.409 . . . . 0.0 110.393 179.897 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 74.7 mt -98.61 134.77 36.05 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.773 0 N-CA-C 106.784 -1.562 . . . . 0.0 106.784 179.03 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' G' G ' 32' ' ' ILE . . . . . 0.417 ' C ' ' H ' ' G' ' 34' ' ' LEU . 34.6 pt -151.11 -169.38 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 CA-C-N 119.657 1.117 . . . . 0.0 109.917 -179.826 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.18 4.79 6.71 Favored Glycine 0 CA--C 1.529 0.926 0 N-CA-C 111.052 -0.819 . . . . 0.0 111.052 179.933 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' G' G ' 34' ' ' LEU . . . . . 0.417 ' H ' ' C ' ' G' ' 32' ' ' ILE . 1.1 tt -74.95 135.74 41.38 Favored 'General case' 0 CA--C 1.544 0.745 0 N-CA-C 109.209 -0.663 . . . . 0.0 109.209 -179.635 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 25.3 ttt -158.86 146.06 17.48 Favored 'General case' 0 N--CA 1.47 0.533 0 N-CA-C 108.695 -0.854 . . . . 0.0 108.695 178.801 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 1.4 m -148.8 163.89 4.72 Favored 'Isoleucine or valine' 0 C--N 1.349 0.566 0 N-CA-C 108.509 -0.922 . . . . 0.0 108.509 -179.293 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.13 68.67 1.57 Allowed Glycine 0 C--N 1.308 -0.997 0 CA-C-N 115.305 -0.862 . . . . 0.0 112.207 177.39 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.33 173.16 18.22 Favored Glycine 0 N--CA 1.475 1.274 0 N-CA-C 110.599 -1.0 . . . . 0.0 110.599 178.934 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 34.1 m -106.88 155.11 7.64 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.873 0 C-N-CA 123.222 0.609 . . . . 0.0 110.668 -179.346 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 25.8 t . . . . . 0 C--O 1.219 -0.532 0 O-C-N 124.035 0.835 . . . . 0.0 110.622 179.721 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 64.4 m-85 . . . . . 0 N--CA 1.473 0.712 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' H' H ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -143.72 142.71 31.07 Favored 'General case' 0 N--CA 1.482 1.133 0 C-N-CA 122.592 0.357 . . . . 0.0 110.1 179.712 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 47.7 t-80 -152.2 119.6 5.98 Favored 'General case' 0 N--CA 1.475 0.788 0 N-CA-C 109.326 -0.62 . . . . 0.0 109.326 178.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -71.57 144.44 49.54 Favored 'General case' 0 N--CA 1.469 0.497 0 C-N-CA 122.767 0.427 . . . . 0.0 111.164 179.89 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' H' H ' 8' ' ' SER . . . . . 0.501 ' OG ' ' O ' ' E' ' 7' ' ' ASP . 52.5 p -164.9 -170.37 1.94 Allowed 'General case' 0 N--CA 1.474 0.754 0 CA-C-O 120.935 0.398 . . . . 0.0 110.48 178.504 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.87 47.17 1.39 Allowed Glycine 0 N--CA 1.48 1.587 0 CA-C-N 115.971 -0.559 . . . . 0.0 111.709 179.604 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 48.2 p90 -65.61 132.67 49.41 Favored 'General case' 0 N--CA 1.473 0.707 0 N-CA-C 111.863 0.32 . . . . 0.0 111.863 -179.69 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 48.4 mt-10 -91.33 151.64 20.79 Favored 'General case' 0 N--CA 1.478 0.951 0 CA-C-O 121.036 0.446 . . . . 0.0 110.257 178.275 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -154.77 127.8 1.13 Allowed 'Isoleucine or valine' 0 CA--C 1.553 1.087 0 N-CA-C 107.815 -1.18 . . . . 0.0 107.815 178.286 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 45.0 m-70 -135.29 145.23 47.32 Favored 'General case' 0 N--CA 1.478 0.956 0 CA-C-N 115.596 -0.729 . . . . 0.0 111.373 -178.303 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -166.92 97.0 0.53 Allowed 'General case' 0 N--CA 1.481 1.116 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.312 179.151 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 15.1 pt20 -109.09 -173.43 2.26 Favored 'General case' 0 CA--C 1.505 -0.771 0 N-CA-C 108.417 -0.957 . . . . 0.0 108.417 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -163.5 97.98 0.89 Allowed 'General case' 0 N--CA 1.474 0.754 0 CA-C-N 114.718 -1.128 . . . . 0.0 108.1 178.565 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 6.4 mp -120.12 154.4 34.77 Favored 'General case' 0 N--CA 1.497 1.885 0 CA-C-O 121.263 0.554 . . . . 0.0 111.881 -177.981 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 43.9 t -113.02 124.79 70.01 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.978 0 CA-C-N 114.936 -1.029 . . . . 0.0 108.292 176.604 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 32.4 m-85 -125.17 121.16 33.39 Favored 'General case' 0 C--N 1.366 1.316 0 CA-C-N 115.56 -0.745 . . . . 0.0 110.735 -179.425 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 68.7 m-85 54.78 72.83 0.44 Allowed 'General case' 0 C--O 1.237 0.407 0 CA-C-N 115.868 -0.605 . . . . 0.0 111.425 178.173 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.31 -78.43 0.13 Allowed 'General case' 0 N--CA 1.469 0.522 0 O-C-N 122.229 -0.294 . . . . 0.0 110.591 -179.379 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 40.9 tt0 -112.62 100.34 8.65 Favored 'General case' 0 C--N 1.322 -0.589 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 179.792 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -157.6 139.47 14.12 Favored 'General case' 0 N--CA 1.477 0.909 0 O-C-N 122.403 -0.186 . . . . 0.0 111.498 179.272 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' H' H ' 24' ' ' VAL . . . . . . . . . . . . . 62.0 t -59.73 167.4 0.56 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.521 0 N-CA-C 107.722 -1.214 . . . . 0.0 107.722 177.182 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . -120.32 49.12 0.9 Allowed Glycine 0 N--CA 1.48 1.572 0 N-CA-C 110.491 -1.043 . . . . 0.0 110.491 -179.314 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -63.23 -166.99 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.675 0 CA-C-N 116.972 0.386 . . . . 0.0 110.092 179.748 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 26.6 t-20 -70.63 76.46 0.59 Allowed 'General case' 0 CA--C 1.535 0.374 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.492 -179.85 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -73.44 143.88 46.53 Favored 'General case' 0 N--CA 1.473 0.685 0 N-CA-C 109.629 -0.508 . . . . 0.0 109.629 179.341 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -65.17 -166.14 1.37 Allowed Glycine 0 C--N 1.337 0.634 0 N-CA-C 109.936 -1.266 . . . . 0.0 109.936 178.889 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.44 114.28 27.12 Favored 'General case' 0 N--CA 1.467 0.408 0 C-N-CA 122.573 0.349 . . . . 0.0 110.617 179.85 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 74.5 mt -98.73 134.73 36.41 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.751 0 N-CA-C 106.8 -1.556 . . . . 0.0 106.8 178.974 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' H' H ' 32' ' ' ILE . . . . . 0.416 ' C ' ' H ' ' H' ' 34' ' ' LEU . 34.2 pt -151.05 -169.24 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.687 0 CA-C-N 119.747 1.158 . . . . 0.0 109.917 -179.93 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.24 4.8 6.81 Favored Glycine 0 CA--C 1.529 0.919 0 N-CA-C 110.95 -0.86 . . . . 0.0 110.95 179.914 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' H' H ' 34' ' ' LEU . . . . . 0.416 ' H ' ' C ' ' H' ' 32' ' ' ILE . 1.1 tt -75.35 135.25 40.85 Favored 'General case' 0 CA--C 1.546 0.792 0 N-CA-C 109.412 -0.588 . . . . 0.0 109.412 -179.414 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 25.2 ttt -158.52 146.15 18.03 Favored 'General case' 0 N--CA 1.472 0.641 0 N-CA-C 108.694 -0.854 . . . . 0.0 108.694 179.065 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 1.5 m -149.08 163.84 4.35 Favored 'Isoleucine or valine' 0 C--N 1.348 0.522 0 N-CA-C 108.449 -0.945 . . . . 0.0 108.449 -179.283 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.35 68.39 1.71 Allowed Glycine 0 C--N 1.309 -0.971 0 CA-C-N 115.16 -0.927 . . . . 0.0 112.064 177.451 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.27 172.35 17.37 Favored Glycine 0 N--CA 1.476 1.307 0 N-CA-C 110.639 -0.985 . . . . 0.0 110.639 178.959 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 33.8 m -106.1 154.93 7.13 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.927 0 C-N-CA 123.199 0.6 . . . . 0.0 110.715 -179.475 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 24.7 t . . . . . 0 C--O 1.219 -0.53 0 O-C-N 124.001 0.813 . . . . 0.0 110.709 179.699 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 66.3 m-85 . . . . . 0 N--CA 1.474 0.745 0 N-CA-C 109.736 -0.468 . . . . 0.0 109.736 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' I' I ' 5' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -144.13 142.47 30.6 Favored 'General case' 0 N--CA 1.484 1.23 0 C-N-CA 122.639 0.376 . . . . 0.0 110.194 179.81 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 47.6 t-80 -152.14 120.12 6.21 Favored 'General case' 0 N--CA 1.474 0.738 0 N-CA-C 109.361 -0.607 . . . . 0.0 109.361 179.007 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -72.32 144.16 48.41 Favored 'General case' 0 N--CA 1.471 0.605 0 C-N-CA 122.725 0.41 . . . . 0.0 111.084 -179.945 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' I' I ' 8' ' ' SER . . . . . 0.495 ' OG ' ' O ' ' F' ' 7' ' ' ASP . 50.8 p -164.73 -170.39 1.98 Allowed 'General case' 0 N--CA 1.475 0.782 0 CA-C-O 120.996 0.427 . . . . 0.0 110.488 178.586 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.82 47.47 1.36 Allowed Glycine 0 N--CA 1.48 1.628 0 N-CA-C 111.629 -0.589 . . . . 0.0 111.629 179.675 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 47.9 p90 -65.92 133.2 50.38 Favored 'General case' 0 N--CA 1.473 0.677 0 CA-C-O 120.803 0.335 . . . . 0.0 111.872 -179.649 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 48.4 mt-10 -91.77 151.7 20.49 Favored 'General case' 0 N--CA 1.478 0.95 0 CA-C-O 120.932 0.396 . . . . 0.0 110.311 178.348 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -154.99 126.92 0.96 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.057 0 N-CA-C 107.909 -1.145 . . . . 0.0 107.909 178.365 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 42.4 m-70 -134.52 144.88 48.27 Favored 'General case' 0 N--CA 1.478 0.967 0 CA-C-N 115.606 -0.724 . . . . 0.0 111.451 -178.382 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -166.43 97.09 0.58 Allowed 'General case' 0 N--CA 1.48 1.056 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.348 179.119 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 15.2 pt20 -109.3 -173.88 2.37 Favored 'General case' 0 CA--C 1.504 -0.797 0 N-CA-C 108.481 -0.933 . . . . 0.0 108.481 -179.99 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -163.08 98.11 0.93 Allowed 'General case' 0 N--CA 1.473 0.715 0 CA-C-N 114.701 -1.136 . . . . 0.0 108.07 178.514 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 6.4 mp -120.2 154.37 34.94 Favored 'General case' 0 N--CA 1.497 1.907 0 CA-C-O 121.24 0.543 . . . . 0.0 111.769 -177.91 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 44.8 t -113.0 125.07 70.2 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.028 0 CA-C-N 114.857 -1.065 . . . . 0.0 108.157 176.646 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 32.9 m-85 -125.57 121.11 32.69 Favored 'General case' 0 C--N 1.367 1.339 0 CA-C-N 115.582 -0.735 . . . . 0.0 110.815 -179.536 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 68.6 m-85 54.9 73.26 0.42 Allowed 'General case' 0 N--CA 1.469 0.51 0 CA-C-N 115.927 -0.579 . . . . 0.0 111.262 178.301 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.99 -78.01 0.15 Allowed 'General case' 0 N--CA 1.472 0.639 0 O-C-N 122.205 -0.309 . . . . 0.0 110.601 -179.268 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 40.9 tt0 -112.84 100.32 8.58 Favored 'General case' 0 C--N 1.323 -0.586 0 N-CA-C 108.088 -1.078 . . . . 0.0 108.088 179.614 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -157.71 139.26 13.8 Favored 'General case' 0 N--CA 1.479 0.983 0 O-C-N 122.344 -0.223 . . . . 0.0 111.433 179.396 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' I' I ' 24' ' ' VAL . . . . . . . . . . . . . 62.0 t -59.48 167.26 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.54 0 N-CA-C 107.847 -1.168 . . . . 0.0 107.847 177.016 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . -120.43 49.52 0.87 Allowed Glycine 0 N--CA 1.482 1.725 0 N-CA-C 110.411 -1.076 . . . . 0.0 110.411 -179.384 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -63.42 -166.9 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.656 0 CA-C-N 116.985 0.393 . . . . 0.0 110.064 179.59 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 26.8 t-20 -70.68 76.71 0.6 Allowed 'General case' 0 N--CA 1.466 0.358 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.35 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 97.8 mttt -73.66 143.62 46.18 Favored 'General case' 0 N--CA 1.474 0.772 0 N-CA-C 109.64 -0.504 . . . . 0.0 109.64 179.284 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.59 -166.08 1.13 Allowed Glycine 0 C--N 1.339 0.703 0 N-CA-C 110.02 -1.232 . . . . 0.0 110.02 178.88 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.53 113.86 26.51 Favored 'General case' 0 N--CA 1.469 0.495 0 C-N-CA 122.691 0.396 . . . . 0.0 110.45 179.877 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 74.2 mt -98.37 135.04 34.66 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.836 0 N-CA-C 106.745 -1.576 . . . . 0.0 106.745 178.849 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' I' I ' 32' ' ' ILE . . . . . 0.417 ' C ' ' H ' ' I' ' 34' ' ' LEU . 33.6 pt -151.38 -169.3 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 CA-C-N 119.698 1.135 . . . . 0.0 109.965 -179.987 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.22 4.71 6.68 Favored Glycine 0 CA--C 1.528 0.897 0 N-CA-C 110.952 -0.859 . . . . 0.0 110.952 179.962 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' I' I ' 34' ' ' LEU . . . . . 0.417 ' H ' ' C ' ' I' ' 32' ' ' ILE . 1.1 tt -74.85 135.29 41.58 Favored 'General case' 0 CA--C 1.544 0.738 0 N-CA-C 109.318 -0.623 . . . . 0.0 109.318 -179.602 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 25.4 ttt -158.44 146.06 18.08 Favored 'General case' 0 N--CA 1.471 0.602 0 N-CA-C 108.53 -0.915 . . . . 0.0 108.53 178.982 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 1.4 m -149.02 163.78 4.41 Favored 'Isoleucine or valine' 0 C--N 1.35 0.616 0 N-CA-C 108.519 -0.919 . . . . 0.0 108.519 -179.401 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.08 68.5 1.65 Allowed Glycine 0 C--N 1.308 -0.991 0 CA-C-N 115.253 -0.885 . . . . 0.0 112.143 177.492 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.45 172.31 17.46 Favored Glycine 0 N--CA 1.474 1.224 0 N-CA-C 110.682 -0.967 . . . . 0.0 110.682 178.982 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 33.9 m -106.15 154.81 7.2 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.915 0 C-N-CA 123.236 0.614 . . . . 0.0 110.663 -179.467 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 25.3 t . . . . . 0 C--O 1.219 -0.524 0 O-C-N 124.06 0.85 . . . . 0.0 110.612 179.621 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 42.0 m-85 . . . . . 0 N--CA 1.474 0.747 0 N-CA-C 110.118 -0.327 . . . . 0.0 110.118 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -143.45 140.62 30.47 Favored 'General case' 0 N--CA 1.481 1.085 0 CA-C-O 120.887 0.375 . . . . 0.0 110.03 179.711 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 42.3 t-80 -151.79 119.39 6.07 Favored 'General case' 0 N--CA 1.47 0.528 0 N-CA-C 109.231 -0.655 . . . . 0.0 109.231 179.176 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' ASP . . . . . 0.516 ' O ' ' OG ' ' D' ' 8' ' ' SER . 4.4 m-20 -68.98 148.77 49.65 Favored 'General case' 0 CA--C 1.537 0.471 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.516 179.816 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' SER . . . . . 0.535 ' H ' ' HG ' ' C' ' 26' ' ' SER . 53.2 p -167.58 -173.5 2.21 Favored 'General case' 0 N--CA 1.483 1.184 0 CA-C-O 121.054 0.454 . . . . 0.0 110.721 179.392 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.62 47.67 1.37 Allowed Glycine 0 N--CA 1.482 1.705 0 CA-C-N 115.966 -0.561 . . . . 0.0 112.08 179.785 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 48.7 p90 -65.86 132.72 49.35 Favored 'General case' 0 N--CA 1.474 0.735 0 O-C-N 122.755 -0.262 . . . . 0.0 111.496 179.712 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 46.0 mt-10 -92.17 152.08 20.06 Favored 'General case' 0 N--CA 1.479 0.986 0 N-CA-C 109.725 -0.472 . . . . 0.0 109.725 178.512 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.0 p -152.89 128.25 1.59 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.612 0 N-CA-C 107.868 -1.16 . . . . 0.0 107.868 178.238 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 47.2 m-70 -135.41 147.8 49.12 Favored 'General case' 0 N--CA 1.493 1.708 0 CA-C-N 119.044 0.838 . . . . 0.0 111.398 -179.013 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 6.4 t60 -165.1 97.02 0.72 Allowed 'General case' 0 N--CA 1.48 1.064 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.624 179.342 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 3.9 pt20 -101.54 -174.16 2.53 Favored 'General case' 0 CA--C 1.507 -0.704 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 -179.82 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -169.9 95.81 0.28 Allowed 'General case' 0 N--CA 1.47 0.53 0 CA-C-N 114.608 -1.178 . . . . 0.0 108.389 178.38 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 6.5 mp -123.36 156.97 34.35 Favored 'General case' 0 N--CA 1.497 1.917 0 CA-C-O 121.794 0.807 . . . . 0.0 111.005 -178.14 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 60.1 t -111.79 126.86 69.22 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.135 0 CA-C-O 117.938 -1.029 . . . . 0.0 108.269 177.608 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 27.1 m-85 -126.89 123.09 36.44 Favored 'General case' 0 N--CA 1.497 1.912 0 CA-C-N 120.13 1.332 . . . . 0.0 110.474 179.5 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 67.9 m-85 53.66 74.71 0.3 Allowed 'General case' 0 CA--C 1.538 0.489 0 CA-C-O 121.414 0.626 . . . . 0.0 111.813 178.634 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -80.0 -78.28 0.17 Allowed 'General case' 0 C--N 1.353 0.727 0 CA-C-N 115.084 -0.962 . . . . 0.0 110.192 -179.922 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 38.2 tt0 -113.39 100.74 8.77 Favored 'General case' 0 N--CA 1.469 0.486 0 N-CA-C 108.191 -1.04 . . . . 0.0 108.191 179.725 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 4.4 p30 -159.18 139.79 12.43 Favored 'General case' 0 N--CA 1.483 1.178 0 O-C-N 122.31 -0.243 . . . . 0.0 111.219 179.147 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 61.2 t -59.97 163.43 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.819 0 N-CA-C 108.104 -1.073 . . . . 0.0 108.104 177.106 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.403 ' H ' ' HB ' ' D' ' 24' ' ' VAL . . . -117.3 48.61 0.92 Allowed Glycine 0 N--CA 1.475 1.252 0 N-CA-C 111.755 -0.538 . . . . 0.0 111.755 -179.402 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' SER . . . . . 0.491 ' HG ' ' H ' ' B' ' 8' ' ' SER . 0.3 OUTLIER -61.73 -167.83 0.01 OUTLIER 'General case' 0 N--CA 1.468 0.45 0 O-C-N 123.843 0.378 . . . . 0.0 110.412 179.522 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 25.1 t-20 -71.06 80.4 0.67 Allowed 'General case' 0 N--CA 1.465 0.284 0 CA-C-N 116.492 -0.322 . . . . 0.0 110.176 179.557 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -77.85 143.76 37.55 Favored 'General case' 0 N--CA 1.473 0.704 0 N-CA-C 109.141 -0.689 . . . . 0.0 109.141 179.332 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.38 -167.51 0.94 Allowed Glycine 0 CA--C 1.525 0.664 0 N-CA-C 109.863 -1.295 . . . . 0.0 109.863 178.629 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.8 114.61 27.88 Favored 'General case' 0 N--CA 1.48 1.038 0 N-CA-C 109.696 -0.483 . . . . 0.0 109.696 179.839 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 64.9 mt -98.41 135.78 31.88 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.552 0 N-CA-C 107.078 -1.453 . . . . 0.0 107.078 178.982 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . 0.418 ' C ' ' H ' ' A' ' 34' ' ' LEU . 34.1 pt -152.31 -176.14 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.734 0 CA-C-O 121.168 0.508 . . . . 0.0 111.18 -179.164 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.62 4.39 9.73 Favored Glycine 0 CA--C 1.524 0.597 0 N-CA-C 110.976 -0.85 . . . . 0.0 110.976 179.758 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . 0.418 ' H ' ' C ' ' A' ' 32' ' ' ILE . 1.6 tt -74.28 127.18 32.33 Favored 'General case' 0 CA--C 1.545 0.767 0 N-CA-C 109.499 -0.556 . . . . 0.0 109.499 -179.604 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 28.5 ttt -163.75 149.81 11.43 Favored 'General case' 0 N--CA 1.465 0.279 0 N-CA-C 108.963 -0.755 . . . . 0.0 108.963 178.782 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 27.5 m -155.22 166.33 1.07 Allowed 'Isoleucine or valine' 0 C--N 1.347 0.482 0 N-CA-C 108.061 -1.088 . . . . 0.0 108.061 179.686 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.1 67.2 2.33 Favored Glycine 0 C--N 1.307 -1.045 0 CA-C-N 115.776 -0.647 . . . . 0.0 112.102 178.422 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.96 -173.23 24.85 Favored Glycine 0 N--CA 1.474 1.195 0 N-CA-C 110.85 -0.9 . . . . 0.0 110.85 179.089 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . 0.474 ' H ' HG11 ' D' ' 39' ' ' VAL . 34.5 m -125.56 156.34 35.03 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.774 0 C-N-CA 123.393 0.677 . . . . 0.0 110.232 -179.645 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 27.1 t . . . . . 0 C--O 1.218 -0.589 0 CA-C-O 118.433 -0.794 . . . . 0.0 110.622 179.853 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 38.9 m-85 . . . . . 0 N--CA 1.473 0.715 0 N-CA-C 110.13 -0.322 . . . . 0.0 110.13 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -143.06 140.44 30.94 Favored 'General case' 0 N--CA 1.483 1.198 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 179.574 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 41.9 t-80 -151.65 119.03 5.98 Favored 'General case' 0 N--CA 1.473 0.692 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 179.001 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 7' ' ' ASP . . . . . 0.494 ' O ' ' OG ' ' E' ' 8' ' ' SER . 4.3 m-20 -68.68 148.55 50.25 Favored 'General case' 0 CA--C 1.537 0.47 0 CA-C-N 116.343 -0.389 . . . . 0.0 110.677 179.907 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 8' ' ' SER . . . . . 0.491 ' H ' ' HG ' ' A' ' 26' ' ' SER . 53.8 p -167.59 -173.53 2.22 Favored 'General case' 0 N--CA 1.482 1.136 0 CA-C-O 120.966 0.412 . . . . 0.0 110.745 179.418 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.92 47.14 1.39 Allowed Glycine 0 N--CA 1.481 1.686 0 CA-C-N 115.985 -0.552 . . . . 0.0 112.126 179.758 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 48.8 p90 -65.57 132.88 49.96 Favored 'General case' 0 N--CA 1.472 0.644 0 CA-C-O 120.665 0.269 . . . . 0.0 111.562 179.819 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 45.3 mt-10 -92.14 152.22 20.01 Favored 'General case' 0 N--CA 1.475 0.824 0 C-N-CA 122.847 0.459 . . . . 0.0 109.816 178.475 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -153.15 128.13 1.5 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.547 0 N-CA-C 107.854 -1.165 . . . . 0.0 107.854 178.266 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 46.9 m-70 -135.46 147.71 49.0 Favored 'General case' 0 N--CA 1.492 1.65 0 CA-C-N 118.915 0.78 . . . . 0.0 111.379 -178.882 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 6.5 t60 -165.14 97.01 0.71 Allowed 'General case' 0 N--CA 1.48 1.052 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.604 179.345 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 3.9 pt20 -101.51 -173.83 2.45 Favored 'General case' 0 CA--C 1.508 -0.638 0 N-CA-C 108.691 -0.855 . . . . 0.0 108.691 -179.764 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -170.22 95.82 0.25 Allowed 'General case' 0 N--CA 1.471 0.575 0 CA-C-N 114.727 -1.124 . . . . 0.0 108.321 178.324 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 6.5 mp -123.15 157.32 33.23 Favored 'General case' 0 N--CA 1.497 1.878 0 CA-C-O 121.73 0.776 . . . . 0.0 110.999 -178.134 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 60.9 t -112.37 127.65 69.46 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.098 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 177.44 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 27.0 m-85 -127.62 123.0 34.6 Favored 'General case' 0 N--CA 1.494 1.753 0 CA-C-N 119.707 1.14 . . . . 0.0 110.302 179.681 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 67.9 m-85 53.27 74.81 0.28 Allowed 'General case' 0 CA--C 1.537 0.476 0 CA-C-O 121.535 0.683 . . . . 0.0 111.919 178.475 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -80.48 -77.93 0.18 Allowed 'General case' 0 C--N 1.352 0.681 0 CA-C-N 115.004 -0.998 . . . . 0.0 110.218 -179.879 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 38.3 tt0 -113.53 100.45 8.52 Favored 'General case' 0 N--CA 1.47 0.565 0 N-CA-C 108.317 -0.994 . . . . 0.0 108.317 179.695 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -158.85 140.17 13.17 Favored 'General case' 0 N--CA 1.483 1.193 0 O-C-N 122.179 -0.326 . . . . 0.0 111.146 179.19 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 61.6 t -60.1 163.63 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.894 0 N-CA-C 108.121 -1.066 . . . . 0.0 108.121 177.072 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 25' ' ' GLY . . . . . 0.406 ' H ' ' HB ' ' E' ' 24' ' ' VAL . . . -117.23 48.32 0.95 Allowed Glycine 0 N--CA 1.476 1.309 0 N-CA-C 111.657 -0.577 . . . . 0.0 111.657 -179.353 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 26' ' ' SER . . . . . 0.486 ' HG ' ' H ' ' C' ' 8' ' ' SER . 0.3 OUTLIER -61.87 -168.58 0.02 OUTLIER 'General case' 0 N--CA 1.469 0.505 0 O-C-N 123.783 0.343 . . . . 0.0 110.348 179.498 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 25.0 t-20 -70.61 81.03 0.59 Allowed 'General case' 0 N--CA 1.467 0.377 0 N-CA-C 110.078 -0.342 . . . . 0.0 110.078 179.636 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -78.48 144.32 35.85 Favored 'General case' 0 N--CA 1.473 0.706 0 N-CA-C 109.077 -0.712 . . . . 0.0 109.077 179.394 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.47 -167.47 0.97 Allowed Glycine 0 C--N 1.336 0.569 0 N-CA-C 109.933 -1.267 . . . . 0.0 109.933 178.676 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.91 114.56 27.89 Favored 'General case' 0 N--CA 1.479 0.988 0 N-CA-C 109.677 -0.49 . . . . 0.0 109.677 179.644 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 64.3 mt -98.51 135.36 33.66 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.507 0 N-CA-C 107.073 -1.454 . . . . 0.0 107.073 178.9 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . 0.405 ' C ' ' H ' ' B' ' 34' ' ' LEU . 33.7 pt -151.99 -176.63 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.353 0.722 0 CA-C-N 116.026 -0.534 . . . . 0.0 111.191 -178.975 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.73 4.76 10.99 Favored Glycine 0 CA--C 1.523 0.57 0 N-CA-C 110.925 -0.87 . . . . 0.0 110.925 179.718 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 34' ' ' LEU . . . . . 0.405 ' H ' ' C ' ' B' ' 32' ' ' ILE . 1.6 tt -74.56 126.71 31.37 Favored 'General case' 0 CA--C 1.546 0.813 0 N-CA-C 109.438 -0.578 . . . . 0.0 109.438 -179.744 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 28.2 ttt -163.05 149.97 12.78 Favored 'General case' 0 N--CA 1.465 0.323 0 N-CA-C 108.935 -0.765 . . . . 0.0 108.935 178.82 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 27.3 m -155.3 166.34 1.06 Allowed 'Isoleucine or valine' 0 C--N 1.348 0.508 0 N-CA-C 108.015 -1.105 . . . . 0.0 108.015 179.706 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.73 67.43 2.21 Favored Glycine 0 C--N 1.307 -1.069 0 CA-C-N 115.742 -0.663 . . . . 0.0 112.094 178.434 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.65 -173.52 24.51 Favored Glycine 0 N--CA 1.474 1.213 0 N-CA-C 110.94 -0.864 . . . . 0.0 110.94 179.034 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 39' ' ' VAL . . . . . 0.493 ' H ' HG11 ' E' ' 39' ' ' VAL . 35.0 m -125.27 156.26 34.34 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.818 0 C-N-CA 123.42 0.688 . . . . 0.0 110.309 -179.591 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 26.6 t . . . . . 0 C--O 1.219 -0.514 0 CA-C-O 118.54 -0.743 . . . . 0.0 110.436 179.758 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 39.7 m-85 . . . . . 0 N--CA 1.474 0.774 0 N-CA-C 110.064 -0.347 . . . . 0.0 110.064 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -143.35 140.42 30.51 Favored 'General case' 0 N--CA 1.483 1.182 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 179.726 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 42.0 t-80 -151.72 119.51 6.15 Favored 'General case' 0 N--CA 1.472 0.648 0 N-CA-C 109.317 -0.623 . . . . 0.0 109.317 179.114 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 7' ' ' ASP . . . . . 0.501 ' O ' ' OG ' ' F' ' 8' ' ' SER . 4.3 m-20 -69.22 148.32 50.01 Favored 'General case' 0 CA--C 1.537 0.472 0 CA-C-N 116.328 -0.397 . . . . 0.0 110.648 179.978 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' C' C ' 8' ' ' SER . . . . . 0.486 ' H ' ' HG ' ' B' ' 26' ' ' SER . 53.5 p -167.31 -173.4 2.25 Favored 'General case' 0 N--CA 1.484 1.246 0 CA-C-O 121.028 0.442 . . . . 0.0 110.692 179.43 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.62 47.1 1.43 Allowed Glycine 0 N--CA 1.482 1.734 0 CA-C-N 115.899 -0.592 . . . . 0.0 112.076 179.787 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 49.1 p90 -65.44 133.06 50.5 Favored 'General case' 0 N--CA 1.473 0.709 0 CA-C-O 120.671 0.272 . . . . 0.0 111.489 179.617 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 46.0 mt-10 -92.48 152.49 19.64 Favored 'General case' 0 N--CA 1.476 0.826 0 CA-C-O 121.1 0.476 . . . . 0.0 109.787 178.436 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -153.21 128.48 1.56 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.545 0 N-CA-C 107.786 -1.19 . . . . 0.0 107.786 178.307 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 47.0 m-70 -135.71 147.56 48.53 Favored 'General case' 0 N--CA 1.492 1.632 0 CA-C-N 118.925 0.784 . . . . 0.0 111.355 -179.081 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 6.5 t60 -164.96 97.17 0.73 Allowed 'General case' 0 N--CA 1.482 1.149 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.507 179.312 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 3.9 pt20 -101.64 -173.75 2.43 Favored 'General case' 0 CA--C 1.507 -0.701 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 -179.749 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -170.22 95.85 0.25 Allowed 'General case' 0 N--CA 1.47 0.553 0 CA-C-N 114.618 -1.174 . . . . 0.0 108.292 178.406 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 6.5 mp -123.37 157.08 34.12 Favored 'General case' 0 N--CA 1.497 1.918 0 CA-C-O 121.745 0.784 . . . . 0.0 111.07 -178.157 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 60.7 t -112.33 127.61 69.43 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.076 0 N-CA-C 108.059 -1.089 . . . . 0.0 108.059 177.53 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 27.7 m-85 -127.58 123.02 34.73 Favored 'General case' 0 N--CA 1.494 1.75 0 CA-C-N 119.6 1.091 . . . . 0.0 110.34 179.614 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 67.0 m-85 53.29 74.75 0.29 Allowed 'General case' 0 CA--C 1.538 0.495 0 CA-C-O 121.55 0.69 . . . . 0.0 111.975 178.441 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -80.34 -78.22 0.18 Allowed 'General case' 0 C--N 1.348 0.537 0 CA-C-N 114.911 -1.04 . . . . 0.0 110.197 -179.791 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 38.0 tt0 -113.31 100.39 8.52 Favored 'General case' 0 N--CA 1.47 0.56 0 N-CA-C 108.161 -1.051 . . . . 0.0 108.161 179.653 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 4.4 p30 -158.71 140.08 13.27 Favored 'General case' 0 N--CA 1.484 1.231 0 O-C-N 122.202 -0.311 . . . . 0.0 111.204 179.085 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 61.8 t -60.0 163.72 0.92 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.852 0 N-CA-C 108.153 -1.054 . . . . 0.0 108.153 177.082 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -117.38 48.31 0.95 Allowed Glycine 0 N--CA 1.477 1.385 0 N-CA-C 111.637 -0.585 . . . . 0.0 111.637 -179.336 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 26' ' ' SER . . . . . 0.535 ' HG ' ' H ' ' A' ' 8' ' ' SER . 0.3 OUTLIER -61.81 -167.99 0.01 OUTLIER 'General case' 0 N--CA 1.468 0.427 0 O-C-N 123.79 0.347 . . . . 0.0 110.361 179.658 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 25.0 t-20 -71.01 80.71 0.66 Allowed 'General case' 0 N--CA 1.465 0.304 0 N-CA-C 110.067 -0.345 . . . . 0.0 110.067 179.495 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -78.22 144.13 36.53 Favored 'General case' 0 N--CA 1.472 0.65 0 N-CA-C 109.117 -0.698 . . . . 0.0 109.117 179.415 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.55 -167.62 1.03 Allowed Glycine 0 CA--C 1.523 0.586 0 N-CA-C 109.965 -1.254 . . . . 0.0 109.965 178.788 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.6 114.34 27.31 Favored 'General case' 0 N--CA 1.48 1.071 0 N-CA-C 109.661 -0.496 . . . . 0.0 109.661 179.775 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 64.8 mt -98.42 135.45 33.16 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.546 0 N-CA-C 107.058 -1.46 . . . . 0.0 107.058 178.911 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 32' ' ' ILE . . . . . 0.419 ' C ' ' H ' ' C' ' 34' ' ' LEU . 33.8 pt -152.01 -176.15 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.352 0.688 0 CA-C-N 115.998 -0.547 . . . . 0.0 111.189 -179.096 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.48 4.49 9.43 Favored Glycine 0 CA--C 1.524 0.615 0 N-CA-C 110.992 -0.843 . . . . 0.0 110.992 179.697 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 34' ' ' LEU . . . . . 0.419 ' H ' ' C ' ' C' ' 32' ' ' ILE . 1.6 tt -74.27 127.27 32.57 Favored 'General case' 0 CA--C 1.547 0.831 0 N-CA-C 109.389 -0.597 . . . . 0.0 109.389 -179.776 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 28.3 ttt -163.52 150.06 12.02 Favored 'General case' 0 N--CA 1.467 0.397 0 N-CA-C 108.86 -0.792 . . . . 0.0 108.86 178.735 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 27.3 m -155.59 166.05 1.07 Allowed 'Isoleucine or valine' 0 C--N 1.347 0.5 0 N-CA-C 108.06 -1.089 . . . . 0.0 108.06 179.657 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.06 67.23 2.32 Favored Glycine 0 C--N 1.307 -1.047 0 CA-C-N 115.721 -0.672 . . . . 0.0 112.077 178.503 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.71 -173.44 24.58 Favored Glycine 0 N--CA 1.473 1.139 0 N-CA-C 110.987 -0.845 . . . . 0.0 110.987 178.959 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 39' ' ' VAL . . . . . 0.494 ' H ' HG11 ' F' ' 39' ' ' VAL . 32.9 m -125.11 156.37 33.98 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.751 0 C-N-CA 123.386 0.674 . . . . 0.0 110.31 -179.572 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 25.6 t . . . . . 0 C--O 1.218 -0.576 0 CA-C-O 118.424 -0.798 . . . . 0.0 110.579 179.77 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 41.4 m-85 . . . . . 0 N--CA 1.473 0.679 0 N-CA-C 108.775 -0.824 . . . . 0.0 108.775 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' D' D ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -145.24 139.15 26.95 Favored 'General case' 0 N--CA 1.478 0.927 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.144 -179.846 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 38.7 t-80 -149.47 123.46 9.4 Favored 'General case' 0 CA--C 1.544 0.744 0 N-CA-C 108.42 -0.956 . . . . 0.0 108.42 175.352 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 7' ' ' ASP . . . . . 0.596 ' O ' ' OG ' ' G' ' 8' ' ' SER . 3.2 m-20 -63.79 133.02 52.69 Favored 'General case' 0 C--N 1.32 -0.702 0 C-N-CA 126.769 2.027 . . . . 0.0 113.965 174.817 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' D' D ' 8' ' ' SER . . . . . 0.53 ' H ' ' HG ' ' F' ' 26' ' ' SER . 53.9 p -154.61 -170.57 3.56 Favored 'General case' 0 N--CA 1.487 1.41 0 CA-C-N 119.397 0.999 . . . . 0.0 111.12 175.622 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.2 47.77 1.2 Allowed Glycine 0 N--CA 1.481 1.651 0 N-CA-C 110.652 -0.979 . . . . 0.0 110.652 174.445 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 51.1 p90 -60.91 131.48 50.81 Favored 'General case' 0 N--CA 1.471 0.614 0 N-CA-C 112.804 0.668 . . . . 0.0 112.804 178.075 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 45.7 mt-10 -89.49 150.83 22.29 Favored 'General case' 0 N--CA 1.481 1.094 0 CA-C-N 117.825 0.284 . . . . 0.0 110.809 175.351 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.0 p -149.46 129.84 4.28 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.611 0 N-CA-C 107.49 -1.3 . . . . 0.0 107.49 173.417 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 42.9 m-70 -129.96 150.74 51.11 Favored 'General case' 0 N--CA 1.483 1.215 0 CA-C-N 118.198 0.454 . . . . 0.0 111.994 176.584 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 6.6 t60 -164.98 104.47 0.78 Allowed 'General case' 0 N--CA 1.483 1.186 0 N-CA-C 108.844 -0.799 . . . . 0.0 108.844 172.171 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 3.9 pt20 -105.12 -176.1 2.98 Favored 'General case' 0 CA--C 1.502 -0.871 0 N-CA-C 108.487 -0.931 . . . . 0.0 108.487 179.177 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -166.23 104.52 0.64 Allowed 'General case' 0 N--CA 1.466 0.335 0 N-CA-C 106.205 -1.776 . . . . 0.0 106.205 174.131 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 5.4 mp -130.35 154.02 48.09 Favored 'General case' 0 N--CA 1.5 2.043 0 CA-C-O 122.062 0.934 . . . . 0.0 110.711 179.458 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 34.5 t -101.25 131.56 48.76 Favored 'Isoleucine or valine' 0 C--O 1.262 1.714 0 CA-C-O 116.779 -1.581 . . . . 0.0 109.686 174.097 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 26.2 m-85 -130.09 126.45 37.62 Favored 'General case' 0 N--CA 1.488 1.457 0 CA-C-N 120.126 1.33 . . . . 0.0 109.864 173.73 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 67.4 m-85 55.48 71.3 0.56 Allowed 'General case' 0 C--O 1.239 0.542 0 CA-C-N 115.712 -0.676 . . . . 0.0 111.837 176.206 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -81.6 -73.43 0.38 Allowed 'General case' 0 N--CA 1.473 0.718 0 CA-C-O 118.585 -0.721 . . . . 0.0 111.063 -177.61 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 38.6 tt0 -116.64 104.28 11.23 Favored 'General case' 0 N--CA 1.482 1.164 0 N-CA-C 106.361 -1.718 . . . . 0.0 106.361 176.324 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -152.15 139.92 19.9 Favored 'General case' 0 N--CA 1.474 0.756 0 CA-C-O 116.8 -1.571 . . . . 0.0 113.647 177.815 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 24' ' ' VAL . . . . . 0.403 ' HB ' ' H ' ' A' ' 25' ' ' GLY . 66.7 t -62.45 166.04 0.98 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.294 0 CA-C-N 121.037 1.744 . . . . 0.0 107.983 174.905 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' D' D ' 25' ' ' GLY . . . . . 0.43 ' H ' ' HB ' ' G' ' 24' ' ' VAL . . . -116.83 51.08 0.75 Allowed Glycine 0 N--CA 1.479 1.52 0 CA-C-O 119.081 -0.844 . . . . 0.0 111.738 178.536 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' D' D ' 26' ' ' SER . . . . . 0.491 ' HG ' ' H ' ' E' ' 8' ' ' SER . 0.2 OUTLIER -57.75 -171.21 0.01 OUTLIER 'General case' 0 C--N 1.323 -0.58 0 C-N-CA 123.618 0.767 . . . . 0.0 111.722 176.054 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 25.8 t-20 -72.11 86.52 1.05 Allowed 'General case' 0 C--N 1.346 0.435 0 N-CA-C 108.585 -0.894 . . . . 0.0 108.585 177.688 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 97.5 mttt -83.53 146.48 28.32 Favored 'General case' 0 N--CA 1.474 0.775 0 N-CA-C 108.056 -1.09 . . . . 0.0 108.056 179.196 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -62.95 -165.4 0.56 Allowed Glycine 0 C--N 1.335 0.476 0 N-CA-C 110.519 -1.032 . . . . 0.0 110.519 179.225 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -101.78 115.95 31.65 Favored 'General case' 0 N--CA 1.471 0.606 0 N-CA-C 109.235 -0.654 . . . . 0.0 109.235 179.594 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 72.6 mt -102.71 142.77 16.16 Favored 'Isoleucine or valine' 0 C--N 1.356 0.891 0 N-CA-C 104.544 -2.391 . . . . 0.0 104.544 179.838 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 32' ' ' ILE . . . . . 0.402 HG23 ' H ' ' G' ' 32' ' ' ILE . 34.8 pt -158.49 -176.96 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.209 0 CA-C-O 120.891 0.377 . . . . 0.0 110.152 -177.537 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 64.31 4.38 12.19 Favored Glycine 0 C--O 1.247 0.958 0 N-CA-C 110.087 -1.205 . . . . 0.0 110.087 -179.011 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 2.0 tt -76.37 132.94 40.02 Favored 'General case' 0 C--N 1.363 1.181 0 N-CA-C 107.185 -1.413 . . . . 0.0 107.185 -177.974 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 28.2 ttt -158.52 161.53 37.36 Favored 'General case' 0 C--O 1.221 -0.419 0 CA-C-O 118.318 -0.849 . . . . 0.0 108.734 173.086 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 27.6 m -164.74 165.07 0.61 Allowed 'Isoleucine or valine' 0 CA--C 1.519 -0.247 0 N-CA-C 107.624 -1.25 . . . . 0.0 107.624 175.835 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 60.36 64.1 4.43 Favored Glycine 0 CA--C 1.524 0.6 0 C-N-CA 119.576 -1.297 . . . . 0.0 113.006 178.572 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 140.95 -171.61 24.04 Favored Glycine 0 N--CA 1.476 1.361 0 CA-C-N 117.328 0.564 . . . . 0.0 111.95 -179.175 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 39' ' ' VAL . . . . . 0.477 ' H ' HG11 ' G' ' 39' ' ' VAL . 35.4 m -128.17 153.5 37.65 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.883 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -176.664 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 25.3 t . . . . . 0 C--O 1.225 -0.204 0 CA-C-O 116.686 -1.626 . . . . 0.0 109.773 178.118 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 37.9 m-85 . . . . . 0 N--CA 1.475 0.825 0 N-CA-C 110.166 -0.309 . . . . 0.0 110.166 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' E' E ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -142.74 140.86 31.61 Favored 'General case' 0 N--CA 1.484 1.257 0 CA-C-O 120.952 0.405 . . . . 0.0 109.997 179.576 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 41.5 t-80 -151.68 119.21 6.05 Favored 'General case' 0 N--CA 1.472 0.625 0 N-CA-C 109.228 -0.656 . . . . 0.0 109.228 178.894 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' E' E ' 7' ' ' ASP . . . . . 0.495 ' O ' ' OG ' ' H' ' 8' ' ' SER . 4.0 m-20 -69.47 148.39 49.59 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 116.389 -0.368 . . . . 0.0 110.82 -179.982 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' E' E ' 8' ' ' SER . . . . . 0.494 ' OG ' ' O ' ' B' ' 7' ' ' ASP . 51.8 p -168.1 -172.13 1.71 Allowed 'General case' 0 N--CA 1.485 1.31 0 CA-C-O 121.153 0.501 . . . . 0.0 110.857 178.995 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.17 47.61 1.31 Allowed Glycine 0 N--CA 1.479 1.516 0 CA-C-N 115.879 -0.601 . . . . 0.0 111.942 179.622 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 46.8 p90 -65.2 133.16 50.91 Favored 'General case' 0 N--CA 1.474 0.762 0 N-CA-C 111.894 0.331 . . . . 0.0 111.894 -179.886 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 46.2 mt-10 -91.84 152.33 20.16 Favored 'General case' 0 N--CA 1.479 0.995 0 CA-C-O 121.211 0.529 . . . . 0.0 109.742 178.007 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -154.34 127.47 1.16 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.586 0 N-CA-C 107.799 -1.186 . . . . 0.0 107.799 178.103 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 44.8 m-70 -135.78 145.71 46.82 Favored 'General case' 0 N--CA 1.481 1.116 0 CA-C-O 120.768 0.318 . . . . 0.0 111.678 -177.861 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 6.4 t60 -163.94 97.1 0.83 Allowed 'General case' 0 N--CA 1.485 1.318 0 CA-C-N 116.374 -0.375 . . . . 0.0 110.61 179.531 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' E' E ' 15' ' ' GLN . . . . . 0.421 HE22 ' CG2' ' E' ' 36' ' ' VAL . 3.9 pt20 -101.3 -173.97 2.49 Favored 'General case' 0 CA--C 1.509 -0.634 0 N-CA-C 108.855 -0.794 . . . . 0.0 108.855 -179.77 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -169.85 94.95 0.27 Allowed 'General case' 0 N--CA 1.474 0.739 0 CA-C-N 114.702 -1.136 . . . . 0.0 108.423 178.468 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 6.4 mp -122.05 156.92 32.53 Favored 'General case' 0 N--CA 1.494 1.772 0 CA-C-O 121.649 0.738 . . . . 0.0 111.532 -177.641 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 48.0 t -113.9 124.35 70.47 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.231 0 N-CA-C 108.178 -1.045 . . . . 0.0 108.178 177.168 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 30.5 m-85 -124.83 121.78 35.54 Favored 'General case' 0 N--CA 1.488 1.427 0 CA-C-O 120.83 0.348 . . . . 0.0 111.086 -179.729 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 68.8 m-85 54.76 73.61 0.4 Allowed 'General case' 0 N--CA 1.467 0.407 0 CA-C-N 115.941 -0.572 . . . . 0.0 111.609 178.173 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -78.53 -78.6 0.14 Allowed 'General case' 0 CA--C 1.535 0.379 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.108 -179.615 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 38.5 tt0 -112.8 101.07 9.17 Favored 'General case' 0 C--N 1.324 -0.532 0 N-CA-C 108.257 -1.016 . . . . 0.0 108.257 179.905 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -158.39 140.12 13.71 Favored 'General case' 0 C--O 1.205 -1.274 0 O-C-N 122.282 -0.262 . . . . 0.0 111.5 178.97 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' E' E ' 24' ' ' VAL . . . . . 0.406 ' HB ' ' H ' ' B' ' 25' ' ' GLY . 57.6 t -58.65 168.53 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.867 0 N-CA-C 107.619 -1.252 . . . . 0.0 107.619 176.943 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . -122.45 49.35 0.89 Allowed Glycine 0 N--CA 1.474 1.212 0 N-CA-C 110.783 -0.927 . . . . 0.0 110.783 -179.296 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' E' E ' 26' ' ' SER . . . . . 0.482 ' HG ' ' H ' ' F' ' 8' ' ' SER . 0.3 OUTLIER -63.24 -167.83 0.02 OUTLIER 'General case' 0 N--CA 1.469 0.489 0 CA-C-O 120.763 0.316 . . . . 0.0 110.466 179.805 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 25.4 t-20 -70.07 77.29 0.5 Allowed 'General case' 0 N--CA 1.466 0.365 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.422 179.961 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -75.17 144.45 42.73 Favored 'General case' 0 N--CA 1.476 0.855 0 N-CA-C 109.552 -0.536 . . . . 0.0 109.552 179.438 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.34 -166.9 1.19 Allowed Glycine 0 CA--C 1.521 0.454 0 N-CA-C 110.439 -1.064 . . . . 0.0 110.439 178.548 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.68 114.15 27.06 Favored 'General case' 0 N--CA 1.472 0.646 0 N-CA-C 109.848 -0.426 . . . . 0.0 109.848 179.769 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 65.6 mt -98.47 135.52 32.97 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.324 0 N-CA-C 106.832 -1.544 . . . . 0.0 106.832 178.979 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' E' E ' 32' ' ' ILE . . . . . 0.419 ' C ' ' H ' ' E' ' 34' ' ' LEU . 36.2 pt -152.01 -174.05 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.208 0 CA-C-O 121.111 0.481 . . . . 0.0 110.713 -179.337 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.29 5.16 5.74 Favored Glycine 0 CA--C 1.529 0.942 0 CA-C-N 115.58 -0.736 . . . . 0.0 111.408 -179.731 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' E' E ' 34' ' ' LEU . . . . . 0.419 ' H ' ' C ' ' E' ' 32' ' ' ILE . 1.6 tt -74.25 126.9 31.63 Favored 'General case' 0 CA--C 1.547 0.852 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 -179.559 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 28.5 ttt -162.74 151.09 14.26 Favored 'General case' 0 C--O 1.209 -1.05 0 N-CA-C 108.995 -0.742 . . . . 0.0 108.995 178.769 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' E' E ' 36' ' ' VAL . . . . . 0.421 ' CG2' HE22 ' E' ' 15' ' ' GLN . 35.4 m -156.62 166.23 0.94 Allowed 'Isoleucine or valine' 0 C--N 1.343 0.292 0 N-CA-C 108.354 -0.98 . . . . 0.0 108.354 179.747 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.72 66.87 2.53 Favored Glycine 0 C--N 1.307 -1.075 0 CA-C-N 115.576 -0.738 . . . . 0.0 111.997 178.442 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 144.1 -173.12 24.99 Favored Glycine 0 N--CA 1.475 1.281 0 N-CA-C 111.23 -0.748 . . . . 0.0 111.23 178.931 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' E' E ' 39' ' ' VAL . . . . . 0.504 ' H ' HG11 ' H' ' 39' ' ' VAL . 34.2 m -125.46 155.31 34.52 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.753 0 C-N-CA 123.405 0.682 . . . . 0.0 110.429 -179.138 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 26.4 t . . . . . 0 C--O 1.219 -0.526 0 O-C-N 124.062 0.851 . . . . 0.0 110.467 179.505 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 36.2 m-85 . . . . . 0 N--CA 1.474 0.75 0 N-CA-C 110.003 -0.369 . . . . 0.0 110.003 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' F' F ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -142.64 141.02 31.83 Favored 'General case' 0 N--CA 1.48 1.051 0 CA-C-O 120.884 0.373 . . . . 0.0 110.175 179.509 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 42.2 t-80 -151.9 118.95 5.85 Favored 'General case' 0 N--CA 1.472 0.639 0 N-CA-C 109.343 -0.614 . . . . 0.0 109.343 179.046 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' F' F ' 7' ' ' ASP . . . . . 0.496 ' O ' ' OG ' ' I' ' 8' ' ' SER . 4.0 m-20 -69.34 148.36 49.8 Favored 'General case' 0 N--CA 1.465 0.324 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.824 -179.902 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' F' F ' 8' ' ' SER . . . . . 0.501 ' OG ' ' O ' ' C' ' 7' ' ' ASP . 50.5 p -168.1 -172.03 1.68 Allowed 'General case' 0 N--CA 1.486 1.335 0 CA-C-O 121.119 0.485 . . . . 0.0 110.953 179.008 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.89 47.16 1.39 Allowed Glycine 0 N--CA 1.479 1.553 0 CA-C-N 115.884 -0.598 . . . . 0.0 111.953 179.629 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 46.2 p90 -64.73 133.4 52.0 Favored 'General case' 0 CA--C 1.543 0.68 0 N-CA-C 111.832 0.308 . . . . 0.0 111.832 -179.924 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 46.2 mt-10 -91.91 152.17 20.19 Favored 'General case' 0 N--CA 1.481 1.081 0 CA-C-O 121.19 0.519 . . . . 0.0 109.736 177.997 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -154.12 127.24 1.15 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.599 0 N-CA-C 107.838 -1.171 . . . . 0.0 107.838 178.131 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 44.5 m-70 -135.53 146.04 47.66 Favored 'General case' 0 N--CA 1.483 1.201 0 CA-C-O 120.88 0.372 . . . . 0.0 111.631 -177.916 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 6.4 t60 -164.07 96.94 0.81 Allowed 'General case' 0 N--CA 1.486 1.369 0 CA-C-N 116.436 -0.347 . . . . 0.0 110.674 179.385 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' F' F ' 15' ' ' GLN . . . . . 0.406 HE22 ' CG2' ' F' ' 36' ' ' VAL . 3.9 pt20 -101.18 -173.84 2.47 Favored 'General case' 0 CA--C 1.507 -0.698 0 N-CA-C 108.871 -0.789 . . . . 0.0 108.871 -179.814 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -169.87 94.93 0.27 Allowed 'General case' 0 N--CA 1.473 0.677 0 CA-C-N 114.609 -1.178 . . . . 0.0 108.443 178.42 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 6.3 mp -121.95 157.07 32.06 Favored 'General case' 0 N--CA 1.494 1.764 0 CA-C-O 121.685 0.755 . . . . 0.0 111.554 -177.676 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 48.1 t -114.02 124.27 70.5 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.217 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 177.162 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 30.0 m-85 -124.71 122.03 36.32 Favored 'General case' 0 N--CA 1.488 1.431 0 CA-C-O 120.863 0.364 . . . . 0.0 110.983 -179.741 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 68.9 m-85 54.61 74.18 0.36 Allowed 'General case' 0 C--N 1.344 0.362 0 CA-C-N 115.873 -0.603 . . . . 0.0 111.705 178.166 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -79.1 -78.5 0.15 Allowed 'General case' 0 CA--C 1.535 0.388 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.197 -179.56 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 38.4 tt0 -112.91 101.03 9.11 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 179.822 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -158.29 139.84 13.59 Favored 'General case' 0 C--O 1.208 -1.124 0 O-C-N 122.279 -0.263 . . . . 0.0 111.572 179.099 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' F' F ' 24' ' ' VAL . . . . . . . . . . . . . 58.3 t -58.55 168.08 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.891 0 N-CA-C 107.507 -1.294 . . . . 0.0 107.507 177.037 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -122.14 49.48 0.89 Allowed Glycine 0 N--CA 1.477 1.43 0 N-CA-C 110.787 -0.925 . . . . 0.0 110.787 -179.427 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' F' F ' 26' ' ' SER . . . . . 0.53 ' HG ' ' H ' ' D' ' 8' ' ' SER . 0.3 OUTLIER -63.27 -167.56 0.02 OUTLIER 'General case' 0 N--CA 1.469 0.509 0 CA-C-O 120.642 0.258 . . . . 0.0 110.441 179.796 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 25.5 t-20 -70.26 77.12 0.53 Allowed 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.451 179.916 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -75.02 144.77 42.91 Favored 'General case' 0 N--CA 1.476 0.845 0 N-CA-C 109.579 -0.526 . . . . 0.0 109.579 179.335 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.46 -167.02 1.25 Allowed Glycine 0 CA--C 1.522 0.484 0 N-CA-C 110.494 -1.042 . . . . 0.0 110.494 178.64 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.17 113.96 26.47 Favored 'General case' 0 N--CA 1.473 0.711 0 N-CA-C 109.808 -0.442 . . . . 0.0 109.808 179.665 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 66.5 mt -98.43 135.27 33.89 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.388 0 N-CA-C 106.837 -1.542 . . . . 0.0 106.837 178.762 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' F' F ' 32' ' ' ILE . . . . . 0.417 ' C ' ' H ' ' F' ' 34' ' ' LEU . 35.2 pt -151.87 -174.29 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.198 0 CA-C-O 121.248 0.547 . . . . 0.0 110.723 -179.373 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.35 5.45 6.31 Favored Glycine 0 CA--C 1.528 0.901 0 CA-C-N 115.55 -0.75 . . . . 0.0 111.443 -179.774 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' F' F ' 34' ' ' LEU . . . . . 0.417 ' H ' ' C ' ' F' ' 32' ' ' ILE . 1.6 tt -74.42 127.05 32.07 Favored 'General case' 0 CA--C 1.549 0.913 0 N-CA-C 109.467 -0.568 . . . . 0.0 109.467 -179.741 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 28.4 ttt -162.69 151.32 14.62 Favored 'General case' 0 C--O 1.209 -1.045 0 N-CA-C 108.963 -0.755 . . . . 0.0 108.963 178.605 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' F' F ' 36' ' ' VAL . . . . . 0.406 ' CG2' HE22 ' F' ' 15' ' ' GLN . 35.4 m -156.82 166.13 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.344 0.347 0 N-CA-C 108.312 -0.995 . . . . 0.0 108.312 179.77 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.78 67.0 2.44 Favored Glycine 0 C--N 1.307 -1.038 0 CA-C-N 115.595 -0.729 . . . . 0.0 112.003 178.49 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.98 -173.0 24.96 Favored Glycine 0 N--CA 1.474 1.179 0 N-CA-C 111.251 -0.74 . . . . 0.0 111.251 178.992 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' F' F ' 39' ' ' VAL . . . . . 0.506 ' H ' HG11 ' I' ' 39' ' ' VAL . 34.2 m -125.62 155.51 34.93 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.729 0 C-N-CA 123.336 0.654 . . . . 0.0 110.365 -179.166 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 25.3 t . . . . . 0 C--O 1.219 -0.551 0 O-C-N 124.004 0.815 . . . . 0.0 110.423 179.593 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 40.2 m-85 . . . . . 0 N--CA 1.474 0.768 0 N-CA-C 109.591 -0.522 . . . . 0.0 109.591 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' G' G ' 5' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -143.0 140.56 31.07 Favored 'General case' 0 N--CA 1.481 1.1 0 C-N-CA 122.498 0.319 . . . . 0.0 110.337 179.837 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 42.3 t-80 -151.27 120.22 6.66 Favored 'General case' 0 N--CA 1.474 0.739 0 N-CA-C 109.441 -0.578 . . . . 0.0 109.441 178.938 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -71.23 144.31 50.12 Favored 'General case' 0 N--CA 1.469 0.51 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.231 -179.829 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' G' G ' 8' ' ' SER . . . . . 0.596 ' OG ' ' O ' ' D' ' 7' ' ' ASP . 45.2 p -165.07 -170.52 1.95 Allowed 'General case' 0 N--CA 1.476 0.832 0 CA-C-O 121.037 0.446 . . . . 0.0 110.545 178.792 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.68 48.0 1.33 Allowed Glycine 0 N--CA 1.479 1.548 0 N-CA-C 111.485 -0.646 . . . . 0.0 111.485 179.468 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 48.8 p90 -65.77 133.43 50.99 Favored 'General case' 0 CA--C 1.543 0.676 0 N-CA-C 111.694 0.257 . . . . 0.0 111.694 -179.694 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 46.1 mt-10 -92.32 151.43 20.29 Favored 'General case' 0 N--CA 1.48 1.043 0 CA-C-O 121.146 0.498 . . . . 0.0 110.163 178.582 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -154.75 127.3 1.06 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.966 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 178.298 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 45.7 m-70 -134.74 147.34 50.01 Favored 'General case' 0 N--CA 1.478 0.965 0 CA-C-N 115.62 -0.718 . . . . 0.0 111.486 -178.291 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 6.6 t60 -165.42 97.35 0.69 Allowed 'General case' 0 N--CA 1.483 1.204 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.242 178.83 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 3.9 pt20 -101.59 -173.67 2.41 Favored 'General case' 0 CA--C 1.507 -0.699 0 N-CA-C 108.662 -0.866 . . . . 0.0 108.662 -179.58 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -170.55 94.22 0.21 Allowed 'General case' 0 N--CA 1.473 0.693 0 CA-C-N 114.654 -1.157 . . . . 0.0 108.076 178.637 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 6.3 mp -121.33 155.85 33.85 Favored 'General case' 0 N--CA 1.498 1.93 0 CA-C-O 121.237 0.541 . . . . 0.0 111.814 -177.8 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 42.9 t -113.43 125.15 70.65 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.011 0 CA-C-N 114.74 -1.118 . . . . 0.0 108.116 176.566 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 31.8 m-85 -125.96 121.54 33.38 Favored 'General case' 0 C--N 1.367 1.337 0 CA-C-N 115.664 -0.698 . . . . 0.0 111.083 -179.446 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 68.4 m-85 54.86 73.11 0.43 Allowed 'General case' 0 N--CA 1.467 0.416 0 CA-C-N 115.858 -0.61 . . . . 0.0 111.545 178.036 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.58 -77.95 0.14 Allowed 'General case' 0 N--CA 1.472 0.64 0 O-C-N 122.212 -0.305 . . . . 0.0 110.355 -179.25 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 38.4 tt0 -113.23 101.14 9.14 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 107.95 -1.13 . . . . 0.0 107.95 179.822 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -158.29 141.02 14.61 Favored 'General case' 0 N--CA 1.477 0.915 0 O-C-N 122.337 -0.227 . . . . 0.0 111.487 179.063 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' G' G ' 24' ' ' VAL . . . . . 0.43 ' HB ' ' H ' ' D' ' 25' ' ' GLY . 59.9 t -60.28 167.07 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.762 0 N-CA-C 107.641 -1.244 . . . . 0.0 107.641 177.26 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -120.45 49.61 0.87 Allowed Glycine 0 N--CA 1.479 1.566 0 N-CA-C 110.504 -1.038 . . . . 0.0 110.504 -179.452 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -64.02 -167.27 0.02 OUTLIER 'General case' 0 N--CA 1.471 0.598 0 CA-C-N 116.953 0.376 . . . . 0.0 110.061 179.829 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 25.8 t-20 -70.45 77.12 0.56 Allowed 'General case' 0 CA--C 1.535 0.401 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.471 179.943 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -74.53 144.14 44.21 Favored 'General case' 0 N--CA 1.476 0.86 0 N-CA-C 109.653 -0.499 . . . . 0.0 109.653 179.361 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.39 -166.11 1.07 Allowed Glycine 0 C--N 1.337 0.619 0 N-CA-C 110.037 -1.225 . . . . 0.0 110.037 178.707 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -98.84 114.06 26.47 Favored 'General case' 0 N--CA 1.471 0.575 0 C-N-CA 122.672 0.389 . . . . 0.0 110.447 179.843 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 67.6 mt -99.16 135.51 34.02 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.698 0 N-CA-C 106.856 -1.535 . . . . 0.0 106.856 178.831 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' G' G ' 32' ' ' ILE . . . . . 0.42 ' C ' ' H ' ' G' ' 34' ' ' LEU . 34.1 pt -152.48 -173.92 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 CA-C-N 119.891 1.223 . . . . 0.0 109.878 -179.725 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.15 5.31 7.61 Favored Glycine 0 N--CA 1.468 0.773 0 N-CA-C 111.061 -0.816 . . . . 0.0 111.061 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' G' G ' 34' ' ' LEU . . . . . 0.42 ' H ' ' C ' ' G' ' 32' ' ' ILE . 1.6 tt -75.04 125.85 29.79 Favored 'General case' 0 CA--C 1.545 0.775 0 N-CA-C 109.524 -0.547 . . . . 0.0 109.524 -179.611 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 27.4 ttt -161.52 152.66 18.42 Favored 'General case' 0 C--O 1.21 -0.986 0 N-CA-C 108.775 -0.824 . . . . 0.0 108.775 178.503 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 35.8 m -157.26 165.17 1.0 Allowed 'Isoleucine or valine' 0 C--N 1.346 0.429 0 N-CA-C 108.528 -0.916 . . . . 0.0 108.528 -179.675 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.39 67.99 1.92 Allowed Glycine 0 C--N 1.307 -1.031 0 CA-C-N 115.531 -0.759 . . . . 0.0 112.206 178.26 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.99 -171.66 25.45 Favored Glycine 0 N--CA 1.476 1.315 0 N-CA-C 110.621 -0.991 . . . . 0.0 110.621 178.998 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' G' G ' 39' ' ' VAL . . . . . 0.477 HG11 ' H ' ' D' ' 39' ' ' VAL . 34.7 m -126.93 156.03 38.04 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.911 0 C-N-CA 123.069 0.548 . . . . 0.0 110.631 -179.357 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 31.5 t . . . . . 0 C--O 1.219 -0.546 0 O-C-N 123.946 0.779 . . . . 0.0 110.737 179.218 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 41.0 m-85 . . . . . 0 N--CA 1.473 0.706 0 N-CA-C 109.627 -0.508 . . . . 0.0 109.627 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' H' H ' 5' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -142.91 141.27 31.46 Favored 'General case' 0 N--CA 1.484 1.273 0 C-N-CA 122.585 0.354 . . . . 0.0 110.169 179.747 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 42.0 t-80 -151.98 120.1 6.28 Favored 'General case' 0 N--CA 1.474 0.731 0 N-CA-C 109.36 -0.607 . . . . 0.0 109.36 179.018 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -71.16 144.17 50.29 Favored 'General case' 0 N--CA 1.469 0.519 0 CA-C-N 116.321 -0.4 . . . . 0.0 111.303 -179.777 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' H' H ' 8' ' ' SER . . . . . 0.495 ' OG ' ' O ' ' E' ' 7' ' ' ASP . 53.1 p -164.77 -170.93 2.12 Favored 'General case' 0 N--CA 1.474 0.751 0 CA-C-O 121.06 0.457 . . . . 0.0 110.472 178.783 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.22 47.35 1.33 Allowed Glycine 0 N--CA 1.48 1.567 0 CA-C-N 115.848 -0.614 . . . . 0.0 111.713 179.47 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 49.2 p90 -65.47 133.09 50.53 Favored 'General case' 0 N--CA 1.471 0.594 0 N-CA-C 111.792 0.293 . . . . 0.0 111.792 -179.627 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 46.2 mt-10 -92.0 151.41 20.49 Favored 'General case' 0 N--CA 1.479 0.982 0 CA-C-O 121.115 0.483 . . . . 0.0 110.225 178.568 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -154.65 127.82 1.16 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.027 0 N-CA-C 107.851 -1.166 . . . . 0.0 107.851 178.233 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 46.6 m-70 -135.29 147.3 49.16 Favored 'General case' 0 N--CA 1.478 0.956 0 CA-C-N 115.653 -0.703 . . . . 0.0 111.409 -178.239 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 6.5 t60 -165.47 97.31 0.68 Allowed 'General case' 0 N--CA 1.483 1.195 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.222 178.887 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 3.9 pt20 -101.5 -173.46 2.37 Favored 'General case' 0 CA--C 1.507 -0.678 0 N-CA-C 108.636 -0.875 . . . . 0.0 108.636 -179.579 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -170.8 94.36 0.2 Allowed 'General case' 0 N--CA 1.472 0.652 0 CA-C-N 114.652 -1.158 . . . . 0.0 108.105 178.626 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 6.4 mp -121.43 155.57 34.57 Favored 'General case' 0 N--CA 1.497 1.911 0 CA-C-O 121.219 0.533 . . . . 0.0 111.938 -177.85 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 42.9 t -113.28 124.71 70.19 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.024 0 CA-C-N 114.782 -1.099 . . . . 0.0 108.134 176.568 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 31.3 m-85 -125.34 121.99 35.55 Favored 'General case' 0 C--N 1.367 1.351 0 CA-C-N 115.497 -0.774 . . . . 0.0 110.914 -179.252 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 68.1 m-85 54.05 73.34 0.39 Allowed 'General case' 0 C--O 1.237 0.436 0 CA-C-N 115.725 -0.67 . . . . 0.0 111.713 178.076 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.53 -78.03 0.14 Allowed 'General case' 0 N--CA 1.472 0.674 0 O-C-N 122.264 -0.273 . . . . 0.0 110.359 -179.218 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 38.3 tt0 -113.15 101.05 9.07 Favored 'General case' 0 C--N 1.322 -0.608 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 179.865 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -158.1 141.01 14.84 Favored 'General case' 0 N--CA 1.478 0.94 0 O-C-N 122.391 -0.193 . . . . 0.0 111.453 179.046 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' H' H ' 24' ' ' VAL . . . . . . . . . . . . . 59.3 t -60.17 167.28 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.569 0 N-CA-C 107.655 -1.239 . . . . 0.0 107.655 177.209 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . -120.65 49.65 0.87 Allowed Glycine 0 N--CA 1.478 1.499 0 N-CA-C 110.513 -1.035 . . . . 0.0 110.513 -179.463 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -64.26 -167.77 0.03 OUTLIER 'General case' 0 N--CA 1.473 0.701 0 CA-C-N 117.005 0.403 . . . . 0.0 110.1 179.755 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 25.9 t-20 -70.01 77.15 0.49 Allowed 'General case' 0 CA--C 1.534 0.34 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.46 -179.974 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -74.65 144.5 43.81 Favored 'General case' 0 N--CA 1.476 0.846 0 N-CA-C 109.552 -0.536 . . . . 0.0 109.552 179.304 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.74 -165.23 1.01 Allowed Glycine 0 C--N 1.338 0.644 0 N-CA-C 109.936 -1.265 . . . . 0.0 109.936 178.833 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.94 113.71 26.46 Favored 'General case' 0 N--CA 1.47 0.54 0 C-N-CA 122.603 0.361 . . . . 0.0 110.548 -179.996 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 66.5 mt -98.6 135.78 32.15 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.758 0 N-CA-C 106.824 -1.547 . . . . 0.0 106.824 178.922 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' H' H ' 32' ' ' ILE . . . . . 0.412 ' C ' ' H ' ' H' ' 34' ' ' LEU . 34.7 pt -152.81 -174.05 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 CA-C-N 119.853 1.206 . . . . 0.0 109.893 -179.797 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.15 5.61 8.3 Favored Glycine 0 N--CA 1.467 0.761 0 N-CA-C 111.004 -0.839 . . . . 0.0 111.004 179.971 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' H' H ' 34' ' ' LEU . . . . . 0.412 ' H ' ' C ' ' H' ' 32' ' ' ILE . 1.6 tt -75.23 125.59 29.28 Favored 'General case' 0 CA--C 1.545 0.772 0 N-CA-C 109.588 -0.523 . . . . 0.0 109.588 -179.582 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 27.5 ttt -161.17 152.59 19.04 Favored 'General case' 0 C--O 1.212 -0.91 0 N-CA-C 108.886 -0.783 . . . . 0.0 108.886 178.61 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 35.3 m -157.41 164.58 1.09 Allowed 'Isoleucine or valine' 0 C--N 1.347 0.458 0 N-CA-C 108.489 -0.93 . . . . 0.0 108.489 -179.582 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.78 67.91 1.96 Allowed Glycine 0 C--N 1.308 -0.997 0 CA-C-N 115.425 -0.807 . . . . 0.0 112.182 178.335 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 144.1 -171.89 25.43 Favored Glycine 0 N--CA 1.475 1.266 0 N-CA-C 110.682 -0.967 . . . . 0.0 110.682 179.11 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' H' H ' 39' ' ' VAL . . . . . 0.504 HG11 ' H ' ' E' ' 39' ' ' VAL . 35.0 m -126.8 155.75 37.65 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.94 0 C-N-CA 123.174 0.59 . . . . 0.0 110.663 -179.255 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 29.5 t . . . . . 0 C--O 1.217 -0.611 0 CA-C-O 118.433 -0.794 . . . . 0.0 110.759 179.341 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 40.5 m-85 . . . . . 0 N--CA 1.474 0.749 0 N-CA-C 109.578 -0.527 . . . . 0.0 109.578 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' I' I ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -143.33 140.58 30.62 Favored 'General case' 0 N--CA 1.483 1.178 0 C-N-CA 122.513 0.325 . . . . 0.0 110.152 -179.987 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 41.6 t-80 -151.67 119.61 6.22 Favored 'General case' 0 N--CA 1.474 0.73 0 N-CA-C 109.435 -0.579 . . . . 0.0 109.435 179.058 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -70.7 144.61 50.94 Favored 'General case' 0 N--CA 1.468 0.472 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.203 -179.807 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' I' I ' 8' ' ' SER . . . . . 0.496 ' OG ' ' O ' ' F' ' 7' ' ' ASP . 52.8 p -165.08 -170.69 1.99 Allowed 'General case' 0 N--CA 1.474 0.752 0 CA-C-O 121.023 0.439 . . . . 0.0 110.521 178.752 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.71 47.77 1.35 Allowed Glycine 0 N--CA 1.481 1.638 0 CA-C-N 115.904 -0.589 . . . . 0.0 111.742 179.56 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 49.1 p90 -65.76 133.13 50.38 Favored 'General case' 0 N--CA 1.472 0.637 0 N-CA-C 111.834 0.309 . . . . 0.0 111.834 -179.771 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 46.2 mt-10 -92.0 151.19 20.6 Favored 'General case' 0 N--CA 1.477 0.923 0 C-N-CA 122.841 0.456 . . . . 0.0 110.249 178.615 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -154.6 127.68 1.15 Allowed 'Isoleucine or valine' 0 CA--C 1.551 0.997 0 N-CA-C 107.86 -1.163 . . . . 0.0 107.86 178.195 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 45.2 m-70 -135.02 147.33 49.63 Favored 'General case' 0 N--CA 1.477 0.918 0 CA-C-N 115.608 -0.724 . . . . 0.0 111.479 -178.252 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 6.5 t60 -165.39 97.31 0.69 Allowed 'General case' 0 N--CA 1.483 1.179 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.218 178.82 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 3.9 pt20 -101.59 -173.43 2.35 Favored 'General case' 0 CA--C 1.507 -0.696 0 N-CA-C 108.622 -0.881 . . . . 0.0 108.622 -179.524 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -170.83 94.48 0.2 Allowed 'General case' 0 N--CA 1.472 0.642 0 CA-C-N 114.631 -1.168 . . . . 0.0 108.076 178.677 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 6.3 mp -121.6 155.52 34.89 Favored 'General case' 0 N--CA 1.496 1.861 0 CA-C-O 121.229 0.538 . . . . 0.0 111.865 -177.851 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 42.0 t -113.09 125.22 70.32 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.015 0 CA-C-N 114.783 -1.099 . . . . 0.0 108.053 176.522 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 31.0 m-85 -125.98 121.63 33.62 Favored 'General case' 0 C--N 1.368 1.396 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.996 -179.17 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 68.2 m-85 54.38 73.05 0.42 Allowed 'General case' 0 N--CA 1.466 0.363 0 CA-C-N 115.836 -0.62 . . . . 0.0 111.584 178.085 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.34 -78.12 0.14 Allowed 'General case' 0 N--CA 1.473 0.712 0 N-CA-C 110.293 -0.262 . . . . 0.0 110.293 -179.218 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 38.6 tt0 -113.05 101.3 9.33 Favored 'General case' 0 C--N 1.323 -0.581 0 N-CA-C 107.994 -1.113 . . . . 0.0 107.994 179.811 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -158.34 141.1 14.61 Favored 'General case' 0 N--CA 1.476 0.867 0 O-C-N 122.368 -0.207 . . . . 0.0 111.444 179.021 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' I' I ' 24' ' ' VAL . . . . . . . . . . . . . 59.6 t -60.31 166.85 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.348 0.534 0 N-CA-C 107.664 -1.236 . . . . 0.0 107.664 177.212 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . -120.27 49.76 0.86 Allowed Glycine 0 N--CA 1.481 1.691 0 N-CA-C 110.542 -1.023 . . . . 0.0 110.542 -179.481 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' I' I ' 26' ' ' SER . . . . . 0.403 ' HG ' ' H ' ' G' ' 8' ' ' SER . 0.3 OUTLIER -64.26 -167.85 0.03 OUTLIER 'General case' 0 N--CA 1.471 0.61 0 CA-C-N 116.922 0.361 . . . . 0.0 110.129 179.714 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 25.7 t-20 -69.9 77.18 0.47 Allowed 'General case' 0 CA--C 1.534 0.345 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.419 -179.99 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -74.74 144.43 43.65 Favored 'General case' 0 N--CA 1.475 0.812 0 N-CA-C 109.641 -0.503 . . . . 0.0 109.641 179.387 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.66 -166.06 1.15 Allowed Glycine 0 C--N 1.337 0.607 0 N-CA-C 110.023 -1.231 . . . . 0.0 110.023 178.71 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.09 113.69 26.03 Favored 'General case' 0 N--CA 1.471 0.586 0 C-N-CA 122.674 0.39 . . . . 0.0 110.468 -179.887 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 67.2 mt -98.68 135.65 32.76 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.73 0 N-CA-C 106.895 -1.52 . . . . 0.0 106.895 178.889 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' I' I ' 32' ' ' ILE . . . . . 0.419 ' C ' ' H ' ' I' ' 34' ' ' LEU . 35.0 pt -152.71 -173.92 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.774 0 CA-C-N 119.837 1.199 . . . . 0.0 109.826 -179.724 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.02 5.45 7.66 Favored Glycine 0 CA--C 1.527 0.811 0 N-CA-C 111.063 -0.815 . . . . 0.0 111.063 -179.942 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' I' I ' 34' ' ' LEU . . . . . 0.419 ' H ' ' C ' ' I' ' 32' ' ' ILE . 1.6 tt -74.97 125.94 29.96 Favored 'General case' 0 CA--C 1.546 0.789 0 N-CA-C 109.549 -0.538 . . . . 0.0 109.549 -179.706 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 27.5 ttt -161.45 152.48 18.35 Favored 'General case' 0 C--O 1.21 -0.981 0 N-CA-C 108.794 -0.817 . . . . 0.0 108.794 178.625 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 35.9 m -157.39 164.82 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.346 0.426 0 N-CA-C 108.468 -0.938 . . . . 0.0 108.468 -179.849 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.62 68.13 1.85 Allowed Glycine 0 C--N 1.308 -0.976 0 CA-C-N 115.501 -0.772 . . . . 0.0 112.137 178.294 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 144.01 -171.86 25.39 Favored Glycine 0 N--CA 1.476 1.302 0 N-CA-C 110.601 -1.0 . . . . 0.0 110.601 179.145 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' I' I ' 39' ' ' VAL . . . . . 0.506 HG11 ' H ' ' F' ' 39' ' ' VAL . 34.9 m -126.95 155.98 38.08 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.935 0 C-N-CA 123.118 0.567 . . . . 0.0 110.617 -179.359 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 31.8 t . . . . . 0 C--O 1.219 -0.542 0 O-C-N 123.953 0.783 . . . . 0.0 110.693 179.402 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 42.4 m-85 . . . . . 0 N--CA 1.474 0.758 0 N-CA-C 110.076 -0.342 . . . . 0.0 110.076 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -142.72 141.24 31.75 Favored 'General case' 0 N--CA 1.481 1.08 0 CA-C-O 120.861 0.363 . . . . 0.0 110.052 179.53 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 45.3 t-80 -152.11 119.03 5.79 Favored 'General case' 0 N--CA 1.471 0.613 0 N-CA-C 109.263 -0.643 . . . . 0.0 109.263 178.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' ASP . . . . . 0.501 ' O ' ' OG ' ' D' ' 8' ' ' SER . 4.5 m-20 -68.93 149.4 48.9 Favored 'General case' 0 CA--C 1.536 0.436 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.448 179.883 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 60.4 p -168.16 -173.78 2.13 Favored 'General case' 0 N--CA 1.484 1.228 0 CA-C-O 120.947 0.404 . . . . 0.0 110.635 179.224 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.37 46.85 1.37 Allowed Glycine 0 N--CA 1.482 1.721 0 CA-C-N 115.972 -0.558 . . . . 0.0 112.114 179.816 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 49.8 p90 -66.16 132.61 48.86 Favored 'General case' 0 N--CA 1.473 0.697 0 O-C-N 122.782 -0.246 . . . . 0.0 111.53 179.766 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 48.7 mt-10 -91.84 152.49 20.08 Favored 'General case' 0 N--CA 1.477 0.911 0 CA-C-O 121.066 0.46 . . . . 0.0 109.776 178.293 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.0 p -153.15 127.63 1.4 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.545 0 N-CA-C 107.915 -1.143 . . . . 0.0 107.915 178.363 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 44.1 m-70 -135.6 148.44 49.05 Favored 'General case' 0 N--CA 1.492 1.645 0 CA-C-N 119.09 0.859 . . . . 0.0 111.324 -179.064 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 7.0 t60 -163.67 97.81 0.87 Allowed 'General case' 0 N--CA 1.481 1.09 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.776 179.395 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . 0.506 HE22 ' H ' ' A' ' 37' ' ' GLY . 3.4 pt20 -107.63 -175.74 2.87 Favored 'General case' 0 CA--C 1.507 -0.68 0 N-CA-C 108.422 -0.955 . . . . 0.0 108.422 -179.98 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -169.63 100.56 0.32 Allowed 'General case' 0 CA--C 1.54 0.582 0 CA-C-N 114.629 -1.169 . . . . 0.0 108.466 179.029 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . 0.502 ' H ' ' CD2' ' D' ' 17' ' ' LEU . 6.9 mt -125.46 153.17 43.91 Favored 'General case' 0 N--CA 1.492 1.675 0 CA-C-O 121.443 0.64 . . . . 0.0 110.975 -178.284 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 60.4 t -107.8 129.26 62.17 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.21 0 CA-C-O 117.896 -1.05 . . . . 0.0 108.392 178.039 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 45.3 m-85 -125.97 122.72 36.73 Favored 'General case' 0 N--CA 1.497 1.919 0 CA-C-N 120.099 1.318 . . . . 0.0 110.367 179.272 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 74.2 m-85 53.09 75.02 0.26 Allowed 'General case' 0 N--CA 1.471 0.594 0 CA-C-O 121.361 0.6 . . . . 0.0 111.935 178.469 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -79.52 -78.32 0.16 Allowed 'General case' 0 C--N 1.353 0.739 0 CA-C-N 115.097 -0.956 . . . . 0.0 110.283 -179.796 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 39.9 tt0 -112.58 100.57 8.83 Favored 'General case' 0 N--CA 1.47 0.564 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 179.805 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -159.33 140.54 12.86 Favored 'General case' 0 C--O 1.207 -1.163 0 O-C-N 122.283 -0.261 . . . . 0.0 111.161 179.175 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 61.5 t -60.33 164.15 0.92 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.836 0 N-CA-C 108.154 -1.054 . . . . 0.0 108.154 177.174 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -117.66 48.89 0.9 Allowed Glycine 0 N--CA 1.477 1.426 0 N-CA-C 111.657 -0.577 . . . . 0.0 111.657 -179.353 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -61.92 -168.23 0.02 OUTLIER 'General case' 0 N--CA 1.469 0.486 0 O-C-N 123.845 0.38 . . . . 0.0 110.371 179.532 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 24.7 t-20 -70.17 81.11 0.51 Allowed 'General case' 0 N--CA 1.465 0.282 0 N-CA-C 110.144 -0.317 . . . . 0.0 110.144 179.792 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -79.65 146.43 32.49 Favored 'General case' 0 N--CA 1.472 0.627 0 N-CA-C 109.087 -0.708 . . . . 0.0 109.087 179.123 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -62.98 -168.54 0.93 Allowed Glycine 0 CA--C 1.524 0.653 0 N-CA-C 109.895 -1.282 . . . . 0.0 109.895 178.752 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -100.19 116.47 32.26 Favored 'General case' 0 N--CA 1.477 0.898 0 N-CA-C 109.685 -0.487 . . . . 0.0 109.685 179.723 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 69.4 mt -97.34 135.33 31.98 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.556 0 N-CA-C 107.102 -1.444 . . . . 0.0 107.102 179.003 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 44.1 pt -151.43 -178.17 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.713 0 CA-C-O 121.222 0.534 . . . . 0.0 111.11 -178.899 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 64.09 5.34 14.66 Favored Glycine 0 CA--C 1.526 0.728 0 N-CA-C 110.815 -0.914 . . . . 0.0 110.815 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 1.4 tt -73.79 128.7 36.2 Favored 'General case' 0 CA--C 1.545 0.776 0 N-CA-C 109.61 -0.515 . . . . 0.0 109.61 -179.714 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 28.7 ttt -163.55 147.39 10.44 Favored 'General case' 0 N--CA 1.465 0.305 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 178.506 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 31.6 m -155.13 163.54 1.55 Allowed 'Isoleucine or valine' 0 C--N 1.347 0.488 0 N-CA-C 108.11 -1.07 . . . . 0.0 108.11 179.503 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . 0.506 ' H ' HE22 ' A' ' 15' ' ' GLN . . . 55.4 68.15 1.84 Allowed Glycine 0 C--N 1.306 -1.134 0 CA-C-N 115.89 -0.596 . . . . 0.0 112.078 178.706 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 141.09 175.35 14.71 Favored Glycine 0 N--CA 1.475 1.273 0 N-CA-C 110.821 -0.912 . . . . 0.0 110.821 179.164 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . 0.424 ' H ' HG11 ' D' ' 39' ' ' VAL . 35.4 m -118.55 159.69 18.85 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.813 0 C-N-CA 123.364 0.666 . . . . 0.0 110.384 -179.998 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 22.1 t . . . . . 0 C--O 1.221 -0.441 0 CA-C-O 118.523 -0.751 . . . . 0.0 110.649 179.488 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 41.2 m-85 . . . . . 0 N--CA 1.474 0.751 0 N-CA-C 110.088 -0.338 . . . . 0.0 110.088 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -142.58 141.06 31.93 Favored 'General case' 0 N--CA 1.483 1.217 0 N-CA-C 109.98 -0.378 . . . . 0.0 109.98 179.437 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 44.4 t-80 -151.94 118.94 5.83 Favored 'General case' 0 N--CA 1.473 0.688 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 178.991 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 7' ' ' ASP . . . . . 0.481 ' O ' ' OG ' ' E' ' 8' ' ' SER . 4.3 m-20 -69.08 148.88 49.38 Favored 'General case' 0 CA--C 1.537 0.473 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.585 179.93 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 8' ' ' SER . . . . . . . . . . . . . 59.9 p -167.76 -173.73 2.23 Favored 'General case' 0 N--CA 1.482 1.144 0 CA-C-O 120.985 0.422 . . . . 0.0 110.644 179.336 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.23 46.72 1.41 Allowed Glycine 0 N--CA 1.482 1.753 0 CA-C-N 115.902 -0.59 . . . . 0.0 112.164 179.944 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 50.2 p90 -66.14 132.51 48.66 Favored 'General case' 0 N--CA 1.472 0.657 0 CA-C-O 120.624 0.25 . . . . 0.0 111.596 179.632 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 48.2 mt-10 -91.7 152.62 20.12 Favored 'General case' 0 N--CA 1.476 0.846 0 CA-C-O 121.076 0.465 . . . . 0.0 109.758 178.307 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.0 p -153.23 128.07 1.47 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.654 0 N-CA-C 107.772 -1.196 . . . . 0.0 107.772 178.167 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 43.6 m-70 -135.72 148.91 49.04 Favored 'General case' 0 N--CA 1.492 1.628 0 CA-C-N 118.837 0.744 . . . . 0.0 111.355 -179.145 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 7.2 t60 -164.3 97.62 0.8 Allowed 'General case' 0 N--CA 1.482 1.139 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.75 179.494 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . 0.521 HE22 ' H ' ' B' ' 37' ' ' GLY . 3.4 pt20 -107.41 -175.37 2.77 Favored 'General case' 0 CA--C 1.509 -0.623 0 N-CA-C 108.255 -1.017 . . . . 0.0 108.255 -179.921 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -169.96 100.18 0.3 Allowed 'General case' 0 N--CA 1.471 0.619 0 CA-C-N 114.667 -1.151 . . . . 0.0 108.415 178.995 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . 0.492 ' H ' ' CD2' ' E' ' 17' ' ' LEU . 6.9 mt -124.92 153.72 42.23 Favored 'General case' 0 N--CA 1.491 1.61 0 CA-C-O 121.506 0.669 . . . . 0.0 111.03 -178.39 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 61.3 t -108.4 130.33 61.25 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.221 0 N-CA-C 108.054 -1.091 . . . . 0.0 108.054 177.933 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 44.2 m-85 -127.24 122.06 32.92 Favored 'General case' 0 N--CA 1.494 1.766 0 CA-C-N 119.721 1.146 . . . . 0.0 110.221 179.524 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 74.7 m-85 52.89 75.28 0.25 Allowed 'General case' 0 CA--C 1.539 0.527 0 CA-C-O 121.427 0.632 . . . . 0.0 111.939 178.47 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -79.92 -78.06 0.17 Allowed 'General case' 0 C--N 1.351 0.666 0 CA-C-N 115.026 -0.988 . . . . 0.0 110.283 -179.839 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 40.2 tt0 -112.58 100.65 8.9 Favored 'General case' 0 N--CA 1.473 0.683 0 N-CA-C 108.349 -0.982 . . . . 0.0 108.349 179.73 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -159.34 141.24 13.4 Favored 'General case' 0 N--CA 1.484 1.235 0 O-C-N 122.222 -0.299 . . . . 0.0 111.144 179.193 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 61.4 t -61.0 163.9 1.05 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.852 0 N-CA-C 108.176 -1.046 . . . . 0.0 108.176 177.238 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -117.19 48.51 0.93 Allowed Glycine 0 N--CA 1.476 1.338 0 N-CA-C 111.581 -0.608 . . . . 0.0 111.581 -179.328 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -61.55 -167.43 0.01 OUTLIER 'General case' 0 N--CA 1.469 0.505 0 O-C-N 123.753 0.325 . . . . 0.0 110.364 179.494 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 24.8 t-20 -71.24 81.18 0.73 Allowed 'General case' 0 N--CA 1.465 0.324 0 N-CA-C 110.076 -0.342 . . . . 0.0 110.076 179.863 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -79.75 146.47 32.33 Favored 'General case' 0 N--CA 1.473 0.69 0 N-CA-C 109.096 -0.705 . . . . 0.0 109.096 179.274 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.03 -168.7 0.97 Allowed Glycine 0 C--N 1.336 0.56 0 N-CA-C 109.914 -1.274 . . . . 0.0 109.914 178.735 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.97 116.76 32.77 Favored 'General case' 0 N--CA 1.476 0.87 0 N-CA-C 109.668 -0.493 . . . . 0.0 109.668 179.789 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 69.8 mt -97.65 135.07 33.37 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.537 0 N-CA-C 107.07 -1.456 . . . . 0.0 107.07 178.972 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 43.7 pt -151.1 -177.94 0.38 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.681 0 CA-C-O 121.299 0.571 . . . . 0.0 111.159 -178.753 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.42 5.94 13.46 Favored Glycine 0 CA--C 1.525 0.692 0 N-CA-C 110.884 -0.887 . . . . 0.0 110.884 -179.967 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 1.4 tt -74.39 128.35 35.33 Favored 'General case' 0 CA--C 1.545 0.774 0 N-CA-C 109.528 -0.545 . . . . 0.0 109.528 -179.745 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 28.6 ttt -162.95 147.76 11.6 Favored 'General case' 0 N--CA 1.468 0.427 0 N-CA-C 108.797 -0.816 . . . . 0.0 108.797 178.607 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 29.9 m -155.68 163.31 1.53 Allowed 'Isoleucine or valine' 0 C--N 1.347 0.49 0 N-CA-C 108.096 -1.075 . . . . 0.0 108.096 179.516 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . 0.521 ' H ' HE22 ' B' ' 15' ' ' GLN . . . 55.67 67.74 2.05 Favored Glycine 0 C--N 1.306 -1.11 0 CA-C-N 115.881 -0.6 . . . . 0.0 112.014 178.676 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 141.17 175.65 14.97 Favored Glycine 0 N--CA 1.475 1.247 0 N-CA-C 110.891 -0.883 . . . . 0.0 110.891 179.079 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 39' ' ' VAL . . . . . 0.424 ' H ' HG11 ' E' ' 39' ' ' VAL . 35.5 m -118.56 159.87 18.73 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.89 0 C-N-CA 123.469 0.708 . . . . 0.0 110.476 -179.934 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 21.9 t . . . . . 0 N--CA 1.468 0.475 0 CA-C-O 118.364 -0.827 . . . . 0.0 110.468 179.362 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 41.3 m-85 . . . . . 0 N--CA 1.475 0.775 0 N-CA-C 110.128 -0.323 . . . . 0.0 110.128 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -143.34 140.49 30.55 Favored 'General case' 0 N--CA 1.481 1.097 0 N-CA-C 110.126 -0.324 . . . . 0.0 110.126 179.608 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 45.4 t-80 -151.51 119.24 6.13 Favored 'General case' 0 N--CA 1.472 0.667 0 N-CA-C 109.286 -0.635 . . . . 0.0 109.286 178.984 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 7' ' ' ASP . . . . . 0.49 ' O ' ' OG ' ' F' ' 8' ' ' SER . 4.4 m-20 -69.32 148.76 49.27 Favored 'General case' 0 CA--C 1.537 0.471 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.591 179.891 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' C' C ' 8' ' ' SER . . . . . . . . . . . . . 59.6 p -167.63 -173.64 2.24 Favored 'General case' 0 N--CA 1.482 1.143 0 CA-C-O 121.04 0.448 . . . . 0.0 110.621 179.202 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.28 47.19 1.34 Allowed Glycine 0 N--CA 1.482 1.702 0 CA-C-N 115.995 -0.548 . . . . 0.0 112.11 179.892 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 49.6 p90 -66.62 132.49 48.29 Favored 'General case' 0 N--CA 1.473 0.713 0 CA-C-O 120.761 0.315 . . . . 0.0 111.571 179.655 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 48.4 mt-10 -91.45 152.63 20.29 Favored 'General case' 0 N--CA 1.475 0.806 0 N-CA-C 109.719 -0.474 . . . . 0.0 109.719 178.253 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -153.33 128.01 1.44 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.548 0 N-CA-C 107.873 -1.158 . . . . 0.0 107.873 178.183 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 43.7 m-70 -135.92 148.51 48.58 Favored 'General case' 0 N--CA 1.492 1.643 0 CA-C-N 118.932 0.787 . . . . 0.0 111.305 -179.055 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 7.1 t60 -163.86 97.56 0.85 Allowed 'General case' 0 N--CA 1.483 1.182 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.794 179.475 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 15' ' ' GLN . . . . . 0.524 HE22 ' H ' ' C' ' 37' ' ' GLY . 3.4 pt20 -107.43 -175.09 2.69 Favored 'General case' 0 CA--C 1.508 -0.662 0 N-CA-C 108.237 -1.023 . . . . 0.0 108.237 -179.96 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -170.29 100.27 0.27 Allowed 'General case' 0 N--CA 1.471 0.577 0 CA-C-N 114.59 -1.186 . . . . 0.0 108.415 179.192 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 17' ' ' LEU . . . . . 0.483 ' H ' ' CD2' ' F' ' 17' ' ' LEU . 6.9 mt -125.14 153.47 42.96 Favored 'General case' 0 N--CA 1.492 1.665 0 CA-C-O 121.52 0.676 . . . . 0.0 111.03 -178.217 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 61.2 t -108.07 130.22 60.97 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.188 0 N-CA-C 108.229 -1.026 . . . . 0.0 108.229 177.844 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 44.3 m-85 -127.16 121.99 32.89 Favored 'General case' 0 N--CA 1.493 1.68 0 CA-C-N 119.655 1.116 . . . . 0.0 110.349 179.454 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 74.2 m-85 52.84 75.22 0.25 Allowed 'General case' 0 N--CA 1.469 0.508 0 CA-C-O 121.518 0.675 . . . . 0.0 111.98 178.529 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -79.83 -77.97 0.17 Allowed 'General case' 0 C--N 1.35 0.6 0 CA-C-N 114.876 -1.056 . . . . 0.0 110.267 -179.814 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 39.8 tt0 -112.68 100.71 8.92 Favored 'General case' 0 N--CA 1.471 0.586 0 N-CA-C 108.3 -1.0 . . . . 0.0 108.3 179.736 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -159.41 140.83 12.98 Favored 'General case' 0 N--CA 1.483 1.178 0 O-C-N 122.22 -0.3 . . . . 0.0 111.226 179.124 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 60.2 t -60.39 164.34 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.871 0 N-CA-C 108.087 -1.079 . . . . 0.0 108.087 177.23 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -117.63 48.82 0.91 Allowed Glycine 0 N--CA 1.479 1.519 0 N-CA-C 111.45 -0.66 . . . . 0.0 111.45 -179.43 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -61.91 -167.92 0.01 OUTLIER 'General case' 0 N--CA 1.468 0.425 0 O-C-N 123.707 0.298 . . . . 0.0 110.386 179.547 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 24.8 t-20 -70.54 80.9 0.58 Allowed 'General case' 0 N--CA 1.466 0.353 0 N-CA-C 110.113 -0.329 . . . . 0.0 110.113 179.692 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -79.51 146.57 32.61 Favored 'General case' 0 N--CA 1.473 0.698 0 N-CA-C 109.065 -0.717 . . . . 0.0 109.065 179.239 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.08 -168.76 1.0 Allowed Glycine 0 CA--C 1.525 0.699 0 N-CA-C 109.98 -1.248 . . . . 0.0 109.98 178.806 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.96 116.35 31.82 Favored 'General case' 0 N--CA 1.478 0.974 0 N-CA-C 109.657 -0.498 . . . . 0.0 109.657 179.757 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 69.3 mt -97.45 135.13 32.87 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.54 0 N-CA-C 107.16 -1.422 . . . . 0.0 107.16 179.034 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 43.9 pt -151.12 -177.91 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.649 0 CA-C-N 115.995 -0.548 . . . . 0.0 111.304 -178.691 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.59 5.58 13.11 Favored Glycine 0 CA--C 1.524 0.6 0 N-CA-C 110.853 -0.899 . . . . 0.0 110.853 -179.987 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 1.4 tt -74.07 128.17 34.84 Favored 'General case' 0 CA--C 1.545 0.774 0 N-CA-C 109.626 -0.509 . . . . 0.0 109.626 -179.738 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 28.5 ttt -162.94 147.38 11.44 Favored 'General case' 0 N--CA 1.466 0.364 0 N-CA-C 108.679 -0.86 . . . . 0.0 108.679 178.666 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 33.7 m -155.25 163.38 1.57 Allowed 'Isoleucine or valine' 0 C--N 1.348 0.516 0 N-CA-C 108.125 -1.065 . . . . 0.0 108.125 179.49 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 37' ' ' GLY . . . . . 0.524 ' H ' HE22 ' C' ' 15' ' ' GLN . . . 55.32 67.85 1.99 Allowed Glycine 0 C--N 1.306 -1.135 0 CA-C-N 115.881 -0.6 . . . . 0.0 112.104 178.712 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 141.67 176.07 15.66 Favored Glycine 0 N--CA 1.475 1.248 0 N-CA-C 110.885 -0.886 . . . . 0.0 110.885 179.11 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 39' ' ' VAL . . . . . 0.415 ' H ' HG11 ' F' ' 39' ' ' VAL . 35.6 m -119.16 159.56 19.77 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.878 0 C-N-CA 123.349 0.66 . . . . 0.0 110.451 179.891 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 21.9 t . . . . . 0 N--CA 1.467 0.4 0 CA-C-O 118.45 -0.786 . . . . 0.0 110.473 179.443 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 42.3 m-85 . . . . . 0 N--CA 1.471 0.611 0 N-CA-C 108.941 -0.763 . . . . 0.0 108.941 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' D' D ' 5' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -144.54 139.7 28.35 Favored 'General case' 0 N--CA 1.475 0.797 0 CA-C-N 116.374 -0.375 . . . . 0.0 110.214 179.869 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 41.0 t-80 -149.77 123.96 9.49 Favored 'General case' 0 CA--C 1.545 0.782 0 N-CA-C 108.142 -1.058 . . . . 0.0 108.142 174.72 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 7' ' ' ASP . . . . . 0.591 ' O ' ' OG ' ' G' ' 8' ' ' SER . 3.1 m-20 -63.6 132.98 52.89 Favored 'General case' 0 C--N 1.321 -0.647 0 C-N-CA 126.846 2.058 . . . . 0.0 114.209 174.62 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' D' D ' 8' ' ' SER . . . . . 0.501 ' OG ' ' O ' ' A' ' 7' ' ' ASP . 59.8 p -154.51 -170.8 3.64 Favored 'General case' 0 N--CA 1.488 1.454 0 CA-C-N 119.675 1.125 . . . . 0.0 111.255 175.246 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.39 47.91 1.17 Allowed Glycine 0 N--CA 1.481 1.666 0 C-N-CA 124.663 1.125 . . . . 0.0 110.632 174.321 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 51.5 p90 -60.99 131.56 51.02 Favored 'General case' 0 N--CA 1.47 0.526 0 N-CA-C 112.613 0.598 . . . . 0.0 112.613 177.559 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 48.3 mt-10 -89.64 151.01 22.11 Favored 'General case' 0 N--CA 1.479 1.025 0 CA-C-N 117.989 0.359 . . . . 0.0 110.662 174.982 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.0 p -149.64 129.95 4.22 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.662 0 N-CA-C 107.307 -1.368 . . . . 0.0 107.307 173.058 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 38.6 m-70 -129.79 151.63 50.16 Favored 'General case' 0 N--CA 1.483 1.182 0 N-CA-C 112.264 0.468 . . . . 0.0 112.264 176.639 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 7.3 t60 -164.68 104.75 0.82 Allowed 'General case' 0 N--CA 1.483 1.201 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 172.261 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 15' ' ' GLN . . . . . 0.482 HE22 ' H ' ' D' ' 37' ' ' GLY . 3.4 pt20 -111.05 -176.47 2.96 Favored 'General case' 0 CA--C 1.502 -0.884 0 N-CA-C 108.002 -1.11 . . . . 0.0 108.002 179.007 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -167.03 106.44 0.59 Allowed 'General case' 0 N--CA 1.466 0.337 0 N-CA-C 106.947 -1.501 . . . . 0.0 106.947 176.404 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 17' ' ' LEU . . . . . 0.517 ' H ' ' CD2' ' G' ' 17' ' ' LEU . 9.9 mt -130.57 152.35 50.04 Favored 'General case' 0 N--CA 1.493 1.702 0 CA-C-O 121.864 0.84 . . . . 0.0 110.493 179.651 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 38.6 t -99.65 133.09 43.73 Favored 'Isoleucine or valine' 0 C--O 1.259 1.596 0 CA-C-O 116.97 -1.49 . . . . 0.0 109.645 175.007 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 40.6 m-85 -130.04 125.97 36.54 Favored 'General case' 0 N--CA 1.489 1.523 0 CA-C-N 119.792 1.178 . . . . 0.0 109.357 174.144 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 74.1 m-85 55.87 71.87 0.53 Allowed 'General case' 0 C--N 1.352 0.693 0 CA-C-N 115.105 -0.952 . . . . 0.0 111.411 176.063 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -81.82 -73.0 0.41 Allowed 'General case' 0 N--CA 1.472 0.66 0 CA-C-O 118.369 -0.824 . . . . 0.0 111.005 -177.305 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 40.3 tt0 -115.98 104.17 11.33 Favored 'General case' 0 N--CA 1.484 1.262 0 N-CA-C 106.404 -1.702 . . . . 0.0 106.404 176.392 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -152.21 140.8 20.77 Favored 'General case' 0 N--CA 1.475 0.789 0 CA-C-O 116.748 -1.596 . . . . 0.0 113.634 177.867 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 24' ' ' VAL . . . . . . . . . . . . . 66.7 t -62.95 166.57 0.97 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.237 0 CA-C-N 121.097 1.771 . . . . 0.0 107.979 174.782 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 25' ' ' GLY . . . . . 0.402 ' H ' ' HB ' ' G' ' 24' ' ' VAL . . . -116.67 51.07 0.75 Allowed Glycine 0 N--CA 1.481 1.667 0 CA-C-O 118.876 -0.958 . . . . 0.0 111.715 178.636 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -58.29 -170.73 0.01 OUTLIER 'General case' 0 C--N 1.322 -0.619 0 C-N-CA 123.38 0.672 . . . . 0.0 111.637 176.638 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 25.4 t-20 -72.43 86.71 1.15 Allowed 'General case' 0 CA--C 1.537 0.453 0 N-CA-C 108.425 -0.954 . . . . 0.0 108.425 178.45 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 97.6 mttt -84.26 148.71 26.55 Favored 'General case' 0 N--CA 1.474 0.758 0 N-CA-C 108.155 -1.054 . . . . 0.0 108.155 178.884 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -62.7 -165.73 0.55 Allowed Glycine 0 C--N 1.337 0.614 0 N-CA-C 110.461 -1.056 . . . . 0.0 110.461 179.374 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -102.09 115.99 31.72 Favored 'General case' 0 N--CA 1.467 0.385 0 C-N-CA 123.186 0.595 . . . . 0.0 109.921 179.832 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 80.4 mt -102.41 142.46 16.6 Favored 'Isoleucine or valine' 0 C--N 1.355 0.836 0 N-CA-C 104.327 -2.472 . . . . 0.0 104.327 -178.908 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 38.6 pt -157.68 -179.05 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.241 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.118 -176.161 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 64.73 5.7 19.6 Favored Glycine 0 C--O 1.244 0.758 0 N-CA-C 110.003 -1.239 . . . . 0.0 110.003 -178.573 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 1.7 tt -76.42 134.14 39.68 Favored 'General case' 0 C--N 1.361 1.084 0 N-CA-C 107.244 -1.391 . . . . 0.0 107.244 -177.829 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 28.2 ttt -157.91 159.99 37.15 Favored 'General case' 0 CA--C 1.517 -0.319 0 N-CA-C 108.225 -1.028 . . . . 0.0 108.225 172.577 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 31.0 m -164.8 163.63 0.71 Allowed 'Isoleucine or valine' 0 C--O 1.223 -0.31 0 N-CA-C 107.765 -1.198 . . . . 0.0 107.765 174.232 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 37' ' ' GLY . . . . . 0.482 ' H ' HE22 ' D' ' 15' ' ' GLN . . . 59.9 63.71 4.84 Favored Glycine 0 CA--C 1.528 0.884 0 C-N-CA 120.435 -0.888 . . . . 0.0 111.335 178.024 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.18 179.66 20.01 Favored Glycine 0 N--CA 1.481 1.651 0 N-CA-C 111.057 -0.817 . . . . 0.0 111.057 178.352 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 39' ' ' VAL . . . . . 0.437 ' H ' HG11 ' G' ' 39' ' ' VAL . 33.9 m -120.54 157.02 23.56 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.822 0 C-N-CA 123.133 0.573 . . . . 0.0 110.94 179.461 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 22.0 t . . . . . 0 C--N 1.333 -0.14 0 CA-C-O 116.665 -1.636 . . . . 0.0 109.536 175.794 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 38.8 m-85 . . . . . 0 N--CA 1.475 0.806 0 N-CA-C 110.152 -0.314 . . . . 0.0 110.152 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' E' E ' 5' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -142.72 140.97 31.69 Favored 'General case' 0 N--CA 1.482 1.126 0 CA-C-O 120.904 0.383 . . . . 0.0 110.077 179.395 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 45.0 t-80 -151.4 118.8 6.0 Favored 'General case' 0 N--CA 1.472 0.669 0 N-CA-C 109.227 -0.657 . . . . 0.0 109.227 178.83 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' E' E ' 7' ' ' ASP . . . . . 0.495 ' O ' ' OG ' ' H' ' 8' ' ' SER . 4.2 m-20 -69.57 148.66 49.1 Favored 'General case' 0 N--CA 1.467 0.379 0 CA-C-N 116.435 -0.348 . . . . 0.0 110.745 179.941 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' E' E ' 8' ' ' SER . . . . . 0.481 ' OG ' ' O ' ' B' ' 7' ' ' ASP . 56.0 p -168.26 -172.51 1.76 Allowed 'General case' 0 N--CA 1.486 1.343 0 CA-C-O 121.099 0.476 . . . . 0.0 110.784 178.917 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.71 47.09 1.31 Allowed Glycine 0 N--CA 1.478 1.493 0 CA-C-N 115.912 -0.585 . . . . 0.0 112.101 179.807 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 47.7 p90 -65.82 133.22 50.51 Favored 'General case' 0 N--CA 1.473 0.721 0 N-CA-C 111.908 0.336 . . . . 0.0 111.908 -179.948 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 48.6 mt-10 -91.47 152.98 20.13 Favored 'General case' 0 N--CA 1.48 1.054 0 CA-C-O 121.245 0.545 . . . . 0.0 109.629 177.943 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -154.97 126.78 0.95 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.63 0 N-CA-C 107.739 -1.208 . . . . 0.0 107.739 178.135 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 42.2 m-70 -135.69 146.86 48.2 Favored 'General case' 0 N--CA 1.482 1.14 0 CA-C-O 120.849 0.357 . . . . 0.0 111.531 -178.126 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 7.1 t60 -163.0 97.64 0.93 Allowed 'General case' 0 N--CA 1.485 1.288 0 CA-C-N 116.365 -0.38 . . . . 0.0 110.717 179.506 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' E' E ' 15' ' ' GLN . . . . . 0.502 HE22 ' H ' ' E' ' 37' ' ' GLY . 3.4 pt20 -106.99 -175.22 2.73 Favored 'General case' 0 CA--C 1.51 -0.564 0 N-CA-C 108.521 -0.918 . . . . 0.0 108.521 -179.928 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -169.84 99.81 0.31 Allowed 'General case' 0 N--CA 1.473 0.713 0 CA-C-N 114.654 -1.157 . . . . 0.0 108.617 179.004 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' E' E ' 17' ' ' LEU . . . . . 0.524 ' H ' ' CD2' ' H' ' 17' ' ' LEU . 7.3 mt -123.9 153.89 40.5 Favored 'General case' 0 N--CA 1.49 1.549 0 CA-C-O 121.348 0.594 . . . . 0.0 111.505 -177.767 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 49.9 t -110.7 126.3 68.04 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.307 0 N-CA-C 108.205 -1.035 . . . . 0.0 108.205 177.604 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 46.6 m-85 -123.79 121.22 34.87 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 123.37 0.419 . . . . 0.0 111.038 -179.821 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 73.7 m-85 54.06 74.33 0.34 Allowed 'General case' 0 N--CA 1.47 0.542 0 CA-C-N 115.922 -0.581 . . . . 0.0 111.594 178.061 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -78.18 -78.96 0.13 Allowed 'General case' 0 CA--C 1.535 0.375 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.095 -179.488 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 39.9 tt0 -111.67 100.97 9.39 Favored 'General case' 0 N--CA 1.469 0.482 0 N-CA-C 108.438 -0.949 . . . . 0.0 108.438 -179.989 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -158.61 140.73 13.95 Favored 'General case' 0 C--O 1.204 -1.296 0 CA-C-O 119.581 -0.247 . . . . 0.0 111.535 179.147 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 57.6 t -58.86 169.03 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.851 0 N-CA-C 107.691 -1.225 . . . . 0.0 107.691 177.017 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . -122.51 49.59 0.88 Allowed Glycine 0 N--CA 1.477 1.383 0 N-CA-C 110.674 -0.971 . . . . 0.0 110.674 -179.479 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -63.07 -167.57 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.553 0 CA-C-O 120.644 0.259 . . . . 0.0 110.601 179.774 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 25.1 t-20 -69.93 78.12 0.48 Allowed 'General case' 0 N--CA 1.466 0.351 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.383 -179.944 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -77.32 146.73 36.58 Favored 'General case' 0 N--CA 1.475 0.81 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 179.28 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.39 -168.33 1.08 Allowed Glycine 0 CA--C 1.522 0.518 0 N-CA-C 110.522 -1.031 . . . . 0.0 110.522 178.623 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.74 115.45 29.55 Favored 'General case' 0 N--CA 1.468 0.461 0 N-CA-C 109.904 -0.406 . . . . 0.0 109.904 179.471 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 70.5 mt -96.38 135.09 31.6 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.282 0 N-CA-C 106.942 -1.503 . . . . 0.0 106.942 179.037 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 39.0 pt -151.1 -176.16 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.229 0 CA-C-O 121.164 0.506 . . . . 0.0 110.737 -179.157 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.2 5.97 9.25 Favored Glycine 0 CA--C 1.529 0.963 0 CA-C-N 115.322 -0.853 . . . . 0.0 111.243 -179.517 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 1.4 tt -73.8 128.68 36.16 Favored 'General case' 0 CA--C 1.548 0.884 0 N-CA-C 109.629 -0.508 . . . . 0.0 109.629 -179.544 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 28.4 ttt -162.93 148.79 12.11 Favored 'General case' 0 C--O 1.209 -1.056 0 N-CA-C 108.925 -0.769 . . . . 0.0 108.925 178.484 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 34.0 m -156.97 162.73 1.5 Allowed 'Isoleucine or valine' 0 C--N 1.344 0.344 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 179.862 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' E' E ' 37' ' ' GLY . . . . . 0.502 ' H ' HE22 ' E' ' 15' ' ' GLN . . . 55.94 66.8 2.59 Favored Glycine 0 C--N 1.307 -1.06 0 CA-C-N 115.933 -0.576 . . . . 0.0 111.939 178.537 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 142.56 176.81 17.01 Favored Glycine 0 N--CA 1.477 1.382 0 N-CA-C 111.149 -0.78 . . . . 0.0 111.149 179.007 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' E' E ' 39' ' ' VAL . . . . . 0.45 ' H ' HG11 ' H' ' 39' ' ' VAL . 33.3 m -119.93 158.62 21.68 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.749 0 C-N-CA 123.392 0.677 . . . . 0.0 110.626 -179.595 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 22.6 t . . . . . 0 C--O 1.22 -0.478 0 CA-C-O 118.448 -0.787 . . . . 0.0 110.482 179.112 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 38.2 m-85 . . . . . 0 N--CA 1.474 0.75 0 N-CA-C 110.135 -0.32 . . . . 0.0 110.135 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' F' F ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -142.47 141.24 32.13 Favored 'General case' 0 N--CA 1.478 0.959 0 CA-C-O 120.805 0.336 . . . . 0.0 110.249 179.41 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 43.9 t-80 -151.92 118.74 5.78 Favored 'General case' 0 N--CA 1.472 0.659 0 N-CA-C 109.315 -0.624 . . . . 0.0 109.315 178.928 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' F' F ' 7' ' ' ASP . . . . . 0.495 ' O ' ' OG ' ' I' ' 8' ' ' SER . 4.3 m-20 -69.35 148.64 49.39 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 116.411 -0.359 . . . . 0.0 110.814 -179.96 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' F' F ' 8' ' ' SER . . . . . 0.49 ' OG ' ' O ' ' C' ' 7' ' ' ASP . 56.1 p -168.33 -172.79 1.81 Allowed 'General case' 0 N--CA 1.487 1.422 0 CA-C-O 121.111 0.482 . . . . 0.0 110.924 178.8 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.93 47.01 1.3 Allowed Glycine 0 N--CA 1.479 1.502 0 CA-C-N 115.978 -0.556 . . . . 0.0 112.064 179.877 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 47.7 p90 -65.57 133.03 50.32 Favored 'General case' 0 CA--C 1.543 0.673 0 N-CA-C 111.852 0.316 . . . . 0.0 111.852 -179.954 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 48.3 mt-10 -91.48 152.33 20.4 Favored 'General case' 0 N--CA 1.48 1.042 0 CA-C-O 121.195 0.521 . . . . 0.0 109.713 177.818 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -154.18 126.87 1.09 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.608 0 N-CA-C 107.825 -1.176 . . . . 0.0 107.825 177.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 41.9 m-70 -135.67 146.9 48.29 Favored 'General case' 0 N--CA 1.483 1.2 0 CA-C-O 120.936 0.398 . . . . 0.0 111.582 -178.142 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 7.1 t60 -162.98 97.49 0.93 Allowed 'General case' 0 N--CA 1.486 1.371 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.821 179.55 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' F' F ' 15' ' ' GLN . . . . . 0.513 HE22 ' H ' ' F' ' 37' ' ' GLY . 3.4 pt20 -107.06 -175.22 2.73 Favored 'General case' 0 CA--C 1.507 -0.675 0 N-CA-C 108.482 -0.932 . . . . 0.0 108.482 -179.939 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -169.77 99.86 0.31 Allowed 'General case' 0 N--CA 1.47 0.572 0 CA-C-N 114.712 -1.131 . . . . 0.0 108.606 179.052 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' F' F ' 17' ' ' LEU . . . . . 0.509 ' H ' ' CD2' ' I' ' 17' ' ' LEU . 7.2 mt -123.81 154.33 39.73 Favored 'General case' 0 N--CA 1.489 1.501 0 CA-C-O 121.273 0.558 . . . . 0.0 111.461 -177.735 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 51.8 t -111.07 126.21 68.45 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.325 0 N-CA-C 108.262 -1.014 . . . . 0.0 108.262 177.529 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 47.0 m-85 -123.71 121.15 34.76 Favored 'General case' 0 C--N 1.367 1.363 0 CA-C-O 120.972 0.415 . . . . 0.0 111.018 -179.819 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 74.1 m-85 54.23 74.31 0.34 Allowed 'General case' 0 N--CA 1.469 0.477 0 CA-C-N 115.871 -0.604 . . . . 0.0 111.743 178.054 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -78.15 -78.98 0.13 Allowed 'General case' 0 N--CA 1.465 0.32 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.228 -179.551 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 39.7 tt0 -111.71 101.19 9.58 Favored 'General case' 0 N--CA 1.469 0.5 0 N-CA-C 108.325 -0.991 . . . . 0.0 108.325 -179.986 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -158.86 140.6 13.53 Favored 'General case' 0 C--O 1.205 -1.277 0 CA-C-O 119.584 -0.246 . . . . 0.0 111.483 179.089 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' F' F ' 24' ' ' VAL . . . . . . . . . . . . . 57.4 t -58.81 168.91 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.885 0 N-CA-C 107.591 -1.263 . . . . 0.0 107.591 177.057 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -122.31 49.4 0.89 Allowed Glycine 0 N--CA 1.477 1.402 0 N-CA-C 110.751 -0.94 . . . . 0.0 110.751 -179.478 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -63.16 -168.39 0.02 OUTLIER 'General case' 0 N--CA 1.469 0.489 0 CA-C-O 120.635 0.255 . . . . 0.0 110.447 -179.975 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 25.1 t-20 -69.11 77.96 0.34 Allowed 'General case' 0 CA--C 1.533 0.292 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.484 -179.908 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -77.18 147.02 36.69 Favored 'General case' 0 N--CA 1.475 0.816 0 N-CA-C 109.468 -0.567 . . . . 0.0 109.468 179.239 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.44 -168.11 1.07 Allowed Glycine 0 CA--C 1.522 0.481 0 N-CA-C 110.612 -0.995 . . . . 0.0 110.612 178.569 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.54 114.85 28.1 Favored 'General case' 0 N--CA 1.469 0.504 0 N-CA-C 109.891 -0.411 . . . . 0.0 109.891 179.484 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 70.6 mt -96.16 135.02 31.59 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.298 0 N-CA-C 106.987 -1.486 . . . . 0.0 106.987 178.895 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 38.6 pt -151.16 -176.32 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.251 0 CA-C-O 121.191 0.519 . . . . 0.0 110.739 -179.184 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.39 6.0 9.79 Favored Glycine 0 CA--C 1.529 0.937 0 CA-C-N 115.29 -0.868 . . . . 0.0 111.186 -179.622 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 1.3 tt -73.64 128.69 36.18 Favored 'General case' 0 CA--C 1.549 0.913 0 N-CA-C 109.538 -0.541 . . . . 0.0 109.538 -179.586 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 28.4 ttt -162.96 148.73 12.03 Favored 'General case' 0 C--O 1.208 -1.094 0 N-CA-C 108.82 -0.807 . . . . 0.0 108.82 178.378 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 34.1 m -156.75 163.0 1.46 Allowed 'Isoleucine or valine' 0 C--N 1.346 0.429 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 179.872 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' F' F ' 37' ' ' GLY . . . . . 0.513 ' H ' HE22 ' F' ' 15' ' ' GLN . . . 55.58 67.1 2.39 Favored Glycine 0 C--N 1.307 -1.061 0 CA-C-N 115.944 -0.571 . . . . 0.0 111.947 178.45 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 142.35 176.85 16.87 Favored Glycine 0 N--CA 1.476 1.325 0 N-CA-C 111.155 -0.778 . . . . 0.0 111.155 179.036 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' F' F ' 39' ' ' VAL . . . . . 0.439 ' H ' HG11 ' I' ' 39' ' ' VAL . 33.4 m -119.95 158.92 21.55 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.629 0 C-N-CA 123.374 0.67 . . . . 0.0 110.649 -179.675 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 23.6 t . . . . . 0 C--O 1.221 -0.417 0 CA-C-O 118.549 -0.738 . . . . 0.0 110.499 179.071 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 40.8 m-85 . . . . . 0 N--CA 1.473 0.719 0 N-CA-C 109.643 -0.503 . . . . 0.0 109.643 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' G' G ' 5' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -142.98 141.02 31.3 Favored 'General case' 0 N--CA 1.482 1.15 0 CA-C-O 120.816 0.341 . . . . 0.0 110.188 179.721 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 44.3 t-80 -151.53 119.48 6.22 Favored 'General case' 0 N--CA 1.474 0.743 0 N-CA-C 109.384 -0.599 . . . . 0.0 109.384 178.948 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -71.04 144.53 50.36 Favored 'General case' 0 N--CA 1.471 0.583 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.212 -179.822 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' G' G ' 8' ' ' SER . . . . . 0.591 ' OG ' ' O ' ' D' ' 7' ' ' ASP . 54.4 p -165.31 -171.22 2.1 Favored 'General case' 0 N--CA 1.476 0.861 0 CA-C-O 121.054 0.454 . . . . 0.0 110.436 178.644 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.88 46.76 1.33 Allowed Glycine 0 N--CA 1.479 1.566 0 CA-C-N 115.809 -0.632 . . . . 0.0 111.607 179.533 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 50.0 p90 -65.44 133.05 50.48 Favored 'General case' 0 N--CA 1.472 0.649 0 N-CA-C 111.835 0.309 . . . . 0.0 111.835 -179.795 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 49.1 mt-10 -91.88 151.89 20.34 Favored 'General case' 0 N--CA 1.479 1.001 0 CA-C-O 121.108 0.48 . . . . 0.0 110.062 178.401 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -155.08 127.04 0.97 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.021 0 N-CA-C 107.886 -1.153 . . . . 0.0 107.886 178.33 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 43.1 m-70 -135.01 148.39 49.94 Favored 'General case' 0 N--CA 1.478 0.944 0 CA-C-N 115.49 -0.777 . . . . 0.0 111.414 -178.399 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 7.2 t60 -164.49 97.29 0.78 Allowed 'General case' 0 N--CA 1.484 1.227 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.486 178.907 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' G' G ' 15' ' ' GLN . . . . . 0.504 HE22 ' H ' ' G' ' 37' ' ' GLY . 3.5 pt20 -106.88 -175.67 2.86 Favored 'General case' 0 CA--C 1.508 -0.664 0 N-CA-C 108.364 -0.976 . . . . 0.0 108.364 -179.821 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -169.98 99.52 0.29 Allowed 'General case' 0 N--CA 1.473 0.691 0 CA-C-N 114.649 -1.159 . . . . 0.0 108.345 179.176 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' G' G ' 17' ' ' LEU . . . . . 0.517 ' CD2' ' H ' ' D' ' 17' ' ' LEU . 8.2 mt -123.4 153.94 39.69 Favored 'General case' 0 N--CA 1.495 1.786 0 CA-C-O 121.085 0.469 . . . . 0.0 111.789 -177.863 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 43.4 t -111.26 126.39 68.65 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.038 0 N-CA-C 108.1 -1.074 . . . . 0.0 108.1 177.021 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 48.0 m-85 -124.12 120.77 33.3 Favored 'General case' 0 C--N 1.367 1.346 0 CA-C-N 115.602 -0.726 . . . . 0.0 111.192 -179.539 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 73.8 m-85 54.46 73.66 0.39 Allowed 'General case' 0 N--CA 1.47 0.526 0 CA-C-N 115.896 -0.593 . . . . 0.0 111.594 178.008 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.04 -78.32 0.13 Allowed 'General case' 0 N--CA 1.471 0.59 0 O-C-N 122.282 -0.262 . . . . 0.0 110.446 -179.032 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 40.4 tt0 -112.25 101.07 9.32 Favored 'General case' 0 C--N 1.322 -0.629 0 N-CA-C 108.108 -1.071 . . . . 0.0 108.108 179.839 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -158.38 142.38 15.6 Favored 'General case' 0 N--CA 1.478 0.926 0 O-C-N 122.387 -0.195 . . . . 0.0 111.442 179.01 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' G' G ' 24' ' ' VAL . . . . . 0.402 ' HB ' ' H ' ' D' ' 25' ' ' GLY . 59.7 t -60.97 167.76 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.644 0 N-CA-C 107.67 -1.233 . . . . 0.0 107.67 177.384 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -120.64 49.95 0.85 Allowed Glycine 0 N--CA 1.482 1.755 0 N-CA-C 110.338 -1.105 . . . . 0.0 110.338 -179.58 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -63.78 -167.61 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.661 0 CA-C-N 116.984 0.392 . . . . 0.0 109.987 179.833 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 25.2 t-20 -70.11 77.71 0.51 Allowed 'General case' 0 CA--C 1.536 0.407 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.451 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -76.16 146.72 38.98 Favored 'General case' 0 N--CA 1.475 0.818 0 N-CA-C 109.506 -0.553 . . . . 0.0 109.506 179.306 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.62 -167.01 0.95 Allowed Glycine 0 C--N 1.336 0.578 0 N-CA-C 110.076 -1.21 . . . . 0.0 110.076 178.721 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.58 115.26 28.98 Favored 'General case' 0 N--CA 1.469 0.516 0 C-N-CA 122.689 0.395 . . . . 0.0 110.438 179.841 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 72.1 mt -97.1 135.99 29.41 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.671 0 N-CA-C 106.87 -1.53 . . . . 0.0 106.87 178.931 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 36.8 pt -152.47 -176.01 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.71 0 CA-C-N 119.855 1.207 . . . . 0.0 109.95 -179.631 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.09 5.83 11.27 Favored Glycine 0 CA--C 1.527 0.811 0 N-CA-C 110.878 -0.889 . . . . 0.0 110.878 -179.763 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 1.4 tt -74.3 127.4 32.89 Favored 'General case' 0 CA--C 1.546 0.796 0 N-CA-C 109.7 -0.482 . . . . 0.0 109.7 -179.503 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 28.1 ttt -161.56 150.22 15.73 Favored 'General case' 0 C--O 1.212 -0.897 0 N-CA-C 108.844 -0.798 . . . . 0.0 108.844 178.533 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 33.9 m -157.4 162.11 1.62 Allowed 'Isoleucine or valine' 0 C--N 1.346 0.451 0 N-CA-C 108.628 -0.878 . . . . 0.0 108.628 -179.819 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' G' G ' 37' ' ' GLY . . . . . 0.504 ' H ' HE22 ' G' ' 15' ' ' GLN . . . 55.61 67.01 2.43 Favored Glycine 0 C--N 1.312 -0.803 0 CA-C-N 115.599 -0.728 . . . . 0.0 112.299 178.111 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.33 178.3 19.02 Favored Glycine 0 N--CA 1.477 1.383 0 N-CA-C 110.569 -1.012 . . . . 0.0 110.569 178.925 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' G' G ' 39' ' ' VAL . . . . . 0.437 HG11 ' H ' ' D' ' 39' ' ' VAL . 34.2 m -121.34 158.37 24.3 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.837 0 C-N-CA 123.128 0.571 . . . . 0.0 110.6 -179.621 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 22.2 t . . . . . 0 N--CA 1.469 0.515 0 O-C-N 123.981 0.801 . . . . 0.0 110.752 179.163 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 42.2 m-85 . . . . . 0 N--CA 1.474 0.744 0 N-CA-C 109.603 -0.517 . . . . 0.0 109.603 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' H' H ' 5' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -142.91 141.35 31.48 Favored 'General case' 0 N--CA 1.484 1.263 0 N-CA-C 110.081 -0.34 . . . . 0.0 110.081 179.732 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 44.3 t-80 -151.89 119.54 6.09 Favored 'General case' 0 N--CA 1.474 0.745 0 N-CA-C 109.334 -0.617 . . . . 0.0 109.334 178.901 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -70.96 144.57 50.49 Favored 'General case' 0 N--CA 1.47 0.57 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.251 -179.884 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' H' H ' 8' ' ' SER . . . . . 0.495 ' OG ' ' O ' ' E' ' 7' ' ' ASP . 60.2 p -165.26 -171.55 2.22 Favored 'General case' 0 N--CA 1.474 0.758 0 CA-C-O 120.976 0.417 . . . . 0.0 110.485 178.751 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.83 46.62 1.36 Allowed Glycine 0 N--CA 1.481 1.645 0 CA-C-N 115.986 -0.552 . . . . 0.0 111.756 179.699 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 50.3 p90 -65.64 133.15 50.52 Favored 'General case' 0 N--CA 1.471 0.625 0 N-CA-C 111.798 0.295 . . . . 0.0 111.798 -179.835 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 48.5 mt-10 -91.75 152.25 20.25 Favored 'General case' 0 N--CA 1.477 0.911 0 CA-C-O 121.127 0.489 . . . . 0.0 110.128 178.446 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -155.2 127.49 1.02 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.049 0 N-CA-C 107.83 -1.174 . . . . 0.0 107.83 178.346 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 44.1 m-70 -135.53 148.01 48.99 Favored 'General case' 0 N--CA 1.477 0.909 0 CA-C-N 115.566 -0.743 . . . . 0.0 111.396 -178.307 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 7.1 t60 -164.32 97.26 0.8 Allowed 'General case' 0 N--CA 1.484 1.226 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.45 178.915 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' H' H ' 15' ' ' GLN . . . . . 0.499 HE22 ' H ' ' H' ' 37' ' ' GLY . 3.5 pt20 -106.8 -175.67 2.86 Favored 'General case' 0 CA--C 1.508 -0.666 0 N-CA-C 108.278 -1.008 . . . . 0.0 108.278 -179.872 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -169.81 99.64 0.31 Allowed 'General case' 0 N--CA 1.472 0.653 0 CA-C-N 114.72 -1.127 . . . . 0.0 108.358 179.124 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' H' H ' 17' ' ' LEU . . . . . 0.524 ' CD2' ' H ' ' E' ' 17' ' ' LEU . 8.6 mt -123.44 154.08 39.57 Favored 'General case' 0 N--CA 1.495 1.819 0 CA-C-O 121.118 0.485 . . . . 0.0 111.86 -177.757 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 43.0 t -111.65 126.05 69.01 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.111 0 N-CA-C 108.077 -1.082 . . . . 0.0 108.077 177.087 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 47.5 m-85 -123.83 120.45 32.63 Favored 'General case' 0 C--N 1.368 1.392 0 CA-C-N 115.456 -0.793 . . . . 0.0 110.981 -179.332 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 73.4 m-85 54.11 74.33 0.34 Allowed 'General case' 0 C--N 1.345 0.399 0 CA-C-N 115.776 -0.647 . . . . 0.0 111.697 178.02 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.25 -78.15 0.13 Allowed 'General case' 0 N--CA 1.472 0.655 0 O-C-N 122.4 -0.188 . . . . 0.0 110.519 -179.117 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 40.3 tt0 -112.41 100.95 9.18 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 108.024 -1.102 . . . . 0.0 108.024 179.899 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -158.31 141.95 15.34 Favored 'General case' 0 N--CA 1.478 0.946 0 O-C-N 122.384 -0.198 . . . . 0.0 111.458 179.104 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' H' H ' 24' ' ' VAL . . . . . . . . . . . . . 59.6 t -60.63 167.89 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.561 0 N-CA-C 107.664 -1.236 . . . . 0.0 107.664 177.389 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . -120.89 49.27 0.89 Allowed Glycine 0 N--CA 1.48 1.609 0 N-CA-C 110.482 -1.047 . . . . 0.0 110.482 -179.385 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -63.24 -167.56 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.642 0 CA-C-N 117.009 0.405 . . . . 0.0 110.201 179.881 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 25.2 t-20 -69.93 78.11 0.48 Allowed 'General case' 0 CA--C 1.535 0.388 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.411 179.903 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -76.76 146.55 37.86 Favored 'General case' 0 N--CA 1.476 0.842 0 N-CA-C 109.501 -0.555 . . . . 0.0 109.501 179.314 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.74 -167.12 1.01 Allowed Glycine 0 C--N 1.336 0.578 0 N-CA-C 110.045 -1.222 . . . . 0.0 110.045 178.757 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.84 115.11 28.82 Favored 'General case' 0 N--CA 1.467 0.378 0 C-N-CA 122.6 0.36 . . . . 0.0 110.579 -179.938 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 71.6 mt -96.84 136.02 29.03 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.729 0 N-CA-C 106.866 -1.531 . . . . 0.0 106.866 179.094 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 36.6 pt -152.42 -175.87 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.761 0 CA-C-N 119.814 1.188 . . . . 0.0 109.898 -179.716 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.5 7.0 12.59 Favored Glycine 0 CA--C 1.526 0.78 0 N-CA-C 110.879 -0.889 . . . . 0.0 110.879 -179.755 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 1.3 tt -75.33 127.12 32.44 Favored 'General case' 0 CA--C 1.545 0.775 0 N-CA-C 109.69 -0.485 . . . . 0.0 109.69 -179.728 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 28.0 ttt -161.31 150.03 16.04 Favored 'General case' 0 C--O 1.212 -0.917 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 178.61 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 34.0 m -157.24 161.74 1.73 Allowed 'Isoleucine or valine' 0 C--N 1.345 0.398 0 N-CA-C 108.742 -0.836 . . . . 0.0 108.742 -179.665 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' H' H ' 37' ' ' GLY . . . . . 0.499 ' H ' HE22 ' H' ' 15' ' ' GLN . . . 55.81 66.89 2.52 Favored Glycine 0 C--N 1.311 -0.833 0 CA-C-N 115.673 -0.694 . . . . 0.0 112.261 178.172 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.46 178.09 18.96 Favored Glycine 0 N--CA 1.477 1.396 0 N-CA-C 110.644 -0.982 . . . . 0.0 110.644 179.026 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' H' H ' 39' ' ' VAL . . . . . 0.45 HG11 ' H ' ' E' ' 39' ' ' VAL . 34.1 m -121.12 158.43 23.81 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.846 0 C-N-CA 123.191 0.597 . . . . 0.0 110.772 -179.646 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 23.7 t . . . . . 0 N--CA 1.47 0.529 0 O-C-N 123.936 0.772 . . . . 0.0 110.694 179.149 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 41.0 m-85 . . . . . 0 N--CA 1.474 0.767 0 N-CA-C 109.579 -0.526 . . . . 0.0 109.579 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' I' I ' 5' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -142.81 141.35 31.62 Favored 'General case' 0 N--CA 1.483 1.224 0 C-N-CA 122.596 0.359 . . . . 0.0 110.143 179.787 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 45.0 t-80 -151.93 119.46 6.04 Favored 'General case' 0 N--CA 1.473 0.708 0 N-CA-C 109.379 -0.6 . . . . 0.0 109.379 178.96 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -71.02 144.41 50.43 Favored 'General case' 0 N--CA 1.469 0.497 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.268 -179.859 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' I' I ' 8' ' ' SER . . . . . 0.495 ' OG ' ' O ' ' F' ' 7' ' ' ASP . 60.5 p -165.02 -171.47 2.24 Favored 'General case' 0 N--CA 1.474 0.771 0 CA-C-O 120.975 0.417 . . . . 0.0 110.469 178.839 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.66 47.03 1.32 Allowed Glycine 0 N--CA 1.479 1.525 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.777 179.598 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 50.0 p90 -66.18 132.8 49.29 Favored 'General case' 0 N--CA 1.472 0.626 0 N-CA-C 111.869 0.322 . . . . 0.0 111.869 -179.805 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 48.5 mt-10 -91.19 152.29 20.61 Favored 'General case' 0 N--CA 1.477 0.907 0 CA-C-O 121.155 0.502 . . . . 0.0 110.202 178.385 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -155.48 126.95 0.91 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.057 0 N-CA-C 107.887 -1.153 . . . . 0.0 107.887 178.201 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 42.9 m-70 -134.92 148.33 50.03 Favored 'General case' 0 N--CA 1.478 0.935 0 CA-C-N 115.488 -0.778 . . . . 0.0 111.432 -178.409 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 7.1 t60 -164.49 97.33 0.78 Allowed 'General case' 0 N--CA 1.481 1.111 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.441 178.995 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' I' I ' 15' ' ' GLN . . . . . 0.516 HE22 ' H ' ' I' ' 37' ' ' GLY . 3.5 pt20 -106.84 -175.36 2.77 Favored 'General case' 0 CA--C 1.508 -0.666 0 N-CA-C 108.208 -1.034 . . . . 0.0 108.208 -179.815 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -170.18 99.53 0.28 Allowed 'General case' 0 N--CA 1.471 0.595 0 CA-C-N 114.592 -1.185 . . . . 0.0 108.25 179.159 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' I' I ' 17' ' ' LEU . . . . . 0.509 ' CD2' ' H ' ' F' ' 17' ' ' LEU . 8.4 mt -123.23 153.76 39.69 Favored 'General case' 0 N--CA 1.495 1.8 0 CA-C-O 121.042 0.449 . . . . 0.0 111.836 -177.829 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 43.8 t -111.3 126.44 68.69 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.02 0 N-CA-C 108.05 -1.093 . . . . 0.0 108.05 176.913 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 47.1 m-85 -124.16 120.77 33.27 Favored 'General case' 0 C--N 1.368 1.389 0 CA-C-N 115.511 -0.768 . . . . 0.0 111.002 -179.294 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 73.4 m-85 53.87 73.84 0.36 Allowed 'General case' 0 N--CA 1.469 0.495 0 CA-C-N 115.898 -0.592 . . . . 0.0 111.637 178.062 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -76.74 -78.43 0.12 Allowed 'General case' 0 N--CA 1.471 0.61 0 O-C-N 122.304 -0.247 . . . . 0.0 110.414 -179.209 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 40.1 tt0 -112.12 101.31 9.58 Favored 'General case' 0 C--N 1.324 -0.512 0 N-CA-C 108.075 -1.083 . . . . 0.0 108.075 179.938 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -158.53 142.4 15.42 Favored 'General case' 0 N--CA 1.477 0.903 0 O-C-N 122.42 -0.175 . . . . 0.0 111.467 179.063 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' I' I ' 24' ' ' VAL . . . . . . . . . . . . . 59.0 t -61.06 167.82 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.561 0 N-CA-C 107.663 -1.236 . . . . 0.0 107.663 177.296 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . -120.8 49.85 0.86 Allowed Glycine 0 N--CA 1.481 1.682 0 N-CA-C 110.45 -1.06 . . . . 0.0 110.45 -179.485 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -63.84 -167.57 0.02 OUTLIER 'General case' 0 N--CA 1.471 0.594 0 CA-C-N 116.927 0.364 . . . . 0.0 110.24 179.879 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 25.2 t-20 -69.8 77.59 0.46 Allowed 'General case' 0 CA--C 1.535 0.37 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.445 179.883 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -76.39 146.66 38.55 Favored 'General case' 0 N--CA 1.474 0.755 0 N-CA-C 109.438 -0.578 . . . . 0.0 109.438 179.305 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.73 -166.79 0.96 Allowed Glycine 0 C--N 1.337 0.638 0 N-CA-C 110.074 -1.21 . . . . 0.0 110.074 178.76 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.84 114.88 28.37 Favored 'General case' 0 N--CA 1.469 0.501 0 C-N-CA 122.771 0.428 . . . . 0.0 110.582 179.913 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 72.0 mt -96.75 136.07 28.78 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.674 0 N-CA-C 106.883 -1.525 . . . . 0.0 106.883 178.981 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 37.5 pt -152.46 -175.94 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 CA-C-N 119.885 1.221 . . . . 0.0 109.907 -179.678 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.63 6.69 12.22 Favored Glycine 0 CA--C 1.526 0.763 0 N-CA-C 110.94 -0.864 . . . . 0.0 110.94 -179.776 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 1.4 tt -75.04 127.13 32.51 Favored 'General case' 0 CA--C 1.547 0.83 0 N-CA-C 109.547 -0.538 . . . . 0.0 109.547 -179.64 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 28.1 ttt -161.1 150.12 16.49 Favored 'General case' 0 C--O 1.211 -0.942 0 N-CA-C 108.738 -0.838 . . . . 0.0 108.738 178.564 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 34.1 m -157.23 162.11 1.63 Allowed 'Isoleucine or valine' 0 C--N 1.347 0.459 0 N-CA-C 108.594 -0.891 . . . . 0.0 108.594 -179.747 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' I' I ' 37' ' ' GLY . . . . . 0.516 ' H ' HE22 ' I' ' 15' ' ' GLN . . . 55.34 67.2 2.33 Favored Glycine 0 C--N 1.311 -0.841 0 CA-C-N 115.643 -0.708 . . . . 0.0 112.241 178.122 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.18 178.28 18.88 Favored Glycine 0 N--CA 1.478 1.47 0 N-CA-C 110.568 -1.013 . . . . 0.0 110.568 178.875 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' I' I ' 39' ' ' VAL . . . . . 0.439 HG11 ' H ' ' F' ' 39' ' ' VAL . 33.9 m -121.33 158.31 24.33 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.856 0 C-N-CA 123.15 0.58 . . . . 0.0 110.723 -179.662 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 23.4 t . . . . . 0 N--CA 1.469 0.523 0 O-C-N 124.046 0.841 . . . . 0.0 110.699 179.041 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 35.1 m-85 . . . . . 0 N--CA 1.475 0.782 0 N-CA-C 110.082 -0.34 . . . . 0.0 110.082 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -144.31 139.65 28.69 Favored 'General case' 0 N--CA 1.481 1.115 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 179.563 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 42.1 t-80 -151.95 119.88 6.2 Favored 'General case' 0 N--CA 1.469 0.509 0 N-CA-C 109.264 -0.643 . . . . 0.0 109.264 179.257 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' ASP . . . . . 0.525 ' O ' ' OG ' ' D' ' 8' ' ' SER . 4.2 m-20 -69.04 148.68 49.72 Favored 'General case' 0 CA--C 1.537 0.476 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.498 179.876 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' SER . . . . . 0.451 ' H ' ' HG ' ' C' ' 26' ' ' SER . 53.9 p -168.2 -174.24 2.25 Favored 'General case' 0 N--CA 1.484 1.262 0 CA-C-O 121.035 0.445 . . . . 0.0 110.747 179.429 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.8 48.26 1.28 Allowed Glycine 0 N--CA 1.481 1.698 0 CA-C-N 115.911 -0.586 . . . . 0.0 111.83 179.725 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 49.7 p90 -64.6 132.39 49.67 Favored 'General case' 0 N--CA 1.473 0.691 0 O-C-N 122.761 -0.258 . . . . 0.0 111.425 179.732 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 83.3 mt-10 -91.71 152.25 20.28 Favored 'General case' 0 N--CA 1.48 1.047 0 C-N-CA 122.781 0.433 . . . . 0.0 109.839 178.379 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -153.23 128.42 1.54 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.617 0 N-CA-C 107.821 -1.177 . . . . 0.0 107.821 178.298 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 48.5 m-70 -135.25 145.98 48.13 Favored 'General case' 0 N--CA 1.492 1.666 0 CA-C-N 118.949 0.795 . . . . 0.0 111.388 -179.003 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 6.1 t60 -165.95 97.18 0.63 Allowed 'General case' 0 N--CA 1.48 1.058 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.848 179.5 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 3.6 pt20 -108.52 -174.69 2.58 Favored 'General case' 0 CA--C 1.506 -0.733 0 N-CA-C 108.432 -0.951 . . . . 0.0 108.432 -179.845 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -164.17 97.57 0.82 Allowed 'General case' 0 N--CA 1.472 0.651 0 CA-C-N 114.562 -1.199 . . . . 0.0 108.299 178.348 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 6.7 mp -122.27 157.78 30.94 Favored 'General case' 0 N--CA 1.497 1.924 0 CA-C-O 121.759 0.79 . . . . 0.0 110.91 -178.338 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 59.8 t -112.57 126.65 69.99 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.124 0 CA-C-O 117.984 -1.008 . . . . 0.0 108.316 177.702 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 28.7 m-85 -126.93 122.5 34.75 Favored 'General case' 0 N--CA 1.497 1.909 0 CA-C-N 120.017 1.28 . . . . 0.0 110.344 179.338 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 67.0 m-85 53.94 74.32 0.33 Allowed 'General case' 0 N--CA 1.47 0.572 0 CA-C-O 121.374 0.606 . . . . 0.0 111.745 178.751 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -80.55 -78.14 0.18 Allowed 'General case' 0 C--N 1.353 0.756 0 CA-C-N 115.139 -0.937 . . . . 0.0 110.334 -179.773 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 40.4 tt0 -112.21 101.59 9.82 Favored 'General case' 0 N--CA 1.469 0.502 0 N-CA-C 108.468 -0.938 . . . . 0.0 108.468 179.738 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 4.4 p30 -158.96 134.5 8.62 Favored 'General case' 0 N--CA 1.482 1.16 0 CA-C-O 119.512 -0.28 . . . . 0.0 111.211 178.936 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 58.7 t -58.05 163.07 0.71 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.853 0 N-CA-C 108.074 -1.084 . . . . 0.0 108.074 176.984 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -115.76 47.95 0.99 Allowed Glycine 0 N--CA 1.477 1.383 0 N-CA-C 111.615 -0.594 . . . . 0.0 111.615 -179.474 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' SER . . . . . 0.412 ' HG ' ' H ' ' B' ' 8' ' ' SER . 0.3 OUTLIER -61.85 -168.65 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.562 0 N-CA-C 110.152 -0.314 . . . . 0.0 110.152 179.338 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 24.5 t-20 -72.05 79.97 0.94 Allowed 'General case' 0 N--CA 1.464 0.257 0 CA-C-N 116.428 -0.351 . . . . 0.0 110.082 179.164 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -73.46 140.32 46.39 Favored 'General case' 0 N--CA 1.476 0.837 0 N-CA-C 108.934 -0.765 . . . . 0.0 108.934 179.375 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.39 -149.76 0.03 OUTLIER Glycine 0 C--N 1.337 0.618 0 N-CA-C 110.183 -1.167 . . . . 0.0 110.183 179.282 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -93.76 128.07 39.8 Favored 'General case' 0 N--CA 1.476 0.825 0 N-CA-C 110.04 -0.356 . . . . 0.0 110.04 -179.905 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 74.8 mt -124.16 117.35 50.54 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.748 0 N-CA-C 106.653 -1.61 . . . . 0.0 106.653 178.876 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 39.2 pt -151.5 -169.78 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.354 0.804 0 CA-C-O 121.22 0.533 . . . . 0.0 111.246 -178.769 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.84 5.08 12.38 Favored Glycine 0 C--N 1.336 0.58 0 N-CA-C 110.797 -0.921 . . . . 0.0 110.797 179.587 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 1.5 tt -78.14 126.77 31.3 Favored 'General case' 0 CA--C 1.546 0.801 0 N-CA-C 109.558 -0.534 . . . . 0.0 109.558 -179.884 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 28.6 ttt -164.69 143.55 6.94 Favored 'General case' 0 N--CA 1.464 0.23 0 N-CA-C 108.871 -0.788 . . . . 0.0 108.871 178.266 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 35.6 m -155.27 162.71 1.73 Allowed 'Isoleucine or valine' 0 C--N 1.348 0.509 0 N-CA-C 108.042 -1.096 . . . . 0.0 108.042 179.327 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.61 66.33 2.93 Favored Glycine 0 C--N 1.307 -1.08 0 CA-C-N 115.834 -0.621 . . . . 0.0 111.874 178.429 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 145.7 172.97 16.53 Favored Glycine 0 N--CA 1.473 1.1 0 N-CA-C 110.994 -0.843 . . . . 0.0 110.994 179.095 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . 0.494 ' H ' HG11 ' D' ' 39' ' ' VAL . 33.7 m -123.01 160.44 25.76 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.616 0 C-N-CA 123.405 0.682 . . . . 0.0 110.087 -179.691 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 23.7 t . . . . . 0 C--O 1.218 -0.556 0 CA-C-O 118.419 -0.8 . . . . 0.0 110.578 179.478 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 34.7 m-85 . . . . . 0 N--CA 1.474 0.752 0 N-CA-C 110.047 -0.353 . . . . 0.0 110.047 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -144.41 139.06 28.16 Favored 'General case' 0 N--CA 1.484 1.225 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 179.585 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 41.5 t-80 -151.24 119.63 6.41 Favored 'General case' 0 N--CA 1.472 0.638 0 N-CA-C 109.256 -0.646 . . . . 0.0 109.256 179.204 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 7' ' ' ASP . . . . . 0.507 ' O ' ' OG ' ' E' ' 8' ' ' SER . 4.0 m-20 -68.83 148.19 50.63 Favored 'General case' 0 CA--C 1.538 0.514 0 CA-C-N 116.295 -0.412 . . . . 0.0 110.721 179.828 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 8' ' ' SER . . . . . 0.412 ' H ' ' HG ' ' A' ' 26' ' ' SER . 54.1 p -167.58 -173.69 2.27 Favored 'General case' 0 N--CA 1.483 1.221 0 CA-C-O 121.045 0.45 . . . . 0.0 110.707 179.525 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.38 48.24 1.33 Allowed Glycine 0 N--CA 1.481 1.692 0 CA-C-N 115.908 -0.587 . . . . 0.0 111.949 179.55 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 50.2 p90 -64.94 132.89 50.55 Favored 'General case' 0 N--CA 1.473 0.687 0 CA-C-O 120.636 0.255 . . . . 0.0 111.496 179.871 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 84.2 mt-10 -92.02 152.75 19.84 Favored 'General case' 0 N--CA 1.478 0.93 0 CA-C-O 121.048 0.451 . . . . 0.0 109.823 178.456 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -153.61 128.39 1.46 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.495 0 N-CA-C 107.922 -1.14 . . . . 0.0 107.922 178.12 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 46.5 m-70 -135.32 145.67 47.69 Favored 'General case' 0 N--CA 1.493 1.723 0 CA-C-N 118.941 0.791 . . . . 0.0 111.289 -179.006 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 6.0 t60 -165.65 96.86 0.66 Allowed 'General case' 0 N--CA 1.48 1.035 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.739 179.38 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 3.6 pt20 -108.12 -174.74 2.59 Favored 'General case' 0 CA--C 1.507 -0.694 0 N-CA-C 108.411 -0.959 . . . . 0.0 108.411 -179.798 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -164.29 97.63 0.8 Allowed 'General case' 0 N--CA 1.473 0.699 0 CA-C-N 114.67 -1.15 . . . . 0.0 108.263 178.342 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 6.6 mp -122.27 157.69 31.13 Favored 'General case' 0 N--CA 1.497 1.906 0 CA-C-O 121.809 0.814 . . . . 0.0 111.023 -178.298 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 61.4 t -112.71 127.75 69.77 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.024 0 N-CA-C 108.069 -1.086 . . . . 0.0 108.069 177.595 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 28.6 m-85 -128.09 122.09 31.22 Favored 'General case' 0 N--CA 1.495 1.787 0 CA-C-N 119.726 1.148 . . . . 0.0 110.192 179.501 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 67.1 m-85 53.6 74.18 0.33 Allowed 'General case' 0 CA--C 1.54 0.581 0 CA-C-O 121.487 0.661 . . . . 0.0 111.799 178.622 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -80.35 -78.32 0.17 Allowed 'General case' 0 C--N 1.352 0.687 0 CA-C-N 115.001 -1.0 . . . . 0.0 110.275 -179.823 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 40.5 tt0 -112.02 101.73 10.0 Favored 'General case' 0 N--CA 1.471 0.613 0 N-CA-C 108.448 -0.945 . . . . 0.0 108.448 179.819 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 4.4 p30 -158.89 134.8 8.89 Favored 'General case' 0 N--CA 1.482 1.169 0 CA-C-O 119.54 -0.266 . . . . 0.0 111.155 178.913 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 58.5 t -58.26 163.2 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.874 0 N-CA-C 108.128 -1.064 . . . . 0.0 108.128 177.018 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -115.57 47.62 1.02 Allowed Glycine 0 N--CA 1.474 1.203 0 N-CA-C 111.65 -0.58 . . . . 0.0 111.65 -179.314 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 26' ' ' SER . . . . . 0.422 ' HG ' ' H ' ' C' ' 8' ' ' SER . 0.3 OUTLIER -61.77 -168.59 0.01 OUTLIER 'General case' 0 N--CA 1.469 0.518 0 N-CA-C 110.25 -0.278 . . . . 0.0 110.25 179.45 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 24.6 t-20 -72.38 79.85 1.02 Allowed 'General case' 0 N--CA 1.468 0.426 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.318 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -73.19 140.6 47.1 Favored 'General case' 0 N--CA 1.477 0.898 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 179.565 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.56 -150.05 0.04 OUTLIER Glycine 0 C--N 1.338 0.639 0 N-CA-C 110.191 -1.163 . . . . 0.0 110.191 179.411 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -93.41 128.33 39.42 Favored 'General case' 0 N--CA 1.475 0.787 0 CA-C-N 116.938 0.369 . . . . 0.0 110.032 179.795 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 76.7 mt -124.46 117.26 50.02 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.658 0 N-CA-C 106.593 -1.632 . . . . 0.0 106.593 178.811 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . 0.401 ' C ' ' H ' ' B' ' 34' ' ' LEU . 39.8 pt -151.19 -169.71 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.355 0.831 0 CA-C-N 115.986 -0.552 . . . . 0.0 111.255 -178.746 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.83 4.95 11.86 Favored Glycine 0 C--N 1.337 0.627 0 N-CA-C 110.945 -0.862 . . . . 0.0 110.945 179.479 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 34' ' ' LEU . . . . . 0.401 ' H ' ' C ' ' B' ' 32' ' ' ILE . 1.5 tt -78.12 126.81 31.35 Favored 'General case' 0 CA--C 1.546 0.819 0 N-CA-C 109.57 -0.53 . . . . 0.0 109.57 -179.778 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 28.5 ttt -164.81 143.53 6.75 Favored 'General case' 0 N--CA 1.465 0.311 0 N-CA-C 108.801 -0.814 . . . . 0.0 108.801 178.225 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 35.4 m -155.37 162.41 1.8 Allowed 'Isoleucine or valine' 0 C--N 1.347 0.499 0 N-CA-C 108.0 -1.111 . . . . 0.0 108.0 179.471 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.71 66.9 2.52 Favored Glycine 0 C--N 1.307 -1.068 0 CA-C-N 115.742 -0.663 . . . . 0.0 111.784 178.415 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 144.97 172.65 15.58 Favored Glycine 0 N--CA 1.472 1.08 0 N-CA-C 110.869 -0.892 . . . . 0.0 110.869 179.179 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 39' ' ' VAL . . . . . 0.514 ' H ' HG11 ' E' ' 39' ' ' VAL . 32.5 m -123.09 159.95 26.49 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.711 0 C-N-CA 123.428 0.691 . . . . 0.0 110.209 -179.553 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 24.4 t . . . . . 0 N--CA 1.468 0.468 0 CA-C-O 118.316 -0.849 . . . . 0.0 110.441 179.475 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 34.6 m-85 . . . . . 0 N--CA 1.475 0.799 0 N-CA-C 110.023 -0.362 . . . . 0.0 110.023 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -144.75 138.85 27.47 Favored 'General case' 0 N--CA 1.482 1.165 0 N-CA-C 109.951 -0.389 . . . . 0.0 109.951 179.69 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 41.7 t-80 -151.16 119.7 6.48 Favored 'General case' 0 N--CA 1.471 0.582 0 N-CA-C 109.381 -0.599 . . . . 0.0 109.381 179.246 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 7' ' ' ASP . . . . . 0.513 ' O ' ' OG ' ' F' ' 8' ' ' SER . 4.3 m-20 -69.1 148.21 50.33 Favored 'General case' 0 CA--C 1.539 0.527 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.66 179.891 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' C' C ' 8' ' ' SER . . . . . 0.422 ' H ' ' HG ' ' B' ' 26' ' ' SER . 54.5 p -167.55 -173.95 2.36 Favored 'General case' 0 N--CA 1.484 1.271 0 CA-C-O 121.028 0.442 . . . . 0.0 110.764 179.455 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.81 48.19 1.29 Allowed Glycine 0 N--CA 1.48 1.616 0 CA-C-N 115.886 -0.597 . . . . 0.0 111.988 179.574 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 49.5 p90 -65.01 132.18 48.54 Favored 'General case' 0 N--CA 1.471 0.604 0 O-C-N 122.751 -0.264 . . . . 0.0 111.463 179.897 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 83.5 mt-10 -91.47 152.59 20.29 Favored 'General case' 0 N--CA 1.476 0.835 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 178.465 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -153.4 128.61 1.54 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.53 0 N-CA-C 107.778 -1.193 . . . . 0.0 107.778 178.237 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 46.8 m-70 -135.35 145.76 47.71 Favored 'General case' 0 N--CA 1.493 1.687 0 CA-C-N 118.986 0.812 . . . . 0.0 111.357 -179.099 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 6.0 t60 -165.69 97.33 0.66 Allowed 'General case' 0 N--CA 1.48 1.059 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.715 179.361 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 3.5 pt20 -108.74 -174.22 2.46 Favored 'General case' 0 CA--C 1.506 -0.722 0 N-CA-C 108.362 -0.977 . . . . 0.0 108.362 -179.891 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -164.66 97.7 0.77 Allowed 'General case' 0 N--CA 1.471 0.62 0 CA-C-N 114.573 -1.194 . . . . 0.0 108.269 178.55 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 6.6 mp -122.45 157.36 32.11 Favored 'General case' 0 N--CA 1.498 1.946 0 CA-C-O 121.883 0.849 . . . . 0.0 111.017 -178.208 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 58.8 t -112.41 127.28 69.71 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.091 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 177.655 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 29.2 m-85 -127.77 122.17 32.1 Favored 'General case' 0 N--CA 1.494 1.75 0 CA-C-N 119.686 1.13 . . . . 0.0 110.266 179.458 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 67.0 m-85 53.54 74.14 0.33 Allowed 'General case' 0 N--CA 1.468 0.448 0 CA-C-O 121.486 0.66 . . . . 0.0 111.915 178.588 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -80.56 -77.84 0.19 Allowed 'General case' 0 C--N 1.349 0.559 0 CA-C-N 114.969 -1.014 . . . . 0.0 110.373 -179.716 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 40.3 tt0 -112.38 101.32 9.52 Favored 'General case' 0 N--CA 1.47 0.535 0 N-CA-C 108.355 -0.98 . . . . 0.0 108.355 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -158.79 134.22 8.61 Favored 'General case' 0 N--CA 1.481 1.096 0 CA-C-O 119.466 -0.302 . . . . 0.0 111.205 178.965 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 59.3 t -57.55 163.55 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.805 0 N-CA-C 108.135 -1.061 . . . . 0.0 108.135 177.002 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -115.91 47.8 1.0 Allowed Glycine 0 N--CA 1.477 1.421 0 N-CA-C 111.519 -0.632 . . . . 0.0 111.519 -179.505 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 26' ' ' SER . . . . . 0.451 ' HG ' ' H ' ' A' ' 8' ' ' SER . 0.3 OUTLIER -62.06 -169.23 0.02 OUTLIER 'General case' 0 N--CA 1.469 0.509 0 N-CA-C 110.17 -0.308 . . . . 0.0 110.17 179.348 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 24.7 t-20 -71.77 79.72 0.86 Allowed 'General case' 0 N--CA 1.468 0.425 0 N-CA-C 110.011 -0.366 . . . . 0.0 110.011 179.455 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -73.19 140.6 47.08 Favored 'General case' 0 N--CA 1.476 0.834 0 N-CA-C 109.011 -0.737 . . . . 0.0 109.011 179.442 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.7 -149.09 0.04 OUTLIER Glycine 0 C--N 1.337 0.594 0 N-CA-C 110.284 -1.126 . . . . 0.0 110.284 179.457 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -94.16 128.03 40.34 Favored 'General case' 0 N--CA 1.477 0.877 0 CA-C-N 116.931 0.365 . . . . 0.0 110.083 179.953 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 74.9 mt -124.28 117.23 50.06 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.697 0 N-CA-C 106.707 -1.59 . . . . 0.0 106.707 178.734 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 39.7 pt -151.3 -169.74 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.355 0.826 0 CA-C-N 115.978 -0.556 . . . . 0.0 111.231 -178.712 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.9 4.81 11.83 Favored Glycine 0 N--CA 1.465 0.609 0 N-CA-C 110.84 -0.904 . . . . 0.0 110.84 179.433 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 1.5 tt -77.96 126.66 31.17 Favored 'General case' 0 CA--C 1.546 0.826 0 N-CA-C 109.566 -0.531 . . . . 0.0 109.566 -179.803 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 28.6 ttt -164.49 143.33 7.13 Favored 'General case' 0 N--CA 1.465 0.298 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 178.298 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 35.5 m -155.19 162.58 1.77 Allowed 'Isoleucine or valine' 0 C--N 1.347 0.485 0 N-CA-C 107.989 -1.115 . . . . 0.0 107.989 179.373 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.64 66.45 2.84 Favored Glycine 0 C--N 1.306 -1.138 0 CA-C-N 115.808 -0.633 . . . . 0.0 111.88 178.422 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 145.46 173.33 16.62 Favored Glycine 0 N--CA 1.472 1.07 0 N-CA-C 111.024 -0.831 . . . . 0.0 111.024 178.946 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 39' ' ' VAL . . . . . 0.512 ' H ' HG11 ' F' ' 39' ' ' VAL . 33.0 m -123.17 160.39 26.18 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.658 0 C-N-CA 123.424 0.69 . . . . 0.0 110.192 -179.787 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 22.8 t . . . . . 0 C--O 1.219 -0.518 0 CA-C-O 118.406 -0.807 . . . . 0.0 110.46 179.546 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 35.1 m-85 . . . . . 0 N--CA 1.472 0.636 0 N-CA-C 108.954 -0.758 . . . . 0.0 108.954 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' D' D ' 5' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -146.07 137.5 24.77 Favored 'General case' 0 N--CA 1.478 0.953 0 C-N-CA 122.814 0.445 . . . . 0.0 110.341 -179.888 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 37.7 t-80 -149.64 123.94 9.57 Favored 'General case' 0 CA--C 1.547 0.827 0 N-CA-C 108.188 -1.041 . . . . 0.0 108.188 175.182 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 7' ' ' ASP . . . . . 0.604 ' O ' ' OG ' ' G' ' 8' ' ' SER . 3.2 m-20 -63.69 132.52 51.33 Favored 'General case' 0 N--CA 1.466 0.363 0 C-N-CA 126.323 1.849 . . . . 0.0 114.361 174.856 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' D' D ' 8' ' ' SER . . . . . 0.525 ' OG ' ' O ' ' A' ' 7' ' ' ASP . 53.8 p -154.39 -171.35 3.83 Favored 'General case' 0 N--CA 1.487 1.385 0 CA-C-N 119.454 1.024 . . . . 0.0 111.255 176.266 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.28 49.0 1.09 Allowed Glycine 0 N--CA 1.483 1.8 0 N-CA-C 110.263 -1.135 . . . . 0.0 110.263 174.144 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 50.8 p90 -61.47 131.71 51.08 Favored 'General case' 0 N--CA 1.472 0.65 0 N-CA-C 112.338 0.495 . . . . 0.0 112.338 178.833 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 84.8 mt-10 -89.24 150.73 22.5 Favored 'General case' 0 N--CA 1.482 1.136 0 CA-C-O 120.564 0.221 . . . . 0.0 110.714 175.645 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.0 p -149.44 130.19 4.58 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.567 0 N-CA-C 107.492 -1.299 . . . . 0.0 107.492 173.114 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 43.2 m-70 -129.89 148.72 51.78 Favored 'General case' 0 N--CA 1.483 1.217 0 CA-C-N 118.074 0.397 . . . . 0.0 111.91 176.444 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 6.1 t60 -165.14 104.43 0.76 Allowed 'General case' 0 N--CA 1.481 1.083 0 N-CA-C 109.029 -0.73 . . . . 0.0 109.029 172.33 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 3.5 pt20 -111.84 -176.14 2.86 Favored 'General case' 0 CA--C 1.497 -1.089 0 N-CA-C 108.29 -1.004 . . . . 0.0 108.29 178.808 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -161.29 105.35 1.3 Allowed 'General case' 0 N--CA 1.469 0.5 0 N-CA-C 106.37 -1.715 . . . . 0.0 106.37 174.965 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 5.6 mp -129.15 154.07 47.08 Favored 'General case' 0 N--CA 1.499 1.989 0 CA-C-O 122.024 0.916 . . . . 0.0 110.581 179.732 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 33.1 t -101.29 131.39 49.14 Favored 'Isoleucine or valine' 0 C--O 1.262 1.75 0 CA-C-O 116.89 -1.529 . . . . 0.0 109.74 174.047 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 26.9 m-85 -130.24 126.63 37.8 Favored 'General case' 0 N--CA 1.491 1.618 0 CA-C-N 119.893 1.224 . . . . 0.0 109.497 173.19 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 67.3 m-85 55.22 71.3 0.55 Allowed 'General case' 0 C--O 1.241 0.658 0 CA-C-N 115.592 -0.731 . . . . 0.0 111.653 176.226 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -82.3 -73.42 0.39 Allowed 'General case' 0 N--CA 1.473 0.701 0 CA-C-O 118.601 -0.714 . . . . 0.0 111.259 -177.414 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 40.7 tt0 -115.35 105.37 12.77 Favored 'General case' 0 N--CA 1.48 1.046 0 N-CA-C 106.463 -1.68 . . . . 0.0 106.463 176.312 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 4.4 p30 -152.19 135.17 15.66 Favored 'General case' 0 N--CA 1.473 0.692 0 CA-C-O 116.67 -1.633 . . . . 0.0 113.493 177.301 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 24' ' ' VAL . . . . . . . . . . . . . 87.7 t -61.35 166.27 0.81 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.218 0 CA-C-N 121.056 1.753 . . . . 0.0 107.759 175.529 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . -116.38 50.99 0.75 Allowed Glycine 0 N--CA 1.478 1.476 0 CA-C-O 119.466 -0.63 . . . . 0.0 111.656 178.621 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 26' ' ' SER . . . . . 0.431 ' HG ' ' H ' ' E' ' 8' ' ' SER . 0.2 OUTLIER -57.14 -171.03 0.01 OUTLIER 'General case' 0 N--CA 1.468 0.463 0 C-N-CA 123.414 0.685 . . . . 0.0 111.805 175.217 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 25.4 t-20 -73.62 86.86 1.63 Allowed 'General case' 0 C--N 1.348 0.512 0 N-CA-C 108.44 -0.948 . . . . 0.0 108.44 176.753 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 97.6 mttt -81.09 143.26 32.56 Favored 'General case' 0 N--CA 1.481 1.101 0 N-CA-C 107.527 -1.286 . . . . 0.0 107.527 179.818 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.72 -144.78 0.02 OUTLIER Glycine 0 C--N 1.349 1.274 0 CA-C-N 114.928 -1.033 . . . . 0.0 111.705 -178.865 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -95.81 127.01 41.47 Favored 'General case' 0 C--O 1.241 0.619 0 N-CA-C 110.196 -0.298 . . . . 0.0 110.196 178.859 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 85.8 mt -125.98 127.61 71.23 Favored 'Isoleucine or valine' 0 C--N 1.354 0.77 0 N-CA-C 103.34 -2.837 . . . . 0.0 103.34 176.89 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 42.8 pt -159.61 -170.82 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.119 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.228 -177.696 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 64.12 4.83 12.78 Favored Glycine 0 C--O 1.243 0.685 0 N-CA-C 110.254 -1.138 . . . . 0.0 110.254 -179.251 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 34' ' ' LEU . . . . . . . . . . . . 0.265 2.0 tt -80.33 133.38 35.93 Favored 'General case' 0 C--N 1.377 1.798 0 C-N-CA 117.22 -1.792 . . . . 0.0 107.353 -178.729 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 28.4 ttt -158.82 156.2 29.25 Favored 'General case' 0 C--O 1.25 1.081 0 CA-C-O 117.938 -1.03 . . . . 0.0 108.691 172.374 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 35.5 m -164.74 163.7 0.71 Allowed 'Isoleucine or valine' 0 CA--C 1.516 -0.364 0 N-CA-C 107.643 -1.243 . . . . 0.0 107.643 174.273 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 60.5 63.03 5.35 Favored Glycine 0 CA--C 1.53 1.011 0 C-N-CA 120.216 -0.993 . . . . 0.0 111.509 177.578 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 144.03 175.53 17.24 Favored Glycine 0 N--CA 1.478 1.469 0 CA-C-N 118.443 1.122 . . . . 0.0 111.378 179.847 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 39' ' ' VAL . . . . . 0.513 ' H ' HG11 ' G' ' 39' ' ' VAL . 36.0 m -126.22 157.4 36.52 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.78 0 C-N-CA 122.937 0.495 . . . . 0.0 109.863 -177.737 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 24.0 t . . . . . 0 C--N 1.331 -0.211 0 CA-C-O 116.331 -1.795 . . . . 0.0 109.479 177.301 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 31.8 m-85 . . . . . 0 N--CA 1.474 0.768 0 N-CA-C 110.135 -0.321 . . . . 0.0 110.135 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' E' E ' 5' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -143.69 139.82 29.71 Favored 'General case' 0 N--CA 1.484 1.256 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 179.374 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 41.3 t-80 -151.57 119.61 6.26 Favored 'General case' 0 N--CA 1.472 0.674 0 N-CA-C 109.276 -0.639 . . . . 0.0 109.276 178.953 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' E' E ' 7' ' ' ASP . . . . . 0.508 ' O ' ' OG ' ' H' ' 8' ' ' SER . 3.9 m-20 -69.6 147.81 50.21 Favored 'General case' 0 CA--C 1.534 0.334 0 CA-C-N 116.414 -0.357 . . . . 0.0 110.94 -179.951 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' E' E ' 8' ' ' SER . . . . . 0.507 ' OG ' ' O ' ' B' ' 7' ' ' ASP . 52.2 p -167.8 -172.72 1.93 Allowed 'General case' 0 N--CA 1.485 1.32 0 CA-C-O 121.18 0.514 . . . . 0.0 110.807 179.014 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.19 48.57 1.21 Allowed Glycine 0 N--CA 1.478 1.479 0 CA-C-N 115.702 -0.681 . . . . 0.0 111.82 179.475 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 47.8 p90 -64.66 133.11 51.49 Favored 'General case' 0 N--CA 1.473 0.688 0 N-CA-C 111.842 0.312 . . . . 0.0 111.842 -179.744 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 86.3 mt-10 -91.53 152.41 20.33 Favored 'General case' 0 N--CA 1.479 1.024 0 CA-C-O 121.175 0.512 . . . . 0.0 109.787 178.06 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -154.59 127.5 1.12 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.575 0 N-CA-C 107.735 -1.209 . . . . 0.0 107.735 178.053 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 46.6 m-70 -135.24 143.8 46.53 Favored 'General case' 0 N--CA 1.482 1.13 0 CA-C-O 120.846 0.355 . . . . 0.0 111.609 -177.942 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 6.1 t60 -164.31 97.25 0.8 Allowed 'General case' 0 N--CA 1.483 1.187 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.671 179.395 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 3.5 pt20 -108.07 -174.58 2.56 Favored 'General case' 0 CA--C 1.509 -0.63 0 N-CA-C 108.544 -0.909 . . . . 0.0 108.544 179.994 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -164.22 96.61 0.79 Allowed 'General case' 0 N--CA 1.477 0.906 0 CA-C-N 114.651 -1.158 . . . . 0.0 108.426 178.367 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 6.5 mp -120.91 157.31 30.15 Favored 'General case' 0 N--CA 1.495 1.788 0 CA-C-O 121.641 0.734 . . . . 0.0 111.557 -177.668 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 48.2 t -114.34 124.42 70.98 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.24 0 N-CA-C 108.277 -1.008 . . . . 0.0 108.277 177.266 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 31.7 m-85 -125.3 121.19 33.3 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 123.256 0.348 . . . . 0.0 110.909 -179.751 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 68.9 m-85 54.87 73.17 0.42 Allowed 'General case' 0 N--CA 1.469 0.504 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.392 178.196 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -78.73 -78.76 0.14 Allowed 'General case' 0 CA--C 1.536 0.419 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.201 -179.566 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 40.3 tt0 -111.5 102.2 10.57 Favored 'General case' 0 C--N 1.322 -0.588 0 N-CA-C 108.49 -0.93 . . . . 0.0 108.49 -179.996 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -158.27 134.62 9.42 Favored 'General case' 0 C--O 1.208 -1.1 0 CA-C-O 119.447 -0.311 . . . . 0.0 111.476 178.846 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 57.3 t -56.73 167.4 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.884 0 N-CA-C 107.564 -1.273 . . . . 0.0 107.564 176.791 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . -120.37 48.96 0.91 Allowed Glycine 0 N--CA 1.472 1.091 0 N-CA-C 110.852 -0.899 . . . . 0.0 110.852 -179.389 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' E' E ' 26' ' ' SER . . . . . 0.403 ' HG ' ' H ' ' F' ' 8' ' ' SER . 0.2 OUTLIER -63.37 -167.92 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.528 0 CA-C-O 120.767 0.318 . . . . 0.0 110.361 179.669 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 25.0 t-20 -71.71 76.35 0.84 Allowed 'General case' 0 N--CA 1.466 0.334 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.324 179.779 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -70.26 140.28 52.35 Favored 'General case' 0 N--CA 1.48 1.061 0 N-CA-C 109.438 -0.579 . . . . 0.0 109.438 179.462 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.47 -149.28 0.05 OUTLIER Glycine 0 C--N 1.335 0.49 0 N-CA-C 110.859 -0.896 . . . . 0.0 110.859 179.42 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -92.78 126.89 38.07 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-N 116.797 0.298 . . . . 0.0 110.402 179.713 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 76.8 mt -123.62 117.25 50.65 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.436 0 N-CA-C 106.365 -1.717 . . . . 0.0 106.365 178.591 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' E' E ' 32' ' ' ILE . . . . . 0.402 ' C ' ' H ' ' E' ' 34' ' ' LEU . 44.2 pt -151.46 -168.19 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.17 0 CA-C-O 121.117 0.484 . . . . 0.0 110.882 -178.868 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.13 5.43 7.85 Favored Glycine 0 CA--C 1.527 0.839 0 N-CA-C 111.315 -0.714 . . . . 0.0 111.315 179.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' E' E ' 34' ' ' LEU . . . . . 0.402 ' H ' ' C ' ' E' ' 32' ' ' ILE . 1.6 tt -77.74 127.23 32.1 Favored 'General case' 0 CA--C 1.548 0.88 0 N-CA-C 109.494 -0.558 . . . . 0.0 109.494 -179.886 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 28.6 ttt -164.7 144.52 7.34 Favored 'General case' 0 N--CA 1.469 0.51 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 178.267 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 32.9 m -156.38 162.84 1.55 Allowed 'Isoleucine or valine' 0 C--N 1.348 0.523 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 179.675 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.05 66.13 3.06 Favored Glycine 0 C--N 1.307 -1.072 0 CA-C-N 115.599 -0.728 . . . . 0.0 111.799 178.34 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 145.97 174.31 18.02 Favored Glycine 0 N--CA 1.474 1.191 0 N-CA-C 111.256 -0.738 . . . . 0.0 111.256 178.8 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' E' E ' 39' ' ' VAL . . . . . 0.521 ' H ' HG11 ' H' ' 39' ' ' VAL . 34.3 m -124.15 159.87 29.1 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.709 0 C-N-CA 123.32 0.648 . . . . 0.0 110.297 -179.206 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 24.6 t . . . . . 0 C--O 1.218 -0.595 0 O-C-N 124.156 0.91 . . . . 0.0 110.43 179.394 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 31.5 m-85 . . . . . 0 N--CA 1.475 0.813 0 N-CA-C 110.019 -0.363 . . . . 0.0 110.019 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' F' F ' 5' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -144.03 139.4 28.96 Favored 'General case' 0 N--CA 1.478 0.966 0 CA-C-O 120.759 0.314 . . . . 0.0 110.214 179.46 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 41.3 t-80 -151.48 119.73 6.35 Favored 'General case' 0 N--CA 1.473 0.695 0 N-CA-C 109.282 -0.636 . . . . 0.0 109.282 179.124 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' F' F ' 7' ' ' ASP . . . . . 0.509 ' O ' ' OG ' ' I' ' 8' ' ' SER . 3.9 m-20 -69.62 147.81 50.19 Favored 'General case' 0 CA--C 1.533 0.317 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.909 179.994 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' F' F ' 8' ' ' SER . . . . . 0.513 ' OG ' ' O ' ' C' ' 7' ' ' ASP . 51.7 p -168.09 -173.12 1.96 Allowed 'General case' 0 N--CA 1.485 1.321 0 CA-C-O 121.22 0.533 . . . . 0.0 110.923 178.977 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.49 48.3 1.22 Allowed Glycine 0 N--CA 1.478 1.457 0 CA-C-N 115.767 -0.651 . . . . 0.0 111.714 179.466 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 47.7 p90 -64.02 132.84 51.81 Favored 'General case' 0 N--CA 1.474 0.736 0 O-C-N 122.648 -0.325 . . . . 0.0 111.792 -179.888 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 86.8 mt-10 -91.28 152.42 20.49 Favored 'General case' 0 N--CA 1.481 1.103 0 CA-C-O 121.166 0.508 . . . . 0.0 109.877 177.873 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -154.57 127.61 1.14 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.627 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 178.008 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 44.4 m-70 -135.44 144.13 46.29 Favored 'General case' 0 N--CA 1.482 1.144 0 CA-C-O 120.807 0.337 . . . . 0.0 111.6 -178.079 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 6.0 t60 -164.57 96.82 0.76 Allowed 'General case' 0 N--CA 1.485 1.284 0 CA-C-N 116.431 -0.349 . . . . 0.0 110.788 179.478 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 3.5 pt20 -107.71 -174.06 2.44 Favored 'General case' 0 CA--C 1.505 -0.778 0 N-CA-C 108.637 -0.875 . . . . 0.0 108.637 -179.97 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -164.53 96.8 0.77 Allowed 'General case' 0 N--CA 1.475 0.802 0 CA-C-N 114.645 -1.161 . . . . 0.0 108.336 178.533 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 6.5 mp -121.01 157.17 30.57 Favored 'General case' 0 N--CA 1.494 1.766 0 CA-C-O 121.51 0.671 . . . . 0.0 111.483 -177.733 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 48.1 t -114.04 124.24 70.49 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.227 0 N-CA-C 108.288 -1.004 . . . . 0.0 108.288 177.11 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 31.6 m-85 -125.03 121.05 33.25 Favored 'General case' 0 N--CA 1.487 1.407 0 CA-C-O 120.787 0.327 . . . . 0.0 110.937 -179.855 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 68.7 m-85 55.2 73.32 0.42 Allowed 'General case' 0 C--N 1.345 0.386 0 CA-C-N 116.0 -0.545 . . . . 0.0 111.654 178.097 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -79.02 -78.65 0.15 Allowed 'General case' 0 C--N 1.345 0.379 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.345 -179.262 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 40.6 tt0 -111.74 102.01 10.33 Favored 'General case' 0 C--N 1.323 -0.555 0 N-CA-C 108.449 -0.945 . . . . 0.0 108.449 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -158.14 134.7 9.61 Favored 'General case' 0 C--O 1.209 -1.046 0 CA-C-O 119.571 -0.252 . . . . 0.0 111.448 178.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' F' F ' 24' ' ' VAL . . . . . . . . . . . . . 63.6 t -57.13 166.89 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.885 0 N-CA-C 107.495 -1.298 . . . . 0.0 107.495 176.98 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -119.97 49.11 0.89 Allowed Glycine 0 N--CA 1.476 1.325 0 N-CA-C 110.792 -0.923 . . . . 0.0 110.792 -179.319 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' F' F ' 26' ' ' SER . . . . . 0.472 ' HG ' ' H ' ' D' ' 8' ' ' SER . 0.2 OUTLIER -63.45 -167.77 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.549 0 CA-C-O 120.779 0.323 . . . . 0.0 110.221 179.579 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 24.8 t-20 -71.72 76.12 0.84 Allowed 'General case' 0 C--O 1.223 -0.321 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.378 179.761 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -70.18 140.49 52.55 Favored 'General case' 0 N--CA 1.478 0.967 0 N-CA-C 109.449 -0.574 . . . . 0.0 109.449 179.587 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.53 -149.8 0.05 OUTLIER Glycine 0 C--N 1.333 0.412 0 N-CA-C 110.852 -0.899 . . . . 0.0 110.852 179.443 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -92.16 126.68 37.34 Favored 'General case' 0 N--CA 1.47 0.573 0 N-CA-C 110.235 -0.283 . . . . 0.0 110.235 179.659 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 78.3 mt -123.65 116.98 49.8 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.512 0 N-CA-C 106.351 -1.722 . . . . 0.0 106.351 178.461 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 44.5 pt -151.31 -167.99 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.192 0 CA-C-O 121.061 0.458 . . . . 0.0 110.862 -178.882 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.98 5.66 8.05 Favored Glycine 0 CA--C 1.527 0.791 0 N-CA-C 111.373 -0.691 . . . . 0.0 111.373 -179.95 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 1.5 tt -77.9 127.18 31.97 Favored 'General case' 0 CA--C 1.548 0.886 0 N-CA-C 109.465 -0.569 . . . . 0.0 109.465 -179.897 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 28.4 ttt -164.45 144.44 7.69 Favored 'General case' 0 N--CA 1.469 0.493 0 N-CA-C 108.773 -0.825 . . . . 0.0 108.773 178.223 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 32.9 m -156.26 162.75 1.59 Allowed 'Isoleucine or valine' 0 C--N 1.348 0.504 0 N-CA-C 108.292 -1.003 . . . . 0.0 108.292 179.566 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.16 66.28 2.96 Favored Glycine 0 C--N 1.307 -1.08 0 CA-C-N 115.691 -0.686 . . . . 0.0 111.854 178.366 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 145.79 174.42 17.95 Favored Glycine 0 N--CA 1.473 1.14 0 N-CA-C 111.313 -0.715 . . . . 0.0 111.313 178.863 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' F' F ' 39' ' ' VAL . . . . . 0.527 ' H ' HG11 ' I' ' 39' ' ' VAL . 34.4 m -124.47 159.78 30.0 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.669 0 C-N-CA 123.301 0.64 . . . . 0.0 110.224 -179.208 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 24.9 t . . . . . 0 C--O 1.218 -0.569 0 O-C-N 124.239 0.962 . . . . 0.0 110.517 179.507 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 35.2 m-85 . . . . . 0 N--CA 1.474 0.736 0 N-CA-C 109.605 -0.517 . . . . 0.0 109.605 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' G' G ' 5' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -144.67 139.11 27.77 Favored 'General case' 0 N--CA 1.482 1.145 0 C-N-CA 122.544 0.338 . . . . 0.0 110.235 179.834 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 42.2 t-80 -150.8 120.87 7.19 Favored 'General case' 0 N--CA 1.474 0.726 0 N-CA-C 109.543 -0.54 . . . . 0.0 109.543 179.023 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -71.82 143.45 49.48 Favored 'General case' 0 N--CA 1.47 0.554 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.28 -179.766 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' G' G ' 8' ' ' SER . . . . . 0.604 ' OG ' ' O ' ' D' ' 7' ' ' ASP . 48.9 p -164.7 -170.93 2.13 Favored 'General case' 0 N--CA 1.476 0.828 0 CA-C-O 121.2 0.524 . . . . 0.0 110.534 178.83 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.52 49.01 1.23 Allowed Glycine 0 N--CA 1.479 1.528 0 N-CA-C 111.35 -0.7 . . . . 0.0 111.35 179.388 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 50.1 p90 -65.03 133.36 51.5 Favored 'General case' 0 N--CA 1.473 0.704 0 CA-C-O 120.673 0.273 . . . . 0.0 111.67 -179.719 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 83.3 mt-10 -92.1 151.64 20.32 Favored 'General case' 0 N--CA 1.48 1.031 0 CA-C-O 121.108 0.48 . . . . 0.0 110.142 178.665 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -154.89 127.45 1.06 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.973 0 N-CA-C 107.853 -1.165 . . . . 0.0 107.853 178.293 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 47.4 m-70 -134.6 144.73 48.08 Favored 'General case' 0 N--CA 1.479 1.005 0 CA-C-N 115.561 -0.745 . . . . 0.0 111.488 -178.298 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 6.1 t60 -165.43 97.37 0.69 Allowed 'General case' 0 N--CA 1.482 1.131 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.377 178.989 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 3.6 pt20 -108.6 -174.72 2.58 Favored 'General case' 0 CA--C 1.506 -0.744 0 N-CA-C 108.433 -0.951 . . . . 0.0 108.433 -179.707 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -164.32 96.17 0.77 Allowed 'General case' 0 N--CA 1.474 0.758 0 CA-C-N 114.699 -1.137 . . . . 0.0 108.121 178.735 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 6.6 mp -120.58 155.61 33.34 Favored 'General case' 0 N--CA 1.497 1.924 0 CA-C-O 121.171 0.51 . . . . 0.0 111.771 -177.846 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 43.0 t -113.16 125.13 70.37 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.884 0 CA-C-N 114.757 -1.11 . . . . 0.0 108.128 176.477 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 33.1 m-85 -126.09 121.15 32.09 Favored 'General case' 0 C--N 1.369 1.424 0 CA-C-N 115.583 -0.735 . . . . 0.0 110.892 -179.699 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 67.2 m-85 54.8 72.95 0.43 Allowed 'General case' 0 C--O 1.238 0.459 0 CA-C-N 115.841 -0.618 . . . . 0.0 111.479 178.145 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -78.08 -77.96 0.15 Allowed 'General case' 0 N--CA 1.471 0.616 0 O-C-N 122.17 -0.331 . . . . 0.0 110.557 -178.939 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 40.4 tt0 -112.24 101.99 10.19 Favored 'General case' 0 C--N 1.323 -0.568 0 N-CA-C 108.093 -1.077 . . . . 0.0 108.093 179.917 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -157.88 135.91 10.8 Favored 'General case' 0 N--CA 1.476 0.867 0 O-C-N 122.401 -0.187 . . . . 0.0 111.488 178.826 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' G' G ' 24' ' ' VAL . . . . . . . . . . . . . 57.3 t -58.27 166.47 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.647 0 N-CA-C 107.555 -1.276 . . . . 0.0 107.555 176.986 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -119.05 49.4 0.87 Allowed Glycine 0 N--CA 1.479 1.524 0 N-CA-C 110.456 -1.058 . . . . 0.0 110.456 -179.47 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' G' G ' 26' ' ' SER . . . . . 0.404 ' HG ' ' CB ' ' E' ' 7' ' ' ASP . 0.2 OUTLIER -64.4 -168.09 0.03 OUTLIER 'General case' 0 N--CA 1.472 0.636 0 N-CA-C 109.904 -0.406 . . . . 0.0 109.904 179.645 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 25.1 t-20 -71.62 76.09 0.82 Allowed 'General case' 0 CA--C 1.536 0.438 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.324 179.928 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -69.57 140.64 53.84 Favored 'General case' 0 N--CA 1.478 0.955 0 N-CA-C 109.562 -0.533 . . . . 0.0 109.562 179.604 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.99 -147.81 0.05 OUTLIER Glycine 0 C--N 1.337 0.587 0 N-CA-C 110.443 -1.063 . . . . 0.0 110.443 179.612 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -92.88 125.99 37.75 Favored 'General case' 0 N--CA 1.467 0.419 0 C-N-CA 122.65 0.38 . . . . 0.0 110.93 -179.824 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 76.6 mt -123.45 117.65 52.03 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.811 0 N-CA-C 106.417 -1.697 . . . . 0.0 106.417 178.238 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 44.0 pt -152.47 -167.61 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 CA-C-N 119.819 1.19 . . . . 0.0 110.031 -179.225 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.29 6.26 10.15 Favored Glycine 0 N--CA 1.466 0.671 0 N-CA-C 111.056 -0.818 . . . . 0.0 111.056 179.881 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 1.5 tt -79.49 125.7 29.91 Favored 'General case' 0 CA--C 1.545 0.773 0 N-CA-C 109.516 -0.55 . . . . 0.0 109.516 -179.702 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 27.7 ttt -162.86 146.17 10.97 Favored 'General case' 0 N--CA 1.47 0.553 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 178.534 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 32.7 m -156.95 162.01 1.69 Allowed 'Isoleucine or valine' 0 C--N 1.35 0.603 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 -179.99 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.48 66.63 2.7 Favored Glycine 0 C--N 1.31 -0.913 0 CA-C-N 115.541 -0.754 . . . . 0.0 112.104 177.818 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 146.72 175.6 19.82 Favored Glycine 0 N--CA 1.475 1.251 0 N-CA-C 110.559 -1.016 . . . . 0.0 110.559 178.994 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' G' G ' 39' ' ' VAL . . . . . 0.513 HG11 ' H ' ' D' ' 39' ' ' VAL . 34.9 m -125.77 159.71 33.4 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.912 0 C-N-CA 123.092 0.557 . . . . 0.0 110.484 -179.408 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 26.3 t . . . . . 0 C--O 1.22 -0.488 0 CA-C-O 118.395 -0.812 . . . . 0.0 110.751 179.082 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 34.9 m-85 . . . . . 0 N--CA 1.474 0.77 0 N-CA-C 109.518 -0.549 . . . . 0.0 109.518 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' H' H ' 5' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -144.74 139.68 28.04 Favored 'General case' 0 N--CA 1.485 1.313 0 N-CA-C 110.04 -0.355 . . . . 0.0 110.04 179.838 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 41.2 t-80 -151.58 120.7 6.72 Favored 'General case' 0 N--CA 1.474 0.76 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 179.068 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -71.65 143.82 49.62 Favored 'General case' 0 N--CA 1.469 0.511 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.308 -179.756 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' H' H ' 8' ' ' SER . . . . . 0.508 ' OG ' ' O ' ' E' ' 7' ' ' ASP . 52.2 p -164.81 -171.18 2.19 Favored 'General case' 0 N--CA 1.475 0.809 0 CA-C-O 121.126 0.489 . . . . 0.0 110.489 178.921 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.76 48.35 1.28 Allowed Glycine 0 N--CA 1.479 1.541 0 CA-C-N 115.783 -0.644 . . . . 0.0 111.551 179.336 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 50.1 p90 -64.51 133.06 51.64 Favored 'General case' 0 N--CA 1.471 0.624 0 N-CA-C 111.785 0.291 . . . . 0.0 111.785 -179.685 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 83.1 mt-10 -91.69 151.56 20.61 Favored 'General case' 0 N--CA 1.479 0.984 0 CA-C-O 121.068 0.461 . . . . 0.0 110.183 178.476 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -154.67 127.88 1.17 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.979 0 N-CA-C 107.885 -1.154 . . . . 0.0 107.885 178.08 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 47.3 m-70 -134.75 145.53 48.52 Favored 'General case' 0 N--CA 1.478 0.955 0 CA-C-N 115.676 -0.693 . . . . 0.0 111.359 -178.419 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 6.0 t60 -166.24 97.37 0.6 Allowed 'General case' 0 N--CA 1.482 1.146 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.346 178.794 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 3.6 pt20 -108.33 -174.3 2.49 Favored 'General case' 0 CA--C 1.505 -0.757 0 N-CA-C 108.425 -0.954 . . . . 0.0 108.425 -179.728 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -164.84 96.22 0.72 Allowed 'General case' 0 N--CA 1.475 0.799 0 CA-C-N 114.647 -1.16 . . . . 0.0 108.018 178.66 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 6.5 mp -120.53 156.02 32.43 Favored 'General case' 0 N--CA 1.497 1.899 0 CA-C-O 121.239 0.543 . . . . 0.0 111.972 -177.949 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 41.4 t -113.7 124.73 70.63 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.07 0 CA-C-N 114.819 -1.082 . . . . 0.0 108.227 176.658 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 33.3 m-85 -125.73 121.31 33.04 Favored 'General case' 0 C--N 1.368 1.388 0 CA-C-N 115.459 -0.792 . . . . 0.0 110.863 -179.491 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 68.0 m-85 54.3 72.69 0.44 Allowed 'General case' 0 C--O 1.237 0.422 0 CA-C-N 115.858 -0.61 . . . . 0.0 111.587 178.11 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.63 -78.13 0.14 Allowed 'General case' 0 N--CA 1.471 0.622 0 O-C-N 122.203 -0.31 . . . . 0.0 110.571 -179.033 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 40.9 tt0 -112.12 101.99 10.22 Favored 'General case' 0 C--N 1.321 -0.632 0 N-CA-C 108.091 -1.077 . . . . 0.0 108.091 -179.99 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -157.97 135.78 10.61 Favored 'General case' 0 N--CA 1.477 0.913 0 N-CA-C 111.445 0.165 . . . . 0.0 111.445 178.863 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' H' H ' 24' ' ' VAL . . . . . . . . . . . . . 59.2 t -58.3 166.35 0.51 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.606 0 N-CA-C 107.682 -1.229 . . . . 0.0 107.682 177.197 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . -118.76 49.42 0.87 Allowed Glycine 0 N--CA 1.478 1.444 0 N-CA-C 110.653 -0.979 . . . . 0.0 110.653 -179.498 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -64.67 -167.85 0.03 OUTLIER 'General case' 0 N--CA 1.472 0.668 0 CA-C-N 116.97 0.385 . . . . 0.0 110.0 179.662 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 24.9 t-20 -71.77 76.39 0.86 Allowed 'General case' 0 CA--C 1.535 0.4 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.317 179.871 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -69.89 140.74 53.18 Favored 'General case' 0 N--CA 1.478 0.953 0 N-CA-C 109.552 -0.536 . . . . 0.0 109.552 179.483 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.96 -147.82 0.05 OUTLIER Glycine 0 C--N 1.338 0.653 0 N-CA-C 110.329 -1.108 . . . . 0.0 110.329 179.541 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -93.5 125.77 38.29 Favored 'General case' 0 N--CA 1.465 0.307 0 C-N-CA 122.58 0.352 . . . . 0.0 110.872 -179.61 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 76.1 mt -122.92 117.55 52.12 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.757 0 N-CA-C 106.431 -1.692 . . . . 0.0 106.431 178.315 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 44.8 pt -152.04 -167.84 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 CA-C-N 119.807 1.185 . . . . 0.0 109.98 -179.469 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.93 5.8 10.53 Favored Glycine 0 N--CA 1.466 0.661 0 N-CA-C 110.964 -0.854 . . . . 0.0 110.964 179.86 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 1.5 tt -79.04 124.95 28.77 Favored 'General case' 0 CA--C 1.544 0.744 0 N-CA-C 109.725 -0.472 . . . . 0.0 109.725 -179.515 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 27.8 ttt -162.19 145.97 12.01 Favored 'General case' 0 N--CA 1.469 0.502 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 178.635 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 32.6 m -157.08 161.69 1.76 Allowed 'Isoleucine or valine' 0 C--N 1.349 0.566 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 -179.895 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.94 66.2 3.01 Favored Glycine 0 C--N 1.309 -0.93 0 CA-C-N 115.498 -0.773 . . . . 0.0 112.17 177.935 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 146.92 175.63 20.01 Favored Glycine 0 N--CA 1.474 1.197 0 N-CA-C 110.639 -0.984 . . . . 0.0 110.639 178.893 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' H' H ' 39' ' ' VAL . . . . . 0.521 HG11 ' H ' ' E' ' 39' ' ' VAL . 34.9 m -125.2 159.96 31.54 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.927 0 C-N-CA 123.173 0.589 . . . . 0.0 110.537 -179.487 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 25.1 t . . . . . 0 N--CA 1.47 0.54 0 CA-C-O 118.439 -0.791 . . . . 0.0 110.819 179.233 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 35.9 m-85 . . . . . 0 N--CA 1.474 0.739 0 N-CA-C 109.538 -0.541 . . . . 0.0 109.538 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' I' I ' 5' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -144.51 139.17 28.08 Favored 'General case' 0 N--CA 1.484 1.255 0 N-CA-C 110.038 -0.356 . . . . 0.0 110.038 179.815 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 41.6 t-80 -150.81 120.73 7.12 Favored 'General case' 0 N--CA 1.473 0.679 0 N-CA-C 109.385 -0.598 . . . . 0.0 109.385 178.907 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 4.0 m-20 -71.48 143.94 49.86 Favored 'General case' 0 N--CA 1.47 0.531 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.141 -179.888 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' I' I ' 8' ' ' SER . . . . . 0.509 ' OG ' ' O ' ' F' ' 7' ' ' ASP . 52.5 p -165.05 -171.14 2.13 Favored 'General case' 0 N--CA 1.474 0.758 0 CA-C-O 121.081 0.467 . . . . 0.0 110.621 178.89 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.53 48.81 1.25 Allowed Glycine 0 N--CA 1.479 1.514 0 N-CA-C 111.502 -0.639 . . . . 0.0 111.502 179.348 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 50.2 p90 -65.12 132.94 50.49 Favored 'General case' 0 N--CA 1.472 0.663 0 N-CA-C 111.772 0.286 . . . . 0.0 111.772 -179.718 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 83.6 mt-10 -91.43 151.57 20.75 Favored 'General case' 0 N--CA 1.478 0.953 0 CA-C-O 121.045 0.45 . . . . 0.0 110.265 178.539 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -154.91 127.42 1.05 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.047 0 N-CA-C 107.91 -1.144 . . . . 0.0 107.91 178.198 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 46.9 m-70 -134.48 145.15 48.54 Favored 'General case' 0 N--CA 1.478 0.933 0 CA-C-N 115.61 -0.723 . . . . 0.0 111.407 -178.196 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 6.1 t60 -165.75 97.25 0.65 Allowed 'General case' 0 N--CA 1.48 1.03 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.378 178.838 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 3.6 pt20 -108.39 -174.55 2.55 Favored 'General case' 0 CA--C 1.504 -0.809 0 N-CA-C 108.381 -0.97 . . . . 0.0 108.381 -179.757 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -164.54 96.33 0.75 Allowed 'General case' 0 N--CA 1.474 0.755 0 CA-C-N 114.608 -1.178 . . . . 0.0 108.116 178.641 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 6.4 mp -120.6 156.07 32.42 Favored 'General case' 0 N--CA 1.497 1.914 0 CA-C-O 121.232 0.539 . . . . 0.0 111.767 -177.882 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 41.4 t -113.77 125.06 70.98 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.884 0 CA-C-N 114.753 -1.112 . . . . 0.0 108.207 176.608 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 33.6 m-85 -126.0 121.38 32.86 Favored 'General case' 0 C--N 1.368 1.41 0 CA-C-N 115.502 -0.772 . . . . 0.0 110.829 -179.449 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 67.9 m-85 54.25 73.29 0.4 Allowed 'General case' 0 C--N 1.347 0.467 0 CA-C-N 115.925 -0.58 . . . . 0.0 111.464 178.136 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -78.18 -78.01 0.15 Allowed 'General case' 0 N--CA 1.475 0.802 0 O-C-N 122.296 -0.253 . . . . 0.0 110.453 -179.079 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 40.7 tt0 -112.02 102.12 10.36 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 108.088 -1.079 . . . . 0.0 108.088 179.802 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -157.88 135.92 10.81 Favored 'General case' 0 N--CA 1.478 0.97 0 N-CA-C 111.409 0.152 . . . . 0.0 111.409 178.784 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' I' I ' 24' ' ' VAL . . . . . . . . . . . . . 59.5 t -58.57 166.32 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.573 0 N-CA-C 107.658 -1.238 . . . . 0.0 107.658 177.203 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . -118.69 49.0 0.89 Allowed Glycine 0 N--CA 1.479 1.524 0 N-CA-C 110.556 -1.017 . . . . 0.0 110.556 -179.392 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' I' I ' 26' ' ' SER . . . . . 0.42 ' HG ' ' CB ' ' D' ' 7' ' ' ASP . 0.2 OUTLIER -64.3 -167.87 0.03 OUTLIER 'General case' 0 N--CA 1.472 0.648 0 CA-C-N 116.951 0.376 . . . . 0.0 110.092 179.641 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 24.9 t-20 -71.74 76.45 0.85 Allowed 'General case' 0 CA--C 1.536 0.419 0 CA-C-N 116.07 -0.513 . . . . 0.0 110.219 179.884 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -70.08 140.86 52.81 Favored 'General case' 0 N--CA 1.478 0.961 0 N-CA-C 109.492 -0.559 . . . . 0.0 109.492 179.496 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -65.02 -147.67 0.05 OUTLIER Glycine 0 C--N 1.337 0.628 0 N-CA-C 110.416 -1.074 . . . . 0.0 110.416 179.577 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -93.3 125.89 38.14 Favored 'General case' 0 N--CA 1.469 0.496 0 C-N-CA 122.587 0.355 . . . . 0.0 110.924 -179.953 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 77.0 mt -123.2 117.3 51.15 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.708 0 N-CA-C 106.474 -1.676 . . . . 0.0 106.474 178.255 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 44.6 pt -152.13 -167.9 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 CA-C-N 119.851 1.205 . . . . 0.0 109.979 -179.284 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.07 5.52 10.2 Favored Glycine 0 N--CA 1.466 0.674 0 N-CA-C 110.969 -0.852 . . . . 0.0 110.969 179.86 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 1.5 tt -78.6 125.82 29.89 Favored 'General case' 0 CA--C 1.546 0.798 0 N-CA-C 109.6 -0.519 . . . . 0.0 109.6 -179.675 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 27.7 ttt -162.76 146.01 11.08 Favored 'General case' 0 N--CA 1.47 0.561 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 178.454 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 32.5 m -157.08 161.78 1.73 Allowed 'Isoleucine or valine' 0 C--N 1.348 0.522 0 N-CA-C 108.6 -0.889 . . . . 0.0 108.6 179.928 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.76 66.42 2.86 Favored Glycine 0 C--N 1.308 -0.981 0 CA-C-N 115.557 -0.747 . . . . 0.0 112.114 177.863 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 146.64 175.76 19.88 Favored Glycine 0 N--CA 1.476 1.334 0 N-CA-C 110.57 -1.012 . . . . 0.0 110.57 178.95 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' I' I ' 39' ' ' VAL . . . . . 0.527 HG11 ' H ' ' F' ' 39' ' ' VAL . 35.0 m -125.69 160.11 32.64 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.915 0 C-N-CA 123.138 0.575 . . . . 0.0 110.53 -179.381 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 25.9 t . . . . . 0 C--O 1.218 -0.557 0 CA-C-O 118.449 -0.786 . . . . 0.0 110.713 179.216 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 39.4 m-85 . . . . . 0 N--CA 1.477 0.882 0 N-CA-C 109.99 -0.374 . . . . 0.0 109.99 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -143.93 140.15 29.54 Favored 'General case' 0 N--CA 1.48 1.048 0 N-CA-C 110.016 -0.364 . . . . 0.0 110.016 179.67 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 43.3 t-80 -151.84 119.67 6.16 Favored 'General case' 0 N--CA 1.47 0.551 0 N-CA-C 109.224 -0.658 . . . . 0.0 109.224 179.291 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' ASP . . . . . 0.513 ' O ' ' OG ' ' D' ' 8' ' ' SER . 4.6 m-20 -69.14 148.9 49.27 Favored 'General case' 0 N--CA 1.466 0.34 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.466 179.879 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 54.8 p -168.21 -173.79 2.12 Favored 'General case' 0 N--CA 1.482 1.162 0 C-N-CA 122.669 0.388 . . . . 0.0 110.718 179.053 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.79 47.79 1.33 Allowed Glycine 0 N--CA 1.482 1.735 0 CA-C-N 116.013 -0.539 . . . . 0.0 112.147 -179.911 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 50.1 p90 -65.06 132.67 49.83 Favored 'General case' 0 N--CA 1.473 0.686 0 CA-C-O 120.716 0.293 . . . . 0.0 111.532 179.899 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 49.0 mt-10 -92.66 152.46 19.54 Favored 'General case' 0 N--CA 1.477 0.918 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 178.398 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.0 p -153.13 128.37 1.55 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.632 0 N-CA-C 107.847 -1.168 . . . . 0.0 107.847 178.382 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 47.2 m-70 -134.87 145.83 48.65 Favored 'General case' 0 N--CA 1.492 1.648 0 CA-C-N 119.096 0.862 . . . . 0.0 111.327 -179.127 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 6.1 t60 -165.73 97.51 0.66 Allowed 'General case' 0 N--CA 1.48 1.05 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.809 179.496 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 11.9 pt20 -111.9 -174.78 2.54 Favored 'General case' 0 CA--C 1.503 -0.86 0 N-CA-C 108.355 -0.98 . . . . 0.0 108.355 -179.849 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -163.27 99.13 0.94 Allowed 'General case' 0 N--CA 1.474 0.749 0 CA-C-N 114.527 -1.215 . . . . 0.0 108.347 178.582 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 6.9 mp -121.83 157.07 31.9 Favored 'General case' 0 N--CA 1.497 1.909 0 CA-C-O 121.945 0.879 . . . . 0.0 110.86 -178.338 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 60.0 t -112.54 126.84 69.98 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.179 0 CA-C-O 117.877 -1.058 . . . . 0.0 108.298 177.808 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 28.8 m-85 -127.11 122.52 34.49 Favored 'General case' 0 N--CA 1.496 1.859 0 CA-C-N 120.197 1.362 . . . . 0.0 110.336 179.302 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 68.3 m-85 53.95 73.98 0.35 Allowed 'General case' 0 N--CA 1.47 0.546 0 CA-C-O 121.544 0.687 . . . . 0.0 111.745 178.51 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -80.22 -78.13 0.18 Allowed 'General case' 0 C--N 1.353 0.758 0 CA-C-N 115.117 -0.947 . . . . 0.0 110.42 -179.739 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 40.3 tt0 -112.07 101.87 10.12 Favored 'General case' 0 N--CA 1.47 0.563 0 N-CA-C 108.493 -0.928 . . . . 0.0 108.493 179.927 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -158.69 134.65 9.0 Favored 'General case' 0 N--CA 1.481 1.092 0 CA-C-O 119.388 -0.339 . . . . 0.0 111.254 179.026 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 61.9 t -58.36 163.4 0.72 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.795 0 N-CA-C 108.227 -1.027 . . . . 0.0 108.227 177.173 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -116.04 48.07 0.98 Allowed Glycine 0 N--CA 1.476 1.326 0 N-CA-C 111.759 -0.536 . . . . 0.0 111.759 -179.402 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -62.07 -168.59 0.02 OUTLIER 'General case' 0 N--CA 1.469 0.499 0 O-C-N 123.834 0.373 . . . . 0.0 110.218 179.284 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 24.7 t-20 -72.43 79.83 1.04 Allowed 'General case' 0 N--CA 1.466 0.335 0 N-CA-C 110.048 -0.352 . . . . 0.0 110.048 179.221 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -73.28 140.32 46.73 Favored 'General case' 0 N--CA 1.471 0.625 0 N-CA-C 109.012 -0.736 . . . . 0.0 109.012 179.43 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.42 -148.9 0.03 OUTLIER Glycine 0 C--N 1.337 0.622 0 N-CA-C 110.383 -1.087 . . . . 0.0 110.383 179.443 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -93.94 128.54 40.31 Favored 'General case' 0 N--CA 1.471 0.604 0 N-CA-C 110.076 -0.342 . . . . 0.0 110.076 179.904 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 72.4 mt -125.0 116.77 48.13 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.874 0 N-CA-C 106.782 -1.562 . . . . 0.0 106.782 178.764 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 38.9 pt -151.01 -169.69 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.356 0.88 0 CA-C-N 115.857 -0.611 . . . . 0.0 111.206 -178.527 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.41 5.37 11.41 Favored Glycine 0 C--N 1.336 0.577 0 N-CA-C 110.912 -0.875 . . . . 0.0 110.912 179.673 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 1.5 tt -78.42 127.12 31.74 Favored 'General case' 0 CA--C 1.543 0.684 0 N-CA-C 109.44 -0.578 . . . . 0.0 109.44 -179.617 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 28.6 ttt -164.59 143.86 7.22 Favored 'General case' 0 N--CA 1.466 0.368 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 178.404 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 35.3 m -155.92 163.28 1.51 Allowed 'Isoleucine or valine' 0 C--O 1.219 -0.525 0 N-CA-C 108.339 -0.985 . . . . 0.0 108.339 179.376 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.78 66.56 2.75 Favored Glycine 0 C--N 1.303 -1.292 0 CA-C-N 116.147 -0.479 . . . . 0.0 112.136 178.631 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 146.0 173.54 17.34 Favored Glycine 0 N--CA 1.475 1.243 0 N-CA-C 110.649 -0.98 . . . . 0.0 110.649 179.138 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . 0.485 ' H ' HG11 ' D' ' 39' ' ' VAL . 35.6 m -123.96 159.98 28.53 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.861 0 C-N-CA 123.579 0.752 . . . . 0.0 110.552 -179.858 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 25.2 t . . . . . 0 C--O 1.22 -0.46 0 CA-C-O 118.323 -0.846 . . . . 0.0 110.78 179.568 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 39.4 m-85 . . . . . 0 N--CA 1.475 0.807 0 N-CA-C 109.99 -0.374 . . . . 0.0 109.99 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -143.71 139.98 29.78 Favored 'General case' 0 N--CA 1.482 1.139 0 N-CA-C 109.977 -0.379 . . . . 0.0 109.977 179.693 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 40.5 t-80 -151.74 119.18 6.0 Favored 'General case' 0 N--CA 1.473 0.724 0 N-CA-C 109.238 -0.652 . . . . 0.0 109.238 179.216 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 7' ' ' ASP . . . . . 0.501 ' O ' ' OG ' ' E' ' 8' ' ' SER . 4.3 m-20 -68.89 148.15 50.64 Favored 'General case' 0 CA--C 1.535 0.385 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.639 179.865 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 8' ' ' SER . . . . . . . . . . . . . 54.3 p -167.44 -173.79 2.34 Favored 'General case' 0 N--CA 1.48 1.068 0 C-N-CA 122.575 0.35 . . . . 0.0 110.701 179.072 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.94 47.92 1.3 Allowed Glycine 0 N--CA 1.482 1.703 0 CA-C-N 115.991 -0.549 . . . . 0.0 112.178 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 50.1 p90 -65.18 132.7 49.8 Favored 'General case' 0 N--CA 1.472 0.633 0 O-C-N 122.716 -0.285 . . . . 0.0 111.663 179.782 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 48.5 mt-10 -92.55 152.77 19.45 Favored 'General case' 0 N--CA 1.477 0.913 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 178.331 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.0 p -153.43 128.45 1.51 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.587 0 N-CA-C 107.737 -1.209 . . . . 0.0 107.737 178.314 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 47.5 m-70 -135.0 145.81 48.45 Favored 'General case' 0 N--CA 1.492 1.639 0 CA-C-N 118.904 0.775 . . . . 0.0 111.303 -179.103 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 6.2 t60 -165.66 97.46 0.66 Allowed 'General case' 0 N--CA 1.482 1.133 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.648 179.452 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 12.0 pt20 -111.76 -174.34 2.44 Favored 'General case' 0 CA--C 1.506 -0.749 0 N-CA-C 108.362 -0.977 . . . . 0.0 108.362 -179.883 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -163.87 99.07 0.87 Allowed 'General case' 0 N--CA 1.474 0.77 0 CA-C-N 114.718 -1.128 . . . . 0.0 108.26 178.608 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 6.8 mp -121.62 157.0 31.77 Favored 'General case' 0 N--CA 1.497 1.916 0 CA-C-O 121.936 0.875 . . . . 0.0 110.998 -178.294 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 61.1 t -112.55 127.6 69.68 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.07 0 N-CA-C 108.122 -1.066 . . . . 0.0 108.122 177.574 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 29.0 m-85 -127.99 122.36 32.11 Favored 'General case' 0 N--CA 1.495 1.802 0 CA-C-N 119.638 1.108 . . . . 0.0 110.219 179.515 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 68.7 m-85 53.23 74.46 0.3 Allowed 'General case' 0 CA--C 1.54 0.566 0 CA-C-O 121.558 0.694 . . . . 0.0 111.735 178.573 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -80.71 -77.85 0.19 Allowed 'General case' 0 C--N 1.35 0.6 0 CA-C-N 115.075 -0.966 . . . . 0.0 110.45 -179.788 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 40.5 tt0 -112.22 101.9 10.1 Favored 'General case' 0 N--CA 1.471 0.615 0 N-CA-C 108.417 -0.957 . . . . 0.0 108.417 179.786 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -158.68 134.54 8.94 Favored 'General case' 0 N--CA 1.484 1.23 0 CA-C-O 119.444 -0.312 . . . . 0.0 111.16 178.85 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 61.1 t -57.98 163.82 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.806 0 N-CA-C 108.249 -1.019 . . . . 0.0 108.249 177.209 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -116.22 48.22 0.96 Allowed Glycine 0 N--CA 1.475 1.288 0 N-CA-C 111.625 -0.59 . . . . 0.0 111.625 -179.446 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -62.27 -169.06 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.531 0 O-C-N 123.76 0.33 . . . . 0.0 110.242 179.238 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 25.1 t-20 -72.2 79.68 0.97 Allowed 'General case' 0 N--CA 1.467 0.393 0 N-CA-C 109.881 -0.414 . . . . 0.0 109.881 179.307 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -72.99 140.66 47.5 Favored 'General case' 0 N--CA 1.472 0.674 0 N-CA-C 109.105 -0.702 . . . . 0.0 109.105 179.417 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.86 -149.1 0.04 OUTLIER Glycine 0 C--N 1.338 0.645 0 N-CA-C 110.349 -1.1 . . . . 0.0 110.349 179.582 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -93.75 128.47 39.99 Favored 'General case' 0 N--CA 1.473 0.679 0 N-CA-C 110.036 -0.357 . . . . 0.0 110.036 179.882 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 72.5 mt -125.08 117.14 49.15 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.859 0 N-CA-C 106.723 -1.584 . . . . 0.0 106.723 178.768 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 39.6 pt -151.47 -169.94 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.356 0.887 0 CA-C-N 115.874 -0.603 . . . . 0.0 111.119 -178.364 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.68 5.26 12.31 Favored Glycine 0 C--N 1.337 0.614 0 N-CA-C 110.894 -0.882 . . . . 0.0 110.894 179.702 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 1.5 tt -78.42 126.67 31.09 Favored 'General case' 0 CA--C 1.545 0.76 0 N-CA-C 109.441 -0.577 . . . . 0.0 109.441 -179.521 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 28.5 ttt -164.12 143.66 7.83 Favored 'General case' 0 N--CA 1.467 0.378 0 N-CA-C 108.722 -0.844 . . . . 0.0 108.722 178.456 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 35.7 m -155.88 162.98 1.57 Allowed 'Isoleucine or valine' 0 C--O 1.22 -0.491 0 N-CA-C 108.343 -0.984 . . . . 0.0 108.343 179.519 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.81 66.95 2.47 Favored Glycine 0 C--N 1.303 -1.291 0 CA-C-N 116.183 -0.462 . . . . 0.0 112.076 178.591 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 145.33 173.24 16.41 Favored Glycine 0 N--CA 1.474 1.208 0 N-CA-C 110.69 -0.964 . . . . 0.0 110.69 179.181 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 39' ' ' VAL . . . . . 0.508 ' H ' HG11 ' E' ' 39' ' ' VAL . 35.7 m -123.65 159.84 27.95 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.934 0 C-N-CA 123.608 0.763 . . . . 0.0 110.713 -179.769 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 24.4 t . . . . . 0 N--CA 1.469 0.522 0 CA-C-O 118.339 -0.839 . . . . 0.0 110.599 179.53 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 40.3 m-85 . . . . . 0 N--CA 1.476 0.842 0 N-CA-C 110.031 -0.359 . . . . 0.0 110.031 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -143.63 139.98 29.89 Favored 'General case' 0 N--CA 1.482 1.134 0 CA-C-O 120.872 0.368 . . . . 0.0 110.05 179.762 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 42.1 t-80 -151.74 119.16 5.99 Favored 'General case' 0 N--CA 1.472 0.656 0 N-CA-C 109.26 -0.644 . . . . 0.0 109.26 179.173 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 7' ' ' ASP . . . . . 0.497 ' O ' ' OG ' ' F' ' 8' ' ' SER . 4.2 m-20 -68.77 148.47 50.28 Favored 'General case' 0 N--CA 1.468 0.443 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.52 179.783 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' C' C ' 8' ' ' SER . . . . . . . . . . . . . 54.2 p -167.97 -173.94 2.23 Favored 'General case' 0 N--CA 1.48 1.049 0 CA-C-O 120.874 0.368 . . . . 0.0 110.677 179.137 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.05 47.75 1.31 Allowed Glycine 0 N--CA 1.482 1.751 0 CA-C-N 115.968 -0.56 . . . . 0.0 112.072 -179.926 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 50.6 p90 -65.04 132.58 49.59 Favored 'General case' 0 N--CA 1.472 0.658 0 CA-C-O 120.778 0.323 . . . . 0.0 111.637 179.737 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 48.6 mt-10 -92.48 152.96 19.39 Favored 'General case' 0 N--CA 1.475 0.79 0 N-CA-C 109.738 -0.468 . . . . 0.0 109.738 178.395 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.0 p -153.65 128.62 1.5 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.523 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 178.263 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 46.1 m-70 -135.17 145.72 48.02 Favored 'General case' 0 N--CA 1.492 1.635 0 CA-C-N 118.931 0.787 . . . . 0.0 111.317 -179.057 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 6.2 t60 -165.52 97.52 0.68 Allowed 'General case' 0 N--CA 1.482 1.162 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.688 179.52 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 12.0 pt20 -112.0 -174.47 2.47 Favored 'General case' 0 CA--C 1.504 -0.825 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 -179.889 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -163.62 99.12 0.9 Allowed 'General case' 0 N--CA 1.473 0.677 0 CA-C-N 114.708 -1.133 . . . . 0.0 108.261 178.777 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 6.8 mp -121.71 157.07 31.74 Favored 'General case' 0 N--CA 1.497 1.902 0 CA-C-O 121.965 0.888 . . . . 0.0 110.994 -178.342 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 61.9 t -112.71 127.4 69.96 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.151 0 N-CA-C 108.146 -1.057 . . . . 0.0 108.146 177.612 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 28.9 m-85 -127.82 122.17 32.01 Favored 'General case' 0 N--CA 1.494 1.765 0 CA-C-N 119.673 1.124 . . . . 0.0 110.197 179.513 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 68.7 m-85 53.42 74.55 0.3 Allowed 'General case' 0 CA--C 1.539 0.523 0 CA-C-O 121.57 0.7 . . . . 0.0 111.787 178.612 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -80.62 -78.12 0.18 Allowed 'General case' 0 C--N 1.35 0.598 0 CA-C-N 114.961 -1.018 . . . . 0.0 110.379 -179.805 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 40.3 tt0 -112.02 102.05 10.3 Favored 'General case' 0 N--CA 1.469 0.522 0 N-CA-C 108.506 -0.924 . . . . 0.0 108.506 179.82 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -158.76 134.67 8.94 Favored 'General case' 0 N--CA 1.482 1.161 0 CA-C-O 119.385 -0.341 . . . . 0.0 111.185 178.906 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 61.0 t -58.14 163.74 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.843 0 N-CA-C 108.217 -1.031 . . . . 0.0 108.217 177.188 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -116.28 48.13 0.97 Allowed Glycine 0 N--CA 1.477 1.372 0 N-CA-C 111.617 -0.593 . . . . 0.0 111.617 -179.352 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -62.3 -169.11 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.532 0 O-C-N 123.726 0.309 . . . . 0.0 110.212 179.312 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 25.2 t-20 -71.98 79.98 0.92 Allowed 'General case' 0 N--CA 1.466 0.368 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.205 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -73.45 140.61 46.62 Favored 'General case' 0 N--CA 1.473 0.692 0 N-CA-C 109.015 -0.735 . . . . 0.0 109.015 179.369 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.71 -148.67 0.03 OUTLIER Glycine 0 C--N 1.338 0.661 0 N-CA-C 110.395 -1.082 . . . . 0.0 110.395 179.548 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -93.99 128.25 40.23 Favored 'General case' 0 N--CA 1.471 0.592 0 CA-C-N 116.866 0.333 . . . . 0.0 110.136 179.825 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 71.8 mt -124.94 116.71 48.02 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.834 0 N-CA-C 106.779 -1.563 . . . . 0.0 106.779 178.654 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 38.8 pt -150.97 -169.71 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.356 0.873 0 CA-C-N 115.903 -0.589 . . . . 0.0 111.183 -178.42 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.37 5.39 11.29 Favored Glycine 0 C--N 1.336 0.555 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 179.659 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 1.5 tt -78.53 126.44 30.76 Favored 'General case' 0 CA--C 1.544 0.744 0 N-CA-C 109.499 -0.556 . . . . 0.0 109.499 -179.613 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 28.6 ttt -163.65 143.76 8.55 Favored 'General case' 0 N--CA 1.468 0.427 0 N-CA-C 108.687 -0.857 . . . . 0.0 108.687 178.42 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 35.5 m -155.9 162.96 1.57 Allowed 'Isoleucine or valine' 0 C--O 1.219 -0.501 0 N-CA-C 108.292 -1.003 . . . . 0.0 108.292 179.384 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.93 66.9 2.51 Favored Glycine 0 C--N 1.303 -1.299 0 CA-C-N 116.195 -0.457 . . . . 0.0 112.058 178.565 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 145.53 173.67 17.01 Favored Glycine 0 N--CA 1.475 1.257 0 N-CA-C 110.663 -0.975 . . . . 0.0 110.663 179.061 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 39' ' ' VAL . . . . . 0.512 ' H ' HG11 ' F' ' 39' ' ' VAL . 35.9 m -124.02 159.87 28.81 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.868 0 C-N-CA 123.678 0.791 . . . . 0.0 110.592 -179.851 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 24.7 t . . . . . 0 C--O 1.219 -0.542 0 CA-C-O 118.355 -0.831 . . . . 0.0 110.611 179.496 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 39.8 m-85 . . . . . 0 N--CA 1.472 0.671 0 N-CA-C 108.898 -0.778 . . . . 0.0 108.898 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' D' D ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -145.9 138.11 25.38 Favored 'General case' 0 N--CA 1.476 0.848 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.396 -179.609 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 39.6 t-80 -149.29 123.69 9.65 Favored 'General case' 0 CA--C 1.546 0.79 0 N-CA-C 108.318 -0.993 . . . . 0.0 108.318 175.746 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 7' ' ' ASP . . . . . 0.598 ' O ' ' OG ' ' G' ' 8' ' ' SER . 3.3 m-20 -64.28 133.08 52.03 Favored 'General case' 0 C--N 1.324 -0.524 0 C-N-CA 126.477 1.911 . . . . 0.0 114.259 174.946 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' D' D ' 8' ' ' SER . . . . . 0.513 ' OG ' ' O ' ' A' ' 7' ' ' ASP . 54.0 p -154.93 -171.12 3.72 Favored 'General case' 0 N--CA 1.486 1.373 0 CA-C-N 119.566 1.075 . . . . 0.0 111.26 175.892 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.44 48.23 1.14 Allowed Glycine 0 N--CA 1.483 1.779 0 N-CA-C 110.517 -1.033 . . . . 0.0 110.517 174.559 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 51.4 p90 -61.0 131.19 49.85 Favored 'General case' 0 N--CA 1.471 0.594 0 N-CA-C 112.782 0.66 . . . . 0.0 112.782 178.433 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 48.5 mt-10 -89.44 151.04 22.23 Favored 'General case' 0 N--CA 1.48 1.07 0 C-N-CA 122.258 0.223 . . . . 0.0 110.826 175.581 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.0 p -149.58 130.01 4.32 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.599 0 N-CA-C 107.515 -1.291 . . . . 0.0 107.515 173.542 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 44.5 m-70 -130.07 148.63 51.94 Favored 'General case' 0 N--CA 1.483 1.212 0 CA-C-N 118.22 0.464 . . . . 0.0 111.78 176.379 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 6.2 t60 -164.96 104.38 0.78 Allowed 'General case' 0 N--CA 1.482 1.163 0 N-CA-C 109.141 -0.689 . . . . 0.0 109.141 172.859 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 11.9 pt20 -115.47 -176.18 2.87 Favored 'General case' 0 CA--C 1.496 -1.12 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 179.061 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -160.36 106.1 1.51 Allowed 'General case' 0 N--CA 1.469 0.506 0 N-CA-C 106.717 -1.586 . . . . 0.0 106.717 175.783 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 5.8 mp -128.17 153.68 46.62 Favored 'General case' 0 N--CA 1.497 1.909 0 CA-C-O 122.23 1.014 . . . . 0.0 110.586 179.989 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 36.1 t -101.29 131.58 48.76 Favored 'Isoleucine or valine' 0 C--O 1.26 1.631 0 CA-C-O 116.674 -1.632 . . . . 0.0 109.7 174.225 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 27.5 m-85 -130.44 126.12 36.16 Favored 'General case' 0 N--CA 1.49 1.547 0 CA-C-N 120.203 1.365 . . . . 0.0 109.552 173.359 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 69.7 m-85 55.53 71.52 0.54 Allowed 'General case' 0 C--O 1.239 0.517 0 CA-C-N 115.781 -0.645 . . . . 0.0 111.23 176.044 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -82.33 -73.28 0.4 Allowed 'General case' 0 N--CA 1.471 0.608 0 CA-C-O 118.555 -0.736 . . . . 0.0 111.171 -177.592 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 40.7 tt0 -115.37 105.67 13.11 Favored 'General case' 0 N--CA 1.481 1.12 0 N-CA-C 106.586 -1.635 . . . . 0.0 106.586 176.629 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 p-10 -152.02 135.13 15.78 Favored 'General case' 0 N--CA 1.474 0.756 0 CA-C-O 116.643 -1.646 . . . . 0.0 113.397 177.471 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 24' ' ' VAL . . . . . . . . . . . . . 68.7 t -61.12 166.54 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.264 0 CA-C-N 121.351 1.887 . . . . 0.0 107.972 175.481 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 25' ' ' GLY . . . . . 0.4 ' H ' ' HB ' ' G' ' 24' ' ' VAL . . . -116.56 50.94 0.75 Allowed Glycine 0 N--CA 1.479 1.513 0 CA-C-O 119.203 -0.776 . . . . 0.0 111.489 178.814 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -57.57 -171.43 0.01 OUTLIER 'General case' 0 N--CA 1.468 0.465 0 C-N-CA 123.255 0.622 . . . . 0.0 111.888 175.556 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 25.5 t-20 -73.08 86.43 1.35 Allowed 'General case' 0 C--N 1.347 0.464 0 N-CA-C 108.635 -0.876 . . . . 0.0 108.635 176.47 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 97.7 mttt -80.8 143.42 32.86 Favored 'General case' 0 N--CA 1.479 1.009 0 N-CA-C 107.712 -1.218 . . . . 0.0 107.712 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.27 -143.69 0.02 OUTLIER Glycine 0 C--N 1.348 1.212 0 C-N-CA 120.224 -0.989 . . . . 0.0 111.618 -178.266 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -95.46 126.42 40.74 Favored 'General case' 0 C--O 1.239 0.515 0 C-N-CA 123.031 0.532 . . . . 0.0 110.276 178.663 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 80.4 mt -125.44 126.86 71.25 Favored 'Isoleucine or valine' 0 C--N 1.358 0.944 0 N-CA-C 104.022 -2.584 . . . . 0.0 104.022 176.281 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 41.9 pt -159.14 -170.92 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.1 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.261 -177.927 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.91 5.04 12.53 Favored Glycine 0 C--O 1.239 0.463 0 N-CA-C 110.237 -1.145 . . . . 0.0 110.237 -178.957 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 1.9 tt -79.54 133.46 36.47 Favored 'General case' 0 C--N 1.369 1.451 0 C-N-CA 117.863 -1.535 . . . . 0.0 107.458 -178.968 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 28.1 ttt -158.71 156.3 29.65 Favored 'General case' 0 CA--C 1.511 -0.52 0 N-CA-C 108.203 -1.036 . . . . 0.0 108.203 171.852 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 35.7 m -164.72 163.77 0.7 Allowed 'Isoleucine or valine' 0 C--O 1.219 -0.506 0 N-CA-C 108.058 -1.09 . . . . 0.0 108.058 173.934 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 59.91 63.65 4.88 Favored Glycine 0 C--N 1.307 -1.066 0 C-N-CA 120.37 -0.919 . . . . 0.0 111.528 177.764 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 144.62 176.04 18.29 Favored Glycine 0 N--CA 1.48 1.6 0 CA-C-N 117.971 0.886 . . . . 0.0 111.145 179.368 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 39' ' ' VAL . . . . . 0.495 ' H ' HG11 ' G' ' 39' ' ' VAL . 34.3 m -125.43 157.08 34.82 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.861 0 C-N-CA 123.409 0.684 . . . . 0.0 111.119 -178.753 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 25.2 t . . . . . 0 C--N 1.329 -0.32 0 CA-C-O 116.333 -1.794 . . . . 0.0 109.748 176.588 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 35.9 m-85 . . . . . 0 N--CA 1.475 0.82 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' E' E ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -143.53 140.04 30.07 Favored 'General case' 0 N--CA 1.48 1.045 0 CA-C-O 120.902 0.382 . . . . 0.0 110.15 179.583 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 43.3 t-80 -151.47 119.35 6.19 Favored 'General case' 0 N--CA 1.474 0.729 0 N-CA-C 109.167 -0.679 . . . . 0.0 109.167 179.085 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' E' E ' 7' ' ' ASP . . . . . 0.503 ' O ' ' OG ' ' H' ' 8' ' ' SER . 3.9 m-20 -69.65 148.15 49.69 Favored 'General case' 0 N--CA 1.466 0.349 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.838 179.998 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' E' E ' 8' ' ' SER . . . . . 0.501 ' OG ' ' O ' ' B' ' 7' ' ' ASP . 52.5 p -168.32 -172.6 1.77 Allowed 'General case' 0 N--CA 1.483 1.21 0 CA-C-O 121.015 0.436 . . . . 0.0 110.854 178.757 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.55 47.66 1.27 Allowed Glycine 0 N--CA 1.479 1.543 0 CA-C-N 116.033 -0.53 . . . . 0.0 111.965 179.917 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 49.1 p90 -64.26 132.53 50.54 Favored 'General case' 0 N--CA 1.473 0.706 0 N-CA-C 112.028 0.381 . . . . 0.0 112.028 -179.894 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 49.4 mt-10 -91.72 153.17 19.82 Favored 'General case' 0 N--CA 1.48 1.066 0 CA-C-O 121.158 0.504 . . . . 0.0 109.665 177.944 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -155.01 127.32 1.02 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.587 0 N-CA-C 107.882 -1.155 . . . . 0.0 107.882 177.968 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 45.1 m-70 -135.04 143.65 46.85 Favored 'General case' 0 N--CA 1.482 1.166 0 CA-C-O 120.787 0.327 . . . . 0.0 111.516 -177.958 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 6.0 t60 -164.26 97.6 0.81 Allowed 'General case' 0 N--CA 1.486 1.371 0 CA-C-N 116.356 -0.383 . . . . 0.0 110.634 179.593 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 12.0 pt20 -111.57 -174.63 2.51 Favored 'General case' 0 CA--C 1.505 -0.761 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 -179.805 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -163.27 98.61 0.93 Allowed 'General case' 0 N--CA 1.476 0.861 0 CA-C-N 114.75 -1.113 . . . . 0.0 108.49 178.633 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 6.5 mp -120.89 156.61 31.63 Favored 'General case' 0 N--CA 1.495 1.777 0 CA-C-O 121.786 0.803 . . . . 0.0 111.52 -177.682 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 48.4 t -114.06 124.62 70.88 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.216 0 N-CA-C 108.276 -1.009 . . . . 0.0 108.276 177.331 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 31.1 m-85 -125.51 121.41 33.65 Favored 'General case' 0 N--CA 1.489 1.51 0 CA-C-O 120.888 0.375 . . . . 0.0 110.846 -179.769 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 70.2 m-85 54.46 73.41 0.4 Allowed 'General case' 0 N--CA 1.469 0.508 0 CA-C-N 115.998 -0.547 . . . . 0.0 111.391 178.201 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -78.78 -78.95 0.14 Allowed 'General case' 0 C--N 1.344 0.348 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.268 -179.475 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 40.4 tt0 -111.2 102.72 11.12 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 -179.978 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -158.16 134.93 9.75 Favored 'General case' 0 C--O 1.208 -1.116 0 CA-C-O 119.484 -0.293 . . . . 0.0 111.378 178.829 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 58.5 t -56.97 167.72 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.941 0 N-CA-C 107.614 -1.254 . . . . 0.0 107.614 176.806 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . -120.73 49.07 0.9 Allowed Glycine 0 N--CA 1.477 1.431 0 N-CA-C 110.765 -0.934 . . . . 0.0 110.765 -179.354 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -63.53 -168.32 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.542 0 CA-C-O 120.691 0.281 . . . . 0.0 110.25 179.622 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 25.2 t-20 -71.7 76.42 0.84 Allowed 'General case' 0 N--CA 1.467 0.403 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.416 179.689 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -70.26 140.75 52.44 Favored 'General case' 0 N--CA 1.477 0.894 0 N-CA-C 109.497 -0.556 . . . . 0.0 109.497 179.557 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.6 -148.68 0.05 OUTLIER Glycine 0 CA--C 1.521 0.467 0 N-CA-C 110.895 -0.882 . . . . 0.0 110.895 179.519 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -92.81 127.18 38.22 Favored 'General case' 0 C--O 1.235 0.292 0 N-CA-C 110.268 -0.271 . . . . 0.0 110.268 179.577 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 74.2 mt -124.34 116.92 49.11 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.608 0 N-CA-C 106.491 -1.67 . . . . 0.0 106.491 178.439 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 43.7 pt -151.43 -168.46 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.182 0 CA-C-O 121.144 0.497 . . . . 0.0 110.622 -178.526 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.4 5.2 7.82 Favored Glycine 0 CA--C 1.528 0.873 0 N-CA-C 111.262 -0.735 . . . . 0.0 111.262 -179.954 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 1.5 tt -77.6 127.09 31.91 Favored 'General case' 0 CA--C 1.545 0.783 0 N-CA-C 109.491 -0.559 . . . . 0.0 109.491 -179.64 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 28.4 ttt -163.86 144.38 8.54 Favored 'General case' 0 N--CA 1.471 0.6 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 178.312 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 32.8 m -156.73 162.62 1.56 Allowed 'Isoleucine or valine' 0 C--O 1.215 -0.712 0 N-CA-C 108.816 -0.809 . . . . 0.0 108.816 179.742 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.98 66.41 2.87 Favored Glycine 0 C--N 1.305 -1.194 0 N-CA-C 111.974 -0.45 . . . . 0.0 111.974 178.55 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 146.07 174.16 17.97 Favored Glycine 0 N--CA 1.477 1.374 0 N-CA-C 111.113 -0.795 . . . . 0.0 111.113 179.038 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' E' E ' 39' ' ' VAL . . . . . 0.513 ' H ' HG11 ' H' ' 39' ' ' VAL . 33.8 m -124.33 159.67 29.8 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.671 0 C-N-CA 123.478 0.711 . . . . 0.0 110.774 -179.566 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 25.8 t . . . . . 0 C--O 1.219 -0.518 0 CA-C-O 118.361 -0.828 . . . . 0.0 110.66 179.321 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 35.3 m-85 . . . . . 0 N--CA 1.475 0.8 0 N-CA-C 109.978 -0.378 . . . . 0.0 109.978 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' F' F ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -143.44 139.88 30.13 Favored 'General case' 0 N--CA 1.479 0.989 0 CA-C-O 120.872 0.368 . . . . 0.0 110.231 179.54 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 42.6 t-80 -151.35 119.02 6.09 Favored 'General case' 0 N--CA 1.474 0.761 0 N-CA-C 109.197 -0.668 . . . . 0.0 109.197 179.076 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' F' F ' 7' ' ' ASP . . . . . 0.497 ' O ' ' OG ' ' I' ' 8' ' ' SER . 4.0 m-20 -69.2 148.28 50.09 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.74 179.912 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' F' F ' 8' ' ' SER . . . . . 0.497 ' OG ' ' O ' ' C' ' 7' ' ' ASP . 52.1 p -168.65 -173.03 1.78 Allowed 'General case' 0 N--CA 1.486 1.329 0 CA-C-O 121.04 0.448 . . . . 0.0 110.858 178.749 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.79 47.55 1.26 Allowed Glycine 0 N--CA 1.479 1.529 0 CA-C-N 115.969 -0.559 . . . . 0.0 111.884 179.785 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 48.2 p90 -64.01 133.06 52.41 Favored 'General case' 0 CA--C 1.543 0.683 0 O-C-N 122.528 -0.395 . . . . 0.0 111.978 -179.821 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 49.2 mt-10 -92.02 152.94 19.74 Favored 'General case' 0 N--CA 1.48 1.056 0 CA-C-O 121.196 0.522 . . . . 0.0 109.727 177.841 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -154.78 127.0 1.01 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.572 0 N-CA-C 107.837 -1.172 . . . . 0.0 107.837 178.085 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 44.7 m-70 -134.71 143.65 47.31 Favored 'General case' 0 N--CA 1.484 1.228 0 CA-C-O 120.867 0.365 . . . . 0.0 111.563 -178.04 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 6.0 t60 -164.12 97.51 0.82 Allowed 'General case' 0 N--CA 1.487 1.391 0 CA-C-N 116.431 -0.349 . . . . 0.0 110.775 179.614 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 12.0 pt20 -111.71 -174.72 2.53 Favored 'General case' 0 CA--C 1.503 -0.847 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 -179.838 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -163.09 98.64 0.94 Allowed 'General case' 0 N--CA 1.473 0.711 0 CA-C-N 114.74 -1.118 . . . . 0.0 108.466 178.689 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 6.7 mp -120.76 156.97 30.7 Favored 'General case' 0 N--CA 1.495 1.795 0 CA-C-O 121.806 0.812 . . . . 0.0 111.498 -177.827 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 48.8 t -114.35 124.45 71.01 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.231 0 N-CA-C 108.186 -1.042 . . . . 0.0 108.186 177.321 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 32.2 m-85 -125.24 121.16 33.28 Favored 'General case' 0 N--CA 1.488 1.452 0 CA-C-O 120.893 0.377 . . . . 0.0 110.857 -179.911 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 70.4 m-85 54.67 73.78 0.38 Allowed 'General case' 0 N--CA 1.467 0.386 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.588 178.277 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -79.12 -78.53 0.15 Allowed 'General case' 0 C--N 1.344 0.354 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.406 -179.431 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 40.9 tt0 -111.71 102.58 10.87 Favored 'General case' 0 N--CA 1.47 0.527 0 N-CA-C 108.402 -0.962 . . . . 0.0 108.402 -179.929 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -158.02 134.77 9.78 Favored 'General case' 0 N--CA 1.481 1.081 0 CA-C-O 119.416 -0.326 . . . . 0.0 111.394 178.822 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' F' F ' 24' ' ' VAL . . . . . . . . . . . . . 58.1 t -56.82 167.97 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.966 0 N-CA-C 107.641 -1.244 . . . . 0.0 107.641 176.938 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -120.97 49.2 0.89 Allowed Glycine 0 N--CA 1.478 1.48 0 N-CA-C 110.745 -0.942 . . . . 0.0 110.745 -179.344 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -63.72 -167.92 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.551 0 CA-C-O 120.731 0.301 . . . . 0.0 110.294 179.66 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 25.2 t-20 -71.92 76.51 0.9 Allowed 'General case' 0 N--CA 1.466 0.372 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.325 179.662 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -70.48 140.44 51.9 Favored 'General case' 0 N--CA 1.477 0.892 0 N-CA-C 109.525 -0.546 . . . . 0.0 109.525 179.562 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.17 -149.09 0.04 OUTLIER Glycine 0 CA--C 1.522 0.504 0 N-CA-C 110.898 -0.881 . . . . 0.0 110.898 179.441 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -92.34 127.14 37.71 Favored 'General case' 0 C--O 1.236 0.352 0 CA-C-O 120.676 0.274 . . . . 0.0 110.276 179.444 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 73.2 mt -124.26 116.93 49.2 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.572 0 N-CA-C 106.479 -1.674 . . . . 0.0 106.479 178.401 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 44.1 pt -151.6 -168.36 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.149 0 CA-C-O 121.071 0.462 . . . . 0.0 110.722 -178.543 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.13 5.54 8.1 Favored Glycine 0 CA--C 1.527 0.818 0 N-CA-C 111.274 -0.73 . . . . 0.0 111.274 -179.889 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 1.5 tt -77.76 126.88 31.54 Favored 'General case' 0 N--CA 1.476 0.839 0 N-CA-C 109.386 -0.598 . . . . 0.0 109.386 -179.689 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 28.4 ttt -163.62 144.36 8.9 Favored 'General case' 0 N--CA 1.471 0.591 0 N-CA-C 108.876 -0.787 . . . . 0.0 108.876 178.283 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 32.8 m -156.63 162.81 1.53 Allowed 'Isoleucine or valine' 0 C--O 1.216 -0.709 0 N-CA-C 108.829 -0.804 . . . . 0.0 108.829 179.638 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.82 66.48 2.81 Favored Glycine 0 C--N 1.305 -1.169 0 N-CA-C 111.992 -0.443 . . . . 0.0 111.992 178.5 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 145.82 174.12 17.71 Favored Glycine 0 N--CA 1.477 1.419 0 N-CA-C 111.031 -0.828 . . . . 0.0 111.031 178.961 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' F' F ' 39' ' ' VAL . . . . . 0.512 HG11 ' H ' ' C' ' 39' ' ' VAL . 33.7 m -124.38 159.75 29.82 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.692 0 C-N-CA 123.366 0.666 . . . . 0.0 110.755 -179.488 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 26.3 t . . . . . 0 C--O 1.22 -0.476 0 CA-C-O 118.249 -0.881 . . . . 0.0 110.609 179.215 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 39.2 m-85 . . . . . 0 N--CA 1.474 0.736 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' G' G ' 5' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -143.79 140.3 29.81 Favored 'General case' 0 N--CA 1.482 1.168 0 CA-C-O 120.846 0.355 . . . . 0.0 110.311 179.825 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 43.3 t-80 -151.54 120.25 6.55 Favored 'General case' 0 N--CA 1.475 0.782 0 N-CA-C 109.342 -0.614 . . . . 0.0 109.342 179.125 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -71.22 144.19 50.19 Favored 'General case' 0 N--CA 1.47 0.547 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.17 -179.937 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' G' G ' 8' ' ' SER . . . . . 0.598 ' OG ' ' O ' ' D' ' 7' ' ' ASP . 47.8 p -165.4 -170.96 2.0 Allowed 'General case' 0 N--CA 1.474 0.767 0 CA-C-O 120.962 0.41 . . . . 0.0 110.589 178.585 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.01 47.92 1.29 Allowed Glycine 0 N--CA 1.48 1.611 0 N-CA-C 111.514 -0.635 . . . . 0.0 111.514 179.441 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 50.4 p90 -64.5 133.02 51.56 Favored 'General case' 0 N--CA 1.473 0.699 0 CA-C-O 120.753 0.311 . . . . 0.0 111.818 -179.544 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 48.6 mt-10 -92.62 151.63 20.01 Favored 'General case' 0 N--CA 1.479 0.982 0 CA-C-O 121.104 0.478 . . . . 0.0 110.105 178.484 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -154.74 127.6 1.11 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.016 0 N-CA-C 107.92 -1.141 . . . . 0.0 107.92 178.361 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 47.0 m-70 -134.49 145.04 48.43 Favored 'General case' 0 N--CA 1.478 0.956 0 CA-C-N 115.542 -0.754 . . . . 0.0 111.399 -178.348 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 6.2 t60 -165.87 97.61 0.64 Allowed 'General case' 0 N--CA 1.483 1.206 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.301 178.963 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 12.1 pt20 -111.74 -174.3 2.43 Favored 'General case' 0 CA--C 1.503 -0.848 0 N-CA-C 108.37 -0.974 . . . . 0.0 108.37 -179.657 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -163.8 98.21 0.86 Allowed 'General case' 0 N--CA 1.474 0.774 0 CA-C-N 114.672 -1.149 . . . . 0.0 108.194 178.856 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 6.6 mp -120.51 155.15 34.2 Favored 'General case' 0 N--CA 1.497 1.896 0 CA-C-O 121.291 0.567 . . . . 0.0 111.74 -177.794 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 43.9 t -113.33 124.91 70.44 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.006 0 CA-C-N 114.804 -1.089 . . . . 0.0 108.234 176.713 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 33.5 m-85 -125.9 121.17 32.39 Favored 'General case' 0 C--N 1.366 1.299 0 C-N-CA 123.437 0.695 . . . . 0.0 110.934 -179.585 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 69.3 m-85 54.75 72.82 0.44 Allowed 'General case' 0 N--CA 1.468 0.462 0 CA-C-N 115.874 -0.603 . . . . 0.0 111.375 178.059 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.7 -78.37 0.14 Allowed 'General case' 0 N--CA 1.472 0.632 0 O-C-N 122.223 -0.298 . . . . 0.0 110.508 -178.981 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 40.7 tt0 -111.78 102.47 10.75 Favored 'General case' 0 C--N 1.321 -0.633 0 N-CA-C 108.212 -1.033 . . . . 0.0 108.212 179.942 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -157.7 136.05 11.1 Favored 'General case' 0 N--CA 1.479 0.98 0 O-C-N 122.43 -0.168 . . . . 0.0 111.415 178.748 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' G' G ' 24' ' ' VAL . . . . . 0.4 ' HB ' ' H ' ' D' ' 25' ' ' GLY . 59.9 t -58.35 167.11 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.639 0 N-CA-C 107.749 -1.204 . . . . 0.0 107.749 177.115 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -119.53 49.4 0.88 Allowed Glycine 0 N--CA 1.48 1.615 0 N-CA-C 110.479 -1.048 . . . . 0.0 110.479 -179.496 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -64.6 -168.66 0.03 OUTLIER 'General case' 0 N--CA 1.471 0.624 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 179.67 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 25.4 t-20 -71.46 76.47 0.77 Allowed 'General case' 0 N--CA 1.468 0.435 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.385 179.796 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -69.82 140.55 53.3 Favored 'General case' 0 N--CA 1.474 0.765 0 N-CA-C 109.626 -0.509 . . . . 0.0 109.626 179.528 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.79 -147.01 0.04 OUTLIER Glycine 0 C--N 1.338 0.663 0 N-CA-C 110.517 -1.033 . . . . 0.0 110.517 179.637 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -93.36 126.12 38.32 Favored 'General case' 0 N--CA 1.468 0.43 0 C-N-CA 122.616 0.366 . . . . 0.0 110.663 -179.738 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 73.4 mt -123.76 117.3 50.7 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.771 0 N-CA-C 106.527 -1.657 . . . . 0.0 106.527 178.105 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 44.8 pt -152.27 -167.68 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 CA-C-N 119.839 1.2 . . . . 0.0 109.858 -179.046 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.37 6.2 10.23 Favored Glycine 0 CA--C 1.525 0.705 0 N-CA-C 110.998 -0.841 . . . . 0.0 110.998 179.824 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 1.5 tt -79.23 125.94 30.12 Favored 'General case' 0 CA--C 1.544 0.746 0 N-CA-C 109.492 -0.559 . . . . 0.0 109.492 -179.575 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 27.5 ttt -162.76 146.01 11.07 Favored 'General case' 0 N--CA 1.47 0.565 0 N-CA-C 108.757 -0.831 . . . . 0.0 108.757 178.418 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 33.2 m -157.37 162.11 1.62 Allowed 'Isoleucine or valine' 0 C--N 1.347 0.461 0 N-CA-C 108.901 -0.777 . . . . 0.0 108.901 -179.959 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.37 66.8 2.58 Favored Glycine 0 C--N 1.312 -0.754 0 CA-C-N 115.712 -0.676 . . . . 0.0 112.271 178.213 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 146.53 175.17 19.29 Favored Glycine 0 N--CA 1.477 1.427 0 N-CA-C 110.516 -1.034 . . . . 0.0 110.516 178.988 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' G' G ' 39' ' ' VAL . . . . . 0.495 HG11 ' H ' ' D' ' 39' ' ' VAL . 34.6 m -125.34 159.94 31.94 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.867 0 C-N-CA 123.09 0.556 . . . . 0.0 110.73 -179.48 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 28.8 t . . . . . 0 N--CA 1.469 0.511 0 CA-C-O 118.388 -0.815 . . . . 0.0 110.796 179.025 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 39.8 m-85 . . . . . 0 N--CA 1.473 0.697 0 N-CA-C 109.549 -0.537 . . . . 0.0 109.549 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' H' H ' 5' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -143.66 140.53 30.12 Favored 'General case' 0 N--CA 1.483 1.185 0 C-N-CA 122.583 0.353 . . . . 0.0 110.13 179.884 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 42.9 t-80 -151.77 120.4 6.5 Favored 'General case' 0 N--CA 1.473 0.701 0 N-CA-C 109.383 -0.599 . . . . 0.0 109.383 179.096 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -71.58 143.9 49.7 Favored 'General case' 0 N--CA 1.471 0.585 0 CA-C-N 116.323 -0.399 . . . . 0.0 111.178 -179.768 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' H' H ' 8' ' ' SER . . . . . 0.503 ' OG ' ' O ' ' E' ' 7' ' ' ASP . 53.7 p -165.07 -171.19 2.14 Favored 'General case' 0 N--CA 1.475 0.815 0 CA-C-O 120.94 0.4 . . . . 0.0 110.509 178.628 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.13 47.61 1.32 Allowed Glycine 0 N--CA 1.48 1.594 0 N-CA-C 111.683 -0.567 . . . . 0.0 111.683 179.642 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 50.4 p90 -64.51 133.13 51.77 Favored 'General case' 0 N--CA 1.472 0.659 0 N-CA-C 111.947 0.351 . . . . 0.0 111.947 -179.637 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 48.4 mt-10 -92.45 151.77 20.04 Favored 'General case' 0 N--CA 1.478 0.929 0 CA-C-O 121.013 0.435 . . . . 0.0 110.215 178.499 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -154.71 127.92 1.16 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.041 0 N-CA-C 107.854 -1.165 . . . . 0.0 107.854 178.251 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 46.4 m-70 -134.72 145.07 48.13 Favored 'General case' 0 N--CA 1.478 0.971 0 CA-C-N 115.5 -0.773 . . . . 0.0 111.394 -178.374 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 6.2 t60 -165.93 97.29 0.63 Allowed 'General case' 0 N--CA 1.483 1.176 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.4 179.012 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 12.1 pt20 -111.39 -174.52 2.48 Favored 'General case' 0 CA--C 1.504 -0.826 0 N-CA-C 108.34 -0.985 . . . . 0.0 108.34 -179.652 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -163.72 98.29 0.87 Allowed 'General case' 0 N--CA 1.475 0.784 0 CA-C-N 114.671 -1.15 . . . . 0.0 108.093 178.757 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 6.7 mp -120.41 155.56 33.21 Favored 'General case' 0 N--CA 1.496 1.873 0 CA-C-O 121.233 0.539 . . . . 0.0 111.849 -177.82 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 42.6 t -113.64 125.23 70.88 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.01 0 CA-C-N 114.869 -1.06 . . . . 0.0 108.231 176.556 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 33.2 m-85 -126.24 121.07 31.66 Favored 'General case' 0 C--N 1.369 1.445 0 CA-C-N 115.518 -0.765 . . . . 0.0 110.775 -179.444 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 69.6 m-85 54.41 73.13 0.41 Allowed 'General case' 0 C--O 1.238 0.453 0 CA-C-N 115.814 -0.63 . . . . 0.0 111.399 178.107 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.75 -78.06 0.14 Allowed 'General case' 0 N--CA 1.472 0.657 0 O-C-N 122.201 -0.312 . . . . 0.0 110.661 -179.147 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 40.4 tt0 -112.09 102.57 10.77 Favored 'General case' 0 C--N 1.321 -0.641 0 N-CA-C 108.236 -1.024 . . . . 0.0 108.236 179.883 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -157.75 136.24 11.2 Favored 'General case' 0 N--CA 1.478 0.974 0 O-C-N 122.417 -0.177 . . . . 0.0 111.368 178.817 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' H' H ' 24' ' ' VAL . . . . . . . . . . . . . 59.1 t -58.49 166.91 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.548 0 N-CA-C 107.71 -1.218 . . . . 0.0 107.71 177.18 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . -119.25 49.2 0.89 Allowed Glycine 0 N--CA 1.479 1.551 0 N-CA-C 110.651 -0.98 . . . . 0.0 110.651 -179.573 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -64.68 -168.33 0.03 OUTLIER 'General case' 0 N--CA 1.472 0.661 0 N-CA-C 109.944 -0.391 . . . . 0.0 109.944 179.722 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 25.6 t-20 -71.55 76.55 0.8 Allowed 'General case' 0 CA--C 1.537 0.472 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.316 179.809 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -70.15 140.56 52.61 Favored 'General case' 0 N--CA 1.474 0.775 0 N-CA-C 109.588 -0.523 . . . . 0.0 109.588 179.593 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.63 -147.69 0.04 OUTLIER Glycine 0 C--N 1.336 0.579 0 N-CA-C 110.376 -1.09 . . . . 0.0 110.376 179.549 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -93.05 126.31 38.07 Favored 'General case' 0 N--CA 1.465 0.298 0 C-N-CA 122.584 0.354 . . . . 0.0 110.781 -179.8 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 74.5 mt -123.87 117.23 50.41 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.776 0 N-CA-C 106.575 -1.639 . . . . 0.0 106.575 178.224 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 44.8 pt -152.11 -167.77 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 CA-C-N 119.761 1.164 . . . . 0.0 109.871 -179.026 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.71 5.76 9.9 Favored Glycine 0 CA--C 1.524 0.641 0 N-CA-C 110.935 -0.866 . . . . 0.0 110.935 179.845 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 1.4 tt -78.7 125.75 29.79 Favored 'General case' 0 CA--C 1.544 0.728 0 N-CA-C 109.555 -0.535 . . . . 0.0 109.555 -179.565 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 27.4 ttt -162.56 145.94 11.37 Favored 'General case' 0 N--CA 1.47 0.572 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 178.323 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 33.2 m -157.35 162.18 1.6 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 N-CA-C 108.874 -0.788 . . . . 0.0 108.874 -179.935 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.25 67.06 2.4 Favored Glycine 0 C--N 1.311 -0.819 0 CA-C-N 115.781 -0.645 . . . . 0.0 112.149 178.286 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 146.42 175.76 19.69 Favored Glycine 0 N--CA 1.479 1.547 0 N-CA-C 110.577 -1.009 . . . . 0.0 110.577 178.892 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' H' H ' 39' ' ' VAL . . . . . 0.513 HG11 ' H ' ' E' ' 39' ' ' VAL . 34.6 m -125.97 159.85 33.75 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.82 0 C-N-CA 123.161 0.585 . . . . 0.0 110.708 -179.499 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 26.7 t . . . . . 0 C--O 1.219 -0.547 0 CA-C-O 118.346 -0.835 . . . . 0.0 110.79 179.263 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 39.7 m-85 . . . . . 0 N--CA 1.475 0.78 0 N-CA-C 109.473 -0.566 . . . . 0.0 109.473 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' I' I ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -143.72 140.28 29.91 Favored 'General case' 0 N--CA 1.482 1.167 0 C-N-CA 122.602 0.361 . . . . 0.0 110.15 179.894 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 43.1 t-80 -151.72 120.28 6.47 Favored 'General case' 0 N--CA 1.474 0.732 0 N-CA-C 109.358 -0.608 . . . . 0.0 109.358 179.04 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -71.23 143.87 50.27 Favored 'General case' 0 N--CA 1.469 0.503 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.234 -179.881 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' I' I ' 8' ' ' SER . . . . . 0.497 ' OG ' ' O ' ' F' ' 7' ' ' ASP . 53.3 p -164.87 -171.4 2.25 Favored 'General case' 0 N--CA 1.474 0.752 0 CA-C-O 120.857 0.36 . . . . 0.0 110.582 178.668 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.08 48.04 1.28 Allowed Glycine 0 N--CA 1.48 1.619 0 N-CA-C 111.693 -0.563 . . . . 0.0 111.693 179.63 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 50.4 p90 -65.1 132.52 49.39 Favored 'General case' 0 N--CA 1.472 0.632 0 N-CA-C 111.934 0.346 . . . . 0.0 111.934 -179.737 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 48.3 mt-10 -91.81 152.24 20.22 Favored 'General case' 0 N--CA 1.478 0.937 0 CA-C-O 121.033 0.445 . . . . 0.0 110.18 178.511 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -155.28 127.58 1.03 Allowed 'Isoleucine or valine' 0 CA--C 1.551 0.999 0 N-CA-C 107.848 -1.167 . . . . 0.0 107.848 178.349 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 46.1 m-70 -134.48 145.08 48.48 Favored 'General case' 0 N--CA 1.477 0.887 0 CA-C-N 115.572 -0.74 . . . . 0.0 111.436 -178.387 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 6.1 t60 -165.61 97.47 0.67 Allowed 'General case' 0 N--CA 1.481 1.105 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.362 178.961 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 12.3 pt20 -111.79 -174.83 2.55 Favored 'General case' 0 CA--C 1.502 -0.894 0 N-CA-C 108.399 -0.963 . . . . 0.0 108.399 -179.689 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -163.39 98.41 0.91 Allowed 'General case' 0 N--CA 1.474 0.762 0 CA-C-N 114.647 -1.16 . . . . 0.0 108.172 178.87 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 6.7 mp -120.53 155.4 33.71 Favored 'General case' 0 N--CA 1.496 1.854 0 CA-C-O 121.266 0.555 . . . . 0.0 111.773 -177.829 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 41.6 t -113.56 125.35 70.82 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.998 0 CA-C-N 114.824 -1.08 . . . . 0.0 108.194 176.568 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 33.6 m-85 -126.32 121.32 32.24 Favored 'General case' 0 C--N 1.368 1.393 0 CA-C-N 115.61 -0.723 . . . . 0.0 110.876 -179.491 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 69.4 m-85 54.16 72.94 0.42 Allowed 'General case' 0 C--O 1.237 0.441 0 CA-C-N 115.918 -0.583 . . . . 0.0 111.375 178.165 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.63 -78.08 0.14 Allowed 'General case' 0 N--CA 1.472 0.657 0 O-C-N 122.302 -0.249 . . . . 0.0 110.598 -179.116 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 40.7 tt0 -112.01 102.73 10.93 Favored 'General case' 0 C--N 1.323 -0.573 0 N-CA-C 108.156 -1.053 . . . . 0.0 108.156 179.948 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -157.95 136.19 10.94 Favored 'General case' 0 N--CA 1.478 0.956 0 O-C-N 122.375 -0.203 . . . . 0.0 111.329 178.858 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' I' I ' 24' ' ' VAL . . . . . . . . . . . . . 58.5 t -58.5 166.92 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.559 0 N-CA-C 107.779 -1.193 . . . . 0.0 107.779 177.134 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . -119.42 49.22 0.88 Allowed Glycine 0 N--CA 1.481 1.661 0 N-CA-C 110.592 -1.003 . . . . 0.0 110.592 -179.404 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -64.54 -168.2 0.03 OUTLIER 'General case' 0 N--CA 1.471 0.602 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 179.702 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 25.5 t-20 -71.71 76.89 0.84 Allowed 'General case' 0 CA--C 1.536 0.439 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.259 179.675 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -70.45 140.6 52.0 Favored 'General case' 0 N--CA 1.475 0.807 0 N-CA-C 109.63 -0.507 . . . . 0.0 109.63 179.472 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.72 -147.32 0.04 OUTLIER Glycine 0 C--N 1.337 0.621 0 N-CA-C 110.496 -1.041 . . . . 0.0 110.496 179.588 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -93.26 125.86 38.07 Favored 'General case' 0 N--CA 1.465 0.314 0 C-N-CA 122.696 0.399 . . . . 0.0 110.752 -179.737 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 73.7 mt -123.47 117.33 51.03 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.768 0 N-CA-C 106.556 -1.646 . . . . 0.0 106.556 178.111 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 44.9 pt -152.17 -167.82 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 CA-C-N 119.758 1.163 . . . . 0.0 109.869 -179.05 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.71 5.86 10.18 Favored Glycine 0 CA--C 1.526 0.738 0 N-CA-C 110.95 -0.86 . . . . 0.0 110.95 179.768 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 1.4 tt -78.89 125.56 29.53 Favored 'General case' 0 CA--C 1.546 0.79 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 -179.593 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 27.4 ttt -162.25 145.79 11.83 Favored 'General case' 0 N--CA 1.47 0.542 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 178.559 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 33.3 m -157.28 162.03 1.65 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.47 0 N-CA-C 108.845 -0.798 . . . . 0.0 108.845 -179.89 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.29 66.87 2.53 Favored Glycine 0 C--N 1.311 -0.85 0 CA-C-N 115.799 -0.637 . . . . 0.0 112.228 178.173 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 146.58 175.82 19.87 Favored Glycine 0 N--CA 1.478 1.497 0 N-CA-C 110.603 -0.999 . . . . 0.0 110.603 178.939 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' I' I ' 39' ' ' VAL . . . . . 0.508 HG11 ' H ' ' F' ' 39' ' ' VAL . 34.5 m -125.92 159.9 33.55 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.866 0 C-N-CA 123.131 0.572 . . . . 0.0 110.755 -179.488 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 29.8 t . . . . . 0 C--O 1.219 -0.513 0 CA-C-O 118.394 -0.812 . . . . 0.0 110.777 179.103 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 78.8 m-85 . . . . . 0 N--CA 1.474 0.766 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 72.4 mtp180 -143.58 142.05 30.92 Favored 'General case' 0 N--CA 1.482 1.164 0 N-CA-C 109.134 -0.691 . . . . 0.0 109.134 -179.883 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 76.6 m80 -149.83 119.74 7.13 Favored 'General case' 0 N--CA 1.47 0.528 0 N-CA-C 108.759 -0.83 . . . . 0.0 108.759 179.102 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 8.5 m-20 -68.32 149.89 48.87 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.189 -179.385 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' SER . . . . . 0.538 ' HG ' ' H ' ' A' ' 9' ' ' GLY . 7.9 t -167.65 171.16 10.42 Favored 'General case' 0 N--CA 1.473 0.706 0 N-CA-C 109.628 -0.508 . . . . 0.0 109.628 178.456 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . 0.538 ' H ' ' HG ' ' A' ' 8' ' ' SER . . . 122.2 24.7 2.17 Favored Glycine 0 N--CA 1.488 2.127 0 N-CA-C 112.114 -0.394 . . . . 0.0 112.114 179.367 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 43.4 p90 -56.26 128.06 33.87 Favored 'General case' 0 N--CA 1.473 0.696 0 N-CA-C 112.175 0.435 . . . . 0.0 112.175 -179.866 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . 0.476 ' CG ' HD22 ' C' ' 27' ' ' ASN . 45.8 mt-10 -84.72 154.24 22.56 Favored 'General case' 0 N--CA 1.469 0.5 0 N-CA-C 109.082 -0.71 . . . . 0.0 109.082 178.445 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -153.25 129.29 1.75 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.341 0 N-CA-C 108.327 -0.99 . . . . 0.0 108.327 178.926 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 49.5 m-70 -134.03 144.72 48.86 Favored 'General case' 0 N--CA 1.489 1.507 0 CA-C-N 118.711 0.687 . . . . 0.0 110.993 -179.156 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 6.3 t60 -164.75 98.8 0.78 Allowed 'General case' 0 N--CA 1.479 0.978 0 CA-C-N 116.642 -0.254 . . . . 0.0 111.194 179.686 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . 0.5 HE22 ' H ' ' A' ' 37' ' ' GLY . 54.2 mt-30 -108.79 -172.26 2.02 Favored 'General case' 0 CA--C 1.502 -0.873 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 179.804 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -166.97 97.67 0.53 Allowed 'General case' 0 N--CA 1.473 0.689 0 CA-C-N 115.201 -0.909 . . . . 0.0 109.486 178.644 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . 0.418 ' CD1' ' N ' ' A' ' 17' ' ' LEU . 4.5 mp -105.66 163.88 12.34 Favored 'General case' 0 N--CA 1.487 1.409 0 N-CA-C 108.543 -0.91 . . . . 0.0 108.543 179.901 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 48.9 t -142.15 118.92 6.79 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.354 0 CA-C-O 118.796 -0.621 . . . . 0.0 110.02 179.452 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 51.6 m-85 -69.98 159.24 34.13 Favored 'General case' 0 N--CA 1.48 1.055 0 N-CA-C 107.592 -1.262 . . . . 0.0 107.592 177.203 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 13.6 t80 -171.15 -58.52 0.02 OUTLIER 'General case' 0 N--CA 1.485 1.3 0 CA-C-O 122.365 1.079 . . . . 0.0 109.712 179.662 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -38.81 90.0 0.0 OUTLIER 'General case' 0 C--O 1.232 0.17 0 CA-C-N 113.782 -1.554 . . . . 0.0 112.938 -177.952 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 38.1 tt0 -66.16 157.65 30.75 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 115.05 -0.977 . . . . 0.0 110.565 179.118 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 66.8 m-20 -139.55 136.78 34.83 Favored 'General case' 0 N--CA 1.481 1.1 0 C-N-CA 123.008 0.523 . . . . 0.0 110.281 179.862 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 18.4 t -84.65 -116.46 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.982 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 179.469 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -109.15 54.81 0.53 Allowed Glycine 0 N--CA 1.474 1.211 0 N-CA-C 111.126 -0.79 . . . . 0.0 111.126 179.909 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 71.1 p -80.07 126.01 30.52 Favored 'General case' 0 C--N 1.328 -0.333 0 N-CA-C 108.799 -0.815 . . . . 0.0 108.799 178.184 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . 0.488 HD22 ' CG ' ' B' ' 11' ' ' GLU . 47.3 t30 -65.93 100.26 0.56 Allowed 'General case' 0 N--CA 1.473 0.719 0 N-CA-C 108.8 -0.815 . . . . 0.0 108.8 178.702 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 66.7 mttm -95.46 117.2 29.95 Favored 'General case' 0 N--CA 1.484 1.229 0 N-CA-C 110.01 -0.367 . . . . 0.0 110.01 -179.067 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.13 -133.55 0.01 OUTLIER Glycine 0 CA--C 1.532 1.12 0 N-CA-C 110.726 -0.95 . . . . 0.0 110.726 178.943 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -113.4 127.81 56.25 Favored 'General case' 0 N--CA 1.478 0.939 0 N-CA-C 109.29 -0.633 . . . . 0.0 109.29 178.934 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 66.7 mt -90.73 130.19 40.34 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.683 0 N-CA-C 107.606 -1.257 . . . . 0.0 107.606 178.715 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 18.1 mt -142.33 152.38 18.13 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.929 0 N-CA-C 109.838 -0.431 . . . . 0.0 109.838 -178.83 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 65.37 48.27 70.83 Favored Glycine 0 CA--C 1.524 0.63 0 CA-C-N 116.062 -0.517 . . . . 0.0 112.531 178.804 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 2.9 tt -98.88 120.39 39.24 Favored 'General case' 0 N--CA 1.478 0.934 0 N-CA-C 107.245 -1.391 . . . . 0.0 107.245 177.903 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 28.1 ttt -152.71 158.26 42.09 Favored 'General case' 0 N--CA 1.471 0.579 0 N-CA-C 108.909 -0.774 . . . . 0.0 108.909 179.463 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 86.1 t -158.29 149.86 8.23 Favored 'Isoleucine or valine' 0 C--O 1.236 0.351 0 N-CA-C 107.012 -1.477 . . . . 0.0 107.012 -179.204 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . 0.5 ' H ' HE22 ' A' ' 15' ' ' GLN . . . 56.66 74.92 0.28 Allowed Glycine 0 C--N 1.313 -0.741 0 CA-C-N 115.622 -0.717 . . . . 0.0 111.658 178.181 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 170.96 -148.92 11.7 Favored Glycine 0 CA--C 1.519 0.299 0 N-CA-C 110.656 -0.978 . . . . 0.0 110.656 179.786 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 33.5 m -133.93 142.64 40.72 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.794 0 N-CA-C 109.688 -0.486 . . . . 0.0 109.688 179.744 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 16.3 t . . . . . 0 CA--C 1.535 0.392 0 CA-C-O 117.969 -1.015 . . . . 0.0 111.058 179.331 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 78.8 m-85 . . . . . 0 N--CA 1.474 0.729 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 71.9 mtp180 -144.09 141.82 30.26 Favored 'General case' 0 N--CA 1.481 1.11 0 N-CA-C 109.123 -0.695 . . . . 0.0 109.123 -179.815 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 76.7 m80 -149.7 119.64 7.15 Favored 'General case' 0 N--CA 1.471 0.611 0 N-CA-C 108.826 -0.805 . . . . 0.0 108.826 179.117 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 7' ' ' ASP . . . . . . . . . . . . . 8.6 m-20 -68.14 149.56 49.44 Favored 'General case' 0 CA--C 1.531 0.215 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.238 -179.439 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 8' ' ' SER . . . . . 0.554 ' HG ' ' H ' ' B' ' 9' ' ' GLY . 8.1 t -167.36 171.87 10.21 Favored 'General case' 0 N--CA 1.473 0.685 0 N-CA-C 109.668 -0.493 . . . . 0.0 109.668 178.368 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 9' ' ' GLY . . . . . 0.554 ' H ' ' HG ' ' B' ' 8' ' ' SER . . . 121.53 24.69 2.32 Favored Glycine 0 N--CA 1.488 2.135 0 N-CA-C 112.102 -0.399 . . . . 0.0 112.102 179.323 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 42.9 p90 -56.15 127.7 31.94 Favored 'General case' 0 N--CA 1.472 0.653 0 N-CA-C 112.236 0.458 . . . . 0.0 112.236 -179.87 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 11' ' ' GLU . . . . . 0.488 ' CG ' HD22 ' A' ' 27' ' ' ASN . 45.6 mt-10 -84.38 154.07 23.07 Favored 'General case' 0 N--CA 1.469 0.515 0 N-CA-C 109.223 -0.658 . . . . 0.0 109.223 178.442 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -153.17 129.65 1.9 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.328 0 N-CA-C 108.301 -1.0 . . . . 0.0 108.301 178.956 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 49.1 m-70 -134.34 145.34 48.92 Favored 'General case' 0 N--CA 1.49 1.552 0 CA-C-N 118.531 0.605 . . . . 0.0 110.975 -179.204 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 6.4 t60 -165.23 98.59 0.72 Allowed 'General case' 0 N--CA 1.482 1.125 0 CA-C-N 116.563 -0.29 . . . . 0.0 111.195 179.658 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . 0.497 HE22 ' H ' ' B' ' 37' ' ' GLY . 54.3 mt-30 -108.57 -172.81 2.13 Favored 'General case' 0 CA--C 1.502 -0.894 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 179.815 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -166.64 97.59 0.56 Allowed 'General case' 0 N--CA 1.472 0.63 0 CA-C-N 115.121 -0.945 . . . . 0.0 109.369 178.821 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . 0.42 ' N ' ' CD1' ' B' ' 17' ' ' LEU . 4.5 mp -105.87 163.88 12.38 Favored 'General case' 0 N--CA 1.487 1.394 0 N-CA-C 108.542 -0.91 . . . . 0.0 108.542 179.881 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 50.5 t -142.27 118.88 6.51 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.3 0 CA-C-O 118.959 -0.543 . . . . 0.0 109.96 179.58 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 53.0 m-85 -70.67 159.22 34.84 Favored 'General case' 0 N--CA 1.478 0.939 0 N-CA-C 107.53 -1.285 . . . . 0.0 107.53 177.248 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 14.9 t80 -171.83 -57.27 0.02 OUTLIER 'General case' 0 N--CA 1.482 1.168 0 CA-C-O 122.151 0.977 . . . . 0.0 109.769 179.631 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -39.1 90.38 0.0 OUTLIER 'General case' 0 CA--C 1.528 0.125 0 CA-C-N 114.125 -1.398 . . . . 0.0 112.768 -178.091 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 38.2 tt0 -66.45 157.45 31.99 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 115.089 -0.96 . . . . 0.0 110.52 179.19 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 67.4 m-20 -139.38 137.24 35.54 Favored 'General case' 0 N--CA 1.479 0.984 0 C-N-CA 123.083 0.553 . . . . 0.0 110.213 179.772 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 18.3 t -85.44 -116.71 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.048 0 N-CA-C 108.562 -0.903 . . . . 0.0 108.562 179.535 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -108.2 54.36 0.56 Allowed Glycine 0 N--CA 1.476 1.353 0 N-CA-C 111.049 -0.82 . . . . 0.0 111.049 179.929 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 71.8 p -80.13 125.55 29.96 Favored 'General case' 0 C--N 1.328 -0.351 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 178.242 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 27' ' ' ASN . . . . . 0.493 HD22 ' CG ' ' C' ' 11' ' ' GLU . 47.7 t30 -65.69 100.4 0.53 Allowed 'General case' 0 N--CA 1.475 0.782 0 N-CA-C 108.812 -0.81 . . . . 0.0 108.812 178.649 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 66.6 mttm -95.58 117.0 29.64 Favored 'General case' 0 N--CA 1.485 1.298 0 N-CA-C 110.041 -0.355 . . . . 0.0 110.041 -179.179 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.85 -133.26 0.01 OUTLIER Glycine 0 CA--C 1.533 1.207 0 N-CA-C 110.723 -0.951 . . . . 0.0 110.723 178.927 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -113.88 127.9 56.18 Favored 'General case' 0 N--CA 1.479 0.981 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 179.031 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 66.6 mt -90.77 130.26 40.26 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.655 0 N-CA-C 107.532 -1.285 . . . . 0.0 107.532 178.692 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 17.8 mt -142.42 152.36 17.99 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.918 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 -178.852 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 65.52 47.55 77.02 Favored Glycine 0 CA--C 1.524 0.638 0 CA-C-N 116.085 -0.507 . . . . 0.0 112.667 178.793 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 2.9 tt -98.07 120.51 38.6 Favored 'General case' 0 N--CA 1.478 0.936 0 N-CA-C 107.25 -1.389 . . . . 0.0 107.25 177.85 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 28.0 ttt -152.81 157.97 41.55 Favored 'General case' 0 N--CA 1.472 0.627 0 N-CA-C 108.849 -0.797 . . . . 0.0 108.849 179.376 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 82.1 t -158.15 149.77 8.47 Favored 'Isoleucine or valine' 0 C--O 1.235 0.306 0 N-CA-C 106.807 -1.553 . . . . 0.0 106.807 -179.147 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . 0.497 ' H ' HE22 ' B' ' 15' ' ' GLN . . . 56.67 75.28 0.26 Allowed Glycine 0 C--N 1.314 -0.689 0 CA-C-N 115.573 -0.74 . . . . 0.0 111.651 178.14 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 170.47 -149.07 12.14 Favored Glycine 0 CA--C 1.518 0.265 0 N-CA-C 110.698 -0.961 . . . . 0.0 110.698 179.772 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 33.8 m -133.59 142.76 40.73 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.842 0 N-CA-C 109.691 -0.485 . . . . 0.0 109.691 179.659 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 16.1 t . . . . . 0 C--O 1.222 -0.353 0 CA-C-O 117.993 -1.003 . . . . 0.0 111.111 179.319 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 79.0 m-85 . . . . . 0 N--CA 1.475 0.784 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 72.4 mtp180 -144.11 141.48 30.03 Favored 'General case' 0 N--CA 1.482 1.157 0 N-CA-C 109.071 -0.714 . . . . 0.0 109.071 -179.834 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 76.8 m80 -149.41 119.67 7.3 Favored 'General case' 0 N--CA 1.471 0.597 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 179.089 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 7' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -68.05 149.5 49.6 Favored 'General case' 0 CA--C 1.53 0.197 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.281 -179.419 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 8' ' ' SER . . . . . 0.529 ' HG ' ' H ' ' C' ' 9' ' ' GLY . 8.0 t -167.27 171.5 10.68 Favored 'General case' 0 N--CA 1.473 0.719 0 N-CA-C 109.564 -0.532 . . . . 0.0 109.564 178.419 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' C' C ' 9' ' ' GLY . . . . . 0.529 ' H ' ' HG ' ' C' ' 8' ' ' SER . . . 121.79 24.79 2.24 Favored Glycine 0 N--CA 1.488 2.111 0 N-CA-C 112.105 -0.398 . . . . 0.0 112.105 179.304 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 42.4 p90 -56.41 128.28 35.19 Favored 'General case' 0 N--CA 1.472 0.669 0 N-CA-C 112.114 0.412 . . . . 0.0 112.114 -179.803 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 11' ' ' GLU . . . . . 0.493 ' CG ' HD22 ' B' ' 27' ' ' ASN . 45.7 mt-10 -84.79 154.41 22.39 Favored 'General case' 0 N--CA 1.468 0.473 0 N-CA-C 109.113 -0.699 . . . . 0.0 109.113 178.504 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -153.54 129.36 1.71 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 N-CA-C 108.409 -0.96 . . . . 0.0 108.409 178.968 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 48.9 m-70 -134.22 144.97 48.74 Favored 'General case' 0 N--CA 1.489 1.518 0 CA-C-N 118.588 0.631 . . . . 0.0 110.968 -179.029 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 6.3 t60 -165.04 98.55 0.74 Allowed 'General case' 0 N--CA 1.481 1.099 0 CA-C-N 116.57 -0.286 . . . . 0.0 111.201 179.791 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 15' ' ' GLN . . . . . 0.512 HE22 ' H ' ' C' ' 37' ' ' GLY . 54.3 mt-30 -108.6 -172.05 1.98 Allowed 'General case' 0 CA--C 1.5 -0.954 0 N-CA-C 108.251 -1.018 . . . . 0.0 108.251 179.765 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -167.25 97.58 0.5 Allowed 'General case' 0 CA--C 1.54 0.58 0 CA-C-N 115.179 -0.918 . . . . 0.0 109.381 178.751 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 17' ' ' LEU . . . . . 0.419 ' N ' ' CD1' ' C' ' 17' ' ' LEU . 4.4 mp -105.66 163.64 12.53 Favored 'General case' 0 N--CA 1.487 1.392 0 N-CA-C 108.563 -0.903 . . . . 0.0 108.563 179.838 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 51.0 t -142.0 118.75 6.95 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.343 0 CA-C-O 119.032 -0.509 . . . . 0.0 109.959 179.495 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 52.6 m-85 -70.33 159.24 34.48 Favored 'General case' 0 N--CA 1.478 0.964 0 N-CA-C 107.502 -1.296 . . . . 0.0 107.502 177.247 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 14.8 t80 -171.82 -57.35 0.02 OUTLIER 'General case' 0 N--CA 1.482 1.153 0 CA-C-O 122.196 0.998 . . . . 0.0 109.777 179.49 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -39.21 90.75 0.0 OUTLIER 'General case' 0 CA--C 1.529 0.15 0 CA-C-N 114.193 -1.367 . . . . 0.0 112.785 -178.053 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 37.7 tt0 -66.77 157.4 32.95 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.063 -0.971 . . . . 0.0 110.539 179.247 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 66.8 m-20 -139.22 137.03 35.62 Favored 'General case' 0 N--CA 1.478 0.937 0 C-N-CA 123.138 0.575 . . . . 0.0 110.297 179.836 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 17.9 t -85.39 -116.67 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.064 0 N-CA-C 108.519 -0.919 . . . . 0.0 108.519 179.558 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -108.16 54.61 0.55 Allowed Glycine 0 N--CA 1.474 1.228 0 N-CA-C 111.1 -0.8 . . . . 0.0 111.1 179.96 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 73.2 p -80.42 125.47 29.96 Favored 'General case' 0 N--CA 1.466 0.336 0 N-CA-C 108.841 -0.8 . . . . 0.0 108.841 178.329 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 27' ' ' ASN . . . . . 0.476 HD22 ' CG ' ' A' ' 11' ' ' GLU . 48.3 t30 -65.64 100.55 0.53 Allowed 'General case' 0 N--CA 1.474 0.757 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 178.684 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 66.8 mttm -95.8 116.86 29.52 Favored 'General case' 0 N--CA 1.485 1.324 0 N-CA-C 109.977 -0.379 . . . . 0.0 109.977 -179.055 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.73 -133.32 0.01 OUTLIER Glycine 0 CA--C 1.534 1.248 0 N-CA-C 110.761 -0.936 . . . . 0.0 110.761 178.954 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -113.73 127.65 56.11 Favored 'General case' 0 N--CA 1.479 1.016 0 N-CA-C 109.231 -0.655 . . . . 0.0 109.231 178.981 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 66.7 mt -90.66 130.15 40.34 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.644 0 N-CA-C 107.492 -1.299 . . . . 0.0 107.492 178.746 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 17.8 mt -142.59 152.49 17.71 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.909 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -178.864 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 65.52 47.44 78.07 Favored Glycine 0 CA--C 1.524 0.604 0 CA-C-N 116.0 -0.545 . . . . 0.0 112.666 178.877 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 2.9 tt -98.16 120.38 38.46 Favored 'General case' 0 N--CA 1.477 0.92 0 N-CA-C 107.231 -1.396 . . . . 0.0 107.231 177.864 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 28.1 ttt -152.48 158.16 42.19 Favored 'General case' 0 N--CA 1.471 0.577 0 N-CA-C 108.834 -0.802 . . . . 0.0 108.834 179.401 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 87.3 t -158.3 149.8 8.24 Favored 'Isoleucine or valine' 0 C--O 1.236 0.393 0 N-CA-C 106.856 -1.535 . . . . 0.0 106.856 -179.205 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 37' ' ' GLY . . . . . 0.512 ' H ' HE22 ' C' ' 15' ' ' GLN . . . 56.66 75.08 0.27 Allowed Glycine 0 C--N 1.313 -0.71 0 CA-C-N 115.608 -0.724 . . . . 0.0 111.675 178.101 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 170.55 -149.11 12.17 Favored Glycine 0 CA--C 1.519 0.336 0 N-CA-C 110.593 -1.003 . . . . 0.0 110.593 179.801 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 33.7 m -133.71 142.81 40.49 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.835 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 179.728 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 16.2 t . . . . . 0 CA--C 1.535 0.39 0 CA-C-O 117.888 -1.053 . . . . 0.0 110.983 179.34 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 86.9 m-85 . . . . . 0 N--CA 1.473 0.698 0 N-CA-C 108.261 -1.014 . . . . 0.0 108.261 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' D' D ' 5' ' ' ARG . . . . . . . . . . . . . 72.0 mtp180 -147.32 141.52 26.16 Favored 'General case' 0 N--CA 1.475 0.821 0 N-CA-C 109.13 -0.692 . . . . 0.0 109.13 179.888 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 76.9 m80 -149.14 123.68 9.74 Favored 'General case' 0 C--O 1.219 -0.541 0 N-CA-C 107.758 -1.201 . . . . 0.0 107.758 175.638 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 7' ' ' ASP . . . . . . . . . . . . . 6.1 m-20 -63.45 133.26 53.64 Favored 'General case' 0 C--N 1.322 -0.613 0 C-N-CA 127.036 2.134 . . . . 0.0 114.832 176.15 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 8' ' ' SER . . . . . 0.551 ' HG ' ' H ' ' D' ' 9' ' ' GLY . 7.0 t -154.2 173.62 15.87 Favored 'General case' 0 N--CA 1.478 0.961 0 CA-C-N 118.609 0.64 . . . . 0.0 110.406 176.996 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' D' D ' 9' ' ' GLY . . . . . 0.551 ' H ' ' HG ' ' D' ' 8' ' ' SER . . . 124.15 20.83 2.41 Favored Glycine 0 N--CA 1.484 1.842 0 N-CA-C 112.159 -0.377 . . . . 0.0 112.159 176.398 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 37.7 p90 -55.56 130.5 43.17 Favored 'General case' 0 CA--C 1.546 0.79 0 CA-C-O 121.176 0.513 . . . . 0.0 111.842 -176.771 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 11' ' ' GLU . . . . . 0.422 ' CG ' HD22 ' F' ' 27' ' ' ASN . 46.0 mt-10 -84.89 152.35 23.62 Favored 'General case' 0 N--CA 1.473 0.698 0 N-CA-C 109.703 -0.48 . . . . 0.0 109.703 177.663 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -149.56 130.13 4.42 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.426 0 N-CA-C 108.409 -0.96 . . . . 0.0 108.409 175.792 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 48.5 m-70 -129.53 148.34 51.42 Favored 'General case' 0 N--CA 1.483 1.184 0 CA-C-N 117.992 0.36 . . . . 0.0 111.116 176.84 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 6.5 t60 -165.02 104.85 0.78 Allowed 'General case' 0 N--CA 1.482 1.145 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 173.76 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 15' ' ' GLN . . . . . 0.531 HE22 ' H ' ' D' ' 37' ' ' GLY . 54.3 mt-30 -111.78 -175.49 2.71 Favored 'General case' 0 CA--C 1.492 -1.255 0 N-CA-C 107.977 -1.12 . . . . 0.0 107.977 179.065 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 88.7 tttt -163.39 106.02 0.99 Allowed 'General case' 0 CA--C 1.536 0.433 0 N-CA-C 107.656 -1.239 . . . . 0.0 107.656 175.62 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 5.5 mp -112.42 162.73 15.25 Favored 'General case' 0 N--CA 1.488 1.447 0 N-CA-C 107.887 -1.153 . . . . 0.0 107.887 179.655 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 47.3 t -141.0 123.81 15.59 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.192 0 N-CA-C 109.053 -0.721 . . . . 0.0 109.053 175.834 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 78.3 m-85 -62.91 151.46 39.29 Favored 'General case' 0 C--N 1.352 0.685 0 C-N-CA 124.74 1.216 . . . . 0.0 110.396 170.501 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 9.8 t80 -170.1 -66.8 0.02 OUTLIER 'General case' 0 N--CA 1.477 0.903 0 N-CA-C 107.666 -1.235 . . . . 0.0 107.666 -179.629 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -37.91 95.66 0.01 OUTLIER 'General case' 0 CA--C 1.536 0.428 0 CA-C-N 114.019 -1.446 . . . . 0.0 111.663 -174.583 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 38.1 tt0 -68.35 158.19 34.07 Favored 'General case' 0 N--CA 1.467 0.388 0 CA-C-N 113.435 -1.711 . . . . 0.0 110.376 178.493 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 67.6 m-20 -139.54 140.65 37.19 Favored 'General case' 0 N--CA 1.476 0.834 0 N-CA-C 109.403 -0.592 . . . . 0.0 109.403 178.558 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 24' ' ' VAL . . . . . . . . . . . . . 19.5 t -88.28 -119.97 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.486 1.347 0 N-CA-C 107.779 -1.193 . . . . 0.0 107.779 179.699 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . -111.72 61.91 0.3 Allowed Glycine 0 C--N 1.371 2.478 0 C-N-CA 118.075 -2.012 . . . . 0.0 109.317 178.824 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 89.0 p -70.57 121.35 17.69 Favored 'General case' 0 C--O 1.243 0.713 0 CA-C-O 116.555 -1.688 . . . . 0.0 111.775 169.24 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 27' ' ' ASN . . . . . 0.409 HD22 ' CG ' ' E' ' 11' ' ' GLU . 54.6 t30 -61.2 101.8 0.18 Allowed 'General case' 0 N--CA 1.476 0.864 0 CA-C-N 121.558 1.981 . . . . 0.0 109.501 172.957 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 66.2 mttm -99.14 119.28 37.59 Favored 'General case' 0 N--CA 1.491 1.621 0 CA-C-N 119.427 1.012 . . . . 0.0 109.127 179.217 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -55.07 -134.39 0.0 OUTLIER Glycine 0 C--N 1.343 0.931 0 CA-C-N 115.607 -0.724 . . . . 0.0 113.379 175.931 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -113.19 132.65 55.41 Favored 'General case' 0 C--N 1.372 1.565 0 N-CA-C 108.591 -0.892 . . . . 0.0 108.591 174.145 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 68.2 mt -91.88 134.34 30.51 Favored 'Isoleucine or valine' 0 C--N 1.347 0.488 0 N-CA-C 106.929 -1.508 . . . . 0.0 106.929 176.459 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 20.0 mt -144.78 155.02 14.34 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.965 0 N-CA-C 109.2 -0.667 . . . . 0.0 109.2 179.137 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 64.11 46.86 90.03 Favored Glycine 0 C--O 1.245 0.841 0 CA-C-O 119.354 -0.692 . . . . 0.0 112.57 179.059 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 3.5 tt -97.7 132.27 43.49 Favored 'General case' 0 C--N 1.372 1.585 0 N-CA-C 104.569 -2.382 . . . . 0.0 104.569 176.408 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 28.3 ttt -155.9 165.23 37.1 Favored 'General case' 0 N--CA 1.474 0.752 0 N-CA-C 107.783 -1.192 . . . . 0.0 107.783 175.819 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 96.3 t -164.1 154.69 2.26 Favored 'Isoleucine or valine' 0 C--O 1.247 0.973 0 N-CA-C 105.564 -2.013 . . . . 0.0 105.564 176.382 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 37' ' ' GLY . . . . . 0.531 ' H ' HE22 ' D' ' 15' ' ' GLN . . . 61.13 66.67 2.52 Favored Glycine 0 N--CA 1.445 -0.731 0 C-N-CA 117.446 -2.312 . . . . 0.0 113.974 176.577 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 167.64 -147.91 12.28 Favored Glycine 0 N--CA 1.466 0.644 0 CA-C-O 117.701 -1.61 . . . . 0.0 112.176 -179.117 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 33.7 m -130.4 142.69 43.07 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.088 0 CA-C-N 119.352 1.576 . . . . 0.0 109.886 -179.065 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 13.6 t . . . . . 0 C--O 1.212 -0.87 0 N-CA-C 109.54 -0.541 . . . . 0.0 109.54 174.466 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 79.4 m-85 . . . . . 0 N--CA 1.474 0.771 0 N-CA-C 109.907 -0.405 . . . . 0.0 109.907 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' E' E ' 5' ' ' ARG . . . . . . . . . . . . . 72.5 mtp180 -143.92 142.52 30.81 Favored 'General case' 0 N--CA 1.476 0.842 0 N-CA-C 109.541 -0.54 . . . . 0.0 109.541 179.858 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 76.5 m80 -150.3 118.27 6.28 Favored 'General case' 0 N--CA 1.473 0.686 0 N-CA-C 108.929 -0.767 . . . . 0.0 108.929 179.169 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' E' E ' 7' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -66.69 149.86 49.9 Favored 'General case' 0 N--CA 1.464 0.236 0 O-C-N 123.541 0.526 . . . . 0.0 111.538 -179.5 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' E' E ' 8' ' ' SER . . . . . 0.524 ' HG ' ' H ' ' E' ' 9' ' ' GLY . 7.1 t -167.92 172.4 9.01 Favored 'General case' 0 N--CA 1.476 0.839 0 N-CA-C 109.573 -0.528 . . . . 0.0 109.573 177.901 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' E' E ' 9' ' ' GLY . . . . . 0.524 ' H ' ' HG ' ' E' ' 8' ' ' SER . . . 122.7 24.34 2.13 Favored Glycine 0 N--CA 1.482 1.731 0 N-CA-C 111.922 -0.471 . . . . 0.0 111.922 179.071 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 39.1 p90 -55.66 127.28 29.18 Favored 'General case' 0 N--CA 1.474 0.733 0 N-CA-C 112.627 0.602 . . . . 0.0 112.627 -179.091 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' E' E ' 11' ' ' GLU . . . . . 0.409 ' CG ' HD22 ' D' ' 27' ' ' ASN . 46.4 mt-10 -83.32 155.08 23.76 Favored 'General case' 0 N--CA 1.474 0.76 0 N-CA-C 109.388 -0.597 . . . . 0.0 109.388 177.938 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -155.18 128.77 1.22 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.494 0 N-CA-C 108.386 -0.968 . . . . 0.0 108.386 178.811 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 46.3 m-70 -134.77 143.21 46.99 Favored 'General case' 0 N--CA 1.481 1.095 0 O-C-N 122.324 -0.235 . . . . 0.0 111.225 -177.99 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 6.2 t60 -163.99 98.39 0.85 Allowed 'General case' 0 N--CA 1.486 1.352 0 CA-C-N 116.765 -0.198 . . . . 0.0 111.147 179.814 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' E' E ' 15' ' ' GLN . . . . . 0.478 HE22 ' H ' ' E' ' 37' ' ' GLY . 54.7 mt-30 -107.82 -172.34 2.05 Favored 'General case' 0 CA--C 1.502 -0.9 0 N-CA-C 108.394 -0.965 . . . . 0.0 108.394 179.89 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -166.99 97.73 0.53 Allowed 'General case' 0 CA--C 1.543 0.686 0 CA-C-N 115.056 -0.975 . . . . 0.0 109.414 178.675 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' E' E ' 17' ' ' LEU . . . . . 0.409 ' N ' ' CD1' ' E' ' 17' ' ' LEU . 4.6 mp -105.69 163.32 12.79 Favored 'General case' 0 N--CA 1.49 1.558 0 N-CA-C 109.084 -0.709 . . . . 0.0 109.084 -179.796 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 39.0 t -142.32 118.39 6.0 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.38 0 C-N-CA 122.512 0.325 . . . . 0.0 110.52 179.078 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 51.0 m-85 -69.76 156.87 38.36 Favored 'General case' 0 C--N 1.358 0.964 0 N-CA-C 107.269 -1.382 . . . . 0.0 107.269 176.585 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 13.3 t80 -173.47 -54.96 0.02 OUTLIER 'General case' 0 N--CA 1.485 1.304 0 CA-C-O 121.606 0.717 . . . . 0.0 110.347 179.545 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.1 88.72 0.0 OUTLIER 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 114.396 -1.274 . . . . 0.0 112.843 -178.994 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 37.8 tt0 -64.62 157.88 25.88 Favored 'General case' 0 N--CA 1.471 0.581 0 CA-C-N 114.86 -1.064 . . . . 0.0 110.719 179.701 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 66.3 m-20 -139.97 136.68 34.03 Favored 'General case' 0 N--CA 1.477 0.883 0 C-N-CA 122.948 0.499 . . . . 0.0 110.399 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 21.8 t -85.23 -115.58 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.109 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 179.523 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . -108.97 54.66 0.54 Allowed Glycine 0 C--N 1.348 1.245 0 N-CA-C 111.237 -0.745 . . . . 0.0 111.237 -179.87 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 69.2 p -79.96 125.02 29.22 Favored 'General case' 0 N--CA 1.473 0.723 0 N-CA-C 109.111 -0.7 . . . . 0.0 109.111 177.947 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' E' E ' 27' ' ' ASN . . . . . 0.435 HD22 ' CG ' ' F' ' 11' ' ' GLU . 48.4 t30 -65.37 100.04 0.45 Allowed 'General case' 0 N--CA 1.474 0.747 0 N-CA-C 108.236 -1.024 . . . . 0.0 108.236 178.552 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 66.2 mttm -95.69 116.74 29.3 Favored 'General case' 0 N--CA 1.486 1.351 0 N-CA-C 109.975 -0.38 . . . . 0.0 109.975 -178.708 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.02 -132.82 0.01 OUTLIER Glycine 0 CA--C 1.534 1.271 0 N-CA-C 111.38 -0.688 . . . . 0.0 111.38 178.858 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -114.02 127.09 55.79 Favored 'General case' 0 N--CA 1.477 0.896 0 N-CA-C 109.394 -0.595 . . . . 0.0 109.394 179.187 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 67.2 mt -90.38 131.19 38.21 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.233 0 N-CA-C 107.132 -1.432 . . . . 0.0 107.132 178.688 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 19.5 mt -142.4 154.44 18.3 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.907 0 N-CA-C 109.125 -0.694 . . . . 0.0 109.125 -179.341 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.39 48.86 74.96 Favored Glycine 0 CA--C 1.523 0.537 0 C-N-CA 121.702 -0.285 . . . . 0.0 113.291 178.944 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 3.0 tt -99.3 120.19 39.16 Favored 'General case' 0 N--CA 1.477 0.907 0 N-CA-C 107.143 -1.429 . . . . 0.0 107.143 177.617 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 28.5 ttt -151.68 159.55 43.96 Favored 'General case' 0 N--CA 1.479 1.019 0 N-CA-C 108.552 -0.907 . . . . 0.0 108.552 179.314 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 96.9 t -159.64 149.85 6.59 Favored 'Isoleucine or valine' 0 C--O 1.236 0.384 0 N-CA-C 106.834 -1.543 . . . . 0.0 106.834 -179.504 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' E' E ' 37' ' ' GLY . . . . . 0.478 ' H ' HE22 ' E' ' 15' ' ' GLN . . . 56.71 74.53 0.32 Allowed Glycine 0 C--N 1.312 -0.751 0 CA-C-N 115.659 -0.701 . . . . 0.0 111.452 178.01 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 171.81 -147.24 9.96 Favored Glycine 0 C--O 1.223 -0.569 0 N-CA-C 111.08 -0.808 . . . . 0.0 111.08 179.67 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 33.2 m -135.28 141.85 41.46 Favored 'Isoleucine or valine' 0 C--N 1.353 0.731 0 N-CA-C 109.248 -0.649 . . . . 0.0 109.248 179.695 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 14.5 t . . . . . 0 CA--C 1.537 0.479 0 CA-C-O 117.916 -1.04 . . . . 0.0 111.24 179.383 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 78.8 m-85 . . . . . 0 N--CA 1.475 0.796 0 N-CA-C 109.981 -0.377 . . . . 0.0 109.981 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' F' F ' 5' ' ' ARG . . . . . . . . . . . . . 72.2 mtp180 -143.88 142.36 30.77 Favored 'General case' 0 N--CA 1.477 0.911 0 N-CA-C 109.283 -0.636 . . . . 0.0 109.283 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 76.7 m80 -150.24 118.11 6.25 Favored 'General case' 0 N--CA 1.474 0.726 0 N-CA-C 108.936 -0.765 . . . . 0.0 108.936 179.045 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' F' F ' 7' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -66.72 149.94 49.8 Favored 'General case' 0 N--CA 1.464 0.252 0 O-C-N 123.386 0.428 . . . . 0.0 111.595 -179.424 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' F' F ' 8' ' ' SER . . . . . 0.508 ' HG ' ' H ' ' F' ' 9' ' ' GLY . 7.2 t -167.96 172.51 8.86 Favored 'General case' 0 N--CA 1.475 0.815 0 CA-C-N 115.944 -0.571 . . . . 0.0 109.574 177.978 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' F' F ' 9' ' ' GLY . . . . . 0.508 ' H ' ' HG ' ' F' ' 8' ' ' SER . . . 122.47 24.7 2.11 Favored Glycine 0 N--CA 1.483 1.776 0 N-CA-C 111.892 -0.483 . . . . 0.0 111.892 178.986 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 38.6 p90 -56.09 127.52 30.97 Favored 'General case' 0 N--CA 1.474 0.733 0 N-CA-C 112.637 0.606 . . . . 0.0 112.637 -179.061 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' F' F ' 11' ' ' GLU . . . . . 0.435 ' CG ' HD22 ' E' ' 27' ' ' ASN . 46.0 mt-10 -83.25 155.03 23.86 Favored 'General case' 0 N--CA 1.474 0.746 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 177.897 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -155.13 128.61 1.2 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.503 0 N-CA-C 108.43 -0.952 . . . . 0.0 108.43 178.775 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 46.9 m-70 -134.7 143.11 47.02 Favored 'General case' 0 N--CA 1.48 1.051 0 O-C-N 122.275 -0.265 . . . . 0.0 111.194 -177.998 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 6.2 t60 -164.11 98.63 0.84 Allowed 'General case' 0 N--CA 1.486 1.342 0 CA-C-N 116.734 -0.212 . . . . 0.0 111.258 179.917 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' F' F ' 15' ' ' GLN . . . . . 0.493 HE22 ' H ' ' F' ' 37' ' ' GLY . 55.0 mt-30 -108.36 -171.42 1.86 Allowed 'General case' 0 CA--C 1.499 -1.011 0 N-CA-C 108.544 -0.91 . . . . 0.0 108.544 179.885 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -167.53 98.01 0.49 Allowed 'General case' 0 CA--C 1.541 0.605 0 CA-C-N 114.933 -1.03 . . . . 0.0 109.484 178.667 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' F' F ' 17' ' ' LEU . . . . . 0.403 ' CD1' ' N ' ' F' ' 17' ' ' LEU . 4.5 mp -105.73 163.14 12.93 Favored 'General case' 0 N--CA 1.49 1.541 0 N-CA-C 109.151 -0.685 . . . . 0.0 109.151 -179.856 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 39.0 t -142.17 118.41 6.3 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.293 0 C-N-CA 122.573 0.349 . . . . 0.0 110.567 179.121 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 52.3 m-85 -69.78 156.7 38.63 Favored 'General case' 0 C--N 1.358 0.955 0 N-CA-C 107.121 -1.437 . . . . 0.0 107.121 176.482 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 13.9 t80 -173.0 -55.27 0.02 OUTLIER 'General case' 0 N--CA 1.485 1.293 0 CA-C-O 121.811 0.815 . . . . 0.0 109.826 179.645 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.86 88.89 0.0 OUTLIER 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 114.436 -1.256 . . . . 0.0 112.916 -178.938 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 37.8 tt0 -64.78 157.68 26.97 Favored 'General case' 0 N--CA 1.472 0.651 0 CA-C-N 114.935 -1.029 . . . . 0.0 110.784 179.464 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 66.1 m-20 -139.84 137.03 34.61 Favored 'General case' 0 N--CA 1.478 0.955 0 C-N-CA 122.944 0.497 . . . . 0.0 110.346 179.887 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' F' F ' 24' ' ' VAL . . . . . . . . . . . . . 21.6 t -85.62 -115.55 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.482 1.126 0 N-CA-C 108.706 -0.849 . . . . 0.0 108.706 179.502 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -108.8 54.06 0.57 Allowed Glycine 0 N--CA 1.477 1.371 0 N-CA-C 111.235 -0.746 . . . . 0.0 111.235 -179.869 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 69.8 p -79.5 125.04 29.05 Favored 'General case' 0 N--CA 1.473 0.675 0 N-CA-C 109.052 -0.721 . . . . 0.0 109.052 177.876 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' F' F ' 27' ' ' ASN . . . . . 0.422 HD22 ' CG ' ' D' ' 11' ' ' GLU . 48.2 t30 -65.46 100.15 0.47 Allowed 'General case' 0 N--CA 1.473 0.69 0 N-CA-C 108.328 -0.99 . . . . 0.0 108.328 178.533 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 66.1 mttm -95.66 116.82 29.41 Favored 'General case' 0 N--CA 1.485 1.281 0 N-CA-C 110.022 -0.362 . . . . 0.0 110.022 -178.669 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.17 -132.77 0.01 OUTLIER Glycine 0 CA--C 1.533 1.197 0 N-CA-C 111.491 -0.644 . . . . 0.0 111.491 178.916 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -113.85 126.37 55.11 Favored 'General case' 0 N--CA 1.478 0.954 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 179.278 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 67.2 mt -89.97 130.66 38.89 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.209 0 N-CA-C 107.175 -1.417 . . . . 0.0 107.175 178.632 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 19.4 mt -142.11 154.32 18.83 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.877 0 N-CA-C 109.106 -0.701 . . . . 0.0 109.106 -179.333 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.63 48.9 73.21 Favored Glycine 0 CA--C 1.524 0.596 0 CA-C-N 116.476 -0.329 . . . . 0.0 113.289 179.016 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 3.0 tt -99.41 120.26 39.31 Favored 'General case' 0 N--CA 1.478 0.946 0 N-CA-C 107.145 -1.428 . . . . 0.0 107.145 177.771 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 28.5 ttt -151.82 159.66 43.81 Favored 'General case' 0 N--CA 1.477 0.925 0 N-CA-C 108.673 -0.862 . . . . 0.0 108.673 179.437 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 94.5 t -159.76 149.89 6.45 Favored 'Isoleucine or valine' 0 C--O 1.235 0.31 0 N-CA-C 106.865 -1.531 . . . . 0.0 106.865 -179.478 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' F' F ' 37' ' ' GLY . . . . . 0.493 ' H ' HE22 ' F' ' 15' ' ' GLN . . . 56.78 74.35 0.34 Allowed Glycine 0 C--N 1.313 -0.722 0 CA-C-N 115.549 -0.75 . . . . 0.0 111.512 177.904 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 171.91 -147.25 9.93 Favored Glycine 0 C--O 1.223 -0.534 0 N-CA-C 111.099 -0.8 . . . . 0.0 111.099 179.818 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 33.2 m -135.33 141.67 41.91 Favored 'Isoleucine or valine' 0 C--N 1.352 0.715 0 N-CA-C 109.27 -0.641 . . . . 0.0 109.27 179.712 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 15.2 t . . . . . 0 CA--C 1.537 0.473 0 CA-C-O 117.934 -1.031 . . . . 0.0 111.155 179.317 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 79.4 m-85 . . . . . 0 N--CA 1.474 0.765 0 N-CA-C 109.543 -0.54 . . . . 0.0 109.543 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' G' G ' 5' ' ' ARG . . . . . . . . . . . . . 72.2 mtp180 -144.05 141.52 30.14 Favored 'General case' 0 N--CA 1.483 1.221 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 -179.612 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 76.8 m80 -149.24 119.29 7.18 Favored 'General case' 0 N--CA 1.473 0.679 0 N-CA-C 108.952 -0.759 . . . . 0.0 108.952 179.026 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 8.9 m-20 -68.55 145.46 53.97 Favored 'General case' 0 N--CA 1.468 0.462 0 O-C-N 123.578 0.549 . . . . 0.0 111.945 -179.319 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' G' G ' 8' ' ' SER . . . . . 0.501 ' HG ' ' H ' ' G' ' 9' ' ' GLY . 6.0 t -164.64 173.52 11.83 Favored 'General case' 0 N--CA 1.468 0.461 0 N-CA-C 109.386 -0.598 . . . . 0.0 109.386 178.208 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' G' G ' 9' ' ' GLY . . . . . 0.501 ' H ' ' HG ' ' G' ' 8' ' ' SER . . . 122.36 24.45 2.19 Favored Glycine 0 N--CA 1.48 1.584 0 N-CA-C 111.639 -0.584 . . . . 0.0 111.639 178.934 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 42.4 p90 -56.24 127.56 31.4 Favored 'General case' 0 N--CA 1.474 0.745 0 N-CA-C 112.516 0.562 . . . . 0.0 112.516 -178.757 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 45.7 mt-10 -83.61 154.24 23.86 Favored 'General case' 0 N--CA 1.471 0.601 0 CA-C-O 120.971 0.415 . . . . 0.0 109.882 178.638 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 2.6 p -155.5 128.51 1.13 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.959 0 N-CA-C 108.431 -0.951 . . . . 0.0 108.431 178.972 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 49.6 m-70 -133.6 144.64 49.41 Favored 'General case' 0 N--CA 1.477 0.876 0 CA-C-N 115.454 -0.793 . . . . 0.0 110.934 -178.177 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 6.3 t60 -165.65 98.62 0.68 Allowed 'General case' 0 N--CA 1.483 1.2 0 CA-C-N 116.589 -0.278 . . . . 0.0 110.805 179.193 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' G' G ' 15' ' ' GLN . . . . . 0.504 HE22 ' H ' ' G' ' 37' ' ' GLY . 54.5 mt-30 -108.49 -171.92 1.95 Allowed 'General case' 0 CA--C 1.501 -0.915 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 179.916 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -167.31 97.91 0.5 Allowed 'General case' 0 CA--C 1.542 0.641 0 CA-C-N 114.96 -1.018 . . . . 0.0 109.388 178.717 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' G' G ' 17' ' ' LEU . . . . . 0.412 ' N ' ' CD1' ' G' ' 17' ' ' LEU . 5.1 mp -105.38 162.41 13.47 Favored 'General case' 0 N--CA 1.487 1.402 0 N-CA-C 109.32 -0.622 . . . . 0.0 109.32 -179.685 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 36.5 t -143.13 118.52 4.6 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.009 0 CA-C-O 120.83 0.348 . . . . 0.0 110.442 178.851 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 46.5 m-85 -69.76 150.32 47.03 Favored 'General case' 0 C--N 1.37 1.481 0 N-CA-C 107.263 -1.384 . . . . 0.0 107.263 176.595 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 11.3 t80 -170.5 -55.06 0.02 OUTLIER 'General case' 0 N--CA 1.487 1.406 0 CA-C-N 117.953 0.342 . . . . 0.0 110.328 -179.583 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.68 89.9 0.0 OUTLIER 'General case' 0 C--N 1.325 -0.491 0 C-N-CA 123.774 0.83 . . . . 0.0 112.508 -179.839 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 38.0 tt0 -65.41 158.54 26.41 Favored 'General case' 0 N--CA 1.469 0.476 0 CA-C-N 114.714 -1.13 . . . . 0.0 109.954 179.146 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 67.4 m-20 -140.09 136.8 33.97 Favored 'General case' 0 N--CA 1.478 0.937 0 C-N-CA 122.874 0.469 . . . . 0.0 109.98 179.904 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' G' G ' 24' ' ' VAL . . . . . . . . . . . . . 21.5 t -85.95 -115.61 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 1.004 0 N-CA-C 108.506 -0.924 . . . . 0.0 108.506 179.555 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -108.61 54.04 0.57 Allowed Glycine 0 N--CA 1.477 1.397 0 N-CA-C 111.492 -0.643 . . . . 0.0 111.492 -179.868 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 72.6 p -79.96 125.57 29.92 Favored 'General case' 0 N--CA 1.467 0.389 0 N-CA-C 108.943 -0.762 . . . . 0.0 108.943 177.971 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 47.5 t30 -65.76 100.98 0.59 Allowed 'General case' 0 N--CA 1.47 0.566 0 N-CA-C 108.567 -0.901 . . . . 0.0 108.567 178.525 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 66.6 mttm -95.76 117.2 30.09 Favored 'General case' 0 N--CA 1.485 1.309 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 -179.13 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.94 -131.95 0.01 OUTLIER Glycine 0 CA--C 1.53 1.005 0 N-CA-C 110.579 -1.008 . . . . 0.0 110.579 178.946 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -113.74 126.48 55.27 Favored 'General case' 0 N--CA 1.469 0.499 0 N-CA-C 109.522 -0.547 . . . . 0.0 109.522 179.542 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 69.3 mt -89.94 131.38 37.34 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.756 0 N-CA-C 107.327 -1.36 . . . . 0.0 107.327 178.495 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 22.7 mt -143.29 155.09 16.74 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.397 0 CA-C-N 118.982 0.81 . . . . 0.0 109.056 -179.751 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.74 48.2 79.29 Favored Glycine 0 CA--C 1.527 0.782 0 CA-C-N 116.659 -0.246 . . . . 0.0 112.835 179.053 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 2.9 tt -98.87 121.19 40.5 Favored 'General case' 0 N--CA 1.478 0.955 0 N-CA-C 107.086 -1.449 . . . . 0.0 107.086 177.75 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 28.7 ttt -153.08 160.21 42.9 Favored 'General case' 0 N--CA 1.477 0.882 0 N-CA-C 108.172 -1.047 . . . . 0.0 108.172 179.493 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 84.4 t -159.81 150.2 6.31 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.255 0 N-CA-C 106.419 -1.697 . . . . 0.0 106.419 -179.354 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' G' G ' 37' ' ' GLY . . . . . 0.504 ' H ' HE22 ' G' ' 15' ' ' GLN . . . 56.59 74.86 0.29 Allowed Glycine 0 C--N 1.312 -0.756 0 C-N-CA 120.975 -0.631 . . . . 0.0 112.049 177.727 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 170.28 -145.79 9.39 Favored Glycine 0 N--CA 1.467 0.702 0 N-CA-C 110.614 -0.995 . . . . 0.0 110.614 179.127 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 33.9 m -135.91 142.06 40.08 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.873 0 N-CA-C 109.911 -0.403 . . . . 0.0 109.911 -179.887 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 15.4 t . . . . . 0 N--CA 1.466 0.349 0 CA-C-O 118.046 -0.978 . . . . 0.0 111.304 179.463 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 80.1 m-85 . . . . . 0 N--CA 1.474 0.769 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' H' H ' 5' ' ' ARG . . . . . . . . . . . . . 72.3 mtp180 -144.11 141.85 30.26 Favored 'General case' 0 N--CA 1.483 1.191 0 N-CA-C 109.294 -0.632 . . . . 0.0 109.294 -179.635 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 76.9 m80 -149.67 118.87 6.78 Favored 'General case' 0 N--CA 1.473 0.695 0 N-CA-C 109.105 -0.702 . . . . 0.0 109.105 179.129 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 8.8 m-20 -68.25 145.2 54.48 Favored 'General case' 0 N--CA 1.469 0.48 0 O-C-N 123.469 0.481 . . . . 0.0 111.924 -179.309 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' H' H ' 8' ' ' SER . . . . . 0.525 ' HG ' ' H ' ' H' ' 9' ' ' GLY . 7.5 t -164.36 172.96 12.77 Favored 'General case' 0 N--CA 1.469 0.507 0 N-CA-C 109.449 -0.575 . . . . 0.0 109.449 178.421 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' H' H ' 9' ' ' GLY . . . . . 0.525 ' H ' ' HG ' ' H' ' 8' ' ' SER . . . 122.43 24.46 2.17 Favored Glycine 0 N--CA 1.481 1.665 0 N-CA-C 111.733 -0.547 . . . . 0.0 111.733 179.112 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 42.1 p90 -56.38 127.51 31.37 Favored 'General case' 0 N--CA 1.473 0.707 0 N-CA-C 112.428 0.529 . . . . 0.0 112.428 -178.795 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 45.4 mt-10 -83.51 154.2 24.0 Favored 'General case' 0 N--CA 1.473 0.676 0 CA-C-O 120.984 0.421 . . . . 0.0 109.874 178.62 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.6 p -155.41 128.41 1.13 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.975 0 N-CA-C 108.433 -0.951 . . . . 0.0 108.433 178.963 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 52.1 m-70 -133.42 144.63 49.65 Favored 'General case' 0 N--CA 1.476 0.863 0 CA-C-N 115.43 -0.804 . . . . 0.0 110.893 -178.16 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 6.4 t60 -165.61 98.48 0.68 Allowed 'General case' 0 N--CA 1.482 1.146 0 CA-C-N 116.527 -0.306 . . . . 0.0 110.839 179.146 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' H' H ' 15' ' ' GLN . . . . . 0.499 HE22 ' H ' ' H' ' 37' ' ' GLY . 54.2 mt-30 -108.24 -172.45 2.06 Favored 'General case' 0 CA--C 1.5 -0.979 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 -179.921 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -167.01 97.78 0.52 Allowed 'General case' 0 CA--C 1.539 0.521 0 CA-C-N 114.989 -1.005 . . . . 0.0 109.402 178.73 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' H' H ' 17' ' ' LEU . . . . . 0.413 ' N ' ' CD1' ' H' ' 17' ' ' LEU . 5.1 mp -105.5 162.13 13.74 Favored 'General case' 0 N--CA 1.488 1.442 0 N-CA-C 109.292 -0.633 . . . . 0.0 109.292 -179.632 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 38.5 t -142.79 118.54 5.16 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.097 0 CA-C-O 120.905 0.383 . . . . 0.0 110.482 178.874 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 47.5 m-85 -70.14 150.89 46.06 Favored 'General case' 0 C--N 1.37 1.498 0 N-CA-C 107.391 -1.336 . . . . 0.0 107.391 176.585 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 11.9 t80 -171.88 -54.41 0.02 OUTLIER 'General case' 0 N--CA 1.485 1.28 0 CA-C-N 117.828 0.286 . . . . 0.0 110.323 -179.456 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.99 90.22 0.0 OUTLIER 'General case' 0 CA--C 1.536 0.437 0 C-N-CA 123.59 0.756 . . . . 0.0 112.262 -179.824 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 37.9 tt0 -65.38 158.63 26.09 Favored 'General case' 0 N--CA 1.468 0.465 0 CA-C-N 114.739 -1.118 . . . . 0.0 110.011 179.318 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 66.8 m-20 -140.18 136.98 34.01 Favored 'General case' 0 N--CA 1.477 0.899 0 C-N-CA 122.942 0.497 . . . . 0.0 109.972 179.872 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' H' H ' 24' ' ' VAL . . . . . . . . . . . . . 21.5 t -86.36 -115.55 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.049 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 179.605 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . -108.3 53.44 0.6 Allowed Glycine 0 N--CA 1.479 1.564 0 N-CA-C 111.395 -0.682 . . . . 0.0 111.395 -179.828 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 70.1 p -79.46 125.28 29.35 Favored 'General case' 0 N--CA 1.468 0.45 0 N-CA-C 108.893 -0.781 . . . . 0.0 108.893 178.004 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 47.5 t30 -65.69 100.91 0.57 Allowed 'General case' 0 N--CA 1.472 0.662 0 N-CA-C 108.497 -0.927 . . . . 0.0 108.497 178.5 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 66.6 mttm -95.89 117.09 29.93 Favored 'General case' 0 N--CA 1.485 1.283 0 N-CA-C 109.97 -0.382 . . . . 0.0 109.97 -179.146 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.66 -131.75 0.01 OUTLIER Glycine 0 CA--C 1.531 1.059 0 N-CA-C 110.802 -0.919 . . . . 0.0 110.802 178.921 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -114.0 126.24 54.91 Favored 'General case' 0 N--CA 1.471 0.604 0 N-CA-C 109.61 -0.515 . . . . 0.0 109.61 179.527 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 69.4 mt -89.79 131.13 37.82 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.701 0 N-CA-C 107.338 -1.356 . . . . 0.0 107.338 178.55 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 23.3 mt -143.11 155.05 17.02 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.339 0 CA-C-N 118.826 0.739 . . . . 0.0 109.024 -179.698 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.65 48.12 80.36 Favored Glycine 0 CA--C 1.524 0.626 0 CA-C-O 120.117 -0.269 . . . . 0.0 112.891 179.045 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 2.9 tt -98.75 121.09 40.25 Favored 'General case' 0 N--CA 1.478 0.969 0 N-CA-C 107.117 -1.438 . . . . 0.0 107.117 177.617 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 28.7 ttt -152.89 159.95 43.03 Favored 'General case' 0 N--CA 1.478 0.974 0 N-CA-C 108.07 -1.085 . . . . 0.0 108.07 179.61 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 87.2 t -159.66 150.34 6.43 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.261 0 N-CA-C 106.448 -1.686 . . . . 0.0 106.448 -179.51 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' H' H ' 37' ' ' GLY . . . . . 0.499 ' H ' HE22 ' H' ' 15' ' ' GLN . . . 56.35 74.96 0.27 Allowed Glycine 0 C--N 1.311 -0.811 0 C-N-CA 120.979 -0.629 . . . . 0.0 112.015 177.804 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 170.24 -146.2 9.7 Favored Glycine 0 N--CA 1.467 0.744 0 N-CA-C 110.539 -1.024 . . . . 0.0 110.539 179.129 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 34.0 m -135.57 142.02 40.64 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.815 0 N-CA-C 109.951 -0.388 . . . . 0.0 109.951 -179.875 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 15.9 t . . . . . 0 N--CA 1.467 0.4 0 CA-C-O 118.058 -0.973 . . . . 0.0 111.327 179.45 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 79.6 m-85 . . . . . 0 N--CA 1.474 0.726 0 N-CA-C 109.643 -0.503 . . . . 0.0 109.643 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' I' I ' 5' ' ' ARG . . . . . . . . . . . . . 72.4 mtp180 -144.48 141.67 29.72 Favored 'General case' 0 N--CA 1.484 1.265 0 N-CA-C 109.224 -0.658 . . . . 0.0 109.224 -179.581 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 76.8 m80 -149.47 119.13 6.99 Favored 'General case' 0 N--CA 1.474 0.728 0 N-CA-C 109.08 -0.711 . . . . 0.0 109.08 178.999 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 8.9 m-20 -68.45 145.19 54.31 Favored 'General case' 0 N--CA 1.469 0.499 0 O-C-N 123.429 0.456 . . . . 0.0 111.866 -179.235 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' I' I ' 8' ' ' SER . . . . . 0.494 ' HG ' ' H ' ' I' ' 9' ' ' GLY . 7.5 t -164.33 172.62 13.25 Favored 'General case' 0 N--CA 1.469 0.509 0 N-CA-C 109.463 -0.569 . . . . 0.0 109.463 178.368 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' I' I ' 9' ' ' GLY . . . . . 0.494 ' H ' ' HG ' ' I' ' 8' ' ' SER . . . 122.92 24.62 2.03 Favored Glycine 0 N--CA 1.481 1.684 0 N-CA-C 111.7 -0.56 . . . . 0.0 111.7 179.104 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 42.4 p90 -56.52 127.53 31.69 Favored 'General case' 0 N--CA 1.474 0.762 0 N-CA-C 112.424 0.528 . . . . 0.0 112.424 -178.758 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 45.7 mt-10 -83.56 154.12 23.98 Favored 'General case' 0 N--CA 1.473 0.719 0 CA-C-O 121.071 0.463 . . . . 0.0 109.816 178.62 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 2.6 p -155.3 128.27 1.12 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.005 0 N-CA-C 108.389 -0.967 . . . . 0.0 108.389 178.956 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 50.9 m-70 -133.35 144.36 49.57 Favored 'General case' 0 N--CA 1.477 0.922 0 CA-C-N 115.45 -0.795 . . . . 0.0 110.966 -178.163 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 6.4 t60 -165.45 98.71 0.7 Allowed 'General case' 0 N--CA 1.483 1.177 0 CA-C-N 116.559 -0.291 . . . . 0.0 110.794 179.203 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' I' I ' 15' ' ' GLN . . . . . 0.514 HE22 ' H ' ' I' ' 37' ' ' GLY . 54.4 mt-30 -108.64 -172.46 2.06 Favored 'General case' 0 CA--C 1.499 -1.001 0 N-CA-C 108.405 -0.961 . . . . 0.0 108.405 179.979 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -166.78 98.02 0.55 Allowed 'General case' 0 CA--C 1.539 0.553 0 CA-C-N 114.933 -1.031 . . . . 0.0 109.423 178.745 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' I' I ' 17' ' ' LEU . . . . . 0.407 ' CD1' ' N ' ' I' ' 17' ' ' LEU . 5.1 mp -105.56 162.19 13.71 Favored 'General case' 0 N--CA 1.487 1.402 0 N-CA-C 109.327 -0.62 . . . . 0.0 109.327 -179.701 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 38.8 t -142.88 118.54 4.98 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.024 0 CA-C-O 120.987 0.423 . . . . 0.0 110.471 178.848 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 47.8 m-85 -70.01 150.89 46.18 Favored 'General case' 0 C--N 1.37 1.465 0 N-CA-C 107.306 -1.368 . . . . 0.0 107.306 176.567 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 12.0 t80 -171.94 -54.29 0.02 OUTLIER 'General case' 0 N--CA 1.483 1.206 0 CA-C-N 117.922 0.328 . . . . 0.0 110.408 -179.49 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.18 90.18 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.447 0 C-N-CA 123.713 0.805 . . . . 0.0 112.302 -179.893 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 38.2 tt0 -65.37 158.57 26.2 Favored 'General case' 0 N--CA 1.469 0.519 0 CA-C-N 114.738 -1.119 . . . . 0.0 110.045 179.254 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 66.3 m-20 -140.27 136.81 33.69 Favored 'General case' 0 N--CA 1.478 0.937 0 C-N-CA 122.859 0.464 . . . . 0.0 109.989 179.844 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' I' I ' 24' ' ' VAL . . . . . . . . . . . . . 21.3 t -86.04 -115.9 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.957 0 N-CA-C 108.542 -0.911 . . . . 0.0 108.542 179.559 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . -108.1 54.12 0.57 Allowed Glycine 0 N--CA 1.478 1.453 0 N-CA-C 111.384 -0.687 . . . . 0.0 111.384 -179.845 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 73.4 p -80.08 125.14 29.42 Favored 'General case' 0 N--CA 1.467 0.399 0 N-CA-C 108.962 -0.755 . . . . 0.0 108.962 177.889 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 48.1 t30 -65.49 101.01 0.54 Allowed 'General case' 0 CA--C 1.54 0.583 0 N-CA-C 108.539 -0.911 . . . . 0.0 108.539 178.588 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 66.5 mttm -95.88 117.07 29.88 Favored 'General case' 0 N--CA 1.485 1.321 0 N-CA-C 109.98 -0.378 . . . . 0.0 109.98 -179.177 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.68 -132.1 0.01 OUTLIER Glycine 0 CA--C 1.533 1.186 0 N-CA-C 110.652 -0.979 . . . . 0.0 110.652 178.975 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -113.55 126.12 54.95 Favored 'General case' 0 N--CA 1.472 0.635 0 C-N-CA 123.009 0.524 . . . . 0.0 109.622 179.547 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 70.1 mt -89.81 131.51 36.89 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.752 0 N-CA-C 107.219 -1.401 . . . . 0.0 107.219 178.567 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 23.5 mt -143.49 155.12 16.42 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.36 0 CA-C-N 118.883 0.765 . . . . 0.0 108.994 -179.69 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.57 48.18 80.17 Favored Glycine 0 CA--C 1.525 0.661 0 CA-C-N 116.635 -0.257 . . . . 0.0 112.846 179.082 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 2.9 tt -98.78 121.19 40.41 Favored 'General case' 0 N--CA 1.478 0.956 0 N-CA-C 107.002 -1.481 . . . . 0.0 107.002 177.625 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 28.6 ttt -153.0 159.93 42.96 Favored 'General case' 0 N--CA 1.478 0.931 0 N-CA-C 108.057 -1.09 . . . . 0.0 108.057 179.543 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 86.9 t -159.67 150.33 6.42 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.243 0 N-CA-C 106.372 -1.714 . . . . 0.0 106.372 -179.518 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' I' I ' 37' ' ' GLY . . . . . 0.514 ' H ' HE22 ' I' ' 15' ' ' GLN . . . 56.52 74.61 0.31 Allowed Glycine 0 C--N 1.312 -0.762 0 C-N-CA 120.898 -0.668 . . . . 0.0 112.083 177.777 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 170.49 -146.12 9.57 Favored Glycine 0 N--CA 1.466 0.664 0 N-CA-C 110.599 -1.0 . . . . 0.0 110.599 179.131 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 34.0 m -135.67 141.99 40.57 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.807 0 N-CA-C 109.882 -0.414 . . . . 0.0 109.882 -179.834 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 16.2 t . . . . . 0 C--O 1.223 -0.315 0 CA-C-O 118.035 -0.984 . . . . 0.0 111.275 179.465 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 20.2 m-85 . . . . . 0 N--CA 1.47 0.56 0 N-CA-C 109.495 -0.557 . . . . 0.0 109.495 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 31.9 mtp180 -67.96 130.38 42.79 Favored 'General case' 0 C--O 1.218 -0.602 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.154 -178.027 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 48.0 m170 -100.34 131.54 46.22 Favored 'General case' 0 N--CA 1.474 0.733 0 N-CA-C 109.461 -0.57 . . . . 0.0 109.461 179.457 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 13.8 m-20 -71.42 141.03 50.31 Favored 'General case' 0 CA--C 1.53 0.19 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.819 -179.748 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' SER . . . . . 0.41 ' O ' ' O ' ' C' ' 25' ' ' GLY . 8.7 t -143.53 -173.35 3.93 Favored 'General case' 0 N--CA 1.48 1.032 0 N-CA-C 109.016 -0.735 . . . . 0.0 109.016 178.498 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 117.88 11.49 8.4 Favored Glycine 0 N--CA 1.486 1.993 0 N-CA-C 112.543 -0.223 . . . . 0.0 112.543 179.197 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 47.8 p90 -59.2 128.36 36.76 Favored 'General case' 0 N--CA 1.471 0.622 0 CA-C-O 120.768 0.318 . . . . 0.0 111.849 -179.593 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 46.6 mt-10 -89.8 154.67 19.73 Favored 'General case' 0 N--CA 1.471 0.598 0 N-CA-C 109.299 -0.63 . . . . 0.0 109.299 178.548 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -153.58 128.92 1.57 Allowed 'Isoleucine or valine' 0 C--O 1.235 0.297 0 N-CA-C 108.072 -1.084 . . . . 0.0 108.072 178.641 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 50.1 m-70 -135.37 147.04 48.95 Favored 'General case' 0 N--CA 1.49 1.565 0 CA-C-N 118.834 0.743 . . . . 0.0 111.114 -179.108 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 6.4 t60 -164.94 97.57 0.74 Allowed 'General case' 0 N--CA 1.48 1.056 0 CA-C-N 116.568 -0.287 . . . . 0.0 111.139 179.632 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . 0.483 HE22 ' H ' ' A' ' 37' ' ' GLY . 55.1 mt-30 -108.87 -172.49 2.06 Favored 'General case' 0 CA--C 1.503 -0.856 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 -179.969 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -166.81 98.0 0.55 Allowed 'General case' 0 N--CA 1.473 0.691 0 CA-C-N 115.179 -0.918 . . . . 0.0 109.391 178.795 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . 0.42 ' CD1' ' N ' ' A' ' 17' ' ' LEU . 4.5 mp -106.05 164.17 12.19 Favored 'General case' 0 N--CA 1.489 1.488 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 179.99 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 57.8 t -142.39 119.0 6.34 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.301 0 CA-C-O 118.962 -0.542 . . . . 0.0 109.904 179.527 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 53.2 m-85 -69.81 159.46 33.57 Favored 'General case' 0 N--CA 1.481 1.094 0 N-CA-C 107.491 -1.3 . . . . 0.0 107.491 177.186 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 11.7 t80 -171.68 -58.0 0.02 OUTLIER 'General case' 0 N--CA 1.487 1.417 0 CA-C-O 122.386 1.089 . . . . 0.0 109.815 179.65 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -39.32 89.73 0.0 OUTLIER 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 113.91 -1.496 . . . . 0.0 112.973 -178.03 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 37.1 tt0 -65.47 158.48 26.72 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.119 -0.946 . . . . 0.0 110.603 179.077 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 11.5 m-20 -140.74 137.63 33.57 Favored 'General case' 0 N--CA 1.479 0.994 0 C-N-CA 122.984 0.513 . . . . 0.0 110.249 179.702 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 17.7 t -91.7 -116.68 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.483 1.187 0 N-CA-C 108.64 -0.874 . . . . 0.0 108.64 179.576 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.404 ' O ' ' O ' ' B' ' 8' ' ' SER . . . -102.82 56.99 0.6 Allowed Glycine 0 N--CA 1.473 1.166 0 N-CA-C 110.954 -0.858 . . . . 0.0 110.954 179.997 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 79.6 p -85.25 124.74 32.23 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 178.068 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 61.7 t30 -64.58 100.88 0.41 Allowed 'General case' 0 N--CA 1.474 0.728 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 178.874 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 64.7 mttm -97.27 113.98 25.67 Favored 'General case' 0 N--CA 1.484 1.265 0 N-CA-C 110.011 -0.366 . . . . 0.0 110.011 -178.967 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.65 -134.26 0.01 OUTLIER Glycine 0 CA--C 1.534 1.235 0 N-CA-C 110.741 -0.944 . . . . 0.0 110.741 179.103 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -112.56 127.74 56.16 Favored 'General case' 0 N--CA 1.481 1.092 0 N-CA-C 109.155 -0.683 . . . . 0.0 109.155 178.997 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 65.0 mt -90.32 129.24 41.49 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.623 0 N-CA-C 107.532 -1.285 . . . . 0.0 107.532 178.755 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 12.4 mt -142.96 151.92 17.25 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.793 0 CA-C-N 116.2 -0.455 . . . . 0.0 109.943 -178.891 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 65.21 48.9 64.94 Favored Glycine 0 CA--C 1.524 0.632 0 CA-C-N 115.997 -0.547 . . . . 0.0 112.495 179.01 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 2.8 tt -99.03 121.1 40.52 Favored 'General case' 0 N--CA 1.479 1.009 0 N-CA-C 107.143 -1.429 . . . . 0.0 107.143 178.088 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 27.5 ttt -153.24 158.08 41.16 Favored 'General case' 0 N--CA 1.47 0.539 0 N-CA-C 108.847 -0.797 . . . . 0.0 108.847 179.576 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 85.0 t -158.19 149.32 8.66 Favored 'Isoleucine or valine' 0 C--O 1.238 0.47 0 N-CA-C 106.868 -1.53 . . . . 0.0 106.868 -179.577 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . 0.483 ' H ' HE22 ' A' ' 15' ' ' GLN . . . 57.38 72.42 0.59 Allowed Glycine 0 C--N 1.315 -0.616 0 N-CA-C 111.318 -0.713 . . . . 0.0 111.318 178.342 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 172.74 -157.78 27.36 Favored Glycine 0 C--N 1.332 0.326 0 N-CA-C 110.804 -0.918 . . . . 0.0 110.804 -179.895 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 33.4 m -124.07 143.33 37.73 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.934 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 179.502 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 16.4 t . . . . . 0 CA--C 1.536 0.412 0 CA-C-O 118.056 -0.973 . . . . 0.0 111.062 179.152 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 21.4 m-85 . . . . . 0 N--CA 1.47 0.561 0 N-CA-C 109.4 -0.593 . . . . 0.0 109.4 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 32.2 mtp180 -67.94 129.8 41.01 Favored 'General case' 0 N--CA 1.47 0.529 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.214 -178.019 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 47.7 m170 -99.81 131.79 45.57 Favored 'General case' 0 N--CA 1.476 0.854 0 N-CA-C 109.551 -0.537 . . . . 0.0 109.551 179.407 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 7' ' ' ASP . . . . . . . . . . . . . 13.2 m-20 -71.86 141.25 49.58 Favored 'General case' 0 CA--C 1.532 0.259 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.786 -179.688 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 8' ' ' SER . . . . . 0.404 ' O ' ' O ' ' A' ' 25' ' ' GLY . 8.7 t -143.54 -172.98 3.83 Favored 'General case' 0 N--CA 1.478 0.953 0 N-CA-C 109.017 -0.734 . . . . 0.0 109.017 178.417 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 117.45 11.79 8.53 Favored Glycine 0 N--CA 1.484 1.89 0 N-CA-C 112.513 -0.235 . . . . 0.0 112.513 179.241 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 47.4 p90 -59.33 128.09 35.36 Favored 'General case' 0 CA--C 1.54 0.583 0 N-CA-C 111.815 0.302 . . . . 0.0 111.815 -179.628 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 46.5 mt-10 -89.58 154.51 19.93 Favored 'General case' 0 N--CA 1.473 0.705 0 N-CA-C 109.418 -0.586 . . . . 0.0 109.418 178.552 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -153.48 128.31 1.47 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.286 0 N-CA-C 108.3 -1.0 . . . . 0.0 108.3 178.682 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 49.3 m-70 -134.89 147.35 49.82 Favored 'General case' 0 N--CA 1.489 1.514 0 CA-C-N 118.69 0.677 . . . . 0.0 111.044 -178.944 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 6.5 t60 -165.14 97.65 0.72 Allowed 'General case' 0 N--CA 1.481 1.125 0 CA-C-N 116.608 -0.269 . . . . 0.0 110.992 179.593 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . 0.49 HE22 ' H ' ' B' ' 37' ' ' GLY . 54.9 mt-30 -108.79 -172.79 2.12 Favored 'General case' 0 CA--C 1.501 -0.934 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 179.995 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -166.83 98.08 0.55 Allowed 'General case' 0 CA--C 1.541 0.616 0 CA-C-N 115.142 -0.935 . . . . 0.0 109.404 178.815 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . 0.423 ' N ' ' CD1' ' B' ' 17' ' ' LEU . 4.5 mp -106.2 164.2 12.19 Favored 'General case' 0 N--CA 1.487 1.41 0 N-CA-C 108.606 -0.887 . . . . 0.0 108.606 -179.948 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 58.9 t -142.52 118.46 5.65 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.258 0 CA-C-O 118.999 -0.524 . . . . 0.0 109.959 179.527 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 53.8 m-85 -70.04 159.55 33.62 Favored 'General case' 0 N--CA 1.478 0.942 0 N-CA-C 107.409 -1.33 . . . . 0.0 107.409 177.296 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 12.8 t80 -172.36 -56.98 0.02 OUTLIER 'General case' 0 N--CA 1.484 1.271 0 CA-C-O 122.233 1.016 . . . . 0.0 109.851 179.622 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -39.63 90.37 0.0 OUTLIER 'General case' 0 CA--C 1.529 0.138 0 CA-C-N 114.148 -1.387 . . . . 0.0 112.823 -178.163 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 36.9 tt0 -66.13 158.11 29.47 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 115.068 -0.969 . . . . 0.0 110.618 179.163 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 11.8 m-20 -140.18 138.38 35.12 Favored 'General case' 0 N--CA 1.48 1.058 0 C-N-CA 122.978 0.511 . . . . 0.0 110.127 179.697 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 17.9 t -92.73 -116.95 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.484 1.232 0 N-CA-C 108.707 -0.849 . . . . 0.0 108.707 179.543 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 25' ' ' GLY . . . . . 0.41 ' O ' ' O ' ' C' ' 8' ' ' SER . . . -101.89 56.43 0.68 Allowed Glycine 0 N--CA 1.474 1.191 0 N-CA-C 110.835 -0.906 . . . . 0.0 110.835 -179.959 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 78.9 p -85.23 124.82 32.31 Favored 'General case' 0 N--CA 1.466 0.354 0 N-CA-C 108.695 -0.854 . . . . 0.0 108.695 178.047 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 62.2 t30 -64.89 101.42 0.49 Allowed 'General case' 0 N--CA 1.473 0.701 0 N-CA-C 108.731 -0.84 . . . . 0.0 108.731 178.845 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 64.6 mttm -97.81 113.46 25.27 Favored 'General case' 0 N--CA 1.485 1.318 0 N-CA-C 110.029 -0.36 . . . . 0.0 110.029 -178.939 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.06 -134.16 0.01 OUTLIER Glycine 0 CA--C 1.534 1.255 0 N-CA-C 110.834 -0.907 . . . . 0.0 110.834 178.988 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -112.92 127.87 56.32 Favored 'General case' 0 N--CA 1.48 1.03 0 N-CA-C 109.114 -0.699 . . . . 0.0 109.114 179.02 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 64.4 mt -90.39 129.49 41.15 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.588 0 N-CA-C 107.52 -1.289 . . . . 0.0 107.52 178.768 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 12.0 mt -143.19 151.62 17.07 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.848 0 CA-C-N 116.06 -0.518 . . . . 0.0 109.905 -178.799 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 65.59 48.14 70.78 Favored Glycine 0 CA--C 1.526 0.722 0 CA-C-N 116.045 -0.525 . . . . 0.0 112.642 178.956 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 2.9 tt -98.12 121.04 39.56 Favored 'General case' 0 N--CA 1.479 0.981 0 N-CA-C 107.269 -1.382 . . . . 0.0 107.269 177.951 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 27.6 ttt -153.19 157.75 40.74 Favored 'General case' 0 N--CA 1.474 0.758 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 179.528 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 81.4 t -157.96 149.44 8.93 Favored 'Isoleucine or valine' 0 C--O 1.238 0.48 0 N-CA-C 106.676 -1.601 . . . . 0.0 106.676 -179.469 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . 0.49 ' H ' HE22 ' B' ' 15' ' ' GLN . . . 56.96 72.48 0.58 Allowed Glycine 0 C--N 1.314 -0.669 0 CA-C-N 115.621 -0.718 . . . . 0.0 111.394 178.331 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 172.86 -157.73 27.17 Favored Glycine 0 N--CA 1.459 0.233 0 N-CA-C 110.662 -0.975 . . . . 0.0 110.662 -179.946 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 33.5 m -124.06 143.3 37.83 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.933 0 C-N-CA 122.778 0.431 . . . . 0.0 109.891 179.402 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 16.2 t . . . . . 0 N--CA 1.468 0.439 0 CA-C-O 118.045 -0.979 . . . . 0.0 110.986 179.199 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 21.1 m-85 . . . . . 0 N--CA 1.47 0.548 0 N-CA-C 109.479 -0.563 . . . . 0.0 109.479 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 31.9 mtp180 -68.31 129.5 40.1 Favored 'General case' 0 N--CA 1.472 0.666 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.215 -178.001 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 47.4 m170 -99.64 131.41 45.65 Favored 'General case' 0 N--CA 1.474 0.75 0 N-CA-C 109.467 -0.568 . . . . 0.0 109.467 179.455 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 7' ' ' ASP . . . . . . . . . . . . . 13.5 m-20 -71.63 141.0 49.95 Favored 'General case' 0 CA--C 1.531 0.232 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.848 -179.691 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 8' ' ' SER . . . . . 0.41 ' O ' ' O ' ' B' ' 25' ' ' GLY . 8.6 t -143.2 -173.19 3.86 Favored 'General case' 0 N--CA 1.479 1.01 0 N-CA-C 109.002 -0.74 . . . . 0.0 109.002 178.477 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 117.78 11.55 8.44 Favored Glycine 0 N--CA 1.486 1.981 0 N-CA-C 112.44 -0.264 . . . . 0.0 112.44 179.159 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 47.4 p90 -59.17 128.31 36.53 Favored 'General case' 0 CA--C 1.54 0.561 0 CA-C-N 116.907 0.353 . . . . 0.0 111.895 -179.626 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 46.3 mt-10 -89.59 154.68 19.79 Favored 'General case' 0 N--CA 1.473 0.704 0 N-CA-C 109.4 -0.593 . . . . 0.0 109.4 178.5 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -153.87 128.32 1.4 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.233 0 N-CA-C 108.254 -1.017 . . . . 0.0 108.254 178.61 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 49.8 m-70 -134.91 147.18 49.76 Favored 'General case' 0 N--CA 1.491 1.588 0 CA-C-N 118.603 0.638 . . . . 0.0 111.139 -178.89 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 6.4 t60 -165.1 98.03 0.73 Allowed 'General case' 0 N--CA 1.482 1.159 0 CA-C-N 116.601 -0.272 . . . . 0.0 111.094 179.575 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 15' ' ' GLN . . . . . 0.499 HE22 ' H ' ' C' ' 37' ' ' GLY . 55.2 mt-30 -109.29 -172.53 2.06 Favored 'General case' 0 CA--C 1.5 -0.955 0 N-CA-C 108.345 -0.983 . . . . 0.0 108.345 179.972 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -166.77 97.93 0.55 Allowed 'General case' 0 N--CA 1.471 0.59 0 CA-C-N 115.086 -0.961 . . . . 0.0 109.413 178.795 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 17' ' ' LEU . . . . . 0.417 ' N ' ' CD1' ' C' ' 17' ' ' LEU . 4.5 mp -105.91 163.87 12.4 Favored 'General case' 0 N--CA 1.488 1.462 0 N-CA-C 108.603 -0.888 . . . . 0.0 108.603 -179.969 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 59.8 t -142.28 118.65 6.29 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.305 0 CA-C-O 119.025 -0.512 . . . . 0.0 109.813 179.552 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 54.1 m-85 -70.17 159.47 33.89 Favored 'General case' 0 N--CA 1.479 0.986 0 N-CA-C 107.485 -1.302 . . . . 0.0 107.485 177.17 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 12.7 t80 -172.34 -57.05 0.02 OUTLIER 'General case' 0 N--CA 1.484 1.258 0 CA-C-O 122.209 1.004 . . . . 0.0 109.928 179.671 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -39.5 90.54 0.0 OUTLIER 'General case' 0 CA--C 1.53 0.187 0 CA-C-N 114.129 -1.396 . . . . 0.0 112.864 -178.221 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 37.1 tt0 -66.31 158.27 29.51 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.08 -0.964 . . . . 0.0 110.625 179.258 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 11.4 m-20 -140.4 138.18 34.58 Favored 'General case' 0 N--CA 1.478 0.967 0 C-N-CA 123.032 0.533 . . . . 0.0 110.175 179.797 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 18.1 t -92.47 -117.01 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.484 1.238 0 N-CA-C 108.721 -0.844 . . . . 0.0 108.721 179.545 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 25' ' ' GLY . . . . . 0.41 ' O ' ' O ' ' A' ' 8' ' ' SER . . . -101.94 56.65 0.67 Allowed Glycine 0 C--N 1.347 1.192 0 N-CA-C 110.927 -0.869 . . . . 0.0 110.927 -179.995 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 79.2 p -85.36 124.83 32.41 Favored 'General case' 0 N--CA 1.467 0.423 0 N-CA-C 108.683 -0.858 . . . . 0.0 108.683 178.149 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 61.9 t30 -64.88 101.16 0.46 Allowed 'General case' 0 N--CA 1.473 0.717 0 N-CA-C 108.73 -0.841 . . . . 0.0 108.73 178.809 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 28' ' ' LYS . . . . . 0.4 ' O ' ' O ' ' C' ' 29' ' ' GLY . 65.2 mttm -97.47 113.65 25.37 Favored 'General case' 0 N--CA 1.486 1.348 0 N-CA-C 110.064 -0.347 . . . . 0.0 110.064 -178.983 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' C' C ' 29' ' ' GLY . . . . . 0.4 ' O ' ' O ' ' C' ' 28' ' ' LYS . . . -60.2 -134.47 0.01 OUTLIER Glycine 0 CA--C 1.535 1.282 0 N-CA-C 110.798 -0.921 . . . . 0.0 110.798 178.982 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -112.5 128.0 56.21 Favored 'General case' 0 N--CA 1.48 1.075 0 N-CA-C 109.181 -0.674 . . . . 0.0 109.181 178.91 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 64.4 mt -90.6 129.26 41.7 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.674 0 N-CA-C 107.486 -1.301 . . . . 0.0 107.486 178.75 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 12.2 mt -142.96 152.12 17.2 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.806 0 CA-C-N 116.053 -0.521 . . . . 0.0 109.871 -178.88 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 65.04 48.37 71.62 Favored Glycine 0 CA--C 1.525 0.697 0 CA-C-N 116.012 -0.54 . . . . 0.0 112.63 178.982 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 2.8 tt -98.46 121.0 39.84 Favored 'General case' 0 N--CA 1.478 0.955 0 N-CA-C 107.158 -1.423 . . . . 0.0 107.158 177.98 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 27.7 ttt -153.07 158.12 41.46 Favored 'General case' 0 N--CA 1.471 0.584 0 N-CA-C 108.814 -0.81 . . . . 0.0 108.814 179.617 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 78.3 t -158.38 149.46 8.3 Favored 'Isoleucine or valine' 0 C--O 1.237 0.432 0 N-CA-C 106.865 -1.531 . . . . 0.0 106.865 -179.526 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 37' ' ' GLY . . . . . 0.499 ' H ' HE22 ' C' ' 15' ' ' GLN . . . 56.94 72.54 0.57 Allowed Glycine 0 C--N 1.315 -0.616 0 CA-C-N 115.641 -0.709 . . . . 0.0 111.414 178.337 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 172.74 -157.45 26.79 Favored Glycine 0 N--CA 1.461 0.357 0 N-CA-C 110.659 -0.976 . . . . 0.0 110.659 -179.885 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 33.4 m -124.42 143.53 37.52 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.904 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 179.474 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 16.3 t . . . . . 0 N--CA 1.467 0.402 0 CA-C-O 118.118 -0.944 . . . . 0.0 111.082 179.285 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 23.1 m-85 . . . . . 0 N--CA 1.478 0.943 0 N-CA-C 107.913 -1.144 . . . . 0.0 107.913 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' D' D ' 5' ' ' ARG . . . . . . . . . . . . 0.297 39.3 mtp180 -76.43 133.58 39.82 Favored 'General case' 0 C--O 1.214 -0.812 0 N-CA-C 106.852 -1.536 . . . . 0.0 106.852 -168.536 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 51.4 m170 -101.78 133.4 46.58 Favored 'General case' 0 C--N 1.363 1.167 0 CA-C-N 113.931 -1.486 . . . . 0.0 107.776 -176.422 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 7' ' ' ASP . . . . . . . . . . . . . 9.3 m-20 -64.69 124.05 20.91 Favored 'General case' 0 C--N 1.314 -0.964 0 C-N-CA 127.987 2.515 . . . . 0.0 115.331 176.692 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 8' ' ' SER . . . . . . . . . . . . . 8.2 t -133.3 -174.83 3.61 Favored 'General case' 0 N--CA 1.483 1.209 0 CA-C-N 119.928 1.24 . . . . 0.0 109.46 177.367 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 121.88 13.75 4.92 Favored Glycine 0 N--CA 1.483 1.79 0 N-CA-C 110.993 -0.843 . . . . 0.0 110.993 175.476 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 44.7 p90 -58.37 130.18 45.5 Favored 'General case' 0 CA--C 1.539 0.526 0 C-N-CA 120.938 -0.305 . . . . 0.0 111.71 -179.209 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 47.0 mt-10 -89.29 152.57 21.48 Favored 'General case' 0 N--CA 1.477 0.903 0 N-CA-C 110.063 -0.347 . . . . 0.0 110.063 176.679 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -149.54 129.99 4.33 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.522 0 N-CA-C 107.975 -1.12 . . . . 0.0 107.975 174.35 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 47.9 m-70 -129.86 150.31 51.21 Favored 'General case' 0 N--CA 1.482 1.17 0 CA-C-N 117.848 0.295 . . . . 0.0 111.567 176.611 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 6.6 t60 -165.05 104.65 0.78 Allowed 'General case' 0 N--CA 1.484 1.233 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 172.974 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 15' ' ' GLN . . . . . 0.518 HE22 ' H ' ' D' ' 37' ' ' GLY . 55.2 mt-30 -112.46 -175.85 2.78 Favored 'General case' 0 CA--C 1.493 -1.222 0 N-CA-C 108.085 -1.079 . . . . 0.0 108.085 179.188 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -162.92 106.13 1.06 Allowed 'General case' 0 CA--C 1.536 0.419 0 N-CA-C 107.803 -1.184 . . . . 0.0 107.803 175.619 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 5.4 mp -112.47 162.86 15.14 Favored 'General case' 0 N--CA 1.488 1.442 0 N-CA-C 108.134 -1.061 . . . . 0.0 108.134 179.583 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 51.5 t -141.0 123.63 15.38 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.194 0 N-CA-C 109.01 -0.737 . . . . 0.0 109.01 175.962 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 78.5 m-85 -62.65 151.53 37.87 Favored 'General case' 0 C--N 1.349 0.569 0 C-N-CA 125.002 1.321 . . . . 0.0 110.395 170.485 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 8.3 t80 -170.17 -66.78 0.02 OUTLIER 'General case' 0 N--CA 1.476 0.831 0 N-CA-C 107.765 -1.198 . . . . 0.0 107.765 -179.584 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -37.94 95.74 0.01 OUTLIER 'General case' 0 CA--C 1.536 0.419 0 CA-C-N 113.889 -1.505 . . . . 0.0 111.706 -174.505 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 37.3 tt0 -68.32 158.97 32.3 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 113.587 -1.642 . . . . 0.0 110.308 178.654 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 11.5 m-20 -140.6 140.58 35.13 Favored 'General case' 0 N--CA 1.474 0.767 0 N-CA-C 109.646 -0.501 . . . . 0.0 109.646 178.795 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 24' ' ' VAL . . . . . . . . . . . . . 16.0 t -94.44 -120.65 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.381 0 N-CA-C 108.242 -1.021 . . . . 0.0 108.242 179.858 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . -104.65 61.93 0.38 Allowed Glycine 0 C--N 1.375 2.718 0 C-N-CA 117.791 -2.147 . . . . 0.0 109.555 178.866 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 90.9 p -71.57 121.07 18.09 Favored 'General case' 0 C--O 1.246 0.872 0 CA-C-O 115.949 -1.977 . . . . 0.0 112.537 168.01 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 64.7 t30 -60.69 102.06 0.17 Allowed 'General case' 0 N--CA 1.478 0.956 0 CA-C-N 122.278 2.308 . . . . 0.0 109.906 172.212 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 28' ' ' LYS . . . . . 0.403 ' O ' ' O ' ' D' ' 29' ' ' GLY . 64.6 mttm -100.95 116.16 32.14 Favored 'General case' 0 N--CA 1.493 1.714 0 CA-C-N 120.028 1.286 . . . . 0.0 109.157 179.461 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' D' D ' 29' ' ' GLY . . . . . 0.403 ' O ' ' O ' ' D' ' 28' ' ' LYS . . . -54.65 -134.6 0.0 OUTLIER Glycine 0 C--N 1.343 0.94 0 CA-C-N 115.51 -0.768 . . . . 0.0 113.433 176.203 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -112.95 132.58 55.28 Favored 'General case' 0 C--N 1.37 1.464 0 N-CA-C 108.46 -0.941 . . . . 0.0 108.46 174.435 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 66.7 mt -91.75 133.85 31.96 Favored 'Isoleucine or valine' 0 C--N 1.346 0.422 0 N-CA-C 106.888 -1.523 . . . . 0.0 106.888 176.682 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 14.2 mt -145.74 154.28 13.34 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.916 0 N-CA-C 109.092 -0.707 . . . . 0.0 109.092 179.276 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 64.09 47.65 83.26 Favored Glycine 0 C--O 1.246 0.877 0 CA-C-O 119.409 -0.662 . . . . 0.0 112.538 179.243 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 3.4 tt -97.81 132.53 43.34 Favored 'General case' 0 C--N 1.372 1.558 0 N-CA-C 104.593 -2.373 . . . . 0.0 104.593 176.44 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 28.2 ttt -155.96 165.32 36.81 Favored 'General case' 0 N--CA 1.475 0.812 0 N-CA-C 107.705 -1.22 . . . . 0.0 107.705 175.8 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 94.4 t -164.04 155.52 2.11 Favored 'Isoleucine or valine' 0 C--O 1.247 0.959 0 N-CA-C 105.204 -2.147 . . . . 0.0 105.204 175.016 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 37' ' ' GLY . . . . . 0.518 ' H ' HE22 ' D' ' 15' ' ' GLN . . . 61.22 65.15 3.46 Favored Glycine 0 CA--C 1.524 0.637 0 C-N-CA 117.97 -2.062 . . . . 0.0 113.042 176.686 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 168.83 -158.55 31.24 Favored Glycine 0 N--CA 1.465 0.633 0 CA-C-N 118.976 1.388 . . . . 0.0 111.58 -177.921 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 33.1 m -120.23 142.47 35.8 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.17 0 CA-C-N 118.426 1.113 . . . . 0.0 110.243 -178.534 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 13.9 t . . . . . 0 C--O 1.212 -0.916 0 N-CA-C 109.606 -0.516 . . . . 0.0 109.606 174.362 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 20.4 m-85 . . . . . 0 N--CA 1.472 0.665 0 N-CA-C 109.959 -0.386 . . . . 0.0 109.959 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' E' E ' 5' ' ' ARG . . . . . . . . . . . . . 30.6 mtp180 -67.7 130.32 42.64 Favored 'General case' 0 C--O 1.219 -0.517 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.503 -178.12 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 47.7 m170 -100.4 131.02 46.56 Favored 'General case' 0 N--CA 1.475 0.802 0 N-CA-C 109.593 -0.521 . . . . 0.0 109.593 179.37 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' E' E ' 7' ' ' ASP . . . . . . . . . . . . . 17.0 m-20 -71.07 142.33 50.84 Favored 'General case' 0 N--CA 1.464 0.234 0 O-C-N 123.389 0.431 . . . . 0.0 110.979 -179.829 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' E' E ' 8' ' ' SER . . . . . . . . . . . . . 8.4 t -144.85 -172.9 3.93 Favored 'General case' 0 N--CA 1.478 0.938 0 N-CA-C 108.994 -0.743 . . . . 0.0 108.994 178.052 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 118.17 12.23 7.73 Favored Glycine 0 N--CA 1.482 1.742 0 N-CA-C 112.191 -0.364 . . . . 0.0 112.191 179.032 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 43.5 p90 -58.91 127.8 34.04 Favored 'General case' 0 CA--C 1.544 0.733 0 N-CA-C 112.107 0.41 . . . . 0.0 112.107 -179.366 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 46.8 mt-10 -88.46 155.16 19.83 Favored 'General case' 0 N--CA 1.476 0.838 0 N-CA-C 109.43 -0.581 . . . . 0.0 109.43 178.12 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -155.3 127.44 1.0 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.557 0 N-CA-C 108.344 -0.984 . . . . 0.0 108.344 178.539 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 48.0 m-70 -135.27 145.3 47.42 Favored 'General case' 0 N--CA 1.483 1.206 0 CA-C-O 120.704 0.287 . . . . 0.0 111.331 -177.826 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 6.3 t60 -164.0 97.53 0.83 Allowed 'General case' 0 N--CA 1.486 1.334 0 CA-C-N 116.752 -0.204 . . . . 0.0 111.048 179.693 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' E' E ' 15' ' ' GLN . . . . . 0.469 HE22 ' H ' ' E' ' 37' ' ' GLY . 55.6 mt-30 -108.35 -172.62 2.09 Favored 'General case' 0 CA--C 1.502 -0.902 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 -179.94 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -166.57 98.2 0.58 Allowed 'General case' 0 CA--C 1.541 0.621 0 CA-C-N 114.992 -1.004 . . . . 0.0 109.453 178.722 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' E' E ' 17' ' ' LEU . . . . . 0.416 ' N ' ' CD1' ' E' ' 17' ' ' LEU . 4.4 mp -106.14 163.1 13.06 Favored 'General case' 0 N--CA 1.49 1.565 0 N-CA-C 109.239 -0.652 . . . . 0.0 109.239 -179.693 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 42.1 t -142.15 118.14 6.11 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.418 0 C-N-CA 122.558 0.343 . . . . 0.0 110.554 179.158 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 52.8 m-85 -69.17 157.27 37.23 Favored 'General case' 0 C--N 1.356 0.867 0 N-CA-C 107.312 -1.366 . . . . 0.0 107.312 176.582 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 11.5 t80 -173.96 -54.7 0.01 OUTLIER 'General case' 0 N--CA 1.484 1.275 0 CA-C-O 121.717 0.77 . . . . 0.0 110.347 179.469 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.35 88.79 0.0 OUTLIER 'General case' 0 C--N 1.319 -0.751 0 CA-C-N 114.356 -1.293 . . . . 0.0 112.83 -178.974 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 37.4 tt0 -64.48 158.28 24.41 Favored 'General case' 0 N--CA 1.47 0.557 0 CA-C-N 114.944 -1.025 . . . . 0.0 110.681 179.702 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 11.0 m-20 -140.51 138.03 34.26 Favored 'General case' 0 N--CA 1.476 0.833 0 C-N-CA 122.985 0.514 . . . . 0.0 110.483 179.887 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 18.9 t -92.22 -116.79 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.288 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 179.587 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . -102.2 55.13 0.72 Allowed Glycine 0 N--CA 1.473 1.137 0 N-CA-C 111.226 -0.749 . . . . 0.0 111.226 -179.881 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 81.1 p -83.37 124.42 30.63 Favored 'General case' 0 N--CA 1.468 0.443 0 N-CA-C 109.205 -0.665 . . . . 0.0 109.205 177.819 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 62.9 t30 -64.58 101.42 0.46 Allowed 'General case' 0 N--CA 1.474 0.728 0 N-CA-C 108.307 -0.998 . . . . 0.0 108.307 178.725 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 64.3 mttm -98.07 113.32 25.16 Favored 'General case' 0 N--CA 1.488 1.469 0 N-CA-C 109.888 -0.412 . . . . 0.0 109.888 -178.603 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.06 -133.62 0.01 OUTLIER Glycine 0 CA--C 1.533 1.215 0 N-CA-C 111.471 -0.652 . . . . 0.0 111.471 178.894 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -113.19 126.87 55.9 Favored 'General case' 0 N--CA 1.477 0.907 0 N-CA-C 109.265 -0.642 . . . . 0.0 109.265 179.382 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 65.6 mt -90.13 130.24 39.72 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.279 0 N-CA-C 107.104 -1.443 . . . . 0.0 107.104 178.797 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 13.5 mt -142.99 153.42 16.99 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.825 0 N-CA-C 109.069 -0.715 . . . . 0.0 109.069 -179.42 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.71 49.94 65.13 Favored Glycine 0 CA--C 1.524 0.651 0 CA-C-N 116.432 -0.349 . . . . 0.0 113.153 179.022 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 2.9 tt -99.62 120.59 39.92 Favored 'General case' 0 N--CA 1.48 1.03 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 177.599 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 28.1 ttt -152.01 159.18 43.8 Favored 'General case' 0 N--CA 1.477 0.916 0 N-CA-C 108.373 -0.973 . . . . 0.0 108.373 179.578 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 95.7 t -159.49 149.23 6.93 Favored 'Isoleucine or valine' 0 C--O 1.237 0.419 0 N-CA-C 106.605 -1.628 . . . . 0.0 106.605 -179.816 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' E' E ' 37' ' ' GLY . . . . . 0.469 ' H ' HE22 ' E' ' 15' ' ' GLN . . . 57.32 72.19 0.62 Allowed Glycine 0 C--N 1.316 -0.579 0 CA-C-N 115.523 -0.762 . . . . 0.0 111.316 178.155 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 173.72 -155.66 22.45 Favored Glycine 0 C--O 1.219 -0.811 0 N-CA-C 111.123 -0.791 . . . . 0.0 111.123 -179.831 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 33.5 m -126.2 142.59 42.39 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.757 0 N-CA-C 109.203 -0.666 . . . . 0.0 109.203 179.379 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 15.1 t . . . . . 0 CA--C 1.538 0.509 0 CA-C-O 118.109 -0.948 . . . . 0.0 111.218 179.279 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 20.2 m-85 . . . . . 0 N--CA 1.474 0.734 0 CA-C-O 120.941 0.401 . . . . 0.0 109.971 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' F' F ' 5' ' ' ARG . . . . . . . . . . . . . 30.5 mtp180 -67.32 129.98 41.63 Favored 'General case' 0 C--O 1.217 -0.63 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.514 -178.162 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 47.8 m170 -100.43 131.21 46.48 Favored 'General case' 0 N--CA 1.477 0.922 0 N-CA-C 109.572 -0.529 . . . . 0.0 109.572 179.358 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' F' F ' 7' ' ' ASP . . . . . . . . . . . . . 16.6 m-20 -71.37 142.02 50.36 Favored 'General case' 0 N--CA 1.464 0.26 0 O-C-N 123.422 0.451 . . . . 0.0 111.066 -179.786 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' F' F ' 8' ' ' SER . . . . . . . . . . . . . 8.4 t -144.67 -173.13 3.97 Favored 'General case' 0 N--CA 1.478 0.971 0 N-CA-C 108.958 -0.756 . . . . 0.0 108.958 178.002 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 118.6 11.73 7.73 Favored Glycine 0 N--CA 1.482 1.745 0 N-CA-C 112.126 -0.39 . . . . 0.0 112.126 179.072 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 43.4 p90 -58.64 128.22 36.08 Favored 'General case' 0 CA--C 1.544 0.738 0 N-CA-C 112.123 0.416 . . . . 0.0 112.123 -179.31 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 46.8 mt-10 -88.77 155.15 19.74 Favored 'General case' 0 N--CA 1.475 0.817 0 CA-C-O 121.303 0.573 . . . . 0.0 109.585 178.031 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -155.21 127.48 1.02 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.574 0 N-CA-C 108.338 -0.986 . . . . 0.0 108.338 178.505 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 48.0 m-70 -135.32 144.94 46.99 Favored 'General case' 0 N--CA 1.481 1.093 0 CA-C-O 120.681 0.277 . . . . 0.0 111.379 -177.923 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 6.3 t60 -163.78 98.16 0.86 Allowed 'General case' 0 N--CA 1.487 1.406 0 CA-C-N 116.697 -0.229 . . . . 0.0 111.145 179.645 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' F' F ' 15' ' ' GLN . . . . . 0.484 HE22 ' H ' ' F' ' 37' ' ' GLY . 55.8 mt-30 -109.29 -171.97 1.95 Allowed 'General case' 0 CA--C 1.499 -1.015 0 N-CA-C 108.625 -0.88 . . . . 0.0 108.625 -179.911 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -166.84 98.57 0.55 Allowed 'General case' 0 CA--C 1.541 0.609 0 CA-C-N 114.895 -1.048 . . . . 0.0 109.483 178.778 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' F' F ' 17' ' ' LEU . . . . . 0.41 ' CD1' ' N ' ' F' ' 17' ' ' LEU . 4.4 mp -106.24 163.14 13.05 Favored 'General case' 0 N--CA 1.489 1.501 0 N-CA-C 109.141 -0.689 . . . . 0.0 109.141 -179.717 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 42.0 t -142.17 118.3 6.2 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.369 0 C-N-CA 122.507 0.323 . . . . 0.0 110.522 179.088 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 52.7 m-85 -69.27 157.17 37.51 Favored 'General case' 0 C--N 1.355 0.811 0 N-CA-C 107.151 -1.426 . . . . 0.0 107.151 176.563 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 12.3 t80 -173.75 -54.8 0.01 OUTLIER 'General case' 0 N--CA 1.486 1.344 0 CA-C-O 121.785 0.802 . . . . 0.0 109.752 179.688 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.35 88.68 0.0 OUTLIER 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 114.484 -1.234 . . . . 0.0 113.007 -178.893 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 37.0 tt0 -64.36 158.43 23.61 Favored 'General case' 0 N--CA 1.472 0.668 0 CA-C-N 114.999 -1.001 . . . . 0.0 110.895 179.481 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 11.8 m-20 -140.87 137.67 33.38 Favored 'General case' 0 N--CA 1.477 0.909 0 C-N-CA 122.893 0.477 . . . . 0.0 110.458 179.973 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' F' F ' 24' ' ' VAL . . . . . . . . . . . . . 18.6 t -91.88 -116.83 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.391 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 179.544 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -102.11 55.32 0.72 Allowed Glycine 0 N--CA 1.477 1.41 0 N-CA-C 110.953 -0.859 . . . . 0.0 110.953 -179.863 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 79.8 p -83.54 124.19 30.5 Favored 'General case' 0 N--CA 1.47 0.552 0 N-CA-C 109.012 -0.736 . . . . 0.0 109.012 177.726 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 62.3 t30 -64.44 101.47 0.45 Allowed 'General case' 0 N--CA 1.473 0.71 0 N-CA-C 108.375 -0.972 . . . . 0.0 108.375 178.684 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 64.3 mttm -98.04 113.26 25.08 Favored 'General case' 0 N--CA 1.488 1.46 0 N-CA-C 110.029 -0.36 . . . . 0.0 110.029 -178.648 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.07 -133.84 0.01 OUTLIER Glycine 0 CA--C 1.534 1.266 0 N-CA-C 111.559 -0.616 . . . . 0.0 111.559 178.901 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -112.69 127.17 56.05 Favored 'General case' 0 N--CA 1.477 0.885 0 N-CA-C 109.228 -0.656 . . . . 0.0 109.228 179.241 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 65.7 mt -90.53 130.15 40.22 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.286 0 N-CA-C 107.086 -1.45 . . . . 0.0 107.086 178.703 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 13.1 mt -142.9 153.6 17.18 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.763 0 N-CA-C 109.115 -0.698 . . . . 0.0 109.115 -179.33 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.59 49.73 67.14 Favored Glycine 0 CA--C 1.524 0.609 0 CA-C-N 116.486 -0.325 . . . . 0.0 113.141 179.098 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 3.0 tt -99.48 120.79 40.2 Favored 'General case' 0 N--CA 1.478 0.944 0 N-CA-C 107.344 -1.354 . . . . 0.0 107.344 177.747 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 28.1 ttt -152.68 159.86 43.17 Favored 'General case' 0 N--CA 1.472 0.667 0 N-CA-C 109.146 -0.687 . . . . 0.0 109.146 179.343 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 95.4 t -159.75 149.4 6.6 Favored 'Isoleucine or valine' 0 C--O 1.237 0.429 0 N-CA-C 106.907 -1.516 . . . . 0.0 106.907 -179.586 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' F' F ' 37' ' ' GLY . . . . . 0.484 ' H ' HE22 ' F' ' 15' ' ' GLN . . . 57.26 72.68 0.55 Allowed Glycine 0 C--N 1.315 -0.596 0 CA-C-N 115.548 -0.751 . . . . 0.0 111.268 178.195 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 173.44 -155.29 22.04 Favored Glycine 0 C--O 1.219 -0.841 0 N-CA-C 111.119 -0.792 . . . . 0.0 111.119 -179.795 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 33.4 m -126.62 142.5 42.98 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.777 0 N-CA-C 109.206 -0.664 . . . . 0.0 109.206 179.372 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 15.3 t . . . . . 0 CA--C 1.539 0.521 0 CA-C-O 118.0 -1.0 . . . . 0.0 111.301 179.306 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 26.7 m-85 . . . . . 0 N--CA 1.473 0.695 0 CA-C-O 120.849 0.357 . . . . 0.0 110.226 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' G' G ' 5' ' ' ARG . . . . . . . . . . . . . 31.5 mtp180 -66.59 129.44 39.87 Favored 'General case' 0 N--CA 1.47 0.543 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.178 -178.297 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 47.1 m170 -99.96 131.04 46.16 Favored 'General case' 0 N--CA 1.474 0.764 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 179.449 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 16.9 m-20 -72.21 137.85 47.15 Favored 'General case' 0 N--CA 1.466 0.358 0 O-C-N 123.638 0.586 . . . . 0.0 111.418 -179.488 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' G' G ' 8' ' ' SER . . . . . . . . . . . . . 8.0 t -142.16 -173.06 3.72 Favored 'General case' 0 N--CA 1.477 0.9 0 N-CA-C 109.114 -0.699 . . . . 0.0 109.114 178.038 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 119.13 12.97 6.66 Favored Glycine 0 N--CA 1.481 1.67 0 N-CA-C 111.725 -0.55 . . . . 0.0 111.725 179.075 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 47.4 p90 -59.52 128.25 36.09 Favored 'General case' 0 CA--C 1.541 0.604 0 N-CA-C 112.002 0.371 . . . . 0.0 112.002 -179.227 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 46.6 mt-10 -89.13 154.5 20.11 Favored 'General case' 0 N--CA 1.474 0.741 0 CA-C-O 121.208 0.528 . . . . 0.0 109.914 178.685 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 2.7 p -155.99 127.17 0.89 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.039 0 N-CA-C 108.334 -0.988 . . . . 0.0 108.334 178.765 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 51.4 m-70 -134.06 146.44 50.32 Favored 'General case' 0 N--CA 1.476 0.855 0 CA-C-N 115.289 -0.869 . . . . 0.0 110.997 -177.98 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 6.3 t60 -165.41 97.47 0.69 Allowed 'General case' 0 N--CA 1.483 1.181 0 CA-C-N 116.542 -0.299 . . . . 0.0 110.691 179.064 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' G' G ' 15' ' ' GLN . . . . . 0.493 HE22 ' H ' ' G' ' 37' ' ' GLY . 55.6 mt-30 -108.62 -172.6 2.09 Favored 'General case' 0 CA--C 1.501 -0.928 0 N-CA-C 108.574 -0.898 . . . . 0.0 108.574 -179.787 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -166.47 98.69 0.59 Allowed 'General case' 0 CA--C 1.541 0.606 0 CA-C-N 115.018 -0.992 . . . . 0.0 109.383 178.714 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' G' G ' 17' ' ' LEU . . . . . 0.414 ' N ' ' CD1' ' G' ' 17' ' ' LEU . 5.1 mp -106.14 161.79 14.2 Favored 'General case' 0 N--CA 1.487 1.383 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 -179.581 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 40.8 t -142.53 118.74 5.83 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.052 0 CA-C-O 120.766 0.317 . . . . 0.0 110.449 178.724 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 45.8 m-85 -69.71 151.12 46.21 Favored 'General case' 0 C--N 1.369 1.417 0 N-CA-C 107.303 -1.369 . . . . 0.0 107.303 176.761 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 10.3 t80 -171.16 -55.1 0.02 OUTLIER 'General case' 0 N--CA 1.486 1.369 0 CA-C-N 118.006 0.367 . . . . 0.0 110.333 -179.662 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.65 90.25 0.0 OUTLIER 'General case' 0 C--N 1.326 -0.428 0 C-N-CA 123.716 0.807 . . . . 0.0 112.582 -179.819 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 37.1 tt0 -65.2 159.39 23.72 Favored 'General case' 0 N--CA 1.469 0.488 0 CA-C-N 114.669 -1.151 . . . . 0.0 110.086 179.076 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 12.0 m-20 -141.45 137.2 32.0 Favored 'General case' 0 N--CA 1.476 0.842 0 C-N-CA 122.905 0.482 . . . . 0.0 109.986 179.927 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' G' G ' 24' ' ' VAL . . . . . . . . . . . . . 15.8 t -92.31 -116.63 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.106 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 179.682 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -101.93 54.35 0.77 Allowed Glycine 0 N--CA 1.476 1.366 0 N-CA-C 111.581 -0.608 . . . . 0.0 111.581 -179.725 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 80.0 p -82.72 124.34 30.14 Favored 'General case' 0 N--CA 1.469 0.501 0 N-CA-C 108.952 -0.758 . . . . 0.0 108.952 177.864 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 59.1 t30 -64.77 101.35 0.47 Allowed 'General case' 0 N--CA 1.471 0.594 0 N-CA-C 108.585 -0.894 . . . . 0.0 108.585 178.586 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 64.7 mttm -97.32 114.43 26.2 Favored 'General case' 0 N--CA 1.486 1.373 0 N-CA-C 109.891 -0.411 . . . . 0.0 109.891 -178.955 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.69 -132.45 0.01 OUTLIER Glycine 0 CA--C 1.532 1.144 0 N-CA-C 110.767 -0.933 . . . . 0.0 110.767 179.045 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -112.81 126.24 55.22 Favored 'General case' 0 N--CA 1.469 0.508 0 C-N-CA 123.006 0.522 . . . . 0.0 109.661 179.602 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 68.7 mt -89.66 130.7 38.53 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.776 0 N-CA-C 107.263 -1.384 . . . . 0.0 107.263 178.555 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 15.9 mt -143.92 154.35 15.74 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.346 0 CA-C-N 118.945 0.793 . . . . 0.0 108.982 -179.91 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.8 49.02 71.24 Favored Glycine 0 CA--C 1.527 0.811 0 C-N-CA 121.803 -0.237 . . . . 0.0 112.75 179.155 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 2.9 tt -98.93 121.96 41.57 Favored 'General case' 0 N--CA 1.479 0.982 0 N-CA-C 106.953 -1.499 . . . . 0.0 106.953 177.723 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 28.2 ttt -153.76 159.83 42.07 Favored 'General case' 0 N--CA 1.48 1.048 0 N-CA-C 107.999 -1.111 . . . . 0.0 107.999 179.661 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 88.6 t -159.58 149.65 6.71 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 N-CA-C 106.231 -1.766 . . . . 0.0 106.231 -179.735 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' G' G ' 37' ' ' GLY . . . . . 0.493 ' H ' HE22 ' G' ' 15' ' ' GLN . . . 57.01 72.75 0.53 Allowed Glycine 0 C--N 1.314 -0.66 0 C-N-CA 121.055 -0.593 . . . . 0.0 111.781 177.921 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 172.15 -154.08 20.75 Favored Glycine 0 C--O 1.219 -0.838 0 N-CA-C 110.517 -1.033 . . . . 0.0 110.517 179.223 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 34.0 m -127.0 142.91 42.13 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.009 0 CA-C-N 117.041 0.421 . . . . 0.0 109.963 179.951 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 15.6 t . . . . . 0 N--CA 1.466 0.363 0 CA-C-O 118.193 -0.908 . . . . 0.0 111.382 179.631 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 26.2 m-85 . . . . . 0 N--CA 1.474 0.735 0 CA-C-O 120.912 0.387 . . . . 0.0 110.171 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' H' H ' 5' ' ' ARG . . . . . . . . . . . . . 31.0 mtp180 -66.46 129.43 39.81 Favored 'General case' 0 N--CA 1.469 0.477 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.309 -178.254 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 46.2 m170 -100.0 131.17 46.12 Favored 'General case' 0 N--CA 1.474 0.773 0 N-CA-C 109.648 -0.501 . . . . 0.0 109.648 179.4 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 16.3 m-20 -72.42 137.7 46.66 Favored 'General case' 0 N--CA 1.466 0.35 0 O-C-N 123.526 0.517 . . . . 0.0 111.361 -179.484 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' H' H ' 8' ' ' SER . . . . . . . . . . . . . 8.4 t -141.86 -173.61 3.85 Favored 'General case' 0 N--CA 1.475 0.807 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 178.282 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 119.35 12.73 6.67 Favored Glycine 0 N--CA 1.484 1.888 0 N-CA-C 111.802 -0.519 . . . . 0.0 111.802 179.061 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 46.8 p90 -59.33 128.17 35.76 Favored 'General case' 0 CA--C 1.542 0.651 0 N-CA-C 112.042 0.386 . . . . 0.0 112.042 -179.338 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 46.6 mt-10 -88.96 154.34 20.3 Favored 'General case' 0 N--CA 1.475 0.78 0 CA-C-O 121.22 0.533 . . . . 0.0 109.892 178.694 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.7 p -155.77 127.2 0.92 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.009 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 178.712 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 50.8 m-70 -134.08 146.18 50.06 Favored 'General case' 0 N--CA 1.476 0.863 0 CA-C-N 115.313 -0.858 . . . . 0.0 111.203 -178.045 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 6.4 t60 -165.08 97.58 0.73 Allowed 'General case' 0 N--CA 1.483 1.197 0 CA-C-N 116.583 -0.28 . . . . 0.0 110.716 179.039 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' H' H ' 15' ' ' GLN . . . . . 0.503 HE22 ' H ' ' H' ' 37' ' ' GLY . 55.3 mt-30 -108.57 -173.2 2.21 Favored 'General case' 0 CA--C 1.5 -0.966 0 N-CA-C 108.45 -0.945 . . . . 0.0 108.45 -179.787 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -166.12 98.39 0.63 Allowed 'General case' 0 N--CA 1.471 0.578 0 CA-C-N 114.984 -1.007 . . . . 0.0 109.341 178.727 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' H' H ' 17' ' ' LEU . . . . . 0.414 ' N ' ' CD1' ' H' ' 17' ' ' LEU . 5.1 mp -106.08 161.93 14.06 Favored 'General case' 0 N--CA 1.487 1.401 0 N-CA-C 109.394 -0.595 . . . . 0.0 109.394 -179.517 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 40.8 t -142.53 118.55 5.69 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.143 0 CA-C-O 120.775 0.321 . . . . 0.0 110.455 178.885 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 47.4 m-85 -69.85 151.44 45.71 Favored 'General case' 0 C--N 1.368 1.399 0 N-CA-C 107.334 -1.358 . . . . 0.0 107.334 176.59 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 10.9 t80 -172.37 -54.55 0.02 OUTLIER 'General case' 0 N--CA 1.484 1.246 0 CA-C-N 117.909 0.322 . . . . 0.0 110.21 -179.542 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.71 90.69 0.0 OUTLIER 'General case' 0 CA--C 1.534 0.356 0 C-N-CA 123.732 0.813 . . . . 0.0 112.298 -179.979 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 37.4 tt0 -65.74 159.29 25.45 Favored 'General case' 0 N--CA 1.47 0.537 0 CA-C-N 114.776 -1.102 . . . . 0.0 110.003 179.364 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 11.3 m-20 -141.29 137.55 32.54 Favored 'General case' 0 N--CA 1.476 0.837 0 C-N-CA 122.892 0.477 . . . . 0.0 109.919 179.861 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' H' H ' 24' ' ' VAL . . . . . . . . . . . . . 15.4 t -92.6 -116.94 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.09 0 N-CA-C 108.673 -0.862 . . . . 0.0 108.673 179.683 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . -101.48 54.25 0.8 Allowed Glycine 0 N--CA 1.479 1.538 0 N-CA-C 111.506 -0.638 . . . . 0.0 111.506 -179.742 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 80.3 p -82.85 124.54 30.41 Favored 'General case' 0 N--CA 1.469 0.497 0 N-CA-C 108.901 -0.778 . . . . 0.0 108.901 177.939 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 59.5 t30 -64.93 101.43 0.5 Allowed 'General case' 0 N--CA 1.472 0.664 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 178.679 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 65.1 mttm -97.33 114.11 25.84 Favored 'General case' 0 N--CA 1.485 1.321 0 N-CA-C 109.978 -0.378 . . . . 0.0 109.978 -179.021 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.42 -132.6 0.01 OUTLIER Glycine 0 CA--C 1.534 1.245 0 N-CA-C 110.845 -0.902 . . . . 0.0 110.845 179.053 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -112.72 126.28 55.24 Favored 'General case' 0 N--CA 1.471 0.603 0 C-N-CA 123.028 0.531 . . . . 0.0 109.662 179.59 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 68.0 mt -89.71 130.59 38.77 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.761 0 N-CA-C 107.35 -1.352 . . . . 0.0 107.35 178.506 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 16.3 mt -143.97 154.04 15.68 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.367 0 CA-C-N 118.922 0.783 . . . . 0.0 108.972 -179.74 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 64.09 49.01 69.75 Favored Glycine 0 CA--C 1.526 0.768 0 C-N-CA 121.717 -0.277 . . . . 0.0 112.81 179.184 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 2.8 tt -99.02 121.66 41.26 Favored 'General case' 0 N--CA 1.477 0.914 0 N-CA-C 107.035 -1.469 . . . . 0.0 107.035 177.782 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 28.2 ttt -153.4 159.75 42.47 Favored 'General case' 0 N--CA 1.48 1.036 0 N-CA-C 107.991 -1.115 . . . . 0.0 107.991 179.665 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 91.1 t -159.51 149.83 6.73 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 N-CA-C 106.278 -1.749 . . . . 0.0 106.278 -179.775 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' H' H ' 37' ' ' GLY . . . . . 0.503 ' H ' HE22 ' H' ' 15' ' ' GLN . . . 56.67 73.13 0.47 Allowed Glycine 0 C--N 1.313 -0.741 0 C-N-CA 120.982 -0.628 . . . . 0.0 111.727 178.117 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 171.65 -154.73 22.65 Favored Glycine 0 N--CA 1.468 0.806 0 N-CA-C 110.505 -1.038 . . . . 0.0 110.505 179.358 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 33.8 m -126.53 143.16 40.94 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.081 0 C-N-CA 122.663 0.385 . . . . 0.0 109.998 179.975 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 15.3 t . . . . . 0 N--CA 1.467 0.414 0 CA-C-O 118.137 -0.935 . . . . 0.0 111.293 179.544 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 25.9 m-85 . . . . . 0 N--CA 1.472 0.666 0 CA-C-O 120.843 0.354 . . . . 0.0 110.168 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' I' I ' 5' ' ' ARG . . . . . . . . . . . . . 31.0 mtp180 -66.72 129.13 38.85 Favored 'General case' 0 N--CA 1.471 0.625 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.293 -178.281 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 46.2 m170 -99.72 130.97 45.98 Favored 'General case' 0 N--CA 1.474 0.768 0 N-CA-C 109.607 -0.516 . . . . 0.0 109.607 179.42 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 16.2 m-20 -72.05 138.02 47.57 Favored 'General case' 0 N--CA 1.466 0.336 0 O-C-N 123.539 0.525 . . . . 0.0 111.425 -179.546 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' I' I ' 8' ' ' SER . . . . . . . . . . . . . 8.5 t -142.26 -173.8 3.94 Favored 'General case' 0 N--CA 1.475 0.791 0 N-CA-C 109.078 -0.712 . . . . 0.0 109.078 178.388 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 119.46 12.66 6.65 Favored Glycine 0 N--CA 1.482 1.759 0 N-CA-C 111.864 -0.494 . . . . 0.0 111.864 179.185 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 47.5 p90 -59.15 128.38 36.86 Favored 'General case' 0 CA--C 1.541 0.625 0 N-CA-C 112.082 0.401 . . . . 0.0 112.082 -179.378 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 46.5 mt-10 -89.28 154.33 20.19 Favored 'General case' 0 N--CA 1.474 0.737 0 CA-C-O 121.101 0.477 . . . . 0.0 109.956 178.672 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 2.7 p -155.73 127.32 0.94 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.039 0 N-CA-C 108.373 -0.973 . . . . 0.0 108.373 178.722 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 50.2 m-70 -134.23 146.29 49.96 Favored 'General case' 0 N--CA 1.476 0.868 0 CA-C-N 115.276 -0.875 . . . . 0.0 111.145 -178.044 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 6.4 t60 -165.35 97.51 0.7 Allowed 'General case' 0 N--CA 1.484 1.244 0 CA-C-N 116.558 -0.292 . . . . 0.0 110.719 179.069 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' I' I ' 15' ' ' GLN . . . . . 0.506 HE22 ' H ' ' I' ' 37' ' ' GLY . 55.3 mt-30 -108.57 -172.75 2.12 Favored 'General case' 0 CA--C 1.499 -1.002 0 N-CA-C 108.458 -0.941 . . . . 0.0 108.458 -179.737 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -166.48 98.45 0.59 Allowed 'General case' 0 CA--C 1.54 0.565 0 CA-C-N 114.921 -1.036 . . . . 0.0 109.29 178.803 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' I' I ' 17' ' ' LEU . . . . . 0.41 ' CD1' ' N ' ' I' ' 17' ' ' LEU . 5.1 mp -105.97 161.99 13.98 Favored 'General case' 0 N--CA 1.486 1.355 0 N-CA-C 109.448 -0.575 . . . . 0.0 109.448 -179.628 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 40.6 t -142.58 118.5 5.56 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.154 0 C-N-CA 122.494 0.318 . . . . 0.0 110.487 178.849 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 46.7 m-85 -69.92 151.34 45.76 Favored 'General case' 0 C--N 1.367 1.365 0 N-CA-C 107.31 -1.367 . . . . 0.0 107.31 176.712 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 10.9 t80 -172.17 -54.67 0.02 OUTLIER 'General case' 0 N--CA 1.485 1.296 0 CA-C-N 117.843 0.292 . . . . 0.0 110.218 -179.518 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.69 90.72 0.0 OUTLIER 'General case' 0 CA--C 1.536 0.408 0 C-N-CA 123.7 0.8 . . . . 0.0 112.251 -179.936 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 37.5 tt0 -65.69 159.31 25.26 Favored 'General case' 0 N--CA 1.47 0.549 0 CA-C-N 114.751 -1.113 . . . . 0.0 109.993 179.326 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 11.1 m-20 -141.34 137.5 32.42 Favored 'General case' 0 N--CA 1.476 0.836 0 C-N-CA 122.872 0.469 . . . . 0.0 110.034 179.839 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' I' I ' 24' ' ' VAL . . . . . . . . . . . . . 14.9 t -92.68 -116.77 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.112 0 N-CA-C 108.691 -0.855 . . . . 0.0 108.691 179.729 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . -101.51 54.45 0.79 Allowed Glycine 0 N--CA 1.476 1.357 0 CA-C-N 118.556 0.617 . . . . 0.0 111.585 -179.759 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 80.4 p -83.31 123.96 30.14 Favored 'General case' 0 N--CA 1.469 0.5 0 N-CA-C 108.916 -0.772 . . . . 0.0 108.916 178.059 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 59.7 t30 -64.53 101.63 0.47 Allowed 'General case' 0 N--CA 1.473 0.681 0 N-CA-C 108.588 -0.893 . . . . 0.0 108.588 178.618 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 64.7 mttm -97.57 114.28 26.16 Favored 'General case' 0 N--CA 1.486 1.354 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -178.952 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.45 -132.63 0.01 OUTLIER Glycine 0 CA--C 1.532 1.137 0 N-CA-C 110.803 -0.919 . . . . 0.0 110.803 179.093 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -112.73 126.09 55.02 Favored 'General case' 0 N--CA 1.471 0.586 0 C-N-CA 123.058 0.543 . . . . 0.0 109.614 179.601 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 68.3 mt -89.68 130.75 38.47 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.783 0 N-CA-C 107.264 -1.384 . . . . 0.0 107.264 178.61 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 16.2 mt -143.98 154.47 15.65 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.337 0 CA-C-N 118.892 0.769 . . . . 0.0 108.984 -179.807 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.75 48.84 73.19 Favored Glycine 0 CA--C 1.526 0.775 0 C-N-CA 121.678 -0.296 . . . . 0.0 112.792 179.134 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 2.9 tt -98.84 121.94 41.43 Favored 'General case' 0 N--CA 1.478 0.947 0 N-CA-C 106.874 -1.528 . . . . 0.0 106.874 177.741 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 28.2 ttt -153.53 159.72 42.3 Favored 'General case' 0 N--CA 1.478 0.963 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 179.616 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 90.9 t -159.54 149.75 6.73 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.224 0 N-CA-C 106.253 -1.758 . . . . 0.0 106.253 -179.804 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' I' I ' 37' ' ' GLY . . . . . 0.506 ' H ' HE22 ' I' ' 15' ' ' GLN . . . 56.94 72.79 0.53 Allowed Glycine 0 C--N 1.314 -0.69 0 C-N-CA 121.022 -0.609 . . . . 0.0 111.778 178.011 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 171.95 -154.4 21.66 Favored Glycine 0 N--CA 1.468 0.767 0 N-CA-C 110.529 -1.029 . . . . 0.0 110.529 179.257 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 33.8 m -126.61 142.84 42.0 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.064 0 C-N-CA 122.743 0.417 . . . . 0.0 109.994 179.943 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 15.5 t . . . . . 0 N--CA 1.465 0.306 0 CA-C-O 118.239 -0.886 . . . . 0.0 111.328 179.539 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 78.9 m-85 . . . . . 0 N--CA 1.475 0.818 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 71.9 mtp180 -143.84 141.28 30.26 Favored 'General case' 0 N--CA 1.481 1.102 0 N-CA-C 109.079 -0.712 . . . . 0.0 109.079 -179.879 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 76.7 m80 -149.53 119.92 7.37 Favored 'General case' 0 N--CA 1.469 0.502 0 N-CA-C 108.79 -0.819 . . . . 0.0 108.79 179.147 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 8.5 m-20 -68.02 149.95 49.06 Favored 'General case' 0 CA--C 1.53 0.196 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.16 -179.391 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 7.6 t -167.13 171.36 11.0 Favored 'General case' 0 N--CA 1.472 0.655 0 N-CA-C 109.551 -0.537 . . . . 0.0 109.551 178.581 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.48 23.65 2.31 Favored Glycine 0 N--CA 1.488 2.156 0 N-CA-C 112.209 -0.356 . . . . 0.0 112.209 179.37 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 42.8 p90 -56.64 128.37 36.02 Favored 'General case' 0 N--CA 1.475 0.815 0 N-CA-C 112.078 0.399 . . . . 0.0 112.078 -179.83 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . 0.481 ' CG ' HD22 ' C' ' 27' ' ' ASN . 45.5 mt-10 -85.05 154.66 21.94 Favored 'General case' 0 C--N 1.344 0.358 0 N-CA-C 109.08 -0.711 . . . . 0.0 109.08 178.535 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -153.69 129.5 1.72 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.371 0 N-CA-C 108.151 -1.055 . . . . 0.0 108.151 178.928 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 48.6 m-70 -134.93 144.99 47.77 Favored 'General case' 0 N--CA 1.489 1.49 0 CA-C-N 118.683 0.674 . . . . 0.0 111.104 -179.116 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -165.9 98.31 0.65 Allowed 'General case' 0 N--CA 1.482 1.169 0 CA-C-N 116.603 -0.271 . . . . 0.0 110.984 179.628 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . 0.486 HE22 ' H ' ' A' ' 37' ' ' GLY . 61.7 mt-30 -108.54 -172.05 1.98 Allowed 'General case' 0 CA--C 1.503 -0.831 0 N-CA-C 108.174 -1.047 . . . . 0.0 108.174 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -165.96 97.24 0.63 Allowed 'General case' 0 N--CA 1.471 0.613 0 CA-C-N 115.16 -0.927 . . . . 0.0 109.348 178.739 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . 0.41 ' CD1' ' N ' ' A' ' 17' ' ' LEU . 4.7 mp -106.03 164.18 12.18 Favored 'General case' 0 N--CA 1.488 1.474 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 179.931 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 49.9 t -141.71 119.18 8.07 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.339 0 CA-C-O 118.888 -0.577 . . . . 0.0 109.98 179.657 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 50.9 m-85 -69.95 159.23 34.13 Favored 'General case' 0 N--CA 1.48 1.071 0 N-CA-C 107.573 -1.269 . . . . 0.0 107.573 177.287 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 12.9 t80 -171.44 -58.02 0.02 OUTLIER 'General case' 0 N--CA 1.485 1.305 0 CA-C-O 122.33 1.062 . . . . 0.0 109.772 179.481 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -38.83 90.48 0.0 OUTLIER 'General case' 0 C--O 1.232 0.165 0 CA-C-N 113.888 -1.505 . . . . 0.0 112.866 -177.929 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 54.4 tt0 -67.57 157.93 33.23 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 115.006 -0.997 . . . . 0.0 110.532 179.145 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 67.3 m-20 -140.02 137.72 34.87 Favored 'General case' 0 N--CA 1.481 1.112 0 C-N-CA 122.891 0.476 . . . . 0.0 110.339 179.762 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 17.2 t -84.42 -116.44 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.912 0 N-CA-C 108.51 -0.922 . . . . 0.0 108.51 179.541 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -110.67 54.5 0.54 Allowed Glycine 0 N--CA 1.473 1.137 0 N-CA-C 111.21 -0.756 . . . . 0.0 111.21 -179.935 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 70.5 p -80.12 126.24 30.83 Favored 'General case' 0 C--O 1.221 -0.434 0 N-CA-C 108.983 -0.747 . . . . 0.0 108.983 178.422 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . 0.491 HD22 ' CG ' ' B' ' 11' ' ' GLU . 50.0 t30 -66.91 100.01 0.69 Allowed 'General case' 0 N--CA 1.472 0.644 0 N-CA-C 108.693 -0.854 . . . . 0.0 108.693 178.582 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 66.7 mttm -96.42 120.13 36.16 Favored 'General case' 0 N--CA 1.484 1.243 0 N-CA-C 110.087 -0.338 . . . . 0.0 110.087 -179.081 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.78 -126.36 0.01 OUTLIER Glycine 0 CA--C 1.532 1.154 0 N-CA-C 110.488 -1.045 . . . . 0.0 110.488 178.615 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -127.48 133.83 49.85 Favored 'General case' 0 N--CA 1.479 1.0 0 N-CA-C 109.294 -0.632 . . . . 0.0 109.294 179.112 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 66.9 mt -83.22 138.61 19.01 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.589 0 N-CA-C 107.136 -1.431 . . . . 0.0 107.136 178.54 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 18.7 mt -128.59 128.75 68.29 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.961 0 O-C-N 123.504 0.503 . . . . 0.0 110.123 -178.547 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 60.78 79.25 0.12 Allowed Glycine 0 CA--C 1.527 0.837 0 CA-C-N 116.003 -0.544 . . . . 0.0 112.95 178.898 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 2.0 tt -110.94 118.85 37.2 Favored 'General case' 0 N--CA 1.478 0.926 0 N-CA-C 106.932 -1.507 . . . . 0.0 106.932 177.432 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 8.8 ttt -155.04 161.02 41.45 Favored 'General case' 0 N--CA 1.469 0.504 0 N-CA-C 109.077 -0.712 . . . . 0.0 109.077 179.339 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 93.6 t -157.96 150.73 8.14 Favored 'Isoleucine or valine' 0 C--O 1.234 0.277 0 N-CA-C 106.83 -1.545 . . . . 0.0 106.83 -179.598 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . 0.486 ' H ' HE22 ' A' ' 15' ' ' GLN . . . 55.6 75.17 0.25 Allowed Glycine 0 C--N 1.314 -0.689 0 CA-C-N 115.703 -0.68 . . . . 0.0 111.739 178.332 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 168.83 -148.72 12.65 Favored Glycine 0 CA--C 1.519 0.305 0 N-CA-C 110.692 -0.963 . . . . 0.0 110.692 179.742 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 21.1 m -132.9 142.47 42.2 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.887 0 N-CA-C 109.624 -0.509 . . . . 0.0 109.624 179.82 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 21.3 t . . . . . 0 N--CA 1.468 0.43 0 CA-C-O 117.851 -1.071 . . . . 0.0 110.725 179.225 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 79.8 m-85 . . . . . 0 N--CA 1.474 0.766 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 71.7 mtp180 -143.94 141.39 30.19 Favored 'General case' 0 N--CA 1.481 1.079 0 N-CA-C 109.136 -0.69 . . . . 0.0 109.136 -179.861 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 76.9 m80 -149.66 120.01 7.36 Favored 'General case' 0 N--CA 1.471 0.581 0 N-CA-C 108.772 -0.825 . . . . 0.0 108.772 179.117 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 7' ' ' ASP . . . . . . . . . . . . . 8.5 m-20 -67.96 149.45 49.75 Favored 'General case' 0 CA--C 1.531 0.217 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.226 -179.414 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 8' ' ' SER . . . . . . . . . . . . . 7.4 t -166.71 171.57 11.4 Favored 'General case' 0 N--CA 1.473 0.691 0 N-CA-C 109.583 -0.525 . . . . 0.0 109.583 178.501 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.26 23.94 2.31 Favored Glycine 0 N--CA 1.488 2.135 0 N-CA-C 112.122 -0.391 . . . . 0.0 112.122 179.425 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 42.4 p90 -56.9 128.11 35.18 Favored 'General case' 0 N--CA 1.473 0.681 0 N-CA-C 112.159 0.429 . . . . 0.0 112.159 -179.864 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 11' ' ' GLU . . . . . 0.491 ' CG ' HD22 ' A' ' 27' ' ' ASN . 45.5 mt-10 -84.79 154.61 22.26 Favored 'General case' 0 N--CA 1.469 0.486 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 178.532 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -153.59 129.32 1.69 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.333 0 N-CA-C 108.268 -1.012 . . . . 0.0 108.268 178.914 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 48.6 m-70 -134.82 145.16 48.08 Favored 'General case' 0 N--CA 1.49 1.559 0 CA-C-N 118.556 0.616 . . . . 0.0 111.052 -179.062 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -166.11 98.33 0.63 Allowed 'General case' 0 N--CA 1.483 1.214 0 CA-C-N 116.607 -0.269 . . . . 0.0 110.96 179.654 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . 0.495 HE22 ' H ' ' B' ' 37' ' ' GLY . 61.9 mt-30 -108.56 -172.2 2.01 Favored 'General case' 0 CA--C 1.503 -0.854 0 N-CA-C 108.201 -1.037 . . . . 0.0 108.201 -179.901 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -165.95 96.95 0.63 Allowed 'General case' 0 CA--C 1.54 0.581 0 CA-C-N 115.121 -0.945 . . . . 0.0 109.337 178.817 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . 0.411 ' N ' ' CD1' ' B' ' 17' ' ' LEU . 4.9 mp -105.88 164.14 12.18 Favored 'General case' 0 N--CA 1.487 1.398 0 N-CA-C 108.611 -0.885 . . . . 0.0 108.611 179.868 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 53.9 t -141.69 119.16 8.08 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.269 0 CA-C-O 118.939 -0.553 . . . . 0.0 109.982 179.577 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 51.6 m-85 -70.41 159.3 34.45 Favored 'General case' 0 N--CA 1.479 0.983 0 N-CA-C 107.557 -1.275 . . . . 0.0 107.557 177.248 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 13.9 t80 -172.14 -57.25 0.02 OUTLIER 'General case' 0 N--CA 1.483 1.211 0 CA-C-O 122.2 1.0 . . . . 0.0 109.792 179.522 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -38.88 90.83 0.0 OUTLIER 'General case' 0 CA--C 1.529 0.159 0 CA-C-N 114.136 -1.393 . . . . 0.0 112.797 -178.005 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 54.2 tt0 -67.93 157.71 34.39 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 115.028 -0.987 . . . . 0.0 110.547 179.314 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 67.3 m-20 -139.86 137.75 35.16 Favored 'General case' 0 N--CA 1.481 1.082 0 C-N-CA 122.954 0.502 . . . . 0.0 110.287 179.71 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 18.1 t -84.66 -116.4 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.988 0 N-CA-C 108.577 -0.897 . . . . 0.0 108.577 179.665 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -110.13 54.37 0.55 Allowed Glycine 0 C--N 1.349 1.253 0 N-CA-C 111.167 -0.773 . . . . 0.0 111.167 -179.951 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 73.1 p -80.39 125.91 30.51 Favored 'General case' 0 C--O 1.221 -0.432 0 N-CA-C 109.037 -0.727 . . . . 0.0 109.037 178.434 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 27' ' ' ASN . . . . . 0.502 HD22 ' CG ' ' C' ' 11' ' ' GLU . 50.4 t30 -66.73 100.41 0.7 Allowed 'General case' 0 N--CA 1.473 0.708 0 N-CA-C 108.657 -0.868 . . . . 0.0 108.657 178.613 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 66.7 mttm -96.81 120.04 36.41 Favored 'General case' 0 N--CA 1.483 1.205 0 N-CA-C 110.132 -0.321 . . . . 0.0 110.132 -179.035 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.57 -126.04 0.01 OUTLIER Glycine 0 CA--C 1.534 1.28 0 N-CA-C 110.453 -1.059 . . . . 0.0 110.453 178.618 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.13 133.75 49.02 Favored 'General case' 0 N--CA 1.48 1.026 0 N-CA-C 109.269 -0.641 . . . . 0.0 109.269 179.185 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 67.0 mt -83.15 138.6 19.04 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.476 0 N-CA-C 107.204 -1.406 . . . . 0.0 107.204 178.535 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 19.1 mt -128.53 128.42 68.02 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.928 0 O-C-N 123.537 0.523 . . . . 0.0 110.21 -178.412 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 60.96 78.98 0.13 Allowed Glycine 0 CA--C 1.526 0.777 0 CA-C-N 116.016 -0.538 . . . . 0.0 112.955 178.848 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 2.0 tt -110.71 118.88 37.38 Favored 'General case' 0 N--CA 1.476 0.869 0 N-CA-C 106.94 -1.504 . . . . 0.0 106.94 177.386 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 8.8 ttt -155.0 161.05 41.48 Favored 'General case' 0 N--CA 1.47 0.552 0 N-CA-C 109.096 -0.705 . . . . 0.0 109.096 179.247 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 92.9 t -158.04 150.73 8.06 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.192 0 N-CA-C 106.744 -1.576 . . . . 0.0 106.744 -179.555 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . 0.495 ' H ' HE22 ' B' ' 15' ' ' GLN . . . 55.44 75.31 0.25 Allowed Glycine 0 C--N 1.314 -0.654 0 CA-C-N 115.628 -0.714 . . . . 0.0 111.797 178.422 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 168.57 -149.14 13.4 Favored Glycine 0 CA--C 1.519 0.292 0 N-CA-C 110.686 -0.966 . . . . 0.0 110.686 179.76 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 21.5 m -132.36 142.7 41.97 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.834 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 179.65 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 21.3 t . . . . . 0 N--CA 1.467 0.41 0 CA-C-O 117.789 -1.101 . . . . 0.0 110.765 179.309 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 78.6 m-85 . . . . . 0 N--CA 1.475 0.797 0 N-CA-C 109.878 -0.416 . . . . 0.0 109.878 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 71.9 mtp180 -143.76 141.36 30.4 Favored 'General case' 0 N--CA 1.482 1.131 0 N-CA-C 109.077 -0.712 . . . . 0.0 109.077 -179.905 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 76.8 m80 -149.63 119.76 7.24 Favored 'General case' 0 N--CA 1.469 0.523 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 179.145 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 7' ' ' ASP . . . . . . . . . . . . . 8.2 m-20 -67.7 149.55 49.85 Favored 'General case' 0 N--CA 1.463 0.199 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.227 -179.41 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 8' ' ' SER . . . . . . . . . . . . . 7.6 t -166.97 171.14 11.44 Favored 'General case' 0 N--CA 1.473 0.682 0 N-CA-C 109.499 -0.556 . . . . 0.0 109.499 178.429 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.83 23.76 2.21 Favored Glycine 0 N--CA 1.487 2.093 0 N-CA-C 112.099 -0.4 . . . . 0.0 112.099 179.355 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 42.1 p90 -56.63 127.99 34.14 Favored 'General case' 0 N--CA 1.473 0.718 0 N-CA-C 112.125 0.417 . . . . 0.0 112.125 -179.847 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 11' ' ' GLU . . . . . 0.502 ' CG ' HD22 ' B' ' 27' ' ' ASN . 45.8 mt-10 -84.74 154.73 22.24 Favored 'General case' 0 N--CA 1.468 0.448 0 N-CA-C 109.126 -0.694 . . . . 0.0 109.126 178.507 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -153.61 129.24 1.65 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.293 0 N-CA-C 108.274 -1.01 . . . . 0.0 108.274 178.863 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 48.7 m-70 -134.71 144.95 48.05 Favored 'General case' 0 N--CA 1.489 1.517 0 CA-C-N 118.635 0.652 . . . . 0.0 111.043 -179.012 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -165.95 98.51 0.64 Allowed 'General case' 0 N--CA 1.483 1.184 0 CA-C-N 116.578 -0.283 . . . . 0.0 111.013 179.665 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' C' C ' 15' ' ' GLN . . . . . 0.478 HE22 ' H ' ' C' ' 37' ' ' GLY . 62.3 mt-30 -108.91 -172.21 2.0 Favored 'General case' 0 CA--C 1.501 -0.939 0 N-CA-C 108.276 -1.009 . . . . 0.0 108.276 -179.959 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -165.87 97.38 0.64 Allowed 'General case' 0 CA--C 1.54 0.587 0 CA-C-N 115.104 -0.953 . . . . 0.0 109.348 178.749 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 17' ' ' LEU . . . . . 0.408 ' N ' ' CD1' ' C' ' 17' ' ' LEU . 4.8 mp -106.07 163.99 12.34 Favored 'General case' 0 N--CA 1.488 1.433 0 N-CA-C 108.577 -0.897 . . . . 0.0 108.577 179.937 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 53.7 t -141.62 119.19 8.28 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.283 0 CA-C-O 119.05 -0.5 . . . . 0.0 109.885 179.529 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 51.2 m-85 -70.47 159.28 34.54 Favored 'General case' 0 N--CA 1.478 0.964 0 N-CA-C 107.469 -1.308 . . . . 0.0 107.469 177.299 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 14.2 t80 -171.96 -57.33 0.02 OUTLIER 'General case' 0 N--CA 1.482 1.15 0 CA-C-O 122.24 1.019 . . . . 0.0 109.847 179.461 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -38.77 90.72 0.0 OUTLIER 'General case' 0 C--O 1.232 0.144 0 CA-C-N 114.129 -1.396 . . . . 0.0 112.804 -178.024 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 54.0 tt0 -67.88 157.7 34.31 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.122 -0.945 . . . . 0.0 110.595 179.254 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 67.4 m-20 -139.86 137.96 35.33 Favored 'General case' 0 N--CA 1.482 1.134 0 C-N-CA 122.854 0.462 . . . . 0.0 110.245 179.728 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 17.7 t -84.85 -116.44 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.985 0 N-CA-C 108.506 -0.924 . . . . 0.0 108.506 179.693 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -110.12 54.27 0.55 Allowed Glycine 0 N--CA 1.474 1.227 0 N-CA-C 111.175 -0.77 . . . . 0.0 111.175 -179.865 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 73.8 p -80.32 126.18 30.82 Favored 'General case' 0 C--O 1.22 -0.455 0 N-CA-C 109.07 -0.715 . . . . 0.0 109.07 178.414 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 27' ' ' ASN . . . . . 0.481 HD22 ' CG ' ' A' ' 11' ' ' GLU . 51.0 t30 -66.94 100.28 0.72 Allowed 'General case' 0 N--CA 1.473 0.704 0 N-CA-C 108.673 -0.862 . . . . 0.0 108.673 178.563 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 66.9 mttm -96.79 119.68 35.72 Favored 'General case' 0 N--CA 1.482 1.172 0 N-CA-C 110.238 -0.282 . . . . 0.0 110.238 -179.169 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.31 -125.96 0.01 OUTLIER Glycine 0 CA--C 1.534 1.268 0 N-CA-C 110.534 -1.026 . . . . 0.0 110.534 178.727 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.01 133.7 49.17 Favored 'General case' 0 N--CA 1.482 1.14 0 N-CA-C 109.263 -0.643 . . . . 0.0 109.263 179.171 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 67.3 mt -83.12 138.54 19.15 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.456 0 N-CA-C 107.129 -1.434 . . . . 0.0 107.129 178.538 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 18.0 mt -128.5 128.74 68.44 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.987 0 O-C-N 123.626 0.579 . . . . 0.0 110.16 -178.519 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 60.67 78.93 0.13 Allowed Glycine 0 CA--C 1.527 0.797 0 CA-C-N 116.018 -0.537 . . . . 0.0 113.033 178.844 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 2.0 tt -110.58 118.94 37.58 Favored 'General case' 0 N--CA 1.477 0.89 0 N-CA-C 106.902 -1.518 . . . . 0.0 106.902 177.37 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 8.7 ttt -155.07 160.94 41.38 Favored 'General case' 0 N--CA 1.469 0.501 0 N-CA-C 109.125 -0.694 . . . . 0.0 109.125 179.185 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 93.0 t -157.93 150.57 8.28 Favored 'Isoleucine or valine' 0 C--O 1.233 0.203 0 N-CA-C 106.74 -1.578 . . . . 0.0 106.74 -179.566 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 37' ' ' GLY . . . . . 0.478 ' H ' HE22 ' C' ' 15' ' ' GLN . . . 55.7 75.32 0.25 Allowed Glycine 0 C--N 1.314 -0.649 0 CA-C-N 115.691 -0.686 . . . . 0.0 111.814 178.368 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 168.61 -148.78 12.84 Favored Glycine 0 CA--C 1.52 0.382 0 N-CA-C 110.631 -0.988 . . . . 0.0 110.631 179.862 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 21.5 m -132.89 142.56 41.97 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.814 0 N-CA-C 109.696 -0.483 . . . . 0.0 109.696 179.707 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 21.3 t . . . . . 0 N--CA 1.468 0.443 0 CA-C-O 117.772 -1.109 . . . . 0.0 110.801 179.376 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 87.7 m-85 . . . . . 0 N--CA 1.473 0.71 0 N-CA-C 108.283 -1.006 . . . . 0.0 108.283 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' D' D ' 5' ' ' ARG . . . . . . . . . . . . . 71.2 mtp180 -147.45 141.35 25.84 Favored 'General case' 0 N--CA 1.475 0.82 0 N-CA-C 108.961 -0.755 . . . . 0.0 108.961 179.746 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 77.1 m80 -149.17 123.6 9.67 Favored 'General case' 0 CA--C 1.538 0.51 0 N-CA-C 107.891 -1.152 . . . . 0.0 107.891 175.875 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 7' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -63.3 133.55 54.34 Favored 'General case' 0 C--N 1.321 -0.668 0 C-N-CA 127.049 2.139 . . . . 0.0 114.697 176.251 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 8' ' ' SER . . . . . . . . . . . . . 6.6 t -154.03 173.56 15.85 Favored 'General case' 0 N--CA 1.478 0.951 0 CA-C-N 118.533 0.606 . . . . 0.0 110.296 177.074 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 124.29 20.45 2.44 Favored Glycine 0 N--CA 1.485 1.917 0 N-CA-C 112.126 -0.39 . . . . 0.0 112.126 176.579 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 37.2 p90 -55.81 130.46 43.56 Favored 'General case' 0 CA--C 1.546 0.804 0 CA-C-O 121.126 0.489 . . . . 0.0 111.889 -177.355 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 11' ' ' GLU . . . . . 0.452 ' CG ' HD22 ' F' ' 27' ' ' ASN . 46.0 mt-10 -85.26 152.42 23.33 Favored 'General case' 0 N--CA 1.473 0.694 0 N-CA-C 109.732 -0.469 . . . . 0.0 109.732 177.763 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -149.51 130.05 4.41 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.472 0 N-CA-C 108.222 -1.029 . . . . 0.0 108.222 175.593 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 46.9 m-70 -129.64 148.07 51.49 Favored 'General case' 0 N--CA 1.483 1.201 0 CA-C-N 118.009 0.368 . . . . 0.0 111.423 176.708 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -165.37 104.76 0.74 Allowed 'General case' 0 N--CA 1.483 1.207 0 N-CA-C 109.623 -0.51 . . . . 0.0 109.623 173.453 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' D' D ' 15' ' ' GLN . . . . . 0.501 HE22 ' H ' ' D' ' 37' ' ' GLY . 61.5 mt-30 -112.02 -175.66 2.74 Favored 'General case' 0 CA--C 1.493 -1.214 0 N-CA-C 108.019 -1.104 . . . . 0.0 108.019 179.348 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 88.7 tttt -162.09 105.9 1.19 Allowed 'General case' 0 CA--C 1.538 0.506 0 N-CA-C 107.603 -1.258 . . . . 0.0 107.603 175.386 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 5.7 mp -112.69 163.07 15.0 Favored 'General case' 0 N--CA 1.487 1.407 0 N-CA-C 108.095 -1.076 . . . . 0.0 108.095 179.536 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 48.1 t -140.92 123.59 15.56 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.072 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 176.158 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 76.1 m-85 -62.77 151.3 39.06 Favored 'General case' 0 C--N 1.351 0.652 0 C-N-CA 124.688 1.195 . . . . 0.0 110.386 170.774 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 9.0 t80 -169.86 -66.59 0.02 OUTLIER 'General case' 0 N--CA 1.476 0.827 0 N-CA-C 107.816 -1.179 . . . . 0.0 107.816 -179.707 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -37.83 96.11 0.01 OUTLIER 'General case' 0 CA--C 1.536 0.425 0 CA-C-N 113.919 -1.491 . . . . 0.0 111.583 -174.353 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 54.1 tt0 -69.98 158.52 35.48 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 113.459 -1.7 . . . . 0.0 110.17 178.767 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 68.1 m-20 -140.14 141.32 36.07 Favored 'General case' 0 N--CA 1.477 0.875 0 N-CA-C 109.496 -0.557 . . . . 0.0 109.496 178.581 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 24' ' ' VAL . . . . . . . . . . . . . 19.7 t -87.7 -119.19 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.486 1.372 0 N-CA-C 107.91 -1.144 . . . . 0.0 107.91 179.816 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . -113.93 61.98 0.33 Allowed Glycine 0 C--N 1.371 2.495 0 C-N-CA 118.073 -2.013 . . . . 0.0 109.441 178.612 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 89.1 p -70.54 121.37 17.7 Favored 'General case' 0 C--O 1.24 0.601 0 CA-C-O 116.521 -1.704 . . . . 0.0 112.184 169.162 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 27' ' ' ASN . . . . . 0.432 HD22 ' CG ' ' E' ' 11' ' ' GLU . 57.1 t30 -61.4 101.83 0.2 Allowed 'General case' 0 N--CA 1.475 0.788 0 CA-C-N 121.625 2.011 . . . . 0.0 109.489 172.464 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 66.5 mttm -100.17 121.44 41.44 Favored 'General case' 0 N--CA 1.488 1.453 0 CA-C-N 119.681 1.128 . . . . 0.0 109.378 178.673 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -53.96 -130.12 0.0 OUTLIER Glycine 0 CA--C 1.529 0.938 0 CA-C-N 115.535 -0.757 . . . . 0.0 112.284 175.008 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -125.23 139.84 53.38 Favored 'General case' 0 C--N 1.37 1.498 0 N-CA-C 108.666 -0.864 . . . . 0.0 108.666 174.278 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 66.4 mt -83.9 141.12 15.2 Favored 'Isoleucine or valine' 0 C--O 1.239 0.527 0 N-CA-C 107.145 -1.428 . . . . 0.0 107.145 176.29 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 25.6 mt -131.31 132.89 62.81 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.058 0 N-CA-C 108.59 -0.893 . . . . 0.0 108.59 178.253 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.88 77.16 0.21 Allowed Glycine 0 C--O 1.248 1.014 0 CA-C-O 118.351 -1.249 . . . . 0.0 112.618 178.791 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 2.5 tt -109.87 131.06 55.41 Favored 'General case' 0 C--N 1.376 1.756 0 N-CA-C 104.135 -2.543 . . . . 0.0 104.135 174.722 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 8.5 ttt -157.12 166.69 32.56 Favored 'General case' 0 C--O 1.219 -0.544 0 N-CA-C 108.794 -0.817 . . . . 0.0 108.794 176.44 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 88.8 t -163.57 154.78 2.45 Favored 'Isoleucine or valine' 0 C--O 1.24 0.566 0 N-CA-C 105.476 -2.046 . . . . 0.0 105.476 175.075 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 37' ' ' GLY . . . . . 0.501 ' H ' HE22 ' D' ' 15' ' ' GLN . . . 61.15 66.54 2.61 Favored Glycine 0 N--CA 1.444 -0.769 0 C-N-CA 117.875 -2.107 . . . . 0.0 113.674 177.125 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 166.82 -147.67 12.28 Favored Glycine 0 N--CA 1.466 0.688 0 CA-C-O 117.807 -1.552 . . . . 0.0 112.2 -179.045 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 22.4 m -130.11 142.88 42.64 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.112 0 CA-C-N 119.304 1.552 . . . . 0.0 109.429 -179.439 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 18.7 t . . . . . 0 C--O 1.214 -0.776 0 N-CA-C 109.169 -0.678 . . . . 0.0 109.169 174.944 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 79.2 m-85 . . . . . 0 N--CA 1.475 0.811 0 N-CA-C 109.949 -0.389 . . . . 0.0 109.949 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' E' E ' 5' ' ' ARG . . . . . . . . . . . . . 71.5 mtp180 -143.77 142.26 30.82 Favored 'General case' 0 N--CA 1.476 0.842 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 179.886 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 76.7 m80 -150.53 118.24 6.17 Favored 'General case' 0 N--CA 1.472 0.662 0 N-CA-C 108.926 -0.768 . . . . 0.0 108.926 179.129 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' E' E ' 7' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -66.16 149.63 50.01 Favored 'General case' 0 N--CA 1.465 0.289 0 O-C-N 123.542 0.526 . . . . 0.0 111.559 -179.606 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' E' E ' 8' ' ' SER . . . . . . . . . . . . . 6.7 t -167.12 172.53 9.94 Favored 'General case' 0 N--CA 1.477 0.891 0 CA-C-N 115.86 -0.609 . . . . 0.0 109.563 178.033 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.95 23.67 2.19 Favored Glycine 0 N--CA 1.482 1.716 0 N-CA-C 112.018 -0.433 . . . . 0.0 112.018 179.096 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 39.2 p90 -56.18 127.26 29.82 Favored 'General case' 0 N--CA 1.473 0.724 0 N-CA-C 112.639 0.607 . . . . 0.0 112.639 -179.149 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' E' E ' 11' ' ' GLU . . . . . 0.432 ' CG ' HD22 ' D' ' 27' ' ' ASN . 46.3 mt-10 -83.41 155.55 23.41 Favored 'General case' 0 N--CA 1.474 0.734 0 N-CA-C 109.302 -0.629 . . . . 0.0 109.302 178.033 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -155.67 128.34 1.09 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.534 0 N-CA-C 108.357 -0.979 . . . . 0.0 108.357 178.782 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 47.5 m-70 -135.17 143.18 46.33 Favored 'General case' 0 N--CA 1.48 1.074 0 CA-C-O 120.746 0.308 . . . . 0.0 111.329 -177.875 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -164.83 98.68 0.77 Allowed 'General case' 0 N--CA 1.488 1.472 0 CA-C-N 116.677 -0.238 . . . . 0.0 110.973 179.73 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' E' E ' 15' ' ' GLN . . . . . 0.488 HE22 ' H ' ' E' ' 37' ' ' GLY . 62.1 mt-30 -108.4 -171.91 1.95 Allowed 'General case' 0 CA--C 1.502 -0.883 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 -179.831 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -166.27 97.31 0.6 Allowed 'General case' 0 CA--C 1.541 0.629 0 CA-C-N 115.043 -0.98 . . . . 0.0 109.327 178.648 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' E' E ' 17' ' ' LEU . . . . . 0.402 ' N ' ' CD1' ' E' ' 17' ' ' LEU . 4.8 mp -105.85 163.56 12.63 Favored 'General case' 0 N--CA 1.49 1.545 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 -179.805 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 40.3 t -141.9 118.57 6.99 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.352 0 C-N-CA 122.612 0.365 . . . . 0.0 110.492 179.126 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 50.9 m-85 -69.49 156.77 38.35 Favored 'General case' 0 C--N 1.357 0.933 0 N-CA-C 107.336 -1.357 . . . . 0.0 107.336 176.56 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 12.4 t80 -173.41 -54.9 0.02 OUTLIER 'General case' 0 N--CA 1.485 1.28 0 CA-C-O 121.822 0.82 . . . . 0.0 110.288 179.457 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.96 89.31 0.0 OUTLIER 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 114.346 -1.297 . . . . 0.0 112.686 -178.783 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 54.7 tt0 -66.14 158.19 29.26 Favored 'General case' 0 N--CA 1.472 0.656 0 CA-C-N 114.823 -1.08 . . . . 0.0 110.651 179.651 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 66.0 m-20 -140.56 137.59 33.85 Favored 'General case' 0 N--CA 1.479 1.005 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.442 179.881 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 21.7 t -84.79 -115.45 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.039 0 N-CA-C 108.681 -0.859 . . . . 0.0 108.681 179.649 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . -110.61 54.16 0.55 Allowed Glycine 0 C--N 1.347 1.163 0 N-CA-C 111.457 -0.657 . . . . 0.0 111.457 -179.715 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 69.0 p -79.75 125.67 29.97 Favored 'General case' 0 N--CA 1.474 0.773 0 N-CA-C 109.384 -0.599 . . . . 0.0 109.384 178.078 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' E' E ' 27' ' ' ASN . . . . . 0.462 HD22 ' CG ' ' F' ' 11' ' ' GLU . 52.5 t30 -66.72 99.5 0.61 Allowed 'General case' 0 N--CA 1.471 0.601 0 N-CA-C 108.081 -1.081 . . . . 0.0 108.081 178.382 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 66.4 mttm -96.44 119.3 34.66 Favored 'General case' 0 N--CA 1.484 1.252 0 N-CA-C 109.995 -0.372 . . . . 0.0 109.995 -178.748 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.57 -124.88 0.01 OUTLIER Glycine 0 CA--C 1.538 1.525 0 N-CA-C 110.95 -0.86 . . . . 0.0 110.95 178.601 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.74 133.33 48.08 Favored 'General case' 0 N--CA 1.482 1.158 0 N-CA-C 109.581 -0.526 . . . . 0.0 109.581 179.65 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 66.3 mt -82.65 138.97 18.5 Favored 'Isoleucine or valine' 0 C--O 1.237 0.405 0 N-CA-C 107.029 -1.471 . . . . 0.0 107.029 178.434 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 21.0 mt -128.32 129.06 69.05 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.865 0 N-CA-C 109.566 -0.531 . . . . 0.0 109.566 -179.433 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 60.97 80.28 0.1 Allowed Glycine 0 CA--C 1.524 0.641 0 CA-C-N 116.064 -0.516 . . . . 0.0 113.505 179.172 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 2.0 tt -111.77 118.86 36.74 Favored 'General case' 0 N--CA 1.477 0.916 0 N-CA-C 107.003 -1.481 . . . . 0.0 107.003 177.34 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 8.6 ttt -154.14 162.64 41.05 Favored 'General case' 0 C--O 1.211 -0.944 0 N-CA-C 108.744 -0.835 . . . . 0.0 108.744 179.203 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 84.1 t -159.71 150.53 6.33 Favored 'Isoleucine or valine' 0 C--O 1.239 0.509 0 N-CA-C 106.632 -1.618 . . . . 0.0 106.632 -179.864 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' E' E ' 37' ' ' GLY . . . . . 0.488 ' H ' HE22 ' E' ' 15' ' ' GLN . . . 55.61 74.94 0.27 Allowed Glycine 0 C--N 1.314 -0.662 0 CA-C-N 115.673 -0.694 . . . . 0.0 111.481 178.48 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 169.95 -147.7 11.08 Favored Glycine 0 C--O 1.222 -0.631 0 N-CA-C 111.321 -0.712 . . . . 0.0 111.321 179.965 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 20.3 m -133.93 141.38 44.12 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.872 0 N-CA-C 109.199 -0.667 . . . . 0.0 109.199 179.444 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 19.0 t . . . . . 0 CA--C 1.535 0.379 0 CA-C-O 117.722 -1.133 . . . . 0.0 110.895 179.453 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 79.4 m-85 . . . . . 0 N--CA 1.475 0.8 0 N-CA-C 109.873 -0.417 . . . . 0.0 109.873 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' F' F ' 5' ' ' ARG . . . . . . . . . . . . . 71.6 mtp180 -143.8 141.84 30.59 Favored 'General case' 0 N--CA 1.477 0.912 0 N-CA-C 109.261 -0.644 . . . . 0.0 109.261 179.998 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 76.9 m80 -150.28 118.41 6.34 Favored 'General case' 0 N--CA 1.473 0.688 0 N-CA-C 108.965 -0.754 . . . . 0.0 108.965 179.072 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' F' F ' 7' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -66.4 149.82 49.83 Favored 'General case' 0 N--CA 1.463 0.203 0 O-C-N 123.414 0.447 . . . . 0.0 111.636 -179.429 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' F' F ' 8' ' ' SER . . . . . . . . . . . . . 6.9 t -167.41 172.28 9.79 Favored 'General case' 0 N--CA 1.476 0.874 0 CA-C-N 115.991 -0.55 . . . . 0.0 109.56 178.04 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 123.19 23.25 2.21 Favored Glycine 0 N--CA 1.482 1.74 0 N-CA-C 112.04 -0.424 . . . . 0.0 112.04 179.109 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 38.7 p90 -55.87 127.72 31.63 Favored 'General case' 0 CA--C 1.543 0.694 0 N-CA-C 112.664 0.616 . . . . 0.0 112.664 -179.151 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' F' F ' 11' ' ' GLU . . . . . 0.462 ' CG ' HD22 ' E' ' 27' ' ' ASN . 46.3 mt-10 -83.74 155.33 23.13 Favored 'General case' 0 N--CA 1.474 0.764 0 N-CA-C 109.436 -0.579 . . . . 0.0 109.436 178.023 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -155.34 128.19 1.11 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.587 0 N-CA-C 108.297 -1.001 . . . . 0.0 108.297 178.79 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 46.1 m-70 -135.01 143.22 46.68 Favored 'General case' 0 N--CA 1.483 1.196 0 CA-C-O 120.63 0.252 . . . . 0.0 111.329 -177.902 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -165.18 99.09 0.73 Allowed 'General case' 0 N--CA 1.487 1.422 0 CA-C-N 116.751 -0.204 . . . . 0.0 111.091 179.74 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' F' F ' 15' ' ' GLN . . . . . 0.478 HE22 ' H ' ' F' ' 37' ' ' GLY . 61.6 mt-30 -109.2 -171.51 1.86 Allowed 'General case' 0 CA--C 1.498 -1.034 0 N-CA-C 108.574 -0.899 . . . . 0.0 108.574 -179.826 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -166.11 97.57 0.62 Allowed 'General case' 0 CA--C 1.542 0.651 0 CA-C-N 114.93 -1.032 . . . . 0.0 109.406 178.769 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' F' F ' 17' ' ' LEU . . . . . 0.401 ' N ' ' CD1' ' F' ' 17' ' ' LEU . 4.7 mp -105.81 163.48 12.69 Favored 'General case' 0 N--CA 1.488 1.469 0 N-CA-C 109.213 -0.662 . . . . 0.0 109.213 -179.923 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 40.0 t -141.9 118.59 7.02 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.305 0 C-N-CA 122.644 0.378 . . . . 0.0 110.613 179.101 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 51.0 m-85 -69.53 156.66 38.54 Favored 'General case' 0 C--N 1.357 0.922 0 N-CA-C 107.221 -1.399 . . . . 0.0 107.221 176.548 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 13.2 t80 -173.19 -55.04 0.02 OUTLIER 'General case' 0 N--CA 1.486 1.372 0 CA-C-O 121.787 0.803 . . . . 0.0 109.85 179.458 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.73 88.99 0.0 OUTLIER 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 114.49 -1.232 . . . . 0.0 112.971 -178.876 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 54.4 tt0 -65.96 158.22 28.74 Favored 'General case' 0 N--CA 1.472 0.666 0 CA-C-N 114.894 -1.048 . . . . 0.0 110.799 179.541 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 66.7 m-20 -140.51 137.83 34.11 Favored 'General case' 0 N--CA 1.48 1.059 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.396 179.96 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' F' F ' 24' ' ' VAL . . . . . . . . . . . . . 21.7 t -85.09 -115.46 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.043 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 179.505 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -110.55 54.11 0.56 Allowed Glycine 0 N--CA 1.479 1.529 0 N-CA-C 111.383 -0.687 . . . . 0.0 111.383 -179.815 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 70.1 p -79.68 125.42 29.62 Favored 'General case' 0 N--CA 1.474 0.733 0 N-CA-C 109.335 -0.617 . . . . 0.0 109.335 177.948 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' F' F ' 27' ' ' ASN . . . . . 0.452 HD22 ' CG ' ' D' ' 11' ' ' GLU . 52.2 t30 -66.5 99.23 0.55 Allowed 'General case' 0 N--CA 1.472 0.638 0 N-CA-C 108.115 -1.069 . . . . 0.0 108.115 178.382 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 66.4 mttm -96.26 119.17 34.27 Favored 'General case' 0 N--CA 1.483 1.19 0 N-CA-C 110.084 -0.339 . . . . 0.0 110.084 -178.804 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.55 -125.41 0.01 OUTLIER Glycine 0 CA--C 1.54 1.6 0 N-CA-C 110.964 -0.854 . . . . 0.0 110.964 178.617 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -127.91 133.08 49.25 Favored 'General case' 0 N--CA 1.484 1.249 0 N-CA-C 109.644 -0.502 . . . . 0.0 109.644 179.588 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 66.9 mt -82.65 138.81 18.77 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.273 0 N-CA-C 106.897 -1.52 . . . . 0.0 106.897 178.421 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 20.3 mt -128.22 129.08 69.22 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.891 0 N-CA-C 109.636 -0.505 . . . . 0.0 109.636 -179.357 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 60.86 80.27 0.1 Allowed Glycine 0 CA--C 1.525 0.688 0 CA-C-N 116.056 -0.52 . . . . 0.0 113.573 179.346 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 2.1 tt -111.85 118.82 36.59 Favored 'General case' 0 N--CA 1.479 0.981 0 N-CA-C 107.067 -1.457 . . . . 0.0 107.067 177.346 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 8.7 ttt -154.15 162.72 41.0 Favored 'General case' 0 C--O 1.209 -1.041 0 N-CA-C 109.009 -0.737 . . . . 0.0 109.009 179.143 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 85.1 t -159.7 150.57 6.32 Favored 'Isoleucine or valine' 0 C--O 1.237 0.402 0 N-CA-C 106.701 -1.592 . . . . 0.0 106.701 -179.823 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' F' F ' 37' ' ' GLY . . . . . 0.478 ' H ' HE22 ' F' ' 15' ' ' GLN . . . 55.8 74.67 0.3 Allowed Glycine 0 C--N 1.315 -0.632 0 CA-C-N 115.523 -0.762 . . . . 0.0 111.447 178.452 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 170.06 -147.82 11.14 Favored Glycine 0 C--O 1.221 -0.7 0 N-CA-C 111.233 -0.747 . . . . 0.0 111.233 179.839 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 20.2 m -133.72 141.37 44.35 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.841 0 N-CA-C 109.158 -0.682 . . . . 0.0 109.158 179.547 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 19.4 t . . . . . 0 CA--C 1.536 0.415 0 CA-C-O 117.746 -1.121 . . . . 0.0 110.75 179.389 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 79.0 m-85 . . . . . 0 N--CA 1.474 0.772 0 N-CA-C 109.644 -0.502 . . . . 0.0 109.644 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' G' G ' 5' ' ' ARG . . . . . . . . . . . . . 71.8 mtp180 -144.01 141.28 30.05 Favored 'General case' 0 N--CA 1.483 1.22 0 N-CA-C 109.178 -0.675 . . . . 0.0 109.178 -179.515 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 76.7 m80 -149.53 119.57 7.19 Favored 'General case' 0 N--CA 1.472 0.671 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 179.078 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 -68.41 145.28 54.27 Favored 'General case' 0 N--CA 1.47 0.526 0 O-C-N 123.505 0.503 . . . . 0.0 111.931 -179.328 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' G' G ' 8' ' ' SER . . . . . . . . . . . . . 5.7 t -163.81 173.54 12.64 Favored 'General case' 0 N--CA 1.47 0.566 0 N-CA-C 109.291 -0.633 . . . . 0.0 109.291 178.147 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.94 23.65 2.2 Favored Glycine 0 N--CA 1.479 1.519 0 N-CA-C 111.755 -0.538 . . . . 0.0 111.755 179.051 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 41.9 p90 -56.98 127.61 32.79 Favored 'General case' 0 N--CA 1.475 0.799 0 N-CA-C 112.437 0.532 . . . . 0.0 112.437 -178.648 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 45.2 mt-10 -83.93 154.34 23.43 Favored 'General case' 0 N--CA 1.471 0.618 0 CA-C-O 121.052 0.453 . . . . 0.0 109.852 178.686 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -155.4 128.51 1.15 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.968 0 N-CA-C 108.304 -0.999 . . . . 0.0 108.304 178.9 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 49.1 m-70 -134.19 144.38 48.44 Favored 'General case' 0 N--CA 1.476 0.865 0 CA-C-N 115.416 -0.811 . . . . 0.0 111.09 -178.136 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -166.35 98.2 0.6 Allowed 'General case' 0 N--CA 1.484 1.245 0 CA-C-N 116.642 -0.254 . . . . 0.0 110.572 179.219 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' G' G ' 15' ' ' GLN . . . . . 0.488 HE22 ' H ' ' G' ' 37' ' ' GLY . 61.7 mt-30 -108.32 -171.89 1.95 Allowed 'General case' 0 CA--C 1.503 -0.839 0 N-CA-C 108.635 -0.876 . . . . 0.0 108.635 -179.775 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -166.03 97.58 0.63 Allowed 'General case' 0 CA--C 1.541 0.618 0 CA-C-N 115.032 -0.985 . . . . 0.0 109.38 178.614 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' G' G ' 17' ' ' LEU . . . . . 0.4 ' N ' ' CD1' ' G' ' 17' ' ' LEU . 5.4 mp -105.73 162.33 13.63 Favored 'General case' 0 N--CA 1.487 1.423 0 N-CA-C 109.4 -0.593 . . . . 0.0 109.4 -179.717 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 39.0 t -142.45 118.83 6.08 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.082 0 CA-C-O 120.895 0.378 . . . . 0.0 110.352 178.773 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 44.9 m-85 -69.65 150.74 46.69 Favored 'General case' 0 C--N 1.369 1.444 0 N-CA-C 107.267 -1.383 . . . . 0.0 107.267 176.583 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 10.9 t80 -170.92 -54.84 0.02 OUTLIER 'General case' 0 N--CA 1.487 1.382 0 CA-C-N 117.847 0.294 . . . . 0.0 110.408 -179.73 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.45 90.27 0.0 OUTLIER 'General case' 0 C--N 1.325 -0.494 0 C-N-CA 123.866 0.866 . . . . 0.0 112.596 -179.918 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 53.8 tt0 -66.88 159.06 29.07 Favored 'General case' 0 N--CA 1.469 0.492 0 CA-C-N 114.634 -1.166 . . . . 0.0 109.923 179.189 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 66.2 m-20 -140.94 137.55 33.18 Favored 'General case' 0 N--CA 1.477 0.904 0 C-N-CA 122.822 0.449 . . . . 0.0 110.046 179.893 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' G' G ' 24' ' ' VAL . . . . . . . . . . . . . 21.4 t -85.42 -115.29 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.919 0 N-CA-C 108.521 -0.918 . . . . 0.0 108.521 179.608 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -110.53 53.97 0.56 Allowed Glycine 0 N--CA 1.477 1.425 0 N-CA-C 111.611 -0.596 . . . . 0.0 111.611 -179.712 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 70.4 p -80.08 126.27 30.85 Favored 'General case' 0 N--CA 1.467 0.393 0 N-CA-C 109.081 -0.711 . . . . 0.0 109.081 177.956 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 50.4 t30 -67.23 99.99 0.75 Allowed 'General case' 0 CA--C 1.538 0.503 0 N-CA-C 108.401 -0.963 . . . . 0.0 108.401 178.434 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 66.9 mttm -96.33 119.91 35.68 Favored 'General case' 0 N--CA 1.482 1.147 0 N-CA-C 110.174 -0.306 . . . . 0.0 110.174 -179.182 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.02 -123.33 0.01 OUTLIER Glycine 0 CA--C 1.534 1.253 0 N-CA-C 110.54 -1.024 . . . . 0.0 110.54 178.787 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -129.58 132.78 46.89 Favored 'General case' 0 N--CA 1.47 0.557 0 N-CA-C 109.514 -0.55 . . . . 0.0 109.514 179.683 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 69.9 mt -81.54 140.91 15.85 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.654 0 N-CA-C 107.2 -1.407 . . . . 0.0 107.2 178.337 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 24.0 mt -130.2 130.52 65.74 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.46 0 CA-C-N 119.044 0.838 . . . . 0.0 109.435 179.785 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 60.96 79.82 0.11 Allowed Glycine 0 CA--C 1.528 0.888 0 CA-C-N 116.281 -0.418 . . . . 0.0 113.038 179.292 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 1.9 tt -111.93 119.55 38.92 Favored 'General case' 0 N--CA 1.478 0.94 0 N-CA-C 106.961 -1.496 . . . . 0.0 106.961 177.479 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 8.5 ttt -155.54 163.14 40.38 Favored 'General case' 0 N--CA 1.476 0.866 0 N-CA-C 108.192 -1.04 . . . . 0.0 108.192 179.503 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 98.6 t -159.8 150.85 6.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 N-CA-C 106.303 -1.74 . . . . 0.0 106.303 -179.899 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' G' G ' 37' ' ' GLY . . . . . 0.488 ' H ' HE22 ' G' ' 15' ' ' GLN . . . 56.1 74.74 0.29 Allowed Glycine 0 C--N 1.313 -0.706 0 CA-C-N 115.888 -0.596 . . . . 0.0 111.913 178.132 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 168.66 -146.42 10.34 Favored Glycine 0 N--CA 1.471 1.008 0 N-CA-C 110.636 -0.986 . . . . 0.0 110.636 179.231 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 23.1 m -134.23 141.62 43.17 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.906 0 CA-C-N 117.031 0.415 . . . . 0.0 109.984 179.881 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 19.2 t . . . . . 0 N--CA 1.47 0.548 0 CA-C-O 117.841 -1.076 . . . . 0.0 110.891 179.613 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 80.4 m-85 . . . . . 0 N--CA 1.475 0.805 0 N-CA-C 109.641 -0.503 . . . . 0.0 109.641 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' H' H ' 5' ' ' ARG . . . . . . . . . . . . . 71.5 mtp180 -144.29 141.4 29.77 Favored 'General case' 0 N--CA 1.48 1.055 0 N-CA-C 109.222 -0.658 . . . . 0.0 109.222 -179.625 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 76.8 m80 -149.72 119.29 6.96 Favored 'General case' 0 N--CA 1.473 0.698 0 N-CA-C 109.095 -0.705 . . . . 0.0 109.095 179.071 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 8.7 m-20 -68.08 145.35 54.5 Favored 'General case' 0 N--CA 1.468 0.45 0 O-C-N 123.466 0.479 . . . . 0.0 111.934 -179.393 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' H' H ' 8' ' ' SER . . . . . . . . . . . . . 7.0 t -163.9 172.83 13.45 Favored 'General case' 0 N--CA 1.468 0.474 0 N-CA-C 109.449 -0.574 . . . . 0.0 109.449 178.466 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 123.15 23.52 2.17 Favored Glycine 0 N--CA 1.481 1.684 0 N-CA-C 111.682 -0.567 . . . . 0.0 111.682 179.154 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 41.6 p90 -56.79 127.65 32.68 Favored 'General case' 0 N--CA 1.472 0.672 0 N-CA-C 112.443 0.534 . . . . 0.0 112.443 -178.763 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 45.4 mt-10 -83.96 154.4 23.36 Favored 'General case' 0 N--CA 1.473 0.679 0 CA-C-O 120.998 0.428 . . . . 0.0 109.893 178.739 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.6 p -155.58 128.11 1.07 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.016 0 N-CA-C 108.42 -0.955 . . . . 0.0 108.42 178.879 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 48.7 m-70 -133.91 144.4 48.83 Favored 'General case' 0 N--CA 1.478 0.947 0 CA-C-N 115.336 -0.847 . . . . 0.0 111.025 -178.072 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -166.29 98.54 0.61 Allowed 'General case' 0 N--CA 1.483 1.218 0 CA-C-N 116.568 -0.287 . . . . 0.0 110.617 179.166 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' H' H ' 15' ' ' GLN . . . . . 0.497 HE22 ' H ' ' H' ' 37' ' ' GLY . 61.6 mt-30 -108.64 -172.37 2.04 Favored 'General case' 0 CA--C 1.501 -0.931 0 N-CA-C 108.416 -0.957 . . . . 0.0 108.416 -179.656 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -165.73 97.35 0.65 Allowed 'General case' 0 CA--C 1.54 0.572 0 CA-C-N 114.951 -1.022 . . . . 0.0 109.364 178.716 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' H' H ' 17' ' ' LEU . . . . . 0.404 ' N ' ' CD1' ' H' ' 17' ' ' LEU . 5.4 mp -105.66 162.23 13.7 Favored 'General case' 0 N--CA 1.487 1.405 0 N-CA-C 109.362 -0.607 . . . . 0.0 109.362 -179.646 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 38.8 t -142.39 118.67 6.08 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.983 0 CA-C-O 120.97 0.414 . . . . 0.0 110.489 178.851 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 46.2 m-85 -69.8 151.07 46.18 Favored 'General case' 0 C--N 1.371 1.503 0 N-CA-C 107.355 -1.35 . . . . 0.0 107.355 176.653 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 11.4 t80 -172.15 -54.6 0.02 OUTLIER 'General case' 0 N--CA 1.485 1.295 0 N-CA-C 110.342 -0.244 . . . . 0.0 110.342 -179.635 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.39 90.41 0.0 OUTLIER 'General case' 0 CA--C 1.535 0.365 0 C-N-CA 123.815 0.846 . . . . 0.0 112.354 -179.958 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 54.0 tt0 -66.73 159.14 28.52 Favored 'General case' 0 N--CA 1.469 0.485 0 CA-C-N 114.69 -1.141 . . . . 0.0 110.012 179.34 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 67.5 m-20 -140.91 138.05 33.58 Favored 'General case' 0 N--CA 1.477 0.885 0 C-N-CA 122.821 0.448 . . . . 0.0 110.051 179.693 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' H' H ' 24' ' ' VAL . . . . . . . . . . . . . 21.4 t -85.93 -115.33 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 1.016 0 N-CA-C 108.609 -0.885 . . . . 0.0 108.609 179.602 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . -110.33 53.9 0.56 Allowed Glycine 0 N--CA 1.48 1.601 0 N-CA-C 111.471 -0.652 . . . . 0.0 111.471 -179.759 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 68.7 p -80.03 126.02 30.52 Favored 'General case' 0 N--CA 1.468 0.446 0 N-CA-C 109.053 -0.721 . . . . 0.0 109.053 178.067 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 50.6 t30 -67.31 100.1 0.78 Allowed 'General case' 0 N--CA 1.47 0.542 0 N-CA-C 108.409 -0.96 . . . . 0.0 108.409 178.492 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 67.0 mttm -96.41 119.76 35.49 Favored 'General case' 0 N--CA 1.484 1.236 0 N-CA-C 110.182 -0.303 . . . . 0.0 110.182 -179.131 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.89 -122.84 0.01 OUTLIER Glycine 0 CA--C 1.535 1.306 0 N-CA-C 110.606 -0.998 . . . . 0.0 110.606 178.735 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -129.95 133.0 46.54 Favored 'General case' 0 N--CA 1.471 0.62 0 C-N-CA 122.946 0.498 . . . . 0.0 109.663 179.709 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 69.5 mt -81.89 140.76 16.01 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.554 0 N-CA-C 107.128 -1.434 . . . . 0.0 107.128 178.446 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 25.1 mt -130.03 130.47 66.08 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.403 0 CA-C-N 119.021 0.828 . . . . 0.0 109.395 179.935 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 60.77 79.81 0.11 Allowed Glycine 0 CA--C 1.528 0.889 0 CA-C-N 116.382 -0.372 . . . . 0.0 113.067 179.193 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 1.9 tt -111.87 119.5 38.77 Favored 'General case' 0 N--CA 1.478 0.944 0 N-CA-C 106.944 -1.502 . . . . 0.0 106.944 177.426 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 8.4 ttt -155.19 163.19 40.54 Favored 'General case' 0 C--O 1.212 -0.91 0 N-CA-C 108.176 -1.046 . . . . 0.0 108.176 179.509 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 96.4 t -159.79 150.77 6.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 N-CA-C 106.254 -1.758 . . . . 0.0 106.254 -179.885 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' H' H ' 37' ' ' GLY . . . . . 0.497 ' H ' HE22 ' H' ' 15' ' ' GLN . . . 56.12 74.95 0.27 Allowed Glycine 0 C--N 1.313 -0.712 0 CA-C-N 115.914 -0.584 . . . . 0.0 111.914 178.124 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 168.32 -146.34 10.37 Favored Glycine 0 N--CA 1.469 0.866 0 N-CA-C 110.631 -0.988 . . . . 0.0 110.631 179.105 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 22.6 m -134.15 141.81 42.74 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.906 0 CA-C-N 116.998 0.399 . . . . 0.0 110.021 179.911 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 19.1 t . . . . . 0 N--CA 1.47 0.557 0 CA-C-O 117.789 -1.101 . . . . 0.0 110.932 179.539 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 79.9 m-85 . . . . . 0 N--CA 1.475 0.78 0 N-CA-C 109.599 -0.519 . . . . 0.0 109.599 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' I' I ' 5' ' ' ARG . . . . . . . . . . . . . 71.6 mtp180 -144.44 141.5 29.66 Favored 'General case' 0 N--CA 1.483 1.192 0 N-CA-C 109.187 -0.671 . . . . 0.0 109.187 -179.696 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 76.7 m80 -149.76 119.06 6.82 Favored 'General case' 0 N--CA 1.472 0.667 0 N-CA-C 109.126 -0.694 . . . . 0.0 109.126 179.082 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 8.6 m-20 -67.86 145.36 54.69 Favored 'General case' 0 N--CA 1.469 0.491 0 O-C-N 123.479 0.487 . . . . 0.0 111.935 -179.371 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' I' I ' 8' ' ' SER . . . . . . . . . . . . . 7.5 t -163.9 172.75 13.55 Favored 'General case' 0 N--CA 1.469 0.496 0 N-CA-C 109.429 -0.582 . . . . 0.0 109.429 178.465 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 123.2 23.77 2.12 Favored Glycine 0 N--CA 1.481 1.639 0 N-CA-C 111.78 -0.528 . . . . 0.0 111.78 179.118 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 41.5 p90 -56.95 127.52 32.27 Favored 'General case' 0 N--CA 1.474 0.737 0 N-CA-C 112.443 0.534 . . . . 0.0 112.443 -178.738 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 45.2 mt-10 -83.66 154.34 23.74 Favored 'General case' 0 N--CA 1.472 0.628 0 CA-C-O 120.998 0.427 . . . . 0.0 109.909 178.675 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -155.49 128.29 1.1 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.015 0 N-CA-C 108.313 -0.995 . . . . 0.0 108.313 178.848 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 49.5 m-70 -134.06 144.56 48.72 Favored 'General case' 0 N--CA 1.478 0.935 0 CA-C-N 115.337 -0.847 . . . . 0.0 111.13 -178.198 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -166.4 98.51 0.6 Allowed 'General case' 0 N--CA 1.484 1.255 0 CA-C-N 116.639 -0.255 . . . . 0.0 110.704 179.127 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' I' I ' 15' ' ' GLN . . . . . 0.492 HE22 ' H ' ' I' ' 37' ' ' GLY . 61.4 mt-30 -108.63 -172.45 2.06 Favored 'General case' 0 CA--C 1.498 -1.029 0 N-CA-C 108.461 -0.94 . . . . 0.0 108.461 -179.765 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -165.69 97.43 0.66 Allowed 'General case' 0 CA--C 1.541 0.61 0 CA-C-N 114.9 -1.046 . . . . 0.0 109.302 178.789 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' I' I ' 17' ' ' LEU . . . . . 0.401 ' CD1' ' N ' ' I' ' 17' ' ' LEU . 5.4 mp -105.68 162.51 13.46 Favored 'General case' 0 N--CA 1.487 1.402 0 N-CA-C 109.306 -0.627 . . . . 0.0 109.306 -179.609 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 39.2 t -142.5 118.81 5.95 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.006 0 CA-C-O 120.94 0.4 . . . . 0.0 110.471 178.851 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 45.8 m-85 -70.02 150.96 46.1 Favored 'General case' 0 C--N 1.369 1.431 0 N-CA-C 107.402 -1.332 . . . . 0.0 107.402 176.601 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 11.5 t80 -171.96 -54.72 0.02 OUTLIER 'General case' 0 N--CA 1.483 1.209 0 CA-C-N 117.765 0.257 . . . . 0.0 110.401 -179.561 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.34 90.22 0.0 OUTLIER 'General case' 0 CA--C 1.535 0.401 0 C-N-CA 123.743 0.817 . . . . 0.0 112.386 -179.942 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 54.1 tt0 -66.46 159.06 27.92 Favored 'General case' 0 N--CA 1.468 0.47 0 CA-C-N 114.667 -1.151 . . . . 0.0 110.061 179.272 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 67.2 m-20 -140.91 138.0 33.54 Favored 'General case' 0 N--CA 1.477 0.921 0 C-N-CA 122.775 0.43 . . . . 0.0 110.001 179.835 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' I' I ' 24' ' ' VAL . . . . . . . . . . . . . 21.3 t -85.99 -115.52 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.926 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 179.653 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . -110.16 53.6 0.58 Allowed Glycine 0 N--CA 1.479 1.501 0 N-CA-C 111.579 -0.609 . . . . 0.0 111.579 -179.702 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 68.7 p -79.74 126.24 30.7 Favored 'General case' 0 N--CA 1.467 0.411 0 N-CA-C 109.036 -0.727 . . . . 0.0 109.036 178.026 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 49.8 t30 -67.52 99.9 0.81 Allowed 'General case' 0 N--CA 1.47 0.527 0 N-CA-C 108.379 -0.971 . . . . 0.0 108.379 178.483 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 67.0 mttm -96.2 119.79 35.32 Favored 'General case' 0 N--CA 1.482 1.165 0 N-CA-C 110.216 -0.29 . . . . 0.0 110.216 -179.135 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.13 -123.23 0.01 OUTLIER Glycine 0 CA--C 1.534 1.254 0 N-CA-C 110.656 -0.978 . . . . 0.0 110.656 178.746 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -129.4 132.74 47.09 Favored 'General case' 0 N--CA 1.473 0.683 0 C-N-CA 122.962 0.505 . . . . 0.0 109.65 179.657 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 69.5 mt -81.75 140.68 16.16 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.637 0 N-CA-C 106.982 -1.488 . . . . 0.0 106.982 178.387 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 23.3 mt -129.89 130.44 66.37 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.383 0 CA-C-N 118.939 0.79 . . . . 0.0 109.361 179.868 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 60.63 80.04 0.11 Allowed Glycine 0 CA--C 1.528 0.846 0 CA-C-N 116.331 -0.395 . . . . 0.0 113.107 179.25 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 1.9 tt -112.0 119.6 39.02 Favored 'General case' 0 N--CA 1.478 0.949 0 N-CA-C 106.891 -1.522 . . . . 0.0 106.891 177.446 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 8.6 ttt -155.29 163.08 40.63 Favored 'General case' 0 N--CA 1.478 0.943 0 N-CA-C 108.256 -1.016 . . . . 0.0 108.256 179.518 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 97.7 t -159.76 150.94 6.17 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 N-CA-C 106.253 -1.758 . . . . 0.0 106.253 -179.915 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' I' I ' 37' ' ' GLY . . . . . 0.492 ' H ' HE22 ' I' ' 15' ' ' GLN . . . 56.14 74.45 0.33 Allowed Glycine 0 C--N 1.313 -0.739 0 CA-C-N 115.891 -0.595 . . . . 0.0 112.023 178.115 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 168.76 -146.4 10.31 Favored Glycine 0 N--CA 1.47 0.915 0 N-CA-C 110.602 -0.999 . . . . 0.0 110.602 179.268 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 22.8 m -134.06 141.79 42.88 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.873 0 CA-C-N 117.01 0.405 . . . . 0.0 109.981 179.921 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 19.2 t . . . . . 0 N--CA 1.469 0.506 0 CA-C-O 117.825 -1.083 . . . . 0.0 110.939 179.507 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 78.5 m-85 . . . . . 0 N--CA 1.475 0.795 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 72.2 mtp180 -143.62 141.17 30.5 Favored 'General case' 0 N--CA 1.481 1.116 0 N-CA-C 109.076 -0.713 . . . . 0.0 109.076 179.964 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 77.0 m80 -149.48 119.65 7.26 Favored 'General case' 0 N--CA 1.47 0.562 0 N-CA-C 108.806 -0.813 . . . . 0.0 108.806 179.136 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 7.4 m-20 -68.3 150.21 48.5 Favored 'General case' 0 CA--C 1.529 0.168 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.258 -179.437 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 8.5 t -166.95 172.27 10.41 Favored 'General case' 0 N--CA 1.472 0.63 0 N-CA-C 109.554 -0.536 . . . . 0.0 109.554 178.476 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.53 23.52 2.32 Favored Glycine 0 N--CA 1.487 2.097 0 N-CA-C 112.239 -0.344 . . . . 0.0 112.239 179.417 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 41.8 p90 -56.98 128.28 36.13 Favored 'General case' 0 N--CA 1.474 0.761 0 N-CA-C 112.088 0.403 . . . . 0.0 112.088 -179.912 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 57.4 mt-10 -85.66 155.38 21.12 Favored 'General case' 0 N--CA 1.469 0.504 0 N-CA-C 109.273 -0.64 . . . . 0.0 109.273 178.493 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -153.75 128.79 1.51 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 N-CA-C 108.107 -1.071 . . . . 0.0 108.107 178.839 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 49.5 m-70 -134.64 146.54 49.64 Favored 'General case' 0 N--CA 1.489 1.503 0 CA-C-N 118.641 0.655 . . . . 0.0 111.154 -179.024 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 6.4 t60 -164.96 97.91 0.74 Allowed 'General case' 0 N--CA 1.48 1.04 0 CA-C-N 116.502 -0.317 . . . . 0.0 111.055 179.582 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 35.0 mt-30 -106.06 -172.7 2.14 Favored 'General case' 0 CA--C 1.505 -0.762 0 N-CA-C 108.369 -0.974 . . . . 0.0 108.369 179.915 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -169.18 96.47 0.34 Allowed 'General case' 0 N--CA 1.472 0.629 0 CA-C-N 115.139 -0.937 . . . . 0.0 109.416 178.703 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . 0.411 ' N ' ' CD1' ' A' ' 17' ' ' LEU . 4.8 mp -106.38 165.01 11.57 Favored 'General case' 0 N--CA 1.489 1.498 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 179.901 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 56.5 t -141.78 119.22 7.96 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.387 0 CA-C-O 118.934 -0.555 . . . . 0.0 109.897 179.68 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 52.4 m-85 -69.9 158.93 34.62 Favored 'General case' 0 N--CA 1.481 1.079 0 N-CA-C 107.592 -1.262 . . . . 0.0 107.592 177.392 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 13.1 t80 -171.22 -58.59 0.02 OUTLIER 'General case' 0 N--CA 1.485 1.324 0 CA-C-O 122.299 1.047 . . . . 0.0 109.73 179.485 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -38.82 90.11 0.0 OUTLIER 'General case' 0 C--O 1.232 0.142 0 CA-C-N 113.926 -1.488 . . . . 0.0 112.968 -177.985 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 37.0 tt0 -66.51 157.81 31.24 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 115.109 -0.95 . . . . 0.0 110.452 179.197 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 66.7 m-20 -139.98 137.38 34.66 Favored 'General case' 0 N--CA 1.48 1.071 0 C-N-CA 123.002 0.521 . . . . 0.0 110.344 179.866 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 17.9 t -84.49 -116.3 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.962 0 N-CA-C 108.444 -0.947 . . . . 0.0 108.444 179.501 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -110.37 54.63 0.54 Allowed Glycine 0 N--CA 1.475 1.265 0 N-CA-C 111.227 -0.749 . . . . 0.0 111.227 179.916 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 74.8 p -79.98 125.96 30.43 Favored 'General case' 0 C--O 1.221 -0.417 0 N-CA-C 108.969 -0.752 . . . . 0.0 108.969 178.378 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 19.9 t-20 -66.6 100.42 0.67 Allowed 'General case' 0 N--CA 1.473 0.725 0 N-CA-C 108.576 -0.898 . . . . 0.0 108.576 178.704 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 66.6 mttm -96.85 120.34 37.01 Favored 'General case' 0 N--CA 1.483 1.182 0 N-CA-C 110.093 -0.336 . . . . 0.0 110.093 -179.157 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.58 -128.41 0.01 OUTLIER Glycine 0 CA--C 1.534 1.223 0 N-CA-C 110.525 -1.03 . . . . 0.0 110.525 178.779 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -126.05 133.86 51.59 Favored 'General case' 0 N--CA 1.48 1.052 0 N-CA-C 109.234 -0.654 . . . . 0.0 109.234 179.097 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 65.4 mt -83.21 137.81 20.34 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.538 0 N-CA-C 107.393 -1.336 . . . . 0.0 107.393 178.683 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 20.9 mt -129.44 129.25 66.95 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.976 0 O-C-N 123.495 0.497 . . . . 0.0 110.053 -178.424 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 60.43 79.05 0.13 Allowed Glycine 0 CA--C 1.525 0.685 0 CA-C-N 115.849 -0.614 . . . . 0.0 113.069 178.949 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 1.9 tt -110.94 119.48 39.21 Favored 'General case' 0 N--CA 1.477 0.915 0 N-CA-C 106.973 -1.492 . . . . 0.0 106.973 177.463 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 8.6 ttt -154.91 161.08 41.54 Favored 'General case' 0 N--CA 1.468 0.443 0 N-CA-C 109.066 -0.716 . . . . 0.0 109.066 179.257 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 63.1 t -157.75 150.48 8.55 Favored 'Isoleucine or valine' 0 C--O 1.232 0.148 0 N-CA-C 106.897 -1.52 . . . . 0.0 106.897 -179.496 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.61 75.42 0.24 Allowed Glycine 0 C--N 1.315 -0.607 0 CA-C-N 115.671 -0.695 . . . . 0.0 111.777 178.201 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 168.83 -149.12 13.2 Favored Glycine 0 CA--C 1.519 0.3 0 N-CA-C 110.744 -0.943 . . . . 0.0 110.744 179.847 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 20.7 m -132.57 142.87 41.38 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.874 0 N-CA-C 109.598 -0.519 . . . . 0.0 109.598 179.658 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 21.2 t . . . . . 0 N--CA 1.467 0.399 0 CA-C-O 117.834 -1.079 . . . . 0.0 110.831 179.29 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 78.9 m-85 . . . . . 0 N--CA 1.474 0.726 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 72.2 mtp180 -143.68 141.14 30.41 Favored 'General case' 0 N--CA 1.481 1.108 0 N-CA-C 109.121 -0.696 . . . . 0.0 109.121 -179.931 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 76.7 m80 -149.51 119.6 7.22 Favored 'General case' 0 N--CA 1.471 0.615 0 N-CA-C 108.841 -0.8 . . . . 0.0 108.841 179.122 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 7' ' ' ASP . . . . . . . . . . . . . 8.5 m-20 -68.09 150.2 48.69 Favored 'General case' 0 CA--C 1.53 0.19 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.281 -179.453 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 8' ' ' SER . . . . . . . . . . . . . 8.4 t -166.98 172.2 10.43 Favored 'General case' 0 N--CA 1.472 0.631 0 N-CA-C 109.537 -0.542 . . . . 0.0 109.537 178.557 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.5 23.38 2.36 Favored Glycine 0 N--CA 1.487 2.051 0 N-CA-C 112.159 -0.377 . . . . 0.0 112.159 179.371 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 41.9 p90 -56.78 128.16 35.22 Favored 'General case' 0 N--CA 1.471 0.616 0 N-CA-C 112.166 0.432 . . . . 0.0 112.166 -179.983 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 57.4 mt-10 -85.58 155.64 21.07 Favored 'General case' 0 N--CA 1.471 0.58 0 N-CA-C 109.297 -0.631 . . . . 0.0 109.297 178.555 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -153.88 128.68 1.46 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 N-CA-C 108.186 -1.042 . . . . 0.0 108.186 178.816 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 50.1 m-70 -134.57 146.75 49.93 Favored 'General case' 0 N--CA 1.489 1.513 0 CA-C-N 118.481 0.582 . . . . 0.0 111.219 -179.018 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 6.5 t60 -165.32 97.82 0.7 Allowed 'General case' 0 N--CA 1.481 1.108 0 CA-C-N 116.519 -0.309 . . . . 0.0 111.022 179.627 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 35.2 mt-30 -105.96 -172.89 2.17 Favored 'General case' 0 CA--C 1.504 -0.789 0 N-CA-C 108.407 -0.96 . . . . 0.0 108.407 179.949 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -169.14 96.35 0.34 Allowed 'General case' 0 CA--C 1.54 0.592 0 CA-C-N 115.193 -0.912 . . . . 0.0 109.447 178.76 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . 0.41 ' N ' ' CD1' ' B' ' 17' ' ' LEU . 4.8 mp -106.41 164.82 11.73 Favored 'General case' 0 N--CA 1.488 1.461 0 N-CA-C 108.575 -0.898 . . . . 0.0 108.575 179.968 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 58.6 t -141.55 119.26 8.53 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.355 0 CA-C-O 118.957 -0.544 . . . . 0.0 109.9 179.566 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 53.3 m-85 -70.53 159.09 34.94 Favored 'General case' 0 N--CA 1.479 0.982 0 N-CA-C 107.52 -1.289 . . . . 0.0 107.52 177.316 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 14.4 t80 -171.84 -57.33 0.02 OUTLIER 'General case' 0 N--CA 1.482 1.138 0 CA-C-O 122.228 1.013 . . . . 0.0 109.838 179.452 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -39.39 90.37 0.0 OUTLIER 'General case' 0 C--O 1.232 0.152 0 CA-C-N 114.09 -1.413 . . . . 0.0 112.874 -178.052 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 36.6 tt0 -66.42 158.03 30.43 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 115.058 -0.973 . . . . 0.0 110.56 179.133 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 67.6 m-20 -140.37 137.42 34.04 Favored 'General case' 0 N--CA 1.481 1.089 0 C-N-CA 122.993 0.517 . . . . 0.0 110.251 179.805 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 17.5 t -84.59 -116.55 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 1.016 0 N-CA-C 108.65 -0.87 . . . . 0.0 108.65 179.482 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -109.46 54.01 0.56 Allowed Glycine 0 N--CA 1.476 1.331 0 N-CA-C 111.189 -0.764 . . . . 0.0 111.189 179.878 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 74.2 p -79.7 126.04 30.42 Favored 'General case' 0 C--O 1.221 -0.405 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 178.386 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 19.7 t-20 -66.89 100.19 0.7 Allowed 'General case' 0 N--CA 1.474 0.761 0 N-CA-C 108.673 -0.862 . . . . 0.0 108.673 178.565 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 66.8 mttm -96.68 120.47 37.06 Favored 'General case' 0 N--CA 1.483 1.186 0 N-CA-C 110.118 -0.327 . . . . 0.0 110.118 -179.142 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.68 -127.73 0.01 OUTLIER Glycine 0 CA--C 1.534 1.246 0 N-CA-C 110.538 -1.025 . . . . 0.0 110.538 178.755 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -126.83 133.62 50.72 Favored 'General case' 0 N--CA 1.481 1.104 0 N-CA-C 109.165 -0.68 . . . . 0.0 109.165 179.252 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 64.4 mt -82.96 137.97 20.11 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.452 0 N-CA-C 107.363 -1.347 . . . . 0.0 107.363 178.59 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 21.6 mt -129.72 129.19 66.26 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.971 0 O-C-N 123.546 0.528 . . . . 0.0 109.941 -178.42 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 60.4 78.76 0.14 Allowed Glycine 0 CA--C 1.524 0.63 0 CA-C-N 115.828 -0.624 . . . . 0.0 113.094 178.915 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 1.9 tt -110.39 119.61 39.77 Favored 'General case' 0 N--CA 1.478 0.953 0 N-CA-C 106.975 -1.491 . . . . 0.0 106.975 177.351 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 8.7 ttt -154.89 160.79 41.43 Favored 'General case' 0 N--CA 1.47 0.562 0 N-CA-C 108.97 -0.752 . . . . 0.0 108.97 179.283 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 63.4 t -157.64 150.31 8.81 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.136 0 N-CA-C 106.825 -1.546 . . . . 0.0 106.825 -179.511 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.54 75.73 0.23 Allowed Glycine 0 C--N 1.314 -0.669 0 CA-C-N 115.659 -0.701 . . . . 0.0 111.771 178.169 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 168.52 -149.09 13.32 Favored Glycine 0 CA--C 1.519 0.306 0 N-CA-C 110.704 -0.958 . . . . 0.0 110.704 179.879 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 20.7 m -132.52 142.91 41.32 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.907 0 N-CA-C 109.643 -0.503 . . . . 0.0 109.643 179.676 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 21.2 t . . . . . 0 N--CA 1.467 0.405 0 CA-C-O 117.812 -1.089 . . . . 0.0 110.848 179.292 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 78.1 m-85 . . . . . 0 N--CA 1.474 0.737 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 72.4 mtp180 -143.61 141.07 30.46 Favored 'General case' 0 N--CA 1.482 1.136 0 N-CA-C 109.043 -0.725 . . . . 0.0 109.043 -179.857 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 76.5 m80 -149.47 119.64 7.26 Favored 'General case' 0 N--CA 1.47 0.571 0 N-CA-C 108.826 -0.805 . . . . 0.0 108.826 179.109 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' C' C ' 7' ' ' ASP . . . . . . . . . . . . . 7.6 m-20 -68.13 150.03 48.86 Favored 'General case' 0 CA--C 1.529 0.168 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.332 -179.381 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' C' C ' 8' ' ' SER . . . . . . . . . . . . . 8.5 t -166.71 172.73 10.27 Favored 'General case' 0 N--CA 1.471 0.618 0 N-CA-C 109.611 -0.514 . . . . 0.0 109.611 178.352 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.13 23.33 2.46 Favored Glycine 0 N--CA 1.487 2.042 0 N-CA-C 112.24 -0.344 . . . . 0.0 112.24 179.484 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 41.5 p90 -56.84 128.34 36.2 Favored 'General case' 0 N--CA 1.472 0.646 0 N-CA-C 112.088 0.403 . . . . 0.0 112.088 -179.896 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 57.5 mt-10 -85.79 155.27 21.08 Favored 'General case' 0 N--CA 1.47 0.556 0 N-CA-C 109.239 -0.652 . . . . 0.0 109.239 178.63 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -153.59 128.61 1.5 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 N-CA-C 108.181 -1.044 . . . . 0.0 108.181 178.853 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 49.5 m-70 -134.49 146.65 49.94 Favored 'General case' 0 N--CA 1.489 1.49 0 CA-C-N 118.541 0.609 . . . . 0.0 111.265 -179.105 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 6.4 t60 -165.15 98.04 0.72 Allowed 'General case' 0 N--CA 1.48 1.067 0 CA-C-N 116.572 -0.286 . . . . 0.0 111.085 179.596 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 35.1 mt-30 -106.36 -172.76 2.15 Favored 'General case' 0 CA--C 1.504 -0.807 0 N-CA-C 108.414 -0.958 . . . . 0.0 108.414 -179.99 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.7 tttt -169.18 96.45 0.34 Allowed 'General case' 0 CA--C 1.54 0.56 0 CA-C-N 115.12 -0.945 . . . . 0.0 109.451 178.751 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' C' C ' 17' ' ' LEU . . . . . 0.411 ' N ' ' CD1' ' C' ' 17' ' ' LEU . 4.8 mp -106.26 164.91 11.63 Favored 'General case' 0 N--CA 1.488 1.472 0 N-CA-C 108.584 -0.895 . . . . 0.0 108.584 179.968 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 58.5 t -141.71 118.94 7.76 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.341 0 CA-C-O 118.95 -0.548 . . . . 0.0 109.879 179.655 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 53.3 m-85 -70.25 159.0 34.84 Favored 'General case' 0 N--CA 1.478 0.956 0 N-CA-C 107.491 -1.3 . . . . 0.0 107.491 177.345 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 14.4 t80 -171.77 -57.41 0.02 OUTLIER 'General case' 0 N--CA 1.481 1.092 0 CA-C-O 122.183 0.992 . . . . 0.0 109.856 179.357 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -39.26 90.61 0.0 OUTLIER 'General case' 0 C--O 1.232 0.14 0 CA-C-N 114.125 -1.398 . . . . 0.0 112.849 -178.049 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 37.0 tt0 -66.74 158.05 31.21 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 115.096 -0.956 . . . . 0.0 110.513 179.219 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 67.2 m-20 -140.33 137.4 34.08 Favored 'General case' 0 N--CA 1.48 1.054 0 C-N-CA 122.944 0.498 . . . . 0.0 110.331 179.794 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 17.7 t -84.53 -116.42 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.967 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 179.588 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -109.86 54.35 0.55 Allowed Glycine 0 N--CA 1.475 1.275 0 N-CA-C 111.172 -0.771 . . . . 0.0 111.172 179.915 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 74.7 p -79.91 126.25 30.77 Favored 'General case' 0 C--O 1.222 -0.358 0 N-CA-C 109.004 -0.739 . . . . 0.0 109.004 178.417 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 19.4 t-20 -66.99 100.37 0.73 Allowed 'General case' 0 N--CA 1.474 0.737 0 N-CA-C 108.682 -0.858 . . . . 0.0 108.682 178.606 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 66.8 mttm -96.86 120.09 36.54 Favored 'General case' 0 N--CA 1.484 1.251 0 N-CA-C 110.161 -0.311 . . . . 0.0 110.161 -179.138 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.34 -128.17 0.01 OUTLIER Glycine 0 CA--C 1.535 1.313 0 N-CA-C 110.529 -1.028 . . . . 0.0 110.529 178.76 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -126.33 133.75 51.29 Favored 'General case' 0 N--CA 1.48 1.073 0 N-CA-C 109.269 -0.641 . . . . 0.0 109.269 179.12 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 65.7 mt -83.06 137.82 20.35 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.525 0 N-CA-C 107.282 -1.377 . . . . 0.0 107.282 178.614 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 20.9 mt -129.59 128.81 66.27 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.935 0 O-C-N 123.545 0.528 . . . . 0.0 110.119 -178.507 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 60.84 78.55 0.15 Allowed Glycine 0 CA--C 1.524 0.654 0 CA-C-N 115.97 -0.559 . . . . 0.0 113.063 178.848 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 1.9 tt -110.41 119.16 38.31 Favored 'General case' 0 N--CA 1.478 0.945 0 N-CA-C 107.021 -1.474 . . . . 0.0 107.021 177.463 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 8.5 ttt -154.44 161.08 41.89 Favored 'General case' 0 N--CA 1.468 0.456 0 N-CA-C 108.976 -0.75 . . . . 0.0 108.976 179.356 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 63.4 t -158.03 150.13 8.42 Favored 'Isoleucine or valine' 0 C--O 1.232 0.158 0 N-CA-C 106.816 -1.55 . . . . 0.0 106.816 -179.393 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.68 75.54 0.24 Allowed Glycine 0 C--N 1.315 -0.635 0 CA-C-N 115.776 -0.647 . . . . 0.0 111.75 178.172 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 168.76 -148.95 12.95 Favored Glycine 0 CA--C 1.519 0.325 0 N-CA-C 110.639 -0.984 . . . . 0.0 110.639 179.88 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 20.1 m -132.79 142.7 41.67 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.875 0 N-CA-C 109.666 -0.494 . . . . 0.0 109.666 179.716 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 21.3 t . . . . . 0 N--CA 1.468 0.454 0 CA-C-O 117.726 -1.13 . . . . 0.0 110.718 179.244 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 86.9 m-85 . . . . . 0 N--CA 1.473 0.689 0 N-CA-C 108.275 -1.009 . . . . 0.0 108.275 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' D' D ' 5' ' ' ARG . . . . . . . . . . . . . 72.5 mtp180 -147.31 141.18 25.82 Favored 'General case' 0 N--CA 1.476 0.829 0 N-CA-C 108.896 -0.779 . . . . 0.0 108.896 179.757 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 77.1 m80 -149.22 123.43 9.53 Favored 'General case' 0 CA--C 1.539 0.527 0 N-CA-C 107.915 -1.143 . . . . 0.0 107.915 175.724 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' D' D ' 7' ' ' ASP . . . . . . . . . . . . . 5.6 m-20 -63.12 133.77 54.96 Favored 'General case' 0 C--N 1.319 -0.719 0 C-N-CA 127.188 2.195 . . . . 0.0 114.882 176.081 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' D' D ' 8' ' ' SER . . . . . . . . . . . . . 7.9 t -154.09 174.36 14.81 Favored 'General case' 0 N--CA 1.477 0.914 0 CA-C-N 118.751 0.705 . . . . 0.0 110.302 176.958 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 124.29 20.25 2.48 Favored Glycine 0 N--CA 1.483 1.787 0 N-CA-C 112.232 -0.347 . . . . 0.0 112.232 176.645 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 37.0 p90 -55.91 130.29 43.11 Favored 'General case' 0 CA--C 1.546 0.79 0 CA-C-O 121.07 0.462 . . . . 0.0 111.881 -177.494 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 57.3 mt-10 -85.71 152.83 22.76 Favored 'General case' 0 N--CA 1.474 0.759 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 177.681 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -149.38 129.97 4.45 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.455 0 N-CA-C 108.009 -1.108 . . . . 0.0 108.009 175.229 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 48.9 m-70 -129.74 149.7 51.38 Favored 'General case' 0 N--CA 1.482 1.128 0 CA-C-N 117.939 0.336 . . . . 0.0 111.503 176.727 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 6.6 t60 -164.81 104.66 0.8 Allowed 'General case' 0 N--CA 1.482 1.133 0 N-CA-C 109.539 -0.541 . . . . 0.0 109.539 173.203 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 35.2 mt-30 -109.32 -175.62 2.81 Favored 'General case' 0 CA--C 1.494 -1.18 0 N-CA-C 108.28 -1.007 . . . . 0.0 108.28 178.978 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 88.7 tttt -165.77 105.25 0.7 Allowed 'General case' 0 CA--C 1.538 0.504 0 N-CA-C 107.637 -1.246 . . . . 0.0 107.637 175.331 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 5.6 mp -113.2 163.2 15.07 Favored 'General case' 0 N--CA 1.488 1.454 0 N-CA-C 108.225 -1.028 . . . . 0.0 108.225 179.699 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 51.8 t -140.9 123.67 15.72 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.187 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 176.215 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 78.7 m-85 -62.43 151.2 37.84 Favored 'General case' 0 C--N 1.353 0.759 0 C-N-CA 124.726 1.21 . . . . 0.0 110.412 170.862 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 9.3 t80 -170.0 -66.64 0.02 OUTLIER 'General case' 0 N--CA 1.476 0.871 0 N-CA-C 107.81 -1.182 . . . . 0.0 107.81 -179.835 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -38.27 95.75 0.01 OUTLIER 'General case' 0 CA--C 1.535 0.39 0 CA-C-N 113.972 -1.467 . . . . 0.0 111.731 -174.603 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 37.2 tt0 -68.7 158.72 33.61 Favored 'General case' 0 N--CA 1.467 0.421 0 CA-C-N 113.36 -1.746 . . . . 0.0 110.243 178.65 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 67.8 m-20 -140.34 141.17 35.69 Favored 'General case' 0 N--CA 1.475 0.822 0 N-CA-C 109.517 -0.549 . . . . 0.0 109.517 178.585 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' D' D ' 24' ' ' VAL . . . . . . . . . . . . . 19.6 t -87.83 -119.62 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.486 1.368 0 N-CA-C 107.752 -1.203 . . . . 0.0 107.752 179.727 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . -113.31 61.85 0.32 Allowed Glycine 0 C--N 1.372 2.559 0 C-N-CA 118.005 -2.045 . . . . 0.0 109.313 178.81 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 90.9 p -70.35 121.44 17.69 Favored 'General case' 0 C--N 1.349 0.574 0 CA-C-O 116.647 -1.644 . . . . 0.0 112.016 169.276 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 17.2 t-20 -61.36 101.67 0.18 Allowed 'General case' 0 N--CA 1.474 0.772 0 CA-C-N 121.558 1.981 . . . . 0.0 109.486 172.485 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 66.3 mttm -100.12 121.75 41.9 Favored 'General case' 0 N--CA 1.49 1.558 0 CA-C-N 119.64 1.109 . . . . 0.0 109.366 178.803 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -54.16 -130.2 0.0 OUTLIER Glycine 0 CA--C 1.529 0.961 0 CA-C-N 115.664 -0.698 . . . . 0.0 112.68 175.57 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -125.17 139.95 53.29 Favored 'General case' 0 C--N 1.373 1.614 0 N-CA-C 108.567 -0.901 . . . . 0.0 108.567 174.052 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 65.3 mt -84.13 140.29 16.35 Favored 'Isoleucine or valine' 0 C--O 1.239 0.506 0 N-CA-C 107.403 -1.332 . . . . 0.0 107.403 176.478 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 29.1 mt -131.89 132.95 61.51 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.017 0 N-CA-C 108.66 -0.866 . . . . 0.0 108.66 178.367 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.31 76.99 0.22 Allowed Glycine 0 C--O 1.248 0.994 0 CA-C-O 118.102 -1.388 . . . . 0.0 112.404 178.449 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 2.4 tt -110.2 131.43 55.07 Favored 'General case' 0 C--N 1.372 1.562 0 N-CA-C 103.96 -2.607 . . . . 0.0 103.96 174.968 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 8.3 ttt -156.85 166.7 32.63 Favored 'General case' 0 N--CA 1.471 0.594 0 N-CA-C 108.679 -0.86 . . . . 0.0 108.679 176.685 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 91.6 t -163.58 154.31 2.55 Favored 'Isoleucine or valine' 0 C--O 1.241 0.647 0 N-CA-C 105.545 -2.02 . . . . 0.0 105.545 175.379 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 61.39 66.51 2.61 Favored Glycine 0 N--CA 1.444 -0.782 0 C-N-CA 118.039 -2.029 . . . . 0.0 113.619 176.76 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 167.27 -148.39 13.05 Favored Glycine 0 N--CA 1.468 0.805 0 CA-C-O 118.163 -1.354 . . . . 0.0 111.859 -178.577 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 21.4 m -129.74 143.04 42.32 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.166 0 CA-C-N 118.896 1.348 . . . . 0.0 109.64 -179.944 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 18.8 t . . . . . 0 C--O 1.215 -0.745 0 N-CA-C 109.204 -0.665 . . . . 0.0 109.204 174.798 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 79.1 m-85 . . . . . 0 N--CA 1.476 0.829 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' E' E ' 5' ' ' ARG . . . . . . . . . . . . . 72.3 mtp180 -143.62 141.96 30.84 Favored 'General case' 0 N--CA 1.478 0.933 0 N-CA-C 109.392 -0.595 . . . . 0.0 109.392 179.893 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 76.8 m80 -150.37 118.23 6.24 Favored 'General case' 0 N--CA 1.473 0.692 0 N-CA-C 108.962 -0.755 . . . . 0.0 108.962 179.123 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' E' E ' 7' ' ' ASP . . . . . . . . . . . . . 7.5 m-20 -66.7 149.96 49.77 Favored 'General case' 0 N--CA 1.463 0.224 0 O-C-N 123.542 0.526 . . . . 0.0 111.639 -179.515 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' E' E ' 8' ' ' SER . . . . . . . . . . . . . 7.9 t -166.95 173.43 9.33 Favored 'General case' 0 N--CA 1.476 0.875 0 CA-C-N 115.965 -0.561 . . . . 0.0 109.549 178.003 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.85 23.59 2.23 Favored Glycine 0 N--CA 1.482 1.737 0 N-CA-C 111.908 -0.477 . . . . 0.0 111.908 179.163 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 38.2 p90 -56.64 127.49 31.65 Favored 'General case' 0 N--CA 1.473 0.676 0 N-CA-C 112.602 0.593 . . . . 0.0 112.602 -179.241 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 57.0 mt-10 -84.34 156.2 21.99 Favored 'General case' 0 N--CA 1.476 0.827 0 N-CA-C 109.482 -0.562 . . . . 0.0 109.482 178.045 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -155.62 127.9 1.03 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.512 0 N-CA-C 108.185 -1.042 . . . . 0.0 108.185 178.702 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 49.0 m-70 -135.08 144.81 47.4 Favored 'General case' 0 N--CA 1.48 1.073 0 CA-C-O 120.757 0.313 . . . . 0.0 111.38 -177.933 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 6.3 t60 -163.94 97.94 0.84 Allowed 'General case' 0 N--CA 1.487 1.379 0 CA-C-N 116.652 -0.249 . . . . 0.0 111.064 179.702 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 35.2 mt-30 -105.51 -172.45 2.1 Favored 'General case' 0 CA--C 1.502 -0.878 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 -179.951 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -169.45 96.56 0.32 Allowed 'General case' 0 CA--C 1.542 0.638 0 CA-C-N 115.018 -0.992 . . . . 0.0 109.402 178.658 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' E' E ' 17' ' ' LEU . . . . . 0.4 ' N ' ' CD1' ' E' ' 17' ' ' LEU . 4.8 mp -106.21 164.11 12.26 Favored 'General case' 0 N--CA 1.49 1.547 0 N-CA-C 109.233 -0.654 . . . . 0.0 109.233 -179.765 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 40.8 t -141.59 118.46 7.5 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 C-N-CA 122.563 0.345 . . . . 0.0 110.551 179.085 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 52.7 m-85 -69.45 156.54 38.69 Favored 'General case' 0 C--N 1.358 0.957 0 N-CA-C 107.397 -1.335 . . . . 0.0 107.397 176.696 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 12.7 t80 -173.28 -55.06 0.02 OUTLIER 'General case' 0 N--CA 1.485 1.299 0 CA-C-O 121.741 0.782 . . . . 0.0 110.368 179.472 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.23 89.1 0.0 OUTLIER 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 114.398 -1.274 . . . . 0.0 112.852 -179.009 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 37.0 tt0 -65.16 158.31 26.37 Favored 'General case' 0 N--CA 1.472 0.646 0 CA-C-N 114.876 -1.056 . . . . 0.0 110.698 179.604 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 66.1 m-20 -140.68 137.03 33.23 Favored 'General case' 0 N--CA 1.479 0.997 0 C-N-CA 122.853 0.461 . . . . 0.0 110.518 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 21.8 t -84.52 -115.5 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.066 0 N-CA-C 108.715 -0.846 . . . . 0.0 108.715 179.48 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . -110.09 54.38 0.55 Allowed Glycine 0 C--N 1.348 1.214 0 N-CA-C 111.362 -0.695 . . . . 0.0 111.362 -179.827 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 73.2 p -79.72 125.27 29.44 Favored 'General case' 0 N--CA 1.473 0.709 0 N-CA-C 109.34 -0.615 . . . . 0.0 109.34 178.059 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 18.4 t-20 -66.27 99.88 0.58 Allowed 'General case' 0 N--CA 1.474 0.765 0 N-CA-C 108.063 -1.088 . . . . 0.0 108.063 178.386 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 65.9 mttm -96.99 119.45 35.5 Favored 'General case' 0 N--CA 1.485 1.293 0 N-CA-C 109.966 -0.383 . . . . 0.0 109.966 -178.744 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.28 -127.32 0.01 OUTLIER Glycine 0 CA--C 1.539 1.581 0 N-CA-C 110.988 -0.845 . . . . 0.0 110.988 178.724 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -126.9 133.2 50.73 Favored 'General case' 0 N--CA 1.481 1.102 0 N-CA-C 109.585 -0.524 . . . . 0.0 109.585 179.614 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 64.8 mt -82.38 138.17 19.88 Favored 'Isoleucine or valine' 0 C--O 1.236 0.35 0 N-CA-C 107.093 -1.447 . . . . 0.0 107.093 178.492 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 22.4 mt -129.3 129.49 67.35 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.858 0 N-CA-C 109.444 -0.576 . . . . 0.0 109.444 -179.426 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 60.65 80.27 0.1 Allowed Glycine 0 CA--C 1.523 0.554 0 CA-C-N 115.982 -0.554 . . . . 0.0 113.654 179.33 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 2.0 tt -111.98 118.99 36.99 Favored 'General case' 0 N--CA 1.479 0.992 0 N-CA-C 107.056 -1.461 . . . . 0.0 107.056 177.358 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 8.2 ttt -153.37 162.88 40.82 Favored 'General case' 0 C--O 1.209 -1.041 0 N-CA-C 108.696 -0.853 . . . . 0.0 108.696 179.202 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 78.0 t -159.65 150.27 6.46 Favored 'Isoleucine or valine' 0 C--O 1.236 0.351 0 N-CA-C 106.591 -1.633 . . . . 0.0 106.591 -179.748 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.53 74.97 0.27 Allowed Glycine 0 C--N 1.314 -0.656 0 CA-C-N 115.63 -0.714 . . . . 0.0 111.535 178.139 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 170.08 -148.14 11.44 Favored Glycine 0 C--O 1.222 -0.653 0 N-CA-C 111.248 -0.741 . . . . 0.0 111.248 -179.995 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 19.4 m -133.42 141.54 44.18 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.846 0 N-CA-C 109.188 -0.671 . . . . 0.0 109.188 179.498 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 19.0 t . . . . . 0 CA--C 1.535 0.372 0 CA-C-O 117.648 -1.168 . . . . 0.0 110.847 179.35 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 78.7 m-85 . . . . . 0 N--CA 1.475 0.798 0 N-CA-C 109.895 -0.409 . . . . 0.0 109.895 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' F' F ' 5' ' ' ARG . . . . . . . . . . . . . 72.4 mtp180 -143.43 141.62 30.91 Favored 'General case' 0 N--CA 1.477 0.878 0 N-CA-C 109.38 -0.6 . . . . 0.0 109.38 179.895 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 76.8 m80 -150.12 117.87 6.21 Favored 'General case' 0 N--CA 1.473 0.714 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 179.207 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' F' F ' 7' ' ' ASP . . . . . . . . . . . . . 7.5 m-20 -66.5 150.42 48.98 Favored 'General case' 0 N--CA 1.461 0.106 0 O-C-N 123.468 0.48 . . . . 0.0 111.711 -179.447 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' F' F ' 8' ' ' SER . . . . . . . . . . . . . 7.8 t -167.53 172.9 9.09 Favored 'General case' 0 N--CA 1.476 0.847 0 CA-C-N 116.015 -0.539 . . . . 0.0 109.568 178.065 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 123.34 23.63 2.12 Favored Glycine 0 N--CA 1.481 1.637 0 N-CA-C 111.997 -0.441 . . . . 0.0 111.997 179.064 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 36.6 p90 -56.74 127.97 34.18 Favored 'General case' 0 CA--C 1.542 0.671 0 N-CA-C 112.599 0.592 . . . . 0.0 112.599 -179.217 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 57.2 mt-10 -84.41 156.37 21.84 Favored 'General case' 0 N--CA 1.475 0.813 0 N-CA-C 109.457 -0.571 . . . . 0.0 109.457 178.063 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -155.77 127.53 0.96 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.586 0 N-CA-C 108.189 -1.041 . . . . 0.0 108.189 178.637 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 50.3 m-70 -134.76 144.73 47.87 Favored 'General case' 0 N--CA 1.481 1.078 0 CA-C-O 120.748 0.309 . . . . 0.0 111.341 -177.819 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 6.3 t60 -164.11 98.13 0.83 Allowed 'General case' 0 N--CA 1.486 1.356 0 CA-C-N 116.707 -0.224 . . . . 0.0 111.169 179.674 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 35.2 mt-30 -106.09 -172.36 2.07 Favored 'General case' 0 CA--C 1.498 -1.05 0 N-CA-C 108.787 -0.82 . . . . 0.0 108.787 179.989 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -169.23 96.87 0.34 Allowed 'General case' 0 CA--C 1.54 0.584 0 CA-C-N 114.891 -1.05 . . . . 0.0 109.443 178.687 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' F' F ' 17' ' ' LEU . . . . . 0.401 ' CD1' ' N ' ' F' ' 17' ' ' LEU . 4.7 mp -106.27 164.1 12.29 Favored 'General case' 0 N--CA 1.489 1.48 0 N-CA-C 109.209 -0.663 . . . . 0.0 109.209 -179.842 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 41.3 t -141.69 118.74 7.6 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.457 0 C-N-CA 122.55 0.34 . . . . 0.0 110.473 179.098 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 53.2 m-85 -69.56 156.49 38.82 Favored 'General case' 0 C--N 1.358 0.949 0 N-CA-C 107.253 -1.388 . . . . 0.0 107.253 176.612 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 13.1 t80 -173.15 -55.48 0.02 OUTLIER 'General case' 0 N--CA 1.484 1.267 0 CA-C-O 121.735 0.778 . . . . 0.0 109.904 179.484 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.73 88.89 0.0 OUTLIER 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 114.428 -1.26 . . . . 0.0 112.95 -179.047 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 36.7 tt0 -65.16 158.2 26.65 Favored 'General case' 0 N--CA 1.47 0.567 0 CA-C-N 114.952 -1.022 . . . . 0.0 110.786 179.504 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 66.5 m-20 -140.84 137.32 33.18 Favored 'General case' 0 N--CA 1.478 0.949 0 C-N-CA 122.813 0.445 . . . . 0.0 110.58 179.994 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' F' F ' 24' ' ' VAL . . . . . . . . . . . . . 21.5 t -84.84 -115.98 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.09 0 N-CA-C 108.811 -0.811 . . . . 0.0 108.811 179.523 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -109.48 54.08 0.56 Allowed Glycine 0 N--CA 1.479 1.511 0 N-CA-C 111.24 -0.744 . . . . 0.0 111.24 -179.836 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 75.6 p -79.46 125.04 29.04 Favored 'General case' 0 N--CA 1.472 0.668 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 177.883 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 18.5 t-20 -66.19 99.71 0.55 Allowed 'General case' 0 N--CA 1.472 0.672 0 N-CA-C 108.125 -1.065 . . . . 0.0 108.125 178.457 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 66.1 mttm -96.78 119.29 34.98 Favored 'General case' 0 N--CA 1.484 1.269 0 N-CA-C 110.056 -0.35 . . . . 0.0 110.056 -178.711 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.19 -127.51 0.01 OUTLIER Glycine 0 CA--C 1.54 1.623 0 N-CA-C 111.093 -0.803 . . . . 0.0 111.093 178.796 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -126.35 133.14 51.43 Favored 'General case' 0 N--CA 1.482 1.161 0 N-CA-C 109.577 -0.527 . . . . 0.0 109.577 179.612 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 65.4 mt -82.73 138.07 19.98 Favored 'Isoleucine or valine' 0 C--O 1.236 0.345 0 N-CA-C 106.958 -1.497 . . . . 0.0 106.958 178.497 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 23.5 mt -129.22 129.61 67.59 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.811 0 N-CA-C 109.381 -0.6 . . . . 0.0 109.381 -179.365 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 60.51 80.17 0.1 Allowed Glycine 0 CA--C 1.522 0.518 0 CA-C-N 115.986 -0.552 . . . . 0.0 113.618 179.271 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 2.0 tt -111.89 119.28 38.0 Favored 'General case' 0 N--CA 1.479 0.991 0 N-CA-C 106.971 -1.492 . . . . 0.0 106.971 177.472 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 8.5 ttt -153.93 162.97 40.8 Favored 'General case' 0 C--O 1.209 -1.075 0 N-CA-C 108.81 -0.811 . . . . 0.0 108.81 179.212 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 81.2 t -159.61 150.64 6.4 Favored 'Isoleucine or valine' 0 C--O 1.237 0.412 0 N-CA-C 106.713 -1.588 . . . . 0.0 106.713 -179.651 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.34 75.0 0.26 Allowed Glycine 0 C--N 1.314 -0.644 0 CA-C-N 115.662 -0.699 . . . . 0.0 111.483 178.089 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 170.1 -147.89 11.19 Favored Glycine 0 C--O 1.221 -0.668 0 N-CA-C 111.226 -0.75 . . . . 0.0 111.226 -179.993 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 19.6 m -133.77 141.42 44.17 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.884 0 N-CA-C 109.203 -0.666 . . . . 0.0 109.203 179.442 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 19.3 t . . . . . 0 CA--C 1.533 0.313 0 CA-C-O 117.605 -1.188 . . . . 0.0 110.868 179.365 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 78.6 m-85 . . . . . 0 N--CA 1.476 0.836 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' G' G ' 5' ' ' ARG . . . . . . . . . . . . . 72.7 mtp180 -143.93 141.16 30.09 Favored 'General case' 0 N--CA 1.483 1.191 0 N-CA-C 109.282 -0.636 . . . . 0.0 109.282 -179.657 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 76.9 m80 -149.49 119.36 7.1 Favored 'General case' 0 N--CA 1.473 0.715 0 N-CA-C 109.05 -0.722 . . . . 0.0 109.05 179.116 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 8.0 m-20 -68.74 145.96 53.36 Favored 'General case' 0 CA--C 1.536 0.411 0 O-C-N 123.472 0.482 . . . . 0.0 111.942 -179.327 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' G' G ' 8' ' ' SER . . . . . . . . . . . . . 7.1 t -163.83 174.2 11.83 Favored 'General case' 0 N--CA 1.47 0.55 0 N-CA-C 109.443 -0.577 . . . . 0.0 109.443 178.171 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 123.06 23.34 2.23 Favored Glycine 0 N--CA 1.48 1.606 0 N-CA-C 111.643 -0.583 . . . . 0.0 111.643 178.89 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 40.8 p90 -56.86 127.86 33.82 Favored 'General case' 0 N--CA 1.473 0.68 0 N-CA-C 112.418 0.525 . . . . 0.0 112.418 -178.89 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 57.6 mt-10 -84.94 154.74 22.0 Favored 'General case' 0 N--CA 1.473 0.717 0 CA-C-O 121.054 0.454 . . . . 0.0 109.981 178.795 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -155.26 127.67 1.04 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.97 0 N-CA-C 108.246 -1.02 . . . . 0.0 108.246 178.847 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 51.6 m-70 -133.77 146.13 50.44 Favored 'General case' 0 N--CA 1.476 0.844 0 CA-C-N 115.443 -0.799 . . . . 0.0 111.09 -178.159 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 6.4 t60 -165.57 97.74 0.68 Allowed 'General case' 0 N--CA 1.483 1.183 0 CA-C-N 116.511 -0.313 . . . . 0.0 110.656 179.123 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 35.8 mt-30 -105.7 -172.64 2.13 Favored 'General case' 0 CA--C 1.503 -0.862 0 N-CA-C 108.726 -0.842 . . . . 0.0 108.726 -179.849 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -169.2 97.07 0.35 Allowed 'General case' 0 CA--C 1.54 0.587 0 CA-C-N 115.0 -1.0 . . . . 0.0 109.444 178.629 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' G' G ' 17' ' ' LEU . . . . . 0.403 ' CD1' ' N ' ' G' ' 17' ' ' LEU . 5.4 mp -106.31 163.14 13.07 Favored 'General case' 0 N--CA 1.487 1.387 0 N-CA-C 109.427 -0.583 . . . . 0.0 109.427 -179.669 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 39.6 t -142.5 118.92 6.04 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.068 0 CA-C-O 120.886 0.374 . . . . 0.0 110.327 178.779 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 47.2 m-85 -69.79 150.32 47.0 Favored 'General case' 0 C--N 1.37 1.482 0 N-CA-C 107.357 -1.349 . . . . 0.0 107.357 176.737 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 10.7 t80 -170.73 -55.26 0.02 OUTLIER 'General case' 0 N--CA 1.486 1.359 0 CA-C-N 117.903 0.319 . . . . 0.0 110.356 -179.601 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.73 90.02 0.0 OUTLIER 'General case' 0 C--N 1.325 -0.477 0 C-N-CA 123.74 0.816 . . . . 0.0 112.574 -179.882 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 37.1 tt0 -65.54 159.3 24.87 Favored 'General case' 0 N--CA 1.468 0.462 0 CA-C-N 114.694 -1.139 . . . . 0.0 109.954 179.069 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 67.2 m-20 -141.23 137.35 32.51 Favored 'General case' 0 N--CA 1.476 0.873 0 C-N-CA 122.792 0.437 . . . . 0.0 109.993 179.962 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' G' G ' 24' ' ' VAL . . . . . . . . . . . . . 21.6 t -85.53 -115.41 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.99 0 N-CA-C 108.408 -0.96 . . . . 0.0 108.408 179.598 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -110.16 53.9 0.57 Allowed Glycine 0 N--CA 1.478 1.443 0 N-CA-C 111.612 -0.595 . . . . 0.0 111.612 -179.812 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 75.8 p -79.67 125.88 30.21 Favored 'General case' 0 N--CA 1.466 0.366 0 N-CA-C 109.119 -0.697 . . . . 0.0 109.119 178.026 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 19.2 t-20 -66.87 100.5 0.73 Allowed 'General case' 0 CA--C 1.54 0.569 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 178.424 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 67.0 mttm -96.7 119.93 36.09 Favored 'General case' 0 N--CA 1.482 1.139 0 N-CA-C 110.085 -0.339 . . . . 0.0 110.085 -179.087 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.76 -125.52 0.01 OUTLIER Glycine 0 CA--C 1.533 1.21 0 N-CA-C 110.571 -1.012 . . . . 0.0 110.571 178.828 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -127.81 133.09 49.41 Favored 'General case' 0 N--CA 1.47 0.555 0 N-CA-C 109.579 -0.526 . . . . 0.0 109.579 179.684 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 68.2 mt -81.93 140.19 16.84 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.646 0 N-CA-C 107.22 -1.4 . . . . 0.0 107.22 178.475 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 27.6 mt -131.1 130.84 63.9 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 CA-C-N 119.057 0.844 . . . . 0.0 109.274 179.912 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 60.46 79.81 0.11 Allowed Glycine 0 CA--C 1.527 0.813 0 CA-C-N 116.269 -0.423 . . . . 0.0 113.127 179.273 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 1.9 tt -111.87 120.29 41.46 Favored 'General case' 0 N--CA 1.479 1.011 0 N-CA-C 106.909 -1.515 . . . . 0.0 106.909 177.394 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 8.4 ttt -155.35 163.08 40.58 Favored 'General case' 0 C--O 1.211 -0.945 0 N-CA-C 108.03 -1.1 . . . . 0.0 108.03 179.466 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 99.6 t -159.44 150.19 6.7 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 N-CA-C 106.295 -1.742 . . . . 0.0 106.295 -179.72 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.41 75.2 0.26 Allowed Glycine 0 C--N 1.312 -0.755 0 C-N-CA 121.093 -0.575 . . . . 0.0 111.956 177.801 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 168.51 -146.24 10.24 Favored Glycine 0 N--CA 1.47 0.928 0 N-CA-C 110.688 -0.965 . . . . 0.0 110.688 179.209 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 22.2 m -134.43 141.61 43.03 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.914 0 CA-C-N 117.039 0.42 . . . . 0.0 109.994 179.873 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 19.3 t . . . . . 0 N--CA 1.471 0.595 0 CA-C-O 117.678 -1.153 . . . . 0.0 110.914 179.541 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 79.4 m-85 . . . . . 0 N--CA 1.474 0.757 0 N-CA-C 109.662 -0.496 . . . . 0.0 109.662 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' H' H ' 5' ' ' ARG . . . . . . . . . . . . . 72.6 mtp180 -144.1 140.95 29.75 Favored 'General case' 0 N--CA 1.482 1.149 0 N-CA-C 109.219 -0.66 . . . . 0.0 109.219 -179.608 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 76.9 m80 -149.35 119.21 7.09 Favored 'General case' 0 N--CA 1.473 0.721 0 N-CA-C 109.076 -0.712 . . . . 0.0 109.076 179.07 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -68.33 145.87 53.79 Favored 'General case' 0 N--CA 1.468 0.431 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.951 -179.413 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' H' H ' 8' ' ' SER . . . . . . . . . . . . . 8.2 t -163.84 173.85 12.25 Favored 'General case' 0 N--CA 1.469 0.508 0 N-CA-C 109.373 -0.602 . . . . 0.0 109.373 178.321 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.89 23.09 2.31 Favored Glycine 0 N--CA 1.48 1.632 0 N-CA-C 111.828 -0.509 . . . . 0.0 111.828 179.125 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 40.4 p90 -56.64 127.81 33.26 Favored 'General case' 0 N--CA 1.474 0.735 0 N-CA-C 112.402 0.519 . . . . 0.0 112.402 -178.996 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 57.7 mt-10 -84.74 155.28 21.95 Favored 'General case' 0 N--CA 1.475 0.806 0 CA-C-O 121.121 0.486 . . . . 0.0 109.917 178.791 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -155.78 127.62 0.97 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.971 0 N-CA-C 108.263 -1.014 . . . . 0.0 108.263 178.847 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 51.3 m-70 -133.79 146.08 50.37 Favored 'General case' 0 N--CA 1.476 0.847 0 CA-C-N 115.423 -0.808 . . . . 0.0 111.239 -178.197 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 6.4 t60 -165.55 97.75 0.68 Allowed 'General case' 0 N--CA 1.482 1.146 0 CA-C-N 116.582 -0.281 . . . . 0.0 110.673 179.159 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 35.3 mt-30 -105.68 -173.04 2.21 Favored 'General case' 0 CA--C 1.501 -0.934 0 N-CA-C 108.549 -0.908 . . . . 0.0 108.549 -179.848 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -169.08 96.74 0.35 Allowed 'General case' 0 CA--C 1.54 0.562 0 CA-C-N 114.941 -1.027 . . . . 0.0 109.276 178.775 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' H' H ' 17' ' ' LEU . . . . . 0.401 ' N ' ' CD1' ' H' ' 17' ' ' LEU . 5.4 mp -106.21 163.29 12.92 Favored 'General case' 0 N--CA 1.487 1.382 0 N-CA-C 109.349 -0.612 . . . . 0.0 109.349 -179.553 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 40.1 t -142.63 118.48 5.44 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.037 0 CA-C-O 120.929 0.395 . . . . 0.0 110.479 178.895 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 48.0 m-85 -69.57 150.72 46.8 Favored 'General case' 0 C--N 1.37 1.483 0 N-CA-C 107.386 -1.338 . . . . 0.0 107.386 176.686 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 11.6 t80 -171.99 -54.66 0.02 OUTLIER 'General case' 0 N--CA 1.485 1.293 0 CA-C-N 117.837 0.289 . . . . 0.0 110.32 -179.537 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.94 90.39 0.0 OUTLIER 'General case' 0 CA--C 1.535 0.371 0 C-N-CA 123.685 0.794 . . . . 0.0 112.299 -179.974 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 37.2 tt0 -65.86 159.07 26.26 Favored 'General case' 0 N--CA 1.469 0.506 0 CA-C-N 114.784 -1.098 . . . . 0.0 110.006 179.254 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 67.0 m-20 -140.99 137.46 33.03 Favored 'General case' 0 N--CA 1.477 0.877 0 C-N-CA 122.845 0.458 . . . . 0.0 110.098 179.884 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' H' H ' 24' ' ' VAL . . . . . . . . . . . . . 21.4 t -85.8 -115.59 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.991 0 N-CA-C 108.531 -0.915 . . . . 0.0 108.531 179.601 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . -109.57 53.88 0.57 Allowed Glycine 0 N--CA 1.481 1.651 0 N-CA-C 111.379 -0.688 . . . . 0.0 111.379 -179.813 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 75.8 p -79.75 125.75 30.07 Favored 'General case' 0 N--CA 1.467 0.386 0 N-CA-C 108.958 -0.756 . . . . 0.0 108.958 178.034 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 19.3 t-20 -66.95 100.59 0.75 Allowed 'General case' 0 N--CA 1.471 0.605 0 N-CA-C 108.352 -0.981 . . . . 0.0 108.352 178.51 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 66.6 mttm -96.79 119.6 35.57 Favored 'General case' 0 N--CA 1.483 1.189 0 N-CA-C 110.097 -0.334 . . . . 0.0 110.097 -179.076 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.41 -125.18 0.01 OUTLIER Glycine 0 CA--C 1.534 1.267 0 N-CA-C 110.738 -0.945 . . . . 0.0 110.738 178.71 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.11 132.81 48.95 Favored 'General case' 0 N--CA 1.47 0.569 0 N-CA-C 109.66 -0.496 . . . . 0.0 109.66 179.839 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 68.7 mt -81.95 139.96 17.18 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.587 0 N-CA-C 107.11 -1.441 . . . . 0.0 107.11 178.525 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 28.0 mt -130.98 130.75 64.17 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.417 0 CA-C-N 118.912 0.778 . . . . 0.0 109.273 -179.978 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 60.48 79.7 0.11 Allowed Glycine 0 CA--C 1.526 0.742 0 CA-C-N 116.301 -0.409 . . . . 0.0 113.126 179.231 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 1.9 tt -111.84 120.05 40.64 Favored 'General case' 0 N--CA 1.479 1.018 0 N-CA-C 106.889 -1.523 . . . . 0.0 106.889 177.42 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 8.5 ttt -154.97 163.18 40.67 Favored 'General case' 0 N--CA 1.479 0.982 0 N-CA-C 107.958 -1.127 . . . . 0.0 107.958 179.505 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 93.6 t -159.78 150.43 6.29 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.254 0 N-CA-C 106.275 -1.75 . . . . 0.0 106.275 -179.735 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.15 75.13 0.26 Allowed Glycine 0 C--N 1.313 -0.731 0 CA-C-N 115.942 -0.572 . . . . 0.0 111.922 177.959 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 168.42 -146.51 10.49 Favored Glycine 0 N--CA 1.471 0.992 0 N-CA-C 110.632 -0.987 . . . . 0.0 110.632 179.273 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 22.3 m -134.23 141.85 42.55 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.924 0 CA-C-N 116.977 0.389 . . . . 0.0 109.998 179.976 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 19.4 t . . . . . 0 N--CA 1.47 0.543 0 CA-C-O 117.768 -1.111 . . . . 0.0 110.918 179.489 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 78.3 m-85 . . . . . 0 N--CA 1.474 0.745 0 N-CA-C 109.651 -0.5 . . . . 0.0 109.651 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' I' I ' 5' ' ' ARG . . . . . . . . . . . . . 72.7 mtp180 -144.49 140.95 29.21 Favored 'General case' 0 N--CA 1.482 1.158 0 N-CA-C 109.232 -0.655 . . . . 0.0 109.232 -179.619 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 76.9 m80 -149.31 118.93 6.97 Favored 'General case' 0 N--CA 1.474 0.753 0 N-CA-C 109.11 -0.7 . . . . 0.0 109.11 179.095 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 8.0 m-20 -68.1 145.87 54.0 Favored 'General case' 0 N--CA 1.467 0.385 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.82 -179.361 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' I' I ' 8' ' ' SER . . . . . . . . . . . . . 8.3 t -163.91 173.7 12.36 Favored 'General case' 0 N--CA 1.47 0.555 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 178.34 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.97 23.32 2.25 Favored Glycine 0 N--CA 1.481 1.657 0 N-CA-C 111.845 -0.502 . . . . 0.0 111.845 179.156 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 41.0 p90 -56.81 128.03 34.61 Favored 'General case' 0 N--CA 1.473 0.683 0 N-CA-C 112.437 0.532 . . . . 0.0 112.437 -178.99 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 57.9 mt-10 -84.86 155.19 21.85 Favored 'General case' 0 N--CA 1.474 0.757 0 CA-C-O 121.074 0.464 . . . . 0.0 109.976 178.755 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -155.7 127.65 0.99 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.977 0 N-CA-C 108.236 -1.024 . . . . 0.0 108.236 178.777 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 51.2 m-70 -133.68 146.41 50.81 Favored 'General case' 0 N--CA 1.476 0.849 0 CA-C-N 115.372 -0.831 . . . . 0.0 111.119 -178.162 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 6.5 t60 -165.99 97.89 0.63 Allowed 'General case' 0 N--CA 1.482 1.164 0 CA-C-N 116.556 -0.293 . . . . 0.0 110.696 179.026 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 35.3 mt-30 -105.85 -172.75 2.15 Favored 'General case' 0 CA--C 1.5 -0.948 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 -179.825 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -169.18 96.82 0.34 Allowed 'General case' 0 CA--C 1.539 0.543 0 CA-C-N 114.901 -1.045 . . . . 0.0 109.355 178.769 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' I' I ' 17' ' ' LEU . . . . . 0.402 ' CD1' ' N ' ' I' ' 17' ' ' LEU . 5.4 mp -106.19 163.15 13.03 Favored 'General case' 0 N--CA 1.488 1.43 0 N-CA-C 109.301 -0.629 . . . . 0.0 109.301 -179.555 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 40.1 t -142.48 118.37 5.66 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.015 0 CA-C-O 120.901 0.382 . . . . 0.0 110.387 178.933 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 48.6 m-85 -69.43 151.02 46.61 Favored 'General case' 0 C--N 1.372 1.553 0 N-CA-C 107.414 -1.328 . . . . 0.0 107.414 176.654 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 11.7 t80 -172.19 -54.98 0.02 OUTLIER 'General case' 0 N--CA 1.483 1.225 0 CA-C-N 117.822 0.283 . . . . 0.0 110.346 -179.587 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.81 90.29 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.465 0 C-N-CA 123.712 0.805 . . . . 0.0 112.327 -179.984 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 37.3 tt0 -65.68 159.15 25.57 Favored 'General case' 0 N--CA 1.468 0.464 0 CA-C-N 114.686 -1.143 . . . . 0.0 110.023 179.304 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 66.6 m-20 -140.92 137.21 32.97 Favored 'General case' 0 N--CA 1.476 0.834 0 C-N-CA 122.906 0.482 . . . . 0.0 110.122 179.835 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' I' I ' 24' ' ' VAL . . . . . . . . . . . . . 21.5 t -85.47 -115.35 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.034 0 N-CA-C 108.479 -0.934 . . . . 0.0 108.479 179.58 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . -109.84 53.44 0.59 Allowed Glycine 0 N--CA 1.48 1.584 0 N-CA-C 111.495 -0.642 . . . . 0.0 111.495 -179.761 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 77.0 p -79.29 125.79 29.95 Favored 'General case' 0 N--CA 1.467 0.388 0 N-CA-C 109.131 -0.692 . . . . 0.0 109.131 177.992 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 19.5 t-20 -67.14 100.54 0.78 Allowed 'General case' 0 N--CA 1.471 0.625 0 N-CA-C 108.395 -0.965 . . . . 0.0 108.395 178.525 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 66.8 mttm -96.71 120.05 36.32 Favored 'General case' 0 N--CA 1.483 1.221 0 N-CA-C 110.129 -0.323 . . . . 0.0 110.129 -179.11 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.7 -125.36 0.01 OUTLIER Glycine 0 CA--C 1.535 1.319 0 N-CA-C 110.688 -0.965 . . . . 0.0 110.688 178.793 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -127.78 132.82 49.47 Favored 'General case' 0 N--CA 1.473 0.682 0 C-N-CA 123.023 0.529 . . . . 0.0 109.653 179.633 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 68.2 mt -81.92 139.91 17.24 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.582 0 N-CA-C 107.13 -1.433 . . . . 0.0 107.13 178.479 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 27.2 mt -130.99 130.87 64.22 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.373 0 CA-C-N 118.977 0.808 . . . . 0.0 109.282 -179.938 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 60.38 79.68 0.11 Allowed Glycine 0 CA--C 1.527 0.805 0 CA-C-N 116.285 -0.416 . . . . 0.0 113.079 179.261 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 1.9 tt -111.9 120.07 40.67 Favored 'General case' 0 N--CA 1.48 1.038 0 N-CA-C 106.823 -1.547 . . . . 0.0 106.823 177.432 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 8.5 ttt -154.9 163.28 40.51 Favored 'General case' 0 C--O 1.211 -0.958 0 N-CA-C 108.005 -1.109 . . . . 0.0 108.005 179.461 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 98.7 t -159.72 150.41 6.35 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.257 0 N-CA-C 106.273 -1.751 . . . . 0.0 106.273 -179.739 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.08 75.23 0.26 Allowed Glycine 0 C--N 1.315 -0.631 0 CA-C-N 115.893 -0.594 . . . . 0.0 111.951 177.907 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 168.46 -146.33 10.33 Favored Glycine 0 N--CA 1.469 0.886 0 N-CA-C 110.643 -0.983 . . . . 0.0 110.643 179.287 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 22.3 m -134.39 141.72 42.75 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.856 0 CA-C-N 116.985 0.392 . . . . 0.0 110.038 179.928 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 18.9 t . . . . . 0 N--CA 1.469 0.488 0 CA-C-O 117.765 -1.112 . . . . 0.0 110.92 179.434 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 55.1 m-85 . . . . . 0 N--CA 1.475 0.804 0 N-CA-C 110.241 -0.281 . . . . 0.0 110.241 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 -144.33 142.14 30.2 Favored 'General case' 0 N--CA 1.482 1.131 0 N-CA-C 110.01 -0.366 . . . . 0.0 110.01 179.713 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 41.7 t-80 -152.43 119.69 5.92 Favored 'General case' 0 N--CA 1.472 0.674 0 N-CA-C 109.23 -0.655 . . . . 0.0 109.23 179.098 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' ASP . . . . . 0.511 ' O ' ' OG ' ' D' ' 8' ' ' SER . 4.6 m-20 -69.02 148.68 49.73 Favored 'General case' 0 CA--C 1.535 0.383 0 CA-C-N 116.341 -0.39 . . . . 0.0 110.412 179.893 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' SER . . . . . 0.463 ' H ' ' HG ' ' C' ' 26' ' ' SER . 54.0 p -167.65 -173.58 2.21 Favored 'General case' 0 N--CA 1.481 1.084 0 CA-C-O 120.92 0.391 . . . . 0.0 110.698 179.217 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.26 47.45 1.32 Allowed Glycine 0 N--CA 1.482 1.742 0 CA-C-N 116.036 -0.529 . . . . 0.0 111.905 -179.941 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 49.7 p90 -66.03 133.03 49.93 Favored 'General case' 0 N--CA 1.473 0.695 0 CA-C-O 120.74 0.305 . . . . 0.0 111.618 179.814 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 84.2 mt-10 -91.82 152.19 20.24 Favored 'General case' 0 N--CA 1.477 0.91 0 N-CA-C 109.662 -0.496 . . . . 0.0 109.662 178.443 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -152.67 128.31 1.68 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.593 0 N-CA-C 107.884 -1.154 . . . . 0.0 107.884 178.074 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 43.7 m-70 -135.9 148.5 48.6 Favored 'General case' 0 N--CA 1.493 1.681 0 CA-C-N 119.025 0.829 . . . . 0.0 111.292 -178.986 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 6.6 t60 -164.82 98.47 0.76 Allowed 'General case' 0 N--CA 1.48 1.053 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.823 179.396 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -91.85 -177.38 4.72 Favored 'General case' 0 CA--C 1.514 -0.432 0 N-CA-C 108.851 -0.796 . . . . 0.0 108.851 -179.933 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -172.06 93.74 0.14 Allowed 'General case' 0 N--CA 1.469 0.489 0 CA-C-N 114.659 -1.155 . . . . 0.0 108.566 177.94 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 6.3 mp -124.77 155.98 38.46 Favored 'General case' 0 N--CA 1.497 1.896 0 CA-C-O 121.744 0.783 . . . . 0.0 110.989 -178.417 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 61.0 t -111.63 124.46 68.4 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.024 0 CA-C-O 117.825 -1.083 . . . . 0.0 108.469 177.77 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 29.4 m-85 -124.27 143.78 50.35 Favored 'General case' 0 N--CA 1.498 1.946 0 CA-C-N 120.177 1.353 . . . . 0.0 110.268 179.227 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 67.2 m-85 52.49 68.33 0.84 Allowed 'General case' 0 N--CA 1.472 0.637 0 CA-C-N 116.367 -0.378 . . . . 0.0 111.875 178.458 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -78.14 -84.62 0.08 Allowed 'General case' 0 C--N 1.361 1.097 0 CA-C-N 115.463 -0.79 . . . . 0.0 110.173 -179.829 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 41.2 tt0 -123.07 96.9 5.19 Favored 'General case' 0 C--N 1.323 -0.547 0 N-CA-C 108.089 -1.078 . . . . 0.0 108.089 179.7 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 4.1 p30 -158.97 143.67 15.78 Favored 'General case' 0 N--CA 1.484 1.261 0 O-C-N 122.313 -0.242 . . . . 0.0 111.102 179.092 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 61.6 t -61.38 162.66 1.36 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.784 0 N-CA-C 107.968 -1.123 . . . . 0.0 107.968 177.206 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.429 ' H ' ' HB ' ' D' ' 24' ' ' VAL . . . -117.71 48.96 0.89 Allowed Glycine 0 N--CA 1.476 1.328 0 N-CA-C 111.81 -0.516 . . . . 0.0 111.81 -179.377 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' SER . . . . . 0.442 ' HG ' ' H ' ' B' ' 8' ' ' SER . 0.4 OUTLIER -61.84 -169.05 0.02 OUTLIER 'General case' 0 N--CA 1.469 0.522 0 O-C-N 123.722 0.307 . . . . 0.0 110.404 179.56 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 15.1 t30 -69.52 80.35 0.4 Allowed 'General case' 0 N--CA 1.464 0.271 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.132 179.717 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -79.8 154.71 28.28 Favored 'General case' 0 N--CA 1.473 0.677 0 N-CA-C 108.883 -0.784 . . . . 0.0 108.883 179.059 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.0 -144.07 0.02 OUTLIER Glycine 0 CA--C 1.526 0.748 0 N-CA-C 109.749 -1.34 . . . . 0.0 109.749 178.496 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -136.89 120.3 16.97 Favored 'General case' 0 N--CA 1.479 0.976 0 CA-C-N 117.247 0.523 . . . . 0.0 109.755 179.38 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 69.5 mt -80.39 124.73 38.67 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.528 0 N-CA-C 106.741 -1.577 . . . . 0.0 106.741 178.339 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . 0.451 ' C ' ' H ' ' A' ' 34' ' ' LEU . 41.5 pt -151.34 162.71 2.93 Favored 'Isoleucine or valine' 0 C--N 1.358 0.958 0 CA-C-N 115.741 -0.663 . . . . 0.0 111.552 -178.805 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 64.88 0.44 5.24 Favored Glycine 0 CA--C 1.524 0.603 0 N-CA-C 111.008 -0.837 . . . . 0.0 111.008 179.611 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . 0.451 ' H ' ' C ' ' A' ' 32' ' ' ILE . 7.8 tt -79.7 148.46 31.55 Favored 'General case' 0 N--CA 1.466 0.346 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 -179.989 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 28.6 ttt -159.89 140.68 12.21 Favored 'General case' 0 N--CA 1.473 0.68 0 N-CA-C 108.816 -0.809 . . . . 0.0 108.816 178.993 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 27.6 m -156.22 162.57 1.64 Allowed 'Isoleucine or valine' 0 C--N 1.347 0.495 0 N-CA-C 108.259 -1.015 . . . . 0.0 108.259 -179.756 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.63 67.55 2.15 Favored Glycine 0 C--N 1.308 -1.026 0 CA-C-N 115.773 -0.649 . . . . 0.0 111.967 178.6 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.91 172.49 17.98 Favored Glycine 0 N--CA 1.475 1.242 0 N-CA-C 110.649 -0.98 . . . . 0.0 110.649 179.28 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . 0.462 ' H ' HG11 ' D' ' 39' ' ' VAL . 34.9 m -125.16 164.42 24.18 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.943 0 C-N-CA 123.549 0.739 . . . . 0.0 110.803 -179.546 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 25.0 t . . . . . 0 C--O 1.221 -0.437 0 CA-C-O 118.382 -0.818 . . . . 0.0 110.766 179.333 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 55.6 m-85 . . . . . 0 N--CA 1.476 0.843 0 N-CA-C 110.272 -0.269 . . . . 0.0 110.272 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 -144.22 142.09 30.28 Favored 'General case' 0 N--CA 1.481 1.124 0 N-CA-C 109.989 -0.375 . . . . 0.0 109.989 179.687 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 41.1 t-80 -152.34 119.46 5.87 Favored 'General case' 0 N--CA 1.473 0.686 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 179.146 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 7' ' ' ASP . . . . . 0.486 ' O ' ' OG ' ' E' ' 8' ' ' SER . 4.4 m-20 -69.01 148.31 50.29 Favored 'General case' 0 CA--C 1.536 0.436 0 CA-C-N 116.435 -0.348 . . . . 0.0 110.465 179.914 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 8' ' ' SER . . . . . 0.442 ' H ' ' HG ' ' A' ' 26' ' ' SER . 54.0 p -167.26 -173.35 2.25 Favored 'General case' 0 N--CA 1.48 1.048 0 CA-C-O 120.873 0.368 . . . . 0.0 110.645 179.214 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.08 47.37 1.35 Allowed Glycine 0 N--CA 1.482 1.762 0 CA-C-N 115.982 -0.554 . . . . 0.0 111.927 179.896 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 49.3 p90 -65.93 133.73 51.49 Favored 'General case' 0 N--CA 1.473 0.679 0 CA-C-O 120.751 0.31 . . . . 0.0 111.714 179.699 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 83.5 mt-10 -92.39 152.51 19.7 Favored 'General case' 0 N--CA 1.476 0.839 0 N-CA-C 109.666 -0.494 . . . . 0.0 109.666 178.398 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -153.14 128.42 1.56 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.609 0 N-CA-C 107.776 -1.194 . . . . 0.0 107.776 178.261 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 43.6 m-70 -136.27 148.35 47.96 Favored 'General case' 0 N--CA 1.492 1.655 0 CA-C-N 118.864 0.756 . . . . 0.0 111.37 -179.033 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 6.7 t60 -164.67 98.06 0.77 Allowed 'General case' 0 N--CA 1.481 1.093 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.694 179.512 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 5.1 pt20 -91.14 -176.86 4.73 Favored 'General case' 0 CA--C 1.515 -0.386 0 N-CA-C 108.74 -0.837 . . . . 0.0 108.74 -179.984 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -172.7 93.77 0.12 Allowed 'General case' 0 N--CA 1.469 0.505 0 CA-C-N 114.711 -1.131 . . . . 0.0 108.405 177.807 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 6.3 mp -124.71 156.1 38.18 Favored 'General case' 0 N--CA 1.497 1.918 0 CA-C-O 121.77 0.795 . . . . 0.0 110.985 -178.465 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 62.0 t -111.85 125.14 69.13 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.007 0 N-CA-C 108.297 -1.001 . . . . 0.0 108.297 177.645 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 29.6 m-85 -124.87 143.76 50.67 Favored 'General case' 0 N--CA 1.495 1.803 0 CA-C-N 119.813 1.188 . . . . 0.0 110.161 179.433 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 68.2 m-85 51.45 68.41 0.8 Allowed 'General case' 0 N--CA 1.468 0.452 0 CA-C-O 121.199 0.524 . . . . 0.0 111.994 178.48 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -78.09 -84.28 0.08 Allowed 'General case' 0 C--N 1.356 0.875 0 CA-C-N 115.198 -0.91 . . . . 0.0 110.055 -179.847 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 41.2 tt0 -123.14 97.42 5.42 Favored 'General case' 0 C--N 1.323 -0.583 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 179.682 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 4.0 p30 -159.34 143.5 15.1 Favored 'General case' 0 N--CA 1.483 1.206 0 O-C-N 122.342 -0.224 . . . . 0.0 111.083 179.103 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 61.9 t -61.17 162.65 1.31 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.89 0 N-CA-C 107.983 -1.117 . . . . 0.0 107.983 177.136 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 25' ' ' GLY . . . . . 0.431 ' H ' ' HB ' ' E' ' 24' ' ' VAL . . . -117.62 49.03 0.89 Allowed Glycine 0 N--CA 1.475 1.294 0 N-CA-C 111.725 -0.55 . . . . 0.0 111.725 -179.281 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 26' ' ' SER . . . . . 0.443 ' HG ' ' H ' ' C' ' 8' ' ' SER . 0.4 OUTLIER -62.2 -168.78 0.02 OUTLIER 'General case' 0 N--CA 1.469 0.514 0 O-C-N 123.616 0.245 . . . . 0.0 110.374 179.598 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 14.9 t30 -69.72 80.64 0.44 Allowed 'General case' 0 N--CA 1.465 0.312 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.043 179.773 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 97.9 mttt -80.2 154.41 27.96 Favored 'General case' 0 N--CA 1.472 0.633 0 N-CA-C 108.882 -0.784 . . . . 0.0 108.882 179.072 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.9 -144.5 0.02 OUTLIER Glycine 0 CA--C 1.526 0.738 0 N-CA-C 109.636 -1.386 . . . . 0.0 109.636 178.476 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -136.39 120.84 18.14 Favored 'General case' 0 N--CA 1.478 0.973 0 CA-C-N 117.142 0.471 . . . . 0.0 109.83 179.376 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 70.1 mt -80.65 124.98 39.12 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.524 0 N-CA-C 106.721 -1.585 . . . . 0.0 106.721 178.249 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . 0.449 ' C ' ' H ' ' B' ' 34' ' ' LEU . 41.3 pt -151.59 162.75 2.8 Favored 'Isoleucine or valine' 0 C--N 1.358 0.951 0 CA-C-N 115.836 -0.62 . . . . 0.0 111.491 -178.728 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 64.61 0.52 5.0 Favored Glycine 0 C--N 1.337 0.635 0 CA-C-N 115.507 -0.77 . . . . 0.0 111.177 179.716 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 34' ' ' LEU . . . . . 0.449 ' H ' ' C ' ' B' ' 32' ' ' ILE . 7.8 tt -79.85 148.15 31.47 Favored 'General case' 0 N--CA 1.465 0.292 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 -179.952 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 28.6 ttt -159.32 140.75 13.03 Favored 'General case' 0 N--CA 1.475 0.795 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 179.051 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 28.3 m -156.35 162.56 1.63 Allowed 'Isoleucine or valine' 0 C--N 1.346 0.422 0 N-CA-C 108.214 -1.032 . . . . 0.0 108.214 -179.796 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.67 67.45 2.2 Favored Glycine 0 C--N 1.306 -1.111 0 CA-C-N 115.756 -0.657 . . . . 0.0 111.932 178.558 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.86 172.8 18.27 Favored Glycine 0 N--CA 1.474 1.202 0 N-CA-C 110.678 -0.969 . . . . 0.0 110.678 179.208 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 39' ' ' VAL . . . . . 0.459 ' H ' HG11 ' E' ' 39' ' ' VAL . 35.2 m -125.3 164.29 24.67 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.082 0 C-N-CA 123.523 0.729 . . . . 0.0 110.819 -179.392 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 24.9 t . . . . . 0 N--CA 1.471 0.576 0 CA-C-O 118.237 -0.887 . . . . 0.0 110.636 179.164 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 54.9 m-85 . . . . . 0 N--CA 1.477 0.922 0 N-CA-C 110.238 -0.282 . . . . 0.0 110.238 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 -144.22 142.12 30.31 Favored 'General case' 0 N--CA 1.482 1.15 0 N-CA-C 109.974 -0.38 . . . . 0.0 109.974 179.645 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 40.8 t-80 -152.37 119.98 6.05 Favored 'General case' 0 N--CA 1.473 0.708 0 N-CA-C 109.251 -0.648 . . . . 0.0 109.251 179.152 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' C' C ' 7' ' ' ASP . . . . . 0.493 ' O ' ' OG ' ' F' ' 8' ' ' SER . 4.4 m-20 -69.45 148.39 49.63 Favored 'General case' 0 CA--C 1.535 0.397 0 CA-C-N 116.352 -0.385 . . . . 0.0 110.518 179.908 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' C' C ' 8' ' ' SER . . . . . 0.443 ' H ' ' HG ' ' B' ' 26' ' ' SER . 55.4 p -167.32 -173.51 2.29 Favored 'General case' 0 N--CA 1.48 1.029 0 CA-C-O 120.839 0.352 . . . . 0.0 110.656 179.272 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.18 47.58 1.31 Allowed Glycine 0 N--CA 1.483 1.795 0 CA-C-N 116.006 -0.543 . . . . 0.0 111.903 179.961 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 49.5 p90 -66.15 133.3 50.41 Favored 'General case' 0 N--CA 1.472 0.665 0 CA-C-N 116.783 0.292 . . . . 0.0 111.681 179.697 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 83.2 mt-10 -92.15 152.08 20.08 Favored 'General case' 0 N--CA 1.476 0.851 0 N-CA-C 109.696 -0.483 . . . . 0.0 109.696 178.4 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -152.61 128.35 1.71 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.588 0 N-CA-C 107.791 -1.189 . . . . 0.0 107.791 178.146 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 42.4 m-70 -136.03 148.38 48.35 Favored 'General case' 0 N--CA 1.492 1.663 0 CA-C-N 118.937 0.79 . . . . 0.0 111.286 -179.102 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 6.7 t60 -164.69 98.55 0.78 Allowed 'General case' 0 N--CA 1.481 1.105 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.685 179.475 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -91.91 -176.99 4.6 Favored 'General case' 0 CA--C 1.512 -0.484 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 -179.937 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -172.49 93.84 0.13 Allowed 'General case' 0 N--CA 1.47 0.533 0 CA-C-N 114.707 -1.133 . . . . 0.0 108.451 177.959 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 6.1 mp -124.93 155.7 39.15 Favored 'General case' 0 N--CA 1.496 1.842 0 CA-C-O 121.768 0.794 . . . . 0.0 111.096 -178.381 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 61.6 t -111.54 125.52 68.86 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.996 0 N-CA-C 108.238 -1.023 . . . . 0.0 108.238 177.754 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 29.3 m-85 -125.31 143.31 51.03 Favored 'General case' 0 N--CA 1.495 1.822 0 CA-C-N 119.673 1.124 . . . . 0.0 110.083 179.369 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 67.5 m-85 51.93 68.46 0.81 Allowed 'General case' 0 N--CA 1.47 0.534 0 CA-C-O 121.215 0.531 . . . . 0.0 111.975 178.501 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -78.09 -84.41 0.08 Allowed 'General case' 0 C--N 1.356 0.873 0 CA-C-N 115.186 -0.915 . . . . 0.0 110.071 -179.851 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 40.9 tt0 -123.14 96.97 5.21 Favored 'General case' 0 C--N 1.323 -0.546 0 N-CA-C 108.08 -1.081 . . . . 0.0 108.08 179.746 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 4.1 p30 -158.8 143.71 16.02 Favored 'General case' 0 N--CA 1.484 1.263 0 CA-C-O 119.672 -0.204 . . . . 0.0 111.118 179.002 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 59.9 t -61.43 162.38 1.45 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.849 0 N-CA-C 107.96 -1.126 . . . . 0.0 107.96 177.129 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' C' C ' 25' ' ' GLY . . . . . 0.41 ' H ' ' HB ' ' F' ' 24' ' ' VAL . . . -117.5 49.49 0.86 Allowed Glycine 0 N--CA 1.477 1.414 0 N-CA-C 111.726 -0.55 . . . . 0.0 111.726 -179.286 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' C' C ' 26' ' ' SER . . . . . 0.463 ' HG ' ' H ' ' A' ' 8' ' ' SER . 0.4 OUTLIER -62.65 -168.51 0.02 OUTLIER 'General case' 0 N--CA 1.468 0.44 0 O-C-N 123.666 0.274 . . . . 0.0 110.443 179.64 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 15.8 t30 -69.88 80.47 0.46 Allowed 'General case' 0 N--CA 1.465 0.322 0 N-CA-C 110.073 -0.343 . . . . 0.0 110.073 179.781 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -79.98 154.62 28.11 Favored 'General case' 0 N--CA 1.472 0.668 0 N-CA-C 108.915 -0.772 . . . . 0.0 108.915 179.111 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.89 -144.17 0.02 OUTLIER Glycine 0 CA--C 1.527 0.821 0 N-CA-C 109.769 -1.332 . . . . 0.0 109.769 178.488 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -136.78 120.47 17.28 Favored 'General case' 0 N--CA 1.481 1.083 0 CA-C-N 117.185 0.493 . . . . 0.0 109.719 179.258 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 70.0 mt -80.49 124.8 38.81 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.541 0 N-CA-C 106.762 -1.57 . . . . 0.0 106.762 178.254 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' C' C ' 32' ' ' ILE . . . . . 0.446 ' C ' ' H ' ' C' ' 34' ' ' LEU . 41.3 pt -151.39 162.53 2.97 Favored 'Isoleucine or valine' 0 C--N 1.359 0.991 0 CA-C-N 115.68 -0.691 . . . . 0.0 111.53 -178.634 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 64.89 0.68 5.5 Favored Glycine 0 N--CA 1.465 0.598 0 N-CA-C 110.973 -0.851 . . . . 0.0 110.973 179.606 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' C' C ' 34' ' ' LEU . . . . . 0.446 ' H ' ' C ' ' C' ' 32' ' ' ILE . 7.7 tt -79.87 148.12 31.45 Favored 'General case' 0 N--CA 1.465 0.302 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 179.955 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 28.6 ttt -159.29 140.85 13.16 Favored 'General case' 0 N--CA 1.474 0.742 0 N-CA-C 108.751 -0.833 . . . . 0.0 108.751 178.955 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 28.1 m -156.5 162.77 1.55 Allowed 'Isoleucine or valine' 0 C--N 1.348 0.511 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 -179.798 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.37 67.14 2.36 Favored Glycine 0 C--N 1.307 -1.07 0 CA-C-N 115.695 -0.684 . . . . 0.0 111.901 178.56 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 148.23 172.58 18.32 Favored Glycine 0 N--CA 1.474 1.218 0 N-CA-C 110.604 -0.998 . . . . 0.0 110.604 179.237 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' C' C ' 39' ' ' VAL . . . . . 0.456 ' H ' HG11 ' F' ' 39' ' ' VAL . 35.1 m -125.25 164.48 24.23 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.996 0 C-N-CA 123.518 0.727 . . . . 0.0 110.789 -179.415 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 25.4 t . . . . . 0 N--CA 1.469 0.484 0 CA-C-O 118.234 -0.889 . . . . 0.0 110.649 179.207 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 61.4 m-85 . . . . . 0 N--CA 1.474 0.765 0 N-CA-C 108.792 -0.818 . . . . 0.0 108.792 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' D' D ' 5' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 -146.43 140.49 26.33 Favored 'General case' 0 N--CA 1.476 0.85 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.236 -179.994 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 38.0 t-80 -149.82 124.02 9.5 Favored 'General case' 0 CA--C 1.545 0.781 0 N-CA-C 108.344 -0.984 . . . . 0.0 108.344 175.303 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' D' D ' 7' ' ' ASP . . . . . 0.589 ' O ' ' OG ' ' G' ' 8' ' ' SER . 3.3 m-20 -63.76 132.46 51.04 Favored 'General case' 0 C--N 1.322 -0.596 0 C-N-CA 126.885 2.074 . . . . 0.0 114.325 174.69 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' D' D ' 8' ' ' SER . . . . . 0.519 ' H ' ' HG ' ' F' ' 26' ' ' SER . 54.2 p -154.63 -170.65 3.58 Favored 'General case' 0 N--CA 1.486 1.334 0 CA-C-N 119.77 1.168 . . . . 0.0 111.22 175.927 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.35 48.15 1.15 Allowed Glycine 0 N--CA 1.483 1.804 0 C-N-CA 124.562 1.077 . . . . 0.0 110.539 174.952 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 51.5 p90 -60.97 131.57 51.09 Favored 'General case' 0 N--CA 1.472 0.626 0 N-CA-C 112.908 0.707 . . . . 0.0 112.908 177.925 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 84.2 mt-10 -89.28 150.91 22.39 Favored 'General case' 0 N--CA 1.481 1.1 0 CA-C-N 117.974 0.352 . . . . 0.0 110.637 175.315 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.0 p -149.58 129.86 4.2 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.637 0 N-CA-C 107.416 -1.328 . . . . 0.0 107.416 173.066 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 38.3 m-70 -129.91 151.28 50.64 Favored 'General case' 0 N--CA 1.484 1.262 0 N-CA-C 112.329 0.492 . . . . 0.0 112.329 176.791 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 6.7 t60 -164.79 104.84 0.81 Allowed 'General case' 0 N--CA 1.482 1.145 0 N-CA-C 109.155 -0.683 . . . . 0.0 109.155 172.664 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' D' D ' 15' ' ' GLN . . . . . 0.401 ' OE1' ' N ' ' G' ' 37' ' ' GLY . 4.9 pt20 -94.96 -177.3 4.12 Favored 'General case' 0 CA--C 1.509 -0.631 0 N-CA-C 108.574 -0.898 . . . . 0.0 108.574 179.044 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -169.75 103.49 0.32 Allowed 'General case' 0 N--CA 1.465 0.308 0 N-CA-C 105.891 -1.892 . . . . 0.0 105.891 173.374 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 5.0 mp -132.19 153.44 50.57 Favored 'General case' 0 N--CA 1.498 1.97 0 CA-C-O 122.011 0.91 . . . . 0.0 110.214 178.912 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 35.8 t -101.12 129.01 52.79 Favored 'Isoleucine or valine' 0 C--O 1.266 1.943 0 CA-C-O 116.373 -1.775 . . . . 0.0 109.693 174.267 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 25.8 m-85 -126.63 149.25 49.59 Favored 'General case' 0 N--CA 1.49 1.562 0 CA-C-N 120.525 1.511 . . . . 0.0 109.472 172.329 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 66.7 m-85 55.14 63.64 2.05 Favored 'General case' 0 C--O 1.24 0.599 0 CA-C-O 118.518 -0.753 . . . . 0.0 111.555 175.097 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -79.99 -81.35 0.12 Allowed 'General case' 0 N--CA 1.474 0.741 0 CA-C-N 118.942 0.792 . . . . 0.0 109.967 -176.345 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 41.3 tt0 -124.91 101.81 7.24 Favored 'General case' 0 N--CA 1.479 0.999 0 N-CA-C 106.036 -1.838 . . . . 0.0 106.036 175.969 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 4.1 p30 -152.44 143.08 22.8 Favored 'General case' 0 N--CA 1.476 0.842 0 CA-C-O 116.792 -1.575 . . . . 0.0 113.624 177.592 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' D' D ' 24' ' ' VAL . . . . . 0.429 ' HB ' ' H ' ' A' ' 25' ' ' GLY . 67.1 t -63.58 165.26 1.29 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.366 0 CA-C-N 120.971 1.714 . . . . 0.0 107.824 174.538 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' D' D ' 25' ' ' GLY . . . . . 0.452 ' H ' ' HB ' ' G' ' 24' ' ' VAL . . . -116.84 51.3 0.74 Allowed Glycine 0 N--CA 1.48 1.613 0 CA-C-O 118.978 -0.901 . . . . 0.0 111.977 178.795 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' D' D ' 26' ' ' SER . . . . . 0.442 ' HG ' ' H ' ' E' ' 8' ' ' SER . 0.3 OUTLIER -58.87 -171.23 0.01 OUTLIER 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 117.558 0.679 . . . . 0.0 111.533 176.88 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 15.7 t30 -71.92 86.66 1.0 Allowed 'General case' 0 CA--C 1.537 0.468 0 N-CA-C 108.432 -0.951 . . . . 0.0 108.432 178.516 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 97.4 mttt -85.34 156.37 20.93 Favored 'General case' 0 N--CA 1.475 0.779 0 N-CA-C 108.124 -1.065 . . . . 0.0 108.124 179.031 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.39 -144.27 0.02 OUTLIER Glycine 0 C--N 1.335 0.488 0 N-CA-C 110.33 -1.108 . . . . 0.0 110.33 179.387 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -136.41 123.74 21.93 Favored 'General case' 0 N--CA 1.474 0.733 0 N-CA-C 109.159 -0.682 . . . . 0.0 109.159 177.648 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 76.4 mt -83.9 134.53 26.74 Favored 'Isoleucine or valine' 0 C--N 1.355 0.819 0 N-CA-C 104.846 -2.279 . . . . 0.0 104.846 178.776 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' D' D ' 32' ' ' ILE . . . . . 0.444 ' C ' ' H ' ' D' ' 34' ' ' LEU . 46.0 pt -159.07 162.47 1.35 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.02 0 CA-C-O 121.407 0.622 . . . . 0.0 110.397 -178.37 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 64.83 0.17 4.89 Favored Glycine 0 CA--C 1.525 0.685 0 CA-C-N 115.46 -0.791 . . . . 0.0 111.186 -178.563 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' D' D ' 34' ' ' LEU . . . . . 0.444 ' H ' ' C ' ' D' ' 32' ' ' ILE . 7.6 tt -79.25 150.04 31.69 Favored 'General case' 0 C--N 1.343 0.325 0 N-CA-C 109.345 -0.613 . . . . 0.0 109.345 -179.49 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 27.7 ttt -155.78 151.44 27.26 Favored 'General case' 0 N--CA 1.474 0.728 0 N-CA-C 107.509 -1.293 . . . . 0.0 107.509 174.348 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 29.7 m -164.52 163.65 0.73 Allowed 'Isoleucine or valine' 0 CA--C 1.513 -0.445 0 N-CA-C 107.661 -1.237 . . . . 0.0 107.661 176.901 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 60.32 63.75 4.75 Favored Glycine 0 CA--C 1.528 0.885 0 C-N-CA 119.584 -1.293 . . . . 0.0 112.359 177.88 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.92 173.2 15.2 Favored Glycine 0 N--CA 1.479 1.519 0 CA-C-N 118.451 1.125 . . . . 0.0 111.567 -177.851 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' D' D ' 39' ' ' VAL . . . . . 0.476 ' H ' HG11 ' G' ' 39' ' ' VAL . 34.6 m -128.14 160.16 38.41 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.061 0 C-N-CA 122.895 0.478 . . . . 0.0 110.422 -175.953 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 24.2 t . . . . . 0 C--N 1.331 -0.213 0 CA-C-O 116.386 -1.769 . . . . 0.0 109.855 177.694 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 53.7 m-85 . . . . . 0 N--CA 1.475 0.81 0 N-CA-C 110.348 -0.241 . . . . 0.0 110.348 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' E' E ' 5' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 -143.5 142.62 31.23 Favored 'General case' 0 N--CA 1.479 0.99 0 CA-C-O 120.794 0.33 . . . . 0.0 110.201 179.565 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 41.2 t-80 -152.46 119.54 5.85 Favored 'General case' 0 N--CA 1.474 0.725 0 N-CA-C 109.247 -0.649 . . . . 0.0 109.247 178.985 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' E' E ' 7' ' ' ASP . . . . . 0.469 ' O ' ' OG ' ' H' ' 8' ' ' SER . 4.3 m-20 -69.58 148.27 49.61 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-N 116.491 -0.322 . . . . 0.0 110.671 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' E' E ' 8' ' ' SER . . . . . 0.486 ' OG ' ' O ' ' B' ' 7' ' ' ASP . 52.5 p -167.92 -172.49 1.84 Allowed 'General case' 0 N--CA 1.486 1.328 0 CA-C-O 121.013 0.435 . . . . 0.0 110.87 178.952 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.87 47.66 1.24 Allowed Glycine 0 N--CA 1.48 1.595 0 N-CA-C 111.781 -0.528 . . . . 0.0 111.781 179.684 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 47.8 p90 -65.45 133.36 51.14 Favored 'General case' 0 N--CA 1.473 0.683 0 N-CA-C 112.06 0.392 . . . . 0.0 112.06 -179.846 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 85.1 mt-10 -91.4 152.68 20.31 Favored 'General case' 0 N--CA 1.479 1.002 0 N-CA-C 109.617 -0.512 . . . . 0.0 109.617 177.996 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -154.67 127.28 1.07 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.619 0 N-CA-C 107.816 -1.179 . . . . 0.0 107.816 178.067 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 40.8 m-70 -136.18 146.72 47.17 Favored 'General case' 0 N--CA 1.482 1.157 0 CA-C-O 120.851 0.357 . . . . 0.0 111.639 -178.047 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 6.6 t60 -163.64 98.39 0.88 Allowed 'General case' 0 N--CA 1.485 1.293 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.735 179.553 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 4.8 pt20 -91.36 -176.87 4.68 Favored 'General case' 0 CA--C 1.514 -0.43 0 N-CA-C 109.028 -0.73 . . . . 0.0 109.028 -179.925 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -172.31 92.72 0.12 Allowed 'General case' 0 N--CA 1.47 0.557 0 CA-C-N 114.77 -1.104 . . . . 0.0 108.693 177.929 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 6.0 mp -123.35 155.77 36.67 Favored 'General case' 0 N--CA 1.496 1.864 0 CA-C-O 121.443 0.64 . . . . 0.0 111.433 -177.901 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 48.0 t -113.33 122.57 67.72 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.198 0 N-CA-C 108.333 -0.988 . . . . 0.0 108.333 177.37 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 32.4 m-85 -122.76 142.51 50.65 Favored 'General case' 0 N--CA 1.491 1.594 0 CA-C-O 120.974 0.416 . . . . 0.0 110.649 -179.928 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 67.8 m-85 52.73 67.71 0.95 Allowed 'General case' 0 C--N 1.346 0.42 0 CA-C-N 115.767 -0.651 . . . . 0.0 111.614 178.245 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.15 -83.66 0.07 Allowed 'General case' 0 CA--C 1.541 0.605 0 N-CA-C 109.981 -0.377 . . . . 0.0 109.981 -179.464 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 41.0 tt0 -123.28 97.14 5.28 Favored 'General case' 0 C--N 1.32 -0.686 0 N-CA-C 108.14 -1.059 . . . . 0.0 108.14 179.938 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 4.1 p30 -158.35 143.46 16.44 Favored 'General case' 0 N--CA 1.48 1.057 0 O-C-N 122.422 -0.174 . . . . 0.0 111.33 179.062 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' E' E ' 24' ' ' VAL . . . . . 0.431 ' HB ' ' H ' ' B' ' 25' ' ' GLY . 57.9 t -59.53 167.42 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.954 0 N-CA-C 107.412 -1.329 . . . . 0.0 107.412 176.991 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . -122.61 49.66 0.88 Allowed Glycine 0 N--CA 1.475 1.266 0 N-CA-C 110.915 -0.874 . . . . 0.0 110.915 -179.386 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' E' E ' 26' ' ' SER . . . . . 0.457 ' HG ' ' H ' ' F' ' 8' ' ' SER . 0.3 OUTLIER -63.24 -168.54 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.639 0 CA-C-O 120.689 0.281 . . . . 0.0 110.572 179.946 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 14.9 t30 -68.98 77.94 0.32 Allowed 'General case' 0 N--CA 1.465 0.281 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.261 179.946 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -78.12 155.28 30.59 Favored 'General case' 0 N--CA 1.475 0.779 0 N-CA-C 109.458 -0.571 . . . . 0.0 109.458 179.279 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.76 -144.74 0.02 OUTLIER Glycine 0 C--N 1.337 0.634 0 N-CA-C 110.34 -1.104 . . . . 0.0 110.34 178.022 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -137.12 117.25 13.42 Favored 'General case' 0 N--CA 1.476 0.831 0 CA-C-O 120.79 0.328 . . . . 0.0 110.286 179.723 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 67.0 mt -77.45 125.15 36.96 Favored 'Isoleucine or valine' 0 C--O 1.238 0.475 0 N-CA-C 107.011 -1.477 . . . . 0.0 107.011 178.411 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' E' E ' 32' ' ' ILE . . . . . 0.446 ' C ' ' H ' ' E' ' 34' ' ' LEU . 46.4 pt -150.96 164.47 2.64 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.085 0 CA-C-O 121.279 0.561 . . . . 0.0 111.019 -178.943 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.82 1.1 3.36 Favored Glycine 0 CA--C 1.529 0.911 0 CA-C-N 115.542 -0.753 . . . . 0.0 111.871 -179.643 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' E' E ' 34' ' ' LEU . . . . . 0.446 ' H ' ' C ' ' E' ' 32' ' ' ILE . 7.9 tt -79.31 148.18 32.2 Favored 'General case' 0 N--CA 1.468 0.462 0 C-N-CA 122.838 0.455 . . . . 0.0 109.832 -179.964 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 28.0 ttt -158.78 140.97 13.93 Favored 'General case' 0 N--CA 1.477 0.922 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 178.784 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 32.4 m -156.52 162.22 1.7 Allowed 'Isoleucine or valine' 0 C--N 1.344 0.368 0 N-CA-C 108.431 -0.951 . . . . 0.0 108.431 -179.598 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.5 67.36 2.25 Favored Glycine 0 C--N 1.308 -1.012 0 CA-C-N 115.975 -0.557 . . . . 0.0 111.894 178.494 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 148.33 173.06 18.87 Favored Glycine 0 N--CA 1.475 1.255 0 N-CA-C 110.875 -0.89 . . . . 0.0 110.875 179.222 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' E' E ' 39' ' ' VAL . . . . . 0.459 HG11 ' H ' ' B' ' 39' ' ' VAL . 32.9 m -126.18 163.08 28.71 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.909 0 C-N-CA 123.41 0.684 . . . . 0.0 111.016 -179.067 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 24.6 t . . . . . 0 N--CA 1.465 0.309 0 CA-C-O 118.253 -0.88 . . . . 0.0 110.466 178.972 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 53.7 m-85 . . . . . 0 N--CA 1.474 0.774 0 N-CA-C 110.234 -0.284 . . . . 0.0 110.234 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' F' F ' 5' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 -143.3 142.42 31.32 Favored 'General case' 0 N--CA 1.478 0.945 0 CA-C-O 120.803 0.335 . . . . 0.0 110.141 179.544 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 38.8 t-80 -152.42 119.3 5.77 Favored 'General case' 0 N--CA 1.472 0.674 0 N-CA-C 109.283 -0.636 . . . . 0.0 109.283 178.966 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' F' F ' 7' ' ' ASP . . . . . 0.481 ' O ' ' OG ' ' I' ' 8' ' ' SER . 4.2 m-20 -69.17 148.39 49.97 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-N 116.471 -0.331 . . . . 0.0 110.746 179.968 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' F' F ' 8' ' ' SER . . . . . 0.493 ' OG ' ' O ' ' C' ' 7' ' ' ASP . 52.6 p -168.01 -171.99 1.69 Allowed 'General case' 0 N--CA 1.486 1.335 0 CA-C-O 120.931 0.396 . . . . 0.0 111.012 178.74 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.35 47.32 1.32 Allowed Glycine 0 N--CA 1.48 1.591 0 N-CA-C 111.746 -0.542 . . . . 0.0 111.746 179.689 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 47.5 p90 -65.4 134.05 52.66 Favored 'General case' 0 N--CA 1.473 0.678 0 N-CA-C 111.981 0.363 . . . . 0.0 111.981 -179.856 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 85.7 mt-10 -91.8 152.88 19.93 Favored 'General case' 0 N--CA 1.479 0.987 0 N-CA-C 109.699 -0.482 . . . . 0.0 109.699 178.002 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -154.61 127.25 1.07 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.594 0 N-CA-C 107.823 -1.177 . . . . 0.0 107.823 178.029 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 42.2 m-70 -136.27 146.48 46.73 Favored 'General case' 0 N--CA 1.483 1.212 0 CA-C-O 120.833 0.349 . . . . 0.0 111.602 -177.948 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 6.5 t60 -163.51 98.74 0.9 Allowed 'General case' 0 N--CA 1.486 1.348 0 CA-C-N 116.343 -0.389 . . . . 0.0 110.736 179.609 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 4.8 pt20 -91.56 -176.95 4.66 Favored 'General case' 0 CA--C 1.51 -0.563 0 N-CA-C 109.109 -0.7 . . . . 0.0 109.109 179.934 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -172.3 92.38 0.12 Allowed 'General case' 0 C--O 1.219 -0.507 0 CA-C-N 114.777 -1.101 . . . . 0.0 108.591 177.961 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 6.0 mp -123.05 155.95 35.86 Favored 'General case' 0 N--CA 1.495 1.794 0 CA-C-O 121.581 0.705 . . . . 0.0 111.455 -177.983 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 48.2 t -113.52 122.5 67.77 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.141 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 177.362 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 32.6 m-85 -122.67 142.52 50.58 Favored 'General case' 0 N--CA 1.489 1.504 0 CA-C-O 120.955 0.407 . . . . 0.0 110.584 179.934 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 67.4 m-85 52.67 68.08 0.89 Allowed 'General case' 0 C--N 1.343 0.318 0 CA-C-N 115.866 -0.606 . . . . 0.0 111.918 178.474 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.42 -83.75 0.07 Allowed 'General case' 0 CA--C 1.54 0.57 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 -179.496 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 40.9 tt0 -123.22 97.68 5.53 Favored 'General case' 0 C--N 1.32 -0.689 0 N-CA-C 108.099 -1.074 . . . . 0.0 108.099 179.849 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 4.1 p30 -158.79 143.51 15.91 Favored 'General case' 0 N--CA 1.48 1.065 0 CA-C-O 119.692 -0.194 . . . . 0.0 111.277 179.059 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' F' F ' 24' ' ' VAL . . . . . 0.41 ' HB ' ' H ' ' C' ' 25' ' ' GLY . 58.0 t -59.95 166.82 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.96 0 N-CA-C 107.341 -1.355 . . . . 0.0 107.341 177.01 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -122.14 49.82 0.87 Allowed Glycine 0 N--CA 1.476 1.343 0 N-CA-C 111.039 -0.824 . . . . 0.0 111.039 -179.407 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' F' F ' 26' ' ' SER . . . . . 0.519 ' HG ' ' H ' ' D' ' 8' ' ' SER . 0.3 OUTLIER -63.41 -168.43 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.526 0 CA-C-O 120.597 0.237 . . . . 0.0 110.505 179.938 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 14.4 t30 -68.93 78.11 0.32 Allowed 'General case' 0 CA--C 1.534 0.359 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.23 -180.0 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -78.26 155.12 30.42 Favored 'General case' 0 N--CA 1.475 0.794 0 N-CA-C 109.408 -0.589 . . . . 0.0 109.408 179.248 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.56 -144.77 0.02 OUTLIER Glycine 0 C--N 1.338 0.679 0 N-CA-C 110.384 -1.087 . . . . 0.0 110.384 178.005 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -136.8 117.35 13.82 Favored 'General case' 0 N--CA 1.476 0.829 0 CA-C-O 120.751 0.31 . . . . 0.0 110.165 179.752 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 68.3 mt -77.69 125.42 37.35 Favored 'Isoleucine or valine' 0 C--O 1.238 0.45 0 N-CA-C 106.948 -1.501 . . . . 0.0 106.948 178.373 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' F' F ' 32' ' ' ILE . . . . . 0.448 ' C ' ' H ' ' F' ' 34' ' ' LEU . 45.8 pt -151.25 164.63 2.46 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.994 0 CA-C-O 121.154 0.502 . . . . 0.0 111.043 -179.018 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.64 1.43 3.53 Favored Glycine 0 CA--C 1.529 0.911 0 CA-C-N 115.583 -0.735 . . . . 0.0 111.864 -179.67 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' F' F ' 34' ' ' LEU . . . . . 0.448 ' H ' ' C ' ' F' ' 32' ' ' ILE . 7.9 tt -79.6 148.16 31.8 Favored 'General case' 0 N--CA 1.468 0.464 0 C-N-CA 122.837 0.455 . . . . 0.0 109.775 179.95 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 28.0 ttt -158.68 140.97 14.07 Favored 'General case' 0 N--CA 1.477 0.914 0 N-CA-C 108.806 -0.812 . . . . 0.0 108.806 178.725 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 32.2 m -156.59 161.86 1.78 Allowed 'Isoleucine or valine' 0 C--N 1.344 0.358 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 -179.611 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.0 67.22 2.33 Favored Glycine 0 C--N 1.307 -1.047 0 CA-C-N 115.962 -0.563 . . . . 0.0 111.887 178.458 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 148.46 173.82 19.63 Favored Glycine 0 N--CA 1.475 1.26 0 N-CA-C 110.943 -0.863 . . . . 0.0 110.943 179.192 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' F' F ' 39' ' ' VAL . . . . . 0.475 ' H ' HG11 ' I' ' 39' ' ' VAL . 33.1 m -126.82 163.08 30.06 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.935 0 C-N-CA 123.416 0.686 . . . . 0.0 110.899 -179.058 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 24.7 t . . . . . 0 C--O 1.223 -0.304 0 CA-C-O 118.29 -0.862 . . . . 0.0 110.435 178.89 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 56.4 m-85 . . . . . 0 N--CA 1.474 0.756 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' G' G ' 5' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 -143.67 142.58 31.06 Favored 'General case' 0 N--CA 1.482 1.131 0 C-N-CA 122.585 0.354 . . . . 0.0 110.301 179.813 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 40.0 t-80 -152.53 120.34 6.12 Favored 'General case' 0 N--CA 1.473 0.712 0 N-CA-C 109.46 -0.57 . . . . 0.0 109.46 179.016 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -71.16 143.88 50.38 Favored 'General case' 0 N--CA 1.471 0.584 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.12 -179.936 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' G' G ' 8' ' ' SER . . . . . 0.589 ' OG ' ' O ' ' D' ' 7' ' ' ASP . 49.1 p -164.54 -170.1 1.94 Allowed 'General case' 0 N--CA 1.475 0.783 0 CA-C-O 120.923 0.392 . . . . 0.0 110.52 178.506 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.11 47.32 1.35 Allowed Glycine 0 N--CA 1.48 1.571 0 N-CA-C 111.37 -0.692 . . . . 0.0 111.37 179.529 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 50.1 p90 -65.62 133.31 50.88 Favored 'General case' 0 CA--C 1.543 0.683 0 N-CA-C 111.875 0.324 . . . . 0.0 111.875 -179.497 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 83.0 mt-10 -91.6 151.89 20.51 Favored 'General case' 0 N--CA 1.478 0.974 0 CA-C-O 120.991 0.424 . . . . 0.0 110.076 178.555 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -154.78 127.41 1.07 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.014 0 N-CA-C 107.864 -1.161 . . . . 0.0 107.864 178.17 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 42.4 m-70 -135.42 148.21 49.24 Favored 'General case' 0 N--CA 1.479 1.004 0 CA-C-N 115.505 -0.77 . . . . 0.0 111.409 -178.258 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 6.6 t60 -165.49 98.97 0.7 Allowed 'General case' 0 N--CA 1.484 1.263 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.307 179.012 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -92.09 -176.73 4.48 Favored 'General case' 0 CA--C 1.513 -0.477 0 N-CA-C 108.901 -0.777 . . . . 0.0 108.901 -179.847 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -172.85 92.28 0.1 Allowed 'General case' 0 N--CA 1.47 0.565 0 CA-C-N 114.86 -1.064 . . . . 0.0 108.37 178.123 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 6.0 mp -123.19 154.77 38.27 Favored 'General case' 0 N--CA 1.498 1.955 0 CA-C-O 121.302 0.572 . . . . 0.0 111.668 -177.995 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 42.4 t -112.83 123.08 68.14 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.99 0 CA-C-N 114.747 -1.115 . . . . 0.0 108.394 176.866 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 34.8 m-85 -123.53 142.05 51.4 Favored 'General case' 0 C--N 1.367 1.35 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.691 -179.807 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 66.9 m-85 53.64 66.25 1.28 Allowed 'General case' 0 C--O 1.237 0.422 0 CA-C-N 115.742 -0.663 . . . . 0.0 111.584 178.192 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -76.02 -83.62 0.06 Allowed 'General case' 0 N--CA 1.471 0.586 0 N-CA-C 110.003 -0.369 . . . . 0.0 110.003 -179.076 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 41.3 tt0 -123.0 97.25 5.35 Favored 'General case' 0 C--N 1.321 -0.673 0 N-CA-C 107.829 -1.174 . . . . 0.0 107.829 -179.976 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 4.1 p30 -158.59 144.2 16.62 Favored 'General case' 0 N--CA 1.479 1.008 0 CA-C-O 120.463 0.173 . . . . 0.0 111.279 178.891 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' G' G ' 24' ' ' VAL . . . . . 0.452 ' HB ' ' H ' ' D' ' 25' ' ' GLY . 61.0 t -60.96 165.62 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.685 0 N-CA-C 107.617 -1.253 . . . . 0.0 107.617 177.347 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -120.36 50.34 0.83 Allowed Glycine 0 N--CA 1.482 1.711 0 N-CA-C 110.567 -1.013 . . . . 0.0 110.567 -179.561 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -64.06 -168.04 0.03 OUTLIER 'General case' 0 N--CA 1.472 0.647 0 CA-C-N 117.002 0.401 . . . . 0.0 109.963 179.875 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 15.5 t30 -69.46 77.92 0.4 Allowed 'General case' 0 CA--C 1.537 0.459 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.444 179.954 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -77.2 155.22 32.37 Favored 'General case' 0 N--CA 1.475 0.788 0 N-CA-C 109.602 -0.518 . . . . 0.0 109.602 179.189 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.03 -142.53 0.02 OUTLIER Glycine 0 CA--C 1.527 0.792 0 N-CA-C 109.918 -1.273 . . . . 0.0 109.918 178.313 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -137.72 117.45 13.12 Favored 'General case' 0 N--CA 1.471 0.583 0 C-N-CA 122.624 0.37 . . . . 0.0 110.737 -179.915 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 71.7 mt -77.79 125.85 37.74 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.496 0 N-CA-C 107.007 -1.479 . . . . 0.0 107.007 178.382 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' G' G ' 32' ' ' ILE . . . . . 0.465 ' C ' ' H ' ' G' ' 34' ' ' LEU . 44.7 pt -152.31 164.95 1.96 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.755 0 CA-C-N 120.091 1.314 . . . . 0.0 110.032 -179.36 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.61 0.64 3.9 Favored Glycine 0 N--CA 1.468 0.779 0 N-CA-C 111.19 -0.764 . . . . 0.0 111.19 -179.912 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' G' G ' 34' ' ' LEU . . . . . 0.465 ' H ' ' C ' ' G' ' 32' ' ' ILE . 7.9 tt -79.71 148.34 31.58 Favored 'General case' 0 N--CA 1.465 0.303 0 C-N-CA 122.832 0.453 . . . . 0.0 109.841 179.855 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 27.1 ttt -159.14 141.98 14.27 Favored 'General case' 0 N--CA 1.476 0.837 0 N-CA-C 108.731 -0.84 . . . . 0.0 108.731 179.004 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 33.8 m -156.68 162.21 1.67 Allowed 'Isoleucine or valine' 0 C--N 1.345 0.412 0 N-CA-C 108.618 -0.882 . . . . 0.0 108.618 -179.492 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' G' G ' 37' ' ' GLY . . . . . 0.401 ' N ' ' OE1' ' D' ' 15' ' ' GLN . . . 54.95 67.86 1.98 Allowed Glycine 0 C--N 1.31 -0.879 0 CA-C-N 115.637 -0.71 . . . . 0.0 112.141 178.134 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 148.75 174.41 20.37 Favored Glycine 0 N--CA 1.475 1.296 0 N-CA-C 110.462 -1.055 . . . . 0.0 110.462 179.229 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' G' G ' 39' ' ' VAL . . . . . 0.476 HG11 ' H ' ' D' ' 39' ' ' VAL . 33.8 m -127.27 162.73 31.82 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.76 0 C-N-CA 123.1 0.56 . . . . 0.0 110.877 -179.308 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 28.1 t . . . . . 0 N--CA 1.469 0.493 0 CA-C-O 118.351 -0.833 . . . . 0.0 110.702 178.773 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 57.5 m-85 . . . . . 0 N--CA 1.473 0.705 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' H' H ' 5' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 -143.91 142.64 30.89 Favored 'General case' 0 N--CA 1.483 1.178 0 C-N-CA 122.551 0.341 . . . . 0.0 110.169 179.846 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 41.9 t-80 -152.55 120.38 6.13 Favored 'General case' 0 N--CA 1.474 0.737 0 N-CA-C 109.409 -0.589 . . . . 0.0 109.409 178.946 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -71.28 143.89 50.18 Favored 'General case' 0 N--CA 1.469 0.518 0 C-N-CA 122.699 0.399 . . . . 0.0 111.158 -179.913 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' H' H ' 8' ' ' SER . . . . . 0.469 ' OG ' ' O ' ' E' ' 7' ' ' ASP . 53.6 p -164.36 -170.42 2.06 Favored 'General case' 0 N--CA 1.474 0.759 0 CA-C-O 120.965 0.412 . . . . 0.0 110.422 178.766 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.95 47.97 1.3 Allowed Glycine 0 N--CA 1.48 1.586 0 N-CA-C 111.461 -0.655 . . . . 0.0 111.461 179.601 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 50.2 p90 -66.28 133.18 50.03 Favored 'General case' 0 N--CA 1.472 0.675 0 N-CA-C 112.046 0.387 . . . . 0.0 112.046 -179.605 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 83.4 mt-10 -91.42 151.66 20.72 Favored 'General case' 0 N--CA 1.478 0.957 0 CA-C-O 121.069 0.461 . . . . 0.0 110.195 178.576 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -154.73 127.41 1.08 Allowed 'Isoleucine or valine' 0 CA--C 1.553 1.059 0 N-CA-C 107.888 -1.153 . . . . 0.0 107.888 178.251 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 42.7 m-70 -135.46 148.2 49.17 Favored 'General case' 0 C--N 1.357 0.912 0 CA-C-N 115.461 -0.79 . . . . 0.0 111.444 -178.293 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 6.6 t60 -165.43 98.75 0.7 Allowed 'General case' 0 N--CA 1.482 1.136 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.427 178.996 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 4.9 pt20 -91.88 -177.02 4.61 Favored 'General case' 0 CA--C 1.513 -0.468 0 N-CA-C 108.799 -0.815 . . . . 0.0 108.799 -179.814 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -172.7 92.13 0.11 Allowed 'General case' 0 N--CA 1.472 0.663 0 CA-C-N 114.707 -1.133 . . . . 0.0 108.239 178.142 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 6.0 mp -122.93 154.72 37.99 Favored 'General case' 0 N--CA 1.499 1.991 0 CA-C-O 121.224 0.535 . . . . 0.0 111.784 -178.064 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 41.5 t -112.72 123.25 68.21 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.947 0 CA-C-N 114.841 -1.072 . . . . 0.0 108.368 176.742 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 34.2 m-85 -123.66 141.58 51.88 Favored 'General case' 0 C--N 1.369 1.425 0 CA-C-N 115.427 -0.806 . . . . 0.0 110.598 -179.65 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 66.9 m-85 53.02 67.44 1.0 Allowed 'General case' 0 C--O 1.237 0.419 0 CA-C-N 115.623 -0.717 . . . . 0.0 111.674 178.389 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -76.66 -83.15 0.07 Allowed 'General case' 0 N--CA 1.469 0.504 0 N-CA-C 110.025 -0.361 . . . . 0.0 110.025 -179.168 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 41.1 tt0 -123.25 96.93 5.19 Favored 'General case' 0 C--N 1.319 -0.726 0 N-CA-C 107.891 -1.151 . . . . 0.0 107.891 -179.969 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 4.2 p30 -158.16 143.98 17.06 Favored 'General case' 0 N--CA 1.478 0.968 0 CA-C-O 120.423 0.154 . . . . 0.0 111.264 179.021 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' H' H ' 24' ' ' VAL . . . . . . . . . . . . . 58.3 t -60.77 165.9 0.77 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.599 0 N-CA-C 107.61 -1.256 . . . . 0.0 107.61 177.285 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . -120.47 49.7 0.86 Allowed Glycine 0 N--CA 1.479 1.518 0 N-CA-C 110.665 -0.974 . . . . 0.0 110.665 -179.472 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -63.71 -168.16 0.02 OUTLIER 'General case' 0 N--CA 1.471 0.625 0 CA-C-N 117.022 0.411 . . . . 0.0 110.125 179.926 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 15.8 t30 -69.52 78.45 0.41 Allowed 'General case' 0 CA--C 1.536 0.413 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.41 179.987 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -77.86 155.44 30.98 Favored 'General case' 0 N--CA 1.474 0.768 0 N-CA-C 109.459 -0.571 . . . . 0.0 109.459 179.262 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.36 -142.76 0.02 OUTLIER Glycine 0 C--N 1.339 0.733 0 N-CA-C 109.798 -1.321 . . . . 0.0 109.798 178.386 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -137.67 117.38 13.09 Favored 'General case' 0 N--CA 1.469 0.522 0 C-N-CA 122.526 0.33 . . . . 0.0 110.758 -179.855 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 71.5 mt -77.49 125.73 37.42 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.506 0 N-CA-C 106.946 -1.502 . . . . 0.0 106.946 178.498 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' H' H ' 32' ' ' ILE . . . . . 0.458 ' C ' ' H ' ' H' ' 34' ' ' LEU . 44.7 pt -152.27 164.92 1.98 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 CA-C-N 120.094 1.316 . . . . 0.0 110.005 -179.452 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.91 0.3 3.97 Favored Glycine 0 CA--C 1.527 0.796 0 N-CA-C 111.202 -0.759 . . . . 0.0 111.202 -179.827 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' H' H ' 34' ' ' LEU . . . . . 0.458 ' H ' ' C ' ' H' ' 32' ' ' ILE . 7.9 tt -79.39 148.36 32.02 Favored 'General case' 0 N--CA 1.465 0.308 0 C-N-CA 122.84 0.456 . . . . 0.0 109.889 179.935 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 27.1 ttt -159.23 141.73 13.95 Favored 'General case' 0 N--CA 1.477 0.915 0 N-CA-C 108.709 -0.848 . . . . 0.0 108.709 178.999 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 35.9 m -156.69 162.13 1.7 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.416 0 N-CA-C 108.599 -0.889 . . . . 0.0 108.599 -179.39 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.04 67.79 2.02 Favored Glycine 0 C--N 1.31 -0.896 0 CA-C-N 115.638 -0.71 . . . . 0.0 112.086 178.239 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 149.01 174.89 20.98 Favored Glycine 0 N--CA 1.475 1.267 0 N-CA-C 110.571 -1.012 . . . . 0.0 110.571 179.19 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' H' H ' 39' ' ' VAL . . . . . 0.459 HG11 ' H ' ' E' ' 39' ' ' VAL . 33.9 m -127.65 162.53 33.09 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.799 0 C-N-CA 123.114 0.565 . . . . 0.0 110.923 -179.368 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 25.9 t . . . . . 0 N--CA 1.47 0.541 0 CA-C-O 118.402 -0.809 . . . . 0.0 110.707 178.74 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 56.3 m-85 . . . . . 0 N--CA 1.474 0.772 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' I' I ' 5' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 -143.93 142.37 30.72 Favored 'General case' 0 N--CA 1.483 1.199 0 C-N-CA 122.569 0.348 . . . . 0.0 110.108 179.827 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 40.7 t-80 -152.36 120.13 6.12 Favored 'General case' 0 N--CA 1.473 0.687 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 178.976 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -71.06 143.98 50.51 Favored 'General case' 0 N--CA 1.47 0.574 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.178 -179.856 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' I' I ' 8' ' ' SER . . . . . 0.481 ' OG ' ' O ' ' F' ' 7' ' ' ASP . 54.1 p -164.5 -170.43 2.04 Favored 'General case' 0 N--CA 1.475 0.781 0 CA-C-O 120.964 0.411 . . . . 0.0 110.456 178.707 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.19 47.24 1.35 Allowed Glycine 0 N--CA 1.48 1.611 0 N-CA-C 111.598 -0.601 . . . . 0.0 111.598 179.67 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 50.4 p90 -65.76 133.48 51.13 Favored 'General case' 0 N--CA 1.473 0.676 0 N-CA-C 112.0 0.37 . . . . 0.0 112.0 -179.566 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 82.6 mt-10 -91.81 151.71 20.47 Favored 'General case' 0 N--CA 1.476 0.871 0 CA-C-O 120.978 0.418 . . . . 0.0 110.184 178.639 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -154.67 127.48 1.1 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.033 0 N-CA-C 107.969 -1.123 . . . . 0.0 107.969 178.16 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 41.7 m-70 -135.5 148.1 49.07 Favored 'General case' 0 N--CA 1.477 0.922 0 CA-C-N 115.407 -0.815 . . . . 0.0 111.467 -178.248 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 6.6 t60 -165.3 99.01 0.72 Allowed 'General case' 0 N--CA 1.483 1.192 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.383 179.013 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -92.07 -176.92 4.54 Favored 'General case' 0 CA--C 1.511 -0.521 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 -179.848 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -172.83 92.08 0.1 Allowed 'General case' 0 N--CA 1.47 0.534 0 CA-C-N 114.74 -1.118 . . . . 0.0 108.291 178.199 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 6.0 mp -122.84 154.91 37.63 Favored 'General case' 0 N--CA 1.499 1.983 0 CA-C-O 121.223 0.535 . . . . 0.0 111.754 -178.054 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 41.3 t -113.09 123.42 68.72 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.927 0 CA-C-N 114.861 -1.063 . . . . 0.0 108.247 176.784 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 33.4 m-85 -123.96 141.18 52.27 Favored 'General case' 0 C--N 1.37 1.461 0 CA-C-N 115.413 -0.812 . . . . 0.0 110.636 -179.444 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 67.1 m-85 53.35 67.15 1.05 Allowed 'General case' 0 C--O 1.238 0.45 0 CA-C-N 115.69 -0.686 . . . . 0.0 111.537 178.41 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -76.32 -83.14 0.07 Allowed 'General case' 0 N--CA 1.47 0.541 0 N-CA-C 109.913 -0.402 . . . . 0.0 109.913 -179.148 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 41.3 tt0 -123.33 97.1 5.25 Favored 'General case' 0 C--N 1.32 -0.712 0 N-CA-C 107.868 -1.16 . . . . 0.0 107.868 -179.924 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 4.1 p30 -158.29 144.36 17.13 Favored 'General case' 0 N--CA 1.479 1.002 0 O-C-N 122.458 -0.151 . . . . 0.0 111.257 178.964 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' I' I ' 24' ' ' VAL . . . . . . . . . . . . . 59.5 t -61.2 165.57 0.86 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.589 0 N-CA-C 107.63 -1.248 . . . . 0.0 107.63 177.345 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . -120.24 49.95 0.85 Allowed Glycine 0 N--CA 1.481 1.661 0 N-CA-C 110.588 -1.005 . . . . 0.0 110.588 -179.383 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -63.8 -168.1 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.649 0 CA-C-N 116.991 0.395 . . . . 0.0 110.134 179.825 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 15.2 t30 -69.56 78.3 0.41 Allowed 'General case' 0 CA--C 1.536 0.421 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.364 179.924 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -77.77 155.34 31.22 Favored 'General case' 0 N--CA 1.475 0.78 0 N-CA-C 109.504 -0.554 . . . . 0.0 109.504 179.263 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.28 -143.0 0.02 OUTLIER Glycine 0 CA--C 1.527 0.842 0 N-CA-C 109.813 -1.315 . . . . 0.0 109.813 178.39 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -137.3 117.36 13.38 Favored 'General case' 0 N--CA 1.471 0.597 0 C-N-CA 122.627 0.371 . . . . 0.0 110.778 -179.863 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 71.7 mt -77.57 125.89 37.6 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.488 0 N-CA-C 106.986 -1.487 . . . . 0.0 106.986 178.389 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' I' I ' 32' ' ' ILE . . . . . 0.457 ' C ' ' H ' ' I' ' 34' ' ' LEU . 44.9 pt -152.34 164.95 1.94 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 CA-C-N 120.143 1.338 . . . . 0.0 110.06 -179.436 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.64 0.98 4.22 Favored Glycine 0 N--CA 1.469 0.844 0 N-CA-C 111.127 -0.789 . . . . 0.0 111.127 -179.909 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' I' I ' 34' ' ' LEU . . . . . 0.457 ' H ' ' C ' ' I' ' 32' ' ' ILE . 8.1 tt -80.1 148.02 31.17 Favored 'General case' 0 CA--C 1.533 0.313 0 C-N-CA 122.845 0.458 . . . . 0.0 109.792 179.895 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 26.9 ttt -158.69 141.68 14.63 Favored 'General case' 0 N--CA 1.476 0.85 0 N-CA-C 108.611 -0.885 . . . . 0.0 108.611 179.086 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 35.9 m -156.65 162.06 1.72 Allowed 'Isoleucine or valine' 0 C--N 1.346 0.442 0 N-CA-C 108.523 -0.917 . . . . 0.0 108.523 -179.562 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.22 67.78 2.03 Favored Glycine 0 C--N 1.312 -0.798 0 CA-C-N 115.638 -0.71 . . . . 0.0 112.107 178.185 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 148.68 174.73 20.59 Favored Glycine 0 N--CA 1.474 1.217 0 N-CA-C 110.461 -1.056 . . . . 0.0 110.461 179.244 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' I' I ' 39' ' ' VAL . . . . . 0.475 HG11 ' H ' ' F' ' 39' ' ' VAL . 33.9 m -127.66 162.76 32.64 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.786 0 C-N-CA 123.1 0.56 . . . . 0.0 110.923 -179.259 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 27.1 t . . . . . 0 N--CA 1.47 0.544 0 CA-C-O 118.377 -0.821 . . . . 0.0 110.56 178.75 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 26.6 m-85 . . . . . 0 CA--C 1.537 0.478 0 N-CA-C 109.142 -0.688 . . . . 0.0 109.142 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 38.2 mtp180 -68.41 147.02 52.67 Favored 'General case' 0 C--O 1.201 -1.452 0 CA-C-N 115.821 -0.627 . . . . 0.0 111.293 -177.505 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 39.2 m80 -109.55 119.1 38.39 Favored 'General case' 0 N--CA 1.482 1.165 0 N-CA-C 108.953 -0.758 . . . . 0.0 108.953 178.289 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' ASP . . . . . 0.459 ' OD1' ' NH2' ' G' ' 5' ' ' ARG . 7.3 m-20 -67.52 140.7 57.01 Favored 'General case' 0 N--CA 1.469 0.502 0 CA-C-O 121.135 0.493 . . . . 0.0 111.795 -178.758 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 39.0 t -158.65 -169.49 2.74 Favored 'General case' 0 N--CA 1.467 0.376 0 CA-C-N 115.848 -0.615 . . . . 0.0 109.662 179.092 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 119.83 32.39 1.2 Allowed Glycine 0 N--CA 1.485 1.922 0 N-CA-C 111.574 -0.61 . . . . 0.0 111.574 179.61 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 46.9 p90 -57.2 130.43 46.16 Favored 'General case' 0 N--CA 1.471 0.61 0 CA-C-N 116.736 0.268 . . . . 0.0 111.49 179.971 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . 0.477 ' CG ' HD22 ' C' ' 27' ' ' ASN . 60.6 mt-10 -90.44 153.15 20.61 Favored 'General case' 0 N--CA 1.473 0.717 0 N-CA-C 109.329 -0.619 . . . . 0.0 109.329 178.69 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.6 p -153.48 126.55 1.15 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 N-CA-C 107.698 -1.223 . . . . 0.0 107.698 177.988 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 45.6 m-70 -136.91 162.06 34.3 Favored 'General case' 0 N--CA 1.49 1.537 0 CA-C-N 118.685 0.675 . . . . 0.0 110.879 -178.721 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 38.3 t60 -152.91 96.43 2.1 Favored 'General case' 0 N--CA 1.486 1.333 0 C-N-CA 122.634 0.374 . . . . 0.0 110.049 179.065 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . 0.68 HE22 ' H ' ' A' ' 38' ' ' GLY . 28.3 mt-30 -90.63 121.52 32.61 Favored 'General case' 0 N--CA 1.452 -0.371 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 -178.964 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -112.98 103.67 11.63 Favored 'General case' 0 N--CA 1.475 0.789 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 176.686 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 57.8 tp -133.34 150.43 51.85 Favored 'General case' 0 N--CA 1.486 1.347 0 N-CA-C 108.766 -0.827 . . . . 0.0 108.766 -179.391 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 84.5 t -145.42 123.13 4.65 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.969 0 CA-C-O 118.523 -0.751 . . . . 0.0 109.137 179.755 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 11.9 m-85 -70.74 158.67 35.89 Favored 'General case' 0 N--CA 1.485 1.324 0 N-CA-C 107.461 -1.311 . . . . 0.0 107.461 177.564 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 18.6 t80 -170.07 -58.44 0.02 OUTLIER 'General case' 0 N--CA 1.481 1.101 0 CA-C-O 122.425 1.107 . . . . 0.0 109.765 179.735 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -39.19 89.68 0.0 OUTLIER 'General case' 0 N--CA 1.456 -0.135 0 CA-C-N 113.807 -1.542 . . . . 0.0 112.844 -178.034 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 38.6 tt0 -64.49 159.59 21.2 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.175 -0.92 . . . . 0.0 110.552 179.245 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 9.6 m-20 -136.23 125.81 25.3 Favored 'General case' 0 N--CA 1.481 1.086 0 C-N-CA 123.297 0.639 . . . . 0.0 109.781 -179.897 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . 0.634 ' CG1' HH22 ' E' ' 5' ' ' ARG . 57.8 t -76.55 -170.44 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.591 0 N-CA-C 108.511 -0.922 . . . . 0.0 108.511 179.673 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.583 ' H ' ' CG1' ' A' ' 24' ' ' VAL . . . -69.11 48.86 0.52 Allowed Glycine 0 CA--C 1.53 1.003 0 CA-C-N 118.344 0.52 . . . . 0.0 112.313 -178.147 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 13.1 p -69.54 137.52 52.52 Favored 'General case' 0 C--O 1.217 -0.61 0 N-CA-C 109.596 -0.52 . . . . 0.0 109.596 178.66 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . 0.482 HD22 ' CG ' ' B' ' 11' ' ' GLU . 34.6 t30 -68.57 95.06 0.61 Allowed 'General case' 0 N--CA 1.47 0.553 0 N-CA-C 108.15 -1.055 . . . . 0.0 108.15 177.847 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 68.6 mttm -92.45 117.66 30.16 Favored 'General case' 0 N--CA 1.481 1.079 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 -179.221 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.33 -134.27 0.01 OUTLIER Glycine 0 CA--C 1.534 1.226 0 N-CA-C 110.771 -0.932 . . . . 0.0 110.771 179.044 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -115.65 127.16 54.98 Favored 'General case' 0 N--CA 1.477 0.897 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 179.12 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 66.1 mt -90.53 134.97 27.76 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.59 0 N-CA-C 107.673 -1.232 . . . . 0.0 107.673 179.012 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 30.3 mt -136.52 138.16 46.92 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.815 0 CA-C-N 115.982 -0.554 . . . . 0.0 109.606 -179.134 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.97 57.46 15.75 Favored Glycine 0 CA--C 1.527 0.842 0 CA-C-N 115.904 -0.589 . . . . 0.0 112.795 178.543 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 25.4 tp -106.11 132.77 51.79 Favored 'General case' 0 N--CA 1.488 1.474 0 N-CA-C 107.508 -1.293 . . . . 0.0 107.508 177.919 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 24.9 ttt -138.2 148.15 44.52 Favored 'General case' 0 N--CA 1.471 0.576 0 N-CA-C 107.769 -1.197 . . . . 0.0 107.769 179.136 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 60.4 t -156.64 160.45 2.25 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.587 0 N-CA-C 106.097 -1.816 . . . . 0.0 106.097 -178.855 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . 0.455 ' O ' ' NE2' ' D' ' 15' ' ' GLN . . . 53.55 74.48 0.3 Allowed Glycine 0 C--N 1.308 -0.993 0 C-N-CA 121.214 -0.517 . . . . 0.0 111.818 177.839 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . 0.68 ' H ' HE22 ' A' ' 15' ' ' GLN . . . 164.73 -168.51 39.02 Favored Glycine 0 N--CA 1.466 0.692 0 N-CA-C 111.042 -0.823 . . . . 0.0 111.042 179.352 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 24.5 m -126.67 148.9 31.38 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.855 0 C-N-CA 122.977 0.511 . . . . 0.0 109.847 179.665 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 9.7 t . . . . . 0 CA--C 1.535 0.385 0 CA-C-O 118.109 -0.948 . . . . 0.0 110.723 178.893 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 27.8 m-85 . . . . . 0 N--CA 1.468 0.435 0 N-CA-C 109.154 -0.684 . . . . 0.0 109.154 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 39.3 mtp180 -68.48 146.74 52.88 Favored 'General case' 0 C--O 1.201 -1.478 0 CA-C-N 115.708 -0.678 . . . . 0.0 111.3 -177.653 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 39.4 m80 -109.35 119.36 39.24 Favored 'General case' 0 N--CA 1.484 1.247 0 N-CA-C 108.995 -0.742 . . . . 0.0 108.995 178.282 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 7' ' ' ASP . . . . . 0.46 ' OD1' ' NH2' ' H' ' 5' ' ' ARG . 7.1 m-20 -67.66 141.02 56.84 Favored 'General case' 0 N--CA 1.469 0.501 0 CA-C-O 121.043 0.449 . . . . 0.0 111.76 -178.745 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 8' ' ' SER . . . . . . . . . . . . . 39.1 t -158.8 -169.45 2.7 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-N 115.814 -0.63 . . . . 0.0 109.634 179.099 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 119.75 32.37 1.21 Allowed Glycine 0 N--CA 1.485 1.92 0 N-CA-C 111.552 -0.619 . . . . 0.0 111.552 179.578 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 46.8 p90 -57.36 130.54 46.71 Favored 'General case' 0 N--CA 1.472 0.651 0 CA-C-O 120.64 0.257 . . . . 0.0 111.514 -179.996 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 11' ' ' GLU . . . . . 0.482 ' CG ' HD22 ' A' ' 27' ' ' ASN . 60.4 mt-10 -90.52 153.16 20.57 Favored 'General case' 0 N--CA 1.472 0.664 0 N-CA-C 109.357 -0.609 . . . . 0.0 109.357 178.857 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.6 p -153.53 126.14 1.09 Allowed 'Isoleucine or valine' 0 C--O 1.234 0.281 0 N-CA-C 107.846 -1.168 . . . . 0.0 107.846 178.086 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 45.6 m-70 -136.63 162.07 34.15 Favored 'General case' 0 N--CA 1.49 1.533 0 CA-C-N 118.648 0.658 . . . . 0.0 110.936 -178.567 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 38.4 t60 -152.86 96.44 2.1 Favored 'General case' 0 N--CA 1.487 1.422 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.087 179.057 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . 0.696 HE22 ' H ' ' B' ' 38' ' ' GLY . 28.3 mt-30 -90.48 121.16 32.2 Favored 'General case' 0 CA--C 1.517 -0.309 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 -179.01 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -112.63 103.49 11.53 Favored 'General case' 0 N--CA 1.474 0.742 0 N-CA-C 107.988 -1.115 . . . . 0.0 107.988 176.619 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 57.8 tp -133.34 150.25 51.86 Favored 'General case' 0 N--CA 1.486 1.369 0 N-CA-C 108.755 -0.831 . . . . 0.0 108.755 -179.368 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 84.6 t -145.41 122.48 4.28 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.011 0 CA-C-O 118.629 -0.7 . . . . 0.0 109.333 179.707 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 12.4 m-85 -70.52 158.91 35.26 Favored 'General case' 0 N--CA 1.486 1.334 0 N-CA-C 107.287 -1.375 . . . . 0.0 107.287 177.572 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 19.9 t80 -170.99 -57.67 0.02 OUTLIER 'General case' 0 N--CA 1.478 0.934 0 CA-C-O 122.22 1.009 . . . . 0.0 109.705 179.651 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -39.4 90.12 0.0 OUTLIER 'General case' 0 C--O 1.231 0.124 0 CA-C-N 113.959 -1.473 . . . . 0.0 112.721 -178.16 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 38.6 tt0 -64.85 159.55 22.35 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 115.1 -0.955 . . . . 0.0 110.559 179.298 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 9.7 m-20 -136.26 125.9 25.4 Favored 'General case' 0 N--CA 1.481 1.118 0 C-N-CA 123.217 0.607 . . . . 0.0 109.765 -179.876 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 24' ' ' VAL . . . . . 0.638 ' CG1' HH22 ' F' ' 5' ' ' ARG . 56.9 t -76.7 -170.39 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.661 0 N-CA-C 108.586 -0.894 . . . . 0.0 108.586 179.722 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 25' ' ' GLY . . . . . 0.58 ' H ' ' CG1' ' B' ' 24' ' ' VAL . . . -68.71 48.42 0.45 Allowed Glycine 0 CA--C 1.531 1.087 0 CA-C-N 118.321 0.509 . . . . 0.0 112.208 -178.126 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 13.3 p -69.72 137.41 52.02 Favored 'General case' 0 C--O 1.219 -0.548 0 N-CA-C 109.591 -0.522 . . . . 0.0 109.591 178.706 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 27' ' ' ASN . . . . . 0.48 HD22 ' CG ' ' C' ' 11' ' ' GLU . 34.8 t30 -68.72 95.07 0.64 Allowed 'General case' 0 N--CA 1.47 0.543 0 N-CA-C 108.159 -1.052 . . . . 0.0 108.159 177.847 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 68.6 mttm -92.34 117.62 30.08 Favored 'General case' 0 N--CA 1.48 1.028 0 N-CA-C 109.997 -0.371 . . . . 0.0 109.997 -179.227 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.3 -134.17 0.01 OUTLIER Glycine 0 CA--C 1.532 1.128 0 N-CA-C 110.769 -0.932 . . . . 0.0 110.769 179.014 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -115.88 127.28 54.89 Favored 'General case' 0 N--CA 1.478 0.955 0 N-CA-C 109.428 -0.582 . . . . 0.0 109.428 179.149 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 66.0 mt -90.55 135.0 27.69 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.536 0 N-CA-C 107.676 -1.231 . . . . 0.0 107.676 179.035 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 30.2 mt -136.45 138.35 46.8 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.714 0 CA-C-N 115.933 -0.576 . . . . 0.0 109.567 -179.115 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.65 57.72 15.16 Favored Glycine 0 CA--C 1.527 0.829 0 CA-C-N 115.876 -0.602 . . . . 0.0 112.82 178.604 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 25.8 tp -106.3 132.83 51.88 Favored 'General case' 0 N--CA 1.486 1.375 0 N-CA-C 107.502 -1.296 . . . . 0.0 107.502 177.897 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 25.0 ttt -138.18 147.83 44.22 Favored 'General case' 0 N--CA 1.473 0.683 0 N-CA-C 107.778 -1.193 . . . . 0.0 107.778 179.216 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 60.8 t -156.67 159.98 2.45 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.625 0 N-CA-C 106.178 -1.786 . . . . 0.0 106.178 -178.928 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . 0.464 ' O ' ' NE2' ' E' ' 15' ' ' GLN . . . 54.12 74.26 0.33 Allowed Glycine 0 C--N 1.308 -0.973 0 N-CA-C 111.739 -0.544 . . . . 0.0 111.739 177.963 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 38' ' ' GLY . . . . . 0.696 ' H ' HE22 ' B' ' 15' ' ' GLN . . . 164.85 -168.44 39.07 Favored Glycine 0 N--CA 1.465 0.58 0 N-CA-C 111.124 -0.791 . . . . 0.0 111.124 179.266 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 24.5 m -126.62 148.89 31.33 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.808 0 C-N-CA 122.992 0.517 . . . . 0.0 109.955 179.601 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 9.7 t . . . . . 0 CA--C 1.535 0.392 0 CA-C-O 118.095 -0.955 . . . . 0.0 110.872 179.001 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 27.7 m-85 . . . . . 0 N--CA 1.468 0.429 0 N-CA-C 109.265 -0.643 . . . . 0.0 109.265 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 39.2 mtp180 -68.67 146.37 53.05 Favored 'General case' 0 C--O 1.201 -1.489 0 CA-C-N 115.849 -0.614 . . . . 0.0 111.221 -177.564 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 39.2 m80 -109.11 119.22 38.9 Favored 'General case' 0 N--CA 1.484 1.232 0 N-CA-C 108.978 -0.749 . . . . 0.0 108.978 178.269 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' C' C ' 7' ' ' ASP . . . . . 0.473 ' OD1' ' NH2' ' I' ' 5' ' ' ARG . 7.3 m-20 -67.64 141.11 56.83 Favored 'General case' 0 N--CA 1.468 0.448 0 CA-C-O 121.049 0.452 . . . . 0.0 111.79 -178.721 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' C' C ' 8' ' ' SER . . . . . . . . . . . . . 39.2 t -158.89 -169.49 2.71 Favored 'General case' 0 N--CA 1.466 0.37 0 CA-C-N 115.837 -0.62 . . . . 0.0 109.604 179.149 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 119.8 32.34 1.21 Allowed Glycine 0 N--CA 1.485 1.94 0 N-CA-C 111.506 -0.638 . . . . 0.0 111.506 179.543 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 46.8 p90 -57.32 130.42 46.15 Favored 'General case' 0 N--CA 1.471 0.587 0 CA-C-O 120.676 0.274 . . . . 0.0 111.53 179.951 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' C' C ' 11' ' ' GLU . . . . . 0.48 ' CG ' HD22 ' B' ' 27' ' ' ASN . 60.5 mt-10 -90.39 153.12 20.65 Favored 'General case' 0 N--CA 1.473 0.722 0 N-CA-C 109.368 -0.605 . . . . 0.0 109.368 178.792 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.6 p -153.47 126.16 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 N-CA-C 107.858 -1.164 . . . . 0.0 107.858 178.017 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 45.8 m-70 -136.59 162.16 33.9 Favored 'General case' 0 N--CA 1.491 1.589 0 CA-C-N 118.604 0.638 . . . . 0.0 110.958 -178.658 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 38.6 t60 -153.01 96.61 2.1 Favored 'General case' 0 N--CA 1.487 1.413 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.1 179.086 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' C' C ' 15' ' ' GLN . . . . . 0.709 HE22 ' H ' ' C' ' 38' ' ' GLY . 28.3 mt-30 -90.72 121.5 32.67 Favored 'General case' 0 CA--C 1.515 -0.381 0 N-CA-C 109.843 -0.429 . . . . 0.0 109.843 -178.99 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -112.92 103.49 11.46 Favored 'General case' 0 N--CA 1.473 0.677 0 N-CA-C 107.898 -1.149 . . . . 0.0 107.898 176.665 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 57.8 tp -133.28 150.23 51.92 Favored 'General case' 0 N--CA 1.486 1.337 0 N-CA-C 108.769 -0.826 . . . . 0.0 108.769 -179.435 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 85.3 t -145.38 122.59 4.37 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.013 0 CA-C-O 118.694 -0.67 . . . . 0.0 109.289 179.714 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 12.4 m-85 -70.63 158.88 35.41 Favored 'General case' 0 N--CA 1.487 1.39 0 N-CA-C 107.345 -1.354 . . . . 0.0 107.345 177.516 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 19.9 t80 -170.9 -57.72 0.02 OUTLIER 'General case' 0 N--CA 1.476 0.86 0 CA-C-O 122.29 1.043 . . . . 0.0 109.731 179.641 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -39.31 90.01 0.0 OUTLIER 'General case' 0 N--CA 1.457 -0.088 0 CA-C-N 113.986 -1.461 . . . . 0.0 112.711 -178.157 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 38.6 tt0 -64.84 159.64 22.11 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 115.183 -0.917 . . . . 0.0 110.593 179.343 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 9.6 m-20 -136.28 125.77 25.15 Favored 'General case' 0 N--CA 1.48 1.048 0 C-N-CA 123.315 0.646 . . . . 0.0 109.798 -179.838 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' C' C ' 24' ' ' VAL . . . . . 0.641 ' CG1' HH22 ' D' ' 5' ' ' ARG . 57.1 t -76.66 -170.4 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.578 0 N-CA-C 108.609 -0.885 . . . . 0.0 108.609 179.708 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' C' C ' 25' ' ' GLY . . . . . 0.574 ' H ' ' CG1' ' C' ' 24' ' ' VAL . . . -68.8 48.56 0.47 Allowed Glycine 0 CA--C 1.533 1.18 0 CA-C-N 118.409 0.549 . . . . 0.0 112.249 -178.066 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 13.3 p -69.73 137.47 52.04 Favored 'General case' 0 C--O 1.22 -0.459 0 N-CA-C 109.646 -0.501 . . . . 0.0 109.646 178.716 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' C' C ' 27' ' ' ASN . . . . . 0.477 HD22 ' CG ' ' A' ' 11' ' ' GLU . 34.8 t30 -68.7 95.04 0.63 Allowed 'General case' 0 N--CA 1.469 0.485 0 N-CA-C 108.179 -1.045 . . . . 0.0 108.179 177.851 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 68.6 mttm -92.36 117.66 30.14 Favored 'General case' 0 N--CA 1.48 1.053 0 N-CA-C 109.988 -0.375 . . . . 0.0 109.988 -179.233 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.32 -134.2 0.01 OUTLIER Glycine 0 CA--C 1.533 1.16 0 N-CA-C 110.784 -0.926 . . . . 0.0 110.784 179.02 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -115.7 127.12 54.91 Favored 'General case' 0 N--CA 1.48 1.067 0 N-CA-C 109.314 -0.625 . . . . 0.0 109.314 179.203 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 66.2 mt -90.57 134.9 28.0 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.574 0 N-CA-C 107.666 -1.235 . . . . 0.0 107.666 178.845 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 30.4 mt -136.51 138.37 46.7 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.77 0 CA-C-N 115.937 -0.574 . . . . 0.0 109.545 -179.099 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.72 57.55 15.76 Favored Glycine 0 CA--C 1.528 0.887 0 CA-C-N 115.866 -0.606 . . . . 0.0 112.791 178.663 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 25.6 tp -106.13 132.75 51.83 Favored 'General case' 0 N--CA 1.486 1.353 0 N-CA-C 107.471 -1.307 . . . . 0.0 107.471 177.832 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 25.1 ttt -138.09 147.96 44.54 Favored 'General case' 0 N--CA 1.47 0.568 0 N-CA-C 107.591 -1.262 . . . . 0.0 107.591 179.315 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 60.6 t -156.81 160.05 2.4 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.546 0 N-CA-C 106.076 -1.824 . . . . 0.0 106.076 -178.959 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' C' C ' 37' ' ' GLY . . . . . 0.46 ' O ' ' NE2' ' F' ' 15' ' ' GLN . . . 54.1 74.12 0.34 Allowed Glycine 0 C--N 1.309 -0.925 0 C-N-CA 121.116 -0.564 . . . . 0.0 111.788 177.848 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' C' C ' 38' ' ' GLY . . . . . 0.709 ' H ' HE22 ' C' ' 15' ' ' GLN . . . 164.9 -168.36 39.07 Favored Glycine 0 N--CA 1.466 0.65 0 N-CA-C 111.104 -0.799 . . . . 0.0 111.104 179.349 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 24.2 m -126.71 148.88 31.43 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.858 0 C-N-CA 122.934 0.494 . . . . 0.0 109.935 179.716 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 9.8 t . . . . . 0 CA--C 1.534 0.364 0 CA-C-O 118.187 -0.911 . . . . 0.0 110.7 178.884 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 28.7 m-85 . . . . . 0 N--CA 1.475 0.789 0 N-CA-C 107.949 -1.13 . . . . 0.0 107.949 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' D' D ' 5' ' ' ARG . . . . . 0.641 HH22 ' CG1' ' C' ' 24' ' ' VAL 0.273 47.8 mtp180 -77.55 143.45 38.37 Favored 'General case' 0 C--O 1.207 -1.15 0 C-N-CA 123.595 0.758 . . . . 0.0 109.044 -169.708 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 40.5 m80 -107.79 124.44 50.05 Favored 'General case' 0 C--N 1.366 1.301 0 N-CA-C 106.87 -1.53 . . . . 0.0 106.87 -176.282 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' D' D ' 7' ' ' ASP . . . . . . . . . . . . . 7.9 m-20 -64.28 131.92 48.73 Favored 'General case' 0 CA--C 1.512 -0.485 0 CA-C-N 113.897 -1.501 . . . . 0.0 114.077 179.004 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' D' D ' 8' ' ' SER . . . . . . . . . . . . . 40.9 t -152.62 -167.8 2.86 Favored 'General case' 0 N--CA 1.482 1.152 0 C-N-CA 120.908 -0.317 . . . . 0.0 110.17 177.028 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 120.71 30.23 1.41 Allowed Glycine 0 N--CA 1.486 1.967 0 N-CA-C 111.35 -0.7 . . . . 0.0 111.35 177.862 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 44.9 p90 -54.46 131.13 41.87 Favored 'General case' 0 CA--C 1.545 0.785 0 CA-C-N 117.085 0.442 . . . . 0.0 111.591 -179.557 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' D' D ' 11' ' ' GLU . . . . . 0.411 ' CG ' HD22 ' F' ' 27' ' ' ASN . 60.3 mt-10 -89.7 151.2 21.98 Favored 'General case' 0 N--CA 1.475 0.808 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 177.324 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -149.66 129.07 3.53 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.529 0 N-CA-C 107.339 -1.356 . . . . 0.0 107.339 172.59 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 36.0 m-70 -130.29 162.59 28.67 Favored 'General case' 0 N--CA 1.48 1.054 0 C-N-CA 123.678 0.791 . . . . 0.0 112.902 178.205 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 41.5 t60 -153.96 104.31 2.65 Favored 'General case' 0 N--CA 1.486 1.35 0 N-CA-C 108.418 -0.956 . . . . 0.0 108.418 171.54 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' D' D ' 15' ' ' GLN . . . . . 0.639 HE22 ' H ' ' D' ' 38' ' ' GLY . 28.1 mt-30 -93.84 116.03 28.46 Favored 'General case' 0 CA--C 1.505 -0.762 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.325 -179.625 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -108.37 111.82 23.93 Favored 'General case' 0 C--N 1.359 0.99 0 N-CA-C 106.059 -1.83 . . . . 0.0 106.059 174.383 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 52.7 tp -134.32 150.73 50.98 Favored 'General case' 0 N--CA 1.484 1.238 0 N-CA-C 108.973 -0.751 . . . . 0.0 108.973 176.074 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 71.0 t -142.39 126.05 15.1 Favored 'Isoleucine or valine' 0 C--O 1.242 0.674 0 N-CA-C 109.141 -0.689 . . . . 0.0 109.141 173.863 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 26.8 m-85 -62.12 151.54 35.42 Favored 'General case' 0 N--CA 1.473 0.699 0 C-N-CA 124.284 1.034 . . . . 0.0 110.325 169.712 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 14.0 t80 -170.13 -66.86 0.02 OUTLIER 'General case' 0 C--N 1.318 -0.766 0 N-CA-C 107.765 -1.198 . . . . 0.0 107.765 -179.703 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -38.17 95.54 0.01 OUTLIER 'General case' 0 N--CA 1.449 -0.502 0 CA-C-N 114.207 -1.361 . . . . 0.0 111.798 -175.017 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 39.2 tt0 -67.51 161.12 26.19 Favored 'General case' 0 N--CA 1.468 0.458 0 CA-C-N 113.628 -1.624 . . . . 0.0 110.139 178.805 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 9.9 m-20 -137.22 126.52 24.79 Favored 'General case' 0 N--CA 1.479 1.019 0 C-N-CA 123.472 0.709 . . . . 0.0 109.942 -179.068 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' D' D ' 24' ' ' VAL . . . . . 0.666 ' CG1' HH22 ' H' ' 5' ' ' ARG . 92.3 t -81.13 -165.64 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.482 1.169 0 N-CA-C 107.566 -1.272 . . . . 0.0 107.566 -178.098 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' D' D ' 25' ' ' GLY . . . . . 0.588 ' H ' ' CG1' ' D' ' 24' ' ' VAL . . . -79.27 56.62 4.4 Favored Glycine 0 C--N 1.362 1.997 0 C-N-CA 117.855 -2.117 . . . . 0.0 110.628 -174.263 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 21.8 p -61.34 132.83 54.82 Favored 'General case' 0 C--N 1.346 0.426 0 CA-C-N 113.545 -1.328 . . . . 0.0 111.965 170.648 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' D' D ' 27' ' ' ASN . . . . . 0.427 HD22 ' CG ' ' E' ' 11' ' ' GLU . 40.6 t30 -65.53 95.06 0.2 Allowed 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 119.908 1.231 . . . . 0.0 108.751 172.971 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 68.3 mttm -93.89 120.97 34.87 Favored 'General case' 0 N--CA 1.484 1.26 0 C-N-CA 119.521 -0.871 . . . . 0.0 108.908 179.756 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -57.45 -135.01 0.01 OUTLIER Glycine 0 C--N 1.341 0.806 0 CA-C-N 115.858 -0.61 . . . . 0.0 113.067 175.974 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -114.22 131.76 56.36 Favored 'General case' 0 C--N 1.367 1.357 0 N-CA-C 109.101 -0.703 . . . . 0.0 109.101 174.572 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 68.6 mt -91.79 138.43 19.82 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.298 0 N-CA-C 107.182 -1.414 . . . . 0.0 107.182 176.845 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 35.2 mt -138.7 140.85 38.4 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.879 0 N-CA-C 108.639 -0.875 . . . . 0.0 108.639 178.518 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.54 55.04 27.62 Favored Glycine 0 CA--C 1.529 0.911 0 CA-C-O 119.381 -0.677 . . . . 0.0 112.588 178.313 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 19.2 tp -102.84 141.59 35.39 Favored 'General case' 0 C--N 1.364 1.207 0 N-CA-C 106.333 -1.728 . . . . 0.0 106.333 176.536 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 23.9 ttt -142.07 156.95 45.42 Favored 'General case' 0 N--CA 1.472 0.664 0 N-CA-C 105.952 -1.87 . . . . 0.0 105.952 175.085 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 73.7 t -164.34 161.89 0.93 Allowed 'Isoleucine or valine' 0 CA--C 1.503 -0.835 0 N-CA-C 105.349 -2.093 . . . . 0.0 105.349 179.19 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' D' D ' 37' ' ' GLY . . . . . 0.457 ' O ' ' NE2' ' G' ' 15' ' ' GLN . . . 60.21 64.44 4.15 Favored Glycine 0 N--CA 1.441 -1.004 0 C-N-CA 118.38 -1.867 . . . . 0.0 112.453 176.301 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' D' D ' 38' ' ' GLY . . . . . 0.639 ' H ' HE22 ' D' ' 15' ' ' GLN . . . 166.46 -163.86 37.23 Favored Glycine 0 C--O 1.215 -1.051 0 CA-C-N 119.308 1.554 . . . . 0.0 112.264 176.493 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 29.4 m -121.64 147.45 25.61 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.067 0 CA-C-O 118.041 -0.981 . . . . 0.0 112.259 179.35 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 7.5 t . . . . . 0 C--O 1.213 -0.864 0 N-CA-C 108.798 -0.815 . . . . 0.0 108.798 171.652 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 24.8 m-85 . . . . . 0 N--CA 1.471 0.579 0 N-CA-C 109.445 -0.576 . . . . 0.0 109.445 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' E' E ' 5' ' ' ARG . . . . . 0.634 HH22 ' CG1' ' A' ' 24' ' ' VAL . 34.9 mtp180 -68.13 148.15 51.31 Favored 'General case' 0 C--O 1.202 -1.419 0 CA-C-N 115.567 -0.742 . . . . 0.0 111.313 -178.012 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 39.2 m80 -109.9 118.97 37.89 Favored 'General case' 0 N--CA 1.483 1.181 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 177.889 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' E' E ' 7' ' ' ASP . . . . . . . . . . . . . 13.0 m-20 -66.31 140.28 58.1 Favored 'General case' 0 N--CA 1.466 0.37 0 CA-C-O 120.91 0.386 . . . . 0.0 112.02 -178.442 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' E' E ' 8' ' ' SER . . . . . . . . . . . . . 38.2 t -158.7 -169.87 2.86 Favored 'General case' 0 N--CA 1.487 1.378 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.194 178.924 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 120.33 32.84 1.09 Allowed Glycine 0 N--CA 1.484 1.867 0 N-CA-C 111.717 -0.553 . . . . 0.0 111.717 179.538 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 43.3 p90 -56.84 130.54 46.19 Favored 'General case' 0 CA--C 1.546 0.796 0 CA-C-N 116.948 0.374 . . . . 0.0 111.64 -179.963 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' E' E ' 11' ' ' GLU . . . . . 0.427 ' CG ' HD22 ' D' ' 27' ' ' ASN . 60.2 mt-10 -89.98 153.49 20.55 Favored 'General case' 0 N--CA 1.478 0.945 0 N-CA-C 109.404 -0.591 . . . . 0.0 109.404 178.606 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.8 p -155.15 124.78 0.74 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.575 0 N-CA-C 108.183 -1.043 . . . . 0.0 108.183 177.872 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 43.9 m-70 -136.04 160.95 37.07 Favored 'General case' 0 N--CA 1.481 1.113 0 CA-C-O 120.746 0.308 . . . . 0.0 111.115 -177.515 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 38.8 t60 -152.96 96.75 2.13 Favored 'General case' 0 N--CA 1.488 1.475 0 C-N-CA 122.687 0.395 . . . . 0.0 109.951 179.241 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' E' E ' 15' ' ' GLN . . . . . 0.606 HE22 ' H ' ' E' ' 38' ' ' GLY . 28.2 mt-30 -90.75 122.25 33.33 Favored 'General case' 0 C--N 1.329 -0.297 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 -179.064 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -113.78 103.5 11.27 Favored 'General case' 0 N--CA 1.474 0.726 0 N-CA-C 107.69 -1.226 . . . . 0.0 107.69 176.638 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 53.9 tp -132.19 149.1 52.47 Favored 'General case' 0 N--CA 1.486 1.343 0 C-N-CA 123.368 0.667 . . . . 0.0 109.269 -178.844 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 57.7 t -145.25 123.59 5.23 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.837 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 179.154 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 11.2 m-85 -71.4 156.35 39.58 Favored 'General case' 0 C--N 1.363 1.155 0 N-CA-C 106.911 -1.515 . . . . 0.0 106.911 176.937 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 17.8 t80 -172.13 -55.94 0.02 OUTLIER 'General case' 0 N--CA 1.481 1.084 0 CA-C-O 121.83 0.824 . . . . 0.0 110.238 179.733 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.99 88.26 0.0 OUTLIER 'General case' 0 C--N 1.319 -0.759 0 CA-C-N 114.107 -1.406 . . . . 0.0 112.87 -178.986 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 39.0 tt0 -63.26 159.72 17.24 Favored 'General case' 0 N--CA 1.471 0.625 0 CA-C-N 114.855 -1.066 . . . . 0.0 110.842 179.831 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 9.6 m-20 -136.56 125.52 24.29 Favored 'General case' 0 N--CA 1.482 1.162 0 C-N-CA 123.3 0.64 . . . . 0.0 110.23 -179.67 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' E' E ' 24' ' ' VAL . . . . . 0.659 ' CG1' HH22 ' I' ' 5' ' ' ARG . 58.5 t -76.08 -170.35 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.484 1.252 0 N-CA-C 108.029 -1.1 . . . . 0.0 108.029 179.436 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' E' E ' 25' ' ' GLY . . . . . 0.61 ' H ' ' CG1' ' E' ' 24' ' ' VAL . . . -68.89 49.65 0.5 Allowed Glycine 0 CA--C 1.531 1.031 0 CA-C-N 118.079 0.4 . . . . 0.0 112.626 -178.132 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 8.1 p -69.16 136.79 52.65 Favored 'General case' 0 C--O 1.219 -0.514 0 N-CA-C 109.705 -0.48 . . . . 0.0 109.705 178.494 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' E' E ' 27' ' ' ASN . . . . . 0.424 HD22 ' CG ' ' F' ' 11' ' ' GLU . 36.2 t30 -68.3 95.5 0.6 Allowed 'General case' 0 N--CA 1.466 0.328 0 N-CA-C 107.481 -1.303 . . . . 0.0 107.481 177.388 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 68.1 mttm -93.33 117.09 29.66 Favored 'General case' 0 N--CA 1.482 1.136 0 N-CA-C 109.612 -0.514 . . . . 0.0 109.612 -178.858 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.16 -133.98 0.01 OUTLIER Glycine 0 CA--C 1.536 1.392 0 N-CA-C 111.308 -0.717 . . . . 0.0 111.308 178.877 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -115.66 126.42 54.13 Favored 'General case' 0 N--CA 1.481 1.081 0 N-CA-C 109.637 -0.505 . . . . 0.0 109.637 179.225 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 66.8 mt -89.35 135.02 27.02 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.213 0 N-CA-C 107.571 -1.27 . . . . 0.0 107.571 178.914 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 33.1 mt -136.21 137.83 47.85 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.867 0 N-CA-C 108.991 -0.744 . . . . 0.0 108.991 -179.768 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.37 59.68 8.54 Favored Glycine 0 CA--C 1.527 0.82 0 CA-C-N 116.047 -0.524 . . . . 0.0 112.947 178.835 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 22.0 tp -107.49 131.81 53.91 Favored 'General case' 0 N--CA 1.487 1.41 0 N-CA-C 107.454 -1.313 . . . . 0.0 107.454 177.741 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 23.6 ttt -137.26 147.82 45.99 Favored 'General case' 0 N--CA 1.472 0.66 0 N-CA-C 107.815 -1.18 . . . . 0.0 107.815 178.709 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 59.8 t -156.7 159.94 2.47 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.693 0 N-CA-C 106.457 -1.683 . . . . 0.0 106.457 -178.899 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' E' E ' 37' ' ' GLY . . . . . 0.425 ' O ' ' NE2' ' H' ' 15' ' ' GLN . . . 54.12 73.4 0.41 Allowed Glycine 0 C--N 1.31 -0.904 0 N-CA-C 111.801 -0.52 . . . . 0.0 111.801 177.787 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' E' E ' 38' ' ' GLY . . . . . 0.606 ' H ' HE22 ' E' ' 15' ' ' GLN . . . 165.83 -166.63 38.71 Favored Glycine 0 C--O 1.21 -1.395 0 N-CA-C 111.278 -0.729 . . . . 0.0 111.278 179.256 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 21.6 m -128.34 148.88 32.8 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.827 0 C-N-CA 122.833 0.453 . . . . 0.0 109.91 179.913 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 7.5 t . . . . . 0 CA--C 1.541 0.598 0 CA-C-O 118.202 -0.904 . . . . 0.0 110.473 178.85 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 25.7 m-85 . . . . . 0 N--CA 1.472 0.645 0 N-CA-C 109.572 -0.529 . . . . 0.0 109.572 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' F' F ' 5' ' ' ARG . . . . . 0.638 HH22 ' CG1' ' B' ' 24' ' ' VAL . 35.5 mtp180 -68.08 147.4 52.4 Favored 'General case' 0 C--O 1.201 -1.476 0 CA-C-N 115.499 -0.773 . . . . 0.0 111.468 -178.017 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 39.2 m80 -109.47 118.89 37.82 Favored 'General case' 0 N--CA 1.484 1.266 0 N-CA-C 109.094 -0.706 . . . . 0.0 109.094 177.815 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' F' F ' 7' ' ' ASP . . . . . . . . . . . . . 13.0 m-20 -66.32 140.27 58.09 Favored 'General case' 0 N--CA 1.466 0.341 0 N-CA-C 112.159 0.429 . . . . 0.0 112.159 -178.453 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' F' F ' 8' ' ' SER . . . . . . . . . . . . . 38.3 t -158.73 -169.81 2.84 Favored 'General case' 0 N--CA 1.486 1.365 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.18 178.9 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 120.33 32.84 1.09 Allowed Glycine 0 N--CA 1.483 1.808 0 N-CA-C 111.679 -0.568 . . . . 0.0 111.679 179.559 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 43.3 p90 -57.02 130.73 47.35 Favored 'General case' 0 CA--C 1.545 0.763 0 CA-C-N 116.945 0.372 . . . . 0.0 111.614 -179.952 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' F' F ' 11' ' ' GLU . . . . . 0.424 ' CG ' HD22 ' E' ' 27' ' ' ASN . 60.3 mt-10 -90.04 153.53 20.5 Favored 'General case' 0 N--CA 1.478 0.959 0 CA-C-O 121.306 0.574 . . . . 0.0 109.457 178.513 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.8 p -155.22 124.78 0.74 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.532 0 N-CA-C 108.071 -1.085 . . . . 0.0 108.071 177.942 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 44.4 m-70 -136.03 160.83 37.42 Favored 'General case' 0 N--CA 1.48 1.062 0 CA-C-O 120.668 0.271 . . . . 0.0 111.142 -177.645 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 39.0 t60 -152.93 97.13 2.17 Favored 'General case' 0 N--CA 1.487 1.406 0 C-N-CA 122.75 0.42 . . . . 0.0 110.06 179.278 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' F' F ' 15' ' ' GLN . . . . . 0.624 HE22 ' H ' ' F' ' 38' ' ' GLY . 28.2 mt-30 -91.21 122.87 34.21 Favored 'General case' 0 CA--C 1.513 -0.474 0 N-CA-C 110.174 -0.306 . . . . 0.0 110.174 -179.141 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -114.23 103.48 11.14 Favored 'General case' 0 N--CA 1.471 0.608 0 N-CA-C 107.808 -1.182 . . . . 0.0 107.808 176.694 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 54.2 tp -132.17 149.13 52.46 Favored 'General case' 0 N--CA 1.486 1.355 0 C-N-CA 123.388 0.675 . . . . 0.0 109.307 -179.041 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 58.7 t -145.24 123.69 5.32 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.805 0 N-CA-C 109.37 -0.604 . . . . 0.0 109.37 179.205 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 11.2 m-85 -71.5 156.14 39.77 Favored 'General case' 0 C--N 1.363 1.195 0 N-CA-C 106.795 -1.557 . . . . 0.0 106.795 176.92 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 18.5 t80 -171.87 -55.96 0.02 OUTLIER 'General case' 0 N--CA 1.481 1.105 0 CA-C-O 121.784 0.802 . . . . 0.0 109.873 179.799 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.02 88.24 0.0 OUTLIER 'General case' 0 C--N 1.319 -0.725 0 CA-C-N 114.235 -1.348 . . . . 0.0 112.968 -178.968 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 38.9 tt0 -63.22 159.91 16.74 Favored 'General case' 0 N--CA 1.472 0.638 0 CA-C-N 114.857 -1.065 . . . . 0.0 110.856 179.756 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 9.7 m-20 -136.82 125.77 24.27 Favored 'General case' 0 N--CA 1.481 1.122 0 C-N-CA 123.271 0.628 . . . . 0.0 110.252 -179.735 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' F' F ' 24' ' ' VAL . . . . . 0.678 ' CG1' HH22 ' G' ' 5' ' ' ARG . 59.1 t -76.28 -170.1 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.484 1.267 0 N-CA-C 108.168 -1.049 . . . . 0.0 108.168 179.485 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' F' F ' 25' ' ' GLY . . . . . 0.597 ' H ' ' CG1' ' F' ' 24' ' ' VAL . . . -68.85 49.4 0.49 Allowed Glycine 0 CA--C 1.528 0.847 0 CA-C-N 118.264 0.484 . . . . 0.0 112.491 -178.305 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 8.1 p -68.96 136.66 52.85 Favored 'General case' 0 C--O 1.219 -0.535 0 N-CA-C 109.536 -0.542 . . . . 0.0 109.536 178.378 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' F' F ' 27' ' ' ASN . . . . . 0.411 HD22 ' CG ' ' D' ' 11' ' ' GLU . 35.4 t30 -68.38 95.73 0.63 Allowed 'General case' 0 CA--C 1.535 0.371 0 N-CA-C 107.35 -1.352 . . . . 0.0 107.35 177.464 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 68.1 mttm -93.41 116.96 29.5 Favored 'General case' 0 N--CA 1.48 1.073 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -178.931 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.13 -134.15 0.01 OUTLIER Glycine 0 CA--C 1.537 1.444 0 N-CA-C 111.383 -0.687 . . . . 0.0 111.383 178.997 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -115.19 125.99 54.05 Favored 'General case' 0 N--CA 1.485 1.277 0 C-N-CA 123.064 0.546 . . . . 0.0 109.615 179.212 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 66.9 mt -89.3 134.88 27.37 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.236 0 N-CA-C 107.457 -1.312 . . . . 0.0 107.457 178.816 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 32.9 mt -136.25 137.87 47.73 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.805 0 N-CA-C 108.984 -0.747 . . . . 0.0 108.984 -179.723 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.24 59.81 8.44 Favored Glycine 0 CA--C 1.525 0.663 0 CA-C-N 116.01 -0.541 . . . . 0.0 112.884 178.878 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 21.8 tp -107.78 132.04 53.81 Favored 'General case' 0 N--CA 1.487 1.376 0 N-CA-C 107.585 -1.265 . . . . 0.0 107.585 177.668 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 23.4 ttt -137.53 147.99 45.61 Favored 'General case' 0 N--CA 1.468 0.434 0 N-CA-C 108.324 -0.991 . . . . 0.0 108.324 178.733 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 60.8 t -156.63 160.03 2.44 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.772 0 N-CA-C 106.579 -1.637 . . . . 0.0 106.579 -178.741 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' F' F ' 37' ' ' GLY . . . . . 0.42 ' O ' ' NE2' ' I' ' 15' ' ' GLN . . . 54.05 73.37 0.42 Allowed Glycine 0 C--N 1.309 -0.964 0 CA-C-N 116.075 -0.512 . . . . 0.0 111.937 177.709 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' F' F ' 38' ' ' GLY . . . . . 0.624 ' H ' HE22 ' F' ' 15' ' ' GLN . . . 165.83 -166.58 38.68 Favored Glycine 0 C--O 1.209 -1.459 0 N-CA-C 111.264 -0.735 . . . . 0.0 111.264 179.315 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 21.1 m -128.46 148.76 32.9 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.811 0 C-N-CA 122.729 0.412 . . . . 0.0 109.906 179.935 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 6.8 t . . . . . 0 CA--C 1.54 0.565 0 CA-C-O 118.207 -0.901 . . . . 0.0 110.423 178.911 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 35.4 m-85 . . . . . 0 N--CA 1.469 0.499 0 CA-C-O 121.173 0.511 . . . . 0.0 109.833 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' G' G ' 5' ' ' ARG . . . . . 0.678 HH22 ' CG1' ' F' ' 24' ' ' VAL . 33.8 mtp180 -68.69 144.92 54.28 Favored 'General case' 0 N--CA 1.469 0.524 0 CA-C-N 115.415 -0.811 . . . . 0.0 111.146 -178.325 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 38.6 m80 -107.98 118.78 37.64 Favored 'General case' 0 N--CA 1.478 0.961 0 N-CA-C 109.226 -0.657 . . . . 0.0 109.226 178.095 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 10.5 m-20 -66.84 139.47 57.77 Favored 'General case' 0 N--CA 1.469 0.49 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.948 -179.061 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' G' G ' 8' ' ' SER . . . . . . . . . . . . . 37.8 t -158.09 -170.23 3.07 Favored 'General case' 0 N--CA 1.471 0.603 0 N-CA-C 109.666 -0.494 . . . . 0.0 109.666 179.024 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 120.37 31.97 1.2 Allowed Glycine 0 N--CA 1.484 1.869 0 N-CA-C 111.539 -0.624 . . . . 0.0 111.539 179.497 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 47.1 p90 -57.11 130.71 47.32 Favored 'General case' 0 N--CA 1.472 0.629 0 CA-C-N 116.825 0.313 . . . . 0.0 111.716 -179.822 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 60.4 mt-10 -90.34 152.58 20.96 Favored 'General case' 0 N--CA 1.474 0.758 0 CA-C-O 121.138 0.494 . . . . 0.0 109.807 179.082 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 3.5 p -155.47 124.83 0.72 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.058 0 N-CA-C 108.175 -1.046 . . . . 0.0 108.175 178.19 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 43.6 m-70 -135.86 160.73 37.68 Favored 'General case' 0 N--CA 1.475 0.781 0 CA-C-N 114.722 -1.126 . . . . 0.0 110.973 -177.619 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 39.6 t60 -153.39 96.93 2.09 Favored 'General case' 0 N--CA 1.484 1.231 0 CA-C-N 115.858 -0.61 . . . . 0.0 109.659 178.855 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' G' G ' 15' ' ' GLN . . . . . 0.64 HE22 ' H ' ' G' ' 38' ' ' GLY . 28.5 mt-30 -90.75 121.52 32.71 Favored 'General case' 0 N--CA 1.451 -0.406 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 -178.896 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -113.03 103.77 11.71 Favored 'General case' 0 N--CA 1.476 0.831 0 N-CA-C 107.694 -1.224 . . . . 0.0 107.694 176.65 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 56.6 tp -132.17 147.33 52.42 Favored 'General case' 0 N--CA 1.486 1.343 0 C-N-CA 123.336 0.654 . . . . 0.0 109.56 -179.288 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 61.3 t -144.99 123.3 5.31 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.861 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 178.664 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 9.6 m-85 -70.39 150.37 46.33 Favored 'General case' 0 C--N 1.376 1.728 0 N-CA-C 106.91 -1.515 . . . . 0.0 106.91 176.699 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 15.6 t80 -169.94 -55.4 0.02 OUTLIER 'General case' 0 N--CA 1.483 1.22 0 N-CA-C 110.248 -0.278 . . . . 0.0 110.248 -179.729 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.0 90.02 0.0 OUTLIER 'General case' 0 C--N 1.323 -0.545 0 C-N-CA 123.72 0.808 . . . . 0.0 112.471 -179.964 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 39.3 tt0 -64.4 160.76 18.36 Favored 'General case' 0 N--CA 1.468 0.467 0 CA-C-N 114.834 -1.076 . . . . 0.0 110.023 179.273 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 9.6 m-20 -137.26 125.38 22.99 Favored 'General case' 0 N--CA 1.48 1.072 0 C-N-CA 123.154 0.582 . . . . 0.0 109.721 -179.701 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' G' G ' 24' ' ' VAL . . . . . 0.577 ' CG1' ' H ' ' G' ' 25' ' ' GLY . 61.9 t -76.75 -169.97 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.827 0 N-CA-C 108.156 -1.053 . . . . 0.0 108.156 179.608 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' G' G ' 25' ' ' GLY . . . . . 0.577 ' H ' ' CG1' ' G' ' 24' ' ' VAL . . . -68.89 49.98 0.5 Allowed Glycine 0 CA--C 1.53 0.973 0 CA-C-N 118.48 0.582 . . . . 0.0 112.726 -178.467 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 8.4 p -69.51 137.63 52.67 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 109.157 -0.682 . . . . 0.0 109.157 177.748 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 34.2 t30 -69.49 94.72 0.77 Allowed 'General case' 0 CA--C 1.532 0.265 0 N-CA-C 107.618 -1.253 . . . . 0.0 107.618 177.562 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -91.63 117.81 30.07 Favored 'General case' 0 N--CA 1.478 0.953 0 N-CA-C 109.713 -0.477 . . . . 0.0 109.713 -179.396 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -62.37 -133.3 0.01 OUTLIER Glycine 0 CA--C 1.532 1.099 0 N-CA-C 110.547 -1.021 . . . . 0.0 110.547 178.927 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -115.19 126.83 55.05 Favored 'General case' 0 N--CA 1.475 0.808 0 N-CA-C 109.615 -0.513 . . . . 0.0 109.615 179.186 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 69.6 mt -89.64 136.14 24.41 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.671 0 N-CA-C 107.598 -1.26 . . . . 0.0 107.598 178.743 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 38.2 mt -137.46 139.18 43.98 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.249 0 CA-C-N 118.782 0.719 . . . . 0.0 109.158 179.721 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.1 57.98 13.56 Favored Glycine 0 CA--C 1.53 0.977 0 CA-C-N 116.11 -0.496 . . . . 0.0 112.624 178.99 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 23.1 tp -105.81 132.23 52.18 Favored 'General case' 0 N--CA 1.484 1.256 0 N-CA-C 107.6 -1.259 . . . . 0.0 107.6 177.775 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 22.1 ttt -137.63 147.97 45.4 Favored 'General case' 0 N--CA 1.474 0.727 0 N-CA-C 108.211 -1.033 . . . . 0.0 108.211 178.788 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 61.2 t -156.77 158.4 3.24 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 106.613 -1.625 . . . . 0.0 106.613 -179.095 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.57 71.74 0.68 Allowed Glycine 0 C--N 1.308 -0.973 0 CA-C-N 115.951 -0.568 . . . . 0.0 112.384 177.549 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' G' G ' 38' ' ' GLY . . . . . 0.64 ' H ' HE22 ' G' ' 15' ' ' GLN . . . 167.75 -165.22 38.55 Favored Glycine 0 C--O 1.212 -1.268 0 N-CA-C 110.747 -0.941 . . . . 0.0 110.747 178.631 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 18.7 m -128.64 148.14 33.07 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.93 0 C-N-CA 122.789 0.435 . . . . 0.0 109.93 179.911 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 8.6 t . . . . . 0 CA--C 1.534 0.337 0 CA-C-O 118.156 -0.926 . . . . 0.0 110.888 178.815 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 35.0 m-85 . . . . . 0 N--CA 1.47 0.557 0 CA-C-O 121.234 0.54 . . . . 0.0 109.756 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' H' H ' 5' ' ' ARG . . . . . 0.666 HH22 ' CG1' ' D' ' 24' ' ' VAL . 33.8 mtp180 -69.04 145.12 53.78 Favored 'General case' 0 N--CA 1.466 0.373 0 CA-C-N 115.387 -0.824 . . . . 0.0 111.229 -178.312 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 38.5 m80 -108.05 118.77 37.63 Favored 'General case' 0 N--CA 1.478 0.958 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 178.265 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 10.5 m-20 -66.91 139.58 57.73 Favored 'General case' 0 N--CA 1.468 0.441 0 CA-C-N 116.275 -0.421 . . . . 0.0 111.889 -179.066 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' H' H ' 8' ' ' SER . . . . . . . . . . . . . 37.9 t -158.12 -170.08 3.01 Favored 'General case' 0 N--CA 1.471 0.595 0 N-CA-C 109.73 -0.47 . . . . 0.0 109.73 178.985 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 120.11 32.09 1.21 Allowed Glycine 0 N--CA 1.483 1.829 0 N-CA-C 111.641 -0.583 . . . . 0.0 111.641 179.549 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 46.9 p90 -57.17 130.79 47.72 Favored 'General case' 0 CA--C 1.542 0.64 0 CA-C-N 116.715 0.258 . . . . 0.0 111.607 -179.777 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 60.5 mt-10 -90.3 152.54 20.99 Favored 'General case' 0 N--CA 1.474 0.771 0 CA-C-O 121.116 0.484 . . . . 0.0 109.859 179.023 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 3.4 p -155.53 124.95 0.72 Allowed 'Isoleucine or valine' 0 CA--C 1.553 1.089 0 N-CA-C 108.161 -1.051 . . . . 0.0 108.161 178.074 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 43.6 m-70 -135.93 160.78 37.55 Favored 'General case' 0 C--N 1.353 0.751 0 CA-C-N 114.627 -1.169 . . . . 0.0 111.072 -177.527 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 39.3 t60 -153.51 96.86 2.07 Favored 'General case' 0 N--CA 1.484 1.268 0 CA-C-N 115.868 -0.606 . . . . 0.0 109.773 178.911 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' H' H ' 15' ' ' GLN . . . . . 0.635 HE22 ' H ' ' H' ' 38' ' ' GLY . 28.3 mt-30 -90.71 121.37 32.55 Favored 'General case' 0 CA--C 1.514 -0.406 0 N-CA-C 109.711 -0.477 . . . . 0.0 109.711 -178.946 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -112.84 103.66 11.65 Favored 'General case' 0 N--CA 1.474 0.726 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 176.672 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 56.3 tp -132.14 147.37 52.42 Favored 'General case' 0 N--CA 1.486 1.374 0 C-N-CA 123.273 0.629 . . . . 0.0 109.488 -179.196 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 61.4 t -144.93 123.21 5.36 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.89 0 N-CA-C 109.368 -0.604 . . . . 0.0 109.368 178.667 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 9.5 m-85 -70.67 150.96 45.45 Favored 'General case' 0 C--N 1.376 1.741 0 N-CA-C 106.951 -1.5 . . . . 0.0 106.951 176.658 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 16.6 t80 -171.19 -55.13 0.02 OUTLIER 'General case' 0 N--CA 1.48 1.061 0 N-CA-C 110.216 -0.291 . . . . 0.0 110.216 -179.696 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.05 89.92 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.472 0 O-C-N 123.971 0.795 . . . . 0.0 112.269 -179.96 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 39.4 tt0 -64.12 160.76 17.56 Favored 'General case' 0 N--CA 1.469 0.487 0 CA-C-N 114.777 -1.102 . . . . 0.0 110.063 179.482 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 9.7 m-20 -137.11 125.43 23.27 Favored 'General case' 0 N--CA 1.481 1.077 0 C-N-CA 123.098 0.559 . . . . 0.0 109.869 -179.791 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' H' H ' 24' ' ' VAL . . . . . 0.576 ' CG1' ' H ' ' H' ' 25' ' ' GLY . 57.4 t -76.69 -170.0 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.475 0.806 0 N-CA-C 108.408 -0.96 . . . . 0.0 108.408 179.612 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' H' H ' 25' ' ' GLY . . . . . 0.576 ' H ' ' CG1' ' H' ' 24' ' ' VAL . . . -68.64 49.56 0.46 Allowed Glycine 0 CA--C 1.53 1.009 0 CA-C-N 118.627 0.649 . . . . 0.0 112.43 -178.468 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 8.5 p -69.56 137.47 52.44 Favored 'General case' 0 C--N 1.33 -0.266 0 N-CA-C 109.152 -0.684 . . . . 0.0 109.152 177.823 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 34.7 t30 -69.57 94.82 0.8 Allowed 'General case' 0 N--CA 1.464 0.258 0 N-CA-C 107.638 -1.245 . . . . 0.0 107.638 177.635 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -91.76 117.88 30.17 Favored 'General case' 0 N--CA 1.477 0.91 0 N-CA-C 109.708 -0.479 . . . . 0.0 109.708 -179.408 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -62.48 -133.15 0.01 OUTLIER Glycine 0 CA--C 1.532 1.107 0 N-CA-C 110.582 -1.007 . . . . 0.0 110.582 178.977 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -115.25 126.89 55.07 Favored 'General case' 0 N--CA 1.474 0.745 0 C-N-CA 122.984 0.514 . . . . 0.0 109.634 179.192 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 69.6 mt -89.67 136.03 24.68 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.621 0 N-CA-C 107.535 -1.283 . . . . 0.0 107.535 178.707 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 37.7 mt -137.4 139.24 44.01 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.263 0 N-CA-C 109.142 -0.688 . . . . 0.0 109.142 179.611 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.23 58.1 12.92 Favored Glycine 0 CA--C 1.529 0.964 0 CA-C-N 116.067 -0.515 . . . . 0.0 112.593 178.967 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 23.5 tp -105.85 131.81 52.73 Favored 'General case' 0 N--CA 1.484 1.256 0 N-CA-C 107.688 -1.227 . . . . 0.0 107.688 177.893 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 22.0 ttt -137.16 147.36 45.89 Favored 'General case' 0 N--CA 1.475 0.808 0 N-CA-C 108.135 -1.061 . . . . 0.0 108.135 178.924 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 61.7 t -156.5 158.14 3.45 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.487 0 N-CA-C 106.634 -1.617 . . . . 0.0 106.634 -179.109 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.68 71.53 0.71 Allowed Glycine 0 C--N 1.308 -0.992 0 CA-C-N 115.901 -0.59 . . . . 0.0 112.352 177.526 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' H' H ' 38' ' ' GLY . . . . . 0.635 ' H ' HE22 ' H' ' 15' ' ' GLN . . . 167.75 -165.75 38.91 Favored Glycine 0 C--O 1.212 -1.277 0 N-CA-C 110.6 -1.0 . . . . 0.0 110.6 178.693 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 18.9 m -128.2 148.45 32.72 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.023 0 C-N-CA 122.777 0.431 . . . . 0.0 109.926 179.966 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 8.6 t . . . . . 0 CA--C 1.535 0.369 0 CA-C-O 118.196 -0.907 . . . . 0.0 110.811 178.764 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 34.6 m-85 . . . . . 0 N--CA 1.47 0.537 0 CA-C-O 121.136 0.493 . . . . 0.0 109.827 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' I' I ' 5' ' ' ARG . . . . . 0.659 HH22 ' CG1' ' E' ' 24' ' ' VAL . 32.8 mtp180 -68.94 144.87 54.04 Favored 'General case' 0 N--CA 1.468 0.475 0 CA-C-N 115.473 -0.785 . . . . 0.0 111.206 -178.343 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 38.6 m80 -107.88 118.59 37.13 Favored 'General case' 0 N--CA 1.477 0.925 0 N-CA-C 109.195 -0.669 . . . . 0.0 109.195 178.314 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 10.5 m-20 -66.77 139.61 57.81 Favored 'General case' 0 N--CA 1.469 0.485 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.916 -179.059 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' I' I ' 8' ' ' SER . . . . . . . . . . . . . 37.8 t -158.08 -170.15 3.05 Favored 'General case' 0 N--CA 1.47 0.557 0 N-CA-C 109.688 -0.486 . . . . 0.0 109.688 178.996 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 120.29 32.0 1.2 Allowed Glycine 0 N--CA 1.483 1.809 0 N-CA-C 111.584 -0.606 . . . . 0.0 111.584 179.413 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 47.1 p90 -57.12 130.75 47.52 Favored 'General case' 0 N--CA 1.473 0.705 0 O-C-N 122.671 -0.311 . . . . 0.0 111.665 -179.815 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 60.5 mt-10 -90.3 152.5 21.01 Favored 'General case' 0 N--CA 1.475 0.813 0 CA-C-O 121.152 0.501 . . . . 0.0 109.865 179.013 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 3.5 p -155.46 124.87 0.73 Allowed 'Isoleucine or valine' 0 CA--C 1.554 1.125 0 N-CA-C 108.194 -1.039 . . . . 0.0 108.194 178.103 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 44.1 m-70 -135.82 160.85 37.29 Favored 'General case' 0 C--N 1.354 0.761 0 CA-C-N 114.6 -1.182 . . . . 0.0 111.0 -177.556 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 39.6 t60 -153.6 97.05 2.08 Favored 'General case' 0 N--CA 1.484 1.262 0 CA-C-N 115.841 -0.618 . . . . 0.0 109.761 178.841 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' I' I ' 15' ' ' GLN . . . . . 0.659 HE22 ' H ' ' I' ' 38' ' ' GLY . 28.4 mt-30 -90.79 121.37 32.6 Favored 'General case' 0 CA--C 1.514 -0.416 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 -178.95 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -112.86 103.69 11.68 Favored 'General case' 0 N--CA 1.473 0.709 0 N-CA-C 107.677 -1.231 . . . . 0.0 107.677 176.6 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 56.5 tp -132.18 147.26 52.41 Favored 'General case' 0 N--CA 1.485 1.296 0 C-N-CA 123.329 0.652 . . . . 0.0 109.436 -179.153 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 61.7 t -144.88 123.12 5.4 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.9 0 N-CA-C 109.425 -0.583 . . . . 0.0 109.425 178.642 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 9.4 m-85 -70.66 150.89 45.53 Favored 'General case' 0 C--N 1.374 1.642 0 N-CA-C 106.853 -1.536 . . . . 0.0 106.853 176.701 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 16.7 t80 -171.14 -55.26 0.02 OUTLIER 'General case' 0 N--CA 1.48 1.073 0 N-CA-C 110.212 -0.292 . . . . 0.0 110.212 -179.561 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.07 90.01 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.45 0 O-C-N 123.998 0.811 . . . . 0.0 112.327 -179.986 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 39.4 tt0 -64.22 160.77 17.85 Favored 'General case' 0 N--CA 1.469 0.511 0 CA-C-N 114.743 -1.117 . . . . 0.0 110.011 179.557 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 9.6 m-20 -137.01 125.31 23.25 Favored 'General case' 0 N--CA 1.481 1.082 0 C-N-CA 123.259 0.624 . . . . 0.0 109.891 -179.771 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' I' I ' 24' ' ' VAL . . . . . 0.567 ' CG1' ' H ' ' I' ' 25' ' ' GLY . 57.3 t -76.58 -169.96 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.757 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 179.568 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' I' I ' 25' ' ' GLY . . . . . 0.567 ' H ' ' CG1' ' I' ' 24' ' ' VAL . . . -68.81 49.72 0.49 Allowed Glycine 0 CA--C 1.531 1.054 0 CA-C-N 118.541 0.61 . . . . 0.0 112.485 -178.457 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 8.5 p -69.63 137.67 52.42 Favored 'General case' 0 C--N 1.33 -0.254 0 N-CA-C 109.166 -0.679 . . . . 0.0 109.166 177.856 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 35.0 t30 -69.57 94.74 0.79 Allowed 'General case' 0 CA--C 1.531 0.234 0 N-CA-C 107.676 -1.231 . . . . 0.0 107.676 177.534 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -91.8 117.84 30.15 Favored 'General case' 0 N--CA 1.478 0.936 0 N-CA-C 109.722 -0.473 . . . . 0.0 109.722 -179.395 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -62.37 -133.19 0.01 OUTLIER Glycine 0 CA--C 1.532 1.14 0 N-CA-C 110.613 -0.995 . . . . 0.0 110.613 178.96 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -115.22 126.54 54.68 Favored 'General case' 0 N--CA 1.474 0.737 0 C-N-CA 123.031 0.532 . . . . 0.0 109.697 179.246 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 69.5 mt -89.46 135.94 24.81 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.657 0 N-CA-C 107.552 -1.277 . . . . 0.0 107.552 178.784 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 37.7 mt -137.44 139.21 43.98 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.28 0 N-CA-C 109.004 -0.739 . . . . 0.0 109.004 179.739 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.24 57.99 13.3 Favored Glycine 0 CA--C 1.529 0.959 0 CA-C-N 115.978 -0.555 . . . . 0.0 112.562 178.908 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 23.1 tp -105.71 131.95 52.44 Favored 'General case' 0 N--CA 1.485 1.298 0 N-CA-C 107.531 -1.285 . . . . 0.0 107.531 177.839 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 22.1 ttt -137.3 147.53 45.72 Favored 'General case' 0 N--CA 1.475 0.783 0 N-CA-C 107.997 -1.112 . . . . 0.0 107.997 178.877 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 61.3 t -156.66 158.2 3.38 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.466 0 N-CA-C 106.623 -1.621 . . . . 0.0 106.623 -179.094 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.63 71.57 0.7 Allowed Glycine 0 C--N 1.308 -1.011 0 CA-C-N 115.953 -0.567 . . . . 0.0 112.376 177.556 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' I' I ' 38' ' ' GLY . . . . . 0.659 ' H ' HE22 ' I' ' 15' ' ' GLN . . . 167.72 -165.68 38.85 Favored Glycine 0 C--O 1.211 -1.337 0 N-CA-C 110.603 -0.999 . . . . 0.0 110.603 178.697 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 18.9 m -128.26 148.4 32.77 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.003 0 C-N-CA 122.831 0.452 . . . . 0.0 109.949 179.965 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 8.9 t . . . . . 0 CA--C 1.535 0.387 0 CA-C-O 118.104 -0.95 . . . . 0.0 110.738 178.824 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 76.6 m-85 . . . . . 0 N--CA 1.474 0.74 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 72.4 mtp180 -144.29 141.82 30.04 Favored 'General case' 0 N--CA 1.483 1.207 0 N-CA-C 109.035 -0.728 . . . . 0.0 109.035 179.866 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 77.2 m80 -149.72 118.51 6.62 Favored 'General case' 0 N--CA 1.472 0.655 0 N-CA-C 108.763 -0.828 . . . . 0.0 108.763 179.037 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 12.2 m-20 -66.83 149.5 50.49 Favored 'General case' 0 CA--C 1.531 0.242 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.193 -179.395 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 7.9 t -167.53 170.08 11.52 Favored 'General case' 0 N--CA 1.473 0.682 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 178.613 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 123.47 24.44 1.95 Allowed Glycine 0 N--CA 1.487 2.051 0 N-CA-C 112.089 -0.405 . . . . 0.0 112.089 179.466 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 41.0 p90 -56.59 128.26 35.4 Favored 'General case' 0 N--CA 1.473 0.714 0 N-CA-C 112.136 0.421 . . . . 0.0 112.136 -179.868 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 46.1 mt-10 -84.61 154.49 22.54 Favored 'General case' 0 N--CA 1.468 0.465 0 N-CA-C 108.847 -0.797 . . . . 0.0 108.847 178.256 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -154.03 129.18 1.54 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 N-CA-C 108.091 -1.077 . . . . 0.0 108.091 178.855 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 51.5 m-70 -134.5 144.77 48.24 Favored 'General case' 0 N--CA 1.487 1.409 0 CA-C-N 118.567 0.621 . . . . 0.0 110.729 -178.951 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 6.2 t60 -164.5 98.38 0.8 Allowed 'General case' 0 N--CA 1.482 1.172 0 CA-C-N 116.744 -0.207 . . . . 0.0 111.204 179.581 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . 0.593 ' NE2' ' H ' ' A' ' 37' ' ' GLY . 75.8 mt-30 -103.03 -172.65 2.15 Favored 'General case' 0 CA--C 1.506 -0.745 0 N-CA-C 108.191 -1.04 . . . . 0.0 108.191 179.338 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -167.25 98.17 0.51 Allowed 'General case' 0 N--CA 1.47 0.531 0 CA-C-N 115.084 -0.962 . . . . 0.0 109.366 178.766 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . 0.401 ' N ' ' CD1' ' A' ' 17' ' ' LEU . 4.9 mp -106.69 162.44 13.76 Favored 'General case' 0 N--CA 1.485 1.303 0 N-CA-C 108.364 -0.976 . . . . 0.0 108.364 179.808 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 55.3 t -142.42 118.63 5.98 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.275 0 CA-C-O 118.804 -0.617 . . . . 0.0 109.899 179.29 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 54.2 m-85 -70.41 158.7 35.53 Favored 'General case' 0 N--CA 1.479 1.006 0 N-CA-C 107.812 -1.181 . . . . 0.0 107.812 177.07 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 15.0 t80 -171.0 -58.75 0.02 OUTLIER 'General case' 0 N--CA 1.483 1.198 0 CA-C-O 122.435 1.112 . . . . 0.0 109.546 179.244 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.33 90.56 0.0 OUTLIER 'General case' 0 N--CA 1.458 -0.073 0 CA-C-N 113.845 -1.525 . . . . 0.0 112.818 -178.113 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 53.6 tt0 -62.88 155.34 27.39 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 115.238 -0.892 . . . . 0.0 110.463 178.952 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 18.1 m-20 -136.51 134.71 37.85 Favored 'General case' 0 N--CA 1.48 1.071 0 C-N-CA 122.967 0.507 . . . . 0.0 109.983 179.851 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 16.2 t -84.74 -117.05 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.763 0 N-CA-C 108.173 -1.047 . . . . 0.0 108.173 179.296 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -107.4 53.27 0.61 Allowed Glycine 0 N--CA 1.474 1.172 0 N-CA-C 111.178 -0.769 . . . . 0.0 111.178 179.867 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 88.7 p -77.04 126.55 31.15 Favored 'General case' 0 N--CA 1.465 0.311 0 N-CA-C 109.023 -0.732 . . . . 0.0 109.023 178.398 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 1.8 t-20 -67.18 100.03 0.74 Allowed 'General case' 0 N--CA 1.472 0.656 0 N-CA-C 108.615 -0.883 . . . . 0.0 108.615 178.664 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 67.3 mttm -94.01 128.26 40.25 Favored 'General case' 0 N--CA 1.479 1.012 0 N-CA-C 109.634 -0.506 . . . . 0.0 109.634 -179.451 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.28 -133.26 0.01 OUTLIER Glycine 0 CA--C 1.53 0.985 0 N-CA-C 110.398 -1.081 . . . . 0.0 110.398 179.11 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.34 127.78 43.32 Favored 'General case' 0 N--CA 1.484 1.243 0 CA-C-N 117.096 0.448 . . . . 0.0 110.178 179.356 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 30.3 mt -91.9 160.52 2.68 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.648 0 N-CA-C 106.824 -1.547 . . . . 0.0 106.824 178.157 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 38.0 mt -138.27 94.14 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.766 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 -179.065 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 53.5 104.82 0.01 OUTLIER Glycine 0 CA--C 1.531 1.085 0 CA-C-N 115.899 -0.592 . . . . 0.0 114.192 176.621 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 91.1 mt -72.22 155.2 40.48 Favored 'General case' 0 N--CA 1.469 0.512 0 N-CA-C 107.502 -1.295 . . . . 0.0 107.502 176.51 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 2.2 ttp -143.84 139.3 29.21 Favored 'General case' 0 N--CA 1.473 0.725 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 178.943 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 59.1 t -159.23 150.05 6.96 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.261 0 N-CA-C 106.714 -1.587 . . . . 0.0 106.714 -179.229 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . 0.593 ' H ' ' NE2' ' A' ' 15' ' ' GLN . . . 54.78 75.15 0.25 Allowed Glycine 0 C--N 1.314 -0.667 0 N-CA-C 111.823 -0.511 . . . . 0.0 111.823 177.909 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 174.14 -148.97 10.33 Favored Glycine 0 CA--C 1.52 0.36 0 N-CA-C 110.974 -0.85 . . . . 0.0 110.974 179.928 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 30.9 m -134.81 146.0 31.44 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.906 0 C-N-CA 122.599 0.36 . . . . 0.0 110.373 -179.72 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 19.6 t . . . . . 0 C--O 1.221 -0.428 0 CA-C-O 117.59 -1.195 . . . . 0.0 110.986 179.153 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 77.1 m-85 . . . . . 0 N--CA 1.473 0.712 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 72.0 mtp180 -144.33 141.61 29.87 Favored 'General case' 0 N--CA 1.48 1.071 0 N-CA-C 108.999 -0.741 . . . . 0.0 108.999 179.955 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 77.2 m80 -149.51 118.65 6.77 Favored 'General case' 0 N--CA 1.474 0.742 0 N-CA-C 108.903 -0.777 . . . . 0.0 108.903 179.04 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 7' ' ' ASP . . . . . . . . . . . . . 12.4 m-20 -66.87 149.03 51.17 Favored 'General case' 0 CA--C 1.532 0.261 0 CA-C-N 116.411 -0.359 . . . . 0.0 111.236 -179.399 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 8' ' ' SER . . . . . . . . . . . . . 7.9 t -167.21 170.21 11.91 Favored 'General case' 0 N--CA 1.471 0.613 0 N-CA-C 109.288 -0.634 . . . . 0.0 109.288 178.459 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 123.43 24.4 1.97 Allowed Glycine 0 N--CA 1.486 2.023 0 N-CA-C 111.982 -0.447 . . . . 0.0 111.982 179.416 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 40.6 p90 -56.63 128.37 36.01 Favored 'General case' 0 N--CA 1.471 0.581 0 N-CA-C 112.091 0.404 . . . . 0.0 112.091 -179.775 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 46.1 mt-10 -84.69 154.54 22.41 Favored 'General case' 0 N--CA 1.469 0.498 0 N-CA-C 108.911 -0.774 . . . . 0.0 108.911 178.327 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -154.01 129.04 1.5 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 N-CA-C 108.173 -1.047 . . . . 0.0 108.173 178.861 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 51.4 m-70 -134.35 144.94 48.54 Favored 'General case' 0 N--CA 1.488 1.429 0 CA-C-N 118.475 0.579 . . . . 0.0 110.777 -178.95 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 6.2 t60 -164.66 98.16 0.78 Allowed 'General case' 0 N--CA 1.484 1.243 0 CA-C-N 116.697 -0.229 . . . . 0.0 111.189 179.596 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . 0.58 ' NE2' ' H ' ' B' ' 37' ' ' GLY . 75.8 mt-30 -102.84 -172.95 2.21 Favored 'General case' 0 CA--C 1.506 -0.743 0 N-CA-C 108.135 -1.061 . . . . 0.0 108.135 179.415 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -167.08 97.94 0.52 Allowed 'General case' 0 N--CA 1.47 0.558 0 CA-C-N 115.034 -0.984 . . . . 0.0 109.309 178.898 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 4.9 mp -106.63 162.19 13.97 Favored 'General case' 0 N--CA 1.486 1.329 0 N-CA-C 108.373 -0.973 . . . . 0.0 108.373 179.819 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 56.8 t -142.31 118.35 5.98 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.243 0 CA-C-O 118.873 -0.584 . . . . 0.0 109.924 179.309 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 56.0 m-85 -70.69 158.81 35.6 Favored 'General case' 0 N--CA 1.478 0.93 0 N-CA-C 107.671 -1.233 . . . . 0.0 107.671 177.036 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 16.0 t80 -171.73 -57.98 0.02 OUTLIER 'General case' 0 N--CA 1.481 1.102 0 CA-C-O 122.254 1.026 . . . . 0.0 109.541 179.233 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.54 90.8 0.0 OUTLIER 'General case' 0 C--O 1.231 0.103 0 CA-C-N 114.1 -1.409 . . . . 0.0 112.67 -178.169 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 53.5 tt0 -63.11 155.34 28.23 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 115.274 -0.875 . . . . 0.0 110.495 179.035 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 18.0 m-20 -136.46 134.91 38.16 Favored 'General case' 0 N--CA 1.481 1.088 0 C-N-CA 122.991 0.516 . . . . 0.0 110.007 179.875 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 16.1 t -85.21 -117.13 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.475 0.795 0 N-CA-C 108.331 -0.988 . . . . 0.0 108.331 179.282 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -106.66 52.74 0.66 Allowed Glycine 0 N--CA 1.476 1.306 0 N-CA-C 111.14 -0.784 . . . . 0.0 111.14 179.915 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 89.5 p -77.02 126.22 30.61 Favored 'General case' 0 N--CA 1.466 0.352 0 N-CA-C 109.207 -0.664 . . . . 0.0 109.207 178.421 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 1.8 t-20 -67.15 100.17 0.75 Allowed 'General case' 0 N--CA 1.473 0.676 0 N-CA-C 108.588 -0.893 . . . . 0.0 108.588 178.674 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 67.4 mttm -94.03 128.22 40.26 Favored 'General case' 0 N--CA 1.479 1.01 0 N-CA-C 109.684 -0.487 . . . . 0.0 109.684 -179.469 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.16 -132.94 0.01 OUTLIER Glycine 0 CA--C 1.53 0.991 0 N-CA-C 110.493 -1.043 . . . . 0.0 110.493 179.067 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.63 127.83 42.99 Favored 'General case' 0 N--CA 1.485 1.286 0 CA-C-N 117.192 0.496 . . . . 0.0 110.09 179.355 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 29.8 mt -92.03 160.3 2.7 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.69 0 N-CA-C 106.896 -1.52 . . . . 0.0 106.896 178.093 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 37.5 mt -138.0 94.05 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.684 0 N-CA-C 109.908 -0.405 . . . . 0.0 109.908 -178.969 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 53.47 104.91 0.01 OUTLIER Glycine 0 CA--C 1.53 1.02 0 CA-C-N 115.899 -0.591 . . . . 0.0 114.229 176.648 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 90.9 mt -72.29 155.26 40.38 Favored 'General case' 0 N--CA 1.471 0.578 0 N-CA-C 107.481 -1.303 . . . . 0.0 107.481 176.524 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 2.2 ttp -143.73 139.02 29.25 Favored 'General case' 0 N--CA 1.476 0.859 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 178.954 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 59.0 t -159.05 149.96 7.17 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.274 0 N-CA-C 106.58 -1.637 . . . . 0.0 106.58 -179.23 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . 0.58 ' H ' ' NE2' ' B' ' 15' ' ' GLN . . . 54.83 75.12 0.25 Allowed Glycine 0 C--N 1.314 -0.647 0 N-CA-C 111.786 -0.526 . . . . 0.0 111.786 177.778 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 174.06 -148.89 10.31 Favored Glycine 0 CA--C 1.521 0.452 0 N-CA-C 110.989 -0.844 . . . . 0.0 110.989 179.869 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 31.5 m -134.83 145.99 31.44 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.942 0 C-N-CA 122.566 0.346 . . . . 0.0 110.35 -179.717 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 20.0 t . . . . . 0 C--O 1.22 -0.448 0 CA-C-O 117.636 -1.173 . . . . 0.0 110.985 179.136 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 76.5 m-85 . . . . . 0 N--CA 1.473 0.72 0 N-CA-C 109.9 -0.407 . . . . 0.0 109.9 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 72.4 mtp180 -144.19 141.56 29.99 Favored 'General case' 0 N--CA 1.483 1.221 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 179.946 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 77.1 m80 -149.49 118.59 6.75 Favored 'General case' 0 N--CA 1.473 0.705 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 179.053 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' C' C ' 7' ' ' ASP . . . . . . . . . . . . . 11.7 m-20 -66.88 149.08 51.1 Favored 'General case' 0 N--CA 1.464 0.251 0 CA-C-N 116.337 -0.392 . . . . 0.0 111.25 -179.416 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' C' C ' 8' ' ' SER . . . . . . . . . . . . . 7.9 t -167.18 170.18 11.99 Favored 'General case' 0 N--CA 1.472 0.642 0 N-CA-C 109.188 -0.671 . . . . 0.0 109.188 178.493 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 123.45 24.42 1.96 Allowed Glycine 0 N--CA 1.486 2.023 0 N-CA-C 111.944 -0.462 . . . . 0.0 111.944 179.37 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 40.7 p90 -56.57 128.21 35.13 Favored 'General case' 0 N--CA 1.472 0.628 0 N-CA-C 112.066 0.395 . . . . 0.0 112.066 -179.836 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 46.0 mt-10 -84.54 154.54 22.59 Favored 'General case' 0 N--CA 1.469 0.51 0 N-CA-C 108.881 -0.785 . . . . 0.0 108.881 178.252 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -154.07 129.02 1.48 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 178.826 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 51.3 m-70 -134.24 144.96 48.71 Favored 'General case' 0 N--CA 1.487 1.411 0 CA-C-N 118.428 0.558 . . . . 0.0 110.827 -178.954 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 6.2 t60 -164.75 98.35 0.77 Allowed 'General case' 0 N--CA 1.484 1.259 0 CA-C-N 116.823 -0.171 . . . . 0.0 111.254 179.6 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' C' C ' 15' ' ' GLN . . . . . 0.59 ' NE2' ' H ' ' C' ' 37' ' ' GLY . 75.8 mt-30 -103.09 -172.73 2.16 Favored 'General case' 0 CA--C 1.503 -0.851 0 N-CA-C 108.244 -1.021 . . . . 0.0 108.244 179.322 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -167.18 98.11 0.51 Allowed 'General case' 0 CA--C 1.538 0.502 0 CA-C-N 114.973 -1.012 . . . . 0.0 109.333 178.861 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 4.9 mp -106.72 162.19 13.99 Favored 'General case' 0 N--CA 1.486 1.344 0 N-CA-C 108.291 -1.003 . . . . 0.0 108.291 179.76 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 57.5 t -142.24 118.41 6.18 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.296 0 CA-C-O 118.934 -0.555 . . . . 0.0 109.944 179.285 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 55.7 m-85 -70.64 158.82 35.53 Favored 'General case' 0 N--CA 1.478 0.946 0 N-CA-C 107.754 -1.202 . . . . 0.0 107.754 176.981 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 16.0 t80 -171.71 -57.94 0.02 OUTLIER 'General case' 0 N--CA 1.479 0.977 0 CA-C-O 122.299 1.047 . . . . 0.0 109.573 179.176 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.6 90.82 0.0 OUTLIER 'General case' 0 C--N 1.338 0.087 0 CA-C-N 114.137 -1.392 . . . . 0.0 112.653 -178.171 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 53.6 tt0 -63.11 155.34 28.24 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 115.226 -0.897 . . . . 0.0 110.462 179.04 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 17.9 m-20 -136.43 134.94 38.25 Favored 'General case' 0 N--CA 1.48 1.069 0 C-N-CA 122.898 0.479 . . . . 0.0 110.002 179.83 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 16.1 t -85.08 -117.23 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.475 0.796 0 N-CA-C 108.344 -0.984 . . . . 0.0 108.344 179.273 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -106.54 52.68 0.66 Allowed Glycine 0 N--CA 1.476 1.327 0 N-CA-C 111.144 -0.782 . . . . 0.0 111.144 179.852 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 89.3 p -77.1 126.45 30.98 Favored 'General case' 0 N--CA 1.466 0.364 0 N-CA-C 109.151 -0.685 . . . . 0.0 109.151 178.494 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 1.8 t-20 -67.24 100.17 0.77 Allowed 'General case' 0 N--CA 1.471 0.615 0 N-CA-C 108.627 -0.879 . . . . 0.0 108.627 178.619 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 67.3 mttm -94.09 128.23 40.35 Favored 'General case' 0 N--CA 1.479 1.016 0 N-CA-C 109.656 -0.498 . . . . 0.0 109.656 -179.41 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.29 -133.09 0.01 OUTLIER Glycine 0 CA--C 1.531 1.039 0 N-CA-C 110.481 -1.047 . . . . 0.0 110.481 179.139 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.37 127.52 42.79 Favored 'General case' 0 N--CA 1.486 1.332 0 CA-C-N 117.195 0.498 . . . . 0.0 110.177 179.379 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 29.6 mt -91.78 160.25 2.71 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.642 0 N-CA-C 106.887 -1.523 . . . . 0.0 106.887 178.063 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 36.9 mt -138.0 94.0 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.696 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 -178.964 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 53.52 104.93 0.01 OUTLIER Glycine 0 CA--C 1.531 1.067 0 CA-C-N 115.885 -0.598 . . . . 0.0 114.118 176.608 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 90.9 mt -72.21 155.17 40.52 Favored 'General case' 0 N--CA 1.47 0.563 0 N-CA-C 107.477 -1.305 . . . . 0.0 107.477 176.463 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 2.2 ttp -143.54 139.09 29.59 Favored 'General case' 0 N--CA 1.473 0.722 0 N-CA-C 108.812 -0.81 . . . . 0.0 108.812 178.9 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 59.3 t -159.2 150.08 6.98 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.258 0 N-CA-C 106.659 -1.608 . . . . 0.0 106.659 -179.279 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' C' C ' 37' ' ' GLY . . . . . 0.59 ' H ' ' NE2' ' C' ' 15' ' ' GLN . . . 54.84 75.04 0.25 Allowed Glycine 0 N--CA 1.465 0.633 0 N-CA-C 111.775 -0.53 . . . . 0.0 111.775 177.837 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 174.04 -148.9 10.32 Favored Glycine 0 CA--C 1.521 0.411 0 N-CA-C 110.967 -0.853 . . . . 0.0 110.967 179.8 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 31.3 m -134.8 145.97 31.5 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.97 0 C-N-CA 122.535 0.334 . . . . 0.0 110.481 -179.739 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 20.1 t . . . . . 0 C--O 1.222 -0.392 0 CA-C-O 117.616 -1.183 . . . . 0.0 110.873 179.116 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 84.5 m-85 . . . . . 0 N--CA 1.472 0.651 0 N-CA-C 108.346 -0.983 . . . . 0.0 108.346 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' D' D ' 5' ' ' ARG . . . . . . . . . . . . . 71.9 mtp180 -147.73 141.4 25.58 Favored 'General case' 0 N--CA 1.472 0.625 0 N-CA-C 109.037 -0.727 . . . . 0.0 109.037 179.779 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 77.5 m80 -149.2 123.46 9.57 Favored 'General case' 0 CA--C 1.541 0.627 0 N-CA-C 107.705 -1.22 . . . . 0.0 107.705 175.53 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' D' D ' 7' ' ' ASP . . . . . . . . . . . . . 7.9 m-20 -63.33 133.5 54.22 Favored 'General case' 0 C--N 1.322 -0.591 0 C-N-CA 126.813 2.045 . . . . 0.0 114.543 176.425 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' D' D ' 8' ' ' SER . . . . . . . . . . . . . 7.0 t -154.22 173.1 16.58 Favored 'General case' 0 N--CA 1.478 0.943 0 CA-C-N 118.468 0.576 . . . . 0.0 110.05 176.977 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 124.48 20.51 2.38 Favored Glycine 0 N--CA 1.484 1.874 0 N-CA-C 112.185 -0.366 . . . . 0.0 112.185 176.649 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 36.2 p90 -55.55 130.46 42.96 Favored 'General case' 0 CA--C 1.546 0.803 0 CA-C-O 121.089 0.471 . . . . 0.0 112.026 -177.341 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 46.2 mt-10 -84.89 152.25 23.69 Favored 'General case' 0 N--CA 1.474 0.755 0 N-CA-C 109.422 -0.584 . . . . 0.0 109.422 177.628 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -149.53 130.09 4.42 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.411 0 N-CA-C 108.158 -1.053 . . . . 0.0 108.158 175.389 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 49.4 m-70 -129.49 148.52 51.4 Favored 'General case' 0 N--CA 1.48 1.062 0 CA-C-N 118.016 0.371 . . . . 0.0 111.021 176.687 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 6.3 t60 -165.0 104.78 0.78 Allowed 'General case' 0 N--CA 1.484 1.256 0 N-CA-C 109.716 -0.476 . . . . 0.0 109.716 173.618 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' D' D ' 15' ' ' GLN . . . . . 0.628 ' NE2' ' H ' ' D' ' 37' ' ' GLY . 75.9 mt-30 -106.3 -175.7 2.87 Favored 'General case' 0 CA--C 1.498 -1.056 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 178.602 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -163.54 106.28 0.98 Allowed 'General case' 0 CA--C 1.536 0.423 0 N-CA-C 107.493 -1.299 . . . . 0.0 107.493 175.514 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 5.9 mp -112.94 162.18 16.14 Favored 'General case' 0 N--CA 1.487 1.381 0 N-CA-C 107.503 -1.295 . . . . 0.0 107.503 179.01 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 48.7 t -141.24 123.44 14.59 Favored 'Isoleucine or valine' 0 C--N 1.362 1.134 0 N-CA-C 109.084 -0.71 . . . . 0.0 109.084 175.344 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 80.4 m-85 -62.85 151.37 39.23 Favored 'General case' 0 C--N 1.349 0.582 0 C-N-CA 124.435 1.094 . . . . 0.0 110.703 170.11 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 11.4 t80 -170.23 -66.84 0.02 OUTLIER 'General case' 0 C--N 1.319 -0.723 0 N-CA-C 107.72 -1.215 . . . . 0.0 107.72 179.31 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -38.37 95.52 0.01 OUTLIER 'General case' 0 N--CA 1.451 -0.38 0 CA-C-N 113.964 -1.471 . . . . 0.0 111.672 -175.501 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 53.6 tt0 -65.39 156.03 33.53 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 114.072 -1.422 . . . . 0.0 110.104 178.587 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 17.9 m-20 -136.49 138.89 41.88 Favored 'General case' 0 N--CA 1.477 0.898 0 N-CA-C 109.256 -0.646 . . . . 0.0 109.256 178.501 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' D' D ' 24' ' ' VAL . . . . . . . . . . . . . 17.3 t -88.5 -120.4 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.482 1.168 0 N-CA-C 107.602 -1.259 . . . . 0.0 107.602 179.607 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . -110.35 61.77 0.3 Allowed Glycine 0 C--N 1.373 2.585 0 C-N-CA 117.706 -2.188 . . . . 0.0 109.162 178.44 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 94.5 p -67.91 121.74 16.67 Favored 'General case' 0 C--O 1.243 0.763 0 CA-C-O 116.524 -1.703 . . . . 0.0 112.307 168.7 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 1.9 t-20 -62.73 101.75 0.28 Allowed 'General case' 0 N--CA 1.476 0.845 0 CA-C-N 121.519 1.963 . . . . 0.0 109.476 172.984 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 67.1 mttm -95.95 127.37 41.91 Favored 'General case' 0 N--CA 1.485 1.277 0 CA-C-N 119.243 0.928 . . . . 0.0 109.102 178.377 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -55.84 -135.05 0.0 OUTLIER Glycine 0 CA--C 1.527 0.803 0 C-N-CA 123.573 0.606 . . . . 0.0 112.443 174.696 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.45 130.94 48.31 Favored 'General case' 0 C--N 1.373 1.62 0 CA-C-N 114.968 -0.616 . . . . 0.0 110.283 175.995 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 35.9 mt -92.08 162.32 2.43 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.455 0 N-CA-C 106.475 -1.676 . . . . 0.0 106.475 177.673 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . 0.267 41.6 mt -140.6 105.49 1.84 Allowed 'Isoleucine or valine' 0 C--N 1.359 1.015 0 N-CA-C 106.728 -1.582 . . . . 0.0 106.728 173.053 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.49 96.24 0.01 OUTLIER Glycine 0 CA--C 1.533 1.171 0 CA-C-O 115.935 -2.592 . . . . 0.0 112.682 169.063 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 95.2 mt -69.65 158.56 35.1 Favored 'General case' 0 N--CA 1.481 1.086 0 CA-C-N 122.731 3.265 . . . . 0.0 107.441 176.507 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 2.9 ttp -143.82 149.53 37.14 Favored 'General case' 0 N--CA 1.481 1.089 0 N-CA-C 106.352 -1.722 . . . . 0.0 106.352 174.293 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 89.6 t -165.18 154.09 1.91 Allowed 'Isoleucine or valine' 0 C--O 1.249 1.032 0 N-CA-C 105.41 -2.07 . . . . 0.0 105.41 177.601 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' D' D ' 37' ' ' GLY . . . . . 0.628 ' H ' ' NE2' ' D' ' 15' ' ' GLN . . . 60.83 66.74 2.5 Favored Glycine 0 N--CA 1.442 -0.953 0 C-N-CA 117.326 -2.369 . . . . 0.0 113.981 174.565 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 168.41 -147.85 11.88 Favored Glycine 0 N--CA 1.466 0.674 0 CA-C-O 117.0 -2.0 . . . . 0.0 112.492 -178.698 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 31.1 m -131.19 145.42 35.39 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.271 0 CA-C-N 119.958 1.879 . . . . 0.0 110.588 -176.988 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 18.0 t . . . . . 0 C--O 1.208 -1.128 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 173.591 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 77.1 m-85 . . . . . 0 N--CA 1.473 0.7 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' E' E ' 5' ' ' ARG . . . . . . . . . . . . . 71.8 mtp180 -144.27 142.32 30.38 Favored 'General case' 0 N--CA 1.476 0.826 0 N-CA-C 109.234 -0.654 . . . . 0.0 109.234 179.666 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 77.3 m80 -150.11 117.62 6.12 Favored 'General case' 0 N--CA 1.475 0.787 0 N-CA-C 109.049 -0.723 . . . . 0.0 109.049 179.073 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' E' E ' 7' ' ' ASP . . . . . . . . . . . . . 12.1 m-20 -65.85 149.19 50.58 Favored 'General case' 0 N--CA 1.463 0.205 0 O-C-N 123.276 0.36 . . . . 0.0 111.482 -179.409 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' E' E ' 8' ' ' SER . . . . . . . . . . . . . 7.2 t -167.6 171.34 10.34 Favored 'General case' 0 N--CA 1.476 0.836 0 N-CA-C 109.219 -0.66 . . . . 0.0 109.219 178.03 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 123.9 23.78 1.98 Allowed Glycine 0 N--CA 1.481 1.655 0 N-CA-C 111.876 -0.489 . . . . 0.0 111.876 179.024 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 37.1 p90 -55.82 127.53 30.64 Favored 'General case' 0 CA--C 1.543 0.694 0 N-CA-C 112.703 0.631 . . . . 0.0 112.703 -179.076 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 46.4 mt-10 -83.05 155.2 24.03 Favored 'General case' 0 N--CA 1.475 0.79 0 N-CA-C 109.234 -0.654 . . . . 0.0 109.234 177.774 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -155.69 127.88 1.02 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.498 0 N-CA-C 108.22 -1.03 . . . . 0.0 108.22 178.622 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 48.5 m-70 -134.29 143.1 47.54 Favored 'General case' 0 N--CA 1.478 0.97 0 C-N-CA 122.491 0.316 . . . . 0.0 111.099 -177.976 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 6.1 t60 -163.52 98.5 0.9 Allowed 'General case' 0 N--CA 1.486 1.359 0 CA-C-O 119.735 -0.174 . . . . 0.0 111.247 179.693 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' E' E ' 15' ' ' GLN . . . . . 0.568 ' NE2' ' H ' ' E' ' 37' ' ' GLY . 76.0 mt-30 -102.66 -172.7 2.17 Favored 'General case' 0 CA--C 1.506 -0.736 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 179.464 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -167.16 98.13 0.52 Allowed 'General case' 0 CA--C 1.54 0.59 0 CA-C-N 114.97 -1.014 . . . . 0.0 109.259 178.617 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 4.9 mp -106.43 161.44 14.58 Favored 'General case' 0 N--CA 1.487 1.411 0 N-CA-C 108.771 -0.826 . . . . 0.0 108.771 -179.95 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 42.0 t -142.4 117.82 5.39 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.379 0 C-N-CA 122.549 0.339 . . . . 0.0 110.463 178.896 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 54.9 m-85 -69.72 156.54 38.83 Favored 'General case' 0 C--N 1.356 0.891 0 N-CA-C 107.636 -1.246 . . . . 0.0 107.636 176.449 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 14.2 t80 -173.23 -56.16 0.02 OUTLIER 'General case' 0 N--CA 1.482 1.129 0 CA-C-O 121.731 0.777 . . . . 0.0 110.018 179.242 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.84 89.1 0.0 OUTLIER 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 114.364 -1.289 . . . . 0.0 112.689 -179.095 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 54.0 tt0 -61.69 155.08 23.55 Favored 'General case' 0 N--CA 1.47 0.55 0 CA-C-N 115.131 -0.94 . . . . 0.0 110.604 179.489 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 17.6 m-20 -136.46 134.54 37.77 Favored 'General case' 0 N--CA 1.479 0.978 0 C-N-CA 122.918 0.487 . . . . 0.0 110.301 -179.931 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 20.2 t -84.85 -116.64 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.873 0 N-CA-C 108.449 -0.945 . . . . 0.0 108.449 179.209 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . -106.84 52.98 0.64 Allowed Glycine 0 C--N 1.346 1.138 0 N-CA-C 111.255 -0.738 . . . . 0.0 111.255 -179.987 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 89.2 p -77.0 125.99 30.24 Favored 'General case' 0 N--CA 1.472 0.664 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 178.169 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 1.8 t-20 -66.66 100.22 0.67 Allowed 'General case' 0 N--CA 1.472 0.633 0 N-CA-C 108.108 -1.071 . . . . 0.0 108.108 178.528 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 66.6 mttm -94.31 127.15 40.01 Favored 'General case' 0 N--CA 1.481 1.101 0 N-CA-C 109.149 -0.685 . . . . 0.0 109.149 -179.463 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.84 -130.58 0.01 OUTLIER Glycine 0 CA--C 1.533 1.218 0 N-CA-C 110.454 -1.058 . . . . 0.0 110.454 179.31 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -129.25 127.56 41.49 Favored 'General case' 0 N--CA 1.484 1.265 0 CA-C-N 117.439 0.62 . . . . 0.0 111.324 -179.906 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 27.8 mt -90.91 161.01 2.65 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.499 0 N-CA-C 106.796 -1.557 . . . . 0.0 106.796 178.152 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 37.3 mt -138.75 94.5 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.479 0.979 0 N-CA-C 109.606 -0.516 . . . . 0.0 109.606 179.872 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 53.62 104.37 0.01 OUTLIER Glycine 0 CA--C 1.531 1.037 0 CA-C-N 116.101 -0.499 . . . . 0.0 114.204 176.791 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 93.8 mt -71.52 155.64 40.34 Favored 'General case' 0 N--CA 1.473 0.682 0 N-CA-C 107.49 -1.3 . . . . 0.0 107.49 176.516 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 2.4 ttp -143.81 139.99 29.62 Favored 'General case' 0 N--CA 1.479 1.019 0 N-CA-C 108.301 -1.0 . . . . 0.0 108.301 178.787 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 65.6 t -160.27 148.8 6.11 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.456 0 N-CA-C 106.618 -1.623 . . . . 0.0 106.618 -179.058 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' E' E ' 37' ' ' GLY . . . . . 0.568 ' H ' ' NE2' ' E' ' 15' ' ' GLN . . . 55.15 75.32 0.24 Allowed Glycine 0 N--CA 1.464 0.516 0 N-CA-C 111.815 -0.514 . . . . 0.0 111.815 178.118 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 174.77 -146.95 8.77 Favored Glycine 0 C--O 1.221 -0.663 0 N-CA-C 111.207 -0.757 . . . . 0.0 111.207 179.881 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 29.8 m -136.69 145.15 30.73 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.794 0 CA-C-N 117.104 0.452 . . . . 0.0 109.808 -179.647 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 19.0 t . . . . . 0 CA--C 1.537 0.449 0 CA-C-O 117.576 -1.202 . . . . 0.0 111.153 179.183 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 77.0 m-85 . . . . . 0 N--CA 1.474 0.75 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' F' F ' 5' ' ' ARG . . . . . . . . . . . . . 72.0 mtp180 -144.11 142.15 30.43 Favored 'General case' 0 N--CA 1.478 0.954 0 N-CA-C 109.092 -0.707 . . . . 0.0 109.092 179.755 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 77.2 m80 -150.14 117.43 6.04 Favored 'General case' 0 N--CA 1.476 0.843 0 N-CA-C 108.983 -0.747 . . . . 0.0 108.983 179.093 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' F' F ' 7' ' ' ASP . . . . . . . . . . . . . 11.5 m-20 -65.74 149.07 50.73 Favored 'General case' 0 N--CA 1.464 0.247 0 O-C-N 123.327 0.392 . . . . 0.0 111.662 -179.433 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' F' F ' 8' ' ' SER . . . . . . . . . . . . . 7.1 t -167.38 171.43 10.58 Favored 'General case' 0 N--CA 1.476 0.87 0 N-CA-C 109.253 -0.647 . . . . 0.0 109.253 178.056 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 123.79 23.71 2.01 Favored Glycine 0 N--CA 1.482 1.746 0 N-CA-C 111.901 -0.48 . . . . 0.0 111.901 179.008 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 37.4 p90 -55.9 127.75 31.81 Favored 'General case' 0 CA--C 1.542 0.647 0 N-CA-C 112.717 0.636 . . . . 0.0 112.717 -179.113 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 46.4 mt-10 -83.21 155.25 23.81 Favored 'General case' 0 N--CA 1.475 0.779 0 N-CA-C 109.2 -0.667 . . . . 0.0 109.2 177.756 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -155.74 127.94 1.02 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.538 0 N-CA-C 108.218 -1.03 . . . . 0.0 108.218 178.551 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 49.0 m-70 -134.29 143.16 47.58 Favored 'General case' 0 N--CA 1.479 1.024 0 C-N-CA 122.419 0.288 . . . . 0.0 110.996 -177.871 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 6.1 t60 -163.81 99.12 0.88 Allowed 'General case' 0 N--CA 1.487 1.38 0 CA-C-N 116.85 -0.159 . . . . 0.0 111.252 179.677 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' F' F ' 15' ' ' GLN . . . . . 0.577 ' NE2' ' H ' ' F' ' 37' ' ' GLY . 76.0 mt-30 -103.58 -171.91 2.02 Favored 'General case' 0 CA--C 1.501 -0.921 0 N-CA-C 108.388 -0.967 . . . . 0.0 108.388 179.384 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -167.6 98.3 0.48 Allowed 'General case' 0 CA--C 1.54 0.59 0 CA-C-N 114.842 -1.072 . . . . 0.0 109.322 178.775 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 4.9 mp -106.45 161.45 14.58 Favored 'General case' 0 N--CA 1.487 1.415 0 N-CA-C 108.721 -0.844 . . . . 0.0 108.721 -179.967 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 41.6 t -142.32 117.96 5.64 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.378 0 C-N-CA 122.638 0.375 . . . . 0.0 110.478 178.921 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 55.2 m-85 -69.82 156.47 38.99 Favored 'General case' 0 C--N 1.357 0.906 0 N-CA-C 107.455 -1.313 . . . . 0.0 107.455 176.363 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 15.0 t80 -173.11 -56.09 0.02 OUTLIER 'General case' 0 N--CA 1.482 1.164 0 CA-C-O 121.743 0.783 . . . . 0.0 109.606 179.233 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.99 89.09 0.0 OUTLIER 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 114.46 -1.245 . . . . 0.0 112.76 -179.02 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 53.9 tt0 -61.6 155.19 22.95 Favored 'General case' 0 N--CA 1.472 0.659 0 CA-C-N 115.151 -0.931 . . . . 0.0 110.641 179.346 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 17.5 m-20 -136.66 134.73 37.59 Favored 'General case' 0 N--CA 1.479 1.006 0 C-N-CA 122.925 0.49 . . . . 0.0 110.345 -179.986 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' F' F ' 24' ' ' VAL . . . . . . . . . . . . . 19.3 t -85.08 -116.69 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.93 0 N-CA-C 108.525 -0.917 . . . . 0.0 108.525 179.241 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -106.6 52.61 0.67 Allowed Glycine 0 N--CA 1.477 1.42 0 N-CA-C 111.172 -0.771 . . . . 0.0 111.172 179.974 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 89.3 p -76.78 125.86 29.99 Favored 'General case' 0 N--CA 1.472 0.655 0 N-CA-C 109.271 -0.64 . . . . 0.0 109.271 178.176 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 1.9 t-20 -66.83 100.35 0.71 Allowed 'General case' 0 N--CA 1.471 0.603 0 N-CA-C 108.134 -1.061 . . . . 0.0 108.134 178.587 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 66.7 mttm -94.31 126.96 39.89 Favored 'General case' 0 N--CA 1.481 1.123 0 N-CA-C 109.169 -0.678 . . . . 0.0 109.169 -179.389 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.81 -130.96 0.01 OUTLIER Glycine 0 CA--C 1.532 1.155 0 N-CA-C 110.591 -1.004 . . . . 0.0 110.591 179.212 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.55 126.94 41.38 Favored 'General case' 0 N--CA 1.488 1.433 0 CA-C-N 117.4 0.6 . . . . 0.0 111.348 -179.765 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 28.1 mt -90.62 160.92 2.68 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.547 0 N-CA-C 106.694 -1.595 . . . . 0.0 106.694 178.033 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 36.8 mt -138.87 94.57 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.093 0 N-CA-C 109.613 -0.514 . . . . 0.0 109.613 179.822 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 53.69 104.3 0.01 OUTLIER Glycine 0 CA--C 1.531 1.075 0 CA-C-N 116.039 -0.528 . . . . 0.0 114.145 176.752 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 94.1 mt -71.47 155.93 40.03 Favored 'General case' 0 N--CA 1.471 0.62 0 N-CA-C 107.524 -1.287 . . . . 0.0 107.524 176.588 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 2.3 ttp -144.13 140.01 29.15 Favored 'General case' 0 N--CA 1.478 0.957 0 N-CA-C 108.691 -0.855 . . . . 0.0 108.691 178.708 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 65.0 t -160.3 148.95 6.08 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.447 0 N-CA-C 106.703 -1.591 . . . . 0.0 106.703 -178.973 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' F' F ' 37' ' ' GLY . . . . . 0.577 ' H ' ' NE2' ' F' ' 15' ' ' GLN . . . 55.16 75.25 0.25 Allowed Glycine 0 N--CA 1.464 0.551 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.812 178.038 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 174.77 -146.94 8.76 Favored Glycine 0 C--O 1.22 -0.738 0 N-CA-C 111.22 -0.752 . . . . 0.0 111.22 179.845 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 30.3 m -136.7 145.05 30.88 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.757 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 -179.644 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 18.7 t . . . . . 0 C--O 1.221 -0.418 0 CA-C-O 117.621 -1.18 . . . . 0.0 111.157 179.215 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 77.1 m-85 . . . . . 0 N--CA 1.472 0.668 0 N-CA-C 109.594 -0.521 . . . . 0.0 109.594 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' G' G ' 5' ' ' ARG . . . . . . . . . . . . . 72.4 mtp180 -144.56 141.94 29.83 Favored 'General case' 0 N--CA 1.48 1.053 0 N-CA-C 109.088 -0.708 . . . . 0.0 109.088 -179.799 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 77.1 m80 -149.85 118.75 6.66 Favored 'General case' 0 N--CA 1.475 0.797 0 N-CA-C 108.979 -0.749 . . . . 0.0 108.979 179.072 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 12.1 m-20 -68.1 144.85 54.87 Favored 'General case' 0 CA--C 1.537 0.467 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.878 -179.2 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' G' G ' 8' ' ' SER . . . . . . . . . . . . . 6.1 t -163.58 173.1 13.44 Favored 'General case' 0 N--CA 1.47 0.552 0 N-CA-C 109.068 -0.715 . . . . 0.0 109.068 178.089 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 123.4 23.12 2.19 Favored Glycine 0 N--CA 1.481 1.644 0 N-CA-C 111.712 -0.555 . . . . 0.0 111.712 178.936 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 40.5 p90 -56.18 127.68 31.87 Favored 'General case' 0 N--CA 1.473 0.718 0 N-CA-C 112.682 0.623 . . . . 0.0 112.682 -178.705 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 46.2 mt-10 -83.44 154.1 24.14 Favored 'General case' 0 N--CA 1.47 0.561 0 N-CA-C 109.632 -0.507 . . . . 0.0 109.632 178.307 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -155.68 128.07 1.05 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.933 0 N-CA-C 108.036 -1.098 . . . . 0.0 108.036 178.846 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 50.2 m-70 -133.66 144.15 49.01 Favored 'General case' 0 N--CA 1.475 0.801 0 CA-C-N 115.353 -0.84 . . . . 0.0 110.773 -178.238 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 6.2 t60 -164.82 98.83 0.77 Allowed 'General case' 0 N--CA 1.483 1.204 0 CA-C-N 116.635 -0.257 . . . . 0.0 110.786 179.033 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' G' G ' 15' ' ' GLN . . . . . 0.598 ' NE2' ' H ' ' G' ' 37' ' ' GLY . 76.1 mt-30 -103.18 -172.32 2.1 Favored 'General case' 0 CA--C 1.506 -0.737 0 N-CA-C 108.358 -0.979 . . . . 0.0 108.358 179.578 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -167.29 98.31 0.51 Allowed 'General case' 0 CA--C 1.539 0.546 0 CA-C-N 115.051 -0.977 . . . . 0.0 109.367 178.7 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 5.4 mp -106.2 160.81 15.05 Favored 'General case' 0 N--CA 1.486 1.335 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 -179.908 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 40.4 t -143.59 117.95 3.84 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.001 0 C-N-CA 122.573 0.349 . . . . 0.0 110.235 178.753 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 49.0 m-85 -69.7 150.84 46.53 Favored 'General case' 0 C--N 1.37 1.487 0 N-CA-C 107.404 -1.332 . . . . 0.0 107.404 176.477 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 12.4 t80 -171.03 -55.9 0.02 OUTLIER 'General case' 0 N--CA 1.485 1.29 0 N-CA-C 110.025 -0.361 . . . . 0.0 110.025 179.957 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.88 90.61 0.0 OUTLIER 'General case' 0 C--N 1.325 -0.481 0 O-C-N 123.938 0.774 . . . . 0.0 112.267 179.986 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 53.7 tt0 -62.81 155.84 25.68 Favored 'General case' 0 N--CA 1.469 0.475 0 CA-C-N 114.838 -1.074 . . . . 0.0 109.718 179.03 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 18.0 m-20 -136.71 134.71 37.48 Favored 'General case' 0 N--CA 1.478 0.96 0 C-N-CA 122.782 0.433 . . . . 0.0 109.87 -179.939 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' G' G ' 24' ' ' VAL . . . . . . . . . . . . . 19.6 t -85.5 -116.02 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.894 0 N-CA-C 108.293 -1.003 . . . . 0.0 108.293 179.289 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -107.28 53.06 0.63 Allowed Glycine 0 N--CA 1.476 1.311 0 N-CA-C 111.286 -0.726 . . . . 0.0 111.286 -179.947 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 89.3 p -77.48 126.2 30.53 Favored 'General case' 0 N--CA 1.466 0.37 0 N-CA-C 109.152 -0.684 . . . . 0.0 109.152 178.139 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 1.9 t-20 -67.16 99.82 0.72 Allowed 'General case' 0 N--CA 1.469 0.495 0 N-CA-C 108.604 -0.887 . . . . 0.0 108.604 178.81 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 67.3 mttm -93.51 127.09 39.01 Favored 'General case' 0 N--CA 1.481 1.081 0 N-CA-C 109.512 -0.551 . . . . 0.0 109.512 -179.662 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.87 -128.71 0.01 OUTLIER Glycine 0 CA--C 1.527 0.801 0 N-CA-C 110.576 -1.01 . . . . 0.0 110.576 179.27 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.84 126.09 35.36 Favored 'General case' 0 CA--C 1.54 0.567 0 C-N-CA 122.814 0.446 . . . . 0.0 110.933 -179.361 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 37.7 mt -90.53 162.26 2.49 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.842 0 N-CA-C 107.0 -1.482 . . . . 0.0 107.0 178.239 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 40.8 mt -139.04 95.96 0.96 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.437 0 CA-C-N 119.714 1.143 . . . . 0.0 110.068 178.173 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 53.64 103.92 0.01 OUTLIER Glycine 0 CA--C 1.53 1.019 0 CA-C-N 116.026 -0.534 . . . . 0.0 114.106 176.818 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 92.3 mt -71.34 154.96 41.19 Favored 'General case' 0 N--CA 1.47 0.57 0 N-CA-C 107.772 -1.196 . . . . 0.0 107.772 176.717 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 2.6 ttp -143.48 140.46 30.34 Favored 'General case' 0 N--CA 1.474 0.756 0 N-CA-C 108.555 -0.906 . . . . 0.0 108.555 178.897 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 69.2 t -160.36 149.11 5.98 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.256 0 N-CA-C 106.636 -1.616 . . . . 0.0 106.636 -179.329 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' G' G ' 37' ' ' GLY . . . . . 0.598 ' H ' ' NE2' ' G' ' 15' ' ' GLN . . . 55.5 75.12 0.26 Allowed Glycine 0 N--CA 1.466 0.637 0 C-N-CA 121.012 -0.613 . . . . 0.0 112.04 177.494 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 173.92 -146.17 8.59 Favored Glycine 0 C--O 1.221 -0.708 0 N-CA-C 110.581 -1.008 . . . . 0.0 110.581 179.339 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 32.9 m -136.76 145.9 29.42 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.923 0 CA-C-N 117.002 0.401 . . . . 0.0 110.185 -179.413 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 20.7 t . . . . . 0 C--O 1.22 -0.467 0 CA-C-O 117.603 -1.189 . . . . 0.0 111.417 179.091 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 77.6 m-85 . . . . . 0 N--CA 1.472 0.666 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' H' H ' 5' ' ' ARG . . . . . . . . . . . . . 72.3 mtp180 -144.6 141.86 29.73 Favored 'General case' 0 N--CA 1.48 1.062 0 N-CA-C 109.13 -0.693 . . . . 0.0 109.13 -179.859 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 77.1 m80 -149.84 118.3 6.49 Favored 'General case' 0 N--CA 1.476 0.831 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 179.096 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 11.9 m-20 -67.54 144.89 55.4 Favored 'General case' 0 N--CA 1.468 0.453 0 O-C-N 123.426 0.453 . . . . 0.0 111.931 -179.29 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' H' H ' 8' ' ' SER . . . . . . . . . . . . . 7.5 t -163.74 172.36 14.29 Favored 'General case' 0 N--CA 1.47 0.532 0 N-CA-C 109.174 -0.676 . . . . 0.0 109.174 178.261 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 123.52 23.36 2.13 Favored Glycine 0 N--CA 1.482 1.714 0 N-CA-C 111.817 -0.513 . . . . 0.0 111.817 179.084 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 40.5 p90 -56.17 127.82 32.56 Favored 'General case' 0 N--CA 1.473 0.714 0 N-CA-C 112.575 0.583 . . . . 0.0 112.575 -178.82 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 46.2 mt-10 -83.53 154.23 23.96 Favored 'General case' 0 N--CA 1.473 0.708 0 N-CA-C 109.597 -0.52 . . . . 0.0 109.597 178.297 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -155.85 127.99 1.02 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.943 0 N-CA-C 108.07 -1.085 . . . . 0.0 108.07 178.8 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 51.4 m-70 -133.54 144.33 49.28 Favored 'General case' 0 N--CA 1.476 0.825 0 CA-C-N 115.274 -0.875 . . . . 0.0 110.81 -178.214 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 6.2 t60 -164.96 98.5 0.75 Allowed 'General case' 0 N--CA 1.483 1.197 0 CA-C-N 116.709 -0.223 . . . . 0.0 110.85 179.034 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' H' H ' 15' ' ' GLN . . . . . 0.58 ' NE2' ' H ' ' H' ' 37' ' ' GLY . 76.0 mt-30 -102.8 -172.8 2.18 Favored 'General case' 0 CA--C 1.505 -0.77 0 N-CA-C 108.26 -1.015 . . . . 0.0 108.26 179.642 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -167.11 98.24 0.52 Allowed 'General case' 0 CA--C 1.539 0.524 0 CA-C-N 114.997 -1.001 . . . . 0.0 109.251 178.719 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 5.4 mp -106.17 160.84 15.02 Favored 'General case' 0 N--CA 1.485 1.279 0 N-CA-C 109.103 -0.702 . . . . 0.0 109.103 -179.823 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 40.4 t -143.52 117.77 3.81 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.089 0 C-N-CA 122.547 0.339 . . . . 0.0 110.25 178.744 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 50.2 m-85 -69.75 151.29 45.97 Favored 'General case' 0 C--N 1.369 1.426 0 N-CA-C 107.527 -1.286 . . . . 0.0 107.527 176.33 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 13.1 t80 -172.25 -55.58 0.02 OUTLIER 'General case' 0 N--CA 1.483 1.177 0 N-CA-C 110.069 -0.345 . . . . 0.0 110.069 180.0 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.96 90.71 0.0 OUTLIER 'General case' 0 CA--C 1.535 0.367 0 C-N-CA 123.517 0.727 . . . . 0.0 112.097 179.924 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 53.7 tt0 -62.61 155.83 24.99 Favored 'General case' 0 N--CA 1.469 0.512 0 CA-C-N 114.849 -1.069 . . . . 0.0 109.919 179.115 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 17.9 m-20 -136.55 134.86 37.93 Favored 'General case' 0 N--CA 1.48 1.025 0 C-N-CA 122.835 0.454 . . . . 0.0 109.917 -179.957 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' H' H ' 24' ' ' VAL . . . . . . . . . . . . . 19.6 t -85.85 -116.13 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.846 0 N-CA-C 108.358 -0.979 . . . . 0.0 108.358 179.364 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . -106.91 52.89 0.64 Allowed Glycine 0 N--CA 1.478 1.483 0 N-CA-C 111.099 -0.8 . . . . 0.0 111.099 -179.969 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 89.0 p -77.45 126.16 30.47 Favored 'General case' 0 N--CA 1.467 0.383 0 N-CA-C 109.006 -0.738 . . . . 0.0 109.006 178.304 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 1.9 t-20 -67.06 100.49 0.76 Allowed 'General case' 0 N--CA 1.469 0.5 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 178.667 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 67.3 mttm -94.39 127.12 40.07 Favored 'General case' 0 N--CA 1.481 1.084 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 -179.598 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.11 -128.54 0.01 OUTLIER Glycine 0 CA--C 1.527 0.783 0 N-CA-C 110.643 -0.983 . . . . 0.0 110.643 179.385 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.97 126.04 34.99 Favored 'General case' 0 N--CA 1.471 0.582 0 C-N-CA 122.853 0.461 . . . . 0.0 111.033 -179.251 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 35.8 mt -90.66 161.81 2.55 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.845 0 N-CA-C 107.014 -1.476 . . . . 0.0 107.014 178.228 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 40.4 mt -138.73 95.93 1.01 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.435 0 CA-C-N 119.511 1.051 . . . . 0.0 109.981 178.38 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 53.58 104.32 0.01 OUTLIER Glycine 0 CA--C 1.53 1.029 0 CA-C-N 116.101 -0.5 . . . . 0.0 114.144 176.832 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 92.1 mt -71.67 154.76 41.16 Favored 'General case' 0 N--CA 1.47 0.57 0 N-CA-C 107.673 -1.232 . . . . 0.0 107.673 176.716 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 2.6 ttp -143.09 140.09 30.74 Favored 'General case' 0 N--CA 1.477 0.889 0 N-CA-C 108.503 -0.925 . . . . 0.0 108.503 178.802 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 69.1 t -159.96 149.34 6.38 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.278 0 N-CA-C 106.525 -1.657 . . . . 0.0 106.525 -179.388 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' H' H ' 37' ' ' GLY . . . . . 0.58 ' H ' ' NE2' ' H' ' 15' ' ' GLN . . . 55.28 74.91 0.27 Allowed Glycine 0 C--N 1.314 -0.643 0 C-N-CA 120.989 -0.624 . . . . 0.0 112.155 177.489 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 173.97 -146.32 8.66 Favored Glycine 0 C--O 1.221 -0.675 0 N-CA-C 110.631 -0.988 . . . . 0.0 110.631 179.393 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 32.7 m -136.68 145.87 29.55 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.87 0 CA-C-N 116.98 0.39 . . . . 0.0 110.327 -179.423 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 21.1 t . . . . . 0 C--O 1.221 -0.4 0 CA-C-O 117.64 -1.171 . . . . 0.0 111.326 179.163 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 77.1 m-85 . . . . . 0 N--CA 1.473 0.704 0 N-CA-C 109.553 -0.536 . . . . 0.0 109.553 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' I' I ' 5' ' ' ARG . . . . . . . . . . . . . 72.3 mtp180 -144.78 141.9 29.56 Favored 'General case' 0 N--CA 1.481 1.094 0 N-CA-C 109.056 -0.72 . . . . 0.0 109.056 -179.834 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 77.1 m80 -149.83 118.34 6.51 Favored 'General case' 0 N--CA 1.476 0.838 0 N-CA-C 109.083 -0.71 . . . . 0.0 109.083 179.093 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 12.0 m-20 -67.62 144.76 55.39 Favored 'General case' 0 CA--C 1.535 0.396 0 CA-C-O 120.979 0.419 . . . . 0.0 111.927 -179.268 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' I' I ' 8' ' ' SER . . . . . . . . . . . . . 7.6 t -163.54 172.31 14.59 Favored 'General case' 0 N--CA 1.469 0.5 0 N-CA-C 109.152 -0.684 . . . . 0.0 109.152 178.276 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 123.7 23.26 2.1 Favored Glycine 0 N--CA 1.483 1.789 0 N-CA-C 111.747 -0.541 . . . . 0.0 111.747 179.027 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 40.3 p90 -56.08 127.82 32.43 Favored 'General case' 0 N--CA 1.474 0.75 0 N-CA-C 112.501 0.556 . . . . 0.0 112.501 -178.792 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 46.2 mt-10 -83.61 154.17 23.89 Favored 'General case' 0 N--CA 1.474 0.73 0 N-CA-C 109.644 -0.502 . . . . 0.0 109.644 178.203 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -155.74 128.01 1.03 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.927 0 N-CA-C 108.125 -1.065 . . . . 0.0 108.125 178.854 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 50.9 m-70 -133.58 144.33 49.24 Favored 'General case' 0 N--CA 1.476 0.832 0 CA-C-N 115.33 -0.85 . . . . 0.0 110.861 -178.236 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 6.2 t60 -165.05 98.61 0.74 Allowed 'General case' 0 N--CA 1.485 1.297 0 CA-C-N 116.687 -0.233 . . . . 0.0 110.914 179.131 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' I' I ' 15' ' ' GLN . . . . . 0.588 ' NE2' ' H ' ' I' ' 37' ' ' GLY . 76.0 mt-30 -103.11 -172.55 2.13 Favored 'General case' 0 CA--C 1.503 -0.852 0 N-CA-C 108.328 -0.99 . . . . 0.0 108.328 179.598 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -167.26 98.23 0.51 Allowed 'General case' 0 CA--C 1.538 0.517 0 CA-C-N 114.977 -1.011 . . . . 0.0 109.279 178.82 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 5.4 mp -106.18 160.77 15.08 Favored 'General case' 0 N--CA 1.484 1.259 0 N-CA-C 109.089 -0.708 . . . . 0.0 109.089 -179.854 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 40.5 t -143.4 117.83 3.95 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.016 0 C-N-CA 122.542 0.337 . . . . 0.0 110.306 178.753 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 49.7 m-85 -69.83 151.3 45.88 Favored 'General case' 0 C--N 1.369 1.431 0 N-CA-C 107.486 -1.302 . . . . 0.0 107.486 176.423 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 13.2 t80 -172.25 -55.55 0.02 OUTLIER 'General case' 0 N--CA 1.481 1.093 0 N-CA-C 110.065 -0.346 . . . . 0.0 110.065 -179.999 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.98 90.8 0.0 OUTLIER 'General case' 0 CA--C 1.535 0.387 0 C-N-CA 123.496 0.718 . . . . 0.0 112.046 179.877 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 53.7 tt0 -62.69 155.96 24.91 Favored 'General case' 0 N--CA 1.469 0.5 0 CA-C-N 114.862 -1.063 . . . . 0.0 109.866 179.141 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 17.9 m-20 -136.69 134.85 37.66 Favored 'General case' 0 N--CA 1.479 0.987 0 C-N-CA 122.804 0.442 . . . . 0.0 109.867 -179.954 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' I' I ' 24' ' ' VAL . . . . . . . . . . . . . 19.4 t -85.76 -116.09 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.878 0 N-CA-C 108.337 -0.986 . . . . 0.0 108.337 179.39 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . -106.98 52.9 0.64 Allowed Glycine 0 N--CA 1.477 1.402 0 N-CA-C 111.225 -0.75 . . . . 0.0 111.225 179.991 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 89.3 p -77.46 126.2 30.53 Favored 'General case' 0 N--CA 1.466 0.372 0 N-CA-C 109.066 -0.716 . . . . 0.0 109.066 178.313 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 1.9 t-20 -67.03 100.4 0.74 Allowed 'General case' 0 N--CA 1.47 0.538 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 178.623 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 67.4 mttm -94.27 127.03 39.88 Favored 'General case' 0 N--CA 1.481 1.111 0 N-CA-C 109.452 -0.573 . . . . 0.0 109.452 -179.659 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.97 -128.78 0.01 OUTLIER Glycine 0 CA--C 1.527 0.831 0 N-CA-C 110.695 -0.962 . . . . 0.0 110.695 179.339 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.69 125.74 34.72 Favored 'General case' 0 N--CA 1.471 0.612 0 C-N-CA 122.957 0.503 . . . . 0.0 111.057 -179.299 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 36.2 mt -90.56 161.85 2.55 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.781 0 N-CA-C 106.933 -1.506 . . . . 0.0 106.933 178.201 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 40.4 mt -138.85 95.79 0.98 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 CA-C-N 119.485 1.039 . . . . 0.0 109.99 178.475 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 53.7 104.23 0.01 OUTLIER Glycine 0 CA--C 1.531 1.039 0 CA-C-N 116.103 -0.499 . . . . 0.0 114.093 176.818 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 91.9 mt -71.56 154.63 41.32 Favored 'General case' 0 N--CA 1.471 0.576 0 N-CA-C 107.683 -1.228 . . . . 0.0 107.683 176.687 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 2.6 ttp -143.03 140.03 30.8 Favored 'General case' 0 N--CA 1.475 0.815 0 N-CA-C 108.497 -0.927 . . . . 0.0 108.497 178.871 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 68.6 t -159.95 149.37 6.39 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.228 0 N-CA-C 106.567 -1.642 . . . . 0.0 106.567 -179.371 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' I' I ' 37' ' ' GLY . . . . . 0.588 ' H ' ' NE2' ' I' ' 15' ' ' GLN . . . 55.2 74.99 0.26 Allowed Glycine 0 N--CA 1.465 0.617 0 C-N-CA 120.942 -0.647 . . . . 0.0 112.152 177.517 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 173.95 -146.24 8.63 Favored Glycine 0 N--CA 1.465 0.633 0 N-CA-C 110.662 -0.975 . . . . 0.0 110.662 179.354 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 32.8 m -136.73 145.91 29.43 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.93 0 CA-C-N 117.013 0.406 . . . . 0.0 110.172 -179.369 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 20.9 t . . . . . 0 C--O 1.221 -0.42 0 CA-C-O 117.648 -1.168 . . . . 0.0 111.381 179.145 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 76.5 m-85 . . . . . 0 N--CA 1.475 0.791 0 N-CA-C 109.98 -0.378 . . . . 0.0 109.98 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 73.7 mtp180 -143.71 141.31 30.45 Favored 'General case' 0 N--CA 1.482 1.152 0 N-CA-C 109.045 -0.724 . . . . 0.0 109.045 -179.968 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 76.7 m80 -149.77 119.53 7.05 Favored 'General case' 0 N--CA 1.47 0.548 0 N-CA-C 108.781 -0.822 . . . . 0.0 108.781 179.137 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 -67.84 149.56 49.7 Favored 'General case' 0 N--CA 1.463 0.187 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.179 -179.62 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' SER . . . . . 0.484 ' HG ' ' H ' ' A' ' 9' ' ' GLY . 7.0 t -167.22 171.28 10.94 Favored 'General case' 0 N--CA 1.473 0.698 0 N-CA-C 109.46 -0.57 . . . . 0.0 109.46 178.496 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . 0.484 ' H ' ' HG ' ' A' ' 8' ' ' SER . . . 122.21 24.07 2.29 Favored Glycine 0 N--CA 1.487 2.065 0 N-CA-C 112.125 -0.39 . . . . 0.0 112.125 179.375 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 41.9 p90 -56.78 128.01 34.45 Favored 'General case' 0 N--CA 1.471 0.623 0 N-CA-C 112.106 0.41 . . . . 0.0 112.106 -179.889 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . 0.411 ' CD ' HD22 ' C' ' 27' ' ' ASN . 46.1 mt-10 -84.86 156.09 21.44 Favored 'General case' 0 N--CA 1.468 0.443 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 178.544 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -154.86 124.48 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 N-CA-C 108.119 -1.067 . . . . 0.0 108.119 178.534 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 35.1 m80 -107.33 161.12 15.09 Favored 'General case' 0 N--CA 1.491 1.624 0 CA-C-N 118.455 0.57 . . . . 0.0 111.213 -178.767 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 57.1 t60 -164.66 99.14 0.79 Allowed 'General case' 0 N--CA 1.485 1.289 0 CA-C-N 116.766 -0.197 . . . . 0.0 111.06 179.63 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . 0.619 HE22 ' H ' ' A' ' 37' ' ' GLY . 68.3 mt-30 -125.67 -175.15 3.26 Favored 'General case' 0 CA--C 1.491 -1.301 0 N-CA-C 107.862 -1.162 . . . . 0.0 107.862 -179.99 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -169.7 103.28 0.33 Allowed 'General case' 0 CA--C 1.542 0.644 0 CA-C-N 115.011 -0.995 . . . . 0.0 109.395 179.026 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 9.3 mp -110.75 151.35 27.88 Favored 'General case' 0 N--CA 1.489 1.515 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 -179.932 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 61.6 t -143.98 119.06 4.0 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.245 0 CA-C-O 118.69 -0.671 . . . . 0.0 109.543 179.084 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 17.3 m-85 -70.19 157.2 38.08 Favored 'General case' 0 N--CA 1.477 0.923 0 N-CA-C 107.727 -1.212 . . . . 0.0 107.727 177.542 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 14.6 t80 -170.99 -60.0 0.02 OUTLIER 'General case' 0 N--CA 1.482 1.156 0 CA-C-O 122.315 1.055 . . . . 0.0 109.482 179.278 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.0 89.64 0.0 OUTLIER 'General case' 0 N--CA 1.456 -0.152 0 CA-C-N 113.891 -1.504 . . . . 0.0 112.875 -177.973 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 43.4 mt-10 -61.42 158.22 15.14 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 115.166 -0.924 . . . . 0.0 110.782 179.037 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 12.0 m-20 -139.98 135.26 32.55 Favored 'General case' 0 N--CA 1.483 1.21 0 C-N-CA 122.769 0.427 . . . . 0.0 110.399 -179.956 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 18.1 t -84.34 -115.98 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.475 0.802 0 N-CA-C 108.35 -0.981 . . . . 0.0 108.35 179.355 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -109.32 54.25 0.55 Allowed Glycine 0 N--CA 1.473 1.112 0 N-CA-C 111.254 -0.738 . . . . 0.0 111.254 -179.986 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' SER . . . . . 0.592 ' HG ' ' HZ2' ' A' ' 28' ' ' LYS . 82.8 p -77.49 126.96 31.72 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 109.0 -0.741 . . . . 0.0 109.0 178.469 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . 0.422 HD22 ' CD ' ' B' ' 11' ' ' GLU . 47.5 t30 -66.7 100.92 0.74 Allowed 'General case' 0 N--CA 1.471 0.599 0 N-CA-C 108.611 -0.885 . . . . 0.0 108.611 178.593 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.592 ' HZ2' ' HG ' ' A' ' 26' ' ' SER . 67.2 mttm -95.3 128.88 42.51 Favored 'General case' 0 N--CA 1.481 1.089 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 -179.155 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.71 -132.12 0.01 OUTLIER Glycine 0 CA--C 1.533 1.203 0 N-CA-C 110.775 -0.93 . . . . 0.0 110.775 178.907 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.77 126.91 37.6 Favored 'General case' 0 N--CA 1.484 1.237 0 CA-C-N 117.097 0.448 . . . . 0.0 110.016 179.345 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 33.0 mt -91.31 159.17 2.83 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.496 0 N-CA-C 106.631 -1.618 . . . . 0.0 106.631 178.416 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 42.9 mt -138.25 92.86 0.83 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.468 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 -178.972 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 54.05 106.23 0.01 OUTLIER Glycine 0 CA--C 1.53 1.002 0 CA-C-N 115.933 -0.576 . . . . 0.0 114.162 177.239 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 97.9 mt -72.26 153.5 41.52 Favored 'General case' 0 CA--C 1.539 0.536 0 N-CA-C 107.27 -1.382 . . . . 0.0 107.27 176.703 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 27.2 ttt -147.07 138.34 24.01 Favored 'General case' 0 N--CA 1.477 0.879 0 N-CA-C 108.761 -0.829 . . . . 0.0 108.761 179.147 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 61.9 t -159.69 153.51 5.02 Favored 'Isoleucine or valine' 0 C--N 1.342 0.262 0 N-CA-C 106.596 -1.631 . . . . 0.0 106.596 -179.279 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . 0.619 ' H ' HE22 ' A' ' 15' ' ' GLN . . . 55.98 73.56 0.42 Allowed Glycine 0 C--N 1.313 -0.697 0 N-CA-C 111.663 -0.575 . . . . 0.0 111.663 177.987 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 174.65 -161.58 31.34 Favored Glycine 0 C--N 1.335 0.483 0 N-CA-C 111.086 -0.806 . . . . 0.0 111.086 -179.828 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 23.5 m -124.29 139.63 50.04 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.951 0 C-N-CA 122.762 0.425 . . . . 0.0 110.084 179.744 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 26.1 t . . . . . 0 C--O 1.221 -0.447 0 CA-C-O 117.635 -1.174 . . . . 0.0 111.108 179.37 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 77.0 m-85 . . . . . 0 N--CA 1.474 0.76 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 73.5 mtp180 -143.69 141.32 30.47 Favored 'General case' 0 N--CA 1.48 1.055 0 N-CA-C 109.092 -0.707 . . . . 0.0 109.092 -179.972 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 76.7 m80 -149.83 119.49 7.01 Favored 'General case' 0 N--CA 1.472 0.627 0 N-CA-C 108.93 -0.767 . . . . 0.0 108.93 179.104 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 7' ' ' ASP . . . . . . . . . . . . . 9.6 m-20 -67.77 149.4 49.97 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.196 -179.609 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 8' ' ' SER . . . . . 0.488 ' HG ' ' H ' ' B' ' 9' ' ' GLY . 7.0 t -167.15 171.4 10.93 Favored 'General case' 0 N--CA 1.473 0.676 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 178.451 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 9' ' ' GLY . . . . . 0.488 ' H ' ' HG ' ' B' ' 8' ' ' SER . . . 122.11 24.06 2.32 Favored Glycine 0 N--CA 1.487 2.072 0 N-CA-C 112.05 -0.42 . . . . 0.0 112.05 179.38 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 41.4 p90 -56.75 128.15 35.11 Favored 'General case' 0 N--CA 1.472 0.669 0 N-CA-C 112.071 0.397 . . . . 0.0 112.071 -179.834 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 11' ' ' GLU . . . . . 0.422 ' CD ' HD22 ' A' ' 27' ' ' ASN . 45.7 mt-10 -84.99 155.63 21.49 Favored 'General case' 0 N--CA 1.47 0.557 0 N-CA-C 109.268 -0.642 . . . . 0.0 109.268 178.589 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -154.47 124.35 0.78 Allowed 'Isoleucine or valine' 0 C--O 1.234 0.249 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 178.538 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 34.2 m80 -107.27 161.2 15.0 Favored 'General case' 0 N--CA 1.491 1.585 0 CA-C-N 118.41 0.55 . . . . 0.0 111.155 -178.774 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 58.2 t60 -164.72 98.87 0.78 Allowed 'General case' 0 N--CA 1.485 1.301 0 CA-C-O 119.64 -0.219 . . . . 0.0 111.001 179.636 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . 0.642 HE22 ' H ' ' B' ' 37' ' ' GLY . 68.3 mt-30 -125.19 -175.48 3.32 Favored 'General case' 0 CA--C 1.492 -1.275 0 N-CA-C 107.832 -1.173 . . . . 0.0 107.832 179.995 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -169.62 103.13 0.33 Allowed 'General case' 0 CA--C 1.541 0.6 0 CA-C-N 114.944 -1.025 . . . . 0.0 109.334 179.023 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 9.4 mp -110.67 151.23 27.94 Favored 'General case' 0 N--CA 1.489 1.507 0 N-CA-C 108.695 -0.854 . . . . 0.0 108.695 -179.951 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 61.9 t -143.92 118.77 3.91 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.139 0 CA-C-O 118.748 -0.644 . . . . 0.0 109.561 179.07 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 16.6 m-85 -70.45 157.17 38.31 Favored 'General case' 0 N--CA 1.475 0.798 0 N-CA-C 107.638 -1.245 . . . . 0.0 107.638 177.413 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 15.8 t80 -171.66 -59.06 0.02 OUTLIER 'General case' 0 N--CA 1.479 1.007 0 CA-C-O 122.261 1.029 . . . . 0.0 109.619 179.23 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.21 89.88 0.0 OUTLIER 'General case' 0 C--O 1.231 0.112 0 CA-C-N 114.051 -1.431 . . . . 0.0 112.764 -178.108 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 43.8 mt-10 -61.53 158.38 15.13 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 115.276 -0.875 . . . . 0.0 110.828 179.095 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 12.2 m-20 -140.25 135.6 32.48 Favored 'General case' 0 N--CA 1.483 1.196 0 C-N-CA 122.793 0.437 . . . . 0.0 110.416 179.955 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 18.1 t -84.97 -116.1 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.906 0 N-CA-C 108.408 -0.96 . . . . 0.0 108.408 179.499 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -108.45 53.65 0.59 Allowed Glycine 0 N--CA 1.476 1.366 0 N-CA-C 111.083 -0.807 . . . . 0.0 111.083 -179.909 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 26' ' ' SER . . . . . 0.592 ' HG ' ' HZ2' ' B' ' 28' ' ' LYS . 86.0 p -77.35 126.58 31.15 Favored 'General case' 0 C--N 1.329 -0.294 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 178.409 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 27' ' ' ASN . . . . . 0.421 HD22 ' CD ' ' C' ' 11' ' ' GLU . 47.5 t30 -66.74 100.98 0.75 Allowed 'General case' 0 N--CA 1.471 0.608 0 N-CA-C 108.593 -0.892 . . . . 0.0 108.593 178.672 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 28' ' ' LYS . . . . . 0.592 ' HZ2' ' HG ' ' B' ' 26' ' ' SER . 67.1 mttm -95.3 128.91 42.52 Favored 'General case' 0 N--CA 1.481 1.121 0 N-CA-C 109.972 -0.381 . . . . 0.0 109.972 -179.226 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.77 -131.63 0.01 OUTLIER Glycine 0 CA--C 1.535 1.33 0 N-CA-C 110.746 -0.942 . . . . 0.0 110.746 178.904 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -131.18 127.12 37.31 Favored 'General case' 0 N--CA 1.485 1.304 0 C-N-CA 122.704 0.402 . . . . 0.0 110.081 179.431 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 32.8 mt -91.75 158.79 2.86 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.538 0 N-CA-C 106.602 -1.629 . . . . 0.0 106.602 178.516 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 43.1 mt -137.81 92.89 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.502 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 -178.816 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 53.85 106.17 0.01 OUTLIER Glycine 0 CA--C 1.53 0.993 0 CA-C-N 116.021 -0.536 . . . . 0.0 114.212 177.237 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 97.7 mt -72.12 153.4 41.69 Favored 'General case' 0 CA--C 1.539 0.53 0 N-CA-C 107.364 -1.346 . . . . 0.0 107.364 176.651 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 27.1 ttt -146.82 138.05 24.16 Favored 'General case' 0 N--CA 1.478 0.954 0 N-CA-C 108.701 -0.851 . . . . 0.0 108.701 179.21 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 62.3 t -159.54 153.47 5.14 Favored 'Isoleucine or valine' 0 C--N 1.344 0.356 0 N-CA-C 106.52 -1.659 . . . . 0.0 106.52 -179.273 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . 0.642 ' H ' HE22 ' B' ' 15' ' ' GLN . . . 56.03 73.23 0.45 Allowed Glycine 0 C--N 1.313 -0.696 0 N-CA-C 111.686 -0.566 . . . . 0.0 111.686 178.005 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 174.98 -161.5 30.92 Favored Glycine 0 C--N 1.334 0.43 0 N-CA-C 111.056 -0.818 . . . . 0.0 111.056 -179.865 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 24.1 m -124.4 139.6 50.21 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.929 0 C-N-CA 122.751 0.421 . . . . 0.0 110.072 179.695 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 26.5 t . . . . . 0 C--O 1.219 -0.52 0 CA-C-O 117.651 -1.166 . . . . 0.0 111.054 179.381 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 77.1 m-85 . . . . . 0 N--CA 1.474 0.75 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 73.7 mtp180 -143.72 141.24 30.4 Favored 'General case' 0 N--CA 1.482 1.141 0 N-CA-C 109.005 -0.739 . . . . 0.0 109.005 -179.858 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 76.8 m80 -149.9 119.39 6.92 Favored 'General case' 0 N--CA 1.471 0.594 0 N-CA-C 108.798 -0.816 . . . . 0.0 108.798 179.159 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' C' C ' 7' ' ' ASP . . . . . . . . . . . . . 9.0 m-20 -67.71 149.29 50.17 Favored 'General case' 0 N--CA 1.463 0.218 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.244 -179.562 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' C' C ' 8' ' ' SER . . . . . 0.445 ' HG ' ' H ' ' C' ' 9' ' ' GLY . 6.7 t -167.12 171.15 11.21 Favored 'General case' 0 N--CA 1.472 0.652 0 N-CA-C 109.502 -0.555 . . . . 0.0 109.502 178.424 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' C' C ' 9' ' ' GLY . . . . . 0.445 ' H ' ' HG ' ' C' ' 8' ' ' SER . . . 122.49 23.92 2.26 Favored Glycine 0 N--CA 1.487 2.034 0 N-CA-C 111.968 -0.453 . . . . 0.0 111.968 179.38 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 41.5 p90 -56.61 128.16 34.93 Favored 'General case' 0 N--CA 1.471 0.614 0 N-CA-C 112.07 0.396 . . . . 0.0 112.07 -179.85 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' C' C ' 11' ' ' GLU . . . . . 0.421 ' CD ' HD22 ' B' ' 27' ' ' ASN . 45.9 mt-10 -85.02 155.97 21.32 Favored 'General case' 0 N--CA 1.47 0.535 0 N-CA-C 109.24 -0.652 . . . . 0.0 109.24 178.592 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -154.76 124.54 0.76 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 N-CA-C 108.168 -1.049 . . . . 0.0 108.168 178.525 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 33.9 m80 -107.39 161.23 15.0 Favored 'General case' 0 N--CA 1.49 1.573 0 CA-C-N 118.397 0.544 . . . . 0.0 111.181 -178.717 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 57.3 t60 -164.83 99.22 0.77 Allowed 'General case' 0 N--CA 1.485 1.286 0 CA-C-N 116.77 -0.196 . . . . 0.0 111.094 179.651 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' C' C ' 15' ' ' GLN . . . . . 0.632 HE22 ' H ' ' C' ' 37' ' ' GLY . 68.1 mt-30 -125.79 -175.34 3.32 Favored 'General case' 0 CA--C 1.489 -1.373 0 N-CA-C 107.904 -1.147 . . . . 0.0 107.904 -179.957 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -169.64 103.19 0.33 Allowed 'General case' 0 CA--C 1.541 0.624 0 CA-C-N 114.888 -1.051 . . . . 0.0 109.331 179.062 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 9.4 mp -110.67 150.92 28.32 Favored 'General case' 0 N--CA 1.488 1.441 0 N-CA-C 108.712 -0.848 . . . . 0.0 108.712 179.968 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 61.1 t -143.66 118.97 4.29 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.175 0 CA-C-O 118.765 -0.636 . . . . 0.0 109.61 179.029 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 16.6 m-85 -70.49 157.28 38.14 Favored 'General case' 0 N--CA 1.475 0.802 0 N-CA-C 107.664 -1.236 . . . . 0.0 107.664 177.436 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 15.4 t80 -171.59 -59.31 0.02 OUTLIER 'General case' 0 N--CA 1.478 0.953 0 CA-C-O 122.259 1.028 . . . . 0.0 109.642 179.195 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.12 89.96 0.0 OUTLIER 'General case' 0 C--O 1.231 0.11 0 CA-C-N 114.041 -1.436 . . . . 0.0 112.753 -178.076 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 43.9 mt-10 -61.6 158.23 15.68 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.219 -0.9 . . . . 0.0 110.833 179.047 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 12.3 m-20 -139.92 135.9 33.32 Favored 'General case' 0 N--CA 1.483 1.199 0 C-N-CA 122.861 0.464 . . . . 0.0 110.343 -179.977 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 18.2 t -85.27 -116.01 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.902 0 N-CA-C 108.414 -0.958 . . . . 0.0 108.414 179.444 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -108.58 53.42 0.6 Allowed Glycine 0 N--CA 1.475 1.257 0 N-CA-C 111.107 -0.797 . . . . 0.0 111.107 -179.918 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' C' C ' 26' ' ' SER . . . . . 0.563 ' HG ' ' HZ2' ' C' ' 28' ' ' LYS . 85.9 p -77.3 126.73 31.4 Favored 'General case' 0 C--N 1.329 -0.32 0 N-CA-C 109.122 -0.695 . . . . 0.0 109.122 178.508 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' C' C ' 27' ' ' ASN . . . . . 0.411 HD22 ' CD ' ' A' ' 11' ' ' GLU . 47.3 t30 -66.79 101.11 0.77 Allowed 'General case' 0 N--CA 1.471 0.582 0 N-CA-C 108.633 -0.877 . . . . 0.0 108.633 178.625 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' C' C ' 28' ' ' LYS . . . . . 0.563 ' HZ2' ' HG ' ' C' ' 26' ' ' SER . 67.1 mttm -95.34 128.99 42.63 Favored 'General case' 0 N--CA 1.483 1.2 0 N-CA-C 109.886 -0.413 . . . . 0.0 109.886 -179.117 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.84 -131.85 0.01 OUTLIER Glycine 0 CA--C 1.535 1.293 0 N-CA-C 110.858 -0.897 . . . . 0.0 110.858 178.844 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.96 126.66 36.63 Favored 'General case' 0 N--CA 1.486 1.356 0 C-N-CA 122.822 0.449 . . . . 0.0 110.003 179.456 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 32.5 mt -91.33 158.81 2.86 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.525 0 N-CA-C 106.684 -1.599 . . . . 0.0 106.684 178.334 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 42.5 mt -137.99 92.89 0.86 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.505 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 -178.799 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 53.93 106.09 0.01 OUTLIER Glycine 0 CA--C 1.529 0.966 0 CA-C-N 115.921 -0.581 . . . . 0.0 114.257 177.229 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 97.6 mt -72.05 153.3 41.82 Favored 'General case' 0 CA--C 1.537 0.461 0 N-CA-C 107.328 -1.36 . . . . 0.0 107.328 176.655 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 27.3 ttt -146.63 138.09 24.42 Favored 'General case' 0 N--CA 1.477 0.891 0 N-CA-C 108.74 -0.837 . . . . 0.0 108.74 179.214 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 61.1 t -159.57 153.56 5.07 Favored 'Isoleucine or valine' 0 C--N 1.345 0.372 0 N-CA-C 106.566 -1.642 . . . . 0.0 106.566 -179.251 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' C' C ' 37' ' ' GLY . . . . . 0.632 ' H ' HE22 ' C' ' 15' ' ' GLN . . . 55.89 73.15 0.46 Allowed Glycine 0 C--N 1.314 -0.671 0 N-CA-C 111.626 -0.59 . . . . 0.0 111.626 177.951 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 175.03 -161.75 31.24 Favored Glycine 0 C--N 1.335 0.479 0 N-CA-C 111.054 -0.818 . . . . 0.0 111.054 -179.865 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 23.5 m -124.2 139.67 49.88 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.923 0 C-N-CA 122.785 0.434 . . . . 0.0 110.054 179.727 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 27.7 t . . . . . 0 C--O 1.221 -0.424 0 CA-C-O 117.655 -1.164 . . . . 0.0 110.98 179.336 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 85.9 m-85 . . . . . 0 N--CA 1.473 0.705 0 N-CA-C 108.113 -1.069 . . . . 0.0 108.113 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' D' D ' 5' ' ' ARG . . . . . . . . . . . . . 73.9 mtp180 -147.52 141.05 25.45 Favored 'General case' 0 N--CA 1.473 0.7 0 N-CA-C 108.967 -0.753 . . . . 0.0 108.967 179.637 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 77.0 m80 -149.2 123.55 9.62 Favored 'General case' 0 CA--C 1.539 0.519 0 N-CA-C 107.926 -1.138 . . . . 0.0 107.926 175.967 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' D' D ' 7' ' ' ASP . . . . . . . . . . . . . 6.3 m-20 -63.42 133.41 53.94 Favored 'General case' 0 C--N 1.32 -0.688 0 C-N-CA 126.937 2.095 . . . . 0.0 114.798 176.152 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' D' D ' 8' ' ' SER . . . . . 0.487 ' HG ' ' H ' ' D' ' 9' ' ' GLY . 5.9 t -154.04 173.52 15.91 Favored 'General case' 0 N--CA 1.477 0.925 0 CA-C-N 118.548 0.613 . . . . 0.0 110.443 176.799 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' D' D ' 9' ' ' GLY . . . . . 0.487 ' H ' ' HG ' ' D' ' 8' ' ' SER . . . 124.23 20.38 2.47 Favored Glycine 0 N--CA 1.484 1.864 0 N-CA-C 111.99 -0.444 . . . . 0.0 111.99 176.203 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 37.2 p90 -55.67 130.32 42.67 Favored 'General case' 0 CA--C 1.545 0.753 0 CA-C-O 121.103 0.478 . . . . 0.0 111.914 -177.388 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' D' D ' 11' ' ' GLU . . . . . 0.454 ' CG ' HD22 ' F' ' 27' ' ' ASN . 46.0 mt-10 -84.87 153.77 22.69 Favored 'General case' 0 N--CA 1.472 0.64 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 177.886 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.0 p -150.91 129.01 2.57 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.594 0 N-CA-C 106.937 -1.505 . . . . 0.0 106.937 172.73 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 24.6 m80 -100.86 161.98 13.22 Favored 'General case' 0 N--CA 1.481 1.116 0 C-N-CA 123.911 0.884 . . . . 0.0 113.168 176.722 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 61.0 t60 -165.0 105.27 0.79 Allowed 'General case' 0 N--CA 1.486 1.354 0 N-CA-C 109.694 -0.484 . . . . 0.0 109.694 172.242 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' D' D ' 15' ' ' GLN . . . . . 0.664 HE22 ' H ' ' D' ' 37' ' ' GLY . 69.1 mt-30 -128.59 -176.33 3.8 Favored 'General case' 0 CA--C 1.485 -1.534 0 N-CA-C 107.255 -1.387 . . . . 0.0 107.255 178.892 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 88.8 tttt -166.87 109.51 0.7 Allowed 'General case' 0 C--O 1.238 0.487 0 N-CA-C 107.926 -1.139 . . . . 0.0 107.926 176.779 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 10.5 mp -115.69 153.16 31.85 Favored 'General case' 0 N--CA 1.489 1.502 0 N-CA-C 107.198 -1.408 . . . . 0.0 107.198 178.205 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 52.5 t -141.95 124.03 13.61 Favored 'Isoleucine or valine' 0 C--N 1.362 1.152 0 N-CA-C 108.668 -0.864 . . . . 0.0 108.668 174.283 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 16.0 m-85 -62.62 150.81 39.77 Favored 'General case' 0 C--N 1.348 0.513 0 C-N-CA 124.308 1.043 . . . . 0.0 110.719 169.695 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 11.3 t80 -170.51 -67.22 0.02 OUTLIER 'General case' 0 N--CA 1.475 0.788 0 N-CA-C 107.983 -1.117 . . . . 0.0 107.983 178.55 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -38.61 94.99 0.01 OUTLIER 'General case' 0 N--CA 1.451 -0.403 0 CA-C-N 113.855 -1.521 . . . . 0.0 111.586 -175.866 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 45.8 mt-10 -64.47 159.09 22.21 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 114.293 -1.321 . . . . 0.0 110.504 178.491 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 12.2 m-20 -139.87 139.47 36.27 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-O 121.253 0.549 . . . . 0.0 109.637 178.609 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' D' D ' 24' ' ' VAL . . . . . . . . . . . . . 19.4 t -88.17 -119.86 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.483 1.217 0 N-CA-C 107.597 -1.26 . . . . 0.0 107.597 179.58 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . -111.47 61.8 0.3 Allowed Glycine 0 C--N 1.368 2.359 0 C-N-CA 118.222 -1.942 . . . . 0.0 109.206 178.763 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' D' D ' 26' ' ' SER . . . . . 0.617 ' HG ' ' HZ2' ' D' ' 28' ' ' LYS . 92.8 p -68.04 121.59 16.44 Favored 'General case' 0 C--O 1.24 0.595 0 CA-C-O 116.453 -1.737 . . . . 0.0 112.517 168.985 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' D' D ' 27' ' ' ASN . . . . . 0.415 HD22 ' CG ' ' E' ' 11' ' ' GLU . 53.8 t30 -62.52 101.79 0.27 Allowed 'General case' 0 N--CA 1.474 0.765 0 CA-C-N 121.603 2.001 . . . . 0.0 109.453 173.65 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' D' D ' 28' ' ' LYS . . . . . 0.617 ' HZ2' ' HG ' ' D' ' 26' ' ' SER . 66.8 mttm -96.84 128.28 43.64 Favored 'General case' 0 N--CA 1.487 1.387 0 CA-C-N 118.842 0.746 . . . . 0.0 109.35 178.996 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -55.21 -134.81 0.0 OUTLIER Glycine 0 CA--C 1.532 1.135 0 C-N-CA 123.793 0.711 . . . . 0.0 112.343 174.925 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -129.42 130.96 46.62 Favored 'General case' 0 C--N 1.371 1.507 0 CA-C-N 115.022 -0.589 . . . . 0.0 110.121 176.231 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 38.8 mt -91.64 161.75 2.52 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.338 0 N-CA-C 106.148 -1.797 . . . . 0.0 106.148 177.499 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . 0.28 43.1 mt -141.01 105.06 1.57 Allowed 'Isoleucine or valine' 0 C--N 1.363 1.191 0 N-CA-C 106.231 -1.766 . . . . 0.0 106.231 172.511 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.6 98.11 0.01 OUTLIER Glycine 0 CA--C 1.533 1.21 0 CA-C-O 116.312 -2.382 . . . . 0.0 112.198 169.074 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 97.0 mt -70.0 157.61 37.17 Favored 'General case' 0 CA--C 1.539 0.55 0 CA-C-N 122.355 3.078 . . . . 0.0 107.217 176.055 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 26.1 ttt -147.18 148.92 32.02 Favored 'General case' 0 N--CA 1.482 1.161 0 N-CA-C 106.373 -1.714 . . . . 0.0 106.373 174.269 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 88.5 t -165.22 159.14 1.18 Allowed 'Isoleucine or valine' 0 C--O 1.248 1.004 0 N-CA-C 105.302 -2.11 . . . . 0.0 105.302 177.15 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' D' D ' 37' ' ' GLY . . . . . 0.664 ' H ' HE22 ' D' ' 15' ' ' GLN . . . 60.54 64.84 3.77 Favored Glycine 0 N--CA 1.442 -0.917 0 C-N-CA 117.24 -2.41 . . . . 0.0 113.756 174.581 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 169.8 -160.7 33.85 Favored Glycine 0 N--CA 1.47 0.956 0 CA-C-O 117.808 -1.551 . . . . 0.0 112.304 -178.987 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 23.2 m -120.37 139.31 48.06 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.256 0 CA-C-N 118.829 1.315 . . . . 0.0 110.348 -177.003 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 25.4 t . . . . . 0 C--O 1.203 -1.35 0 CA-C-N 118.211 0.46 . . . . 0.0 110.102 173.766 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 77.8 m-85 . . . . . 0 N--CA 1.475 0.812 0 N-CA-C 109.904 -0.406 . . . . 0.0 109.904 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' E' E ' 5' ' ' ARG . . . . . . . . . . . . . 74.1 mtp180 -143.55 141.72 30.81 Favored 'General case' 0 N--CA 1.476 0.837 0 N-CA-C 109.388 -0.597 . . . . 0.0 109.388 179.875 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 76.7 m80 -150.31 118.57 6.38 Favored 'General case' 0 N--CA 1.471 0.62 0 N-CA-C 108.994 -0.743 . . . . 0.0 108.994 179.215 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' E' E ' 7' ' ' ASP . . . . . . . . . . . . . 8.6 m-20 -66.82 149.48 50.51 Favored 'General case' 0 N--CA 1.464 0.24 0 O-C-N 123.388 0.43 . . . . 0.0 111.608 -179.552 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' E' E ' 8' ' ' SER . . . . . 0.463 ' HG ' ' H ' ' E' ' 9' ' ' GLY . 6.0 t -167.63 171.72 9.98 Favored 'General case' 0 N--CA 1.477 0.878 0 CA-C-N 115.938 -0.574 . . . . 0.0 109.606 178.077 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' E' E ' 9' ' ' GLY . . . . . 0.463 ' H ' ' HG ' ' E' ' 8' ' ' SER . . . 123.22 23.91 2.09 Favored Glycine 0 N--CA 1.482 1.754 0 N-CA-C 111.843 -0.503 . . . . 0.0 111.843 179.078 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 37.4 p90 -56.29 127.33 30.36 Favored 'General case' 0 N--CA 1.472 0.674 0 N-CA-C 112.621 0.6 . . . . 0.0 112.621 -179.283 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' E' E ' 11' ' ' GLU . . . . . 0.415 ' CG ' HD22 ' D' ' 27' ' ' ASN . 46.0 mt-10 -83.36 156.77 22.83 Favored 'General case' 0 N--CA 1.476 0.856 0 N-CA-C 109.489 -0.56 . . . . 0.0 109.489 177.973 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -156.54 122.89 0.54 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.646 0 N-CA-C 108.324 -0.991 . . . . 0.0 108.324 178.257 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 36.5 m80 -106.88 160.24 15.66 Favored 'General case' 0 N--CA 1.482 1.135 0 C-N-CA 122.855 0.462 . . . . 0.0 111.238 -177.944 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 58.1 t60 -164.61 99.18 0.79 Allowed 'General case' 0 N--CA 1.487 1.38 0 CA-C-N 116.859 -0.155 . . . . 0.0 111.013 -179.842 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' E' E ' 15' ' ' GLN . . . . . 0.638 HE22 ' H ' ' E' ' 37' ' ' GLY . 69.3 mt-30 -125.42 -175.06 3.22 Favored 'General case' 0 CA--C 1.492 -1.263 0 N-CA-C 107.835 -1.172 . . . . 0.0 107.835 -179.98 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -169.54 103.85 0.34 Allowed 'General case' 0 CA--C 1.54 0.591 0 CA-C-N 114.9 -1.045 . . . . 0.0 109.109 179.015 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 9.6 mp -111.03 150.16 29.7 Favored 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 -179.639 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 46.1 t -144.04 118.17 3.52 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.22 0 CA-C-O 118.928 -0.558 . . . . 0.0 109.903 178.646 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 19.7 m-85 -69.32 155.27 40.7 Favored 'General case' 0 C--N 1.357 0.908 0 N-CA-C 107.569 -1.271 . . . . 0.0 107.569 176.798 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 14.0 t80 -173.41 -56.94 0.02 OUTLIER 'General case' 0 N--CA 1.48 1.072 0 CA-C-O 121.624 0.726 . . . . 0.0 110.136 179.163 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -42.74 88.48 0.0 OUTLIER 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 114.425 -1.261 . . . . 0.0 112.76 -179.051 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 44.4 mt-10 -60.11 158.37 11.36 Favored 'General case' 0 N--CA 1.471 0.619 0 CA-C-N 115.039 -0.982 . . . . 0.0 110.944 179.535 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 11.7 m-20 -140.34 135.02 31.75 Favored 'General case' 0 N--CA 1.483 1.183 0 C-N-CA 122.653 0.381 . . . . 0.0 110.687 -179.829 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 21.4 t -84.55 -115.51 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.939 0 N-CA-C 108.61 -0.885 . . . . 0.0 108.61 179.416 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . -108.65 53.65 0.58 Allowed Glycine 0 C--N 1.347 1.139 0 N-CA-C 111.317 -0.713 . . . . 0.0 111.317 -179.91 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' E' E ' 26' ' ' SER . . . . . 0.619 ' HG ' ' HZ2' ' E' ' 28' ' ' LYS . 86.1 p -77.15 126.37 30.84 Favored 'General case' 0 N--CA 1.471 0.577 0 N-CA-C 109.336 -0.616 . . . . 0.0 109.336 178.259 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' E' E ' 27' ' ' ASN . . . . . 0.436 HD22 ' CG ' ' F' ' 11' ' ' GLU . 49.2 t30 -66.22 100.64 0.63 Allowed 'General case' 0 N--CA 1.471 0.612 0 N-CA-C 108.079 -1.082 . . . . 0.0 108.079 178.442 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' E' E ' 28' ' ' LYS . . . . . 0.619 ' HZ2' ' HG ' ' E' ' 26' ' ' SER . 66.5 mttm -95.39 127.67 41.62 Favored 'General case' 0 N--CA 1.483 1.182 0 N-CA-C 109.305 -0.628 . . . . 0.0 109.305 -179.15 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.36 -128.93 0.01 OUTLIER Glycine 0 CA--C 1.537 1.462 0 N-CA-C 111.013 -0.835 . . . . 0.0 111.013 179.163 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -131.67 127.1 36.24 Favored 'General case' 0 N--CA 1.484 1.236 0 CA-C-N 117.307 0.554 . . . . 0.0 110.939 -179.62 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 31.2 mt -91.09 160.4 2.71 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.238 0 N-CA-C 106.338 -1.727 . . . . 0.0 106.338 178.306 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 41.6 mt -139.29 93.69 0.78 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.766 0 N-CA-C 109.653 -0.499 . . . . 0.0 109.653 179.879 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 53.54 105.96 0.01 OUTLIER Glycine 0 CA--C 1.531 1.053 0 CA-C-N 116.11 -0.495 . . . . 0.0 114.157 177.603 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 97.7 mt -72.03 153.72 41.58 Favored 'General case' 0 CA--C 1.542 0.636 0 N-CA-C 107.206 -1.405 . . . . 0.0 107.206 176.523 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 27.6 ttt -146.41 140.23 26.16 Favored 'General case' 0 N--CA 1.485 1.285 0 N-CA-C 108.005 -1.109 . . . . 0.0 108.005 178.841 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 80.2 t -161.18 152.86 4.31 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.389 0 N-CA-C 106.358 -1.719 . . . . 0.0 106.358 -179.208 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' E' E ' 37' ' ' GLY . . . . . 0.638 ' H ' HE22 ' E' ' 15' ' ' GLN . . . 55.56 73.81 0.39 Allowed Glycine 0 C--N 1.316 -0.54 0 N-CA-C 111.633 -0.587 . . . . 0.0 111.633 178.199 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 175.91 -159.34 26.79 Favored Glycine 0 C--O 1.213 -1.166 0 N-CA-C 111.313 -0.715 . . . . 0.0 111.313 -179.708 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 23.7 m -127.16 138.81 53.71 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.83 0 N-CA-C 109.332 -0.618 . . . . 0.0 109.332 179.776 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 27.6 t . . . . . 0 CA--C 1.537 0.453 0 CA-C-O 117.986 -1.007 . . . . 0.0 111.106 179.739 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 77.7 m-85 . . . . . 0 N--CA 1.476 0.831 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' F' F ' 5' ' ' ARG . . . . . . . . . . . . . 74.2 mtp180 -143.54 141.39 30.68 Favored 'General case' 0 N--CA 1.479 1.023 0 N-CA-C 109.07 -0.715 . . . . 0.0 109.07 179.933 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 76.8 m80 -150.08 118.48 6.46 Favored 'General case' 0 N--CA 1.472 0.658 0 N-CA-C 108.957 -0.757 . . . . 0.0 108.957 179.139 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' F' F ' 7' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -66.97 149.79 50.14 Favored 'General case' 0 N--CA 1.463 0.21 0 O-C-N 123.434 0.459 . . . . 0.0 111.632 -179.366 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' F' F ' 8' ' ' SER . . . . . 0.446 ' HG ' ' H ' ' F' ' 9' ' ' GLY . 6.1 t -167.73 172.27 9.37 Favored 'General case' 0 N--CA 1.476 0.869 0 CA-C-N 115.885 -0.598 . . . . 0.0 109.564 178.068 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' F' F ' 9' ' ' GLY . . . . . 0.446 ' H ' ' HG ' ' F' ' 8' ' ' SER . . . 122.76 23.64 2.24 Favored Glycine 0 N--CA 1.483 1.789 0 N-CA-C 111.903 -0.479 . . . . 0.0 111.903 179.003 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 37.6 p90 -56.1 127.47 30.74 Favored 'General case' 0 N--CA 1.473 0.679 0 N-CA-C 112.615 0.598 . . . . 0.0 112.615 -179.296 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' F' F ' 11' ' ' GLU . . . . . 0.436 ' CG ' HD22 ' E' ' 27' ' ' ASN . 45.9 mt-10 -83.45 156.79 22.72 Favored 'General case' 0 N--CA 1.477 0.875 0 N-CA-C 109.514 -0.55 . . . . 0.0 109.514 177.994 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -156.45 122.75 0.54 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.696 0 N-CA-C 108.297 -1.001 . . . . 0.0 108.297 178.274 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 37.5 m80 -106.65 160.36 15.51 Favored 'General case' 0 N--CA 1.483 1.218 0 C-N-CA 122.8 0.44 . . . . 0.0 111.294 -177.997 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 58.7 t60 -164.86 99.65 0.77 Allowed 'General case' 0 N--CA 1.486 1.374 0 CA-C-N 116.865 -0.152 . . . . 0.0 111.131 -179.775 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' F' F ' 15' ' ' GLN . . . . . 0.629 HE22 ' H ' ' F' ' 37' ' ' GLY . 69.3 mt-30 -126.15 -174.68 3.16 Favored 'General case' 0 CA--C 1.488 -1.428 0 N-CA-C 108.02 -1.104 . . . . 0.0 108.02 -179.893 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -169.86 103.93 0.32 Allowed 'General case' 0 CA--C 1.541 0.61 0 CA-C-N 114.677 -1.147 . . . . 0.0 109.218 178.969 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 9.6 mp -110.93 149.92 29.96 Favored 'General case' 0 N--CA 1.489 1.518 0 N-CA-C 108.933 -0.766 . . . . 0.0 108.933 -179.704 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 46.3 t -143.85 118.32 3.77 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.223 0 CA-C-O 118.975 -0.536 . . . . 0.0 109.827 178.653 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 19.5 m-85 -69.4 155.15 40.92 Favored 'General case' 0 C--N 1.358 0.96 0 N-CA-C 107.506 -1.294 . . . . 0.0 107.506 176.721 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 14.9 t80 -173.13 -57.1 0.02 OUTLIER 'General case' 0 N--CA 1.483 1.198 0 CA-C-O 121.564 0.697 . . . . 0.0 109.613 179.245 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -42.52 88.47 0.0 OUTLIER 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 114.716 -1.129 . . . . 0.0 112.856 -179.015 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 44.1 mt-10 -60.28 158.2 12.1 Favored 'General case' 0 N--CA 1.472 0.643 0 CA-C-N 115.085 -0.961 . . . . 0.0 110.999 179.437 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 12.1 m-20 -140.2 134.97 31.9 Favored 'General case' 0 N--CA 1.482 1.132 0 C-N-CA 122.752 0.421 . . . . 0.0 110.784 -179.822 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' F' F ' 24' ' ' VAL . . . . . . . . . . . . . 21.3 t -84.51 -115.73 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.986 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 179.327 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -108.36 53.31 0.6 Allowed Glycine 0 N--CA 1.477 1.373 0 N-CA-C 111.154 -0.778 . . . . 0.0 111.154 -179.872 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' F' F ' 26' ' ' SER . . . . . 0.596 ' HG ' ' HZ2' ' F' ' 28' ' ' LYS . 87.3 p -76.75 126.36 30.85 Favored 'General case' 0 N--CA 1.47 0.535 0 N-CA-C 109.313 -0.625 . . . . 0.0 109.313 178.141 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' F' F ' 27' ' ' ASN . . . . . 0.454 HD22 ' CG ' ' D' ' 11' ' ' GLU . 48.7 t30 -66.48 100.7 0.68 Allowed 'General case' 0 N--CA 1.471 0.609 0 N-CA-C 108.195 -1.039 . . . . 0.0 108.195 178.412 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' F' F ' 28' ' ' LYS . . . . . 0.596 ' HZ2' ' HG ' ' F' ' 26' ' ' SER . 66.6 mttm -95.39 127.65 41.61 Favored 'General case' 0 N--CA 1.483 1.221 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 -179.082 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.53 -129.15 0.01 OUTLIER Glycine 0 CA--C 1.539 1.576 0 N-CA-C 111.139 -0.784 . . . . 0.0 111.139 179.161 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -131.17 126.67 36.23 Favored 'General case' 0 N--CA 1.488 1.451 0 CA-C-N 117.308 0.554 . . . . 0.0 111.058 -179.668 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 32.2 mt -90.95 160.14 2.74 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.237 0 N-CA-C 106.236 -1.764 . . . . 0.0 106.236 178.265 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 41.0 mt -139.09 93.65 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.763 0 N-CA-C 109.671 -0.492 . . . . 0.0 109.671 179.864 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 53.61 106.0 0.01 OUTLIER Glycine 0 CA--C 1.532 1.114 0 CA-C-N 116.099 -0.5 . . . . 0.0 114.121 177.607 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 97.8 mt -72.0 153.94 41.47 Favored 'General case' 0 CA--C 1.54 0.561 0 N-CA-C 107.295 -1.372 . . . . 0.0 107.295 176.589 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 27.5 ttt -146.75 140.21 25.7 Favored 'General case' 0 N--CA 1.481 1.087 0 N-CA-C 108.408 -0.96 . . . . 0.0 108.408 178.819 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 75.8 t -161.13 153.02 4.29 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.472 0 N-CA-C 106.452 -1.685 . . . . 0.0 106.452 -179.073 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' F' F ' 37' ' ' GLY . . . . . 0.629 ' H ' HE22 ' F' ' 15' ' ' GLN . . . 55.67 73.83 0.39 Allowed Glycine 0 C--N 1.316 -0.573 0 N-CA-C 111.543 -0.623 . . . . 0.0 111.543 178.049 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 175.5 -159.99 28.2 Favored Glycine 0 C--O 1.213 -1.195 0 N-CA-C 111.202 -0.759 . . . . 0.0 111.202 -179.723 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 23.3 m -126.36 139.01 52.89 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.824 0 N-CA-C 109.414 -0.588 . . . . 0.0 109.414 179.764 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 28.0 t . . . . . 0 CA--C 1.537 0.48 0 CA-C-O 117.957 -1.021 . . . . 0.0 111.181 179.703 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 77.4 m-85 . . . . . 0 N--CA 1.474 0.744 0 N-CA-C 109.583 -0.525 . . . . 0.0 109.583 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' G' G ' 5' ' ' ARG . . . . . . . . . . . . . 74.1 mtp180 -144.01 140.97 29.88 Favored 'General case' 0 N--CA 1.482 1.162 0 N-CA-C 109.178 -0.675 . . . . 0.0 109.178 -179.671 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 76.6 m80 -149.47 119.84 7.36 Favored 'General case' 0 N--CA 1.472 0.666 0 N-CA-C 109.04 -0.726 . . . . 0.0 109.04 179.016 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 8.7 m-20 -69.05 145.27 53.62 Favored 'General case' 0 CA--C 1.537 0.462 0 O-C-N 123.509 0.505 . . . . 0.0 112.062 -179.167 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' G' G ' 8' ' ' SER . . . . . 0.457 ' HG ' ' H ' ' G' ' 9' ' ' GLY . 5.6 t -163.98 173.6 12.41 Favored 'General case' 0 N--CA 1.47 0.534 0 N-CA-C 109.474 -0.565 . . . . 0.0 109.474 178.2 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' G' G ' 9' ' ' GLY . . . . . 0.457 ' H ' ' HG ' ' G' ' 8' ' ' SER . . . 122.47 23.33 2.37 Favored Glycine 0 N--CA 1.48 1.613 0 N-CA-C 111.731 -0.548 . . . . 0.0 111.731 178.942 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 41.7 p90 -56.55 127.68 32.46 Favored 'General case' 0 N--CA 1.475 0.8 0 N-CA-C 112.381 0.511 . . . . 0.0 112.381 -178.862 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 46.1 mt-10 -84.02 155.74 22.59 Favored 'General case' 0 N--CA 1.472 0.638 0 CA-C-O 121.05 0.452 . . . . 0.0 109.935 178.595 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -156.4 123.28 0.57 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.05 0 N-CA-C 108.277 -1.009 . . . . 0.0 108.277 178.545 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 35.3 m80 -106.36 160.21 15.55 Favored 'General case' 0 N--CA 1.481 1.093 0 CA-C-N 115.213 -0.903 . . . . 0.0 110.845 -178.419 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 59.2 t60 -165.64 99.27 0.68 Allowed 'General case' 0 N--CA 1.484 1.238 0 CA-C-N 116.453 -0.339 . . . . 0.0 110.777 179.51 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' G' G ' 15' ' ' GLN . . . . . 0.616 HE22 ' H ' ' G' ' 37' ' ' GLY . 69.4 mt-30 -125.18 -175.0 3.19 Favored 'General case' 0 CA--C 1.493 -1.237 0 N-CA-C 108.031 -1.099 . . . . 0.0 108.031 -179.94 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -169.76 103.46 0.32 Allowed 'General case' 0 CA--C 1.541 0.624 0 CA-C-N 114.904 -1.043 . . . . 0.0 109.338 179.013 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 9.6 mp -109.89 149.5 29.79 Favored 'General case' 0 N--CA 1.49 1.533 0 N-CA-C 109.21 -0.663 . . . . 0.0 109.21 -179.793 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 43.9 t -145.24 117.64 2.31 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.841 0 N-CA-C 109.607 -0.516 . . . . 0.0 109.607 178.33 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 28.8 m-85 -68.11 149.45 49.6 Favored 'General case' 0 C--N 1.37 1.495 0 O-C-N 124.873 1.358 . . . . 0.0 107.842 176.653 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' G' G ' 20' ' ' PHE . . . . . 0.402 ' O ' ' N ' ' G' ' 22' ' ' GLU . 12.0 t80 -171.46 -56.15 0.02 OUTLIER 'General case' 0 N--CA 1.484 1.274 0 N-CA-C 110.205 -0.294 . . . . 0.0 110.205 179.943 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -42.99 90.01 0.0 OUTLIER 'General case' 0 C--N 1.325 -0.485 0 C-N-CA 123.521 0.729 . . . . 0.0 112.343 179.895 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' G' G ' 22' ' ' GLU . . . . . 0.402 ' N ' ' O ' ' G' ' 20' ' ' PHE . 46.1 mt-10 -61.44 158.65 14.28 Favored 'General case' 0 N--CA 1.468 0.43 0 CA-C-N 114.895 -1.048 . . . . 0.0 110.149 179.087 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 12.0 m-20 -140.11 135.49 32.59 Favored 'General case' 0 N--CA 1.481 1.103 0 C-N-CA 122.702 0.401 . . . . 0.0 110.3 -179.897 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' G' G ' 24' ' ' VAL . . . . . . . . . . . . . 21.4 t -85.63 -115.24 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.96 0 N-CA-C 108.331 -0.989 . . . . 0.0 108.331 179.356 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -108.8 53.87 0.57 Allowed Glycine 0 N--CA 1.477 1.43 0 N-CA-C 111.382 -0.687 . . . . 0.0 111.382 -179.883 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' G' G ' 26' ' ' SER . . . . . 0.602 ' HG ' ' HZ2' ' G' ' 28' ' ' LYS . 86.8 p -77.32 126.6 31.19 Favored 'General case' 0 C--N 1.327 -0.413 0 N-CA-C 109.146 -0.686 . . . . 0.0 109.146 178.08 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' G' G ' 27' ' ' ASN . . . . . 0.419 HD22 ' CG ' ' H' ' 11' ' ' GLU . 48.1 t30 -66.38 100.31 0.63 Allowed 'General case' 0 N--CA 1.469 0.504 0 N-CA-C 108.531 -0.915 . . . . 0.0 108.531 178.542 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' G' G ' 28' ' ' LYS . . . . . 0.602 ' HZ2' ' HG ' ' G' ' 26' ' ' SER . 67.1 mttm -94.65 127.56 40.7 Favored 'General case' 0 N--CA 1.484 1.259 0 N-CA-C 109.646 -0.501 . . . . 0.0 109.646 -179.452 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -62.95 -127.11 0.01 OUTLIER Glycine 0 CA--C 1.529 0.962 0 N-CA-C 111.166 -0.774 . . . . 0.0 111.166 179.227 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -132.81 125.73 30.71 Favored 'General case' 0 N--CA 1.47 0.532 0 C-N-CA 122.874 0.47 . . . . 0.0 110.563 -179.141 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 40.9 mt -90.23 162.15 2.52 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.667 0 N-CA-C 106.477 -1.675 . . . . 0.0 106.477 178.356 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 45.0 mt -140.11 95.01 0.78 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.312 0 CA-C-N 119.756 1.162 . . . . 0.0 109.834 178.212 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 53.98 105.26 0.01 OUTLIER Glycine 0 CA--C 1.532 1.115 0 N-CA-C 114.07 0.388 . . . . 0.0 114.07 177.53 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 98.8 mt -71.93 152.85 42.23 Favored 'General case' 0 CA--C 1.539 0.536 0 N-CA-C 107.366 -1.346 . . . . 0.0 107.366 176.729 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 27.5 ttt -146.27 141.13 27.03 Favored 'General case' 0 N--CA 1.477 0.913 0 N-CA-C 107.996 -1.113 . . . . 0.0 107.996 179.084 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 93.0 t -161.45 153.09 4.06 Favored 'Isoleucine or valine' 0 C--O 1.233 0.206 0 N-CA-C 106.553 -1.647 . . . . 0.0 106.553 -179.423 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' G' G ' 37' ' ' GLY . . . . . 0.616 ' H ' HE22 ' G' ' 15' ' ' GLN . . . 55.64 73.84 0.38 Allowed Glycine 0 C--N 1.313 -0.696 0 C-N-CA 121.035 -0.602 . . . . 0.0 111.951 177.701 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 174.75 -158.82 27.11 Favored Glycine 0 C--O 1.215 -1.067 0 N-CA-C 110.499 -1.04 . . . . 0.0 110.499 179.462 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 27.8 m -126.61 139.07 52.79 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.095 0 CA-C-N 117.249 0.525 . . . . 0.0 109.989 -179.824 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 36.3 t . . . . . 0 N--CA 1.469 0.503 0 CA-C-O 117.8 -1.095 . . . . 0.0 111.327 179.581 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 77.9 m-85 . . . . . 0 N--CA 1.474 0.765 0 N-CA-C 109.526 -0.546 . . . . 0.0 109.526 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' H' H ' 5' ' ' ARG . . . . . . . . . . . . . 74.2 mtp180 -144.22 140.87 29.54 Favored 'General case' 0 N--CA 1.481 1.103 0 N-CA-C 109.162 -0.681 . . . . 0.0 109.162 -179.65 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 76.9 m80 -149.46 119.79 7.34 Favored 'General case' 0 N--CA 1.475 0.79 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 179.07 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 8.8 m-20 -69.05 145.27 53.63 Favored 'General case' 0 N--CA 1.468 0.43 0 CA-C-N 116.203 -0.453 . . . . 0.0 112.092 -179.305 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' H' H ' 8' ' ' SER . . . . . 0.465 ' HG ' ' H ' ' H' ' 9' ' ' GLY . 6.3 t -163.97 172.82 13.38 Favored 'General case' 0 N--CA 1.47 0.555 0 N-CA-C 109.458 -0.571 . . . . 0.0 109.458 178.555 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' H' H ' 9' ' ' GLY . . . . . 0.465 ' H ' ' HG ' ' H' ' 8' ' ' SER . . . 122.69 23.5 2.29 Favored Glycine 0 N--CA 1.481 1.67 0 N-CA-C 111.77 -0.532 . . . . 0.0 111.77 179.008 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 40.8 p90 -56.49 127.58 31.9 Favored 'General case' 0 N--CA 1.472 0.674 0 N-CA-C 112.461 0.541 . . . . 0.0 112.461 -178.986 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' H' H ' 11' ' ' GLU . . . . . 0.419 ' CG ' HD22 ' G' ' 27' ' ' ASN . 46.1 mt-10 -83.94 155.85 22.63 Favored 'General case' 0 N--CA 1.473 0.687 0 CA-C-O 121.086 0.469 . . . . 0.0 109.906 178.706 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -156.63 122.92 0.53 Allowed 'Isoleucine or valine' 0 CA--C 1.554 1.126 0 N-CA-C 108.335 -0.987 . . . . 0.0 108.335 178.649 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 34.1 m80 -106.08 160.45 15.3 Favored 'General case' 0 N--CA 1.48 1.047 0 CA-C-N 115.167 -0.924 . . . . 0.0 110.943 -178.385 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 58.1 t60 -165.86 99.43 0.66 Allowed 'General case' 0 N--CA 1.483 1.204 0 CA-C-N 116.532 -0.303 . . . . 0.0 110.854 179.533 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' H' H ' 15' ' ' GLN . . . . . 0.642 HE22 ' H ' ' H' ' 37' ' ' GLY . 70.0 mt-30 -125.34 -175.33 3.29 Favored 'General case' 0 CA--C 1.49 -1.335 0 N-CA-C 107.834 -1.172 . . . . 0.0 107.834 -179.829 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -169.51 103.95 0.35 Allowed 'General case' 0 CA--C 1.541 0.623 0 CA-C-N 114.808 -1.087 . . . . 0.0 109.182 178.987 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 9.7 mp -110.34 149.15 30.64 Favored 'General case' 0 N--CA 1.489 1.502 0 N-CA-C 109.115 -0.698 . . . . 0.0 109.115 -179.746 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 43.7 t -144.99 117.51 2.38 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.818 0 N-CA-C 109.705 -0.48 . . . . 0.0 109.705 178.386 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 29.1 m-85 -68.64 149.74 48.78 Favored 'General case' 0 C--N 1.37 1.489 0 O-C-N 124.83 1.331 . . . . 0.0 107.855 176.741 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 12.5 t80 -172.45 -56.23 0.02 OUTLIER 'General case' 0 N--CA 1.482 1.162 0 N-CA-C 110.209 -0.293 . . . . 0.0 110.209 -179.882 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -42.88 90.2 0.0 OUTLIER 'General case' 0 CA--C 1.536 0.406 0 C-N-CA 123.429 0.692 . . . . 0.0 112.031 -179.971 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 46.0 mt-10 -61.34 158.95 13.34 Favored 'General case' 0 N--CA 1.469 0.522 0 CA-C-N 114.907 -1.042 . . . . 0.0 110.22 179.245 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 12.3 m-20 -140.14 135.74 32.79 Favored 'General case' 0 N--CA 1.482 1.148 0 C-N-CA 122.658 0.383 . . . . 0.0 110.301 -179.949 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' H' H ' 24' ' ' VAL . . . . . . . . . . . . . 21.3 t -85.81 -115.48 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.991 0 N-CA-C 108.467 -0.938 . . . . 0.0 108.467 179.366 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . -108.3 53.3 0.6 Allowed Glycine 0 N--CA 1.479 1.558 0 N-CA-C 111.138 -0.785 . . . . 0.0 111.138 -179.878 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' H' H ' 26' ' ' SER . . . . . 0.6 ' HG ' ' HZ2' ' H' ' 28' ' ' LYS . 85.5 p -77.04 126.64 31.31 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 109.11 -0.7 . . . . 0.0 109.11 178.195 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' H' H ' 27' ' ' ASN . . . . . 0.412 HD22 ' CG ' ' I' ' 11' ' ' GLU . 47.7 t30 -66.7 100.81 0.73 Allowed 'General case' 0 N--CA 1.469 0.516 0 N-CA-C 108.479 -0.934 . . . . 0.0 108.479 178.589 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' H' H ' 28' ' ' LYS . . . . . 0.6 ' HZ2' ' HG ' ' H' ' 26' ' ' SER . 67.1 mttm -95.21 127.62 41.4 Favored 'General case' 0 N--CA 1.485 1.299 0 N-CA-C 109.605 -0.517 . . . . 0.0 109.605 -179.408 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.01 -126.85 0.01 OUTLIER Glycine 0 CA--C 1.528 0.877 0 N-CA-C 111.137 -0.785 . . . . 0.0 111.137 179.26 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -133.16 125.82 30.31 Favored 'General case' 0 N--CA 1.47 0.563 0 C-N-CA 122.824 0.45 . . . . 0.0 110.718 -179.126 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 40.1 mt -90.4 161.83 2.56 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.67 0 N-CA-C 106.496 -1.668 . . . . 0.0 106.496 178.369 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 46.0 mt -139.97 94.84 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.324 0 CA-C-N 119.533 1.06 . . . . 0.0 109.789 178.343 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 53.99 105.93 0.01 OUTLIER Glycine 0 CA--C 1.532 1.135 0 CA-C-N 116.291 -0.413 . . . . 0.0 114.042 177.617 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 99.1 mt -72.42 152.64 41.87 Favored 'General case' 0 CA--C 1.54 0.579 0 N-CA-C 107.255 -1.387 . . . . 0.0 107.255 176.706 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 27.6 ttt -145.94 140.82 27.22 Favored 'General case' 0 N--CA 1.478 0.975 0 N-CA-C 107.941 -1.133 . . . . 0.0 107.941 179.062 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 90.1 t -161.24 153.22 4.15 Favored 'Isoleucine or valine' 0 C--O 1.233 0.216 0 N-CA-C 106.488 -1.671 . . . . 0.0 106.488 -179.39 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' H' H ' 37' ' ' GLY . . . . . 0.642 ' H ' HE22 ' H' ' 15' ' ' GLN . . . 55.42 73.78 0.39 Allowed Glycine 0 C--N 1.314 -0.679 0 C-N-CA 121.255 -0.498 . . . . 0.0 111.949 177.796 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 174.93 -158.63 26.59 Favored Glycine 0 C--O 1.215 -1.057 0 N-CA-C 110.527 -1.029 . . . . 0.0 110.527 179.469 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 27.0 m -126.81 138.97 53.16 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.161 0 CA-C-N 117.084 0.442 . . . . 0.0 109.964 -179.823 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 35.8 t . . . . . 0 N--CA 1.468 0.431 0 CA-C-O 117.801 -1.095 . . . . 0.0 111.436 179.61 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 77.4 m-85 . . . . . 0 N--CA 1.475 0.825 0 N-CA-C 109.54 -0.541 . . . . 0.0 109.54 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' I' I ' 5' ' ' ARG . . . . . . . . . . . . . 74.0 mtp180 -144.39 141.02 29.4 Favored 'General case' 0 N--CA 1.482 1.169 0 N-CA-C 109.079 -0.712 . . . . 0.0 109.079 -179.687 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 76.8 m80 -149.62 119.41 7.06 Favored 'General case' 0 N--CA 1.472 0.636 0 N-CA-C 109.017 -0.734 . . . . 0.0 109.017 179.17 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 8.6 m-20 -68.67 145.42 53.89 Favored 'General case' 0 N--CA 1.467 0.406 0 O-C-N 123.455 0.472 . . . . 0.0 112.024 -179.244 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' I' I ' 8' ' ' SER . . . . . 0.451 ' HG ' ' H ' ' I' ' 9' ' ' GLY . 6.6 t -164.17 172.9 13.06 Favored 'General case' 0 N--CA 1.469 0.502 0 N-CA-C 109.529 -0.545 . . . . 0.0 109.529 178.435 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' I' I ' 9' ' ' GLY . . . . . 0.451 ' H ' ' HG ' ' I' ' 8' ' ' SER . . . 122.68 23.48 2.29 Favored Glycine 0 N--CA 1.48 1.626 0 N-CA-C 111.76 -0.536 . . . . 0.0 111.76 179.052 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 40.9 p90 -56.54 127.57 31.92 Favored 'General case' 0 N--CA 1.474 0.744 0 N-CA-C 112.398 0.518 . . . . 0.0 112.398 -178.995 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' I' I ' 11' ' ' GLU . . . . . 0.412 ' CG ' HD22 ' H' ' 27' ' ' ASN . 46.0 mt-10 -83.92 155.83 22.67 Favored 'General case' 0 N--CA 1.474 0.76 0 CA-C-O 121.096 0.474 . . . . 0.0 109.896 178.632 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -156.54 123.05 0.54 Allowed 'Isoleucine or valine' 0 CA--C 1.553 1.082 0 N-CA-C 108.299 -1.0 . . . . 0.0 108.299 178.586 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 35.0 m80 -106.04 160.08 15.57 Favored 'General case' 0 N--CA 1.481 1.081 0 CA-C-N 115.128 -0.942 . . . . 0.0 110.978 -178.336 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 58.4 t60 -165.65 99.38 0.68 Allowed 'General case' 0 N--CA 1.484 1.239 0 CA-C-N 116.563 -0.289 . . . . 0.0 110.943 179.459 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' I' I ' 15' ' ' GLN . . . . . 0.633 HE22 ' H ' ' I' ' 37' ' ' GLY . 70.0 mt-30 -125.38 -175.12 3.23 Favored 'General case' 0 CA--C 1.489 -1.403 0 N-CA-C 107.905 -1.146 . . . . 0.0 107.905 -179.865 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -169.65 104.12 0.34 Allowed 'General case' 0 CA--C 1.541 0.615 0 CA-C-N 114.8 -1.091 . . . . 0.0 109.255 179.047 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 9.7 mp -110.43 149.34 30.42 Favored 'General case' 0 N--CA 1.488 1.465 0 N-CA-C 109.16 -0.682 . . . . 0.0 109.16 -179.763 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 43.7 t -145.2 117.57 2.3 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.863 0 N-CA-C 109.649 -0.5 . . . . 0.0 109.649 178.391 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 28.8 m-85 -68.7 149.79 48.66 Favored 'General case' 0 C--N 1.371 1.536 0 O-C-N 124.773 1.296 . . . . 0.0 107.817 176.72 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' I' I ' 20' ' ' PHE . . . . . 0.403 ' O ' ' N ' ' I' ' 22' ' ' GLU . 12.6 t80 -172.54 -56.14 0.02 OUTLIER 'General case' 0 N--CA 1.481 1.115 0 N-CA-C 110.205 -0.294 . . . . 0.0 110.205 -179.855 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -43.0 90.2 0.0 OUTLIER 'General case' 0 CA--C 1.535 0.381 0 C-N-CA 123.378 0.671 . . . . 0.0 112.06 -179.98 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' I' I ' 22' ' ' GLU . . . . . 0.403 ' N ' ' O ' ' I' ' 20' ' ' PHE . 46.1 mt-10 -61.17 158.93 12.88 Favored 'General case' 0 N--CA 1.47 0.528 0 CA-C-N 114.893 -1.049 . . . . 0.0 110.267 179.241 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 12.2 m-20 -140.22 135.68 32.61 Favored 'General case' 0 N--CA 1.482 1.143 0 C-N-CA 122.597 0.359 . . . . 0.0 110.304 -179.992 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' I' I ' 24' ' ' VAL . . . . . . . . . . . . . 21.2 t -85.8 -115.51 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.96 0 N-CA-C 108.463 -0.94 . . . . 0.0 108.463 179.386 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . -108.31 53.29 0.6 Allowed Glycine 0 N--CA 1.478 1.469 0 N-CA-C 111.249 -0.74 . . . . 0.0 111.249 -179.909 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' I' I ' 26' ' ' SER . . . . . 0.571 ' HG ' ' HZ2' ' I' ' 28' ' ' LYS . 85.9 p -77.01 126.73 31.46 Favored 'General case' 0 C--N 1.329 -0.289 0 N-CA-C 109.202 -0.666 . . . . 0.0 109.202 178.148 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 47.9 t30 -66.67 100.97 0.74 Allowed 'General case' 0 N--CA 1.469 0.488 0 N-CA-C 108.474 -0.936 . . . . 0.0 108.474 178.56 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' I' I ' 28' ' ' LYS . . . . . 0.571 ' HZ2' ' HG ' ' I' ' 26' ' ' SER . 67.2 mttm -95.38 127.52 41.5 Favored 'General case' 0 N--CA 1.483 1.224 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 -179.431 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -62.99 -127.4 0.01 OUTLIER Glycine 0 CA--C 1.53 0.969 0 N-CA-C 111.099 -0.8 . . . . 0.0 111.099 179.33 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -132.38 125.86 31.84 Favored 'General case' 0 N--CA 1.471 0.624 0 C-N-CA 122.906 0.482 . . . . 0.0 110.719 -179.109 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 39.8 mt -90.61 161.41 2.61 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.624 0 N-CA-C 106.458 -1.682 . . . . 0.0 106.458 178.233 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 47.0 mt -139.54 94.73 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.297 0 CA-C-N 119.586 1.085 . . . . 0.0 109.8 178.374 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 54.1 105.87 0.01 OUTLIER Glycine 0 CA--C 1.532 1.103 0 CA-C-N 116.32 -0.4 . . . . 0.0 114.011 177.568 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 98.7 mt -72.35 152.79 41.85 Favored 'General case' 0 CA--C 1.539 0.527 0 N-CA-C 107.295 -1.372 . . . . 0.0 107.295 176.721 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 27.6 ttt -146.02 140.77 27.06 Favored 'General case' 0 N--CA 1.478 0.956 0 N-CA-C 107.877 -1.157 . . . . 0.0 107.877 179.157 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 94.9 t -161.12 153.46 4.13 Favored 'Isoleucine or valine' 0 C--O 1.233 0.193 0 N-CA-C 106.382 -1.71 . . . . 0.0 106.382 -179.45 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' I' I ' 37' ' ' GLY . . . . . 0.633 ' H ' HE22 ' I' ' 15' ' ' GLN . . . 55.08 73.95 0.37 Allowed Glycine 0 C--N 1.313 -0.724 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.894 177.762 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 174.95 -158.67 26.65 Favored Glycine 0 C--O 1.216 -1.012 0 N-CA-C 110.547 -1.021 . . . . 0.0 110.547 179.43 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 27.3 m -126.88 138.82 53.65 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.097 0 CA-C-N 117.186 0.493 . . . . 0.0 109.86 -179.722 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 36.8 t . . . . . 0 N--CA 1.469 0.517 0 CA-C-O 117.849 -1.072 . . . . 0.0 111.329 179.525 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 16.5 m-85 . . . . . 0 N--CA 1.469 0.498 0 N-CA-C 109.369 -0.604 . . . . 0.0 109.369 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 54.0 mtp180 -68.03 129.7 40.71 Favored 'General case' 0 N--CA 1.467 0.383 0 CA-C-N 115.868 -0.606 . . . . 0.0 110.533 -177.798 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 45.2 m170 -96.1 125.59 40.74 Favored 'General case' 0 N--CA 1.473 0.691 0 N-CA-C 109.725 -0.472 . . . . 0.0 109.725 179.002 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 10.0 m-20 -72.23 144.81 48.32 Favored 'General case' 0 CA--C 1.532 0.255 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.109 -179.81 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 23.0 t -160.72 179.47 8.51 Favored 'General case' 0 N--CA 1.471 0.615 0 N-CA-C 109.329 -0.619 . . . . 0.0 109.329 178.89 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 124.52 19.86 2.49 Favored Glycine 0 N--CA 1.487 2.064 0 N-CA-C 111.886 -0.486 . . . . 0.0 111.886 179.896 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 43.6 p90 -57.43 129.2 40.74 Favored 'General case' 0 N--CA 1.475 0.82 0 O-C-N 122.458 -0.436 . . . . 0.0 112.084 -179.707 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 46.7 mt-10 -85.54 154.7 21.57 Favored 'General case' 0 N--CA 1.469 0.512 0 N-CA-C 109.046 -0.724 . . . . 0.0 109.046 178.406 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -153.76 129.3 1.64 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 N-CA-C 108.046 -1.094 . . . . 0.0 108.046 178.895 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 51.3 m-70 -135.05 143.75 46.89 Favored 'General case' 0 N--CA 1.49 1.543 0 CA-C-N 118.803 0.729 . . . . 0.0 110.956 -179.218 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -165.98 98.21 0.64 Allowed 'General case' 0 N--CA 1.482 1.16 0 CA-C-N 116.688 -0.233 . . . . 0.0 111.099 179.673 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . 0.501 HE21 ' CA ' ' A' ' 37' ' ' GLY . 49.6 mt-30 -108.06 -171.98 1.97 Allowed 'General case' 0 CA--C 1.503 -0.851 0 N-CA-C 108.176 -1.046 . . . . 0.0 108.176 179.712 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -164.34 97.86 0.8 Allowed 'General case' 0 N--CA 1.472 0.651 0 CA-C-N 115.243 -0.889 . . . . 0.0 109.516 178.686 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . 0.406 ' CD1' ' N ' ' A' ' 17' ' ' LEU . 4.8 mp -107.02 163.85 12.64 Favored 'General case' 0 N--CA 1.488 1.44 0 N-CA-C 108.59 -0.893 . . . . 0.0 108.59 179.916 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 56.3 t -141.28 119.05 8.84 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.31 0 CA-C-O 118.772 -0.632 . . . . 0.0 109.847 179.433 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 54.5 m-85 -70.13 158.55 35.55 Favored 'General case' 0 N--CA 1.479 1.021 0 N-CA-C 107.706 -1.22 . . . . 0.0 107.706 177.275 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 13.8 t80 -171.03 -58.46 0.02 OUTLIER 'General case' 0 N--CA 1.483 1.217 0 CA-C-O 122.424 1.107 . . . . 0.0 109.672 179.333 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.42 90.05 0.0 OUTLIER 'General case' 0 N--CA 1.457 -0.092 0 CA-C-N 113.927 -1.488 . . . . 0.0 112.852 -178.078 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 37.7 tt0 -62.13 156.51 21.42 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 115.166 -0.925 . . . . 0.0 110.618 178.891 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 12.2 m-20 -138.09 129.75 28.09 Favored 'General case' 0 N--CA 1.482 1.132 0 C-N-CA 122.93 0.492 . . . . 0.0 110.246 -179.659 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . 0.633 ' CG1' ' H ' ' A' ' 25' ' ' GLY . 39.6 t -79.6 -164.37 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 1.024 0 N-CA-C 108.518 -0.919 . . . . 0.0 108.518 179.583 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.633 ' H ' ' CG1' ' A' ' 24' ' ' VAL . . . -71.42 51.43 1.08 Allowed Glycine 0 CA--C 1.527 0.827 0 CA-C-N 118.399 0.545 . . . . 0.0 112.038 -179.086 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 27.1 p -72.36 136.45 46.14 Favored 'General case' 0 C--O 1.22 -0.488 0 N-CA-C 109.564 -0.532 . . . . 0.0 109.564 178.877 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 2.0 t-20 -68.66 95.5 0.66 Allowed 'General case' 0 N--CA 1.468 0.463 0 N-CA-C 108.479 -0.934 . . . . 0.0 108.479 178.139 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 67.8 mttm -93.34 119.26 32.27 Favored 'General case' 0 N--CA 1.481 1.108 0 N-CA-C 110.295 -0.261 . . . . 0.0 110.295 -179.104 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.12 -126.12 0.01 OUTLIER Glycine 0 CA--C 1.533 1.166 0 N-CA-C 110.485 -1.046 . . . . 0.0 110.485 178.639 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.24 134.23 48.94 Favored 'General case' 0 N--CA 1.48 1.035 0 N-CA-C 109.078 -0.712 . . . . 0.0 109.078 179.111 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 65.4 mt -83.3 138.05 19.95 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.467 0 N-CA-C 107.3 -1.37 . . . . 0.0 107.3 178.657 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 31.3 mt -130.46 127.71 62.8 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.914 0 O-C-N 123.472 0.483 . . . . 0.0 110.044 -178.592 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.27 78.9 0.14 Allowed Glycine 0 CA--C 1.524 0.653 0 CA-C-N 115.885 -0.598 . . . . 0.0 112.869 178.7 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 1.7 tt -109.94 120.82 43.67 Favored 'General case' 0 N--CA 1.481 1.077 0 N-CA-C 107.175 -1.417 . . . . 0.0 107.175 177.653 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 8.8 mtp -154.08 161.24 42.05 Favored 'General case' 0 N--CA 1.472 0.647 0 N-CA-C 108.662 -0.866 . . . . 0.0 108.662 179.736 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 78.1 t -158.07 144.76 8.81 Favored 'Isoleucine or valine' 0 C--O 1.234 0.261 0 N-CA-C 106.774 -1.565 . . . . 0.0 106.774 -179.789 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . 0.501 ' CA ' HE21 ' A' ' 15' ' ' GLN . . . 55.77 74.06 0.36 Allowed Glycine 0 C--N 1.315 -0.616 0 N-CA-C 111.511 -0.636 . . . . 0.0 111.511 178.675 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 169.99 -149.07 12.43 Favored Glycine 0 CA--C 1.519 0.324 0 N-CA-C 110.898 -0.881 . . . . 0.0 110.898 179.938 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 16.0 m -134.65 148.74 29.36 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.84 0 C-N-CA 122.675 0.39 . . . . 0.0 109.951 179.955 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 21.9 t . . . . . 0 C--O 1.22 -0.497 0 CA-C-O 117.81 -1.09 . . . . 0.0 111.043 178.931 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 17.3 m-85 . . . . . 0 N--CA 1.47 0.548 0 N-CA-C 109.404 -0.591 . . . . 0.0 109.404 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 54.3 mtp180 -68.36 129.61 40.45 Favored 'General case' 0 CA--C 1.534 0.349 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.525 -177.748 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 44.0 m170 -95.99 125.6 40.65 Favored 'General case' 0 N--CA 1.473 0.703 0 N-CA-C 109.797 -0.446 . . . . 0.0 109.797 179.048 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 7' ' ' ASP . . . . . . . . . . . . . 10.0 m-20 -72.18 144.98 48.34 Favored 'General case' 0 CA--C 1.532 0.269 0 CA-C-N 116.464 -0.334 . . . . 0.0 111.163 -179.863 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 8' ' ' SER . . . . . . . . . . . . . 23.1 t -160.82 179.49 8.47 Favored 'General case' 0 N--CA 1.47 0.539 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 178.851 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 124.37 19.88 2.52 Favored Glycine 0 N--CA 1.487 2.081 0 N-CA-C 111.8 -0.52 . . . . 0.0 111.8 179.854 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 43.3 p90 -57.36 129.24 40.92 Favored 'General case' 0 N--CA 1.474 0.736 0 O-C-N 122.489 -0.418 . . . . 0.0 112.073 -179.788 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 46.6 mt-10 -85.55 154.79 21.51 Favored 'General case' 0 N--CA 1.47 0.557 0 N-CA-C 109.15 -0.685 . . . . 0.0 109.15 178.389 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -153.8 129.09 1.56 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.328 0 N-CA-C 108.188 -1.041 . . . . 0.0 108.188 178.839 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 50.9 m-70 -134.8 143.87 47.33 Favored 'General case' 0 N--CA 1.49 1.566 0 CA-C-N 118.79 0.723 . . . . 0.0 110.91 -179.089 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -166.02 98.23 0.63 Allowed 'General case' 0 N--CA 1.483 1.203 0 CA-C-N 116.616 -0.266 . . . . 0.0 111.117 179.619 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . 0.495 HE21 ' CA ' ' B' ' 37' ' ' GLY . 49.7 mt-30 -108.09 -172.52 2.08 Favored 'General case' 0 CA--C 1.502 -0.896 0 N-CA-C 108.168 -1.049 . . . . 0.0 108.168 179.805 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -164.06 97.69 0.83 Allowed 'General case' 0 N--CA 1.473 0.698 0 CA-C-N 115.152 -0.931 . . . . 0.0 109.411 178.747 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . 0.41 ' N ' ' CD1' ' B' ' 17' ' ' LEU . 4.8 mp -106.97 163.91 12.58 Favored 'General case' 0 N--CA 1.488 1.427 0 N-CA-C 108.506 -0.924 . . . . 0.0 108.506 179.867 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 58.7 t -141.37 118.7 8.22 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.358 0 CA-C-O 118.957 -0.544 . . . . 0.0 109.821 179.512 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 56.0 m-85 -70.39 158.64 35.62 Favored 'General case' 0 N--CA 1.477 0.907 0 N-CA-C 107.614 -1.254 . . . . 0.0 107.614 177.25 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 14.5 t80 -171.64 -57.7 0.02 OUTLIER 'General case' 0 N--CA 1.482 1.164 0 CA-C-O 122.284 1.04 . . . . 0.0 109.764 179.288 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.56 90.49 0.0 OUTLIER 'General case' 0 C--O 1.232 0.156 0 CA-C-N 114.098 -1.41 . . . . 0.0 112.682 -178.126 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 37.6 tt0 -62.55 156.37 23.28 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 115.173 -0.921 . . . . 0.0 110.544 179.038 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 12.3 m-20 -138.0 130.16 28.88 Favored 'General case' 0 N--CA 1.483 1.196 0 C-N-CA 123.01 0.524 . . . . 0.0 110.193 -179.671 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 24' ' ' VAL . . . . . 0.649 ' CG1' ' H ' ' B' ' 25' ' ' GLY . 39.2 t -80.13 -163.89 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.037 0 N-CA-C 108.593 -0.891 . . . . 0.0 108.593 179.618 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 25' ' ' GLY . . . . . 0.649 ' H ' ' CG1' ' B' ' 24' ' ' VAL . . . -71.36 50.93 1.05 Allowed Glycine 0 C--N 1.342 0.897 0 CA-C-N 118.324 0.511 . . . . 0.0 112.045 -179.182 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 28.9 p -72.16 136.16 46.38 Favored 'General case' 0 C--O 1.22 -0.476 0 N-CA-C 109.644 -0.502 . . . . 0.0 109.644 178.798 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 2.0 t-20 -68.61 95.39 0.64 Allowed 'General case' 0 N--CA 1.469 0.5 0 N-CA-C 108.495 -0.928 . . . . 0.0 108.495 178.137 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 67.9 mttm -93.19 119.12 32.03 Favored 'General case' 0 N--CA 1.481 1.1 0 N-CA-C 110.358 -0.238 . . . . 0.0 110.358 -179.061 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.08 -125.67 0.01 OUTLIER Glycine 0 CA--C 1.534 1.28 0 N-CA-C 110.511 -1.036 . . . . 0.0 110.511 178.64 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.65 134.36 48.51 Favored 'General case' 0 N--CA 1.481 1.103 0 N-CA-C 109.159 -0.682 . . . . 0.0 109.159 179.141 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 65.6 mt -83.43 138.25 19.6 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.462 0 N-CA-C 107.288 -1.375 . . . . 0.0 107.288 178.626 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 29.9 mt -130.78 127.56 61.82 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.884 0 O-C-N 123.541 0.525 . . . . 0.0 110.012 -178.523 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.46 78.56 0.15 Allowed Glycine 0 CA--C 1.526 0.745 0 CA-C-N 115.898 -0.592 . . . . 0.0 112.888 178.642 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 1.7 tt -109.6 120.65 43.14 Favored 'General case' 0 N--CA 1.48 1.061 0 N-CA-C 107.163 -1.421 . . . . 0.0 107.163 177.629 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 8.9 mtp -153.81 161.07 42.37 Favored 'General case' 0 N--CA 1.473 0.682 0 N-CA-C 108.704 -0.85 . . . . 0.0 108.704 179.574 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 72.8 t -157.93 144.65 9.0 Favored 'Isoleucine or valine' 0 C--O 1.233 0.201 0 N-CA-C 106.786 -1.561 . . . . 0.0 106.786 -179.739 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . 0.495 ' CA ' HE21 ' B' ' 15' ' ' GLN . . . 55.71 74.08 0.36 Allowed Glycine 0 C--N 1.317 -0.526 0 N-CA-C 111.544 -0.622 . . . . 0.0 111.544 178.713 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 169.97 -148.9 12.23 Favored Glycine 0 CA--C 1.519 0.319 0 N-CA-C 110.796 -0.922 . . . . 0.0 110.796 179.886 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 16.1 m -134.69 148.73 29.32 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.823 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 -179.914 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 21.9 t . . . . . 0 N--CA 1.47 0.54 0 CA-C-O 117.717 -1.135 . . . . 0.0 110.959 178.801 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 17.4 m-85 . . . . . 0 N--CA 1.469 0.516 0 N-CA-C 109.473 -0.565 . . . . 0.0 109.473 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 54.4 mtp180 -68.37 129.25 39.36 Favored 'General case' 0 N--CA 1.468 0.469 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.481 -177.729 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 44.7 m170 -95.74 125.66 40.47 Favored 'General case' 0 N--CA 1.474 0.733 0 N-CA-C 109.714 -0.476 . . . . 0.0 109.714 178.978 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' C' C ' 7' ' ' ASP . . . . . . . . . . . . . 10.1 m-20 -72.33 145.18 47.97 Favored 'General case' 0 CA--C 1.53 0.208 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.198 -179.842 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' C' C ' 8' ' ' SER . . . . . . . . . . . . . 22.9 t -160.91 179.53 8.4 Favored 'General case' 0 N--CA 1.469 0.506 0 N-CA-C 109.343 -0.614 . . . . 0.0 109.343 178.835 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 124.46 19.83 2.51 Favored Glycine 0 N--CA 1.487 2.055 0 N-CA-C 111.772 -0.531 . . . . 0.0 111.772 179.822 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 43.9 p90 -57.24 128.96 39.64 Favored 'General case' 0 N--CA 1.473 0.705 0 O-C-N 122.403 -0.469 . . . . 0.0 112.127 -179.767 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 46.5 mt-10 -85.35 154.95 21.54 Favored 'General case' 0 N--CA 1.47 0.553 0 N-CA-C 109.049 -0.723 . . . . 0.0 109.049 178.426 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -154.08 129.05 1.49 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 N-CA-C 108.174 -1.047 . . . . 0.0 108.174 178.802 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 50.7 m-70 -134.68 144.2 47.66 Favored 'General case' 0 N--CA 1.491 1.624 0 CA-C-N 118.716 0.689 . . . . 0.0 110.974 -179.117 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -166.38 98.16 0.6 Allowed 'General case' 0 N--CA 1.482 1.174 0 CA-C-N 116.674 -0.239 . . . . 0.0 111.161 179.753 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' C' C ' 15' ' ' GLN . . . . . 0.501 HE21 ' CA ' ' C' ' 37' ' ' GLY . 49.7 mt-30 -108.31 -172.12 2.0 Allowed 'General case' 0 CA--C 1.501 -0.941 0 N-CA-C 108.177 -1.046 . . . . 0.0 108.177 179.796 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -164.29 97.84 0.81 Allowed 'General case' 0 N--CA 1.472 0.626 0 CA-C-N 115.143 -0.935 . . . . 0.0 109.443 178.761 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' C' C ' 17' ' ' LEU . . . . . 0.406 ' N ' ' CD1' ' C' ' 17' ' ' LEU . 4.8 mp -106.96 163.81 12.65 Favored 'General case' 0 N--CA 1.487 1.406 0 N-CA-C 108.559 -0.904 . . . . 0.0 108.559 179.89 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 58.0 t -141.28 118.81 8.54 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.293 0 CA-C-O 118.917 -0.563 . . . . 0.0 109.805 179.48 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 55.1 m-85 -70.49 158.73 35.55 Favored 'General case' 0 N--CA 1.478 0.926 0 N-CA-C 107.529 -1.285 . . . . 0.0 107.529 177.317 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 14.7 t80 -171.63 -57.67 0.02 OUTLIER 'General case' 0 N--CA 1.481 1.104 0 CA-C-O 122.246 1.022 . . . . 0.0 109.857 179.21 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.59 90.4 0.0 OUTLIER 'General case' 0 C--O 1.231 0.107 0 CA-C-N 114.181 -1.372 . . . . 0.0 112.79 -178.168 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 38.0 tt0 -62.32 156.45 22.25 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.223 -0.899 . . . . 0.0 110.577 179.09 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 12.2 m-20 -138.05 129.93 28.42 Favored 'General case' 0 N--CA 1.482 1.156 0 C-N-CA 123.026 0.531 . . . . 0.0 110.255 -179.689 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' C' C ' 24' ' ' VAL . . . . . 0.651 ' CG1' ' H ' ' C' ' 25' ' ' GLY . 40.4 t -79.99 -164.08 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.035 0 N-CA-C 108.523 -0.917 . . . . 0.0 108.523 179.639 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' C' C ' 25' ' ' GLY . . . . . 0.651 ' H ' ' CG1' ' C' ' 24' ' ' VAL . . . -71.34 50.96 1.04 Allowed Glycine 0 CA--C 1.527 0.812 0 CA-C-N 118.363 0.529 . . . . 0.0 112.042 -179.019 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 27.3 p -72.13 136.43 46.52 Favored 'General case' 0 C--O 1.221 -0.414 0 N-CA-C 109.526 -0.546 . . . . 0.0 109.526 178.902 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 2.0 t-20 -68.87 95.65 0.7 Allowed 'General case' 0 N--CA 1.468 0.472 0 N-CA-C 108.419 -0.956 . . . . 0.0 108.419 178.107 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 67.9 mttm -93.46 119.07 32.11 Favored 'General case' 0 N--CA 1.481 1.105 0 N-CA-C 110.354 -0.239 . . . . 0.0 110.354 -179.092 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.93 -126.03 0.01 OUTLIER Glycine 0 CA--C 1.534 1.281 0 N-CA-C 110.563 -1.015 . . . . 0.0 110.563 178.606 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.28 134.12 48.89 Favored 'General case' 0 N--CA 1.481 1.102 0 N-CA-C 109.105 -0.702 . . . . 0.0 109.105 179.135 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 65.3 mt -83.26 138.0 20.02 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.451 0 N-CA-C 107.311 -1.366 . . . . 0.0 107.311 178.538 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 30.7 mt -130.41 127.79 63.03 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.931 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.015 -178.537 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.14 78.57 0.15 Allowed Glycine 0 CA--C 1.525 0.68 0 CA-C-N 115.908 -0.587 . . . . 0.0 112.933 178.677 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 1.7 tt -109.49 120.77 43.51 Favored 'General case' 0 N--CA 1.48 1.035 0 N-CA-C 107.202 -1.407 . . . . 0.0 107.202 177.606 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 8.8 mtp -153.93 161.22 42.16 Favored 'General case' 0 N--CA 1.469 0.524 0 N-CA-C 108.664 -0.865 . . . . 0.0 108.664 179.665 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 79.2 t -158.05 144.86 8.89 Favored 'Isoleucine or valine' 0 C--O 1.233 0.232 0 N-CA-C 106.845 -1.539 . . . . 0.0 106.845 -179.832 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' C' C ' 37' ' ' GLY . . . . . 0.501 ' CA ' HE21 ' C' ' 15' ' ' GLN . . . 55.65 74.03 0.37 Allowed Glycine 0 C--N 1.316 -0.535 0 CA-C-N 115.812 -0.631 . . . . 0.0 111.537 178.687 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 169.95 -149.12 12.54 Favored Glycine 0 CA--C 1.518 0.275 0 N-CA-C 110.815 -0.914 . . . . 0.0 110.815 179.941 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 16.4 m -134.58 148.85 29.41 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.872 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 -179.964 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 22.0 t . . . . . 0 N--CA 1.469 0.507 0 CA-C-O 117.717 -1.135 . . . . 0.0 110.952 178.916 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 18.7 m-85 . . . . . 0 N--CA 1.478 0.957 0 N-CA-C 107.9 -1.148 . . . . 0.0 107.9 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' D' D ' 5' ' ' ARG . . . . . 0.469 HH21 ' CG1' ' C' ' 24' ' ' VAL 0.344 64.5 mtp180 -77.03 133.52 39.09 Favored 'General case' 0 C--N 1.355 0.821 0 CA-C-O 123.248 1.499 . . . . 0.0 107.088 -167.987 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 45.2 m170 -94.27 128.13 40.56 Favored 'General case' 0 C--N 1.365 1.273 0 CA-C-N 113.371 -1.741 . . . . 0.0 108.502 -177.669 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' D' D ' 7' ' ' ASP . . . . . . . . . . . . . 6.7 m-20 -66.35 130.48 43.37 Favored 'General case' 0 C--N 1.31 -1.134 0 C-N-CA 127.505 2.322 . . . . 0.0 115.117 175.029 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' D' D ' 8' ' ' SER . . . . . . . . . . . . . 22.9 t -152.11 -178.53 6.84 Favored 'General case' 0 N--CA 1.478 0.954 0 CA-C-N 119.168 0.895 . . . . 0.0 109.411 177.145 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 124.58 18.85 2.64 Favored Glycine 0 N--CA 1.485 1.914 0 N-CA-C 111.788 -0.525 . . . . 0.0 111.788 178.691 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 40.2 p90 -56.21 130.62 45.09 Favored 'General case' 0 CA--C 1.544 0.74 0 N-CA-C 112.134 0.42 . . . . 0.0 112.134 -179.209 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 46.7 mt-10 -85.6 152.5 23.08 Favored 'General case' 0 N--CA 1.475 0.78 0 N-CA-C 109.649 -0.5 . . . . 0.0 109.649 177.479 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -149.6 130.1 4.37 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.447 0 N-CA-C 108.1 -1.074 . . . . 0.0 108.1 175.357 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 48.5 m-70 -129.81 146.97 51.53 Favored 'General case' 0 N--CA 1.483 1.218 0 CA-C-N 117.867 0.303 . . . . 0.0 111.286 176.482 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -165.35 104.84 0.74 Allowed 'General case' 0 N--CA 1.483 1.209 0 N-CA-C 109.688 -0.486 . . . . 0.0 109.688 173.354 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' D' D ' 15' ' ' GLN . . . . . 0.51 HE21 ' CA ' ' D' ' 37' ' ' GLY . 49.1 mt-30 -111.62 -175.59 2.73 Favored 'General case' 0 CA--C 1.493 -1.249 0 N-CA-C 108.018 -1.104 . . . . 0.0 108.018 179.092 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 88.7 tttt -160.56 106.12 1.47 Allowed 'General case' 0 CA--C 1.538 0.5 0 N-CA-C 107.683 -1.228 . . . . 0.0 107.683 175.383 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 5.7 mp -113.38 163.03 15.38 Favored 'General case' 0 N--CA 1.488 1.456 0 N-CA-C 107.945 -1.132 . . . . 0.0 107.945 179.457 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 53.3 t -140.96 123.63 15.5 Favored 'Isoleucine or valine' 0 C--N 1.362 1.136 0 N-CA-C 108.753 -0.832 . . . . 0.0 108.753 175.964 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 79.1 m-85 -62.97 151.3 39.99 Favored 'General case' 0 C--N 1.355 0.82 0 C-N-CA 124.517 1.127 . . . . 0.0 110.515 170.967 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 9.9 t80 -170.11 -66.91 0.02 OUTLIER 'General case' 0 N--CA 1.475 0.789 0 N-CA-C 107.781 -1.192 . . . . 0.0 107.781 179.834 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -38.27 95.43 0.01 OUTLIER 'General case' 0 CA--C 1.535 0.39 0 CA-C-N 113.99 -1.459 . . . . 0.0 111.731 -175.293 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 38.3 tt0 -65.18 157.61 28.3 Favored 'General case' 0 N--CA 1.467 0.418 0 CA-C-N 113.919 -1.491 . . . . 0.0 110.122 178.469 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 12.0 m-20 -138.68 130.46 27.82 Favored 'General case' 0 N--CA 1.479 0.985 0 C-N-CA 123.181 0.592 . . . . 0.0 110.407 -178.969 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' D' D ' 24' ' ' VAL . . . . . 0.628 ' CG1' ' H ' ' D' ' 25' ' ' GLY . 48.7 t -84.42 -160.12 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.299 0 N-CA-C 107.742 -1.206 . . . . 0.0 107.742 -178.346 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' D' D ' 25' ' ' GLY . . . . . 0.628 ' H ' ' CG1' ' D' ' 24' ' ' VAL . . . -80.3 57.19 4.67 Favored Glycine 0 C--N 1.359 1.84 0 C-N-CA 118.198 -1.953 . . . . 0.0 110.695 -175.556 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 54.0 p -61.81 132.36 52.84 Favored 'General case' 0 C--N 1.346 0.431 0 CA-C-O 117.515 -1.231 . . . . 0.0 112.187 170.377 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 2.0 t-20 -65.53 95.32 0.21 Allowed 'General case' 0 C--O 1.242 0.666 0 CA-C-N 120.263 1.392 . . . . 0.0 109.044 172.049 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 67.6 mttm -95.0 122.17 37.37 Favored 'General case' 0 N--CA 1.483 1.219 0 C-N-CA 119.627 -0.829 . . . . 0.0 109.245 179.537 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -55.84 -130.18 0.01 OUTLIER Glycine 0 CA--C 1.528 0.893 0 C-N-CA 123.804 0.716 . . . . 0.0 112.045 174.717 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -125.33 139.97 53.23 Favored 'General case' 0 C--N 1.369 1.421 0 N-CA-C 108.669 -0.863 . . . . 0.0 108.669 174.602 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 65.2 mt -83.86 140.54 16.04 Favored 'Isoleucine or valine' 0 C--O 1.238 0.47 0 N-CA-C 107.374 -1.343 . . . . 0.0 107.374 176.342 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 42.1 mt -132.79 132.21 59.48 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.996 0 N-CA-C 108.329 -0.989 . . . . 0.0 108.329 178.079 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.22 76.96 0.22 Allowed Glycine 0 C--O 1.245 0.799 0 CA-C-O 118.552 -1.138 . . . . 0.0 112.519 178.351 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 2.1 tt -109.32 132.17 54.38 Favored 'General case' 0 C--N 1.371 1.528 0 N-CA-C 104.73 -2.322 . . . . 0.0 104.73 175.275 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 9.0 mtp -156.43 166.72 32.61 Favored 'General case' 0 N--CA 1.475 0.822 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 177.494 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 93.2 t -163.73 150.72 3.06 Favored 'Isoleucine or valine' 0 C--O 1.237 0.401 0 N-CA-C 104.989 -2.226 . . . . 0.0 104.989 173.986 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' D' D ' 37' ' ' GLY . . . . . 0.51 ' CA ' HE21 ' D' ' 15' ' ' GLN . . . 60.95 66.91 2.38 Favored Glycine 0 N--CA 1.444 -0.794 0 C-N-CA 118.509 -1.805 . . . . 0.0 112.129 177.13 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 166.8 -148.06 12.82 Favored Glycine 0 N--CA 1.468 0.767 0 CA-C-N 119.085 1.443 . . . . 0.0 112.296 -179.589 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 14.1 m -131.15 147.92 32.95 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.263 0 CA-C-N 119.009 1.405 . . . . 0.0 110.332 -178.908 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 21.2 t . . . . . 0 C--O 1.212 -0.897 0 N-CA-C 109.388 -0.597 . . . . 0.0 109.388 173.574 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 15.9 m-85 . . . . . 0 N--CA 1.472 0.631 0 CA-C-O 121.171 0.51 . . . . 0.0 109.864 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' E' E ' 5' ' ' ARG . . . . . 0.437 HH21 ' CG1' ' A' ' 24' ' ' VAL . 53.0 mtp180 -68.14 130.15 42.07 Favored 'General case' 0 CA--C 1.535 0.398 0 CA-C-N 115.579 -0.737 . . . . 0.0 110.585 -177.917 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 45.6 m170 -96.42 125.3 40.81 Favored 'General case' 0 N--CA 1.476 0.854 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 178.958 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' E' E ' 7' ' ' ASP . . . . . . . . . . . . . 11.6 m-20 -71.75 145.24 48.89 Favored 'General case' 0 N--CA 1.465 0.31 0 O-C-N 123.286 0.366 . . . . 0.0 111.301 -179.823 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' E' E ' 8' ' ' SER . . . . . . . . . . . . . 22.6 t -161.05 179.88 8.07 Favored 'General case' 0 N--CA 1.473 0.702 0 N-CA-C 109.263 -0.643 . . . . 0.0 109.263 178.521 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 125.16 20.12 2.28 Favored Glycine 0 N--CA 1.482 1.754 0 N-CA-C 111.757 -0.537 . . . . 0.0 111.757 179.612 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 40.3 p90 -57.17 128.49 37.24 Favored 'General case' 0 N--CA 1.473 0.682 0 N-CA-C 112.607 0.595 . . . . 0.0 112.607 -179.214 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 45.8 mt-10 -84.37 155.08 22.48 Favored 'General case' 0 N--CA 1.475 0.813 0 N-CA-C 109.228 -0.656 . . . . 0.0 109.228 178.111 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -155.29 127.76 1.05 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.543 0 N-CA-C 108.367 -0.975 . . . . 0.0 108.367 178.764 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 47.4 m-70 -134.63 142.12 46.79 Favored 'General case' 0 N--CA 1.482 1.139 0 CA-C-O 120.591 0.234 . . . . 0.0 111.337 -177.995 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -165.17 98.38 0.73 Allowed 'General case' 0 N--CA 1.486 1.37 0 CA-C-N 116.688 -0.233 . . . . 0.0 111.127 179.711 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' E' E ' 15' ' ' GLN . . . . . 0.507 HE21 ' CA ' ' E' ' 37' ' ' GLY . 49.2 mt-30 -107.73 -172.2 2.02 Favored 'General case' 0 CA--C 1.501 -0.925 0 N-CA-C 108.393 -0.965 . . . . 0.0 108.393 179.81 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -164.34 97.88 0.8 Allowed 'General case' 0 CA--C 1.542 0.635 0 CA-C-N 115.007 -0.997 . . . . 0.0 109.337 178.697 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' E' E ' 17' ' ' LEU . . . . . 0.401 ' N ' ' CD1' ' E' ' 17' ' ' LEU . 4.7 mp -106.85 163.34 13.03 Favored 'General case' 0 N--CA 1.49 1.538 0 N-CA-C 109.075 -0.713 . . . . 0.0 109.075 -179.876 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 41.6 t -141.66 118.05 6.93 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.319 0 C-N-CA 122.684 0.394 . . . . 0.0 110.442 178.952 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 54.7 m-85 -69.43 156.31 39.05 Favored 'General case' 0 C--N 1.358 0.969 0 N-CA-C 107.489 -1.3 . . . . 0.0 107.489 176.621 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 13.1 t80 -173.29 -55.33 0.02 OUTLIER 'General case' 0 N--CA 1.484 1.244 0 CA-C-O 121.724 0.773 . . . . 0.0 110.292 179.333 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -42.35 88.94 0.0 OUTLIER 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 114.502 -1.226 . . . . 0.0 112.654 -179.036 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 37.7 tt0 -61.1 156.42 18.14 Favored 'General case' 0 N--CA 1.47 0.554 0 CA-C-N 115.014 -0.994 . . . . 0.0 110.733 179.416 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 12.0 m-20 -138.16 129.39 27.43 Favored 'General case' 0 N--CA 1.481 1.101 0 C-N-CA 123.003 0.521 . . . . 0.0 110.551 -179.52 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' E' E ' 24' ' ' VAL . . . . . 0.651 ' CG1' ' H ' ' E' ' 25' ' ' GLY . 40.4 t -79.94 -164.25 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.484 1.238 0 N-CA-C 108.164 -1.05 . . . . 0.0 108.164 179.557 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' E' E ' 25' ' ' GLY . . . . . 0.651 ' H ' ' CG1' ' E' ' 24' ' ' VAL . . . -70.79 52.25 0.92 Allowed Glycine 0 CA--C 1.529 0.928 0 CA-C-N 118.422 0.556 . . . . 0.0 112.534 -178.807 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 18.1 p -72.68 135.32 45.39 Favored 'General case' 0 C--O 1.219 -0.512 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 178.645 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 2.0 t-20 -68.36 95.33 0.6 Allowed 'General case' 0 CA--C 1.536 0.421 0 N-CA-C 107.681 -1.229 . . . . 0.0 107.681 177.866 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 67.4 mttm -93.74 118.38 31.34 Favored 'General case' 0 N--CA 1.483 1.187 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 -178.586 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.93 -124.97 0.01 OUTLIER Glycine 0 CA--C 1.539 1.587 0 N-CA-C 110.998 -0.841 . . . . 0.0 110.998 178.588 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -129.05 133.65 47.79 Favored 'General case' 0 N--CA 1.48 1.057 0 N-CA-C 109.511 -0.551 . . . . 0.0 109.511 179.493 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 65.3 mt -82.44 138.53 19.26 Favored 'Isoleucine or valine' 0 C--O 1.235 0.29 0 N-CA-C 107.158 -1.423 . . . . 0.0 107.158 178.617 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 36.2 mt -130.33 127.85 63.3 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.895 0 N-CA-C 109.437 -0.579 . . . . 0.0 109.437 -179.447 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.64 79.89 0.12 Allowed Glycine 0 CA--C 1.522 0.485 0 CA-C-N 115.914 -0.585 . . . . 0.0 113.299 179.021 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 1.8 tt -110.56 120.26 41.83 Favored 'General case' 0 N--CA 1.48 1.044 0 N-CA-C 107.312 -1.366 . . . . 0.0 107.312 177.419 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 8.7 mtp -152.4 163.23 39.92 Favored 'General case' 0 C--O 1.213 -0.864 0 N-CA-C 108.32 -0.992 . . . . 0.0 108.32 179.421 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 97.5 t -159.85 145.3 6.17 Favored 'Isoleucine or valine' 0 C--O 1.233 0.235 0 N-CA-C 106.693 -1.595 . . . . 0.0 106.693 179.919 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' E' E ' 37' ' ' GLY . . . . . 0.507 ' CA ' HE21 ' E' ' 15' ' ' GLN . . . 55.03 73.62 0.4 Allowed Glycine 0 C--N 1.316 -0.54 0 N-CA-C 111.202 -0.759 . . . . 0.0 111.202 178.769 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 171.03 -148.22 11.07 Favored Glycine 0 C--O 1.221 -0.688 0 C-N-CA 120.882 -0.675 . . . . 0.0 111.459 -179.807 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 14.0 m -136.04 147.89 27.97 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.918 0 N-CA-C 109.239 -0.652 . . . . 0.0 109.239 -179.833 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 21.5 t . . . . . 0 C--O 1.221 -0.395 0 CA-C-O 117.8 -1.095 . . . . 0.0 111.19 179.168 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 15.7 m-85 . . . . . 0 N--CA 1.473 0.691 0 CA-C-O 121.143 0.497 . . . . 0.0 110.015 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' F' F ' 5' ' ' ARG . . . . . 0.442 HH21 ' CG1' ' B' ' 24' ' ' VAL . 53.3 mtp180 -68.03 129.75 40.87 Favored 'General case' 0 CA--C 1.537 0.465 0 CA-C-N 115.422 -0.808 . . . . 0.0 110.602 -177.962 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 45.4 m170 -96.39 125.33 40.81 Favored 'General case' 0 N--CA 1.476 0.874 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 178.885 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' F' F ' 7' ' ' ASP . . . . . . . . . . . . . 11.7 m-20 -71.72 145.05 49.06 Favored 'General case' 0 N--CA 1.465 0.307 0 O-C-N 123.293 0.37 . . . . 0.0 111.423 -179.842 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' F' F ' 8' ' ' SER . . . . . . . . . . . . . 22.8 t -161.06 179.35 8.5 Favored 'General case' 0 N--CA 1.473 0.685 0 N-CA-C 109.277 -0.638 . . . . 0.0 109.277 178.448 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 125.78 19.84 2.19 Favored Glycine 0 N--CA 1.482 1.742 0 N-CA-C 111.752 -0.539 . . . . 0.0 111.752 179.634 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 40.4 p90 -57.07 128.87 39.18 Favored 'General case' 0 N--CA 1.474 0.756 0 N-CA-C 112.528 0.566 . . . . 0.0 112.528 -179.18 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 45.8 mt-10 -84.49 155.34 22.22 Favored 'General case' 0 N--CA 1.474 0.732 0 N-CA-C 109.318 -0.623 . . . . 0.0 109.318 177.986 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -155.49 127.81 1.03 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.53 0 N-CA-C 108.31 -0.996 . . . . 0.0 108.31 178.742 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 48.6 m-70 -134.74 141.97 46.62 Favored 'General case' 0 N--CA 1.482 1.128 0 CA-C-O 120.606 0.241 . . . . 0.0 111.387 -178.034 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -165.19 99.14 0.73 Allowed 'General case' 0 N--CA 1.485 1.3 0 CA-C-N 116.811 -0.177 . . . . 0.0 111.191 179.702 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' F' F ' 15' ' ' GLN . . . . . 0.513 HE21 ' CA ' ' F' ' 37' ' ' GLY . 49.1 mt-30 -108.84 -171.44 1.85 Allowed 'General case' 0 CA--C 1.499 -0.981 0 N-CA-C 108.525 -0.917 . . . . 0.0 108.525 179.817 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -164.6 98.08 0.78 Allowed 'General case' 0 CA--C 1.54 0.58 0 CA-C-N 114.883 -1.053 . . . . 0.0 109.537 178.657 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 4.8 mp -106.78 163.14 13.18 Favored 'General case' 0 N--CA 1.49 1.573 0 N-CA-C 109.029 -0.73 . . . . 0.0 109.029 -179.899 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 42.4 t -141.54 118.19 7.31 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.308 0 C-N-CA 122.584 0.354 . . . . 0.0 110.361 179.071 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 55.1 m-85 -69.51 156.06 39.48 Favored 'General case' 0 C--N 1.357 0.932 0 N-CA-C 107.329 -1.36 . . . . 0.0 107.329 176.602 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 13.6 t80 -172.92 -55.69 0.02 OUTLIER 'General case' 0 N--CA 1.483 1.22 0 CA-C-O 121.868 0.842 . . . . 0.0 109.799 179.456 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -42.24 88.8 0.0 OUTLIER 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 114.534 -1.212 . . . . 0.0 112.789 -178.992 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 38.0 tt0 -61.12 156.33 18.4 Favored 'General case' 0 N--CA 1.471 0.617 0 CA-C-N 114.943 -1.026 . . . . 0.0 110.802 179.268 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 12.0 m-20 -138.1 129.63 27.89 Favored 'General case' 0 N--CA 1.482 1.134 0 C-N-CA 122.96 0.504 . . . . 0.0 110.637 -179.638 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' F' F ' 24' ' ' VAL . . . . . 0.646 ' CG1' ' H ' ' F' ' 25' ' ' GLY . 40.0 t -80.1 -164.07 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.283 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 179.613 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' F' F ' 25' ' ' GLY . . . . . 0.646 ' H ' ' CG1' ' F' ' 24' ' ' VAL . . . -70.82 52.25 0.93 Allowed Glycine 0 C--N 1.342 0.888 0 CA-C-N 118.608 0.64 . . . . 0.0 112.378 -178.779 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 19.8 p -72.79 134.97 45.17 Favored 'General case' 0 C--O 1.218 -0.558 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 178.525 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 2.0 t-20 -68.21 95.16 0.56 Allowed 'General case' 0 CA--C 1.536 0.422 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 177.967 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 67.4 mttm -93.56 118.21 31.07 Favored 'General case' 0 N--CA 1.482 1.134 0 N-CA-C 110.066 -0.346 . . . . 0.0 110.066 -178.657 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.8 -125.33 0.01 OUTLIER Glycine 0 CA--C 1.539 1.565 0 N-CA-C 111.022 -0.831 . . . . 0.0 111.022 178.629 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.49 133.46 48.47 Favored 'General case' 0 N--CA 1.483 1.193 0 N-CA-C 109.533 -0.543 . . . . 0.0 109.533 179.479 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 65.7 mt -82.47 138.64 19.07 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.306 0 N-CA-C 107.051 -1.463 . . . . 0.0 107.051 178.587 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 35.0 mt -130.34 127.82 63.23 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.833 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 -179.437 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.56 80.05 0.11 Allowed Glycine 0 CA--C 1.525 0.67 0 CA-C-N 115.929 -0.578 . . . . 0.0 113.241 179.023 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 1.8 tt -110.65 121.23 44.81 Favored 'General case' 0 N--CA 1.48 1.067 0 N-CA-C 107.298 -1.371 . . . . 0.0 107.298 177.59 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 8.7 mtp -153.83 163.85 39.35 Favored 'General case' 0 C--O 1.212 -0.894 0 N-CA-C 108.97 -0.752 . . . . 0.0 108.97 179.314 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 98.3 t -160.19 145.48 5.79 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.27 0 N-CA-C 106.906 -1.516 . . . . 0.0 106.906 -179.857 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' F' F ' 37' ' ' GLY . . . . . 0.513 ' CA ' HE21 ' F' ' 15' ' ' GLN . . . 55.15 73.84 0.38 Allowed Glycine 0 C--N 1.317 -0.507 0 N-CA-C 111.188 -0.765 . . . . 0.0 111.188 178.624 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 170.73 -148.17 11.16 Favored Glycine 0 C--O 1.222 -0.635 0 C-N-CA 120.832 -0.699 . . . . 0.0 111.493 -179.728 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 14.1 m -136.22 147.99 27.7 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.981 0 N-CA-C 109.119 -0.697 . . . . 0.0 109.119 -179.793 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 21.6 t . . . . . 0 C--O 1.221 -0.405 0 CA-C-O 117.722 -1.132 . . . . 0.0 111.129 179.138 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 21.7 m-85 . . . . . 0 N--CA 1.475 0.778 0 CA-C-O 120.991 0.424 . . . . 0.0 110.149 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' G' G ' 5' ' ' ARG . . . . . . . . . . . . . 55.0 mtp180 -67.13 129.1 38.79 Favored 'General case' 0 N--CA 1.469 0.512 0 CA-C-N 115.65 -0.705 . . . . 0.0 110.287 -178.152 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 44.2 m170 -96.09 125.48 40.65 Favored 'General case' 0 N--CA 1.474 0.726 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 178.904 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 9.8 m-20 -72.37 141.5 48.74 Favored 'General case' 0 N--CA 1.468 0.437 0 O-C-N 123.742 0.652 . . . . 0.0 111.52 -179.698 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' G' G ' 8' ' ' SER . . . . . . . . . . . . . 23.2 t -158.58 -179.76 8.38 Favored 'General case' 0 N--CA 1.472 0.665 0 N-CA-C 109.196 -0.668 . . . . 0.0 109.196 178.408 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 125.02 20.16 2.31 Favored Glycine 0 N--CA 1.481 1.675 0 N-CA-C 111.617 -0.593 . . . . 0.0 111.617 179.477 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 43.1 p90 -57.75 128.7 38.41 Favored 'General case' 0 N--CA 1.474 0.727 0 N-CA-C 112.362 0.505 . . . . 0.0 112.362 -178.939 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 46.9 mt-10 -84.51 154.44 22.69 Favored 'General case' 0 N--CA 1.473 0.684 0 CA-C-O 121.055 0.455 . . . . 0.0 109.803 178.611 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 2.6 p -155.8 127.82 1.0 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.028 0 N-CA-C 108.353 -0.98 . . . . 0.0 108.353 178.926 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 50.2 m-70 -134.02 142.99 47.83 Favored 'General case' 0 N--CA 1.476 0.832 0 CA-C-N 115.154 -0.93 . . . . 0.0 111.077 -178.214 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -166.32 98.33 0.6 Allowed 'General case' 0 N--CA 1.484 1.227 0 CA-C-N 116.52 -0.309 . . . . 0.0 110.655 179.129 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' G' G ' 15' ' ' GLN . . . . . 0.518 HE21 ' CA ' ' G' ' 37' ' ' GLY . 49.5 mt-30 -107.92 -171.91 1.96 Allowed 'General case' 0 CA--C 1.5 -0.943 0 N-CA-C 108.544 -0.91 . . . . 0.0 108.544 179.959 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -164.35 98.18 0.81 Allowed 'General case' 0 N--CA 1.472 0.627 0 CA-C-N 115.083 -0.962 . . . . 0.0 109.441 178.567 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' G' G ' 17' ' ' LEU . . . . . 0.4 ' N ' ' CD1' ' G' ' 17' ' ' LEU . 5.3 mp -106.83 162.28 13.95 Favored 'General case' 0 N--CA 1.486 1.36 0 N-CA-C 109.33 -0.619 . . . . 0.0 109.33 -179.757 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 41.0 t -142.46 118.27 5.62 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.974 0 C-N-CA 122.601 0.361 . . . . 0.0 110.18 178.823 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 48.7 m-85 -69.33 150.49 47.29 Favored 'General case' 0 C--N 1.371 1.524 0 N-CA-C 107.454 -1.313 . . . . 0.0 107.454 176.709 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 11.4 t80 -171.09 -55.29 0.02 OUTLIER 'General case' 0 N--CA 1.486 1.351 0 CA-C-N 117.802 0.274 . . . . 0.0 110.263 -179.926 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.88 90.09 0.0 OUTLIER 'General case' 0 C--N 1.326 -0.446 0 C-N-CA 123.655 0.782 . . . . 0.0 112.339 179.925 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 38.4 tt0 -61.93 156.66 20.36 Favored 'General case' 0 N--CA 1.469 0.484 0 CA-C-N 114.855 -1.066 . . . . 0.0 110.029 178.886 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 12.1 m-20 -138.31 129.85 27.76 Favored 'General case' 0 N--CA 1.481 1.101 0 C-N-CA 122.958 0.503 . . . . 0.0 110.148 -179.557 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' G' G ' 24' ' ' VAL . . . . . 0.62 ' CG1' ' H ' ' G' ' 25' ' ' GLY . 39.5 t -81.03 -164.03 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.972 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 179.578 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' G' G ' 25' ' ' GLY . . . . . 0.62 ' H ' ' CG1' ' G' ' 24' ' ' VAL . . . -70.48 51.51 0.84 Allowed Glycine 0 CA--C 1.527 0.836 0 CA-C-N 118.383 0.538 . . . . 0.0 112.452 -179.016 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 18.0 p -72.34 135.9 46.03 Favored 'General case' 0 C--N 1.329 -0.294 0 N-CA-C 109.175 -0.676 . . . . 0.0 109.175 177.936 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 2.0 t-20 -69.1 94.5 0.67 Allowed 'General case' 0 CA--C 1.536 0.416 0 N-CA-C 107.902 -1.147 . . . . 0.0 107.902 177.814 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 68.0 mttm -92.14 118.94 31.32 Favored 'General case' 0 N--CA 1.482 1.134 0 N-CA-C 110.06 -0.348 . . . . 0.0 110.06 -179.2 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.45 -123.37 0.01 OUTLIER Glycine 0 CA--C 1.534 1.247 0 N-CA-C 110.517 -1.033 . . . . 0.0 110.517 178.608 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -129.91 133.54 46.92 Favored 'General case' 0 N--CA 1.47 0.547 0 N-CA-C 109.526 -0.546 . . . . 0.0 109.526 179.604 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 68.8 mt -81.9 140.23 16.78 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.664 0 N-CA-C 107.37 -1.344 . . . . 0.0 107.37 178.626 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 41.3 mt -131.81 129.27 60.94 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.402 0 CA-C-N 119.135 0.88 . . . . 0.0 109.375 179.698 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.47 79.41 0.13 Allowed Glycine 0 CA--C 1.527 0.816 0 CA-C-N 116.302 -0.408 . . . . 0.0 112.882 179.13 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 1.7 tt -110.34 121.69 45.88 Favored 'General case' 0 N--CA 1.482 1.142 0 N-CA-C 107.146 -1.427 . . . . 0.0 107.146 177.616 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 9.2 mtp -154.34 163.91 39.43 Favored 'General case' 0 N--CA 1.477 0.917 0 N-CA-C 107.94 -1.133 . . . . 0.0 107.94 179.583 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 91.6 t -160.03 145.22 5.92 Favored 'Isoleucine or valine' 0 C--O 1.232 0.167 0 N-CA-C 106.376 -1.713 . . . . 0.0 106.376 179.901 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' G' G ' 37' ' ' GLY . . . . . 0.518 ' CA ' HE21 ' G' ' 15' ' ' GLN . . . 55.75 73.88 0.38 Allowed Glycine 0 C--N 1.316 -0.561 0 N-CA-C 111.58 -0.608 . . . . 0.0 111.58 178.355 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 169.69 -146.96 10.46 Favored Glycine 0 N--CA 1.469 0.886 0 N-CA-C 110.834 -0.907 . . . . 0.0 110.834 179.583 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 15.3 m -136.33 148.31 27.41 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.932 0 CA-C-N 117.042 0.421 . . . . 0.0 109.995 -179.768 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 21.2 t . . . . . 0 N--CA 1.472 0.649 0 CA-C-O 117.881 -1.057 . . . . 0.0 111.232 179.257 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 21.8 m-85 . . . . . 0 N--CA 1.473 0.7 0 CA-C-O 121.064 0.459 . . . . 0.0 110.105 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' H' H ' 5' ' ' ARG . . . . . . . . . . . . . 54.5 mtp180 -67.16 129.12 38.88 Favored 'General case' 0 N--CA 1.469 0.489 0 CA-C-N 115.591 -0.731 . . . . 0.0 110.382 -178.15 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 44.5 m170 -96.13 125.27 40.55 Favored 'General case' 0 N--CA 1.474 0.772 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 179.0 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 9.7 m-20 -72.34 141.29 48.79 Favored 'General case' 0 N--CA 1.468 0.458 0 O-C-N 123.453 0.47 . . . . 0.0 111.506 -179.643 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' H' H ' 8' ' ' SER . . . . . . . . . . . . . 22.7 t -158.25 -179.83 8.47 Favored 'General case' 0 N--CA 1.472 0.642 0 N-CA-C 109.192 -0.669 . . . . 0.0 109.192 178.626 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 124.74 20.23 2.36 Favored Glycine 0 N--CA 1.481 1.645 0 N-CA-C 111.67 -0.572 . . . . 0.0 111.67 179.573 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 42.5 p90 -57.77 128.81 38.94 Favored 'General case' 0 N--CA 1.473 0.708 0 N-CA-C 112.344 0.498 . . . . 0.0 112.344 -179.038 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 46.9 mt-10 -84.48 154.36 22.77 Favored 'General case' 0 N--CA 1.475 0.795 0 CA-C-O 121.074 0.464 . . . . 0.0 109.839 178.571 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.6 p -155.69 128.03 1.04 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.048 0 N-CA-C 108.373 -0.973 . . . . 0.0 108.373 178.867 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 50.2 m-70 -134.11 143.27 47.88 Favored 'General case' 0 N--CA 1.476 0.851 0 CA-C-N 115.158 -0.928 . . . . 0.0 111.151 -178.171 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -166.75 98.32 0.56 Allowed 'General case' 0 N--CA 1.482 1.168 0 CA-C-N 116.65 -0.25 . . . . 0.0 110.726 179.131 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' H' H ' 15' ' ' GLN . . . . . 0.512 HE21 ' CA ' ' H' ' 37' ' ' GLY . 49.0 mt-30 -108.0 -172.39 2.05 Favored 'General case' 0 CA--C 1.499 -1.001 0 N-CA-C 108.42 -0.956 . . . . 0.0 108.42 -179.964 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -164.1 97.94 0.83 Allowed 'General case' 0 N--CA 1.471 0.582 0 CA-C-N 115.083 -0.962 . . . . 0.0 109.277 178.748 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' H' H ' 17' ' ' LEU . . . . . 0.405 ' N ' ' CD1' ' H' ' 17' ' ' LEU . 5.3 mp -106.67 162.24 13.94 Favored 'General case' 0 N--CA 1.486 1.354 0 N-CA-C 109.259 -0.645 . . . . 0.0 109.259 -179.774 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 41.0 t -142.35 118.15 5.73 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.032 0 C-N-CA 122.613 0.365 . . . . 0.0 110.209 178.899 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 49.1 m-85 -69.65 150.88 46.55 Favored 'General case' 0 C--N 1.371 1.502 0 N-CA-C 107.517 -1.29 . . . . 0.0 107.517 176.631 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 12.1 t80 -172.31 -54.88 0.02 OUTLIER 'General case' 0 N--CA 1.482 1.163 0 N-CA-C 110.213 -0.292 . . . . 0.0 110.213 -179.752 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -42.14 90.55 0.0 OUTLIER 'General case' 0 CA--C 1.534 0.352 0 C-N-CA 123.543 0.737 . . . . 0.0 112.095 179.942 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 38.5 tt0 -62.09 156.64 20.95 Favored 'General case' 0 N--CA 1.469 0.493 0 CA-C-N 114.815 -1.084 . . . . 0.0 110.105 179.087 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 12.0 m-20 -138.16 129.98 28.27 Favored 'General case' 0 N--CA 1.48 1.066 0 C-N-CA 122.968 0.507 . . . . 0.0 110.215 -179.536 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' H' H ' 24' ' ' VAL . . . . . 0.632 ' CG1' ' H ' ' H' ' 25' ' ' GLY . 39.4 t -81.3 -164.1 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.992 0 N-CA-C 108.376 -0.972 . . . . 0.0 108.376 179.664 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' H' H ' 25' ' ' GLY . . . . . 0.632 ' H ' ' CG1' ' H' ' 24' ' ' VAL . . . -70.18 51.32 0.77 Allowed Glycine 0 CA--C 1.529 0.932 0 CA-C-N 118.483 0.583 . . . . 0.0 112.268 -179.095 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 17.9 p -72.44 135.96 45.89 Favored 'General case' 0 C--N 1.33 -0.254 0 N-CA-C 109.3 -0.63 . . . . 0.0 109.3 177.945 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 2.0 t-20 -69.2 94.58 0.69 Allowed 'General case' 0 CA--C 1.535 0.368 0 N-CA-C 107.968 -1.123 . . . . 0.0 107.968 177.944 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 68.0 mttm -92.27 118.86 31.31 Favored 'General case' 0 N--CA 1.48 1.066 0 N-CA-C 110.111 -0.329 . . . . 0.0 110.111 -179.21 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.47 -123.02 0.01 OUTLIER Glycine 0 CA--C 1.535 1.291 0 N-CA-C 110.477 -1.049 . . . . 0.0 110.477 178.601 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.04 133.77 46.94 Favored 'General case' 0 N--CA 1.471 0.616 0 C-N-CA 123.0 0.52 . . . . 0.0 109.61 179.715 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 68.5 mt -82.2 140.1 16.93 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.591 0 N-CA-C 107.315 -1.365 . . . . 0.0 107.315 178.57 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 41.6 mt -131.74 129.46 61.26 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.278 0 CA-C-N 119.092 0.86 . . . . 0.0 109.317 179.826 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.14 79.48 0.12 Allowed Glycine 0 CA--C 1.527 0.788 0 CA-C-N 116.239 -0.437 . . . . 0.0 112.933 179.155 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 1.7 tt -110.44 121.76 46.09 Favored 'General case' 0 N--CA 1.481 1.099 0 N-CA-C 107.082 -1.451 . . . . 0.0 107.082 177.592 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 9.3 mtp -154.3 163.71 39.73 Favored 'General case' 0 N--CA 1.476 0.85 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 179.679 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 89.9 t -160.05 145.2 5.89 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.163 0 N-CA-C 106.415 -1.698 . . . . 0.0 106.415 179.838 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' H' H ' 37' ' ' GLY . . . . . 0.512 ' CA ' HE21 ' H' ' 15' ' ' GLN . . . 55.75 73.77 0.39 Allowed Glycine 0 C--N 1.316 -0.537 0 N-CA-C 111.536 -0.625 . . . . 0.0 111.536 178.433 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 169.9 -147.19 10.6 Favored Glycine 0 N--CA 1.469 0.899 0 N-CA-C 110.779 -0.928 . . . . 0.0 110.779 179.641 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 15.1 m -136.25 148.18 27.57 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.918 0 CA-C-N 116.938 0.369 . . . . 0.0 110.033 -179.763 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 21.3 t . . . . . 0 N--CA 1.471 0.625 0 CA-C-O 117.864 -1.065 . . . . 0.0 111.138 179.227 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 21.8 m-85 . . . . . 0 N--CA 1.473 0.712 0 CA-C-O 120.981 0.42 . . . . 0.0 110.169 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' I' I ' 5' ' ' ARG . . . . . . . . . . . . . 54.6 mtp180 -67.18 128.89 38.07 Favored 'General case' 0 N--CA 1.468 0.455 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.378 -178.214 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 44.3 m170 -95.87 125.22 40.27 Favored 'General case' 0 N--CA 1.475 0.777 0 N-CA-C 109.736 -0.468 . . . . 0.0 109.736 178.99 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 9.8 m-20 -72.21 141.76 49.0 Favored 'General case' 0 N--CA 1.468 0.442 0 O-C-N 123.484 0.49 . . . . 0.0 111.397 -179.682 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' I' I ' 8' ' ' SER . . . . . . . . . . . . . 22.7 t -158.65 179.94 8.65 Favored 'General case' 0 N--CA 1.472 0.63 0 N-CA-C 109.201 -0.666 . . . . 0.0 109.201 178.636 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 124.87 20.29 2.32 Favored Glycine 0 N--CA 1.482 1.739 0 N-CA-C 111.646 -0.582 . . . . 0.0 111.646 179.487 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 42.8 p90 -57.71 128.75 38.62 Favored 'General case' 0 N--CA 1.474 0.765 0 N-CA-C 112.342 0.497 . . . . 0.0 112.342 -179.053 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 46.8 mt-10 -84.39 154.48 22.8 Favored 'General case' 0 N--CA 1.474 0.773 0 CA-C-O 121.043 0.449 . . . . 0.0 109.806 178.538 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 2.6 p -155.82 128.04 1.03 Allowed 'Isoleucine or valine' 0 CA--C 1.553 1.062 0 N-CA-C 108.332 -0.988 . . . . 0.0 108.332 178.843 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 50.4 m-70 -134.17 143.27 47.81 Favored 'General case' 0 N--CA 1.476 0.848 0 CA-C-N 115.094 -0.957 . . . . 0.0 111.094 -178.182 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -166.75 98.37 0.56 Allowed 'General case' 0 N--CA 1.483 1.198 0 CA-C-N 116.626 -0.261 . . . . 0.0 110.795 179.125 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' I' I ' 15' ' ' GLN . . . . . 0.52 HE21 ' CA ' ' I' ' 37' ' ' GLY . 48.9 mt-30 -108.12 -172.15 2.01 Favored 'General case' 0 CA--C 1.499 -0.99 0 N-CA-C 108.441 -0.948 . . . . 0.0 108.441 -179.981 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -164.21 98.03 0.82 Allowed 'General case' 0 N--CA 1.471 0.606 0 CA-C-N 114.992 -1.004 . . . . 0.0 109.333 178.691 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' I' I ' 17' ' ' LEU . . . . . 0.4 ' N ' ' CD1' ' I' ' 17' ' ' LEU . 5.3 mp -106.64 162.21 13.96 Favored 'General case' 0 N--CA 1.487 1.388 0 N-CA-C 109.278 -0.638 . . . . 0.0 109.278 -179.749 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 40.7 t -142.24 118.12 5.93 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.059 0 C-N-CA 122.632 0.373 . . . . 0.0 110.223 178.851 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 49.2 m-85 -69.61 150.81 46.66 Favored 'General case' 0 C--N 1.37 1.494 0 N-CA-C 107.49 -1.3 . . . . 0.0 107.49 176.599 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 12.2 t80 -172.2 -55.0 0.02 OUTLIER 'General case' 0 N--CA 1.483 1.201 0 N-CA-C 110.231 -0.285 . . . . 0.0 110.231 -179.826 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -42.08 90.45 0.0 OUTLIER 'General case' 0 CA--C 1.535 0.389 0 C-N-CA 123.657 0.783 . . . . 0.0 112.084 179.958 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 38.3 tt0 -62.02 156.68 20.65 Favored 'General case' 0 N--CA 1.469 0.519 0 CA-C-N 114.793 -1.094 . . . . 0.0 110.043 179.147 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 12.3 m-20 -138.17 129.83 28.04 Favored 'General case' 0 N--CA 1.481 1.097 0 C-N-CA 122.973 0.509 . . . . 0.0 110.217 -179.624 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' I' I ' 24' ' ' VAL . . . . . 0.633 ' CG1' ' H ' ' I' ' 25' ' ' GLY . 38.8 t -80.96 -163.87 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 1.005 0 N-CA-C 108.381 -0.97 . . . . 0.0 108.381 179.618 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' I' I ' 25' ' ' GLY . . . . . 0.633 ' H ' ' CG1' ' I' ' 24' ' ' VAL . . . -70.57 51.33 0.85 Allowed Glycine 0 CA--C 1.528 0.895 0 CA-C-N 118.364 0.529 . . . . 0.0 112.376 -179.074 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 17.7 p -72.34 136.04 46.07 Favored 'General case' 0 C--N 1.33 -0.252 0 N-CA-C 109.252 -0.647 . . . . 0.0 109.252 177.947 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 2.0 t-20 -69.23 94.58 0.7 Allowed 'General case' 0 CA--C 1.535 0.371 0 N-CA-C 107.953 -1.128 . . . . 0.0 107.953 177.888 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 68.1 mttm -92.32 118.96 31.43 Favored 'General case' 0 N--CA 1.48 1.068 0 N-CA-C 110.15 -0.315 . . . . 0.0 110.15 -179.15 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.52 -123.31 0.01 OUTLIER Glycine 0 CA--C 1.534 1.249 0 N-CA-C 110.632 -0.987 . . . . 0.0 110.632 178.648 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -129.77 133.21 46.86 Favored 'General case' 0 N--CA 1.472 0.665 0 C-N-CA 123.047 0.539 . . . . 0.0 109.594 179.715 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 68.5 mt -81.86 139.99 17.15 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.555 0 N-CA-C 107.266 -1.383 . . . . 0.0 107.266 178.605 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 41.1 mt -131.62 129.48 61.62 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.359 0 CA-C-N 119.023 0.829 . . . . 0.0 109.318 179.807 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.13 79.36 0.13 Allowed Glycine 0 CA--C 1.527 0.814 0 CA-C-N 116.289 -0.414 . . . . 0.0 112.936 179.085 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 1.7 tt -110.28 121.73 45.97 Favored 'General case' 0 N--CA 1.481 1.087 0 N-CA-C 107.163 -1.421 . . . . 0.0 107.163 177.55 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 9.4 mtp -154.26 163.7 39.72 Favored 'General case' 0 N--CA 1.475 0.786 0 N-CA-C 107.971 -1.122 . . . . 0.0 107.971 179.786 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 89.5 t -160.04 145.31 5.94 Favored 'Isoleucine or valine' 0 C--O 1.232 0.162 0 N-CA-C 106.423 -1.695 . . . . 0.0 106.423 179.801 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' I' I ' 37' ' ' GLY . . . . . 0.52 ' CA ' HE21 ' I' ' 15' ' ' GLN . . . 55.55 74.03 0.36 Allowed Glycine 0 C--N 1.315 -0.599 0 N-CA-C 111.573 -0.611 . . . . 0.0 111.573 178.484 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 169.68 -147.04 10.53 Favored Glycine 0 N--CA 1.469 0.877 0 N-CA-C 110.806 -0.918 . . . . 0.0 110.806 179.587 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 15.1 m -136.3 148.27 27.47 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.96 0 CA-C-N 116.979 0.389 . . . . 0.0 110.06 -179.79 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 21.4 t . . . . . 0 N--CA 1.471 0.61 0 CA-C-O 117.899 -1.048 . . . . 0.0 111.07 179.139 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 21.1 p90 . . . . . 0 N--CA 1.471 0.578 0 N-CA-C 110.384 -0.228 . . . . 0.0 110.384 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 99.0 mtt180 -136.73 153.18 50.93 Favored 'General case' 0 N--CA 1.482 1.137 0 N-CA-C 109.527 -0.546 . . . . 0.0 109.527 178.523 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 58.5 t-80 -113.98 114.82 26.69 Favored 'General case' 0 N--CA 1.477 0.9 0 C-N-CA 123.094 0.557 . . . . 0.0 109.627 179.493 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' ASP . . . . . 0.437 ' O ' ' OG ' ' D' ' 8' ' ' SER . 8.9 m-20 -72.99 156.36 38.91 Favored 'General case' 0 N--CA 1.465 0.307 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.062 179.053 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 9.5 p -166.17 -177.08 3.97 Favored 'General case' 0 N--CA 1.483 1.181 0 CA-C-O 120.913 0.387 . . . . 0.0 110.528 178.736 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.9 43.94 1.58 Allowed Glycine 0 N--CA 1.482 1.708 0 CA-C-N 115.747 -0.661 . . . . 0.0 112.19 179.427 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 51.2 p90 -65.32 131.86 47.54 Favored 'General case' 0 N--CA 1.473 0.715 0 CA-C-N 116.83 0.315 . . . . 0.0 111.479 179.751 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 84.4 mt-10 -94.3 153.52 17.97 Favored 'General case' 0 N--CA 1.476 0.853 0 N-CA-C 109.655 -0.498 . . . . 0.0 109.655 178.587 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -153.28 128.52 1.55 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.583 0 N-CA-C 107.781 -1.192 . . . . 0.0 107.781 178.126 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 50.9 m-70 -135.13 144.88 47.34 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 119.144 0.884 . . . . 0.0 111.221 -179.143 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 6.3 t60 -165.83 99.0 0.66 Allowed 'General case' 0 N--CA 1.48 1.061 0 CA-C-N 116.394 -0.366 . . . . 0.0 110.588 179.465 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 22.2 pt20 -124.41 155.33 39.01 Favored 'General case' 0 CA--C 1.501 -0.927 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 -179.609 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -124.99 106.02 9.64 Favored 'General case' 0 N--CA 1.478 0.974 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 177.986 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 6.1 mp -121.16 148.88 43.62 Favored 'General case' 0 N--CA 1.497 1.908 0 CA-C-O 121.412 0.625 . . . . 0.0 110.797 -178.528 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 30.8 t -107.57 123.77 63.12 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.018 0 N-CA-C 108.077 -1.083 . . . . 0.0 108.077 177.612 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.506 ' O ' ' N ' ' A' ' 21' ' ' ALA . 25.7 m-85 -119.57 -160.89 0.83 Allowed 'General case' 0 N--CA 1.498 1.962 0 CA-C-N 120.232 1.378 . . . . 0.0 109.178 -179.966 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.492 ' O ' ' HA ' ' D' ' 20' ' ' PHE . 78.7 m-85 -50.94 76.8 0.0 OUTLIER 'General case' 0 C--O 1.2 -1.511 0 C-N-CA 123.772 0.829 . . . . 0.0 111.318 -179.164 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . 0.506 ' N ' ' O ' ' A' ' 19' ' ' PHE . . . -88.47 -75.61 0.42 Allowed 'General case' 0 N--CA 1.471 0.597 0 CA-C-N 115.691 -0.686 . . . . 0.0 110.158 -179.614 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 40.4 tt0 -96.12 98.65 10.51 Favored 'General case' 0 N--CA 1.463 0.205 0 N-CA-C 108.461 -0.94 . . . . 0.0 108.461 179.349 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 4.1 p30 -159.45 145.03 15.91 Favored 'General case' 0 N--CA 1.484 1.242 0 O-C-N 122.334 -0.229 . . . . 0.0 110.828 179.598 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 88.6 t -63.04 163.91 1.46 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.799 0 N-CA-C 107.619 -1.252 . . . . 0.0 107.619 176.998 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.439 ' H ' ' HB ' ' D' ' 24' ' ' VAL . . . -117.8 45.62 1.25 Allowed Glycine 0 N--CA 1.474 1.183 0 CA-C-O 119.649 -0.529 . . . . 0.0 111.927 -179.409 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -60.32 -165.21 0.01 OUTLIER 'General case' 0 N--CA 1.471 0.622 0 O-C-N 123.805 0.356 . . . . 0.0 110.461 179.618 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 24.0 t-20 -70.23 80.77 0.52 Allowed 'General case' 0 N--CA 1.463 0.197 0 CA-C-N 116.378 -0.373 . . . . 0.0 110.384 179.654 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 96.9 mttt -79.73 138.23 37.25 Favored 'General case' 0 N--CA 1.472 0.635 0 N-CA-C 109.195 -0.668 . . . . 0.0 109.195 179.365 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.84 -166.13 0.9 Allowed Glycine 0 C--N 1.337 0.621 0 N-CA-C 109.68 -1.368 . . . . 0.0 109.68 178.189 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.73 113.99 26.83 Favored 'General case' 0 N--CA 1.474 0.772 0 N-CA-C 109.546 -0.538 . . . . 0.0 109.546 179.505 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 76.5 mt -99.58 135.39 35.2 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.601 0 N-CA-C 107.054 -1.462 . . . . 0.0 107.054 178.734 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . 0.442 ' C ' ' H ' ' A' ' 34' ' ' LEU . 26.7 pt -150.78 -172.1 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.353 0.743 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.326 -179.27 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.57 2.53 6.0 Favored Glycine 0 CA--C 1.525 0.711 0 N-CA-C 110.864 -0.894 . . . . 0.0 110.864 -179.905 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . 0.442 ' H ' ' C ' ' A' ' 32' ' ' ILE . 1.1 tt -74.66 133.58 42.1 Favored 'General case' 0 CA--C 1.544 0.735 0 N-CA-C 109.247 -0.649 . . . . 0.0 109.247 -179.611 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 26.6 ttt -159.44 151.4 20.68 Favored 'General case' 0 N--CA 1.47 0.527 0 N-CA-C 108.297 -1.001 . . . . 0.0 108.297 178.924 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 63.3 t -154.49 162.89 1.81 Allowed 'Isoleucine or valine' 0 C--N 1.344 0.353 0 N-CA-C 107.774 -1.195 . . . . 0.0 107.774 -179.52 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 57.57 67.32 2.27 Favored Glycine 0 C--N 1.306 -1.091 0 CA-C-N 115.606 -0.725 . . . . 0.0 112.133 178.717 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.7 177.83 22.44 Favored Glycine 0 N--CA 1.476 1.325 0 N-CA-C 111.045 -0.822 . . . . 0.0 111.045 178.717 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 33.4 m -109.69 152.71 11.66 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.612 0 C-N-CA 123.419 0.687 . . . . 0.0 110.217 -179.58 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 21.9 t . . . . . 0 C--O 1.216 -0.678 0 CA-C-O 118.319 -0.848 . . . . 0.0 110.531 179.615 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 20.5 p90 . . . . . 0 N--CA 1.47 0.549 0 N-CA-C 110.546 -0.168 . . . . 0.0 110.546 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 99.0 mtt180 -136.56 152.98 51.08 Favored 'General case' 0 N--CA 1.481 1.094 0 N-CA-C 109.517 -0.549 . . . . 0.0 109.517 178.534 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 58.4 t-80 -113.91 114.85 26.8 Favored 'General case' 0 N--CA 1.477 0.918 0 C-N-CA 123.156 0.582 . . . . 0.0 109.691 179.522 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 7' ' ' ASP . . . . . 0.427 ' O ' ' OG ' ' E' ' 8' ' ' SER . 8.4 m-20 -73.13 155.95 39.15 Favored 'General case' 0 N--CA 1.467 0.41 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.124 179.151 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 8' ' ' SER . . . . . . . . . . . . . 9.6 p -165.94 -176.93 4.0 Favored 'General case' 0 N--CA 1.481 1.105 0 CA-C-O 120.942 0.401 . . . . 0.0 110.567 178.847 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.67 44.08 1.6 Allowed Glycine 0 N--CA 1.483 1.779 0 CA-C-N 115.701 -0.681 . . . . 0.0 112.232 179.528 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 51.0 p90 -65.66 132.02 47.78 Favored 'General case' 0 N--CA 1.472 0.649 0 CA-C-O 120.688 0.28 . . . . 0.0 111.492 179.823 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 84.2 mt-10 -94.28 153.71 17.89 Favored 'General case' 0 N--CA 1.477 0.876 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 178.483 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -153.41 128.38 1.5 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.511 0 N-CA-C 107.738 -1.208 . . . . 0.0 107.738 178.119 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 49.9 m-70 -135.19 144.5 47.02 Favored 'General case' 0 N--CA 1.492 1.664 0 CA-C-N 119.042 0.837 . . . . 0.0 111.218 -179.091 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 6.3 t60 -165.45 98.71 0.7 Allowed 'General case' 0 N--CA 1.481 1.088 0 CA-C-N 116.461 -0.336 . . . . 0.0 110.482 179.573 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 22.2 pt20 -124.14 155.38 38.54 Favored 'General case' 0 CA--C 1.501 -0.909 0 N-CA-C 107.988 -1.116 . . . . 0.0 107.988 -179.694 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -124.99 106.13 9.73 Favored 'General case' 0 N--CA 1.479 1.016 0 N-CA-C 108.121 -1.066 . . . . 0.0 108.121 178.037 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 6.1 mp -121.25 148.82 43.77 Favored 'General case' 0 N--CA 1.497 1.901 0 CA-C-O 121.397 0.618 . . . . 0.0 110.809 -178.518 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 29.8 t -107.6 124.59 63.72 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.038 0 N-CA-C 107.949 -1.13 . . . . 0.0 107.949 177.502 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 19' ' ' PHE . . . . . 0.514 ' O ' ' N ' ' B' ' 21' ' ' ALA . 25.5 m-85 -120.65 -161.12 0.87 Allowed 'General case' 0 N--CA 1.496 1.842 0 CA-C-N 119.906 1.23 . . . . 0.0 109.09 -179.779 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . 0.478 ' O ' ' HA ' ' E' ' 20' ' ' PHE . 77.7 m-85 -51.1 76.56 0.0 OUTLIER 'General case' 0 C--O 1.202 -1.421 0 C-N-CA 123.684 0.794 . . . . 0.0 111.451 -179.129 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 21' ' ' ALA . . . . . 0.514 ' N ' ' O ' ' B' ' 19' ' ' PHE . . . -88.35 -75.9 0.41 Allowed 'General case' 0 N--CA 1.47 0.539 0 CA-C-N 115.628 -0.715 . . . . 0.0 110.1 -179.692 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 40.5 tt0 -95.9 98.95 10.8 Favored 'General case' 0 N--CA 1.464 0.231 0 N-CA-C 108.49 -0.929 . . . . 0.0 108.49 179.358 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 4.1 p30 -159.65 144.96 15.55 Favored 'General case' 0 N--CA 1.483 1.212 0 O-C-N 122.407 -0.183 . . . . 0.0 110.892 179.578 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 94.0 t -62.9 163.76 1.46 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.808 0 N-CA-C 107.609 -1.256 . . . . 0.0 107.609 177.088 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 25' ' ' GLY . . . . . 0.425 ' H ' ' HB ' ' E' ' 24' ' ' VAL . . . -117.54 45.67 1.24 Allowed Glycine 0 N--CA 1.474 1.231 0 N-CA-C 111.903 -0.479 . . . . 0.0 111.903 -179.371 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -60.67 -165.05 0.01 OUTLIER 'General case' 0 N--CA 1.472 0.643 0 O-C-N 123.62 0.247 . . . . 0.0 110.452 179.688 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 24.1 t-20 -70.4 80.93 0.55 Allowed 'General case' 0 N--CA 1.464 0.272 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.268 179.664 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 96.8 mttt -79.87 138.28 37.13 Favored 'General case' 0 N--CA 1.472 0.656 0 N-CA-C 109.187 -0.672 . . . . 0.0 109.187 179.373 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.82 -166.14 0.9 Allowed Glycine 0 C--N 1.337 0.602 0 N-CA-C 109.638 -1.385 . . . . 0.0 109.638 178.231 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.68 113.84 26.55 Favored 'General case' 0 N--CA 1.474 0.729 0 N-CA-C 109.639 -0.504 . . . . 0.0 109.639 179.475 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 76.0 mt -99.44 135.32 35.25 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.527 0 N-CA-C 107.054 -1.461 . . . . 0.0 107.054 178.733 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . 0.431 ' C ' ' H ' ' B' ' 34' ' ' LEU . 26.6 pt -150.73 -172.05 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.353 0.729 0 CA-C-O 121.185 0.517 . . . . 0.0 111.259 -179.278 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.67 2.35 5.94 Favored Glycine 0 CA--C 1.525 0.692 0 N-CA-C 110.776 -0.93 . . . . 0.0 110.776 -179.919 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 34' ' ' LEU . . . . . 0.431 ' H ' ' C ' ' B' ' 32' ' ' ILE . 1.1 tt -74.55 133.2 42.28 Favored 'General case' 0 CA--C 1.545 0.773 0 N-CA-C 109.209 -0.663 . . . . 0.0 109.209 -179.588 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 26.6 ttt -159.04 150.76 20.68 Favored 'General case' 0 N--CA 1.47 0.562 0 N-CA-C 108.362 -0.977 . . . . 0.0 108.362 178.722 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 64.0 t -153.79 162.51 2.08 Favored 'Isoleucine or valine' 0 C--N 1.345 0.394 0 N-CA-C 107.838 -1.171 . . . . 0.0 107.838 -179.599 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 58.07 67.13 2.36 Favored Glycine 0 C--N 1.307 -1.043 0 CA-C-N 115.586 -0.734 . . . . 0.0 112.071 178.627 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.85 177.31 22.14 Favored Glycine 0 N--CA 1.475 1.298 0 N-CA-C 111.042 -0.823 . . . . 0.0 111.042 178.797 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 33.6 m -109.21 152.5 11.25 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.621 0 C-N-CA 123.37 0.668 . . . . 0.0 110.316 -179.599 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 22.0 t . . . . . 0 C--O 1.215 -0.758 0 CA-C-O 118.379 -0.82 . . . . 0.0 110.422 179.604 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 20.4 p90 . . . . . 0 N--CA 1.47 0.542 0 N-CA-C 110.566 -0.161 . . . . 0.0 110.566 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 99.0 mtt180 -136.68 153.09 50.99 Favored 'General case' 0 N--CA 1.481 1.089 0 N-CA-C 109.546 -0.539 . . . . 0.0 109.546 178.528 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 58.3 t-80 -113.86 115.06 27.14 Favored 'General case' 0 N--CA 1.478 0.951 0 C-N-CA 123.052 0.541 . . . . 0.0 109.6 179.634 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' C' C ' 7' ' ' ASP . . . . . 0.429 ' O ' ' OG ' ' F' ' 8' ' ' SER . 8.6 m-20 -73.38 155.75 39.04 Favored 'General case' 0 N--CA 1.467 0.385 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.167 179.086 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' C' C ' 8' ' ' SER . . . . . . . . . . . . . 9.5 p -165.67 -176.98 4.13 Favored 'General case' 0 N--CA 1.482 1.167 0 CA-C-O 120.909 0.385 . . . . 0.0 110.567 178.748 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.87 44.01 1.58 Allowed Glycine 0 N--CA 1.483 1.781 0 CA-C-N 115.728 -0.669 . . . . 0.0 112.284 179.49 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 51.0 p90 -65.49 132.0 47.83 Favored 'General case' 0 N--CA 1.473 0.724 0 O-C-N 122.653 -0.322 . . . . 0.0 111.465 179.789 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 83.7 mt-10 -94.27 153.78 17.86 Favored 'General case' 0 N--CA 1.476 0.84 0 N-CA-C 109.634 -0.506 . . . . 0.0 109.634 178.507 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -153.43 128.52 1.52 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.61 0 N-CA-C 107.757 -1.201 . . . . 0.0 107.757 178.135 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 50.0 m-70 -135.33 144.57 46.78 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 119.084 0.856 . . . . 0.0 111.142 -179.104 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 6.3 t60 -165.65 98.71 0.68 Allowed 'General case' 0 N--CA 1.48 1.066 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.458 179.549 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 21.9 pt20 -124.24 155.47 38.53 Favored 'General case' 0 CA--C 1.503 -0.859 0 N-CA-C 107.865 -1.161 . . . . 0.0 107.865 -179.66 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -124.97 106.31 9.87 Favored 'General case' 0 N--CA 1.479 1.004 0 N-CA-C 108.208 -1.034 . . . . 0.0 108.208 177.969 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 6.1 mp -121.34 148.88 43.76 Favored 'General case' 0 N--CA 1.498 1.966 0 CA-C-O 121.474 0.654 . . . . 0.0 110.796 -178.433 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 29.0 t -107.74 124.53 63.88 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.088 0 N-CA-C 107.968 -1.123 . . . . 0.0 107.968 177.51 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' C' C ' 19' ' ' PHE . . . . . 0.517 ' O ' ' N ' ' C' ' 21' ' ' ALA . 25.5 m-85 -120.55 -161.05 0.86 Allowed 'General case' 0 N--CA 1.496 1.857 0 CA-C-N 119.936 1.244 . . . . 0.0 109.13 -179.674 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' C' C ' 20' ' ' PHE . . . . . 0.482 ' O ' ' HA ' ' F' ' 20' ' ' PHE . 77.8 m-85 -51.25 76.46 0.0 OUTLIER 'General case' 0 C--O 1.202 -1.414 0 C-N-CA 123.716 0.807 . . . . 0.0 111.404 -179.186 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' C' C ' 21' ' ' ALA . . . . . 0.517 ' N ' ' O ' ' C' ' 19' ' ' PHE . . . -88.26 -75.89 0.41 Allowed 'General case' 0 N--CA 1.47 0.533 0 CA-C-N 115.604 -0.725 . . . . 0.0 110.142 -179.7 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 40.8 tt0 -95.74 98.62 10.6 Favored 'General case' 0 N--CA 1.464 0.265 0 N-CA-C 108.482 -0.933 . . . . 0.0 108.482 179.326 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 4.1 p30 -159.51 144.77 15.66 Favored 'General case' 0 N--CA 1.482 1.172 0 O-C-N 122.287 -0.258 . . . . 0.0 110.985 179.616 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 89.7 t -62.76 163.8 1.43 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.765 0 N-CA-C 107.681 -1.229 . . . . 0.0 107.681 177.067 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' C' C ' 25' ' ' GLY . . . . . 0.445 ' H ' ' HB ' ' F' ' 24' ' ' VAL . . . -117.65 45.72 1.24 Allowed Glycine 0 N--CA 1.476 1.364 0 N-CA-C 111.724 -0.55 . . . . 0.0 111.724 -179.377 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -60.47 -165.1 0.01 OUTLIER 'General case' 0 N--CA 1.472 0.647 0 CA-C-O 120.61 0.243 . . . . 0.0 110.421 179.616 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 24.1 t-20 -70.52 80.62 0.57 Allowed 'General case' 0 N--CA 1.464 0.258 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.308 179.684 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -79.41 138.5 37.65 Favored 'General case' 0 N--CA 1.472 0.639 0 N-CA-C 109.222 -0.659 . . . . 0.0 109.222 179.333 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.96 -165.68 0.87 Allowed Glycine 0 CA--C 1.523 0.588 0 N-CA-C 109.614 -1.394 . . . . 0.0 109.614 178.322 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.88 113.81 26.6 Favored 'General case' 0 N--CA 1.474 0.745 0 N-CA-C 109.617 -0.512 . . . . 0.0 109.617 179.459 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 76.0 mt -99.67 135.12 36.5 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.591 0 N-CA-C 107.041 -1.466 . . . . 0.0 107.041 178.83 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' C' C ' 32' ' ' ILE . . . . . 0.447 ' C ' ' H ' ' C' ' 34' ' ' LEU . 26.8 pt -150.61 -171.91 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.353 0.741 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.296 -179.305 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.59 2.24 5.67 Favored Glycine 0 CA--C 1.524 0.615 0 N-CA-C 110.808 -0.917 . . . . 0.0 110.808 -179.893 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' C' C ' 34' ' ' LEU . . . . . 0.447 ' H ' ' C ' ' C' ' 32' ' ' ILE . 1.1 tt -74.43 133.28 42.42 Favored 'General case' 0 CA--C 1.544 0.725 0 N-CA-C 109.275 -0.639 . . . . 0.0 109.275 -179.59 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 26.6 ttt -159.03 150.69 20.65 Favored 'General case' 0 N--CA 1.47 0.557 0 N-CA-C 108.477 -0.934 . . . . 0.0 108.477 178.786 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 62.7 t -153.64 162.82 2.01 Favored 'Isoleucine or valine' 0 C--N 1.344 0.336 0 N-CA-C 107.78 -1.193 . . . . 0.0 107.78 -179.695 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 57.85 67.37 2.24 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-N 115.488 -0.778 . . . . 0.0 112.043 178.549 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.65 177.41 22.06 Favored Glycine 0 N--CA 1.475 1.271 0 N-CA-C 111.027 -0.829 . . . . 0.0 111.027 178.736 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 33.6 m -109.16 152.67 11.15 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.647 0 C-N-CA 123.303 0.641 . . . . 0.0 110.19 -179.601 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 22.0 t . . . . . 0 C--O 1.216 -0.687 0 CA-C-O 118.273 -0.87 . . . . 0.0 110.581 179.608 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 34.1 p90 . . . . . 0 C--O 1.221 -0.423 0 N-CA-C 108.43 -0.952 . . . . 0.0 108.43 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' D' D ' 5' ' ' ARG . . . . . . . . . . . . . 99.1 mtt180 -132.18 154.67 49.32 Favored 'General case' 0 N--CA 1.477 0.921 0 N-CA-C 109.163 -0.68 . . . . 0.0 109.163 -177.501 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 55.5 t-80 -115.78 121.65 43.06 Favored 'General case' 0 C--N 1.37 1.466 0 N-CA-C 107.827 -1.175 . . . . 0.0 107.827 176.283 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' D' D ' 7' ' ' ASP . . . . . 0.533 ' O ' ' OG ' ' G' ' 8' ' ' SER 0.279 5.0 m-20 -65.11 136.91 57.27 Favored 'General case' 0 C--N 1.313 -1.005 0 C-N-CA 129.589 3.155 . . . . 0.0 115.638 171.6 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' D' D ' 8' ' ' SER . . . . . 0.437 ' OG ' ' O ' ' A' ' 7' ' ' ASP . 7.0 p -153.4 -174.21 4.86 Favored 'General case' 0 N--CA 1.487 1.411 0 CA-C-N 120.825 1.648 . . . . 0.0 111.062 174.704 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 105.07 46.5 1.25 Allowed Glycine 0 N--CA 1.483 1.769 0 C-N-CA 125.071 1.319 . . . . 0.0 110.558 174.78 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 52.6 p90 -60.96 130.69 47.68 Favored 'General case' 0 N--CA 1.472 0.637 0 N-CA-C 112.543 0.572 . . . . 0.0 112.543 177.151 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 84.9 mt-10 -90.94 151.83 20.95 Favored 'General case' 0 N--CA 1.48 1.027 0 CA-C-N 118.029 0.377 . . . . 0.0 110.857 174.946 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -149.62 130.1 4.35 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.615 0 N-CA-C 107.355 -1.35 . . . . 0.0 107.355 172.829 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 47.0 m-70 -129.92 147.61 51.69 Favored 'General case' 0 N--CA 1.483 1.223 0 CA-C-N 118.102 0.41 . . . . 0.0 111.774 176.32 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 6.3 t60 -165.32 104.98 0.75 Allowed 'General case' 0 N--CA 1.485 1.303 0 N-CA-C 109.366 -0.605 . . . . 0.0 109.366 173.233 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 23.2 pt20 -128.59 148.38 50.78 Favored 'General case' 0 C--N 1.296 -1.726 0 C-N-CA 123.764 0.826 . . . . 0.0 108.879 -178.631 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -118.64 111.5 18.62 Favored 'General case' 0 N--CA 1.476 0.846 0 N-CA-C 107.486 -1.302 . . . . 0.0 107.486 177.054 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 5.0 mp -126.77 148.71 49.9 Favored 'General case' 0 N--CA 1.5 2.059 0 CA-C-O 122.068 0.937 . . . . 0.0 109.983 179.169 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 12.9 t -99.91 128.44 51.79 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.769 0 CA-C-O 116.37 -1.776 . . . . 0.0 109.691 174.939 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' D' D ' 19' ' ' PHE . . . . . 0.511 ' O ' ' N ' ' D' ' 21' ' ' ALA . 25.2 m-85 -127.43 -163.06 1.22 Allowed 'General case' 0 N--CA 1.499 1.977 0 CA-C-N 120.686 1.584 . . . . 0.0 107.681 -179.966 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' D' D ' 20' ' ' PHE . . . . . 0.492 ' HA ' ' O ' ' A' ' 20' ' ' PHE . 90.1 m-85 -53.22 70.73 0.0 OUTLIER 'General case' 0 C--O 1.198 -1.62 0 C-N-CA 126.344 1.857 . . . . 0.0 111.44 -174.517 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' D' D ' 21' ' ' ALA . . . . . 0.511 ' N ' ' O ' ' D' ' 19' ' ' PHE . . . -86.39 -74.18 0.43 Allowed 'General case' 0 C--N 1.362 1.117 0 CA-C-N 114.922 -1.036 . . . . 0.0 109.701 -175.945 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 41.1 tt0 -98.82 102.99 14.9 Favored 'General case' 0 N--CA 1.483 1.212 0 N-CA-C 106.577 -1.638 . . . . 0.0 106.577 178.108 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 4.2 p30 -152.4 143.92 23.43 Favored 'General case' 0 N--CA 1.476 0.872 0 CA-C-O 116.783 -1.58 . . . . 0.0 113.501 178.551 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' D' D ' 24' ' ' VAL . . . . . 0.439 ' HB ' ' H ' ' A' ' 25' ' ' GLY . 89.3 t -64.46 165.26 1.46 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.351 0 CA-C-N 120.952 1.705 . . . . 0.0 107.584 173.953 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' D' D ' 25' ' ' GLY . . . . . 0.474 ' H ' ' HB ' ' G' ' 24' ' ' VAL . . . -117.02 51.1 0.75 Allowed Glycine 0 N--CA 1.48 1.573 0 CA-C-O 118.885 -0.953 . . . . 0.0 111.575 177.849 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -57.87 -168.74 0.01 OUTLIER 'General case' 0 C--N 1.321 -0.655 0 C-N-CA 124.037 0.935 . . . . 0.0 111.491 175.509 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 25.7 t-20 -72.33 86.86 1.12 Allowed 'General case' 0 C--N 1.35 0.588 0 C-N-CA 119.003 -1.079 . . . . 0.0 108.598 178.455 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 96.4 mttt -83.47 141.19 31.84 Favored 'General case' 0 C--N 1.352 0.688 0 N-CA-C 108.181 -1.044 . . . . 0.0 108.181 178.596 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -62.47 -164.69 0.43 Allowed Glycine 0 C--N 1.333 0.394 0 N-CA-C 110.451 -1.06 . . . . 0.0 110.451 177.463 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -102.28 115.88 31.48 Favored 'General case' 0 N--CA 1.471 0.595 0 N-CA-C 108.727 -0.842 . . . . 0.0 108.727 178.735 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 82.9 mt -102.91 142.57 16.66 Favored 'Isoleucine or valine' 0 C--N 1.356 0.889 0 N-CA-C 104.949 -2.241 . . . . 0.0 104.949 179.215 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' D' D ' 32' ' ' ILE . . . . . 0.428 ' C ' ' H ' ' D' ' 34' ' ' LEU . 27.4 pt -157.18 -172.41 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.109 0 CA-C-O 120.759 0.314 . . . . 0.0 110.219 -178.141 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.95 2.13 6.12 Favored Glycine 0 N--CA 1.465 0.615 0 N-CA-C 110.513 -1.035 . . . . 0.0 110.513 -178.706 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' D' D ' 34' ' ' LEU . . . . . 0.428 ' H ' ' C ' ' D' ' 32' ' ' ILE . 1.3 tt -75.85 138.05 40.86 Favored 'General case' 0 C--N 1.354 0.777 0 N-CA-C 107.729 -1.211 . . . . 0.0 107.729 -178.311 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 25.3 ttt -156.5 160.73 39.8 Favored 'General case' 0 C--O 1.237 0.444 0 N-CA-C 107.877 -1.157 . . . . 0.0 107.877 175.009 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 97.0 t -163.2 163.83 0.8 Allowed 'Isoleucine or valine' 0 CA--C 1.517 -0.326 0 N-CA-C 107.021 -1.474 . . . . 0.0 107.021 177.03 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 60.61 63.55 4.89 Favored Glycine 0 CA--C 1.528 0.874 0 C-N-CA 120.075 -1.06 . . . . 0.0 112.888 179.869 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 146.24 178.63 21.81 Favored Glycine 0 N--CA 1.481 1.639 0 CA-C-N 117.801 0.8 . . . . 0.0 111.588 179.803 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 34.5 m -112.69 149.89 15.04 Favored 'Isoleucine or valine' 0 C--N 1.357 0.911 0 N-CA-C 109.432 -0.581 . . . . 0.0 109.432 -176.943 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 21.8 t . . . . . 0 CA--C 1.52 -0.179 0 CA-C-O 115.976 -1.964 . . . . 0.0 109.604 178.486 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 21.7 p90 . . . . . 0 C--O 1.217 -0.626 0 CA-C-O 119.475 -0.298 . . . . 0.0 110.662 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' E' E ' 5' ' ' ARG . . . . . . . . . . . . . 99.0 mtt180 -136.89 154.11 50.56 Favored 'General case' 0 N--CA 1.479 0.992 0 N-CA-C 109.433 -0.58 . . . . 0.0 109.433 178.539 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 58.4 t-80 -114.31 114.5 26.02 Favored 'General case' 0 N--CA 1.48 1.032 0 N-CA-C 109.68 -0.489 . . . . 0.0 109.68 179.581 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' E' E ' 7' ' ' ASP . . . . . 0.433 ' O ' ' OG ' ' H' ' 8' ' ' SER . 7.9 m-20 -73.27 156.29 38.63 Favored 'General case' 0 N--CA 1.466 0.352 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.173 179.095 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' E' E ' 8' ' ' SER . . . . . 0.427 ' OG ' ' O ' ' B' ' 7' ' ' ASP . 5.4 p -166.72 -175.06 2.98 Favored 'General case' 0 N--CA 1.485 1.31 0 CA-C-O 121.17 0.509 . . . . 0.0 110.727 178.388 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.48 44.12 1.61 Allowed Glycine 0 N--CA 1.48 1.59 0 CA-C-N 115.577 -0.738 . . . . 0.0 112.169 179.294 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 49.7 p90 -64.9 131.93 48.02 Favored 'General case' 0 CA--C 1.542 0.672 0 N-CA-C 111.769 0.285 . . . . 0.0 111.769 -179.922 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 86.8 mt-10 -93.55 153.81 18.22 Favored 'General case' 0 N--CA 1.48 1.027 0 CA-C-O 121.163 0.506 . . . . 0.0 109.654 178.074 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -154.72 127.24 1.05 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.546 0 N-CA-C 107.782 -1.192 . . . . 0.0 107.782 177.917 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 48.7 m-70 -135.09 142.61 46.3 Favored 'General case' 0 N--CA 1.483 1.185 0 CA-C-O 120.739 0.304 . . . . 0.0 111.473 -178.009 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 6.2 t60 -164.46 98.83 0.81 Allowed 'General case' 0 N--CA 1.486 1.364 0 CA-C-N 116.448 -0.342 . . . . 0.0 110.327 179.594 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 22.1 pt20 -123.63 155.57 37.46 Favored 'General case' 0 CA--C 1.503 -0.83 0 N-CA-C 108.243 -1.021 . . . . 0.0 108.243 -179.588 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -125.14 105.88 9.49 Favored 'General case' 0 N--CA 1.484 1.269 0 N-CA-C 108.216 -1.031 . . . . 0.0 108.216 178.145 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 6.0 mp -120.58 148.42 43.9 Favored 'General case' 0 N--CA 1.494 1.74 0 CA-C-O 121.123 0.487 . . . . 0.0 111.293 -178.063 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 21.8 t -109.62 120.53 60.97 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.146 0 N-CA-C 108.126 -1.065 . . . . 0.0 108.126 177.313 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' E' E ' 19' ' ' PHE . . . . . 0.54 ' O ' ' N ' ' E' ' 21' ' ' ALA . 28.5 m-85 -117.11 -162.98 0.89 Allowed 'General case' 0 N--CA 1.495 1.8 0 C-N-CA 122.911 0.485 . . . . 0.0 109.749 -179.365 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' E' E ' 20' ' ' PHE . . . . . 0.478 ' HA ' ' O ' ' B' ' 20' ' ' PHE . 77.2 m-85 -47.76 75.3 0.0 OUTLIER 'General case' 0 C--O 1.206 -1.202 0 C-N-CA 124.288 1.035 . . . . 0.0 111.551 -179.887 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' E' E ' 21' ' ' ALA . . . . . 0.54 ' N ' ' O ' ' E' ' 19' ' ' PHE . . . -87.82 -75.46 0.41 Allowed 'General case' 0 N--CA 1.469 0.52 0 C-N-CA 122.536 0.335 . . . . 0.0 110.399 -179.162 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 41.2 tt0 -96.78 98.92 10.54 Favored 'General case' 0 N--CA 1.463 0.197 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 179.469 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 4.1 p30 -158.58 144.59 16.9 Favored 'General case' 0 N--CA 1.481 1.078 0 O-C-N 122.356 -0.215 . . . . 0.0 111.166 179.821 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' E' E ' 24' ' ' VAL . . . . . 0.425 ' HB ' ' H ' ' B' ' 25' ' ' GLY . 89.5 t -61.8 167.32 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.944 0 N-CA-C 106.925 -1.509 . . . . 0.0 106.925 176.86 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' E' E ' 25' ' ' GLY . . . . . 0.426 ' H ' ' HB ' ' H' ' 24' ' ' VAL . . . -121.48 46.76 1.08 Allowed Glycine 0 N--CA 1.472 1.069 0 N-CA-C 111.163 -0.775 . . . . 0.0 111.163 -179.195 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -61.81 -164.43 0.01 OUTLIER 'General case' 0 N--CA 1.471 0.58 0 CA-C-N 116.943 0.371 . . . . 0.0 110.541 -179.948 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 24.6 t-20 -70.07 77.23 0.5 Allowed 'General case' 0 CA--C 1.533 0.319 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.693 -179.785 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 97.1 mttt -76.14 139.0 41.1 Favored 'General case' 0 N--CA 1.474 0.754 0 N-CA-C 109.715 -0.476 . . . . 0.0 109.715 179.394 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.64 -165.62 1.06 Allowed Glycine 0 C--N 1.335 0.486 0 N-CA-C 109.909 -1.276 . . . . 0.0 109.909 178.011 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.68 113.09 25.32 Favored 'General case' 0 N--CA 1.473 0.711 0 N-CA-C 109.805 -0.442 . . . . 0.0 109.805 179.494 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 75.9 mt -99.07 135.24 34.98 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.447 0 N-CA-C 106.893 -1.521 . . . . 0.0 106.893 178.768 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' E' E ' 32' ' ' ILE . . . . . 0.439 ' C ' ' H ' ' E' ' 34' ' ' LEU . 28.3 pt -150.58 -170.31 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.099 0 CA-C-O 120.949 0.404 . . . . 0.0 110.755 -179.471 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.9 2.49 3.72 Favored Glycine 0 CA--C 1.529 0.92 0 N-CA-C 111.476 -0.65 . . . . 0.0 111.476 -179.59 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' E' E ' 34' ' ' LEU . . . . . 0.439 ' H ' ' C ' ' E' ' 32' ' ' ILE . 1.1 tt -73.89 133.73 43.15 Favored 'General case' 0 CA--C 1.545 0.78 0 N-CA-C 109.095 -0.706 . . . . 0.0 109.095 -179.7 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 25.0 ttt -159.34 149.56 19.12 Favored 'General case' 0 N--CA 1.473 0.69 0 N-CA-C 108.567 -0.901 . . . . 0.0 108.567 178.751 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 61.6 t -152.68 162.78 2.3 Favored 'Isoleucine or valine' 0 C--N 1.345 0.384 0 N-CA-C 108.228 -1.027 . . . . 0.0 108.228 -179.681 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 57.1 67.44 2.22 Favored Glycine 0 C--N 1.309 -0.93 0 CA-C-N 115.473 -0.785 . . . . 0.0 112.012 178.694 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.29 174.94 19.73 Favored Glycine 0 N--CA 1.476 1.325 0 N-CA-C 111.285 -0.726 . . . . 0.0 111.285 178.825 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 31.2 m -107.16 152.55 8.65 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.638 0 C-N-CA 123.475 0.71 . . . . 0.0 110.372 -179.079 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 21.9 t . . . . . 0 C--O 1.214 -0.784 0 O-C-N 124.222 0.951 . . . . 0.0 110.519 179.922 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 22.5 p90 . . . . . 0 C--O 1.218 -0.587 0 CA-C-O 119.582 -0.247 . . . . 0.0 110.575 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' F' F ' 5' ' ' ARG . . . . . . . . . . . . . 99.0 mtt180 -136.73 154.04 50.7 Favored 'General case' 0 N--CA 1.478 0.937 0 N-CA-C 109.409 -0.589 . . . . 0.0 109.409 178.49 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 58.1 t-80 -114.45 114.54 25.96 Favored 'General case' 0 N--CA 1.48 1.027 0 C-N-CA 122.909 0.483 . . . . 0.0 109.76 179.534 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' F' F ' 7' ' ' ASP . . . . . 0.435 ' O ' ' OG ' ' I' ' 8' ' ' SER . 7.8 m-20 -73.28 156.39 38.52 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.274 179.129 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' F' F ' 8' ' ' SER . . . . . 0.429 ' OG ' ' O ' ' C' ' 7' ' ' ASP . 5.4 p -166.87 -174.99 2.9 Favored 'General case' 0 N--CA 1.485 1.301 0 CA-C-O 121.023 0.439 . . . . 0.0 110.936 178.468 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.38 43.69 1.69 Allowed Glycine 0 N--CA 1.479 1.543 0 CA-C-N 115.757 -0.656 . . . . 0.0 112.149 179.199 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 49.9 p90 -64.4 132.31 49.69 Favored 'General case' 0 CA--C 1.544 0.724 0 O-C-N 122.632 -0.334 . . . . 0.0 111.813 -179.945 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 86.7 mt-10 -93.73 153.59 18.25 Favored 'General case' 0 N--CA 1.48 1.067 0 N-CA-C 109.636 -0.505 . . . . 0.0 109.636 178.085 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -154.57 127.18 1.07 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.545 0 N-CA-C 107.811 -1.181 . . . . 0.0 107.811 177.885 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 46.6 m-70 -135.06 142.77 46.4 Favored 'General case' 0 N--CA 1.483 1.215 0 CA-C-O 120.77 0.319 . . . . 0.0 111.515 -178.131 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 6.2 t60 -164.55 98.7 0.8 Allowed 'General case' 0 N--CA 1.485 1.302 0 CA-C-N 116.465 -0.334 . . . . 0.0 110.437 179.62 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 22.2 pt20 -123.52 155.61 37.23 Favored 'General case' 0 CA--C 1.501 -0.914 0 N-CA-C 108.225 -1.028 . . . . 0.0 108.225 -179.527 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -125.09 105.89 9.51 Favored 'General case' 0 N--CA 1.485 1.286 0 N-CA-C 108.245 -1.02 . . . . 0.0 108.245 178.104 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 6.0 mp -120.64 148.21 44.21 Favored 'General case' 0 N--CA 1.495 1.811 0 CA-C-O 121.168 0.509 . . . . 0.0 111.181 -178.009 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 21.7 t -109.45 120.3 60.42 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.167 0 N-CA-C 108.13 -1.063 . . . . 0.0 108.13 177.244 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' F' F ' 19' ' ' PHE . . . . . 0.539 ' O ' ' N ' ' F' ' 21' ' ' ALA . 28.4 m-85 -116.76 -162.7 0.87 Allowed 'General case' 0 N--CA 1.494 1.763 0 C-N-CA 122.919 0.487 . . . . 0.0 109.864 -179.436 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' F' F ' 20' ' ' PHE . . . . . 0.482 ' HA ' ' O ' ' C' ' 20' ' ' PHE . 78.3 m-85 -48.04 75.1 0.0 OUTLIER 'General case' 0 C--O 1.206 -1.229 0 C-N-CA 124.3 1.04 . . . . 0.0 111.466 -179.878 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' F' F ' 21' ' ' ALA . . . . . 0.539 ' N ' ' O ' ' F' ' 19' ' ' PHE . . . -87.38 -77.08 0.35 Allowed 'General case' 0 N--CA 1.466 0.369 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.044 -179.386 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 41.2 tt0 -95.21 99.29 11.27 Favored 'General case' 0 N--CA 1.462 0.173 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 179.49 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 4.1 p30 -158.8 144.8 16.73 Favored 'General case' 0 N--CA 1.481 1.097 0 CA-C-O 119.655 -0.212 . . . . 0.0 111.304 179.745 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' F' F ' 24' ' ' VAL . . . . . 0.445 ' HB ' ' H ' ' C' ' 25' ' ' GLY . 88.8 t -61.98 167.3 0.77 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.93 0 N-CA-C 106.933 -1.506 . . . . 0.0 106.933 176.894 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' F' F ' 25' ' ' GLY . . . . . 0.422 ' H ' ' HB ' ' I' ' 24' ' ' VAL . . . -121.67 46.88 1.07 Allowed Glycine 0 N--CA 1.478 1.44 0 N-CA-C 110.88 -0.888 . . . . 0.0 110.88 -179.239 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' F' F ' 26' ' ' SER . . . . . 0.413 ' HG ' ' H ' ' D' ' 8' ' ' SER . 0.2 OUTLIER -61.89 -164.43 0.01 OUTLIER 'General case' 0 N--CA 1.471 0.612 0 CA-C-N 116.887 0.343 . . . . 0.0 110.436 -179.977 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 24.6 t-20 -69.88 77.11 0.47 Allowed 'General case' 0 CA--C 1.533 0.297 0 CA-C-N 116.319 -0.401 . . . . 0.0 110.752 -179.779 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -76.09 138.97 41.14 Favored 'General case' 0 N--CA 1.475 0.807 0 N-CA-C 109.638 -0.504 . . . . 0.0 109.638 179.451 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.47 -165.36 0.96 Allowed Glycine 0 C--N 1.335 0.484 0 N-CA-C 110.081 -1.207 . . . . 0.0 110.081 177.99 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.92 112.82 25.08 Favored 'General case' 0 N--CA 1.472 0.638 0 N-CA-C 109.695 -0.483 . . . . 0.0 109.695 179.511 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 76.1 mt -98.99 135.3 34.6 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.498 0 N-CA-C 106.882 -1.525 . . . . 0.0 106.882 178.84 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' F' F ' 32' ' ' ILE . . . . . 0.449 ' C ' ' H ' ' F' ' 34' ' ' LEU . 28.2 pt -150.64 -170.19 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.128 0 CA-C-O 120.988 0.423 . . . . 0.0 110.777 -179.516 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.99 2.28 3.65 Favored Glycine 0 CA--C 1.53 1.006 0 N-CA-C 111.409 -0.676 . . . . 0.0 111.409 -179.673 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' F' F ' 34' ' ' LEU . . . . . 0.449 ' H ' ' C ' ' F' ' 32' ' ' ILE . 1.1 tt -73.91 133.72 43.13 Favored 'General case' 0 CA--C 1.546 0.798 0 N-CA-C 109.128 -0.693 . . . . 0.0 109.128 -179.654 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 25.1 ttt -159.4 149.74 19.16 Favored 'General case' 0 N--CA 1.47 0.573 0 N-CA-C 108.563 -0.903 . . . . 0.0 108.563 178.832 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 62.2 t -152.83 162.84 2.21 Favored 'Isoleucine or valine' 0 C--N 1.345 0.37 0 N-CA-C 108.169 -1.049 . . . . 0.0 108.169 -179.667 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 57.1 67.44 2.22 Favored Glycine 0 C--N 1.308 -0.974 0 CA-C-N 115.433 -0.803 . . . . 0.0 112.004 178.626 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.34 175.04 19.85 Favored Glycine 0 N--CA 1.475 1.275 0 N-CA-C 111.248 -0.741 . . . . 0.0 111.248 178.848 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 31.4 m -107.27 152.41 8.85 Favored 'Isoleucine or valine' 0 C--N 1.35 0.597 0 C-N-CA 123.546 0.738 . . . . 0.0 110.361 -179.025 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 22.0 t . . . . . 0 C--O 1.213 -0.821 0 O-C-N 124.216 0.948 . . . . 0.0 110.385 179.804 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 20.1 p90 . . . . . 0 N--CA 1.472 0.625 0 N-CA-C 110.339 -0.245 . . . . 0.0 110.339 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' G' G ' 5' ' ' ARG . . . . . . . . . . . . . 99.1 mtt180 -136.54 154.04 50.83 Favored 'General case' 0 N--CA 1.482 1.13 0 N-CA-C 109.463 -0.569 . . . . 0.0 109.463 178.555 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 58.3 t-80 -114.1 115.54 27.7 Favored 'General case' 0 N--CA 1.483 1.207 0 C-N-CA 122.823 0.449 . . . . 0.0 109.891 179.649 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 -75.86 152.46 37.2 Favored 'General case' 0 N--CA 1.47 0.569 0 CA-C-N 116.0 -0.545 . . . . 0.0 110.772 179.279 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' G' G ' 8' ' ' SER . . . . . 0.533 ' OG ' ' O ' ' D' ' 7' ' ' ASP . 4.9 p -164.03 -172.39 2.78 Favored 'General case' 0 N--CA 1.475 0.775 0 CA-C-O 121.105 0.479 . . . . 0.0 110.596 178.621 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.12 43.6 1.87 Allowed Glycine 0 N--CA 1.479 1.563 0 CA-C-N 115.633 -0.712 . . . . 0.0 111.655 178.983 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 51.0 p90 -64.2 132.23 49.75 Favored 'General case' 0 CA--C 1.542 0.67 0 CA-C-O 120.648 0.261 . . . . 0.0 111.664 -179.772 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 84.1 mt-10 -94.01 152.88 18.49 Favored 'General case' 0 N--CA 1.479 1.008 0 CA-C-O 121.035 0.445 . . . . 0.0 110.057 178.644 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -155.21 127.55 1.03 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.016 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 178.179 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 49.9 m-70 -134.63 144.05 47.65 Favored 'General case' 0 N--CA 1.478 0.925 0 CA-C-N 115.416 -0.811 . . . . 0.0 111.405 -178.326 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 6.3 t60 -166.12 98.74 0.63 Allowed 'General case' 0 N--CA 1.481 1.12 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.122 178.977 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 22.3 pt20 -123.91 154.95 38.99 Favored 'General case' 0 CA--C 1.497 -1.07 0 N-CA-C 107.998 -1.112 . . . . 0.0 107.998 -179.287 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -124.8 106.19 9.85 Favored 'General case' 0 N--CA 1.483 1.192 0 N-CA-C 108.04 -1.096 . . . . 0.0 108.04 178.151 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 6.0 mp -120.22 148.76 43.27 Favored 'General case' 0 N--CA 1.496 1.85 0 CA-C-O 121.091 0.472 . . . . 0.0 111.625 -178.244 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 20.4 t -111.11 120.21 61.29 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.043 0 N-CA-C 107.775 -1.194 . . . . 0.0 107.775 176.909 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' G' G ' 19' ' ' PHE . . . . . 0.556 ' O ' ' N ' ' G' ' 21' ' ' ALA . 28.1 m-85 -117.17 -164.58 1.0 Allowed 'General case' 0 N--CA 1.494 1.728 0 C-N-CA 124.372 1.069 . . . . 0.0 110.225 -178.846 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' G' G ' 20' ' ' PHE . . . . . 0.472 ' HA ' ' O ' ' D' ' 20' ' ' PHE . 78.4 m-85 -47.13 73.02 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.03 0 C-N-CA 124.522 1.129 . . . . 0.0 111.664 -179.83 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' G' G ' 21' ' ' ALA . . . . . 0.556 ' N ' ' O ' ' G' ' 19' ' ' PHE . . . -85.37 -78.23 0.27 Allowed 'General case' 0 N--CA 1.466 0.364 0 C-N-CA 122.715 0.406 . . . . 0.0 110.246 -178.901 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 41.0 tt0 -94.6 99.8 11.87 Favored 'General case' 0 N--CA 1.465 0.284 0 N-CA-C 108.284 -1.006 . . . . 0.0 108.284 179.364 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 4.1 p30 -159.17 144.83 16.23 Favored 'General case' 0 N--CA 1.477 0.91 0 O-C-N 122.313 -0.242 . . . . 0.0 111.226 179.745 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' G' G ' 24' ' ' VAL . . . . . 0.474 ' HB ' ' H ' ' D' ' 25' ' ' GLY . 92.4 t -62.48 165.74 1.02 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.655 0 N-CA-C 107.283 -1.377 . . . . 0.0 107.283 177.231 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -119.86 48.85 0.91 Allowed Glycine 0 N--CA 1.482 1.734 0 N-CA-C 110.587 -1.005 . . . . 0.0 110.587 -179.66 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -64.11 -164.65 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.669 0 CA-C-N 117.194 0.497 . . . . 0.0 109.752 179.787 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 24.8 t-20 -69.97 76.81 0.48 Allowed 'General case' 0 N--CA 1.467 0.415 0 CA-C-N 116.428 -0.351 . . . . 0.0 110.775 -179.699 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -75.2 139.02 42.35 Favored 'General case' 0 N--CA 1.474 0.759 0 N-CA-C 109.724 -0.473 . . . . 0.0 109.724 179.319 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.75 -164.48 0.9 Allowed Glycine 0 C--N 1.337 0.63 0 N-CA-C 109.679 -1.369 . . . . 0.0 109.679 178.185 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.71 113.04 25.25 Favored 'General case' 0 N--CA 1.467 0.412 0 C-N-CA 122.681 0.392 . . . . 0.0 110.204 179.627 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 77.8 mt -99.7 135.42 35.27 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.825 0 N-CA-C 106.932 -1.506 . . . . 0.0 106.932 178.789 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' G' G ' 32' ' ' ILE . . . . . 0.455 ' C ' ' H ' ' G' ' 34' ' ' LEU . 30.4 pt -151.09 -169.13 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.745 0 CA-C-N 119.448 1.022 . . . . 0.0 109.946 179.963 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.98 2.42 3.76 Favored Glycine 0 CA--C 1.528 0.861 0 N-CA-C 111.253 -0.739 . . . . 0.0 111.253 -179.749 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' G' G ' 34' ' ' LEU . . . . . 0.455 ' H ' ' C ' ' G' ' 32' ' ' ILE . 1.1 tt -74.57 133.28 42.25 Favored 'General case' 0 CA--C 1.543 0.687 0 N-CA-C 109.156 -0.683 . . . . 0.0 109.156 -179.586 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 23.8 ttt -159.04 150.27 20.26 Favored 'General case' 0 N--CA 1.469 0.486 0 N-CA-C 108.59 -0.893 . . . . 0.0 108.59 179.126 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 62.5 t -153.8 161.35 2.44 Favored 'Isoleucine or valine' 0 C--N 1.346 0.426 0 N-CA-C 108.05 -1.093 . . . . 0.0 108.05 -179.5 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 58.43 67.45 2.19 Favored Glycine 0 C--N 1.309 -0.957 0 CA-C-N 115.331 -0.85 . . . . 0.0 111.91 178.566 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.44 174.37 19.36 Favored Glycine 0 N--CA 1.477 1.383 0 N-CA-C 110.641 -0.983 . . . . 0.0 110.641 178.872 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 32.9 m -107.02 152.16 8.62 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.912 0 C-N-CA 123.256 0.622 . . . . 0.0 110.487 -179.453 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 22.7 t . . . . . 0 C--O 1.217 -0.63 0 CA-C-O 118.373 -0.822 . . . . 0.0 110.688 179.867 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 20.4 p90 . . . . . 0 N--CA 1.472 0.636 0 CA-C-O 119.549 -0.262 . . . . 0.0 110.313 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' H' H ' 5' ' ' ARG . . . . . . . . . . . . . 99.1 mtt180 -136.18 153.84 51.13 Favored 'General case' 0 N--CA 1.484 1.258 0 N-CA-C 109.398 -0.593 . . . . 0.0 109.398 178.571 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 58.4 t-80 -113.91 115.31 27.48 Favored 'General case' 0 N--CA 1.482 1.129 0 C-N-CA 122.829 0.452 . . . . 0.0 109.96 179.521 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -75.55 152.7 37.72 Favored 'General case' 0 N--CA 1.47 0.57 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.681 179.295 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' H' H ' 8' ' ' SER . . . . . 0.433 ' OG ' ' O ' ' E' ' 7' ' ' ASP . 6.9 p -164.17 -172.67 2.85 Favored 'General case' 0 N--CA 1.474 0.731 0 CA-C-O 121.113 0.482 . . . . 0.0 110.683 178.63 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.13 43.67 1.86 Allowed Glycine 0 N--CA 1.48 1.599 0 CA-C-N 115.79 -0.641 . . . . 0.0 111.765 179.157 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 51.0 p90 -64.44 132.28 49.56 Favored 'General case' 0 CA--C 1.541 0.61 0 O-C-N 122.68 -0.306 . . . . 0.0 111.709 -179.878 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 84.4 mt-10 -94.04 152.92 18.45 Favored 'General case' 0 N--CA 1.478 0.936 0 CA-C-O 121.095 0.474 . . . . 0.0 110.082 178.651 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -155.27 127.12 0.96 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.032 0 N-CA-C 108.03 -1.1 . . . . 0.0 108.03 178.176 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 48.9 m-70 -134.32 143.84 47.93 Favored 'General case' 0 N--CA 1.479 1.016 0 CA-C-N 115.415 -0.811 . . . . 0.0 111.348 -178.183 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 6.3 t60 -165.96 98.94 0.65 Allowed 'General case' 0 N--CA 1.484 1.227 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.012 178.958 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 22.5 pt20 -124.07 154.77 39.47 Favored 'General case' 0 CA--C 1.495 -1.135 0 N-CA-C 108.054 -1.091 . . . . 0.0 108.054 -179.339 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -124.52 106.06 9.87 Favored 'General case' 0 N--CA 1.483 1.204 0 N-CA-C 108.156 -1.054 . . . . 0.0 108.156 178.107 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 6.0 mp -120.17 148.58 43.46 Favored 'General case' 0 N--CA 1.496 1.868 0 CA-C-O 121.072 0.463 . . . . 0.0 111.567 -178.201 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 20.2 t -110.61 121.02 62.64 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.008 0 N-CA-C 107.777 -1.194 . . . . 0.0 107.777 176.776 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' H' H ' 19' ' ' PHE . . . . . 0.56 ' O ' ' N ' ' H' ' 21' ' ' ALA . 27.4 m-85 -117.95 -164.32 1.0 Allowed 'General case' 0 N--CA 1.492 1.675 0 C-N-CA 124.268 1.027 . . . . 0.0 110.127 -178.734 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' H' H ' 20' ' ' PHE . . . . . 0.454 ' HA ' ' O ' ' E' ' 20' ' ' PHE . 79.1 m-85 -47.53 73.03 0.0 OUTLIER 'General case' 0 N--CA 1.481 1.081 0 C-N-CA 124.425 1.09 . . . . 0.0 111.621 -179.78 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' H' H ' 21' ' ' ALA . . . . . 0.56 ' N ' ' O ' ' H' ' 19' ' ' PHE . . . -85.13 -77.8 0.27 Allowed 'General case' 0 N--CA 1.466 0.339 0 C-N-CA 122.744 0.417 . . . . 0.0 110.432 -179.018 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 41.1 tt0 -95.14 99.48 11.45 Favored 'General case' 0 N--CA 1.465 0.303 0 N-CA-C 108.313 -0.995 . . . . 0.0 108.313 179.439 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 4.2 p30 -158.76 145.06 16.97 Favored 'General case' 0 N--CA 1.478 0.938 0 O-C-N 122.475 -0.14 . . . . 0.0 111.188 179.874 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' H' H ' 24' ' ' VAL . . . . . 0.426 ' HB ' ' H ' ' E' ' 25' ' ' GLY . 88.8 t -62.65 165.45 1.09 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.594 0 N-CA-C 107.247 -1.39 . . . . 0.0 107.247 177.113 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . -119.49 48.69 0.92 Allowed Glycine 0 N--CA 1.48 1.582 0 N-CA-C 110.625 -0.99 . . . . 0.0 110.625 -179.579 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -64.31 -164.83 0.02 OUTLIER 'General case' 0 N--CA 1.473 0.685 0 CA-C-N 117.233 0.517 . . . . 0.0 109.852 179.897 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 24.7 t-20 -69.68 76.95 0.44 Allowed 'General case' 0 N--CA 1.467 0.395 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.71 -179.733 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -75.57 139.29 42.02 Favored 'General case' 0 N--CA 1.472 0.672 0 N-CA-C 109.695 -0.483 . . . . 0.0 109.695 179.326 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -65.15 -164.65 1.07 Allowed Glycine 0 C--N 1.336 0.574 0 N-CA-C 109.651 -1.38 . . . . 0.0 109.651 178.27 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.56 112.92 25.07 Favored 'General case' 0 N--CA 1.468 0.443 0 C-N-CA 122.714 0.406 . . . . 0.0 110.22 179.761 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 76.6 mt -99.6 135.28 35.68 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.812 0 N-CA-C 106.986 -1.487 . . . . 0.0 106.986 178.774 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' H' H ' 32' ' ' ILE . . . . . 0.455 ' C ' ' H ' ' H' ' 34' ' ' LEU . 30.5 pt -151.05 -169.16 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.707 0 CA-C-N 119.494 1.043 . . . . 0.0 109.836 -179.914 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.06 2.2 3.66 Favored Glycine 0 CA--C 1.528 0.852 0 N-CA-C 111.167 -0.773 . . . . 0.0 111.167 -179.834 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' H' H ' 34' ' ' LEU . . . . . 0.455 ' H ' ' C ' ' H' ' 32' ' ' ILE . 1.1 tt -74.28 133.13 42.61 Favored 'General case' 0 CA--C 1.544 0.733 0 N-CA-C 109.223 -0.658 . . . . 0.0 109.223 -179.58 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 23.9 ttt -158.85 150.29 20.64 Favored 'General case' 0 N--CA 1.468 0.465 0 N-CA-C 108.644 -0.873 . . . . 0.0 108.644 179.066 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 59.9 t -153.83 161.38 2.43 Favored 'Isoleucine or valine' 0 C--N 1.346 0.425 0 N-CA-C 108.005 -1.109 . . . . 0.0 108.005 -179.438 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 58.35 67.35 2.24 Favored Glycine 0 C--N 1.309 -0.955 0 CA-C-N 115.349 -0.841 . . . . 0.0 111.902 178.52 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.29 173.8 18.75 Favored Glycine 0 N--CA 1.477 1.39 0 N-CA-C 110.708 -0.957 . . . . 0.0 110.708 178.907 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 32.7 m -106.35 152.08 8.12 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.914 0 C-N-CA 123.341 0.656 . . . . 0.0 110.554 -179.438 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 22.1 t . . . . . 0 C--O 1.218 -0.588 0 CA-C-O 118.321 -0.847 . . . . 0.0 110.644 179.843 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 20.4 p90 . . . . . 0 N--CA 1.471 0.615 0 CA-C-O 119.517 -0.278 . . . . 0.0 110.325 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' I' I ' 5' ' ' ARG . . . . . . . . . . . . . 99.1 mtt180 -136.11 153.92 51.15 Favored 'General case' 0 N--CA 1.483 1.213 0 N-CA-C 109.47 -0.566 . . . . 0.0 109.47 178.62 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 58.2 t-80 -114.12 115.53 27.68 Favored 'General case' 0 N--CA 1.482 1.153 0 C-N-CA 122.809 0.444 . . . . 0.0 109.863 179.545 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 8.0 m-20 -75.98 152.33 37.02 Favored 'General case' 0 N--CA 1.47 0.567 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.697 179.335 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' I' I ' 8' ' ' SER . . . . . 0.435 ' OG ' ' O ' ' F' ' 7' ' ' ASP . 6.7 p -163.89 -172.82 2.97 Favored 'General case' 0 N--CA 1.475 0.78 0 CA-C-O 121.124 0.487 . . . . 0.0 110.681 178.801 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.35 43.61 1.84 Allowed Glycine 0 N--CA 1.481 1.676 0 CA-C-N 115.773 -0.649 . . . . 0.0 111.71 179.105 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 51.1 p90 -64.32 132.38 50.03 Favored 'General case' 0 CA--C 1.541 0.622 0 O-C-N 122.681 -0.306 . . . . 0.0 111.722 -179.853 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 84.1 mt-10 -94.06 152.92 18.44 Favored 'General case' 0 N--CA 1.477 0.921 0 CA-C-O 121.11 0.481 . . . . 0.0 110.033 178.619 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -155.33 127.31 0.98 Allowed 'Isoleucine or valine' 0 CA--C 1.553 1.069 0 N-CA-C 107.978 -1.119 . . . . 0.0 107.978 178.098 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 50.3 m-70 -134.48 144.02 47.83 Favored 'General case' 0 N--CA 1.477 0.92 0 CA-C-N 115.387 -0.824 . . . . 0.0 111.391 -178.269 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 6.3 t60 -166.09 98.59 0.63 Allowed 'General case' 0 N--CA 1.483 1.183 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.06 179.094 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 22.6 pt20 -123.84 154.77 39.15 Favored 'General case' 0 CA--C 1.497 -1.082 0 N-CA-C 108.014 -1.106 . . . . 0.0 108.014 -179.323 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -124.54 106.07 9.87 Favored 'General case' 0 N--CA 1.483 1.199 0 N-CA-C 108.154 -1.054 . . . . 0.0 108.154 178.125 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 6.0 mp -120.25 148.61 43.47 Favored 'General case' 0 N--CA 1.495 1.819 0 CA-C-O 121.06 0.457 . . . . 0.0 111.593 -178.179 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 20.2 t -110.61 121.1 62.78 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.01 0 N-CA-C 107.799 -1.186 . . . . 0.0 107.799 176.87 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' I' I ' 19' ' ' PHE . . . . . 0.559 ' O ' ' N ' ' I' ' 21' ' ' ALA . 27.2 m-85 -118.11 -164.1 0.99 Allowed 'General case' 0 N--CA 1.495 1.776 0 C-N-CA 124.229 1.012 . . . . 0.0 110.095 -178.659 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' I' I ' 20' ' ' PHE . . . . . 0.455 ' HA ' ' O ' ' F' ' 20' ' ' PHE . 79.6 m-85 -47.61 72.97 0.0 OUTLIER 'General case' 0 N--CA 1.481 1.085 0 C-N-CA 124.54 1.136 . . . . 0.0 111.502 -179.771 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' I' I ' 21' ' ' ALA . . . . . 0.559 ' N ' ' O ' ' I' ' 19' ' ' PHE . . . -85.11 -78.82 0.24 Allowed 'General case' 0 N--CA 1.468 0.43 0 C-N-CA 122.76 0.424 . . . . 0.0 110.12 -178.935 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 41.3 tt0 -93.95 99.48 11.81 Favored 'General case' 0 N--CA 1.464 0.274 0 N-CA-C 108.469 -0.938 . . . . 0.0 108.469 179.247 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 4.2 p30 -158.87 145.26 16.94 Favored 'General case' 0 N--CA 1.478 0.928 0 O-C-N 122.388 -0.195 . . . . 0.0 111.214 179.616 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' I' I ' 24' ' ' VAL . . . . . 0.422 ' HB ' ' H ' ' F' ' 25' ' ' GLY . 92.1 t -62.78 165.71 1.07 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.606 0 N-CA-C 107.257 -1.386 . . . . 0.0 107.257 177.154 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . -119.94 48.8 0.92 Allowed Glycine 0 N--CA 1.48 1.619 0 N-CA-C 110.546 -1.022 . . . . 0.0 110.546 -179.559 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -64.08 -164.37 0.02 OUTLIER 'General case' 0 N--CA 1.473 0.684 0 CA-C-N 117.168 0.484 . . . . 0.0 109.747 179.865 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 24.9 t-20 -70.27 77.2 0.53 Allowed 'General case' 0 CA--C 1.536 0.42 0 CA-C-N 116.394 -0.366 . . . . 0.0 110.63 -179.701 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -75.65 139.06 41.77 Favored 'General case' 0 N--CA 1.473 0.713 0 N-CA-C 109.62 -0.511 . . . . 0.0 109.62 179.367 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.83 -164.62 0.94 Allowed Glycine 0 C--N 1.337 0.59 0 N-CA-C 109.76 -1.336 . . . . 0.0 109.76 178.179 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.4 112.75 24.88 Favored 'General case' 0 CA--C 1.535 0.379 0 C-N-CA 122.723 0.409 . . . . 0.0 110.251 179.668 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 77.0 mt -99.52 135.21 35.84 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.852 0 N-CA-C 106.927 -1.508 . . . . 0.0 106.927 178.829 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' I' I ' 32' ' ' ILE . . . . . 0.46 ' C ' ' H ' ' I' ' 34' ' ' LEU . 30.3 pt -151.05 -169.08 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 CA-C-N 119.487 1.039 . . . . 0.0 109.876 179.956 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.05 2.25 3.7 Favored Glycine 0 CA--C 1.527 0.827 0 N-CA-C 111.22 -0.752 . . . . 0.0 111.22 -179.751 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' I' I ' 34' ' ' LEU . . . . . 0.46 ' H ' ' C ' ' I' ' 32' ' ' ILE . 1.1 tt -74.27 133.2 42.62 Favored 'General case' 0 CA--C 1.545 0.761 0 N-CA-C 109.122 -0.696 . . . . 0.0 109.122 -179.598 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 23.8 ttt -158.95 150.13 20.31 Favored 'General case' 0 N--CA 1.468 0.443 0 N-CA-C 108.612 -0.884 . . . . 0.0 108.612 179.04 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 60.4 t -153.79 161.24 2.48 Favored 'Isoleucine or valine' 0 C--N 1.345 0.396 0 N-CA-C 107.959 -1.126 . . . . 0.0 107.959 -179.46 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 58.45 67.41 2.21 Favored Glycine 0 C--N 1.311 -0.86 0 CA-C-N 115.275 -0.875 . . . . 0.0 111.935 178.564 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.28 173.92 18.84 Favored Glycine 0 N--CA 1.476 1.312 0 N-CA-C 110.674 -0.97 . . . . 0.0 110.674 178.841 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 32.8 m -106.51 151.98 8.28 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.923 0 C-N-CA 123.28 0.632 . . . . 0.0 110.643 -179.48 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 22.3 t . . . . . 0 C--O 1.217 -0.614 0 CA-C-O 118.413 -0.803 . . . . 0.0 110.752 179.908 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 77.9 m-85 . . . . . 0 N--CA 1.473 0.694 0 N-CA-C 109.658 -0.497 . . . . 0.0 109.658 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 35.6 mtp180 -142.43 143.03 32.45 Favored 'General case' 0 N--CA 1.48 1.059 0 N-CA-C 109.285 -0.635 . . . . 0.0 109.285 -179.951 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 74.4 m80 -150.29 117.84 6.13 Favored 'General case' 0 N--CA 1.472 0.64 0 N-CA-C 108.991 -0.744 . . . . 0.0 108.991 178.749 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 10.1 m-20 -68.31 149.4 49.47 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.822 -179.848 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 4.3 t -168.42 176.34 5.87 Favored 'General case' 0 N--CA 1.473 0.695 0 N-CA-C 109.643 -0.503 . . . . 0.0 109.643 178.592 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 105.08 51.54 0.88 Allowed Glycine 0 N--CA 1.484 1.884 0 N-CA-C 112.065 -0.414 . . . . 0.0 112.065 179.276 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 45.9 p90 -64.8 131.85 47.92 Favored 'General case' 0 N--CA 1.471 0.617 0 CA-C-O 120.51 0.195 . . . . 0.0 111.524 179.652 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . 0.424 ' OE2' ' ND2' ' F' ' 27' ' ' ASN . 43.2 mt-10 -82.78 150.49 26.61 Favored 'General case' 0 N--CA 1.472 0.669 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 177.756 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -154.17 128.98 1.45 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 N-CA-C 108.094 -1.076 . . . . 0.0 108.094 178.167 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 56.7 m-70 -133.39 145.22 50.12 Favored 'General case' 0 N--CA 1.488 1.451 0 CA-C-N 118.616 0.644 . . . . 0.0 110.806 -178.959 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 5.9 t60 -166.11 98.16 0.62 Allowed 'General case' 0 N--CA 1.482 1.141 0 N-CA-C 111.392 0.145 . . . . 0.0 111.392 179.476 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . 0.458 HE22 ' H ' ' A' ' 37' ' ' GLY . 49.8 mt-30 -107.44 -172.65 2.11 Favored 'General case' 0 CA--C 1.502 -0.886 0 N-CA-C 107.948 -1.13 . . . . 0.0 107.948 179.219 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -163.13 97.92 0.92 Allowed 'General case' 0 N--CA 1.471 0.576 0 CA-C-N 115.121 -0.945 . . . . 0.0 109.291 178.739 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 6.2 mp -108.7 163.98 12.78 Favored 'General case' 0 N--CA 1.487 1.394 0 N-CA-C 108.05 -1.093 . . . . 0.0 108.05 179.792 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 55.3 t -141.84 120.25 9.18 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.395 0 CA-C-O 118.663 -0.684 . . . . 0.0 110.33 179.77 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 52.9 m-85 -72.97 158.07 36.19 Favored 'General case' 0 N--CA 1.482 1.172 0 N-CA-C 107.383 -1.34 . . . . 0.0 107.383 176.917 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 24.8 t80 -169.29 -58.22 0.02 OUTLIER 'General case' 0 N--CA 1.481 1.076 0 CA-C-O 122.553 1.168 . . . . 0.0 109.475 -179.82 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -39.76 91.12 0.0 OUTLIER 'General case' 0 N--CA 1.457 -0.092 0 CA-C-N 113.665 -1.607 . . . . 0.0 112.709 -178.115 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 36.4 tt0 -58.2 131.95 52.12 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-N 115.143 -0.935 . . . . 0.0 111.128 179.429 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 9.0 m-20 -80.45 162.89 24.18 Favored 'General case' 0 N--CA 1.478 0.961 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 179.772 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 98.3 t -161.2 -74.25 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.484 1.267 0 N-CA-C 107.609 -1.256 . . . . 0.0 107.609 -178.612 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -38.96 91.01 0.01 OUTLIER Glycine 0 N--CA 1.471 1.002 0 CA-C-N 115.385 -0.825 . . . . 0.0 111.981 -179.736 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 89.1 p -37.46 -99.91 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.917 0 C-N-CA 123.714 0.806 . . . . 0.0 112.9 -176.622 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 40.8 t30 -61.23 126.35 27.04 Favored 'General case' 0 CA--C 1.546 0.807 0 CA-C-N 119.495 1.043 . . . . 0.0 108.855 179.465 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 62.8 mttm -106.36 -178.95 3.8 Favored 'General case' 0 N--CA 1.484 1.259 0 N-CA-C 109.249 -0.648 . . . . 0.0 109.249 -179.728 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.83 -141.27 0.02 OUTLIER Glycine 0 CA--C 1.528 0.888 0 N-CA-C 109.39 -1.484 . . . . 0.0 109.39 177.967 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.79 119.42 22.25 Favored 'General case' 0 N--CA 1.477 0.922 0 N-CA-C 109.257 -0.645 . . . . 0.0 109.257 178.439 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 68.9 mt -100.76 146.3 9.61 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.876 0 N-CA-C 107.856 -1.164 . . . . 0.0 107.856 178.614 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 28.4 mt -146.07 124.59 4.87 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.745 0 N-CA-C 109.435 -0.579 . . . . 0.0 109.435 -177.877 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.55 83.91 0.07 OUTLIER Glycine 0 C--N 1.338 0.677 0 CA-C-N 116.138 -0.483 . . . . 0.0 112.93 178.08 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 14.6 tp -101.9 123.2 45.42 Favored 'General case' 0 N--CA 1.484 1.263 0 N-CA-C 107.112 -1.44 . . . . 0.0 107.112 177.394 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 13.5 ttt -158.37 158.06 33.55 Favored 'General case' 0 N--CA 1.468 0.452 0 N-CA-C 109.018 -0.734 . . . . 0.0 109.018 179.94 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 89.5 t -155.93 152.46 8.52 Favored 'Isoleucine or valine' 0 C--O 1.234 0.262 0 N-CA-C 107.37 -1.345 . . . . 0.0 107.37 -179.435 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . 0.458 ' H ' HE22 ' A' ' 15' ' ' GLN . . . 57.22 73.34 0.46 Allowed Glycine 0 C--N 1.31 -0.881 0 CA-C-N 115.569 -0.741 . . . . 0.0 111.834 178.398 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 169.84 -150.03 14.19 Favored Glycine 0 N--CA 1.462 0.394 0 N-CA-C 110.744 -0.942 . . . . 0.0 110.744 179.432 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 33.1 m -133.77 144.77 34.8 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.875 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 179.93 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 19.8 t . . . . . 0 C--O 1.222 -0.393 0 CA-C-O 117.787 -1.101 . . . . 0.0 110.924 179.753 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 78.1 m-85 . . . . . 0 N--CA 1.471 0.621 0 N-CA-C 109.656 -0.498 . . . . 0.0 109.656 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 35.7 mtp180 -142.58 143.15 32.31 Favored 'General case' 0 N--CA 1.479 1.015 0 N-CA-C 109.296 -0.631 . . . . 0.0 109.296 -179.93 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 74.5 m80 -150.38 118.04 6.16 Favored 'General case' 0 N--CA 1.473 0.701 0 N-CA-C 109.045 -0.724 . . . . 0.0 109.045 178.768 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 7' ' ' ASP . . . . . . . . . . . . . 10.0 m-20 -68.46 149.05 49.75 Favored 'General case' 0 N--CA 1.464 0.233 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.929 -179.884 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 8' ' ' SER . . . . . . . . . . . . . 4.3 t -168.14 176.44 6.04 Favored 'General case' 0 N--CA 1.472 0.666 0 N-CA-C 109.614 -0.513 . . . . 0.0 109.614 178.575 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 105.03 51.31 0.89 Allowed Glycine 0 N--CA 1.483 1.814 0 N-CA-C 112.042 -0.423 . . . . 0.0 112.042 179.296 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 46.7 p90 -64.49 131.9 48.43 Favored 'General case' 0 N--CA 1.471 0.618 0 CA-C-O 120.583 0.23 . . . . 0.0 111.538 179.596 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 11' ' ' GLU . . . . . 0.432 ' OE2' ' ND2' ' D' ' 27' ' ' ASN . 43.2 mt-10 -82.88 150.61 26.42 Favored 'General case' 0 N--CA 1.473 0.696 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 177.787 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -154.29 128.9 1.41 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 N-CA-C 108.214 -1.032 . . . . 0.0 108.214 178.162 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 56.8 m-70 -133.4 145.35 50.23 Favored 'General case' 0 N--CA 1.489 1.479 0 CA-C-N 118.458 0.572 . . . . 0.0 110.762 -178.84 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 5.9 t60 -166.25 97.91 0.61 Allowed 'General case' 0 N--CA 1.484 1.27 0 CA-C-O 119.694 -0.193 . . . . 0.0 111.236 179.554 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . 0.448 HE22 ' H ' ' B' ' 37' ' ' GLY . 49.7 mt-30 -107.21 -172.77 2.14 Favored 'General case' 0 CA--C 1.504 -0.803 0 N-CA-C 107.862 -1.162 . . . . 0.0 107.862 179.238 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -163.11 97.9 0.93 Allowed 'General case' 0 N--CA 1.471 0.625 0 CA-C-N 115.154 -0.93 . . . . 0.0 109.192 178.748 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 6.1 mp -108.77 163.96 12.81 Favored 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 108.075 -1.083 . . . . 0.0 108.075 179.784 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 57.6 t -141.98 119.92 8.39 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.31 0 CA-C-O 118.724 -0.655 . . . . 0.0 110.293 179.868 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 55.4 m-85 -73.14 158.29 35.58 Favored 'General case' 0 N--CA 1.48 1.036 0 N-CA-C 107.343 -1.355 . . . . 0.0 107.343 176.792 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 26.1 t80 -170.33 -57.25 0.02 OUTLIER 'General case' 0 N--CA 1.478 0.953 0 CA-C-O 122.354 1.073 . . . . 0.0 109.533 -179.962 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -39.87 91.07 0.0 OUTLIER 'General case' 0 C--N 1.34 0.161 0 CA-C-N 113.999 -1.455 . . . . 0.0 112.558 -178.314 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 36.1 tt0 -58.19 132.0 52.25 Favored 'General case' 0 C--N 1.317 -0.811 0 CA-C-N 115.142 -0.936 . . . . 0.0 111.219 179.545 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 -80.58 162.71 24.14 Favored 'General case' 0 N--CA 1.479 1.015 0 N-CA-C 109.491 -0.559 . . . . 0.0 109.491 179.776 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 98.5 t -160.99 -74.13 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.483 1.192 0 C-N-CA 124.76 1.224 . . . . 0.0 107.732 -178.526 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -39.38 91.04 0.01 OUTLIER Glycine 0 N--CA 1.473 1.154 0 CA-C-N 115.42 -0.809 . . . . 0.0 111.828 -179.709 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 92.4 p -37.08 -99.93 0.0 OUTLIER 'General case' 0 N--CA 1.481 1.107 0 C-N-CA 123.881 0.873 . . . . 0.0 112.615 -177.045 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 41.6 t30 -61.23 126.35 27.03 Favored 'General case' 0 CA--C 1.544 0.746 0 CA-C-N 119.547 1.067 . . . . 0.0 109.076 179.508 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 62.9 mttm -106.43 -179.03 3.82 Favored 'General case' 0 N--CA 1.483 1.178 0 N-CA-C 109.223 -0.658 . . . . 0.0 109.223 -179.703 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.85 -141.22 0.02 OUTLIER Glycine 0 CA--C 1.527 0.814 0 N-CA-C 109.411 -1.476 . . . . 0.0 109.411 177.924 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.77 119.36 22.18 Favored 'General case' 0 N--CA 1.478 0.962 0 N-CA-C 109.304 -0.628 . . . . 0.0 109.304 178.488 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 69.0 mt -100.84 146.03 10.13 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.901 0 N-CA-C 107.862 -1.162 . . . . 0.0 107.862 178.551 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 28.7 mt -145.9 124.59 5.1 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.755 0 N-CA-C 109.428 -0.582 . . . . 0.0 109.428 -177.817 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.87 83.87 0.07 OUTLIER Glycine 0 C--N 1.338 0.678 0 CA-C-N 116.119 -0.492 . . . . 0.0 112.872 178.005 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 15.0 tp -102.27 121.52 42.43 Favored 'General case' 0 N--CA 1.486 1.335 0 N-CA-C 107.386 -1.338 . . . . 0.0 107.386 177.441 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 13.3 ttt -156.75 158.18 36.41 Favored 'General case' 0 N--CA 1.466 0.327 0 N-CA-C 109.27 -0.641 . . . . 0.0 109.27 179.836 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 89.1 t -155.97 152.32 8.64 Favored 'Isoleucine or valine' 0 C--O 1.235 0.317 0 N-CA-C 107.256 -1.387 . . . . 0.0 107.256 -179.444 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . 0.448 ' H ' HE22 ' B' ' 15' ' ' GLN . . . 57.39 73.24 0.47 Allowed Glycine 0 C--N 1.312 -0.797 0 CA-C-N 115.525 -0.762 . . . . 0.0 111.789 178.332 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 169.79 -149.99 14.16 Favored Glycine 0 N--CA 1.462 0.412 0 N-CA-C 110.751 -0.94 . . . . 0.0 110.751 179.408 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 33.1 m -133.78 144.83 34.62 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.91 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 179.996 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 20.4 t . . . . . 0 C--O 1.221 -0.425 0 CA-C-O 117.766 -1.111 . . . . 0.0 110.877 179.708 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 78.2 m-85 . . . . . 0 N--CA 1.473 0.714 0 N-CA-C 109.605 -0.517 . . . . 0.0 109.605 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 35.7 mtp180 -142.66 143.11 32.2 Favored 'General case' 0 N--CA 1.48 1.057 0 N-CA-C 109.227 -0.657 . . . . 0.0 109.227 -179.93 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 74.6 m80 -150.44 118.08 6.15 Favored 'General case' 0 N--CA 1.472 0.641 0 N-CA-C 108.958 -0.756 . . . . 0.0 108.958 178.765 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' C' C ' 7' ' ' ASP . . . . . . . . . . . . . 10.0 m-20 -68.52 149.17 49.55 Favored 'General case' 0 N--CA 1.462 0.17 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.994 -179.92 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' C' C ' 8' ' ' SER . . . . . . . . . . . . . 4.3 t -168.22 176.49 5.95 Favored 'General case' 0 N--CA 1.472 0.655 0 N-CA-C 109.546 -0.539 . . . . 0.0 109.546 178.631 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 105.01 51.35 0.89 Allowed Glycine 0 N--CA 1.483 1.821 0 N-CA-C 112.006 -0.438 . . . . 0.0 112.006 179.275 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 46.1 p90 -64.64 131.82 48.02 Favored 'General case' 0 N--CA 1.471 0.602 0 CA-C-O 120.57 0.224 . . . . 0.0 111.509 179.648 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' C' C ' 11' ' ' GLU . . . . . 0.435 ' OE2' ' ND2' ' E' ' 27' ' ' ASN . 43.2 mt-10 -82.76 150.44 26.66 Favored 'General case' 0 N--CA 1.473 0.68 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 177.815 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -154.11 129.04 1.48 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 178.133 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 56.8 m-70 -133.44 145.41 50.22 Favored 'General case' 0 N--CA 1.489 1.507 0 CA-C-N 118.496 0.589 . . . . 0.0 110.81 -178.914 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 5.9 t60 -166.36 98.04 0.6 Allowed 'General case' 0 N--CA 1.483 1.204 0 CA-C-O 119.79 -0.148 . . . . 0.0 111.3 179.534 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' C' C ' 15' ' ' GLN . . . . . 0.437 HE22 ' H ' ' C' ' 37' ' ' GLY . 49.7 mt-30 -107.42 -172.69 2.12 Favored 'General case' 0 CA--C 1.5 -0.945 0 N-CA-C 107.999 -1.111 . . . . 0.0 107.999 179.246 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -163.15 97.86 0.92 Allowed 'General case' 0 N--CA 1.47 0.532 0 CA-C-N 115.181 -0.918 . . . . 0.0 109.308 178.782 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 6.1 mp -108.69 163.96 12.79 Favored 'General case' 0 N--CA 1.487 1.395 0 N-CA-C 108.037 -1.097 . . . . 0.0 108.037 179.879 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 57.3 t -141.93 119.97 8.59 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.365 0 CA-C-O 118.721 -0.657 . . . . 0.0 110.257 179.836 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 55.1 m-85 -73.14 158.28 35.61 Favored 'General case' 0 N--CA 1.479 1.016 0 N-CA-C 107.293 -1.373 . . . . 0.0 107.293 176.761 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 26.1 t80 -170.23 -57.21 0.02 OUTLIER 'General case' 0 N--CA 1.477 0.898 0 CA-C-O 122.358 1.075 . . . . 0.0 109.587 179.978 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -39.93 91.26 0.0 OUTLIER 'General case' 0 C--N 1.34 0.169 0 CA-C-N 114.028 -1.442 . . . . 0.0 112.549 -178.294 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 36.1 tt0 -58.3 131.88 51.96 Favored 'General case' 0 C--N 1.317 -0.847 0 CA-C-N 115.129 -0.941 . . . . 0.0 111.165 179.501 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 -80.45 162.76 24.25 Favored 'General case' 0 N--CA 1.479 0.994 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 179.722 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 98.2 t -161.07 -74.27 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.483 1.21 0 C-N-CA 124.753 1.221 . . . . 0.0 107.744 -178.556 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -39.46 91.09 0.01 OUTLIER Glycine 0 N--CA 1.473 1.105 0 CA-C-N 115.463 -0.79 . . . . 0.0 111.84 -179.68 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 91.1 p -37.03 -99.88 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.036 0 C-N-CA 123.831 0.852 . . . . 0.0 112.748 -177.0 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 41.6 t30 -61.17 126.37 27.12 Favored 'General case' 0 CA--C 1.545 0.752 0 CA-C-N 119.506 1.048 . . . . 0.0 109.061 179.484 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 62.9 mttm -106.46 -179.12 3.85 Favored 'General case' 0 N--CA 1.483 1.185 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 -179.713 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.79 -141.25 0.02 OUTLIER Glycine 0 CA--C 1.528 0.878 0 N-CA-C 109.362 -1.495 . . . . 0.0 109.362 177.996 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.73 119.34 22.21 Favored 'General case' 0 N--CA 1.477 0.882 0 N-CA-C 109.37 -0.604 . . . . 0.0 109.37 178.436 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 68.7 mt -100.81 146.01 10.15 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.945 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 178.598 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 28.6 mt -145.96 124.63 5.03 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.726 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 -177.793 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.74 83.78 0.07 OUTLIER Glycine 0 C--N 1.339 0.701 0 CA-C-N 116.127 -0.488 . . . . 0.0 112.92 178.05 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 15.2 tp -102.12 121.39 42.11 Favored 'General case' 0 N--CA 1.484 1.26 0 N-CA-C 107.485 -1.302 . . . . 0.0 107.485 177.349 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 13.4 ttt -156.62 158.23 36.67 Favored 'General case' 0 N--CA 1.465 0.32 0 N-CA-C 109.254 -0.647 . . . . 0.0 109.254 179.848 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 87.9 t -155.94 152.44 8.53 Favored 'Isoleucine or valine' 0 C--O 1.235 0.314 0 N-CA-C 107.331 -1.359 . . . . 0.0 107.331 -179.48 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' C' C ' 37' ' ' GLY . . . . . 0.437 ' H ' HE22 ' C' ' 15' ' ' GLN . . . 57.26 73.27 0.47 Allowed Glycine 0 C--N 1.311 -0.82 0 CA-C-N 115.535 -0.757 . . . . 0.0 111.812 178.384 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 169.78 -150.0 14.19 Favored Glycine 0 N--CA 1.462 0.433 0 N-CA-C 110.716 -0.954 . . . . 0.0 110.716 179.377 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 33.2 m -133.7 144.82 34.72 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.883 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 179.98 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 20.3 t . . . . . 0 N--CA 1.467 0.403 0 CA-C-O 117.747 -1.121 . . . . 0.0 110.864 179.667 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 85.5 m-85 . . . . . 0 N--CA 1.472 0.664 0 N-CA-C 108.142 -1.058 . . . . 0.0 108.142 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' D' D ' 5' ' ' ARG . . . . . . . . . . . . . 36.8 mtp180 -145.95 141.99 28.27 Favored 'General case' 0 N--CA 1.474 0.76 0 N-CA-C 109.365 -0.606 . . . . 0.0 109.365 -179.834 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 75.5 m80 -149.13 123.39 9.57 Favored 'General case' 0 CA--C 1.543 0.684 0 N-CA-C 107.815 -1.18 . . . . 0.0 107.815 174.618 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' D' D ' 7' ' ' ASP . . . . . . . . . . . . . 6.7 m-20 -63.71 133.13 53.02 Favored 'General case' 0 C--N 1.322 -0.615 0 C-N-CA 126.968 2.107 . . . . 0.0 114.675 175.231 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' D' D ' 8' ' ' SER . . . . . . . . . . . . . 3.5 t -154.59 -179.74 8.27 Favored 'General case' 0 N--CA 1.475 0.823 0 CA-C-N 119.081 0.855 . . . . 0.0 110.214 175.99 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.36 49.92 1.02 Allowed Glycine 0 N--CA 1.482 1.743 0 N-CA-C 112.047 -0.421 . . . . 0.0 112.047 175.194 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 46.4 p90 -61.49 132.31 52.98 Favored 'General case' 0 CA--C 1.54 0.575 0 N-CA-C 112.116 0.413 . . . . 0.0 112.116 179.505 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' D' D ' 11' ' ' GLU . . . . . 0.401 ' CG ' ' ND2' ' F' ' 27' ' ' ASN . 42.7 mt-10 -83.23 148.97 27.1 Favored 'General case' 0 N--CA 1.48 1.065 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 176.661 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -149.84 130.15 4.19 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.341 0 N-CA-C 108.325 -0.991 . . . . 0.0 108.325 174.876 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 54.7 m-70 -129.42 148.05 51.29 Favored 'General case' 0 N--CA 1.482 1.137 0 CA-C-N 118.158 0.436 . . . . 0.0 110.897 176.801 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' D' D ' 14' ' ' HIS . . . . . 0.41 ' ND1' ' O ' ' G' ' 14' ' ' HIS . 6.0 t60 -165.34 104.64 0.74 Allowed 'General case' 0 N--CA 1.484 1.246 0 CA-C-O 119.016 -0.516 . . . . 0.0 109.667 173.637 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' D' D ' 15' ' ' GLN . . . . . 0.477 HE22 ' H ' ' D' ' 37' ' ' GLY . 49.7 mt-30 -110.63 -175.72 2.79 Favored 'General case' 0 CA--C 1.492 -1.268 0 N-CA-C 107.551 -1.277 . . . . 0.0 107.551 178.285 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -159.54 105.88 1.67 Allowed 'General case' 0 CA--C 1.536 0.431 0 N-CA-C 107.679 -1.23 . . . . 0.0 107.679 175.619 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 6.9 mp -114.87 162.65 16.63 Favored 'General case' 0 N--CA 1.487 1.419 0 N-CA-C 107.638 -1.245 . . . . 0.0 107.638 179.401 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 48.1 t -140.99 123.78 15.58 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.147 0 N-CA-C 109.483 -0.562 . . . . 0.0 109.483 176.319 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 82.7 m-85 -63.25 151.08 41.53 Favored 'General case' 0 C--N 1.357 0.923 0 C-N-CA 124.569 1.147 . . . . 0.0 110.634 169.586 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 19.0 t80 -169.68 -66.85 0.02 OUTLIER 'General case' 0 C--N 1.315 -0.916 0 N-CA-C 107.456 -1.312 . . . . 0.0 107.456 -179.877 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -37.98 95.82 0.01 OUTLIER 'General case' 0 CA--C 1.536 0.42 0 CA-C-N 114.162 -1.381 . . . . 0.0 111.683 -175.407 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 36.6 tt0 -60.38 134.34 56.97 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 113.709 -1.587 . . . . 0.0 111.018 179.297 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 9.5 m-20 -82.57 168.27 17.52 Favored 'General case' 0 C--O 1.205 -1.285 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 179.558 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' D' D ' 24' ' ' VAL . . . . . . . . . . . . 0.288 46.3 t -168.93 -94.15 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.505 2.291 0 N-CA-C 103.507 -2.775 . . . . 0.0 103.507 -164.215 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . -26.35 77.14 0.0 OUTLIER Glycine 0 C--N 1.259 -3.721 0 C-N-CA 129.754 3.549 . . . . 0.0 116.908 -179.957 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' D' D ' 26' ' ' SER . . . . . 0.459 ' OG ' ' N ' ' D' ' 27' ' ' ASN 0.51 75.0 p -59.05 -93.05 0.0 OUTLIER 'General case' 0 C--O 1.28 2.692 1 CA-C-O 107.247 -6.12 . . . . 0.0 104.856 -155.503 . . . . . . . . 4 3 . 1 . 018 nuclear orig core ' D' D ' 27' ' ' ASN . . . . . 0.459 ' N ' ' OG ' ' D' ' 26' ' ' SER 0.293 32.8 t30 -62.98 135.82 57.5 Favored 'General case' 0 N--CA 1.491 1.581 1 CA-C-N 133.294 7.315 . . . . 0.0 108.193 -172.984 . . . . . . . . 4 3 . 1 . 018 nuclear orig core ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 60.0 mttm -102.76 178.58 4.53 Favored 'General case' 0 N--CA 1.475 0.82 0 C-N-CA 125.3 1.44 . . . . 0.0 111.632 177.889 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.02 -145.83 0.01 OUTLIER Glycine 0 CA--C 1.537 1.447 0 N-CA-C 111.267 -0.733 . . . . 0.0 111.267 171.401 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -126.9 122.02 33.44 Favored 'General case' 0 C--N 1.369 1.421 0 N-CA-C 108.779 -0.823 . . . . 0.0 108.779 174.689 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 68.4 mt -97.81 152.27 4.17 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.758 0 N-CA-C 107.829 -1.174 . . . . 0.0 107.829 175.492 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 34.7 mt -152.04 128.68 1.99 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.006 0 N-CA-C 107.884 -1.154 . . . . 0.0 107.884 177.226 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 64.06 80.47 0.13 Allowed Glycine 0 C--N 1.35 1.344 0 CA-C-O 117.996 -1.447 . . . . 0.0 113.185 178.06 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 10.5 tp -101.42 131.98 47.24 Favored 'General case' 0 C--N 1.38 1.931 0 N-CA-C 104.792 -2.299 . . . . 0.0 104.792 176.402 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 12.5 ttt -157.3 165.69 35.15 Favored 'General case' 0 N--CA 1.467 0.395 0 N-CA-C 108.721 -0.844 . . . . 0.0 108.721 176.756 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 81.4 t -163.19 156.61 2.11 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.485 0 N-CA-C 106.145 -1.798 . . . . 0.0 106.145 175.089 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' D' D ' 37' ' ' GLY . . . . . 0.477 ' H ' HE22 ' D' ' 15' ' ' GLN . . . 61.25 66.17 2.83 Favored Glycine 0 N--CA 1.447 -0.633 0 C-N-CA 117.956 -2.068 . . . . 0.0 113.754 178.087 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 167.1 -148.95 13.88 Favored Glycine 0 N--CA 1.467 0.751 0 CA-C-O 118.011 -1.438 . . . . 0.0 112.105 179.982 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 33.0 m -130.67 144.47 37.81 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.225 0 CA-C-N 119.02 1.41 . . . . 0.0 109.956 -178.821 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 18.4 t . . . . . 0 C--O 1.214 -0.802 0 N-CA-C 109.2 -0.667 . . . . 0.0 109.2 174.99 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 77.6 m-85 . . . . . 0 N--CA 1.474 0.763 0 N-CA-C 109.703 -0.48 . . . . 0.0 109.703 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' E' E ' 5' ' ' ARG . . . . . . . . . . . . . 37.1 mtp180 -142.62 143.56 32.45 Favored 'General case' 0 N--CA 1.477 0.888 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 179.906 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 74.7 m80 -150.56 117.55 5.92 Favored 'General case' 0 N--CA 1.473 0.699 0 N-CA-C 109.136 -0.691 . . . . 0.0 109.136 178.653 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' E' E ' 7' ' ' ASP . . . . . . . . . . . . . 9.5 m-20 -68.06 149.18 49.98 Favored 'General case' 0 CA--C 1.529 0.171 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.043 -179.816 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' E' E ' 8' ' ' SER . . . . . . . . . . . . . 3.4 t -168.5 178.06 4.98 Favored 'General case' 0 N--CA 1.475 0.806 0 N-CA-C 109.574 -0.528 . . . . 0.0 109.574 178.224 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.85 50.9 0.92 Allowed Glycine 0 N--CA 1.477 1.385 0 N-CA-C 111.97 -0.452 . . . . 0.0 111.97 179.124 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 44.2 p90 -63.78 131.21 47.13 Favored 'General case' 0 CA--C 1.545 0.756 0 N-CA-C 111.895 0.332 . . . . 0.0 111.895 -179.861 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 41.4 mt-10 -81.78 151.42 27.43 Favored 'General case' 0 N--CA 1.479 1.008 0 N-CA-C 108.683 -0.858 . . . . 0.0 108.683 177.433 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.6 p -155.92 127.91 1.0 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.449 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 177.906 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 52.2 m-70 -133.5 143.51 48.82 Favored 'General case' 0 N--CA 1.48 1.034 0 O-C-N 122.259 -0.276 . . . . 0.0 111.073 -177.884 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 5.9 t60 -165.35 97.43 0.7 Allowed 'General case' 0 N--CA 1.488 1.437 0 CA-C-O 119.602 -0.237 . . . . 0.0 111.211 179.816 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' E' E ' 15' ' ' GLN . . . . . 0.434 HE22 ' H ' ' E' ' 37' ' ' GLY . 50.0 mt-30 -106.44 -172.29 2.06 Favored 'General case' 0 CA--C 1.505 -0.769 0 N-CA-C 107.969 -1.123 . . . . 0.0 107.969 179.228 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -163.23 98.0 0.92 Allowed 'General case' 0 N--CA 1.47 0.575 0 CA-C-N 115.135 -0.938 . . . . 0.0 109.241 178.634 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 6.2 mp -108.54 163.13 13.5 Favored 'General case' 0 N--CA 1.488 1.441 0 N-CA-C 108.636 -0.876 . . . . 0.0 108.636 -179.919 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 40.6 t -141.86 120.79 9.83 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.281 0 C-N-CA 122.465 0.306 . . . . 0.0 110.631 179.194 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 51.9 m-85 -73.64 155.6 38.87 Favored 'General case' 0 C--N 1.362 1.138 0 N-CA-C 106.823 -1.547 . . . . 0.0 106.823 176.349 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 23.6 t80 -171.78 -54.82 0.02 OUTLIER 'General case' 0 N--CA 1.479 1.01 0 CA-C-O 121.682 0.753 . . . . 0.0 110.161 -179.942 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.95 89.63 0.0 OUTLIER 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 114.426 -1.261 . . . . 0.0 112.634 -179.436 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 36.0 tt0 -56.2 133.47 52.4 Favored 'General case' 0 CA--C 1.539 0.536 0 CA-C-N 114.912 -1.04 . . . . 0.0 111.291 179.861 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 9.2 m-20 -81.72 162.25 23.05 Favored 'General case' 0 N--CA 1.475 0.779 0 N-CA-C 109.66 -0.496 . . . . 0.0 109.66 179.782 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 95.0 t -160.7 -74.64 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.291 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 -179.003 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . -38.81 91.22 0.01 OUTLIER Glycine 0 CA--C 1.53 0.974 0 CA-C-N 115.263 -0.88 . . . . 0.0 112.403 -179.673 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 84.8 p -37.7 -101.33 0.0 OUTLIER 'General case' 0 N--CA 1.481 1.079 0 N-CA-C 113.725 1.009 . . . . 0.0 113.725 -177.429 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' E' E ' 27' ' ' ASN . . . . . 0.435 ' ND2' ' OE2' ' C' ' 11' ' ' GLU . 40.2 t30 -60.01 124.63 20.8 Favored 'General case' 0 CA--C 1.542 0.663 0 CA-C-N 119.482 1.037 . . . . 0.0 108.781 -179.89 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 62.8 mttm -105.38 -178.65 3.71 Favored 'General case' 0 N--CA 1.483 1.214 0 N-CA-C 108.889 -0.782 . . . . 0.0 108.889 -179.613 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -65.35 -141.45 0.03 OUTLIER Glycine 0 CA--C 1.532 1.102 0 N-CA-C 110.421 -1.072 . . . . 0.0 110.421 178.02 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.93 118.31 22.44 Favored 'General case' 0 C--N 1.349 0.582 0 C-N-CA 123.234 0.614 . . . . 0.0 109.46 178.471 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 71.6 mt -100.28 148.76 6.44 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.816 0 N-CA-C 106.88 -1.526 . . . . 0.0 106.88 178.103 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 34.1 mt -148.17 125.0 2.77 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.958 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 -179.434 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.76 85.49 0.05 OUTLIER Glycine 0 C--N 1.34 0.767 0 CA-C-N 115.966 -0.561 . . . . 0.0 112.827 178.493 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 13.2 tp -103.39 121.38 42.68 Favored 'General case' 0 N--CA 1.484 1.258 0 N-CA-C 106.97 -1.492 . . . . 0.0 106.97 177.371 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 12.6 ttt -156.08 158.93 38.6 Favored 'General case' 0 N--CA 1.476 0.859 0 N-CA-C 108.883 -0.784 . . . . 0.0 108.883 179.661 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 95.3 t -156.76 151.98 8.33 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.416 0 N-CA-C 107.493 -1.299 . . . . 0.0 107.493 -179.693 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' E' E ' 37' ' ' GLY . . . . . 0.434 ' H ' HE22 ' E' ' 15' ' ' GLN . . . 57.59 72.41 0.59 Allowed Glycine 0 C--N 1.313 -0.74 0 CA-C-N 115.397 -0.819 . . . . 0.0 111.481 178.168 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 171.62 -148.81 11.31 Favored Glycine 0 CA--C 1.524 0.624 0 N-CA-C 111.025 -0.83 . . . . 0.0 111.025 179.606 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 32.9 m -135.53 144.06 34.95 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.826 0 N-CA-C 109.095 -0.705 . . . . 0.0 109.095 179.906 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 19.5 t . . . . . 0 CA--C 1.537 0.471 0 CA-C-O 117.66 -1.162 . . . . 0.0 110.817 -179.988 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 77.6 m-85 . . . . . 0 N--CA 1.475 0.777 0 N-CA-C 109.625 -0.509 . . . . 0.0 109.625 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' F' F ' 5' ' ' ARG . . . . . . . . . . . . . 37.1 mtp180 -142.51 143.43 32.53 Favored 'General case' 0 N--CA 1.477 0.898 0 N-CA-C 109.396 -0.594 . . . . 0.0 109.396 179.979 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 74.8 m80 -150.59 117.65 5.94 Favored 'General case' 0 N--CA 1.474 0.744 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 178.626 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' F' F ' 7' ' ' ASP . . . . . . . . . . . . . 9.5 m-20 -68.05 149.11 50.08 Favored 'General case' 0 N--CA 1.463 0.21 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.057 -179.812 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' F' F ' 8' ' ' SER . . . . . . . . . . . . . 3.4 t -168.65 177.7 5.04 Favored 'General case' 0 N--CA 1.474 0.773 0 N-CA-C 109.521 -0.548 . . . . 0.0 109.521 178.153 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 105.13 50.95 0.9 Allowed Glycine 0 N--CA 1.478 1.496 0 N-CA-C 111.858 -0.497 . . . . 0.0 111.858 179.054 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 43.8 p90 -64.07 131.74 48.44 Favored 'General case' 0 CA--C 1.543 0.697 0 N-CA-C 112.0 0.37 . . . . 0.0 112.0 -179.867 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 41.5 mt-10 -82.01 151.56 27.07 Favored 'General case' 0 N--CA 1.479 0.994 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 177.448 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.6 p -156.0 127.88 0.98 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.46 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 177.921 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 52.3 m-70 -133.49 143.63 48.92 Favored 'General case' 0 N--CA 1.481 1.122 0 O-C-N 122.25 -0.281 . . . . 0.0 110.965 -177.856 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 5.9 t60 -165.44 97.73 0.69 Allowed 'General case' 0 N--CA 1.486 1.341 0 CA-C-O 119.604 -0.236 . . . . 0.0 111.386 179.777 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' F' F ' 15' ' ' GLN . . . . . 0.412 HE22 ' H ' ' F' ' 37' ' ' GLY . 50.0 mt-30 -106.75 -172.31 2.06 Favored 'General case' 0 CA--C 1.497 -1.064 0 N-CA-C 108.088 -1.078 . . . . 0.0 108.088 179.177 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -163.26 97.86 0.91 Allowed 'General case' 0 CA--C 1.539 0.551 0 CA-C-N 114.96 -1.018 . . . . 0.0 109.16 178.77 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 6.2 mp -108.46 163.14 13.48 Favored 'General case' 0 N--CA 1.489 1.488 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 -179.914 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 40.5 t -141.89 120.72 9.66 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.227 0 C-N-CA 122.549 0.339 . . . . 0.0 110.648 179.261 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 52.4 m-85 -73.59 155.43 39.11 Favored 'General case' 0 C--N 1.362 1.125 0 N-CA-C 106.765 -1.568 . . . . 0.0 106.765 176.219 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 24.3 t80 -171.48 -55.1 0.02 OUTLIER 'General case' 0 N--CA 1.481 1.084 0 CA-C-O 121.739 0.781 . . . . 0.0 109.75 -179.861 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.83 89.72 0.0 OUTLIER 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 114.49 -1.232 . . . . 0.0 112.693 -179.342 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 36.0 tt0 -56.4 133.4 52.99 Favored 'General case' 0 CA--C 1.54 0.586 0 CA-C-N 114.953 -1.021 . . . . 0.0 111.283 179.79 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 -81.7 162.39 23.01 Favored 'General case' 0 N--CA 1.475 0.793 0 N-CA-C 109.627 -0.508 . . . . 0.0 109.627 179.826 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' F' F ' 24' ' ' VAL . . . . . . . . . . . . . 95.8 t -160.7 -74.96 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.486 1.333 0 N-CA-C 107.095 -1.446 . . . . 0.0 107.095 -179.005 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -38.49 91.01 0.01 OUTLIER Glycine 0 CA--C 1.529 0.91 0 CA-C-N 115.305 -0.862 . . . . 0.0 112.451 -179.779 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 84.9 p -37.58 -100.97 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.067 0 N-CA-C 113.69 0.996 . . . . 0.0 113.69 -177.443 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' F' F ' 27' ' ' ASN . . . . . 0.424 ' ND2' ' OE2' ' A' ' 11' ' ' GLU . 39.9 t30 -60.18 124.91 21.7 Favored 'General case' 0 CA--C 1.542 0.642 0 CA-C-N 119.492 1.042 . . . . 0.0 108.769 -179.954 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 62.8 mttm -105.65 -178.6 3.7 Favored 'General case' 0 N--CA 1.483 1.197 0 N-CA-C 108.893 -0.78 . . . . 0.0 108.893 -179.737 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -65.29 -141.67 0.03 OUTLIER Glycine 0 CA--C 1.532 1.152 0 N-CA-C 110.463 -1.055 . . . . 0.0 110.463 178.008 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.65 117.79 21.8 Favored 'General case' 0 C--N 1.351 0.633 0 C-N-CA 123.351 0.66 . . . . 0.0 109.399 178.468 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 71.6 mt -99.81 148.86 6.15 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.871 0 N-CA-C 106.934 -1.506 . . . . 0.0 106.934 178.021 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 34.6 mt -148.15 124.99 2.78 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.912 0 N-CA-C 108.874 -0.787 . . . . 0.0 108.874 -179.399 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.71 85.5 0.05 OUTLIER Glycine 0 C--N 1.339 0.741 0 CA-C-N 115.967 -0.561 . . . . 0.0 112.793 178.526 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 13.1 tp -103.44 121.43 42.8 Favored 'General case' 0 N--CA 1.483 1.208 0 N-CA-C 106.945 -1.502 . . . . 0.0 106.945 177.43 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 12.5 ttt -156.17 159.01 38.6 Favored 'General case' 0 N--CA 1.474 0.771 0 N-CA-C 109.058 -0.719 . . . . 0.0 109.058 179.639 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 93.3 t -156.76 151.96 8.35 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.437 0 N-CA-C 107.615 -1.254 . . . . 0.0 107.615 -179.663 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' F' F ' 37' ' ' GLY . . . . . 0.412 ' H ' HE22 ' F' ' 15' ' ' GLN . . . 57.73 72.38 0.6 Allowed Glycine 0 C--N 1.312 -0.759 0 CA-C-N 115.491 -0.777 . . . . 0.0 111.508 178.162 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 171.57 -148.92 11.42 Favored Glycine 0 CA--C 1.523 0.578 0 N-CA-C 111.035 -0.826 . . . . 0.0 111.035 179.686 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 32.9 m -135.42 144.04 35.16 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.837 0 N-CA-C 109.054 -0.721 . . . . 0.0 109.054 179.932 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 19.6 t . . . . . 0 CA--C 1.537 0.454 0 CA-C-O 117.658 -1.163 . . . . 0.0 110.853 179.996 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 78.3 m-85 . . . . . 0 N--CA 1.473 0.691 0 N-CA-C 109.413 -0.588 . . . . 0.0 109.413 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' G' G ' 5' ' ' ARG . . . . . . . . . . . . . 37.0 mtp180 -142.79 143.37 32.15 Favored 'General case' 0 N--CA 1.481 1.113 0 N-CA-C 109.422 -0.585 . . . . 0.0 109.422 -179.635 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 74.7 m80 -150.41 118.81 6.43 Favored 'General case' 0 N--CA 1.473 0.711 0 N-CA-C 109.173 -0.677 . . . . 0.0 109.173 178.69 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 9.7 m-20 -70.0 144.41 52.3 Favored 'General case' 0 CA--C 1.538 0.482 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.642 -179.717 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' G' G ' 8' ' ' SER . . . . . . . . . . . . . 2.9 t -164.46 179.74 6.53 Favored 'General case' 0 N--CA 1.471 0.595 0 N-CA-C 109.465 -0.568 . . . . 0.0 109.465 177.998 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.3 50.7 0.97 Allowed Glycine 0 N--CA 1.476 1.327 0 N-CA-C 111.919 -0.472 . . . . 0.0 111.919 179.049 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 46.9 p90 -64.78 131.86 47.96 Favored 'General case' 0 N--CA 1.474 0.753 0 N-CA-C 112.097 0.406 . . . . 0.0 112.097 -179.484 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 44.0 mt-10 -82.08 150.39 27.54 Favored 'General case' 0 N--CA 1.474 0.748 0 N-CA-C 109.141 -0.688 . . . . 0.0 109.141 177.969 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 3.0 p -156.26 127.82 0.94 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.976 0 N-CA-C 108.285 -1.005 . . . . 0.0 108.285 178.168 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 55.9 m-70 -132.89 144.03 49.9 Favored 'General case' 0 N--CA 1.476 0.827 0 CA-C-N 115.392 -0.822 . . . . 0.0 110.718 -177.935 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' G' G ' 14' ' ' HIS . . . . . 0.41 ' O ' ' ND1' ' D' ' 14' ' ' HIS . 6.0 t60 -165.94 98.29 0.64 Allowed 'General case' 0 N--CA 1.483 1.19 0 CA-C-O 119.599 -0.239 . . . . 0.0 110.765 179.129 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' G' G ' 15' ' ' GLN . . . . . 0.453 HE22 ' H ' ' G' ' 37' ' ' GLY . 50.0 mt-30 -107.42 -172.24 2.03 Favored 'General case' 0 CA--C 1.503 -0.85 0 N-CA-C 108.194 -1.039 . . . . 0.0 108.194 179.306 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -163.19 98.27 0.93 Allowed 'General case' 0 N--CA 1.472 0.653 0 CA-C-N 115.05 -0.977 . . . . 0.0 109.281 178.718 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 6.6 mp -108.47 162.18 14.36 Favored 'General case' 0 N--CA 1.486 1.367 0 N-CA-C 108.946 -0.761 . . . . 0.0 108.946 -179.751 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 36.5 t -142.99 120.48 6.38 Favored 'Isoleucine or valine' 0 CA--C 1.551 1.019 0 CA-C-O 121.223 0.535 . . . . 0.0 110.435 178.973 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 47.3 m-85 -72.73 149.83 43.4 Favored 'General case' 0 C--N 1.375 1.71 0 N-CA-C 106.8 -1.555 . . . . 0.0 106.8 176.166 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 20.0 t80 -169.84 -54.23 0.02 OUTLIER 'General case' 0 N--CA 1.484 1.252 0 N-CA-C 110.194 -0.298 . . . . 0.0 110.194 -179.349 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -42.34 91.43 0.0 OUTLIER 'General case' 0 C--N 1.323 -0.571 0 O-C-N 123.942 0.776 . . . . 0.0 112.129 179.69 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 36.9 tt0 -57.83 133.67 55.62 Favored 'General case' 0 CA--C 1.539 0.542 0 CA-C-N 114.795 -1.093 . . . . 0.0 110.741 179.426 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 -81.08 161.51 24.12 Favored 'General case' 0 N--CA 1.474 0.749 0 N-CA-C 109.714 -0.476 . . . . 0.0 109.714 179.992 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' G' G ' 24' ' ' VAL . . . . . . . . . . . . . 94.8 t -159.44 -76.96 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.957 0 N-CA-C 106.839 -1.541 . . . . 0.0 106.839 -179.027 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -35.35 90.18 0.01 OUTLIER Glycine 0 C--O 1.225 -0.46 0 CA-C-N 114.876 -1.056 . . . . 0.0 112.765 179.381 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 94.2 p -37.78 -99.1 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.899 0 C-N-CA 123.626 0.771 . . . . 0.0 112.708 -176.861 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' G' G ' 27' ' ' ASN . . . . . 0.415 ' ND2' ' CG ' ' H' ' 11' ' ' GLU . 40.8 t30 -61.84 126.54 27.72 Favored 'General case' 0 CA--C 1.545 0.773 0 CA-C-N 119.474 1.034 . . . . 0.0 109.161 179.064 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 63.3 mttm -107.03 -179.09 3.83 Favored 'General case' 0 N--CA 1.483 1.184 0 N-CA-C 109.307 -0.627 . . . . 0.0 109.307 -179.76 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.97 -141.27 0.02 OUTLIER Glycine 0 N--CA 1.464 0.523 0 N-CA-C 109.848 -1.301 . . . . 0.0 109.848 178.422 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.96 115.2 17.45 Favored 'General case' 0 C--O 1.218 -0.558 0 C-N-CA 123.213 0.605 . . . . 0.0 109.413 179.572 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 74.5 mt -97.45 150.96 4.39 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.046 0 N-CA-C 106.92 -1.511 . . . . 0.0 106.92 178.1 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 35.8 mt -149.53 126.91 2.53 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.345 0 N-CA-C 108.876 -0.787 . . . . 0.0 108.876 178.405 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.28 85.95 0.04 OUTLIER Glycine 0 C--N 1.341 0.835 0 CA-C-N 115.957 -0.565 . . . . 0.0 112.823 178.559 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 14.4 tp -103.17 123.66 47.12 Favored 'General case' 0 N--CA 1.484 1.264 0 N-CA-C 107.029 -1.471 . . . . 0.0 107.029 177.271 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 11.9 ttt -158.75 158.57 33.88 Favored 'General case' 0 N--CA 1.469 0.494 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 179.973 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 94.5 t -156.47 153.13 7.42 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.289 0 N-CA-C 106.897 -1.519 . . . . 0.0 106.897 -179.663 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' G' G ' 37' ' ' GLY . . . . . 0.453 ' H ' HE22 ' G' ' 15' ' ' GLN . . . 56.89 73.18 0.47 Allowed Glycine 0 C--N 1.311 -0.811 0 CA-C-N 115.761 -0.654 . . . . 0.0 111.978 178.292 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 169.98 -148.05 11.4 Favored Glycine 0 N--CA 1.469 0.846 0 N-CA-C 110.703 -0.959 . . . . 0.0 110.703 179.019 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 33.5 m -135.48 144.03 35.11 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.009 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 -179.803 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 20.2 t . . . . . 0 N--CA 1.468 0.426 0 CA-C-O 117.776 -1.106 . . . . 0.0 110.838 179.914 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 78.7 m-85 . . . . . 0 N--CA 1.473 0.714 0 N-CA-C 109.362 -0.607 . . . . 0.0 109.362 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' H' H ' 5' ' ' ARG . . . . . . . . . . . . . 37.2 mtp180 -142.99 143.28 31.85 Favored 'General case' 0 N--CA 1.482 1.157 0 N-CA-C 109.302 -0.629 . . . . 0.0 109.302 -179.638 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 74.6 m80 -150.43 118.7 6.38 Favored 'General case' 0 N--CA 1.473 0.68 0 N-CA-C 109.252 -0.648 . . . . 0.0 109.252 178.642 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 9.4 m-20 -69.86 144.35 52.55 Favored 'General case' 0 N--CA 1.468 0.44 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.579 -179.693 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' H' H ' 8' ' ' SER . . . . . . . . . . . . . 3.6 t -164.38 179.09 6.99 Favored 'General case' 0 N--CA 1.47 0.538 0 N-CA-C 109.517 -0.549 . . . . 0.0 109.517 178.091 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.56 50.9 0.94 Allowed Glycine 0 N--CA 1.478 1.442 0 N-CA-C 111.948 -0.461 . . . . 0.0 111.948 179.054 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 46.7 p90 -64.79 131.87 48.0 Favored 'General case' 0 N--CA 1.474 0.765 0 N-CA-C 112.015 0.376 . . . . 0.0 112.015 -179.546 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' H' H ' 11' ' ' GLU . . . . . 0.415 ' CG ' ' ND2' ' G' ' 27' ' ' ASN . 44.0 mt-10 -82.05 150.38 27.59 Favored 'General case' 0 N--CA 1.474 0.749 0 N-CA-C 109.186 -0.672 . . . . 0.0 109.186 177.929 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 3.0 p -156.4 127.82 0.92 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.044 0 N-CA-C 108.291 -1.003 . . . . 0.0 108.291 178.108 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 56.0 m-70 -132.74 144.14 50.07 Favored 'General case' 0 N--CA 1.475 0.804 0 CA-C-N 115.22 -0.9 . . . . 0.0 110.731 -177.906 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 6.0 t60 -166.12 97.74 0.62 Allowed 'General case' 0 N--CA 1.482 1.163 0 CA-C-O 119.554 -0.26 . . . . 0.0 110.775 179.105 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' H' H ' 15' ' ' GLN . . . . . 0.447 HE22 ' H ' ' H' ' 37' ' ' GLY . 49.9 mt-30 -106.87 -172.56 2.1 Favored 'General case' 0 CA--C 1.505 -0.768 0 N-CA-C 108.099 -1.074 . . . . 0.0 108.099 179.403 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -163.0 98.24 0.94 Allowed 'General case' 0 N--CA 1.472 0.643 0 CA-C-N 115.268 -0.878 . . . . 0.0 109.218 178.679 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 6.6 mp -108.48 162.24 14.31 Favored 'General case' 0 N--CA 1.485 1.312 0 N-CA-C 108.978 -0.749 . . . . 0.0 108.978 -179.769 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 37.0 t -142.99 120.15 6.08 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.037 0 CA-C-O 121.16 0.505 . . . . 0.0 110.553 178.994 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 48.2 m-85 -72.76 150.41 42.84 Favored 'General case' 0 C--N 1.373 1.629 0 N-CA-C 106.909 -1.515 . . . . 0.0 106.909 176.182 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 21.3 t80 -171.25 -53.95 0.02 OUTLIER 'General case' 0 N--CA 1.481 1.093 0 N-CA-C 110.202 -0.295 . . . . 0.0 110.202 -179.361 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -42.26 91.6 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.463 0 O-C-N 123.872 0.732 . . . . 0.0 111.896 179.613 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 37.0 tt0 -57.81 133.89 55.8 Favored 'General case' 0 CA--C 1.54 0.564 0 CA-C-N 114.777 -1.102 . . . . 0.0 110.694 179.793 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 9.0 m-20 -81.24 161.44 23.96 Favored 'General case' 0 N--CA 1.474 0.768 0 N-CA-C 109.69 -0.485 . . . . 0.0 109.69 -179.986 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' H' H ' 24' ' ' VAL . . . . . . . . . . . . . 95.0 t -159.77 -77.03 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.99 0 N-CA-C 106.983 -1.488 . . . . 0.0 106.983 -179.037 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . -35.43 89.96 0.01 OUTLIER Glycine 0 N--CA 1.47 0.924 0 CA-C-N 115.086 -0.961 . . . . 0.0 112.245 179.547 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 97.5 p -37.47 -98.79 0.0 OUTLIER 'General case' 0 N--CA 1.478 0.954 0 C-N-CA 123.693 0.797 . . . . 0.0 112.739 -176.711 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' H' H ' 27' ' ' ASN . . . . . 0.409 ' ND2' ' CG ' ' I' ' 11' ' ' GLU . 40.1 t30 -61.62 126.69 28.23 Favored 'General case' 0 CA--C 1.543 0.689 0 CA-C-N 119.368 0.985 . . . . 0.0 109.144 179.01 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 63.3 mttm -106.97 -178.9 3.78 Favored 'General case' 0 N--CA 1.484 1.241 0 N-CA-C 109.365 -0.606 . . . . 0.0 109.365 -179.797 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.92 -141.19 0.02 OUTLIER Glycine 0 CA--C 1.522 0.521 0 N-CA-C 109.935 -1.266 . . . . 0.0 109.935 178.207 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -129.0 115.51 17.9 Favored 'General case' 0 C--O 1.217 -0.643 0 C-N-CA 123.263 0.625 . . . . 0.0 109.437 179.499 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 74.6 mt -97.86 150.6 4.65 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.027 0 N-CA-C 106.908 -1.515 . . . . 0.0 106.908 178.13 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 35.4 mt -149.32 126.89 2.62 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.309 0 N-CA-C 108.912 -0.773 . . . . 0.0 108.912 178.579 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.3 85.65 0.05 OUTLIER Glycine 0 C--N 1.34 0.801 0 CA-C-N 115.946 -0.57 . . . . 0.0 112.994 178.586 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 14.5 tp -102.97 123.28 46.29 Favored 'General case' 0 N--CA 1.482 1.158 0 N-CA-C 107.04 -1.466 . . . . 0.0 107.04 177.332 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 11.8 ttt -158.38 158.48 34.34 Favored 'General case' 0 N--CA 1.469 0.516 0 N-CA-C 108.585 -0.895 . . . . 0.0 108.585 -179.958 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 96.9 t -156.51 152.4 8.12 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.357 0 N-CA-C 107.076 -1.453 . . . . 0.0 107.076 -179.782 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' H' H ' 37' ' ' GLY . . . . . 0.447 ' H ' HE22 ' H' ' 15' ' ' GLN . . . 57.46 73.03 0.5 Allowed Glycine 0 C--N 1.313 -0.698 0 CA-C-N 115.644 -0.707 . . . . 0.0 112.028 178.169 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 169.98 -148.17 11.52 Favored Glycine 0 N--CA 1.468 0.792 0 N-CA-C 110.566 -1.014 . . . . 0.0 110.566 179.068 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 33.4 m -135.36 144.01 35.31 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.995 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.706 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 20.3 t . . . . . 0 C--O 1.222 -0.385 0 CA-C-O 117.852 -1.07 . . . . 0.0 110.916 179.99 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 79.0 m-85 . . . . . 0 N--CA 1.474 0.764 0 N-CA-C 109.323 -0.621 . . . . 0.0 109.323 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' I' I ' 5' ' ' ARG . . . . . . . . . . . . . 37.1 mtp180 -143.15 143.36 31.78 Favored 'General case' 0 N--CA 1.482 1.17 0 N-CA-C 109.273 -0.64 . . . . 0.0 109.273 -179.687 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 74.6 m80 -150.51 118.55 6.29 Favored 'General case' 0 N--CA 1.474 0.729 0 N-CA-C 109.243 -0.651 . . . . 0.0 109.243 178.691 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 9.5 m-20 -69.72 144.21 52.85 Favored 'General case' 0 CA--C 1.537 0.444 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.681 -179.696 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' I' I ' 8' ' ' SER . . . . . . . . . . . . . 3.6 t -164.23 179.11 7.06 Favored 'General case' 0 N--CA 1.469 0.514 0 N-CA-C 109.492 -0.558 . . . . 0.0 109.492 178.182 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.58 50.9 0.94 Allowed Glycine 0 N--CA 1.477 1.426 0 N-CA-C 111.929 -0.469 . . . . 0.0 111.929 179.047 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 47.1 p90 -64.85 131.91 48.01 Favored 'General case' 0 N--CA 1.474 0.734 0 N-CA-C 112.104 0.409 . . . . 0.0 112.104 -179.573 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' I' I ' 11' ' ' GLU . . . . . 0.409 ' CG ' ' ND2' ' H' ' 27' ' ' ASN . 43.9 mt-10 -82.14 150.39 27.48 Favored 'General case' 0 N--CA 1.473 0.71 0 N-CA-C 109.249 -0.648 . . . . 0.0 109.249 177.934 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 3.1 p -156.38 127.7 0.91 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.971 0 N-CA-C 108.366 -0.976 . . . . 0.0 108.366 178.209 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 55.5 m-70 -132.8 144.13 50.02 Favored 'General case' 0 N--CA 1.475 0.779 0 CA-C-N 115.24 -0.891 . . . . 0.0 110.735 -177.839 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 6.0 t60 -166.21 97.98 0.61 Allowed 'General case' 0 N--CA 1.483 1.181 0 CA-C-N 116.664 -0.244 . . . . 0.0 110.818 179.228 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' I' I ' 15' ' ' GLN . . . . . 0.43 HE22 ' H ' ' I' ' 37' ' ' GLY . 49.8 mt-30 -107.11 -172.21 2.03 Favored 'General case' 0 CA--C 1.501 -0.918 0 N-CA-C 108.12 -1.067 . . . . 0.0 108.12 179.322 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -163.24 98.27 0.92 Allowed 'General case' 0 N--CA 1.47 0.563 0 CA-C-N 115.109 -0.95 . . . . 0.0 109.22 178.704 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 6.6 mp -108.45 162.12 14.41 Favored 'General case' 0 N--CA 1.485 1.323 0 N-CA-C 108.968 -0.753 . . . . 0.0 108.968 -179.751 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 37.7 t -142.9 120.18 6.35 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.048 0 CA-C-O 121.2 0.524 . . . . 0.0 110.483 178.987 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 47.7 m-85 -72.81 150.39 42.78 Favored 'General case' 0 C--N 1.374 1.645 0 N-CA-C 106.759 -1.571 . . . . 0.0 106.759 176.196 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 21.3 t80 -171.17 -54.15 0.02 OUTLIER 'General case' 0 N--CA 1.48 1.048 0 N-CA-C 110.217 -0.29 . . . . 0.0 110.217 -179.304 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -42.25 91.58 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.461 0 CA-C-O 121.632 0.729 . . . . 0.0 111.856 179.656 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 37.0 tt0 -57.75 133.82 55.7 Favored 'General case' 0 CA--C 1.539 0.558 0 CA-C-N 114.769 -1.105 . . . . 0.0 110.773 179.691 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 -81.09 161.38 24.16 Favored 'General case' 0 N--CA 1.473 0.716 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 179.936 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' I' I ' 24' ' ' VAL . . . . . . . . . . . . . 95.1 t -159.75 -77.11 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.04 0 N-CA-C 107.045 -1.465 . . . . 0.0 107.045 -179.095 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . -35.53 90.09 0.01 OUTLIER Glycine 0 C--N 1.34 0.804 0 CA-C-N 115.073 -0.967 . . . . 0.0 112.25 179.611 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 97.5 p -37.4 -98.95 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.875 0 C-N-CA 123.794 0.838 . . . . 0.0 112.82 -176.733 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 40.5 t30 -61.5 126.62 28.02 Favored 'General case' 0 CA--C 1.542 0.645 0 CA-C-N 119.431 1.014 . . . . 0.0 109.148 179.005 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 63.2 mttm -106.96 -178.95 3.79 Favored 'General case' 0 N--CA 1.484 1.275 0 N-CA-C 109.356 -0.609 . . . . 0.0 109.356 -179.791 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.92 -141.27 0.02 OUTLIER Glycine 0 CA--C 1.523 0.58 0 N-CA-C 109.906 -1.278 . . . . 0.0 109.906 178.254 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.86 115.46 17.93 Favored 'General case' 0 C--O 1.218 -0.584 0 C-N-CA 123.247 0.619 . . . . 0.0 109.434 179.537 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 74.6 mt -97.94 150.67 4.64 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.047 0 N-CA-C 106.878 -1.527 . . . . 0.0 106.878 178.186 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 35.7 mt -149.31 126.93 2.65 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.292 0 N-CA-C 108.863 -0.791 . . . . 0.0 108.863 178.646 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.28 85.69 0.05 OUTLIER Glycine 0 C--N 1.339 0.71 0 CA-C-N 115.986 -0.552 . . . . 0.0 112.919 178.571 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 14.6 tp -102.91 123.25 46.19 Favored 'General case' 0 N--CA 1.482 1.151 0 N-CA-C 107.008 -1.479 . . . . 0.0 107.008 177.208 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 11.8 ttt -158.31 158.51 34.51 Favored 'General case' 0 N--CA 1.469 0.489 0 N-CA-C 108.56 -0.904 . . . . 0.0 108.56 179.97 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 96.6 t -156.57 152.39 8.09 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.297 0 N-CA-C 107.007 -1.479 . . . . 0.0 107.007 -179.776 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' I' I ' 37' ' ' GLY . . . . . 0.43 ' H ' HE22 ' I' ' 15' ' ' GLN . . . 57.44 73.2 0.48 Allowed Glycine 0 C--N 1.313 -0.734 0 CA-C-N 115.661 -0.7 . . . . 0.0 111.932 178.141 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 169.9 -148.29 11.66 Favored Glycine 0 N--CA 1.467 0.719 0 N-CA-C 110.651 -0.979 . . . . 0.0 110.651 179.094 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 33.4 m -135.21 144.01 35.49 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.947 0 C-N-CA 122.765 0.426 . . . . 0.0 109.904 -179.83 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 20.3 t . . . . . 0 C--O 1.222 -0.378 0 CA-C-O 117.803 -1.094 . . . . 0.0 110.932 179.996 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 29.1 m-85 . . . . . 0 N--CA 1.476 0.864 0 N-CA-C 108.637 -0.875 . . . . 0.0 108.637 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 5' ' ' ARG . . . . . 0.512 ' NH1' HH21 ' D' ' 5' ' ' ARG . 6.2 ptm180 -165.06 146.65 7.73 Favored 'General case' 0 N--CA 1.478 0.954 0 N-CA-C 112.349 0.5 . . . . 0.0 112.349 -179.738 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 21.2 p80 -151.89 107.79 3.38 Favored 'General case' 0 N--CA 1.475 0.788 0 CA-C-O 120.884 0.374 . . . . 0.0 110.552 177.93 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -78.13 151.69 33.2 Favored 'General case' 0 N--CA 1.475 0.805 0 CA-C-O 121.03 0.443 . . . . 0.0 109.827 178.961 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 99.8 p -155.2 173.67 16.29 Favored 'General case' 0 N--CA 1.475 0.794 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.595 -179.766 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 125.13 78.99 0.35 Allowed Glycine 0 N--CA 1.481 1.692 0 N-CA-C 111.441 -0.664 . . . . 0.0 111.441 -179.969 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 23.6 p90 -55.14 156.05 4.33 Favored 'General case' 0 N--CA 1.478 0.954 0 C-N-CA 122.528 0.331 . . . . 0.0 110.698 178.982 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 65.7 mt-10 -119.65 127.21 52.7 Favored 'General case' 0 N--CA 1.486 1.366 0 N-CA-C 109.708 -0.479 . . . . 0.0 109.708 179.281 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 40.2 t -101.69 139.83 21.85 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.705 0 N-CA-C 109.194 -0.669 . . . . 0.0 109.194 178.815 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 42.3 m80 -140.42 138.98 35.16 Favored 'General case' 0 N--CA 1.488 1.445 0 CA-C-N 118.762 0.71 . . . . 0.0 109.98 178.494 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 13.0 t60 -167.55 97.31 0.48 Allowed 'General case' 0 N--CA 1.481 1.119 0 CA-C-O 119.745 -0.169 . . . . 0.0 110.632 178.979 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 55.2 mt-30 -100.55 116.48 32.6 Favored 'General case' 0 CA--C 1.512 -0.493 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 -179.484 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 64.4 tttp -104.32 105.95 16.27 Favored 'General case' 0 N--CA 1.48 1.07 0 N-CA-C 108.648 -0.871 . . . . 0.0 108.648 178.148 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 10.0 mp -122.63 165.17 16.92 Favored 'General case' 0 N--CA 1.487 1.412 0 N-CA-C 108.712 -0.847 . . . . 0.0 108.712 -179.55 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 62.1 t -142.57 111.28 2.19 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.09 0 N-CA-C 108.499 -0.926 . . . . 0.0 108.499 177.757 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 59.7 m-85 -101.24 164.92 11.55 Favored 'General case' 0 N--CA 1.475 0.821 0 N-CA-C 109.29 -0.633 . . . . 0.0 109.29 178.244 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.453 ' O ' ' O ' ' D' ' 21' ' ' ALA . 77.7 t80 -165.53 -83.46 0.02 OUTLIER 'General case' 0 C--O 1.209 -1.052 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 177.205 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -88.29 94.08 9.72 Favored 'General case' 0 C--N 1.353 0.726 0 N-CA-C 108.249 -1.019 . . . . 0.0 108.249 177.567 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 11.2 mm-40 -73.85 -170.13 0.84 Allowed 'General case' 0 N--CA 1.482 1.153 0 C-N-CA 120.344 -0.542 . . . . 0.0 110.771 179.812 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . 0.411 ' HB2' ' HZ2' ' A' ' 28' ' ' LYS . 8.2 m-20 -73.17 153.35 40.75 Favored 'General case' 0 N--CA 1.473 0.712 0 CA-C-O 121.886 0.85 . . . . 0.0 112.995 -177.637 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . 0.495 ' CG1' HH12 ' B' ' 5' ' ' ARG . 71.2 t -155.23 94.35 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.466 0.369 0 CA-C-N 114.551 -1.204 . . . . 0.0 108.244 177.005 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -121.56 60.3 0.55 Allowed Glycine 0 N--CA 1.481 1.638 0 N-CA-C 110.995 -0.842 . . . . 0.0 110.995 179.038 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 15.3 m 47.32 -143.34 0.38 Allowed 'General case' 0 N--CA 1.484 1.261 0 CA-C-N 118.164 0.982 . . . . 0.0 110.479 -179.633 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 3.9 m-80 -79.67 92.38 5.37 Favored 'General case' 0 N--CA 1.47 0.527 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 177.636 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.411 ' HZ2' ' HB2' ' A' ' 23' ' ' ASP . 96.4 mttt -65.76 146.21 55.05 Favored 'General case' 0 CA--C 1.539 0.537 0 CA-C-O 121.264 0.554 . . . . 0.0 110.537 -178.559 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -70.17 -129.17 0.06 OUTLIER Glycine 0 CA--C 1.525 0.688 0 N-CA-C 109.445 -1.462 . . . . 0.0 109.445 178.533 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -85.01 131.35 34.48 Favored 'General case' 0 N--CA 1.465 0.3 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 179.69 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 18.3 tt -165.54 173.52 0.17 Allowed 'Isoleucine or valine' 0 C--O 1.215 -0.745 0 N-CA-C 108.815 -0.809 . . . . 0.0 108.815 -177.85 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 24.3 mt -140.27 145.21 26.41 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.487 0 N-CA-C 107.179 -1.415 . . . . 0.0 107.179 -179.288 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -52.0 168.17 0.71 Allowed Glycine 0 N--CA 1.473 1.14 0 C-N-CA 121.268 -0.491 . . . . 0.0 112.147 -179.328 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 2.7 pp -65.99 158.08 29.17 Favored 'General case' 0 N--CA 1.465 0.293 0 N-CA-C 109.671 -0.492 . . . . 0.0 109.671 179.741 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 21.3 ttt -142.57 154.76 44.72 Favored 'General case' 0 N--CA 1.473 0.676 0 N-CA-C 108.965 -0.754 . . . . 0.0 108.965 -179.919 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 41.3 t -149.49 139.33 16.03 Favored 'Isoleucine or valine' 0 C--O 1.235 0.318 0 N-CA-C 107.241 -1.392 . . . . 0.0 107.241 -179.695 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 60.54 67.44 2.14 Favored Glycine 0 C--N 1.318 -0.437 0 N-CA-C 109.006 -1.637 . . . . 0.0 109.006 -179.85 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -82.22 130.08 9.47 Favored Glycine 0 N--CA 1.468 0.788 0 N-CA-C 111.312 -0.715 . . . . 0.0 111.312 -178.818 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 1.9 t -146.71 113.43 1.05 Allowed 'Isoleucine or valine' 0 CA--C 1.561 1.373 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 179.257 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 19.1 t . . . . . 0 N--CA 1.497 1.899 0 CA-C-O 118.475 -0.774 . . . . 0.0 112.477 -177.877 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 29.0 m-85 . . . . . 0 N--CA 1.476 0.847 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' B' B ' 5' ' ' ARG . . . . . 0.496 ' NH1' HH21 ' E' ' 5' ' ' ARG . 6.3 ptm180 -165.39 146.59 7.31 Favored 'General case' 0 N--CA 1.474 0.773 0 C-N-CA 120.569 -0.452 . . . . 0.0 112.165 -179.698 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 20.9 p80 -151.79 108.07 3.43 Favored 'General case' 0 N--CA 1.476 0.838 0 CA-C-O 120.831 0.348 . . . . 0.0 110.562 177.867 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 7' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -78.56 151.1 32.64 Favored 'General case' 0 N--CA 1.476 0.834 0 CA-C-O 121.088 0.471 . . . . 0.0 109.889 179.042 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 8' ' ' SER . . . . . . . . . . . . . 99.3 p -154.54 173.72 15.92 Favored 'General case' 0 N--CA 1.473 0.718 0 CA-C-N 115.784 -0.643 . . . . 0.0 110.731 -179.759 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 125.2 78.91 0.34 Allowed Glycine 0 N--CA 1.48 1.621 0 N-CA-C 111.433 -0.667 . . . . 0.0 111.433 -179.972 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 23.9 p90 -55.28 156.05 4.55 Favored 'General case' 0 N--CA 1.478 0.927 0 C-N-CA 122.401 0.28 . . . . 0.0 110.742 179.054 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 65.6 mt-10 -119.55 127.43 52.98 Favored 'General case' 0 N--CA 1.486 1.367 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 179.288 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 40.0 t -102.04 139.66 22.55 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.708 0 N-CA-C 109.194 -0.669 . . . . 0.0 109.194 178.85 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 41.9 m80 -140.41 139.09 35.2 Favored 'General case' 0 N--CA 1.484 1.272 0 CA-C-N 118.689 0.677 . . . . 0.0 110.011 178.729 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 13.2 t60 -167.87 97.37 0.45 Allowed 'General case' 0 N--CA 1.482 1.165 0 N-CA-C 110.507 -0.183 . . . . 0.0 110.507 179.017 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 55.4 mt-30 -100.67 116.86 33.56 Favored 'General case' 0 CA--C 1.511 -0.546 0 N-CA-C 108.604 -0.887 . . . . 0.0 108.604 -179.533 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 64.6 tttp -104.51 105.97 16.29 Favored 'General case' 0 N--CA 1.479 1.014 0 N-CA-C 108.674 -0.861 . . . . 0.0 108.674 178.106 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 10.0 mp -122.83 165.05 17.26 Favored 'General case' 0 N--CA 1.489 1.516 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 -179.51 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 61.6 t -142.45 110.24 2.04 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.117 0 N-CA-C 108.743 -0.836 . . . . 0.0 108.743 177.838 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 61.1 m-85 -100.11 164.32 12.03 Favored 'General case' 0 N--CA 1.474 0.746 0 CA-C-N 118.745 0.702 . . . . 0.0 109.456 178.275 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . 0.433 ' O ' ' O ' ' E' ' 21' ' ' ALA . 76.4 t80 -164.38 -83.59 0.03 OUTLIER 'General case' 0 C--O 1.212 -0.881 0 N-CA-C 109.277 -0.638 . . . . 0.0 109.277 177.238 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -88.73 94.3 9.86 Favored 'General case' 0 C--N 1.35 0.59 0 N-CA-C 108.171 -1.048 . . . . 0.0 108.171 177.599 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 11.4 mm-40 -73.73 -170.24 0.84 Allowed 'General case' 0 N--CA 1.481 1.124 0 C-N-CA 120.487 -0.485 . . . . 0.0 110.791 179.881 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 23' ' ' ASP . . . . . 0.413 ' HB2' ' HZ2' ' B' ' 28' ' ' LYS . 8.2 m-20 -73.24 153.45 40.63 Favored 'General case' 0 N--CA 1.473 0.709 0 CA-C-O 121.943 0.878 . . . . 0.0 112.971 -177.598 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 24' ' ' VAL . . . . . 0.498 ' CG1' HH12 ' C' ' 5' ' ' ARG . 65.5 t -155.22 94.3 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.391 0 CA-C-N 114.586 -1.188 . . . . 0.0 108.166 177.013 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -121.35 60.16 0.55 Allowed Glycine 0 N--CA 1.479 1.547 0 N-CA-C 111.138 -0.785 . . . . 0.0 111.138 178.874 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 15.3 m 47.4 -143.72 0.36 Allowed 'General case' 0 N--CA 1.485 1.281 0 CA-C-N 118.209 1.005 . . . . 0.0 110.317 -179.574 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 4.1 m-80 -79.43 92.45 5.23 Favored 'General case' 0 N--CA 1.469 0.497 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 177.661 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 28' ' ' LYS . . . . . 0.413 ' HZ2' ' HB2' ' B' ' 23' ' ' ASP . 96.4 mttt -65.87 146.47 54.71 Favored 'General case' 0 CA--C 1.54 0.569 0 CA-C-O 121.333 0.587 . . . . 0.0 110.42 -178.472 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -70.33 -129.11 0.06 OUTLIER Glycine 0 CA--C 1.526 0.745 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 178.523 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -85.0 131.32 34.48 Favored 'General case' 0 C--O 1.235 0.291 0 N-CA-C 109.413 -0.588 . . . . 0.0 109.413 179.628 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 18.3 tt -165.61 173.44 0.17 Allowed 'Isoleucine or valine' 0 C--O 1.215 -0.751 0 N-CA-C 108.753 -0.832 . . . . 0.0 108.753 -177.8 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 24.6 mt -140.25 145.14 26.53 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.475 0 N-CA-C 107.194 -1.41 . . . . 0.0 107.194 -179.24 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -51.94 168.25 0.68 Allowed Glycine 0 N--CA 1.472 1.078 0 C-N-CA 121.202 -0.523 . . . . 0.0 112.195 -179.372 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 2.7 pp -66.13 157.76 30.39 Favored 'General case' 0 N--CA 1.465 0.28 0 N-CA-C 109.646 -0.501 . . . . 0.0 109.646 179.79 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 21.3 ttt -142.25 154.93 45.16 Favored 'General case' 0 N--CA 1.473 0.677 0 N-CA-C 109.02 -0.733 . . . . 0.0 109.02 -179.975 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 41.0 t -149.46 139.51 16.21 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.313 0 N-CA-C 107.267 -1.382 . . . . 0.0 107.267 -179.638 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 60.1 67.41 2.17 Favored Glycine 0 C--N 1.318 -0.445 0 N-CA-C 109.152 -1.579 . . . . 0.0 109.152 -179.803 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . -82.16 129.98 9.41 Favored Glycine 0 CA--C 1.526 0.769 0 N-CA-C 111.284 -0.726 . . . . 0.0 111.284 -178.892 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 1.9 t -146.68 113.46 1.06 Allowed 'Isoleucine or valine' 0 CA--C 1.561 1.371 0 N-CA-C 108.459 -0.941 . . . . 0.0 108.459 179.192 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 19.8 t . . . . . 0 N--CA 1.498 1.937 0 CA-C-O 118.409 -0.805 . . . . 0.0 112.195 -177.997 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 28.6 m-85 . . . . . 0 N--CA 1.477 0.92 0 N-CA-C 108.653 -0.869 . . . . 0.0 108.653 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' C' C ' 5' ' ' ARG . . . . . 0.505 ' NH1' HH21 ' F' ' 5' ' ' ARG . 6.3 ptm180 -164.98 146.54 7.79 Favored 'General case' 0 N--CA 1.476 0.86 0 N-CA-C 112.231 0.456 . . . . 0.0 112.231 -179.706 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 21.2 p80 -151.78 107.92 3.42 Favored 'General case' 0 N--CA 1.476 0.868 0 CA-C-O 120.804 0.335 . . . . 0.0 110.554 177.883 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' C' C ' 7' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -78.51 150.91 32.81 Favored 'General case' 0 N--CA 1.476 0.862 0 CA-C-O 121.061 0.457 . . . . 0.0 109.861 179.038 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' C' C ' 8' ' ' SER . . . . . . . . . . . . . 99.3 p -154.38 173.86 15.64 Favored 'General case' 0 N--CA 1.475 0.796 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.711 -179.856 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 125.07 78.96 0.35 Allowed Glycine 0 N--CA 1.48 1.627 0 N-CA-C 111.447 -0.661 . . . . 0.0 111.447 179.984 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 24.3 p90 -55.24 156.01 4.53 Favored 'General case' 0 N--CA 1.478 0.925 0 C-N-CA 122.501 0.32 . . . . 0.0 110.757 178.959 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 65.5 mt-10 -119.49 127.33 52.94 Favored 'General case' 0 N--CA 1.485 1.325 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 179.326 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 39.9 t -101.87 139.59 22.61 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.717 0 N-CA-C 109.266 -0.642 . . . . 0.0 109.266 178.76 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 42.0 m80 -140.41 138.92 35.12 Favored 'General case' 0 N--CA 1.486 1.366 0 CA-C-N 118.635 0.652 . . . . 0.0 110.009 178.662 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 13.2 t60 -167.67 97.46 0.47 Allowed 'General case' 0 N--CA 1.481 1.109 0 N-CA-C 110.542 -0.17 . . . . 0.0 110.542 178.939 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 55.5 mt-30 -100.58 116.71 33.14 Favored 'General case' 0 CA--C 1.513 -0.474 0 N-CA-C 108.608 -0.886 . . . . 0.0 108.608 -179.491 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 64.6 tttp -104.39 106.07 16.43 Favored 'General case' 0 N--CA 1.481 1.111 0 N-CA-C 108.632 -0.877 . . . . 0.0 108.632 178.062 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 10.0 mp -122.91 164.88 17.63 Favored 'General case' 0 N--CA 1.488 1.452 0 N-CA-C 108.599 -0.889 . . . . 0.0 108.599 -179.567 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 60.8 t -142.21 110.31 2.19 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 N-CA-C 108.587 -0.894 . . . . 0.0 108.587 177.836 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 61.4 m-85 -100.09 164.3 12.04 Favored 'General case' 0 N--CA 1.476 0.839 0 CA-C-N 118.734 0.697 . . . . 0.0 109.426 178.202 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' C' C ' 20' ' ' PHE . . . . . 0.44 ' O ' ' O ' ' F' ' 21' ' ' ALA . 76.1 t80 -164.23 -83.66 0.03 OUTLIER 'General case' 0 C--O 1.211 -0.955 0 N-CA-C 109.441 -0.577 . . . . 0.0 109.441 177.132 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -88.61 94.27 9.83 Favored 'General case' 0 C--N 1.349 0.554 0 N-CA-C 108.124 -1.065 . . . . 0.0 108.124 177.633 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 11.3 mm-40 -73.81 -170.14 0.84 Allowed 'General case' 0 N--CA 1.48 1.074 0 C-N-CA 120.393 -0.523 . . . . 0.0 110.816 179.928 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' C' C ' 23' ' ' ASP . . . . . 0.413 ' HB2' ' HZ2' ' C' ' 28' ' ' LYS . 8.2 m-20 -73.2 153.41 40.69 Favored 'General case' 0 N--CA 1.474 0.76 0 CA-C-O 122.04 0.924 . . . . 0.0 112.864 -177.613 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' C' C ' 24' ' ' VAL . . . . . 0.497 ' CG1' HH12 ' A' ' 5' ' ' ARG . 65.5 t -155.31 94.43 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.39 0 CA-C-N 114.418 -1.264 . . . . 0.0 108.147 176.958 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -121.57 60.41 0.55 Allowed Glycine 0 N--CA 1.48 1.598 0 N-CA-C 110.984 -0.846 . . . . 0.0 110.984 178.96 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 15.4 m 47.23 -143.79 0.35 Allowed 'General case' 0 N--CA 1.484 1.265 0 CA-C-N 118.21 1.005 . . . . 0.0 110.456 -179.554 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 4.1 m-80 -79.33 92.44 5.17 Favored 'General case' 0 N--CA 1.469 0.512 0 N-CA-C 108.71 -0.848 . . . . 0.0 108.71 177.613 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' C' C ' 28' ' ' LYS . . . . . 0.413 ' HZ2' ' HB2' ' C' ' 23' ' ' ASP . 96.4 mttt -65.87 146.2 55.03 Favored 'General case' 0 CA--C 1.541 0.603 0 CA-C-O 121.292 0.567 . . . . 0.0 110.502 -178.458 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -70.13 -129.0 0.06 OUTLIER Glycine 0 C--N 1.339 0.708 0 N-CA-C 109.591 -1.404 . . . . 0.0 109.591 178.483 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -85.01 131.25 34.49 Favored 'General case' 0 C--O 1.234 0.277 0 N-CA-C 109.423 -0.584 . . . . 0.0 109.423 179.65 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 18.3 tt -165.5 173.53 0.17 Allowed 'Isoleucine or valine' 0 C--O 1.215 -0.749 0 N-CA-C 108.832 -0.803 . . . . 0.0 108.832 -177.954 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 24.4 mt -140.25 145.22 26.43 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.466 0 N-CA-C 107.123 -1.436 . . . . 0.0 107.123 -179.22 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -52.01 168.19 0.71 Allowed Glycine 0 N--CA 1.473 1.113 0 C-N-CA 121.253 -0.499 . . . . 0.0 112.213 -179.442 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 2.7 pp -66.0 157.85 29.8 Favored 'General case' 0 N--CA 1.464 0.274 0 N-CA-C 109.679 -0.489 . . . . 0.0 109.679 179.736 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 21.4 ttt -142.28 154.79 45.01 Favored 'General case' 0 N--CA 1.473 0.68 0 N-CA-C 108.966 -0.753 . . . . 0.0 108.966 -179.939 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 41.1 t -149.4 139.65 16.37 Favored 'Isoleucine or valine' 0 C--O 1.234 0.288 0 N-CA-C 107.165 -1.42 . . . . 0.0 107.165 -179.71 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 60.01 67.3 2.22 Favored Glycine 0 C--N 1.32 -0.331 0 N-CA-C 109.173 -1.571 . . . . 0.0 109.173 -179.868 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . -81.97 130.04 9.45 Favored Glycine 0 CA--C 1.526 0.754 0 N-CA-C 111.264 -0.735 . . . . 0.0 111.264 -178.91 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 1.9 t -146.67 113.48 1.06 Allowed 'Isoleucine or valine' 0 CA--C 1.558 1.284 0 N-CA-C 108.47 -0.937 . . . . 0.0 108.47 179.131 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 19.9 t . . . . . 0 N--CA 1.495 1.789 0 CA-C-O 118.467 -0.778 . . . . 0.0 112.399 -177.894 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' D' D ' 4' ' ' PHE . . . . . 0.41 ' N ' ' CD1' ' D' ' 4' ' ' PHE 0.289 35.2 m-85 . . . . . 0 N--CA 1.486 1.339 0 N-CA-C 106.381 -1.711 . . . . 0.0 106.381 . . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' D' D ' 5' ' ' ARG . . . . . 0.519 HH12 ' CG1' ' F' ' 24' ' ' VAL . 6.0 ptm180 -154.59 150.01 27.26 Favored 'General case' 0 C--O 1.247 0.924 0 CA-C-O 116.565 -1.683 . . . . 0.0 113.175 176.423 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 15.4 p80 -150.75 117.98 5.99 Favored 'General case' 0 N--CA 1.481 1.102 0 CA-C-N 119.992 1.269 . . . . 0.0 107.882 163.217 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' D' D ' 7' ' ' ASP . . . . . . . . . . . . 0.367 0.7 OUTLIER -66.25 141.64 57.97 Favored 'General case' 0 C--N 1.324 -0.522 0 C-N-CA 128.565 2.746 . . . . 0.0 115.839 168.32 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' D' D ' 8' ' ' SER . . . . . . . . . . . . . 97.9 p -151.16 175.45 12.14 Favored 'General case' 0 N--CA 1.488 1.437 0 CA-C-N 119.452 1.024 . . . . 0.0 111.471 175.404 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.37 77.12 0.4 Allowed Glycine 0 N--CA 1.48 1.567 0 CA-C-N 116.056 -0.52 . . . . 0.0 112.762 179.594 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 25.9 p90 -50.98 152.25 2.26 Favored 'General case' 0 N--CA 1.48 1.053 0 C-N-CA 123.662 0.785 . . . . 0.0 111.967 177.768 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 64.9 mt-10 -117.39 131.13 56.83 Favored 'General case' 0 N--CA 1.49 1.568 0 C-N-CA 118.94 -1.104 . . . . 0.0 108.524 175.992 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 21.3 t -95.22 140.26 17.22 Favored 'Isoleucine or valine' 0 C--O 1.245 0.856 0 CA-C-O 117.678 -1.153 . . . . 0.0 111.083 173.673 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 39.6 m80 -138.64 140.62 38.95 Favored 'General case' 0 N--CA 1.483 1.185 0 CA-C-N 119.543 1.065 . . . . 0.0 110.236 172.544 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 14.0 t60 -165.5 104.47 0.73 Allowed 'General case' 0 N--CA 1.48 1.066 0 N-CA-C 108.922 -0.77 . . . . 0.0 108.922 173.611 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 55.8 mt-30 -104.19 114.95 29.55 Favored 'General case' 0 C--N 1.311 -1.067 0 N-CA-C 108.698 -0.853 . . . . 0.0 108.698 179.15 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 64.6 tttp -102.49 112.89 25.82 Favored 'General case' 0 C--N 1.358 0.964 0 N-CA-C 107.677 -1.231 . . . . 0.0 107.677 177.073 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 9.3 mp -126.69 162.26 26.2 Favored 'General case' 0 N--CA 1.488 1.439 0 N-CA-C 108.409 -0.96 . . . . 0.0 108.409 179.499 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . 0.365 89.7 t -140.62 119.65 11.34 Favored 'Isoleucine or valine' 0 C--N 1.372 1.563 0 N-CA-C 105.636 -1.987 . . . . 0.0 105.636 168.099 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' D' D ' 19' ' ' PHE . . . . . . . . . . . . 0.69 57.8 m-85 -67.33 150.34 49.12 Favored 'General case' 0 N--CA 1.423 -1.794 1 C-N-CA 135.005 5.322 . . . . 0.0 121.46 159.418 . . . . . . . . 3 2 . 1 . 019 nuclear orig core ' D' D ' 20' ' ' PHE . . . . . 0.403 ' O ' ' O ' ' G' ' 21' ' ' ALA 0.315 82.4 t80 -169.25 -67.79 0.02 OUTLIER 'General case' 0 N--CA 1.477 0.922 0 CA-C-O 114.713 -2.565 . . . . 0.0 113.794 152.691 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' D' D ' 21' ' ' ALA . . . . . 0.453 ' O ' ' O ' ' A' ' 20' ' ' PHE 0.354 . . -68.91 91.56 0.47 Allowed 'General case' 0 C--O 1.259 1.597 0 CA-C-O 113.016 -3.373 . . . . 0.0 113.057 160.959 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 11.8 mm-40 -76.88 -169.13 1.2 Allowed 'General case' 0 C--N 1.282 -2.34 1 CA-C-N 126.396 4.18 . . . . 0.0 111.316 177.061 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 9.7 m-20 -75.92 154.87 35.64 Favored 'General case' 0 C--O 1.241 0.625 0 CA-C-O 121.708 0.766 . . . . 0.0 111.233 -176.399 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' D' D ' 24' ' ' VAL . . . . . 0.485 ' CG1' HH12 ' E' ' 5' ' ' ARG 0.294 42.7 t -154.72 103.71 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.663 0 N-CA-C 104.002 -2.592 . . . . 0.0 104.002 170.27 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . -118.43 63.33 0.42 Allowed Glycine 0 C--N 1.361 1.929 0 CA-C-O 117.303 -1.831 . . . . 0.0 111.876 170.345 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 14.7 m 54.72 -143.15 0.76 Allowed 'General case' 0 N--CA 1.481 1.093 0 CA-C-N 121.411 2.606 . . . . 0.0 110.396 175.727 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 3.5 m-80 -82.36 92.49 7.0 Favored 'General case' 0 N--CA 1.471 0.624 0 C-N-CA 123.78 0.832 . . . . 0.0 109.012 173.051 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 94.5 mttt -71.64 149.54 45.47 Favored 'General case' 0 CA--C 1.548 0.879 0 CA-C-O 122.601 1.191 . . . . 0.0 108.66 -175.815 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -70.01 -132.7 0.08 OUTLIER Glycine 0 N--CA 1.466 0.658 0 N-CA-C 107.804 -2.118 . . . . 0.0 107.804 179.481 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -89.42 132.89 34.78 Favored 'General case' 0 C--N 1.353 0.749 0 N-CA-C 106.923 -1.51 . . . . 0.0 106.923 -176.754 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' D' D ' 31' ' ' ILE . . . . . 0.409 ' N ' ' O ' ' E' ' 40' ' ' VAL . 18.9 tt -165.32 173.05 0.18 Allowed 'Isoleucine or valine' 0 C--O 1.218 -0.567 0 CA-C-N 113.21 -1.814 . . . . 0.0 109.085 -175.245 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 26.9 mt -141.65 145.49 24.37 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.623 0 N-CA-C 107.095 -1.446 . . . . 0.0 107.095 -179.659 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -52.33 169.15 0.66 Allowed Glycine 0 N--CA 1.473 1.115 0 C-N-CA 121.312 -0.471 . . . . 0.0 112.111 -178.581 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 2.5 pp -68.33 158.58 33.17 Favored 'General case' 0 N--CA 1.464 0.273 0 N-CA-C 109.34 -0.615 . . . . 0.0 109.34 -178.813 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 22.7 ttt -140.41 161.03 38.67 Favored 'General case' 0 N--CA 1.474 0.769 0 N-CA-C 107.98 -1.119 . . . . 0.0 107.98 179.168 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' D' D ' 36' ' ' VAL . . . . . . . . . . . . 0.284 62.0 t -155.71 147.05 12.5 Favored 'Isoleucine or valine' 0 C--N 1.349 0.573 0 N-CA-C 104.971 -2.233 . . . . 0.0 104.971 174.25 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 61.55 66.46 2.63 Favored Glycine 0 CA--C 1.535 1.326 0 N-CA-C 106.468 -2.653 . . . . 0.0 106.468 179.549 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . -80.74 129.9 9.37 Favored Glycine 0 C--N 1.313 -0.723 0 CA-C-N 118.683 1.242 . . . . 0.0 111.987 -179.077 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 2.4 t -148.74 122.74 1.8 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.789 0 N-CA-C 105.114 -2.18 . . . . 0.0 105.114 173.546 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 12.7 t . . . . . 0 N--CA 1.485 1.315 0 CA-C-O 116.567 -1.682 . . . . 0.0 113.769 179.317 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 27.3 m-85 . . . . . 0 N--CA 1.478 0.926 0 N-CA-C 108.379 -0.971 . . . . 0.0 108.379 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' E' E ' 5' ' ' ARG . . . . . 0.508 ' NH1' HH21 ' H' ' 5' ' ' ARG . 6.3 ptm180 -165.06 147.37 8.02 Favored 'General case' 0 C--O 1.217 -0.637 0 C-N-CA 120.365 -0.534 . . . . 0.0 112.166 -179.973 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 20.6 p80 -152.17 106.84 3.21 Favored 'General case' 0 N--CA 1.477 0.899 0 CA-C-O 120.839 0.352 . . . . 0.0 110.58 178.047 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' E' E ' 7' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -77.98 152.35 33.17 Favored 'General case' 0 N--CA 1.474 0.744 0 CA-C-O 121.556 0.693 . . . . 0.0 110.091 178.939 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' E' E ' 8' ' ' SER . . . . . . . . . . . . . 92.8 p -156.34 172.9 17.69 Favored 'General case' 0 N--CA 1.487 1.4 0 CA-C-N 115.07 -0.968 . . . . 0.0 111.377 -178.815 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 125.7 79.56 0.35 Allowed Glycine 0 N--CA 1.481 1.669 0 N-CA-C 111.441 -0.664 . . . . 0.0 111.441 179.543 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 18.4 p90 -53.48 157.65 2.03 Favored 'General case' 0 N--CA 1.479 0.986 0 C-N-CA 122.393 0.277 . . . . 0.0 111.125 179.298 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 65.6 mt-10 -120.11 126.96 52.03 Favored 'General case' 0 N--CA 1.49 1.551 0 N-CA-C 109.229 -0.656 . . . . 0.0 109.229 178.429 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 39.6 t -103.52 136.95 33.99 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.685 0 N-CA-C 109.014 -0.736 . . . . 0.0 109.014 178.255 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 35.9 m80 -138.64 138.63 38.0 Favored 'General case' 0 N--CA 1.481 1.102 0 C-N-CA 122.326 0.25 . . . . 0.0 110.585 179.748 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 13.2 t60 -167.96 97.45 0.45 Allowed 'General case' 0 N--CA 1.484 1.258 0 C-N-CA 122.239 0.215 . . . . 0.0 110.593 179.303 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 55.1 mt-30 -100.57 117.12 34.06 Favored 'General case' 0 CA--C 1.512 -0.509 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 -179.681 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 64.6 tttp -104.63 105.63 15.8 Favored 'General case' 0 N--CA 1.48 1.042 0 N-CA-C 108.657 -0.868 . . . . 0.0 108.657 178.225 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 9.9 mp -122.06 164.06 18.35 Favored 'General case' 0 N--CA 1.487 1.408 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 -179.239 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 54.8 t -142.58 113.22 2.75 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.848 0 N-CA-C 108.097 -1.075 . . . . 0.0 108.097 177.167 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 60.3 m-85 -102.86 163.46 12.2 Favored 'General case' 0 C--N 1.362 1.121 0 O-C-N 124.005 0.816 . . . . 0.0 109.459 178.12 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' E' E ' 20' ' ' PHE . . . . . 0.431 ' O ' ' O ' ' H' ' 21' ' ' ALA . 69.1 t80 -166.59 -84.41 0.02 OUTLIER 'General case' 0 C--O 1.215 -0.74 0 CA-C-N 115.907 -0.588 . . . . 0.0 109.726 177.335 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' E' E ' 21' ' ' ALA . . . . . 0.433 ' O ' ' O ' ' B' ' 20' ' ' PHE . . . -85.39 91.3 8.16 Favored 'General case' 0 N--CA 1.474 0.763 0 N-CA-C 108.28 -1.007 . . . . 0.0 108.28 178.498 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 11.2 mm-40 -70.89 -172.84 0.71 Allowed 'General case' 0 N--CA 1.481 1.086 0 C-N-CA 119.67 -0.812 . . . . 0.0 111.061 -179.932 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' E' E ' 23' ' ' ASP . . . . . 0.411 ' HB2' ' HZ2' ' E' ' 28' ' ' LYS . 8.5 m-20 -71.34 154.07 41.87 Favored 'General case' 0 N--CA 1.472 0.665 0 CA-C-O 121.749 0.785 . . . . 0.0 112.623 -177.405 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' E' E ' 24' ' ' VAL . . . . . 0.525 ' CG1' HH12 ' F' ' 5' ' ' ARG . 53.0 t -155.37 92.15 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.762 0 CA-C-N 114.733 -1.122 . . . . 0.0 108.072 177.274 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . -119.45 61.13 0.49 Allowed Glycine 0 N--CA 1.478 1.439 0 N-CA-C 110.87 -0.892 . . . . 0.0 110.87 178.798 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 15.8 m 45.95 -143.2 0.28 Allowed 'General case' 0 N--CA 1.485 1.294 0 CA-C-N 118.299 1.049 . . . . 0.0 110.701 -179.8 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 3.6 m-80 -79.9 92.44 5.52 Favored 'General case' 0 N--CA 1.472 0.631 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 177.474 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' E' E ' 28' ' ' LYS . . . . . 0.411 ' HZ2' ' HB2' ' E' ' 23' ' ' ASP . 96.4 mttt -65.97 146.53 54.6 Favored 'General case' 0 CA--C 1.543 0.675 0 CA-C-O 121.193 0.52 . . . . 0.0 110.635 -178.565 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -71.29 -129.27 0.08 OUTLIER Glycine 0 CA--C 1.538 1.486 0 N-CA-C 109.912 -1.275 . . . . 0.0 109.912 178.492 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -82.22 131.28 35.23 Favored 'General case' 0 N--CA 1.439 -1.005 0 CA-C-N 117.637 0.719 . . . . 0.0 109.391 178.743 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 18.4 tt -165.28 173.31 0.18 Allowed 'Isoleucine or valine' 0 C--O 1.219 -0.532 0 N-CA-C 108.587 -0.894 . . . . 0.0 108.587 -178.737 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 25.5 mt -141.31 145.6 24.62 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.438 0 N-CA-C 107.106 -1.442 . . . . 0.0 107.106 179.674 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -51.63 167.93 0.64 Allowed Glycine 0 N--CA 1.474 1.209 0 C-N-CA 121.383 -0.437 . . . . 0.0 112.662 -179.333 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 2.7 pp -65.71 157.28 30.56 Favored 'General case' 0 N--CA 1.466 0.362 0 N-CA-C 109.97 -0.381 . . . . 0.0 109.97 179.746 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 23.0 ttt -142.37 154.24 44.47 Favored 'General case' 0 N--CA 1.478 0.949 0 N-CA-C 108.996 -0.742 . . . . 0.0 108.996 -179.956 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 40.3 t -149.41 138.54 15.42 Favored 'Isoleucine or valine' 0 C--O 1.238 0.458 0 N-CA-C 107.543 -1.28 . . . . 0.0 107.543 -179.57 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 60.94 67.96 1.89 Allowed Glycine 0 C--N 1.32 -0.336 0 N-CA-C 108.724 -1.751 . . . . 0.0 108.724 -179.882 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . -82.86 131.02 10.07 Favored Glycine 0 C--N 1.334 0.467 0 N-CA-C 111.286 -0.726 . . . . 0.0 111.286 -178.434 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 1.9 t -147.49 113.52 0.92 Allowed 'Isoleucine or valine' 0 N--CA 1.5 2.045 0 N-CA-C 108.447 -0.946 . . . . 0.0 108.447 179.389 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' E' E ' 40' ' ' VAL . . . . . 0.409 ' O ' ' N ' ' D' ' 31' ' ' ILE . 19.3 t . . . . . 0 N--CA 1.495 1.8 0 CA-C-O 118.074 -0.965 . . . . 0.0 112.127 -177.664 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 27.0 m-85 . . . . . 0 N--CA 1.476 0.873 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' F' F ' 5' ' ' ARG . . . . . 0.525 HH12 ' CG1' ' E' ' 24' ' ' VAL . 6.3 ptm180 -164.45 146.94 8.81 Favored 'General case' 0 N--CA 1.473 0.701 0 C-N-CA 120.291 -0.564 . . . . 0.0 112.063 -179.894 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 20.9 p80 -152.0 106.56 3.21 Favored 'General case' 0 N--CA 1.477 0.883 0 CA-C-O 120.793 0.33 . . . . 0.0 110.605 178.039 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' F' F ' 7' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -77.98 152.43 33.12 Favored 'General case' 0 N--CA 1.474 0.748 0 CA-C-O 121.573 0.701 . . . . 0.0 110.004 179.047 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' F' F ' 8' ' ' SER . . . . . . . . . . . . . 93.5 p -156.24 173.76 16.39 Favored 'General case' 0 N--CA 1.487 1.376 0 CA-C-N 114.933 -1.031 . . . . 0.0 111.488 -178.88 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 124.59 79.49 0.39 Allowed Glycine 0 N--CA 1.481 1.66 0 N-CA-C 111.424 -0.67 . . . . 0.0 111.424 179.669 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 18.3 p90 -53.89 158.11 2.16 Favored 'General case' 0 N--CA 1.479 0.996 0 C-N-CA 122.418 0.287 . . . . 0.0 111.136 179.252 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 65.3 mt-10 -120.23 126.97 51.95 Favored 'General case' 0 N--CA 1.489 1.483 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 178.506 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 39.3 t -103.44 136.87 34.24 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.687 0 N-CA-C 109.022 -0.733 . . . . 0.0 109.022 178.188 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 35.8 m80 -138.52 138.52 38.11 Favored 'General case' 0 N--CA 1.481 1.075 0 C-N-CA 122.417 0.287 . . . . 0.0 110.591 179.757 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 13.1 t60 -167.89 97.31 0.45 Allowed 'General case' 0 N--CA 1.483 1.191 0 C-N-CA 122.249 0.219 . . . . 0.0 110.626 179.198 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 55.3 mt-30 -100.29 117.24 34.09 Favored 'General case' 0 CA--C 1.513 -0.448 0 N-CA-C 108.399 -0.963 . . . . 0.0 108.399 -179.56 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 64.7 tttp -104.76 105.7 15.88 Favored 'General case' 0 N--CA 1.481 1.121 0 N-CA-C 108.558 -0.905 . . . . 0.0 108.558 178.104 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 9.9 mp -122.06 164.05 18.36 Favored 'General case' 0 N--CA 1.488 1.436 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 -179.398 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 55.2 t -142.39 112.75 2.76 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.911 0 N-CA-C 108.008 -1.108 . . . . 0.0 108.008 177.102 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 60.7 m-85 -102.09 163.68 12.11 Favored 'General case' 0 C--N 1.359 1.007 0 O-C-N 124.028 0.83 . . . . 0.0 109.107 177.779 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' F' F ' 20' ' ' PHE . . . . . 0.409 ' O ' ' O ' ' I' ' 21' ' ' ALA . 72.8 t80 -166.54 -84.12 0.02 OUTLIER 'General case' 0 C--O 1.215 -0.73 0 N-CA-C 109.399 -0.593 . . . . 0.0 109.399 177.173 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' F' F ' 21' ' ' ALA . . . . . 0.44 ' O ' ' O ' ' C' ' 20' ' ' PHE . . . -85.83 91.7 8.41 Favored 'General case' 0 N--CA 1.478 0.931 0 N-CA-C 108.302 -0.999 . . . . 0.0 108.302 178.547 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 11.1 mm-40 -71.14 -172.79 0.75 Allowed 'General case' 0 N--CA 1.481 1.124 0 C-N-CA 119.668 -0.813 . . . . 0.0 111.25 -179.842 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' F' F ' 23' ' ' ASP . . . . . 0.408 ' HB2' ' HZ2' ' F' ' 28' ' ' LYS . 8.5 m-20 -71.46 153.98 41.85 Favored 'General case' 0 N--CA 1.473 0.722 0 CA-C-O 121.847 0.832 . . . . 0.0 112.597 -177.334 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' F' F ' 24' ' ' VAL . . . . . 0.519 ' CG1' HH12 ' D' ' 5' ' ' ARG . 54.9 t -155.25 91.97 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.473 0.702 0 CA-C-N 114.65 -1.159 . . . . 0.0 108.261 177.302 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -119.51 61.33 0.49 Allowed Glycine 0 N--CA 1.482 1.703 0 N-CA-C 110.929 -0.868 . . . . 0.0 110.929 178.792 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 15.9 m 45.91 -143.18 0.28 Allowed 'General case' 0 N--CA 1.484 1.247 0 CA-C-N 118.206 1.003 . . . . 0.0 110.688 -179.973 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 3.6 m-80 -79.86 92.5 5.5 Favored 'General case' 0 N--CA 1.472 0.637 0 N-CA-C 108.818 -0.808 . . . . 0.0 108.818 177.413 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' F' F ' 28' ' ' LYS . . . . . 0.408 ' HZ2' ' HB2' ' F' ' 23' ' ' ASP . 96.4 mttt -66.1 146.4 54.7 Favored 'General case' 0 CA--C 1.542 0.639 0 CA-C-O 121.229 0.538 . . . . 0.0 110.626 -178.582 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -71.26 -129.45 0.08 OUTLIER Glycine 0 CA--C 1.538 1.529 0 N-CA-C 109.874 -1.29 . . . . 0.0 109.874 178.578 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.97 131.31 35.25 Favored 'General case' 0 N--CA 1.436 -1.137 0 CA-C-N 117.528 0.664 . . . . 0.0 109.484 178.754 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 18.4 tt -165.22 173.65 0.17 Allowed 'Isoleucine or valine' 0 C--O 1.218 -0.553 0 N-CA-C 108.571 -0.9 . . . . 0.0 108.571 -178.756 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 25.9 mt -141.48 145.59 24.43 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.524 0 N-CA-C 107.016 -1.476 . . . . 0.0 107.016 179.665 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -51.78 167.9 0.69 Allowed Glycine 0 N--CA 1.476 1.354 0 C-N-CA 121.316 -0.469 . . . . 0.0 112.567 -179.38 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 2.6 pp -65.64 157.29 30.36 Favored 'General case' 0 N--CA 1.466 0.351 0 CA-C-O 120.834 0.35 . . . . 0.0 110.061 179.772 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 22.9 ttt -142.29 154.02 44.37 Favored 'General case' 0 N--CA 1.476 0.858 0 N-CA-C 109.111 -0.7 . . . . 0.0 109.111 -179.984 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 40.6 t -149.19 138.68 15.77 Favored 'Isoleucine or valine' 0 C--O 1.237 0.399 0 N-CA-C 107.559 -1.274 . . . . 0.0 107.559 -179.625 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 60.97 67.83 1.95 Allowed Glycine 0 C--N 1.321 -0.251 0 N-CA-C 108.721 -1.751 . . . . 0.0 108.721 -179.974 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -82.69 130.86 9.96 Favored Glycine 0 C--N 1.334 0.462 0 N-CA-C 111.335 -0.706 . . . . 0.0 111.335 -178.38 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 1.9 t -147.3 113.57 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.5 2.052 0 N-CA-C 108.494 -0.928 . . . . 0.0 108.494 179.324 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 19.4 t . . . . . 0 N--CA 1.492 1.653 0 CA-C-O 118.215 -0.898 . . . . 0.0 112.5 -177.474 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 31.9 m-85 . . . . . 0 N--CA 1.48 1.046 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' G' G ' 5' ' ' ARG . . . . . 0.527 HH12 ' CG1' ' I' ' 24' ' ' VAL . 6.1 ptm180 -165.07 148.81 8.58 Favored 'General case' 0 N--CA 1.47 0.555 0 C-N-CA 120.446 -0.502 . . . . 0.0 111.933 -179.907 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' G' G ' 6' ' ' HIS . . . . . 0.404 ' O ' ' ND1' ' G' ' 6' ' ' HIS . 21.8 p80 -153.81 106.71 2.89 Favored 'General case' 0 N--CA 1.474 0.767 0 CA-C-O 121.06 0.457 . . . . 0.0 110.719 178.224 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -77.39 152.11 34.52 Favored 'General case' 0 N--CA 1.474 0.727 0 CA-C-O 121.084 0.468 . . . . 0.0 110.276 179.008 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' G' G ' 8' ' ' SER . . . . . . . . . . . . . 99.2 p -155.7 174.5 15.2 Favored 'General case' 0 N--CA 1.474 0.75 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.846 179.996 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 124.61 78.87 0.37 Allowed Glycine 0 N--CA 1.478 1.466 0 N-CA-C 111.202 -0.759 . . . . 0.0 111.202 179.582 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 24.0 p90 -54.23 157.47 2.67 Favored 'General case' 0 N--CA 1.476 0.827 0 O-C-N 122.802 -0.234 . . . . 0.0 111.107 179.358 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 64.6 mt-10 -120.15 126.93 51.92 Favored 'General case' 0 N--CA 1.487 1.376 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 179.257 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 29.9 t -103.79 136.12 38.28 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.021 0 N-CA-C 109.158 -0.682 . . . . 0.0 109.158 178.658 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 38.6 m80 -137.92 138.4 38.96 Favored 'General case' 0 N--CA 1.481 1.092 0 C-N-CA 122.827 0.451 . . . . 0.0 110.634 179.926 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 13.1 t60 -168.26 97.4 0.42 Allowed 'General case' 0 N--CA 1.481 1.125 0 N-CA-C 110.355 -0.239 . . . . 0.0 110.355 178.727 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 55.3 mt-30 -100.4 117.53 34.77 Favored 'General case' 0 CA--C 1.512 -0.5 0 N-CA-C 108.476 -0.935 . . . . 0.0 108.476 -179.652 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 64.6 tttp -104.97 105.67 15.82 Favored 'General case' 0 N--CA 1.482 1.142 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 178.323 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 9.8 mp -121.71 161.97 21.62 Favored 'General case' 0 N--CA 1.486 1.345 0 C-N-CA 123.478 0.711 . . . . 0.0 109.413 -179.204 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 43.6 t -142.59 112.78 2.59 Favored 'Isoleucine or valine' 0 C--O 1.246 0.891 0 N-CA-C 108.269 -1.012 . . . . 0.0 108.269 176.734 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 61.4 m-85 -101.73 161.01 13.97 Favored 'General case' 0 C--N 1.371 1.539 0 O-C-N 125.566 1.791 . . . . 0.0 109.959 177.307 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 68.7 t80 -167.95 -82.5 0.02 OUTLIER 'General case' 0 CA--C 1.539 0.527 0 CA-C-N 115.7 -0.682 . . . . 0.0 109.36 177.389 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' G' G ' 21' ' ' ALA . . . . . 0.403 ' O ' ' O ' ' D' ' 20' ' ' PHE . . . -84.96 90.69 7.88 Favored 'General case' 0 N--CA 1.474 0.754 0 N-CA-C 108.302 -0.999 . . . . 0.0 108.302 179.184 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 11.6 mm-40 -70.36 -175.09 0.94 Allowed 'General case' 0 N--CA 1.483 1.177 0 C-N-CA 119.691 -0.803 . . . . 0.0 111.167 -179.935 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' G' G ' 23' ' ' ASP . . . . . 0.403 ' CB ' ' HZ2' ' G' ' 28' ' ' LYS . 8.9 m-20 -70.97 154.47 41.79 Favored 'General case' 0 N--CA 1.475 0.82 0 CA-C-O 121.3 0.571 . . . . 0.0 112.169 -177.218 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' G' G ' 24' ' ' VAL . . . . . 0.507 ' CG1' HH12 ' H' ' 5' ' ' ARG . 65.2 t -156.63 92.8 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.471 0.597 0 CA-C-N 114.951 -1.022 . . . . 0.0 108.323 177.085 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -119.34 61.38 0.48 Allowed Glycine 0 N--CA 1.477 1.43 0 N-CA-C 110.93 -0.868 . . . . 0.0 110.93 179.107 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 17.2 m 47.0 -139.02 0.62 Allowed 'General case' 0 N--CA 1.484 1.233 0 CA-C-N 118.23 1.015 . . . . 0.0 110.815 179.691 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 3.7 m-80 -84.31 91.72 7.83 Favored 'General case' 0 N--CA 1.473 0.697 0 N-CA-C 108.087 -1.079 . . . . 0.0 108.087 177.511 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' G' G ' 28' ' ' LYS . . . . . 0.403 ' HZ2' ' CB ' ' G' ' 23' ' ' ASP . 96.5 mttt -65.3 146.61 54.7 Favored 'General case' 0 CA--C 1.539 0.539 0 CA-C-O 121.249 0.547 . . . . 0.0 110.576 -178.176 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -72.22 -127.84 0.09 OUTLIER Glycine 0 CA--C 1.526 0.779 0 N-CA-C 109.417 -1.473 . . . . 0.0 109.417 178.541 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.95 128.4 34.03 Favored 'General case' 0 CA--C 1.528 0.104 0 C-N-CA 122.66 0.384 . . . . 0.0 110.179 179.718 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 18.8 tt -164.41 172.88 0.21 Allowed 'Isoleucine or valine' 0 CA--C 1.506 -0.736 0 N-CA-C 109.53 -0.544 . . . . 0.0 109.53 -178.836 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 32.1 mt -139.42 146.9 24.87 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.092 0 N-CA-C 107.117 -1.438 . . . . 0.0 107.117 177.975 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -52.05 167.72 0.79 Allowed Glycine 0 N--CA 1.474 1.188 0 C-N-CA 121.489 -0.386 . . . . 0.0 112.187 -179.463 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 2.6 pp -65.87 157.61 30.1 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-O 120.793 0.33 . . . . 0.0 110.208 -179.935 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 22.8 ttt -142.74 154.54 44.37 Favored 'General case' 0 N--CA 1.472 0.669 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 -179.934 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 39.0 t -149.28 139.13 16.1 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.258 0 N-CA-C 107.712 -1.218 . . . . 0.0 107.712 -179.709 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 60.32 68.26 1.76 Allowed Glycine 0 C--N 1.319 -0.375 0 N-CA-C 108.956 -1.658 . . . . 0.0 108.956 179.963 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . -83.27 131.0 10.06 Favored Glycine 0 N--CA 1.465 0.599 0 N-CA-C 111.335 -0.706 . . . . 0.0 111.335 -178.703 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 2.1 t -146.97 113.2 0.96 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.91 0 N-CA-C 108.515 -0.92 . . . . 0.0 108.515 179.604 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 21.4 t . . . . . 0 N--CA 1.492 1.648 0 CA-C-O 118.205 -0.902 . . . . 0.0 111.958 -178.304 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 32.4 m-85 . . . . . 0 N--CA 1.48 1.068 0 N-CA-C 108.486 -0.931 . . . . 0.0 108.486 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' H' H ' 5' ' ' ARG . . . . . 0.508 HH21 ' NH1' ' E' ' 5' ' ' ARG . 6.1 ptm180 -165.33 148.78 8.23 Favored 'General case' 0 N--CA 1.47 0.558 0 C-N-CA 120.533 -0.467 . . . . 0.0 112.031 -179.968 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' H' H ' 6' ' ' HIS . . . . . 0.403 ' O ' ' ND1' ' H' ' 6' ' ' HIS . 21.7 p80 -153.89 106.76 2.88 Favored 'General case' 0 N--CA 1.475 0.79 0 CA-C-O 120.993 0.425 . . . . 0.0 110.645 178.204 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -77.58 151.75 34.28 Favored 'General case' 0 N--CA 1.474 0.745 0 CA-C-O 121.039 0.447 . . . . 0.0 110.261 179.016 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' H' H ' 8' ' ' SER . . . . . . . . . . . . . 99.3 p -155.22 174.89 14.57 Favored 'General case' 0 N--CA 1.475 0.808 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.839 179.99 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 124.15 78.89 0.39 Allowed Glycine 0 N--CA 1.478 1.472 0 N-CA-C 111.305 -0.718 . . . . 0.0 111.305 179.714 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 24.2 p90 -54.36 157.73 2.65 Favored 'General case' 0 N--CA 1.475 0.789 0 O-C-N 122.747 -0.267 . . . . 0.0 111.137 179.29 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 64.8 mt-10 -120.31 126.93 51.77 Favored 'General case' 0 N--CA 1.485 1.3 0 C-N-CA 122.694 0.397 . . . . 0.0 109.931 179.347 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 28.1 t -103.97 135.94 39.36 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.998 0 N-CA-C 109.153 -0.684 . . . . 0.0 109.153 178.683 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 38.6 m80 -137.76 138.65 39.47 Favored 'General case' 0 N--CA 1.481 1.107 0 C-N-CA 122.981 0.512 . . . . 0.0 110.584 -179.949 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 13.2 t60 -168.56 97.48 0.4 Allowed 'General case' 0 N--CA 1.482 1.127 0 N-CA-C 110.31 -0.256 . . . . 0.0 110.31 178.66 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 55.5 mt-30 -100.56 116.97 33.73 Favored 'General case' 0 CA--C 1.512 -0.49 0 N-CA-C 108.72 -0.845 . . . . 0.0 108.72 -179.619 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 64.5 tttp -104.35 105.72 15.96 Favored 'General case' 0 N--CA 1.482 1.136 0 N-CA-C 108.62 -0.882 . . . . 0.0 108.62 178.282 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 9.8 mp -121.91 162.29 21.29 Favored 'General case' 0 N--CA 1.487 1.386 0 C-N-CA 123.494 0.718 . . . . 0.0 109.224 -179.262 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 45.8 t -142.35 111.96 2.55 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.601 0 N-CA-C 108.372 -0.974 . . . . 0.0 108.372 176.921 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 61.1 m-85 -100.6 161.37 13.65 Favored 'General case' 0 C--N 1.364 1.228 0 O-C-N 124.724 1.265 . . . . 0.0 109.944 177.404 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 67.2 t80 -167.26 -83.15 0.02 OUTLIER 'General case' 0 N--CA 1.469 0.48 0 CA-C-N 115.696 -0.684 . . . . 0.0 109.572 177.214 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' H' H ' 21' ' ' ALA . . . . . 0.431 ' O ' ' O ' ' E' ' 20' ' ' PHE . . . -84.91 90.33 7.78 Favored 'General case' 0 N--CA 1.473 0.715 0 N-CA-C 108.406 -0.961 . . . . 0.0 108.406 179.22 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 11.7 mm-40 -69.76 -175.02 0.81 Allowed 'General case' 0 N--CA 1.483 1.176 0 C-N-CA 119.694 -0.803 . . . . 0.0 111.171 -179.872 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' H' H ' 23' ' ' ASP . . . . . 0.403 ' HB2' ' HZ2' ' H' ' 28' ' ' LYS . 8.8 m-20 -71.2 154.36 41.74 Favored 'General case' 0 N--CA 1.473 0.691 0 CA-C-O 121.333 0.587 . . . . 0.0 112.245 -177.093 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' H' H ' 24' ' ' VAL . . . . . 0.513 ' CG1' HH12 ' I' ' 5' ' ' ARG . 65.7 t -156.36 92.8 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.471 0.619 0 CA-C-N 114.943 -1.026 . . . . 0.0 108.407 177.095 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . -119.45 61.46 0.49 Allowed Glycine 0 N--CA 1.48 1.615 0 N-CA-C 110.961 -0.856 . . . . 0.0 110.961 179.226 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 17.2 m 46.82 -138.83 0.61 Allowed 'General case' 0 N--CA 1.485 1.296 0 CA-C-N 118.082 0.941 . . . . 0.0 110.832 -179.979 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 3.4 m-80 -84.26 91.9 7.85 Favored 'General case' 0 N--CA 1.473 0.691 0 N-CA-C 108.027 -1.101 . . . . 0.0 108.027 177.417 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' H' H ' 28' ' ' LYS . . . . . 0.403 ' HZ2' ' HB2' ' H' ' 23' ' ' ASP . 96.4 mttt -65.47 146.75 54.48 Favored 'General case' 0 CA--C 1.539 0.549 0 CA-C-O 121.373 0.606 . . . . 0.0 110.487 -178.212 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -72.16 -127.87 0.09 OUTLIER Glycine 0 CA--C 1.528 0.856 0 N-CA-C 109.554 -1.419 . . . . 0.0 109.554 178.542 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.91 128.8 34.43 Favored 'General case' 0 C--O 1.231 0.086 0 N-CA-C 110.05 -0.352 . . . . 0.0 110.05 179.591 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 18.9 tt -164.73 172.57 0.21 Allowed 'Isoleucine or valine' 0 CA--C 1.505 -0.778 0 N-CA-C 109.578 -0.527 . . . . 0.0 109.578 -178.719 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 31.9 mt -139.34 147.01 24.78 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.038 0 N-CA-C 107.132 -1.433 . . . . 0.0 107.132 177.974 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -52.25 167.59 0.87 Allowed Glycine 0 N--CA 1.472 1.088 0 C-N-CA 121.505 -0.378 . . . . 0.0 112.267 -179.454 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 2.6 pp -65.5 157.84 28.52 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-O 120.937 0.399 . . . . 0.0 110.123 -179.95 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 22.8 ttt -142.97 154.48 44.08 Favored 'General case' 0 N--CA 1.473 0.712 0 N-CA-C 109.225 -0.657 . . . . 0.0 109.225 -179.859 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 39.2 t -149.54 139.11 15.82 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.216 0 N-CA-C 107.566 -1.272 . . . . 0.0 107.566 -179.578 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 60.19 67.88 1.94 Allowed Glycine 0 C--N 1.32 -0.335 0 N-CA-C 109.093 -1.603 . . . . 0.0 109.093 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . -83.02 131.17 10.17 Favored Glycine 0 N--CA 1.464 0.544 0 N-CA-C 111.45 -0.66 . . . . 0.0 111.45 -178.765 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 2.1 t -147.04 113.36 0.96 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.927 0 N-CA-C 108.324 -0.991 . . . . 0.0 108.324 179.539 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 21.7 t . . . . . 0 N--CA 1.491 1.589 0 CA-C-O 118.298 -0.858 . . . . 0.0 111.574 -178.358 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 32.8 m-85 . . . . . 0 N--CA 1.48 1.041 0 N-CA-C 108.46 -0.941 . . . . 0.0 108.46 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' I' I ' 5' ' ' ARG . . . . . 0.513 HH21 ' NH1' ' F' ' 5' ' ' ARG . 6.1 ptm180 -165.24 148.48 8.23 Favored 'General case' 0 N--CA 1.47 0.545 0 C-N-CA 120.567 -0.453 . . . . 0.0 112.017 -179.881 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' I' I ' 6' ' ' HIS . . . . . 0.401 ' ND1' ' O ' ' I' ' 6' ' ' HIS . 21.6 p80 -153.66 106.83 2.94 Favored 'General case' 0 N--CA 1.475 0.793 0 CA-C-O 121.008 0.432 . . . . 0.0 110.61 178.198 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -77.59 151.83 34.23 Favored 'General case' 0 N--CA 1.474 0.775 0 CA-C-O 121.072 0.463 . . . . 0.0 110.249 178.958 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' I' I ' 8' ' ' SER . . . . . . . . . . . . . 98.2 p -155.23 174.88 14.58 Favored 'General case' 0 N--CA 1.476 0.849 0 CA-C-N 115.945 -0.57 . . . . 0.0 110.854 179.915 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 124.23 78.92 0.39 Allowed Glycine 0 N--CA 1.479 1.56 0 N-CA-C 111.256 -0.738 . . . . 0.0 111.256 179.663 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 24.0 p90 -54.58 157.63 2.86 Favored 'General case' 0 N--CA 1.477 0.891 0 O-C-N 122.803 -0.234 . . . . 0.0 111.045 179.308 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 64.5 mt-10 -120.23 126.92 51.81 Favored 'General case' 0 N--CA 1.484 1.266 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 179.391 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 27.2 t -103.9 135.86 39.66 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.937 0 N-CA-C 109.16 -0.681 . . . . 0.0 109.16 178.679 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 38.5 m80 -137.76 138.53 39.37 Favored 'General case' 0 N--CA 1.482 1.15 0 C-N-CA 122.966 0.506 . . . . 0.0 110.579 -179.943 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 13.2 t60 -168.47 97.27 0.4 Allowed 'General case' 0 N--CA 1.482 1.136 0 N-CA-C 110.278 -0.267 . . . . 0.0 110.278 178.736 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 55.8 mt-30 -100.38 116.93 33.5 Favored 'General case' 0 C--N 1.326 -0.436 0 N-CA-C 108.611 -0.885 . . . . 0.0 108.611 -179.585 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 64.6 tttp -104.35 105.7 15.92 Favored 'General case' 0 N--CA 1.482 1.143 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 178.236 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 9.8 mp -121.88 162.35 21.14 Favored 'General case' 0 N--CA 1.487 1.416 0 C-N-CA 123.475 0.71 . . . . 0.0 109.21 -179.244 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 45.7 t -142.35 111.99 2.57 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.579 0 N-CA-C 108.32 -0.993 . . . . 0.0 108.32 176.937 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 60.8 m-85 -100.75 161.41 13.62 Favored 'General case' 0 C--N 1.364 1.208 0 O-C-N 124.79 1.306 . . . . 0.0 109.949 177.434 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 66.9 t80 -167.28 -83.39 0.02 OUTLIER 'General case' 0 N--CA 1.468 0.446 0 CA-C-N 115.629 -0.714 . . . . 0.0 109.649 177.267 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' I' I ' 21' ' ' ALA . . . . . 0.409 ' O ' ' O ' ' F' ' 20' ' ' PHE . . . -84.7 90.62 7.75 Favored 'General case' 0 N--CA 1.471 0.62 0 N-CA-C 108.274 -1.01 . . . . 0.0 108.274 179.243 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 11.7 mm-40 -70.16 -175.01 0.88 Allowed 'General case' 0 N--CA 1.482 1.17 0 C-N-CA 119.725 -0.79 . . . . 0.0 111.114 -179.836 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' I' I ' 23' ' ' ASP . . . . . 0.402 ' CB ' ' HZ2' ' I' ' 28' ' ' LYS . 8.8 m-20 -71.21 154.17 41.89 Favored 'General case' 0 N--CA 1.473 0.701 0 CA-C-O 121.296 0.57 . . . . 0.0 112.292 -177.067 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' I' I ' 24' ' ' VAL . . . . . 0.527 ' CG1' HH12 ' G' ' 5' ' ' ARG . 65.6 t -156.22 92.75 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.47 0.528 0 CA-C-N 115.023 -0.99 . . . . 0.0 108.396 177.08 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . -119.17 61.36 0.48 Allowed Glycine 0 N--CA 1.48 1.628 0 N-CA-C 110.981 -0.848 . . . . 0.0 110.981 179.148 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 17.4 m 46.81 -138.84 0.61 Allowed 'General case' 0 N--CA 1.486 1.36 0 CA-C-N 118.214 1.007 . . . . 0.0 110.707 179.948 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 3.3 m-80 -84.29 91.97 7.88 Favored 'General case' 0 N--CA 1.472 0.665 0 N-CA-C 108.089 -1.078 . . . . 0.0 108.089 177.413 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' I' I ' 28' ' ' LYS . . . . . 0.402 ' HZ2' ' CB ' ' I' ' 23' ' ' ASP . 96.4 mttt -65.52 146.58 54.68 Favored 'General case' 0 CA--C 1.539 0.555 0 CA-C-O 121.378 0.608 . . . . 0.0 110.512 -178.195 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -71.92 -128.13 0.09 OUTLIER Glycine 0 CA--C 1.527 0.835 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 178.49 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.87 128.47 34.07 Favored 'General case' 0 CA--C 1.529 0.155 0 C-N-CA 122.709 0.404 . . . . 0.0 109.939 179.698 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 18.8 tt -164.38 172.64 0.22 Allowed 'Isoleucine or valine' 0 CA--C 1.506 -0.716 0 N-CA-C 109.553 -0.536 . . . . 0.0 109.553 -178.695 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 31.7 mt -139.31 146.99 24.85 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.101 0 N-CA-C 107.214 -1.402 . . . . 0.0 107.214 177.896 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -52.25 167.62 0.87 Allowed Glycine 0 N--CA 1.473 1.163 0 C-N-CA 121.528 -0.367 . . . . 0.0 112.234 -179.444 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 2.6 pp -65.59 157.59 29.41 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-O 120.892 0.377 . . . . 0.0 110.086 -179.956 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 22.9 ttt -142.73 154.17 44.03 Favored 'General case' 0 N--CA 1.472 0.655 0 N-CA-C 109.172 -0.677 . . . . 0.0 109.172 -179.827 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 39.6 t -149.26 139.27 16.23 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.252 0 N-CA-C 107.551 -1.277 . . . . 0.0 107.551 -179.719 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 60.09 67.93 1.92 Allowed Glycine 0 N--CA 1.461 0.344 0 N-CA-C 109.135 -1.586 . . . . 0.0 109.135 -179.921 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . -82.99 131.22 10.21 Favored Glycine 0 N--CA 1.464 0.564 0 N-CA-C 111.359 -0.697 . . . . 0.0 111.359 -178.702 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 2.1 t -147.16 113.39 0.95 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.908 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 179.527 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 21.6 t . . . . . 0 N--CA 1.489 1.521 0 CA-C-O 118.192 -0.909 . . . . 0.0 111.766 -178.315 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 29.8 m-85 . . . . . 0 N--CA 1.472 0.659 0 N-CA-C 109.426 -0.583 . . . . 0.0 109.426 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 77.1 mtt85 -139.85 145.58 38.26 Favored 'General case' 0 N--CA 1.478 0.925 0 CA-C-N 115.886 -0.597 . . . . 0.0 109.885 179.776 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 57.6 t-80 -150.51 116.96 5.73 Favored 'General case' 0 N--CA 1.476 0.863 0 N-CA-C 109.631 -0.507 . . . . 0.0 109.631 179.164 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 9.9 m-20 -66.94 144.6 56.13 Favored 'General case' 0 N--CA 1.474 0.75 0 C-N-CA 122.897 0.479 . . . . 0.0 111.83 -179.809 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 1.7 t -164.3 -176.89 4.64 Favored 'General case' 0 N--CA 1.471 0.597 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 177.986 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 85.54 70.46 1.33 Allowed Glycine 0 CA--C 1.53 1.029 0 CA-C-N 115.837 -0.62 . . . . 0.0 112.087 178.725 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 40.3 p90 -73.01 122.16 21.28 Favored 'General case' 0 N--CA 1.477 0.888 0 CA-C-N 117.255 0.527 . . . . 0.0 110.892 179.976 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 17.7 pt-20 -82.76 151.82 25.99 Favored 'General case' 0 N--CA 1.477 0.903 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 178.853 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 13.7 t -144.68 117.72 2.73 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.877 0 CA-C-O 121.578 0.704 . . . . 0.0 109.365 178.302 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 73.5 m80 -95.79 164.87 12.57 Favored 'General case' 0 C--N 1.358 0.941 0 CA-C-N 114.641 -1.163 . . . . 0.0 109.29 177.996 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . 0.46 ' HE2' ' NZ ' ' A' ' 16' ' ' LYS . 17.2 t60 -164.74 99.27 0.78 Allowed 'General case' 0 N--CA 1.476 0.855 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.12 179.223 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -91.66 111.58 23.15 Favored 'General case' 0 CA--C 1.517 -0.326 0 N-CA-C 108.386 -0.968 . . . . 0.0 108.386 179.668 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . 0.46 ' NZ ' ' HE2' ' A' ' 14' ' ' HIS . 8.5 ttmm -94.37 171.38 8.85 Favored 'General case' 0 N--CA 1.483 1.206 0 N-CA-C 108.893 -0.781 . . . . 0.0 108.893 179.926 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 9.6 mp -55.09 157.9 3.16 Favored 'General case' 0 N--CA 1.476 0.837 0 N-CA-C 110.002 -0.37 . . . . 0.0 110.002 -178.408 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 71.2 t -140.81 150.22 20.69 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.714 0 C-N-CA 123.206 0.602 . . . . 0.0 109.76 -177.798 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.671 ' HB3' ' O ' ' D' ' 18' ' ' VAL . 43.9 p90 -40.44 162.34 0.01 OUTLIER 'General case' 0 CA--C 1.542 0.666 0 N-CA-C 120.228 3.418 . . . . 0.0 120.228 -178.729 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.409 ' O ' ' CD2' ' A' ' 20' ' ' PHE . 20.9 p90 -119.75 69.82 0.85 Allowed 'General case' 0 CA--C 1.56 1.352 0 CA-C-N 112.033 -2.349 . . . . 0.0 109.449 173.552 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -62.97 95.04 0.07 Allowed 'General case' 0 C--N 1.325 -0.493 0 N-CA-C 108.38 -0.97 . . . . 0.0 108.38 176.767 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 77.5 mt-10 -49.61 123.73 8.3 Favored 'General case' 0 N--CA 1.475 0.813 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.517 -179.954 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 16.6 t70 -76.73 169.37 18.43 Favored 'General case' 0 N--CA 1.471 0.624 0 CA-C-O 120.983 0.42 . . . . 0.0 110.648 -178.901 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . 0.505 HG13 ' H ' ' A' ' 25' ' ' GLY . 0.7 OUTLIER 178.28 -79.05 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.542 0.636 0 N-CA-C 107.298 -1.371 . . . . 0.0 107.298 -179.865 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.505 ' H ' HG13 ' A' ' 24' ' ' VAL . . . -34.03 84.4 0.0 OUTLIER Glycine 0 N--CA 1.473 1.166 0 C-N-CA 124.425 1.012 . . . . 0.0 113.461 178.546 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' SER . . . . . 0.438 ' N ' ' O ' ' A' ' 24' ' ' VAL . 87.9 p -41.25 -105.55 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.65 0 N-CA-C 113.676 0.991 . . . . 0.0 113.676 -177.401 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 16.8 p-10 -59.97 112.47 1.88 Allowed 'General case' 0 N--CA 1.469 0.488 0 CA-C-N 118.833 0.742 . . . . 0.0 110.417 -178.637 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 41.8 mttm -96.83 164.57 12.5 Favored 'General case' 0 N--CA 1.475 0.801 0 C-N-CA 123.31 0.644 . . . . 0.0 110.008 -179.564 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -72.95 -141.45 0.45 Allowed Glycine 0 N--CA 1.461 0.342 0 N-CA-C 107.876 -2.089 . . . . 0.0 107.876 176.548 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . 0.458 ' O ' ' O ' ' D' ' 31' ' ' ILE . . . -90.42 123.12 33.88 Favored 'General case' 0 C--O 1.208 -1.084 0 N-CA-C 106.836 -1.542 . . . . 0.0 106.836 176.524 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 16.7 tt -148.28 155.6 9.41 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.884 0 N-CA-C 107.996 -1.113 . . . . 0.0 107.996 179.192 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 20.5 pt -150.88 138.89 14.24 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 CA-C-N 119.042 0.837 . . . . 0.0 109.394 178.56 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -56.68 154.3 17.7 Favored Glycine 0 CA--C 1.533 1.167 0 CA-C-N 116.605 -0.27 . . . . 0.0 112.591 -178.537 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 2.5 pp -76.29 158.92 31.06 Favored 'General case' 0 N--CA 1.472 0.673 0 N-CA-C 109.68 -0.489 . . . . 0.0 109.68 179.242 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 11.9 ttp -102.84 151.59 22.25 Favored 'General case' 0 N--CA 1.481 1.08 0 N-CA-C 109.383 -0.599 . . . . 0.0 109.383 179.711 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 7.3 p -168.62 159.82 0.71 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.553 0 N-CA-C 108.044 -1.095 . . . . 0.0 108.044 179.772 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.41 69.86 1.14 Allowed Glycine 0 C--N 1.31 -0.862 0 N-CA-C 111.665 -0.574 . . . . 0.0 111.665 178.836 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 152.04 -177.49 29.84 Favored Glycine 0 N--CA 1.468 0.828 0 N-CA-C 110.214 -1.154 . . . . 0.0 110.214 179.659 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 4.6 t -124.99 139.14 51.99 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.758 0 N-CA-C 107.206 -1.405 . . . . 0.0 107.206 -179.502 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 72.7 t . . . . . 0 N--CA 1.481 1.081 0 CA-C-O 117.776 -1.107 . . . . 0.0 109.64 -177.501 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 30.1 m-85 . . . . . 0 N--CA 1.473 0.72 0 N-CA-C 109.531 -0.544 . . . . 0.0 109.531 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 77.1 mtt85 -140.05 145.61 37.93 Favored 'General case' 0 N--CA 1.477 0.92 0 CA-C-N 115.941 -0.572 . . . . 0.0 109.991 179.724 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 58.1 t-80 -150.43 117.29 5.87 Favored 'General case' 0 N--CA 1.475 0.814 0 N-CA-C 109.644 -0.502 . . . . 0.0 109.644 179.153 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 7' ' ' ASP . . . . . . . . . . . . . 9.8 m-20 -67.16 144.38 56.06 Favored 'General case' 0 N--CA 1.472 0.671 0 C-N-CA 122.863 0.465 . . . . 0.0 111.682 -179.713 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 8' ' ' SER . . . . . . . . . . . . . 2.2 t -163.96 -177.63 5.18 Favored 'General case' 0 N--CA 1.471 0.578 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 178.148 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 85.88 70.5 1.32 Allowed Glycine 0 CA--C 1.532 1.154 0 CA-C-N 115.916 -0.584 . . . . 0.0 112.158 178.775 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 40.1 p90 -72.81 121.99 20.83 Favored 'General case' 0 N--CA 1.478 0.931 0 CA-C-N 117.295 0.548 . . . . 0.0 110.87 179.833 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 17.7 pt-20 -82.67 151.92 26.06 Favored 'General case' 0 N--CA 1.479 0.986 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 178.828 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 13.1 t -144.75 117.81 2.71 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.842 0 CA-C-O 121.598 0.713 . . . . 0.0 109.318 178.362 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 73.5 m80 -96.02 164.66 12.61 Favored 'General case' 0 C--N 1.357 0.932 0 CA-C-N 114.616 -1.175 . . . . 0.0 109.333 177.919 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 14' ' ' HIS . . . . . 0.448 ' NE2' ' NZ ' ' B' ' 16' ' ' LYS . 17.2 t60 -164.59 99.25 0.8 Allowed 'General case' 0 N--CA 1.476 0.839 0 CA-C-N 116.471 -0.331 . . . . 0.0 110.113 179.224 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -91.44 111.54 23.08 Favored 'General case' 0 CA--C 1.515 -0.381 0 N-CA-C 108.441 -0.948 . . . . 0.0 108.441 179.585 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 16' ' ' LYS . . . . . 0.448 ' NZ ' ' NE2' ' B' ' 14' ' ' HIS . 8.5 ttmm -94.33 171.49 8.79 Favored 'General case' 0 N--CA 1.483 1.197 0 N-CA-C 108.899 -0.778 . . . . 0.0 108.899 179.995 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 9.7 mp -55.25 157.83 3.38 Favored 'General case' 0 N--CA 1.476 0.836 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 -178.41 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 71.3 t -140.87 150.46 20.49 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.763 0 C-N-CA 123.113 0.565 . . . . 0.0 109.652 -177.767 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 19' ' ' PHE . . . . . 0.691 ' HB3' ' O ' ' E' ' 18' ' ' VAL . 44.4 p90 -40.58 162.07 0.01 OUTLIER 'General case' 0 CA--C 1.543 0.7 0 N-CA-C 120.055 3.354 . . . . 0.0 120.055 -178.738 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . 0.418 ' CD2' ' O ' ' B' ' 20' ' ' PHE . 21.1 p90 -119.61 69.68 0.84 Allowed 'General case' 0 CA--C 1.561 1.371 0 CA-C-N 111.946 -2.388 . . . . 0.0 109.257 173.545 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -62.75 95.11 0.07 Allowed 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 108.409 -0.959 . . . . 0.0 108.409 176.759 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 77.2 mt-10 -49.62 123.73 8.3 Favored 'General case' 0 N--CA 1.476 0.849 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.421 -179.892 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 16.7 t70 -76.74 169.27 18.61 Favored 'General case' 0 N--CA 1.471 0.609 0 CA-C-O 121.007 0.432 . . . . 0.0 110.702 -179.044 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 24' ' ' VAL . . . . . 0.5 HG13 ' H ' ' B' ' 25' ' ' GLY . 0.7 OUTLIER 178.2 -79.11 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.545 0.755 0 N-CA-C 107.333 -1.358 . . . . 0.0 107.333 -179.608 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' B' B ' 25' ' ' GLY . . . . . 0.5 ' H ' HG13 ' B' ' 24' ' ' VAL . . . -34.1 84.12 0.0 OUTLIER Glycine 0 N--CA 1.48 1.633 0 C-N-CA 124.334 0.969 . . . . 0.0 113.258 178.7 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 26' ' ' SER . . . . . 0.453 ' N ' ' O ' ' B' ' 24' ' ' VAL . 88.0 p -41.02 -105.38 0.0 OUTLIER 'General case' 0 N--CA 1.475 0.817 0 N-CA-C 113.602 0.964 . . . . 0.0 113.602 -177.411 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 16.6 p-10 -60.02 112.27 1.81 Allowed 'General case' 0 N--CA 1.471 0.578 0 CA-C-N 118.83 0.741 . . . . 0.0 110.357 -178.631 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 41.6 mttm -96.53 164.43 12.62 Favored 'General case' 0 N--CA 1.474 0.773 0 C-N-CA 123.203 0.601 . . . . 0.0 110.195 -179.628 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -72.82 -141.03 0.42 Allowed Glycine 0 N--CA 1.461 0.365 0 N-CA-C 107.816 -2.114 . . . . 0.0 107.816 176.574 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 30' ' ' ALA . . . . . 0.491 ' O ' ' O ' ' E' ' 31' ' ' ILE . . . -91.05 123.4 34.48 Favored 'General case' 0 C--O 1.208 -1.128 0 N-CA-C 106.734 -1.58 . . . . 0.0 106.734 176.587 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 16.6 tt -148.35 155.6 9.33 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.829 0 N-CA-C 107.91 -1.144 . . . . 0.0 107.91 179.194 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 20.5 pt -150.79 138.92 14.37 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.469 0 CA-C-N 118.949 0.795 . . . . 0.0 109.246 178.664 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -56.81 154.29 18.32 Favored Glycine 0 CA--C 1.532 1.148 0 CA-C-N 116.598 -0.274 . . . . 0.0 112.63 -178.691 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 2.5 pp -76.18 158.81 31.3 Favored 'General case' 0 N--CA 1.472 0.635 0 C-N-CA 122.707 0.403 . . . . 0.0 109.971 179.161 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 11.8 ttp -102.73 151.21 22.66 Favored 'General case' 0 N--CA 1.481 1.078 0 N-CA-C 109.507 -0.553 . . . . 0.0 109.507 179.717 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 7.3 p -168.37 159.89 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.524 0 N-CA-C 108.035 -1.098 . . . . 0.0 108.035 179.826 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.42 69.6 1.22 Allowed Glycine 0 C--N 1.313 -0.746 0 N-CA-C 111.617 -0.593 . . . . 0.0 111.617 178.774 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 152.14 -177.75 29.77 Favored Glycine 0 N--CA 1.468 0.795 0 N-CA-C 110.217 -1.153 . . . . 0.0 110.217 179.696 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 4.4 t -124.69 139.05 52.05 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.717 0 N-CA-C 107.31 -1.367 . . . . 0.0 107.31 -179.515 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 74.2 t . . . . . 0 N--CA 1.481 1.115 0 CA-C-O 117.756 -1.116 . . . . 0.0 109.647 -177.522 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 29.9 m-85 . . . . . 0 N--CA 1.473 0.698 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 77.4 mtt85 -140.08 145.46 37.68 Favored 'General case' 0 N--CA 1.478 0.965 0 C-N-CA 122.999 0.52 . . . . 0.0 109.797 179.766 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 57.9 t-80 -150.37 116.94 5.78 Favored 'General case' 0 N--CA 1.476 0.864 0 N-CA-C 109.655 -0.498 . . . . 0.0 109.655 179.087 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' C' C ' 7' ' ' ASP . . . . . . . . . . . . . 9.9 m-20 -66.89 144.39 56.28 Favored 'General case' 0 N--CA 1.472 0.643 0 O-C-N 123.444 0.465 . . . . 0.0 111.777 -179.728 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' C' C ' 8' ' ' SER . . . . . . . . . . . . . 2.3 t -163.92 -177.68 5.22 Favored 'General case' 0 N--CA 1.471 0.589 0 N-CA-C 109.873 -0.417 . . . . 0.0 109.873 178.247 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 85.97 70.47 1.32 Allowed Glycine 0 CA--C 1.532 1.125 0 CA-C-N 115.904 -0.589 . . . . 0.0 112.165 178.736 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 40.4 p90 -72.92 122.17 21.22 Favored 'General case' 0 N--CA 1.477 0.882 0 CA-C-N 117.331 0.565 . . . . 0.0 110.882 179.886 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 17.7 pt-20 -82.8 151.9 25.9 Favored 'General case' 0 N--CA 1.478 0.962 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 178.859 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 13.0 t -144.69 117.87 2.78 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.889 0 CA-C-O 121.621 0.724 . . . . 0.0 109.361 178.343 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 73.6 m80 -96.07 164.76 12.56 Favored 'General case' 0 C--N 1.358 0.947 0 CA-C-N 114.623 -1.171 . . . . 0.0 109.263 177.96 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' C' C ' 14' ' ' HIS . . . . . 0.462 ' HE2' ' NZ ' ' C' ' 16' ' ' LYS . 17.1 t60 -164.68 99.38 0.79 Allowed 'General case' 0 N--CA 1.476 0.83 0 N-CA-C 110.038 -0.356 . . . . 0.0 110.038 179.221 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -91.74 111.72 23.36 Favored 'General case' 0 CA--C 1.516 -0.359 0 N-CA-C 108.381 -0.97 . . . . 0.0 108.381 179.574 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' C' C ' 16' ' ' LYS . . . . . 0.462 ' NZ ' ' HE2' ' C' ' 14' ' ' HIS . 8.5 ttmm -94.51 171.45 8.8 Favored 'General case' 0 N--CA 1.483 1.185 0 N-CA-C 108.831 -0.803 . . . . 0.0 108.831 -179.841 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 9.7 mp -55.11 157.75 3.25 Favored 'General case' 0 N--CA 1.475 0.809 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 -178.424 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 71.3 t -140.75 150.43 20.69 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 C-N-CA 123.188 0.595 . . . . 0.0 109.663 -177.769 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' C' C ' 19' ' ' PHE . . . . . 0.681 ' HB3' ' O ' ' F' ' 18' ' ' VAL . 44.5 p90 -40.67 162.2 0.01 OUTLIER 'General case' 0 CA--C 1.543 0.677 0 N-CA-C 120.081 3.363 . . . . 0.0 120.081 -178.675 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' C' C ' 20' ' ' PHE . . . . . 0.414 ' CD2' ' O ' ' C' ' 20' ' ' PHE . 20.8 p90 -119.65 69.65 0.84 Allowed 'General case' 0 CA--C 1.562 1.437 0 CA-C-N 112.048 -2.342 . . . . 0.0 109.299 173.568 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -62.85 95.19 0.07 Allowed 'General case' 0 C--N 1.326 -0.454 0 N-CA-C 108.42 -0.956 . . . . 0.0 108.42 176.824 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 77.3 mt-10 -49.7 123.76 8.45 Favored 'General case' 0 N--CA 1.475 0.814 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.495 -179.862 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 16.5 t70 -76.63 169.16 18.8 Favored 'General case' 0 N--CA 1.472 0.631 0 CA-C-O 121.002 0.43 . . . . 0.0 110.713 -179.009 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' C' C ' 24' ' ' VAL . . . . . 0.487 HG13 ' H ' ' C' ' 25' ' ' GLY . 0.7 OUTLIER 178.25 -79.28 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.544 0.729 0 N-CA-C 107.458 -1.312 . . . . 0.0 107.458 -179.658 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' C' C ' 25' ' ' GLY . . . . . 0.487 ' H ' HG13 ' C' ' 24' ' ' VAL . . . -34.09 84.25 0.0 OUTLIER Glycine 0 N--CA 1.48 1.62 0 C-N-CA 124.356 0.979 . . . . 0.0 113.254 178.591 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' C' C ' 26' ' ' SER . . . . . 0.451 ' N ' ' O ' ' C' ' 24' ' ' VAL . 88.7 p -41.15 -105.25 0.0 OUTLIER 'General case' 0 N--CA 1.473 0.702 0 N-CA-C 113.692 0.997 . . . . 0.0 113.692 -177.334 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 16.6 p-10 -59.98 112.21 1.78 Allowed 'General case' 0 N--CA 1.468 0.474 0 CA-C-N 118.874 0.761 . . . . 0.0 110.381 -178.632 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 41.7 mttm -96.55 164.51 12.58 Favored 'General case' 0 N--CA 1.475 0.78 0 C-N-CA 123.204 0.602 . . . . 0.0 110.113 -179.53 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -72.87 -141.31 0.44 Allowed Glycine 0 N--CA 1.462 0.398 0 N-CA-C 107.769 -2.132 . . . . 0.0 107.769 176.535 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' C' C ' 30' ' ' ALA . . . . . 0.489 ' O ' ' O ' ' F' ' 31' ' ' ILE . . . -90.68 123.16 34.07 Favored 'General case' 0 C--O 1.211 -0.968 0 N-CA-C 106.775 -1.565 . . . . 0.0 106.775 176.58 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 16.6 tt -148.08 155.59 9.7 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.889 0 N-CA-C 107.888 -1.153 . . . . 0.0 107.888 179.186 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 20.2 pt -150.79 138.85 14.28 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.469 0 CA-C-N 118.943 0.792 . . . . 0.0 109.266 178.674 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -56.78 154.3 18.17 Favored Glycine 0 CA--C 1.531 1.088 0 CA-C-N 116.606 -0.27 . . . . 0.0 112.56 -178.656 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 2.5 pp -76.32 158.76 31.19 Favored 'General case' 0 N--CA 1.472 0.644 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 179.232 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 11.6 ttp -102.58 151.47 22.3 Favored 'General case' 0 N--CA 1.481 1.091 0 N-CA-C 109.449 -0.574 . . . . 0.0 109.449 179.649 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 7.3 p -168.55 159.88 0.71 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.542 0 N-CA-C 108.038 -1.097 . . . . 0.0 108.038 179.764 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.45 69.69 1.19 Allowed Glycine 0 C--N 1.312 -0.774 0 N-CA-C 111.611 -0.596 . . . . 0.0 111.611 178.826 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 151.95 -177.82 29.57 Favored Glycine 0 N--CA 1.468 0.792 0 N-CA-C 110.25 -1.14 . . . . 0.0 110.25 179.669 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 4.4 t -124.57 138.8 52.81 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.722 0 N-CA-C 107.335 -1.358 . . . . 0.0 107.335 -179.445 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 74.3 t . . . . . 0 N--CA 1.48 1.032 0 CA-C-O 117.771 -1.109 . . . . 0.0 109.696 -177.589 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 30.0 m-85 . . . . . 0 N--CA 1.475 0.784 0 N-CA-C 109.117 -0.698 . . . . 0.0 109.117 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' D' D ' 5' ' ' ARG . . . . . . . . . . . . . 76.7 mtt85 -140.11 141.91 36.09 Favored 'General case' 0 N--CA 1.474 0.761 0 C-N-CA 123.974 0.909 . . . . 0.0 110.559 -178.702 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 54.3 t-80 -148.63 123.39 9.89 Favored 'General case' 0 CA--C 1.547 0.852 0 N-CA-C 107.86 -1.163 . . . . 0.0 107.86 174.848 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' D' D ' 7' ' ' ASP . . . . . . . . . . . . . 8.8 m-20 -63.47 133.17 53.45 Favored 'General case' 0 N--CA 1.469 0.496 0 C-N-CA 126.9 2.08 . . . . 0.0 114.15 176.313 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' D' D ' 8' ' ' SER . . . . . . . . . . . . . 2.4 t -154.35 -177.31 6.36 Favored 'General case' 0 N--CA 1.473 0.712 0 CA-C-N 118.895 0.771 . . . . 0.0 110.555 176.242 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 88.11 69.45 1.28 Allowed Glycine 0 N--CA 1.475 1.279 0 N-CA-C 111.33 -0.708 . . . . 0.0 111.33 174.523 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 35.2 p90 -70.82 124.34 24.09 Favored 'General case' 0 N--CA 1.476 0.837 0 CA-C-N 118.134 0.967 . . . . 0.0 110.507 -179.907 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 17.6 pt-20 -81.0 154.04 27.12 Favored 'General case' 0 C--N 1.363 1.162 0 C-N-CA 119.982 -0.687 . . . . 0.0 109.948 175.935 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 21.8 t -141.29 124.07 15.21 Favored 'Isoleucine or valine' 0 C--N 1.357 0.925 0 N-CA-C 107.945 -1.131 . . . . 0.0 107.945 171.011 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 61.5 m80 -89.03 164.37 15.1 Favored 'General case' 0 N--CA 1.472 0.657 0 C-N-CA 125.229 1.412 . . . . 0.0 112.607 171.865 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' D' D ' 14' ' ' HIS . . . . . 0.46 ' HE2' ' NZ ' ' D' ' 16' ' ' LYS . 17.1 t60 -163.82 104.91 0.92 Allowed 'General case' 0 N--CA 1.478 0.949 0 N-CA-C 109.0 -0.741 . . . . 0.0 109.0 171.671 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -95.24 111.45 23.3 Favored 'General case' 0 C--O 1.218 -0.59 0 N-CA-C 107.913 -1.143 . . . . 0.0 107.913 178.885 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' D' D ' 16' ' ' LYS . . . . . 0.46 ' NZ ' ' HE2' ' D' ' 14' ' ' HIS . 8.6 ttmm -95.49 169.93 9.7 Favored 'General case' 0 N--CA 1.487 1.409 0 C-N-CA 125.749 1.619 . . . . 0.0 108.715 -178.385 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 10.7 mp -65.79 156.23 33.82 Favored 'General case' 0 C--O 1.21 -0.975 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 -172.779 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' D' D ' 18' ' ' VAL . . . . . 0.671 ' O ' ' HB3' ' A' ' 19' ' ' PHE . 88.5 t -139.74 146.72 24.79 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.143 0 C-N-CA 126.183 1.793 . . . . 0.0 109.015 -168.808 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' D' D ' 19' ' ' PHE . . . . . 0.722 ' HB3' ' O ' ' G' ' 18' ' ' VAL 0.485 37.4 p90 -57.67 162.4 3.09 Favored 'General case' 0 C--N 1.391 2.403 0 N-CA-C 118.552 2.797 . . . . 0.0 118.552 -169.325 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' D' D ' 20' ' ' PHE . . . . . 0.404 ' O ' ' CD2' ' D' ' 20' ' ' PHE . 21.5 p90 -114.48 66.24 0.68 Allowed 'General case' 0 C--N 1.375 1.684 0 CA-C-N 112.958 -1.928 . . . . 0.0 110.608 -178.781 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -50.2 92.47 0.01 OUTLIER 'General case' 0 N--CA 1.441 -0.91 0 CA-C-N 113.448 -1.705 . . . . 0.0 110.669 173.675 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 77.0 mt-10 -52.69 125.53 16.98 Favored 'General case' 0 CA--C 1.547 0.843 0 CA-C-N 118.881 0.764 . . . . 0.0 110.306 -179.652 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 14.6 t70 -78.04 168.75 19.39 Favored 'General case' 0 N--CA 1.475 0.802 0 C-N-CA 122.764 0.426 . . . . 0.0 110.163 -179.747 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' D' D ' 24' ' ' VAL . . . . . 0.45 HG13 ' H ' ' D' ' 25' ' ' GLY 0.624 2.7 p -179.4 -100.54 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.203 -1.395 0 CA-C-O 125.938 2.78 . . . . 0.0 106.256 -164.685 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' D' D ' 25' ' ' GLY . . . . . 0.45 ' H ' HG13 ' D' ' 24' ' ' VAL . . . -24.32 71.59 0.0 OUTLIER Glycine 0 C--N 1.3 -1.46 0 C-N-CA 129.459 3.409 . . . . 0.0 116.907 178.476 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' D' D ' 26' ' ' SER . . . . . 0.401 ' OG ' ' N ' ' D' ' 27' ' ' ASN 0.381 78.9 p -52.69 -100.46 0.0 OUTLIER 'General case' 0 C--O 1.273 2.318 1 CA-C-O 110.787 -4.435 . . . . 0.0 107.203 -162.704 . . . . . . . . 4 3 . 1 . 020 nuclear orig core ' D' D ' 27' ' ' ASN . . . . . 0.503 ' N ' ' OD1' ' D' ' 27' ' ' ASN 0.409 11.7 p-10 -70.38 121.87 18.53 Favored 'General case' 0 N--CA 1.481 1.109 1 CA-C-N 129.149 5.431 . . . . 0.0 108.818 -168.719 . . . . . . . . 4 3 . 1 . 020 nuclear orig core ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 31.7 mttm -86.24 161.18 18.92 Favored 'General case' 0 C--N 1.364 1.23 0 CA-C-N 110.65 -2.977 . . . . 0.0 113.104 177.762 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -66.89 -145.13 0.07 OUTLIER Glycine 0 CA--C 1.535 1.331 0 N-CA-C 108.997 -1.641 . . . . 0.0 108.997 167.354 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' D' D ' 30' ' ' ALA . . . . . 0.489 ' O ' ' O ' ' G' ' 31' ' ' ILE . . . -92.12 123.45 35.47 Favored 'General case' 0 C--N 1.358 0.945 0 N-CA-C 106.708 -1.59 . . . . 0.0 106.708 174.207 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' D' D ' 31' ' ' ILE . . . . . 0.458 ' O ' ' O ' ' A' ' 30' ' ' ALA . 17.3 tt -144.73 155.42 14.42 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.451 0 N-CA-C 109.107 -0.701 . . . . 0.0 109.107 178.959 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 23.4 pt -150.99 135.31 8.94 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.912 0 CA-C-N 118.402 0.546 . . . . 0.0 110.035 178.939 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -52.85 153.9 6.47 Favored Glycine 0 N--CA 1.476 1.317 0 CA-C-N 116.32 -0.4 . . . . 0.0 112.891 -179.492 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 2.5 pp -76.46 159.85 30.05 Favored 'General case' 0 N--CA 1.473 0.677 0 N-CA-C 110.0 -0.37 . . . . 0.0 110.0 178.433 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 8.2 ttp -103.38 155.14 18.7 Favored 'General case' 0 N--CA 1.48 1.06 0 N-CA-C 108.655 -0.868 . . . . 0.0 108.655 178.781 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 6.7 p -167.04 163.73 0.58 Allowed 'Isoleucine or valine' 0 CA--C 1.507 -0.708 0 N-CA-C 107.456 -1.313 . . . . 0.0 107.456 177.054 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 59.32 63.9 4.74 Favored Glycine 0 C--N 1.319 -0.364 0 C-N-CA 118.733 -1.699 . . . . 0.0 113.143 174.397 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 148.4 179.73 24.58 Favored Glycine 0 N--CA 1.471 1.026 0 CA-C-N 118.0 0.9 . . . . 0.0 111.225 -177.175 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 5.5 t -122.2 138.42 52.47 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.86 0 N-CA-C 106.412 -1.699 . . . . 0.0 106.412 -177.546 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 77.1 t . . . . . 0 C--O 1.212 -0.887 0 N-CA-C 108.224 -1.028 . . . . 0.0 108.224 178.886 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 27.7 m-85 . . . . . 0 N--CA 1.474 0.727 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' E' E ' 5' ' ' ARG . . . . . . . . . . . . . 76.9 mtt85 -139.71 145.75 38.74 Favored 'General case' 0 N--CA 1.477 0.917 0 CA-C-N 115.978 -0.556 . . . . 0.0 110.015 179.378 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 57.9 t-80 -150.52 116.44 5.58 Favored 'General case' 0 N--CA 1.475 0.796 0 N-CA-C 109.472 -0.566 . . . . 0.0 109.472 179.239 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' E' E ' 7' ' ' ASP . . . . . . . . . . . . . 9.7 m-20 -66.11 148.64 51.51 Favored 'General case' 0 N--CA 1.47 0.549 0 O-C-N 123.259 0.349 . . . . 0.0 111.136 -179.825 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' E' E ' 8' ' ' SER . . . . . . . . . . . . . 2.2 t -167.45 -178.04 3.83 Favored 'General case' 0 N--CA 1.471 0.611 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 178.28 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 86.11 70.21 1.32 Allowed Glycine 0 CA--C 1.533 1.168 0 CA-C-N 115.964 -0.562 . . . . 0.0 112.089 178.779 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 34.2 p90 -71.65 121.87 19.58 Favored 'General case' 0 N--CA 1.479 1.008 0 CA-C-N 117.52 0.66 . . . . 0.0 110.771 179.704 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 17.4 pt-20 -83.01 152.77 25.27 Favored 'General case' 0 N--CA 1.482 1.159 0 N-CA-C 109.405 -0.591 . . . . 0.0 109.405 178.136 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 19.2 t -144.83 117.03 2.35 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.667 0 N-CA-C 109.478 -0.564 . . . . 0.0 109.478 178.831 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 73.8 m80 -95.33 165.89 12.16 Favored 'General case' 0 N--CA 1.475 0.794 0 N-CA-C 109.701 -0.481 . . . . 0.0 109.701 178.588 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' E' E ' 14' ' ' HIS . . . . . 0.447 ' NE2' ' NZ ' ' E' ' 16' ' ' LYS . 16.5 t60 -164.71 99.12 0.78 Allowed 'General case' 0 N--CA 1.478 0.971 0 N-CA-C 110.095 -0.335 . . . . 0.0 110.095 179.327 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -92.06 110.96 22.33 Favored 'General case' 0 CA--C 1.511 -0.548 0 N-CA-C 108.442 -0.948 . . . . 0.0 108.442 179.721 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' E' E ' 16' ' ' LYS . . . . . 0.447 ' NZ ' ' NE2' ' E' ' 14' ' ' HIS . 9.5 ttmm -93.53 172.04 8.52 Favored 'General case' 0 N--CA 1.485 1.303 0 N-CA-C 109.279 -0.638 . . . . 0.0 109.279 179.999 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 9.2 mp -55.11 155.98 4.32 Favored 'General case' 0 C--O 1.216 -0.693 0 N-CA-C 109.981 -0.377 . . . . 0.0 109.981 -178.599 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' E' E ' 18' ' ' VAL . . . . . 0.691 ' O ' ' HB3' ' B' ' 19' ' ' PHE . 79.5 t -141.48 150.61 19.62 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.966 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 -178.475 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' E' E ' 19' ' ' PHE . . . . . 0.693 ' HB3' ' O ' ' H' ' 18' ' ' VAL . 38.9 p90 -43.69 153.95 0.11 Allowed 'General case' 0 C--N 1.385 2.139 0 N-CA-C 120.387 3.477 . . . . 0.0 120.387 -177.216 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' E' E ' 20' ' ' PHE . . . . . 0.403 ' CD2' ' O ' ' E' ' 20' ' ' PHE . 20.8 p90 -111.62 66.95 0.64 Allowed 'General case' 0 N--CA 1.484 1.243 0 CA-C-N 113.938 -1.483 . . . . 0.0 111.495 175.007 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -58.64 93.96 0.02 OUTLIER 'General case' 0 N--CA 1.441 -0.919 0 CA-C-N 114.133 -1.394 . . . . 0.0 109.212 177.919 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 76.1 mt-10 -50.0 122.16 6.33 Favored 'General case' 0 N--CA 1.474 0.749 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.25 -179.712 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 18.4 t70 -75.03 173.51 10.62 Favored 'General case' 0 N--CA 1.466 0.349 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 -178.823 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' E' E ' 24' ' ' VAL . . . . . 0.522 HG13 ' H ' ' E' ' 25' ' ' GLY . 0.9 OUTLIER 173.71 -77.9 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.472 0.656 0 N-CA-C 107.896 -1.15 . . . . 0.0 107.896 -179.925 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' E' E ' 25' ' ' GLY . . . . . 0.522 ' H ' HG13 ' E' ' 24' ' ' VAL . . . -36.51 84.47 0.0 OUTLIER Glycine 0 CA--C 1.538 1.523 0 C-N-CA 124.102 0.858 . . . . 0.0 113.396 179.132 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' E' E ' 26' ' ' SER . . . . . 0.451 ' N ' ' O ' ' E' ' 24' ' ' VAL . 95.2 p -40.81 -107.11 0.0 OUTLIER 'General case' 0 N--CA 1.482 1.133 0 N-CA-C 114.25 1.204 . . . . 0.0 114.25 -177.544 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 16.5 p-10 -58.36 111.57 1.27 Allowed 'General case' 0 N--CA 1.473 0.688 0 CA-C-N 118.858 0.754 . . . . 0.0 110.067 -178.664 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 39.1 mttm -95.15 167.82 11.13 Favored 'General case' 0 N--CA 1.476 0.851 0 O-C-N 123.786 0.679 . . . . 0.0 109.588 -179.592 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -76.14 -140.17 0.94 Allowed Glycine 0 CA--C 1.524 0.652 0 N-CA-C 106.996 -2.441 . . . . 0.0 106.996 176.396 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' E' E ' 30' ' ' ALA . . . . . 0.458 ' O ' ' O ' ' H' ' 31' ' ' ILE . . . -91.82 126.34 36.87 Favored 'General case' 0 C--O 1.215 -0.723 0 N-CA-C 106.507 -1.664 . . . . 0.0 106.507 175.682 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' E' E ' 31' ' ' ILE . . . . . 0.491 ' O ' ' O ' ' B' ' 30' ' ' ALA . 16.6 tt -149.87 155.62 7.81 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.604 0 N-CA-C 108.077 -1.083 . . . . 0.0 108.077 179.07 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 19.2 pt -152.61 138.14 11.21 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.628 0 N-CA-C 109.096 -0.705 . . . . 0.0 109.096 -179.509 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -57.56 154.65 20.98 Favored Glycine 0 N--CA 1.474 1.174 0 CA-C-N 115.407 -0.815 . . . . 0.0 112.66 -177.851 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 2.5 pp -75.98 160.32 29.97 Favored 'General case' 0 N--CA 1.469 0.505 0 N-CA-C 109.64 -0.504 . . . . 0.0 109.64 179.244 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 7.7 ttp -104.91 151.95 23.24 Favored 'General case' 0 N--CA 1.48 1.052 0 N-CA-C 109.259 -0.645 . . . . 0.0 109.259 179.454 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 7.5 p -168.13 159.93 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.446 -0.641 0 N-CA-C 107.844 -1.169 . . . . 0.0 107.844 179.744 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 53.85 70.87 0.81 Allowed Glycine 0 C--N 1.313 -0.72 0 O-C-N 123.381 0.426 . . . . 0.0 112.328 179.365 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 153.06 -177.14 30.86 Favored Glycine 0 N--CA 1.461 0.367 0 N-CA-C 110.131 -1.188 . . . . 0.0 110.131 179.556 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 5.5 t -126.7 137.08 58.93 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.361 0 N-CA-C 106.259 -1.756 . . . . 0.0 106.259 -178.867 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 75.1 t . . . . . 0 N--CA 1.474 0.754 0 CA-C-O 117.649 -1.167 . . . . 0.0 109.504 -176.889 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 27.7 m-85 . . . . . 0 N--CA 1.472 0.672 0 N-CA-C 109.676 -0.49 . . . . 0.0 109.676 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' F' F ' 5' ' ' ARG . . . . . . . . . . . . . 76.8 mtt85 -139.61 145.34 38.4 Favored 'General case' 0 N--CA 1.479 0.98 0 CA-C-N 115.861 -0.609 . . . . 0.0 109.96 179.427 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 57.7 t-80 -150.33 116.31 5.61 Favored 'General case' 0 N--CA 1.475 0.776 0 N-CA-C 109.61 -0.515 . . . . 0.0 109.61 179.158 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' F' F ' 7' ' ' ASP . . . . . . . . . . . . . 9.8 m-20 -65.84 148.42 51.81 Favored 'General case' 0 N--CA 1.469 0.515 0 O-C-N 123.261 0.351 . . . . 0.0 111.301 -179.813 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' F' F ' 8' ' ' SER . . . . . . . . . . . . . 2.2 t -167.37 -178.0 3.85 Favored 'General case' 0 N--CA 1.471 0.59 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 178.214 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 86.25 70.15 1.32 Allowed Glycine 0 CA--C 1.532 1.143 0 CA-C-N 115.972 -0.558 . . . . 0.0 112.113 178.734 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 34.6 p90 -71.7 121.71 19.34 Favored 'General case' 0 N--CA 1.476 0.858 0 CA-C-N 117.514 0.657 . . . . 0.0 110.95 179.739 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 17.4 pt-20 -82.79 152.69 25.57 Favored 'General case' 0 N--CA 1.481 1.116 0 N-CA-C 109.399 -0.593 . . . . 0.0 109.399 178.156 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 19.3 t -144.83 117.02 2.35 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.635 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 178.795 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 73.8 m80 -95.3 165.94 12.14 Favored 'General case' 0 N--CA 1.476 0.871 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 178.534 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' F' F ' 14' ' ' HIS . . . . . 0.468 ' HE2' ' NZ ' ' F' ' 16' ' ' LYS . 16.4 t60 -164.66 98.86 0.79 Allowed 'General case' 0 N--CA 1.478 0.969 0 N-CA-C 110.224 -0.287 . . . . 0.0 110.224 179.394 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -91.74 110.93 22.27 Favored 'General case' 0 CA--C 1.507 -0.693 0 N-CA-C 108.376 -0.972 . . . . 0.0 108.376 179.655 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' F' F ' 16' ' ' LYS . . . . . 0.468 ' NZ ' ' HE2' ' F' ' 14' ' ' HIS . 9.7 ttmm -93.59 171.75 8.7 Favored 'General case' 0 N--CA 1.484 1.258 0 N-CA-C 109.224 -0.658 . . . . 0.0 109.224 179.919 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 9.2 mp -54.8 155.84 4.05 Favored 'General case' 0 N--CA 1.472 0.671 0 N-CA-C 110.044 -0.354 . . . . 0.0 110.044 -178.625 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' F' F ' 18' ' ' VAL . . . . . 0.681 ' O ' ' HB3' ' C' ' 19' ' ' PHE . 79.0 t -141.43 150.49 19.75 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.955 0 N-CA-C 107.929 -1.138 . . . . 0.0 107.929 -178.409 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' F' F ' 19' ' ' PHE . . . . . 0.715 ' HB3' ' O ' ' I' ' 18' ' ' VAL . 38.6 p90 -43.48 153.63 0.11 Allowed 'General case' 0 C--N 1.384 2.101 0 N-CA-C 120.41 3.485 . . . . 0.0 120.41 -177.232 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' F' F ' 20' ' ' PHE . . . . . 0.415 ' O ' ' CD2' ' F' ' 20' ' ' PHE . 20.1 p90 -111.46 67.25 0.64 Allowed 'General case' 0 N--CA 1.48 1.053 0 CA-C-N 113.947 -1.479 . . . . 0.0 111.538 175.029 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -58.82 94.27 0.02 OUTLIER 'General case' 0 C--N 1.317 -0.843 0 CA-C-N 114.211 -1.359 . . . . 0.0 109.262 178.074 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 76.5 mt-10 -50.29 122.28 6.71 Favored 'General case' 0 N--CA 1.476 0.85 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.296 -179.743 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 18.2 t70 -75.06 173.54 10.6 Favored 'General case' 0 N--CA 1.468 0.429 0 N-CA-C 110.031 -0.359 . . . . 0.0 110.031 -178.852 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' F' F ' 24' ' ' VAL . . . . . 0.498 HG13 ' H ' ' F' ' 25' ' ' GLY . 0.9 OUTLIER 173.83 -78.35 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.728 0 N-CA-C 107.934 -1.136 . . . . 0.0 107.934 -179.828 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' F' F ' 25' ' ' GLY . . . . . 0.498 ' H ' HG13 ' F' ' 24' ' ' VAL . . . -36.7 84.95 0.01 OUTLIER Glycine 0 CA--C 1.536 1.382 0 C-N-CA 124.045 0.831 . . . . 0.0 113.354 179.294 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' F' F ' 26' ' ' SER . . . . . 0.45 ' N ' ' O ' ' F' ' 24' ' ' VAL . 96.0 p -40.82 -107.11 0.0 OUTLIER 'General case' 0 N--CA 1.479 0.989 0 N-CA-C 114.19 1.181 . . . . 0.0 114.19 -177.696 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 16.6 p-10 -58.42 111.55 1.27 Allowed 'General case' 0 N--CA 1.472 0.654 0 CA-C-N 118.804 0.729 . . . . 0.0 110.171 -178.69 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 38.9 mttm -95.08 167.71 11.21 Favored 'General case' 0 N--CA 1.477 0.918 0 C-N-CA 123.392 0.677 . . . . 0.0 109.597 -179.553 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -76.03 -139.98 0.9 Allowed Glycine 0 CA--C 1.525 0.702 0 N-CA-C 107.113 -2.395 . . . . 0.0 107.113 176.403 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' F' F ' 30' ' ' ALA . . . . . 0.456 ' O ' ' O ' ' I' ' 31' ' ' ILE . . . -91.97 126.37 37.03 Favored 'General case' 0 N--CA 1.472 0.635 0 N-CA-C 106.227 -1.768 . . . . 0.0 106.227 175.706 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' F' F ' 31' ' ' ILE . . . . . 0.489 ' O ' ' O ' ' C' ' 30' ' ' ALA . 16.6 tt -150.01 155.29 8.01 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.619 0 N-CA-C 108.078 -1.082 . . . . 0.0 108.078 179.221 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 19.3 pt -152.48 138.34 11.7 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.651 0 N-CA-C 109.157 -0.683 . . . . 0.0 109.157 -179.482 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -57.63 154.54 21.62 Favored Glycine 0 N--CA 1.474 1.18 0 CA-C-N 115.421 -0.808 . . . . 0.0 112.622 -177.74 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 2.5 pp -75.96 160.51 29.8 Favored 'General case' 0 N--CA 1.47 0.543 0 N-CA-C 109.58 -0.526 . . . . 0.0 109.58 179.14 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 7.6 ttp -105.15 152.08 23.24 Favored 'General case' 0 N--CA 1.479 0.986 0 N-CA-C 109.313 -0.625 . . . . 0.0 109.313 179.528 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 7.5 p -168.19 160.23 0.72 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.625 0 N-CA-C 107.837 -1.172 . . . . 0.0 107.837 179.631 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 53.76 70.89 0.8 Allowed Glycine 0 C--N 1.313 -0.745 0 O-C-N 123.448 0.467 . . . . 0.0 112.425 179.4 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 152.97 -177.19 30.77 Favored Glycine 0 N--CA 1.461 0.364 0 N-CA-C 110.08 -1.208 . . . . 0.0 110.08 179.538 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 5.3 t -126.45 136.81 59.7 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.347 0 N-CA-C 106.242 -1.762 . . . . 0.0 106.242 -178.852 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 76.4 t . . . . . 0 N--CA 1.47 0.567 0 CA-C-O 117.597 -1.192 . . . . 0.0 109.692 -176.926 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 30.3 m-85 . . . . . 0 N--CA 1.474 0.748 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' G' G ' 5' ' ' ARG . . . . . . . . . . . . . 77.0 mtt85 -140.01 145.14 37.41 Favored 'General case' 0 N--CA 1.481 1.095 0 N-CA-C 109.688 -0.486 . . . . 0.0 109.688 179.515 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 58.7 t-80 -150.03 117.38 6.06 Favored 'General case' 0 N--CA 1.473 0.675 0 N-CA-C 109.209 -0.663 . . . . 0.0 109.209 179.217 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 12.4 m-20 -66.89 148.39 52.0 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.961 -179.83 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' G' G ' 8' ' ' SER . . . . . . . . . . . . . 3.5 t -166.93 -179.38 4.67 Favored 'General case' 0 N--CA 1.472 0.674 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.095 178.342 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 85.44 71.95 1.3 Allowed Glycine 0 N--CA 1.477 1.406 0 CA-C-N 116.144 -0.48 . . . . 0.0 112.247 179.015 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 38.5 p90 -72.84 122.03 20.92 Favored 'General case' 0 N--CA 1.477 0.887 0 CA-C-N 117.098 0.449 . . . . 0.0 110.76 179.353 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 17.7 pt-20 -83.28 153.16 24.8 Favored 'General case' 0 N--CA 1.478 0.932 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 178.263 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 22.0 t -143.76 117.64 3.53 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.006 0 CA-C-O 118.527 -0.749 . . . . 0.0 109.032 179.003 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 76.7 m80 -95.42 167.36 11.37 Favored 'General case' 0 N--CA 1.486 1.374 0 CA-C-N 119.569 1.077 . . . . 0.0 109.521 178.597 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' G' G ' 14' ' ' HIS . . . . . 0.455 ' HE2' ' NZ ' ' G' ' 16' ' ' LYS . 16.1 t60 -164.42 98.1 0.8 Allowed 'General case' 0 N--CA 1.479 1.014 0 N-CA-C 110.061 -0.348 . . . . 0.0 110.061 179.216 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -91.63 111.67 23.28 Favored 'General case' 0 CA--C 1.509 -0.6 0 N-CA-C 107.904 -1.146 . . . . 0.0 107.904 179.479 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' G' G ' 16' ' ' LYS . . . . . 0.455 ' NZ ' ' HE2' ' G' ' 14' ' ' HIS . 9.1 ttmm -93.61 171.97 8.56 Favored 'General case' 0 N--CA 1.485 1.315 0 N-CA-C 109.314 -0.624 . . . . 0.0 109.314 -179.86 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 9.5 mp -55.14 152.24 8.23 Favored 'General case' 0 N--CA 1.471 0.606 0 CA-C-O 121.147 0.498 . . . . 0.0 110.366 -178.829 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' G' G ' 18' ' ' VAL . . . . . 0.722 ' O ' ' HB3' ' D' ' 19' ' ' PHE . 87.0 t -138.13 150.9 24.77 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.622 0 N-CA-C 107.635 -1.246 . . . . 0.0 107.635 -179.166 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' G' G ' 19' ' ' PHE . . . . . 0.475 ' O ' ' CG ' ' D' ' 19' ' ' PHE . 29.3 p90 -44.26 149.22 0.38 Allowed 'General case' 0 C--N 1.406 3.034 0 O-C-N 128.483 3.615 . . . . 0.0 117.721 -175.283 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' G' G ' 20' ' ' PHE . . . . . 0.401 ' CD2' ' O ' ' G' ' 20' ' ' PHE . 23.0 p90 -109.77 62.54 0.6 Allowed 'General case' 0 N--CA 1.496 1.855 0 CA-C-O 122.787 1.28 . . . . 0.0 112.681 177.685 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -53.66 94.3 0.01 OUTLIER 'General case' 0 N--CA 1.445 -0.709 0 CA-C-N 113.928 -1.487 . . . . 0.0 110.303 179.933 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 74.5 mt-10 -51.3 120.3 4.9 Favored 'General case' 0 CA--C 1.541 0.612 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.274 179.912 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 19.2 t70 -73.47 173.66 9.31 Favored 'General case' 0 N--CA 1.468 0.443 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 -178.905 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' G' G ' 24' ' ' VAL . . . . . 0.486 HG13 ' H ' ' G' ' 25' ' ' GLY . 0.9 OUTLIER 174.18 -79.19 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.755 0 N-CA-C 108.221 -1.029 . . . . 0.0 108.221 -179.773 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' G' G ' 25' ' ' GLY . . . . . 0.486 ' H ' HG13 ' G' ' 24' ' ' VAL . . . -37.51 85.91 0.01 OUTLIER Glycine 0 N--CA 1.479 1.54 0 C-N-CA 123.698 0.666 . . . . 0.0 113.171 179.658 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' G' G ' 26' ' ' SER . . . . . 0.441 ' N ' ' O ' ' G' ' 24' ' ' VAL . 90.6 p -40.95 -105.81 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.882 0 N-CA-C 113.877 1.066 . . . . 0.0 113.877 -177.506 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 16.9 p-10 -59.46 110.38 1.1 Allowed 'General case' 0 N--CA 1.473 0.71 0 CA-C-N 118.908 0.776 . . . . 0.0 110.63 -178.795 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 41.7 mttm -93.27 167.82 11.49 Favored 'General case' 0 N--CA 1.47 0.542 0 CA-C-N 115.823 -0.626 . . . . 0.0 109.669 -179.728 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -75.76 -140.28 0.87 Allowed Glycine 0 CA--C 1.525 0.698 0 N-CA-C 106.209 -2.757 . . . . 0.0 106.209 176.236 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -93.64 125.95 38.54 Favored 'General case' 0 N--CA 1.469 0.489 0 N-CA-C 107.154 -1.425 . . . . 0.0 107.154 176.23 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' G' G ' 31' ' ' ILE . . . . . 0.489 ' O ' ' O ' ' D' ' 30' ' ' ALA . 16.4 tt -149.86 155.37 8.04 Favored 'Isoleucine or valine' 0 C--O 1.211 -0.936 0 N-CA-C 108.783 -0.821 . . . . 0.0 108.783 179.786 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 26.7 pt -151.42 136.33 10.21 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.434 0 N-CA-C 109.287 -0.634 . . . . 0.0 109.287 -177.588 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -56.58 154.3 17.24 Favored Glycine 0 CA--C 1.526 0.76 0 CA-C-N 116.147 -0.479 . . . . 0.0 112.179 -178.543 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 2.5 pp -75.63 160.7 29.82 Favored 'General case' 0 N--CA 1.466 0.369 0 N-CA-C 109.499 -0.556 . . . . 0.0 109.499 179.313 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 6.6 ttp -104.78 152.21 22.84 Favored 'General case' 0 N--CA 1.48 1.046 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 179.378 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 7.4 p -168.69 162.22 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 N-CA-C 107.343 -1.355 . . . . 0.0 107.343 179.632 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 54.08 68.93 1.4 Allowed Glycine 0 C--N 1.312 -0.774 0 N-CA-C 111.848 -0.501 . . . . 0.0 111.848 178.77 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 152.66 -178.31 29.88 Favored Glycine 0 N--CA 1.465 0.581 0 N-CA-C 110.473 -1.051 . . . . 0.0 110.473 179.7 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 4.3 t -124.67 138.59 53.55 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.844 0 N-CA-C 107.098 -1.445 . . . . 0.0 107.098 -180.0 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 74.1 t . . . . . 0 N--CA 1.482 1.135 0 CA-C-O 117.788 -1.101 . . . . 0.0 109.8 -177.213 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 31.6 m-85 . . . . . 0 N--CA 1.473 0.712 0 N-CA-C 109.641 -0.503 . . . . 0.0 109.641 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' H' H ' 5' ' ' ARG . . . . . . . . . . . . . 77.1 mtt85 -140.26 145.31 37.15 Favored 'General case' 0 N--CA 1.479 0.979 0 C-N-CA 122.86 0.464 . . . . 0.0 109.801 179.485 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 58.7 t-80 -150.28 117.59 6.04 Favored 'General case' 0 N--CA 1.475 0.786 0 N-CA-C 109.423 -0.584 . . . . 0.0 109.423 179.216 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 12.6 m-20 -67.02 148.17 52.29 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-N 116.386 -0.37 . . . . 0.0 111.078 -179.79 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' H' H ' 8' ' ' SER . . . . . . . . . . . . . 3.5 t -166.86 -179.29 4.66 Favored 'General case' 0 N--CA 1.471 0.598 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.151 178.326 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 85.36 71.68 1.31 Allowed Glycine 0 N--CA 1.477 1.406 0 CA-C-N 116.166 -0.47 . . . . 0.0 112.211 179.098 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 38.3 p90 -72.62 122.2 21.0 Favored 'General case' 0 N--CA 1.474 0.762 0 O-C-N 122.437 -0.449 . . . . 0.0 110.712 179.468 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 17.7 pt-20 -83.39 153.03 24.75 Favored 'General case' 0 N--CA 1.48 1.042 0 N-CA-C 109.294 -0.632 . . . . 0.0 109.294 178.37 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 21.8 t -143.81 116.83 3.12 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.029 0 CA-C-O 118.546 -0.74 . . . . 0.0 109.292 178.952 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 76.5 m80 -94.66 167.26 11.57 Favored 'General case' 0 N--CA 1.484 1.272 0 CA-C-N 119.441 1.018 . . . . 0.0 109.603 178.556 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' H' H ' 14' ' ' HIS . . . . . 0.442 ' NE2' ' NZ ' ' H' ' 16' ' ' LYS . 16.1 t60 -164.41 98.12 0.8 Allowed 'General case' 0 N--CA 1.479 0.979 0 N-CA-C 110.019 -0.363 . . . . 0.0 110.019 179.184 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -91.5 111.76 23.4 Favored 'General case' 0 CA--C 1.511 -0.544 0 N-CA-C 107.891 -1.151 . . . . 0.0 107.891 179.459 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' H' H ' 16' ' ' LYS . . . . . 0.442 ' NZ ' ' NE2' ' H' ' 14' ' ' HIS . 9.1 ttmm -93.72 172.06 8.49 Favored 'General case' 0 N--CA 1.486 1.338 0 N-CA-C 109.344 -0.613 . . . . 0.0 109.344 -179.768 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 9.4 mp -55.16 152.29 8.2 Favored 'General case' 0 N--CA 1.472 0.656 0 CA-C-O 121.152 0.501 . . . . 0.0 110.382 -178.921 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' H' H ' 18' ' ' VAL . . . . . 0.693 ' O ' ' HB3' ' E' ' 19' ' ' PHE . 89.0 t -138.23 151.15 24.71 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.711 0 N-CA-C 107.783 -1.191 . . . . 0.0 107.783 -179.158 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' H' H ' 19' ' ' PHE . . . . . 0.47 ' O ' ' CG ' ' E' ' 19' ' ' PHE . 29.5 p90 -44.73 149.0 0.45 Allowed 'General case' 0 C--N 1.406 3.033 0 O-C-N 128.487 3.617 . . . . 0.0 117.613 -175.055 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 23.3 p90 -109.56 62.45 0.6 Allowed 'General case' 0 N--CA 1.498 1.953 0 CA-C-O 122.758 1.266 . . . . 0.0 112.533 177.805 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -53.64 94.37 0.01 OUTLIER 'General case' 0 N--CA 1.446 -0.652 0 CA-C-N 113.954 -1.475 . . . . 0.0 110.211 179.947 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 74.8 mt-10 -51.45 120.18 4.85 Favored 'General case' 0 CA--C 1.541 0.62 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.297 179.91 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 19.0 t70 -73.47 173.34 9.77 Favored 'General case' 0 N--CA 1.466 0.355 0 N-CA-C 109.943 -0.391 . . . . 0.0 109.943 -178.897 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' H' H ' 24' ' ' VAL . . . . . 0.493 HG13 ' H ' ' H' ' 25' ' ' GLY . 0.9 OUTLIER 174.52 -79.16 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.542 0.661 0 N-CA-C 108.149 -1.056 . . . . 0.0 108.149 -179.693 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' H' H ' 25' ' ' GLY . . . . . 0.493 ' H ' HG13 ' H' ' 24' ' ' VAL . . . -37.33 85.74 0.01 OUTLIER Glycine 0 N--CA 1.478 1.455 0 C-N-CA 123.732 0.682 . . . . 0.0 113.269 179.646 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' H' H ' 26' ' ' SER . . . . . 0.437 ' N ' ' O ' ' H' ' 24' ' ' VAL . 89.5 p -40.64 -106.07 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.885 0 N-CA-C 113.614 0.968 . . . . 0.0 113.614 -177.789 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 17.0 p-10 -59.35 110.36 1.07 Allowed 'General case' 0 N--CA 1.473 0.686 0 CA-C-N 118.941 0.791 . . . . 0.0 110.68 -178.771 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 41.7 mttm -93.46 167.42 11.72 Favored 'General case' 0 N--CA 1.468 0.461 0 CA-C-N 115.757 -0.656 . . . . 0.0 109.701 -179.896 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -75.43 -140.22 0.79 Allowed Glycine 0 CA--C 1.524 0.645 0 N-CA-C 106.262 -2.735 . . . . 0.0 106.262 176.218 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -93.7 125.92 38.58 Favored 'General case' 0 N--CA 1.47 0.529 0 N-CA-C 107.14 -1.43 . . . . 0.0 107.14 176.342 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' H' H ' 31' ' ' ILE . . . . . 0.458 ' O ' ' O ' ' E' ' 30' ' ' ALA . 16.4 tt -150.02 155.32 7.97 Favored 'Isoleucine or valine' 0 C--O 1.213 -0.846 0 N-CA-C 108.658 -0.867 . . . . 0.0 108.658 179.673 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 27.3 pt -151.38 136.27 10.16 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.399 0 N-CA-C 109.243 -0.651 . . . . 0.0 109.243 -177.526 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -56.69 154.49 17.26 Favored Glycine 0 CA--C 1.528 0.854 0 CA-C-N 116.166 -0.47 . . . . 0.0 112.193 -178.442 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 2.5 pp -75.59 160.78 29.76 Favored 'General case' 0 N--CA 1.467 0.418 0 N-CA-C 109.515 -0.55 . . . . 0.0 109.515 179.37 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 6.5 ttp -104.83 152.17 22.93 Favored 'General case' 0 N--CA 1.48 1.027 0 N-CA-C 109.102 -0.703 . . . . 0.0 109.102 179.343 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 7.4 p -168.81 162.29 0.56 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.487 0 N-CA-C 107.209 -1.404 . . . . 0.0 107.209 179.639 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 54.14 68.87 1.43 Allowed Glycine 0 C--N 1.311 -0.828 0 N-CA-C 111.853 -0.499 . . . . 0.0 111.853 178.721 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 152.41 -178.26 29.7 Favored Glycine 0 N--CA 1.466 0.697 0 N-CA-C 110.564 -1.014 . . . . 0.0 110.564 179.781 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 4.4 t -124.58 138.58 53.54 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.788 0 N-CA-C 107.077 -1.453 . . . . 0.0 107.077 -179.931 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 75.2 t . . . . . 0 N--CA 1.483 1.217 0 CA-C-O 117.755 -1.117 . . . . 0.0 109.813 -177.254 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 31.0 m-85 . . . . . 0 N--CA 1.474 0.763 0 N-CA-C 109.7 -0.481 . . . . 0.0 109.7 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' I' I ' 5' ' ' ARG . . . . . . . . . . . . . 77.0 mtt85 -140.3 145.26 37.02 Favored 'General case' 0 N--CA 1.48 1.038 0 C-N-CA 122.896 0.478 . . . . 0.0 109.798 179.514 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 58.7 t-80 -150.25 117.4 5.98 Favored 'General case' 0 N--CA 1.474 0.746 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 179.226 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 12.3 m-20 -66.76 148.15 52.31 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-N 116.379 -0.373 . . . . 0.0 111.014 -179.848 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' I' I ' 8' ' ' SER . . . . . . . . . . . . . 3.5 t -166.81 -179.31 4.7 Favored 'General case' 0 N--CA 1.472 0.67 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.082 178.3 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 85.36 71.72 1.31 Allowed Glycine 0 N--CA 1.476 1.355 0 CA-C-N 116.14 -0.482 . . . . 0.0 112.232 179.086 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 38.0 p90 -72.48 121.95 20.46 Favored 'General case' 0 N--CA 1.476 0.837 0 O-C-N 122.356 -0.496 . . . . 0.0 110.745 179.38 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 17.7 pt-20 -83.2 153.02 24.96 Favored 'General case' 0 N--CA 1.478 0.959 0 N-CA-C 109.279 -0.638 . . . . 0.0 109.279 178.361 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 21.8 t -143.78 116.83 3.14 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.097 0 CA-C-O 118.584 -0.722 . . . . 0.0 109.326 178.928 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 76.5 m80 -94.69 167.24 11.58 Favored 'General case' 0 N--CA 1.485 1.317 0 CA-C-N 119.505 1.048 . . . . 0.0 109.574 178.603 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' I' I ' 14' ' ' HIS . . . . . 0.458 ' HE2' ' NZ ' ' I' ' 16' ' ' LYS . 15.9 t60 -164.41 98.01 0.8 Allowed 'General case' 0 N--CA 1.479 0.991 0 N-CA-C 110.181 -0.303 . . . . 0.0 110.181 179.149 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -91.43 111.63 23.21 Favored 'General case' 0 CA--C 1.509 -0.632 0 N-CA-C 107.94 -1.133 . . . . 0.0 107.94 179.49 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' I' I ' 16' ' ' LYS . . . . . 0.458 ' NZ ' ' HE2' ' I' ' 14' ' ' HIS . 9.1 ttmm -93.62 172.11 8.47 Favored 'General case' 0 N--CA 1.485 1.304 0 N-CA-C 109.362 -0.607 . . . . 0.0 109.362 -179.778 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 9.5 mp -55.17 152.29 8.24 Favored 'General case' 0 N--CA 1.472 0.652 0 CA-C-O 121.15 0.5 . . . . 0.0 110.3 -178.857 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' I' I ' 18' ' ' VAL . . . . . 0.715 ' O ' ' HB3' ' F' ' 19' ' ' PHE . 88.8 t -138.21 151.28 24.86 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.634 0 N-CA-C 107.683 -1.228 . . . . 0.0 107.683 -179.218 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' I' I ' 19' ' ' PHE . . . . . 0.466 ' O ' ' CG ' ' F' ' 19' ' ' PHE . 29.1 p90 -44.83 148.93 0.47 Allowed 'General case' 0 C--N 1.407 3.093 0 O-C-N 128.378 3.549 . . . . 0.0 117.57 -175.06 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 23.2 p90 -109.5 62.48 0.6 Allowed 'General case' 0 N--CA 1.497 1.904 0 CA-C-O 122.764 1.268 . . . . 0.0 112.522 177.763 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -53.65 94.42 0.01 OUTLIER 'General case' 0 N--CA 1.446 -0.673 0 CA-C-N 113.901 -1.499 . . . . 0.0 110.201 179.947 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 74.5 mt-10 -51.4 120.17 4.82 Favored 'General case' 0 CA--C 1.541 0.634 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.375 179.929 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 18.9 t70 -73.52 173.13 10.11 Favored 'General case' 0 N--CA 1.467 0.404 0 N-CA-C 109.98 -0.378 . . . . 0.0 109.98 -178.9 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' I' I ' 24' ' ' VAL . . . . . 0.468 HG13 ' H ' ' I' ' 25' ' ' GLY . 0.9 OUTLIER 174.61 -79.24 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.544 0.738 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 -179.745 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' I' I ' 25' ' ' GLY . . . . . 0.468 ' H ' HG13 ' I' ' 24' ' ' VAL . . . -37.29 85.87 0.01 OUTLIER Glycine 0 N--CA 1.48 1.63 0 C-N-CA 123.61 0.624 . . . . 0.0 113.229 179.636 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' I' I ' 26' ' ' SER . . . . . 0.44 ' N ' ' O ' ' I' ' 24' ' ' VAL . 87.7 p -40.77 -105.58 0.0 OUTLIER 'General case' 0 N--CA 1.478 0.949 0 N-CA-C 113.6 0.963 . . . . 0.0 113.6 -177.748 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 17.0 p-10 -59.68 110.4 1.13 Allowed 'General case' 0 N--CA 1.473 0.688 0 CA-C-N 118.993 0.815 . . . . 0.0 110.64 -178.754 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 41.6 mttm -93.53 167.53 11.63 Favored 'General case' 0 N--CA 1.469 0.517 0 CA-C-N 115.788 -0.642 . . . . 0.0 109.778 -179.912 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -75.39 -140.21 0.78 Allowed Glycine 0 CA--C 1.525 0.709 0 N-CA-C 106.361 -2.695 . . . . 0.0 106.361 176.289 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -93.65 125.82 38.47 Favored 'General case' 0 N--CA 1.469 0.508 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 176.242 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' I' I ' 31' ' ' ILE . . . . . 0.456 ' O ' ' O ' ' F' ' 30' ' ' ALA . 16.3 tt -149.91 155.24 8.12 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.806 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 179.688 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 27.5 pt -151.3 136.26 10.26 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.413 0 N-CA-C 109.311 -0.626 . . . . 0.0 109.311 -177.468 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -56.55 154.45 16.76 Favored Glycine 0 CA--C 1.526 0.762 0 CA-C-N 116.238 -0.437 . . . . 0.0 112.244 -178.468 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 2.5 pp -75.64 160.78 29.73 Favored 'General case' 0 N--CA 1.467 0.38 0 N-CA-C 109.448 -0.575 . . . . 0.0 109.448 179.338 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 6.5 ttp -104.78 152.32 22.7 Favored 'General case' 0 N--CA 1.48 1.045 0 N-CA-C 109.04 -0.726 . . . . 0.0 109.04 179.417 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 7.4 p -168.87 162.26 0.56 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.529 0 N-CA-C 107.324 -1.362 . . . . 0.0 107.324 179.582 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 54.04 68.95 1.39 Allowed Glycine 0 C--N 1.312 -0.795 0 N-CA-C 111.924 -0.471 . . . . 0.0 111.924 178.801 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 152.37 -178.25 29.67 Favored Glycine 0 N--CA 1.466 0.646 0 N-CA-C 110.525 -1.03 . . . . 0.0 110.525 179.716 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 4.2 t -124.49 138.34 54.29 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.803 0 N-CA-C 107.193 -1.41 . . . . 0.0 107.193 -179.967 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 74.0 t . . . . . 0 N--CA 1.481 1.125 0 CA-C-O 117.719 -1.134 . . . . 0.0 109.822 -177.304 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 15.8 m-20 . . . . . 0 N--CA 1.488 1.472 0 N-CA-C 108.785 -0.821 . . . . 0.0 108.785 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -76.93 129.37 36.08 Favored 'General case' 0 N--CA 1.466 0.345 0 N-CA-C 109.996 -0.372 . . . . 0.0 109.996 -179.864 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 45.0 mt-10 -119.56 107.39 13.22 Favored 'General case' 0 N--CA 1.478 0.937 0 C-N-CA 122.66 0.384 . . . . 0.0 110.25 179.676 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 22.6 m-85 -72.88 172.41 10.91 Favored 'General case' 0 N--CA 1.473 0.705 0 N-CA-C 109.589 -0.523 . . . . 0.0 109.589 179.391 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 87.5 mtt180 -68.87 133.01 47.67 Favored 'General case' 0 N--CA 1.473 0.698 0 CA-C-N 116.612 -0.267 . . . . 0.0 111.101 -178.211 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 6.9 t-160 -98.71 127.77 44.75 Favored 'General case' 0 N--CA 1.474 0.732 0 N-CA-C 109.351 -0.611 . . . . 0.0 109.351 179.347 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' ASP . . . . . 0.447 ' O ' ' OG ' ' D' ' 8' ' ' SER . 4.1 m-20 -72.68 139.89 47.54 Favored 'General case' 0 CA--C 1.538 0.487 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.406 178.545 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 28.0 p -163.24 -168.91 1.84 Allowed 'General case' 0 N--CA 1.481 1.102 0 C-N-CA 122.508 0.323 . . . . 0.0 110.694 179.37 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 105.03 44.39 1.51 Allowed Glycine 0 N--CA 1.483 1.798 0 N-CA-C 111.764 -0.534 . . . . 0.0 111.764 -179.475 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 49.0 p90 -64.11 132.79 51.53 Favored 'General case' 0 N--CA 1.472 0.65 0 O-C-N 122.641 -0.329 . . . . 0.0 111.698 -179.899 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 48.7 mt-10 -90.98 152.34 20.72 Favored 'General case' 0 N--CA 1.477 0.907 0 N-CA-C 109.705 -0.48 . . . . 0.0 109.705 178.37 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -152.98 128.07 1.52 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.655 0 N-CA-C 107.805 -1.183 . . . . 0.0 107.805 178.268 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 46.1 m-70 -135.25 147.4 49.26 Favored 'General case' 0 N--CA 1.492 1.672 0 CA-C-N 119.083 0.856 . . . . 0.0 111.388 -178.965 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 6.5 t60 -164.53 97.39 0.78 Allowed 'General case' 0 N--CA 1.481 1.102 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.733 179.191 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 3.9 pt20 -102.15 -174.12 2.5 Favored 'General case' 0 CA--C 1.509 -0.634 0 N-CA-C 108.654 -0.869 . . . . 0.0 108.654 -179.755 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -169.77 95.68 0.29 Allowed 'General case' 0 N--CA 1.47 0.542 0 CA-C-N 114.565 -1.198 . . . . 0.0 108.345 178.351 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 6.3 mp -123.69 157.04 34.79 Favored 'General case' 0 N--CA 1.498 1.94 0 CA-C-O 121.882 0.848 . . . . 0.0 111.122 -178.151 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 60.2 t -111.92 127.11 69.3 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.099 0 CA-C-O 117.886 -1.054 . . . . 0.0 108.266 177.575 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 26.9 m-85 -126.91 123.05 36.33 Favored 'General case' 0 N--CA 1.497 1.903 0 CA-C-N 120.15 1.341 . . . . 0.0 110.418 179.559 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 66.0 m-85 53.45 74.83 0.29 Allowed 'General case' 0 N--CA 1.469 0.496 0 CA-C-O 121.483 0.659 . . . . 0.0 111.78 178.43 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -79.94 -77.77 0.18 Allowed 'General case' 0 C--N 1.352 0.703 0 CA-C-N 115.044 -0.98 . . . . 0.0 110.319 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 40.8 tt0 -113.96 100.79 8.68 Favored 'General case' 0 N--CA 1.47 0.527 0 N-CA-C 108.247 -1.02 . . . . 0.0 108.247 179.614 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 4.4 p30 -158.53 140.26 13.65 Favored 'General case' 0 N--CA 1.485 1.283 0 O-C-N 122.245 -0.284 . . . . 0.0 111.142 179.079 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 60.4 t -59.72 163.58 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.865 0 N-CA-C 108.042 -1.096 . . . . 0.0 108.042 177.108 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.443 ' H ' ' HB ' ' D' ' 24' ' ' VAL . . . -117.87 47.52 1.02 Allowed Glycine 0 N--CA 1.475 1.299 0 N-CA-C 111.776 -0.53 . . . . 0.0 111.776 -179.372 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -61.19 -168.01 0.01 OUTLIER 'General case' 0 N--CA 1.469 0.479 0 O-C-N 123.762 0.331 . . . . 0.0 110.337 179.529 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 26.6 t-20 -70.59 80.7 0.59 Allowed 'General case' 0 N--CA 1.465 0.277 0 CA-C-N 116.401 -0.363 . . . . 0.0 110.17 179.596 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 97.9 mttt -78.03 143.91 37.09 Favored 'General case' 0 N--CA 1.472 0.642 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 179.216 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.81 -167.27 1.07 Allowed Glycine 0 CA--C 1.524 0.625 0 N-CA-C 109.872 -1.291 . . . . 0.0 109.872 178.737 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.83 114.68 28.03 Favored 'General case' 0 N--CA 1.478 0.971 0 N-CA-C 109.67 -0.493 . . . . 0.0 109.67 179.691 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 66.2 mt -98.45 135.83 31.72 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.608 0 N-CA-C 106.883 -1.525 . . . . 0.0 106.883 179.067 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . 0.412 ' C ' ' H ' ' A' ' 34' ' ' LEU . 40.0 pt -152.44 -176.53 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.354 0.763 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.141 -178.765 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.35 4.85 9.61 Favored Glycine 0 CA--C 1.525 0.694 0 N-CA-C 110.861 -0.896 . . . . 0.0 110.861 179.956 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . 0.412 ' H ' ' C ' ' A' ' 32' ' ' ILE . 1.6 tt -75.07 126.58 31.32 Favored 'General case' 0 CA--C 1.544 0.731 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 -179.614 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 28.0 ttt -163.05 150.33 13.05 Favored 'General case' 0 C--O 1.224 -0.253 0 N-CA-C 109.002 -0.74 . . . . 0.0 109.002 178.73 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 27.9 m -155.78 165.58 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.346 0.447 0 N-CA-C 108.193 -1.04 . . . . 0.0 108.193 179.587 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.92 66.9 2.51 Favored Glycine 0 C--N 1.306 -1.105 0 CA-C-N 115.714 -0.675 . . . . 0.0 112.145 178.693 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.78 -173.12 24.77 Favored Glycine 0 N--CA 1.475 1.276 0 N-CA-C 110.817 -0.913 . . . . 0.0 110.817 179.052 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.403 ' H ' HG11 ' D' ' 39' ' ' VAL . 35.3 m -125.55 157.51 34.83 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.819 0 C-N-CA 123.436 0.694 . . . . 0.0 110.419 -179.863 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 26.2 t . . . . . 0 C--O 1.218 -0.568 0 CA-C-O 118.451 -0.785 . . . . 0.0 110.758 179.775 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' B' B ' 1' ' ' ASP . . . . . . . . . . . . . 15.8 m-20 . . . . . 0 N--CA 1.489 1.52 0 N-CA-C 108.971 -0.752 . . . . 0.0 108.971 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' B' B ' 2' ' ' ALA . . . . . . . . . . . . . . . -76.44 128.66 35.23 Favored 'General case' 0 N--CA 1.466 0.375 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.07 -179.836 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 3' ' ' GLU . . . . . . . . . . . . . 44.6 mt-10 -118.76 107.2 13.36 Favored 'General case' 0 N--CA 1.479 0.987 0 C-N-CA 122.705 0.402 . . . . 0.0 110.277 179.691 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 24.4 m-85 -72.51 172.74 9.97 Favored 'General case' 0 N--CA 1.474 0.737 0 N-CA-C 109.699 -0.482 . . . . 0.0 109.699 179.461 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 87.9 mtt180 -69.06 132.16 46.17 Favored 'General case' 0 N--CA 1.474 0.767 0 CA-C-O 120.631 0.253 . . . . 0.0 110.995 -178.225 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 6.8 t-160 -97.95 127.68 44.05 Favored 'General case' 0 N--CA 1.474 0.751 0 N-CA-C 109.298 -0.631 . . . . 0.0 109.298 179.312 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 7' ' ' ASP . . . . . 0.445 ' O ' ' OG ' ' E' ' 8' ' ' SER . 4.1 m-20 -72.93 139.53 46.84 Favored 'General case' 0 CA--C 1.539 0.544 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.446 178.526 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 8' ' ' SER . . . . . . . . . . . . . 29.2 p -162.56 -168.51 1.84 Allowed 'General case' 0 N--CA 1.481 1.076 0 C-N-CA 122.52 0.328 . . . . 0.0 110.705 179.225 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.63 45.06 1.46 Allowed Glycine 0 N--CA 1.483 1.773 0 N-CA-C 111.732 -0.547 . . . . 0.0 111.732 -179.48 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 49.0 p90 -64.79 132.95 50.94 Favored 'General case' 0 N--CA 1.471 0.607 0 O-C-N 122.662 -0.316 . . . . 0.0 111.684 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 48.7 mt-10 -91.07 152.39 20.65 Favored 'General case' 0 N--CA 1.476 0.873 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 178.293 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -153.06 128.32 1.55 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.638 0 N-CA-C 107.734 -1.21 . . . . 0.0 107.734 178.335 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 45.6 m-70 -135.71 147.42 48.47 Favored 'General case' 0 N--CA 1.493 1.698 0 CA-C-N 118.917 0.78 . . . . 0.0 111.33 -178.958 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 6.5 t60 -164.65 97.33 0.76 Allowed 'General case' 0 N--CA 1.481 1.078 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.586 179.302 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . 0.405 HE22 ' CG2' ' B' ' 36' ' ' VAL . 3.9 pt20 -101.87 -173.68 2.41 Favored 'General case' 0 CA--C 1.51 -0.568 0 N-CA-C 108.639 -0.875 . . . . 0.0 108.639 -179.804 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -170.22 95.63 0.25 Allowed 'General case' 0 N--CA 1.471 0.591 0 CA-C-N 114.63 -1.168 . . . . 0.0 108.259 178.415 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 6.3 mp -123.71 157.05 34.79 Favored 'General case' 0 N--CA 1.497 1.896 0 CA-C-O 121.826 0.822 . . . . 0.0 111.123 -178.113 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 61.8 t -112.31 127.29 69.59 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.074 0 N-CA-C 108.016 -1.105 . . . . 0.0 108.016 177.501 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 27.0 m-85 -127.33 122.86 34.91 Favored 'General case' 0 N--CA 1.495 1.797 0 CA-C-N 119.667 1.121 . . . . 0.0 110.314 179.779 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 66.3 m-85 53.1 74.79 0.28 Allowed 'General case' 0 CA--C 1.539 0.547 0 CA-C-O 121.545 0.688 . . . . 0.0 111.859 178.397 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -79.98 -78.01 0.17 Allowed 'General case' 0 C--N 1.351 0.657 0 CA-C-N 115.016 -0.993 . . . . 0.0 110.278 179.966 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 40.5 tt0 -113.66 100.88 8.81 Favored 'General case' 0 N--CA 1.471 0.594 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 179.569 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 4.4 p30 -158.55 140.88 14.16 Favored 'General case' 0 N--CA 1.484 1.272 0 CA-C-O 119.494 -0.289 . . . . 0.0 111.151 179.021 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 59.0 t -60.13 163.81 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.91 0 N-CA-C 108.116 -1.068 . . . . 0.0 108.116 177.199 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . 0.449 ' H ' ' HB ' ' E' ' 24' ' ' VAL . . . -117.9 47.53 1.02 Allowed Glycine 0 N--CA 1.475 1.276 0 N-CA-C 111.739 -0.544 . . . . 0.0 111.739 -179.397 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -61.18 -167.74 0.01 OUTLIER 'General case' 0 N--CA 1.47 0.545 0 O-C-N 123.651 0.265 . . . . 0.0 110.379 179.396 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 26.9 t-20 -71.1 80.73 0.69 Allowed 'General case' 0 N--CA 1.466 0.348 0 N-CA-C 110.091 -0.337 . . . . 0.0 110.091 179.673 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -78.01 143.92 37.11 Favored 'General case' 0 N--CA 1.472 0.666 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 179.267 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.71 -166.7 0.94 Allowed Glycine 0 CA--C 1.524 0.628 0 N-CA-C 109.895 -1.282 . . . . 0.0 109.895 178.752 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -100.4 114.55 28.2 Favored 'General case' 0 N--CA 1.478 0.958 0 N-CA-C 109.668 -0.493 . . . . 0.0 109.668 179.628 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 65.5 mt -98.26 135.39 33.14 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.556 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 178.965 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . 0.404 ' C ' ' H ' ' B' ' 34' ' ' LEU . 38.1 pt -151.73 -176.51 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.353 0.733 0 CA-C-N 115.962 -0.563 . . . . 0.0 111.151 -178.789 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.37 4.73 9.45 Favored Glycine 0 CA--C 1.525 0.703 0 N-CA-C 110.947 -0.861 . . . . 0.0 110.947 179.833 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 34' ' ' LEU . . . . . 0.404 ' H ' ' C ' ' B' ' 32' ' ' ILE . 1.6 tt -74.95 126.69 31.53 Favored 'General case' 0 CA--C 1.544 0.744 0 N-CA-C 109.37 -0.604 . . . . 0.0 109.37 -179.617 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 27.4 ttt -163.04 150.17 12.96 Favored 'General case' 0 N--CA 1.467 0.378 0 N-CA-C 108.915 -0.772 . . . . 0.0 108.915 178.672 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 36' ' ' VAL . . . . . 0.405 ' CG2' HE22 ' B' ' 15' ' ' GLN . 27.8 m -155.8 165.26 1.15 Allowed 'Isoleucine or valine' 0 C--N 1.347 0.495 0 N-CA-C 108.155 -1.054 . . . . 0.0 108.155 179.6 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.09 67.16 2.36 Favored Glycine 0 C--N 1.307 -1.059 0 CA-C-N 115.674 -0.694 . . . . 0.0 112.098 178.649 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.54 -172.57 24.83 Favored Glycine 0 N--CA 1.476 1.318 0 N-CA-C 110.806 -0.917 . . . . 0.0 110.806 179.046 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 39' ' ' VAL . . . . . 0.422 ' H ' HG11 ' E' ' 39' ' ' VAL . 35.5 m -126.12 157.42 36.27 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.98 0 C-N-CA 123.448 0.699 . . . . 0.0 110.454 -179.651 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 26.0 t . . . . . 0 C--O 1.219 -0.509 0 CA-C-O 118.429 -0.796 . . . . 0.0 110.602 179.664 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' C' C ' 1' ' ' ASP . . . . . . . . . . . . . 14.9 m-20 . . . . . 0 N--CA 1.488 1.436 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' C' C ' 2' ' ' ALA . . . . . . . . . . . . . . . -76.92 128.75 35.11 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.035 -179.889 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 3' ' ' GLU . . . . . . . . . . . . . 45.3 mt-10 -119.03 107.27 13.31 Favored 'General case' 0 N--CA 1.479 0.991 0 C-N-CA 122.69 0.396 . . . . 0.0 110.255 179.713 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 23.9 m-85 -72.63 172.94 9.69 Favored 'General case' 0 N--CA 1.475 0.794 0 N-CA-C 109.683 -0.488 . . . . 0.0 109.683 179.343 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 87.4 mtt180 -69.28 131.91 45.62 Favored 'General case' 0 N--CA 1.477 0.904 0 CA-C-O 120.714 0.292 . . . . 0.0 110.955 -178.236 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 6.8 t-160 -97.79 128.16 44.23 Favored 'General case' 0 N--CA 1.473 0.689 0 N-CA-C 109.262 -0.644 . . . . 0.0 109.262 179.215 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 7' ' ' ASP . . . . . 0.443 ' O ' ' OG ' ' F' ' 8' ' ' SER . 4.1 m-20 -73.33 139.77 46.26 Favored 'General case' 0 CA--C 1.538 0.49 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.428 178.583 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 8' ' ' SER . . . . . . . . . . . . . 29.8 p -162.99 -168.71 1.83 Allowed 'General case' 0 N--CA 1.481 1.092 0 CA-C-O 120.828 0.347 . . . . 0.0 110.671 179.249 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.92 44.25 1.54 Allowed Glycine 0 N--CA 1.483 1.798 0 N-CA-C 111.759 -0.537 . . . . 0.0 111.759 -179.498 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 49.3 p90 -64.21 133.29 52.56 Favored 'General case' 0 N--CA 1.472 0.667 0 O-C-N 122.672 -0.311 . . . . 0.0 111.687 -179.935 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 48.3 mt-10 -91.4 152.28 20.47 Favored 'General case' 0 N--CA 1.476 0.858 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 178.356 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -152.83 128.15 1.59 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.598 0 N-CA-C 107.814 -1.18 . . . . 0.0 107.814 178.327 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 45.4 m-70 -135.43 147.69 49.05 Favored 'General case' 0 N--CA 1.493 1.695 0 CA-C-N 118.948 0.794 . . . . 0.0 111.306 -178.969 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 6.5 t60 -164.85 97.31 0.74 Allowed 'General case' 0 N--CA 1.481 1.101 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.646 179.293 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 3.9 pt20 -102.05 -173.85 2.44 Favored 'General case' 0 CA--C 1.508 -0.645 0 N-CA-C 108.606 -0.887 . . . . 0.0 108.606 -179.735 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -170.06 95.81 0.27 Allowed 'General case' 0 N--CA 1.468 0.47 0 CA-C-N 114.623 -1.171 . . . . 0.0 108.292 178.298 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 6.4 mp -123.73 157.17 34.58 Favored 'General case' 0 N--CA 1.497 1.899 0 CA-C-O 121.808 0.813 . . . . 0.0 111.189 -178.194 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 61.7 t -112.32 127.63 69.41 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.057 0 N-CA-C 108.111 -1.07 . . . . 0.0 108.111 177.516 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 27.4 m-85 -127.58 122.77 34.09 Favored 'General case' 0 N--CA 1.493 1.723 0 CA-C-N 119.688 1.131 . . . . 0.0 110.305 179.861 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 66.6 m-85 53.28 74.77 0.28 Allowed 'General case' 0 CA--C 1.538 0.492 0 CA-C-O 121.488 0.661 . . . . 0.0 111.851 178.304 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -79.96 -78.23 0.17 Allowed 'General case' 0 C--N 1.35 0.621 0 CA-C-N 115.008 -0.996 . . . . 0.0 110.291 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 40.1 tt0 -113.58 100.66 8.67 Favored 'General case' 0 N--CA 1.471 0.591 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 179.629 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 4.4 p30 -158.29 140.41 14.09 Favored 'General case' 0 N--CA 1.484 1.229 0 O-C-N 122.264 -0.272 . . . . 0.0 111.117 179.183 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 59.4 t -59.88 163.51 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.868 0 N-CA-C 108.072 -1.084 . . . . 0.0 108.072 177.096 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 25' ' ' GLY . . . . . 0.426 ' H ' ' HB ' ' F' ' 24' ' ' VAL . . . -117.79 47.94 0.99 Allowed Glycine 0 N--CA 1.478 1.492 0 N-CA-C 111.597 -0.601 . . . . 0.0 111.597 -179.314 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -61.59 -168.18 0.01 OUTLIER 'General case' 0 N--CA 1.469 0.487 0 N-CA-C 110.268 -0.271 . . . . 0.0 110.268 179.447 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 26.7 t-20 -70.51 80.99 0.57 Allowed 'General case' 0 N--CA 1.466 0.332 0 N-CA-C 110.026 -0.361 . . . . 0.0 110.026 179.595 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -78.3 143.76 36.7 Favored 'General case' 0 N--CA 1.472 0.66 0 N-CA-C 109.089 -0.708 . . . . 0.0 109.089 179.312 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.45 -167.34 0.95 Allowed Glycine 0 CA--C 1.525 0.672 0 N-CA-C 109.937 -1.265 . . . . 0.0 109.937 178.689 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.86 113.97 26.86 Favored 'General case' 0 N--CA 1.48 1.028 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 179.657 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 66.0 mt -97.88 135.57 31.92 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.557 0 N-CA-C 106.942 -1.503 . . . . 0.0 106.942 178.992 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 32' ' ' ILE . . . . . 0.414 ' C ' ' H ' ' C' ' 34' ' ' LEU . 38.8 pt -152.01 -176.42 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.354 0.768 0 CA-C-N 115.902 -0.59 . . . . 0.0 111.122 -178.791 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.45 4.52 9.36 Favored Glycine 0 CA--C 1.525 0.717 0 N-CA-C 110.907 -0.877 . . . . 0.0 110.907 179.882 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 34' ' ' LEU . . . . . 0.414 ' H ' ' C ' ' C' ' 32' ' ' ILE . 1.6 tt -74.75 126.34 30.68 Favored 'General case' 0 CA--C 1.543 0.692 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 -179.619 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 27.5 ttt -162.57 150.36 13.97 Favored 'General case' 0 N--CA 1.466 0.349 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 178.763 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 27.6 m -156.09 165.22 1.12 Allowed 'Isoleucine or valine' 0 C--N 1.347 0.48 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 179.543 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.14 66.74 2.63 Favored Glycine 0 C--N 1.306 -1.106 0 CA-C-N 115.721 -0.672 . . . . 0.0 112.072 178.548 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.84 -172.47 25.06 Favored Glycine 0 N--CA 1.476 1.308 0 N-CA-C 110.813 -0.915 . . . . 0.0 110.813 178.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 39' ' ' VAL . . . . . 0.411 ' H ' HG11 ' F' ' 39' ' ' VAL . 35.6 m -126.21 157.66 36.36 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.892 0 C-N-CA 123.429 0.692 . . . . 0.0 110.421 -179.667 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 27.2 t . . . . . 0 C--O 1.219 -0.512 0 CA-C-O 118.43 -0.795 . . . . 0.0 110.526 179.722 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' D' D ' 1' ' ' ASP . . . . . . . . . . . . . 14.8 m-20 . . . . . 0 N--CA 1.488 1.443 0 N-CA-C 109.228 -0.656 . . . . 0.0 109.228 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' D' D ' 2' ' ' ALA . . . . . . . . . . . . . . . -77.28 129.8 36.36 Favored 'General case' 0 C--O 1.239 0.506 0 N-CA-C 109.726 -0.472 . . . . 0.0 109.726 -179.568 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 3' ' ' GLU . . . . . . . . . . . . . 44.1 mt-10 -119.6 110.66 17.12 Favored 'General case' 0 C--O 1.208 -1.083 0 N-CA-C 109.523 -0.547 . . . . 0.0 109.523 -179.492 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 26.7 m-85 -77.33 166.98 22.46 Favored 'General case' 0 N--CA 1.485 1.276 0 C-N-CA 126.7 2.0 . . . . 0.0 108.304 -179.52 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 5' ' ' ARG . . . . . . . . . . . . 0.314 94.1 mtt180 -77.63 134.01 38.29 Favored 'General case' 0 N--CA 1.483 1.179 0 CA-C-O 123.01 1.386 . . . . 0.0 107.946 -169.394 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 6.2 t-160 -95.14 130.81 41.71 Favored 'General case' 0 C--N 1.364 1.231 0 CA-C-N 113.53 -1.668 . . . . 0.0 108.662 -177.259 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 7' ' ' ASP . . . . . 0.502 ' O ' ' OG ' ' G' ' 8' ' ' SER . 2.8 m-20 -66.29 125.44 25.59 Favored 'General case' 0 C--N 1.309 -1.161 0 C-N-CA 126.841 2.056 . . . . 0.0 114.989 173.304 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 8' ' ' SER . . . . . 0.447 ' OG ' ' O ' ' A' ' 7' ' ' ASP . 27.6 p -153.35 -167.15 2.62 Favored 'General case' 0 N--CA 1.488 1.458 0 CA-C-N 120.187 1.358 . . . . 0.0 110.962 176.868 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.78 47.15 1.2 Allowed Glycine 0 N--CA 1.484 1.897 0 C-N-CA 124.797 1.189 . . . . 0.0 110.741 176.961 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 51.0 p90 -60.79 131.66 51.41 Favored 'General case' 0 N--CA 1.47 0.553 0 N-CA-C 112.838 0.681 . . . . 0.0 112.838 177.657 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 48.5 mt-10 -88.6 150.95 22.78 Favored 'General case' 0 N--CA 1.48 1.067 0 CA-C-N 117.862 0.301 . . . . 0.0 110.591 175.553 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -149.5 129.9 4.3 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.609 0 N-CA-C 107.377 -1.342 . . . . 0.0 107.377 173.464 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 42.4 m-70 -129.96 150.69 51.13 Favored 'General case' 0 N--CA 1.483 1.176 0 N-CA-C 112.05 0.389 . . . . 0.0 112.05 176.757 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 6.6 t60 -165.04 104.37 0.77 Allowed 'General case' 0 N--CA 1.483 1.194 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 172.32 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 3.9 pt20 -105.48 -176.17 3.0 Favored 'General case' 0 CA--C 1.501 -0.908 0 N-CA-C 108.491 -0.929 . . . . 0.0 108.491 179.243 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -166.03 104.59 0.67 Allowed 'General case' 0 N--CA 1.466 0.327 0 N-CA-C 106.064 -1.828 . . . . 0.0 106.064 174.26 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 5.4 mp -130.87 153.86 48.68 Favored 'General case' 0 N--CA 1.499 1.988 0 CA-C-O 122.188 0.994 . . . . 0.0 110.604 179.563 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 35.8 t -101.29 131.79 48.35 Favored 'Isoleucine or valine' 0 C--O 1.259 1.57 0 CA-C-O 116.884 -1.531 . . . . 0.0 109.563 174.11 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 25.0 m-85 -130.45 126.3 36.62 Favored 'General case' 0 N--CA 1.49 1.544 0 CA-C-N 120.063 1.302 . . . . 0.0 109.591 173.9 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 66.3 m-85 55.65 71.69 0.53 Allowed 'General case' 0 C--N 1.348 0.535 0 CA-C-N 115.618 -0.719 . . . . 0.0 111.521 175.989 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -81.92 -73.03 0.41 Allowed 'General case' 0 C--N 1.35 0.607 0 CA-C-O 118.478 -0.772 . . . . 0.0 110.988 -177.647 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 40.9 tt0 -117.0 104.62 11.45 Favored 'General case' 0 N--CA 1.482 1.14 0 N-CA-C 106.404 -1.702 . . . . 0.0 106.404 176.32 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -152.06 140.43 20.51 Favored 'General case' 0 N--CA 1.476 0.865 0 CA-C-O 116.797 -1.573 . . . . 0.0 113.494 177.995 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 24' ' ' VAL . . . . . 0.443 ' HB ' ' H ' ' A' ' 25' ' ' GLY . 79.3 t -62.53 165.93 1.01 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.282 0 CA-C-N 121.063 1.756 . . . . 0.0 108.013 175.027 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 25' ' ' GLY . . . . . 0.465 ' H ' ' HB ' ' G' ' 24' ' ' VAL . . . -116.92 51.15 0.74 Allowed Glycine 0 N--CA 1.479 1.508 0 CA-C-O 119.003 -0.887 . . . . 0.0 111.78 178.196 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -57.72 -170.71 0.01 OUTLIER 'General case' 0 C--N 1.32 -0.689 0 C-N-CA 123.563 0.745 . . . . 0.0 111.643 176.042 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 28.2 t-20 -72.73 86.62 1.24 Allowed 'General case' 0 C--N 1.346 0.435 0 N-CA-C 108.421 -0.955 . . . . 0.0 108.421 177.952 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 97.4 mttt -83.27 146.21 28.67 Favored 'General case' 0 C--N 1.352 0.708 0 N-CA-C 108.063 -1.088 . . . . 0.0 108.063 179.138 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -62.8 -164.98 0.5 Allowed Glycine 0 C--N 1.337 0.592 0 N-CA-C 110.626 -0.99 . . . . 0.0 110.626 179.1 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -102.38 116.13 32.0 Favored 'General case' 0 N--CA 1.47 0.533 0 N-CA-C 109.155 -0.683 . . . . 0.0 109.155 179.394 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 73.9 mt -102.68 142.59 16.5 Favored 'Isoleucine or valine' 0 C--N 1.356 0.867 0 N-CA-C 104.505 -2.406 . . . . 0.0 104.505 -179.917 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 39.4 pt -158.25 -177.39 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.126 0 CA-C-O 120.939 0.4 . . . . 0.0 110.186 -177.075 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 64.32 4.64 13.06 Favored Glycine 0 C--O 1.241 0.562 0 N-CA-C 110.132 -1.187 . . . . 0.0 110.132 -178.828 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 2.1 tt -77.52 133.39 38.55 Favored 'General case' 0 C--N 1.369 1.438 0 C-N-CA 117.944 -1.502 . . . . 0.0 107.155 -177.801 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 27.9 ttt -158.3 161.48 37.67 Favored 'General case' 0 CA--C 1.509 -0.62 0 CA-C-O 118.213 -0.899 . . . . 0.0 108.858 173.574 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 27.7 m -164.63 164.36 0.66 Allowed 'Isoleucine or valine' 0 CA--C 1.517 -0.319 0 N-CA-C 108.064 -1.088 . . . . 0.0 108.064 175.62 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 60.18 64.05 4.5 Favored Glycine 0 C--N 1.313 -0.706 0 C-N-CA 119.759 -1.21 . . . . 0.0 112.883 178.318 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 140.68 -171.27 24.12 Favored Glycine 0 N--CA 1.48 1.581 0 CA-C-N 117.319 0.559 . . . . 0.0 111.769 -179.221 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 39' ' ' VAL . . . . . 0.413 ' H ' HG11 ' G' ' 39' ' ' VAL . 34.9 m -128.37 154.81 39.6 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.851 0 C-N-CA 122.716 0.406 . . . . 0.0 110.146 -176.877 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 25.3 t . . . . . 0 C--N 1.332 -0.16 0 CA-C-O 116.657 -1.64 . . . . 0.0 110.051 178.19 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' E' E ' 1' ' ' ASP . . . . . . . . . . . . . 14.1 m-20 . . . . . 0 N--CA 1.491 1.603 0 N-CA-C 109.365 -0.605 . . . . 0.0 109.365 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' E' E ' 2' ' ' ALA . . . . . . . . . . . . . . . -77.18 128.23 34.04 Favored 'General case' 0 N--CA 1.469 0.515 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.004 -179.732 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 3' ' ' GLU . . . . . . . . . . . . . 44.0 mt-10 -117.45 106.66 13.42 Favored 'General case' 0 N--CA 1.482 1.137 0 C-N-CA 122.312 0.245 . . . . 0.0 110.543 -179.806 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 24.0 m-85 -70.46 172.61 8.12 Favored 'General case' 0 N--CA 1.475 0.794 0 N-CA-C 109.962 -0.384 . . . . 0.0 109.962 179.322 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 5' ' ' ARG . . . . . . . . . . . . . 86.2 mtt180 -68.94 131.89 45.82 Favored 'General case' 0 N--CA 1.475 0.804 0 CA-C-N 116.423 -0.353 . . . . 0.0 111.153 -178.36 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 6.5 t-160 -97.66 129.03 44.77 Favored 'General case' 0 N--CA 1.475 0.789 0 N-CA-C 109.194 -0.669 . . . . 0.0 109.194 179.08 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 7' ' ' ASP . . . . . 0.44 ' O ' ' OG ' ' H' ' 8' ' ' SER . 4.2 m-20 -74.42 139.91 44.33 Favored 'General case' 0 N--CA 1.468 0.445 0 CA-C-N 116.513 -0.312 . . . . 0.0 110.531 178.725 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' E' E ' 8' ' ' SER . . . . . 0.445 ' OG ' ' O ' ' B' ' 7' ' ' ASP . 24.8 p -163.68 -168.25 1.6 Allowed 'General case' 0 N--CA 1.485 1.301 0 CA-C-O 120.888 0.375 . . . . 0.0 110.886 178.922 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 105.57 44.84 1.39 Allowed Glycine 0 N--CA 1.482 1.732 0 N-CA-C 111.485 -0.646 . . . . 0.0 111.485 -179.682 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 47.0 p90 -63.84 133.45 53.4 Favored 'General case' 0 N--CA 1.475 0.783 0 N-CA-C 112.02 0.378 . . . . 0.0 112.02 -179.806 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 47.2 mt-10 -90.73 152.39 20.84 Favored 'General case' 0 N--CA 1.48 1.036 0 CA-C-O 121.111 0.481 . . . . 0.0 109.747 177.777 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -154.09 127.44 1.19 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.574 0 N-CA-C 107.795 -1.187 . . . . 0.0 107.795 178.003 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 45.0 m-70 -135.74 146.38 47.61 Favored 'General case' 0 N--CA 1.483 1.215 0 CA-C-O 120.869 0.366 . . . . 0.0 111.542 -178.025 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 6.5 t60 -164.32 97.15 0.79 Allowed 'General case' 0 N--CA 1.486 1.344 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.592 179.459 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 15' ' ' GLN . . . . . 0.421 HE22 ' CG2' ' E' ' 36' ' ' VAL . 3.9 pt20 -101.4 -173.83 2.46 Favored 'General case' 0 CA--C 1.51 -0.588 0 N-CA-C 108.924 -0.769 . . . . 0.0 108.924 -179.728 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -169.77 94.67 0.27 Allowed 'General case' 0 N--CA 1.472 0.647 0 CA-C-N 114.774 -1.103 . . . . 0.0 108.464 178.347 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 6.2 mp -122.4 156.72 33.41 Favored 'General case' 0 N--CA 1.495 1.787 0 CA-C-O 121.698 0.761 . . . . 0.0 111.641 -177.546 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 48.3 t -113.88 124.36 70.46 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.232 0 N-CA-C 108.212 -1.033 . . . . 0.0 108.212 177.245 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 29.8 m-85 -124.83 121.97 36.07 Favored 'General case' 0 N--CA 1.489 1.524 0 CA-C-O 120.907 0.384 . . . . 0.0 110.974 -179.563 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 67.2 m-85 54.47 73.57 0.39 Allowed 'General case' 0 N--CA 1.469 0.476 0 CA-C-N 115.892 -0.594 . . . . 0.0 111.53 177.931 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -78.27 -78.46 0.14 Allowed 'General case' 0 CA--C 1.535 0.377 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.258 -179.711 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 40.9 tt0 -113.02 101.56 9.58 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 108.319 -0.993 . . . . 0.0 108.319 179.683 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -158.15 140.58 14.41 Favored 'General case' 0 C--O 1.205 -1.285 0 CA-C-O 119.488 -0.292 . . . . 0.0 111.481 179.17 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 24' ' ' VAL . . . . . 0.449 ' HB ' ' H ' ' B' ' 25' ' ' GLY . 63.3 t -58.7 168.46 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.973 0 N-CA-C 107.629 -1.248 . . . . 0.0 107.629 177.034 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' E' E ' 25' ' ' GLY . . . . . 0.406 ' H ' ' HB ' ' H' ' 24' ' ' VAL . . . -122.57 47.68 1.0 Allowed Glycine 0 N--CA 1.475 1.264 0 N-CA-C 110.931 -0.867 . . . . 0.0 110.931 -179.347 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -61.81 -167.48 0.01 OUTLIER 'General case' 0 N--CA 1.47 0.548 0 CA-C-O 120.704 0.288 . . . . 0.0 110.469 179.808 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 27.2 t-20 -70.68 77.85 0.6 Allowed 'General case' 0 N--CA 1.467 0.377 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.393 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -75.48 144.56 42.0 Favored 'General case' 0 N--CA 1.475 0.817 0 N-CA-C 109.567 -0.531 . . . . 0.0 109.567 179.331 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.46 -166.4 1.14 Allowed Glycine 0 CA--C 1.522 0.474 0 N-CA-C 110.421 -1.072 . . . . 0.0 110.421 178.629 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -100.08 113.36 25.92 Favored 'General case' 0 N--CA 1.468 0.443 0 N-CA-C 109.961 -0.385 . . . . 0.0 109.961 179.659 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 66.3 mt -97.36 135.28 32.2 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.443 0 N-CA-C 106.752 -1.573 . . . . 0.0 106.752 179.146 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 32' ' ' ILE . . . . . 0.402 ' C ' ' H ' ' E' ' 34' ' ' LEU . 39.2 pt -151.74 -174.73 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.123 0 CA-C-O 121.165 0.507 . . . . 0.0 110.682 -179.072 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.5 5.66 6.97 Favored Glycine 0 CA--C 1.53 1.03 0 CA-C-N 115.504 -0.771 . . . . 0.0 111.34 -179.674 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 34' ' ' LEU . . . . . 0.402 ' H ' ' C ' ' E' ' 32' ' ' ILE . 1.7 tt -74.86 126.62 31.34 Favored 'General case' 0 CA--C 1.545 0.787 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 -179.613 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 28.2 ttt -162.14 151.11 15.41 Favored 'General case' 0 C--O 1.203 -1.348 0 N-CA-C 108.972 -0.751 . . . . 0.0 108.972 178.776 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 36' ' ' VAL . . . . . 0.421 ' CG2' HE22 ' E' ' 15' ' ' GLN . 32.9 m -157.04 165.22 1.01 Allowed 'Isoleucine or valine' 0 C--N 1.343 0.287 0 N-CA-C 108.434 -0.95 . . . . 0.0 108.434 179.596 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.61 67.08 2.39 Favored Glycine 0 C--N 1.306 -1.096 0 CA-C-N 115.762 -0.654 . . . . 0.0 111.95 178.774 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.88 -172.48 25.08 Favored Glycine 0 N--CA 1.476 1.362 0 N-CA-C 111.16 -0.776 . . . . 0.0 111.16 179.034 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 39' ' ' VAL . . . . . 0.438 ' H ' HG11 ' H' ' 39' ' ' VAL . 33.4 m -126.29 156.78 36.86 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.703 0 C-N-CA 123.452 0.701 . . . . 0.0 110.682 -179.402 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 26.1 t . . . . . 0 C--O 1.218 -0.56 0 CA-C-O 118.451 -0.785 . . . . 0.0 110.701 179.525 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' F' F ' 1' ' ' ASP . . . . . . . . . . . . . 14.9 m-20 . . . . . 0 N--CA 1.489 1.519 0 N-CA-C 109.263 -0.643 . . . . 0.0 109.263 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' F' F ' 2' ' ' ALA . . . . . . . . . . . . . . . -76.63 129.0 35.78 Favored 'General case' 0 N--CA 1.469 0.516 0 CA-C-N 116.298 -0.41 . . . . 0.0 109.984 -179.73 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 3' ' ' GLU . . . . . . . . . . . . . 43.9 mt-10 -118.33 106.81 13.15 Favored 'General case' 0 N--CA 1.483 1.189 0 N-CA-C 110.402 -0.222 . . . . 0.0 110.402 -179.78 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 24.0 m-85 -70.67 172.57 8.44 Favored 'General case' 0 N--CA 1.474 0.754 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 179.348 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 5' ' ' ARG . . . . . . . . . . . . . 87.2 mtt180 -69.0 132.66 47.02 Favored 'General case' 0 C--O 1.217 -0.634 0 CA-C-N 116.419 -0.355 . . . . 0.0 111.289 -178.244 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 6.6 t-160 -98.31 128.69 44.86 Favored 'General case' 0 N--CA 1.477 0.889 0 N-CA-C 109.323 -0.621 . . . . 0.0 109.323 179.31 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 7' ' ' ASP . . . . . 0.43 ' O ' ' OG ' ' I' ' 8' ' ' SER . 4.3 m-20 -74.1 139.54 44.66 Favored 'General case' 0 N--CA 1.467 0.42 0 CA-C-N 116.542 -0.299 . . . . 0.0 110.662 178.678 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' F' F ' 8' ' ' SER . . . . . 0.443 ' OG ' ' O ' ' C' ' 7' ' ' ASP . 24.7 p -163.6 -168.33 1.63 Allowed 'General case' 0 N--CA 1.486 1.327 0 CA-C-O 120.963 0.411 . . . . 0.0 110.945 178.905 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 105.7 44.84 1.37 Allowed Glycine 0 N--CA 1.482 1.745 0 N-CA-C 111.459 -0.656 . . . . 0.0 111.459 -179.729 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 46.2 p90 -63.67 133.72 54.13 Favored 'General case' 0 CA--C 1.543 0.707 0 N-CA-C 112.094 0.405 . . . . 0.0 112.094 -179.639 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 47.2 mt-10 -90.89 152.24 20.82 Favored 'General case' 0 N--CA 1.481 1.085 0 CA-C-O 121.172 0.51 . . . . 0.0 109.74 177.794 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -153.92 127.19 1.18 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.601 0 N-CA-C 107.776 -1.194 . . . . 0.0 107.776 178.034 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 44.3 m-70 -135.53 145.93 47.54 Favored 'General case' 0 N--CA 1.484 1.232 0 CA-C-O 120.796 0.331 . . . . 0.0 111.635 -177.959 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 6.6 t60 -163.94 97.26 0.83 Allowed 'General case' 0 N--CA 1.486 1.335 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.697 179.442 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 15' ' ' GLN . . . . . 0.415 HE22 ' CG2' ' F' ' 36' ' ' VAL . 3.9 pt20 -101.68 -173.96 2.48 Favored 'General case' 0 CA--C 1.507 -0.698 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 -179.711 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -169.5 94.71 0.29 Allowed 'General case' 0 N--CA 1.471 0.597 0 CA-C-N 114.633 -1.167 . . . . 0.0 108.424 178.357 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 6.3 mp -122.16 156.84 32.83 Favored 'General case' 0 N--CA 1.495 1.817 0 CA-C-O 121.628 0.728 . . . . 0.0 111.623 -177.687 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 48.6 t -113.94 124.35 70.51 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.181 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 177.185 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 29.8 m-85 -124.72 121.69 35.37 Favored 'General case' 0 N--CA 1.489 1.49 0 CA-C-O 120.888 0.375 . . . . 0.0 110.984 -179.57 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 67.3 m-85 54.41 74.08 0.36 Allowed 'General case' 0 C--N 1.344 0.353 0 CA-C-N 115.917 -0.583 . . . . 0.0 111.68 178.032 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -78.4 -78.42 0.14 Allowed 'General case' 0 CA--C 1.535 0.375 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.282 -179.707 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 40.8 tt0 -113.19 101.39 9.38 Favored 'General case' 0 C--N 1.325 -0.477 0 N-CA-C 108.312 -0.996 . . . . 0.0 108.312 179.777 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -158.08 140.52 14.45 Favored 'General case' 0 C--O 1.204 -1.308 0 CA-C-O 119.537 -0.268 . . . . 0.0 111.419 179.045 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 24' ' ' VAL . . . . . 0.426 ' HB ' ' H ' ' C' ' 25' ' ' GLY . 60.6 t -58.61 168.61 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.962 0 N-CA-C 107.644 -1.243 . . . . 0.0 107.644 177.047 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' F' F ' 25' ' ' GLY . . . . . 0.409 ' H ' ' HB ' ' I' ' 24' ' ' VAL . . . -122.71 48.07 0.98 Allowed Glycine 0 N--CA 1.477 1.381 0 N-CA-C 110.822 -0.911 . . . . 0.0 110.822 -179.398 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -62.24 -167.63 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.559 0 CA-C-O 120.75 0.309 . . . . 0.0 110.417 179.807 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 27.2 t-20 -70.16 77.54 0.51 Allowed 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.432 -179.936 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -75.49 144.18 42.17 Favored 'General case' 0 N--CA 1.475 0.814 0 N-CA-C 109.551 -0.537 . . . . 0.0 109.551 179.489 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.14 -166.58 1.07 Allowed Glycine 0 CA--C 1.522 0.512 0 N-CA-C 110.55 -1.02 . . . . 0.0 110.55 178.596 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.72 113.69 26.33 Favored 'General case' 0 N--CA 1.471 0.589 0 N-CA-C 109.879 -0.415 . . . . 0.0 109.879 179.649 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 66.2 mt -97.85 135.22 33.15 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.43 0 N-CA-C 106.796 -1.557 . . . . 0.0 106.796 179.058 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 32' ' ' ILE . . . . . 0.409 ' C ' ' H ' ' F' ' 34' ' ' LEU . 39.7 pt -151.65 -174.43 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.136 0 CA-C-O 121.208 0.527 . . . . 0.0 110.64 -179.049 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.11 6.0 6.59 Favored Glycine 0 CA--C 1.53 0.97 0 CA-C-N 115.426 -0.806 . . . . 0.0 111.345 -179.778 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 34' ' ' LEU . . . . . 0.409 ' H ' ' C ' ' F' ' 32' ' ' ILE . 1.7 tt -75.43 127.28 32.76 Favored 'General case' 0 N--CA 1.475 0.783 0 N-CA-C 109.31 -0.626 . . . . 0.0 109.31 -179.5 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 28.2 ttt -163.18 152.02 14.45 Favored 'General case' 0 C--O 1.204 -1.306 0 N-CA-C 109.203 -0.665 . . . . 0.0 109.203 178.437 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 36' ' ' VAL . . . . . 0.415 ' CG2' HE22 ' F' ' 15' ' ' GLN . 32.6 m -157.21 165.69 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.342 0.26 0 N-CA-C 108.408 -0.96 . . . . 0.0 108.408 179.897 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.34 67.41 2.22 Favored Glycine 0 C--N 1.307 -1.081 0 CA-C-N 115.717 -0.674 . . . . 0.0 111.979 178.56 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.33 -172.33 24.78 Favored Glycine 0 N--CA 1.477 1.378 0 N-CA-C 111.084 -0.807 . . . . 0.0 111.084 178.992 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 39' ' ' VAL . . . . . 0.437 ' H ' HG11 ' I' ' 39' ' ' VAL . 33.3 m -126.39 157.01 37.17 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.685 0 C-N-CA 123.425 0.69 . . . . 0.0 110.688 -179.285 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 26.0 t . . . . . 0 C--O 1.22 -0.496 0 O-C-N 124.017 0.823 . . . . 0.0 110.599 179.358 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' G' G ' 1' ' ' ASP . . . . . . . . . . . . . 14.2 m-20 . . . . . 0 N--CA 1.491 1.608 0 N-CA-C 109.376 -0.602 . . . . 0.0 109.376 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' G' G ' 2' ' ' ALA . . . . . . . . . . . . . . . -76.54 130.3 37.71 Favored 'General case' 0 N--CA 1.473 0.705 0 CA-C-N 116.268 -0.424 . . . . 0.0 109.956 -179.858 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 3' ' ' GLU . . . . . . . . . . . . . 41.3 mt-10 -118.22 108.54 15.27 Favored 'General case' 0 N--CA 1.485 1.297 0 C-N-CA 122.203 0.201 . . . . 0.0 110.498 -179.517 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 29.4 m-85 -70.69 170.41 12.41 Favored 'General case' 0 N--CA 1.476 0.851 0 C-N-CA 122.71 0.404 . . . . 0.0 109.936 179.298 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 5' ' ' ARG . . . . . . . . . . . . . 86.5 mtt180 -67.53 132.18 47.07 Favored 'General case' 0 N--CA 1.473 0.723 0 CA-C-N 116.33 -0.396 . . . . 0.0 110.846 -178.615 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 6.4 t-160 -98.27 129.92 44.98 Favored 'General case' 0 N--CA 1.474 0.761 0 N-CA-C 109.415 -0.587 . . . . 0.0 109.415 179.108 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -75.92 135.73 40.09 Favored 'General case' 0 N--CA 1.47 0.554 0 C-N-CA 122.714 0.406 . . . . 0.0 111.097 179.006 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 8' ' ' SER . . . . . 0.502 ' OG ' ' O ' ' D' ' 7' ' ' ASP . 24.7 p -160.11 -166.23 1.65 Allowed 'General case' 0 N--CA 1.477 0.903 0 CA-C-O 120.971 0.415 . . . . 0.0 110.512 178.73 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.42 45.51 1.43 Allowed Glycine 0 N--CA 1.481 1.684 0 N-CA-C 111.211 -0.756 . . . . 0.0 111.211 179.866 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 48.9 p90 -64.59 133.43 52.28 Favored 'General case' 0 CA--C 1.542 0.641 0 N-CA-C 111.91 0.337 . . . . 0.0 111.91 -179.562 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 49.4 mt-10 -90.97 151.76 20.96 Favored 'General case' 0 N--CA 1.479 1.018 0 CA-C-O 121.006 0.432 . . . . 0.0 110.036 178.41 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -154.82 127.53 1.08 Allowed 'Isoleucine or valine' 0 CA--C 1.553 1.088 0 N-CA-C 107.845 -1.169 . . . . 0.0 107.845 178.359 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 46.0 m-70 -135.23 147.11 49.21 Favored 'General case' 0 N--CA 1.478 0.934 0 CA-C-N 115.433 -0.803 . . . . 0.0 111.471 -178.135 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 6.6 t60 -165.22 97.63 0.71 Allowed 'General case' 0 N--CA 1.483 1.22 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.214 178.82 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 3.9 pt20 -102.06 -173.81 2.43 Favored 'General case' 0 CA--C 1.507 -0.678 0 N-CA-C 108.688 -0.856 . . . . 0.0 108.688 -179.595 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -170.32 94.37 0.23 Allowed 'General case' 0 N--CA 1.471 0.624 0 CA-C-N 114.663 -1.153 . . . . 0.0 108.224 178.54 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 6.3 mp -121.86 155.94 34.32 Favored 'General case' 0 N--CA 1.498 1.935 0 CA-C-O 121.298 0.571 . . . . 0.0 111.881 -177.812 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 43.2 t -113.63 124.53 70.36 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.013 0 CA-C-N 114.746 -1.115 . . . . 0.0 108.156 176.617 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 31.5 m-85 -125.13 121.76 35.16 Favored 'General case' 0 C--N 1.366 1.314 0 C-N-CA 123.358 0.663 . . . . 0.0 111.01 -179.324 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 66.7 m-85 54.4 73.43 0.4 Allowed 'General case' 0 N--CA 1.467 0.407 0 CA-C-N 115.865 -0.607 . . . . 0.0 111.532 177.898 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.49 -77.86 0.14 Allowed 'General case' 0 N--CA 1.473 0.682 0 O-C-N 122.296 -0.252 . . . . 0.0 110.451 -179.426 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 40.9 tt0 -113.59 101.61 9.49 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 108.048 -1.093 . . . . 0.0 108.048 179.806 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -158.25 141.65 15.18 Favored 'General case' 0 N--CA 1.478 0.964 0 O-C-N 122.368 -0.207 . . . . 0.0 111.438 179.067 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 24' ' ' VAL . . . . . 0.465 ' HB ' ' H ' ' D' ' 25' ' ' GLY . 58.8 t -60.23 167.12 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.637 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 177.338 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -120.71 48.51 0.94 Allowed Glycine 0 N--CA 1.481 1.662 0 N-CA-C 110.548 -1.021 . . . . 0.0 110.548 -179.499 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -62.93 -167.73 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.648 0 CA-C-N 117.03 0.415 . . . . 0.0 109.943 179.825 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 27.6 t-20 -70.28 77.2 0.54 Allowed 'General case' 0 CA--C 1.536 0.413 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.456 -179.979 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 97.9 mttt -74.29 144.23 44.66 Favored 'General case' 0 N--CA 1.475 0.807 0 N-CA-C 109.642 -0.503 . . . . 0.0 109.642 179.292 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.56 -164.98 0.92 Allowed Glycine 0 C--N 1.337 0.609 0 N-CA-C 110.061 -1.216 . . . . 0.0 110.061 178.623 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -100.03 113.48 26.11 Favored 'General case' 0 N--CA 1.469 0.52 0 C-N-CA 122.737 0.415 . . . . 0.0 110.577 179.865 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 67.6 mt -98.33 135.51 32.81 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.838 0 N-CA-C 106.827 -1.546 . . . . 0.0 106.827 179.062 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 32' ' ' ILE . . . . . 0.413 ' C ' ' H ' ' G' ' 34' ' ' LEU . 39.6 pt -152.27 -174.32 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.725 0 CA-C-N 119.784 1.174 . . . . 0.0 109.897 -179.473 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.06 5.63 8.14 Favored Glycine 0 CA--C 1.527 0.789 0 N-CA-C 111.03 -0.828 . . . . 0.0 111.03 -179.928 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 34' ' ' LEU . . . . . 0.413 ' H ' ' C ' ' G' ' 32' ' ' ILE . 1.6 tt -75.71 125.46 29.09 Favored 'General case' 0 CA--C 1.544 0.733 0 N-CA-C 109.561 -0.533 . . . . 0.0 109.561 -179.574 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 28.1 ttt -161.04 152.91 19.67 Favored 'General case' 0 C--O 1.206 -1.194 0 N-CA-C 108.861 -0.792 . . . . 0.0 108.861 178.712 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 30.4 m -157.8 164.28 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.343 0.293 0 N-CA-C 108.471 -0.937 . . . . 0.0 108.471 -179.836 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.42 67.63 2.11 Favored Glycine 0 C--N 1.309 -0.955 0 CA-C-N 115.602 -0.726 . . . . 0.0 112.207 178.457 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.89 -171.64 25.39 Favored Glycine 0 N--CA 1.478 1.438 0 N-CA-C 110.6 -1.0 . . . . 0.0 110.6 178.981 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 39' ' ' VAL . . . . . 0.413 HG11 ' H ' ' D' ' 39' ' ' VAL . 33.9 m -127.04 157.22 38.59 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.763 0 C-N-CA 123.138 0.575 . . . . 0.0 110.807 -179.43 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 28.0 t . . . . . 0 C--O 1.219 -0.51 0 O-C-N 123.976 0.797 . . . . 0.0 110.85 179.364 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' H' H ' 1' ' ' ASP . . . . . . . . . . . . . 15.2 m-20 . . . . . 0 N--CA 1.49 1.567 0 N-CA-C 109.438 -0.579 . . . . 0.0 109.438 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' H' H ' 2' ' ' ALA . . . . . . . . . . . . . . . -76.78 129.45 36.3 Favored 'General case' 0 N--CA 1.473 0.724 0 CA-C-N 116.22 -0.446 . . . . 0.0 109.942 -179.741 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 3' ' ' GLU . . . . . . . . . . . . . 41.7 mt-10 -117.38 108.79 16.0 Favored 'General case' 0 N--CA 1.483 1.217 0 C-N-CA 122.212 0.205 . . . . 0.0 110.525 -179.498 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 29.7 m-85 -70.97 170.74 12.11 Favored 'General case' 0 N--CA 1.476 0.833 0 C-N-CA 122.739 0.416 . . . . 0.0 109.963 179.209 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 5' ' ' ARG . . . . . . . . . . . . . 86.4 mtt180 -67.7 131.72 46.11 Favored 'General case' 0 N--CA 1.475 0.782 0 CA-C-N 116.421 -0.354 . . . . 0.0 110.798 -178.603 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 6.3 t-160 -98.09 129.5 44.91 Favored 'General case' 0 N--CA 1.475 0.78 0 N-CA-C 109.253 -0.647 . . . . 0.0 109.253 179.114 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -75.42 136.18 40.73 Favored 'General case' 0 N--CA 1.47 0.551 0 C-N-CA 122.666 0.386 . . . . 0.0 111.049 178.936 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 8' ' ' SER . . . . . 0.44 ' OG ' ' O ' ' E' ' 7' ' ' ASP . 27.2 p -160.39 -166.52 1.68 Allowed 'General case' 0 N--CA 1.475 0.794 0 CA-C-O 120.85 0.357 . . . . 0.0 110.476 178.786 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.27 46.16 1.37 Allowed Glycine 0 N--CA 1.481 1.674 0 N-CA-C 111.292 -0.723 . . . . 0.0 111.292 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 48.6 p90 -65.46 133.73 51.92 Favored 'General case' 0 CA--C 1.542 0.665 0 N-CA-C 111.894 0.331 . . . . 0.0 111.894 -179.635 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 48.8 mt-10 -91.2 151.63 20.87 Favored 'General case' 0 N--CA 1.479 0.98 0 CA-C-O 121.0 0.429 . . . . 0.0 110.154 178.481 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -154.52 127.66 1.16 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.057 0 N-CA-C 107.874 -1.158 . . . . 0.0 107.874 178.267 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 45.9 m-70 -135.25 147.0 49.14 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.438 -0.801 . . . . 0.0 111.408 -178.073 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 6.5 t60 -165.22 97.33 0.71 Allowed 'General case' 0 N--CA 1.483 1.192 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.264 178.837 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 3.9 pt20 -101.64 -173.77 2.43 Favored 'General case' 0 CA--C 1.511 -0.555 0 N-CA-C 108.637 -0.875 . . . . 0.0 108.637 -179.592 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -170.31 94.22 0.23 Allowed 'General case' 0 N--CA 1.472 0.652 0 CA-C-N 114.664 -1.153 . . . . 0.0 108.116 178.503 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 6.3 mp -121.81 155.66 34.86 Favored 'General case' 0 N--CA 1.498 1.964 0 CA-C-O 121.29 0.567 . . . . 0.0 111.96 -177.778 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 42.2 t -113.33 124.74 70.27 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.044 0 CA-C-N 114.766 -1.106 . . . . 0.0 108.159 176.521 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 30.9 m-85 -125.4 121.06 32.78 Favored 'General case' 0 C--N 1.368 1.401 0 CA-C-N 115.524 -0.762 . . . . 0.0 110.904 -179.082 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 67.2 m-85 54.55 73.63 0.39 Allowed 'General case' 0 C--O 1.236 0.389 0 CA-C-N 115.815 -0.63 . . . . 0.0 111.535 177.9 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.33 -77.98 0.14 Allowed 'General case' 0 N--CA 1.472 0.634 0 O-C-N 122.248 -0.283 . . . . 0.0 110.611 -179.526 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 41.0 tt0 -113.4 101.34 9.29 Favored 'General case' 0 C--N 1.323 -0.578 0 N-CA-C 108.1 -1.074 . . . . 0.0 108.1 179.731 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -157.7 141.87 16.07 Favored 'General case' 0 N--CA 1.478 0.971 0 O-C-N 122.453 -0.155 . . . . 0.0 111.371 179.095 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 24' ' ' VAL . . . . . 0.406 ' HB ' ' H ' ' E' ' 25' ' ' GLY . 57.4 t -60.45 166.92 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.617 0 N-CA-C 107.632 -1.247 . . . . 0.0 107.632 177.246 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . -120.6 49.36 0.88 Allowed Glycine 0 N--CA 1.48 1.603 0 N-CA-C 110.528 -1.029 . . . . 0.0 110.528 -179.592 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -63.77 -167.63 0.02 OUTLIER 'General case' 0 N--CA 1.473 0.697 0 CA-C-N 116.99 0.395 . . . . 0.0 110.028 179.812 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 27.4 t-20 -70.2 77.38 0.52 Allowed 'General case' 0 CA--C 1.536 0.41 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.445 179.883 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -74.8 144.21 43.62 Favored 'General case' 0 N--CA 1.474 0.754 0 N-CA-C 109.626 -0.509 . . . . 0.0 109.626 179.366 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.83 -165.42 1.08 Allowed Glycine 0 C--N 1.337 0.607 0 N-CA-C 109.978 -1.249 . . . . 0.0 109.978 178.731 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.66 113.57 26.1 Favored 'General case' 0 N--CA 1.468 0.431 0 C-N-CA 122.632 0.373 . . . . 0.0 110.593 179.902 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 66.6 mt -98.06 135.65 31.88 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.803 0 N-CA-C 106.81 -1.552 . . . . 0.0 106.81 178.964 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 32' ' ' ILE . . . . . 0.404 ' C ' ' H ' ' H' ' 34' ' ' LEU . 39.1 pt -152.38 -174.31 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 CA-C-N 119.838 1.199 . . . . 0.0 109.832 -179.637 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.05 5.92 8.75 Favored Glycine 0 CA--C 1.528 0.86 0 N-CA-C 110.974 -0.85 . . . . 0.0 110.974 -179.929 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 34' ' ' LEU . . . . . 0.404 ' H ' ' C ' ' H' ' 32' ' ' ILE . 1.6 tt -75.84 125.19 28.6 Favored 'General case' 0 CA--C 1.545 0.761 0 N-CA-C 109.512 -0.551 . . . . 0.0 109.512 -179.602 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 28.3 ttt -160.76 152.79 20.03 Favored 'General case' 0 C--O 1.207 -1.144 0 N-CA-C 108.925 -0.768 . . . . 0.0 108.925 178.595 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 28.4 m -157.8 164.17 1.14 Allowed 'Isoleucine or valine' 0 C--N 1.343 0.294 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 -179.81 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.54 67.81 2.01 Favored Glycine 0 C--N 1.309 -0.964 0 CA-C-N 115.559 -0.746 . . . . 0.0 112.168 178.542 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.55 -171.59 25.2 Favored Glycine 0 N--CA 1.478 1.475 0 N-CA-C 110.621 -0.992 . . . . 0.0 110.621 179.05 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 39' ' ' VAL . . . . . 0.438 HG11 ' H ' ' E' ' 39' ' ' VAL . 33.8 m -126.99 157.71 38.23 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.82 0 C-N-CA 123.168 0.587 . . . . 0.0 110.795 -179.456 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 29.7 t . . . . . 0 N--CA 1.469 0.506 0 O-C-N 123.985 0.803 . . . . 0.0 110.745 179.281 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' I' I ' 1' ' ' ASP . . . . . . . . . . . . . 14.2 m-20 . . . . . 0 N--CA 1.491 1.611 0 N-CA-C 109.499 -0.556 . . . . 0.0 109.499 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' I' I ' 2' ' ' ALA . . . . . . . . . . . . . . . -76.19 129.82 37.31 Favored 'General case' 0 N--CA 1.473 0.714 0 CA-C-N 116.282 -0.417 . . . . 0.0 109.947 -179.819 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 3' ' ' GLU . . . . . . . . . . . . . 42.6 mt-10 -117.81 108.63 15.59 Favored 'General case' 0 N--CA 1.484 1.247 0 C-N-CA 122.207 0.203 . . . . 0.0 110.502 -179.565 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 29.3 m-85 -70.74 171.15 10.98 Favored 'General case' 0 N--CA 1.476 0.868 0 C-N-CA 122.733 0.413 . . . . 0.0 109.929 179.236 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 5' ' ' ARG . . . . . . . . . . . . . 86.5 mtt180 -68.18 131.72 45.9 Favored 'General case' 0 N--CA 1.476 0.837 0 CA-C-N 116.435 -0.348 . . . . 0.0 110.719 -178.569 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 6.4 t-160 -97.89 129.56 44.83 Favored 'General case' 0 N--CA 1.473 0.718 0 N-CA-C 109.333 -0.617 . . . . 0.0 109.333 179.051 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -75.48 135.98 40.66 Favored 'General case' 0 CA--C 1.539 0.533 0 C-N-CA 122.707 0.403 . . . . 0.0 111.003 178.955 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 8' ' ' SER . . . . . 0.43 ' OG ' ' O ' ' F' ' 7' ' ' ASP . 25.0 p -160.41 -166.63 1.7 Allowed 'General case' 0 N--CA 1.476 0.833 0 CA-C-O 120.936 0.398 . . . . 0.0 110.494 178.841 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.37 45.97 1.38 Allowed Glycine 0 N--CA 1.481 1.693 0 N-CA-C 111.29 -0.724 . . . . 0.0 111.29 179.942 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 49.3 p90 -65.28 133.48 51.55 Favored 'General case' 0 N--CA 1.473 0.681 0 N-CA-C 111.942 0.349 . . . . 0.0 111.942 -179.599 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 49.1 mt-10 -90.93 151.71 21.0 Favored 'General case' 0 N--CA 1.478 0.949 0 CA-C-O 121.077 0.465 . . . . 0.0 110.165 178.463 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -154.72 127.55 1.1 Allowed 'Isoleucine or valine' 0 CA--C 1.553 1.073 0 N-CA-C 107.91 -1.144 . . . . 0.0 107.91 178.248 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 47.0 m-70 -135.22 146.84 49.04 Favored 'General case' 0 N--CA 1.477 0.915 0 CA-C-N 115.45 -0.796 . . . . 0.0 111.404 -178.002 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 6.5 t60 -165.05 97.41 0.73 Allowed 'General case' 0 N--CA 1.483 1.207 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.27 178.884 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 3.9 pt20 -101.82 -173.71 2.42 Favored 'General case' 0 CA--C 1.509 -0.627 0 N-CA-C 108.681 -0.859 . . . . 0.0 108.681 -179.612 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -170.36 94.02 0.22 Allowed 'General case' 0 N--CA 1.472 0.638 0 CA-C-N 114.628 -1.169 . . . . 0.0 108.128 178.607 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 6.3 mp -121.62 155.86 34.18 Favored 'General case' 0 N--CA 1.497 1.904 0 CA-C-O 121.257 0.551 . . . . 0.0 111.92 -177.751 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 42.1 t -113.53 125.09 70.75 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.997 0 CA-C-N 114.789 -1.096 . . . . 0.0 108.1 176.54 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 31.2 m-85 -125.73 121.41 33.31 Favored 'General case' 0 C--N 1.366 1.325 0 CA-C-N 115.61 -0.723 . . . . 0.0 110.945 -179.229 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 67.1 m-85 54.46 73.3 0.41 Allowed 'General case' 0 C--O 1.237 0.429 0 CA-C-N 115.911 -0.586 . . . . 0.0 111.482 177.885 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.15 -77.92 0.14 Allowed 'General case' 0 N--CA 1.473 0.702 0 O-C-N 122.272 -0.268 . . . . 0.0 110.5 -179.55 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 40.8 tt0 -113.4 101.54 9.48 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 108.069 -1.086 . . . . 0.0 108.069 179.692 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -157.91 141.59 15.56 Favored 'General case' 0 N--CA 1.479 1.004 0 O-C-N 122.42 -0.175 . . . . 0.0 111.361 179.087 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 24' ' ' VAL . . . . . 0.409 ' HB ' ' H ' ' F' ' 25' ' ' GLY . 59.0 t -60.26 167.27 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.631 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 177.22 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . -120.89 49.3 0.89 Allowed Glycine 0 N--CA 1.481 1.683 0 N-CA-C 110.523 -1.031 . . . . 0.0 110.523 -179.572 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -63.75 -167.65 0.02 OUTLIER 'General case' 0 N--CA 1.473 0.682 0 CA-C-N 117.002 0.401 . . . . 0.0 109.949 179.768 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 27.6 t-20 -70.21 77.27 0.52 Allowed 'General case' 0 CA--C 1.535 0.401 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.411 179.913 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -74.66 143.92 44.04 Favored 'General case' 0 N--CA 1.475 0.8 0 N-CA-C 109.617 -0.512 . . . . 0.0 109.617 179.424 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.44 -165.8 1.03 Allowed Glycine 0 C--N 1.337 0.601 0 N-CA-C 110.009 -1.236 . . . . 0.0 110.009 178.653 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.26 113.7 26.13 Favored 'General case' 0 N--CA 1.468 0.471 0 C-N-CA 122.729 0.412 . . . . 0.0 110.583 179.991 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 66.9 mt -98.5 135.49 33.12 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.842 0 N-CA-C 106.833 -1.543 . . . . 0.0 106.833 178.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 32' ' ' ILE . . . . . 0.41 ' C ' ' H ' ' I' ' 34' ' ' LEU . 39.2 pt -152.36 -174.3 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.725 0 CA-C-N 119.8 1.182 . . . . 0.0 109.84 -179.567 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.04 5.84 8.56 Favored Glycine 0 CA--C 1.527 0.819 0 N-CA-C 110.999 -0.84 . . . . 0.0 110.999 -179.874 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 34' ' ' LEU . . . . . 0.41 ' H ' ' C ' ' I' ' 32' ' ' ILE . 1.6 tt -75.82 125.42 29.05 Favored 'General case' 0 CA--C 1.545 0.753 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 -179.644 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 28.3 ttt -160.88 152.59 19.57 Favored 'General case' 0 C--O 1.206 -1.186 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 178.723 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 26.7 m -157.59 164.1 1.17 Allowed 'Isoleucine or valine' 0 C--N 1.342 0.262 0 N-CA-C 108.448 -0.945 . . . . 0.0 108.448 -179.988 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.57 67.91 1.96 Allowed Glycine 0 C--N 1.309 -0.951 0 CA-C-N 115.602 -0.727 . . . . 0.0 112.122 178.571 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.58 -171.86 25.11 Favored Glycine 0 N--CA 1.478 1.445 0 N-CA-C 110.644 -0.982 . . . . 0.0 110.644 178.97 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 39' ' ' VAL . . . . . 0.437 HG11 ' H ' ' F' ' 39' ' ' VAL . 33.9 m -126.82 157.26 38.07 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.792 0 C-N-CA 123.181 0.592 . . . . 0.0 110.832 -179.452 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 26.0 t . . . . . 0 C--O 1.22 -0.5 0 O-C-N 123.964 0.79 . . . . 0.0 110.825 179.347 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . 0.478 ' H3 ' ' CB ' ' D' ' 1' ' ' ASP . 16.2 m-20 . . . . . 0 N--CA 1.489 1.49 0 N-CA-C 108.939 -0.763 . . . . 0.0 108.939 . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -66.19 133.78 51.36 Favored 'General case' 0 CA--C 1.538 0.514 0 N-CA-C 110.075 -0.343 . . . . 0.0 110.075 -179.873 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 49.3 tt0 -169.65 106.08 0.36 Allowed 'General case' 0 N--CA 1.474 0.736 0 N-CA-C 109.961 -0.385 . . . . 0.0 109.961 -179.17 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 63.1 m-85 -83.97 145.68 28.41 Favored 'General case' 0 N--CA 1.474 0.769 0 N-CA-C 110.309 -0.256 . . . . 0.0 110.309 179.484 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -144.45 142.51 30.34 Favored 'General case' 0 N--CA 1.483 1.221 0 N-CA-C 109.958 -0.386 . . . . 0.0 109.958 179.721 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 45.1 t-80 -152.61 118.77 5.51 Favored 'General case' 0 N--CA 1.469 0.524 0 N-CA-C 109.26 -0.645 . . . . 0.0 109.26 178.967 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' ASP . . . . . 0.515 ' O ' ' OG ' ' D' ' 8' ' ' SER . 4.0 m-20 -69.52 149.62 48.03 Favored 'General case' 0 CA--C 1.538 0.49 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.468 179.898 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 52.1 p -168.07 -173.24 2.0 Allowed 'General case' 0 N--CA 1.484 1.249 0 CA-C-O 121.075 0.464 . . . . 0.0 110.706 179.461 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.77 46.85 1.44 Allowed Glycine 0 N--CA 1.483 1.802 0 CA-C-N 115.962 -0.563 . . . . 0.0 111.941 179.808 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 47.8 p90 -65.27 132.56 49.37 Favored 'General case' 0 N--CA 1.471 0.616 0 CA-C-N 116.71 0.255 . . . . 0.0 111.62 179.764 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 48.1 mt-10 -91.87 151.77 20.4 Favored 'General case' 0 N--CA 1.478 0.935 0 N-CA-C 109.692 -0.484 . . . . 0.0 109.692 178.437 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.0 p -152.79 128.19 1.61 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.61 0 N-CA-C 107.894 -1.15 . . . . 0.0 107.894 178.239 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 45.3 m-70 -135.46 146.31 48.06 Favored 'General case' 0 N--CA 1.493 1.687 0 CA-C-N 118.993 0.815 . . . . 0.0 111.253 -178.916 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 6.0 t60 -165.8 96.78 0.64 Allowed 'General case' 0 N--CA 1.478 0.958 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.941 179.398 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . 0.667 HE22 ' H ' ' A' ' 37' ' ' GLY . 5.9 pt20 -108.27 -174.39 2.51 Favored 'General case' 0 CA--C 1.508 -0.645 0 N-CA-C 108.293 -1.003 . . . . 0.0 108.293 -179.781 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -164.22 98.79 0.83 Allowed 'General case' 0 N--CA 1.472 0.626 0 CA-C-N 114.477 -1.238 . . . . 0.0 108.285 178.38 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 6.5 mp -122.04 155.76 34.94 Favored 'General case' 0 N--CA 1.499 2.002 0 CA-C-O 121.837 0.827 . . . . 0.0 110.926 -178.341 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 60.2 t -111.55 126.73 68.97 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.093 0 CA-C-O 117.908 -1.044 . . . . 0.0 108.235 177.737 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 28.1 m-85 -126.43 122.99 36.87 Favored 'General case' 0 N--CA 1.497 1.902 0 CA-C-N 120.08 1.309 . . . . 0.0 110.477 179.203 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 67.0 m-85 54.08 73.79 0.37 Allowed 'General case' 0 N--CA 1.469 0.493 0 CA-C-O 121.306 0.574 . . . . 0.0 111.828 178.757 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -79.99 -77.97 0.18 Allowed 'General case' 0 C--N 1.351 0.665 0 CA-C-N 115.193 -0.912 . . . . 0.0 110.203 -179.752 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 40.6 tt0 -113.53 99.6 7.87 Favored 'General case' 0 N--CA 1.468 0.461 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 179.855 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -158.41 138.84 12.59 Favored 'General case' 0 C--O 1.206 -1.22 0 O-C-N 122.231 -0.293 . . . . 0.0 111.249 179.098 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 59.8 t -59.53 163.37 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.921 0 N-CA-C 107.941 -1.133 . . . . 0.0 107.941 177.071 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -116.88 47.61 1.02 Allowed Glycine 0 N--CA 1.476 1.359 0 N-CA-C 111.834 -0.506 . . . . 0.0 111.834 -179.417 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -60.61 -167.5 0.01 OUTLIER 'General case' 0 N--CA 1.469 0.478 0 O-C-N 123.786 0.345 . . . . 0.0 110.305 179.56 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 25.4 t-20 -71.02 80.46 0.66 Allowed 'General case' 0 N--CA 1.465 0.29 0 CA-C-N 116.45 -0.341 . . . . 0.0 110.246 179.539 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 97.7 mttt -77.45 142.95 38.92 Favored 'General case' 0 N--CA 1.474 0.744 0 N-CA-C 109.183 -0.673 . . . . 0.0 109.183 179.283 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.66 -167.89 1.12 Allowed Glycine 0 C--N 1.338 0.648 0 N-CA-C 109.957 -1.257 . . . . 0.0 109.957 178.757 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.44 115.12 28.54 Favored 'General case' 0 N--CA 1.478 0.951 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 179.727 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 71.0 mt -98.58 134.71 36.23 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.576 0 N-CA-C 107.202 -1.407 . . . . 0.0 107.202 178.722 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . 0.402 ' C ' ' H ' ' A' ' 34' ' ' LEU . 31.1 pt -150.63 -171.43 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.352 0.696 0 CA-C-O 121.168 0.508 . . . . 0.0 111.122 -179.259 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.39 4.95 9.96 Favored Glycine 0 N--CA 1.466 0.636 0 N-CA-C 110.735 -0.946 . . . . 0.0 110.735 179.843 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . 0.402 ' H ' ' C ' ' A' ' 32' ' ' ILE . 1.1 tt -75.38 135.21 40.81 Favored 'General case' 0 CA--C 1.545 0.77 0 N-CA-C 109.395 -0.594 . . . . 0.0 109.395 -179.727 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 27.1 ttt -158.82 146.46 17.79 Favored 'General case' 0 N--CA 1.467 0.418 0 N-CA-C 108.619 -0.882 . . . . 0.0 108.619 178.608 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 1.9 m -148.9 165.65 4.01 Favored 'Isoleucine or valine' 0 C--N 1.348 0.517 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 -179.625 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . 0.667 ' H ' HE22 ' A' ' 15' ' ' GLN . . . 54.87 68.44 1.68 Allowed Glycine 0 C--N 1.306 -1.118 0 CA-C-N 115.49 -0.777 . . . . 0.0 112.32 177.518 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.53 176.59 21.3 Favored Glycine 0 N--CA 1.472 1.072 0 N-CA-C 111.11 -0.796 . . . . 0.0 111.11 178.7 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 34.3 m -109.31 156.28 10.08 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.658 0 C-N-CA 123.385 0.674 . . . . 0.0 110.201 -179.689 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 24.4 t . . . . . 0 C--O 1.219 -0.55 0 CA-C-O 118.42 -0.8 . . . . 0.0 110.492 179.397 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' B' B ' 1' ' ' ASP . . . . . 0.479 ' H3 ' ' CB ' ' E' ' 1' ' ' ASP . 15.8 m-20 . . . . . 0 N--CA 1.49 1.529 0 N-CA-C 108.962 -0.755 . . . . 0.0 108.962 . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.72 133.23 50.63 Favored 'General case' 0 N--CA 1.47 0.547 0 CA-C-N 116.455 -0.339 . . . . 0.0 110.127 -179.845 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 3' ' ' GLU . . . . . . . . . . . . . 48.2 tt0 -169.11 105.55 0.4 Allowed 'General case' 0 N--CA 1.475 0.786 0 N-CA-C 110.077 -0.342 . . . . 0.0 110.077 -179.114 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 63.8 m-85 -83.39 145.4 29.03 Favored 'General case' 0 N--CA 1.473 0.678 0 N-CA-C 110.264 -0.272 . . . . 0.0 110.264 179.372 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -144.2 142.42 30.51 Favored 'General case' 0 N--CA 1.483 1.186 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 179.682 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 44.8 t-80 -152.45 118.63 5.53 Favored 'General case' 0 N--CA 1.471 0.582 0 N-CA-C 109.395 -0.594 . . . . 0.0 109.395 178.829 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 7' ' ' ASP . . . . . 0.502 ' O ' ' OG ' ' E' ' 8' ' ' SER . 3.8 m-20 -69.36 149.18 48.69 Favored 'General case' 0 CA--C 1.539 0.546 0 CA-C-N 116.4 -0.364 . . . . 0.0 110.622 179.896 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 8' ' ' SER . . . . . . . . . . . . . 52.7 p -167.52 -173.26 2.15 Favored 'General case' 0 N--CA 1.484 1.235 0 CA-C-O 121.033 0.444 . . . . 0.0 110.818 179.381 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.89 46.95 1.41 Allowed Glycine 0 N--CA 1.481 1.674 0 CA-C-N 115.966 -0.561 . . . . 0.0 112.015 179.661 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 47.7 p90 -65.79 132.53 48.94 Favored 'General case' 0 N--CA 1.472 0.652 0 CA-C-O 120.719 0.295 . . . . 0.0 111.649 179.837 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 47.9 mt-10 -91.65 151.86 20.49 Favored 'General case' 0 N--CA 1.477 0.894 0 N-CA-C 109.655 -0.498 . . . . 0.0 109.655 178.436 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -152.92 127.95 1.51 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.47 0 N-CA-C 107.972 -1.121 . . . . 0.0 107.972 178.13 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 43.5 m-70 -135.18 146.42 48.69 Favored 'General case' 0 N--CA 1.493 1.686 0 CA-C-N 118.869 0.759 . . . . 0.0 111.345 -178.93 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 6.1 t60 -165.79 97.02 0.65 Allowed 'General case' 0 N--CA 1.48 1.041 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.768 179.378 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . 0.665 HE22 ' H ' ' B' ' 37' ' ' GLY . 5.9 pt20 -108.37 -174.18 2.46 Favored 'General case' 0 CA--C 1.509 -0.603 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 -179.772 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -164.63 98.88 0.79 Allowed 'General case' 0 N--CA 1.474 0.755 0 CA-C-N 114.683 -1.144 . . . . 0.0 108.195 178.363 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 6.6 mp -122.04 156.04 34.35 Favored 'General case' 0 N--CA 1.497 1.925 0 CA-C-O 121.727 0.775 . . . . 0.0 111.012 -178.27 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 61.8 t -112.03 127.63 69.1 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.075 0 N-CA-C 108.028 -1.101 . . . . 0.0 108.028 177.605 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 28.2 m-85 -127.56 122.48 33.36 Favored 'General case' 0 N--CA 1.495 1.781 0 CA-C-N 119.678 1.126 . . . . 0.0 110.307 179.565 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 67.4 m-85 53.71 74.21 0.33 Allowed 'General case' 0 CA--C 1.538 0.504 0 CA-C-O 121.491 0.662 . . . . 0.0 111.846 178.792 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -80.55 -78.03 0.18 Allowed 'General case' 0 C--N 1.35 0.628 0 CA-C-N 115.065 -0.97 . . . . 0.0 110.116 -179.573 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 40.4 tt0 -113.15 99.57 7.93 Favored 'General case' 0 N--CA 1.47 0.543 0 N-CA-C 108.236 -1.024 . . . . 0.0 108.236 179.812 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -158.6 138.79 12.31 Favored 'General case' 0 C--O 1.205 -1.272 0 CA-C-O 119.524 -0.275 . . . . 0.0 111.236 179.1 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 57.1 t -59.41 163.8 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.857 0 N-CA-C 108.012 -1.107 . . . . 0.0 108.012 177.191 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . 0.402 ' H ' ' HB ' ' E' ' 24' ' ' VAL . . . -117.18 47.64 1.02 Allowed Glycine 0 N--CA 1.475 1.244 0 N-CA-C 111.773 -0.531 . . . . 0.0 111.773 -179.465 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -60.67 -167.62 0.01 OUTLIER 'General case' 0 N--CA 1.469 0.52 0 O-C-N 123.708 0.299 . . . . 0.0 110.202 179.457 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 25.4 t-20 -71.1 81.12 0.69 Allowed 'General case' 0 N--CA 1.465 0.29 0 CA-C-N 116.481 -0.327 . . . . 0.0 110.186 179.548 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 97.8 mttt -78.07 142.55 38.08 Favored 'General case' 0 N--CA 1.474 0.762 0 N-CA-C 109.015 -0.735 . . . . 0.0 109.015 179.418 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.22 -167.76 0.92 Allowed Glycine 0 C--N 1.336 0.557 0 N-CA-C 109.917 -1.273 . . . . 0.0 109.917 178.659 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.54 115.53 29.56 Favored 'General case' 0 N--CA 1.478 0.959 0 N-CA-C 109.599 -0.519 . . . . 0.0 109.599 179.77 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 70.9 mt -98.96 134.68 36.96 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.505 0 N-CA-C 107.107 -1.442 . . . . 0.0 107.107 178.6 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . 0.407 ' C ' ' H ' ' B' ' 34' ' ' LEU . 29.7 pt -150.77 -171.85 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.724 0 CA-C-O 121.141 0.496 . . . . 0.0 111.17 -179.022 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.76 4.58 10.68 Favored Glycine 0 C--N 1.337 0.595 0 N-CA-C 110.915 -0.874 . . . . 0.0 110.915 179.935 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 34' ' ' LEU . . . . . 0.407 ' H ' ' C ' ' B' ' 32' ' ' ILE . 1.1 tt -75.07 135.07 41.23 Favored 'General case' 0 CA--C 1.545 0.767 0 N-CA-C 109.497 -0.557 . . . . 0.0 109.497 -179.689 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 27.0 ttt -158.54 146.42 18.18 Favored 'General case' 0 N--CA 1.471 0.582 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 178.64 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 1.9 m -149.08 165.54 3.83 Favored 'Isoleucine or valine' 0 C--N 1.347 0.48 0 N-CA-C 108.094 -1.076 . . . . 0.0 108.094 -179.642 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . 0.665 ' H ' HE22 ' B' ' 15' ' ' GLN . . . 55.19 68.21 1.81 Allowed Glycine 0 C--N 1.306 -1.097 0 CA-C-N 115.469 -0.787 . . . . 0.0 112.367 177.54 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.24 176.75 21.21 Favored Glycine 0 N--CA 1.473 1.105 0 N-CA-C 111.113 -0.795 . . . . 0.0 111.113 178.674 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 39' ' ' VAL . . . . . 0.401 ' H ' HG11 ' E' ' 39' ' ' VAL . 34.4 m -109.35 155.81 10.31 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.655 0 C-N-CA 123.376 0.67 . . . . 0.0 110.299 -179.546 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 25.1 t . . . . . 0 C--O 1.22 -0.497 0 O-C-N 123.99 0.806 . . . . 0.0 110.407 179.317 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' C' C ' 1' ' ' ASP . . . . . 0.467 ' H3 ' ' CB ' ' F' ' 1' ' ' ASP . 15.5 m-20 . . . . . 0 N--CA 1.489 1.492 0 N-CA-C 108.941 -0.763 . . . . 0.0 108.941 . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.72 133.47 51.13 Favored 'General case' 0 CA--C 1.538 0.509 0 CA-C-N 116.479 -0.328 . . . . 0.0 110.217 -179.756 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 3' ' ' GLU . . . . . . . . . . . . . 49.3 tt0 -169.38 105.92 0.38 Allowed 'General case' 0 N--CA 1.473 0.693 0 N-CA-C 110.038 -0.356 . . . . 0.0 110.038 -179.044 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 64.8 m-85 -83.85 145.42 28.65 Favored 'General case' 0 N--CA 1.474 0.767 0 N-CA-C 110.25 -0.278 . . . . 0.0 110.25 179.397 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -144.22 142.4 30.48 Favored 'General case' 0 N--CA 1.484 1.244 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 179.769 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 45.2 t-80 -152.47 119.05 5.66 Favored 'General case' 0 N--CA 1.471 0.586 0 N-CA-C 109.397 -0.594 . . . . 0.0 109.397 179.013 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 7' ' ' ASP . . . . . 0.495 ' O ' ' OG ' ' F' ' 8' ' ' SER . 4.1 m-20 -70.1 149.03 48.04 Favored 'General case' 0 CA--C 1.538 0.493 0 CA-C-N 116.376 -0.375 . . . . 0.0 110.647 -179.983 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 8' ' ' SER . . . . . . . . . . . . . 54.0 p -167.28 -172.97 2.13 Favored 'General case' 0 N--CA 1.484 1.235 0 CA-C-O 121.061 0.457 . . . . 0.0 110.744 179.566 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.48 46.9 1.47 Allowed Glycine 0 N--CA 1.482 1.715 0 CA-C-N 115.945 -0.57 . . . . 0.0 112.035 179.688 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 47.7 p90 -65.78 132.35 48.51 Favored 'General case' 0 N--CA 1.471 0.591 0 O-C-N 122.745 -0.268 . . . . 0.0 111.686 179.826 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 47.7 mt-10 -91.41 151.82 20.66 Favored 'General case' 0 N--CA 1.475 0.782 0 N-CA-C 109.713 -0.477 . . . . 0.0 109.713 178.432 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -152.77 128.17 1.61 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.515 0 N-CA-C 107.833 -1.173 . . . . 0.0 107.833 177.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 41.7 m-70 -135.27 146.5 48.61 Favored 'General case' 0 N--CA 1.492 1.65 0 CA-C-N 118.916 0.78 . . . . 0.0 111.272 -179.056 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 6.0 t60 -165.88 96.84 0.63 Allowed 'General case' 0 N--CA 1.481 1.111 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.719 179.459 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 15' ' ' GLN . . . . . 0.666 HE22 ' H ' ' C' ' 37' ' ' GLY . 5.9 pt20 -108.39 -173.98 2.41 Favored 'General case' 0 CA--C 1.505 -0.77 0 N-CA-C 108.396 -0.965 . . . . 0.0 108.396 -179.898 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -164.63 98.85 0.79 Allowed 'General case' 0 N--CA 1.473 0.678 0 CA-C-N 114.617 -1.174 . . . . 0.0 108.223 178.502 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 6.6 mp -121.9 155.77 34.74 Favored 'General case' 0 N--CA 1.497 1.901 0 CA-C-O 121.84 0.828 . . . . 0.0 110.927 -178.35 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 61.2 t -111.68 127.55 68.77 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.117 0 N-CA-C 107.932 -1.136 . . . . 0.0 107.932 177.511 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 28.1 m-85 -127.51 123.06 35.0 Favored 'General case' 0 N--CA 1.495 1.782 0 CA-C-N 119.606 1.094 . . . . 0.0 110.272 179.395 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 67.0 m-85 53.08 74.12 0.32 Allowed 'General case' 0 N--CA 1.468 0.449 0 CA-C-O 121.558 0.694 . . . . 0.0 111.919 178.851 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -80.22 -78.29 0.17 Allowed 'General case' 0 C--N 1.35 0.62 0 CA-C-N 115.012 -0.994 . . . . 0.0 110.065 -179.595 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 40.4 tt0 -113.03 99.69 8.05 Favored 'General case' 0 N--CA 1.471 0.62 0 N-CA-C 108.153 -1.055 . . . . 0.0 108.153 179.899 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -158.45 139.15 12.8 Favored 'General case' 0 C--O 1.205 -1.246 0 O-C-N 122.309 -0.245 . . . . 0.0 111.203 179.131 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 60.7 t -59.94 163.3 0.96 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.878 0 N-CA-C 108.075 -1.083 . . . . 0.0 108.075 177.051 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 25' ' ' GLY . . . . . 0.402 ' H ' ' HB ' ' F' ' 24' ' ' VAL . . . -116.64 47.3 1.05 Allowed Glycine 0 N--CA 1.477 1.387 0 N-CA-C 111.722 -0.551 . . . . 0.0 111.722 -179.29 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -60.43 -167.38 0.01 OUTLIER 'General case' 0 N--CA 1.468 0.462 0 O-C-N 123.658 0.269 . . . . 0.0 110.284 179.539 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 25.5 t-20 -71.29 80.69 0.74 Allowed 'General case' 0 N--CA 1.466 0.333 0 CA-C-N 116.442 -0.344 . . . . 0.0 110.132 179.495 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 97.7 mttt -77.53 143.06 38.69 Favored 'General case' 0 N--CA 1.474 0.741 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 179.253 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.83 -167.68 1.15 Allowed Glycine 0 CA--C 1.524 0.617 0 N-CA-C 109.994 -1.242 . . . . 0.0 109.994 178.705 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.49 115.11 28.55 Favored 'General case' 0 N--CA 1.482 1.144 0 N-CA-C 109.677 -0.49 . . . . 0.0 109.677 179.879 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 71.1 mt -98.78 134.21 38.45 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.48 0 N-CA-C 107.296 -1.372 . . . . 0.0 107.296 178.591 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 29.7 pt -150.3 -171.49 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.724 0 CA-C-O 121.227 0.537 . . . . 0.0 111.173 -179.107 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.31 5.11 10.05 Favored Glycine 0 CA--C 1.524 0.62 0 N-CA-C 110.838 -0.905 . . . . 0.0 110.838 179.881 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 1.1 tt -75.46 134.77 40.77 Favored 'General case' 0 CA--C 1.546 0.813 0 N-CA-C 109.38 -0.6 . . . . 0.0 109.38 -179.703 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 27.1 ttt -158.19 146.57 18.79 Favored 'General case' 0 N--CA 1.47 0.531 0 N-CA-C 108.426 -0.953 . . . . 0.0 108.426 178.686 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 1.7 m -149.33 165.28 3.72 Favored 'Isoleucine or valine' 0 C--N 1.348 0.532 0 N-CA-C 108.142 -1.059 . . . . 0.0 108.142 -179.556 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 37' ' ' GLY . . . . . 0.666 ' H ' HE22 ' C' ' 15' ' ' GLN . . . 54.77 68.7 1.55 Allowed Glycine 0 C--N 1.306 -1.096 0 CA-C-N 115.413 -0.812 . . . . 0.0 112.317 177.782 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.26 176.42 20.94 Favored Glycine 0 N--CA 1.473 1.101 0 N-CA-C 111.078 -0.809 . . . . 0.0 111.078 178.698 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 34.4 m -109.38 155.73 10.38 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.624 0 C-N-CA 123.328 0.651 . . . . 0.0 110.443 -179.641 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 25.1 t . . . . . 0 C--O 1.219 -0.538 0 O-C-N 124.009 0.818 . . . . 0.0 110.491 179.386 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' D' D ' 1' ' ' ASP . . . . . 0.478 ' CB ' ' H3 ' ' A' ' 1' ' ' ASP . 15.8 m-20 . . . . . 0 N--CA 1.49 1.559 0 N-CA-C 109.221 -0.659 . . . . 0.0 109.221 . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.44 131.34 46.88 Favored 'General case' 0 CA--C 1.536 0.439 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.429 179.796 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 3' ' ' GLU . . . . . . . . . . . . . 48.2 tt0 -169.26 108.91 0.44 Allowed 'General case' 0 N--CA 1.472 0.649 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 179.658 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 72.3 m-85 -87.93 151.59 22.7 Favored 'General case' 0 C--N 1.362 1.117 0 C-N-CA 119.361 -0.936 . . . . 0.0 108.948 179.643 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 5' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -146.87 140.99 26.12 Favored 'General case' 0 N--CA 1.476 0.86 0 N-CA-C 110.059 -0.348 . . . . 0.0 110.059 179.764 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 41.6 t-80 -149.75 123.52 9.26 Favored 'General case' 0 CA--C 1.545 0.774 0 N-CA-C 108.499 -0.926 . . . . 0.0 108.499 174.468 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 7' ' ' ASP . . . . . 0.598 ' O ' ' OG ' ' G' ' 8' ' ' SER . 2.8 m-20 -63.81 133.32 53.2 Favored 'General case' 0 C--N 1.32 -0.688 0 C-N-CA 126.61 1.964 . . . . 0.0 114.339 174.029 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' D' D ' 8' ' ' SER . . . . . 0.515 ' OG ' ' O ' ' A' ' 7' ' ' ASP . 52.3 p -154.04 -170.53 3.59 Favored 'General case' 0 N--CA 1.488 1.438 0 CA-C-N 119.649 1.113 . . . . 0.0 111.131 175.534 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.43 48.05 1.16 Allowed Glycine 0 N--CA 1.484 1.88 0 N-CA-C 109.941 -1.264 . . . . 0.0 109.941 173.365 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 50.9 p90 -60.66 131.01 49.35 Favored 'General case' 0 N--CA 1.468 0.434 0 N-CA-C 113.155 0.798 . . . . 0.0 113.155 177.697 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 47.8 mt-10 -88.84 150.65 22.8 Favored 'General case' 0 N--CA 1.481 1.084 0 CA-C-N 118.175 0.443 . . . . 0.0 110.946 174.98 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.0 p -149.49 130.03 4.41 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.594 0 N-CA-C 107.423 -1.325 . . . . 0.0 107.423 173.128 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 40.9 m-70 -130.03 149.25 51.83 Favored 'General case' 0 N--CA 1.484 1.232 0 CA-C-N 118.03 0.377 . . . . 0.0 111.907 176.41 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 6.1 t60 -164.99 104.38 0.78 Allowed 'General case' 0 N--CA 1.48 1.035 0 N-CA-C 109.175 -0.676 . . . . 0.0 109.175 172.13 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 15' ' ' GLN . . . . . 0.642 HE22 ' H ' ' D' ' 37' ' ' GLY . 5.9 pt20 -111.97 -176.05 2.84 Favored 'General case' 0 CA--C 1.499 -1.002 0 N-CA-C 108.228 -1.027 . . . . 0.0 108.228 178.911 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -161.04 105.96 1.36 Allowed 'General case' 0 N--CA 1.468 0.433 0 N-CA-C 106.634 -1.617 . . . . 0.0 106.634 175.151 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 5.5 mp -128.38 153.22 47.3 Favored 'General case' 0 N--CA 1.498 1.945 0 CA-C-O 122.06 0.934 . . . . 0.0 110.582 179.662 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 35.8 t -100.97 131.82 47.88 Favored 'Isoleucine or valine' 0 C--O 1.262 1.761 0 CA-C-O 116.723 -1.608 . . . . 0.0 109.546 174.2 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 25.7 m-85 -130.49 126.35 36.66 Favored 'General case' 0 N--CA 1.491 1.583 0 CA-C-N 120.149 1.34 . . . . 0.0 109.528 173.366 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 68.2 m-85 55.85 71.53 0.55 Allowed 'General case' 0 C--O 1.241 0.651 0 CA-C-N 115.493 -0.776 . . . . 0.0 111.258 176.357 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -82.43 -73.18 0.41 Allowed 'General case' 0 N--CA 1.475 0.794 0 CA-C-O 118.52 -0.752 . . . . 0.0 111.106 -177.507 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 40.8 tt0 -116.52 103.81 10.79 Favored 'General case' 0 N--CA 1.482 1.174 0 N-CA-C 106.195 -1.78 . . . . 0.0 106.195 176.217 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -151.9 138.79 18.98 Favored 'General case' 0 N--CA 1.474 0.752 0 CA-C-O 116.686 -1.626 . . . . 0.0 113.738 177.697 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 24' ' ' VAL . . . . . . . . . . . . . 64.1 t -62.27 166.23 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.206 0 CA-C-N 121.101 1.773 . . . . 0.0 107.834 175.184 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 25' ' ' GLY . . . . . 0.434 ' H ' ' HB ' ' G' ' 24' ' ' VAL . . . -116.79 51.14 0.74 Allowed Glycine 0 N--CA 1.478 1.46 0 CA-C-O 119.095 -0.836 . . . . 0.0 111.833 178.451 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -57.28 -170.42 0.01 OUTLIER 'General case' 0 C--N 1.322 -0.595 0 C-N-CA 123.706 0.802 . . . . 0.0 111.559 175.937 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 26.3 t-20 -72.89 86.69 1.29 Allowed 'General case' 0 C--N 1.347 0.466 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 177.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 97.2 mttt -82.87 145.56 29.38 Favored 'General case' 0 N--CA 1.476 0.84 0 N-CA-C 108.014 -1.106 . . . . 0.0 108.014 179.134 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.17 -165.34 0.61 Allowed Glycine 0 C--N 1.336 0.57 0 N-CA-C 110.45 -1.06 . . . . 0.0 110.45 179.171 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -102.35 116.11 31.95 Favored 'General case' 0 N--CA 1.476 0.851 0 N-CA-C 109.099 -0.704 . . . . 0.0 109.099 179.846 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 80.4 mt -102.52 142.24 17.07 Favored 'Isoleucine or valine' 0 C--N 1.358 0.941 0 N-CA-C 104.84 -2.281 . . . . 0.0 104.84 179.793 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 31.1 pt -157.43 -172.51 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.482 1.157 0 CA-C-O 120.84 0.353 . . . . 0.0 110.155 -177.332 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 64.27 4.55 12.59 Favored Glycine 0 N--CA 1.465 0.601 0 N-CA-C 110.387 -1.085 . . . . 0.0 110.387 -178.926 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 1.3 tt -76.52 140.47 41.17 Favored 'General case' 0 C--N 1.355 0.824 0 N-CA-C 107.787 -1.19 . . . . 0.0 107.787 -178.329 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 26.4 ttt -156.41 155.91 32.94 Favored 'General case' 0 C--O 1.247 0.955 0 N-CA-C 107.894 -1.15 . . . . 0.0 107.894 174.482 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 1.9 m -157.91 163.86 1.18 Allowed 'Isoleucine or valine' 0 CA--C 1.516 -0.334 0 N-CA-C 107.618 -1.252 . . . . 0.0 107.618 177.826 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 37' ' ' GLY . . . . . 0.642 ' H ' HE22 ' D' ' 15' ' ' GLN . . . 61.36 63.84 4.53 Favored Glycine 0 C--N 1.312 -0.76 0 C-N-CA 119.758 -1.211 . . . . 0.0 112.179 177.452 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 145.76 177.75 20.72 Favored Glycine 0 N--CA 1.476 1.365 0 CA-C-N 118.309 1.054 . . . . 0.0 111.776 179.756 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 35.2 m -112.5 152.76 14.24 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.895 0 N-CA-C 109.681 -0.489 . . . . 0.0 109.681 -176.824 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 25.2 t . . . . . 0 C--N 1.334 -0.066 0 CA-C-O 116.119 -1.896 . . . . 0.0 109.533 178.0 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' E' E ' 1' ' ' ASP . . . . . 0.487 ' H3 ' ' CB ' ' H' ' 1' ' ' ASP . 15.4 m-20 . . . . . 0 N--CA 1.49 1.543 0 N-CA-C 109.436 -0.579 . . . . 0.0 109.436 . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' E' E ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.07 131.24 46.95 Favored 'General case' 0 N--CA 1.469 0.517 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.414 179.926 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' E' E ' 3' ' ' GLU . . . . . . . . . . . . . 48.1 tt0 -168.52 105.71 0.45 Allowed 'General case' 0 N--CA 1.472 0.674 0 N-CA-C 110.544 -0.169 . . . . 0.0 110.544 -179.693 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 65.8 m-85 -84.39 145.06 28.4 Favored 'General case' 0 N--CA 1.474 0.756 0 O-C-N 122.247 -0.283 . . . . 0.0 110.257 179.177 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' E' E ' 5' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -143.72 142.79 31.12 Favored 'General case' 0 N--CA 1.481 1.078 0 N-CA-C 110.113 -0.329 . . . . 0.0 110.113 179.458 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 45.1 t-80 -152.46 118.67 5.54 Favored 'General case' 0 N--CA 1.469 0.516 0 N-CA-C 109.294 -0.632 . . . . 0.0 109.294 178.86 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' E' E ' 7' ' ' ASP . . . . . 0.506 ' O ' ' OG ' ' H' ' 8' ' ' SER . 3.6 m-20 -70.14 149.14 47.87 Favored 'General case' 0 CA--C 1.535 0.391 0 CA-C-N 116.488 -0.324 . . . . 0.0 110.754 179.938 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' E' E ' 8' ' ' SER . . . . . 0.502 ' OG ' ' O ' ' B' ' 7' ' ' ASP . 43.7 p -168.26 -172.1 1.66 Allowed 'General case' 0 N--CA 1.486 1.33 0 CA-C-O 121.192 0.52 . . . . 0.0 110.854 179.18 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.24 47.7 1.3 Allowed Glycine 0 N--CA 1.478 1.485 0 CA-C-N 115.876 -0.602 . . . . 0.0 111.797 179.54 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 46.3 p90 -65.56 132.62 49.32 Favored 'General case' 0 N--CA 1.471 0.621 0 N-CA-C 112.064 0.394 . . . . 0.0 112.064 -179.891 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 49.0 mt-10 -90.98 152.29 20.74 Favored 'General case' 0 N--CA 1.481 1.123 0 CA-C-O 121.313 0.578 . . . . 0.0 109.575 177.954 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -154.65 127.07 1.04 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.588 0 N-CA-C 107.874 -1.158 . . . . 0.0 107.874 177.96 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 42.9 m-70 -135.42 144.4 46.49 Favored 'General case' 0 N--CA 1.482 1.149 0 CA-C-O 120.903 0.382 . . . . 0.0 111.478 -177.859 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 6.0 t60 -164.4 97.19 0.79 Allowed 'General case' 0 N--CA 1.484 1.237 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.694 179.419 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' E' E ' 15' ' ' GLN . . . . . 0.663 HE22 ' H ' ' E' ' 37' ' ' GLY . 6.0 pt20 -108.21 -174.33 2.49 Favored 'General case' 0 CA--C 1.507 -0.686 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 -179.924 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -164.18 97.73 0.82 Allowed 'General case' 0 N--CA 1.476 0.839 0 CA-C-N 114.698 -1.137 . . . . 0.0 108.436 178.563 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 6.5 mp -120.52 155.66 33.17 Favored 'General case' 0 N--CA 1.494 1.775 0 CA-C-O 121.533 0.682 . . . . 0.0 111.588 -177.867 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 48.8 t -113.44 124.66 70.3 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.254 0 N-CA-C 108.176 -1.046 . . . . 0.0 108.176 177.131 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 30.8 m-85 -124.94 121.8 35.51 Favored 'General case' 0 N--CA 1.489 1.495 0 CA-C-O 120.836 0.351 . . . . 0.0 110.934 -179.891 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 68.8 m-85 54.79 73.29 0.42 Allowed 'General case' 0 N--CA 1.468 0.429 0 CA-C-N 115.92 -0.582 . . . . 0.0 111.478 178.34 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -78.83 -79.03 0.14 Allowed 'General case' 0 CA--C 1.537 0.459 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.03 -179.378 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 40.5 tt0 -112.1 100.02 8.52 Favored 'General case' 0 C--N 1.323 -0.548 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 -179.987 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -157.89 138.84 13.22 Favored 'General case' 0 C--O 1.201 -1.458 0 N-CA-C 111.621 0.23 . . . . 0.0 111.621 179.029 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' E' E ' 24' ' ' VAL . . . . . 0.402 ' HB ' ' H ' ' B' ' 25' ' ' GLY . 59.0 t -58.15 168.28 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.927 0 N-CA-C 107.403 -1.332 . . . . 0.0 107.403 177.056 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . -122.0 48.63 0.94 Allowed Glycine 0 N--CA 1.473 1.157 0 N-CA-C 110.963 -0.855 . . . . 0.0 110.963 -179.38 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -62.12 -166.9 0.01 OUTLIER 'General case' 0 N--CA 1.47 0.541 0 CA-C-O 120.737 0.303 . . . . 0.0 110.482 179.892 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 26.0 t-20 -70.68 76.88 0.6 Allowed 'General case' 0 C--O 1.222 -0.362 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.481 -179.956 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 97.9 mttt -74.36 143.67 44.75 Favored 'General case' 0 N--CA 1.476 0.873 0 N-CA-C 109.554 -0.536 . . . . 0.0 109.554 179.403 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.68 -167.38 1.43 Allowed Glycine 0 C--N 1.333 0.414 0 N-CA-C 110.408 -1.077 . . . . 0.0 110.408 178.534 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.54 113.99 26.72 Favored 'General case' 0 N--CA 1.476 0.834 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 179.953 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 72.0 mt -97.8 134.48 35.86 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.265 0 N-CA-C 106.986 -1.487 . . . . 0.0 106.986 178.768 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' E' E ' 32' ' ' ILE . . . . . 0.41 ' C ' ' H ' ' E' ' 34' ' ' LEU . 31.4 pt -150.34 -169.7 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.174 0 CA-C-O 121.182 0.515 . . . . 0.0 110.753 -179.451 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.65 5.18 6.41 Favored Glycine 0 CA--C 1.527 0.834 0 CA-C-N 115.684 -0.689 . . . . 0.0 111.423 -179.796 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' E' E ' 34' ' ' LEU . . . . . 0.41 ' H ' ' C ' ' E' ' 32' ' ' ILE . 1.1 tt -74.75 135.26 41.77 Favored 'General case' 0 CA--C 1.549 0.941 0 N-CA-C 109.293 -0.632 . . . . 0.0 109.293 -179.616 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 26.3 ttt -158.37 145.78 17.98 Favored 'General case' 0 N--CA 1.473 0.724 0 N-CA-C 108.611 -0.885 . . . . 0.0 108.611 178.466 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 1.5 m -148.65 165.08 4.56 Favored 'Isoleucine or valine' 0 C--N 1.347 0.48 0 N-CA-C 108.5 -0.926 . . . . 0.0 108.5 -179.447 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' E' E ' 37' ' ' GLY . . . . . 0.663 ' H ' HE22 ' E' ' 15' ' ' GLN . . . 54.28 68.56 1.6 Allowed Glycine 0 C--N 1.308 -1.024 0 CA-C-N 115.324 -0.853 . . . . 0.0 112.231 177.888 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 146.65 173.76 18.16 Favored Glycine 0 N--CA 1.473 1.11 0 N-CA-C 111.41 -0.676 . . . . 0.0 111.41 178.734 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' E' E ' 39' ' ' VAL . . . . . 0.401 HG11 ' H ' ' B' ' 39' ' ' VAL . 32.7 m -107.0 155.69 7.59 Favored 'Isoleucine or valine' 0 C--N 1.352 0.702 0 C-N-CA 123.629 0.772 . . . . 0.0 110.645 -178.711 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 25.4 t . . . . . 0 C--O 1.218 -0.599 0 O-C-N 124.18 0.925 . . . . 0.0 110.25 179.615 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' F' F ' 1' ' ' ASP . . . . . 0.467 ' CB ' ' H3 ' ' C' ' 1' ' ' ASP . 16.0 m-20 . . . . . 0 N--CA 1.49 1.56 0 N-CA-C 109.286 -0.635 . . . . 0.0 109.286 . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.19 131.54 47.72 Favored 'General case' 0 N--CA 1.467 0.41 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.46 179.886 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 3' ' ' GLU . . . . . . . . . . . . . 48.6 tt0 -168.6 105.82 0.45 Allowed 'General case' 0 C--O 1.215 -0.748 0 N-CA-C 110.397 -0.223 . . . . 0.0 110.397 -179.743 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 65.1 m-85 -84.61 144.81 28.38 Favored 'General case' 0 N--CA 1.474 0.77 0 O-C-N 122.233 -0.292 . . . . 0.0 110.235 179.266 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 5' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -143.56 142.66 31.19 Favored 'General case' 0 N--CA 1.478 0.97 0 CA-C-O 120.838 0.351 . . . . 0.0 110.091 179.657 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 45.0 t-80 -152.45 119.26 5.75 Favored 'General case' 0 N--CA 1.471 0.614 0 N-CA-C 109.429 -0.582 . . . . 0.0 109.429 178.783 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 7' ' ' ASP . . . . . 0.496 ' O ' ' OG ' ' I' ' 8' ' ' SER . 3.7 m-20 -70.76 149.33 47.01 Favored 'General case' 0 CA--C 1.535 0.382 0 CA-C-N 116.418 -0.356 . . . . 0.0 110.844 -179.929 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' F' F ' 8' ' ' SER . . . . . 0.495 ' OG ' ' O ' ' C' ' 7' ' ' ASP . 43.2 p -168.56 -171.63 1.48 Allowed 'General case' 0 N--CA 1.484 1.262 0 CA-C-O 121.236 0.541 . . . . 0.0 110.935 179.169 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.95 46.82 1.42 Allowed Glycine 0 N--CA 1.478 1.492 0 CA-C-N 115.855 -0.611 . . . . 0.0 111.761 179.551 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 46.6 p90 -64.64 132.42 49.69 Favored 'General case' 0 CA--C 1.542 0.642 0 N-CA-C 112.01 0.374 . . . . 0.0 112.01 -179.886 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 48.6 mt-10 -91.04 152.29 20.71 Favored 'General case' 0 N--CA 1.482 1.13 0 CA-C-O 121.266 0.555 . . . . 0.0 109.685 177.89 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -154.49 126.98 1.05 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.67 0 N-CA-C 107.855 -1.165 . . . . 0.0 107.855 178.058 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 42.5 m-70 -135.24 144.81 47.09 Favored 'General case' 0 N--CA 1.483 1.179 0 CA-C-O 120.847 0.356 . . . . 0.0 111.522 -177.919 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 6.0 t60 -164.88 96.91 0.74 Allowed 'General case' 0 N--CA 1.484 1.27 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.805 179.539 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 15' ' ' GLN . . . . . 0.667 HE22 ' H ' ' F' ' 37' ' ' GLY . 6.0 pt20 -108.02 -174.17 2.46 Favored 'General case' 0 CA--C 1.505 -0.751 0 N-CA-C 108.574 -0.899 . . . . 0.0 108.574 -179.875 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -164.17 97.79 0.82 Allowed 'General case' 0 N--CA 1.473 0.719 0 CA-C-N 114.578 -1.192 . . . . 0.0 108.397 178.561 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 6.4 mp -120.55 155.73 33.05 Favored 'General case' 0 N--CA 1.494 1.773 0 CA-C-O 121.667 0.746 . . . . 0.0 111.456 -177.727 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 48.4 t -113.64 124.38 70.23 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.25 0 N-CA-C 108.199 -1.037 . . . . 0.0 108.199 177.17 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 30.5 m-85 -124.7 121.19 33.97 Favored 'General case' 0 N--CA 1.488 1.439 0 CA-C-O 120.77 0.319 . . . . 0.0 111.015 -179.783 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 67.9 m-85 55.27 73.23 0.43 Allowed 'General case' 0 C--N 1.344 0.342 0 CA-C-N 115.953 -0.567 . . . . 0.0 111.733 178.322 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -78.92 -78.58 0.15 Allowed 'General case' 0 N--CA 1.467 0.419 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.147 -179.27 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 40.3 tt0 -112.66 99.99 8.36 Favored 'General case' 0 C--N 1.324 -0.524 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 -179.825 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -157.88 138.8 13.2 Favored 'General case' 0 C--O 1.203 -1.361 0 N-CA-C 111.681 0.252 . . . . 0.0 111.681 179.052 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 24' ' ' VAL . . . . . 0.402 ' HB ' ' H ' ' C' ' 25' ' ' GLY . 60.0 t -58.13 168.24 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.935 0 N-CA-C 107.398 -1.334 . . . . 0.0 107.398 177.116 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -121.92 48.53 0.94 Allowed Glycine 0 N--CA 1.476 1.35 0 N-CA-C 110.877 -0.889 . . . . 0.0 110.877 -179.394 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -62.11 -167.4 0.01 OUTLIER 'General case' 0 N--CA 1.47 0.565 0 CA-C-O 120.782 0.325 . . . . 0.0 110.285 179.895 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 25.8 t-20 -70.1 77.0 0.51 Allowed 'General case' 0 N--CA 1.466 0.338 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.589 179.979 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 97.8 mttt -74.57 143.81 44.28 Favored 'General case' 0 N--CA 1.478 0.957 0 N-CA-C 109.483 -0.562 . . . . 0.0 109.483 179.524 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.39 -167.11 1.25 Allowed Glycine 0 C--N 1.334 0.425 0 N-CA-C 110.486 -1.046 . . . . 0.0 110.486 178.539 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.69 113.65 26.25 Favored 'General case' 0 N--CA 1.477 0.917 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 179.752 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 72.0 mt -97.71 134.59 35.28 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.285 0 N-CA-C 106.981 -1.489 . . . . 0.0 106.981 178.717 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 32' ' ' ILE . . . . . 0.411 ' C ' ' H ' ' F' ' 34' ' ' LEU . 32.1 pt -150.74 -169.6 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.198 0 CA-C-O 121.126 0.489 . . . . 0.0 110.7 -179.476 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.64 5.12 6.29 Favored Glycine 0 CA--C 1.527 0.82 0 CA-C-N 115.688 -0.687 . . . . 0.0 111.407 -179.78 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 34' ' ' LEU . . . . . 0.411 ' H ' ' C ' ' F' ' 32' ' ' ILE . 1.1 tt -74.66 135.83 41.93 Favored 'General case' 0 CA--C 1.549 0.922 0 N-CA-C 109.18 -0.674 . . . . 0.0 109.18 -179.669 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 26.0 ttt -158.72 145.92 17.58 Favored 'General case' 0 N--CA 1.47 0.561 0 N-CA-C 108.66 -0.867 . . . . 0.0 108.66 178.446 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 1.5 m -148.78 165.14 4.35 Favored 'Isoleucine or valine' 0 C--N 1.349 0.547 0 N-CA-C 108.425 -0.954 . . . . 0.0 108.425 -179.495 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 37' ' ' GLY . . . . . 0.667 ' H ' HE22 ' F' ' 15' ' ' GLN . . . 54.33 68.37 1.7 Allowed Glycine 0 C--N 1.306 -1.108 0 CA-C-N 115.328 -0.851 . . . . 0.0 112.331 177.808 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 146.97 174.09 18.74 Favored Glycine 0 N--CA 1.472 1.097 0 N-CA-C 111.415 -0.674 . . . . 0.0 111.415 178.645 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 39' ' ' VAL . . . . . 0.408 ' H ' HG11 ' I' ' 39' ' ' VAL . 33.1 m -107.22 155.54 7.88 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.714 0 C-N-CA 123.471 0.708 . . . . 0.0 110.588 -178.803 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 26.8 t . . . . . 0 C--O 1.219 -0.55 0 O-C-N 124.286 0.991 . . . . 0.0 110.3 179.601 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' G' G ' 1' ' ' ASP . . . . . 0.462 ' CB ' ' H3 ' ' D' ' 1' ' ' ASP . 15.0 m-20 . . . . . 0 N--CA 1.492 1.635 0 N-CA-C 109.303 -0.629 . . . . 0.0 109.303 . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.74 129.82 42.22 Favored 'General case' 0 N--CA 1.47 0.536 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.563 179.525 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 3' ' ' GLU . . . . . . . . . . . . . 46.9 tt0 -168.65 107.12 0.46 Allowed 'General case' 0 N--CA 1.475 0.821 0 N-CA-C 110.565 -0.161 . . . . 0.0 110.565 179.706 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 67.1 m-85 -86.52 144.61 27.15 Favored 'General case' 0 N--CA 1.473 0.692 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 179.169 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 5' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -143.91 142.77 30.95 Favored 'General case' 0 N--CA 1.483 1.189 0 CA-C-O 120.828 0.347 . . . . 0.0 110.162 179.983 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 45.8 t-80 -152.31 119.5 5.9 Favored 'General case' 0 N--CA 1.473 0.682 0 N-CA-C 109.574 -0.528 . . . . 0.0 109.574 178.794 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 4.0 m-20 -71.82 144.49 49.11 Favored 'General case' 0 CA--C 1.538 0.519 0 C-N-CA 122.716 0.406 . . . . 0.0 111.176 -179.938 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 8' ' ' SER . . . . . 0.598 ' OG ' ' O ' ' D' ' 7' ' ' ASP . 35.5 p -164.77 -169.62 1.76 Allowed 'General case' 0 N--CA 1.476 0.86 0 CA-C-O 121.178 0.513 . . . . 0.0 110.512 178.672 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.21 47.73 1.41 Allowed Glycine 0 N--CA 1.48 1.63 0 N-CA-C 111.344 -0.703 . . . . 0.0 111.344 179.291 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 48.0 p90 -65.69 133.16 50.51 Favored 'General case' 0 CA--C 1.542 0.636 0 N-CA-C 111.872 0.323 . . . . 0.0 111.872 -179.627 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 47.9 mt-10 -91.76 151.48 20.6 Favored 'General case' 0 N--CA 1.479 1.022 0 CA-C-O 121.162 0.506 . . . . 0.0 110.0 178.576 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -154.99 127.28 1.01 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.004 0 N-CA-C 107.851 -1.166 . . . . 0.0 107.851 178.196 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 44.2 m-70 -134.67 146.06 49.14 Favored 'General case' 0 N--CA 1.48 1.05 0 CA-C-N 115.667 -0.697 . . . . 0.0 111.45 -178.363 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 6.0 t60 -166.24 97.05 0.6 Allowed 'General case' 0 N--CA 1.481 1.115 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.385 178.946 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 15' ' ' GLN . . . . . 0.655 HE22 ' H ' ' G' ' 37' ' ' GLY . 6.0 pt20 -108.42 -174.51 2.54 Favored 'General case' 0 CA--C 1.508 -0.641 0 N-CA-C 108.31 -0.996 . . . . 0.0 108.31 -179.702 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -164.27 97.72 0.81 Allowed 'General case' 0 N--CA 1.475 0.802 0 CA-C-N 114.606 -1.179 . . . . 0.0 108.12 178.667 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 6.4 mp -120.4 154.8 34.64 Favored 'General case' 0 N--CA 1.498 1.934 0 CA-C-O 121.247 0.546 . . . . 0.0 111.774 -177.883 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 43.1 t -113.33 124.66 70.19 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.942 0 CA-C-N 114.777 -1.101 . . . . 0.0 108.186 176.55 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 32.1 m-85 -125.29 121.19 33.3 Favored 'General case' 0 C--N 1.367 1.349 0 C-N-CA 123.437 0.695 . . . . 0.0 110.979 -179.602 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 68.0 m-85 55.37 72.57 0.47 Allowed 'General case' 0 N--CA 1.467 0.393 0 CA-C-N 115.898 -0.592 . . . . 0.0 111.496 178.274 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.78 -77.99 0.14 Allowed 'General case' 0 N--CA 1.473 0.697 0 O-C-N 122.237 -0.289 . . . . 0.0 110.407 -178.932 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 41.1 tt0 -113.02 100.2 8.44 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 107.812 -1.181 . . . . 0.0 107.812 179.909 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -157.73 139.75 14.21 Favored 'General case' 0 N--CA 1.476 0.865 0 N-CA-C 111.649 0.24 . . . . 0.0 111.649 178.959 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 24' ' ' VAL . . . . . 0.434 ' HB ' ' H ' ' D' ' 25' ' ' GLY . 62.0 t -59.62 166.97 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.656 0 N-CA-C 107.564 -1.273 . . . . 0.0 107.564 177.353 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -120.13 49.32 0.88 Allowed Glycine 0 N--CA 1.479 1.538 0 N-CA-C 110.617 -0.993 . . . . 0.0 110.617 -179.507 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -63.45 -166.59 0.02 OUTLIER 'General case' 0 N--CA 1.471 0.62 0 N-CA-C 109.895 -0.409 . . . . 0.0 109.895 179.904 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 26.2 t-20 -70.99 76.96 0.65 Allowed 'General case' 0 CA--C 1.535 0.386 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.599 -179.89 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 97.9 mttt -73.95 143.14 45.81 Favored 'General case' 0 N--CA 1.475 0.808 0 N-CA-C 109.623 -0.51 . . . . 0.0 109.623 179.427 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.08 -166.17 0.98 Allowed Glycine 0 C--N 1.337 0.592 0 N-CA-C 110.019 -1.232 . . . . 0.0 110.019 178.642 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.57 114.28 27.2 Favored 'General case' 0 N--CA 1.472 0.659 0 C-N-CA 122.708 0.403 . . . . 0.0 110.138 -179.977 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 73.6 mt -98.51 135.02 34.97 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.649 0 N-CA-C 107.054 -1.461 . . . . 0.0 107.054 178.67 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 32' ' ' ILE . . . . . 0.419 ' C ' ' H ' ' G' ' 34' ' ' LEU . 34.3 pt -151.5 -169.28 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 CA-C-N 119.723 1.147 . . . . 0.0 109.916 -179.813 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.28 4.78 6.85 Favored Glycine 0 N--CA 1.468 0.774 0 N-CA-C 111.132 -0.787 . . . . 0.0 111.132 -179.864 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 34' ' ' LEU . . . . . 0.419 ' H ' ' C ' ' G' ' 32' ' ' ILE . 1.1 tt -74.95 135.12 41.41 Favored 'General case' 0 CA--C 1.545 0.775 0 N-CA-C 109.295 -0.631 . . . . 0.0 109.295 -179.757 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 25.0 ttt -158.28 146.06 18.31 Favored 'General case' 0 N--CA 1.47 0.566 0 N-CA-C 108.64 -0.874 . . . . 0.0 108.64 178.823 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 1.5 m -148.82 163.4 4.85 Favored 'Isoleucine or valine' 0 C--N 1.349 0.561 0 N-CA-C 108.587 -0.894 . . . . 0.0 108.587 -179.469 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 37' ' ' GLY . . . . . 0.655 ' H ' HE22 ' G' ' 15' ' ' GLN . . . 55.4 68.76 1.52 Allowed Glycine 0 C--N 1.308 -1.001 0 CA-C-N 115.226 -0.897 . . . . 0.0 112.293 177.596 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.39 172.35 17.46 Favored Glycine 0 N--CA 1.476 1.314 0 N-CA-C 110.569 -1.012 . . . . 0.0 110.569 178.892 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 33.9 m -106.01 155.64 6.92 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.923 0 C-N-CA 123.198 0.599 . . . . 0.0 110.452 -179.541 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 27.5 t . . . . . 0 C--O 1.22 -0.46 0 O-C-N 123.961 0.788 . . . . 0.0 110.563 179.371 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' H' H ' 1' ' ' ASP . . . . . 0.487 ' CB ' ' H3 ' ' E' ' 1' ' ' ASP . 16.4 m-20 . . . . . 0 N--CA 1.491 1.606 0 N-CA-C 109.445 -0.576 . . . . 0.0 109.445 . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' H' H ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.39 129.75 42.1 Favored 'General case' 0 N--CA 1.47 0.526 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.541 179.799 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' H' H ' 3' ' ' GLU . . . . . . . . . . . . . 47.3 tt0 -168.39 106.89 0.48 Allowed 'General case' 0 N--CA 1.472 0.635 0 CA-C-O 120.464 0.173 . . . . 0.0 110.634 179.697 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 68.8 m-85 -86.06 144.91 27.31 Favored 'General case' 0 N--CA 1.473 0.71 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 179.166 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' H' H ' 5' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -144.21 142.92 30.81 Favored 'General case' 0 N--CA 1.483 1.217 0 N-CA-C 110.046 -0.353 . . . . 0.0 110.046 -179.98 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 46.6 t-80 -152.65 119.69 5.82 Favored 'General case' 0 N--CA 1.472 0.636 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 178.812 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 3.9 m-20 -72.19 144.56 48.47 Favored 'General case' 0 N--CA 1.469 0.481 0 CA-C-N 116.319 -0.401 . . . . 0.0 111.222 -179.781 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' H' H ' 8' ' ' SER . . . . . 0.506 ' OG ' ' O ' ' E' ' 7' ' ' ASP . 52.2 p -164.72 -170.07 1.9 Allowed 'General case' 0 N--CA 1.475 0.776 0 CA-C-O 121.129 0.49 . . . . 0.0 110.492 178.912 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.48 47.63 1.39 Allowed Glycine 0 N--CA 1.478 1.499 0 N-CA-C 111.557 -0.617 . . . . 0.0 111.557 179.409 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 48.4 p90 -65.97 133.14 50.22 Favored 'General case' 0 CA--C 1.54 0.584 0 N-CA-C 111.861 0.319 . . . . 0.0 111.861 -179.587 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 47.8 mt-10 -91.67 151.44 20.67 Favored 'General case' 0 N--CA 1.477 0.921 0 CA-C-O 121.064 0.459 . . . . 0.0 110.065 178.583 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -154.98 127.35 1.03 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.004 0 N-CA-C 107.92 -1.141 . . . . 0.0 107.92 178.13 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 43.5 m-70 -134.67 146.36 49.43 Favored 'General case' 0 N--CA 1.479 0.98 0 CA-C-N 115.694 -0.685 . . . . 0.0 111.311 -178.321 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 6.1 t60 -166.43 96.71 0.57 Allowed 'General case' 0 N--CA 1.481 1.102 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.508 178.912 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' H' H ' 15' ' ' GLN . . . . . 0.65 HE22 ' H ' ' H' ' 37' ' ' GLY . 5.9 pt20 -107.97 -174.13 2.45 Favored 'General case' 0 CA--C 1.507 -0.681 0 N-CA-C 108.304 -0.999 . . . . 0.0 108.304 -179.624 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -164.68 97.5 0.76 Allowed 'General case' 0 N--CA 1.474 0.757 0 CA-C-N 114.584 -1.189 . . . . 0.0 108.127 178.61 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 6.4 mp -120.21 154.92 34.16 Favored 'General case' 0 N--CA 1.496 1.857 0 CA-C-O 121.265 0.555 . . . . 0.0 111.838 -177.939 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 43.2 t -113.4 124.65 70.25 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.079 0 CA-C-N 114.817 -1.083 . . . . 0.0 108.158 176.668 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 32.2 m-85 -125.22 121.28 33.65 Favored 'General case' 0 C--N 1.366 1.313 0 C-N-CA 123.471 0.708 . . . . 0.0 110.885 -179.443 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 68.3 m-85 54.72 72.92 0.43 Allowed 'General case' 0 C--O 1.238 0.455 0 CA-C-N 115.698 -0.683 . . . . 0.0 111.672 178.342 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.68 -78.31 0.14 Allowed 'General case' 0 N--CA 1.473 0.676 0 O-C-N 122.154 -0.341 . . . . 0.0 110.349 -178.914 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 40.8 tt0 -112.85 99.77 8.15 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 107.878 -1.156 . . . . 0.0 107.878 -179.946 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -157.24 139.96 15.02 Favored 'General case' 0 N--CA 1.477 0.887 0 O-C-N 122.346 -0.221 . . . . 0.0 111.471 178.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' H' H ' 24' ' ' VAL . . . . . . . . . . . . . 59.7 t -59.7 167.65 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.592 0 N-CA-C 107.458 -1.312 . . . . 0.0 107.458 177.313 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . -120.63 49.27 0.89 Allowed Glycine 0 N--CA 1.479 1.5 0 N-CA-C 110.622 -0.991 . . . . 0.0 110.622 -179.581 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -63.6 -167.33 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.643 0 CA-C-N 117.033 0.417 . . . . 0.0 110.036 179.766 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 26.2 t-20 -70.05 77.04 0.5 Allowed 'General case' 0 N--CA 1.465 0.318 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.587 -179.945 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 97.8 mttt -74.1 143.45 45.38 Favored 'General case' 0 N--CA 1.475 0.819 0 N-CA-C 109.5 -0.556 . . . . 0.0 109.5 179.41 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.67 -166.39 1.21 Allowed Glycine 0 C--N 1.338 0.669 0 N-CA-C 109.997 -1.241 . . . . 0.0 109.997 178.641 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.4 114.29 27.13 Favored 'General case' 0 N--CA 1.47 0.554 0 C-N-CA 122.683 0.393 . . . . 0.0 110.293 -179.995 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 74.0 mt -98.46 135.09 34.6 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.693 0 N-CA-C 106.992 -1.484 . . . . 0.0 106.992 178.672 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' H' H ' 32' ' ' ILE . . . . . 0.414 ' C ' ' H ' ' H' ' 34' ' ' LEU . 34.8 pt -151.51 -169.02 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.759 0 CA-C-N 119.667 1.121 . . . . 0.0 109.826 -179.929 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.08 5.28 7.42 Favored Glycine 0 N--CA 1.467 0.706 0 N-CA-C 111.055 -0.818 . . . . 0.0 111.055 -179.979 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' H' H ' 34' ' ' LEU . . . . . 0.414 ' H ' ' C ' ' H' ' 32' ' ' ILE . 1.1 tt -75.44 135.24 40.73 Favored 'General case' 0 CA--C 1.545 0.784 0 N-CA-C 109.4 -0.593 . . . . 0.0 109.4 -179.744 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 25.4 ttt -158.41 146.01 18.08 Favored 'General case' 0 N--CA 1.469 0.514 0 N-CA-C 108.698 -0.853 . . . . 0.0 108.698 178.882 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 1.5 m -148.91 163.83 4.57 Favored 'Isoleucine or valine' 0 C--N 1.35 0.594 0 N-CA-C 108.56 -0.904 . . . . 0.0 108.56 -179.467 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' H' H ' 37' ' ' GLY . . . . . 0.65 ' H ' HE22 ' H' ' 15' ' ' GLN . . . 55.29 68.29 1.76 Allowed Glycine 0 C--N 1.306 -1.087 0 CA-C-N 115.237 -0.892 . . . . 0.0 112.32 177.612 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.54 172.72 17.96 Favored Glycine 0 N--CA 1.475 1.24 0 N-CA-C 110.745 -0.942 . . . . 0.0 110.745 178.959 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 34.1 m -106.13 155.75 6.98 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.0 0 C-N-CA 123.32 0.648 . . . . 0.0 110.575 -179.497 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 25.9 t . . . . . 0 C--O 1.219 -0.533 0 O-C-N 123.991 0.807 . . . . 0.0 110.61 179.424 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' I' I ' 1' ' ' ASP . . . . . 0.463 ' CB ' ' H3 ' ' F' ' 1' ' ' ASP . 16.8 m-20 . . . . . 0 N--CA 1.491 1.615 0 N-CA-C 109.45 -0.574 . . . . 0.0 109.45 . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' I' I ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.3 129.63 41.59 Favored 'General case' 0 N--CA 1.469 0.52 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.573 179.716 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' I' I ' 3' ' ' GLU . . . . . . . . . . . . . 46.8 tt0 -168.42 107.07 0.48 Allowed 'General case' 0 N--CA 1.473 0.709 0 CA-C-O 120.484 0.183 . . . . 0.0 110.567 179.769 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 67.2 m-85 -86.46 144.81 27.1 Favored 'General case' 0 N--CA 1.475 0.788 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 179.226 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' I' I ' 5' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -144.12 142.48 30.61 Favored 'General case' 0 N--CA 1.482 1.153 0 N-CA-C 110.023 -0.362 . . . . 0.0 110.023 -179.931 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 45.1 t-80 -152.28 119.61 5.95 Favored 'General case' 0 N--CA 1.472 0.629 0 N-CA-C 109.503 -0.554 . . . . 0.0 109.503 178.824 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -71.96 144.81 48.77 Favored 'General case' 0 N--CA 1.469 0.481 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.105 -179.758 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' I' I ' 8' ' ' SER . . . . . 0.496 ' OG ' ' O ' ' F' ' 7' ' ' ASP . 51.7 p -164.95 -170.21 1.89 Allowed 'General case' 0 N--CA 1.474 0.742 0 CA-C-O 121.139 0.495 . . . . 0.0 110.547 178.956 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.27 47.72 1.4 Allowed Glycine 0 N--CA 1.479 1.518 0 N-CA-C 111.592 -0.603 . . . . 0.0 111.592 179.544 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 47.5 p90 -65.89 132.9 49.76 Favored 'General case' 0 N--CA 1.471 0.586 0 N-CA-C 111.883 0.327 . . . . 0.0 111.883 -179.789 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 48.4 mt-10 -91.57 151.13 20.87 Favored 'General case' 0 N--CA 1.478 0.936 0 CA-C-O 121.149 0.499 . . . . 0.0 110.013 178.654 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -154.75 127.32 1.06 Allowed 'Isoleucine or valine' 0 CA--C 1.551 0.983 0 N-CA-C 107.979 -1.119 . . . . 0.0 107.979 178.252 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 44.0 m-70 -134.83 146.2 49.06 Favored 'General case' 0 N--CA 1.479 0.993 0 CA-C-N 115.68 -0.691 . . . . 0.0 111.384 -178.149 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 6.0 t60 -166.31 96.87 0.59 Allowed 'General case' 0 N--CA 1.48 1.051 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.399 178.91 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' I' I ' 15' ' ' GLN . . . . . 0.662 HE22 ' H ' ' I' ' 37' ' ' GLY . 5.9 pt20 -108.17 -174.48 2.53 Favored 'General case' 0 CA--C 1.505 -0.762 0 N-CA-C 108.272 -1.01 . . . . 0.0 108.272 -179.731 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -164.3 97.84 0.81 Allowed 'General case' 0 N--CA 1.475 0.794 0 CA-C-N 114.58 -1.191 . . . . 0.0 108.043 178.698 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 6.4 mp -120.65 154.34 35.64 Favored 'General case' 0 N--CA 1.497 1.902 0 CA-C-O 121.215 0.531 . . . . 0.0 111.837 -177.938 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 42.9 t -112.72 125.16 69.95 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.949 0 N-CA-C 108.067 -1.086 . . . . 0.0 108.067 176.595 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 30.7 m-85 -125.71 121.37 33.24 Favored 'General case' 0 C--N 1.367 1.341 0 CA-C-N 115.585 -0.734 . . . . 0.0 110.815 -179.285 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 68.9 m-85 54.59 72.52 0.46 Allowed 'General case' 0 C--N 1.345 0.38 0 CA-C-N 115.916 -0.584 . . . . 0.0 111.49 178.27 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.33 -78.25 0.13 Allowed 'General case' 0 N--CA 1.473 0.72 0 N-CA-C 110.294 -0.262 . . . . 0.0 110.294 -178.971 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 40.9 tt0 -112.77 99.86 8.24 Favored 'General case' 0 C--N 1.323 -0.566 0 N-CA-C 107.978 -1.119 . . . . 0.0 107.978 -179.959 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 4.7 p30 -157.31 139.91 14.88 Favored 'General case' 0 N--CA 1.477 0.891 0 N-CA-C 111.487 0.18 . . . . 0.0 111.487 178.978 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' I' I ' 24' ' ' VAL . . . . . . . . . . . . . 61.2 t -59.76 167.26 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.56 0 N-CA-C 107.567 -1.271 . . . . 0.0 107.567 177.243 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . -120.34 49.62 0.87 Allowed Glycine 0 N--CA 1.479 1.516 0 N-CA-C 110.669 -0.972 . . . . 0.0 110.669 -179.494 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -63.73 -166.89 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.572 0 N-CA-C 110.036 -0.357 . . . . 0.0 110.036 179.881 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 26.4 t-20 -70.58 76.56 0.58 Allowed 'General case' 0 CA--C 1.533 0.294 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.584 179.983 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 97.9 mttt -73.65 143.63 46.2 Favored 'General case' 0 N--CA 1.475 0.816 0 N-CA-C 109.561 -0.533 . . . . 0.0 109.561 179.422 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.74 -166.31 1.22 Allowed Glycine 0 C--N 1.336 0.548 0 N-CA-C 110.016 -1.233 . . . . 0.0 110.016 178.647 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.24 114.11 26.74 Favored 'General case' 0 N--CA 1.473 0.721 0 C-N-CA 122.706 0.402 . . . . 0.0 110.315 179.937 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 75.1 mt -98.3 135.08 34.38 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.631 0 N-CA-C 106.94 -1.504 . . . . 0.0 106.94 178.695 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' I' I ' 32' ' ' ILE . . . . . 0.411 ' C ' ' H ' ' I' ' 34' ' ' LEU . 35.1 pt -151.5 -169.16 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.831 0 CA-C-N 119.62 1.1 . . . . 0.0 109.771 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.36 5.11 7.53 Favored Glycine 0 N--CA 1.466 0.686 0 N-CA-C 111.054 -0.818 . . . . 0.0 111.054 -179.893 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' I' I ' 34' ' ' LEU . . . . . 0.411 ' H ' ' C ' ' I' ' 32' ' ' ILE . 1.1 tt -75.21 134.92 41.07 Favored 'General case' 0 N--CA 1.474 0.77 0 N-CA-C 109.336 -0.616 . . . . 0.0 109.336 -179.646 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 24.7 ttt -158.06 145.97 18.55 Favored 'General case' 0 N--CA 1.47 0.555 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 178.906 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 1.5 m -149.08 163.67 4.41 Favored 'Isoleucine or valine' 0 C--N 1.35 0.616 0 N-CA-C 108.491 -0.929 . . . . 0.0 108.491 -179.455 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' I' I ' 37' ' ' GLY . . . . . 0.662 ' H ' HE22 ' I' ' 15' ' ' GLN . . . 55.25 68.58 1.61 Allowed Glycine 0 C--N 1.308 -1.015 0 CA-C-N 115.218 -0.901 . . . . 0.0 112.282 177.706 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.25 172.5 17.51 Favored Glycine 0 N--CA 1.475 1.234 0 N-CA-C 110.646 -0.982 . . . . 0.0 110.646 178.923 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' I' I ' 39' ' ' VAL . . . . . 0.408 HG11 ' H ' ' F' ' 39' ' ' VAL . 34.4 m -106.17 155.49 7.06 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.993 0 C-N-CA 123.185 0.594 . . . . 0.0 110.635 -179.382 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 25.9 t . . . . . 0 C--O 1.218 -0.559 0 O-C-N 123.955 0.784 . . . . 0.0 110.599 179.433 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . 0.46 ' H1 ' ' CB ' ' D' ' 1' ' ' ASP . 16.8 m-20 . . . . . 0 N--CA 1.49 1.532 0 N-CA-C 108.831 -0.803 . . . . 0.0 108.831 . . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -66.27 133.65 51.02 Favored 'General case' 0 CA--C 1.539 0.537 0 CA-C-N 116.526 -0.306 . . . . 0.0 110.219 -179.773 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 48.8 tt0 -169.52 105.85 0.37 Allowed 'General case' 0 C--O 1.216 -0.696 0 N-CA-C 110.0 -0.37 . . . . 0.0 110.0 -179.296 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 64.9 m-85 -83.95 145.72 28.4 Favored 'General case' 0 N--CA 1.474 0.77 0 N-CA-C 110.173 -0.306 . . . . 0.0 110.173 179.54 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -144.11 142.94 30.89 Favored 'General case' 0 N--CA 1.481 1.098 0 CA-C-O 120.925 0.393 . . . . 0.0 110.031 179.417 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 46.7 t-80 -152.83 118.99 5.49 Favored 'General case' 0 N--CA 1.472 0.654 0 N-CA-C 109.157 -0.683 . . . . 0.0 109.157 179.19 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' ASP . . . . . 0.512 ' O ' ' OG ' ' D' ' 8' ' ' SER . 4.3 m-20 -69.58 149.59 48.0 Favored 'General case' 0 N--CA 1.467 0.406 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.331 179.794 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 52.4 p -168.03 -173.27 2.02 Favored 'General case' 0 N--CA 1.484 1.243 0 CA-C-O 121.006 0.431 . . . . 0.0 110.698 179.107 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.79 46.49 1.49 Allowed Glycine 0 N--CA 1.481 1.686 0 CA-C-N 116.009 -0.541 . . . . 0.0 112.11 -179.941 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 49.1 p90 -65.12 132.43 49.14 Favored 'General case' 0 N--CA 1.473 0.685 0 O-C-N 122.687 -0.302 . . . . 0.0 111.561 179.631 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 49.2 mt-10 -91.83 152.13 20.26 Favored 'General case' 0 N--CA 1.477 0.889 0 N-CA-C 109.87 -0.419 . . . . 0.0 109.87 178.297 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -152.73 128.45 1.69 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.592 0 N-CA-C 107.849 -1.167 . . . . 0.0 107.849 178.248 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 44.5 m-70 -135.54 145.94 47.54 Favored 'General case' 0 N--CA 1.491 1.617 0 CA-C-N 119.011 0.823 . . . . 0.0 111.374 -179.107 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -166.9 97.25 0.53 Allowed 'General case' 0 N--CA 1.481 1.107 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.635 179.571 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 14.7 pt20 -109.69 -174.01 2.4 Favored 'General case' 0 CA--C 1.505 -0.788 0 N-CA-C 108.36 -0.978 . . . . 0.0 108.36 179.887 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -162.71 98.98 1.0 Allowed 'General case' 0 N--CA 1.472 0.669 0 CA-C-N 114.59 -1.186 . . . . 0.0 108.309 178.274 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 6.7 mp -121.45 155.55 34.64 Favored 'General case' 0 N--CA 1.497 1.901 0 CA-C-O 121.832 0.825 . . . . 0.0 110.938 -178.347 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 58.3 t -111.59 126.47 68.98 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.046 0 CA-C-O 117.894 -1.05 . . . . 0.0 108.344 177.742 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 29.2 m-85 -126.27 122.9 36.84 Favored 'General case' 0 N--CA 1.496 1.862 0 CA-C-N 120.147 1.34 . . . . 0.0 110.284 179.281 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 68.1 m-85 54.02 74.02 0.35 Allowed 'General case' 0 N--CA 1.47 0.538 0 CA-C-O 121.398 0.618 . . . . 0.0 111.66 178.729 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -79.77 -78.29 0.16 Allowed 'General case' 0 C--N 1.353 0.734 0 CA-C-N 115.175 -0.92 . . . . 0.0 110.442 -179.902 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 40.8 tt0 -113.15 100.19 8.4 Favored 'General case' 0 N--CA 1.47 0.565 0 N-CA-C 108.327 -0.99 . . . . 0.0 108.327 179.603 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 4.4 p30 -158.74 138.72 12.09 Favored 'General case' 0 N--CA 1.485 1.282 0 CA-C-O 119.403 -0.332 . . . . 0.0 111.226 179.271 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 57.4 t -59.83 163.9 0.87 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.783 0 N-CA-C 108.224 -1.028 . . . . 0.0 108.224 176.932 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -117.06 47.15 1.06 Allowed Glycine 0 N--CA 1.477 1.39 0 N-CA-C 111.753 -0.539 . . . . 0.0 111.753 -179.219 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -60.11 -167.79 0.01 OUTLIER 'General case' 0 N--CA 1.469 0.512 0 O-C-N 123.852 0.384 . . . . 0.0 110.405 179.272 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 26.1 t-20 -70.98 81.05 0.66 Allowed 'General case' 0 CA--C 1.531 0.219 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.212 179.6 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 97.7 mttt -77.93 143.16 37.9 Favored 'General case' 0 N--CA 1.471 0.582 0 N-CA-C 109.163 -0.68 . . . . 0.0 109.163 179.396 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.67 -167.51 1.06 Allowed Glycine 0 CA--C 1.525 0.707 0 N-CA-C 109.926 -1.269 . . . . 0.0 109.926 178.962 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.91 115.02 28.67 Favored 'General case' 0 N--CA 1.476 0.846 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 179.677 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 72.3 mt -98.68 134.46 37.34 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.518 0 N-CA-C 107.025 -1.472 . . . . 0.0 107.025 179.021 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 29.3 pt -150.68 -172.0 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.708 0 CA-C-O 121.209 0.528 . . . . 0.0 111.184 -179.14 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.63 4.73 10.5 Favored Glycine 0 CA--C 1.527 0.785 0 N-CA-C 110.699 -0.96 . . . . 0.0 110.699 179.882 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 1.1 tt -75.43 135.16 40.75 Favored 'General case' 0 CA--C 1.544 0.726 0 N-CA-C 109.405 -0.591 . . . . 0.0 109.405 -179.56 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 27.2 ttt -158.54 146.64 18.33 Favored 'General case' 0 N--CA 1.47 0.546 0 N-CA-C 108.557 -0.905 . . . . 0.0 108.557 178.705 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 1.7 m -149.16 165.49 3.78 Favored 'Isoleucine or valine' 0 C--N 1.349 0.579 0 N-CA-C 108.056 -1.09 . . . . 0.0 108.056 -179.584 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.19 68.36 1.73 Allowed Glycine 0 C--N 1.305 -1.158 0 CA-C-N 115.521 -0.763 . . . . 0.0 112.316 177.581 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.32 177.32 21.73 Favored Glycine 0 N--CA 1.474 1.192 0 N-CA-C 111.008 -0.837 . . . . 0.0 111.008 178.514 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 34.3 m -109.81 155.59 10.95 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.623 0 C-N-CA 123.432 0.693 . . . . 0.0 110.354 -179.643 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 23.4 t . . . . . 0 C--O 1.219 -0.501 0 O-C-N 124.031 0.832 . . . . 0.0 110.663 179.633 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' B' B ' 1' ' ' ASP . . . . . 0.47 ' H1 ' ' CB ' ' E' ' 1' ' ' ASP . 16.1 m-20 . . . . . 0 N--CA 1.489 1.475 0 N-CA-C 109.036 -0.727 . . . . 0.0 109.036 . . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.98 133.4 50.77 Favored 'General case' 0 CA--C 1.54 0.575 0 N-CA-C 110.137 -0.319 . . . . 0.0 110.137 -179.788 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 3' ' ' GLU . . . . . . . . . . . . . 48.5 tt0 -169.38 105.68 0.38 Allowed 'General case' 0 N--CA 1.473 0.683 0 N-CA-C 110.055 -0.35 . . . . 0.0 110.055 -179.057 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 63.9 m-85 -83.78 145.65 28.58 Favored 'General case' 0 N--CA 1.475 0.804 0 N-CA-C 110.154 -0.313 . . . . 0.0 110.154 179.504 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -144.32 141.92 30.07 Favored 'General case' 0 N--CA 1.481 1.089 0 N-CA-C 109.881 -0.414 . . . . 0.0 109.881 179.513 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 47.2 t-80 -151.71 118.55 5.8 Favored 'General case' 0 N--CA 1.473 0.715 0 N-CA-C 109.319 -0.623 . . . . 0.0 109.319 178.989 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 7' ' ' ASP . . . . . 0.496 ' O ' ' OG ' ' E' ' 8' ' ' SER . 3.9 m-20 -69.2 148.9 49.21 Favored 'General case' 0 N--CA 1.469 0.485 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.525 179.761 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 8' ' ' SER . . . . . . . . . . . . . 49.4 p -167.52 -173.49 2.22 Favored 'General case' 0 N--CA 1.481 1.125 0 CA-C-O 120.974 0.416 . . . . 0.0 110.653 179.155 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.26 46.92 1.38 Allowed Glycine 0 N--CA 1.482 1.728 0 CA-C-N 116.007 -0.542 . . . . 0.0 112.158 179.987 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 48.7 p90 -65.74 132.33 48.48 Favored 'General case' 0 N--CA 1.472 0.668 0 O-C-N 122.733 -0.274 . . . . 0.0 111.618 179.663 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 48.6 mt-10 -91.52 152.32 20.37 Favored 'General case' 0 N--CA 1.475 0.819 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 178.167 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -153.05 128.25 1.54 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.581 0 N-CA-C 107.783 -1.191 . . . . 0.0 107.783 178.148 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 45.5 m-70 -135.4 145.86 47.72 Favored 'General case' 0 N--CA 1.493 1.692 0 CA-C-N 118.843 0.747 . . . . 0.0 111.37 -179.141 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -166.57 97.15 0.56 Allowed 'General case' 0 N--CA 1.48 1.05 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.651 179.485 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 14.9 pt20 -109.54 -173.62 2.3 Favored 'General case' 0 CA--C 1.507 -0.7 0 N-CA-C 108.324 -0.991 . . . . 0.0 108.324 179.854 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -163.2 98.82 0.94 Allowed 'General case' 0 N--CA 1.473 0.696 0 CA-C-N 114.699 -1.137 . . . . 0.0 108.279 178.357 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 6.6 mp -121.17 155.56 34.27 Favored 'General case' 0 N--CA 1.498 1.925 0 CA-C-O 121.894 0.854 . . . . 0.0 110.927 -178.298 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 60.4 t -111.77 127.69 68.78 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.082 0 N-CA-C 108.037 -1.097 . . . . 0.0 108.037 177.538 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 28.5 m-85 -127.66 122.34 32.78 Favored 'General case' 0 N--CA 1.495 1.821 0 CA-C-N 119.665 1.12 . . . . 0.0 110.161 179.566 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 67.4 m-85 53.96 73.65 0.37 Allowed 'General case' 0 CA--C 1.54 0.571 0 CA-C-O 121.505 0.669 . . . . 0.0 111.67 178.615 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -79.65 -78.0 0.17 Allowed 'General case' 0 C--N 1.351 0.649 0 CA-C-N 115.078 -0.965 . . . . 0.0 110.435 -179.917 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 41.0 tt0 -113.4 99.62 7.92 Favored 'General case' 0 N--CA 1.47 0.56 0 N-CA-C 108.499 -0.926 . . . . 0.0 108.499 179.624 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -157.99 139.15 13.35 Favored 'General case' 0 C--O 1.205 -1.266 0 CA-C-O 119.447 -0.311 . . . . 0.0 111.208 179.204 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 59.9 t -60.15 163.49 0.98 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.824 0 N-CA-C 108.212 -1.033 . . . . 0.0 108.212 176.976 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . 0.407 ' H ' ' HB ' ' E' ' 24' ' ' VAL . . . -116.42 47.63 1.02 Allowed Glycine 0 N--CA 1.476 1.357 0 N-CA-C 111.628 -0.589 . . . . 0.0 111.628 -179.167 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -60.69 -167.68 0.01 OUTLIER 'General case' 0 N--CA 1.468 0.46 0 O-C-N 123.782 0.342 . . . . 0.0 110.306 179.414 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 26.0 t-20 -71.17 81.01 0.71 Allowed 'General case' 0 CA--C 1.532 0.27 0 N-CA-C 110.074 -0.343 . . . . 0.0 110.074 179.616 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 97.7 mttt -77.9 143.1 38.01 Favored 'General case' 0 N--CA 1.472 0.638 0 N-CA-C 109.105 -0.702 . . . . 0.0 109.105 179.442 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.49 -167.42 0.97 Allowed Glycine 0 C--N 1.337 0.618 0 N-CA-C 109.92 -1.272 . . . . 0.0 109.92 178.894 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -100.25 114.78 28.49 Favored 'General case' 0 N--CA 1.475 0.786 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 179.757 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 71.5 mt -98.46 134.51 36.8 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.501 0 N-CA-C 107.105 -1.443 . . . . 0.0 107.105 178.889 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . 0.414 ' C ' ' H ' ' B' ' 34' ' ' LEU . 30.1 pt -150.31 -171.37 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.647 0 CA-C-O 121.115 0.484 . . . . 0.0 111.227 -179.166 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.1 4.57 8.11 Favored Glycine 0 CA--C 1.526 0.752 0 N-CA-C 110.835 -0.906 . . . . 0.0 110.835 179.748 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 34' ' ' LEU . . . . . 0.414 ' H ' ' C ' ' B' ' 32' ' ' ILE . 1.1 tt -75.11 135.08 41.18 Favored 'General case' 0 CA--C 1.544 0.726 0 N-CA-C 109.376 -0.601 . . . . 0.0 109.376 -179.554 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 27.1 ttt -158.24 146.63 18.77 Favored 'General case' 0 N--CA 1.472 0.628 0 N-CA-C 108.57 -0.9 . . . . 0.0 108.57 178.547 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 1.6 m -149.29 165.45 3.7 Favored 'Isoleucine or valine' 0 C--N 1.347 0.48 0 N-CA-C 108.018 -1.105 . . . . 0.0 108.018 -179.503 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 54.81 68.67 1.56 Allowed Glycine 0 C--N 1.305 -1.158 0 CA-C-N 115.354 -0.839 . . . . 0.0 112.23 177.654 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 146.95 176.89 21.09 Favored Glycine 0 N--CA 1.474 1.194 0 N-CA-C 111.106 -0.797 . . . . 0.0 111.106 178.612 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 39' ' ' VAL . . . . . 0.401 ' H ' HG11 ' E' ' 39' ' ' VAL . 34.1 m -109.68 155.22 10.92 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.698 0 C-N-CA 123.412 0.685 . . . . 0.0 110.415 -179.501 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 23.2 t . . . . . 0 C--O 1.218 -0.569 0 O-C-N 123.991 0.807 . . . . 0.0 110.331 179.552 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' C' C ' 1' ' ' ASP . . . . . 0.464 ' H1 ' ' CB ' ' F' ' 1' ' ' ASP . 16.0 m-20 . . . . . 0 N--CA 1.49 1.543 0 N-CA-C 108.818 -0.808 . . . . 0.0 108.818 . . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.91 132.86 49.65 Favored 'General case' 0 CA--C 1.54 0.569 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.248 -179.757 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 3' ' ' GLU . . . . . . . . . . . . . 49.4 tt0 -168.85 105.95 0.43 Allowed 'General case' 0 C--O 1.216 -0.667 0 N-CA-C 110.014 -0.365 . . . . 0.0 110.014 -179.274 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 62.0 m-85 -83.78 145.83 28.48 Favored 'General case' 0 N--CA 1.476 0.87 0 N-CA-C 110.179 -0.304 . . . . 0.0 110.179 179.449 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -144.38 142.27 30.24 Favored 'General case' 0 N--CA 1.482 1.139 0 N-CA-C 109.994 -0.373 . . . . 0.0 109.994 179.426 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 46.7 t-80 -152.19 118.97 5.74 Favored 'General case' 0 N--CA 1.472 0.673 0 N-CA-C 109.216 -0.661 . . . . 0.0 109.216 179.216 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 7' ' ' ASP . . . . . 0.493 ' O ' ' OG ' ' F' ' 8' ' ' SER . 4.1 m-20 -69.69 149.11 48.41 Favored 'General case' 0 N--CA 1.467 0.423 0 CA-C-N 116.356 -0.384 . . . . 0.0 110.485 179.793 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 8' ' ' SER . . . . . . . . . . . . . 52.3 p -167.7 -173.18 2.08 Favored 'General case' 0 N--CA 1.483 1.192 0 CA-C-O 121.018 0.437 . . . . 0.0 110.604 179.051 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.01 46.8 1.42 Allowed Glycine 0 N--CA 1.481 1.651 0 CA-C-N 115.898 -0.592 . . . . 0.0 112.201 -179.978 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 48.4 p90 -65.81 132.34 48.47 Favored 'General case' 0 N--CA 1.474 0.737 0 CA-C-O 120.699 0.285 . . . . 0.0 111.532 179.805 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 48.2 mt-10 -91.4 152.4 20.42 Favored 'General case' 0 N--CA 1.474 0.759 0 CA-C-O 121.001 0.429 . . . . 0.0 109.871 178.141 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -152.96 128.29 1.57 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.514 0 N-CA-C 107.81 -1.181 . . . . 0.0 107.81 178.193 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 42.8 m-70 -135.42 145.87 47.68 Favored 'General case' 0 N--CA 1.492 1.647 0 CA-C-N 118.939 0.79 . . . . 0.0 111.309 -179.141 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -166.74 97.19 0.55 Allowed 'General case' 0 N--CA 1.481 1.09 0 CA-C-N 116.414 -0.357 . . . . 0.0 110.571 179.481 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 14.8 pt20 -109.58 -173.68 2.32 Favored 'General case' 0 CA--C 1.504 -0.799 0 N-CA-C 108.381 -0.97 . . . . 0.0 108.381 179.884 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -163.19 98.91 0.94 Allowed 'General case' 0 N--CA 1.471 0.601 0 CA-C-N 114.695 -1.139 . . . . 0.0 108.304 178.332 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 6.6 mp -121.37 155.35 34.98 Favored 'General case' 0 N--CA 1.497 1.906 0 CA-C-O 121.846 0.832 . . . . 0.0 111.0 -178.32 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 61.0 t -111.43 127.45 68.57 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.065 0 N-CA-C 108.183 -1.043 . . . . 0.0 108.183 177.532 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 28.5 m-85 -127.28 122.52 34.07 Favored 'General case' 0 N--CA 1.494 1.747 0 CA-C-N 119.674 1.125 . . . . 0.0 110.152 179.527 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 68.0 m-85 53.57 73.98 0.34 Allowed 'General case' 0 CA--C 1.539 0.545 0 CA-C-O 121.502 0.668 . . . . 0.0 111.745 178.615 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -79.88 -78.12 0.17 Allowed 'General case' 0 C--N 1.351 0.644 0 CA-C-N 114.999 -1.001 . . . . 0.0 110.342 -179.864 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 40.9 tt0 -113.24 99.86 8.13 Favored 'General case' 0 N--CA 1.47 0.556 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 179.675 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 4.4 p30 -158.41 138.73 12.51 Favored 'General case' 0 N--CA 1.484 1.236 0 CA-C-O 119.46 -0.305 . . . . 0.0 111.23 179.112 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 62.1 t -59.55 164.23 0.8 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.87 0 N-CA-C 108.124 -1.065 . . . . 0.0 108.124 177.107 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -117.14 47.3 1.05 Allowed Glycine 0 N--CA 1.477 1.368 0 N-CA-C 111.553 -0.619 . . . . 0.0 111.553 -179.298 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -60.31 -168.11 0.01 OUTLIER 'General case' 0 N--CA 1.468 0.465 0 O-C-N 123.747 0.322 . . . . 0.0 110.335 179.301 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 25.9 t-20 -70.78 80.96 0.62 Allowed 'General case' 0 N--CA 1.465 0.317 0 N-CA-C 110.087 -0.338 . . . . 0.0 110.087 179.478 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 97.7 mttt -77.76 142.91 38.38 Favored 'General case' 0 N--CA 1.472 0.665 0 N-CA-C 109.151 -0.685 . . . . 0.0 109.151 179.32 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.51 -167.87 1.06 Allowed Glycine 0 CA--C 1.524 0.621 0 N-CA-C 109.938 -1.265 . . . . 0.0 109.938 178.826 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.5 114.84 28.06 Favored 'General case' 0 N--CA 1.477 0.894 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 179.708 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 71.5 mt -98.64 134.21 38.19 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.591 0 N-CA-C 106.98 -1.489 . . . . 0.0 106.98 178.85 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 32' ' ' ILE . . . . . 0.406 ' C ' ' H ' ' C' ' 34' ' ' LEU . 29.9 pt -150.18 -171.57 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.352 0.713 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.21 -179.217 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.2 4.81 8.86 Favored Glycine 0 CA--C 1.526 0.767 0 N-CA-C 110.795 -0.922 . . . . 0.0 110.795 179.815 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 34' ' ' LEU . . . . . 0.406 ' H ' ' C ' ' C' ' 32' ' ' ILE . 1.1 tt -75.32 135.15 40.9 Favored 'General case' 0 CA--C 1.545 0.759 0 N-CA-C 109.273 -0.639 . . . . 0.0 109.273 -179.579 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 27.3 ttt -158.41 146.4 18.35 Favored 'General case' 0 N--CA 1.471 0.585 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 178.734 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 1.6 m -149.25 165.44 3.73 Favored 'Isoleucine or valine' 0 C--N 1.348 0.506 0 N-CA-C 107.985 -1.117 . . . . 0.0 107.985 -179.476 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.08 68.56 1.62 Allowed Glycine 0 C--N 1.306 -1.13 0 CA-C-N 115.384 -0.825 . . . . 0.0 112.186 177.563 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.0 177.21 21.39 Favored Glycine 0 N--CA 1.473 1.132 0 N-CA-C 111.019 -0.832 . . . . 0.0 111.019 178.579 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 34.4 m -109.94 155.57 11.1 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.681 0 C-N-CA 123.401 0.68 . . . . 0.0 110.351 -179.523 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 23.6 t . . . . . 0 C--O 1.219 -0.514 0 O-C-N 124.021 0.826 . . . . 0.0 110.478 179.645 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' D' D ' 1' ' ' ASP . . . . . 0.46 ' CB ' ' H1 ' ' A' ' 1' ' ' ASP . 16.2 m-20 . . . . . 0 N--CA 1.49 1.559 0 N-CA-C 109.271 -0.64 . . . . 0.0 109.271 . . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.29 131.18 46.55 Favored 'General case' 0 CA--C 1.534 0.358 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.569 179.82 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 3' ' ' GLU . . . . . . . . . . . . . 48.0 tt0 -169.28 108.86 0.44 Allowed 'General case' 0 N--CA 1.47 0.567 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 179.781 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 72.1 m-85 -88.45 151.95 22.21 Favored 'General case' 0 C--N 1.363 1.195 0 C-N-CA 119.196 -1.002 . . . . 0.0 108.608 179.829 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -146.89 140.56 25.77 Favored 'General case' 0 N--CA 1.475 0.822 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.276 179.794 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 43.6 t-80 -149.78 123.69 9.33 Favored 'General case' 0 CA--C 1.545 0.78 0 N-CA-C 108.19 -1.041 . . . . 0.0 108.19 175.005 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 7' ' ' ASP . . . . . 0.598 ' O ' ' OG ' ' G' ' 8' ' ' SER . 2.9 m-20 -63.89 132.83 51.96 Favored 'General case' 0 C--N 1.321 -0.664 0 C-N-CA 127.068 2.147 . . . . 0.0 114.479 174.269 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' D' D ' 8' ' ' SER . . . . . 0.512 ' OG ' ' O ' ' A' ' 7' ' ' ASP . 51.9 p -154.8 -170.22 3.44 Favored 'General case' 0 N--CA 1.485 1.313 0 CA-C-N 120.046 1.294 . . . . 0.0 111.317 175.159 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.38 47.89 1.18 Allowed Glycine 0 N--CA 1.481 1.639 0 C-N-CA 124.553 1.073 . . . . 0.0 110.419 174.688 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 50.9 p90 -61.06 131.05 49.34 Favored 'General case' 0 N--CA 1.472 0.634 0 N-CA-C 112.725 0.639 . . . . 0.0 112.725 177.928 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 48.4 mt-10 -88.94 150.96 22.59 Favored 'General case' 0 N--CA 1.481 1.086 0 CA-C-N 117.961 0.346 . . . . 0.0 110.752 175.125 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -149.57 130.04 4.35 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.533 0 N-CA-C 107.518 -1.29 . . . . 0.0 107.518 173.119 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 40.9 m-70 -130.03 148.36 51.87 Favored 'General case' 0 N--CA 1.484 1.249 0 CA-C-N 118.098 0.408 . . . . 0.0 111.98 176.4 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -165.35 104.47 0.74 Allowed 'General case' 0 N--CA 1.481 1.098 0 N-CA-C 109.079 -0.711 . . . . 0.0 109.079 172.352 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 14.8 pt20 -113.36 -175.89 2.77 Favored 'General case' 0 CA--C 1.496 -1.127 0 N-CA-C 108.227 -1.027 . . . . 0.0 108.227 178.669 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -159.41 106.22 1.71 Allowed 'General case' 0 N--CA 1.468 0.444 0 N-CA-C 106.552 -1.648 . . . . 0.0 106.552 175.352 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 5.5 mp -128.01 152.87 47.4 Favored 'General case' 0 N--CA 1.499 2.008 0 CA-C-O 122.187 0.994 . . . . 0.0 110.396 179.795 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 38.4 t -101.01 131.66 48.24 Favored 'Isoleucine or valine' 0 C--O 1.258 1.518 0 CA-C-O 116.845 -1.55 . . . . 0.0 109.741 174.102 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 26.6 m-85 -130.27 126.39 37.15 Favored 'General case' 0 N--CA 1.491 1.617 0 CA-C-N 120.074 1.306 . . . . 0.0 109.417 173.61 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 68.5 m-85 55.27 71.67 0.53 Allowed 'General case' 0 C--N 1.35 0.597 0 CA-C-N 115.508 -0.769 . . . . 0.0 111.441 176.664 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -82.13 -73.21 0.4 Allowed 'General case' 0 C--N 1.353 0.721 0 CA-C-O 118.415 -0.803 . . . . 0.0 111.197 -177.693 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 41.1 tt0 -116.45 103.9 10.9 Favored 'General case' 0 N--CA 1.48 1.074 0 N-CA-C 106.434 -1.691 . . . . 0.0 106.434 176.124 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -151.82 138.5 18.79 Favored 'General case' 0 N--CA 1.477 0.896 0 CA-C-O 116.592 -1.671 . . . . 0.0 113.559 177.983 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 24' ' ' VAL . . . . . . . . . . . . . 63.5 t -62.26 166.41 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.267 0 CA-C-N 121.264 1.847 . . . . 0.0 107.964 174.961 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 25' ' ' GLY . . . . . 0.43 ' H ' ' HB ' ' G' ' 24' ' ' VAL . . . -116.78 51.04 0.75 Allowed Glycine 0 N--CA 1.479 1.556 0 CA-C-O 118.964 -0.909 . . . . 0.0 111.654 178.593 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -57.1 -170.91 0.01 OUTLIER 'General case' 0 C--N 1.322 -0.627 0 C-N-CA 123.688 0.795 . . . . 0.0 111.639 175.768 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 26.7 t-20 -72.54 86.81 1.19 Allowed 'General case' 0 C--N 1.347 0.475 0 C-N-CA 119.286 -0.965 . . . . 0.0 108.572 177.928 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 97.2 mttt -83.04 146.01 28.97 Favored 'General case' 0 N--CA 1.473 0.716 0 N-CA-C 107.948 -1.13 . . . . 0.0 107.948 179.281 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.45 -165.61 0.72 Allowed Glycine 0 C--N 1.337 0.609 0 N-CA-C 110.356 -1.098 . . . . 0.0 110.356 179.524 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -102.04 116.04 31.83 Favored 'General case' 0 N--CA 1.472 0.627 0 N-CA-C 109.36 -0.607 . . . . 0.0 109.36 179.594 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 80.8 mt -102.59 142.22 17.15 Favored 'Isoleucine or valine' 0 C--N 1.357 0.933 0 N-CA-C 104.568 -2.382 . . . . 0.0 104.568 179.979 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 30.0 pt -157.37 -172.59 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.482 1.148 0 CA-C-O 120.84 0.353 . . . . 0.0 110.189 -177.479 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 64.23 4.31 11.72 Favored Glycine 0 N--CA 1.466 0.668 0 N-CA-C 110.27 -1.132 . . . . 0.0 110.27 -178.917 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 1.3 tt -76.29 140.28 41.45 Favored 'General case' 0 CA--C 1.543 0.708 0 N-CA-C 107.797 -1.186 . . . . 0.0 107.797 -178.142 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 26.8 ttt -156.45 156.17 33.33 Favored 'General case' 0 C--O 1.244 0.782 0 N-CA-C 107.774 -1.195 . . . . 0.0 107.774 174.436 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 1.8 m -158.04 164.05 1.14 Allowed 'Isoleucine or valine' 0 CA--C 1.515 -0.399 0 N-CA-C 107.53 -1.285 . . . . 0.0 107.53 177.973 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 61.42 63.66 4.67 Favored Glycine 0 CA--C 1.526 0.742 0 C-N-CA 119.773 -1.203 . . . . 0.0 112.101 177.212 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 145.71 177.87 20.77 Favored Glycine 0 N--CA 1.478 1.469 0 CA-C-N 118.388 1.094 . . . . 0.0 111.665 179.885 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 35.2 m -112.64 152.36 14.43 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.881 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -176.89 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 23.5 t . . . . . 0 CA--C 1.522 -0.12 0 CA-C-O 116.166 -1.873 . . . . 0.0 109.597 178.315 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' E' E ' 1' ' ' ASP . . . . . 0.47 ' CB ' ' H1 ' ' B' ' 1' ' ' ASP . 15.7 m-20 . . . . . 0 N--CA 1.488 1.454 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 . . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' E' E ' 2' ' ' ALA . . . . . . . . . . . . . . . -63.95 131.65 48.3 Favored 'General case' 0 N--CA 1.469 0.501 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.43 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' E' E ' 3' ' ' GLU . . . . . . . . . . . . . 47.9 tt0 -169.04 105.72 0.41 Allowed 'General case' 0 C--O 1.215 -0.754 0 CA-C-N 116.825 -0.17 . . . . 0.0 110.632 -179.766 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 63.2 m-85 -84.51 145.09 28.29 Favored 'General case' 0 N--CA 1.477 0.902 0 N-CA-C 110.27 -0.27 . . . . 0.0 110.27 179.308 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' E' E ' 5' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -143.6 142.69 31.17 Favored 'General case' 0 N--CA 1.48 1.039 0 CA-C-O 120.857 0.361 . . . . 0.0 110.163 179.356 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 45.7 t-80 -152.27 119.16 5.78 Favored 'General case' 0 N--CA 1.473 0.707 0 N-CA-C 109.194 -0.669 . . . . 0.0 109.194 179.027 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' E' E ' 7' ' ' ASP . . . . . 0.501 ' O ' ' OG ' ' H' ' 8' ' ' SER . 3.9 m-20 -70.23 149.26 47.66 Favored 'General case' 0 N--CA 1.469 0.501 0 CA-C-N 116.425 -0.352 . . . . 0.0 110.633 179.805 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' E' E ' 8' ' ' SER . . . . . 0.496 ' OG ' ' O ' ' B' ' 7' ' ' ASP . 44.5 p -168.68 -171.69 1.46 Allowed 'General case' 0 N--CA 1.484 1.234 0 CA-C-O 121.02 0.438 . . . . 0.0 110.842 178.591 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.05 47.02 1.38 Allowed Glycine 0 N--CA 1.478 1.476 0 CA-C-N 115.946 -0.57 . . . . 0.0 111.958 179.905 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 46.5 p90 -65.12 132.91 50.41 Favored 'General case' 0 N--CA 1.474 0.738 0 N-CA-C 111.881 0.326 . . . . 0.0 111.881 -179.873 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 48.9 mt-10 -91.45 152.71 20.26 Favored 'General case' 0 N--CA 1.479 0.989 0 CA-C-O 121.13 0.49 . . . . 0.0 109.75 177.885 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -154.58 127.59 1.13 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.538 0 N-CA-C 107.849 -1.167 . . . . 0.0 107.849 178.093 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 43.3 m-70 -135.89 143.97 45.3 Favored 'General case' 0 N--CA 1.482 1.135 0 CA-C-O 120.857 0.36 . . . . 0.0 111.609 -178.049 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -165.57 96.72 0.66 Allowed 'General case' 0 N--CA 1.484 1.256 0 CA-C-N 116.442 -0.345 . . . . 0.0 110.693 179.681 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 15.0 pt20 -108.71 -173.67 2.33 Favored 'General case' 0 CA--C 1.507 -0.688 0 N-CA-C 108.56 -0.904 . . . . 0.0 108.56 179.909 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -162.87 98.11 0.96 Allowed 'General case' 0 N--CA 1.477 0.903 0 CA-C-N 114.693 -1.139 . . . . 0.0 108.376 178.351 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 6.5 mp -120.07 155.48 32.87 Favored 'General case' 0 N--CA 1.495 1.78 0 CA-C-O 121.604 0.716 . . . . 0.0 111.5 -177.87 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 48.9 t -113.61 124.5 70.31 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.244 0 N-CA-C 108.249 -1.019 . . . . 0.0 108.249 177.167 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 31.3 m-85 -124.73 121.69 35.36 Favored 'General case' 0 N--CA 1.49 1.535 0 CA-C-O 120.921 0.391 . . . . 0.0 110.792 -179.769 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 70.0 m-85 54.75 73.21 0.42 Allowed 'General case' 0 N--CA 1.469 0.511 0 CA-C-N 115.969 -0.559 . . . . 0.0 111.281 178.219 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -78.39 -78.72 0.14 Allowed 'General case' 0 C--N 1.345 0.377 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.358 -179.594 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 40.4 tt0 -112.55 100.09 8.47 Favored 'General case' 0 C--N 1.325 -0.474 0 N-CA-C 108.467 -0.938 . . . . 0.0 108.467 179.758 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -157.31 138.5 13.6 Favored 'General case' 0 C--O 1.203 -1.369 0 CA-C-O 119.371 -0.347 . . . . 0.0 111.553 179.287 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' E' E ' 24' ' ' VAL . . . . . 0.407 ' HB ' ' H ' ' B' ' 25' ' ' GLY . 59.3 t -58.02 168.52 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.903 0 N-CA-C 107.663 -1.236 . . . . 0.0 107.663 176.615 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . -122.05 48.44 0.95 Allowed Glycine 0 N--CA 1.476 1.325 0 N-CA-C 110.735 -0.946 . . . . 0.0 110.735 -179.104 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -61.93 -167.41 0.01 OUTLIER 'General case' 0 N--CA 1.47 0.559 0 CA-C-O 120.729 0.3 . . . . 0.0 110.514 179.74 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 26.6 t-20 -70.34 77.33 0.55 Allowed 'General case' 0 N--CA 1.465 0.285 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.45 -179.939 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 97.8 mttt -74.69 143.55 44.16 Favored 'General case' 0 N--CA 1.474 0.765 0 N-CA-C 109.646 -0.502 . . . . 0.0 109.646 179.484 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.29 -167.44 1.29 Allowed Glycine 0 CA--C 1.522 0.496 0 N-CA-C 110.339 -1.105 . . . . 0.0 110.339 178.71 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.56 114.26 27.17 Favored 'General case' 0 N--CA 1.476 0.838 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 179.693 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 70.8 mt -98.32 134.23 37.64 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.35 0 N-CA-C 106.812 -1.551 . . . . 0.0 106.812 179.02 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' E' E ' 32' ' ' ILE . . . . . 0.411 ' C ' ' H ' ' E' ' 34' ' ' LEU . 30.9 pt -150.24 -169.8 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.149 0 CA-C-O 120.998 0.428 . . . . 0.0 110.785 -179.313 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.41 5.2 6.02 Favored Glycine 0 CA--C 1.531 1.056 0 N-CA-C 111.288 -0.725 . . . . 0.0 111.288 -179.781 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' E' E ' 34' ' ' LEU . . . . . 0.411 ' H ' ' C ' ' E' ' 32' ' ' ILE . 1.1 tt -74.88 135.64 41.52 Favored 'General case' 0 CA--C 1.547 0.86 0 N-CA-C 109.304 -0.628 . . . . 0.0 109.304 -179.597 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 26.6 ttt -158.82 145.57 17.22 Favored 'General case' 0 N--CA 1.474 0.734 0 N-CA-C 108.638 -0.875 . . . . 0.0 108.638 178.811 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 1.4 m -148.53 165.44 4.61 Favored 'Isoleucine or valine' 0 C--N 1.347 0.495 0 N-CA-C 108.388 -0.967 . . . . 0.0 108.388 -179.546 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 54.56 68.27 1.76 Allowed Glycine 0 C--N 1.308 -0.998 0 CA-C-N 115.266 -0.879 . . . . 0.0 112.1 177.573 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 146.81 174.28 18.77 Favored Glycine 0 N--CA 1.472 1.081 0 N-CA-C 111.381 -0.687 . . . . 0.0 111.381 178.685 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' E' E ' 39' ' ' VAL . . . . . 0.401 HG11 ' H ' ' B' ' 39' ' ' VAL . 33.1 m -107.58 154.97 8.47 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.768 0 C-N-CA 123.624 0.77 . . . . 0.0 110.568 -178.843 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 25.2 t . . . . . 0 C--O 1.219 -0.535 0 O-C-N 124.263 0.977 . . . . 0.0 110.263 179.802 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' F' F ' 1' ' ' ASP . . . . . 0.464 ' CB ' ' H1 ' ' C' ' 1' ' ' ASP . 15.5 m-20 . . . . . 0 N--CA 1.49 1.532 0 N-CA-C 109.316 -0.624 . . . . 0.0 109.316 . . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' F' F ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.53 131.34 46.78 Favored 'General case' 0 N--CA 1.468 0.461 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.361 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' F' F ' 3' ' ' GLU . . . . . . . . . . . . . 47.9 tt0 -168.54 106.13 0.46 Allowed 'General case' 0 C--O 1.214 -0.808 0 N-CA-C 110.572 -0.159 . . . . 0.0 110.572 -179.789 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 63.8 m-85 -84.97 145.19 27.85 Favored 'General case' 0 N--CA 1.474 0.752 0 O-C-N 122.209 -0.307 . . . . 0.0 110.199 179.317 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' F' F ' 5' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -143.51 143.26 31.48 Favored 'General case' 0 N--CA 1.477 0.908 0 CA-C-O 120.817 0.342 . . . . 0.0 110.195 179.318 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 46.1 t-80 -152.98 118.87 5.39 Favored 'General case' 0 N--CA 1.473 0.72 0 N-CA-C 109.275 -0.639 . . . . 0.0 109.275 179.055 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' F' F ' 7' ' ' ASP . . . . . 0.495 ' O ' ' OG ' ' I' ' 8' ' ' SER . 3.9 m-20 -70.2 149.03 47.92 Favored 'General case' 0 N--CA 1.468 0.447 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.68 179.981 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' F' F ' 8' ' ' SER . . . . . 0.493 ' OG ' ' O ' ' C' ' 7' ' ' ASP . 41.7 p -168.56 -171.74 1.5 Allowed 'General case' 0 N--CA 1.486 1.35 0 CA-C-O 121.039 0.447 . . . . 0.0 110.936 178.679 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.14 46.69 1.42 Allowed Glycine 0 N--CA 1.478 1.492 0 CA-C-N 115.951 -0.568 . . . . 0.0 111.984 179.955 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 46.3 p90 -64.65 132.74 50.57 Favored 'General case' 0 N--CA 1.474 0.734 0 O-C-N 122.623 -0.34 . . . . 0.0 111.913 -179.866 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 49.2 mt-10 -91.27 152.53 20.46 Favored 'General case' 0 N--CA 1.48 1.036 0 CA-C-O 121.158 0.504 . . . . 0.0 109.796 177.777 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -154.43 127.06 1.07 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.584 0 N-CA-C 107.828 -1.175 . . . . 0.0 107.828 178.13 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 42.0 m-70 -135.47 143.86 46.09 Favored 'General case' 0 N--CA 1.485 1.279 0 CA-C-O 120.849 0.357 . . . . 0.0 111.558 -178.045 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -165.32 97.11 0.69 Allowed 'General case' 0 N--CA 1.483 1.221 0 CA-C-N 116.43 -0.35 . . . . 0.0 110.771 179.754 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 15.0 pt20 -109.48 -174.17 2.44 Favored 'General case' 0 CA--C 1.503 -0.851 0 N-CA-C 108.629 -0.878 . . . . 0.0 108.629 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -162.22 98.46 1.04 Allowed 'General case' 0 N--CA 1.474 0.734 0 CA-C-N 114.694 -1.139 . . . . 0.0 108.401 178.384 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 6.4 mp -120.36 155.28 33.7 Favored 'General case' 0 N--CA 1.494 1.757 0 CA-C-O 121.532 0.682 . . . . 0.0 111.518 -177.854 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 50.2 t -113.41 124.2 69.81 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.246 0 N-CA-C 108.341 -0.985 . . . . 0.0 108.341 177.257 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 31.2 m-85 -124.56 121.58 35.18 Favored 'General case' 0 N--CA 1.489 1.49 0 CA-C-O 120.91 0.386 . . . . 0.0 110.796 -179.846 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 69.0 m-85 54.79 73.79 0.39 Allowed 'General case' 0 N--CA 1.468 0.437 0 CA-C-N 115.938 -0.574 . . . . 0.0 111.464 178.399 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -78.98 -78.31 0.15 Allowed 'General case' 0 C--N 1.344 0.359 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.537 -179.607 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 40.8 tt0 -112.76 100.09 8.42 Favored 'General case' 0 C--N 1.325 -0.471 0 N-CA-C 108.341 -0.985 . . . . 0.0 108.341 179.664 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -157.53 138.65 13.49 Favored 'General case' 0 C--O 1.205 -1.243 0 CA-C-O 119.422 -0.323 . . . . 0.0 111.532 179.282 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' F' F ' 24' ' ' VAL . . . . . . . . . . . . . 59.6 t -58.46 168.35 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.94 0 N-CA-C 107.646 -1.242 . . . . 0.0 107.646 176.757 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -121.73 48.07 0.98 Allowed Glycine 0 N--CA 1.477 1.418 0 N-CA-C 110.789 -0.924 . . . . 0.0 110.789 -179.163 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -61.62 -167.05 0.01 OUTLIER 'General case' 0 N--CA 1.469 0.481 0 CA-C-N 116.768 0.284 . . . . 0.0 110.453 179.771 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 26.7 t-20 -70.67 76.84 0.6 Allowed 'General case' 0 N--CA 1.466 0.367 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.441 -179.881 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -74.01 143.86 45.38 Favored 'General case' 0 N--CA 1.473 0.709 0 N-CA-C 109.691 -0.485 . . . . 0.0 109.691 179.242 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.57 -167.19 1.34 Allowed Glycine 0 CA--C 1.522 0.517 0 N-CA-C 110.426 -1.07 . . . . 0.0 110.426 178.712 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.6 113.81 26.47 Favored 'General case' 0 N--CA 1.472 0.662 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.837 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 72.0 mt -98.09 134.54 36.08 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.372 0 N-CA-C 106.84 -1.541 . . . . 0.0 106.84 179.038 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' F' F ' 32' ' ' ILE . . . . . 0.411 ' C ' ' H ' ' F' ' 34' ' ' LEU . 31.8 pt -150.47 -169.83 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.118 0 CA-C-O 121.052 0.453 . . . . 0.0 110.751 -179.409 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.64 4.9 5.95 Favored Glycine 0 CA--C 1.53 1.015 0 N-CA-C 111.261 -0.736 . . . . 0.0 111.261 -179.87 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' F' F ' 34' ' ' LEU . . . . . 0.411 ' H ' ' C ' ' F' ' 32' ' ' ILE . 1.1 tt -74.77 135.82 41.72 Favored 'General case' 0 CA--C 1.546 0.822 0 N-CA-C 109.241 -0.652 . . . . 0.0 109.241 -179.612 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 26.5 ttt -158.89 145.86 17.3 Favored 'General case' 0 N--CA 1.473 0.686 0 N-CA-C 108.494 -0.928 . . . . 0.0 108.494 178.804 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 1.5 m -148.72 165.33 4.38 Favored 'Isoleucine or valine' 0 C--N 1.348 0.537 0 N-CA-C 108.366 -0.976 . . . . 0.0 108.366 -179.449 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 54.33 68.61 1.58 Allowed Glycine 0 C--N 1.308 -1.021 0 CA-C-N 115.307 -0.861 . . . . 0.0 112.113 177.634 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 146.6 174.07 18.39 Favored Glycine 0 N--CA 1.473 1.118 0 N-CA-C 111.355 -0.698 . . . . 0.0 111.355 178.722 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 33.0 m -107.42 155.0 8.27 Favored 'Isoleucine or valine' 0 C--N 1.352 0.696 0 C-N-CA 123.528 0.731 . . . . 0.0 110.604 -178.773 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 25.9 t . . . . . 0 C--O 1.219 -0.543 0 O-C-N 124.365 1.041 . . . . 0.0 110.356 179.892 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' G' G ' 1' ' ' ASP . . . . . 0.441 ' CB ' ' H1 ' ' D' ' 1' ' ' ASP . 16.9 m-20 . . . . . 0 N--CA 1.491 1.601 0 N-CA-C 109.323 -0.621 . . . . 0.0 109.323 . . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' G' G ' 2' ' ' ALA . . . . . . . . . . . . . . . -63.0 129.44 40.37 Favored 'General case' 0 N--CA 1.469 0.481 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.662 179.781 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' G' G ' 3' ' ' GLU . . . . . . . . . . . . . 46.6 tt0 -168.5 107.36 0.48 Allowed 'General case' 0 N--CA 1.471 0.613 0 CA-C-O 120.479 0.18 . . . . 0.0 110.745 179.638 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 64.8 m-85 -86.62 145.01 26.9 Favored 'General case' 0 N--CA 1.475 0.785 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 179.164 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' G' G ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -144.09 142.09 30.42 Favored 'General case' 0 N--CA 1.481 1.091 0 CA-C-O 120.823 0.345 . . . . 0.0 110.205 179.726 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 46.8 t-80 -151.69 119.59 6.2 Favored 'General case' 0 N--CA 1.473 0.676 0 N-CA-C 109.46 -0.57 . . . . 0.0 109.46 179.016 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 4.1 m-20 -71.94 144.41 48.94 Favored 'General case' 0 N--CA 1.471 0.603 0 C-N-CA 122.763 0.425 . . . . 0.0 111.154 -179.833 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' G' G ' 8' ' ' SER . . . . . 0.598 ' OG ' ' O ' ' D' ' 7' ' ' ASP . 37.5 p -164.69 -169.24 1.68 Allowed 'General case' 0 N--CA 1.476 0.86 0 CA-C-O 121.049 0.452 . . . . 0.0 110.496 178.535 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 101.95 47.59 1.46 Allowed Glycine 0 N--CA 1.478 1.488 0 N-CA-C 111.529 -0.628 . . . . 0.0 111.529 179.553 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 48.6 p90 -65.93 132.71 49.27 Favored 'General case' 0 N--CA 1.473 0.692 0 N-CA-C 111.803 0.297 . . . . 0.0 111.803 -179.688 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 48.4 mt-10 -91.5 152.03 20.51 Favored 'General case' 0 N--CA 1.479 1.018 0 CA-C-O 121.043 0.449 . . . . 0.0 110.163 178.374 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -154.96 127.81 1.1 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.008 0 N-CA-C 107.864 -1.161 . . . . 0.0 107.864 178.221 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 44.9 m-70 -135.25 144.83 47.07 Favored 'General case' 0 N--CA 1.477 0.922 0 CA-C-N 115.702 -0.681 . . . . 0.0 111.407 -178.259 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -166.52 96.85 0.57 Allowed 'General case' 0 N--CA 1.483 1.181 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.288 179.132 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 15.0 pt20 -109.11 -173.75 2.34 Favored 'General case' 0 CA--C 1.503 -0.831 0 N-CA-C 108.391 -0.966 . . . . 0.0 108.391 179.88 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -163.15 98.03 0.93 Allowed 'General case' 0 N--CA 1.474 0.747 0 CA-C-N 114.701 -1.136 . . . . 0.0 108.132 178.558 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 6.4 mp -120.06 154.29 34.85 Favored 'General case' 0 N--CA 1.496 1.86 0 CA-C-O 121.204 0.526 . . . . 0.0 111.793 -177.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 44.5 t -112.83 125.39 70.09 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.968 0 CA-C-N 114.898 -1.046 . . . . 0.0 108.19 176.548 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 32.2 m-85 -125.88 121.15 32.38 Favored 'General case' 0 C--N 1.366 1.315 0 C-N-CA 123.39 0.676 . . . . 0.0 110.853 -179.532 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 69.3 m-85 55.13 72.76 0.45 Allowed 'General case' 0 N--CA 1.469 0.521 0 CA-C-N 115.882 -0.599 . . . . 0.0 111.292 178.24 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.67 -78.26 0.14 Allowed 'General case' 0 N--CA 1.471 0.583 0 O-C-N 122.244 -0.285 . . . . 0.0 110.55 -179.189 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 41.3 tt0 -112.57 100.43 8.73 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 108.124 -1.065 . . . . 0.0 108.124 179.646 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -157.86 139.78 14.08 Favored 'General case' 0 N--CA 1.478 0.949 0 N-CA-C 111.516 0.191 . . . . 0.0 111.516 179.153 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' G' G ' 24' ' ' VAL . . . . . 0.43 ' HB ' ' H ' ' D' ' 25' ' ' GLY . 61.4 t -59.96 167.25 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.624 0 N-CA-C 107.669 -1.234 . . . . 0.0 107.669 177.268 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -120.35 49.68 0.87 Allowed Glycine 0 N--CA 1.482 1.718 0 N-CA-C 110.313 -1.115 . . . . 0.0 110.313 -179.453 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -63.56 -167.51 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.658 0 CA-C-N 117.001 0.401 . . . . 0.0 109.953 179.484 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 26.6 t-20 -70.11 76.69 0.51 Allowed 'General case' 0 CA--C 1.535 0.386 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.478 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 97.9 mttt -73.36 143.92 46.66 Favored 'General case' 0 N--CA 1.474 0.77 0 N-CA-C 109.701 -0.481 . . . . 0.0 109.701 179.209 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.64 -166.08 1.14 Allowed Glycine 0 C--N 1.337 0.593 0 N-CA-C 110.069 -1.212 . . . . 0.0 110.069 178.723 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.82 113.93 26.76 Favored 'General case' 0 N--CA 1.47 0.541 0 C-N-CA 122.723 0.409 . . . . 0.0 110.393 179.897 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 74.7 mt -98.61 134.77 36.05 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.773 0 N-CA-C 106.784 -1.562 . . . . 0.0 106.784 179.03 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' G' G ' 32' ' ' ILE . . . . . 0.417 ' C ' ' H ' ' G' ' 34' ' ' LEU . 34.6 pt -151.11 -169.38 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 CA-C-N 119.657 1.117 . . . . 0.0 109.917 -179.826 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.18 4.79 6.71 Favored Glycine 0 CA--C 1.529 0.926 0 N-CA-C 111.052 -0.819 . . . . 0.0 111.052 179.933 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' G' G ' 34' ' ' LEU . . . . . 0.417 ' H ' ' C ' ' G' ' 32' ' ' ILE . 1.1 tt -74.95 135.74 41.38 Favored 'General case' 0 CA--C 1.544 0.745 0 N-CA-C 109.209 -0.663 . . . . 0.0 109.209 -179.635 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 25.3 ttt -158.86 146.06 17.48 Favored 'General case' 0 N--CA 1.47 0.533 0 N-CA-C 108.695 -0.854 . . . . 0.0 108.695 178.801 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 1.4 m -148.8 163.89 4.72 Favored 'Isoleucine or valine' 0 C--N 1.349 0.566 0 N-CA-C 108.509 -0.922 . . . . 0.0 108.509 -179.293 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.13 68.67 1.57 Allowed Glycine 0 C--N 1.308 -0.997 0 CA-C-N 115.305 -0.862 . . . . 0.0 112.207 177.39 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.33 173.16 18.22 Favored Glycine 0 N--CA 1.475 1.274 0 N-CA-C 110.599 -1.0 . . . . 0.0 110.599 178.934 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 34.1 m -106.88 155.11 7.64 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.873 0 C-N-CA 123.222 0.609 . . . . 0.0 110.668 -179.346 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 25.8 t . . . . . 0 C--O 1.219 -0.532 0 O-C-N 124.035 0.835 . . . . 0.0 110.622 179.721 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' H' H ' 1' ' ' ASP . . . . . 0.461 ' CB ' ' H1 ' ' E' ' 1' ' ' ASP . 17.6 m-20 . . . . . 0 N--CA 1.491 1.602 0 N-CA-C 109.453 -0.573 . . . . 0.0 109.453 . . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' H' H ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.76 129.69 41.6 Favored 'General case' 0 N--CA 1.469 0.494 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.517 179.72 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' H' H ' 3' ' ' GLU . . . . . . . . . . . . . 46.7 tt0 -168.58 107.39 0.48 Allowed 'General case' 0 N--CA 1.471 0.601 0 CA-C-O 120.449 0.166 . . . . 0.0 110.643 179.735 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 64.4 m-85 -86.9 144.67 26.87 Favored 'General case' 0 N--CA 1.473 0.712 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 179.181 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' H' H ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -143.72 142.71 31.07 Favored 'General case' 0 N--CA 1.482 1.133 0 C-N-CA 122.592 0.357 . . . . 0.0 110.1 179.712 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 47.7 t-80 -152.2 119.6 5.98 Favored 'General case' 0 N--CA 1.475 0.788 0 N-CA-C 109.326 -0.62 . . . . 0.0 109.326 178.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -71.57 144.44 49.54 Favored 'General case' 0 N--CA 1.469 0.497 0 C-N-CA 122.767 0.427 . . . . 0.0 111.164 179.89 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' H' H ' 8' ' ' SER . . . . . 0.501 ' OG ' ' O ' ' E' ' 7' ' ' ASP . 52.5 p -164.9 -170.37 1.94 Allowed 'General case' 0 N--CA 1.474 0.754 0 CA-C-O 120.935 0.398 . . . . 0.0 110.48 178.504 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.87 47.17 1.39 Allowed Glycine 0 N--CA 1.48 1.587 0 CA-C-N 115.971 -0.559 . . . . 0.0 111.709 179.604 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 48.2 p90 -65.61 132.67 49.41 Favored 'General case' 0 N--CA 1.473 0.707 0 N-CA-C 111.863 0.32 . . . . 0.0 111.863 -179.69 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 48.4 mt-10 -91.33 151.64 20.79 Favored 'General case' 0 N--CA 1.478 0.951 0 CA-C-O 121.036 0.446 . . . . 0.0 110.257 178.275 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -154.77 127.8 1.13 Allowed 'Isoleucine or valine' 0 CA--C 1.553 1.087 0 N-CA-C 107.815 -1.18 . . . . 0.0 107.815 178.286 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 45.0 m-70 -135.29 145.23 47.32 Favored 'General case' 0 N--CA 1.478 0.956 0 CA-C-N 115.596 -0.729 . . . . 0.0 111.373 -178.303 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -166.92 97.0 0.53 Allowed 'General case' 0 N--CA 1.481 1.116 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.312 179.151 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 15.1 pt20 -109.09 -173.43 2.26 Favored 'General case' 0 CA--C 1.505 -0.771 0 N-CA-C 108.417 -0.957 . . . . 0.0 108.417 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -163.5 97.98 0.89 Allowed 'General case' 0 N--CA 1.474 0.754 0 CA-C-N 114.718 -1.128 . . . . 0.0 108.1 178.565 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 6.4 mp -120.12 154.4 34.77 Favored 'General case' 0 N--CA 1.497 1.885 0 CA-C-O 121.263 0.554 . . . . 0.0 111.881 -177.981 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 43.9 t -113.02 124.79 70.01 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.978 0 CA-C-N 114.936 -1.029 . . . . 0.0 108.292 176.604 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 32.4 m-85 -125.17 121.16 33.39 Favored 'General case' 0 C--N 1.366 1.316 0 CA-C-N 115.56 -0.745 . . . . 0.0 110.735 -179.425 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 68.7 m-85 54.78 72.83 0.44 Allowed 'General case' 0 C--O 1.237 0.407 0 CA-C-N 115.868 -0.605 . . . . 0.0 111.425 178.173 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.31 -78.43 0.13 Allowed 'General case' 0 N--CA 1.469 0.522 0 O-C-N 122.229 -0.294 . . . . 0.0 110.591 -179.379 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 40.9 tt0 -112.62 100.34 8.65 Favored 'General case' 0 C--N 1.322 -0.589 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 179.792 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -157.6 139.47 14.12 Favored 'General case' 0 N--CA 1.477 0.909 0 O-C-N 122.403 -0.186 . . . . 0.0 111.498 179.272 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' H' H ' 24' ' ' VAL . . . . . . . . . . . . . 62.0 t -59.73 167.4 0.56 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.521 0 N-CA-C 107.722 -1.214 . . . . 0.0 107.722 177.182 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . -120.32 49.12 0.9 Allowed Glycine 0 N--CA 1.48 1.572 0 N-CA-C 110.491 -1.043 . . . . 0.0 110.491 -179.314 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -63.23 -166.99 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.675 0 CA-C-N 116.972 0.386 . . . . 0.0 110.092 179.748 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 26.6 t-20 -70.63 76.46 0.59 Allowed 'General case' 0 CA--C 1.535 0.374 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.492 -179.85 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -73.44 143.88 46.53 Favored 'General case' 0 N--CA 1.473 0.685 0 N-CA-C 109.629 -0.508 . . . . 0.0 109.629 179.341 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -65.17 -166.14 1.37 Allowed Glycine 0 C--N 1.337 0.634 0 N-CA-C 109.936 -1.266 . . . . 0.0 109.936 178.889 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.44 114.28 27.12 Favored 'General case' 0 N--CA 1.467 0.408 0 C-N-CA 122.573 0.349 . . . . 0.0 110.617 179.85 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 74.5 mt -98.73 134.73 36.41 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.751 0 N-CA-C 106.8 -1.556 . . . . 0.0 106.8 178.974 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' H' H ' 32' ' ' ILE . . . . . 0.416 ' C ' ' H ' ' H' ' 34' ' ' LEU . 34.2 pt -151.05 -169.24 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.687 0 CA-C-N 119.747 1.158 . . . . 0.0 109.917 -179.93 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.24 4.8 6.81 Favored Glycine 0 CA--C 1.529 0.919 0 N-CA-C 110.95 -0.86 . . . . 0.0 110.95 179.914 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' H' H ' 34' ' ' LEU . . . . . 0.416 ' H ' ' C ' ' H' ' 32' ' ' ILE . 1.1 tt -75.35 135.25 40.85 Favored 'General case' 0 CA--C 1.546 0.792 0 N-CA-C 109.412 -0.588 . . . . 0.0 109.412 -179.414 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 25.2 ttt -158.52 146.15 18.03 Favored 'General case' 0 N--CA 1.472 0.641 0 N-CA-C 108.694 -0.854 . . . . 0.0 108.694 179.065 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 1.5 m -149.08 163.84 4.35 Favored 'Isoleucine or valine' 0 C--N 1.348 0.522 0 N-CA-C 108.449 -0.945 . . . . 0.0 108.449 -179.283 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.35 68.39 1.71 Allowed Glycine 0 C--N 1.309 -0.971 0 CA-C-N 115.16 -0.927 . . . . 0.0 112.064 177.451 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.27 172.35 17.37 Favored Glycine 0 N--CA 1.476 1.307 0 N-CA-C 110.639 -0.985 . . . . 0.0 110.639 178.959 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 33.8 m -106.1 154.93 7.13 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.927 0 C-N-CA 123.199 0.6 . . . . 0.0 110.715 -179.475 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 24.7 t . . . . . 0 C--O 1.219 -0.53 0 O-C-N 124.001 0.813 . . . . 0.0 110.709 179.699 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' I' I ' 1' ' ' ASP . . . . . 0.438 ' CB ' ' H1 ' ' F' ' 1' ' ' ASP . 16.4 m-20 . . . . . 0 N--CA 1.492 1.63 0 N-CA-C 109.487 -0.56 . . . . 0.0 109.487 . . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' I' I ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.66 129.43 40.53 Favored 'General case' 0 N--CA 1.469 0.519 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.468 179.697 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' I' I ' 3' ' ' GLU . . . . . . . . . . . . . 46.9 tt0 -168.41 107.14 0.49 Allowed 'General case' 0 N--CA 1.472 0.646 0 CA-C-O 120.445 0.165 . . . . 0.0 110.597 179.737 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 66.3 m-85 -86.54 145.1 26.92 Favored 'General case' 0 N--CA 1.474 0.745 0 N-CA-C 109.736 -0.468 . . . . 0.0 109.736 179.264 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' I' I ' 5' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -144.13 142.47 30.6 Favored 'General case' 0 N--CA 1.484 1.23 0 C-N-CA 122.639 0.376 . . . . 0.0 110.194 179.81 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 47.6 t-80 -152.14 120.12 6.21 Favored 'General case' 0 N--CA 1.474 0.738 0 N-CA-C 109.361 -0.607 . . . . 0.0 109.361 179.007 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -72.32 144.16 48.41 Favored 'General case' 0 N--CA 1.471 0.605 0 C-N-CA 122.725 0.41 . . . . 0.0 111.084 -179.945 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' I' I ' 8' ' ' SER . . . . . 0.495 ' OG ' ' O ' ' F' ' 7' ' ' ASP . 50.8 p -164.73 -170.39 1.98 Allowed 'General case' 0 N--CA 1.475 0.782 0 CA-C-O 120.996 0.427 . . . . 0.0 110.488 178.586 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.82 47.47 1.36 Allowed Glycine 0 N--CA 1.48 1.628 0 N-CA-C 111.629 -0.589 . . . . 0.0 111.629 179.675 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 47.9 p90 -65.92 133.2 50.38 Favored 'General case' 0 N--CA 1.473 0.677 0 CA-C-O 120.803 0.335 . . . . 0.0 111.872 -179.649 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 48.4 mt-10 -91.77 151.7 20.49 Favored 'General case' 0 N--CA 1.478 0.95 0 CA-C-O 120.932 0.396 . . . . 0.0 110.311 178.348 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -154.99 126.92 0.96 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.057 0 N-CA-C 107.909 -1.145 . . . . 0.0 107.909 178.365 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 42.4 m-70 -134.52 144.88 48.27 Favored 'General case' 0 N--CA 1.478 0.967 0 CA-C-N 115.606 -0.724 . . . . 0.0 111.451 -178.382 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -166.43 97.09 0.58 Allowed 'General case' 0 N--CA 1.48 1.056 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.348 179.119 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 15.2 pt20 -109.3 -173.88 2.37 Favored 'General case' 0 CA--C 1.504 -0.797 0 N-CA-C 108.481 -0.933 . . . . 0.0 108.481 -179.99 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -163.08 98.11 0.93 Allowed 'General case' 0 N--CA 1.473 0.715 0 CA-C-N 114.701 -1.136 . . . . 0.0 108.07 178.514 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 6.4 mp -120.2 154.37 34.94 Favored 'General case' 0 N--CA 1.497 1.907 0 CA-C-O 121.24 0.543 . . . . 0.0 111.769 -177.91 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 44.8 t -113.0 125.07 70.2 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.028 0 CA-C-N 114.857 -1.065 . . . . 0.0 108.157 176.646 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 32.9 m-85 -125.57 121.11 32.69 Favored 'General case' 0 C--N 1.367 1.339 0 CA-C-N 115.582 -0.735 . . . . 0.0 110.815 -179.536 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 68.6 m-85 54.9 73.26 0.42 Allowed 'General case' 0 N--CA 1.469 0.51 0 CA-C-N 115.927 -0.579 . . . . 0.0 111.262 178.301 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.99 -78.01 0.15 Allowed 'General case' 0 N--CA 1.472 0.639 0 O-C-N 122.205 -0.309 . . . . 0.0 110.601 -179.268 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 40.9 tt0 -112.84 100.32 8.58 Favored 'General case' 0 C--N 1.323 -0.586 0 N-CA-C 108.088 -1.078 . . . . 0.0 108.088 179.614 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -157.71 139.26 13.8 Favored 'General case' 0 N--CA 1.479 0.983 0 O-C-N 122.344 -0.223 . . . . 0.0 111.433 179.396 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' I' I ' 24' ' ' VAL . . . . . . . . . . . . . 62.0 t -59.48 167.26 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.54 0 N-CA-C 107.847 -1.168 . . . . 0.0 107.847 177.016 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . -120.43 49.52 0.87 Allowed Glycine 0 N--CA 1.482 1.725 0 N-CA-C 110.411 -1.076 . . . . 0.0 110.411 -179.384 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -63.42 -166.9 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.656 0 CA-C-N 116.985 0.393 . . . . 0.0 110.064 179.59 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 26.8 t-20 -70.68 76.71 0.6 Allowed 'General case' 0 N--CA 1.466 0.358 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.35 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 97.8 mttt -73.66 143.62 46.18 Favored 'General case' 0 N--CA 1.474 0.772 0 N-CA-C 109.64 -0.504 . . . . 0.0 109.64 179.284 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.59 -166.08 1.13 Allowed Glycine 0 C--N 1.339 0.703 0 N-CA-C 110.02 -1.232 . . . . 0.0 110.02 178.88 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.53 113.86 26.51 Favored 'General case' 0 N--CA 1.469 0.495 0 C-N-CA 122.691 0.396 . . . . 0.0 110.45 179.877 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 74.2 mt -98.37 135.04 34.66 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.836 0 N-CA-C 106.745 -1.576 . . . . 0.0 106.745 178.849 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' I' I ' 32' ' ' ILE . . . . . 0.417 ' C ' ' H ' ' I' ' 34' ' ' LEU . 33.6 pt -151.38 -169.3 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 CA-C-N 119.698 1.135 . . . . 0.0 109.965 -179.987 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.22 4.71 6.68 Favored Glycine 0 CA--C 1.528 0.897 0 N-CA-C 110.952 -0.859 . . . . 0.0 110.952 179.962 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' I' I ' 34' ' ' LEU . . . . . 0.417 ' H ' ' C ' ' I' ' 32' ' ' ILE . 1.1 tt -74.85 135.29 41.58 Favored 'General case' 0 CA--C 1.544 0.738 0 N-CA-C 109.318 -0.623 . . . . 0.0 109.318 -179.602 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 25.4 ttt -158.44 146.06 18.08 Favored 'General case' 0 N--CA 1.471 0.602 0 N-CA-C 108.53 -0.915 . . . . 0.0 108.53 178.982 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 1.4 m -149.02 163.78 4.41 Favored 'Isoleucine or valine' 0 C--N 1.35 0.616 0 N-CA-C 108.519 -0.919 . . . . 0.0 108.519 -179.401 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.08 68.5 1.65 Allowed Glycine 0 C--N 1.308 -0.991 0 CA-C-N 115.253 -0.885 . . . . 0.0 112.143 177.492 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.45 172.31 17.46 Favored Glycine 0 N--CA 1.474 1.224 0 N-CA-C 110.682 -0.967 . . . . 0.0 110.682 178.982 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 33.9 m -106.15 154.81 7.2 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.915 0 C-N-CA 123.236 0.614 . . . . 0.0 110.663 -179.467 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 25.3 t . . . . . 0 C--O 1.219 -0.524 0 O-C-N 124.06 0.85 . . . . 0.0 110.612 179.621 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 14.7 m-20 . . . . . 0 N--CA 1.491 1.587 0 N-CA-C 108.906 -0.776 . . . . 0.0 108.906 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.91 132.83 49.57 Favored 'General case' 0 CA--C 1.538 0.503 0 CA-C-N 116.548 -0.296 . . . . 0.0 110.24 -179.832 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 44.7 tt0 -168.21 105.4 0.47 Allowed 'General case' 0 C--O 1.215 -0.727 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 -179.295 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 42.0 m-85 -85.85 152.16 23.22 Favored 'General case' 0 N--CA 1.474 0.747 0 N-CA-C 110.118 -0.327 . . . . 0.0 110.118 179.589 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -143.45 140.62 30.47 Favored 'General case' 0 N--CA 1.481 1.085 0 CA-C-O 120.887 0.375 . . . . 0.0 110.03 179.711 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 42.3 t-80 -151.79 119.39 6.07 Favored 'General case' 0 N--CA 1.47 0.528 0 N-CA-C 109.231 -0.655 . . . . 0.0 109.231 179.176 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' ASP . . . . . 0.516 ' O ' ' OG ' ' D' ' 8' ' ' SER . 4.4 m-20 -68.98 148.77 49.65 Favored 'General case' 0 CA--C 1.537 0.471 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.516 179.816 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' SER . . . . . 0.535 ' H ' ' HG ' ' C' ' 26' ' ' SER . 53.2 p -167.58 -173.5 2.21 Favored 'General case' 0 N--CA 1.483 1.184 0 CA-C-O 121.054 0.454 . . . . 0.0 110.721 179.392 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.62 47.67 1.37 Allowed Glycine 0 N--CA 1.482 1.705 0 CA-C-N 115.966 -0.561 . . . . 0.0 112.08 179.785 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 48.7 p90 -65.86 132.72 49.35 Favored 'General case' 0 N--CA 1.474 0.735 0 O-C-N 122.755 -0.262 . . . . 0.0 111.496 179.712 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 46.0 mt-10 -92.17 152.08 20.06 Favored 'General case' 0 N--CA 1.479 0.986 0 N-CA-C 109.725 -0.472 . . . . 0.0 109.725 178.512 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.0 p -152.89 128.25 1.59 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.612 0 N-CA-C 107.868 -1.16 . . . . 0.0 107.868 178.238 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 47.2 m-70 -135.41 147.8 49.12 Favored 'General case' 0 N--CA 1.493 1.708 0 CA-C-N 119.044 0.838 . . . . 0.0 111.398 -179.013 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 6.4 t60 -165.1 97.02 0.72 Allowed 'General case' 0 N--CA 1.48 1.064 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.624 179.342 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 3.9 pt20 -101.54 -174.16 2.53 Favored 'General case' 0 CA--C 1.507 -0.704 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 -179.82 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -169.9 95.81 0.28 Allowed 'General case' 0 N--CA 1.47 0.53 0 CA-C-N 114.608 -1.178 . . . . 0.0 108.389 178.38 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 6.5 mp -123.36 156.97 34.35 Favored 'General case' 0 N--CA 1.497 1.917 0 CA-C-O 121.794 0.807 . . . . 0.0 111.005 -178.14 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 60.1 t -111.79 126.86 69.22 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.135 0 CA-C-O 117.938 -1.029 . . . . 0.0 108.269 177.608 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 27.1 m-85 -126.89 123.09 36.44 Favored 'General case' 0 N--CA 1.497 1.912 0 CA-C-N 120.13 1.332 . . . . 0.0 110.474 179.5 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 67.9 m-85 53.66 74.71 0.3 Allowed 'General case' 0 CA--C 1.538 0.489 0 CA-C-O 121.414 0.626 . . . . 0.0 111.813 178.634 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -80.0 -78.28 0.17 Allowed 'General case' 0 C--N 1.353 0.727 0 CA-C-N 115.084 -0.962 . . . . 0.0 110.192 -179.922 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 38.2 tt0 -113.39 100.74 8.77 Favored 'General case' 0 N--CA 1.469 0.486 0 N-CA-C 108.191 -1.04 . . . . 0.0 108.191 179.725 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 4.4 p30 -159.18 139.79 12.43 Favored 'General case' 0 N--CA 1.483 1.178 0 O-C-N 122.31 -0.243 . . . . 0.0 111.219 179.147 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 61.2 t -59.97 163.43 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.819 0 N-CA-C 108.104 -1.073 . . . . 0.0 108.104 177.106 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.403 ' H ' ' HB ' ' D' ' 24' ' ' VAL . . . -117.3 48.61 0.92 Allowed Glycine 0 N--CA 1.475 1.252 0 N-CA-C 111.755 -0.538 . . . . 0.0 111.755 -179.402 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' SER . . . . . 0.491 ' HG ' ' H ' ' B' ' 8' ' ' SER . 0.3 OUTLIER -61.73 -167.83 0.01 OUTLIER 'General case' 0 N--CA 1.468 0.45 0 O-C-N 123.843 0.378 . . . . 0.0 110.412 179.522 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 25.1 t-20 -71.06 80.4 0.67 Allowed 'General case' 0 N--CA 1.465 0.284 0 CA-C-N 116.492 -0.322 . . . . 0.0 110.176 179.557 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -77.85 143.76 37.55 Favored 'General case' 0 N--CA 1.473 0.704 0 N-CA-C 109.141 -0.689 . . . . 0.0 109.141 179.332 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.38 -167.51 0.94 Allowed Glycine 0 CA--C 1.525 0.664 0 N-CA-C 109.863 -1.295 . . . . 0.0 109.863 178.629 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.8 114.61 27.88 Favored 'General case' 0 N--CA 1.48 1.038 0 N-CA-C 109.696 -0.483 . . . . 0.0 109.696 179.839 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 64.9 mt -98.41 135.78 31.88 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.552 0 N-CA-C 107.078 -1.453 . . . . 0.0 107.078 178.982 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . 0.418 ' C ' ' H ' ' A' ' 34' ' ' LEU . 34.1 pt -152.31 -176.14 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.734 0 CA-C-O 121.168 0.508 . . . . 0.0 111.18 -179.164 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.62 4.39 9.73 Favored Glycine 0 CA--C 1.524 0.597 0 N-CA-C 110.976 -0.85 . . . . 0.0 110.976 179.758 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . 0.418 ' H ' ' C ' ' A' ' 32' ' ' ILE . 1.6 tt -74.28 127.18 32.33 Favored 'General case' 0 CA--C 1.545 0.767 0 N-CA-C 109.499 -0.556 . . . . 0.0 109.499 -179.604 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 28.5 ttt -163.75 149.81 11.43 Favored 'General case' 0 N--CA 1.465 0.279 0 N-CA-C 108.963 -0.755 . . . . 0.0 108.963 178.782 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 27.5 m -155.22 166.33 1.07 Allowed 'Isoleucine or valine' 0 C--N 1.347 0.482 0 N-CA-C 108.061 -1.088 . . . . 0.0 108.061 179.686 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.1 67.2 2.33 Favored Glycine 0 C--N 1.307 -1.045 0 CA-C-N 115.776 -0.647 . . . . 0.0 112.102 178.422 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.96 -173.23 24.85 Favored Glycine 0 N--CA 1.474 1.195 0 N-CA-C 110.85 -0.9 . . . . 0.0 110.85 179.089 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.474 ' H ' HG11 ' D' ' 39' ' ' VAL . 34.5 m -125.56 156.34 35.03 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.774 0 C-N-CA 123.393 0.677 . . . . 0.0 110.232 -179.645 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 27.1 t . . . . . 0 C--O 1.218 -0.589 0 CA-C-O 118.433 -0.794 . . . . 0.0 110.622 179.853 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' B' B ' 1' ' ' ASP . . . . . . . . . . . . . 14.4 m-20 . . . . . 0 N--CA 1.489 1.487 0 N-CA-C 109.084 -0.709 . . . . 0.0 109.084 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' B' B ' 2' ' ' ALA . . . . . . . . . . . . . . . -66.13 132.71 49.11 Favored 'General case' 0 CA--C 1.54 0.562 0 N-CA-C 110.075 -0.343 . . . . 0.0 110.075 -179.755 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 3' ' ' GLU . . . . . . . . . . . . . 44.7 tt0 -168.22 105.04 0.47 Allowed 'General case' 0 N--CA 1.475 0.8 0 N-CA-C 110.029 -0.36 . . . . 0.0 110.029 -179.245 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 38.9 m-85 -85.43 151.9 23.63 Favored 'General case' 0 N--CA 1.473 0.715 0 N-CA-C 110.13 -0.322 . . . . 0.0 110.13 179.513 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -143.06 140.44 30.94 Favored 'General case' 0 N--CA 1.483 1.198 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 179.574 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 41.9 t-80 -151.65 119.03 5.98 Favored 'General case' 0 N--CA 1.473 0.692 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 179.001 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 7' ' ' ASP . . . . . 0.494 ' O ' ' OG ' ' E' ' 8' ' ' SER . 4.3 m-20 -68.68 148.55 50.25 Favored 'General case' 0 CA--C 1.537 0.47 0 CA-C-N 116.343 -0.389 . . . . 0.0 110.677 179.907 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 8' ' ' SER . . . . . 0.491 ' H ' ' HG ' ' A' ' 26' ' ' SER . 53.8 p -167.59 -173.53 2.22 Favored 'General case' 0 N--CA 1.482 1.136 0 CA-C-O 120.966 0.412 . . . . 0.0 110.745 179.418 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.92 47.14 1.39 Allowed Glycine 0 N--CA 1.481 1.686 0 CA-C-N 115.985 -0.552 . . . . 0.0 112.126 179.758 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 48.8 p90 -65.57 132.88 49.96 Favored 'General case' 0 N--CA 1.472 0.644 0 CA-C-O 120.665 0.269 . . . . 0.0 111.562 179.819 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 45.3 mt-10 -92.14 152.22 20.01 Favored 'General case' 0 N--CA 1.475 0.824 0 C-N-CA 122.847 0.459 . . . . 0.0 109.816 178.475 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -153.15 128.13 1.5 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.547 0 N-CA-C 107.854 -1.165 . . . . 0.0 107.854 178.266 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 46.9 m-70 -135.46 147.71 49.0 Favored 'General case' 0 N--CA 1.492 1.65 0 CA-C-N 118.915 0.78 . . . . 0.0 111.379 -178.882 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 6.5 t60 -165.14 97.01 0.71 Allowed 'General case' 0 N--CA 1.48 1.052 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.604 179.345 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 3.9 pt20 -101.51 -173.83 2.45 Favored 'General case' 0 CA--C 1.508 -0.638 0 N-CA-C 108.691 -0.855 . . . . 0.0 108.691 -179.764 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -170.22 95.82 0.25 Allowed 'General case' 0 N--CA 1.471 0.575 0 CA-C-N 114.727 -1.124 . . . . 0.0 108.321 178.324 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 6.5 mp -123.15 157.32 33.23 Favored 'General case' 0 N--CA 1.497 1.878 0 CA-C-O 121.73 0.776 . . . . 0.0 110.999 -178.134 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 60.9 t -112.37 127.65 69.46 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.098 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 177.44 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 27.0 m-85 -127.62 123.0 34.6 Favored 'General case' 0 N--CA 1.494 1.753 0 CA-C-N 119.707 1.14 . . . . 0.0 110.302 179.681 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 67.9 m-85 53.27 74.81 0.28 Allowed 'General case' 0 CA--C 1.537 0.476 0 CA-C-O 121.535 0.683 . . . . 0.0 111.919 178.475 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -80.48 -77.93 0.18 Allowed 'General case' 0 C--N 1.352 0.681 0 CA-C-N 115.004 -0.998 . . . . 0.0 110.218 -179.879 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 38.3 tt0 -113.53 100.45 8.52 Favored 'General case' 0 N--CA 1.47 0.565 0 N-CA-C 108.317 -0.994 . . . . 0.0 108.317 179.695 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -158.85 140.17 13.17 Favored 'General case' 0 N--CA 1.483 1.193 0 O-C-N 122.179 -0.326 . . . . 0.0 111.146 179.19 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 61.6 t -60.1 163.63 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.894 0 N-CA-C 108.121 -1.066 . . . . 0.0 108.121 177.072 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . 0.406 ' H ' ' HB ' ' E' ' 24' ' ' VAL . . . -117.23 48.32 0.95 Allowed Glycine 0 N--CA 1.476 1.309 0 N-CA-C 111.657 -0.577 . . . . 0.0 111.657 -179.353 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 26' ' ' SER . . . . . 0.486 ' HG ' ' H ' ' C' ' 8' ' ' SER . 0.3 OUTLIER -61.87 -168.58 0.02 OUTLIER 'General case' 0 N--CA 1.469 0.505 0 O-C-N 123.783 0.343 . . . . 0.0 110.348 179.498 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 25.0 t-20 -70.61 81.03 0.59 Allowed 'General case' 0 N--CA 1.467 0.377 0 N-CA-C 110.078 -0.342 . . . . 0.0 110.078 179.636 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -78.48 144.32 35.85 Favored 'General case' 0 N--CA 1.473 0.706 0 N-CA-C 109.077 -0.712 . . . . 0.0 109.077 179.394 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.47 -167.47 0.97 Allowed Glycine 0 C--N 1.336 0.569 0 N-CA-C 109.933 -1.267 . . . . 0.0 109.933 178.676 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.91 114.56 27.89 Favored 'General case' 0 N--CA 1.479 0.988 0 N-CA-C 109.677 -0.49 . . . . 0.0 109.677 179.644 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 64.3 mt -98.51 135.36 33.66 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.507 0 N-CA-C 107.073 -1.454 . . . . 0.0 107.073 178.9 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . 0.405 ' C ' ' H ' ' B' ' 34' ' ' LEU . 33.7 pt -151.99 -176.63 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.353 0.722 0 CA-C-N 116.026 -0.534 . . . . 0.0 111.191 -178.975 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.73 4.76 10.99 Favored Glycine 0 CA--C 1.523 0.57 0 N-CA-C 110.925 -0.87 . . . . 0.0 110.925 179.718 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 34' ' ' LEU . . . . . 0.405 ' H ' ' C ' ' B' ' 32' ' ' ILE . 1.6 tt -74.56 126.71 31.37 Favored 'General case' 0 CA--C 1.546 0.813 0 N-CA-C 109.438 -0.578 . . . . 0.0 109.438 -179.744 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 28.2 ttt -163.05 149.97 12.78 Favored 'General case' 0 N--CA 1.465 0.323 0 N-CA-C 108.935 -0.765 . . . . 0.0 108.935 178.82 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 27.3 m -155.3 166.34 1.06 Allowed 'Isoleucine or valine' 0 C--N 1.348 0.508 0 N-CA-C 108.015 -1.105 . . . . 0.0 108.015 179.706 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.73 67.43 2.21 Favored Glycine 0 C--N 1.307 -1.069 0 CA-C-N 115.742 -0.663 . . . . 0.0 112.094 178.434 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.65 -173.52 24.51 Favored Glycine 0 N--CA 1.474 1.213 0 N-CA-C 110.94 -0.864 . . . . 0.0 110.94 179.034 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 39' ' ' VAL . . . . . 0.493 ' H ' HG11 ' E' ' 39' ' ' VAL . 35.0 m -125.27 156.26 34.34 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.818 0 C-N-CA 123.42 0.688 . . . . 0.0 110.309 -179.591 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 26.6 t . . . . . 0 C--O 1.219 -0.514 0 CA-C-O 118.54 -0.743 . . . . 0.0 110.436 179.758 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' C' C ' 1' ' ' ASP . . . . . . . . . . . . . 14.4 m-20 . . . . . 0 N--CA 1.49 1.563 0 N-CA-C 108.783 -0.821 . . . . 0.0 108.783 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' C' C ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.99 132.74 49.28 Favored 'General case' 0 CA--C 1.539 0.535 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.243 -179.841 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 3' ' ' GLU . . . . . . . . . . . . . 44.6 tt0 -168.3 105.48 0.47 Allowed 'General case' 0 N--CA 1.474 0.768 0 N-CA-C 109.984 -0.376 . . . . 0.0 109.984 -179.275 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 39.7 m-85 -85.88 152.12 23.23 Favored 'General case' 0 N--CA 1.474 0.774 0 N-CA-C 110.064 -0.347 . . . . 0.0 110.064 179.573 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -143.35 140.42 30.51 Favored 'General case' 0 N--CA 1.483 1.182 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 179.726 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 42.0 t-80 -151.72 119.51 6.15 Favored 'General case' 0 N--CA 1.472 0.648 0 N-CA-C 109.317 -0.623 . . . . 0.0 109.317 179.114 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 7' ' ' ASP . . . . . 0.501 ' O ' ' OG ' ' F' ' 8' ' ' SER . 4.3 m-20 -69.22 148.32 50.01 Favored 'General case' 0 CA--C 1.537 0.472 0 CA-C-N 116.328 -0.397 . . . . 0.0 110.648 179.978 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 8' ' ' SER . . . . . 0.486 ' H ' ' HG ' ' B' ' 26' ' ' SER . 53.5 p -167.31 -173.4 2.25 Favored 'General case' 0 N--CA 1.484 1.246 0 CA-C-O 121.028 0.442 . . . . 0.0 110.692 179.43 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.62 47.1 1.43 Allowed Glycine 0 N--CA 1.482 1.734 0 CA-C-N 115.899 -0.592 . . . . 0.0 112.076 179.787 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 49.1 p90 -65.44 133.06 50.5 Favored 'General case' 0 N--CA 1.473 0.709 0 CA-C-O 120.671 0.272 . . . . 0.0 111.489 179.617 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 46.0 mt-10 -92.48 152.49 19.64 Favored 'General case' 0 N--CA 1.476 0.826 0 CA-C-O 121.1 0.476 . . . . 0.0 109.787 178.436 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -153.21 128.48 1.56 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.545 0 N-CA-C 107.786 -1.19 . . . . 0.0 107.786 178.307 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 47.0 m-70 -135.71 147.56 48.53 Favored 'General case' 0 N--CA 1.492 1.632 0 CA-C-N 118.925 0.784 . . . . 0.0 111.355 -179.081 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 6.5 t60 -164.96 97.17 0.73 Allowed 'General case' 0 N--CA 1.482 1.149 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.507 179.312 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 3.9 pt20 -101.64 -173.75 2.43 Favored 'General case' 0 CA--C 1.507 -0.701 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 -179.749 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -170.22 95.85 0.25 Allowed 'General case' 0 N--CA 1.47 0.553 0 CA-C-N 114.618 -1.174 . . . . 0.0 108.292 178.406 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 6.5 mp -123.37 157.08 34.12 Favored 'General case' 0 N--CA 1.497 1.918 0 CA-C-O 121.745 0.784 . . . . 0.0 111.07 -178.157 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 60.7 t -112.33 127.61 69.43 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.076 0 N-CA-C 108.059 -1.089 . . . . 0.0 108.059 177.53 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 27.7 m-85 -127.58 123.02 34.73 Favored 'General case' 0 N--CA 1.494 1.75 0 CA-C-N 119.6 1.091 . . . . 0.0 110.34 179.614 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 67.0 m-85 53.29 74.75 0.29 Allowed 'General case' 0 CA--C 1.538 0.495 0 CA-C-O 121.55 0.69 . . . . 0.0 111.975 178.441 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -80.34 -78.22 0.18 Allowed 'General case' 0 C--N 1.348 0.537 0 CA-C-N 114.911 -1.04 . . . . 0.0 110.197 -179.791 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 38.0 tt0 -113.31 100.39 8.52 Favored 'General case' 0 N--CA 1.47 0.56 0 N-CA-C 108.161 -1.051 . . . . 0.0 108.161 179.653 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 4.4 p30 -158.71 140.08 13.27 Favored 'General case' 0 N--CA 1.484 1.231 0 O-C-N 122.202 -0.311 . . . . 0.0 111.204 179.085 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 61.8 t -60.0 163.72 0.92 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.852 0 N-CA-C 108.153 -1.054 . . . . 0.0 108.153 177.082 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -117.38 48.31 0.95 Allowed Glycine 0 N--CA 1.477 1.385 0 N-CA-C 111.637 -0.585 . . . . 0.0 111.637 -179.336 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 26' ' ' SER . . . . . 0.535 ' HG ' ' H ' ' A' ' 8' ' ' SER . 0.3 OUTLIER -61.81 -167.99 0.01 OUTLIER 'General case' 0 N--CA 1.468 0.427 0 O-C-N 123.79 0.347 . . . . 0.0 110.361 179.658 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 25.0 t-20 -71.01 80.71 0.66 Allowed 'General case' 0 N--CA 1.465 0.304 0 N-CA-C 110.067 -0.345 . . . . 0.0 110.067 179.495 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -78.22 144.13 36.53 Favored 'General case' 0 N--CA 1.472 0.65 0 N-CA-C 109.117 -0.698 . . . . 0.0 109.117 179.415 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.55 -167.62 1.03 Allowed Glycine 0 CA--C 1.523 0.586 0 N-CA-C 109.965 -1.254 . . . . 0.0 109.965 178.788 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.6 114.34 27.31 Favored 'General case' 0 N--CA 1.48 1.071 0 N-CA-C 109.661 -0.496 . . . . 0.0 109.661 179.775 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 64.8 mt -98.42 135.45 33.16 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.546 0 N-CA-C 107.058 -1.46 . . . . 0.0 107.058 178.911 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 32' ' ' ILE . . . . . 0.419 ' C ' ' H ' ' C' ' 34' ' ' LEU . 33.8 pt -152.01 -176.15 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.352 0.688 0 CA-C-N 115.998 -0.547 . . . . 0.0 111.189 -179.096 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.48 4.49 9.43 Favored Glycine 0 CA--C 1.524 0.615 0 N-CA-C 110.992 -0.843 . . . . 0.0 110.992 179.697 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 34' ' ' LEU . . . . . 0.419 ' H ' ' C ' ' C' ' 32' ' ' ILE . 1.6 tt -74.27 127.27 32.57 Favored 'General case' 0 CA--C 1.547 0.831 0 N-CA-C 109.389 -0.597 . . . . 0.0 109.389 -179.776 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 28.3 ttt -163.52 150.06 12.02 Favored 'General case' 0 N--CA 1.467 0.397 0 N-CA-C 108.86 -0.792 . . . . 0.0 108.86 178.735 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 27.3 m -155.59 166.05 1.07 Allowed 'Isoleucine or valine' 0 C--N 1.347 0.5 0 N-CA-C 108.06 -1.089 . . . . 0.0 108.06 179.657 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.06 67.23 2.32 Favored Glycine 0 C--N 1.307 -1.047 0 CA-C-N 115.721 -0.672 . . . . 0.0 112.077 178.503 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.71 -173.44 24.58 Favored Glycine 0 N--CA 1.473 1.139 0 N-CA-C 110.987 -0.845 . . . . 0.0 110.987 178.959 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 39' ' ' VAL . . . . . 0.494 ' H ' HG11 ' F' ' 39' ' ' VAL . 32.9 m -125.11 156.37 33.98 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.751 0 C-N-CA 123.386 0.674 . . . . 0.0 110.31 -179.572 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 25.6 t . . . . . 0 C--O 1.218 -0.576 0 CA-C-O 118.424 -0.798 . . . . 0.0 110.579 179.77 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' D' D ' 1' ' ' ASP . . . . . . . . . . . . . 14.7 m-20 . . . . . 0 N--CA 1.49 1.554 0 N-CA-C 109.216 -0.661 . . . . 0.0 109.216 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' D' D ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.28 131.05 46.21 Favored 'General case' 0 CA--C 1.535 0.388 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.541 179.804 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 3' ' ' GLU . . . . . . . . . . . . . 44.3 tt0 -169.31 107.98 0.42 Allowed 'General case' 0 N--CA 1.472 0.641 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 -179.953 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 41.4 m-85 -90.2 156.98 17.94 Favored 'General case' 0 C--N 1.358 0.971 0 N-CA-C 108.775 -0.824 . . . . 0.0 108.775 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -145.24 139.15 26.95 Favored 'General case' 0 N--CA 1.478 0.927 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.144 -179.846 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 38.7 t-80 -149.47 123.46 9.4 Favored 'General case' 0 CA--C 1.544 0.744 0 N-CA-C 108.42 -0.956 . . . . 0.0 108.42 175.352 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 7' ' ' ASP . . . . . 0.596 ' O ' ' OG ' ' G' ' 8' ' ' SER . 3.2 m-20 -63.79 133.02 52.69 Favored 'General case' 0 C--N 1.32 -0.702 0 C-N-CA 126.769 2.027 . . . . 0.0 113.965 174.817 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' D' D ' 8' ' ' SER . . . . . 0.53 ' H ' ' HG ' ' F' ' 26' ' ' SER . 53.9 p -154.61 -170.57 3.56 Favored 'General case' 0 N--CA 1.487 1.41 0 CA-C-N 119.397 0.999 . . . . 0.0 111.12 175.622 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.2 47.77 1.2 Allowed Glycine 0 N--CA 1.481 1.651 0 N-CA-C 110.652 -0.979 . . . . 0.0 110.652 174.445 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 51.1 p90 -60.91 131.48 50.81 Favored 'General case' 0 N--CA 1.471 0.614 0 N-CA-C 112.804 0.668 . . . . 0.0 112.804 178.075 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 45.7 mt-10 -89.49 150.83 22.29 Favored 'General case' 0 N--CA 1.481 1.094 0 CA-C-N 117.825 0.284 . . . . 0.0 110.809 175.351 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.0 p -149.46 129.84 4.28 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.611 0 N-CA-C 107.49 -1.3 . . . . 0.0 107.49 173.417 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 42.9 m-70 -129.96 150.74 51.11 Favored 'General case' 0 N--CA 1.483 1.215 0 CA-C-N 118.198 0.454 . . . . 0.0 111.994 176.584 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 6.6 t60 -164.98 104.47 0.78 Allowed 'General case' 0 N--CA 1.483 1.186 0 N-CA-C 108.844 -0.799 . . . . 0.0 108.844 172.171 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 3.9 pt20 -105.12 -176.1 2.98 Favored 'General case' 0 CA--C 1.502 -0.871 0 N-CA-C 108.487 -0.931 . . . . 0.0 108.487 179.177 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -166.23 104.52 0.64 Allowed 'General case' 0 N--CA 1.466 0.335 0 N-CA-C 106.205 -1.776 . . . . 0.0 106.205 174.131 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 5.4 mp -130.35 154.02 48.09 Favored 'General case' 0 N--CA 1.5 2.043 0 CA-C-O 122.062 0.934 . . . . 0.0 110.711 179.458 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 34.5 t -101.25 131.56 48.76 Favored 'Isoleucine or valine' 0 C--O 1.262 1.714 0 CA-C-O 116.779 -1.581 . . . . 0.0 109.686 174.097 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 26.2 m-85 -130.09 126.45 37.62 Favored 'General case' 0 N--CA 1.488 1.457 0 CA-C-N 120.126 1.33 . . . . 0.0 109.864 173.73 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 67.4 m-85 55.48 71.3 0.56 Allowed 'General case' 0 C--O 1.239 0.542 0 CA-C-N 115.712 -0.676 . . . . 0.0 111.837 176.206 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -81.6 -73.43 0.38 Allowed 'General case' 0 N--CA 1.473 0.718 0 CA-C-O 118.585 -0.721 . . . . 0.0 111.063 -177.61 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 38.6 tt0 -116.64 104.28 11.23 Favored 'General case' 0 N--CA 1.482 1.164 0 N-CA-C 106.361 -1.718 . . . . 0.0 106.361 176.324 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -152.15 139.92 19.9 Favored 'General case' 0 N--CA 1.474 0.756 0 CA-C-O 116.8 -1.571 . . . . 0.0 113.647 177.815 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 24' ' ' VAL . . . . . 0.403 ' HB ' ' H ' ' A' ' 25' ' ' GLY . 66.7 t -62.45 166.04 0.98 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.294 0 CA-C-N 121.037 1.744 . . . . 0.0 107.983 174.905 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' D' D ' 25' ' ' GLY . . . . . 0.43 ' H ' ' HB ' ' G' ' 24' ' ' VAL . . . -116.83 51.08 0.75 Allowed Glycine 0 N--CA 1.479 1.52 0 CA-C-O 119.081 -0.844 . . . . 0.0 111.738 178.536 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' D' D ' 26' ' ' SER . . . . . 0.491 ' HG ' ' H ' ' E' ' 8' ' ' SER . 0.2 OUTLIER -57.75 -171.21 0.01 OUTLIER 'General case' 0 C--N 1.323 -0.58 0 C-N-CA 123.618 0.767 . . . . 0.0 111.722 176.054 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 25.8 t-20 -72.11 86.52 1.05 Allowed 'General case' 0 C--N 1.346 0.435 0 N-CA-C 108.585 -0.894 . . . . 0.0 108.585 177.688 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 97.5 mttt -83.53 146.48 28.32 Favored 'General case' 0 N--CA 1.474 0.775 0 N-CA-C 108.056 -1.09 . . . . 0.0 108.056 179.196 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -62.95 -165.4 0.56 Allowed Glycine 0 C--N 1.335 0.476 0 N-CA-C 110.519 -1.032 . . . . 0.0 110.519 179.225 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -101.78 115.95 31.65 Favored 'General case' 0 N--CA 1.471 0.606 0 N-CA-C 109.235 -0.654 . . . . 0.0 109.235 179.594 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 72.6 mt -102.71 142.77 16.16 Favored 'Isoleucine or valine' 0 C--N 1.356 0.891 0 N-CA-C 104.544 -2.391 . . . . 0.0 104.544 179.838 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 32' ' ' ILE . . . . . 0.402 HG23 ' H ' ' G' ' 32' ' ' ILE . 34.8 pt -158.49 -176.96 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.209 0 CA-C-O 120.891 0.377 . . . . 0.0 110.152 -177.537 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 64.31 4.38 12.19 Favored Glycine 0 C--O 1.247 0.958 0 N-CA-C 110.087 -1.205 . . . . 0.0 110.087 -179.011 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 2.0 tt -76.37 132.94 40.02 Favored 'General case' 0 C--N 1.363 1.181 0 N-CA-C 107.185 -1.413 . . . . 0.0 107.185 -177.974 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 28.2 ttt -158.52 161.53 37.36 Favored 'General case' 0 C--O 1.221 -0.419 0 CA-C-O 118.318 -0.849 . . . . 0.0 108.734 173.086 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 27.6 m -164.74 165.07 0.61 Allowed 'Isoleucine or valine' 0 CA--C 1.519 -0.247 0 N-CA-C 107.624 -1.25 . . . . 0.0 107.624 175.835 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 60.36 64.1 4.43 Favored Glycine 0 CA--C 1.524 0.6 0 C-N-CA 119.576 -1.297 . . . . 0.0 113.006 178.572 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 140.95 -171.61 24.04 Favored Glycine 0 N--CA 1.476 1.361 0 CA-C-N 117.328 0.564 . . . . 0.0 111.95 -179.175 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 39' ' ' VAL . . . . . 0.477 ' H ' HG11 ' G' ' 39' ' ' VAL . 35.4 m -128.17 153.5 37.65 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.883 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -176.664 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 25.3 t . . . . . 0 C--O 1.225 -0.204 0 CA-C-O 116.686 -1.626 . . . . 0.0 109.773 178.118 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' E' E ' 1' ' ' ASP . . . . . . . . . . . . . 15.4 m-20 . . . . . 0 N--CA 1.488 1.457 0 N-CA-C 109.5 -0.555 . . . . 0.0 109.5 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' E' E ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.5 129.8 41.24 Favored 'General case' 0 N--CA 1.468 0.461 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.423 -179.892 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' E' E ' 3' ' ' GLU . . . . . . . . . . . . . 44.1 tt0 -167.14 105.29 0.56 Allowed 'General case' 0 C--O 1.213 -0.839 0 CA-C-N 116.775 -0.193 . . . . 0.0 110.634 -179.678 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 37.9 m-85 -86.62 151.76 23.16 Favored 'General case' 0 N--CA 1.475 0.825 0 N-CA-C 110.166 -0.309 . . . . 0.0 110.166 179.353 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' E' E ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -142.74 140.86 31.61 Favored 'General case' 0 N--CA 1.484 1.257 0 CA-C-O 120.952 0.405 . . . . 0.0 109.997 179.576 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 41.5 t-80 -151.68 119.21 6.05 Favored 'General case' 0 N--CA 1.472 0.625 0 N-CA-C 109.228 -0.656 . . . . 0.0 109.228 178.894 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' E' E ' 7' ' ' ASP . . . . . 0.495 ' O ' ' OG ' ' H' ' 8' ' ' SER . 4.0 m-20 -69.47 148.39 49.59 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 116.389 -0.368 . . . . 0.0 110.82 -179.982 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' E' E ' 8' ' ' SER . . . . . 0.494 ' OG ' ' O ' ' B' ' 7' ' ' ASP . 51.8 p -168.1 -172.13 1.71 Allowed 'General case' 0 N--CA 1.485 1.31 0 CA-C-O 121.153 0.501 . . . . 0.0 110.857 178.995 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.17 47.61 1.31 Allowed Glycine 0 N--CA 1.479 1.516 0 CA-C-N 115.879 -0.601 . . . . 0.0 111.942 179.622 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 46.8 p90 -65.2 133.16 50.91 Favored 'General case' 0 N--CA 1.474 0.762 0 N-CA-C 111.894 0.331 . . . . 0.0 111.894 -179.886 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 46.2 mt-10 -91.84 152.33 20.16 Favored 'General case' 0 N--CA 1.479 0.995 0 CA-C-O 121.211 0.529 . . . . 0.0 109.742 178.007 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -154.34 127.47 1.16 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.586 0 N-CA-C 107.799 -1.186 . . . . 0.0 107.799 178.103 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 44.8 m-70 -135.78 145.71 46.82 Favored 'General case' 0 N--CA 1.481 1.116 0 CA-C-O 120.768 0.318 . . . . 0.0 111.678 -177.861 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 6.4 t60 -163.94 97.1 0.83 Allowed 'General case' 0 N--CA 1.485 1.318 0 CA-C-N 116.374 -0.375 . . . . 0.0 110.61 179.531 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' E' E ' 15' ' ' GLN . . . . . 0.421 HE22 ' CG2' ' E' ' 36' ' ' VAL . 3.9 pt20 -101.3 -173.97 2.49 Favored 'General case' 0 CA--C 1.509 -0.634 0 N-CA-C 108.855 -0.794 . . . . 0.0 108.855 -179.77 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -169.85 94.95 0.27 Allowed 'General case' 0 N--CA 1.474 0.739 0 CA-C-N 114.702 -1.136 . . . . 0.0 108.423 178.468 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 6.4 mp -122.05 156.92 32.53 Favored 'General case' 0 N--CA 1.494 1.772 0 CA-C-O 121.649 0.738 . . . . 0.0 111.532 -177.641 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 48.0 t -113.9 124.35 70.47 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.231 0 N-CA-C 108.178 -1.045 . . . . 0.0 108.178 177.168 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 30.5 m-85 -124.83 121.78 35.54 Favored 'General case' 0 N--CA 1.488 1.427 0 CA-C-O 120.83 0.348 . . . . 0.0 111.086 -179.729 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 68.8 m-85 54.76 73.61 0.4 Allowed 'General case' 0 N--CA 1.467 0.407 0 CA-C-N 115.941 -0.572 . . . . 0.0 111.609 178.173 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -78.53 -78.6 0.14 Allowed 'General case' 0 CA--C 1.535 0.379 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.108 -179.615 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 38.5 tt0 -112.8 101.07 9.17 Favored 'General case' 0 C--N 1.324 -0.532 0 N-CA-C 108.257 -1.016 . . . . 0.0 108.257 179.905 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -158.39 140.12 13.71 Favored 'General case' 0 C--O 1.205 -1.274 0 O-C-N 122.282 -0.262 . . . . 0.0 111.5 178.97 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' E' E ' 24' ' ' VAL . . . . . 0.406 ' HB ' ' H ' ' B' ' 25' ' ' GLY . 57.6 t -58.65 168.53 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.867 0 N-CA-C 107.619 -1.252 . . . . 0.0 107.619 176.943 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . -122.45 49.35 0.89 Allowed Glycine 0 N--CA 1.474 1.212 0 N-CA-C 110.783 -0.927 . . . . 0.0 110.783 -179.296 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' E' E ' 26' ' ' SER . . . . . 0.482 ' HG ' ' H ' ' F' ' 8' ' ' SER . 0.3 OUTLIER -63.24 -167.83 0.02 OUTLIER 'General case' 0 N--CA 1.469 0.489 0 CA-C-O 120.763 0.316 . . . . 0.0 110.466 179.805 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 25.4 t-20 -70.07 77.29 0.5 Allowed 'General case' 0 N--CA 1.466 0.365 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.422 179.961 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -75.17 144.45 42.73 Favored 'General case' 0 N--CA 1.476 0.855 0 N-CA-C 109.552 -0.536 . . . . 0.0 109.552 179.438 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.34 -166.9 1.19 Allowed Glycine 0 CA--C 1.521 0.454 0 N-CA-C 110.439 -1.064 . . . . 0.0 110.439 178.548 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.68 114.15 27.06 Favored 'General case' 0 N--CA 1.472 0.646 0 N-CA-C 109.848 -0.426 . . . . 0.0 109.848 179.769 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 65.6 mt -98.47 135.52 32.97 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.324 0 N-CA-C 106.832 -1.544 . . . . 0.0 106.832 178.979 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' E' E ' 32' ' ' ILE . . . . . 0.419 ' C ' ' H ' ' E' ' 34' ' ' LEU . 36.2 pt -152.01 -174.05 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.208 0 CA-C-O 121.111 0.481 . . . . 0.0 110.713 -179.337 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.29 5.16 5.74 Favored Glycine 0 CA--C 1.529 0.942 0 CA-C-N 115.58 -0.736 . . . . 0.0 111.408 -179.731 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' E' E ' 34' ' ' LEU . . . . . 0.419 ' H ' ' C ' ' E' ' 32' ' ' ILE . 1.6 tt -74.25 126.9 31.63 Favored 'General case' 0 CA--C 1.547 0.852 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 -179.559 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 28.5 ttt -162.74 151.09 14.26 Favored 'General case' 0 C--O 1.209 -1.05 0 N-CA-C 108.995 -0.742 . . . . 0.0 108.995 178.769 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' E' E ' 36' ' ' VAL . . . . . 0.421 ' CG2' HE22 ' E' ' 15' ' ' GLN . 35.4 m -156.62 166.23 0.94 Allowed 'Isoleucine or valine' 0 C--N 1.343 0.292 0 N-CA-C 108.354 -0.98 . . . . 0.0 108.354 179.747 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.72 66.87 2.53 Favored Glycine 0 C--N 1.307 -1.075 0 CA-C-N 115.576 -0.738 . . . . 0.0 111.997 178.442 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 144.1 -173.12 24.99 Favored Glycine 0 N--CA 1.475 1.281 0 N-CA-C 111.23 -0.748 . . . . 0.0 111.23 178.931 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' E' E ' 39' ' ' VAL . . . . . 0.504 ' H ' HG11 ' H' ' 39' ' ' VAL . 34.2 m -125.46 155.31 34.52 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.753 0 C-N-CA 123.405 0.682 . . . . 0.0 110.429 -179.138 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 26.4 t . . . . . 0 C--O 1.219 -0.526 0 O-C-N 124.062 0.851 . . . . 0.0 110.467 179.505 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' F' F ' 1' ' ' ASP . . . . . . . . . . . . . 14.5 m-20 . . . . . 0 N--CA 1.49 1.562 0 N-CA-C 109.302 -0.629 . . . . 0.0 109.302 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' F' F ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.58 130.19 42.72 Favored 'General case' 0 CA--C 1.536 0.42 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.354 179.982 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 3' ' ' GLU . . . . . . . . . . . . . 44.3 tt0 -167.53 106.05 0.54 Allowed 'General case' 0 C--O 1.213 -0.838 0 CA-C-N 116.71 -0.223 . . . . 0.0 110.505 -179.767 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 36.2 m-85 -87.49 151.77 22.76 Favored 'General case' 0 N--CA 1.474 0.75 0 N-CA-C 110.003 -0.369 . . . . 0.0 110.003 179.481 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -142.64 141.02 31.83 Favored 'General case' 0 N--CA 1.48 1.051 0 CA-C-O 120.884 0.373 . . . . 0.0 110.175 179.509 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 42.2 t-80 -151.9 118.95 5.85 Favored 'General case' 0 N--CA 1.472 0.639 0 N-CA-C 109.343 -0.614 . . . . 0.0 109.343 179.046 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 7' ' ' ASP . . . . . 0.496 ' O ' ' OG ' ' I' ' 8' ' ' SER . 4.0 m-20 -69.34 148.36 49.8 Favored 'General case' 0 N--CA 1.465 0.324 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.824 -179.902 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' F' F ' 8' ' ' SER . . . . . 0.501 ' OG ' ' O ' ' C' ' 7' ' ' ASP . 50.5 p -168.1 -172.03 1.68 Allowed 'General case' 0 N--CA 1.486 1.335 0 CA-C-O 121.119 0.485 . . . . 0.0 110.953 179.008 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.89 47.16 1.39 Allowed Glycine 0 N--CA 1.479 1.553 0 CA-C-N 115.884 -0.598 . . . . 0.0 111.953 179.629 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 46.2 p90 -64.73 133.4 52.0 Favored 'General case' 0 CA--C 1.543 0.68 0 N-CA-C 111.832 0.308 . . . . 0.0 111.832 -179.924 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 46.2 mt-10 -91.91 152.17 20.19 Favored 'General case' 0 N--CA 1.481 1.081 0 CA-C-O 121.19 0.519 . . . . 0.0 109.736 177.997 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -154.12 127.24 1.15 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.599 0 N-CA-C 107.838 -1.171 . . . . 0.0 107.838 178.131 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 44.5 m-70 -135.53 146.04 47.66 Favored 'General case' 0 N--CA 1.483 1.201 0 CA-C-O 120.88 0.372 . . . . 0.0 111.631 -177.916 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 6.4 t60 -164.07 96.94 0.81 Allowed 'General case' 0 N--CA 1.486 1.369 0 CA-C-N 116.436 -0.347 . . . . 0.0 110.674 179.385 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 15' ' ' GLN . . . . . 0.406 HE22 ' CG2' ' F' ' 36' ' ' VAL . 3.9 pt20 -101.18 -173.84 2.47 Favored 'General case' 0 CA--C 1.507 -0.698 0 N-CA-C 108.871 -0.789 . . . . 0.0 108.871 -179.814 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -169.87 94.93 0.27 Allowed 'General case' 0 N--CA 1.473 0.677 0 CA-C-N 114.609 -1.178 . . . . 0.0 108.443 178.42 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 6.3 mp -121.95 157.07 32.06 Favored 'General case' 0 N--CA 1.494 1.764 0 CA-C-O 121.685 0.755 . . . . 0.0 111.554 -177.676 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 48.1 t -114.02 124.27 70.5 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.217 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 177.162 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 30.0 m-85 -124.71 122.03 36.32 Favored 'General case' 0 N--CA 1.488 1.431 0 CA-C-O 120.863 0.364 . . . . 0.0 110.983 -179.741 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 68.9 m-85 54.61 74.18 0.36 Allowed 'General case' 0 C--N 1.344 0.362 0 CA-C-N 115.873 -0.603 . . . . 0.0 111.705 178.166 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -79.1 -78.5 0.15 Allowed 'General case' 0 CA--C 1.535 0.388 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.197 -179.56 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 38.4 tt0 -112.91 101.03 9.11 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 179.822 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -158.29 139.84 13.59 Favored 'General case' 0 C--O 1.208 -1.124 0 O-C-N 122.279 -0.263 . . . . 0.0 111.572 179.099 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 24' ' ' VAL . . . . . . . . . . . . . 58.3 t -58.55 168.08 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.891 0 N-CA-C 107.507 -1.294 . . . . 0.0 107.507 177.037 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -122.14 49.48 0.89 Allowed Glycine 0 N--CA 1.477 1.43 0 N-CA-C 110.787 -0.925 . . . . 0.0 110.787 -179.427 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 26' ' ' SER . . . . . 0.53 ' HG ' ' H ' ' D' ' 8' ' ' SER . 0.3 OUTLIER -63.27 -167.56 0.02 OUTLIER 'General case' 0 N--CA 1.469 0.509 0 CA-C-O 120.642 0.258 . . . . 0.0 110.441 179.796 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 25.5 t-20 -70.26 77.12 0.53 Allowed 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.451 179.916 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -75.02 144.77 42.91 Favored 'General case' 0 N--CA 1.476 0.845 0 N-CA-C 109.579 -0.526 . . . . 0.0 109.579 179.335 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.46 -167.02 1.25 Allowed Glycine 0 CA--C 1.522 0.484 0 N-CA-C 110.494 -1.042 . . . . 0.0 110.494 178.64 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.17 113.96 26.47 Favored 'General case' 0 N--CA 1.473 0.711 0 N-CA-C 109.808 -0.442 . . . . 0.0 109.808 179.665 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 66.5 mt -98.43 135.27 33.89 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.388 0 N-CA-C 106.837 -1.542 . . . . 0.0 106.837 178.762 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 32' ' ' ILE . . . . . 0.417 ' C ' ' H ' ' F' ' 34' ' ' LEU . 35.2 pt -151.87 -174.29 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.198 0 CA-C-O 121.248 0.547 . . . . 0.0 110.723 -179.373 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.35 5.45 6.31 Favored Glycine 0 CA--C 1.528 0.901 0 CA-C-N 115.55 -0.75 . . . . 0.0 111.443 -179.774 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 34' ' ' LEU . . . . . 0.417 ' H ' ' C ' ' F' ' 32' ' ' ILE . 1.6 tt -74.42 127.05 32.07 Favored 'General case' 0 CA--C 1.549 0.913 0 N-CA-C 109.467 -0.568 . . . . 0.0 109.467 -179.741 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 28.4 ttt -162.69 151.32 14.62 Favored 'General case' 0 C--O 1.209 -1.045 0 N-CA-C 108.963 -0.755 . . . . 0.0 108.963 178.605 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 36' ' ' VAL . . . . . 0.406 ' CG2' HE22 ' F' ' 15' ' ' GLN . 35.4 m -156.82 166.13 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.344 0.347 0 N-CA-C 108.312 -0.995 . . . . 0.0 108.312 179.77 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.78 67.0 2.44 Favored Glycine 0 C--N 1.307 -1.038 0 CA-C-N 115.595 -0.729 . . . . 0.0 112.003 178.49 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.98 -173.0 24.96 Favored Glycine 0 N--CA 1.474 1.179 0 N-CA-C 111.251 -0.74 . . . . 0.0 111.251 178.992 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 39' ' ' VAL . . . . . 0.506 ' H ' HG11 ' I' ' 39' ' ' VAL . 34.2 m -125.62 155.51 34.93 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.729 0 C-N-CA 123.336 0.654 . . . . 0.0 110.365 -179.166 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 25.3 t . . . . . 0 C--O 1.219 -0.551 0 O-C-N 124.004 0.815 . . . . 0.0 110.423 179.593 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' G' G ' 1' ' ' ASP . . . . . . . . . . . . . 14.8 m-20 . . . . . 0 N--CA 1.492 1.664 0 N-CA-C 109.336 -0.616 . . . . 0.0 109.336 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' G' G ' 2' ' ' ALA . . . . . . . . . . . . . . . -63.34 128.64 36.77 Favored 'General case' 0 N--CA 1.468 0.473 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.666 179.692 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 3' ' ' GLU . . . . . . . . . . . . . 43.7 tt0 -167.86 107.0 0.53 Allowed 'General case' 0 N--CA 1.473 0.711 0 CA-C-O 120.495 0.188 . . . . 0.0 110.828 179.732 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 40.2 m-85 -89.19 151.51 22.12 Favored 'General case' 0 N--CA 1.474 0.768 0 N-CA-C 109.591 -0.522 . . . . 0.0 109.591 179.288 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 5' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -143.0 140.56 31.07 Favored 'General case' 0 N--CA 1.481 1.1 0 C-N-CA 122.498 0.319 . . . . 0.0 110.337 179.837 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 42.3 t-80 -151.27 120.22 6.66 Favored 'General case' 0 N--CA 1.474 0.739 0 N-CA-C 109.441 -0.578 . . . . 0.0 109.441 178.938 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -71.23 144.31 50.12 Favored 'General case' 0 N--CA 1.469 0.51 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.231 -179.829 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 8' ' ' SER . . . . . 0.596 ' OG ' ' O ' ' D' ' 7' ' ' ASP . 45.2 p -165.07 -170.52 1.95 Allowed 'General case' 0 N--CA 1.476 0.832 0 CA-C-O 121.037 0.446 . . . . 0.0 110.545 178.792 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.68 48.0 1.33 Allowed Glycine 0 N--CA 1.479 1.548 0 N-CA-C 111.485 -0.646 . . . . 0.0 111.485 179.468 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 48.8 p90 -65.77 133.43 50.99 Favored 'General case' 0 CA--C 1.543 0.676 0 N-CA-C 111.694 0.257 . . . . 0.0 111.694 -179.694 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 46.1 mt-10 -92.32 151.43 20.29 Favored 'General case' 0 N--CA 1.48 1.043 0 CA-C-O 121.146 0.498 . . . . 0.0 110.163 178.582 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -154.75 127.3 1.06 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.966 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 178.298 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 45.7 m-70 -134.74 147.34 50.01 Favored 'General case' 0 N--CA 1.478 0.965 0 CA-C-N 115.62 -0.718 . . . . 0.0 111.486 -178.291 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 6.6 t60 -165.42 97.35 0.69 Allowed 'General case' 0 N--CA 1.483 1.204 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.242 178.83 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 3.9 pt20 -101.59 -173.67 2.41 Favored 'General case' 0 CA--C 1.507 -0.699 0 N-CA-C 108.662 -0.866 . . . . 0.0 108.662 -179.58 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -170.55 94.22 0.21 Allowed 'General case' 0 N--CA 1.473 0.693 0 CA-C-N 114.654 -1.157 . . . . 0.0 108.076 178.637 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 6.3 mp -121.33 155.85 33.85 Favored 'General case' 0 N--CA 1.498 1.93 0 CA-C-O 121.237 0.541 . . . . 0.0 111.814 -177.8 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 42.9 t -113.43 125.15 70.65 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.011 0 CA-C-N 114.74 -1.118 . . . . 0.0 108.116 176.566 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 31.8 m-85 -125.96 121.54 33.38 Favored 'General case' 0 C--N 1.367 1.337 0 CA-C-N 115.664 -0.698 . . . . 0.0 111.083 -179.446 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 68.4 m-85 54.86 73.11 0.43 Allowed 'General case' 0 N--CA 1.467 0.416 0 CA-C-N 115.858 -0.61 . . . . 0.0 111.545 178.036 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.58 -77.95 0.14 Allowed 'General case' 0 N--CA 1.472 0.64 0 O-C-N 122.212 -0.305 . . . . 0.0 110.355 -179.25 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 38.4 tt0 -113.23 101.14 9.14 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 107.95 -1.13 . . . . 0.0 107.95 179.822 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -158.29 141.02 14.61 Favored 'General case' 0 N--CA 1.477 0.915 0 O-C-N 122.337 -0.227 . . . . 0.0 111.487 179.063 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 24' ' ' VAL . . . . . 0.43 ' HB ' ' H ' ' D' ' 25' ' ' GLY . 59.9 t -60.28 167.07 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.762 0 N-CA-C 107.641 -1.244 . . . . 0.0 107.641 177.26 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -120.45 49.61 0.87 Allowed Glycine 0 N--CA 1.479 1.566 0 N-CA-C 110.504 -1.038 . . . . 0.0 110.504 -179.452 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -64.02 -167.27 0.02 OUTLIER 'General case' 0 N--CA 1.471 0.598 0 CA-C-N 116.953 0.376 . . . . 0.0 110.061 179.829 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 25.8 t-20 -70.45 77.12 0.56 Allowed 'General case' 0 CA--C 1.535 0.401 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.471 179.943 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -74.53 144.14 44.21 Favored 'General case' 0 N--CA 1.476 0.86 0 N-CA-C 109.653 -0.499 . . . . 0.0 109.653 179.361 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.39 -166.11 1.07 Allowed Glycine 0 C--N 1.337 0.619 0 N-CA-C 110.037 -1.225 . . . . 0.0 110.037 178.707 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -98.84 114.06 26.47 Favored 'General case' 0 N--CA 1.471 0.575 0 C-N-CA 122.672 0.389 . . . . 0.0 110.447 179.843 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 67.6 mt -99.16 135.51 34.02 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.698 0 N-CA-C 106.856 -1.535 . . . . 0.0 106.856 178.831 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 32' ' ' ILE . . . . . 0.42 ' C ' ' H ' ' G' ' 34' ' ' LEU . 34.1 pt -152.48 -173.92 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 CA-C-N 119.891 1.223 . . . . 0.0 109.878 -179.725 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.15 5.31 7.61 Favored Glycine 0 N--CA 1.468 0.773 0 N-CA-C 111.061 -0.816 . . . . 0.0 111.061 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 34' ' ' LEU . . . . . 0.42 ' H ' ' C ' ' G' ' 32' ' ' ILE . 1.6 tt -75.04 125.85 29.79 Favored 'General case' 0 CA--C 1.545 0.775 0 N-CA-C 109.524 -0.547 . . . . 0.0 109.524 -179.611 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 27.4 ttt -161.52 152.66 18.42 Favored 'General case' 0 C--O 1.21 -0.986 0 N-CA-C 108.775 -0.824 . . . . 0.0 108.775 178.503 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 35.8 m -157.26 165.17 1.0 Allowed 'Isoleucine or valine' 0 C--N 1.346 0.429 0 N-CA-C 108.528 -0.916 . . . . 0.0 108.528 -179.675 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.39 67.99 1.92 Allowed Glycine 0 C--N 1.307 -1.031 0 CA-C-N 115.531 -0.759 . . . . 0.0 112.206 178.26 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.99 -171.66 25.45 Favored Glycine 0 N--CA 1.476 1.315 0 N-CA-C 110.621 -0.991 . . . . 0.0 110.621 178.998 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 39' ' ' VAL . . . . . 0.477 HG11 ' H ' ' D' ' 39' ' ' VAL . 34.7 m -126.93 156.03 38.04 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.911 0 C-N-CA 123.069 0.548 . . . . 0.0 110.631 -179.357 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 31.5 t . . . . . 0 C--O 1.219 -0.546 0 O-C-N 123.946 0.779 . . . . 0.0 110.737 179.218 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' H' H ' 1' ' ' ASP . . . . . . . . . . . . . 15.1 m-20 . . . . . 0 N--CA 1.49 1.567 0 N-CA-C 109.446 -0.575 . . . . 0.0 109.446 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' H' H ' 2' ' ' ALA . . . . . . . . . . . . . . . -63.0 128.63 36.74 Favored 'General case' 0 N--CA 1.469 0.487 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.587 179.766 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' H' H ' 3' ' ' GLU . . . . . . . . . . . . . 43.9 tt0 -167.82 106.41 0.53 Allowed 'General case' 0 N--CA 1.471 0.612 0 CA-C-O 120.581 0.229 . . . . 0.0 110.666 179.678 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 41.0 m-85 -88.57 151.5 22.46 Favored 'General case' 0 N--CA 1.473 0.706 0 N-CA-C 109.627 -0.508 . . . . 0.0 109.627 179.074 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' H' H ' 5' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -142.91 141.27 31.46 Favored 'General case' 0 N--CA 1.484 1.273 0 C-N-CA 122.585 0.354 . . . . 0.0 110.169 179.747 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 42.0 t-80 -151.98 120.1 6.28 Favored 'General case' 0 N--CA 1.474 0.731 0 N-CA-C 109.36 -0.607 . . . . 0.0 109.36 179.018 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -71.16 144.17 50.29 Favored 'General case' 0 N--CA 1.469 0.519 0 CA-C-N 116.321 -0.4 . . . . 0.0 111.303 -179.777 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' H' H ' 8' ' ' SER . . . . . 0.495 ' OG ' ' O ' ' E' ' 7' ' ' ASP . 53.1 p -164.77 -170.93 2.12 Favored 'General case' 0 N--CA 1.474 0.751 0 CA-C-O 121.06 0.457 . . . . 0.0 110.472 178.783 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.22 47.35 1.33 Allowed Glycine 0 N--CA 1.48 1.567 0 CA-C-N 115.848 -0.614 . . . . 0.0 111.713 179.47 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 49.2 p90 -65.47 133.09 50.53 Favored 'General case' 0 N--CA 1.471 0.594 0 N-CA-C 111.792 0.293 . . . . 0.0 111.792 -179.627 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 46.2 mt-10 -92.0 151.41 20.49 Favored 'General case' 0 N--CA 1.479 0.982 0 CA-C-O 121.115 0.483 . . . . 0.0 110.225 178.568 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -154.65 127.82 1.16 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.027 0 N-CA-C 107.851 -1.166 . . . . 0.0 107.851 178.233 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 46.6 m-70 -135.29 147.3 49.16 Favored 'General case' 0 N--CA 1.478 0.956 0 CA-C-N 115.653 -0.703 . . . . 0.0 111.409 -178.239 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 6.5 t60 -165.47 97.31 0.68 Allowed 'General case' 0 N--CA 1.483 1.195 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.222 178.887 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 3.9 pt20 -101.5 -173.46 2.37 Favored 'General case' 0 CA--C 1.507 -0.678 0 N-CA-C 108.636 -0.875 . . . . 0.0 108.636 -179.579 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -170.8 94.36 0.2 Allowed 'General case' 0 N--CA 1.472 0.652 0 CA-C-N 114.652 -1.158 . . . . 0.0 108.105 178.626 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 6.4 mp -121.43 155.57 34.57 Favored 'General case' 0 N--CA 1.497 1.911 0 CA-C-O 121.219 0.533 . . . . 0.0 111.938 -177.85 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 42.9 t -113.28 124.71 70.19 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.024 0 CA-C-N 114.782 -1.099 . . . . 0.0 108.134 176.568 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 31.3 m-85 -125.34 121.99 35.55 Favored 'General case' 0 C--N 1.367 1.351 0 CA-C-N 115.497 -0.774 . . . . 0.0 110.914 -179.252 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 68.1 m-85 54.05 73.34 0.39 Allowed 'General case' 0 C--O 1.237 0.436 0 CA-C-N 115.725 -0.67 . . . . 0.0 111.713 178.076 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.53 -78.03 0.14 Allowed 'General case' 0 N--CA 1.472 0.674 0 O-C-N 122.264 -0.273 . . . . 0.0 110.359 -179.218 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 38.3 tt0 -113.15 101.05 9.07 Favored 'General case' 0 C--N 1.322 -0.608 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 179.865 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -158.1 141.01 14.84 Favored 'General case' 0 N--CA 1.478 0.94 0 O-C-N 122.391 -0.193 . . . . 0.0 111.453 179.046 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' H' H ' 24' ' ' VAL . . . . . . . . . . . . . 59.3 t -60.17 167.28 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.569 0 N-CA-C 107.655 -1.239 . . . . 0.0 107.655 177.209 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . -120.65 49.65 0.87 Allowed Glycine 0 N--CA 1.478 1.499 0 N-CA-C 110.513 -1.035 . . . . 0.0 110.513 -179.463 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -64.26 -167.77 0.03 OUTLIER 'General case' 0 N--CA 1.473 0.701 0 CA-C-N 117.005 0.403 . . . . 0.0 110.1 179.755 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 25.9 t-20 -70.01 77.15 0.49 Allowed 'General case' 0 CA--C 1.534 0.34 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.46 -179.974 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -74.65 144.5 43.81 Favored 'General case' 0 N--CA 1.476 0.846 0 N-CA-C 109.552 -0.536 . . . . 0.0 109.552 179.304 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.74 -165.23 1.01 Allowed Glycine 0 C--N 1.338 0.644 0 N-CA-C 109.936 -1.265 . . . . 0.0 109.936 178.833 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.94 113.71 26.46 Favored 'General case' 0 N--CA 1.47 0.54 0 C-N-CA 122.603 0.361 . . . . 0.0 110.548 -179.996 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 66.5 mt -98.6 135.78 32.15 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.758 0 N-CA-C 106.824 -1.547 . . . . 0.0 106.824 178.922 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' H' H ' 32' ' ' ILE . . . . . 0.412 ' C ' ' H ' ' H' ' 34' ' ' LEU . 34.7 pt -152.81 -174.05 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 CA-C-N 119.853 1.206 . . . . 0.0 109.893 -179.797 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.15 5.61 8.3 Favored Glycine 0 N--CA 1.467 0.761 0 N-CA-C 111.004 -0.839 . . . . 0.0 111.004 179.971 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' H' H ' 34' ' ' LEU . . . . . 0.412 ' H ' ' C ' ' H' ' 32' ' ' ILE . 1.6 tt -75.23 125.59 29.28 Favored 'General case' 0 CA--C 1.545 0.772 0 N-CA-C 109.588 -0.523 . . . . 0.0 109.588 -179.582 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 27.5 ttt -161.17 152.59 19.04 Favored 'General case' 0 C--O 1.212 -0.91 0 N-CA-C 108.886 -0.783 . . . . 0.0 108.886 178.61 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 35.3 m -157.41 164.58 1.09 Allowed 'Isoleucine or valine' 0 C--N 1.347 0.458 0 N-CA-C 108.489 -0.93 . . . . 0.0 108.489 -179.582 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.78 67.91 1.96 Allowed Glycine 0 C--N 1.308 -0.997 0 CA-C-N 115.425 -0.807 . . . . 0.0 112.182 178.335 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 144.1 -171.89 25.43 Favored Glycine 0 N--CA 1.475 1.266 0 N-CA-C 110.682 -0.967 . . . . 0.0 110.682 179.11 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' H' H ' 39' ' ' VAL . . . . . 0.504 HG11 ' H ' ' E' ' 39' ' ' VAL . 35.0 m -126.8 155.75 37.65 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.94 0 C-N-CA 123.174 0.59 . . . . 0.0 110.663 -179.255 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 29.5 t . . . . . 0 C--O 1.217 -0.611 0 CA-C-O 118.433 -0.794 . . . . 0.0 110.759 179.341 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' I' I ' 1' ' ' ASP . . . . . . . . . . . . . 14.5 m-20 . . . . . 0 N--CA 1.492 1.665 0 N-CA-C 109.43 -0.581 . . . . 0.0 109.43 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' I' I ' 2' ' ' ALA . . . . . . . . . . . . . . . -63.18 128.62 36.68 Favored 'General case' 0 N--CA 1.469 0.483 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.595 179.801 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' I' I ' 3' ' ' GLU . . . . . . . . . . . . . 44.0 tt0 -167.68 107.03 0.55 Allowed 'General case' 0 N--CA 1.472 0.635 0 CA-C-O 120.516 0.198 . . . . 0.0 110.687 179.665 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 40.5 m-85 -89.04 151.89 22.0 Favored 'General case' 0 N--CA 1.474 0.749 0 N-CA-C 109.578 -0.527 . . . . 0.0 109.578 179.263 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' I' I ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -143.33 140.58 30.62 Favored 'General case' 0 N--CA 1.483 1.178 0 C-N-CA 122.513 0.325 . . . . 0.0 110.152 -179.987 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 41.6 t-80 -151.67 119.61 6.22 Favored 'General case' 0 N--CA 1.474 0.73 0 N-CA-C 109.435 -0.579 . . . . 0.0 109.435 179.058 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -70.7 144.61 50.94 Favored 'General case' 0 N--CA 1.468 0.472 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.203 -179.807 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' I' I ' 8' ' ' SER . . . . . 0.496 ' OG ' ' O ' ' F' ' 7' ' ' ASP . 52.8 p -165.08 -170.69 1.99 Allowed 'General case' 0 N--CA 1.474 0.752 0 CA-C-O 121.023 0.439 . . . . 0.0 110.521 178.752 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.71 47.77 1.35 Allowed Glycine 0 N--CA 1.481 1.638 0 CA-C-N 115.904 -0.589 . . . . 0.0 111.742 179.56 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 49.1 p90 -65.76 133.13 50.38 Favored 'General case' 0 N--CA 1.472 0.637 0 N-CA-C 111.834 0.309 . . . . 0.0 111.834 -179.771 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 46.2 mt-10 -92.0 151.19 20.6 Favored 'General case' 0 N--CA 1.477 0.923 0 C-N-CA 122.841 0.456 . . . . 0.0 110.249 178.615 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -154.6 127.68 1.15 Allowed 'Isoleucine or valine' 0 CA--C 1.551 0.997 0 N-CA-C 107.86 -1.163 . . . . 0.0 107.86 178.195 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 45.2 m-70 -135.02 147.33 49.63 Favored 'General case' 0 N--CA 1.477 0.918 0 CA-C-N 115.608 -0.724 . . . . 0.0 111.479 -178.252 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 6.5 t60 -165.39 97.31 0.69 Allowed 'General case' 0 N--CA 1.483 1.179 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.218 178.82 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 3.9 pt20 -101.59 -173.43 2.35 Favored 'General case' 0 CA--C 1.507 -0.696 0 N-CA-C 108.622 -0.881 . . . . 0.0 108.622 -179.524 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -170.83 94.48 0.2 Allowed 'General case' 0 N--CA 1.472 0.642 0 CA-C-N 114.631 -1.168 . . . . 0.0 108.076 178.677 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 6.3 mp -121.6 155.52 34.89 Favored 'General case' 0 N--CA 1.496 1.861 0 CA-C-O 121.229 0.538 . . . . 0.0 111.865 -177.851 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 42.0 t -113.09 125.22 70.32 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.015 0 CA-C-N 114.783 -1.099 . . . . 0.0 108.053 176.522 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 31.0 m-85 -125.98 121.63 33.62 Favored 'General case' 0 C--N 1.368 1.396 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.996 -179.17 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 68.2 m-85 54.38 73.05 0.42 Allowed 'General case' 0 N--CA 1.466 0.363 0 CA-C-N 115.836 -0.62 . . . . 0.0 111.584 178.085 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.34 -78.12 0.14 Allowed 'General case' 0 N--CA 1.473 0.712 0 N-CA-C 110.293 -0.262 . . . . 0.0 110.293 -179.218 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 38.6 tt0 -113.05 101.3 9.33 Favored 'General case' 0 C--N 1.323 -0.581 0 N-CA-C 107.994 -1.113 . . . . 0.0 107.994 179.811 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -158.34 141.1 14.61 Favored 'General case' 0 N--CA 1.476 0.867 0 O-C-N 122.368 -0.207 . . . . 0.0 111.444 179.021 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' I' I ' 24' ' ' VAL . . . . . . . . . . . . . 59.6 t -60.31 166.85 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.348 0.534 0 N-CA-C 107.664 -1.236 . . . . 0.0 107.664 177.212 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . -120.27 49.76 0.86 Allowed Glycine 0 N--CA 1.481 1.691 0 N-CA-C 110.542 -1.023 . . . . 0.0 110.542 -179.481 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' I' I ' 26' ' ' SER . . . . . 0.403 ' HG ' ' H ' ' G' ' 8' ' ' SER . 0.3 OUTLIER -64.26 -167.85 0.03 OUTLIER 'General case' 0 N--CA 1.471 0.61 0 CA-C-N 116.922 0.361 . . . . 0.0 110.129 179.714 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 25.7 t-20 -69.9 77.18 0.47 Allowed 'General case' 0 CA--C 1.534 0.345 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.419 -179.99 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -74.74 144.43 43.65 Favored 'General case' 0 N--CA 1.475 0.812 0 N-CA-C 109.641 -0.503 . . . . 0.0 109.641 179.387 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.66 -166.06 1.15 Allowed Glycine 0 C--N 1.337 0.607 0 N-CA-C 110.023 -1.231 . . . . 0.0 110.023 178.71 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.09 113.69 26.03 Favored 'General case' 0 N--CA 1.471 0.586 0 C-N-CA 122.674 0.39 . . . . 0.0 110.468 -179.887 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 67.2 mt -98.68 135.65 32.76 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.73 0 N-CA-C 106.895 -1.52 . . . . 0.0 106.895 178.889 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' I' I ' 32' ' ' ILE . . . . . 0.419 ' C ' ' H ' ' I' ' 34' ' ' LEU . 35.0 pt -152.71 -173.92 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.774 0 CA-C-N 119.837 1.199 . . . . 0.0 109.826 -179.724 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.02 5.45 7.66 Favored Glycine 0 CA--C 1.527 0.811 0 N-CA-C 111.063 -0.815 . . . . 0.0 111.063 -179.942 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' I' I ' 34' ' ' LEU . . . . . 0.419 ' H ' ' C ' ' I' ' 32' ' ' ILE . 1.6 tt -74.97 125.94 29.96 Favored 'General case' 0 CA--C 1.546 0.789 0 N-CA-C 109.549 -0.538 . . . . 0.0 109.549 -179.706 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 27.5 ttt -161.45 152.48 18.35 Favored 'General case' 0 C--O 1.21 -0.981 0 N-CA-C 108.794 -0.817 . . . . 0.0 108.794 178.625 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 35.9 m -157.39 164.82 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.346 0.426 0 N-CA-C 108.468 -0.938 . . . . 0.0 108.468 -179.849 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.62 68.13 1.85 Allowed Glycine 0 C--N 1.308 -0.976 0 CA-C-N 115.501 -0.772 . . . . 0.0 112.137 178.294 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 144.01 -171.86 25.39 Favored Glycine 0 N--CA 1.476 1.302 0 N-CA-C 110.601 -1.0 . . . . 0.0 110.601 179.145 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' I' I ' 39' ' ' VAL . . . . . 0.506 HG11 ' H ' ' F' ' 39' ' ' VAL . 34.9 m -126.95 155.98 38.08 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.935 0 C-N-CA 123.118 0.567 . . . . 0.0 110.617 -179.359 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 31.8 t . . . . . 0 C--O 1.219 -0.542 0 O-C-N 123.953 0.783 . . . . 0.0 110.693 179.402 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 15.5 m-20 . . . . . 0 N--CA 1.49 1.531 0 N-CA-C 108.889 -0.782 . . . . 0.0 108.889 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.63 132.51 49.0 Favored 'General case' 0 CA--C 1.539 0.551 0 CA-C-N 116.55 -0.296 . . . . 0.0 110.276 -179.731 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 44.7 tt0 -168.05 106.29 0.5 Allowed 'General case' 0 C--O 1.213 -0.838 0 N-CA-C 109.879 -0.415 . . . . 0.0 109.879 -179.265 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 42.4 m-85 -85.48 151.33 24.05 Favored 'General case' 0 N--CA 1.474 0.758 0 N-CA-C 110.076 -0.342 . . . . 0.0 110.076 179.5 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -142.72 141.24 31.75 Favored 'General case' 0 N--CA 1.481 1.08 0 CA-C-O 120.861 0.363 . . . . 0.0 110.052 179.53 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 45.3 t-80 -152.11 119.03 5.79 Favored 'General case' 0 N--CA 1.471 0.613 0 N-CA-C 109.263 -0.643 . . . . 0.0 109.263 178.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' ASP . . . . . 0.501 ' O ' ' OG ' ' D' ' 8' ' ' SER . 4.5 m-20 -68.93 149.4 48.9 Favored 'General case' 0 CA--C 1.536 0.436 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.448 179.883 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 60.4 p -168.16 -173.78 2.13 Favored 'General case' 0 N--CA 1.484 1.228 0 CA-C-O 120.947 0.404 . . . . 0.0 110.635 179.224 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.37 46.85 1.37 Allowed Glycine 0 N--CA 1.482 1.721 0 CA-C-N 115.972 -0.558 . . . . 0.0 112.114 179.816 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 49.8 p90 -66.16 132.61 48.86 Favored 'General case' 0 N--CA 1.473 0.697 0 O-C-N 122.782 -0.246 . . . . 0.0 111.53 179.766 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 48.7 mt-10 -91.84 152.49 20.08 Favored 'General case' 0 N--CA 1.477 0.911 0 CA-C-O 121.066 0.46 . . . . 0.0 109.776 178.293 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.0 p -153.15 127.63 1.4 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.545 0 N-CA-C 107.915 -1.143 . . . . 0.0 107.915 178.363 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 44.1 m-70 -135.6 148.44 49.05 Favored 'General case' 0 N--CA 1.492 1.645 0 CA-C-N 119.09 0.859 . . . . 0.0 111.324 -179.064 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 7.0 t60 -163.67 97.81 0.87 Allowed 'General case' 0 N--CA 1.481 1.09 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.776 179.395 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . 0.506 HE22 ' H ' ' A' ' 37' ' ' GLY . 3.4 pt20 -107.63 -175.74 2.87 Favored 'General case' 0 CA--C 1.507 -0.68 0 N-CA-C 108.422 -0.955 . . . . 0.0 108.422 -179.98 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -169.63 100.56 0.32 Allowed 'General case' 0 CA--C 1.54 0.582 0 CA-C-N 114.629 -1.169 . . . . 0.0 108.466 179.029 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . 0.502 ' H ' ' CD2' ' D' ' 17' ' ' LEU . 6.9 mt -125.46 153.17 43.91 Favored 'General case' 0 N--CA 1.492 1.675 0 CA-C-O 121.443 0.64 . . . . 0.0 110.975 -178.284 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 60.4 t -107.8 129.26 62.17 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.21 0 CA-C-O 117.896 -1.05 . . . . 0.0 108.392 178.039 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 45.3 m-85 -125.97 122.72 36.73 Favored 'General case' 0 N--CA 1.497 1.919 0 CA-C-N 120.099 1.318 . . . . 0.0 110.367 179.272 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 74.2 m-85 53.09 75.02 0.26 Allowed 'General case' 0 N--CA 1.471 0.594 0 CA-C-O 121.361 0.6 . . . . 0.0 111.935 178.469 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -79.52 -78.32 0.16 Allowed 'General case' 0 C--N 1.353 0.739 0 CA-C-N 115.097 -0.956 . . . . 0.0 110.283 -179.796 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 39.9 tt0 -112.58 100.57 8.83 Favored 'General case' 0 N--CA 1.47 0.564 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 179.805 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -159.33 140.54 12.86 Favored 'General case' 0 C--O 1.207 -1.163 0 O-C-N 122.283 -0.261 . . . . 0.0 111.161 179.175 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 61.5 t -60.33 164.15 0.92 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.836 0 N-CA-C 108.154 -1.054 . . . . 0.0 108.154 177.174 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -117.66 48.89 0.9 Allowed Glycine 0 N--CA 1.477 1.426 0 N-CA-C 111.657 -0.577 . . . . 0.0 111.657 -179.353 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -61.92 -168.23 0.02 OUTLIER 'General case' 0 N--CA 1.469 0.486 0 O-C-N 123.845 0.38 . . . . 0.0 110.371 179.532 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 24.7 t-20 -70.17 81.11 0.51 Allowed 'General case' 0 N--CA 1.465 0.282 0 N-CA-C 110.144 -0.317 . . . . 0.0 110.144 179.792 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -79.65 146.43 32.49 Favored 'General case' 0 N--CA 1.472 0.627 0 N-CA-C 109.087 -0.708 . . . . 0.0 109.087 179.123 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -62.98 -168.54 0.93 Allowed Glycine 0 CA--C 1.524 0.653 0 N-CA-C 109.895 -1.282 . . . . 0.0 109.895 178.752 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -100.19 116.47 32.26 Favored 'General case' 0 N--CA 1.477 0.898 0 N-CA-C 109.685 -0.487 . . . . 0.0 109.685 179.723 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 69.4 mt -97.34 135.33 31.98 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.556 0 N-CA-C 107.102 -1.444 . . . . 0.0 107.102 179.003 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 44.1 pt -151.43 -178.17 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.713 0 CA-C-O 121.222 0.534 . . . . 0.0 111.11 -178.899 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 64.09 5.34 14.66 Favored Glycine 0 CA--C 1.526 0.728 0 N-CA-C 110.815 -0.914 . . . . 0.0 110.815 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 1.4 tt -73.79 128.7 36.2 Favored 'General case' 0 CA--C 1.545 0.776 0 N-CA-C 109.61 -0.515 . . . . 0.0 109.61 -179.714 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 28.7 ttt -163.55 147.39 10.44 Favored 'General case' 0 N--CA 1.465 0.305 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 178.506 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 31.6 m -155.13 163.54 1.55 Allowed 'Isoleucine or valine' 0 C--N 1.347 0.488 0 N-CA-C 108.11 -1.07 . . . . 0.0 108.11 179.503 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . 0.506 ' H ' HE22 ' A' ' 15' ' ' GLN . . . 55.4 68.15 1.84 Allowed Glycine 0 C--N 1.306 -1.134 0 CA-C-N 115.89 -0.596 . . . . 0.0 112.078 178.706 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 141.09 175.35 14.71 Favored Glycine 0 N--CA 1.475 1.273 0 N-CA-C 110.821 -0.912 . . . . 0.0 110.821 179.164 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.424 ' H ' HG11 ' D' ' 39' ' ' VAL . 35.4 m -118.55 159.69 18.85 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.813 0 C-N-CA 123.364 0.666 . . . . 0.0 110.384 -179.998 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 22.1 t . . . . . 0 C--O 1.221 -0.441 0 CA-C-O 118.523 -0.751 . . . . 0.0 110.649 179.488 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' B' B ' 1' ' ' ASP . . . . . . . . . . . . . 13.9 m-20 . . . . . 0 N--CA 1.49 1.558 0 N-CA-C 109.091 -0.707 . . . . 0.0 109.091 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' B' B ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.06 132.7 49.89 Favored 'General case' 0 N--CA 1.47 0.547 0 N-CA-C 110.19 -0.3 . . . . 0.0 110.19 -179.76 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 3' ' ' GLU . . . . . . . . . . . . . 44.5 tt0 -168.33 105.5 0.46 Allowed 'General case' 0 C--O 1.214 -0.767 0 N-CA-C 110.011 -0.366 . . . . 0.0 110.011 -179.099 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 41.2 m-85 -84.82 151.22 24.48 Favored 'General case' 0 N--CA 1.474 0.751 0 N-CA-C 110.088 -0.338 . . . . 0.0 110.088 179.505 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -142.58 141.06 31.93 Favored 'General case' 0 N--CA 1.483 1.217 0 N-CA-C 109.98 -0.378 . . . . 0.0 109.98 179.437 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 44.4 t-80 -151.94 118.94 5.83 Favored 'General case' 0 N--CA 1.473 0.688 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 178.991 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 7' ' ' ASP . . . . . 0.481 ' O ' ' OG ' ' E' ' 8' ' ' SER . 4.3 m-20 -69.08 148.88 49.38 Favored 'General case' 0 CA--C 1.537 0.473 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.585 179.93 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 8' ' ' SER . . . . . . . . . . . . . 59.9 p -167.76 -173.73 2.23 Favored 'General case' 0 N--CA 1.482 1.144 0 CA-C-O 120.985 0.422 . . . . 0.0 110.644 179.336 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.23 46.72 1.41 Allowed Glycine 0 N--CA 1.482 1.753 0 CA-C-N 115.902 -0.59 . . . . 0.0 112.164 179.944 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 50.2 p90 -66.14 132.51 48.66 Favored 'General case' 0 N--CA 1.472 0.657 0 CA-C-O 120.624 0.25 . . . . 0.0 111.596 179.632 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 48.2 mt-10 -91.7 152.62 20.12 Favored 'General case' 0 N--CA 1.476 0.846 0 CA-C-O 121.076 0.465 . . . . 0.0 109.758 178.307 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.0 p -153.23 128.07 1.47 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.654 0 N-CA-C 107.772 -1.196 . . . . 0.0 107.772 178.167 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 43.6 m-70 -135.72 148.91 49.04 Favored 'General case' 0 N--CA 1.492 1.628 0 CA-C-N 118.837 0.744 . . . . 0.0 111.355 -179.145 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 7.2 t60 -164.3 97.62 0.8 Allowed 'General case' 0 N--CA 1.482 1.139 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.75 179.494 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . 0.521 HE22 ' H ' ' B' ' 37' ' ' GLY . 3.4 pt20 -107.41 -175.37 2.77 Favored 'General case' 0 CA--C 1.509 -0.623 0 N-CA-C 108.255 -1.017 . . . . 0.0 108.255 -179.921 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -169.96 100.18 0.3 Allowed 'General case' 0 N--CA 1.471 0.619 0 CA-C-N 114.667 -1.151 . . . . 0.0 108.415 178.995 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . 0.492 ' H ' ' CD2' ' E' ' 17' ' ' LEU . 6.9 mt -124.92 153.72 42.23 Favored 'General case' 0 N--CA 1.491 1.61 0 CA-C-O 121.506 0.669 . . . . 0.0 111.03 -178.39 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 61.3 t -108.4 130.33 61.25 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.221 0 N-CA-C 108.054 -1.091 . . . . 0.0 108.054 177.933 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 44.2 m-85 -127.24 122.06 32.92 Favored 'General case' 0 N--CA 1.494 1.766 0 CA-C-N 119.721 1.146 . . . . 0.0 110.221 179.524 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 74.7 m-85 52.89 75.28 0.25 Allowed 'General case' 0 CA--C 1.539 0.527 0 CA-C-O 121.427 0.632 . . . . 0.0 111.939 178.47 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -79.92 -78.06 0.17 Allowed 'General case' 0 C--N 1.351 0.666 0 CA-C-N 115.026 -0.988 . . . . 0.0 110.283 -179.839 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 40.2 tt0 -112.58 100.65 8.9 Favored 'General case' 0 N--CA 1.473 0.683 0 N-CA-C 108.349 -0.982 . . . . 0.0 108.349 179.73 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -159.34 141.24 13.4 Favored 'General case' 0 N--CA 1.484 1.235 0 O-C-N 122.222 -0.299 . . . . 0.0 111.144 179.193 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 61.4 t -61.0 163.9 1.05 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.852 0 N-CA-C 108.176 -1.046 . . . . 0.0 108.176 177.238 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -117.19 48.51 0.93 Allowed Glycine 0 N--CA 1.476 1.338 0 N-CA-C 111.581 -0.608 . . . . 0.0 111.581 -179.328 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -61.55 -167.43 0.01 OUTLIER 'General case' 0 N--CA 1.469 0.505 0 O-C-N 123.753 0.325 . . . . 0.0 110.364 179.494 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 24.8 t-20 -71.24 81.18 0.73 Allowed 'General case' 0 N--CA 1.465 0.324 0 N-CA-C 110.076 -0.342 . . . . 0.0 110.076 179.863 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -79.75 146.47 32.33 Favored 'General case' 0 N--CA 1.473 0.69 0 N-CA-C 109.096 -0.705 . . . . 0.0 109.096 179.274 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.03 -168.7 0.97 Allowed Glycine 0 C--N 1.336 0.56 0 N-CA-C 109.914 -1.274 . . . . 0.0 109.914 178.735 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.97 116.76 32.77 Favored 'General case' 0 N--CA 1.476 0.87 0 N-CA-C 109.668 -0.493 . . . . 0.0 109.668 179.789 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 69.8 mt -97.65 135.07 33.37 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.537 0 N-CA-C 107.07 -1.456 . . . . 0.0 107.07 178.972 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 43.7 pt -151.1 -177.94 0.38 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.681 0 CA-C-O 121.299 0.571 . . . . 0.0 111.159 -178.753 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.42 5.94 13.46 Favored Glycine 0 CA--C 1.525 0.692 0 N-CA-C 110.884 -0.887 . . . . 0.0 110.884 -179.967 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 1.4 tt -74.39 128.35 35.33 Favored 'General case' 0 CA--C 1.545 0.774 0 N-CA-C 109.528 -0.545 . . . . 0.0 109.528 -179.745 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 28.6 ttt -162.95 147.76 11.6 Favored 'General case' 0 N--CA 1.468 0.427 0 N-CA-C 108.797 -0.816 . . . . 0.0 108.797 178.607 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 29.9 m -155.68 163.31 1.53 Allowed 'Isoleucine or valine' 0 C--N 1.347 0.49 0 N-CA-C 108.096 -1.075 . . . . 0.0 108.096 179.516 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . 0.521 ' H ' HE22 ' B' ' 15' ' ' GLN . . . 55.67 67.74 2.05 Favored Glycine 0 C--N 1.306 -1.11 0 CA-C-N 115.881 -0.6 . . . . 0.0 112.014 178.676 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 141.17 175.65 14.97 Favored Glycine 0 N--CA 1.475 1.247 0 N-CA-C 110.891 -0.883 . . . . 0.0 110.891 179.079 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 39' ' ' VAL . . . . . 0.424 ' H ' HG11 ' E' ' 39' ' ' VAL . 35.5 m -118.56 159.87 18.73 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.89 0 C-N-CA 123.469 0.708 . . . . 0.0 110.476 -179.934 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 21.9 t . . . . . 0 N--CA 1.468 0.475 0 CA-C-O 118.364 -0.827 . . . . 0.0 110.468 179.362 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' C' C ' 1' ' ' ASP . . . . . . . . . . . . . 14.1 m-20 . . . . . 0 N--CA 1.49 1.553 0 N-CA-C 108.894 -0.78 . . . . 0.0 108.894 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' C' C ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.08 132.72 49.94 Favored 'General case' 0 CA--C 1.54 0.561 0 CA-C-N 116.509 -0.314 . . . . 0.0 110.229 -179.792 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 3' ' ' GLU . . . . . . . . . . . . . 44.6 tt0 -168.35 105.94 0.47 Allowed 'General case' 0 C--O 1.215 -0.749 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 -179.162 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 41.3 m-85 -85.07 151.89 23.82 Favored 'General case' 0 N--CA 1.475 0.775 0 N-CA-C 110.128 -0.323 . . . . 0.0 110.128 179.547 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -143.34 140.49 30.55 Favored 'General case' 0 N--CA 1.481 1.097 0 N-CA-C 110.126 -0.324 . . . . 0.0 110.126 179.608 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 45.4 t-80 -151.51 119.24 6.13 Favored 'General case' 0 N--CA 1.472 0.667 0 N-CA-C 109.286 -0.635 . . . . 0.0 109.286 178.984 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 7' ' ' ASP . . . . . 0.49 ' O ' ' OG ' ' F' ' 8' ' ' SER . 4.4 m-20 -69.32 148.76 49.27 Favored 'General case' 0 CA--C 1.537 0.471 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.591 179.891 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 8' ' ' SER . . . . . . . . . . . . . 59.6 p -167.63 -173.64 2.24 Favored 'General case' 0 N--CA 1.482 1.143 0 CA-C-O 121.04 0.448 . . . . 0.0 110.621 179.202 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.28 47.19 1.34 Allowed Glycine 0 N--CA 1.482 1.702 0 CA-C-N 115.995 -0.548 . . . . 0.0 112.11 179.892 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 49.6 p90 -66.62 132.49 48.29 Favored 'General case' 0 N--CA 1.473 0.713 0 CA-C-O 120.761 0.315 . . . . 0.0 111.571 179.655 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 48.4 mt-10 -91.45 152.63 20.29 Favored 'General case' 0 N--CA 1.475 0.806 0 N-CA-C 109.719 -0.474 . . . . 0.0 109.719 178.253 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -153.33 128.01 1.44 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.548 0 N-CA-C 107.873 -1.158 . . . . 0.0 107.873 178.183 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 43.7 m-70 -135.92 148.51 48.58 Favored 'General case' 0 N--CA 1.492 1.643 0 CA-C-N 118.932 0.787 . . . . 0.0 111.305 -179.055 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 7.1 t60 -163.86 97.56 0.85 Allowed 'General case' 0 N--CA 1.483 1.182 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.794 179.475 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 15' ' ' GLN . . . . . 0.524 HE22 ' H ' ' C' ' 37' ' ' GLY . 3.4 pt20 -107.43 -175.09 2.69 Favored 'General case' 0 CA--C 1.508 -0.662 0 N-CA-C 108.237 -1.023 . . . . 0.0 108.237 -179.96 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -170.29 100.27 0.27 Allowed 'General case' 0 N--CA 1.471 0.577 0 CA-C-N 114.59 -1.186 . . . . 0.0 108.415 179.192 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 17' ' ' LEU . . . . . 0.483 ' H ' ' CD2' ' F' ' 17' ' ' LEU . 6.9 mt -125.14 153.47 42.96 Favored 'General case' 0 N--CA 1.492 1.665 0 CA-C-O 121.52 0.676 . . . . 0.0 111.03 -178.217 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 61.2 t -108.07 130.22 60.97 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.188 0 N-CA-C 108.229 -1.026 . . . . 0.0 108.229 177.844 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 44.3 m-85 -127.16 121.99 32.89 Favored 'General case' 0 N--CA 1.493 1.68 0 CA-C-N 119.655 1.116 . . . . 0.0 110.349 179.454 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 74.2 m-85 52.84 75.22 0.25 Allowed 'General case' 0 N--CA 1.469 0.508 0 CA-C-O 121.518 0.675 . . . . 0.0 111.98 178.529 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -79.83 -77.97 0.17 Allowed 'General case' 0 C--N 1.35 0.6 0 CA-C-N 114.876 -1.056 . . . . 0.0 110.267 -179.814 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 39.8 tt0 -112.68 100.71 8.92 Favored 'General case' 0 N--CA 1.471 0.586 0 N-CA-C 108.3 -1.0 . . . . 0.0 108.3 179.736 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -159.41 140.83 12.98 Favored 'General case' 0 N--CA 1.483 1.178 0 O-C-N 122.22 -0.3 . . . . 0.0 111.226 179.124 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 60.2 t -60.39 164.34 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.871 0 N-CA-C 108.087 -1.079 . . . . 0.0 108.087 177.23 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -117.63 48.82 0.91 Allowed Glycine 0 N--CA 1.479 1.519 0 N-CA-C 111.45 -0.66 . . . . 0.0 111.45 -179.43 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -61.91 -167.92 0.01 OUTLIER 'General case' 0 N--CA 1.468 0.425 0 O-C-N 123.707 0.298 . . . . 0.0 110.386 179.547 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 24.8 t-20 -70.54 80.9 0.58 Allowed 'General case' 0 N--CA 1.466 0.353 0 N-CA-C 110.113 -0.329 . . . . 0.0 110.113 179.692 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -79.51 146.57 32.61 Favored 'General case' 0 N--CA 1.473 0.698 0 N-CA-C 109.065 -0.717 . . . . 0.0 109.065 179.239 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.08 -168.76 1.0 Allowed Glycine 0 CA--C 1.525 0.699 0 N-CA-C 109.98 -1.248 . . . . 0.0 109.98 178.806 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.96 116.35 31.82 Favored 'General case' 0 N--CA 1.478 0.974 0 N-CA-C 109.657 -0.498 . . . . 0.0 109.657 179.757 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 69.3 mt -97.45 135.13 32.87 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.54 0 N-CA-C 107.16 -1.422 . . . . 0.0 107.16 179.034 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 43.9 pt -151.12 -177.91 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.649 0 CA-C-N 115.995 -0.548 . . . . 0.0 111.304 -178.691 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.59 5.58 13.11 Favored Glycine 0 CA--C 1.524 0.6 0 N-CA-C 110.853 -0.899 . . . . 0.0 110.853 -179.987 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 1.4 tt -74.07 128.17 34.84 Favored 'General case' 0 CA--C 1.545 0.774 0 N-CA-C 109.626 -0.509 . . . . 0.0 109.626 -179.738 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 28.5 ttt -162.94 147.38 11.44 Favored 'General case' 0 N--CA 1.466 0.364 0 N-CA-C 108.679 -0.86 . . . . 0.0 108.679 178.666 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 33.7 m -155.25 163.38 1.57 Allowed 'Isoleucine or valine' 0 C--N 1.348 0.516 0 N-CA-C 108.125 -1.065 . . . . 0.0 108.125 179.49 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 37' ' ' GLY . . . . . 0.524 ' H ' HE22 ' C' ' 15' ' ' GLN . . . 55.32 67.85 1.99 Allowed Glycine 0 C--N 1.306 -1.135 0 CA-C-N 115.881 -0.6 . . . . 0.0 112.104 178.712 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 141.67 176.07 15.66 Favored Glycine 0 N--CA 1.475 1.248 0 N-CA-C 110.885 -0.886 . . . . 0.0 110.885 179.11 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 39' ' ' VAL . . . . . 0.415 ' H ' HG11 ' F' ' 39' ' ' VAL . 35.6 m -119.16 159.56 19.77 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.878 0 C-N-CA 123.349 0.66 . . . . 0.0 110.451 179.891 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 21.9 t . . . . . 0 N--CA 1.467 0.4 0 CA-C-O 118.45 -0.786 . . . . 0.0 110.473 179.443 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' D' D ' 1' ' ' ASP . . . . . . . . . . . . . 14.6 m-20 . . . . . 0 N--CA 1.49 1.534 0 N-CA-C 109.035 -0.728 . . . . 0.0 109.035 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' D' D ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.42 131.05 46.09 Favored 'General case' 0 CA--C 1.537 0.474 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.366 -179.824 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 3' ' ' GLU . . . . . . . . . . . . . 44.2 tt0 -169.23 108.01 0.43 Allowed 'General case' 0 C--O 1.217 -0.621 0 N-CA-C 110.028 -0.36 . . . . 0.0 110.028 -179.582 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 42.3 m-85 -89.17 156.12 18.99 Favored 'General case' 0 C--N 1.358 0.944 0 N-CA-C 108.941 -0.763 . . . . 0.0 108.941 -179.977 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 5' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -144.54 139.7 28.35 Favored 'General case' 0 N--CA 1.475 0.797 0 CA-C-N 116.374 -0.375 . . . . 0.0 110.214 179.869 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 41.0 t-80 -149.77 123.96 9.49 Favored 'General case' 0 CA--C 1.545 0.782 0 N-CA-C 108.142 -1.058 . . . . 0.0 108.142 174.72 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 7' ' ' ASP . . . . . 0.591 ' O ' ' OG ' ' G' ' 8' ' ' SER . 3.1 m-20 -63.6 132.98 52.89 Favored 'General case' 0 C--N 1.321 -0.647 0 C-N-CA 126.846 2.058 . . . . 0.0 114.209 174.62 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' D' D ' 8' ' ' SER . . . . . 0.501 ' OG ' ' O ' ' A' ' 7' ' ' ASP . 59.8 p -154.51 -170.8 3.64 Favored 'General case' 0 N--CA 1.488 1.454 0 CA-C-N 119.675 1.125 . . . . 0.0 111.255 175.246 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.39 47.91 1.17 Allowed Glycine 0 N--CA 1.481 1.666 0 C-N-CA 124.663 1.125 . . . . 0.0 110.632 174.321 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 51.5 p90 -60.99 131.56 51.02 Favored 'General case' 0 N--CA 1.47 0.526 0 N-CA-C 112.613 0.598 . . . . 0.0 112.613 177.559 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 48.3 mt-10 -89.64 151.01 22.11 Favored 'General case' 0 N--CA 1.479 1.025 0 CA-C-N 117.989 0.359 . . . . 0.0 110.662 174.982 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.0 p -149.64 129.95 4.22 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.662 0 N-CA-C 107.307 -1.368 . . . . 0.0 107.307 173.058 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 38.6 m-70 -129.79 151.63 50.16 Favored 'General case' 0 N--CA 1.483 1.182 0 N-CA-C 112.264 0.468 . . . . 0.0 112.264 176.639 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 7.3 t60 -164.68 104.75 0.82 Allowed 'General case' 0 N--CA 1.483 1.201 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 172.261 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 15' ' ' GLN . . . . . 0.482 HE22 ' H ' ' D' ' 37' ' ' GLY . 3.4 pt20 -111.05 -176.47 2.96 Favored 'General case' 0 CA--C 1.502 -0.884 0 N-CA-C 108.002 -1.11 . . . . 0.0 108.002 179.007 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -167.03 106.44 0.59 Allowed 'General case' 0 N--CA 1.466 0.337 0 N-CA-C 106.947 -1.501 . . . . 0.0 106.947 176.404 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 17' ' ' LEU . . . . . 0.517 ' H ' ' CD2' ' G' ' 17' ' ' LEU . 9.9 mt -130.57 152.35 50.04 Favored 'General case' 0 N--CA 1.493 1.702 0 CA-C-O 121.864 0.84 . . . . 0.0 110.493 179.651 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 38.6 t -99.65 133.09 43.73 Favored 'Isoleucine or valine' 0 C--O 1.259 1.596 0 CA-C-O 116.97 -1.49 . . . . 0.0 109.645 175.007 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 40.6 m-85 -130.04 125.97 36.54 Favored 'General case' 0 N--CA 1.489 1.523 0 CA-C-N 119.792 1.178 . . . . 0.0 109.357 174.144 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 74.1 m-85 55.87 71.87 0.53 Allowed 'General case' 0 C--N 1.352 0.693 0 CA-C-N 115.105 -0.952 . . . . 0.0 111.411 176.063 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -81.82 -73.0 0.41 Allowed 'General case' 0 N--CA 1.472 0.66 0 CA-C-O 118.369 -0.824 . . . . 0.0 111.005 -177.305 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 40.3 tt0 -115.98 104.17 11.33 Favored 'General case' 0 N--CA 1.484 1.262 0 N-CA-C 106.404 -1.702 . . . . 0.0 106.404 176.392 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -152.21 140.8 20.77 Favored 'General case' 0 N--CA 1.475 0.789 0 CA-C-O 116.748 -1.596 . . . . 0.0 113.634 177.867 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 24' ' ' VAL . . . . . . . . . . . . . 66.7 t -62.95 166.57 0.97 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.237 0 CA-C-N 121.097 1.771 . . . . 0.0 107.979 174.782 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 25' ' ' GLY . . . . . 0.402 ' H ' ' HB ' ' G' ' 24' ' ' VAL . . . -116.67 51.07 0.75 Allowed Glycine 0 N--CA 1.481 1.667 0 CA-C-O 118.876 -0.958 . . . . 0.0 111.715 178.636 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -58.29 -170.73 0.01 OUTLIER 'General case' 0 C--N 1.322 -0.619 0 C-N-CA 123.38 0.672 . . . . 0.0 111.637 176.638 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 25.4 t-20 -72.43 86.71 1.15 Allowed 'General case' 0 CA--C 1.537 0.453 0 N-CA-C 108.425 -0.954 . . . . 0.0 108.425 178.45 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 97.6 mttt -84.26 148.71 26.55 Favored 'General case' 0 N--CA 1.474 0.758 0 N-CA-C 108.155 -1.054 . . . . 0.0 108.155 178.884 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -62.7 -165.73 0.55 Allowed Glycine 0 C--N 1.337 0.614 0 N-CA-C 110.461 -1.056 . . . . 0.0 110.461 179.374 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -102.09 115.99 31.72 Favored 'General case' 0 N--CA 1.467 0.385 0 C-N-CA 123.186 0.595 . . . . 0.0 109.921 179.832 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 80.4 mt -102.41 142.46 16.6 Favored 'Isoleucine or valine' 0 C--N 1.355 0.836 0 N-CA-C 104.327 -2.472 . . . . 0.0 104.327 -178.908 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 38.6 pt -157.68 -179.05 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.241 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.118 -176.161 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 64.73 5.7 19.6 Favored Glycine 0 C--O 1.244 0.758 0 N-CA-C 110.003 -1.239 . . . . 0.0 110.003 -178.573 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 1.7 tt -76.42 134.14 39.68 Favored 'General case' 0 C--N 1.361 1.084 0 N-CA-C 107.244 -1.391 . . . . 0.0 107.244 -177.829 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 28.2 ttt -157.91 159.99 37.15 Favored 'General case' 0 CA--C 1.517 -0.319 0 N-CA-C 108.225 -1.028 . . . . 0.0 108.225 172.577 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 31.0 m -164.8 163.63 0.71 Allowed 'Isoleucine or valine' 0 C--O 1.223 -0.31 0 N-CA-C 107.765 -1.198 . . . . 0.0 107.765 174.232 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 37' ' ' GLY . . . . . 0.482 ' H ' HE22 ' D' ' 15' ' ' GLN . . . 59.9 63.71 4.84 Favored Glycine 0 CA--C 1.528 0.884 0 C-N-CA 120.435 -0.888 . . . . 0.0 111.335 178.024 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.18 179.66 20.01 Favored Glycine 0 N--CA 1.481 1.651 0 N-CA-C 111.057 -0.817 . . . . 0.0 111.057 178.352 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 39' ' ' VAL . . . . . 0.437 ' H ' HG11 ' G' ' 39' ' ' VAL . 33.9 m -120.54 157.02 23.56 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.822 0 C-N-CA 123.133 0.573 . . . . 0.0 110.94 179.461 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 22.0 t . . . . . 0 C--N 1.333 -0.14 0 CA-C-O 116.665 -1.636 . . . . 0.0 109.536 175.794 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' E' E ' 1' ' ' ASP . . . . . . . . . . . . . 14.6 m-20 . . . . . 0 N--CA 1.49 1.535 0 N-CA-C 109.427 -0.582 . . . . 0.0 109.427 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' E' E ' 2' ' ' ALA . . . . . . . . . . . . . . . -63.67 129.69 41.2 Favored 'General case' 0 N--CA 1.468 0.472 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.455 -179.939 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 3' ' ' GLU . . . . . . . . . . . . . 44.2 tt0 -167.26 106.03 0.57 Allowed 'General case' 0 C--O 1.213 -0.858 0 CA-C-N 116.732 -0.213 . . . . 0.0 110.648 -179.723 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 38.8 m-85 -86.04 151.43 23.72 Favored 'General case' 0 N--CA 1.475 0.806 0 N-CA-C 110.152 -0.314 . . . . 0.0 110.152 179.297 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 5' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -142.72 140.97 31.69 Favored 'General case' 0 N--CA 1.482 1.126 0 CA-C-O 120.904 0.383 . . . . 0.0 110.077 179.395 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 45.0 t-80 -151.4 118.8 6.0 Favored 'General case' 0 N--CA 1.472 0.669 0 N-CA-C 109.227 -0.657 . . . . 0.0 109.227 178.83 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 7' ' ' ASP . . . . . 0.495 ' O ' ' OG ' ' H' ' 8' ' ' SER . 4.2 m-20 -69.57 148.66 49.1 Favored 'General case' 0 N--CA 1.467 0.379 0 CA-C-N 116.435 -0.348 . . . . 0.0 110.745 179.941 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' E' E ' 8' ' ' SER . . . . . 0.481 ' OG ' ' O ' ' B' ' 7' ' ' ASP . 56.0 p -168.26 -172.51 1.76 Allowed 'General case' 0 N--CA 1.486 1.343 0 CA-C-O 121.099 0.476 . . . . 0.0 110.784 178.917 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.71 47.09 1.31 Allowed Glycine 0 N--CA 1.478 1.493 0 CA-C-N 115.912 -0.585 . . . . 0.0 112.101 179.807 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 47.7 p90 -65.82 133.22 50.51 Favored 'General case' 0 N--CA 1.473 0.721 0 N-CA-C 111.908 0.336 . . . . 0.0 111.908 -179.948 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 48.6 mt-10 -91.47 152.98 20.13 Favored 'General case' 0 N--CA 1.48 1.054 0 CA-C-O 121.245 0.545 . . . . 0.0 109.629 177.943 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -154.97 126.78 0.95 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.63 0 N-CA-C 107.739 -1.208 . . . . 0.0 107.739 178.135 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 42.2 m-70 -135.69 146.86 48.2 Favored 'General case' 0 N--CA 1.482 1.14 0 CA-C-O 120.849 0.357 . . . . 0.0 111.531 -178.126 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 7.1 t60 -163.0 97.64 0.93 Allowed 'General case' 0 N--CA 1.485 1.288 0 CA-C-N 116.365 -0.38 . . . . 0.0 110.717 179.506 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 15' ' ' GLN . . . . . 0.502 HE22 ' H ' ' E' ' 37' ' ' GLY . 3.4 pt20 -106.99 -175.22 2.73 Favored 'General case' 0 CA--C 1.51 -0.564 0 N-CA-C 108.521 -0.918 . . . . 0.0 108.521 -179.928 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -169.84 99.81 0.31 Allowed 'General case' 0 N--CA 1.473 0.713 0 CA-C-N 114.654 -1.157 . . . . 0.0 108.617 179.004 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 17' ' ' LEU . . . . . 0.524 ' H ' ' CD2' ' H' ' 17' ' ' LEU . 7.3 mt -123.9 153.89 40.5 Favored 'General case' 0 N--CA 1.49 1.549 0 CA-C-O 121.348 0.594 . . . . 0.0 111.505 -177.767 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 49.9 t -110.7 126.3 68.04 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.307 0 N-CA-C 108.205 -1.035 . . . . 0.0 108.205 177.604 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 46.6 m-85 -123.79 121.22 34.87 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 123.37 0.419 . . . . 0.0 111.038 -179.821 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 73.7 m-85 54.06 74.33 0.34 Allowed 'General case' 0 N--CA 1.47 0.542 0 CA-C-N 115.922 -0.581 . . . . 0.0 111.594 178.061 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -78.18 -78.96 0.13 Allowed 'General case' 0 CA--C 1.535 0.375 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.095 -179.488 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 39.9 tt0 -111.67 100.97 9.39 Favored 'General case' 0 N--CA 1.469 0.482 0 N-CA-C 108.438 -0.949 . . . . 0.0 108.438 -179.989 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -158.61 140.73 13.95 Favored 'General case' 0 C--O 1.204 -1.296 0 CA-C-O 119.581 -0.247 . . . . 0.0 111.535 179.147 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 57.6 t -58.86 169.03 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.851 0 N-CA-C 107.691 -1.225 . . . . 0.0 107.691 177.017 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . -122.51 49.59 0.88 Allowed Glycine 0 N--CA 1.477 1.383 0 N-CA-C 110.674 -0.971 . . . . 0.0 110.674 -179.479 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -63.07 -167.57 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.553 0 CA-C-O 120.644 0.259 . . . . 0.0 110.601 179.774 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 25.1 t-20 -69.93 78.12 0.48 Allowed 'General case' 0 N--CA 1.466 0.351 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.383 -179.944 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -77.32 146.73 36.58 Favored 'General case' 0 N--CA 1.475 0.81 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 179.28 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.39 -168.33 1.08 Allowed Glycine 0 CA--C 1.522 0.518 0 N-CA-C 110.522 -1.031 . . . . 0.0 110.522 178.623 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.74 115.45 29.55 Favored 'General case' 0 N--CA 1.468 0.461 0 N-CA-C 109.904 -0.406 . . . . 0.0 109.904 179.471 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 70.5 mt -96.38 135.09 31.6 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.282 0 N-CA-C 106.942 -1.503 . . . . 0.0 106.942 179.037 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 39.0 pt -151.1 -176.16 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.229 0 CA-C-O 121.164 0.506 . . . . 0.0 110.737 -179.157 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.2 5.97 9.25 Favored Glycine 0 CA--C 1.529 0.963 0 CA-C-N 115.322 -0.853 . . . . 0.0 111.243 -179.517 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 1.4 tt -73.8 128.68 36.16 Favored 'General case' 0 CA--C 1.548 0.884 0 N-CA-C 109.629 -0.508 . . . . 0.0 109.629 -179.544 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 28.4 ttt -162.93 148.79 12.11 Favored 'General case' 0 C--O 1.209 -1.056 0 N-CA-C 108.925 -0.769 . . . . 0.0 108.925 178.484 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 34.0 m -156.97 162.73 1.5 Allowed 'Isoleucine or valine' 0 C--N 1.344 0.344 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 179.862 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 37' ' ' GLY . . . . . 0.502 ' H ' HE22 ' E' ' 15' ' ' GLN . . . 55.94 66.8 2.59 Favored Glycine 0 C--N 1.307 -1.06 0 CA-C-N 115.933 -0.576 . . . . 0.0 111.939 178.537 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 142.56 176.81 17.01 Favored Glycine 0 N--CA 1.477 1.382 0 N-CA-C 111.149 -0.78 . . . . 0.0 111.149 179.007 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 39' ' ' VAL . . . . . 0.45 ' H ' HG11 ' H' ' 39' ' ' VAL . 33.3 m -119.93 158.62 21.68 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.749 0 C-N-CA 123.392 0.677 . . . . 0.0 110.626 -179.595 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 22.6 t . . . . . 0 C--O 1.22 -0.478 0 CA-C-O 118.448 -0.787 . . . . 0.0 110.482 179.112 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' F' F ' 1' ' ' ASP . . . . . . . . . . . . . 15.0 m-20 . . . . . 0 N--CA 1.49 1.571 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' F' F ' 2' ' ' ALA . . . . . . . . . . . . . . . -63.68 130.01 42.48 Favored 'General case' 0 N--CA 1.467 0.422 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.504 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 3' ' ' GLU . . . . . . . . . . . . . 44.2 tt0 -167.49 106.12 0.55 Allowed 'General case' 0 C--O 1.212 -0.918 0 CA-C-N 116.743 -0.208 . . . . 0.0 110.466 -179.666 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 38.2 m-85 -86.29 151.29 23.72 Favored 'General case' 0 N--CA 1.474 0.75 0 N-CA-C 110.135 -0.32 . . . . 0.0 110.135 179.264 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -142.47 141.24 32.13 Favored 'General case' 0 N--CA 1.478 0.959 0 CA-C-O 120.805 0.336 . . . . 0.0 110.249 179.41 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 43.9 t-80 -151.92 118.74 5.78 Favored 'General case' 0 N--CA 1.472 0.659 0 N-CA-C 109.315 -0.624 . . . . 0.0 109.315 178.928 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 7' ' ' ASP . . . . . 0.495 ' O ' ' OG ' ' I' ' 8' ' ' SER . 4.3 m-20 -69.35 148.64 49.39 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 116.411 -0.359 . . . . 0.0 110.814 -179.96 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' F' F ' 8' ' ' SER . . . . . 0.49 ' OG ' ' O ' ' C' ' 7' ' ' ASP . 56.1 p -168.33 -172.79 1.81 Allowed 'General case' 0 N--CA 1.487 1.422 0 CA-C-O 121.111 0.482 . . . . 0.0 110.924 178.8 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.93 47.01 1.3 Allowed Glycine 0 N--CA 1.479 1.502 0 CA-C-N 115.978 -0.556 . . . . 0.0 112.064 179.877 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 47.7 p90 -65.57 133.03 50.32 Favored 'General case' 0 CA--C 1.543 0.673 0 N-CA-C 111.852 0.316 . . . . 0.0 111.852 -179.954 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 48.3 mt-10 -91.48 152.33 20.4 Favored 'General case' 0 N--CA 1.48 1.042 0 CA-C-O 121.195 0.521 . . . . 0.0 109.713 177.818 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -154.18 126.87 1.09 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.608 0 N-CA-C 107.825 -1.176 . . . . 0.0 107.825 177.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 41.9 m-70 -135.67 146.9 48.29 Favored 'General case' 0 N--CA 1.483 1.2 0 CA-C-O 120.936 0.398 . . . . 0.0 111.582 -178.142 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 7.1 t60 -162.98 97.49 0.93 Allowed 'General case' 0 N--CA 1.486 1.371 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.821 179.55 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 15' ' ' GLN . . . . . 0.513 HE22 ' H ' ' F' ' 37' ' ' GLY . 3.4 pt20 -107.06 -175.22 2.73 Favored 'General case' 0 CA--C 1.507 -0.675 0 N-CA-C 108.482 -0.932 . . . . 0.0 108.482 -179.939 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -169.77 99.86 0.31 Allowed 'General case' 0 N--CA 1.47 0.572 0 CA-C-N 114.712 -1.131 . . . . 0.0 108.606 179.052 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 17' ' ' LEU . . . . . 0.509 ' H ' ' CD2' ' I' ' 17' ' ' LEU . 7.2 mt -123.81 154.33 39.73 Favored 'General case' 0 N--CA 1.489 1.501 0 CA-C-O 121.273 0.558 . . . . 0.0 111.461 -177.735 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 51.8 t -111.07 126.21 68.45 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.325 0 N-CA-C 108.262 -1.014 . . . . 0.0 108.262 177.529 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 47.0 m-85 -123.71 121.15 34.76 Favored 'General case' 0 C--N 1.367 1.363 0 CA-C-O 120.972 0.415 . . . . 0.0 111.018 -179.819 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 74.1 m-85 54.23 74.31 0.34 Allowed 'General case' 0 N--CA 1.469 0.477 0 CA-C-N 115.871 -0.604 . . . . 0.0 111.743 178.054 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -78.15 -78.98 0.13 Allowed 'General case' 0 N--CA 1.465 0.32 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.228 -179.551 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 39.7 tt0 -111.71 101.19 9.58 Favored 'General case' 0 N--CA 1.469 0.5 0 N-CA-C 108.325 -0.991 . . . . 0.0 108.325 -179.986 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -158.86 140.6 13.53 Favored 'General case' 0 C--O 1.205 -1.277 0 CA-C-O 119.584 -0.246 . . . . 0.0 111.483 179.089 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 24' ' ' VAL . . . . . . . . . . . . . 57.4 t -58.81 168.91 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.885 0 N-CA-C 107.591 -1.263 . . . . 0.0 107.591 177.057 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -122.31 49.4 0.89 Allowed Glycine 0 N--CA 1.477 1.402 0 N-CA-C 110.751 -0.94 . . . . 0.0 110.751 -179.478 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -63.16 -168.39 0.02 OUTLIER 'General case' 0 N--CA 1.469 0.489 0 CA-C-O 120.635 0.255 . . . . 0.0 110.447 -179.975 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 25.1 t-20 -69.11 77.96 0.34 Allowed 'General case' 0 CA--C 1.533 0.292 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.484 -179.908 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -77.18 147.02 36.69 Favored 'General case' 0 N--CA 1.475 0.816 0 N-CA-C 109.468 -0.567 . . . . 0.0 109.468 179.239 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.44 -168.11 1.07 Allowed Glycine 0 CA--C 1.522 0.481 0 N-CA-C 110.612 -0.995 . . . . 0.0 110.612 178.569 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.54 114.85 28.1 Favored 'General case' 0 N--CA 1.469 0.504 0 N-CA-C 109.891 -0.411 . . . . 0.0 109.891 179.484 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 70.6 mt -96.16 135.02 31.59 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.298 0 N-CA-C 106.987 -1.486 . . . . 0.0 106.987 178.895 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 38.6 pt -151.16 -176.32 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.251 0 CA-C-O 121.191 0.519 . . . . 0.0 110.739 -179.184 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.39 6.0 9.79 Favored Glycine 0 CA--C 1.529 0.937 0 CA-C-N 115.29 -0.868 . . . . 0.0 111.186 -179.622 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 1.3 tt -73.64 128.69 36.18 Favored 'General case' 0 CA--C 1.549 0.913 0 N-CA-C 109.538 -0.541 . . . . 0.0 109.538 -179.586 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 28.4 ttt -162.96 148.73 12.03 Favored 'General case' 0 C--O 1.208 -1.094 0 N-CA-C 108.82 -0.807 . . . . 0.0 108.82 178.378 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 34.1 m -156.75 163.0 1.46 Allowed 'Isoleucine or valine' 0 C--N 1.346 0.429 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 179.872 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 37' ' ' GLY . . . . . 0.513 ' H ' HE22 ' F' ' 15' ' ' GLN . . . 55.58 67.1 2.39 Favored Glycine 0 C--N 1.307 -1.061 0 CA-C-N 115.944 -0.571 . . . . 0.0 111.947 178.45 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 142.35 176.85 16.87 Favored Glycine 0 N--CA 1.476 1.325 0 N-CA-C 111.155 -0.778 . . . . 0.0 111.155 179.036 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 39' ' ' VAL . . . . . 0.439 ' H ' HG11 ' I' ' 39' ' ' VAL . 33.4 m -119.95 158.92 21.55 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.629 0 C-N-CA 123.374 0.67 . . . . 0.0 110.649 -179.675 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 23.6 t . . . . . 0 C--O 1.221 -0.417 0 CA-C-O 118.549 -0.738 . . . . 0.0 110.499 179.071 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' G' G ' 1' ' ' ASP . . . . . . . . . . . . . 14.2 m-20 . . . . . 0 N--CA 1.492 1.645 0 N-CA-C 109.392 -0.596 . . . . 0.0 109.392 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' G' G ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.81 128.84 37.77 Favored 'General case' 0 N--CA 1.468 0.448 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.637 179.642 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 3' ' ' GLU . . . . . . . . . . . . . 43.6 tt0 -168.1 107.01 0.51 Allowed 'General case' 0 N--CA 1.472 0.641 0 CA-C-O 120.52 0.2 . . . . 0.0 110.806 179.841 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 40.8 m-85 -87.98 151.22 22.94 Favored 'General case' 0 N--CA 1.473 0.719 0 N-CA-C 109.643 -0.503 . . . . 0.0 109.643 179.142 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 5' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -142.98 141.02 31.3 Favored 'General case' 0 N--CA 1.482 1.15 0 CA-C-O 120.816 0.341 . . . . 0.0 110.188 179.721 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 44.3 t-80 -151.53 119.48 6.22 Favored 'General case' 0 N--CA 1.474 0.743 0 N-CA-C 109.384 -0.599 . . . . 0.0 109.384 178.948 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -71.04 144.53 50.36 Favored 'General case' 0 N--CA 1.471 0.583 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.212 -179.822 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 8' ' ' SER . . . . . 0.591 ' OG ' ' O ' ' D' ' 7' ' ' ASP . 54.4 p -165.31 -171.22 2.1 Favored 'General case' 0 N--CA 1.476 0.861 0 CA-C-O 121.054 0.454 . . . . 0.0 110.436 178.644 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.88 46.76 1.33 Allowed Glycine 0 N--CA 1.479 1.566 0 CA-C-N 115.809 -0.632 . . . . 0.0 111.607 179.533 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 50.0 p90 -65.44 133.05 50.48 Favored 'General case' 0 N--CA 1.472 0.649 0 N-CA-C 111.835 0.309 . . . . 0.0 111.835 -179.795 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 49.1 mt-10 -91.88 151.89 20.34 Favored 'General case' 0 N--CA 1.479 1.001 0 CA-C-O 121.108 0.48 . . . . 0.0 110.062 178.401 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -155.08 127.04 0.97 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.021 0 N-CA-C 107.886 -1.153 . . . . 0.0 107.886 178.33 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 43.1 m-70 -135.01 148.39 49.94 Favored 'General case' 0 N--CA 1.478 0.944 0 CA-C-N 115.49 -0.777 . . . . 0.0 111.414 -178.399 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 7.2 t60 -164.49 97.29 0.78 Allowed 'General case' 0 N--CA 1.484 1.227 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.486 178.907 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 15' ' ' GLN . . . . . 0.504 HE22 ' H ' ' G' ' 37' ' ' GLY . 3.5 pt20 -106.88 -175.67 2.86 Favored 'General case' 0 CA--C 1.508 -0.664 0 N-CA-C 108.364 -0.976 . . . . 0.0 108.364 -179.821 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -169.98 99.52 0.29 Allowed 'General case' 0 N--CA 1.473 0.691 0 CA-C-N 114.649 -1.159 . . . . 0.0 108.345 179.176 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 17' ' ' LEU . . . . . 0.517 ' CD2' ' H ' ' D' ' 17' ' ' LEU . 8.2 mt -123.4 153.94 39.69 Favored 'General case' 0 N--CA 1.495 1.786 0 CA-C-O 121.085 0.469 . . . . 0.0 111.789 -177.863 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 43.4 t -111.26 126.39 68.65 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.038 0 N-CA-C 108.1 -1.074 . . . . 0.0 108.1 177.021 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 48.0 m-85 -124.12 120.77 33.3 Favored 'General case' 0 C--N 1.367 1.346 0 CA-C-N 115.602 -0.726 . . . . 0.0 111.192 -179.539 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 73.8 m-85 54.46 73.66 0.39 Allowed 'General case' 0 N--CA 1.47 0.526 0 CA-C-N 115.896 -0.593 . . . . 0.0 111.594 178.008 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.04 -78.32 0.13 Allowed 'General case' 0 N--CA 1.471 0.59 0 O-C-N 122.282 -0.262 . . . . 0.0 110.446 -179.032 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 40.4 tt0 -112.25 101.07 9.32 Favored 'General case' 0 C--N 1.322 -0.629 0 N-CA-C 108.108 -1.071 . . . . 0.0 108.108 179.839 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -158.38 142.38 15.6 Favored 'General case' 0 N--CA 1.478 0.926 0 O-C-N 122.387 -0.195 . . . . 0.0 111.442 179.01 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 24' ' ' VAL . . . . . 0.402 ' HB ' ' H ' ' D' ' 25' ' ' GLY . 59.7 t -60.97 167.76 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.644 0 N-CA-C 107.67 -1.233 . . . . 0.0 107.67 177.384 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -120.64 49.95 0.85 Allowed Glycine 0 N--CA 1.482 1.755 0 N-CA-C 110.338 -1.105 . . . . 0.0 110.338 -179.58 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -63.78 -167.61 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.661 0 CA-C-N 116.984 0.392 . . . . 0.0 109.987 179.833 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 25.2 t-20 -70.11 77.71 0.51 Allowed 'General case' 0 CA--C 1.536 0.407 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.451 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -76.16 146.72 38.98 Favored 'General case' 0 N--CA 1.475 0.818 0 N-CA-C 109.506 -0.553 . . . . 0.0 109.506 179.306 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.62 -167.01 0.95 Allowed Glycine 0 C--N 1.336 0.578 0 N-CA-C 110.076 -1.21 . . . . 0.0 110.076 178.721 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.58 115.26 28.98 Favored 'General case' 0 N--CA 1.469 0.516 0 C-N-CA 122.689 0.395 . . . . 0.0 110.438 179.841 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 72.1 mt -97.1 135.99 29.41 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.671 0 N-CA-C 106.87 -1.53 . . . . 0.0 106.87 178.931 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 36.8 pt -152.47 -176.01 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.71 0 CA-C-N 119.855 1.207 . . . . 0.0 109.95 -179.631 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.09 5.83 11.27 Favored Glycine 0 CA--C 1.527 0.811 0 N-CA-C 110.878 -0.889 . . . . 0.0 110.878 -179.763 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 1.4 tt -74.3 127.4 32.89 Favored 'General case' 0 CA--C 1.546 0.796 0 N-CA-C 109.7 -0.482 . . . . 0.0 109.7 -179.503 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 28.1 ttt -161.56 150.22 15.73 Favored 'General case' 0 C--O 1.212 -0.897 0 N-CA-C 108.844 -0.798 . . . . 0.0 108.844 178.533 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 33.9 m -157.4 162.11 1.62 Allowed 'Isoleucine or valine' 0 C--N 1.346 0.451 0 N-CA-C 108.628 -0.878 . . . . 0.0 108.628 -179.819 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 37' ' ' GLY . . . . . 0.504 ' H ' HE22 ' G' ' 15' ' ' GLN . . . 55.61 67.01 2.43 Favored Glycine 0 C--N 1.312 -0.803 0 CA-C-N 115.599 -0.728 . . . . 0.0 112.299 178.111 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.33 178.3 19.02 Favored Glycine 0 N--CA 1.477 1.383 0 N-CA-C 110.569 -1.012 . . . . 0.0 110.569 178.925 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 39' ' ' VAL . . . . . 0.437 HG11 ' H ' ' D' ' 39' ' ' VAL . 34.2 m -121.34 158.37 24.3 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.837 0 C-N-CA 123.128 0.571 . . . . 0.0 110.6 -179.621 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 22.2 t . . . . . 0 N--CA 1.469 0.515 0 O-C-N 123.981 0.801 . . . . 0.0 110.752 179.163 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' H' H ' 1' ' ' ASP . . . . . . . . . . . . . 14.7 m-20 . . . . . 0 N--CA 1.491 1.612 0 N-CA-C 109.4 -0.593 . . . . 0.0 109.4 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' H' H ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.75 128.83 37.74 Favored 'General case' 0 N--CA 1.467 0.4 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.612 179.843 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' H' H ' 3' ' ' GLU . . . . . . . . . . . . . 43.7 tt0 -168.12 106.88 0.51 Allowed 'General case' 0 N--CA 1.471 0.603 0 CA-C-O 120.567 0.222 . . . . 0.0 110.736 179.819 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 42.2 m-85 -87.81 151.2 23.05 Favored 'General case' 0 N--CA 1.474 0.744 0 N-CA-C 109.603 -0.517 . . . . 0.0 109.603 179.136 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' H' H ' 5' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -142.91 141.35 31.48 Favored 'General case' 0 N--CA 1.484 1.263 0 N-CA-C 110.081 -0.34 . . . . 0.0 110.081 179.732 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 44.3 t-80 -151.89 119.54 6.09 Favored 'General case' 0 N--CA 1.474 0.745 0 N-CA-C 109.334 -0.617 . . . . 0.0 109.334 178.901 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -70.96 144.57 50.49 Favored 'General case' 0 N--CA 1.47 0.57 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.251 -179.884 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' H' H ' 8' ' ' SER . . . . . 0.495 ' OG ' ' O ' ' E' ' 7' ' ' ASP . 60.2 p -165.26 -171.55 2.22 Favored 'General case' 0 N--CA 1.474 0.758 0 CA-C-O 120.976 0.417 . . . . 0.0 110.485 178.751 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.83 46.62 1.36 Allowed Glycine 0 N--CA 1.481 1.645 0 CA-C-N 115.986 -0.552 . . . . 0.0 111.756 179.699 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 50.3 p90 -65.64 133.15 50.52 Favored 'General case' 0 N--CA 1.471 0.625 0 N-CA-C 111.798 0.295 . . . . 0.0 111.798 -179.835 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 48.5 mt-10 -91.75 152.25 20.25 Favored 'General case' 0 N--CA 1.477 0.911 0 CA-C-O 121.127 0.489 . . . . 0.0 110.128 178.446 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -155.2 127.49 1.02 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.049 0 N-CA-C 107.83 -1.174 . . . . 0.0 107.83 178.346 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 44.1 m-70 -135.53 148.01 48.99 Favored 'General case' 0 N--CA 1.477 0.909 0 CA-C-N 115.566 -0.743 . . . . 0.0 111.396 -178.307 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 7.1 t60 -164.32 97.26 0.8 Allowed 'General case' 0 N--CA 1.484 1.226 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.45 178.915 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' H' H ' 15' ' ' GLN . . . . . 0.499 HE22 ' H ' ' H' ' 37' ' ' GLY . 3.5 pt20 -106.8 -175.67 2.86 Favored 'General case' 0 CA--C 1.508 -0.666 0 N-CA-C 108.278 -1.008 . . . . 0.0 108.278 -179.872 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -169.81 99.64 0.31 Allowed 'General case' 0 N--CA 1.472 0.653 0 CA-C-N 114.72 -1.127 . . . . 0.0 108.358 179.124 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' H' H ' 17' ' ' LEU . . . . . 0.524 ' CD2' ' H ' ' E' ' 17' ' ' LEU . 8.6 mt -123.44 154.08 39.57 Favored 'General case' 0 N--CA 1.495 1.819 0 CA-C-O 121.118 0.485 . . . . 0.0 111.86 -177.757 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 43.0 t -111.65 126.05 69.01 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.111 0 N-CA-C 108.077 -1.082 . . . . 0.0 108.077 177.087 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 47.5 m-85 -123.83 120.45 32.63 Favored 'General case' 0 C--N 1.368 1.392 0 CA-C-N 115.456 -0.793 . . . . 0.0 110.981 -179.332 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 73.4 m-85 54.11 74.33 0.34 Allowed 'General case' 0 C--N 1.345 0.399 0 CA-C-N 115.776 -0.647 . . . . 0.0 111.697 178.02 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.25 -78.15 0.13 Allowed 'General case' 0 N--CA 1.472 0.655 0 O-C-N 122.4 -0.188 . . . . 0.0 110.519 -179.117 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 40.3 tt0 -112.41 100.95 9.18 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 108.024 -1.102 . . . . 0.0 108.024 179.899 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -158.31 141.95 15.34 Favored 'General case' 0 N--CA 1.478 0.946 0 O-C-N 122.384 -0.198 . . . . 0.0 111.458 179.104 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' H' H ' 24' ' ' VAL . . . . . . . . . . . . . 59.6 t -60.63 167.89 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.561 0 N-CA-C 107.664 -1.236 . . . . 0.0 107.664 177.389 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . -120.89 49.27 0.89 Allowed Glycine 0 N--CA 1.48 1.609 0 N-CA-C 110.482 -1.047 . . . . 0.0 110.482 -179.385 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -63.24 -167.56 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.642 0 CA-C-N 117.009 0.405 . . . . 0.0 110.201 179.881 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 25.2 t-20 -69.93 78.11 0.48 Allowed 'General case' 0 CA--C 1.535 0.388 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.411 179.903 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -76.76 146.55 37.86 Favored 'General case' 0 N--CA 1.476 0.842 0 N-CA-C 109.501 -0.555 . . . . 0.0 109.501 179.314 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.74 -167.12 1.01 Allowed Glycine 0 C--N 1.336 0.578 0 N-CA-C 110.045 -1.222 . . . . 0.0 110.045 178.757 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.84 115.11 28.82 Favored 'General case' 0 N--CA 1.467 0.378 0 C-N-CA 122.6 0.36 . . . . 0.0 110.579 -179.938 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 71.6 mt -96.84 136.02 29.03 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.729 0 N-CA-C 106.866 -1.531 . . . . 0.0 106.866 179.094 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 36.6 pt -152.42 -175.87 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.761 0 CA-C-N 119.814 1.188 . . . . 0.0 109.898 -179.716 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.5 7.0 12.59 Favored Glycine 0 CA--C 1.526 0.78 0 N-CA-C 110.879 -0.889 . . . . 0.0 110.879 -179.755 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 1.3 tt -75.33 127.12 32.44 Favored 'General case' 0 CA--C 1.545 0.775 0 N-CA-C 109.69 -0.485 . . . . 0.0 109.69 -179.728 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 28.0 ttt -161.31 150.03 16.04 Favored 'General case' 0 C--O 1.212 -0.917 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 178.61 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 34.0 m -157.24 161.74 1.73 Allowed 'Isoleucine or valine' 0 C--N 1.345 0.398 0 N-CA-C 108.742 -0.836 . . . . 0.0 108.742 -179.665 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' H' H ' 37' ' ' GLY . . . . . 0.499 ' H ' HE22 ' H' ' 15' ' ' GLN . . . 55.81 66.89 2.52 Favored Glycine 0 C--N 1.311 -0.833 0 CA-C-N 115.673 -0.694 . . . . 0.0 112.261 178.172 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.46 178.09 18.96 Favored Glycine 0 N--CA 1.477 1.396 0 N-CA-C 110.644 -0.982 . . . . 0.0 110.644 179.026 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' H' H ' 39' ' ' VAL . . . . . 0.45 HG11 ' H ' ' E' ' 39' ' ' VAL . 34.1 m -121.12 158.43 23.81 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.846 0 C-N-CA 123.191 0.597 . . . . 0.0 110.772 -179.646 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 23.7 t . . . . . 0 N--CA 1.47 0.529 0 O-C-N 123.936 0.772 . . . . 0.0 110.694 179.149 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' I' I ' 1' ' ' ASP . . . . . . . . . . . . . 14.7 m-20 . . . . . 0 N--CA 1.49 1.566 0 N-CA-C 109.465 -0.569 . . . . 0.0 109.465 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' I' I ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.96 128.78 37.46 Favored 'General case' 0 N--CA 1.468 0.468 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.578 179.91 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' I' I ' 3' ' ' GLU . . . . . . . . . . . . . 43.6 tt0 -167.91 107.01 0.53 Allowed 'General case' 0 N--CA 1.471 0.61 0 CA-C-O 120.501 0.191 . . . . 0.0 110.796 179.781 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 41.0 m-85 -88.0 151.13 23.0 Favored 'General case' 0 N--CA 1.474 0.767 0 N-CA-C 109.579 -0.526 . . . . 0.0 109.579 179.176 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' I' I ' 5' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -142.81 141.35 31.62 Favored 'General case' 0 N--CA 1.483 1.224 0 C-N-CA 122.596 0.359 . . . . 0.0 110.143 179.787 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 45.0 t-80 -151.93 119.46 6.04 Favored 'General case' 0 N--CA 1.473 0.708 0 N-CA-C 109.379 -0.6 . . . . 0.0 109.379 178.96 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -71.02 144.41 50.43 Favored 'General case' 0 N--CA 1.469 0.497 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.268 -179.859 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' I' I ' 8' ' ' SER . . . . . 0.495 ' OG ' ' O ' ' F' ' 7' ' ' ASP . 60.5 p -165.02 -171.47 2.24 Favored 'General case' 0 N--CA 1.474 0.771 0 CA-C-O 120.975 0.417 . . . . 0.0 110.469 178.839 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.66 47.03 1.32 Allowed Glycine 0 N--CA 1.479 1.525 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.777 179.598 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 50.0 p90 -66.18 132.8 49.29 Favored 'General case' 0 N--CA 1.472 0.626 0 N-CA-C 111.869 0.322 . . . . 0.0 111.869 -179.805 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 48.5 mt-10 -91.19 152.29 20.61 Favored 'General case' 0 N--CA 1.477 0.907 0 CA-C-O 121.155 0.502 . . . . 0.0 110.202 178.385 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -155.48 126.95 0.91 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.057 0 N-CA-C 107.887 -1.153 . . . . 0.0 107.887 178.201 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 42.9 m-70 -134.92 148.33 50.03 Favored 'General case' 0 N--CA 1.478 0.935 0 CA-C-N 115.488 -0.778 . . . . 0.0 111.432 -178.409 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 7.1 t60 -164.49 97.33 0.78 Allowed 'General case' 0 N--CA 1.481 1.111 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.441 178.995 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' I' I ' 15' ' ' GLN . . . . . 0.516 HE22 ' H ' ' I' ' 37' ' ' GLY . 3.5 pt20 -106.84 -175.36 2.77 Favored 'General case' 0 CA--C 1.508 -0.666 0 N-CA-C 108.208 -1.034 . . . . 0.0 108.208 -179.815 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -170.18 99.53 0.28 Allowed 'General case' 0 N--CA 1.471 0.595 0 CA-C-N 114.592 -1.185 . . . . 0.0 108.25 179.159 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' I' I ' 17' ' ' LEU . . . . . 0.509 ' CD2' ' H ' ' F' ' 17' ' ' LEU . 8.4 mt -123.23 153.76 39.69 Favored 'General case' 0 N--CA 1.495 1.8 0 CA-C-O 121.042 0.449 . . . . 0.0 111.836 -177.829 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 43.8 t -111.3 126.44 68.69 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.02 0 N-CA-C 108.05 -1.093 . . . . 0.0 108.05 176.913 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 47.1 m-85 -124.16 120.77 33.27 Favored 'General case' 0 C--N 1.368 1.389 0 CA-C-N 115.511 -0.768 . . . . 0.0 111.002 -179.294 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 73.4 m-85 53.87 73.84 0.36 Allowed 'General case' 0 N--CA 1.469 0.495 0 CA-C-N 115.898 -0.592 . . . . 0.0 111.637 178.062 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -76.74 -78.43 0.12 Allowed 'General case' 0 N--CA 1.471 0.61 0 O-C-N 122.304 -0.247 . . . . 0.0 110.414 -179.209 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 40.1 tt0 -112.12 101.31 9.58 Favored 'General case' 0 C--N 1.324 -0.512 0 N-CA-C 108.075 -1.083 . . . . 0.0 108.075 179.938 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -158.53 142.4 15.42 Favored 'General case' 0 N--CA 1.477 0.903 0 O-C-N 122.42 -0.175 . . . . 0.0 111.467 179.063 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' I' I ' 24' ' ' VAL . . . . . . . . . . . . . 59.0 t -61.06 167.82 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.561 0 N-CA-C 107.663 -1.236 . . . . 0.0 107.663 177.296 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . -120.8 49.85 0.86 Allowed Glycine 0 N--CA 1.481 1.682 0 N-CA-C 110.45 -1.06 . . . . 0.0 110.45 -179.485 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -63.84 -167.57 0.02 OUTLIER 'General case' 0 N--CA 1.471 0.594 0 CA-C-N 116.927 0.364 . . . . 0.0 110.24 179.879 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 25.2 t-20 -69.8 77.59 0.46 Allowed 'General case' 0 CA--C 1.535 0.37 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.445 179.883 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -76.39 146.66 38.55 Favored 'General case' 0 N--CA 1.474 0.755 0 N-CA-C 109.438 -0.578 . . . . 0.0 109.438 179.305 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.73 -166.79 0.96 Allowed Glycine 0 C--N 1.337 0.638 0 N-CA-C 110.074 -1.21 . . . . 0.0 110.074 178.76 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.84 114.88 28.37 Favored 'General case' 0 N--CA 1.469 0.501 0 C-N-CA 122.771 0.428 . . . . 0.0 110.582 179.913 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 72.0 mt -96.75 136.07 28.78 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.674 0 N-CA-C 106.883 -1.525 . . . . 0.0 106.883 178.981 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 37.5 pt -152.46 -175.94 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 CA-C-N 119.885 1.221 . . . . 0.0 109.907 -179.678 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.63 6.69 12.22 Favored Glycine 0 CA--C 1.526 0.763 0 N-CA-C 110.94 -0.864 . . . . 0.0 110.94 -179.776 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 1.4 tt -75.04 127.13 32.51 Favored 'General case' 0 CA--C 1.547 0.83 0 N-CA-C 109.547 -0.538 . . . . 0.0 109.547 -179.64 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 28.1 ttt -161.1 150.12 16.49 Favored 'General case' 0 C--O 1.211 -0.942 0 N-CA-C 108.738 -0.838 . . . . 0.0 108.738 178.564 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 34.1 m -157.23 162.11 1.63 Allowed 'Isoleucine or valine' 0 C--N 1.347 0.459 0 N-CA-C 108.594 -0.891 . . . . 0.0 108.594 -179.747 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' I' I ' 37' ' ' GLY . . . . . 0.516 ' H ' HE22 ' I' ' 15' ' ' GLN . . . 55.34 67.2 2.33 Favored Glycine 0 C--N 1.311 -0.841 0 CA-C-N 115.643 -0.708 . . . . 0.0 112.241 178.122 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.18 178.28 18.88 Favored Glycine 0 N--CA 1.478 1.47 0 N-CA-C 110.568 -1.013 . . . . 0.0 110.568 178.875 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' I' I ' 39' ' ' VAL . . . . . 0.439 HG11 ' H ' ' F' ' 39' ' ' VAL . 33.9 m -121.33 158.31 24.33 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.856 0 C-N-CA 123.15 0.58 . . . . 0.0 110.723 -179.662 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 23.4 t . . . . . 0 N--CA 1.469 0.523 0 O-C-N 124.046 0.841 . . . . 0.0 110.699 179.041 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 13.4 m-20 . . . . . 0 N--CA 1.49 1.528 0 N-CA-C 108.942 -0.762 . . . . 0.0 108.942 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.89 132.93 49.83 Favored 'General case' 0 CA--C 1.538 0.518 0 N-CA-C 110.185 -0.302 . . . . 0.0 110.185 -179.785 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 44.1 tt0 -168.64 104.53 0.43 Allowed 'General case' 0 N--CA 1.473 0.703 0 N-CA-C 110.062 -0.347 . . . . 0.0 110.062 -179.152 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 35.1 m-85 -86.5 154.73 20.89 Favored 'General case' 0 N--CA 1.475 0.782 0 N-CA-C 110.082 -0.34 . . . . 0.0 110.082 179.697 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -144.31 139.65 28.69 Favored 'General case' 0 N--CA 1.481 1.115 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 179.563 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 42.1 t-80 -151.95 119.88 6.2 Favored 'General case' 0 N--CA 1.469 0.509 0 N-CA-C 109.264 -0.643 . . . . 0.0 109.264 179.257 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' ASP . . . . . 0.525 ' O ' ' OG ' ' D' ' 8' ' ' SER . 4.2 m-20 -69.04 148.68 49.72 Favored 'General case' 0 CA--C 1.537 0.476 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.498 179.876 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' SER . . . . . 0.451 ' H ' ' HG ' ' C' ' 26' ' ' SER . 53.9 p -168.2 -174.24 2.25 Favored 'General case' 0 N--CA 1.484 1.262 0 CA-C-O 121.035 0.445 . . . . 0.0 110.747 179.429 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.8 48.26 1.28 Allowed Glycine 0 N--CA 1.481 1.698 0 CA-C-N 115.911 -0.586 . . . . 0.0 111.83 179.725 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 49.7 p90 -64.6 132.39 49.67 Favored 'General case' 0 N--CA 1.473 0.691 0 O-C-N 122.761 -0.258 . . . . 0.0 111.425 179.732 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 83.3 mt-10 -91.71 152.25 20.28 Favored 'General case' 0 N--CA 1.48 1.047 0 C-N-CA 122.781 0.433 . . . . 0.0 109.839 178.379 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -153.23 128.42 1.54 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.617 0 N-CA-C 107.821 -1.177 . . . . 0.0 107.821 178.298 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 48.5 m-70 -135.25 145.98 48.13 Favored 'General case' 0 N--CA 1.492 1.666 0 CA-C-N 118.949 0.795 . . . . 0.0 111.388 -179.003 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 6.1 t60 -165.95 97.18 0.63 Allowed 'General case' 0 N--CA 1.48 1.058 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.848 179.5 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 3.6 pt20 -108.52 -174.69 2.58 Favored 'General case' 0 CA--C 1.506 -0.733 0 N-CA-C 108.432 -0.951 . . . . 0.0 108.432 -179.845 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -164.17 97.57 0.82 Allowed 'General case' 0 N--CA 1.472 0.651 0 CA-C-N 114.562 -1.199 . . . . 0.0 108.299 178.348 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 6.7 mp -122.27 157.78 30.94 Favored 'General case' 0 N--CA 1.497 1.924 0 CA-C-O 121.759 0.79 . . . . 0.0 110.91 -178.338 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 59.8 t -112.57 126.65 69.99 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.124 0 CA-C-O 117.984 -1.008 . . . . 0.0 108.316 177.702 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 28.7 m-85 -126.93 122.5 34.75 Favored 'General case' 0 N--CA 1.497 1.909 0 CA-C-N 120.017 1.28 . . . . 0.0 110.344 179.338 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 67.0 m-85 53.94 74.32 0.33 Allowed 'General case' 0 N--CA 1.47 0.572 0 CA-C-O 121.374 0.606 . . . . 0.0 111.745 178.751 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -80.55 -78.14 0.18 Allowed 'General case' 0 C--N 1.353 0.756 0 CA-C-N 115.139 -0.937 . . . . 0.0 110.334 -179.773 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 40.4 tt0 -112.21 101.59 9.82 Favored 'General case' 0 N--CA 1.469 0.502 0 N-CA-C 108.468 -0.938 . . . . 0.0 108.468 179.738 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 4.4 p30 -158.96 134.5 8.62 Favored 'General case' 0 N--CA 1.482 1.16 0 CA-C-O 119.512 -0.28 . . . . 0.0 111.211 178.936 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 58.7 t -58.05 163.07 0.71 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.853 0 N-CA-C 108.074 -1.084 . . . . 0.0 108.074 176.984 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -115.76 47.95 0.99 Allowed Glycine 0 N--CA 1.477 1.383 0 N-CA-C 111.615 -0.594 . . . . 0.0 111.615 -179.474 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' SER . . . . . 0.412 ' HG ' ' H ' ' B' ' 8' ' ' SER . 0.3 OUTLIER -61.85 -168.65 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.562 0 N-CA-C 110.152 -0.314 . . . . 0.0 110.152 179.338 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 24.5 t-20 -72.05 79.97 0.94 Allowed 'General case' 0 N--CA 1.464 0.257 0 CA-C-N 116.428 -0.351 . . . . 0.0 110.082 179.164 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -73.46 140.32 46.39 Favored 'General case' 0 N--CA 1.476 0.837 0 N-CA-C 108.934 -0.765 . . . . 0.0 108.934 179.375 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.39 -149.76 0.03 OUTLIER Glycine 0 C--N 1.337 0.618 0 N-CA-C 110.183 -1.167 . . . . 0.0 110.183 179.282 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -93.76 128.07 39.8 Favored 'General case' 0 N--CA 1.476 0.825 0 N-CA-C 110.04 -0.356 . . . . 0.0 110.04 -179.905 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 74.8 mt -124.16 117.35 50.54 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.748 0 N-CA-C 106.653 -1.61 . . . . 0.0 106.653 178.876 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 39.2 pt -151.5 -169.78 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.354 0.804 0 CA-C-O 121.22 0.533 . . . . 0.0 111.246 -178.769 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.84 5.08 12.38 Favored Glycine 0 C--N 1.336 0.58 0 N-CA-C 110.797 -0.921 . . . . 0.0 110.797 179.587 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 1.5 tt -78.14 126.77 31.3 Favored 'General case' 0 CA--C 1.546 0.801 0 N-CA-C 109.558 -0.534 . . . . 0.0 109.558 -179.884 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 28.6 ttt -164.69 143.55 6.94 Favored 'General case' 0 N--CA 1.464 0.23 0 N-CA-C 108.871 -0.788 . . . . 0.0 108.871 178.266 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 35.6 m -155.27 162.71 1.73 Allowed 'Isoleucine or valine' 0 C--N 1.348 0.509 0 N-CA-C 108.042 -1.096 . . . . 0.0 108.042 179.327 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.61 66.33 2.93 Favored Glycine 0 C--N 1.307 -1.08 0 CA-C-N 115.834 -0.621 . . . . 0.0 111.874 178.429 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 145.7 172.97 16.53 Favored Glycine 0 N--CA 1.473 1.1 0 N-CA-C 110.994 -0.843 . . . . 0.0 110.994 179.095 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.494 ' H ' HG11 ' D' ' 39' ' ' VAL . 33.7 m -123.01 160.44 25.76 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.616 0 C-N-CA 123.405 0.682 . . . . 0.0 110.087 -179.691 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 23.7 t . . . . . 0 C--O 1.218 -0.556 0 CA-C-O 118.419 -0.8 . . . . 0.0 110.578 179.478 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' B' B ' 1' ' ' ASP . . . . . . . . . . . . . 12.5 m-20 . . . . . 0 N--CA 1.489 1.49 0 N-CA-C 108.992 -0.744 . . . . 0.0 108.992 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' B' B ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.48 132.61 49.35 Favored 'General case' 0 CA--C 1.539 0.554 0 N-CA-C 110.151 -0.315 . . . . 0.0 110.151 -179.704 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 3' ' ' GLU . . . . . . . . . . . . . 44.0 tt0 -168.33 104.47 0.45 Allowed 'General case' 0 N--CA 1.474 0.742 0 N-CA-C 110.085 -0.339 . . . . 0.0 110.085 -179.15 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 34.7 m-85 -86.39 154.69 20.99 Favored 'General case' 0 N--CA 1.474 0.752 0 N-CA-C 110.047 -0.353 . . . . 0.0 110.047 179.617 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -144.41 139.06 28.16 Favored 'General case' 0 N--CA 1.484 1.225 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 179.585 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 41.5 t-80 -151.24 119.63 6.41 Favored 'General case' 0 N--CA 1.472 0.638 0 N-CA-C 109.256 -0.646 . . . . 0.0 109.256 179.204 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 7' ' ' ASP . . . . . 0.507 ' O ' ' OG ' ' E' ' 8' ' ' SER . 4.0 m-20 -68.83 148.19 50.63 Favored 'General case' 0 CA--C 1.538 0.514 0 CA-C-N 116.295 -0.412 . . . . 0.0 110.721 179.828 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 8' ' ' SER . . . . . 0.412 ' H ' ' HG ' ' A' ' 26' ' ' SER . 54.1 p -167.58 -173.69 2.27 Favored 'General case' 0 N--CA 1.483 1.221 0 CA-C-O 121.045 0.45 . . . . 0.0 110.707 179.525 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.38 48.24 1.33 Allowed Glycine 0 N--CA 1.481 1.692 0 CA-C-N 115.908 -0.587 . . . . 0.0 111.949 179.55 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 50.2 p90 -64.94 132.89 50.55 Favored 'General case' 0 N--CA 1.473 0.687 0 CA-C-O 120.636 0.255 . . . . 0.0 111.496 179.871 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 84.2 mt-10 -92.02 152.75 19.84 Favored 'General case' 0 N--CA 1.478 0.93 0 CA-C-O 121.048 0.451 . . . . 0.0 109.823 178.456 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -153.61 128.39 1.46 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.495 0 N-CA-C 107.922 -1.14 . . . . 0.0 107.922 178.12 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 46.5 m-70 -135.32 145.67 47.69 Favored 'General case' 0 N--CA 1.493 1.723 0 CA-C-N 118.941 0.791 . . . . 0.0 111.289 -179.006 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 6.0 t60 -165.65 96.86 0.66 Allowed 'General case' 0 N--CA 1.48 1.035 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.739 179.38 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 3.6 pt20 -108.12 -174.74 2.59 Favored 'General case' 0 CA--C 1.507 -0.694 0 N-CA-C 108.411 -0.959 . . . . 0.0 108.411 -179.798 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -164.29 97.63 0.8 Allowed 'General case' 0 N--CA 1.473 0.699 0 CA-C-N 114.67 -1.15 . . . . 0.0 108.263 178.342 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 6.6 mp -122.27 157.69 31.13 Favored 'General case' 0 N--CA 1.497 1.906 0 CA-C-O 121.809 0.814 . . . . 0.0 111.023 -178.298 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 61.4 t -112.71 127.75 69.77 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.024 0 N-CA-C 108.069 -1.086 . . . . 0.0 108.069 177.595 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 28.6 m-85 -128.09 122.09 31.22 Favored 'General case' 0 N--CA 1.495 1.787 0 CA-C-N 119.726 1.148 . . . . 0.0 110.192 179.501 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 67.1 m-85 53.6 74.18 0.33 Allowed 'General case' 0 CA--C 1.54 0.581 0 CA-C-O 121.487 0.661 . . . . 0.0 111.799 178.622 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -80.35 -78.32 0.17 Allowed 'General case' 0 C--N 1.352 0.687 0 CA-C-N 115.001 -1.0 . . . . 0.0 110.275 -179.823 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 40.5 tt0 -112.02 101.73 10.0 Favored 'General case' 0 N--CA 1.471 0.613 0 N-CA-C 108.448 -0.945 . . . . 0.0 108.448 179.819 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 4.4 p30 -158.89 134.8 8.89 Favored 'General case' 0 N--CA 1.482 1.169 0 CA-C-O 119.54 -0.266 . . . . 0.0 111.155 178.913 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 58.5 t -58.26 163.2 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.874 0 N-CA-C 108.128 -1.064 . . . . 0.0 108.128 177.018 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -115.57 47.62 1.02 Allowed Glycine 0 N--CA 1.474 1.203 0 N-CA-C 111.65 -0.58 . . . . 0.0 111.65 -179.314 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 26' ' ' SER . . . . . 0.422 ' HG ' ' H ' ' C' ' 8' ' ' SER . 0.3 OUTLIER -61.77 -168.59 0.01 OUTLIER 'General case' 0 N--CA 1.469 0.518 0 N-CA-C 110.25 -0.278 . . . . 0.0 110.25 179.45 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 24.6 t-20 -72.38 79.85 1.02 Allowed 'General case' 0 N--CA 1.468 0.426 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.318 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -73.19 140.6 47.1 Favored 'General case' 0 N--CA 1.477 0.898 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 179.565 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.56 -150.05 0.04 OUTLIER Glycine 0 C--N 1.338 0.639 0 N-CA-C 110.191 -1.163 . . . . 0.0 110.191 179.411 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -93.41 128.33 39.42 Favored 'General case' 0 N--CA 1.475 0.787 0 CA-C-N 116.938 0.369 . . . . 0.0 110.032 179.795 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 76.7 mt -124.46 117.26 50.02 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.658 0 N-CA-C 106.593 -1.632 . . . . 0.0 106.593 178.811 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . 0.401 ' C ' ' H ' ' B' ' 34' ' ' LEU . 39.8 pt -151.19 -169.71 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.355 0.831 0 CA-C-N 115.986 -0.552 . . . . 0.0 111.255 -178.746 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.83 4.95 11.86 Favored Glycine 0 C--N 1.337 0.627 0 N-CA-C 110.945 -0.862 . . . . 0.0 110.945 179.479 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 34' ' ' LEU . . . . . 0.401 ' H ' ' C ' ' B' ' 32' ' ' ILE . 1.5 tt -78.12 126.81 31.35 Favored 'General case' 0 CA--C 1.546 0.819 0 N-CA-C 109.57 -0.53 . . . . 0.0 109.57 -179.778 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 28.5 ttt -164.81 143.53 6.75 Favored 'General case' 0 N--CA 1.465 0.311 0 N-CA-C 108.801 -0.814 . . . . 0.0 108.801 178.225 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 35.4 m -155.37 162.41 1.8 Allowed 'Isoleucine or valine' 0 C--N 1.347 0.499 0 N-CA-C 108.0 -1.111 . . . . 0.0 108.0 179.471 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.71 66.9 2.52 Favored Glycine 0 C--N 1.307 -1.068 0 CA-C-N 115.742 -0.663 . . . . 0.0 111.784 178.415 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 144.97 172.65 15.58 Favored Glycine 0 N--CA 1.472 1.08 0 N-CA-C 110.869 -0.892 . . . . 0.0 110.869 179.179 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 39' ' ' VAL . . . . . 0.514 ' H ' HG11 ' E' ' 39' ' ' VAL . 32.5 m -123.09 159.95 26.49 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.711 0 C-N-CA 123.428 0.691 . . . . 0.0 110.209 -179.553 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 24.4 t . . . . . 0 N--CA 1.468 0.468 0 CA-C-O 118.316 -0.849 . . . . 0.0 110.441 179.475 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' C' C ' 1' ' ' ASP . . . . . . . . . . . . . 13.0 m-20 . . . . . 0 N--CA 1.489 1.525 0 N-CA-C 108.861 -0.792 . . . . 0.0 108.861 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' C' C ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.95 132.56 49.65 Favored 'General case' 0 CA--C 1.539 0.519 0 CA-C-N 116.421 -0.354 . . . . 0.0 110.298 -179.681 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 3' ' ' GLU . . . . . . . . . . . . . 44.1 tt0 -168.18 104.89 0.47 Allowed 'General case' 0 N--CA 1.473 0.7 0 N-CA-C 110.012 -0.366 . . . . 0.0 110.012 -179.303 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 34.6 m-85 -86.67 154.98 20.58 Favored 'General case' 0 N--CA 1.475 0.799 0 N-CA-C 110.023 -0.362 . . . . 0.0 110.023 179.608 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -144.75 138.85 27.47 Favored 'General case' 0 N--CA 1.482 1.165 0 N-CA-C 109.951 -0.389 . . . . 0.0 109.951 179.69 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 41.7 t-80 -151.16 119.7 6.48 Favored 'General case' 0 N--CA 1.471 0.582 0 N-CA-C 109.381 -0.599 . . . . 0.0 109.381 179.246 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 7' ' ' ASP . . . . . 0.513 ' O ' ' OG ' ' F' ' 8' ' ' SER . 4.3 m-20 -69.1 148.21 50.33 Favored 'General case' 0 CA--C 1.539 0.527 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.66 179.891 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' C' C ' 8' ' ' SER . . . . . 0.422 ' H ' ' HG ' ' B' ' 26' ' ' SER . 54.5 p -167.55 -173.95 2.36 Favored 'General case' 0 N--CA 1.484 1.271 0 CA-C-O 121.028 0.442 . . . . 0.0 110.764 179.455 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.81 48.19 1.29 Allowed Glycine 0 N--CA 1.48 1.616 0 CA-C-N 115.886 -0.597 . . . . 0.0 111.988 179.574 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 49.5 p90 -65.01 132.18 48.54 Favored 'General case' 0 N--CA 1.471 0.604 0 O-C-N 122.751 -0.264 . . . . 0.0 111.463 179.897 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 83.5 mt-10 -91.47 152.59 20.29 Favored 'General case' 0 N--CA 1.476 0.835 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 178.465 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -153.4 128.61 1.54 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.53 0 N-CA-C 107.778 -1.193 . . . . 0.0 107.778 178.237 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 46.8 m-70 -135.35 145.76 47.71 Favored 'General case' 0 N--CA 1.493 1.687 0 CA-C-N 118.986 0.812 . . . . 0.0 111.357 -179.099 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 6.0 t60 -165.69 97.33 0.66 Allowed 'General case' 0 N--CA 1.48 1.059 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.715 179.361 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 3.5 pt20 -108.74 -174.22 2.46 Favored 'General case' 0 CA--C 1.506 -0.722 0 N-CA-C 108.362 -0.977 . . . . 0.0 108.362 -179.891 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -164.66 97.7 0.77 Allowed 'General case' 0 N--CA 1.471 0.62 0 CA-C-N 114.573 -1.194 . . . . 0.0 108.269 178.55 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 6.6 mp -122.45 157.36 32.11 Favored 'General case' 0 N--CA 1.498 1.946 0 CA-C-O 121.883 0.849 . . . . 0.0 111.017 -178.208 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 58.8 t -112.41 127.28 69.71 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.091 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 177.655 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 29.2 m-85 -127.77 122.17 32.1 Favored 'General case' 0 N--CA 1.494 1.75 0 CA-C-N 119.686 1.13 . . . . 0.0 110.266 179.458 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 67.0 m-85 53.54 74.14 0.33 Allowed 'General case' 0 N--CA 1.468 0.448 0 CA-C-O 121.486 0.66 . . . . 0.0 111.915 178.588 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -80.56 -77.84 0.19 Allowed 'General case' 0 C--N 1.349 0.559 0 CA-C-N 114.969 -1.014 . . . . 0.0 110.373 -179.716 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 40.3 tt0 -112.38 101.32 9.52 Favored 'General case' 0 N--CA 1.47 0.535 0 N-CA-C 108.355 -0.98 . . . . 0.0 108.355 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -158.79 134.22 8.61 Favored 'General case' 0 N--CA 1.481 1.096 0 CA-C-O 119.466 -0.302 . . . . 0.0 111.205 178.965 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 59.3 t -57.55 163.55 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.805 0 N-CA-C 108.135 -1.061 . . . . 0.0 108.135 177.002 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -115.91 47.8 1.0 Allowed Glycine 0 N--CA 1.477 1.421 0 N-CA-C 111.519 -0.632 . . . . 0.0 111.519 -179.505 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 26' ' ' SER . . . . . 0.451 ' HG ' ' H ' ' A' ' 8' ' ' SER . 0.3 OUTLIER -62.06 -169.23 0.02 OUTLIER 'General case' 0 N--CA 1.469 0.509 0 N-CA-C 110.17 -0.308 . . . . 0.0 110.17 179.348 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 24.7 t-20 -71.77 79.72 0.86 Allowed 'General case' 0 N--CA 1.468 0.425 0 N-CA-C 110.011 -0.366 . . . . 0.0 110.011 179.455 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -73.19 140.6 47.08 Favored 'General case' 0 N--CA 1.476 0.834 0 N-CA-C 109.011 -0.737 . . . . 0.0 109.011 179.442 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.7 -149.09 0.04 OUTLIER Glycine 0 C--N 1.337 0.594 0 N-CA-C 110.284 -1.126 . . . . 0.0 110.284 179.457 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -94.16 128.03 40.34 Favored 'General case' 0 N--CA 1.477 0.877 0 CA-C-N 116.931 0.365 . . . . 0.0 110.083 179.953 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 74.9 mt -124.28 117.23 50.06 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.697 0 N-CA-C 106.707 -1.59 . . . . 0.0 106.707 178.734 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 39.7 pt -151.3 -169.74 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.355 0.826 0 CA-C-N 115.978 -0.556 . . . . 0.0 111.231 -178.712 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.9 4.81 11.83 Favored Glycine 0 N--CA 1.465 0.609 0 N-CA-C 110.84 -0.904 . . . . 0.0 110.84 179.433 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 1.5 tt -77.96 126.66 31.17 Favored 'General case' 0 CA--C 1.546 0.826 0 N-CA-C 109.566 -0.531 . . . . 0.0 109.566 -179.803 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 28.6 ttt -164.49 143.33 7.13 Favored 'General case' 0 N--CA 1.465 0.298 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 178.298 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 35.5 m -155.19 162.58 1.77 Allowed 'Isoleucine or valine' 0 C--N 1.347 0.485 0 N-CA-C 107.989 -1.115 . . . . 0.0 107.989 179.373 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.64 66.45 2.84 Favored Glycine 0 C--N 1.306 -1.138 0 CA-C-N 115.808 -0.633 . . . . 0.0 111.88 178.422 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 145.46 173.33 16.62 Favored Glycine 0 N--CA 1.472 1.07 0 N-CA-C 111.024 -0.831 . . . . 0.0 111.024 178.946 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 39' ' ' VAL . . . . . 0.512 ' H ' HG11 ' F' ' 39' ' ' VAL . 33.0 m -123.17 160.39 26.18 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.658 0 C-N-CA 123.424 0.69 . . . . 0.0 110.192 -179.787 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 22.8 t . . . . . 0 C--O 1.219 -0.518 0 CA-C-O 118.406 -0.807 . . . . 0.0 110.46 179.546 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' D' D ' 1' ' ' ASP . . . . . . . . . . . . . 13.2 m-20 . . . . . 0 N--CA 1.49 1.528 0 N-CA-C 109.227 -0.657 . . . . 0.0 109.227 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' D' D ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.71 131.32 46.57 Favored 'General case' 0 CA--C 1.534 0.35 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.48 179.872 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 3' ' ' GLU . . . . . . . . . . . . . 43.7 tt0 -169.38 107.25 0.4 Allowed 'General case' 0 N--CA 1.471 0.59 0 N-CA-C 110.096 -0.335 . . . . 0.0 110.096 -179.962 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 35.1 m-85 -90.8 159.33 16.34 Favored 'General case' 0 C--N 1.355 0.843 0 N-CA-C 108.954 -0.758 . . . . 0.0 108.954 179.952 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 5' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -146.07 137.5 24.77 Favored 'General case' 0 N--CA 1.478 0.953 0 C-N-CA 122.814 0.445 . . . . 0.0 110.341 -179.888 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 37.7 t-80 -149.64 123.94 9.57 Favored 'General case' 0 CA--C 1.547 0.827 0 N-CA-C 108.188 -1.041 . . . . 0.0 108.188 175.182 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 7' ' ' ASP . . . . . 0.604 ' O ' ' OG ' ' G' ' 8' ' ' SER . 3.2 m-20 -63.69 132.52 51.33 Favored 'General case' 0 N--CA 1.466 0.363 0 C-N-CA 126.323 1.849 . . . . 0.0 114.361 174.856 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' D' D ' 8' ' ' SER . . . . . 0.525 ' OG ' ' O ' ' A' ' 7' ' ' ASP . 53.8 p -154.39 -171.35 3.83 Favored 'General case' 0 N--CA 1.487 1.385 0 CA-C-N 119.454 1.024 . . . . 0.0 111.255 176.266 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.28 49.0 1.09 Allowed Glycine 0 N--CA 1.483 1.8 0 N-CA-C 110.263 -1.135 . . . . 0.0 110.263 174.144 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 50.8 p90 -61.47 131.71 51.08 Favored 'General case' 0 N--CA 1.472 0.65 0 N-CA-C 112.338 0.495 . . . . 0.0 112.338 178.833 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 84.8 mt-10 -89.24 150.73 22.5 Favored 'General case' 0 N--CA 1.482 1.136 0 CA-C-O 120.564 0.221 . . . . 0.0 110.714 175.645 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.0 p -149.44 130.19 4.58 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.567 0 N-CA-C 107.492 -1.299 . . . . 0.0 107.492 173.114 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 43.2 m-70 -129.89 148.72 51.78 Favored 'General case' 0 N--CA 1.483 1.217 0 CA-C-N 118.074 0.397 . . . . 0.0 111.91 176.444 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 6.1 t60 -165.14 104.43 0.76 Allowed 'General case' 0 N--CA 1.481 1.083 0 N-CA-C 109.029 -0.73 . . . . 0.0 109.029 172.33 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 3.5 pt20 -111.84 -176.14 2.86 Favored 'General case' 0 CA--C 1.497 -1.089 0 N-CA-C 108.29 -1.004 . . . . 0.0 108.29 178.808 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -161.29 105.35 1.3 Allowed 'General case' 0 N--CA 1.469 0.5 0 N-CA-C 106.37 -1.715 . . . . 0.0 106.37 174.965 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 5.6 mp -129.15 154.07 47.08 Favored 'General case' 0 N--CA 1.499 1.989 0 CA-C-O 122.024 0.916 . . . . 0.0 110.581 179.732 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 33.1 t -101.29 131.39 49.14 Favored 'Isoleucine or valine' 0 C--O 1.262 1.75 0 CA-C-O 116.89 -1.529 . . . . 0.0 109.74 174.047 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 26.9 m-85 -130.24 126.63 37.8 Favored 'General case' 0 N--CA 1.491 1.618 0 CA-C-N 119.893 1.224 . . . . 0.0 109.497 173.19 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 67.3 m-85 55.22 71.3 0.55 Allowed 'General case' 0 C--O 1.241 0.658 0 CA-C-N 115.592 -0.731 . . . . 0.0 111.653 176.226 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -82.3 -73.42 0.39 Allowed 'General case' 0 N--CA 1.473 0.701 0 CA-C-O 118.601 -0.714 . . . . 0.0 111.259 -177.414 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 40.7 tt0 -115.35 105.37 12.77 Favored 'General case' 0 N--CA 1.48 1.046 0 N-CA-C 106.463 -1.68 . . . . 0.0 106.463 176.312 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 4.4 p30 -152.19 135.17 15.66 Favored 'General case' 0 N--CA 1.473 0.692 0 CA-C-O 116.67 -1.633 . . . . 0.0 113.493 177.301 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 24' ' ' VAL . . . . . . . . . . . . . 87.7 t -61.35 166.27 0.81 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.218 0 CA-C-N 121.056 1.753 . . . . 0.0 107.759 175.529 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . -116.38 50.99 0.75 Allowed Glycine 0 N--CA 1.478 1.476 0 CA-C-O 119.466 -0.63 . . . . 0.0 111.656 178.621 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 26' ' ' SER . . . . . 0.431 ' HG ' ' H ' ' E' ' 8' ' ' SER . 0.2 OUTLIER -57.14 -171.03 0.01 OUTLIER 'General case' 0 N--CA 1.468 0.463 0 C-N-CA 123.414 0.685 . . . . 0.0 111.805 175.217 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 25.4 t-20 -73.62 86.86 1.63 Allowed 'General case' 0 C--N 1.348 0.512 0 N-CA-C 108.44 -0.948 . . . . 0.0 108.44 176.753 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 97.6 mttt -81.09 143.26 32.56 Favored 'General case' 0 N--CA 1.481 1.101 0 N-CA-C 107.527 -1.286 . . . . 0.0 107.527 179.818 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.72 -144.78 0.02 OUTLIER Glycine 0 C--N 1.349 1.274 0 CA-C-N 114.928 -1.033 . . . . 0.0 111.705 -178.865 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -95.81 127.01 41.47 Favored 'General case' 0 C--O 1.241 0.619 0 N-CA-C 110.196 -0.298 . . . . 0.0 110.196 178.859 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 85.8 mt -125.98 127.61 71.23 Favored 'Isoleucine or valine' 0 C--N 1.354 0.77 0 N-CA-C 103.34 -2.837 . . . . 0.0 103.34 176.89 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 42.8 pt -159.61 -170.82 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.119 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.228 -177.696 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 64.12 4.83 12.78 Favored Glycine 0 C--O 1.243 0.685 0 N-CA-C 110.254 -1.138 . . . . 0.0 110.254 -179.251 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 34' ' ' LEU . . . . . . . . . . . . 0.265 2.0 tt -80.33 133.38 35.93 Favored 'General case' 0 C--N 1.377 1.798 0 C-N-CA 117.22 -1.792 . . . . 0.0 107.353 -178.729 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 28.4 ttt -158.82 156.2 29.25 Favored 'General case' 0 C--O 1.25 1.081 0 CA-C-O 117.938 -1.03 . . . . 0.0 108.691 172.374 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 35.5 m -164.74 163.7 0.71 Allowed 'Isoleucine or valine' 0 CA--C 1.516 -0.364 0 N-CA-C 107.643 -1.243 . . . . 0.0 107.643 174.273 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 60.5 63.03 5.35 Favored Glycine 0 CA--C 1.53 1.011 0 C-N-CA 120.216 -0.993 . . . . 0.0 111.509 177.578 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 144.03 175.53 17.24 Favored Glycine 0 N--CA 1.478 1.469 0 CA-C-N 118.443 1.122 . . . . 0.0 111.378 179.847 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 39' ' ' VAL . . . . . 0.513 ' H ' HG11 ' G' ' 39' ' ' VAL . 36.0 m -126.22 157.4 36.52 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.78 0 C-N-CA 122.937 0.495 . . . . 0.0 109.863 -177.737 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 24.0 t . . . . . 0 C--N 1.331 -0.211 0 CA-C-O 116.331 -1.795 . . . . 0.0 109.479 177.301 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' E' E ' 1' ' ' ASP . . . . . . . . . . . . . 13.1 m-20 . . . . . 0 N--CA 1.488 1.449 0 N-CA-C 109.58 -0.526 . . . . 0.0 109.58 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' E' E ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.1 130.02 42.32 Favored 'General case' 0 N--CA 1.468 0.458 0 CA-C-N 116.295 -0.412 . . . . 0.0 110.422 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' E' E ' 3' ' ' GLU . . . . . . . . . . . . . 43.7 tt0 -167.47 104.89 0.52 Allowed 'General case' 0 N--CA 1.472 0.64 0 CA-C-N 116.866 -0.152 . . . . 0.0 110.684 -179.808 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 31.8 m-85 -87.65 154.34 20.67 Favored 'General case' 0 N--CA 1.474 0.768 0 N-CA-C 110.135 -0.321 . . . . 0.0 110.135 179.351 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' E' E ' 5' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -143.69 139.82 29.71 Favored 'General case' 0 N--CA 1.484 1.256 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 179.374 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 41.3 t-80 -151.57 119.61 6.26 Favored 'General case' 0 N--CA 1.472 0.674 0 N-CA-C 109.276 -0.639 . . . . 0.0 109.276 178.953 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' E' E ' 7' ' ' ASP . . . . . 0.508 ' O ' ' OG ' ' H' ' 8' ' ' SER . 3.9 m-20 -69.6 147.81 50.21 Favored 'General case' 0 CA--C 1.534 0.334 0 CA-C-N 116.414 -0.357 . . . . 0.0 110.94 -179.951 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' E' E ' 8' ' ' SER . . . . . 0.507 ' OG ' ' O ' ' B' ' 7' ' ' ASP . 52.2 p -167.8 -172.72 1.93 Allowed 'General case' 0 N--CA 1.485 1.32 0 CA-C-O 121.18 0.514 . . . . 0.0 110.807 179.014 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.19 48.57 1.21 Allowed Glycine 0 N--CA 1.478 1.479 0 CA-C-N 115.702 -0.681 . . . . 0.0 111.82 179.475 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 47.8 p90 -64.66 133.11 51.49 Favored 'General case' 0 N--CA 1.473 0.688 0 N-CA-C 111.842 0.312 . . . . 0.0 111.842 -179.744 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 86.3 mt-10 -91.53 152.41 20.33 Favored 'General case' 0 N--CA 1.479 1.024 0 CA-C-O 121.175 0.512 . . . . 0.0 109.787 178.06 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -154.59 127.5 1.12 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.575 0 N-CA-C 107.735 -1.209 . . . . 0.0 107.735 178.053 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 46.6 m-70 -135.24 143.8 46.53 Favored 'General case' 0 N--CA 1.482 1.13 0 CA-C-O 120.846 0.355 . . . . 0.0 111.609 -177.942 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 6.1 t60 -164.31 97.25 0.8 Allowed 'General case' 0 N--CA 1.483 1.187 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.671 179.395 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 3.5 pt20 -108.07 -174.58 2.56 Favored 'General case' 0 CA--C 1.509 -0.63 0 N-CA-C 108.544 -0.909 . . . . 0.0 108.544 179.994 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -164.22 96.61 0.79 Allowed 'General case' 0 N--CA 1.477 0.906 0 CA-C-N 114.651 -1.158 . . . . 0.0 108.426 178.367 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 6.5 mp -120.91 157.31 30.15 Favored 'General case' 0 N--CA 1.495 1.788 0 CA-C-O 121.641 0.734 . . . . 0.0 111.557 -177.668 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 48.2 t -114.34 124.42 70.98 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.24 0 N-CA-C 108.277 -1.008 . . . . 0.0 108.277 177.266 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 31.7 m-85 -125.3 121.19 33.3 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 123.256 0.348 . . . . 0.0 110.909 -179.751 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 68.9 m-85 54.87 73.17 0.42 Allowed 'General case' 0 N--CA 1.469 0.504 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.392 178.196 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -78.73 -78.76 0.14 Allowed 'General case' 0 CA--C 1.536 0.419 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.201 -179.566 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 40.3 tt0 -111.5 102.2 10.57 Favored 'General case' 0 C--N 1.322 -0.588 0 N-CA-C 108.49 -0.93 . . . . 0.0 108.49 -179.996 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -158.27 134.62 9.42 Favored 'General case' 0 C--O 1.208 -1.1 0 CA-C-O 119.447 -0.311 . . . . 0.0 111.476 178.846 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 57.3 t -56.73 167.4 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.884 0 N-CA-C 107.564 -1.273 . . . . 0.0 107.564 176.791 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . -120.37 48.96 0.91 Allowed Glycine 0 N--CA 1.472 1.091 0 N-CA-C 110.852 -0.899 . . . . 0.0 110.852 -179.389 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' E' E ' 26' ' ' SER . . . . . 0.403 ' HG ' ' H ' ' F' ' 8' ' ' SER . 0.2 OUTLIER -63.37 -167.92 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.528 0 CA-C-O 120.767 0.318 . . . . 0.0 110.361 179.669 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 25.0 t-20 -71.71 76.35 0.84 Allowed 'General case' 0 N--CA 1.466 0.334 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.324 179.779 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -70.26 140.28 52.35 Favored 'General case' 0 N--CA 1.48 1.061 0 N-CA-C 109.438 -0.579 . . . . 0.0 109.438 179.462 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.47 -149.28 0.05 OUTLIER Glycine 0 C--N 1.335 0.49 0 N-CA-C 110.859 -0.896 . . . . 0.0 110.859 179.42 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -92.78 126.89 38.07 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-N 116.797 0.298 . . . . 0.0 110.402 179.713 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 76.8 mt -123.62 117.25 50.65 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.436 0 N-CA-C 106.365 -1.717 . . . . 0.0 106.365 178.591 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' E' E ' 32' ' ' ILE . . . . . 0.402 ' C ' ' H ' ' E' ' 34' ' ' LEU . 44.2 pt -151.46 -168.19 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.17 0 CA-C-O 121.117 0.484 . . . . 0.0 110.882 -178.868 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.13 5.43 7.85 Favored Glycine 0 CA--C 1.527 0.839 0 N-CA-C 111.315 -0.714 . . . . 0.0 111.315 179.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' E' E ' 34' ' ' LEU . . . . . 0.402 ' H ' ' C ' ' E' ' 32' ' ' ILE . 1.6 tt -77.74 127.23 32.1 Favored 'General case' 0 CA--C 1.548 0.88 0 N-CA-C 109.494 -0.558 . . . . 0.0 109.494 -179.886 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 28.6 ttt -164.7 144.52 7.34 Favored 'General case' 0 N--CA 1.469 0.51 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 178.267 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 32.9 m -156.38 162.84 1.55 Allowed 'Isoleucine or valine' 0 C--N 1.348 0.523 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 179.675 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.05 66.13 3.06 Favored Glycine 0 C--N 1.307 -1.072 0 CA-C-N 115.599 -0.728 . . . . 0.0 111.799 178.34 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 145.97 174.31 18.02 Favored Glycine 0 N--CA 1.474 1.191 0 N-CA-C 111.256 -0.738 . . . . 0.0 111.256 178.8 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' E' E ' 39' ' ' VAL . . . . . 0.521 ' H ' HG11 ' H' ' 39' ' ' VAL . 34.3 m -124.15 159.87 29.1 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.709 0 C-N-CA 123.32 0.648 . . . . 0.0 110.297 -179.206 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 24.6 t . . . . . 0 C--O 1.218 -0.595 0 O-C-N 124.156 0.91 . . . . 0.0 110.43 179.394 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' F' F ' 1' ' ' ASP . . . . . . . . . . . . . 11.7 m-20 . . . . . 0 N--CA 1.491 1.619 0 N-CA-C 109.221 -0.659 . . . . 0.0 109.221 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' F' F ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.23 129.95 41.98 Favored 'General case' 0 N--CA 1.468 0.435 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.46 -179.89 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 3' ' ' GLU . . . . . . . . . . . . . 43.5 tt0 -167.26 105.22 0.55 Allowed 'General case' 0 C--O 1.216 -0.671 0 N-CA-C 110.552 -0.166 . . . . 0.0 110.552 -179.782 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 31.5 m-85 -87.88 154.67 20.35 Favored 'General case' 0 N--CA 1.475 0.813 0 N-CA-C 110.019 -0.363 . . . . 0.0 110.019 179.434 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 5' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -144.03 139.4 28.96 Favored 'General case' 0 N--CA 1.478 0.966 0 CA-C-O 120.759 0.314 . . . . 0.0 110.214 179.46 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 41.3 t-80 -151.48 119.73 6.35 Favored 'General case' 0 N--CA 1.473 0.695 0 N-CA-C 109.282 -0.636 . . . . 0.0 109.282 179.124 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 7' ' ' ASP . . . . . 0.509 ' O ' ' OG ' ' I' ' 8' ' ' SER . 3.9 m-20 -69.62 147.81 50.19 Favored 'General case' 0 CA--C 1.533 0.317 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.909 179.994 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' F' F ' 8' ' ' SER . . . . . 0.513 ' OG ' ' O ' ' C' ' 7' ' ' ASP . 51.7 p -168.09 -173.12 1.96 Allowed 'General case' 0 N--CA 1.485 1.321 0 CA-C-O 121.22 0.533 . . . . 0.0 110.923 178.977 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.49 48.3 1.22 Allowed Glycine 0 N--CA 1.478 1.457 0 CA-C-N 115.767 -0.651 . . . . 0.0 111.714 179.466 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 47.7 p90 -64.02 132.84 51.81 Favored 'General case' 0 N--CA 1.474 0.736 0 O-C-N 122.648 -0.325 . . . . 0.0 111.792 -179.888 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 86.8 mt-10 -91.28 152.42 20.49 Favored 'General case' 0 N--CA 1.481 1.103 0 CA-C-O 121.166 0.508 . . . . 0.0 109.877 177.873 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -154.57 127.61 1.14 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.627 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 178.008 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 44.4 m-70 -135.44 144.13 46.29 Favored 'General case' 0 N--CA 1.482 1.144 0 CA-C-O 120.807 0.337 . . . . 0.0 111.6 -178.079 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 6.0 t60 -164.57 96.82 0.76 Allowed 'General case' 0 N--CA 1.485 1.284 0 CA-C-N 116.431 -0.349 . . . . 0.0 110.788 179.478 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 3.5 pt20 -107.71 -174.06 2.44 Favored 'General case' 0 CA--C 1.505 -0.778 0 N-CA-C 108.637 -0.875 . . . . 0.0 108.637 -179.97 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -164.53 96.8 0.77 Allowed 'General case' 0 N--CA 1.475 0.802 0 CA-C-N 114.645 -1.161 . . . . 0.0 108.336 178.533 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 6.5 mp -121.01 157.17 30.57 Favored 'General case' 0 N--CA 1.494 1.766 0 CA-C-O 121.51 0.671 . . . . 0.0 111.483 -177.733 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 48.1 t -114.04 124.24 70.49 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.227 0 N-CA-C 108.288 -1.004 . . . . 0.0 108.288 177.11 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 31.6 m-85 -125.03 121.05 33.25 Favored 'General case' 0 N--CA 1.487 1.407 0 CA-C-O 120.787 0.327 . . . . 0.0 110.937 -179.855 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 68.7 m-85 55.2 73.32 0.42 Allowed 'General case' 0 C--N 1.345 0.386 0 CA-C-N 116.0 -0.545 . . . . 0.0 111.654 178.097 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -79.02 -78.65 0.15 Allowed 'General case' 0 C--N 1.345 0.379 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.345 -179.262 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 40.6 tt0 -111.74 102.01 10.33 Favored 'General case' 0 C--N 1.323 -0.555 0 N-CA-C 108.449 -0.945 . . . . 0.0 108.449 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -158.14 134.7 9.61 Favored 'General case' 0 C--O 1.209 -1.046 0 CA-C-O 119.571 -0.252 . . . . 0.0 111.448 178.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 24' ' ' VAL . . . . . . . . . . . . . 63.6 t -57.13 166.89 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.885 0 N-CA-C 107.495 -1.298 . . . . 0.0 107.495 176.98 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -119.97 49.11 0.89 Allowed Glycine 0 N--CA 1.476 1.325 0 N-CA-C 110.792 -0.923 . . . . 0.0 110.792 -179.319 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 26' ' ' SER . . . . . 0.472 ' HG ' ' H ' ' D' ' 8' ' ' SER . 0.2 OUTLIER -63.45 -167.77 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.549 0 CA-C-O 120.779 0.323 . . . . 0.0 110.221 179.579 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 24.8 t-20 -71.72 76.12 0.84 Allowed 'General case' 0 C--O 1.223 -0.321 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.378 179.761 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -70.18 140.49 52.55 Favored 'General case' 0 N--CA 1.478 0.967 0 N-CA-C 109.449 -0.574 . . . . 0.0 109.449 179.587 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.53 -149.8 0.05 OUTLIER Glycine 0 C--N 1.333 0.412 0 N-CA-C 110.852 -0.899 . . . . 0.0 110.852 179.443 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -92.16 126.68 37.34 Favored 'General case' 0 N--CA 1.47 0.573 0 N-CA-C 110.235 -0.283 . . . . 0.0 110.235 179.659 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 78.3 mt -123.65 116.98 49.8 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.512 0 N-CA-C 106.351 -1.722 . . . . 0.0 106.351 178.461 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 44.5 pt -151.31 -167.99 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.192 0 CA-C-O 121.061 0.458 . . . . 0.0 110.862 -178.882 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.98 5.66 8.05 Favored Glycine 0 CA--C 1.527 0.791 0 N-CA-C 111.373 -0.691 . . . . 0.0 111.373 -179.95 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 1.5 tt -77.9 127.18 31.97 Favored 'General case' 0 CA--C 1.548 0.886 0 N-CA-C 109.465 -0.569 . . . . 0.0 109.465 -179.897 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 28.4 ttt -164.45 144.44 7.69 Favored 'General case' 0 N--CA 1.469 0.493 0 N-CA-C 108.773 -0.825 . . . . 0.0 108.773 178.223 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 32.9 m -156.26 162.75 1.59 Allowed 'Isoleucine or valine' 0 C--N 1.348 0.504 0 N-CA-C 108.292 -1.003 . . . . 0.0 108.292 179.566 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.16 66.28 2.96 Favored Glycine 0 C--N 1.307 -1.08 0 CA-C-N 115.691 -0.686 . . . . 0.0 111.854 178.366 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 145.79 174.42 17.95 Favored Glycine 0 N--CA 1.473 1.14 0 N-CA-C 111.313 -0.715 . . . . 0.0 111.313 178.863 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 39' ' ' VAL . . . . . 0.527 ' H ' HG11 ' I' ' 39' ' ' VAL . 34.4 m -124.47 159.78 30.0 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.669 0 C-N-CA 123.301 0.64 . . . . 0.0 110.224 -179.208 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 24.9 t . . . . . 0 C--O 1.218 -0.569 0 O-C-N 124.239 0.962 . . . . 0.0 110.517 179.507 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' G' G ' 1' ' ' ASP . . . . . . . . . . . . . 13.2 m-20 . . . . . 0 N--CA 1.491 1.598 0 N-CA-C 109.269 -0.641 . . . . 0.0 109.269 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' G' G ' 2' ' ' ALA . . . . . . . . . . . . . . . -63.17 128.84 37.7 Favored 'General case' 0 N--CA 1.468 0.426 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.69 179.67 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' G' G ' 3' ' ' GLU . . . . . . . . . . . . . 43.4 tt0 -168.06 106.36 0.5 Allowed 'General case' 0 N--CA 1.473 0.71 0 CA-C-O 120.424 0.154 . . . . 0.0 110.761 179.664 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 35.2 m-85 -89.79 154.69 19.71 Favored 'General case' 0 N--CA 1.474 0.736 0 N-CA-C 109.605 -0.517 . . . . 0.0 109.605 179.14 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' G' G ' 5' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -144.67 139.11 27.77 Favored 'General case' 0 N--CA 1.482 1.145 0 C-N-CA 122.544 0.338 . . . . 0.0 110.235 179.834 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 42.2 t-80 -150.8 120.87 7.19 Favored 'General case' 0 N--CA 1.474 0.726 0 N-CA-C 109.543 -0.54 . . . . 0.0 109.543 179.023 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -71.82 143.45 49.48 Favored 'General case' 0 N--CA 1.47 0.554 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.28 -179.766 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' G' G ' 8' ' ' SER . . . . . 0.604 ' OG ' ' O ' ' D' ' 7' ' ' ASP . 48.9 p -164.7 -170.93 2.13 Favored 'General case' 0 N--CA 1.476 0.828 0 CA-C-O 121.2 0.524 . . . . 0.0 110.534 178.83 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.52 49.01 1.23 Allowed Glycine 0 N--CA 1.479 1.528 0 N-CA-C 111.35 -0.7 . . . . 0.0 111.35 179.388 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 50.1 p90 -65.03 133.36 51.5 Favored 'General case' 0 N--CA 1.473 0.704 0 CA-C-O 120.673 0.273 . . . . 0.0 111.67 -179.719 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 83.3 mt-10 -92.1 151.64 20.32 Favored 'General case' 0 N--CA 1.48 1.031 0 CA-C-O 121.108 0.48 . . . . 0.0 110.142 178.665 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -154.89 127.45 1.06 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.973 0 N-CA-C 107.853 -1.165 . . . . 0.0 107.853 178.293 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 47.4 m-70 -134.6 144.73 48.08 Favored 'General case' 0 N--CA 1.479 1.005 0 CA-C-N 115.561 -0.745 . . . . 0.0 111.488 -178.298 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 6.1 t60 -165.43 97.37 0.69 Allowed 'General case' 0 N--CA 1.482 1.131 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.377 178.989 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 3.6 pt20 -108.6 -174.72 2.58 Favored 'General case' 0 CA--C 1.506 -0.744 0 N-CA-C 108.433 -0.951 . . . . 0.0 108.433 -179.707 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -164.32 96.17 0.77 Allowed 'General case' 0 N--CA 1.474 0.758 0 CA-C-N 114.699 -1.137 . . . . 0.0 108.121 178.735 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 6.6 mp -120.58 155.61 33.34 Favored 'General case' 0 N--CA 1.497 1.924 0 CA-C-O 121.171 0.51 . . . . 0.0 111.771 -177.846 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 43.0 t -113.16 125.13 70.37 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.884 0 CA-C-N 114.757 -1.11 . . . . 0.0 108.128 176.477 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 33.1 m-85 -126.09 121.15 32.09 Favored 'General case' 0 C--N 1.369 1.424 0 CA-C-N 115.583 -0.735 . . . . 0.0 110.892 -179.699 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 67.2 m-85 54.8 72.95 0.43 Allowed 'General case' 0 C--O 1.238 0.459 0 CA-C-N 115.841 -0.618 . . . . 0.0 111.479 178.145 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -78.08 -77.96 0.15 Allowed 'General case' 0 N--CA 1.471 0.616 0 O-C-N 122.17 -0.331 . . . . 0.0 110.557 -178.939 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 40.4 tt0 -112.24 101.99 10.19 Favored 'General case' 0 C--N 1.323 -0.568 0 N-CA-C 108.093 -1.077 . . . . 0.0 108.093 179.917 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -157.88 135.91 10.8 Favored 'General case' 0 N--CA 1.476 0.867 0 O-C-N 122.401 -0.187 . . . . 0.0 111.488 178.826 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' G' G ' 24' ' ' VAL . . . . . . . . . . . . . 57.3 t -58.27 166.47 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.647 0 N-CA-C 107.555 -1.276 . . . . 0.0 107.555 176.986 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -119.05 49.4 0.87 Allowed Glycine 0 N--CA 1.479 1.524 0 N-CA-C 110.456 -1.058 . . . . 0.0 110.456 -179.47 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' G' G ' 26' ' ' SER . . . . . 0.404 ' HG ' ' CB ' ' E' ' 7' ' ' ASP . 0.2 OUTLIER -64.4 -168.09 0.03 OUTLIER 'General case' 0 N--CA 1.472 0.636 0 N-CA-C 109.904 -0.406 . . . . 0.0 109.904 179.645 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 25.1 t-20 -71.62 76.09 0.82 Allowed 'General case' 0 CA--C 1.536 0.438 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.324 179.928 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -69.57 140.64 53.84 Favored 'General case' 0 N--CA 1.478 0.955 0 N-CA-C 109.562 -0.533 . . . . 0.0 109.562 179.604 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.99 -147.81 0.05 OUTLIER Glycine 0 C--N 1.337 0.587 0 N-CA-C 110.443 -1.063 . . . . 0.0 110.443 179.612 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -92.88 125.99 37.75 Favored 'General case' 0 N--CA 1.467 0.419 0 C-N-CA 122.65 0.38 . . . . 0.0 110.93 -179.824 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 76.6 mt -123.45 117.65 52.03 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.811 0 N-CA-C 106.417 -1.697 . . . . 0.0 106.417 178.238 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 44.0 pt -152.47 -167.61 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 CA-C-N 119.819 1.19 . . . . 0.0 110.031 -179.225 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.29 6.26 10.15 Favored Glycine 0 N--CA 1.466 0.671 0 N-CA-C 111.056 -0.818 . . . . 0.0 111.056 179.881 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 1.5 tt -79.49 125.7 29.91 Favored 'General case' 0 CA--C 1.545 0.773 0 N-CA-C 109.516 -0.55 . . . . 0.0 109.516 -179.702 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 27.7 ttt -162.86 146.17 10.97 Favored 'General case' 0 N--CA 1.47 0.553 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 178.534 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 32.7 m -156.95 162.01 1.69 Allowed 'Isoleucine or valine' 0 C--N 1.35 0.603 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 -179.99 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.48 66.63 2.7 Favored Glycine 0 C--N 1.31 -0.913 0 CA-C-N 115.541 -0.754 . . . . 0.0 112.104 177.818 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 146.72 175.6 19.82 Favored Glycine 0 N--CA 1.475 1.251 0 N-CA-C 110.559 -1.016 . . . . 0.0 110.559 178.994 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' G' G ' 39' ' ' VAL . . . . . 0.513 HG11 ' H ' ' D' ' 39' ' ' VAL . 34.9 m -125.77 159.71 33.4 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.912 0 C-N-CA 123.092 0.557 . . . . 0.0 110.484 -179.408 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 26.3 t . . . . . 0 C--O 1.22 -0.488 0 CA-C-O 118.395 -0.812 . . . . 0.0 110.751 179.082 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' H' H ' 1' ' ' ASP . . . . . . . . . . . . . 13.3 m-20 . . . . . 0 N--CA 1.492 1.66 0 N-CA-C 109.343 -0.614 . . . . 0.0 109.343 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' H' H ' 2' ' ' ALA . . . . . . . . . . . . . . . -63.01 128.63 36.76 Favored 'General case' 0 N--CA 1.469 0.485 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.581 179.777 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' H' H ' 3' ' ' GLU . . . . . . . . . . . . . 43.2 tt0 -167.89 106.48 0.52 Allowed 'General case' 0 N--CA 1.471 0.586 0 CA-C-O 120.496 0.189 . . . . 0.0 110.722 179.642 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 34.9 m-85 -89.89 154.77 19.61 Favored 'General case' 0 N--CA 1.474 0.77 0 N-CA-C 109.518 -0.549 . . . . 0.0 109.518 179.263 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' H' H ' 5' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -144.74 139.68 28.04 Favored 'General case' 0 N--CA 1.485 1.313 0 N-CA-C 110.04 -0.355 . . . . 0.0 110.04 179.838 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 41.2 t-80 -151.58 120.7 6.72 Favored 'General case' 0 N--CA 1.474 0.76 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 179.068 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -71.65 143.82 49.62 Favored 'General case' 0 N--CA 1.469 0.511 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.308 -179.756 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' H' H ' 8' ' ' SER . . . . . 0.508 ' OG ' ' O ' ' E' ' 7' ' ' ASP . 52.2 p -164.81 -171.18 2.19 Favored 'General case' 0 N--CA 1.475 0.809 0 CA-C-O 121.126 0.489 . . . . 0.0 110.489 178.921 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.76 48.35 1.28 Allowed Glycine 0 N--CA 1.479 1.541 0 CA-C-N 115.783 -0.644 . . . . 0.0 111.551 179.336 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 50.1 p90 -64.51 133.06 51.64 Favored 'General case' 0 N--CA 1.471 0.624 0 N-CA-C 111.785 0.291 . . . . 0.0 111.785 -179.685 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 83.1 mt-10 -91.69 151.56 20.61 Favored 'General case' 0 N--CA 1.479 0.984 0 CA-C-O 121.068 0.461 . . . . 0.0 110.183 178.476 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -154.67 127.88 1.17 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.979 0 N-CA-C 107.885 -1.154 . . . . 0.0 107.885 178.08 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 47.3 m-70 -134.75 145.53 48.52 Favored 'General case' 0 N--CA 1.478 0.955 0 CA-C-N 115.676 -0.693 . . . . 0.0 111.359 -178.419 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 6.0 t60 -166.24 97.37 0.6 Allowed 'General case' 0 N--CA 1.482 1.146 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.346 178.794 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 3.6 pt20 -108.33 -174.3 2.49 Favored 'General case' 0 CA--C 1.505 -0.757 0 N-CA-C 108.425 -0.954 . . . . 0.0 108.425 -179.728 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -164.84 96.22 0.72 Allowed 'General case' 0 N--CA 1.475 0.799 0 CA-C-N 114.647 -1.16 . . . . 0.0 108.018 178.66 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 6.5 mp -120.53 156.02 32.43 Favored 'General case' 0 N--CA 1.497 1.899 0 CA-C-O 121.239 0.543 . . . . 0.0 111.972 -177.949 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 41.4 t -113.7 124.73 70.63 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.07 0 CA-C-N 114.819 -1.082 . . . . 0.0 108.227 176.658 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 33.3 m-85 -125.73 121.31 33.04 Favored 'General case' 0 C--N 1.368 1.388 0 CA-C-N 115.459 -0.792 . . . . 0.0 110.863 -179.491 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 68.0 m-85 54.3 72.69 0.44 Allowed 'General case' 0 C--O 1.237 0.422 0 CA-C-N 115.858 -0.61 . . . . 0.0 111.587 178.11 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.63 -78.13 0.14 Allowed 'General case' 0 N--CA 1.471 0.622 0 O-C-N 122.203 -0.31 . . . . 0.0 110.571 -179.033 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 40.9 tt0 -112.12 101.99 10.22 Favored 'General case' 0 C--N 1.321 -0.632 0 N-CA-C 108.091 -1.077 . . . . 0.0 108.091 -179.99 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -157.97 135.78 10.61 Favored 'General case' 0 N--CA 1.477 0.913 0 N-CA-C 111.445 0.165 . . . . 0.0 111.445 178.863 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' H' H ' 24' ' ' VAL . . . . . . . . . . . . . 59.2 t -58.3 166.35 0.51 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.606 0 N-CA-C 107.682 -1.229 . . . . 0.0 107.682 177.197 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . -118.76 49.42 0.87 Allowed Glycine 0 N--CA 1.478 1.444 0 N-CA-C 110.653 -0.979 . . . . 0.0 110.653 -179.498 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -64.67 -167.85 0.03 OUTLIER 'General case' 0 N--CA 1.472 0.668 0 CA-C-N 116.97 0.385 . . . . 0.0 110.0 179.662 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 24.9 t-20 -71.77 76.39 0.86 Allowed 'General case' 0 CA--C 1.535 0.4 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.317 179.871 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -69.89 140.74 53.18 Favored 'General case' 0 N--CA 1.478 0.953 0 N-CA-C 109.552 -0.536 . . . . 0.0 109.552 179.483 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.96 -147.82 0.05 OUTLIER Glycine 0 C--N 1.338 0.653 0 N-CA-C 110.329 -1.108 . . . . 0.0 110.329 179.541 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -93.5 125.77 38.29 Favored 'General case' 0 N--CA 1.465 0.307 0 C-N-CA 122.58 0.352 . . . . 0.0 110.872 -179.61 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 76.1 mt -122.92 117.55 52.12 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.757 0 N-CA-C 106.431 -1.692 . . . . 0.0 106.431 178.315 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 44.8 pt -152.04 -167.84 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 CA-C-N 119.807 1.185 . . . . 0.0 109.98 -179.469 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.93 5.8 10.53 Favored Glycine 0 N--CA 1.466 0.661 0 N-CA-C 110.964 -0.854 . . . . 0.0 110.964 179.86 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 1.5 tt -79.04 124.95 28.77 Favored 'General case' 0 CA--C 1.544 0.744 0 N-CA-C 109.725 -0.472 . . . . 0.0 109.725 -179.515 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 27.8 ttt -162.19 145.97 12.01 Favored 'General case' 0 N--CA 1.469 0.502 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 178.635 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 32.6 m -157.08 161.69 1.76 Allowed 'Isoleucine or valine' 0 C--N 1.349 0.566 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 -179.895 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.94 66.2 3.01 Favored Glycine 0 C--N 1.309 -0.93 0 CA-C-N 115.498 -0.773 . . . . 0.0 112.17 177.935 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 146.92 175.63 20.01 Favored Glycine 0 N--CA 1.474 1.197 0 N-CA-C 110.639 -0.984 . . . . 0.0 110.639 178.893 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' H' H ' 39' ' ' VAL . . . . . 0.521 HG11 ' H ' ' E' ' 39' ' ' VAL . 34.9 m -125.2 159.96 31.54 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.927 0 C-N-CA 123.173 0.589 . . . . 0.0 110.537 -179.487 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 25.1 t . . . . . 0 N--CA 1.47 0.54 0 CA-C-O 118.439 -0.791 . . . . 0.0 110.819 179.233 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' I' I ' 1' ' ' ASP . . . . . . . . . . . . . 13.0 m-20 . . . . . 0 N--CA 1.491 1.578 0 N-CA-C 109.461 -0.57 . . . . 0.0 109.461 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' I' I ' 2' ' ' ALA . . . . . . . . . . . . . . . -63.5 128.5 36.12 Favored 'General case' 0 N--CA 1.468 0.475 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.598 179.752 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' I' I ' 3' ' ' GLU . . . . . . . . . . . . . 43.3 tt0 -167.7 106.9 0.55 Allowed 'General case' 0 N--CA 1.471 0.61 0 CA-C-O 120.547 0.213 . . . . 0.0 110.704 179.709 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 35.9 m-85 -90.33 154.56 19.61 Favored 'General case' 0 N--CA 1.474 0.739 0 N-CA-C 109.538 -0.541 . . . . 0.0 109.538 179.152 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' I' I ' 5' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -144.51 139.17 28.08 Favored 'General case' 0 N--CA 1.484 1.255 0 N-CA-C 110.038 -0.356 . . . . 0.0 110.038 179.815 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 41.6 t-80 -150.81 120.73 7.12 Favored 'General case' 0 N--CA 1.473 0.679 0 N-CA-C 109.385 -0.598 . . . . 0.0 109.385 178.907 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 4.0 m-20 -71.48 143.94 49.86 Favored 'General case' 0 N--CA 1.47 0.531 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.141 -179.888 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' I' I ' 8' ' ' SER . . . . . 0.509 ' OG ' ' O ' ' F' ' 7' ' ' ASP . 52.5 p -165.05 -171.14 2.13 Favored 'General case' 0 N--CA 1.474 0.758 0 CA-C-O 121.081 0.467 . . . . 0.0 110.621 178.89 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.53 48.81 1.25 Allowed Glycine 0 N--CA 1.479 1.514 0 N-CA-C 111.502 -0.639 . . . . 0.0 111.502 179.348 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 50.2 p90 -65.12 132.94 50.49 Favored 'General case' 0 N--CA 1.472 0.663 0 N-CA-C 111.772 0.286 . . . . 0.0 111.772 -179.718 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 83.6 mt-10 -91.43 151.57 20.75 Favored 'General case' 0 N--CA 1.478 0.953 0 CA-C-O 121.045 0.45 . . . . 0.0 110.265 178.539 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -154.91 127.42 1.05 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.047 0 N-CA-C 107.91 -1.144 . . . . 0.0 107.91 178.198 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 46.9 m-70 -134.48 145.15 48.54 Favored 'General case' 0 N--CA 1.478 0.933 0 CA-C-N 115.61 -0.723 . . . . 0.0 111.407 -178.196 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 6.1 t60 -165.75 97.25 0.65 Allowed 'General case' 0 N--CA 1.48 1.03 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.378 178.838 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 3.6 pt20 -108.39 -174.55 2.55 Favored 'General case' 0 CA--C 1.504 -0.809 0 N-CA-C 108.381 -0.97 . . . . 0.0 108.381 -179.757 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -164.54 96.33 0.75 Allowed 'General case' 0 N--CA 1.474 0.755 0 CA-C-N 114.608 -1.178 . . . . 0.0 108.116 178.641 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 6.4 mp -120.6 156.07 32.42 Favored 'General case' 0 N--CA 1.497 1.914 0 CA-C-O 121.232 0.539 . . . . 0.0 111.767 -177.882 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 41.4 t -113.77 125.06 70.98 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.884 0 CA-C-N 114.753 -1.112 . . . . 0.0 108.207 176.608 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 33.6 m-85 -126.0 121.38 32.86 Favored 'General case' 0 C--N 1.368 1.41 0 CA-C-N 115.502 -0.772 . . . . 0.0 110.829 -179.449 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 67.9 m-85 54.25 73.29 0.4 Allowed 'General case' 0 C--N 1.347 0.467 0 CA-C-N 115.925 -0.58 . . . . 0.0 111.464 178.136 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -78.18 -78.01 0.15 Allowed 'General case' 0 N--CA 1.475 0.802 0 O-C-N 122.296 -0.253 . . . . 0.0 110.453 -179.079 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 40.7 tt0 -112.02 102.12 10.36 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 108.088 -1.079 . . . . 0.0 108.088 179.802 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -157.88 135.92 10.81 Favored 'General case' 0 N--CA 1.478 0.97 0 N-CA-C 111.409 0.152 . . . . 0.0 111.409 178.784 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' I' I ' 24' ' ' VAL . . . . . . . . . . . . . 59.5 t -58.57 166.32 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.573 0 N-CA-C 107.658 -1.238 . . . . 0.0 107.658 177.203 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . -118.69 49.0 0.89 Allowed Glycine 0 N--CA 1.479 1.524 0 N-CA-C 110.556 -1.017 . . . . 0.0 110.556 -179.392 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' I' I ' 26' ' ' SER . . . . . 0.42 ' HG ' ' CB ' ' D' ' 7' ' ' ASP . 0.2 OUTLIER -64.3 -167.87 0.03 OUTLIER 'General case' 0 N--CA 1.472 0.648 0 CA-C-N 116.951 0.376 . . . . 0.0 110.092 179.641 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 24.9 t-20 -71.74 76.45 0.85 Allowed 'General case' 0 CA--C 1.536 0.419 0 CA-C-N 116.07 -0.513 . . . . 0.0 110.219 179.884 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -70.08 140.86 52.81 Favored 'General case' 0 N--CA 1.478 0.961 0 N-CA-C 109.492 -0.559 . . . . 0.0 109.492 179.496 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -65.02 -147.67 0.05 OUTLIER Glycine 0 C--N 1.337 0.628 0 N-CA-C 110.416 -1.074 . . . . 0.0 110.416 179.577 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -93.3 125.89 38.14 Favored 'General case' 0 N--CA 1.469 0.496 0 C-N-CA 122.587 0.355 . . . . 0.0 110.924 -179.953 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 77.0 mt -123.2 117.3 51.15 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.708 0 N-CA-C 106.474 -1.676 . . . . 0.0 106.474 178.255 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 44.6 pt -152.13 -167.9 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 CA-C-N 119.851 1.205 . . . . 0.0 109.979 -179.284 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.07 5.52 10.2 Favored Glycine 0 N--CA 1.466 0.674 0 N-CA-C 110.969 -0.852 . . . . 0.0 110.969 179.86 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 1.5 tt -78.6 125.82 29.89 Favored 'General case' 0 CA--C 1.546 0.798 0 N-CA-C 109.6 -0.519 . . . . 0.0 109.6 -179.675 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 27.7 ttt -162.76 146.01 11.08 Favored 'General case' 0 N--CA 1.47 0.561 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 178.454 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 32.5 m -157.08 161.78 1.73 Allowed 'Isoleucine or valine' 0 C--N 1.348 0.522 0 N-CA-C 108.6 -0.889 . . . . 0.0 108.6 179.928 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.76 66.42 2.86 Favored Glycine 0 C--N 1.308 -0.981 0 CA-C-N 115.557 -0.747 . . . . 0.0 112.114 177.863 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 146.64 175.76 19.88 Favored Glycine 0 N--CA 1.476 1.334 0 N-CA-C 110.57 -1.012 . . . . 0.0 110.57 178.95 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' I' I ' 39' ' ' VAL . . . . . 0.527 HG11 ' H ' ' F' ' 39' ' ' VAL . 35.0 m -125.69 160.11 32.64 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.915 0 C-N-CA 123.138 0.575 . . . . 0.0 110.53 -179.381 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 25.9 t . . . . . 0 C--O 1.218 -0.557 0 CA-C-O 118.449 -0.786 . . . . 0.0 110.713 179.216 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 9.3 m-20 . . . . . 0 N--CA 1.489 1.492 0 N-CA-C 108.992 -0.744 . . . . 0.0 108.992 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.85 132.42 48.64 Favored 'General case' 0 CA--C 1.539 0.529 0 N-CA-C 110.202 -0.295 . . . . 0.0 110.202 -179.754 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 44.7 tt0 -168.23 105.58 0.47 Allowed 'General case' 0 C--O 1.213 -0.843 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 -179.237 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 39.4 m-85 -85.66 152.67 22.92 Favored 'General case' 0 N--CA 1.477 0.882 0 N-CA-C 109.99 -0.374 . . . . 0.0 109.99 179.489 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -143.93 140.15 29.54 Favored 'General case' 0 N--CA 1.48 1.048 0 N-CA-C 110.016 -0.364 . . . . 0.0 110.016 179.67 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 43.3 t-80 -151.84 119.67 6.16 Favored 'General case' 0 N--CA 1.47 0.551 0 N-CA-C 109.224 -0.658 . . . . 0.0 109.224 179.291 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' ASP . . . . . 0.513 ' O ' ' OG ' ' D' ' 8' ' ' SER . 4.6 m-20 -69.14 148.9 49.27 Favored 'General case' 0 N--CA 1.466 0.34 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.466 179.879 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 54.8 p -168.21 -173.79 2.12 Favored 'General case' 0 N--CA 1.482 1.162 0 C-N-CA 122.669 0.388 . . . . 0.0 110.718 179.053 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.79 47.79 1.33 Allowed Glycine 0 N--CA 1.482 1.735 0 CA-C-N 116.013 -0.539 . . . . 0.0 112.147 -179.911 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 50.1 p90 -65.06 132.67 49.83 Favored 'General case' 0 N--CA 1.473 0.686 0 CA-C-O 120.716 0.293 . . . . 0.0 111.532 179.899 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 49.0 mt-10 -92.66 152.46 19.54 Favored 'General case' 0 N--CA 1.477 0.918 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 178.398 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.0 p -153.13 128.37 1.55 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.632 0 N-CA-C 107.847 -1.168 . . . . 0.0 107.847 178.382 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 47.2 m-70 -134.87 145.83 48.65 Favored 'General case' 0 N--CA 1.492 1.648 0 CA-C-N 119.096 0.862 . . . . 0.0 111.327 -179.127 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 6.1 t60 -165.73 97.51 0.66 Allowed 'General case' 0 N--CA 1.48 1.05 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.809 179.496 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 11.9 pt20 -111.9 -174.78 2.54 Favored 'General case' 0 CA--C 1.503 -0.86 0 N-CA-C 108.355 -0.98 . . . . 0.0 108.355 -179.849 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -163.27 99.13 0.94 Allowed 'General case' 0 N--CA 1.474 0.749 0 CA-C-N 114.527 -1.215 . . . . 0.0 108.347 178.582 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 6.9 mp -121.83 157.07 31.9 Favored 'General case' 0 N--CA 1.497 1.909 0 CA-C-O 121.945 0.879 . . . . 0.0 110.86 -178.338 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 60.0 t -112.54 126.84 69.98 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.179 0 CA-C-O 117.877 -1.058 . . . . 0.0 108.298 177.808 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 28.8 m-85 -127.11 122.52 34.49 Favored 'General case' 0 N--CA 1.496 1.859 0 CA-C-N 120.197 1.362 . . . . 0.0 110.336 179.302 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 68.3 m-85 53.95 73.98 0.35 Allowed 'General case' 0 N--CA 1.47 0.546 0 CA-C-O 121.544 0.687 . . . . 0.0 111.745 178.51 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -80.22 -78.13 0.18 Allowed 'General case' 0 C--N 1.353 0.758 0 CA-C-N 115.117 -0.947 . . . . 0.0 110.42 -179.739 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 40.3 tt0 -112.07 101.87 10.12 Favored 'General case' 0 N--CA 1.47 0.563 0 N-CA-C 108.493 -0.928 . . . . 0.0 108.493 179.927 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -158.69 134.65 9.0 Favored 'General case' 0 N--CA 1.481 1.092 0 CA-C-O 119.388 -0.339 . . . . 0.0 111.254 179.026 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 61.9 t -58.36 163.4 0.72 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.795 0 N-CA-C 108.227 -1.027 . . . . 0.0 108.227 177.173 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -116.04 48.07 0.98 Allowed Glycine 0 N--CA 1.476 1.326 0 N-CA-C 111.759 -0.536 . . . . 0.0 111.759 -179.402 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -62.07 -168.59 0.02 OUTLIER 'General case' 0 N--CA 1.469 0.499 0 O-C-N 123.834 0.373 . . . . 0.0 110.218 179.284 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 24.7 t-20 -72.43 79.83 1.04 Allowed 'General case' 0 N--CA 1.466 0.335 0 N-CA-C 110.048 -0.352 . . . . 0.0 110.048 179.221 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -73.28 140.32 46.73 Favored 'General case' 0 N--CA 1.471 0.625 0 N-CA-C 109.012 -0.736 . . . . 0.0 109.012 179.43 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.42 -148.9 0.03 OUTLIER Glycine 0 C--N 1.337 0.622 0 N-CA-C 110.383 -1.087 . . . . 0.0 110.383 179.443 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -93.94 128.54 40.31 Favored 'General case' 0 N--CA 1.471 0.604 0 N-CA-C 110.076 -0.342 . . . . 0.0 110.076 179.904 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 72.4 mt -125.0 116.77 48.13 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.874 0 N-CA-C 106.782 -1.562 . . . . 0.0 106.782 178.764 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 38.9 pt -151.01 -169.69 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.356 0.88 0 CA-C-N 115.857 -0.611 . . . . 0.0 111.206 -178.527 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.41 5.37 11.41 Favored Glycine 0 C--N 1.336 0.577 0 N-CA-C 110.912 -0.875 . . . . 0.0 110.912 179.673 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 1.5 tt -78.42 127.12 31.74 Favored 'General case' 0 CA--C 1.543 0.684 0 N-CA-C 109.44 -0.578 . . . . 0.0 109.44 -179.617 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 28.6 ttt -164.59 143.86 7.22 Favored 'General case' 0 N--CA 1.466 0.368 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 178.404 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 35.3 m -155.92 163.28 1.51 Allowed 'Isoleucine or valine' 0 C--O 1.219 -0.525 0 N-CA-C 108.339 -0.985 . . . . 0.0 108.339 179.376 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.78 66.56 2.75 Favored Glycine 0 C--N 1.303 -1.292 0 CA-C-N 116.147 -0.479 . . . . 0.0 112.136 178.631 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 146.0 173.54 17.34 Favored Glycine 0 N--CA 1.475 1.243 0 N-CA-C 110.649 -0.98 . . . . 0.0 110.649 179.138 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.485 ' H ' HG11 ' D' ' 39' ' ' VAL . 35.6 m -123.96 159.98 28.53 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.861 0 C-N-CA 123.579 0.752 . . . . 0.0 110.552 -179.858 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 25.2 t . . . . . 0 C--O 1.22 -0.46 0 CA-C-O 118.323 -0.846 . . . . 0.0 110.78 179.568 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' B' B ' 1' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 . . . . . 0 N--CA 1.49 1.534 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' B' B ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.39 132.33 48.71 Favored 'General case' 0 CA--C 1.54 0.593 0 CA-C-N 116.56 -0.291 . . . . 0.0 110.229 -179.821 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 3' ' ' GLU . . . . . . . . . . . . . 44.6 tt0 -168.2 105.51 0.48 Allowed 'General case' 0 N--CA 1.474 0.728 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 -179.169 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 39.4 m-85 -85.59 152.47 23.11 Favored 'General case' 0 N--CA 1.475 0.807 0 N-CA-C 109.99 -0.374 . . . . 0.0 109.99 179.534 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -143.71 139.98 29.78 Favored 'General case' 0 N--CA 1.482 1.139 0 N-CA-C 109.977 -0.379 . . . . 0.0 109.977 179.693 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 40.5 t-80 -151.74 119.18 6.0 Favored 'General case' 0 N--CA 1.473 0.724 0 N-CA-C 109.238 -0.652 . . . . 0.0 109.238 179.216 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 7' ' ' ASP . . . . . 0.501 ' O ' ' OG ' ' E' ' 8' ' ' SER . 4.3 m-20 -68.89 148.15 50.64 Favored 'General case' 0 CA--C 1.535 0.385 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.639 179.865 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 8' ' ' SER . . . . . . . . . . . . . 54.3 p -167.44 -173.79 2.34 Favored 'General case' 0 N--CA 1.48 1.068 0 C-N-CA 122.575 0.35 . . . . 0.0 110.701 179.072 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.94 47.92 1.3 Allowed Glycine 0 N--CA 1.482 1.703 0 CA-C-N 115.991 -0.549 . . . . 0.0 112.178 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 50.1 p90 -65.18 132.7 49.8 Favored 'General case' 0 N--CA 1.472 0.633 0 O-C-N 122.716 -0.285 . . . . 0.0 111.663 179.782 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 48.5 mt-10 -92.55 152.77 19.45 Favored 'General case' 0 N--CA 1.477 0.913 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 178.331 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.0 p -153.43 128.45 1.51 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.587 0 N-CA-C 107.737 -1.209 . . . . 0.0 107.737 178.314 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 47.5 m-70 -135.0 145.81 48.45 Favored 'General case' 0 N--CA 1.492 1.639 0 CA-C-N 118.904 0.775 . . . . 0.0 111.303 -179.103 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 6.2 t60 -165.66 97.46 0.66 Allowed 'General case' 0 N--CA 1.482 1.133 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.648 179.452 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 12.0 pt20 -111.76 -174.34 2.44 Favored 'General case' 0 CA--C 1.506 -0.749 0 N-CA-C 108.362 -0.977 . . . . 0.0 108.362 -179.883 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -163.87 99.07 0.87 Allowed 'General case' 0 N--CA 1.474 0.77 0 CA-C-N 114.718 -1.128 . . . . 0.0 108.26 178.608 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 6.8 mp -121.62 157.0 31.77 Favored 'General case' 0 N--CA 1.497 1.916 0 CA-C-O 121.936 0.875 . . . . 0.0 110.998 -178.294 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 61.1 t -112.55 127.6 69.68 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.07 0 N-CA-C 108.122 -1.066 . . . . 0.0 108.122 177.574 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 29.0 m-85 -127.99 122.36 32.11 Favored 'General case' 0 N--CA 1.495 1.802 0 CA-C-N 119.638 1.108 . . . . 0.0 110.219 179.515 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 68.7 m-85 53.23 74.46 0.3 Allowed 'General case' 0 CA--C 1.54 0.566 0 CA-C-O 121.558 0.694 . . . . 0.0 111.735 178.573 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -80.71 -77.85 0.19 Allowed 'General case' 0 C--N 1.35 0.6 0 CA-C-N 115.075 -0.966 . . . . 0.0 110.45 -179.788 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 40.5 tt0 -112.22 101.9 10.1 Favored 'General case' 0 N--CA 1.471 0.615 0 N-CA-C 108.417 -0.957 . . . . 0.0 108.417 179.786 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -158.68 134.54 8.94 Favored 'General case' 0 N--CA 1.484 1.23 0 CA-C-O 119.444 -0.312 . . . . 0.0 111.16 178.85 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 61.1 t -57.98 163.82 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.806 0 N-CA-C 108.249 -1.019 . . . . 0.0 108.249 177.209 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -116.22 48.22 0.96 Allowed Glycine 0 N--CA 1.475 1.288 0 N-CA-C 111.625 -0.59 . . . . 0.0 111.625 -179.446 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -62.27 -169.06 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.531 0 O-C-N 123.76 0.33 . . . . 0.0 110.242 179.238 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 25.1 t-20 -72.2 79.68 0.97 Allowed 'General case' 0 N--CA 1.467 0.393 0 N-CA-C 109.881 -0.414 . . . . 0.0 109.881 179.307 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -72.99 140.66 47.5 Favored 'General case' 0 N--CA 1.472 0.674 0 N-CA-C 109.105 -0.702 . . . . 0.0 109.105 179.417 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.86 -149.1 0.04 OUTLIER Glycine 0 C--N 1.338 0.645 0 N-CA-C 110.349 -1.1 . . . . 0.0 110.349 179.582 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -93.75 128.47 39.99 Favored 'General case' 0 N--CA 1.473 0.679 0 N-CA-C 110.036 -0.357 . . . . 0.0 110.036 179.882 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 72.5 mt -125.08 117.14 49.15 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.859 0 N-CA-C 106.723 -1.584 . . . . 0.0 106.723 178.768 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 39.6 pt -151.47 -169.94 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.356 0.887 0 CA-C-N 115.874 -0.603 . . . . 0.0 111.119 -178.364 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.68 5.26 12.31 Favored Glycine 0 C--N 1.337 0.614 0 N-CA-C 110.894 -0.882 . . . . 0.0 110.894 179.702 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 1.5 tt -78.42 126.67 31.09 Favored 'General case' 0 CA--C 1.545 0.76 0 N-CA-C 109.441 -0.577 . . . . 0.0 109.441 -179.521 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 28.5 ttt -164.12 143.66 7.83 Favored 'General case' 0 N--CA 1.467 0.378 0 N-CA-C 108.722 -0.844 . . . . 0.0 108.722 178.456 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 35.7 m -155.88 162.98 1.57 Allowed 'Isoleucine or valine' 0 C--O 1.22 -0.491 0 N-CA-C 108.343 -0.984 . . . . 0.0 108.343 179.519 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.81 66.95 2.47 Favored Glycine 0 C--N 1.303 -1.291 0 CA-C-N 116.183 -0.462 . . . . 0.0 112.076 178.591 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 145.33 173.24 16.41 Favored Glycine 0 N--CA 1.474 1.208 0 N-CA-C 110.69 -0.964 . . . . 0.0 110.69 179.181 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 39' ' ' VAL . . . . . 0.508 ' H ' HG11 ' E' ' 39' ' ' VAL . 35.7 m -123.65 159.84 27.95 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.934 0 C-N-CA 123.608 0.763 . . . . 0.0 110.713 -179.769 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 24.4 t . . . . . 0 N--CA 1.469 0.522 0 CA-C-O 118.339 -0.839 . . . . 0.0 110.599 179.53 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' C' C ' 1' ' ' ASP . . . . . . . . . . . . . 8.9 m-20 . . . . . 0 N--CA 1.49 1.548 0 N-CA-C 108.795 -0.817 . . . . 0.0 108.795 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' C' C ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.77 132.73 49.43 Favored 'General case' 0 CA--C 1.539 0.538 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.213 -179.745 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 3' ' ' GLU . . . . . . . . . . . . . 44.6 tt0 -168.5 105.61 0.45 Allowed 'General case' 0 C--O 1.214 -0.776 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 -179.192 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 40.3 m-85 -85.75 152.45 23.05 Favored 'General case' 0 N--CA 1.476 0.842 0 N-CA-C 110.031 -0.359 . . . . 0.0 110.031 179.532 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -143.63 139.98 29.89 Favored 'General case' 0 N--CA 1.482 1.134 0 CA-C-O 120.872 0.368 . . . . 0.0 110.05 179.762 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 42.1 t-80 -151.74 119.16 5.99 Favored 'General case' 0 N--CA 1.472 0.656 0 N-CA-C 109.26 -0.644 . . . . 0.0 109.26 179.173 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 7' ' ' ASP . . . . . 0.497 ' O ' ' OG ' ' F' ' 8' ' ' SER . 4.2 m-20 -68.77 148.47 50.28 Favored 'General case' 0 N--CA 1.468 0.443 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.52 179.783 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' C' C ' 8' ' ' SER . . . . . . . . . . . . . 54.2 p -167.97 -173.94 2.23 Favored 'General case' 0 N--CA 1.48 1.049 0 CA-C-O 120.874 0.368 . . . . 0.0 110.677 179.137 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.05 47.75 1.31 Allowed Glycine 0 N--CA 1.482 1.751 0 CA-C-N 115.968 -0.56 . . . . 0.0 112.072 -179.926 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 50.6 p90 -65.04 132.58 49.59 Favored 'General case' 0 N--CA 1.472 0.658 0 CA-C-O 120.778 0.323 . . . . 0.0 111.637 179.737 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 48.6 mt-10 -92.48 152.96 19.39 Favored 'General case' 0 N--CA 1.475 0.79 0 N-CA-C 109.738 -0.468 . . . . 0.0 109.738 178.395 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.0 p -153.65 128.62 1.5 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.523 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 178.263 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 46.1 m-70 -135.17 145.72 48.02 Favored 'General case' 0 N--CA 1.492 1.635 0 CA-C-N 118.931 0.787 . . . . 0.0 111.317 -179.057 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 6.2 t60 -165.52 97.52 0.68 Allowed 'General case' 0 N--CA 1.482 1.162 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.688 179.52 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 12.0 pt20 -112.0 -174.47 2.47 Favored 'General case' 0 CA--C 1.504 -0.825 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 -179.889 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -163.62 99.12 0.9 Allowed 'General case' 0 N--CA 1.473 0.677 0 CA-C-N 114.708 -1.133 . . . . 0.0 108.261 178.777 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 6.8 mp -121.71 157.07 31.74 Favored 'General case' 0 N--CA 1.497 1.902 0 CA-C-O 121.965 0.888 . . . . 0.0 110.994 -178.342 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 61.9 t -112.71 127.4 69.96 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.151 0 N-CA-C 108.146 -1.057 . . . . 0.0 108.146 177.612 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 28.9 m-85 -127.82 122.17 32.01 Favored 'General case' 0 N--CA 1.494 1.765 0 CA-C-N 119.673 1.124 . . . . 0.0 110.197 179.513 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 68.7 m-85 53.42 74.55 0.3 Allowed 'General case' 0 CA--C 1.539 0.523 0 CA-C-O 121.57 0.7 . . . . 0.0 111.787 178.612 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -80.62 -78.12 0.18 Allowed 'General case' 0 C--N 1.35 0.598 0 CA-C-N 114.961 -1.018 . . . . 0.0 110.379 -179.805 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 40.3 tt0 -112.02 102.05 10.3 Favored 'General case' 0 N--CA 1.469 0.522 0 N-CA-C 108.506 -0.924 . . . . 0.0 108.506 179.82 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -158.76 134.67 8.94 Favored 'General case' 0 N--CA 1.482 1.161 0 CA-C-O 119.385 -0.341 . . . . 0.0 111.185 178.906 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 61.0 t -58.14 163.74 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.843 0 N-CA-C 108.217 -1.031 . . . . 0.0 108.217 177.188 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -116.28 48.13 0.97 Allowed Glycine 0 N--CA 1.477 1.372 0 N-CA-C 111.617 -0.593 . . . . 0.0 111.617 -179.352 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -62.3 -169.11 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.532 0 O-C-N 123.726 0.309 . . . . 0.0 110.212 179.312 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 25.2 t-20 -71.98 79.98 0.92 Allowed 'General case' 0 N--CA 1.466 0.368 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.205 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -73.45 140.61 46.62 Favored 'General case' 0 N--CA 1.473 0.692 0 N-CA-C 109.015 -0.735 . . . . 0.0 109.015 179.369 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.71 -148.67 0.03 OUTLIER Glycine 0 C--N 1.338 0.661 0 N-CA-C 110.395 -1.082 . . . . 0.0 110.395 179.548 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -93.99 128.25 40.23 Favored 'General case' 0 N--CA 1.471 0.592 0 CA-C-N 116.866 0.333 . . . . 0.0 110.136 179.825 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 71.8 mt -124.94 116.71 48.02 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.834 0 N-CA-C 106.779 -1.563 . . . . 0.0 106.779 178.654 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 38.8 pt -150.97 -169.71 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.356 0.873 0 CA-C-N 115.903 -0.589 . . . . 0.0 111.183 -178.42 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.37 5.39 11.29 Favored Glycine 0 C--N 1.336 0.555 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 179.659 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 1.5 tt -78.53 126.44 30.76 Favored 'General case' 0 CA--C 1.544 0.744 0 N-CA-C 109.499 -0.556 . . . . 0.0 109.499 -179.613 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 28.6 ttt -163.65 143.76 8.55 Favored 'General case' 0 N--CA 1.468 0.427 0 N-CA-C 108.687 -0.857 . . . . 0.0 108.687 178.42 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 35.5 m -155.9 162.96 1.57 Allowed 'Isoleucine or valine' 0 C--O 1.219 -0.501 0 N-CA-C 108.292 -1.003 . . . . 0.0 108.292 179.384 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.93 66.9 2.51 Favored Glycine 0 C--N 1.303 -1.299 0 CA-C-N 116.195 -0.457 . . . . 0.0 112.058 178.565 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 145.53 173.67 17.01 Favored Glycine 0 N--CA 1.475 1.257 0 N-CA-C 110.663 -0.975 . . . . 0.0 110.663 179.061 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 39' ' ' VAL . . . . . 0.512 ' H ' HG11 ' F' ' 39' ' ' VAL . 35.9 m -124.02 159.87 28.81 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.868 0 C-N-CA 123.678 0.791 . . . . 0.0 110.592 -179.851 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 24.7 t . . . . . 0 C--O 1.219 -0.542 0 CA-C-O 118.355 -0.831 . . . . 0.0 110.611 179.496 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' D' D ' 1' ' ' ASP . . . . . . . . . . . . . 9.5 m-20 . . . . . 0 N--CA 1.491 1.6 0 N-CA-C 109.116 -0.698 . . . . 0.0 109.116 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' D' D ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.5 131.02 45.9 Favored 'General case' 0 CA--C 1.538 0.486 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.357 -179.897 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 3' ' ' GLU . . . . . . . . . . . . . 44.5 tt0 -169.34 107.97 0.42 Allowed 'General case' 0 N--CA 1.47 0.569 0 N-CA-C 109.978 -0.378 . . . . 0.0 109.978 -179.959 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 39.8 m-85 -89.68 157.33 18.04 Favored 'General case' 0 C--N 1.359 0.982 0 N-CA-C 108.898 -0.778 . . . . 0.0 108.898 179.862 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -145.9 138.11 25.38 Favored 'General case' 0 N--CA 1.476 0.848 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.396 -179.609 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 39.6 t-80 -149.29 123.69 9.65 Favored 'General case' 0 CA--C 1.546 0.79 0 N-CA-C 108.318 -0.993 . . . . 0.0 108.318 175.746 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 7' ' ' ASP . . . . . 0.598 ' O ' ' OG ' ' G' ' 8' ' ' SER . 3.3 m-20 -64.28 133.08 52.03 Favored 'General case' 0 C--N 1.324 -0.524 0 C-N-CA 126.477 1.911 . . . . 0.0 114.259 174.946 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' D' D ' 8' ' ' SER . . . . . 0.513 ' OG ' ' O ' ' A' ' 7' ' ' ASP . 54.0 p -154.93 -171.12 3.72 Favored 'General case' 0 N--CA 1.486 1.373 0 CA-C-N 119.566 1.075 . . . . 0.0 111.26 175.892 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.44 48.23 1.14 Allowed Glycine 0 N--CA 1.483 1.779 0 N-CA-C 110.517 -1.033 . . . . 0.0 110.517 174.559 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 51.4 p90 -61.0 131.19 49.85 Favored 'General case' 0 N--CA 1.471 0.594 0 N-CA-C 112.782 0.66 . . . . 0.0 112.782 178.433 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 48.5 mt-10 -89.44 151.04 22.23 Favored 'General case' 0 N--CA 1.48 1.07 0 C-N-CA 122.258 0.223 . . . . 0.0 110.826 175.581 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.0 p -149.58 130.01 4.32 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.599 0 N-CA-C 107.515 -1.291 . . . . 0.0 107.515 173.542 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 44.5 m-70 -130.07 148.63 51.94 Favored 'General case' 0 N--CA 1.483 1.212 0 CA-C-N 118.22 0.464 . . . . 0.0 111.78 176.379 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 6.2 t60 -164.96 104.38 0.78 Allowed 'General case' 0 N--CA 1.482 1.163 0 N-CA-C 109.141 -0.689 . . . . 0.0 109.141 172.859 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 11.9 pt20 -115.47 -176.18 2.87 Favored 'General case' 0 CA--C 1.496 -1.12 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 179.061 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -160.36 106.1 1.51 Allowed 'General case' 0 N--CA 1.469 0.506 0 N-CA-C 106.717 -1.586 . . . . 0.0 106.717 175.783 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 5.8 mp -128.17 153.68 46.62 Favored 'General case' 0 N--CA 1.497 1.909 0 CA-C-O 122.23 1.014 . . . . 0.0 110.586 179.989 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 36.1 t -101.29 131.58 48.76 Favored 'Isoleucine or valine' 0 C--O 1.26 1.631 0 CA-C-O 116.674 -1.632 . . . . 0.0 109.7 174.225 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 27.5 m-85 -130.44 126.12 36.16 Favored 'General case' 0 N--CA 1.49 1.547 0 CA-C-N 120.203 1.365 . . . . 0.0 109.552 173.359 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 69.7 m-85 55.53 71.52 0.54 Allowed 'General case' 0 C--O 1.239 0.517 0 CA-C-N 115.781 -0.645 . . . . 0.0 111.23 176.044 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -82.33 -73.28 0.4 Allowed 'General case' 0 N--CA 1.471 0.608 0 CA-C-O 118.555 -0.736 . . . . 0.0 111.171 -177.592 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 40.7 tt0 -115.37 105.67 13.11 Favored 'General case' 0 N--CA 1.481 1.12 0 N-CA-C 106.586 -1.635 . . . . 0.0 106.586 176.629 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 p-10 -152.02 135.13 15.78 Favored 'General case' 0 N--CA 1.474 0.756 0 CA-C-O 116.643 -1.646 . . . . 0.0 113.397 177.471 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 24' ' ' VAL . . . . . . . . . . . . . 68.7 t -61.12 166.54 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.264 0 CA-C-N 121.351 1.887 . . . . 0.0 107.972 175.481 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 25' ' ' GLY . . . . . 0.4 ' H ' ' HB ' ' G' ' 24' ' ' VAL . . . -116.56 50.94 0.75 Allowed Glycine 0 N--CA 1.479 1.513 0 CA-C-O 119.203 -0.776 . . . . 0.0 111.489 178.814 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -57.57 -171.43 0.01 OUTLIER 'General case' 0 N--CA 1.468 0.465 0 C-N-CA 123.255 0.622 . . . . 0.0 111.888 175.556 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 25.5 t-20 -73.08 86.43 1.35 Allowed 'General case' 0 C--N 1.347 0.464 0 N-CA-C 108.635 -0.876 . . . . 0.0 108.635 176.47 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 97.7 mttt -80.8 143.42 32.86 Favored 'General case' 0 N--CA 1.479 1.009 0 N-CA-C 107.712 -1.218 . . . . 0.0 107.712 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.27 -143.69 0.02 OUTLIER Glycine 0 C--N 1.348 1.212 0 C-N-CA 120.224 -0.989 . . . . 0.0 111.618 -178.266 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -95.46 126.42 40.74 Favored 'General case' 0 C--O 1.239 0.515 0 C-N-CA 123.031 0.532 . . . . 0.0 110.276 178.663 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 80.4 mt -125.44 126.86 71.25 Favored 'Isoleucine or valine' 0 C--N 1.358 0.944 0 N-CA-C 104.022 -2.584 . . . . 0.0 104.022 176.281 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 41.9 pt -159.14 -170.92 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.1 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.261 -177.927 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.91 5.04 12.53 Favored Glycine 0 C--O 1.239 0.463 0 N-CA-C 110.237 -1.145 . . . . 0.0 110.237 -178.957 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 1.9 tt -79.54 133.46 36.47 Favored 'General case' 0 C--N 1.369 1.451 0 C-N-CA 117.863 -1.535 . . . . 0.0 107.458 -178.968 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 28.1 ttt -158.71 156.3 29.65 Favored 'General case' 0 CA--C 1.511 -0.52 0 N-CA-C 108.203 -1.036 . . . . 0.0 108.203 171.852 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 35.7 m -164.72 163.77 0.7 Allowed 'Isoleucine or valine' 0 C--O 1.219 -0.506 0 N-CA-C 108.058 -1.09 . . . . 0.0 108.058 173.934 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 59.91 63.65 4.88 Favored Glycine 0 C--N 1.307 -1.066 0 C-N-CA 120.37 -0.919 . . . . 0.0 111.528 177.764 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 144.62 176.04 18.29 Favored Glycine 0 N--CA 1.48 1.6 0 CA-C-N 117.971 0.886 . . . . 0.0 111.145 179.368 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 39' ' ' VAL . . . . . 0.495 ' H ' HG11 ' G' ' 39' ' ' VAL . 34.3 m -125.43 157.08 34.82 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.861 0 C-N-CA 123.409 0.684 . . . . 0.0 111.119 -178.753 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 25.2 t . . . . . 0 C--N 1.329 -0.32 0 CA-C-O 116.333 -1.794 . . . . 0.0 109.748 176.588 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' E' E ' 1' ' ' ASP . . . . . . . . . . . . . 9.4 m-20 . . . . . 0 N--CA 1.488 1.451 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' E' E ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.34 129.73 41.04 Favored 'General case' 0 CA--C 1.538 0.504 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.486 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' E' E ' 3' ' ' GLU . . . . . . . . . . . . . 44.5 tt0 -167.5 105.85 0.54 Allowed 'General case' 0 C--O 1.213 -0.839 0 CA-C-N 116.755 -0.202 . . . . 0.0 110.636 -179.74 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 35.9 m-85 -86.63 152.55 22.48 Favored 'General case' 0 N--CA 1.475 0.82 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 179.257 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' E' E ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -143.53 140.04 30.07 Favored 'General case' 0 N--CA 1.48 1.045 0 CA-C-O 120.902 0.382 . . . . 0.0 110.15 179.583 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 43.3 t-80 -151.47 119.35 6.19 Favored 'General case' 0 N--CA 1.474 0.729 0 N-CA-C 109.167 -0.679 . . . . 0.0 109.167 179.085 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' E' E ' 7' ' ' ASP . . . . . 0.503 ' O ' ' OG ' ' H' ' 8' ' ' SER . 3.9 m-20 -69.65 148.15 49.69 Favored 'General case' 0 N--CA 1.466 0.349 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.838 179.998 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' E' E ' 8' ' ' SER . . . . . 0.501 ' OG ' ' O ' ' B' ' 7' ' ' ASP . 52.5 p -168.32 -172.6 1.77 Allowed 'General case' 0 N--CA 1.483 1.21 0 CA-C-O 121.015 0.436 . . . . 0.0 110.854 178.757 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.55 47.66 1.27 Allowed Glycine 0 N--CA 1.479 1.543 0 CA-C-N 116.033 -0.53 . . . . 0.0 111.965 179.917 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 49.1 p90 -64.26 132.53 50.54 Favored 'General case' 0 N--CA 1.473 0.706 0 N-CA-C 112.028 0.381 . . . . 0.0 112.028 -179.894 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 49.4 mt-10 -91.72 153.17 19.82 Favored 'General case' 0 N--CA 1.48 1.066 0 CA-C-O 121.158 0.504 . . . . 0.0 109.665 177.944 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -155.01 127.32 1.02 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.587 0 N-CA-C 107.882 -1.155 . . . . 0.0 107.882 177.968 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 45.1 m-70 -135.04 143.65 46.85 Favored 'General case' 0 N--CA 1.482 1.166 0 CA-C-O 120.787 0.327 . . . . 0.0 111.516 -177.958 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 6.0 t60 -164.26 97.6 0.81 Allowed 'General case' 0 N--CA 1.486 1.371 0 CA-C-N 116.356 -0.383 . . . . 0.0 110.634 179.593 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 12.0 pt20 -111.57 -174.63 2.51 Favored 'General case' 0 CA--C 1.505 -0.761 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 -179.805 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -163.27 98.61 0.93 Allowed 'General case' 0 N--CA 1.476 0.861 0 CA-C-N 114.75 -1.113 . . . . 0.0 108.49 178.633 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 6.5 mp -120.89 156.61 31.63 Favored 'General case' 0 N--CA 1.495 1.777 0 CA-C-O 121.786 0.803 . . . . 0.0 111.52 -177.682 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 48.4 t -114.06 124.62 70.88 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.216 0 N-CA-C 108.276 -1.009 . . . . 0.0 108.276 177.331 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 31.1 m-85 -125.51 121.41 33.65 Favored 'General case' 0 N--CA 1.489 1.51 0 CA-C-O 120.888 0.375 . . . . 0.0 110.846 -179.769 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 70.2 m-85 54.46 73.41 0.4 Allowed 'General case' 0 N--CA 1.469 0.508 0 CA-C-N 115.998 -0.547 . . . . 0.0 111.391 178.201 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -78.78 -78.95 0.14 Allowed 'General case' 0 C--N 1.344 0.348 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.268 -179.475 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 40.4 tt0 -111.2 102.72 11.12 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 -179.978 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -158.16 134.93 9.75 Favored 'General case' 0 C--O 1.208 -1.116 0 CA-C-O 119.484 -0.293 . . . . 0.0 111.378 178.829 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 58.5 t -56.97 167.72 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.941 0 N-CA-C 107.614 -1.254 . . . . 0.0 107.614 176.806 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . -120.73 49.07 0.9 Allowed Glycine 0 N--CA 1.477 1.431 0 N-CA-C 110.765 -0.934 . . . . 0.0 110.765 -179.354 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -63.53 -168.32 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.542 0 CA-C-O 120.691 0.281 . . . . 0.0 110.25 179.622 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 25.2 t-20 -71.7 76.42 0.84 Allowed 'General case' 0 N--CA 1.467 0.403 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.416 179.689 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -70.26 140.75 52.44 Favored 'General case' 0 N--CA 1.477 0.894 0 N-CA-C 109.497 -0.556 . . . . 0.0 109.497 179.557 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.6 -148.68 0.05 OUTLIER Glycine 0 CA--C 1.521 0.467 0 N-CA-C 110.895 -0.882 . . . . 0.0 110.895 179.519 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -92.81 127.18 38.22 Favored 'General case' 0 C--O 1.235 0.292 0 N-CA-C 110.268 -0.271 . . . . 0.0 110.268 179.577 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 74.2 mt -124.34 116.92 49.11 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.608 0 N-CA-C 106.491 -1.67 . . . . 0.0 106.491 178.439 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 43.7 pt -151.43 -168.46 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.182 0 CA-C-O 121.144 0.497 . . . . 0.0 110.622 -178.526 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.4 5.2 7.82 Favored Glycine 0 CA--C 1.528 0.873 0 N-CA-C 111.262 -0.735 . . . . 0.0 111.262 -179.954 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 1.5 tt -77.6 127.09 31.91 Favored 'General case' 0 CA--C 1.545 0.783 0 N-CA-C 109.491 -0.559 . . . . 0.0 109.491 -179.64 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 28.4 ttt -163.86 144.38 8.54 Favored 'General case' 0 N--CA 1.471 0.6 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 178.312 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 32.8 m -156.73 162.62 1.56 Allowed 'Isoleucine or valine' 0 C--O 1.215 -0.712 0 N-CA-C 108.816 -0.809 . . . . 0.0 108.816 179.742 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.98 66.41 2.87 Favored Glycine 0 C--N 1.305 -1.194 0 N-CA-C 111.974 -0.45 . . . . 0.0 111.974 178.55 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 146.07 174.16 17.97 Favored Glycine 0 N--CA 1.477 1.374 0 N-CA-C 111.113 -0.795 . . . . 0.0 111.113 179.038 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' E' E ' 39' ' ' VAL . . . . . 0.513 ' H ' HG11 ' H' ' 39' ' ' VAL . 33.8 m -124.33 159.67 29.8 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.671 0 C-N-CA 123.478 0.711 . . . . 0.0 110.774 -179.566 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 25.8 t . . . . . 0 C--O 1.219 -0.518 0 CA-C-O 118.361 -0.828 . . . . 0.0 110.66 179.321 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' F' F ' 1' ' ' ASP . . . . . . . . . . . . . 9.5 m-20 . . . . . 0 N--CA 1.489 1.511 0 N-CA-C 109.293 -0.632 . . . . 0.0 109.293 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' F' F ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.02 129.85 41.67 Favored 'General case' 0 C--O 1.238 0.452 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.504 -179.968 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 3' ' ' GLU . . . . . . . . . . . . . 44.7 tt0 -167.54 106.03 0.54 Allowed 'General case' 0 C--O 1.213 -0.855 0 CA-C-N 116.733 -0.212 . . . . 0.0 110.511 -179.771 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 35.3 m-85 -86.77 152.56 22.4 Favored 'General case' 0 N--CA 1.475 0.8 0 N-CA-C 109.978 -0.378 . . . . 0.0 109.978 179.233 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -143.44 139.88 30.13 Favored 'General case' 0 N--CA 1.479 0.989 0 CA-C-O 120.872 0.368 . . . . 0.0 110.231 179.54 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 42.6 t-80 -151.35 119.02 6.09 Favored 'General case' 0 N--CA 1.474 0.761 0 N-CA-C 109.197 -0.668 . . . . 0.0 109.197 179.076 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 7' ' ' ASP . . . . . 0.497 ' O ' ' OG ' ' I' ' 8' ' ' SER . 4.0 m-20 -69.2 148.28 50.09 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.74 179.912 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' F' F ' 8' ' ' SER . . . . . 0.497 ' OG ' ' O ' ' C' ' 7' ' ' ASP . 52.1 p -168.65 -173.03 1.78 Allowed 'General case' 0 N--CA 1.486 1.329 0 CA-C-O 121.04 0.448 . . . . 0.0 110.858 178.749 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.79 47.55 1.26 Allowed Glycine 0 N--CA 1.479 1.529 0 CA-C-N 115.969 -0.559 . . . . 0.0 111.884 179.785 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 48.2 p90 -64.01 133.06 52.41 Favored 'General case' 0 CA--C 1.543 0.683 0 O-C-N 122.528 -0.395 . . . . 0.0 111.978 -179.821 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 49.2 mt-10 -92.02 152.94 19.74 Favored 'General case' 0 N--CA 1.48 1.056 0 CA-C-O 121.196 0.522 . . . . 0.0 109.727 177.841 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -154.78 127.0 1.01 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.572 0 N-CA-C 107.837 -1.172 . . . . 0.0 107.837 178.085 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 44.7 m-70 -134.71 143.65 47.31 Favored 'General case' 0 N--CA 1.484 1.228 0 CA-C-O 120.867 0.365 . . . . 0.0 111.563 -178.04 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 6.0 t60 -164.12 97.51 0.82 Allowed 'General case' 0 N--CA 1.487 1.391 0 CA-C-N 116.431 -0.349 . . . . 0.0 110.775 179.614 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 12.0 pt20 -111.71 -174.72 2.53 Favored 'General case' 0 CA--C 1.503 -0.847 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 -179.838 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -163.09 98.64 0.94 Allowed 'General case' 0 N--CA 1.473 0.711 0 CA-C-N 114.74 -1.118 . . . . 0.0 108.466 178.689 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 6.7 mp -120.76 156.97 30.7 Favored 'General case' 0 N--CA 1.495 1.795 0 CA-C-O 121.806 0.812 . . . . 0.0 111.498 -177.827 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 48.8 t -114.35 124.45 71.01 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.231 0 N-CA-C 108.186 -1.042 . . . . 0.0 108.186 177.321 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 32.2 m-85 -125.24 121.16 33.28 Favored 'General case' 0 N--CA 1.488 1.452 0 CA-C-O 120.893 0.377 . . . . 0.0 110.857 -179.911 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 70.4 m-85 54.67 73.78 0.38 Allowed 'General case' 0 N--CA 1.467 0.386 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.588 178.277 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -79.12 -78.53 0.15 Allowed 'General case' 0 C--N 1.344 0.354 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.406 -179.431 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 40.9 tt0 -111.71 102.58 10.87 Favored 'General case' 0 N--CA 1.47 0.527 0 N-CA-C 108.402 -0.962 . . . . 0.0 108.402 -179.929 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -158.02 134.77 9.78 Favored 'General case' 0 N--CA 1.481 1.081 0 CA-C-O 119.416 -0.326 . . . . 0.0 111.394 178.822 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 24' ' ' VAL . . . . . . . . . . . . . 58.1 t -56.82 167.97 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.966 0 N-CA-C 107.641 -1.244 . . . . 0.0 107.641 176.938 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -120.97 49.2 0.89 Allowed Glycine 0 N--CA 1.478 1.48 0 N-CA-C 110.745 -0.942 . . . . 0.0 110.745 -179.344 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -63.72 -167.92 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.551 0 CA-C-O 120.731 0.301 . . . . 0.0 110.294 179.66 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 25.2 t-20 -71.92 76.51 0.9 Allowed 'General case' 0 N--CA 1.466 0.372 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.325 179.662 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -70.48 140.44 51.9 Favored 'General case' 0 N--CA 1.477 0.892 0 N-CA-C 109.525 -0.546 . . . . 0.0 109.525 179.562 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.17 -149.09 0.04 OUTLIER Glycine 0 CA--C 1.522 0.504 0 N-CA-C 110.898 -0.881 . . . . 0.0 110.898 179.441 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -92.34 127.14 37.71 Favored 'General case' 0 C--O 1.236 0.352 0 CA-C-O 120.676 0.274 . . . . 0.0 110.276 179.444 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 73.2 mt -124.26 116.93 49.2 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.572 0 N-CA-C 106.479 -1.674 . . . . 0.0 106.479 178.401 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 44.1 pt -151.6 -168.36 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.149 0 CA-C-O 121.071 0.462 . . . . 0.0 110.722 -178.543 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.13 5.54 8.1 Favored Glycine 0 CA--C 1.527 0.818 0 N-CA-C 111.274 -0.73 . . . . 0.0 111.274 -179.889 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 1.5 tt -77.76 126.88 31.54 Favored 'General case' 0 N--CA 1.476 0.839 0 N-CA-C 109.386 -0.598 . . . . 0.0 109.386 -179.689 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 28.4 ttt -163.62 144.36 8.9 Favored 'General case' 0 N--CA 1.471 0.591 0 N-CA-C 108.876 -0.787 . . . . 0.0 108.876 178.283 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 32.8 m -156.63 162.81 1.53 Allowed 'Isoleucine or valine' 0 C--O 1.216 -0.709 0 N-CA-C 108.829 -0.804 . . . . 0.0 108.829 179.638 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.82 66.48 2.81 Favored Glycine 0 C--N 1.305 -1.169 0 N-CA-C 111.992 -0.443 . . . . 0.0 111.992 178.5 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 145.82 174.12 17.71 Favored Glycine 0 N--CA 1.477 1.419 0 N-CA-C 111.031 -0.828 . . . . 0.0 111.031 178.961 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 39' ' ' VAL . . . . . 0.512 HG11 ' H ' ' C' ' 39' ' ' VAL . 33.7 m -124.38 159.75 29.82 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.692 0 C-N-CA 123.366 0.666 . . . . 0.0 110.755 -179.488 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 26.3 t . . . . . 0 C--O 1.22 -0.476 0 CA-C-O 118.249 -0.881 . . . . 0.0 110.609 179.215 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' G' G ' 1' ' ' ASP . . . . . . . . . . . . . 9.6 m-20 . . . . . 0 N--CA 1.492 1.631 0 N-CA-C 109.344 -0.613 . . . . 0.0 109.344 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' G' G ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.77 128.25 35.04 Favored 'General case' 0 CA--C 1.537 0.444 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.693 179.664 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 3' ' ' GLU . . . . . . . . . . . . . 43.9 tt0 -167.84 106.79 0.53 Allowed 'General case' 0 N--CA 1.473 0.677 0 CA-C-O 120.518 0.199 . . . . 0.0 110.891 179.744 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 39.2 m-85 -88.58 152.31 21.93 Favored 'General case' 0 N--CA 1.474 0.736 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 179.12 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 5' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -143.79 140.3 29.81 Favored 'General case' 0 N--CA 1.482 1.168 0 CA-C-O 120.846 0.355 . . . . 0.0 110.311 179.825 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 43.3 t-80 -151.54 120.25 6.55 Favored 'General case' 0 N--CA 1.475 0.782 0 N-CA-C 109.342 -0.614 . . . . 0.0 109.342 179.125 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -71.22 144.19 50.19 Favored 'General case' 0 N--CA 1.47 0.547 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.17 -179.937 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 8' ' ' SER . . . . . 0.598 ' OG ' ' O ' ' D' ' 7' ' ' ASP . 47.8 p -165.4 -170.96 2.0 Allowed 'General case' 0 N--CA 1.474 0.767 0 CA-C-O 120.962 0.41 . . . . 0.0 110.589 178.585 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.01 47.92 1.29 Allowed Glycine 0 N--CA 1.48 1.611 0 N-CA-C 111.514 -0.635 . . . . 0.0 111.514 179.441 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 50.4 p90 -64.5 133.02 51.56 Favored 'General case' 0 N--CA 1.473 0.699 0 CA-C-O 120.753 0.311 . . . . 0.0 111.818 -179.544 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 48.6 mt-10 -92.62 151.63 20.01 Favored 'General case' 0 N--CA 1.479 0.982 0 CA-C-O 121.104 0.478 . . . . 0.0 110.105 178.484 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -154.74 127.6 1.11 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.016 0 N-CA-C 107.92 -1.141 . . . . 0.0 107.92 178.361 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 47.0 m-70 -134.49 145.04 48.43 Favored 'General case' 0 N--CA 1.478 0.956 0 CA-C-N 115.542 -0.754 . . . . 0.0 111.399 -178.348 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 6.2 t60 -165.87 97.61 0.64 Allowed 'General case' 0 N--CA 1.483 1.206 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.301 178.963 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 12.1 pt20 -111.74 -174.3 2.43 Favored 'General case' 0 CA--C 1.503 -0.848 0 N-CA-C 108.37 -0.974 . . . . 0.0 108.37 -179.657 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -163.8 98.21 0.86 Allowed 'General case' 0 N--CA 1.474 0.774 0 CA-C-N 114.672 -1.149 . . . . 0.0 108.194 178.856 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 6.6 mp -120.51 155.15 34.2 Favored 'General case' 0 N--CA 1.497 1.896 0 CA-C-O 121.291 0.567 . . . . 0.0 111.74 -177.794 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 43.9 t -113.33 124.91 70.44 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.006 0 CA-C-N 114.804 -1.089 . . . . 0.0 108.234 176.713 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 33.5 m-85 -125.9 121.17 32.39 Favored 'General case' 0 C--N 1.366 1.299 0 C-N-CA 123.437 0.695 . . . . 0.0 110.934 -179.585 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 69.3 m-85 54.75 72.82 0.44 Allowed 'General case' 0 N--CA 1.468 0.462 0 CA-C-N 115.874 -0.603 . . . . 0.0 111.375 178.059 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.7 -78.37 0.14 Allowed 'General case' 0 N--CA 1.472 0.632 0 O-C-N 122.223 -0.298 . . . . 0.0 110.508 -178.981 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 40.7 tt0 -111.78 102.47 10.75 Favored 'General case' 0 C--N 1.321 -0.633 0 N-CA-C 108.212 -1.033 . . . . 0.0 108.212 179.942 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -157.7 136.05 11.1 Favored 'General case' 0 N--CA 1.479 0.98 0 O-C-N 122.43 -0.168 . . . . 0.0 111.415 178.748 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 24' ' ' VAL . . . . . 0.4 ' HB ' ' H ' ' D' ' 25' ' ' GLY . 59.9 t -58.35 167.11 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.639 0 N-CA-C 107.749 -1.204 . . . . 0.0 107.749 177.115 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -119.53 49.4 0.88 Allowed Glycine 0 N--CA 1.48 1.615 0 N-CA-C 110.479 -1.048 . . . . 0.0 110.479 -179.496 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -64.6 -168.66 0.03 OUTLIER 'General case' 0 N--CA 1.471 0.624 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 179.67 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 25.4 t-20 -71.46 76.47 0.77 Allowed 'General case' 0 N--CA 1.468 0.435 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.385 179.796 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -69.82 140.55 53.3 Favored 'General case' 0 N--CA 1.474 0.765 0 N-CA-C 109.626 -0.509 . . . . 0.0 109.626 179.528 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.79 -147.01 0.04 OUTLIER Glycine 0 C--N 1.338 0.663 0 N-CA-C 110.517 -1.033 . . . . 0.0 110.517 179.637 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -93.36 126.12 38.32 Favored 'General case' 0 N--CA 1.468 0.43 0 C-N-CA 122.616 0.366 . . . . 0.0 110.663 -179.738 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 73.4 mt -123.76 117.3 50.7 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.771 0 N-CA-C 106.527 -1.657 . . . . 0.0 106.527 178.105 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 44.8 pt -152.27 -167.68 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 CA-C-N 119.839 1.2 . . . . 0.0 109.858 -179.046 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.37 6.2 10.23 Favored Glycine 0 CA--C 1.525 0.705 0 N-CA-C 110.998 -0.841 . . . . 0.0 110.998 179.824 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 1.5 tt -79.23 125.94 30.12 Favored 'General case' 0 CA--C 1.544 0.746 0 N-CA-C 109.492 -0.559 . . . . 0.0 109.492 -179.575 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 27.5 ttt -162.76 146.01 11.07 Favored 'General case' 0 N--CA 1.47 0.565 0 N-CA-C 108.757 -0.831 . . . . 0.0 108.757 178.418 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 33.2 m -157.37 162.11 1.62 Allowed 'Isoleucine or valine' 0 C--N 1.347 0.461 0 N-CA-C 108.901 -0.777 . . . . 0.0 108.901 -179.959 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.37 66.8 2.58 Favored Glycine 0 C--N 1.312 -0.754 0 CA-C-N 115.712 -0.676 . . . . 0.0 112.271 178.213 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 146.53 175.17 19.29 Favored Glycine 0 N--CA 1.477 1.427 0 N-CA-C 110.516 -1.034 . . . . 0.0 110.516 178.988 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 39' ' ' VAL . . . . . 0.495 HG11 ' H ' ' D' ' 39' ' ' VAL . 34.6 m -125.34 159.94 31.94 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.867 0 C-N-CA 123.09 0.556 . . . . 0.0 110.73 -179.48 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 28.8 t . . . . . 0 N--CA 1.469 0.511 0 CA-C-O 118.388 -0.815 . . . . 0.0 110.796 179.025 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' H' H ' 1' ' ' ASP . . . . . . . . . . . . . 9.5 m-20 . . . . . 0 N--CA 1.491 1.58 0 N-CA-C 109.434 -0.58 . . . . 0.0 109.434 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' H' H ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.94 128.67 36.93 Favored 'General case' 0 CA--C 1.536 0.408 0 CA-C-N 115.949 -0.568 . . . . 0.0 110.613 179.77 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 3' ' ' GLU . . . . . . . . . . . . . 43.9 tt0 -168.27 106.89 0.49 Allowed 'General case' 0 N--CA 1.471 0.616 0 CA-C-O 120.529 0.204 . . . . 0.0 110.842 179.783 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 39.8 m-85 -88.57 152.15 22.03 Favored 'General case' 0 N--CA 1.473 0.697 0 N-CA-C 109.549 -0.537 . . . . 0.0 109.549 179.017 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 5' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -143.66 140.53 30.12 Favored 'General case' 0 N--CA 1.483 1.185 0 C-N-CA 122.583 0.353 . . . . 0.0 110.13 179.884 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 42.9 t-80 -151.77 120.4 6.5 Favored 'General case' 0 N--CA 1.473 0.701 0 N-CA-C 109.383 -0.599 . . . . 0.0 109.383 179.096 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -71.58 143.9 49.7 Favored 'General case' 0 N--CA 1.471 0.585 0 CA-C-N 116.323 -0.399 . . . . 0.0 111.178 -179.768 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 8' ' ' SER . . . . . 0.503 ' OG ' ' O ' ' E' ' 7' ' ' ASP . 53.7 p -165.07 -171.19 2.14 Favored 'General case' 0 N--CA 1.475 0.815 0 CA-C-O 120.94 0.4 . . . . 0.0 110.509 178.628 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.13 47.61 1.32 Allowed Glycine 0 N--CA 1.48 1.594 0 N-CA-C 111.683 -0.567 . . . . 0.0 111.683 179.642 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 50.4 p90 -64.51 133.13 51.77 Favored 'General case' 0 N--CA 1.472 0.659 0 N-CA-C 111.947 0.351 . . . . 0.0 111.947 -179.637 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 48.4 mt-10 -92.45 151.77 20.04 Favored 'General case' 0 N--CA 1.478 0.929 0 CA-C-O 121.013 0.435 . . . . 0.0 110.215 178.499 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -154.71 127.92 1.16 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.041 0 N-CA-C 107.854 -1.165 . . . . 0.0 107.854 178.251 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 46.4 m-70 -134.72 145.07 48.13 Favored 'General case' 0 N--CA 1.478 0.971 0 CA-C-N 115.5 -0.773 . . . . 0.0 111.394 -178.374 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 6.2 t60 -165.93 97.29 0.63 Allowed 'General case' 0 N--CA 1.483 1.176 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.4 179.012 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 12.1 pt20 -111.39 -174.52 2.48 Favored 'General case' 0 CA--C 1.504 -0.826 0 N-CA-C 108.34 -0.985 . . . . 0.0 108.34 -179.652 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -163.72 98.29 0.87 Allowed 'General case' 0 N--CA 1.475 0.784 0 CA-C-N 114.671 -1.15 . . . . 0.0 108.093 178.757 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 6.7 mp -120.41 155.56 33.21 Favored 'General case' 0 N--CA 1.496 1.873 0 CA-C-O 121.233 0.539 . . . . 0.0 111.849 -177.82 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 42.6 t -113.64 125.23 70.88 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.01 0 CA-C-N 114.869 -1.06 . . . . 0.0 108.231 176.556 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 33.2 m-85 -126.24 121.07 31.66 Favored 'General case' 0 C--N 1.369 1.445 0 CA-C-N 115.518 -0.765 . . . . 0.0 110.775 -179.444 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 69.6 m-85 54.41 73.13 0.41 Allowed 'General case' 0 C--O 1.238 0.453 0 CA-C-N 115.814 -0.63 . . . . 0.0 111.399 178.107 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.75 -78.06 0.14 Allowed 'General case' 0 N--CA 1.472 0.657 0 O-C-N 122.201 -0.312 . . . . 0.0 110.661 -179.147 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 40.4 tt0 -112.09 102.57 10.77 Favored 'General case' 0 C--N 1.321 -0.641 0 N-CA-C 108.236 -1.024 . . . . 0.0 108.236 179.883 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -157.75 136.24 11.2 Favored 'General case' 0 N--CA 1.478 0.974 0 O-C-N 122.417 -0.177 . . . . 0.0 111.368 178.817 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 24' ' ' VAL . . . . . . . . . . . . . 59.1 t -58.49 166.91 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.548 0 N-CA-C 107.71 -1.218 . . . . 0.0 107.71 177.18 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . -119.25 49.2 0.89 Allowed Glycine 0 N--CA 1.479 1.551 0 N-CA-C 110.651 -0.98 . . . . 0.0 110.651 -179.573 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -64.68 -168.33 0.03 OUTLIER 'General case' 0 N--CA 1.472 0.661 0 N-CA-C 109.944 -0.391 . . . . 0.0 109.944 179.722 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 25.6 t-20 -71.55 76.55 0.8 Allowed 'General case' 0 CA--C 1.537 0.472 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.316 179.809 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -70.15 140.56 52.61 Favored 'General case' 0 N--CA 1.474 0.775 0 N-CA-C 109.588 -0.523 . . . . 0.0 109.588 179.593 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.63 -147.69 0.04 OUTLIER Glycine 0 C--N 1.336 0.579 0 N-CA-C 110.376 -1.09 . . . . 0.0 110.376 179.549 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -93.05 126.31 38.07 Favored 'General case' 0 N--CA 1.465 0.298 0 C-N-CA 122.584 0.354 . . . . 0.0 110.781 -179.8 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 74.5 mt -123.87 117.23 50.41 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.776 0 N-CA-C 106.575 -1.639 . . . . 0.0 106.575 178.224 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 44.8 pt -152.11 -167.77 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 CA-C-N 119.761 1.164 . . . . 0.0 109.871 -179.026 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.71 5.76 9.9 Favored Glycine 0 CA--C 1.524 0.641 0 N-CA-C 110.935 -0.866 . . . . 0.0 110.935 179.845 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 1.4 tt -78.7 125.75 29.79 Favored 'General case' 0 CA--C 1.544 0.728 0 N-CA-C 109.555 -0.535 . . . . 0.0 109.555 -179.565 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 27.4 ttt -162.56 145.94 11.37 Favored 'General case' 0 N--CA 1.47 0.572 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 178.323 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 33.2 m -157.35 162.18 1.6 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 N-CA-C 108.874 -0.788 . . . . 0.0 108.874 -179.935 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.25 67.06 2.4 Favored Glycine 0 C--N 1.311 -0.819 0 CA-C-N 115.781 -0.645 . . . . 0.0 112.149 178.286 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 146.42 175.76 19.69 Favored Glycine 0 N--CA 1.479 1.547 0 N-CA-C 110.577 -1.009 . . . . 0.0 110.577 178.892 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 39' ' ' VAL . . . . . 0.513 HG11 ' H ' ' E' ' 39' ' ' VAL . 34.6 m -125.97 159.85 33.75 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.82 0 C-N-CA 123.161 0.585 . . . . 0.0 110.708 -179.499 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 26.7 t . . . . . 0 C--O 1.219 -0.547 0 CA-C-O 118.346 -0.835 . . . . 0.0 110.79 179.263 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' I' I ' 1' ' ' ASP . . . . . . . . . . . . . 9.6 m-20 . . . . . 0 N--CA 1.492 1.647 0 N-CA-C 109.471 -0.566 . . . . 0.0 109.471 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' I' I ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.87 128.55 36.44 Favored 'General case' 0 CA--C 1.537 0.454 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.553 179.777 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' I' I ' 3' ' ' GLU . . . . . . . . . . . . . 43.8 tt0 -167.97 107.07 0.53 Allowed 'General case' 0 N--CA 1.472 0.648 0 CA-C-O 120.423 0.154 . . . . 0.0 110.803 179.756 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 39.7 m-85 -88.77 152.3 21.86 Favored 'General case' 0 N--CA 1.475 0.78 0 N-CA-C 109.473 -0.566 . . . . 0.0 109.473 179.063 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' I' I ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -143.72 140.28 29.91 Favored 'General case' 0 N--CA 1.482 1.167 0 C-N-CA 122.602 0.361 . . . . 0.0 110.15 179.894 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 43.1 t-80 -151.72 120.28 6.47 Favored 'General case' 0 N--CA 1.474 0.732 0 N-CA-C 109.358 -0.608 . . . . 0.0 109.358 179.04 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -71.23 143.87 50.27 Favored 'General case' 0 N--CA 1.469 0.503 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.234 -179.881 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' I' I ' 8' ' ' SER . . . . . 0.497 ' OG ' ' O ' ' F' ' 7' ' ' ASP . 53.3 p -164.87 -171.4 2.25 Favored 'General case' 0 N--CA 1.474 0.752 0 CA-C-O 120.857 0.36 . . . . 0.0 110.582 178.668 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.08 48.04 1.28 Allowed Glycine 0 N--CA 1.48 1.619 0 N-CA-C 111.693 -0.563 . . . . 0.0 111.693 179.63 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 50.4 p90 -65.1 132.52 49.39 Favored 'General case' 0 N--CA 1.472 0.632 0 N-CA-C 111.934 0.346 . . . . 0.0 111.934 -179.737 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 48.3 mt-10 -91.81 152.24 20.22 Favored 'General case' 0 N--CA 1.478 0.937 0 CA-C-O 121.033 0.445 . . . . 0.0 110.18 178.511 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -155.28 127.58 1.03 Allowed 'Isoleucine or valine' 0 CA--C 1.551 0.999 0 N-CA-C 107.848 -1.167 . . . . 0.0 107.848 178.349 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 46.1 m-70 -134.48 145.08 48.48 Favored 'General case' 0 N--CA 1.477 0.887 0 CA-C-N 115.572 -0.74 . . . . 0.0 111.436 -178.387 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 6.1 t60 -165.61 97.47 0.67 Allowed 'General case' 0 N--CA 1.481 1.105 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.362 178.961 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 12.3 pt20 -111.79 -174.83 2.55 Favored 'General case' 0 CA--C 1.502 -0.894 0 N-CA-C 108.399 -0.963 . . . . 0.0 108.399 -179.689 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -163.39 98.41 0.91 Allowed 'General case' 0 N--CA 1.474 0.762 0 CA-C-N 114.647 -1.16 . . . . 0.0 108.172 178.87 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 6.7 mp -120.53 155.4 33.71 Favored 'General case' 0 N--CA 1.496 1.854 0 CA-C-O 121.266 0.555 . . . . 0.0 111.773 -177.829 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 41.6 t -113.56 125.35 70.82 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.998 0 CA-C-N 114.824 -1.08 . . . . 0.0 108.194 176.568 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 33.6 m-85 -126.32 121.32 32.24 Favored 'General case' 0 C--N 1.368 1.393 0 CA-C-N 115.61 -0.723 . . . . 0.0 110.876 -179.491 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 69.4 m-85 54.16 72.94 0.42 Allowed 'General case' 0 C--O 1.237 0.441 0 CA-C-N 115.918 -0.583 . . . . 0.0 111.375 178.165 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.63 -78.08 0.14 Allowed 'General case' 0 N--CA 1.472 0.657 0 O-C-N 122.302 -0.249 . . . . 0.0 110.598 -179.116 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 40.7 tt0 -112.01 102.73 10.93 Favored 'General case' 0 C--N 1.323 -0.573 0 N-CA-C 108.156 -1.053 . . . . 0.0 108.156 179.948 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -157.95 136.19 10.94 Favored 'General case' 0 N--CA 1.478 0.956 0 O-C-N 122.375 -0.203 . . . . 0.0 111.329 178.858 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' I' I ' 24' ' ' VAL . . . . . . . . . . . . . 58.5 t -58.5 166.92 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.559 0 N-CA-C 107.779 -1.193 . . . . 0.0 107.779 177.134 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . -119.42 49.22 0.88 Allowed Glycine 0 N--CA 1.481 1.661 0 N-CA-C 110.592 -1.003 . . . . 0.0 110.592 -179.404 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -64.54 -168.2 0.03 OUTLIER 'General case' 0 N--CA 1.471 0.602 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 179.702 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 25.5 t-20 -71.71 76.89 0.84 Allowed 'General case' 0 CA--C 1.536 0.439 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.259 179.675 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -70.45 140.6 52.0 Favored 'General case' 0 N--CA 1.475 0.807 0 N-CA-C 109.63 -0.507 . . . . 0.0 109.63 179.472 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.72 -147.32 0.04 OUTLIER Glycine 0 C--N 1.337 0.621 0 N-CA-C 110.496 -1.041 . . . . 0.0 110.496 179.588 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -93.26 125.86 38.07 Favored 'General case' 0 N--CA 1.465 0.314 0 C-N-CA 122.696 0.399 . . . . 0.0 110.752 -179.737 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 73.7 mt -123.47 117.33 51.03 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.768 0 N-CA-C 106.556 -1.646 . . . . 0.0 106.556 178.111 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 44.9 pt -152.17 -167.82 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 CA-C-N 119.758 1.163 . . . . 0.0 109.869 -179.05 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.71 5.86 10.18 Favored Glycine 0 CA--C 1.526 0.738 0 N-CA-C 110.95 -0.86 . . . . 0.0 110.95 179.768 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 1.4 tt -78.89 125.56 29.53 Favored 'General case' 0 CA--C 1.546 0.79 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 -179.593 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 27.4 ttt -162.25 145.79 11.83 Favored 'General case' 0 N--CA 1.47 0.542 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 178.559 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 33.3 m -157.28 162.03 1.65 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.47 0 N-CA-C 108.845 -0.798 . . . . 0.0 108.845 -179.89 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.29 66.87 2.53 Favored Glycine 0 C--N 1.311 -0.85 0 CA-C-N 115.799 -0.637 . . . . 0.0 112.228 178.173 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 146.58 175.82 19.87 Favored Glycine 0 N--CA 1.478 1.497 0 N-CA-C 110.603 -0.999 . . . . 0.0 110.603 178.939 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' I' I ' 39' ' ' VAL . . . . . 0.508 HG11 ' H ' ' F' ' 39' ' ' VAL . 34.5 m -125.92 159.9 33.55 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.866 0 C-N-CA 123.131 0.572 . . . . 0.0 110.755 -179.488 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 29.8 t . . . . . 0 C--O 1.219 -0.513 0 CA-C-O 118.394 -0.812 . . . . 0.0 110.777 179.103 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 8.5 m-20 . . . . . 0 N--CA 1.489 1.513 0 N-CA-C 109.035 -0.728 . . . . 0.0 109.035 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.8 133.02 50.1 Favored 'General case' 0 CA--C 1.538 0.513 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.138 -179.924 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 54.8 tt0 -169.66 108.66 0.41 Allowed 'General case' 0 N--CA 1.47 0.544 0 N-CA-C 109.66 -0.496 . . . . 0.0 109.66 -179.158 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 78.8 m-85 -84.19 140.03 31.99 Favored 'General case' 0 N--CA 1.474 0.766 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 179.562 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 72.4 mtp180 -143.58 142.05 30.92 Favored 'General case' 0 N--CA 1.482 1.164 0 N-CA-C 109.134 -0.691 . . . . 0.0 109.134 -179.883 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 76.6 m80 -149.83 119.74 7.13 Favored 'General case' 0 N--CA 1.47 0.528 0 N-CA-C 108.759 -0.83 . . . . 0.0 108.759 179.102 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 8.5 m-20 -68.32 149.89 48.87 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.189 -179.385 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' SER . . . . . 0.538 ' HG ' ' H ' ' A' ' 9' ' ' GLY . 7.9 t -167.65 171.16 10.42 Favored 'General case' 0 N--CA 1.473 0.706 0 N-CA-C 109.628 -0.508 . . . . 0.0 109.628 178.456 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . 0.538 ' H ' ' HG ' ' A' ' 8' ' ' SER . . . 122.2 24.7 2.17 Favored Glycine 0 N--CA 1.488 2.127 0 N-CA-C 112.114 -0.394 . . . . 0.0 112.114 179.367 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 43.4 p90 -56.26 128.06 33.87 Favored 'General case' 0 N--CA 1.473 0.696 0 N-CA-C 112.175 0.435 . . . . 0.0 112.175 -179.866 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . 0.476 ' CG ' HD22 ' C' ' 27' ' ' ASN . 45.8 mt-10 -84.72 154.24 22.56 Favored 'General case' 0 N--CA 1.469 0.5 0 N-CA-C 109.082 -0.71 . . . . 0.0 109.082 178.445 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -153.25 129.29 1.75 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.341 0 N-CA-C 108.327 -0.99 . . . . 0.0 108.327 178.926 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 49.5 m-70 -134.03 144.72 48.86 Favored 'General case' 0 N--CA 1.489 1.507 0 CA-C-N 118.711 0.687 . . . . 0.0 110.993 -179.156 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 6.3 t60 -164.75 98.8 0.78 Allowed 'General case' 0 N--CA 1.479 0.978 0 CA-C-N 116.642 -0.254 . . . . 0.0 111.194 179.686 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . 0.5 HE22 ' H ' ' A' ' 37' ' ' GLY . 54.2 mt-30 -108.79 -172.26 2.02 Favored 'General case' 0 CA--C 1.502 -0.873 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 179.804 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -166.97 97.67 0.53 Allowed 'General case' 0 N--CA 1.473 0.689 0 CA-C-N 115.201 -0.909 . . . . 0.0 109.486 178.644 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . 0.418 ' CD1' ' N ' ' A' ' 17' ' ' LEU . 4.5 mp -105.66 163.88 12.34 Favored 'General case' 0 N--CA 1.487 1.409 0 N-CA-C 108.543 -0.91 . . . . 0.0 108.543 179.901 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 48.9 t -142.15 118.92 6.79 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.354 0 CA-C-O 118.796 -0.621 . . . . 0.0 110.02 179.452 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 51.6 m-85 -69.98 159.24 34.13 Favored 'General case' 0 N--CA 1.48 1.055 0 N-CA-C 107.592 -1.262 . . . . 0.0 107.592 177.203 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 13.6 t80 -171.15 -58.52 0.02 OUTLIER 'General case' 0 N--CA 1.485 1.3 0 CA-C-O 122.365 1.079 . . . . 0.0 109.712 179.662 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -38.81 90.0 0.0 OUTLIER 'General case' 0 C--O 1.232 0.17 0 CA-C-N 113.782 -1.554 . . . . 0.0 112.938 -177.952 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 38.1 tt0 -66.16 157.65 30.75 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 115.05 -0.977 . . . . 0.0 110.565 179.118 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 66.8 m-20 -139.55 136.78 34.83 Favored 'General case' 0 N--CA 1.481 1.1 0 C-N-CA 123.008 0.523 . . . . 0.0 110.281 179.862 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 18.4 t -84.65 -116.46 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.982 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 179.469 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -109.15 54.81 0.53 Allowed Glycine 0 N--CA 1.474 1.211 0 N-CA-C 111.126 -0.79 . . . . 0.0 111.126 179.909 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 71.1 p -80.07 126.01 30.52 Favored 'General case' 0 C--N 1.328 -0.333 0 N-CA-C 108.799 -0.815 . . . . 0.0 108.799 178.184 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . 0.488 HD22 ' CG ' ' B' ' 11' ' ' GLU . 47.3 t30 -65.93 100.26 0.56 Allowed 'General case' 0 N--CA 1.473 0.719 0 N-CA-C 108.8 -0.815 . . . . 0.0 108.8 178.702 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 66.7 mttm -95.46 117.2 29.95 Favored 'General case' 0 N--CA 1.484 1.229 0 N-CA-C 110.01 -0.367 . . . . 0.0 110.01 -179.067 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.13 -133.55 0.01 OUTLIER Glycine 0 CA--C 1.532 1.12 0 N-CA-C 110.726 -0.95 . . . . 0.0 110.726 178.943 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -113.4 127.81 56.25 Favored 'General case' 0 N--CA 1.478 0.939 0 N-CA-C 109.29 -0.633 . . . . 0.0 109.29 178.934 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 66.7 mt -90.73 130.19 40.34 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.683 0 N-CA-C 107.606 -1.257 . . . . 0.0 107.606 178.715 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 18.1 mt -142.33 152.38 18.13 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.929 0 N-CA-C 109.838 -0.431 . . . . 0.0 109.838 -178.83 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 65.37 48.27 70.83 Favored Glycine 0 CA--C 1.524 0.63 0 CA-C-N 116.062 -0.517 . . . . 0.0 112.531 178.804 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 2.9 tt -98.88 120.39 39.24 Favored 'General case' 0 N--CA 1.478 0.934 0 N-CA-C 107.245 -1.391 . . . . 0.0 107.245 177.903 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 28.1 ttt -152.71 158.26 42.09 Favored 'General case' 0 N--CA 1.471 0.579 0 N-CA-C 108.909 -0.774 . . . . 0.0 108.909 179.463 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 86.1 t -158.29 149.86 8.23 Favored 'Isoleucine or valine' 0 C--O 1.236 0.351 0 N-CA-C 107.012 -1.477 . . . . 0.0 107.012 -179.204 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . 0.5 ' H ' HE22 ' A' ' 15' ' ' GLN . . . 56.66 74.92 0.28 Allowed Glycine 0 C--N 1.313 -0.741 0 CA-C-N 115.622 -0.717 . . . . 0.0 111.658 178.181 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 170.96 -148.92 11.7 Favored Glycine 0 CA--C 1.519 0.299 0 N-CA-C 110.656 -0.978 . . . . 0.0 110.656 179.786 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 33.5 m -133.93 142.64 40.72 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.794 0 N-CA-C 109.688 -0.486 . . . . 0.0 109.688 179.744 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 16.3 t . . . . . 0 CA--C 1.535 0.392 0 CA-C-O 117.969 -1.015 . . . . 0.0 111.058 179.331 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' B' B ' 1' ' ' ASP . . . . . . . . . . . . . 7.6 m-20 . . . . . 0 N--CA 1.487 1.424 0 N-CA-C 109.14 -0.689 . . . . 0.0 109.14 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' B' B ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.46 132.63 49.43 Favored 'General case' 0 CA--C 1.538 0.507 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.172 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 3' ' ' GLU . . . . . . . . . . . . . 55.2 tt0 -169.32 108.83 0.44 Allowed 'General case' 0 N--CA 1.47 0.543 0 N-CA-C 109.541 -0.54 . . . . 0.0 109.541 -179.115 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 78.8 m-85 -84.17 140.52 31.68 Favored 'General case' 0 N--CA 1.474 0.729 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 179.489 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 71.9 mtp180 -144.09 141.82 30.26 Favored 'General case' 0 N--CA 1.481 1.11 0 N-CA-C 109.123 -0.695 . . . . 0.0 109.123 -179.815 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 76.7 m80 -149.7 119.64 7.15 Favored 'General case' 0 N--CA 1.471 0.611 0 N-CA-C 108.826 -0.805 . . . . 0.0 108.826 179.117 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 7' ' ' ASP . . . . . . . . . . . . . 8.6 m-20 -68.14 149.56 49.44 Favored 'General case' 0 CA--C 1.531 0.215 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.238 -179.439 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 8' ' ' SER . . . . . 0.554 ' HG ' ' H ' ' B' ' 9' ' ' GLY . 8.1 t -167.36 171.87 10.21 Favored 'General case' 0 N--CA 1.473 0.685 0 N-CA-C 109.668 -0.493 . . . . 0.0 109.668 178.368 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 9' ' ' GLY . . . . . 0.554 ' H ' ' HG ' ' B' ' 8' ' ' SER . . . 121.53 24.69 2.32 Favored Glycine 0 N--CA 1.488 2.135 0 N-CA-C 112.102 -0.399 . . . . 0.0 112.102 179.323 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 42.9 p90 -56.15 127.7 31.94 Favored 'General case' 0 N--CA 1.472 0.653 0 N-CA-C 112.236 0.458 . . . . 0.0 112.236 -179.87 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 11' ' ' GLU . . . . . 0.488 ' CG ' HD22 ' A' ' 27' ' ' ASN . 45.6 mt-10 -84.38 154.07 23.07 Favored 'General case' 0 N--CA 1.469 0.515 0 N-CA-C 109.223 -0.658 . . . . 0.0 109.223 178.442 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -153.17 129.65 1.9 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.328 0 N-CA-C 108.301 -1.0 . . . . 0.0 108.301 178.956 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 49.1 m-70 -134.34 145.34 48.92 Favored 'General case' 0 N--CA 1.49 1.552 0 CA-C-N 118.531 0.605 . . . . 0.0 110.975 -179.204 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 6.4 t60 -165.23 98.59 0.72 Allowed 'General case' 0 N--CA 1.482 1.125 0 CA-C-N 116.563 -0.29 . . . . 0.0 111.195 179.658 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . 0.497 HE22 ' H ' ' B' ' 37' ' ' GLY . 54.3 mt-30 -108.57 -172.81 2.13 Favored 'General case' 0 CA--C 1.502 -0.894 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 179.815 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -166.64 97.59 0.56 Allowed 'General case' 0 N--CA 1.472 0.63 0 CA-C-N 115.121 -0.945 . . . . 0.0 109.369 178.821 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . 0.42 ' N ' ' CD1' ' B' ' 17' ' ' LEU . 4.5 mp -105.87 163.88 12.38 Favored 'General case' 0 N--CA 1.487 1.394 0 N-CA-C 108.542 -0.91 . . . . 0.0 108.542 179.881 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 50.5 t -142.27 118.88 6.51 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.3 0 CA-C-O 118.959 -0.543 . . . . 0.0 109.96 179.58 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 53.0 m-85 -70.67 159.22 34.84 Favored 'General case' 0 N--CA 1.478 0.939 0 N-CA-C 107.53 -1.285 . . . . 0.0 107.53 177.248 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 14.9 t80 -171.83 -57.27 0.02 OUTLIER 'General case' 0 N--CA 1.482 1.168 0 CA-C-O 122.151 0.977 . . . . 0.0 109.769 179.631 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -39.1 90.38 0.0 OUTLIER 'General case' 0 CA--C 1.528 0.125 0 CA-C-N 114.125 -1.398 . . . . 0.0 112.768 -178.091 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 38.2 tt0 -66.45 157.45 31.99 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 115.089 -0.96 . . . . 0.0 110.52 179.19 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 67.4 m-20 -139.38 137.24 35.54 Favored 'General case' 0 N--CA 1.479 0.984 0 C-N-CA 123.083 0.553 . . . . 0.0 110.213 179.772 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 18.3 t -85.44 -116.71 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.048 0 N-CA-C 108.562 -0.903 . . . . 0.0 108.562 179.535 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -108.2 54.36 0.56 Allowed Glycine 0 N--CA 1.476 1.353 0 N-CA-C 111.049 -0.82 . . . . 0.0 111.049 179.929 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 71.8 p -80.13 125.55 29.96 Favored 'General case' 0 C--N 1.328 -0.351 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 178.242 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 27' ' ' ASN . . . . . 0.493 HD22 ' CG ' ' C' ' 11' ' ' GLU . 47.7 t30 -65.69 100.4 0.53 Allowed 'General case' 0 N--CA 1.475 0.782 0 N-CA-C 108.812 -0.81 . . . . 0.0 108.812 178.649 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 66.6 mttm -95.58 117.0 29.64 Favored 'General case' 0 N--CA 1.485 1.298 0 N-CA-C 110.041 -0.355 . . . . 0.0 110.041 -179.179 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.85 -133.26 0.01 OUTLIER Glycine 0 CA--C 1.533 1.207 0 N-CA-C 110.723 -0.951 . . . . 0.0 110.723 178.927 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -113.88 127.9 56.18 Favored 'General case' 0 N--CA 1.479 0.981 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 179.031 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 66.6 mt -90.77 130.26 40.26 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.655 0 N-CA-C 107.532 -1.285 . . . . 0.0 107.532 178.692 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 17.8 mt -142.42 152.36 17.99 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.918 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 -178.852 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 65.52 47.55 77.02 Favored Glycine 0 CA--C 1.524 0.638 0 CA-C-N 116.085 -0.507 . . . . 0.0 112.667 178.793 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 2.9 tt -98.07 120.51 38.6 Favored 'General case' 0 N--CA 1.478 0.936 0 N-CA-C 107.25 -1.389 . . . . 0.0 107.25 177.85 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 28.0 ttt -152.81 157.97 41.55 Favored 'General case' 0 N--CA 1.472 0.627 0 N-CA-C 108.849 -0.797 . . . . 0.0 108.849 179.376 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 82.1 t -158.15 149.77 8.47 Favored 'Isoleucine or valine' 0 C--O 1.235 0.306 0 N-CA-C 106.807 -1.553 . . . . 0.0 106.807 -179.147 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . 0.497 ' H ' HE22 ' B' ' 15' ' ' GLN . . . 56.67 75.28 0.26 Allowed Glycine 0 C--N 1.314 -0.689 0 CA-C-N 115.573 -0.74 . . . . 0.0 111.651 178.14 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 170.47 -149.07 12.14 Favored Glycine 0 CA--C 1.518 0.265 0 N-CA-C 110.698 -0.961 . . . . 0.0 110.698 179.772 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 33.8 m -133.59 142.76 40.73 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.842 0 N-CA-C 109.691 -0.485 . . . . 0.0 109.691 179.659 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 16.1 t . . . . . 0 C--O 1.222 -0.353 0 CA-C-O 117.993 -1.003 . . . . 0.0 111.111 179.319 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' C' C ' 1' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 . . . . . 0 N--CA 1.488 1.465 0 N-CA-C 109.106 -0.701 . . . . 0.0 109.106 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' C' C ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.51 132.66 49.46 Favored 'General case' 0 CA--C 1.538 0.517 0 CA-C-N 116.374 -0.375 . . . . 0.0 110.23 -179.921 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 3' ' ' GLU . . . . . . . . . . . . . 54.1 tt0 -169.35 108.59 0.43 Allowed 'General case' 0 N--CA 1.47 0.555 0 N-CA-C 109.637 -0.505 . . . . 0.0 109.637 -179.09 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 79.0 m-85 -83.95 140.43 31.93 Favored 'General case' 0 N--CA 1.475 0.784 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 179.515 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 72.4 mtp180 -144.11 141.48 30.03 Favored 'General case' 0 N--CA 1.482 1.157 0 N-CA-C 109.071 -0.714 . . . . 0.0 109.071 -179.834 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 76.8 m80 -149.41 119.67 7.3 Favored 'General case' 0 N--CA 1.471 0.597 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 179.089 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 7' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -68.05 149.5 49.6 Favored 'General case' 0 CA--C 1.53 0.197 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.281 -179.419 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 8' ' ' SER . . . . . 0.529 ' HG ' ' H ' ' C' ' 9' ' ' GLY . 8.0 t -167.27 171.5 10.68 Favored 'General case' 0 N--CA 1.473 0.719 0 N-CA-C 109.564 -0.532 . . . . 0.0 109.564 178.419 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 9' ' ' GLY . . . . . 0.529 ' H ' ' HG ' ' C' ' 8' ' ' SER . . . 121.79 24.79 2.24 Favored Glycine 0 N--CA 1.488 2.111 0 N-CA-C 112.105 -0.398 . . . . 0.0 112.105 179.304 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 42.4 p90 -56.41 128.28 35.19 Favored 'General case' 0 N--CA 1.472 0.669 0 N-CA-C 112.114 0.412 . . . . 0.0 112.114 -179.803 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 11' ' ' GLU . . . . . 0.493 ' CG ' HD22 ' B' ' 27' ' ' ASN . 45.7 mt-10 -84.79 154.41 22.39 Favored 'General case' 0 N--CA 1.468 0.473 0 N-CA-C 109.113 -0.699 . . . . 0.0 109.113 178.504 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -153.54 129.36 1.71 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 N-CA-C 108.409 -0.96 . . . . 0.0 108.409 178.968 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 48.9 m-70 -134.22 144.97 48.74 Favored 'General case' 0 N--CA 1.489 1.518 0 CA-C-N 118.588 0.631 . . . . 0.0 110.968 -179.029 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 6.3 t60 -165.04 98.55 0.74 Allowed 'General case' 0 N--CA 1.481 1.099 0 CA-C-N 116.57 -0.286 . . . . 0.0 111.201 179.791 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 15' ' ' GLN . . . . . 0.512 HE22 ' H ' ' C' ' 37' ' ' GLY . 54.3 mt-30 -108.6 -172.05 1.98 Allowed 'General case' 0 CA--C 1.5 -0.954 0 N-CA-C 108.251 -1.018 . . . . 0.0 108.251 179.765 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -167.25 97.58 0.5 Allowed 'General case' 0 CA--C 1.54 0.58 0 CA-C-N 115.179 -0.918 . . . . 0.0 109.381 178.751 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 17' ' ' LEU . . . . . 0.419 ' N ' ' CD1' ' C' ' 17' ' ' LEU . 4.4 mp -105.66 163.64 12.53 Favored 'General case' 0 N--CA 1.487 1.392 0 N-CA-C 108.563 -0.903 . . . . 0.0 108.563 179.838 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 51.0 t -142.0 118.75 6.95 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.343 0 CA-C-O 119.032 -0.509 . . . . 0.0 109.959 179.495 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 52.6 m-85 -70.33 159.24 34.48 Favored 'General case' 0 N--CA 1.478 0.964 0 N-CA-C 107.502 -1.296 . . . . 0.0 107.502 177.247 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 14.8 t80 -171.82 -57.35 0.02 OUTLIER 'General case' 0 N--CA 1.482 1.153 0 CA-C-O 122.196 0.998 . . . . 0.0 109.777 179.49 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -39.21 90.75 0.0 OUTLIER 'General case' 0 CA--C 1.529 0.15 0 CA-C-N 114.193 -1.367 . . . . 0.0 112.785 -178.053 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 37.7 tt0 -66.77 157.4 32.95 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.063 -0.971 . . . . 0.0 110.539 179.247 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 66.8 m-20 -139.22 137.03 35.62 Favored 'General case' 0 N--CA 1.478 0.937 0 C-N-CA 123.138 0.575 . . . . 0.0 110.297 179.836 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 17.9 t -85.39 -116.67 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.064 0 N-CA-C 108.519 -0.919 . . . . 0.0 108.519 179.558 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -108.16 54.61 0.55 Allowed Glycine 0 N--CA 1.474 1.228 0 N-CA-C 111.1 -0.8 . . . . 0.0 111.1 179.96 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 73.2 p -80.42 125.47 29.96 Favored 'General case' 0 N--CA 1.466 0.336 0 N-CA-C 108.841 -0.8 . . . . 0.0 108.841 178.329 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 27' ' ' ASN . . . . . 0.476 HD22 ' CG ' ' A' ' 11' ' ' GLU . 48.3 t30 -65.64 100.55 0.53 Allowed 'General case' 0 N--CA 1.474 0.757 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 178.684 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 66.8 mttm -95.8 116.86 29.52 Favored 'General case' 0 N--CA 1.485 1.324 0 N-CA-C 109.977 -0.379 . . . . 0.0 109.977 -179.055 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.73 -133.32 0.01 OUTLIER Glycine 0 CA--C 1.534 1.248 0 N-CA-C 110.761 -0.936 . . . . 0.0 110.761 178.954 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -113.73 127.65 56.11 Favored 'General case' 0 N--CA 1.479 1.016 0 N-CA-C 109.231 -0.655 . . . . 0.0 109.231 178.981 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 66.7 mt -90.66 130.15 40.34 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.644 0 N-CA-C 107.492 -1.299 . . . . 0.0 107.492 178.746 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 17.8 mt -142.59 152.49 17.71 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.909 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -178.864 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 65.52 47.44 78.07 Favored Glycine 0 CA--C 1.524 0.604 0 CA-C-N 116.0 -0.545 . . . . 0.0 112.666 178.877 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 2.9 tt -98.16 120.38 38.46 Favored 'General case' 0 N--CA 1.477 0.92 0 N-CA-C 107.231 -1.396 . . . . 0.0 107.231 177.864 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 28.1 ttt -152.48 158.16 42.19 Favored 'General case' 0 N--CA 1.471 0.577 0 N-CA-C 108.834 -0.802 . . . . 0.0 108.834 179.401 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 87.3 t -158.3 149.8 8.24 Favored 'Isoleucine or valine' 0 C--O 1.236 0.393 0 N-CA-C 106.856 -1.535 . . . . 0.0 106.856 -179.205 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 37' ' ' GLY . . . . . 0.512 ' H ' HE22 ' C' ' 15' ' ' GLN . . . 56.66 75.08 0.27 Allowed Glycine 0 C--N 1.313 -0.71 0 CA-C-N 115.608 -0.724 . . . . 0.0 111.675 178.101 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 170.55 -149.11 12.17 Favored Glycine 0 CA--C 1.519 0.336 0 N-CA-C 110.593 -1.003 . . . . 0.0 110.593 179.801 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 33.7 m -133.71 142.81 40.49 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.835 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 179.728 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 16.2 t . . . . . 0 CA--C 1.535 0.39 0 CA-C-O 117.888 -1.053 . . . . 0.0 110.983 179.34 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' D' D ' 1' ' ' ASP . . . . . . . . . . . . . 8.5 m-20 . . . . . 0 N--CA 1.492 1.626 0 N-CA-C 109.143 -0.688 . . . . 0.0 109.143 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' D' D ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.47 131.29 46.7 Favored 'General case' 0 CA--C 1.535 0.387 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.376 179.851 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 3' ' ' GLU . . . . . . . . . . . . . 54.1 tt0 -169.34 110.83 0.47 Allowed 'General case' 0 N--CA 1.47 0.525 0 N-CA-C 109.379 -0.601 . . . . 0.0 109.379 179.676 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 86.9 m-85 -87.46 147.69 25.29 Favored 'General case' 0 C--N 1.363 1.158 0 C-N-CA 118.671 -1.211 . . . . 0.0 108.261 179.771 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 5' ' ' ARG . . . . . . . . . . . . . 72.0 mtp180 -147.32 141.52 26.16 Favored 'General case' 0 N--CA 1.475 0.821 0 N-CA-C 109.13 -0.692 . . . . 0.0 109.13 179.888 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 76.9 m80 -149.14 123.68 9.74 Favored 'General case' 0 C--O 1.219 -0.541 0 N-CA-C 107.758 -1.201 . . . . 0.0 107.758 175.638 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 7' ' ' ASP . . . . . . . . . . . . . 6.1 m-20 -63.45 133.26 53.64 Favored 'General case' 0 C--N 1.322 -0.613 0 C-N-CA 127.036 2.134 . . . . 0.0 114.832 176.15 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 8' ' ' SER . . . . . 0.551 ' HG ' ' H ' ' D' ' 9' ' ' GLY . 7.0 t -154.2 173.62 15.87 Favored 'General case' 0 N--CA 1.478 0.961 0 CA-C-N 118.609 0.64 . . . . 0.0 110.406 176.996 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' D' D ' 9' ' ' GLY . . . . . 0.551 ' H ' ' HG ' ' D' ' 8' ' ' SER . . . 124.15 20.83 2.41 Favored Glycine 0 N--CA 1.484 1.842 0 N-CA-C 112.159 -0.377 . . . . 0.0 112.159 176.398 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 37.7 p90 -55.56 130.5 43.17 Favored 'General case' 0 CA--C 1.546 0.79 0 CA-C-O 121.176 0.513 . . . . 0.0 111.842 -176.771 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 11' ' ' GLU . . . . . 0.422 ' CG ' HD22 ' F' ' 27' ' ' ASN . 46.0 mt-10 -84.89 152.35 23.62 Favored 'General case' 0 N--CA 1.473 0.698 0 N-CA-C 109.703 -0.48 . . . . 0.0 109.703 177.663 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -149.56 130.13 4.42 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.426 0 N-CA-C 108.409 -0.96 . . . . 0.0 108.409 175.792 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 48.5 m-70 -129.53 148.34 51.42 Favored 'General case' 0 N--CA 1.483 1.184 0 CA-C-N 117.992 0.36 . . . . 0.0 111.116 176.84 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 6.5 t60 -165.02 104.85 0.78 Allowed 'General case' 0 N--CA 1.482 1.145 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 173.76 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 15' ' ' GLN . . . . . 0.531 HE22 ' H ' ' D' ' 37' ' ' GLY . 54.3 mt-30 -111.78 -175.49 2.71 Favored 'General case' 0 CA--C 1.492 -1.255 0 N-CA-C 107.977 -1.12 . . . . 0.0 107.977 179.065 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 88.7 tttt -163.39 106.02 0.99 Allowed 'General case' 0 CA--C 1.536 0.433 0 N-CA-C 107.656 -1.239 . . . . 0.0 107.656 175.62 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 5.5 mp -112.42 162.73 15.25 Favored 'General case' 0 N--CA 1.488 1.447 0 N-CA-C 107.887 -1.153 . . . . 0.0 107.887 179.655 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 47.3 t -141.0 123.81 15.59 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.192 0 N-CA-C 109.053 -0.721 . . . . 0.0 109.053 175.834 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 78.3 m-85 -62.91 151.46 39.29 Favored 'General case' 0 C--N 1.352 0.685 0 C-N-CA 124.74 1.216 . . . . 0.0 110.396 170.501 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 9.8 t80 -170.1 -66.8 0.02 OUTLIER 'General case' 0 N--CA 1.477 0.903 0 N-CA-C 107.666 -1.235 . . . . 0.0 107.666 -179.629 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -37.91 95.66 0.01 OUTLIER 'General case' 0 CA--C 1.536 0.428 0 CA-C-N 114.019 -1.446 . . . . 0.0 111.663 -174.583 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 38.1 tt0 -68.35 158.19 34.07 Favored 'General case' 0 N--CA 1.467 0.388 0 CA-C-N 113.435 -1.711 . . . . 0.0 110.376 178.493 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 67.6 m-20 -139.54 140.65 37.19 Favored 'General case' 0 N--CA 1.476 0.834 0 N-CA-C 109.403 -0.592 . . . . 0.0 109.403 178.558 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 24' ' ' VAL . . . . . . . . . . . . . 19.5 t -88.28 -119.97 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.486 1.347 0 N-CA-C 107.779 -1.193 . . . . 0.0 107.779 179.699 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . -111.72 61.91 0.3 Allowed Glycine 0 C--N 1.371 2.478 0 C-N-CA 118.075 -2.012 . . . . 0.0 109.317 178.824 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 89.0 p -70.57 121.35 17.69 Favored 'General case' 0 C--O 1.243 0.713 0 CA-C-O 116.555 -1.688 . . . . 0.0 111.775 169.24 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 27' ' ' ASN . . . . . 0.409 HD22 ' CG ' ' E' ' 11' ' ' GLU . 54.6 t30 -61.2 101.8 0.18 Allowed 'General case' 0 N--CA 1.476 0.864 0 CA-C-N 121.558 1.981 . . . . 0.0 109.501 172.957 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 66.2 mttm -99.14 119.28 37.59 Favored 'General case' 0 N--CA 1.491 1.621 0 CA-C-N 119.427 1.012 . . . . 0.0 109.127 179.217 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -55.07 -134.39 0.0 OUTLIER Glycine 0 C--N 1.343 0.931 0 CA-C-N 115.607 -0.724 . . . . 0.0 113.379 175.931 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -113.19 132.65 55.41 Favored 'General case' 0 C--N 1.372 1.565 0 N-CA-C 108.591 -0.892 . . . . 0.0 108.591 174.145 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 68.2 mt -91.88 134.34 30.51 Favored 'Isoleucine or valine' 0 C--N 1.347 0.488 0 N-CA-C 106.929 -1.508 . . . . 0.0 106.929 176.459 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 20.0 mt -144.78 155.02 14.34 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.965 0 N-CA-C 109.2 -0.667 . . . . 0.0 109.2 179.137 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 64.11 46.86 90.03 Favored Glycine 0 C--O 1.245 0.841 0 CA-C-O 119.354 -0.692 . . . . 0.0 112.57 179.059 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 3.5 tt -97.7 132.27 43.49 Favored 'General case' 0 C--N 1.372 1.585 0 N-CA-C 104.569 -2.382 . . . . 0.0 104.569 176.408 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 28.3 ttt -155.9 165.23 37.1 Favored 'General case' 0 N--CA 1.474 0.752 0 N-CA-C 107.783 -1.192 . . . . 0.0 107.783 175.819 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 96.3 t -164.1 154.69 2.26 Favored 'Isoleucine or valine' 0 C--O 1.247 0.973 0 N-CA-C 105.564 -2.013 . . . . 0.0 105.564 176.382 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 37' ' ' GLY . . . . . 0.531 ' H ' HE22 ' D' ' 15' ' ' GLN . . . 61.13 66.67 2.52 Favored Glycine 0 N--CA 1.445 -0.731 0 C-N-CA 117.446 -2.312 . . . . 0.0 113.974 176.577 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 167.64 -147.91 12.28 Favored Glycine 0 N--CA 1.466 0.644 0 CA-C-O 117.701 -1.61 . . . . 0.0 112.176 -179.117 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 33.7 m -130.4 142.69 43.07 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.088 0 CA-C-N 119.352 1.576 . . . . 0.0 109.886 -179.065 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 13.6 t . . . . . 0 C--O 1.212 -0.87 0 N-CA-C 109.54 -0.541 . . . . 0.0 109.54 174.466 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' E' E ' 1' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 . . . . . 0 N--CA 1.489 1.485 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' E' E ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.15 131.25 46.91 Favored 'General case' 0 CA--C 1.536 0.418 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.366 179.807 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' E' E ' 3' ' ' GLU . . . . . . . . . . . . . 54.5 tt0 -169.01 108.85 0.46 Allowed 'General case' 0 N--CA 1.469 0.486 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 -179.847 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 79.4 m-85 -84.88 140.52 31.08 Favored 'General case' 0 N--CA 1.474 0.771 0 N-CA-C 109.907 -0.405 . . . . 0.0 109.907 179.44 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' E' E ' 5' ' ' ARG . . . . . . . . . . . . . 72.5 mtp180 -143.92 142.52 30.81 Favored 'General case' 0 N--CA 1.476 0.842 0 N-CA-C 109.541 -0.54 . . . . 0.0 109.541 179.858 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 76.5 m80 -150.3 118.27 6.28 Favored 'General case' 0 N--CA 1.473 0.686 0 N-CA-C 108.929 -0.767 . . . . 0.0 108.929 179.169 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' E' E ' 7' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -66.69 149.86 49.9 Favored 'General case' 0 N--CA 1.464 0.236 0 O-C-N 123.541 0.526 . . . . 0.0 111.538 -179.5 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' E' E ' 8' ' ' SER . . . . . 0.524 ' HG ' ' H ' ' E' ' 9' ' ' GLY . 7.1 t -167.92 172.4 9.01 Favored 'General case' 0 N--CA 1.476 0.839 0 N-CA-C 109.573 -0.528 . . . . 0.0 109.573 177.901 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' E' E ' 9' ' ' GLY . . . . . 0.524 ' H ' ' HG ' ' E' ' 8' ' ' SER . . . 122.7 24.34 2.13 Favored Glycine 0 N--CA 1.482 1.731 0 N-CA-C 111.922 -0.471 . . . . 0.0 111.922 179.071 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 39.1 p90 -55.66 127.28 29.18 Favored 'General case' 0 N--CA 1.474 0.733 0 N-CA-C 112.627 0.602 . . . . 0.0 112.627 -179.091 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' E' E ' 11' ' ' GLU . . . . . 0.409 ' CG ' HD22 ' D' ' 27' ' ' ASN . 46.4 mt-10 -83.32 155.08 23.76 Favored 'General case' 0 N--CA 1.474 0.76 0 N-CA-C 109.388 -0.597 . . . . 0.0 109.388 177.938 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -155.18 128.77 1.22 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.494 0 N-CA-C 108.386 -0.968 . . . . 0.0 108.386 178.811 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 46.3 m-70 -134.77 143.21 46.99 Favored 'General case' 0 N--CA 1.481 1.095 0 O-C-N 122.324 -0.235 . . . . 0.0 111.225 -177.99 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 6.2 t60 -163.99 98.39 0.85 Allowed 'General case' 0 N--CA 1.486 1.352 0 CA-C-N 116.765 -0.198 . . . . 0.0 111.147 179.814 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' E' E ' 15' ' ' GLN . . . . . 0.478 HE22 ' H ' ' E' ' 37' ' ' GLY . 54.7 mt-30 -107.82 -172.34 2.05 Favored 'General case' 0 CA--C 1.502 -0.9 0 N-CA-C 108.394 -0.965 . . . . 0.0 108.394 179.89 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -166.99 97.73 0.53 Allowed 'General case' 0 CA--C 1.543 0.686 0 CA-C-N 115.056 -0.975 . . . . 0.0 109.414 178.675 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' E' E ' 17' ' ' LEU . . . . . 0.409 ' N ' ' CD1' ' E' ' 17' ' ' LEU . 4.6 mp -105.69 163.32 12.79 Favored 'General case' 0 N--CA 1.49 1.558 0 N-CA-C 109.084 -0.709 . . . . 0.0 109.084 -179.796 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 39.0 t -142.32 118.39 6.0 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.38 0 C-N-CA 122.512 0.325 . . . . 0.0 110.52 179.078 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 51.0 m-85 -69.76 156.87 38.36 Favored 'General case' 0 C--N 1.358 0.964 0 N-CA-C 107.269 -1.382 . . . . 0.0 107.269 176.585 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 13.3 t80 -173.47 -54.96 0.02 OUTLIER 'General case' 0 N--CA 1.485 1.304 0 CA-C-O 121.606 0.717 . . . . 0.0 110.347 179.545 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.1 88.72 0.0 OUTLIER 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 114.396 -1.274 . . . . 0.0 112.843 -178.994 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 37.8 tt0 -64.62 157.88 25.88 Favored 'General case' 0 N--CA 1.471 0.581 0 CA-C-N 114.86 -1.064 . . . . 0.0 110.719 179.701 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 66.3 m-20 -139.97 136.68 34.03 Favored 'General case' 0 N--CA 1.477 0.883 0 C-N-CA 122.948 0.499 . . . . 0.0 110.399 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 21.8 t -85.23 -115.58 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.109 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 179.523 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . -108.97 54.66 0.54 Allowed Glycine 0 C--N 1.348 1.245 0 N-CA-C 111.237 -0.745 . . . . 0.0 111.237 -179.87 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 69.2 p -79.96 125.02 29.22 Favored 'General case' 0 N--CA 1.473 0.723 0 N-CA-C 109.111 -0.7 . . . . 0.0 109.111 177.947 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' E' E ' 27' ' ' ASN . . . . . 0.435 HD22 ' CG ' ' F' ' 11' ' ' GLU . 48.4 t30 -65.37 100.04 0.45 Allowed 'General case' 0 N--CA 1.474 0.747 0 N-CA-C 108.236 -1.024 . . . . 0.0 108.236 178.552 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 66.2 mttm -95.69 116.74 29.3 Favored 'General case' 0 N--CA 1.486 1.351 0 N-CA-C 109.975 -0.38 . . . . 0.0 109.975 -178.708 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.02 -132.82 0.01 OUTLIER Glycine 0 CA--C 1.534 1.271 0 N-CA-C 111.38 -0.688 . . . . 0.0 111.38 178.858 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -114.02 127.09 55.79 Favored 'General case' 0 N--CA 1.477 0.896 0 N-CA-C 109.394 -0.595 . . . . 0.0 109.394 179.187 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 67.2 mt -90.38 131.19 38.21 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.233 0 N-CA-C 107.132 -1.432 . . . . 0.0 107.132 178.688 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 19.5 mt -142.4 154.44 18.3 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.907 0 N-CA-C 109.125 -0.694 . . . . 0.0 109.125 -179.341 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.39 48.86 74.96 Favored Glycine 0 CA--C 1.523 0.537 0 C-N-CA 121.702 -0.285 . . . . 0.0 113.291 178.944 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 3.0 tt -99.3 120.19 39.16 Favored 'General case' 0 N--CA 1.477 0.907 0 N-CA-C 107.143 -1.429 . . . . 0.0 107.143 177.617 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 28.5 ttt -151.68 159.55 43.96 Favored 'General case' 0 N--CA 1.479 1.019 0 N-CA-C 108.552 -0.907 . . . . 0.0 108.552 179.314 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 96.9 t -159.64 149.85 6.59 Favored 'Isoleucine or valine' 0 C--O 1.236 0.384 0 N-CA-C 106.834 -1.543 . . . . 0.0 106.834 -179.504 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' E' E ' 37' ' ' GLY . . . . . 0.478 ' H ' HE22 ' E' ' 15' ' ' GLN . . . 56.71 74.53 0.32 Allowed Glycine 0 C--N 1.312 -0.751 0 CA-C-N 115.659 -0.701 . . . . 0.0 111.452 178.01 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 171.81 -147.24 9.96 Favored Glycine 0 C--O 1.223 -0.569 0 N-CA-C 111.08 -0.808 . . . . 0.0 111.08 179.67 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 33.2 m -135.28 141.85 41.46 Favored 'Isoleucine or valine' 0 C--N 1.353 0.731 0 N-CA-C 109.248 -0.649 . . . . 0.0 109.248 179.695 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 14.5 t . . . . . 0 CA--C 1.537 0.479 0 CA-C-O 117.916 -1.04 . . . . 0.0 111.24 179.383 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' F' F ' 1' ' ' ASP . . . . . . . . . . . . . 8.8 m-20 . . . . . 0 N--CA 1.491 1.602 0 N-CA-C 109.167 -0.679 . . . . 0.0 109.167 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' F' F ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.6 131.13 46.14 Favored 'General case' 0 N--CA 1.467 0.416 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.46 179.777 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 3' ' ' GLU . . . . . . . . . . . . . 55.0 tt0 -168.82 108.68 0.48 Allowed 'General case' 0 N--CA 1.469 0.524 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 -179.736 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 78.8 m-85 -84.68 140.55 31.23 Favored 'General case' 0 N--CA 1.475 0.796 0 N-CA-C 109.981 -0.377 . . . . 0.0 109.981 179.339 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 5' ' ' ARG . . . . . . . . . . . . . 72.2 mtp180 -143.88 142.36 30.77 Favored 'General case' 0 N--CA 1.477 0.911 0 N-CA-C 109.283 -0.636 . . . . 0.0 109.283 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 76.7 m80 -150.24 118.11 6.25 Favored 'General case' 0 N--CA 1.474 0.726 0 N-CA-C 108.936 -0.765 . . . . 0.0 108.936 179.045 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 7' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -66.72 149.94 49.8 Favored 'General case' 0 N--CA 1.464 0.252 0 O-C-N 123.386 0.428 . . . . 0.0 111.595 -179.424 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 8' ' ' SER . . . . . 0.508 ' HG ' ' H ' ' F' ' 9' ' ' GLY . 7.2 t -167.96 172.51 8.86 Favored 'General case' 0 N--CA 1.475 0.815 0 CA-C-N 115.944 -0.571 . . . . 0.0 109.574 177.978 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' F' F ' 9' ' ' GLY . . . . . 0.508 ' H ' ' HG ' ' F' ' 8' ' ' SER . . . 122.47 24.7 2.11 Favored Glycine 0 N--CA 1.483 1.776 0 N-CA-C 111.892 -0.483 . . . . 0.0 111.892 178.986 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 38.6 p90 -56.09 127.52 30.97 Favored 'General case' 0 N--CA 1.474 0.733 0 N-CA-C 112.637 0.606 . . . . 0.0 112.637 -179.061 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 11' ' ' GLU . . . . . 0.435 ' CG ' HD22 ' E' ' 27' ' ' ASN . 46.0 mt-10 -83.25 155.03 23.86 Favored 'General case' 0 N--CA 1.474 0.746 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 177.897 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -155.13 128.61 1.2 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.503 0 N-CA-C 108.43 -0.952 . . . . 0.0 108.43 178.775 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 46.9 m-70 -134.7 143.11 47.02 Favored 'General case' 0 N--CA 1.48 1.051 0 O-C-N 122.275 -0.265 . . . . 0.0 111.194 -177.998 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 6.2 t60 -164.11 98.63 0.84 Allowed 'General case' 0 N--CA 1.486 1.342 0 CA-C-N 116.734 -0.212 . . . . 0.0 111.258 179.917 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 15' ' ' GLN . . . . . 0.493 HE22 ' H ' ' F' ' 37' ' ' GLY . 55.0 mt-30 -108.36 -171.42 1.86 Allowed 'General case' 0 CA--C 1.499 -1.011 0 N-CA-C 108.544 -0.91 . . . . 0.0 108.544 179.885 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -167.53 98.01 0.49 Allowed 'General case' 0 CA--C 1.541 0.605 0 CA-C-N 114.933 -1.03 . . . . 0.0 109.484 178.667 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 17' ' ' LEU . . . . . 0.403 ' CD1' ' N ' ' F' ' 17' ' ' LEU . 4.5 mp -105.73 163.14 12.93 Favored 'General case' 0 N--CA 1.49 1.541 0 N-CA-C 109.151 -0.685 . . . . 0.0 109.151 -179.856 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 39.0 t -142.17 118.41 6.3 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.293 0 C-N-CA 122.573 0.349 . . . . 0.0 110.567 179.121 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 52.3 m-85 -69.78 156.7 38.63 Favored 'General case' 0 C--N 1.358 0.955 0 N-CA-C 107.121 -1.437 . . . . 0.0 107.121 176.482 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 13.9 t80 -173.0 -55.27 0.02 OUTLIER 'General case' 0 N--CA 1.485 1.293 0 CA-C-O 121.811 0.815 . . . . 0.0 109.826 179.645 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.86 88.89 0.0 OUTLIER 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 114.436 -1.256 . . . . 0.0 112.916 -178.938 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 37.8 tt0 -64.78 157.68 26.97 Favored 'General case' 0 N--CA 1.472 0.651 0 CA-C-N 114.935 -1.029 . . . . 0.0 110.784 179.464 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 66.1 m-20 -139.84 137.03 34.61 Favored 'General case' 0 N--CA 1.478 0.955 0 C-N-CA 122.944 0.497 . . . . 0.0 110.346 179.887 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 24' ' ' VAL . . . . . . . . . . . . . 21.6 t -85.62 -115.55 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.482 1.126 0 N-CA-C 108.706 -0.849 . . . . 0.0 108.706 179.502 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -108.8 54.06 0.57 Allowed Glycine 0 N--CA 1.477 1.371 0 N-CA-C 111.235 -0.746 . . . . 0.0 111.235 -179.869 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 69.8 p -79.5 125.04 29.05 Favored 'General case' 0 N--CA 1.473 0.675 0 N-CA-C 109.052 -0.721 . . . . 0.0 109.052 177.876 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 27' ' ' ASN . . . . . 0.422 HD22 ' CG ' ' D' ' 11' ' ' GLU . 48.2 t30 -65.46 100.15 0.47 Allowed 'General case' 0 N--CA 1.473 0.69 0 N-CA-C 108.328 -0.99 . . . . 0.0 108.328 178.533 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 66.1 mttm -95.66 116.82 29.41 Favored 'General case' 0 N--CA 1.485 1.281 0 N-CA-C 110.022 -0.362 . . . . 0.0 110.022 -178.669 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.17 -132.77 0.01 OUTLIER Glycine 0 CA--C 1.533 1.197 0 N-CA-C 111.491 -0.644 . . . . 0.0 111.491 178.916 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -113.85 126.37 55.11 Favored 'General case' 0 N--CA 1.478 0.954 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 179.278 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 67.2 mt -89.97 130.66 38.89 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.209 0 N-CA-C 107.175 -1.417 . . . . 0.0 107.175 178.632 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 19.4 mt -142.11 154.32 18.83 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.877 0 N-CA-C 109.106 -0.701 . . . . 0.0 109.106 -179.333 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.63 48.9 73.21 Favored Glycine 0 CA--C 1.524 0.596 0 CA-C-N 116.476 -0.329 . . . . 0.0 113.289 179.016 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 3.0 tt -99.41 120.26 39.31 Favored 'General case' 0 N--CA 1.478 0.946 0 N-CA-C 107.145 -1.428 . . . . 0.0 107.145 177.771 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 28.5 ttt -151.82 159.66 43.81 Favored 'General case' 0 N--CA 1.477 0.925 0 N-CA-C 108.673 -0.862 . . . . 0.0 108.673 179.437 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 94.5 t -159.76 149.89 6.45 Favored 'Isoleucine or valine' 0 C--O 1.235 0.31 0 N-CA-C 106.865 -1.531 . . . . 0.0 106.865 -179.478 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 37' ' ' GLY . . . . . 0.493 ' H ' HE22 ' F' ' 15' ' ' GLN . . . 56.78 74.35 0.34 Allowed Glycine 0 C--N 1.313 -0.722 0 CA-C-N 115.549 -0.75 . . . . 0.0 111.512 177.904 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 171.91 -147.25 9.93 Favored Glycine 0 C--O 1.223 -0.534 0 N-CA-C 111.099 -0.8 . . . . 0.0 111.099 179.818 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 33.2 m -135.33 141.67 41.91 Favored 'Isoleucine or valine' 0 C--N 1.352 0.715 0 N-CA-C 109.27 -0.641 . . . . 0.0 109.27 179.712 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 15.2 t . . . . . 0 CA--C 1.537 0.473 0 CA-C-O 117.934 -1.031 . . . . 0.0 111.155 179.317 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' G' G ' 1' ' ' ASP . . . . . . . . . . . . . 8.6 m-20 . . . . . 0 N--CA 1.493 1.681 0 N-CA-C 109.521 -0.548 . . . . 0.0 109.521 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' G' G ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.59 129.36 40.24 Favored 'General case' 0 N--CA 1.469 0.481 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.544 179.616 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 3' ' ' GLU . . . . . . . . . . . . . 52.3 tt0 -168.64 108.71 0.5 Allowed 'General case' 0 N--CA 1.471 0.614 0 N-CA-C 110.104 -0.332 . . . . 0.0 110.104 179.742 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 79.4 m-85 -85.48 139.88 31.14 Favored 'General case' 0 N--CA 1.474 0.765 0 N-CA-C 109.543 -0.54 . . . . 0.0 109.543 179.333 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 5' ' ' ARG . . . . . . . . . . . . . 72.2 mtp180 -144.05 141.52 30.14 Favored 'General case' 0 N--CA 1.483 1.221 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 -179.612 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 76.8 m80 -149.24 119.29 7.18 Favored 'General case' 0 N--CA 1.473 0.679 0 N-CA-C 108.952 -0.759 . . . . 0.0 108.952 179.026 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 8.9 m-20 -68.55 145.46 53.97 Favored 'General case' 0 N--CA 1.468 0.462 0 O-C-N 123.578 0.549 . . . . 0.0 111.945 -179.319 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 8' ' ' SER . . . . . 0.501 ' HG ' ' H ' ' G' ' 9' ' ' GLY . 6.0 t -164.64 173.52 11.83 Favored 'General case' 0 N--CA 1.468 0.461 0 N-CA-C 109.386 -0.598 . . . . 0.0 109.386 178.208 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' G' G ' 9' ' ' GLY . . . . . 0.501 ' H ' ' HG ' ' G' ' 8' ' ' SER . . . 122.36 24.45 2.19 Favored Glycine 0 N--CA 1.48 1.584 0 N-CA-C 111.639 -0.584 . . . . 0.0 111.639 178.934 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 42.4 p90 -56.24 127.56 31.4 Favored 'General case' 0 N--CA 1.474 0.745 0 N-CA-C 112.516 0.562 . . . . 0.0 112.516 -178.757 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 45.7 mt-10 -83.61 154.24 23.86 Favored 'General case' 0 N--CA 1.471 0.601 0 CA-C-O 120.971 0.415 . . . . 0.0 109.882 178.638 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 2.6 p -155.5 128.51 1.13 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.959 0 N-CA-C 108.431 -0.951 . . . . 0.0 108.431 178.972 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 49.6 m-70 -133.6 144.64 49.41 Favored 'General case' 0 N--CA 1.477 0.876 0 CA-C-N 115.454 -0.793 . . . . 0.0 110.934 -178.177 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 6.3 t60 -165.65 98.62 0.68 Allowed 'General case' 0 N--CA 1.483 1.2 0 CA-C-N 116.589 -0.278 . . . . 0.0 110.805 179.193 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 15' ' ' GLN . . . . . 0.504 HE22 ' H ' ' G' ' 37' ' ' GLY . 54.5 mt-30 -108.49 -171.92 1.95 Allowed 'General case' 0 CA--C 1.501 -0.915 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 179.916 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -167.31 97.91 0.5 Allowed 'General case' 0 CA--C 1.542 0.641 0 CA-C-N 114.96 -1.018 . . . . 0.0 109.388 178.717 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 17' ' ' LEU . . . . . 0.412 ' N ' ' CD1' ' G' ' 17' ' ' LEU . 5.1 mp -105.38 162.41 13.47 Favored 'General case' 0 N--CA 1.487 1.402 0 N-CA-C 109.32 -0.622 . . . . 0.0 109.32 -179.685 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 36.5 t -143.13 118.52 4.6 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.009 0 CA-C-O 120.83 0.348 . . . . 0.0 110.442 178.851 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 46.5 m-85 -69.76 150.32 47.03 Favored 'General case' 0 C--N 1.37 1.481 0 N-CA-C 107.263 -1.384 . . . . 0.0 107.263 176.595 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 11.3 t80 -170.5 -55.06 0.02 OUTLIER 'General case' 0 N--CA 1.487 1.406 0 CA-C-N 117.953 0.342 . . . . 0.0 110.328 -179.583 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.68 89.9 0.0 OUTLIER 'General case' 0 C--N 1.325 -0.491 0 C-N-CA 123.774 0.83 . . . . 0.0 112.508 -179.839 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 38.0 tt0 -65.41 158.54 26.41 Favored 'General case' 0 N--CA 1.469 0.476 0 CA-C-N 114.714 -1.13 . . . . 0.0 109.954 179.146 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 67.4 m-20 -140.09 136.8 33.97 Favored 'General case' 0 N--CA 1.478 0.937 0 C-N-CA 122.874 0.469 . . . . 0.0 109.98 179.904 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 24' ' ' VAL . . . . . . . . . . . . . 21.5 t -85.95 -115.61 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 1.004 0 N-CA-C 108.506 -0.924 . . . . 0.0 108.506 179.555 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -108.61 54.04 0.57 Allowed Glycine 0 N--CA 1.477 1.397 0 N-CA-C 111.492 -0.643 . . . . 0.0 111.492 -179.868 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 72.6 p -79.96 125.57 29.92 Favored 'General case' 0 N--CA 1.467 0.389 0 N-CA-C 108.943 -0.762 . . . . 0.0 108.943 177.971 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 47.5 t30 -65.76 100.98 0.59 Allowed 'General case' 0 N--CA 1.47 0.566 0 N-CA-C 108.567 -0.901 . . . . 0.0 108.567 178.525 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 66.6 mttm -95.76 117.2 30.09 Favored 'General case' 0 N--CA 1.485 1.309 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 -179.13 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.94 -131.95 0.01 OUTLIER Glycine 0 CA--C 1.53 1.005 0 N-CA-C 110.579 -1.008 . . . . 0.0 110.579 178.946 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -113.74 126.48 55.27 Favored 'General case' 0 N--CA 1.469 0.499 0 N-CA-C 109.522 -0.547 . . . . 0.0 109.522 179.542 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 69.3 mt -89.94 131.38 37.34 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.756 0 N-CA-C 107.327 -1.36 . . . . 0.0 107.327 178.495 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 22.7 mt -143.29 155.09 16.74 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.397 0 CA-C-N 118.982 0.81 . . . . 0.0 109.056 -179.751 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.74 48.2 79.29 Favored Glycine 0 CA--C 1.527 0.782 0 CA-C-N 116.659 -0.246 . . . . 0.0 112.835 179.053 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 2.9 tt -98.87 121.19 40.5 Favored 'General case' 0 N--CA 1.478 0.955 0 N-CA-C 107.086 -1.449 . . . . 0.0 107.086 177.75 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 28.7 ttt -153.08 160.21 42.9 Favored 'General case' 0 N--CA 1.477 0.882 0 N-CA-C 108.172 -1.047 . . . . 0.0 108.172 179.493 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 84.4 t -159.81 150.2 6.31 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.255 0 N-CA-C 106.419 -1.697 . . . . 0.0 106.419 -179.354 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 37' ' ' GLY . . . . . 0.504 ' H ' HE22 ' G' ' 15' ' ' GLN . . . 56.59 74.86 0.29 Allowed Glycine 0 C--N 1.312 -0.756 0 C-N-CA 120.975 -0.631 . . . . 0.0 112.049 177.727 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 170.28 -145.79 9.39 Favored Glycine 0 N--CA 1.467 0.702 0 N-CA-C 110.614 -0.995 . . . . 0.0 110.614 179.127 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 33.9 m -135.91 142.06 40.08 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.873 0 N-CA-C 109.911 -0.403 . . . . 0.0 109.911 -179.887 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 15.4 t . . . . . 0 N--CA 1.466 0.349 0 CA-C-O 118.046 -0.978 . . . . 0.0 111.304 179.463 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' H' H ' 1' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 . . . . . 0 N--CA 1.49 1.566 0 N-CA-C 109.669 -0.493 . . . . 0.0 109.669 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' H' H ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.56 129.48 40.8 Favored 'General case' 0 N--CA 1.468 0.466 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.472 179.597 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' H' H ' 3' ' ' GLU . . . . . . . . . . . . . 53.5 tt0 -168.66 108.52 0.49 Allowed 'General case' 0 N--CA 1.469 0.519 0 N-CA-C 110.099 -0.334 . . . . 0.0 110.099 179.804 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 80.1 m-85 -85.18 140.04 31.21 Favored 'General case' 0 N--CA 1.474 0.769 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 179.333 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' H' H ' 5' ' ' ARG . . . . . . . . . . . . . 72.3 mtp180 -144.11 141.85 30.26 Favored 'General case' 0 N--CA 1.483 1.191 0 N-CA-C 109.294 -0.632 . . . . 0.0 109.294 -179.635 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 76.9 m80 -149.67 118.87 6.78 Favored 'General case' 0 N--CA 1.473 0.695 0 N-CA-C 109.105 -0.702 . . . . 0.0 109.105 179.129 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 8.8 m-20 -68.25 145.2 54.48 Favored 'General case' 0 N--CA 1.469 0.48 0 O-C-N 123.469 0.481 . . . . 0.0 111.924 -179.309 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' H' H ' 8' ' ' SER . . . . . 0.525 ' HG ' ' H ' ' H' ' 9' ' ' GLY . 7.5 t -164.36 172.96 12.77 Favored 'General case' 0 N--CA 1.469 0.507 0 N-CA-C 109.449 -0.575 . . . . 0.0 109.449 178.421 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' H' H ' 9' ' ' GLY . . . . . 0.525 ' H ' ' HG ' ' H' ' 8' ' ' SER . . . 122.43 24.46 2.17 Favored Glycine 0 N--CA 1.481 1.665 0 N-CA-C 111.733 -0.547 . . . . 0.0 111.733 179.112 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 42.1 p90 -56.38 127.51 31.37 Favored 'General case' 0 N--CA 1.473 0.707 0 N-CA-C 112.428 0.529 . . . . 0.0 112.428 -178.795 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 45.4 mt-10 -83.51 154.2 24.0 Favored 'General case' 0 N--CA 1.473 0.676 0 CA-C-O 120.984 0.421 . . . . 0.0 109.874 178.62 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.6 p -155.41 128.41 1.13 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.975 0 N-CA-C 108.433 -0.951 . . . . 0.0 108.433 178.963 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 52.1 m-70 -133.42 144.63 49.65 Favored 'General case' 0 N--CA 1.476 0.863 0 CA-C-N 115.43 -0.804 . . . . 0.0 110.893 -178.16 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 6.4 t60 -165.61 98.48 0.68 Allowed 'General case' 0 N--CA 1.482 1.146 0 CA-C-N 116.527 -0.306 . . . . 0.0 110.839 179.146 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' H' H ' 15' ' ' GLN . . . . . 0.499 HE22 ' H ' ' H' ' 37' ' ' GLY . 54.2 mt-30 -108.24 -172.45 2.06 Favored 'General case' 0 CA--C 1.5 -0.979 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 -179.921 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -167.01 97.78 0.52 Allowed 'General case' 0 CA--C 1.539 0.521 0 CA-C-N 114.989 -1.005 . . . . 0.0 109.402 178.73 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' H' H ' 17' ' ' LEU . . . . . 0.413 ' N ' ' CD1' ' H' ' 17' ' ' LEU . 5.1 mp -105.5 162.13 13.74 Favored 'General case' 0 N--CA 1.488 1.442 0 N-CA-C 109.292 -0.633 . . . . 0.0 109.292 -179.632 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 38.5 t -142.79 118.54 5.16 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.097 0 CA-C-O 120.905 0.383 . . . . 0.0 110.482 178.874 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 47.5 m-85 -70.14 150.89 46.06 Favored 'General case' 0 C--N 1.37 1.498 0 N-CA-C 107.391 -1.336 . . . . 0.0 107.391 176.585 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 11.9 t80 -171.88 -54.41 0.02 OUTLIER 'General case' 0 N--CA 1.485 1.28 0 CA-C-N 117.828 0.286 . . . . 0.0 110.323 -179.456 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.99 90.22 0.0 OUTLIER 'General case' 0 CA--C 1.536 0.437 0 C-N-CA 123.59 0.756 . . . . 0.0 112.262 -179.824 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 37.9 tt0 -65.38 158.63 26.09 Favored 'General case' 0 N--CA 1.468 0.465 0 CA-C-N 114.739 -1.118 . . . . 0.0 110.011 179.318 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 66.8 m-20 -140.18 136.98 34.01 Favored 'General case' 0 N--CA 1.477 0.899 0 C-N-CA 122.942 0.497 . . . . 0.0 109.972 179.872 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' H' H ' 24' ' ' VAL . . . . . . . . . . . . . 21.5 t -86.36 -115.55 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.049 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 179.605 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . -108.3 53.44 0.6 Allowed Glycine 0 N--CA 1.479 1.564 0 N-CA-C 111.395 -0.682 . . . . 0.0 111.395 -179.828 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 70.1 p -79.46 125.28 29.35 Favored 'General case' 0 N--CA 1.468 0.45 0 N-CA-C 108.893 -0.781 . . . . 0.0 108.893 178.004 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 47.5 t30 -65.69 100.91 0.57 Allowed 'General case' 0 N--CA 1.472 0.662 0 N-CA-C 108.497 -0.927 . . . . 0.0 108.497 178.5 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 66.6 mttm -95.89 117.09 29.93 Favored 'General case' 0 N--CA 1.485 1.283 0 N-CA-C 109.97 -0.382 . . . . 0.0 109.97 -179.146 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.66 -131.75 0.01 OUTLIER Glycine 0 CA--C 1.531 1.059 0 N-CA-C 110.802 -0.919 . . . . 0.0 110.802 178.921 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -114.0 126.24 54.91 Favored 'General case' 0 N--CA 1.471 0.604 0 N-CA-C 109.61 -0.515 . . . . 0.0 109.61 179.527 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 69.4 mt -89.79 131.13 37.82 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.701 0 N-CA-C 107.338 -1.356 . . . . 0.0 107.338 178.55 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 23.3 mt -143.11 155.05 17.02 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.339 0 CA-C-N 118.826 0.739 . . . . 0.0 109.024 -179.698 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.65 48.12 80.36 Favored Glycine 0 CA--C 1.524 0.626 0 CA-C-O 120.117 -0.269 . . . . 0.0 112.891 179.045 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 2.9 tt -98.75 121.09 40.25 Favored 'General case' 0 N--CA 1.478 0.969 0 N-CA-C 107.117 -1.438 . . . . 0.0 107.117 177.617 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 28.7 ttt -152.89 159.95 43.03 Favored 'General case' 0 N--CA 1.478 0.974 0 N-CA-C 108.07 -1.085 . . . . 0.0 108.07 179.61 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 87.2 t -159.66 150.34 6.43 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.261 0 N-CA-C 106.448 -1.686 . . . . 0.0 106.448 -179.51 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' H' H ' 37' ' ' GLY . . . . . 0.499 ' H ' HE22 ' H' ' 15' ' ' GLN . . . 56.35 74.96 0.27 Allowed Glycine 0 C--N 1.311 -0.811 0 C-N-CA 120.979 -0.629 . . . . 0.0 112.015 177.804 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 170.24 -146.2 9.7 Favored Glycine 0 N--CA 1.467 0.744 0 N-CA-C 110.539 -1.024 . . . . 0.0 110.539 179.129 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 34.0 m -135.57 142.02 40.64 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.815 0 N-CA-C 109.951 -0.388 . . . . 0.0 109.951 -179.875 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 15.9 t . . . . . 0 N--CA 1.467 0.4 0 CA-C-O 118.058 -0.973 . . . . 0.0 111.327 179.45 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' I' I ' 1' ' ' ASP . . . . . . . . . . . . . 8.7 m-20 . . . . . 0 N--CA 1.492 1.628 0 N-CA-C 109.572 -0.529 . . . . 0.0 109.572 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' I' I ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.85 129.62 41.26 Favored 'General case' 0 N--CA 1.468 0.456 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.403 179.625 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' I' I ' 3' ' ' GLU . . . . . . . . . . . . . 53.6 tt0 -168.75 108.31 0.48 Allowed 'General case' 0 N--CA 1.47 0.548 0 N-CA-C 110.166 -0.309 . . . . 0.0 110.166 179.773 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 79.6 m-85 -84.96 140.3 31.17 Favored 'General case' 0 N--CA 1.474 0.726 0 N-CA-C 109.643 -0.503 . . . . 0.0 109.643 179.333 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' I' I ' 5' ' ' ARG . . . . . . . . . . . . . 72.4 mtp180 -144.48 141.67 29.72 Favored 'General case' 0 N--CA 1.484 1.265 0 N-CA-C 109.224 -0.658 . . . . 0.0 109.224 -179.581 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 76.8 m80 -149.47 119.13 6.99 Favored 'General case' 0 N--CA 1.474 0.728 0 N-CA-C 109.08 -0.711 . . . . 0.0 109.08 178.999 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 8.9 m-20 -68.45 145.19 54.31 Favored 'General case' 0 N--CA 1.469 0.499 0 O-C-N 123.429 0.456 . . . . 0.0 111.866 -179.235 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' I' I ' 8' ' ' SER . . . . . 0.494 ' HG ' ' H ' ' I' ' 9' ' ' GLY . 7.5 t -164.33 172.62 13.25 Favored 'General case' 0 N--CA 1.469 0.509 0 N-CA-C 109.463 -0.569 . . . . 0.0 109.463 178.368 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' I' I ' 9' ' ' GLY . . . . . 0.494 ' H ' ' HG ' ' I' ' 8' ' ' SER . . . 122.92 24.62 2.03 Favored Glycine 0 N--CA 1.481 1.684 0 N-CA-C 111.7 -0.56 . . . . 0.0 111.7 179.104 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 42.4 p90 -56.52 127.53 31.69 Favored 'General case' 0 N--CA 1.474 0.762 0 N-CA-C 112.424 0.528 . . . . 0.0 112.424 -178.758 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 45.7 mt-10 -83.56 154.12 23.98 Favored 'General case' 0 N--CA 1.473 0.719 0 CA-C-O 121.071 0.463 . . . . 0.0 109.816 178.62 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 2.6 p -155.3 128.27 1.12 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.005 0 N-CA-C 108.389 -0.967 . . . . 0.0 108.389 178.956 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 50.9 m-70 -133.35 144.36 49.57 Favored 'General case' 0 N--CA 1.477 0.922 0 CA-C-N 115.45 -0.795 . . . . 0.0 110.966 -178.163 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 6.4 t60 -165.45 98.71 0.7 Allowed 'General case' 0 N--CA 1.483 1.177 0 CA-C-N 116.559 -0.291 . . . . 0.0 110.794 179.203 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' I' I ' 15' ' ' GLN . . . . . 0.514 HE22 ' H ' ' I' ' 37' ' ' GLY . 54.4 mt-30 -108.64 -172.46 2.06 Favored 'General case' 0 CA--C 1.499 -1.001 0 N-CA-C 108.405 -0.961 . . . . 0.0 108.405 179.979 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -166.78 98.02 0.55 Allowed 'General case' 0 CA--C 1.539 0.553 0 CA-C-N 114.933 -1.031 . . . . 0.0 109.423 178.745 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' I' I ' 17' ' ' LEU . . . . . 0.407 ' CD1' ' N ' ' I' ' 17' ' ' LEU . 5.1 mp -105.56 162.19 13.71 Favored 'General case' 0 N--CA 1.487 1.402 0 N-CA-C 109.327 -0.62 . . . . 0.0 109.327 -179.701 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 38.8 t -142.88 118.54 4.98 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.024 0 CA-C-O 120.987 0.423 . . . . 0.0 110.471 178.848 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 47.8 m-85 -70.01 150.89 46.18 Favored 'General case' 0 C--N 1.37 1.465 0 N-CA-C 107.306 -1.368 . . . . 0.0 107.306 176.567 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 12.0 t80 -171.94 -54.29 0.02 OUTLIER 'General case' 0 N--CA 1.483 1.206 0 CA-C-N 117.922 0.328 . . . . 0.0 110.408 -179.49 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.18 90.18 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.447 0 C-N-CA 123.713 0.805 . . . . 0.0 112.302 -179.893 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 38.2 tt0 -65.37 158.57 26.2 Favored 'General case' 0 N--CA 1.469 0.519 0 CA-C-N 114.738 -1.119 . . . . 0.0 110.045 179.254 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 66.3 m-20 -140.27 136.81 33.69 Favored 'General case' 0 N--CA 1.478 0.937 0 C-N-CA 122.859 0.464 . . . . 0.0 109.989 179.844 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' I' I ' 24' ' ' VAL . . . . . . . . . . . . . 21.3 t -86.04 -115.9 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.957 0 N-CA-C 108.542 -0.911 . . . . 0.0 108.542 179.559 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . -108.1 54.12 0.57 Allowed Glycine 0 N--CA 1.478 1.453 0 N-CA-C 111.384 -0.687 . . . . 0.0 111.384 -179.845 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 73.4 p -80.08 125.14 29.42 Favored 'General case' 0 N--CA 1.467 0.399 0 N-CA-C 108.962 -0.755 . . . . 0.0 108.962 177.889 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 48.1 t30 -65.49 101.01 0.54 Allowed 'General case' 0 CA--C 1.54 0.583 0 N-CA-C 108.539 -0.911 . . . . 0.0 108.539 178.588 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 66.5 mttm -95.88 117.07 29.88 Favored 'General case' 0 N--CA 1.485 1.321 0 N-CA-C 109.98 -0.378 . . . . 0.0 109.98 -179.177 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.68 -132.1 0.01 OUTLIER Glycine 0 CA--C 1.533 1.186 0 N-CA-C 110.652 -0.979 . . . . 0.0 110.652 178.975 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -113.55 126.12 54.95 Favored 'General case' 0 N--CA 1.472 0.635 0 C-N-CA 123.009 0.524 . . . . 0.0 109.622 179.547 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 70.1 mt -89.81 131.51 36.89 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.752 0 N-CA-C 107.219 -1.401 . . . . 0.0 107.219 178.567 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 23.5 mt -143.49 155.12 16.42 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.36 0 CA-C-N 118.883 0.765 . . . . 0.0 108.994 -179.69 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.57 48.18 80.17 Favored Glycine 0 CA--C 1.525 0.661 0 CA-C-N 116.635 -0.257 . . . . 0.0 112.846 179.082 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 2.9 tt -98.78 121.19 40.41 Favored 'General case' 0 N--CA 1.478 0.956 0 N-CA-C 107.002 -1.481 . . . . 0.0 107.002 177.625 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 28.6 ttt -153.0 159.93 42.96 Favored 'General case' 0 N--CA 1.478 0.931 0 N-CA-C 108.057 -1.09 . . . . 0.0 108.057 179.543 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 86.9 t -159.67 150.33 6.42 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.243 0 N-CA-C 106.372 -1.714 . . . . 0.0 106.372 -179.518 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' I' I ' 37' ' ' GLY . . . . . 0.514 ' H ' HE22 ' I' ' 15' ' ' GLN . . . 56.52 74.61 0.31 Allowed Glycine 0 C--N 1.312 -0.762 0 C-N-CA 120.898 -0.668 . . . . 0.0 112.083 177.777 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 170.49 -146.12 9.57 Favored Glycine 0 N--CA 1.466 0.664 0 N-CA-C 110.599 -1.0 . . . . 0.0 110.599 179.131 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 34.0 m -135.67 141.99 40.57 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.807 0 N-CA-C 109.882 -0.414 . . . . 0.0 109.882 -179.834 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 16.2 t . . . . . 0 C--O 1.223 -0.315 0 CA-C-O 118.035 -0.984 . . . . 0.0 111.275 179.465 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 9.6 m-20 . . . . . 0 N--CA 1.49 1.538 0 N-CA-C 109.098 -0.704 . . . . 0.0 109.098 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -66.45 148.26 52.13 Favored 'General case' 0 N--CA 1.467 0.399 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.119 179.674 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 56.0 tt0 -162.14 104.17 1.14 Allowed 'General case' 0 N--CA 1.472 0.628 0 N-CA-C 110.035 -0.358 . . . . 0.0 110.035 179.641 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 20.2 m-85 -71.02 172.54 8.9 Favored 'General case' 0 N--CA 1.47 0.56 0 N-CA-C 109.495 -0.557 . . . . 0.0 109.495 179.533 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 31.9 mtp180 -67.96 130.38 42.79 Favored 'General case' 0 C--O 1.218 -0.602 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.154 -178.027 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 48.0 m170 -100.34 131.54 46.22 Favored 'General case' 0 N--CA 1.474 0.733 0 N-CA-C 109.461 -0.57 . . . . 0.0 109.461 179.457 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 13.8 m-20 -71.42 141.03 50.31 Favored 'General case' 0 CA--C 1.53 0.19 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.819 -179.748 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' SER . . . . . 0.41 ' O ' ' O ' ' C' ' 25' ' ' GLY . 8.7 t -143.53 -173.35 3.93 Favored 'General case' 0 N--CA 1.48 1.032 0 N-CA-C 109.016 -0.735 . . . . 0.0 109.016 178.498 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 117.88 11.49 8.4 Favored Glycine 0 N--CA 1.486 1.993 0 N-CA-C 112.543 -0.223 . . . . 0.0 112.543 179.197 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 47.8 p90 -59.2 128.36 36.76 Favored 'General case' 0 N--CA 1.471 0.622 0 CA-C-O 120.768 0.318 . . . . 0.0 111.849 -179.593 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 46.6 mt-10 -89.8 154.67 19.73 Favored 'General case' 0 N--CA 1.471 0.598 0 N-CA-C 109.299 -0.63 . . . . 0.0 109.299 178.548 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -153.58 128.92 1.57 Allowed 'Isoleucine or valine' 0 C--O 1.235 0.297 0 N-CA-C 108.072 -1.084 . . . . 0.0 108.072 178.641 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 50.1 m-70 -135.37 147.04 48.95 Favored 'General case' 0 N--CA 1.49 1.565 0 CA-C-N 118.834 0.743 . . . . 0.0 111.114 -179.108 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 6.4 t60 -164.94 97.57 0.74 Allowed 'General case' 0 N--CA 1.48 1.056 0 CA-C-N 116.568 -0.287 . . . . 0.0 111.139 179.632 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . 0.483 HE22 ' H ' ' A' ' 37' ' ' GLY . 55.1 mt-30 -108.87 -172.49 2.06 Favored 'General case' 0 CA--C 1.503 -0.856 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 -179.969 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -166.81 98.0 0.55 Allowed 'General case' 0 N--CA 1.473 0.691 0 CA-C-N 115.179 -0.918 . . . . 0.0 109.391 178.795 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . 0.42 ' CD1' ' N ' ' A' ' 17' ' ' LEU . 4.5 mp -106.05 164.17 12.19 Favored 'General case' 0 N--CA 1.489 1.488 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 179.99 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 57.8 t -142.39 119.0 6.34 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.301 0 CA-C-O 118.962 -0.542 . . . . 0.0 109.904 179.527 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 53.2 m-85 -69.81 159.46 33.57 Favored 'General case' 0 N--CA 1.481 1.094 0 N-CA-C 107.491 -1.3 . . . . 0.0 107.491 177.186 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 11.7 t80 -171.68 -58.0 0.02 OUTLIER 'General case' 0 N--CA 1.487 1.417 0 CA-C-O 122.386 1.089 . . . . 0.0 109.815 179.65 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -39.32 89.73 0.0 OUTLIER 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 113.91 -1.496 . . . . 0.0 112.973 -178.03 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 37.1 tt0 -65.47 158.48 26.72 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.119 -0.946 . . . . 0.0 110.603 179.077 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 11.5 m-20 -140.74 137.63 33.57 Favored 'General case' 0 N--CA 1.479 0.994 0 C-N-CA 122.984 0.513 . . . . 0.0 110.249 179.702 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 17.7 t -91.7 -116.68 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.483 1.187 0 N-CA-C 108.64 -0.874 . . . . 0.0 108.64 179.576 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.404 ' O ' ' O ' ' B' ' 8' ' ' SER . . . -102.82 56.99 0.6 Allowed Glycine 0 N--CA 1.473 1.166 0 N-CA-C 110.954 -0.858 . . . . 0.0 110.954 179.997 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 79.6 p -85.25 124.74 32.23 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 178.068 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 61.7 t30 -64.58 100.88 0.41 Allowed 'General case' 0 N--CA 1.474 0.728 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 178.874 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 64.7 mttm -97.27 113.98 25.67 Favored 'General case' 0 N--CA 1.484 1.265 0 N-CA-C 110.011 -0.366 . . . . 0.0 110.011 -178.967 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.65 -134.26 0.01 OUTLIER Glycine 0 CA--C 1.534 1.235 0 N-CA-C 110.741 -0.944 . . . . 0.0 110.741 179.103 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -112.56 127.74 56.16 Favored 'General case' 0 N--CA 1.481 1.092 0 N-CA-C 109.155 -0.683 . . . . 0.0 109.155 178.997 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 65.0 mt -90.32 129.24 41.49 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.623 0 N-CA-C 107.532 -1.285 . . . . 0.0 107.532 178.755 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 12.4 mt -142.96 151.92 17.25 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.793 0 CA-C-N 116.2 -0.455 . . . . 0.0 109.943 -178.891 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 65.21 48.9 64.94 Favored Glycine 0 CA--C 1.524 0.632 0 CA-C-N 115.997 -0.547 . . . . 0.0 112.495 179.01 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 2.8 tt -99.03 121.1 40.52 Favored 'General case' 0 N--CA 1.479 1.009 0 N-CA-C 107.143 -1.429 . . . . 0.0 107.143 178.088 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 27.5 ttt -153.24 158.08 41.16 Favored 'General case' 0 N--CA 1.47 0.539 0 N-CA-C 108.847 -0.797 . . . . 0.0 108.847 179.576 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 85.0 t -158.19 149.32 8.66 Favored 'Isoleucine or valine' 0 C--O 1.238 0.47 0 N-CA-C 106.868 -1.53 . . . . 0.0 106.868 -179.577 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . 0.483 ' H ' HE22 ' A' ' 15' ' ' GLN . . . 57.38 72.42 0.59 Allowed Glycine 0 C--N 1.315 -0.616 0 N-CA-C 111.318 -0.713 . . . . 0.0 111.318 178.342 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 172.74 -157.78 27.36 Favored Glycine 0 C--N 1.332 0.326 0 N-CA-C 110.804 -0.918 . . . . 0.0 110.804 -179.895 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 33.4 m -124.07 143.33 37.73 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.934 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 179.502 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 16.4 t . . . . . 0 CA--C 1.536 0.412 0 CA-C-O 118.056 -0.973 . . . . 0.0 111.062 179.152 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' B' B ' 1' ' ' ASP . . . . . . . . . . . . . 9.5 m-20 . . . . . 0 N--CA 1.49 1.569 0 N-CA-C 109.107 -0.701 . . . . 0.0 109.107 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' B' B ' 2' ' ' ALA . . . . . . . . . . . . . . . -66.56 148.25 52.15 Favored 'General case' 0 N--CA 1.466 0.342 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.09 179.594 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 3' ' ' GLU . . . . . . . . . . . . . 56.3 tt0 -162.09 104.13 1.14 Allowed 'General case' 0 N--CA 1.472 0.644 0 N-CA-C 109.999 -0.371 . . . . 0.0 109.999 179.663 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 21.4 m-85 -71.04 172.49 9.01 Favored 'General case' 0 N--CA 1.47 0.561 0 N-CA-C 109.4 -0.593 . . . . 0.0 109.4 179.622 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 32.2 mtp180 -67.94 129.8 41.01 Favored 'General case' 0 N--CA 1.47 0.529 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.214 -178.019 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 47.7 m170 -99.81 131.79 45.57 Favored 'General case' 0 N--CA 1.476 0.854 0 N-CA-C 109.551 -0.537 . . . . 0.0 109.551 179.407 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 7' ' ' ASP . . . . . . . . . . . . . 13.2 m-20 -71.86 141.25 49.58 Favored 'General case' 0 CA--C 1.532 0.259 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.786 -179.688 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 8' ' ' SER . . . . . 0.404 ' O ' ' O ' ' A' ' 25' ' ' GLY . 8.7 t -143.54 -172.98 3.83 Favored 'General case' 0 N--CA 1.478 0.953 0 N-CA-C 109.017 -0.734 . . . . 0.0 109.017 178.417 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 117.45 11.79 8.53 Favored Glycine 0 N--CA 1.484 1.89 0 N-CA-C 112.513 -0.235 . . . . 0.0 112.513 179.241 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 47.4 p90 -59.33 128.09 35.36 Favored 'General case' 0 CA--C 1.54 0.583 0 N-CA-C 111.815 0.302 . . . . 0.0 111.815 -179.628 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 46.5 mt-10 -89.58 154.51 19.93 Favored 'General case' 0 N--CA 1.473 0.705 0 N-CA-C 109.418 -0.586 . . . . 0.0 109.418 178.552 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -153.48 128.31 1.47 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.286 0 N-CA-C 108.3 -1.0 . . . . 0.0 108.3 178.682 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 49.3 m-70 -134.89 147.35 49.82 Favored 'General case' 0 N--CA 1.489 1.514 0 CA-C-N 118.69 0.677 . . . . 0.0 111.044 -178.944 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 6.5 t60 -165.14 97.65 0.72 Allowed 'General case' 0 N--CA 1.481 1.125 0 CA-C-N 116.608 -0.269 . . . . 0.0 110.992 179.593 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . 0.49 HE22 ' H ' ' B' ' 37' ' ' GLY . 54.9 mt-30 -108.79 -172.79 2.12 Favored 'General case' 0 CA--C 1.501 -0.934 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 179.995 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -166.83 98.08 0.55 Allowed 'General case' 0 CA--C 1.541 0.616 0 CA-C-N 115.142 -0.935 . . . . 0.0 109.404 178.815 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . 0.423 ' N ' ' CD1' ' B' ' 17' ' ' LEU . 4.5 mp -106.2 164.2 12.19 Favored 'General case' 0 N--CA 1.487 1.41 0 N-CA-C 108.606 -0.887 . . . . 0.0 108.606 -179.948 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 58.9 t -142.52 118.46 5.65 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.258 0 CA-C-O 118.999 -0.524 . . . . 0.0 109.959 179.527 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 53.8 m-85 -70.04 159.55 33.62 Favored 'General case' 0 N--CA 1.478 0.942 0 N-CA-C 107.409 -1.33 . . . . 0.0 107.409 177.296 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 12.8 t80 -172.36 -56.98 0.02 OUTLIER 'General case' 0 N--CA 1.484 1.271 0 CA-C-O 122.233 1.016 . . . . 0.0 109.851 179.622 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -39.63 90.37 0.0 OUTLIER 'General case' 0 CA--C 1.529 0.138 0 CA-C-N 114.148 -1.387 . . . . 0.0 112.823 -178.163 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 36.9 tt0 -66.13 158.11 29.47 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 115.068 -0.969 . . . . 0.0 110.618 179.163 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 11.8 m-20 -140.18 138.38 35.12 Favored 'General case' 0 N--CA 1.48 1.058 0 C-N-CA 122.978 0.511 . . . . 0.0 110.127 179.697 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 17.9 t -92.73 -116.95 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.484 1.232 0 N-CA-C 108.707 -0.849 . . . . 0.0 108.707 179.543 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . 0.41 ' O ' ' O ' ' C' ' 8' ' ' SER . . . -101.89 56.43 0.68 Allowed Glycine 0 N--CA 1.474 1.191 0 N-CA-C 110.835 -0.906 . . . . 0.0 110.835 -179.959 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 78.9 p -85.23 124.82 32.31 Favored 'General case' 0 N--CA 1.466 0.354 0 N-CA-C 108.695 -0.854 . . . . 0.0 108.695 178.047 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 62.2 t30 -64.89 101.42 0.49 Allowed 'General case' 0 N--CA 1.473 0.701 0 N-CA-C 108.731 -0.84 . . . . 0.0 108.731 178.845 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 64.6 mttm -97.81 113.46 25.27 Favored 'General case' 0 N--CA 1.485 1.318 0 N-CA-C 110.029 -0.36 . . . . 0.0 110.029 -178.939 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.06 -134.16 0.01 OUTLIER Glycine 0 CA--C 1.534 1.255 0 N-CA-C 110.834 -0.907 . . . . 0.0 110.834 178.988 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -112.92 127.87 56.32 Favored 'General case' 0 N--CA 1.48 1.03 0 N-CA-C 109.114 -0.699 . . . . 0.0 109.114 179.02 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 64.4 mt -90.39 129.49 41.15 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.588 0 N-CA-C 107.52 -1.289 . . . . 0.0 107.52 178.768 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 12.0 mt -143.19 151.62 17.07 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.848 0 CA-C-N 116.06 -0.518 . . . . 0.0 109.905 -178.799 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 65.59 48.14 70.78 Favored Glycine 0 CA--C 1.526 0.722 0 CA-C-N 116.045 -0.525 . . . . 0.0 112.642 178.956 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 2.9 tt -98.12 121.04 39.56 Favored 'General case' 0 N--CA 1.479 0.981 0 N-CA-C 107.269 -1.382 . . . . 0.0 107.269 177.951 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 27.6 ttt -153.19 157.75 40.74 Favored 'General case' 0 N--CA 1.474 0.758 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 179.528 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 81.4 t -157.96 149.44 8.93 Favored 'Isoleucine or valine' 0 C--O 1.238 0.48 0 N-CA-C 106.676 -1.601 . . . . 0.0 106.676 -179.469 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . 0.49 ' H ' HE22 ' B' ' 15' ' ' GLN . . . 56.96 72.48 0.58 Allowed Glycine 0 C--N 1.314 -0.669 0 CA-C-N 115.621 -0.718 . . . . 0.0 111.394 178.331 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 172.86 -157.73 27.17 Favored Glycine 0 N--CA 1.459 0.233 0 N-CA-C 110.662 -0.975 . . . . 0.0 110.662 -179.946 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 33.5 m -124.06 143.3 37.83 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.933 0 C-N-CA 122.778 0.431 . . . . 0.0 109.891 179.402 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 16.2 t . . . . . 0 N--CA 1.468 0.439 0 CA-C-O 118.045 -0.979 . . . . 0.0 110.986 179.199 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' C' C ' 1' ' ' ASP . . . . . . . . . . . . . 9.2 m-20 . . . . . 0 N--CA 1.489 1.497 0 N-CA-C 109.082 -0.71 . . . . 0.0 109.082 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' C' C ' 2' ' ' ALA . . . . . . . . . . . . . . . -66.65 148.25 52.16 Favored 'General case' 0 N--CA 1.467 0.411 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.121 179.639 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 3' ' ' GLU . . . . . . . . . . . . . 57.2 tt0 -162.11 104.48 1.15 Allowed 'General case' 0 N--CA 1.472 0.66 0 CA-C-N 116.411 -0.359 . . . . 0.0 110.058 179.661 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 21.1 m-85 -71.29 172.84 8.64 Favored 'General case' 0 N--CA 1.47 0.548 0 N-CA-C 109.479 -0.563 . . . . 0.0 109.479 179.548 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 31.9 mtp180 -68.31 129.5 40.1 Favored 'General case' 0 N--CA 1.472 0.666 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.215 -178.001 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 47.4 m170 -99.64 131.41 45.65 Favored 'General case' 0 N--CA 1.474 0.75 0 N-CA-C 109.467 -0.568 . . . . 0.0 109.467 179.455 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 7' ' ' ASP . . . . . . . . . . . . . 13.5 m-20 -71.63 141.0 49.95 Favored 'General case' 0 CA--C 1.531 0.232 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.848 -179.691 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 8' ' ' SER . . . . . 0.41 ' O ' ' O ' ' B' ' 25' ' ' GLY . 8.6 t -143.2 -173.19 3.86 Favored 'General case' 0 N--CA 1.479 1.01 0 N-CA-C 109.002 -0.74 . . . . 0.0 109.002 178.477 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 117.78 11.55 8.44 Favored Glycine 0 N--CA 1.486 1.981 0 N-CA-C 112.44 -0.264 . . . . 0.0 112.44 179.159 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 47.4 p90 -59.17 128.31 36.53 Favored 'General case' 0 CA--C 1.54 0.561 0 CA-C-N 116.907 0.353 . . . . 0.0 111.895 -179.626 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 46.3 mt-10 -89.59 154.68 19.79 Favored 'General case' 0 N--CA 1.473 0.704 0 N-CA-C 109.4 -0.593 . . . . 0.0 109.4 178.5 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -153.87 128.32 1.4 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.233 0 N-CA-C 108.254 -1.017 . . . . 0.0 108.254 178.61 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 49.8 m-70 -134.91 147.18 49.76 Favored 'General case' 0 N--CA 1.491 1.588 0 CA-C-N 118.603 0.638 . . . . 0.0 111.139 -178.89 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 6.4 t60 -165.1 98.03 0.73 Allowed 'General case' 0 N--CA 1.482 1.159 0 CA-C-N 116.601 -0.272 . . . . 0.0 111.094 179.575 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 15' ' ' GLN . . . . . 0.499 HE22 ' H ' ' C' ' 37' ' ' GLY . 55.2 mt-30 -109.29 -172.53 2.06 Favored 'General case' 0 CA--C 1.5 -0.955 0 N-CA-C 108.345 -0.983 . . . . 0.0 108.345 179.972 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -166.77 97.93 0.55 Allowed 'General case' 0 N--CA 1.471 0.59 0 CA-C-N 115.086 -0.961 . . . . 0.0 109.413 178.795 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 17' ' ' LEU . . . . . 0.417 ' N ' ' CD1' ' C' ' 17' ' ' LEU . 4.5 mp -105.91 163.87 12.4 Favored 'General case' 0 N--CA 1.488 1.462 0 N-CA-C 108.603 -0.888 . . . . 0.0 108.603 -179.969 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 59.8 t -142.28 118.65 6.29 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.305 0 CA-C-O 119.025 -0.512 . . . . 0.0 109.813 179.552 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 54.1 m-85 -70.17 159.47 33.89 Favored 'General case' 0 N--CA 1.479 0.986 0 N-CA-C 107.485 -1.302 . . . . 0.0 107.485 177.17 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 12.7 t80 -172.34 -57.05 0.02 OUTLIER 'General case' 0 N--CA 1.484 1.258 0 CA-C-O 122.209 1.004 . . . . 0.0 109.928 179.671 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -39.5 90.54 0.0 OUTLIER 'General case' 0 CA--C 1.53 0.187 0 CA-C-N 114.129 -1.396 . . . . 0.0 112.864 -178.221 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 37.1 tt0 -66.31 158.27 29.51 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.08 -0.964 . . . . 0.0 110.625 179.258 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 11.4 m-20 -140.4 138.18 34.58 Favored 'General case' 0 N--CA 1.478 0.967 0 C-N-CA 123.032 0.533 . . . . 0.0 110.175 179.797 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 18.1 t -92.47 -117.01 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.484 1.238 0 N-CA-C 108.721 -0.844 . . . . 0.0 108.721 179.545 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 25' ' ' GLY . . . . . 0.41 ' O ' ' O ' ' A' ' 8' ' ' SER . . . -101.94 56.65 0.67 Allowed Glycine 0 C--N 1.347 1.192 0 N-CA-C 110.927 -0.869 . . . . 0.0 110.927 -179.995 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 79.2 p -85.36 124.83 32.41 Favored 'General case' 0 N--CA 1.467 0.423 0 N-CA-C 108.683 -0.858 . . . . 0.0 108.683 178.149 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 61.9 t30 -64.88 101.16 0.46 Allowed 'General case' 0 N--CA 1.473 0.717 0 N-CA-C 108.73 -0.841 . . . . 0.0 108.73 178.809 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 28' ' ' LYS . . . . . 0.4 ' O ' ' O ' ' C' ' 29' ' ' GLY . 65.2 mttm -97.47 113.65 25.37 Favored 'General case' 0 N--CA 1.486 1.348 0 N-CA-C 110.064 -0.347 . . . . 0.0 110.064 -178.983 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' C' C ' 29' ' ' GLY . . . . . 0.4 ' O ' ' O ' ' C' ' 28' ' ' LYS . . . -60.2 -134.47 0.01 OUTLIER Glycine 0 CA--C 1.535 1.282 0 N-CA-C 110.798 -0.921 . . . . 0.0 110.798 178.982 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -112.5 128.0 56.21 Favored 'General case' 0 N--CA 1.48 1.075 0 N-CA-C 109.181 -0.674 . . . . 0.0 109.181 178.91 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 64.4 mt -90.6 129.26 41.7 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.674 0 N-CA-C 107.486 -1.301 . . . . 0.0 107.486 178.75 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 12.2 mt -142.96 152.12 17.2 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.806 0 CA-C-N 116.053 -0.521 . . . . 0.0 109.871 -178.88 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 65.04 48.37 71.62 Favored Glycine 0 CA--C 1.525 0.697 0 CA-C-N 116.012 -0.54 . . . . 0.0 112.63 178.982 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 2.8 tt -98.46 121.0 39.84 Favored 'General case' 0 N--CA 1.478 0.955 0 N-CA-C 107.158 -1.423 . . . . 0.0 107.158 177.98 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 27.7 ttt -153.07 158.12 41.46 Favored 'General case' 0 N--CA 1.471 0.584 0 N-CA-C 108.814 -0.81 . . . . 0.0 108.814 179.617 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 78.3 t -158.38 149.46 8.3 Favored 'Isoleucine or valine' 0 C--O 1.237 0.432 0 N-CA-C 106.865 -1.531 . . . . 0.0 106.865 -179.526 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 37' ' ' GLY . . . . . 0.499 ' H ' HE22 ' C' ' 15' ' ' GLN . . . 56.94 72.54 0.57 Allowed Glycine 0 C--N 1.315 -0.616 0 CA-C-N 115.641 -0.709 . . . . 0.0 111.414 178.337 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 172.74 -157.45 26.79 Favored Glycine 0 N--CA 1.461 0.357 0 N-CA-C 110.659 -0.976 . . . . 0.0 110.659 -179.885 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 33.4 m -124.42 143.53 37.52 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.904 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 179.474 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 16.3 t . . . . . 0 N--CA 1.467 0.402 0 CA-C-O 118.118 -0.944 . . . . 0.0 111.082 179.285 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' D' D ' 1' ' ' ASP . . . . . . . . . . . . . 8.9 m-20 . . . . . 0 N--CA 1.488 1.46 0 N-CA-C 109.096 -0.705 . . . . 0.0 109.096 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' D' D ' 2' ' ' ALA . . . . . . . . . . . . . . . -67.98 148.91 50.4 Favored 'General case' 0 N--CA 1.469 0.523 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.484 179.381 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 3' ' ' GLU . . . . . . . . . . . . . 57.1 tt0 -160.86 107.37 1.46 Allowed 'General case' 0 C--O 1.202 -1.398 0 N-CA-C 109.678 -0.489 . . . . 0.0 109.678 -179.956 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 23.1 m-85 -77.21 167.98 20.83 Favored 'General case' 0 C--N 1.302 -1.486 0 C-N-CA 126.137 1.775 . . . . 0.0 107.913 -179.073 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 5' ' ' ARG . . . . . . . . . . . . 0.297 39.3 mtp180 -76.43 133.58 39.82 Favored 'General case' 0 C--O 1.214 -0.812 0 N-CA-C 106.852 -1.536 . . . . 0.0 106.852 -168.536 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 51.4 m170 -101.78 133.4 46.58 Favored 'General case' 0 C--N 1.363 1.167 0 CA-C-N 113.931 -1.486 . . . . 0.0 107.776 -176.422 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 7' ' ' ASP . . . . . . . . . . . . . 9.3 m-20 -64.69 124.05 20.91 Favored 'General case' 0 C--N 1.314 -0.964 0 C-N-CA 127.987 2.515 . . . . 0.0 115.331 176.692 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 8' ' ' SER . . . . . . . . . . . . . 8.2 t -133.3 -174.83 3.61 Favored 'General case' 0 N--CA 1.483 1.209 0 CA-C-N 119.928 1.24 . . . . 0.0 109.46 177.367 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 121.88 13.75 4.92 Favored Glycine 0 N--CA 1.483 1.79 0 N-CA-C 110.993 -0.843 . . . . 0.0 110.993 175.476 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 44.7 p90 -58.37 130.18 45.5 Favored 'General case' 0 CA--C 1.539 0.526 0 C-N-CA 120.938 -0.305 . . . . 0.0 111.71 -179.209 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 47.0 mt-10 -89.29 152.57 21.48 Favored 'General case' 0 N--CA 1.477 0.903 0 N-CA-C 110.063 -0.347 . . . . 0.0 110.063 176.679 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -149.54 129.99 4.33 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.522 0 N-CA-C 107.975 -1.12 . . . . 0.0 107.975 174.35 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 47.9 m-70 -129.86 150.31 51.21 Favored 'General case' 0 N--CA 1.482 1.17 0 CA-C-N 117.848 0.295 . . . . 0.0 111.567 176.611 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 6.6 t60 -165.05 104.65 0.78 Allowed 'General case' 0 N--CA 1.484 1.233 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 172.974 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 15' ' ' GLN . . . . . 0.518 HE22 ' H ' ' D' ' 37' ' ' GLY . 55.2 mt-30 -112.46 -175.85 2.78 Favored 'General case' 0 CA--C 1.493 -1.222 0 N-CA-C 108.085 -1.079 . . . . 0.0 108.085 179.188 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -162.92 106.13 1.06 Allowed 'General case' 0 CA--C 1.536 0.419 0 N-CA-C 107.803 -1.184 . . . . 0.0 107.803 175.619 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 5.4 mp -112.47 162.86 15.14 Favored 'General case' 0 N--CA 1.488 1.442 0 N-CA-C 108.134 -1.061 . . . . 0.0 108.134 179.583 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 51.5 t -141.0 123.63 15.38 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.194 0 N-CA-C 109.01 -0.737 . . . . 0.0 109.01 175.962 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 78.5 m-85 -62.65 151.53 37.87 Favored 'General case' 0 C--N 1.349 0.569 0 C-N-CA 125.002 1.321 . . . . 0.0 110.395 170.485 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 8.3 t80 -170.17 -66.78 0.02 OUTLIER 'General case' 0 N--CA 1.476 0.831 0 N-CA-C 107.765 -1.198 . . . . 0.0 107.765 -179.584 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -37.94 95.74 0.01 OUTLIER 'General case' 0 CA--C 1.536 0.419 0 CA-C-N 113.889 -1.505 . . . . 0.0 111.706 -174.505 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 37.3 tt0 -68.32 158.97 32.3 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 113.587 -1.642 . . . . 0.0 110.308 178.654 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 11.5 m-20 -140.6 140.58 35.13 Favored 'General case' 0 N--CA 1.474 0.767 0 N-CA-C 109.646 -0.501 . . . . 0.0 109.646 178.795 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 24' ' ' VAL . . . . . . . . . . . . . 16.0 t -94.44 -120.65 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.381 0 N-CA-C 108.242 -1.021 . . . . 0.0 108.242 179.858 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . -104.65 61.93 0.38 Allowed Glycine 0 C--N 1.375 2.718 0 C-N-CA 117.791 -2.147 . . . . 0.0 109.555 178.866 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 90.9 p -71.57 121.07 18.09 Favored 'General case' 0 C--O 1.246 0.872 0 CA-C-O 115.949 -1.977 . . . . 0.0 112.537 168.01 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 64.7 t30 -60.69 102.06 0.17 Allowed 'General case' 0 N--CA 1.478 0.956 0 CA-C-N 122.278 2.308 . . . . 0.0 109.906 172.212 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 28' ' ' LYS . . . . . 0.403 ' O ' ' O ' ' D' ' 29' ' ' GLY . 64.6 mttm -100.95 116.16 32.14 Favored 'General case' 0 N--CA 1.493 1.714 0 CA-C-N 120.028 1.286 . . . . 0.0 109.157 179.461 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' D' D ' 29' ' ' GLY . . . . . 0.403 ' O ' ' O ' ' D' ' 28' ' ' LYS . . . -54.65 -134.6 0.0 OUTLIER Glycine 0 C--N 1.343 0.94 0 CA-C-N 115.51 -0.768 . . . . 0.0 113.433 176.203 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -112.95 132.58 55.28 Favored 'General case' 0 C--N 1.37 1.464 0 N-CA-C 108.46 -0.941 . . . . 0.0 108.46 174.435 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 66.7 mt -91.75 133.85 31.96 Favored 'Isoleucine or valine' 0 C--N 1.346 0.422 0 N-CA-C 106.888 -1.523 . . . . 0.0 106.888 176.682 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 14.2 mt -145.74 154.28 13.34 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.916 0 N-CA-C 109.092 -0.707 . . . . 0.0 109.092 179.276 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 64.09 47.65 83.26 Favored Glycine 0 C--O 1.246 0.877 0 CA-C-O 119.409 -0.662 . . . . 0.0 112.538 179.243 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 3.4 tt -97.81 132.53 43.34 Favored 'General case' 0 C--N 1.372 1.558 0 N-CA-C 104.593 -2.373 . . . . 0.0 104.593 176.44 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 28.2 ttt -155.96 165.32 36.81 Favored 'General case' 0 N--CA 1.475 0.812 0 N-CA-C 107.705 -1.22 . . . . 0.0 107.705 175.8 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 94.4 t -164.04 155.52 2.11 Favored 'Isoleucine or valine' 0 C--O 1.247 0.959 0 N-CA-C 105.204 -2.147 . . . . 0.0 105.204 175.016 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 37' ' ' GLY . . . . . 0.518 ' H ' HE22 ' D' ' 15' ' ' GLN . . . 61.22 65.15 3.46 Favored Glycine 0 CA--C 1.524 0.637 0 C-N-CA 117.97 -2.062 . . . . 0.0 113.042 176.686 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 168.83 -158.55 31.24 Favored Glycine 0 N--CA 1.465 0.633 0 CA-C-N 118.976 1.388 . . . . 0.0 111.58 -177.921 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 33.1 m -120.23 142.47 35.8 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.17 0 CA-C-N 118.426 1.113 . . . . 0.0 110.243 -178.534 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 13.9 t . . . . . 0 C--O 1.212 -0.916 0 N-CA-C 109.606 -0.516 . . . . 0.0 109.606 174.362 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' E' E ' 1' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 . . . . . 0 N--CA 1.487 1.419 0 N-CA-C 109.19 -0.67 . . . . 0.0 109.19 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' E' E ' 2' ' ' ALA . . . . . . . . . . . . . . . -67.76 149.4 49.99 Favored 'General case' 0 N--CA 1.468 0.456 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.321 179.557 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 3' ' ' GLU . . . . . . . . . . . . . 57.5 tt0 -162.58 102.31 1.05 Allowed 'General case' 0 C--O 1.211 -0.964 0 N-CA-C 110.075 -0.343 . . . . 0.0 110.075 -179.796 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 20.4 m-85 -68.12 172.48 5.66 Favored 'General case' 0 N--CA 1.472 0.665 0 N-CA-C 109.959 -0.386 . . . . 0.0 109.959 179.523 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 5' ' ' ARG . . . . . . . . . . . . . 30.6 mtp180 -67.7 130.32 42.64 Favored 'General case' 0 C--O 1.219 -0.517 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.503 -178.12 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 47.7 m170 -100.4 131.02 46.56 Favored 'General case' 0 N--CA 1.475 0.802 0 N-CA-C 109.593 -0.521 . . . . 0.0 109.593 179.37 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 7' ' ' ASP . . . . . . . . . . . . . 17.0 m-20 -71.07 142.33 50.84 Favored 'General case' 0 N--CA 1.464 0.234 0 O-C-N 123.389 0.431 . . . . 0.0 110.979 -179.829 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 8' ' ' SER . . . . . . . . . . . . . 8.4 t -144.85 -172.9 3.93 Favored 'General case' 0 N--CA 1.478 0.938 0 N-CA-C 108.994 -0.743 . . . . 0.0 108.994 178.052 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 118.17 12.23 7.73 Favored Glycine 0 N--CA 1.482 1.742 0 N-CA-C 112.191 -0.364 . . . . 0.0 112.191 179.032 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 43.5 p90 -58.91 127.8 34.04 Favored 'General case' 0 CA--C 1.544 0.733 0 N-CA-C 112.107 0.41 . . . . 0.0 112.107 -179.366 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 46.8 mt-10 -88.46 155.16 19.83 Favored 'General case' 0 N--CA 1.476 0.838 0 N-CA-C 109.43 -0.581 . . . . 0.0 109.43 178.12 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -155.3 127.44 1.0 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.557 0 N-CA-C 108.344 -0.984 . . . . 0.0 108.344 178.539 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 48.0 m-70 -135.27 145.3 47.42 Favored 'General case' 0 N--CA 1.483 1.206 0 CA-C-O 120.704 0.287 . . . . 0.0 111.331 -177.826 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 6.3 t60 -164.0 97.53 0.83 Allowed 'General case' 0 N--CA 1.486 1.334 0 CA-C-N 116.752 -0.204 . . . . 0.0 111.048 179.693 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 15' ' ' GLN . . . . . 0.469 HE22 ' H ' ' E' ' 37' ' ' GLY . 55.6 mt-30 -108.35 -172.62 2.09 Favored 'General case' 0 CA--C 1.502 -0.902 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 -179.94 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -166.57 98.2 0.58 Allowed 'General case' 0 CA--C 1.541 0.621 0 CA-C-N 114.992 -1.004 . . . . 0.0 109.453 178.722 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 17' ' ' LEU . . . . . 0.416 ' N ' ' CD1' ' E' ' 17' ' ' LEU . 4.4 mp -106.14 163.1 13.06 Favored 'General case' 0 N--CA 1.49 1.565 0 N-CA-C 109.239 -0.652 . . . . 0.0 109.239 -179.693 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 42.1 t -142.15 118.14 6.11 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.418 0 C-N-CA 122.558 0.343 . . . . 0.0 110.554 179.158 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 52.8 m-85 -69.17 157.27 37.23 Favored 'General case' 0 C--N 1.356 0.867 0 N-CA-C 107.312 -1.366 . . . . 0.0 107.312 176.582 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 11.5 t80 -173.96 -54.7 0.01 OUTLIER 'General case' 0 N--CA 1.484 1.275 0 CA-C-O 121.717 0.77 . . . . 0.0 110.347 179.469 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.35 88.79 0.0 OUTLIER 'General case' 0 C--N 1.319 -0.751 0 CA-C-N 114.356 -1.293 . . . . 0.0 112.83 -178.974 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 37.4 tt0 -64.48 158.28 24.41 Favored 'General case' 0 N--CA 1.47 0.557 0 CA-C-N 114.944 -1.025 . . . . 0.0 110.681 179.702 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 11.0 m-20 -140.51 138.03 34.26 Favored 'General case' 0 N--CA 1.476 0.833 0 C-N-CA 122.985 0.514 . . . . 0.0 110.483 179.887 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 18.9 t -92.22 -116.79 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.288 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 179.587 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . -102.2 55.13 0.72 Allowed Glycine 0 N--CA 1.473 1.137 0 N-CA-C 111.226 -0.749 . . . . 0.0 111.226 -179.881 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 81.1 p -83.37 124.42 30.63 Favored 'General case' 0 N--CA 1.468 0.443 0 N-CA-C 109.205 -0.665 . . . . 0.0 109.205 177.819 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 62.9 t30 -64.58 101.42 0.46 Allowed 'General case' 0 N--CA 1.474 0.728 0 N-CA-C 108.307 -0.998 . . . . 0.0 108.307 178.725 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 64.3 mttm -98.07 113.32 25.16 Favored 'General case' 0 N--CA 1.488 1.469 0 N-CA-C 109.888 -0.412 . . . . 0.0 109.888 -178.603 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.06 -133.62 0.01 OUTLIER Glycine 0 CA--C 1.533 1.215 0 N-CA-C 111.471 -0.652 . . . . 0.0 111.471 178.894 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -113.19 126.87 55.9 Favored 'General case' 0 N--CA 1.477 0.907 0 N-CA-C 109.265 -0.642 . . . . 0.0 109.265 179.382 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 65.6 mt -90.13 130.24 39.72 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.279 0 N-CA-C 107.104 -1.443 . . . . 0.0 107.104 178.797 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 13.5 mt -142.99 153.42 16.99 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.825 0 N-CA-C 109.069 -0.715 . . . . 0.0 109.069 -179.42 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.71 49.94 65.13 Favored Glycine 0 CA--C 1.524 0.651 0 CA-C-N 116.432 -0.349 . . . . 0.0 113.153 179.022 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 2.9 tt -99.62 120.59 39.92 Favored 'General case' 0 N--CA 1.48 1.03 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 177.599 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 28.1 ttt -152.01 159.18 43.8 Favored 'General case' 0 N--CA 1.477 0.916 0 N-CA-C 108.373 -0.973 . . . . 0.0 108.373 179.578 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 95.7 t -159.49 149.23 6.93 Favored 'Isoleucine or valine' 0 C--O 1.237 0.419 0 N-CA-C 106.605 -1.628 . . . . 0.0 106.605 -179.816 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 37' ' ' GLY . . . . . 0.469 ' H ' HE22 ' E' ' 15' ' ' GLN . . . 57.32 72.19 0.62 Allowed Glycine 0 C--N 1.316 -0.579 0 CA-C-N 115.523 -0.762 . . . . 0.0 111.316 178.155 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 173.72 -155.66 22.45 Favored Glycine 0 C--O 1.219 -0.811 0 N-CA-C 111.123 -0.791 . . . . 0.0 111.123 -179.831 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 33.5 m -126.2 142.59 42.39 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.757 0 N-CA-C 109.203 -0.666 . . . . 0.0 109.203 179.379 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 15.1 t . . . . . 0 CA--C 1.538 0.509 0 CA-C-O 118.109 -0.948 . . . . 0.0 111.218 179.279 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' F' F ' 1' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 . . . . . 0 N--CA 1.488 1.432 0 N-CA-C 109.075 -0.713 . . . . 0.0 109.075 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' F' F ' 2' ' ' ALA . . . . . . . . . . . . . . . -68.19 149.82 49.08 Favored 'General case' 0 N--CA 1.47 0.529 0 CA-C-N 116.306 -0.407 . . . . 0.0 110.335 179.607 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 3' ' ' GLU . . . . . . . . . . . . . 57.4 tt0 -162.71 102.67 1.03 Allowed 'General case' 0 C--O 1.21 -1.003 0 CA-C-N 116.44 -0.346 . . . . 0.0 110.085 -179.845 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 20.2 m-85 -68.46 172.52 5.97 Favored 'General case' 0 N--CA 1.474 0.734 0 CA-C-O 120.941 0.401 . . . . 0.0 109.971 179.561 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 5' ' ' ARG . . . . . . . . . . . . . 30.5 mtp180 -67.32 129.98 41.63 Favored 'General case' 0 C--O 1.217 -0.63 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.514 -178.162 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 47.8 m170 -100.43 131.21 46.48 Favored 'General case' 0 N--CA 1.477 0.922 0 N-CA-C 109.572 -0.529 . . . . 0.0 109.572 179.358 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 7' ' ' ASP . . . . . . . . . . . . . 16.6 m-20 -71.37 142.02 50.36 Favored 'General case' 0 N--CA 1.464 0.26 0 O-C-N 123.422 0.451 . . . . 0.0 111.066 -179.786 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 8' ' ' SER . . . . . . . . . . . . . 8.4 t -144.67 -173.13 3.97 Favored 'General case' 0 N--CA 1.478 0.971 0 N-CA-C 108.958 -0.756 . . . . 0.0 108.958 178.002 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 118.6 11.73 7.73 Favored Glycine 0 N--CA 1.482 1.745 0 N-CA-C 112.126 -0.39 . . . . 0.0 112.126 179.072 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 43.4 p90 -58.64 128.22 36.08 Favored 'General case' 0 CA--C 1.544 0.738 0 N-CA-C 112.123 0.416 . . . . 0.0 112.123 -179.31 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 46.8 mt-10 -88.77 155.15 19.74 Favored 'General case' 0 N--CA 1.475 0.817 0 CA-C-O 121.303 0.573 . . . . 0.0 109.585 178.031 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -155.21 127.48 1.02 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.574 0 N-CA-C 108.338 -0.986 . . . . 0.0 108.338 178.505 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 48.0 m-70 -135.32 144.94 46.99 Favored 'General case' 0 N--CA 1.481 1.093 0 CA-C-O 120.681 0.277 . . . . 0.0 111.379 -177.923 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 6.3 t60 -163.78 98.16 0.86 Allowed 'General case' 0 N--CA 1.487 1.406 0 CA-C-N 116.697 -0.229 . . . . 0.0 111.145 179.645 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 15' ' ' GLN . . . . . 0.484 HE22 ' H ' ' F' ' 37' ' ' GLY . 55.8 mt-30 -109.29 -171.97 1.95 Allowed 'General case' 0 CA--C 1.499 -1.015 0 N-CA-C 108.625 -0.88 . . . . 0.0 108.625 -179.911 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -166.84 98.57 0.55 Allowed 'General case' 0 CA--C 1.541 0.609 0 CA-C-N 114.895 -1.048 . . . . 0.0 109.483 178.778 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 17' ' ' LEU . . . . . 0.41 ' CD1' ' N ' ' F' ' 17' ' ' LEU . 4.4 mp -106.24 163.14 13.05 Favored 'General case' 0 N--CA 1.489 1.501 0 N-CA-C 109.141 -0.689 . . . . 0.0 109.141 -179.717 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 42.0 t -142.17 118.3 6.2 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.369 0 C-N-CA 122.507 0.323 . . . . 0.0 110.522 179.088 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 52.7 m-85 -69.27 157.17 37.51 Favored 'General case' 0 C--N 1.355 0.811 0 N-CA-C 107.151 -1.426 . . . . 0.0 107.151 176.563 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 12.3 t80 -173.75 -54.8 0.01 OUTLIER 'General case' 0 N--CA 1.486 1.344 0 CA-C-O 121.785 0.802 . . . . 0.0 109.752 179.688 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.35 88.68 0.0 OUTLIER 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 114.484 -1.234 . . . . 0.0 113.007 -178.893 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 37.0 tt0 -64.36 158.43 23.61 Favored 'General case' 0 N--CA 1.472 0.668 0 CA-C-N 114.999 -1.001 . . . . 0.0 110.895 179.481 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 11.8 m-20 -140.87 137.67 33.38 Favored 'General case' 0 N--CA 1.477 0.909 0 C-N-CA 122.893 0.477 . . . . 0.0 110.458 179.973 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 24' ' ' VAL . . . . . . . . . . . . . 18.6 t -91.88 -116.83 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.391 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 179.544 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -102.11 55.32 0.72 Allowed Glycine 0 N--CA 1.477 1.41 0 N-CA-C 110.953 -0.859 . . . . 0.0 110.953 -179.863 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 79.8 p -83.54 124.19 30.5 Favored 'General case' 0 N--CA 1.47 0.552 0 N-CA-C 109.012 -0.736 . . . . 0.0 109.012 177.726 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 62.3 t30 -64.44 101.47 0.45 Allowed 'General case' 0 N--CA 1.473 0.71 0 N-CA-C 108.375 -0.972 . . . . 0.0 108.375 178.684 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 64.3 mttm -98.04 113.26 25.08 Favored 'General case' 0 N--CA 1.488 1.46 0 N-CA-C 110.029 -0.36 . . . . 0.0 110.029 -178.648 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.07 -133.84 0.01 OUTLIER Glycine 0 CA--C 1.534 1.266 0 N-CA-C 111.559 -0.616 . . . . 0.0 111.559 178.901 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -112.69 127.17 56.05 Favored 'General case' 0 N--CA 1.477 0.885 0 N-CA-C 109.228 -0.656 . . . . 0.0 109.228 179.241 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 65.7 mt -90.53 130.15 40.22 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.286 0 N-CA-C 107.086 -1.45 . . . . 0.0 107.086 178.703 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 13.1 mt -142.9 153.6 17.18 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.763 0 N-CA-C 109.115 -0.698 . . . . 0.0 109.115 -179.33 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.59 49.73 67.14 Favored Glycine 0 CA--C 1.524 0.609 0 CA-C-N 116.486 -0.325 . . . . 0.0 113.141 179.098 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 3.0 tt -99.48 120.79 40.2 Favored 'General case' 0 N--CA 1.478 0.944 0 N-CA-C 107.344 -1.354 . . . . 0.0 107.344 177.747 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 28.1 ttt -152.68 159.86 43.17 Favored 'General case' 0 N--CA 1.472 0.667 0 N-CA-C 109.146 -0.687 . . . . 0.0 109.146 179.343 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 95.4 t -159.75 149.4 6.6 Favored 'Isoleucine or valine' 0 C--O 1.237 0.429 0 N-CA-C 106.907 -1.516 . . . . 0.0 106.907 -179.586 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 37' ' ' GLY . . . . . 0.484 ' H ' HE22 ' F' ' 15' ' ' GLN . . . 57.26 72.68 0.55 Allowed Glycine 0 C--N 1.315 -0.596 0 CA-C-N 115.548 -0.751 . . . . 0.0 111.268 178.195 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 173.44 -155.29 22.04 Favored Glycine 0 C--O 1.219 -0.841 0 N-CA-C 111.119 -0.792 . . . . 0.0 111.119 -179.795 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 33.4 m -126.62 142.5 42.98 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.777 0 N-CA-C 109.206 -0.664 . . . . 0.0 109.206 179.372 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 15.3 t . . . . . 0 CA--C 1.539 0.521 0 CA-C-O 118.0 -1.0 . . . . 0.0 111.301 179.306 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' G' G ' 1' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 . . . . . 0 N--CA 1.49 1.552 0 N-CA-C 109.434 -0.58 . . . . 0.0 109.434 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' G' G ' 2' ' ' ALA . . . . . . . . . . . . . . . -68.38 151.01 47.48 Favored 'General case' 0 CA--C 1.535 0.388 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.39 179.788 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 3' ' ' GLU . . . . . . . . . . . . . 57.3 tt0 -162.63 102.95 1.05 Allowed 'General case' 0 C--O 1.213 -0.845 0 N-CA-C 110.113 -0.329 . . . . 0.0 110.113 -179.382 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 26.7 m-85 -67.72 170.71 7.42 Favored 'General case' 0 N--CA 1.473 0.695 0 CA-C-O 120.849 0.357 . . . . 0.0 110.226 179.396 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 5' ' ' ARG . . . . . . . . . . . . . 31.5 mtp180 -66.59 129.44 39.87 Favored 'General case' 0 N--CA 1.47 0.543 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.178 -178.297 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 47.1 m170 -99.96 131.04 46.16 Favored 'General case' 0 N--CA 1.474 0.764 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 179.449 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 16.9 m-20 -72.21 137.85 47.15 Favored 'General case' 0 N--CA 1.466 0.358 0 O-C-N 123.638 0.586 . . . . 0.0 111.418 -179.488 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 8' ' ' SER . . . . . . . . . . . . . 8.0 t -142.16 -173.06 3.72 Favored 'General case' 0 N--CA 1.477 0.9 0 N-CA-C 109.114 -0.699 . . . . 0.0 109.114 178.038 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 119.13 12.97 6.66 Favored Glycine 0 N--CA 1.481 1.67 0 N-CA-C 111.725 -0.55 . . . . 0.0 111.725 179.075 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 47.4 p90 -59.52 128.25 36.09 Favored 'General case' 0 CA--C 1.541 0.604 0 N-CA-C 112.002 0.371 . . . . 0.0 112.002 -179.227 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 46.6 mt-10 -89.13 154.5 20.11 Favored 'General case' 0 N--CA 1.474 0.741 0 CA-C-O 121.208 0.528 . . . . 0.0 109.914 178.685 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 2.7 p -155.99 127.17 0.89 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.039 0 N-CA-C 108.334 -0.988 . . . . 0.0 108.334 178.765 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 51.4 m-70 -134.06 146.44 50.32 Favored 'General case' 0 N--CA 1.476 0.855 0 CA-C-N 115.289 -0.869 . . . . 0.0 110.997 -177.98 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 6.3 t60 -165.41 97.47 0.69 Allowed 'General case' 0 N--CA 1.483 1.181 0 CA-C-N 116.542 -0.299 . . . . 0.0 110.691 179.064 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 15' ' ' GLN . . . . . 0.493 HE22 ' H ' ' G' ' 37' ' ' GLY . 55.6 mt-30 -108.62 -172.6 2.09 Favored 'General case' 0 CA--C 1.501 -0.928 0 N-CA-C 108.574 -0.898 . . . . 0.0 108.574 -179.787 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -166.47 98.69 0.59 Allowed 'General case' 0 CA--C 1.541 0.606 0 CA-C-N 115.018 -0.992 . . . . 0.0 109.383 178.714 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 17' ' ' LEU . . . . . 0.414 ' N ' ' CD1' ' G' ' 17' ' ' LEU . 5.1 mp -106.14 161.79 14.2 Favored 'General case' 0 N--CA 1.487 1.383 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 -179.581 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 40.8 t -142.53 118.74 5.83 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.052 0 CA-C-O 120.766 0.317 . . . . 0.0 110.449 178.724 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 45.8 m-85 -69.71 151.12 46.21 Favored 'General case' 0 C--N 1.369 1.417 0 N-CA-C 107.303 -1.369 . . . . 0.0 107.303 176.761 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 10.3 t80 -171.16 -55.1 0.02 OUTLIER 'General case' 0 N--CA 1.486 1.369 0 CA-C-N 118.006 0.367 . . . . 0.0 110.333 -179.662 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.65 90.25 0.0 OUTLIER 'General case' 0 C--N 1.326 -0.428 0 C-N-CA 123.716 0.807 . . . . 0.0 112.582 -179.819 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 37.1 tt0 -65.2 159.39 23.72 Favored 'General case' 0 N--CA 1.469 0.488 0 CA-C-N 114.669 -1.151 . . . . 0.0 110.086 179.076 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 12.0 m-20 -141.45 137.2 32.0 Favored 'General case' 0 N--CA 1.476 0.842 0 C-N-CA 122.905 0.482 . . . . 0.0 109.986 179.927 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 24' ' ' VAL . . . . . . . . . . . . . 15.8 t -92.31 -116.63 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.106 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 179.682 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -101.93 54.35 0.77 Allowed Glycine 0 N--CA 1.476 1.366 0 N-CA-C 111.581 -0.608 . . . . 0.0 111.581 -179.725 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 80.0 p -82.72 124.34 30.14 Favored 'General case' 0 N--CA 1.469 0.501 0 N-CA-C 108.952 -0.758 . . . . 0.0 108.952 177.864 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 59.1 t30 -64.77 101.35 0.47 Allowed 'General case' 0 N--CA 1.471 0.594 0 N-CA-C 108.585 -0.894 . . . . 0.0 108.585 178.586 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 64.7 mttm -97.32 114.43 26.2 Favored 'General case' 0 N--CA 1.486 1.373 0 N-CA-C 109.891 -0.411 . . . . 0.0 109.891 -178.955 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.69 -132.45 0.01 OUTLIER Glycine 0 CA--C 1.532 1.144 0 N-CA-C 110.767 -0.933 . . . . 0.0 110.767 179.045 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -112.81 126.24 55.22 Favored 'General case' 0 N--CA 1.469 0.508 0 C-N-CA 123.006 0.522 . . . . 0.0 109.661 179.602 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 68.7 mt -89.66 130.7 38.53 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.776 0 N-CA-C 107.263 -1.384 . . . . 0.0 107.263 178.555 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 15.9 mt -143.92 154.35 15.74 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.346 0 CA-C-N 118.945 0.793 . . . . 0.0 108.982 -179.91 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.8 49.02 71.24 Favored Glycine 0 CA--C 1.527 0.811 0 C-N-CA 121.803 -0.237 . . . . 0.0 112.75 179.155 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 2.9 tt -98.93 121.96 41.57 Favored 'General case' 0 N--CA 1.479 0.982 0 N-CA-C 106.953 -1.499 . . . . 0.0 106.953 177.723 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 28.2 ttt -153.76 159.83 42.07 Favored 'General case' 0 N--CA 1.48 1.048 0 N-CA-C 107.999 -1.111 . . . . 0.0 107.999 179.661 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 88.6 t -159.58 149.65 6.71 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 N-CA-C 106.231 -1.766 . . . . 0.0 106.231 -179.735 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 37' ' ' GLY . . . . . 0.493 ' H ' HE22 ' G' ' 15' ' ' GLN . . . 57.01 72.75 0.53 Allowed Glycine 0 C--N 1.314 -0.66 0 C-N-CA 121.055 -0.593 . . . . 0.0 111.781 177.921 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 172.15 -154.08 20.75 Favored Glycine 0 C--O 1.219 -0.838 0 N-CA-C 110.517 -1.033 . . . . 0.0 110.517 179.223 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 34.0 m -127.0 142.91 42.13 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.009 0 CA-C-N 117.041 0.421 . . . . 0.0 109.963 179.951 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 15.6 t . . . . . 0 N--CA 1.466 0.363 0 CA-C-O 118.193 -0.908 . . . . 0.0 111.382 179.631 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' H' H ' 1' ' ' ASP . . . . . . . . . . . . . 7.9 m-20 . . . . . 0 N--CA 1.489 1.505 0 N-CA-C 109.481 -0.563 . . . . 0.0 109.481 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' H' H ' 2' ' ' ALA . . . . . . . . . . . . . . . -68.13 150.56 48.21 Favored 'General case' 0 N--CA 1.467 0.406 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.336 179.731 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 3' ' ' GLU . . . . . . . . . . . . . 57.2 tt0 -162.23 102.97 1.11 Allowed 'General case' 0 C--O 1.213 -0.823 0 N-CA-C 110.063 -0.347 . . . . 0.0 110.063 -179.346 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 26.2 m-85 -67.75 170.75 7.4 Favored 'General case' 0 N--CA 1.474 0.735 0 CA-C-O 120.912 0.387 . . . . 0.0 110.171 179.434 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 5' ' ' ARG . . . . . . . . . . . . . 31.0 mtp180 -66.46 129.43 39.81 Favored 'General case' 0 N--CA 1.469 0.477 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.309 -178.254 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 46.2 m170 -100.0 131.17 46.12 Favored 'General case' 0 N--CA 1.474 0.773 0 N-CA-C 109.648 -0.501 . . . . 0.0 109.648 179.4 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 16.3 m-20 -72.42 137.7 46.66 Favored 'General case' 0 N--CA 1.466 0.35 0 O-C-N 123.526 0.517 . . . . 0.0 111.361 -179.484 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 8' ' ' SER . . . . . . . . . . . . . 8.4 t -141.86 -173.61 3.85 Favored 'General case' 0 N--CA 1.475 0.807 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 178.282 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 119.35 12.73 6.67 Favored Glycine 0 N--CA 1.484 1.888 0 N-CA-C 111.802 -0.519 . . . . 0.0 111.802 179.061 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 46.8 p90 -59.33 128.17 35.76 Favored 'General case' 0 CA--C 1.542 0.651 0 N-CA-C 112.042 0.386 . . . . 0.0 112.042 -179.338 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 46.6 mt-10 -88.96 154.34 20.3 Favored 'General case' 0 N--CA 1.475 0.78 0 CA-C-O 121.22 0.533 . . . . 0.0 109.892 178.694 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.7 p -155.77 127.2 0.92 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.009 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 178.712 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 50.8 m-70 -134.08 146.18 50.06 Favored 'General case' 0 N--CA 1.476 0.863 0 CA-C-N 115.313 -0.858 . . . . 0.0 111.203 -178.045 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 6.4 t60 -165.08 97.58 0.73 Allowed 'General case' 0 N--CA 1.483 1.197 0 CA-C-N 116.583 -0.28 . . . . 0.0 110.716 179.039 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 15' ' ' GLN . . . . . 0.503 HE22 ' H ' ' H' ' 37' ' ' GLY . 55.3 mt-30 -108.57 -173.2 2.21 Favored 'General case' 0 CA--C 1.5 -0.966 0 N-CA-C 108.45 -0.945 . . . . 0.0 108.45 -179.787 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -166.12 98.39 0.63 Allowed 'General case' 0 N--CA 1.471 0.578 0 CA-C-N 114.984 -1.007 . . . . 0.0 109.341 178.727 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 17' ' ' LEU . . . . . 0.414 ' N ' ' CD1' ' H' ' 17' ' ' LEU . 5.1 mp -106.08 161.93 14.06 Favored 'General case' 0 N--CA 1.487 1.401 0 N-CA-C 109.394 -0.595 . . . . 0.0 109.394 -179.517 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 40.8 t -142.53 118.55 5.69 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.143 0 CA-C-O 120.775 0.321 . . . . 0.0 110.455 178.885 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 47.4 m-85 -69.85 151.44 45.71 Favored 'General case' 0 C--N 1.368 1.399 0 N-CA-C 107.334 -1.358 . . . . 0.0 107.334 176.59 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 10.9 t80 -172.37 -54.55 0.02 OUTLIER 'General case' 0 N--CA 1.484 1.246 0 CA-C-N 117.909 0.322 . . . . 0.0 110.21 -179.542 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.71 90.69 0.0 OUTLIER 'General case' 0 CA--C 1.534 0.356 0 C-N-CA 123.732 0.813 . . . . 0.0 112.298 -179.979 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 37.4 tt0 -65.74 159.29 25.45 Favored 'General case' 0 N--CA 1.47 0.537 0 CA-C-N 114.776 -1.102 . . . . 0.0 110.003 179.364 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 11.3 m-20 -141.29 137.55 32.54 Favored 'General case' 0 N--CA 1.476 0.837 0 C-N-CA 122.892 0.477 . . . . 0.0 109.919 179.861 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 24' ' ' VAL . . . . . . . . . . . . . 15.4 t -92.6 -116.94 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.09 0 N-CA-C 108.673 -0.862 . . . . 0.0 108.673 179.683 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . -101.48 54.25 0.8 Allowed Glycine 0 N--CA 1.479 1.538 0 N-CA-C 111.506 -0.638 . . . . 0.0 111.506 -179.742 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 80.3 p -82.85 124.54 30.41 Favored 'General case' 0 N--CA 1.469 0.497 0 N-CA-C 108.901 -0.778 . . . . 0.0 108.901 177.939 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 59.5 t30 -64.93 101.43 0.5 Allowed 'General case' 0 N--CA 1.472 0.664 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 178.679 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 65.1 mttm -97.33 114.11 25.84 Favored 'General case' 0 N--CA 1.485 1.321 0 N-CA-C 109.978 -0.378 . . . . 0.0 109.978 -179.021 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.42 -132.6 0.01 OUTLIER Glycine 0 CA--C 1.534 1.245 0 N-CA-C 110.845 -0.902 . . . . 0.0 110.845 179.053 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -112.72 126.28 55.24 Favored 'General case' 0 N--CA 1.471 0.603 0 C-N-CA 123.028 0.531 . . . . 0.0 109.662 179.59 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 68.0 mt -89.71 130.59 38.77 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.761 0 N-CA-C 107.35 -1.352 . . . . 0.0 107.35 178.506 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 16.3 mt -143.97 154.04 15.68 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.367 0 CA-C-N 118.922 0.783 . . . . 0.0 108.972 -179.74 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 64.09 49.01 69.75 Favored Glycine 0 CA--C 1.526 0.768 0 C-N-CA 121.717 -0.277 . . . . 0.0 112.81 179.184 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 2.8 tt -99.02 121.66 41.26 Favored 'General case' 0 N--CA 1.477 0.914 0 N-CA-C 107.035 -1.469 . . . . 0.0 107.035 177.782 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 28.2 ttt -153.4 159.75 42.47 Favored 'General case' 0 N--CA 1.48 1.036 0 N-CA-C 107.991 -1.115 . . . . 0.0 107.991 179.665 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 91.1 t -159.51 149.83 6.73 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 N-CA-C 106.278 -1.749 . . . . 0.0 106.278 -179.775 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 37' ' ' GLY . . . . . 0.503 ' H ' HE22 ' H' ' 15' ' ' GLN . . . 56.67 73.13 0.47 Allowed Glycine 0 C--N 1.313 -0.741 0 C-N-CA 120.982 -0.628 . . . . 0.0 111.727 178.117 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 171.65 -154.73 22.65 Favored Glycine 0 N--CA 1.468 0.806 0 N-CA-C 110.505 -1.038 . . . . 0.0 110.505 179.358 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 33.8 m -126.53 143.16 40.94 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.081 0 C-N-CA 122.663 0.385 . . . . 0.0 109.998 179.975 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 15.3 t . . . . . 0 N--CA 1.467 0.414 0 CA-C-O 118.137 -0.935 . . . . 0.0 111.293 179.544 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' I' I ' 1' ' ' ASP . . . . . . . . . . . . . 8.2 m-20 . . . . . 0 N--CA 1.489 1.506 0 N-CA-C 109.485 -0.561 . . . . 0.0 109.485 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' I' I ' 2' ' ' ALA . . . . . . . . . . . . . . . -68.61 151.19 47.06 Favored 'General case' 0 N--CA 1.466 0.358 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.324 179.675 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' I' I ' 3' ' ' GLU . . . . . . . . . . . . . 56.7 tt0 -162.76 102.87 1.03 Allowed 'General case' 0 C--O 1.213 -0.835 0 N-CA-C 110.09 -0.337 . . . . 0.0 110.09 -179.344 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 25.9 m-85 -67.68 170.91 7.03 Favored 'General case' 0 N--CA 1.472 0.666 0 CA-C-O 120.843 0.354 . . . . 0.0 110.168 179.461 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' I' I ' 5' ' ' ARG . . . . . . . . . . . . . 31.0 mtp180 -66.72 129.13 38.85 Favored 'General case' 0 N--CA 1.471 0.625 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.293 -178.281 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 46.2 m170 -99.72 130.97 45.98 Favored 'General case' 0 N--CA 1.474 0.768 0 N-CA-C 109.607 -0.516 . . . . 0.0 109.607 179.42 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 16.2 m-20 -72.05 138.02 47.57 Favored 'General case' 0 N--CA 1.466 0.336 0 O-C-N 123.539 0.525 . . . . 0.0 111.425 -179.546 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' I' I ' 8' ' ' SER . . . . . . . . . . . . . 8.5 t -142.26 -173.8 3.94 Favored 'General case' 0 N--CA 1.475 0.791 0 N-CA-C 109.078 -0.712 . . . . 0.0 109.078 178.388 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 119.46 12.66 6.65 Favored Glycine 0 N--CA 1.482 1.759 0 N-CA-C 111.864 -0.494 . . . . 0.0 111.864 179.185 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 47.5 p90 -59.15 128.38 36.86 Favored 'General case' 0 CA--C 1.541 0.625 0 N-CA-C 112.082 0.401 . . . . 0.0 112.082 -179.378 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 46.5 mt-10 -89.28 154.33 20.19 Favored 'General case' 0 N--CA 1.474 0.737 0 CA-C-O 121.101 0.477 . . . . 0.0 109.956 178.672 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 2.7 p -155.73 127.32 0.94 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.039 0 N-CA-C 108.373 -0.973 . . . . 0.0 108.373 178.722 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 50.2 m-70 -134.23 146.29 49.96 Favored 'General case' 0 N--CA 1.476 0.868 0 CA-C-N 115.276 -0.875 . . . . 0.0 111.145 -178.044 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 6.4 t60 -165.35 97.51 0.7 Allowed 'General case' 0 N--CA 1.484 1.244 0 CA-C-N 116.558 -0.292 . . . . 0.0 110.719 179.069 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' I' I ' 15' ' ' GLN . . . . . 0.506 HE22 ' H ' ' I' ' 37' ' ' GLY . 55.3 mt-30 -108.57 -172.75 2.12 Favored 'General case' 0 CA--C 1.499 -1.002 0 N-CA-C 108.458 -0.941 . . . . 0.0 108.458 -179.737 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -166.48 98.45 0.59 Allowed 'General case' 0 CA--C 1.54 0.565 0 CA-C-N 114.921 -1.036 . . . . 0.0 109.29 178.803 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' I' I ' 17' ' ' LEU . . . . . 0.41 ' CD1' ' N ' ' I' ' 17' ' ' LEU . 5.1 mp -105.97 161.99 13.98 Favored 'General case' 0 N--CA 1.486 1.355 0 N-CA-C 109.448 -0.575 . . . . 0.0 109.448 -179.628 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 40.6 t -142.58 118.5 5.56 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.154 0 C-N-CA 122.494 0.318 . . . . 0.0 110.487 178.849 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 46.7 m-85 -69.92 151.34 45.76 Favored 'General case' 0 C--N 1.367 1.365 0 N-CA-C 107.31 -1.367 . . . . 0.0 107.31 176.712 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 10.9 t80 -172.17 -54.67 0.02 OUTLIER 'General case' 0 N--CA 1.485 1.296 0 CA-C-N 117.843 0.292 . . . . 0.0 110.218 -179.518 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.69 90.72 0.0 OUTLIER 'General case' 0 CA--C 1.536 0.408 0 C-N-CA 123.7 0.8 . . . . 0.0 112.251 -179.936 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 37.5 tt0 -65.69 159.31 25.26 Favored 'General case' 0 N--CA 1.47 0.549 0 CA-C-N 114.751 -1.113 . . . . 0.0 109.993 179.326 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 11.1 m-20 -141.34 137.5 32.42 Favored 'General case' 0 N--CA 1.476 0.836 0 C-N-CA 122.872 0.469 . . . . 0.0 110.034 179.839 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' I' I ' 24' ' ' VAL . . . . . . . . . . . . . 14.9 t -92.68 -116.77 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.112 0 N-CA-C 108.691 -0.855 . . . . 0.0 108.691 179.729 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . -101.51 54.45 0.79 Allowed Glycine 0 N--CA 1.476 1.357 0 CA-C-N 118.556 0.617 . . . . 0.0 111.585 -179.759 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 80.4 p -83.31 123.96 30.14 Favored 'General case' 0 N--CA 1.469 0.5 0 N-CA-C 108.916 -0.772 . . . . 0.0 108.916 178.059 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 59.7 t30 -64.53 101.63 0.47 Allowed 'General case' 0 N--CA 1.473 0.681 0 N-CA-C 108.588 -0.893 . . . . 0.0 108.588 178.618 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 64.7 mttm -97.57 114.28 26.16 Favored 'General case' 0 N--CA 1.486 1.354 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -178.952 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.45 -132.63 0.01 OUTLIER Glycine 0 CA--C 1.532 1.137 0 N-CA-C 110.803 -0.919 . . . . 0.0 110.803 179.093 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -112.73 126.09 55.02 Favored 'General case' 0 N--CA 1.471 0.586 0 C-N-CA 123.058 0.543 . . . . 0.0 109.614 179.601 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 68.3 mt -89.68 130.75 38.47 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.783 0 N-CA-C 107.264 -1.384 . . . . 0.0 107.264 178.61 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 16.2 mt -143.98 154.47 15.65 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.337 0 CA-C-N 118.892 0.769 . . . . 0.0 108.984 -179.807 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.75 48.84 73.19 Favored Glycine 0 CA--C 1.526 0.775 0 C-N-CA 121.678 -0.296 . . . . 0.0 112.792 179.134 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 2.9 tt -98.84 121.94 41.43 Favored 'General case' 0 N--CA 1.478 0.947 0 N-CA-C 106.874 -1.528 . . . . 0.0 106.874 177.741 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 28.2 ttt -153.53 159.72 42.3 Favored 'General case' 0 N--CA 1.478 0.963 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 179.616 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 90.9 t -159.54 149.75 6.73 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.224 0 N-CA-C 106.253 -1.758 . . . . 0.0 106.253 -179.804 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' I' I ' 37' ' ' GLY . . . . . 0.506 ' H ' HE22 ' I' ' 15' ' ' GLN . . . 56.94 72.79 0.53 Allowed Glycine 0 C--N 1.314 -0.69 0 C-N-CA 121.022 -0.609 . . . . 0.0 111.778 178.011 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 171.95 -154.4 21.66 Favored Glycine 0 N--CA 1.468 0.767 0 N-CA-C 110.529 -1.029 . . . . 0.0 110.529 179.257 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 33.8 m -126.61 142.84 42.0 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.064 0 C-N-CA 122.743 0.417 . . . . 0.0 109.994 179.943 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 15.5 t . . . . . 0 N--CA 1.465 0.306 0 CA-C-O 118.239 -0.886 . . . . 0.0 111.328 179.539 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . 0.424 ' H1 ' ' CG ' ' D' ' 1' ' ' ASP . 9.1 m-20 . . . . . 0 N--CA 1.487 1.387 0 N-CA-C 108.963 -0.754 . . . . 0.0 108.963 . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.47 132.47 49.0 Favored 'General case' 0 CA--C 1.539 0.552 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.207 -179.876 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 39.3 tt0 -169.7 108.85 0.41 Allowed 'General case' 0 N--CA 1.469 0.516 0 N-CA-C 109.598 -0.519 . . . . 0.0 109.598 -179.206 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 78.9 m-85 -83.87 140.22 32.13 Favored 'General case' 0 N--CA 1.475 0.818 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 179.464 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 71.9 mtp180 -143.84 141.28 30.26 Favored 'General case' 0 N--CA 1.481 1.102 0 N-CA-C 109.079 -0.712 . . . . 0.0 109.079 -179.879 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 76.7 m80 -149.53 119.92 7.37 Favored 'General case' 0 N--CA 1.469 0.502 0 N-CA-C 108.79 -0.819 . . . . 0.0 108.79 179.147 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 8.5 m-20 -68.02 149.95 49.06 Favored 'General case' 0 CA--C 1.53 0.196 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.16 -179.391 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 7.6 t -167.13 171.36 11.0 Favored 'General case' 0 N--CA 1.472 0.655 0 N-CA-C 109.551 -0.537 . . . . 0.0 109.551 178.581 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.48 23.65 2.31 Favored Glycine 0 N--CA 1.488 2.156 0 N-CA-C 112.209 -0.356 . . . . 0.0 112.209 179.37 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 42.8 p90 -56.64 128.37 36.02 Favored 'General case' 0 N--CA 1.475 0.815 0 N-CA-C 112.078 0.399 . . . . 0.0 112.078 -179.83 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . 0.481 ' CG ' HD22 ' C' ' 27' ' ' ASN . 45.5 mt-10 -85.05 154.66 21.94 Favored 'General case' 0 C--N 1.344 0.358 0 N-CA-C 109.08 -0.711 . . . . 0.0 109.08 178.535 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -153.69 129.5 1.72 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.371 0 N-CA-C 108.151 -1.055 . . . . 0.0 108.151 178.928 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 48.6 m-70 -134.93 144.99 47.77 Favored 'General case' 0 N--CA 1.489 1.49 0 CA-C-N 118.683 0.674 . . . . 0.0 111.104 -179.116 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -165.9 98.31 0.65 Allowed 'General case' 0 N--CA 1.482 1.169 0 CA-C-N 116.603 -0.271 . . . . 0.0 110.984 179.628 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . 0.486 HE22 ' H ' ' A' ' 37' ' ' GLY . 61.7 mt-30 -108.54 -172.05 1.98 Allowed 'General case' 0 CA--C 1.503 -0.831 0 N-CA-C 108.174 -1.047 . . . . 0.0 108.174 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -165.96 97.24 0.63 Allowed 'General case' 0 N--CA 1.471 0.613 0 CA-C-N 115.16 -0.927 . . . . 0.0 109.348 178.739 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . 0.41 ' CD1' ' N ' ' A' ' 17' ' ' LEU . 4.7 mp -106.03 164.18 12.18 Favored 'General case' 0 N--CA 1.488 1.474 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 179.931 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 49.9 t -141.71 119.18 8.07 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.339 0 CA-C-O 118.888 -0.577 . . . . 0.0 109.98 179.657 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 50.9 m-85 -69.95 159.23 34.13 Favored 'General case' 0 N--CA 1.48 1.071 0 N-CA-C 107.573 -1.269 . . . . 0.0 107.573 177.287 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 12.9 t80 -171.44 -58.02 0.02 OUTLIER 'General case' 0 N--CA 1.485 1.305 0 CA-C-O 122.33 1.062 . . . . 0.0 109.772 179.481 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -38.83 90.48 0.0 OUTLIER 'General case' 0 C--O 1.232 0.165 0 CA-C-N 113.888 -1.505 . . . . 0.0 112.866 -177.929 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 54.4 tt0 -67.57 157.93 33.23 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 115.006 -0.997 . . . . 0.0 110.532 179.145 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 67.3 m-20 -140.02 137.72 34.87 Favored 'General case' 0 N--CA 1.481 1.112 0 C-N-CA 122.891 0.476 . . . . 0.0 110.339 179.762 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 17.2 t -84.42 -116.44 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.912 0 N-CA-C 108.51 -0.922 . . . . 0.0 108.51 179.541 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -110.67 54.5 0.54 Allowed Glycine 0 N--CA 1.473 1.137 0 N-CA-C 111.21 -0.756 . . . . 0.0 111.21 -179.935 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 70.5 p -80.12 126.24 30.83 Favored 'General case' 0 C--O 1.221 -0.434 0 N-CA-C 108.983 -0.747 . . . . 0.0 108.983 178.422 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . 0.491 HD22 ' CG ' ' B' ' 11' ' ' GLU . 50.0 t30 -66.91 100.01 0.69 Allowed 'General case' 0 N--CA 1.472 0.644 0 N-CA-C 108.693 -0.854 . . . . 0.0 108.693 178.582 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 66.7 mttm -96.42 120.13 36.16 Favored 'General case' 0 N--CA 1.484 1.243 0 N-CA-C 110.087 -0.338 . . . . 0.0 110.087 -179.081 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.78 -126.36 0.01 OUTLIER Glycine 0 CA--C 1.532 1.154 0 N-CA-C 110.488 -1.045 . . . . 0.0 110.488 178.615 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -127.48 133.83 49.85 Favored 'General case' 0 N--CA 1.479 1.0 0 N-CA-C 109.294 -0.632 . . . . 0.0 109.294 179.112 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 66.9 mt -83.22 138.61 19.01 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.589 0 N-CA-C 107.136 -1.431 . . . . 0.0 107.136 178.54 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 18.7 mt -128.59 128.75 68.29 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.961 0 O-C-N 123.504 0.503 . . . . 0.0 110.123 -178.547 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 60.78 79.25 0.12 Allowed Glycine 0 CA--C 1.527 0.837 0 CA-C-N 116.003 -0.544 . . . . 0.0 112.95 178.898 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 2.0 tt -110.94 118.85 37.2 Favored 'General case' 0 N--CA 1.478 0.926 0 N-CA-C 106.932 -1.507 . . . . 0.0 106.932 177.432 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 8.8 ttt -155.04 161.02 41.45 Favored 'General case' 0 N--CA 1.469 0.504 0 N-CA-C 109.077 -0.712 . . . . 0.0 109.077 179.339 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 93.6 t -157.96 150.73 8.14 Favored 'Isoleucine or valine' 0 C--O 1.234 0.277 0 N-CA-C 106.83 -1.545 . . . . 0.0 106.83 -179.598 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . 0.486 ' H ' HE22 ' A' ' 15' ' ' GLN . . . 55.6 75.17 0.25 Allowed Glycine 0 C--N 1.314 -0.689 0 CA-C-N 115.703 -0.68 . . . . 0.0 111.739 178.332 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 168.83 -148.72 12.65 Favored Glycine 0 CA--C 1.519 0.305 0 N-CA-C 110.692 -0.963 . . . . 0.0 110.692 179.742 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 21.1 m -132.9 142.47 42.2 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.887 0 N-CA-C 109.624 -0.509 . . . . 0.0 109.624 179.82 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 21.3 t . . . . . 0 N--CA 1.468 0.43 0 CA-C-O 117.851 -1.071 . . . . 0.0 110.725 179.225 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' B' B ' 1' ' ' ASP . . . . . 0.404 ' N ' ' CB ' ' E' ' 1' ' ' ASP . 9.3 m-20 . . . . . 0 N--CA 1.488 1.451 0 N-CA-C 109.112 -0.699 . . . . 0.0 109.112 . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.5 132.35 48.69 Favored 'General case' 0 CA--C 1.538 0.517 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.218 -179.904 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 3' ' ' GLU . . . . . . . . . . . . . 39.2 tt0 -169.45 108.89 0.43 Allowed 'General case' 0 N--CA 1.47 0.531 0 N-CA-C 109.536 -0.542 . . . . 0.0 109.536 -179.107 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 79.8 m-85 -83.92 140.06 32.19 Favored 'General case' 0 N--CA 1.474 0.766 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 179.435 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 71.7 mtp180 -143.94 141.39 30.19 Favored 'General case' 0 N--CA 1.481 1.079 0 N-CA-C 109.136 -0.69 . . . . 0.0 109.136 -179.861 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 76.9 m80 -149.66 120.01 7.36 Favored 'General case' 0 N--CA 1.471 0.581 0 N-CA-C 108.772 -0.825 . . . . 0.0 108.772 179.117 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 7' ' ' ASP . . . . . . . . . . . . . 8.5 m-20 -67.96 149.45 49.75 Favored 'General case' 0 CA--C 1.531 0.217 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.226 -179.414 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 8' ' ' SER . . . . . . . . . . . . . 7.4 t -166.71 171.57 11.4 Favored 'General case' 0 N--CA 1.473 0.691 0 N-CA-C 109.583 -0.525 . . . . 0.0 109.583 178.501 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.26 23.94 2.31 Favored Glycine 0 N--CA 1.488 2.135 0 N-CA-C 112.122 -0.391 . . . . 0.0 112.122 179.425 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 42.4 p90 -56.9 128.11 35.18 Favored 'General case' 0 N--CA 1.473 0.681 0 N-CA-C 112.159 0.429 . . . . 0.0 112.159 -179.864 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 11' ' ' GLU . . . . . 0.491 ' CG ' HD22 ' A' ' 27' ' ' ASN . 45.5 mt-10 -84.79 154.61 22.26 Favored 'General case' 0 N--CA 1.469 0.486 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 178.532 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -153.59 129.32 1.69 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.333 0 N-CA-C 108.268 -1.012 . . . . 0.0 108.268 178.914 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 48.6 m-70 -134.82 145.16 48.08 Favored 'General case' 0 N--CA 1.49 1.559 0 CA-C-N 118.556 0.616 . . . . 0.0 111.052 -179.062 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -166.11 98.33 0.63 Allowed 'General case' 0 N--CA 1.483 1.214 0 CA-C-N 116.607 -0.269 . . . . 0.0 110.96 179.654 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . 0.495 HE22 ' H ' ' B' ' 37' ' ' GLY . 61.9 mt-30 -108.56 -172.2 2.01 Favored 'General case' 0 CA--C 1.503 -0.854 0 N-CA-C 108.201 -1.037 . . . . 0.0 108.201 -179.901 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -165.95 96.95 0.63 Allowed 'General case' 0 CA--C 1.54 0.581 0 CA-C-N 115.121 -0.945 . . . . 0.0 109.337 178.817 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . 0.411 ' N ' ' CD1' ' B' ' 17' ' ' LEU . 4.9 mp -105.88 164.14 12.18 Favored 'General case' 0 N--CA 1.487 1.398 0 N-CA-C 108.611 -0.885 . . . . 0.0 108.611 179.868 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 53.9 t -141.69 119.16 8.08 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.269 0 CA-C-O 118.939 -0.553 . . . . 0.0 109.982 179.577 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 51.6 m-85 -70.41 159.3 34.45 Favored 'General case' 0 N--CA 1.479 0.983 0 N-CA-C 107.557 -1.275 . . . . 0.0 107.557 177.248 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 13.9 t80 -172.14 -57.25 0.02 OUTLIER 'General case' 0 N--CA 1.483 1.211 0 CA-C-O 122.2 1.0 . . . . 0.0 109.792 179.522 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -38.88 90.83 0.0 OUTLIER 'General case' 0 CA--C 1.529 0.159 0 CA-C-N 114.136 -1.393 . . . . 0.0 112.797 -178.005 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 54.2 tt0 -67.93 157.71 34.39 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 115.028 -0.987 . . . . 0.0 110.547 179.314 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 67.3 m-20 -139.86 137.75 35.16 Favored 'General case' 0 N--CA 1.481 1.082 0 C-N-CA 122.954 0.502 . . . . 0.0 110.287 179.71 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 18.1 t -84.66 -116.4 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.988 0 N-CA-C 108.577 -0.897 . . . . 0.0 108.577 179.665 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -110.13 54.37 0.55 Allowed Glycine 0 C--N 1.349 1.253 0 N-CA-C 111.167 -0.773 . . . . 0.0 111.167 -179.951 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 73.1 p -80.39 125.91 30.51 Favored 'General case' 0 C--O 1.221 -0.432 0 N-CA-C 109.037 -0.727 . . . . 0.0 109.037 178.434 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 27' ' ' ASN . . . . . 0.502 HD22 ' CG ' ' C' ' 11' ' ' GLU . 50.4 t30 -66.73 100.41 0.7 Allowed 'General case' 0 N--CA 1.473 0.708 0 N-CA-C 108.657 -0.868 . . . . 0.0 108.657 178.613 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 66.7 mttm -96.81 120.04 36.41 Favored 'General case' 0 N--CA 1.483 1.205 0 N-CA-C 110.132 -0.321 . . . . 0.0 110.132 -179.035 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.57 -126.04 0.01 OUTLIER Glycine 0 CA--C 1.534 1.28 0 N-CA-C 110.453 -1.059 . . . . 0.0 110.453 178.618 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.13 133.75 49.02 Favored 'General case' 0 N--CA 1.48 1.026 0 N-CA-C 109.269 -0.641 . . . . 0.0 109.269 179.185 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 67.0 mt -83.15 138.6 19.04 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.476 0 N-CA-C 107.204 -1.406 . . . . 0.0 107.204 178.535 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 19.1 mt -128.53 128.42 68.02 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.928 0 O-C-N 123.537 0.523 . . . . 0.0 110.21 -178.412 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 60.96 78.98 0.13 Allowed Glycine 0 CA--C 1.526 0.777 0 CA-C-N 116.016 -0.538 . . . . 0.0 112.955 178.848 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 2.0 tt -110.71 118.88 37.38 Favored 'General case' 0 N--CA 1.476 0.869 0 N-CA-C 106.94 -1.504 . . . . 0.0 106.94 177.386 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 8.8 ttt -155.0 161.05 41.48 Favored 'General case' 0 N--CA 1.47 0.552 0 N-CA-C 109.096 -0.705 . . . . 0.0 109.096 179.247 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 92.9 t -158.04 150.73 8.06 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.192 0 N-CA-C 106.744 -1.576 . . . . 0.0 106.744 -179.555 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . 0.495 ' H ' HE22 ' B' ' 15' ' ' GLN . . . 55.44 75.31 0.25 Allowed Glycine 0 C--N 1.314 -0.654 0 CA-C-N 115.628 -0.714 . . . . 0.0 111.797 178.422 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 168.57 -149.14 13.4 Favored Glycine 0 CA--C 1.519 0.292 0 N-CA-C 110.686 -0.966 . . . . 0.0 110.686 179.76 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 21.5 m -132.36 142.7 41.97 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.834 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 179.65 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 21.3 t . . . . . 0 N--CA 1.467 0.41 0 CA-C-O 117.789 -1.101 . . . . 0.0 110.765 179.309 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' C' C ' 1' ' ' ASP . . . . . 0.405 ' H1 ' ' CG ' ' F' ' 1' ' ' ASP . 9.1 m-20 . . . . . 0 N--CA 1.487 1.423 0 N-CA-C 109.056 -0.72 . . . . 0.0 109.056 . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.35 132.48 49.12 Favored 'General case' 0 CA--C 1.54 0.57 0 CA-C-N 116.367 -0.379 . . . . 0.0 110.162 -179.845 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 3' ' ' GLU . . . . . . . . . . . . . 39.5 tt0 -169.64 108.89 0.41 Allowed 'General case' 0 N--CA 1.47 0.554 0 N-CA-C 109.592 -0.522 . . . . 0.0 109.592 -179.274 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 78.6 m-85 -83.8 139.98 32.34 Favored 'General case' 0 N--CA 1.475 0.797 0 N-CA-C 109.878 -0.416 . . . . 0.0 109.878 179.459 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 71.9 mtp180 -143.76 141.36 30.4 Favored 'General case' 0 N--CA 1.482 1.131 0 N-CA-C 109.077 -0.712 . . . . 0.0 109.077 -179.905 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 76.8 m80 -149.63 119.76 7.24 Favored 'General case' 0 N--CA 1.469 0.523 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 179.145 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 7' ' ' ASP . . . . . . . . . . . . . 8.2 m-20 -67.7 149.55 49.85 Favored 'General case' 0 N--CA 1.463 0.199 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.227 -179.41 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 8' ' ' SER . . . . . . . . . . . . . 7.6 t -166.97 171.14 11.44 Favored 'General case' 0 N--CA 1.473 0.682 0 N-CA-C 109.499 -0.556 . . . . 0.0 109.499 178.429 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.83 23.76 2.21 Favored Glycine 0 N--CA 1.487 2.093 0 N-CA-C 112.099 -0.4 . . . . 0.0 112.099 179.355 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 42.1 p90 -56.63 127.99 34.14 Favored 'General case' 0 N--CA 1.473 0.718 0 N-CA-C 112.125 0.417 . . . . 0.0 112.125 -179.847 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 11' ' ' GLU . . . . . 0.502 ' CG ' HD22 ' B' ' 27' ' ' ASN . 45.8 mt-10 -84.74 154.73 22.24 Favored 'General case' 0 N--CA 1.468 0.448 0 N-CA-C 109.126 -0.694 . . . . 0.0 109.126 178.507 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -153.61 129.24 1.65 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.293 0 N-CA-C 108.274 -1.01 . . . . 0.0 108.274 178.863 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 48.7 m-70 -134.71 144.95 48.05 Favored 'General case' 0 N--CA 1.489 1.517 0 CA-C-N 118.635 0.652 . . . . 0.0 111.043 -179.012 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -165.95 98.51 0.64 Allowed 'General case' 0 N--CA 1.483 1.184 0 CA-C-N 116.578 -0.283 . . . . 0.0 111.013 179.665 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 15' ' ' GLN . . . . . 0.478 HE22 ' H ' ' C' ' 37' ' ' GLY . 62.3 mt-30 -108.91 -172.21 2.0 Favored 'General case' 0 CA--C 1.501 -0.939 0 N-CA-C 108.276 -1.009 . . . . 0.0 108.276 -179.959 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -165.87 97.38 0.64 Allowed 'General case' 0 CA--C 1.54 0.587 0 CA-C-N 115.104 -0.953 . . . . 0.0 109.348 178.749 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 17' ' ' LEU . . . . . 0.408 ' N ' ' CD1' ' C' ' 17' ' ' LEU . 4.8 mp -106.07 163.99 12.34 Favored 'General case' 0 N--CA 1.488 1.433 0 N-CA-C 108.577 -0.897 . . . . 0.0 108.577 179.937 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 53.7 t -141.62 119.19 8.28 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.283 0 CA-C-O 119.05 -0.5 . . . . 0.0 109.885 179.529 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 51.2 m-85 -70.47 159.28 34.54 Favored 'General case' 0 N--CA 1.478 0.964 0 N-CA-C 107.469 -1.308 . . . . 0.0 107.469 177.299 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 14.2 t80 -171.96 -57.33 0.02 OUTLIER 'General case' 0 N--CA 1.482 1.15 0 CA-C-O 122.24 1.019 . . . . 0.0 109.847 179.461 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -38.77 90.72 0.0 OUTLIER 'General case' 0 C--O 1.232 0.144 0 CA-C-N 114.129 -1.396 . . . . 0.0 112.804 -178.024 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 54.0 tt0 -67.88 157.7 34.31 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.122 -0.945 . . . . 0.0 110.595 179.254 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 67.4 m-20 -139.86 137.96 35.33 Favored 'General case' 0 N--CA 1.482 1.134 0 C-N-CA 122.854 0.462 . . . . 0.0 110.245 179.728 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 17.7 t -84.85 -116.44 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.985 0 N-CA-C 108.506 -0.924 . . . . 0.0 108.506 179.693 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -110.12 54.27 0.55 Allowed Glycine 0 N--CA 1.474 1.227 0 N-CA-C 111.175 -0.77 . . . . 0.0 111.175 -179.865 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 73.8 p -80.32 126.18 30.82 Favored 'General case' 0 C--O 1.22 -0.455 0 N-CA-C 109.07 -0.715 . . . . 0.0 109.07 178.414 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 27' ' ' ASN . . . . . 0.481 HD22 ' CG ' ' A' ' 11' ' ' GLU . 51.0 t30 -66.94 100.28 0.72 Allowed 'General case' 0 N--CA 1.473 0.704 0 N-CA-C 108.673 -0.862 . . . . 0.0 108.673 178.563 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 66.9 mttm -96.79 119.68 35.72 Favored 'General case' 0 N--CA 1.482 1.172 0 N-CA-C 110.238 -0.282 . . . . 0.0 110.238 -179.169 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.31 -125.96 0.01 OUTLIER Glycine 0 CA--C 1.534 1.268 0 N-CA-C 110.534 -1.026 . . . . 0.0 110.534 178.727 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.01 133.7 49.17 Favored 'General case' 0 N--CA 1.482 1.14 0 N-CA-C 109.263 -0.643 . . . . 0.0 109.263 179.171 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 67.3 mt -83.12 138.54 19.15 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.456 0 N-CA-C 107.129 -1.434 . . . . 0.0 107.129 178.538 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 18.0 mt -128.5 128.74 68.44 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.987 0 O-C-N 123.626 0.579 . . . . 0.0 110.16 -178.519 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 60.67 78.93 0.13 Allowed Glycine 0 CA--C 1.527 0.797 0 CA-C-N 116.018 -0.537 . . . . 0.0 113.033 178.844 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 2.0 tt -110.58 118.94 37.58 Favored 'General case' 0 N--CA 1.477 0.89 0 N-CA-C 106.902 -1.518 . . . . 0.0 106.902 177.37 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 8.7 ttt -155.07 160.94 41.38 Favored 'General case' 0 N--CA 1.469 0.501 0 N-CA-C 109.125 -0.694 . . . . 0.0 109.125 179.185 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 93.0 t -157.93 150.57 8.28 Favored 'Isoleucine or valine' 0 C--O 1.233 0.203 0 N-CA-C 106.74 -1.578 . . . . 0.0 106.74 -179.566 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 37' ' ' GLY . . . . . 0.478 ' H ' HE22 ' C' ' 15' ' ' GLN . . . 55.7 75.32 0.25 Allowed Glycine 0 C--N 1.314 -0.649 0 CA-C-N 115.691 -0.686 . . . . 0.0 111.814 178.368 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 168.61 -148.78 12.84 Favored Glycine 0 CA--C 1.52 0.382 0 N-CA-C 110.631 -0.988 . . . . 0.0 110.631 179.862 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 21.5 m -132.89 142.56 41.97 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.814 0 N-CA-C 109.696 -0.483 . . . . 0.0 109.696 179.707 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 21.3 t . . . . . 0 N--CA 1.468 0.443 0 CA-C-O 117.772 -1.109 . . . . 0.0 110.801 179.376 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' D' D ' 1' ' ' ASP . . . . . 0.424 ' CG ' ' H1 ' ' A' ' 1' ' ' ASP . 9.4 m-20 . . . . . 0 N--CA 1.491 1.588 0 N-CA-C 109.037 -0.727 . . . . 0.0 109.037 . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.28 131.02 46.1 Favored 'General case' 0 CA--C 1.536 0.412 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.371 179.969 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 3' ' ' GLU . . . . . . . . . . . . . 39.2 tt0 -169.39 110.91 0.47 Allowed 'General case' 0 N--CA 1.469 0.494 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 179.698 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 87.7 m-85 -87.23 147.71 25.44 Favored 'General case' 0 C--N 1.363 1.155 0 C-N-CA 118.592 -1.243 . . . . 0.0 108.283 179.695 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 5' ' ' ARG . . . . . . . . . . . . . 71.2 mtp180 -147.45 141.35 25.84 Favored 'General case' 0 N--CA 1.475 0.82 0 N-CA-C 108.961 -0.755 . . . . 0.0 108.961 179.746 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 77.1 m80 -149.17 123.6 9.67 Favored 'General case' 0 CA--C 1.538 0.51 0 N-CA-C 107.891 -1.152 . . . . 0.0 107.891 175.875 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 7' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -63.3 133.55 54.34 Favored 'General case' 0 C--N 1.321 -0.668 0 C-N-CA 127.049 2.139 . . . . 0.0 114.697 176.251 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 8' ' ' SER . . . . . . . . . . . . . 6.6 t -154.03 173.56 15.85 Favored 'General case' 0 N--CA 1.478 0.951 0 CA-C-N 118.533 0.606 . . . . 0.0 110.296 177.074 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 124.29 20.45 2.44 Favored Glycine 0 N--CA 1.485 1.917 0 N-CA-C 112.126 -0.39 . . . . 0.0 112.126 176.579 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 37.2 p90 -55.81 130.46 43.56 Favored 'General case' 0 CA--C 1.546 0.804 0 CA-C-O 121.126 0.489 . . . . 0.0 111.889 -177.355 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 11' ' ' GLU . . . . . 0.452 ' CG ' HD22 ' F' ' 27' ' ' ASN . 46.0 mt-10 -85.26 152.42 23.33 Favored 'General case' 0 N--CA 1.473 0.694 0 N-CA-C 109.732 -0.469 . . . . 0.0 109.732 177.763 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -149.51 130.05 4.41 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.472 0 N-CA-C 108.222 -1.029 . . . . 0.0 108.222 175.593 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 46.9 m-70 -129.64 148.07 51.49 Favored 'General case' 0 N--CA 1.483 1.201 0 CA-C-N 118.009 0.368 . . . . 0.0 111.423 176.708 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -165.37 104.76 0.74 Allowed 'General case' 0 N--CA 1.483 1.207 0 N-CA-C 109.623 -0.51 . . . . 0.0 109.623 173.453 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' D' D ' 15' ' ' GLN . . . . . 0.501 HE22 ' H ' ' D' ' 37' ' ' GLY . 61.5 mt-30 -112.02 -175.66 2.74 Favored 'General case' 0 CA--C 1.493 -1.214 0 N-CA-C 108.019 -1.104 . . . . 0.0 108.019 179.348 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 88.7 tttt -162.09 105.9 1.19 Allowed 'General case' 0 CA--C 1.538 0.506 0 N-CA-C 107.603 -1.258 . . . . 0.0 107.603 175.386 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 5.7 mp -112.69 163.07 15.0 Favored 'General case' 0 N--CA 1.487 1.407 0 N-CA-C 108.095 -1.076 . . . . 0.0 108.095 179.536 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 48.1 t -140.92 123.59 15.56 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.072 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 176.158 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 76.1 m-85 -62.77 151.3 39.06 Favored 'General case' 0 C--N 1.351 0.652 0 C-N-CA 124.688 1.195 . . . . 0.0 110.386 170.774 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 9.0 t80 -169.86 -66.59 0.02 OUTLIER 'General case' 0 N--CA 1.476 0.827 0 N-CA-C 107.816 -1.179 . . . . 0.0 107.816 -179.707 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -37.83 96.11 0.01 OUTLIER 'General case' 0 CA--C 1.536 0.425 0 CA-C-N 113.919 -1.491 . . . . 0.0 111.583 -174.353 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 54.1 tt0 -69.98 158.52 35.48 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 113.459 -1.7 . . . . 0.0 110.17 178.767 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 68.1 m-20 -140.14 141.32 36.07 Favored 'General case' 0 N--CA 1.477 0.875 0 N-CA-C 109.496 -0.557 . . . . 0.0 109.496 178.581 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 24' ' ' VAL . . . . . . . . . . . . . 19.7 t -87.7 -119.19 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.486 1.372 0 N-CA-C 107.91 -1.144 . . . . 0.0 107.91 179.816 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . -113.93 61.98 0.33 Allowed Glycine 0 C--N 1.371 2.495 0 C-N-CA 118.073 -2.013 . . . . 0.0 109.441 178.612 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 89.1 p -70.54 121.37 17.7 Favored 'General case' 0 C--O 1.24 0.601 0 CA-C-O 116.521 -1.704 . . . . 0.0 112.184 169.162 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 27' ' ' ASN . . . . . 0.432 HD22 ' CG ' ' E' ' 11' ' ' GLU . 57.1 t30 -61.4 101.83 0.2 Allowed 'General case' 0 N--CA 1.475 0.788 0 CA-C-N 121.625 2.011 . . . . 0.0 109.489 172.464 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 66.5 mttm -100.17 121.44 41.44 Favored 'General case' 0 N--CA 1.488 1.453 0 CA-C-N 119.681 1.128 . . . . 0.0 109.378 178.673 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -53.96 -130.12 0.0 OUTLIER Glycine 0 CA--C 1.529 0.938 0 CA-C-N 115.535 -0.757 . . . . 0.0 112.284 175.008 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -125.23 139.84 53.38 Favored 'General case' 0 C--N 1.37 1.498 0 N-CA-C 108.666 -0.864 . . . . 0.0 108.666 174.278 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 66.4 mt -83.9 141.12 15.2 Favored 'Isoleucine or valine' 0 C--O 1.239 0.527 0 N-CA-C 107.145 -1.428 . . . . 0.0 107.145 176.29 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 25.6 mt -131.31 132.89 62.81 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.058 0 N-CA-C 108.59 -0.893 . . . . 0.0 108.59 178.253 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.88 77.16 0.21 Allowed Glycine 0 C--O 1.248 1.014 0 CA-C-O 118.351 -1.249 . . . . 0.0 112.618 178.791 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 2.5 tt -109.87 131.06 55.41 Favored 'General case' 0 C--N 1.376 1.756 0 N-CA-C 104.135 -2.543 . . . . 0.0 104.135 174.722 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 8.5 ttt -157.12 166.69 32.56 Favored 'General case' 0 C--O 1.219 -0.544 0 N-CA-C 108.794 -0.817 . . . . 0.0 108.794 176.44 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 88.8 t -163.57 154.78 2.45 Favored 'Isoleucine or valine' 0 C--O 1.24 0.566 0 N-CA-C 105.476 -2.046 . . . . 0.0 105.476 175.075 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 37' ' ' GLY . . . . . 0.501 ' H ' HE22 ' D' ' 15' ' ' GLN . . . 61.15 66.54 2.61 Favored Glycine 0 N--CA 1.444 -0.769 0 C-N-CA 117.875 -2.107 . . . . 0.0 113.674 177.125 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 166.82 -147.67 12.28 Favored Glycine 0 N--CA 1.466 0.688 0 CA-C-O 117.807 -1.552 . . . . 0.0 112.2 -179.045 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 22.4 m -130.11 142.88 42.64 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.112 0 CA-C-N 119.304 1.552 . . . . 0.0 109.429 -179.439 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 18.7 t . . . . . 0 C--O 1.214 -0.776 0 N-CA-C 109.169 -0.678 . . . . 0.0 109.169 174.944 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' E' E ' 1' ' ' ASP . . . . . 0.406 ' H1 ' ' CG ' ' H' ' 1' ' ' ASP . 9.7 m-20 . . . . . 0 N--CA 1.49 1.545 0 N-CA-C 109.174 -0.676 . . . . 0.0 109.174 . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' E' E ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.3 130.72 44.94 Favored 'General case' 0 CA--C 1.535 0.396 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.369 179.843 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' E' E ' 3' ' ' GLU . . . . . . . . . . . . . 39.4 tt0 -169.03 108.95 0.46 Allowed 'General case' 0 N--CA 1.47 0.557 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 -179.844 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 79.2 m-85 -84.64 140.28 31.46 Favored 'General case' 0 N--CA 1.475 0.811 0 N-CA-C 109.949 -0.389 . . . . 0.0 109.949 179.4 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' E' E ' 5' ' ' ARG . . . . . . . . . . . . . 71.5 mtp180 -143.77 142.26 30.82 Favored 'General case' 0 N--CA 1.476 0.842 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 179.886 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 76.7 m80 -150.53 118.24 6.17 Favored 'General case' 0 N--CA 1.472 0.662 0 N-CA-C 108.926 -0.768 . . . . 0.0 108.926 179.129 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' E' E ' 7' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -66.16 149.63 50.01 Favored 'General case' 0 N--CA 1.465 0.289 0 O-C-N 123.542 0.526 . . . . 0.0 111.559 -179.606 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' E' E ' 8' ' ' SER . . . . . . . . . . . . . 6.7 t -167.12 172.53 9.94 Favored 'General case' 0 N--CA 1.477 0.891 0 CA-C-N 115.86 -0.609 . . . . 0.0 109.563 178.033 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.95 23.67 2.19 Favored Glycine 0 N--CA 1.482 1.716 0 N-CA-C 112.018 -0.433 . . . . 0.0 112.018 179.096 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 39.2 p90 -56.18 127.26 29.82 Favored 'General case' 0 N--CA 1.473 0.724 0 N-CA-C 112.639 0.607 . . . . 0.0 112.639 -179.149 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' E' E ' 11' ' ' GLU . . . . . 0.432 ' CG ' HD22 ' D' ' 27' ' ' ASN . 46.3 mt-10 -83.41 155.55 23.41 Favored 'General case' 0 N--CA 1.474 0.734 0 N-CA-C 109.302 -0.629 . . . . 0.0 109.302 178.033 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -155.67 128.34 1.09 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.534 0 N-CA-C 108.357 -0.979 . . . . 0.0 108.357 178.782 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 47.5 m-70 -135.17 143.18 46.33 Favored 'General case' 0 N--CA 1.48 1.074 0 CA-C-O 120.746 0.308 . . . . 0.0 111.329 -177.875 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -164.83 98.68 0.77 Allowed 'General case' 0 N--CA 1.488 1.472 0 CA-C-N 116.677 -0.238 . . . . 0.0 110.973 179.73 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' E' E ' 15' ' ' GLN . . . . . 0.488 HE22 ' H ' ' E' ' 37' ' ' GLY . 62.1 mt-30 -108.4 -171.91 1.95 Allowed 'General case' 0 CA--C 1.502 -0.883 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 -179.831 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -166.27 97.31 0.6 Allowed 'General case' 0 CA--C 1.541 0.629 0 CA-C-N 115.043 -0.98 . . . . 0.0 109.327 178.648 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' E' E ' 17' ' ' LEU . . . . . 0.402 ' N ' ' CD1' ' E' ' 17' ' ' LEU . 4.8 mp -105.85 163.56 12.63 Favored 'General case' 0 N--CA 1.49 1.545 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 -179.805 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 40.3 t -141.9 118.57 6.99 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.352 0 C-N-CA 122.612 0.365 . . . . 0.0 110.492 179.126 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 50.9 m-85 -69.49 156.77 38.35 Favored 'General case' 0 C--N 1.357 0.933 0 N-CA-C 107.336 -1.357 . . . . 0.0 107.336 176.56 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 12.4 t80 -173.41 -54.9 0.02 OUTLIER 'General case' 0 N--CA 1.485 1.28 0 CA-C-O 121.822 0.82 . . . . 0.0 110.288 179.457 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.96 89.31 0.0 OUTLIER 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 114.346 -1.297 . . . . 0.0 112.686 -178.783 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 54.7 tt0 -66.14 158.19 29.26 Favored 'General case' 0 N--CA 1.472 0.656 0 CA-C-N 114.823 -1.08 . . . . 0.0 110.651 179.651 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 66.0 m-20 -140.56 137.59 33.85 Favored 'General case' 0 N--CA 1.479 1.005 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.442 179.881 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 21.7 t -84.79 -115.45 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.039 0 N-CA-C 108.681 -0.859 . . . . 0.0 108.681 179.649 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . -110.61 54.16 0.55 Allowed Glycine 0 C--N 1.347 1.163 0 N-CA-C 111.457 -0.657 . . . . 0.0 111.457 -179.715 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 69.0 p -79.75 125.67 29.97 Favored 'General case' 0 N--CA 1.474 0.773 0 N-CA-C 109.384 -0.599 . . . . 0.0 109.384 178.078 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' E' E ' 27' ' ' ASN . . . . . 0.462 HD22 ' CG ' ' F' ' 11' ' ' GLU . 52.5 t30 -66.72 99.5 0.61 Allowed 'General case' 0 N--CA 1.471 0.601 0 N-CA-C 108.081 -1.081 . . . . 0.0 108.081 178.382 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 66.4 mttm -96.44 119.3 34.66 Favored 'General case' 0 N--CA 1.484 1.252 0 N-CA-C 109.995 -0.372 . . . . 0.0 109.995 -178.748 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.57 -124.88 0.01 OUTLIER Glycine 0 CA--C 1.538 1.525 0 N-CA-C 110.95 -0.86 . . . . 0.0 110.95 178.601 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.74 133.33 48.08 Favored 'General case' 0 N--CA 1.482 1.158 0 N-CA-C 109.581 -0.526 . . . . 0.0 109.581 179.65 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 66.3 mt -82.65 138.97 18.5 Favored 'Isoleucine or valine' 0 C--O 1.237 0.405 0 N-CA-C 107.029 -1.471 . . . . 0.0 107.029 178.434 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 21.0 mt -128.32 129.06 69.05 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.865 0 N-CA-C 109.566 -0.531 . . . . 0.0 109.566 -179.433 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 60.97 80.28 0.1 Allowed Glycine 0 CA--C 1.524 0.641 0 CA-C-N 116.064 -0.516 . . . . 0.0 113.505 179.172 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 2.0 tt -111.77 118.86 36.74 Favored 'General case' 0 N--CA 1.477 0.916 0 N-CA-C 107.003 -1.481 . . . . 0.0 107.003 177.34 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 8.6 ttt -154.14 162.64 41.05 Favored 'General case' 0 C--O 1.211 -0.944 0 N-CA-C 108.744 -0.835 . . . . 0.0 108.744 179.203 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 84.1 t -159.71 150.53 6.33 Favored 'Isoleucine or valine' 0 C--O 1.239 0.509 0 N-CA-C 106.632 -1.618 . . . . 0.0 106.632 -179.864 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' E' E ' 37' ' ' GLY . . . . . 0.488 ' H ' HE22 ' E' ' 15' ' ' GLN . . . 55.61 74.94 0.27 Allowed Glycine 0 C--N 1.314 -0.662 0 CA-C-N 115.673 -0.694 . . . . 0.0 111.481 178.48 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 169.95 -147.7 11.08 Favored Glycine 0 C--O 1.222 -0.631 0 N-CA-C 111.321 -0.712 . . . . 0.0 111.321 179.965 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 20.3 m -133.93 141.38 44.12 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.872 0 N-CA-C 109.199 -0.667 . . . . 0.0 109.199 179.444 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 19.0 t . . . . . 0 CA--C 1.535 0.379 0 CA-C-O 117.722 -1.133 . . . . 0.0 110.895 179.453 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' F' F ' 1' ' ' ASP . . . . . 0.418 ' H1 ' ' CG ' ' I' ' 1' ' ' ASP . 9.3 m-20 . . . . . 0 N--CA 1.489 1.525 0 N-CA-C 109.161 -0.681 . . . . 0.0 109.161 . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' F' F ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.11 130.9 45.81 Favored 'General case' 0 CA--C 1.536 0.428 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.359 179.884 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' F' F ' 3' ' ' GLU . . . . . . . . . . . . . 39.3 tt0 -169.22 108.84 0.45 Allowed 'General case' 0 N--CA 1.468 0.473 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 -179.859 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 79.4 m-85 -84.56 140.45 31.4 Favored 'General case' 0 N--CA 1.475 0.8 0 N-CA-C 109.873 -0.417 . . . . 0.0 109.873 179.344 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' F' F ' 5' ' ' ARG . . . . . . . . . . . . . 71.6 mtp180 -143.8 141.84 30.59 Favored 'General case' 0 N--CA 1.477 0.912 0 N-CA-C 109.261 -0.644 . . . . 0.0 109.261 179.998 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 76.9 m80 -150.28 118.41 6.34 Favored 'General case' 0 N--CA 1.473 0.688 0 N-CA-C 108.965 -0.754 . . . . 0.0 108.965 179.072 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' F' F ' 7' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -66.4 149.82 49.83 Favored 'General case' 0 N--CA 1.463 0.203 0 O-C-N 123.414 0.447 . . . . 0.0 111.636 -179.429 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' F' F ' 8' ' ' SER . . . . . . . . . . . . . 6.9 t -167.41 172.28 9.79 Favored 'General case' 0 N--CA 1.476 0.874 0 CA-C-N 115.991 -0.55 . . . . 0.0 109.56 178.04 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 123.19 23.25 2.21 Favored Glycine 0 N--CA 1.482 1.74 0 N-CA-C 112.04 -0.424 . . . . 0.0 112.04 179.109 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 38.7 p90 -55.87 127.72 31.63 Favored 'General case' 0 CA--C 1.543 0.694 0 N-CA-C 112.664 0.616 . . . . 0.0 112.664 -179.151 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' F' F ' 11' ' ' GLU . . . . . 0.462 ' CG ' HD22 ' E' ' 27' ' ' ASN . 46.3 mt-10 -83.74 155.33 23.13 Favored 'General case' 0 N--CA 1.474 0.764 0 N-CA-C 109.436 -0.579 . . . . 0.0 109.436 178.023 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -155.34 128.19 1.11 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.587 0 N-CA-C 108.297 -1.001 . . . . 0.0 108.297 178.79 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 46.1 m-70 -135.01 143.22 46.68 Favored 'General case' 0 N--CA 1.483 1.196 0 CA-C-O 120.63 0.252 . . . . 0.0 111.329 -177.902 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -165.18 99.09 0.73 Allowed 'General case' 0 N--CA 1.487 1.422 0 CA-C-N 116.751 -0.204 . . . . 0.0 111.091 179.74 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' F' F ' 15' ' ' GLN . . . . . 0.478 HE22 ' H ' ' F' ' 37' ' ' GLY . 61.6 mt-30 -109.2 -171.51 1.86 Allowed 'General case' 0 CA--C 1.498 -1.034 0 N-CA-C 108.574 -0.899 . . . . 0.0 108.574 -179.826 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -166.11 97.57 0.62 Allowed 'General case' 0 CA--C 1.542 0.651 0 CA-C-N 114.93 -1.032 . . . . 0.0 109.406 178.769 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' F' F ' 17' ' ' LEU . . . . . 0.401 ' N ' ' CD1' ' F' ' 17' ' ' LEU . 4.7 mp -105.81 163.48 12.69 Favored 'General case' 0 N--CA 1.488 1.469 0 N-CA-C 109.213 -0.662 . . . . 0.0 109.213 -179.923 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 40.0 t -141.9 118.59 7.02 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.305 0 C-N-CA 122.644 0.378 . . . . 0.0 110.613 179.101 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 51.0 m-85 -69.53 156.66 38.54 Favored 'General case' 0 C--N 1.357 0.922 0 N-CA-C 107.221 -1.399 . . . . 0.0 107.221 176.548 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 13.2 t80 -173.19 -55.04 0.02 OUTLIER 'General case' 0 N--CA 1.486 1.372 0 CA-C-O 121.787 0.803 . . . . 0.0 109.85 179.458 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.73 88.99 0.0 OUTLIER 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 114.49 -1.232 . . . . 0.0 112.971 -178.876 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 54.4 tt0 -65.96 158.22 28.74 Favored 'General case' 0 N--CA 1.472 0.666 0 CA-C-N 114.894 -1.048 . . . . 0.0 110.799 179.541 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 66.7 m-20 -140.51 137.83 34.11 Favored 'General case' 0 N--CA 1.48 1.059 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.396 179.96 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' F' F ' 24' ' ' VAL . . . . . . . . . . . . . 21.7 t -85.09 -115.46 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.043 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 179.505 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -110.55 54.11 0.56 Allowed Glycine 0 N--CA 1.479 1.529 0 N-CA-C 111.383 -0.687 . . . . 0.0 111.383 -179.815 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 70.1 p -79.68 125.42 29.62 Favored 'General case' 0 N--CA 1.474 0.733 0 N-CA-C 109.335 -0.617 . . . . 0.0 109.335 177.948 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' F' F ' 27' ' ' ASN . . . . . 0.452 HD22 ' CG ' ' D' ' 11' ' ' GLU . 52.2 t30 -66.5 99.23 0.55 Allowed 'General case' 0 N--CA 1.472 0.638 0 N-CA-C 108.115 -1.069 . . . . 0.0 108.115 178.382 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 66.4 mttm -96.26 119.17 34.27 Favored 'General case' 0 N--CA 1.483 1.19 0 N-CA-C 110.084 -0.339 . . . . 0.0 110.084 -178.804 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.55 -125.41 0.01 OUTLIER Glycine 0 CA--C 1.54 1.6 0 N-CA-C 110.964 -0.854 . . . . 0.0 110.964 178.617 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -127.91 133.08 49.25 Favored 'General case' 0 N--CA 1.484 1.249 0 N-CA-C 109.644 -0.502 . . . . 0.0 109.644 179.588 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 66.9 mt -82.65 138.81 18.77 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.273 0 N-CA-C 106.897 -1.52 . . . . 0.0 106.897 178.421 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 20.3 mt -128.22 129.08 69.22 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.891 0 N-CA-C 109.636 -0.505 . . . . 0.0 109.636 -179.357 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 60.86 80.27 0.1 Allowed Glycine 0 CA--C 1.525 0.688 0 CA-C-N 116.056 -0.52 . . . . 0.0 113.573 179.346 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 2.1 tt -111.85 118.82 36.59 Favored 'General case' 0 N--CA 1.479 0.981 0 N-CA-C 107.067 -1.457 . . . . 0.0 107.067 177.346 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 8.7 ttt -154.15 162.72 41.0 Favored 'General case' 0 C--O 1.209 -1.041 0 N-CA-C 109.009 -0.737 . . . . 0.0 109.009 179.143 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 85.1 t -159.7 150.57 6.32 Favored 'Isoleucine or valine' 0 C--O 1.237 0.402 0 N-CA-C 106.701 -1.592 . . . . 0.0 106.701 -179.823 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' F' F ' 37' ' ' GLY . . . . . 0.478 ' H ' HE22 ' F' ' 15' ' ' GLN . . . 55.8 74.67 0.3 Allowed Glycine 0 C--N 1.315 -0.632 0 CA-C-N 115.523 -0.762 . . . . 0.0 111.447 178.452 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 170.06 -147.82 11.14 Favored Glycine 0 C--O 1.221 -0.7 0 N-CA-C 111.233 -0.747 . . . . 0.0 111.233 179.839 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 20.2 m -133.72 141.37 44.35 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.841 0 N-CA-C 109.158 -0.682 . . . . 0.0 109.158 179.547 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 19.4 t . . . . . 0 CA--C 1.536 0.415 0 CA-C-O 117.746 -1.121 . . . . 0.0 110.75 179.389 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' G' G ' 1' ' ' ASP . . . . . 0.41 ' CG ' ' H1 ' ' D' ' 1' ' ' ASP . 8.7 m-20 . . . . . 0 N--CA 1.49 1.565 0 N-CA-C 109.723 -0.473 . . . . 0.0 109.723 . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.44 129.27 39.9 Favored 'General case' 0 N--CA 1.469 0.514 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.44 179.636 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 3' ' ' GLU . . . . . . . . . . . . . 39.0 tt0 -169.08 108.59 0.45 Allowed 'General case' 0 N--CA 1.471 0.605 0 N-CA-C 110.117 -0.327 . . . . 0.0 110.117 179.758 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 79.0 m-85 -85.07 139.72 31.53 Favored 'General case' 0 N--CA 1.474 0.772 0 N-CA-C 109.644 -0.502 . . . . 0.0 109.644 179.199 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 5' ' ' ARG . . . . . . . . . . . . . 71.8 mtp180 -144.01 141.28 30.05 Favored 'General case' 0 N--CA 1.483 1.22 0 N-CA-C 109.178 -0.675 . . . . 0.0 109.178 -179.515 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 76.7 m80 -149.53 119.57 7.19 Favored 'General case' 0 N--CA 1.472 0.671 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 179.078 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 -68.41 145.28 54.27 Favored 'General case' 0 N--CA 1.47 0.526 0 O-C-N 123.505 0.503 . . . . 0.0 111.931 -179.328 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 8' ' ' SER . . . . . . . . . . . . . 5.7 t -163.81 173.54 12.64 Favored 'General case' 0 N--CA 1.47 0.566 0 N-CA-C 109.291 -0.633 . . . . 0.0 109.291 178.147 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.94 23.65 2.2 Favored Glycine 0 N--CA 1.479 1.519 0 N-CA-C 111.755 -0.538 . . . . 0.0 111.755 179.051 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 41.9 p90 -56.98 127.61 32.79 Favored 'General case' 0 N--CA 1.475 0.799 0 N-CA-C 112.437 0.532 . . . . 0.0 112.437 -178.648 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 45.2 mt-10 -83.93 154.34 23.43 Favored 'General case' 0 N--CA 1.471 0.618 0 CA-C-O 121.052 0.453 . . . . 0.0 109.852 178.686 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -155.4 128.51 1.15 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.968 0 N-CA-C 108.304 -0.999 . . . . 0.0 108.304 178.9 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 49.1 m-70 -134.19 144.38 48.44 Favored 'General case' 0 N--CA 1.476 0.865 0 CA-C-N 115.416 -0.811 . . . . 0.0 111.09 -178.136 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -166.35 98.2 0.6 Allowed 'General case' 0 N--CA 1.484 1.245 0 CA-C-N 116.642 -0.254 . . . . 0.0 110.572 179.219 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' G' G ' 15' ' ' GLN . . . . . 0.488 HE22 ' H ' ' G' ' 37' ' ' GLY . 61.7 mt-30 -108.32 -171.89 1.95 Allowed 'General case' 0 CA--C 1.503 -0.839 0 N-CA-C 108.635 -0.876 . . . . 0.0 108.635 -179.775 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -166.03 97.58 0.63 Allowed 'General case' 0 CA--C 1.541 0.618 0 CA-C-N 115.032 -0.985 . . . . 0.0 109.38 178.614 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 17' ' ' LEU . . . . . 0.4 ' N ' ' CD1' ' G' ' 17' ' ' LEU . 5.4 mp -105.73 162.33 13.63 Favored 'General case' 0 N--CA 1.487 1.423 0 N-CA-C 109.4 -0.593 . . . . 0.0 109.4 -179.717 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 39.0 t -142.45 118.83 6.08 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.082 0 CA-C-O 120.895 0.378 . . . . 0.0 110.352 178.773 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 44.9 m-85 -69.65 150.74 46.69 Favored 'General case' 0 C--N 1.369 1.444 0 N-CA-C 107.267 -1.383 . . . . 0.0 107.267 176.583 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 10.9 t80 -170.92 -54.84 0.02 OUTLIER 'General case' 0 N--CA 1.487 1.382 0 CA-C-N 117.847 0.294 . . . . 0.0 110.408 -179.73 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.45 90.27 0.0 OUTLIER 'General case' 0 C--N 1.325 -0.494 0 C-N-CA 123.866 0.866 . . . . 0.0 112.596 -179.918 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 53.8 tt0 -66.88 159.06 29.07 Favored 'General case' 0 N--CA 1.469 0.492 0 CA-C-N 114.634 -1.166 . . . . 0.0 109.923 179.189 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 66.2 m-20 -140.94 137.55 33.18 Favored 'General case' 0 N--CA 1.477 0.904 0 C-N-CA 122.822 0.449 . . . . 0.0 110.046 179.893 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 24' ' ' VAL . . . . . . . . . . . . . 21.4 t -85.42 -115.29 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.919 0 N-CA-C 108.521 -0.918 . . . . 0.0 108.521 179.608 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -110.53 53.97 0.56 Allowed Glycine 0 N--CA 1.477 1.425 0 N-CA-C 111.611 -0.596 . . . . 0.0 111.611 -179.712 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 70.4 p -80.08 126.27 30.85 Favored 'General case' 0 N--CA 1.467 0.393 0 N-CA-C 109.081 -0.711 . . . . 0.0 109.081 177.956 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 50.4 t30 -67.23 99.99 0.75 Allowed 'General case' 0 CA--C 1.538 0.503 0 N-CA-C 108.401 -0.963 . . . . 0.0 108.401 178.434 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 66.9 mttm -96.33 119.91 35.68 Favored 'General case' 0 N--CA 1.482 1.147 0 N-CA-C 110.174 -0.306 . . . . 0.0 110.174 -179.182 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.02 -123.33 0.01 OUTLIER Glycine 0 CA--C 1.534 1.253 0 N-CA-C 110.54 -1.024 . . . . 0.0 110.54 178.787 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -129.58 132.78 46.89 Favored 'General case' 0 N--CA 1.47 0.557 0 N-CA-C 109.514 -0.55 . . . . 0.0 109.514 179.683 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 69.9 mt -81.54 140.91 15.85 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.654 0 N-CA-C 107.2 -1.407 . . . . 0.0 107.2 178.337 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 24.0 mt -130.2 130.52 65.74 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.46 0 CA-C-N 119.044 0.838 . . . . 0.0 109.435 179.785 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 60.96 79.82 0.11 Allowed Glycine 0 CA--C 1.528 0.888 0 CA-C-N 116.281 -0.418 . . . . 0.0 113.038 179.292 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 1.9 tt -111.93 119.55 38.92 Favored 'General case' 0 N--CA 1.478 0.94 0 N-CA-C 106.961 -1.496 . . . . 0.0 106.961 177.479 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 8.5 ttt -155.54 163.14 40.38 Favored 'General case' 0 N--CA 1.476 0.866 0 N-CA-C 108.192 -1.04 . . . . 0.0 108.192 179.503 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 98.6 t -159.8 150.85 6.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 N-CA-C 106.303 -1.74 . . . . 0.0 106.303 -179.899 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 37' ' ' GLY . . . . . 0.488 ' H ' HE22 ' G' ' 15' ' ' GLN . . . 56.1 74.74 0.29 Allowed Glycine 0 C--N 1.313 -0.706 0 CA-C-N 115.888 -0.596 . . . . 0.0 111.913 178.132 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 168.66 -146.42 10.34 Favored Glycine 0 N--CA 1.471 1.008 0 N-CA-C 110.636 -0.986 . . . . 0.0 110.636 179.231 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 23.1 m -134.23 141.62 43.17 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.906 0 CA-C-N 117.031 0.415 . . . . 0.0 109.984 179.881 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 19.2 t . . . . . 0 N--CA 1.47 0.548 0 CA-C-O 117.841 -1.076 . . . . 0.0 110.891 179.613 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' H' H ' 1' ' ' ASP . . . . . 0.406 ' CG ' ' H1 ' ' E' ' 1' ' ' ASP . 9.7 m-20 . . . . . 0 N--CA 1.491 1.59 0 N-CA-C 109.661 -0.496 . . . . 0.0 109.661 . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' H' H ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.56 129.07 38.95 Favored 'General case' 0 N--CA 1.468 0.473 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.491 179.716 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' H' H ' 3' ' ' GLU . . . . . . . . . . . . . 39.3 tt0 -168.96 108.58 0.46 Allowed 'General case' 0 N--CA 1.47 0.557 0 N-CA-C 110.114 -0.328 . . . . 0.0 110.114 179.745 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 80.4 m-85 -84.77 140.13 31.46 Favored 'General case' 0 N--CA 1.475 0.805 0 N-CA-C 109.641 -0.503 . . . . 0.0 109.641 179.342 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' H' H ' 5' ' ' ARG . . . . . . . . . . . . . 71.5 mtp180 -144.29 141.4 29.77 Favored 'General case' 0 N--CA 1.48 1.055 0 N-CA-C 109.222 -0.658 . . . . 0.0 109.222 -179.625 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 76.8 m80 -149.72 119.29 6.96 Favored 'General case' 0 N--CA 1.473 0.698 0 N-CA-C 109.095 -0.705 . . . . 0.0 109.095 179.071 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 8.7 m-20 -68.08 145.35 54.5 Favored 'General case' 0 N--CA 1.468 0.45 0 O-C-N 123.466 0.479 . . . . 0.0 111.934 -179.393 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' H' H ' 8' ' ' SER . . . . . . . . . . . . . 7.0 t -163.9 172.83 13.45 Favored 'General case' 0 N--CA 1.468 0.474 0 N-CA-C 109.449 -0.574 . . . . 0.0 109.449 178.466 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 123.15 23.52 2.17 Favored Glycine 0 N--CA 1.481 1.684 0 N-CA-C 111.682 -0.567 . . . . 0.0 111.682 179.154 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 41.6 p90 -56.79 127.65 32.68 Favored 'General case' 0 N--CA 1.472 0.672 0 N-CA-C 112.443 0.534 . . . . 0.0 112.443 -178.763 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 45.4 mt-10 -83.96 154.4 23.36 Favored 'General case' 0 N--CA 1.473 0.679 0 CA-C-O 120.998 0.428 . . . . 0.0 109.893 178.739 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.6 p -155.58 128.11 1.07 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.016 0 N-CA-C 108.42 -0.955 . . . . 0.0 108.42 178.879 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 48.7 m-70 -133.91 144.4 48.83 Favored 'General case' 0 N--CA 1.478 0.947 0 CA-C-N 115.336 -0.847 . . . . 0.0 111.025 -178.072 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -166.29 98.54 0.61 Allowed 'General case' 0 N--CA 1.483 1.218 0 CA-C-N 116.568 -0.287 . . . . 0.0 110.617 179.166 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' H' H ' 15' ' ' GLN . . . . . 0.497 HE22 ' H ' ' H' ' 37' ' ' GLY . 61.6 mt-30 -108.64 -172.37 2.04 Favored 'General case' 0 CA--C 1.501 -0.931 0 N-CA-C 108.416 -0.957 . . . . 0.0 108.416 -179.656 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -165.73 97.35 0.65 Allowed 'General case' 0 CA--C 1.54 0.572 0 CA-C-N 114.951 -1.022 . . . . 0.0 109.364 178.716 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' H' H ' 17' ' ' LEU . . . . . 0.404 ' N ' ' CD1' ' H' ' 17' ' ' LEU . 5.4 mp -105.66 162.23 13.7 Favored 'General case' 0 N--CA 1.487 1.405 0 N-CA-C 109.362 -0.607 . . . . 0.0 109.362 -179.646 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 38.8 t -142.39 118.67 6.08 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.983 0 CA-C-O 120.97 0.414 . . . . 0.0 110.489 178.851 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 46.2 m-85 -69.8 151.07 46.18 Favored 'General case' 0 C--N 1.371 1.503 0 N-CA-C 107.355 -1.35 . . . . 0.0 107.355 176.653 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 11.4 t80 -172.15 -54.6 0.02 OUTLIER 'General case' 0 N--CA 1.485 1.295 0 N-CA-C 110.342 -0.244 . . . . 0.0 110.342 -179.635 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.39 90.41 0.0 OUTLIER 'General case' 0 CA--C 1.535 0.365 0 C-N-CA 123.815 0.846 . . . . 0.0 112.354 -179.958 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 54.0 tt0 -66.73 159.14 28.52 Favored 'General case' 0 N--CA 1.469 0.485 0 CA-C-N 114.69 -1.141 . . . . 0.0 110.012 179.34 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 67.5 m-20 -140.91 138.05 33.58 Favored 'General case' 0 N--CA 1.477 0.885 0 C-N-CA 122.821 0.448 . . . . 0.0 110.051 179.693 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' H' H ' 24' ' ' VAL . . . . . . . . . . . . . 21.4 t -85.93 -115.33 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 1.016 0 N-CA-C 108.609 -0.885 . . . . 0.0 108.609 179.602 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . -110.33 53.9 0.56 Allowed Glycine 0 N--CA 1.48 1.601 0 N-CA-C 111.471 -0.652 . . . . 0.0 111.471 -179.759 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 68.7 p -80.03 126.02 30.52 Favored 'General case' 0 N--CA 1.468 0.446 0 N-CA-C 109.053 -0.721 . . . . 0.0 109.053 178.067 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 50.6 t30 -67.31 100.1 0.78 Allowed 'General case' 0 N--CA 1.47 0.542 0 N-CA-C 108.409 -0.96 . . . . 0.0 108.409 178.492 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 67.0 mttm -96.41 119.76 35.49 Favored 'General case' 0 N--CA 1.484 1.236 0 N-CA-C 110.182 -0.303 . . . . 0.0 110.182 -179.131 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.89 -122.84 0.01 OUTLIER Glycine 0 CA--C 1.535 1.306 0 N-CA-C 110.606 -0.998 . . . . 0.0 110.606 178.735 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -129.95 133.0 46.54 Favored 'General case' 0 N--CA 1.471 0.62 0 C-N-CA 122.946 0.498 . . . . 0.0 109.663 179.709 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 69.5 mt -81.89 140.76 16.01 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.554 0 N-CA-C 107.128 -1.434 . . . . 0.0 107.128 178.446 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 25.1 mt -130.03 130.47 66.08 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.403 0 CA-C-N 119.021 0.828 . . . . 0.0 109.395 179.935 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 60.77 79.81 0.11 Allowed Glycine 0 CA--C 1.528 0.889 0 CA-C-N 116.382 -0.372 . . . . 0.0 113.067 179.193 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 1.9 tt -111.87 119.5 38.77 Favored 'General case' 0 N--CA 1.478 0.944 0 N-CA-C 106.944 -1.502 . . . . 0.0 106.944 177.426 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 8.4 ttt -155.19 163.19 40.54 Favored 'General case' 0 C--O 1.212 -0.91 0 N-CA-C 108.176 -1.046 . . . . 0.0 108.176 179.509 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 96.4 t -159.79 150.77 6.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 N-CA-C 106.254 -1.758 . . . . 0.0 106.254 -179.885 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' H' H ' 37' ' ' GLY . . . . . 0.497 ' H ' HE22 ' H' ' 15' ' ' GLN . . . 56.12 74.95 0.27 Allowed Glycine 0 C--N 1.313 -0.712 0 CA-C-N 115.914 -0.584 . . . . 0.0 111.914 178.124 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 168.32 -146.34 10.37 Favored Glycine 0 N--CA 1.469 0.866 0 N-CA-C 110.631 -0.988 . . . . 0.0 110.631 179.105 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 22.6 m -134.15 141.81 42.74 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.906 0 CA-C-N 116.998 0.399 . . . . 0.0 110.021 179.911 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 19.1 t . . . . . 0 N--CA 1.47 0.557 0 CA-C-O 117.789 -1.101 . . . . 0.0 110.932 179.539 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' I' I ' 1' ' ' ASP . . . . . 0.418 ' CG ' ' H1 ' ' F' ' 1' ' ' ASP . 9.6 m-20 . . . . . 0 N--CA 1.491 1.589 0 N-CA-C 109.607 -0.516 . . . . 0.0 109.607 . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' I' I ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.67 129.19 39.43 Favored 'General case' 0 N--CA 1.469 0.491 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.441 179.635 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' I' I ' 3' ' ' GLU . . . . . . . . . . . . . 39.0 tt0 -169.0 108.67 0.46 Allowed 'General case' 0 N--CA 1.47 0.563 0 N-CA-C 110.147 -0.316 . . . . 0.0 110.147 179.771 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 79.9 m-85 -84.96 140.32 31.16 Favored 'General case' 0 N--CA 1.475 0.78 0 N-CA-C 109.599 -0.519 . . . . 0.0 109.599 179.298 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' I' I ' 5' ' ' ARG . . . . . . . . . . . . . 71.6 mtp180 -144.44 141.5 29.66 Favored 'General case' 0 N--CA 1.483 1.192 0 N-CA-C 109.187 -0.671 . . . . 0.0 109.187 -179.696 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 76.7 m80 -149.76 119.06 6.82 Favored 'General case' 0 N--CA 1.472 0.667 0 N-CA-C 109.126 -0.694 . . . . 0.0 109.126 179.082 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 8.6 m-20 -67.86 145.36 54.69 Favored 'General case' 0 N--CA 1.469 0.491 0 O-C-N 123.479 0.487 . . . . 0.0 111.935 -179.371 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' I' I ' 8' ' ' SER . . . . . . . . . . . . . 7.5 t -163.9 172.75 13.55 Favored 'General case' 0 N--CA 1.469 0.496 0 N-CA-C 109.429 -0.582 . . . . 0.0 109.429 178.465 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 123.2 23.77 2.12 Favored Glycine 0 N--CA 1.481 1.639 0 N-CA-C 111.78 -0.528 . . . . 0.0 111.78 179.118 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 41.5 p90 -56.95 127.52 32.27 Favored 'General case' 0 N--CA 1.474 0.737 0 N-CA-C 112.443 0.534 . . . . 0.0 112.443 -178.738 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 45.2 mt-10 -83.66 154.34 23.74 Favored 'General case' 0 N--CA 1.472 0.628 0 CA-C-O 120.998 0.427 . . . . 0.0 109.909 178.675 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -155.49 128.29 1.1 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.015 0 N-CA-C 108.313 -0.995 . . . . 0.0 108.313 178.848 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 49.5 m-70 -134.06 144.56 48.72 Favored 'General case' 0 N--CA 1.478 0.935 0 CA-C-N 115.337 -0.847 . . . . 0.0 111.13 -178.198 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -166.4 98.51 0.6 Allowed 'General case' 0 N--CA 1.484 1.255 0 CA-C-N 116.639 -0.255 . . . . 0.0 110.704 179.127 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' I' I ' 15' ' ' GLN . . . . . 0.492 HE22 ' H ' ' I' ' 37' ' ' GLY . 61.4 mt-30 -108.63 -172.45 2.06 Favored 'General case' 0 CA--C 1.498 -1.029 0 N-CA-C 108.461 -0.94 . . . . 0.0 108.461 -179.765 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -165.69 97.43 0.66 Allowed 'General case' 0 CA--C 1.541 0.61 0 CA-C-N 114.9 -1.046 . . . . 0.0 109.302 178.789 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' I' I ' 17' ' ' LEU . . . . . 0.401 ' CD1' ' N ' ' I' ' 17' ' ' LEU . 5.4 mp -105.68 162.51 13.46 Favored 'General case' 0 N--CA 1.487 1.402 0 N-CA-C 109.306 -0.627 . . . . 0.0 109.306 -179.609 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 39.2 t -142.5 118.81 5.95 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.006 0 CA-C-O 120.94 0.4 . . . . 0.0 110.471 178.851 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 45.8 m-85 -70.02 150.96 46.1 Favored 'General case' 0 C--N 1.369 1.431 0 N-CA-C 107.402 -1.332 . . . . 0.0 107.402 176.601 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 11.5 t80 -171.96 -54.72 0.02 OUTLIER 'General case' 0 N--CA 1.483 1.209 0 CA-C-N 117.765 0.257 . . . . 0.0 110.401 -179.561 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.34 90.22 0.0 OUTLIER 'General case' 0 CA--C 1.535 0.401 0 C-N-CA 123.743 0.817 . . . . 0.0 112.386 -179.942 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 54.1 tt0 -66.46 159.06 27.92 Favored 'General case' 0 N--CA 1.468 0.47 0 CA-C-N 114.667 -1.151 . . . . 0.0 110.061 179.272 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 67.2 m-20 -140.91 138.0 33.54 Favored 'General case' 0 N--CA 1.477 0.921 0 C-N-CA 122.775 0.43 . . . . 0.0 110.001 179.835 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' I' I ' 24' ' ' VAL . . . . . . . . . . . . . 21.3 t -85.99 -115.52 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.926 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 179.653 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . -110.16 53.6 0.58 Allowed Glycine 0 N--CA 1.479 1.501 0 N-CA-C 111.579 -0.609 . . . . 0.0 111.579 -179.702 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 68.7 p -79.74 126.24 30.7 Favored 'General case' 0 N--CA 1.467 0.411 0 N-CA-C 109.036 -0.727 . . . . 0.0 109.036 178.026 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 49.8 t30 -67.52 99.9 0.81 Allowed 'General case' 0 N--CA 1.47 0.527 0 N-CA-C 108.379 -0.971 . . . . 0.0 108.379 178.483 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 67.0 mttm -96.2 119.79 35.32 Favored 'General case' 0 N--CA 1.482 1.165 0 N-CA-C 110.216 -0.29 . . . . 0.0 110.216 -179.135 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.13 -123.23 0.01 OUTLIER Glycine 0 CA--C 1.534 1.254 0 N-CA-C 110.656 -0.978 . . . . 0.0 110.656 178.746 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -129.4 132.74 47.09 Favored 'General case' 0 N--CA 1.473 0.683 0 C-N-CA 122.962 0.505 . . . . 0.0 109.65 179.657 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 69.5 mt -81.75 140.68 16.16 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.637 0 N-CA-C 106.982 -1.488 . . . . 0.0 106.982 178.387 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 23.3 mt -129.89 130.44 66.37 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.383 0 CA-C-N 118.939 0.79 . . . . 0.0 109.361 179.868 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 60.63 80.04 0.11 Allowed Glycine 0 CA--C 1.528 0.846 0 CA-C-N 116.331 -0.395 . . . . 0.0 113.107 179.25 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 1.9 tt -112.0 119.6 39.02 Favored 'General case' 0 N--CA 1.478 0.949 0 N-CA-C 106.891 -1.522 . . . . 0.0 106.891 177.446 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 8.6 ttt -155.29 163.08 40.63 Favored 'General case' 0 N--CA 1.478 0.943 0 N-CA-C 108.256 -1.016 . . . . 0.0 108.256 179.518 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 97.7 t -159.76 150.94 6.17 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 N-CA-C 106.253 -1.758 . . . . 0.0 106.253 -179.915 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' I' I ' 37' ' ' GLY . . . . . 0.492 ' H ' HE22 ' I' ' 15' ' ' GLN . . . 56.14 74.45 0.33 Allowed Glycine 0 C--N 1.313 -0.739 0 CA-C-N 115.891 -0.595 . . . . 0.0 112.023 178.115 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 168.76 -146.4 10.31 Favored Glycine 0 N--CA 1.47 0.915 0 N-CA-C 110.602 -0.999 . . . . 0.0 110.602 179.268 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 22.8 m -134.06 141.79 42.88 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.873 0 CA-C-N 117.01 0.405 . . . . 0.0 109.981 179.921 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 19.2 t . . . . . 0 N--CA 1.469 0.506 0 CA-C-O 117.825 -1.083 . . . . 0.0 110.939 179.507 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 8.6 m-20 . . . . . 0 N--CA 1.49 1.536 0 N-CA-C 109.048 -0.723 . . . . 0.0 109.048 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.95 132.72 49.29 Favored 'General case' 0 CA--C 1.538 0.491 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.201 -179.877 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 41.1 tt0 -169.33 108.32 0.43 Allowed 'General case' 0 N--CA 1.47 0.545 0 N-CA-C 109.693 -0.484 . . . . 0.0 109.693 -179.242 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 78.5 m-85 -83.56 140.52 32.2 Favored 'General case' 0 N--CA 1.475 0.795 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 179.469 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 72.2 mtp180 -143.62 141.17 30.5 Favored 'General case' 0 N--CA 1.481 1.116 0 N-CA-C 109.076 -0.713 . . . . 0.0 109.076 179.964 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 77.0 m80 -149.48 119.65 7.26 Favored 'General case' 0 N--CA 1.47 0.562 0 N-CA-C 108.806 -0.813 . . . . 0.0 108.806 179.136 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 7.4 m-20 -68.3 150.21 48.5 Favored 'General case' 0 CA--C 1.529 0.168 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.258 -179.437 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 8.5 t -166.95 172.27 10.41 Favored 'General case' 0 N--CA 1.472 0.63 0 N-CA-C 109.554 -0.536 . . . . 0.0 109.554 178.476 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.53 23.52 2.32 Favored Glycine 0 N--CA 1.487 2.097 0 N-CA-C 112.239 -0.344 . . . . 0.0 112.239 179.417 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 41.8 p90 -56.98 128.28 36.13 Favored 'General case' 0 N--CA 1.474 0.761 0 N-CA-C 112.088 0.403 . . . . 0.0 112.088 -179.912 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 57.4 mt-10 -85.66 155.38 21.12 Favored 'General case' 0 N--CA 1.469 0.504 0 N-CA-C 109.273 -0.64 . . . . 0.0 109.273 178.493 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -153.75 128.79 1.51 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 N-CA-C 108.107 -1.071 . . . . 0.0 108.107 178.839 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 49.5 m-70 -134.64 146.54 49.64 Favored 'General case' 0 N--CA 1.489 1.503 0 CA-C-N 118.641 0.655 . . . . 0.0 111.154 -179.024 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 6.4 t60 -164.96 97.91 0.74 Allowed 'General case' 0 N--CA 1.48 1.04 0 CA-C-N 116.502 -0.317 . . . . 0.0 111.055 179.582 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 35.0 mt-30 -106.06 -172.7 2.14 Favored 'General case' 0 CA--C 1.505 -0.762 0 N-CA-C 108.369 -0.974 . . . . 0.0 108.369 179.915 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -169.18 96.47 0.34 Allowed 'General case' 0 N--CA 1.472 0.629 0 CA-C-N 115.139 -0.937 . . . . 0.0 109.416 178.703 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . 0.411 ' N ' ' CD1' ' A' ' 17' ' ' LEU . 4.8 mp -106.38 165.01 11.57 Favored 'General case' 0 N--CA 1.489 1.498 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 179.901 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 56.5 t -141.78 119.22 7.96 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.387 0 CA-C-O 118.934 -0.555 . . . . 0.0 109.897 179.68 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 52.4 m-85 -69.9 158.93 34.62 Favored 'General case' 0 N--CA 1.481 1.079 0 N-CA-C 107.592 -1.262 . . . . 0.0 107.592 177.392 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 13.1 t80 -171.22 -58.59 0.02 OUTLIER 'General case' 0 N--CA 1.485 1.324 0 CA-C-O 122.299 1.047 . . . . 0.0 109.73 179.485 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -38.82 90.11 0.0 OUTLIER 'General case' 0 C--O 1.232 0.142 0 CA-C-N 113.926 -1.488 . . . . 0.0 112.968 -177.985 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 37.0 tt0 -66.51 157.81 31.24 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 115.109 -0.95 . . . . 0.0 110.452 179.197 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 66.7 m-20 -139.98 137.38 34.66 Favored 'General case' 0 N--CA 1.48 1.071 0 C-N-CA 123.002 0.521 . . . . 0.0 110.344 179.866 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 17.9 t -84.49 -116.3 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.962 0 N-CA-C 108.444 -0.947 . . . . 0.0 108.444 179.501 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -110.37 54.63 0.54 Allowed Glycine 0 N--CA 1.475 1.265 0 N-CA-C 111.227 -0.749 . . . . 0.0 111.227 179.916 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 74.8 p -79.98 125.96 30.43 Favored 'General case' 0 C--O 1.221 -0.417 0 N-CA-C 108.969 -0.752 . . . . 0.0 108.969 178.378 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 19.9 t-20 -66.6 100.42 0.67 Allowed 'General case' 0 N--CA 1.473 0.725 0 N-CA-C 108.576 -0.898 . . . . 0.0 108.576 178.704 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 66.6 mttm -96.85 120.34 37.01 Favored 'General case' 0 N--CA 1.483 1.182 0 N-CA-C 110.093 -0.336 . . . . 0.0 110.093 -179.157 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.58 -128.41 0.01 OUTLIER Glycine 0 CA--C 1.534 1.223 0 N-CA-C 110.525 -1.03 . . . . 0.0 110.525 178.779 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -126.05 133.86 51.59 Favored 'General case' 0 N--CA 1.48 1.052 0 N-CA-C 109.234 -0.654 . . . . 0.0 109.234 179.097 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 65.4 mt -83.21 137.81 20.34 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.538 0 N-CA-C 107.393 -1.336 . . . . 0.0 107.393 178.683 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 20.9 mt -129.44 129.25 66.95 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.976 0 O-C-N 123.495 0.497 . . . . 0.0 110.053 -178.424 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 60.43 79.05 0.13 Allowed Glycine 0 CA--C 1.525 0.685 0 CA-C-N 115.849 -0.614 . . . . 0.0 113.069 178.949 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 1.9 tt -110.94 119.48 39.21 Favored 'General case' 0 N--CA 1.477 0.915 0 N-CA-C 106.973 -1.492 . . . . 0.0 106.973 177.463 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 8.6 ttt -154.91 161.08 41.54 Favored 'General case' 0 N--CA 1.468 0.443 0 N-CA-C 109.066 -0.716 . . . . 0.0 109.066 179.257 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 63.1 t -157.75 150.48 8.55 Favored 'Isoleucine or valine' 0 C--O 1.232 0.148 0 N-CA-C 106.897 -1.52 . . . . 0.0 106.897 -179.496 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.61 75.42 0.24 Allowed Glycine 0 C--N 1.315 -0.607 0 CA-C-N 115.671 -0.695 . . . . 0.0 111.777 178.201 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 168.83 -149.12 13.2 Favored Glycine 0 CA--C 1.519 0.3 0 N-CA-C 110.744 -0.943 . . . . 0.0 110.744 179.847 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 20.7 m -132.57 142.87 41.38 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.874 0 N-CA-C 109.598 -0.519 . . . . 0.0 109.598 179.658 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 21.2 t . . . . . 0 N--CA 1.467 0.399 0 CA-C-O 117.834 -1.079 . . . . 0.0 110.831 179.29 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' B' B ' 1' ' ' ASP . . . . . . . . . . . . . 9.2 m-20 . . . . . 0 N--CA 1.489 1.479 0 N-CA-C 109.124 -0.695 . . . . 0.0 109.124 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' B' B ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.68 132.83 49.75 Favored 'General case' 0 CA--C 1.538 0.483 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.204 -179.865 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 3' ' ' GLU . . . . . . . . . . . . . 41.4 tt0 -169.55 108.29 0.41 Allowed 'General case' 0 N--CA 1.471 0.589 0 N-CA-C 109.584 -0.525 . . . . 0.0 109.584 -179.125 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 78.9 m-85 -83.58 140.49 32.21 Favored 'General case' 0 N--CA 1.474 0.726 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 179.474 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 72.2 mtp180 -143.68 141.14 30.41 Favored 'General case' 0 N--CA 1.481 1.108 0 N-CA-C 109.121 -0.696 . . . . 0.0 109.121 -179.931 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 76.7 m80 -149.51 119.6 7.22 Favored 'General case' 0 N--CA 1.471 0.615 0 N-CA-C 108.841 -0.8 . . . . 0.0 108.841 179.122 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 7' ' ' ASP . . . . . . . . . . . . . 8.5 m-20 -68.09 150.2 48.69 Favored 'General case' 0 CA--C 1.53 0.19 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.281 -179.453 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 8' ' ' SER . . . . . . . . . . . . . 8.4 t -166.98 172.2 10.43 Favored 'General case' 0 N--CA 1.472 0.631 0 N-CA-C 109.537 -0.542 . . . . 0.0 109.537 178.557 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.5 23.38 2.36 Favored Glycine 0 N--CA 1.487 2.051 0 N-CA-C 112.159 -0.377 . . . . 0.0 112.159 179.371 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 41.9 p90 -56.78 128.16 35.22 Favored 'General case' 0 N--CA 1.471 0.616 0 N-CA-C 112.166 0.432 . . . . 0.0 112.166 -179.983 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 57.4 mt-10 -85.58 155.64 21.07 Favored 'General case' 0 N--CA 1.471 0.58 0 N-CA-C 109.297 -0.631 . . . . 0.0 109.297 178.555 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -153.88 128.68 1.46 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 N-CA-C 108.186 -1.042 . . . . 0.0 108.186 178.816 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 50.1 m-70 -134.57 146.75 49.93 Favored 'General case' 0 N--CA 1.489 1.513 0 CA-C-N 118.481 0.582 . . . . 0.0 111.219 -179.018 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 6.5 t60 -165.32 97.82 0.7 Allowed 'General case' 0 N--CA 1.481 1.108 0 CA-C-N 116.519 -0.309 . . . . 0.0 111.022 179.627 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 35.2 mt-30 -105.96 -172.89 2.17 Favored 'General case' 0 CA--C 1.504 -0.789 0 N-CA-C 108.407 -0.96 . . . . 0.0 108.407 179.949 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -169.14 96.35 0.34 Allowed 'General case' 0 CA--C 1.54 0.592 0 CA-C-N 115.193 -0.912 . . . . 0.0 109.447 178.76 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . 0.41 ' N ' ' CD1' ' B' ' 17' ' ' LEU . 4.8 mp -106.41 164.82 11.73 Favored 'General case' 0 N--CA 1.488 1.461 0 N-CA-C 108.575 -0.898 . . . . 0.0 108.575 179.968 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 58.6 t -141.55 119.26 8.53 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.355 0 CA-C-O 118.957 -0.544 . . . . 0.0 109.9 179.566 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 53.3 m-85 -70.53 159.09 34.94 Favored 'General case' 0 N--CA 1.479 0.982 0 N-CA-C 107.52 -1.289 . . . . 0.0 107.52 177.316 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 14.4 t80 -171.84 -57.33 0.02 OUTLIER 'General case' 0 N--CA 1.482 1.138 0 CA-C-O 122.228 1.013 . . . . 0.0 109.838 179.452 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -39.39 90.37 0.0 OUTLIER 'General case' 0 C--O 1.232 0.152 0 CA-C-N 114.09 -1.413 . . . . 0.0 112.874 -178.052 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 36.6 tt0 -66.42 158.03 30.43 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 115.058 -0.973 . . . . 0.0 110.56 179.133 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 67.6 m-20 -140.37 137.42 34.04 Favored 'General case' 0 N--CA 1.481 1.089 0 C-N-CA 122.993 0.517 . . . . 0.0 110.251 179.805 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 17.5 t -84.59 -116.55 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 1.016 0 N-CA-C 108.65 -0.87 . . . . 0.0 108.65 179.482 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -109.46 54.01 0.56 Allowed Glycine 0 N--CA 1.476 1.331 0 N-CA-C 111.189 -0.764 . . . . 0.0 111.189 179.878 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 74.2 p -79.7 126.04 30.42 Favored 'General case' 0 C--O 1.221 -0.405 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 178.386 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 19.7 t-20 -66.89 100.19 0.7 Allowed 'General case' 0 N--CA 1.474 0.761 0 N-CA-C 108.673 -0.862 . . . . 0.0 108.673 178.565 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 66.8 mttm -96.68 120.47 37.06 Favored 'General case' 0 N--CA 1.483 1.186 0 N-CA-C 110.118 -0.327 . . . . 0.0 110.118 -179.142 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.68 -127.73 0.01 OUTLIER Glycine 0 CA--C 1.534 1.246 0 N-CA-C 110.538 -1.025 . . . . 0.0 110.538 178.755 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -126.83 133.62 50.72 Favored 'General case' 0 N--CA 1.481 1.104 0 N-CA-C 109.165 -0.68 . . . . 0.0 109.165 179.252 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 64.4 mt -82.96 137.97 20.11 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.452 0 N-CA-C 107.363 -1.347 . . . . 0.0 107.363 178.59 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 21.6 mt -129.72 129.19 66.26 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.971 0 O-C-N 123.546 0.528 . . . . 0.0 109.941 -178.42 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 60.4 78.76 0.14 Allowed Glycine 0 CA--C 1.524 0.63 0 CA-C-N 115.828 -0.624 . . . . 0.0 113.094 178.915 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 1.9 tt -110.39 119.61 39.77 Favored 'General case' 0 N--CA 1.478 0.953 0 N-CA-C 106.975 -1.491 . . . . 0.0 106.975 177.351 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 8.7 ttt -154.89 160.79 41.43 Favored 'General case' 0 N--CA 1.47 0.562 0 N-CA-C 108.97 -0.752 . . . . 0.0 108.97 179.283 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 63.4 t -157.64 150.31 8.81 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.136 0 N-CA-C 106.825 -1.546 . . . . 0.0 106.825 -179.511 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.54 75.73 0.23 Allowed Glycine 0 C--N 1.314 -0.669 0 CA-C-N 115.659 -0.701 . . . . 0.0 111.771 178.169 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 168.52 -149.09 13.32 Favored Glycine 0 CA--C 1.519 0.306 0 N-CA-C 110.704 -0.958 . . . . 0.0 110.704 179.879 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 20.7 m -132.52 142.91 41.32 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.907 0 N-CA-C 109.643 -0.503 . . . . 0.0 109.643 179.676 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 21.2 t . . . . . 0 N--CA 1.467 0.405 0 CA-C-O 117.812 -1.089 . . . . 0.0 110.848 179.292 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' C' C ' 1' ' ' ASP . . . . . . . . . . . . . 8.5 m-20 . . . . . 0 N--CA 1.487 1.419 0 N-CA-C 109.066 -0.716 . . . . 0.0 109.066 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' C' C ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.41 132.76 49.78 Favored 'General case' 0 CA--C 1.538 0.513 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.189 -179.935 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 3' ' ' GLU . . . . . . . . . . . . . 41.5 tt0 -169.56 108.38 0.41 Allowed 'General case' 0 N--CA 1.47 0.543 0 N-CA-C 109.588 -0.523 . . . . 0.0 109.588 -179.276 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 78.1 m-85 -83.65 140.42 32.19 Favored 'General case' 0 N--CA 1.474 0.737 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 179.433 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 72.4 mtp180 -143.61 141.07 30.46 Favored 'General case' 0 N--CA 1.482 1.136 0 N-CA-C 109.043 -0.725 . . . . 0.0 109.043 -179.857 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 76.5 m80 -149.47 119.64 7.26 Favored 'General case' 0 N--CA 1.47 0.571 0 N-CA-C 108.826 -0.805 . . . . 0.0 108.826 179.109 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 7' ' ' ASP . . . . . . . . . . . . . 7.6 m-20 -68.13 150.03 48.86 Favored 'General case' 0 CA--C 1.529 0.168 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.332 -179.381 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 8' ' ' SER . . . . . . . . . . . . . 8.5 t -166.71 172.73 10.27 Favored 'General case' 0 N--CA 1.471 0.618 0 N-CA-C 109.611 -0.514 . . . . 0.0 109.611 178.352 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.13 23.33 2.46 Favored Glycine 0 N--CA 1.487 2.042 0 N-CA-C 112.24 -0.344 . . . . 0.0 112.24 179.484 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 41.5 p90 -56.84 128.34 36.2 Favored 'General case' 0 N--CA 1.472 0.646 0 N-CA-C 112.088 0.403 . . . . 0.0 112.088 -179.896 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 57.5 mt-10 -85.79 155.27 21.08 Favored 'General case' 0 N--CA 1.47 0.556 0 N-CA-C 109.239 -0.652 . . . . 0.0 109.239 178.63 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -153.59 128.61 1.5 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 N-CA-C 108.181 -1.044 . . . . 0.0 108.181 178.853 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 49.5 m-70 -134.49 146.65 49.94 Favored 'General case' 0 N--CA 1.489 1.49 0 CA-C-N 118.541 0.609 . . . . 0.0 111.265 -179.105 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 6.4 t60 -165.15 98.04 0.72 Allowed 'General case' 0 N--CA 1.48 1.067 0 CA-C-N 116.572 -0.286 . . . . 0.0 111.085 179.596 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 35.1 mt-30 -106.36 -172.76 2.15 Favored 'General case' 0 CA--C 1.504 -0.807 0 N-CA-C 108.414 -0.958 . . . . 0.0 108.414 -179.99 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.7 tttt -169.18 96.45 0.34 Allowed 'General case' 0 CA--C 1.54 0.56 0 CA-C-N 115.12 -0.945 . . . . 0.0 109.451 178.751 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 17' ' ' LEU . . . . . 0.411 ' N ' ' CD1' ' C' ' 17' ' ' LEU . 4.8 mp -106.26 164.91 11.63 Favored 'General case' 0 N--CA 1.488 1.472 0 N-CA-C 108.584 -0.895 . . . . 0.0 108.584 179.968 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 58.5 t -141.71 118.94 7.76 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.341 0 CA-C-O 118.95 -0.548 . . . . 0.0 109.879 179.655 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 53.3 m-85 -70.25 159.0 34.84 Favored 'General case' 0 N--CA 1.478 0.956 0 N-CA-C 107.491 -1.3 . . . . 0.0 107.491 177.345 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 14.4 t80 -171.77 -57.41 0.02 OUTLIER 'General case' 0 N--CA 1.481 1.092 0 CA-C-O 122.183 0.992 . . . . 0.0 109.856 179.357 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -39.26 90.61 0.0 OUTLIER 'General case' 0 C--O 1.232 0.14 0 CA-C-N 114.125 -1.398 . . . . 0.0 112.849 -178.049 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 37.0 tt0 -66.74 158.05 31.21 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 115.096 -0.956 . . . . 0.0 110.513 179.219 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 67.2 m-20 -140.33 137.4 34.08 Favored 'General case' 0 N--CA 1.48 1.054 0 C-N-CA 122.944 0.498 . . . . 0.0 110.331 179.794 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 17.7 t -84.53 -116.42 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.967 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 179.588 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -109.86 54.35 0.55 Allowed Glycine 0 N--CA 1.475 1.275 0 N-CA-C 111.172 -0.771 . . . . 0.0 111.172 179.915 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 74.7 p -79.91 126.25 30.77 Favored 'General case' 0 C--O 1.222 -0.358 0 N-CA-C 109.004 -0.739 . . . . 0.0 109.004 178.417 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 19.4 t-20 -66.99 100.37 0.73 Allowed 'General case' 0 N--CA 1.474 0.737 0 N-CA-C 108.682 -0.858 . . . . 0.0 108.682 178.606 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 66.8 mttm -96.86 120.09 36.54 Favored 'General case' 0 N--CA 1.484 1.251 0 N-CA-C 110.161 -0.311 . . . . 0.0 110.161 -179.138 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.34 -128.17 0.01 OUTLIER Glycine 0 CA--C 1.535 1.313 0 N-CA-C 110.529 -1.028 . . . . 0.0 110.529 178.76 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -126.33 133.75 51.29 Favored 'General case' 0 N--CA 1.48 1.073 0 N-CA-C 109.269 -0.641 . . . . 0.0 109.269 179.12 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 65.7 mt -83.06 137.82 20.35 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.525 0 N-CA-C 107.282 -1.377 . . . . 0.0 107.282 178.614 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 20.9 mt -129.59 128.81 66.27 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.935 0 O-C-N 123.545 0.528 . . . . 0.0 110.119 -178.507 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 60.84 78.55 0.15 Allowed Glycine 0 CA--C 1.524 0.654 0 CA-C-N 115.97 -0.559 . . . . 0.0 113.063 178.848 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 1.9 tt -110.41 119.16 38.31 Favored 'General case' 0 N--CA 1.478 0.945 0 N-CA-C 107.021 -1.474 . . . . 0.0 107.021 177.463 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 8.5 ttt -154.44 161.08 41.89 Favored 'General case' 0 N--CA 1.468 0.456 0 N-CA-C 108.976 -0.75 . . . . 0.0 108.976 179.356 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 63.4 t -158.03 150.13 8.42 Favored 'Isoleucine or valine' 0 C--O 1.232 0.158 0 N-CA-C 106.816 -1.55 . . . . 0.0 106.816 -179.393 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.68 75.54 0.24 Allowed Glycine 0 C--N 1.315 -0.635 0 CA-C-N 115.776 -0.647 . . . . 0.0 111.75 178.172 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 168.76 -148.95 12.95 Favored Glycine 0 CA--C 1.519 0.325 0 N-CA-C 110.639 -0.984 . . . . 0.0 110.639 179.88 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 20.1 m -132.79 142.7 41.67 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.875 0 N-CA-C 109.666 -0.494 . . . . 0.0 109.666 179.716 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 21.3 t . . . . . 0 N--CA 1.468 0.454 0 CA-C-O 117.726 -1.13 . . . . 0.0 110.718 179.244 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' D' D ' 1' ' ' ASP . . . . . . . . . . . . . 8.8 m-20 . . . . . 0 N--CA 1.49 1.543 0 N-CA-C 109.154 -0.684 . . . . 0.0 109.154 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' D' D ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.4 131.24 46.64 Favored 'General case' 0 CA--C 1.535 0.391 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.376 179.789 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' D' D ' 3' ' ' GLU . . . . . . . . . . . . . 41.0 tt0 -169.39 110.58 0.47 Allowed 'General case' 0 N--CA 1.47 0.533 0 N-CA-C 109.387 -0.597 . . . . 0.0 109.387 179.472 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 86.9 m-85 -87.04 148.2 25.38 Favored 'General case' 0 C--N 1.363 1.171 0 C-N-CA 118.526 -1.27 . . . . 0.0 108.275 179.768 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' D' D ' 5' ' ' ARG . . . . . . . . . . . . . 72.5 mtp180 -147.31 141.18 25.82 Favored 'General case' 0 N--CA 1.476 0.829 0 N-CA-C 108.896 -0.779 . . . . 0.0 108.896 179.757 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 77.1 m80 -149.22 123.43 9.53 Favored 'General case' 0 CA--C 1.539 0.527 0 N-CA-C 107.915 -1.143 . . . . 0.0 107.915 175.724 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' D' D ' 7' ' ' ASP . . . . . . . . . . . . . 5.6 m-20 -63.12 133.77 54.96 Favored 'General case' 0 C--N 1.319 -0.719 0 C-N-CA 127.188 2.195 . . . . 0.0 114.882 176.081 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' D' D ' 8' ' ' SER . . . . . . . . . . . . . 7.9 t -154.09 174.36 14.81 Favored 'General case' 0 N--CA 1.477 0.914 0 CA-C-N 118.751 0.705 . . . . 0.0 110.302 176.958 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 124.29 20.25 2.48 Favored Glycine 0 N--CA 1.483 1.787 0 N-CA-C 112.232 -0.347 . . . . 0.0 112.232 176.645 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 37.0 p90 -55.91 130.29 43.11 Favored 'General case' 0 CA--C 1.546 0.79 0 CA-C-O 121.07 0.462 . . . . 0.0 111.881 -177.494 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 57.3 mt-10 -85.71 152.83 22.76 Favored 'General case' 0 N--CA 1.474 0.759 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 177.681 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -149.38 129.97 4.45 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.455 0 N-CA-C 108.009 -1.108 . . . . 0.0 108.009 175.229 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 48.9 m-70 -129.74 149.7 51.38 Favored 'General case' 0 N--CA 1.482 1.128 0 CA-C-N 117.939 0.336 . . . . 0.0 111.503 176.727 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 6.6 t60 -164.81 104.66 0.8 Allowed 'General case' 0 N--CA 1.482 1.133 0 N-CA-C 109.539 -0.541 . . . . 0.0 109.539 173.203 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 35.2 mt-30 -109.32 -175.62 2.81 Favored 'General case' 0 CA--C 1.494 -1.18 0 N-CA-C 108.28 -1.007 . . . . 0.0 108.28 178.978 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 88.7 tttt -165.77 105.25 0.7 Allowed 'General case' 0 CA--C 1.538 0.504 0 N-CA-C 107.637 -1.246 . . . . 0.0 107.637 175.331 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 5.6 mp -113.2 163.2 15.07 Favored 'General case' 0 N--CA 1.488 1.454 0 N-CA-C 108.225 -1.028 . . . . 0.0 108.225 179.699 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 51.8 t -140.9 123.67 15.72 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.187 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 176.215 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 78.7 m-85 -62.43 151.2 37.84 Favored 'General case' 0 C--N 1.353 0.759 0 C-N-CA 124.726 1.21 . . . . 0.0 110.412 170.862 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 9.3 t80 -170.0 -66.64 0.02 OUTLIER 'General case' 0 N--CA 1.476 0.871 0 N-CA-C 107.81 -1.182 . . . . 0.0 107.81 -179.835 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -38.27 95.75 0.01 OUTLIER 'General case' 0 CA--C 1.535 0.39 0 CA-C-N 113.972 -1.467 . . . . 0.0 111.731 -174.603 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 37.2 tt0 -68.7 158.72 33.61 Favored 'General case' 0 N--CA 1.467 0.421 0 CA-C-N 113.36 -1.746 . . . . 0.0 110.243 178.65 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 67.8 m-20 -140.34 141.17 35.69 Favored 'General case' 0 N--CA 1.475 0.822 0 N-CA-C 109.517 -0.549 . . . . 0.0 109.517 178.585 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' D' D ' 24' ' ' VAL . . . . . . . . . . . . . 19.6 t -87.83 -119.62 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.486 1.368 0 N-CA-C 107.752 -1.203 . . . . 0.0 107.752 179.727 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . -113.31 61.85 0.32 Allowed Glycine 0 C--N 1.372 2.559 0 C-N-CA 118.005 -2.045 . . . . 0.0 109.313 178.81 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 90.9 p -70.35 121.44 17.69 Favored 'General case' 0 C--N 1.349 0.574 0 CA-C-O 116.647 -1.644 . . . . 0.0 112.016 169.276 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 17.2 t-20 -61.36 101.67 0.18 Allowed 'General case' 0 N--CA 1.474 0.772 0 CA-C-N 121.558 1.981 . . . . 0.0 109.486 172.485 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 66.3 mttm -100.12 121.75 41.9 Favored 'General case' 0 N--CA 1.49 1.558 0 CA-C-N 119.64 1.109 . . . . 0.0 109.366 178.803 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -54.16 -130.2 0.0 OUTLIER Glycine 0 CA--C 1.529 0.961 0 CA-C-N 115.664 -0.698 . . . . 0.0 112.68 175.57 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -125.17 139.95 53.29 Favored 'General case' 0 C--N 1.373 1.614 0 N-CA-C 108.567 -0.901 . . . . 0.0 108.567 174.052 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 65.3 mt -84.13 140.29 16.35 Favored 'Isoleucine or valine' 0 C--O 1.239 0.506 0 N-CA-C 107.403 -1.332 . . . . 0.0 107.403 176.478 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 29.1 mt -131.89 132.95 61.51 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.017 0 N-CA-C 108.66 -0.866 . . . . 0.0 108.66 178.367 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.31 76.99 0.22 Allowed Glycine 0 C--O 1.248 0.994 0 CA-C-O 118.102 -1.388 . . . . 0.0 112.404 178.449 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 2.4 tt -110.2 131.43 55.07 Favored 'General case' 0 C--N 1.372 1.562 0 N-CA-C 103.96 -2.607 . . . . 0.0 103.96 174.968 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 8.3 ttt -156.85 166.7 32.63 Favored 'General case' 0 N--CA 1.471 0.594 0 N-CA-C 108.679 -0.86 . . . . 0.0 108.679 176.685 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 91.6 t -163.58 154.31 2.55 Favored 'Isoleucine or valine' 0 C--O 1.241 0.647 0 N-CA-C 105.545 -2.02 . . . . 0.0 105.545 175.379 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 61.39 66.51 2.61 Favored Glycine 0 N--CA 1.444 -0.782 0 C-N-CA 118.039 -2.029 . . . . 0.0 113.619 176.76 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 167.27 -148.39 13.05 Favored Glycine 0 N--CA 1.468 0.805 0 CA-C-O 118.163 -1.354 . . . . 0.0 111.859 -178.577 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 21.4 m -129.74 143.04 42.32 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.166 0 CA-C-N 118.896 1.348 . . . . 0.0 109.64 -179.944 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 18.8 t . . . . . 0 C--O 1.215 -0.745 0 N-CA-C 109.204 -0.665 . . . . 0.0 109.204 174.798 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' E' E ' 1' ' ' ASP . . . . . . . . . . . . . 8.5 m-20 . . . . . 0 N--CA 1.489 1.498 0 N-CA-C 109.225 -0.657 . . . . 0.0 109.225 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' E' E ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.46 131.18 46.4 Favored 'General case' 0 N--CA 1.468 0.443 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.371 179.927 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' E' E ' 3' ' ' GLU . . . . . . . . . . . . . 41.4 tt0 -168.83 108.53 0.48 Allowed 'General case' 0 N--CA 1.469 0.504 0 N-CA-C 109.978 -0.379 . . . . 0.0 109.978 -179.851 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 79.1 m-85 -84.5 140.69 31.29 Favored 'General case' 0 N--CA 1.476 0.829 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 179.434 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' E' E ' 5' ' ' ARG . . . . . . . . . . . . . 72.3 mtp180 -143.62 141.96 30.84 Favored 'General case' 0 N--CA 1.478 0.933 0 N-CA-C 109.392 -0.595 . . . . 0.0 109.392 179.893 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 76.8 m80 -150.37 118.23 6.24 Favored 'General case' 0 N--CA 1.473 0.692 0 N-CA-C 108.962 -0.755 . . . . 0.0 108.962 179.123 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' E' E ' 7' ' ' ASP . . . . . . . . . . . . . 7.5 m-20 -66.7 149.96 49.77 Favored 'General case' 0 N--CA 1.463 0.224 0 O-C-N 123.542 0.526 . . . . 0.0 111.639 -179.515 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' E' E ' 8' ' ' SER . . . . . . . . . . . . . 7.9 t -166.95 173.43 9.33 Favored 'General case' 0 N--CA 1.476 0.875 0 CA-C-N 115.965 -0.561 . . . . 0.0 109.549 178.003 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.85 23.59 2.23 Favored Glycine 0 N--CA 1.482 1.737 0 N-CA-C 111.908 -0.477 . . . . 0.0 111.908 179.163 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 38.2 p90 -56.64 127.49 31.65 Favored 'General case' 0 N--CA 1.473 0.676 0 N-CA-C 112.602 0.593 . . . . 0.0 112.602 -179.241 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 57.0 mt-10 -84.34 156.2 21.99 Favored 'General case' 0 N--CA 1.476 0.827 0 N-CA-C 109.482 -0.562 . . . . 0.0 109.482 178.045 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -155.62 127.9 1.03 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.512 0 N-CA-C 108.185 -1.042 . . . . 0.0 108.185 178.702 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 49.0 m-70 -135.08 144.81 47.4 Favored 'General case' 0 N--CA 1.48 1.073 0 CA-C-O 120.757 0.313 . . . . 0.0 111.38 -177.933 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 6.3 t60 -163.94 97.94 0.84 Allowed 'General case' 0 N--CA 1.487 1.379 0 CA-C-N 116.652 -0.249 . . . . 0.0 111.064 179.702 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 35.2 mt-30 -105.51 -172.45 2.1 Favored 'General case' 0 CA--C 1.502 -0.878 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 -179.951 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -169.45 96.56 0.32 Allowed 'General case' 0 CA--C 1.542 0.638 0 CA-C-N 115.018 -0.992 . . . . 0.0 109.402 178.658 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' E' E ' 17' ' ' LEU . . . . . 0.4 ' N ' ' CD1' ' E' ' 17' ' ' LEU . 4.8 mp -106.21 164.11 12.26 Favored 'General case' 0 N--CA 1.49 1.547 0 N-CA-C 109.233 -0.654 . . . . 0.0 109.233 -179.765 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 40.8 t -141.59 118.46 7.5 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 C-N-CA 122.563 0.345 . . . . 0.0 110.551 179.085 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 52.7 m-85 -69.45 156.54 38.69 Favored 'General case' 0 C--N 1.358 0.957 0 N-CA-C 107.397 -1.335 . . . . 0.0 107.397 176.696 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 12.7 t80 -173.28 -55.06 0.02 OUTLIER 'General case' 0 N--CA 1.485 1.299 0 CA-C-O 121.741 0.782 . . . . 0.0 110.368 179.472 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.23 89.1 0.0 OUTLIER 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 114.398 -1.274 . . . . 0.0 112.852 -179.009 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 37.0 tt0 -65.16 158.31 26.37 Favored 'General case' 0 N--CA 1.472 0.646 0 CA-C-N 114.876 -1.056 . . . . 0.0 110.698 179.604 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 66.1 m-20 -140.68 137.03 33.23 Favored 'General case' 0 N--CA 1.479 0.997 0 C-N-CA 122.853 0.461 . . . . 0.0 110.518 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 21.8 t -84.52 -115.5 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.066 0 N-CA-C 108.715 -0.846 . . . . 0.0 108.715 179.48 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . -110.09 54.38 0.55 Allowed Glycine 0 C--N 1.348 1.214 0 N-CA-C 111.362 -0.695 . . . . 0.0 111.362 -179.827 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 73.2 p -79.72 125.27 29.44 Favored 'General case' 0 N--CA 1.473 0.709 0 N-CA-C 109.34 -0.615 . . . . 0.0 109.34 178.059 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 18.4 t-20 -66.27 99.88 0.58 Allowed 'General case' 0 N--CA 1.474 0.765 0 N-CA-C 108.063 -1.088 . . . . 0.0 108.063 178.386 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 65.9 mttm -96.99 119.45 35.5 Favored 'General case' 0 N--CA 1.485 1.293 0 N-CA-C 109.966 -0.383 . . . . 0.0 109.966 -178.744 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.28 -127.32 0.01 OUTLIER Glycine 0 CA--C 1.539 1.581 0 N-CA-C 110.988 -0.845 . . . . 0.0 110.988 178.724 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -126.9 133.2 50.73 Favored 'General case' 0 N--CA 1.481 1.102 0 N-CA-C 109.585 -0.524 . . . . 0.0 109.585 179.614 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 64.8 mt -82.38 138.17 19.88 Favored 'Isoleucine or valine' 0 C--O 1.236 0.35 0 N-CA-C 107.093 -1.447 . . . . 0.0 107.093 178.492 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 22.4 mt -129.3 129.49 67.35 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.858 0 N-CA-C 109.444 -0.576 . . . . 0.0 109.444 -179.426 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 60.65 80.27 0.1 Allowed Glycine 0 CA--C 1.523 0.554 0 CA-C-N 115.982 -0.554 . . . . 0.0 113.654 179.33 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 2.0 tt -111.98 118.99 36.99 Favored 'General case' 0 N--CA 1.479 0.992 0 N-CA-C 107.056 -1.461 . . . . 0.0 107.056 177.358 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 8.2 ttt -153.37 162.88 40.82 Favored 'General case' 0 C--O 1.209 -1.041 0 N-CA-C 108.696 -0.853 . . . . 0.0 108.696 179.202 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 78.0 t -159.65 150.27 6.46 Favored 'Isoleucine or valine' 0 C--O 1.236 0.351 0 N-CA-C 106.591 -1.633 . . . . 0.0 106.591 -179.748 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.53 74.97 0.27 Allowed Glycine 0 C--N 1.314 -0.656 0 CA-C-N 115.63 -0.714 . . . . 0.0 111.535 178.139 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 170.08 -148.14 11.44 Favored Glycine 0 C--O 1.222 -0.653 0 N-CA-C 111.248 -0.741 . . . . 0.0 111.248 -179.995 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 19.4 m -133.42 141.54 44.18 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.846 0 N-CA-C 109.188 -0.671 . . . . 0.0 109.188 179.498 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 19.0 t . . . . . 0 CA--C 1.535 0.372 0 CA-C-O 117.648 -1.168 . . . . 0.0 110.847 179.35 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' F' F ' 1' ' ' ASP . . . . . . . . . . . . . 9.0 m-20 . . . . . 0 N--CA 1.492 1.638 0 N-CA-C 109.131 -0.692 . . . . 0.0 109.131 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' F' F ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.67 131.38 46.78 Favored 'General case' 0 CA--C 1.535 0.386 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.402 179.792 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' F' F ' 3' ' ' GLU . . . . . . . . . . . . . 41.1 tt0 -169.15 108.65 0.45 Allowed 'General case' 0 N--CA 1.471 0.578 0 N-CA-C 109.907 -0.405 . . . . 0.0 109.907 -179.859 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 78.7 m-85 -84.61 140.59 31.26 Favored 'General case' 0 N--CA 1.475 0.798 0 O-C-N 122.031 -0.418 . . . . 0.0 109.895 179.347 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' F' F ' 5' ' ' ARG . . . . . . . . . . . . . 72.4 mtp180 -143.43 141.62 30.91 Favored 'General case' 0 N--CA 1.477 0.878 0 N-CA-C 109.38 -0.6 . . . . 0.0 109.38 179.895 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 76.8 m80 -150.12 117.87 6.21 Favored 'General case' 0 N--CA 1.473 0.714 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 179.207 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' F' F ' 7' ' ' ASP . . . . . . . . . . . . . 7.5 m-20 -66.5 150.42 48.98 Favored 'General case' 0 N--CA 1.461 0.106 0 O-C-N 123.468 0.48 . . . . 0.0 111.711 -179.447 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' F' F ' 8' ' ' SER . . . . . . . . . . . . . 7.8 t -167.53 172.9 9.09 Favored 'General case' 0 N--CA 1.476 0.847 0 CA-C-N 116.015 -0.539 . . . . 0.0 109.568 178.065 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 123.34 23.63 2.12 Favored Glycine 0 N--CA 1.481 1.637 0 N-CA-C 111.997 -0.441 . . . . 0.0 111.997 179.064 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 36.6 p90 -56.74 127.97 34.18 Favored 'General case' 0 CA--C 1.542 0.671 0 N-CA-C 112.599 0.592 . . . . 0.0 112.599 -179.217 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 57.2 mt-10 -84.41 156.37 21.84 Favored 'General case' 0 N--CA 1.475 0.813 0 N-CA-C 109.457 -0.571 . . . . 0.0 109.457 178.063 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -155.77 127.53 0.96 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.586 0 N-CA-C 108.189 -1.041 . . . . 0.0 108.189 178.637 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 50.3 m-70 -134.76 144.73 47.87 Favored 'General case' 0 N--CA 1.481 1.078 0 CA-C-O 120.748 0.309 . . . . 0.0 111.341 -177.819 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 6.3 t60 -164.11 98.13 0.83 Allowed 'General case' 0 N--CA 1.486 1.356 0 CA-C-N 116.707 -0.224 . . . . 0.0 111.169 179.674 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 35.2 mt-30 -106.09 -172.36 2.07 Favored 'General case' 0 CA--C 1.498 -1.05 0 N-CA-C 108.787 -0.82 . . . . 0.0 108.787 179.989 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -169.23 96.87 0.34 Allowed 'General case' 0 CA--C 1.54 0.584 0 CA-C-N 114.891 -1.05 . . . . 0.0 109.443 178.687 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' F' F ' 17' ' ' LEU . . . . . 0.401 ' CD1' ' N ' ' F' ' 17' ' ' LEU . 4.7 mp -106.27 164.1 12.29 Favored 'General case' 0 N--CA 1.489 1.48 0 N-CA-C 109.209 -0.663 . . . . 0.0 109.209 -179.842 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 41.3 t -141.69 118.74 7.6 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.457 0 C-N-CA 122.55 0.34 . . . . 0.0 110.473 179.098 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 53.2 m-85 -69.56 156.49 38.82 Favored 'General case' 0 C--N 1.358 0.949 0 N-CA-C 107.253 -1.388 . . . . 0.0 107.253 176.612 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 13.1 t80 -173.15 -55.48 0.02 OUTLIER 'General case' 0 N--CA 1.484 1.267 0 CA-C-O 121.735 0.778 . . . . 0.0 109.904 179.484 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.73 88.89 0.0 OUTLIER 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 114.428 -1.26 . . . . 0.0 112.95 -179.047 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 36.7 tt0 -65.16 158.2 26.65 Favored 'General case' 0 N--CA 1.47 0.567 0 CA-C-N 114.952 -1.022 . . . . 0.0 110.786 179.504 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 66.5 m-20 -140.84 137.32 33.18 Favored 'General case' 0 N--CA 1.478 0.949 0 C-N-CA 122.813 0.445 . . . . 0.0 110.58 179.994 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' F' F ' 24' ' ' VAL . . . . . . . . . . . . . 21.5 t -84.84 -115.98 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.09 0 N-CA-C 108.811 -0.811 . . . . 0.0 108.811 179.523 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -109.48 54.08 0.56 Allowed Glycine 0 N--CA 1.479 1.511 0 N-CA-C 111.24 -0.744 . . . . 0.0 111.24 -179.836 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 75.6 p -79.46 125.04 29.04 Favored 'General case' 0 N--CA 1.472 0.668 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 177.883 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 18.5 t-20 -66.19 99.71 0.55 Allowed 'General case' 0 N--CA 1.472 0.672 0 N-CA-C 108.125 -1.065 . . . . 0.0 108.125 178.457 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 66.1 mttm -96.78 119.29 34.98 Favored 'General case' 0 N--CA 1.484 1.269 0 N-CA-C 110.056 -0.35 . . . . 0.0 110.056 -178.711 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.19 -127.51 0.01 OUTLIER Glycine 0 CA--C 1.54 1.623 0 N-CA-C 111.093 -0.803 . . . . 0.0 111.093 178.796 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -126.35 133.14 51.43 Favored 'General case' 0 N--CA 1.482 1.161 0 N-CA-C 109.577 -0.527 . . . . 0.0 109.577 179.612 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 65.4 mt -82.73 138.07 19.98 Favored 'Isoleucine or valine' 0 C--O 1.236 0.345 0 N-CA-C 106.958 -1.497 . . . . 0.0 106.958 178.497 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 23.5 mt -129.22 129.61 67.59 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.811 0 N-CA-C 109.381 -0.6 . . . . 0.0 109.381 -179.365 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 60.51 80.17 0.1 Allowed Glycine 0 CA--C 1.522 0.518 0 CA-C-N 115.986 -0.552 . . . . 0.0 113.618 179.271 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 2.0 tt -111.89 119.28 38.0 Favored 'General case' 0 N--CA 1.479 0.991 0 N-CA-C 106.971 -1.492 . . . . 0.0 106.971 177.472 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 8.5 ttt -153.93 162.97 40.8 Favored 'General case' 0 C--O 1.209 -1.075 0 N-CA-C 108.81 -0.811 . . . . 0.0 108.81 179.212 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 81.2 t -159.61 150.64 6.4 Favored 'Isoleucine or valine' 0 C--O 1.237 0.412 0 N-CA-C 106.713 -1.588 . . . . 0.0 106.713 -179.651 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.34 75.0 0.26 Allowed Glycine 0 C--N 1.314 -0.644 0 CA-C-N 115.662 -0.699 . . . . 0.0 111.483 178.089 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 170.1 -147.89 11.19 Favored Glycine 0 C--O 1.221 -0.668 0 N-CA-C 111.226 -0.75 . . . . 0.0 111.226 -179.993 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 19.6 m -133.77 141.42 44.17 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.884 0 N-CA-C 109.203 -0.666 . . . . 0.0 109.203 179.442 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 19.3 t . . . . . 0 CA--C 1.533 0.313 0 CA-C-O 117.605 -1.188 . . . . 0.0 110.868 179.365 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' G' G ' 1' ' ' ASP . . . . . . . . . . . . . 8.7 m-20 . . . . . 0 N--CA 1.491 1.608 0 N-CA-C 109.624 -0.509 . . . . 0.0 109.624 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' G' G ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.71 129.47 40.68 Favored 'General case' 0 N--CA 1.468 0.471 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.445 179.661 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' G' G ' 3' ' ' GLU . . . . . . . . . . . . . 40.7 tt0 -168.87 108.14 0.46 Allowed 'General case' 0 N--CA 1.469 0.512 0 N-CA-C 110.233 -0.284 . . . . 0.0 110.233 179.709 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 78.6 m-85 -84.87 140.19 31.33 Favored 'General case' 0 N--CA 1.476 0.836 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 179.227 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' G' G ' 5' ' ' ARG . . . . . . . . . . . . . 72.7 mtp180 -143.93 141.16 30.09 Favored 'General case' 0 N--CA 1.483 1.191 0 N-CA-C 109.282 -0.636 . . . . 0.0 109.282 -179.657 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 76.9 m80 -149.49 119.36 7.1 Favored 'General case' 0 N--CA 1.473 0.715 0 N-CA-C 109.05 -0.722 . . . . 0.0 109.05 179.116 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 8.0 m-20 -68.74 145.96 53.36 Favored 'General case' 0 CA--C 1.536 0.411 0 O-C-N 123.472 0.482 . . . . 0.0 111.942 -179.327 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' G' G ' 8' ' ' SER . . . . . . . . . . . . . 7.1 t -163.83 174.2 11.83 Favored 'General case' 0 N--CA 1.47 0.55 0 N-CA-C 109.443 -0.577 . . . . 0.0 109.443 178.171 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 123.06 23.34 2.23 Favored Glycine 0 N--CA 1.48 1.606 0 N-CA-C 111.643 -0.583 . . . . 0.0 111.643 178.89 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 40.8 p90 -56.86 127.86 33.82 Favored 'General case' 0 N--CA 1.473 0.68 0 N-CA-C 112.418 0.525 . . . . 0.0 112.418 -178.89 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 57.6 mt-10 -84.94 154.74 22.0 Favored 'General case' 0 N--CA 1.473 0.717 0 CA-C-O 121.054 0.454 . . . . 0.0 109.981 178.795 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -155.26 127.67 1.04 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.97 0 N-CA-C 108.246 -1.02 . . . . 0.0 108.246 178.847 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 51.6 m-70 -133.77 146.13 50.44 Favored 'General case' 0 N--CA 1.476 0.844 0 CA-C-N 115.443 -0.799 . . . . 0.0 111.09 -178.159 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 6.4 t60 -165.57 97.74 0.68 Allowed 'General case' 0 N--CA 1.483 1.183 0 CA-C-N 116.511 -0.313 . . . . 0.0 110.656 179.123 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 35.8 mt-30 -105.7 -172.64 2.13 Favored 'General case' 0 CA--C 1.503 -0.862 0 N-CA-C 108.726 -0.842 . . . . 0.0 108.726 -179.849 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -169.2 97.07 0.35 Allowed 'General case' 0 CA--C 1.54 0.587 0 CA-C-N 115.0 -1.0 . . . . 0.0 109.444 178.629 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' G' G ' 17' ' ' LEU . . . . . 0.403 ' CD1' ' N ' ' G' ' 17' ' ' LEU . 5.4 mp -106.31 163.14 13.07 Favored 'General case' 0 N--CA 1.487 1.387 0 N-CA-C 109.427 -0.583 . . . . 0.0 109.427 -179.669 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 39.6 t -142.5 118.92 6.04 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.068 0 CA-C-O 120.886 0.374 . . . . 0.0 110.327 178.779 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 47.2 m-85 -69.79 150.32 47.0 Favored 'General case' 0 C--N 1.37 1.482 0 N-CA-C 107.357 -1.349 . . . . 0.0 107.357 176.737 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 10.7 t80 -170.73 -55.26 0.02 OUTLIER 'General case' 0 N--CA 1.486 1.359 0 CA-C-N 117.903 0.319 . . . . 0.0 110.356 -179.601 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.73 90.02 0.0 OUTLIER 'General case' 0 C--N 1.325 -0.477 0 C-N-CA 123.74 0.816 . . . . 0.0 112.574 -179.882 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 37.1 tt0 -65.54 159.3 24.87 Favored 'General case' 0 N--CA 1.468 0.462 0 CA-C-N 114.694 -1.139 . . . . 0.0 109.954 179.069 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 67.2 m-20 -141.23 137.35 32.51 Favored 'General case' 0 N--CA 1.476 0.873 0 C-N-CA 122.792 0.437 . . . . 0.0 109.993 179.962 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' G' G ' 24' ' ' VAL . . . . . . . . . . . . . 21.6 t -85.53 -115.41 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.99 0 N-CA-C 108.408 -0.96 . . . . 0.0 108.408 179.598 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -110.16 53.9 0.57 Allowed Glycine 0 N--CA 1.478 1.443 0 N-CA-C 111.612 -0.595 . . . . 0.0 111.612 -179.812 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 75.8 p -79.67 125.88 30.21 Favored 'General case' 0 N--CA 1.466 0.366 0 N-CA-C 109.119 -0.697 . . . . 0.0 109.119 178.026 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 19.2 t-20 -66.87 100.5 0.73 Allowed 'General case' 0 CA--C 1.54 0.569 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 178.424 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 67.0 mttm -96.7 119.93 36.09 Favored 'General case' 0 N--CA 1.482 1.139 0 N-CA-C 110.085 -0.339 . . . . 0.0 110.085 -179.087 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.76 -125.52 0.01 OUTLIER Glycine 0 CA--C 1.533 1.21 0 N-CA-C 110.571 -1.012 . . . . 0.0 110.571 178.828 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -127.81 133.09 49.41 Favored 'General case' 0 N--CA 1.47 0.555 0 N-CA-C 109.579 -0.526 . . . . 0.0 109.579 179.684 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 68.2 mt -81.93 140.19 16.84 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.646 0 N-CA-C 107.22 -1.4 . . . . 0.0 107.22 178.475 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 27.6 mt -131.1 130.84 63.9 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 CA-C-N 119.057 0.844 . . . . 0.0 109.274 179.912 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 60.46 79.81 0.11 Allowed Glycine 0 CA--C 1.527 0.813 0 CA-C-N 116.269 -0.423 . . . . 0.0 113.127 179.273 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 1.9 tt -111.87 120.29 41.46 Favored 'General case' 0 N--CA 1.479 1.011 0 N-CA-C 106.909 -1.515 . . . . 0.0 106.909 177.394 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 8.4 ttt -155.35 163.08 40.58 Favored 'General case' 0 C--O 1.211 -0.945 0 N-CA-C 108.03 -1.1 . . . . 0.0 108.03 179.466 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 99.6 t -159.44 150.19 6.7 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 N-CA-C 106.295 -1.742 . . . . 0.0 106.295 -179.72 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.41 75.2 0.26 Allowed Glycine 0 C--N 1.312 -0.755 0 C-N-CA 121.093 -0.575 . . . . 0.0 111.956 177.801 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 168.51 -146.24 10.24 Favored Glycine 0 N--CA 1.47 0.928 0 N-CA-C 110.688 -0.965 . . . . 0.0 110.688 179.209 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 22.2 m -134.43 141.61 43.03 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.914 0 CA-C-N 117.039 0.42 . . . . 0.0 109.994 179.873 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 19.3 t . . . . . 0 N--CA 1.471 0.595 0 CA-C-O 117.678 -1.153 . . . . 0.0 110.914 179.541 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' H' H ' 1' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 . . . . . 0 N--CA 1.49 1.561 0 N-CA-C 109.654 -0.499 . . . . 0.0 109.654 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' H' H ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.79 129.26 39.7 Favored 'General case' 0 N--CA 1.468 0.442 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.453 179.578 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' H' H ' 3' ' ' GLU . . . . . . . . . . . . . 40.7 tt0 -168.6 108.4 0.5 Allowed 'General case' 0 N--CA 1.47 0.53 0 N-CA-C 110.146 -0.316 . . . . 0.0 110.146 179.775 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 79.4 m-85 -84.93 140.33 31.17 Favored 'General case' 0 N--CA 1.474 0.757 0 N-CA-C 109.662 -0.496 . . . . 0.0 109.662 179.233 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' H' H ' 5' ' ' ARG . . . . . . . . . . . . . 72.6 mtp180 -144.1 140.95 29.75 Favored 'General case' 0 N--CA 1.482 1.149 0 N-CA-C 109.219 -0.66 . . . . 0.0 109.219 -179.608 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 76.9 m80 -149.35 119.21 7.09 Favored 'General case' 0 N--CA 1.473 0.721 0 N-CA-C 109.076 -0.712 . . . . 0.0 109.076 179.07 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -68.33 145.87 53.79 Favored 'General case' 0 N--CA 1.468 0.431 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.951 -179.413 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' H' H ' 8' ' ' SER . . . . . . . . . . . . . 8.2 t -163.84 173.85 12.25 Favored 'General case' 0 N--CA 1.469 0.508 0 N-CA-C 109.373 -0.602 . . . . 0.0 109.373 178.321 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.89 23.09 2.31 Favored Glycine 0 N--CA 1.48 1.632 0 N-CA-C 111.828 -0.509 . . . . 0.0 111.828 179.125 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 40.4 p90 -56.64 127.81 33.26 Favored 'General case' 0 N--CA 1.474 0.735 0 N-CA-C 112.402 0.519 . . . . 0.0 112.402 -178.996 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 57.7 mt-10 -84.74 155.28 21.95 Favored 'General case' 0 N--CA 1.475 0.806 0 CA-C-O 121.121 0.486 . . . . 0.0 109.917 178.791 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -155.78 127.62 0.97 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.971 0 N-CA-C 108.263 -1.014 . . . . 0.0 108.263 178.847 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 51.3 m-70 -133.79 146.08 50.37 Favored 'General case' 0 N--CA 1.476 0.847 0 CA-C-N 115.423 -0.808 . . . . 0.0 111.239 -178.197 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 6.4 t60 -165.55 97.75 0.68 Allowed 'General case' 0 N--CA 1.482 1.146 0 CA-C-N 116.582 -0.281 . . . . 0.0 110.673 179.159 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 35.3 mt-30 -105.68 -173.04 2.21 Favored 'General case' 0 CA--C 1.501 -0.934 0 N-CA-C 108.549 -0.908 . . . . 0.0 108.549 -179.848 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -169.08 96.74 0.35 Allowed 'General case' 0 CA--C 1.54 0.562 0 CA-C-N 114.941 -1.027 . . . . 0.0 109.276 178.775 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' H' H ' 17' ' ' LEU . . . . . 0.401 ' N ' ' CD1' ' H' ' 17' ' ' LEU . 5.4 mp -106.21 163.29 12.92 Favored 'General case' 0 N--CA 1.487 1.382 0 N-CA-C 109.349 -0.612 . . . . 0.0 109.349 -179.553 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 40.1 t -142.63 118.48 5.44 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.037 0 CA-C-O 120.929 0.395 . . . . 0.0 110.479 178.895 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 48.0 m-85 -69.57 150.72 46.8 Favored 'General case' 0 C--N 1.37 1.483 0 N-CA-C 107.386 -1.338 . . . . 0.0 107.386 176.686 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 11.6 t80 -171.99 -54.66 0.02 OUTLIER 'General case' 0 N--CA 1.485 1.293 0 CA-C-N 117.837 0.289 . . . . 0.0 110.32 -179.537 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.94 90.39 0.0 OUTLIER 'General case' 0 CA--C 1.535 0.371 0 C-N-CA 123.685 0.794 . . . . 0.0 112.299 -179.974 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 37.2 tt0 -65.86 159.07 26.26 Favored 'General case' 0 N--CA 1.469 0.506 0 CA-C-N 114.784 -1.098 . . . . 0.0 110.006 179.254 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 67.0 m-20 -140.99 137.46 33.03 Favored 'General case' 0 N--CA 1.477 0.877 0 C-N-CA 122.845 0.458 . . . . 0.0 110.098 179.884 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' H' H ' 24' ' ' VAL . . . . . . . . . . . . . 21.4 t -85.8 -115.59 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.991 0 N-CA-C 108.531 -0.915 . . . . 0.0 108.531 179.601 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . -109.57 53.88 0.57 Allowed Glycine 0 N--CA 1.481 1.651 0 N-CA-C 111.379 -0.688 . . . . 0.0 111.379 -179.813 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 75.8 p -79.75 125.75 30.07 Favored 'General case' 0 N--CA 1.467 0.386 0 N-CA-C 108.958 -0.756 . . . . 0.0 108.958 178.034 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 19.3 t-20 -66.95 100.59 0.75 Allowed 'General case' 0 N--CA 1.471 0.605 0 N-CA-C 108.352 -0.981 . . . . 0.0 108.352 178.51 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 66.6 mttm -96.79 119.6 35.57 Favored 'General case' 0 N--CA 1.483 1.189 0 N-CA-C 110.097 -0.334 . . . . 0.0 110.097 -179.076 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.41 -125.18 0.01 OUTLIER Glycine 0 CA--C 1.534 1.267 0 N-CA-C 110.738 -0.945 . . . . 0.0 110.738 178.71 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.11 132.81 48.95 Favored 'General case' 0 N--CA 1.47 0.569 0 N-CA-C 109.66 -0.496 . . . . 0.0 109.66 179.839 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 68.7 mt -81.95 139.96 17.18 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.587 0 N-CA-C 107.11 -1.441 . . . . 0.0 107.11 178.525 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 28.0 mt -130.98 130.75 64.17 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.417 0 CA-C-N 118.912 0.778 . . . . 0.0 109.273 -179.978 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 60.48 79.7 0.11 Allowed Glycine 0 CA--C 1.526 0.742 0 CA-C-N 116.301 -0.409 . . . . 0.0 113.126 179.231 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 1.9 tt -111.84 120.05 40.64 Favored 'General case' 0 N--CA 1.479 1.018 0 N-CA-C 106.889 -1.523 . . . . 0.0 106.889 177.42 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 8.5 ttt -154.97 163.18 40.67 Favored 'General case' 0 N--CA 1.479 0.982 0 N-CA-C 107.958 -1.127 . . . . 0.0 107.958 179.505 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 93.6 t -159.78 150.43 6.29 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.254 0 N-CA-C 106.275 -1.75 . . . . 0.0 106.275 -179.735 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.15 75.13 0.26 Allowed Glycine 0 C--N 1.313 -0.731 0 CA-C-N 115.942 -0.572 . . . . 0.0 111.922 177.959 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 168.42 -146.51 10.49 Favored Glycine 0 N--CA 1.471 0.992 0 N-CA-C 110.632 -0.987 . . . . 0.0 110.632 179.273 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 22.3 m -134.23 141.85 42.55 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.924 0 CA-C-N 116.977 0.389 . . . . 0.0 109.998 179.976 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 19.4 t . . . . . 0 N--CA 1.47 0.543 0 CA-C-O 117.768 -1.111 . . . . 0.0 110.918 179.489 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' I' I ' 1' ' ' ASP . . . . . . . . . . . . . 8.8 m-20 . . . . . 0 N--CA 1.491 1.606 0 N-CA-C 109.608 -0.516 . . . . 0.0 109.608 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' I' I ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.93 129.39 40.19 Favored 'General case' 0 N--CA 1.468 0.472 0 CA-C-N 115.903 -0.589 . . . . 0.0 110.381 179.669 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' I' I ' 3' ' ' GLU . . . . . . . . . . . . . 40.5 tt0 -168.76 107.98 0.47 Allowed 'General case' 0 N--CA 1.47 0.552 0 N-CA-C 110.221 -0.288 . . . . 0.0 110.221 179.765 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 78.3 m-85 -84.5 140.81 31.2 Favored 'General case' 0 N--CA 1.474 0.745 0 N-CA-C 109.651 -0.5 . . . . 0.0 109.651 179.253 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' I' I ' 5' ' ' ARG . . . . . . . . . . . . . 72.7 mtp180 -144.49 140.95 29.21 Favored 'General case' 0 N--CA 1.482 1.158 0 N-CA-C 109.232 -0.655 . . . . 0.0 109.232 -179.619 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 76.9 m80 -149.31 118.93 6.97 Favored 'General case' 0 N--CA 1.474 0.753 0 N-CA-C 109.11 -0.7 . . . . 0.0 109.11 179.095 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 8.0 m-20 -68.1 145.87 54.0 Favored 'General case' 0 N--CA 1.467 0.385 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.82 -179.361 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' I' I ' 8' ' ' SER . . . . . . . . . . . . . 8.3 t -163.91 173.7 12.36 Favored 'General case' 0 N--CA 1.47 0.555 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 178.34 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.97 23.32 2.25 Favored Glycine 0 N--CA 1.481 1.657 0 N-CA-C 111.845 -0.502 . . . . 0.0 111.845 179.156 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 41.0 p90 -56.81 128.03 34.61 Favored 'General case' 0 N--CA 1.473 0.683 0 N-CA-C 112.437 0.532 . . . . 0.0 112.437 -178.99 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 57.9 mt-10 -84.86 155.19 21.85 Favored 'General case' 0 N--CA 1.474 0.757 0 CA-C-O 121.074 0.464 . . . . 0.0 109.976 178.755 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -155.7 127.65 0.99 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.977 0 N-CA-C 108.236 -1.024 . . . . 0.0 108.236 178.777 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 51.2 m-70 -133.68 146.41 50.81 Favored 'General case' 0 N--CA 1.476 0.849 0 CA-C-N 115.372 -0.831 . . . . 0.0 111.119 -178.162 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 6.5 t60 -165.99 97.89 0.63 Allowed 'General case' 0 N--CA 1.482 1.164 0 CA-C-N 116.556 -0.293 . . . . 0.0 110.696 179.026 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 35.3 mt-30 -105.85 -172.75 2.15 Favored 'General case' 0 CA--C 1.5 -0.948 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 -179.825 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -169.18 96.82 0.34 Allowed 'General case' 0 CA--C 1.539 0.543 0 CA-C-N 114.901 -1.045 . . . . 0.0 109.355 178.769 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' I' I ' 17' ' ' LEU . . . . . 0.402 ' CD1' ' N ' ' I' ' 17' ' ' LEU . 5.4 mp -106.19 163.15 13.03 Favored 'General case' 0 N--CA 1.488 1.43 0 N-CA-C 109.301 -0.629 . . . . 0.0 109.301 -179.555 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 40.1 t -142.48 118.37 5.66 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.015 0 CA-C-O 120.901 0.382 . . . . 0.0 110.387 178.933 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 48.6 m-85 -69.43 151.02 46.61 Favored 'General case' 0 C--N 1.372 1.553 0 N-CA-C 107.414 -1.328 . . . . 0.0 107.414 176.654 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 11.7 t80 -172.19 -54.98 0.02 OUTLIER 'General case' 0 N--CA 1.483 1.225 0 CA-C-N 117.822 0.283 . . . . 0.0 110.346 -179.587 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.81 90.29 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.465 0 C-N-CA 123.712 0.805 . . . . 0.0 112.327 -179.984 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 37.3 tt0 -65.68 159.15 25.57 Favored 'General case' 0 N--CA 1.468 0.464 0 CA-C-N 114.686 -1.143 . . . . 0.0 110.023 179.304 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 66.6 m-20 -140.92 137.21 32.97 Favored 'General case' 0 N--CA 1.476 0.834 0 C-N-CA 122.906 0.482 . . . . 0.0 110.122 179.835 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' I' I ' 24' ' ' VAL . . . . . . . . . . . . . 21.5 t -85.47 -115.35 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.034 0 N-CA-C 108.479 -0.934 . . . . 0.0 108.479 179.58 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . -109.84 53.44 0.59 Allowed Glycine 0 N--CA 1.48 1.584 0 N-CA-C 111.495 -0.642 . . . . 0.0 111.495 -179.761 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 77.0 p -79.29 125.79 29.95 Favored 'General case' 0 N--CA 1.467 0.388 0 N-CA-C 109.131 -0.692 . . . . 0.0 109.131 177.992 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 19.5 t-20 -67.14 100.54 0.78 Allowed 'General case' 0 N--CA 1.471 0.625 0 N-CA-C 108.395 -0.965 . . . . 0.0 108.395 178.525 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 66.8 mttm -96.71 120.05 36.32 Favored 'General case' 0 N--CA 1.483 1.221 0 N-CA-C 110.129 -0.323 . . . . 0.0 110.129 -179.11 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.7 -125.36 0.01 OUTLIER Glycine 0 CA--C 1.535 1.319 0 N-CA-C 110.688 -0.965 . . . . 0.0 110.688 178.793 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -127.78 132.82 49.47 Favored 'General case' 0 N--CA 1.473 0.682 0 C-N-CA 123.023 0.529 . . . . 0.0 109.653 179.633 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 68.2 mt -81.92 139.91 17.24 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.582 0 N-CA-C 107.13 -1.433 . . . . 0.0 107.13 178.479 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 27.2 mt -130.99 130.87 64.22 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.373 0 CA-C-N 118.977 0.808 . . . . 0.0 109.282 -179.938 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 60.38 79.68 0.11 Allowed Glycine 0 CA--C 1.527 0.805 0 CA-C-N 116.285 -0.416 . . . . 0.0 113.079 179.261 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 1.9 tt -111.9 120.07 40.67 Favored 'General case' 0 N--CA 1.48 1.038 0 N-CA-C 106.823 -1.547 . . . . 0.0 106.823 177.432 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 8.5 ttt -154.9 163.28 40.51 Favored 'General case' 0 C--O 1.211 -0.958 0 N-CA-C 108.005 -1.109 . . . . 0.0 108.005 179.461 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 98.7 t -159.72 150.41 6.35 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.257 0 N-CA-C 106.273 -1.751 . . . . 0.0 106.273 -179.739 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.08 75.23 0.26 Allowed Glycine 0 C--N 1.315 -0.631 0 CA-C-N 115.893 -0.594 . . . . 0.0 111.951 177.907 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 168.46 -146.33 10.33 Favored Glycine 0 N--CA 1.469 0.886 0 N-CA-C 110.643 -0.983 . . . . 0.0 110.643 179.287 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 22.3 m -134.39 141.72 42.75 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.856 0 CA-C-N 116.985 0.392 . . . . 0.0 110.038 179.928 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 18.9 t . . . . . 0 N--CA 1.469 0.488 0 CA-C-O 117.765 -1.112 . . . . 0.0 110.92 179.434 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . 0.47 ' H3 ' ' CB ' ' D' ' 1' ' ' ASP . 65.9 m-20 . . . . . 0 N--CA 1.49 1.555 0 N-CA-C 108.808 -0.812 . . . . 0.0 108.808 . . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.31 133.2 50.9 Favored 'General case' 0 CA--C 1.539 0.537 0 CA-C-N 116.528 -0.306 . . . . 0.0 110.287 -179.743 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 43.2 tt0 -169.09 105.91 0.41 Allowed 'General case' 0 N--CA 1.472 0.646 0 N-CA-C 109.873 -0.417 . . . . 0.0 109.873 -179.197 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 55.1 m-85 -85.12 147.54 26.58 Favored 'General case' 0 N--CA 1.475 0.804 0 N-CA-C 110.241 -0.281 . . . . 0.0 110.241 179.573 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 -144.33 142.14 30.2 Favored 'General case' 0 N--CA 1.482 1.131 0 N-CA-C 110.01 -0.366 . . . . 0.0 110.01 179.713 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 41.7 t-80 -152.43 119.69 5.92 Favored 'General case' 0 N--CA 1.472 0.674 0 N-CA-C 109.23 -0.655 . . . . 0.0 109.23 179.098 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' ASP . . . . . 0.511 ' O ' ' OG ' ' D' ' 8' ' ' SER . 4.6 m-20 -69.02 148.68 49.73 Favored 'General case' 0 CA--C 1.535 0.383 0 CA-C-N 116.341 -0.39 . . . . 0.0 110.412 179.893 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' SER . . . . . 0.463 ' H ' ' HG ' ' C' ' 26' ' ' SER . 54.0 p -167.65 -173.58 2.21 Favored 'General case' 0 N--CA 1.481 1.084 0 CA-C-O 120.92 0.391 . . . . 0.0 110.698 179.217 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.26 47.45 1.32 Allowed Glycine 0 N--CA 1.482 1.742 0 CA-C-N 116.036 -0.529 . . . . 0.0 111.905 -179.941 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 49.7 p90 -66.03 133.03 49.93 Favored 'General case' 0 N--CA 1.473 0.695 0 CA-C-O 120.74 0.305 . . . . 0.0 111.618 179.814 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 84.2 mt-10 -91.82 152.19 20.24 Favored 'General case' 0 N--CA 1.477 0.91 0 N-CA-C 109.662 -0.496 . . . . 0.0 109.662 178.443 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -152.67 128.31 1.68 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.593 0 N-CA-C 107.884 -1.154 . . . . 0.0 107.884 178.074 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 43.7 m-70 -135.9 148.5 48.6 Favored 'General case' 0 N--CA 1.493 1.681 0 CA-C-N 119.025 0.829 . . . . 0.0 111.292 -178.986 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 6.6 t60 -164.82 98.47 0.76 Allowed 'General case' 0 N--CA 1.48 1.053 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.823 179.396 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -91.85 -177.38 4.72 Favored 'General case' 0 CA--C 1.514 -0.432 0 N-CA-C 108.851 -0.796 . . . . 0.0 108.851 -179.933 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -172.06 93.74 0.14 Allowed 'General case' 0 N--CA 1.469 0.489 0 CA-C-N 114.659 -1.155 . . . . 0.0 108.566 177.94 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 6.3 mp -124.77 155.98 38.46 Favored 'General case' 0 N--CA 1.497 1.896 0 CA-C-O 121.744 0.783 . . . . 0.0 110.989 -178.417 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 61.0 t -111.63 124.46 68.4 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.024 0 CA-C-O 117.825 -1.083 . . . . 0.0 108.469 177.77 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 29.4 m-85 -124.27 143.78 50.35 Favored 'General case' 0 N--CA 1.498 1.946 0 CA-C-N 120.177 1.353 . . . . 0.0 110.268 179.227 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 67.2 m-85 52.49 68.33 0.84 Allowed 'General case' 0 N--CA 1.472 0.637 0 CA-C-N 116.367 -0.378 . . . . 0.0 111.875 178.458 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -78.14 -84.62 0.08 Allowed 'General case' 0 C--N 1.361 1.097 0 CA-C-N 115.463 -0.79 . . . . 0.0 110.173 -179.829 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 41.2 tt0 -123.07 96.9 5.19 Favored 'General case' 0 C--N 1.323 -0.547 0 N-CA-C 108.089 -1.078 . . . . 0.0 108.089 179.7 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 4.1 p30 -158.97 143.67 15.78 Favored 'General case' 0 N--CA 1.484 1.261 0 O-C-N 122.313 -0.242 . . . . 0.0 111.102 179.092 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 61.6 t -61.38 162.66 1.36 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.784 0 N-CA-C 107.968 -1.123 . . . . 0.0 107.968 177.206 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.429 ' H ' ' HB ' ' D' ' 24' ' ' VAL . . . -117.71 48.96 0.89 Allowed Glycine 0 N--CA 1.476 1.328 0 N-CA-C 111.81 -0.516 . . . . 0.0 111.81 -179.377 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' SER . . . . . 0.442 ' HG ' ' H ' ' B' ' 8' ' ' SER . 0.4 OUTLIER -61.84 -169.05 0.02 OUTLIER 'General case' 0 N--CA 1.469 0.522 0 O-C-N 123.722 0.307 . . . . 0.0 110.404 179.56 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 15.1 t30 -69.52 80.35 0.4 Allowed 'General case' 0 N--CA 1.464 0.271 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.132 179.717 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -79.8 154.71 28.28 Favored 'General case' 0 N--CA 1.473 0.677 0 N-CA-C 108.883 -0.784 . . . . 0.0 108.883 179.059 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.0 -144.07 0.02 OUTLIER Glycine 0 CA--C 1.526 0.748 0 N-CA-C 109.749 -1.34 . . . . 0.0 109.749 178.496 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -136.89 120.3 16.97 Favored 'General case' 0 N--CA 1.479 0.976 0 CA-C-N 117.247 0.523 . . . . 0.0 109.755 179.38 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 69.5 mt -80.39 124.73 38.67 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.528 0 N-CA-C 106.741 -1.577 . . . . 0.0 106.741 178.339 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . 0.451 ' C ' ' H ' ' A' ' 34' ' ' LEU . 41.5 pt -151.34 162.71 2.93 Favored 'Isoleucine or valine' 0 C--N 1.358 0.958 0 CA-C-N 115.741 -0.663 . . . . 0.0 111.552 -178.805 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 64.88 0.44 5.24 Favored Glycine 0 CA--C 1.524 0.603 0 N-CA-C 111.008 -0.837 . . . . 0.0 111.008 179.611 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . 0.451 ' H ' ' C ' ' A' ' 32' ' ' ILE . 7.8 tt -79.7 148.46 31.55 Favored 'General case' 0 N--CA 1.466 0.346 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 -179.989 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 28.6 ttt -159.89 140.68 12.21 Favored 'General case' 0 N--CA 1.473 0.68 0 N-CA-C 108.816 -0.809 . . . . 0.0 108.816 178.993 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 27.6 m -156.22 162.57 1.64 Allowed 'Isoleucine or valine' 0 C--N 1.347 0.495 0 N-CA-C 108.259 -1.015 . . . . 0.0 108.259 -179.756 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.63 67.55 2.15 Favored Glycine 0 C--N 1.308 -1.026 0 CA-C-N 115.773 -0.649 . . . . 0.0 111.967 178.6 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.91 172.49 17.98 Favored Glycine 0 N--CA 1.475 1.242 0 N-CA-C 110.649 -0.98 . . . . 0.0 110.649 179.28 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.462 ' H ' HG11 ' D' ' 39' ' ' VAL . 34.9 m -125.16 164.42 24.18 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.943 0 C-N-CA 123.549 0.739 . . . . 0.0 110.803 -179.546 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 25.0 t . . . . . 0 C--O 1.221 -0.437 0 CA-C-O 118.382 -0.818 . . . . 0.0 110.766 179.333 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' B' B ' 1' ' ' ASP . . . . . 0.473 ' H3 ' ' CB ' ' E' ' 1' ' ' ASP . 65.7 m-20 . . . . . 0 N--CA 1.488 1.469 0 N-CA-C 108.989 -0.745 . . . . 0.0 108.989 . . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.61 133.1 50.45 Favored 'General case' 0 CA--C 1.539 0.552 0 CA-C-N 116.513 -0.312 . . . . 0.0 110.178 -179.752 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 3' ' ' GLU . . . . . . . . . . . . . 42.6 tt0 -169.1 105.73 0.4 Allowed 'General case' 0 N--CA 1.472 0.671 0 N-CA-C 109.971 -0.381 . . . . 0.0 109.971 -179.188 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 55.6 m-85 -84.89 147.49 26.74 Favored 'General case' 0 N--CA 1.476 0.843 0 N-CA-C 110.272 -0.269 . . . . 0.0 110.272 179.439 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 -144.22 142.09 30.28 Favored 'General case' 0 N--CA 1.481 1.124 0 N-CA-C 109.989 -0.375 . . . . 0.0 109.989 179.687 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 41.1 t-80 -152.34 119.46 5.87 Favored 'General case' 0 N--CA 1.473 0.686 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 179.146 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 7' ' ' ASP . . . . . 0.486 ' O ' ' OG ' ' E' ' 8' ' ' SER . 4.4 m-20 -69.01 148.31 50.29 Favored 'General case' 0 CA--C 1.536 0.436 0 CA-C-N 116.435 -0.348 . . . . 0.0 110.465 179.914 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 8' ' ' SER . . . . . 0.442 ' H ' ' HG ' ' A' ' 26' ' ' SER . 54.0 p -167.26 -173.35 2.25 Favored 'General case' 0 N--CA 1.48 1.048 0 CA-C-O 120.873 0.368 . . . . 0.0 110.645 179.214 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.08 47.37 1.35 Allowed Glycine 0 N--CA 1.482 1.762 0 CA-C-N 115.982 -0.554 . . . . 0.0 111.927 179.896 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 49.3 p90 -65.93 133.73 51.49 Favored 'General case' 0 N--CA 1.473 0.679 0 CA-C-O 120.751 0.31 . . . . 0.0 111.714 179.699 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 83.5 mt-10 -92.39 152.51 19.7 Favored 'General case' 0 N--CA 1.476 0.839 0 N-CA-C 109.666 -0.494 . . . . 0.0 109.666 178.398 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -153.14 128.42 1.56 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.609 0 N-CA-C 107.776 -1.194 . . . . 0.0 107.776 178.261 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 43.6 m-70 -136.27 148.35 47.96 Favored 'General case' 0 N--CA 1.492 1.655 0 CA-C-N 118.864 0.756 . . . . 0.0 111.37 -179.033 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 6.7 t60 -164.67 98.06 0.77 Allowed 'General case' 0 N--CA 1.481 1.093 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.694 179.512 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 5.1 pt20 -91.14 -176.86 4.73 Favored 'General case' 0 CA--C 1.515 -0.386 0 N-CA-C 108.74 -0.837 . . . . 0.0 108.74 -179.984 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -172.7 93.77 0.12 Allowed 'General case' 0 N--CA 1.469 0.505 0 CA-C-N 114.711 -1.131 . . . . 0.0 108.405 177.807 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 6.3 mp -124.71 156.1 38.18 Favored 'General case' 0 N--CA 1.497 1.918 0 CA-C-O 121.77 0.795 . . . . 0.0 110.985 -178.465 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 62.0 t -111.85 125.14 69.13 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.007 0 N-CA-C 108.297 -1.001 . . . . 0.0 108.297 177.645 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 29.6 m-85 -124.87 143.76 50.67 Favored 'General case' 0 N--CA 1.495 1.803 0 CA-C-N 119.813 1.188 . . . . 0.0 110.161 179.433 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 68.2 m-85 51.45 68.41 0.8 Allowed 'General case' 0 N--CA 1.468 0.452 0 CA-C-O 121.199 0.524 . . . . 0.0 111.994 178.48 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -78.09 -84.28 0.08 Allowed 'General case' 0 C--N 1.356 0.875 0 CA-C-N 115.198 -0.91 . . . . 0.0 110.055 -179.847 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 41.2 tt0 -123.14 97.42 5.42 Favored 'General case' 0 C--N 1.323 -0.583 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 179.682 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 4.0 p30 -159.34 143.5 15.1 Favored 'General case' 0 N--CA 1.483 1.206 0 O-C-N 122.342 -0.224 . . . . 0.0 111.083 179.103 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 61.9 t -61.17 162.65 1.31 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.89 0 N-CA-C 107.983 -1.117 . . . . 0.0 107.983 177.136 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . 0.431 ' H ' ' HB ' ' E' ' 24' ' ' VAL . . . -117.62 49.03 0.89 Allowed Glycine 0 N--CA 1.475 1.294 0 N-CA-C 111.725 -0.55 . . . . 0.0 111.725 -179.281 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 26' ' ' SER . . . . . 0.443 ' HG ' ' H ' ' C' ' 8' ' ' SER . 0.4 OUTLIER -62.2 -168.78 0.02 OUTLIER 'General case' 0 N--CA 1.469 0.514 0 O-C-N 123.616 0.245 . . . . 0.0 110.374 179.598 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 14.9 t30 -69.72 80.64 0.44 Allowed 'General case' 0 N--CA 1.465 0.312 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.043 179.773 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 97.9 mttt -80.2 154.41 27.96 Favored 'General case' 0 N--CA 1.472 0.633 0 N-CA-C 108.882 -0.784 . . . . 0.0 108.882 179.072 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.9 -144.5 0.02 OUTLIER Glycine 0 CA--C 1.526 0.738 0 N-CA-C 109.636 -1.386 . . . . 0.0 109.636 178.476 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -136.39 120.84 18.14 Favored 'General case' 0 N--CA 1.478 0.973 0 CA-C-N 117.142 0.471 . . . . 0.0 109.83 179.376 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 70.1 mt -80.65 124.98 39.12 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.524 0 N-CA-C 106.721 -1.585 . . . . 0.0 106.721 178.249 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . 0.449 ' C ' ' H ' ' B' ' 34' ' ' LEU . 41.3 pt -151.59 162.75 2.8 Favored 'Isoleucine or valine' 0 C--N 1.358 0.951 0 CA-C-N 115.836 -0.62 . . . . 0.0 111.491 -178.728 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 64.61 0.52 5.0 Favored Glycine 0 C--N 1.337 0.635 0 CA-C-N 115.507 -0.77 . . . . 0.0 111.177 179.716 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 34' ' ' LEU . . . . . 0.449 ' H ' ' C ' ' B' ' 32' ' ' ILE . 7.8 tt -79.85 148.15 31.47 Favored 'General case' 0 N--CA 1.465 0.292 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 -179.952 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 28.6 ttt -159.32 140.75 13.03 Favored 'General case' 0 N--CA 1.475 0.795 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 179.051 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 28.3 m -156.35 162.56 1.63 Allowed 'Isoleucine or valine' 0 C--N 1.346 0.422 0 N-CA-C 108.214 -1.032 . . . . 0.0 108.214 -179.796 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.67 67.45 2.2 Favored Glycine 0 C--N 1.306 -1.111 0 CA-C-N 115.756 -0.657 . . . . 0.0 111.932 178.558 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.86 172.8 18.27 Favored Glycine 0 N--CA 1.474 1.202 0 N-CA-C 110.678 -0.969 . . . . 0.0 110.678 179.208 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 39' ' ' VAL . . . . . 0.459 ' H ' HG11 ' E' ' 39' ' ' VAL . 35.2 m -125.3 164.29 24.67 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.082 0 C-N-CA 123.523 0.729 . . . . 0.0 110.819 -179.392 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 24.9 t . . . . . 0 N--CA 1.471 0.576 0 CA-C-O 118.237 -0.887 . . . . 0.0 110.636 179.164 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' C' C ' 1' ' ' ASP . . . . . 0.488 ' H3 ' ' CB ' ' F' ' 1' ' ' ASP . 66.2 m-20 . . . . . 0 N--CA 1.491 1.589 0 N-CA-C 108.86 -0.793 . . . . 0.0 108.86 . . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' C' C ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.4 133.13 50.68 Favored 'General case' 0 CA--C 1.54 0.562 0 CA-C-N 116.454 -0.339 . . . . 0.0 110.235 -179.782 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' C' C ' 3' ' ' GLU . . . . . . . . . . . . . 43.0 tt0 -169.19 105.71 0.4 Allowed 'General case' 0 N--CA 1.471 0.614 0 N-CA-C 109.884 -0.413 . . . . 0.0 109.884 -179.102 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 54.9 m-85 -84.98 147.41 26.71 Favored 'General case' 0 N--CA 1.477 0.922 0 N-CA-C 110.238 -0.282 . . . . 0.0 110.238 179.462 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 -144.22 142.12 30.31 Favored 'General case' 0 N--CA 1.482 1.15 0 N-CA-C 109.974 -0.38 . . . . 0.0 109.974 179.645 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 40.8 t-80 -152.37 119.98 6.05 Favored 'General case' 0 N--CA 1.473 0.708 0 N-CA-C 109.251 -0.648 . . . . 0.0 109.251 179.152 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' C' C ' 7' ' ' ASP . . . . . 0.493 ' O ' ' OG ' ' F' ' 8' ' ' SER . 4.4 m-20 -69.45 148.39 49.63 Favored 'General case' 0 CA--C 1.535 0.397 0 CA-C-N 116.352 -0.385 . . . . 0.0 110.518 179.908 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' C' C ' 8' ' ' SER . . . . . 0.443 ' H ' ' HG ' ' B' ' 26' ' ' SER . 55.4 p -167.32 -173.51 2.29 Favored 'General case' 0 N--CA 1.48 1.029 0 CA-C-O 120.839 0.352 . . . . 0.0 110.656 179.272 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.18 47.58 1.31 Allowed Glycine 0 N--CA 1.483 1.795 0 CA-C-N 116.006 -0.543 . . . . 0.0 111.903 179.961 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 49.5 p90 -66.15 133.3 50.41 Favored 'General case' 0 N--CA 1.472 0.665 0 CA-C-N 116.783 0.292 . . . . 0.0 111.681 179.697 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 83.2 mt-10 -92.15 152.08 20.08 Favored 'General case' 0 N--CA 1.476 0.851 0 N-CA-C 109.696 -0.483 . . . . 0.0 109.696 178.4 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -152.61 128.35 1.71 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.588 0 N-CA-C 107.791 -1.189 . . . . 0.0 107.791 178.146 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 42.4 m-70 -136.03 148.38 48.35 Favored 'General case' 0 N--CA 1.492 1.663 0 CA-C-N 118.937 0.79 . . . . 0.0 111.286 -179.102 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 6.7 t60 -164.69 98.55 0.78 Allowed 'General case' 0 N--CA 1.481 1.105 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.685 179.475 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -91.91 -176.99 4.6 Favored 'General case' 0 CA--C 1.512 -0.484 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 -179.937 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -172.49 93.84 0.13 Allowed 'General case' 0 N--CA 1.47 0.533 0 CA-C-N 114.707 -1.133 . . . . 0.0 108.451 177.959 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 6.1 mp -124.93 155.7 39.15 Favored 'General case' 0 N--CA 1.496 1.842 0 CA-C-O 121.768 0.794 . . . . 0.0 111.096 -178.381 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 61.6 t -111.54 125.52 68.86 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.996 0 N-CA-C 108.238 -1.023 . . . . 0.0 108.238 177.754 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 29.3 m-85 -125.31 143.31 51.03 Favored 'General case' 0 N--CA 1.495 1.822 0 CA-C-N 119.673 1.124 . . . . 0.0 110.083 179.369 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 67.5 m-85 51.93 68.46 0.81 Allowed 'General case' 0 N--CA 1.47 0.534 0 CA-C-O 121.215 0.531 . . . . 0.0 111.975 178.501 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -78.09 -84.41 0.08 Allowed 'General case' 0 C--N 1.356 0.873 0 CA-C-N 115.186 -0.915 . . . . 0.0 110.071 -179.851 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 40.9 tt0 -123.14 96.97 5.21 Favored 'General case' 0 C--N 1.323 -0.546 0 N-CA-C 108.08 -1.081 . . . . 0.0 108.08 179.746 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 4.1 p30 -158.8 143.71 16.02 Favored 'General case' 0 N--CA 1.484 1.263 0 CA-C-O 119.672 -0.204 . . . . 0.0 111.118 179.002 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 59.9 t -61.43 162.38 1.45 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.849 0 N-CA-C 107.96 -1.126 . . . . 0.0 107.96 177.129 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' C' C ' 25' ' ' GLY . . . . . 0.41 ' H ' ' HB ' ' F' ' 24' ' ' VAL . . . -117.5 49.49 0.86 Allowed Glycine 0 N--CA 1.477 1.414 0 N-CA-C 111.726 -0.55 . . . . 0.0 111.726 -179.286 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' C' C ' 26' ' ' SER . . . . . 0.463 ' HG ' ' H ' ' A' ' 8' ' ' SER . 0.4 OUTLIER -62.65 -168.51 0.02 OUTLIER 'General case' 0 N--CA 1.468 0.44 0 O-C-N 123.666 0.274 . . . . 0.0 110.443 179.64 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 15.8 t30 -69.88 80.47 0.46 Allowed 'General case' 0 N--CA 1.465 0.322 0 N-CA-C 110.073 -0.343 . . . . 0.0 110.073 179.781 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -79.98 154.62 28.11 Favored 'General case' 0 N--CA 1.472 0.668 0 N-CA-C 108.915 -0.772 . . . . 0.0 108.915 179.111 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.89 -144.17 0.02 OUTLIER Glycine 0 CA--C 1.527 0.821 0 N-CA-C 109.769 -1.332 . . . . 0.0 109.769 178.488 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -136.78 120.47 17.28 Favored 'General case' 0 N--CA 1.481 1.083 0 CA-C-N 117.185 0.493 . . . . 0.0 109.719 179.258 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 70.0 mt -80.49 124.8 38.81 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.541 0 N-CA-C 106.762 -1.57 . . . . 0.0 106.762 178.254 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' C' C ' 32' ' ' ILE . . . . . 0.446 ' C ' ' H ' ' C' ' 34' ' ' LEU . 41.3 pt -151.39 162.53 2.97 Favored 'Isoleucine or valine' 0 C--N 1.359 0.991 0 CA-C-N 115.68 -0.691 . . . . 0.0 111.53 -178.634 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 64.89 0.68 5.5 Favored Glycine 0 N--CA 1.465 0.598 0 N-CA-C 110.973 -0.851 . . . . 0.0 110.973 179.606 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' C' C ' 34' ' ' LEU . . . . . 0.446 ' H ' ' C ' ' C' ' 32' ' ' ILE . 7.7 tt -79.87 148.12 31.45 Favored 'General case' 0 N--CA 1.465 0.302 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 179.955 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 28.6 ttt -159.29 140.85 13.16 Favored 'General case' 0 N--CA 1.474 0.742 0 N-CA-C 108.751 -0.833 . . . . 0.0 108.751 178.955 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 28.1 m -156.5 162.77 1.55 Allowed 'Isoleucine or valine' 0 C--N 1.348 0.511 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 -179.798 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.37 67.14 2.36 Favored Glycine 0 C--N 1.307 -1.07 0 CA-C-N 115.695 -0.684 . . . . 0.0 111.901 178.56 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 148.23 172.58 18.32 Favored Glycine 0 N--CA 1.474 1.218 0 N-CA-C 110.604 -0.998 . . . . 0.0 110.604 179.237 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' C' C ' 39' ' ' VAL . . . . . 0.456 ' H ' HG11 ' F' ' 39' ' ' VAL . 35.1 m -125.25 164.48 24.23 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.996 0 C-N-CA 123.518 0.727 . . . . 0.0 110.789 -179.415 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 25.4 t . . . . . 0 N--CA 1.469 0.484 0 CA-C-O 118.234 -0.889 . . . . 0.0 110.649 179.207 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' D' D ' 1' ' ' ASP . . . . . 0.47 ' CB ' ' H3 ' ' A' ' 1' ' ' ASP . 66.4 m-20 . . . . . 0 N--CA 1.49 1.551 0 N-CA-C 109.084 -0.71 . . . . 0.0 109.084 . . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' D' D ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.14 131.14 46.59 Favored 'General case' 0 CA--C 1.535 0.38 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.535 179.902 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' D' D ' 3' ' ' GLU . . . . . . . . . . . . . 41.8 tt0 -169.22 108.49 0.44 Allowed 'General case' 0 N--CA 1.47 0.573 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 179.852 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 61.4 m-85 -89.42 153.05 21.14 Favored 'General case' 0 C--N 1.36 1.055 0 C-N-CA 119.473 -0.891 . . . . 0.0 108.792 179.729 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' D' D ' 5' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 -146.43 140.49 26.33 Favored 'General case' 0 N--CA 1.476 0.85 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.236 -179.994 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 38.0 t-80 -149.82 124.02 9.5 Favored 'General case' 0 CA--C 1.545 0.781 0 N-CA-C 108.344 -0.984 . . . . 0.0 108.344 175.303 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' D' D ' 7' ' ' ASP . . . . . 0.589 ' O ' ' OG ' ' G' ' 8' ' ' SER . 3.3 m-20 -63.76 132.46 51.04 Favored 'General case' 0 C--N 1.322 -0.596 0 C-N-CA 126.885 2.074 . . . . 0.0 114.325 174.69 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' D' D ' 8' ' ' SER . . . . . 0.519 ' H ' ' HG ' ' F' ' 26' ' ' SER . 54.2 p -154.63 -170.65 3.58 Favored 'General case' 0 N--CA 1.486 1.334 0 CA-C-N 119.77 1.168 . . . . 0.0 111.22 175.927 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.35 48.15 1.15 Allowed Glycine 0 N--CA 1.483 1.804 0 C-N-CA 124.562 1.077 . . . . 0.0 110.539 174.952 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 51.5 p90 -60.97 131.57 51.09 Favored 'General case' 0 N--CA 1.472 0.626 0 N-CA-C 112.908 0.707 . . . . 0.0 112.908 177.925 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 84.2 mt-10 -89.28 150.91 22.39 Favored 'General case' 0 N--CA 1.481 1.1 0 CA-C-N 117.974 0.352 . . . . 0.0 110.637 175.315 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.0 p -149.58 129.86 4.2 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.637 0 N-CA-C 107.416 -1.328 . . . . 0.0 107.416 173.066 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 38.3 m-70 -129.91 151.28 50.64 Favored 'General case' 0 N--CA 1.484 1.262 0 N-CA-C 112.329 0.492 . . . . 0.0 112.329 176.791 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 6.7 t60 -164.79 104.84 0.81 Allowed 'General case' 0 N--CA 1.482 1.145 0 N-CA-C 109.155 -0.683 . . . . 0.0 109.155 172.664 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' D' D ' 15' ' ' GLN . . . . . 0.401 ' OE1' ' N ' ' G' ' 37' ' ' GLY . 4.9 pt20 -94.96 -177.3 4.12 Favored 'General case' 0 CA--C 1.509 -0.631 0 N-CA-C 108.574 -0.898 . . . . 0.0 108.574 179.044 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -169.75 103.49 0.32 Allowed 'General case' 0 N--CA 1.465 0.308 0 N-CA-C 105.891 -1.892 . . . . 0.0 105.891 173.374 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 5.0 mp -132.19 153.44 50.57 Favored 'General case' 0 N--CA 1.498 1.97 0 CA-C-O 122.011 0.91 . . . . 0.0 110.214 178.912 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 35.8 t -101.12 129.01 52.79 Favored 'Isoleucine or valine' 0 C--O 1.266 1.943 0 CA-C-O 116.373 -1.775 . . . . 0.0 109.693 174.267 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 25.8 m-85 -126.63 149.25 49.59 Favored 'General case' 0 N--CA 1.49 1.562 0 CA-C-N 120.525 1.511 . . . . 0.0 109.472 172.329 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 66.7 m-85 55.14 63.64 2.05 Favored 'General case' 0 C--O 1.24 0.599 0 CA-C-O 118.518 -0.753 . . . . 0.0 111.555 175.097 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -79.99 -81.35 0.12 Allowed 'General case' 0 N--CA 1.474 0.741 0 CA-C-N 118.942 0.792 . . . . 0.0 109.967 -176.345 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 41.3 tt0 -124.91 101.81 7.24 Favored 'General case' 0 N--CA 1.479 0.999 0 N-CA-C 106.036 -1.838 . . . . 0.0 106.036 175.969 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 4.1 p30 -152.44 143.08 22.8 Favored 'General case' 0 N--CA 1.476 0.842 0 CA-C-O 116.792 -1.575 . . . . 0.0 113.624 177.592 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' D' D ' 24' ' ' VAL . . . . . 0.429 ' HB ' ' H ' ' A' ' 25' ' ' GLY . 67.1 t -63.58 165.26 1.29 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.366 0 CA-C-N 120.971 1.714 . . . . 0.0 107.824 174.538 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' D' D ' 25' ' ' GLY . . . . . 0.452 ' H ' ' HB ' ' G' ' 24' ' ' VAL . . . -116.84 51.3 0.74 Allowed Glycine 0 N--CA 1.48 1.613 0 CA-C-O 118.978 -0.901 . . . . 0.0 111.977 178.795 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' D' D ' 26' ' ' SER . . . . . 0.442 ' HG ' ' H ' ' E' ' 8' ' ' SER . 0.3 OUTLIER -58.87 -171.23 0.01 OUTLIER 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 117.558 0.679 . . . . 0.0 111.533 176.88 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 15.7 t30 -71.92 86.66 1.0 Allowed 'General case' 0 CA--C 1.537 0.468 0 N-CA-C 108.432 -0.951 . . . . 0.0 108.432 178.516 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 97.4 mttt -85.34 156.37 20.93 Favored 'General case' 0 N--CA 1.475 0.779 0 N-CA-C 108.124 -1.065 . . . . 0.0 108.124 179.031 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.39 -144.27 0.02 OUTLIER Glycine 0 C--N 1.335 0.488 0 N-CA-C 110.33 -1.108 . . . . 0.0 110.33 179.387 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -136.41 123.74 21.93 Favored 'General case' 0 N--CA 1.474 0.733 0 N-CA-C 109.159 -0.682 . . . . 0.0 109.159 177.648 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 76.4 mt -83.9 134.53 26.74 Favored 'Isoleucine or valine' 0 C--N 1.355 0.819 0 N-CA-C 104.846 -2.279 . . . . 0.0 104.846 178.776 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' D' D ' 32' ' ' ILE . . . . . 0.444 ' C ' ' H ' ' D' ' 34' ' ' LEU . 46.0 pt -159.07 162.47 1.35 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.02 0 CA-C-O 121.407 0.622 . . . . 0.0 110.397 -178.37 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 64.83 0.17 4.89 Favored Glycine 0 CA--C 1.525 0.685 0 CA-C-N 115.46 -0.791 . . . . 0.0 111.186 -178.563 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' D' D ' 34' ' ' LEU . . . . . 0.444 ' H ' ' C ' ' D' ' 32' ' ' ILE . 7.6 tt -79.25 150.04 31.69 Favored 'General case' 0 C--N 1.343 0.325 0 N-CA-C 109.345 -0.613 . . . . 0.0 109.345 -179.49 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 27.7 ttt -155.78 151.44 27.26 Favored 'General case' 0 N--CA 1.474 0.728 0 N-CA-C 107.509 -1.293 . . . . 0.0 107.509 174.348 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 29.7 m -164.52 163.65 0.73 Allowed 'Isoleucine or valine' 0 CA--C 1.513 -0.445 0 N-CA-C 107.661 -1.237 . . . . 0.0 107.661 176.901 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 60.32 63.75 4.75 Favored Glycine 0 CA--C 1.528 0.885 0 C-N-CA 119.584 -1.293 . . . . 0.0 112.359 177.88 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.92 173.2 15.2 Favored Glycine 0 N--CA 1.479 1.519 0 CA-C-N 118.451 1.125 . . . . 0.0 111.567 -177.851 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' D' D ' 39' ' ' VAL . . . . . 0.476 ' H ' HG11 ' G' ' 39' ' ' VAL . 34.6 m -128.14 160.16 38.41 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.061 0 C-N-CA 122.895 0.478 . . . . 0.0 110.422 -175.953 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 24.2 t . . . . . 0 C--N 1.331 -0.213 0 CA-C-O 116.386 -1.769 . . . . 0.0 109.855 177.694 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' E' E ' 1' ' ' ASP . . . . . 0.473 ' CB ' ' H3 ' ' B' ' 1' ' ' ASP . 65.8 m-20 . . . . . 0 N--CA 1.489 1.485 0 N-CA-C 109.369 -0.604 . . . . 0.0 109.369 . . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' E' E ' 2' ' ' ALA . . . . . . . . . . . . . . . -63.76 131.06 46.69 Favored 'General case' 0 N--CA 1.468 0.449 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.414 179.966 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' E' E ' 3' ' ' GLU . . . . . . . . . . . . . 41.7 tt0 -168.71 105.78 0.44 Allowed 'General case' 0 C--O 1.215 -0.735 0 N-CA-C 110.477 -0.194 . . . . 0.0 110.477 -179.722 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 53.7 m-85 -85.94 146.94 26.47 Favored 'General case' 0 N--CA 1.475 0.81 0 N-CA-C 110.348 -0.241 . . . . 0.0 110.348 179.131 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' E' E ' 5' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 -143.5 142.62 31.23 Favored 'General case' 0 N--CA 1.479 0.99 0 CA-C-O 120.794 0.33 . . . . 0.0 110.201 179.565 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 41.2 t-80 -152.46 119.54 5.85 Favored 'General case' 0 N--CA 1.474 0.725 0 N-CA-C 109.247 -0.649 . . . . 0.0 109.247 178.985 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' E' E ' 7' ' ' ASP . . . . . 0.469 ' O ' ' OG ' ' H' ' 8' ' ' SER . 4.3 m-20 -69.58 148.27 49.61 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-N 116.491 -0.322 . . . . 0.0 110.671 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' E' E ' 8' ' ' SER . . . . . 0.486 ' OG ' ' O ' ' B' ' 7' ' ' ASP . 52.5 p -167.92 -172.49 1.84 Allowed 'General case' 0 N--CA 1.486 1.328 0 CA-C-O 121.013 0.435 . . . . 0.0 110.87 178.952 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.87 47.66 1.24 Allowed Glycine 0 N--CA 1.48 1.595 0 N-CA-C 111.781 -0.528 . . . . 0.0 111.781 179.684 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 47.8 p90 -65.45 133.36 51.14 Favored 'General case' 0 N--CA 1.473 0.683 0 N-CA-C 112.06 0.392 . . . . 0.0 112.06 -179.846 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 85.1 mt-10 -91.4 152.68 20.31 Favored 'General case' 0 N--CA 1.479 1.002 0 N-CA-C 109.617 -0.512 . . . . 0.0 109.617 177.996 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -154.67 127.28 1.07 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.619 0 N-CA-C 107.816 -1.179 . . . . 0.0 107.816 178.067 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 40.8 m-70 -136.18 146.72 47.17 Favored 'General case' 0 N--CA 1.482 1.157 0 CA-C-O 120.851 0.357 . . . . 0.0 111.639 -178.047 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 6.6 t60 -163.64 98.39 0.88 Allowed 'General case' 0 N--CA 1.485 1.293 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.735 179.553 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 4.8 pt20 -91.36 -176.87 4.68 Favored 'General case' 0 CA--C 1.514 -0.43 0 N-CA-C 109.028 -0.73 . . . . 0.0 109.028 -179.925 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -172.31 92.72 0.12 Allowed 'General case' 0 N--CA 1.47 0.557 0 CA-C-N 114.77 -1.104 . . . . 0.0 108.693 177.929 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 6.0 mp -123.35 155.77 36.67 Favored 'General case' 0 N--CA 1.496 1.864 0 CA-C-O 121.443 0.64 . . . . 0.0 111.433 -177.901 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 48.0 t -113.33 122.57 67.72 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.198 0 N-CA-C 108.333 -0.988 . . . . 0.0 108.333 177.37 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 32.4 m-85 -122.76 142.51 50.65 Favored 'General case' 0 N--CA 1.491 1.594 0 CA-C-O 120.974 0.416 . . . . 0.0 110.649 -179.928 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 67.8 m-85 52.73 67.71 0.95 Allowed 'General case' 0 C--N 1.346 0.42 0 CA-C-N 115.767 -0.651 . . . . 0.0 111.614 178.245 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.15 -83.66 0.07 Allowed 'General case' 0 CA--C 1.541 0.605 0 N-CA-C 109.981 -0.377 . . . . 0.0 109.981 -179.464 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 41.0 tt0 -123.28 97.14 5.28 Favored 'General case' 0 C--N 1.32 -0.686 0 N-CA-C 108.14 -1.059 . . . . 0.0 108.14 179.938 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 4.1 p30 -158.35 143.46 16.44 Favored 'General case' 0 N--CA 1.48 1.057 0 O-C-N 122.422 -0.174 . . . . 0.0 111.33 179.062 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' E' E ' 24' ' ' VAL . . . . . 0.431 ' HB ' ' H ' ' B' ' 25' ' ' GLY . 57.9 t -59.53 167.42 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.954 0 N-CA-C 107.412 -1.329 . . . . 0.0 107.412 176.991 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . -122.61 49.66 0.88 Allowed Glycine 0 N--CA 1.475 1.266 0 N-CA-C 110.915 -0.874 . . . . 0.0 110.915 -179.386 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' E' E ' 26' ' ' SER . . . . . 0.457 ' HG ' ' H ' ' F' ' 8' ' ' SER . 0.3 OUTLIER -63.24 -168.54 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.639 0 CA-C-O 120.689 0.281 . . . . 0.0 110.572 179.946 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 14.9 t30 -68.98 77.94 0.32 Allowed 'General case' 0 N--CA 1.465 0.281 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.261 179.946 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -78.12 155.28 30.59 Favored 'General case' 0 N--CA 1.475 0.779 0 N-CA-C 109.458 -0.571 . . . . 0.0 109.458 179.279 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.76 -144.74 0.02 OUTLIER Glycine 0 C--N 1.337 0.634 0 N-CA-C 110.34 -1.104 . . . . 0.0 110.34 178.022 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -137.12 117.25 13.42 Favored 'General case' 0 N--CA 1.476 0.831 0 CA-C-O 120.79 0.328 . . . . 0.0 110.286 179.723 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 67.0 mt -77.45 125.15 36.96 Favored 'Isoleucine or valine' 0 C--O 1.238 0.475 0 N-CA-C 107.011 -1.477 . . . . 0.0 107.011 178.411 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' E' E ' 32' ' ' ILE . . . . . 0.446 ' C ' ' H ' ' E' ' 34' ' ' LEU . 46.4 pt -150.96 164.47 2.64 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.085 0 CA-C-O 121.279 0.561 . . . . 0.0 111.019 -178.943 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.82 1.1 3.36 Favored Glycine 0 CA--C 1.529 0.911 0 CA-C-N 115.542 -0.753 . . . . 0.0 111.871 -179.643 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' E' E ' 34' ' ' LEU . . . . . 0.446 ' H ' ' C ' ' E' ' 32' ' ' ILE . 7.9 tt -79.31 148.18 32.2 Favored 'General case' 0 N--CA 1.468 0.462 0 C-N-CA 122.838 0.455 . . . . 0.0 109.832 -179.964 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 28.0 ttt -158.78 140.97 13.93 Favored 'General case' 0 N--CA 1.477 0.922 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 178.784 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 32.4 m -156.52 162.22 1.7 Allowed 'Isoleucine or valine' 0 C--N 1.344 0.368 0 N-CA-C 108.431 -0.951 . . . . 0.0 108.431 -179.598 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.5 67.36 2.25 Favored Glycine 0 C--N 1.308 -1.012 0 CA-C-N 115.975 -0.557 . . . . 0.0 111.894 178.494 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 148.33 173.06 18.87 Favored Glycine 0 N--CA 1.475 1.255 0 N-CA-C 110.875 -0.89 . . . . 0.0 110.875 179.222 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' E' E ' 39' ' ' VAL . . . . . 0.459 HG11 ' H ' ' B' ' 39' ' ' VAL . 32.9 m -126.18 163.08 28.71 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.909 0 C-N-CA 123.41 0.684 . . . . 0.0 111.016 -179.067 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 24.6 t . . . . . 0 N--CA 1.465 0.309 0 CA-C-O 118.253 -0.88 . . . . 0.0 110.466 178.972 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' F' F ' 1' ' ' ASP . . . . . 0.488 ' CB ' ' H3 ' ' C' ' 1' ' ' ASP . 66.1 m-20 . . . . . 0 N--CA 1.49 1.561 0 N-CA-C 109.218 -0.66 . . . . 0.0 109.218 . . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' F' F ' 2' ' ' ALA . . . . . . . . . . . . . . . -63.78 131.0 46.48 Favored 'General case' 0 N--CA 1.468 0.456 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.487 179.97 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' F' F ' 3' ' ' GLU . . . . . . . . . . . . . 41.6 tt0 -168.52 105.74 0.45 Allowed 'General case' 0 C--O 1.215 -0.733 0 N-CA-C 110.467 -0.197 . . . . 0.0 110.467 -179.765 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 53.7 m-85 -85.95 146.69 26.57 Favored 'General case' 0 N--CA 1.474 0.774 0 N-CA-C 110.234 -0.284 . . . . 0.0 110.234 179.25 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' F' F ' 5' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 -143.3 142.42 31.32 Favored 'General case' 0 N--CA 1.478 0.945 0 CA-C-O 120.803 0.335 . . . . 0.0 110.141 179.544 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 38.8 t-80 -152.42 119.3 5.77 Favored 'General case' 0 N--CA 1.472 0.674 0 N-CA-C 109.283 -0.636 . . . . 0.0 109.283 178.966 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' F' F ' 7' ' ' ASP . . . . . 0.481 ' O ' ' OG ' ' I' ' 8' ' ' SER . 4.2 m-20 -69.17 148.39 49.97 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-N 116.471 -0.331 . . . . 0.0 110.746 179.968 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' F' F ' 8' ' ' SER . . . . . 0.493 ' OG ' ' O ' ' C' ' 7' ' ' ASP . 52.6 p -168.01 -171.99 1.69 Allowed 'General case' 0 N--CA 1.486 1.335 0 CA-C-O 120.931 0.396 . . . . 0.0 111.012 178.74 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.35 47.32 1.32 Allowed Glycine 0 N--CA 1.48 1.591 0 N-CA-C 111.746 -0.542 . . . . 0.0 111.746 179.689 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 47.5 p90 -65.4 134.05 52.66 Favored 'General case' 0 N--CA 1.473 0.678 0 N-CA-C 111.981 0.363 . . . . 0.0 111.981 -179.856 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 85.7 mt-10 -91.8 152.88 19.93 Favored 'General case' 0 N--CA 1.479 0.987 0 N-CA-C 109.699 -0.482 . . . . 0.0 109.699 178.002 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -154.61 127.25 1.07 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.594 0 N-CA-C 107.823 -1.177 . . . . 0.0 107.823 178.029 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 42.2 m-70 -136.27 146.48 46.73 Favored 'General case' 0 N--CA 1.483 1.212 0 CA-C-O 120.833 0.349 . . . . 0.0 111.602 -177.948 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 6.5 t60 -163.51 98.74 0.9 Allowed 'General case' 0 N--CA 1.486 1.348 0 CA-C-N 116.343 -0.389 . . . . 0.0 110.736 179.609 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 4.8 pt20 -91.56 -176.95 4.66 Favored 'General case' 0 CA--C 1.51 -0.563 0 N-CA-C 109.109 -0.7 . . . . 0.0 109.109 179.934 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -172.3 92.38 0.12 Allowed 'General case' 0 C--O 1.219 -0.507 0 CA-C-N 114.777 -1.101 . . . . 0.0 108.591 177.961 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 6.0 mp -123.05 155.95 35.86 Favored 'General case' 0 N--CA 1.495 1.794 0 CA-C-O 121.581 0.705 . . . . 0.0 111.455 -177.983 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 48.2 t -113.52 122.5 67.77 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.141 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 177.362 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 32.6 m-85 -122.67 142.52 50.58 Favored 'General case' 0 N--CA 1.489 1.504 0 CA-C-O 120.955 0.407 . . . . 0.0 110.584 179.934 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 67.4 m-85 52.67 68.08 0.89 Allowed 'General case' 0 C--N 1.343 0.318 0 CA-C-N 115.866 -0.606 . . . . 0.0 111.918 178.474 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.42 -83.75 0.07 Allowed 'General case' 0 CA--C 1.54 0.57 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 -179.496 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 40.9 tt0 -123.22 97.68 5.53 Favored 'General case' 0 C--N 1.32 -0.689 0 N-CA-C 108.099 -1.074 . . . . 0.0 108.099 179.849 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 4.1 p30 -158.79 143.51 15.91 Favored 'General case' 0 N--CA 1.48 1.065 0 CA-C-O 119.692 -0.194 . . . . 0.0 111.277 179.059 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' F' F ' 24' ' ' VAL . . . . . 0.41 ' HB ' ' H ' ' C' ' 25' ' ' GLY . 58.0 t -59.95 166.82 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.96 0 N-CA-C 107.341 -1.355 . . . . 0.0 107.341 177.01 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -122.14 49.82 0.87 Allowed Glycine 0 N--CA 1.476 1.343 0 N-CA-C 111.039 -0.824 . . . . 0.0 111.039 -179.407 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' F' F ' 26' ' ' SER . . . . . 0.519 ' HG ' ' H ' ' D' ' 8' ' ' SER . 0.3 OUTLIER -63.41 -168.43 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.526 0 CA-C-O 120.597 0.237 . . . . 0.0 110.505 179.938 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 14.4 t30 -68.93 78.11 0.32 Allowed 'General case' 0 CA--C 1.534 0.359 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.23 -180.0 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -78.26 155.12 30.42 Favored 'General case' 0 N--CA 1.475 0.794 0 N-CA-C 109.408 -0.589 . . . . 0.0 109.408 179.248 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.56 -144.77 0.02 OUTLIER Glycine 0 C--N 1.338 0.679 0 N-CA-C 110.384 -1.087 . . . . 0.0 110.384 178.005 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -136.8 117.35 13.82 Favored 'General case' 0 N--CA 1.476 0.829 0 CA-C-O 120.751 0.31 . . . . 0.0 110.165 179.752 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 68.3 mt -77.69 125.42 37.35 Favored 'Isoleucine or valine' 0 C--O 1.238 0.45 0 N-CA-C 106.948 -1.501 . . . . 0.0 106.948 178.373 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' F' F ' 32' ' ' ILE . . . . . 0.448 ' C ' ' H ' ' F' ' 34' ' ' LEU . 45.8 pt -151.25 164.63 2.46 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.994 0 CA-C-O 121.154 0.502 . . . . 0.0 111.043 -179.018 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.64 1.43 3.53 Favored Glycine 0 CA--C 1.529 0.911 0 CA-C-N 115.583 -0.735 . . . . 0.0 111.864 -179.67 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' F' F ' 34' ' ' LEU . . . . . 0.448 ' H ' ' C ' ' F' ' 32' ' ' ILE . 7.9 tt -79.6 148.16 31.8 Favored 'General case' 0 N--CA 1.468 0.464 0 C-N-CA 122.837 0.455 . . . . 0.0 109.775 179.95 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 28.0 ttt -158.68 140.97 14.07 Favored 'General case' 0 N--CA 1.477 0.914 0 N-CA-C 108.806 -0.812 . . . . 0.0 108.806 178.725 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 32.2 m -156.59 161.86 1.78 Allowed 'Isoleucine or valine' 0 C--N 1.344 0.358 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 -179.611 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.0 67.22 2.33 Favored Glycine 0 C--N 1.307 -1.047 0 CA-C-N 115.962 -0.563 . . . . 0.0 111.887 178.458 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 148.46 173.82 19.63 Favored Glycine 0 N--CA 1.475 1.26 0 N-CA-C 110.943 -0.863 . . . . 0.0 110.943 179.192 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' F' F ' 39' ' ' VAL . . . . . 0.475 ' H ' HG11 ' I' ' 39' ' ' VAL . 33.1 m -126.82 163.08 30.06 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.935 0 C-N-CA 123.416 0.686 . . . . 0.0 110.899 -179.058 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 24.7 t . . . . . 0 C--O 1.223 -0.304 0 CA-C-O 118.29 -0.862 . . . . 0.0 110.435 178.89 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' G' G ' 1' ' ' ASP . . . . . 0.453 ' CB ' ' H3 ' ' D' ' 1' ' ' ASP . 67.0 m-20 . . . . . 0 N--CA 1.491 1.62 0 N-CA-C 109.342 -0.614 . . . . 0.0 109.342 . . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' G' G ' 2' ' ' ALA . . . . . . . . . . . . . . . -61.79 129.21 39.92 Favored 'General case' 0 N--CA 1.468 0.46 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.632 179.687 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' G' G ' 3' ' ' GLU . . . . . . . . . . . . . 41.0 tt0 -168.62 106.78 0.46 Allowed 'General case' 0 N--CA 1.473 0.692 0 CA-C-O 120.398 0.142 . . . . 0.0 110.668 179.572 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 56.4 m-85 -87.62 146.45 25.73 Favored 'General case' 0 N--CA 1.474 0.756 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 179.215 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' G' G ' 5' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 -143.67 142.58 31.06 Favored 'General case' 0 N--CA 1.482 1.131 0 C-N-CA 122.585 0.354 . . . . 0.0 110.301 179.813 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 40.0 t-80 -152.53 120.34 6.12 Favored 'General case' 0 N--CA 1.473 0.712 0 N-CA-C 109.46 -0.57 . . . . 0.0 109.46 179.016 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -71.16 143.88 50.38 Favored 'General case' 0 N--CA 1.471 0.584 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.12 -179.936 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' G' G ' 8' ' ' SER . . . . . 0.589 ' OG ' ' O ' ' D' ' 7' ' ' ASP . 49.1 p -164.54 -170.1 1.94 Allowed 'General case' 0 N--CA 1.475 0.783 0 CA-C-O 120.923 0.392 . . . . 0.0 110.52 178.506 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.11 47.32 1.35 Allowed Glycine 0 N--CA 1.48 1.571 0 N-CA-C 111.37 -0.692 . . . . 0.0 111.37 179.529 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 50.1 p90 -65.62 133.31 50.88 Favored 'General case' 0 CA--C 1.543 0.683 0 N-CA-C 111.875 0.324 . . . . 0.0 111.875 -179.497 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 83.0 mt-10 -91.6 151.89 20.51 Favored 'General case' 0 N--CA 1.478 0.974 0 CA-C-O 120.991 0.424 . . . . 0.0 110.076 178.555 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -154.78 127.41 1.07 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.014 0 N-CA-C 107.864 -1.161 . . . . 0.0 107.864 178.17 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 42.4 m-70 -135.42 148.21 49.24 Favored 'General case' 0 N--CA 1.479 1.004 0 CA-C-N 115.505 -0.77 . . . . 0.0 111.409 -178.258 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 6.6 t60 -165.49 98.97 0.7 Allowed 'General case' 0 N--CA 1.484 1.263 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.307 179.012 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -92.09 -176.73 4.48 Favored 'General case' 0 CA--C 1.513 -0.477 0 N-CA-C 108.901 -0.777 . . . . 0.0 108.901 -179.847 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -172.85 92.28 0.1 Allowed 'General case' 0 N--CA 1.47 0.565 0 CA-C-N 114.86 -1.064 . . . . 0.0 108.37 178.123 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 6.0 mp -123.19 154.77 38.27 Favored 'General case' 0 N--CA 1.498 1.955 0 CA-C-O 121.302 0.572 . . . . 0.0 111.668 -177.995 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 42.4 t -112.83 123.08 68.14 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.99 0 CA-C-N 114.747 -1.115 . . . . 0.0 108.394 176.866 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 34.8 m-85 -123.53 142.05 51.4 Favored 'General case' 0 C--N 1.367 1.35 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.691 -179.807 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 66.9 m-85 53.64 66.25 1.28 Allowed 'General case' 0 C--O 1.237 0.422 0 CA-C-N 115.742 -0.663 . . . . 0.0 111.584 178.192 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -76.02 -83.62 0.06 Allowed 'General case' 0 N--CA 1.471 0.586 0 N-CA-C 110.003 -0.369 . . . . 0.0 110.003 -179.076 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 41.3 tt0 -123.0 97.25 5.35 Favored 'General case' 0 C--N 1.321 -0.673 0 N-CA-C 107.829 -1.174 . . . . 0.0 107.829 -179.976 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 4.1 p30 -158.59 144.2 16.62 Favored 'General case' 0 N--CA 1.479 1.008 0 CA-C-O 120.463 0.173 . . . . 0.0 111.279 178.891 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' G' G ' 24' ' ' VAL . . . . . 0.452 ' HB ' ' H ' ' D' ' 25' ' ' GLY . 61.0 t -60.96 165.62 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.685 0 N-CA-C 107.617 -1.253 . . . . 0.0 107.617 177.347 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -120.36 50.34 0.83 Allowed Glycine 0 N--CA 1.482 1.711 0 N-CA-C 110.567 -1.013 . . . . 0.0 110.567 -179.561 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -64.06 -168.04 0.03 OUTLIER 'General case' 0 N--CA 1.472 0.647 0 CA-C-N 117.002 0.401 . . . . 0.0 109.963 179.875 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 15.5 t30 -69.46 77.92 0.4 Allowed 'General case' 0 CA--C 1.537 0.459 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.444 179.954 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -77.2 155.22 32.37 Favored 'General case' 0 N--CA 1.475 0.788 0 N-CA-C 109.602 -0.518 . . . . 0.0 109.602 179.189 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.03 -142.53 0.02 OUTLIER Glycine 0 CA--C 1.527 0.792 0 N-CA-C 109.918 -1.273 . . . . 0.0 109.918 178.313 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -137.72 117.45 13.12 Favored 'General case' 0 N--CA 1.471 0.583 0 C-N-CA 122.624 0.37 . . . . 0.0 110.737 -179.915 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 71.7 mt -77.79 125.85 37.74 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.496 0 N-CA-C 107.007 -1.479 . . . . 0.0 107.007 178.382 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' G' G ' 32' ' ' ILE . . . . . 0.465 ' C ' ' H ' ' G' ' 34' ' ' LEU . 44.7 pt -152.31 164.95 1.96 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.755 0 CA-C-N 120.091 1.314 . . . . 0.0 110.032 -179.36 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.61 0.64 3.9 Favored Glycine 0 N--CA 1.468 0.779 0 N-CA-C 111.19 -0.764 . . . . 0.0 111.19 -179.912 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' G' G ' 34' ' ' LEU . . . . . 0.465 ' H ' ' C ' ' G' ' 32' ' ' ILE . 7.9 tt -79.71 148.34 31.58 Favored 'General case' 0 N--CA 1.465 0.303 0 C-N-CA 122.832 0.453 . . . . 0.0 109.841 179.855 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 27.1 ttt -159.14 141.98 14.27 Favored 'General case' 0 N--CA 1.476 0.837 0 N-CA-C 108.731 -0.84 . . . . 0.0 108.731 179.004 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 33.8 m -156.68 162.21 1.67 Allowed 'Isoleucine or valine' 0 C--N 1.345 0.412 0 N-CA-C 108.618 -0.882 . . . . 0.0 108.618 -179.492 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' G' G ' 37' ' ' GLY . . . . . 0.401 ' N ' ' OE1' ' D' ' 15' ' ' GLN . . . 54.95 67.86 1.98 Allowed Glycine 0 C--N 1.31 -0.879 0 CA-C-N 115.637 -0.71 . . . . 0.0 112.141 178.134 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 148.75 174.41 20.37 Favored Glycine 0 N--CA 1.475 1.296 0 N-CA-C 110.462 -1.055 . . . . 0.0 110.462 179.229 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' G' G ' 39' ' ' VAL . . . . . 0.476 HG11 ' H ' ' D' ' 39' ' ' VAL . 33.8 m -127.27 162.73 31.82 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.76 0 C-N-CA 123.1 0.56 . . . . 0.0 110.877 -179.308 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 28.1 t . . . . . 0 N--CA 1.469 0.493 0 CA-C-O 118.351 -0.833 . . . . 0.0 110.702 178.773 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' H' H ' 1' ' ' ASP . . . . . 0.465 ' CB ' ' H3 ' ' E' ' 1' ' ' ASP . 67.0 m-20 . . . . . 0 N--CA 1.49 1.561 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 . . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' H' H ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.36 129.14 39.33 Favored 'General case' 0 N--CA 1.467 0.416 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.601 179.693 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' H' H ' 3' ' ' GLU . . . . . . . . . . . . . 41.1 tt0 -168.48 106.86 0.48 Allowed 'General case' 0 N--CA 1.471 0.617 0 CA-C-O 120.425 0.155 . . . . 0.0 110.705 179.711 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 57.5 m-85 -87.56 146.63 25.68 Favored 'General case' 0 N--CA 1.473 0.705 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 179.129 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' H' H ' 5' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 -143.91 142.64 30.89 Favored 'General case' 0 N--CA 1.483 1.178 0 C-N-CA 122.551 0.341 . . . . 0.0 110.169 179.846 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 41.9 t-80 -152.55 120.38 6.13 Favored 'General case' 0 N--CA 1.474 0.737 0 N-CA-C 109.409 -0.589 . . . . 0.0 109.409 178.946 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -71.28 143.89 50.18 Favored 'General case' 0 N--CA 1.469 0.518 0 C-N-CA 122.699 0.399 . . . . 0.0 111.158 -179.913 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' H' H ' 8' ' ' SER . . . . . 0.469 ' OG ' ' O ' ' E' ' 7' ' ' ASP . 53.6 p -164.36 -170.42 2.06 Favored 'General case' 0 N--CA 1.474 0.759 0 CA-C-O 120.965 0.412 . . . . 0.0 110.422 178.766 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.95 47.97 1.3 Allowed Glycine 0 N--CA 1.48 1.586 0 N-CA-C 111.461 -0.655 . . . . 0.0 111.461 179.601 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 50.2 p90 -66.28 133.18 50.03 Favored 'General case' 0 N--CA 1.472 0.675 0 N-CA-C 112.046 0.387 . . . . 0.0 112.046 -179.605 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 83.4 mt-10 -91.42 151.66 20.72 Favored 'General case' 0 N--CA 1.478 0.957 0 CA-C-O 121.069 0.461 . . . . 0.0 110.195 178.576 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -154.73 127.41 1.08 Allowed 'Isoleucine or valine' 0 CA--C 1.553 1.059 0 N-CA-C 107.888 -1.153 . . . . 0.0 107.888 178.251 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 42.7 m-70 -135.46 148.2 49.17 Favored 'General case' 0 C--N 1.357 0.912 0 CA-C-N 115.461 -0.79 . . . . 0.0 111.444 -178.293 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 6.6 t60 -165.43 98.75 0.7 Allowed 'General case' 0 N--CA 1.482 1.136 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.427 178.996 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 4.9 pt20 -91.88 -177.02 4.61 Favored 'General case' 0 CA--C 1.513 -0.468 0 N-CA-C 108.799 -0.815 . . . . 0.0 108.799 -179.814 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -172.7 92.13 0.11 Allowed 'General case' 0 N--CA 1.472 0.663 0 CA-C-N 114.707 -1.133 . . . . 0.0 108.239 178.142 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 6.0 mp -122.93 154.72 37.99 Favored 'General case' 0 N--CA 1.499 1.991 0 CA-C-O 121.224 0.535 . . . . 0.0 111.784 -178.064 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 41.5 t -112.72 123.25 68.21 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.947 0 CA-C-N 114.841 -1.072 . . . . 0.0 108.368 176.742 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 34.2 m-85 -123.66 141.58 51.88 Favored 'General case' 0 C--N 1.369 1.425 0 CA-C-N 115.427 -0.806 . . . . 0.0 110.598 -179.65 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 66.9 m-85 53.02 67.44 1.0 Allowed 'General case' 0 C--O 1.237 0.419 0 CA-C-N 115.623 -0.717 . . . . 0.0 111.674 178.389 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -76.66 -83.15 0.07 Allowed 'General case' 0 N--CA 1.469 0.504 0 N-CA-C 110.025 -0.361 . . . . 0.0 110.025 -179.168 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 41.1 tt0 -123.25 96.93 5.19 Favored 'General case' 0 C--N 1.319 -0.726 0 N-CA-C 107.891 -1.151 . . . . 0.0 107.891 -179.969 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 4.2 p30 -158.16 143.98 17.06 Favored 'General case' 0 N--CA 1.478 0.968 0 CA-C-O 120.423 0.154 . . . . 0.0 111.264 179.021 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' H' H ' 24' ' ' VAL . . . . . . . . . . . . . 58.3 t -60.77 165.9 0.77 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.599 0 N-CA-C 107.61 -1.256 . . . . 0.0 107.61 177.285 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . -120.47 49.7 0.86 Allowed Glycine 0 N--CA 1.479 1.518 0 N-CA-C 110.665 -0.974 . . . . 0.0 110.665 -179.472 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -63.71 -168.16 0.02 OUTLIER 'General case' 0 N--CA 1.471 0.625 0 CA-C-N 117.022 0.411 . . . . 0.0 110.125 179.926 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 15.8 t30 -69.52 78.45 0.41 Allowed 'General case' 0 CA--C 1.536 0.413 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.41 179.987 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -77.86 155.44 30.98 Favored 'General case' 0 N--CA 1.474 0.768 0 N-CA-C 109.459 -0.571 . . . . 0.0 109.459 179.262 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.36 -142.76 0.02 OUTLIER Glycine 0 C--N 1.339 0.733 0 N-CA-C 109.798 -1.321 . . . . 0.0 109.798 178.386 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -137.67 117.38 13.09 Favored 'General case' 0 N--CA 1.469 0.522 0 C-N-CA 122.526 0.33 . . . . 0.0 110.758 -179.855 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 71.5 mt -77.49 125.73 37.42 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.506 0 N-CA-C 106.946 -1.502 . . . . 0.0 106.946 178.498 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' H' H ' 32' ' ' ILE . . . . . 0.458 ' C ' ' H ' ' H' ' 34' ' ' LEU . 44.7 pt -152.27 164.92 1.98 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 CA-C-N 120.094 1.316 . . . . 0.0 110.005 -179.452 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.91 0.3 3.97 Favored Glycine 0 CA--C 1.527 0.796 0 N-CA-C 111.202 -0.759 . . . . 0.0 111.202 -179.827 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' H' H ' 34' ' ' LEU . . . . . 0.458 ' H ' ' C ' ' H' ' 32' ' ' ILE . 7.9 tt -79.39 148.36 32.02 Favored 'General case' 0 N--CA 1.465 0.308 0 C-N-CA 122.84 0.456 . . . . 0.0 109.889 179.935 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 27.1 ttt -159.23 141.73 13.95 Favored 'General case' 0 N--CA 1.477 0.915 0 N-CA-C 108.709 -0.848 . . . . 0.0 108.709 178.999 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 35.9 m -156.69 162.13 1.7 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.416 0 N-CA-C 108.599 -0.889 . . . . 0.0 108.599 -179.39 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.04 67.79 2.02 Favored Glycine 0 C--N 1.31 -0.896 0 CA-C-N 115.638 -0.71 . . . . 0.0 112.086 178.239 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 149.01 174.89 20.98 Favored Glycine 0 N--CA 1.475 1.267 0 N-CA-C 110.571 -1.012 . . . . 0.0 110.571 179.19 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' H' H ' 39' ' ' VAL . . . . . 0.459 HG11 ' H ' ' E' ' 39' ' ' VAL . 33.9 m -127.65 162.53 33.09 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.799 0 C-N-CA 123.114 0.565 . . . . 0.0 110.923 -179.368 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 25.9 t . . . . . 0 N--CA 1.47 0.541 0 CA-C-O 118.402 -0.809 . . . . 0.0 110.707 178.74 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' I' I ' 1' ' ' ASP . . . . . 0.461 ' CB ' ' H3 ' ' F' ' 1' ' ' ASP . 66.4 m-20 . . . . . 0 N--CA 1.492 1.629 0 N-CA-C 109.442 -0.577 . . . . 0.0 109.442 . . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' I' I ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.15 129.27 40.02 Favored 'General case' 0 N--CA 1.468 0.436 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.617 179.685 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' I' I ' 3' ' ' GLU . . . . . . . . . . . . . 40.6 tt0 -168.6 106.91 0.47 Allowed 'General case' 0 N--CA 1.471 0.616 0 CA-C-O 120.397 0.142 . . . . 0.0 110.644 179.693 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 56.3 m-85 -87.66 146.69 25.59 Favored 'General case' 0 N--CA 1.474 0.772 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 179.054 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' I' I ' 5' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 -143.93 142.37 30.72 Favored 'General case' 0 N--CA 1.483 1.199 0 C-N-CA 122.569 0.348 . . . . 0.0 110.108 179.827 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 40.7 t-80 -152.36 120.13 6.12 Favored 'General case' 0 N--CA 1.473 0.687 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 178.976 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -71.06 143.98 50.51 Favored 'General case' 0 N--CA 1.47 0.574 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.178 -179.856 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' I' I ' 8' ' ' SER . . . . . 0.481 ' OG ' ' O ' ' F' ' 7' ' ' ASP . 54.1 p -164.5 -170.43 2.04 Favored 'General case' 0 N--CA 1.475 0.781 0 CA-C-O 120.964 0.411 . . . . 0.0 110.456 178.707 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.19 47.24 1.35 Allowed Glycine 0 N--CA 1.48 1.611 0 N-CA-C 111.598 -0.601 . . . . 0.0 111.598 179.67 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 50.4 p90 -65.76 133.48 51.13 Favored 'General case' 0 N--CA 1.473 0.676 0 N-CA-C 112.0 0.37 . . . . 0.0 112.0 -179.566 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 82.6 mt-10 -91.81 151.71 20.47 Favored 'General case' 0 N--CA 1.476 0.871 0 CA-C-O 120.978 0.418 . . . . 0.0 110.184 178.639 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -154.67 127.48 1.1 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.033 0 N-CA-C 107.969 -1.123 . . . . 0.0 107.969 178.16 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 41.7 m-70 -135.5 148.1 49.07 Favored 'General case' 0 N--CA 1.477 0.922 0 CA-C-N 115.407 -0.815 . . . . 0.0 111.467 -178.248 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 6.6 t60 -165.3 99.01 0.72 Allowed 'General case' 0 N--CA 1.483 1.192 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.383 179.013 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -92.07 -176.92 4.54 Favored 'General case' 0 CA--C 1.511 -0.521 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 -179.848 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -172.83 92.08 0.1 Allowed 'General case' 0 N--CA 1.47 0.534 0 CA-C-N 114.74 -1.118 . . . . 0.0 108.291 178.199 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 6.0 mp -122.84 154.91 37.63 Favored 'General case' 0 N--CA 1.499 1.983 0 CA-C-O 121.223 0.535 . . . . 0.0 111.754 -178.054 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 41.3 t -113.09 123.42 68.72 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.927 0 CA-C-N 114.861 -1.063 . . . . 0.0 108.247 176.784 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 33.4 m-85 -123.96 141.18 52.27 Favored 'General case' 0 C--N 1.37 1.461 0 CA-C-N 115.413 -0.812 . . . . 0.0 110.636 -179.444 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 67.1 m-85 53.35 67.15 1.05 Allowed 'General case' 0 C--O 1.238 0.45 0 CA-C-N 115.69 -0.686 . . . . 0.0 111.537 178.41 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -76.32 -83.14 0.07 Allowed 'General case' 0 N--CA 1.47 0.541 0 N-CA-C 109.913 -0.402 . . . . 0.0 109.913 -179.148 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 41.3 tt0 -123.33 97.1 5.25 Favored 'General case' 0 C--N 1.32 -0.712 0 N-CA-C 107.868 -1.16 . . . . 0.0 107.868 -179.924 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 4.1 p30 -158.29 144.36 17.13 Favored 'General case' 0 N--CA 1.479 1.002 0 O-C-N 122.458 -0.151 . . . . 0.0 111.257 178.964 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' I' I ' 24' ' ' VAL . . . . . . . . . . . . . 59.5 t -61.2 165.57 0.86 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.589 0 N-CA-C 107.63 -1.248 . . . . 0.0 107.63 177.345 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . -120.24 49.95 0.85 Allowed Glycine 0 N--CA 1.481 1.661 0 N-CA-C 110.588 -1.005 . . . . 0.0 110.588 -179.383 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -63.8 -168.1 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.649 0 CA-C-N 116.991 0.395 . . . . 0.0 110.134 179.825 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 15.2 t30 -69.56 78.3 0.41 Allowed 'General case' 0 CA--C 1.536 0.421 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.364 179.924 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -77.77 155.34 31.22 Favored 'General case' 0 N--CA 1.475 0.78 0 N-CA-C 109.504 -0.554 . . . . 0.0 109.504 179.263 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.28 -143.0 0.02 OUTLIER Glycine 0 CA--C 1.527 0.842 0 N-CA-C 109.813 -1.315 . . . . 0.0 109.813 178.39 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -137.3 117.36 13.38 Favored 'General case' 0 N--CA 1.471 0.597 0 C-N-CA 122.627 0.371 . . . . 0.0 110.778 -179.863 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 71.7 mt -77.57 125.89 37.6 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.488 0 N-CA-C 106.986 -1.487 . . . . 0.0 106.986 178.389 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' I' I ' 32' ' ' ILE . . . . . 0.457 ' C ' ' H ' ' I' ' 34' ' ' LEU . 44.9 pt -152.34 164.95 1.94 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 CA-C-N 120.143 1.338 . . . . 0.0 110.06 -179.436 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.64 0.98 4.22 Favored Glycine 0 N--CA 1.469 0.844 0 N-CA-C 111.127 -0.789 . . . . 0.0 111.127 -179.909 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' I' I ' 34' ' ' LEU . . . . . 0.457 ' H ' ' C ' ' I' ' 32' ' ' ILE . 8.1 tt -80.1 148.02 31.17 Favored 'General case' 0 CA--C 1.533 0.313 0 C-N-CA 122.845 0.458 . . . . 0.0 109.792 179.895 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 26.9 ttt -158.69 141.68 14.63 Favored 'General case' 0 N--CA 1.476 0.85 0 N-CA-C 108.611 -0.885 . . . . 0.0 108.611 179.086 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 35.9 m -156.65 162.06 1.72 Allowed 'Isoleucine or valine' 0 C--N 1.346 0.442 0 N-CA-C 108.523 -0.917 . . . . 0.0 108.523 -179.562 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.22 67.78 2.03 Favored Glycine 0 C--N 1.312 -0.798 0 CA-C-N 115.638 -0.71 . . . . 0.0 112.107 178.185 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 148.68 174.73 20.59 Favored Glycine 0 N--CA 1.474 1.217 0 N-CA-C 110.461 -1.056 . . . . 0.0 110.461 179.244 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' I' I ' 39' ' ' VAL . . . . . 0.475 HG11 ' H ' ' F' ' 39' ' ' VAL . 33.9 m -127.66 162.76 32.64 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.786 0 C-N-CA 123.1 0.56 . . . . 0.0 110.923 -179.259 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 27.1 t . . . . . 0 N--CA 1.47 0.544 0 CA-C-O 118.377 -0.821 . . . . 0.0 110.56 178.75 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 9.4 m-20 . . . . . 0 N--CA 1.493 1.694 0 N-CA-C 109.835 -0.431 . . . . 0.0 109.835 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.35 129.74 42.1 Favored 'General case' 0 N--CA 1.47 0.529 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.228 179.473 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 38.6 tt0 -138.7 104.54 5.13 Favored 'General case' 0 N--CA 1.48 1.043 0 N-CA-C 109.555 -0.535 . . . . 0.0 109.555 179.427 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 26.6 m-85 -73.16 169.12 17.7 Favored 'General case' 0 CA--C 1.537 0.478 0 N-CA-C 109.142 -0.688 . . . . 0.0 109.142 179.512 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 38.2 mtp180 -68.41 147.02 52.67 Favored 'General case' 0 C--O 1.201 -1.452 0 CA-C-N 115.821 -0.627 . . . . 0.0 111.293 -177.505 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 39.2 m80 -109.55 119.1 38.39 Favored 'General case' 0 N--CA 1.482 1.165 0 N-CA-C 108.953 -0.758 . . . . 0.0 108.953 178.289 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' ASP . . . . . 0.459 ' OD1' ' NH2' ' G' ' 5' ' ' ARG . 7.3 m-20 -67.52 140.7 57.01 Favored 'General case' 0 N--CA 1.469 0.502 0 CA-C-O 121.135 0.493 . . . . 0.0 111.795 -178.758 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 39.0 t -158.65 -169.49 2.74 Favored 'General case' 0 N--CA 1.467 0.376 0 CA-C-N 115.848 -0.615 . . . . 0.0 109.662 179.092 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 119.83 32.39 1.2 Allowed Glycine 0 N--CA 1.485 1.922 0 N-CA-C 111.574 -0.61 . . . . 0.0 111.574 179.61 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 46.9 p90 -57.2 130.43 46.16 Favored 'General case' 0 N--CA 1.471 0.61 0 CA-C-N 116.736 0.268 . . . . 0.0 111.49 179.971 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . 0.477 ' CG ' HD22 ' C' ' 27' ' ' ASN . 60.6 mt-10 -90.44 153.15 20.61 Favored 'General case' 0 N--CA 1.473 0.717 0 N-CA-C 109.329 -0.619 . . . . 0.0 109.329 178.69 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.6 p -153.48 126.55 1.15 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 N-CA-C 107.698 -1.223 . . . . 0.0 107.698 177.988 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 45.6 m-70 -136.91 162.06 34.3 Favored 'General case' 0 N--CA 1.49 1.537 0 CA-C-N 118.685 0.675 . . . . 0.0 110.879 -178.721 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 38.3 t60 -152.91 96.43 2.1 Favored 'General case' 0 N--CA 1.486 1.333 0 C-N-CA 122.634 0.374 . . . . 0.0 110.049 179.065 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . 0.68 HE22 ' H ' ' A' ' 38' ' ' GLY . 28.3 mt-30 -90.63 121.52 32.61 Favored 'General case' 0 N--CA 1.452 -0.371 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 -178.964 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -112.98 103.67 11.63 Favored 'General case' 0 N--CA 1.475 0.789 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 176.686 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 57.8 tp -133.34 150.43 51.85 Favored 'General case' 0 N--CA 1.486 1.347 0 N-CA-C 108.766 -0.827 . . . . 0.0 108.766 -179.391 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 84.5 t -145.42 123.13 4.65 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.969 0 CA-C-O 118.523 -0.751 . . . . 0.0 109.137 179.755 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 11.9 m-85 -70.74 158.67 35.89 Favored 'General case' 0 N--CA 1.485 1.324 0 N-CA-C 107.461 -1.311 . . . . 0.0 107.461 177.564 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 18.6 t80 -170.07 -58.44 0.02 OUTLIER 'General case' 0 N--CA 1.481 1.101 0 CA-C-O 122.425 1.107 . . . . 0.0 109.765 179.735 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -39.19 89.68 0.0 OUTLIER 'General case' 0 N--CA 1.456 -0.135 0 CA-C-N 113.807 -1.542 . . . . 0.0 112.844 -178.034 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 38.6 tt0 -64.49 159.59 21.2 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.175 -0.92 . . . . 0.0 110.552 179.245 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 9.6 m-20 -136.23 125.81 25.3 Favored 'General case' 0 N--CA 1.481 1.086 0 C-N-CA 123.297 0.639 . . . . 0.0 109.781 -179.897 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . 0.634 ' CG1' HH22 ' E' ' 5' ' ' ARG . 57.8 t -76.55 -170.44 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.591 0 N-CA-C 108.511 -0.922 . . . . 0.0 108.511 179.673 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.583 ' H ' ' CG1' ' A' ' 24' ' ' VAL . . . -69.11 48.86 0.52 Allowed Glycine 0 CA--C 1.53 1.003 0 CA-C-N 118.344 0.52 . . . . 0.0 112.313 -178.147 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 13.1 p -69.54 137.52 52.52 Favored 'General case' 0 C--O 1.217 -0.61 0 N-CA-C 109.596 -0.52 . . . . 0.0 109.596 178.66 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . 0.482 HD22 ' CG ' ' B' ' 11' ' ' GLU . 34.6 t30 -68.57 95.06 0.61 Allowed 'General case' 0 N--CA 1.47 0.553 0 N-CA-C 108.15 -1.055 . . . . 0.0 108.15 177.847 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 68.6 mttm -92.45 117.66 30.16 Favored 'General case' 0 N--CA 1.481 1.079 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 -179.221 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.33 -134.27 0.01 OUTLIER Glycine 0 CA--C 1.534 1.226 0 N-CA-C 110.771 -0.932 . . . . 0.0 110.771 179.044 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -115.65 127.16 54.98 Favored 'General case' 0 N--CA 1.477 0.897 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 179.12 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 66.1 mt -90.53 134.97 27.76 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.59 0 N-CA-C 107.673 -1.232 . . . . 0.0 107.673 179.012 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 30.3 mt -136.52 138.16 46.92 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.815 0 CA-C-N 115.982 -0.554 . . . . 0.0 109.606 -179.134 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.97 57.46 15.75 Favored Glycine 0 CA--C 1.527 0.842 0 CA-C-N 115.904 -0.589 . . . . 0.0 112.795 178.543 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 25.4 tp -106.11 132.77 51.79 Favored 'General case' 0 N--CA 1.488 1.474 0 N-CA-C 107.508 -1.293 . . . . 0.0 107.508 177.919 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 24.9 ttt -138.2 148.15 44.52 Favored 'General case' 0 N--CA 1.471 0.576 0 N-CA-C 107.769 -1.197 . . . . 0.0 107.769 179.136 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 60.4 t -156.64 160.45 2.25 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.587 0 N-CA-C 106.097 -1.816 . . . . 0.0 106.097 -178.855 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . 0.455 ' O ' ' NE2' ' D' ' 15' ' ' GLN . . . 53.55 74.48 0.3 Allowed Glycine 0 C--N 1.308 -0.993 0 C-N-CA 121.214 -0.517 . . . . 0.0 111.818 177.839 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . 0.68 ' H ' HE22 ' A' ' 15' ' ' GLN . . . 164.73 -168.51 39.02 Favored Glycine 0 N--CA 1.466 0.692 0 N-CA-C 111.042 -0.823 . . . . 0.0 111.042 179.352 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 24.5 m -126.67 148.9 31.38 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.855 0 C-N-CA 122.977 0.511 . . . . 0.0 109.847 179.665 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 9.7 t . . . . . 0 CA--C 1.535 0.385 0 CA-C-O 118.109 -0.948 . . . . 0.0 110.723 178.893 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' B' B ' 1' ' ' ASP . . . . . . . . . . . . . 9.5 m-20 . . . . . 0 N--CA 1.494 1.74 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' B' B ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.28 129.85 42.65 Favored 'General case' 0 N--CA 1.47 0.544 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.238 179.47 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 3' ' ' GLU . . . . . . . . . . . . . 38.6 tt0 -138.77 104.59 5.13 Favored 'General case' 0 N--CA 1.48 1.029 0 N-CA-C 109.515 -0.55 . . . . 0.0 109.515 179.333 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 27.8 m-85 -72.9 169.03 17.7 Favored 'General case' 0 N--CA 1.468 0.435 0 N-CA-C 109.154 -0.684 . . . . 0.0 109.154 179.428 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 39.3 mtp180 -68.48 146.74 52.88 Favored 'General case' 0 C--O 1.201 -1.478 0 CA-C-N 115.708 -0.678 . . . . 0.0 111.3 -177.653 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 39.4 m80 -109.35 119.36 39.24 Favored 'General case' 0 N--CA 1.484 1.247 0 N-CA-C 108.995 -0.742 . . . . 0.0 108.995 178.282 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 7' ' ' ASP . . . . . 0.46 ' OD1' ' NH2' ' H' ' 5' ' ' ARG . 7.1 m-20 -67.66 141.02 56.84 Favored 'General case' 0 N--CA 1.469 0.501 0 CA-C-O 121.043 0.449 . . . . 0.0 111.76 -178.745 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 8' ' ' SER . . . . . . . . . . . . . 39.1 t -158.8 -169.45 2.7 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-N 115.814 -0.63 . . . . 0.0 109.634 179.099 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 119.75 32.37 1.21 Allowed Glycine 0 N--CA 1.485 1.92 0 N-CA-C 111.552 -0.619 . . . . 0.0 111.552 179.578 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 46.8 p90 -57.36 130.54 46.71 Favored 'General case' 0 N--CA 1.472 0.651 0 CA-C-O 120.64 0.257 . . . . 0.0 111.514 -179.996 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 11' ' ' GLU . . . . . 0.482 ' CG ' HD22 ' A' ' 27' ' ' ASN . 60.4 mt-10 -90.52 153.16 20.57 Favored 'General case' 0 N--CA 1.472 0.664 0 N-CA-C 109.357 -0.609 . . . . 0.0 109.357 178.857 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.6 p -153.53 126.14 1.09 Allowed 'Isoleucine or valine' 0 C--O 1.234 0.281 0 N-CA-C 107.846 -1.168 . . . . 0.0 107.846 178.086 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 45.6 m-70 -136.63 162.07 34.15 Favored 'General case' 0 N--CA 1.49 1.533 0 CA-C-N 118.648 0.658 . . . . 0.0 110.936 -178.567 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 38.4 t60 -152.86 96.44 2.1 Favored 'General case' 0 N--CA 1.487 1.422 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.087 179.057 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . 0.696 HE22 ' H ' ' B' ' 38' ' ' GLY . 28.3 mt-30 -90.48 121.16 32.2 Favored 'General case' 0 CA--C 1.517 -0.309 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 -179.01 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -112.63 103.49 11.53 Favored 'General case' 0 N--CA 1.474 0.742 0 N-CA-C 107.988 -1.115 . . . . 0.0 107.988 176.619 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 57.8 tp -133.34 150.25 51.86 Favored 'General case' 0 N--CA 1.486 1.369 0 N-CA-C 108.755 -0.831 . . . . 0.0 108.755 -179.368 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 84.6 t -145.41 122.48 4.28 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.011 0 CA-C-O 118.629 -0.7 . . . . 0.0 109.333 179.707 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 12.4 m-85 -70.52 158.91 35.26 Favored 'General case' 0 N--CA 1.486 1.334 0 N-CA-C 107.287 -1.375 . . . . 0.0 107.287 177.572 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 19.9 t80 -170.99 -57.67 0.02 OUTLIER 'General case' 0 N--CA 1.478 0.934 0 CA-C-O 122.22 1.009 . . . . 0.0 109.705 179.651 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -39.4 90.12 0.0 OUTLIER 'General case' 0 C--O 1.231 0.124 0 CA-C-N 113.959 -1.473 . . . . 0.0 112.721 -178.16 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 38.6 tt0 -64.85 159.55 22.35 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 115.1 -0.955 . . . . 0.0 110.559 179.298 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 9.7 m-20 -136.26 125.9 25.4 Favored 'General case' 0 N--CA 1.481 1.118 0 C-N-CA 123.217 0.607 . . . . 0.0 109.765 -179.876 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . 0.638 ' CG1' HH22 ' F' ' 5' ' ' ARG . 56.9 t -76.7 -170.39 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.661 0 N-CA-C 108.586 -0.894 . . . . 0.0 108.586 179.722 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . 0.58 ' H ' ' CG1' ' B' ' 24' ' ' VAL . . . -68.71 48.42 0.45 Allowed Glycine 0 CA--C 1.531 1.087 0 CA-C-N 118.321 0.509 . . . . 0.0 112.208 -178.126 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 13.3 p -69.72 137.41 52.02 Favored 'General case' 0 C--O 1.219 -0.548 0 N-CA-C 109.591 -0.522 . . . . 0.0 109.591 178.706 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 27' ' ' ASN . . . . . 0.48 HD22 ' CG ' ' C' ' 11' ' ' GLU . 34.8 t30 -68.72 95.07 0.64 Allowed 'General case' 0 N--CA 1.47 0.543 0 N-CA-C 108.159 -1.052 . . . . 0.0 108.159 177.847 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 68.6 mttm -92.34 117.62 30.08 Favored 'General case' 0 N--CA 1.48 1.028 0 N-CA-C 109.997 -0.371 . . . . 0.0 109.997 -179.227 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.3 -134.17 0.01 OUTLIER Glycine 0 CA--C 1.532 1.128 0 N-CA-C 110.769 -0.932 . . . . 0.0 110.769 179.014 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -115.88 127.28 54.89 Favored 'General case' 0 N--CA 1.478 0.955 0 N-CA-C 109.428 -0.582 . . . . 0.0 109.428 179.149 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 66.0 mt -90.55 135.0 27.69 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.536 0 N-CA-C 107.676 -1.231 . . . . 0.0 107.676 179.035 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 30.2 mt -136.45 138.35 46.8 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.714 0 CA-C-N 115.933 -0.576 . . . . 0.0 109.567 -179.115 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.65 57.72 15.16 Favored Glycine 0 CA--C 1.527 0.829 0 CA-C-N 115.876 -0.602 . . . . 0.0 112.82 178.604 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 25.8 tp -106.3 132.83 51.88 Favored 'General case' 0 N--CA 1.486 1.375 0 N-CA-C 107.502 -1.296 . . . . 0.0 107.502 177.897 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 25.0 ttt -138.18 147.83 44.22 Favored 'General case' 0 N--CA 1.473 0.683 0 N-CA-C 107.778 -1.193 . . . . 0.0 107.778 179.216 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 60.8 t -156.67 159.98 2.45 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.625 0 N-CA-C 106.178 -1.786 . . . . 0.0 106.178 -178.928 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . 0.464 ' O ' ' NE2' ' E' ' 15' ' ' GLN . . . 54.12 74.26 0.33 Allowed Glycine 0 C--N 1.308 -0.973 0 N-CA-C 111.739 -0.544 . . . . 0.0 111.739 177.963 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 38' ' ' GLY . . . . . 0.696 ' H ' HE22 ' B' ' 15' ' ' GLN . . . 164.85 -168.44 39.07 Favored Glycine 0 N--CA 1.465 0.58 0 N-CA-C 111.124 -0.791 . . . . 0.0 111.124 179.266 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 24.5 m -126.62 148.89 31.33 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.808 0 C-N-CA 122.992 0.517 . . . . 0.0 109.955 179.601 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 9.7 t . . . . . 0 CA--C 1.535 0.392 0 CA-C-O 118.095 -0.955 . . . . 0.0 110.872 179.001 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' C' C ' 1' ' ' ASP . . . . . . . . . . . . . 9.5 m-20 . . . . . 0 N--CA 1.494 1.727 0 N-CA-C 109.703 -0.48 . . . . 0.0 109.703 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' C' C ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.4 129.73 42.02 Favored 'General case' 0 N--CA 1.47 0.538 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.29 179.4 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 3' ' ' GLU . . . . . . . . . . . . . 38.6 tt0 -138.64 104.6 5.16 Favored 'General case' 0 N--CA 1.48 1.062 0 N-CA-C 109.635 -0.506 . . . . 0.0 109.635 179.33 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 27.7 m-85 -72.93 169.23 17.32 Favored 'General case' 0 N--CA 1.468 0.429 0 N-CA-C 109.265 -0.643 . . . . 0.0 109.265 179.448 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 39.2 mtp180 -68.67 146.37 53.05 Favored 'General case' 0 C--O 1.201 -1.489 0 CA-C-N 115.849 -0.614 . . . . 0.0 111.221 -177.564 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 39.2 m80 -109.11 119.22 38.9 Favored 'General case' 0 N--CA 1.484 1.232 0 N-CA-C 108.978 -0.749 . . . . 0.0 108.978 178.269 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 7' ' ' ASP . . . . . 0.473 ' OD1' ' NH2' ' I' ' 5' ' ' ARG . 7.3 m-20 -67.64 141.11 56.83 Favored 'General case' 0 N--CA 1.468 0.448 0 CA-C-O 121.049 0.452 . . . . 0.0 111.79 -178.721 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' C' C ' 8' ' ' SER . . . . . . . . . . . . . 39.2 t -158.89 -169.49 2.71 Favored 'General case' 0 N--CA 1.466 0.37 0 CA-C-N 115.837 -0.62 . . . . 0.0 109.604 179.149 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 119.8 32.34 1.21 Allowed Glycine 0 N--CA 1.485 1.94 0 N-CA-C 111.506 -0.638 . . . . 0.0 111.506 179.543 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 46.8 p90 -57.32 130.42 46.15 Favored 'General case' 0 N--CA 1.471 0.587 0 CA-C-O 120.676 0.274 . . . . 0.0 111.53 179.951 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 11' ' ' GLU . . . . . 0.48 ' CG ' HD22 ' B' ' 27' ' ' ASN . 60.5 mt-10 -90.39 153.12 20.65 Favored 'General case' 0 N--CA 1.473 0.722 0 N-CA-C 109.368 -0.605 . . . . 0.0 109.368 178.792 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.6 p -153.47 126.16 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 N-CA-C 107.858 -1.164 . . . . 0.0 107.858 178.017 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 45.8 m-70 -136.59 162.16 33.9 Favored 'General case' 0 N--CA 1.491 1.589 0 CA-C-N 118.604 0.638 . . . . 0.0 110.958 -178.658 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 38.6 t60 -153.01 96.61 2.1 Favored 'General case' 0 N--CA 1.487 1.413 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.1 179.086 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 15' ' ' GLN . . . . . 0.709 HE22 ' H ' ' C' ' 38' ' ' GLY . 28.3 mt-30 -90.72 121.5 32.67 Favored 'General case' 0 CA--C 1.515 -0.381 0 N-CA-C 109.843 -0.429 . . . . 0.0 109.843 -178.99 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -112.92 103.49 11.46 Favored 'General case' 0 N--CA 1.473 0.677 0 N-CA-C 107.898 -1.149 . . . . 0.0 107.898 176.665 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 57.8 tp -133.28 150.23 51.92 Favored 'General case' 0 N--CA 1.486 1.337 0 N-CA-C 108.769 -0.826 . . . . 0.0 108.769 -179.435 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 85.3 t -145.38 122.59 4.37 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.013 0 CA-C-O 118.694 -0.67 . . . . 0.0 109.289 179.714 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 12.4 m-85 -70.63 158.88 35.41 Favored 'General case' 0 N--CA 1.487 1.39 0 N-CA-C 107.345 -1.354 . . . . 0.0 107.345 177.516 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 19.9 t80 -170.9 -57.72 0.02 OUTLIER 'General case' 0 N--CA 1.476 0.86 0 CA-C-O 122.29 1.043 . . . . 0.0 109.731 179.641 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -39.31 90.01 0.0 OUTLIER 'General case' 0 N--CA 1.457 -0.088 0 CA-C-N 113.986 -1.461 . . . . 0.0 112.711 -178.157 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 38.6 tt0 -64.84 159.64 22.11 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 115.183 -0.917 . . . . 0.0 110.593 179.343 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 9.6 m-20 -136.28 125.77 25.15 Favored 'General case' 0 N--CA 1.48 1.048 0 C-N-CA 123.315 0.646 . . . . 0.0 109.798 -179.838 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 24' ' ' VAL . . . . . 0.641 ' CG1' HH22 ' D' ' 5' ' ' ARG . 57.1 t -76.66 -170.4 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.578 0 N-CA-C 108.609 -0.885 . . . . 0.0 108.609 179.708 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' C' C ' 25' ' ' GLY . . . . . 0.574 ' H ' ' CG1' ' C' ' 24' ' ' VAL . . . -68.8 48.56 0.47 Allowed Glycine 0 CA--C 1.533 1.18 0 CA-C-N 118.409 0.549 . . . . 0.0 112.249 -178.066 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 13.3 p -69.73 137.47 52.04 Favored 'General case' 0 C--O 1.22 -0.459 0 N-CA-C 109.646 -0.501 . . . . 0.0 109.646 178.716 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 27' ' ' ASN . . . . . 0.477 HD22 ' CG ' ' A' ' 11' ' ' GLU . 34.8 t30 -68.7 95.04 0.63 Allowed 'General case' 0 N--CA 1.469 0.485 0 N-CA-C 108.179 -1.045 . . . . 0.0 108.179 177.851 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 68.6 mttm -92.36 117.66 30.14 Favored 'General case' 0 N--CA 1.48 1.053 0 N-CA-C 109.988 -0.375 . . . . 0.0 109.988 -179.233 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.32 -134.2 0.01 OUTLIER Glycine 0 CA--C 1.533 1.16 0 N-CA-C 110.784 -0.926 . . . . 0.0 110.784 179.02 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -115.7 127.12 54.91 Favored 'General case' 0 N--CA 1.48 1.067 0 N-CA-C 109.314 -0.625 . . . . 0.0 109.314 179.203 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 66.2 mt -90.57 134.9 28.0 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.574 0 N-CA-C 107.666 -1.235 . . . . 0.0 107.666 178.845 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 30.4 mt -136.51 138.37 46.7 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.77 0 CA-C-N 115.937 -0.574 . . . . 0.0 109.545 -179.099 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.72 57.55 15.76 Favored Glycine 0 CA--C 1.528 0.887 0 CA-C-N 115.866 -0.606 . . . . 0.0 112.791 178.663 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 25.6 tp -106.13 132.75 51.83 Favored 'General case' 0 N--CA 1.486 1.353 0 N-CA-C 107.471 -1.307 . . . . 0.0 107.471 177.832 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 25.1 ttt -138.09 147.96 44.54 Favored 'General case' 0 N--CA 1.47 0.568 0 N-CA-C 107.591 -1.262 . . . . 0.0 107.591 179.315 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 60.6 t -156.81 160.05 2.4 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.546 0 N-CA-C 106.076 -1.824 . . . . 0.0 106.076 -178.959 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 37' ' ' GLY . . . . . 0.46 ' O ' ' NE2' ' F' ' 15' ' ' GLN . . . 54.1 74.12 0.34 Allowed Glycine 0 C--N 1.309 -0.925 0 C-N-CA 121.116 -0.564 . . . . 0.0 111.788 177.848 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' C' C ' 38' ' ' GLY . . . . . 0.709 ' H ' HE22 ' C' ' 15' ' ' GLN . . . 164.9 -168.36 39.07 Favored Glycine 0 N--CA 1.466 0.65 0 N-CA-C 111.104 -0.799 . . . . 0.0 111.104 179.349 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 24.2 m -126.71 148.88 31.43 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.858 0 C-N-CA 122.934 0.494 . . . . 0.0 109.935 179.716 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 9.8 t . . . . . 0 CA--C 1.534 0.364 0 CA-C-O 118.187 -0.911 . . . . 0.0 110.7 178.884 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' D' D ' 1' ' ' ASP . . . . . . . . . . . . . 9.5 m-20 . . . . . 0 N--CA 1.492 1.633 0 N-CA-C 108.994 -0.743 . . . . 0.0 108.994 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' D' D ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.18 130.94 45.16 Favored 'General case' 0 N--CA 1.468 0.449 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.289 -179.9 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' D' D ' 3' ' ' GLU . . . . . . . . . . . . . 38.8 tt0 -136.81 108.62 7.06 Favored 'General case' 0 C--O 1.212 -0.886 0 C-N-CA 123.14 0.576 . . . . 0.0 109.492 179.463 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 28.7 m-85 -77.57 165.4 24.36 Favored 'General case' 0 C--N 1.306 -1.294 0 C-N-CA 125.804 1.642 . . . . 0.0 107.949 179.843 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' D' D ' 5' ' ' ARG . . . . . 0.641 HH22 ' CG1' ' C' ' 24' ' ' VAL 0.273 47.8 mtp180 -77.55 143.45 38.37 Favored 'General case' 0 C--O 1.207 -1.15 0 C-N-CA 123.595 0.758 . . . . 0.0 109.044 -169.708 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 40.5 m80 -107.79 124.44 50.05 Favored 'General case' 0 C--N 1.366 1.301 0 N-CA-C 106.87 -1.53 . . . . 0.0 106.87 -176.282 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' D' D ' 7' ' ' ASP . . . . . . . . . . . . . 7.9 m-20 -64.28 131.92 48.73 Favored 'General case' 0 CA--C 1.512 -0.485 0 CA-C-N 113.897 -1.501 . . . . 0.0 114.077 179.004 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' D' D ' 8' ' ' SER . . . . . . . . . . . . . 40.9 t -152.62 -167.8 2.86 Favored 'General case' 0 N--CA 1.482 1.152 0 C-N-CA 120.908 -0.317 . . . . 0.0 110.17 177.028 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 120.71 30.23 1.41 Allowed Glycine 0 N--CA 1.486 1.967 0 N-CA-C 111.35 -0.7 . . . . 0.0 111.35 177.862 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 44.9 p90 -54.46 131.13 41.87 Favored 'General case' 0 CA--C 1.545 0.785 0 CA-C-N 117.085 0.442 . . . . 0.0 111.591 -179.557 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' D' D ' 11' ' ' GLU . . . . . 0.411 ' CG ' HD22 ' F' ' 27' ' ' ASN . 60.3 mt-10 -89.7 151.2 21.98 Favored 'General case' 0 N--CA 1.475 0.808 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 177.324 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -149.66 129.07 3.53 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.529 0 N-CA-C 107.339 -1.356 . . . . 0.0 107.339 172.59 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 36.0 m-70 -130.29 162.59 28.67 Favored 'General case' 0 N--CA 1.48 1.054 0 C-N-CA 123.678 0.791 . . . . 0.0 112.902 178.205 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 41.5 t60 -153.96 104.31 2.65 Favored 'General case' 0 N--CA 1.486 1.35 0 N-CA-C 108.418 -0.956 . . . . 0.0 108.418 171.54 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' D' D ' 15' ' ' GLN . . . . . 0.639 HE22 ' H ' ' D' ' 38' ' ' GLY . 28.1 mt-30 -93.84 116.03 28.46 Favored 'General case' 0 CA--C 1.505 -0.762 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.325 -179.625 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -108.37 111.82 23.93 Favored 'General case' 0 C--N 1.359 0.99 0 N-CA-C 106.059 -1.83 . . . . 0.0 106.059 174.383 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 52.7 tp -134.32 150.73 50.98 Favored 'General case' 0 N--CA 1.484 1.238 0 N-CA-C 108.973 -0.751 . . . . 0.0 108.973 176.074 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 71.0 t -142.39 126.05 15.1 Favored 'Isoleucine or valine' 0 C--O 1.242 0.674 0 N-CA-C 109.141 -0.689 . . . . 0.0 109.141 173.863 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 26.8 m-85 -62.12 151.54 35.42 Favored 'General case' 0 N--CA 1.473 0.699 0 C-N-CA 124.284 1.034 . . . . 0.0 110.325 169.712 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 14.0 t80 -170.13 -66.86 0.02 OUTLIER 'General case' 0 C--N 1.318 -0.766 0 N-CA-C 107.765 -1.198 . . . . 0.0 107.765 -179.703 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -38.17 95.54 0.01 OUTLIER 'General case' 0 N--CA 1.449 -0.502 0 CA-C-N 114.207 -1.361 . . . . 0.0 111.798 -175.017 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 39.2 tt0 -67.51 161.12 26.19 Favored 'General case' 0 N--CA 1.468 0.458 0 CA-C-N 113.628 -1.624 . . . . 0.0 110.139 178.805 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 9.9 m-20 -137.22 126.52 24.79 Favored 'General case' 0 N--CA 1.479 1.019 0 C-N-CA 123.472 0.709 . . . . 0.0 109.942 -179.068 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' D' D ' 24' ' ' VAL . . . . . 0.666 ' CG1' HH22 ' H' ' 5' ' ' ARG . 92.3 t -81.13 -165.64 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.482 1.169 0 N-CA-C 107.566 -1.272 . . . . 0.0 107.566 -178.098 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' D' D ' 25' ' ' GLY . . . . . 0.588 ' H ' ' CG1' ' D' ' 24' ' ' VAL . . . -79.27 56.62 4.4 Favored Glycine 0 C--N 1.362 1.997 0 C-N-CA 117.855 -2.117 . . . . 0.0 110.628 -174.263 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 21.8 p -61.34 132.83 54.82 Favored 'General case' 0 C--N 1.346 0.426 0 CA-C-N 113.545 -1.328 . . . . 0.0 111.965 170.648 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' D' D ' 27' ' ' ASN . . . . . 0.427 HD22 ' CG ' ' E' ' 11' ' ' GLU . 40.6 t30 -65.53 95.06 0.2 Allowed 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 119.908 1.231 . . . . 0.0 108.751 172.971 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 68.3 mttm -93.89 120.97 34.87 Favored 'General case' 0 N--CA 1.484 1.26 0 C-N-CA 119.521 -0.871 . . . . 0.0 108.908 179.756 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -57.45 -135.01 0.01 OUTLIER Glycine 0 C--N 1.341 0.806 0 CA-C-N 115.858 -0.61 . . . . 0.0 113.067 175.974 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -114.22 131.76 56.36 Favored 'General case' 0 C--N 1.367 1.357 0 N-CA-C 109.101 -0.703 . . . . 0.0 109.101 174.572 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 68.6 mt -91.79 138.43 19.82 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.298 0 N-CA-C 107.182 -1.414 . . . . 0.0 107.182 176.845 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 35.2 mt -138.7 140.85 38.4 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.879 0 N-CA-C 108.639 -0.875 . . . . 0.0 108.639 178.518 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.54 55.04 27.62 Favored Glycine 0 CA--C 1.529 0.911 0 CA-C-O 119.381 -0.677 . . . . 0.0 112.588 178.313 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 19.2 tp -102.84 141.59 35.39 Favored 'General case' 0 C--N 1.364 1.207 0 N-CA-C 106.333 -1.728 . . . . 0.0 106.333 176.536 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 23.9 ttt -142.07 156.95 45.42 Favored 'General case' 0 N--CA 1.472 0.664 0 N-CA-C 105.952 -1.87 . . . . 0.0 105.952 175.085 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 73.7 t -164.34 161.89 0.93 Allowed 'Isoleucine or valine' 0 CA--C 1.503 -0.835 0 N-CA-C 105.349 -2.093 . . . . 0.0 105.349 179.19 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' D' D ' 37' ' ' GLY . . . . . 0.457 ' O ' ' NE2' ' G' ' 15' ' ' GLN . . . 60.21 64.44 4.15 Favored Glycine 0 N--CA 1.441 -1.004 0 C-N-CA 118.38 -1.867 . . . . 0.0 112.453 176.301 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' D' D ' 38' ' ' GLY . . . . . 0.639 ' H ' HE22 ' D' ' 15' ' ' GLN . . . 166.46 -163.86 37.23 Favored Glycine 0 C--O 1.215 -1.051 0 CA-C-N 119.308 1.554 . . . . 0.0 112.264 176.493 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 29.4 m -121.64 147.45 25.61 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.067 0 CA-C-O 118.041 -0.981 . . . . 0.0 112.259 179.35 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 7.5 t . . . . . 0 C--O 1.213 -0.864 0 N-CA-C 108.798 -0.815 . . . . 0.0 108.798 171.652 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' E' E ' 1' ' ' ASP . . . . . . . . . . . . . 9.5 m-20 . . . . . 0 N--CA 1.491 1.585 0 N-CA-C 108.965 -0.754 . . . . 0.0 108.965 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' E' E ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.65 132.01 48.53 Favored 'General case' 0 N--CA 1.467 0.407 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.21 179.693 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' E' E ' 3' ' ' GLU . . . . . . . . . . . . . 38.8 tt0 -139.08 103.12 4.69 Favored 'General case' 0 N--CA 1.48 1.059 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 -179.794 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 24.8 m-85 -70.29 169.23 14.21 Favored 'General case' 0 N--CA 1.471 0.579 0 N-CA-C 109.445 -0.576 . . . . 0.0 109.445 179.354 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' E' E ' 5' ' ' ARG . . . . . 0.634 HH22 ' CG1' ' A' ' 24' ' ' VAL . 34.9 mtp180 -68.13 148.15 51.31 Favored 'General case' 0 C--O 1.202 -1.419 0 CA-C-N 115.567 -0.742 . . . . 0.0 111.313 -178.012 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 39.2 m80 -109.9 118.97 37.89 Favored 'General case' 0 N--CA 1.483 1.181 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 177.889 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' E' E ' 7' ' ' ASP . . . . . . . . . . . . . 13.0 m-20 -66.31 140.28 58.1 Favored 'General case' 0 N--CA 1.466 0.37 0 CA-C-O 120.91 0.386 . . . . 0.0 112.02 -178.442 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' E' E ' 8' ' ' SER . . . . . . . . . . . . . 38.2 t -158.7 -169.87 2.86 Favored 'General case' 0 N--CA 1.487 1.378 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.194 178.924 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 120.33 32.84 1.09 Allowed Glycine 0 N--CA 1.484 1.867 0 N-CA-C 111.717 -0.553 . . . . 0.0 111.717 179.538 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 43.3 p90 -56.84 130.54 46.19 Favored 'General case' 0 CA--C 1.546 0.796 0 CA-C-N 116.948 0.374 . . . . 0.0 111.64 -179.963 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' E' E ' 11' ' ' GLU . . . . . 0.427 ' CG ' HD22 ' D' ' 27' ' ' ASN . 60.2 mt-10 -89.98 153.49 20.55 Favored 'General case' 0 N--CA 1.478 0.945 0 N-CA-C 109.404 -0.591 . . . . 0.0 109.404 178.606 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.8 p -155.15 124.78 0.74 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.575 0 N-CA-C 108.183 -1.043 . . . . 0.0 108.183 177.872 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 43.9 m-70 -136.04 160.95 37.07 Favored 'General case' 0 N--CA 1.481 1.113 0 CA-C-O 120.746 0.308 . . . . 0.0 111.115 -177.515 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 38.8 t60 -152.96 96.75 2.13 Favored 'General case' 0 N--CA 1.488 1.475 0 C-N-CA 122.687 0.395 . . . . 0.0 109.951 179.241 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' E' E ' 15' ' ' GLN . . . . . 0.606 HE22 ' H ' ' E' ' 38' ' ' GLY . 28.2 mt-30 -90.75 122.25 33.33 Favored 'General case' 0 C--N 1.329 -0.297 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 -179.064 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -113.78 103.5 11.27 Favored 'General case' 0 N--CA 1.474 0.726 0 N-CA-C 107.69 -1.226 . . . . 0.0 107.69 176.638 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 53.9 tp -132.19 149.1 52.47 Favored 'General case' 0 N--CA 1.486 1.343 0 C-N-CA 123.368 0.667 . . . . 0.0 109.269 -178.844 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 57.7 t -145.25 123.59 5.23 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.837 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 179.154 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 11.2 m-85 -71.4 156.35 39.58 Favored 'General case' 0 C--N 1.363 1.155 0 N-CA-C 106.911 -1.515 . . . . 0.0 106.911 176.937 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 17.8 t80 -172.13 -55.94 0.02 OUTLIER 'General case' 0 N--CA 1.481 1.084 0 CA-C-O 121.83 0.824 . . . . 0.0 110.238 179.733 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.99 88.26 0.0 OUTLIER 'General case' 0 C--N 1.319 -0.759 0 CA-C-N 114.107 -1.406 . . . . 0.0 112.87 -178.986 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 39.0 tt0 -63.26 159.72 17.24 Favored 'General case' 0 N--CA 1.471 0.625 0 CA-C-N 114.855 -1.066 . . . . 0.0 110.842 179.831 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 9.6 m-20 -136.56 125.52 24.29 Favored 'General case' 0 N--CA 1.482 1.162 0 C-N-CA 123.3 0.64 . . . . 0.0 110.23 -179.67 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' E' E ' 24' ' ' VAL . . . . . 0.659 ' CG1' HH22 ' I' ' 5' ' ' ARG . 58.5 t -76.08 -170.35 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.484 1.252 0 N-CA-C 108.029 -1.1 . . . . 0.0 108.029 179.436 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' E' E ' 25' ' ' GLY . . . . . 0.61 ' H ' ' CG1' ' E' ' 24' ' ' VAL . . . -68.89 49.65 0.5 Allowed Glycine 0 CA--C 1.531 1.031 0 CA-C-N 118.079 0.4 . . . . 0.0 112.626 -178.132 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 8.1 p -69.16 136.79 52.65 Favored 'General case' 0 C--O 1.219 -0.514 0 N-CA-C 109.705 -0.48 . . . . 0.0 109.705 178.494 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' E' E ' 27' ' ' ASN . . . . . 0.424 HD22 ' CG ' ' F' ' 11' ' ' GLU . 36.2 t30 -68.3 95.5 0.6 Allowed 'General case' 0 N--CA 1.466 0.328 0 N-CA-C 107.481 -1.303 . . . . 0.0 107.481 177.388 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 68.1 mttm -93.33 117.09 29.66 Favored 'General case' 0 N--CA 1.482 1.136 0 N-CA-C 109.612 -0.514 . . . . 0.0 109.612 -178.858 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.16 -133.98 0.01 OUTLIER Glycine 0 CA--C 1.536 1.392 0 N-CA-C 111.308 -0.717 . . . . 0.0 111.308 178.877 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -115.66 126.42 54.13 Favored 'General case' 0 N--CA 1.481 1.081 0 N-CA-C 109.637 -0.505 . . . . 0.0 109.637 179.225 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 66.8 mt -89.35 135.02 27.02 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.213 0 N-CA-C 107.571 -1.27 . . . . 0.0 107.571 178.914 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 33.1 mt -136.21 137.83 47.85 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.867 0 N-CA-C 108.991 -0.744 . . . . 0.0 108.991 -179.768 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.37 59.68 8.54 Favored Glycine 0 CA--C 1.527 0.82 0 CA-C-N 116.047 -0.524 . . . . 0.0 112.947 178.835 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 22.0 tp -107.49 131.81 53.91 Favored 'General case' 0 N--CA 1.487 1.41 0 N-CA-C 107.454 -1.313 . . . . 0.0 107.454 177.741 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 23.6 ttt -137.26 147.82 45.99 Favored 'General case' 0 N--CA 1.472 0.66 0 N-CA-C 107.815 -1.18 . . . . 0.0 107.815 178.709 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 59.8 t -156.7 159.94 2.47 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.693 0 N-CA-C 106.457 -1.683 . . . . 0.0 106.457 -178.899 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' E' E ' 37' ' ' GLY . . . . . 0.425 ' O ' ' NE2' ' H' ' 15' ' ' GLN . . . 54.12 73.4 0.41 Allowed Glycine 0 C--N 1.31 -0.904 0 N-CA-C 111.801 -0.52 . . . . 0.0 111.801 177.787 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' E' E ' 38' ' ' GLY . . . . . 0.606 ' H ' HE22 ' E' ' 15' ' ' GLN . . . 165.83 -166.63 38.71 Favored Glycine 0 C--O 1.21 -1.395 0 N-CA-C 111.278 -0.729 . . . . 0.0 111.278 179.256 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 21.6 m -128.34 148.88 32.8 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.827 0 C-N-CA 122.833 0.453 . . . . 0.0 109.91 179.913 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 7.5 t . . . . . 0 CA--C 1.541 0.598 0 CA-C-O 118.202 -0.904 . . . . 0.0 110.473 178.85 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' F' F ' 1' ' ' ASP . . . . . . . . . . . . . 9.6 m-20 . . . . . 0 N--CA 1.492 1.633 0 N-CA-C 108.88 -0.785 . . . . 0.0 108.88 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' F' F ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.71 132.11 48.75 Favored 'General case' 0 N--CA 1.468 0.449 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.191 179.692 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' F' F ' 3' ' ' GLU . . . . . . . . . . . . . 38.7 tt0 -139.16 103.08 4.67 Favored 'General case' 0 N--CA 1.482 1.157 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 -179.833 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 25.7 m-85 -70.2 169.52 13.48 Favored 'General case' 0 N--CA 1.472 0.645 0 N-CA-C 109.572 -0.529 . . . . 0.0 109.572 179.393 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' F' F ' 5' ' ' ARG . . . . . 0.638 HH22 ' CG1' ' B' ' 24' ' ' VAL . 35.5 mtp180 -68.08 147.4 52.4 Favored 'General case' 0 C--O 1.201 -1.476 0 CA-C-N 115.499 -0.773 . . . . 0.0 111.468 -178.017 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 39.2 m80 -109.47 118.89 37.82 Favored 'General case' 0 N--CA 1.484 1.266 0 N-CA-C 109.094 -0.706 . . . . 0.0 109.094 177.815 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' F' F ' 7' ' ' ASP . . . . . . . . . . . . . 13.0 m-20 -66.32 140.27 58.09 Favored 'General case' 0 N--CA 1.466 0.341 0 N-CA-C 112.159 0.429 . . . . 0.0 112.159 -178.453 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' F' F ' 8' ' ' SER . . . . . . . . . . . . . 38.3 t -158.73 -169.81 2.84 Favored 'General case' 0 N--CA 1.486 1.365 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.18 178.9 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 120.33 32.84 1.09 Allowed Glycine 0 N--CA 1.483 1.808 0 N-CA-C 111.679 -0.568 . . . . 0.0 111.679 179.559 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 43.3 p90 -57.02 130.73 47.35 Favored 'General case' 0 CA--C 1.545 0.763 0 CA-C-N 116.945 0.372 . . . . 0.0 111.614 -179.952 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' F' F ' 11' ' ' GLU . . . . . 0.424 ' CG ' HD22 ' E' ' 27' ' ' ASN . 60.3 mt-10 -90.04 153.53 20.5 Favored 'General case' 0 N--CA 1.478 0.959 0 CA-C-O 121.306 0.574 . . . . 0.0 109.457 178.513 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.8 p -155.22 124.78 0.74 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.532 0 N-CA-C 108.071 -1.085 . . . . 0.0 108.071 177.942 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 44.4 m-70 -136.03 160.83 37.42 Favored 'General case' 0 N--CA 1.48 1.062 0 CA-C-O 120.668 0.271 . . . . 0.0 111.142 -177.645 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 39.0 t60 -152.93 97.13 2.17 Favored 'General case' 0 N--CA 1.487 1.406 0 C-N-CA 122.75 0.42 . . . . 0.0 110.06 179.278 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' F' F ' 15' ' ' GLN . . . . . 0.624 HE22 ' H ' ' F' ' 38' ' ' GLY . 28.2 mt-30 -91.21 122.87 34.21 Favored 'General case' 0 CA--C 1.513 -0.474 0 N-CA-C 110.174 -0.306 . . . . 0.0 110.174 -179.141 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -114.23 103.48 11.14 Favored 'General case' 0 N--CA 1.471 0.608 0 N-CA-C 107.808 -1.182 . . . . 0.0 107.808 176.694 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 54.2 tp -132.17 149.13 52.46 Favored 'General case' 0 N--CA 1.486 1.355 0 C-N-CA 123.388 0.675 . . . . 0.0 109.307 -179.041 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 58.7 t -145.24 123.69 5.32 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.805 0 N-CA-C 109.37 -0.604 . . . . 0.0 109.37 179.205 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 11.2 m-85 -71.5 156.14 39.77 Favored 'General case' 0 C--N 1.363 1.195 0 N-CA-C 106.795 -1.557 . . . . 0.0 106.795 176.92 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 18.5 t80 -171.87 -55.96 0.02 OUTLIER 'General case' 0 N--CA 1.481 1.105 0 CA-C-O 121.784 0.802 . . . . 0.0 109.873 179.799 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.02 88.24 0.0 OUTLIER 'General case' 0 C--N 1.319 -0.725 0 CA-C-N 114.235 -1.348 . . . . 0.0 112.968 -178.968 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 38.9 tt0 -63.22 159.91 16.74 Favored 'General case' 0 N--CA 1.472 0.638 0 CA-C-N 114.857 -1.065 . . . . 0.0 110.856 179.756 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 9.7 m-20 -136.82 125.77 24.27 Favored 'General case' 0 N--CA 1.481 1.122 0 C-N-CA 123.271 0.628 . . . . 0.0 110.252 -179.735 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' F' F ' 24' ' ' VAL . . . . . 0.678 ' CG1' HH22 ' G' ' 5' ' ' ARG . 59.1 t -76.28 -170.1 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.484 1.267 0 N-CA-C 108.168 -1.049 . . . . 0.0 108.168 179.485 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' F' F ' 25' ' ' GLY . . . . . 0.597 ' H ' ' CG1' ' F' ' 24' ' ' VAL . . . -68.85 49.4 0.49 Allowed Glycine 0 CA--C 1.528 0.847 0 CA-C-N 118.264 0.484 . . . . 0.0 112.491 -178.305 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 8.1 p -68.96 136.66 52.85 Favored 'General case' 0 C--O 1.219 -0.535 0 N-CA-C 109.536 -0.542 . . . . 0.0 109.536 178.378 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' F' F ' 27' ' ' ASN . . . . . 0.411 HD22 ' CG ' ' D' ' 11' ' ' GLU . 35.4 t30 -68.38 95.73 0.63 Allowed 'General case' 0 CA--C 1.535 0.371 0 N-CA-C 107.35 -1.352 . . . . 0.0 107.35 177.464 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 68.1 mttm -93.41 116.96 29.5 Favored 'General case' 0 N--CA 1.48 1.073 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -178.931 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.13 -134.15 0.01 OUTLIER Glycine 0 CA--C 1.537 1.444 0 N-CA-C 111.383 -0.687 . . . . 0.0 111.383 178.997 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -115.19 125.99 54.05 Favored 'General case' 0 N--CA 1.485 1.277 0 C-N-CA 123.064 0.546 . . . . 0.0 109.615 179.212 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 66.9 mt -89.3 134.88 27.37 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.236 0 N-CA-C 107.457 -1.312 . . . . 0.0 107.457 178.816 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 32.9 mt -136.25 137.87 47.73 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.805 0 N-CA-C 108.984 -0.747 . . . . 0.0 108.984 -179.723 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.24 59.81 8.44 Favored Glycine 0 CA--C 1.525 0.663 0 CA-C-N 116.01 -0.541 . . . . 0.0 112.884 178.878 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 21.8 tp -107.78 132.04 53.81 Favored 'General case' 0 N--CA 1.487 1.376 0 N-CA-C 107.585 -1.265 . . . . 0.0 107.585 177.668 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 23.4 ttt -137.53 147.99 45.61 Favored 'General case' 0 N--CA 1.468 0.434 0 N-CA-C 108.324 -0.991 . . . . 0.0 108.324 178.733 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 60.8 t -156.63 160.03 2.44 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.772 0 N-CA-C 106.579 -1.637 . . . . 0.0 106.579 -178.741 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' F' F ' 37' ' ' GLY . . . . . 0.42 ' O ' ' NE2' ' I' ' 15' ' ' GLN . . . 54.05 73.37 0.42 Allowed Glycine 0 C--N 1.309 -0.964 0 CA-C-N 116.075 -0.512 . . . . 0.0 111.937 177.709 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' F' F ' 38' ' ' GLY . . . . . 0.624 ' H ' HE22 ' F' ' 15' ' ' GLN . . . 165.83 -166.58 38.68 Favored Glycine 0 C--O 1.209 -1.459 0 N-CA-C 111.264 -0.735 . . . . 0.0 111.264 179.315 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 21.1 m -128.46 148.76 32.9 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.811 0 C-N-CA 122.729 0.412 . . . . 0.0 109.906 179.935 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 6.8 t . . . . . 0 CA--C 1.54 0.565 0 CA-C-O 118.207 -0.901 . . . . 0.0 110.423 178.911 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' G' G ' 1' ' ' ASP . . . . . . . . . . . . . 9.3 m-20 . . . . . 0 N--CA 1.487 1.404 0 N-CA-C 108.763 -0.829 . . . . 0.0 108.763 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' G' G ' 2' ' ' ALA . . . . . . . . . . . . . . . -66.63 133.82 51.06 Favored 'General case' 0 CA--C 1.538 0.486 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 -179.776 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' G' G ' 3' ' ' GLU . . . . . . . . . . . . . 38.9 tt0 -139.01 104.93 5.16 Favored 'General case' 0 N--CA 1.477 0.911 0 C-N-CA 123.097 0.559 . . . . 0.0 109.815 -178.969 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 35.4 m-85 -71.12 169.15 15.65 Favored 'General case' 0 N--CA 1.469 0.499 0 CA-C-O 121.173 0.511 . . . . 0.0 109.833 179.367 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' G' G ' 5' ' ' ARG . . . . . 0.678 HH22 ' CG1' ' F' ' 24' ' ' VAL . 33.8 mtp180 -68.69 144.92 54.28 Favored 'General case' 0 N--CA 1.469 0.524 0 CA-C-N 115.415 -0.811 . . . . 0.0 111.146 -178.325 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 38.6 m80 -107.98 118.78 37.64 Favored 'General case' 0 N--CA 1.478 0.961 0 N-CA-C 109.226 -0.657 . . . . 0.0 109.226 178.095 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 10.5 m-20 -66.84 139.47 57.77 Favored 'General case' 0 N--CA 1.469 0.49 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.948 -179.061 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' G' G ' 8' ' ' SER . . . . . . . . . . . . . 37.8 t -158.09 -170.23 3.07 Favored 'General case' 0 N--CA 1.471 0.603 0 N-CA-C 109.666 -0.494 . . . . 0.0 109.666 179.024 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 120.37 31.97 1.2 Allowed Glycine 0 N--CA 1.484 1.869 0 N-CA-C 111.539 -0.624 . . . . 0.0 111.539 179.497 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 47.1 p90 -57.11 130.71 47.32 Favored 'General case' 0 N--CA 1.472 0.629 0 CA-C-N 116.825 0.313 . . . . 0.0 111.716 -179.822 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 60.4 mt-10 -90.34 152.58 20.96 Favored 'General case' 0 N--CA 1.474 0.758 0 CA-C-O 121.138 0.494 . . . . 0.0 109.807 179.082 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 3.5 p -155.47 124.83 0.72 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.058 0 N-CA-C 108.175 -1.046 . . . . 0.0 108.175 178.19 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 43.6 m-70 -135.86 160.73 37.68 Favored 'General case' 0 N--CA 1.475 0.781 0 CA-C-N 114.722 -1.126 . . . . 0.0 110.973 -177.619 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 39.6 t60 -153.39 96.93 2.09 Favored 'General case' 0 N--CA 1.484 1.231 0 CA-C-N 115.858 -0.61 . . . . 0.0 109.659 178.855 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' G' G ' 15' ' ' GLN . . . . . 0.64 HE22 ' H ' ' G' ' 38' ' ' GLY . 28.5 mt-30 -90.75 121.52 32.71 Favored 'General case' 0 N--CA 1.451 -0.406 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 -178.896 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -113.03 103.77 11.71 Favored 'General case' 0 N--CA 1.476 0.831 0 N-CA-C 107.694 -1.224 . . . . 0.0 107.694 176.65 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 56.6 tp -132.17 147.33 52.42 Favored 'General case' 0 N--CA 1.486 1.343 0 C-N-CA 123.336 0.654 . . . . 0.0 109.56 -179.288 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 61.3 t -144.99 123.3 5.31 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.861 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 178.664 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 9.6 m-85 -70.39 150.37 46.33 Favored 'General case' 0 C--N 1.376 1.728 0 N-CA-C 106.91 -1.515 . . . . 0.0 106.91 176.699 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 15.6 t80 -169.94 -55.4 0.02 OUTLIER 'General case' 0 N--CA 1.483 1.22 0 N-CA-C 110.248 -0.278 . . . . 0.0 110.248 -179.729 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.0 90.02 0.0 OUTLIER 'General case' 0 C--N 1.323 -0.545 0 C-N-CA 123.72 0.808 . . . . 0.0 112.471 -179.964 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 39.3 tt0 -64.4 160.76 18.36 Favored 'General case' 0 N--CA 1.468 0.467 0 CA-C-N 114.834 -1.076 . . . . 0.0 110.023 179.273 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 9.6 m-20 -137.26 125.38 22.99 Favored 'General case' 0 N--CA 1.48 1.072 0 C-N-CA 123.154 0.582 . . . . 0.0 109.721 -179.701 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' G' G ' 24' ' ' VAL . . . . . 0.577 ' CG1' ' H ' ' G' ' 25' ' ' GLY . 61.9 t -76.75 -169.97 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.827 0 N-CA-C 108.156 -1.053 . . . . 0.0 108.156 179.608 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' G' G ' 25' ' ' GLY . . . . . 0.577 ' H ' ' CG1' ' G' ' 24' ' ' VAL . . . -68.89 49.98 0.5 Allowed Glycine 0 CA--C 1.53 0.973 0 CA-C-N 118.48 0.582 . . . . 0.0 112.726 -178.467 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 8.4 p -69.51 137.63 52.67 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 109.157 -0.682 . . . . 0.0 109.157 177.748 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 34.2 t30 -69.49 94.72 0.77 Allowed 'General case' 0 CA--C 1.532 0.265 0 N-CA-C 107.618 -1.253 . . . . 0.0 107.618 177.562 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -91.63 117.81 30.07 Favored 'General case' 0 N--CA 1.478 0.953 0 N-CA-C 109.713 -0.477 . . . . 0.0 109.713 -179.396 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -62.37 -133.3 0.01 OUTLIER Glycine 0 CA--C 1.532 1.099 0 N-CA-C 110.547 -1.021 . . . . 0.0 110.547 178.927 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -115.19 126.83 55.05 Favored 'General case' 0 N--CA 1.475 0.808 0 N-CA-C 109.615 -0.513 . . . . 0.0 109.615 179.186 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 69.6 mt -89.64 136.14 24.41 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.671 0 N-CA-C 107.598 -1.26 . . . . 0.0 107.598 178.743 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 38.2 mt -137.46 139.18 43.98 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.249 0 CA-C-N 118.782 0.719 . . . . 0.0 109.158 179.721 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.1 57.98 13.56 Favored Glycine 0 CA--C 1.53 0.977 0 CA-C-N 116.11 -0.496 . . . . 0.0 112.624 178.99 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 23.1 tp -105.81 132.23 52.18 Favored 'General case' 0 N--CA 1.484 1.256 0 N-CA-C 107.6 -1.259 . . . . 0.0 107.6 177.775 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 22.1 ttt -137.63 147.97 45.4 Favored 'General case' 0 N--CA 1.474 0.727 0 N-CA-C 108.211 -1.033 . . . . 0.0 108.211 178.788 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 61.2 t -156.77 158.4 3.24 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 106.613 -1.625 . . . . 0.0 106.613 -179.095 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.57 71.74 0.68 Allowed Glycine 0 C--N 1.308 -0.973 0 CA-C-N 115.951 -0.568 . . . . 0.0 112.384 177.549 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' G' G ' 38' ' ' GLY . . . . . 0.64 ' H ' HE22 ' G' ' 15' ' ' GLN . . . 167.75 -165.22 38.55 Favored Glycine 0 C--O 1.212 -1.268 0 N-CA-C 110.747 -0.941 . . . . 0.0 110.747 178.631 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 18.7 m -128.64 148.14 33.07 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.93 0 C-N-CA 122.789 0.435 . . . . 0.0 109.93 179.911 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 8.6 t . . . . . 0 CA--C 1.534 0.337 0 CA-C-O 118.156 -0.926 . . . . 0.0 110.888 178.815 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' H' H ' 1' ' ' ASP . . . . . . . . . . . . . 9.3 m-20 . . . . . 0 N--CA 1.488 1.43 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' H' H ' 2' ' ' ALA . . . . . . . . . . . . . . . -66.49 133.78 51.09 Favored 'General case' 0 CA--C 1.537 0.453 0 N-CA-C 109.886 -0.413 . . . . 0.0 109.886 -179.813 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' H' H ' 3' ' ' GLU . . . . . . . . . . . . . 38.9 tt0 -138.89 104.71 5.13 Favored 'General case' 0 N--CA 1.478 0.968 0 C-N-CA 123.064 0.546 . . . . 0.0 109.807 -178.855 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 35.0 m-85 -70.95 169.31 15.12 Favored 'General case' 0 N--CA 1.47 0.557 0 CA-C-O 121.234 0.54 . . . . 0.0 109.756 179.448 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' H' H ' 5' ' ' ARG . . . . . 0.666 HH22 ' CG1' ' D' ' 24' ' ' VAL . 33.8 mtp180 -69.04 145.12 53.78 Favored 'General case' 0 N--CA 1.466 0.373 0 CA-C-N 115.387 -0.824 . . . . 0.0 111.229 -178.312 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 38.5 m80 -108.05 118.77 37.63 Favored 'General case' 0 N--CA 1.478 0.958 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 178.265 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 10.5 m-20 -66.91 139.58 57.73 Favored 'General case' 0 N--CA 1.468 0.441 0 CA-C-N 116.275 -0.421 . . . . 0.0 111.889 -179.066 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' H' H ' 8' ' ' SER . . . . . . . . . . . . . 37.9 t -158.12 -170.08 3.01 Favored 'General case' 0 N--CA 1.471 0.595 0 N-CA-C 109.73 -0.47 . . . . 0.0 109.73 178.985 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 120.11 32.09 1.21 Allowed Glycine 0 N--CA 1.483 1.829 0 N-CA-C 111.641 -0.583 . . . . 0.0 111.641 179.549 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 46.9 p90 -57.17 130.79 47.72 Favored 'General case' 0 CA--C 1.542 0.64 0 CA-C-N 116.715 0.258 . . . . 0.0 111.607 -179.777 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 60.5 mt-10 -90.3 152.54 20.99 Favored 'General case' 0 N--CA 1.474 0.771 0 CA-C-O 121.116 0.484 . . . . 0.0 109.859 179.023 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 3.4 p -155.53 124.95 0.72 Allowed 'Isoleucine or valine' 0 CA--C 1.553 1.089 0 N-CA-C 108.161 -1.051 . . . . 0.0 108.161 178.074 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 43.6 m-70 -135.93 160.78 37.55 Favored 'General case' 0 C--N 1.353 0.751 0 CA-C-N 114.627 -1.169 . . . . 0.0 111.072 -177.527 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 39.3 t60 -153.51 96.86 2.07 Favored 'General case' 0 N--CA 1.484 1.268 0 CA-C-N 115.868 -0.606 . . . . 0.0 109.773 178.911 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' H' H ' 15' ' ' GLN . . . . . 0.635 HE22 ' H ' ' H' ' 38' ' ' GLY . 28.3 mt-30 -90.71 121.37 32.55 Favored 'General case' 0 CA--C 1.514 -0.406 0 N-CA-C 109.711 -0.477 . . . . 0.0 109.711 -178.946 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -112.84 103.66 11.65 Favored 'General case' 0 N--CA 1.474 0.726 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 176.672 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 56.3 tp -132.14 147.37 52.42 Favored 'General case' 0 N--CA 1.486 1.374 0 C-N-CA 123.273 0.629 . . . . 0.0 109.488 -179.196 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 61.4 t -144.93 123.21 5.36 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.89 0 N-CA-C 109.368 -0.604 . . . . 0.0 109.368 178.667 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 9.5 m-85 -70.67 150.96 45.45 Favored 'General case' 0 C--N 1.376 1.741 0 N-CA-C 106.951 -1.5 . . . . 0.0 106.951 176.658 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 16.6 t80 -171.19 -55.13 0.02 OUTLIER 'General case' 0 N--CA 1.48 1.061 0 N-CA-C 110.216 -0.291 . . . . 0.0 110.216 -179.696 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.05 89.92 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.472 0 O-C-N 123.971 0.795 . . . . 0.0 112.269 -179.96 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 39.4 tt0 -64.12 160.76 17.56 Favored 'General case' 0 N--CA 1.469 0.487 0 CA-C-N 114.777 -1.102 . . . . 0.0 110.063 179.482 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 9.7 m-20 -137.11 125.43 23.27 Favored 'General case' 0 N--CA 1.481 1.077 0 C-N-CA 123.098 0.559 . . . . 0.0 109.869 -179.791 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' H' H ' 24' ' ' VAL . . . . . 0.576 ' CG1' ' H ' ' H' ' 25' ' ' GLY . 57.4 t -76.69 -170.0 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.475 0.806 0 N-CA-C 108.408 -0.96 . . . . 0.0 108.408 179.612 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' H' H ' 25' ' ' GLY . . . . . 0.576 ' H ' ' CG1' ' H' ' 24' ' ' VAL . . . -68.64 49.56 0.46 Allowed Glycine 0 CA--C 1.53 1.009 0 CA-C-N 118.627 0.649 . . . . 0.0 112.43 -178.468 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 8.5 p -69.56 137.47 52.44 Favored 'General case' 0 C--N 1.33 -0.266 0 N-CA-C 109.152 -0.684 . . . . 0.0 109.152 177.823 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 34.7 t30 -69.57 94.82 0.8 Allowed 'General case' 0 N--CA 1.464 0.258 0 N-CA-C 107.638 -1.245 . . . . 0.0 107.638 177.635 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -91.76 117.88 30.17 Favored 'General case' 0 N--CA 1.477 0.91 0 N-CA-C 109.708 -0.479 . . . . 0.0 109.708 -179.408 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -62.48 -133.15 0.01 OUTLIER Glycine 0 CA--C 1.532 1.107 0 N-CA-C 110.582 -1.007 . . . . 0.0 110.582 178.977 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -115.25 126.89 55.07 Favored 'General case' 0 N--CA 1.474 0.745 0 C-N-CA 122.984 0.514 . . . . 0.0 109.634 179.192 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 69.6 mt -89.67 136.03 24.68 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.621 0 N-CA-C 107.535 -1.283 . . . . 0.0 107.535 178.707 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 37.7 mt -137.4 139.24 44.01 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.263 0 N-CA-C 109.142 -0.688 . . . . 0.0 109.142 179.611 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.23 58.1 12.92 Favored Glycine 0 CA--C 1.529 0.964 0 CA-C-N 116.067 -0.515 . . . . 0.0 112.593 178.967 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 23.5 tp -105.85 131.81 52.73 Favored 'General case' 0 N--CA 1.484 1.256 0 N-CA-C 107.688 -1.227 . . . . 0.0 107.688 177.893 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 22.0 ttt -137.16 147.36 45.89 Favored 'General case' 0 N--CA 1.475 0.808 0 N-CA-C 108.135 -1.061 . . . . 0.0 108.135 178.924 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 61.7 t -156.5 158.14 3.45 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.487 0 N-CA-C 106.634 -1.617 . . . . 0.0 106.634 -179.109 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.68 71.53 0.71 Allowed Glycine 0 C--N 1.308 -0.992 0 CA-C-N 115.901 -0.59 . . . . 0.0 112.352 177.526 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' H' H ' 38' ' ' GLY . . . . . 0.635 ' H ' HE22 ' H' ' 15' ' ' GLN . . . 167.75 -165.75 38.91 Favored Glycine 0 C--O 1.212 -1.277 0 N-CA-C 110.6 -1.0 . . . . 0.0 110.6 178.693 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 18.9 m -128.2 148.45 32.72 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.023 0 C-N-CA 122.777 0.431 . . . . 0.0 109.926 179.966 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 8.6 t . . . . . 0 CA--C 1.535 0.369 0 CA-C-O 118.196 -0.907 . . . . 0.0 110.811 178.764 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' I' I ' 1' ' ' ASP . . . . . . . . . . . . . 9.3 m-20 . . . . . 0 N--CA 1.487 1.414 0 N-CA-C 108.828 -0.804 . . . . 0.0 108.828 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' I' I ' 2' ' ' ALA . . . . . . . . . . . . . . . -66.56 133.91 51.29 Favored 'General case' 0 CA--C 1.538 0.499 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 -179.836 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' I' I ' 3' ' ' GLU . . . . . . . . . . . . . 38.9 tt0 -139.0 104.83 5.14 Favored 'General case' 0 N--CA 1.478 0.975 0 C-N-CA 123.062 0.545 . . . . 0.0 109.846 -178.909 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 34.6 m-85 -71.1 169.2 15.52 Favored 'General case' 0 N--CA 1.47 0.537 0 CA-C-O 121.136 0.493 . . . . 0.0 109.827 179.465 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' I' I ' 5' ' ' ARG . . . . . 0.659 HH22 ' CG1' ' E' ' 24' ' ' VAL . 32.8 mtp180 -68.94 144.87 54.04 Favored 'General case' 0 N--CA 1.468 0.475 0 CA-C-N 115.473 -0.785 . . . . 0.0 111.206 -178.343 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 38.6 m80 -107.88 118.59 37.13 Favored 'General case' 0 N--CA 1.477 0.925 0 N-CA-C 109.195 -0.669 . . . . 0.0 109.195 178.314 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 10.5 m-20 -66.77 139.61 57.81 Favored 'General case' 0 N--CA 1.469 0.485 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.916 -179.059 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' I' I ' 8' ' ' SER . . . . . . . . . . . . . 37.8 t -158.08 -170.15 3.05 Favored 'General case' 0 N--CA 1.47 0.557 0 N-CA-C 109.688 -0.486 . . . . 0.0 109.688 178.996 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 120.29 32.0 1.2 Allowed Glycine 0 N--CA 1.483 1.809 0 N-CA-C 111.584 -0.606 . . . . 0.0 111.584 179.413 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 47.1 p90 -57.12 130.75 47.52 Favored 'General case' 0 N--CA 1.473 0.705 0 O-C-N 122.671 -0.311 . . . . 0.0 111.665 -179.815 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 60.5 mt-10 -90.3 152.5 21.01 Favored 'General case' 0 N--CA 1.475 0.813 0 CA-C-O 121.152 0.501 . . . . 0.0 109.865 179.013 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 3.5 p -155.46 124.87 0.73 Allowed 'Isoleucine or valine' 0 CA--C 1.554 1.125 0 N-CA-C 108.194 -1.039 . . . . 0.0 108.194 178.103 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 44.1 m-70 -135.82 160.85 37.29 Favored 'General case' 0 C--N 1.354 0.761 0 CA-C-N 114.6 -1.182 . . . . 0.0 111.0 -177.556 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 39.6 t60 -153.6 97.05 2.08 Favored 'General case' 0 N--CA 1.484 1.262 0 CA-C-N 115.841 -0.618 . . . . 0.0 109.761 178.841 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' I' I ' 15' ' ' GLN . . . . . 0.659 HE22 ' H ' ' I' ' 38' ' ' GLY . 28.4 mt-30 -90.79 121.37 32.6 Favored 'General case' 0 CA--C 1.514 -0.416 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 -178.95 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -112.86 103.69 11.68 Favored 'General case' 0 N--CA 1.473 0.709 0 N-CA-C 107.677 -1.231 . . . . 0.0 107.677 176.6 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 56.5 tp -132.18 147.26 52.41 Favored 'General case' 0 N--CA 1.485 1.296 0 C-N-CA 123.329 0.652 . . . . 0.0 109.436 -179.153 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 61.7 t -144.88 123.12 5.4 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.9 0 N-CA-C 109.425 -0.583 . . . . 0.0 109.425 178.642 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 9.4 m-85 -70.66 150.89 45.53 Favored 'General case' 0 C--N 1.374 1.642 0 N-CA-C 106.853 -1.536 . . . . 0.0 106.853 176.701 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 16.7 t80 -171.14 -55.26 0.02 OUTLIER 'General case' 0 N--CA 1.48 1.073 0 N-CA-C 110.212 -0.292 . . . . 0.0 110.212 -179.561 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.07 90.01 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.45 0 O-C-N 123.998 0.811 . . . . 0.0 112.327 -179.986 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 39.4 tt0 -64.22 160.77 17.85 Favored 'General case' 0 N--CA 1.469 0.511 0 CA-C-N 114.743 -1.117 . . . . 0.0 110.011 179.557 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 9.6 m-20 -137.01 125.31 23.25 Favored 'General case' 0 N--CA 1.481 1.082 0 C-N-CA 123.259 0.624 . . . . 0.0 109.891 -179.771 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' I' I ' 24' ' ' VAL . . . . . 0.567 ' CG1' ' H ' ' I' ' 25' ' ' GLY . 57.3 t -76.58 -169.96 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.757 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 179.568 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' I' I ' 25' ' ' GLY . . . . . 0.567 ' H ' ' CG1' ' I' ' 24' ' ' VAL . . . -68.81 49.72 0.49 Allowed Glycine 0 CA--C 1.531 1.054 0 CA-C-N 118.541 0.61 . . . . 0.0 112.485 -178.457 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 8.5 p -69.63 137.67 52.42 Favored 'General case' 0 C--N 1.33 -0.254 0 N-CA-C 109.166 -0.679 . . . . 0.0 109.166 177.856 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 35.0 t30 -69.57 94.74 0.79 Allowed 'General case' 0 CA--C 1.531 0.234 0 N-CA-C 107.676 -1.231 . . . . 0.0 107.676 177.534 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -91.8 117.84 30.15 Favored 'General case' 0 N--CA 1.478 0.936 0 N-CA-C 109.722 -0.473 . . . . 0.0 109.722 -179.395 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -62.37 -133.19 0.01 OUTLIER Glycine 0 CA--C 1.532 1.14 0 N-CA-C 110.613 -0.995 . . . . 0.0 110.613 178.96 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -115.22 126.54 54.68 Favored 'General case' 0 N--CA 1.474 0.737 0 C-N-CA 123.031 0.532 . . . . 0.0 109.697 179.246 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 69.5 mt -89.46 135.94 24.81 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.657 0 N-CA-C 107.552 -1.277 . . . . 0.0 107.552 178.784 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 37.7 mt -137.44 139.21 43.98 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.28 0 N-CA-C 109.004 -0.739 . . . . 0.0 109.004 179.739 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.24 57.99 13.3 Favored Glycine 0 CA--C 1.529 0.959 0 CA-C-N 115.978 -0.555 . . . . 0.0 112.562 178.908 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 23.1 tp -105.71 131.95 52.44 Favored 'General case' 0 N--CA 1.485 1.298 0 N-CA-C 107.531 -1.285 . . . . 0.0 107.531 177.839 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 22.1 ttt -137.3 147.53 45.72 Favored 'General case' 0 N--CA 1.475 0.783 0 N-CA-C 107.997 -1.112 . . . . 0.0 107.997 178.877 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 61.3 t -156.66 158.2 3.38 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.466 0 N-CA-C 106.623 -1.621 . . . . 0.0 106.623 -179.094 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.63 71.57 0.7 Allowed Glycine 0 C--N 1.308 -1.011 0 CA-C-N 115.953 -0.567 . . . . 0.0 112.376 177.556 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' I' I ' 38' ' ' GLY . . . . . 0.659 ' H ' HE22 ' I' ' 15' ' ' GLN . . . 167.72 -165.68 38.85 Favored Glycine 0 C--O 1.211 -1.337 0 N-CA-C 110.603 -0.999 . . . . 0.0 110.603 178.697 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 18.9 m -128.26 148.4 32.77 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.003 0 C-N-CA 122.831 0.452 . . . . 0.0 109.949 179.965 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 8.9 t . . . . . 0 CA--C 1.535 0.387 0 CA-C-O 118.104 -0.95 . . . . 0.0 110.738 178.824 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 . . . . . 0 N--CA 1.49 1.537 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.55 132.44 48.89 Favored 'General case' 0 CA--C 1.54 0.58 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.215 -179.893 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 55.0 tt0 -169.45 108.16 0.42 Allowed 'General case' 0 N--CA 1.47 0.528 0 N-CA-C 109.621 -0.511 . . . . 0.0 109.621 -179.164 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 76.6 m-85 -83.51 141.22 31.8 Favored 'General case' 0 N--CA 1.474 0.74 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 179.516 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 72.4 mtp180 -144.29 141.82 30.04 Favored 'General case' 0 N--CA 1.483 1.207 0 N-CA-C 109.035 -0.728 . . . . 0.0 109.035 179.866 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 77.2 m80 -149.72 118.51 6.62 Favored 'General case' 0 N--CA 1.472 0.655 0 N-CA-C 108.763 -0.828 . . . . 0.0 108.763 179.037 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 12.2 m-20 -66.83 149.5 50.49 Favored 'General case' 0 CA--C 1.531 0.242 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.193 -179.395 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 7.9 t -167.53 170.08 11.52 Favored 'General case' 0 N--CA 1.473 0.682 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 178.613 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 123.47 24.44 1.95 Allowed Glycine 0 N--CA 1.487 2.051 0 N-CA-C 112.089 -0.405 . . . . 0.0 112.089 179.466 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 41.0 p90 -56.59 128.26 35.4 Favored 'General case' 0 N--CA 1.473 0.714 0 N-CA-C 112.136 0.421 . . . . 0.0 112.136 -179.868 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 46.1 mt-10 -84.61 154.49 22.54 Favored 'General case' 0 N--CA 1.468 0.465 0 N-CA-C 108.847 -0.797 . . . . 0.0 108.847 178.256 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -154.03 129.18 1.54 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 N-CA-C 108.091 -1.077 . . . . 0.0 108.091 178.855 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 51.5 m-70 -134.5 144.77 48.24 Favored 'General case' 0 N--CA 1.487 1.409 0 CA-C-N 118.567 0.621 . . . . 0.0 110.729 -178.951 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 6.2 t60 -164.5 98.38 0.8 Allowed 'General case' 0 N--CA 1.482 1.172 0 CA-C-N 116.744 -0.207 . . . . 0.0 111.204 179.581 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . 0.593 ' NE2' ' H ' ' A' ' 37' ' ' GLY . 75.8 mt-30 -103.03 -172.65 2.15 Favored 'General case' 0 CA--C 1.506 -0.745 0 N-CA-C 108.191 -1.04 . . . . 0.0 108.191 179.338 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -167.25 98.17 0.51 Allowed 'General case' 0 N--CA 1.47 0.531 0 CA-C-N 115.084 -0.962 . . . . 0.0 109.366 178.766 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . 0.401 ' N ' ' CD1' ' A' ' 17' ' ' LEU . 4.9 mp -106.69 162.44 13.76 Favored 'General case' 0 N--CA 1.485 1.303 0 N-CA-C 108.364 -0.976 . . . . 0.0 108.364 179.808 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 55.3 t -142.42 118.63 5.98 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.275 0 CA-C-O 118.804 -0.617 . . . . 0.0 109.899 179.29 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 54.2 m-85 -70.41 158.7 35.53 Favored 'General case' 0 N--CA 1.479 1.006 0 N-CA-C 107.812 -1.181 . . . . 0.0 107.812 177.07 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 15.0 t80 -171.0 -58.75 0.02 OUTLIER 'General case' 0 N--CA 1.483 1.198 0 CA-C-O 122.435 1.112 . . . . 0.0 109.546 179.244 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.33 90.56 0.0 OUTLIER 'General case' 0 N--CA 1.458 -0.073 0 CA-C-N 113.845 -1.525 . . . . 0.0 112.818 -178.113 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 53.6 tt0 -62.88 155.34 27.39 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 115.238 -0.892 . . . . 0.0 110.463 178.952 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 18.1 m-20 -136.51 134.71 37.85 Favored 'General case' 0 N--CA 1.48 1.071 0 C-N-CA 122.967 0.507 . . . . 0.0 109.983 179.851 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 16.2 t -84.74 -117.05 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.763 0 N-CA-C 108.173 -1.047 . . . . 0.0 108.173 179.296 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -107.4 53.27 0.61 Allowed Glycine 0 N--CA 1.474 1.172 0 N-CA-C 111.178 -0.769 . . . . 0.0 111.178 179.867 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 88.7 p -77.04 126.55 31.15 Favored 'General case' 0 N--CA 1.465 0.311 0 N-CA-C 109.023 -0.732 . . . . 0.0 109.023 178.398 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 1.8 t-20 -67.18 100.03 0.74 Allowed 'General case' 0 N--CA 1.472 0.656 0 N-CA-C 108.615 -0.883 . . . . 0.0 108.615 178.664 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 67.3 mttm -94.01 128.26 40.25 Favored 'General case' 0 N--CA 1.479 1.012 0 N-CA-C 109.634 -0.506 . . . . 0.0 109.634 -179.451 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.28 -133.26 0.01 OUTLIER Glycine 0 CA--C 1.53 0.985 0 N-CA-C 110.398 -1.081 . . . . 0.0 110.398 179.11 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.34 127.78 43.32 Favored 'General case' 0 N--CA 1.484 1.243 0 CA-C-N 117.096 0.448 . . . . 0.0 110.178 179.356 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 30.3 mt -91.9 160.52 2.68 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.648 0 N-CA-C 106.824 -1.547 . . . . 0.0 106.824 178.157 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 38.0 mt -138.27 94.14 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.766 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 -179.065 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 53.5 104.82 0.01 OUTLIER Glycine 0 CA--C 1.531 1.085 0 CA-C-N 115.899 -0.592 . . . . 0.0 114.192 176.621 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 91.1 mt -72.22 155.2 40.48 Favored 'General case' 0 N--CA 1.469 0.512 0 N-CA-C 107.502 -1.295 . . . . 0.0 107.502 176.51 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 2.2 ttp -143.84 139.3 29.21 Favored 'General case' 0 N--CA 1.473 0.725 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 178.943 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 59.1 t -159.23 150.05 6.96 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.261 0 N-CA-C 106.714 -1.587 . . . . 0.0 106.714 -179.229 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . 0.593 ' H ' ' NE2' ' A' ' 15' ' ' GLN . . . 54.78 75.15 0.25 Allowed Glycine 0 C--N 1.314 -0.667 0 N-CA-C 111.823 -0.511 . . . . 0.0 111.823 177.909 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 174.14 -148.97 10.33 Favored Glycine 0 CA--C 1.52 0.36 0 N-CA-C 110.974 -0.85 . . . . 0.0 110.974 179.928 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 30.9 m -134.81 146.0 31.44 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.906 0 C-N-CA 122.599 0.36 . . . . 0.0 110.373 -179.72 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 19.6 t . . . . . 0 C--O 1.221 -0.428 0 CA-C-O 117.59 -1.195 . . . . 0.0 110.986 179.153 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' B' B ' 1' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 . . . . . 0 N--CA 1.489 1.497 0 N-CA-C 109.124 -0.695 . . . . 0.0 109.124 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' B' B ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.64 132.44 48.83 Favored 'General case' 0 CA--C 1.539 0.528 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.142 -179.877 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 3' ' ' GLU . . . . . . . . . . . . . 55.0 tt0 -169.45 108.21 0.42 Allowed 'General case' 0 N--CA 1.47 0.57 0 N-CA-C 109.608 -0.515 . . . . 0.0 109.608 -179.166 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 77.1 m-85 -83.53 141.22 31.78 Favored 'General case' 0 N--CA 1.473 0.712 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 179.531 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 72.0 mtp180 -144.33 141.61 29.87 Favored 'General case' 0 N--CA 1.48 1.071 0 N-CA-C 108.999 -0.741 . . . . 0.0 108.999 179.955 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 77.2 m80 -149.51 118.65 6.77 Favored 'General case' 0 N--CA 1.474 0.742 0 N-CA-C 108.903 -0.777 . . . . 0.0 108.903 179.04 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 7' ' ' ASP . . . . . . . . . . . . . 12.4 m-20 -66.87 149.03 51.17 Favored 'General case' 0 CA--C 1.532 0.261 0 CA-C-N 116.411 -0.359 . . . . 0.0 111.236 -179.399 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 8' ' ' SER . . . . . . . . . . . . . 7.9 t -167.21 170.21 11.91 Favored 'General case' 0 N--CA 1.471 0.613 0 N-CA-C 109.288 -0.634 . . . . 0.0 109.288 178.459 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 123.43 24.4 1.97 Allowed Glycine 0 N--CA 1.486 2.023 0 N-CA-C 111.982 -0.447 . . . . 0.0 111.982 179.416 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 40.6 p90 -56.63 128.37 36.01 Favored 'General case' 0 N--CA 1.471 0.581 0 N-CA-C 112.091 0.404 . . . . 0.0 112.091 -179.775 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 46.1 mt-10 -84.69 154.54 22.41 Favored 'General case' 0 N--CA 1.469 0.498 0 N-CA-C 108.911 -0.774 . . . . 0.0 108.911 178.327 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -154.01 129.04 1.5 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 N-CA-C 108.173 -1.047 . . . . 0.0 108.173 178.861 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 51.4 m-70 -134.35 144.94 48.54 Favored 'General case' 0 N--CA 1.488 1.429 0 CA-C-N 118.475 0.579 . . . . 0.0 110.777 -178.95 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 6.2 t60 -164.66 98.16 0.78 Allowed 'General case' 0 N--CA 1.484 1.243 0 CA-C-N 116.697 -0.229 . . . . 0.0 111.189 179.596 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . 0.58 ' NE2' ' H ' ' B' ' 37' ' ' GLY . 75.8 mt-30 -102.84 -172.95 2.21 Favored 'General case' 0 CA--C 1.506 -0.743 0 N-CA-C 108.135 -1.061 . . . . 0.0 108.135 179.415 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -167.08 97.94 0.52 Allowed 'General case' 0 N--CA 1.47 0.558 0 CA-C-N 115.034 -0.984 . . . . 0.0 109.309 178.898 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 4.9 mp -106.63 162.19 13.97 Favored 'General case' 0 N--CA 1.486 1.329 0 N-CA-C 108.373 -0.973 . . . . 0.0 108.373 179.819 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 56.8 t -142.31 118.35 5.98 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.243 0 CA-C-O 118.873 -0.584 . . . . 0.0 109.924 179.309 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 56.0 m-85 -70.69 158.81 35.6 Favored 'General case' 0 N--CA 1.478 0.93 0 N-CA-C 107.671 -1.233 . . . . 0.0 107.671 177.036 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 16.0 t80 -171.73 -57.98 0.02 OUTLIER 'General case' 0 N--CA 1.481 1.102 0 CA-C-O 122.254 1.026 . . . . 0.0 109.541 179.233 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.54 90.8 0.0 OUTLIER 'General case' 0 C--O 1.231 0.103 0 CA-C-N 114.1 -1.409 . . . . 0.0 112.67 -178.169 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 53.5 tt0 -63.11 155.34 28.23 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 115.274 -0.875 . . . . 0.0 110.495 179.035 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 18.0 m-20 -136.46 134.91 38.16 Favored 'General case' 0 N--CA 1.481 1.088 0 C-N-CA 122.991 0.516 . . . . 0.0 110.007 179.875 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 16.1 t -85.21 -117.13 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.475 0.795 0 N-CA-C 108.331 -0.988 . . . . 0.0 108.331 179.282 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -106.66 52.74 0.66 Allowed Glycine 0 N--CA 1.476 1.306 0 N-CA-C 111.14 -0.784 . . . . 0.0 111.14 179.915 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 89.5 p -77.02 126.22 30.61 Favored 'General case' 0 N--CA 1.466 0.352 0 N-CA-C 109.207 -0.664 . . . . 0.0 109.207 178.421 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 1.8 t-20 -67.15 100.17 0.75 Allowed 'General case' 0 N--CA 1.473 0.676 0 N-CA-C 108.588 -0.893 . . . . 0.0 108.588 178.674 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 67.4 mttm -94.03 128.22 40.26 Favored 'General case' 0 N--CA 1.479 1.01 0 N-CA-C 109.684 -0.487 . . . . 0.0 109.684 -179.469 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.16 -132.94 0.01 OUTLIER Glycine 0 CA--C 1.53 0.991 0 N-CA-C 110.493 -1.043 . . . . 0.0 110.493 179.067 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.63 127.83 42.99 Favored 'General case' 0 N--CA 1.485 1.286 0 CA-C-N 117.192 0.496 . . . . 0.0 110.09 179.355 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 29.8 mt -92.03 160.3 2.7 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.69 0 N-CA-C 106.896 -1.52 . . . . 0.0 106.896 178.093 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 37.5 mt -138.0 94.05 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.684 0 N-CA-C 109.908 -0.405 . . . . 0.0 109.908 -178.969 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 53.47 104.91 0.01 OUTLIER Glycine 0 CA--C 1.53 1.02 0 CA-C-N 115.899 -0.591 . . . . 0.0 114.229 176.648 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 90.9 mt -72.29 155.26 40.38 Favored 'General case' 0 N--CA 1.471 0.578 0 N-CA-C 107.481 -1.303 . . . . 0.0 107.481 176.524 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 2.2 ttp -143.73 139.02 29.25 Favored 'General case' 0 N--CA 1.476 0.859 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 178.954 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 59.0 t -159.05 149.96 7.17 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.274 0 N-CA-C 106.58 -1.637 . . . . 0.0 106.58 -179.23 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . 0.58 ' H ' ' NE2' ' B' ' 15' ' ' GLN . . . 54.83 75.12 0.25 Allowed Glycine 0 C--N 1.314 -0.647 0 N-CA-C 111.786 -0.526 . . . . 0.0 111.786 177.778 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 174.06 -148.89 10.31 Favored Glycine 0 CA--C 1.521 0.452 0 N-CA-C 110.989 -0.844 . . . . 0.0 110.989 179.869 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 31.5 m -134.83 145.99 31.44 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.942 0 C-N-CA 122.566 0.346 . . . . 0.0 110.35 -179.717 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 20.0 t . . . . . 0 C--O 1.22 -0.448 0 CA-C-O 117.636 -1.173 . . . . 0.0 110.985 179.136 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' C' C ' 1' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 . . . . . 0 N--CA 1.489 1.507 0 N-CA-C 109.013 -0.736 . . . . 0.0 109.013 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' C' C ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.51 132.41 48.83 Favored 'General case' 0 CA--C 1.539 0.535 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.202 -179.966 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 3' ' ' GLU . . . . . . . . . . . . . 55.0 tt0 -169.43 108.32 0.42 Allowed 'General case' 0 N--CA 1.471 0.62 0 N-CA-C 109.584 -0.524 . . . . 0.0 109.584 -179.247 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 76.5 m-85 -83.58 141.05 31.86 Favored 'General case' 0 N--CA 1.473 0.72 0 N-CA-C 109.9 -0.407 . . . . 0.0 109.9 179.472 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 72.4 mtp180 -144.19 141.56 29.99 Favored 'General case' 0 N--CA 1.483 1.221 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 179.946 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 77.1 m80 -149.49 118.59 6.75 Favored 'General case' 0 N--CA 1.473 0.705 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 179.053 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 7' ' ' ASP . . . . . . . . . . . . . 11.7 m-20 -66.88 149.08 51.1 Favored 'General case' 0 N--CA 1.464 0.251 0 CA-C-N 116.337 -0.392 . . . . 0.0 111.25 -179.416 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 8' ' ' SER . . . . . . . . . . . . . 7.9 t -167.18 170.18 11.99 Favored 'General case' 0 N--CA 1.472 0.642 0 N-CA-C 109.188 -0.671 . . . . 0.0 109.188 178.493 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 123.45 24.42 1.96 Allowed Glycine 0 N--CA 1.486 2.023 0 N-CA-C 111.944 -0.462 . . . . 0.0 111.944 179.37 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 40.7 p90 -56.57 128.21 35.13 Favored 'General case' 0 N--CA 1.472 0.628 0 N-CA-C 112.066 0.395 . . . . 0.0 112.066 -179.836 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 46.0 mt-10 -84.54 154.54 22.59 Favored 'General case' 0 N--CA 1.469 0.51 0 N-CA-C 108.881 -0.785 . . . . 0.0 108.881 178.252 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -154.07 129.02 1.48 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 178.826 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 51.3 m-70 -134.24 144.96 48.71 Favored 'General case' 0 N--CA 1.487 1.411 0 CA-C-N 118.428 0.558 . . . . 0.0 110.827 -178.954 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 6.2 t60 -164.75 98.35 0.77 Allowed 'General case' 0 N--CA 1.484 1.259 0 CA-C-N 116.823 -0.171 . . . . 0.0 111.254 179.6 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 15' ' ' GLN . . . . . 0.59 ' NE2' ' H ' ' C' ' 37' ' ' GLY . 75.8 mt-30 -103.09 -172.73 2.16 Favored 'General case' 0 CA--C 1.503 -0.851 0 N-CA-C 108.244 -1.021 . . . . 0.0 108.244 179.322 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -167.18 98.11 0.51 Allowed 'General case' 0 CA--C 1.538 0.502 0 CA-C-N 114.973 -1.012 . . . . 0.0 109.333 178.861 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 4.9 mp -106.72 162.19 13.99 Favored 'General case' 0 N--CA 1.486 1.344 0 N-CA-C 108.291 -1.003 . . . . 0.0 108.291 179.76 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 57.5 t -142.24 118.41 6.18 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.296 0 CA-C-O 118.934 -0.555 . . . . 0.0 109.944 179.285 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 55.7 m-85 -70.64 158.82 35.53 Favored 'General case' 0 N--CA 1.478 0.946 0 N-CA-C 107.754 -1.202 . . . . 0.0 107.754 176.981 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 16.0 t80 -171.71 -57.94 0.02 OUTLIER 'General case' 0 N--CA 1.479 0.977 0 CA-C-O 122.299 1.047 . . . . 0.0 109.573 179.176 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.6 90.82 0.0 OUTLIER 'General case' 0 C--N 1.338 0.087 0 CA-C-N 114.137 -1.392 . . . . 0.0 112.653 -178.171 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 53.6 tt0 -63.11 155.34 28.24 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 115.226 -0.897 . . . . 0.0 110.462 179.04 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 17.9 m-20 -136.43 134.94 38.25 Favored 'General case' 0 N--CA 1.48 1.069 0 C-N-CA 122.898 0.479 . . . . 0.0 110.002 179.83 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 16.1 t -85.08 -117.23 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.475 0.796 0 N-CA-C 108.344 -0.984 . . . . 0.0 108.344 179.273 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -106.54 52.68 0.66 Allowed Glycine 0 N--CA 1.476 1.327 0 N-CA-C 111.144 -0.782 . . . . 0.0 111.144 179.852 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 89.3 p -77.1 126.45 30.98 Favored 'General case' 0 N--CA 1.466 0.364 0 N-CA-C 109.151 -0.685 . . . . 0.0 109.151 178.494 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 1.8 t-20 -67.24 100.17 0.77 Allowed 'General case' 0 N--CA 1.471 0.615 0 N-CA-C 108.627 -0.879 . . . . 0.0 108.627 178.619 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 67.3 mttm -94.09 128.23 40.35 Favored 'General case' 0 N--CA 1.479 1.016 0 N-CA-C 109.656 -0.498 . . . . 0.0 109.656 -179.41 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.29 -133.09 0.01 OUTLIER Glycine 0 CA--C 1.531 1.039 0 N-CA-C 110.481 -1.047 . . . . 0.0 110.481 179.139 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.37 127.52 42.79 Favored 'General case' 0 N--CA 1.486 1.332 0 CA-C-N 117.195 0.498 . . . . 0.0 110.177 179.379 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 29.6 mt -91.78 160.25 2.71 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.642 0 N-CA-C 106.887 -1.523 . . . . 0.0 106.887 178.063 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 36.9 mt -138.0 94.0 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.696 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 -178.964 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 53.52 104.93 0.01 OUTLIER Glycine 0 CA--C 1.531 1.067 0 CA-C-N 115.885 -0.598 . . . . 0.0 114.118 176.608 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 90.9 mt -72.21 155.17 40.52 Favored 'General case' 0 N--CA 1.47 0.563 0 N-CA-C 107.477 -1.305 . . . . 0.0 107.477 176.463 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 2.2 ttp -143.54 139.09 29.59 Favored 'General case' 0 N--CA 1.473 0.722 0 N-CA-C 108.812 -0.81 . . . . 0.0 108.812 178.9 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 59.3 t -159.2 150.08 6.98 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.258 0 N-CA-C 106.659 -1.608 . . . . 0.0 106.659 -179.279 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 37' ' ' GLY . . . . . 0.59 ' H ' ' NE2' ' C' ' 15' ' ' GLN . . . 54.84 75.04 0.25 Allowed Glycine 0 N--CA 1.465 0.633 0 N-CA-C 111.775 -0.53 . . . . 0.0 111.775 177.837 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 174.04 -148.9 10.32 Favored Glycine 0 CA--C 1.521 0.411 0 N-CA-C 110.967 -0.853 . . . . 0.0 110.967 179.8 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 31.3 m -134.8 145.97 31.5 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.97 0 C-N-CA 122.535 0.334 . . . . 0.0 110.481 -179.739 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 20.1 t . . . . . 0 C--O 1.222 -0.392 0 CA-C-O 117.616 -1.183 . . . . 0.0 110.873 179.116 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' D' D ' 1' ' ' ASP . . . . . . . . . . . . . 8.6 m-20 . . . . . 0 N--CA 1.491 1.597 0 N-CA-C 109.075 -0.713 . . . . 0.0 109.075 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' D' D ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.29 131.1 46.33 Favored 'General case' 0 CA--C 1.536 0.427 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.431 179.769 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' D' D ' 3' ' ' GLU . . . . . . . . . . . . . 54.5 tt0 -169.36 110.52 0.47 Allowed 'General case' 0 N--CA 1.469 0.507 0 N-CA-C 109.333 -0.617 . . . . 0.0 109.333 179.51 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 84.5 m-85 -87.0 148.55 25.27 Favored 'General case' 0 C--N 1.361 1.103 0 C-N-CA 118.619 -1.232 . . . . 0.0 108.346 179.664 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' D' D ' 5' ' ' ARG . . . . . . . . . . . . . 71.9 mtp180 -147.73 141.4 25.58 Favored 'General case' 0 N--CA 1.472 0.625 0 N-CA-C 109.037 -0.727 . . . . 0.0 109.037 179.779 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 77.5 m80 -149.2 123.46 9.57 Favored 'General case' 0 CA--C 1.541 0.627 0 N-CA-C 107.705 -1.22 . . . . 0.0 107.705 175.53 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' D' D ' 7' ' ' ASP . . . . . . . . . . . . . 7.9 m-20 -63.33 133.5 54.22 Favored 'General case' 0 C--N 1.322 -0.591 0 C-N-CA 126.813 2.045 . . . . 0.0 114.543 176.425 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' D' D ' 8' ' ' SER . . . . . . . . . . . . . 7.0 t -154.22 173.1 16.58 Favored 'General case' 0 N--CA 1.478 0.943 0 CA-C-N 118.468 0.576 . . . . 0.0 110.05 176.977 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 124.48 20.51 2.38 Favored Glycine 0 N--CA 1.484 1.874 0 N-CA-C 112.185 -0.366 . . . . 0.0 112.185 176.649 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 36.2 p90 -55.55 130.46 42.96 Favored 'General case' 0 CA--C 1.546 0.803 0 CA-C-O 121.089 0.471 . . . . 0.0 112.026 -177.341 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 46.2 mt-10 -84.89 152.25 23.69 Favored 'General case' 0 N--CA 1.474 0.755 0 N-CA-C 109.422 -0.584 . . . . 0.0 109.422 177.628 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -149.53 130.09 4.42 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.411 0 N-CA-C 108.158 -1.053 . . . . 0.0 108.158 175.389 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 49.4 m-70 -129.49 148.52 51.4 Favored 'General case' 0 N--CA 1.48 1.062 0 CA-C-N 118.016 0.371 . . . . 0.0 111.021 176.687 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 6.3 t60 -165.0 104.78 0.78 Allowed 'General case' 0 N--CA 1.484 1.256 0 N-CA-C 109.716 -0.476 . . . . 0.0 109.716 173.618 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' D' D ' 15' ' ' GLN . . . . . 0.628 ' NE2' ' H ' ' D' ' 37' ' ' GLY . 75.9 mt-30 -106.3 -175.7 2.87 Favored 'General case' 0 CA--C 1.498 -1.056 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 178.602 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -163.54 106.28 0.98 Allowed 'General case' 0 CA--C 1.536 0.423 0 N-CA-C 107.493 -1.299 . . . . 0.0 107.493 175.514 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 5.9 mp -112.94 162.18 16.14 Favored 'General case' 0 N--CA 1.487 1.381 0 N-CA-C 107.503 -1.295 . . . . 0.0 107.503 179.01 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 48.7 t -141.24 123.44 14.59 Favored 'Isoleucine or valine' 0 C--N 1.362 1.134 0 N-CA-C 109.084 -0.71 . . . . 0.0 109.084 175.344 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 80.4 m-85 -62.85 151.37 39.23 Favored 'General case' 0 C--N 1.349 0.582 0 C-N-CA 124.435 1.094 . . . . 0.0 110.703 170.11 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 11.4 t80 -170.23 -66.84 0.02 OUTLIER 'General case' 0 C--N 1.319 -0.723 0 N-CA-C 107.72 -1.215 . . . . 0.0 107.72 179.31 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -38.37 95.52 0.01 OUTLIER 'General case' 0 N--CA 1.451 -0.38 0 CA-C-N 113.964 -1.471 . . . . 0.0 111.672 -175.501 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 53.6 tt0 -65.39 156.03 33.53 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 114.072 -1.422 . . . . 0.0 110.104 178.587 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 17.9 m-20 -136.49 138.89 41.88 Favored 'General case' 0 N--CA 1.477 0.898 0 N-CA-C 109.256 -0.646 . . . . 0.0 109.256 178.501 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' D' D ' 24' ' ' VAL . . . . . . . . . . . . . 17.3 t -88.5 -120.4 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.482 1.168 0 N-CA-C 107.602 -1.259 . . . . 0.0 107.602 179.607 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . -110.35 61.77 0.3 Allowed Glycine 0 C--N 1.373 2.585 0 C-N-CA 117.706 -2.188 . . . . 0.0 109.162 178.44 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 94.5 p -67.91 121.74 16.67 Favored 'General case' 0 C--O 1.243 0.763 0 CA-C-O 116.524 -1.703 . . . . 0.0 112.307 168.7 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 1.9 t-20 -62.73 101.75 0.28 Allowed 'General case' 0 N--CA 1.476 0.845 0 CA-C-N 121.519 1.963 . . . . 0.0 109.476 172.984 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 67.1 mttm -95.95 127.37 41.91 Favored 'General case' 0 N--CA 1.485 1.277 0 CA-C-N 119.243 0.928 . . . . 0.0 109.102 178.377 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -55.84 -135.05 0.0 OUTLIER Glycine 0 CA--C 1.527 0.803 0 C-N-CA 123.573 0.606 . . . . 0.0 112.443 174.696 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.45 130.94 48.31 Favored 'General case' 0 C--N 1.373 1.62 0 CA-C-N 114.968 -0.616 . . . . 0.0 110.283 175.995 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 35.9 mt -92.08 162.32 2.43 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.455 0 N-CA-C 106.475 -1.676 . . . . 0.0 106.475 177.673 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . 0.267 41.6 mt -140.6 105.49 1.84 Allowed 'Isoleucine or valine' 0 C--N 1.359 1.015 0 N-CA-C 106.728 -1.582 . . . . 0.0 106.728 173.053 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.49 96.24 0.01 OUTLIER Glycine 0 CA--C 1.533 1.171 0 CA-C-O 115.935 -2.592 . . . . 0.0 112.682 169.063 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 95.2 mt -69.65 158.56 35.1 Favored 'General case' 0 N--CA 1.481 1.086 0 CA-C-N 122.731 3.265 . . . . 0.0 107.441 176.507 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 2.9 ttp -143.82 149.53 37.14 Favored 'General case' 0 N--CA 1.481 1.089 0 N-CA-C 106.352 -1.722 . . . . 0.0 106.352 174.293 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 89.6 t -165.18 154.09 1.91 Allowed 'Isoleucine or valine' 0 C--O 1.249 1.032 0 N-CA-C 105.41 -2.07 . . . . 0.0 105.41 177.601 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' D' D ' 37' ' ' GLY . . . . . 0.628 ' H ' ' NE2' ' D' ' 15' ' ' GLN . . . 60.83 66.74 2.5 Favored Glycine 0 N--CA 1.442 -0.953 0 C-N-CA 117.326 -2.369 . . . . 0.0 113.981 174.565 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 168.41 -147.85 11.88 Favored Glycine 0 N--CA 1.466 0.674 0 CA-C-O 117.0 -2.0 . . . . 0.0 112.492 -178.698 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 31.1 m -131.19 145.42 35.39 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.271 0 CA-C-N 119.958 1.879 . . . . 0.0 110.588 -176.988 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 18.0 t . . . . . 0 C--O 1.208 -1.128 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 173.591 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' E' E ' 1' ' ' ASP . . . . . . . . . . . . . 8.6 m-20 . . . . . 0 N--CA 1.49 1.531 0 N-CA-C 109.196 -0.668 . . . . 0.0 109.196 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' E' E ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.3 131.14 46.44 Favored 'General case' 0 CA--C 1.536 0.416 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.373 179.866 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' E' E ' 3' ' ' GLU . . . . . . . . . . . . . 54.5 tt0 -169.14 108.32 0.44 Allowed 'General case' 0 N--CA 1.469 0.503 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 -179.784 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 77.1 m-85 -84.36 141.31 30.98 Favored 'General case' 0 N--CA 1.473 0.7 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 179.416 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' E' E ' 5' ' ' ARG . . . . . . . . . . . . . 71.8 mtp180 -144.27 142.32 30.38 Favored 'General case' 0 N--CA 1.476 0.826 0 N-CA-C 109.234 -0.654 . . . . 0.0 109.234 179.666 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 77.3 m80 -150.11 117.62 6.12 Favored 'General case' 0 N--CA 1.475 0.787 0 N-CA-C 109.049 -0.723 . . . . 0.0 109.049 179.073 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' E' E ' 7' ' ' ASP . . . . . . . . . . . . . 12.1 m-20 -65.85 149.19 50.58 Favored 'General case' 0 N--CA 1.463 0.205 0 O-C-N 123.276 0.36 . . . . 0.0 111.482 -179.409 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' E' E ' 8' ' ' SER . . . . . . . . . . . . . 7.2 t -167.6 171.34 10.34 Favored 'General case' 0 N--CA 1.476 0.836 0 N-CA-C 109.219 -0.66 . . . . 0.0 109.219 178.03 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 123.9 23.78 1.98 Allowed Glycine 0 N--CA 1.481 1.655 0 N-CA-C 111.876 -0.489 . . . . 0.0 111.876 179.024 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 37.1 p90 -55.82 127.53 30.64 Favored 'General case' 0 CA--C 1.543 0.694 0 N-CA-C 112.703 0.631 . . . . 0.0 112.703 -179.076 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 46.4 mt-10 -83.05 155.2 24.03 Favored 'General case' 0 N--CA 1.475 0.79 0 N-CA-C 109.234 -0.654 . . . . 0.0 109.234 177.774 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -155.69 127.88 1.02 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.498 0 N-CA-C 108.22 -1.03 . . . . 0.0 108.22 178.622 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 48.5 m-70 -134.29 143.1 47.54 Favored 'General case' 0 N--CA 1.478 0.97 0 C-N-CA 122.491 0.316 . . . . 0.0 111.099 -177.976 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 6.1 t60 -163.52 98.5 0.9 Allowed 'General case' 0 N--CA 1.486 1.359 0 CA-C-O 119.735 -0.174 . . . . 0.0 111.247 179.693 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' E' E ' 15' ' ' GLN . . . . . 0.568 ' NE2' ' H ' ' E' ' 37' ' ' GLY . 76.0 mt-30 -102.66 -172.7 2.17 Favored 'General case' 0 CA--C 1.506 -0.736 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 179.464 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -167.16 98.13 0.52 Allowed 'General case' 0 CA--C 1.54 0.59 0 CA-C-N 114.97 -1.014 . . . . 0.0 109.259 178.617 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 4.9 mp -106.43 161.44 14.58 Favored 'General case' 0 N--CA 1.487 1.411 0 N-CA-C 108.771 -0.826 . . . . 0.0 108.771 -179.95 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 42.0 t -142.4 117.82 5.39 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.379 0 C-N-CA 122.549 0.339 . . . . 0.0 110.463 178.896 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 54.9 m-85 -69.72 156.54 38.83 Favored 'General case' 0 C--N 1.356 0.891 0 N-CA-C 107.636 -1.246 . . . . 0.0 107.636 176.449 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 14.2 t80 -173.23 -56.16 0.02 OUTLIER 'General case' 0 N--CA 1.482 1.129 0 CA-C-O 121.731 0.777 . . . . 0.0 110.018 179.242 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.84 89.1 0.0 OUTLIER 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 114.364 -1.289 . . . . 0.0 112.689 -179.095 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 54.0 tt0 -61.69 155.08 23.55 Favored 'General case' 0 N--CA 1.47 0.55 0 CA-C-N 115.131 -0.94 . . . . 0.0 110.604 179.489 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 17.6 m-20 -136.46 134.54 37.77 Favored 'General case' 0 N--CA 1.479 0.978 0 C-N-CA 122.918 0.487 . . . . 0.0 110.301 -179.931 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 20.2 t -84.85 -116.64 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.873 0 N-CA-C 108.449 -0.945 . . . . 0.0 108.449 179.209 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . -106.84 52.98 0.64 Allowed Glycine 0 C--N 1.346 1.138 0 N-CA-C 111.255 -0.738 . . . . 0.0 111.255 -179.987 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 89.2 p -77.0 125.99 30.24 Favored 'General case' 0 N--CA 1.472 0.664 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 178.169 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 1.8 t-20 -66.66 100.22 0.67 Allowed 'General case' 0 N--CA 1.472 0.633 0 N-CA-C 108.108 -1.071 . . . . 0.0 108.108 178.528 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 66.6 mttm -94.31 127.15 40.01 Favored 'General case' 0 N--CA 1.481 1.101 0 N-CA-C 109.149 -0.685 . . . . 0.0 109.149 -179.463 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.84 -130.58 0.01 OUTLIER Glycine 0 CA--C 1.533 1.218 0 N-CA-C 110.454 -1.058 . . . . 0.0 110.454 179.31 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -129.25 127.56 41.49 Favored 'General case' 0 N--CA 1.484 1.265 0 CA-C-N 117.439 0.62 . . . . 0.0 111.324 -179.906 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 27.8 mt -90.91 161.01 2.65 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.499 0 N-CA-C 106.796 -1.557 . . . . 0.0 106.796 178.152 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 37.3 mt -138.75 94.5 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.479 0.979 0 N-CA-C 109.606 -0.516 . . . . 0.0 109.606 179.872 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 53.62 104.37 0.01 OUTLIER Glycine 0 CA--C 1.531 1.037 0 CA-C-N 116.101 -0.499 . . . . 0.0 114.204 176.791 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 93.8 mt -71.52 155.64 40.34 Favored 'General case' 0 N--CA 1.473 0.682 0 N-CA-C 107.49 -1.3 . . . . 0.0 107.49 176.516 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 2.4 ttp -143.81 139.99 29.62 Favored 'General case' 0 N--CA 1.479 1.019 0 N-CA-C 108.301 -1.0 . . . . 0.0 108.301 178.787 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 65.6 t -160.27 148.8 6.11 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.456 0 N-CA-C 106.618 -1.623 . . . . 0.0 106.618 -179.058 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' E' E ' 37' ' ' GLY . . . . . 0.568 ' H ' ' NE2' ' E' ' 15' ' ' GLN . . . 55.15 75.32 0.24 Allowed Glycine 0 N--CA 1.464 0.516 0 N-CA-C 111.815 -0.514 . . . . 0.0 111.815 178.118 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 174.77 -146.95 8.77 Favored Glycine 0 C--O 1.221 -0.663 0 N-CA-C 111.207 -0.757 . . . . 0.0 111.207 179.881 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 29.8 m -136.69 145.15 30.73 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.794 0 CA-C-N 117.104 0.452 . . . . 0.0 109.808 -179.647 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 19.0 t . . . . . 0 CA--C 1.537 0.449 0 CA-C-O 117.576 -1.202 . . . . 0.0 111.153 179.183 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' F' F ' 1' ' ' ASP . . . . . . . . . . . . . 8.6 m-20 . . . . . 0 N--CA 1.49 1.573 0 N-CA-C 109.177 -0.675 . . . . 0.0 109.177 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' F' F ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.31 131.16 46.49 Favored 'General case' 0 CA--C 1.536 0.441 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.382 179.832 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' F' F ' 3' ' ' GLU . . . . . . . . . . . . . 54.5 tt0 -169.19 108.34 0.44 Allowed 'General case' 0 N--CA 1.469 0.523 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 -179.824 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 77.0 m-85 -84.38 141.25 30.99 Favored 'General case' 0 N--CA 1.474 0.75 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 179.414 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' F' F ' 5' ' ' ARG . . . . . . . . . . . . . 72.0 mtp180 -144.11 142.15 30.43 Favored 'General case' 0 N--CA 1.478 0.954 0 N-CA-C 109.092 -0.707 . . . . 0.0 109.092 179.755 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 77.2 m80 -150.14 117.43 6.04 Favored 'General case' 0 N--CA 1.476 0.843 0 N-CA-C 108.983 -0.747 . . . . 0.0 108.983 179.093 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' F' F ' 7' ' ' ASP . . . . . . . . . . . . . 11.5 m-20 -65.74 149.07 50.73 Favored 'General case' 0 N--CA 1.464 0.247 0 O-C-N 123.327 0.392 . . . . 0.0 111.662 -179.433 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' F' F ' 8' ' ' SER . . . . . . . . . . . . . 7.1 t -167.38 171.43 10.58 Favored 'General case' 0 N--CA 1.476 0.87 0 N-CA-C 109.253 -0.647 . . . . 0.0 109.253 178.056 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 123.79 23.71 2.01 Favored Glycine 0 N--CA 1.482 1.746 0 N-CA-C 111.901 -0.48 . . . . 0.0 111.901 179.008 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 37.4 p90 -55.9 127.75 31.81 Favored 'General case' 0 CA--C 1.542 0.647 0 N-CA-C 112.717 0.636 . . . . 0.0 112.717 -179.113 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 46.4 mt-10 -83.21 155.25 23.81 Favored 'General case' 0 N--CA 1.475 0.779 0 N-CA-C 109.2 -0.667 . . . . 0.0 109.2 177.756 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -155.74 127.94 1.02 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.538 0 N-CA-C 108.218 -1.03 . . . . 0.0 108.218 178.551 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 49.0 m-70 -134.29 143.16 47.58 Favored 'General case' 0 N--CA 1.479 1.024 0 C-N-CA 122.419 0.288 . . . . 0.0 110.996 -177.871 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 6.1 t60 -163.81 99.12 0.88 Allowed 'General case' 0 N--CA 1.487 1.38 0 CA-C-N 116.85 -0.159 . . . . 0.0 111.252 179.677 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' F' F ' 15' ' ' GLN . . . . . 0.577 ' NE2' ' H ' ' F' ' 37' ' ' GLY . 76.0 mt-30 -103.58 -171.91 2.02 Favored 'General case' 0 CA--C 1.501 -0.921 0 N-CA-C 108.388 -0.967 . . . . 0.0 108.388 179.384 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -167.6 98.3 0.48 Allowed 'General case' 0 CA--C 1.54 0.59 0 CA-C-N 114.842 -1.072 . . . . 0.0 109.322 178.775 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 4.9 mp -106.45 161.45 14.58 Favored 'General case' 0 N--CA 1.487 1.415 0 N-CA-C 108.721 -0.844 . . . . 0.0 108.721 -179.967 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 41.6 t -142.32 117.96 5.64 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.378 0 C-N-CA 122.638 0.375 . . . . 0.0 110.478 178.921 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 55.2 m-85 -69.82 156.47 38.99 Favored 'General case' 0 C--N 1.357 0.906 0 N-CA-C 107.455 -1.313 . . . . 0.0 107.455 176.363 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 15.0 t80 -173.11 -56.09 0.02 OUTLIER 'General case' 0 N--CA 1.482 1.164 0 CA-C-O 121.743 0.783 . . . . 0.0 109.606 179.233 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.99 89.09 0.0 OUTLIER 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 114.46 -1.245 . . . . 0.0 112.76 -179.02 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 53.9 tt0 -61.6 155.19 22.95 Favored 'General case' 0 N--CA 1.472 0.659 0 CA-C-N 115.151 -0.931 . . . . 0.0 110.641 179.346 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 17.5 m-20 -136.66 134.73 37.59 Favored 'General case' 0 N--CA 1.479 1.006 0 C-N-CA 122.925 0.49 . . . . 0.0 110.345 -179.986 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' F' F ' 24' ' ' VAL . . . . . . . . . . . . . 19.3 t -85.08 -116.69 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.93 0 N-CA-C 108.525 -0.917 . . . . 0.0 108.525 179.241 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -106.6 52.61 0.67 Allowed Glycine 0 N--CA 1.477 1.42 0 N-CA-C 111.172 -0.771 . . . . 0.0 111.172 179.974 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 89.3 p -76.78 125.86 29.99 Favored 'General case' 0 N--CA 1.472 0.655 0 N-CA-C 109.271 -0.64 . . . . 0.0 109.271 178.176 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 1.9 t-20 -66.83 100.35 0.71 Allowed 'General case' 0 N--CA 1.471 0.603 0 N-CA-C 108.134 -1.061 . . . . 0.0 108.134 178.587 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 66.7 mttm -94.31 126.96 39.89 Favored 'General case' 0 N--CA 1.481 1.123 0 N-CA-C 109.169 -0.678 . . . . 0.0 109.169 -179.389 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.81 -130.96 0.01 OUTLIER Glycine 0 CA--C 1.532 1.155 0 N-CA-C 110.591 -1.004 . . . . 0.0 110.591 179.212 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.55 126.94 41.38 Favored 'General case' 0 N--CA 1.488 1.433 0 CA-C-N 117.4 0.6 . . . . 0.0 111.348 -179.765 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 28.1 mt -90.62 160.92 2.68 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.547 0 N-CA-C 106.694 -1.595 . . . . 0.0 106.694 178.033 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 36.8 mt -138.87 94.57 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.093 0 N-CA-C 109.613 -0.514 . . . . 0.0 109.613 179.822 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 53.69 104.3 0.01 OUTLIER Glycine 0 CA--C 1.531 1.075 0 CA-C-N 116.039 -0.528 . . . . 0.0 114.145 176.752 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 94.1 mt -71.47 155.93 40.03 Favored 'General case' 0 N--CA 1.471 0.62 0 N-CA-C 107.524 -1.287 . . . . 0.0 107.524 176.588 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 2.3 ttp -144.13 140.01 29.15 Favored 'General case' 0 N--CA 1.478 0.957 0 N-CA-C 108.691 -0.855 . . . . 0.0 108.691 178.708 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 65.0 t -160.3 148.95 6.08 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.447 0 N-CA-C 106.703 -1.591 . . . . 0.0 106.703 -178.973 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' F' F ' 37' ' ' GLY . . . . . 0.577 ' H ' ' NE2' ' F' ' 15' ' ' GLN . . . 55.16 75.25 0.25 Allowed Glycine 0 N--CA 1.464 0.551 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.812 178.038 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 174.77 -146.94 8.76 Favored Glycine 0 C--O 1.22 -0.738 0 N-CA-C 111.22 -0.752 . . . . 0.0 111.22 179.845 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 30.3 m -136.7 145.05 30.88 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.757 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 -179.644 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 18.7 t . . . . . 0 C--O 1.221 -0.418 0 CA-C-O 117.621 -1.18 . . . . 0.0 111.157 179.215 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' G' G ' 1' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 . . . . . 0 N--CA 1.492 1.643 0 N-CA-C 109.494 -0.558 . . . . 0.0 109.494 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' G' G ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.72 129.55 41.02 Favored 'General case' 0 N--CA 1.469 0.514 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.416 179.698 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' G' G ' 3' ' ' GLU . . . . . . . . . . . . . 53.7 tt0 -169.16 108.17 0.44 Allowed 'General case' 0 N--CA 1.47 0.53 0 N-CA-C 110.114 -0.328 . . . . 0.0 110.114 179.763 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 77.1 m-85 -84.88 140.85 30.83 Favored 'General case' 0 N--CA 1.472 0.668 0 N-CA-C 109.594 -0.521 . . . . 0.0 109.594 179.314 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' G' G ' 5' ' ' ARG . . . . . . . . . . . . . 72.4 mtp180 -144.56 141.94 29.83 Favored 'General case' 0 N--CA 1.48 1.053 0 N-CA-C 109.088 -0.708 . . . . 0.0 109.088 -179.799 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 77.1 m80 -149.85 118.75 6.66 Favored 'General case' 0 N--CA 1.475 0.797 0 N-CA-C 108.979 -0.749 . . . . 0.0 108.979 179.072 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 12.1 m-20 -68.1 144.85 54.87 Favored 'General case' 0 CA--C 1.537 0.467 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.878 -179.2 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' G' G ' 8' ' ' SER . . . . . . . . . . . . . 6.1 t -163.58 173.1 13.44 Favored 'General case' 0 N--CA 1.47 0.552 0 N-CA-C 109.068 -0.715 . . . . 0.0 109.068 178.089 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 123.4 23.12 2.19 Favored Glycine 0 N--CA 1.481 1.644 0 N-CA-C 111.712 -0.555 . . . . 0.0 111.712 178.936 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 40.5 p90 -56.18 127.68 31.87 Favored 'General case' 0 N--CA 1.473 0.718 0 N-CA-C 112.682 0.623 . . . . 0.0 112.682 -178.705 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 46.2 mt-10 -83.44 154.1 24.14 Favored 'General case' 0 N--CA 1.47 0.561 0 N-CA-C 109.632 -0.507 . . . . 0.0 109.632 178.307 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -155.68 128.07 1.05 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.933 0 N-CA-C 108.036 -1.098 . . . . 0.0 108.036 178.846 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 50.2 m-70 -133.66 144.15 49.01 Favored 'General case' 0 N--CA 1.475 0.801 0 CA-C-N 115.353 -0.84 . . . . 0.0 110.773 -178.238 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 6.2 t60 -164.82 98.83 0.77 Allowed 'General case' 0 N--CA 1.483 1.204 0 CA-C-N 116.635 -0.257 . . . . 0.0 110.786 179.033 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' G' G ' 15' ' ' GLN . . . . . 0.598 ' NE2' ' H ' ' G' ' 37' ' ' GLY . 76.1 mt-30 -103.18 -172.32 2.1 Favored 'General case' 0 CA--C 1.506 -0.737 0 N-CA-C 108.358 -0.979 . . . . 0.0 108.358 179.578 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -167.29 98.31 0.51 Allowed 'General case' 0 CA--C 1.539 0.546 0 CA-C-N 115.051 -0.977 . . . . 0.0 109.367 178.7 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 5.4 mp -106.2 160.81 15.05 Favored 'General case' 0 N--CA 1.486 1.335 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 -179.908 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 40.4 t -143.59 117.95 3.84 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.001 0 C-N-CA 122.573 0.349 . . . . 0.0 110.235 178.753 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 49.0 m-85 -69.7 150.84 46.53 Favored 'General case' 0 C--N 1.37 1.487 0 N-CA-C 107.404 -1.332 . . . . 0.0 107.404 176.477 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 12.4 t80 -171.03 -55.9 0.02 OUTLIER 'General case' 0 N--CA 1.485 1.29 0 N-CA-C 110.025 -0.361 . . . . 0.0 110.025 179.957 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.88 90.61 0.0 OUTLIER 'General case' 0 C--N 1.325 -0.481 0 O-C-N 123.938 0.774 . . . . 0.0 112.267 179.986 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 53.7 tt0 -62.81 155.84 25.68 Favored 'General case' 0 N--CA 1.469 0.475 0 CA-C-N 114.838 -1.074 . . . . 0.0 109.718 179.03 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 18.0 m-20 -136.71 134.71 37.48 Favored 'General case' 0 N--CA 1.478 0.96 0 C-N-CA 122.782 0.433 . . . . 0.0 109.87 -179.939 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' G' G ' 24' ' ' VAL . . . . . . . . . . . . . 19.6 t -85.5 -116.02 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.894 0 N-CA-C 108.293 -1.003 . . . . 0.0 108.293 179.289 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -107.28 53.06 0.63 Allowed Glycine 0 N--CA 1.476 1.311 0 N-CA-C 111.286 -0.726 . . . . 0.0 111.286 -179.947 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 89.3 p -77.48 126.2 30.53 Favored 'General case' 0 N--CA 1.466 0.37 0 N-CA-C 109.152 -0.684 . . . . 0.0 109.152 178.139 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 1.9 t-20 -67.16 99.82 0.72 Allowed 'General case' 0 N--CA 1.469 0.495 0 N-CA-C 108.604 -0.887 . . . . 0.0 108.604 178.81 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 67.3 mttm -93.51 127.09 39.01 Favored 'General case' 0 N--CA 1.481 1.081 0 N-CA-C 109.512 -0.551 . . . . 0.0 109.512 -179.662 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.87 -128.71 0.01 OUTLIER Glycine 0 CA--C 1.527 0.801 0 N-CA-C 110.576 -1.01 . . . . 0.0 110.576 179.27 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.84 126.09 35.36 Favored 'General case' 0 CA--C 1.54 0.567 0 C-N-CA 122.814 0.446 . . . . 0.0 110.933 -179.361 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 37.7 mt -90.53 162.26 2.49 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.842 0 N-CA-C 107.0 -1.482 . . . . 0.0 107.0 178.239 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 40.8 mt -139.04 95.96 0.96 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.437 0 CA-C-N 119.714 1.143 . . . . 0.0 110.068 178.173 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 53.64 103.92 0.01 OUTLIER Glycine 0 CA--C 1.53 1.019 0 CA-C-N 116.026 -0.534 . . . . 0.0 114.106 176.818 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 92.3 mt -71.34 154.96 41.19 Favored 'General case' 0 N--CA 1.47 0.57 0 N-CA-C 107.772 -1.196 . . . . 0.0 107.772 176.717 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 2.6 ttp -143.48 140.46 30.34 Favored 'General case' 0 N--CA 1.474 0.756 0 N-CA-C 108.555 -0.906 . . . . 0.0 108.555 178.897 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 69.2 t -160.36 149.11 5.98 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.256 0 N-CA-C 106.636 -1.616 . . . . 0.0 106.636 -179.329 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' G' G ' 37' ' ' GLY . . . . . 0.598 ' H ' ' NE2' ' G' ' 15' ' ' GLN . . . 55.5 75.12 0.26 Allowed Glycine 0 N--CA 1.466 0.637 0 C-N-CA 121.012 -0.613 . . . . 0.0 112.04 177.494 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 173.92 -146.17 8.59 Favored Glycine 0 C--O 1.221 -0.708 0 N-CA-C 110.581 -1.008 . . . . 0.0 110.581 179.339 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 32.9 m -136.76 145.9 29.42 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.923 0 CA-C-N 117.002 0.401 . . . . 0.0 110.185 -179.413 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 20.7 t . . . . . 0 C--O 1.22 -0.467 0 CA-C-O 117.603 -1.189 . . . . 0.0 111.417 179.091 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' H' H ' 1' ' ' ASP . . . . . . . . . . . . . 8.5 m-20 . . . . . 0 N--CA 1.491 1.577 0 N-CA-C 109.568 -0.53 . . . . 0.0 109.568 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' H' H ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.83 129.47 40.59 Favored 'General case' 0 N--CA 1.469 0.5 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.381 179.711 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' H' H ' 3' ' ' GLU . . . . . . . . . . . . . 53.8 tt0 -169.04 108.12 0.45 Allowed 'General case' 0 N--CA 1.469 0.505 0 N-CA-C 110.137 -0.32 . . . . 0.0 110.137 179.78 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 77.6 m-85 -84.64 141.04 30.92 Favored 'General case' 0 N--CA 1.472 0.666 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 179.387 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' H' H ' 5' ' ' ARG . . . . . . . . . . . . . 72.3 mtp180 -144.6 141.86 29.73 Favored 'General case' 0 N--CA 1.48 1.062 0 N-CA-C 109.13 -0.693 . . . . 0.0 109.13 -179.859 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 77.1 m80 -149.84 118.3 6.49 Favored 'General case' 0 N--CA 1.476 0.831 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 179.096 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 11.9 m-20 -67.54 144.89 55.4 Favored 'General case' 0 N--CA 1.468 0.453 0 O-C-N 123.426 0.453 . . . . 0.0 111.931 -179.29 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' H' H ' 8' ' ' SER . . . . . . . . . . . . . 7.5 t -163.74 172.36 14.29 Favored 'General case' 0 N--CA 1.47 0.532 0 N-CA-C 109.174 -0.676 . . . . 0.0 109.174 178.261 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 123.52 23.36 2.13 Favored Glycine 0 N--CA 1.482 1.714 0 N-CA-C 111.817 -0.513 . . . . 0.0 111.817 179.084 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 40.5 p90 -56.17 127.82 32.56 Favored 'General case' 0 N--CA 1.473 0.714 0 N-CA-C 112.575 0.583 . . . . 0.0 112.575 -178.82 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 46.2 mt-10 -83.53 154.23 23.96 Favored 'General case' 0 N--CA 1.473 0.708 0 N-CA-C 109.597 -0.52 . . . . 0.0 109.597 178.297 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -155.85 127.99 1.02 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.943 0 N-CA-C 108.07 -1.085 . . . . 0.0 108.07 178.8 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 51.4 m-70 -133.54 144.33 49.28 Favored 'General case' 0 N--CA 1.476 0.825 0 CA-C-N 115.274 -0.875 . . . . 0.0 110.81 -178.214 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 6.2 t60 -164.96 98.5 0.75 Allowed 'General case' 0 N--CA 1.483 1.197 0 CA-C-N 116.709 -0.223 . . . . 0.0 110.85 179.034 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' H' H ' 15' ' ' GLN . . . . . 0.58 ' NE2' ' H ' ' H' ' 37' ' ' GLY . 76.0 mt-30 -102.8 -172.8 2.18 Favored 'General case' 0 CA--C 1.505 -0.77 0 N-CA-C 108.26 -1.015 . . . . 0.0 108.26 179.642 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -167.11 98.24 0.52 Allowed 'General case' 0 CA--C 1.539 0.524 0 CA-C-N 114.997 -1.001 . . . . 0.0 109.251 178.719 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 5.4 mp -106.17 160.84 15.02 Favored 'General case' 0 N--CA 1.485 1.279 0 N-CA-C 109.103 -0.702 . . . . 0.0 109.103 -179.823 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 40.4 t -143.52 117.77 3.81 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.089 0 C-N-CA 122.547 0.339 . . . . 0.0 110.25 178.744 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 50.2 m-85 -69.75 151.29 45.97 Favored 'General case' 0 C--N 1.369 1.426 0 N-CA-C 107.527 -1.286 . . . . 0.0 107.527 176.33 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 13.1 t80 -172.25 -55.58 0.02 OUTLIER 'General case' 0 N--CA 1.483 1.177 0 N-CA-C 110.069 -0.345 . . . . 0.0 110.069 180.0 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.96 90.71 0.0 OUTLIER 'General case' 0 CA--C 1.535 0.367 0 C-N-CA 123.517 0.727 . . . . 0.0 112.097 179.924 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 53.7 tt0 -62.61 155.83 24.99 Favored 'General case' 0 N--CA 1.469 0.512 0 CA-C-N 114.849 -1.069 . . . . 0.0 109.919 179.115 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 17.9 m-20 -136.55 134.86 37.93 Favored 'General case' 0 N--CA 1.48 1.025 0 C-N-CA 122.835 0.454 . . . . 0.0 109.917 -179.957 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' H' H ' 24' ' ' VAL . . . . . . . . . . . . . 19.6 t -85.85 -116.13 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.846 0 N-CA-C 108.358 -0.979 . . . . 0.0 108.358 179.364 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . -106.91 52.89 0.64 Allowed Glycine 0 N--CA 1.478 1.483 0 N-CA-C 111.099 -0.8 . . . . 0.0 111.099 -179.969 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 89.0 p -77.45 126.16 30.47 Favored 'General case' 0 N--CA 1.467 0.383 0 N-CA-C 109.006 -0.738 . . . . 0.0 109.006 178.304 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 1.9 t-20 -67.06 100.49 0.76 Allowed 'General case' 0 N--CA 1.469 0.5 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 178.667 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 67.3 mttm -94.39 127.12 40.07 Favored 'General case' 0 N--CA 1.481 1.084 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 -179.598 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.11 -128.54 0.01 OUTLIER Glycine 0 CA--C 1.527 0.783 0 N-CA-C 110.643 -0.983 . . . . 0.0 110.643 179.385 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.97 126.04 34.99 Favored 'General case' 0 N--CA 1.471 0.582 0 C-N-CA 122.853 0.461 . . . . 0.0 111.033 -179.251 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 35.8 mt -90.66 161.81 2.55 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.845 0 N-CA-C 107.014 -1.476 . . . . 0.0 107.014 178.228 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 40.4 mt -138.73 95.93 1.01 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.435 0 CA-C-N 119.511 1.051 . . . . 0.0 109.981 178.38 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 53.58 104.32 0.01 OUTLIER Glycine 0 CA--C 1.53 1.029 0 CA-C-N 116.101 -0.5 . . . . 0.0 114.144 176.832 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 92.1 mt -71.67 154.76 41.16 Favored 'General case' 0 N--CA 1.47 0.57 0 N-CA-C 107.673 -1.232 . . . . 0.0 107.673 176.716 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 2.6 ttp -143.09 140.09 30.74 Favored 'General case' 0 N--CA 1.477 0.889 0 N-CA-C 108.503 -0.925 . . . . 0.0 108.503 178.802 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 69.1 t -159.96 149.34 6.38 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.278 0 N-CA-C 106.525 -1.657 . . . . 0.0 106.525 -179.388 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' H' H ' 37' ' ' GLY . . . . . 0.58 ' H ' ' NE2' ' H' ' 15' ' ' GLN . . . 55.28 74.91 0.27 Allowed Glycine 0 C--N 1.314 -0.643 0 C-N-CA 120.989 -0.624 . . . . 0.0 112.155 177.489 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 173.97 -146.32 8.66 Favored Glycine 0 C--O 1.221 -0.675 0 N-CA-C 110.631 -0.988 . . . . 0.0 110.631 179.393 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 32.7 m -136.68 145.87 29.55 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.87 0 CA-C-N 116.98 0.39 . . . . 0.0 110.327 -179.423 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 21.1 t . . . . . 0 C--O 1.221 -0.4 0 CA-C-O 117.64 -1.171 . . . . 0.0 111.326 179.163 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' I' I ' 1' ' ' ASP . . . . . . . . . . . . . 8.5 m-20 . . . . . 0 N--CA 1.492 1.634 0 N-CA-C 109.435 -0.58 . . . . 0.0 109.435 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' I' I ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.77 129.43 40.44 Favored 'General case' 0 N--CA 1.469 0.502 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.478 179.672 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' I' I ' 3' ' ' GLU . . . . . . . . . . . . . 53.8 tt0 -169.02 108.2 0.45 Allowed 'General case' 0 N--CA 1.468 0.452 0 N-CA-C 110.13 -0.322 . . . . 0.0 110.13 179.833 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 77.1 m-85 -84.75 141.18 30.72 Favored 'General case' 0 N--CA 1.473 0.704 0 N-CA-C 109.553 -0.536 . . . . 0.0 109.553 179.377 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' I' I ' 5' ' ' ARG . . . . . . . . . . . . . 72.3 mtp180 -144.78 141.9 29.56 Favored 'General case' 0 N--CA 1.481 1.094 0 N-CA-C 109.056 -0.72 . . . . 0.0 109.056 -179.834 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 77.1 m80 -149.83 118.34 6.51 Favored 'General case' 0 N--CA 1.476 0.838 0 N-CA-C 109.083 -0.71 . . . . 0.0 109.083 179.093 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 12.0 m-20 -67.62 144.76 55.39 Favored 'General case' 0 CA--C 1.535 0.396 0 CA-C-O 120.979 0.419 . . . . 0.0 111.927 -179.268 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' I' I ' 8' ' ' SER . . . . . . . . . . . . . 7.6 t -163.54 172.31 14.59 Favored 'General case' 0 N--CA 1.469 0.5 0 N-CA-C 109.152 -0.684 . . . . 0.0 109.152 178.276 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 123.7 23.26 2.1 Favored Glycine 0 N--CA 1.483 1.789 0 N-CA-C 111.747 -0.541 . . . . 0.0 111.747 179.027 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 40.3 p90 -56.08 127.82 32.43 Favored 'General case' 0 N--CA 1.474 0.75 0 N-CA-C 112.501 0.556 . . . . 0.0 112.501 -178.792 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 46.2 mt-10 -83.61 154.17 23.89 Favored 'General case' 0 N--CA 1.474 0.73 0 N-CA-C 109.644 -0.502 . . . . 0.0 109.644 178.203 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -155.74 128.01 1.03 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.927 0 N-CA-C 108.125 -1.065 . . . . 0.0 108.125 178.854 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 50.9 m-70 -133.58 144.33 49.24 Favored 'General case' 0 N--CA 1.476 0.832 0 CA-C-N 115.33 -0.85 . . . . 0.0 110.861 -178.236 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 6.2 t60 -165.05 98.61 0.74 Allowed 'General case' 0 N--CA 1.485 1.297 0 CA-C-N 116.687 -0.233 . . . . 0.0 110.914 179.131 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' I' I ' 15' ' ' GLN . . . . . 0.588 ' NE2' ' H ' ' I' ' 37' ' ' GLY . 76.0 mt-30 -103.11 -172.55 2.13 Favored 'General case' 0 CA--C 1.503 -0.852 0 N-CA-C 108.328 -0.99 . . . . 0.0 108.328 179.598 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -167.26 98.23 0.51 Allowed 'General case' 0 CA--C 1.538 0.517 0 CA-C-N 114.977 -1.011 . . . . 0.0 109.279 178.82 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 5.4 mp -106.18 160.77 15.08 Favored 'General case' 0 N--CA 1.484 1.259 0 N-CA-C 109.089 -0.708 . . . . 0.0 109.089 -179.854 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 40.5 t -143.4 117.83 3.95 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.016 0 C-N-CA 122.542 0.337 . . . . 0.0 110.306 178.753 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 49.7 m-85 -69.83 151.3 45.88 Favored 'General case' 0 C--N 1.369 1.431 0 N-CA-C 107.486 -1.302 . . . . 0.0 107.486 176.423 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 13.2 t80 -172.25 -55.55 0.02 OUTLIER 'General case' 0 N--CA 1.481 1.093 0 N-CA-C 110.065 -0.346 . . . . 0.0 110.065 -179.999 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.98 90.8 0.0 OUTLIER 'General case' 0 CA--C 1.535 0.387 0 C-N-CA 123.496 0.718 . . . . 0.0 112.046 179.877 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 53.7 tt0 -62.69 155.96 24.91 Favored 'General case' 0 N--CA 1.469 0.5 0 CA-C-N 114.862 -1.063 . . . . 0.0 109.866 179.141 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 17.9 m-20 -136.69 134.85 37.66 Favored 'General case' 0 N--CA 1.479 0.987 0 C-N-CA 122.804 0.442 . . . . 0.0 109.867 -179.954 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' I' I ' 24' ' ' VAL . . . . . . . . . . . . . 19.4 t -85.76 -116.09 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.878 0 N-CA-C 108.337 -0.986 . . . . 0.0 108.337 179.39 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . -106.98 52.9 0.64 Allowed Glycine 0 N--CA 1.477 1.402 0 N-CA-C 111.225 -0.75 . . . . 0.0 111.225 179.991 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 89.3 p -77.46 126.2 30.53 Favored 'General case' 0 N--CA 1.466 0.372 0 N-CA-C 109.066 -0.716 . . . . 0.0 109.066 178.313 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 1.9 t-20 -67.03 100.4 0.74 Allowed 'General case' 0 N--CA 1.47 0.538 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 178.623 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 67.4 mttm -94.27 127.03 39.88 Favored 'General case' 0 N--CA 1.481 1.111 0 N-CA-C 109.452 -0.573 . . . . 0.0 109.452 -179.659 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.97 -128.78 0.01 OUTLIER Glycine 0 CA--C 1.527 0.831 0 N-CA-C 110.695 -0.962 . . . . 0.0 110.695 179.339 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.69 125.74 34.72 Favored 'General case' 0 N--CA 1.471 0.612 0 C-N-CA 122.957 0.503 . . . . 0.0 111.057 -179.299 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 36.2 mt -90.56 161.85 2.55 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.781 0 N-CA-C 106.933 -1.506 . . . . 0.0 106.933 178.201 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 40.4 mt -138.85 95.79 0.98 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 CA-C-N 119.485 1.039 . . . . 0.0 109.99 178.475 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 53.7 104.23 0.01 OUTLIER Glycine 0 CA--C 1.531 1.039 0 CA-C-N 116.103 -0.499 . . . . 0.0 114.093 176.818 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 91.9 mt -71.56 154.63 41.32 Favored 'General case' 0 N--CA 1.471 0.576 0 N-CA-C 107.683 -1.228 . . . . 0.0 107.683 176.687 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 2.6 ttp -143.03 140.03 30.8 Favored 'General case' 0 N--CA 1.475 0.815 0 N-CA-C 108.497 -0.927 . . . . 0.0 108.497 178.871 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 68.6 t -159.95 149.37 6.39 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.228 0 N-CA-C 106.567 -1.642 . . . . 0.0 106.567 -179.371 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' I' I ' 37' ' ' GLY . . . . . 0.588 ' H ' ' NE2' ' I' ' 15' ' ' GLN . . . 55.2 74.99 0.26 Allowed Glycine 0 N--CA 1.465 0.617 0 C-N-CA 120.942 -0.647 . . . . 0.0 112.152 177.517 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 173.95 -146.24 8.63 Favored Glycine 0 N--CA 1.465 0.633 0 N-CA-C 110.662 -0.975 . . . . 0.0 110.662 179.354 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 32.8 m -136.73 145.91 29.43 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.93 0 CA-C-N 117.013 0.406 . . . . 0.0 110.172 -179.369 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 20.9 t . . . . . 0 C--O 1.221 -0.42 0 CA-C-O 117.648 -1.168 . . . . 0.0 111.381 179.145 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . 0.402 ' H3 ' ' CG ' ' D' ' 1' ' ' ASP . 8.6 m-20 . . . . . 0 N--CA 1.487 1.413 0 N-CA-C 109.04 -0.726 . . . . 0.0 109.04 . . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.49 132.45 48.95 Favored 'General case' 0 CA--C 1.539 0.528 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.18 -179.879 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 38.9 tt0 -169.44 108.27 0.42 Allowed 'General case' 0 N--CA 1.47 0.542 0 N-CA-C 109.558 -0.534 . . . . 0.0 109.558 -179.12 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 76.5 m-85 -83.59 140.78 32.02 Favored 'General case' 0 N--CA 1.475 0.791 0 N-CA-C 109.98 -0.378 . . . . 0.0 109.98 179.449 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 73.7 mtp180 -143.71 141.31 30.45 Favored 'General case' 0 N--CA 1.482 1.152 0 N-CA-C 109.045 -0.724 . . . . 0.0 109.045 -179.968 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 76.7 m80 -149.77 119.53 7.05 Favored 'General case' 0 N--CA 1.47 0.548 0 N-CA-C 108.781 -0.822 . . . . 0.0 108.781 179.137 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 -67.84 149.56 49.7 Favored 'General case' 0 N--CA 1.463 0.187 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.179 -179.62 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' SER . . . . . 0.484 ' HG ' ' H ' ' A' ' 9' ' ' GLY . 7.0 t -167.22 171.28 10.94 Favored 'General case' 0 N--CA 1.473 0.698 0 N-CA-C 109.46 -0.57 . . . . 0.0 109.46 178.496 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . 0.484 ' H ' ' HG ' ' A' ' 8' ' ' SER . . . 122.21 24.07 2.29 Favored Glycine 0 N--CA 1.487 2.065 0 N-CA-C 112.125 -0.39 . . . . 0.0 112.125 179.375 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 41.9 p90 -56.78 128.01 34.45 Favored 'General case' 0 N--CA 1.471 0.623 0 N-CA-C 112.106 0.41 . . . . 0.0 112.106 -179.889 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . 0.411 ' CD ' HD22 ' C' ' 27' ' ' ASN . 46.1 mt-10 -84.86 156.09 21.44 Favored 'General case' 0 N--CA 1.468 0.443 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 178.544 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -154.86 124.48 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 N-CA-C 108.119 -1.067 . . . . 0.0 108.119 178.534 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 35.1 m80 -107.33 161.12 15.09 Favored 'General case' 0 N--CA 1.491 1.624 0 CA-C-N 118.455 0.57 . . . . 0.0 111.213 -178.767 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 57.1 t60 -164.66 99.14 0.79 Allowed 'General case' 0 N--CA 1.485 1.289 0 CA-C-N 116.766 -0.197 . . . . 0.0 111.06 179.63 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . 0.619 HE22 ' H ' ' A' ' 37' ' ' GLY . 68.3 mt-30 -125.67 -175.15 3.26 Favored 'General case' 0 CA--C 1.491 -1.301 0 N-CA-C 107.862 -1.162 . . . . 0.0 107.862 -179.99 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -169.7 103.28 0.33 Allowed 'General case' 0 CA--C 1.542 0.644 0 CA-C-N 115.011 -0.995 . . . . 0.0 109.395 179.026 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 9.3 mp -110.75 151.35 27.88 Favored 'General case' 0 N--CA 1.489 1.515 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 -179.932 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 61.6 t -143.98 119.06 4.0 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.245 0 CA-C-O 118.69 -0.671 . . . . 0.0 109.543 179.084 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 17.3 m-85 -70.19 157.2 38.08 Favored 'General case' 0 N--CA 1.477 0.923 0 N-CA-C 107.727 -1.212 . . . . 0.0 107.727 177.542 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 14.6 t80 -170.99 -60.0 0.02 OUTLIER 'General case' 0 N--CA 1.482 1.156 0 CA-C-O 122.315 1.055 . . . . 0.0 109.482 179.278 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.0 89.64 0.0 OUTLIER 'General case' 0 N--CA 1.456 -0.152 0 CA-C-N 113.891 -1.504 . . . . 0.0 112.875 -177.973 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 43.4 mt-10 -61.42 158.22 15.14 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 115.166 -0.924 . . . . 0.0 110.782 179.037 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 12.0 m-20 -139.98 135.26 32.55 Favored 'General case' 0 N--CA 1.483 1.21 0 C-N-CA 122.769 0.427 . . . . 0.0 110.399 -179.956 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 18.1 t -84.34 -115.98 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.475 0.802 0 N-CA-C 108.35 -0.981 . . . . 0.0 108.35 179.355 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -109.32 54.25 0.55 Allowed Glycine 0 N--CA 1.473 1.112 0 N-CA-C 111.254 -0.738 . . . . 0.0 111.254 -179.986 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' SER . . . . . 0.592 ' HG ' ' HZ2' ' A' ' 28' ' ' LYS . 82.8 p -77.49 126.96 31.72 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 109.0 -0.741 . . . . 0.0 109.0 178.469 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . 0.422 HD22 ' CD ' ' B' ' 11' ' ' GLU . 47.5 t30 -66.7 100.92 0.74 Allowed 'General case' 0 N--CA 1.471 0.599 0 N-CA-C 108.611 -0.885 . . . . 0.0 108.611 178.593 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.592 ' HZ2' ' HG ' ' A' ' 26' ' ' SER . 67.2 mttm -95.3 128.88 42.51 Favored 'General case' 0 N--CA 1.481 1.089 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 -179.155 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.71 -132.12 0.01 OUTLIER Glycine 0 CA--C 1.533 1.203 0 N-CA-C 110.775 -0.93 . . . . 0.0 110.775 178.907 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.77 126.91 37.6 Favored 'General case' 0 N--CA 1.484 1.237 0 CA-C-N 117.097 0.448 . . . . 0.0 110.016 179.345 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 33.0 mt -91.31 159.17 2.83 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.496 0 N-CA-C 106.631 -1.618 . . . . 0.0 106.631 178.416 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 42.9 mt -138.25 92.86 0.83 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.468 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 -178.972 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 54.05 106.23 0.01 OUTLIER Glycine 0 CA--C 1.53 1.002 0 CA-C-N 115.933 -0.576 . . . . 0.0 114.162 177.239 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 97.9 mt -72.26 153.5 41.52 Favored 'General case' 0 CA--C 1.539 0.536 0 N-CA-C 107.27 -1.382 . . . . 0.0 107.27 176.703 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 27.2 ttt -147.07 138.34 24.01 Favored 'General case' 0 N--CA 1.477 0.879 0 N-CA-C 108.761 -0.829 . . . . 0.0 108.761 179.147 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 61.9 t -159.69 153.51 5.02 Favored 'Isoleucine or valine' 0 C--N 1.342 0.262 0 N-CA-C 106.596 -1.631 . . . . 0.0 106.596 -179.279 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . 0.619 ' H ' HE22 ' A' ' 15' ' ' GLN . . . 55.98 73.56 0.42 Allowed Glycine 0 C--N 1.313 -0.697 0 N-CA-C 111.663 -0.575 . . . . 0.0 111.663 177.987 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 174.65 -161.58 31.34 Favored Glycine 0 C--N 1.335 0.483 0 N-CA-C 111.086 -0.806 . . . . 0.0 111.086 -179.828 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 23.5 m -124.29 139.63 50.04 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.951 0 C-N-CA 122.762 0.425 . . . . 0.0 110.084 179.744 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 26.1 t . . . . . 0 C--O 1.221 -0.447 0 CA-C-O 117.635 -1.174 . . . . 0.0 111.108 179.37 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' B' B ' 1' ' ' ASP . . . . . . . . . . . . . 8.7 m-20 . . . . . 0 N--CA 1.488 1.461 0 N-CA-C 109.144 -0.687 . . . . 0.0 109.144 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' B' B ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.3 132.35 48.82 Favored 'General case' 0 CA--C 1.538 0.507 0 CA-C-N 116.385 -0.371 . . . . 0.0 110.234 -179.852 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 3' ' ' GLU . . . . . . . . . . . . . 39.1 tt0 -169.29 108.36 0.43 Allowed 'General case' 0 N--CA 1.469 0.509 0 N-CA-C 109.569 -0.53 . . . . 0.0 109.569 -179.153 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 77.0 m-85 -83.6 140.88 31.94 Favored 'General case' 0 N--CA 1.474 0.76 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 179.44 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 73.5 mtp180 -143.69 141.32 30.47 Favored 'General case' 0 N--CA 1.48 1.055 0 N-CA-C 109.092 -0.707 . . . . 0.0 109.092 -179.972 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 76.7 m80 -149.83 119.49 7.01 Favored 'General case' 0 N--CA 1.472 0.627 0 N-CA-C 108.93 -0.767 . . . . 0.0 108.93 179.104 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 7' ' ' ASP . . . . . . . . . . . . . 9.6 m-20 -67.77 149.4 49.97 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.196 -179.609 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 8' ' ' SER . . . . . 0.488 ' HG ' ' H ' ' B' ' 9' ' ' GLY . 7.0 t -167.15 171.4 10.93 Favored 'General case' 0 N--CA 1.473 0.676 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 178.451 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 9' ' ' GLY . . . . . 0.488 ' H ' ' HG ' ' B' ' 8' ' ' SER . . . 122.11 24.06 2.32 Favored Glycine 0 N--CA 1.487 2.072 0 N-CA-C 112.05 -0.42 . . . . 0.0 112.05 179.38 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 41.4 p90 -56.75 128.15 35.11 Favored 'General case' 0 N--CA 1.472 0.669 0 N-CA-C 112.071 0.397 . . . . 0.0 112.071 -179.834 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 11' ' ' GLU . . . . . 0.422 ' CD ' HD22 ' A' ' 27' ' ' ASN . 45.7 mt-10 -84.99 155.63 21.49 Favored 'General case' 0 N--CA 1.47 0.557 0 N-CA-C 109.268 -0.642 . . . . 0.0 109.268 178.589 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -154.47 124.35 0.78 Allowed 'Isoleucine or valine' 0 C--O 1.234 0.249 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 178.538 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 34.2 m80 -107.27 161.2 15.0 Favored 'General case' 0 N--CA 1.491 1.585 0 CA-C-N 118.41 0.55 . . . . 0.0 111.155 -178.774 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 58.2 t60 -164.72 98.87 0.78 Allowed 'General case' 0 N--CA 1.485 1.301 0 CA-C-O 119.64 -0.219 . . . . 0.0 111.001 179.636 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . 0.642 HE22 ' H ' ' B' ' 37' ' ' GLY . 68.3 mt-30 -125.19 -175.48 3.32 Favored 'General case' 0 CA--C 1.492 -1.275 0 N-CA-C 107.832 -1.173 . . . . 0.0 107.832 179.995 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -169.62 103.13 0.33 Allowed 'General case' 0 CA--C 1.541 0.6 0 CA-C-N 114.944 -1.025 . . . . 0.0 109.334 179.023 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 9.4 mp -110.67 151.23 27.94 Favored 'General case' 0 N--CA 1.489 1.507 0 N-CA-C 108.695 -0.854 . . . . 0.0 108.695 -179.951 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 61.9 t -143.92 118.77 3.91 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.139 0 CA-C-O 118.748 -0.644 . . . . 0.0 109.561 179.07 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 16.6 m-85 -70.45 157.17 38.31 Favored 'General case' 0 N--CA 1.475 0.798 0 N-CA-C 107.638 -1.245 . . . . 0.0 107.638 177.413 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 15.8 t80 -171.66 -59.06 0.02 OUTLIER 'General case' 0 N--CA 1.479 1.007 0 CA-C-O 122.261 1.029 . . . . 0.0 109.619 179.23 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.21 89.88 0.0 OUTLIER 'General case' 0 C--O 1.231 0.112 0 CA-C-N 114.051 -1.431 . . . . 0.0 112.764 -178.108 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 43.8 mt-10 -61.53 158.38 15.13 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 115.276 -0.875 . . . . 0.0 110.828 179.095 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 12.2 m-20 -140.25 135.6 32.48 Favored 'General case' 0 N--CA 1.483 1.196 0 C-N-CA 122.793 0.437 . . . . 0.0 110.416 179.955 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 18.1 t -84.97 -116.1 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.906 0 N-CA-C 108.408 -0.96 . . . . 0.0 108.408 179.499 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -108.45 53.65 0.59 Allowed Glycine 0 N--CA 1.476 1.366 0 N-CA-C 111.083 -0.807 . . . . 0.0 111.083 -179.909 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 26' ' ' SER . . . . . 0.592 ' HG ' ' HZ2' ' B' ' 28' ' ' LYS . 86.0 p -77.35 126.58 31.15 Favored 'General case' 0 C--N 1.329 -0.294 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 178.409 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 27' ' ' ASN . . . . . 0.421 HD22 ' CD ' ' C' ' 11' ' ' GLU . 47.5 t30 -66.74 100.98 0.75 Allowed 'General case' 0 N--CA 1.471 0.608 0 N-CA-C 108.593 -0.892 . . . . 0.0 108.593 178.672 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 28' ' ' LYS . . . . . 0.592 ' HZ2' ' HG ' ' B' ' 26' ' ' SER . 67.1 mttm -95.3 128.91 42.52 Favored 'General case' 0 N--CA 1.481 1.121 0 N-CA-C 109.972 -0.381 . . . . 0.0 109.972 -179.226 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.77 -131.63 0.01 OUTLIER Glycine 0 CA--C 1.535 1.33 0 N-CA-C 110.746 -0.942 . . . . 0.0 110.746 178.904 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -131.18 127.12 37.31 Favored 'General case' 0 N--CA 1.485 1.304 0 C-N-CA 122.704 0.402 . . . . 0.0 110.081 179.431 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 32.8 mt -91.75 158.79 2.86 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.538 0 N-CA-C 106.602 -1.629 . . . . 0.0 106.602 178.516 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 43.1 mt -137.81 92.89 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.502 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 -178.816 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 53.85 106.17 0.01 OUTLIER Glycine 0 CA--C 1.53 0.993 0 CA-C-N 116.021 -0.536 . . . . 0.0 114.212 177.237 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 97.7 mt -72.12 153.4 41.69 Favored 'General case' 0 CA--C 1.539 0.53 0 N-CA-C 107.364 -1.346 . . . . 0.0 107.364 176.651 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 27.1 ttt -146.82 138.05 24.16 Favored 'General case' 0 N--CA 1.478 0.954 0 N-CA-C 108.701 -0.851 . . . . 0.0 108.701 179.21 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 62.3 t -159.54 153.47 5.14 Favored 'Isoleucine or valine' 0 C--N 1.344 0.356 0 N-CA-C 106.52 -1.659 . . . . 0.0 106.52 -179.273 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . 0.642 ' H ' HE22 ' B' ' 15' ' ' GLN . . . 56.03 73.23 0.45 Allowed Glycine 0 C--N 1.313 -0.696 0 N-CA-C 111.686 -0.566 . . . . 0.0 111.686 178.005 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 174.98 -161.5 30.92 Favored Glycine 0 C--N 1.334 0.43 0 N-CA-C 111.056 -0.818 . . . . 0.0 111.056 -179.865 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 24.1 m -124.4 139.6 50.21 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.929 0 C-N-CA 122.751 0.421 . . . . 0.0 110.072 179.695 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 26.5 t . . . . . 0 C--O 1.219 -0.52 0 CA-C-O 117.651 -1.166 . . . . 0.0 111.054 179.381 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' C' C ' 1' ' ' ASP . . . . . . . . . . . . . 9.0 m-20 . . . . . 0 N--CA 1.489 1.5 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' C' C ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.28 132.42 49.01 Favored 'General case' 0 CA--C 1.538 0.519 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.181 -179.791 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 3' ' ' GLU . . . . . . . . . . . . . 39.0 tt0 -169.42 108.42 0.42 Allowed 'General case' 0 N--CA 1.47 0.55 0 N-CA-C 109.657 -0.497 . . . . 0.0 109.657 -179.2 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 77.1 m-85 -83.77 140.88 31.8 Favored 'General case' 0 N--CA 1.474 0.75 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 179.495 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 73.7 mtp180 -143.72 141.24 30.4 Favored 'General case' 0 N--CA 1.482 1.141 0 N-CA-C 109.005 -0.739 . . . . 0.0 109.005 -179.858 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 76.8 m80 -149.9 119.39 6.92 Favored 'General case' 0 N--CA 1.471 0.594 0 N-CA-C 108.798 -0.816 . . . . 0.0 108.798 179.159 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 7' ' ' ASP . . . . . . . . . . . . . 9.0 m-20 -67.71 149.29 50.17 Favored 'General case' 0 N--CA 1.463 0.218 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.244 -179.562 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 8' ' ' SER . . . . . 0.445 ' HG ' ' H ' ' C' ' 9' ' ' GLY . 6.7 t -167.12 171.15 11.21 Favored 'General case' 0 N--CA 1.472 0.652 0 N-CA-C 109.502 -0.555 . . . . 0.0 109.502 178.424 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' C' C ' 9' ' ' GLY . . . . . 0.445 ' H ' ' HG ' ' C' ' 8' ' ' SER . . . 122.49 23.92 2.26 Favored Glycine 0 N--CA 1.487 2.034 0 N-CA-C 111.968 -0.453 . . . . 0.0 111.968 179.38 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 41.5 p90 -56.61 128.16 34.93 Favored 'General case' 0 N--CA 1.471 0.614 0 N-CA-C 112.07 0.396 . . . . 0.0 112.07 -179.85 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 11' ' ' GLU . . . . . 0.421 ' CD ' HD22 ' B' ' 27' ' ' ASN . 45.9 mt-10 -85.02 155.97 21.32 Favored 'General case' 0 N--CA 1.47 0.535 0 N-CA-C 109.24 -0.652 . . . . 0.0 109.24 178.592 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -154.76 124.54 0.76 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 N-CA-C 108.168 -1.049 . . . . 0.0 108.168 178.525 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 33.9 m80 -107.39 161.23 15.0 Favored 'General case' 0 N--CA 1.49 1.573 0 CA-C-N 118.397 0.544 . . . . 0.0 111.181 -178.717 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 57.3 t60 -164.83 99.22 0.77 Allowed 'General case' 0 N--CA 1.485 1.286 0 CA-C-N 116.77 -0.196 . . . . 0.0 111.094 179.651 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 15' ' ' GLN . . . . . 0.632 HE22 ' H ' ' C' ' 37' ' ' GLY . 68.1 mt-30 -125.79 -175.34 3.32 Favored 'General case' 0 CA--C 1.489 -1.373 0 N-CA-C 107.904 -1.147 . . . . 0.0 107.904 -179.957 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -169.64 103.19 0.33 Allowed 'General case' 0 CA--C 1.541 0.624 0 CA-C-N 114.888 -1.051 . . . . 0.0 109.331 179.062 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 9.4 mp -110.67 150.92 28.32 Favored 'General case' 0 N--CA 1.488 1.441 0 N-CA-C 108.712 -0.848 . . . . 0.0 108.712 179.968 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 61.1 t -143.66 118.97 4.29 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.175 0 CA-C-O 118.765 -0.636 . . . . 0.0 109.61 179.029 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 16.6 m-85 -70.49 157.28 38.14 Favored 'General case' 0 N--CA 1.475 0.802 0 N-CA-C 107.664 -1.236 . . . . 0.0 107.664 177.436 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 15.4 t80 -171.59 -59.31 0.02 OUTLIER 'General case' 0 N--CA 1.478 0.953 0 CA-C-O 122.259 1.028 . . . . 0.0 109.642 179.195 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.12 89.96 0.0 OUTLIER 'General case' 0 C--O 1.231 0.11 0 CA-C-N 114.041 -1.436 . . . . 0.0 112.753 -178.076 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 43.9 mt-10 -61.6 158.23 15.68 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.219 -0.9 . . . . 0.0 110.833 179.047 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 12.3 m-20 -139.92 135.9 33.32 Favored 'General case' 0 N--CA 1.483 1.199 0 C-N-CA 122.861 0.464 . . . . 0.0 110.343 -179.977 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 18.2 t -85.27 -116.01 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.902 0 N-CA-C 108.414 -0.958 . . . . 0.0 108.414 179.444 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -108.58 53.42 0.6 Allowed Glycine 0 N--CA 1.475 1.257 0 N-CA-C 111.107 -0.797 . . . . 0.0 111.107 -179.918 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 26' ' ' SER . . . . . 0.563 ' HG ' ' HZ2' ' C' ' 28' ' ' LYS . 85.9 p -77.3 126.73 31.4 Favored 'General case' 0 C--N 1.329 -0.32 0 N-CA-C 109.122 -0.695 . . . . 0.0 109.122 178.508 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' C' C ' 27' ' ' ASN . . . . . 0.411 HD22 ' CD ' ' A' ' 11' ' ' GLU . 47.3 t30 -66.79 101.11 0.77 Allowed 'General case' 0 N--CA 1.471 0.582 0 N-CA-C 108.633 -0.877 . . . . 0.0 108.633 178.625 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' C' C ' 28' ' ' LYS . . . . . 0.563 ' HZ2' ' HG ' ' C' ' 26' ' ' SER . 67.1 mttm -95.34 128.99 42.63 Favored 'General case' 0 N--CA 1.483 1.2 0 N-CA-C 109.886 -0.413 . . . . 0.0 109.886 -179.117 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.84 -131.85 0.01 OUTLIER Glycine 0 CA--C 1.535 1.293 0 N-CA-C 110.858 -0.897 . . . . 0.0 110.858 178.844 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.96 126.66 36.63 Favored 'General case' 0 N--CA 1.486 1.356 0 C-N-CA 122.822 0.449 . . . . 0.0 110.003 179.456 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 32.5 mt -91.33 158.81 2.86 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.525 0 N-CA-C 106.684 -1.599 . . . . 0.0 106.684 178.334 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 42.5 mt -137.99 92.89 0.86 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.505 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 -178.799 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 53.93 106.09 0.01 OUTLIER Glycine 0 CA--C 1.529 0.966 0 CA-C-N 115.921 -0.581 . . . . 0.0 114.257 177.229 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 97.6 mt -72.05 153.3 41.82 Favored 'General case' 0 CA--C 1.537 0.461 0 N-CA-C 107.328 -1.36 . . . . 0.0 107.328 176.655 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 27.3 ttt -146.63 138.09 24.42 Favored 'General case' 0 N--CA 1.477 0.891 0 N-CA-C 108.74 -0.837 . . . . 0.0 108.74 179.214 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 61.1 t -159.57 153.56 5.07 Favored 'Isoleucine or valine' 0 C--N 1.345 0.372 0 N-CA-C 106.566 -1.642 . . . . 0.0 106.566 -179.251 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 37' ' ' GLY . . . . . 0.632 ' H ' HE22 ' C' ' 15' ' ' GLN . . . 55.89 73.15 0.46 Allowed Glycine 0 C--N 1.314 -0.671 0 N-CA-C 111.626 -0.59 . . . . 0.0 111.626 177.951 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 175.03 -161.75 31.24 Favored Glycine 0 C--N 1.335 0.479 0 N-CA-C 111.054 -0.818 . . . . 0.0 111.054 -179.865 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 23.5 m -124.2 139.67 49.88 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.923 0 C-N-CA 122.785 0.434 . . . . 0.0 110.054 179.727 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 27.7 t . . . . . 0 C--O 1.221 -0.424 0 CA-C-O 117.655 -1.164 . . . . 0.0 110.98 179.336 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' D' D ' 1' ' ' ASP . . . . . 0.402 ' CG ' ' H3 ' ' A' ' 1' ' ' ASP . 9.1 m-20 . . . . . 0 N--CA 1.49 1.565 0 N-CA-C 109.196 -0.668 . . . . 0.0 109.196 . . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' D' D ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.29 130.96 45.9 Favored 'General case' 0 CA--C 1.535 0.4 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.369 179.931 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' D' D ' 3' ' ' GLU . . . . . . . . . . . . . 38.7 tt0 -169.3 110.97 0.48 Allowed 'General case' 0 N--CA 1.47 0.534 0 N-CA-C 109.196 -0.668 . . . . 0.0 109.196 179.524 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 85.9 m-85 -87.31 148.61 24.99 Favored 'General case' 0 C--N 1.366 1.285 0 C-N-CA 118.584 -1.246 . . . . 0.0 108.113 179.765 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' D' D ' 5' ' ' ARG . . . . . . . . . . . . . 73.9 mtp180 -147.52 141.05 25.45 Favored 'General case' 0 N--CA 1.473 0.7 0 N-CA-C 108.967 -0.753 . . . . 0.0 108.967 179.637 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 77.0 m80 -149.2 123.55 9.62 Favored 'General case' 0 CA--C 1.539 0.519 0 N-CA-C 107.926 -1.138 . . . . 0.0 107.926 175.967 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' D' D ' 7' ' ' ASP . . . . . . . . . . . . . 6.3 m-20 -63.42 133.41 53.94 Favored 'General case' 0 C--N 1.32 -0.688 0 C-N-CA 126.937 2.095 . . . . 0.0 114.798 176.152 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' D' D ' 8' ' ' SER . . . . . 0.487 ' HG ' ' H ' ' D' ' 9' ' ' GLY . 5.9 t -154.04 173.52 15.91 Favored 'General case' 0 N--CA 1.477 0.925 0 CA-C-N 118.548 0.613 . . . . 0.0 110.443 176.799 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' D' D ' 9' ' ' GLY . . . . . 0.487 ' H ' ' HG ' ' D' ' 8' ' ' SER . . . 124.23 20.38 2.47 Favored Glycine 0 N--CA 1.484 1.864 0 N-CA-C 111.99 -0.444 . . . . 0.0 111.99 176.203 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 37.2 p90 -55.67 130.32 42.67 Favored 'General case' 0 CA--C 1.545 0.753 0 CA-C-O 121.103 0.478 . . . . 0.0 111.914 -177.388 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' D' D ' 11' ' ' GLU . . . . . 0.454 ' CG ' HD22 ' F' ' 27' ' ' ASN . 46.0 mt-10 -84.87 153.77 22.69 Favored 'General case' 0 N--CA 1.472 0.64 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 177.886 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.0 p -150.91 129.01 2.57 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.594 0 N-CA-C 106.937 -1.505 . . . . 0.0 106.937 172.73 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 24.6 m80 -100.86 161.98 13.22 Favored 'General case' 0 N--CA 1.481 1.116 0 C-N-CA 123.911 0.884 . . . . 0.0 113.168 176.722 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 61.0 t60 -165.0 105.27 0.79 Allowed 'General case' 0 N--CA 1.486 1.354 0 N-CA-C 109.694 -0.484 . . . . 0.0 109.694 172.242 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' D' D ' 15' ' ' GLN . . . . . 0.664 HE22 ' H ' ' D' ' 37' ' ' GLY . 69.1 mt-30 -128.59 -176.33 3.8 Favored 'General case' 0 CA--C 1.485 -1.534 0 N-CA-C 107.255 -1.387 . . . . 0.0 107.255 178.892 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 88.8 tttt -166.87 109.51 0.7 Allowed 'General case' 0 C--O 1.238 0.487 0 N-CA-C 107.926 -1.139 . . . . 0.0 107.926 176.779 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 10.5 mp -115.69 153.16 31.85 Favored 'General case' 0 N--CA 1.489 1.502 0 N-CA-C 107.198 -1.408 . . . . 0.0 107.198 178.205 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 52.5 t -141.95 124.03 13.61 Favored 'Isoleucine or valine' 0 C--N 1.362 1.152 0 N-CA-C 108.668 -0.864 . . . . 0.0 108.668 174.283 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 16.0 m-85 -62.62 150.81 39.77 Favored 'General case' 0 C--N 1.348 0.513 0 C-N-CA 124.308 1.043 . . . . 0.0 110.719 169.695 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 11.3 t80 -170.51 -67.22 0.02 OUTLIER 'General case' 0 N--CA 1.475 0.788 0 N-CA-C 107.983 -1.117 . . . . 0.0 107.983 178.55 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -38.61 94.99 0.01 OUTLIER 'General case' 0 N--CA 1.451 -0.403 0 CA-C-N 113.855 -1.521 . . . . 0.0 111.586 -175.866 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 45.8 mt-10 -64.47 159.09 22.21 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 114.293 -1.321 . . . . 0.0 110.504 178.491 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 12.2 m-20 -139.87 139.47 36.27 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-O 121.253 0.549 . . . . 0.0 109.637 178.609 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' D' D ' 24' ' ' VAL . . . . . . . . . . . . . 19.4 t -88.17 -119.86 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.483 1.217 0 N-CA-C 107.597 -1.26 . . . . 0.0 107.597 179.58 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . -111.47 61.8 0.3 Allowed Glycine 0 C--N 1.368 2.359 0 C-N-CA 118.222 -1.942 . . . . 0.0 109.206 178.763 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' D' D ' 26' ' ' SER . . . . . 0.617 ' HG ' ' HZ2' ' D' ' 28' ' ' LYS . 92.8 p -68.04 121.59 16.44 Favored 'General case' 0 C--O 1.24 0.595 0 CA-C-O 116.453 -1.737 . . . . 0.0 112.517 168.985 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' D' D ' 27' ' ' ASN . . . . . 0.415 HD22 ' CG ' ' E' ' 11' ' ' GLU . 53.8 t30 -62.52 101.79 0.27 Allowed 'General case' 0 N--CA 1.474 0.765 0 CA-C-N 121.603 2.001 . . . . 0.0 109.453 173.65 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' D' D ' 28' ' ' LYS . . . . . 0.617 ' HZ2' ' HG ' ' D' ' 26' ' ' SER . 66.8 mttm -96.84 128.28 43.64 Favored 'General case' 0 N--CA 1.487 1.387 0 CA-C-N 118.842 0.746 . . . . 0.0 109.35 178.996 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -55.21 -134.81 0.0 OUTLIER Glycine 0 CA--C 1.532 1.135 0 C-N-CA 123.793 0.711 . . . . 0.0 112.343 174.925 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -129.42 130.96 46.62 Favored 'General case' 0 C--N 1.371 1.507 0 CA-C-N 115.022 -0.589 . . . . 0.0 110.121 176.231 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 38.8 mt -91.64 161.75 2.52 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.338 0 N-CA-C 106.148 -1.797 . . . . 0.0 106.148 177.499 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . 0.28 43.1 mt -141.01 105.06 1.57 Allowed 'Isoleucine or valine' 0 C--N 1.363 1.191 0 N-CA-C 106.231 -1.766 . . . . 0.0 106.231 172.511 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.6 98.11 0.01 OUTLIER Glycine 0 CA--C 1.533 1.21 0 CA-C-O 116.312 -2.382 . . . . 0.0 112.198 169.074 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 97.0 mt -70.0 157.61 37.17 Favored 'General case' 0 CA--C 1.539 0.55 0 CA-C-N 122.355 3.078 . . . . 0.0 107.217 176.055 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 26.1 ttt -147.18 148.92 32.02 Favored 'General case' 0 N--CA 1.482 1.161 0 N-CA-C 106.373 -1.714 . . . . 0.0 106.373 174.269 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 88.5 t -165.22 159.14 1.18 Allowed 'Isoleucine or valine' 0 C--O 1.248 1.004 0 N-CA-C 105.302 -2.11 . . . . 0.0 105.302 177.15 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' D' D ' 37' ' ' GLY . . . . . 0.664 ' H ' HE22 ' D' ' 15' ' ' GLN . . . 60.54 64.84 3.77 Favored Glycine 0 N--CA 1.442 -0.917 0 C-N-CA 117.24 -2.41 . . . . 0.0 113.756 174.581 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 169.8 -160.7 33.85 Favored Glycine 0 N--CA 1.47 0.956 0 CA-C-O 117.808 -1.551 . . . . 0.0 112.304 -178.987 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 23.2 m -120.37 139.31 48.06 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.256 0 CA-C-N 118.829 1.315 . . . . 0.0 110.348 -177.003 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 25.4 t . . . . . 0 C--O 1.203 -1.35 0 CA-C-N 118.211 0.46 . . . . 0.0 110.102 173.766 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' E' E ' 1' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 . . . . . 0 N--CA 1.488 1.454 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' E' E ' 2' ' ' ALA . . . . . . . . . . . . . . . -63.86 131.1 46.72 Favored 'General case' 0 N--CA 1.468 0.468 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.375 179.862 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' E' E ' 3' ' ' GLU . . . . . . . . . . . . . 38.6 tt0 -169.04 108.43 0.45 Allowed 'General case' 0 N--CA 1.47 0.54 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 -179.811 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 77.8 m-85 -84.47 140.91 31.16 Favored 'General case' 0 N--CA 1.475 0.812 0 N-CA-C 109.904 -0.406 . . . . 0.0 109.904 179.451 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' E' E ' 5' ' ' ARG . . . . . . . . . . . . . 74.1 mtp180 -143.55 141.72 30.81 Favored 'General case' 0 N--CA 1.476 0.837 0 N-CA-C 109.388 -0.597 . . . . 0.0 109.388 179.875 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 76.7 m80 -150.31 118.57 6.38 Favored 'General case' 0 N--CA 1.471 0.62 0 N-CA-C 108.994 -0.743 . . . . 0.0 108.994 179.215 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' E' E ' 7' ' ' ASP . . . . . . . . . . . . . 8.6 m-20 -66.82 149.48 50.51 Favored 'General case' 0 N--CA 1.464 0.24 0 O-C-N 123.388 0.43 . . . . 0.0 111.608 -179.552 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' E' E ' 8' ' ' SER . . . . . 0.463 ' HG ' ' H ' ' E' ' 9' ' ' GLY . 6.0 t -167.63 171.72 9.98 Favored 'General case' 0 N--CA 1.477 0.878 0 CA-C-N 115.938 -0.574 . . . . 0.0 109.606 178.077 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' E' E ' 9' ' ' GLY . . . . . 0.463 ' H ' ' HG ' ' E' ' 8' ' ' SER . . . 123.22 23.91 2.09 Favored Glycine 0 N--CA 1.482 1.754 0 N-CA-C 111.843 -0.503 . . . . 0.0 111.843 179.078 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 37.4 p90 -56.29 127.33 30.36 Favored 'General case' 0 N--CA 1.472 0.674 0 N-CA-C 112.621 0.6 . . . . 0.0 112.621 -179.283 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' E' E ' 11' ' ' GLU . . . . . 0.415 ' CG ' HD22 ' D' ' 27' ' ' ASN . 46.0 mt-10 -83.36 156.77 22.83 Favored 'General case' 0 N--CA 1.476 0.856 0 N-CA-C 109.489 -0.56 . . . . 0.0 109.489 177.973 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -156.54 122.89 0.54 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.646 0 N-CA-C 108.324 -0.991 . . . . 0.0 108.324 178.257 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 36.5 m80 -106.88 160.24 15.66 Favored 'General case' 0 N--CA 1.482 1.135 0 C-N-CA 122.855 0.462 . . . . 0.0 111.238 -177.944 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 58.1 t60 -164.61 99.18 0.79 Allowed 'General case' 0 N--CA 1.487 1.38 0 CA-C-N 116.859 -0.155 . . . . 0.0 111.013 -179.842 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' E' E ' 15' ' ' GLN . . . . . 0.638 HE22 ' H ' ' E' ' 37' ' ' GLY . 69.3 mt-30 -125.42 -175.06 3.22 Favored 'General case' 0 CA--C 1.492 -1.263 0 N-CA-C 107.835 -1.172 . . . . 0.0 107.835 -179.98 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -169.54 103.85 0.34 Allowed 'General case' 0 CA--C 1.54 0.591 0 CA-C-N 114.9 -1.045 . . . . 0.0 109.109 179.015 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 9.6 mp -111.03 150.16 29.7 Favored 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 -179.639 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 46.1 t -144.04 118.17 3.52 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.22 0 CA-C-O 118.928 -0.558 . . . . 0.0 109.903 178.646 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 19.7 m-85 -69.32 155.27 40.7 Favored 'General case' 0 C--N 1.357 0.908 0 N-CA-C 107.569 -1.271 . . . . 0.0 107.569 176.798 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 14.0 t80 -173.41 -56.94 0.02 OUTLIER 'General case' 0 N--CA 1.48 1.072 0 CA-C-O 121.624 0.726 . . . . 0.0 110.136 179.163 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -42.74 88.48 0.0 OUTLIER 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 114.425 -1.261 . . . . 0.0 112.76 -179.051 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 44.4 mt-10 -60.11 158.37 11.36 Favored 'General case' 0 N--CA 1.471 0.619 0 CA-C-N 115.039 -0.982 . . . . 0.0 110.944 179.535 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 11.7 m-20 -140.34 135.02 31.75 Favored 'General case' 0 N--CA 1.483 1.183 0 C-N-CA 122.653 0.381 . . . . 0.0 110.687 -179.829 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 21.4 t -84.55 -115.51 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.939 0 N-CA-C 108.61 -0.885 . . . . 0.0 108.61 179.416 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . -108.65 53.65 0.58 Allowed Glycine 0 C--N 1.347 1.139 0 N-CA-C 111.317 -0.713 . . . . 0.0 111.317 -179.91 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' E' E ' 26' ' ' SER . . . . . 0.619 ' HG ' ' HZ2' ' E' ' 28' ' ' LYS . 86.1 p -77.15 126.37 30.84 Favored 'General case' 0 N--CA 1.471 0.577 0 N-CA-C 109.336 -0.616 . . . . 0.0 109.336 178.259 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' E' E ' 27' ' ' ASN . . . . . 0.436 HD22 ' CG ' ' F' ' 11' ' ' GLU . 49.2 t30 -66.22 100.64 0.63 Allowed 'General case' 0 N--CA 1.471 0.612 0 N-CA-C 108.079 -1.082 . . . . 0.0 108.079 178.442 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' E' E ' 28' ' ' LYS . . . . . 0.619 ' HZ2' ' HG ' ' E' ' 26' ' ' SER . 66.5 mttm -95.39 127.67 41.62 Favored 'General case' 0 N--CA 1.483 1.182 0 N-CA-C 109.305 -0.628 . . . . 0.0 109.305 -179.15 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.36 -128.93 0.01 OUTLIER Glycine 0 CA--C 1.537 1.462 0 N-CA-C 111.013 -0.835 . . . . 0.0 111.013 179.163 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -131.67 127.1 36.24 Favored 'General case' 0 N--CA 1.484 1.236 0 CA-C-N 117.307 0.554 . . . . 0.0 110.939 -179.62 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 31.2 mt -91.09 160.4 2.71 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.238 0 N-CA-C 106.338 -1.727 . . . . 0.0 106.338 178.306 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 41.6 mt -139.29 93.69 0.78 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.766 0 N-CA-C 109.653 -0.499 . . . . 0.0 109.653 179.879 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 53.54 105.96 0.01 OUTLIER Glycine 0 CA--C 1.531 1.053 0 CA-C-N 116.11 -0.495 . . . . 0.0 114.157 177.603 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 97.7 mt -72.03 153.72 41.58 Favored 'General case' 0 CA--C 1.542 0.636 0 N-CA-C 107.206 -1.405 . . . . 0.0 107.206 176.523 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 27.6 ttt -146.41 140.23 26.16 Favored 'General case' 0 N--CA 1.485 1.285 0 N-CA-C 108.005 -1.109 . . . . 0.0 108.005 178.841 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 80.2 t -161.18 152.86 4.31 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.389 0 N-CA-C 106.358 -1.719 . . . . 0.0 106.358 -179.208 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' E' E ' 37' ' ' GLY . . . . . 0.638 ' H ' HE22 ' E' ' 15' ' ' GLN . . . 55.56 73.81 0.39 Allowed Glycine 0 C--N 1.316 -0.54 0 N-CA-C 111.633 -0.587 . . . . 0.0 111.633 178.199 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 175.91 -159.34 26.79 Favored Glycine 0 C--O 1.213 -1.166 0 N-CA-C 111.313 -0.715 . . . . 0.0 111.313 -179.708 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 23.7 m -127.16 138.81 53.71 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.83 0 N-CA-C 109.332 -0.618 . . . . 0.0 109.332 179.776 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 27.6 t . . . . . 0 CA--C 1.537 0.453 0 CA-C-O 117.986 -1.007 . . . . 0.0 111.106 179.739 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' F' F ' 1' ' ' ASP . . . . . . . . . . . . . 9.3 m-20 . . . . . 0 N--CA 1.49 1.561 0 N-CA-C 109.106 -0.701 . . . . 0.0 109.106 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' F' F ' 2' ' ' ALA . . . . . . . . . . . . . . . -63.79 131.05 46.62 Favored 'General case' 0 N--CA 1.468 0.432 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.47 179.85 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' F' F ' 3' ' ' GLU . . . . . . . . . . . . . 38.7 tt0 -168.99 108.54 0.46 Allowed 'General case' 0 N--CA 1.469 0.513 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 -179.861 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 77.7 m-85 -84.53 140.85 31.15 Favored 'General case' 0 N--CA 1.476 0.831 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 179.353 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' F' F ' 5' ' ' ARG . . . . . . . . . . . . . 74.2 mtp180 -143.54 141.39 30.68 Favored 'General case' 0 N--CA 1.479 1.023 0 N-CA-C 109.07 -0.715 . . . . 0.0 109.07 179.933 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 76.8 m80 -150.08 118.48 6.46 Favored 'General case' 0 N--CA 1.472 0.658 0 N-CA-C 108.957 -0.757 . . . . 0.0 108.957 179.139 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' F' F ' 7' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -66.97 149.79 50.14 Favored 'General case' 0 N--CA 1.463 0.21 0 O-C-N 123.434 0.459 . . . . 0.0 111.632 -179.366 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' F' F ' 8' ' ' SER . . . . . 0.446 ' HG ' ' H ' ' F' ' 9' ' ' GLY . 6.1 t -167.73 172.27 9.37 Favored 'General case' 0 N--CA 1.476 0.869 0 CA-C-N 115.885 -0.598 . . . . 0.0 109.564 178.068 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' F' F ' 9' ' ' GLY . . . . . 0.446 ' H ' ' HG ' ' F' ' 8' ' ' SER . . . 122.76 23.64 2.24 Favored Glycine 0 N--CA 1.483 1.789 0 N-CA-C 111.903 -0.479 . . . . 0.0 111.903 179.003 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 37.6 p90 -56.1 127.47 30.74 Favored 'General case' 0 N--CA 1.473 0.679 0 N-CA-C 112.615 0.598 . . . . 0.0 112.615 -179.296 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' F' F ' 11' ' ' GLU . . . . . 0.436 ' CG ' HD22 ' E' ' 27' ' ' ASN . 45.9 mt-10 -83.45 156.79 22.72 Favored 'General case' 0 N--CA 1.477 0.875 0 N-CA-C 109.514 -0.55 . . . . 0.0 109.514 177.994 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -156.45 122.75 0.54 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.696 0 N-CA-C 108.297 -1.001 . . . . 0.0 108.297 178.274 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 37.5 m80 -106.65 160.36 15.51 Favored 'General case' 0 N--CA 1.483 1.218 0 C-N-CA 122.8 0.44 . . . . 0.0 111.294 -177.997 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 58.7 t60 -164.86 99.65 0.77 Allowed 'General case' 0 N--CA 1.486 1.374 0 CA-C-N 116.865 -0.152 . . . . 0.0 111.131 -179.775 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' F' F ' 15' ' ' GLN . . . . . 0.629 HE22 ' H ' ' F' ' 37' ' ' GLY . 69.3 mt-30 -126.15 -174.68 3.16 Favored 'General case' 0 CA--C 1.488 -1.428 0 N-CA-C 108.02 -1.104 . . . . 0.0 108.02 -179.893 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -169.86 103.93 0.32 Allowed 'General case' 0 CA--C 1.541 0.61 0 CA-C-N 114.677 -1.147 . . . . 0.0 109.218 178.969 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 9.6 mp -110.93 149.92 29.96 Favored 'General case' 0 N--CA 1.489 1.518 0 N-CA-C 108.933 -0.766 . . . . 0.0 108.933 -179.704 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 46.3 t -143.85 118.32 3.77 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.223 0 CA-C-O 118.975 -0.536 . . . . 0.0 109.827 178.653 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 19.5 m-85 -69.4 155.15 40.92 Favored 'General case' 0 C--N 1.358 0.96 0 N-CA-C 107.506 -1.294 . . . . 0.0 107.506 176.721 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 14.9 t80 -173.13 -57.1 0.02 OUTLIER 'General case' 0 N--CA 1.483 1.198 0 CA-C-O 121.564 0.697 . . . . 0.0 109.613 179.245 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -42.52 88.47 0.0 OUTLIER 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 114.716 -1.129 . . . . 0.0 112.856 -179.015 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 44.1 mt-10 -60.28 158.2 12.1 Favored 'General case' 0 N--CA 1.472 0.643 0 CA-C-N 115.085 -0.961 . . . . 0.0 110.999 179.437 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 12.1 m-20 -140.2 134.97 31.9 Favored 'General case' 0 N--CA 1.482 1.132 0 C-N-CA 122.752 0.421 . . . . 0.0 110.784 -179.822 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' F' F ' 24' ' ' VAL . . . . . . . . . . . . . 21.3 t -84.51 -115.73 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.986 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 179.327 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -108.36 53.31 0.6 Allowed Glycine 0 N--CA 1.477 1.373 0 N-CA-C 111.154 -0.778 . . . . 0.0 111.154 -179.872 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' F' F ' 26' ' ' SER . . . . . 0.596 ' HG ' ' HZ2' ' F' ' 28' ' ' LYS . 87.3 p -76.75 126.36 30.85 Favored 'General case' 0 N--CA 1.47 0.535 0 N-CA-C 109.313 -0.625 . . . . 0.0 109.313 178.141 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' F' F ' 27' ' ' ASN . . . . . 0.454 HD22 ' CG ' ' D' ' 11' ' ' GLU . 48.7 t30 -66.48 100.7 0.68 Allowed 'General case' 0 N--CA 1.471 0.609 0 N-CA-C 108.195 -1.039 . . . . 0.0 108.195 178.412 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' F' F ' 28' ' ' LYS . . . . . 0.596 ' HZ2' ' HG ' ' F' ' 26' ' ' SER . 66.6 mttm -95.39 127.65 41.61 Favored 'General case' 0 N--CA 1.483 1.221 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 -179.082 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.53 -129.15 0.01 OUTLIER Glycine 0 CA--C 1.539 1.576 0 N-CA-C 111.139 -0.784 . . . . 0.0 111.139 179.161 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -131.17 126.67 36.23 Favored 'General case' 0 N--CA 1.488 1.451 0 CA-C-N 117.308 0.554 . . . . 0.0 111.058 -179.668 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 32.2 mt -90.95 160.14 2.74 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.237 0 N-CA-C 106.236 -1.764 . . . . 0.0 106.236 178.265 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 41.0 mt -139.09 93.65 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.763 0 N-CA-C 109.671 -0.492 . . . . 0.0 109.671 179.864 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 53.61 106.0 0.01 OUTLIER Glycine 0 CA--C 1.532 1.114 0 CA-C-N 116.099 -0.5 . . . . 0.0 114.121 177.607 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 97.8 mt -72.0 153.94 41.47 Favored 'General case' 0 CA--C 1.54 0.561 0 N-CA-C 107.295 -1.372 . . . . 0.0 107.295 176.589 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 27.5 ttt -146.75 140.21 25.7 Favored 'General case' 0 N--CA 1.481 1.087 0 N-CA-C 108.408 -0.96 . . . . 0.0 108.408 178.819 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 75.8 t -161.13 153.02 4.29 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.472 0 N-CA-C 106.452 -1.685 . . . . 0.0 106.452 -179.073 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' F' F ' 37' ' ' GLY . . . . . 0.629 ' H ' HE22 ' F' ' 15' ' ' GLN . . . 55.67 73.83 0.39 Allowed Glycine 0 C--N 1.316 -0.573 0 N-CA-C 111.543 -0.623 . . . . 0.0 111.543 178.049 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 175.5 -159.99 28.2 Favored Glycine 0 C--O 1.213 -1.195 0 N-CA-C 111.202 -0.759 . . . . 0.0 111.202 -179.723 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 23.3 m -126.36 139.01 52.89 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.824 0 N-CA-C 109.414 -0.588 . . . . 0.0 109.414 179.764 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 28.0 t . . . . . 0 CA--C 1.537 0.48 0 CA-C-O 117.957 -1.021 . . . . 0.0 111.181 179.703 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' G' G ' 1' ' ' ASP . . . . . . . . . . . . . 8.8 m-20 . . . . . 0 N--CA 1.491 1.588 0 N-CA-C 109.514 -0.55 . . . . 0.0 109.514 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' G' G ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.42 129.33 40.17 Favored 'General case' 0 N--CA 1.47 0.531 0 CA-C-N 115.89 -0.596 . . . . 0.0 110.511 179.69 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' G' G ' 3' ' ' GLU . . . . . . . . . . . . . 38.3 tt0 -168.92 108.1 0.46 Allowed 'General case' 0 N--CA 1.471 0.576 0 N-CA-C 110.158 -0.312 . . . . 0.0 110.158 179.631 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 77.4 m-85 -84.72 140.55 31.2 Favored 'General case' 0 N--CA 1.474 0.744 0 N-CA-C 109.583 -0.525 . . . . 0.0 109.583 179.287 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' G' G ' 5' ' ' ARG . . . . . . . . . . . . . 74.1 mtp180 -144.01 140.97 29.88 Favored 'General case' 0 N--CA 1.482 1.162 0 N-CA-C 109.178 -0.675 . . . . 0.0 109.178 -179.671 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 76.6 m80 -149.47 119.84 7.36 Favored 'General case' 0 N--CA 1.472 0.666 0 N-CA-C 109.04 -0.726 . . . . 0.0 109.04 179.016 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 8.7 m-20 -69.05 145.27 53.62 Favored 'General case' 0 CA--C 1.537 0.462 0 O-C-N 123.509 0.505 . . . . 0.0 112.062 -179.167 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' G' G ' 8' ' ' SER . . . . . 0.457 ' HG ' ' H ' ' G' ' 9' ' ' GLY . 5.6 t -163.98 173.6 12.41 Favored 'General case' 0 N--CA 1.47 0.534 0 N-CA-C 109.474 -0.565 . . . . 0.0 109.474 178.2 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' G' G ' 9' ' ' GLY . . . . . 0.457 ' H ' ' HG ' ' G' ' 8' ' ' SER . . . 122.47 23.33 2.37 Favored Glycine 0 N--CA 1.48 1.613 0 N-CA-C 111.731 -0.548 . . . . 0.0 111.731 178.942 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 41.7 p90 -56.55 127.68 32.46 Favored 'General case' 0 N--CA 1.475 0.8 0 N-CA-C 112.381 0.511 . . . . 0.0 112.381 -178.862 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 46.1 mt-10 -84.02 155.74 22.59 Favored 'General case' 0 N--CA 1.472 0.638 0 CA-C-O 121.05 0.452 . . . . 0.0 109.935 178.595 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -156.4 123.28 0.57 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.05 0 N-CA-C 108.277 -1.009 . . . . 0.0 108.277 178.545 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 35.3 m80 -106.36 160.21 15.55 Favored 'General case' 0 N--CA 1.481 1.093 0 CA-C-N 115.213 -0.903 . . . . 0.0 110.845 -178.419 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 59.2 t60 -165.64 99.27 0.68 Allowed 'General case' 0 N--CA 1.484 1.238 0 CA-C-N 116.453 -0.339 . . . . 0.0 110.777 179.51 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' G' G ' 15' ' ' GLN . . . . . 0.616 HE22 ' H ' ' G' ' 37' ' ' GLY . 69.4 mt-30 -125.18 -175.0 3.19 Favored 'General case' 0 CA--C 1.493 -1.237 0 N-CA-C 108.031 -1.099 . . . . 0.0 108.031 -179.94 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -169.76 103.46 0.32 Allowed 'General case' 0 CA--C 1.541 0.624 0 CA-C-N 114.904 -1.043 . . . . 0.0 109.338 179.013 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 9.6 mp -109.89 149.5 29.79 Favored 'General case' 0 N--CA 1.49 1.533 0 N-CA-C 109.21 -0.663 . . . . 0.0 109.21 -179.793 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 43.9 t -145.24 117.64 2.31 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.841 0 N-CA-C 109.607 -0.516 . . . . 0.0 109.607 178.33 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 28.8 m-85 -68.11 149.45 49.6 Favored 'General case' 0 C--N 1.37 1.495 0 O-C-N 124.873 1.358 . . . . 0.0 107.842 176.653 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' G' G ' 20' ' ' PHE . . . . . 0.402 ' O ' ' N ' ' G' ' 22' ' ' GLU . 12.0 t80 -171.46 -56.15 0.02 OUTLIER 'General case' 0 N--CA 1.484 1.274 0 N-CA-C 110.205 -0.294 . . . . 0.0 110.205 179.943 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -42.99 90.01 0.0 OUTLIER 'General case' 0 C--N 1.325 -0.485 0 C-N-CA 123.521 0.729 . . . . 0.0 112.343 179.895 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' G' G ' 22' ' ' GLU . . . . . 0.402 ' N ' ' O ' ' G' ' 20' ' ' PHE . 46.1 mt-10 -61.44 158.65 14.28 Favored 'General case' 0 N--CA 1.468 0.43 0 CA-C-N 114.895 -1.048 . . . . 0.0 110.149 179.087 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 12.0 m-20 -140.11 135.49 32.59 Favored 'General case' 0 N--CA 1.481 1.103 0 C-N-CA 122.702 0.401 . . . . 0.0 110.3 -179.897 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' G' G ' 24' ' ' VAL . . . . . . . . . . . . . 21.4 t -85.63 -115.24 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.96 0 N-CA-C 108.331 -0.989 . . . . 0.0 108.331 179.356 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -108.8 53.87 0.57 Allowed Glycine 0 N--CA 1.477 1.43 0 N-CA-C 111.382 -0.687 . . . . 0.0 111.382 -179.883 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' G' G ' 26' ' ' SER . . . . . 0.602 ' HG ' ' HZ2' ' G' ' 28' ' ' LYS . 86.8 p -77.32 126.6 31.19 Favored 'General case' 0 C--N 1.327 -0.413 0 N-CA-C 109.146 -0.686 . . . . 0.0 109.146 178.08 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' G' G ' 27' ' ' ASN . . . . . 0.419 HD22 ' CG ' ' H' ' 11' ' ' GLU . 48.1 t30 -66.38 100.31 0.63 Allowed 'General case' 0 N--CA 1.469 0.504 0 N-CA-C 108.531 -0.915 . . . . 0.0 108.531 178.542 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' G' G ' 28' ' ' LYS . . . . . 0.602 ' HZ2' ' HG ' ' G' ' 26' ' ' SER . 67.1 mttm -94.65 127.56 40.7 Favored 'General case' 0 N--CA 1.484 1.259 0 N-CA-C 109.646 -0.501 . . . . 0.0 109.646 -179.452 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -62.95 -127.11 0.01 OUTLIER Glycine 0 CA--C 1.529 0.962 0 N-CA-C 111.166 -0.774 . . . . 0.0 111.166 179.227 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -132.81 125.73 30.71 Favored 'General case' 0 N--CA 1.47 0.532 0 C-N-CA 122.874 0.47 . . . . 0.0 110.563 -179.141 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 40.9 mt -90.23 162.15 2.52 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.667 0 N-CA-C 106.477 -1.675 . . . . 0.0 106.477 178.356 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 45.0 mt -140.11 95.01 0.78 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.312 0 CA-C-N 119.756 1.162 . . . . 0.0 109.834 178.212 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 53.98 105.26 0.01 OUTLIER Glycine 0 CA--C 1.532 1.115 0 N-CA-C 114.07 0.388 . . . . 0.0 114.07 177.53 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 98.8 mt -71.93 152.85 42.23 Favored 'General case' 0 CA--C 1.539 0.536 0 N-CA-C 107.366 -1.346 . . . . 0.0 107.366 176.729 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 27.5 ttt -146.27 141.13 27.03 Favored 'General case' 0 N--CA 1.477 0.913 0 N-CA-C 107.996 -1.113 . . . . 0.0 107.996 179.084 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 93.0 t -161.45 153.09 4.06 Favored 'Isoleucine or valine' 0 C--O 1.233 0.206 0 N-CA-C 106.553 -1.647 . . . . 0.0 106.553 -179.423 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' G' G ' 37' ' ' GLY . . . . . 0.616 ' H ' HE22 ' G' ' 15' ' ' GLN . . . 55.64 73.84 0.38 Allowed Glycine 0 C--N 1.313 -0.696 0 C-N-CA 121.035 -0.602 . . . . 0.0 111.951 177.701 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 174.75 -158.82 27.11 Favored Glycine 0 C--O 1.215 -1.067 0 N-CA-C 110.499 -1.04 . . . . 0.0 110.499 179.462 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 27.8 m -126.61 139.07 52.79 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.095 0 CA-C-N 117.249 0.525 . . . . 0.0 109.989 -179.824 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 36.3 t . . . . . 0 N--CA 1.469 0.503 0 CA-C-O 117.8 -1.095 . . . . 0.0 111.327 179.581 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' H' H ' 1' ' ' ASP . . . . . . . . . . . . . 9.5 m-20 . . . . . 0 N--CA 1.49 1.571 0 N-CA-C 109.625 -0.509 . . . . 0.0 109.625 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' H' H ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.2 129.35 40.37 Favored 'General case' 0 N--CA 1.468 0.448 0 CA-C-N 115.947 -0.57 . . . . 0.0 110.491 179.607 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' H' H ' 3' ' ' GLU . . . . . . . . . . . . . 38.8 tt0 -168.98 107.88 0.45 Allowed 'General case' 0 N--CA 1.47 0.546 0 N-CA-C 110.047 -0.353 . . . . 0.0 110.047 179.8 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 77.9 m-85 -84.52 140.86 31.15 Favored 'General case' 0 N--CA 1.474 0.765 0 N-CA-C 109.526 -0.546 . . . . 0.0 109.526 179.313 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' H' H ' 5' ' ' ARG . . . . . . . . . . . . . 74.2 mtp180 -144.22 140.87 29.54 Favored 'General case' 0 N--CA 1.481 1.103 0 N-CA-C 109.162 -0.681 . . . . 0.0 109.162 -179.65 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 76.9 m80 -149.46 119.79 7.34 Favored 'General case' 0 N--CA 1.475 0.79 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 179.07 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 8.8 m-20 -69.05 145.27 53.63 Favored 'General case' 0 N--CA 1.468 0.43 0 CA-C-N 116.203 -0.453 . . . . 0.0 112.092 -179.305 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' H' H ' 8' ' ' SER . . . . . 0.465 ' HG ' ' H ' ' H' ' 9' ' ' GLY . 6.3 t -163.97 172.82 13.38 Favored 'General case' 0 N--CA 1.47 0.555 0 N-CA-C 109.458 -0.571 . . . . 0.0 109.458 178.555 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' H' H ' 9' ' ' GLY . . . . . 0.465 ' H ' ' HG ' ' H' ' 8' ' ' SER . . . 122.69 23.5 2.29 Favored Glycine 0 N--CA 1.481 1.67 0 N-CA-C 111.77 -0.532 . . . . 0.0 111.77 179.008 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 40.8 p90 -56.49 127.58 31.9 Favored 'General case' 0 N--CA 1.472 0.674 0 N-CA-C 112.461 0.541 . . . . 0.0 112.461 -178.986 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' H' H ' 11' ' ' GLU . . . . . 0.419 ' CG ' HD22 ' G' ' 27' ' ' ASN . 46.1 mt-10 -83.94 155.85 22.63 Favored 'General case' 0 N--CA 1.473 0.687 0 CA-C-O 121.086 0.469 . . . . 0.0 109.906 178.706 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -156.63 122.92 0.53 Allowed 'Isoleucine or valine' 0 CA--C 1.554 1.126 0 N-CA-C 108.335 -0.987 . . . . 0.0 108.335 178.649 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 34.1 m80 -106.08 160.45 15.3 Favored 'General case' 0 N--CA 1.48 1.047 0 CA-C-N 115.167 -0.924 . . . . 0.0 110.943 -178.385 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 58.1 t60 -165.86 99.43 0.66 Allowed 'General case' 0 N--CA 1.483 1.204 0 CA-C-N 116.532 -0.303 . . . . 0.0 110.854 179.533 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' H' H ' 15' ' ' GLN . . . . . 0.642 HE22 ' H ' ' H' ' 37' ' ' GLY . 70.0 mt-30 -125.34 -175.33 3.29 Favored 'General case' 0 CA--C 1.49 -1.335 0 N-CA-C 107.834 -1.172 . . . . 0.0 107.834 -179.829 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -169.51 103.95 0.35 Allowed 'General case' 0 CA--C 1.541 0.623 0 CA-C-N 114.808 -1.087 . . . . 0.0 109.182 178.987 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 9.7 mp -110.34 149.15 30.64 Favored 'General case' 0 N--CA 1.489 1.502 0 N-CA-C 109.115 -0.698 . . . . 0.0 109.115 -179.746 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 43.7 t -144.99 117.51 2.38 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.818 0 N-CA-C 109.705 -0.48 . . . . 0.0 109.705 178.386 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 29.1 m-85 -68.64 149.74 48.78 Favored 'General case' 0 C--N 1.37 1.489 0 O-C-N 124.83 1.331 . . . . 0.0 107.855 176.741 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 12.5 t80 -172.45 -56.23 0.02 OUTLIER 'General case' 0 N--CA 1.482 1.162 0 N-CA-C 110.209 -0.293 . . . . 0.0 110.209 -179.882 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -42.88 90.2 0.0 OUTLIER 'General case' 0 CA--C 1.536 0.406 0 C-N-CA 123.429 0.692 . . . . 0.0 112.031 -179.971 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 46.0 mt-10 -61.34 158.95 13.34 Favored 'General case' 0 N--CA 1.469 0.522 0 CA-C-N 114.907 -1.042 . . . . 0.0 110.22 179.245 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 12.3 m-20 -140.14 135.74 32.79 Favored 'General case' 0 N--CA 1.482 1.148 0 C-N-CA 122.658 0.383 . . . . 0.0 110.301 -179.949 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' H' H ' 24' ' ' VAL . . . . . . . . . . . . . 21.3 t -85.81 -115.48 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.991 0 N-CA-C 108.467 -0.938 . . . . 0.0 108.467 179.366 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . -108.3 53.3 0.6 Allowed Glycine 0 N--CA 1.479 1.558 0 N-CA-C 111.138 -0.785 . . . . 0.0 111.138 -179.878 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' H' H ' 26' ' ' SER . . . . . 0.6 ' HG ' ' HZ2' ' H' ' 28' ' ' LYS . 85.5 p -77.04 126.64 31.31 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 109.11 -0.7 . . . . 0.0 109.11 178.195 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' H' H ' 27' ' ' ASN . . . . . 0.412 HD22 ' CG ' ' I' ' 11' ' ' GLU . 47.7 t30 -66.7 100.81 0.73 Allowed 'General case' 0 N--CA 1.469 0.516 0 N-CA-C 108.479 -0.934 . . . . 0.0 108.479 178.589 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' H' H ' 28' ' ' LYS . . . . . 0.6 ' HZ2' ' HG ' ' H' ' 26' ' ' SER . 67.1 mttm -95.21 127.62 41.4 Favored 'General case' 0 N--CA 1.485 1.299 0 N-CA-C 109.605 -0.517 . . . . 0.0 109.605 -179.408 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.01 -126.85 0.01 OUTLIER Glycine 0 CA--C 1.528 0.877 0 N-CA-C 111.137 -0.785 . . . . 0.0 111.137 179.26 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -133.16 125.82 30.31 Favored 'General case' 0 N--CA 1.47 0.563 0 C-N-CA 122.824 0.45 . . . . 0.0 110.718 -179.126 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 40.1 mt -90.4 161.83 2.56 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.67 0 N-CA-C 106.496 -1.668 . . . . 0.0 106.496 178.369 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 46.0 mt -139.97 94.84 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.324 0 CA-C-N 119.533 1.06 . . . . 0.0 109.789 178.343 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 53.99 105.93 0.01 OUTLIER Glycine 0 CA--C 1.532 1.135 0 CA-C-N 116.291 -0.413 . . . . 0.0 114.042 177.617 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 99.1 mt -72.42 152.64 41.87 Favored 'General case' 0 CA--C 1.54 0.579 0 N-CA-C 107.255 -1.387 . . . . 0.0 107.255 176.706 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 27.6 ttt -145.94 140.82 27.22 Favored 'General case' 0 N--CA 1.478 0.975 0 N-CA-C 107.941 -1.133 . . . . 0.0 107.941 179.062 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 90.1 t -161.24 153.22 4.15 Favored 'Isoleucine or valine' 0 C--O 1.233 0.216 0 N-CA-C 106.488 -1.671 . . . . 0.0 106.488 -179.39 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' H' H ' 37' ' ' GLY . . . . . 0.642 ' H ' HE22 ' H' ' 15' ' ' GLN . . . 55.42 73.78 0.39 Allowed Glycine 0 C--N 1.314 -0.679 0 C-N-CA 121.255 -0.498 . . . . 0.0 111.949 177.796 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 174.93 -158.63 26.59 Favored Glycine 0 C--O 1.215 -1.057 0 N-CA-C 110.527 -1.029 . . . . 0.0 110.527 179.469 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 27.0 m -126.81 138.97 53.16 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.161 0 CA-C-N 117.084 0.442 . . . . 0.0 109.964 -179.823 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 35.8 t . . . . . 0 N--CA 1.468 0.431 0 CA-C-O 117.801 -1.095 . . . . 0.0 111.436 179.61 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' I' I ' 1' ' ' ASP . . . . . . . . . . . . . 9.4 m-20 . . . . . 0 N--CA 1.492 1.641 0 N-CA-C 109.488 -0.56 . . . . 0.0 109.488 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' I' I ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.69 129.29 39.88 Favored 'General case' 0 N--CA 1.469 0.509 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.448 179.677 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' I' I ' 3' ' ' GLU . . . . . . . . . . . . . 38.4 tt0 -168.92 108.07 0.46 Allowed 'General case' 0 N--CA 1.471 0.612 0 N-CA-C 110.076 -0.342 . . . . 0.0 110.076 179.8 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 77.4 m-85 -84.68 141.01 30.9 Favored 'General case' 0 N--CA 1.475 0.825 0 N-CA-C 109.54 -0.541 . . . . 0.0 109.54 179.277 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' I' I ' 5' ' ' ARG . . . . . . . . . . . . . 74.0 mtp180 -144.39 141.02 29.4 Favored 'General case' 0 N--CA 1.482 1.169 0 N-CA-C 109.079 -0.712 . . . . 0.0 109.079 -179.687 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 76.8 m80 -149.62 119.41 7.06 Favored 'General case' 0 N--CA 1.472 0.636 0 N-CA-C 109.017 -0.734 . . . . 0.0 109.017 179.17 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 8.6 m-20 -68.67 145.42 53.89 Favored 'General case' 0 N--CA 1.467 0.406 0 O-C-N 123.455 0.472 . . . . 0.0 112.024 -179.244 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' I' I ' 8' ' ' SER . . . . . 0.451 ' HG ' ' H ' ' I' ' 9' ' ' GLY . 6.6 t -164.17 172.9 13.06 Favored 'General case' 0 N--CA 1.469 0.502 0 N-CA-C 109.529 -0.545 . . . . 0.0 109.529 178.435 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' I' I ' 9' ' ' GLY . . . . . 0.451 ' H ' ' HG ' ' I' ' 8' ' ' SER . . . 122.68 23.48 2.29 Favored Glycine 0 N--CA 1.48 1.626 0 N-CA-C 111.76 -0.536 . . . . 0.0 111.76 179.052 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 40.9 p90 -56.54 127.57 31.92 Favored 'General case' 0 N--CA 1.474 0.744 0 N-CA-C 112.398 0.518 . . . . 0.0 112.398 -178.995 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' I' I ' 11' ' ' GLU . . . . . 0.412 ' CG ' HD22 ' H' ' 27' ' ' ASN . 46.0 mt-10 -83.92 155.83 22.67 Favored 'General case' 0 N--CA 1.474 0.76 0 CA-C-O 121.096 0.474 . . . . 0.0 109.896 178.632 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -156.54 123.05 0.54 Allowed 'Isoleucine or valine' 0 CA--C 1.553 1.082 0 N-CA-C 108.299 -1.0 . . . . 0.0 108.299 178.586 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 35.0 m80 -106.04 160.08 15.57 Favored 'General case' 0 N--CA 1.481 1.081 0 CA-C-N 115.128 -0.942 . . . . 0.0 110.978 -178.336 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 58.4 t60 -165.65 99.38 0.68 Allowed 'General case' 0 N--CA 1.484 1.239 0 CA-C-N 116.563 -0.289 . . . . 0.0 110.943 179.459 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' I' I ' 15' ' ' GLN . . . . . 0.633 HE22 ' H ' ' I' ' 37' ' ' GLY . 70.0 mt-30 -125.38 -175.12 3.23 Favored 'General case' 0 CA--C 1.489 -1.403 0 N-CA-C 107.905 -1.146 . . . . 0.0 107.905 -179.865 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -169.65 104.12 0.34 Allowed 'General case' 0 CA--C 1.541 0.615 0 CA-C-N 114.8 -1.091 . . . . 0.0 109.255 179.047 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 9.7 mp -110.43 149.34 30.42 Favored 'General case' 0 N--CA 1.488 1.465 0 N-CA-C 109.16 -0.682 . . . . 0.0 109.16 -179.763 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 43.7 t -145.2 117.57 2.3 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.863 0 N-CA-C 109.649 -0.5 . . . . 0.0 109.649 178.391 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 28.8 m-85 -68.7 149.79 48.66 Favored 'General case' 0 C--N 1.371 1.536 0 O-C-N 124.773 1.296 . . . . 0.0 107.817 176.72 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' I' I ' 20' ' ' PHE . . . . . 0.403 ' O ' ' N ' ' I' ' 22' ' ' GLU . 12.6 t80 -172.54 -56.14 0.02 OUTLIER 'General case' 0 N--CA 1.481 1.115 0 N-CA-C 110.205 -0.294 . . . . 0.0 110.205 -179.855 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -43.0 90.2 0.0 OUTLIER 'General case' 0 CA--C 1.535 0.381 0 C-N-CA 123.378 0.671 . . . . 0.0 112.06 -179.98 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' I' I ' 22' ' ' GLU . . . . . 0.403 ' N ' ' O ' ' I' ' 20' ' ' PHE . 46.1 mt-10 -61.17 158.93 12.88 Favored 'General case' 0 N--CA 1.47 0.528 0 CA-C-N 114.893 -1.049 . . . . 0.0 110.267 179.241 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 12.2 m-20 -140.22 135.68 32.61 Favored 'General case' 0 N--CA 1.482 1.143 0 C-N-CA 122.597 0.359 . . . . 0.0 110.304 -179.992 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' I' I ' 24' ' ' VAL . . . . . . . . . . . . . 21.2 t -85.8 -115.51 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.96 0 N-CA-C 108.463 -0.94 . . . . 0.0 108.463 179.386 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . -108.31 53.29 0.6 Allowed Glycine 0 N--CA 1.478 1.469 0 N-CA-C 111.249 -0.74 . . . . 0.0 111.249 -179.909 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' I' I ' 26' ' ' SER . . . . . 0.571 ' HG ' ' HZ2' ' I' ' 28' ' ' LYS . 85.9 p -77.01 126.73 31.46 Favored 'General case' 0 C--N 1.329 -0.289 0 N-CA-C 109.202 -0.666 . . . . 0.0 109.202 178.148 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 47.9 t30 -66.67 100.97 0.74 Allowed 'General case' 0 N--CA 1.469 0.488 0 N-CA-C 108.474 -0.936 . . . . 0.0 108.474 178.56 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' I' I ' 28' ' ' LYS . . . . . 0.571 ' HZ2' ' HG ' ' I' ' 26' ' ' SER . 67.2 mttm -95.38 127.52 41.5 Favored 'General case' 0 N--CA 1.483 1.224 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 -179.431 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -62.99 -127.4 0.01 OUTLIER Glycine 0 CA--C 1.53 0.969 0 N-CA-C 111.099 -0.8 . . . . 0.0 111.099 179.33 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -132.38 125.86 31.84 Favored 'General case' 0 N--CA 1.471 0.624 0 C-N-CA 122.906 0.482 . . . . 0.0 110.719 -179.109 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 39.8 mt -90.61 161.41 2.61 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.624 0 N-CA-C 106.458 -1.682 . . . . 0.0 106.458 178.233 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 47.0 mt -139.54 94.73 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.297 0 CA-C-N 119.586 1.085 . . . . 0.0 109.8 178.374 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 54.1 105.87 0.01 OUTLIER Glycine 0 CA--C 1.532 1.103 0 CA-C-N 116.32 -0.4 . . . . 0.0 114.011 177.568 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 98.7 mt -72.35 152.79 41.85 Favored 'General case' 0 CA--C 1.539 0.527 0 N-CA-C 107.295 -1.372 . . . . 0.0 107.295 176.721 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 27.6 ttt -146.02 140.77 27.06 Favored 'General case' 0 N--CA 1.478 0.956 0 N-CA-C 107.877 -1.157 . . . . 0.0 107.877 179.157 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 94.9 t -161.12 153.46 4.13 Favored 'Isoleucine or valine' 0 C--O 1.233 0.193 0 N-CA-C 106.382 -1.71 . . . . 0.0 106.382 -179.45 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' I' I ' 37' ' ' GLY . . . . . 0.633 ' H ' HE22 ' I' ' 15' ' ' GLN . . . 55.08 73.95 0.37 Allowed Glycine 0 C--N 1.313 -0.724 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.894 177.762 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 174.95 -158.67 26.65 Favored Glycine 0 C--O 1.216 -1.012 0 N-CA-C 110.547 -1.021 . . . . 0.0 110.547 179.43 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 27.3 m -126.88 138.82 53.65 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.097 0 CA-C-N 117.186 0.493 . . . . 0.0 109.86 -179.722 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 36.8 t . . . . . 0 N--CA 1.469 0.517 0 CA-C-O 117.849 -1.072 . . . . 0.0 111.329 179.525 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 9.8 m-20 . . . . . 0 N--CA 1.491 1.592 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.78 147.74 52.89 Favored 'General case' 0 N--CA 1.47 0.555 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.045 179.6 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 39.5 tt0 -162.18 104.77 1.14 Allowed 'General case' 0 N--CA 1.472 0.646 0 N-CA-C 110.075 -0.343 . . . . 0.0 110.075 179.669 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 16.5 m-85 -71.32 172.3 9.62 Favored 'General case' 0 N--CA 1.469 0.498 0 N-CA-C 109.369 -0.604 . . . . 0.0 109.369 179.681 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 54.0 mtp180 -68.03 129.7 40.71 Favored 'General case' 0 N--CA 1.467 0.383 0 CA-C-N 115.868 -0.606 . . . . 0.0 110.533 -177.798 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 45.2 m170 -96.1 125.59 40.74 Favored 'General case' 0 N--CA 1.473 0.691 0 N-CA-C 109.725 -0.472 . . . . 0.0 109.725 179.002 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 10.0 m-20 -72.23 144.81 48.32 Favored 'General case' 0 CA--C 1.532 0.255 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.109 -179.81 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 23.0 t -160.72 179.47 8.51 Favored 'General case' 0 N--CA 1.471 0.615 0 N-CA-C 109.329 -0.619 . . . . 0.0 109.329 178.89 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 124.52 19.86 2.49 Favored Glycine 0 N--CA 1.487 2.064 0 N-CA-C 111.886 -0.486 . . . . 0.0 111.886 179.896 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 43.6 p90 -57.43 129.2 40.74 Favored 'General case' 0 N--CA 1.475 0.82 0 O-C-N 122.458 -0.436 . . . . 0.0 112.084 -179.707 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 46.7 mt-10 -85.54 154.7 21.57 Favored 'General case' 0 N--CA 1.469 0.512 0 N-CA-C 109.046 -0.724 . . . . 0.0 109.046 178.406 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -153.76 129.3 1.64 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 N-CA-C 108.046 -1.094 . . . . 0.0 108.046 178.895 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 51.3 m-70 -135.05 143.75 46.89 Favored 'General case' 0 N--CA 1.49 1.543 0 CA-C-N 118.803 0.729 . . . . 0.0 110.956 -179.218 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -165.98 98.21 0.64 Allowed 'General case' 0 N--CA 1.482 1.16 0 CA-C-N 116.688 -0.233 . . . . 0.0 111.099 179.673 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . 0.501 HE21 ' CA ' ' A' ' 37' ' ' GLY . 49.6 mt-30 -108.06 -171.98 1.97 Allowed 'General case' 0 CA--C 1.503 -0.851 0 N-CA-C 108.176 -1.046 . . . . 0.0 108.176 179.712 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -164.34 97.86 0.8 Allowed 'General case' 0 N--CA 1.472 0.651 0 CA-C-N 115.243 -0.889 . . . . 0.0 109.516 178.686 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . 0.406 ' CD1' ' N ' ' A' ' 17' ' ' LEU . 4.8 mp -107.02 163.85 12.64 Favored 'General case' 0 N--CA 1.488 1.44 0 N-CA-C 108.59 -0.893 . . . . 0.0 108.59 179.916 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 56.3 t -141.28 119.05 8.84 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.31 0 CA-C-O 118.772 -0.632 . . . . 0.0 109.847 179.433 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 54.5 m-85 -70.13 158.55 35.55 Favored 'General case' 0 N--CA 1.479 1.021 0 N-CA-C 107.706 -1.22 . . . . 0.0 107.706 177.275 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 13.8 t80 -171.03 -58.46 0.02 OUTLIER 'General case' 0 N--CA 1.483 1.217 0 CA-C-O 122.424 1.107 . . . . 0.0 109.672 179.333 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.42 90.05 0.0 OUTLIER 'General case' 0 N--CA 1.457 -0.092 0 CA-C-N 113.927 -1.488 . . . . 0.0 112.852 -178.078 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 37.7 tt0 -62.13 156.51 21.42 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 115.166 -0.925 . . . . 0.0 110.618 178.891 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 12.2 m-20 -138.09 129.75 28.09 Favored 'General case' 0 N--CA 1.482 1.132 0 C-N-CA 122.93 0.492 . . . . 0.0 110.246 -179.659 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . 0.633 ' CG1' ' H ' ' A' ' 25' ' ' GLY . 39.6 t -79.6 -164.37 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 1.024 0 N-CA-C 108.518 -0.919 . . . . 0.0 108.518 179.583 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.633 ' H ' ' CG1' ' A' ' 24' ' ' VAL . . . -71.42 51.43 1.08 Allowed Glycine 0 CA--C 1.527 0.827 0 CA-C-N 118.399 0.545 . . . . 0.0 112.038 -179.086 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 27.1 p -72.36 136.45 46.14 Favored 'General case' 0 C--O 1.22 -0.488 0 N-CA-C 109.564 -0.532 . . . . 0.0 109.564 178.877 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 2.0 t-20 -68.66 95.5 0.66 Allowed 'General case' 0 N--CA 1.468 0.463 0 N-CA-C 108.479 -0.934 . . . . 0.0 108.479 178.139 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 67.8 mttm -93.34 119.26 32.27 Favored 'General case' 0 N--CA 1.481 1.108 0 N-CA-C 110.295 -0.261 . . . . 0.0 110.295 -179.104 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.12 -126.12 0.01 OUTLIER Glycine 0 CA--C 1.533 1.166 0 N-CA-C 110.485 -1.046 . . . . 0.0 110.485 178.639 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.24 134.23 48.94 Favored 'General case' 0 N--CA 1.48 1.035 0 N-CA-C 109.078 -0.712 . . . . 0.0 109.078 179.111 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 65.4 mt -83.3 138.05 19.95 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.467 0 N-CA-C 107.3 -1.37 . . . . 0.0 107.3 178.657 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 31.3 mt -130.46 127.71 62.8 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.914 0 O-C-N 123.472 0.483 . . . . 0.0 110.044 -178.592 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.27 78.9 0.14 Allowed Glycine 0 CA--C 1.524 0.653 0 CA-C-N 115.885 -0.598 . . . . 0.0 112.869 178.7 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 1.7 tt -109.94 120.82 43.67 Favored 'General case' 0 N--CA 1.481 1.077 0 N-CA-C 107.175 -1.417 . . . . 0.0 107.175 177.653 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 8.8 mtp -154.08 161.24 42.05 Favored 'General case' 0 N--CA 1.472 0.647 0 N-CA-C 108.662 -0.866 . . . . 0.0 108.662 179.736 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 78.1 t -158.07 144.76 8.81 Favored 'Isoleucine or valine' 0 C--O 1.234 0.261 0 N-CA-C 106.774 -1.565 . . . . 0.0 106.774 -179.789 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . 0.501 ' CA ' HE21 ' A' ' 15' ' ' GLN . . . 55.77 74.06 0.36 Allowed Glycine 0 C--N 1.315 -0.616 0 N-CA-C 111.511 -0.636 . . . . 0.0 111.511 178.675 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 169.99 -149.07 12.43 Favored Glycine 0 CA--C 1.519 0.324 0 N-CA-C 110.898 -0.881 . . . . 0.0 110.898 179.938 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 16.0 m -134.65 148.74 29.36 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.84 0 C-N-CA 122.675 0.39 . . . . 0.0 109.951 179.955 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 21.9 t . . . . . 0 C--O 1.22 -0.497 0 CA-C-O 117.81 -1.09 . . . . 0.0 111.043 178.931 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' B' B ' 1' ' ' ASP . . . . . . . . . . . . . 9.2 m-20 . . . . . 0 N--CA 1.491 1.61 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' B' B ' 2' ' ' ALA . . . . . . . . . . . . . . . -66.16 147.83 52.75 Favored 'General case' 0 N--CA 1.47 0.537 0 CA-C-N 116.204 -0.453 . . . . 0.0 109.98 179.636 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 3' ' ' GLU . . . . . . . . . . . . . 39.8 tt0 -162.31 104.66 1.12 Allowed 'General case' 0 N--CA 1.473 0.718 0 N-CA-C 110.072 -0.344 . . . . 0.0 110.072 179.64 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 17.3 m-85 -71.11 172.51 9.05 Favored 'General case' 0 N--CA 1.47 0.548 0 N-CA-C 109.404 -0.591 . . . . 0.0 109.404 179.625 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 54.3 mtp180 -68.36 129.61 40.45 Favored 'General case' 0 CA--C 1.534 0.349 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.525 -177.748 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 44.0 m170 -95.99 125.6 40.65 Favored 'General case' 0 N--CA 1.473 0.703 0 N-CA-C 109.797 -0.446 . . . . 0.0 109.797 179.048 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 7' ' ' ASP . . . . . . . . . . . . . 10.0 m-20 -72.18 144.98 48.34 Favored 'General case' 0 CA--C 1.532 0.269 0 CA-C-N 116.464 -0.334 . . . . 0.0 111.163 -179.863 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 8' ' ' SER . . . . . . . . . . . . . 23.1 t -160.82 179.49 8.47 Favored 'General case' 0 N--CA 1.47 0.539 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 178.851 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 124.37 19.88 2.52 Favored Glycine 0 N--CA 1.487 2.081 0 N-CA-C 111.8 -0.52 . . . . 0.0 111.8 179.854 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 43.3 p90 -57.36 129.24 40.92 Favored 'General case' 0 N--CA 1.474 0.736 0 O-C-N 122.489 -0.418 . . . . 0.0 112.073 -179.788 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 46.6 mt-10 -85.55 154.79 21.51 Favored 'General case' 0 N--CA 1.47 0.557 0 N-CA-C 109.15 -0.685 . . . . 0.0 109.15 178.389 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -153.8 129.09 1.56 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.328 0 N-CA-C 108.188 -1.041 . . . . 0.0 108.188 178.839 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 50.9 m-70 -134.8 143.87 47.33 Favored 'General case' 0 N--CA 1.49 1.566 0 CA-C-N 118.79 0.723 . . . . 0.0 110.91 -179.089 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -166.02 98.23 0.63 Allowed 'General case' 0 N--CA 1.483 1.203 0 CA-C-N 116.616 -0.266 . . . . 0.0 111.117 179.619 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . 0.495 HE21 ' CA ' ' B' ' 37' ' ' GLY . 49.7 mt-30 -108.09 -172.52 2.08 Favored 'General case' 0 CA--C 1.502 -0.896 0 N-CA-C 108.168 -1.049 . . . . 0.0 108.168 179.805 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -164.06 97.69 0.83 Allowed 'General case' 0 N--CA 1.473 0.698 0 CA-C-N 115.152 -0.931 . . . . 0.0 109.411 178.747 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . 0.41 ' N ' ' CD1' ' B' ' 17' ' ' LEU . 4.8 mp -106.97 163.91 12.58 Favored 'General case' 0 N--CA 1.488 1.427 0 N-CA-C 108.506 -0.924 . . . . 0.0 108.506 179.867 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 58.7 t -141.37 118.7 8.22 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.358 0 CA-C-O 118.957 -0.544 . . . . 0.0 109.821 179.512 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 56.0 m-85 -70.39 158.64 35.62 Favored 'General case' 0 N--CA 1.477 0.907 0 N-CA-C 107.614 -1.254 . . . . 0.0 107.614 177.25 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 14.5 t80 -171.64 -57.7 0.02 OUTLIER 'General case' 0 N--CA 1.482 1.164 0 CA-C-O 122.284 1.04 . . . . 0.0 109.764 179.288 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.56 90.49 0.0 OUTLIER 'General case' 0 C--O 1.232 0.156 0 CA-C-N 114.098 -1.41 . . . . 0.0 112.682 -178.126 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 37.6 tt0 -62.55 156.37 23.28 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 115.173 -0.921 . . . . 0.0 110.544 179.038 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 12.3 m-20 -138.0 130.16 28.88 Favored 'General case' 0 N--CA 1.483 1.196 0 C-N-CA 123.01 0.524 . . . . 0.0 110.193 -179.671 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . 0.649 ' CG1' ' H ' ' B' ' 25' ' ' GLY . 39.2 t -80.13 -163.89 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.037 0 N-CA-C 108.593 -0.891 . . . . 0.0 108.593 179.618 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . 0.649 ' H ' ' CG1' ' B' ' 24' ' ' VAL . . . -71.36 50.93 1.05 Allowed Glycine 0 C--N 1.342 0.897 0 CA-C-N 118.324 0.511 . . . . 0.0 112.045 -179.182 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 28.9 p -72.16 136.16 46.38 Favored 'General case' 0 C--O 1.22 -0.476 0 N-CA-C 109.644 -0.502 . . . . 0.0 109.644 178.798 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 2.0 t-20 -68.61 95.39 0.64 Allowed 'General case' 0 N--CA 1.469 0.5 0 N-CA-C 108.495 -0.928 . . . . 0.0 108.495 178.137 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 67.9 mttm -93.19 119.12 32.03 Favored 'General case' 0 N--CA 1.481 1.1 0 N-CA-C 110.358 -0.238 . . . . 0.0 110.358 -179.061 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.08 -125.67 0.01 OUTLIER Glycine 0 CA--C 1.534 1.28 0 N-CA-C 110.511 -1.036 . . . . 0.0 110.511 178.64 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.65 134.36 48.51 Favored 'General case' 0 N--CA 1.481 1.103 0 N-CA-C 109.159 -0.682 . . . . 0.0 109.159 179.141 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 65.6 mt -83.43 138.25 19.6 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.462 0 N-CA-C 107.288 -1.375 . . . . 0.0 107.288 178.626 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 29.9 mt -130.78 127.56 61.82 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.884 0 O-C-N 123.541 0.525 . . . . 0.0 110.012 -178.523 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.46 78.56 0.15 Allowed Glycine 0 CA--C 1.526 0.745 0 CA-C-N 115.898 -0.592 . . . . 0.0 112.888 178.642 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 1.7 tt -109.6 120.65 43.14 Favored 'General case' 0 N--CA 1.48 1.061 0 N-CA-C 107.163 -1.421 . . . . 0.0 107.163 177.629 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 8.9 mtp -153.81 161.07 42.37 Favored 'General case' 0 N--CA 1.473 0.682 0 N-CA-C 108.704 -0.85 . . . . 0.0 108.704 179.574 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 72.8 t -157.93 144.65 9.0 Favored 'Isoleucine or valine' 0 C--O 1.233 0.201 0 N-CA-C 106.786 -1.561 . . . . 0.0 106.786 -179.739 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . 0.495 ' CA ' HE21 ' B' ' 15' ' ' GLN . . . 55.71 74.08 0.36 Allowed Glycine 0 C--N 1.317 -0.526 0 N-CA-C 111.544 -0.622 . . . . 0.0 111.544 178.713 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 169.97 -148.9 12.23 Favored Glycine 0 CA--C 1.519 0.319 0 N-CA-C 110.796 -0.922 . . . . 0.0 110.796 179.886 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 16.1 m -134.69 148.73 29.32 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.823 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 -179.914 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 21.9 t . . . . . 0 N--CA 1.47 0.54 0 CA-C-O 117.717 -1.135 . . . . 0.0 110.959 178.801 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' C' C ' 1' ' ' ASP . . . . . . . . . . . . . 9.0 m-20 . . . . . 0 N--CA 1.49 1.551 0 N-CA-C 109.4 -0.593 . . . . 0.0 109.4 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' C' C ' 2' ' ' ALA . . . . . . . . . . . . . . . -66.0 147.69 52.96 Favored 'General case' 0 N--CA 1.469 0.491 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.128 179.562 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' C' C ' 3' ' ' GLU . . . . . . . . . . . . . 39.5 tt0 -162.14 104.83 1.15 Allowed 'General case' 0 N--CA 1.472 0.659 0 N-CA-C 110.145 -0.317 . . . . 0.0 110.145 179.69 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 17.4 m-85 -71.3 172.61 9.05 Favored 'General case' 0 N--CA 1.469 0.516 0 N-CA-C 109.473 -0.565 . . . . 0.0 109.473 179.677 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 54.4 mtp180 -68.37 129.25 39.36 Favored 'General case' 0 N--CA 1.468 0.469 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.481 -177.729 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 44.7 m170 -95.74 125.66 40.47 Favored 'General case' 0 N--CA 1.474 0.733 0 N-CA-C 109.714 -0.476 . . . . 0.0 109.714 178.978 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' C' C ' 7' ' ' ASP . . . . . . . . . . . . . 10.1 m-20 -72.33 145.18 47.97 Favored 'General case' 0 CA--C 1.53 0.208 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.198 -179.842 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' C' C ' 8' ' ' SER . . . . . . . . . . . . . 22.9 t -160.91 179.53 8.4 Favored 'General case' 0 N--CA 1.469 0.506 0 N-CA-C 109.343 -0.614 . . . . 0.0 109.343 178.835 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 124.46 19.83 2.51 Favored Glycine 0 N--CA 1.487 2.055 0 N-CA-C 111.772 -0.531 . . . . 0.0 111.772 179.822 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 43.9 p90 -57.24 128.96 39.64 Favored 'General case' 0 N--CA 1.473 0.705 0 O-C-N 122.403 -0.469 . . . . 0.0 112.127 -179.767 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 46.5 mt-10 -85.35 154.95 21.54 Favored 'General case' 0 N--CA 1.47 0.553 0 N-CA-C 109.049 -0.723 . . . . 0.0 109.049 178.426 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -154.08 129.05 1.49 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 N-CA-C 108.174 -1.047 . . . . 0.0 108.174 178.802 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 50.7 m-70 -134.68 144.2 47.66 Favored 'General case' 0 N--CA 1.491 1.624 0 CA-C-N 118.716 0.689 . . . . 0.0 110.974 -179.117 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -166.38 98.16 0.6 Allowed 'General case' 0 N--CA 1.482 1.174 0 CA-C-N 116.674 -0.239 . . . . 0.0 111.161 179.753 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' C' C ' 15' ' ' GLN . . . . . 0.501 HE21 ' CA ' ' C' ' 37' ' ' GLY . 49.7 mt-30 -108.31 -172.12 2.0 Allowed 'General case' 0 CA--C 1.501 -0.941 0 N-CA-C 108.177 -1.046 . . . . 0.0 108.177 179.796 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -164.29 97.84 0.81 Allowed 'General case' 0 N--CA 1.472 0.626 0 CA-C-N 115.143 -0.935 . . . . 0.0 109.443 178.761 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' C' C ' 17' ' ' LEU . . . . . 0.406 ' N ' ' CD1' ' C' ' 17' ' ' LEU . 4.8 mp -106.96 163.81 12.65 Favored 'General case' 0 N--CA 1.487 1.406 0 N-CA-C 108.559 -0.904 . . . . 0.0 108.559 179.89 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 58.0 t -141.28 118.81 8.54 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.293 0 CA-C-O 118.917 -0.563 . . . . 0.0 109.805 179.48 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 55.1 m-85 -70.49 158.73 35.55 Favored 'General case' 0 N--CA 1.478 0.926 0 N-CA-C 107.529 -1.285 . . . . 0.0 107.529 177.317 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 14.7 t80 -171.63 -57.67 0.02 OUTLIER 'General case' 0 N--CA 1.481 1.104 0 CA-C-O 122.246 1.022 . . . . 0.0 109.857 179.21 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.59 90.4 0.0 OUTLIER 'General case' 0 C--O 1.231 0.107 0 CA-C-N 114.181 -1.372 . . . . 0.0 112.79 -178.168 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 38.0 tt0 -62.32 156.45 22.25 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.223 -0.899 . . . . 0.0 110.577 179.09 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 12.2 m-20 -138.05 129.93 28.42 Favored 'General case' 0 N--CA 1.482 1.156 0 C-N-CA 123.026 0.531 . . . . 0.0 110.255 -179.689 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' C' C ' 24' ' ' VAL . . . . . 0.651 ' CG1' ' H ' ' C' ' 25' ' ' GLY . 40.4 t -79.99 -164.08 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.035 0 N-CA-C 108.523 -0.917 . . . . 0.0 108.523 179.639 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' C' C ' 25' ' ' GLY . . . . . 0.651 ' H ' ' CG1' ' C' ' 24' ' ' VAL . . . -71.34 50.96 1.04 Allowed Glycine 0 CA--C 1.527 0.812 0 CA-C-N 118.363 0.529 . . . . 0.0 112.042 -179.019 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 27.3 p -72.13 136.43 46.52 Favored 'General case' 0 C--O 1.221 -0.414 0 N-CA-C 109.526 -0.546 . . . . 0.0 109.526 178.902 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 2.0 t-20 -68.87 95.65 0.7 Allowed 'General case' 0 N--CA 1.468 0.472 0 N-CA-C 108.419 -0.956 . . . . 0.0 108.419 178.107 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 67.9 mttm -93.46 119.07 32.11 Favored 'General case' 0 N--CA 1.481 1.105 0 N-CA-C 110.354 -0.239 . . . . 0.0 110.354 -179.092 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.93 -126.03 0.01 OUTLIER Glycine 0 CA--C 1.534 1.281 0 N-CA-C 110.563 -1.015 . . . . 0.0 110.563 178.606 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.28 134.12 48.89 Favored 'General case' 0 N--CA 1.481 1.102 0 N-CA-C 109.105 -0.702 . . . . 0.0 109.105 179.135 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 65.3 mt -83.26 138.0 20.02 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.451 0 N-CA-C 107.311 -1.366 . . . . 0.0 107.311 178.538 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 30.7 mt -130.41 127.79 63.03 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.931 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.015 -178.537 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.14 78.57 0.15 Allowed Glycine 0 CA--C 1.525 0.68 0 CA-C-N 115.908 -0.587 . . . . 0.0 112.933 178.677 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 1.7 tt -109.49 120.77 43.51 Favored 'General case' 0 N--CA 1.48 1.035 0 N-CA-C 107.202 -1.407 . . . . 0.0 107.202 177.606 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 8.8 mtp -153.93 161.22 42.16 Favored 'General case' 0 N--CA 1.469 0.524 0 N-CA-C 108.664 -0.865 . . . . 0.0 108.664 179.665 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 79.2 t -158.05 144.86 8.89 Favored 'Isoleucine or valine' 0 C--O 1.233 0.232 0 N-CA-C 106.845 -1.539 . . . . 0.0 106.845 -179.832 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' C' C ' 37' ' ' GLY . . . . . 0.501 ' CA ' HE21 ' C' ' 15' ' ' GLN . . . 55.65 74.03 0.37 Allowed Glycine 0 C--N 1.316 -0.535 0 CA-C-N 115.812 -0.631 . . . . 0.0 111.537 178.687 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 169.95 -149.12 12.54 Favored Glycine 0 CA--C 1.518 0.275 0 N-CA-C 110.815 -0.914 . . . . 0.0 110.815 179.941 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 16.4 m -134.58 148.85 29.41 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.872 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 -179.964 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 22.0 t . . . . . 0 N--CA 1.469 0.507 0 CA-C-O 117.717 -1.135 . . . . 0.0 110.952 178.916 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' D' D ' 1' ' ' ASP . . . . . . . . . . . . . 9.2 m-20 . . . . . 0 N--CA 1.489 1.511 0 N-CA-C 109.0 -0.741 . . . . 0.0 109.0 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' D' D ' 2' ' ' ALA . . . . . . . . . . . . . . . -67.96 148.78 50.61 Favored 'General case' 0 N--CA 1.467 0.411 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.383 179.337 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' D' D ' 3' ' ' GLU . . . . . . . . . . . . . 40.0 tt0 -160.99 107.28 1.43 Allowed 'General case' 0 C--O 1.204 -1.291 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.005 -179.8 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 18.7 m-85 -77.12 167.66 21.4 Favored 'General case' 0 C--N 1.303 -1.428 0 C-N-CA 126.343 1.857 . . . . 0.0 107.9 -178.876 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' D' D ' 5' ' ' ARG . . . . . 0.469 HH21 ' CG1' ' C' ' 24' ' ' VAL 0.344 64.5 mtp180 -77.03 133.52 39.09 Favored 'General case' 0 C--N 1.355 0.821 0 CA-C-O 123.248 1.499 . . . . 0.0 107.088 -167.987 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 45.2 m170 -94.27 128.13 40.56 Favored 'General case' 0 C--N 1.365 1.273 0 CA-C-N 113.371 -1.741 . . . . 0.0 108.502 -177.669 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' D' D ' 7' ' ' ASP . . . . . . . . . . . . . 6.7 m-20 -66.35 130.48 43.37 Favored 'General case' 0 C--N 1.31 -1.134 0 C-N-CA 127.505 2.322 . . . . 0.0 115.117 175.029 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' D' D ' 8' ' ' SER . . . . . . . . . . . . . 22.9 t -152.11 -178.53 6.84 Favored 'General case' 0 N--CA 1.478 0.954 0 CA-C-N 119.168 0.895 . . . . 0.0 109.411 177.145 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 124.58 18.85 2.64 Favored Glycine 0 N--CA 1.485 1.914 0 N-CA-C 111.788 -0.525 . . . . 0.0 111.788 178.691 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 40.2 p90 -56.21 130.62 45.09 Favored 'General case' 0 CA--C 1.544 0.74 0 N-CA-C 112.134 0.42 . . . . 0.0 112.134 -179.209 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 46.7 mt-10 -85.6 152.5 23.08 Favored 'General case' 0 N--CA 1.475 0.78 0 N-CA-C 109.649 -0.5 . . . . 0.0 109.649 177.479 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -149.6 130.1 4.37 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.447 0 N-CA-C 108.1 -1.074 . . . . 0.0 108.1 175.357 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 48.5 m-70 -129.81 146.97 51.53 Favored 'General case' 0 N--CA 1.483 1.218 0 CA-C-N 117.867 0.303 . . . . 0.0 111.286 176.482 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -165.35 104.84 0.74 Allowed 'General case' 0 N--CA 1.483 1.209 0 N-CA-C 109.688 -0.486 . . . . 0.0 109.688 173.354 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' D' D ' 15' ' ' GLN . . . . . 0.51 HE21 ' CA ' ' D' ' 37' ' ' GLY . 49.1 mt-30 -111.62 -175.59 2.73 Favored 'General case' 0 CA--C 1.493 -1.249 0 N-CA-C 108.018 -1.104 . . . . 0.0 108.018 179.092 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 88.7 tttt -160.56 106.12 1.47 Allowed 'General case' 0 CA--C 1.538 0.5 0 N-CA-C 107.683 -1.228 . . . . 0.0 107.683 175.383 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 5.7 mp -113.38 163.03 15.38 Favored 'General case' 0 N--CA 1.488 1.456 0 N-CA-C 107.945 -1.132 . . . . 0.0 107.945 179.457 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 53.3 t -140.96 123.63 15.5 Favored 'Isoleucine or valine' 0 C--N 1.362 1.136 0 N-CA-C 108.753 -0.832 . . . . 0.0 108.753 175.964 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 79.1 m-85 -62.97 151.3 39.99 Favored 'General case' 0 C--N 1.355 0.82 0 C-N-CA 124.517 1.127 . . . . 0.0 110.515 170.967 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 9.9 t80 -170.11 -66.91 0.02 OUTLIER 'General case' 0 N--CA 1.475 0.789 0 N-CA-C 107.781 -1.192 . . . . 0.0 107.781 179.834 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -38.27 95.43 0.01 OUTLIER 'General case' 0 CA--C 1.535 0.39 0 CA-C-N 113.99 -1.459 . . . . 0.0 111.731 -175.293 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 38.3 tt0 -65.18 157.61 28.3 Favored 'General case' 0 N--CA 1.467 0.418 0 CA-C-N 113.919 -1.491 . . . . 0.0 110.122 178.469 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 12.0 m-20 -138.68 130.46 27.82 Favored 'General case' 0 N--CA 1.479 0.985 0 C-N-CA 123.181 0.592 . . . . 0.0 110.407 -178.969 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' D' D ' 24' ' ' VAL . . . . . 0.628 ' CG1' ' H ' ' D' ' 25' ' ' GLY . 48.7 t -84.42 -160.12 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.299 0 N-CA-C 107.742 -1.206 . . . . 0.0 107.742 -178.346 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' D' D ' 25' ' ' GLY . . . . . 0.628 ' H ' ' CG1' ' D' ' 24' ' ' VAL . . . -80.3 57.19 4.67 Favored Glycine 0 C--N 1.359 1.84 0 C-N-CA 118.198 -1.953 . . . . 0.0 110.695 -175.556 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 54.0 p -61.81 132.36 52.84 Favored 'General case' 0 C--N 1.346 0.431 0 CA-C-O 117.515 -1.231 . . . . 0.0 112.187 170.377 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 2.0 t-20 -65.53 95.32 0.21 Allowed 'General case' 0 C--O 1.242 0.666 0 CA-C-N 120.263 1.392 . . . . 0.0 109.044 172.049 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 67.6 mttm -95.0 122.17 37.37 Favored 'General case' 0 N--CA 1.483 1.219 0 C-N-CA 119.627 -0.829 . . . . 0.0 109.245 179.537 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -55.84 -130.18 0.01 OUTLIER Glycine 0 CA--C 1.528 0.893 0 C-N-CA 123.804 0.716 . . . . 0.0 112.045 174.717 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -125.33 139.97 53.23 Favored 'General case' 0 C--N 1.369 1.421 0 N-CA-C 108.669 -0.863 . . . . 0.0 108.669 174.602 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 65.2 mt -83.86 140.54 16.04 Favored 'Isoleucine or valine' 0 C--O 1.238 0.47 0 N-CA-C 107.374 -1.343 . . . . 0.0 107.374 176.342 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 42.1 mt -132.79 132.21 59.48 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.996 0 N-CA-C 108.329 -0.989 . . . . 0.0 108.329 178.079 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.22 76.96 0.22 Allowed Glycine 0 C--O 1.245 0.799 0 CA-C-O 118.552 -1.138 . . . . 0.0 112.519 178.351 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 2.1 tt -109.32 132.17 54.38 Favored 'General case' 0 C--N 1.371 1.528 0 N-CA-C 104.73 -2.322 . . . . 0.0 104.73 175.275 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 9.0 mtp -156.43 166.72 32.61 Favored 'General case' 0 N--CA 1.475 0.822 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 177.494 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 93.2 t -163.73 150.72 3.06 Favored 'Isoleucine or valine' 0 C--O 1.237 0.401 0 N-CA-C 104.989 -2.226 . . . . 0.0 104.989 173.986 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' D' D ' 37' ' ' GLY . . . . . 0.51 ' CA ' HE21 ' D' ' 15' ' ' GLN . . . 60.95 66.91 2.38 Favored Glycine 0 N--CA 1.444 -0.794 0 C-N-CA 118.509 -1.805 . . . . 0.0 112.129 177.13 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 166.8 -148.06 12.82 Favored Glycine 0 N--CA 1.468 0.767 0 CA-C-N 119.085 1.443 . . . . 0.0 112.296 -179.589 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 14.1 m -131.15 147.92 32.95 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.263 0 CA-C-N 119.009 1.405 . . . . 0.0 110.332 -178.908 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 21.2 t . . . . . 0 C--O 1.212 -0.897 0 N-CA-C 109.388 -0.597 . . . . 0.0 109.388 173.574 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' E' E ' 1' ' ' ASP . . . . . . . . . . . . . 9.7 m-20 . . . . . 0 N--CA 1.487 1.422 0 N-CA-C 109.204 -0.665 . . . . 0.0 109.204 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' E' E ' 2' ' ' ALA . . . . . . . . . . . . . . . -67.86 149.48 49.79 Favored 'General case' 0 N--CA 1.468 0.442 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.34 179.429 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' E' E ' 3' ' ' GLU . . . . . . . . . . . . . 39.9 tt0 -162.97 103.29 1.0 Allowed 'General case' 0 C--O 1.214 -0.801 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.182 -179.704 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 15.9 m-85 -68.41 172.84 5.5 Favored 'General case' 0 N--CA 1.472 0.631 0 CA-C-O 121.171 0.51 . . . . 0.0 109.864 179.479 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' E' E ' 5' ' ' ARG . . . . . 0.437 HH21 ' CG1' ' A' ' 24' ' ' VAL . 53.0 mtp180 -68.14 130.15 42.07 Favored 'General case' 0 CA--C 1.535 0.398 0 CA-C-N 115.579 -0.737 . . . . 0.0 110.585 -177.917 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 45.6 m170 -96.42 125.3 40.81 Favored 'General case' 0 N--CA 1.476 0.854 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 178.958 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' E' E ' 7' ' ' ASP . . . . . . . . . . . . . 11.6 m-20 -71.75 145.24 48.89 Favored 'General case' 0 N--CA 1.465 0.31 0 O-C-N 123.286 0.366 . . . . 0.0 111.301 -179.823 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' E' E ' 8' ' ' SER . . . . . . . . . . . . . 22.6 t -161.05 179.88 8.07 Favored 'General case' 0 N--CA 1.473 0.702 0 N-CA-C 109.263 -0.643 . . . . 0.0 109.263 178.521 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 125.16 20.12 2.28 Favored Glycine 0 N--CA 1.482 1.754 0 N-CA-C 111.757 -0.537 . . . . 0.0 111.757 179.612 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 40.3 p90 -57.17 128.49 37.24 Favored 'General case' 0 N--CA 1.473 0.682 0 N-CA-C 112.607 0.595 . . . . 0.0 112.607 -179.214 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 45.8 mt-10 -84.37 155.08 22.48 Favored 'General case' 0 N--CA 1.475 0.813 0 N-CA-C 109.228 -0.656 . . . . 0.0 109.228 178.111 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -155.29 127.76 1.05 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.543 0 N-CA-C 108.367 -0.975 . . . . 0.0 108.367 178.764 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 47.4 m-70 -134.63 142.12 46.79 Favored 'General case' 0 N--CA 1.482 1.139 0 CA-C-O 120.591 0.234 . . . . 0.0 111.337 -177.995 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -165.17 98.38 0.73 Allowed 'General case' 0 N--CA 1.486 1.37 0 CA-C-N 116.688 -0.233 . . . . 0.0 111.127 179.711 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' E' E ' 15' ' ' GLN . . . . . 0.507 HE21 ' CA ' ' E' ' 37' ' ' GLY . 49.2 mt-30 -107.73 -172.2 2.02 Favored 'General case' 0 CA--C 1.501 -0.925 0 N-CA-C 108.393 -0.965 . . . . 0.0 108.393 179.81 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -164.34 97.88 0.8 Allowed 'General case' 0 CA--C 1.542 0.635 0 CA-C-N 115.007 -0.997 . . . . 0.0 109.337 178.697 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' E' E ' 17' ' ' LEU . . . . . 0.401 ' N ' ' CD1' ' E' ' 17' ' ' LEU . 4.7 mp -106.85 163.34 13.03 Favored 'General case' 0 N--CA 1.49 1.538 0 N-CA-C 109.075 -0.713 . . . . 0.0 109.075 -179.876 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 41.6 t -141.66 118.05 6.93 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.319 0 C-N-CA 122.684 0.394 . . . . 0.0 110.442 178.952 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 54.7 m-85 -69.43 156.31 39.05 Favored 'General case' 0 C--N 1.358 0.969 0 N-CA-C 107.489 -1.3 . . . . 0.0 107.489 176.621 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 13.1 t80 -173.29 -55.33 0.02 OUTLIER 'General case' 0 N--CA 1.484 1.244 0 CA-C-O 121.724 0.773 . . . . 0.0 110.292 179.333 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -42.35 88.94 0.0 OUTLIER 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 114.502 -1.226 . . . . 0.0 112.654 -179.036 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 37.7 tt0 -61.1 156.42 18.14 Favored 'General case' 0 N--CA 1.47 0.554 0 CA-C-N 115.014 -0.994 . . . . 0.0 110.733 179.416 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 12.0 m-20 -138.16 129.39 27.43 Favored 'General case' 0 N--CA 1.481 1.101 0 C-N-CA 123.003 0.521 . . . . 0.0 110.551 -179.52 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' E' E ' 24' ' ' VAL . . . . . 0.651 ' CG1' ' H ' ' E' ' 25' ' ' GLY . 40.4 t -79.94 -164.25 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.484 1.238 0 N-CA-C 108.164 -1.05 . . . . 0.0 108.164 179.557 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' E' E ' 25' ' ' GLY . . . . . 0.651 ' H ' ' CG1' ' E' ' 24' ' ' VAL . . . -70.79 52.25 0.92 Allowed Glycine 0 CA--C 1.529 0.928 0 CA-C-N 118.422 0.556 . . . . 0.0 112.534 -178.807 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 18.1 p -72.68 135.32 45.39 Favored 'General case' 0 C--O 1.219 -0.512 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 178.645 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 2.0 t-20 -68.36 95.33 0.6 Allowed 'General case' 0 CA--C 1.536 0.421 0 N-CA-C 107.681 -1.229 . . . . 0.0 107.681 177.866 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 67.4 mttm -93.74 118.38 31.34 Favored 'General case' 0 N--CA 1.483 1.187 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 -178.586 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.93 -124.97 0.01 OUTLIER Glycine 0 CA--C 1.539 1.587 0 N-CA-C 110.998 -0.841 . . . . 0.0 110.998 178.588 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -129.05 133.65 47.79 Favored 'General case' 0 N--CA 1.48 1.057 0 N-CA-C 109.511 -0.551 . . . . 0.0 109.511 179.493 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 65.3 mt -82.44 138.53 19.26 Favored 'Isoleucine or valine' 0 C--O 1.235 0.29 0 N-CA-C 107.158 -1.423 . . . . 0.0 107.158 178.617 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 36.2 mt -130.33 127.85 63.3 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.895 0 N-CA-C 109.437 -0.579 . . . . 0.0 109.437 -179.447 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.64 79.89 0.12 Allowed Glycine 0 CA--C 1.522 0.485 0 CA-C-N 115.914 -0.585 . . . . 0.0 113.299 179.021 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 1.8 tt -110.56 120.26 41.83 Favored 'General case' 0 N--CA 1.48 1.044 0 N-CA-C 107.312 -1.366 . . . . 0.0 107.312 177.419 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 8.7 mtp -152.4 163.23 39.92 Favored 'General case' 0 C--O 1.213 -0.864 0 N-CA-C 108.32 -0.992 . . . . 0.0 108.32 179.421 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 97.5 t -159.85 145.3 6.17 Favored 'Isoleucine or valine' 0 C--O 1.233 0.235 0 N-CA-C 106.693 -1.595 . . . . 0.0 106.693 179.919 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' E' E ' 37' ' ' GLY . . . . . 0.507 ' CA ' HE21 ' E' ' 15' ' ' GLN . . . 55.03 73.62 0.4 Allowed Glycine 0 C--N 1.316 -0.54 0 N-CA-C 111.202 -0.759 . . . . 0.0 111.202 178.769 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 171.03 -148.22 11.07 Favored Glycine 0 C--O 1.221 -0.688 0 C-N-CA 120.882 -0.675 . . . . 0.0 111.459 -179.807 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 14.0 m -136.04 147.89 27.97 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.918 0 N-CA-C 109.239 -0.652 . . . . 0.0 109.239 -179.833 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 21.5 t . . . . . 0 C--O 1.221 -0.395 0 CA-C-O 117.8 -1.095 . . . . 0.0 111.19 179.168 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' F' F ' 1' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 . . . . . 0 N--CA 1.488 1.471 0 N-CA-C 109.166 -0.679 . . . . 0.0 109.166 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' F' F ' 2' ' ' ALA . . . . . . . . . . . . . . . -67.95 149.69 49.44 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-N 116.501 -0.318 . . . . 0.0 110.285 179.519 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' F' F ' 3' ' ' GLU . . . . . . . . . . . . . 40.2 tt0 -163.11 103.23 0.98 Allowed 'General case' 0 C--O 1.212 -0.89 0 CA-C-N 116.428 -0.351 . . . . 0.0 110.054 -179.679 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 15.7 m-85 -68.3 173.17 5.04 Favored 'General case' 0 N--CA 1.473 0.691 0 CA-C-O 121.143 0.497 . . . . 0.0 110.015 179.419 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' F' F ' 5' ' ' ARG . . . . . 0.442 HH21 ' CG1' ' B' ' 24' ' ' VAL . 53.3 mtp180 -68.03 129.75 40.87 Favored 'General case' 0 CA--C 1.537 0.465 0 CA-C-N 115.422 -0.808 . . . . 0.0 110.602 -177.962 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 45.4 m170 -96.39 125.33 40.81 Favored 'General case' 0 N--CA 1.476 0.874 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 178.885 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' F' F ' 7' ' ' ASP . . . . . . . . . . . . . 11.7 m-20 -71.72 145.05 49.06 Favored 'General case' 0 N--CA 1.465 0.307 0 O-C-N 123.293 0.37 . . . . 0.0 111.423 -179.842 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' F' F ' 8' ' ' SER . . . . . . . . . . . . . 22.8 t -161.06 179.35 8.5 Favored 'General case' 0 N--CA 1.473 0.685 0 N-CA-C 109.277 -0.638 . . . . 0.0 109.277 178.448 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 125.78 19.84 2.19 Favored Glycine 0 N--CA 1.482 1.742 0 N-CA-C 111.752 -0.539 . . . . 0.0 111.752 179.634 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 40.4 p90 -57.07 128.87 39.18 Favored 'General case' 0 N--CA 1.474 0.756 0 N-CA-C 112.528 0.566 . . . . 0.0 112.528 -179.18 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 45.8 mt-10 -84.49 155.34 22.22 Favored 'General case' 0 N--CA 1.474 0.732 0 N-CA-C 109.318 -0.623 . . . . 0.0 109.318 177.986 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -155.49 127.81 1.03 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.53 0 N-CA-C 108.31 -0.996 . . . . 0.0 108.31 178.742 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 48.6 m-70 -134.74 141.97 46.62 Favored 'General case' 0 N--CA 1.482 1.128 0 CA-C-O 120.606 0.241 . . . . 0.0 111.387 -178.034 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -165.19 99.14 0.73 Allowed 'General case' 0 N--CA 1.485 1.3 0 CA-C-N 116.811 -0.177 . . . . 0.0 111.191 179.702 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' F' F ' 15' ' ' GLN . . . . . 0.513 HE21 ' CA ' ' F' ' 37' ' ' GLY . 49.1 mt-30 -108.84 -171.44 1.85 Allowed 'General case' 0 CA--C 1.499 -0.981 0 N-CA-C 108.525 -0.917 . . . . 0.0 108.525 179.817 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -164.6 98.08 0.78 Allowed 'General case' 0 CA--C 1.54 0.58 0 CA-C-N 114.883 -1.053 . . . . 0.0 109.537 178.657 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 4.8 mp -106.78 163.14 13.18 Favored 'General case' 0 N--CA 1.49 1.573 0 N-CA-C 109.029 -0.73 . . . . 0.0 109.029 -179.899 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 42.4 t -141.54 118.19 7.31 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.308 0 C-N-CA 122.584 0.354 . . . . 0.0 110.361 179.071 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 55.1 m-85 -69.51 156.06 39.48 Favored 'General case' 0 C--N 1.357 0.932 0 N-CA-C 107.329 -1.36 . . . . 0.0 107.329 176.602 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 13.6 t80 -172.92 -55.69 0.02 OUTLIER 'General case' 0 N--CA 1.483 1.22 0 CA-C-O 121.868 0.842 . . . . 0.0 109.799 179.456 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -42.24 88.8 0.0 OUTLIER 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 114.534 -1.212 . . . . 0.0 112.789 -178.992 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 38.0 tt0 -61.12 156.33 18.4 Favored 'General case' 0 N--CA 1.471 0.617 0 CA-C-N 114.943 -1.026 . . . . 0.0 110.802 179.268 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 12.0 m-20 -138.1 129.63 27.89 Favored 'General case' 0 N--CA 1.482 1.134 0 C-N-CA 122.96 0.504 . . . . 0.0 110.637 -179.638 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' F' F ' 24' ' ' VAL . . . . . 0.646 ' CG1' ' H ' ' F' ' 25' ' ' GLY . 40.0 t -80.1 -164.07 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.283 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 179.613 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' F' F ' 25' ' ' GLY . . . . . 0.646 ' H ' ' CG1' ' F' ' 24' ' ' VAL . . . -70.82 52.25 0.93 Allowed Glycine 0 C--N 1.342 0.888 0 CA-C-N 118.608 0.64 . . . . 0.0 112.378 -178.779 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 19.8 p -72.79 134.97 45.17 Favored 'General case' 0 C--O 1.218 -0.558 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 178.525 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 2.0 t-20 -68.21 95.16 0.56 Allowed 'General case' 0 CA--C 1.536 0.422 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 177.967 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 67.4 mttm -93.56 118.21 31.07 Favored 'General case' 0 N--CA 1.482 1.134 0 N-CA-C 110.066 -0.346 . . . . 0.0 110.066 -178.657 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.8 -125.33 0.01 OUTLIER Glycine 0 CA--C 1.539 1.565 0 N-CA-C 111.022 -0.831 . . . . 0.0 111.022 178.629 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.49 133.46 48.47 Favored 'General case' 0 N--CA 1.483 1.193 0 N-CA-C 109.533 -0.543 . . . . 0.0 109.533 179.479 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 65.7 mt -82.47 138.64 19.07 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.306 0 N-CA-C 107.051 -1.463 . . . . 0.0 107.051 178.587 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 35.0 mt -130.34 127.82 63.23 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.833 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 -179.437 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.56 80.05 0.11 Allowed Glycine 0 CA--C 1.525 0.67 0 CA-C-N 115.929 -0.578 . . . . 0.0 113.241 179.023 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 1.8 tt -110.65 121.23 44.81 Favored 'General case' 0 N--CA 1.48 1.067 0 N-CA-C 107.298 -1.371 . . . . 0.0 107.298 177.59 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 8.7 mtp -153.83 163.85 39.35 Favored 'General case' 0 C--O 1.212 -0.894 0 N-CA-C 108.97 -0.752 . . . . 0.0 108.97 179.314 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 98.3 t -160.19 145.48 5.79 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.27 0 N-CA-C 106.906 -1.516 . . . . 0.0 106.906 -179.857 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' F' F ' 37' ' ' GLY . . . . . 0.513 ' CA ' HE21 ' F' ' 15' ' ' GLN . . . 55.15 73.84 0.38 Allowed Glycine 0 C--N 1.317 -0.507 0 N-CA-C 111.188 -0.765 . . . . 0.0 111.188 178.624 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 170.73 -148.17 11.16 Favored Glycine 0 C--O 1.222 -0.635 0 C-N-CA 120.832 -0.699 . . . . 0.0 111.493 -179.728 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 14.1 m -136.22 147.99 27.7 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.981 0 N-CA-C 109.119 -0.697 . . . . 0.0 109.119 -179.793 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 21.6 t . . . . . 0 C--O 1.221 -0.405 0 CA-C-O 117.722 -1.132 . . . . 0.0 111.129 179.138 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' G' G ' 1' ' ' ASP . . . . . . . . . . . . . 8.0 m-20 . . . . . 0 N--CA 1.487 1.41 0 N-CA-C 109.338 -0.616 . . . . 0.0 109.338 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' G' G ' 2' ' ' ALA . . . . . . . . . . . . . . . -68.85 151.1 47.03 Favored 'General case' 0 CA--C 1.533 0.291 0 CA-C-O 120.855 0.359 . . . . 0.0 110.243 179.779 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' G' G ' 3' ' ' GLU . . . . . . . . . . . . . 40.4 tt0 -162.89 103.89 1.02 Allowed 'General case' 0 C--O 1.216 -0.706 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.088 -179.286 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 21.7 m-85 -67.93 171.49 6.66 Favored 'General case' 0 N--CA 1.475 0.778 0 CA-C-O 120.991 0.424 . . . . 0.0 110.149 179.422 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' G' G ' 5' ' ' ARG . . . . . . . . . . . . . 55.0 mtp180 -67.13 129.1 38.79 Favored 'General case' 0 N--CA 1.469 0.512 0 CA-C-N 115.65 -0.705 . . . . 0.0 110.287 -178.152 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 44.2 m170 -96.09 125.48 40.65 Favored 'General case' 0 N--CA 1.474 0.726 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 178.904 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 9.8 m-20 -72.37 141.5 48.74 Favored 'General case' 0 N--CA 1.468 0.437 0 O-C-N 123.742 0.652 . . . . 0.0 111.52 -179.698 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' G' G ' 8' ' ' SER . . . . . . . . . . . . . 23.2 t -158.58 -179.76 8.38 Favored 'General case' 0 N--CA 1.472 0.665 0 N-CA-C 109.196 -0.668 . . . . 0.0 109.196 178.408 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 125.02 20.16 2.31 Favored Glycine 0 N--CA 1.481 1.675 0 N-CA-C 111.617 -0.593 . . . . 0.0 111.617 179.477 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 43.1 p90 -57.75 128.7 38.41 Favored 'General case' 0 N--CA 1.474 0.727 0 N-CA-C 112.362 0.505 . . . . 0.0 112.362 -178.939 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 46.9 mt-10 -84.51 154.44 22.69 Favored 'General case' 0 N--CA 1.473 0.684 0 CA-C-O 121.055 0.455 . . . . 0.0 109.803 178.611 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 2.6 p -155.8 127.82 1.0 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.028 0 N-CA-C 108.353 -0.98 . . . . 0.0 108.353 178.926 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 50.2 m-70 -134.02 142.99 47.83 Favored 'General case' 0 N--CA 1.476 0.832 0 CA-C-N 115.154 -0.93 . . . . 0.0 111.077 -178.214 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -166.32 98.33 0.6 Allowed 'General case' 0 N--CA 1.484 1.227 0 CA-C-N 116.52 -0.309 . . . . 0.0 110.655 179.129 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' G' G ' 15' ' ' GLN . . . . . 0.518 HE21 ' CA ' ' G' ' 37' ' ' GLY . 49.5 mt-30 -107.92 -171.91 1.96 Allowed 'General case' 0 CA--C 1.5 -0.943 0 N-CA-C 108.544 -0.91 . . . . 0.0 108.544 179.959 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -164.35 98.18 0.81 Allowed 'General case' 0 N--CA 1.472 0.627 0 CA-C-N 115.083 -0.962 . . . . 0.0 109.441 178.567 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' G' G ' 17' ' ' LEU . . . . . 0.4 ' N ' ' CD1' ' G' ' 17' ' ' LEU . 5.3 mp -106.83 162.28 13.95 Favored 'General case' 0 N--CA 1.486 1.36 0 N-CA-C 109.33 -0.619 . . . . 0.0 109.33 -179.757 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 41.0 t -142.46 118.27 5.62 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.974 0 C-N-CA 122.601 0.361 . . . . 0.0 110.18 178.823 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 48.7 m-85 -69.33 150.49 47.29 Favored 'General case' 0 C--N 1.371 1.524 0 N-CA-C 107.454 -1.313 . . . . 0.0 107.454 176.709 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 11.4 t80 -171.09 -55.29 0.02 OUTLIER 'General case' 0 N--CA 1.486 1.351 0 CA-C-N 117.802 0.274 . . . . 0.0 110.263 -179.926 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.88 90.09 0.0 OUTLIER 'General case' 0 C--N 1.326 -0.446 0 C-N-CA 123.655 0.782 . . . . 0.0 112.339 179.925 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 38.4 tt0 -61.93 156.66 20.36 Favored 'General case' 0 N--CA 1.469 0.484 0 CA-C-N 114.855 -1.066 . . . . 0.0 110.029 178.886 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 12.1 m-20 -138.31 129.85 27.76 Favored 'General case' 0 N--CA 1.481 1.101 0 C-N-CA 122.958 0.503 . . . . 0.0 110.148 -179.557 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' G' G ' 24' ' ' VAL . . . . . 0.62 ' CG1' ' H ' ' G' ' 25' ' ' GLY . 39.5 t -81.03 -164.03 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.972 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 179.578 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' G' G ' 25' ' ' GLY . . . . . 0.62 ' H ' ' CG1' ' G' ' 24' ' ' VAL . . . -70.48 51.51 0.84 Allowed Glycine 0 CA--C 1.527 0.836 0 CA-C-N 118.383 0.538 . . . . 0.0 112.452 -179.016 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 18.0 p -72.34 135.9 46.03 Favored 'General case' 0 C--N 1.329 -0.294 0 N-CA-C 109.175 -0.676 . . . . 0.0 109.175 177.936 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 2.0 t-20 -69.1 94.5 0.67 Allowed 'General case' 0 CA--C 1.536 0.416 0 N-CA-C 107.902 -1.147 . . . . 0.0 107.902 177.814 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 68.0 mttm -92.14 118.94 31.32 Favored 'General case' 0 N--CA 1.482 1.134 0 N-CA-C 110.06 -0.348 . . . . 0.0 110.06 -179.2 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.45 -123.37 0.01 OUTLIER Glycine 0 CA--C 1.534 1.247 0 N-CA-C 110.517 -1.033 . . . . 0.0 110.517 178.608 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -129.91 133.54 46.92 Favored 'General case' 0 N--CA 1.47 0.547 0 N-CA-C 109.526 -0.546 . . . . 0.0 109.526 179.604 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 68.8 mt -81.9 140.23 16.78 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.664 0 N-CA-C 107.37 -1.344 . . . . 0.0 107.37 178.626 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 41.3 mt -131.81 129.27 60.94 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.402 0 CA-C-N 119.135 0.88 . . . . 0.0 109.375 179.698 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.47 79.41 0.13 Allowed Glycine 0 CA--C 1.527 0.816 0 CA-C-N 116.302 -0.408 . . . . 0.0 112.882 179.13 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 1.7 tt -110.34 121.69 45.88 Favored 'General case' 0 N--CA 1.482 1.142 0 N-CA-C 107.146 -1.427 . . . . 0.0 107.146 177.616 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 9.2 mtp -154.34 163.91 39.43 Favored 'General case' 0 N--CA 1.477 0.917 0 N-CA-C 107.94 -1.133 . . . . 0.0 107.94 179.583 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 91.6 t -160.03 145.22 5.92 Favored 'Isoleucine or valine' 0 C--O 1.232 0.167 0 N-CA-C 106.376 -1.713 . . . . 0.0 106.376 179.901 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' G' G ' 37' ' ' GLY . . . . . 0.518 ' CA ' HE21 ' G' ' 15' ' ' GLN . . . 55.75 73.88 0.38 Allowed Glycine 0 C--N 1.316 -0.561 0 N-CA-C 111.58 -0.608 . . . . 0.0 111.58 178.355 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 169.69 -146.96 10.46 Favored Glycine 0 N--CA 1.469 0.886 0 N-CA-C 110.834 -0.907 . . . . 0.0 110.834 179.583 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 15.3 m -136.33 148.31 27.41 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.932 0 CA-C-N 117.042 0.421 . . . . 0.0 109.995 -179.768 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 21.2 t . . . . . 0 N--CA 1.472 0.649 0 CA-C-O 117.881 -1.057 . . . . 0.0 111.232 179.257 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' H' H ' 1' ' ' ASP . . . . . . . . . . . . . 8.5 m-20 . . . . . 0 N--CA 1.488 1.468 0 N-CA-C 109.366 -0.605 . . . . 0.0 109.366 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' H' H ' 2' ' ' ALA . . . . . . . . . . . . . . . -68.85 150.96 47.2 Favored 'General case' 0 CA--C 1.532 0.286 0 CA-C-N 116.482 -0.326 . . . . 0.0 110.268 179.719 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' H' H ' 3' ' ' GLU . . . . . . . . . . . . . 39.9 tt0 -162.86 103.65 1.02 Allowed 'General case' 0 N--CA 1.472 0.673 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.16 -179.23 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 21.8 m-85 -67.82 171.56 6.43 Favored 'General case' 0 N--CA 1.473 0.7 0 CA-C-O 121.064 0.459 . . . . 0.0 110.105 179.489 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' H' H ' 5' ' ' ARG . . . . . . . . . . . . . 54.5 mtp180 -67.16 129.12 38.88 Favored 'General case' 0 N--CA 1.469 0.489 0 CA-C-N 115.591 -0.731 . . . . 0.0 110.382 -178.15 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 44.5 m170 -96.13 125.27 40.55 Favored 'General case' 0 N--CA 1.474 0.772 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 179.0 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 9.7 m-20 -72.34 141.29 48.79 Favored 'General case' 0 N--CA 1.468 0.458 0 O-C-N 123.453 0.47 . . . . 0.0 111.506 -179.643 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' H' H ' 8' ' ' SER . . . . . . . . . . . . . 22.7 t -158.25 -179.83 8.47 Favored 'General case' 0 N--CA 1.472 0.642 0 N-CA-C 109.192 -0.669 . . . . 0.0 109.192 178.626 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 124.74 20.23 2.36 Favored Glycine 0 N--CA 1.481 1.645 0 N-CA-C 111.67 -0.572 . . . . 0.0 111.67 179.573 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 42.5 p90 -57.77 128.81 38.94 Favored 'General case' 0 N--CA 1.473 0.708 0 N-CA-C 112.344 0.498 . . . . 0.0 112.344 -179.038 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 46.9 mt-10 -84.48 154.36 22.77 Favored 'General case' 0 N--CA 1.475 0.795 0 CA-C-O 121.074 0.464 . . . . 0.0 109.839 178.571 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.6 p -155.69 128.03 1.04 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.048 0 N-CA-C 108.373 -0.973 . . . . 0.0 108.373 178.867 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 50.2 m-70 -134.11 143.27 47.88 Favored 'General case' 0 N--CA 1.476 0.851 0 CA-C-N 115.158 -0.928 . . . . 0.0 111.151 -178.171 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -166.75 98.32 0.56 Allowed 'General case' 0 N--CA 1.482 1.168 0 CA-C-N 116.65 -0.25 . . . . 0.0 110.726 179.131 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' H' H ' 15' ' ' GLN . . . . . 0.512 HE21 ' CA ' ' H' ' 37' ' ' GLY . 49.0 mt-30 -108.0 -172.39 2.05 Favored 'General case' 0 CA--C 1.499 -1.001 0 N-CA-C 108.42 -0.956 . . . . 0.0 108.42 -179.964 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -164.1 97.94 0.83 Allowed 'General case' 0 N--CA 1.471 0.582 0 CA-C-N 115.083 -0.962 . . . . 0.0 109.277 178.748 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' H' H ' 17' ' ' LEU . . . . . 0.405 ' N ' ' CD1' ' H' ' 17' ' ' LEU . 5.3 mp -106.67 162.24 13.94 Favored 'General case' 0 N--CA 1.486 1.354 0 N-CA-C 109.259 -0.645 . . . . 0.0 109.259 -179.774 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 41.0 t -142.35 118.15 5.73 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.032 0 C-N-CA 122.613 0.365 . . . . 0.0 110.209 178.899 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 49.1 m-85 -69.65 150.88 46.55 Favored 'General case' 0 C--N 1.371 1.502 0 N-CA-C 107.517 -1.29 . . . . 0.0 107.517 176.631 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 12.1 t80 -172.31 -54.88 0.02 OUTLIER 'General case' 0 N--CA 1.482 1.163 0 N-CA-C 110.213 -0.292 . . . . 0.0 110.213 -179.752 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -42.14 90.55 0.0 OUTLIER 'General case' 0 CA--C 1.534 0.352 0 C-N-CA 123.543 0.737 . . . . 0.0 112.095 179.942 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 38.5 tt0 -62.09 156.64 20.95 Favored 'General case' 0 N--CA 1.469 0.493 0 CA-C-N 114.815 -1.084 . . . . 0.0 110.105 179.087 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 12.0 m-20 -138.16 129.98 28.27 Favored 'General case' 0 N--CA 1.48 1.066 0 C-N-CA 122.968 0.507 . . . . 0.0 110.215 -179.536 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' H' H ' 24' ' ' VAL . . . . . 0.632 ' CG1' ' H ' ' H' ' 25' ' ' GLY . 39.4 t -81.3 -164.1 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.992 0 N-CA-C 108.376 -0.972 . . . . 0.0 108.376 179.664 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' H' H ' 25' ' ' GLY . . . . . 0.632 ' H ' ' CG1' ' H' ' 24' ' ' VAL . . . -70.18 51.32 0.77 Allowed Glycine 0 CA--C 1.529 0.932 0 CA-C-N 118.483 0.583 . . . . 0.0 112.268 -179.095 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 17.9 p -72.44 135.96 45.89 Favored 'General case' 0 C--N 1.33 -0.254 0 N-CA-C 109.3 -0.63 . . . . 0.0 109.3 177.945 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 2.0 t-20 -69.2 94.58 0.69 Allowed 'General case' 0 CA--C 1.535 0.368 0 N-CA-C 107.968 -1.123 . . . . 0.0 107.968 177.944 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 68.0 mttm -92.27 118.86 31.31 Favored 'General case' 0 N--CA 1.48 1.066 0 N-CA-C 110.111 -0.329 . . . . 0.0 110.111 -179.21 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.47 -123.02 0.01 OUTLIER Glycine 0 CA--C 1.535 1.291 0 N-CA-C 110.477 -1.049 . . . . 0.0 110.477 178.601 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.04 133.77 46.94 Favored 'General case' 0 N--CA 1.471 0.616 0 C-N-CA 123.0 0.52 . . . . 0.0 109.61 179.715 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 68.5 mt -82.2 140.1 16.93 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.591 0 N-CA-C 107.315 -1.365 . . . . 0.0 107.315 178.57 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 41.6 mt -131.74 129.46 61.26 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.278 0 CA-C-N 119.092 0.86 . . . . 0.0 109.317 179.826 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.14 79.48 0.12 Allowed Glycine 0 CA--C 1.527 0.788 0 CA-C-N 116.239 -0.437 . . . . 0.0 112.933 179.155 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 1.7 tt -110.44 121.76 46.09 Favored 'General case' 0 N--CA 1.481 1.099 0 N-CA-C 107.082 -1.451 . . . . 0.0 107.082 177.592 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 9.3 mtp -154.3 163.71 39.73 Favored 'General case' 0 N--CA 1.476 0.85 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 179.679 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 89.9 t -160.05 145.2 5.89 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.163 0 N-CA-C 106.415 -1.698 . . . . 0.0 106.415 179.838 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' H' H ' 37' ' ' GLY . . . . . 0.512 ' CA ' HE21 ' H' ' 15' ' ' GLN . . . 55.75 73.77 0.39 Allowed Glycine 0 C--N 1.316 -0.537 0 N-CA-C 111.536 -0.625 . . . . 0.0 111.536 178.433 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 169.9 -147.19 10.6 Favored Glycine 0 N--CA 1.469 0.899 0 N-CA-C 110.779 -0.928 . . . . 0.0 110.779 179.641 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 15.1 m -136.25 148.18 27.57 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.918 0 CA-C-N 116.938 0.369 . . . . 0.0 110.033 -179.763 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 21.3 t . . . . . 0 N--CA 1.471 0.625 0 CA-C-O 117.864 -1.065 . . . . 0.0 111.138 179.227 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' I' I ' 1' ' ' ASP . . . . . . . . . . . . . 8.5 m-20 . . . . . 0 N--CA 1.488 1.442 0 N-CA-C 109.306 -0.627 . . . . 0.0 109.306 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' I' I ' 2' ' ' ALA . . . . . . . . . . . . . . . -69.19 151.29 46.51 Favored 'General case' 0 CA--C 1.533 0.298 0 CA-C-O 120.956 0.407 . . . . 0.0 110.171 179.789 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' I' I ' 3' ' ' GLU . . . . . . . . . . . . . 40.4 tt0 -163.1 103.96 0.99 Allowed 'General case' 0 N--CA 1.471 0.624 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.105 -179.266 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 21.8 m-85 -67.97 171.48 6.72 Favored 'General case' 0 N--CA 1.473 0.712 0 CA-C-O 120.981 0.42 . . . . 0.0 110.169 179.433 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' I' I ' 5' ' ' ARG . . . . . . . . . . . . . 54.6 mtp180 -67.18 128.89 38.07 Favored 'General case' 0 N--CA 1.468 0.455 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.378 -178.214 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 44.3 m170 -95.87 125.22 40.27 Favored 'General case' 0 N--CA 1.475 0.777 0 N-CA-C 109.736 -0.468 . . . . 0.0 109.736 178.99 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 9.8 m-20 -72.21 141.76 49.0 Favored 'General case' 0 N--CA 1.468 0.442 0 O-C-N 123.484 0.49 . . . . 0.0 111.397 -179.682 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' I' I ' 8' ' ' SER . . . . . . . . . . . . . 22.7 t -158.65 179.94 8.65 Favored 'General case' 0 N--CA 1.472 0.63 0 N-CA-C 109.201 -0.666 . . . . 0.0 109.201 178.636 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 124.87 20.29 2.32 Favored Glycine 0 N--CA 1.482 1.739 0 N-CA-C 111.646 -0.582 . . . . 0.0 111.646 179.487 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 42.8 p90 -57.71 128.75 38.62 Favored 'General case' 0 N--CA 1.474 0.765 0 N-CA-C 112.342 0.497 . . . . 0.0 112.342 -179.053 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 46.8 mt-10 -84.39 154.48 22.8 Favored 'General case' 0 N--CA 1.474 0.773 0 CA-C-O 121.043 0.449 . . . . 0.0 109.806 178.538 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 2.6 p -155.82 128.04 1.03 Allowed 'Isoleucine or valine' 0 CA--C 1.553 1.062 0 N-CA-C 108.332 -0.988 . . . . 0.0 108.332 178.843 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 50.4 m-70 -134.17 143.27 47.81 Favored 'General case' 0 N--CA 1.476 0.848 0 CA-C-N 115.094 -0.957 . . . . 0.0 111.094 -178.182 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -166.75 98.37 0.56 Allowed 'General case' 0 N--CA 1.483 1.198 0 CA-C-N 116.626 -0.261 . . . . 0.0 110.795 179.125 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' I' I ' 15' ' ' GLN . . . . . 0.52 HE21 ' CA ' ' I' ' 37' ' ' GLY . 48.9 mt-30 -108.12 -172.15 2.01 Favored 'General case' 0 CA--C 1.499 -0.99 0 N-CA-C 108.441 -0.948 . . . . 0.0 108.441 -179.981 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -164.21 98.03 0.82 Allowed 'General case' 0 N--CA 1.471 0.606 0 CA-C-N 114.992 -1.004 . . . . 0.0 109.333 178.691 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' I' I ' 17' ' ' LEU . . . . . 0.4 ' N ' ' CD1' ' I' ' 17' ' ' LEU . 5.3 mp -106.64 162.21 13.96 Favored 'General case' 0 N--CA 1.487 1.388 0 N-CA-C 109.278 -0.638 . . . . 0.0 109.278 -179.749 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 40.7 t -142.24 118.12 5.93 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.059 0 C-N-CA 122.632 0.373 . . . . 0.0 110.223 178.851 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 49.2 m-85 -69.61 150.81 46.66 Favored 'General case' 0 C--N 1.37 1.494 0 N-CA-C 107.49 -1.3 . . . . 0.0 107.49 176.599 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 12.2 t80 -172.2 -55.0 0.02 OUTLIER 'General case' 0 N--CA 1.483 1.201 0 N-CA-C 110.231 -0.285 . . . . 0.0 110.231 -179.826 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -42.08 90.45 0.0 OUTLIER 'General case' 0 CA--C 1.535 0.389 0 C-N-CA 123.657 0.783 . . . . 0.0 112.084 179.958 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 38.3 tt0 -62.02 156.68 20.65 Favored 'General case' 0 N--CA 1.469 0.519 0 CA-C-N 114.793 -1.094 . . . . 0.0 110.043 179.147 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 12.3 m-20 -138.17 129.83 28.04 Favored 'General case' 0 N--CA 1.481 1.097 0 C-N-CA 122.973 0.509 . . . . 0.0 110.217 -179.624 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' I' I ' 24' ' ' VAL . . . . . 0.633 ' CG1' ' H ' ' I' ' 25' ' ' GLY . 38.8 t -80.96 -163.87 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 1.005 0 N-CA-C 108.381 -0.97 . . . . 0.0 108.381 179.618 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' I' I ' 25' ' ' GLY . . . . . 0.633 ' H ' ' CG1' ' I' ' 24' ' ' VAL . . . -70.57 51.33 0.85 Allowed Glycine 0 CA--C 1.528 0.895 0 CA-C-N 118.364 0.529 . . . . 0.0 112.376 -179.074 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 17.7 p -72.34 136.04 46.07 Favored 'General case' 0 C--N 1.33 -0.252 0 N-CA-C 109.252 -0.647 . . . . 0.0 109.252 177.947 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 2.0 t-20 -69.23 94.58 0.7 Allowed 'General case' 0 CA--C 1.535 0.371 0 N-CA-C 107.953 -1.128 . . . . 0.0 107.953 177.888 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 68.1 mttm -92.32 118.96 31.43 Favored 'General case' 0 N--CA 1.48 1.068 0 N-CA-C 110.15 -0.315 . . . . 0.0 110.15 -179.15 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.52 -123.31 0.01 OUTLIER Glycine 0 CA--C 1.534 1.249 0 N-CA-C 110.632 -0.987 . . . . 0.0 110.632 178.648 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -129.77 133.21 46.86 Favored 'General case' 0 N--CA 1.472 0.665 0 C-N-CA 123.047 0.539 . . . . 0.0 109.594 179.715 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 68.5 mt -81.86 139.99 17.15 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.555 0 N-CA-C 107.266 -1.383 . . . . 0.0 107.266 178.605 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 41.1 mt -131.62 129.48 61.62 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.359 0 CA-C-N 119.023 0.829 . . . . 0.0 109.318 179.807 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.13 79.36 0.13 Allowed Glycine 0 CA--C 1.527 0.814 0 CA-C-N 116.289 -0.414 . . . . 0.0 112.936 179.085 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 1.7 tt -110.28 121.73 45.97 Favored 'General case' 0 N--CA 1.481 1.087 0 N-CA-C 107.163 -1.421 . . . . 0.0 107.163 177.55 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 9.4 mtp -154.26 163.7 39.72 Favored 'General case' 0 N--CA 1.475 0.786 0 N-CA-C 107.971 -1.122 . . . . 0.0 107.971 179.786 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 89.5 t -160.04 145.31 5.94 Favored 'Isoleucine or valine' 0 C--O 1.232 0.162 0 N-CA-C 106.423 -1.695 . . . . 0.0 106.423 179.801 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' I' I ' 37' ' ' GLY . . . . . 0.52 ' CA ' HE21 ' I' ' 15' ' ' GLN . . . 55.55 74.03 0.36 Allowed Glycine 0 C--N 1.315 -0.599 0 N-CA-C 111.573 -0.611 . . . . 0.0 111.573 178.484 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 169.68 -147.04 10.53 Favored Glycine 0 N--CA 1.469 0.877 0 N-CA-C 110.806 -0.918 . . . . 0.0 110.806 179.587 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 15.1 m -136.3 148.27 27.47 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.96 0 CA-C-N 116.979 0.389 . . . . 0.0 110.06 -179.79 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 21.4 t . . . . . 0 N--CA 1.471 0.61 0 CA-C-O 117.899 -1.048 . . . . 0.0 111.07 179.139 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 67.6 m-20 . . . . . 0 N--CA 1.49 1.573 0 N-CA-C 109.385 -0.598 . . . . 0.0 109.385 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -63.02 -170.59 0.03 OUTLIER 'General case' 0 N--CA 1.468 0.457 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.507 179.867 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 26.7 tt0 -153.21 165.98 33.97 Favored 'General case' 0 N--CA 1.475 0.798 0 N-CA-C 109.966 -0.383 . . . . 0.0 109.966 -179.904 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 21.1 p90 -67.45 137.44 55.87 Favored 'General case' 0 N--CA 1.471 0.578 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.384 -178.525 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 99.0 mtt180 -136.73 153.18 50.93 Favored 'General case' 0 N--CA 1.482 1.137 0 N-CA-C 109.527 -0.546 . . . . 0.0 109.527 178.523 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 58.5 t-80 -113.98 114.82 26.69 Favored 'General case' 0 N--CA 1.477 0.9 0 C-N-CA 123.094 0.557 . . . . 0.0 109.627 179.493 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' ASP . . . . . 0.437 ' O ' ' OG ' ' D' ' 8' ' ' SER . 8.9 m-20 -72.99 156.36 38.91 Favored 'General case' 0 N--CA 1.465 0.307 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.062 179.053 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 9.5 p -166.17 -177.08 3.97 Favored 'General case' 0 N--CA 1.483 1.181 0 CA-C-O 120.913 0.387 . . . . 0.0 110.528 178.736 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.9 43.94 1.58 Allowed Glycine 0 N--CA 1.482 1.708 0 CA-C-N 115.747 -0.661 . . . . 0.0 112.19 179.427 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 51.2 p90 -65.32 131.86 47.54 Favored 'General case' 0 N--CA 1.473 0.715 0 CA-C-N 116.83 0.315 . . . . 0.0 111.479 179.751 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 84.4 mt-10 -94.3 153.52 17.97 Favored 'General case' 0 N--CA 1.476 0.853 0 N-CA-C 109.655 -0.498 . . . . 0.0 109.655 178.587 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -153.28 128.52 1.55 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.583 0 N-CA-C 107.781 -1.192 . . . . 0.0 107.781 178.126 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 50.9 m-70 -135.13 144.88 47.34 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 119.144 0.884 . . . . 0.0 111.221 -179.143 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 6.3 t60 -165.83 99.0 0.66 Allowed 'General case' 0 N--CA 1.48 1.061 0 CA-C-N 116.394 -0.366 . . . . 0.0 110.588 179.465 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 22.2 pt20 -124.41 155.33 39.01 Favored 'General case' 0 CA--C 1.501 -0.927 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 -179.609 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -124.99 106.02 9.64 Favored 'General case' 0 N--CA 1.478 0.974 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 177.986 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 6.1 mp -121.16 148.88 43.62 Favored 'General case' 0 N--CA 1.497 1.908 0 CA-C-O 121.412 0.625 . . . . 0.0 110.797 -178.528 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 30.8 t -107.57 123.77 63.12 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.018 0 N-CA-C 108.077 -1.083 . . . . 0.0 108.077 177.612 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.506 ' O ' ' N ' ' A' ' 21' ' ' ALA . 25.7 m-85 -119.57 -160.89 0.83 Allowed 'General case' 0 N--CA 1.498 1.962 0 CA-C-N 120.232 1.378 . . . . 0.0 109.178 -179.966 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.492 ' O ' ' HA ' ' D' ' 20' ' ' PHE . 78.7 m-85 -50.94 76.8 0.0 OUTLIER 'General case' 0 C--O 1.2 -1.511 0 C-N-CA 123.772 0.829 . . . . 0.0 111.318 -179.164 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . 0.506 ' N ' ' O ' ' A' ' 19' ' ' PHE . . . -88.47 -75.61 0.42 Allowed 'General case' 0 N--CA 1.471 0.597 0 CA-C-N 115.691 -0.686 . . . . 0.0 110.158 -179.614 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 40.4 tt0 -96.12 98.65 10.51 Favored 'General case' 0 N--CA 1.463 0.205 0 N-CA-C 108.461 -0.94 . . . . 0.0 108.461 179.349 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 4.1 p30 -159.45 145.03 15.91 Favored 'General case' 0 N--CA 1.484 1.242 0 O-C-N 122.334 -0.229 . . . . 0.0 110.828 179.598 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 88.6 t -63.04 163.91 1.46 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.799 0 N-CA-C 107.619 -1.252 . . . . 0.0 107.619 176.998 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.439 ' H ' ' HB ' ' D' ' 24' ' ' VAL . . . -117.8 45.62 1.25 Allowed Glycine 0 N--CA 1.474 1.183 0 CA-C-O 119.649 -0.529 . . . . 0.0 111.927 -179.409 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -60.32 -165.21 0.01 OUTLIER 'General case' 0 N--CA 1.471 0.622 0 O-C-N 123.805 0.356 . . . . 0.0 110.461 179.618 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 24.0 t-20 -70.23 80.77 0.52 Allowed 'General case' 0 N--CA 1.463 0.197 0 CA-C-N 116.378 -0.373 . . . . 0.0 110.384 179.654 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 96.9 mttt -79.73 138.23 37.25 Favored 'General case' 0 N--CA 1.472 0.635 0 N-CA-C 109.195 -0.668 . . . . 0.0 109.195 179.365 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.84 -166.13 0.9 Allowed Glycine 0 C--N 1.337 0.621 0 N-CA-C 109.68 -1.368 . . . . 0.0 109.68 178.189 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.73 113.99 26.83 Favored 'General case' 0 N--CA 1.474 0.772 0 N-CA-C 109.546 -0.538 . . . . 0.0 109.546 179.505 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 76.5 mt -99.58 135.39 35.2 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.601 0 N-CA-C 107.054 -1.462 . . . . 0.0 107.054 178.734 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . 0.442 ' C ' ' H ' ' A' ' 34' ' ' LEU . 26.7 pt -150.78 -172.1 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.353 0.743 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.326 -179.27 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.57 2.53 6.0 Favored Glycine 0 CA--C 1.525 0.711 0 N-CA-C 110.864 -0.894 . . . . 0.0 110.864 -179.905 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . 0.442 ' H ' ' C ' ' A' ' 32' ' ' ILE . 1.1 tt -74.66 133.58 42.1 Favored 'General case' 0 CA--C 1.544 0.735 0 N-CA-C 109.247 -0.649 . . . . 0.0 109.247 -179.611 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 26.6 ttt -159.44 151.4 20.68 Favored 'General case' 0 N--CA 1.47 0.527 0 N-CA-C 108.297 -1.001 . . . . 0.0 108.297 178.924 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 63.3 t -154.49 162.89 1.81 Allowed 'Isoleucine or valine' 0 C--N 1.344 0.353 0 N-CA-C 107.774 -1.195 . . . . 0.0 107.774 -179.52 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 57.57 67.32 2.27 Favored Glycine 0 C--N 1.306 -1.091 0 CA-C-N 115.606 -0.725 . . . . 0.0 112.133 178.717 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.7 177.83 22.44 Favored Glycine 0 N--CA 1.476 1.325 0 N-CA-C 111.045 -0.822 . . . . 0.0 111.045 178.717 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 33.4 m -109.69 152.71 11.66 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.612 0 C-N-CA 123.419 0.687 . . . . 0.0 110.217 -179.58 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 21.9 t . . . . . 0 C--O 1.216 -0.678 0 CA-C-O 118.319 -0.848 . . . . 0.0 110.531 179.615 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' B' B ' 1' ' ' ASP . . . . . . . . . . . . . 67.0 m-20 . . . . . 0 N--CA 1.49 1.566 0 N-CA-C 109.403 -0.592 . . . . 0.0 109.403 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' B' B ' 2' ' ' ALA . . . . . . . . . . . . . . . -63.5 -170.34 0.03 OUTLIER 'General case' 0 N--CA 1.468 0.427 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.562 179.798 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 3' ' ' GLU . . . . . . . . . . . . . 26.7 tt0 -153.5 166.09 33.8 Favored 'General case' 0 N--CA 1.475 0.799 0 N-CA-C 110.005 -0.369 . . . . 0.0 110.005 -179.935 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 20.5 p90 -67.29 137.26 55.96 Favored 'General case' 0 N--CA 1.47 0.549 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.546 -178.564 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 99.0 mtt180 -136.56 152.98 51.08 Favored 'General case' 0 N--CA 1.481 1.094 0 N-CA-C 109.517 -0.549 . . . . 0.0 109.517 178.534 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 58.4 t-80 -113.91 114.85 26.8 Favored 'General case' 0 N--CA 1.477 0.918 0 C-N-CA 123.156 0.582 . . . . 0.0 109.691 179.522 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 7' ' ' ASP . . . . . 0.427 ' O ' ' OG ' ' E' ' 8' ' ' SER . 8.4 m-20 -73.13 155.95 39.15 Favored 'General case' 0 N--CA 1.467 0.41 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.124 179.151 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 8' ' ' SER . . . . . . . . . . . . . 9.6 p -165.94 -176.93 4.0 Favored 'General case' 0 N--CA 1.481 1.105 0 CA-C-O 120.942 0.401 . . . . 0.0 110.567 178.847 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.67 44.08 1.6 Allowed Glycine 0 N--CA 1.483 1.779 0 CA-C-N 115.701 -0.681 . . . . 0.0 112.232 179.528 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 51.0 p90 -65.66 132.02 47.78 Favored 'General case' 0 N--CA 1.472 0.649 0 CA-C-O 120.688 0.28 . . . . 0.0 111.492 179.823 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 84.2 mt-10 -94.28 153.71 17.89 Favored 'General case' 0 N--CA 1.477 0.876 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 178.483 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -153.41 128.38 1.5 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.511 0 N-CA-C 107.738 -1.208 . . . . 0.0 107.738 178.119 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 49.9 m-70 -135.19 144.5 47.02 Favored 'General case' 0 N--CA 1.492 1.664 0 CA-C-N 119.042 0.837 . . . . 0.0 111.218 -179.091 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 6.3 t60 -165.45 98.71 0.7 Allowed 'General case' 0 N--CA 1.481 1.088 0 CA-C-N 116.461 -0.336 . . . . 0.0 110.482 179.573 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 22.2 pt20 -124.14 155.38 38.54 Favored 'General case' 0 CA--C 1.501 -0.909 0 N-CA-C 107.988 -1.116 . . . . 0.0 107.988 -179.694 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -124.99 106.13 9.73 Favored 'General case' 0 N--CA 1.479 1.016 0 N-CA-C 108.121 -1.066 . . . . 0.0 108.121 178.037 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 6.1 mp -121.25 148.82 43.77 Favored 'General case' 0 N--CA 1.497 1.901 0 CA-C-O 121.397 0.618 . . . . 0.0 110.809 -178.518 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 29.8 t -107.6 124.59 63.72 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.038 0 N-CA-C 107.949 -1.13 . . . . 0.0 107.949 177.502 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 19' ' ' PHE . . . . . 0.514 ' O ' ' N ' ' B' ' 21' ' ' ALA . 25.5 m-85 -120.65 -161.12 0.87 Allowed 'General case' 0 N--CA 1.496 1.842 0 CA-C-N 119.906 1.23 . . . . 0.0 109.09 -179.779 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . 0.478 ' O ' ' HA ' ' E' ' 20' ' ' PHE . 77.7 m-85 -51.1 76.56 0.0 OUTLIER 'General case' 0 C--O 1.202 -1.421 0 C-N-CA 123.684 0.794 . . . . 0.0 111.451 -179.129 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 21' ' ' ALA . . . . . 0.514 ' N ' ' O ' ' B' ' 19' ' ' PHE . . . -88.35 -75.9 0.41 Allowed 'General case' 0 N--CA 1.47 0.539 0 CA-C-N 115.628 -0.715 . . . . 0.0 110.1 -179.692 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 40.5 tt0 -95.9 98.95 10.8 Favored 'General case' 0 N--CA 1.464 0.231 0 N-CA-C 108.49 -0.929 . . . . 0.0 108.49 179.358 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 4.1 p30 -159.65 144.96 15.55 Favored 'General case' 0 N--CA 1.483 1.212 0 O-C-N 122.407 -0.183 . . . . 0.0 110.892 179.578 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 94.0 t -62.9 163.76 1.46 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.808 0 N-CA-C 107.609 -1.256 . . . . 0.0 107.609 177.088 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . 0.425 ' H ' ' HB ' ' E' ' 24' ' ' VAL . . . -117.54 45.67 1.24 Allowed Glycine 0 N--CA 1.474 1.231 0 N-CA-C 111.903 -0.479 . . . . 0.0 111.903 -179.371 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -60.67 -165.05 0.01 OUTLIER 'General case' 0 N--CA 1.472 0.643 0 O-C-N 123.62 0.247 . . . . 0.0 110.452 179.688 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 24.1 t-20 -70.4 80.93 0.55 Allowed 'General case' 0 N--CA 1.464 0.272 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.268 179.664 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 96.8 mttt -79.87 138.28 37.13 Favored 'General case' 0 N--CA 1.472 0.656 0 N-CA-C 109.187 -0.672 . . . . 0.0 109.187 179.373 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.82 -166.14 0.9 Allowed Glycine 0 C--N 1.337 0.602 0 N-CA-C 109.638 -1.385 . . . . 0.0 109.638 178.231 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.68 113.84 26.55 Favored 'General case' 0 N--CA 1.474 0.729 0 N-CA-C 109.639 -0.504 . . . . 0.0 109.639 179.475 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 76.0 mt -99.44 135.32 35.25 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.527 0 N-CA-C 107.054 -1.461 . . . . 0.0 107.054 178.733 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . 0.431 ' C ' ' H ' ' B' ' 34' ' ' LEU . 26.6 pt -150.73 -172.05 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.353 0.729 0 CA-C-O 121.185 0.517 . . . . 0.0 111.259 -179.278 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.67 2.35 5.94 Favored Glycine 0 CA--C 1.525 0.692 0 N-CA-C 110.776 -0.93 . . . . 0.0 110.776 -179.919 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 34' ' ' LEU . . . . . 0.431 ' H ' ' C ' ' B' ' 32' ' ' ILE . 1.1 tt -74.55 133.2 42.28 Favored 'General case' 0 CA--C 1.545 0.773 0 N-CA-C 109.209 -0.663 . . . . 0.0 109.209 -179.588 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 26.6 ttt -159.04 150.76 20.68 Favored 'General case' 0 N--CA 1.47 0.562 0 N-CA-C 108.362 -0.977 . . . . 0.0 108.362 178.722 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 64.0 t -153.79 162.51 2.08 Favored 'Isoleucine or valine' 0 C--N 1.345 0.394 0 N-CA-C 107.838 -1.171 . . . . 0.0 107.838 -179.599 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 58.07 67.13 2.36 Favored Glycine 0 C--N 1.307 -1.043 0 CA-C-N 115.586 -0.734 . . . . 0.0 112.071 178.627 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.85 177.31 22.14 Favored Glycine 0 N--CA 1.475 1.298 0 N-CA-C 111.042 -0.823 . . . . 0.0 111.042 178.797 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 33.6 m -109.21 152.5 11.25 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.621 0 C-N-CA 123.37 0.668 . . . . 0.0 110.316 -179.599 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 22.0 t . . . . . 0 C--O 1.215 -0.758 0 CA-C-O 118.379 -0.82 . . . . 0.0 110.422 179.604 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' C' C ' 1' ' ' ASP . . . . . . . . . . . . . 66.9 m-20 . . . . . 0 N--CA 1.491 1.596 0 N-CA-C 109.422 -0.584 . . . . 0.0 109.422 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' C' C ' 2' ' ' ALA . . . . . . . . . . . . . . . -63.45 -170.53 0.03 OUTLIER 'General case' 0 N--CA 1.466 0.374 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.437 179.906 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' C' C ' 3' ' ' GLU . . . . . . . . . . . . . 26.2 tt0 -153.25 166.38 32.76 Favored 'General case' 0 N--CA 1.474 0.763 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 -179.877 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 20.4 p90 -67.69 137.34 55.45 Favored 'General case' 0 N--CA 1.47 0.542 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.566 -178.58 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 99.0 mtt180 -136.68 153.09 50.99 Favored 'General case' 0 N--CA 1.481 1.089 0 N-CA-C 109.546 -0.539 . . . . 0.0 109.546 178.528 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 58.3 t-80 -113.86 115.06 27.14 Favored 'General case' 0 N--CA 1.478 0.951 0 C-N-CA 123.052 0.541 . . . . 0.0 109.6 179.634 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' C' C ' 7' ' ' ASP . . . . . 0.429 ' O ' ' OG ' ' F' ' 8' ' ' SER . 8.6 m-20 -73.38 155.75 39.04 Favored 'General case' 0 N--CA 1.467 0.385 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.167 179.086 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' C' C ' 8' ' ' SER . . . . . . . . . . . . . 9.5 p -165.67 -176.98 4.13 Favored 'General case' 0 N--CA 1.482 1.167 0 CA-C-O 120.909 0.385 . . . . 0.0 110.567 178.748 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.87 44.01 1.58 Allowed Glycine 0 N--CA 1.483 1.781 0 CA-C-N 115.728 -0.669 . . . . 0.0 112.284 179.49 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 51.0 p90 -65.49 132.0 47.83 Favored 'General case' 0 N--CA 1.473 0.724 0 O-C-N 122.653 -0.322 . . . . 0.0 111.465 179.789 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 83.7 mt-10 -94.27 153.78 17.86 Favored 'General case' 0 N--CA 1.476 0.84 0 N-CA-C 109.634 -0.506 . . . . 0.0 109.634 178.507 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -153.43 128.52 1.52 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.61 0 N-CA-C 107.757 -1.201 . . . . 0.0 107.757 178.135 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 50.0 m-70 -135.33 144.57 46.78 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 119.084 0.856 . . . . 0.0 111.142 -179.104 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 6.3 t60 -165.65 98.71 0.68 Allowed 'General case' 0 N--CA 1.48 1.066 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.458 179.549 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 21.9 pt20 -124.24 155.47 38.53 Favored 'General case' 0 CA--C 1.503 -0.859 0 N-CA-C 107.865 -1.161 . . . . 0.0 107.865 -179.66 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -124.97 106.31 9.87 Favored 'General case' 0 N--CA 1.479 1.004 0 N-CA-C 108.208 -1.034 . . . . 0.0 108.208 177.969 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 6.1 mp -121.34 148.88 43.76 Favored 'General case' 0 N--CA 1.498 1.966 0 CA-C-O 121.474 0.654 . . . . 0.0 110.796 -178.433 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 29.0 t -107.74 124.53 63.88 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.088 0 N-CA-C 107.968 -1.123 . . . . 0.0 107.968 177.51 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' C' C ' 19' ' ' PHE . . . . . 0.517 ' O ' ' N ' ' C' ' 21' ' ' ALA . 25.5 m-85 -120.55 -161.05 0.86 Allowed 'General case' 0 N--CA 1.496 1.857 0 CA-C-N 119.936 1.244 . . . . 0.0 109.13 -179.674 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' C' C ' 20' ' ' PHE . . . . . 0.482 ' O ' ' HA ' ' F' ' 20' ' ' PHE . 77.8 m-85 -51.25 76.46 0.0 OUTLIER 'General case' 0 C--O 1.202 -1.414 0 C-N-CA 123.716 0.807 . . . . 0.0 111.404 -179.186 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' C' C ' 21' ' ' ALA . . . . . 0.517 ' N ' ' O ' ' C' ' 19' ' ' PHE . . . -88.26 -75.89 0.41 Allowed 'General case' 0 N--CA 1.47 0.533 0 CA-C-N 115.604 -0.725 . . . . 0.0 110.142 -179.7 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 40.8 tt0 -95.74 98.62 10.6 Favored 'General case' 0 N--CA 1.464 0.265 0 N-CA-C 108.482 -0.933 . . . . 0.0 108.482 179.326 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 4.1 p30 -159.51 144.77 15.66 Favored 'General case' 0 N--CA 1.482 1.172 0 O-C-N 122.287 -0.258 . . . . 0.0 110.985 179.616 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 89.7 t -62.76 163.8 1.43 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.765 0 N-CA-C 107.681 -1.229 . . . . 0.0 107.681 177.067 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' C' C ' 25' ' ' GLY . . . . . 0.445 ' H ' ' HB ' ' F' ' 24' ' ' VAL . . . -117.65 45.72 1.24 Allowed Glycine 0 N--CA 1.476 1.364 0 N-CA-C 111.724 -0.55 . . . . 0.0 111.724 -179.377 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -60.47 -165.1 0.01 OUTLIER 'General case' 0 N--CA 1.472 0.647 0 CA-C-O 120.61 0.243 . . . . 0.0 110.421 179.616 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 24.1 t-20 -70.52 80.62 0.57 Allowed 'General case' 0 N--CA 1.464 0.258 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.308 179.684 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -79.41 138.5 37.65 Favored 'General case' 0 N--CA 1.472 0.639 0 N-CA-C 109.222 -0.659 . . . . 0.0 109.222 179.333 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.96 -165.68 0.87 Allowed Glycine 0 CA--C 1.523 0.588 0 N-CA-C 109.614 -1.394 . . . . 0.0 109.614 178.322 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.88 113.81 26.6 Favored 'General case' 0 N--CA 1.474 0.745 0 N-CA-C 109.617 -0.512 . . . . 0.0 109.617 179.459 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 76.0 mt -99.67 135.12 36.5 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.591 0 N-CA-C 107.041 -1.466 . . . . 0.0 107.041 178.83 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' C' C ' 32' ' ' ILE . . . . . 0.447 ' C ' ' H ' ' C' ' 34' ' ' LEU . 26.8 pt -150.61 -171.91 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.353 0.741 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.296 -179.305 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.59 2.24 5.67 Favored Glycine 0 CA--C 1.524 0.615 0 N-CA-C 110.808 -0.917 . . . . 0.0 110.808 -179.893 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' C' C ' 34' ' ' LEU . . . . . 0.447 ' H ' ' C ' ' C' ' 32' ' ' ILE . 1.1 tt -74.43 133.28 42.42 Favored 'General case' 0 CA--C 1.544 0.725 0 N-CA-C 109.275 -0.639 . . . . 0.0 109.275 -179.59 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 26.6 ttt -159.03 150.69 20.65 Favored 'General case' 0 N--CA 1.47 0.557 0 N-CA-C 108.477 -0.934 . . . . 0.0 108.477 178.786 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 62.7 t -153.64 162.82 2.01 Favored 'Isoleucine or valine' 0 C--N 1.344 0.336 0 N-CA-C 107.78 -1.193 . . . . 0.0 107.78 -179.695 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 57.85 67.37 2.24 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-N 115.488 -0.778 . . . . 0.0 112.043 178.549 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.65 177.41 22.06 Favored Glycine 0 N--CA 1.475 1.271 0 N-CA-C 111.027 -0.829 . . . . 0.0 111.027 178.736 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 33.6 m -109.16 152.67 11.15 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.647 0 C-N-CA 123.303 0.641 . . . . 0.0 110.19 -179.601 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 22.0 t . . . . . 0 C--O 1.216 -0.687 0 CA-C-O 118.273 -0.87 . . . . 0.0 110.581 179.608 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' D' D ' 1' ' ' ASP . . . . . . . . . . . . . 65.2 m-20 . . . . . 0 N--CA 1.491 1.587 0 N-CA-C 109.35 -0.611 . . . . 0.0 109.35 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' D' D ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.91 -170.31 0.08 Allowed 'General case' 0 CA--C 1.533 0.305 0 C-N-CA 123.252 0.621 . . . . 0.0 109.797 179.373 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' D' D ' 3' ' ' GLU . . . . . . . . . . . . . 23.6 tt0 -156.45 161.93 40.03 Favored 'General case' 0 N--CA 1.473 0.676 0 C-N-CA 123.522 0.729 . . . . 0.0 110.37 -172.856 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 34.1 p90 -75.12 135.42 41.14 Favored 'General case' 0 C--O 1.221 -0.423 0 N-CA-C 108.43 -0.952 . . . . 0.0 108.43 -172.236 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' D' D ' 5' ' ' ARG . . . . . . . . . . . . . 99.1 mtt180 -132.18 154.67 49.32 Favored 'General case' 0 N--CA 1.477 0.921 0 N-CA-C 109.163 -0.68 . . . . 0.0 109.163 -177.501 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 55.5 t-80 -115.78 121.65 43.06 Favored 'General case' 0 C--N 1.37 1.466 0 N-CA-C 107.827 -1.175 . . . . 0.0 107.827 176.283 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' D' D ' 7' ' ' ASP . . . . . 0.533 ' O ' ' OG ' ' G' ' 8' ' ' SER 0.279 5.0 m-20 -65.11 136.91 57.27 Favored 'General case' 0 C--N 1.313 -1.005 0 C-N-CA 129.589 3.155 . . . . 0.0 115.638 171.6 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' D' D ' 8' ' ' SER . . . . . 0.437 ' OG ' ' O ' ' A' ' 7' ' ' ASP . 7.0 p -153.4 -174.21 4.86 Favored 'General case' 0 N--CA 1.487 1.411 0 CA-C-N 120.825 1.648 . . . . 0.0 111.062 174.704 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 105.07 46.5 1.25 Allowed Glycine 0 N--CA 1.483 1.769 0 C-N-CA 125.071 1.319 . . . . 0.0 110.558 174.78 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 52.6 p90 -60.96 130.69 47.68 Favored 'General case' 0 N--CA 1.472 0.637 0 N-CA-C 112.543 0.572 . . . . 0.0 112.543 177.151 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 84.9 mt-10 -90.94 151.83 20.95 Favored 'General case' 0 N--CA 1.48 1.027 0 CA-C-N 118.029 0.377 . . . . 0.0 110.857 174.946 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -149.62 130.1 4.35 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.615 0 N-CA-C 107.355 -1.35 . . . . 0.0 107.355 172.829 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 47.0 m-70 -129.92 147.61 51.69 Favored 'General case' 0 N--CA 1.483 1.223 0 CA-C-N 118.102 0.41 . . . . 0.0 111.774 176.32 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 6.3 t60 -165.32 104.98 0.75 Allowed 'General case' 0 N--CA 1.485 1.303 0 N-CA-C 109.366 -0.605 . . . . 0.0 109.366 173.233 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 23.2 pt20 -128.59 148.38 50.78 Favored 'General case' 0 C--N 1.296 -1.726 0 C-N-CA 123.764 0.826 . . . . 0.0 108.879 -178.631 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -118.64 111.5 18.62 Favored 'General case' 0 N--CA 1.476 0.846 0 N-CA-C 107.486 -1.302 . . . . 0.0 107.486 177.054 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 5.0 mp -126.77 148.71 49.9 Favored 'General case' 0 N--CA 1.5 2.059 0 CA-C-O 122.068 0.937 . . . . 0.0 109.983 179.169 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 12.9 t -99.91 128.44 51.79 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.769 0 CA-C-O 116.37 -1.776 . . . . 0.0 109.691 174.939 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' D' D ' 19' ' ' PHE . . . . . 0.511 ' O ' ' N ' ' D' ' 21' ' ' ALA . 25.2 m-85 -127.43 -163.06 1.22 Allowed 'General case' 0 N--CA 1.499 1.977 0 CA-C-N 120.686 1.584 . . . . 0.0 107.681 -179.966 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' D' D ' 20' ' ' PHE . . . . . 0.492 ' HA ' ' O ' ' A' ' 20' ' ' PHE . 90.1 m-85 -53.22 70.73 0.0 OUTLIER 'General case' 0 C--O 1.198 -1.62 0 C-N-CA 126.344 1.857 . . . . 0.0 111.44 -174.517 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' D' D ' 21' ' ' ALA . . . . . 0.511 ' N ' ' O ' ' D' ' 19' ' ' PHE . . . -86.39 -74.18 0.43 Allowed 'General case' 0 C--N 1.362 1.117 0 CA-C-N 114.922 -1.036 . . . . 0.0 109.701 -175.945 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 41.1 tt0 -98.82 102.99 14.9 Favored 'General case' 0 N--CA 1.483 1.212 0 N-CA-C 106.577 -1.638 . . . . 0.0 106.577 178.108 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 4.2 p30 -152.4 143.92 23.43 Favored 'General case' 0 N--CA 1.476 0.872 0 CA-C-O 116.783 -1.58 . . . . 0.0 113.501 178.551 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' D' D ' 24' ' ' VAL . . . . . 0.439 ' HB ' ' H ' ' A' ' 25' ' ' GLY . 89.3 t -64.46 165.26 1.46 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.351 0 CA-C-N 120.952 1.705 . . . . 0.0 107.584 173.953 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' D' D ' 25' ' ' GLY . . . . . 0.474 ' H ' ' HB ' ' G' ' 24' ' ' VAL . . . -117.02 51.1 0.75 Allowed Glycine 0 N--CA 1.48 1.573 0 CA-C-O 118.885 -0.953 . . . . 0.0 111.575 177.849 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -57.87 -168.74 0.01 OUTLIER 'General case' 0 C--N 1.321 -0.655 0 C-N-CA 124.037 0.935 . . . . 0.0 111.491 175.509 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 25.7 t-20 -72.33 86.86 1.12 Allowed 'General case' 0 C--N 1.35 0.588 0 C-N-CA 119.003 -1.079 . . . . 0.0 108.598 178.455 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 96.4 mttt -83.47 141.19 31.84 Favored 'General case' 0 C--N 1.352 0.688 0 N-CA-C 108.181 -1.044 . . . . 0.0 108.181 178.596 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -62.47 -164.69 0.43 Allowed Glycine 0 C--N 1.333 0.394 0 N-CA-C 110.451 -1.06 . . . . 0.0 110.451 177.463 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -102.28 115.88 31.48 Favored 'General case' 0 N--CA 1.471 0.595 0 N-CA-C 108.727 -0.842 . . . . 0.0 108.727 178.735 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 82.9 mt -102.91 142.57 16.66 Favored 'Isoleucine or valine' 0 C--N 1.356 0.889 0 N-CA-C 104.949 -2.241 . . . . 0.0 104.949 179.215 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' D' D ' 32' ' ' ILE . . . . . 0.428 ' C ' ' H ' ' D' ' 34' ' ' LEU . 27.4 pt -157.18 -172.41 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.109 0 CA-C-O 120.759 0.314 . . . . 0.0 110.219 -178.141 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.95 2.13 6.12 Favored Glycine 0 N--CA 1.465 0.615 0 N-CA-C 110.513 -1.035 . . . . 0.0 110.513 -178.706 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' D' D ' 34' ' ' LEU . . . . . 0.428 ' H ' ' C ' ' D' ' 32' ' ' ILE . 1.3 tt -75.85 138.05 40.86 Favored 'General case' 0 C--N 1.354 0.777 0 N-CA-C 107.729 -1.211 . . . . 0.0 107.729 -178.311 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 25.3 ttt -156.5 160.73 39.8 Favored 'General case' 0 C--O 1.237 0.444 0 N-CA-C 107.877 -1.157 . . . . 0.0 107.877 175.009 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 97.0 t -163.2 163.83 0.8 Allowed 'Isoleucine or valine' 0 CA--C 1.517 -0.326 0 N-CA-C 107.021 -1.474 . . . . 0.0 107.021 177.03 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 60.61 63.55 4.89 Favored Glycine 0 CA--C 1.528 0.874 0 C-N-CA 120.075 -1.06 . . . . 0.0 112.888 179.869 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 146.24 178.63 21.81 Favored Glycine 0 N--CA 1.481 1.639 0 CA-C-N 117.801 0.8 . . . . 0.0 111.588 179.803 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 34.5 m -112.69 149.89 15.04 Favored 'Isoleucine or valine' 0 C--N 1.357 0.911 0 N-CA-C 109.432 -0.581 . . . . 0.0 109.432 -176.943 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 21.8 t . . . . . 0 CA--C 1.52 -0.179 0 CA-C-O 115.976 -1.964 . . . . 0.0 109.604 178.486 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' E' E ' 1' ' ' ASP . . . . . . . . . . . . . 66.4 m-20 . . . . . 0 N--CA 1.491 1.575 0 N-CA-C 109.362 -0.607 . . . . 0.0 109.362 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' E' E ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.13 -168.6 0.04 OUTLIER 'General case' 0 N--CA 1.467 0.379 0 CA-C-N 116.319 -0.401 . . . . 0.0 110.74 -179.967 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' E' E ' 3' ' ' GLU . . . . . . . . . . . . . 25.0 tt0 -153.82 166.8 31.77 Favored 'General case' 0 N--CA 1.473 0.692 0 CA-C-N 116.508 -0.314 . . . . 0.0 110.37 -179.574 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 21.7 p90 -67.02 137.59 56.58 Favored 'General case' 0 C--O 1.217 -0.626 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.662 -178.476 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' E' E ' 5' ' ' ARG . . . . . . . . . . . . . 99.0 mtt180 -136.89 154.11 50.56 Favored 'General case' 0 N--CA 1.479 0.992 0 N-CA-C 109.433 -0.58 . . . . 0.0 109.433 178.539 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 58.4 t-80 -114.31 114.5 26.02 Favored 'General case' 0 N--CA 1.48 1.032 0 N-CA-C 109.68 -0.489 . . . . 0.0 109.68 179.581 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' E' E ' 7' ' ' ASP . . . . . 0.433 ' O ' ' OG ' ' H' ' 8' ' ' SER . 7.9 m-20 -73.27 156.29 38.63 Favored 'General case' 0 N--CA 1.466 0.352 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.173 179.095 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' E' E ' 8' ' ' SER . . . . . 0.427 ' OG ' ' O ' ' B' ' 7' ' ' ASP . 5.4 p -166.72 -175.06 2.98 Favored 'General case' 0 N--CA 1.485 1.31 0 CA-C-O 121.17 0.509 . . . . 0.0 110.727 178.388 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.48 44.12 1.61 Allowed Glycine 0 N--CA 1.48 1.59 0 CA-C-N 115.577 -0.738 . . . . 0.0 112.169 179.294 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 49.7 p90 -64.9 131.93 48.02 Favored 'General case' 0 CA--C 1.542 0.672 0 N-CA-C 111.769 0.285 . . . . 0.0 111.769 -179.922 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 86.8 mt-10 -93.55 153.81 18.22 Favored 'General case' 0 N--CA 1.48 1.027 0 CA-C-O 121.163 0.506 . . . . 0.0 109.654 178.074 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -154.72 127.24 1.05 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.546 0 N-CA-C 107.782 -1.192 . . . . 0.0 107.782 177.917 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 48.7 m-70 -135.09 142.61 46.3 Favored 'General case' 0 N--CA 1.483 1.185 0 CA-C-O 120.739 0.304 . . . . 0.0 111.473 -178.009 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 6.2 t60 -164.46 98.83 0.81 Allowed 'General case' 0 N--CA 1.486 1.364 0 CA-C-N 116.448 -0.342 . . . . 0.0 110.327 179.594 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 22.1 pt20 -123.63 155.57 37.46 Favored 'General case' 0 CA--C 1.503 -0.83 0 N-CA-C 108.243 -1.021 . . . . 0.0 108.243 -179.588 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -125.14 105.88 9.49 Favored 'General case' 0 N--CA 1.484 1.269 0 N-CA-C 108.216 -1.031 . . . . 0.0 108.216 178.145 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 6.0 mp -120.58 148.42 43.9 Favored 'General case' 0 N--CA 1.494 1.74 0 CA-C-O 121.123 0.487 . . . . 0.0 111.293 -178.063 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 21.8 t -109.62 120.53 60.97 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.146 0 N-CA-C 108.126 -1.065 . . . . 0.0 108.126 177.313 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' E' E ' 19' ' ' PHE . . . . . 0.54 ' O ' ' N ' ' E' ' 21' ' ' ALA . 28.5 m-85 -117.11 -162.98 0.89 Allowed 'General case' 0 N--CA 1.495 1.8 0 C-N-CA 122.911 0.485 . . . . 0.0 109.749 -179.365 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' E' E ' 20' ' ' PHE . . . . . 0.478 ' HA ' ' O ' ' B' ' 20' ' ' PHE . 77.2 m-85 -47.76 75.3 0.0 OUTLIER 'General case' 0 C--O 1.206 -1.202 0 C-N-CA 124.288 1.035 . . . . 0.0 111.551 -179.887 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' E' E ' 21' ' ' ALA . . . . . 0.54 ' N ' ' O ' ' E' ' 19' ' ' PHE . . . -87.82 -75.46 0.41 Allowed 'General case' 0 N--CA 1.469 0.52 0 C-N-CA 122.536 0.335 . . . . 0.0 110.399 -179.162 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 41.2 tt0 -96.78 98.92 10.54 Favored 'General case' 0 N--CA 1.463 0.197 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 179.469 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 4.1 p30 -158.58 144.59 16.9 Favored 'General case' 0 N--CA 1.481 1.078 0 O-C-N 122.356 -0.215 . . . . 0.0 111.166 179.821 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' E' E ' 24' ' ' VAL . . . . . 0.425 ' HB ' ' H ' ' B' ' 25' ' ' GLY . 89.5 t -61.8 167.32 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.944 0 N-CA-C 106.925 -1.509 . . . . 0.0 106.925 176.86 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' E' E ' 25' ' ' GLY . . . . . 0.426 ' H ' ' HB ' ' H' ' 24' ' ' VAL . . . -121.48 46.76 1.08 Allowed Glycine 0 N--CA 1.472 1.069 0 N-CA-C 111.163 -0.775 . . . . 0.0 111.163 -179.195 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -61.81 -164.43 0.01 OUTLIER 'General case' 0 N--CA 1.471 0.58 0 CA-C-N 116.943 0.371 . . . . 0.0 110.541 -179.948 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 24.6 t-20 -70.07 77.23 0.5 Allowed 'General case' 0 CA--C 1.533 0.319 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.693 -179.785 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 97.1 mttt -76.14 139.0 41.1 Favored 'General case' 0 N--CA 1.474 0.754 0 N-CA-C 109.715 -0.476 . . . . 0.0 109.715 179.394 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.64 -165.62 1.06 Allowed Glycine 0 C--N 1.335 0.486 0 N-CA-C 109.909 -1.276 . . . . 0.0 109.909 178.011 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.68 113.09 25.32 Favored 'General case' 0 N--CA 1.473 0.711 0 N-CA-C 109.805 -0.442 . . . . 0.0 109.805 179.494 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 75.9 mt -99.07 135.24 34.98 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.447 0 N-CA-C 106.893 -1.521 . . . . 0.0 106.893 178.768 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' E' E ' 32' ' ' ILE . . . . . 0.439 ' C ' ' H ' ' E' ' 34' ' ' LEU . 28.3 pt -150.58 -170.31 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.099 0 CA-C-O 120.949 0.404 . . . . 0.0 110.755 -179.471 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.9 2.49 3.72 Favored Glycine 0 CA--C 1.529 0.92 0 N-CA-C 111.476 -0.65 . . . . 0.0 111.476 -179.59 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' E' E ' 34' ' ' LEU . . . . . 0.439 ' H ' ' C ' ' E' ' 32' ' ' ILE . 1.1 tt -73.89 133.73 43.15 Favored 'General case' 0 CA--C 1.545 0.78 0 N-CA-C 109.095 -0.706 . . . . 0.0 109.095 -179.7 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 25.0 ttt -159.34 149.56 19.12 Favored 'General case' 0 N--CA 1.473 0.69 0 N-CA-C 108.567 -0.901 . . . . 0.0 108.567 178.751 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 61.6 t -152.68 162.78 2.3 Favored 'Isoleucine or valine' 0 C--N 1.345 0.384 0 N-CA-C 108.228 -1.027 . . . . 0.0 108.228 -179.681 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 57.1 67.44 2.22 Favored Glycine 0 C--N 1.309 -0.93 0 CA-C-N 115.473 -0.785 . . . . 0.0 112.012 178.694 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.29 174.94 19.73 Favored Glycine 0 N--CA 1.476 1.325 0 N-CA-C 111.285 -0.726 . . . . 0.0 111.285 178.825 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 31.2 m -107.16 152.55 8.65 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.638 0 C-N-CA 123.475 0.71 . . . . 0.0 110.372 -179.079 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 21.9 t . . . . . 0 C--O 1.214 -0.784 0 O-C-N 124.222 0.951 . . . . 0.0 110.519 179.922 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' F' F ' 1' ' ' ASP . . . . . . . . . . . . . 66.1 m-20 . . . . . 0 N--CA 1.492 1.637 0 N-CA-C 109.327 -0.62 . . . . 0.0 109.327 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' F' F ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.75 -168.24 0.03 OUTLIER 'General case' 0 N--CA 1.467 0.394 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.602 -179.943 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' F' F ' 3' ' ' GLU . . . . . . . . . . . . . 24.8 tt0 -154.02 166.86 31.69 Favored 'General case' 0 N--CA 1.474 0.733 0 CA-C-N 116.429 -0.35 . . . . 0.0 110.291 -179.523 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 22.5 p90 -67.26 137.57 56.23 Favored 'General case' 0 C--O 1.218 -0.587 0 CA-C-N 116.251 -0.432 . . . . 0.0 110.575 -178.497 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' F' F ' 5' ' ' ARG . . . . . . . . . . . . . 99.0 mtt180 -136.73 154.04 50.7 Favored 'General case' 0 N--CA 1.478 0.937 0 N-CA-C 109.409 -0.589 . . . . 0.0 109.409 178.49 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 58.1 t-80 -114.45 114.54 25.96 Favored 'General case' 0 N--CA 1.48 1.027 0 C-N-CA 122.909 0.483 . . . . 0.0 109.76 179.534 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' F' F ' 7' ' ' ASP . . . . . 0.435 ' O ' ' OG ' ' I' ' 8' ' ' SER . 7.8 m-20 -73.28 156.39 38.52 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.274 179.129 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' F' F ' 8' ' ' SER . . . . . 0.429 ' OG ' ' O ' ' C' ' 7' ' ' ASP . 5.4 p -166.87 -174.99 2.9 Favored 'General case' 0 N--CA 1.485 1.301 0 CA-C-O 121.023 0.439 . . . . 0.0 110.936 178.468 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.38 43.69 1.69 Allowed Glycine 0 N--CA 1.479 1.543 0 CA-C-N 115.757 -0.656 . . . . 0.0 112.149 179.199 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 49.9 p90 -64.4 132.31 49.69 Favored 'General case' 0 CA--C 1.544 0.724 0 O-C-N 122.632 -0.334 . . . . 0.0 111.813 -179.945 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 86.7 mt-10 -93.73 153.59 18.25 Favored 'General case' 0 N--CA 1.48 1.067 0 N-CA-C 109.636 -0.505 . . . . 0.0 109.636 178.085 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -154.57 127.18 1.07 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.545 0 N-CA-C 107.811 -1.181 . . . . 0.0 107.811 177.885 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 46.6 m-70 -135.06 142.77 46.4 Favored 'General case' 0 N--CA 1.483 1.215 0 CA-C-O 120.77 0.319 . . . . 0.0 111.515 -178.131 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 6.2 t60 -164.55 98.7 0.8 Allowed 'General case' 0 N--CA 1.485 1.302 0 CA-C-N 116.465 -0.334 . . . . 0.0 110.437 179.62 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 22.2 pt20 -123.52 155.61 37.23 Favored 'General case' 0 CA--C 1.501 -0.914 0 N-CA-C 108.225 -1.028 . . . . 0.0 108.225 -179.527 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -125.09 105.89 9.51 Favored 'General case' 0 N--CA 1.485 1.286 0 N-CA-C 108.245 -1.02 . . . . 0.0 108.245 178.104 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 6.0 mp -120.64 148.21 44.21 Favored 'General case' 0 N--CA 1.495 1.811 0 CA-C-O 121.168 0.509 . . . . 0.0 111.181 -178.009 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 21.7 t -109.45 120.3 60.42 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.167 0 N-CA-C 108.13 -1.063 . . . . 0.0 108.13 177.244 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' F' F ' 19' ' ' PHE . . . . . 0.539 ' O ' ' N ' ' F' ' 21' ' ' ALA . 28.4 m-85 -116.76 -162.7 0.87 Allowed 'General case' 0 N--CA 1.494 1.763 0 C-N-CA 122.919 0.487 . . . . 0.0 109.864 -179.436 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' F' F ' 20' ' ' PHE . . . . . 0.482 ' HA ' ' O ' ' C' ' 20' ' ' PHE . 78.3 m-85 -48.04 75.1 0.0 OUTLIER 'General case' 0 C--O 1.206 -1.229 0 C-N-CA 124.3 1.04 . . . . 0.0 111.466 -179.878 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' F' F ' 21' ' ' ALA . . . . . 0.539 ' N ' ' O ' ' F' ' 19' ' ' PHE . . . -87.38 -77.08 0.35 Allowed 'General case' 0 N--CA 1.466 0.369 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.044 -179.386 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 41.2 tt0 -95.21 99.29 11.27 Favored 'General case' 0 N--CA 1.462 0.173 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 179.49 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 4.1 p30 -158.8 144.8 16.73 Favored 'General case' 0 N--CA 1.481 1.097 0 CA-C-O 119.655 -0.212 . . . . 0.0 111.304 179.745 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' F' F ' 24' ' ' VAL . . . . . 0.445 ' HB ' ' H ' ' C' ' 25' ' ' GLY . 88.8 t -61.98 167.3 0.77 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.93 0 N-CA-C 106.933 -1.506 . . . . 0.0 106.933 176.894 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' F' F ' 25' ' ' GLY . . . . . 0.422 ' H ' ' HB ' ' I' ' 24' ' ' VAL . . . -121.67 46.88 1.07 Allowed Glycine 0 N--CA 1.478 1.44 0 N-CA-C 110.88 -0.888 . . . . 0.0 110.88 -179.239 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' F' F ' 26' ' ' SER . . . . . 0.413 ' HG ' ' H ' ' D' ' 8' ' ' SER . 0.2 OUTLIER -61.89 -164.43 0.01 OUTLIER 'General case' 0 N--CA 1.471 0.612 0 CA-C-N 116.887 0.343 . . . . 0.0 110.436 -179.977 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 24.6 t-20 -69.88 77.11 0.47 Allowed 'General case' 0 CA--C 1.533 0.297 0 CA-C-N 116.319 -0.401 . . . . 0.0 110.752 -179.779 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -76.09 138.97 41.14 Favored 'General case' 0 N--CA 1.475 0.807 0 N-CA-C 109.638 -0.504 . . . . 0.0 109.638 179.451 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.47 -165.36 0.96 Allowed Glycine 0 C--N 1.335 0.484 0 N-CA-C 110.081 -1.207 . . . . 0.0 110.081 177.99 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.92 112.82 25.08 Favored 'General case' 0 N--CA 1.472 0.638 0 N-CA-C 109.695 -0.483 . . . . 0.0 109.695 179.511 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 76.1 mt -98.99 135.3 34.6 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.498 0 N-CA-C 106.882 -1.525 . . . . 0.0 106.882 178.84 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' F' F ' 32' ' ' ILE . . . . . 0.449 ' C ' ' H ' ' F' ' 34' ' ' LEU . 28.2 pt -150.64 -170.19 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.128 0 CA-C-O 120.988 0.423 . . . . 0.0 110.777 -179.516 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.99 2.28 3.65 Favored Glycine 0 CA--C 1.53 1.006 0 N-CA-C 111.409 -0.676 . . . . 0.0 111.409 -179.673 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' F' F ' 34' ' ' LEU . . . . . 0.449 ' H ' ' C ' ' F' ' 32' ' ' ILE . 1.1 tt -73.91 133.72 43.13 Favored 'General case' 0 CA--C 1.546 0.798 0 N-CA-C 109.128 -0.693 . . . . 0.0 109.128 -179.654 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 25.1 ttt -159.4 149.74 19.16 Favored 'General case' 0 N--CA 1.47 0.573 0 N-CA-C 108.563 -0.903 . . . . 0.0 108.563 178.832 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 62.2 t -152.83 162.84 2.21 Favored 'Isoleucine or valine' 0 C--N 1.345 0.37 0 N-CA-C 108.169 -1.049 . . . . 0.0 108.169 -179.667 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 57.1 67.44 2.22 Favored Glycine 0 C--N 1.308 -0.974 0 CA-C-N 115.433 -0.803 . . . . 0.0 112.004 178.626 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.34 175.04 19.85 Favored Glycine 0 N--CA 1.475 1.275 0 N-CA-C 111.248 -0.741 . . . . 0.0 111.248 178.848 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 31.4 m -107.27 152.41 8.85 Favored 'Isoleucine or valine' 0 C--N 1.35 0.597 0 C-N-CA 123.546 0.738 . . . . 0.0 110.361 -179.025 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 22.0 t . . . . . 0 C--O 1.213 -0.821 0 O-C-N 124.216 0.948 . . . . 0.0 110.385 179.804 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' G' G ' 1' ' ' ASP . . . . . . . . . . . . . 65.3 m-20 . . . . . 0 N--CA 1.49 1.558 0 N-CA-C 109.029 -0.73 . . . . 0.0 109.029 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' G' G ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.78 -165.98 0.03 OUTLIER 'General case' 0 N--CA 1.467 0.4 0 CA-C-N 116.591 -0.277 . . . . 0.0 110.758 -179.814 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' G' G ' 3' ' ' GLU . . . . . . . . . . . . . 24.8 tt0 -154.87 166.95 31.9 Favored 'General case' 0 N--CA 1.474 0.74 0 CA-C-O 120.709 0.29 . . . . 0.0 110.632 -179.056 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 20.1 p90 -66.71 137.3 56.58 Favored 'General case' 0 N--CA 1.472 0.625 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.339 -178.643 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' G' G ' 5' ' ' ARG . . . . . . . . . . . . . 99.1 mtt180 -136.54 154.04 50.83 Favored 'General case' 0 N--CA 1.482 1.13 0 N-CA-C 109.463 -0.569 . . . . 0.0 109.463 178.555 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 58.3 t-80 -114.1 115.54 27.7 Favored 'General case' 0 N--CA 1.483 1.207 0 C-N-CA 122.823 0.449 . . . . 0.0 109.891 179.649 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 -75.86 152.46 37.2 Favored 'General case' 0 N--CA 1.47 0.569 0 CA-C-N 116.0 -0.545 . . . . 0.0 110.772 179.279 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' G' G ' 8' ' ' SER . . . . . 0.533 ' OG ' ' O ' ' D' ' 7' ' ' ASP . 4.9 p -164.03 -172.39 2.78 Favored 'General case' 0 N--CA 1.475 0.775 0 CA-C-O 121.105 0.479 . . . . 0.0 110.596 178.621 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.12 43.6 1.87 Allowed Glycine 0 N--CA 1.479 1.563 0 CA-C-N 115.633 -0.712 . . . . 0.0 111.655 178.983 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 51.0 p90 -64.2 132.23 49.75 Favored 'General case' 0 CA--C 1.542 0.67 0 CA-C-O 120.648 0.261 . . . . 0.0 111.664 -179.772 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 84.1 mt-10 -94.01 152.88 18.49 Favored 'General case' 0 N--CA 1.479 1.008 0 CA-C-O 121.035 0.445 . . . . 0.0 110.057 178.644 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -155.21 127.55 1.03 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.016 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 178.179 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 49.9 m-70 -134.63 144.05 47.65 Favored 'General case' 0 N--CA 1.478 0.925 0 CA-C-N 115.416 -0.811 . . . . 0.0 111.405 -178.326 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 6.3 t60 -166.12 98.74 0.63 Allowed 'General case' 0 N--CA 1.481 1.12 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.122 178.977 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 22.3 pt20 -123.91 154.95 38.99 Favored 'General case' 0 CA--C 1.497 -1.07 0 N-CA-C 107.998 -1.112 . . . . 0.0 107.998 -179.287 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -124.8 106.19 9.85 Favored 'General case' 0 N--CA 1.483 1.192 0 N-CA-C 108.04 -1.096 . . . . 0.0 108.04 178.151 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 6.0 mp -120.22 148.76 43.27 Favored 'General case' 0 N--CA 1.496 1.85 0 CA-C-O 121.091 0.472 . . . . 0.0 111.625 -178.244 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 20.4 t -111.11 120.21 61.29 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.043 0 N-CA-C 107.775 -1.194 . . . . 0.0 107.775 176.909 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' G' G ' 19' ' ' PHE . . . . . 0.556 ' O ' ' N ' ' G' ' 21' ' ' ALA . 28.1 m-85 -117.17 -164.58 1.0 Allowed 'General case' 0 N--CA 1.494 1.728 0 C-N-CA 124.372 1.069 . . . . 0.0 110.225 -178.846 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' G' G ' 20' ' ' PHE . . . . . 0.472 ' HA ' ' O ' ' D' ' 20' ' ' PHE . 78.4 m-85 -47.13 73.02 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.03 0 C-N-CA 124.522 1.129 . . . . 0.0 111.664 -179.83 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' G' G ' 21' ' ' ALA . . . . . 0.556 ' N ' ' O ' ' G' ' 19' ' ' PHE . . . -85.37 -78.23 0.27 Allowed 'General case' 0 N--CA 1.466 0.364 0 C-N-CA 122.715 0.406 . . . . 0.0 110.246 -178.901 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 41.0 tt0 -94.6 99.8 11.87 Favored 'General case' 0 N--CA 1.465 0.284 0 N-CA-C 108.284 -1.006 . . . . 0.0 108.284 179.364 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 4.1 p30 -159.17 144.83 16.23 Favored 'General case' 0 N--CA 1.477 0.91 0 O-C-N 122.313 -0.242 . . . . 0.0 111.226 179.745 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' G' G ' 24' ' ' VAL . . . . . 0.474 ' HB ' ' H ' ' D' ' 25' ' ' GLY . 92.4 t -62.48 165.74 1.02 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.655 0 N-CA-C 107.283 -1.377 . . . . 0.0 107.283 177.231 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -119.86 48.85 0.91 Allowed Glycine 0 N--CA 1.482 1.734 0 N-CA-C 110.587 -1.005 . . . . 0.0 110.587 -179.66 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -64.11 -164.65 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.669 0 CA-C-N 117.194 0.497 . . . . 0.0 109.752 179.787 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 24.8 t-20 -69.97 76.81 0.48 Allowed 'General case' 0 N--CA 1.467 0.415 0 CA-C-N 116.428 -0.351 . . . . 0.0 110.775 -179.699 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -75.2 139.02 42.35 Favored 'General case' 0 N--CA 1.474 0.759 0 N-CA-C 109.724 -0.473 . . . . 0.0 109.724 179.319 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.75 -164.48 0.9 Allowed Glycine 0 C--N 1.337 0.63 0 N-CA-C 109.679 -1.369 . . . . 0.0 109.679 178.185 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.71 113.04 25.25 Favored 'General case' 0 N--CA 1.467 0.412 0 C-N-CA 122.681 0.392 . . . . 0.0 110.204 179.627 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 77.8 mt -99.7 135.42 35.27 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.825 0 N-CA-C 106.932 -1.506 . . . . 0.0 106.932 178.789 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' G' G ' 32' ' ' ILE . . . . . 0.455 ' C ' ' H ' ' G' ' 34' ' ' LEU . 30.4 pt -151.09 -169.13 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.745 0 CA-C-N 119.448 1.022 . . . . 0.0 109.946 179.963 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.98 2.42 3.76 Favored Glycine 0 CA--C 1.528 0.861 0 N-CA-C 111.253 -0.739 . . . . 0.0 111.253 -179.749 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' G' G ' 34' ' ' LEU . . . . . 0.455 ' H ' ' C ' ' G' ' 32' ' ' ILE . 1.1 tt -74.57 133.28 42.25 Favored 'General case' 0 CA--C 1.543 0.687 0 N-CA-C 109.156 -0.683 . . . . 0.0 109.156 -179.586 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 23.8 ttt -159.04 150.27 20.26 Favored 'General case' 0 N--CA 1.469 0.486 0 N-CA-C 108.59 -0.893 . . . . 0.0 108.59 179.126 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 62.5 t -153.8 161.35 2.44 Favored 'Isoleucine or valine' 0 C--N 1.346 0.426 0 N-CA-C 108.05 -1.093 . . . . 0.0 108.05 -179.5 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 58.43 67.45 2.19 Favored Glycine 0 C--N 1.309 -0.957 0 CA-C-N 115.331 -0.85 . . . . 0.0 111.91 178.566 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.44 174.37 19.36 Favored Glycine 0 N--CA 1.477 1.383 0 N-CA-C 110.641 -0.983 . . . . 0.0 110.641 178.872 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 32.9 m -107.02 152.16 8.62 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.912 0 C-N-CA 123.256 0.622 . . . . 0.0 110.487 -179.453 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 22.7 t . . . . . 0 C--O 1.217 -0.63 0 CA-C-O 118.373 -0.822 . . . . 0.0 110.688 179.867 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' H' H ' 1' ' ' ASP . . . . . . . . . . . . . 64.8 m-20 . . . . . 0 N--CA 1.49 1.57 0 N-CA-C 109.215 -0.661 . . . . 0.0 109.215 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' H' H ' 2' ' ' ALA . . . . . . . . . . . . . . . -66.07 -165.65 0.03 OUTLIER 'General case' 0 N--CA 1.466 0.339 0 CA-C-N 116.588 -0.278 . . . . 0.0 110.709 -179.758 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' H' H ' 3' ' ' GLU . . . . . . . . . . . . . 24.5 tt0 -155.22 166.91 32.09 Favored 'General case' 0 N--CA 1.473 0.694 0 CA-C-O 120.739 0.304 . . . . 0.0 110.588 -178.982 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 20.4 p90 -66.77 137.03 56.34 Favored 'General case' 0 N--CA 1.472 0.636 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.313 -178.592 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' H' H ' 5' ' ' ARG . . . . . . . . . . . . . 99.1 mtt180 -136.18 153.84 51.13 Favored 'General case' 0 N--CA 1.484 1.258 0 N-CA-C 109.398 -0.593 . . . . 0.0 109.398 178.571 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 58.4 t-80 -113.91 115.31 27.48 Favored 'General case' 0 N--CA 1.482 1.129 0 C-N-CA 122.829 0.452 . . . . 0.0 109.96 179.521 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -75.55 152.7 37.72 Favored 'General case' 0 N--CA 1.47 0.57 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.681 179.295 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' H' H ' 8' ' ' SER . . . . . 0.433 ' OG ' ' O ' ' E' ' 7' ' ' ASP . 6.9 p -164.17 -172.67 2.85 Favored 'General case' 0 N--CA 1.474 0.731 0 CA-C-O 121.113 0.482 . . . . 0.0 110.683 178.63 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.13 43.67 1.86 Allowed Glycine 0 N--CA 1.48 1.599 0 CA-C-N 115.79 -0.641 . . . . 0.0 111.765 179.157 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 51.0 p90 -64.44 132.28 49.56 Favored 'General case' 0 CA--C 1.541 0.61 0 O-C-N 122.68 -0.306 . . . . 0.0 111.709 -179.878 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 84.4 mt-10 -94.04 152.92 18.45 Favored 'General case' 0 N--CA 1.478 0.936 0 CA-C-O 121.095 0.474 . . . . 0.0 110.082 178.651 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -155.27 127.12 0.96 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.032 0 N-CA-C 108.03 -1.1 . . . . 0.0 108.03 178.176 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 48.9 m-70 -134.32 143.84 47.93 Favored 'General case' 0 N--CA 1.479 1.016 0 CA-C-N 115.415 -0.811 . . . . 0.0 111.348 -178.183 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 6.3 t60 -165.96 98.94 0.65 Allowed 'General case' 0 N--CA 1.484 1.227 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.012 178.958 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 22.5 pt20 -124.07 154.77 39.47 Favored 'General case' 0 CA--C 1.495 -1.135 0 N-CA-C 108.054 -1.091 . . . . 0.0 108.054 -179.339 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -124.52 106.06 9.87 Favored 'General case' 0 N--CA 1.483 1.204 0 N-CA-C 108.156 -1.054 . . . . 0.0 108.156 178.107 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 6.0 mp -120.17 148.58 43.46 Favored 'General case' 0 N--CA 1.496 1.868 0 CA-C-O 121.072 0.463 . . . . 0.0 111.567 -178.201 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 20.2 t -110.61 121.02 62.64 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.008 0 N-CA-C 107.777 -1.194 . . . . 0.0 107.777 176.776 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' H' H ' 19' ' ' PHE . . . . . 0.56 ' O ' ' N ' ' H' ' 21' ' ' ALA . 27.4 m-85 -117.95 -164.32 1.0 Allowed 'General case' 0 N--CA 1.492 1.675 0 C-N-CA 124.268 1.027 . . . . 0.0 110.127 -178.734 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' H' H ' 20' ' ' PHE . . . . . 0.454 ' HA ' ' O ' ' E' ' 20' ' ' PHE . 79.1 m-85 -47.53 73.03 0.0 OUTLIER 'General case' 0 N--CA 1.481 1.081 0 C-N-CA 124.425 1.09 . . . . 0.0 111.621 -179.78 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' H' H ' 21' ' ' ALA . . . . . 0.56 ' N ' ' O ' ' H' ' 19' ' ' PHE . . . -85.13 -77.8 0.27 Allowed 'General case' 0 N--CA 1.466 0.339 0 C-N-CA 122.744 0.417 . . . . 0.0 110.432 -179.018 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 41.1 tt0 -95.14 99.48 11.45 Favored 'General case' 0 N--CA 1.465 0.303 0 N-CA-C 108.313 -0.995 . . . . 0.0 108.313 179.439 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 4.2 p30 -158.76 145.06 16.97 Favored 'General case' 0 N--CA 1.478 0.938 0 O-C-N 122.475 -0.14 . . . . 0.0 111.188 179.874 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' H' H ' 24' ' ' VAL . . . . . 0.426 ' HB ' ' H ' ' E' ' 25' ' ' GLY . 88.8 t -62.65 165.45 1.09 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.594 0 N-CA-C 107.247 -1.39 . . . . 0.0 107.247 177.113 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . -119.49 48.69 0.92 Allowed Glycine 0 N--CA 1.48 1.582 0 N-CA-C 110.625 -0.99 . . . . 0.0 110.625 -179.579 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -64.31 -164.83 0.02 OUTLIER 'General case' 0 N--CA 1.473 0.685 0 CA-C-N 117.233 0.517 . . . . 0.0 109.852 179.897 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 24.7 t-20 -69.68 76.95 0.44 Allowed 'General case' 0 N--CA 1.467 0.395 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.71 -179.733 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -75.57 139.29 42.02 Favored 'General case' 0 N--CA 1.472 0.672 0 N-CA-C 109.695 -0.483 . . . . 0.0 109.695 179.326 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -65.15 -164.65 1.07 Allowed Glycine 0 C--N 1.336 0.574 0 N-CA-C 109.651 -1.38 . . . . 0.0 109.651 178.27 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.56 112.92 25.07 Favored 'General case' 0 N--CA 1.468 0.443 0 C-N-CA 122.714 0.406 . . . . 0.0 110.22 179.761 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 76.6 mt -99.6 135.28 35.68 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.812 0 N-CA-C 106.986 -1.487 . . . . 0.0 106.986 178.774 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' H' H ' 32' ' ' ILE . . . . . 0.455 ' C ' ' H ' ' H' ' 34' ' ' LEU . 30.5 pt -151.05 -169.16 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.707 0 CA-C-N 119.494 1.043 . . . . 0.0 109.836 -179.914 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.06 2.2 3.66 Favored Glycine 0 CA--C 1.528 0.852 0 N-CA-C 111.167 -0.773 . . . . 0.0 111.167 -179.834 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' H' H ' 34' ' ' LEU . . . . . 0.455 ' H ' ' C ' ' H' ' 32' ' ' ILE . 1.1 tt -74.28 133.13 42.61 Favored 'General case' 0 CA--C 1.544 0.733 0 N-CA-C 109.223 -0.658 . . . . 0.0 109.223 -179.58 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 23.9 ttt -158.85 150.29 20.64 Favored 'General case' 0 N--CA 1.468 0.465 0 N-CA-C 108.644 -0.873 . . . . 0.0 108.644 179.066 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 59.9 t -153.83 161.38 2.43 Favored 'Isoleucine or valine' 0 C--N 1.346 0.425 0 N-CA-C 108.005 -1.109 . . . . 0.0 108.005 -179.438 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 58.35 67.35 2.24 Favored Glycine 0 C--N 1.309 -0.955 0 CA-C-N 115.349 -0.841 . . . . 0.0 111.902 178.52 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.29 173.8 18.75 Favored Glycine 0 N--CA 1.477 1.39 0 N-CA-C 110.708 -0.957 . . . . 0.0 110.708 178.907 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 32.7 m -106.35 152.08 8.12 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.914 0 C-N-CA 123.341 0.656 . . . . 0.0 110.554 -179.438 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 22.1 t . . . . . 0 C--O 1.218 -0.588 0 CA-C-O 118.321 -0.847 . . . . 0.0 110.644 179.843 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' I' I ' 1' ' ' ASP . . . . . . . . . . . . . 65.3 m-20 . . . . . 0 N--CA 1.49 1.552 0 N-CA-C 109.173 -0.677 . . . . 0.0 109.173 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' I' I ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.8 -166.05 0.03 OUTLIER 'General case' 0 N--CA 1.467 0.412 0 CA-C-N 116.577 -0.283 . . . . 0.0 110.77 -179.857 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' I' I ' 3' ' ' GLU . . . . . . . . . . . . . 24.3 tt0 -154.72 167.14 31.18 Favored 'General case' 0 N--CA 1.474 0.741 0 CA-C-O 120.704 0.287 . . . . 0.0 110.71 -179.058 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 20.4 p90 -66.97 137.0 56.19 Favored 'General case' 0 N--CA 1.471 0.615 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.325 -178.602 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' I' I ' 5' ' ' ARG . . . . . . . . . . . . . 99.1 mtt180 -136.11 153.92 51.15 Favored 'General case' 0 N--CA 1.483 1.213 0 N-CA-C 109.47 -0.566 . . . . 0.0 109.47 178.62 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 58.2 t-80 -114.12 115.53 27.68 Favored 'General case' 0 N--CA 1.482 1.153 0 C-N-CA 122.809 0.444 . . . . 0.0 109.863 179.545 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 8.0 m-20 -75.98 152.33 37.02 Favored 'General case' 0 N--CA 1.47 0.567 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.697 179.335 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' I' I ' 8' ' ' SER . . . . . 0.435 ' OG ' ' O ' ' F' ' 7' ' ' ASP . 6.7 p -163.89 -172.82 2.97 Favored 'General case' 0 N--CA 1.475 0.78 0 CA-C-O 121.124 0.487 . . . . 0.0 110.681 178.801 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.35 43.61 1.84 Allowed Glycine 0 N--CA 1.481 1.676 0 CA-C-N 115.773 -0.649 . . . . 0.0 111.71 179.105 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 51.1 p90 -64.32 132.38 50.03 Favored 'General case' 0 CA--C 1.541 0.622 0 O-C-N 122.681 -0.306 . . . . 0.0 111.722 -179.853 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 84.1 mt-10 -94.06 152.92 18.44 Favored 'General case' 0 N--CA 1.477 0.921 0 CA-C-O 121.11 0.481 . . . . 0.0 110.033 178.619 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -155.33 127.31 0.98 Allowed 'Isoleucine or valine' 0 CA--C 1.553 1.069 0 N-CA-C 107.978 -1.119 . . . . 0.0 107.978 178.098 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 50.3 m-70 -134.48 144.02 47.83 Favored 'General case' 0 N--CA 1.477 0.92 0 CA-C-N 115.387 -0.824 . . . . 0.0 111.391 -178.269 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 6.3 t60 -166.09 98.59 0.63 Allowed 'General case' 0 N--CA 1.483 1.183 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.06 179.094 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 22.6 pt20 -123.84 154.77 39.15 Favored 'General case' 0 CA--C 1.497 -1.082 0 N-CA-C 108.014 -1.106 . . . . 0.0 108.014 -179.323 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -124.54 106.07 9.87 Favored 'General case' 0 N--CA 1.483 1.199 0 N-CA-C 108.154 -1.054 . . . . 0.0 108.154 178.125 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 6.0 mp -120.25 148.61 43.47 Favored 'General case' 0 N--CA 1.495 1.819 0 CA-C-O 121.06 0.457 . . . . 0.0 111.593 -178.179 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 20.2 t -110.61 121.1 62.78 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.01 0 N-CA-C 107.799 -1.186 . . . . 0.0 107.799 176.87 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' I' I ' 19' ' ' PHE . . . . . 0.559 ' O ' ' N ' ' I' ' 21' ' ' ALA . 27.2 m-85 -118.11 -164.1 0.99 Allowed 'General case' 0 N--CA 1.495 1.776 0 C-N-CA 124.229 1.012 . . . . 0.0 110.095 -178.659 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' I' I ' 20' ' ' PHE . . . . . 0.455 ' HA ' ' O ' ' F' ' 20' ' ' PHE . 79.6 m-85 -47.61 72.97 0.0 OUTLIER 'General case' 0 N--CA 1.481 1.085 0 C-N-CA 124.54 1.136 . . . . 0.0 111.502 -179.771 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' I' I ' 21' ' ' ALA . . . . . 0.559 ' N ' ' O ' ' I' ' 19' ' ' PHE . . . -85.11 -78.82 0.24 Allowed 'General case' 0 N--CA 1.468 0.43 0 C-N-CA 122.76 0.424 . . . . 0.0 110.12 -178.935 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 41.3 tt0 -93.95 99.48 11.81 Favored 'General case' 0 N--CA 1.464 0.274 0 N-CA-C 108.469 -0.938 . . . . 0.0 108.469 179.247 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 4.2 p30 -158.87 145.26 16.94 Favored 'General case' 0 N--CA 1.478 0.928 0 O-C-N 122.388 -0.195 . . . . 0.0 111.214 179.616 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' I' I ' 24' ' ' VAL . . . . . 0.422 ' HB ' ' H ' ' F' ' 25' ' ' GLY . 92.1 t -62.78 165.71 1.07 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.606 0 N-CA-C 107.257 -1.386 . . . . 0.0 107.257 177.154 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . -119.94 48.8 0.92 Allowed Glycine 0 N--CA 1.48 1.619 0 N-CA-C 110.546 -1.022 . . . . 0.0 110.546 -179.559 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -64.08 -164.37 0.02 OUTLIER 'General case' 0 N--CA 1.473 0.684 0 CA-C-N 117.168 0.484 . . . . 0.0 109.747 179.865 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 24.9 t-20 -70.27 77.2 0.53 Allowed 'General case' 0 CA--C 1.536 0.42 0 CA-C-N 116.394 -0.366 . . . . 0.0 110.63 -179.701 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -75.65 139.06 41.77 Favored 'General case' 0 N--CA 1.473 0.713 0 N-CA-C 109.62 -0.511 . . . . 0.0 109.62 179.367 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.83 -164.62 0.94 Allowed Glycine 0 C--N 1.337 0.59 0 N-CA-C 109.76 -1.336 . . . . 0.0 109.76 178.179 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.4 112.75 24.88 Favored 'General case' 0 CA--C 1.535 0.379 0 C-N-CA 122.723 0.409 . . . . 0.0 110.251 179.668 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 77.0 mt -99.52 135.21 35.84 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.852 0 N-CA-C 106.927 -1.508 . . . . 0.0 106.927 178.829 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' I' I ' 32' ' ' ILE . . . . . 0.46 ' C ' ' H ' ' I' ' 34' ' ' LEU . 30.3 pt -151.05 -169.08 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 CA-C-N 119.487 1.039 . . . . 0.0 109.876 179.956 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.05 2.25 3.7 Favored Glycine 0 CA--C 1.527 0.827 0 N-CA-C 111.22 -0.752 . . . . 0.0 111.22 -179.751 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' I' I ' 34' ' ' LEU . . . . . 0.46 ' H ' ' C ' ' I' ' 32' ' ' ILE . 1.1 tt -74.27 133.2 42.62 Favored 'General case' 0 CA--C 1.545 0.761 0 N-CA-C 109.122 -0.696 . . . . 0.0 109.122 -179.598 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 23.8 ttt -158.95 150.13 20.31 Favored 'General case' 0 N--CA 1.468 0.443 0 N-CA-C 108.612 -0.884 . . . . 0.0 108.612 179.04 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 60.4 t -153.79 161.24 2.48 Favored 'Isoleucine or valine' 0 C--N 1.345 0.396 0 N-CA-C 107.959 -1.126 . . . . 0.0 107.959 -179.46 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 58.45 67.41 2.21 Favored Glycine 0 C--N 1.311 -0.86 0 CA-C-N 115.275 -0.875 . . . . 0.0 111.935 178.564 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.28 173.92 18.84 Favored Glycine 0 N--CA 1.476 1.312 0 N-CA-C 110.674 -0.97 . . . . 0.0 110.674 178.841 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 32.8 m -106.51 151.98 8.28 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.923 0 C-N-CA 123.28 0.632 . . . . 0.0 110.643 -179.48 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 22.3 t . . . . . 0 C--O 1.217 -0.614 0 CA-C-O 118.413 -0.803 . . . . 0.0 110.752 179.908 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . 0.422 ' H2 ' ' CB ' ' D' ' 1' ' ' ASP . 9.0 m-20 . . . . . 0 N--CA 1.487 1.383 0 N-CA-C 109.126 -0.694 . . . . 0.0 109.126 . . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.15 132.27 48.7 Favored 'General case' 0 CA--C 1.539 0.526 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.108 -179.922 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 39.8 tt0 -169.4 108.84 0.43 Allowed 'General case' 0 N--CA 1.47 0.573 0 N-CA-C 109.556 -0.535 . . . . 0.0 109.556 -179.139 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 77.9 m-85 -83.75 141.38 31.47 Favored 'General case' 0 N--CA 1.473 0.694 0 N-CA-C 109.658 -0.497 . . . . 0.0 109.658 179.363 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 35.6 mtp180 -142.43 143.03 32.45 Favored 'General case' 0 N--CA 1.48 1.059 0 N-CA-C 109.285 -0.635 . . . . 0.0 109.285 -179.951 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 74.4 m80 -150.29 117.84 6.13 Favored 'General case' 0 N--CA 1.472 0.64 0 N-CA-C 108.991 -0.744 . . . . 0.0 108.991 178.749 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 10.1 m-20 -68.31 149.4 49.47 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.822 -179.848 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 4.3 t -168.42 176.34 5.87 Favored 'General case' 0 N--CA 1.473 0.695 0 N-CA-C 109.643 -0.503 . . . . 0.0 109.643 178.592 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 105.08 51.54 0.88 Allowed Glycine 0 N--CA 1.484 1.884 0 N-CA-C 112.065 -0.414 . . . . 0.0 112.065 179.276 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 45.9 p90 -64.8 131.85 47.92 Favored 'General case' 0 N--CA 1.471 0.617 0 CA-C-O 120.51 0.195 . . . . 0.0 111.524 179.652 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . 0.424 ' OE2' ' ND2' ' F' ' 27' ' ' ASN . 43.2 mt-10 -82.78 150.49 26.61 Favored 'General case' 0 N--CA 1.472 0.669 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 177.756 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -154.17 128.98 1.45 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 N-CA-C 108.094 -1.076 . . . . 0.0 108.094 178.167 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 56.7 m-70 -133.39 145.22 50.12 Favored 'General case' 0 N--CA 1.488 1.451 0 CA-C-N 118.616 0.644 . . . . 0.0 110.806 -178.959 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 5.9 t60 -166.11 98.16 0.62 Allowed 'General case' 0 N--CA 1.482 1.141 0 N-CA-C 111.392 0.145 . . . . 0.0 111.392 179.476 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . 0.458 HE22 ' H ' ' A' ' 37' ' ' GLY . 49.8 mt-30 -107.44 -172.65 2.11 Favored 'General case' 0 CA--C 1.502 -0.886 0 N-CA-C 107.948 -1.13 . . . . 0.0 107.948 179.219 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -163.13 97.92 0.92 Allowed 'General case' 0 N--CA 1.471 0.576 0 CA-C-N 115.121 -0.945 . . . . 0.0 109.291 178.739 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 6.2 mp -108.7 163.98 12.78 Favored 'General case' 0 N--CA 1.487 1.394 0 N-CA-C 108.05 -1.093 . . . . 0.0 108.05 179.792 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 55.3 t -141.84 120.25 9.18 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.395 0 CA-C-O 118.663 -0.684 . . . . 0.0 110.33 179.77 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 52.9 m-85 -72.97 158.07 36.19 Favored 'General case' 0 N--CA 1.482 1.172 0 N-CA-C 107.383 -1.34 . . . . 0.0 107.383 176.917 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 24.8 t80 -169.29 -58.22 0.02 OUTLIER 'General case' 0 N--CA 1.481 1.076 0 CA-C-O 122.553 1.168 . . . . 0.0 109.475 -179.82 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -39.76 91.12 0.0 OUTLIER 'General case' 0 N--CA 1.457 -0.092 0 CA-C-N 113.665 -1.607 . . . . 0.0 112.709 -178.115 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 36.4 tt0 -58.2 131.95 52.12 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-N 115.143 -0.935 . . . . 0.0 111.128 179.429 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 9.0 m-20 -80.45 162.89 24.18 Favored 'General case' 0 N--CA 1.478 0.961 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 179.772 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 98.3 t -161.2 -74.25 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.484 1.267 0 N-CA-C 107.609 -1.256 . . . . 0.0 107.609 -178.612 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -38.96 91.01 0.01 OUTLIER Glycine 0 N--CA 1.471 1.002 0 CA-C-N 115.385 -0.825 . . . . 0.0 111.981 -179.736 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 89.1 p -37.46 -99.91 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.917 0 C-N-CA 123.714 0.806 . . . . 0.0 112.9 -176.622 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 40.8 t30 -61.23 126.35 27.04 Favored 'General case' 0 CA--C 1.546 0.807 0 CA-C-N 119.495 1.043 . . . . 0.0 108.855 179.465 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 62.8 mttm -106.36 -178.95 3.8 Favored 'General case' 0 N--CA 1.484 1.259 0 N-CA-C 109.249 -0.648 . . . . 0.0 109.249 -179.728 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.83 -141.27 0.02 OUTLIER Glycine 0 CA--C 1.528 0.888 0 N-CA-C 109.39 -1.484 . . . . 0.0 109.39 177.967 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.79 119.42 22.25 Favored 'General case' 0 N--CA 1.477 0.922 0 N-CA-C 109.257 -0.645 . . . . 0.0 109.257 178.439 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 68.9 mt -100.76 146.3 9.61 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.876 0 N-CA-C 107.856 -1.164 . . . . 0.0 107.856 178.614 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 28.4 mt -146.07 124.59 4.87 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.745 0 N-CA-C 109.435 -0.579 . . . . 0.0 109.435 -177.877 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.55 83.91 0.07 OUTLIER Glycine 0 C--N 1.338 0.677 0 CA-C-N 116.138 -0.483 . . . . 0.0 112.93 178.08 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 14.6 tp -101.9 123.2 45.42 Favored 'General case' 0 N--CA 1.484 1.263 0 N-CA-C 107.112 -1.44 . . . . 0.0 107.112 177.394 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 13.5 ttt -158.37 158.06 33.55 Favored 'General case' 0 N--CA 1.468 0.452 0 N-CA-C 109.018 -0.734 . . . . 0.0 109.018 179.94 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 89.5 t -155.93 152.46 8.52 Favored 'Isoleucine or valine' 0 C--O 1.234 0.262 0 N-CA-C 107.37 -1.345 . . . . 0.0 107.37 -179.435 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . 0.458 ' H ' HE22 ' A' ' 15' ' ' GLN . . . 57.22 73.34 0.46 Allowed Glycine 0 C--N 1.31 -0.881 0 CA-C-N 115.569 -0.741 . . . . 0.0 111.834 178.398 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 169.84 -150.03 14.19 Favored Glycine 0 N--CA 1.462 0.394 0 N-CA-C 110.744 -0.942 . . . . 0.0 110.744 179.432 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 33.1 m -133.77 144.77 34.8 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.875 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 179.93 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 19.8 t . . . . . 0 C--O 1.222 -0.393 0 CA-C-O 117.787 -1.101 . . . . 0.0 110.924 179.753 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' B' B ' 1' ' ' ASP . . . . . 0.411 ' H2 ' ' CB ' ' E' ' 1' ' ' ASP . 9.1 m-20 . . . . . 0 N--CA 1.488 1.441 0 N-CA-C 109.113 -0.699 . . . . 0.0 109.113 . . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.18 132.2 48.5 Favored 'General case' 0 CA--C 1.538 0.487 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.16 -179.945 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 3' ' ' GLU . . . . . . . . . . . . . 39.9 tt0 -169.35 108.77 0.43 Allowed 'General case' 0 N--CA 1.47 0.548 0 N-CA-C 109.519 -0.548 . . . . 0.0 109.519 -179.077 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 78.1 m-85 -83.67 141.52 31.43 Favored 'General case' 0 N--CA 1.471 0.621 0 N-CA-C 109.656 -0.498 . . . . 0.0 109.656 179.33 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 35.7 mtp180 -142.58 143.15 32.31 Favored 'General case' 0 N--CA 1.479 1.015 0 N-CA-C 109.296 -0.631 . . . . 0.0 109.296 -179.93 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 74.5 m80 -150.38 118.04 6.16 Favored 'General case' 0 N--CA 1.473 0.701 0 N-CA-C 109.045 -0.724 . . . . 0.0 109.045 178.768 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 7' ' ' ASP . . . . . . . . . . . . . 10.0 m-20 -68.46 149.05 49.75 Favored 'General case' 0 N--CA 1.464 0.233 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.929 -179.884 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 8' ' ' SER . . . . . . . . . . . . . 4.3 t -168.14 176.44 6.04 Favored 'General case' 0 N--CA 1.472 0.666 0 N-CA-C 109.614 -0.513 . . . . 0.0 109.614 178.575 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 105.03 51.31 0.89 Allowed Glycine 0 N--CA 1.483 1.814 0 N-CA-C 112.042 -0.423 . . . . 0.0 112.042 179.296 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 46.7 p90 -64.49 131.9 48.43 Favored 'General case' 0 N--CA 1.471 0.618 0 CA-C-O 120.583 0.23 . . . . 0.0 111.538 179.596 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 11' ' ' GLU . . . . . 0.432 ' OE2' ' ND2' ' D' ' 27' ' ' ASN . 43.2 mt-10 -82.88 150.61 26.42 Favored 'General case' 0 N--CA 1.473 0.696 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 177.787 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -154.29 128.9 1.41 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 N-CA-C 108.214 -1.032 . . . . 0.0 108.214 178.162 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 56.8 m-70 -133.4 145.35 50.23 Favored 'General case' 0 N--CA 1.489 1.479 0 CA-C-N 118.458 0.572 . . . . 0.0 110.762 -178.84 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 5.9 t60 -166.25 97.91 0.61 Allowed 'General case' 0 N--CA 1.484 1.27 0 CA-C-O 119.694 -0.193 . . . . 0.0 111.236 179.554 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . 0.448 HE22 ' H ' ' B' ' 37' ' ' GLY . 49.7 mt-30 -107.21 -172.77 2.14 Favored 'General case' 0 CA--C 1.504 -0.803 0 N-CA-C 107.862 -1.162 . . . . 0.0 107.862 179.238 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -163.11 97.9 0.93 Allowed 'General case' 0 N--CA 1.471 0.625 0 CA-C-N 115.154 -0.93 . . . . 0.0 109.192 178.748 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 6.1 mp -108.77 163.96 12.81 Favored 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 108.075 -1.083 . . . . 0.0 108.075 179.784 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 57.6 t -141.98 119.92 8.39 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.31 0 CA-C-O 118.724 -0.655 . . . . 0.0 110.293 179.868 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 55.4 m-85 -73.14 158.29 35.58 Favored 'General case' 0 N--CA 1.48 1.036 0 N-CA-C 107.343 -1.355 . . . . 0.0 107.343 176.792 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 26.1 t80 -170.33 -57.25 0.02 OUTLIER 'General case' 0 N--CA 1.478 0.953 0 CA-C-O 122.354 1.073 . . . . 0.0 109.533 -179.962 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -39.87 91.07 0.0 OUTLIER 'General case' 0 C--N 1.34 0.161 0 CA-C-N 113.999 -1.455 . . . . 0.0 112.558 -178.314 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 36.1 tt0 -58.19 132.0 52.25 Favored 'General case' 0 C--N 1.317 -0.811 0 CA-C-N 115.142 -0.936 . . . . 0.0 111.219 179.545 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 -80.58 162.71 24.14 Favored 'General case' 0 N--CA 1.479 1.015 0 N-CA-C 109.491 -0.559 . . . . 0.0 109.491 179.776 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 98.5 t -160.99 -74.13 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.483 1.192 0 C-N-CA 124.76 1.224 . . . . 0.0 107.732 -178.526 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -39.38 91.04 0.01 OUTLIER Glycine 0 N--CA 1.473 1.154 0 CA-C-N 115.42 -0.809 . . . . 0.0 111.828 -179.709 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 92.4 p -37.08 -99.93 0.0 OUTLIER 'General case' 0 N--CA 1.481 1.107 0 C-N-CA 123.881 0.873 . . . . 0.0 112.615 -177.045 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 41.6 t30 -61.23 126.35 27.03 Favored 'General case' 0 CA--C 1.544 0.746 0 CA-C-N 119.547 1.067 . . . . 0.0 109.076 179.508 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 62.9 mttm -106.43 -179.03 3.82 Favored 'General case' 0 N--CA 1.483 1.178 0 N-CA-C 109.223 -0.658 . . . . 0.0 109.223 -179.703 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.85 -141.22 0.02 OUTLIER Glycine 0 CA--C 1.527 0.814 0 N-CA-C 109.411 -1.476 . . . . 0.0 109.411 177.924 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.77 119.36 22.18 Favored 'General case' 0 N--CA 1.478 0.962 0 N-CA-C 109.304 -0.628 . . . . 0.0 109.304 178.488 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 69.0 mt -100.84 146.03 10.13 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.901 0 N-CA-C 107.862 -1.162 . . . . 0.0 107.862 178.551 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 28.7 mt -145.9 124.59 5.1 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.755 0 N-CA-C 109.428 -0.582 . . . . 0.0 109.428 -177.817 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.87 83.87 0.07 OUTLIER Glycine 0 C--N 1.338 0.678 0 CA-C-N 116.119 -0.492 . . . . 0.0 112.872 178.005 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 15.0 tp -102.27 121.52 42.43 Favored 'General case' 0 N--CA 1.486 1.335 0 N-CA-C 107.386 -1.338 . . . . 0.0 107.386 177.441 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 13.3 ttt -156.75 158.18 36.41 Favored 'General case' 0 N--CA 1.466 0.327 0 N-CA-C 109.27 -0.641 . . . . 0.0 109.27 179.836 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 89.1 t -155.97 152.32 8.64 Favored 'Isoleucine or valine' 0 C--O 1.235 0.317 0 N-CA-C 107.256 -1.387 . . . . 0.0 107.256 -179.444 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . 0.448 ' H ' HE22 ' B' ' 15' ' ' GLN . . . 57.39 73.24 0.47 Allowed Glycine 0 C--N 1.312 -0.797 0 CA-C-N 115.525 -0.762 . . . . 0.0 111.789 178.332 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 169.79 -149.99 14.16 Favored Glycine 0 N--CA 1.462 0.412 0 N-CA-C 110.751 -0.94 . . . . 0.0 110.751 179.408 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 33.1 m -133.78 144.83 34.62 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.91 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 179.996 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 20.4 t . . . . . 0 C--O 1.221 -0.425 0 CA-C-O 117.766 -1.111 . . . . 0.0 110.877 179.708 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' C' C ' 1' ' ' ASP . . . . . 0.407 ' N ' ' CB ' ' F' ' 1' ' ' ASP . 9.2 m-20 . . . . . 0 N--CA 1.489 1.494 0 N-CA-C 109.011 -0.737 . . . . 0.0 109.011 . . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' C' C ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.29 132.23 48.53 Favored 'General case' 0 CA--C 1.539 0.535 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.214 -179.896 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' C' C ' 3' ' ' GLU . . . . . . . . . . . . . 39.8 tt0 -169.42 108.92 0.43 Allowed 'General case' 0 N--CA 1.47 0.537 0 N-CA-C 109.553 -0.536 . . . . 0.0 109.553 -179.054 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 78.2 m-85 -83.74 141.59 31.32 Favored 'General case' 0 N--CA 1.473 0.714 0 N-CA-C 109.605 -0.517 . . . . 0.0 109.605 179.297 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 35.7 mtp180 -142.66 143.11 32.2 Favored 'General case' 0 N--CA 1.48 1.057 0 N-CA-C 109.227 -0.657 . . . . 0.0 109.227 -179.93 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 74.6 m80 -150.44 118.08 6.15 Favored 'General case' 0 N--CA 1.472 0.641 0 N-CA-C 108.958 -0.756 . . . . 0.0 108.958 178.765 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' C' C ' 7' ' ' ASP . . . . . . . . . . . . . 10.0 m-20 -68.52 149.17 49.55 Favored 'General case' 0 N--CA 1.462 0.17 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.994 -179.92 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' C' C ' 8' ' ' SER . . . . . . . . . . . . . 4.3 t -168.22 176.49 5.95 Favored 'General case' 0 N--CA 1.472 0.655 0 N-CA-C 109.546 -0.539 . . . . 0.0 109.546 178.631 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 105.01 51.35 0.89 Allowed Glycine 0 N--CA 1.483 1.821 0 N-CA-C 112.006 -0.438 . . . . 0.0 112.006 179.275 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 46.1 p90 -64.64 131.82 48.02 Favored 'General case' 0 N--CA 1.471 0.602 0 CA-C-O 120.57 0.224 . . . . 0.0 111.509 179.648 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' C' C ' 11' ' ' GLU . . . . . 0.435 ' OE2' ' ND2' ' E' ' 27' ' ' ASN . 43.2 mt-10 -82.76 150.44 26.66 Favored 'General case' 0 N--CA 1.473 0.68 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 177.815 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -154.11 129.04 1.48 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 178.133 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 56.8 m-70 -133.44 145.41 50.22 Favored 'General case' 0 N--CA 1.489 1.507 0 CA-C-N 118.496 0.589 . . . . 0.0 110.81 -178.914 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 5.9 t60 -166.36 98.04 0.6 Allowed 'General case' 0 N--CA 1.483 1.204 0 CA-C-O 119.79 -0.148 . . . . 0.0 111.3 179.534 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' C' C ' 15' ' ' GLN . . . . . 0.437 HE22 ' H ' ' C' ' 37' ' ' GLY . 49.7 mt-30 -107.42 -172.69 2.12 Favored 'General case' 0 CA--C 1.5 -0.945 0 N-CA-C 107.999 -1.111 . . . . 0.0 107.999 179.246 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -163.15 97.86 0.92 Allowed 'General case' 0 N--CA 1.47 0.532 0 CA-C-N 115.181 -0.918 . . . . 0.0 109.308 178.782 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 6.1 mp -108.69 163.96 12.79 Favored 'General case' 0 N--CA 1.487 1.395 0 N-CA-C 108.037 -1.097 . . . . 0.0 108.037 179.879 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 57.3 t -141.93 119.97 8.59 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.365 0 CA-C-O 118.721 -0.657 . . . . 0.0 110.257 179.836 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 55.1 m-85 -73.14 158.28 35.61 Favored 'General case' 0 N--CA 1.479 1.016 0 N-CA-C 107.293 -1.373 . . . . 0.0 107.293 176.761 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 26.1 t80 -170.23 -57.21 0.02 OUTLIER 'General case' 0 N--CA 1.477 0.898 0 CA-C-O 122.358 1.075 . . . . 0.0 109.587 179.978 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -39.93 91.26 0.0 OUTLIER 'General case' 0 C--N 1.34 0.169 0 CA-C-N 114.028 -1.442 . . . . 0.0 112.549 -178.294 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 36.1 tt0 -58.3 131.88 51.96 Favored 'General case' 0 C--N 1.317 -0.847 0 CA-C-N 115.129 -0.941 . . . . 0.0 111.165 179.501 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 -80.45 162.76 24.25 Favored 'General case' 0 N--CA 1.479 0.994 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 179.722 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 98.2 t -161.07 -74.27 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.483 1.21 0 C-N-CA 124.753 1.221 . . . . 0.0 107.744 -178.556 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -39.46 91.09 0.01 OUTLIER Glycine 0 N--CA 1.473 1.105 0 CA-C-N 115.463 -0.79 . . . . 0.0 111.84 -179.68 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 91.1 p -37.03 -99.88 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.036 0 C-N-CA 123.831 0.852 . . . . 0.0 112.748 -177.0 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 41.6 t30 -61.17 126.37 27.12 Favored 'General case' 0 CA--C 1.545 0.752 0 CA-C-N 119.506 1.048 . . . . 0.0 109.061 179.484 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 62.9 mttm -106.46 -179.12 3.85 Favored 'General case' 0 N--CA 1.483 1.185 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 -179.713 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.79 -141.25 0.02 OUTLIER Glycine 0 CA--C 1.528 0.878 0 N-CA-C 109.362 -1.495 . . . . 0.0 109.362 177.996 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.73 119.34 22.21 Favored 'General case' 0 N--CA 1.477 0.882 0 N-CA-C 109.37 -0.604 . . . . 0.0 109.37 178.436 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 68.7 mt -100.81 146.01 10.15 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.945 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 178.598 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 28.6 mt -145.96 124.63 5.03 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.726 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 -177.793 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.74 83.78 0.07 OUTLIER Glycine 0 C--N 1.339 0.701 0 CA-C-N 116.127 -0.488 . . . . 0.0 112.92 178.05 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 15.2 tp -102.12 121.39 42.11 Favored 'General case' 0 N--CA 1.484 1.26 0 N-CA-C 107.485 -1.302 . . . . 0.0 107.485 177.349 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 13.4 ttt -156.62 158.23 36.67 Favored 'General case' 0 N--CA 1.465 0.32 0 N-CA-C 109.254 -0.647 . . . . 0.0 109.254 179.848 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 87.9 t -155.94 152.44 8.53 Favored 'Isoleucine or valine' 0 C--O 1.235 0.314 0 N-CA-C 107.331 -1.359 . . . . 0.0 107.331 -179.48 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' C' C ' 37' ' ' GLY . . . . . 0.437 ' H ' HE22 ' C' ' 15' ' ' GLN . . . 57.26 73.27 0.47 Allowed Glycine 0 C--N 1.311 -0.82 0 CA-C-N 115.535 -0.757 . . . . 0.0 111.812 178.384 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 169.78 -150.0 14.19 Favored Glycine 0 N--CA 1.462 0.433 0 N-CA-C 110.716 -0.954 . . . . 0.0 110.716 179.377 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 33.2 m -133.7 144.82 34.72 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.883 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 179.98 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 20.3 t . . . . . 0 N--CA 1.467 0.403 0 CA-C-O 117.747 -1.121 . . . . 0.0 110.864 179.667 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' D' D ' 1' ' ' ASP . . . . . 0.422 ' CB ' ' H2 ' ' A' ' 1' ' ' ASP . 9.4 m-20 . . . . . 0 N--CA 1.489 1.477 0 N-CA-C 109.269 -0.641 . . . . 0.0 109.269 . . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' D' D ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.45 131.11 46.21 Favored 'General case' 0 CA--C 1.536 0.409 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.229 179.956 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' D' D ' 3' ' ' GLU . . . . . . . . . . . . . 39.6 tt0 -169.32 110.59 0.47 Allowed 'General case' 0 N--CA 1.469 0.487 0 N-CA-C 109.29 -0.633 . . . . 0.0 109.29 179.975 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 85.5 m-85 -86.8 148.82 25.23 Favored 'General case' 0 C--N 1.362 1.11 0 C-N-CA 118.68 -1.208 . . . . 0.0 108.142 179.59 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' D' D ' 5' ' ' ARG . . . . . . . . . . . . . 36.8 mtp180 -145.95 141.99 28.27 Favored 'General case' 0 N--CA 1.474 0.76 0 N-CA-C 109.365 -0.606 . . . . 0.0 109.365 -179.834 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 75.5 m80 -149.13 123.39 9.57 Favored 'General case' 0 CA--C 1.543 0.684 0 N-CA-C 107.815 -1.18 . . . . 0.0 107.815 174.618 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' D' D ' 7' ' ' ASP . . . . . . . . . . . . . 6.7 m-20 -63.71 133.13 53.02 Favored 'General case' 0 C--N 1.322 -0.615 0 C-N-CA 126.968 2.107 . . . . 0.0 114.675 175.231 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' D' D ' 8' ' ' SER . . . . . . . . . . . . . 3.5 t -154.59 -179.74 8.27 Favored 'General case' 0 N--CA 1.475 0.823 0 CA-C-N 119.081 0.855 . . . . 0.0 110.214 175.99 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.36 49.92 1.02 Allowed Glycine 0 N--CA 1.482 1.743 0 N-CA-C 112.047 -0.421 . . . . 0.0 112.047 175.194 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 46.4 p90 -61.49 132.31 52.98 Favored 'General case' 0 CA--C 1.54 0.575 0 N-CA-C 112.116 0.413 . . . . 0.0 112.116 179.505 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' D' D ' 11' ' ' GLU . . . . . 0.401 ' CG ' ' ND2' ' F' ' 27' ' ' ASN . 42.7 mt-10 -83.23 148.97 27.1 Favored 'General case' 0 N--CA 1.48 1.065 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 176.661 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -149.84 130.15 4.19 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.341 0 N-CA-C 108.325 -0.991 . . . . 0.0 108.325 174.876 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 54.7 m-70 -129.42 148.05 51.29 Favored 'General case' 0 N--CA 1.482 1.137 0 CA-C-N 118.158 0.436 . . . . 0.0 110.897 176.801 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' D' D ' 14' ' ' HIS . . . . . 0.41 ' ND1' ' O ' ' G' ' 14' ' ' HIS . 6.0 t60 -165.34 104.64 0.74 Allowed 'General case' 0 N--CA 1.484 1.246 0 CA-C-O 119.016 -0.516 . . . . 0.0 109.667 173.637 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' D' D ' 15' ' ' GLN . . . . . 0.477 HE22 ' H ' ' D' ' 37' ' ' GLY . 49.7 mt-30 -110.63 -175.72 2.79 Favored 'General case' 0 CA--C 1.492 -1.268 0 N-CA-C 107.551 -1.277 . . . . 0.0 107.551 178.285 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -159.54 105.88 1.67 Allowed 'General case' 0 CA--C 1.536 0.431 0 N-CA-C 107.679 -1.23 . . . . 0.0 107.679 175.619 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 6.9 mp -114.87 162.65 16.63 Favored 'General case' 0 N--CA 1.487 1.419 0 N-CA-C 107.638 -1.245 . . . . 0.0 107.638 179.401 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 48.1 t -140.99 123.78 15.58 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.147 0 N-CA-C 109.483 -0.562 . . . . 0.0 109.483 176.319 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 82.7 m-85 -63.25 151.08 41.53 Favored 'General case' 0 C--N 1.357 0.923 0 C-N-CA 124.569 1.147 . . . . 0.0 110.634 169.586 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 19.0 t80 -169.68 -66.85 0.02 OUTLIER 'General case' 0 C--N 1.315 -0.916 0 N-CA-C 107.456 -1.312 . . . . 0.0 107.456 -179.877 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -37.98 95.82 0.01 OUTLIER 'General case' 0 CA--C 1.536 0.42 0 CA-C-N 114.162 -1.381 . . . . 0.0 111.683 -175.407 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 36.6 tt0 -60.38 134.34 56.97 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 113.709 -1.587 . . . . 0.0 111.018 179.297 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 9.5 m-20 -82.57 168.27 17.52 Favored 'General case' 0 C--O 1.205 -1.285 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 179.558 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' D' D ' 24' ' ' VAL . . . . . . . . . . . . 0.288 46.3 t -168.93 -94.15 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.505 2.291 0 N-CA-C 103.507 -2.775 . . . . 0.0 103.507 -164.215 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . -26.35 77.14 0.0 OUTLIER Glycine 0 C--N 1.259 -3.721 0 C-N-CA 129.754 3.549 . . . . 0.0 116.908 -179.957 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' D' D ' 26' ' ' SER . . . . . 0.459 ' OG ' ' N ' ' D' ' 27' ' ' ASN 0.51 75.0 p -59.05 -93.05 0.0 OUTLIER 'General case' 0 C--O 1.28 2.692 1 CA-C-O 107.247 -6.12 . . . . 0.0 104.856 -155.503 . . . . . . . . 4 3 . 1 . 018 nuclear orig full ' D' D ' 27' ' ' ASN . . . . . 0.459 ' N ' ' OG ' ' D' ' 26' ' ' SER 0.293 32.8 t30 -62.98 135.82 57.5 Favored 'General case' 0 N--CA 1.491 1.581 1 CA-C-N 133.294 7.315 . . . . 0.0 108.193 -172.984 . . . . . . . . 4 3 . 1 . 018 nuclear orig full ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 60.0 mttm -102.76 178.58 4.53 Favored 'General case' 0 N--CA 1.475 0.82 0 C-N-CA 125.3 1.44 . . . . 0.0 111.632 177.889 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.02 -145.83 0.01 OUTLIER Glycine 0 CA--C 1.537 1.447 0 N-CA-C 111.267 -0.733 . . . . 0.0 111.267 171.401 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -126.9 122.02 33.44 Favored 'General case' 0 C--N 1.369 1.421 0 N-CA-C 108.779 -0.823 . . . . 0.0 108.779 174.689 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 68.4 mt -97.81 152.27 4.17 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.758 0 N-CA-C 107.829 -1.174 . . . . 0.0 107.829 175.492 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 34.7 mt -152.04 128.68 1.99 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.006 0 N-CA-C 107.884 -1.154 . . . . 0.0 107.884 177.226 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 64.06 80.47 0.13 Allowed Glycine 0 C--N 1.35 1.344 0 CA-C-O 117.996 -1.447 . . . . 0.0 113.185 178.06 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 10.5 tp -101.42 131.98 47.24 Favored 'General case' 0 C--N 1.38 1.931 0 N-CA-C 104.792 -2.299 . . . . 0.0 104.792 176.402 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 12.5 ttt -157.3 165.69 35.15 Favored 'General case' 0 N--CA 1.467 0.395 0 N-CA-C 108.721 -0.844 . . . . 0.0 108.721 176.756 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 81.4 t -163.19 156.61 2.11 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.485 0 N-CA-C 106.145 -1.798 . . . . 0.0 106.145 175.089 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' D' D ' 37' ' ' GLY . . . . . 0.477 ' H ' HE22 ' D' ' 15' ' ' GLN . . . 61.25 66.17 2.83 Favored Glycine 0 N--CA 1.447 -0.633 0 C-N-CA 117.956 -2.068 . . . . 0.0 113.754 178.087 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 167.1 -148.95 13.88 Favored Glycine 0 N--CA 1.467 0.751 0 CA-C-O 118.011 -1.438 . . . . 0.0 112.105 179.982 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 33.0 m -130.67 144.47 37.81 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.225 0 CA-C-N 119.02 1.41 . . . . 0.0 109.956 -178.821 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 18.4 t . . . . . 0 C--O 1.214 -0.802 0 N-CA-C 109.2 -0.667 . . . . 0.0 109.2 174.99 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' E' E ' 1' ' ' ASP . . . . . 0.411 ' CB ' ' H2 ' ' B' ' 1' ' ' ASP . 9.3 m-20 . . . . . 0 N--CA 1.487 1.407 0 N-CA-C 109.323 -0.621 . . . . 0.0 109.323 . . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' E' E ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.12 130.98 46.11 Favored 'General case' 0 CA--C 1.536 0.405 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.27 179.83 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' E' E ' 3' ' ' GLU . . . . . . . . . . . . . 39.7 tt0 -169.11 108.62 0.45 Allowed 'General case' 0 N--CA 1.469 0.516 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 -179.665 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 77.6 m-85 -84.26 141.83 30.69 Favored 'General case' 0 N--CA 1.474 0.763 0 N-CA-C 109.703 -0.48 . . . . 0.0 109.703 179.235 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' E' E ' 5' ' ' ARG . . . . . . . . . . . . . 37.1 mtp180 -142.62 143.56 32.45 Favored 'General case' 0 N--CA 1.477 0.888 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 179.906 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 74.7 m80 -150.56 117.55 5.92 Favored 'General case' 0 N--CA 1.473 0.699 0 N-CA-C 109.136 -0.691 . . . . 0.0 109.136 178.653 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' E' E ' 7' ' ' ASP . . . . . . . . . . . . . 9.5 m-20 -68.06 149.18 49.98 Favored 'General case' 0 CA--C 1.529 0.171 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.043 -179.816 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' E' E ' 8' ' ' SER . . . . . . . . . . . . . 3.4 t -168.5 178.06 4.98 Favored 'General case' 0 N--CA 1.475 0.806 0 N-CA-C 109.574 -0.528 . . . . 0.0 109.574 178.224 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.85 50.9 0.92 Allowed Glycine 0 N--CA 1.477 1.385 0 N-CA-C 111.97 -0.452 . . . . 0.0 111.97 179.124 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 44.2 p90 -63.78 131.21 47.13 Favored 'General case' 0 CA--C 1.545 0.756 0 N-CA-C 111.895 0.332 . . . . 0.0 111.895 -179.861 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 41.4 mt-10 -81.78 151.42 27.43 Favored 'General case' 0 N--CA 1.479 1.008 0 N-CA-C 108.683 -0.858 . . . . 0.0 108.683 177.433 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.6 p -155.92 127.91 1.0 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.449 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 177.906 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 52.2 m-70 -133.5 143.51 48.82 Favored 'General case' 0 N--CA 1.48 1.034 0 O-C-N 122.259 -0.276 . . . . 0.0 111.073 -177.884 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 5.9 t60 -165.35 97.43 0.7 Allowed 'General case' 0 N--CA 1.488 1.437 0 CA-C-O 119.602 -0.237 . . . . 0.0 111.211 179.816 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' E' E ' 15' ' ' GLN . . . . . 0.434 HE22 ' H ' ' E' ' 37' ' ' GLY . 50.0 mt-30 -106.44 -172.29 2.06 Favored 'General case' 0 CA--C 1.505 -0.769 0 N-CA-C 107.969 -1.123 . . . . 0.0 107.969 179.228 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -163.23 98.0 0.92 Allowed 'General case' 0 N--CA 1.47 0.575 0 CA-C-N 115.135 -0.938 . . . . 0.0 109.241 178.634 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 6.2 mp -108.54 163.13 13.5 Favored 'General case' 0 N--CA 1.488 1.441 0 N-CA-C 108.636 -0.876 . . . . 0.0 108.636 -179.919 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 40.6 t -141.86 120.79 9.83 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.281 0 C-N-CA 122.465 0.306 . . . . 0.0 110.631 179.194 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 51.9 m-85 -73.64 155.6 38.87 Favored 'General case' 0 C--N 1.362 1.138 0 N-CA-C 106.823 -1.547 . . . . 0.0 106.823 176.349 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 23.6 t80 -171.78 -54.82 0.02 OUTLIER 'General case' 0 N--CA 1.479 1.01 0 CA-C-O 121.682 0.753 . . . . 0.0 110.161 -179.942 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.95 89.63 0.0 OUTLIER 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 114.426 -1.261 . . . . 0.0 112.634 -179.436 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 36.0 tt0 -56.2 133.47 52.4 Favored 'General case' 0 CA--C 1.539 0.536 0 CA-C-N 114.912 -1.04 . . . . 0.0 111.291 179.861 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 9.2 m-20 -81.72 162.25 23.05 Favored 'General case' 0 N--CA 1.475 0.779 0 N-CA-C 109.66 -0.496 . . . . 0.0 109.66 179.782 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 95.0 t -160.7 -74.64 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.291 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 -179.003 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . -38.81 91.22 0.01 OUTLIER Glycine 0 CA--C 1.53 0.974 0 CA-C-N 115.263 -0.88 . . . . 0.0 112.403 -179.673 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 84.8 p -37.7 -101.33 0.0 OUTLIER 'General case' 0 N--CA 1.481 1.079 0 N-CA-C 113.725 1.009 . . . . 0.0 113.725 -177.429 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' E' E ' 27' ' ' ASN . . . . . 0.435 ' ND2' ' OE2' ' C' ' 11' ' ' GLU . 40.2 t30 -60.01 124.63 20.8 Favored 'General case' 0 CA--C 1.542 0.663 0 CA-C-N 119.482 1.037 . . . . 0.0 108.781 -179.89 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 62.8 mttm -105.38 -178.65 3.71 Favored 'General case' 0 N--CA 1.483 1.214 0 N-CA-C 108.889 -0.782 . . . . 0.0 108.889 -179.613 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -65.35 -141.45 0.03 OUTLIER Glycine 0 CA--C 1.532 1.102 0 N-CA-C 110.421 -1.072 . . . . 0.0 110.421 178.02 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.93 118.31 22.44 Favored 'General case' 0 C--N 1.349 0.582 0 C-N-CA 123.234 0.614 . . . . 0.0 109.46 178.471 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 71.6 mt -100.28 148.76 6.44 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.816 0 N-CA-C 106.88 -1.526 . . . . 0.0 106.88 178.103 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 34.1 mt -148.17 125.0 2.77 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.958 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 -179.434 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.76 85.49 0.05 OUTLIER Glycine 0 C--N 1.34 0.767 0 CA-C-N 115.966 -0.561 . . . . 0.0 112.827 178.493 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 13.2 tp -103.39 121.38 42.68 Favored 'General case' 0 N--CA 1.484 1.258 0 N-CA-C 106.97 -1.492 . . . . 0.0 106.97 177.371 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 12.6 ttt -156.08 158.93 38.6 Favored 'General case' 0 N--CA 1.476 0.859 0 N-CA-C 108.883 -0.784 . . . . 0.0 108.883 179.661 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 95.3 t -156.76 151.98 8.33 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.416 0 N-CA-C 107.493 -1.299 . . . . 0.0 107.493 -179.693 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' E' E ' 37' ' ' GLY . . . . . 0.434 ' H ' HE22 ' E' ' 15' ' ' GLN . . . 57.59 72.41 0.59 Allowed Glycine 0 C--N 1.313 -0.74 0 CA-C-N 115.397 -0.819 . . . . 0.0 111.481 178.168 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 171.62 -148.81 11.31 Favored Glycine 0 CA--C 1.524 0.624 0 N-CA-C 111.025 -0.83 . . . . 0.0 111.025 179.606 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 32.9 m -135.53 144.06 34.95 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.826 0 N-CA-C 109.095 -0.705 . . . . 0.0 109.095 179.906 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 19.5 t . . . . . 0 CA--C 1.537 0.471 0 CA-C-O 117.66 -1.162 . . . . 0.0 110.817 -179.988 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' F' F ' 1' ' ' ASP . . . . . 0.413 ' H2 ' ' CG ' ' I' ' 1' ' ' ASP . 9.4 m-20 . . . . . 0 N--CA 1.489 1.476 0 N-CA-C 109.286 -0.635 . . . . 0.0 109.286 . . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' F' F ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.13 131.05 46.34 Favored 'General case' 0 CA--C 1.536 0.421 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.322 179.804 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' F' F ' 3' ' ' GLU . . . . . . . . . . . . . 39.7 tt0 -169.1 108.56 0.45 Allowed 'General case' 0 N--CA 1.469 0.484 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 -179.632 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 77.6 m-85 -84.24 141.83 30.71 Favored 'General case' 0 N--CA 1.475 0.777 0 N-CA-C 109.625 -0.509 . . . . 0.0 109.625 179.228 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' F' F ' 5' ' ' ARG . . . . . . . . . . . . . 37.1 mtp180 -142.51 143.43 32.53 Favored 'General case' 0 N--CA 1.477 0.898 0 N-CA-C 109.396 -0.594 . . . . 0.0 109.396 179.979 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 74.8 m80 -150.59 117.65 5.94 Favored 'General case' 0 N--CA 1.474 0.744 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 178.626 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' F' F ' 7' ' ' ASP . . . . . . . . . . . . . 9.5 m-20 -68.05 149.11 50.08 Favored 'General case' 0 N--CA 1.463 0.21 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.057 -179.812 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' F' F ' 8' ' ' SER . . . . . . . . . . . . . 3.4 t -168.65 177.7 5.04 Favored 'General case' 0 N--CA 1.474 0.773 0 N-CA-C 109.521 -0.548 . . . . 0.0 109.521 178.153 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 105.13 50.95 0.9 Allowed Glycine 0 N--CA 1.478 1.496 0 N-CA-C 111.858 -0.497 . . . . 0.0 111.858 179.054 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 43.8 p90 -64.07 131.74 48.44 Favored 'General case' 0 CA--C 1.543 0.697 0 N-CA-C 112.0 0.37 . . . . 0.0 112.0 -179.867 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 41.5 mt-10 -82.01 151.56 27.07 Favored 'General case' 0 N--CA 1.479 0.994 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 177.448 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.6 p -156.0 127.88 0.98 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.46 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 177.921 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 52.3 m-70 -133.49 143.63 48.92 Favored 'General case' 0 N--CA 1.481 1.122 0 O-C-N 122.25 -0.281 . . . . 0.0 110.965 -177.856 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 5.9 t60 -165.44 97.73 0.69 Allowed 'General case' 0 N--CA 1.486 1.341 0 CA-C-O 119.604 -0.236 . . . . 0.0 111.386 179.777 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' F' F ' 15' ' ' GLN . . . . . 0.412 HE22 ' H ' ' F' ' 37' ' ' GLY . 50.0 mt-30 -106.75 -172.31 2.06 Favored 'General case' 0 CA--C 1.497 -1.064 0 N-CA-C 108.088 -1.078 . . . . 0.0 108.088 179.177 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -163.26 97.86 0.91 Allowed 'General case' 0 CA--C 1.539 0.551 0 CA-C-N 114.96 -1.018 . . . . 0.0 109.16 178.77 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 6.2 mp -108.46 163.14 13.48 Favored 'General case' 0 N--CA 1.489 1.488 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 -179.914 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 40.5 t -141.89 120.72 9.66 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.227 0 C-N-CA 122.549 0.339 . . . . 0.0 110.648 179.261 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 52.4 m-85 -73.59 155.43 39.11 Favored 'General case' 0 C--N 1.362 1.125 0 N-CA-C 106.765 -1.568 . . . . 0.0 106.765 176.219 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 24.3 t80 -171.48 -55.1 0.02 OUTLIER 'General case' 0 N--CA 1.481 1.084 0 CA-C-O 121.739 0.781 . . . . 0.0 109.75 -179.861 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.83 89.72 0.0 OUTLIER 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 114.49 -1.232 . . . . 0.0 112.693 -179.342 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 36.0 tt0 -56.4 133.4 52.99 Favored 'General case' 0 CA--C 1.54 0.586 0 CA-C-N 114.953 -1.021 . . . . 0.0 111.283 179.79 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 -81.7 162.39 23.01 Favored 'General case' 0 N--CA 1.475 0.793 0 N-CA-C 109.627 -0.508 . . . . 0.0 109.627 179.826 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' F' F ' 24' ' ' VAL . . . . . . . . . . . . . 95.8 t -160.7 -74.96 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.486 1.333 0 N-CA-C 107.095 -1.446 . . . . 0.0 107.095 -179.005 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -38.49 91.01 0.01 OUTLIER Glycine 0 CA--C 1.529 0.91 0 CA-C-N 115.305 -0.862 . . . . 0.0 112.451 -179.779 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 84.9 p -37.58 -100.97 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.067 0 N-CA-C 113.69 0.996 . . . . 0.0 113.69 -177.443 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' F' F ' 27' ' ' ASN . . . . . 0.424 ' ND2' ' OE2' ' A' ' 11' ' ' GLU . 39.9 t30 -60.18 124.91 21.7 Favored 'General case' 0 CA--C 1.542 0.642 0 CA-C-N 119.492 1.042 . . . . 0.0 108.769 -179.954 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 62.8 mttm -105.65 -178.6 3.7 Favored 'General case' 0 N--CA 1.483 1.197 0 N-CA-C 108.893 -0.78 . . . . 0.0 108.893 -179.737 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -65.29 -141.67 0.03 OUTLIER Glycine 0 CA--C 1.532 1.152 0 N-CA-C 110.463 -1.055 . . . . 0.0 110.463 178.008 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.65 117.79 21.8 Favored 'General case' 0 C--N 1.351 0.633 0 C-N-CA 123.351 0.66 . . . . 0.0 109.399 178.468 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 71.6 mt -99.81 148.86 6.15 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.871 0 N-CA-C 106.934 -1.506 . . . . 0.0 106.934 178.021 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 34.6 mt -148.15 124.99 2.78 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.912 0 N-CA-C 108.874 -0.787 . . . . 0.0 108.874 -179.399 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.71 85.5 0.05 OUTLIER Glycine 0 C--N 1.339 0.741 0 CA-C-N 115.967 -0.561 . . . . 0.0 112.793 178.526 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 13.1 tp -103.44 121.43 42.8 Favored 'General case' 0 N--CA 1.483 1.208 0 N-CA-C 106.945 -1.502 . . . . 0.0 106.945 177.43 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 12.5 ttt -156.17 159.01 38.6 Favored 'General case' 0 N--CA 1.474 0.771 0 N-CA-C 109.058 -0.719 . . . . 0.0 109.058 179.639 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 93.3 t -156.76 151.96 8.35 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.437 0 N-CA-C 107.615 -1.254 . . . . 0.0 107.615 -179.663 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' F' F ' 37' ' ' GLY . . . . . 0.412 ' H ' HE22 ' F' ' 15' ' ' GLN . . . 57.73 72.38 0.6 Allowed Glycine 0 C--N 1.312 -0.759 0 CA-C-N 115.491 -0.777 . . . . 0.0 111.508 178.162 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 171.57 -148.92 11.42 Favored Glycine 0 CA--C 1.523 0.578 0 N-CA-C 111.035 -0.826 . . . . 0.0 111.035 179.686 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 32.9 m -135.42 144.04 35.16 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.837 0 N-CA-C 109.054 -0.721 . . . . 0.0 109.054 179.932 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 19.6 t . . . . . 0 CA--C 1.537 0.454 0 CA-C-O 117.658 -1.163 . . . . 0.0 110.853 179.996 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' G' G ' 1' ' ' ASP . . . . . . . . . . . . . 9.6 m-20 . . . . . 0 N--CA 1.49 1.569 0 N-CA-C 109.556 -0.535 . . . . 0.0 109.556 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' G' G ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.66 129.52 40.91 Favored 'General case' 0 N--CA 1.469 0.512 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.445 179.587 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' G' G ' 3' ' ' GLU . . . . . . . . . . . . . 39.5 tt0 -168.99 108.33 0.46 Allowed 'General case' 0 N--CA 1.47 0.557 0 N-CA-C 110.013 -0.365 . . . . 0.0 110.013 179.854 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 78.3 m-85 -84.51 141.17 30.94 Favored 'General case' 0 N--CA 1.473 0.691 0 N-CA-C 109.413 -0.588 . . . . 0.0 109.413 179.174 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' G' G ' 5' ' ' ARG . . . . . . . . . . . . . 37.0 mtp180 -142.79 143.37 32.15 Favored 'General case' 0 N--CA 1.481 1.113 0 N-CA-C 109.422 -0.585 . . . . 0.0 109.422 -179.635 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 74.7 m80 -150.41 118.81 6.43 Favored 'General case' 0 N--CA 1.473 0.711 0 N-CA-C 109.173 -0.677 . . . . 0.0 109.173 178.69 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 9.7 m-20 -70.0 144.41 52.3 Favored 'General case' 0 CA--C 1.538 0.482 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.642 -179.717 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' G' G ' 8' ' ' SER . . . . . . . . . . . . . 2.9 t -164.46 179.74 6.53 Favored 'General case' 0 N--CA 1.471 0.595 0 N-CA-C 109.465 -0.568 . . . . 0.0 109.465 177.998 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.3 50.7 0.97 Allowed Glycine 0 N--CA 1.476 1.327 0 N-CA-C 111.919 -0.472 . . . . 0.0 111.919 179.049 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 46.9 p90 -64.78 131.86 47.96 Favored 'General case' 0 N--CA 1.474 0.753 0 N-CA-C 112.097 0.406 . . . . 0.0 112.097 -179.484 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 44.0 mt-10 -82.08 150.39 27.54 Favored 'General case' 0 N--CA 1.474 0.748 0 N-CA-C 109.141 -0.688 . . . . 0.0 109.141 177.969 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 3.0 p -156.26 127.82 0.94 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.976 0 N-CA-C 108.285 -1.005 . . . . 0.0 108.285 178.168 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 55.9 m-70 -132.89 144.03 49.9 Favored 'General case' 0 N--CA 1.476 0.827 0 CA-C-N 115.392 -0.822 . . . . 0.0 110.718 -177.935 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' G' G ' 14' ' ' HIS . . . . . 0.41 ' O ' ' ND1' ' D' ' 14' ' ' HIS . 6.0 t60 -165.94 98.29 0.64 Allowed 'General case' 0 N--CA 1.483 1.19 0 CA-C-O 119.599 -0.239 . . . . 0.0 110.765 179.129 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' G' G ' 15' ' ' GLN . . . . . 0.453 HE22 ' H ' ' G' ' 37' ' ' GLY . 50.0 mt-30 -107.42 -172.24 2.03 Favored 'General case' 0 CA--C 1.503 -0.85 0 N-CA-C 108.194 -1.039 . . . . 0.0 108.194 179.306 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -163.19 98.27 0.93 Allowed 'General case' 0 N--CA 1.472 0.653 0 CA-C-N 115.05 -0.977 . . . . 0.0 109.281 178.718 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 6.6 mp -108.47 162.18 14.36 Favored 'General case' 0 N--CA 1.486 1.367 0 N-CA-C 108.946 -0.761 . . . . 0.0 108.946 -179.751 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 36.5 t -142.99 120.48 6.38 Favored 'Isoleucine or valine' 0 CA--C 1.551 1.019 0 CA-C-O 121.223 0.535 . . . . 0.0 110.435 178.973 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 47.3 m-85 -72.73 149.83 43.4 Favored 'General case' 0 C--N 1.375 1.71 0 N-CA-C 106.8 -1.555 . . . . 0.0 106.8 176.166 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 20.0 t80 -169.84 -54.23 0.02 OUTLIER 'General case' 0 N--CA 1.484 1.252 0 N-CA-C 110.194 -0.298 . . . . 0.0 110.194 -179.349 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -42.34 91.43 0.0 OUTLIER 'General case' 0 C--N 1.323 -0.571 0 O-C-N 123.942 0.776 . . . . 0.0 112.129 179.69 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 36.9 tt0 -57.83 133.67 55.62 Favored 'General case' 0 CA--C 1.539 0.542 0 CA-C-N 114.795 -1.093 . . . . 0.0 110.741 179.426 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 -81.08 161.51 24.12 Favored 'General case' 0 N--CA 1.474 0.749 0 N-CA-C 109.714 -0.476 . . . . 0.0 109.714 179.992 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' G' G ' 24' ' ' VAL . . . . . . . . . . . . . 94.8 t -159.44 -76.96 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.957 0 N-CA-C 106.839 -1.541 . . . . 0.0 106.839 -179.027 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -35.35 90.18 0.01 OUTLIER Glycine 0 C--O 1.225 -0.46 0 CA-C-N 114.876 -1.056 . . . . 0.0 112.765 179.381 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 94.2 p -37.78 -99.1 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.899 0 C-N-CA 123.626 0.771 . . . . 0.0 112.708 -176.861 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' G' G ' 27' ' ' ASN . . . . . 0.415 ' ND2' ' CG ' ' H' ' 11' ' ' GLU . 40.8 t30 -61.84 126.54 27.72 Favored 'General case' 0 CA--C 1.545 0.773 0 CA-C-N 119.474 1.034 . . . . 0.0 109.161 179.064 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 63.3 mttm -107.03 -179.09 3.83 Favored 'General case' 0 N--CA 1.483 1.184 0 N-CA-C 109.307 -0.627 . . . . 0.0 109.307 -179.76 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.97 -141.27 0.02 OUTLIER Glycine 0 N--CA 1.464 0.523 0 N-CA-C 109.848 -1.301 . . . . 0.0 109.848 178.422 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.96 115.2 17.45 Favored 'General case' 0 C--O 1.218 -0.558 0 C-N-CA 123.213 0.605 . . . . 0.0 109.413 179.572 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 74.5 mt -97.45 150.96 4.39 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.046 0 N-CA-C 106.92 -1.511 . . . . 0.0 106.92 178.1 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 35.8 mt -149.53 126.91 2.53 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.345 0 N-CA-C 108.876 -0.787 . . . . 0.0 108.876 178.405 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.28 85.95 0.04 OUTLIER Glycine 0 C--N 1.341 0.835 0 CA-C-N 115.957 -0.565 . . . . 0.0 112.823 178.559 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 14.4 tp -103.17 123.66 47.12 Favored 'General case' 0 N--CA 1.484 1.264 0 N-CA-C 107.029 -1.471 . . . . 0.0 107.029 177.271 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 11.9 ttt -158.75 158.57 33.88 Favored 'General case' 0 N--CA 1.469 0.494 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 179.973 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 94.5 t -156.47 153.13 7.42 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.289 0 N-CA-C 106.897 -1.519 . . . . 0.0 106.897 -179.663 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' G' G ' 37' ' ' GLY . . . . . 0.453 ' H ' HE22 ' G' ' 15' ' ' GLN . . . 56.89 73.18 0.47 Allowed Glycine 0 C--N 1.311 -0.811 0 CA-C-N 115.761 -0.654 . . . . 0.0 111.978 178.292 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 169.98 -148.05 11.4 Favored Glycine 0 N--CA 1.469 0.846 0 N-CA-C 110.703 -0.959 . . . . 0.0 110.703 179.019 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 33.5 m -135.48 144.03 35.11 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.009 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 -179.803 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 20.2 t . . . . . 0 N--CA 1.468 0.426 0 CA-C-O 117.776 -1.106 . . . . 0.0 110.838 179.914 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' H' H ' 1' ' ' ASP . . . . . . . . . . . . . 9.7 m-20 . . . . . 0 N--CA 1.491 1.603 0 N-CA-C 109.591 -0.522 . . . . 0.0 109.591 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' H' H ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.75 129.5 40.79 Favored 'General case' 0 N--CA 1.469 0.494 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.374 179.641 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' H' H ' 3' ' ' GLU . . . . . . . . . . . . . 39.5 tt0 -168.91 108.28 0.46 Allowed 'General case' 0 N--CA 1.47 0.541 0 N-CA-C 109.981 -0.377 . . . . 0.0 109.981 179.845 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 78.7 m-85 -84.25 141.56 30.89 Favored 'General case' 0 N--CA 1.473 0.714 0 N-CA-C 109.362 -0.607 . . . . 0.0 109.362 179.183 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' H' H ' 5' ' ' ARG . . . . . . . . . . . . . 37.2 mtp180 -142.99 143.28 31.85 Favored 'General case' 0 N--CA 1.482 1.157 0 N-CA-C 109.302 -0.629 . . . . 0.0 109.302 -179.638 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 74.6 m80 -150.43 118.7 6.38 Favored 'General case' 0 N--CA 1.473 0.68 0 N-CA-C 109.252 -0.648 . . . . 0.0 109.252 178.642 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 9.4 m-20 -69.86 144.35 52.55 Favored 'General case' 0 N--CA 1.468 0.44 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.579 -179.693 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' H' H ' 8' ' ' SER . . . . . . . . . . . . . 3.6 t -164.38 179.09 6.99 Favored 'General case' 0 N--CA 1.47 0.538 0 N-CA-C 109.517 -0.549 . . . . 0.0 109.517 178.091 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.56 50.9 0.94 Allowed Glycine 0 N--CA 1.478 1.442 0 N-CA-C 111.948 -0.461 . . . . 0.0 111.948 179.054 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 46.7 p90 -64.79 131.87 48.0 Favored 'General case' 0 N--CA 1.474 0.765 0 N-CA-C 112.015 0.376 . . . . 0.0 112.015 -179.546 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' H' H ' 11' ' ' GLU . . . . . 0.415 ' CG ' ' ND2' ' G' ' 27' ' ' ASN . 44.0 mt-10 -82.05 150.38 27.59 Favored 'General case' 0 N--CA 1.474 0.749 0 N-CA-C 109.186 -0.672 . . . . 0.0 109.186 177.929 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 3.0 p -156.4 127.82 0.92 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.044 0 N-CA-C 108.291 -1.003 . . . . 0.0 108.291 178.108 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 56.0 m-70 -132.74 144.14 50.07 Favored 'General case' 0 N--CA 1.475 0.804 0 CA-C-N 115.22 -0.9 . . . . 0.0 110.731 -177.906 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 6.0 t60 -166.12 97.74 0.62 Allowed 'General case' 0 N--CA 1.482 1.163 0 CA-C-O 119.554 -0.26 . . . . 0.0 110.775 179.105 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' H' H ' 15' ' ' GLN . . . . . 0.447 HE22 ' H ' ' H' ' 37' ' ' GLY . 49.9 mt-30 -106.87 -172.56 2.1 Favored 'General case' 0 CA--C 1.505 -0.768 0 N-CA-C 108.099 -1.074 . . . . 0.0 108.099 179.403 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -163.0 98.24 0.94 Allowed 'General case' 0 N--CA 1.472 0.643 0 CA-C-N 115.268 -0.878 . . . . 0.0 109.218 178.679 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 6.6 mp -108.48 162.24 14.31 Favored 'General case' 0 N--CA 1.485 1.312 0 N-CA-C 108.978 -0.749 . . . . 0.0 108.978 -179.769 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 37.0 t -142.99 120.15 6.08 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.037 0 CA-C-O 121.16 0.505 . . . . 0.0 110.553 178.994 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 48.2 m-85 -72.76 150.41 42.84 Favored 'General case' 0 C--N 1.373 1.629 0 N-CA-C 106.909 -1.515 . . . . 0.0 106.909 176.182 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 21.3 t80 -171.25 -53.95 0.02 OUTLIER 'General case' 0 N--CA 1.481 1.093 0 N-CA-C 110.202 -0.295 . . . . 0.0 110.202 -179.361 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -42.26 91.6 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.463 0 O-C-N 123.872 0.732 . . . . 0.0 111.896 179.613 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 37.0 tt0 -57.81 133.89 55.8 Favored 'General case' 0 CA--C 1.54 0.564 0 CA-C-N 114.777 -1.102 . . . . 0.0 110.694 179.793 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 9.0 m-20 -81.24 161.44 23.96 Favored 'General case' 0 N--CA 1.474 0.768 0 N-CA-C 109.69 -0.485 . . . . 0.0 109.69 -179.986 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' H' H ' 24' ' ' VAL . . . . . . . . . . . . . 95.0 t -159.77 -77.03 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.99 0 N-CA-C 106.983 -1.488 . . . . 0.0 106.983 -179.037 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . -35.43 89.96 0.01 OUTLIER Glycine 0 N--CA 1.47 0.924 0 CA-C-N 115.086 -0.961 . . . . 0.0 112.245 179.547 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 97.5 p -37.47 -98.79 0.0 OUTLIER 'General case' 0 N--CA 1.478 0.954 0 C-N-CA 123.693 0.797 . . . . 0.0 112.739 -176.711 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' H' H ' 27' ' ' ASN . . . . . 0.409 ' ND2' ' CG ' ' I' ' 11' ' ' GLU . 40.1 t30 -61.62 126.69 28.23 Favored 'General case' 0 CA--C 1.543 0.689 0 CA-C-N 119.368 0.985 . . . . 0.0 109.144 179.01 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 63.3 mttm -106.97 -178.9 3.78 Favored 'General case' 0 N--CA 1.484 1.241 0 N-CA-C 109.365 -0.606 . . . . 0.0 109.365 -179.797 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.92 -141.19 0.02 OUTLIER Glycine 0 CA--C 1.522 0.521 0 N-CA-C 109.935 -1.266 . . . . 0.0 109.935 178.207 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -129.0 115.51 17.9 Favored 'General case' 0 C--O 1.217 -0.643 0 C-N-CA 123.263 0.625 . . . . 0.0 109.437 179.499 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 74.6 mt -97.86 150.6 4.65 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.027 0 N-CA-C 106.908 -1.515 . . . . 0.0 106.908 178.13 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 35.4 mt -149.32 126.89 2.62 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.309 0 N-CA-C 108.912 -0.773 . . . . 0.0 108.912 178.579 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.3 85.65 0.05 OUTLIER Glycine 0 C--N 1.34 0.801 0 CA-C-N 115.946 -0.57 . . . . 0.0 112.994 178.586 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 14.5 tp -102.97 123.28 46.29 Favored 'General case' 0 N--CA 1.482 1.158 0 N-CA-C 107.04 -1.466 . . . . 0.0 107.04 177.332 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 11.8 ttt -158.38 158.48 34.34 Favored 'General case' 0 N--CA 1.469 0.516 0 N-CA-C 108.585 -0.895 . . . . 0.0 108.585 -179.958 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 96.9 t -156.51 152.4 8.12 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.357 0 N-CA-C 107.076 -1.453 . . . . 0.0 107.076 -179.782 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' H' H ' 37' ' ' GLY . . . . . 0.447 ' H ' HE22 ' H' ' 15' ' ' GLN . . . 57.46 73.03 0.5 Allowed Glycine 0 C--N 1.313 -0.698 0 CA-C-N 115.644 -0.707 . . . . 0.0 112.028 178.169 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 169.98 -148.17 11.52 Favored Glycine 0 N--CA 1.468 0.792 0 N-CA-C 110.566 -1.014 . . . . 0.0 110.566 179.068 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 33.4 m -135.36 144.01 35.31 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.995 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.706 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 20.3 t . . . . . 0 C--O 1.222 -0.385 0 CA-C-O 117.852 -1.07 . . . . 0.0 110.916 179.99 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' I' I ' 1' ' ' ASP . . . . . 0.413 ' CG ' ' H2 ' ' F' ' 1' ' ' ASP . 9.7 m-20 . . . . . 0 N--CA 1.491 1.603 0 N-CA-C 109.64 -0.504 . . . . 0.0 109.64 . . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' I' I ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.67 129.64 41.42 Favored 'General case' 0 N--CA 1.47 0.544 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.345 179.64 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' I' I ' 3' ' ' GLU . . . . . . . . . . . . . 39.4 tt0 -169.04 108.21 0.45 Allowed 'General case' 0 N--CA 1.47 0.527 0 N-CA-C 109.935 -0.394 . . . . 0.0 109.935 179.811 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 79.0 m-85 -84.27 141.63 30.82 Favored 'General case' 0 N--CA 1.474 0.764 0 N-CA-C 109.323 -0.621 . . . . 0.0 109.323 179.191 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' I' I ' 5' ' ' ARG . . . . . . . . . . . . . 37.1 mtp180 -143.15 143.36 31.78 Favored 'General case' 0 N--CA 1.482 1.17 0 N-CA-C 109.273 -0.64 . . . . 0.0 109.273 -179.687 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 74.6 m80 -150.51 118.55 6.29 Favored 'General case' 0 N--CA 1.474 0.729 0 N-CA-C 109.243 -0.651 . . . . 0.0 109.243 178.691 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 9.5 m-20 -69.72 144.21 52.85 Favored 'General case' 0 CA--C 1.537 0.444 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.681 -179.696 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' I' I ' 8' ' ' SER . . . . . . . . . . . . . 3.6 t -164.23 179.11 7.06 Favored 'General case' 0 N--CA 1.469 0.514 0 N-CA-C 109.492 -0.558 . . . . 0.0 109.492 178.182 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.58 50.9 0.94 Allowed Glycine 0 N--CA 1.477 1.426 0 N-CA-C 111.929 -0.469 . . . . 0.0 111.929 179.047 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 47.1 p90 -64.85 131.91 48.01 Favored 'General case' 0 N--CA 1.474 0.734 0 N-CA-C 112.104 0.409 . . . . 0.0 112.104 -179.573 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' I' I ' 11' ' ' GLU . . . . . 0.409 ' CG ' ' ND2' ' H' ' 27' ' ' ASN . 43.9 mt-10 -82.14 150.39 27.48 Favored 'General case' 0 N--CA 1.473 0.71 0 N-CA-C 109.249 -0.648 . . . . 0.0 109.249 177.934 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 3.1 p -156.38 127.7 0.91 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.971 0 N-CA-C 108.366 -0.976 . . . . 0.0 108.366 178.209 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 55.5 m-70 -132.8 144.13 50.02 Favored 'General case' 0 N--CA 1.475 0.779 0 CA-C-N 115.24 -0.891 . . . . 0.0 110.735 -177.839 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 6.0 t60 -166.21 97.98 0.61 Allowed 'General case' 0 N--CA 1.483 1.181 0 CA-C-N 116.664 -0.244 . . . . 0.0 110.818 179.228 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' I' I ' 15' ' ' GLN . . . . . 0.43 HE22 ' H ' ' I' ' 37' ' ' GLY . 49.8 mt-30 -107.11 -172.21 2.03 Favored 'General case' 0 CA--C 1.501 -0.918 0 N-CA-C 108.12 -1.067 . . . . 0.0 108.12 179.322 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -163.24 98.27 0.92 Allowed 'General case' 0 N--CA 1.47 0.563 0 CA-C-N 115.109 -0.95 . . . . 0.0 109.22 178.704 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 6.6 mp -108.45 162.12 14.41 Favored 'General case' 0 N--CA 1.485 1.323 0 N-CA-C 108.968 -0.753 . . . . 0.0 108.968 -179.751 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 37.7 t -142.9 120.18 6.35 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.048 0 CA-C-O 121.2 0.524 . . . . 0.0 110.483 178.987 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 47.7 m-85 -72.81 150.39 42.78 Favored 'General case' 0 C--N 1.374 1.645 0 N-CA-C 106.759 -1.571 . . . . 0.0 106.759 176.196 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 21.3 t80 -171.17 -54.15 0.02 OUTLIER 'General case' 0 N--CA 1.48 1.048 0 N-CA-C 110.217 -0.29 . . . . 0.0 110.217 -179.304 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -42.25 91.58 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.461 0 CA-C-O 121.632 0.729 . . . . 0.0 111.856 179.656 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 37.0 tt0 -57.75 133.82 55.7 Favored 'General case' 0 CA--C 1.539 0.558 0 CA-C-N 114.769 -1.105 . . . . 0.0 110.773 179.691 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 -81.09 161.38 24.16 Favored 'General case' 0 N--CA 1.473 0.716 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 179.936 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' I' I ' 24' ' ' VAL . . . . . . . . . . . . . 95.1 t -159.75 -77.11 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.04 0 N-CA-C 107.045 -1.465 . . . . 0.0 107.045 -179.095 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . -35.53 90.09 0.01 OUTLIER Glycine 0 C--N 1.34 0.804 0 CA-C-N 115.073 -0.967 . . . . 0.0 112.25 179.611 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 97.5 p -37.4 -98.95 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.875 0 C-N-CA 123.794 0.838 . . . . 0.0 112.82 -176.733 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 40.5 t30 -61.5 126.62 28.02 Favored 'General case' 0 CA--C 1.542 0.645 0 CA-C-N 119.431 1.014 . . . . 0.0 109.148 179.005 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 63.2 mttm -106.96 -178.95 3.79 Favored 'General case' 0 N--CA 1.484 1.275 0 N-CA-C 109.356 -0.609 . . . . 0.0 109.356 -179.791 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.92 -141.27 0.02 OUTLIER Glycine 0 CA--C 1.523 0.58 0 N-CA-C 109.906 -1.278 . . . . 0.0 109.906 178.254 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.86 115.46 17.93 Favored 'General case' 0 C--O 1.218 -0.584 0 C-N-CA 123.247 0.619 . . . . 0.0 109.434 179.537 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 74.6 mt -97.94 150.67 4.64 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.047 0 N-CA-C 106.878 -1.527 . . . . 0.0 106.878 178.186 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 35.7 mt -149.31 126.93 2.65 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.292 0 N-CA-C 108.863 -0.791 . . . . 0.0 108.863 178.646 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.28 85.69 0.05 OUTLIER Glycine 0 C--N 1.339 0.71 0 CA-C-N 115.986 -0.552 . . . . 0.0 112.919 178.571 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 14.6 tp -102.91 123.25 46.19 Favored 'General case' 0 N--CA 1.482 1.151 0 N-CA-C 107.008 -1.479 . . . . 0.0 107.008 177.208 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 11.8 ttt -158.31 158.51 34.51 Favored 'General case' 0 N--CA 1.469 0.489 0 N-CA-C 108.56 -0.904 . . . . 0.0 108.56 179.97 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 96.6 t -156.57 152.39 8.09 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.297 0 N-CA-C 107.007 -1.479 . . . . 0.0 107.007 -179.776 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' I' I ' 37' ' ' GLY . . . . . 0.43 ' H ' HE22 ' I' ' 15' ' ' GLN . . . 57.44 73.2 0.48 Allowed Glycine 0 C--N 1.313 -0.734 0 CA-C-N 115.661 -0.7 . . . . 0.0 111.932 178.141 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 169.9 -148.29 11.66 Favored Glycine 0 N--CA 1.467 0.719 0 N-CA-C 110.651 -0.979 . . . . 0.0 110.651 179.094 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 33.4 m -135.21 144.01 35.49 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.947 0 C-N-CA 122.765 0.426 . . . . 0.0 109.904 -179.83 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 20.3 t . . . . . 0 C--O 1.222 -0.378 0 CA-C-O 117.803 -1.094 . . . . 0.0 110.932 179.996 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 8.8 m-20 . . . . . 0 N--CA 1.49 1.538 0 N-CA-C 108.49 -0.93 . . . . 0.0 108.49 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.82 132.54 49.76 Favored 'General case' 0 CA--C 1.541 0.614 0 CA-C-N 116.452 -0.34 . . . . 0.0 110.085 -179.943 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 54.6 tt0 -169.32 126.8 0.94 Allowed 'General case' 0 N--CA 1.472 0.653 0 N-CA-C 109.707 -0.479 . . . . 0.0 109.707 -179.133 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 29.1 m-85 -117.15 126.97 53.65 Favored 'General case' 0 N--CA 1.476 0.864 0 N-CA-C 108.637 -0.875 . . . . 0.0 108.637 179.578 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' ARG . . . . . 0.512 ' NH1' HH21 ' D' ' 5' ' ' ARG . 6.2 ptm180 -165.06 146.65 7.73 Favored 'General case' 0 N--CA 1.478 0.954 0 N-CA-C 112.349 0.5 . . . . 0.0 112.349 -179.738 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 21.2 p80 -151.89 107.79 3.38 Favored 'General case' 0 N--CA 1.475 0.788 0 CA-C-O 120.884 0.374 . . . . 0.0 110.552 177.93 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -78.13 151.69 33.2 Favored 'General case' 0 N--CA 1.475 0.805 0 CA-C-O 121.03 0.443 . . . . 0.0 109.827 178.961 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 99.8 p -155.2 173.67 16.29 Favored 'General case' 0 N--CA 1.475 0.794 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.595 -179.766 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 125.13 78.99 0.35 Allowed Glycine 0 N--CA 1.481 1.692 0 N-CA-C 111.441 -0.664 . . . . 0.0 111.441 -179.969 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 23.6 p90 -55.14 156.05 4.33 Favored 'General case' 0 N--CA 1.478 0.954 0 C-N-CA 122.528 0.331 . . . . 0.0 110.698 178.982 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 65.7 mt-10 -119.65 127.21 52.7 Favored 'General case' 0 N--CA 1.486 1.366 0 N-CA-C 109.708 -0.479 . . . . 0.0 109.708 179.281 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 40.2 t -101.69 139.83 21.85 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.705 0 N-CA-C 109.194 -0.669 . . . . 0.0 109.194 178.815 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 42.3 m80 -140.42 138.98 35.16 Favored 'General case' 0 N--CA 1.488 1.445 0 CA-C-N 118.762 0.71 . . . . 0.0 109.98 178.494 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 13.0 t60 -167.55 97.31 0.48 Allowed 'General case' 0 N--CA 1.481 1.119 0 CA-C-O 119.745 -0.169 . . . . 0.0 110.632 178.979 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 55.2 mt-30 -100.55 116.48 32.6 Favored 'General case' 0 CA--C 1.512 -0.493 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 -179.484 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 64.4 tttp -104.32 105.95 16.27 Favored 'General case' 0 N--CA 1.48 1.07 0 N-CA-C 108.648 -0.871 . . . . 0.0 108.648 178.148 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 10.0 mp -122.63 165.17 16.92 Favored 'General case' 0 N--CA 1.487 1.412 0 N-CA-C 108.712 -0.847 . . . . 0.0 108.712 -179.55 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 62.1 t -142.57 111.28 2.19 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.09 0 N-CA-C 108.499 -0.926 . . . . 0.0 108.499 177.757 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 59.7 m-85 -101.24 164.92 11.55 Favored 'General case' 0 N--CA 1.475 0.821 0 N-CA-C 109.29 -0.633 . . . . 0.0 109.29 178.244 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.453 ' O ' ' O ' ' D' ' 21' ' ' ALA . 77.7 t80 -165.53 -83.46 0.02 OUTLIER 'General case' 0 C--O 1.209 -1.052 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 177.205 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -88.29 94.08 9.72 Favored 'General case' 0 C--N 1.353 0.726 0 N-CA-C 108.249 -1.019 . . . . 0.0 108.249 177.567 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 11.2 mm-40 -73.85 -170.13 0.84 Allowed 'General case' 0 N--CA 1.482 1.153 0 C-N-CA 120.344 -0.542 . . . . 0.0 110.771 179.812 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . 0.411 ' HB2' ' HZ2' ' A' ' 28' ' ' LYS . 8.2 m-20 -73.17 153.35 40.75 Favored 'General case' 0 N--CA 1.473 0.712 0 CA-C-O 121.886 0.85 . . . . 0.0 112.995 -177.637 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . 0.495 ' CG1' HH12 ' B' ' 5' ' ' ARG . 71.2 t -155.23 94.35 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.466 0.369 0 CA-C-N 114.551 -1.204 . . . . 0.0 108.244 177.005 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -121.56 60.3 0.55 Allowed Glycine 0 N--CA 1.481 1.638 0 N-CA-C 110.995 -0.842 . . . . 0.0 110.995 179.038 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 15.3 m 47.32 -143.34 0.38 Allowed 'General case' 0 N--CA 1.484 1.261 0 CA-C-N 118.164 0.982 . . . . 0.0 110.479 -179.633 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 3.9 m-80 -79.67 92.38 5.37 Favored 'General case' 0 N--CA 1.47 0.527 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 177.636 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.411 ' HZ2' ' HB2' ' A' ' 23' ' ' ASP . 96.4 mttt -65.76 146.21 55.05 Favored 'General case' 0 CA--C 1.539 0.537 0 CA-C-O 121.264 0.554 . . . . 0.0 110.537 -178.559 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -70.17 -129.17 0.06 OUTLIER Glycine 0 CA--C 1.525 0.688 0 N-CA-C 109.445 -1.462 . . . . 0.0 109.445 178.533 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -85.01 131.35 34.48 Favored 'General case' 0 N--CA 1.465 0.3 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 179.69 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 18.3 tt -165.54 173.52 0.17 Allowed 'Isoleucine or valine' 0 C--O 1.215 -0.745 0 N-CA-C 108.815 -0.809 . . . . 0.0 108.815 -177.85 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 24.3 mt -140.27 145.21 26.41 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.487 0 N-CA-C 107.179 -1.415 . . . . 0.0 107.179 -179.288 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -52.0 168.17 0.71 Allowed Glycine 0 N--CA 1.473 1.14 0 C-N-CA 121.268 -0.491 . . . . 0.0 112.147 -179.328 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 2.7 pp -65.99 158.08 29.17 Favored 'General case' 0 N--CA 1.465 0.293 0 N-CA-C 109.671 -0.492 . . . . 0.0 109.671 179.741 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 21.3 ttt -142.57 154.76 44.72 Favored 'General case' 0 N--CA 1.473 0.676 0 N-CA-C 108.965 -0.754 . . . . 0.0 108.965 -179.919 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 41.3 t -149.49 139.33 16.03 Favored 'Isoleucine or valine' 0 C--O 1.235 0.318 0 N-CA-C 107.241 -1.392 . . . . 0.0 107.241 -179.695 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 60.54 67.44 2.14 Favored Glycine 0 C--N 1.318 -0.437 0 N-CA-C 109.006 -1.637 . . . . 0.0 109.006 -179.85 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -82.22 130.08 9.47 Favored Glycine 0 N--CA 1.468 0.788 0 N-CA-C 111.312 -0.715 . . . . 0.0 111.312 -178.818 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 1.9 t -146.71 113.43 1.05 Allowed 'Isoleucine or valine' 0 CA--C 1.561 1.373 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 179.257 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 19.1 t . . . . . 0 N--CA 1.497 1.899 0 CA-C-O 118.475 -0.774 . . . . 0.0 112.477 -177.877 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' B' B ' 1' ' ' ASP . . . . . . . . . . . . . 8.5 m-20 . . . . . 0 N--CA 1.488 1.447 0 N-CA-C 108.799 -0.815 . . . . 0.0 108.799 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' B' B ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.87 132.33 49.14 Favored 'General case' 0 CA--C 1.54 0.582 0 N-CA-C 110.019 -0.363 . . . . 0.0 110.019 -179.906 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 3' ' ' GLU . . . . . . . . . . . . . 54.6 tt0 -169.28 126.62 0.94 Allowed 'General case' 0 CA--C 1.541 0.606 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 -179.056 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 29.0 m-85 -117.03 127.3 54.03 Favored 'General case' 0 N--CA 1.476 0.847 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 179.481 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 5' ' ' ARG . . . . . 0.496 ' NH1' HH21 ' E' ' 5' ' ' ARG . 6.3 ptm180 -165.39 146.59 7.31 Favored 'General case' 0 N--CA 1.474 0.773 0 C-N-CA 120.569 -0.452 . . . . 0.0 112.165 -179.698 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 20.9 p80 -151.79 108.07 3.43 Favored 'General case' 0 N--CA 1.476 0.838 0 CA-C-O 120.831 0.348 . . . . 0.0 110.562 177.867 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 7' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -78.56 151.1 32.64 Favored 'General case' 0 N--CA 1.476 0.834 0 CA-C-O 121.088 0.471 . . . . 0.0 109.889 179.042 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 8' ' ' SER . . . . . . . . . . . . . 99.3 p -154.54 173.72 15.92 Favored 'General case' 0 N--CA 1.473 0.718 0 CA-C-N 115.784 -0.643 . . . . 0.0 110.731 -179.759 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 125.2 78.91 0.34 Allowed Glycine 0 N--CA 1.48 1.621 0 N-CA-C 111.433 -0.667 . . . . 0.0 111.433 -179.972 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 23.9 p90 -55.28 156.05 4.55 Favored 'General case' 0 N--CA 1.478 0.927 0 C-N-CA 122.401 0.28 . . . . 0.0 110.742 179.054 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 65.6 mt-10 -119.55 127.43 52.98 Favored 'General case' 0 N--CA 1.486 1.367 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 179.288 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 40.0 t -102.04 139.66 22.55 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.708 0 N-CA-C 109.194 -0.669 . . . . 0.0 109.194 178.85 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 41.9 m80 -140.41 139.09 35.2 Favored 'General case' 0 N--CA 1.484 1.272 0 CA-C-N 118.689 0.677 . . . . 0.0 110.011 178.729 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 13.2 t60 -167.87 97.37 0.45 Allowed 'General case' 0 N--CA 1.482 1.165 0 N-CA-C 110.507 -0.183 . . . . 0.0 110.507 179.017 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 55.4 mt-30 -100.67 116.86 33.56 Favored 'General case' 0 CA--C 1.511 -0.546 0 N-CA-C 108.604 -0.887 . . . . 0.0 108.604 -179.533 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 64.6 tttp -104.51 105.97 16.29 Favored 'General case' 0 N--CA 1.479 1.014 0 N-CA-C 108.674 -0.861 . . . . 0.0 108.674 178.106 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 10.0 mp -122.83 165.05 17.26 Favored 'General case' 0 N--CA 1.489 1.516 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 -179.51 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 61.6 t -142.45 110.24 2.04 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.117 0 N-CA-C 108.743 -0.836 . . . . 0.0 108.743 177.838 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 61.1 m-85 -100.11 164.32 12.03 Favored 'General case' 0 N--CA 1.474 0.746 0 CA-C-N 118.745 0.702 . . . . 0.0 109.456 178.275 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . 0.433 ' O ' ' O ' ' E' ' 21' ' ' ALA . 76.4 t80 -164.38 -83.59 0.03 OUTLIER 'General case' 0 C--O 1.212 -0.881 0 N-CA-C 109.277 -0.638 . . . . 0.0 109.277 177.238 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -88.73 94.3 9.86 Favored 'General case' 0 C--N 1.35 0.59 0 N-CA-C 108.171 -1.048 . . . . 0.0 108.171 177.599 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 11.4 mm-40 -73.73 -170.24 0.84 Allowed 'General case' 0 N--CA 1.481 1.124 0 C-N-CA 120.487 -0.485 . . . . 0.0 110.791 179.881 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 23' ' ' ASP . . . . . 0.413 ' HB2' ' HZ2' ' B' ' 28' ' ' LYS . 8.2 m-20 -73.24 153.45 40.63 Favored 'General case' 0 N--CA 1.473 0.709 0 CA-C-O 121.943 0.878 . . . . 0.0 112.971 -177.598 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . 0.498 ' CG1' HH12 ' C' ' 5' ' ' ARG . 65.5 t -155.22 94.3 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.391 0 CA-C-N 114.586 -1.188 . . . . 0.0 108.166 177.013 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -121.35 60.16 0.55 Allowed Glycine 0 N--CA 1.479 1.547 0 N-CA-C 111.138 -0.785 . . . . 0.0 111.138 178.874 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 15.3 m 47.4 -143.72 0.36 Allowed 'General case' 0 N--CA 1.485 1.281 0 CA-C-N 118.209 1.005 . . . . 0.0 110.317 -179.574 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 4.1 m-80 -79.43 92.45 5.23 Favored 'General case' 0 N--CA 1.469 0.497 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 177.661 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 28' ' ' LYS . . . . . 0.413 ' HZ2' ' HB2' ' B' ' 23' ' ' ASP . 96.4 mttt -65.87 146.47 54.71 Favored 'General case' 0 CA--C 1.54 0.569 0 CA-C-O 121.333 0.587 . . . . 0.0 110.42 -178.472 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -70.33 -129.11 0.06 OUTLIER Glycine 0 CA--C 1.526 0.745 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 178.523 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -85.0 131.32 34.48 Favored 'General case' 0 C--O 1.235 0.291 0 N-CA-C 109.413 -0.588 . . . . 0.0 109.413 179.628 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 18.3 tt -165.61 173.44 0.17 Allowed 'Isoleucine or valine' 0 C--O 1.215 -0.751 0 N-CA-C 108.753 -0.832 . . . . 0.0 108.753 -177.8 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 24.6 mt -140.25 145.14 26.53 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.475 0 N-CA-C 107.194 -1.41 . . . . 0.0 107.194 -179.24 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -51.94 168.25 0.68 Allowed Glycine 0 N--CA 1.472 1.078 0 C-N-CA 121.202 -0.523 . . . . 0.0 112.195 -179.372 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 2.7 pp -66.13 157.76 30.39 Favored 'General case' 0 N--CA 1.465 0.28 0 N-CA-C 109.646 -0.501 . . . . 0.0 109.646 179.79 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 21.3 ttt -142.25 154.93 45.16 Favored 'General case' 0 N--CA 1.473 0.677 0 N-CA-C 109.02 -0.733 . . . . 0.0 109.02 -179.975 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 41.0 t -149.46 139.51 16.21 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.313 0 N-CA-C 107.267 -1.382 . . . . 0.0 107.267 -179.638 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 60.1 67.41 2.17 Favored Glycine 0 C--N 1.318 -0.445 0 N-CA-C 109.152 -1.579 . . . . 0.0 109.152 -179.803 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . -82.16 129.98 9.41 Favored Glycine 0 CA--C 1.526 0.769 0 N-CA-C 111.284 -0.726 . . . . 0.0 111.284 -178.892 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 1.9 t -146.68 113.46 1.06 Allowed 'Isoleucine or valine' 0 CA--C 1.561 1.371 0 N-CA-C 108.459 -0.941 . . . . 0.0 108.459 179.192 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 19.8 t . . . . . 0 N--CA 1.498 1.937 0 CA-C-O 118.409 -0.805 . . . . 0.0 112.195 -177.997 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' C' C ' 1' ' ' ASP . . . . . . . . . . . . . 8.6 m-20 . . . . . 0 N--CA 1.488 1.436 0 N-CA-C 108.833 -0.802 . . . . 0.0 108.833 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' C' C ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.68 132.29 49.26 Favored 'General case' 0 CA--C 1.54 0.577 0 N-CA-C 110.109 -0.33 . . . . 0.0 110.109 -179.987 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' C' C ' 3' ' ' GLU . . . . . . . . . . . . . 54.5 tt0 -169.2 126.49 0.95 Allowed 'General case' 0 CA--C 1.541 0.596 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 -179.059 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 28.6 m-85 -116.88 126.99 53.83 Favored 'General case' 0 N--CA 1.477 0.92 0 N-CA-C 108.653 -0.869 . . . . 0.0 108.653 179.432 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' C' C ' 5' ' ' ARG . . . . . 0.505 ' NH1' HH21 ' F' ' 5' ' ' ARG . 6.3 ptm180 -164.98 146.54 7.79 Favored 'General case' 0 N--CA 1.476 0.86 0 N-CA-C 112.231 0.456 . . . . 0.0 112.231 -179.706 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 21.2 p80 -151.78 107.92 3.42 Favored 'General case' 0 N--CA 1.476 0.868 0 CA-C-O 120.804 0.335 . . . . 0.0 110.554 177.883 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' C' C ' 7' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -78.51 150.91 32.81 Favored 'General case' 0 N--CA 1.476 0.862 0 CA-C-O 121.061 0.457 . . . . 0.0 109.861 179.038 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' C' C ' 8' ' ' SER . . . . . . . . . . . . . 99.3 p -154.38 173.86 15.64 Favored 'General case' 0 N--CA 1.475 0.796 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.711 -179.856 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 125.07 78.96 0.35 Allowed Glycine 0 N--CA 1.48 1.627 0 N-CA-C 111.447 -0.661 . . . . 0.0 111.447 179.984 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 24.3 p90 -55.24 156.01 4.53 Favored 'General case' 0 N--CA 1.478 0.925 0 C-N-CA 122.501 0.32 . . . . 0.0 110.757 178.959 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 65.5 mt-10 -119.49 127.33 52.94 Favored 'General case' 0 N--CA 1.485 1.325 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 179.326 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 39.9 t -101.87 139.59 22.61 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.717 0 N-CA-C 109.266 -0.642 . . . . 0.0 109.266 178.76 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 42.0 m80 -140.41 138.92 35.12 Favored 'General case' 0 N--CA 1.486 1.366 0 CA-C-N 118.635 0.652 . . . . 0.0 110.009 178.662 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 13.2 t60 -167.67 97.46 0.47 Allowed 'General case' 0 N--CA 1.481 1.109 0 N-CA-C 110.542 -0.17 . . . . 0.0 110.542 178.939 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 55.5 mt-30 -100.58 116.71 33.14 Favored 'General case' 0 CA--C 1.513 -0.474 0 N-CA-C 108.608 -0.886 . . . . 0.0 108.608 -179.491 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 64.6 tttp -104.39 106.07 16.43 Favored 'General case' 0 N--CA 1.481 1.111 0 N-CA-C 108.632 -0.877 . . . . 0.0 108.632 178.062 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 10.0 mp -122.91 164.88 17.63 Favored 'General case' 0 N--CA 1.488 1.452 0 N-CA-C 108.599 -0.889 . . . . 0.0 108.599 -179.567 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 60.8 t -142.21 110.31 2.19 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 N-CA-C 108.587 -0.894 . . . . 0.0 108.587 177.836 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 61.4 m-85 -100.09 164.3 12.04 Favored 'General case' 0 N--CA 1.476 0.839 0 CA-C-N 118.734 0.697 . . . . 0.0 109.426 178.202 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' C' C ' 20' ' ' PHE . . . . . 0.44 ' O ' ' O ' ' F' ' 21' ' ' ALA . 76.1 t80 -164.23 -83.66 0.03 OUTLIER 'General case' 0 C--O 1.211 -0.955 0 N-CA-C 109.441 -0.577 . . . . 0.0 109.441 177.132 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -88.61 94.27 9.83 Favored 'General case' 0 C--N 1.349 0.554 0 N-CA-C 108.124 -1.065 . . . . 0.0 108.124 177.633 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 11.3 mm-40 -73.81 -170.14 0.84 Allowed 'General case' 0 N--CA 1.48 1.074 0 C-N-CA 120.393 -0.523 . . . . 0.0 110.816 179.928 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' C' C ' 23' ' ' ASP . . . . . 0.413 ' HB2' ' HZ2' ' C' ' 28' ' ' LYS . 8.2 m-20 -73.2 153.41 40.69 Favored 'General case' 0 N--CA 1.474 0.76 0 CA-C-O 122.04 0.924 . . . . 0.0 112.864 -177.613 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' C' C ' 24' ' ' VAL . . . . . 0.497 ' CG1' HH12 ' A' ' 5' ' ' ARG . 65.5 t -155.31 94.43 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.39 0 CA-C-N 114.418 -1.264 . . . . 0.0 108.147 176.958 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -121.57 60.41 0.55 Allowed Glycine 0 N--CA 1.48 1.598 0 N-CA-C 110.984 -0.846 . . . . 0.0 110.984 178.96 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 15.4 m 47.23 -143.79 0.35 Allowed 'General case' 0 N--CA 1.484 1.265 0 CA-C-N 118.21 1.005 . . . . 0.0 110.456 -179.554 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 4.1 m-80 -79.33 92.44 5.17 Favored 'General case' 0 N--CA 1.469 0.512 0 N-CA-C 108.71 -0.848 . . . . 0.0 108.71 177.613 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' C' C ' 28' ' ' LYS . . . . . 0.413 ' HZ2' ' HB2' ' C' ' 23' ' ' ASP . 96.4 mttt -65.87 146.2 55.03 Favored 'General case' 0 CA--C 1.541 0.603 0 CA-C-O 121.292 0.567 . . . . 0.0 110.502 -178.458 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -70.13 -129.0 0.06 OUTLIER Glycine 0 C--N 1.339 0.708 0 N-CA-C 109.591 -1.404 . . . . 0.0 109.591 178.483 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -85.01 131.25 34.49 Favored 'General case' 0 C--O 1.234 0.277 0 N-CA-C 109.423 -0.584 . . . . 0.0 109.423 179.65 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 18.3 tt -165.5 173.53 0.17 Allowed 'Isoleucine or valine' 0 C--O 1.215 -0.749 0 N-CA-C 108.832 -0.803 . . . . 0.0 108.832 -177.954 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 24.4 mt -140.25 145.22 26.43 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.466 0 N-CA-C 107.123 -1.436 . . . . 0.0 107.123 -179.22 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -52.01 168.19 0.71 Allowed Glycine 0 N--CA 1.473 1.113 0 C-N-CA 121.253 -0.499 . . . . 0.0 112.213 -179.442 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 2.7 pp -66.0 157.85 29.8 Favored 'General case' 0 N--CA 1.464 0.274 0 N-CA-C 109.679 -0.489 . . . . 0.0 109.679 179.736 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 21.4 ttt -142.28 154.79 45.01 Favored 'General case' 0 N--CA 1.473 0.68 0 N-CA-C 108.966 -0.753 . . . . 0.0 108.966 -179.939 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 41.1 t -149.4 139.65 16.37 Favored 'Isoleucine or valine' 0 C--O 1.234 0.288 0 N-CA-C 107.165 -1.42 . . . . 0.0 107.165 -179.71 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 60.01 67.3 2.22 Favored Glycine 0 C--N 1.32 -0.331 0 N-CA-C 109.173 -1.571 . . . . 0.0 109.173 -179.868 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . -81.97 130.04 9.45 Favored Glycine 0 CA--C 1.526 0.754 0 N-CA-C 111.264 -0.735 . . . . 0.0 111.264 -178.91 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 1.9 t -146.67 113.48 1.06 Allowed 'Isoleucine or valine' 0 CA--C 1.558 1.284 0 N-CA-C 108.47 -0.937 . . . . 0.0 108.47 179.131 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 19.9 t . . . . . 0 N--CA 1.495 1.789 0 CA-C-O 118.467 -0.778 . . . . 0.0 112.399 -177.894 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' D' D ' 1' ' ' ASP . . . . . . . . . . . . . 8.6 m-20 . . . . . 0 N--CA 1.482 1.152 0 N-CA-C 109.707 -0.479 . . . . 0.0 109.707 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' D' D ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.13 131.36 47.26 Favored 'General case' 0 N--CA 1.472 0.625 0 CA-C-N 116.503 -0.317 . . . . 0.0 110.438 179.57 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' D' D ' 3' ' ' GLU . . . . . . . . . . . . . 53.6 tt0 -169.53 121.13 0.71 Allowed 'General case' 0 C--O 1.245 0.843 0 CA-C-O 119.124 -0.465 . . . . 0.0 111.062 -176.737 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' D' D ' 4' ' ' PHE . . . . . 0.41 ' N ' ' CD1' ' D' ' 4' ' ' PHE 0.289 35.2 m-85 -116.63 131.53 56.93 Favored 'General case' 0 C--N 1.379 1.88 0 N-CA-C 106.381 -1.711 . . . . 0.0 106.381 177.108 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' D' D ' 5' ' ' ARG . . . . . 0.519 HH12 ' CG1' ' F' ' 24' ' ' VAL . 6.0 ptm180 -154.59 150.01 27.26 Favored 'General case' 0 C--O 1.247 0.924 0 CA-C-O 116.565 -1.683 . . . . 0.0 113.175 176.423 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 15.4 p80 -150.75 117.98 5.99 Favored 'General case' 0 N--CA 1.481 1.102 0 CA-C-N 119.992 1.269 . . . . 0.0 107.882 163.217 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' D' D ' 7' ' ' ASP . . . . . . . . . . . . 0.367 0.7 OUTLIER -66.25 141.64 57.97 Favored 'General case' 0 C--N 1.324 -0.522 0 C-N-CA 128.565 2.746 . . . . 0.0 115.839 168.32 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' D' D ' 8' ' ' SER . . . . . . . . . . . . . 97.9 p -151.16 175.45 12.14 Favored 'General case' 0 N--CA 1.488 1.437 0 CA-C-N 119.452 1.024 . . . . 0.0 111.471 175.404 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.37 77.12 0.4 Allowed Glycine 0 N--CA 1.48 1.567 0 CA-C-N 116.056 -0.52 . . . . 0.0 112.762 179.594 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 25.9 p90 -50.98 152.25 2.26 Favored 'General case' 0 N--CA 1.48 1.053 0 C-N-CA 123.662 0.785 . . . . 0.0 111.967 177.768 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 64.9 mt-10 -117.39 131.13 56.83 Favored 'General case' 0 N--CA 1.49 1.568 0 C-N-CA 118.94 -1.104 . . . . 0.0 108.524 175.992 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 21.3 t -95.22 140.26 17.22 Favored 'Isoleucine or valine' 0 C--O 1.245 0.856 0 CA-C-O 117.678 -1.153 . . . . 0.0 111.083 173.673 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 39.6 m80 -138.64 140.62 38.95 Favored 'General case' 0 N--CA 1.483 1.185 0 CA-C-N 119.543 1.065 . . . . 0.0 110.236 172.544 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 14.0 t60 -165.5 104.47 0.73 Allowed 'General case' 0 N--CA 1.48 1.066 0 N-CA-C 108.922 -0.77 . . . . 0.0 108.922 173.611 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 55.8 mt-30 -104.19 114.95 29.55 Favored 'General case' 0 C--N 1.311 -1.067 0 N-CA-C 108.698 -0.853 . . . . 0.0 108.698 179.15 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 64.6 tttp -102.49 112.89 25.82 Favored 'General case' 0 C--N 1.358 0.964 0 N-CA-C 107.677 -1.231 . . . . 0.0 107.677 177.073 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 9.3 mp -126.69 162.26 26.2 Favored 'General case' 0 N--CA 1.488 1.439 0 N-CA-C 108.409 -0.96 . . . . 0.0 108.409 179.499 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . 0.365 89.7 t -140.62 119.65 11.34 Favored 'Isoleucine or valine' 0 C--N 1.372 1.563 0 N-CA-C 105.636 -1.987 . . . . 0.0 105.636 168.099 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' D' D ' 19' ' ' PHE . . . . . . . . . . . . 0.69 57.8 m-85 -67.33 150.34 49.12 Favored 'General case' 0 N--CA 1.423 -1.794 1 C-N-CA 135.005 5.322 . . . . 0.0 121.46 159.418 . . . . . . . . 3 2 . 1 . 019 nuclear orig full ' D' D ' 20' ' ' PHE . . . . . 0.403 ' O ' ' O ' ' G' ' 21' ' ' ALA 0.315 82.4 t80 -169.25 -67.79 0.02 OUTLIER 'General case' 0 N--CA 1.477 0.922 0 CA-C-O 114.713 -2.565 . . . . 0.0 113.794 152.691 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' D' D ' 21' ' ' ALA . . . . . 0.453 ' O ' ' O ' ' A' ' 20' ' ' PHE 0.354 . . -68.91 91.56 0.47 Allowed 'General case' 0 C--O 1.259 1.597 0 CA-C-O 113.016 -3.373 . . . . 0.0 113.057 160.959 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 11.8 mm-40 -76.88 -169.13 1.2 Allowed 'General case' 0 C--N 1.282 -2.34 1 CA-C-N 126.396 4.18 . . . . 0.0 111.316 177.061 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 9.7 m-20 -75.92 154.87 35.64 Favored 'General case' 0 C--O 1.241 0.625 0 CA-C-O 121.708 0.766 . . . . 0.0 111.233 -176.399 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' D' D ' 24' ' ' VAL . . . . . 0.485 ' CG1' HH12 ' E' ' 5' ' ' ARG 0.294 42.7 t -154.72 103.71 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.663 0 N-CA-C 104.002 -2.592 . . . . 0.0 104.002 170.27 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . -118.43 63.33 0.42 Allowed Glycine 0 C--N 1.361 1.929 0 CA-C-O 117.303 -1.831 . . . . 0.0 111.876 170.345 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 14.7 m 54.72 -143.15 0.76 Allowed 'General case' 0 N--CA 1.481 1.093 0 CA-C-N 121.411 2.606 . . . . 0.0 110.396 175.727 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 3.5 m-80 -82.36 92.49 7.0 Favored 'General case' 0 N--CA 1.471 0.624 0 C-N-CA 123.78 0.832 . . . . 0.0 109.012 173.051 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 94.5 mttt -71.64 149.54 45.47 Favored 'General case' 0 CA--C 1.548 0.879 0 CA-C-O 122.601 1.191 . . . . 0.0 108.66 -175.815 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -70.01 -132.7 0.08 OUTLIER Glycine 0 N--CA 1.466 0.658 0 N-CA-C 107.804 -2.118 . . . . 0.0 107.804 179.481 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -89.42 132.89 34.78 Favored 'General case' 0 C--N 1.353 0.749 0 N-CA-C 106.923 -1.51 . . . . 0.0 106.923 -176.754 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' D' D ' 31' ' ' ILE . . . . . 0.409 ' N ' ' O ' ' E' ' 40' ' ' VAL . 18.9 tt -165.32 173.05 0.18 Allowed 'Isoleucine or valine' 0 C--O 1.218 -0.567 0 CA-C-N 113.21 -1.814 . . . . 0.0 109.085 -175.245 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 26.9 mt -141.65 145.49 24.37 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.623 0 N-CA-C 107.095 -1.446 . . . . 0.0 107.095 -179.659 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -52.33 169.15 0.66 Allowed Glycine 0 N--CA 1.473 1.115 0 C-N-CA 121.312 -0.471 . . . . 0.0 112.111 -178.581 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 2.5 pp -68.33 158.58 33.17 Favored 'General case' 0 N--CA 1.464 0.273 0 N-CA-C 109.34 -0.615 . . . . 0.0 109.34 -178.813 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 22.7 ttt -140.41 161.03 38.67 Favored 'General case' 0 N--CA 1.474 0.769 0 N-CA-C 107.98 -1.119 . . . . 0.0 107.98 179.168 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' D' D ' 36' ' ' VAL . . . . . . . . . . . . 0.284 62.0 t -155.71 147.05 12.5 Favored 'Isoleucine or valine' 0 C--N 1.349 0.573 0 N-CA-C 104.971 -2.233 . . . . 0.0 104.971 174.25 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 61.55 66.46 2.63 Favored Glycine 0 CA--C 1.535 1.326 0 N-CA-C 106.468 -2.653 . . . . 0.0 106.468 179.549 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . -80.74 129.9 9.37 Favored Glycine 0 C--N 1.313 -0.723 0 CA-C-N 118.683 1.242 . . . . 0.0 111.987 -179.077 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 2.4 t -148.74 122.74 1.8 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.789 0 N-CA-C 105.114 -2.18 . . . . 0.0 105.114 173.546 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 12.7 t . . . . . 0 N--CA 1.485 1.315 0 CA-C-O 116.567 -1.682 . . . . 0.0 113.769 179.317 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' E' E ' 1' ' ' ASP . . . . . . . . . . . . . 8.9 m-20 . . . . . 0 N--CA 1.485 1.323 0 N-CA-C 109.579 -0.526 . . . . 0.0 109.579 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' E' E ' 2' ' ' ALA . . . . . . . . . . . . . . . -63.66 131.17 47.12 Favored 'General case' 0 N--CA 1.469 0.515 0 N-CA-C 110.119 -0.326 . . . . 0.0 110.119 179.681 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' E' E ' 3' ' ' GLU . . . . . . . . . . . . . 54.0 tt0 -169.38 127.31 0.96 Allowed 'General case' 0 N--CA 1.47 0.562 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 -179.457 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 27.3 m-85 -118.24 127.74 54.02 Favored 'General case' 0 N--CA 1.478 0.926 0 N-CA-C 108.379 -0.971 . . . . 0.0 108.379 179.367 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' E' E ' 5' ' ' ARG . . . . . 0.508 ' NH1' HH21 ' H' ' 5' ' ' ARG . 6.3 ptm180 -165.06 147.37 8.02 Favored 'General case' 0 C--O 1.217 -0.637 0 C-N-CA 120.365 -0.534 . . . . 0.0 112.166 -179.973 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 20.6 p80 -152.17 106.84 3.21 Favored 'General case' 0 N--CA 1.477 0.899 0 CA-C-O 120.839 0.352 . . . . 0.0 110.58 178.047 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' E' E ' 7' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -77.98 152.35 33.17 Favored 'General case' 0 N--CA 1.474 0.744 0 CA-C-O 121.556 0.693 . . . . 0.0 110.091 178.939 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' E' E ' 8' ' ' SER . . . . . . . . . . . . . 92.8 p -156.34 172.9 17.69 Favored 'General case' 0 N--CA 1.487 1.4 0 CA-C-N 115.07 -0.968 . . . . 0.0 111.377 -178.815 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 125.7 79.56 0.35 Allowed Glycine 0 N--CA 1.481 1.669 0 N-CA-C 111.441 -0.664 . . . . 0.0 111.441 179.543 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 18.4 p90 -53.48 157.65 2.03 Favored 'General case' 0 N--CA 1.479 0.986 0 C-N-CA 122.393 0.277 . . . . 0.0 111.125 179.298 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 65.6 mt-10 -120.11 126.96 52.03 Favored 'General case' 0 N--CA 1.49 1.551 0 N-CA-C 109.229 -0.656 . . . . 0.0 109.229 178.429 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 39.6 t -103.52 136.95 33.99 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.685 0 N-CA-C 109.014 -0.736 . . . . 0.0 109.014 178.255 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 35.9 m80 -138.64 138.63 38.0 Favored 'General case' 0 N--CA 1.481 1.102 0 C-N-CA 122.326 0.25 . . . . 0.0 110.585 179.748 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 13.2 t60 -167.96 97.45 0.45 Allowed 'General case' 0 N--CA 1.484 1.258 0 C-N-CA 122.239 0.215 . . . . 0.0 110.593 179.303 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 55.1 mt-30 -100.57 117.12 34.06 Favored 'General case' 0 CA--C 1.512 -0.509 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 -179.681 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 64.6 tttp -104.63 105.63 15.8 Favored 'General case' 0 N--CA 1.48 1.042 0 N-CA-C 108.657 -0.868 . . . . 0.0 108.657 178.225 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 9.9 mp -122.06 164.06 18.35 Favored 'General case' 0 N--CA 1.487 1.408 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 -179.239 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 54.8 t -142.58 113.22 2.75 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.848 0 N-CA-C 108.097 -1.075 . . . . 0.0 108.097 177.167 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 60.3 m-85 -102.86 163.46 12.2 Favored 'General case' 0 C--N 1.362 1.121 0 O-C-N 124.005 0.816 . . . . 0.0 109.459 178.12 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' E' E ' 20' ' ' PHE . . . . . 0.431 ' O ' ' O ' ' H' ' 21' ' ' ALA . 69.1 t80 -166.59 -84.41 0.02 OUTLIER 'General case' 0 C--O 1.215 -0.74 0 CA-C-N 115.907 -0.588 . . . . 0.0 109.726 177.335 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' E' E ' 21' ' ' ALA . . . . . 0.433 ' O ' ' O ' ' B' ' 20' ' ' PHE . . . -85.39 91.3 8.16 Favored 'General case' 0 N--CA 1.474 0.763 0 N-CA-C 108.28 -1.007 . . . . 0.0 108.28 178.498 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 11.2 mm-40 -70.89 -172.84 0.71 Allowed 'General case' 0 N--CA 1.481 1.086 0 C-N-CA 119.67 -0.812 . . . . 0.0 111.061 -179.932 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' E' E ' 23' ' ' ASP . . . . . 0.411 ' HB2' ' HZ2' ' E' ' 28' ' ' LYS . 8.5 m-20 -71.34 154.07 41.87 Favored 'General case' 0 N--CA 1.472 0.665 0 CA-C-O 121.749 0.785 . . . . 0.0 112.623 -177.405 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' E' E ' 24' ' ' VAL . . . . . 0.525 ' CG1' HH12 ' F' ' 5' ' ' ARG . 53.0 t -155.37 92.15 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.762 0 CA-C-N 114.733 -1.122 . . . . 0.0 108.072 177.274 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . -119.45 61.13 0.49 Allowed Glycine 0 N--CA 1.478 1.439 0 N-CA-C 110.87 -0.892 . . . . 0.0 110.87 178.798 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 15.8 m 45.95 -143.2 0.28 Allowed 'General case' 0 N--CA 1.485 1.294 0 CA-C-N 118.299 1.049 . . . . 0.0 110.701 -179.8 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 3.6 m-80 -79.9 92.44 5.52 Favored 'General case' 0 N--CA 1.472 0.631 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 177.474 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' E' E ' 28' ' ' LYS . . . . . 0.411 ' HZ2' ' HB2' ' E' ' 23' ' ' ASP . 96.4 mttt -65.97 146.53 54.6 Favored 'General case' 0 CA--C 1.543 0.675 0 CA-C-O 121.193 0.52 . . . . 0.0 110.635 -178.565 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -71.29 -129.27 0.08 OUTLIER Glycine 0 CA--C 1.538 1.486 0 N-CA-C 109.912 -1.275 . . . . 0.0 109.912 178.492 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -82.22 131.28 35.23 Favored 'General case' 0 N--CA 1.439 -1.005 0 CA-C-N 117.637 0.719 . . . . 0.0 109.391 178.743 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 18.4 tt -165.28 173.31 0.18 Allowed 'Isoleucine or valine' 0 C--O 1.219 -0.532 0 N-CA-C 108.587 -0.894 . . . . 0.0 108.587 -178.737 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 25.5 mt -141.31 145.6 24.62 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.438 0 N-CA-C 107.106 -1.442 . . . . 0.0 107.106 179.674 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -51.63 167.93 0.64 Allowed Glycine 0 N--CA 1.474 1.209 0 C-N-CA 121.383 -0.437 . . . . 0.0 112.662 -179.333 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 2.7 pp -65.71 157.28 30.56 Favored 'General case' 0 N--CA 1.466 0.362 0 N-CA-C 109.97 -0.381 . . . . 0.0 109.97 179.746 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 23.0 ttt -142.37 154.24 44.47 Favored 'General case' 0 N--CA 1.478 0.949 0 N-CA-C 108.996 -0.742 . . . . 0.0 108.996 -179.956 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 40.3 t -149.41 138.54 15.42 Favored 'Isoleucine or valine' 0 C--O 1.238 0.458 0 N-CA-C 107.543 -1.28 . . . . 0.0 107.543 -179.57 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 60.94 67.96 1.89 Allowed Glycine 0 C--N 1.32 -0.336 0 N-CA-C 108.724 -1.751 . . . . 0.0 108.724 -179.882 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . -82.86 131.02 10.07 Favored Glycine 0 C--N 1.334 0.467 0 N-CA-C 111.286 -0.726 . . . . 0.0 111.286 -178.434 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 1.9 t -147.49 113.52 0.92 Allowed 'Isoleucine or valine' 0 N--CA 1.5 2.045 0 N-CA-C 108.447 -0.946 . . . . 0.0 108.447 179.389 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' E' E ' 40' ' ' VAL . . . . . 0.409 ' O ' ' N ' ' D' ' 31' ' ' ILE . 19.3 t . . . . . 0 N--CA 1.495 1.8 0 CA-C-O 118.074 -0.965 . . . . 0.0 112.127 -177.664 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' F' F ' 1' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 . . . . . 0 N--CA 1.486 1.335 0 N-CA-C 109.434 -0.58 . . . . 0.0 109.434 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' F' F ' 2' ' ' ALA . . . . . . . . . . . . . . . -63.64 131.24 47.37 Favored 'General case' 0 N--CA 1.469 0.512 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.152 179.749 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' F' F ' 3' ' ' GLU . . . . . . . . . . . . . 53.8 tt0 -169.42 127.04 0.94 Allowed 'General case' 0 N--CA 1.469 0.52 0 N-CA-C 109.911 -0.403 . . . . 0.0 109.911 -179.474 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 27.0 m-85 -117.88 127.43 53.85 Favored 'General case' 0 N--CA 1.476 0.873 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 179.361 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' F' F ' 5' ' ' ARG . . . . . 0.525 HH12 ' CG1' ' E' ' 24' ' ' VAL . 6.3 ptm180 -164.45 146.94 8.81 Favored 'General case' 0 N--CA 1.473 0.701 0 C-N-CA 120.291 -0.564 . . . . 0.0 112.063 -179.894 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 20.9 p80 -152.0 106.56 3.21 Favored 'General case' 0 N--CA 1.477 0.883 0 CA-C-O 120.793 0.33 . . . . 0.0 110.605 178.039 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' F' F ' 7' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -77.98 152.43 33.12 Favored 'General case' 0 N--CA 1.474 0.748 0 CA-C-O 121.573 0.701 . . . . 0.0 110.004 179.047 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' F' F ' 8' ' ' SER . . . . . . . . . . . . . 93.5 p -156.24 173.76 16.39 Favored 'General case' 0 N--CA 1.487 1.376 0 CA-C-N 114.933 -1.031 . . . . 0.0 111.488 -178.88 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 124.59 79.49 0.39 Allowed Glycine 0 N--CA 1.481 1.66 0 N-CA-C 111.424 -0.67 . . . . 0.0 111.424 179.669 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 18.3 p90 -53.89 158.11 2.16 Favored 'General case' 0 N--CA 1.479 0.996 0 C-N-CA 122.418 0.287 . . . . 0.0 111.136 179.252 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 65.3 mt-10 -120.23 126.97 51.95 Favored 'General case' 0 N--CA 1.489 1.483 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 178.506 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 39.3 t -103.44 136.87 34.24 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.687 0 N-CA-C 109.022 -0.733 . . . . 0.0 109.022 178.188 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 35.8 m80 -138.52 138.52 38.11 Favored 'General case' 0 N--CA 1.481 1.075 0 C-N-CA 122.417 0.287 . . . . 0.0 110.591 179.757 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 13.1 t60 -167.89 97.31 0.45 Allowed 'General case' 0 N--CA 1.483 1.191 0 C-N-CA 122.249 0.219 . . . . 0.0 110.626 179.198 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 55.3 mt-30 -100.29 117.24 34.09 Favored 'General case' 0 CA--C 1.513 -0.448 0 N-CA-C 108.399 -0.963 . . . . 0.0 108.399 -179.56 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 64.7 tttp -104.76 105.7 15.88 Favored 'General case' 0 N--CA 1.481 1.121 0 N-CA-C 108.558 -0.905 . . . . 0.0 108.558 178.104 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 9.9 mp -122.06 164.05 18.36 Favored 'General case' 0 N--CA 1.488 1.436 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 -179.398 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 55.2 t -142.39 112.75 2.76 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.911 0 N-CA-C 108.008 -1.108 . . . . 0.0 108.008 177.102 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 60.7 m-85 -102.09 163.68 12.11 Favored 'General case' 0 C--N 1.359 1.007 0 O-C-N 124.028 0.83 . . . . 0.0 109.107 177.779 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' F' F ' 20' ' ' PHE . . . . . 0.409 ' O ' ' O ' ' I' ' 21' ' ' ALA . 72.8 t80 -166.54 -84.12 0.02 OUTLIER 'General case' 0 C--O 1.215 -0.73 0 N-CA-C 109.399 -0.593 . . . . 0.0 109.399 177.173 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' F' F ' 21' ' ' ALA . . . . . 0.44 ' O ' ' O ' ' C' ' 20' ' ' PHE . . . -85.83 91.7 8.41 Favored 'General case' 0 N--CA 1.478 0.931 0 N-CA-C 108.302 -0.999 . . . . 0.0 108.302 178.547 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 11.1 mm-40 -71.14 -172.79 0.75 Allowed 'General case' 0 N--CA 1.481 1.124 0 C-N-CA 119.668 -0.813 . . . . 0.0 111.25 -179.842 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' F' F ' 23' ' ' ASP . . . . . 0.408 ' HB2' ' HZ2' ' F' ' 28' ' ' LYS . 8.5 m-20 -71.46 153.98 41.85 Favored 'General case' 0 N--CA 1.473 0.722 0 CA-C-O 121.847 0.832 . . . . 0.0 112.597 -177.334 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' F' F ' 24' ' ' VAL . . . . . 0.519 ' CG1' HH12 ' D' ' 5' ' ' ARG . 54.9 t -155.25 91.97 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.473 0.702 0 CA-C-N 114.65 -1.159 . . . . 0.0 108.261 177.302 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -119.51 61.33 0.49 Allowed Glycine 0 N--CA 1.482 1.703 0 N-CA-C 110.929 -0.868 . . . . 0.0 110.929 178.792 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 15.9 m 45.91 -143.18 0.28 Allowed 'General case' 0 N--CA 1.484 1.247 0 CA-C-N 118.206 1.003 . . . . 0.0 110.688 -179.973 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 3.6 m-80 -79.86 92.5 5.5 Favored 'General case' 0 N--CA 1.472 0.637 0 N-CA-C 108.818 -0.808 . . . . 0.0 108.818 177.413 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' F' F ' 28' ' ' LYS . . . . . 0.408 ' HZ2' ' HB2' ' F' ' 23' ' ' ASP . 96.4 mttt -66.1 146.4 54.7 Favored 'General case' 0 CA--C 1.542 0.639 0 CA-C-O 121.229 0.538 . . . . 0.0 110.626 -178.582 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -71.26 -129.45 0.08 OUTLIER Glycine 0 CA--C 1.538 1.529 0 N-CA-C 109.874 -1.29 . . . . 0.0 109.874 178.578 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.97 131.31 35.25 Favored 'General case' 0 N--CA 1.436 -1.137 0 CA-C-N 117.528 0.664 . . . . 0.0 109.484 178.754 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 18.4 tt -165.22 173.65 0.17 Allowed 'Isoleucine or valine' 0 C--O 1.218 -0.553 0 N-CA-C 108.571 -0.9 . . . . 0.0 108.571 -178.756 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 25.9 mt -141.48 145.59 24.43 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.524 0 N-CA-C 107.016 -1.476 . . . . 0.0 107.016 179.665 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -51.78 167.9 0.69 Allowed Glycine 0 N--CA 1.476 1.354 0 C-N-CA 121.316 -0.469 . . . . 0.0 112.567 -179.38 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 2.6 pp -65.64 157.29 30.36 Favored 'General case' 0 N--CA 1.466 0.351 0 CA-C-O 120.834 0.35 . . . . 0.0 110.061 179.772 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 22.9 ttt -142.29 154.02 44.37 Favored 'General case' 0 N--CA 1.476 0.858 0 N-CA-C 109.111 -0.7 . . . . 0.0 109.111 -179.984 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 40.6 t -149.19 138.68 15.77 Favored 'Isoleucine or valine' 0 C--O 1.237 0.399 0 N-CA-C 107.559 -1.274 . . . . 0.0 107.559 -179.625 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 60.97 67.83 1.95 Allowed Glycine 0 C--N 1.321 -0.251 0 N-CA-C 108.721 -1.751 . . . . 0.0 108.721 -179.974 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -82.69 130.86 9.96 Favored Glycine 0 C--N 1.334 0.462 0 N-CA-C 111.335 -0.706 . . . . 0.0 111.335 -178.38 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 1.9 t -147.3 113.57 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.5 2.052 0 N-CA-C 108.494 -0.928 . . . . 0.0 108.494 179.324 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 19.4 t . . . . . 0 N--CA 1.492 1.653 0 CA-C-O 118.215 -0.898 . . . . 0.0 112.5 -177.474 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' G' G ' 1' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 . . . . . 0 N--CA 1.491 1.596 0 N-CA-C 109.54 -0.541 . . . . 0.0 109.54 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' G' G ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.81 130.36 44.53 Favored 'General case' 0 N--CA 1.472 0.647 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.305 179.53 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' G' G ' 3' ' ' GLU . . . . . . . . . . . . . 53.6 tt0 -169.73 125.85 0.85 Allowed 'General case' 0 N--CA 1.471 0.575 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 -179.986 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 31.9 m-85 -117.63 127.93 54.43 Favored 'General case' 0 N--CA 1.48 1.046 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 179.317 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' G' G ' 5' ' ' ARG . . . . . 0.527 HH12 ' CG1' ' I' ' 24' ' ' VAL . 6.1 ptm180 -165.07 148.81 8.58 Favored 'General case' 0 N--CA 1.47 0.555 0 C-N-CA 120.446 -0.502 . . . . 0.0 111.933 -179.907 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' G' G ' 6' ' ' HIS . . . . . 0.404 ' O ' ' ND1' ' G' ' 6' ' ' HIS . 21.8 p80 -153.81 106.71 2.89 Favored 'General case' 0 N--CA 1.474 0.767 0 CA-C-O 121.06 0.457 . . . . 0.0 110.719 178.224 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -77.39 152.11 34.52 Favored 'General case' 0 N--CA 1.474 0.727 0 CA-C-O 121.084 0.468 . . . . 0.0 110.276 179.008 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' G' G ' 8' ' ' SER . . . . . . . . . . . . . 99.2 p -155.7 174.5 15.2 Favored 'General case' 0 N--CA 1.474 0.75 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.846 179.996 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 124.61 78.87 0.37 Allowed Glycine 0 N--CA 1.478 1.466 0 N-CA-C 111.202 -0.759 . . . . 0.0 111.202 179.582 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 24.0 p90 -54.23 157.47 2.67 Favored 'General case' 0 N--CA 1.476 0.827 0 O-C-N 122.802 -0.234 . . . . 0.0 111.107 179.358 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 64.6 mt-10 -120.15 126.93 51.92 Favored 'General case' 0 N--CA 1.487 1.376 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 179.257 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 29.9 t -103.79 136.12 38.28 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.021 0 N-CA-C 109.158 -0.682 . . . . 0.0 109.158 178.658 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 38.6 m80 -137.92 138.4 38.96 Favored 'General case' 0 N--CA 1.481 1.092 0 C-N-CA 122.827 0.451 . . . . 0.0 110.634 179.926 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 13.1 t60 -168.26 97.4 0.42 Allowed 'General case' 0 N--CA 1.481 1.125 0 N-CA-C 110.355 -0.239 . . . . 0.0 110.355 178.727 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 55.3 mt-30 -100.4 117.53 34.77 Favored 'General case' 0 CA--C 1.512 -0.5 0 N-CA-C 108.476 -0.935 . . . . 0.0 108.476 -179.652 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 64.6 tttp -104.97 105.67 15.82 Favored 'General case' 0 N--CA 1.482 1.142 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 178.323 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 9.8 mp -121.71 161.97 21.62 Favored 'General case' 0 N--CA 1.486 1.345 0 C-N-CA 123.478 0.711 . . . . 0.0 109.413 -179.204 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 43.6 t -142.59 112.78 2.59 Favored 'Isoleucine or valine' 0 C--O 1.246 0.891 0 N-CA-C 108.269 -1.012 . . . . 0.0 108.269 176.734 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 61.4 m-85 -101.73 161.01 13.97 Favored 'General case' 0 C--N 1.371 1.539 0 O-C-N 125.566 1.791 . . . . 0.0 109.959 177.307 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 68.7 t80 -167.95 -82.5 0.02 OUTLIER 'General case' 0 CA--C 1.539 0.527 0 CA-C-N 115.7 -0.682 . . . . 0.0 109.36 177.389 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' G' G ' 21' ' ' ALA . . . . . 0.403 ' O ' ' O ' ' D' ' 20' ' ' PHE . . . -84.96 90.69 7.88 Favored 'General case' 0 N--CA 1.474 0.754 0 N-CA-C 108.302 -0.999 . . . . 0.0 108.302 179.184 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 11.6 mm-40 -70.36 -175.09 0.94 Allowed 'General case' 0 N--CA 1.483 1.177 0 C-N-CA 119.691 -0.803 . . . . 0.0 111.167 -179.935 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' G' G ' 23' ' ' ASP . . . . . 0.403 ' CB ' ' HZ2' ' G' ' 28' ' ' LYS . 8.9 m-20 -70.97 154.47 41.79 Favored 'General case' 0 N--CA 1.475 0.82 0 CA-C-O 121.3 0.571 . . . . 0.0 112.169 -177.218 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' G' G ' 24' ' ' VAL . . . . . 0.507 ' CG1' HH12 ' H' ' 5' ' ' ARG . 65.2 t -156.63 92.8 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.471 0.597 0 CA-C-N 114.951 -1.022 . . . . 0.0 108.323 177.085 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -119.34 61.38 0.48 Allowed Glycine 0 N--CA 1.477 1.43 0 N-CA-C 110.93 -0.868 . . . . 0.0 110.93 179.107 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 17.2 m 47.0 -139.02 0.62 Allowed 'General case' 0 N--CA 1.484 1.233 0 CA-C-N 118.23 1.015 . . . . 0.0 110.815 179.691 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 3.7 m-80 -84.31 91.72 7.83 Favored 'General case' 0 N--CA 1.473 0.697 0 N-CA-C 108.087 -1.079 . . . . 0.0 108.087 177.511 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' G' G ' 28' ' ' LYS . . . . . 0.403 ' HZ2' ' CB ' ' G' ' 23' ' ' ASP . 96.5 mttt -65.3 146.61 54.7 Favored 'General case' 0 CA--C 1.539 0.539 0 CA-C-O 121.249 0.547 . . . . 0.0 110.576 -178.176 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -72.22 -127.84 0.09 OUTLIER Glycine 0 CA--C 1.526 0.779 0 N-CA-C 109.417 -1.473 . . . . 0.0 109.417 178.541 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.95 128.4 34.03 Favored 'General case' 0 CA--C 1.528 0.104 0 C-N-CA 122.66 0.384 . . . . 0.0 110.179 179.718 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 18.8 tt -164.41 172.88 0.21 Allowed 'Isoleucine or valine' 0 CA--C 1.506 -0.736 0 N-CA-C 109.53 -0.544 . . . . 0.0 109.53 -178.836 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 32.1 mt -139.42 146.9 24.87 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.092 0 N-CA-C 107.117 -1.438 . . . . 0.0 107.117 177.975 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -52.05 167.72 0.79 Allowed Glycine 0 N--CA 1.474 1.188 0 C-N-CA 121.489 -0.386 . . . . 0.0 112.187 -179.463 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 2.6 pp -65.87 157.61 30.1 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-O 120.793 0.33 . . . . 0.0 110.208 -179.935 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 22.8 ttt -142.74 154.54 44.37 Favored 'General case' 0 N--CA 1.472 0.669 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 -179.934 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 39.0 t -149.28 139.13 16.1 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.258 0 N-CA-C 107.712 -1.218 . . . . 0.0 107.712 -179.709 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 60.32 68.26 1.76 Allowed Glycine 0 C--N 1.319 -0.375 0 N-CA-C 108.956 -1.658 . . . . 0.0 108.956 179.963 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . -83.27 131.0 10.06 Favored Glycine 0 N--CA 1.465 0.599 0 N-CA-C 111.335 -0.706 . . . . 0.0 111.335 -178.703 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 2.1 t -146.97 113.2 0.96 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.91 0 N-CA-C 108.515 -0.92 . . . . 0.0 108.515 179.604 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 21.4 t . . . . . 0 N--CA 1.492 1.648 0 CA-C-O 118.205 -0.902 . . . . 0.0 111.958 -178.304 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' H' H ' 1' ' ' ASP . . . . . . . . . . . . . 9.0 m-20 . . . . . 0 N--CA 1.491 1.576 0 N-CA-C 109.608 -0.516 . . . . 0.0 109.608 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' H' H ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.72 130.09 43.43 Favored 'General case' 0 N--CA 1.471 0.597 0 CA-C-N 116.284 -0.417 . . . . 0.0 110.315 179.455 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' H' H ' 3' ' ' GLU . . . . . . . . . . . . . 53.9 tt0 -169.61 125.7 0.86 Allowed 'General case' 0 N--CA 1.471 0.593 0 N-CA-C 110.009 -0.367 . . . . 0.0 110.009 179.948 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 32.4 m-85 -117.21 128.24 54.9 Favored 'General case' 0 N--CA 1.48 1.068 0 N-CA-C 108.486 -0.931 . . . . 0.0 108.486 179.22 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' H' H ' 5' ' ' ARG . . . . . 0.508 HH21 ' NH1' ' E' ' 5' ' ' ARG . 6.1 ptm180 -165.33 148.78 8.23 Favored 'General case' 0 N--CA 1.47 0.558 0 C-N-CA 120.533 -0.467 . . . . 0.0 112.031 -179.968 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' H' H ' 6' ' ' HIS . . . . . 0.403 ' O ' ' ND1' ' H' ' 6' ' ' HIS . 21.7 p80 -153.89 106.76 2.88 Favored 'General case' 0 N--CA 1.475 0.79 0 CA-C-O 120.993 0.425 . . . . 0.0 110.645 178.204 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -77.58 151.75 34.28 Favored 'General case' 0 N--CA 1.474 0.745 0 CA-C-O 121.039 0.447 . . . . 0.0 110.261 179.016 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' H' H ' 8' ' ' SER . . . . . . . . . . . . . 99.3 p -155.22 174.89 14.57 Favored 'General case' 0 N--CA 1.475 0.808 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.839 179.99 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 124.15 78.89 0.39 Allowed Glycine 0 N--CA 1.478 1.472 0 N-CA-C 111.305 -0.718 . . . . 0.0 111.305 179.714 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 24.2 p90 -54.36 157.73 2.65 Favored 'General case' 0 N--CA 1.475 0.789 0 O-C-N 122.747 -0.267 . . . . 0.0 111.137 179.29 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 64.8 mt-10 -120.31 126.93 51.77 Favored 'General case' 0 N--CA 1.485 1.3 0 C-N-CA 122.694 0.397 . . . . 0.0 109.931 179.347 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 28.1 t -103.97 135.94 39.36 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.998 0 N-CA-C 109.153 -0.684 . . . . 0.0 109.153 178.683 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 38.6 m80 -137.76 138.65 39.47 Favored 'General case' 0 N--CA 1.481 1.107 0 C-N-CA 122.981 0.512 . . . . 0.0 110.584 -179.949 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 13.2 t60 -168.56 97.48 0.4 Allowed 'General case' 0 N--CA 1.482 1.127 0 N-CA-C 110.31 -0.256 . . . . 0.0 110.31 178.66 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 55.5 mt-30 -100.56 116.97 33.73 Favored 'General case' 0 CA--C 1.512 -0.49 0 N-CA-C 108.72 -0.845 . . . . 0.0 108.72 -179.619 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 64.5 tttp -104.35 105.72 15.96 Favored 'General case' 0 N--CA 1.482 1.136 0 N-CA-C 108.62 -0.882 . . . . 0.0 108.62 178.282 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 9.8 mp -121.91 162.29 21.29 Favored 'General case' 0 N--CA 1.487 1.386 0 C-N-CA 123.494 0.718 . . . . 0.0 109.224 -179.262 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 45.8 t -142.35 111.96 2.55 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.601 0 N-CA-C 108.372 -0.974 . . . . 0.0 108.372 176.921 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 61.1 m-85 -100.6 161.37 13.65 Favored 'General case' 0 C--N 1.364 1.228 0 O-C-N 124.724 1.265 . . . . 0.0 109.944 177.404 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 67.2 t80 -167.26 -83.15 0.02 OUTLIER 'General case' 0 N--CA 1.469 0.48 0 CA-C-N 115.696 -0.684 . . . . 0.0 109.572 177.214 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' H' H ' 21' ' ' ALA . . . . . 0.431 ' O ' ' O ' ' E' ' 20' ' ' PHE . . . -84.91 90.33 7.78 Favored 'General case' 0 N--CA 1.473 0.715 0 N-CA-C 108.406 -0.961 . . . . 0.0 108.406 179.22 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 11.7 mm-40 -69.76 -175.02 0.81 Allowed 'General case' 0 N--CA 1.483 1.176 0 C-N-CA 119.694 -0.803 . . . . 0.0 111.171 -179.872 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' H' H ' 23' ' ' ASP . . . . . 0.403 ' HB2' ' HZ2' ' H' ' 28' ' ' LYS . 8.8 m-20 -71.2 154.36 41.74 Favored 'General case' 0 N--CA 1.473 0.691 0 CA-C-O 121.333 0.587 . . . . 0.0 112.245 -177.093 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' H' H ' 24' ' ' VAL . . . . . 0.513 ' CG1' HH12 ' I' ' 5' ' ' ARG . 65.7 t -156.36 92.8 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.471 0.619 0 CA-C-N 114.943 -1.026 . . . . 0.0 108.407 177.095 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . -119.45 61.46 0.49 Allowed Glycine 0 N--CA 1.48 1.615 0 N-CA-C 110.961 -0.856 . . . . 0.0 110.961 179.226 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 17.2 m 46.82 -138.83 0.61 Allowed 'General case' 0 N--CA 1.485 1.296 0 CA-C-N 118.082 0.941 . . . . 0.0 110.832 -179.979 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 3.4 m-80 -84.26 91.9 7.85 Favored 'General case' 0 N--CA 1.473 0.691 0 N-CA-C 108.027 -1.101 . . . . 0.0 108.027 177.417 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' H' H ' 28' ' ' LYS . . . . . 0.403 ' HZ2' ' HB2' ' H' ' 23' ' ' ASP . 96.4 mttt -65.47 146.75 54.48 Favored 'General case' 0 CA--C 1.539 0.549 0 CA-C-O 121.373 0.606 . . . . 0.0 110.487 -178.212 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -72.16 -127.87 0.09 OUTLIER Glycine 0 CA--C 1.528 0.856 0 N-CA-C 109.554 -1.419 . . . . 0.0 109.554 178.542 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.91 128.8 34.43 Favored 'General case' 0 C--O 1.231 0.086 0 N-CA-C 110.05 -0.352 . . . . 0.0 110.05 179.591 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 18.9 tt -164.73 172.57 0.21 Allowed 'Isoleucine or valine' 0 CA--C 1.505 -0.778 0 N-CA-C 109.578 -0.527 . . . . 0.0 109.578 -178.719 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 31.9 mt -139.34 147.01 24.78 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.038 0 N-CA-C 107.132 -1.433 . . . . 0.0 107.132 177.974 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -52.25 167.59 0.87 Allowed Glycine 0 N--CA 1.472 1.088 0 C-N-CA 121.505 -0.378 . . . . 0.0 112.267 -179.454 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 2.6 pp -65.5 157.84 28.52 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-O 120.937 0.399 . . . . 0.0 110.123 -179.95 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 22.8 ttt -142.97 154.48 44.08 Favored 'General case' 0 N--CA 1.473 0.712 0 N-CA-C 109.225 -0.657 . . . . 0.0 109.225 -179.859 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 39.2 t -149.54 139.11 15.82 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.216 0 N-CA-C 107.566 -1.272 . . . . 0.0 107.566 -179.578 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 60.19 67.88 1.94 Allowed Glycine 0 C--N 1.32 -0.335 0 N-CA-C 109.093 -1.603 . . . . 0.0 109.093 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . -83.02 131.17 10.17 Favored Glycine 0 N--CA 1.464 0.544 0 N-CA-C 111.45 -0.66 . . . . 0.0 111.45 -178.765 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 2.1 t -147.04 113.36 0.96 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.927 0 N-CA-C 108.324 -0.991 . . . . 0.0 108.324 179.539 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 21.7 t . . . . . 0 N--CA 1.491 1.589 0 CA-C-O 118.298 -0.858 . . . . 0.0 111.574 -178.358 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' I' I ' 1' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 . . . . . 0 N--CA 1.491 1.613 0 N-CA-C 109.532 -0.544 . . . . 0.0 109.532 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' I' I ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.66 130.2 43.97 Favored 'General case' 0 N--CA 1.472 0.641 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.308 179.448 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' I' I ' 3' ' ' GLU . . . . . . . . . . . . . 53.7 tt0 -169.77 125.66 0.84 Allowed 'General case' 0 N--CA 1.47 0.559 0 N-CA-C 109.97 -0.382 . . . . 0.0 109.97 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 32.8 m-85 -117.32 128.15 54.77 Favored 'General case' 0 N--CA 1.48 1.041 0 N-CA-C 108.46 -0.941 . . . . 0.0 108.46 179.247 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' I' I ' 5' ' ' ARG . . . . . 0.513 HH21 ' NH1' ' F' ' 5' ' ' ARG . 6.1 ptm180 -165.24 148.48 8.23 Favored 'General case' 0 N--CA 1.47 0.545 0 C-N-CA 120.567 -0.453 . . . . 0.0 112.017 -179.881 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' I' I ' 6' ' ' HIS . . . . . 0.401 ' ND1' ' O ' ' I' ' 6' ' ' HIS . 21.6 p80 -153.66 106.83 2.94 Favored 'General case' 0 N--CA 1.475 0.793 0 CA-C-O 121.008 0.432 . . . . 0.0 110.61 178.198 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -77.59 151.83 34.23 Favored 'General case' 0 N--CA 1.474 0.775 0 CA-C-O 121.072 0.463 . . . . 0.0 110.249 178.958 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' I' I ' 8' ' ' SER . . . . . . . . . . . . . 98.2 p -155.23 174.88 14.58 Favored 'General case' 0 N--CA 1.476 0.849 0 CA-C-N 115.945 -0.57 . . . . 0.0 110.854 179.915 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 124.23 78.92 0.39 Allowed Glycine 0 N--CA 1.479 1.56 0 N-CA-C 111.256 -0.738 . . . . 0.0 111.256 179.663 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 24.0 p90 -54.58 157.63 2.86 Favored 'General case' 0 N--CA 1.477 0.891 0 O-C-N 122.803 -0.234 . . . . 0.0 111.045 179.308 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 64.5 mt-10 -120.23 126.92 51.81 Favored 'General case' 0 N--CA 1.484 1.266 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 179.391 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 27.2 t -103.9 135.86 39.66 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.937 0 N-CA-C 109.16 -0.681 . . . . 0.0 109.16 178.679 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 38.5 m80 -137.76 138.53 39.37 Favored 'General case' 0 N--CA 1.482 1.15 0 C-N-CA 122.966 0.506 . . . . 0.0 110.579 -179.943 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 13.2 t60 -168.47 97.27 0.4 Allowed 'General case' 0 N--CA 1.482 1.136 0 N-CA-C 110.278 -0.267 . . . . 0.0 110.278 178.736 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 55.8 mt-30 -100.38 116.93 33.5 Favored 'General case' 0 C--N 1.326 -0.436 0 N-CA-C 108.611 -0.885 . . . . 0.0 108.611 -179.585 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 64.6 tttp -104.35 105.7 15.92 Favored 'General case' 0 N--CA 1.482 1.143 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 178.236 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 9.8 mp -121.88 162.35 21.14 Favored 'General case' 0 N--CA 1.487 1.416 0 C-N-CA 123.475 0.71 . . . . 0.0 109.21 -179.244 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 45.7 t -142.35 111.99 2.57 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.579 0 N-CA-C 108.32 -0.993 . . . . 0.0 108.32 176.937 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 60.8 m-85 -100.75 161.41 13.62 Favored 'General case' 0 C--N 1.364 1.208 0 O-C-N 124.79 1.306 . . . . 0.0 109.949 177.434 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 66.9 t80 -167.28 -83.39 0.02 OUTLIER 'General case' 0 N--CA 1.468 0.446 0 CA-C-N 115.629 -0.714 . . . . 0.0 109.649 177.267 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' I' I ' 21' ' ' ALA . . . . . 0.409 ' O ' ' O ' ' F' ' 20' ' ' PHE . . . -84.7 90.62 7.75 Favored 'General case' 0 N--CA 1.471 0.62 0 N-CA-C 108.274 -1.01 . . . . 0.0 108.274 179.243 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 11.7 mm-40 -70.16 -175.01 0.88 Allowed 'General case' 0 N--CA 1.482 1.17 0 C-N-CA 119.725 -0.79 . . . . 0.0 111.114 -179.836 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' I' I ' 23' ' ' ASP . . . . . 0.402 ' CB ' ' HZ2' ' I' ' 28' ' ' LYS . 8.8 m-20 -71.21 154.17 41.89 Favored 'General case' 0 N--CA 1.473 0.701 0 CA-C-O 121.296 0.57 . . . . 0.0 112.292 -177.067 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' I' I ' 24' ' ' VAL . . . . . 0.527 ' CG1' HH12 ' G' ' 5' ' ' ARG . 65.6 t -156.22 92.75 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.47 0.528 0 CA-C-N 115.023 -0.99 . . . . 0.0 108.396 177.08 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . -119.17 61.36 0.48 Allowed Glycine 0 N--CA 1.48 1.628 0 N-CA-C 110.981 -0.848 . . . . 0.0 110.981 179.148 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 17.4 m 46.81 -138.84 0.61 Allowed 'General case' 0 N--CA 1.486 1.36 0 CA-C-N 118.214 1.007 . . . . 0.0 110.707 179.948 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 3.3 m-80 -84.29 91.97 7.88 Favored 'General case' 0 N--CA 1.472 0.665 0 N-CA-C 108.089 -1.078 . . . . 0.0 108.089 177.413 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' I' I ' 28' ' ' LYS . . . . . 0.402 ' HZ2' ' CB ' ' I' ' 23' ' ' ASP . 96.4 mttt -65.52 146.58 54.68 Favored 'General case' 0 CA--C 1.539 0.555 0 CA-C-O 121.378 0.608 . . . . 0.0 110.512 -178.195 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -71.92 -128.13 0.09 OUTLIER Glycine 0 CA--C 1.527 0.835 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 178.49 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.87 128.47 34.07 Favored 'General case' 0 CA--C 1.529 0.155 0 C-N-CA 122.709 0.404 . . . . 0.0 109.939 179.698 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 18.8 tt -164.38 172.64 0.22 Allowed 'Isoleucine or valine' 0 CA--C 1.506 -0.716 0 N-CA-C 109.553 -0.536 . . . . 0.0 109.553 -178.695 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 31.7 mt -139.31 146.99 24.85 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.101 0 N-CA-C 107.214 -1.402 . . . . 0.0 107.214 177.896 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -52.25 167.62 0.87 Allowed Glycine 0 N--CA 1.473 1.163 0 C-N-CA 121.528 -0.367 . . . . 0.0 112.234 -179.444 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 2.6 pp -65.59 157.59 29.41 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-O 120.892 0.377 . . . . 0.0 110.086 -179.956 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 22.9 ttt -142.73 154.17 44.03 Favored 'General case' 0 N--CA 1.472 0.655 0 N-CA-C 109.172 -0.677 . . . . 0.0 109.172 -179.827 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 39.6 t -149.26 139.27 16.23 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.252 0 N-CA-C 107.551 -1.277 . . . . 0.0 107.551 -179.719 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 60.09 67.93 1.92 Allowed Glycine 0 N--CA 1.461 0.344 0 N-CA-C 109.135 -1.586 . . . . 0.0 109.135 -179.921 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . -82.99 131.22 10.21 Favored Glycine 0 N--CA 1.464 0.564 0 N-CA-C 111.359 -0.697 . . . . 0.0 111.359 -178.702 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 2.1 t -147.16 113.39 0.95 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.908 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 179.527 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 21.6 t . . . . . 0 N--CA 1.489 1.521 0 CA-C-O 118.192 -0.909 . . . . 0.0 111.766 -178.315 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 3.9 p-10 . . . . . 0 N--CA 1.49 1.574 0 N-CA-C 109.165 -0.68 . . . . 0.0 109.165 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.62 130.32 43.19 Favored 'General case' 0 N--CA 1.47 0.535 0 CA-C-N 116.378 -0.374 . . . . 0.0 111.406 -179.593 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 13.4 pt-20 -170.69 108.84 0.33 Allowed 'General case' 0 CA--C 1.545 0.781 0 CA-C-O 121.275 0.56 . . . . 0.0 110.143 179.08 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 29.8 m-85 -87.47 156.97 19.31 Favored 'General case' 0 N--CA 1.472 0.659 0 N-CA-C 109.426 -0.583 . . . . 0.0 109.426 -179.813 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 77.1 mtt85 -139.85 145.58 38.26 Favored 'General case' 0 N--CA 1.478 0.925 0 CA-C-N 115.886 -0.597 . . . . 0.0 109.885 179.776 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 57.6 t-80 -150.51 116.96 5.73 Favored 'General case' 0 N--CA 1.476 0.863 0 N-CA-C 109.631 -0.507 . . . . 0.0 109.631 179.164 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 9.9 m-20 -66.94 144.6 56.13 Favored 'General case' 0 N--CA 1.474 0.75 0 C-N-CA 122.897 0.479 . . . . 0.0 111.83 -179.809 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 1.7 t -164.3 -176.89 4.64 Favored 'General case' 0 N--CA 1.471 0.597 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 177.986 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 85.54 70.46 1.33 Allowed Glycine 0 CA--C 1.53 1.029 0 CA-C-N 115.837 -0.62 . . . . 0.0 112.087 178.725 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 40.3 p90 -73.01 122.16 21.28 Favored 'General case' 0 N--CA 1.477 0.888 0 CA-C-N 117.255 0.527 . . . . 0.0 110.892 179.976 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 17.7 pt-20 -82.76 151.82 25.99 Favored 'General case' 0 N--CA 1.477 0.903 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 178.853 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 13.7 t -144.68 117.72 2.73 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.877 0 CA-C-O 121.578 0.704 . . . . 0.0 109.365 178.302 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 73.5 m80 -95.79 164.87 12.57 Favored 'General case' 0 C--N 1.358 0.941 0 CA-C-N 114.641 -1.163 . . . . 0.0 109.29 177.996 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . 0.46 ' HE2' ' NZ ' ' A' ' 16' ' ' LYS . 17.2 t60 -164.74 99.27 0.78 Allowed 'General case' 0 N--CA 1.476 0.855 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.12 179.223 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -91.66 111.58 23.15 Favored 'General case' 0 CA--C 1.517 -0.326 0 N-CA-C 108.386 -0.968 . . . . 0.0 108.386 179.668 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . 0.46 ' NZ ' ' HE2' ' A' ' 14' ' ' HIS . 8.5 ttmm -94.37 171.38 8.85 Favored 'General case' 0 N--CA 1.483 1.206 0 N-CA-C 108.893 -0.781 . . . . 0.0 108.893 179.926 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 9.6 mp -55.09 157.9 3.16 Favored 'General case' 0 N--CA 1.476 0.837 0 N-CA-C 110.002 -0.37 . . . . 0.0 110.002 -178.408 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 71.2 t -140.81 150.22 20.69 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.714 0 C-N-CA 123.206 0.602 . . . . 0.0 109.76 -177.798 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.671 ' HB3' ' O ' ' D' ' 18' ' ' VAL . 43.9 p90 -40.44 162.34 0.01 OUTLIER 'General case' 0 CA--C 1.542 0.666 0 N-CA-C 120.228 3.418 . . . . 0.0 120.228 -178.729 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.409 ' O ' ' CD2' ' A' ' 20' ' ' PHE . 20.9 p90 -119.75 69.82 0.85 Allowed 'General case' 0 CA--C 1.56 1.352 0 CA-C-N 112.033 -2.349 . . . . 0.0 109.449 173.552 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -62.97 95.04 0.07 Allowed 'General case' 0 C--N 1.325 -0.493 0 N-CA-C 108.38 -0.97 . . . . 0.0 108.38 176.767 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 77.5 mt-10 -49.61 123.73 8.3 Favored 'General case' 0 N--CA 1.475 0.813 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.517 -179.954 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 16.6 t70 -76.73 169.37 18.43 Favored 'General case' 0 N--CA 1.471 0.624 0 CA-C-O 120.983 0.42 . . . . 0.0 110.648 -178.901 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . 0.505 HG13 ' H ' ' A' ' 25' ' ' GLY . 0.7 OUTLIER 178.28 -79.05 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.542 0.636 0 N-CA-C 107.298 -1.371 . . . . 0.0 107.298 -179.865 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.505 ' H ' HG13 ' A' ' 24' ' ' VAL . . . -34.03 84.4 0.0 OUTLIER Glycine 0 N--CA 1.473 1.166 0 C-N-CA 124.425 1.012 . . . . 0.0 113.461 178.546 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' SER . . . . . 0.438 ' N ' ' O ' ' A' ' 24' ' ' VAL . 87.9 p -41.25 -105.55 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.65 0 N-CA-C 113.676 0.991 . . . . 0.0 113.676 -177.401 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 16.8 p-10 -59.97 112.47 1.88 Allowed 'General case' 0 N--CA 1.469 0.488 0 CA-C-N 118.833 0.742 . . . . 0.0 110.417 -178.637 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 41.8 mttm -96.83 164.57 12.5 Favored 'General case' 0 N--CA 1.475 0.801 0 C-N-CA 123.31 0.644 . . . . 0.0 110.008 -179.564 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -72.95 -141.45 0.45 Allowed Glycine 0 N--CA 1.461 0.342 0 N-CA-C 107.876 -2.089 . . . . 0.0 107.876 176.548 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . 0.458 ' O ' ' O ' ' D' ' 31' ' ' ILE . . . -90.42 123.12 33.88 Favored 'General case' 0 C--O 1.208 -1.084 0 N-CA-C 106.836 -1.542 . . . . 0.0 106.836 176.524 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 16.7 tt -148.28 155.6 9.41 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.884 0 N-CA-C 107.996 -1.113 . . . . 0.0 107.996 179.192 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 20.5 pt -150.88 138.89 14.24 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 CA-C-N 119.042 0.837 . . . . 0.0 109.394 178.56 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -56.68 154.3 17.7 Favored Glycine 0 CA--C 1.533 1.167 0 CA-C-N 116.605 -0.27 . . . . 0.0 112.591 -178.537 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 2.5 pp -76.29 158.92 31.06 Favored 'General case' 0 N--CA 1.472 0.673 0 N-CA-C 109.68 -0.489 . . . . 0.0 109.68 179.242 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 11.9 ttp -102.84 151.59 22.25 Favored 'General case' 0 N--CA 1.481 1.08 0 N-CA-C 109.383 -0.599 . . . . 0.0 109.383 179.711 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 7.3 p -168.62 159.82 0.71 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.553 0 N-CA-C 108.044 -1.095 . . . . 0.0 108.044 179.772 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.41 69.86 1.14 Allowed Glycine 0 C--N 1.31 -0.862 0 N-CA-C 111.665 -0.574 . . . . 0.0 111.665 178.836 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 152.04 -177.49 29.84 Favored Glycine 0 N--CA 1.468 0.828 0 N-CA-C 110.214 -1.154 . . . . 0.0 110.214 179.659 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 4.6 t -124.99 139.14 51.99 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.758 0 N-CA-C 107.206 -1.405 . . . . 0.0 107.206 -179.502 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 72.7 t . . . . . 0 N--CA 1.481 1.081 0 CA-C-O 117.776 -1.107 . . . . 0.0 109.64 -177.501 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' B' B ' 1' ' ' ASP . . . . . 0.401 ' CG ' ' H1 ' ' E' ' 1' ' ' ASP . 3.9 p-10 . . . . . 0 N--CA 1.489 1.493 0 N-CA-C 109.194 -0.669 . . . . 0.0 109.194 . . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.52 130.19 42.74 Favored 'General case' 0 N--CA 1.469 0.496 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.403 -179.671 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 3' ' ' GLU . . . . . . . . . . . . . 13.3 pt-20 -170.69 108.86 0.33 Allowed 'General case' 0 CA--C 1.546 0.818 0 CA-C-O 121.334 0.588 . . . . 0.0 110.111 179.01 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 30.1 m-85 -87.29 157.16 19.36 Favored 'General case' 0 N--CA 1.473 0.72 0 N-CA-C 109.531 -0.544 . . . . 0.0 109.531 -179.808 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 77.1 mtt85 -140.05 145.61 37.93 Favored 'General case' 0 N--CA 1.477 0.92 0 CA-C-N 115.941 -0.572 . . . . 0.0 109.991 179.724 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 58.1 t-80 -150.43 117.29 5.87 Favored 'General case' 0 N--CA 1.475 0.814 0 N-CA-C 109.644 -0.502 . . . . 0.0 109.644 179.153 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 7' ' ' ASP . . . . . . . . . . . . . 9.8 m-20 -67.16 144.38 56.06 Favored 'General case' 0 N--CA 1.472 0.671 0 C-N-CA 122.863 0.465 . . . . 0.0 111.682 -179.713 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 8' ' ' SER . . . . . . . . . . . . . 2.2 t -163.96 -177.63 5.18 Favored 'General case' 0 N--CA 1.471 0.578 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 178.148 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 85.88 70.5 1.32 Allowed Glycine 0 CA--C 1.532 1.154 0 CA-C-N 115.916 -0.584 . . . . 0.0 112.158 178.775 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 40.1 p90 -72.81 121.99 20.83 Favored 'General case' 0 N--CA 1.478 0.931 0 CA-C-N 117.295 0.548 . . . . 0.0 110.87 179.833 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 17.7 pt-20 -82.67 151.92 26.06 Favored 'General case' 0 N--CA 1.479 0.986 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 178.828 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 13.1 t -144.75 117.81 2.71 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.842 0 CA-C-O 121.598 0.713 . . . . 0.0 109.318 178.362 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 73.5 m80 -96.02 164.66 12.61 Favored 'General case' 0 C--N 1.357 0.932 0 CA-C-N 114.616 -1.175 . . . . 0.0 109.333 177.919 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 14' ' ' HIS . . . . . 0.448 ' NE2' ' NZ ' ' B' ' 16' ' ' LYS . 17.2 t60 -164.59 99.25 0.8 Allowed 'General case' 0 N--CA 1.476 0.839 0 CA-C-N 116.471 -0.331 . . . . 0.0 110.113 179.224 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -91.44 111.54 23.08 Favored 'General case' 0 CA--C 1.515 -0.381 0 N-CA-C 108.441 -0.948 . . . . 0.0 108.441 179.585 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 16' ' ' LYS . . . . . 0.448 ' NZ ' ' NE2' ' B' ' 14' ' ' HIS . 8.5 ttmm -94.33 171.49 8.79 Favored 'General case' 0 N--CA 1.483 1.197 0 N-CA-C 108.899 -0.778 . . . . 0.0 108.899 179.995 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 9.7 mp -55.25 157.83 3.38 Favored 'General case' 0 N--CA 1.476 0.836 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 -178.41 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 71.3 t -140.87 150.46 20.49 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.763 0 C-N-CA 123.113 0.565 . . . . 0.0 109.652 -177.767 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 19' ' ' PHE . . . . . 0.691 ' HB3' ' O ' ' E' ' 18' ' ' VAL . 44.4 p90 -40.58 162.07 0.01 OUTLIER 'General case' 0 CA--C 1.543 0.7 0 N-CA-C 120.055 3.354 . . . . 0.0 120.055 -178.738 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . 0.418 ' CD2' ' O ' ' B' ' 20' ' ' PHE . 21.1 p90 -119.61 69.68 0.84 Allowed 'General case' 0 CA--C 1.561 1.371 0 CA-C-N 111.946 -2.388 . . . . 0.0 109.257 173.545 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -62.75 95.11 0.07 Allowed 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 108.409 -0.959 . . . . 0.0 108.409 176.759 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 77.2 mt-10 -49.62 123.73 8.3 Favored 'General case' 0 N--CA 1.476 0.849 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.421 -179.892 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 16.7 t70 -76.74 169.27 18.61 Favored 'General case' 0 N--CA 1.471 0.609 0 CA-C-O 121.007 0.432 . . . . 0.0 110.702 -179.044 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . 0.5 HG13 ' H ' ' B' ' 25' ' ' GLY . 0.7 OUTLIER 178.2 -79.11 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.545 0.755 0 N-CA-C 107.333 -1.358 . . . . 0.0 107.333 -179.608 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . 0.5 ' H ' HG13 ' B' ' 24' ' ' VAL . . . -34.1 84.12 0.0 OUTLIER Glycine 0 N--CA 1.48 1.633 0 C-N-CA 124.334 0.969 . . . . 0.0 113.258 178.7 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 26' ' ' SER . . . . . 0.453 ' N ' ' O ' ' B' ' 24' ' ' VAL . 88.0 p -41.02 -105.38 0.0 OUTLIER 'General case' 0 N--CA 1.475 0.817 0 N-CA-C 113.602 0.964 . . . . 0.0 113.602 -177.411 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 16.6 p-10 -60.02 112.27 1.81 Allowed 'General case' 0 N--CA 1.471 0.578 0 CA-C-N 118.83 0.741 . . . . 0.0 110.357 -178.631 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 41.6 mttm -96.53 164.43 12.62 Favored 'General case' 0 N--CA 1.474 0.773 0 C-N-CA 123.203 0.601 . . . . 0.0 110.195 -179.628 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -72.82 -141.03 0.42 Allowed Glycine 0 N--CA 1.461 0.365 0 N-CA-C 107.816 -2.114 . . . . 0.0 107.816 176.574 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 30' ' ' ALA . . . . . 0.491 ' O ' ' O ' ' E' ' 31' ' ' ILE . . . -91.05 123.4 34.48 Favored 'General case' 0 C--O 1.208 -1.128 0 N-CA-C 106.734 -1.58 . . . . 0.0 106.734 176.587 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 16.6 tt -148.35 155.6 9.33 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.829 0 N-CA-C 107.91 -1.144 . . . . 0.0 107.91 179.194 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 20.5 pt -150.79 138.92 14.37 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.469 0 CA-C-N 118.949 0.795 . . . . 0.0 109.246 178.664 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -56.81 154.29 18.32 Favored Glycine 0 CA--C 1.532 1.148 0 CA-C-N 116.598 -0.274 . . . . 0.0 112.63 -178.691 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 2.5 pp -76.18 158.81 31.3 Favored 'General case' 0 N--CA 1.472 0.635 0 C-N-CA 122.707 0.403 . . . . 0.0 109.971 179.161 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 11.8 ttp -102.73 151.21 22.66 Favored 'General case' 0 N--CA 1.481 1.078 0 N-CA-C 109.507 -0.553 . . . . 0.0 109.507 179.717 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 7.3 p -168.37 159.89 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.524 0 N-CA-C 108.035 -1.098 . . . . 0.0 108.035 179.826 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.42 69.6 1.22 Allowed Glycine 0 C--N 1.313 -0.746 0 N-CA-C 111.617 -0.593 . . . . 0.0 111.617 178.774 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 152.14 -177.75 29.77 Favored Glycine 0 N--CA 1.468 0.795 0 N-CA-C 110.217 -1.153 . . . . 0.0 110.217 179.696 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 4.4 t -124.69 139.05 52.05 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.717 0 N-CA-C 107.31 -1.367 . . . . 0.0 107.31 -179.515 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 74.2 t . . . . . 0 N--CA 1.481 1.115 0 CA-C-O 117.756 -1.116 . . . . 0.0 109.647 -177.522 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' C' C ' 1' ' ' ASP . . . . . 0.402 ' CG ' ' H1 ' ' F' ' 1' ' ' ASP . 3.9 p-10 . . . . . 0 N--CA 1.488 1.451 0 N-CA-C 109.317 -0.624 . . . . 0.0 109.317 . . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' C' C ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.22 130.46 43.98 Favored 'General case' 0 CA--C 1.538 0.493 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.368 -179.708 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' C' C ' 3' ' ' GLU . . . . . . . . . . . . . 13.4 pt-20 -171.01 108.87 0.3 Allowed 'General case' 0 CA--C 1.546 0.79 0 CA-C-O 121.267 0.555 . . . . 0.0 110.053 179.039 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 29.9 m-85 -87.29 157.23 19.34 Favored 'General case' 0 N--CA 1.473 0.698 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 -179.846 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 77.4 mtt85 -140.08 145.46 37.68 Favored 'General case' 0 N--CA 1.478 0.965 0 C-N-CA 122.999 0.52 . . . . 0.0 109.797 179.766 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 57.9 t-80 -150.37 116.94 5.78 Favored 'General case' 0 N--CA 1.476 0.864 0 N-CA-C 109.655 -0.498 . . . . 0.0 109.655 179.087 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' C' C ' 7' ' ' ASP . . . . . . . . . . . . . 9.9 m-20 -66.89 144.39 56.28 Favored 'General case' 0 N--CA 1.472 0.643 0 O-C-N 123.444 0.465 . . . . 0.0 111.777 -179.728 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' C' C ' 8' ' ' SER . . . . . . . . . . . . . 2.3 t -163.92 -177.68 5.22 Favored 'General case' 0 N--CA 1.471 0.589 0 N-CA-C 109.873 -0.417 . . . . 0.0 109.873 178.247 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 85.97 70.47 1.32 Allowed Glycine 0 CA--C 1.532 1.125 0 CA-C-N 115.904 -0.589 . . . . 0.0 112.165 178.736 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 40.4 p90 -72.92 122.17 21.22 Favored 'General case' 0 N--CA 1.477 0.882 0 CA-C-N 117.331 0.565 . . . . 0.0 110.882 179.886 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 17.7 pt-20 -82.8 151.9 25.9 Favored 'General case' 0 N--CA 1.478 0.962 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 178.859 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 13.0 t -144.69 117.87 2.78 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.889 0 CA-C-O 121.621 0.724 . . . . 0.0 109.361 178.343 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 73.6 m80 -96.07 164.76 12.56 Favored 'General case' 0 C--N 1.358 0.947 0 CA-C-N 114.623 -1.171 . . . . 0.0 109.263 177.96 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' C' C ' 14' ' ' HIS . . . . . 0.462 ' HE2' ' NZ ' ' C' ' 16' ' ' LYS . 17.1 t60 -164.68 99.38 0.79 Allowed 'General case' 0 N--CA 1.476 0.83 0 N-CA-C 110.038 -0.356 . . . . 0.0 110.038 179.221 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -91.74 111.72 23.36 Favored 'General case' 0 CA--C 1.516 -0.359 0 N-CA-C 108.381 -0.97 . . . . 0.0 108.381 179.574 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' C' C ' 16' ' ' LYS . . . . . 0.462 ' NZ ' ' HE2' ' C' ' 14' ' ' HIS . 8.5 ttmm -94.51 171.45 8.8 Favored 'General case' 0 N--CA 1.483 1.185 0 N-CA-C 108.831 -0.803 . . . . 0.0 108.831 -179.841 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 9.7 mp -55.11 157.75 3.25 Favored 'General case' 0 N--CA 1.475 0.809 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 -178.424 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 71.3 t -140.75 150.43 20.69 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 C-N-CA 123.188 0.595 . . . . 0.0 109.663 -177.769 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' C' C ' 19' ' ' PHE . . . . . 0.681 ' HB3' ' O ' ' F' ' 18' ' ' VAL . 44.5 p90 -40.67 162.2 0.01 OUTLIER 'General case' 0 CA--C 1.543 0.677 0 N-CA-C 120.081 3.363 . . . . 0.0 120.081 -178.675 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' C' C ' 20' ' ' PHE . . . . . 0.414 ' CD2' ' O ' ' C' ' 20' ' ' PHE . 20.8 p90 -119.65 69.65 0.84 Allowed 'General case' 0 CA--C 1.562 1.437 0 CA-C-N 112.048 -2.342 . . . . 0.0 109.299 173.568 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -62.85 95.19 0.07 Allowed 'General case' 0 C--N 1.326 -0.454 0 N-CA-C 108.42 -0.956 . . . . 0.0 108.42 176.824 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 77.3 mt-10 -49.7 123.76 8.45 Favored 'General case' 0 N--CA 1.475 0.814 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.495 -179.862 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 16.5 t70 -76.63 169.16 18.8 Favored 'General case' 0 N--CA 1.472 0.631 0 CA-C-O 121.002 0.43 . . . . 0.0 110.713 -179.009 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' C' C ' 24' ' ' VAL . . . . . 0.487 HG13 ' H ' ' C' ' 25' ' ' GLY . 0.7 OUTLIER 178.25 -79.28 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.544 0.729 0 N-CA-C 107.458 -1.312 . . . . 0.0 107.458 -179.658 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' C' C ' 25' ' ' GLY . . . . . 0.487 ' H ' HG13 ' C' ' 24' ' ' VAL . . . -34.09 84.25 0.0 OUTLIER Glycine 0 N--CA 1.48 1.62 0 C-N-CA 124.356 0.979 . . . . 0.0 113.254 178.591 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' C' C ' 26' ' ' SER . . . . . 0.451 ' N ' ' O ' ' C' ' 24' ' ' VAL . 88.7 p -41.15 -105.25 0.0 OUTLIER 'General case' 0 N--CA 1.473 0.702 0 N-CA-C 113.692 0.997 . . . . 0.0 113.692 -177.334 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 16.6 p-10 -59.98 112.21 1.78 Allowed 'General case' 0 N--CA 1.468 0.474 0 CA-C-N 118.874 0.761 . . . . 0.0 110.381 -178.632 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 41.7 mttm -96.55 164.51 12.58 Favored 'General case' 0 N--CA 1.475 0.78 0 C-N-CA 123.204 0.602 . . . . 0.0 110.113 -179.53 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -72.87 -141.31 0.44 Allowed Glycine 0 N--CA 1.462 0.398 0 N-CA-C 107.769 -2.132 . . . . 0.0 107.769 176.535 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' C' C ' 30' ' ' ALA . . . . . 0.489 ' O ' ' O ' ' F' ' 31' ' ' ILE . . . -90.68 123.16 34.07 Favored 'General case' 0 C--O 1.211 -0.968 0 N-CA-C 106.775 -1.565 . . . . 0.0 106.775 176.58 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 16.6 tt -148.08 155.59 9.7 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.889 0 N-CA-C 107.888 -1.153 . . . . 0.0 107.888 179.186 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 20.2 pt -150.79 138.85 14.28 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.469 0 CA-C-N 118.943 0.792 . . . . 0.0 109.266 178.674 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -56.78 154.3 18.17 Favored Glycine 0 CA--C 1.531 1.088 0 CA-C-N 116.606 -0.27 . . . . 0.0 112.56 -178.656 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 2.5 pp -76.32 158.76 31.19 Favored 'General case' 0 N--CA 1.472 0.644 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 179.232 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 11.6 ttp -102.58 151.47 22.3 Favored 'General case' 0 N--CA 1.481 1.091 0 N-CA-C 109.449 -0.574 . . . . 0.0 109.449 179.649 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 7.3 p -168.55 159.88 0.71 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.542 0 N-CA-C 108.038 -1.097 . . . . 0.0 108.038 179.764 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.45 69.69 1.19 Allowed Glycine 0 C--N 1.312 -0.774 0 N-CA-C 111.611 -0.596 . . . . 0.0 111.611 178.826 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 151.95 -177.82 29.57 Favored Glycine 0 N--CA 1.468 0.792 0 N-CA-C 110.25 -1.14 . . . . 0.0 110.25 179.669 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 4.4 t -124.57 138.8 52.81 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.722 0 N-CA-C 107.335 -1.358 . . . . 0.0 107.335 -179.445 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 74.3 t . . . . . 0 N--CA 1.48 1.032 0 CA-C-O 117.771 -1.109 . . . . 0.0 109.696 -177.589 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' D' D ' 1' ' ' ASP . . . . . 0.403 ' CG ' ' H1 ' ' G' ' 1' ' ' ASP . 3.9 p-10 . . . . . 0 N--CA 1.487 1.396 0 N-CA-C 109.013 -0.736 . . . . 0.0 109.013 . . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' D' D ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.62 131.75 47.86 Favored 'General case' 0 N--CA 1.469 0.485 0 CA-C-N 116.501 -0.318 . . . . 0.0 111.441 -179.675 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' D' D ' 3' ' ' GLU . . . . . . . . . . . . . 13.2 pt-20 -169.65 108.24 0.4 Allowed 'General case' 0 CA--C 1.542 0.646 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.208 179.114 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 30.0 m-85 -88.09 159.89 18.04 Favored 'General case' 0 N--CA 1.475 0.784 0 N-CA-C 109.117 -0.698 . . . . 0.0 109.117 -179.318 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' D' D ' 5' ' ' ARG . . . . . . . . . . . . . 76.7 mtt85 -140.11 141.91 36.09 Favored 'General case' 0 N--CA 1.474 0.761 0 C-N-CA 123.974 0.909 . . . . 0.0 110.559 -178.702 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 54.3 t-80 -148.63 123.39 9.89 Favored 'General case' 0 CA--C 1.547 0.852 0 N-CA-C 107.86 -1.163 . . . . 0.0 107.86 174.848 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' D' D ' 7' ' ' ASP . . . . . . . . . . . . . 8.8 m-20 -63.47 133.17 53.45 Favored 'General case' 0 N--CA 1.469 0.496 0 C-N-CA 126.9 2.08 . . . . 0.0 114.15 176.313 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' D' D ' 8' ' ' SER . . . . . . . . . . . . . 2.4 t -154.35 -177.31 6.36 Favored 'General case' 0 N--CA 1.473 0.712 0 CA-C-N 118.895 0.771 . . . . 0.0 110.555 176.242 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 88.11 69.45 1.28 Allowed Glycine 0 N--CA 1.475 1.279 0 N-CA-C 111.33 -0.708 . . . . 0.0 111.33 174.523 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 35.2 p90 -70.82 124.34 24.09 Favored 'General case' 0 N--CA 1.476 0.837 0 CA-C-N 118.134 0.967 . . . . 0.0 110.507 -179.907 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 17.6 pt-20 -81.0 154.04 27.12 Favored 'General case' 0 C--N 1.363 1.162 0 C-N-CA 119.982 -0.687 . . . . 0.0 109.948 175.935 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 21.8 t -141.29 124.07 15.21 Favored 'Isoleucine or valine' 0 C--N 1.357 0.925 0 N-CA-C 107.945 -1.131 . . . . 0.0 107.945 171.011 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 61.5 m80 -89.03 164.37 15.1 Favored 'General case' 0 N--CA 1.472 0.657 0 C-N-CA 125.229 1.412 . . . . 0.0 112.607 171.865 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' D' D ' 14' ' ' HIS . . . . . 0.46 ' HE2' ' NZ ' ' D' ' 16' ' ' LYS . 17.1 t60 -163.82 104.91 0.92 Allowed 'General case' 0 N--CA 1.478 0.949 0 N-CA-C 109.0 -0.741 . . . . 0.0 109.0 171.671 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -95.24 111.45 23.3 Favored 'General case' 0 C--O 1.218 -0.59 0 N-CA-C 107.913 -1.143 . . . . 0.0 107.913 178.885 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' D' D ' 16' ' ' LYS . . . . . 0.46 ' NZ ' ' HE2' ' D' ' 14' ' ' HIS . 8.6 ttmm -95.49 169.93 9.7 Favored 'General case' 0 N--CA 1.487 1.409 0 C-N-CA 125.749 1.619 . . . . 0.0 108.715 -178.385 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 10.7 mp -65.79 156.23 33.82 Favored 'General case' 0 C--O 1.21 -0.975 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 -172.779 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' D' D ' 18' ' ' VAL . . . . . 0.671 ' O ' ' HB3' ' A' ' 19' ' ' PHE . 88.5 t -139.74 146.72 24.79 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.143 0 C-N-CA 126.183 1.793 . . . . 0.0 109.015 -168.808 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' D' D ' 19' ' ' PHE . . . . . 0.722 ' HB3' ' O ' ' G' ' 18' ' ' VAL 0.485 37.4 p90 -57.67 162.4 3.09 Favored 'General case' 0 C--N 1.391 2.403 0 N-CA-C 118.552 2.797 . . . . 0.0 118.552 -169.325 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' D' D ' 20' ' ' PHE . . . . . 0.404 ' O ' ' CD2' ' D' ' 20' ' ' PHE . 21.5 p90 -114.48 66.24 0.68 Allowed 'General case' 0 C--N 1.375 1.684 0 CA-C-N 112.958 -1.928 . . . . 0.0 110.608 -178.781 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -50.2 92.47 0.01 OUTLIER 'General case' 0 N--CA 1.441 -0.91 0 CA-C-N 113.448 -1.705 . . . . 0.0 110.669 173.675 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 77.0 mt-10 -52.69 125.53 16.98 Favored 'General case' 0 CA--C 1.547 0.843 0 CA-C-N 118.881 0.764 . . . . 0.0 110.306 -179.652 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 14.6 t70 -78.04 168.75 19.39 Favored 'General case' 0 N--CA 1.475 0.802 0 C-N-CA 122.764 0.426 . . . . 0.0 110.163 -179.747 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' D' D ' 24' ' ' VAL . . . . . 0.45 HG13 ' H ' ' D' ' 25' ' ' GLY 0.624 2.7 p -179.4 -100.54 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.203 -1.395 0 CA-C-O 125.938 2.78 . . . . 0.0 106.256 -164.685 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' D' D ' 25' ' ' GLY . . . . . 0.45 ' H ' HG13 ' D' ' 24' ' ' VAL . . . -24.32 71.59 0.0 OUTLIER Glycine 0 C--N 1.3 -1.46 0 C-N-CA 129.459 3.409 . . . . 0.0 116.907 178.476 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' D' D ' 26' ' ' SER . . . . . 0.401 ' OG ' ' N ' ' D' ' 27' ' ' ASN 0.381 78.9 p -52.69 -100.46 0.0 OUTLIER 'General case' 0 C--O 1.273 2.318 1 CA-C-O 110.787 -4.435 . . . . 0.0 107.203 -162.704 . . . . . . . . 4 3 . 1 . 020 nuclear orig full ' D' D ' 27' ' ' ASN . . . . . 0.503 ' N ' ' OD1' ' D' ' 27' ' ' ASN 0.409 11.7 p-10 -70.38 121.87 18.53 Favored 'General case' 0 N--CA 1.481 1.109 1 CA-C-N 129.149 5.431 . . . . 0.0 108.818 -168.719 . . . . . . . . 4 3 . 1 . 020 nuclear orig full ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 31.7 mttm -86.24 161.18 18.92 Favored 'General case' 0 C--N 1.364 1.23 0 CA-C-N 110.65 -2.977 . . . . 0.0 113.104 177.762 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -66.89 -145.13 0.07 OUTLIER Glycine 0 CA--C 1.535 1.331 0 N-CA-C 108.997 -1.641 . . . . 0.0 108.997 167.354 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' D' D ' 30' ' ' ALA . . . . . 0.489 ' O ' ' O ' ' G' ' 31' ' ' ILE . . . -92.12 123.45 35.47 Favored 'General case' 0 C--N 1.358 0.945 0 N-CA-C 106.708 -1.59 . . . . 0.0 106.708 174.207 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' D' D ' 31' ' ' ILE . . . . . 0.458 ' O ' ' O ' ' A' ' 30' ' ' ALA . 17.3 tt -144.73 155.42 14.42 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.451 0 N-CA-C 109.107 -0.701 . . . . 0.0 109.107 178.959 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 23.4 pt -150.99 135.31 8.94 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.912 0 CA-C-N 118.402 0.546 . . . . 0.0 110.035 178.939 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -52.85 153.9 6.47 Favored Glycine 0 N--CA 1.476 1.317 0 CA-C-N 116.32 -0.4 . . . . 0.0 112.891 -179.492 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 2.5 pp -76.46 159.85 30.05 Favored 'General case' 0 N--CA 1.473 0.677 0 N-CA-C 110.0 -0.37 . . . . 0.0 110.0 178.433 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 8.2 ttp -103.38 155.14 18.7 Favored 'General case' 0 N--CA 1.48 1.06 0 N-CA-C 108.655 -0.868 . . . . 0.0 108.655 178.781 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 6.7 p -167.04 163.73 0.58 Allowed 'Isoleucine or valine' 0 CA--C 1.507 -0.708 0 N-CA-C 107.456 -1.313 . . . . 0.0 107.456 177.054 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 59.32 63.9 4.74 Favored Glycine 0 C--N 1.319 -0.364 0 C-N-CA 118.733 -1.699 . . . . 0.0 113.143 174.397 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 148.4 179.73 24.58 Favored Glycine 0 N--CA 1.471 1.026 0 CA-C-N 118.0 0.9 . . . . 0.0 111.225 -177.175 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 5.5 t -122.2 138.42 52.47 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.86 0 N-CA-C 106.412 -1.699 . . . . 0.0 106.412 -177.546 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 77.1 t . . . . . 0 C--O 1.212 -0.887 0 N-CA-C 108.224 -1.028 . . . . 0.0 108.224 178.886 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' E' E ' 1' ' ' ASP . . . . . 0.405 ' CG ' ' H1 ' ' H' ' 1' ' ' ASP . 4.0 p-10 . . . . . 0 N--CA 1.485 1.321 0 N-CA-C 109.189 -0.671 . . . . 0.0 109.189 . . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' E' E ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.12 131.09 45.64 Favored 'General case' 0 CA--C 1.539 0.543 0 CA-C-O 120.835 0.35 . . . . 0.0 111.244 -179.265 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' E' E ' 3' ' ' GLU . . . . . . . . . . . . . 13.3 pt-20 -170.01 108.76 0.38 Allowed 'General case' 0 CA--C 1.543 0.709 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.059 179.397 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 27.7 m-85 -86.74 156.67 19.85 Favored 'General case' 0 N--CA 1.474 0.727 0 O-C-N 121.935 -0.478 . . . . 0.0 109.822 -179.696 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' E' E ' 5' ' ' ARG . . . . . . . . . . . . . 76.9 mtt85 -139.71 145.75 38.74 Favored 'General case' 0 N--CA 1.477 0.917 0 CA-C-N 115.978 -0.556 . . . . 0.0 110.015 179.378 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 57.9 t-80 -150.52 116.44 5.58 Favored 'General case' 0 N--CA 1.475 0.796 0 N-CA-C 109.472 -0.566 . . . . 0.0 109.472 179.239 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' E' E ' 7' ' ' ASP . . . . . . . . . . . . . 9.7 m-20 -66.11 148.64 51.51 Favored 'General case' 0 N--CA 1.47 0.549 0 O-C-N 123.259 0.349 . . . . 0.0 111.136 -179.825 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' E' E ' 8' ' ' SER . . . . . . . . . . . . . 2.2 t -167.45 -178.04 3.83 Favored 'General case' 0 N--CA 1.471 0.611 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 178.28 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 86.11 70.21 1.32 Allowed Glycine 0 CA--C 1.533 1.168 0 CA-C-N 115.964 -0.562 . . . . 0.0 112.089 178.779 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 34.2 p90 -71.65 121.87 19.58 Favored 'General case' 0 N--CA 1.479 1.008 0 CA-C-N 117.52 0.66 . . . . 0.0 110.771 179.704 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 17.4 pt-20 -83.01 152.77 25.27 Favored 'General case' 0 N--CA 1.482 1.159 0 N-CA-C 109.405 -0.591 . . . . 0.0 109.405 178.136 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 19.2 t -144.83 117.03 2.35 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.667 0 N-CA-C 109.478 -0.564 . . . . 0.0 109.478 178.831 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 73.8 m80 -95.33 165.89 12.16 Favored 'General case' 0 N--CA 1.475 0.794 0 N-CA-C 109.701 -0.481 . . . . 0.0 109.701 178.588 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' E' E ' 14' ' ' HIS . . . . . 0.447 ' NE2' ' NZ ' ' E' ' 16' ' ' LYS . 16.5 t60 -164.71 99.12 0.78 Allowed 'General case' 0 N--CA 1.478 0.971 0 N-CA-C 110.095 -0.335 . . . . 0.0 110.095 179.327 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -92.06 110.96 22.33 Favored 'General case' 0 CA--C 1.511 -0.548 0 N-CA-C 108.442 -0.948 . . . . 0.0 108.442 179.721 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' E' E ' 16' ' ' LYS . . . . . 0.447 ' NZ ' ' NE2' ' E' ' 14' ' ' HIS . 9.5 ttmm -93.53 172.04 8.52 Favored 'General case' 0 N--CA 1.485 1.303 0 N-CA-C 109.279 -0.638 . . . . 0.0 109.279 179.999 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 9.2 mp -55.11 155.98 4.32 Favored 'General case' 0 C--O 1.216 -0.693 0 N-CA-C 109.981 -0.377 . . . . 0.0 109.981 -178.599 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' E' E ' 18' ' ' VAL . . . . . 0.691 ' O ' ' HB3' ' B' ' 19' ' ' PHE . 79.5 t -141.48 150.61 19.62 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.966 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 -178.475 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' E' E ' 19' ' ' PHE . . . . . 0.693 ' HB3' ' O ' ' H' ' 18' ' ' VAL . 38.9 p90 -43.69 153.95 0.11 Allowed 'General case' 0 C--N 1.385 2.139 0 N-CA-C 120.387 3.477 . . . . 0.0 120.387 -177.216 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' E' E ' 20' ' ' PHE . . . . . 0.403 ' CD2' ' O ' ' E' ' 20' ' ' PHE . 20.8 p90 -111.62 66.95 0.64 Allowed 'General case' 0 N--CA 1.484 1.243 0 CA-C-N 113.938 -1.483 . . . . 0.0 111.495 175.007 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -58.64 93.96 0.02 OUTLIER 'General case' 0 N--CA 1.441 -0.919 0 CA-C-N 114.133 -1.394 . . . . 0.0 109.212 177.919 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 76.1 mt-10 -50.0 122.16 6.33 Favored 'General case' 0 N--CA 1.474 0.749 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.25 -179.712 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 18.4 t70 -75.03 173.51 10.62 Favored 'General case' 0 N--CA 1.466 0.349 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 -178.823 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' E' E ' 24' ' ' VAL . . . . . 0.522 HG13 ' H ' ' E' ' 25' ' ' GLY . 0.9 OUTLIER 173.71 -77.9 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.472 0.656 0 N-CA-C 107.896 -1.15 . . . . 0.0 107.896 -179.925 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' E' E ' 25' ' ' GLY . . . . . 0.522 ' H ' HG13 ' E' ' 24' ' ' VAL . . . -36.51 84.47 0.0 OUTLIER Glycine 0 CA--C 1.538 1.523 0 C-N-CA 124.102 0.858 . . . . 0.0 113.396 179.132 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' E' E ' 26' ' ' SER . . . . . 0.451 ' N ' ' O ' ' E' ' 24' ' ' VAL . 95.2 p -40.81 -107.11 0.0 OUTLIER 'General case' 0 N--CA 1.482 1.133 0 N-CA-C 114.25 1.204 . . . . 0.0 114.25 -177.544 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 16.5 p-10 -58.36 111.57 1.27 Allowed 'General case' 0 N--CA 1.473 0.688 0 CA-C-N 118.858 0.754 . . . . 0.0 110.067 -178.664 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 39.1 mttm -95.15 167.82 11.13 Favored 'General case' 0 N--CA 1.476 0.851 0 O-C-N 123.786 0.679 . . . . 0.0 109.588 -179.592 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -76.14 -140.17 0.94 Allowed Glycine 0 CA--C 1.524 0.652 0 N-CA-C 106.996 -2.441 . . . . 0.0 106.996 176.396 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' E' E ' 30' ' ' ALA . . . . . 0.458 ' O ' ' O ' ' H' ' 31' ' ' ILE . . . -91.82 126.34 36.87 Favored 'General case' 0 C--O 1.215 -0.723 0 N-CA-C 106.507 -1.664 . . . . 0.0 106.507 175.682 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' E' E ' 31' ' ' ILE . . . . . 0.491 ' O ' ' O ' ' B' ' 30' ' ' ALA . 16.6 tt -149.87 155.62 7.81 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.604 0 N-CA-C 108.077 -1.083 . . . . 0.0 108.077 179.07 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 19.2 pt -152.61 138.14 11.21 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.628 0 N-CA-C 109.096 -0.705 . . . . 0.0 109.096 -179.509 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -57.56 154.65 20.98 Favored Glycine 0 N--CA 1.474 1.174 0 CA-C-N 115.407 -0.815 . . . . 0.0 112.66 -177.851 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 2.5 pp -75.98 160.32 29.97 Favored 'General case' 0 N--CA 1.469 0.505 0 N-CA-C 109.64 -0.504 . . . . 0.0 109.64 179.244 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 7.7 ttp -104.91 151.95 23.24 Favored 'General case' 0 N--CA 1.48 1.052 0 N-CA-C 109.259 -0.645 . . . . 0.0 109.259 179.454 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 7.5 p -168.13 159.93 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.446 -0.641 0 N-CA-C 107.844 -1.169 . . . . 0.0 107.844 179.744 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 53.85 70.87 0.81 Allowed Glycine 0 C--N 1.313 -0.72 0 O-C-N 123.381 0.426 . . . . 0.0 112.328 179.365 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 153.06 -177.14 30.86 Favored Glycine 0 N--CA 1.461 0.367 0 N-CA-C 110.131 -1.188 . . . . 0.0 110.131 179.556 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 5.5 t -126.7 137.08 58.93 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.361 0 N-CA-C 106.259 -1.756 . . . . 0.0 106.259 -178.867 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 75.1 t . . . . . 0 N--CA 1.474 0.754 0 CA-C-O 117.649 -1.167 . . . . 0.0 109.504 -176.889 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' F' F ' 1' ' ' ASP . . . . . 0.413 ' CG ' ' H1 ' ' I' ' 1' ' ' ASP . 4.0 p-10 . . . . . 0 N--CA 1.487 1.398 0 N-CA-C 109.157 -0.682 . . . . 0.0 109.157 . . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' F' F ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.14 131.26 46.07 Favored 'General case' 0 CA--C 1.539 0.554 0 CA-C-O 120.808 0.337 . . . . 0.0 111.132 -179.206 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' F' F ' 3' ' ' GLU . . . . . . . . . . . . . 13.3 pt-20 -170.17 108.73 0.37 Allowed 'General case' 0 CA--C 1.545 0.767 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.002 179.436 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 27.7 m-85 -86.76 156.66 19.84 Favored 'General case' 0 N--CA 1.472 0.672 0 N-CA-C 109.676 -0.49 . . . . 0.0 109.676 -179.673 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' F' F ' 5' ' ' ARG . . . . . . . . . . . . . 76.8 mtt85 -139.61 145.34 38.4 Favored 'General case' 0 N--CA 1.479 0.98 0 CA-C-N 115.861 -0.609 . . . . 0.0 109.96 179.427 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 57.7 t-80 -150.33 116.31 5.61 Favored 'General case' 0 N--CA 1.475 0.776 0 N-CA-C 109.61 -0.515 . . . . 0.0 109.61 179.158 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' F' F ' 7' ' ' ASP . . . . . . . . . . . . . 9.8 m-20 -65.84 148.42 51.81 Favored 'General case' 0 N--CA 1.469 0.515 0 O-C-N 123.261 0.351 . . . . 0.0 111.301 -179.813 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' F' F ' 8' ' ' SER . . . . . . . . . . . . . 2.2 t -167.37 -178.0 3.85 Favored 'General case' 0 N--CA 1.471 0.59 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 178.214 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 86.25 70.15 1.32 Allowed Glycine 0 CA--C 1.532 1.143 0 CA-C-N 115.972 -0.558 . . . . 0.0 112.113 178.734 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 34.6 p90 -71.7 121.71 19.34 Favored 'General case' 0 N--CA 1.476 0.858 0 CA-C-N 117.514 0.657 . . . . 0.0 110.95 179.739 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 17.4 pt-20 -82.79 152.69 25.57 Favored 'General case' 0 N--CA 1.481 1.116 0 N-CA-C 109.399 -0.593 . . . . 0.0 109.399 178.156 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 19.3 t -144.83 117.02 2.35 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.635 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 178.795 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 73.8 m80 -95.3 165.94 12.14 Favored 'General case' 0 N--CA 1.476 0.871 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 178.534 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' F' F ' 14' ' ' HIS . . . . . 0.468 ' HE2' ' NZ ' ' F' ' 16' ' ' LYS . 16.4 t60 -164.66 98.86 0.79 Allowed 'General case' 0 N--CA 1.478 0.969 0 N-CA-C 110.224 -0.287 . . . . 0.0 110.224 179.394 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -91.74 110.93 22.27 Favored 'General case' 0 CA--C 1.507 -0.693 0 N-CA-C 108.376 -0.972 . . . . 0.0 108.376 179.655 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' F' F ' 16' ' ' LYS . . . . . 0.468 ' NZ ' ' HE2' ' F' ' 14' ' ' HIS . 9.7 ttmm -93.59 171.75 8.7 Favored 'General case' 0 N--CA 1.484 1.258 0 N-CA-C 109.224 -0.658 . . . . 0.0 109.224 179.919 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 9.2 mp -54.8 155.84 4.05 Favored 'General case' 0 N--CA 1.472 0.671 0 N-CA-C 110.044 -0.354 . . . . 0.0 110.044 -178.625 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' F' F ' 18' ' ' VAL . . . . . 0.681 ' O ' ' HB3' ' C' ' 19' ' ' PHE . 79.0 t -141.43 150.49 19.75 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.955 0 N-CA-C 107.929 -1.138 . . . . 0.0 107.929 -178.409 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' F' F ' 19' ' ' PHE . . . . . 0.715 ' HB3' ' O ' ' I' ' 18' ' ' VAL . 38.6 p90 -43.48 153.63 0.11 Allowed 'General case' 0 C--N 1.384 2.101 0 N-CA-C 120.41 3.485 . . . . 0.0 120.41 -177.232 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' F' F ' 20' ' ' PHE . . . . . 0.415 ' O ' ' CD2' ' F' ' 20' ' ' PHE . 20.1 p90 -111.46 67.25 0.64 Allowed 'General case' 0 N--CA 1.48 1.053 0 CA-C-N 113.947 -1.479 . . . . 0.0 111.538 175.029 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -58.82 94.27 0.02 OUTLIER 'General case' 0 C--N 1.317 -0.843 0 CA-C-N 114.211 -1.359 . . . . 0.0 109.262 178.074 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 76.5 mt-10 -50.29 122.28 6.71 Favored 'General case' 0 N--CA 1.476 0.85 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.296 -179.743 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 18.2 t70 -75.06 173.54 10.6 Favored 'General case' 0 N--CA 1.468 0.429 0 N-CA-C 110.031 -0.359 . . . . 0.0 110.031 -178.852 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' F' F ' 24' ' ' VAL . . . . . 0.498 HG13 ' H ' ' F' ' 25' ' ' GLY . 0.9 OUTLIER 173.83 -78.35 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.728 0 N-CA-C 107.934 -1.136 . . . . 0.0 107.934 -179.828 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' F' F ' 25' ' ' GLY . . . . . 0.498 ' H ' HG13 ' F' ' 24' ' ' VAL . . . -36.7 84.95 0.01 OUTLIER Glycine 0 CA--C 1.536 1.382 0 C-N-CA 124.045 0.831 . . . . 0.0 113.354 179.294 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' F' F ' 26' ' ' SER . . . . . 0.45 ' N ' ' O ' ' F' ' 24' ' ' VAL . 96.0 p -40.82 -107.11 0.0 OUTLIER 'General case' 0 N--CA 1.479 0.989 0 N-CA-C 114.19 1.181 . . . . 0.0 114.19 -177.696 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 16.6 p-10 -58.42 111.55 1.27 Allowed 'General case' 0 N--CA 1.472 0.654 0 CA-C-N 118.804 0.729 . . . . 0.0 110.171 -178.69 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 38.9 mttm -95.08 167.71 11.21 Favored 'General case' 0 N--CA 1.477 0.918 0 C-N-CA 123.392 0.677 . . . . 0.0 109.597 -179.553 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -76.03 -139.98 0.9 Allowed Glycine 0 CA--C 1.525 0.702 0 N-CA-C 107.113 -2.395 . . . . 0.0 107.113 176.403 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' F' F ' 30' ' ' ALA . . . . . 0.456 ' O ' ' O ' ' I' ' 31' ' ' ILE . . . -91.97 126.37 37.03 Favored 'General case' 0 N--CA 1.472 0.635 0 N-CA-C 106.227 -1.768 . . . . 0.0 106.227 175.706 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' F' F ' 31' ' ' ILE . . . . . 0.489 ' O ' ' O ' ' C' ' 30' ' ' ALA . 16.6 tt -150.01 155.29 8.01 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.619 0 N-CA-C 108.078 -1.082 . . . . 0.0 108.078 179.221 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 19.3 pt -152.48 138.34 11.7 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.651 0 N-CA-C 109.157 -0.683 . . . . 0.0 109.157 -179.482 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -57.63 154.54 21.62 Favored Glycine 0 N--CA 1.474 1.18 0 CA-C-N 115.421 -0.808 . . . . 0.0 112.622 -177.74 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 2.5 pp -75.96 160.51 29.8 Favored 'General case' 0 N--CA 1.47 0.543 0 N-CA-C 109.58 -0.526 . . . . 0.0 109.58 179.14 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 7.6 ttp -105.15 152.08 23.24 Favored 'General case' 0 N--CA 1.479 0.986 0 N-CA-C 109.313 -0.625 . . . . 0.0 109.313 179.528 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 7.5 p -168.19 160.23 0.72 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.625 0 N-CA-C 107.837 -1.172 . . . . 0.0 107.837 179.631 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 53.76 70.89 0.8 Allowed Glycine 0 C--N 1.313 -0.745 0 O-C-N 123.448 0.467 . . . . 0.0 112.425 179.4 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 152.97 -177.19 30.77 Favored Glycine 0 N--CA 1.461 0.364 0 N-CA-C 110.08 -1.208 . . . . 0.0 110.08 179.538 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 5.3 t -126.45 136.81 59.7 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.347 0 N-CA-C 106.242 -1.762 . . . . 0.0 106.242 -178.852 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 76.4 t . . . . . 0 N--CA 1.47 0.567 0 CA-C-O 117.597 -1.192 . . . . 0.0 109.692 -176.926 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' G' G ' 1' ' ' ASP . . . . . 0.403 ' H1 ' ' CG ' ' D' ' 1' ' ' ASP . 4.1 p-10 . . . . . 0 N--CA 1.486 1.337 0 N-CA-C 108.508 -0.923 . . . . 0.0 108.508 . . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' G' G ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.61 132.82 49.77 Favored 'General case' 0 CA--C 1.538 0.505 0 CA-C-O 120.828 0.347 . . . . 0.0 110.97 -178.906 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' G' G ' 3' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -170.2 108.74 0.37 Allowed 'General case' 0 CA--C 1.544 0.727 0 N-CA-C 109.636 -0.505 . . . . 0.0 109.636 179.63 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 30.3 m-85 -85.87 156.94 20.33 Favored 'General case' 0 N--CA 1.474 0.748 0 O-C-N 122.015 -0.428 . . . . 0.0 109.849 -179.342 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' G' G ' 5' ' ' ARG . . . . . . . . . . . . . 77.0 mtt85 -140.01 145.14 37.41 Favored 'General case' 0 N--CA 1.481 1.095 0 N-CA-C 109.688 -0.486 . . . . 0.0 109.688 179.515 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 58.7 t-80 -150.03 117.38 6.06 Favored 'General case' 0 N--CA 1.473 0.675 0 N-CA-C 109.209 -0.663 . . . . 0.0 109.209 179.217 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 12.4 m-20 -66.89 148.39 52.0 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.961 -179.83 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' G' G ' 8' ' ' SER . . . . . . . . . . . . . 3.5 t -166.93 -179.38 4.67 Favored 'General case' 0 N--CA 1.472 0.674 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.095 178.342 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 85.44 71.95 1.3 Allowed Glycine 0 N--CA 1.477 1.406 0 CA-C-N 116.144 -0.48 . . . . 0.0 112.247 179.015 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 38.5 p90 -72.84 122.03 20.92 Favored 'General case' 0 N--CA 1.477 0.887 0 CA-C-N 117.098 0.449 . . . . 0.0 110.76 179.353 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 17.7 pt-20 -83.28 153.16 24.8 Favored 'General case' 0 N--CA 1.478 0.932 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 178.263 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 22.0 t -143.76 117.64 3.53 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.006 0 CA-C-O 118.527 -0.749 . . . . 0.0 109.032 179.003 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 76.7 m80 -95.42 167.36 11.37 Favored 'General case' 0 N--CA 1.486 1.374 0 CA-C-N 119.569 1.077 . . . . 0.0 109.521 178.597 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' G' G ' 14' ' ' HIS . . . . . 0.455 ' HE2' ' NZ ' ' G' ' 16' ' ' LYS . 16.1 t60 -164.42 98.1 0.8 Allowed 'General case' 0 N--CA 1.479 1.014 0 N-CA-C 110.061 -0.348 . . . . 0.0 110.061 179.216 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -91.63 111.67 23.28 Favored 'General case' 0 CA--C 1.509 -0.6 0 N-CA-C 107.904 -1.146 . . . . 0.0 107.904 179.479 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' G' G ' 16' ' ' LYS . . . . . 0.455 ' NZ ' ' HE2' ' G' ' 14' ' ' HIS . 9.1 ttmm -93.61 171.97 8.56 Favored 'General case' 0 N--CA 1.485 1.315 0 N-CA-C 109.314 -0.624 . . . . 0.0 109.314 -179.86 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 9.5 mp -55.14 152.24 8.23 Favored 'General case' 0 N--CA 1.471 0.606 0 CA-C-O 121.147 0.498 . . . . 0.0 110.366 -178.829 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' G' G ' 18' ' ' VAL . . . . . 0.722 ' O ' ' HB3' ' D' ' 19' ' ' PHE . 87.0 t -138.13 150.9 24.77 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.622 0 N-CA-C 107.635 -1.246 . . . . 0.0 107.635 -179.166 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' G' G ' 19' ' ' PHE . . . . . 0.475 ' O ' ' CG ' ' D' ' 19' ' ' PHE . 29.3 p90 -44.26 149.22 0.38 Allowed 'General case' 0 C--N 1.406 3.034 0 O-C-N 128.483 3.615 . . . . 0.0 117.721 -175.283 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' G' G ' 20' ' ' PHE . . . . . 0.401 ' CD2' ' O ' ' G' ' 20' ' ' PHE . 23.0 p90 -109.77 62.54 0.6 Allowed 'General case' 0 N--CA 1.496 1.855 0 CA-C-O 122.787 1.28 . . . . 0.0 112.681 177.685 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -53.66 94.3 0.01 OUTLIER 'General case' 0 N--CA 1.445 -0.709 0 CA-C-N 113.928 -1.487 . . . . 0.0 110.303 179.933 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 74.5 mt-10 -51.3 120.3 4.9 Favored 'General case' 0 CA--C 1.541 0.612 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.274 179.912 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 19.2 t70 -73.47 173.66 9.31 Favored 'General case' 0 N--CA 1.468 0.443 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 -178.905 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' G' G ' 24' ' ' VAL . . . . . 0.486 HG13 ' H ' ' G' ' 25' ' ' GLY . 0.9 OUTLIER 174.18 -79.19 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.755 0 N-CA-C 108.221 -1.029 . . . . 0.0 108.221 -179.773 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' G' G ' 25' ' ' GLY . . . . . 0.486 ' H ' HG13 ' G' ' 24' ' ' VAL . . . -37.51 85.91 0.01 OUTLIER Glycine 0 N--CA 1.479 1.54 0 C-N-CA 123.698 0.666 . . . . 0.0 113.171 179.658 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' G' G ' 26' ' ' SER . . . . . 0.441 ' N ' ' O ' ' G' ' 24' ' ' VAL . 90.6 p -40.95 -105.81 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.882 0 N-CA-C 113.877 1.066 . . . . 0.0 113.877 -177.506 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 16.9 p-10 -59.46 110.38 1.1 Allowed 'General case' 0 N--CA 1.473 0.71 0 CA-C-N 118.908 0.776 . . . . 0.0 110.63 -178.795 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 41.7 mttm -93.27 167.82 11.49 Favored 'General case' 0 N--CA 1.47 0.542 0 CA-C-N 115.823 -0.626 . . . . 0.0 109.669 -179.728 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -75.76 -140.28 0.87 Allowed Glycine 0 CA--C 1.525 0.698 0 N-CA-C 106.209 -2.757 . . . . 0.0 106.209 176.236 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -93.64 125.95 38.54 Favored 'General case' 0 N--CA 1.469 0.489 0 N-CA-C 107.154 -1.425 . . . . 0.0 107.154 176.23 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' G' G ' 31' ' ' ILE . . . . . 0.489 ' O ' ' O ' ' D' ' 30' ' ' ALA . 16.4 tt -149.86 155.37 8.04 Favored 'Isoleucine or valine' 0 C--O 1.211 -0.936 0 N-CA-C 108.783 -0.821 . . . . 0.0 108.783 179.786 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 26.7 pt -151.42 136.33 10.21 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.434 0 N-CA-C 109.287 -0.634 . . . . 0.0 109.287 -177.588 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -56.58 154.3 17.24 Favored Glycine 0 CA--C 1.526 0.76 0 CA-C-N 116.147 -0.479 . . . . 0.0 112.179 -178.543 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 2.5 pp -75.63 160.7 29.82 Favored 'General case' 0 N--CA 1.466 0.369 0 N-CA-C 109.499 -0.556 . . . . 0.0 109.499 179.313 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 6.6 ttp -104.78 152.21 22.84 Favored 'General case' 0 N--CA 1.48 1.046 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 179.378 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 7.4 p -168.69 162.22 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 N-CA-C 107.343 -1.355 . . . . 0.0 107.343 179.632 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 54.08 68.93 1.4 Allowed Glycine 0 C--N 1.312 -0.774 0 N-CA-C 111.848 -0.501 . . . . 0.0 111.848 178.77 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 152.66 -178.31 29.88 Favored Glycine 0 N--CA 1.465 0.581 0 N-CA-C 110.473 -1.051 . . . . 0.0 110.473 179.7 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 4.3 t -124.67 138.59 53.55 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.844 0 N-CA-C 107.098 -1.445 . . . . 0.0 107.098 -180.0 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 74.1 t . . . . . 0 N--CA 1.482 1.135 0 CA-C-O 117.788 -1.101 . . . . 0.0 109.8 -177.213 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' H' H ' 1' ' ' ASP . . . . . 0.405 ' H1 ' ' CG ' ' E' ' 1' ' ' ASP . 4.0 p-10 . . . . . 0 N--CA 1.487 1.421 0 N-CA-C 108.509 -0.923 . . . . 0.0 108.509 . . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' H' H ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.74 132.99 50.08 Favored 'General case' 0 N--CA 1.469 0.495 0 CA-C-O 120.904 0.383 . . . . 0.0 110.94 -179.035 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' H' H ' 3' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -170.24 108.77 0.36 Allowed 'General case' 0 CA--C 1.542 0.661 0 N-CA-C 109.552 -0.536 . . . . 0.0 109.552 179.662 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 31.6 m-85 -85.98 157.21 20.17 Favored 'General case' 0 N--CA 1.473 0.712 0 N-CA-C 109.641 -0.503 . . . . 0.0 109.641 -179.325 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' H' H ' 5' ' ' ARG . . . . . . . . . . . . . 77.1 mtt85 -140.26 145.31 37.15 Favored 'General case' 0 N--CA 1.479 0.979 0 C-N-CA 122.86 0.464 . . . . 0.0 109.801 179.485 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 58.7 t-80 -150.28 117.59 6.04 Favored 'General case' 0 N--CA 1.475 0.786 0 N-CA-C 109.423 -0.584 . . . . 0.0 109.423 179.216 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 12.6 m-20 -67.02 148.17 52.29 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-N 116.386 -0.37 . . . . 0.0 111.078 -179.79 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' H' H ' 8' ' ' SER . . . . . . . . . . . . . 3.5 t -166.86 -179.29 4.66 Favored 'General case' 0 N--CA 1.471 0.598 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.151 178.326 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 85.36 71.68 1.31 Allowed Glycine 0 N--CA 1.477 1.406 0 CA-C-N 116.166 -0.47 . . . . 0.0 112.211 179.098 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 38.3 p90 -72.62 122.2 21.0 Favored 'General case' 0 N--CA 1.474 0.762 0 O-C-N 122.437 -0.449 . . . . 0.0 110.712 179.468 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 17.7 pt-20 -83.39 153.03 24.75 Favored 'General case' 0 N--CA 1.48 1.042 0 N-CA-C 109.294 -0.632 . . . . 0.0 109.294 178.37 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 21.8 t -143.81 116.83 3.12 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.029 0 CA-C-O 118.546 -0.74 . . . . 0.0 109.292 178.952 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 76.5 m80 -94.66 167.26 11.57 Favored 'General case' 0 N--CA 1.484 1.272 0 CA-C-N 119.441 1.018 . . . . 0.0 109.603 178.556 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' H' H ' 14' ' ' HIS . . . . . 0.442 ' NE2' ' NZ ' ' H' ' 16' ' ' LYS . 16.1 t60 -164.41 98.12 0.8 Allowed 'General case' 0 N--CA 1.479 0.979 0 N-CA-C 110.019 -0.363 . . . . 0.0 110.019 179.184 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -91.5 111.76 23.4 Favored 'General case' 0 CA--C 1.511 -0.544 0 N-CA-C 107.891 -1.151 . . . . 0.0 107.891 179.459 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' H' H ' 16' ' ' LYS . . . . . 0.442 ' NZ ' ' NE2' ' H' ' 14' ' ' HIS . 9.1 ttmm -93.72 172.06 8.49 Favored 'General case' 0 N--CA 1.486 1.338 0 N-CA-C 109.344 -0.613 . . . . 0.0 109.344 -179.768 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 9.4 mp -55.16 152.29 8.2 Favored 'General case' 0 N--CA 1.472 0.656 0 CA-C-O 121.152 0.501 . . . . 0.0 110.382 -178.921 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' H' H ' 18' ' ' VAL . . . . . 0.693 ' O ' ' HB3' ' E' ' 19' ' ' PHE . 89.0 t -138.23 151.15 24.71 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.711 0 N-CA-C 107.783 -1.191 . . . . 0.0 107.783 -179.158 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' H' H ' 19' ' ' PHE . . . . . 0.47 ' O ' ' CG ' ' E' ' 19' ' ' PHE . 29.5 p90 -44.73 149.0 0.45 Allowed 'General case' 0 C--N 1.406 3.033 0 O-C-N 128.487 3.617 . . . . 0.0 117.613 -175.055 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 23.3 p90 -109.56 62.45 0.6 Allowed 'General case' 0 N--CA 1.498 1.953 0 CA-C-O 122.758 1.266 . . . . 0.0 112.533 177.805 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -53.64 94.37 0.01 OUTLIER 'General case' 0 N--CA 1.446 -0.652 0 CA-C-N 113.954 -1.475 . . . . 0.0 110.211 179.947 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 74.8 mt-10 -51.45 120.18 4.85 Favored 'General case' 0 CA--C 1.541 0.62 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.297 179.91 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 19.0 t70 -73.47 173.34 9.77 Favored 'General case' 0 N--CA 1.466 0.355 0 N-CA-C 109.943 -0.391 . . . . 0.0 109.943 -178.897 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' H' H ' 24' ' ' VAL . . . . . 0.493 HG13 ' H ' ' H' ' 25' ' ' GLY . 0.9 OUTLIER 174.52 -79.16 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.542 0.661 0 N-CA-C 108.149 -1.056 . . . . 0.0 108.149 -179.693 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' H' H ' 25' ' ' GLY . . . . . 0.493 ' H ' HG13 ' H' ' 24' ' ' VAL . . . -37.33 85.74 0.01 OUTLIER Glycine 0 N--CA 1.478 1.455 0 C-N-CA 123.732 0.682 . . . . 0.0 113.269 179.646 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' H' H ' 26' ' ' SER . . . . . 0.437 ' N ' ' O ' ' H' ' 24' ' ' VAL . 89.5 p -40.64 -106.07 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.885 0 N-CA-C 113.614 0.968 . . . . 0.0 113.614 -177.789 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 17.0 p-10 -59.35 110.36 1.07 Allowed 'General case' 0 N--CA 1.473 0.686 0 CA-C-N 118.941 0.791 . . . . 0.0 110.68 -178.771 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 41.7 mttm -93.46 167.42 11.72 Favored 'General case' 0 N--CA 1.468 0.461 0 CA-C-N 115.757 -0.656 . . . . 0.0 109.701 -179.896 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -75.43 -140.22 0.79 Allowed Glycine 0 CA--C 1.524 0.645 0 N-CA-C 106.262 -2.735 . . . . 0.0 106.262 176.218 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -93.7 125.92 38.58 Favored 'General case' 0 N--CA 1.47 0.529 0 N-CA-C 107.14 -1.43 . . . . 0.0 107.14 176.342 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' H' H ' 31' ' ' ILE . . . . . 0.458 ' O ' ' O ' ' E' ' 30' ' ' ALA . 16.4 tt -150.02 155.32 7.97 Favored 'Isoleucine or valine' 0 C--O 1.213 -0.846 0 N-CA-C 108.658 -0.867 . . . . 0.0 108.658 179.673 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 27.3 pt -151.38 136.27 10.16 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.399 0 N-CA-C 109.243 -0.651 . . . . 0.0 109.243 -177.526 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -56.69 154.49 17.26 Favored Glycine 0 CA--C 1.528 0.854 0 CA-C-N 116.166 -0.47 . . . . 0.0 112.193 -178.442 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 2.5 pp -75.59 160.78 29.76 Favored 'General case' 0 N--CA 1.467 0.418 0 N-CA-C 109.515 -0.55 . . . . 0.0 109.515 179.37 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 6.5 ttp -104.83 152.17 22.93 Favored 'General case' 0 N--CA 1.48 1.027 0 N-CA-C 109.102 -0.703 . . . . 0.0 109.102 179.343 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 7.4 p -168.81 162.29 0.56 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.487 0 N-CA-C 107.209 -1.404 . . . . 0.0 107.209 179.639 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 54.14 68.87 1.43 Allowed Glycine 0 C--N 1.311 -0.828 0 N-CA-C 111.853 -0.499 . . . . 0.0 111.853 178.721 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 152.41 -178.26 29.7 Favored Glycine 0 N--CA 1.466 0.697 0 N-CA-C 110.564 -1.014 . . . . 0.0 110.564 179.781 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 4.4 t -124.58 138.58 53.54 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.788 0 N-CA-C 107.077 -1.453 . . . . 0.0 107.077 -179.931 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 75.2 t . . . . . 0 N--CA 1.483 1.217 0 CA-C-O 117.755 -1.117 . . . . 0.0 109.813 -177.254 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' I' I ' 1' ' ' ASP . . . . . 0.413 ' H1 ' ' CG ' ' F' ' 1' ' ' ASP . 4.0 p-10 . . . . . 0 N--CA 1.487 1.414 0 N-CA-C 108.509 -0.923 . . . . 0.0 108.509 . . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' I' I ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.68 132.83 49.75 Favored 'General case' 0 CA--C 1.538 0.494 0 CA-C-O 120.916 0.388 . . . . 0.0 110.883 -178.955 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' I' I ' 3' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -170.16 108.61 0.37 Allowed 'General case' 0 CA--C 1.542 0.659 0 CA-C-N 116.068 -0.515 . . . . 0.0 109.613 179.684 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 31.0 m-85 -85.84 157.24 20.26 Favored 'General case' 0 N--CA 1.474 0.763 0 O-C-N 121.9 -0.5 . . . . 0.0 109.7 -179.293 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' I' I ' 5' ' ' ARG . . . . . . . . . . . . . 77.0 mtt85 -140.3 145.26 37.02 Favored 'General case' 0 N--CA 1.48 1.038 0 C-N-CA 122.896 0.478 . . . . 0.0 109.798 179.514 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 58.7 t-80 -150.25 117.4 5.98 Favored 'General case' 0 N--CA 1.474 0.746 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 179.226 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 12.3 m-20 -66.76 148.15 52.31 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-N 116.379 -0.373 . . . . 0.0 111.014 -179.848 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' I' I ' 8' ' ' SER . . . . . . . . . . . . . 3.5 t -166.81 -179.31 4.7 Favored 'General case' 0 N--CA 1.472 0.67 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.082 178.3 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 85.36 71.72 1.31 Allowed Glycine 0 N--CA 1.476 1.355 0 CA-C-N 116.14 -0.482 . . . . 0.0 112.232 179.086 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 38.0 p90 -72.48 121.95 20.46 Favored 'General case' 0 N--CA 1.476 0.837 0 O-C-N 122.356 -0.496 . . . . 0.0 110.745 179.38 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 17.7 pt-20 -83.2 153.02 24.96 Favored 'General case' 0 N--CA 1.478 0.959 0 N-CA-C 109.279 -0.638 . . . . 0.0 109.279 178.361 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 21.8 t -143.78 116.83 3.14 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.097 0 CA-C-O 118.584 -0.722 . . . . 0.0 109.326 178.928 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 76.5 m80 -94.69 167.24 11.58 Favored 'General case' 0 N--CA 1.485 1.317 0 CA-C-N 119.505 1.048 . . . . 0.0 109.574 178.603 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' I' I ' 14' ' ' HIS . . . . . 0.458 ' HE2' ' NZ ' ' I' ' 16' ' ' LYS . 15.9 t60 -164.41 98.01 0.8 Allowed 'General case' 0 N--CA 1.479 0.991 0 N-CA-C 110.181 -0.303 . . . . 0.0 110.181 179.149 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -91.43 111.63 23.21 Favored 'General case' 0 CA--C 1.509 -0.632 0 N-CA-C 107.94 -1.133 . . . . 0.0 107.94 179.49 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' I' I ' 16' ' ' LYS . . . . . 0.458 ' NZ ' ' HE2' ' I' ' 14' ' ' HIS . 9.1 ttmm -93.62 172.11 8.47 Favored 'General case' 0 N--CA 1.485 1.304 0 N-CA-C 109.362 -0.607 . . . . 0.0 109.362 -179.778 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 9.5 mp -55.17 152.29 8.24 Favored 'General case' 0 N--CA 1.472 0.652 0 CA-C-O 121.15 0.5 . . . . 0.0 110.3 -178.857 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' I' I ' 18' ' ' VAL . . . . . 0.715 ' O ' ' HB3' ' F' ' 19' ' ' PHE . 88.8 t -138.21 151.28 24.86 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.634 0 N-CA-C 107.683 -1.228 . . . . 0.0 107.683 -179.218 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' I' I ' 19' ' ' PHE . . . . . 0.466 ' O ' ' CG ' ' F' ' 19' ' ' PHE . 29.1 p90 -44.83 148.93 0.47 Allowed 'General case' 0 C--N 1.407 3.093 0 O-C-N 128.378 3.549 . . . . 0.0 117.57 -175.06 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 23.2 p90 -109.5 62.48 0.6 Allowed 'General case' 0 N--CA 1.497 1.904 0 CA-C-O 122.764 1.268 . . . . 0.0 112.522 177.763 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -53.65 94.42 0.01 OUTLIER 'General case' 0 N--CA 1.446 -0.673 0 CA-C-N 113.901 -1.499 . . . . 0.0 110.201 179.947 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 74.5 mt-10 -51.4 120.17 4.82 Favored 'General case' 0 CA--C 1.541 0.634 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.375 179.929 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 18.9 t70 -73.52 173.13 10.11 Favored 'General case' 0 N--CA 1.467 0.404 0 N-CA-C 109.98 -0.378 . . . . 0.0 109.98 -178.9 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' I' I ' 24' ' ' VAL . . . . . 0.468 HG13 ' H ' ' I' ' 25' ' ' GLY . 0.9 OUTLIER 174.61 -79.24 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.544 0.738 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 -179.745 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' I' I ' 25' ' ' GLY . . . . . 0.468 ' H ' HG13 ' I' ' 24' ' ' VAL . . . -37.29 85.87 0.01 OUTLIER Glycine 0 N--CA 1.48 1.63 0 C-N-CA 123.61 0.624 . . . . 0.0 113.229 179.636 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' I' I ' 26' ' ' SER . . . . . 0.44 ' N ' ' O ' ' I' ' 24' ' ' VAL . 87.7 p -40.77 -105.58 0.0 OUTLIER 'General case' 0 N--CA 1.478 0.949 0 N-CA-C 113.6 0.963 . . . . 0.0 113.6 -177.748 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 17.0 p-10 -59.68 110.4 1.13 Allowed 'General case' 0 N--CA 1.473 0.688 0 CA-C-N 118.993 0.815 . . . . 0.0 110.64 -178.754 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 41.6 mttm -93.53 167.53 11.63 Favored 'General case' 0 N--CA 1.469 0.517 0 CA-C-N 115.788 -0.642 . . . . 0.0 109.778 -179.912 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -75.39 -140.21 0.78 Allowed Glycine 0 CA--C 1.525 0.709 0 N-CA-C 106.361 -2.695 . . . . 0.0 106.361 176.289 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -93.65 125.82 38.47 Favored 'General case' 0 N--CA 1.469 0.508 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 176.242 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' I' I ' 31' ' ' ILE . . . . . 0.456 ' O ' ' O ' ' F' ' 30' ' ' ALA . 16.3 tt -149.91 155.24 8.12 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.806 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 179.688 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 27.5 pt -151.3 136.26 10.26 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.413 0 N-CA-C 109.311 -0.626 . . . . 0.0 109.311 -177.468 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -56.55 154.45 16.76 Favored Glycine 0 CA--C 1.526 0.762 0 CA-C-N 116.238 -0.437 . . . . 0.0 112.244 -178.468 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 2.5 pp -75.64 160.78 29.73 Favored 'General case' 0 N--CA 1.467 0.38 0 N-CA-C 109.448 -0.575 . . . . 0.0 109.448 179.338 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 6.5 ttp -104.78 152.32 22.7 Favored 'General case' 0 N--CA 1.48 1.045 0 N-CA-C 109.04 -0.726 . . . . 0.0 109.04 179.417 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 7.4 p -168.87 162.26 0.56 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.529 0 N-CA-C 107.324 -1.362 . . . . 0.0 107.324 179.582 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 54.04 68.95 1.39 Allowed Glycine 0 C--N 1.312 -0.795 0 N-CA-C 111.924 -0.471 . . . . 0.0 111.924 178.801 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 152.37 -178.25 29.67 Favored Glycine 0 N--CA 1.466 0.646 0 N-CA-C 110.525 -1.03 . . . . 0.0 110.525 179.716 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 4.2 t -124.49 138.34 54.29 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.803 0 N-CA-C 107.193 -1.41 . . . . 0.0 107.193 -179.967 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 74.0 t . . . . . 0 N--CA 1.481 1.125 0 CA-C-O 117.719 -1.134 . . . . 0.0 109.822 -177.304 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 22.6 m-85 . . . . . 0 N--CA 1.473 0.705 0 N-CA-C 109.589 -0.523 . . . . 0.0 109.589 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 87.5 mtt180 -68.87 133.01 47.67 Favored 'General case' 0 N--CA 1.473 0.698 0 CA-C-N 116.612 -0.267 . . . . 0.0 111.101 -178.211 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 6' ' ' HIS . . . . . 0.426 ' CE1' ' O ' ' A' ' 7' ' ' ASP . 1.6 t60 -98.71 127.77 44.75 Favored 'General case' 0 N--CA 1.474 0.732 0 N-CA-C 109.351 -0.611 . . . . 0.0 109.351 179.347 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 7' ' ' ASP . . . . . 0.426 ' O ' ' CE1' ' A' ' 6' ' ' HIS . 4.1 m-20 -72.68 139.89 47.54 Favored 'General case' 0 CA--C 1.538 0.487 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.406 178.545 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 28.0 p -163.24 -168.91 1.84 Allowed 'General case' 0 N--CA 1.481 1.102 0 C-N-CA 122.508 0.323 . . . . 0.0 110.694 179.37 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 105.03 44.39 1.51 Allowed Glycine 0 N--CA 1.483 1.798 0 N-CA-C 111.764 -0.534 . . . . 0.0 111.764 -179.475 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 49.0 p90 -64.11 132.79 51.53 Favored 'General case' 0 N--CA 1.472 0.65 0 O-C-N 122.641 -0.329 . . . . 0.0 111.698 -179.899 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 48.7 mt-10 -90.98 152.34 20.72 Favored 'General case' 0 N--CA 1.477 0.907 0 N-CA-C 109.705 -0.48 . . . . 0.0 109.705 178.37 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -152.98 128.07 1.52 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.655 0 N-CA-C 107.805 -1.183 . . . . 0.0 107.805 178.268 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 46.1 m-70 -135.25 147.4 49.26 Favored 'General case' 0 N--CA 1.492 1.672 0 CA-C-N 119.083 0.856 . . . . 0.0 111.388 -178.965 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 6.5 t60 -164.53 97.39 0.78 Allowed 'General case' 0 N--CA 1.481 1.102 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.733 179.191 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' GLN . . . . . 0.722 HE22 HG23 ' A' ' 36' ' ' VAL . 13.7 pt20 -102.15 -174.12 2.5 Favored 'General case' 0 CA--C 1.509 -0.634 0 N-CA-C 108.654 -0.869 . . . . 0.0 108.654 -179.755 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -169.77 95.68 0.29 Allowed 'General case' 0 N--CA 1.47 0.542 0 CA-C-N 114.565 -1.198 . . . . 0.0 108.345 178.351 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 6.3 mp -123.69 157.04 34.79 Favored 'General case' 0 N--CA 1.498 1.94 0 CA-C-O 121.882 0.848 . . . . 0.0 111.122 -178.151 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 60.2 t -111.92 127.11 69.3 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.099 0 CA-C-O 117.886 -1.054 . . . . 0.0 108.266 177.575 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 26.9 m-85 -126.91 123.05 36.33 Favored 'General case' 0 N--CA 1.497 1.903 0 CA-C-N 120.15 1.341 . . . . 0.0 110.418 179.559 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 66.0 m-85 53.45 74.83 0.29 Allowed 'General case' 0 N--CA 1.469 0.496 0 CA-C-O 121.483 0.659 . . . . 0.0 111.78 178.43 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -79.94 -77.77 0.18 Allowed 'General case' 0 C--N 1.352 0.703 0 CA-C-N 115.044 -0.98 . . . . 0.0 110.319 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 40.8 tt0 -113.96 100.79 8.68 Favored 'General case' 0 N--CA 1.47 0.527 0 N-CA-C 108.247 -1.02 . . . . 0.0 108.247 179.614 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 4.4 p30 -158.53 140.26 13.65 Favored 'General case' 0 N--CA 1.485 1.283 0 O-C-N 122.245 -0.284 . . . . 0.0 111.142 179.079 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.404 HG12 ' N ' ' A' ' 25' ' ' GLY . 60.4 t -59.72 163.58 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.865 0 N-CA-C 108.042 -1.096 . . . . 0.0 108.042 177.108 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.51 ' H ' ' HB ' ' D' ' 24' ' ' VAL . . . -117.87 47.52 1.02 Allowed Glycine 0 N--CA 1.475 1.299 0 N-CA-C 111.776 -0.53 . . . . 0.0 111.776 -179.372 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -61.19 -168.01 0.01 OUTLIER 'General case' 0 N--CA 1.469 0.479 0 O-C-N 123.762 0.331 . . . . 0.0 110.337 179.529 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 26.6 t-20 -70.59 80.7 0.59 Allowed 'General case' 0 N--CA 1.465 0.277 0 CA-C-N 116.401 -0.363 . . . . 0.0 110.17 179.596 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 97.9 mttt -78.03 143.91 37.09 Favored 'General case' 0 N--CA 1.472 0.642 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 179.216 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.81 -167.27 1.07 Allowed Glycine 0 CA--C 1.524 0.625 0 N-CA-C 109.872 -1.291 . . . . 0.0 109.872 178.737 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.83 114.68 28.03 Favored 'General case' 0 N--CA 1.478 0.971 0 N-CA-C 109.67 -0.493 . . . . 0.0 109.67 179.691 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 66.2 mt -98.45 135.83 31.72 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.608 0 N-CA-C 106.883 -1.525 . . . . 0.0 106.883 179.067 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 40.0 pt -152.44 -176.53 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.354 0.763 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.141 -178.765 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.35 4.85 9.61 Favored Glycine 0 CA--C 1.525 0.694 0 N-CA-C 110.861 -0.896 . . . . 0.0 110.861 179.956 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 1.6 tt -75.07 126.58 31.32 Favored 'General case' 0 CA--C 1.544 0.731 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 -179.614 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 28.0 ttt -163.05 150.33 13.05 Favored 'General case' 0 C--O 1.224 -0.253 0 N-CA-C 109.002 -0.74 . . . . 0.0 109.002 178.73 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.722 HG23 HE22 ' A' ' 15' ' ' GLN . 27.9 m -155.78 165.58 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.346 0.447 0 N-CA-C 108.193 -1.04 . . . . 0.0 108.193 179.587 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.92 66.9 2.51 Favored Glycine 0 C--N 1.306 -1.105 0 CA-C-N 115.714 -0.675 . . . . 0.0 112.145 178.693 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.78 -173.12 24.77 Favored Glycine 0 N--CA 1.475 1.276 0 N-CA-C 110.817 -0.913 . . . . 0.0 110.817 179.052 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.493 ' H ' HG12 ' D' ' 39' ' ' VAL . 35.3 m -125.55 157.51 34.83 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.819 0 C-N-CA 123.436 0.694 . . . . 0.0 110.419 -179.863 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 26.2 t . . . . . 0 C--O 1.218 -0.568 0 CA-C-O 118.451 -0.785 . . . . 0.0 110.758 179.775 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 24.4 m-85 . . . . . 0 N--CA 1.474 0.737 0 N-CA-C 109.699 -0.482 . . . . 0.0 109.699 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 87.9 mtt180 -69.06 132.16 46.17 Favored 'General case' 0 N--CA 1.474 0.767 0 CA-C-O 120.631 0.253 . . . . 0.0 110.995 -178.225 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 6' ' ' HIS . . . . . 0.415 ' CE1' ' O ' ' B' ' 7' ' ' ASP . 1.6 t60 -97.95 127.68 44.05 Favored 'General case' 0 N--CA 1.474 0.751 0 N-CA-C 109.298 -0.631 . . . . 0.0 109.298 179.312 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 7' ' ' ASP . . . . . 0.415 ' O ' ' CE1' ' B' ' 6' ' ' HIS . 4.1 m-20 -72.93 139.53 46.84 Favored 'General case' 0 CA--C 1.539 0.544 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.446 178.526 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 8' ' ' SER . . . . . . . . . . . . . 29.2 p -162.56 -168.51 1.84 Allowed 'General case' 0 N--CA 1.481 1.076 0 C-N-CA 122.52 0.328 . . . . 0.0 110.705 179.225 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.63 45.06 1.46 Allowed Glycine 0 N--CA 1.483 1.773 0 N-CA-C 111.732 -0.547 . . . . 0.0 111.732 -179.48 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 49.0 p90 -64.79 132.95 50.94 Favored 'General case' 0 N--CA 1.471 0.607 0 O-C-N 122.662 -0.316 . . . . 0.0 111.684 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 48.7 mt-10 -91.07 152.39 20.65 Favored 'General case' 0 N--CA 1.476 0.873 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 178.293 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -153.06 128.32 1.55 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.638 0 N-CA-C 107.734 -1.21 . . . . 0.0 107.734 178.335 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 45.6 m-70 -135.71 147.42 48.47 Favored 'General case' 0 N--CA 1.493 1.698 0 CA-C-N 118.917 0.78 . . . . 0.0 111.33 -178.958 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 6.5 t60 -164.65 97.33 0.76 Allowed 'General case' 0 N--CA 1.481 1.078 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.586 179.302 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 15' ' ' GLN . . . . . 0.722 HE22 HG23 ' B' ' 36' ' ' VAL . 13.5 pt20 -101.87 -173.68 2.41 Favored 'General case' 0 CA--C 1.51 -0.568 0 N-CA-C 108.639 -0.875 . . . . 0.0 108.639 -179.804 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -170.22 95.63 0.25 Allowed 'General case' 0 N--CA 1.471 0.591 0 CA-C-N 114.63 -1.168 . . . . 0.0 108.259 178.415 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 6.3 mp -123.71 157.05 34.79 Favored 'General case' 0 N--CA 1.497 1.896 0 CA-C-O 121.826 0.822 . . . . 0.0 111.123 -178.113 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 61.8 t -112.31 127.29 69.59 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.074 0 N-CA-C 108.016 -1.105 . . . . 0.0 108.016 177.501 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 27.0 m-85 -127.33 122.86 34.91 Favored 'General case' 0 N--CA 1.495 1.797 0 CA-C-N 119.667 1.121 . . . . 0.0 110.314 179.779 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 66.3 m-85 53.1 74.79 0.28 Allowed 'General case' 0 CA--C 1.539 0.547 0 CA-C-O 121.545 0.688 . . . . 0.0 111.859 178.397 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -79.98 -78.01 0.17 Allowed 'General case' 0 C--N 1.351 0.657 0 CA-C-N 115.016 -0.993 . . . . 0.0 110.278 179.966 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 40.5 tt0 -113.66 100.88 8.81 Favored 'General case' 0 N--CA 1.471 0.594 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 179.569 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 4.4 p30 -158.55 140.88 14.16 Favored 'General case' 0 N--CA 1.484 1.272 0 CA-C-O 119.494 -0.289 . . . . 0.0 111.151 179.021 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 59.0 t -60.13 163.81 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.91 0 N-CA-C 108.116 -1.068 . . . . 0.0 108.116 177.199 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 25' ' ' GLY . . . . . 0.516 ' H ' ' HB ' ' E' ' 24' ' ' VAL . . . -117.9 47.53 1.02 Allowed Glycine 0 N--CA 1.475 1.276 0 N-CA-C 111.739 -0.544 . . . . 0.0 111.739 -179.397 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -61.18 -167.74 0.01 OUTLIER 'General case' 0 N--CA 1.47 0.545 0 O-C-N 123.651 0.265 . . . . 0.0 110.379 179.396 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 26.9 t-20 -71.1 80.73 0.69 Allowed 'General case' 0 N--CA 1.466 0.348 0 N-CA-C 110.091 -0.337 . . . . 0.0 110.091 179.673 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -78.01 143.92 37.11 Favored 'General case' 0 N--CA 1.472 0.666 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 179.267 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.71 -166.7 0.94 Allowed Glycine 0 CA--C 1.524 0.628 0 N-CA-C 109.895 -1.282 . . . . 0.0 109.895 178.752 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -100.4 114.55 28.2 Favored 'General case' 0 N--CA 1.478 0.958 0 N-CA-C 109.668 -0.493 . . . . 0.0 109.668 179.628 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 65.5 mt -98.26 135.39 33.14 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.556 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 178.965 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 38.1 pt -151.73 -176.51 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.353 0.733 0 CA-C-N 115.962 -0.563 . . . . 0.0 111.151 -178.789 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.37 4.73 9.45 Favored Glycine 0 CA--C 1.525 0.703 0 N-CA-C 110.947 -0.861 . . . . 0.0 110.947 179.833 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 34' ' ' LEU . . . . . 0.412 HD23 ' N ' ' B' ' 35' ' ' MET . 1.6 tt -74.95 126.69 31.53 Favored 'General case' 0 CA--C 1.544 0.744 0 N-CA-C 109.37 -0.604 . . . . 0.0 109.37 -179.617 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 35' ' ' MET . . . . . 0.412 ' N ' HD23 ' B' ' 34' ' ' LEU . 27.4 ttt -163.04 150.17 12.96 Favored 'General case' 0 N--CA 1.467 0.378 0 N-CA-C 108.915 -0.772 . . . . 0.0 108.915 178.672 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 36' ' ' VAL . . . . . 0.722 HG23 HE22 ' B' ' 15' ' ' GLN . 27.8 m -155.8 165.26 1.15 Allowed 'Isoleucine or valine' 0 C--N 1.347 0.495 0 N-CA-C 108.155 -1.054 . . . . 0.0 108.155 179.6 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.09 67.16 2.36 Favored Glycine 0 C--N 1.307 -1.059 0 CA-C-N 115.674 -0.694 . . . . 0.0 112.098 178.649 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.54 -172.57 24.83 Favored Glycine 0 N--CA 1.476 1.318 0 N-CA-C 110.806 -0.917 . . . . 0.0 110.806 179.046 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 39' ' ' VAL . . . . . 0.513 ' H ' HG12 ' E' ' 39' ' ' VAL . 35.5 m -126.12 157.42 36.27 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.98 0 C-N-CA 123.448 0.699 . . . . 0.0 110.454 -179.651 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 26.0 t . . . . . 0 C--O 1.219 -0.509 0 CA-C-O 118.429 -0.796 . . . . 0.0 110.602 179.664 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 23.9 m-85 . . . . . 0 N--CA 1.475 0.794 0 N-CA-C 109.683 -0.488 . . . . 0.0 109.683 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 87.4 mtt180 -69.28 131.91 45.62 Favored 'General case' 0 N--CA 1.477 0.904 0 CA-C-O 120.714 0.292 . . . . 0.0 110.955 -178.236 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 6' ' ' HIS . . . . . 0.427 ' CE1' ' O ' ' C' ' 7' ' ' ASP . 1.6 t60 -97.79 128.16 44.23 Favored 'General case' 0 N--CA 1.473 0.689 0 N-CA-C 109.262 -0.644 . . . . 0.0 109.262 179.215 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 7' ' ' ASP . . . . . 0.427 ' O ' ' CE1' ' C' ' 6' ' ' HIS . 4.1 m-20 -73.33 139.77 46.26 Favored 'General case' 0 CA--C 1.538 0.49 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.428 178.583 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 8' ' ' SER . . . . . . . . . . . . . 29.8 p -162.99 -168.71 1.83 Allowed 'General case' 0 N--CA 1.481 1.092 0 CA-C-O 120.828 0.347 . . . . 0.0 110.671 179.249 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.92 44.25 1.54 Allowed Glycine 0 N--CA 1.483 1.798 0 N-CA-C 111.759 -0.537 . . . . 0.0 111.759 -179.498 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 49.3 p90 -64.21 133.29 52.56 Favored 'General case' 0 N--CA 1.472 0.667 0 O-C-N 122.672 -0.311 . . . . 0.0 111.687 -179.935 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 48.3 mt-10 -91.4 152.28 20.47 Favored 'General case' 0 N--CA 1.476 0.858 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 178.356 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -152.83 128.15 1.59 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.598 0 N-CA-C 107.814 -1.18 . . . . 0.0 107.814 178.327 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 45.4 m-70 -135.43 147.69 49.05 Favored 'General case' 0 N--CA 1.493 1.695 0 CA-C-N 118.948 0.794 . . . . 0.0 111.306 -178.969 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 6.5 t60 -164.85 97.31 0.74 Allowed 'General case' 0 N--CA 1.481 1.101 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.646 179.293 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 15' ' ' GLN . . . . . 0.712 HE22 HG23 ' C' ' 36' ' ' VAL . 13.6 pt20 -102.05 -173.85 2.44 Favored 'General case' 0 CA--C 1.508 -0.645 0 N-CA-C 108.606 -0.887 . . . . 0.0 108.606 -179.735 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -170.06 95.81 0.27 Allowed 'General case' 0 N--CA 1.468 0.47 0 CA-C-N 114.623 -1.171 . . . . 0.0 108.292 178.298 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 6.4 mp -123.73 157.17 34.58 Favored 'General case' 0 N--CA 1.497 1.899 0 CA-C-O 121.808 0.813 . . . . 0.0 111.189 -178.194 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 61.7 t -112.32 127.63 69.41 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.057 0 N-CA-C 108.111 -1.07 . . . . 0.0 108.111 177.516 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 27.4 m-85 -127.58 122.77 34.09 Favored 'General case' 0 N--CA 1.493 1.723 0 CA-C-N 119.688 1.131 . . . . 0.0 110.305 179.861 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 66.6 m-85 53.28 74.77 0.28 Allowed 'General case' 0 CA--C 1.538 0.492 0 CA-C-O 121.488 0.661 . . . . 0.0 111.851 178.304 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -79.96 -78.23 0.17 Allowed 'General case' 0 C--N 1.35 0.621 0 CA-C-N 115.008 -0.996 . . . . 0.0 110.291 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 40.1 tt0 -113.58 100.66 8.67 Favored 'General case' 0 N--CA 1.471 0.591 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 179.629 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 4.4 p30 -158.29 140.41 14.09 Favored 'General case' 0 N--CA 1.484 1.229 0 O-C-N 122.264 -0.272 . . . . 0.0 111.117 179.183 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 24' ' ' VAL . . . . . 0.402 HG12 ' N ' ' C' ' 25' ' ' GLY . 59.4 t -59.88 163.51 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.868 0 N-CA-C 108.072 -1.084 . . . . 0.0 108.072 177.096 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 25' ' ' GLY . . . . . 0.501 ' H ' ' HB ' ' F' ' 24' ' ' VAL . . . -117.79 47.94 0.99 Allowed Glycine 0 N--CA 1.478 1.492 0 N-CA-C 111.597 -0.601 . . . . 0.0 111.597 -179.314 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -61.59 -168.18 0.01 OUTLIER 'General case' 0 N--CA 1.469 0.487 0 N-CA-C 110.268 -0.271 . . . . 0.0 110.268 179.447 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 26.7 t-20 -70.51 80.99 0.57 Allowed 'General case' 0 N--CA 1.466 0.332 0 N-CA-C 110.026 -0.361 . . . . 0.0 110.026 179.595 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -78.3 143.76 36.7 Favored 'General case' 0 N--CA 1.472 0.66 0 N-CA-C 109.089 -0.708 . . . . 0.0 109.089 179.312 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.45 -167.34 0.95 Allowed Glycine 0 CA--C 1.525 0.672 0 N-CA-C 109.937 -1.265 . . . . 0.0 109.937 178.689 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.86 113.97 26.86 Favored 'General case' 0 N--CA 1.48 1.028 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 179.657 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 66.0 mt -97.88 135.57 31.92 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.557 0 N-CA-C 106.942 -1.503 . . . . 0.0 106.942 178.992 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 38.8 pt -152.01 -176.42 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.354 0.768 0 CA-C-N 115.902 -0.59 . . . . 0.0 111.122 -178.791 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.45 4.52 9.36 Favored Glycine 0 CA--C 1.525 0.717 0 N-CA-C 110.907 -0.877 . . . . 0.0 110.907 179.882 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 34' ' ' LEU . . . . . 0.403 HD23 ' N ' ' C' ' 35' ' ' MET . 1.6 tt -74.75 126.34 30.68 Favored 'General case' 0 CA--C 1.543 0.692 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 -179.619 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 35' ' ' MET . . . . . 0.403 ' N ' HD23 ' C' ' 34' ' ' LEU . 27.5 ttt -162.57 150.36 13.97 Favored 'General case' 0 N--CA 1.466 0.349 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 178.763 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 36' ' ' VAL . . . . . 0.712 HG23 HE22 ' C' ' 15' ' ' GLN . 27.6 m -156.09 165.22 1.12 Allowed 'Isoleucine or valine' 0 C--N 1.347 0.48 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 179.543 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.14 66.74 2.63 Favored Glycine 0 C--N 1.306 -1.106 0 CA-C-N 115.721 -0.672 . . . . 0.0 112.072 178.548 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.84 -172.47 25.06 Favored Glycine 0 N--CA 1.476 1.308 0 N-CA-C 110.813 -0.915 . . . . 0.0 110.813 178.999 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 39' ' ' VAL . . . . . 0.505 ' H ' HG12 ' F' ' 39' ' ' VAL . 35.6 m -126.21 157.66 36.36 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.892 0 C-N-CA 123.429 0.692 . . . . 0.0 110.421 -179.667 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 27.2 t . . . . . 0 C--O 1.219 -0.512 0 CA-C-O 118.43 -0.795 . . . . 0.0 110.526 179.722 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 26.7 m-85 . . . . . 0 N--CA 1.485 1.276 0 N-CA-C 108.304 -0.998 . . . . 0.0 108.304 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' D' D ' 5' ' ' ARG . . . . . . . . . . . . 0.314 94.1 mtt180 -77.63 134.01 38.29 Favored 'General case' 0 N--CA 1.483 1.179 0 CA-C-O 123.01 1.386 . . . . 0.0 107.946 -169.394 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 6.2 t-160 -95.14 130.81 41.71 Favored 'General case' 0 C--N 1.364 1.231 0 CA-C-N 113.53 -1.668 . . . . 0.0 108.662 -177.259 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' D' D ' 7' ' ' ASP . . . . . 0.474 ' O ' ' OG ' ' G' ' 8' ' ' SER . 2.8 m-20 -66.29 125.44 25.59 Favored 'General case' 0 C--N 1.309 -1.161 0 C-N-CA 126.841 2.056 . . . . 0.0 114.989 173.304 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' D' D ' 8' ' ' SER . . . . . . . . . . . . . 27.6 p -153.35 -167.15 2.62 Favored 'General case' 0 N--CA 1.488 1.458 0 CA-C-N 120.187 1.358 . . . . 0.0 110.962 176.868 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.78 47.15 1.2 Allowed Glycine 0 N--CA 1.484 1.897 0 C-N-CA 124.797 1.189 . . . . 0.0 110.741 176.961 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 51.0 p90 -60.79 131.66 51.41 Favored 'General case' 0 N--CA 1.47 0.553 0 N-CA-C 112.838 0.681 . . . . 0.0 112.838 177.657 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 48.5 mt-10 -88.6 150.95 22.78 Favored 'General case' 0 N--CA 1.48 1.067 0 CA-C-N 117.862 0.301 . . . . 0.0 110.591 175.553 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -149.5 129.9 4.3 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.609 0 N-CA-C 107.377 -1.342 . . . . 0.0 107.377 173.464 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 42.4 m-70 -129.96 150.69 51.13 Favored 'General case' 0 N--CA 1.483 1.176 0 N-CA-C 112.05 0.389 . . . . 0.0 112.05 176.757 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 6.6 t60 -165.04 104.37 0.77 Allowed 'General case' 0 N--CA 1.483 1.194 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 172.32 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' D' D ' 15' ' ' GLN . . . . . 0.748 HE22 HG23 ' D' ' 36' ' ' VAL . 13.5 pt20 -105.48 -176.17 3.0 Favored 'General case' 0 CA--C 1.501 -0.908 0 N-CA-C 108.491 -0.929 . . . . 0.0 108.491 179.243 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -166.03 104.59 0.67 Allowed 'General case' 0 N--CA 1.466 0.327 0 N-CA-C 106.064 -1.828 . . . . 0.0 106.064 174.26 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 5.4 mp -130.87 153.86 48.68 Favored 'General case' 0 N--CA 1.499 1.988 0 CA-C-O 122.188 0.994 . . . . 0.0 110.604 179.563 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 35.8 t -101.29 131.79 48.35 Favored 'Isoleucine or valine' 0 C--O 1.259 1.57 0 CA-C-O 116.884 -1.531 . . . . 0.0 109.563 174.11 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 25.0 m-85 -130.45 126.3 36.62 Favored 'General case' 0 N--CA 1.49 1.544 0 CA-C-N 120.063 1.302 . . . . 0.0 109.591 173.9 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 66.3 m-85 55.65 71.69 0.53 Allowed 'General case' 0 C--N 1.348 0.535 0 CA-C-N 115.618 -0.719 . . . . 0.0 111.521 175.989 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -81.92 -73.03 0.41 Allowed 'General case' 0 C--N 1.35 0.607 0 CA-C-O 118.478 -0.772 . . . . 0.0 110.988 -177.647 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 40.9 tt0 -117.0 104.62 11.45 Favored 'General case' 0 N--CA 1.482 1.14 0 N-CA-C 106.404 -1.702 . . . . 0.0 106.404 176.32 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -152.06 140.43 20.51 Favored 'General case' 0 N--CA 1.476 0.865 0 CA-C-O 116.797 -1.573 . . . . 0.0 113.494 177.995 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' D' D ' 24' ' ' VAL . . . . . 0.51 ' HB ' ' H ' ' A' ' 25' ' ' GLY . 79.3 t -62.53 165.93 1.01 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.282 0 CA-C-N 121.063 1.756 . . . . 0.0 108.013 175.027 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' D' D ' 25' ' ' GLY . . . . . 0.571 ' H ' ' HB ' ' G' ' 24' ' ' VAL . . . -116.92 51.15 0.74 Allowed Glycine 0 N--CA 1.479 1.508 0 CA-C-O 119.003 -0.887 . . . . 0.0 111.78 178.196 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -57.72 -170.71 0.01 OUTLIER 'General case' 0 C--N 1.32 -0.689 0 C-N-CA 123.563 0.745 . . . . 0.0 111.643 176.042 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 28.2 t-20 -72.73 86.62 1.24 Allowed 'General case' 0 C--N 1.346 0.435 0 N-CA-C 108.421 -0.955 . . . . 0.0 108.421 177.952 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 97.4 mttt -83.27 146.21 28.67 Favored 'General case' 0 C--N 1.352 0.708 0 N-CA-C 108.063 -1.088 . . . . 0.0 108.063 179.138 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -62.8 -164.98 0.5 Allowed Glycine 0 C--N 1.337 0.592 0 N-CA-C 110.626 -0.99 . . . . 0.0 110.626 179.1 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -102.38 116.13 32.0 Favored 'General case' 0 N--CA 1.47 0.533 0 N-CA-C 109.155 -0.683 . . . . 0.0 109.155 179.394 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 73.9 mt -102.68 142.59 16.5 Favored 'Isoleucine or valine' 0 C--N 1.356 0.867 0 N-CA-C 104.505 -2.406 . . . . 0.0 104.505 -179.917 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' D' D ' 32' ' ' ILE . . . . . 0.431 HG22 ' H ' ' G' ' 32' ' ' ILE . 39.4 pt -158.25 -177.39 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.126 0 CA-C-O 120.939 0.4 . . . . 0.0 110.186 -177.075 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 64.32 4.64 13.06 Favored Glycine 0 C--O 1.241 0.562 0 N-CA-C 110.132 -1.187 . . . . 0.0 110.132 -178.828 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 2.1 tt -77.52 133.39 38.55 Favored 'General case' 0 C--N 1.369 1.438 0 C-N-CA 117.944 -1.502 . . . . 0.0 107.155 -177.801 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' D' D ' 35' ' ' MET . . . . . 0.415 ' O ' HG13 ' D' ' 36' ' ' VAL . 27.9 ttt -158.3 161.48 37.67 Favored 'General case' 0 CA--C 1.509 -0.62 0 CA-C-O 118.213 -0.899 . . . . 0.0 108.858 173.574 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' D' D ' 36' ' ' VAL . . . . . 0.748 HG23 HE22 ' D' ' 15' ' ' GLN . 27.7 m -164.63 164.36 0.66 Allowed 'Isoleucine or valine' 0 CA--C 1.517 -0.319 0 N-CA-C 108.064 -1.088 . . . . 0.0 108.064 175.62 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 60.18 64.05 4.5 Favored Glycine 0 C--N 1.313 -0.706 0 C-N-CA 119.759 -1.21 . . . . 0.0 112.883 178.318 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 140.68 -171.27 24.12 Favored Glycine 0 N--CA 1.48 1.581 0 CA-C-N 117.319 0.559 . . . . 0.0 111.769 -179.221 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' D' D ' 39' ' ' VAL . . . . . 0.522 ' H ' HG12 ' G' ' 39' ' ' VAL . 34.9 m -128.37 154.81 39.6 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.851 0 C-N-CA 122.716 0.406 . . . . 0.0 110.146 -176.877 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 25.3 t . . . . . 0 C--N 1.332 -0.16 0 CA-C-O 116.657 -1.64 . . . . 0.0 110.051 178.19 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 24.0 m-85 . . . . . 0 N--CA 1.475 0.794 0 N-CA-C 109.962 -0.384 . . . . 0.0 109.962 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' E' E ' 5' ' ' ARG . . . . . . . . . . . . . 86.2 mtt180 -68.94 131.89 45.82 Favored 'General case' 0 N--CA 1.475 0.804 0 CA-C-N 116.423 -0.353 . . . . 0.0 111.153 -178.36 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' E' E ' 6' ' ' HIS . . . . . 0.418 ' CE1' ' O ' ' E' ' 7' ' ' ASP . 1.5 t60 -97.66 129.03 44.77 Favored 'General case' 0 N--CA 1.475 0.789 0 N-CA-C 109.194 -0.669 . . . . 0.0 109.194 179.08 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' E' E ' 7' ' ' ASP . . . . . 0.418 ' O ' ' CE1' ' E' ' 6' ' ' HIS . 4.2 m-20 -74.42 139.91 44.33 Favored 'General case' 0 N--CA 1.468 0.445 0 CA-C-N 116.513 -0.312 . . . . 0.0 110.531 178.725 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' E' E ' 8' ' ' SER . . . . . . . . . . . . . 24.8 p -163.68 -168.25 1.6 Allowed 'General case' 0 N--CA 1.485 1.301 0 CA-C-O 120.888 0.375 . . . . 0.0 110.886 178.922 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 105.57 44.84 1.39 Allowed Glycine 0 N--CA 1.482 1.732 0 N-CA-C 111.485 -0.646 . . . . 0.0 111.485 -179.682 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 47.0 p90 -63.84 133.45 53.4 Favored 'General case' 0 N--CA 1.475 0.783 0 N-CA-C 112.02 0.378 . . . . 0.0 112.02 -179.806 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 47.2 mt-10 -90.73 152.39 20.84 Favored 'General case' 0 N--CA 1.48 1.036 0 CA-C-O 121.111 0.481 . . . . 0.0 109.747 177.777 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -154.09 127.44 1.19 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.574 0 N-CA-C 107.795 -1.187 . . . . 0.0 107.795 178.003 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 45.0 m-70 -135.74 146.38 47.61 Favored 'General case' 0 N--CA 1.483 1.215 0 CA-C-O 120.869 0.366 . . . . 0.0 111.542 -178.025 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 6.5 t60 -164.32 97.15 0.79 Allowed 'General case' 0 N--CA 1.486 1.344 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.592 179.459 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' E' E ' 15' ' ' GLN . . . . . 0.762 HE22 HG23 ' E' ' 36' ' ' VAL . 13.6 pt20 -101.4 -173.83 2.46 Favored 'General case' 0 CA--C 1.51 -0.588 0 N-CA-C 108.924 -0.769 . . . . 0.0 108.924 -179.728 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -169.77 94.67 0.27 Allowed 'General case' 0 N--CA 1.472 0.647 0 CA-C-N 114.774 -1.103 . . . . 0.0 108.464 178.347 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 6.2 mp -122.4 156.72 33.41 Favored 'General case' 0 N--CA 1.495 1.787 0 CA-C-O 121.698 0.761 . . . . 0.0 111.641 -177.546 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 48.3 t -113.88 124.36 70.46 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.232 0 N-CA-C 108.212 -1.033 . . . . 0.0 108.212 177.245 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 29.8 m-85 -124.83 121.97 36.07 Favored 'General case' 0 N--CA 1.489 1.524 0 CA-C-O 120.907 0.384 . . . . 0.0 110.974 -179.563 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 67.2 m-85 54.47 73.57 0.39 Allowed 'General case' 0 N--CA 1.469 0.476 0 CA-C-N 115.892 -0.594 . . . . 0.0 111.53 177.931 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -78.27 -78.46 0.14 Allowed 'General case' 0 CA--C 1.535 0.377 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.258 -179.711 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 40.9 tt0 -113.02 101.56 9.58 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 108.319 -0.993 . . . . 0.0 108.319 179.683 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -158.15 140.58 14.41 Favored 'General case' 0 C--O 1.205 -1.285 0 CA-C-O 119.488 -0.292 . . . . 0.0 111.481 179.17 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' E' E ' 24' ' ' VAL . . . . . 0.516 ' HB ' ' H ' ' B' ' 25' ' ' GLY . 63.3 t -58.7 168.46 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.973 0 N-CA-C 107.629 -1.248 . . . . 0.0 107.629 177.034 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' E' E ' 25' ' ' GLY . . . . . 0.471 ' H ' ' HB ' ' H' ' 24' ' ' VAL . . . -122.57 47.68 1.0 Allowed Glycine 0 N--CA 1.475 1.264 0 N-CA-C 110.931 -0.867 . . . . 0.0 110.931 -179.347 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -61.81 -167.48 0.01 OUTLIER 'General case' 0 N--CA 1.47 0.548 0 CA-C-O 120.704 0.288 . . . . 0.0 110.469 179.808 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 27.2 t-20 -70.68 77.85 0.6 Allowed 'General case' 0 N--CA 1.467 0.377 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.393 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -75.48 144.56 42.0 Favored 'General case' 0 N--CA 1.475 0.817 0 N-CA-C 109.567 -0.531 . . . . 0.0 109.567 179.331 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.46 -166.4 1.14 Allowed Glycine 0 CA--C 1.522 0.474 0 N-CA-C 110.421 -1.072 . . . . 0.0 110.421 178.629 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -100.08 113.36 25.92 Favored 'General case' 0 N--CA 1.468 0.443 0 N-CA-C 109.961 -0.385 . . . . 0.0 109.961 179.659 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 66.3 mt -97.36 135.28 32.2 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.443 0 N-CA-C 106.752 -1.573 . . . . 0.0 106.752 179.146 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' E' E ' 32' ' ' ILE . . . . . 0.427 HG22 ' H ' ' H' ' 32' ' ' ILE . 39.2 pt -151.74 -174.73 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.123 0 CA-C-O 121.165 0.507 . . . . 0.0 110.682 -179.072 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.5 5.66 6.97 Favored Glycine 0 CA--C 1.53 1.03 0 CA-C-N 115.504 -0.771 . . . . 0.0 111.34 -179.674 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' E' E ' 34' ' ' LEU . . . . . 0.402 HD23 ' N ' ' E' ' 35' ' ' MET . 1.7 tt -74.86 126.62 31.34 Favored 'General case' 0 CA--C 1.545 0.787 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 -179.613 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' E' E ' 35' ' ' MET . . . . . 0.402 ' N ' HD23 ' E' ' 34' ' ' LEU . 28.2 ttt -162.14 151.11 15.41 Favored 'General case' 0 C--O 1.203 -1.348 0 N-CA-C 108.972 -0.751 . . . . 0.0 108.972 178.776 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' E' E ' 36' ' ' VAL . . . . . 0.762 HG23 HE22 ' E' ' 15' ' ' GLN . 32.9 m -157.04 165.22 1.01 Allowed 'Isoleucine or valine' 0 C--N 1.343 0.287 0 N-CA-C 108.434 -0.95 . . . . 0.0 108.434 179.596 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.61 67.08 2.39 Favored Glycine 0 C--N 1.306 -1.096 0 CA-C-N 115.762 -0.654 . . . . 0.0 111.95 178.774 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.88 -172.48 25.08 Favored Glycine 0 N--CA 1.476 1.362 0 N-CA-C 111.16 -0.776 . . . . 0.0 111.16 179.034 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' E' E ' 39' ' ' VAL . . . . . 0.53 ' H ' HG12 ' H' ' 39' ' ' VAL . 33.4 m -126.29 156.78 36.86 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.703 0 C-N-CA 123.452 0.701 . . . . 0.0 110.682 -179.402 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 26.1 t . . . . . 0 C--O 1.218 -0.56 0 CA-C-O 118.451 -0.785 . . . . 0.0 110.701 179.525 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 24.0 m-85 . . . . . 0 N--CA 1.474 0.754 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' F' F ' 5' ' ' ARG . . . . . . . . . . . . . 87.2 mtt180 -69.0 132.66 47.02 Favored 'General case' 0 C--O 1.217 -0.634 0 CA-C-N 116.419 -0.355 . . . . 0.0 111.289 -178.244 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' F' F ' 6' ' ' HIS . . . . . 0.415 ' CE1' ' O ' ' F' ' 7' ' ' ASP . 1.5 t60 -98.31 128.69 44.86 Favored 'General case' 0 N--CA 1.477 0.889 0 N-CA-C 109.323 -0.621 . . . . 0.0 109.323 179.31 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' F' F ' 7' ' ' ASP . . . . . 0.415 ' O ' ' CE1' ' F' ' 6' ' ' HIS . 4.3 m-20 -74.1 139.54 44.66 Favored 'General case' 0 N--CA 1.467 0.42 0 CA-C-N 116.542 -0.299 . . . . 0.0 110.662 178.678 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' F' F ' 8' ' ' SER . . . . . . . . . . . . . 24.7 p -163.6 -168.33 1.63 Allowed 'General case' 0 N--CA 1.486 1.327 0 CA-C-O 120.963 0.411 . . . . 0.0 110.945 178.905 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 105.7 44.84 1.37 Allowed Glycine 0 N--CA 1.482 1.745 0 N-CA-C 111.459 -0.656 . . . . 0.0 111.459 -179.729 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 46.2 p90 -63.67 133.72 54.13 Favored 'General case' 0 CA--C 1.543 0.707 0 N-CA-C 112.094 0.405 . . . . 0.0 112.094 -179.639 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 47.2 mt-10 -90.89 152.24 20.82 Favored 'General case' 0 N--CA 1.481 1.085 0 CA-C-O 121.172 0.51 . . . . 0.0 109.74 177.794 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -153.92 127.19 1.18 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.601 0 N-CA-C 107.776 -1.194 . . . . 0.0 107.776 178.034 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 44.3 m-70 -135.53 145.93 47.54 Favored 'General case' 0 N--CA 1.484 1.232 0 CA-C-O 120.796 0.331 . . . . 0.0 111.635 -177.959 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 6.6 t60 -163.94 97.26 0.83 Allowed 'General case' 0 N--CA 1.486 1.335 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.697 179.442 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' F' F ' 15' ' ' GLN . . . . . 0.726 HE22 HG23 ' F' ' 36' ' ' VAL . 13.3 pt20 -101.68 -173.96 2.48 Favored 'General case' 0 CA--C 1.507 -0.698 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 -179.711 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -169.5 94.71 0.29 Allowed 'General case' 0 N--CA 1.471 0.597 0 CA-C-N 114.633 -1.167 . . . . 0.0 108.424 178.357 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 6.3 mp -122.16 156.84 32.83 Favored 'General case' 0 N--CA 1.495 1.817 0 CA-C-O 121.628 0.728 . . . . 0.0 111.623 -177.687 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 48.6 t -113.94 124.35 70.51 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.181 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 177.185 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 29.8 m-85 -124.72 121.69 35.37 Favored 'General case' 0 N--CA 1.489 1.49 0 CA-C-O 120.888 0.375 . . . . 0.0 110.984 -179.57 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 67.3 m-85 54.41 74.08 0.36 Allowed 'General case' 0 C--N 1.344 0.353 0 CA-C-N 115.917 -0.583 . . . . 0.0 111.68 178.032 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -78.4 -78.42 0.14 Allowed 'General case' 0 CA--C 1.535 0.375 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.282 -179.707 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 40.8 tt0 -113.19 101.39 9.38 Favored 'General case' 0 C--N 1.325 -0.477 0 N-CA-C 108.312 -0.996 . . . . 0.0 108.312 179.777 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -158.08 140.52 14.45 Favored 'General case' 0 C--O 1.204 -1.308 0 CA-C-O 119.537 -0.268 . . . . 0.0 111.419 179.045 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' F' F ' 24' ' ' VAL . . . . . 0.501 ' HB ' ' H ' ' C' ' 25' ' ' GLY . 60.6 t -58.61 168.61 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.962 0 N-CA-C 107.644 -1.243 . . . . 0.0 107.644 177.047 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' F' F ' 25' ' ' GLY . . . . . 0.467 ' H ' ' HB ' ' I' ' 24' ' ' VAL . . . -122.71 48.07 0.98 Allowed Glycine 0 N--CA 1.477 1.381 0 N-CA-C 110.822 -0.911 . . . . 0.0 110.822 -179.398 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -62.24 -167.63 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.559 0 CA-C-O 120.75 0.309 . . . . 0.0 110.417 179.807 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 27.2 t-20 -70.16 77.54 0.51 Allowed 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.432 -179.936 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -75.49 144.18 42.17 Favored 'General case' 0 N--CA 1.475 0.814 0 N-CA-C 109.551 -0.537 . . . . 0.0 109.551 179.489 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.14 -166.58 1.07 Allowed Glycine 0 CA--C 1.522 0.512 0 N-CA-C 110.55 -1.02 . . . . 0.0 110.55 178.596 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.72 113.69 26.33 Favored 'General case' 0 N--CA 1.471 0.589 0 N-CA-C 109.879 -0.415 . . . . 0.0 109.879 179.649 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 66.2 mt -97.85 135.22 33.15 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.43 0 N-CA-C 106.796 -1.557 . . . . 0.0 106.796 179.058 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' F' F ' 32' ' ' ILE . . . . . 0.43 HG22 ' H ' ' I' ' 32' ' ' ILE . 39.7 pt -151.65 -174.43 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.136 0 CA-C-O 121.208 0.527 . . . . 0.0 110.64 -179.049 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.11 6.0 6.59 Favored Glycine 0 CA--C 1.53 0.97 0 CA-C-N 115.426 -0.806 . . . . 0.0 111.345 -179.778 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' F' F ' 34' ' ' LEU . . . . . 0.422 HD23 ' N ' ' F' ' 35' ' ' MET . 1.7 tt -75.43 127.28 32.76 Favored 'General case' 0 N--CA 1.475 0.783 0 N-CA-C 109.31 -0.626 . . . . 0.0 109.31 -179.5 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' F' F ' 35' ' ' MET . . . . . 0.422 ' N ' HD23 ' F' ' 34' ' ' LEU . 28.2 ttt -163.18 152.02 14.45 Favored 'General case' 0 C--O 1.204 -1.306 0 N-CA-C 109.203 -0.665 . . . . 0.0 109.203 178.437 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' F' F ' 36' ' ' VAL . . . . . 0.726 HG23 HE22 ' F' ' 15' ' ' GLN . 32.6 m -157.21 165.69 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.342 0.26 0 N-CA-C 108.408 -0.96 . . . . 0.0 108.408 179.897 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.34 67.41 2.22 Favored Glycine 0 C--N 1.307 -1.081 0 CA-C-N 115.717 -0.674 . . . . 0.0 111.979 178.56 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.33 -172.33 24.78 Favored Glycine 0 N--CA 1.477 1.378 0 N-CA-C 111.084 -0.807 . . . . 0.0 111.084 178.992 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' F' F ' 39' ' ' VAL . . . . . 0.531 ' H ' HG12 ' I' ' 39' ' ' VAL . 33.3 m -126.39 157.01 37.17 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.685 0 C-N-CA 123.425 0.69 . . . . 0.0 110.688 -179.285 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 26.0 t . . . . . 0 C--O 1.22 -0.496 0 O-C-N 124.017 0.823 . . . . 0.0 110.599 179.358 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 29.4 m-85 . . . . . 0 N--CA 1.476 0.851 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' G' G ' 5' ' ' ARG . . . . . . . . . . . . . 86.5 mtt180 -67.53 132.18 47.07 Favored 'General case' 0 N--CA 1.473 0.723 0 CA-C-N 116.33 -0.396 . . . . 0.0 110.846 -178.615 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 6.4 t-160 -98.27 129.92 44.98 Favored 'General case' 0 N--CA 1.474 0.761 0 N-CA-C 109.415 -0.587 . . . . 0.0 109.415 179.108 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -75.92 135.73 40.09 Favored 'General case' 0 N--CA 1.47 0.554 0 C-N-CA 122.714 0.406 . . . . 0.0 111.097 179.006 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' G' G ' 8' ' ' SER . . . . . 0.474 ' OG ' ' O ' ' D' ' 7' ' ' ASP . 24.7 p -160.11 -166.23 1.65 Allowed 'General case' 0 N--CA 1.477 0.903 0 CA-C-O 120.971 0.415 . . . . 0.0 110.512 178.73 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.42 45.51 1.43 Allowed Glycine 0 N--CA 1.481 1.684 0 N-CA-C 111.211 -0.756 . . . . 0.0 111.211 179.866 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 48.9 p90 -64.59 133.43 52.28 Favored 'General case' 0 CA--C 1.542 0.641 0 N-CA-C 111.91 0.337 . . . . 0.0 111.91 -179.562 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 49.4 mt-10 -90.97 151.76 20.96 Favored 'General case' 0 N--CA 1.479 1.018 0 CA-C-O 121.006 0.432 . . . . 0.0 110.036 178.41 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -154.82 127.53 1.08 Allowed 'Isoleucine or valine' 0 CA--C 1.553 1.088 0 N-CA-C 107.845 -1.169 . . . . 0.0 107.845 178.359 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 46.0 m-70 -135.23 147.11 49.21 Favored 'General case' 0 N--CA 1.478 0.934 0 CA-C-N 115.433 -0.803 . . . . 0.0 111.471 -178.135 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 33.2 t-80 -165.22 97.63 0.71 Allowed 'General case' 0 N--CA 1.483 1.22 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.214 178.82 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' G' G ' 15' ' ' GLN . . . . . 0.777 HE22 HG23 ' G' ' 36' ' ' VAL . 13.7 pt20 -102.06 -173.81 2.43 Favored 'General case' 0 CA--C 1.507 -0.678 0 N-CA-C 108.688 -0.856 . . . . 0.0 108.688 -179.595 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -170.32 94.37 0.23 Allowed 'General case' 0 N--CA 1.471 0.624 0 CA-C-N 114.663 -1.153 . . . . 0.0 108.224 178.54 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 6.3 mp -121.86 155.94 34.32 Favored 'General case' 0 N--CA 1.498 1.935 0 CA-C-O 121.298 0.571 . . . . 0.0 111.881 -177.812 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 43.2 t -113.63 124.53 70.36 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.013 0 CA-C-N 114.746 -1.115 . . . . 0.0 108.156 176.617 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 31.5 m-85 -125.13 121.76 35.16 Favored 'General case' 0 C--N 1.366 1.314 0 C-N-CA 123.358 0.663 . . . . 0.0 111.01 -179.324 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 66.7 m-85 54.4 73.43 0.4 Allowed 'General case' 0 N--CA 1.467 0.407 0 CA-C-N 115.865 -0.607 . . . . 0.0 111.532 177.898 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.49 -77.86 0.14 Allowed 'General case' 0 N--CA 1.473 0.682 0 O-C-N 122.296 -0.252 . . . . 0.0 110.451 -179.426 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 40.9 tt0 -113.59 101.61 9.49 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 108.048 -1.093 . . . . 0.0 108.048 179.806 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -158.25 141.65 15.18 Favored 'General case' 0 N--CA 1.478 0.964 0 O-C-N 122.368 -0.207 . . . . 0.0 111.438 179.067 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' G' G ' 24' ' ' VAL . . . . . 0.571 ' HB ' ' H ' ' D' ' 25' ' ' GLY . 58.8 t -60.23 167.12 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.637 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 177.338 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' G' G ' 25' ' ' GLY . . . . . 0.426 ' N ' HG12 ' G' ' 24' ' ' VAL . . . -120.71 48.51 0.94 Allowed Glycine 0 N--CA 1.481 1.662 0 N-CA-C 110.548 -1.021 . . . . 0.0 110.548 -179.499 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -62.93 -167.73 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.648 0 CA-C-N 117.03 0.415 . . . . 0.0 109.943 179.825 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 27.6 t-20 -70.28 77.2 0.54 Allowed 'General case' 0 CA--C 1.536 0.413 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.456 -179.979 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 97.9 mttt -74.29 144.23 44.66 Favored 'General case' 0 N--CA 1.475 0.807 0 N-CA-C 109.642 -0.503 . . . . 0.0 109.642 179.292 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.56 -164.98 0.92 Allowed Glycine 0 C--N 1.337 0.609 0 N-CA-C 110.061 -1.216 . . . . 0.0 110.061 178.623 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -100.03 113.48 26.11 Favored 'General case' 0 N--CA 1.469 0.52 0 C-N-CA 122.737 0.415 . . . . 0.0 110.577 179.865 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 67.6 mt -98.33 135.51 32.81 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.838 0 N-CA-C 106.827 -1.546 . . . . 0.0 106.827 179.062 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' G' G ' 32' ' ' ILE . . . . . 0.431 ' H ' HG22 ' D' ' 32' ' ' ILE . 39.6 pt -152.27 -174.32 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.725 0 CA-C-N 119.784 1.174 . . . . 0.0 109.897 -179.473 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.06 5.63 8.14 Favored Glycine 0 CA--C 1.527 0.789 0 N-CA-C 111.03 -0.828 . . . . 0.0 111.03 -179.928 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 1.6 tt -75.71 125.46 29.09 Favored 'General case' 0 CA--C 1.544 0.733 0 N-CA-C 109.561 -0.533 . . . . 0.0 109.561 -179.574 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 28.1 ttt -161.04 152.91 19.67 Favored 'General case' 0 C--O 1.206 -1.194 0 N-CA-C 108.861 -0.792 . . . . 0.0 108.861 178.712 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' G' G ' 36' ' ' VAL . . . . . 0.777 HG23 HE22 ' G' ' 15' ' ' GLN . 30.4 m -157.8 164.28 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.343 0.293 0 N-CA-C 108.471 -0.937 . . . . 0.0 108.471 -179.836 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.42 67.63 2.11 Favored Glycine 0 C--N 1.309 -0.955 0 CA-C-N 115.602 -0.726 . . . . 0.0 112.207 178.457 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.89 -171.64 25.39 Favored Glycine 0 N--CA 1.478 1.438 0 N-CA-C 110.6 -1.0 . . . . 0.0 110.6 178.981 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' G' G ' 39' ' ' VAL . . . . . 0.522 HG12 ' H ' ' D' ' 39' ' ' VAL . 33.9 m -127.04 157.22 38.59 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.763 0 C-N-CA 123.138 0.575 . . . . 0.0 110.807 -179.43 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 28.0 t . . . . . 0 C--O 1.219 -0.51 0 O-C-N 123.976 0.797 . . . . 0.0 110.85 179.364 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 29.7 m-85 . . . . . 0 N--CA 1.476 0.833 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' H' H ' 5' ' ' ARG . . . . . . . . . . . . . 86.4 mtt180 -67.7 131.72 46.11 Favored 'General case' 0 N--CA 1.475 0.782 0 CA-C-N 116.421 -0.354 . . . . 0.0 110.798 -178.603 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 6.3 t-160 -98.09 129.5 44.91 Favored 'General case' 0 N--CA 1.475 0.78 0 N-CA-C 109.253 -0.647 . . . . 0.0 109.253 179.114 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -75.42 136.18 40.73 Favored 'General case' 0 N--CA 1.47 0.551 0 C-N-CA 122.666 0.386 . . . . 0.0 111.049 178.936 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' H' H ' 8' ' ' SER . . . . . . . . . . . . . 27.2 p -160.39 -166.52 1.68 Allowed 'General case' 0 N--CA 1.475 0.794 0 CA-C-O 120.85 0.357 . . . . 0.0 110.476 178.786 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.27 46.16 1.37 Allowed Glycine 0 N--CA 1.481 1.674 0 N-CA-C 111.292 -0.723 . . . . 0.0 111.292 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 48.6 p90 -65.46 133.73 51.92 Favored 'General case' 0 CA--C 1.542 0.665 0 N-CA-C 111.894 0.331 . . . . 0.0 111.894 -179.635 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 48.8 mt-10 -91.2 151.63 20.87 Favored 'General case' 0 N--CA 1.479 0.98 0 CA-C-O 121.0 0.429 . . . . 0.0 110.154 178.481 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -154.52 127.66 1.16 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.057 0 N-CA-C 107.874 -1.158 . . . . 0.0 107.874 178.267 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 45.9 m-70 -135.25 147.0 49.14 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.438 -0.801 . . . . 0.0 111.408 -178.073 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 32.0 t-80 -165.22 97.33 0.71 Allowed 'General case' 0 N--CA 1.483 1.192 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.264 178.837 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' H' H ' 15' ' ' GLN . . . . . 0.763 HE22 HG23 ' H' ' 36' ' ' VAL . 13.8 pt20 -101.64 -173.77 2.43 Favored 'General case' 0 CA--C 1.511 -0.555 0 N-CA-C 108.637 -0.875 . . . . 0.0 108.637 -179.592 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -170.31 94.22 0.23 Allowed 'General case' 0 N--CA 1.472 0.652 0 CA-C-N 114.664 -1.153 . . . . 0.0 108.116 178.503 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 6.3 mp -121.81 155.66 34.86 Favored 'General case' 0 N--CA 1.498 1.964 0 CA-C-O 121.29 0.567 . . . . 0.0 111.96 -177.778 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 42.2 t -113.33 124.74 70.27 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.044 0 CA-C-N 114.766 -1.106 . . . . 0.0 108.159 176.521 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 30.9 m-85 -125.4 121.06 32.78 Favored 'General case' 0 C--N 1.368 1.401 0 CA-C-N 115.524 -0.762 . . . . 0.0 110.904 -179.082 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 67.2 m-85 54.55 73.63 0.39 Allowed 'General case' 0 C--O 1.236 0.389 0 CA-C-N 115.815 -0.63 . . . . 0.0 111.535 177.9 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.33 -77.98 0.14 Allowed 'General case' 0 N--CA 1.472 0.634 0 O-C-N 122.248 -0.283 . . . . 0.0 110.611 -179.526 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 41.0 tt0 -113.4 101.34 9.29 Favored 'General case' 0 C--N 1.323 -0.578 0 N-CA-C 108.1 -1.074 . . . . 0.0 108.1 179.731 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -157.7 141.87 16.07 Favored 'General case' 0 N--CA 1.478 0.971 0 O-C-N 122.453 -0.155 . . . . 0.0 111.371 179.095 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' H' H ' 24' ' ' VAL . . . . . 0.471 ' HB ' ' H ' ' E' ' 25' ' ' GLY . 57.4 t -60.45 166.92 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.617 0 N-CA-C 107.632 -1.247 . . . . 0.0 107.632 177.246 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' H' H ' 25' ' ' GLY . . . . . 0.423 ' N ' HG12 ' H' ' 24' ' ' VAL . . . -120.6 49.36 0.88 Allowed Glycine 0 N--CA 1.48 1.603 0 N-CA-C 110.528 -1.029 . . . . 0.0 110.528 -179.592 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -63.77 -167.63 0.02 OUTLIER 'General case' 0 N--CA 1.473 0.697 0 CA-C-N 116.99 0.395 . . . . 0.0 110.028 179.812 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 27.4 t-20 -70.2 77.38 0.52 Allowed 'General case' 0 CA--C 1.536 0.41 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.445 179.883 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -74.8 144.21 43.62 Favored 'General case' 0 N--CA 1.474 0.754 0 N-CA-C 109.626 -0.509 . . . . 0.0 109.626 179.366 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.83 -165.42 1.08 Allowed Glycine 0 C--N 1.337 0.607 0 N-CA-C 109.978 -1.249 . . . . 0.0 109.978 178.731 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.66 113.57 26.1 Favored 'General case' 0 N--CA 1.468 0.431 0 C-N-CA 122.632 0.373 . . . . 0.0 110.593 179.902 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 66.6 mt -98.06 135.65 31.88 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.803 0 N-CA-C 106.81 -1.552 . . . . 0.0 106.81 178.964 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' H' H ' 32' ' ' ILE . . . . . 0.427 ' H ' HG22 ' E' ' 32' ' ' ILE . 39.1 pt -152.38 -174.31 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 CA-C-N 119.838 1.199 . . . . 0.0 109.832 -179.637 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.05 5.92 8.75 Favored Glycine 0 CA--C 1.528 0.86 0 N-CA-C 110.974 -0.85 . . . . 0.0 110.974 -179.929 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' H' H ' 34' ' ' LEU . . . . . 0.401 HD23 ' N ' ' H' ' 35' ' ' MET . 1.6 tt -75.84 125.19 28.6 Favored 'General case' 0 CA--C 1.545 0.761 0 N-CA-C 109.512 -0.551 . . . . 0.0 109.512 -179.602 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' H' H ' 35' ' ' MET . . . . . 0.401 ' N ' HD23 ' H' ' 34' ' ' LEU . 28.3 ttt -160.76 152.79 20.03 Favored 'General case' 0 C--O 1.207 -1.144 0 N-CA-C 108.925 -0.768 . . . . 0.0 108.925 178.595 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' H' H ' 36' ' ' VAL . . . . . 0.763 HG23 HE22 ' H' ' 15' ' ' GLN . 28.4 m -157.8 164.17 1.14 Allowed 'Isoleucine or valine' 0 C--N 1.343 0.294 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 -179.81 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.54 67.81 2.01 Favored Glycine 0 C--N 1.309 -0.964 0 CA-C-N 115.559 -0.746 . . . . 0.0 112.168 178.542 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.55 -171.59 25.2 Favored Glycine 0 N--CA 1.478 1.475 0 N-CA-C 110.621 -0.992 . . . . 0.0 110.621 179.05 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' H' H ' 39' ' ' VAL . . . . . 0.53 HG12 ' H ' ' E' ' 39' ' ' VAL . 33.8 m -126.99 157.71 38.23 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.82 0 C-N-CA 123.168 0.587 . . . . 0.0 110.795 -179.456 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 29.7 t . . . . . 0 N--CA 1.469 0.506 0 O-C-N 123.985 0.803 . . . . 0.0 110.745 179.281 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 29.3 m-85 . . . . . 0 N--CA 1.476 0.868 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' I' I ' 5' ' ' ARG . . . . . . . . . . . . . 86.5 mtt180 -68.18 131.72 45.9 Favored 'General case' 0 N--CA 1.476 0.837 0 CA-C-N 116.435 -0.348 . . . . 0.0 110.719 -178.569 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 6.4 t-160 -97.89 129.56 44.83 Favored 'General case' 0 N--CA 1.473 0.718 0 N-CA-C 109.333 -0.617 . . . . 0.0 109.333 179.051 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -75.48 135.98 40.66 Favored 'General case' 0 CA--C 1.539 0.533 0 C-N-CA 122.707 0.403 . . . . 0.0 111.003 178.955 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' I' I ' 8' ' ' SER . . . . . . . . . . . . . 25.0 p -160.41 -166.63 1.7 Allowed 'General case' 0 N--CA 1.476 0.833 0 CA-C-O 120.936 0.398 . . . . 0.0 110.494 178.841 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.37 45.97 1.38 Allowed Glycine 0 N--CA 1.481 1.693 0 N-CA-C 111.29 -0.724 . . . . 0.0 111.29 179.942 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 49.3 p90 -65.28 133.48 51.55 Favored 'General case' 0 N--CA 1.473 0.681 0 N-CA-C 111.942 0.349 . . . . 0.0 111.942 -179.599 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 49.1 mt-10 -90.93 151.71 21.0 Favored 'General case' 0 N--CA 1.478 0.949 0 CA-C-O 121.077 0.465 . . . . 0.0 110.165 178.463 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -154.72 127.55 1.1 Allowed 'Isoleucine or valine' 0 CA--C 1.553 1.073 0 N-CA-C 107.91 -1.144 . . . . 0.0 107.91 178.248 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 47.0 m-70 -135.22 146.84 49.04 Favored 'General case' 0 N--CA 1.477 0.915 0 CA-C-N 115.45 -0.796 . . . . 0.0 111.404 -178.002 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 31.8 t-80 -165.05 97.41 0.73 Allowed 'General case' 0 N--CA 1.483 1.207 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.27 178.884 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' I' I ' 15' ' ' GLN . . . . . 0.743 HE22 HG23 ' I' ' 36' ' ' VAL . 13.8 pt20 -101.82 -173.71 2.42 Favored 'General case' 0 CA--C 1.509 -0.627 0 N-CA-C 108.681 -0.859 . . . . 0.0 108.681 -179.612 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -170.36 94.02 0.22 Allowed 'General case' 0 N--CA 1.472 0.638 0 CA-C-N 114.628 -1.169 . . . . 0.0 108.128 178.607 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 6.3 mp -121.62 155.86 34.18 Favored 'General case' 0 N--CA 1.497 1.904 0 CA-C-O 121.257 0.551 . . . . 0.0 111.92 -177.751 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 42.1 t -113.53 125.09 70.75 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.997 0 CA-C-N 114.789 -1.096 . . . . 0.0 108.1 176.54 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 31.2 m-85 -125.73 121.41 33.31 Favored 'General case' 0 C--N 1.366 1.325 0 CA-C-N 115.61 -0.723 . . . . 0.0 110.945 -179.229 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 67.1 m-85 54.46 73.3 0.41 Allowed 'General case' 0 C--O 1.237 0.429 0 CA-C-N 115.911 -0.586 . . . . 0.0 111.482 177.885 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.15 -77.92 0.14 Allowed 'General case' 0 N--CA 1.473 0.702 0 O-C-N 122.272 -0.268 . . . . 0.0 110.5 -179.55 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 40.8 tt0 -113.4 101.54 9.48 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 108.069 -1.086 . . . . 0.0 108.069 179.692 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -157.91 141.59 15.56 Favored 'General case' 0 N--CA 1.479 1.004 0 O-C-N 122.42 -0.175 . . . . 0.0 111.361 179.087 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' I' I ' 24' ' ' VAL . . . . . 0.467 ' HB ' ' H ' ' F' ' 25' ' ' GLY . 59.0 t -60.26 167.27 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.631 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 177.22 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' I' I ' 25' ' ' GLY . . . . . 0.44 ' N ' HG12 ' I' ' 24' ' ' VAL . . . -120.89 49.3 0.89 Allowed Glycine 0 N--CA 1.481 1.683 0 N-CA-C 110.523 -1.031 . . . . 0.0 110.523 -179.572 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -63.75 -167.65 0.02 OUTLIER 'General case' 0 N--CA 1.473 0.682 0 CA-C-N 117.002 0.401 . . . . 0.0 109.949 179.768 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 27.6 t-20 -70.21 77.27 0.52 Allowed 'General case' 0 CA--C 1.535 0.401 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.411 179.913 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -74.66 143.92 44.04 Favored 'General case' 0 N--CA 1.475 0.8 0 N-CA-C 109.617 -0.512 . . . . 0.0 109.617 179.424 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.44 -165.8 1.03 Allowed Glycine 0 C--N 1.337 0.601 0 N-CA-C 110.009 -1.236 . . . . 0.0 110.009 178.653 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.26 113.7 26.13 Favored 'General case' 0 N--CA 1.468 0.471 0 C-N-CA 122.729 0.412 . . . . 0.0 110.583 179.991 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 66.9 mt -98.5 135.49 33.12 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.842 0 N-CA-C 106.833 -1.543 . . . . 0.0 106.833 178.98 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' I' I ' 32' ' ' ILE . . . . . 0.43 ' H ' HG22 ' F' ' 32' ' ' ILE . 39.2 pt -152.36 -174.3 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.725 0 CA-C-N 119.8 1.182 . . . . 0.0 109.84 -179.567 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.04 5.84 8.56 Favored Glycine 0 CA--C 1.527 0.819 0 N-CA-C 110.999 -0.84 . . . . 0.0 110.999 -179.874 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' I' I ' 34' ' ' LEU . . . . . 0.402 HD23 ' N ' ' I' ' 35' ' ' MET . 1.6 tt -75.82 125.42 29.05 Favored 'General case' 0 CA--C 1.545 0.753 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 -179.644 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' I' I ' 35' ' ' MET . . . . . 0.402 ' N ' HD23 ' I' ' 34' ' ' LEU . 28.3 ttt -160.88 152.59 19.57 Favored 'General case' 0 C--O 1.206 -1.186 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 178.723 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' I' I ' 36' ' ' VAL . . . . . 0.743 HG23 HE22 ' I' ' 15' ' ' GLN . 26.7 m -157.59 164.1 1.17 Allowed 'Isoleucine or valine' 0 C--N 1.342 0.262 0 N-CA-C 108.448 -0.945 . . . . 0.0 108.448 -179.988 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.57 67.91 1.96 Allowed Glycine 0 C--N 1.309 -0.951 0 CA-C-N 115.602 -0.727 . . . . 0.0 112.122 178.571 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.58 -171.86 25.11 Favored Glycine 0 N--CA 1.478 1.445 0 N-CA-C 110.644 -0.982 . . . . 0.0 110.644 178.97 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' I' I ' 39' ' ' VAL . . . . . 0.531 HG12 ' H ' ' F' ' 39' ' ' VAL . 33.9 m -126.82 157.26 38.07 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.792 0 C-N-CA 123.181 0.592 . . . . 0.0 110.832 -179.452 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 26.0 t . . . . . 0 C--O 1.22 -0.5 0 O-C-N 123.964 0.79 . . . . 0.0 110.825 179.347 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 63.1 m-85 . . . . . 0 N--CA 1.474 0.769 0 N-CA-C 110.309 -0.256 . . . . 0.0 110.309 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -144.45 142.51 30.34 Favored 'General case' 0 N--CA 1.483 1.221 0 N-CA-C 109.958 -0.386 . . . . 0.0 109.958 179.721 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 45.1 t-80 -152.61 118.77 5.51 Favored 'General case' 0 N--CA 1.469 0.524 0 N-CA-C 109.26 -0.645 . . . . 0.0 109.26 178.967 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 7' ' ' ASP . . . . . 0.51 ' O ' ' OG ' ' D' ' 8' ' ' SER . 4.0 m-20 -69.52 149.62 48.03 Favored 'General case' 0 CA--C 1.538 0.49 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.468 179.898 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 52.1 p -168.07 -173.24 2.0 Allowed 'General case' 0 N--CA 1.484 1.249 0 CA-C-O 121.075 0.464 . . . . 0.0 110.706 179.461 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.77 46.85 1.44 Allowed Glycine 0 N--CA 1.483 1.802 0 CA-C-N 115.962 -0.563 . . . . 0.0 111.941 179.808 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 47.8 p90 -65.27 132.56 49.37 Favored 'General case' 0 N--CA 1.471 0.616 0 CA-C-N 116.71 0.255 . . . . 0.0 111.62 179.764 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 48.1 mt-10 -91.87 151.77 20.4 Favored 'General case' 0 N--CA 1.478 0.935 0 N-CA-C 109.692 -0.484 . . . . 0.0 109.692 178.437 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.0 p -152.79 128.19 1.61 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.61 0 N-CA-C 107.894 -1.15 . . . . 0.0 107.894 178.239 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 45.3 m-70 -135.46 146.31 48.06 Favored 'General case' 0 N--CA 1.493 1.687 0 CA-C-N 118.993 0.815 . . . . 0.0 111.253 -178.916 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 6.0 t60 -165.8 96.78 0.64 Allowed 'General case' 0 N--CA 1.478 0.958 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.941 179.398 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 15' ' ' GLN . . . . . 0.708 HE22 ' H ' ' A' ' 37' ' ' GLY . 5.9 pt20 -108.27 -174.39 2.51 Favored 'General case' 0 CA--C 1.508 -0.645 0 N-CA-C 108.293 -1.003 . . . . 0.0 108.293 -179.781 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -164.22 98.79 0.83 Allowed 'General case' 0 N--CA 1.472 0.626 0 CA-C-N 114.477 -1.238 . . . . 0.0 108.285 178.38 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 6.5 mp -122.04 155.76 34.94 Favored 'General case' 0 N--CA 1.499 2.002 0 CA-C-O 121.837 0.827 . . . . 0.0 110.926 -178.341 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 60.2 t -111.55 126.73 68.97 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.093 0 CA-C-O 117.908 -1.044 . . . . 0.0 108.235 177.737 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 28.1 m-85 -126.43 122.99 36.87 Favored 'General case' 0 N--CA 1.497 1.902 0 CA-C-N 120.08 1.309 . . . . 0.0 110.477 179.203 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 67.0 m-85 54.08 73.79 0.37 Allowed 'General case' 0 N--CA 1.469 0.493 0 CA-C-O 121.306 0.574 . . . . 0.0 111.828 178.757 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -79.99 -77.97 0.18 Allowed 'General case' 0 C--N 1.351 0.665 0 CA-C-N 115.193 -0.912 . . . . 0.0 110.203 -179.752 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 40.6 tt0 -113.53 99.6 7.87 Favored 'General case' 0 N--CA 1.468 0.461 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 179.855 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -158.41 138.84 12.59 Favored 'General case' 0 C--O 1.206 -1.22 0 O-C-N 122.231 -0.293 . . . . 0.0 111.249 179.098 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.401 HG12 ' N ' ' A' ' 25' ' ' GLY . 59.8 t -59.53 163.37 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.921 0 N-CA-C 107.941 -1.133 . . . . 0.0 107.941 177.071 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.461 ' H ' ' HB ' ' D' ' 24' ' ' VAL . . . -116.88 47.61 1.02 Allowed Glycine 0 N--CA 1.476 1.359 0 N-CA-C 111.834 -0.506 . . . . 0.0 111.834 -179.417 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -60.61 -167.5 0.01 OUTLIER 'General case' 0 N--CA 1.469 0.478 0 O-C-N 123.786 0.345 . . . . 0.0 110.305 179.56 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 25.4 t-20 -71.02 80.46 0.66 Allowed 'General case' 0 N--CA 1.465 0.29 0 CA-C-N 116.45 -0.341 . . . . 0.0 110.246 179.539 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 97.7 mttt -77.45 142.95 38.92 Favored 'General case' 0 N--CA 1.474 0.744 0 N-CA-C 109.183 -0.673 . . . . 0.0 109.183 179.283 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.66 -167.89 1.12 Allowed Glycine 0 C--N 1.338 0.648 0 N-CA-C 109.957 -1.257 . . . . 0.0 109.957 178.757 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.44 115.12 28.54 Favored 'General case' 0 N--CA 1.478 0.951 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 179.727 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 71.0 mt -98.58 134.71 36.23 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.576 0 N-CA-C 107.202 -1.407 . . . . 0.0 107.202 178.722 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 31.1 pt -150.63 -171.43 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.352 0.696 0 CA-C-O 121.168 0.508 . . . . 0.0 111.122 -179.259 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.39 4.95 9.96 Favored Glycine 0 N--CA 1.466 0.636 0 N-CA-C 110.735 -0.946 . . . . 0.0 110.735 179.843 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.427 HD23 ' N ' ' A' ' 35' ' ' MET . 1.1 tt -75.38 135.21 40.81 Favored 'General case' 0 CA--C 1.545 0.77 0 N-CA-C 109.395 -0.594 . . . . 0.0 109.395 -179.727 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 35' ' ' MET . . . . . 0.427 ' N ' HD23 ' A' ' 34' ' ' LEU . 27.1 ttt -158.82 146.46 17.79 Favored 'General case' 0 N--CA 1.467 0.418 0 N-CA-C 108.619 -0.882 . . . . 0.0 108.619 178.608 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 1.9 m -148.9 165.65 4.01 Favored 'Isoleucine or valine' 0 C--N 1.348 0.517 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 -179.625 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 37' ' ' GLY . . . . . 0.708 ' H ' HE22 ' A' ' 15' ' ' GLN . . . 54.87 68.44 1.68 Allowed Glycine 0 C--N 1.306 -1.118 0 CA-C-N 115.49 -0.777 . . . . 0.0 112.32 177.518 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.53 176.59 21.3 Favored Glycine 0 N--CA 1.472 1.072 0 N-CA-C 111.11 -0.796 . . . . 0.0 111.11 178.7 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.439 ' H ' HG12 ' D' ' 39' ' ' VAL . 34.3 m -109.31 156.28 10.08 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.658 0 C-N-CA 123.385 0.674 . . . . 0.0 110.201 -179.689 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 24.4 t . . . . . 0 C--O 1.219 -0.55 0 CA-C-O 118.42 -0.8 . . . . 0.0 110.492 179.397 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 63.8 m-85 . . . . . 0 N--CA 1.473 0.678 0 N-CA-C 110.264 -0.272 . . . . 0.0 110.264 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -144.2 142.42 30.51 Favored 'General case' 0 N--CA 1.483 1.186 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 179.682 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 44.8 t-80 -152.45 118.63 5.53 Favored 'General case' 0 N--CA 1.471 0.582 0 N-CA-C 109.395 -0.594 . . . . 0.0 109.395 178.829 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 7' ' ' ASP . . . . . 0.457 ' O ' ' OG ' ' E' ' 8' ' ' SER . 3.8 m-20 -69.36 149.18 48.69 Favored 'General case' 0 CA--C 1.539 0.546 0 CA-C-N 116.4 -0.364 . . . . 0.0 110.622 179.896 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 8' ' ' SER . . . . . . . . . . . . . 52.7 p -167.52 -173.26 2.15 Favored 'General case' 0 N--CA 1.484 1.235 0 CA-C-O 121.033 0.444 . . . . 0.0 110.818 179.381 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.89 46.95 1.41 Allowed Glycine 0 N--CA 1.481 1.674 0 CA-C-N 115.966 -0.561 . . . . 0.0 112.015 179.661 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 47.7 p90 -65.79 132.53 48.94 Favored 'General case' 0 N--CA 1.472 0.652 0 CA-C-O 120.719 0.295 . . . . 0.0 111.649 179.837 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 47.9 mt-10 -91.65 151.86 20.49 Favored 'General case' 0 N--CA 1.477 0.894 0 N-CA-C 109.655 -0.498 . . . . 0.0 109.655 178.436 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -152.92 127.95 1.51 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.47 0 N-CA-C 107.972 -1.121 . . . . 0.0 107.972 178.13 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 43.5 m-70 -135.18 146.42 48.69 Favored 'General case' 0 N--CA 1.493 1.686 0 CA-C-N 118.869 0.759 . . . . 0.0 111.345 -178.93 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 6.1 t60 -165.79 97.02 0.65 Allowed 'General case' 0 N--CA 1.48 1.041 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.768 179.378 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 15' ' ' GLN . . . . . 0.715 HE22 ' H ' ' B' ' 37' ' ' GLY . 5.9 pt20 -108.37 -174.18 2.46 Favored 'General case' 0 CA--C 1.509 -0.603 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 -179.772 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -164.63 98.88 0.79 Allowed 'General case' 0 N--CA 1.474 0.755 0 CA-C-N 114.683 -1.144 . . . . 0.0 108.195 178.363 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 6.6 mp -122.04 156.04 34.35 Favored 'General case' 0 N--CA 1.497 1.925 0 CA-C-O 121.727 0.775 . . . . 0.0 111.012 -178.27 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 61.8 t -112.03 127.63 69.1 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.075 0 N-CA-C 108.028 -1.101 . . . . 0.0 108.028 177.605 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 28.2 m-85 -127.56 122.48 33.36 Favored 'General case' 0 N--CA 1.495 1.781 0 CA-C-N 119.678 1.126 . . . . 0.0 110.307 179.565 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 67.4 m-85 53.71 74.21 0.33 Allowed 'General case' 0 CA--C 1.538 0.504 0 CA-C-O 121.491 0.662 . . . . 0.0 111.846 178.792 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -80.55 -78.03 0.18 Allowed 'General case' 0 C--N 1.35 0.628 0 CA-C-N 115.065 -0.97 . . . . 0.0 110.116 -179.573 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 40.4 tt0 -113.15 99.57 7.93 Favored 'General case' 0 N--CA 1.47 0.543 0 N-CA-C 108.236 -1.024 . . . . 0.0 108.236 179.812 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -158.6 138.79 12.31 Favored 'General case' 0 C--O 1.205 -1.272 0 CA-C-O 119.524 -0.275 . . . . 0.0 111.236 179.1 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 24' ' ' VAL . . . . . 0.401 HG12 ' N ' ' B' ' 25' ' ' GLY . 57.1 t -59.41 163.8 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.857 0 N-CA-C 108.012 -1.107 . . . . 0.0 108.012 177.191 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 25' ' ' GLY . . . . . 0.471 ' H ' ' HB ' ' E' ' 24' ' ' VAL . . . -117.18 47.64 1.02 Allowed Glycine 0 N--CA 1.475 1.244 0 N-CA-C 111.773 -0.531 . . . . 0.0 111.773 -179.465 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -60.67 -167.62 0.01 OUTLIER 'General case' 0 N--CA 1.469 0.52 0 O-C-N 123.708 0.299 . . . . 0.0 110.202 179.457 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 4.1 t30 -71.1 81.12 0.69 Allowed 'General case' 0 N--CA 1.465 0.29 0 CA-C-N 116.481 -0.327 . . . . 0.0 110.186 179.548 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 97.8 mttt -78.07 142.55 38.08 Favored 'General case' 0 N--CA 1.474 0.762 0 N-CA-C 109.015 -0.735 . . . . 0.0 109.015 179.418 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.22 -167.76 0.92 Allowed Glycine 0 C--N 1.336 0.557 0 N-CA-C 109.917 -1.273 . . . . 0.0 109.917 178.659 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.54 115.53 29.56 Favored 'General case' 0 N--CA 1.478 0.959 0 N-CA-C 109.599 -0.519 . . . . 0.0 109.599 179.77 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 70.9 mt -98.96 134.68 36.96 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.505 0 N-CA-C 107.107 -1.442 . . . . 0.0 107.107 178.6 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 32' ' ' ILE . . . . . 0.405 HG22 ' H ' ' E' ' 32' ' ' ILE . 29.7 pt -150.77 -171.85 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.724 0 CA-C-O 121.141 0.496 . . . . 0.0 111.17 -179.022 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.76 4.58 10.68 Favored Glycine 0 C--N 1.337 0.595 0 N-CA-C 110.915 -0.874 . . . . 0.0 110.915 179.935 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 34' ' ' LEU . . . . . 0.42 HD23 ' N ' ' B' ' 35' ' ' MET . 1.1 tt -75.07 135.07 41.23 Favored 'General case' 0 CA--C 1.545 0.767 0 N-CA-C 109.497 -0.557 . . . . 0.0 109.497 -179.689 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 35' ' ' MET . . . . . 0.42 ' N ' HD23 ' B' ' 34' ' ' LEU . 27.0 ttt -158.54 146.42 18.18 Favored 'General case' 0 N--CA 1.471 0.582 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 178.64 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 1.9 m -149.08 165.54 3.83 Favored 'Isoleucine or valine' 0 C--N 1.347 0.48 0 N-CA-C 108.094 -1.076 . . . . 0.0 108.094 -179.642 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 37' ' ' GLY . . . . . 0.715 ' H ' HE22 ' B' ' 15' ' ' GLN . . . 55.19 68.21 1.81 Allowed Glycine 0 C--N 1.306 -1.097 0 CA-C-N 115.469 -0.787 . . . . 0.0 112.367 177.54 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.24 176.75 21.21 Favored Glycine 0 N--CA 1.473 1.105 0 N-CA-C 111.113 -0.795 . . . . 0.0 111.113 178.674 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 39' ' ' VAL . . . . . 0.438 ' H ' HG12 ' E' ' 39' ' ' VAL . 34.4 m -109.35 155.81 10.31 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.655 0 C-N-CA 123.376 0.67 . . . . 0.0 110.299 -179.546 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 25.1 t . . . . . 0 C--O 1.22 -0.497 0 O-C-N 123.99 0.806 . . . . 0.0 110.407 179.317 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 64.8 m-85 . . . . . 0 N--CA 1.474 0.767 0 N-CA-C 110.25 -0.278 . . . . 0.0 110.25 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -144.22 142.4 30.48 Favored 'General case' 0 N--CA 1.484 1.244 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 179.769 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 45.2 t-80 -152.47 119.05 5.66 Favored 'General case' 0 N--CA 1.471 0.586 0 N-CA-C 109.397 -0.594 . . . . 0.0 109.397 179.013 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 7' ' ' ASP . . . . . 0.495 ' O ' ' OG ' ' F' ' 8' ' ' SER . 4.1 m-20 -70.1 149.03 48.04 Favored 'General case' 0 CA--C 1.538 0.493 0 CA-C-N 116.376 -0.375 . . . . 0.0 110.647 -179.983 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 8' ' ' SER . . . . . . . . . . . . . 54.0 p -167.28 -172.97 2.13 Favored 'General case' 0 N--CA 1.484 1.235 0 CA-C-O 121.061 0.457 . . . . 0.0 110.744 179.566 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.48 46.9 1.47 Allowed Glycine 0 N--CA 1.482 1.715 0 CA-C-N 115.945 -0.57 . . . . 0.0 112.035 179.688 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 47.7 p90 -65.78 132.35 48.51 Favored 'General case' 0 N--CA 1.471 0.591 0 O-C-N 122.745 -0.268 . . . . 0.0 111.686 179.826 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 47.7 mt-10 -91.41 151.82 20.66 Favored 'General case' 0 N--CA 1.475 0.782 0 N-CA-C 109.713 -0.477 . . . . 0.0 109.713 178.432 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -152.77 128.17 1.61 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.515 0 N-CA-C 107.833 -1.173 . . . . 0.0 107.833 177.999 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 41.7 m-70 -135.27 146.5 48.61 Favored 'General case' 0 N--CA 1.492 1.65 0 CA-C-N 118.916 0.78 . . . . 0.0 111.272 -179.056 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 6.0 t60 -165.88 96.84 0.63 Allowed 'General case' 0 N--CA 1.481 1.111 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.719 179.459 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 15' ' ' GLN . . . . . 0.69 HE22 ' H ' ' C' ' 37' ' ' GLY . 5.9 pt20 -108.39 -173.98 2.41 Favored 'General case' 0 CA--C 1.505 -0.77 0 N-CA-C 108.396 -0.965 . . . . 0.0 108.396 -179.898 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -164.63 98.85 0.79 Allowed 'General case' 0 N--CA 1.473 0.678 0 CA-C-N 114.617 -1.174 . . . . 0.0 108.223 178.502 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 6.6 mp -121.9 155.77 34.74 Favored 'General case' 0 N--CA 1.497 1.901 0 CA-C-O 121.84 0.828 . . . . 0.0 110.927 -178.35 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 61.2 t -111.68 127.55 68.77 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.117 0 N-CA-C 107.932 -1.136 . . . . 0.0 107.932 177.511 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 28.1 m-85 -127.51 123.06 35.0 Favored 'General case' 0 N--CA 1.495 1.782 0 CA-C-N 119.606 1.094 . . . . 0.0 110.272 179.395 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 67.0 m-85 53.08 74.12 0.32 Allowed 'General case' 0 N--CA 1.468 0.449 0 CA-C-O 121.558 0.694 . . . . 0.0 111.919 178.851 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -80.22 -78.29 0.17 Allowed 'General case' 0 C--N 1.35 0.62 0 CA-C-N 115.012 -0.994 . . . . 0.0 110.065 -179.595 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 40.4 tt0 -113.03 99.69 8.05 Favored 'General case' 0 N--CA 1.471 0.62 0 N-CA-C 108.153 -1.055 . . . . 0.0 108.153 179.899 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -158.45 139.15 12.8 Favored 'General case' 0 C--O 1.205 -1.246 0 O-C-N 122.309 -0.245 . . . . 0.0 111.203 179.131 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 60.7 t -59.94 163.3 0.96 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.878 0 N-CA-C 108.075 -1.083 . . . . 0.0 108.075 177.051 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 25' ' ' GLY . . . . . 0.479 ' H ' ' HB ' ' F' ' 24' ' ' VAL . . . -116.64 47.3 1.05 Allowed Glycine 0 N--CA 1.477 1.387 0 N-CA-C 111.722 -0.551 . . . . 0.0 111.722 -179.29 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -60.43 -167.38 0.01 OUTLIER 'General case' 0 N--CA 1.468 0.462 0 O-C-N 123.658 0.269 . . . . 0.0 110.284 179.539 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 4.3 t30 -71.29 80.69 0.74 Allowed 'General case' 0 N--CA 1.466 0.333 0 CA-C-N 116.442 -0.344 . . . . 0.0 110.132 179.495 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 97.7 mttt -77.53 143.06 38.69 Favored 'General case' 0 N--CA 1.474 0.741 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 179.253 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.83 -167.68 1.15 Allowed Glycine 0 CA--C 1.524 0.617 0 N-CA-C 109.994 -1.242 . . . . 0.0 109.994 178.705 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.49 115.11 28.55 Favored 'General case' 0 N--CA 1.482 1.144 0 N-CA-C 109.677 -0.49 . . . . 0.0 109.677 179.879 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 71.1 mt -98.78 134.21 38.45 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.48 0 N-CA-C 107.296 -1.372 . . . . 0.0 107.296 178.591 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 29.7 pt -150.3 -171.49 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.724 0 CA-C-O 121.227 0.537 . . . . 0.0 111.173 -179.107 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.31 5.11 10.05 Favored Glycine 0 CA--C 1.524 0.62 0 N-CA-C 110.838 -0.905 . . . . 0.0 110.838 179.881 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 34' ' ' LEU . . . . . 0.427 HD23 ' N ' ' C' ' 35' ' ' MET . 1.1 tt -75.46 134.77 40.77 Favored 'General case' 0 CA--C 1.546 0.813 0 N-CA-C 109.38 -0.6 . . . . 0.0 109.38 -179.703 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 35' ' ' MET . . . . . 0.427 ' N ' HD23 ' C' ' 34' ' ' LEU . 27.1 ttt -158.19 146.57 18.79 Favored 'General case' 0 N--CA 1.47 0.531 0 N-CA-C 108.426 -0.953 . . . . 0.0 108.426 178.686 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 1.7 m -149.33 165.28 3.72 Favored 'Isoleucine or valine' 0 C--N 1.348 0.532 0 N-CA-C 108.142 -1.059 . . . . 0.0 108.142 -179.556 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 37' ' ' GLY . . . . . 0.69 ' H ' HE22 ' C' ' 15' ' ' GLN . . . 54.77 68.7 1.55 Allowed Glycine 0 C--N 1.306 -1.096 0 CA-C-N 115.413 -0.812 . . . . 0.0 112.317 177.782 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.26 176.42 20.94 Favored Glycine 0 N--CA 1.473 1.101 0 N-CA-C 111.078 -0.809 . . . . 0.0 111.078 178.698 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 39' ' ' VAL . . . . . 0.444 ' H ' HG12 ' F' ' 39' ' ' VAL . 34.4 m -109.38 155.73 10.38 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.624 0 C-N-CA 123.328 0.651 . . . . 0.0 110.443 -179.641 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 25.1 t . . . . . 0 C--O 1.219 -0.538 0 O-C-N 124.009 0.818 . . . . 0.0 110.491 179.386 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 72.3 m-85 . . . . . 0 N--CA 1.471 0.599 0 N-CA-C 108.948 -0.76 . . . . 0.0 108.948 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' D' D ' 5' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -146.87 140.99 26.12 Favored 'General case' 0 N--CA 1.476 0.86 0 N-CA-C 110.059 -0.348 . . . . 0.0 110.059 179.764 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 41.6 t-80 -149.75 123.52 9.26 Favored 'General case' 0 CA--C 1.545 0.774 0 N-CA-C 108.499 -0.926 . . . . 0.0 108.499 174.468 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' D' D ' 7' ' ' ASP . . . . . 0.591 ' O ' ' OG ' ' G' ' 8' ' ' SER . 2.8 m-20 -63.81 133.32 53.2 Favored 'General case' 0 C--N 1.32 -0.688 0 C-N-CA 126.61 1.964 . . . . 0.0 114.339 174.029 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' D' D ' 8' ' ' SER . . . . . 0.51 ' OG ' ' O ' ' A' ' 7' ' ' ASP . 52.3 p -154.04 -170.53 3.59 Favored 'General case' 0 N--CA 1.488 1.438 0 CA-C-N 119.649 1.113 . . . . 0.0 111.131 175.534 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.43 48.05 1.16 Allowed Glycine 0 N--CA 1.484 1.88 0 N-CA-C 109.941 -1.264 . . . . 0.0 109.941 173.365 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 50.9 p90 -60.66 131.01 49.35 Favored 'General case' 0 N--CA 1.468 0.434 0 N-CA-C 113.155 0.798 . . . . 0.0 113.155 177.697 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 47.8 mt-10 -88.84 150.65 22.8 Favored 'General case' 0 N--CA 1.481 1.084 0 CA-C-N 118.175 0.443 . . . . 0.0 110.946 174.98 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.0 p -149.49 130.03 4.41 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.594 0 N-CA-C 107.423 -1.325 . . . . 0.0 107.423 173.128 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 40.9 m-70 -130.03 149.25 51.83 Favored 'General case' 0 N--CA 1.484 1.232 0 CA-C-N 118.03 0.377 . . . . 0.0 111.907 176.41 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 6.1 t60 -164.99 104.38 0.78 Allowed 'General case' 0 N--CA 1.48 1.035 0 N-CA-C 109.175 -0.676 . . . . 0.0 109.175 172.13 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' D' D ' 15' ' ' GLN . . . . . 0.65 HE22 ' H ' ' D' ' 37' ' ' GLY . 5.9 pt20 -111.97 -176.05 2.84 Favored 'General case' 0 CA--C 1.499 -1.002 0 N-CA-C 108.228 -1.027 . . . . 0.0 108.228 178.911 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -161.04 105.96 1.36 Allowed 'General case' 0 N--CA 1.468 0.433 0 N-CA-C 106.634 -1.617 . . . . 0.0 106.634 175.151 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 5.5 mp -128.38 153.22 47.3 Favored 'General case' 0 N--CA 1.498 1.945 0 CA-C-O 122.06 0.934 . . . . 0.0 110.582 179.662 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 35.8 t -100.97 131.82 47.88 Favored 'Isoleucine or valine' 0 C--O 1.262 1.761 0 CA-C-O 116.723 -1.608 . . . . 0.0 109.546 174.2 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 25.7 m-85 -130.49 126.35 36.66 Favored 'General case' 0 N--CA 1.491 1.583 0 CA-C-N 120.149 1.34 . . . . 0.0 109.528 173.366 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 68.2 m-85 55.85 71.53 0.55 Allowed 'General case' 0 C--O 1.241 0.651 0 CA-C-N 115.493 -0.776 . . . . 0.0 111.258 176.357 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -82.43 -73.18 0.41 Allowed 'General case' 0 N--CA 1.475 0.794 0 CA-C-O 118.52 -0.752 . . . . 0.0 111.106 -177.507 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 40.8 tt0 -116.52 103.81 10.79 Favored 'General case' 0 N--CA 1.482 1.174 0 N-CA-C 106.195 -1.78 . . . . 0.0 106.195 176.217 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -151.9 138.79 18.98 Favored 'General case' 0 N--CA 1.474 0.752 0 CA-C-O 116.686 -1.626 . . . . 0.0 113.738 177.697 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' D' D ' 24' ' ' VAL . . . . . 0.461 ' HB ' ' H ' ' A' ' 25' ' ' GLY . 64.1 t -62.27 166.23 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.206 0 CA-C-N 121.101 1.773 . . . . 0.0 107.834 175.184 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' D' D ' 25' ' ' GLY . . . . . 0.539 ' H ' ' HB ' ' G' ' 24' ' ' VAL . . . -116.79 51.14 0.74 Allowed Glycine 0 N--CA 1.478 1.46 0 CA-C-O 119.095 -0.836 . . . . 0.0 111.833 178.451 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -57.28 -170.42 0.01 OUTLIER 'General case' 0 C--N 1.322 -0.595 0 C-N-CA 123.706 0.802 . . . . 0.0 111.559 175.937 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 26.3 t-20 -72.89 86.69 1.29 Allowed 'General case' 0 C--N 1.347 0.466 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 177.976 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 97.2 mttt -82.87 145.56 29.38 Favored 'General case' 0 N--CA 1.476 0.84 0 N-CA-C 108.014 -1.106 . . . . 0.0 108.014 179.134 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.17 -165.34 0.61 Allowed Glycine 0 C--N 1.336 0.57 0 N-CA-C 110.45 -1.06 . . . . 0.0 110.45 179.171 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -102.35 116.11 31.95 Favored 'General case' 0 N--CA 1.476 0.851 0 N-CA-C 109.099 -0.704 . . . . 0.0 109.099 179.846 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 80.4 mt -102.52 142.24 17.07 Favored 'Isoleucine or valine' 0 C--N 1.358 0.941 0 N-CA-C 104.84 -2.281 . . . . 0.0 104.84 179.793 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' D' D ' 32' ' ' ILE . . . . . 0.45 HG22 ' H ' ' G' ' 32' ' ' ILE . 31.1 pt -157.43 -172.51 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.482 1.157 0 CA-C-O 120.84 0.353 . . . . 0.0 110.155 -177.332 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 64.27 4.55 12.59 Favored Glycine 0 N--CA 1.465 0.601 0 N-CA-C 110.387 -1.085 . . . . 0.0 110.387 -178.926 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 1.3 tt -76.52 140.47 41.17 Favored 'General case' 0 C--N 1.355 0.824 0 N-CA-C 107.787 -1.19 . . . . 0.0 107.787 -178.329 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 26.4 ttt -156.41 155.91 32.94 Favored 'General case' 0 C--O 1.247 0.955 0 N-CA-C 107.894 -1.15 . . . . 0.0 107.894 174.482 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 1.9 m -157.91 163.86 1.18 Allowed 'Isoleucine or valine' 0 CA--C 1.516 -0.334 0 N-CA-C 107.618 -1.252 . . . . 0.0 107.618 177.826 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' D' D ' 37' ' ' GLY . . . . . 0.65 ' H ' HE22 ' D' ' 15' ' ' GLN . . . 61.36 63.84 4.53 Favored Glycine 0 C--N 1.312 -0.76 0 C-N-CA 119.758 -1.211 . . . . 0.0 112.179 177.452 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 145.76 177.75 20.72 Favored Glycine 0 N--CA 1.476 1.365 0 CA-C-N 118.309 1.054 . . . . 0.0 111.776 179.756 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' D' D ' 39' ' ' VAL . . . . . 0.439 HG12 ' H ' ' A' ' 39' ' ' VAL . 35.2 m -112.5 152.76 14.24 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.895 0 N-CA-C 109.681 -0.489 . . . . 0.0 109.681 -176.824 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 25.2 t . . . . . 0 C--N 1.334 -0.066 0 CA-C-O 116.119 -1.896 . . . . 0.0 109.533 178.0 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 65.8 m-85 . . . . . 0 N--CA 1.474 0.756 0 N-CA-C 110.257 -0.275 . . . . 0.0 110.257 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' E' E ' 5' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -143.72 142.79 31.12 Favored 'General case' 0 N--CA 1.481 1.078 0 N-CA-C 110.113 -0.329 . . . . 0.0 110.113 179.458 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 45.1 t-80 -152.46 118.67 5.54 Favored 'General case' 0 N--CA 1.469 0.516 0 N-CA-C 109.294 -0.632 . . . . 0.0 109.294 178.86 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' E' E ' 7' ' ' ASP . . . . . 0.445 ' O ' ' OG ' ' H' ' 8' ' ' SER . 3.6 m-20 -70.14 149.14 47.87 Favored 'General case' 0 CA--C 1.535 0.391 0 CA-C-N 116.488 -0.324 . . . . 0.0 110.754 179.938 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' E' E ' 8' ' ' SER . . . . . 0.457 ' OG ' ' O ' ' B' ' 7' ' ' ASP . 43.7 p -168.26 -172.1 1.66 Allowed 'General case' 0 N--CA 1.486 1.33 0 CA-C-O 121.192 0.52 . . . . 0.0 110.854 179.18 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.24 47.7 1.3 Allowed Glycine 0 N--CA 1.478 1.485 0 CA-C-N 115.876 -0.602 . . . . 0.0 111.797 179.54 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 46.3 p90 -65.56 132.62 49.32 Favored 'General case' 0 N--CA 1.471 0.621 0 N-CA-C 112.064 0.394 . . . . 0.0 112.064 -179.891 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 49.0 mt-10 -90.98 152.29 20.74 Favored 'General case' 0 N--CA 1.481 1.123 0 CA-C-O 121.313 0.578 . . . . 0.0 109.575 177.954 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -154.65 127.07 1.04 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.588 0 N-CA-C 107.874 -1.158 . . . . 0.0 107.874 177.96 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 42.9 m-70 -135.42 144.4 46.49 Favored 'General case' 0 N--CA 1.482 1.149 0 CA-C-O 120.903 0.382 . . . . 0.0 111.478 -177.859 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 6.0 t60 -164.4 97.19 0.79 Allowed 'General case' 0 N--CA 1.484 1.237 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.694 179.419 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' E' E ' 15' ' ' GLN . . . . . 0.613 HE21 HD11 ' H' ' 17' ' ' LEU . 17.0 pt20 -108.21 -174.33 2.49 Favored 'General case' 0 CA--C 1.507 -0.686 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 -179.924 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -164.18 97.73 0.82 Allowed 'General case' 0 N--CA 1.476 0.839 0 CA-C-N 114.698 -1.137 . . . . 0.0 108.436 178.563 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 6.5 mp -120.52 155.66 33.17 Favored 'General case' 0 N--CA 1.494 1.775 0 CA-C-O 121.533 0.682 . . . . 0.0 111.588 -177.867 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 48.8 t -113.44 124.66 70.3 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.254 0 N-CA-C 108.176 -1.046 . . . . 0.0 108.176 177.131 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 30.8 m-85 -124.94 121.8 35.51 Favored 'General case' 0 N--CA 1.489 1.495 0 CA-C-O 120.836 0.351 . . . . 0.0 110.934 -179.891 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 68.8 m-85 54.79 73.29 0.42 Allowed 'General case' 0 N--CA 1.468 0.429 0 CA-C-N 115.92 -0.582 . . . . 0.0 111.478 178.34 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -78.83 -79.03 0.14 Allowed 'General case' 0 CA--C 1.537 0.459 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.03 -179.378 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 40.5 tt0 -112.1 100.02 8.52 Favored 'General case' 0 C--N 1.323 -0.548 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 -179.987 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -157.89 138.84 13.22 Favored 'General case' 0 C--O 1.201 -1.458 0 N-CA-C 111.621 0.23 . . . . 0.0 111.621 179.029 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' E' E ' 24' ' ' VAL . . . . . 0.471 ' HB ' ' H ' ' B' ' 25' ' ' GLY . 59.0 t -58.15 168.28 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.927 0 N-CA-C 107.403 -1.332 . . . . 0.0 107.403 177.056 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' E' E ' 25' ' ' GLY . . . . . 0.438 ' H ' ' HB ' ' H' ' 24' ' ' VAL . . . -122.0 48.63 0.94 Allowed Glycine 0 N--CA 1.473 1.157 0 N-CA-C 110.963 -0.855 . . . . 0.0 110.963 -179.38 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -62.12 -166.9 0.01 OUTLIER 'General case' 0 N--CA 1.47 0.541 0 CA-C-O 120.737 0.303 . . . . 0.0 110.482 179.892 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 5.1 t30 -70.68 76.88 0.6 Allowed 'General case' 0 C--O 1.222 -0.362 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.481 -179.956 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 97.9 mttt -74.36 143.67 44.75 Favored 'General case' 0 N--CA 1.476 0.873 0 N-CA-C 109.554 -0.536 . . . . 0.0 109.554 179.403 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.68 -167.38 1.43 Allowed Glycine 0 C--N 1.333 0.414 0 N-CA-C 110.408 -1.077 . . . . 0.0 110.408 178.534 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.54 113.99 26.72 Favored 'General case' 0 N--CA 1.476 0.834 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 179.953 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 72.0 mt -97.8 134.48 35.86 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.265 0 N-CA-C 106.986 -1.487 . . . . 0.0 106.986 178.768 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' E' E ' 32' ' ' ILE . . . . . 0.45 HG22 ' H ' ' H' ' 32' ' ' ILE . 31.4 pt -150.34 -169.7 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.174 0 CA-C-O 121.182 0.515 . . . . 0.0 110.753 -179.451 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.65 5.18 6.41 Favored Glycine 0 CA--C 1.527 0.834 0 CA-C-N 115.684 -0.689 . . . . 0.0 111.423 -179.796 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' E' E ' 34' ' ' LEU . . . . . 0.409 HD23 ' N ' ' E' ' 35' ' ' MET . 1.1 tt -74.75 135.26 41.77 Favored 'General case' 0 CA--C 1.549 0.941 0 N-CA-C 109.293 -0.632 . . . . 0.0 109.293 -179.616 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' E' E ' 35' ' ' MET . . . . . 0.409 ' N ' HD23 ' E' ' 34' ' ' LEU . 26.3 ttt -158.37 145.78 17.98 Favored 'General case' 0 N--CA 1.473 0.724 0 N-CA-C 108.611 -0.885 . . . . 0.0 108.611 178.466 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 1.5 m -148.65 165.08 4.56 Favored 'Isoleucine or valine' 0 C--N 1.347 0.48 0 N-CA-C 108.5 -0.926 . . . . 0.0 108.5 -179.447 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 54.28 68.56 1.6 Allowed Glycine 0 C--N 1.308 -1.024 0 CA-C-N 115.324 -0.853 . . . . 0.0 112.231 177.888 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 146.65 173.76 18.16 Favored Glycine 0 N--CA 1.473 1.11 0 N-CA-C 111.41 -0.676 . . . . 0.0 111.41 178.734 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' E' E ' 39' ' ' VAL . . . . . 0.438 HG12 ' H ' ' B' ' 39' ' ' VAL . 32.7 m -107.0 155.69 7.59 Favored 'Isoleucine or valine' 0 C--N 1.352 0.702 0 C-N-CA 123.629 0.772 . . . . 0.0 110.645 -178.711 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 25.4 t . . . . . 0 C--O 1.218 -0.599 0 O-C-N 124.18 0.925 . . . . 0.0 110.25 179.615 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 65.1 m-85 . . . . . 0 N--CA 1.474 0.77 0 N-CA-C 110.235 -0.283 . . . . 0.0 110.235 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' F' F ' 5' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -143.56 142.66 31.19 Favored 'General case' 0 N--CA 1.478 0.97 0 CA-C-O 120.838 0.351 . . . . 0.0 110.091 179.657 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 45.0 t-80 -152.45 119.26 5.75 Favored 'General case' 0 N--CA 1.471 0.614 0 N-CA-C 109.429 -0.582 . . . . 0.0 109.429 178.783 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' F' F ' 7' ' ' ASP . . . . . 0.486 ' O ' ' OG ' ' I' ' 8' ' ' SER . 3.7 m-20 -70.76 149.33 47.01 Favored 'General case' 0 CA--C 1.535 0.382 0 CA-C-N 116.418 -0.356 . . . . 0.0 110.844 -179.929 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' F' F ' 8' ' ' SER . . . . . 0.495 ' OG ' ' O ' ' C' ' 7' ' ' ASP . 43.2 p -168.56 -171.63 1.48 Allowed 'General case' 0 N--CA 1.484 1.262 0 CA-C-O 121.236 0.541 . . . . 0.0 110.935 179.169 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.95 46.82 1.42 Allowed Glycine 0 N--CA 1.478 1.492 0 CA-C-N 115.855 -0.611 . . . . 0.0 111.761 179.551 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 46.6 p90 -64.64 132.42 49.69 Favored 'General case' 0 CA--C 1.542 0.642 0 N-CA-C 112.01 0.374 . . . . 0.0 112.01 -179.886 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 48.6 mt-10 -91.04 152.29 20.71 Favored 'General case' 0 N--CA 1.482 1.13 0 CA-C-O 121.266 0.555 . . . . 0.0 109.685 177.89 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -154.49 126.98 1.05 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.67 0 N-CA-C 107.855 -1.165 . . . . 0.0 107.855 178.058 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 42.5 m-70 -135.24 144.81 47.09 Favored 'General case' 0 N--CA 1.483 1.179 0 CA-C-O 120.847 0.356 . . . . 0.0 111.522 -177.919 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 6.0 t60 -164.88 96.91 0.74 Allowed 'General case' 0 N--CA 1.484 1.27 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.805 179.539 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' F' F ' 15' ' ' GLN . . . . . 0.577 HE21 HD11 ' I' ' 17' ' ' LEU . 16.9 pt20 -108.02 -174.17 2.46 Favored 'General case' 0 CA--C 1.505 -0.751 0 N-CA-C 108.574 -0.899 . . . . 0.0 108.574 -179.875 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -164.17 97.79 0.82 Allowed 'General case' 0 N--CA 1.473 0.719 0 CA-C-N 114.578 -1.192 . . . . 0.0 108.397 178.561 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 6.4 mp -120.55 155.73 33.05 Favored 'General case' 0 N--CA 1.494 1.773 0 CA-C-O 121.667 0.746 . . . . 0.0 111.456 -177.727 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 48.4 t -113.64 124.38 70.23 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.25 0 N-CA-C 108.199 -1.037 . . . . 0.0 108.199 177.17 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 30.5 m-85 -124.7 121.19 33.97 Favored 'General case' 0 N--CA 1.488 1.439 0 CA-C-O 120.77 0.319 . . . . 0.0 111.015 -179.783 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 67.9 m-85 55.27 73.23 0.43 Allowed 'General case' 0 C--N 1.344 0.342 0 CA-C-N 115.953 -0.567 . . . . 0.0 111.733 178.322 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -78.92 -78.58 0.15 Allowed 'General case' 0 N--CA 1.467 0.419 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.147 -179.27 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 40.3 tt0 -112.66 99.99 8.36 Favored 'General case' 0 C--N 1.324 -0.524 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 -179.825 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -157.88 138.8 13.2 Favored 'General case' 0 C--O 1.203 -1.361 0 N-CA-C 111.681 0.252 . . . . 0.0 111.681 179.052 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' F' F ' 24' ' ' VAL . . . . . 0.479 ' HB ' ' H ' ' C' ' 25' ' ' GLY . 60.0 t -58.13 168.24 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.935 0 N-CA-C 107.398 -1.334 . . . . 0.0 107.398 177.116 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' F' F ' 25' ' ' GLY . . . . . 0.434 ' H ' ' HB ' ' I' ' 24' ' ' VAL . . . -121.92 48.53 0.94 Allowed Glycine 0 N--CA 1.476 1.35 0 N-CA-C 110.877 -0.889 . . . . 0.0 110.877 -179.394 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -62.11 -167.4 0.01 OUTLIER 'General case' 0 N--CA 1.47 0.565 0 CA-C-O 120.782 0.325 . . . . 0.0 110.285 179.895 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 4.9 t30 -70.1 77.0 0.51 Allowed 'General case' 0 N--CA 1.466 0.338 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.589 179.979 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 97.8 mttt -74.57 143.81 44.28 Favored 'General case' 0 N--CA 1.478 0.957 0 N-CA-C 109.483 -0.562 . . . . 0.0 109.483 179.524 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.39 -167.11 1.25 Allowed Glycine 0 C--N 1.334 0.425 0 N-CA-C 110.486 -1.046 . . . . 0.0 110.486 178.539 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.69 113.65 26.25 Favored 'General case' 0 N--CA 1.477 0.917 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 179.752 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 72.0 mt -97.71 134.59 35.28 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.285 0 N-CA-C 106.981 -1.489 . . . . 0.0 106.981 178.717 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' F' F ' 32' ' ' ILE . . . . . 0.446 HG22 ' H ' ' I' ' 32' ' ' ILE . 32.1 pt -150.74 -169.6 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.198 0 CA-C-O 121.126 0.489 . . . . 0.0 110.7 -179.476 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.64 5.12 6.29 Favored Glycine 0 CA--C 1.527 0.82 0 CA-C-N 115.688 -0.687 . . . . 0.0 111.407 -179.78 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' F' F ' 34' ' ' LEU . . . . . 0.419 HD23 ' N ' ' F' ' 35' ' ' MET . 1.1 tt -74.66 135.83 41.93 Favored 'General case' 0 CA--C 1.549 0.922 0 N-CA-C 109.18 -0.674 . . . . 0.0 109.18 -179.669 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' F' F ' 35' ' ' MET . . . . . 0.419 ' N ' HD23 ' F' ' 34' ' ' LEU . 26.0 ttt -158.72 145.92 17.58 Favored 'General case' 0 N--CA 1.47 0.561 0 N-CA-C 108.66 -0.867 . . . . 0.0 108.66 178.446 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 1.5 m -148.78 165.14 4.35 Favored 'Isoleucine or valine' 0 C--N 1.349 0.547 0 N-CA-C 108.425 -0.954 . . . . 0.0 108.425 -179.495 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 54.33 68.37 1.7 Allowed Glycine 0 C--N 1.306 -1.108 0 CA-C-N 115.328 -0.851 . . . . 0.0 112.331 177.808 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 146.97 174.09 18.74 Favored Glycine 0 N--CA 1.472 1.097 0 N-CA-C 111.415 -0.674 . . . . 0.0 111.415 178.645 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' F' F ' 39' ' ' VAL . . . . . 0.444 HG12 ' H ' ' C' ' 39' ' ' VAL . 33.1 m -107.22 155.54 7.88 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.714 0 C-N-CA 123.471 0.708 . . . . 0.0 110.588 -178.803 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 26.8 t . . . . . 0 C--O 1.219 -0.55 0 O-C-N 124.286 0.991 . . . . 0.0 110.3 179.601 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 67.1 m-85 . . . . . 0 N--CA 1.473 0.692 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' G' G ' 5' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -143.91 142.77 30.95 Favored 'General case' 0 N--CA 1.483 1.189 0 CA-C-O 120.828 0.347 . . . . 0.0 110.162 179.983 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 45.8 t-80 -152.31 119.5 5.9 Favored 'General case' 0 N--CA 1.473 0.682 0 N-CA-C 109.574 -0.528 . . . . 0.0 109.574 178.794 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 4.0 m-20 -71.82 144.49 49.11 Favored 'General case' 0 CA--C 1.538 0.519 0 C-N-CA 122.716 0.406 . . . . 0.0 111.176 -179.938 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' G' G ' 8' ' ' SER . . . . . 0.591 ' OG ' ' O ' ' D' ' 7' ' ' ASP . 35.5 p -164.77 -169.62 1.76 Allowed 'General case' 0 N--CA 1.476 0.86 0 CA-C-O 121.178 0.513 . . . . 0.0 110.512 178.672 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.21 47.73 1.41 Allowed Glycine 0 N--CA 1.48 1.63 0 N-CA-C 111.344 -0.703 . . . . 0.0 111.344 179.291 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 48.0 p90 -65.69 133.16 50.51 Favored 'General case' 0 CA--C 1.542 0.636 0 N-CA-C 111.872 0.323 . . . . 0.0 111.872 -179.627 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 47.9 mt-10 -91.76 151.48 20.6 Favored 'General case' 0 N--CA 1.479 1.022 0 CA-C-O 121.162 0.506 . . . . 0.0 110.0 178.576 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -154.99 127.28 1.01 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.004 0 N-CA-C 107.851 -1.166 . . . . 0.0 107.851 178.196 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 44.2 m-70 -134.67 146.06 49.14 Favored 'General case' 0 N--CA 1.48 1.05 0 CA-C-N 115.667 -0.697 . . . . 0.0 111.45 -178.363 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 28.5 t-80 -166.24 97.05 0.6 Allowed 'General case' 0 N--CA 1.481 1.115 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.385 178.946 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 17.0 pt20 -108.42 -174.51 2.54 Favored 'General case' 0 CA--C 1.508 -0.641 0 N-CA-C 108.31 -0.996 . . . . 0.0 108.31 -179.702 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -164.27 97.72 0.81 Allowed 'General case' 0 N--CA 1.475 0.802 0 CA-C-N 114.606 -1.179 . . . . 0.0 108.12 178.667 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 6.4 mp -120.4 154.8 34.64 Favored 'General case' 0 N--CA 1.498 1.934 0 CA-C-O 121.247 0.546 . . . . 0.0 111.774 -177.883 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 43.1 t -113.33 124.66 70.19 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.942 0 CA-C-N 114.777 -1.101 . . . . 0.0 108.186 176.55 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 32.1 m-85 -125.29 121.19 33.3 Favored 'General case' 0 C--N 1.367 1.349 0 C-N-CA 123.437 0.695 . . . . 0.0 110.979 -179.602 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 68.0 m-85 55.37 72.57 0.47 Allowed 'General case' 0 N--CA 1.467 0.393 0 CA-C-N 115.898 -0.592 . . . . 0.0 111.496 178.274 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.78 -77.99 0.14 Allowed 'General case' 0 N--CA 1.473 0.697 0 O-C-N 122.237 -0.289 . . . . 0.0 110.407 -178.932 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 41.1 tt0 -113.02 100.2 8.44 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 107.812 -1.181 . . . . 0.0 107.812 179.909 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -157.73 139.75 14.21 Favored 'General case' 0 N--CA 1.476 0.865 0 N-CA-C 111.649 0.24 . . . . 0.0 111.649 178.959 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' G' G ' 24' ' ' VAL . . . . . 0.539 ' HB ' ' H ' ' D' ' 25' ' ' GLY . 62.0 t -59.62 166.97 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.656 0 N-CA-C 107.564 -1.273 . . . . 0.0 107.564 177.353 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' G' G ' 25' ' ' GLY . . . . . 0.421 ' N ' HG12 ' G' ' 24' ' ' VAL . . . -120.13 49.32 0.88 Allowed Glycine 0 N--CA 1.479 1.538 0 N-CA-C 110.617 -0.993 . . . . 0.0 110.617 -179.507 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -63.45 -166.59 0.02 OUTLIER 'General case' 0 N--CA 1.471 0.62 0 N-CA-C 109.895 -0.409 . . . . 0.0 109.895 179.904 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 26.2 t-20 -70.99 76.96 0.65 Allowed 'General case' 0 CA--C 1.535 0.386 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.599 -179.89 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 97.9 mttt -73.95 143.14 45.81 Favored 'General case' 0 N--CA 1.475 0.808 0 N-CA-C 109.623 -0.51 . . . . 0.0 109.623 179.427 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.08 -166.17 0.98 Allowed Glycine 0 C--N 1.337 0.592 0 N-CA-C 110.019 -1.232 . . . . 0.0 110.019 178.642 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.57 114.28 27.2 Favored 'General case' 0 N--CA 1.472 0.659 0 C-N-CA 122.708 0.403 . . . . 0.0 110.138 -179.977 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 73.6 mt -98.51 135.02 34.97 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.649 0 N-CA-C 107.054 -1.461 . . . . 0.0 107.054 178.67 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' G' G ' 32' ' ' ILE . . . . . 0.45 ' H ' HG22 ' D' ' 32' ' ' ILE . 34.3 pt -151.5 -169.28 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 CA-C-N 119.723 1.147 . . . . 0.0 109.916 -179.813 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.28 4.78 6.85 Favored Glycine 0 N--CA 1.468 0.774 0 N-CA-C 111.132 -0.787 . . . . 0.0 111.132 -179.864 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' G' G ' 34' ' ' LEU . . . . . 0.433 HD23 ' N ' ' G' ' 35' ' ' MET . 1.1 tt -74.95 135.12 41.41 Favored 'General case' 0 CA--C 1.545 0.775 0 N-CA-C 109.295 -0.631 . . . . 0.0 109.295 -179.757 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' G' G ' 35' ' ' MET . . . . . 0.433 ' N ' HD23 ' G' ' 34' ' ' LEU . 25.0 ttt -158.28 146.06 18.31 Favored 'General case' 0 N--CA 1.47 0.566 0 N-CA-C 108.64 -0.874 . . . . 0.0 108.64 178.823 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 1.5 m -148.82 163.4 4.85 Favored 'Isoleucine or valine' 0 C--N 1.349 0.561 0 N-CA-C 108.587 -0.894 . . . . 0.0 108.587 -179.469 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.4 68.76 1.52 Allowed Glycine 0 C--N 1.308 -1.001 0 CA-C-N 115.226 -0.897 . . . . 0.0 112.293 177.596 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.39 172.35 17.46 Favored Glycine 0 N--CA 1.476 1.314 0 N-CA-C 110.569 -1.012 . . . . 0.0 110.569 178.892 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' G' G ' 39' ' ' VAL . . . . . 0.414 HG12 ' H ' ' D' ' 39' ' ' VAL . 33.9 m -106.01 155.64 6.92 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.923 0 C-N-CA 123.198 0.599 . . . . 0.0 110.452 -179.541 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 27.5 t . . . . . 0 C--O 1.22 -0.46 0 O-C-N 123.961 0.788 . . . . 0.0 110.563 179.371 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 68.8 m-85 . . . . . 0 N--CA 1.473 0.71 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' H' H ' 5' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -144.21 142.92 30.81 Favored 'General case' 0 N--CA 1.483 1.217 0 N-CA-C 110.046 -0.353 . . . . 0.0 110.046 -179.98 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 46.6 t-80 -152.65 119.69 5.82 Favored 'General case' 0 N--CA 1.472 0.636 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 178.812 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 3.9 m-20 -72.19 144.56 48.47 Favored 'General case' 0 N--CA 1.469 0.481 0 CA-C-N 116.319 -0.401 . . . . 0.0 111.222 -179.781 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' H' H ' 8' ' ' SER . . . . . 0.445 ' OG ' ' O ' ' E' ' 7' ' ' ASP . 52.2 p -164.72 -170.07 1.9 Allowed 'General case' 0 N--CA 1.475 0.776 0 CA-C-O 121.129 0.49 . . . . 0.0 110.492 178.912 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.48 47.63 1.39 Allowed Glycine 0 N--CA 1.478 1.499 0 N-CA-C 111.557 -0.617 . . . . 0.0 111.557 179.409 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 48.4 p90 -65.97 133.14 50.22 Favored 'General case' 0 CA--C 1.54 0.584 0 N-CA-C 111.861 0.319 . . . . 0.0 111.861 -179.587 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 47.8 mt-10 -91.67 151.44 20.67 Favored 'General case' 0 N--CA 1.477 0.921 0 CA-C-O 121.064 0.459 . . . . 0.0 110.065 178.583 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -154.98 127.35 1.03 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.004 0 N-CA-C 107.92 -1.141 . . . . 0.0 107.92 178.13 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 43.5 m-70 -134.67 146.36 49.43 Favored 'General case' 0 N--CA 1.479 0.98 0 CA-C-N 115.694 -0.685 . . . . 0.0 111.311 -178.321 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 29.5 t-80 -166.43 96.71 0.57 Allowed 'General case' 0 N--CA 1.481 1.102 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.508 178.912 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 17.1 pt20 -107.97 -174.13 2.45 Favored 'General case' 0 CA--C 1.507 -0.681 0 N-CA-C 108.304 -0.999 . . . . 0.0 108.304 -179.624 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -164.68 97.5 0.76 Allowed 'General case' 0 N--CA 1.474 0.757 0 CA-C-N 114.584 -1.189 . . . . 0.0 108.127 178.61 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' H' H ' 17' ' ' LEU . . . . . 0.613 HD11 HE21 ' E' ' 15' ' ' GLN . 6.4 mp -120.21 154.92 34.16 Favored 'General case' 0 N--CA 1.496 1.857 0 CA-C-O 121.265 0.555 . . . . 0.0 111.838 -177.939 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 43.2 t -113.4 124.65 70.25 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.079 0 CA-C-N 114.817 -1.083 . . . . 0.0 108.158 176.668 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 32.2 m-85 -125.22 121.28 33.65 Favored 'General case' 0 C--N 1.366 1.313 0 C-N-CA 123.471 0.708 . . . . 0.0 110.885 -179.443 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 68.3 m-85 54.72 72.92 0.43 Allowed 'General case' 0 C--O 1.238 0.455 0 CA-C-N 115.698 -0.683 . . . . 0.0 111.672 178.342 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.68 -78.31 0.14 Allowed 'General case' 0 N--CA 1.473 0.676 0 O-C-N 122.154 -0.341 . . . . 0.0 110.349 -178.914 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 40.8 tt0 -112.85 99.77 8.15 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 107.878 -1.156 . . . . 0.0 107.878 -179.946 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -157.24 139.96 15.02 Favored 'General case' 0 N--CA 1.477 0.887 0 O-C-N 122.346 -0.221 . . . . 0.0 111.471 178.976 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' H' H ' 24' ' ' VAL . . . . . 0.438 ' HB ' ' H ' ' E' ' 25' ' ' GLY . 59.7 t -59.7 167.65 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.592 0 N-CA-C 107.458 -1.312 . . . . 0.0 107.458 177.313 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' H' H ' 25' ' ' GLY . . . . . 0.43 ' N ' HG12 ' H' ' 24' ' ' VAL . . . -120.63 49.27 0.89 Allowed Glycine 0 N--CA 1.479 1.5 0 N-CA-C 110.622 -0.991 . . . . 0.0 110.622 -179.581 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -63.6 -167.33 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.643 0 CA-C-N 117.033 0.417 . . . . 0.0 110.036 179.766 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 5.0 t30 -70.05 77.04 0.5 Allowed 'General case' 0 N--CA 1.465 0.318 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.587 -179.945 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 97.8 mttt -74.1 143.45 45.38 Favored 'General case' 0 N--CA 1.475 0.819 0 N-CA-C 109.5 -0.556 . . . . 0.0 109.5 179.41 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.67 -166.39 1.21 Allowed Glycine 0 C--N 1.338 0.669 0 N-CA-C 109.997 -1.241 . . . . 0.0 109.997 178.641 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.4 114.29 27.13 Favored 'General case' 0 N--CA 1.47 0.554 0 C-N-CA 122.683 0.393 . . . . 0.0 110.293 -179.995 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 74.0 mt -98.46 135.09 34.6 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.693 0 N-CA-C 106.992 -1.484 . . . . 0.0 106.992 178.672 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' H' H ' 32' ' ' ILE . . . . . 0.45 ' H ' HG22 ' E' ' 32' ' ' ILE . 34.8 pt -151.51 -169.02 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.759 0 CA-C-N 119.667 1.121 . . . . 0.0 109.826 -179.929 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.08 5.28 7.42 Favored Glycine 0 N--CA 1.467 0.706 0 N-CA-C 111.055 -0.818 . . . . 0.0 111.055 -179.979 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' H' H ' 34' ' ' LEU . . . . . 0.425 HD23 ' N ' ' H' ' 35' ' ' MET . 1.1 tt -75.44 135.24 40.73 Favored 'General case' 0 CA--C 1.545 0.784 0 N-CA-C 109.4 -0.593 . . . . 0.0 109.4 -179.744 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' H' H ' 35' ' ' MET . . . . . 0.425 ' N ' HD23 ' H' ' 34' ' ' LEU . 25.4 ttt -158.41 146.01 18.08 Favored 'General case' 0 N--CA 1.469 0.514 0 N-CA-C 108.698 -0.853 . . . . 0.0 108.698 178.882 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 1.5 m -148.91 163.83 4.57 Favored 'Isoleucine or valine' 0 C--N 1.35 0.594 0 N-CA-C 108.56 -0.904 . . . . 0.0 108.56 -179.467 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.29 68.29 1.76 Allowed Glycine 0 C--N 1.306 -1.087 0 CA-C-N 115.237 -0.892 . . . . 0.0 112.32 177.612 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.54 172.72 17.96 Favored Glycine 0 N--CA 1.475 1.24 0 N-CA-C 110.745 -0.942 . . . . 0.0 110.745 178.959 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' H' H ' 39' ' ' VAL . . . . . 0.43 HG12 ' H ' ' E' ' 39' ' ' VAL . 34.1 m -106.13 155.75 6.98 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.0 0 C-N-CA 123.32 0.648 . . . . 0.0 110.575 -179.497 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 25.9 t . . . . . 0 C--O 1.219 -0.533 0 O-C-N 123.991 0.807 . . . . 0.0 110.61 179.424 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 67.2 m-85 . . . . . 0 N--CA 1.475 0.788 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' I' I ' 5' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -144.12 142.48 30.61 Favored 'General case' 0 N--CA 1.482 1.153 0 N-CA-C 110.023 -0.362 . . . . 0.0 110.023 -179.931 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 45.1 t-80 -152.28 119.61 5.95 Favored 'General case' 0 N--CA 1.472 0.629 0 N-CA-C 109.503 -0.554 . . . . 0.0 109.503 178.824 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -71.96 144.81 48.77 Favored 'General case' 0 N--CA 1.469 0.481 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.105 -179.758 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' I' I ' 8' ' ' SER . . . . . 0.486 ' OG ' ' O ' ' F' ' 7' ' ' ASP . 51.7 p -164.95 -170.21 1.89 Allowed 'General case' 0 N--CA 1.474 0.742 0 CA-C-O 121.139 0.495 . . . . 0.0 110.547 178.956 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.27 47.72 1.4 Allowed Glycine 0 N--CA 1.479 1.518 0 N-CA-C 111.592 -0.603 . . . . 0.0 111.592 179.544 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 47.5 p90 -65.89 132.9 49.76 Favored 'General case' 0 N--CA 1.471 0.586 0 N-CA-C 111.883 0.327 . . . . 0.0 111.883 -179.789 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 48.4 mt-10 -91.57 151.13 20.87 Favored 'General case' 0 N--CA 1.478 0.936 0 CA-C-O 121.149 0.499 . . . . 0.0 110.013 178.654 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -154.75 127.32 1.06 Allowed 'Isoleucine or valine' 0 CA--C 1.551 0.983 0 N-CA-C 107.979 -1.119 . . . . 0.0 107.979 178.252 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 44.0 m-70 -134.83 146.2 49.06 Favored 'General case' 0 N--CA 1.479 0.993 0 CA-C-N 115.68 -0.691 . . . . 0.0 111.384 -178.149 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 28.3 t-80 -166.31 96.87 0.59 Allowed 'General case' 0 N--CA 1.48 1.051 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.399 178.91 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 17.1 pt20 -108.17 -174.48 2.53 Favored 'General case' 0 CA--C 1.505 -0.762 0 N-CA-C 108.272 -1.01 . . . . 0.0 108.272 -179.731 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -164.3 97.84 0.81 Allowed 'General case' 0 N--CA 1.475 0.794 0 CA-C-N 114.58 -1.191 . . . . 0.0 108.043 178.698 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' I' I ' 17' ' ' LEU . . . . . 0.577 HD11 HE21 ' F' ' 15' ' ' GLN . 6.4 mp -120.65 154.34 35.64 Favored 'General case' 0 N--CA 1.497 1.902 0 CA-C-O 121.215 0.531 . . . . 0.0 111.837 -177.938 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 42.9 t -112.72 125.16 69.95 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.949 0 N-CA-C 108.067 -1.086 . . . . 0.0 108.067 176.595 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 30.7 m-85 -125.71 121.37 33.24 Favored 'General case' 0 C--N 1.367 1.341 0 CA-C-N 115.585 -0.734 . . . . 0.0 110.815 -179.285 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 68.9 m-85 54.59 72.52 0.46 Allowed 'General case' 0 C--N 1.345 0.38 0 CA-C-N 115.916 -0.584 . . . . 0.0 111.49 178.27 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.33 -78.25 0.13 Allowed 'General case' 0 N--CA 1.473 0.72 0 N-CA-C 110.294 -0.262 . . . . 0.0 110.294 -178.971 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 40.9 tt0 -112.77 99.86 8.24 Favored 'General case' 0 C--N 1.323 -0.566 0 N-CA-C 107.978 -1.119 . . . . 0.0 107.978 -179.959 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 4.7 p30 -157.31 139.91 14.88 Favored 'General case' 0 N--CA 1.477 0.891 0 N-CA-C 111.487 0.18 . . . . 0.0 111.487 178.978 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' I' I ' 24' ' ' VAL . . . . . 0.434 ' HB ' ' H ' ' F' ' 25' ' ' GLY . 61.2 t -59.76 167.26 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.56 0 N-CA-C 107.567 -1.271 . . . . 0.0 107.567 177.243 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' I' I ' 25' ' ' GLY . . . . . 0.428 ' N ' HG12 ' I' ' 24' ' ' VAL . . . -120.34 49.62 0.87 Allowed Glycine 0 N--CA 1.479 1.516 0 N-CA-C 110.669 -0.972 . . . . 0.0 110.669 -179.494 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -63.73 -166.89 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.572 0 N-CA-C 110.036 -0.357 . . . . 0.0 110.036 179.881 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 5.0 t30 -70.58 76.56 0.58 Allowed 'General case' 0 CA--C 1.533 0.294 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.584 179.983 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 97.9 mttt -73.65 143.63 46.2 Favored 'General case' 0 N--CA 1.475 0.816 0 N-CA-C 109.561 -0.533 . . . . 0.0 109.561 179.422 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.74 -166.31 1.22 Allowed Glycine 0 C--N 1.336 0.548 0 N-CA-C 110.016 -1.233 . . . . 0.0 110.016 178.647 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.24 114.11 26.74 Favored 'General case' 0 N--CA 1.473 0.721 0 C-N-CA 122.706 0.402 . . . . 0.0 110.315 179.937 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 75.1 mt -98.3 135.08 34.38 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.631 0 N-CA-C 106.94 -1.504 . . . . 0.0 106.94 178.695 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' I' I ' 32' ' ' ILE . . . . . 0.446 ' H ' HG22 ' F' ' 32' ' ' ILE . 35.1 pt -151.5 -169.16 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.831 0 CA-C-N 119.62 1.1 . . . . 0.0 109.771 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.36 5.11 7.53 Favored Glycine 0 N--CA 1.466 0.686 0 N-CA-C 111.054 -0.818 . . . . 0.0 111.054 -179.893 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' I' I ' 34' ' ' LEU . . . . . 0.425 HD23 ' N ' ' I' ' 35' ' ' MET . 1.1 tt -75.21 134.92 41.07 Favored 'General case' 0 N--CA 1.474 0.77 0 N-CA-C 109.336 -0.616 . . . . 0.0 109.336 -179.646 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' I' I ' 35' ' ' MET . . . . . 0.425 ' N ' HD23 ' I' ' 34' ' ' LEU . 24.7 ttt -158.06 145.97 18.55 Favored 'General case' 0 N--CA 1.47 0.555 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 178.906 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 1.5 m -149.08 163.67 4.41 Favored 'Isoleucine or valine' 0 C--N 1.35 0.616 0 N-CA-C 108.491 -0.929 . . . . 0.0 108.491 -179.455 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.25 68.58 1.61 Allowed Glycine 0 C--N 1.308 -1.015 0 CA-C-N 115.218 -0.901 . . . . 0.0 112.282 177.706 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.25 172.5 17.51 Favored Glycine 0 N--CA 1.475 1.234 0 N-CA-C 110.646 -0.982 . . . . 0.0 110.646 178.923 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' I' I ' 39' ' ' VAL . . . . . 0.443 HG12 ' H ' ' F' ' 39' ' ' VAL . 34.4 m -106.17 155.49 7.06 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.993 0 C-N-CA 123.185 0.594 . . . . 0.0 110.635 -179.382 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 25.9 t . . . . . 0 C--O 1.218 -0.559 0 O-C-N 123.955 0.784 . . . . 0.0 110.599 179.433 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 64.9 m-85 . . . . . 0 N--CA 1.474 0.77 0 N-CA-C 110.173 -0.306 . . . . 0.0 110.173 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -144.11 142.94 30.89 Favored 'General case' 0 N--CA 1.481 1.098 0 CA-C-O 120.925 0.393 . . . . 0.0 110.031 179.417 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 46.7 t-80 -152.83 118.99 5.49 Favored 'General case' 0 N--CA 1.472 0.654 0 N-CA-C 109.157 -0.683 . . . . 0.0 109.157 179.19 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 7' ' ' ASP . . . . . 0.508 ' O ' ' OG ' ' D' ' 8' ' ' SER . 4.3 m-20 -69.58 149.59 48.0 Favored 'General case' 0 N--CA 1.467 0.406 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.331 179.794 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 52.4 p -168.03 -173.27 2.02 Favored 'General case' 0 N--CA 1.484 1.243 0 CA-C-O 121.006 0.431 . . . . 0.0 110.698 179.107 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.79 46.49 1.49 Allowed Glycine 0 N--CA 1.481 1.686 0 CA-C-N 116.009 -0.541 . . . . 0.0 112.11 -179.941 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 49.1 p90 -65.12 132.43 49.14 Favored 'General case' 0 N--CA 1.473 0.685 0 O-C-N 122.687 -0.302 . . . . 0.0 111.561 179.631 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 49.2 mt-10 -91.83 152.13 20.26 Favored 'General case' 0 N--CA 1.477 0.889 0 N-CA-C 109.87 -0.419 . . . . 0.0 109.87 178.297 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -152.73 128.45 1.69 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.592 0 N-CA-C 107.849 -1.167 . . . . 0.0 107.849 178.248 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 44.5 m-70 -135.54 145.94 47.54 Favored 'General case' 0 N--CA 1.491 1.617 0 CA-C-N 119.011 0.823 . . . . 0.0 111.374 -179.107 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -166.9 97.25 0.53 Allowed 'General case' 0 N--CA 1.481 1.107 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.635 179.571 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 14.7 pt20 -109.69 -174.01 2.4 Favored 'General case' 0 CA--C 1.505 -0.788 0 N-CA-C 108.36 -0.978 . . . . 0.0 108.36 179.887 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -162.71 98.98 1.0 Allowed 'General case' 0 N--CA 1.472 0.669 0 CA-C-N 114.59 -1.186 . . . . 0.0 108.309 178.274 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 6.7 mp -121.45 155.55 34.64 Favored 'General case' 0 N--CA 1.497 1.901 0 CA-C-O 121.832 0.825 . . . . 0.0 110.938 -178.347 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 58.3 t -111.59 126.47 68.98 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.046 0 CA-C-O 117.894 -1.05 . . . . 0.0 108.344 177.742 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 29.2 m-85 -126.27 122.9 36.84 Favored 'General case' 0 N--CA 1.496 1.862 0 CA-C-N 120.147 1.34 . . . . 0.0 110.284 179.281 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 68.1 m-85 54.02 74.02 0.35 Allowed 'General case' 0 N--CA 1.47 0.538 0 CA-C-O 121.398 0.618 . . . . 0.0 111.66 178.729 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -79.77 -78.29 0.16 Allowed 'General case' 0 C--N 1.353 0.734 0 CA-C-N 115.175 -0.92 . . . . 0.0 110.442 -179.902 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 40.8 tt0 -113.15 100.19 8.4 Favored 'General case' 0 N--CA 1.47 0.565 0 N-CA-C 108.327 -0.99 . . . . 0.0 108.327 179.603 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 4.4 p30 -158.74 138.72 12.09 Favored 'General case' 0 N--CA 1.485 1.282 0 CA-C-O 119.403 -0.332 . . . . 0.0 111.226 179.271 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.41 HG12 ' N ' ' A' ' 25' ' ' GLY . 57.4 t -59.83 163.9 0.87 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.783 0 N-CA-C 108.224 -1.028 . . . . 0.0 108.224 176.932 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.46 ' H ' ' HB ' ' D' ' 24' ' ' VAL . . . -117.06 47.15 1.06 Allowed Glycine 0 N--CA 1.477 1.39 0 N-CA-C 111.753 -0.539 . . . . 0.0 111.753 -179.219 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -60.11 -167.79 0.01 OUTLIER 'General case' 0 N--CA 1.469 0.512 0 O-C-N 123.852 0.384 . . . . 0.0 110.405 179.272 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 4.9 t30 -70.98 81.05 0.66 Allowed 'General case' 0 CA--C 1.531 0.219 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.212 179.6 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 97.7 mttt -77.93 143.16 37.9 Favored 'General case' 0 N--CA 1.471 0.582 0 N-CA-C 109.163 -0.68 . . . . 0.0 109.163 179.396 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.67 -167.51 1.06 Allowed Glycine 0 CA--C 1.525 0.707 0 N-CA-C 109.926 -1.269 . . . . 0.0 109.926 178.962 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.91 115.02 28.67 Favored 'General case' 0 N--CA 1.476 0.846 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 179.677 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 72.3 mt -98.68 134.46 37.34 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.518 0 N-CA-C 107.025 -1.472 . . . . 0.0 107.025 179.021 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 29.3 pt -150.68 -172.0 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.708 0 CA-C-O 121.209 0.528 . . . . 0.0 111.184 -179.14 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.63 4.73 10.5 Favored Glycine 0 CA--C 1.527 0.785 0 N-CA-C 110.699 -0.96 . . . . 0.0 110.699 179.882 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.431 HD23 ' N ' ' A' ' 35' ' ' MET . 1.1 tt -75.43 135.16 40.75 Favored 'General case' 0 CA--C 1.544 0.726 0 N-CA-C 109.405 -0.591 . . . . 0.0 109.405 -179.56 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 35' ' ' MET . . . . . 0.431 ' N ' HD23 ' A' ' 34' ' ' LEU . 27.2 ttt -158.54 146.64 18.33 Favored 'General case' 0 N--CA 1.47 0.546 0 N-CA-C 108.557 -0.905 . . . . 0.0 108.557 178.705 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 1.7 m -149.16 165.49 3.78 Favored 'Isoleucine or valine' 0 C--N 1.349 0.579 0 N-CA-C 108.056 -1.09 . . . . 0.0 108.056 -179.584 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.19 68.36 1.73 Allowed Glycine 0 C--N 1.305 -1.158 0 CA-C-N 115.521 -0.763 . . . . 0.0 112.316 177.581 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.32 177.32 21.73 Favored Glycine 0 N--CA 1.474 1.192 0 N-CA-C 111.008 -0.837 . . . . 0.0 111.008 178.514 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.437 ' H ' HG12 ' D' ' 39' ' ' VAL . 34.3 m -109.81 155.59 10.95 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.623 0 C-N-CA 123.432 0.693 . . . . 0.0 110.354 -179.643 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 23.4 t . . . . . 0 C--O 1.219 -0.501 0 O-C-N 124.031 0.832 . . . . 0.0 110.663 179.633 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 63.9 m-85 . . . . . 0 N--CA 1.475 0.804 0 N-CA-C 110.154 -0.313 . . . . 0.0 110.154 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -144.32 141.92 30.07 Favored 'General case' 0 N--CA 1.481 1.089 0 N-CA-C 109.881 -0.414 . . . . 0.0 109.881 179.513 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 47.2 t-80 -151.71 118.55 5.8 Favored 'General case' 0 N--CA 1.473 0.715 0 N-CA-C 109.319 -0.623 . . . . 0.0 109.319 178.989 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 7' ' ' ASP . . . . . 0.449 ' O ' ' OG ' ' E' ' 8' ' ' SER . 3.9 m-20 -69.2 148.9 49.21 Favored 'General case' 0 N--CA 1.469 0.485 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.525 179.761 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 8' ' ' SER . . . . . . . . . . . . . 49.4 p -167.52 -173.49 2.22 Favored 'General case' 0 N--CA 1.481 1.125 0 CA-C-O 120.974 0.416 . . . . 0.0 110.653 179.155 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.26 46.92 1.38 Allowed Glycine 0 N--CA 1.482 1.728 0 CA-C-N 116.007 -0.542 . . . . 0.0 112.158 179.987 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 48.7 p90 -65.74 132.33 48.48 Favored 'General case' 0 N--CA 1.472 0.668 0 O-C-N 122.733 -0.274 . . . . 0.0 111.618 179.663 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 48.6 mt-10 -91.52 152.32 20.37 Favored 'General case' 0 N--CA 1.475 0.819 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 178.167 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -153.05 128.25 1.54 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.581 0 N-CA-C 107.783 -1.191 . . . . 0.0 107.783 178.148 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 45.5 m-70 -135.4 145.86 47.72 Favored 'General case' 0 N--CA 1.493 1.692 0 CA-C-N 118.843 0.747 . . . . 0.0 111.37 -179.141 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -166.57 97.15 0.56 Allowed 'General case' 0 N--CA 1.48 1.05 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.651 179.485 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 14.9 pt20 -109.54 -173.62 2.3 Favored 'General case' 0 CA--C 1.507 -0.7 0 N-CA-C 108.324 -0.991 . . . . 0.0 108.324 179.854 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -163.2 98.82 0.94 Allowed 'General case' 0 N--CA 1.473 0.696 0 CA-C-N 114.699 -1.137 . . . . 0.0 108.279 178.357 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 6.6 mp -121.17 155.56 34.27 Favored 'General case' 0 N--CA 1.498 1.925 0 CA-C-O 121.894 0.854 . . . . 0.0 110.927 -178.298 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 60.4 t -111.77 127.69 68.78 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.082 0 N-CA-C 108.037 -1.097 . . . . 0.0 108.037 177.538 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 28.5 m-85 -127.66 122.34 32.78 Favored 'General case' 0 N--CA 1.495 1.821 0 CA-C-N 119.665 1.12 . . . . 0.0 110.161 179.566 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 67.4 m-85 53.96 73.65 0.37 Allowed 'General case' 0 CA--C 1.54 0.571 0 CA-C-O 121.505 0.669 . . . . 0.0 111.67 178.615 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -79.65 -78.0 0.17 Allowed 'General case' 0 C--N 1.351 0.649 0 CA-C-N 115.078 -0.965 . . . . 0.0 110.435 -179.917 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 41.0 tt0 -113.4 99.62 7.92 Favored 'General case' 0 N--CA 1.47 0.56 0 N-CA-C 108.499 -0.926 . . . . 0.0 108.499 179.624 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -157.99 139.15 13.35 Favored 'General case' 0 C--O 1.205 -1.266 0 CA-C-O 119.447 -0.311 . . . . 0.0 111.208 179.204 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 59.9 t -60.15 163.49 0.98 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.824 0 N-CA-C 108.212 -1.033 . . . . 0.0 108.212 176.976 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 25' ' ' GLY . . . . . 0.472 ' H ' ' HB ' ' E' ' 24' ' ' VAL . . . -116.42 47.63 1.02 Allowed Glycine 0 N--CA 1.476 1.357 0 N-CA-C 111.628 -0.589 . . . . 0.0 111.628 -179.167 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -60.69 -167.68 0.01 OUTLIER 'General case' 0 N--CA 1.468 0.46 0 O-C-N 123.782 0.342 . . . . 0.0 110.306 179.414 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 4.5 t30 -71.17 81.01 0.71 Allowed 'General case' 0 CA--C 1.532 0.27 0 N-CA-C 110.074 -0.343 . . . . 0.0 110.074 179.616 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 97.7 mttt -77.9 143.1 38.01 Favored 'General case' 0 N--CA 1.472 0.638 0 N-CA-C 109.105 -0.702 . . . . 0.0 109.105 179.442 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.49 -167.42 0.97 Allowed Glycine 0 C--N 1.337 0.618 0 N-CA-C 109.92 -1.272 . . . . 0.0 109.92 178.894 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -100.25 114.78 28.49 Favored 'General case' 0 N--CA 1.475 0.786 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 179.757 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 71.5 mt -98.46 134.51 36.8 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.501 0 N-CA-C 107.105 -1.443 . . . . 0.0 107.105 178.889 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 30.1 pt -150.31 -171.37 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.647 0 CA-C-O 121.115 0.484 . . . . 0.0 111.227 -179.166 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.1 4.57 8.11 Favored Glycine 0 CA--C 1.526 0.752 0 N-CA-C 110.835 -0.906 . . . . 0.0 110.835 179.748 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 34' ' ' LEU . . . . . 0.421 HD23 ' N ' ' B' ' 35' ' ' MET . 1.1 tt -75.11 135.08 41.18 Favored 'General case' 0 CA--C 1.544 0.726 0 N-CA-C 109.376 -0.601 . . . . 0.0 109.376 -179.554 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 35' ' ' MET . . . . . 0.421 ' N ' HD23 ' B' ' 34' ' ' LEU . 27.1 ttt -158.24 146.63 18.77 Favored 'General case' 0 N--CA 1.472 0.628 0 N-CA-C 108.57 -0.9 . . . . 0.0 108.57 178.547 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 1.6 m -149.29 165.45 3.7 Favored 'Isoleucine or valine' 0 C--N 1.347 0.48 0 N-CA-C 108.018 -1.105 . . . . 0.0 108.018 -179.503 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 54.81 68.67 1.56 Allowed Glycine 0 C--N 1.305 -1.158 0 CA-C-N 115.354 -0.839 . . . . 0.0 112.23 177.654 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 146.95 176.89 21.09 Favored Glycine 0 N--CA 1.474 1.194 0 N-CA-C 111.106 -0.797 . . . . 0.0 111.106 178.612 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 39' ' ' VAL . . . . . 0.436 ' H ' HG12 ' E' ' 39' ' ' VAL . 34.1 m -109.68 155.22 10.92 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.698 0 C-N-CA 123.412 0.685 . . . . 0.0 110.415 -179.501 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 23.2 t . . . . . 0 C--O 1.218 -0.569 0 O-C-N 123.991 0.807 . . . . 0.0 110.331 179.552 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 62.0 m-85 . . . . . 0 N--CA 1.476 0.87 0 N-CA-C 110.179 -0.304 . . . . 0.0 110.179 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -144.38 142.27 30.24 Favored 'General case' 0 N--CA 1.482 1.139 0 N-CA-C 109.994 -0.373 . . . . 0.0 109.994 179.426 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 46.7 t-80 -152.19 118.97 5.74 Favored 'General case' 0 N--CA 1.472 0.673 0 N-CA-C 109.216 -0.661 . . . . 0.0 109.216 179.216 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 7' ' ' ASP . . . . . 0.492 ' O ' ' OG ' ' F' ' 8' ' ' SER . 4.1 m-20 -69.69 149.11 48.41 Favored 'General case' 0 N--CA 1.467 0.423 0 CA-C-N 116.356 -0.384 . . . . 0.0 110.485 179.793 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 8' ' ' SER . . . . . . . . . . . . . 52.3 p -167.7 -173.18 2.08 Favored 'General case' 0 N--CA 1.483 1.192 0 CA-C-O 121.018 0.437 . . . . 0.0 110.604 179.051 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.01 46.8 1.42 Allowed Glycine 0 N--CA 1.481 1.651 0 CA-C-N 115.898 -0.592 . . . . 0.0 112.201 -179.978 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 48.4 p90 -65.81 132.34 48.47 Favored 'General case' 0 N--CA 1.474 0.737 0 CA-C-O 120.699 0.285 . . . . 0.0 111.532 179.805 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 48.2 mt-10 -91.4 152.4 20.42 Favored 'General case' 0 N--CA 1.474 0.759 0 CA-C-O 121.001 0.429 . . . . 0.0 109.871 178.141 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -152.96 128.29 1.57 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.514 0 N-CA-C 107.81 -1.181 . . . . 0.0 107.81 178.193 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 42.8 m-70 -135.42 145.87 47.68 Favored 'General case' 0 N--CA 1.492 1.647 0 CA-C-N 118.939 0.79 . . . . 0.0 111.309 -179.141 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -166.74 97.19 0.55 Allowed 'General case' 0 N--CA 1.481 1.09 0 CA-C-N 116.414 -0.357 . . . . 0.0 110.571 179.481 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 14.8 pt20 -109.58 -173.68 2.32 Favored 'General case' 0 CA--C 1.504 -0.799 0 N-CA-C 108.381 -0.97 . . . . 0.0 108.381 179.884 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -163.19 98.91 0.94 Allowed 'General case' 0 N--CA 1.471 0.601 0 CA-C-N 114.695 -1.139 . . . . 0.0 108.304 178.332 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 6.6 mp -121.37 155.35 34.98 Favored 'General case' 0 N--CA 1.497 1.906 0 CA-C-O 121.846 0.832 . . . . 0.0 111.0 -178.32 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 61.0 t -111.43 127.45 68.57 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.065 0 N-CA-C 108.183 -1.043 . . . . 0.0 108.183 177.532 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 28.5 m-85 -127.28 122.52 34.07 Favored 'General case' 0 N--CA 1.494 1.747 0 CA-C-N 119.674 1.125 . . . . 0.0 110.152 179.527 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 68.0 m-85 53.57 73.98 0.34 Allowed 'General case' 0 CA--C 1.539 0.545 0 CA-C-O 121.502 0.668 . . . . 0.0 111.745 178.615 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -79.88 -78.12 0.17 Allowed 'General case' 0 C--N 1.351 0.644 0 CA-C-N 114.999 -1.001 . . . . 0.0 110.342 -179.864 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 40.9 tt0 -113.24 99.86 8.13 Favored 'General case' 0 N--CA 1.47 0.556 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 179.675 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 4.4 p30 -158.41 138.73 12.51 Favored 'General case' 0 N--CA 1.484 1.236 0 CA-C-O 119.46 -0.305 . . . . 0.0 111.23 179.112 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 24' ' ' VAL . . . . . 0.405 HG12 ' N ' ' C' ' 25' ' ' GLY . 62.1 t -59.55 164.23 0.8 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.87 0 N-CA-C 108.124 -1.065 . . . . 0.0 108.124 177.107 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 25' ' ' GLY . . . . . 0.471 ' H ' ' HB ' ' F' ' 24' ' ' VAL . . . -117.14 47.3 1.05 Allowed Glycine 0 N--CA 1.477 1.368 0 N-CA-C 111.553 -0.619 . . . . 0.0 111.553 -179.298 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -60.31 -168.11 0.01 OUTLIER 'General case' 0 N--CA 1.468 0.465 0 O-C-N 123.747 0.322 . . . . 0.0 110.335 179.301 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 4.7 t30 -70.78 80.96 0.62 Allowed 'General case' 0 N--CA 1.465 0.317 0 N-CA-C 110.087 -0.338 . . . . 0.0 110.087 179.478 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 97.7 mttt -77.76 142.91 38.38 Favored 'General case' 0 N--CA 1.472 0.665 0 N-CA-C 109.151 -0.685 . . . . 0.0 109.151 179.32 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.51 -167.87 1.06 Allowed Glycine 0 CA--C 1.524 0.621 0 N-CA-C 109.938 -1.265 . . . . 0.0 109.938 178.826 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.5 114.84 28.06 Favored 'General case' 0 N--CA 1.477 0.894 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 179.708 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 71.5 mt -98.64 134.21 38.19 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.591 0 N-CA-C 106.98 -1.489 . . . . 0.0 106.98 178.85 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 29.9 pt -150.18 -171.57 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.352 0.713 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.21 -179.217 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.2 4.81 8.86 Favored Glycine 0 CA--C 1.526 0.767 0 N-CA-C 110.795 -0.922 . . . . 0.0 110.795 179.815 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 34' ' ' LEU . . . . . 0.429 HD23 ' N ' ' C' ' 35' ' ' MET . 1.1 tt -75.32 135.15 40.9 Favored 'General case' 0 CA--C 1.545 0.759 0 N-CA-C 109.273 -0.639 . . . . 0.0 109.273 -179.579 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 35' ' ' MET . . . . . 0.429 ' N ' HD23 ' C' ' 34' ' ' LEU . 27.3 ttt -158.41 146.4 18.35 Favored 'General case' 0 N--CA 1.471 0.585 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 178.734 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 1.6 m -149.25 165.44 3.73 Favored 'Isoleucine or valine' 0 C--N 1.348 0.506 0 N-CA-C 107.985 -1.117 . . . . 0.0 107.985 -179.476 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.08 68.56 1.62 Allowed Glycine 0 C--N 1.306 -1.13 0 CA-C-N 115.384 -0.825 . . . . 0.0 112.186 177.563 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.0 177.21 21.39 Favored Glycine 0 N--CA 1.473 1.132 0 N-CA-C 111.019 -0.832 . . . . 0.0 111.019 178.579 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 39' ' ' VAL . . . . . 0.437 ' H ' HG12 ' F' ' 39' ' ' VAL . 34.4 m -109.94 155.57 11.1 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.681 0 C-N-CA 123.401 0.68 . . . . 0.0 110.351 -179.523 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 23.6 t . . . . . 0 C--O 1.219 -0.514 0 O-C-N 124.021 0.826 . . . . 0.0 110.478 179.645 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 72.1 m-85 . . . . . 0 N--CA 1.474 0.748 0 N-CA-C 108.608 -0.886 . . . . 0.0 108.608 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' D' D ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -146.89 140.56 25.77 Favored 'General case' 0 N--CA 1.475 0.822 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.276 179.794 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 43.6 t-80 -149.78 123.69 9.33 Favored 'General case' 0 CA--C 1.545 0.78 0 N-CA-C 108.19 -1.041 . . . . 0.0 108.19 175.005 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' D' D ' 7' ' ' ASP . . . . . 0.593 ' O ' ' OG ' ' G' ' 8' ' ' SER . 2.9 m-20 -63.89 132.83 51.96 Favored 'General case' 0 C--N 1.321 -0.664 0 C-N-CA 127.068 2.147 . . . . 0.0 114.479 174.269 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' D' D ' 8' ' ' SER . . . . . 0.508 ' OG ' ' O ' ' A' ' 7' ' ' ASP . 51.9 p -154.8 -170.22 3.44 Favored 'General case' 0 N--CA 1.485 1.313 0 CA-C-N 120.046 1.294 . . . . 0.0 111.317 175.159 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.38 47.89 1.18 Allowed Glycine 0 N--CA 1.481 1.639 0 C-N-CA 124.553 1.073 . . . . 0.0 110.419 174.688 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 50.9 p90 -61.06 131.05 49.34 Favored 'General case' 0 N--CA 1.472 0.634 0 N-CA-C 112.725 0.639 . . . . 0.0 112.725 177.928 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 48.4 mt-10 -88.94 150.96 22.59 Favored 'General case' 0 N--CA 1.481 1.086 0 CA-C-N 117.961 0.346 . . . . 0.0 110.752 175.125 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -149.57 130.04 4.35 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.533 0 N-CA-C 107.518 -1.29 . . . . 0.0 107.518 173.119 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 40.9 m-70 -130.03 148.36 51.87 Favored 'General case' 0 N--CA 1.484 1.249 0 CA-C-N 118.098 0.408 . . . . 0.0 111.98 176.4 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -165.35 104.47 0.74 Allowed 'General case' 0 N--CA 1.481 1.098 0 N-CA-C 109.079 -0.711 . . . . 0.0 109.079 172.352 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 14.8 pt20 -113.36 -175.89 2.77 Favored 'General case' 0 CA--C 1.496 -1.127 0 N-CA-C 108.227 -1.027 . . . . 0.0 108.227 178.669 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -159.41 106.22 1.71 Allowed 'General case' 0 N--CA 1.468 0.444 0 N-CA-C 106.552 -1.648 . . . . 0.0 106.552 175.352 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 5.5 mp -128.01 152.87 47.4 Favored 'General case' 0 N--CA 1.499 2.008 0 CA-C-O 122.187 0.994 . . . . 0.0 110.396 179.795 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 38.4 t -101.01 131.66 48.24 Favored 'Isoleucine or valine' 0 C--O 1.258 1.518 0 CA-C-O 116.845 -1.55 . . . . 0.0 109.741 174.102 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 26.6 m-85 -130.27 126.39 37.15 Favored 'General case' 0 N--CA 1.491 1.617 0 CA-C-N 120.074 1.306 . . . . 0.0 109.417 173.61 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 68.5 m-85 55.27 71.67 0.53 Allowed 'General case' 0 C--N 1.35 0.597 0 CA-C-N 115.508 -0.769 . . . . 0.0 111.441 176.664 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -82.13 -73.21 0.4 Allowed 'General case' 0 C--N 1.353 0.721 0 CA-C-O 118.415 -0.803 . . . . 0.0 111.197 -177.693 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 41.1 tt0 -116.45 103.9 10.9 Favored 'General case' 0 N--CA 1.48 1.074 0 N-CA-C 106.434 -1.691 . . . . 0.0 106.434 176.124 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -151.82 138.5 18.79 Favored 'General case' 0 N--CA 1.477 0.896 0 CA-C-O 116.592 -1.671 . . . . 0.0 113.559 177.983 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' D' D ' 24' ' ' VAL . . . . . 0.46 ' HB ' ' H ' ' A' ' 25' ' ' GLY . 63.5 t -62.26 166.41 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.267 0 CA-C-N 121.264 1.847 . . . . 0.0 107.964 174.961 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' D' D ' 25' ' ' GLY . . . . . 0.531 ' H ' ' HB ' ' G' ' 24' ' ' VAL . . . -116.78 51.04 0.75 Allowed Glycine 0 N--CA 1.479 1.556 0 CA-C-O 118.964 -0.909 . . . . 0.0 111.654 178.593 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -57.1 -170.91 0.01 OUTLIER 'General case' 0 C--N 1.322 -0.627 0 C-N-CA 123.688 0.795 . . . . 0.0 111.639 175.768 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 5.6 t30 -72.54 86.81 1.19 Allowed 'General case' 0 C--N 1.347 0.475 0 C-N-CA 119.286 -0.965 . . . . 0.0 108.572 177.928 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 97.2 mttt -83.04 146.01 28.97 Favored 'General case' 0 N--CA 1.473 0.716 0 N-CA-C 107.948 -1.13 . . . . 0.0 107.948 179.281 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.45 -165.61 0.72 Allowed Glycine 0 C--N 1.337 0.609 0 N-CA-C 110.356 -1.098 . . . . 0.0 110.356 179.524 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -102.04 116.04 31.83 Favored 'General case' 0 N--CA 1.472 0.627 0 N-CA-C 109.36 -0.607 . . . . 0.0 109.36 179.594 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 80.8 mt -102.59 142.22 17.15 Favored 'Isoleucine or valine' 0 C--N 1.357 0.933 0 N-CA-C 104.568 -2.382 . . . . 0.0 104.568 179.979 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' D' D ' 32' ' ' ILE . . . . . 0.444 HG22 ' H ' ' G' ' 32' ' ' ILE . 30.0 pt -157.37 -172.59 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.482 1.148 0 CA-C-O 120.84 0.353 . . . . 0.0 110.189 -177.479 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 64.23 4.31 11.72 Favored Glycine 0 N--CA 1.466 0.668 0 N-CA-C 110.27 -1.132 . . . . 0.0 110.27 -178.917 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 1.3 tt -76.29 140.28 41.45 Favored 'General case' 0 CA--C 1.543 0.708 0 N-CA-C 107.797 -1.186 . . . . 0.0 107.797 -178.142 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 26.8 ttt -156.45 156.17 33.33 Favored 'General case' 0 C--O 1.244 0.782 0 N-CA-C 107.774 -1.195 . . . . 0.0 107.774 174.436 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 1.8 m -158.04 164.05 1.14 Allowed 'Isoleucine or valine' 0 CA--C 1.515 -0.399 0 N-CA-C 107.53 -1.285 . . . . 0.0 107.53 177.973 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 61.42 63.66 4.67 Favored Glycine 0 CA--C 1.526 0.742 0 C-N-CA 119.773 -1.203 . . . . 0.0 112.101 177.212 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 145.71 177.87 20.77 Favored Glycine 0 N--CA 1.478 1.469 0 CA-C-N 118.388 1.094 . . . . 0.0 111.665 179.885 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' D' D ' 39' ' ' VAL . . . . . 0.437 HG12 ' H ' ' A' ' 39' ' ' VAL . 35.2 m -112.64 152.36 14.43 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.881 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -176.89 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 23.5 t . . . . . 0 CA--C 1.522 -0.12 0 CA-C-O 116.166 -1.873 . . . . 0.0 109.597 178.315 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 63.2 m-85 . . . . . 0 N--CA 1.477 0.902 0 N-CA-C 110.27 -0.27 . . . . 0.0 110.27 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' E' E ' 5' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -143.6 142.69 31.17 Favored 'General case' 0 N--CA 1.48 1.039 0 CA-C-O 120.857 0.361 . . . . 0.0 110.163 179.356 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 45.7 t-80 -152.27 119.16 5.78 Favored 'General case' 0 N--CA 1.473 0.707 0 N-CA-C 109.194 -0.669 . . . . 0.0 109.194 179.027 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' E' E ' 7' ' ' ASP . . . . . 0.441 ' O ' ' OG ' ' H' ' 8' ' ' SER . 3.9 m-20 -70.23 149.26 47.66 Favored 'General case' 0 N--CA 1.469 0.501 0 CA-C-N 116.425 -0.352 . . . . 0.0 110.633 179.805 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' E' E ' 8' ' ' SER . . . . . 0.449 ' OG ' ' O ' ' B' ' 7' ' ' ASP . 44.5 p -168.68 -171.69 1.46 Allowed 'General case' 0 N--CA 1.484 1.234 0 CA-C-O 121.02 0.438 . . . . 0.0 110.842 178.591 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.05 47.02 1.38 Allowed Glycine 0 N--CA 1.478 1.476 0 CA-C-N 115.946 -0.57 . . . . 0.0 111.958 179.905 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 46.5 p90 -65.12 132.91 50.41 Favored 'General case' 0 N--CA 1.474 0.738 0 N-CA-C 111.881 0.326 . . . . 0.0 111.881 -179.873 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 48.9 mt-10 -91.45 152.71 20.26 Favored 'General case' 0 N--CA 1.479 0.989 0 CA-C-O 121.13 0.49 . . . . 0.0 109.75 177.885 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -154.58 127.59 1.13 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.538 0 N-CA-C 107.849 -1.167 . . . . 0.0 107.849 178.093 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 43.3 m-70 -135.89 143.97 45.3 Favored 'General case' 0 N--CA 1.482 1.135 0 CA-C-O 120.857 0.36 . . . . 0.0 111.609 -178.049 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -165.57 96.72 0.66 Allowed 'General case' 0 N--CA 1.484 1.256 0 CA-C-N 116.442 -0.345 . . . . 0.0 110.693 179.681 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 15.0 pt20 -108.71 -173.67 2.33 Favored 'General case' 0 CA--C 1.507 -0.688 0 N-CA-C 108.56 -0.904 . . . . 0.0 108.56 179.909 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -162.87 98.11 0.96 Allowed 'General case' 0 N--CA 1.477 0.903 0 CA-C-N 114.693 -1.139 . . . . 0.0 108.376 178.351 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 6.5 mp -120.07 155.48 32.87 Favored 'General case' 0 N--CA 1.495 1.78 0 CA-C-O 121.604 0.716 . . . . 0.0 111.5 -177.87 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 48.9 t -113.61 124.5 70.31 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.244 0 N-CA-C 108.249 -1.019 . . . . 0.0 108.249 177.167 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 31.3 m-85 -124.73 121.69 35.36 Favored 'General case' 0 N--CA 1.49 1.535 0 CA-C-O 120.921 0.391 . . . . 0.0 110.792 -179.769 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 70.0 m-85 54.75 73.21 0.42 Allowed 'General case' 0 N--CA 1.469 0.511 0 CA-C-N 115.969 -0.559 . . . . 0.0 111.281 178.219 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -78.39 -78.72 0.14 Allowed 'General case' 0 C--N 1.345 0.377 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.358 -179.594 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 40.4 tt0 -112.55 100.09 8.47 Favored 'General case' 0 C--N 1.325 -0.474 0 N-CA-C 108.467 -0.938 . . . . 0.0 108.467 179.758 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -157.31 138.5 13.6 Favored 'General case' 0 C--O 1.203 -1.369 0 CA-C-O 119.371 -0.347 . . . . 0.0 111.553 179.287 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' E' E ' 24' ' ' VAL . . . . . 0.472 ' HB ' ' H ' ' B' ' 25' ' ' GLY . 59.3 t -58.02 168.52 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.903 0 N-CA-C 107.663 -1.236 . . . . 0.0 107.663 176.615 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' E' E ' 25' ' ' GLY . . . . . 0.427 ' H ' ' HB ' ' H' ' 24' ' ' VAL . . . -122.05 48.44 0.95 Allowed Glycine 0 N--CA 1.476 1.325 0 N-CA-C 110.735 -0.946 . . . . 0.0 110.735 -179.104 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -61.93 -167.41 0.01 OUTLIER 'General case' 0 N--CA 1.47 0.559 0 CA-C-O 120.729 0.3 . . . . 0.0 110.514 179.74 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 5.7 t30 -70.34 77.33 0.55 Allowed 'General case' 0 N--CA 1.465 0.285 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.45 -179.939 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 97.8 mttt -74.69 143.55 44.16 Favored 'General case' 0 N--CA 1.474 0.765 0 N-CA-C 109.646 -0.502 . . . . 0.0 109.646 179.484 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.29 -167.44 1.29 Allowed Glycine 0 CA--C 1.522 0.496 0 N-CA-C 110.339 -1.105 . . . . 0.0 110.339 178.71 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.56 114.26 27.17 Favored 'General case' 0 N--CA 1.476 0.838 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 179.693 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 70.8 mt -98.32 134.23 37.64 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.35 0 N-CA-C 106.812 -1.551 . . . . 0.0 106.812 179.02 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' E' E ' 32' ' ' ILE . . . . . 0.439 HG22 ' H ' ' H' ' 32' ' ' ILE . 30.9 pt -150.24 -169.8 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.149 0 CA-C-O 120.998 0.428 . . . . 0.0 110.785 -179.313 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.41 5.2 6.02 Favored Glycine 0 CA--C 1.531 1.056 0 N-CA-C 111.288 -0.725 . . . . 0.0 111.288 -179.781 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' E' E ' 34' ' ' LEU . . . . . 0.419 HD23 ' N ' ' E' ' 35' ' ' MET . 1.1 tt -74.88 135.64 41.52 Favored 'General case' 0 CA--C 1.547 0.86 0 N-CA-C 109.304 -0.628 . . . . 0.0 109.304 -179.597 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' E' E ' 35' ' ' MET . . . . . 0.419 ' N ' HD23 ' E' ' 34' ' ' LEU . 26.6 ttt -158.82 145.57 17.22 Favored 'General case' 0 N--CA 1.474 0.734 0 N-CA-C 108.638 -0.875 . . . . 0.0 108.638 178.811 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 1.4 m -148.53 165.44 4.61 Favored 'Isoleucine or valine' 0 C--N 1.347 0.495 0 N-CA-C 108.388 -0.967 . . . . 0.0 108.388 -179.546 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 54.56 68.27 1.76 Allowed Glycine 0 C--N 1.308 -0.998 0 CA-C-N 115.266 -0.879 . . . . 0.0 112.1 177.573 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 146.81 174.28 18.77 Favored Glycine 0 N--CA 1.472 1.081 0 N-CA-C 111.381 -0.687 . . . . 0.0 111.381 178.685 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' E' E ' 39' ' ' VAL . . . . . 0.436 HG12 ' H ' ' B' ' 39' ' ' VAL . 33.1 m -107.58 154.97 8.47 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.768 0 C-N-CA 123.624 0.77 . . . . 0.0 110.568 -178.843 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 25.2 t . . . . . 0 C--O 1.219 -0.535 0 O-C-N 124.263 0.977 . . . . 0.0 110.263 179.802 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 63.8 m-85 . . . . . 0 N--CA 1.474 0.752 0 N-CA-C 110.199 -0.297 . . . . 0.0 110.199 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' F' F ' 5' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -143.51 143.26 31.48 Favored 'General case' 0 N--CA 1.477 0.908 0 CA-C-O 120.817 0.342 . . . . 0.0 110.195 179.318 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 46.1 t-80 -152.98 118.87 5.39 Favored 'General case' 0 N--CA 1.473 0.72 0 N-CA-C 109.275 -0.639 . . . . 0.0 109.275 179.055 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' F' F ' 7' ' ' ASP . . . . . 0.483 ' O ' ' OG ' ' I' ' 8' ' ' SER . 3.9 m-20 -70.2 149.03 47.92 Favored 'General case' 0 N--CA 1.468 0.447 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.68 179.981 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' F' F ' 8' ' ' SER . . . . . 0.492 ' OG ' ' O ' ' C' ' 7' ' ' ASP . 41.7 p -168.56 -171.74 1.5 Allowed 'General case' 0 N--CA 1.486 1.35 0 CA-C-O 121.039 0.447 . . . . 0.0 110.936 178.679 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.14 46.69 1.42 Allowed Glycine 0 N--CA 1.478 1.492 0 CA-C-N 115.951 -0.568 . . . . 0.0 111.984 179.955 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 46.3 p90 -64.65 132.74 50.57 Favored 'General case' 0 N--CA 1.474 0.734 0 O-C-N 122.623 -0.34 . . . . 0.0 111.913 -179.866 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 49.2 mt-10 -91.27 152.53 20.46 Favored 'General case' 0 N--CA 1.48 1.036 0 CA-C-O 121.158 0.504 . . . . 0.0 109.796 177.777 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -154.43 127.06 1.07 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.584 0 N-CA-C 107.828 -1.175 . . . . 0.0 107.828 178.13 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 42.0 m-70 -135.47 143.86 46.09 Favored 'General case' 0 N--CA 1.485 1.279 0 CA-C-O 120.849 0.357 . . . . 0.0 111.558 -178.045 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -165.32 97.11 0.69 Allowed 'General case' 0 N--CA 1.483 1.221 0 CA-C-N 116.43 -0.35 . . . . 0.0 110.771 179.754 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 15.0 pt20 -109.48 -174.17 2.44 Favored 'General case' 0 CA--C 1.503 -0.851 0 N-CA-C 108.629 -0.878 . . . . 0.0 108.629 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -162.22 98.46 1.04 Allowed 'General case' 0 N--CA 1.474 0.734 0 CA-C-N 114.694 -1.139 . . . . 0.0 108.401 178.384 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 6.4 mp -120.36 155.28 33.7 Favored 'General case' 0 N--CA 1.494 1.757 0 CA-C-O 121.532 0.682 . . . . 0.0 111.518 -177.854 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 50.2 t -113.41 124.2 69.81 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.246 0 N-CA-C 108.341 -0.985 . . . . 0.0 108.341 177.257 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 31.2 m-85 -124.56 121.58 35.18 Favored 'General case' 0 N--CA 1.489 1.49 0 CA-C-O 120.91 0.386 . . . . 0.0 110.796 -179.846 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 69.0 m-85 54.79 73.79 0.39 Allowed 'General case' 0 N--CA 1.468 0.437 0 CA-C-N 115.938 -0.574 . . . . 0.0 111.464 178.399 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -78.98 -78.31 0.15 Allowed 'General case' 0 C--N 1.344 0.359 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.537 -179.607 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 40.8 tt0 -112.76 100.09 8.42 Favored 'General case' 0 C--N 1.325 -0.471 0 N-CA-C 108.341 -0.985 . . . . 0.0 108.341 179.664 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -157.53 138.65 13.49 Favored 'General case' 0 C--O 1.205 -1.243 0 CA-C-O 119.422 -0.323 . . . . 0.0 111.532 179.282 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' F' F ' 24' ' ' VAL . . . . . 0.471 ' HB ' ' H ' ' C' ' 25' ' ' GLY . 59.6 t -58.46 168.35 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.94 0 N-CA-C 107.646 -1.242 . . . . 0.0 107.646 176.757 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' F' F ' 25' ' ' GLY . . . . . 0.435 ' H ' ' HB ' ' I' ' 24' ' ' VAL . . . -121.73 48.07 0.98 Allowed Glycine 0 N--CA 1.477 1.418 0 N-CA-C 110.789 -0.924 . . . . 0.0 110.789 -179.163 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -61.62 -167.05 0.01 OUTLIER 'General case' 0 N--CA 1.469 0.481 0 CA-C-N 116.768 0.284 . . . . 0.0 110.453 179.771 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 5.7 t30 -70.67 76.84 0.6 Allowed 'General case' 0 N--CA 1.466 0.367 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.441 -179.881 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -74.01 143.86 45.38 Favored 'General case' 0 N--CA 1.473 0.709 0 N-CA-C 109.691 -0.485 . . . . 0.0 109.691 179.242 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.57 -167.19 1.34 Allowed Glycine 0 CA--C 1.522 0.517 0 N-CA-C 110.426 -1.07 . . . . 0.0 110.426 178.712 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.6 113.81 26.47 Favored 'General case' 0 N--CA 1.472 0.662 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.837 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 72.0 mt -98.09 134.54 36.08 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.372 0 N-CA-C 106.84 -1.541 . . . . 0.0 106.84 179.038 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' F' F ' 32' ' ' ILE . . . . . 0.43 HG22 ' H ' ' I' ' 32' ' ' ILE . 31.8 pt -150.47 -169.83 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.118 0 CA-C-O 121.052 0.453 . . . . 0.0 110.751 -179.409 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.64 4.9 5.95 Favored Glycine 0 CA--C 1.53 1.015 0 N-CA-C 111.261 -0.736 . . . . 0.0 111.261 -179.87 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' F' F ' 34' ' ' LEU . . . . . 0.425 HD23 ' N ' ' F' ' 35' ' ' MET . 1.1 tt -74.77 135.82 41.72 Favored 'General case' 0 CA--C 1.546 0.822 0 N-CA-C 109.241 -0.652 . . . . 0.0 109.241 -179.612 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' F' F ' 35' ' ' MET . . . . . 0.425 ' N ' HD23 ' F' ' 34' ' ' LEU . 26.5 ttt -158.89 145.86 17.3 Favored 'General case' 0 N--CA 1.473 0.686 0 N-CA-C 108.494 -0.928 . . . . 0.0 108.494 178.804 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 1.5 m -148.72 165.33 4.38 Favored 'Isoleucine or valine' 0 C--N 1.348 0.537 0 N-CA-C 108.366 -0.976 . . . . 0.0 108.366 -179.449 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 54.33 68.61 1.58 Allowed Glycine 0 C--N 1.308 -1.021 0 CA-C-N 115.307 -0.861 . . . . 0.0 112.113 177.634 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 146.6 174.07 18.39 Favored Glycine 0 N--CA 1.473 1.118 0 N-CA-C 111.355 -0.698 . . . . 0.0 111.355 178.722 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' F' F ' 39' ' ' VAL . . . . . 0.437 HG12 ' H ' ' C' ' 39' ' ' VAL . 33.0 m -107.42 155.0 8.27 Favored 'Isoleucine or valine' 0 C--N 1.352 0.696 0 C-N-CA 123.528 0.731 . . . . 0.0 110.604 -178.773 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 25.9 t . . . . . 0 C--O 1.219 -0.543 0 O-C-N 124.365 1.041 . . . . 0.0 110.356 179.892 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 64.8 m-85 . . . . . 0 N--CA 1.475 0.785 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' G' G ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -144.09 142.09 30.42 Favored 'General case' 0 N--CA 1.481 1.091 0 CA-C-O 120.823 0.345 . . . . 0.0 110.205 179.726 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 46.8 t-80 -151.69 119.59 6.2 Favored 'General case' 0 N--CA 1.473 0.676 0 N-CA-C 109.46 -0.57 . . . . 0.0 109.46 179.016 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 4.1 m-20 -71.94 144.41 48.94 Favored 'General case' 0 N--CA 1.471 0.603 0 C-N-CA 122.763 0.425 . . . . 0.0 111.154 -179.833 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' G' G ' 8' ' ' SER . . . . . 0.593 ' OG ' ' O ' ' D' ' 7' ' ' ASP . 37.5 p -164.69 -169.24 1.68 Allowed 'General case' 0 N--CA 1.476 0.86 0 CA-C-O 121.049 0.452 . . . . 0.0 110.496 178.535 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 101.95 47.59 1.46 Allowed Glycine 0 N--CA 1.478 1.488 0 N-CA-C 111.529 -0.628 . . . . 0.0 111.529 179.553 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 48.6 p90 -65.93 132.71 49.27 Favored 'General case' 0 N--CA 1.473 0.692 0 N-CA-C 111.803 0.297 . . . . 0.0 111.803 -179.688 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 48.4 mt-10 -91.5 152.03 20.51 Favored 'General case' 0 N--CA 1.479 1.018 0 CA-C-O 121.043 0.449 . . . . 0.0 110.163 178.374 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -154.96 127.81 1.1 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.008 0 N-CA-C 107.864 -1.161 . . . . 0.0 107.864 178.221 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 44.9 m-70 -135.25 144.83 47.07 Favored 'General case' 0 N--CA 1.477 0.922 0 CA-C-N 115.702 -0.681 . . . . 0.0 111.407 -178.259 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -166.52 96.85 0.57 Allowed 'General case' 0 N--CA 1.483 1.181 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.288 179.132 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 15.0 pt20 -109.11 -173.75 2.34 Favored 'General case' 0 CA--C 1.503 -0.831 0 N-CA-C 108.391 -0.966 . . . . 0.0 108.391 179.88 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -163.15 98.03 0.93 Allowed 'General case' 0 N--CA 1.474 0.747 0 CA-C-N 114.701 -1.136 . . . . 0.0 108.132 178.558 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 6.4 mp -120.06 154.29 34.85 Favored 'General case' 0 N--CA 1.496 1.86 0 CA-C-O 121.204 0.526 . . . . 0.0 111.793 -177.935 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 44.5 t -112.83 125.39 70.09 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.968 0 CA-C-N 114.898 -1.046 . . . . 0.0 108.19 176.548 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 32.2 m-85 -125.88 121.15 32.38 Favored 'General case' 0 C--N 1.366 1.315 0 C-N-CA 123.39 0.676 . . . . 0.0 110.853 -179.532 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 69.3 m-85 55.13 72.76 0.45 Allowed 'General case' 0 N--CA 1.469 0.521 0 CA-C-N 115.882 -0.599 . . . . 0.0 111.292 178.24 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.67 -78.26 0.14 Allowed 'General case' 0 N--CA 1.471 0.583 0 O-C-N 122.244 -0.285 . . . . 0.0 110.55 -179.189 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 41.3 tt0 -112.57 100.43 8.73 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 108.124 -1.065 . . . . 0.0 108.124 179.646 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -157.86 139.78 14.08 Favored 'General case' 0 N--CA 1.478 0.949 0 N-CA-C 111.516 0.191 . . . . 0.0 111.516 179.153 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' G' G ' 24' ' ' VAL . . . . . 0.531 ' HB ' ' H ' ' D' ' 25' ' ' GLY . 61.4 t -59.96 167.25 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.624 0 N-CA-C 107.669 -1.234 . . . . 0.0 107.669 177.268 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' G' G ' 25' ' ' GLY . . . . . 0.428 ' N ' HG12 ' G' ' 24' ' ' VAL . . . -120.35 49.68 0.87 Allowed Glycine 0 N--CA 1.482 1.718 0 N-CA-C 110.313 -1.115 . . . . 0.0 110.313 -179.453 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -63.56 -167.51 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.658 0 CA-C-N 117.001 0.401 . . . . 0.0 109.953 179.484 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 5.3 t30 -70.11 76.69 0.51 Allowed 'General case' 0 CA--C 1.535 0.386 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.478 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 97.9 mttt -73.36 143.92 46.66 Favored 'General case' 0 N--CA 1.474 0.77 0 N-CA-C 109.701 -0.481 . . . . 0.0 109.701 179.209 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.64 -166.08 1.14 Allowed Glycine 0 C--N 1.337 0.593 0 N-CA-C 110.069 -1.212 . . . . 0.0 110.069 178.723 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.82 113.93 26.76 Favored 'General case' 0 N--CA 1.47 0.541 0 C-N-CA 122.723 0.409 . . . . 0.0 110.393 179.897 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 74.7 mt -98.61 134.77 36.05 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.773 0 N-CA-C 106.784 -1.562 . . . . 0.0 106.784 179.03 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' G' G ' 32' ' ' ILE . . . . . 0.444 ' H ' HG22 ' D' ' 32' ' ' ILE . 34.6 pt -151.11 -169.38 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 CA-C-N 119.657 1.117 . . . . 0.0 109.917 -179.826 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.18 4.79 6.71 Favored Glycine 0 CA--C 1.529 0.926 0 N-CA-C 111.052 -0.819 . . . . 0.0 111.052 179.933 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' G' G ' 34' ' ' LEU . . . . . 0.44 HD23 ' N ' ' G' ' 35' ' ' MET . 1.1 tt -74.95 135.74 41.38 Favored 'General case' 0 CA--C 1.544 0.745 0 N-CA-C 109.209 -0.663 . . . . 0.0 109.209 -179.635 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' G' G ' 35' ' ' MET . . . . . 0.44 ' N ' HD23 ' G' ' 34' ' ' LEU . 25.3 ttt -158.86 146.06 17.48 Favored 'General case' 0 N--CA 1.47 0.533 0 N-CA-C 108.695 -0.854 . . . . 0.0 108.695 178.801 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 1.4 m -148.8 163.89 4.72 Favored 'Isoleucine or valine' 0 C--N 1.349 0.566 0 N-CA-C 108.509 -0.922 . . . . 0.0 108.509 -179.293 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.13 68.67 1.57 Allowed Glycine 0 C--N 1.308 -0.997 0 CA-C-N 115.305 -0.862 . . . . 0.0 112.207 177.39 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.33 173.16 18.22 Favored Glycine 0 N--CA 1.475 1.274 0 N-CA-C 110.599 -1.0 . . . . 0.0 110.599 178.934 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' G' G ' 39' ' ' VAL . . . . . 0.405 HG12 ' H ' ' D' ' 39' ' ' VAL . 34.1 m -106.88 155.11 7.64 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.873 0 C-N-CA 123.222 0.609 . . . . 0.0 110.668 -179.346 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 25.8 t . . . . . 0 C--O 1.219 -0.532 0 O-C-N 124.035 0.835 . . . . 0.0 110.622 179.721 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 64.4 m-85 . . . . . 0 N--CA 1.473 0.712 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' H' H ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -143.72 142.71 31.07 Favored 'General case' 0 N--CA 1.482 1.133 0 C-N-CA 122.592 0.357 . . . . 0.0 110.1 179.712 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 47.7 t-80 -152.2 119.6 5.98 Favored 'General case' 0 N--CA 1.475 0.788 0 N-CA-C 109.326 -0.62 . . . . 0.0 109.326 178.991 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -71.57 144.44 49.54 Favored 'General case' 0 N--CA 1.469 0.497 0 C-N-CA 122.767 0.427 . . . . 0.0 111.164 179.89 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' H' H ' 8' ' ' SER . . . . . 0.441 ' OG ' ' O ' ' E' ' 7' ' ' ASP . 52.5 p -164.9 -170.37 1.94 Allowed 'General case' 0 N--CA 1.474 0.754 0 CA-C-O 120.935 0.398 . . . . 0.0 110.48 178.504 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.87 47.17 1.39 Allowed Glycine 0 N--CA 1.48 1.587 0 CA-C-N 115.971 -0.559 . . . . 0.0 111.709 179.604 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 48.2 p90 -65.61 132.67 49.41 Favored 'General case' 0 N--CA 1.473 0.707 0 N-CA-C 111.863 0.32 . . . . 0.0 111.863 -179.69 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 48.4 mt-10 -91.33 151.64 20.79 Favored 'General case' 0 N--CA 1.478 0.951 0 CA-C-O 121.036 0.446 . . . . 0.0 110.257 178.275 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -154.77 127.8 1.13 Allowed 'Isoleucine or valine' 0 CA--C 1.553 1.087 0 N-CA-C 107.815 -1.18 . . . . 0.0 107.815 178.286 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 45.0 m-70 -135.29 145.23 47.32 Favored 'General case' 0 N--CA 1.478 0.956 0 CA-C-N 115.596 -0.729 . . . . 0.0 111.373 -178.303 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -166.92 97.0 0.53 Allowed 'General case' 0 N--CA 1.481 1.116 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.312 179.151 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 15.1 pt20 -109.09 -173.43 2.26 Favored 'General case' 0 CA--C 1.505 -0.771 0 N-CA-C 108.417 -0.957 . . . . 0.0 108.417 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -163.5 97.98 0.89 Allowed 'General case' 0 N--CA 1.474 0.754 0 CA-C-N 114.718 -1.128 . . . . 0.0 108.1 178.565 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 6.4 mp -120.12 154.4 34.77 Favored 'General case' 0 N--CA 1.497 1.885 0 CA-C-O 121.263 0.554 . . . . 0.0 111.881 -177.981 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 43.9 t -113.02 124.79 70.01 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.978 0 CA-C-N 114.936 -1.029 . . . . 0.0 108.292 176.604 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 32.4 m-85 -125.17 121.16 33.39 Favored 'General case' 0 C--N 1.366 1.316 0 CA-C-N 115.56 -0.745 . . . . 0.0 110.735 -179.425 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 68.7 m-85 54.78 72.83 0.44 Allowed 'General case' 0 C--O 1.237 0.407 0 CA-C-N 115.868 -0.605 . . . . 0.0 111.425 178.173 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.31 -78.43 0.13 Allowed 'General case' 0 N--CA 1.469 0.522 0 O-C-N 122.229 -0.294 . . . . 0.0 110.591 -179.379 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 40.9 tt0 -112.62 100.34 8.65 Favored 'General case' 0 C--N 1.322 -0.589 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 179.792 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -157.6 139.47 14.12 Favored 'General case' 0 N--CA 1.477 0.909 0 O-C-N 122.403 -0.186 . . . . 0.0 111.498 179.272 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' H' H ' 24' ' ' VAL . . . . . 0.427 ' HB ' ' H ' ' E' ' 25' ' ' GLY . 62.0 t -59.73 167.4 0.56 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.521 0 N-CA-C 107.722 -1.214 . . . . 0.0 107.722 177.182 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' H' H ' 25' ' ' GLY . . . . . 0.425 ' N ' HG12 ' H' ' 24' ' ' VAL . . . -120.32 49.12 0.9 Allowed Glycine 0 N--CA 1.48 1.572 0 N-CA-C 110.491 -1.043 . . . . 0.0 110.491 -179.314 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -63.23 -166.99 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.675 0 CA-C-N 116.972 0.386 . . . . 0.0 110.092 179.748 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 5.3 t30 -70.63 76.46 0.59 Allowed 'General case' 0 CA--C 1.535 0.374 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.492 -179.85 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -73.44 143.88 46.53 Favored 'General case' 0 N--CA 1.473 0.685 0 N-CA-C 109.629 -0.508 . . . . 0.0 109.629 179.341 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -65.17 -166.14 1.37 Allowed Glycine 0 C--N 1.337 0.634 0 N-CA-C 109.936 -1.266 . . . . 0.0 109.936 178.889 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.44 114.28 27.12 Favored 'General case' 0 N--CA 1.467 0.408 0 C-N-CA 122.573 0.349 . . . . 0.0 110.617 179.85 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 74.5 mt -98.73 134.73 36.41 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.751 0 N-CA-C 106.8 -1.556 . . . . 0.0 106.8 178.974 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' H' H ' 32' ' ' ILE . . . . . 0.439 ' H ' HG22 ' E' ' 32' ' ' ILE . 34.2 pt -151.05 -169.24 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.687 0 CA-C-N 119.747 1.158 . . . . 0.0 109.917 -179.93 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.24 4.8 6.81 Favored Glycine 0 CA--C 1.529 0.919 0 N-CA-C 110.95 -0.86 . . . . 0.0 110.95 179.914 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' H' H ' 34' ' ' LEU . . . . . 0.431 HD23 ' N ' ' H' ' 35' ' ' MET . 1.1 tt -75.35 135.25 40.85 Favored 'General case' 0 CA--C 1.546 0.792 0 N-CA-C 109.412 -0.588 . . . . 0.0 109.412 -179.414 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' H' H ' 35' ' ' MET . . . . . 0.431 ' N ' HD23 ' H' ' 34' ' ' LEU . 25.2 ttt -158.52 146.15 18.03 Favored 'General case' 0 N--CA 1.472 0.641 0 N-CA-C 108.694 -0.854 . . . . 0.0 108.694 179.065 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 1.5 m -149.08 163.84 4.35 Favored 'Isoleucine or valine' 0 C--N 1.348 0.522 0 N-CA-C 108.449 -0.945 . . . . 0.0 108.449 -179.283 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.35 68.39 1.71 Allowed Glycine 0 C--N 1.309 -0.971 0 CA-C-N 115.16 -0.927 . . . . 0.0 112.064 177.451 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.27 172.35 17.37 Favored Glycine 0 N--CA 1.476 1.307 0 N-CA-C 110.639 -0.985 . . . . 0.0 110.639 178.959 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' H' H ' 39' ' ' VAL . . . . . 0.425 HG12 ' H ' ' E' ' 39' ' ' VAL . 33.8 m -106.1 154.93 7.13 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.927 0 C-N-CA 123.199 0.6 . . . . 0.0 110.715 -179.475 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 24.7 t . . . . . 0 C--O 1.219 -0.53 0 O-C-N 124.001 0.813 . . . . 0.0 110.709 179.699 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 66.3 m-85 . . . . . 0 N--CA 1.474 0.745 0 N-CA-C 109.736 -0.468 . . . . 0.0 109.736 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' I' I ' 5' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -144.13 142.47 30.6 Favored 'General case' 0 N--CA 1.484 1.23 0 C-N-CA 122.639 0.376 . . . . 0.0 110.194 179.81 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 47.6 t-80 -152.14 120.12 6.21 Favored 'General case' 0 N--CA 1.474 0.738 0 N-CA-C 109.361 -0.607 . . . . 0.0 109.361 179.007 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -72.32 144.16 48.41 Favored 'General case' 0 N--CA 1.471 0.605 0 C-N-CA 122.725 0.41 . . . . 0.0 111.084 -179.945 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' I' I ' 8' ' ' SER . . . . . 0.483 ' OG ' ' O ' ' F' ' 7' ' ' ASP . 50.8 p -164.73 -170.39 1.98 Allowed 'General case' 0 N--CA 1.475 0.782 0 CA-C-O 120.996 0.427 . . . . 0.0 110.488 178.586 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.82 47.47 1.36 Allowed Glycine 0 N--CA 1.48 1.628 0 N-CA-C 111.629 -0.589 . . . . 0.0 111.629 179.675 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 47.9 p90 -65.92 133.2 50.38 Favored 'General case' 0 N--CA 1.473 0.677 0 CA-C-O 120.803 0.335 . . . . 0.0 111.872 -179.649 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 48.4 mt-10 -91.77 151.7 20.49 Favored 'General case' 0 N--CA 1.478 0.95 0 CA-C-O 120.932 0.396 . . . . 0.0 110.311 178.348 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -154.99 126.92 0.96 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.057 0 N-CA-C 107.909 -1.145 . . . . 0.0 107.909 178.365 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 42.4 m-70 -134.52 144.88 48.27 Favored 'General case' 0 N--CA 1.478 0.967 0 CA-C-N 115.606 -0.724 . . . . 0.0 111.451 -178.382 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -166.43 97.09 0.58 Allowed 'General case' 0 N--CA 1.48 1.056 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.348 179.119 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 15.2 pt20 -109.3 -173.88 2.37 Favored 'General case' 0 CA--C 1.504 -0.797 0 N-CA-C 108.481 -0.933 . . . . 0.0 108.481 -179.99 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -163.08 98.11 0.93 Allowed 'General case' 0 N--CA 1.473 0.715 0 CA-C-N 114.701 -1.136 . . . . 0.0 108.07 178.514 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 6.4 mp -120.2 154.37 34.94 Favored 'General case' 0 N--CA 1.497 1.907 0 CA-C-O 121.24 0.543 . . . . 0.0 111.769 -177.91 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 44.8 t -113.0 125.07 70.2 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.028 0 CA-C-N 114.857 -1.065 . . . . 0.0 108.157 176.646 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 32.9 m-85 -125.57 121.11 32.69 Favored 'General case' 0 C--N 1.367 1.339 0 CA-C-N 115.582 -0.735 . . . . 0.0 110.815 -179.536 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 68.6 m-85 54.9 73.26 0.42 Allowed 'General case' 0 N--CA 1.469 0.51 0 CA-C-N 115.927 -0.579 . . . . 0.0 111.262 178.301 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.99 -78.01 0.15 Allowed 'General case' 0 N--CA 1.472 0.639 0 O-C-N 122.205 -0.309 . . . . 0.0 110.601 -179.268 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 40.9 tt0 -112.84 100.32 8.58 Favored 'General case' 0 C--N 1.323 -0.586 0 N-CA-C 108.088 -1.078 . . . . 0.0 108.088 179.614 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -157.71 139.26 13.8 Favored 'General case' 0 N--CA 1.479 0.983 0 O-C-N 122.344 -0.223 . . . . 0.0 111.433 179.396 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' I' I ' 24' ' ' VAL . . . . . 0.435 ' HB ' ' H ' ' F' ' 25' ' ' GLY . 62.0 t -59.48 167.26 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.54 0 N-CA-C 107.847 -1.168 . . . . 0.0 107.847 177.016 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' I' I ' 25' ' ' GLY . . . . . 0.432 ' N ' HG12 ' I' ' 24' ' ' VAL . . . -120.43 49.52 0.87 Allowed Glycine 0 N--CA 1.482 1.725 0 N-CA-C 110.411 -1.076 . . . . 0.0 110.411 -179.384 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -63.42 -166.9 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.656 0 CA-C-N 116.985 0.393 . . . . 0.0 110.064 179.59 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 5.5 t30 -70.68 76.71 0.6 Allowed 'General case' 0 N--CA 1.466 0.358 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.35 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 97.8 mttt -73.66 143.62 46.18 Favored 'General case' 0 N--CA 1.474 0.772 0 N-CA-C 109.64 -0.504 . . . . 0.0 109.64 179.284 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.59 -166.08 1.13 Allowed Glycine 0 C--N 1.339 0.703 0 N-CA-C 110.02 -1.232 . . . . 0.0 110.02 178.88 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.53 113.86 26.51 Favored 'General case' 0 N--CA 1.469 0.495 0 C-N-CA 122.691 0.396 . . . . 0.0 110.45 179.877 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 74.2 mt -98.37 135.04 34.66 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.836 0 N-CA-C 106.745 -1.576 . . . . 0.0 106.745 178.849 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' I' I ' 32' ' ' ILE . . . . . 0.43 ' H ' HG22 ' F' ' 32' ' ' ILE . 33.6 pt -151.38 -169.3 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 CA-C-N 119.698 1.135 . . . . 0.0 109.965 -179.987 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.22 4.71 6.68 Favored Glycine 0 CA--C 1.528 0.897 0 N-CA-C 110.952 -0.859 . . . . 0.0 110.952 179.962 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' I' I ' 34' ' ' LEU . . . . . 0.431 HD23 ' N ' ' I' ' 35' ' ' MET . 1.1 tt -74.85 135.29 41.58 Favored 'General case' 0 CA--C 1.544 0.738 0 N-CA-C 109.318 -0.623 . . . . 0.0 109.318 -179.602 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' I' I ' 35' ' ' MET . . . . . 0.431 ' N ' HD23 ' I' ' 34' ' ' LEU . 25.4 ttt -158.44 146.06 18.08 Favored 'General case' 0 N--CA 1.471 0.602 0 N-CA-C 108.53 -0.915 . . . . 0.0 108.53 178.982 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 1.4 m -149.02 163.78 4.41 Favored 'Isoleucine or valine' 0 C--N 1.35 0.616 0 N-CA-C 108.519 -0.919 . . . . 0.0 108.519 -179.401 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.08 68.5 1.65 Allowed Glycine 0 C--N 1.308 -0.991 0 CA-C-N 115.253 -0.885 . . . . 0.0 112.143 177.492 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.45 172.31 17.46 Favored Glycine 0 N--CA 1.474 1.224 0 N-CA-C 110.682 -0.967 . . . . 0.0 110.682 178.982 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' I' I ' 39' ' ' VAL . . . . . 0.426 HG12 ' H ' ' F' ' 39' ' ' VAL . 33.9 m -106.15 154.81 7.2 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.915 0 C-N-CA 123.236 0.614 . . . . 0.0 110.663 -179.467 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 25.3 t . . . . . 0 C--O 1.219 -0.524 0 O-C-N 124.06 0.85 . . . . 0.0 110.612 179.621 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 42.0 m-85 . . . . . 0 N--CA 1.474 0.747 0 N-CA-C 110.118 -0.327 . . . . 0.0 110.118 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -143.45 140.62 30.47 Favored 'General case' 0 N--CA 1.481 1.085 0 CA-C-O 120.887 0.375 . . . . 0.0 110.03 179.711 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 42.3 t-80 -151.79 119.39 6.07 Favored 'General case' 0 N--CA 1.47 0.528 0 N-CA-C 109.231 -0.655 . . . . 0.0 109.231 179.176 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 7' ' ' ASP . . . . . 0.499 ' O ' ' OG ' ' D' ' 8' ' ' SER . 4.4 m-20 -68.98 148.77 49.65 Favored 'General case' 0 CA--C 1.537 0.471 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.516 179.816 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 53.2 p -167.58 -173.5 2.21 Favored 'General case' 0 N--CA 1.483 1.184 0 CA-C-O 121.054 0.454 . . . . 0.0 110.721 179.392 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.62 47.67 1.37 Allowed Glycine 0 N--CA 1.482 1.705 0 CA-C-N 115.966 -0.561 . . . . 0.0 112.08 179.785 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 48.7 p90 -65.86 132.72 49.35 Favored 'General case' 0 N--CA 1.474 0.735 0 O-C-N 122.755 -0.262 . . . . 0.0 111.496 179.712 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 46.0 mt-10 -92.17 152.08 20.06 Favored 'General case' 0 N--CA 1.479 0.986 0 N-CA-C 109.725 -0.472 . . . . 0.0 109.725 178.512 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.0 p -152.89 128.25 1.59 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.612 0 N-CA-C 107.868 -1.16 . . . . 0.0 107.868 178.238 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 47.2 m-70 -135.41 147.8 49.12 Favored 'General case' 0 N--CA 1.493 1.708 0 CA-C-N 119.044 0.838 . . . . 0.0 111.398 -179.013 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 6.4 t60 -165.1 97.02 0.72 Allowed 'General case' 0 N--CA 1.48 1.064 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.624 179.342 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' GLN . . . . . 0.731 HE22 HG23 ' A' ' 36' ' ' VAL . 13.9 pt20 -101.54 -174.16 2.53 Favored 'General case' 0 CA--C 1.507 -0.704 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 -179.82 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -169.9 95.81 0.28 Allowed 'General case' 0 N--CA 1.47 0.53 0 CA-C-N 114.608 -1.178 . . . . 0.0 108.389 178.38 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 6.5 mp -123.36 156.97 34.35 Favored 'General case' 0 N--CA 1.497 1.917 0 CA-C-O 121.794 0.807 . . . . 0.0 111.005 -178.14 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 60.1 t -111.79 126.86 69.22 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.135 0 CA-C-O 117.938 -1.029 . . . . 0.0 108.269 177.608 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 27.1 m-85 -126.89 123.09 36.44 Favored 'General case' 0 N--CA 1.497 1.912 0 CA-C-N 120.13 1.332 . . . . 0.0 110.474 179.5 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 67.9 m-85 53.66 74.71 0.3 Allowed 'General case' 0 CA--C 1.538 0.489 0 CA-C-O 121.414 0.626 . . . . 0.0 111.813 178.634 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -80.0 -78.28 0.17 Allowed 'General case' 0 C--N 1.353 0.727 0 CA-C-N 115.084 -0.962 . . . . 0.0 110.192 -179.922 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 38.2 tt0 -113.39 100.74 8.77 Favored 'General case' 0 N--CA 1.469 0.486 0 N-CA-C 108.191 -1.04 . . . . 0.0 108.191 179.725 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 4.4 p30 -159.18 139.79 12.43 Favored 'General case' 0 N--CA 1.483 1.178 0 O-C-N 122.31 -0.243 . . . . 0.0 111.219 179.147 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.405 HG12 ' N ' ' A' ' 25' ' ' GLY . 61.2 t -59.97 163.43 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.819 0 N-CA-C 108.104 -1.073 . . . . 0.0 108.104 177.106 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.469 ' H ' ' HB ' ' D' ' 24' ' ' VAL . . . -117.3 48.61 0.92 Allowed Glycine 0 N--CA 1.475 1.252 0 N-CA-C 111.755 -0.538 . . . . 0.0 111.755 -179.402 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -61.73 -167.83 0.01 OUTLIER 'General case' 0 N--CA 1.468 0.45 0 O-C-N 123.843 0.378 . . . . 0.0 110.412 179.522 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 3.7 t30 -71.06 80.4 0.67 Allowed 'General case' 0 N--CA 1.465 0.284 0 CA-C-N 116.492 -0.322 . . . . 0.0 110.176 179.557 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -77.85 143.76 37.55 Favored 'General case' 0 N--CA 1.473 0.704 0 N-CA-C 109.141 -0.689 . . . . 0.0 109.141 179.332 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.38 -167.51 0.94 Allowed Glycine 0 CA--C 1.525 0.664 0 N-CA-C 109.863 -1.295 . . . . 0.0 109.863 178.629 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.8 114.61 27.88 Favored 'General case' 0 N--CA 1.48 1.038 0 N-CA-C 109.696 -0.483 . . . . 0.0 109.696 179.839 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 64.9 mt -98.41 135.78 31.88 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.552 0 N-CA-C 107.078 -1.453 . . . . 0.0 107.078 178.982 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 34.1 pt -152.31 -176.14 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.734 0 CA-C-O 121.168 0.508 . . . . 0.0 111.18 -179.164 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.62 4.39 9.73 Favored Glycine 0 CA--C 1.524 0.597 0 N-CA-C 110.976 -0.85 . . . . 0.0 110.976 179.758 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 1.6 tt -74.28 127.18 32.33 Favored 'General case' 0 CA--C 1.545 0.767 0 N-CA-C 109.499 -0.556 . . . . 0.0 109.499 -179.604 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 28.5 ttt -163.75 149.81 11.43 Favored 'General case' 0 N--CA 1.465 0.279 0 N-CA-C 108.963 -0.755 . . . . 0.0 108.963 178.782 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.731 HG23 HE22 ' A' ' 15' ' ' GLN . 27.5 m -155.22 166.33 1.07 Allowed 'Isoleucine or valine' 0 C--N 1.347 0.482 0 N-CA-C 108.061 -1.088 . . . . 0.0 108.061 179.686 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.1 67.2 2.33 Favored Glycine 0 C--N 1.307 -1.045 0 CA-C-N 115.776 -0.647 . . . . 0.0 112.102 178.422 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.96 -173.23 24.85 Favored Glycine 0 N--CA 1.474 1.195 0 N-CA-C 110.85 -0.9 . . . . 0.0 110.85 179.089 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.561 ' H ' HG12 ' D' ' 39' ' ' VAL . 34.5 m -125.56 156.34 35.03 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.774 0 C-N-CA 123.393 0.677 . . . . 0.0 110.232 -179.645 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 27.1 t . . . . . 0 C--O 1.218 -0.589 0 CA-C-O 118.433 -0.794 . . . . 0.0 110.622 179.853 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 38.9 m-85 . . . . . 0 N--CA 1.473 0.715 0 N-CA-C 110.13 -0.322 . . . . 0.0 110.13 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -143.06 140.44 30.94 Favored 'General case' 0 N--CA 1.483 1.198 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 179.574 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 41.9 t-80 -151.65 119.03 5.98 Favored 'General case' 0 N--CA 1.473 0.692 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 179.001 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 7' ' ' ASP . . . . . 0.448 ' O ' ' OG ' ' E' ' 8' ' ' SER . 4.3 m-20 -68.68 148.55 50.25 Favored 'General case' 0 CA--C 1.537 0.47 0 CA-C-N 116.343 -0.389 . . . . 0.0 110.677 179.907 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 8' ' ' SER . . . . . . . . . . . . . 53.8 p -167.59 -173.53 2.22 Favored 'General case' 0 N--CA 1.482 1.136 0 CA-C-O 120.966 0.412 . . . . 0.0 110.745 179.418 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.92 47.14 1.39 Allowed Glycine 0 N--CA 1.481 1.686 0 CA-C-N 115.985 -0.552 . . . . 0.0 112.126 179.758 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 48.8 p90 -65.57 132.88 49.96 Favored 'General case' 0 N--CA 1.472 0.644 0 CA-C-O 120.665 0.269 . . . . 0.0 111.562 179.819 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 45.3 mt-10 -92.14 152.22 20.01 Favored 'General case' 0 N--CA 1.475 0.824 0 C-N-CA 122.847 0.459 . . . . 0.0 109.816 178.475 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -153.15 128.13 1.5 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.547 0 N-CA-C 107.854 -1.165 . . . . 0.0 107.854 178.266 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 46.9 m-70 -135.46 147.71 49.0 Favored 'General case' 0 N--CA 1.492 1.65 0 CA-C-N 118.915 0.78 . . . . 0.0 111.379 -178.882 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 6.5 t60 -165.14 97.01 0.71 Allowed 'General case' 0 N--CA 1.48 1.052 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.604 179.345 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 15' ' ' GLN . . . . . 0.745 HE22 HG23 ' B' ' 36' ' ' VAL . 13.9 pt20 -101.51 -173.83 2.45 Favored 'General case' 0 CA--C 1.508 -0.638 0 N-CA-C 108.691 -0.855 . . . . 0.0 108.691 -179.764 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -170.22 95.82 0.25 Allowed 'General case' 0 N--CA 1.471 0.575 0 CA-C-N 114.727 -1.124 . . . . 0.0 108.321 178.324 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 6.5 mp -123.15 157.32 33.23 Favored 'General case' 0 N--CA 1.497 1.878 0 CA-C-O 121.73 0.776 . . . . 0.0 110.999 -178.134 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 60.9 t -112.37 127.65 69.46 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.098 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 177.44 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 27.0 m-85 -127.62 123.0 34.6 Favored 'General case' 0 N--CA 1.494 1.753 0 CA-C-N 119.707 1.14 . . . . 0.0 110.302 179.681 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 67.9 m-85 53.27 74.81 0.28 Allowed 'General case' 0 CA--C 1.537 0.476 0 CA-C-O 121.535 0.683 . . . . 0.0 111.919 178.475 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -80.48 -77.93 0.18 Allowed 'General case' 0 C--N 1.352 0.681 0 CA-C-N 115.004 -0.998 . . . . 0.0 110.218 -179.879 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 38.3 tt0 -113.53 100.45 8.52 Favored 'General case' 0 N--CA 1.47 0.565 0 N-CA-C 108.317 -0.994 . . . . 0.0 108.317 179.695 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -158.85 140.17 13.17 Favored 'General case' 0 N--CA 1.483 1.193 0 O-C-N 122.179 -0.326 . . . . 0.0 111.146 179.19 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 61.6 t -60.1 163.63 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.894 0 N-CA-C 108.121 -1.066 . . . . 0.0 108.121 177.072 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 25' ' ' GLY . . . . . 0.474 ' H ' ' HB ' ' E' ' 24' ' ' VAL . . . -117.23 48.32 0.95 Allowed Glycine 0 N--CA 1.476 1.309 0 N-CA-C 111.657 -0.577 . . . . 0.0 111.657 -179.353 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -61.87 -168.58 0.02 OUTLIER 'General case' 0 N--CA 1.469 0.505 0 O-C-N 123.783 0.343 . . . . 0.0 110.348 179.498 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 3.5 t30 -70.61 81.03 0.59 Allowed 'General case' 0 N--CA 1.467 0.377 0 N-CA-C 110.078 -0.342 . . . . 0.0 110.078 179.636 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -78.48 144.32 35.85 Favored 'General case' 0 N--CA 1.473 0.706 0 N-CA-C 109.077 -0.712 . . . . 0.0 109.077 179.394 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.47 -167.47 0.97 Allowed Glycine 0 C--N 1.336 0.569 0 N-CA-C 109.933 -1.267 . . . . 0.0 109.933 178.676 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.91 114.56 27.89 Favored 'General case' 0 N--CA 1.479 0.988 0 N-CA-C 109.677 -0.49 . . . . 0.0 109.677 179.644 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 64.3 mt -98.51 135.36 33.66 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.507 0 N-CA-C 107.073 -1.454 . . . . 0.0 107.073 178.9 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 32' ' ' ILE . . . . . 0.413 HG22 ' H ' ' E' ' 32' ' ' ILE . 33.7 pt -151.99 -176.63 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.353 0.722 0 CA-C-N 116.026 -0.534 . . . . 0.0 111.191 -178.975 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.73 4.76 10.99 Favored Glycine 0 CA--C 1.523 0.57 0 N-CA-C 110.925 -0.87 . . . . 0.0 110.925 179.718 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 1.6 tt -74.56 126.71 31.37 Favored 'General case' 0 CA--C 1.546 0.813 0 N-CA-C 109.438 -0.578 . . . . 0.0 109.438 -179.744 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 28.2 ttt -163.05 149.97 12.78 Favored 'General case' 0 N--CA 1.465 0.323 0 N-CA-C 108.935 -0.765 . . . . 0.0 108.935 178.82 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 36' ' ' VAL . . . . . 0.745 HG23 HE22 ' B' ' 15' ' ' GLN . 27.3 m -155.3 166.34 1.06 Allowed 'Isoleucine or valine' 0 C--N 1.348 0.508 0 N-CA-C 108.015 -1.105 . . . . 0.0 108.015 179.706 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.73 67.43 2.21 Favored Glycine 0 C--N 1.307 -1.069 0 CA-C-N 115.742 -0.663 . . . . 0.0 112.094 178.434 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.65 -173.52 24.51 Favored Glycine 0 N--CA 1.474 1.213 0 N-CA-C 110.94 -0.864 . . . . 0.0 110.94 179.034 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 39' ' ' VAL . . . . . 0.585 ' H ' HG12 ' E' ' 39' ' ' VAL . 35.0 m -125.27 156.26 34.34 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.818 0 C-N-CA 123.42 0.688 . . . . 0.0 110.309 -179.591 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 26.6 t . . . . . 0 C--O 1.219 -0.514 0 CA-C-O 118.54 -0.743 . . . . 0.0 110.436 179.758 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 39.7 m-85 . . . . . 0 N--CA 1.474 0.774 0 N-CA-C 110.064 -0.347 . . . . 0.0 110.064 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -143.35 140.42 30.51 Favored 'General case' 0 N--CA 1.483 1.182 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 179.726 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 42.0 t-80 -151.72 119.51 6.15 Favored 'General case' 0 N--CA 1.472 0.648 0 N-CA-C 109.317 -0.623 . . . . 0.0 109.317 179.114 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 7' ' ' ASP . . . . . 0.49 ' O ' ' OG ' ' F' ' 8' ' ' SER . 4.3 m-20 -69.22 148.32 50.01 Favored 'General case' 0 CA--C 1.537 0.472 0 CA-C-N 116.328 -0.397 . . . . 0.0 110.648 179.978 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 8' ' ' SER . . . . . . . . . . . . . 53.5 p -167.31 -173.4 2.25 Favored 'General case' 0 N--CA 1.484 1.246 0 CA-C-O 121.028 0.442 . . . . 0.0 110.692 179.43 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.62 47.1 1.43 Allowed Glycine 0 N--CA 1.482 1.734 0 CA-C-N 115.899 -0.592 . . . . 0.0 112.076 179.787 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 49.1 p90 -65.44 133.06 50.5 Favored 'General case' 0 N--CA 1.473 0.709 0 CA-C-O 120.671 0.272 . . . . 0.0 111.489 179.617 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 46.0 mt-10 -92.48 152.49 19.64 Favored 'General case' 0 N--CA 1.476 0.826 0 CA-C-O 121.1 0.476 . . . . 0.0 109.787 178.436 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -153.21 128.48 1.56 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.545 0 N-CA-C 107.786 -1.19 . . . . 0.0 107.786 178.307 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 47.0 m-70 -135.71 147.56 48.53 Favored 'General case' 0 N--CA 1.492 1.632 0 CA-C-N 118.925 0.784 . . . . 0.0 111.355 -179.081 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 6.5 t60 -164.96 97.17 0.73 Allowed 'General case' 0 N--CA 1.482 1.149 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.507 179.312 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 15' ' ' GLN . . . . . 0.717 HE22 HG23 ' C' ' 36' ' ' VAL . 13.8 pt20 -101.64 -173.75 2.43 Favored 'General case' 0 CA--C 1.507 -0.701 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 -179.749 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -170.22 95.85 0.25 Allowed 'General case' 0 N--CA 1.47 0.553 0 CA-C-N 114.618 -1.174 . . . . 0.0 108.292 178.406 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 6.5 mp -123.37 157.08 34.12 Favored 'General case' 0 N--CA 1.497 1.918 0 CA-C-O 121.745 0.784 . . . . 0.0 111.07 -178.157 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 60.7 t -112.33 127.61 69.43 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.076 0 N-CA-C 108.059 -1.089 . . . . 0.0 108.059 177.53 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 27.7 m-85 -127.58 123.02 34.73 Favored 'General case' 0 N--CA 1.494 1.75 0 CA-C-N 119.6 1.091 . . . . 0.0 110.34 179.614 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 67.0 m-85 53.29 74.75 0.29 Allowed 'General case' 0 CA--C 1.538 0.495 0 CA-C-O 121.55 0.69 . . . . 0.0 111.975 178.441 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -80.34 -78.22 0.18 Allowed 'General case' 0 C--N 1.348 0.537 0 CA-C-N 114.911 -1.04 . . . . 0.0 110.197 -179.791 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 38.0 tt0 -113.31 100.39 8.52 Favored 'General case' 0 N--CA 1.47 0.56 0 N-CA-C 108.161 -1.051 . . . . 0.0 108.161 179.653 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 4.4 p30 -158.71 140.08 13.27 Favored 'General case' 0 N--CA 1.484 1.231 0 O-C-N 122.202 -0.311 . . . . 0.0 111.204 179.085 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 24' ' ' VAL . . . . . 0.401 HG12 ' N ' ' C' ' 25' ' ' GLY . 61.8 t -60.0 163.72 0.92 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.852 0 N-CA-C 108.153 -1.054 . . . . 0.0 108.153 177.082 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 25' ' ' GLY . . . . . 0.472 ' H ' ' HB ' ' F' ' 24' ' ' VAL . . . -117.38 48.31 0.95 Allowed Glycine 0 N--CA 1.477 1.385 0 N-CA-C 111.637 -0.585 . . . . 0.0 111.637 -179.336 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -61.81 -167.99 0.01 OUTLIER 'General case' 0 N--CA 1.468 0.427 0 O-C-N 123.79 0.347 . . . . 0.0 110.361 179.658 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 3.5 t30 -71.01 80.71 0.66 Allowed 'General case' 0 N--CA 1.465 0.304 0 N-CA-C 110.067 -0.345 . . . . 0.0 110.067 179.495 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -78.22 144.13 36.53 Favored 'General case' 0 N--CA 1.472 0.65 0 N-CA-C 109.117 -0.698 . . . . 0.0 109.117 179.415 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.55 -167.62 1.03 Allowed Glycine 0 CA--C 1.523 0.586 0 N-CA-C 109.965 -1.254 . . . . 0.0 109.965 178.788 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.6 114.34 27.31 Favored 'General case' 0 N--CA 1.48 1.071 0 N-CA-C 109.661 -0.496 . . . . 0.0 109.661 179.775 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 64.8 mt -98.42 135.45 33.16 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.546 0 N-CA-C 107.058 -1.46 . . . . 0.0 107.058 178.911 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 32' ' ' ILE . . . . . 0.414 HG22 ' H ' ' F' ' 32' ' ' ILE . 33.8 pt -152.01 -176.15 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.352 0.688 0 CA-C-N 115.998 -0.547 . . . . 0.0 111.189 -179.096 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.48 4.49 9.43 Favored Glycine 0 CA--C 1.524 0.615 0 N-CA-C 110.992 -0.843 . . . . 0.0 110.992 179.697 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 1.6 tt -74.27 127.27 32.57 Favored 'General case' 0 CA--C 1.547 0.831 0 N-CA-C 109.389 -0.597 . . . . 0.0 109.389 -179.776 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 28.3 ttt -163.52 150.06 12.02 Favored 'General case' 0 N--CA 1.467 0.397 0 N-CA-C 108.86 -0.792 . . . . 0.0 108.86 178.735 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 36' ' ' VAL . . . . . 0.717 HG23 HE22 ' C' ' 15' ' ' GLN . 27.3 m -155.59 166.05 1.07 Allowed 'Isoleucine or valine' 0 C--N 1.347 0.5 0 N-CA-C 108.06 -1.089 . . . . 0.0 108.06 179.657 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.06 67.23 2.32 Favored Glycine 0 C--N 1.307 -1.047 0 CA-C-N 115.721 -0.672 . . . . 0.0 112.077 178.503 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.71 -173.44 24.58 Favored Glycine 0 N--CA 1.473 1.139 0 N-CA-C 110.987 -0.845 . . . . 0.0 110.987 178.959 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 39' ' ' VAL . . . . . 0.587 ' H ' HG12 ' F' ' 39' ' ' VAL . 32.9 m -125.11 156.37 33.98 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.751 0 C-N-CA 123.386 0.674 . . . . 0.0 110.31 -179.572 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 25.6 t . . . . . 0 C--O 1.218 -0.576 0 CA-C-O 118.424 -0.798 . . . . 0.0 110.579 179.77 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 41.4 m-85 . . . . . 0 N--CA 1.473 0.679 0 N-CA-C 108.775 -0.824 . . . . 0.0 108.775 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' D' D ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -145.24 139.15 26.95 Favored 'General case' 0 N--CA 1.478 0.927 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.144 -179.846 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 38.7 t-80 -149.47 123.46 9.4 Favored 'General case' 0 CA--C 1.544 0.744 0 N-CA-C 108.42 -0.956 . . . . 0.0 108.42 175.352 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' D' D ' 7' ' ' ASP . . . . . 0.586 ' O ' ' OG ' ' G' ' 8' ' ' SER . 3.2 m-20 -63.79 133.02 52.69 Favored 'General case' 0 C--N 1.32 -0.702 0 C-N-CA 126.769 2.027 . . . . 0.0 113.965 174.817 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' D' D ' 8' ' ' SER . . . . . 0.499 ' OG ' ' O ' ' A' ' 7' ' ' ASP . 53.9 p -154.61 -170.57 3.56 Favored 'General case' 0 N--CA 1.487 1.41 0 CA-C-N 119.397 0.999 . . . . 0.0 111.12 175.622 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.2 47.77 1.2 Allowed Glycine 0 N--CA 1.481 1.651 0 N-CA-C 110.652 -0.979 . . . . 0.0 110.652 174.445 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 51.1 p90 -60.91 131.48 50.81 Favored 'General case' 0 N--CA 1.471 0.614 0 N-CA-C 112.804 0.668 . . . . 0.0 112.804 178.075 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 45.7 mt-10 -89.49 150.83 22.29 Favored 'General case' 0 N--CA 1.481 1.094 0 CA-C-N 117.825 0.284 . . . . 0.0 110.809 175.351 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.0 p -149.46 129.84 4.28 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.611 0 N-CA-C 107.49 -1.3 . . . . 0.0 107.49 173.417 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 42.9 m-70 -129.96 150.74 51.11 Favored 'General case' 0 N--CA 1.483 1.215 0 CA-C-N 118.198 0.454 . . . . 0.0 111.994 176.584 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 6.6 t60 -164.98 104.47 0.78 Allowed 'General case' 0 N--CA 1.483 1.186 0 N-CA-C 108.844 -0.799 . . . . 0.0 108.844 172.171 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' D' D ' 15' ' ' GLN . . . . . 0.764 HE22 HG23 ' D' ' 36' ' ' VAL . 13.7 pt20 -105.12 -176.1 2.98 Favored 'General case' 0 CA--C 1.502 -0.871 0 N-CA-C 108.487 -0.931 . . . . 0.0 108.487 179.177 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -166.23 104.52 0.64 Allowed 'General case' 0 N--CA 1.466 0.335 0 N-CA-C 106.205 -1.776 . . . . 0.0 106.205 174.131 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 5.4 mp -130.35 154.02 48.09 Favored 'General case' 0 N--CA 1.5 2.043 0 CA-C-O 122.062 0.934 . . . . 0.0 110.711 179.458 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 34.5 t -101.25 131.56 48.76 Favored 'Isoleucine or valine' 0 C--O 1.262 1.714 0 CA-C-O 116.779 -1.581 . . . . 0.0 109.686 174.097 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 26.2 m-85 -130.09 126.45 37.62 Favored 'General case' 0 N--CA 1.488 1.457 0 CA-C-N 120.126 1.33 . . . . 0.0 109.864 173.73 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 67.4 m-85 55.48 71.3 0.56 Allowed 'General case' 0 C--O 1.239 0.542 0 CA-C-N 115.712 -0.676 . . . . 0.0 111.837 176.206 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -81.6 -73.43 0.38 Allowed 'General case' 0 N--CA 1.473 0.718 0 CA-C-O 118.585 -0.721 . . . . 0.0 111.063 -177.61 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 38.6 tt0 -116.64 104.28 11.23 Favored 'General case' 0 N--CA 1.482 1.164 0 N-CA-C 106.361 -1.718 . . . . 0.0 106.361 176.324 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -152.15 139.92 19.9 Favored 'General case' 0 N--CA 1.474 0.756 0 CA-C-O 116.8 -1.571 . . . . 0.0 113.647 177.815 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' D' D ' 24' ' ' VAL . . . . . 0.469 ' HB ' ' H ' ' A' ' 25' ' ' GLY . 66.7 t -62.45 166.04 0.98 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.294 0 CA-C-N 121.037 1.744 . . . . 0.0 107.983 174.905 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' D' D ' 25' ' ' GLY . . . . . 0.526 ' H ' ' HB ' ' G' ' 24' ' ' VAL . . . -116.83 51.08 0.75 Allowed Glycine 0 N--CA 1.479 1.52 0 CA-C-O 119.081 -0.844 . . . . 0.0 111.738 178.536 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -57.75 -171.21 0.01 OUTLIER 'General case' 0 C--N 1.323 -0.58 0 C-N-CA 123.618 0.767 . . . . 0.0 111.722 176.054 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 4.5 t30 -72.11 86.52 1.05 Allowed 'General case' 0 C--N 1.346 0.435 0 N-CA-C 108.585 -0.894 . . . . 0.0 108.585 177.688 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 97.5 mttt -83.53 146.48 28.32 Favored 'General case' 0 N--CA 1.474 0.775 0 N-CA-C 108.056 -1.09 . . . . 0.0 108.056 179.196 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -62.95 -165.4 0.56 Allowed Glycine 0 C--N 1.335 0.476 0 N-CA-C 110.519 -1.032 . . . . 0.0 110.519 179.225 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -101.78 115.95 31.65 Favored 'General case' 0 N--CA 1.471 0.606 0 N-CA-C 109.235 -0.654 . . . . 0.0 109.235 179.594 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 72.6 mt -102.71 142.77 16.16 Favored 'Isoleucine or valine' 0 C--N 1.356 0.891 0 N-CA-C 104.544 -2.391 . . . . 0.0 104.544 179.838 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' D' D ' 32' ' ' ILE . . . . . 0.459 HG22 ' H ' ' G' ' 32' ' ' ILE . 34.8 pt -158.49 -176.96 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.209 0 CA-C-O 120.891 0.377 . . . . 0.0 110.152 -177.537 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 64.31 4.38 12.19 Favored Glycine 0 C--O 1.247 0.958 0 N-CA-C 110.087 -1.205 . . . . 0.0 110.087 -179.011 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 2.0 tt -76.37 132.94 40.02 Favored 'General case' 0 C--N 1.363 1.181 0 N-CA-C 107.185 -1.413 . . . . 0.0 107.185 -177.974 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' D' D ' 35' ' ' MET . . . . . 0.404 ' O ' HG13 ' D' ' 36' ' ' VAL . 28.2 ttt -158.52 161.53 37.36 Favored 'General case' 0 C--O 1.221 -0.419 0 CA-C-O 118.318 -0.849 . . . . 0.0 108.734 173.086 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' D' D ' 36' ' ' VAL . . . . . 0.764 HG23 HE22 ' D' ' 15' ' ' GLN . 27.6 m -164.74 165.07 0.61 Allowed 'Isoleucine or valine' 0 CA--C 1.519 -0.247 0 N-CA-C 107.624 -1.25 . . . . 0.0 107.624 175.835 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 60.36 64.1 4.43 Favored Glycine 0 CA--C 1.524 0.6 0 C-N-CA 119.576 -1.297 . . . . 0.0 113.006 178.572 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 140.95 -171.61 24.04 Favored Glycine 0 N--CA 1.476 1.361 0 CA-C-N 117.328 0.564 . . . . 0.0 111.95 -179.175 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' D' D ' 39' ' ' VAL . . . . . 0.587 ' H ' HG12 ' G' ' 39' ' ' VAL . 35.4 m -128.17 153.5 37.65 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.883 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -176.664 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 25.3 t . . . . . 0 C--O 1.225 -0.204 0 CA-C-O 116.686 -1.626 . . . . 0.0 109.773 178.118 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 37.9 m-85 . . . . . 0 N--CA 1.475 0.825 0 N-CA-C 110.166 -0.309 . . . . 0.0 110.166 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' E' E ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -142.74 140.86 31.61 Favored 'General case' 0 N--CA 1.484 1.257 0 CA-C-O 120.952 0.405 . . . . 0.0 109.997 179.576 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 41.5 t-80 -151.68 119.21 6.05 Favored 'General case' 0 N--CA 1.472 0.625 0 N-CA-C 109.228 -0.656 . . . . 0.0 109.228 178.894 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' E' E ' 7' ' ' ASP . . . . . 0.432 ' O ' ' OG ' ' H' ' 8' ' ' SER . 4.0 m-20 -69.47 148.39 49.59 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 116.389 -0.368 . . . . 0.0 110.82 -179.982 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' E' E ' 8' ' ' SER . . . . . 0.448 ' OG ' ' O ' ' B' ' 7' ' ' ASP . 51.8 p -168.1 -172.13 1.71 Allowed 'General case' 0 N--CA 1.485 1.31 0 CA-C-O 121.153 0.501 . . . . 0.0 110.857 178.995 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.17 47.61 1.31 Allowed Glycine 0 N--CA 1.479 1.516 0 CA-C-N 115.879 -0.601 . . . . 0.0 111.942 179.622 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 46.8 p90 -65.2 133.16 50.91 Favored 'General case' 0 N--CA 1.474 0.762 0 N-CA-C 111.894 0.331 . . . . 0.0 111.894 -179.886 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 46.2 mt-10 -91.84 152.33 20.16 Favored 'General case' 0 N--CA 1.479 0.995 0 CA-C-O 121.211 0.529 . . . . 0.0 109.742 178.007 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -154.34 127.47 1.16 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.586 0 N-CA-C 107.799 -1.186 . . . . 0.0 107.799 178.103 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 44.8 m-70 -135.78 145.71 46.82 Favored 'General case' 0 N--CA 1.481 1.116 0 CA-C-O 120.768 0.318 . . . . 0.0 111.678 -177.861 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 6.4 t60 -163.94 97.1 0.83 Allowed 'General case' 0 N--CA 1.485 1.318 0 CA-C-N 116.374 -0.375 . . . . 0.0 110.61 179.531 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' E' E ' 15' ' ' GLN . . . . . 0.775 HE22 HG23 ' E' ' 36' ' ' VAL . 14.0 pt20 -101.3 -173.97 2.49 Favored 'General case' 0 CA--C 1.509 -0.634 0 N-CA-C 108.855 -0.794 . . . . 0.0 108.855 -179.77 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -169.85 94.95 0.27 Allowed 'General case' 0 N--CA 1.474 0.739 0 CA-C-N 114.702 -1.136 . . . . 0.0 108.423 178.468 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 6.4 mp -122.05 156.92 32.53 Favored 'General case' 0 N--CA 1.494 1.772 0 CA-C-O 121.649 0.738 . . . . 0.0 111.532 -177.641 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 48.0 t -113.9 124.35 70.47 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.231 0 N-CA-C 108.178 -1.045 . . . . 0.0 108.178 177.168 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 30.5 m-85 -124.83 121.78 35.54 Favored 'General case' 0 N--CA 1.488 1.427 0 CA-C-O 120.83 0.348 . . . . 0.0 111.086 -179.729 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 68.8 m-85 54.76 73.61 0.4 Allowed 'General case' 0 N--CA 1.467 0.407 0 CA-C-N 115.941 -0.572 . . . . 0.0 111.609 178.173 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -78.53 -78.6 0.14 Allowed 'General case' 0 CA--C 1.535 0.379 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.108 -179.615 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 38.5 tt0 -112.8 101.07 9.17 Favored 'General case' 0 C--N 1.324 -0.532 0 N-CA-C 108.257 -1.016 . . . . 0.0 108.257 179.905 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -158.39 140.12 13.71 Favored 'General case' 0 C--O 1.205 -1.274 0 O-C-N 122.282 -0.262 . . . . 0.0 111.5 178.97 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' E' E ' 24' ' ' VAL . . . . . 0.474 ' HB ' ' H ' ' B' ' 25' ' ' GLY . 57.6 t -58.65 168.53 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.867 0 N-CA-C 107.619 -1.252 . . . . 0.0 107.619 176.943 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' E' E ' 25' ' ' GLY . . . . . 0.432 ' H ' ' HB ' ' H' ' 24' ' ' VAL . . . -122.45 49.35 0.89 Allowed Glycine 0 N--CA 1.474 1.212 0 N-CA-C 110.783 -0.927 . . . . 0.0 110.783 -179.296 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -63.24 -167.83 0.02 OUTLIER 'General case' 0 N--CA 1.469 0.489 0 CA-C-O 120.763 0.316 . . . . 0.0 110.466 179.805 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 4.4 t30 -70.07 77.29 0.5 Allowed 'General case' 0 N--CA 1.466 0.365 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.422 179.961 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -75.17 144.45 42.73 Favored 'General case' 0 N--CA 1.476 0.855 0 N-CA-C 109.552 -0.536 . . . . 0.0 109.552 179.438 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.34 -166.9 1.19 Allowed Glycine 0 CA--C 1.521 0.454 0 N-CA-C 110.439 -1.064 . . . . 0.0 110.439 178.548 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.68 114.15 27.06 Favored 'General case' 0 N--CA 1.472 0.646 0 N-CA-C 109.848 -0.426 . . . . 0.0 109.848 179.769 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 65.6 mt -98.47 135.52 32.97 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.324 0 N-CA-C 106.832 -1.544 . . . . 0.0 106.832 178.979 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' E' E ' 32' ' ' ILE . . . . . 0.45 HG22 ' H ' ' H' ' 32' ' ' ILE . 36.2 pt -152.01 -174.05 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.208 0 CA-C-O 121.111 0.481 . . . . 0.0 110.713 -179.337 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.29 5.16 5.74 Favored Glycine 0 CA--C 1.529 0.942 0 CA-C-N 115.58 -0.736 . . . . 0.0 111.408 -179.731 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 1.6 tt -74.25 126.9 31.63 Favored 'General case' 0 CA--C 1.547 0.852 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 -179.559 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 28.5 ttt -162.74 151.09 14.26 Favored 'General case' 0 C--O 1.209 -1.05 0 N-CA-C 108.995 -0.742 . . . . 0.0 108.995 178.769 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' E' E ' 36' ' ' VAL . . . . . 0.775 HG23 HE22 ' E' ' 15' ' ' GLN . 35.4 m -156.62 166.23 0.94 Allowed 'Isoleucine or valine' 0 C--N 1.343 0.292 0 N-CA-C 108.354 -0.98 . . . . 0.0 108.354 179.747 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.72 66.87 2.53 Favored Glycine 0 C--N 1.307 -1.075 0 CA-C-N 115.576 -0.738 . . . . 0.0 111.997 178.442 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 144.1 -173.12 24.99 Favored Glycine 0 N--CA 1.475 1.281 0 N-CA-C 111.23 -0.748 . . . . 0.0 111.23 178.931 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' E' E ' 39' ' ' VAL . . . . . 0.596 ' H ' HG12 ' H' ' 39' ' ' VAL . 34.2 m -125.46 155.31 34.52 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.753 0 C-N-CA 123.405 0.682 . . . . 0.0 110.429 -179.138 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 26.4 t . . . . . 0 C--O 1.219 -0.526 0 O-C-N 124.062 0.851 . . . . 0.0 110.467 179.505 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 36.2 m-85 . . . . . 0 N--CA 1.474 0.75 0 N-CA-C 110.003 -0.369 . . . . 0.0 110.003 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' F' F ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -142.64 141.02 31.83 Favored 'General case' 0 N--CA 1.48 1.051 0 CA-C-O 120.884 0.373 . . . . 0.0 110.175 179.509 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 42.2 t-80 -151.9 118.95 5.85 Favored 'General case' 0 N--CA 1.472 0.639 0 N-CA-C 109.343 -0.614 . . . . 0.0 109.343 179.046 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' F' F ' 7' ' ' ASP . . . . . 0.478 ' O ' ' OG ' ' I' ' 8' ' ' SER . 4.0 m-20 -69.34 148.36 49.8 Favored 'General case' 0 N--CA 1.465 0.324 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.824 -179.902 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' F' F ' 8' ' ' SER . . . . . 0.49 ' OG ' ' O ' ' C' ' 7' ' ' ASP . 50.5 p -168.1 -172.03 1.68 Allowed 'General case' 0 N--CA 1.486 1.335 0 CA-C-O 121.119 0.485 . . . . 0.0 110.953 179.008 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.89 47.16 1.39 Allowed Glycine 0 N--CA 1.479 1.553 0 CA-C-N 115.884 -0.598 . . . . 0.0 111.953 179.629 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 46.2 p90 -64.73 133.4 52.0 Favored 'General case' 0 CA--C 1.543 0.68 0 N-CA-C 111.832 0.308 . . . . 0.0 111.832 -179.924 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 46.2 mt-10 -91.91 152.17 20.19 Favored 'General case' 0 N--CA 1.481 1.081 0 CA-C-O 121.19 0.519 . . . . 0.0 109.736 177.997 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -154.12 127.24 1.15 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.599 0 N-CA-C 107.838 -1.171 . . . . 0.0 107.838 178.131 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 44.5 m-70 -135.53 146.04 47.66 Favored 'General case' 0 N--CA 1.483 1.201 0 CA-C-O 120.88 0.372 . . . . 0.0 111.631 -177.916 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 6.4 t60 -164.07 96.94 0.81 Allowed 'General case' 0 N--CA 1.486 1.369 0 CA-C-N 116.436 -0.347 . . . . 0.0 110.674 179.385 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' F' F ' 15' ' ' GLN . . . . . 0.735 HE22 HG23 ' F' ' 36' ' ' VAL . 13.8 pt20 -101.18 -173.84 2.47 Favored 'General case' 0 CA--C 1.507 -0.698 0 N-CA-C 108.871 -0.789 . . . . 0.0 108.871 -179.814 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -169.87 94.93 0.27 Allowed 'General case' 0 N--CA 1.473 0.677 0 CA-C-N 114.609 -1.178 . . . . 0.0 108.443 178.42 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 6.3 mp -121.95 157.07 32.06 Favored 'General case' 0 N--CA 1.494 1.764 0 CA-C-O 121.685 0.755 . . . . 0.0 111.554 -177.676 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 48.1 t -114.02 124.27 70.5 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.217 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 177.162 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 30.0 m-85 -124.71 122.03 36.32 Favored 'General case' 0 N--CA 1.488 1.431 0 CA-C-O 120.863 0.364 . . . . 0.0 110.983 -179.741 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 68.9 m-85 54.61 74.18 0.36 Allowed 'General case' 0 C--N 1.344 0.362 0 CA-C-N 115.873 -0.603 . . . . 0.0 111.705 178.166 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -79.1 -78.5 0.15 Allowed 'General case' 0 CA--C 1.535 0.388 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.197 -179.56 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 38.4 tt0 -112.91 101.03 9.11 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 179.822 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -158.29 139.84 13.59 Favored 'General case' 0 C--O 1.208 -1.124 0 O-C-N 122.279 -0.263 . . . . 0.0 111.572 179.099 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' F' F ' 24' ' ' VAL . . . . . 0.472 ' HB ' ' H ' ' C' ' 25' ' ' GLY . 58.3 t -58.55 168.08 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.891 0 N-CA-C 107.507 -1.294 . . . . 0.0 107.507 177.037 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' F' F ' 25' ' ' GLY . . . . . 0.436 ' H ' ' HB ' ' I' ' 24' ' ' VAL . . . -122.14 49.48 0.89 Allowed Glycine 0 N--CA 1.477 1.43 0 N-CA-C 110.787 -0.925 . . . . 0.0 110.787 -179.427 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -63.27 -167.56 0.02 OUTLIER 'General case' 0 N--CA 1.469 0.509 0 CA-C-O 120.642 0.258 . . . . 0.0 110.441 179.796 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 4.3 t30 -70.26 77.12 0.53 Allowed 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.451 179.916 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -75.02 144.77 42.91 Favored 'General case' 0 N--CA 1.476 0.845 0 N-CA-C 109.579 -0.526 . . . . 0.0 109.579 179.335 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.46 -167.02 1.25 Allowed Glycine 0 CA--C 1.522 0.484 0 N-CA-C 110.494 -1.042 . . . . 0.0 110.494 178.64 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.17 113.96 26.47 Favored 'General case' 0 N--CA 1.473 0.711 0 N-CA-C 109.808 -0.442 . . . . 0.0 109.808 179.665 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 66.5 mt -98.43 135.27 33.89 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.388 0 N-CA-C 106.837 -1.542 . . . . 0.0 106.837 178.762 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' F' F ' 32' ' ' ILE . . . . . 0.445 HG22 ' H ' ' I' ' 32' ' ' ILE . 35.2 pt -151.87 -174.29 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.198 0 CA-C-O 121.248 0.547 . . . . 0.0 110.723 -179.373 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.35 5.45 6.31 Favored Glycine 0 CA--C 1.528 0.901 0 CA-C-N 115.55 -0.75 . . . . 0.0 111.443 -179.774 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 1.6 tt -74.42 127.05 32.07 Favored 'General case' 0 CA--C 1.549 0.913 0 N-CA-C 109.467 -0.568 . . . . 0.0 109.467 -179.741 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 28.4 ttt -162.69 151.32 14.62 Favored 'General case' 0 C--O 1.209 -1.045 0 N-CA-C 108.963 -0.755 . . . . 0.0 108.963 178.605 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' F' F ' 36' ' ' VAL . . . . . 0.735 HG23 HE22 ' F' ' 15' ' ' GLN . 35.4 m -156.82 166.13 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.344 0.347 0 N-CA-C 108.312 -0.995 . . . . 0.0 108.312 179.77 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.78 67.0 2.44 Favored Glycine 0 C--N 1.307 -1.038 0 CA-C-N 115.595 -0.729 . . . . 0.0 112.003 178.49 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.98 -173.0 24.96 Favored Glycine 0 N--CA 1.474 1.179 0 N-CA-C 111.251 -0.74 . . . . 0.0 111.251 178.992 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' F' F ' 39' ' ' VAL . . . . . 0.597 ' H ' HG12 ' I' ' 39' ' ' VAL . 34.2 m -125.62 155.51 34.93 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.729 0 C-N-CA 123.336 0.654 . . . . 0.0 110.365 -179.166 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 25.3 t . . . . . 0 C--O 1.219 -0.551 0 O-C-N 124.004 0.815 . . . . 0.0 110.423 179.593 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 40.2 m-85 . . . . . 0 N--CA 1.474 0.768 0 N-CA-C 109.591 -0.522 . . . . 0.0 109.591 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' G' G ' 5' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -143.0 140.56 31.07 Favored 'General case' 0 N--CA 1.481 1.1 0 C-N-CA 122.498 0.319 . . . . 0.0 110.337 179.837 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 42.3 t-80 -151.27 120.22 6.66 Favored 'General case' 0 N--CA 1.474 0.739 0 N-CA-C 109.441 -0.578 . . . . 0.0 109.441 178.938 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -71.23 144.31 50.12 Favored 'General case' 0 N--CA 1.469 0.51 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.231 -179.829 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' G' G ' 8' ' ' SER . . . . . 0.586 ' OG ' ' O ' ' D' ' 7' ' ' ASP . 45.2 p -165.07 -170.52 1.95 Allowed 'General case' 0 N--CA 1.476 0.832 0 CA-C-O 121.037 0.446 . . . . 0.0 110.545 178.792 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.68 48.0 1.33 Allowed Glycine 0 N--CA 1.479 1.548 0 N-CA-C 111.485 -0.646 . . . . 0.0 111.485 179.468 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 48.8 p90 -65.77 133.43 50.99 Favored 'General case' 0 CA--C 1.543 0.676 0 N-CA-C 111.694 0.257 . . . . 0.0 111.694 -179.694 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 46.1 mt-10 -92.32 151.43 20.29 Favored 'General case' 0 N--CA 1.48 1.043 0 CA-C-O 121.146 0.498 . . . . 0.0 110.163 178.582 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -154.75 127.3 1.06 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.966 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 178.298 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 45.7 m-70 -134.74 147.34 50.01 Favored 'General case' 0 N--CA 1.478 0.965 0 CA-C-N 115.62 -0.718 . . . . 0.0 111.486 -178.291 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 32.7 t-80 -165.42 97.35 0.69 Allowed 'General case' 0 N--CA 1.483 1.204 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.242 178.83 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' G' G ' 15' ' ' GLN . . . . . 0.794 HE22 HG23 ' G' ' 36' ' ' VAL . 14.0 pt20 -101.59 -173.67 2.41 Favored 'General case' 0 CA--C 1.507 -0.699 0 N-CA-C 108.662 -0.866 . . . . 0.0 108.662 -179.58 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -170.55 94.22 0.21 Allowed 'General case' 0 N--CA 1.473 0.693 0 CA-C-N 114.654 -1.157 . . . . 0.0 108.076 178.637 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 6.3 mp -121.33 155.85 33.85 Favored 'General case' 0 N--CA 1.498 1.93 0 CA-C-O 121.237 0.541 . . . . 0.0 111.814 -177.8 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 42.9 t -113.43 125.15 70.65 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.011 0 CA-C-N 114.74 -1.118 . . . . 0.0 108.116 176.566 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 31.8 m-85 -125.96 121.54 33.38 Favored 'General case' 0 C--N 1.367 1.337 0 CA-C-N 115.664 -0.698 . . . . 0.0 111.083 -179.446 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 68.4 m-85 54.86 73.11 0.43 Allowed 'General case' 0 N--CA 1.467 0.416 0 CA-C-N 115.858 -0.61 . . . . 0.0 111.545 178.036 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.58 -77.95 0.14 Allowed 'General case' 0 N--CA 1.472 0.64 0 O-C-N 122.212 -0.305 . . . . 0.0 110.355 -179.25 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 38.4 tt0 -113.23 101.14 9.14 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 107.95 -1.13 . . . . 0.0 107.95 179.822 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -158.29 141.02 14.61 Favored 'General case' 0 N--CA 1.477 0.915 0 O-C-N 122.337 -0.227 . . . . 0.0 111.487 179.063 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' G' G ' 24' ' ' VAL . . . . . 0.526 ' HB ' ' H ' ' D' ' 25' ' ' GLY . 59.9 t -60.28 167.07 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.762 0 N-CA-C 107.641 -1.244 . . . . 0.0 107.641 177.26 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' G' G ' 25' ' ' GLY . . . . . 0.426 ' N ' HG12 ' G' ' 24' ' ' VAL . . . -120.45 49.61 0.87 Allowed Glycine 0 N--CA 1.479 1.566 0 N-CA-C 110.504 -1.038 . . . . 0.0 110.504 -179.452 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -64.02 -167.27 0.02 OUTLIER 'General case' 0 N--CA 1.471 0.598 0 CA-C-N 116.953 0.376 . . . . 0.0 110.061 179.829 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 4.3 t30 -70.45 77.12 0.56 Allowed 'General case' 0 CA--C 1.535 0.401 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.471 179.943 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -74.53 144.14 44.21 Favored 'General case' 0 N--CA 1.476 0.86 0 N-CA-C 109.653 -0.499 . . . . 0.0 109.653 179.361 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.39 -166.11 1.07 Allowed Glycine 0 C--N 1.337 0.619 0 N-CA-C 110.037 -1.225 . . . . 0.0 110.037 178.707 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -98.84 114.06 26.47 Favored 'General case' 0 N--CA 1.471 0.575 0 C-N-CA 122.672 0.389 . . . . 0.0 110.447 179.843 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 67.6 mt -99.16 135.51 34.02 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.698 0 N-CA-C 106.856 -1.535 . . . . 0.0 106.856 178.831 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' G' G ' 32' ' ' ILE . . . . . 0.459 ' H ' HG22 ' D' ' 32' ' ' ILE . 34.1 pt -152.48 -173.92 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 CA-C-N 119.891 1.223 . . . . 0.0 109.878 -179.725 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.15 5.31 7.61 Favored Glycine 0 N--CA 1.468 0.773 0 N-CA-C 111.061 -0.816 . . . . 0.0 111.061 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 1.6 tt -75.04 125.85 29.79 Favored 'General case' 0 CA--C 1.545 0.775 0 N-CA-C 109.524 -0.547 . . . . 0.0 109.524 -179.611 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 27.4 ttt -161.52 152.66 18.42 Favored 'General case' 0 C--O 1.21 -0.986 0 N-CA-C 108.775 -0.824 . . . . 0.0 108.775 178.503 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' G' G ' 36' ' ' VAL . . . . . 0.794 HG23 HE22 ' G' ' 15' ' ' GLN . 35.8 m -157.26 165.17 1.0 Allowed 'Isoleucine or valine' 0 C--N 1.346 0.429 0 N-CA-C 108.528 -0.916 . . . . 0.0 108.528 -179.675 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.39 67.99 1.92 Allowed Glycine 0 C--N 1.307 -1.031 0 CA-C-N 115.531 -0.759 . . . . 0.0 112.206 178.26 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.99 -171.66 25.45 Favored Glycine 0 N--CA 1.476 1.315 0 N-CA-C 110.621 -0.991 . . . . 0.0 110.621 178.998 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' G' G ' 39' ' ' VAL . . . . . 0.587 HG12 ' H ' ' D' ' 39' ' ' VAL . 34.7 m -126.93 156.03 38.04 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.911 0 C-N-CA 123.069 0.548 . . . . 0.0 110.631 -179.357 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 31.5 t . . . . . 0 C--O 1.219 -0.546 0 O-C-N 123.946 0.779 . . . . 0.0 110.737 179.218 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 41.0 m-85 . . . . . 0 N--CA 1.473 0.706 0 N-CA-C 109.627 -0.508 . . . . 0.0 109.627 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' H' H ' 5' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -142.91 141.27 31.46 Favored 'General case' 0 N--CA 1.484 1.273 0 C-N-CA 122.585 0.354 . . . . 0.0 110.169 179.747 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 42.0 t-80 -151.98 120.1 6.28 Favored 'General case' 0 N--CA 1.474 0.731 0 N-CA-C 109.36 -0.607 . . . . 0.0 109.36 179.018 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -71.16 144.17 50.29 Favored 'General case' 0 N--CA 1.469 0.519 0 CA-C-N 116.321 -0.4 . . . . 0.0 111.303 -179.777 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' H' H ' 8' ' ' SER . . . . . 0.432 ' OG ' ' O ' ' E' ' 7' ' ' ASP . 53.1 p -164.77 -170.93 2.12 Favored 'General case' 0 N--CA 1.474 0.751 0 CA-C-O 121.06 0.457 . . . . 0.0 110.472 178.783 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.22 47.35 1.33 Allowed Glycine 0 N--CA 1.48 1.567 0 CA-C-N 115.848 -0.614 . . . . 0.0 111.713 179.47 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 49.2 p90 -65.47 133.09 50.53 Favored 'General case' 0 N--CA 1.471 0.594 0 N-CA-C 111.792 0.293 . . . . 0.0 111.792 -179.627 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 46.2 mt-10 -92.0 151.41 20.49 Favored 'General case' 0 N--CA 1.479 0.982 0 CA-C-O 121.115 0.483 . . . . 0.0 110.225 178.568 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -154.65 127.82 1.16 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.027 0 N-CA-C 107.851 -1.166 . . . . 0.0 107.851 178.233 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 46.6 m-70 -135.29 147.3 49.16 Favored 'General case' 0 N--CA 1.478 0.956 0 CA-C-N 115.653 -0.703 . . . . 0.0 111.409 -178.239 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 31.8 t-80 -165.47 97.31 0.68 Allowed 'General case' 0 N--CA 1.483 1.195 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.222 178.887 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' H' H ' 15' ' ' GLN . . . . . 0.781 HE22 HG23 ' H' ' 36' ' ' VAL . 13.9 pt20 -101.5 -173.46 2.37 Favored 'General case' 0 CA--C 1.507 -0.678 0 N-CA-C 108.636 -0.875 . . . . 0.0 108.636 -179.579 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -170.8 94.36 0.2 Allowed 'General case' 0 N--CA 1.472 0.652 0 CA-C-N 114.652 -1.158 . . . . 0.0 108.105 178.626 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 6.4 mp -121.43 155.57 34.57 Favored 'General case' 0 N--CA 1.497 1.911 0 CA-C-O 121.219 0.533 . . . . 0.0 111.938 -177.85 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 42.9 t -113.28 124.71 70.19 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.024 0 CA-C-N 114.782 -1.099 . . . . 0.0 108.134 176.568 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 31.3 m-85 -125.34 121.99 35.55 Favored 'General case' 0 C--N 1.367 1.351 0 CA-C-N 115.497 -0.774 . . . . 0.0 110.914 -179.252 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 68.1 m-85 54.05 73.34 0.39 Allowed 'General case' 0 C--O 1.237 0.436 0 CA-C-N 115.725 -0.67 . . . . 0.0 111.713 178.076 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.53 -78.03 0.14 Allowed 'General case' 0 N--CA 1.472 0.674 0 O-C-N 122.264 -0.273 . . . . 0.0 110.359 -179.218 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 38.3 tt0 -113.15 101.05 9.07 Favored 'General case' 0 C--N 1.322 -0.608 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 179.865 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -158.1 141.01 14.84 Favored 'General case' 0 N--CA 1.478 0.94 0 O-C-N 122.391 -0.193 . . . . 0.0 111.453 179.046 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' H' H ' 24' ' ' VAL . . . . . 0.432 ' HB ' ' H ' ' E' ' 25' ' ' GLY . 59.3 t -60.17 167.28 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.569 0 N-CA-C 107.655 -1.239 . . . . 0.0 107.655 177.209 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' H' H ' 25' ' ' GLY . . . . . 0.425 ' N ' HG12 ' H' ' 24' ' ' VAL . . . -120.65 49.65 0.87 Allowed Glycine 0 N--CA 1.478 1.499 0 N-CA-C 110.513 -1.035 . . . . 0.0 110.513 -179.463 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -64.26 -167.77 0.03 OUTLIER 'General case' 0 N--CA 1.473 0.701 0 CA-C-N 117.005 0.403 . . . . 0.0 110.1 179.755 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 4.5 t30 -70.01 77.15 0.49 Allowed 'General case' 0 CA--C 1.534 0.34 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.46 -179.974 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -74.65 144.5 43.81 Favored 'General case' 0 N--CA 1.476 0.846 0 N-CA-C 109.552 -0.536 . . . . 0.0 109.552 179.304 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.74 -165.23 1.01 Allowed Glycine 0 C--N 1.338 0.644 0 N-CA-C 109.936 -1.265 . . . . 0.0 109.936 178.833 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.94 113.71 26.46 Favored 'General case' 0 N--CA 1.47 0.54 0 C-N-CA 122.603 0.361 . . . . 0.0 110.548 -179.996 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 66.5 mt -98.6 135.78 32.15 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.758 0 N-CA-C 106.824 -1.547 . . . . 0.0 106.824 178.922 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' H' H ' 32' ' ' ILE . . . . . 0.45 ' H ' HG22 ' E' ' 32' ' ' ILE . 34.7 pt -152.81 -174.05 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 CA-C-N 119.853 1.206 . . . . 0.0 109.893 -179.797 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.15 5.61 8.3 Favored Glycine 0 N--CA 1.467 0.761 0 N-CA-C 111.004 -0.839 . . . . 0.0 111.004 179.971 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 1.6 tt -75.23 125.59 29.28 Favored 'General case' 0 CA--C 1.545 0.772 0 N-CA-C 109.588 -0.523 . . . . 0.0 109.588 -179.582 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 27.5 ttt -161.17 152.59 19.04 Favored 'General case' 0 C--O 1.212 -0.91 0 N-CA-C 108.886 -0.783 . . . . 0.0 108.886 178.61 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' H' H ' 36' ' ' VAL . . . . . 0.781 HG23 HE22 ' H' ' 15' ' ' GLN . 35.3 m -157.41 164.58 1.09 Allowed 'Isoleucine or valine' 0 C--N 1.347 0.458 0 N-CA-C 108.489 -0.93 . . . . 0.0 108.489 -179.582 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.78 67.91 1.96 Allowed Glycine 0 C--N 1.308 -0.997 0 CA-C-N 115.425 -0.807 . . . . 0.0 112.182 178.335 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 144.1 -171.89 25.43 Favored Glycine 0 N--CA 1.475 1.266 0 N-CA-C 110.682 -0.967 . . . . 0.0 110.682 179.11 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' H' H ' 39' ' ' VAL . . . . . 0.596 HG12 ' H ' ' E' ' 39' ' ' VAL . 35.0 m -126.8 155.75 37.65 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.94 0 C-N-CA 123.174 0.59 . . . . 0.0 110.663 -179.255 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 29.5 t . . . . . 0 C--O 1.217 -0.611 0 CA-C-O 118.433 -0.794 . . . . 0.0 110.759 179.341 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 40.5 m-85 . . . . . 0 N--CA 1.474 0.749 0 N-CA-C 109.578 -0.527 . . . . 0.0 109.578 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' I' I ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -143.33 140.58 30.62 Favored 'General case' 0 N--CA 1.483 1.178 0 C-N-CA 122.513 0.325 . . . . 0.0 110.152 -179.987 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 41.6 t-80 -151.67 119.61 6.22 Favored 'General case' 0 N--CA 1.474 0.73 0 N-CA-C 109.435 -0.579 . . . . 0.0 109.435 179.058 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -70.7 144.61 50.94 Favored 'General case' 0 N--CA 1.468 0.472 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.203 -179.807 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' I' I ' 8' ' ' SER . . . . . 0.478 ' OG ' ' O ' ' F' ' 7' ' ' ASP . 52.8 p -165.08 -170.69 1.99 Allowed 'General case' 0 N--CA 1.474 0.752 0 CA-C-O 121.023 0.439 . . . . 0.0 110.521 178.752 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.71 47.77 1.35 Allowed Glycine 0 N--CA 1.481 1.638 0 CA-C-N 115.904 -0.589 . . . . 0.0 111.742 179.56 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 49.1 p90 -65.76 133.13 50.38 Favored 'General case' 0 N--CA 1.472 0.637 0 N-CA-C 111.834 0.309 . . . . 0.0 111.834 -179.771 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 46.2 mt-10 -92.0 151.19 20.6 Favored 'General case' 0 N--CA 1.477 0.923 0 C-N-CA 122.841 0.456 . . . . 0.0 110.249 178.615 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -154.6 127.68 1.15 Allowed 'Isoleucine or valine' 0 CA--C 1.551 0.997 0 N-CA-C 107.86 -1.163 . . . . 0.0 107.86 178.195 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 45.2 m-70 -135.02 147.33 49.63 Favored 'General case' 0 N--CA 1.477 0.918 0 CA-C-N 115.608 -0.724 . . . . 0.0 111.479 -178.252 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 32.1 t-80 -165.39 97.31 0.69 Allowed 'General case' 0 N--CA 1.483 1.179 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.218 178.82 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' I' I ' 15' ' ' GLN . . . . . 0.756 HE22 HG23 ' I' ' 36' ' ' VAL . 13.6 pt20 -101.59 -173.43 2.35 Favored 'General case' 0 CA--C 1.507 -0.696 0 N-CA-C 108.622 -0.881 . . . . 0.0 108.622 -179.524 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -170.83 94.48 0.2 Allowed 'General case' 0 N--CA 1.472 0.642 0 CA-C-N 114.631 -1.168 . . . . 0.0 108.076 178.677 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 6.3 mp -121.6 155.52 34.89 Favored 'General case' 0 N--CA 1.496 1.861 0 CA-C-O 121.229 0.538 . . . . 0.0 111.865 -177.851 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 42.0 t -113.09 125.22 70.32 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.015 0 CA-C-N 114.783 -1.099 . . . . 0.0 108.053 176.522 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 31.0 m-85 -125.98 121.63 33.62 Favored 'General case' 0 C--N 1.368 1.396 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.996 -179.17 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 68.2 m-85 54.38 73.05 0.42 Allowed 'General case' 0 N--CA 1.466 0.363 0 CA-C-N 115.836 -0.62 . . . . 0.0 111.584 178.085 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.34 -78.12 0.14 Allowed 'General case' 0 N--CA 1.473 0.712 0 N-CA-C 110.293 -0.262 . . . . 0.0 110.293 -179.218 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 38.6 tt0 -113.05 101.3 9.33 Favored 'General case' 0 C--N 1.323 -0.581 0 N-CA-C 107.994 -1.113 . . . . 0.0 107.994 179.811 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -158.34 141.1 14.61 Favored 'General case' 0 N--CA 1.476 0.867 0 O-C-N 122.368 -0.207 . . . . 0.0 111.444 179.021 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' I' I ' 24' ' ' VAL . . . . . 0.436 ' HB ' ' H ' ' F' ' 25' ' ' GLY . 59.6 t -60.31 166.85 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.348 0.534 0 N-CA-C 107.664 -1.236 . . . . 0.0 107.664 177.212 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' I' I ' 25' ' ' GLY . . . . . 0.43 ' N ' HG12 ' I' ' 24' ' ' VAL . . . -120.27 49.76 0.86 Allowed Glycine 0 N--CA 1.481 1.691 0 N-CA-C 110.542 -1.023 . . . . 0.0 110.542 -179.481 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -64.26 -167.85 0.03 OUTLIER 'General case' 0 N--CA 1.471 0.61 0 CA-C-N 116.922 0.361 . . . . 0.0 110.129 179.714 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 4.4 t30 -69.9 77.18 0.47 Allowed 'General case' 0 CA--C 1.534 0.345 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.419 -179.99 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -74.74 144.43 43.65 Favored 'General case' 0 N--CA 1.475 0.812 0 N-CA-C 109.641 -0.503 . . . . 0.0 109.641 179.387 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.66 -166.06 1.15 Allowed Glycine 0 C--N 1.337 0.607 0 N-CA-C 110.023 -1.231 . . . . 0.0 110.023 178.71 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.09 113.69 26.03 Favored 'General case' 0 N--CA 1.471 0.586 0 C-N-CA 122.674 0.39 . . . . 0.0 110.468 -179.887 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 67.2 mt -98.68 135.65 32.76 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.73 0 N-CA-C 106.895 -1.52 . . . . 0.0 106.895 178.889 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' I' I ' 32' ' ' ILE . . . . . 0.445 ' H ' HG22 ' F' ' 32' ' ' ILE . 35.0 pt -152.71 -173.92 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.774 0 CA-C-N 119.837 1.199 . . . . 0.0 109.826 -179.724 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.02 5.45 7.66 Favored Glycine 0 CA--C 1.527 0.811 0 N-CA-C 111.063 -0.815 . . . . 0.0 111.063 -179.942 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 1.6 tt -74.97 125.94 29.96 Favored 'General case' 0 CA--C 1.546 0.789 0 N-CA-C 109.549 -0.538 . . . . 0.0 109.549 -179.706 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 27.5 ttt -161.45 152.48 18.35 Favored 'General case' 0 C--O 1.21 -0.981 0 N-CA-C 108.794 -0.817 . . . . 0.0 108.794 178.625 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' I' I ' 36' ' ' VAL . . . . . 0.756 HG23 HE22 ' I' ' 15' ' ' GLN . 35.9 m -157.39 164.82 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.346 0.426 0 N-CA-C 108.468 -0.938 . . . . 0.0 108.468 -179.849 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.62 68.13 1.85 Allowed Glycine 0 C--N 1.308 -0.976 0 CA-C-N 115.501 -0.772 . . . . 0.0 112.137 178.294 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 144.01 -171.86 25.39 Favored Glycine 0 N--CA 1.476 1.302 0 N-CA-C 110.601 -1.0 . . . . 0.0 110.601 179.145 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' I' I ' 39' ' ' VAL . . . . . 0.597 HG12 ' H ' ' F' ' 39' ' ' VAL . 34.9 m -126.95 155.98 38.08 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.935 0 C-N-CA 123.118 0.567 . . . . 0.0 110.617 -179.359 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 31.8 t . . . . . 0 C--O 1.219 -0.542 0 O-C-N 123.953 0.783 . . . . 0.0 110.693 179.402 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 42.4 m-85 . . . . . 0 N--CA 1.474 0.758 0 N-CA-C 110.076 -0.342 . . . . 0.0 110.076 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -142.72 141.24 31.75 Favored 'General case' 0 N--CA 1.481 1.08 0 CA-C-O 120.861 0.363 . . . . 0.0 110.052 179.53 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 45.3 t-80 -152.11 119.03 5.79 Favored 'General case' 0 N--CA 1.471 0.613 0 N-CA-C 109.263 -0.643 . . . . 0.0 109.263 178.997 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 7' ' ' ASP . . . . . 0.488 ' O ' ' OG ' ' D' ' 8' ' ' SER . 4.5 m-20 -68.93 149.4 48.9 Favored 'General case' 0 CA--C 1.536 0.436 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.448 179.883 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 60.4 p -168.16 -173.78 2.13 Favored 'General case' 0 N--CA 1.484 1.228 0 CA-C-O 120.947 0.404 . . . . 0.0 110.635 179.224 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.37 46.85 1.37 Allowed Glycine 0 N--CA 1.482 1.721 0 CA-C-N 115.972 -0.558 . . . . 0.0 112.114 179.816 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 49.8 p90 -66.16 132.61 48.86 Favored 'General case' 0 N--CA 1.473 0.697 0 O-C-N 122.782 -0.246 . . . . 0.0 111.53 179.766 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 48.7 mt-10 -91.84 152.49 20.08 Favored 'General case' 0 N--CA 1.477 0.911 0 CA-C-O 121.066 0.46 . . . . 0.0 109.776 178.293 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.0 p -153.15 127.63 1.4 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.545 0 N-CA-C 107.915 -1.143 . . . . 0.0 107.915 178.363 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 44.1 m-70 -135.6 148.44 49.05 Favored 'General case' 0 N--CA 1.492 1.645 0 CA-C-N 119.09 0.859 . . . . 0.0 111.324 -179.064 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 7.0 t60 -163.67 97.81 0.87 Allowed 'General case' 0 N--CA 1.481 1.09 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.776 179.395 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' GLN . . . . . 0.531 HE22 ' H ' ' A' ' 37' ' ' GLY . 3.4 pt20 -107.63 -175.74 2.87 Favored 'General case' 0 CA--C 1.507 -0.68 0 N-CA-C 108.422 -0.955 . . . . 0.0 108.422 -179.98 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -169.63 100.56 0.32 Allowed 'General case' 0 CA--C 1.54 0.582 0 CA-C-N 114.629 -1.169 . . . . 0.0 108.466 179.029 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.547 ' H ' ' CD2' ' D' ' 17' ' ' LEU . 6.9 mt -125.46 153.17 43.91 Favored 'General case' 0 N--CA 1.492 1.675 0 CA-C-O 121.443 0.64 . . . . 0.0 110.975 -178.284 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 60.4 t -107.8 129.26 62.17 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.21 0 CA-C-O 117.896 -1.05 . . . . 0.0 108.392 178.039 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 45.3 m-85 -125.97 122.72 36.73 Favored 'General case' 0 N--CA 1.497 1.919 0 CA-C-N 120.099 1.318 . . . . 0.0 110.367 179.272 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 74.2 m-85 53.09 75.02 0.26 Allowed 'General case' 0 N--CA 1.471 0.594 0 CA-C-O 121.361 0.6 . . . . 0.0 111.935 178.469 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -79.52 -78.32 0.16 Allowed 'General case' 0 C--N 1.353 0.739 0 CA-C-N 115.097 -0.956 . . . . 0.0 110.283 -179.796 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 39.9 tt0 -112.58 100.57 8.83 Favored 'General case' 0 N--CA 1.47 0.564 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 179.805 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -159.33 140.54 12.86 Favored 'General case' 0 C--O 1.207 -1.163 0 O-C-N 122.283 -0.261 . . . . 0.0 111.161 179.175 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.417 HG12 ' N ' ' A' ' 25' ' ' GLY . 61.5 t -60.33 164.15 0.92 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.836 0 N-CA-C 108.154 -1.054 . . . . 0.0 108.154 177.174 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.444 ' H ' ' HB ' ' D' ' 24' ' ' VAL . . . -117.66 48.89 0.9 Allowed Glycine 0 N--CA 1.477 1.426 0 N-CA-C 111.657 -0.577 . . . . 0.0 111.657 -179.353 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -61.92 -168.23 0.02 OUTLIER 'General case' 0 N--CA 1.469 0.486 0 O-C-N 123.845 0.38 . . . . 0.0 110.371 179.532 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 3.1 t30 -70.17 81.11 0.51 Allowed 'General case' 0 N--CA 1.465 0.282 0 N-CA-C 110.144 -0.317 . . . . 0.0 110.144 179.792 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -79.65 146.43 32.49 Favored 'General case' 0 N--CA 1.472 0.627 0 N-CA-C 109.087 -0.708 . . . . 0.0 109.087 179.123 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -62.98 -168.54 0.93 Allowed Glycine 0 CA--C 1.524 0.653 0 N-CA-C 109.895 -1.282 . . . . 0.0 109.895 178.752 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -100.19 116.47 32.26 Favored 'General case' 0 N--CA 1.477 0.898 0 N-CA-C 109.685 -0.487 . . . . 0.0 109.685 179.723 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 69.4 mt -97.34 135.33 31.98 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.556 0 N-CA-C 107.102 -1.444 . . . . 0.0 107.102 179.003 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 44.1 pt -151.43 -178.17 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.713 0 CA-C-O 121.222 0.534 . . . . 0.0 111.11 -178.899 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 64.09 5.34 14.66 Favored Glycine 0 CA--C 1.526 0.728 0 N-CA-C 110.815 -0.914 . . . . 0.0 110.815 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.414 HD23 ' N ' ' A' ' 35' ' ' MET . 1.4 tt -73.79 128.7 36.2 Favored 'General case' 0 CA--C 1.545 0.776 0 N-CA-C 109.61 -0.515 . . . . 0.0 109.61 -179.714 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 35' ' ' MET . . . . . 0.414 ' N ' HD23 ' A' ' 34' ' ' LEU . 28.7 ttt -163.55 147.39 10.44 Favored 'General case' 0 N--CA 1.465 0.305 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 178.506 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.539 HG22 HG12 ' D' ' 36' ' ' VAL . 31.6 m -155.13 163.54 1.55 Allowed 'Isoleucine or valine' 0 C--N 1.347 0.488 0 N-CA-C 108.11 -1.07 . . . . 0.0 108.11 179.503 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 37' ' ' GLY . . . . . 0.531 ' H ' HE22 ' A' ' 15' ' ' GLN . . . 55.4 68.15 1.84 Allowed Glycine 0 C--N 1.306 -1.134 0 CA-C-N 115.89 -0.596 . . . . 0.0 112.078 178.706 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 141.09 175.35 14.71 Favored Glycine 0 N--CA 1.475 1.273 0 N-CA-C 110.821 -0.912 . . . . 0.0 110.821 179.164 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.512 ' H ' HG12 ' D' ' 39' ' ' VAL . 35.4 m -118.55 159.69 18.85 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.813 0 C-N-CA 123.364 0.666 . . . . 0.0 110.384 -179.998 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 22.1 t . . . . . 0 C--O 1.221 -0.441 0 CA-C-O 118.523 -0.751 . . . . 0.0 110.649 179.488 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 41.2 m-85 . . . . . 0 N--CA 1.474 0.751 0 N-CA-C 110.088 -0.338 . . . . 0.0 110.088 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -142.58 141.06 31.93 Favored 'General case' 0 N--CA 1.483 1.217 0 N-CA-C 109.98 -0.378 . . . . 0.0 109.98 179.437 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 44.4 t-80 -151.94 118.94 5.83 Favored 'General case' 0 N--CA 1.473 0.688 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 178.991 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 7' ' ' ASP . . . . . 0.441 ' O ' ' OG ' ' E' ' 8' ' ' SER . 4.3 m-20 -69.08 148.88 49.38 Favored 'General case' 0 CA--C 1.537 0.473 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.585 179.93 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 8' ' ' SER . . . . . . . . . . . . . 59.9 p -167.76 -173.73 2.23 Favored 'General case' 0 N--CA 1.482 1.144 0 CA-C-O 120.985 0.422 . . . . 0.0 110.644 179.336 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.23 46.72 1.41 Allowed Glycine 0 N--CA 1.482 1.753 0 CA-C-N 115.902 -0.59 . . . . 0.0 112.164 179.944 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 50.2 p90 -66.14 132.51 48.66 Favored 'General case' 0 N--CA 1.472 0.657 0 CA-C-O 120.624 0.25 . . . . 0.0 111.596 179.632 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 48.2 mt-10 -91.7 152.62 20.12 Favored 'General case' 0 N--CA 1.476 0.846 0 CA-C-O 121.076 0.465 . . . . 0.0 109.758 178.307 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.0 p -153.23 128.07 1.47 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.654 0 N-CA-C 107.772 -1.196 . . . . 0.0 107.772 178.167 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 43.6 m-70 -135.72 148.91 49.04 Favored 'General case' 0 N--CA 1.492 1.628 0 CA-C-N 118.837 0.744 . . . . 0.0 111.355 -179.145 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 7.2 t60 -164.3 97.62 0.8 Allowed 'General case' 0 N--CA 1.482 1.139 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.75 179.494 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 15' ' ' GLN . . . . . 0.532 HE22 ' H ' ' B' ' 37' ' ' GLY . 3.4 pt20 -107.41 -175.37 2.77 Favored 'General case' 0 CA--C 1.509 -0.623 0 N-CA-C 108.255 -1.017 . . . . 0.0 108.255 -179.921 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -169.96 100.18 0.3 Allowed 'General case' 0 N--CA 1.471 0.619 0 CA-C-N 114.667 -1.151 . . . . 0.0 108.415 178.995 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 17' ' ' LEU . . . . . 0.534 ' H ' ' CD2' ' E' ' 17' ' ' LEU . 6.9 mt -124.92 153.72 42.23 Favored 'General case' 0 N--CA 1.491 1.61 0 CA-C-O 121.506 0.669 . . . . 0.0 111.03 -178.39 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 61.3 t -108.4 130.33 61.25 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.221 0 N-CA-C 108.054 -1.091 . . . . 0.0 108.054 177.933 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 44.2 m-85 -127.24 122.06 32.92 Favored 'General case' 0 N--CA 1.494 1.766 0 CA-C-N 119.721 1.146 . . . . 0.0 110.221 179.524 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 74.7 m-85 52.89 75.28 0.25 Allowed 'General case' 0 CA--C 1.539 0.527 0 CA-C-O 121.427 0.632 . . . . 0.0 111.939 178.47 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -79.92 -78.06 0.17 Allowed 'General case' 0 C--N 1.351 0.666 0 CA-C-N 115.026 -0.988 . . . . 0.0 110.283 -179.839 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 40.2 tt0 -112.58 100.65 8.9 Favored 'General case' 0 N--CA 1.473 0.683 0 N-CA-C 108.349 -0.982 . . . . 0.0 108.349 179.73 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -159.34 141.24 13.4 Favored 'General case' 0 N--CA 1.484 1.235 0 O-C-N 122.222 -0.299 . . . . 0.0 111.144 179.193 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 61.4 t -61.0 163.9 1.05 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.852 0 N-CA-C 108.176 -1.046 . . . . 0.0 108.176 177.238 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 25' ' ' GLY . . . . . 0.466 ' H ' ' HB ' ' E' ' 24' ' ' VAL . . . -117.19 48.51 0.93 Allowed Glycine 0 N--CA 1.476 1.338 0 N-CA-C 111.581 -0.608 . . . . 0.0 111.581 -179.328 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -61.55 -167.43 0.01 OUTLIER 'General case' 0 N--CA 1.469 0.505 0 O-C-N 123.753 0.325 . . . . 0.0 110.364 179.494 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 3.1 t30 -71.24 81.18 0.73 Allowed 'General case' 0 N--CA 1.465 0.324 0 N-CA-C 110.076 -0.342 . . . . 0.0 110.076 179.863 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -79.75 146.47 32.33 Favored 'General case' 0 N--CA 1.473 0.69 0 N-CA-C 109.096 -0.705 . . . . 0.0 109.096 179.274 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.03 -168.7 0.97 Allowed Glycine 0 C--N 1.336 0.56 0 N-CA-C 109.914 -1.274 . . . . 0.0 109.914 178.735 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.97 116.76 32.77 Favored 'General case' 0 N--CA 1.476 0.87 0 N-CA-C 109.668 -0.493 . . . . 0.0 109.668 179.789 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 69.8 mt -97.65 135.07 33.37 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.537 0 N-CA-C 107.07 -1.456 . . . . 0.0 107.07 178.972 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 43.7 pt -151.1 -177.94 0.38 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.681 0 CA-C-O 121.299 0.571 . . . . 0.0 111.159 -178.753 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.42 5.94 13.46 Favored Glycine 0 CA--C 1.525 0.692 0 N-CA-C 110.884 -0.887 . . . . 0.0 110.884 -179.967 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 34' ' ' LEU . . . . . 0.4 HD23 ' N ' ' B' ' 35' ' ' MET . 1.4 tt -74.39 128.35 35.33 Favored 'General case' 0 CA--C 1.545 0.774 0 N-CA-C 109.528 -0.545 . . . . 0.0 109.528 -179.745 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 35' ' ' MET . . . . . 0.4 ' N ' HD23 ' B' ' 34' ' ' LEU . 28.6 ttt -162.95 147.76 11.6 Favored 'General case' 0 N--CA 1.468 0.427 0 N-CA-C 108.797 -0.816 . . . . 0.0 108.797 178.607 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 36' ' ' VAL . . . . . 0.497 HG22 HG12 ' E' ' 36' ' ' VAL . 29.9 m -155.68 163.31 1.53 Allowed 'Isoleucine or valine' 0 C--N 1.347 0.49 0 N-CA-C 108.096 -1.075 . . . . 0.0 108.096 179.516 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 37' ' ' GLY . . . . . 0.532 ' H ' HE22 ' B' ' 15' ' ' GLN . . . 55.67 67.74 2.05 Favored Glycine 0 C--N 1.306 -1.11 0 CA-C-N 115.881 -0.6 . . . . 0.0 112.014 178.676 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 141.17 175.65 14.97 Favored Glycine 0 N--CA 1.475 1.247 0 N-CA-C 110.891 -0.883 . . . . 0.0 110.891 179.079 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 39' ' ' VAL . . . . . 0.514 ' H ' HG12 ' E' ' 39' ' ' VAL . 35.5 m -118.56 159.87 18.73 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.89 0 C-N-CA 123.469 0.708 . . . . 0.0 110.476 -179.934 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 21.9 t . . . . . 0 N--CA 1.468 0.475 0 CA-C-O 118.364 -0.827 . . . . 0.0 110.468 179.362 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 41.3 m-85 . . . . . 0 N--CA 1.475 0.775 0 N-CA-C 110.128 -0.323 . . . . 0.0 110.128 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -143.34 140.49 30.55 Favored 'General case' 0 N--CA 1.481 1.097 0 N-CA-C 110.126 -0.324 . . . . 0.0 110.126 179.608 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 45.4 t-80 -151.51 119.24 6.13 Favored 'General case' 0 N--CA 1.472 0.667 0 N-CA-C 109.286 -0.635 . . . . 0.0 109.286 178.984 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 7' ' ' ASP . . . . . 0.482 ' O ' ' OG ' ' F' ' 8' ' ' SER . 4.4 m-20 -69.32 148.76 49.27 Favored 'General case' 0 CA--C 1.537 0.471 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.591 179.891 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 8' ' ' SER . . . . . . . . . . . . . 59.6 p -167.63 -173.64 2.24 Favored 'General case' 0 N--CA 1.482 1.143 0 CA-C-O 121.04 0.448 . . . . 0.0 110.621 179.202 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.28 47.19 1.34 Allowed Glycine 0 N--CA 1.482 1.702 0 CA-C-N 115.995 -0.548 . . . . 0.0 112.11 179.892 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 49.6 p90 -66.62 132.49 48.29 Favored 'General case' 0 N--CA 1.473 0.713 0 CA-C-O 120.761 0.315 . . . . 0.0 111.571 179.655 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 48.4 mt-10 -91.45 152.63 20.29 Favored 'General case' 0 N--CA 1.475 0.806 0 N-CA-C 109.719 -0.474 . . . . 0.0 109.719 178.253 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -153.33 128.01 1.44 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.548 0 N-CA-C 107.873 -1.158 . . . . 0.0 107.873 178.183 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 43.7 m-70 -135.92 148.51 48.58 Favored 'General case' 0 N--CA 1.492 1.643 0 CA-C-N 118.932 0.787 . . . . 0.0 111.305 -179.055 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 7.1 t60 -163.86 97.56 0.85 Allowed 'General case' 0 N--CA 1.483 1.182 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.794 179.475 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 15' ' ' GLN . . . . . 0.539 HE22 ' H ' ' C' ' 37' ' ' GLY . 3.4 pt20 -107.43 -175.09 2.69 Favored 'General case' 0 CA--C 1.508 -0.662 0 N-CA-C 108.237 -1.023 . . . . 0.0 108.237 -179.96 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -170.29 100.27 0.27 Allowed 'General case' 0 N--CA 1.471 0.577 0 CA-C-N 114.59 -1.186 . . . . 0.0 108.415 179.192 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 17' ' ' LEU . . . . . 0.525 ' H ' ' CD2' ' F' ' 17' ' ' LEU . 6.9 mt -125.14 153.47 42.96 Favored 'General case' 0 N--CA 1.492 1.665 0 CA-C-O 121.52 0.676 . . . . 0.0 111.03 -178.217 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 61.2 t -108.07 130.22 60.97 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.188 0 N-CA-C 108.229 -1.026 . . . . 0.0 108.229 177.844 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 44.3 m-85 -127.16 121.99 32.89 Favored 'General case' 0 N--CA 1.493 1.68 0 CA-C-N 119.655 1.116 . . . . 0.0 110.349 179.454 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 74.2 m-85 52.84 75.22 0.25 Allowed 'General case' 0 N--CA 1.469 0.508 0 CA-C-O 121.518 0.675 . . . . 0.0 111.98 178.529 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -79.83 -77.97 0.17 Allowed 'General case' 0 C--N 1.35 0.6 0 CA-C-N 114.876 -1.056 . . . . 0.0 110.267 -179.814 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 39.8 tt0 -112.68 100.71 8.92 Favored 'General case' 0 N--CA 1.471 0.586 0 N-CA-C 108.3 -1.0 . . . . 0.0 108.3 179.736 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -159.41 140.83 12.98 Favored 'General case' 0 N--CA 1.483 1.178 0 O-C-N 122.22 -0.3 . . . . 0.0 111.226 179.124 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 24' ' ' VAL . . . . . 0.416 HG12 ' N ' ' C' ' 25' ' ' GLY . 60.2 t -60.39 164.34 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.871 0 N-CA-C 108.087 -1.079 . . . . 0.0 108.087 177.23 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 25' ' ' GLY . . . . . 0.447 ' H ' ' HB ' ' F' ' 24' ' ' VAL . . . -117.63 48.82 0.91 Allowed Glycine 0 N--CA 1.479 1.519 0 N-CA-C 111.45 -0.66 . . . . 0.0 111.45 -179.43 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -61.91 -167.92 0.01 OUTLIER 'General case' 0 N--CA 1.468 0.425 0 O-C-N 123.707 0.298 . . . . 0.0 110.386 179.547 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 3.2 t30 -70.54 80.9 0.58 Allowed 'General case' 0 N--CA 1.466 0.353 0 N-CA-C 110.113 -0.329 . . . . 0.0 110.113 179.692 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -79.51 146.57 32.61 Favored 'General case' 0 N--CA 1.473 0.698 0 N-CA-C 109.065 -0.717 . . . . 0.0 109.065 179.239 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.08 -168.76 1.0 Allowed Glycine 0 CA--C 1.525 0.699 0 N-CA-C 109.98 -1.248 . . . . 0.0 109.98 178.806 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.96 116.35 31.82 Favored 'General case' 0 N--CA 1.478 0.974 0 N-CA-C 109.657 -0.498 . . . . 0.0 109.657 179.757 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 69.3 mt -97.45 135.13 32.87 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.54 0 N-CA-C 107.16 -1.422 . . . . 0.0 107.16 179.034 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 43.9 pt -151.12 -177.91 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.649 0 CA-C-N 115.995 -0.548 . . . . 0.0 111.304 -178.691 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.59 5.58 13.11 Favored Glycine 0 CA--C 1.524 0.6 0 N-CA-C 110.853 -0.899 . . . . 0.0 110.853 -179.987 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 34' ' ' LEU . . . . . 0.413 HD23 ' N ' ' C' ' 35' ' ' MET . 1.4 tt -74.07 128.17 34.84 Favored 'General case' 0 CA--C 1.545 0.774 0 N-CA-C 109.626 -0.509 . . . . 0.0 109.626 -179.738 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 35' ' ' MET . . . . . 0.413 ' N ' HD23 ' C' ' 34' ' ' LEU . 28.5 ttt -162.94 147.38 11.44 Favored 'General case' 0 N--CA 1.466 0.364 0 N-CA-C 108.679 -0.86 . . . . 0.0 108.679 178.666 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 36' ' ' VAL . . . . . 0.521 HG22 HG12 ' F' ' 36' ' ' VAL . 33.7 m -155.25 163.38 1.57 Allowed 'Isoleucine or valine' 0 C--N 1.348 0.516 0 N-CA-C 108.125 -1.065 . . . . 0.0 108.125 179.49 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 37' ' ' GLY . . . . . 0.539 ' H ' HE22 ' C' ' 15' ' ' GLN . . . 55.32 67.85 1.99 Allowed Glycine 0 C--N 1.306 -1.135 0 CA-C-N 115.881 -0.6 . . . . 0.0 112.104 178.712 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 141.67 176.07 15.66 Favored Glycine 0 N--CA 1.475 1.248 0 N-CA-C 110.885 -0.886 . . . . 0.0 110.885 179.11 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 39' ' ' VAL . . . . . 0.505 ' H ' HG12 ' F' ' 39' ' ' VAL . 35.6 m -119.16 159.56 19.77 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.878 0 C-N-CA 123.349 0.66 . . . . 0.0 110.451 179.891 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 21.9 t . . . . . 0 N--CA 1.467 0.4 0 CA-C-O 118.45 -0.786 . . . . 0.0 110.473 179.443 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 42.3 m-85 . . . . . 0 N--CA 1.471 0.611 0 N-CA-C 108.941 -0.763 . . . . 0.0 108.941 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' D' D ' 5' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -144.54 139.7 28.35 Favored 'General case' 0 N--CA 1.475 0.797 0 CA-C-N 116.374 -0.375 . . . . 0.0 110.214 179.869 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 41.0 t-80 -149.77 123.96 9.49 Favored 'General case' 0 CA--C 1.545 0.782 0 N-CA-C 108.142 -1.058 . . . . 0.0 108.142 174.72 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' D' D ' 7' ' ' ASP . . . . . 0.584 ' O ' ' OG ' ' G' ' 8' ' ' SER . 3.1 m-20 -63.6 132.98 52.89 Favored 'General case' 0 C--N 1.321 -0.647 0 C-N-CA 126.846 2.058 . . . . 0.0 114.209 174.62 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' D' D ' 8' ' ' SER . . . . . 0.488 ' OG ' ' O ' ' A' ' 7' ' ' ASP . 59.8 p -154.51 -170.8 3.64 Favored 'General case' 0 N--CA 1.488 1.454 0 CA-C-N 119.675 1.125 . . . . 0.0 111.255 175.246 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.39 47.91 1.17 Allowed Glycine 0 N--CA 1.481 1.666 0 C-N-CA 124.663 1.125 . . . . 0.0 110.632 174.321 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 51.5 p90 -60.99 131.56 51.02 Favored 'General case' 0 N--CA 1.47 0.526 0 N-CA-C 112.613 0.598 . . . . 0.0 112.613 177.559 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 48.3 mt-10 -89.64 151.01 22.11 Favored 'General case' 0 N--CA 1.479 1.025 0 CA-C-N 117.989 0.359 . . . . 0.0 110.662 174.982 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.0 p -149.64 129.95 4.22 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.662 0 N-CA-C 107.307 -1.368 . . . . 0.0 107.307 173.058 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 38.6 m-70 -129.79 151.63 50.16 Favored 'General case' 0 N--CA 1.483 1.182 0 N-CA-C 112.264 0.468 . . . . 0.0 112.264 176.639 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 7.3 t60 -164.68 104.75 0.82 Allowed 'General case' 0 N--CA 1.483 1.201 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 172.261 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' D' D ' 15' ' ' GLN . . . . . 0.482 HE22 ' H ' ' D' ' 37' ' ' GLY . 3.4 pt20 -111.05 -176.47 2.96 Favored 'General case' 0 CA--C 1.502 -0.884 0 N-CA-C 108.002 -1.11 . . . . 0.0 108.002 179.007 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -167.03 106.44 0.59 Allowed 'General case' 0 N--CA 1.466 0.337 0 N-CA-C 106.947 -1.501 . . . . 0.0 106.947 176.404 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' D' D ' 17' ' ' LEU . . . . . 0.554 ' H ' ' CD2' ' G' ' 17' ' ' LEU . 9.9 mt -130.57 152.35 50.04 Favored 'General case' 0 N--CA 1.493 1.702 0 CA-C-O 121.864 0.84 . . . . 0.0 110.493 179.651 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 38.6 t -99.65 133.09 43.73 Favored 'Isoleucine or valine' 0 C--O 1.259 1.596 0 CA-C-O 116.97 -1.49 . . . . 0.0 109.645 175.007 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 40.6 m-85 -130.04 125.97 36.54 Favored 'General case' 0 N--CA 1.489 1.523 0 CA-C-N 119.792 1.178 . . . . 0.0 109.357 174.144 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 74.1 m-85 55.87 71.87 0.53 Allowed 'General case' 0 C--N 1.352 0.693 0 CA-C-N 115.105 -0.952 . . . . 0.0 111.411 176.063 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -81.82 -73.0 0.41 Allowed 'General case' 0 N--CA 1.472 0.66 0 CA-C-O 118.369 -0.824 . . . . 0.0 111.005 -177.305 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 40.3 tt0 -115.98 104.17 11.33 Favored 'General case' 0 N--CA 1.484 1.262 0 N-CA-C 106.404 -1.702 . . . . 0.0 106.404 176.392 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -152.21 140.8 20.77 Favored 'General case' 0 N--CA 1.475 0.789 0 CA-C-O 116.748 -1.596 . . . . 0.0 113.634 177.867 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' D' D ' 24' ' ' VAL . . . . . 0.444 ' HB ' ' H ' ' A' ' 25' ' ' GLY . 66.7 t -62.95 166.57 0.97 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.237 0 CA-C-N 121.097 1.771 . . . . 0.0 107.979 174.782 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' D' D ' 25' ' ' GLY . . . . . 0.503 ' H ' ' HB ' ' G' ' 24' ' ' VAL . . . -116.67 51.07 0.75 Allowed Glycine 0 N--CA 1.481 1.667 0 CA-C-O 118.876 -0.958 . . . . 0.0 111.715 178.636 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -58.29 -170.73 0.01 OUTLIER 'General case' 0 C--N 1.322 -0.619 0 C-N-CA 123.38 0.672 . . . . 0.0 111.637 176.638 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 3.9 t30 -72.43 86.71 1.15 Allowed 'General case' 0 CA--C 1.537 0.453 0 N-CA-C 108.425 -0.954 . . . . 0.0 108.425 178.45 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 97.6 mttt -84.26 148.71 26.55 Favored 'General case' 0 N--CA 1.474 0.758 0 N-CA-C 108.155 -1.054 . . . . 0.0 108.155 178.884 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -62.7 -165.73 0.55 Allowed Glycine 0 C--N 1.337 0.614 0 N-CA-C 110.461 -1.056 . . . . 0.0 110.461 179.374 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -102.09 115.99 31.72 Favored 'General case' 0 N--CA 1.467 0.385 0 C-N-CA 123.186 0.595 . . . . 0.0 109.921 179.832 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 80.4 mt -102.41 142.46 16.6 Favored 'Isoleucine or valine' 0 C--N 1.355 0.836 0 N-CA-C 104.327 -2.472 . . . . 0.0 104.327 -178.908 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 38.6 pt -157.68 -179.05 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.241 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.118 -176.161 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 64.73 5.7 19.6 Favored Glycine 0 C--O 1.244 0.758 0 N-CA-C 110.003 -1.239 . . . . 0.0 110.003 -178.573 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 1.7 tt -76.42 134.14 39.68 Favored 'General case' 0 C--N 1.361 1.084 0 N-CA-C 107.244 -1.391 . . . . 0.0 107.244 -177.829 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' D' D ' 35' ' ' MET . . . . . 0.405 ' C ' HG13 ' D' ' 36' ' ' VAL . 28.2 ttt -157.91 159.99 37.15 Favored 'General case' 0 CA--C 1.517 -0.319 0 N-CA-C 108.225 -1.028 . . . . 0.0 108.225 172.577 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' D' D ' 36' ' ' VAL . . . . . 0.578 HG22 HG12 ' G' ' 36' ' ' VAL . 31.0 m -164.8 163.63 0.71 Allowed 'Isoleucine or valine' 0 C--O 1.223 -0.31 0 N-CA-C 107.765 -1.198 . . . . 0.0 107.765 174.232 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' D' D ' 37' ' ' GLY . . . . . 0.482 ' H ' HE22 ' D' ' 15' ' ' GLN . . . 59.9 63.71 4.84 Favored Glycine 0 CA--C 1.528 0.884 0 C-N-CA 120.435 -0.888 . . . . 0.0 111.335 178.024 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.18 179.66 20.01 Favored Glycine 0 N--CA 1.481 1.651 0 N-CA-C 111.057 -0.817 . . . . 0.0 111.057 178.352 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' D' D ' 39' ' ' VAL . . . . . 0.529 ' H ' HG12 ' G' ' 39' ' ' VAL . 33.9 m -120.54 157.02 23.56 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.822 0 C-N-CA 123.133 0.573 . . . . 0.0 110.94 179.461 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 22.0 t . . . . . 0 C--N 1.333 -0.14 0 CA-C-O 116.665 -1.636 . . . . 0.0 109.536 175.794 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 38.8 m-85 . . . . . 0 N--CA 1.475 0.806 0 N-CA-C 110.152 -0.314 . . . . 0.0 110.152 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' E' E ' 5' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -142.72 140.97 31.69 Favored 'General case' 0 N--CA 1.482 1.126 0 CA-C-O 120.904 0.383 . . . . 0.0 110.077 179.395 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 45.0 t-80 -151.4 118.8 6.0 Favored 'General case' 0 N--CA 1.472 0.669 0 N-CA-C 109.227 -0.657 . . . . 0.0 109.227 178.83 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' E' E ' 7' ' ' ASP . . . . . 0.441 ' O ' ' OG ' ' H' ' 8' ' ' SER . 4.2 m-20 -69.57 148.66 49.1 Favored 'General case' 0 N--CA 1.467 0.379 0 CA-C-N 116.435 -0.348 . . . . 0.0 110.745 179.941 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' E' E ' 8' ' ' SER . . . . . 0.441 ' OG ' ' O ' ' B' ' 7' ' ' ASP . 56.0 p -168.26 -172.51 1.76 Allowed 'General case' 0 N--CA 1.486 1.343 0 CA-C-O 121.099 0.476 . . . . 0.0 110.784 178.917 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.71 47.09 1.31 Allowed Glycine 0 N--CA 1.478 1.493 0 CA-C-N 115.912 -0.585 . . . . 0.0 112.101 179.807 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 47.7 p90 -65.82 133.22 50.51 Favored 'General case' 0 N--CA 1.473 0.721 0 N-CA-C 111.908 0.336 . . . . 0.0 111.908 -179.948 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 48.6 mt-10 -91.47 152.98 20.13 Favored 'General case' 0 N--CA 1.48 1.054 0 CA-C-O 121.245 0.545 . . . . 0.0 109.629 177.943 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -154.97 126.78 0.95 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.63 0 N-CA-C 107.739 -1.208 . . . . 0.0 107.739 178.135 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 42.2 m-70 -135.69 146.86 48.2 Favored 'General case' 0 N--CA 1.482 1.14 0 CA-C-O 120.849 0.357 . . . . 0.0 111.531 -178.126 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 7.1 t60 -163.0 97.64 0.93 Allowed 'General case' 0 N--CA 1.485 1.288 0 CA-C-N 116.365 -0.38 . . . . 0.0 110.717 179.506 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' E' E ' 15' ' ' GLN . . . . . 0.515 HE22 ' H ' ' E' ' 37' ' ' GLY . 3.4 pt20 -106.99 -175.22 2.73 Favored 'General case' 0 CA--C 1.51 -0.564 0 N-CA-C 108.521 -0.918 . . . . 0.0 108.521 -179.928 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -169.84 99.81 0.31 Allowed 'General case' 0 N--CA 1.473 0.713 0 CA-C-N 114.654 -1.157 . . . . 0.0 108.617 179.004 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' E' E ' 17' ' ' LEU . . . . . 0.563 ' H ' ' CD2' ' H' ' 17' ' ' LEU . 7.3 mt -123.9 153.89 40.5 Favored 'General case' 0 N--CA 1.49 1.549 0 CA-C-O 121.348 0.594 . . . . 0.0 111.505 -177.767 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 49.9 t -110.7 126.3 68.04 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.307 0 N-CA-C 108.205 -1.035 . . . . 0.0 108.205 177.604 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 46.6 m-85 -123.79 121.22 34.87 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 123.37 0.419 . . . . 0.0 111.038 -179.821 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 73.7 m-85 54.06 74.33 0.34 Allowed 'General case' 0 N--CA 1.47 0.542 0 CA-C-N 115.922 -0.581 . . . . 0.0 111.594 178.061 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -78.18 -78.96 0.13 Allowed 'General case' 0 CA--C 1.535 0.375 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.095 -179.488 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 39.9 tt0 -111.67 100.97 9.39 Favored 'General case' 0 N--CA 1.469 0.482 0 N-CA-C 108.438 -0.949 . . . . 0.0 108.438 -179.989 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -158.61 140.73 13.95 Favored 'General case' 0 C--O 1.204 -1.296 0 CA-C-O 119.581 -0.247 . . . . 0.0 111.535 179.147 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' E' E ' 24' ' ' VAL . . . . . 0.466 ' HB ' ' H ' ' B' ' 25' ' ' GLY . 57.6 t -58.86 169.03 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.851 0 N-CA-C 107.691 -1.225 . . . . 0.0 107.691 177.017 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' E' E ' 25' ' ' GLY . . . . . 0.432 ' N ' HG12 ' E' ' 24' ' ' VAL . . . -122.51 49.59 0.88 Allowed Glycine 0 N--CA 1.477 1.383 0 N-CA-C 110.674 -0.971 . . . . 0.0 110.674 -179.479 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -63.07 -167.57 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.553 0 CA-C-O 120.644 0.259 . . . . 0.0 110.601 179.774 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 4.0 t30 -69.93 78.12 0.48 Allowed 'General case' 0 N--CA 1.466 0.351 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.383 -179.944 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -77.32 146.73 36.58 Favored 'General case' 0 N--CA 1.475 0.81 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 179.28 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.39 -168.33 1.08 Allowed Glycine 0 CA--C 1.522 0.518 0 N-CA-C 110.522 -1.031 . . . . 0.0 110.522 178.623 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.74 115.45 29.55 Favored 'General case' 0 N--CA 1.468 0.461 0 N-CA-C 109.904 -0.406 . . . . 0.0 109.904 179.471 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 70.5 mt -96.38 135.09 31.6 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.282 0 N-CA-C 106.942 -1.503 . . . . 0.0 106.942 179.037 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 39.0 pt -151.1 -176.16 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.229 0 CA-C-O 121.164 0.506 . . . . 0.0 110.737 -179.157 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.2 5.97 9.25 Favored Glycine 0 CA--C 1.529 0.963 0 CA-C-N 115.322 -0.853 . . . . 0.0 111.243 -179.517 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 1.4 tt -73.8 128.68 36.16 Favored 'General case' 0 CA--C 1.548 0.884 0 N-CA-C 109.629 -0.508 . . . . 0.0 109.629 -179.544 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 28.4 ttt -162.93 148.79 12.11 Favored 'General case' 0 C--O 1.209 -1.056 0 N-CA-C 108.925 -0.769 . . . . 0.0 108.925 178.484 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' E' E ' 36' ' ' VAL . . . . . 0.572 HG22 HG12 ' H' ' 36' ' ' VAL . 34.0 m -156.97 162.73 1.5 Allowed 'Isoleucine or valine' 0 C--N 1.344 0.344 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 179.862 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' E' E ' 37' ' ' GLY . . . . . 0.515 ' H ' HE22 ' E' ' 15' ' ' GLN . . . 55.94 66.8 2.59 Favored Glycine 0 C--N 1.307 -1.06 0 CA-C-N 115.933 -0.576 . . . . 0.0 111.939 178.537 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 142.56 176.81 17.01 Favored Glycine 0 N--CA 1.477 1.382 0 N-CA-C 111.149 -0.78 . . . . 0.0 111.149 179.007 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' E' E ' 39' ' ' VAL . . . . . 0.544 ' H ' HG12 ' H' ' 39' ' ' VAL . 33.3 m -119.93 158.62 21.68 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.749 0 C-N-CA 123.392 0.677 . . . . 0.0 110.626 -179.595 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 22.6 t . . . . . 0 C--O 1.22 -0.478 0 CA-C-O 118.448 -0.787 . . . . 0.0 110.482 179.112 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 38.2 m-85 . . . . . 0 N--CA 1.474 0.75 0 N-CA-C 110.135 -0.32 . . . . 0.0 110.135 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' F' F ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -142.47 141.24 32.13 Favored 'General case' 0 N--CA 1.478 0.959 0 CA-C-O 120.805 0.336 . . . . 0.0 110.249 179.41 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 43.9 t-80 -151.92 118.74 5.78 Favored 'General case' 0 N--CA 1.472 0.659 0 N-CA-C 109.315 -0.624 . . . . 0.0 109.315 178.928 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' F' F ' 7' ' ' ASP . . . . . 0.477 ' O ' ' OG ' ' I' ' 8' ' ' SER . 4.3 m-20 -69.35 148.64 49.39 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 116.411 -0.359 . . . . 0.0 110.814 -179.96 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' F' F ' 8' ' ' SER . . . . . 0.482 ' OG ' ' O ' ' C' ' 7' ' ' ASP . 56.1 p -168.33 -172.79 1.81 Allowed 'General case' 0 N--CA 1.487 1.422 0 CA-C-O 121.111 0.482 . . . . 0.0 110.924 178.8 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.93 47.01 1.3 Allowed Glycine 0 N--CA 1.479 1.502 0 CA-C-N 115.978 -0.556 . . . . 0.0 112.064 179.877 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 47.7 p90 -65.57 133.03 50.32 Favored 'General case' 0 CA--C 1.543 0.673 0 N-CA-C 111.852 0.316 . . . . 0.0 111.852 -179.954 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 48.3 mt-10 -91.48 152.33 20.4 Favored 'General case' 0 N--CA 1.48 1.042 0 CA-C-O 121.195 0.521 . . . . 0.0 109.713 177.818 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -154.18 126.87 1.09 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.608 0 N-CA-C 107.825 -1.176 . . . . 0.0 107.825 177.997 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 41.9 m-70 -135.67 146.9 48.29 Favored 'General case' 0 N--CA 1.483 1.2 0 CA-C-O 120.936 0.398 . . . . 0.0 111.582 -178.142 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 7.1 t60 -162.98 97.49 0.93 Allowed 'General case' 0 N--CA 1.486 1.371 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.821 179.55 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' F' F ' 15' ' ' GLN . . . . . 0.526 HE22 ' H ' ' F' ' 37' ' ' GLY . 3.4 pt20 -107.06 -175.22 2.73 Favored 'General case' 0 CA--C 1.507 -0.675 0 N-CA-C 108.482 -0.932 . . . . 0.0 108.482 -179.939 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -169.77 99.86 0.31 Allowed 'General case' 0 N--CA 1.47 0.572 0 CA-C-N 114.712 -1.131 . . . . 0.0 108.606 179.052 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' F' F ' 17' ' ' LEU . . . . . 0.559 ' H ' ' CD2' ' I' ' 17' ' ' LEU . 7.2 mt -123.81 154.33 39.73 Favored 'General case' 0 N--CA 1.489 1.501 0 CA-C-O 121.273 0.558 . . . . 0.0 111.461 -177.735 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 51.8 t -111.07 126.21 68.45 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.325 0 N-CA-C 108.262 -1.014 . . . . 0.0 108.262 177.529 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 47.0 m-85 -123.71 121.15 34.76 Favored 'General case' 0 C--N 1.367 1.363 0 CA-C-O 120.972 0.415 . . . . 0.0 111.018 -179.819 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 74.1 m-85 54.23 74.31 0.34 Allowed 'General case' 0 N--CA 1.469 0.477 0 CA-C-N 115.871 -0.604 . . . . 0.0 111.743 178.054 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -78.15 -78.98 0.13 Allowed 'General case' 0 N--CA 1.465 0.32 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.228 -179.551 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 39.7 tt0 -111.71 101.19 9.58 Favored 'General case' 0 N--CA 1.469 0.5 0 N-CA-C 108.325 -0.991 . . . . 0.0 108.325 -179.986 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -158.86 140.6 13.53 Favored 'General case' 0 C--O 1.205 -1.277 0 CA-C-O 119.584 -0.246 . . . . 0.0 111.483 179.089 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' F' F ' 24' ' ' VAL . . . . . 0.447 ' HB ' ' H ' ' C' ' 25' ' ' GLY . 57.4 t -58.81 168.91 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.885 0 N-CA-C 107.591 -1.263 . . . . 0.0 107.591 177.057 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' F' F ' 25' ' ' GLY . . . . . 0.436 ' N ' HG12 ' F' ' 24' ' ' VAL . . . -122.31 49.4 0.89 Allowed Glycine 0 N--CA 1.477 1.402 0 N-CA-C 110.751 -0.94 . . . . 0.0 110.751 -179.478 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -63.16 -168.39 0.02 OUTLIER 'General case' 0 N--CA 1.469 0.489 0 CA-C-O 120.635 0.255 . . . . 0.0 110.447 -179.975 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 4.0 t30 -69.11 77.96 0.34 Allowed 'General case' 0 CA--C 1.533 0.292 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.484 -179.908 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -77.18 147.02 36.69 Favored 'General case' 0 N--CA 1.475 0.816 0 N-CA-C 109.468 -0.567 . . . . 0.0 109.468 179.239 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.44 -168.11 1.07 Allowed Glycine 0 CA--C 1.522 0.481 0 N-CA-C 110.612 -0.995 . . . . 0.0 110.612 178.569 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.54 114.85 28.1 Favored 'General case' 0 N--CA 1.469 0.504 0 N-CA-C 109.891 -0.411 . . . . 0.0 109.891 179.484 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 70.6 mt -96.16 135.02 31.59 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.298 0 N-CA-C 106.987 -1.486 . . . . 0.0 106.987 178.895 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 38.6 pt -151.16 -176.32 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.251 0 CA-C-O 121.191 0.519 . . . . 0.0 110.739 -179.184 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.39 6.0 9.79 Favored Glycine 0 CA--C 1.529 0.937 0 CA-C-N 115.29 -0.868 . . . . 0.0 111.186 -179.622 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' F' F ' 34' ' ' LEU . . . . . 0.403 HD23 ' N ' ' F' ' 35' ' ' MET . 1.3 tt -73.64 128.69 36.18 Favored 'General case' 0 CA--C 1.549 0.913 0 N-CA-C 109.538 -0.541 . . . . 0.0 109.538 -179.586 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' F' F ' 35' ' ' MET . . . . . 0.403 ' N ' HD23 ' F' ' 34' ' ' LEU . 28.4 ttt -162.96 148.73 12.03 Favored 'General case' 0 C--O 1.208 -1.094 0 N-CA-C 108.82 -0.807 . . . . 0.0 108.82 178.378 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' F' F ' 36' ' ' VAL . . . . . 0.575 HG22 HG12 ' I' ' 36' ' ' VAL . 34.1 m -156.75 163.0 1.46 Allowed 'Isoleucine or valine' 0 C--N 1.346 0.429 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 179.872 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' F' F ' 37' ' ' GLY . . . . . 0.526 ' H ' HE22 ' F' ' 15' ' ' GLN . . . 55.58 67.1 2.39 Favored Glycine 0 C--N 1.307 -1.061 0 CA-C-N 115.944 -0.571 . . . . 0.0 111.947 178.45 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 142.35 176.85 16.87 Favored Glycine 0 N--CA 1.476 1.325 0 N-CA-C 111.155 -0.778 . . . . 0.0 111.155 179.036 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' F' F ' 39' ' ' VAL . . . . . 0.531 ' H ' HG12 ' I' ' 39' ' ' VAL . 33.4 m -119.95 158.92 21.55 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.629 0 C-N-CA 123.374 0.67 . . . . 0.0 110.649 -179.675 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 23.6 t . . . . . 0 C--O 1.221 -0.417 0 CA-C-O 118.549 -0.738 . . . . 0.0 110.499 179.071 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 40.8 m-85 . . . . . 0 N--CA 1.473 0.719 0 N-CA-C 109.643 -0.503 . . . . 0.0 109.643 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' G' G ' 5' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -142.98 141.02 31.3 Favored 'General case' 0 N--CA 1.482 1.15 0 CA-C-O 120.816 0.341 . . . . 0.0 110.188 179.721 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 44.3 t-80 -151.53 119.48 6.22 Favored 'General case' 0 N--CA 1.474 0.743 0 N-CA-C 109.384 -0.599 . . . . 0.0 109.384 178.948 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -71.04 144.53 50.36 Favored 'General case' 0 N--CA 1.471 0.583 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.212 -179.822 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' G' G ' 8' ' ' SER . . . . . 0.584 ' OG ' ' O ' ' D' ' 7' ' ' ASP . 54.4 p -165.31 -171.22 2.1 Favored 'General case' 0 N--CA 1.476 0.861 0 CA-C-O 121.054 0.454 . . . . 0.0 110.436 178.644 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.88 46.76 1.33 Allowed Glycine 0 N--CA 1.479 1.566 0 CA-C-N 115.809 -0.632 . . . . 0.0 111.607 179.533 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 50.0 p90 -65.44 133.05 50.48 Favored 'General case' 0 N--CA 1.472 0.649 0 N-CA-C 111.835 0.309 . . . . 0.0 111.835 -179.795 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 49.1 mt-10 -91.88 151.89 20.34 Favored 'General case' 0 N--CA 1.479 1.001 0 CA-C-O 121.108 0.48 . . . . 0.0 110.062 178.401 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -155.08 127.04 0.97 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.021 0 N-CA-C 107.886 -1.153 . . . . 0.0 107.886 178.33 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 43.1 m-70 -135.01 148.39 49.94 Favored 'General case' 0 N--CA 1.478 0.944 0 CA-C-N 115.49 -0.777 . . . . 0.0 111.414 -178.399 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 35.5 t-80 -164.49 97.29 0.78 Allowed 'General case' 0 N--CA 1.484 1.227 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.486 178.907 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' G' G ' 15' ' ' GLN . . . . . 0.527 HE22 ' H ' ' G' ' 37' ' ' GLY . 3.5 pt20 -106.88 -175.67 2.86 Favored 'General case' 0 CA--C 1.508 -0.664 0 N-CA-C 108.364 -0.976 . . . . 0.0 108.364 -179.821 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -169.98 99.52 0.29 Allowed 'General case' 0 N--CA 1.473 0.691 0 CA-C-N 114.649 -1.159 . . . . 0.0 108.345 179.176 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' G' G ' 17' ' ' LEU . . . . . 0.554 ' CD2' ' H ' ' D' ' 17' ' ' LEU . 8.2 mt -123.4 153.94 39.69 Favored 'General case' 0 N--CA 1.495 1.786 0 CA-C-O 121.085 0.469 . . . . 0.0 111.789 -177.863 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 43.4 t -111.26 126.39 68.65 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.038 0 N-CA-C 108.1 -1.074 . . . . 0.0 108.1 177.021 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 48.0 m-85 -124.12 120.77 33.3 Favored 'General case' 0 C--N 1.367 1.346 0 CA-C-N 115.602 -0.726 . . . . 0.0 111.192 -179.539 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 73.8 m-85 54.46 73.66 0.39 Allowed 'General case' 0 N--CA 1.47 0.526 0 CA-C-N 115.896 -0.593 . . . . 0.0 111.594 178.008 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.04 -78.32 0.13 Allowed 'General case' 0 N--CA 1.471 0.59 0 O-C-N 122.282 -0.262 . . . . 0.0 110.446 -179.032 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 40.4 tt0 -112.25 101.07 9.32 Favored 'General case' 0 C--N 1.322 -0.629 0 N-CA-C 108.108 -1.071 . . . . 0.0 108.108 179.839 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -158.38 142.38 15.6 Favored 'General case' 0 N--CA 1.478 0.926 0 O-C-N 122.387 -0.195 . . . . 0.0 111.442 179.01 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' G' G ' 24' ' ' VAL . . . . . 0.503 ' HB ' ' H ' ' D' ' 25' ' ' GLY . 59.7 t -60.97 167.76 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.644 0 N-CA-C 107.67 -1.233 . . . . 0.0 107.67 177.384 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' G' G ' 25' ' ' GLY . . . . . 0.437 ' N ' HG12 ' G' ' 24' ' ' VAL . . . -120.64 49.95 0.85 Allowed Glycine 0 N--CA 1.482 1.755 0 N-CA-C 110.338 -1.105 . . . . 0.0 110.338 -179.58 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -63.78 -167.61 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.661 0 CA-C-N 116.984 0.392 . . . . 0.0 109.987 179.833 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 3.4 t30 -70.11 77.71 0.51 Allowed 'General case' 0 CA--C 1.536 0.407 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.451 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -76.16 146.72 38.98 Favored 'General case' 0 N--CA 1.475 0.818 0 N-CA-C 109.506 -0.553 . . . . 0.0 109.506 179.306 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.62 -167.01 0.95 Allowed Glycine 0 C--N 1.336 0.578 0 N-CA-C 110.076 -1.21 . . . . 0.0 110.076 178.721 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.58 115.26 28.98 Favored 'General case' 0 N--CA 1.469 0.516 0 C-N-CA 122.689 0.395 . . . . 0.0 110.438 179.841 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 72.1 mt -97.1 135.99 29.41 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.671 0 N-CA-C 106.87 -1.53 . . . . 0.0 106.87 178.931 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 36.8 pt -152.47 -176.01 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.71 0 CA-C-N 119.855 1.207 . . . . 0.0 109.95 -179.631 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.09 5.83 11.27 Favored Glycine 0 CA--C 1.527 0.811 0 N-CA-C 110.878 -0.889 . . . . 0.0 110.878 -179.763 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' G' G ' 34' ' ' LEU . . . . . 0.408 HD23 ' N ' ' G' ' 35' ' ' MET . 1.4 tt -74.3 127.4 32.89 Favored 'General case' 0 CA--C 1.546 0.796 0 N-CA-C 109.7 -0.482 . . . . 0.0 109.7 -179.503 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' G' G ' 35' ' ' MET . . . . . 0.408 ' N ' HD23 ' G' ' 34' ' ' LEU . 28.1 ttt -161.56 150.22 15.73 Favored 'General case' 0 C--O 1.212 -0.897 0 N-CA-C 108.844 -0.798 . . . . 0.0 108.844 178.533 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' G' G ' 36' ' ' VAL . . . . . 0.578 HG12 HG22 ' D' ' 36' ' ' VAL . 33.9 m -157.4 162.11 1.62 Allowed 'Isoleucine or valine' 0 C--N 1.346 0.451 0 N-CA-C 108.628 -0.878 . . . . 0.0 108.628 -179.819 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' G' G ' 37' ' ' GLY . . . . . 0.527 ' H ' HE22 ' G' ' 15' ' ' GLN . . . 55.61 67.01 2.43 Favored Glycine 0 C--N 1.312 -0.803 0 CA-C-N 115.599 -0.728 . . . . 0.0 112.299 178.111 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.33 178.3 19.02 Favored Glycine 0 N--CA 1.477 1.383 0 N-CA-C 110.569 -1.012 . . . . 0.0 110.569 178.925 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' G' G ' 39' ' ' VAL . . . . . 0.529 HG12 ' H ' ' D' ' 39' ' ' VAL . 34.2 m -121.34 158.37 24.3 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.837 0 C-N-CA 123.128 0.571 . . . . 0.0 110.6 -179.621 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 22.2 t . . . . . 0 N--CA 1.469 0.515 0 O-C-N 123.981 0.801 . . . . 0.0 110.752 179.163 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 42.2 m-85 . . . . . 0 N--CA 1.474 0.744 0 N-CA-C 109.603 -0.517 . . . . 0.0 109.603 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' H' H ' 5' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -142.91 141.35 31.48 Favored 'General case' 0 N--CA 1.484 1.263 0 N-CA-C 110.081 -0.34 . . . . 0.0 110.081 179.732 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 44.3 t-80 -151.89 119.54 6.09 Favored 'General case' 0 N--CA 1.474 0.745 0 N-CA-C 109.334 -0.617 . . . . 0.0 109.334 178.901 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -70.96 144.57 50.49 Favored 'General case' 0 N--CA 1.47 0.57 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.251 -179.884 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' H' H ' 8' ' ' SER . . . . . 0.441 ' OG ' ' O ' ' E' ' 7' ' ' ASP . 60.2 p -165.26 -171.55 2.22 Favored 'General case' 0 N--CA 1.474 0.758 0 CA-C-O 120.976 0.417 . . . . 0.0 110.485 178.751 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.83 46.62 1.36 Allowed Glycine 0 N--CA 1.481 1.645 0 CA-C-N 115.986 -0.552 . . . . 0.0 111.756 179.699 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 50.3 p90 -65.64 133.15 50.52 Favored 'General case' 0 N--CA 1.471 0.625 0 N-CA-C 111.798 0.295 . . . . 0.0 111.798 -179.835 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 48.5 mt-10 -91.75 152.25 20.25 Favored 'General case' 0 N--CA 1.477 0.911 0 CA-C-O 121.127 0.489 . . . . 0.0 110.128 178.446 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -155.2 127.49 1.02 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.049 0 N-CA-C 107.83 -1.174 . . . . 0.0 107.83 178.346 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 44.1 m-70 -135.53 148.01 48.99 Favored 'General case' 0 N--CA 1.477 0.909 0 CA-C-N 115.566 -0.743 . . . . 0.0 111.396 -178.307 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 7.1 t60 -164.32 97.26 0.8 Allowed 'General case' 0 N--CA 1.484 1.226 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.45 178.915 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' H' H ' 15' ' ' GLN . . . . . 0.512 HE22 ' H ' ' H' ' 37' ' ' GLY . 3.5 pt20 -106.8 -175.67 2.86 Favored 'General case' 0 CA--C 1.508 -0.666 0 N-CA-C 108.278 -1.008 . . . . 0.0 108.278 -179.872 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -169.81 99.64 0.31 Allowed 'General case' 0 N--CA 1.472 0.653 0 CA-C-N 114.72 -1.127 . . . . 0.0 108.358 179.124 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' H' H ' 17' ' ' LEU . . . . . 0.563 ' CD2' ' H ' ' E' ' 17' ' ' LEU . 8.6 mt -123.44 154.08 39.57 Favored 'General case' 0 N--CA 1.495 1.819 0 CA-C-O 121.118 0.485 . . . . 0.0 111.86 -177.757 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 43.0 t -111.65 126.05 69.01 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.111 0 N-CA-C 108.077 -1.082 . . . . 0.0 108.077 177.087 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 47.5 m-85 -123.83 120.45 32.63 Favored 'General case' 0 C--N 1.368 1.392 0 CA-C-N 115.456 -0.793 . . . . 0.0 110.981 -179.332 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 73.4 m-85 54.11 74.33 0.34 Allowed 'General case' 0 C--N 1.345 0.399 0 CA-C-N 115.776 -0.647 . . . . 0.0 111.697 178.02 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.25 -78.15 0.13 Allowed 'General case' 0 N--CA 1.472 0.655 0 O-C-N 122.4 -0.188 . . . . 0.0 110.519 -179.117 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 40.3 tt0 -112.41 100.95 9.18 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 108.024 -1.102 . . . . 0.0 108.024 179.899 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -158.31 141.95 15.34 Favored 'General case' 0 N--CA 1.478 0.946 0 O-C-N 122.384 -0.198 . . . . 0.0 111.458 179.104 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' H' H ' 24' ' ' VAL . . . . . 0.433 HG12 ' N ' ' H' ' 25' ' ' GLY . 59.6 t -60.63 167.89 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.561 0 N-CA-C 107.664 -1.236 . . . . 0.0 107.664 177.389 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' H' H ' 25' ' ' GLY . . . . . 0.433 ' N ' HG12 ' H' ' 24' ' ' VAL . . . -120.89 49.27 0.89 Allowed Glycine 0 N--CA 1.48 1.609 0 N-CA-C 110.482 -1.047 . . . . 0.0 110.482 -179.385 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -63.24 -167.56 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.642 0 CA-C-N 117.009 0.405 . . . . 0.0 110.201 179.881 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 3.5 t30 -69.93 78.11 0.48 Allowed 'General case' 0 CA--C 1.535 0.388 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.411 179.903 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -76.76 146.55 37.86 Favored 'General case' 0 N--CA 1.476 0.842 0 N-CA-C 109.501 -0.555 . . . . 0.0 109.501 179.314 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.74 -167.12 1.01 Allowed Glycine 0 C--N 1.336 0.578 0 N-CA-C 110.045 -1.222 . . . . 0.0 110.045 178.757 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.84 115.11 28.82 Favored 'General case' 0 N--CA 1.467 0.378 0 C-N-CA 122.6 0.36 . . . . 0.0 110.579 -179.938 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 71.6 mt -96.84 136.02 29.03 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.729 0 N-CA-C 106.866 -1.531 . . . . 0.0 106.866 179.094 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 36.6 pt -152.42 -175.87 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.761 0 CA-C-N 119.814 1.188 . . . . 0.0 109.898 -179.716 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.5 7.0 12.59 Favored Glycine 0 CA--C 1.526 0.78 0 N-CA-C 110.879 -0.889 . . . . 0.0 110.879 -179.755 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 1.3 tt -75.33 127.12 32.44 Favored 'General case' 0 CA--C 1.545 0.775 0 N-CA-C 109.69 -0.485 . . . . 0.0 109.69 -179.728 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 28.0 ttt -161.31 150.03 16.04 Favored 'General case' 0 C--O 1.212 -0.917 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 178.61 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' H' H ' 36' ' ' VAL . . . . . 0.572 HG12 HG22 ' E' ' 36' ' ' VAL . 34.0 m -157.24 161.74 1.73 Allowed 'Isoleucine or valine' 0 C--N 1.345 0.398 0 N-CA-C 108.742 -0.836 . . . . 0.0 108.742 -179.665 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' H' H ' 37' ' ' GLY . . . . . 0.512 ' H ' HE22 ' H' ' 15' ' ' GLN . . . 55.81 66.89 2.52 Favored Glycine 0 C--N 1.311 -0.833 0 CA-C-N 115.673 -0.694 . . . . 0.0 112.261 178.172 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.46 178.09 18.96 Favored Glycine 0 N--CA 1.477 1.396 0 N-CA-C 110.644 -0.982 . . . . 0.0 110.644 179.026 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' H' H ' 39' ' ' VAL . . . . . 0.544 HG12 ' H ' ' E' ' 39' ' ' VAL . 34.1 m -121.12 158.43 23.81 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.846 0 C-N-CA 123.191 0.597 . . . . 0.0 110.772 -179.646 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 23.7 t . . . . . 0 N--CA 1.47 0.529 0 O-C-N 123.936 0.772 . . . . 0.0 110.694 179.149 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 41.0 m-85 . . . . . 0 N--CA 1.474 0.767 0 N-CA-C 109.579 -0.526 . . . . 0.0 109.579 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' I' I ' 5' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -142.81 141.35 31.62 Favored 'General case' 0 N--CA 1.483 1.224 0 C-N-CA 122.596 0.359 . . . . 0.0 110.143 179.787 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 45.0 t-80 -151.93 119.46 6.04 Favored 'General case' 0 N--CA 1.473 0.708 0 N-CA-C 109.379 -0.6 . . . . 0.0 109.379 178.96 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -71.02 144.41 50.43 Favored 'General case' 0 N--CA 1.469 0.497 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.268 -179.859 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' I' I ' 8' ' ' SER . . . . . 0.477 ' OG ' ' O ' ' F' ' 7' ' ' ASP . 60.5 p -165.02 -171.47 2.24 Favored 'General case' 0 N--CA 1.474 0.771 0 CA-C-O 120.975 0.417 . . . . 0.0 110.469 178.839 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.66 47.03 1.32 Allowed Glycine 0 N--CA 1.479 1.525 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.777 179.598 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 50.0 p90 -66.18 132.8 49.29 Favored 'General case' 0 N--CA 1.472 0.626 0 N-CA-C 111.869 0.322 . . . . 0.0 111.869 -179.805 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 48.5 mt-10 -91.19 152.29 20.61 Favored 'General case' 0 N--CA 1.477 0.907 0 CA-C-O 121.155 0.502 . . . . 0.0 110.202 178.385 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -155.48 126.95 0.91 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.057 0 N-CA-C 107.887 -1.153 . . . . 0.0 107.887 178.201 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 42.9 m-70 -134.92 148.33 50.03 Favored 'General case' 0 N--CA 1.478 0.935 0 CA-C-N 115.488 -0.778 . . . . 0.0 111.432 -178.409 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 33.6 t-80 -164.49 97.33 0.78 Allowed 'General case' 0 N--CA 1.481 1.111 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.441 178.995 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' I' I ' 15' ' ' GLN . . . . . 0.534 HE22 ' H ' ' I' ' 37' ' ' GLY . 3.5 pt20 -106.84 -175.36 2.77 Favored 'General case' 0 CA--C 1.508 -0.666 0 N-CA-C 108.208 -1.034 . . . . 0.0 108.208 -179.815 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -170.18 99.53 0.28 Allowed 'General case' 0 N--CA 1.471 0.595 0 CA-C-N 114.592 -1.185 . . . . 0.0 108.25 179.159 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' I' I ' 17' ' ' LEU . . . . . 0.559 ' CD2' ' H ' ' F' ' 17' ' ' LEU . 8.4 mt -123.23 153.76 39.69 Favored 'General case' 0 N--CA 1.495 1.8 0 CA-C-O 121.042 0.449 . . . . 0.0 111.836 -177.829 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 43.8 t -111.3 126.44 68.69 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.02 0 N-CA-C 108.05 -1.093 . . . . 0.0 108.05 176.913 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 47.1 m-85 -124.16 120.77 33.27 Favored 'General case' 0 C--N 1.368 1.389 0 CA-C-N 115.511 -0.768 . . . . 0.0 111.002 -179.294 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 73.4 m-85 53.87 73.84 0.36 Allowed 'General case' 0 N--CA 1.469 0.495 0 CA-C-N 115.898 -0.592 . . . . 0.0 111.637 178.062 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -76.74 -78.43 0.12 Allowed 'General case' 0 N--CA 1.471 0.61 0 O-C-N 122.304 -0.247 . . . . 0.0 110.414 -179.209 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 40.1 tt0 -112.12 101.31 9.58 Favored 'General case' 0 C--N 1.324 -0.512 0 N-CA-C 108.075 -1.083 . . . . 0.0 108.075 179.938 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -158.53 142.4 15.42 Favored 'General case' 0 N--CA 1.477 0.903 0 O-C-N 122.42 -0.175 . . . . 0.0 111.467 179.063 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' I' I ' 24' ' ' VAL . . . . . 0.447 HG12 ' N ' ' I' ' 25' ' ' GLY . 59.0 t -61.06 167.82 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.561 0 N-CA-C 107.663 -1.236 . . . . 0.0 107.663 177.296 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' I' I ' 25' ' ' GLY . . . . . 0.447 ' N ' HG12 ' I' ' 24' ' ' VAL . . . -120.8 49.85 0.86 Allowed Glycine 0 N--CA 1.481 1.682 0 N-CA-C 110.45 -1.06 . . . . 0.0 110.45 -179.485 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -63.84 -167.57 0.02 OUTLIER 'General case' 0 N--CA 1.471 0.594 0 CA-C-N 116.927 0.364 . . . . 0.0 110.24 179.879 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 3.6 t30 -69.8 77.59 0.46 Allowed 'General case' 0 CA--C 1.535 0.37 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.445 179.883 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -76.39 146.66 38.55 Favored 'General case' 0 N--CA 1.474 0.755 0 N-CA-C 109.438 -0.578 . . . . 0.0 109.438 179.305 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.73 -166.79 0.96 Allowed Glycine 0 C--N 1.337 0.638 0 N-CA-C 110.074 -1.21 . . . . 0.0 110.074 178.76 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.84 114.88 28.37 Favored 'General case' 0 N--CA 1.469 0.501 0 C-N-CA 122.771 0.428 . . . . 0.0 110.582 179.913 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 72.0 mt -96.75 136.07 28.78 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.674 0 N-CA-C 106.883 -1.525 . . . . 0.0 106.883 178.981 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 37.5 pt -152.46 -175.94 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 CA-C-N 119.885 1.221 . . . . 0.0 109.907 -179.678 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.63 6.69 12.22 Favored Glycine 0 CA--C 1.526 0.763 0 N-CA-C 110.94 -0.864 . . . . 0.0 110.94 -179.776 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' I' I ' 34' ' ' LEU . . . . . 0.408 HD23 ' N ' ' I' ' 35' ' ' MET . 1.4 tt -75.04 127.13 32.51 Favored 'General case' 0 CA--C 1.547 0.83 0 N-CA-C 109.547 -0.538 . . . . 0.0 109.547 -179.64 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' I' I ' 35' ' ' MET . . . . . 0.408 ' N ' HD23 ' I' ' 34' ' ' LEU . 28.1 ttt -161.1 150.12 16.49 Favored 'General case' 0 C--O 1.211 -0.942 0 N-CA-C 108.738 -0.838 . . . . 0.0 108.738 178.564 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' I' I ' 36' ' ' VAL . . . . . 0.575 HG12 HG22 ' F' ' 36' ' ' VAL . 34.1 m -157.23 162.11 1.63 Allowed 'Isoleucine or valine' 0 C--N 1.347 0.459 0 N-CA-C 108.594 -0.891 . . . . 0.0 108.594 -179.747 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' I' I ' 37' ' ' GLY . . . . . 0.534 ' H ' HE22 ' I' ' 15' ' ' GLN . . . 55.34 67.2 2.33 Favored Glycine 0 C--N 1.311 -0.841 0 CA-C-N 115.643 -0.708 . . . . 0.0 112.241 178.122 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.18 178.28 18.88 Favored Glycine 0 N--CA 1.478 1.47 0 N-CA-C 110.568 -1.013 . . . . 0.0 110.568 178.875 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' I' I ' 39' ' ' VAL . . . . . 0.531 HG12 ' H ' ' F' ' 39' ' ' VAL . 33.9 m -121.33 158.31 24.33 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.856 0 C-N-CA 123.15 0.58 . . . . 0.0 110.723 -179.662 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 23.4 t . . . . . 0 N--CA 1.469 0.523 0 O-C-N 124.046 0.841 . . . . 0.0 110.699 179.041 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 35.1 m-85 . . . . . 0 N--CA 1.475 0.782 0 N-CA-C 110.082 -0.34 . . . . 0.0 110.082 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -144.31 139.65 28.69 Favored 'General case' 0 N--CA 1.481 1.115 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 179.563 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 42.1 t-80 -151.95 119.88 6.2 Favored 'General case' 0 N--CA 1.469 0.509 0 N-CA-C 109.264 -0.643 . . . . 0.0 109.264 179.257 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 7' ' ' ASP . . . . . 0.5 ' O ' ' OG ' ' D' ' 8' ' ' SER . 4.2 m-20 -69.04 148.68 49.72 Favored 'General case' 0 CA--C 1.537 0.476 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.498 179.876 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 53.9 p -168.2 -174.24 2.25 Favored 'General case' 0 N--CA 1.484 1.262 0 CA-C-O 121.035 0.445 . . . . 0.0 110.747 179.429 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.8 48.26 1.28 Allowed Glycine 0 N--CA 1.481 1.698 0 CA-C-N 115.911 -0.586 . . . . 0.0 111.83 179.725 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 49.7 p90 -64.6 132.39 49.67 Favored 'General case' 0 N--CA 1.473 0.691 0 O-C-N 122.761 -0.258 . . . . 0.0 111.425 179.732 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 83.3 mt-10 -91.71 152.25 20.28 Favored 'General case' 0 N--CA 1.48 1.047 0 C-N-CA 122.781 0.433 . . . . 0.0 109.839 178.379 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -153.23 128.42 1.54 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.617 0 N-CA-C 107.821 -1.177 . . . . 0.0 107.821 178.298 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 48.5 m-70 -135.25 145.98 48.13 Favored 'General case' 0 N--CA 1.492 1.666 0 CA-C-N 118.949 0.795 . . . . 0.0 111.388 -179.003 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 6.1 t60 -165.95 97.18 0.63 Allowed 'General case' 0 N--CA 1.48 1.058 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.848 179.5 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 3.6 pt20 -108.52 -174.69 2.58 Favored 'General case' 0 CA--C 1.506 -0.733 0 N-CA-C 108.432 -0.951 . . . . 0.0 108.432 -179.845 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -164.17 97.57 0.82 Allowed 'General case' 0 N--CA 1.472 0.651 0 CA-C-N 114.562 -1.199 . . . . 0.0 108.299 178.348 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 6.7 mp -122.27 157.78 30.94 Favored 'General case' 0 N--CA 1.497 1.924 0 CA-C-O 121.759 0.79 . . . . 0.0 110.91 -178.338 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 59.8 t -112.57 126.65 69.99 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.124 0 CA-C-O 117.984 -1.008 . . . . 0.0 108.316 177.702 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 28.7 m-85 -126.93 122.5 34.75 Favored 'General case' 0 N--CA 1.497 1.909 0 CA-C-N 120.017 1.28 . . . . 0.0 110.344 179.338 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 67.0 m-85 53.94 74.32 0.33 Allowed 'General case' 0 N--CA 1.47 0.572 0 CA-C-O 121.374 0.606 . . . . 0.0 111.745 178.751 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -80.55 -78.14 0.18 Allowed 'General case' 0 C--N 1.353 0.756 0 CA-C-N 115.139 -0.937 . . . . 0.0 110.334 -179.773 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 40.4 tt0 -112.21 101.59 9.82 Favored 'General case' 0 N--CA 1.469 0.502 0 N-CA-C 108.468 -0.938 . . . . 0.0 108.468 179.738 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 4.4 p30 -158.96 134.5 8.62 Favored 'General case' 0 N--CA 1.482 1.16 0 CA-C-O 119.512 -0.28 . . . . 0.0 111.211 178.936 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 58.7 t -58.05 163.07 0.71 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.853 0 N-CA-C 108.074 -1.084 . . . . 0.0 108.074 176.984 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.421 ' H ' ' HB ' ' D' ' 24' ' ' VAL . . . -115.76 47.95 0.99 Allowed Glycine 0 N--CA 1.477 1.383 0 N-CA-C 111.615 -0.594 . . . . 0.0 111.615 -179.474 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -61.85 -168.65 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.562 0 N-CA-C 110.152 -0.314 . . . . 0.0 110.152 179.338 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 2.8 t30 -72.05 79.97 0.94 Allowed 'General case' 0 N--CA 1.464 0.257 0 CA-C-N 116.428 -0.351 . . . . 0.0 110.082 179.164 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -73.46 140.32 46.39 Favored 'General case' 0 N--CA 1.476 0.837 0 N-CA-C 108.934 -0.765 . . . . 0.0 108.934 179.375 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.39 -149.76 0.03 OUTLIER Glycine 0 C--N 1.337 0.618 0 N-CA-C 110.183 -1.167 . . . . 0.0 110.183 179.282 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -93.76 128.07 39.8 Favored 'General case' 0 N--CA 1.476 0.825 0 N-CA-C 110.04 -0.356 . . . . 0.0 110.04 -179.905 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 74.8 mt -124.16 117.35 50.54 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.748 0 N-CA-C 106.653 -1.61 . . . . 0.0 106.653 178.876 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 39.2 pt -151.5 -169.78 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.354 0.804 0 CA-C-O 121.22 0.533 . . . . 0.0 111.246 -178.769 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.84 5.08 12.38 Favored Glycine 0 C--N 1.336 0.58 0 N-CA-C 110.797 -0.921 . . . . 0.0 110.797 179.587 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 1.5 tt -78.14 126.77 31.3 Favored 'General case' 0 CA--C 1.546 0.801 0 N-CA-C 109.558 -0.534 . . . . 0.0 109.558 -179.884 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 28.6 ttt -164.69 143.55 6.94 Favored 'General case' 0 N--CA 1.464 0.23 0 N-CA-C 108.871 -0.788 . . . . 0.0 108.871 178.266 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.426 HG22 HG12 ' D' ' 36' ' ' VAL . 35.6 m -155.27 162.71 1.73 Allowed 'Isoleucine or valine' 0 C--N 1.348 0.509 0 N-CA-C 108.042 -1.096 . . . . 0.0 108.042 179.327 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.61 66.33 2.93 Favored Glycine 0 C--N 1.307 -1.08 0 CA-C-N 115.834 -0.621 . . . . 0.0 111.874 178.429 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 145.7 172.97 16.53 Favored Glycine 0 N--CA 1.473 1.1 0 N-CA-C 110.994 -0.843 . . . . 0.0 110.994 179.095 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.583 ' H ' HG12 ' D' ' 39' ' ' VAL . 33.7 m -123.01 160.44 25.76 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.616 0 C-N-CA 123.405 0.682 . . . . 0.0 110.087 -179.691 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 23.7 t . . . . . 0 C--O 1.218 -0.556 0 CA-C-O 118.419 -0.8 . . . . 0.0 110.578 179.478 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 34.7 m-85 . . . . . 0 N--CA 1.474 0.752 0 N-CA-C 110.047 -0.353 . . . . 0.0 110.047 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -144.41 139.06 28.16 Favored 'General case' 0 N--CA 1.484 1.225 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 179.585 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 41.5 t-80 -151.24 119.63 6.41 Favored 'General case' 0 N--CA 1.472 0.638 0 N-CA-C 109.256 -0.646 . . . . 0.0 109.256 179.204 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 7' ' ' ASP . . . . . 0.507 ' O ' ' OG ' ' E' ' 8' ' ' SER . 4.0 m-20 -68.83 148.19 50.63 Favored 'General case' 0 CA--C 1.538 0.514 0 CA-C-N 116.295 -0.412 . . . . 0.0 110.721 179.828 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 8' ' ' SER . . . . . . . . . . . . . 54.1 p -167.58 -173.69 2.27 Favored 'General case' 0 N--CA 1.483 1.221 0 CA-C-O 121.045 0.45 . . . . 0.0 110.707 179.525 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.38 48.24 1.33 Allowed Glycine 0 N--CA 1.481 1.692 0 CA-C-N 115.908 -0.587 . . . . 0.0 111.949 179.55 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 50.2 p90 -64.94 132.89 50.55 Favored 'General case' 0 N--CA 1.473 0.687 0 CA-C-O 120.636 0.255 . . . . 0.0 111.496 179.871 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 84.2 mt-10 -92.02 152.75 19.84 Favored 'General case' 0 N--CA 1.478 0.93 0 CA-C-O 121.048 0.451 . . . . 0.0 109.823 178.456 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -153.61 128.39 1.46 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.495 0 N-CA-C 107.922 -1.14 . . . . 0.0 107.922 178.12 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 46.5 m-70 -135.32 145.67 47.69 Favored 'General case' 0 N--CA 1.493 1.723 0 CA-C-N 118.941 0.791 . . . . 0.0 111.289 -179.006 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 6.0 t60 -165.65 96.86 0.66 Allowed 'General case' 0 N--CA 1.48 1.035 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.739 179.38 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 3.6 pt20 -108.12 -174.74 2.59 Favored 'General case' 0 CA--C 1.507 -0.694 0 N-CA-C 108.411 -0.959 . . . . 0.0 108.411 -179.798 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -164.29 97.63 0.8 Allowed 'General case' 0 N--CA 1.473 0.699 0 CA-C-N 114.67 -1.15 . . . . 0.0 108.263 178.342 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 6.6 mp -122.27 157.69 31.13 Favored 'General case' 0 N--CA 1.497 1.906 0 CA-C-O 121.809 0.814 . . . . 0.0 111.023 -178.298 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 61.4 t -112.71 127.75 69.77 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.024 0 N-CA-C 108.069 -1.086 . . . . 0.0 108.069 177.595 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 28.6 m-85 -128.09 122.09 31.22 Favored 'General case' 0 N--CA 1.495 1.787 0 CA-C-N 119.726 1.148 . . . . 0.0 110.192 179.501 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 67.1 m-85 53.6 74.18 0.33 Allowed 'General case' 0 CA--C 1.54 0.581 0 CA-C-O 121.487 0.661 . . . . 0.0 111.799 178.622 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -80.35 -78.32 0.17 Allowed 'General case' 0 C--N 1.352 0.687 0 CA-C-N 115.001 -1.0 . . . . 0.0 110.275 -179.823 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 40.5 tt0 -112.02 101.73 10.0 Favored 'General case' 0 N--CA 1.471 0.613 0 N-CA-C 108.448 -0.945 . . . . 0.0 108.448 179.819 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 4.4 p30 -158.89 134.8 8.89 Favored 'General case' 0 N--CA 1.482 1.169 0 CA-C-O 119.54 -0.266 . . . . 0.0 111.155 178.913 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 58.5 t -58.26 163.2 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.874 0 N-CA-C 108.128 -1.064 . . . . 0.0 108.128 177.018 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 25' ' ' GLY . . . . . 0.436 ' H ' ' HB ' ' E' ' 24' ' ' VAL . . . -115.57 47.62 1.02 Allowed Glycine 0 N--CA 1.474 1.203 0 N-CA-C 111.65 -0.58 . . . . 0.0 111.65 -179.314 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -61.77 -168.59 0.01 OUTLIER 'General case' 0 N--CA 1.469 0.518 0 N-CA-C 110.25 -0.278 . . . . 0.0 110.25 179.45 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 24.6 t-20 -72.38 79.85 1.02 Allowed 'General case' 0 N--CA 1.468 0.426 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.318 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -73.19 140.6 47.1 Favored 'General case' 0 N--CA 1.477 0.898 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 179.565 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.56 -150.05 0.04 OUTLIER Glycine 0 C--N 1.338 0.639 0 N-CA-C 110.191 -1.163 . . . . 0.0 110.191 179.411 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -93.41 128.33 39.42 Favored 'General case' 0 N--CA 1.475 0.787 0 CA-C-N 116.938 0.369 . . . . 0.0 110.032 179.795 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 76.7 mt -124.46 117.26 50.02 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.658 0 N-CA-C 106.593 -1.632 . . . . 0.0 106.593 178.811 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 39.8 pt -151.19 -169.71 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.355 0.831 0 CA-C-N 115.986 -0.552 . . . . 0.0 111.255 -178.746 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.83 4.95 11.86 Favored Glycine 0 C--N 1.337 0.627 0 N-CA-C 110.945 -0.862 . . . . 0.0 110.945 179.479 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 1.5 tt -78.12 126.81 31.35 Favored 'General case' 0 CA--C 1.546 0.819 0 N-CA-C 109.57 -0.53 . . . . 0.0 109.57 -179.778 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 28.5 ttt -164.81 143.53 6.75 Favored 'General case' 0 N--CA 1.465 0.311 0 N-CA-C 108.801 -0.814 . . . . 0.0 108.801 178.225 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 35.4 m -155.37 162.41 1.8 Allowed 'Isoleucine or valine' 0 C--N 1.347 0.499 0 N-CA-C 108.0 -1.111 . . . . 0.0 108.0 179.471 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.71 66.9 2.52 Favored Glycine 0 C--N 1.307 -1.068 0 CA-C-N 115.742 -0.663 . . . . 0.0 111.784 178.415 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 144.97 172.65 15.58 Favored Glycine 0 N--CA 1.472 1.08 0 N-CA-C 110.869 -0.892 . . . . 0.0 110.869 179.179 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 39' ' ' VAL . . . . . 0.605 ' H ' HG12 ' E' ' 39' ' ' VAL . 32.5 m -123.09 159.95 26.49 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.711 0 C-N-CA 123.428 0.691 . . . . 0.0 110.209 -179.553 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 24.4 t . . . . . 0 N--CA 1.468 0.468 0 CA-C-O 118.316 -0.849 . . . . 0.0 110.441 179.475 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 34.6 m-85 . . . . . 0 N--CA 1.475 0.799 0 N-CA-C 110.023 -0.362 . . . . 0.0 110.023 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -144.75 138.85 27.47 Favored 'General case' 0 N--CA 1.482 1.165 0 N-CA-C 109.951 -0.389 . . . . 0.0 109.951 179.69 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 41.7 t-80 -151.16 119.7 6.48 Favored 'General case' 0 N--CA 1.471 0.582 0 N-CA-C 109.381 -0.599 . . . . 0.0 109.381 179.246 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 7' ' ' ASP . . . . . 0.482 ' O ' ' OG ' ' F' ' 8' ' ' SER . 4.3 m-20 -69.1 148.21 50.33 Favored 'General case' 0 CA--C 1.539 0.527 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.66 179.891 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 8' ' ' SER . . . . . . . . . . . . . 54.5 p -167.55 -173.95 2.36 Favored 'General case' 0 N--CA 1.484 1.271 0 CA-C-O 121.028 0.442 . . . . 0.0 110.764 179.455 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.81 48.19 1.29 Allowed Glycine 0 N--CA 1.48 1.616 0 CA-C-N 115.886 -0.597 . . . . 0.0 111.988 179.574 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 49.5 p90 -65.01 132.18 48.54 Favored 'General case' 0 N--CA 1.471 0.604 0 O-C-N 122.751 -0.264 . . . . 0.0 111.463 179.897 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 83.5 mt-10 -91.47 152.59 20.29 Favored 'General case' 0 N--CA 1.476 0.835 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 178.465 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -153.4 128.61 1.54 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.53 0 N-CA-C 107.778 -1.193 . . . . 0.0 107.778 178.237 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 46.8 m-70 -135.35 145.76 47.71 Favored 'General case' 0 N--CA 1.493 1.687 0 CA-C-N 118.986 0.812 . . . . 0.0 111.357 -179.099 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 6.0 t60 -165.69 97.33 0.66 Allowed 'General case' 0 N--CA 1.48 1.059 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.715 179.361 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 3.5 pt20 -108.74 -174.22 2.46 Favored 'General case' 0 CA--C 1.506 -0.722 0 N-CA-C 108.362 -0.977 . . . . 0.0 108.362 -179.891 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -164.66 97.7 0.77 Allowed 'General case' 0 N--CA 1.471 0.62 0 CA-C-N 114.573 -1.194 . . . . 0.0 108.269 178.55 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 6.6 mp -122.45 157.36 32.11 Favored 'General case' 0 N--CA 1.498 1.946 0 CA-C-O 121.883 0.849 . . . . 0.0 111.017 -178.208 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 58.8 t -112.41 127.28 69.71 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.091 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 177.655 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 29.2 m-85 -127.77 122.17 32.1 Favored 'General case' 0 N--CA 1.494 1.75 0 CA-C-N 119.686 1.13 . . . . 0.0 110.266 179.458 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 67.0 m-85 53.54 74.14 0.33 Allowed 'General case' 0 N--CA 1.468 0.448 0 CA-C-O 121.486 0.66 . . . . 0.0 111.915 178.588 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -80.56 -77.84 0.19 Allowed 'General case' 0 C--N 1.349 0.559 0 CA-C-N 114.969 -1.014 . . . . 0.0 110.373 -179.716 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 40.3 tt0 -112.38 101.32 9.52 Favored 'General case' 0 N--CA 1.47 0.535 0 N-CA-C 108.355 -0.98 . . . . 0.0 108.355 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -158.79 134.22 8.61 Favored 'General case' 0 N--CA 1.481 1.096 0 CA-C-O 119.466 -0.302 . . . . 0.0 111.205 178.965 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 59.3 t -57.55 163.55 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.805 0 N-CA-C 108.135 -1.061 . . . . 0.0 108.135 177.002 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 25' ' ' GLY . . . . . 0.437 ' H ' ' HB ' ' F' ' 24' ' ' VAL . . . -115.91 47.8 1.0 Allowed Glycine 0 N--CA 1.477 1.421 0 N-CA-C 111.519 -0.632 . . . . 0.0 111.519 -179.505 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -62.06 -169.23 0.02 OUTLIER 'General case' 0 N--CA 1.469 0.509 0 N-CA-C 110.17 -0.308 . . . . 0.0 110.17 179.348 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 24.7 t-20 -71.77 79.72 0.86 Allowed 'General case' 0 N--CA 1.468 0.425 0 N-CA-C 110.011 -0.366 . . . . 0.0 110.011 179.455 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -73.19 140.6 47.08 Favored 'General case' 0 N--CA 1.476 0.834 0 N-CA-C 109.011 -0.737 . . . . 0.0 109.011 179.442 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.7 -149.09 0.04 OUTLIER Glycine 0 C--N 1.337 0.594 0 N-CA-C 110.284 -1.126 . . . . 0.0 110.284 179.457 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -94.16 128.03 40.34 Favored 'General case' 0 N--CA 1.477 0.877 0 CA-C-N 116.931 0.365 . . . . 0.0 110.083 179.953 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 74.9 mt -124.28 117.23 50.06 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.697 0 N-CA-C 106.707 -1.59 . . . . 0.0 106.707 178.734 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 39.7 pt -151.3 -169.74 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.355 0.826 0 CA-C-N 115.978 -0.556 . . . . 0.0 111.231 -178.712 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.9 4.81 11.83 Favored Glycine 0 N--CA 1.465 0.609 0 N-CA-C 110.84 -0.904 . . . . 0.0 110.84 179.433 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 1.5 tt -77.96 126.66 31.17 Favored 'General case' 0 CA--C 1.546 0.826 0 N-CA-C 109.566 -0.531 . . . . 0.0 109.566 -179.803 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 28.6 ttt -164.49 143.33 7.13 Favored 'General case' 0 N--CA 1.465 0.298 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 178.298 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 35.5 m -155.19 162.58 1.77 Allowed 'Isoleucine or valine' 0 C--N 1.347 0.485 0 N-CA-C 107.989 -1.115 . . . . 0.0 107.989 179.373 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.64 66.45 2.84 Favored Glycine 0 C--N 1.306 -1.138 0 CA-C-N 115.808 -0.633 . . . . 0.0 111.88 178.422 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 145.46 173.33 16.62 Favored Glycine 0 N--CA 1.472 1.07 0 N-CA-C 111.024 -0.831 . . . . 0.0 111.024 178.946 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 39' ' ' VAL . . . . . 0.598 ' H ' HG12 ' F' ' 39' ' ' VAL . 33.0 m -123.17 160.39 26.18 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.658 0 C-N-CA 123.424 0.69 . . . . 0.0 110.192 -179.787 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 22.8 t . . . . . 0 C--O 1.219 -0.518 0 CA-C-O 118.406 -0.807 . . . . 0.0 110.46 179.546 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 35.1 m-85 . . . . . 0 N--CA 1.472 0.636 0 N-CA-C 108.954 -0.758 . . . . 0.0 108.954 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' D' D ' 5' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -146.07 137.5 24.77 Favored 'General case' 0 N--CA 1.478 0.953 0 C-N-CA 122.814 0.445 . . . . 0.0 110.341 -179.888 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 37.7 t-80 -149.64 123.94 9.57 Favored 'General case' 0 CA--C 1.547 0.827 0 N-CA-C 108.188 -1.041 . . . . 0.0 108.188 175.182 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' D' D ' 7' ' ' ASP . . . . . 0.604 ' O ' ' OG ' ' G' ' 8' ' ' SER . 3.2 m-20 -63.69 132.52 51.33 Favored 'General case' 0 N--CA 1.466 0.363 0 C-N-CA 126.323 1.849 . . . . 0.0 114.361 174.856 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' D' D ' 8' ' ' SER . . . . . 0.5 ' OG ' ' O ' ' A' ' 7' ' ' ASP . 53.8 p -154.39 -171.35 3.83 Favored 'General case' 0 N--CA 1.487 1.385 0 CA-C-N 119.454 1.024 . . . . 0.0 111.255 176.266 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.28 49.0 1.09 Allowed Glycine 0 N--CA 1.483 1.8 0 N-CA-C 110.263 -1.135 . . . . 0.0 110.263 174.144 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 50.8 p90 -61.47 131.71 51.08 Favored 'General case' 0 N--CA 1.472 0.65 0 N-CA-C 112.338 0.495 . . . . 0.0 112.338 178.833 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 84.8 mt-10 -89.24 150.73 22.5 Favored 'General case' 0 N--CA 1.482 1.136 0 CA-C-O 120.564 0.221 . . . . 0.0 110.714 175.645 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.0 p -149.44 130.19 4.58 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.567 0 N-CA-C 107.492 -1.299 . . . . 0.0 107.492 173.114 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 43.2 m-70 -129.89 148.72 51.78 Favored 'General case' 0 N--CA 1.483 1.217 0 CA-C-N 118.074 0.397 . . . . 0.0 111.91 176.444 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 6.1 t60 -165.14 104.43 0.76 Allowed 'General case' 0 N--CA 1.481 1.083 0 N-CA-C 109.029 -0.73 . . . . 0.0 109.029 172.33 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 3.5 pt20 -111.84 -176.14 2.86 Favored 'General case' 0 CA--C 1.497 -1.089 0 N-CA-C 108.29 -1.004 . . . . 0.0 108.29 178.808 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -161.29 105.35 1.3 Allowed 'General case' 0 N--CA 1.469 0.5 0 N-CA-C 106.37 -1.715 . . . . 0.0 106.37 174.965 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 5.6 mp -129.15 154.07 47.08 Favored 'General case' 0 N--CA 1.499 1.989 0 CA-C-O 122.024 0.916 . . . . 0.0 110.581 179.732 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 33.1 t -101.29 131.39 49.14 Favored 'Isoleucine or valine' 0 C--O 1.262 1.75 0 CA-C-O 116.89 -1.529 . . . . 0.0 109.74 174.047 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 26.9 m-85 -130.24 126.63 37.8 Favored 'General case' 0 N--CA 1.491 1.618 0 CA-C-N 119.893 1.224 . . . . 0.0 109.497 173.19 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 67.3 m-85 55.22 71.3 0.55 Allowed 'General case' 0 C--O 1.241 0.658 0 CA-C-N 115.592 -0.731 . . . . 0.0 111.653 176.226 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -82.3 -73.42 0.39 Allowed 'General case' 0 N--CA 1.473 0.701 0 CA-C-O 118.601 -0.714 . . . . 0.0 111.259 -177.414 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 40.7 tt0 -115.35 105.37 12.77 Favored 'General case' 0 N--CA 1.48 1.046 0 N-CA-C 106.463 -1.68 . . . . 0.0 106.463 176.312 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 4.4 p30 -152.19 135.17 15.66 Favored 'General case' 0 N--CA 1.473 0.692 0 CA-C-O 116.67 -1.633 . . . . 0.0 113.493 177.301 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' D' D ' 24' ' ' VAL . . . . . 0.421 ' HB ' ' H ' ' A' ' 25' ' ' GLY . 87.7 t -61.35 166.27 0.81 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.218 0 CA-C-N 121.056 1.753 . . . . 0.0 107.759 175.529 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' D' D ' 25' ' ' GLY . . . . . 0.485 ' H ' ' HB ' ' G' ' 24' ' ' VAL . . . -116.38 50.99 0.75 Allowed Glycine 0 N--CA 1.478 1.476 0 CA-C-O 119.466 -0.63 . . . . 0.0 111.656 178.621 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -57.14 -171.03 0.01 OUTLIER 'General case' 0 N--CA 1.468 0.463 0 C-N-CA 123.414 0.685 . . . . 0.0 111.805 175.217 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 3.6 t30 -73.62 86.86 1.63 Allowed 'General case' 0 C--N 1.348 0.512 0 N-CA-C 108.44 -0.948 . . . . 0.0 108.44 176.753 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 97.6 mttt -81.09 143.26 32.56 Favored 'General case' 0 N--CA 1.481 1.101 0 N-CA-C 107.527 -1.286 . . . . 0.0 107.527 179.818 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.72 -144.78 0.02 OUTLIER Glycine 0 C--N 1.349 1.274 0 CA-C-N 114.928 -1.033 . . . . 0.0 111.705 -178.865 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -95.81 127.01 41.47 Favored 'General case' 0 C--O 1.241 0.619 0 N-CA-C 110.196 -0.298 . . . . 0.0 110.196 178.859 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 85.8 mt -125.98 127.61 71.23 Favored 'Isoleucine or valine' 0 C--N 1.354 0.77 0 N-CA-C 103.34 -2.837 . . . . 0.0 103.34 176.89 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' D' D ' 32' ' ' ILE . . . . . 0.408 HG22 ' H ' ' G' ' 32' ' ' ILE . 42.8 pt -159.61 -170.82 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.119 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.228 -177.696 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 64.12 4.83 12.78 Favored Glycine 0 C--O 1.243 0.685 0 N-CA-C 110.254 -1.138 . . . . 0.0 110.254 -179.251 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' D' D ' 34' ' ' LEU . . . . . . . . . . . . 0.265 2.0 tt -80.33 133.38 35.93 Favored 'General case' 0 C--N 1.377 1.798 0 C-N-CA 117.22 -1.792 . . . . 0.0 107.353 -178.729 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' D' D ' 35' ' ' MET . . . . . 0.406 ' C ' HG13 ' D' ' 36' ' ' VAL . 28.4 ttt -158.82 156.2 29.25 Favored 'General case' 0 C--O 1.25 1.081 0 CA-C-O 117.938 -1.03 . . . . 0.0 108.691 172.374 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' D' D ' 36' ' ' VAL . . . . . 0.488 HG22 HG12 ' G' ' 36' ' ' VAL . 35.5 m -164.74 163.7 0.71 Allowed 'Isoleucine or valine' 0 CA--C 1.516 -0.364 0 N-CA-C 107.643 -1.243 . . . . 0.0 107.643 174.273 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 60.5 63.03 5.35 Favored Glycine 0 CA--C 1.53 1.011 0 C-N-CA 120.216 -0.993 . . . . 0.0 111.509 177.578 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 144.03 175.53 17.24 Favored Glycine 0 N--CA 1.478 1.469 0 CA-C-N 118.443 1.122 . . . . 0.0 111.378 179.847 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' D' D ' 39' ' ' VAL . . . . . 0.624 ' H ' HG12 ' G' ' 39' ' ' VAL . 36.0 m -126.22 157.4 36.52 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.78 0 C-N-CA 122.937 0.495 . . . . 0.0 109.863 -177.737 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 24.0 t . . . . . 0 C--N 1.331 -0.211 0 CA-C-O 116.331 -1.795 . . . . 0.0 109.479 177.301 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 31.8 m-85 . . . . . 0 N--CA 1.474 0.768 0 N-CA-C 110.135 -0.321 . . . . 0.0 110.135 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' E' E ' 5' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -143.69 139.82 29.71 Favored 'General case' 0 N--CA 1.484 1.256 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 179.374 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 41.3 t-80 -151.57 119.61 6.26 Favored 'General case' 0 N--CA 1.472 0.674 0 N-CA-C 109.276 -0.639 . . . . 0.0 109.276 178.953 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' E' E ' 7' ' ' ASP . . . . . 0.501 ' O ' ' OG ' ' H' ' 8' ' ' SER . 3.9 m-20 -69.6 147.81 50.21 Favored 'General case' 0 CA--C 1.534 0.334 0 CA-C-N 116.414 -0.357 . . . . 0.0 110.94 -179.951 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' E' E ' 8' ' ' SER . . . . . 0.507 ' OG ' ' O ' ' B' ' 7' ' ' ASP . 52.2 p -167.8 -172.72 1.93 Allowed 'General case' 0 N--CA 1.485 1.32 0 CA-C-O 121.18 0.514 . . . . 0.0 110.807 179.014 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.19 48.57 1.21 Allowed Glycine 0 N--CA 1.478 1.479 0 CA-C-N 115.702 -0.681 . . . . 0.0 111.82 179.475 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 47.8 p90 -64.66 133.11 51.49 Favored 'General case' 0 N--CA 1.473 0.688 0 N-CA-C 111.842 0.312 . . . . 0.0 111.842 -179.744 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 86.3 mt-10 -91.53 152.41 20.33 Favored 'General case' 0 N--CA 1.479 1.024 0 CA-C-O 121.175 0.512 . . . . 0.0 109.787 178.06 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -154.59 127.5 1.12 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.575 0 N-CA-C 107.735 -1.209 . . . . 0.0 107.735 178.053 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 46.6 m-70 -135.24 143.8 46.53 Favored 'General case' 0 N--CA 1.482 1.13 0 CA-C-O 120.846 0.355 . . . . 0.0 111.609 -177.942 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 6.1 t60 -164.31 97.25 0.8 Allowed 'General case' 0 N--CA 1.483 1.187 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.671 179.395 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 3.5 pt20 -108.07 -174.58 2.56 Favored 'General case' 0 CA--C 1.509 -0.63 0 N-CA-C 108.544 -0.909 . . . . 0.0 108.544 179.994 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -164.22 96.61 0.79 Allowed 'General case' 0 N--CA 1.477 0.906 0 CA-C-N 114.651 -1.158 . . . . 0.0 108.426 178.367 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' E' E ' 17' ' ' LEU . . . . . 0.412 ' H ' ' CD1' ' H' ' 17' ' ' LEU . 6.5 mp -120.91 157.31 30.15 Favored 'General case' 0 N--CA 1.495 1.788 0 CA-C-O 121.641 0.734 . . . . 0.0 111.557 -177.668 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 48.2 t -114.34 124.42 70.98 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.24 0 N-CA-C 108.277 -1.008 . . . . 0.0 108.277 177.266 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 31.7 m-85 -125.3 121.19 33.3 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 123.256 0.348 . . . . 0.0 110.909 -179.751 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 68.9 m-85 54.87 73.17 0.42 Allowed 'General case' 0 N--CA 1.469 0.504 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.392 178.196 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -78.73 -78.76 0.14 Allowed 'General case' 0 CA--C 1.536 0.419 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.201 -179.566 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 40.3 tt0 -111.5 102.2 10.57 Favored 'General case' 0 C--N 1.322 -0.588 0 N-CA-C 108.49 -0.93 . . . . 0.0 108.49 -179.996 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -158.27 134.62 9.42 Favored 'General case' 0 C--O 1.208 -1.1 0 CA-C-O 119.447 -0.311 . . . . 0.0 111.476 178.846 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' E' E ' 24' ' ' VAL . . . . . 0.436 ' HB ' ' H ' ' B' ' 25' ' ' GLY . 57.3 t -56.73 167.4 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.884 0 N-CA-C 107.564 -1.273 . . . . 0.0 107.564 176.791 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' E' E ' 25' ' ' GLY . . . . . 0.411 ' N ' HG12 ' E' ' 24' ' ' VAL . . . -120.37 48.96 0.91 Allowed Glycine 0 N--CA 1.472 1.091 0 N-CA-C 110.852 -0.899 . . . . 0.0 110.852 -179.389 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -63.37 -167.92 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.528 0 CA-C-O 120.767 0.318 . . . . 0.0 110.361 179.669 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 25.0 t-20 -71.71 76.35 0.84 Allowed 'General case' 0 N--CA 1.466 0.334 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.324 179.779 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -70.26 140.28 52.35 Favored 'General case' 0 N--CA 1.48 1.061 0 N-CA-C 109.438 -0.579 . . . . 0.0 109.438 179.462 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.47 -149.28 0.05 OUTLIER Glycine 0 C--N 1.335 0.49 0 N-CA-C 110.859 -0.896 . . . . 0.0 110.859 179.42 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -92.78 126.89 38.07 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-N 116.797 0.298 . . . . 0.0 110.402 179.713 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 76.8 mt -123.62 117.25 50.65 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.436 0 N-CA-C 106.365 -1.717 . . . . 0.0 106.365 178.591 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' E' E ' 32' ' ' ILE . . . . . 0.415 HG22 ' H ' ' H' ' 32' ' ' ILE . 44.2 pt -151.46 -168.19 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.17 0 CA-C-O 121.117 0.484 . . . . 0.0 110.882 -178.868 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.13 5.43 7.85 Favored Glycine 0 CA--C 1.527 0.839 0 N-CA-C 111.315 -0.714 . . . . 0.0 111.315 179.975 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 1.6 tt -77.74 127.23 32.1 Favored 'General case' 0 CA--C 1.548 0.88 0 N-CA-C 109.494 -0.558 . . . . 0.0 109.494 -179.886 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 28.6 ttt -164.7 144.52 7.34 Favored 'General case' 0 N--CA 1.469 0.51 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 178.267 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' E' E ' 36' ' ' VAL . . . . . 0.463 HG22 HG12 ' H' ' 36' ' ' VAL . 32.9 m -156.38 162.84 1.55 Allowed 'Isoleucine or valine' 0 C--N 1.348 0.523 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 179.675 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.05 66.13 3.06 Favored Glycine 0 C--N 1.307 -1.072 0 CA-C-N 115.599 -0.728 . . . . 0.0 111.799 178.34 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 145.97 174.31 18.02 Favored Glycine 0 N--CA 1.474 1.191 0 N-CA-C 111.256 -0.738 . . . . 0.0 111.256 178.8 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' E' E ' 39' ' ' VAL . . . . . 0.614 ' H ' HG12 ' H' ' 39' ' ' VAL . 34.3 m -124.15 159.87 29.1 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.709 0 C-N-CA 123.32 0.648 . . . . 0.0 110.297 -179.206 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 24.6 t . . . . . 0 C--O 1.218 -0.595 0 O-C-N 124.156 0.91 . . . . 0.0 110.43 179.394 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 31.5 m-85 . . . . . 0 N--CA 1.475 0.813 0 N-CA-C 110.019 -0.363 . . . . 0.0 110.019 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' F' F ' 5' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -144.03 139.4 28.96 Favored 'General case' 0 N--CA 1.478 0.966 0 CA-C-O 120.759 0.314 . . . . 0.0 110.214 179.46 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 41.3 t-80 -151.48 119.73 6.35 Favored 'General case' 0 N--CA 1.473 0.695 0 N-CA-C 109.282 -0.636 . . . . 0.0 109.282 179.124 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' F' F ' 7' ' ' ASP . . . . . 0.465 ' O ' ' OG ' ' I' ' 8' ' ' SER . 3.9 m-20 -69.62 147.81 50.19 Favored 'General case' 0 CA--C 1.533 0.317 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.909 179.994 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' F' F ' 8' ' ' SER . . . . . 0.482 ' OG ' ' O ' ' C' ' 7' ' ' ASP . 51.7 p -168.09 -173.12 1.96 Allowed 'General case' 0 N--CA 1.485 1.321 0 CA-C-O 121.22 0.533 . . . . 0.0 110.923 178.977 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.49 48.3 1.22 Allowed Glycine 0 N--CA 1.478 1.457 0 CA-C-N 115.767 -0.651 . . . . 0.0 111.714 179.466 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 47.7 p90 -64.02 132.84 51.81 Favored 'General case' 0 N--CA 1.474 0.736 0 O-C-N 122.648 -0.325 . . . . 0.0 111.792 -179.888 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 86.8 mt-10 -91.28 152.42 20.49 Favored 'General case' 0 N--CA 1.481 1.103 0 CA-C-O 121.166 0.508 . . . . 0.0 109.877 177.873 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -154.57 127.61 1.14 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.627 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 178.008 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 44.4 m-70 -135.44 144.13 46.29 Favored 'General case' 0 N--CA 1.482 1.144 0 CA-C-O 120.807 0.337 . . . . 0.0 111.6 -178.079 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 6.0 t60 -164.57 96.82 0.76 Allowed 'General case' 0 N--CA 1.485 1.284 0 CA-C-N 116.431 -0.349 . . . . 0.0 110.788 179.478 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 3.5 pt20 -107.71 -174.06 2.44 Favored 'General case' 0 CA--C 1.505 -0.778 0 N-CA-C 108.637 -0.875 . . . . 0.0 108.637 -179.97 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -164.53 96.8 0.77 Allowed 'General case' 0 N--CA 1.475 0.802 0 CA-C-N 114.645 -1.161 . . . . 0.0 108.336 178.533 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' F' F ' 17' ' ' LEU . . . . . 0.406 ' H ' ' CD1' ' I' ' 17' ' ' LEU . 6.5 mp -121.01 157.17 30.57 Favored 'General case' 0 N--CA 1.494 1.766 0 CA-C-O 121.51 0.671 . . . . 0.0 111.483 -177.733 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 48.1 t -114.04 124.24 70.49 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.227 0 N-CA-C 108.288 -1.004 . . . . 0.0 108.288 177.11 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 31.6 m-85 -125.03 121.05 33.25 Favored 'General case' 0 N--CA 1.487 1.407 0 CA-C-O 120.787 0.327 . . . . 0.0 110.937 -179.855 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 68.7 m-85 55.2 73.32 0.42 Allowed 'General case' 0 C--N 1.345 0.386 0 CA-C-N 116.0 -0.545 . . . . 0.0 111.654 178.097 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -79.02 -78.65 0.15 Allowed 'General case' 0 C--N 1.345 0.379 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.345 -179.262 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 40.6 tt0 -111.74 102.01 10.33 Favored 'General case' 0 C--N 1.323 -0.555 0 N-CA-C 108.449 -0.945 . . . . 0.0 108.449 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -158.14 134.7 9.61 Favored 'General case' 0 C--O 1.209 -1.046 0 CA-C-O 119.571 -0.252 . . . . 0.0 111.448 178.975 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' F' F ' 24' ' ' VAL . . . . . 0.437 ' HB ' ' H ' ' C' ' 25' ' ' GLY . 63.6 t -57.13 166.89 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.885 0 N-CA-C 107.495 -1.298 . . . . 0.0 107.495 176.98 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' F' F ' 25' ' ' GLY . . . . . 0.413 ' H ' ' HB ' ' I' ' 24' ' ' VAL . . . -119.97 49.11 0.89 Allowed Glycine 0 N--CA 1.476 1.325 0 N-CA-C 110.792 -0.923 . . . . 0.0 110.792 -179.319 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -63.45 -167.77 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.549 0 CA-C-O 120.779 0.323 . . . . 0.0 110.221 179.579 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 24.8 t-20 -71.72 76.12 0.84 Allowed 'General case' 0 C--O 1.223 -0.321 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.378 179.761 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -70.18 140.49 52.55 Favored 'General case' 0 N--CA 1.478 0.967 0 N-CA-C 109.449 -0.574 . . . . 0.0 109.449 179.587 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.53 -149.8 0.05 OUTLIER Glycine 0 C--N 1.333 0.412 0 N-CA-C 110.852 -0.899 . . . . 0.0 110.852 179.443 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -92.16 126.68 37.34 Favored 'General case' 0 N--CA 1.47 0.573 0 N-CA-C 110.235 -0.283 . . . . 0.0 110.235 179.659 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 78.3 mt -123.65 116.98 49.8 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.512 0 N-CA-C 106.351 -1.722 . . . . 0.0 106.351 178.461 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' F' F ' 32' ' ' ILE . . . . . 0.42 HG22 ' H ' ' I' ' 32' ' ' ILE . 44.5 pt -151.31 -167.99 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.192 0 CA-C-O 121.061 0.458 . . . . 0.0 110.862 -178.882 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.98 5.66 8.05 Favored Glycine 0 CA--C 1.527 0.791 0 N-CA-C 111.373 -0.691 . . . . 0.0 111.373 -179.95 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 1.5 tt -77.9 127.18 31.97 Favored 'General case' 0 CA--C 1.548 0.886 0 N-CA-C 109.465 -0.569 . . . . 0.0 109.465 -179.897 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 28.4 ttt -164.45 144.44 7.69 Favored 'General case' 0 N--CA 1.469 0.493 0 N-CA-C 108.773 -0.825 . . . . 0.0 108.773 178.223 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' F' F ' 36' ' ' VAL . . . . . 0.473 HG22 HG12 ' I' ' 36' ' ' VAL . 32.9 m -156.26 162.75 1.59 Allowed 'Isoleucine or valine' 0 C--N 1.348 0.504 0 N-CA-C 108.292 -1.003 . . . . 0.0 108.292 179.566 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.16 66.28 2.96 Favored Glycine 0 C--N 1.307 -1.08 0 CA-C-N 115.691 -0.686 . . . . 0.0 111.854 178.366 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 145.79 174.42 17.95 Favored Glycine 0 N--CA 1.473 1.14 0 N-CA-C 111.313 -0.715 . . . . 0.0 111.313 178.863 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' F' F ' 39' ' ' VAL . . . . . 0.616 ' H ' HG12 ' I' ' 39' ' ' VAL . 34.4 m -124.47 159.78 30.0 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.669 0 C-N-CA 123.301 0.64 . . . . 0.0 110.224 -179.208 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 24.9 t . . . . . 0 C--O 1.218 -0.569 0 O-C-N 124.239 0.962 . . . . 0.0 110.517 179.507 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 35.2 m-85 . . . . . 0 N--CA 1.474 0.736 0 N-CA-C 109.605 -0.517 . . . . 0.0 109.605 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' G' G ' 5' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -144.67 139.11 27.77 Favored 'General case' 0 N--CA 1.482 1.145 0 C-N-CA 122.544 0.338 . . . . 0.0 110.235 179.834 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 42.2 t-80 -150.8 120.87 7.19 Favored 'General case' 0 N--CA 1.474 0.726 0 N-CA-C 109.543 -0.54 . . . . 0.0 109.543 179.023 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -71.82 143.45 49.48 Favored 'General case' 0 N--CA 1.47 0.554 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.28 -179.766 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' G' G ' 8' ' ' SER . . . . . 0.604 ' OG ' ' O ' ' D' ' 7' ' ' ASP . 48.9 p -164.7 -170.93 2.13 Favored 'General case' 0 N--CA 1.476 0.828 0 CA-C-O 121.2 0.524 . . . . 0.0 110.534 178.83 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.52 49.01 1.23 Allowed Glycine 0 N--CA 1.479 1.528 0 N-CA-C 111.35 -0.7 . . . . 0.0 111.35 179.388 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 50.1 p90 -65.03 133.36 51.5 Favored 'General case' 0 N--CA 1.473 0.704 0 CA-C-O 120.673 0.273 . . . . 0.0 111.67 -179.719 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 83.3 mt-10 -92.1 151.64 20.32 Favored 'General case' 0 N--CA 1.48 1.031 0 CA-C-O 121.108 0.48 . . . . 0.0 110.142 178.665 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -154.89 127.45 1.06 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.973 0 N-CA-C 107.853 -1.165 . . . . 0.0 107.853 178.293 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 47.4 m-70 -134.6 144.73 48.08 Favored 'General case' 0 N--CA 1.479 1.005 0 CA-C-N 115.561 -0.745 . . . . 0.0 111.488 -178.298 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 29.5 t-80 -165.43 97.37 0.69 Allowed 'General case' 0 N--CA 1.482 1.131 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.377 178.989 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 3.6 pt20 -108.6 -174.72 2.58 Favored 'General case' 0 CA--C 1.506 -0.744 0 N-CA-C 108.433 -0.951 . . . . 0.0 108.433 -179.707 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -164.32 96.17 0.77 Allowed 'General case' 0 N--CA 1.474 0.758 0 CA-C-N 114.699 -1.137 . . . . 0.0 108.121 178.735 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 6.6 mp -120.58 155.61 33.34 Favored 'General case' 0 N--CA 1.497 1.924 0 CA-C-O 121.171 0.51 . . . . 0.0 111.771 -177.846 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 43.0 t -113.16 125.13 70.37 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.884 0 CA-C-N 114.757 -1.11 . . . . 0.0 108.128 176.477 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 33.1 m-85 -126.09 121.15 32.09 Favored 'General case' 0 C--N 1.369 1.424 0 CA-C-N 115.583 -0.735 . . . . 0.0 110.892 -179.699 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 67.2 m-85 54.8 72.95 0.43 Allowed 'General case' 0 C--O 1.238 0.459 0 CA-C-N 115.841 -0.618 . . . . 0.0 111.479 178.145 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -78.08 -77.96 0.15 Allowed 'General case' 0 N--CA 1.471 0.616 0 O-C-N 122.17 -0.331 . . . . 0.0 110.557 -178.939 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 40.4 tt0 -112.24 101.99 10.19 Favored 'General case' 0 C--N 1.323 -0.568 0 N-CA-C 108.093 -1.077 . . . . 0.0 108.093 179.917 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -157.88 135.91 10.8 Favored 'General case' 0 N--CA 1.476 0.867 0 O-C-N 122.401 -0.187 . . . . 0.0 111.488 178.826 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' G' G ' 24' ' ' VAL . . . . . 0.485 ' HB ' ' H ' ' D' ' 25' ' ' GLY . 57.3 t -58.27 166.47 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.647 0 N-CA-C 107.555 -1.276 . . . . 0.0 107.555 176.986 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' G' G ' 25' ' ' GLY . . . . . 0.413 ' N ' HG12 ' G' ' 24' ' ' VAL . . . -119.05 49.4 0.87 Allowed Glycine 0 N--CA 1.479 1.524 0 N-CA-C 110.456 -1.058 . . . . 0.0 110.456 -179.47 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -64.4 -168.09 0.03 OUTLIER 'General case' 0 N--CA 1.472 0.636 0 N-CA-C 109.904 -0.406 . . . . 0.0 109.904 179.645 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 3.3 t30 -71.62 76.09 0.82 Allowed 'General case' 0 CA--C 1.536 0.438 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.324 179.928 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -69.57 140.64 53.84 Favored 'General case' 0 N--CA 1.478 0.955 0 N-CA-C 109.562 -0.533 . . . . 0.0 109.562 179.604 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.99 -147.81 0.05 OUTLIER Glycine 0 C--N 1.337 0.587 0 N-CA-C 110.443 -1.063 . . . . 0.0 110.443 179.612 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -92.88 125.99 37.75 Favored 'General case' 0 N--CA 1.467 0.419 0 C-N-CA 122.65 0.38 . . . . 0.0 110.93 -179.824 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 76.6 mt -123.45 117.65 52.03 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.811 0 N-CA-C 106.417 -1.697 . . . . 0.0 106.417 178.238 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' G' G ' 32' ' ' ILE . . . . . 0.408 ' H ' HG22 ' D' ' 32' ' ' ILE . 44.0 pt -152.47 -167.61 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 CA-C-N 119.819 1.19 . . . . 0.0 110.031 -179.225 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.29 6.26 10.15 Favored Glycine 0 N--CA 1.466 0.671 0 N-CA-C 111.056 -0.818 . . . . 0.0 111.056 179.881 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 1.5 tt -79.49 125.7 29.91 Favored 'General case' 0 CA--C 1.545 0.773 0 N-CA-C 109.516 -0.55 . . . . 0.0 109.516 -179.702 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 27.7 ttt -162.86 146.17 10.97 Favored 'General case' 0 N--CA 1.47 0.553 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 178.534 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' G' G ' 36' ' ' VAL . . . . . 0.488 HG12 HG22 ' D' ' 36' ' ' VAL . 32.7 m -156.95 162.01 1.69 Allowed 'Isoleucine or valine' 0 C--N 1.35 0.603 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 -179.99 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.48 66.63 2.7 Favored Glycine 0 C--N 1.31 -0.913 0 CA-C-N 115.541 -0.754 . . . . 0.0 112.104 177.818 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 146.72 175.6 19.82 Favored Glycine 0 N--CA 1.475 1.251 0 N-CA-C 110.559 -1.016 . . . . 0.0 110.559 178.994 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' G' G ' 39' ' ' VAL . . . . . 0.624 HG12 ' H ' ' D' ' 39' ' ' VAL . 34.9 m -125.77 159.71 33.4 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.912 0 C-N-CA 123.092 0.557 . . . . 0.0 110.484 -179.408 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 26.3 t . . . . . 0 C--O 1.22 -0.488 0 CA-C-O 118.395 -0.812 . . . . 0.0 110.751 179.082 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 34.9 m-85 . . . . . 0 N--CA 1.474 0.77 0 N-CA-C 109.518 -0.549 . . . . 0.0 109.518 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' H' H ' 5' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -144.74 139.68 28.04 Favored 'General case' 0 N--CA 1.485 1.313 0 N-CA-C 110.04 -0.355 . . . . 0.0 110.04 179.838 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 41.2 t-80 -151.58 120.7 6.72 Favored 'General case' 0 N--CA 1.474 0.76 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 179.068 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -71.65 143.82 49.62 Favored 'General case' 0 N--CA 1.469 0.511 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.308 -179.756 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' H' H ' 8' ' ' SER . . . . . 0.501 ' OG ' ' O ' ' E' ' 7' ' ' ASP . 52.2 p -164.81 -171.18 2.19 Favored 'General case' 0 N--CA 1.475 0.809 0 CA-C-O 121.126 0.489 . . . . 0.0 110.489 178.921 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.76 48.35 1.28 Allowed Glycine 0 N--CA 1.479 1.541 0 CA-C-N 115.783 -0.644 . . . . 0.0 111.551 179.336 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 50.1 p90 -64.51 133.06 51.64 Favored 'General case' 0 N--CA 1.471 0.624 0 N-CA-C 111.785 0.291 . . . . 0.0 111.785 -179.685 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 83.1 mt-10 -91.69 151.56 20.61 Favored 'General case' 0 N--CA 1.479 0.984 0 CA-C-O 121.068 0.461 . . . . 0.0 110.183 178.476 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -154.67 127.88 1.17 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.979 0 N-CA-C 107.885 -1.154 . . . . 0.0 107.885 178.08 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 47.3 m-70 -134.75 145.53 48.52 Favored 'General case' 0 N--CA 1.478 0.955 0 CA-C-N 115.676 -0.693 . . . . 0.0 111.359 -178.419 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 27.9 t-80 -166.24 97.37 0.6 Allowed 'General case' 0 N--CA 1.482 1.146 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.346 178.794 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 3.6 pt20 -108.33 -174.3 2.49 Favored 'General case' 0 CA--C 1.505 -0.757 0 N-CA-C 108.425 -0.954 . . . . 0.0 108.425 -179.728 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -164.84 96.22 0.72 Allowed 'General case' 0 N--CA 1.475 0.799 0 CA-C-N 114.647 -1.16 . . . . 0.0 108.018 178.66 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' H' H ' 17' ' ' LEU . . . . . 0.412 ' CD1' ' H ' ' E' ' 17' ' ' LEU . 6.5 mp -120.53 156.02 32.43 Favored 'General case' 0 N--CA 1.497 1.899 0 CA-C-O 121.239 0.543 . . . . 0.0 111.972 -177.949 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 41.4 t -113.7 124.73 70.63 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.07 0 CA-C-N 114.819 -1.082 . . . . 0.0 108.227 176.658 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 33.3 m-85 -125.73 121.31 33.04 Favored 'General case' 0 C--N 1.368 1.388 0 CA-C-N 115.459 -0.792 . . . . 0.0 110.863 -179.491 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 68.0 m-85 54.3 72.69 0.44 Allowed 'General case' 0 C--O 1.237 0.422 0 CA-C-N 115.858 -0.61 . . . . 0.0 111.587 178.11 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.63 -78.13 0.14 Allowed 'General case' 0 N--CA 1.471 0.622 0 O-C-N 122.203 -0.31 . . . . 0.0 110.571 -179.033 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 40.9 tt0 -112.12 101.99 10.22 Favored 'General case' 0 C--N 1.321 -0.632 0 N-CA-C 108.091 -1.077 . . . . 0.0 108.091 -179.99 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -157.97 135.78 10.61 Favored 'General case' 0 N--CA 1.477 0.913 0 N-CA-C 111.445 0.165 . . . . 0.0 111.445 178.863 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' H' H ' 24' ' ' VAL . . . . . 0.41 HG12 ' N ' ' H' ' 25' ' ' GLY . 59.2 t -58.3 166.35 0.51 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.606 0 N-CA-C 107.682 -1.229 . . . . 0.0 107.682 177.197 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' H' H ' 25' ' ' GLY . . . . . 0.41 ' N ' HG12 ' H' ' 24' ' ' VAL . . . -118.76 49.42 0.87 Allowed Glycine 0 N--CA 1.478 1.444 0 N-CA-C 110.653 -0.979 . . . . 0.0 110.653 -179.498 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -64.67 -167.85 0.03 OUTLIER 'General case' 0 N--CA 1.472 0.668 0 CA-C-N 116.97 0.385 . . . . 0.0 110.0 179.662 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 24.9 t-20 -71.77 76.39 0.86 Allowed 'General case' 0 CA--C 1.535 0.4 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.317 179.871 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -69.89 140.74 53.18 Favored 'General case' 0 N--CA 1.478 0.953 0 N-CA-C 109.552 -0.536 . . . . 0.0 109.552 179.483 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.96 -147.82 0.05 OUTLIER Glycine 0 C--N 1.338 0.653 0 N-CA-C 110.329 -1.108 . . . . 0.0 110.329 179.541 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -93.5 125.77 38.29 Favored 'General case' 0 N--CA 1.465 0.307 0 C-N-CA 122.58 0.352 . . . . 0.0 110.872 -179.61 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 76.1 mt -122.92 117.55 52.12 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.757 0 N-CA-C 106.431 -1.692 . . . . 0.0 106.431 178.315 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' H' H ' 32' ' ' ILE . . . . . 0.415 ' H ' HG22 ' E' ' 32' ' ' ILE . 44.8 pt -152.04 -167.84 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 CA-C-N 119.807 1.185 . . . . 0.0 109.98 -179.469 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.93 5.8 10.53 Favored Glycine 0 N--CA 1.466 0.661 0 N-CA-C 110.964 -0.854 . . . . 0.0 110.964 179.86 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 1.5 tt -79.04 124.95 28.77 Favored 'General case' 0 CA--C 1.544 0.744 0 N-CA-C 109.725 -0.472 . . . . 0.0 109.725 -179.515 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 27.8 ttt -162.19 145.97 12.01 Favored 'General case' 0 N--CA 1.469 0.502 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 178.635 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' H' H ' 36' ' ' VAL . . . . . 0.463 HG12 HG22 ' E' ' 36' ' ' VAL . 32.6 m -157.08 161.69 1.76 Allowed 'Isoleucine or valine' 0 C--N 1.349 0.566 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 -179.895 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.94 66.2 3.01 Favored Glycine 0 C--N 1.309 -0.93 0 CA-C-N 115.498 -0.773 . . . . 0.0 112.17 177.935 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 146.92 175.63 20.01 Favored Glycine 0 N--CA 1.474 1.197 0 N-CA-C 110.639 -0.984 . . . . 0.0 110.639 178.893 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' H' H ' 39' ' ' VAL . . . . . 0.614 HG12 ' H ' ' E' ' 39' ' ' VAL . 34.9 m -125.2 159.96 31.54 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.927 0 C-N-CA 123.173 0.589 . . . . 0.0 110.537 -179.487 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 25.1 t . . . . . 0 N--CA 1.47 0.54 0 CA-C-O 118.439 -0.791 . . . . 0.0 110.819 179.233 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 35.9 m-85 . . . . . 0 N--CA 1.474 0.739 0 N-CA-C 109.538 -0.541 . . . . 0.0 109.538 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' I' I ' 5' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -144.51 139.17 28.08 Favored 'General case' 0 N--CA 1.484 1.255 0 N-CA-C 110.038 -0.356 . . . . 0.0 110.038 179.815 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 41.6 t-80 -150.81 120.73 7.12 Favored 'General case' 0 N--CA 1.473 0.679 0 N-CA-C 109.385 -0.598 . . . . 0.0 109.385 178.907 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 4.0 m-20 -71.48 143.94 49.86 Favored 'General case' 0 N--CA 1.47 0.531 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.141 -179.888 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' I' I ' 8' ' ' SER . . . . . 0.465 ' OG ' ' O ' ' F' ' 7' ' ' ASP . 52.5 p -165.05 -171.14 2.13 Favored 'General case' 0 N--CA 1.474 0.758 0 CA-C-O 121.081 0.467 . . . . 0.0 110.621 178.89 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.53 48.81 1.25 Allowed Glycine 0 N--CA 1.479 1.514 0 N-CA-C 111.502 -0.639 . . . . 0.0 111.502 179.348 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 50.2 p90 -65.12 132.94 50.49 Favored 'General case' 0 N--CA 1.472 0.663 0 N-CA-C 111.772 0.286 . . . . 0.0 111.772 -179.718 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 83.6 mt-10 -91.43 151.57 20.75 Favored 'General case' 0 N--CA 1.478 0.953 0 CA-C-O 121.045 0.45 . . . . 0.0 110.265 178.539 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -154.91 127.42 1.05 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.047 0 N-CA-C 107.91 -1.144 . . . . 0.0 107.91 178.198 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 46.9 m-70 -134.48 145.15 48.54 Favored 'General case' 0 N--CA 1.478 0.933 0 CA-C-N 115.61 -0.723 . . . . 0.0 111.407 -178.196 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 29.1 t-80 -165.75 97.25 0.65 Allowed 'General case' 0 N--CA 1.48 1.03 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.378 178.838 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 3.6 pt20 -108.39 -174.55 2.55 Favored 'General case' 0 CA--C 1.504 -0.809 0 N-CA-C 108.381 -0.97 . . . . 0.0 108.381 -179.757 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -164.54 96.33 0.75 Allowed 'General case' 0 N--CA 1.474 0.755 0 CA-C-N 114.608 -1.178 . . . . 0.0 108.116 178.641 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' I' I ' 17' ' ' LEU . . . . . 0.406 ' CD1' ' H ' ' F' ' 17' ' ' LEU . 6.4 mp -120.6 156.07 32.42 Favored 'General case' 0 N--CA 1.497 1.914 0 CA-C-O 121.232 0.539 . . . . 0.0 111.767 -177.882 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 41.4 t -113.77 125.06 70.98 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.884 0 CA-C-N 114.753 -1.112 . . . . 0.0 108.207 176.608 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 33.6 m-85 -126.0 121.38 32.86 Favored 'General case' 0 C--N 1.368 1.41 0 CA-C-N 115.502 -0.772 . . . . 0.0 110.829 -179.449 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 67.9 m-85 54.25 73.29 0.4 Allowed 'General case' 0 C--N 1.347 0.467 0 CA-C-N 115.925 -0.58 . . . . 0.0 111.464 178.136 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -78.18 -78.01 0.15 Allowed 'General case' 0 N--CA 1.475 0.802 0 O-C-N 122.296 -0.253 . . . . 0.0 110.453 -179.079 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 40.7 tt0 -112.02 102.12 10.36 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 108.088 -1.079 . . . . 0.0 108.088 179.802 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -157.88 135.92 10.81 Favored 'General case' 0 N--CA 1.478 0.97 0 N-CA-C 111.409 0.152 . . . . 0.0 111.409 178.784 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' I' I ' 24' ' ' VAL . . . . . 0.42 HG12 ' N ' ' I' ' 25' ' ' GLY . 59.5 t -58.57 166.32 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.573 0 N-CA-C 107.658 -1.238 . . . . 0.0 107.658 177.203 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' I' I ' 25' ' ' GLY . . . . . 0.42 ' N ' HG12 ' I' ' 24' ' ' VAL . . . -118.69 49.0 0.89 Allowed Glycine 0 N--CA 1.479 1.524 0 N-CA-C 110.556 -1.017 . . . . 0.0 110.556 -179.392 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -64.3 -167.87 0.03 OUTLIER 'General case' 0 N--CA 1.472 0.648 0 CA-C-N 116.951 0.376 . . . . 0.0 110.092 179.641 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 24.9 t-20 -71.74 76.45 0.85 Allowed 'General case' 0 CA--C 1.536 0.419 0 CA-C-N 116.07 -0.513 . . . . 0.0 110.219 179.884 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -70.08 140.86 52.81 Favored 'General case' 0 N--CA 1.478 0.961 0 N-CA-C 109.492 -0.559 . . . . 0.0 109.492 179.496 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -65.02 -147.67 0.05 OUTLIER Glycine 0 C--N 1.337 0.628 0 N-CA-C 110.416 -1.074 . . . . 0.0 110.416 179.577 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -93.3 125.89 38.14 Favored 'General case' 0 N--CA 1.469 0.496 0 C-N-CA 122.587 0.355 . . . . 0.0 110.924 -179.953 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 77.0 mt -123.2 117.3 51.15 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.708 0 N-CA-C 106.474 -1.676 . . . . 0.0 106.474 178.255 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' I' I ' 32' ' ' ILE . . . . . 0.42 ' H ' HG22 ' F' ' 32' ' ' ILE . 44.6 pt -152.13 -167.9 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 CA-C-N 119.851 1.205 . . . . 0.0 109.979 -179.284 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.07 5.52 10.2 Favored Glycine 0 N--CA 1.466 0.674 0 N-CA-C 110.969 -0.852 . . . . 0.0 110.969 179.86 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 1.5 tt -78.6 125.82 29.89 Favored 'General case' 0 CA--C 1.546 0.798 0 N-CA-C 109.6 -0.519 . . . . 0.0 109.6 -179.675 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 27.7 ttt -162.76 146.01 11.08 Favored 'General case' 0 N--CA 1.47 0.561 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 178.454 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' I' I ' 36' ' ' VAL . . . . . 0.473 HG12 HG22 ' F' ' 36' ' ' VAL . 32.5 m -157.08 161.78 1.73 Allowed 'Isoleucine or valine' 0 C--N 1.348 0.522 0 N-CA-C 108.6 -0.889 . . . . 0.0 108.6 179.928 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.76 66.42 2.86 Favored Glycine 0 C--N 1.308 -0.981 0 CA-C-N 115.557 -0.747 . . . . 0.0 112.114 177.863 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 146.64 175.76 19.88 Favored Glycine 0 N--CA 1.476 1.334 0 N-CA-C 110.57 -1.012 . . . . 0.0 110.57 178.95 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' I' I ' 39' ' ' VAL . . . . . 0.616 HG12 ' H ' ' F' ' 39' ' ' VAL . 35.0 m -125.69 160.11 32.64 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.915 0 C-N-CA 123.138 0.575 . . . . 0.0 110.53 -179.381 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 25.9 t . . . . . 0 C--O 1.218 -0.557 0 CA-C-O 118.449 -0.786 . . . . 0.0 110.713 179.216 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 39.4 m-85 . . . . . 0 N--CA 1.477 0.882 0 N-CA-C 109.99 -0.374 . . . . 0.0 109.99 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -143.93 140.15 29.54 Favored 'General case' 0 N--CA 1.48 1.048 0 N-CA-C 110.016 -0.364 . . . . 0.0 110.016 179.67 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 43.3 t-80 -151.84 119.67 6.16 Favored 'General case' 0 N--CA 1.47 0.551 0 N-CA-C 109.224 -0.658 . . . . 0.0 109.224 179.291 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 7' ' ' ASP . . . . . 0.495 ' O ' ' OG ' ' D' ' 8' ' ' SER . 4.6 m-20 -69.14 148.9 49.27 Favored 'General case' 0 N--CA 1.466 0.34 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.466 179.879 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 54.8 p -168.21 -173.79 2.12 Favored 'General case' 0 N--CA 1.482 1.162 0 C-N-CA 122.669 0.388 . . . . 0.0 110.718 179.053 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.79 47.79 1.33 Allowed Glycine 0 N--CA 1.482 1.735 0 CA-C-N 116.013 -0.539 . . . . 0.0 112.147 -179.911 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 50.1 p90 -65.06 132.67 49.83 Favored 'General case' 0 N--CA 1.473 0.686 0 CA-C-O 120.716 0.293 . . . . 0.0 111.532 179.899 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 49.0 mt-10 -92.66 152.46 19.54 Favored 'General case' 0 N--CA 1.477 0.918 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 178.398 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.0 p -153.13 128.37 1.55 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.632 0 N-CA-C 107.847 -1.168 . . . . 0.0 107.847 178.382 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 47.2 m-70 -134.87 145.83 48.65 Favored 'General case' 0 N--CA 1.492 1.648 0 CA-C-N 119.096 0.862 . . . . 0.0 111.327 -179.127 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 6.1 t60 -165.73 97.51 0.66 Allowed 'General case' 0 N--CA 1.48 1.05 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.809 179.496 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 3.9 pt20 -111.9 -174.78 2.54 Favored 'General case' 0 CA--C 1.503 -0.86 0 N-CA-C 108.355 -0.98 . . . . 0.0 108.355 -179.849 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -163.27 99.13 0.94 Allowed 'General case' 0 N--CA 1.474 0.749 0 CA-C-N 114.527 -1.215 . . . . 0.0 108.347 178.582 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 6.9 mp -121.83 157.07 31.9 Favored 'General case' 0 N--CA 1.497 1.909 0 CA-C-O 121.945 0.879 . . . . 0.0 110.86 -178.338 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 60.0 t -112.54 126.84 69.98 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.179 0 CA-C-O 117.877 -1.058 . . . . 0.0 108.298 177.808 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 28.8 m-85 -127.11 122.52 34.49 Favored 'General case' 0 N--CA 1.496 1.859 0 CA-C-N 120.197 1.362 . . . . 0.0 110.336 179.302 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 68.3 m-85 53.95 73.98 0.35 Allowed 'General case' 0 N--CA 1.47 0.546 0 CA-C-O 121.544 0.687 . . . . 0.0 111.745 178.51 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -80.22 -78.13 0.18 Allowed 'General case' 0 C--N 1.353 0.758 0 CA-C-N 115.117 -0.947 . . . . 0.0 110.42 -179.739 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 40.3 tt0 -112.07 101.87 10.12 Favored 'General case' 0 N--CA 1.47 0.563 0 N-CA-C 108.493 -0.928 . . . . 0.0 108.493 179.927 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -158.69 134.65 9.0 Favored 'General case' 0 N--CA 1.481 1.092 0 CA-C-O 119.388 -0.339 . . . . 0.0 111.254 179.026 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 61.9 t -58.36 163.4 0.72 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.795 0 N-CA-C 108.227 -1.027 . . . . 0.0 108.227 177.173 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.422 ' H ' ' HB ' ' D' ' 24' ' ' VAL . . . -116.04 48.07 0.98 Allowed Glycine 0 N--CA 1.476 1.326 0 N-CA-C 111.759 -0.536 . . . . 0.0 111.759 -179.402 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -62.07 -168.59 0.02 OUTLIER 'General case' 0 N--CA 1.469 0.499 0 O-C-N 123.834 0.373 . . . . 0.0 110.218 179.284 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 2.8 t30 -72.43 79.83 1.04 Allowed 'General case' 0 N--CA 1.466 0.335 0 N-CA-C 110.048 -0.352 . . . . 0.0 110.048 179.221 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -73.28 140.32 46.73 Favored 'General case' 0 N--CA 1.471 0.625 0 N-CA-C 109.012 -0.736 . . . . 0.0 109.012 179.43 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.42 -148.9 0.03 OUTLIER Glycine 0 C--N 1.337 0.622 0 N-CA-C 110.383 -1.087 . . . . 0.0 110.383 179.443 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -93.94 128.54 40.31 Favored 'General case' 0 N--CA 1.471 0.604 0 N-CA-C 110.076 -0.342 . . . . 0.0 110.076 179.904 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 72.4 mt -125.0 116.77 48.13 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.874 0 N-CA-C 106.782 -1.562 . . . . 0.0 106.782 178.764 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 38.9 pt -151.01 -169.69 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.356 0.88 0 CA-C-N 115.857 -0.611 . . . . 0.0 111.206 -178.527 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.41 5.37 11.41 Favored Glycine 0 C--N 1.336 0.577 0 N-CA-C 110.912 -0.875 . . . . 0.0 110.912 179.673 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.403 HD23 ' N ' ' A' ' 35' ' ' MET . 1.5 tt -78.42 127.12 31.74 Favored 'General case' 0 CA--C 1.543 0.684 0 N-CA-C 109.44 -0.578 . . . . 0.0 109.44 -179.617 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 35' ' ' MET . . . . . 0.403 ' N ' HD23 ' A' ' 34' ' ' LEU . 28.6 ttt -164.59 143.86 7.22 Favored 'General case' 0 N--CA 1.466 0.368 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 178.404 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.403 HG22 HG12 ' D' ' 36' ' ' VAL . 35.3 m -155.92 163.28 1.51 Allowed 'Isoleucine or valine' 0 C--O 1.219 -0.525 0 N-CA-C 108.339 -0.985 . . . . 0.0 108.339 179.376 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.78 66.56 2.75 Favored Glycine 0 C--N 1.303 -1.292 0 CA-C-N 116.147 -0.479 . . . . 0.0 112.136 178.631 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 146.0 173.54 17.34 Favored Glycine 0 N--CA 1.475 1.243 0 N-CA-C 110.649 -0.98 . . . . 0.0 110.649 179.138 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.578 ' H ' HG12 ' D' ' 39' ' ' VAL . 35.6 m -123.96 159.98 28.53 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.861 0 C-N-CA 123.579 0.752 . . . . 0.0 110.552 -179.858 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 25.2 t . . . . . 0 C--O 1.22 -0.46 0 CA-C-O 118.323 -0.846 . . . . 0.0 110.78 179.568 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 39.4 m-85 . . . . . 0 N--CA 1.475 0.807 0 N-CA-C 109.99 -0.374 . . . . 0.0 109.99 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -143.71 139.98 29.78 Favored 'General case' 0 N--CA 1.482 1.139 0 N-CA-C 109.977 -0.379 . . . . 0.0 109.977 179.693 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 40.5 t-80 -151.74 119.18 6.0 Favored 'General case' 0 N--CA 1.473 0.724 0 N-CA-C 109.238 -0.652 . . . . 0.0 109.238 179.216 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 7' ' ' ASP . . . . . 0.501 ' O ' ' OG ' ' E' ' 8' ' ' SER . 4.3 m-20 -68.89 148.15 50.64 Favored 'General case' 0 CA--C 1.535 0.385 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.639 179.865 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 8' ' ' SER . . . . . . . . . . . . . 54.3 p -167.44 -173.79 2.34 Favored 'General case' 0 N--CA 1.48 1.068 0 C-N-CA 122.575 0.35 . . . . 0.0 110.701 179.072 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.94 47.92 1.3 Allowed Glycine 0 N--CA 1.482 1.703 0 CA-C-N 115.991 -0.549 . . . . 0.0 112.178 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 50.1 p90 -65.18 132.7 49.8 Favored 'General case' 0 N--CA 1.472 0.633 0 O-C-N 122.716 -0.285 . . . . 0.0 111.663 179.782 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 48.5 mt-10 -92.55 152.77 19.45 Favored 'General case' 0 N--CA 1.477 0.913 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 178.331 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.0 p -153.43 128.45 1.51 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.587 0 N-CA-C 107.737 -1.209 . . . . 0.0 107.737 178.314 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 47.5 m-70 -135.0 145.81 48.45 Favored 'General case' 0 N--CA 1.492 1.639 0 CA-C-N 118.904 0.775 . . . . 0.0 111.303 -179.103 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 6.2 t60 -165.66 97.46 0.66 Allowed 'General case' 0 N--CA 1.482 1.133 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.648 179.452 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 3.9 pt20 -111.76 -174.34 2.44 Favored 'General case' 0 CA--C 1.506 -0.749 0 N-CA-C 108.362 -0.977 . . . . 0.0 108.362 -179.883 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -163.87 99.07 0.87 Allowed 'General case' 0 N--CA 1.474 0.77 0 CA-C-N 114.718 -1.128 . . . . 0.0 108.26 178.608 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 6.8 mp -121.62 157.0 31.77 Favored 'General case' 0 N--CA 1.497 1.916 0 CA-C-O 121.936 0.875 . . . . 0.0 110.998 -178.294 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 61.1 t -112.55 127.6 69.68 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.07 0 N-CA-C 108.122 -1.066 . . . . 0.0 108.122 177.574 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 29.0 m-85 -127.99 122.36 32.11 Favored 'General case' 0 N--CA 1.495 1.802 0 CA-C-N 119.638 1.108 . . . . 0.0 110.219 179.515 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 68.7 m-85 53.23 74.46 0.3 Allowed 'General case' 0 CA--C 1.54 0.566 0 CA-C-O 121.558 0.694 . . . . 0.0 111.735 178.573 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -80.71 -77.85 0.19 Allowed 'General case' 0 C--N 1.35 0.6 0 CA-C-N 115.075 -0.966 . . . . 0.0 110.45 -179.788 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 40.5 tt0 -112.22 101.9 10.1 Favored 'General case' 0 N--CA 1.471 0.615 0 N-CA-C 108.417 -0.957 . . . . 0.0 108.417 179.786 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -158.68 134.54 8.94 Favored 'General case' 0 N--CA 1.484 1.23 0 CA-C-O 119.444 -0.312 . . . . 0.0 111.16 178.85 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 24' ' ' VAL . . . . . 0.403 HG12 ' N ' ' B' ' 25' ' ' GLY . 61.1 t -57.98 163.82 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.806 0 N-CA-C 108.249 -1.019 . . . . 0.0 108.249 177.209 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 25' ' ' GLY . . . . . 0.437 ' H ' ' HB ' ' E' ' 24' ' ' VAL . . . -116.22 48.22 0.96 Allowed Glycine 0 N--CA 1.475 1.288 0 N-CA-C 111.625 -0.59 . . . . 0.0 111.625 -179.446 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -62.27 -169.06 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.531 0 O-C-N 123.76 0.33 . . . . 0.0 110.242 179.238 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 3.1 t30 -72.2 79.68 0.97 Allowed 'General case' 0 N--CA 1.467 0.393 0 N-CA-C 109.881 -0.414 . . . . 0.0 109.881 179.307 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -72.99 140.66 47.5 Favored 'General case' 0 N--CA 1.472 0.674 0 N-CA-C 109.105 -0.702 . . . . 0.0 109.105 179.417 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.86 -149.1 0.04 OUTLIER Glycine 0 C--N 1.338 0.645 0 N-CA-C 110.349 -1.1 . . . . 0.0 110.349 179.582 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -93.75 128.47 39.99 Favored 'General case' 0 N--CA 1.473 0.679 0 N-CA-C 110.036 -0.357 . . . . 0.0 110.036 179.882 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 72.5 mt -125.08 117.14 49.15 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.859 0 N-CA-C 106.723 -1.584 . . . . 0.0 106.723 178.768 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 39.6 pt -151.47 -169.94 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.356 0.887 0 CA-C-N 115.874 -0.603 . . . . 0.0 111.119 -178.364 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.68 5.26 12.31 Favored Glycine 0 C--N 1.337 0.614 0 N-CA-C 110.894 -0.882 . . . . 0.0 110.894 179.702 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 1.5 tt -78.42 126.67 31.09 Favored 'General case' 0 CA--C 1.545 0.76 0 N-CA-C 109.441 -0.577 . . . . 0.0 109.441 -179.521 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 28.5 ttt -164.12 143.66 7.83 Favored 'General case' 0 N--CA 1.467 0.378 0 N-CA-C 108.722 -0.844 . . . . 0.0 108.722 178.456 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 35.7 m -155.88 162.98 1.57 Allowed 'Isoleucine or valine' 0 C--O 1.22 -0.491 0 N-CA-C 108.343 -0.984 . . . . 0.0 108.343 179.519 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.81 66.95 2.47 Favored Glycine 0 C--N 1.303 -1.291 0 CA-C-N 116.183 -0.462 . . . . 0.0 112.076 178.591 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 145.33 173.24 16.41 Favored Glycine 0 N--CA 1.474 1.208 0 N-CA-C 110.69 -0.964 . . . . 0.0 110.69 179.181 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 39' ' ' VAL . . . . . 0.611 ' H ' HG12 ' E' ' 39' ' ' VAL . 35.7 m -123.65 159.84 27.95 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.934 0 C-N-CA 123.608 0.763 . . . . 0.0 110.713 -179.769 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 24.4 t . . . . . 0 N--CA 1.469 0.522 0 CA-C-O 118.339 -0.839 . . . . 0.0 110.599 179.53 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 40.3 m-85 . . . . . 0 N--CA 1.476 0.842 0 N-CA-C 110.031 -0.359 . . . . 0.0 110.031 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -143.63 139.98 29.89 Favored 'General case' 0 N--CA 1.482 1.134 0 CA-C-O 120.872 0.368 . . . . 0.0 110.05 179.762 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 42.1 t-80 -151.74 119.16 5.99 Favored 'General case' 0 N--CA 1.472 0.656 0 N-CA-C 109.26 -0.644 . . . . 0.0 109.26 179.173 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 7' ' ' ASP . . . . . 0.471 ' O ' ' OG ' ' F' ' 8' ' ' SER . 4.2 m-20 -68.77 148.47 50.28 Favored 'General case' 0 N--CA 1.468 0.443 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.52 179.783 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 8' ' ' SER . . . . . . . . . . . . . 54.2 p -167.97 -173.94 2.23 Favored 'General case' 0 N--CA 1.48 1.049 0 CA-C-O 120.874 0.368 . . . . 0.0 110.677 179.137 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.05 47.75 1.31 Allowed Glycine 0 N--CA 1.482 1.751 0 CA-C-N 115.968 -0.56 . . . . 0.0 112.072 -179.926 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 50.6 p90 -65.04 132.58 49.59 Favored 'General case' 0 N--CA 1.472 0.658 0 CA-C-O 120.778 0.323 . . . . 0.0 111.637 179.737 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 48.6 mt-10 -92.48 152.96 19.39 Favored 'General case' 0 N--CA 1.475 0.79 0 N-CA-C 109.738 -0.468 . . . . 0.0 109.738 178.395 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.0 p -153.65 128.62 1.5 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.523 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 178.263 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 46.1 m-70 -135.17 145.72 48.02 Favored 'General case' 0 N--CA 1.492 1.635 0 CA-C-N 118.931 0.787 . . . . 0.0 111.317 -179.057 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 6.2 t60 -165.52 97.52 0.68 Allowed 'General case' 0 N--CA 1.482 1.162 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.688 179.52 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 3.9 pt20 -112.0 -174.47 2.47 Favored 'General case' 0 CA--C 1.504 -0.825 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 -179.889 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -163.62 99.12 0.9 Allowed 'General case' 0 N--CA 1.473 0.677 0 CA-C-N 114.708 -1.133 . . . . 0.0 108.261 178.777 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 6.8 mp -121.71 157.07 31.74 Favored 'General case' 0 N--CA 1.497 1.902 0 CA-C-O 121.965 0.888 . . . . 0.0 110.994 -178.342 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 61.9 t -112.71 127.4 69.96 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.151 0 N-CA-C 108.146 -1.057 . . . . 0.0 108.146 177.612 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 28.9 m-85 -127.82 122.17 32.01 Favored 'General case' 0 N--CA 1.494 1.765 0 CA-C-N 119.673 1.124 . . . . 0.0 110.197 179.513 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 68.7 m-85 53.42 74.55 0.3 Allowed 'General case' 0 CA--C 1.539 0.523 0 CA-C-O 121.57 0.7 . . . . 0.0 111.787 178.612 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -80.62 -78.12 0.18 Allowed 'General case' 0 C--N 1.35 0.598 0 CA-C-N 114.961 -1.018 . . . . 0.0 110.379 -179.805 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 40.3 tt0 -112.02 102.05 10.3 Favored 'General case' 0 N--CA 1.469 0.522 0 N-CA-C 108.506 -0.924 . . . . 0.0 108.506 179.82 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -158.76 134.67 8.94 Favored 'General case' 0 N--CA 1.482 1.161 0 CA-C-O 119.385 -0.341 . . . . 0.0 111.185 178.906 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 61.0 t -58.14 163.74 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.843 0 N-CA-C 108.217 -1.031 . . . . 0.0 108.217 177.188 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 25' ' ' GLY . . . . . 0.443 ' H ' ' HB ' ' F' ' 24' ' ' VAL . . . -116.28 48.13 0.97 Allowed Glycine 0 N--CA 1.477 1.372 0 N-CA-C 111.617 -0.593 . . . . 0.0 111.617 -179.352 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -62.3 -169.11 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.532 0 O-C-N 123.726 0.309 . . . . 0.0 110.212 179.312 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 25.2 t-20 -71.98 79.98 0.92 Allowed 'General case' 0 N--CA 1.466 0.368 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.205 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -73.45 140.61 46.62 Favored 'General case' 0 N--CA 1.473 0.692 0 N-CA-C 109.015 -0.735 . . . . 0.0 109.015 179.369 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.71 -148.67 0.03 OUTLIER Glycine 0 C--N 1.338 0.661 0 N-CA-C 110.395 -1.082 . . . . 0.0 110.395 179.548 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -93.99 128.25 40.23 Favored 'General case' 0 N--CA 1.471 0.592 0 CA-C-N 116.866 0.333 . . . . 0.0 110.136 179.825 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 71.8 mt -124.94 116.71 48.02 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.834 0 N-CA-C 106.779 -1.563 . . . . 0.0 106.779 178.654 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 38.8 pt -150.97 -169.71 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.356 0.873 0 CA-C-N 115.903 -0.589 . . . . 0.0 111.183 -178.42 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.37 5.39 11.29 Favored Glycine 0 C--N 1.336 0.555 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 179.659 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 1.5 tt -78.53 126.44 30.76 Favored 'General case' 0 CA--C 1.544 0.744 0 N-CA-C 109.499 -0.556 . . . . 0.0 109.499 -179.613 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 28.6 ttt -163.65 143.76 8.55 Favored 'General case' 0 N--CA 1.468 0.427 0 N-CA-C 108.687 -0.857 . . . . 0.0 108.687 178.42 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 35.5 m -155.9 162.96 1.57 Allowed 'Isoleucine or valine' 0 C--O 1.219 -0.501 0 N-CA-C 108.292 -1.003 . . . . 0.0 108.292 179.384 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.93 66.9 2.51 Favored Glycine 0 C--N 1.303 -1.299 0 CA-C-N 116.195 -0.457 . . . . 0.0 112.058 178.565 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 145.53 173.67 17.01 Favored Glycine 0 N--CA 1.475 1.257 0 N-CA-C 110.663 -0.975 . . . . 0.0 110.663 179.061 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 39' ' ' VAL . . . . . 0.608 ' H ' HG12 ' F' ' 39' ' ' VAL . 35.9 m -124.02 159.87 28.81 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.868 0 C-N-CA 123.678 0.791 . . . . 0.0 110.592 -179.851 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 24.7 t . . . . . 0 C--O 1.219 -0.542 0 CA-C-O 118.355 -0.831 . . . . 0.0 110.611 179.496 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 39.8 m-85 . . . . . 0 N--CA 1.472 0.671 0 N-CA-C 108.898 -0.778 . . . . 0.0 108.898 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' D' D ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -145.9 138.11 25.38 Favored 'General case' 0 N--CA 1.476 0.848 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.396 -179.609 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 39.6 t-80 -149.29 123.69 9.65 Favored 'General case' 0 CA--C 1.546 0.79 0 N-CA-C 108.318 -0.993 . . . . 0.0 108.318 175.746 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' D' D ' 7' ' ' ASP . . . . . 0.598 ' O ' ' OG ' ' G' ' 8' ' ' SER . 3.3 m-20 -64.28 133.08 52.03 Favored 'General case' 0 C--N 1.324 -0.524 0 C-N-CA 126.477 1.911 . . . . 0.0 114.259 174.946 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' D' D ' 8' ' ' SER . . . . . 0.495 ' OG ' ' O ' ' A' ' 7' ' ' ASP . 54.0 p -154.93 -171.12 3.72 Favored 'General case' 0 N--CA 1.486 1.373 0 CA-C-N 119.566 1.075 . . . . 0.0 111.26 175.892 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.44 48.23 1.14 Allowed Glycine 0 N--CA 1.483 1.779 0 N-CA-C 110.517 -1.033 . . . . 0.0 110.517 174.559 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 51.4 p90 -61.0 131.19 49.85 Favored 'General case' 0 N--CA 1.471 0.594 0 N-CA-C 112.782 0.66 . . . . 0.0 112.782 178.433 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 48.5 mt-10 -89.44 151.04 22.23 Favored 'General case' 0 N--CA 1.48 1.07 0 C-N-CA 122.258 0.223 . . . . 0.0 110.826 175.581 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.0 p -149.58 130.01 4.32 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.599 0 N-CA-C 107.515 -1.291 . . . . 0.0 107.515 173.542 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 44.5 m-70 -130.07 148.63 51.94 Favored 'General case' 0 N--CA 1.483 1.212 0 CA-C-N 118.22 0.464 . . . . 0.0 111.78 176.379 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 6.2 t60 -164.96 104.38 0.78 Allowed 'General case' 0 N--CA 1.482 1.163 0 N-CA-C 109.141 -0.689 . . . . 0.0 109.141 172.859 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 3.9 pt20 -115.47 -176.18 2.87 Favored 'General case' 0 CA--C 1.496 -1.12 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 179.061 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -160.36 106.1 1.51 Allowed 'General case' 0 N--CA 1.469 0.506 0 N-CA-C 106.717 -1.586 . . . . 0.0 106.717 175.783 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 5.8 mp -128.17 153.68 46.62 Favored 'General case' 0 N--CA 1.497 1.909 0 CA-C-O 122.23 1.014 . . . . 0.0 110.586 179.989 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 36.1 t -101.29 131.58 48.76 Favored 'Isoleucine or valine' 0 C--O 1.26 1.631 0 CA-C-O 116.674 -1.632 . . . . 0.0 109.7 174.225 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 27.5 m-85 -130.44 126.12 36.16 Favored 'General case' 0 N--CA 1.49 1.547 0 CA-C-N 120.203 1.365 . . . . 0.0 109.552 173.359 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 69.7 m-85 55.53 71.52 0.54 Allowed 'General case' 0 C--O 1.239 0.517 0 CA-C-N 115.781 -0.645 . . . . 0.0 111.23 176.044 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -82.33 -73.28 0.4 Allowed 'General case' 0 N--CA 1.471 0.608 0 CA-C-O 118.555 -0.736 . . . . 0.0 111.171 -177.592 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 40.7 tt0 -115.37 105.67 13.11 Favored 'General case' 0 N--CA 1.481 1.12 0 N-CA-C 106.586 -1.635 . . . . 0.0 106.586 176.629 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 p-10 -152.02 135.13 15.78 Favored 'General case' 0 N--CA 1.474 0.756 0 CA-C-O 116.643 -1.646 . . . . 0.0 113.397 177.471 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' D' D ' 24' ' ' VAL . . . . . 0.422 ' HB ' ' H ' ' A' ' 25' ' ' GLY . 68.7 t -61.12 166.54 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.264 0 CA-C-N 121.351 1.887 . . . . 0.0 107.972 175.481 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' D' D ' 25' ' ' GLY . . . . . 0.496 ' H ' ' HB ' ' G' ' 24' ' ' VAL . . . -116.56 50.94 0.75 Allowed Glycine 0 N--CA 1.479 1.513 0 CA-C-O 119.203 -0.776 . . . . 0.0 111.489 178.814 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -57.57 -171.43 0.01 OUTLIER 'General case' 0 N--CA 1.468 0.465 0 C-N-CA 123.255 0.622 . . . . 0.0 111.888 175.556 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 3.9 t30 -73.08 86.43 1.35 Allowed 'General case' 0 C--N 1.347 0.464 0 N-CA-C 108.635 -0.876 . . . . 0.0 108.635 176.47 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 97.7 mttt -80.8 143.42 32.86 Favored 'General case' 0 N--CA 1.479 1.009 0 N-CA-C 107.712 -1.218 . . . . 0.0 107.712 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.27 -143.69 0.02 OUTLIER Glycine 0 C--N 1.348 1.212 0 C-N-CA 120.224 -0.989 . . . . 0.0 111.618 -178.266 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -95.46 126.42 40.74 Favored 'General case' 0 C--O 1.239 0.515 0 C-N-CA 123.031 0.532 . . . . 0.0 110.276 178.663 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 80.4 mt -125.44 126.86 71.25 Favored 'Isoleucine or valine' 0 C--N 1.358 0.944 0 N-CA-C 104.022 -2.584 . . . . 0.0 104.022 176.281 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' D' D ' 32' ' ' ILE . . . . . 0.421 HG22 ' H ' ' G' ' 32' ' ' ILE . 41.9 pt -159.14 -170.92 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.1 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.261 -177.927 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.91 5.04 12.53 Favored Glycine 0 C--O 1.239 0.463 0 N-CA-C 110.237 -1.145 . . . . 0.0 110.237 -178.957 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 1.9 tt -79.54 133.46 36.47 Favored 'General case' 0 C--N 1.369 1.451 0 C-N-CA 117.863 -1.535 . . . . 0.0 107.458 -178.968 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' D' D ' 35' ' ' MET . . . . . 0.4 ' C ' HG13 ' D' ' 36' ' ' VAL . 28.1 ttt -158.71 156.3 29.65 Favored 'General case' 0 CA--C 1.511 -0.52 0 N-CA-C 108.203 -1.036 . . . . 0.0 108.203 171.852 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' D' D ' 36' ' ' VAL . . . . . 0.464 HG22 HG12 ' G' ' 36' ' ' VAL . 35.7 m -164.72 163.77 0.7 Allowed 'Isoleucine or valine' 0 C--O 1.219 -0.506 0 N-CA-C 108.058 -1.09 . . . . 0.0 108.058 173.934 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 59.91 63.65 4.88 Favored Glycine 0 C--N 1.307 -1.066 0 C-N-CA 120.37 -0.919 . . . . 0.0 111.528 177.764 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 144.62 176.04 18.29 Favored Glycine 0 N--CA 1.48 1.6 0 CA-C-N 117.971 0.886 . . . . 0.0 111.145 179.368 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' D' D ' 39' ' ' VAL . . . . . 0.605 ' H ' HG12 ' G' ' 39' ' ' VAL . 34.3 m -125.43 157.08 34.82 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.861 0 C-N-CA 123.409 0.684 . . . . 0.0 111.119 -178.753 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 25.2 t . . . . . 0 C--N 1.329 -0.32 0 CA-C-O 116.333 -1.794 . . . . 0.0 109.748 176.588 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 35.9 m-85 . . . . . 0 N--CA 1.475 0.82 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' E' E ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -143.53 140.04 30.07 Favored 'General case' 0 N--CA 1.48 1.045 0 CA-C-O 120.902 0.382 . . . . 0.0 110.15 179.583 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 43.3 t-80 -151.47 119.35 6.19 Favored 'General case' 0 N--CA 1.474 0.729 0 N-CA-C 109.167 -0.679 . . . . 0.0 109.167 179.085 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' E' E ' 7' ' ' ASP . . . . . 0.497 ' O ' ' OG ' ' H' ' 8' ' ' SER . 3.9 m-20 -69.65 148.15 49.69 Favored 'General case' 0 N--CA 1.466 0.349 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.838 179.998 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' E' E ' 8' ' ' SER . . . . . 0.501 ' OG ' ' O ' ' B' ' 7' ' ' ASP . 52.5 p -168.32 -172.6 1.77 Allowed 'General case' 0 N--CA 1.483 1.21 0 CA-C-O 121.015 0.436 . . . . 0.0 110.854 178.757 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.55 47.66 1.27 Allowed Glycine 0 N--CA 1.479 1.543 0 CA-C-N 116.033 -0.53 . . . . 0.0 111.965 179.917 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 49.1 p90 -64.26 132.53 50.54 Favored 'General case' 0 N--CA 1.473 0.706 0 N-CA-C 112.028 0.381 . . . . 0.0 112.028 -179.894 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 49.4 mt-10 -91.72 153.17 19.82 Favored 'General case' 0 N--CA 1.48 1.066 0 CA-C-O 121.158 0.504 . . . . 0.0 109.665 177.944 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -155.01 127.32 1.02 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.587 0 N-CA-C 107.882 -1.155 . . . . 0.0 107.882 177.968 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 45.1 m-70 -135.04 143.65 46.85 Favored 'General case' 0 N--CA 1.482 1.166 0 CA-C-O 120.787 0.327 . . . . 0.0 111.516 -177.958 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 6.0 t60 -164.26 97.6 0.81 Allowed 'General case' 0 N--CA 1.486 1.371 0 CA-C-N 116.356 -0.383 . . . . 0.0 110.634 179.593 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 3.9 pt20 -111.57 -174.63 2.51 Favored 'General case' 0 CA--C 1.505 -0.761 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 -179.805 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -163.27 98.61 0.93 Allowed 'General case' 0 N--CA 1.476 0.861 0 CA-C-N 114.75 -1.113 . . . . 0.0 108.49 178.633 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 6.5 mp -120.89 156.61 31.63 Favored 'General case' 0 N--CA 1.495 1.777 0 CA-C-O 121.786 0.803 . . . . 0.0 111.52 -177.682 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 48.4 t -114.06 124.62 70.88 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.216 0 N-CA-C 108.276 -1.009 . . . . 0.0 108.276 177.331 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 31.1 m-85 -125.51 121.41 33.65 Favored 'General case' 0 N--CA 1.489 1.51 0 CA-C-O 120.888 0.375 . . . . 0.0 110.846 -179.769 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 70.2 m-85 54.46 73.41 0.4 Allowed 'General case' 0 N--CA 1.469 0.508 0 CA-C-N 115.998 -0.547 . . . . 0.0 111.391 178.201 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -78.78 -78.95 0.14 Allowed 'General case' 0 C--N 1.344 0.348 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.268 -179.475 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 40.4 tt0 -111.2 102.72 11.12 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 -179.978 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -158.16 134.93 9.75 Favored 'General case' 0 C--O 1.208 -1.116 0 CA-C-O 119.484 -0.293 . . . . 0.0 111.378 178.829 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' E' E ' 24' ' ' VAL . . . . . 0.437 ' HB ' ' H ' ' B' ' 25' ' ' GLY . 58.5 t -56.97 167.72 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.941 0 N-CA-C 107.614 -1.254 . . . . 0.0 107.614 176.806 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' E' E ' 25' ' ' GLY . . . . . 0.413 ' N ' HG12 ' E' ' 24' ' ' VAL . . . -120.73 49.07 0.9 Allowed Glycine 0 N--CA 1.477 1.431 0 N-CA-C 110.765 -0.934 . . . . 0.0 110.765 -179.354 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -63.53 -168.32 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.542 0 CA-C-O 120.691 0.281 . . . . 0.0 110.25 179.622 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 3.6 t30 -71.7 76.42 0.84 Allowed 'General case' 0 N--CA 1.467 0.403 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.416 179.689 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -70.26 140.75 52.44 Favored 'General case' 0 N--CA 1.477 0.894 0 N-CA-C 109.497 -0.556 . . . . 0.0 109.497 179.557 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.6 -148.68 0.05 OUTLIER Glycine 0 CA--C 1.521 0.467 0 N-CA-C 110.895 -0.882 . . . . 0.0 110.895 179.519 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -92.81 127.18 38.22 Favored 'General case' 0 C--O 1.235 0.292 0 N-CA-C 110.268 -0.271 . . . . 0.0 110.268 179.577 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 74.2 mt -124.34 116.92 49.11 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.608 0 N-CA-C 106.491 -1.67 . . . . 0.0 106.491 178.439 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' E' E ' 32' ' ' ILE . . . . . 0.421 HG22 ' H ' ' H' ' 32' ' ' ILE . 43.7 pt -151.43 -168.46 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.182 0 CA-C-O 121.144 0.497 . . . . 0.0 110.622 -178.526 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.4 5.2 7.82 Favored Glycine 0 CA--C 1.528 0.873 0 N-CA-C 111.262 -0.735 . . . . 0.0 111.262 -179.954 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 1.5 tt -77.6 127.09 31.91 Favored 'General case' 0 CA--C 1.545 0.783 0 N-CA-C 109.491 -0.559 . . . . 0.0 109.491 -179.64 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 28.4 ttt -163.86 144.38 8.54 Favored 'General case' 0 N--CA 1.471 0.6 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 178.312 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' E' E ' 36' ' ' VAL . . . . . 0.444 HG22 HG12 ' H' ' 36' ' ' VAL . 32.8 m -156.73 162.62 1.56 Allowed 'Isoleucine or valine' 0 C--O 1.215 -0.712 0 N-CA-C 108.816 -0.809 . . . . 0.0 108.816 179.742 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.98 66.41 2.87 Favored Glycine 0 C--N 1.305 -1.194 0 N-CA-C 111.974 -0.45 . . . . 0.0 111.974 178.55 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 146.07 174.16 17.97 Favored Glycine 0 N--CA 1.477 1.374 0 N-CA-C 111.113 -0.795 . . . . 0.0 111.113 179.038 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' E' E ' 39' ' ' VAL . . . . . 0.611 HG12 ' H ' ' B' ' 39' ' ' VAL . 33.8 m -124.33 159.67 29.8 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.671 0 C-N-CA 123.478 0.711 . . . . 0.0 110.774 -179.566 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 25.8 t . . . . . 0 C--O 1.219 -0.518 0 CA-C-O 118.361 -0.828 . . . . 0.0 110.66 179.321 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 35.3 m-85 . . . . . 0 N--CA 1.475 0.8 0 N-CA-C 109.978 -0.378 . . . . 0.0 109.978 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' F' F ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -143.44 139.88 30.13 Favored 'General case' 0 N--CA 1.479 0.989 0 CA-C-O 120.872 0.368 . . . . 0.0 110.231 179.54 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 42.6 t-80 -151.35 119.02 6.09 Favored 'General case' 0 N--CA 1.474 0.761 0 N-CA-C 109.197 -0.668 . . . . 0.0 109.197 179.076 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' F' F ' 7' ' ' ASP . . . . . 0.463 ' O ' ' OG ' ' I' ' 8' ' ' SER . 4.0 m-20 -69.2 148.28 50.09 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.74 179.912 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' F' F ' 8' ' ' SER . . . . . 0.471 ' OG ' ' O ' ' C' ' 7' ' ' ASP . 52.1 p -168.65 -173.03 1.78 Allowed 'General case' 0 N--CA 1.486 1.329 0 CA-C-O 121.04 0.448 . . . . 0.0 110.858 178.749 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.79 47.55 1.26 Allowed Glycine 0 N--CA 1.479 1.529 0 CA-C-N 115.969 -0.559 . . . . 0.0 111.884 179.785 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 48.2 p90 -64.01 133.06 52.41 Favored 'General case' 0 CA--C 1.543 0.683 0 O-C-N 122.528 -0.395 . . . . 0.0 111.978 -179.821 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 49.2 mt-10 -92.02 152.94 19.74 Favored 'General case' 0 N--CA 1.48 1.056 0 CA-C-O 121.196 0.522 . . . . 0.0 109.727 177.841 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -154.78 127.0 1.01 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.572 0 N-CA-C 107.837 -1.172 . . . . 0.0 107.837 178.085 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 44.7 m-70 -134.71 143.65 47.31 Favored 'General case' 0 N--CA 1.484 1.228 0 CA-C-O 120.867 0.365 . . . . 0.0 111.563 -178.04 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 6.0 t60 -164.12 97.51 0.82 Allowed 'General case' 0 N--CA 1.487 1.391 0 CA-C-N 116.431 -0.349 . . . . 0.0 110.775 179.614 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 3.9 pt20 -111.71 -174.72 2.53 Favored 'General case' 0 CA--C 1.503 -0.847 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 -179.838 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -163.09 98.64 0.94 Allowed 'General case' 0 N--CA 1.473 0.711 0 CA-C-N 114.74 -1.118 . . . . 0.0 108.466 178.689 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 6.7 mp -120.76 156.97 30.7 Favored 'General case' 0 N--CA 1.495 1.795 0 CA-C-O 121.806 0.812 . . . . 0.0 111.498 -177.827 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 48.8 t -114.35 124.45 71.01 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.231 0 N-CA-C 108.186 -1.042 . . . . 0.0 108.186 177.321 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 32.2 m-85 -125.24 121.16 33.28 Favored 'General case' 0 N--CA 1.488 1.452 0 CA-C-O 120.893 0.377 . . . . 0.0 110.857 -179.911 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 70.4 m-85 54.67 73.78 0.38 Allowed 'General case' 0 N--CA 1.467 0.386 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.588 178.277 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -79.12 -78.53 0.15 Allowed 'General case' 0 C--N 1.344 0.354 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.406 -179.431 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 40.9 tt0 -111.71 102.58 10.87 Favored 'General case' 0 N--CA 1.47 0.527 0 N-CA-C 108.402 -0.962 . . . . 0.0 108.402 -179.929 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -158.02 134.77 9.78 Favored 'General case' 0 N--CA 1.481 1.081 0 CA-C-O 119.416 -0.326 . . . . 0.0 111.394 178.822 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' F' F ' 24' ' ' VAL . . . . . 0.443 ' HB ' ' H ' ' C' ' 25' ' ' GLY . 58.1 t -56.82 167.97 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.966 0 N-CA-C 107.641 -1.244 . . . . 0.0 107.641 176.938 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' F' F ' 25' ' ' GLY . . . . . 0.415 ' H ' ' HB ' ' I' ' 24' ' ' VAL . . . -120.97 49.2 0.89 Allowed Glycine 0 N--CA 1.478 1.48 0 N-CA-C 110.745 -0.942 . . . . 0.0 110.745 -179.344 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -63.72 -167.92 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.551 0 CA-C-O 120.731 0.301 . . . . 0.0 110.294 179.66 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 25.2 t-20 -71.92 76.51 0.9 Allowed 'General case' 0 N--CA 1.466 0.372 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.325 179.662 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -70.48 140.44 51.9 Favored 'General case' 0 N--CA 1.477 0.892 0 N-CA-C 109.525 -0.546 . . . . 0.0 109.525 179.562 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.17 -149.09 0.04 OUTLIER Glycine 0 CA--C 1.522 0.504 0 N-CA-C 110.898 -0.881 . . . . 0.0 110.898 179.441 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -92.34 127.14 37.71 Favored 'General case' 0 C--O 1.236 0.352 0 CA-C-O 120.676 0.274 . . . . 0.0 110.276 179.444 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 73.2 mt -124.26 116.93 49.2 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.572 0 N-CA-C 106.479 -1.674 . . . . 0.0 106.479 178.401 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' F' F ' 32' ' ' ILE . . . . . 0.417 HG22 ' H ' ' I' ' 32' ' ' ILE . 44.1 pt -151.6 -168.36 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.149 0 CA-C-O 121.071 0.462 . . . . 0.0 110.722 -178.543 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.13 5.54 8.1 Favored Glycine 0 CA--C 1.527 0.818 0 N-CA-C 111.274 -0.73 . . . . 0.0 111.274 -179.889 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 1.5 tt -77.76 126.88 31.54 Favored 'General case' 0 N--CA 1.476 0.839 0 N-CA-C 109.386 -0.598 . . . . 0.0 109.386 -179.689 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 28.4 ttt -163.62 144.36 8.9 Favored 'General case' 0 N--CA 1.471 0.591 0 N-CA-C 108.876 -0.787 . . . . 0.0 108.876 178.283 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' F' F ' 36' ' ' VAL . . . . . 0.455 HG22 HG12 ' I' ' 36' ' ' VAL . 32.8 m -156.63 162.81 1.53 Allowed 'Isoleucine or valine' 0 C--O 1.216 -0.709 0 N-CA-C 108.829 -0.804 . . . . 0.0 108.829 179.638 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.82 66.48 2.81 Favored Glycine 0 C--N 1.305 -1.169 0 N-CA-C 111.992 -0.443 . . . . 0.0 111.992 178.5 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 145.82 174.12 17.71 Favored Glycine 0 N--CA 1.477 1.419 0 N-CA-C 111.031 -0.828 . . . . 0.0 111.031 178.961 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' F' F ' 39' ' ' VAL . . . . . 0.608 HG12 ' H ' ' C' ' 39' ' ' VAL . 33.7 m -124.38 159.75 29.82 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.692 0 C-N-CA 123.366 0.666 . . . . 0.0 110.755 -179.488 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 26.3 t . . . . . 0 C--O 1.22 -0.476 0 CA-C-O 118.249 -0.881 . . . . 0.0 110.609 179.215 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 39.2 m-85 . . . . . 0 N--CA 1.474 0.736 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' G' G ' 5' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -143.79 140.3 29.81 Favored 'General case' 0 N--CA 1.482 1.168 0 CA-C-O 120.846 0.355 . . . . 0.0 110.311 179.825 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 43.3 t-80 -151.54 120.25 6.55 Favored 'General case' 0 N--CA 1.475 0.782 0 N-CA-C 109.342 -0.614 . . . . 0.0 109.342 179.125 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -71.22 144.19 50.19 Favored 'General case' 0 N--CA 1.47 0.547 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.17 -179.937 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' G' G ' 8' ' ' SER . . . . . 0.598 ' OG ' ' O ' ' D' ' 7' ' ' ASP . 47.8 p -165.4 -170.96 2.0 Allowed 'General case' 0 N--CA 1.474 0.767 0 CA-C-O 120.962 0.41 . . . . 0.0 110.589 178.585 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.01 47.92 1.29 Allowed Glycine 0 N--CA 1.48 1.611 0 N-CA-C 111.514 -0.635 . . . . 0.0 111.514 179.441 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 50.4 p90 -64.5 133.02 51.56 Favored 'General case' 0 N--CA 1.473 0.699 0 CA-C-O 120.753 0.311 . . . . 0.0 111.818 -179.544 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 48.6 mt-10 -92.62 151.63 20.01 Favored 'General case' 0 N--CA 1.479 0.982 0 CA-C-O 121.104 0.478 . . . . 0.0 110.105 178.484 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -154.74 127.6 1.11 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.016 0 N-CA-C 107.92 -1.141 . . . . 0.0 107.92 178.361 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 47.0 m-70 -134.49 145.04 48.43 Favored 'General case' 0 N--CA 1.478 0.956 0 CA-C-N 115.542 -0.754 . . . . 0.0 111.399 -178.348 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 30.3 t-80 -165.87 97.61 0.64 Allowed 'General case' 0 N--CA 1.483 1.206 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.301 178.963 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 3.9 pt20 -111.74 -174.3 2.43 Favored 'General case' 0 CA--C 1.503 -0.848 0 N-CA-C 108.37 -0.974 . . . . 0.0 108.37 -179.657 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -163.8 98.21 0.86 Allowed 'General case' 0 N--CA 1.474 0.774 0 CA-C-N 114.672 -1.149 . . . . 0.0 108.194 178.856 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 6.6 mp -120.51 155.15 34.2 Favored 'General case' 0 N--CA 1.497 1.896 0 CA-C-O 121.291 0.567 . . . . 0.0 111.74 -177.794 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 43.9 t -113.33 124.91 70.44 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.006 0 CA-C-N 114.804 -1.089 . . . . 0.0 108.234 176.713 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 33.5 m-85 -125.9 121.17 32.39 Favored 'General case' 0 C--N 1.366 1.299 0 C-N-CA 123.437 0.695 . . . . 0.0 110.934 -179.585 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 69.3 m-85 54.75 72.82 0.44 Allowed 'General case' 0 N--CA 1.468 0.462 0 CA-C-N 115.874 -0.603 . . . . 0.0 111.375 178.059 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.7 -78.37 0.14 Allowed 'General case' 0 N--CA 1.472 0.632 0 O-C-N 122.223 -0.298 . . . . 0.0 110.508 -178.981 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 40.7 tt0 -111.78 102.47 10.75 Favored 'General case' 0 C--N 1.321 -0.633 0 N-CA-C 108.212 -1.033 . . . . 0.0 108.212 179.942 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -157.7 136.05 11.1 Favored 'General case' 0 N--CA 1.479 0.98 0 O-C-N 122.43 -0.168 . . . . 0.0 111.415 178.748 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' G' G ' 24' ' ' VAL . . . . . 0.496 ' HB ' ' H ' ' D' ' 25' ' ' GLY . 59.9 t -58.35 167.11 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.639 0 N-CA-C 107.749 -1.204 . . . . 0.0 107.749 177.115 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' G' G ' 25' ' ' GLY . . . . . 0.42 ' N ' HG12 ' G' ' 24' ' ' VAL . . . -119.53 49.4 0.88 Allowed Glycine 0 N--CA 1.48 1.615 0 N-CA-C 110.479 -1.048 . . . . 0.0 110.479 -179.496 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -64.6 -168.66 0.03 OUTLIER 'General case' 0 N--CA 1.471 0.624 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 179.67 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 3.7 t30 -71.46 76.47 0.77 Allowed 'General case' 0 N--CA 1.468 0.435 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.385 179.796 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -69.82 140.55 53.3 Favored 'General case' 0 N--CA 1.474 0.765 0 N-CA-C 109.626 -0.509 . . . . 0.0 109.626 179.528 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.79 -147.01 0.04 OUTLIER Glycine 0 C--N 1.338 0.663 0 N-CA-C 110.517 -1.033 . . . . 0.0 110.517 179.637 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -93.36 126.12 38.32 Favored 'General case' 0 N--CA 1.468 0.43 0 C-N-CA 122.616 0.366 . . . . 0.0 110.663 -179.738 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 73.4 mt -123.76 117.3 50.7 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.771 0 N-CA-C 106.527 -1.657 . . . . 0.0 106.527 178.105 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' G' G ' 32' ' ' ILE . . . . . 0.421 ' H ' HG22 ' D' ' 32' ' ' ILE . 44.8 pt -152.27 -167.68 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 CA-C-N 119.839 1.2 . . . . 0.0 109.858 -179.046 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.37 6.2 10.23 Favored Glycine 0 CA--C 1.525 0.705 0 N-CA-C 110.998 -0.841 . . . . 0.0 110.998 179.824 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 1.5 tt -79.23 125.94 30.12 Favored 'General case' 0 CA--C 1.544 0.746 0 N-CA-C 109.492 -0.559 . . . . 0.0 109.492 -179.575 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 27.5 ttt -162.76 146.01 11.07 Favored 'General case' 0 N--CA 1.47 0.565 0 N-CA-C 108.757 -0.831 . . . . 0.0 108.757 178.418 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' G' G ' 36' ' ' VAL . . . . . 0.464 HG12 HG22 ' D' ' 36' ' ' VAL . 33.2 m -157.37 162.11 1.62 Allowed 'Isoleucine or valine' 0 C--N 1.347 0.461 0 N-CA-C 108.901 -0.777 . . . . 0.0 108.901 -179.959 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.37 66.8 2.58 Favored Glycine 0 C--N 1.312 -0.754 0 CA-C-N 115.712 -0.676 . . . . 0.0 112.271 178.213 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 146.53 175.17 19.29 Favored Glycine 0 N--CA 1.477 1.427 0 N-CA-C 110.516 -1.034 . . . . 0.0 110.516 178.988 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' G' G ' 39' ' ' VAL . . . . . 0.605 HG12 ' H ' ' D' ' 39' ' ' VAL . 34.6 m -125.34 159.94 31.94 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.867 0 C-N-CA 123.09 0.556 . . . . 0.0 110.73 -179.48 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 28.8 t . . . . . 0 N--CA 1.469 0.511 0 CA-C-O 118.388 -0.815 . . . . 0.0 110.796 179.025 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 39.8 m-85 . . . . . 0 N--CA 1.473 0.697 0 N-CA-C 109.549 -0.537 . . . . 0.0 109.549 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' H' H ' 5' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -143.66 140.53 30.12 Favored 'General case' 0 N--CA 1.483 1.185 0 C-N-CA 122.583 0.353 . . . . 0.0 110.13 179.884 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 42.9 t-80 -151.77 120.4 6.5 Favored 'General case' 0 N--CA 1.473 0.701 0 N-CA-C 109.383 -0.599 . . . . 0.0 109.383 179.096 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -71.58 143.9 49.7 Favored 'General case' 0 N--CA 1.471 0.585 0 CA-C-N 116.323 -0.399 . . . . 0.0 111.178 -179.768 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' H' H ' 8' ' ' SER . . . . . 0.497 ' OG ' ' O ' ' E' ' 7' ' ' ASP . 53.7 p -165.07 -171.19 2.14 Favored 'General case' 0 N--CA 1.475 0.815 0 CA-C-O 120.94 0.4 . . . . 0.0 110.509 178.628 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.13 47.61 1.32 Allowed Glycine 0 N--CA 1.48 1.594 0 N-CA-C 111.683 -0.567 . . . . 0.0 111.683 179.642 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 50.4 p90 -64.51 133.13 51.77 Favored 'General case' 0 N--CA 1.472 0.659 0 N-CA-C 111.947 0.351 . . . . 0.0 111.947 -179.637 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 48.4 mt-10 -92.45 151.77 20.04 Favored 'General case' 0 N--CA 1.478 0.929 0 CA-C-O 121.013 0.435 . . . . 0.0 110.215 178.499 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -154.71 127.92 1.16 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.041 0 N-CA-C 107.854 -1.165 . . . . 0.0 107.854 178.251 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 46.4 m-70 -134.72 145.07 48.13 Favored 'General case' 0 N--CA 1.478 0.971 0 CA-C-N 115.5 -0.773 . . . . 0.0 111.394 -178.374 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 30.3 t-80 -165.93 97.29 0.63 Allowed 'General case' 0 N--CA 1.483 1.176 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.4 179.012 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 3.9 pt20 -111.39 -174.52 2.48 Favored 'General case' 0 CA--C 1.504 -0.826 0 N-CA-C 108.34 -0.985 . . . . 0.0 108.34 -179.652 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -163.72 98.29 0.87 Allowed 'General case' 0 N--CA 1.475 0.784 0 CA-C-N 114.671 -1.15 . . . . 0.0 108.093 178.757 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 6.7 mp -120.41 155.56 33.21 Favored 'General case' 0 N--CA 1.496 1.873 0 CA-C-O 121.233 0.539 . . . . 0.0 111.849 -177.82 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 42.6 t -113.64 125.23 70.88 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.01 0 CA-C-N 114.869 -1.06 . . . . 0.0 108.231 176.556 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 33.2 m-85 -126.24 121.07 31.66 Favored 'General case' 0 C--N 1.369 1.445 0 CA-C-N 115.518 -0.765 . . . . 0.0 110.775 -179.444 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 69.6 m-85 54.41 73.13 0.41 Allowed 'General case' 0 C--O 1.238 0.453 0 CA-C-N 115.814 -0.63 . . . . 0.0 111.399 178.107 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.75 -78.06 0.14 Allowed 'General case' 0 N--CA 1.472 0.657 0 O-C-N 122.201 -0.312 . . . . 0.0 110.661 -179.147 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 40.4 tt0 -112.09 102.57 10.77 Favored 'General case' 0 C--N 1.321 -0.641 0 N-CA-C 108.236 -1.024 . . . . 0.0 108.236 179.883 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -157.75 136.24 11.2 Favored 'General case' 0 N--CA 1.478 0.974 0 O-C-N 122.417 -0.177 . . . . 0.0 111.368 178.817 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' H' H ' 24' ' ' VAL . . . . . 0.418 HG12 ' N ' ' H' ' 25' ' ' GLY . 59.1 t -58.49 166.91 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.548 0 N-CA-C 107.71 -1.218 . . . . 0.0 107.71 177.18 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' H' H ' 25' ' ' GLY . . . . . 0.418 ' N ' HG12 ' H' ' 24' ' ' VAL . . . -119.25 49.2 0.89 Allowed Glycine 0 N--CA 1.479 1.551 0 N-CA-C 110.651 -0.98 . . . . 0.0 110.651 -179.573 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -64.68 -168.33 0.03 OUTLIER 'General case' 0 N--CA 1.472 0.661 0 N-CA-C 109.944 -0.391 . . . . 0.0 109.944 179.722 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 3.9 t30 -71.55 76.55 0.8 Allowed 'General case' 0 CA--C 1.537 0.472 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.316 179.809 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -70.15 140.56 52.61 Favored 'General case' 0 N--CA 1.474 0.775 0 N-CA-C 109.588 -0.523 . . . . 0.0 109.588 179.593 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.63 -147.69 0.04 OUTLIER Glycine 0 C--N 1.336 0.579 0 N-CA-C 110.376 -1.09 . . . . 0.0 110.376 179.549 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -93.05 126.31 38.07 Favored 'General case' 0 N--CA 1.465 0.298 0 C-N-CA 122.584 0.354 . . . . 0.0 110.781 -179.8 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 74.5 mt -123.87 117.23 50.41 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.776 0 N-CA-C 106.575 -1.639 . . . . 0.0 106.575 178.224 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' H' H ' 32' ' ' ILE . . . . . 0.421 ' H ' HG22 ' E' ' 32' ' ' ILE . 44.8 pt -152.11 -167.77 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 CA-C-N 119.761 1.164 . . . . 0.0 109.871 -179.026 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.71 5.76 9.9 Favored Glycine 0 CA--C 1.524 0.641 0 N-CA-C 110.935 -0.866 . . . . 0.0 110.935 179.845 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 1.4 tt -78.7 125.75 29.79 Favored 'General case' 0 CA--C 1.544 0.728 0 N-CA-C 109.555 -0.535 . . . . 0.0 109.555 -179.565 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 27.4 ttt -162.56 145.94 11.37 Favored 'General case' 0 N--CA 1.47 0.572 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 178.323 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' H' H ' 36' ' ' VAL . . . . . 0.444 HG12 HG22 ' E' ' 36' ' ' VAL . 33.2 m -157.35 162.18 1.6 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 N-CA-C 108.874 -0.788 . . . . 0.0 108.874 -179.935 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.25 67.06 2.4 Favored Glycine 0 C--N 1.311 -0.819 0 CA-C-N 115.781 -0.645 . . . . 0.0 112.149 178.286 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 146.42 175.76 19.69 Favored Glycine 0 N--CA 1.479 1.547 0 N-CA-C 110.577 -1.009 . . . . 0.0 110.577 178.892 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' H' H ' 39' ' ' VAL . . . . . 0.611 HG12 ' H ' ' E' ' 39' ' ' VAL . 34.6 m -125.97 159.85 33.75 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.82 0 C-N-CA 123.161 0.585 . . . . 0.0 110.708 -179.499 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 26.7 t . . . . . 0 C--O 1.219 -0.547 0 CA-C-O 118.346 -0.835 . . . . 0.0 110.79 179.263 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 39.7 m-85 . . . . . 0 N--CA 1.475 0.78 0 N-CA-C 109.473 -0.566 . . . . 0.0 109.473 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' I' I ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -143.72 140.28 29.91 Favored 'General case' 0 N--CA 1.482 1.167 0 C-N-CA 122.602 0.361 . . . . 0.0 110.15 179.894 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 43.1 t-80 -151.72 120.28 6.47 Favored 'General case' 0 N--CA 1.474 0.732 0 N-CA-C 109.358 -0.608 . . . . 0.0 109.358 179.04 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -71.23 143.87 50.27 Favored 'General case' 0 N--CA 1.469 0.503 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.234 -179.881 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' I' I ' 8' ' ' SER . . . . . 0.463 ' OG ' ' O ' ' F' ' 7' ' ' ASP . 53.3 p -164.87 -171.4 2.25 Favored 'General case' 0 N--CA 1.474 0.752 0 CA-C-O 120.857 0.36 . . . . 0.0 110.582 178.668 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.08 48.04 1.28 Allowed Glycine 0 N--CA 1.48 1.619 0 N-CA-C 111.693 -0.563 . . . . 0.0 111.693 179.63 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 50.4 p90 -65.1 132.52 49.39 Favored 'General case' 0 N--CA 1.472 0.632 0 N-CA-C 111.934 0.346 . . . . 0.0 111.934 -179.737 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 48.3 mt-10 -91.81 152.24 20.22 Favored 'General case' 0 N--CA 1.478 0.937 0 CA-C-O 121.033 0.445 . . . . 0.0 110.18 178.511 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -155.28 127.58 1.03 Allowed 'Isoleucine or valine' 0 CA--C 1.551 0.999 0 N-CA-C 107.848 -1.167 . . . . 0.0 107.848 178.349 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 46.1 m-70 -134.48 145.08 48.48 Favored 'General case' 0 N--CA 1.477 0.887 0 CA-C-N 115.572 -0.74 . . . . 0.0 111.436 -178.387 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 29.6 t-80 -165.61 97.47 0.67 Allowed 'General case' 0 N--CA 1.481 1.105 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.362 178.961 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 3.9 pt20 -111.79 -174.83 2.55 Favored 'General case' 0 CA--C 1.502 -0.894 0 N-CA-C 108.399 -0.963 . . . . 0.0 108.399 -179.689 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -163.39 98.41 0.91 Allowed 'General case' 0 N--CA 1.474 0.762 0 CA-C-N 114.647 -1.16 . . . . 0.0 108.172 178.87 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 6.7 mp -120.53 155.4 33.71 Favored 'General case' 0 N--CA 1.496 1.854 0 CA-C-O 121.266 0.555 . . . . 0.0 111.773 -177.829 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 41.6 t -113.56 125.35 70.82 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.998 0 CA-C-N 114.824 -1.08 . . . . 0.0 108.194 176.568 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 33.6 m-85 -126.32 121.32 32.24 Favored 'General case' 0 C--N 1.368 1.393 0 CA-C-N 115.61 -0.723 . . . . 0.0 110.876 -179.491 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 69.4 m-85 54.16 72.94 0.42 Allowed 'General case' 0 C--O 1.237 0.441 0 CA-C-N 115.918 -0.583 . . . . 0.0 111.375 178.165 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.63 -78.08 0.14 Allowed 'General case' 0 N--CA 1.472 0.657 0 O-C-N 122.302 -0.249 . . . . 0.0 110.598 -179.116 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 40.7 tt0 -112.01 102.73 10.93 Favored 'General case' 0 C--N 1.323 -0.573 0 N-CA-C 108.156 -1.053 . . . . 0.0 108.156 179.948 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -157.95 136.19 10.94 Favored 'General case' 0 N--CA 1.478 0.956 0 O-C-N 122.375 -0.203 . . . . 0.0 111.329 178.858 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' I' I ' 24' ' ' VAL . . . . . 0.425 HG12 ' N ' ' I' ' 25' ' ' GLY . 58.5 t -58.5 166.92 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.559 0 N-CA-C 107.779 -1.193 . . . . 0.0 107.779 177.134 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' I' I ' 25' ' ' GLY . . . . . 0.425 ' N ' HG12 ' I' ' 24' ' ' VAL . . . -119.42 49.22 0.88 Allowed Glycine 0 N--CA 1.481 1.661 0 N-CA-C 110.592 -1.003 . . . . 0.0 110.592 -179.404 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -64.54 -168.2 0.03 OUTLIER 'General case' 0 N--CA 1.471 0.602 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 179.702 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 25.5 t-20 -71.71 76.89 0.84 Allowed 'General case' 0 CA--C 1.536 0.439 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.259 179.675 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -70.45 140.6 52.0 Favored 'General case' 0 N--CA 1.475 0.807 0 N-CA-C 109.63 -0.507 . . . . 0.0 109.63 179.472 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.72 -147.32 0.04 OUTLIER Glycine 0 C--N 1.337 0.621 0 N-CA-C 110.496 -1.041 . . . . 0.0 110.496 179.588 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -93.26 125.86 38.07 Favored 'General case' 0 N--CA 1.465 0.314 0 C-N-CA 122.696 0.399 . . . . 0.0 110.752 -179.737 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 73.7 mt -123.47 117.33 51.03 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.768 0 N-CA-C 106.556 -1.646 . . . . 0.0 106.556 178.111 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' I' I ' 32' ' ' ILE . . . . . 0.417 ' H ' HG22 ' F' ' 32' ' ' ILE . 44.9 pt -152.17 -167.82 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 CA-C-N 119.758 1.163 . . . . 0.0 109.869 -179.05 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.71 5.86 10.18 Favored Glycine 0 CA--C 1.526 0.738 0 N-CA-C 110.95 -0.86 . . . . 0.0 110.95 179.768 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 1.4 tt -78.89 125.56 29.53 Favored 'General case' 0 CA--C 1.546 0.79 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 -179.593 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 27.4 ttt -162.25 145.79 11.83 Favored 'General case' 0 N--CA 1.47 0.542 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 178.559 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' I' I ' 36' ' ' VAL . . . . . 0.455 HG12 HG22 ' F' ' 36' ' ' VAL . 33.3 m -157.28 162.03 1.65 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.47 0 N-CA-C 108.845 -0.798 . . . . 0.0 108.845 -179.89 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.29 66.87 2.53 Favored Glycine 0 C--N 1.311 -0.85 0 CA-C-N 115.799 -0.637 . . . . 0.0 112.228 178.173 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 146.58 175.82 19.87 Favored Glycine 0 N--CA 1.478 1.497 0 N-CA-C 110.603 -0.999 . . . . 0.0 110.603 178.939 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' I' I ' 39' ' ' VAL . . . . . 0.603 HG12 ' H ' ' F' ' 39' ' ' VAL . 34.5 m -125.92 159.9 33.55 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.866 0 C-N-CA 123.131 0.572 . . . . 0.0 110.755 -179.488 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 29.8 t . . . . . 0 C--O 1.219 -0.513 0 CA-C-O 118.394 -0.812 . . . . 0.0 110.777 179.103 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 78.8 m-85 . . . . . 0 N--CA 1.474 0.766 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 72.4 mtp180 -143.58 142.05 30.92 Favored 'General case' 0 N--CA 1.482 1.164 0 N-CA-C 109.134 -0.691 . . . . 0.0 109.134 -179.883 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 76.6 m80 -149.83 119.74 7.13 Favored 'General case' 0 N--CA 1.47 0.528 0 N-CA-C 108.759 -0.83 . . . . 0.0 108.759 179.102 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 8.5 m-20 -68.32 149.89 48.87 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.189 -179.385 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 7.9 t -167.65 171.16 10.42 Favored 'General case' 0 N--CA 1.473 0.706 0 N-CA-C 109.628 -0.508 . . . . 0.0 109.628 178.456 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.2 24.7 2.17 Favored Glycine 0 N--CA 1.488 2.127 0 N-CA-C 112.114 -0.394 . . . . 0.0 112.114 179.367 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 43.4 p90 -56.26 128.06 33.87 Favored 'General case' 0 N--CA 1.473 0.696 0 N-CA-C 112.175 0.435 . . . . 0.0 112.175 -179.866 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 11' ' ' GLU . . . . . 0.51 ' CG ' HD21 ' C' ' 27' ' ' ASN . 45.8 mt-10 -84.72 154.24 22.56 Favored 'General case' 0 N--CA 1.469 0.5 0 N-CA-C 109.082 -0.71 . . . . 0.0 109.082 178.445 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -153.25 129.29 1.75 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.341 0 N-CA-C 108.327 -0.99 . . . . 0.0 108.327 178.926 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 49.5 m-70 -134.03 144.72 48.86 Favored 'General case' 0 N--CA 1.489 1.507 0 CA-C-N 118.711 0.687 . . . . 0.0 110.993 -179.156 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 6.3 t60 -164.75 98.8 0.78 Allowed 'General case' 0 N--CA 1.479 0.978 0 CA-C-N 116.642 -0.254 . . . . 0.0 111.194 179.686 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 46.0 mt-30 -108.79 -172.26 2.02 Favored 'General case' 0 CA--C 1.502 -0.873 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 179.804 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -166.97 97.67 0.53 Allowed 'General case' 0 N--CA 1.473 0.689 0 CA-C-N 115.201 -0.909 . . . . 0.0 109.486 178.644 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.596 ' N ' HD12 ' A' ' 17' ' ' LEU . 4.5 mp -105.66 163.88 12.34 Favored 'General case' 0 N--CA 1.487 1.409 0 N-CA-C 108.543 -0.91 . . . . 0.0 108.543 179.901 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 48.9 t -142.15 118.92 6.79 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.354 0 CA-C-O 118.796 -0.621 . . . . 0.0 110.02 179.452 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 51.6 m-85 -69.98 159.24 34.13 Favored 'General case' 0 N--CA 1.48 1.055 0 N-CA-C 107.592 -1.262 . . . . 0.0 107.592 177.203 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 13.6 t80 -171.15 -58.52 0.02 OUTLIER 'General case' 0 N--CA 1.485 1.3 0 CA-C-O 122.365 1.079 . . . . 0.0 109.712 179.662 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -38.81 90.0 0.0 OUTLIER 'General case' 0 C--O 1.232 0.17 0 CA-C-N 113.782 -1.554 . . . . 0.0 112.938 -177.952 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 38.1 tt0 -66.16 157.65 30.75 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 115.05 -0.977 . . . . 0.0 110.565 179.118 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 66.8 m-20 -139.55 136.78 34.83 Favored 'General case' 0 N--CA 1.481 1.1 0 C-N-CA 123.008 0.523 . . . . 0.0 110.281 179.862 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 18.4 t -84.65 -116.46 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.982 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 179.469 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -109.15 54.81 0.53 Allowed Glycine 0 N--CA 1.474 1.211 0 N-CA-C 111.126 -0.79 . . . . 0.0 111.126 179.909 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 71.1 p -80.07 126.01 30.52 Favored 'General case' 0 C--N 1.328 -0.333 0 N-CA-C 108.799 -0.815 . . . . 0.0 108.799 178.184 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 27' ' ' ASN . . . . . 0.524 HD21 ' CG ' ' B' ' 11' ' ' GLU . 47.3 t30 -65.93 100.26 0.56 Allowed 'General case' 0 N--CA 1.473 0.719 0 N-CA-C 108.8 -0.815 . . . . 0.0 108.8 178.702 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 66.7 mttm -95.46 117.2 29.95 Favored 'General case' 0 N--CA 1.484 1.229 0 N-CA-C 110.01 -0.367 . . . . 0.0 110.01 -179.067 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.13 -133.55 0.01 OUTLIER Glycine 0 CA--C 1.532 1.12 0 N-CA-C 110.726 -0.95 . . . . 0.0 110.726 178.943 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -113.4 127.81 56.25 Favored 'General case' 0 N--CA 1.478 0.939 0 N-CA-C 109.29 -0.633 . . . . 0.0 109.29 178.934 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 66.7 mt -90.73 130.19 40.34 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.683 0 N-CA-C 107.606 -1.257 . . . . 0.0 107.606 178.715 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 18.1 mt -142.33 152.38 18.13 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.929 0 N-CA-C 109.838 -0.431 . . . . 0.0 109.838 -178.83 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 65.37 48.27 70.83 Favored Glycine 0 CA--C 1.524 0.63 0 CA-C-N 116.062 -0.517 . . . . 0.0 112.531 178.804 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.401 HD23 ' N ' ' A' ' 35' ' ' MET . 2.9 tt -98.88 120.39 39.24 Favored 'General case' 0 N--CA 1.478 0.934 0 N-CA-C 107.245 -1.391 . . . . 0.0 107.245 177.903 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 35' ' ' MET . . . . . 0.401 ' N ' HD23 ' A' ' 34' ' ' LEU . 28.1 ttt -152.71 158.26 42.09 Favored 'General case' 0 N--CA 1.471 0.579 0 N-CA-C 108.909 -0.774 . . . . 0.0 108.909 179.463 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.432 HG12 HE22 ' D' ' 15' ' ' GLN . 86.1 t -158.29 149.86 8.23 Favored 'Isoleucine or valine' 0 C--O 1.236 0.351 0 N-CA-C 107.012 -1.477 . . . . 0.0 107.012 -179.204 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.66 74.92 0.28 Allowed Glycine 0 C--N 1.313 -0.741 0 CA-C-N 115.622 -0.717 . . . . 0.0 111.658 178.181 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 170.96 -148.92 11.7 Favored Glycine 0 CA--C 1.519 0.299 0 N-CA-C 110.656 -0.978 . . . . 0.0 110.656 179.786 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 33.5 m -133.93 142.64 40.72 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.794 0 N-CA-C 109.688 -0.486 . . . . 0.0 109.688 179.744 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 16.3 t . . . . . 0 CA--C 1.535 0.392 0 CA-C-O 117.969 -1.015 . . . . 0.0 111.058 179.331 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 78.8 m-85 . . . . . 0 N--CA 1.474 0.729 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 71.9 mtp180 -144.09 141.82 30.26 Favored 'General case' 0 N--CA 1.481 1.11 0 N-CA-C 109.123 -0.695 . . . . 0.0 109.123 -179.815 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 76.7 m80 -149.7 119.64 7.15 Favored 'General case' 0 N--CA 1.471 0.611 0 N-CA-C 108.826 -0.805 . . . . 0.0 108.826 179.117 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 7' ' ' ASP . . . . . . . . . . . . . 8.6 m-20 -68.14 149.56 49.44 Favored 'General case' 0 CA--C 1.531 0.215 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.238 -179.439 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 8' ' ' SER . . . . . . . . . . . . . 8.1 t -167.36 171.87 10.21 Favored 'General case' 0 N--CA 1.473 0.685 0 N-CA-C 109.668 -0.493 . . . . 0.0 109.668 178.368 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 121.53 24.69 2.32 Favored Glycine 0 N--CA 1.488 2.135 0 N-CA-C 112.102 -0.399 . . . . 0.0 112.102 179.323 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 42.9 p90 -56.15 127.7 31.94 Favored 'General case' 0 N--CA 1.472 0.653 0 N-CA-C 112.236 0.458 . . . . 0.0 112.236 -179.87 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 11' ' ' GLU . . . . . 0.524 ' CG ' HD21 ' A' ' 27' ' ' ASN . 45.6 mt-10 -84.38 154.07 23.07 Favored 'General case' 0 N--CA 1.469 0.515 0 N-CA-C 109.223 -0.658 . . . . 0.0 109.223 178.442 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -153.17 129.65 1.9 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.328 0 N-CA-C 108.301 -1.0 . . . . 0.0 108.301 178.956 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 49.1 m-70 -134.34 145.34 48.92 Favored 'General case' 0 N--CA 1.49 1.552 0 CA-C-N 118.531 0.605 . . . . 0.0 110.975 -179.204 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 6.4 t60 -165.23 98.59 0.72 Allowed 'General case' 0 N--CA 1.482 1.125 0 CA-C-N 116.563 -0.29 . . . . 0.0 111.195 179.658 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 45.6 mt-30 -108.57 -172.81 2.13 Favored 'General case' 0 CA--C 1.502 -0.894 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 179.815 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -166.64 97.59 0.56 Allowed 'General case' 0 N--CA 1.472 0.63 0 CA-C-N 115.121 -0.945 . . . . 0.0 109.369 178.821 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 17' ' ' LEU . . . . . 0.596 ' N ' HD12 ' B' ' 17' ' ' LEU . 4.5 mp -105.87 163.88 12.38 Favored 'General case' 0 N--CA 1.487 1.394 0 N-CA-C 108.542 -0.91 . . . . 0.0 108.542 179.881 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 50.5 t -142.27 118.88 6.51 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.3 0 CA-C-O 118.959 -0.543 . . . . 0.0 109.96 179.58 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 53.0 m-85 -70.67 159.22 34.84 Favored 'General case' 0 N--CA 1.478 0.939 0 N-CA-C 107.53 -1.285 . . . . 0.0 107.53 177.248 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 14.9 t80 -171.83 -57.27 0.02 OUTLIER 'General case' 0 N--CA 1.482 1.168 0 CA-C-O 122.151 0.977 . . . . 0.0 109.769 179.631 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -39.1 90.38 0.0 OUTLIER 'General case' 0 CA--C 1.528 0.125 0 CA-C-N 114.125 -1.398 . . . . 0.0 112.768 -178.091 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 38.2 tt0 -66.45 157.45 31.99 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 115.089 -0.96 . . . . 0.0 110.52 179.19 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 67.4 m-20 -139.38 137.24 35.54 Favored 'General case' 0 N--CA 1.479 0.984 0 C-N-CA 123.083 0.553 . . . . 0.0 110.213 179.772 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 18.3 t -85.44 -116.71 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.048 0 N-CA-C 108.562 -0.903 . . . . 0.0 108.562 179.535 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -108.2 54.36 0.56 Allowed Glycine 0 N--CA 1.476 1.353 0 N-CA-C 111.049 -0.82 . . . . 0.0 111.049 179.929 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 71.8 p -80.13 125.55 29.96 Favored 'General case' 0 C--N 1.328 -0.351 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 178.242 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 27' ' ' ASN . . . . . 0.593 HD21 ' HB3' ' E' ' 27' ' ' ASN . 4.0 t-20 -65.69 100.4 0.53 Allowed 'General case' 0 N--CA 1.475 0.782 0 N-CA-C 108.812 -0.81 . . . . 0.0 108.812 178.649 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 66.6 mttm -95.58 117.0 29.64 Favored 'General case' 0 N--CA 1.485 1.298 0 N-CA-C 110.041 -0.355 . . . . 0.0 110.041 -179.179 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.85 -133.26 0.01 OUTLIER Glycine 0 CA--C 1.533 1.207 0 N-CA-C 110.723 -0.951 . . . . 0.0 110.723 178.927 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -113.88 127.9 56.18 Favored 'General case' 0 N--CA 1.479 0.981 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 179.031 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 66.6 mt -90.77 130.26 40.26 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.655 0 N-CA-C 107.532 -1.285 . . . . 0.0 107.532 178.692 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 17.8 mt -142.42 152.36 17.99 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.918 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 -178.852 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 65.52 47.55 77.02 Favored Glycine 0 CA--C 1.524 0.638 0 CA-C-N 116.085 -0.507 . . . . 0.0 112.667 178.793 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 2.9 tt -98.07 120.51 38.6 Favored 'General case' 0 N--CA 1.478 0.936 0 N-CA-C 107.25 -1.389 . . . . 0.0 107.25 177.85 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 28.0 ttt -152.81 157.97 41.55 Favored 'General case' 0 N--CA 1.472 0.627 0 N-CA-C 108.849 -0.797 . . . . 0.0 108.849 179.376 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 36' ' ' VAL . . . . . 0.416 HG12 HE22 ' E' ' 15' ' ' GLN . 82.1 t -158.15 149.77 8.47 Favored 'Isoleucine or valine' 0 C--O 1.235 0.306 0 N-CA-C 106.807 -1.553 . . . . 0.0 106.807 -179.147 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.67 75.28 0.26 Allowed Glycine 0 C--N 1.314 -0.689 0 CA-C-N 115.573 -0.74 . . . . 0.0 111.651 178.14 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 170.47 -149.07 12.14 Favored Glycine 0 CA--C 1.518 0.265 0 N-CA-C 110.698 -0.961 . . . . 0.0 110.698 179.772 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 33.8 m -133.59 142.76 40.73 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.842 0 N-CA-C 109.691 -0.485 . . . . 0.0 109.691 179.659 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 16.1 t . . . . . 0 C--O 1.222 -0.353 0 CA-C-O 117.993 -1.003 . . . . 0.0 111.111 179.319 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 79.0 m-85 . . . . . 0 N--CA 1.475 0.784 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 72.4 mtp180 -144.11 141.48 30.03 Favored 'General case' 0 N--CA 1.482 1.157 0 N-CA-C 109.071 -0.714 . . . . 0.0 109.071 -179.834 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 76.8 m80 -149.41 119.67 7.3 Favored 'General case' 0 N--CA 1.471 0.597 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 179.089 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 7' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -68.05 149.5 49.6 Favored 'General case' 0 CA--C 1.53 0.197 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.281 -179.419 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 8' ' ' SER . . . . . . . . . . . . . 8.0 t -167.27 171.5 10.68 Favored 'General case' 0 N--CA 1.473 0.719 0 N-CA-C 109.564 -0.532 . . . . 0.0 109.564 178.419 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 121.79 24.79 2.24 Favored Glycine 0 N--CA 1.488 2.111 0 N-CA-C 112.105 -0.398 . . . . 0.0 112.105 179.304 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 42.4 p90 -56.41 128.28 35.19 Favored 'General case' 0 N--CA 1.472 0.669 0 N-CA-C 112.114 0.412 . . . . 0.0 112.114 -179.803 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 45.7 mt-10 -84.79 154.41 22.39 Favored 'General case' 0 N--CA 1.468 0.473 0 N-CA-C 109.113 -0.699 . . . . 0.0 109.113 178.504 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -153.54 129.36 1.71 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 N-CA-C 108.409 -0.96 . . . . 0.0 108.409 178.968 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 48.9 m-70 -134.22 144.97 48.74 Favored 'General case' 0 N--CA 1.489 1.518 0 CA-C-N 118.588 0.631 . . . . 0.0 110.968 -179.029 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 6.3 t60 -165.04 98.55 0.74 Allowed 'General case' 0 N--CA 1.481 1.099 0 CA-C-N 116.57 -0.286 . . . . 0.0 111.201 179.791 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 45.5 mt-30 -108.6 -172.05 1.98 Allowed 'General case' 0 CA--C 1.5 -0.954 0 N-CA-C 108.251 -1.018 . . . . 0.0 108.251 179.765 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -167.25 97.58 0.5 Allowed 'General case' 0 CA--C 1.54 0.58 0 CA-C-N 115.179 -0.918 . . . . 0.0 109.381 178.751 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 17' ' ' LEU . . . . . 0.599 ' N ' HD12 ' C' ' 17' ' ' LEU . 4.4 mp -105.66 163.64 12.53 Favored 'General case' 0 N--CA 1.487 1.392 0 N-CA-C 108.563 -0.903 . . . . 0.0 108.563 179.838 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 51.0 t -142.0 118.75 6.95 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.343 0 CA-C-O 119.032 -0.509 . . . . 0.0 109.959 179.495 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 52.6 m-85 -70.33 159.24 34.48 Favored 'General case' 0 N--CA 1.478 0.964 0 N-CA-C 107.502 -1.296 . . . . 0.0 107.502 177.247 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 14.8 t80 -171.82 -57.35 0.02 OUTLIER 'General case' 0 N--CA 1.482 1.153 0 CA-C-O 122.196 0.998 . . . . 0.0 109.777 179.49 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -39.21 90.75 0.0 OUTLIER 'General case' 0 CA--C 1.529 0.15 0 CA-C-N 114.193 -1.367 . . . . 0.0 112.785 -178.053 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 37.7 tt0 -66.77 157.4 32.95 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.063 -0.971 . . . . 0.0 110.539 179.247 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 66.8 m-20 -139.22 137.03 35.62 Favored 'General case' 0 N--CA 1.478 0.937 0 C-N-CA 123.138 0.575 . . . . 0.0 110.297 179.836 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 17.9 t -85.39 -116.67 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.064 0 N-CA-C 108.519 -0.919 . . . . 0.0 108.519 179.558 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -108.16 54.61 0.55 Allowed Glycine 0 N--CA 1.474 1.228 0 N-CA-C 111.1 -0.8 . . . . 0.0 111.1 179.96 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 73.2 p -80.42 125.47 29.96 Favored 'General case' 0 N--CA 1.466 0.336 0 N-CA-C 108.841 -0.8 . . . . 0.0 108.841 178.329 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 27' ' ' ASN . . . . . 0.51 HD21 ' CG ' ' A' ' 11' ' ' GLU . 48.3 t30 -65.64 100.55 0.53 Allowed 'General case' 0 N--CA 1.474 0.757 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 178.684 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 66.8 mttm -95.8 116.86 29.52 Favored 'General case' 0 N--CA 1.485 1.324 0 N-CA-C 109.977 -0.379 . . . . 0.0 109.977 -179.055 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.73 -133.32 0.01 OUTLIER Glycine 0 CA--C 1.534 1.248 0 N-CA-C 110.761 -0.936 . . . . 0.0 110.761 178.954 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -113.73 127.65 56.11 Favored 'General case' 0 N--CA 1.479 1.016 0 N-CA-C 109.231 -0.655 . . . . 0.0 109.231 178.981 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 66.7 mt -90.66 130.15 40.34 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.644 0 N-CA-C 107.492 -1.299 . . . . 0.0 107.492 178.746 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 17.8 mt -142.59 152.49 17.71 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.909 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -178.864 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 65.52 47.44 78.07 Favored Glycine 0 CA--C 1.524 0.604 0 CA-C-N 116.0 -0.545 . . . . 0.0 112.666 178.877 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 2.9 tt -98.16 120.38 38.46 Favored 'General case' 0 N--CA 1.477 0.92 0 N-CA-C 107.231 -1.396 . . . . 0.0 107.231 177.864 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 28.1 ttt -152.48 158.16 42.19 Favored 'General case' 0 N--CA 1.471 0.577 0 N-CA-C 108.834 -0.802 . . . . 0.0 108.834 179.401 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 36' ' ' VAL . . . . . 0.439 HG12 HE22 ' F' ' 15' ' ' GLN . 87.3 t -158.3 149.8 8.24 Favored 'Isoleucine or valine' 0 C--O 1.236 0.393 0 N-CA-C 106.856 -1.535 . . . . 0.0 106.856 -179.205 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.66 75.08 0.27 Allowed Glycine 0 C--N 1.313 -0.71 0 CA-C-N 115.608 -0.724 . . . . 0.0 111.675 178.101 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 170.55 -149.11 12.17 Favored Glycine 0 CA--C 1.519 0.336 0 N-CA-C 110.593 -1.003 . . . . 0.0 110.593 179.801 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 33.7 m -133.71 142.81 40.49 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.835 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 179.728 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 16.2 t . . . . . 0 CA--C 1.535 0.39 0 CA-C-O 117.888 -1.053 . . . . 0.0 110.983 179.34 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 86.9 m-85 . . . . . 0 N--CA 1.473 0.698 0 N-CA-C 108.261 -1.014 . . . . 0.0 108.261 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' D' D ' 5' ' ' ARG . . . . . . . . . . . . . 72.0 mtp180 -147.32 141.52 26.16 Favored 'General case' 0 N--CA 1.475 0.821 0 N-CA-C 109.13 -0.692 . . . . 0.0 109.13 179.888 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 76.9 m80 -149.14 123.68 9.74 Favored 'General case' 0 C--O 1.219 -0.541 0 N-CA-C 107.758 -1.201 . . . . 0.0 107.758 175.638 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' D' D ' 7' ' ' ASP . . . . . . . . . . . . . 6.1 m-20 -63.45 133.26 53.64 Favored 'General case' 0 C--N 1.322 -0.613 0 C-N-CA 127.036 2.134 . . . . 0.0 114.832 176.15 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' D' D ' 8' ' ' SER . . . . . . . . . . . . . 7.0 t -154.2 173.62 15.87 Favored 'General case' 0 N--CA 1.478 0.961 0 CA-C-N 118.609 0.64 . . . . 0.0 110.406 176.996 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 124.15 20.83 2.41 Favored Glycine 0 N--CA 1.484 1.842 0 N-CA-C 112.159 -0.377 . . . . 0.0 112.159 176.398 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 37.7 p90 -55.56 130.5 43.17 Favored 'General case' 0 CA--C 1.546 0.79 0 CA-C-O 121.176 0.513 . . . . 0.0 111.842 -176.771 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' D' D ' 11' ' ' GLU . . . . . 0.446 ' CG ' HD21 ' F' ' 27' ' ' ASN . 46.0 mt-10 -84.89 152.35 23.62 Favored 'General case' 0 N--CA 1.473 0.698 0 N-CA-C 109.703 -0.48 . . . . 0.0 109.703 177.663 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -149.56 130.13 4.42 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.426 0 N-CA-C 108.409 -0.96 . . . . 0.0 108.409 175.792 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 48.5 m-70 -129.53 148.34 51.42 Favored 'General case' 0 N--CA 1.483 1.184 0 CA-C-N 117.992 0.36 . . . . 0.0 111.116 176.84 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 6.5 t60 -165.02 104.85 0.78 Allowed 'General case' 0 N--CA 1.482 1.145 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 173.76 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' D' D ' 15' ' ' GLN . . . . . 0.432 HE22 HG12 ' A' ' 36' ' ' VAL . 44.9 mt-30 -111.78 -175.49 2.71 Favored 'General case' 0 CA--C 1.492 -1.255 0 N-CA-C 107.977 -1.12 . . . . 0.0 107.977 179.065 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' D' D ' 16' ' ' LYS . . . . . 0.437 ' C ' HD12 ' D' ' 17' ' ' LEU . 88.7 tttt -163.39 106.02 0.99 Allowed 'General case' 0 CA--C 1.536 0.433 0 N-CA-C 107.656 -1.239 . . . . 0.0 107.656 175.62 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' D' D ' 17' ' ' LEU . . . . . 0.539 ' N ' HD12 ' D' ' 17' ' ' LEU . 5.5 mp -112.42 162.73 15.25 Favored 'General case' 0 N--CA 1.488 1.447 0 N-CA-C 107.887 -1.153 . . . . 0.0 107.887 179.655 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 47.3 t -141.0 123.81 15.59 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.192 0 N-CA-C 109.053 -0.721 . . . . 0.0 109.053 175.834 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 78.3 m-85 -62.91 151.46 39.29 Favored 'General case' 0 C--N 1.352 0.685 0 C-N-CA 124.74 1.216 . . . . 0.0 110.396 170.501 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 9.8 t80 -170.1 -66.8 0.02 OUTLIER 'General case' 0 N--CA 1.477 0.903 0 N-CA-C 107.666 -1.235 . . . . 0.0 107.666 -179.629 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -37.91 95.66 0.01 OUTLIER 'General case' 0 CA--C 1.536 0.428 0 CA-C-N 114.019 -1.446 . . . . 0.0 111.663 -174.583 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 38.1 tt0 -68.35 158.19 34.07 Favored 'General case' 0 N--CA 1.467 0.388 0 CA-C-N 113.435 -1.711 . . . . 0.0 110.376 178.493 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 67.6 m-20 -139.54 140.65 37.19 Favored 'General case' 0 N--CA 1.476 0.834 0 N-CA-C 109.403 -0.592 . . . . 0.0 109.403 178.558 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' D' D ' 24' ' ' VAL . . . . . . . . . . . . . 19.5 t -88.28 -119.97 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.486 1.347 0 N-CA-C 107.779 -1.193 . . . . 0.0 107.779 179.699 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . -111.72 61.91 0.3 Allowed Glycine 0 C--N 1.371 2.478 0 C-N-CA 118.075 -2.012 . . . . 0.0 109.317 178.824 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 89.0 p -70.57 121.35 17.69 Favored 'General case' 0 C--O 1.243 0.713 0 CA-C-O 116.555 -1.688 . . . . 0.0 111.775 169.24 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' D' D ' 27' ' ' ASN . . . . . 0.44 HD21 ' CG ' ' E' ' 11' ' ' GLU . 54.6 t30 -61.2 101.8 0.18 Allowed 'General case' 0 N--CA 1.476 0.864 0 CA-C-N 121.558 1.981 . . . . 0.0 109.501 172.957 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 66.2 mttm -99.14 119.28 37.59 Favored 'General case' 0 N--CA 1.491 1.621 0 CA-C-N 119.427 1.012 . . . . 0.0 109.127 179.217 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -55.07 -134.39 0.0 OUTLIER Glycine 0 C--N 1.343 0.931 0 CA-C-N 115.607 -0.724 . . . . 0.0 113.379 175.931 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -113.19 132.65 55.41 Favored 'General case' 0 C--N 1.372 1.565 0 N-CA-C 108.591 -0.892 . . . . 0.0 108.591 174.145 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 68.2 mt -91.88 134.34 30.51 Favored 'Isoleucine or valine' 0 C--N 1.347 0.488 0 N-CA-C 106.929 -1.508 . . . . 0.0 106.929 176.459 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 20.0 mt -144.78 155.02 14.34 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.965 0 N-CA-C 109.2 -0.667 . . . . 0.0 109.2 179.137 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 64.11 46.86 90.03 Favored Glycine 0 C--O 1.245 0.841 0 CA-C-O 119.354 -0.692 . . . . 0.0 112.57 179.059 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 3.5 tt -97.7 132.27 43.49 Favored 'General case' 0 C--N 1.372 1.585 0 N-CA-C 104.569 -2.382 . . . . 0.0 104.569 176.408 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 28.3 ttt -155.9 165.23 37.1 Favored 'General case' 0 N--CA 1.474 0.752 0 N-CA-C 107.783 -1.192 . . . . 0.0 107.783 175.819 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' D' D ' 36' ' ' VAL . . . . . 0.41 HG12 HE22 ' G' ' 15' ' ' GLN . 96.3 t -164.1 154.69 2.26 Favored 'Isoleucine or valine' 0 C--O 1.247 0.973 0 N-CA-C 105.564 -2.013 . . . . 0.0 105.564 176.382 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 61.13 66.67 2.52 Favored Glycine 0 N--CA 1.445 -0.731 0 C-N-CA 117.446 -2.312 . . . . 0.0 113.974 176.577 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 167.64 -147.91 12.28 Favored Glycine 0 N--CA 1.466 0.644 0 CA-C-O 117.701 -1.61 . . . . 0.0 112.176 -179.117 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 33.7 m -130.4 142.69 43.07 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.088 0 CA-C-N 119.352 1.576 . . . . 0.0 109.886 -179.065 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 13.6 t . . . . . 0 C--O 1.212 -0.87 0 N-CA-C 109.54 -0.541 . . . . 0.0 109.54 174.466 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 79.4 m-85 . . . . . 0 N--CA 1.474 0.771 0 N-CA-C 109.907 -0.405 . . . . 0.0 109.907 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' E' E ' 5' ' ' ARG . . . . . . . . . . . . . 72.5 mtp180 -143.92 142.52 30.81 Favored 'General case' 0 N--CA 1.476 0.842 0 N-CA-C 109.541 -0.54 . . . . 0.0 109.541 179.858 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 76.5 m80 -150.3 118.27 6.28 Favored 'General case' 0 N--CA 1.473 0.686 0 N-CA-C 108.929 -0.767 . . . . 0.0 108.929 179.169 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' E' E ' 7' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -66.69 149.86 49.9 Favored 'General case' 0 N--CA 1.464 0.236 0 O-C-N 123.541 0.526 . . . . 0.0 111.538 -179.5 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' E' E ' 8' ' ' SER . . . . . . . . . . . . . 7.1 t -167.92 172.4 9.01 Favored 'General case' 0 N--CA 1.476 0.839 0 N-CA-C 109.573 -0.528 . . . . 0.0 109.573 177.901 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.7 24.34 2.13 Favored Glycine 0 N--CA 1.482 1.731 0 N-CA-C 111.922 -0.471 . . . . 0.0 111.922 179.071 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 39.1 p90 -55.66 127.28 29.18 Favored 'General case' 0 N--CA 1.474 0.733 0 N-CA-C 112.627 0.602 . . . . 0.0 112.627 -179.091 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' E' E ' 11' ' ' GLU . . . . . 0.44 ' CG ' HD21 ' D' ' 27' ' ' ASN . 46.4 mt-10 -83.32 155.08 23.76 Favored 'General case' 0 N--CA 1.474 0.76 0 N-CA-C 109.388 -0.597 . . . . 0.0 109.388 177.938 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -155.18 128.77 1.22 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.494 0 N-CA-C 108.386 -0.968 . . . . 0.0 108.386 178.811 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 46.3 m-70 -134.77 143.21 46.99 Favored 'General case' 0 N--CA 1.481 1.095 0 O-C-N 122.324 -0.235 . . . . 0.0 111.225 -177.99 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 6.2 t60 -163.99 98.39 0.85 Allowed 'General case' 0 N--CA 1.486 1.352 0 CA-C-N 116.765 -0.198 . . . . 0.0 111.147 179.814 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' E' E ' 15' ' ' GLN . . . . . 0.416 HE22 HG12 ' B' ' 36' ' ' VAL . 44.5 mt-30 -107.82 -172.34 2.05 Favored 'General case' 0 CA--C 1.502 -0.9 0 N-CA-C 108.394 -0.965 . . . . 0.0 108.394 179.89 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -166.99 97.73 0.53 Allowed 'General case' 0 CA--C 1.543 0.686 0 CA-C-N 115.056 -0.975 . . . . 0.0 109.414 178.675 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' E' E ' 17' ' ' LEU . . . . . 0.583 ' N ' HD12 ' E' ' 17' ' ' LEU . 4.6 mp -105.69 163.32 12.79 Favored 'General case' 0 N--CA 1.49 1.558 0 N-CA-C 109.084 -0.709 . . . . 0.0 109.084 -179.796 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 39.0 t -142.32 118.39 6.0 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.38 0 C-N-CA 122.512 0.325 . . . . 0.0 110.52 179.078 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 51.0 m-85 -69.76 156.87 38.36 Favored 'General case' 0 C--N 1.358 0.964 0 N-CA-C 107.269 -1.382 . . . . 0.0 107.269 176.585 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 13.3 t80 -173.47 -54.96 0.02 OUTLIER 'General case' 0 N--CA 1.485 1.304 0 CA-C-O 121.606 0.717 . . . . 0.0 110.347 179.545 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.1 88.72 0.0 OUTLIER 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 114.396 -1.274 . . . . 0.0 112.843 -178.994 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 37.8 tt0 -64.62 157.88 25.88 Favored 'General case' 0 N--CA 1.471 0.581 0 CA-C-N 114.86 -1.064 . . . . 0.0 110.719 179.701 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 66.3 m-20 -139.97 136.68 34.03 Favored 'General case' 0 N--CA 1.477 0.883 0 C-N-CA 122.948 0.499 . . . . 0.0 110.399 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 21.8 t -85.23 -115.58 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.109 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 179.523 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . -108.97 54.66 0.54 Allowed Glycine 0 C--N 1.348 1.245 0 N-CA-C 111.237 -0.745 . . . . 0.0 111.237 -179.87 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 69.2 p -79.96 125.02 29.22 Favored 'General case' 0 N--CA 1.473 0.723 0 N-CA-C 109.111 -0.7 . . . . 0.0 109.111 177.947 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' E' E ' 27' ' ' ASN . . . . . 0.615 HD21 ' HB3' ' H' ' 27' ' ' ASN . 4.4 t-20 -65.37 100.04 0.45 Allowed 'General case' 0 N--CA 1.474 0.747 0 N-CA-C 108.236 -1.024 . . . . 0.0 108.236 178.552 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 66.2 mttm -95.69 116.74 29.3 Favored 'General case' 0 N--CA 1.486 1.351 0 N-CA-C 109.975 -0.38 . . . . 0.0 109.975 -178.708 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.02 -132.82 0.01 OUTLIER Glycine 0 CA--C 1.534 1.271 0 N-CA-C 111.38 -0.688 . . . . 0.0 111.38 178.858 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -114.02 127.09 55.79 Favored 'General case' 0 N--CA 1.477 0.896 0 N-CA-C 109.394 -0.595 . . . . 0.0 109.394 179.187 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 67.2 mt -90.38 131.19 38.21 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.233 0 N-CA-C 107.132 -1.432 . . . . 0.0 107.132 178.688 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 19.5 mt -142.4 154.44 18.3 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.907 0 N-CA-C 109.125 -0.694 . . . . 0.0 109.125 -179.341 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.39 48.86 74.96 Favored Glycine 0 CA--C 1.523 0.537 0 C-N-CA 121.702 -0.285 . . . . 0.0 113.291 178.944 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 3.0 tt -99.3 120.19 39.16 Favored 'General case' 0 N--CA 1.477 0.907 0 N-CA-C 107.143 -1.429 . . . . 0.0 107.143 177.617 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 28.5 ttt -151.68 159.55 43.96 Favored 'General case' 0 N--CA 1.479 1.019 0 N-CA-C 108.552 -0.907 . . . . 0.0 108.552 179.314 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' E' E ' 36' ' ' VAL . . . . . 0.416 HG12 HE22 ' H' ' 15' ' ' GLN . 96.9 t -159.64 149.85 6.59 Favored 'Isoleucine or valine' 0 C--O 1.236 0.384 0 N-CA-C 106.834 -1.543 . . . . 0.0 106.834 -179.504 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.71 74.53 0.32 Allowed Glycine 0 C--N 1.312 -0.751 0 CA-C-N 115.659 -0.701 . . . . 0.0 111.452 178.01 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 171.81 -147.24 9.96 Favored Glycine 0 C--O 1.223 -0.569 0 N-CA-C 111.08 -0.808 . . . . 0.0 111.08 179.67 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 33.2 m -135.28 141.85 41.46 Favored 'Isoleucine or valine' 0 C--N 1.353 0.731 0 N-CA-C 109.248 -0.649 . . . . 0.0 109.248 179.695 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 14.5 t . . . . . 0 CA--C 1.537 0.479 0 CA-C-O 117.916 -1.04 . . . . 0.0 111.24 179.383 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 78.8 m-85 . . . . . 0 N--CA 1.475 0.796 0 N-CA-C 109.981 -0.377 . . . . 0.0 109.981 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' F' F ' 5' ' ' ARG . . . . . . . . . . . . . 72.2 mtp180 -143.88 142.36 30.77 Favored 'General case' 0 N--CA 1.477 0.911 0 N-CA-C 109.283 -0.636 . . . . 0.0 109.283 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 76.7 m80 -150.24 118.11 6.25 Favored 'General case' 0 N--CA 1.474 0.726 0 N-CA-C 108.936 -0.765 . . . . 0.0 108.936 179.045 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' F' F ' 7' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -66.72 149.94 49.8 Favored 'General case' 0 N--CA 1.464 0.252 0 O-C-N 123.386 0.428 . . . . 0.0 111.595 -179.424 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' F' F ' 8' ' ' SER . . . . . . . . . . . . . 7.2 t -167.96 172.51 8.86 Favored 'General case' 0 N--CA 1.475 0.815 0 CA-C-N 115.944 -0.571 . . . . 0.0 109.574 177.978 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.47 24.7 2.11 Favored Glycine 0 N--CA 1.483 1.776 0 N-CA-C 111.892 -0.483 . . . . 0.0 111.892 178.986 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 38.6 p90 -56.09 127.52 30.97 Favored 'General case' 0 N--CA 1.474 0.733 0 N-CA-C 112.637 0.606 . . . . 0.0 112.637 -179.061 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 46.0 mt-10 -83.25 155.03 23.86 Favored 'General case' 0 N--CA 1.474 0.746 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 177.897 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -155.13 128.61 1.2 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.503 0 N-CA-C 108.43 -0.952 . . . . 0.0 108.43 178.775 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 46.9 m-70 -134.7 143.11 47.02 Favored 'General case' 0 N--CA 1.48 1.051 0 O-C-N 122.275 -0.265 . . . . 0.0 111.194 -177.998 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 6.2 t60 -164.11 98.63 0.84 Allowed 'General case' 0 N--CA 1.486 1.342 0 CA-C-N 116.734 -0.212 . . . . 0.0 111.258 179.917 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' F' F ' 15' ' ' GLN . . . . . 0.439 HE22 HG12 ' C' ' 36' ' ' VAL . 44.3 mt-30 -108.36 -171.42 1.86 Allowed 'General case' 0 CA--C 1.499 -1.011 0 N-CA-C 108.544 -0.91 . . . . 0.0 108.544 179.885 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -167.53 98.01 0.49 Allowed 'General case' 0 CA--C 1.541 0.605 0 CA-C-N 114.933 -1.03 . . . . 0.0 109.484 178.667 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' F' F ' 17' ' ' LEU . . . . . 0.583 ' N ' HD12 ' F' ' 17' ' ' LEU . 4.5 mp -105.73 163.14 12.93 Favored 'General case' 0 N--CA 1.49 1.541 0 N-CA-C 109.151 -0.685 . . . . 0.0 109.151 -179.856 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 39.0 t -142.17 118.41 6.3 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.293 0 C-N-CA 122.573 0.349 . . . . 0.0 110.567 179.121 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 52.3 m-85 -69.78 156.7 38.63 Favored 'General case' 0 C--N 1.358 0.955 0 N-CA-C 107.121 -1.437 . . . . 0.0 107.121 176.482 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 13.9 t80 -173.0 -55.27 0.02 OUTLIER 'General case' 0 N--CA 1.485 1.293 0 CA-C-O 121.811 0.815 . . . . 0.0 109.826 179.645 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.86 88.89 0.0 OUTLIER 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 114.436 -1.256 . . . . 0.0 112.916 -178.938 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 37.8 tt0 -64.78 157.68 26.97 Favored 'General case' 0 N--CA 1.472 0.651 0 CA-C-N 114.935 -1.029 . . . . 0.0 110.784 179.464 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 66.1 m-20 -139.84 137.03 34.61 Favored 'General case' 0 N--CA 1.478 0.955 0 C-N-CA 122.944 0.497 . . . . 0.0 110.346 179.887 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' F' F ' 24' ' ' VAL . . . . . . . . . . . . . 21.6 t -85.62 -115.55 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.482 1.126 0 N-CA-C 108.706 -0.849 . . . . 0.0 108.706 179.502 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -108.8 54.06 0.57 Allowed Glycine 0 N--CA 1.477 1.371 0 N-CA-C 111.235 -0.746 . . . . 0.0 111.235 -179.869 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 69.8 p -79.5 125.04 29.05 Favored 'General case' 0 N--CA 1.473 0.675 0 N-CA-C 109.052 -0.721 . . . . 0.0 109.052 177.876 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' F' F ' 27' ' ' ASN . . . . . 0.446 HD21 ' CG ' ' D' ' 11' ' ' GLU . 48.2 t30 -65.46 100.15 0.47 Allowed 'General case' 0 N--CA 1.473 0.69 0 N-CA-C 108.328 -0.99 . . . . 0.0 108.328 178.533 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 66.1 mttm -95.66 116.82 29.41 Favored 'General case' 0 N--CA 1.485 1.281 0 N-CA-C 110.022 -0.362 . . . . 0.0 110.022 -178.669 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.17 -132.77 0.01 OUTLIER Glycine 0 CA--C 1.533 1.197 0 N-CA-C 111.491 -0.644 . . . . 0.0 111.491 178.916 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -113.85 126.37 55.11 Favored 'General case' 0 N--CA 1.478 0.954 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 179.278 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 67.2 mt -89.97 130.66 38.89 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.209 0 N-CA-C 107.175 -1.417 . . . . 0.0 107.175 178.632 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 19.4 mt -142.11 154.32 18.83 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.877 0 N-CA-C 109.106 -0.701 . . . . 0.0 109.106 -179.333 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.63 48.9 73.21 Favored Glycine 0 CA--C 1.524 0.596 0 CA-C-N 116.476 -0.329 . . . . 0.0 113.289 179.016 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 3.0 tt -99.41 120.26 39.31 Favored 'General case' 0 N--CA 1.478 0.946 0 N-CA-C 107.145 -1.428 . . . . 0.0 107.145 177.771 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 28.5 ttt -151.82 159.66 43.81 Favored 'General case' 0 N--CA 1.477 0.925 0 N-CA-C 108.673 -0.862 . . . . 0.0 108.673 179.437 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' F' F ' 36' ' ' VAL . . . . . 0.435 HG12 HE22 ' I' ' 15' ' ' GLN . 94.5 t -159.76 149.89 6.45 Favored 'Isoleucine or valine' 0 C--O 1.235 0.31 0 N-CA-C 106.865 -1.531 . . . . 0.0 106.865 -179.478 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.78 74.35 0.34 Allowed Glycine 0 C--N 1.313 -0.722 0 CA-C-N 115.549 -0.75 . . . . 0.0 111.512 177.904 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 171.91 -147.25 9.93 Favored Glycine 0 C--O 1.223 -0.534 0 N-CA-C 111.099 -0.8 . . . . 0.0 111.099 179.818 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 33.2 m -135.33 141.67 41.91 Favored 'Isoleucine or valine' 0 C--N 1.352 0.715 0 N-CA-C 109.27 -0.641 . . . . 0.0 109.27 179.712 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 15.2 t . . . . . 0 CA--C 1.537 0.473 0 CA-C-O 117.934 -1.031 . . . . 0.0 111.155 179.317 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 79.4 m-85 . . . . . 0 N--CA 1.474 0.765 0 N-CA-C 109.543 -0.54 . . . . 0.0 109.543 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' G' G ' 5' ' ' ARG . . . . . . . . . . . . . 72.2 mtp180 -144.05 141.52 30.14 Favored 'General case' 0 N--CA 1.483 1.221 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 -179.612 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 76.8 m80 -149.24 119.29 7.18 Favored 'General case' 0 N--CA 1.473 0.679 0 N-CA-C 108.952 -0.759 . . . . 0.0 108.952 179.026 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 8.9 m-20 -68.55 145.46 53.97 Favored 'General case' 0 N--CA 1.468 0.462 0 O-C-N 123.578 0.549 . . . . 0.0 111.945 -179.319 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' G' G ' 8' ' ' SER . . . . . . . . . . . . . 6.0 t -164.64 173.52 11.83 Favored 'General case' 0 N--CA 1.468 0.461 0 N-CA-C 109.386 -0.598 . . . . 0.0 109.386 178.208 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.36 24.45 2.19 Favored Glycine 0 N--CA 1.48 1.584 0 N-CA-C 111.639 -0.584 . . . . 0.0 111.639 178.934 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 42.4 p90 -56.24 127.56 31.4 Favored 'General case' 0 N--CA 1.474 0.745 0 N-CA-C 112.516 0.562 . . . . 0.0 112.516 -178.757 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 45.7 mt-10 -83.61 154.24 23.86 Favored 'General case' 0 N--CA 1.471 0.601 0 CA-C-O 120.971 0.415 . . . . 0.0 109.882 178.638 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 2.6 p -155.5 128.51 1.13 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.959 0 N-CA-C 108.431 -0.951 . . . . 0.0 108.431 178.972 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 49.6 m-70 -133.6 144.64 49.41 Favored 'General case' 0 N--CA 1.477 0.876 0 CA-C-N 115.454 -0.793 . . . . 0.0 110.934 -178.177 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 32.2 t-80 -165.65 98.62 0.68 Allowed 'General case' 0 N--CA 1.483 1.2 0 CA-C-N 116.589 -0.278 . . . . 0.0 110.805 179.193 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' G' G ' 15' ' ' GLN . . . . . 0.41 HE22 HG12 ' D' ' 36' ' ' VAL . 45.0 mt-30 -108.49 -171.92 1.95 Allowed 'General case' 0 CA--C 1.501 -0.915 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 179.916 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -167.31 97.91 0.5 Allowed 'General case' 0 CA--C 1.542 0.641 0 CA-C-N 114.96 -1.018 . . . . 0.0 109.388 178.717 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' G' G ' 17' ' ' LEU . . . . . 0.589 ' N ' HD12 ' G' ' 17' ' ' LEU . 5.1 mp -105.38 162.41 13.47 Favored 'General case' 0 N--CA 1.487 1.402 0 N-CA-C 109.32 -0.622 . . . . 0.0 109.32 -179.685 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 36.5 t -143.13 118.52 4.6 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.009 0 CA-C-O 120.83 0.348 . . . . 0.0 110.442 178.851 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 46.5 m-85 -69.76 150.32 47.03 Favored 'General case' 0 C--N 1.37 1.481 0 N-CA-C 107.263 -1.384 . . . . 0.0 107.263 176.595 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 11.3 t80 -170.5 -55.06 0.02 OUTLIER 'General case' 0 N--CA 1.487 1.406 0 CA-C-N 117.953 0.342 . . . . 0.0 110.328 -179.583 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.68 89.9 0.0 OUTLIER 'General case' 0 C--N 1.325 -0.491 0 C-N-CA 123.774 0.83 . . . . 0.0 112.508 -179.839 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 38.0 tt0 -65.41 158.54 26.41 Favored 'General case' 0 N--CA 1.469 0.476 0 CA-C-N 114.714 -1.13 . . . . 0.0 109.954 179.146 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 67.4 m-20 -140.09 136.8 33.97 Favored 'General case' 0 N--CA 1.478 0.937 0 C-N-CA 122.874 0.469 . . . . 0.0 109.98 179.904 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' G' G ' 24' ' ' VAL . . . . . . . . . . . . . 21.5 t -85.95 -115.61 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 1.004 0 N-CA-C 108.506 -0.924 . . . . 0.0 108.506 179.555 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -108.61 54.04 0.57 Allowed Glycine 0 N--CA 1.477 1.397 0 N-CA-C 111.492 -0.643 . . . . 0.0 111.492 -179.868 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 72.6 p -79.96 125.57 29.92 Favored 'General case' 0 N--CA 1.467 0.389 0 N-CA-C 108.943 -0.762 . . . . 0.0 108.943 177.971 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 3.8 t-20 -65.76 100.98 0.59 Allowed 'General case' 0 N--CA 1.47 0.566 0 N-CA-C 108.567 -0.901 . . . . 0.0 108.567 178.525 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 66.6 mttm -95.76 117.2 30.09 Favored 'General case' 0 N--CA 1.485 1.309 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 -179.13 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.94 -131.95 0.01 OUTLIER Glycine 0 CA--C 1.53 1.005 0 N-CA-C 110.579 -1.008 . . . . 0.0 110.579 178.946 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -113.74 126.48 55.27 Favored 'General case' 0 N--CA 1.469 0.499 0 N-CA-C 109.522 -0.547 . . . . 0.0 109.522 179.542 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 69.3 mt -89.94 131.38 37.34 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.756 0 N-CA-C 107.327 -1.36 . . . . 0.0 107.327 178.495 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 22.7 mt -143.29 155.09 16.74 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.397 0 CA-C-N 118.982 0.81 . . . . 0.0 109.056 -179.751 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.74 48.2 79.29 Favored Glycine 0 CA--C 1.527 0.782 0 CA-C-N 116.659 -0.246 . . . . 0.0 112.835 179.053 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' G' G ' 34' ' ' LEU . . . . . 0.405 HD23 ' N ' ' G' ' 35' ' ' MET . 2.9 tt -98.87 121.19 40.5 Favored 'General case' 0 N--CA 1.478 0.955 0 N-CA-C 107.086 -1.449 . . . . 0.0 107.086 177.75 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' G' G ' 35' ' ' MET . . . . . 0.405 ' N ' HD23 ' G' ' 34' ' ' LEU . 28.7 ttt -153.08 160.21 42.9 Favored 'General case' 0 N--CA 1.477 0.882 0 N-CA-C 108.172 -1.047 . . . . 0.0 108.172 179.493 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 84.4 t -159.81 150.2 6.31 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.255 0 N-CA-C 106.419 -1.697 . . . . 0.0 106.419 -179.354 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.59 74.86 0.29 Allowed Glycine 0 C--N 1.312 -0.756 0 C-N-CA 120.975 -0.631 . . . . 0.0 112.049 177.727 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 170.28 -145.79 9.39 Favored Glycine 0 N--CA 1.467 0.702 0 N-CA-C 110.614 -0.995 . . . . 0.0 110.614 179.127 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 33.9 m -135.91 142.06 40.08 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.873 0 N-CA-C 109.911 -0.403 . . . . 0.0 109.911 -179.887 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 15.4 t . . . . . 0 N--CA 1.466 0.349 0 CA-C-O 118.046 -0.978 . . . . 0.0 111.304 179.463 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 80.1 m-85 . . . . . 0 N--CA 1.474 0.769 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' H' H ' 5' ' ' ARG . . . . . . . . . . . . . 72.3 mtp180 -144.11 141.85 30.26 Favored 'General case' 0 N--CA 1.483 1.191 0 N-CA-C 109.294 -0.632 . . . . 0.0 109.294 -179.635 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 76.9 m80 -149.67 118.87 6.78 Favored 'General case' 0 N--CA 1.473 0.695 0 N-CA-C 109.105 -0.702 . . . . 0.0 109.105 179.129 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 8.8 m-20 -68.25 145.2 54.48 Favored 'General case' 0 N--CA 1.469 0.48 0 O-C-N 123.469 0.481 . . . . 0.0 111.924 -179.309 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' H' H ' 8' ' ' SER . . . . . . . . . . . . . 7.5 t -164.36 172.96 12.77 Favored 'General case' 0 N--CA 1.469 0.507 0 N-CA-C 109.449 -0.575 . . . . 0.0 109.449 178.421 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.43 24.46 2.17 Favored Glycine 0 N--CA 1.481 1.665 0 N-CA-C 111.733 -0.547 . . . . 0.0 111.733 179.112 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 42.1 p90 -56.38 127.51 31.37 Favored 'General case' 0 N--CA 1.473 0.707 0 N-CA-C 112.428 0.529 . . . . 0.0 112.428 -178.795 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 45.4 mt-10 -83.51 154.2 24.0 Favored 'General case' 0 N--CA 1.473 0.676 0 CA-C-O 120.984 0.421 . . . . 0.0 109.874 178.62 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.6 p -155.41 128.41 1.13 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.975 0 N-CA-C 108.433 -0.951 . . . . 0.0 108.433 178.963 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 52.1 m-70 -133.42 144.63 49.65 Favored 'General case' 0 N--CA 1.476 0.863 0 CA-C-N 115.43 -0.804 . . . . 0.0 110.893 -178.16 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 6.4 t60 -165.61 98.48 0.68 Allowed 'General case' 0 N--CA 1.482 1.146 0 CA-C-N 116.527 -0.306 . . . . 0.0 110.839 179.146 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' H' H ' 15' ' ' GLN . . . . . 0.416 HE22 HG12 ' E' ' 36' ' ' VAL . 44.9 mt-30 -108.24 -172.45 2.06 Favored 'General case' 0 CA--C 1.5 -0.979 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 -179.921 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -167.01 97.78 0.52 Allowed 'General case' 0 CA--C 1.539 0.521 0 CA-C-N 114.989 -1.005 . . . . 0.0 109.402 178.73 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' H' H ' 17' ' ' LEU . . . . . 0.589 ' N ' HD12 ' H' ' 17' ' ' LEU . 5.1 mp -105.5 162.13 13.74 Favored 'General case' 0 N--CA 1.488 1.442 0 N-CA-C 109.292 -0.633 . . . . 0.0 109.292 -179.632 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 38.5 t -142.79 118.54 5.16 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.097 0 CA-C-O 120.905 0.383 . . . . 0.0 110.482 178.874 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 47.5 m-85 -70.14 150.89 46.06 Favored 'General case' 0 C--N 1.37 1.498 0 N-CA-C 107.391 -1.336 . . . . 0.0 107.391 176.585 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 11.9 t80 -171.88 -54.41 0.02 OUTLIER 'General case' 0 N--CA 1.485 1.28 0 CA-C-N 117.828 0.286 . . . . 0.0 110.323 -179.456 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.99 90.22 0.0 OUTLIER 'General case' 0 CA--C 1.536 0.437 0 C-N-CA 123.59 0.756 . . . . 0.0 112.262 -179.824 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 37.9 tt0 -65.38 158.63 26.09 Favored 'General case' 0 N--CA 1.468 0.465 0 CA-C-N 114.739 -1.118 . . . . 0.0 110.011 179.318 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 66.8 m-20 -140.18 136.98 34.01 Favored 'General case' 0 N--CA 1.477 0.899 0 C-N-CA 122.942 0.497 . . . . 0.0 109.972 179.872 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' H' H ' 24' ' ' VAL . . . . . . . . . . . . . 21.5 t -86.36 -115.55 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.049 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 179.605 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . -108.3 53.44 0.6 Allowed Glycine 0 N--CA 1.479 1.564 0 N-CA-C 111.395 -0.682 . . . . 0.0 111.395 -179.828 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 70.1 p -79.46 125.28 29.35 Favored 'General case' 0 N--CA 1.468 0.45 0 N-CA-C 108.893 -0.781 . . . . 0.0 108.893 178.004 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' H' H ' 27' ' ' ASN . . . . . 0.615 ' HB3' HD21 ' E' ' 27' ' ' ASN . 3.9 t-20 -65.69 100.91 0.57 Allowed 'General case' 0 N--CA 1.472 0.662 0 N-CA-C 108.497 -0.927 . . . . 0.0 108.497 178.5 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 66.6 mttm -95.89 117.09 29.93 Favored 'General case' 0 N--CA 1.485 1.283 0 N-CA-C 109.97 -0.382 . . . . 0.0 109.97 -179.146 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.66 -131.75 0.01 OUTLIER Glycine 0 CA--C 1.531 1.059 0 N-CA-C 110.802 -0.919 . . . . 0.0 110.802 178.921 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -114.0 126.24 54.91 Favored 'General case' 0 N--CA 1.471 0.604 0 N-CA-C 109.61 -0.515 . . . . 0.0 109.61 179.527 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 69.4 mt -89.79 131.13 37.82 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.701 0 N-CA-C 107.338 -1.356 . . . . 0.0 107.338 178.55 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 23.3 mt -143.11 155.05 17.02 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.339 0 CA-C-N 118.826 0.739 . . . . 0.0 109.024 -179.698 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.65 48.12 80.36 Favored Glycine 0 CA--C 1.524 0.626 0 CA-C-O 120.117 -0.269 . . . . 0.0 112.891 179.045 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 2.9 tt -98.75 121.09 40.25 Favored 'General case' 0 N--CA 1.478 0.969 0 N-CA-C 107.117 -1.438 . . . . 0.0 107.117 177.617 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 28.7 ttt -152.89 159.95 43.03 Favored 'General case' 0 N--CA 1.478 0.974 0 N-CA-C 108.07 -1.085 . . . . 0.0 108.07 179.61 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 87.2 t -159.66 150.34 6.43 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.261 0 N-CA-C 106.448 -1.686 . . . . 0.0 106.448 -179.51 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.35 74.96 0.27 Allowed Glycine 0 C--N 1.311 -0.811 0 C-N-CA 120.979 -0.629 . . . . 0.0 112.015 177.804 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 170.24 -146.2 9.7 Favored Glycine 0 N--CA 1.467 0.744 0 N-CA-C 110.539 -1.024 . . . . 0.0 110.539 179.129 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 34.0 m -135.57 142.02 40.64 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.815 0 N-CA-C 109.951 -0.388 . . . . 0.0 109.951 -179.875 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 15.9 t . . . . . 0 N--CA 1.467 0.4 0 CA-C-O 118.058 -0.973 . . . . 0.0 111.327 179.45 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 79.6 m-85 . . . . . 0 N--CA 1.474 0.726 0 N-CA-C 109.643 -0.503 . . . . 0.0 109.643 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' I' I ' 5' ' ' ARG . . . . . . . . . . . . . 72.4 mtp180 -144.48 141.67 29.72 Favored 'General case' 0 N--CA 1.484 1.265 0 N-CA-C 109.224 -0.658 . . . . 0.0 109.224 -179.581 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 76.8 m80 -149.47 119.13 6.99 Favored 'General case' 0 N--CA 1.474 0.728 0 N-CA-C 109.08 -0.711 . . . . 0.0 109.08 178.999 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 8.9 m-20 -68.45 145.19 54.31 Favored 'General case' 0 N--CA 1.469 0.499 0 O-C-N 123.429 0.456 . . . . 0.0 111.866 -179.235 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' I' I ' 8' ' ' SER . . . . . . . . . . . . . 7.5 t -164.33 172.62 13.25 Favored 'General case' 0 N--CA 1.469 0.509 0 N-CA-C 109.463 -0.569 . . . . 0.0 109.463 178.368 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.92 24.62 2.03 Favored Glycine 0 N--CA 1.481 1.684 0 N-CA-C 111.7 -0.56 . . . . 0.0 111.7 179.104 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 42.4 p90 -56.52 127.53 31.69 Favored 'General case' 0 N--CA 1.474 0.762 0 N-CA-C 112.424 0.528 . . . . 0.0 112.424 -178.758 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 45.7 mt-10 -83.56 154.12 23.98 Favored 'General case' 0 N--CA 1.473 0.719 0 CA-C-O 121.071 0.463 . . . . 0.0 109.816 178.62 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 2.6 p -155.3 128.27 1.12 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.005 0 N-CA-C 108.389 -0.967 . . . . 0.0 108.389 178.956 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 50.9 m-70 -133.35 144.36 49.57 Favored 'General case' 0 N--CA 1.477 0.922 0 CA-C-N 115.45 -0.795 . . . . 0.0 110.966 -178.163 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 32.6 t-80 -165.45 98.71 0.7 Allowed 'General case' 0 N--CA 1.483 1.177 0 CA-C-N 116.559 -0.291 . . . . 0.0 110.794 179.203 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' I' I ' 15' ' ' GLN . . . . . 0.435 HE22 HG12 ' F' ' 36' ' ' VAL . 44.6 mt-30 -108.64 -172.46 2.06 Favored 'General case' 0 CA--C 1.499 -1.001 0 N-CA-C 108.405 -0.961 . . . . 0.0 108.405 179.979 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -166.78 98.02 0.55 Allowed 'General case' 0 CA--C 1.539 0.553 0 CA-C-N 114.933 -1.031 . . . . 0.0 109.423 178.745 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' I' I ' 17' ' ' LEU . . . . . 0.589 ' N ' HD12 ' I' ' 17' ' ' LEU . 5.1 mp -105.56 162.19 13.71 Favored 'General case' 0 N--CA 1.487 1.402 0 N-CA-C 109.327 -0.62 . . . . 0.0 109.327 -179.701 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 38.8 t -142.88 118.54 4.98 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.024 0 CA-C-O 120.987 0.423 . . . . 0.0 110.471 178.848 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 47.8 m-85 -70.01 150.89 46.18 Favored 'General case' 0 C--N 1.37 1.465 0 N-CA-C 107.306 -1.368 . . . . 0.0 107.306 176.567 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 12.0 t80 -171.94 -54.29 0.02 OUTLIER 'General case' 0 N--CA 1.483 1.206 0 CA-C-N 117.922 0.328 . . . . 0.0 110.408 -179.49 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.18 90.18 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.447 0 C-N-CA 123.713 0.805 . . . . 0.0 112.302 -179.893 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 38.2 tt0 -65.37 158.57 26.2 Favored 'General case' 0 N--CA 1.469 0.519 0 CA-C-N 114.738 -1.119 . . . . 0.0 110.045 179.254 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 66.3 m-20 -140.27 136.81 33.69 Favored 'General case' 0 N--CA 1.478 0.937 0 C-N-CA 122.859 0.464 . . . . 0.0 109.989 179.844 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' I' I ' 24' ' ' VAL . . . . . . . . . . . . . 21.3 t -86.04 -115.9 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.957 0 N-CA-C 108.542 -0.911 . . . . 0.0 108.542 179.559 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . -108.1 54.12 0.57 Allowed Glycine 0 N--CA 1.478 1.453 0 N-CA-C 111.384 -0.687 . . . . 0.0 111.384 -179.845 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 73.4 p -80.08 125.14 29.42 Favored 'General case' 0 N--CA 1.467 0.399 0 N-CA-C 108.962 -0.755 . . . . 0.0 108.962 177.889 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 3.9 t-20 -65.49 101.01 0.54 Allowed 'General case' 0 CA--C 1.54 0.583 0 N-CA-C 108.539 -0.911 . . . . 0.0 108.539 178.588 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 66.5 mttm -95.88 117.07 29.88 Favored 'General case' 0 N--CA 1.485 1.321 0 N-CA-C 109.98 -0.378 . . . . 0.0 109.98 -179.177 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.68 -132.1 0.01 OUTLIER Glycine 0 CA--C 1.533 1.186 0 N-CA-C 110.652 -0.979 . . . . 0.0 110.652 178.975 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -113.55 126.12 54.95 Favored 'General case' 0 N--CA 1.472 0.635 0 C-N-CA 123.009 0.524 . . . . 0.0 109.622 179.547 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 70.1 mt -89.81 131.51 36.89 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.752 0 N-CA-C 107.219 -1.401 . . . . 0.0 107.219 178.567 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 23.5 mt -143.49 155.12 16.42 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.36 0 CA-C-N 118.883 0.765 . . . . 0.0 108.994 -179.69 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.57 48.18 80.17 Favored Glycine 0 CA--C 1.525 0.661 0 CA-C-N 116.635 -0.257 . . . . 0.0 112.846 179.082 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 2.9 tt -98.78 121.19 40.41 Favored 'General case' 0 N--CA 1.478 0.956 0 N-CA-C 107.002 -1.481 . . . . 0.0 107.002 177.625 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 28.6 ttt -153.0 159.93 42.96 Favored 'General case' 0 N--CA 1.478 0.931 0 N-CA-C 108.057 -1.09 . . . . 0.0 108.057 179.543 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 86.9 t -159.67 150.33 6.42 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.243 0 N-CA-C 106.372 -1.714 . . . . 0.0 106.372 -179.518 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.52 74.61 0.31 Allowed Glycine 0 C--N 1.312 -0.762 0 C-N-CA 120.898 -0.668 . . . . 0.0 112.083 177.777 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 170.49 -146.12 9.57 Favored Glycine 0 N--CA 1.466 0.664 0 N-CA-C 110.599 -1.0 . . . . 0.0 110.599 179.131 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 34.0 m -135.67 141.99 40.57 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.807 0 N-CA-C 109.882 -0.414 . . . . 0.0 109.882 -179.834 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 16.2 t . . . . . 0 C--O 1.223 -0.315 0 CA-C-O 118.035 -0.984 . . . . 0.0 111.275 179.465 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 20.2 m-85 . . . . . 0 N--CA 1.47 0.56 0 N-CA-C 109.495 -0.557 . . . . 0.0 109.495 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 31.9 mtp180 -67.96 130.38 42.79 Favored 'General case' 0 C--O 1.218 -0.602 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.154 -178.027 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 4.1 m-70 -100.34 131.54 46.22 Favored 'General case' 0 N--CA 1.474 0.733 0 N-CA-C 109.461 -0.57 . . . . 0.0 109.461 179.457 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 13.8 m-20 -71.42 141.03 50.31 Favored 'General case' 0 CA--C 1.53 0.19 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.819 -179.748 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 8' ' ' SER . . . . . 0.41 ' O ' ' O ' ' C' ' 25' ' ' GLY . 8.7 t -143.53 -173.35 3.93 Favored 'General case' 0 N--CA 1.48 1.032 0 N-CA-C 109.016 -0.735 . . . . 0.0 109.016 178.498 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 117.88 11.49 8.4 Favored Glycine 0 N--CA 1.486 1.993 0 N-CA-C 112.543 -0.223 . . . . 0.0 112.543 179.197 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 47.8 p90 -59.2 128.36 36.76 Favored 'General case' 0 N--CA 1.471 0.622 0 CA-C-O 120.768 0.318 . . . . 0.0 111.849 -179.593 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 46.6 mt-10 -89.8 154.67 19.73 Favored 'General case' 0 N--CA 1.471 0.598 0 N-CA-C 109.299 -0.63 . . . . 0.0 109.299 178.548 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -153.58 128.92 1.57 Allowed 'Isoleucine or valine' 0 C--O 1.235 0.297 0 N-CA-C 108.072 -1.084 . . . . 0.0 108.072 178.641 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 50.1 m-70 -135.37 147.04 48.95 Favored 'General case' 0 N--CA 1.49 1.565 0 CA-C-N 118.834 0.743 . . . . 0.0 111.114 -179.108 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 6.4 t60 -164.94 97.57 0.74 Allowed 'General case' 0 N--CA 1.48 1.056 0 CA-C-N 116.568 -0.287 . . . . 0.0 111.139 179.632 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 45.0 mt-30 -108.87 -172.49 2.06 Favored 'General case' 0 CA--C 1.503 -0.856 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 -179.969 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -166.81 98.0 0.55 Allowed 'General case' 0 N--CA 1.473 0.691 0 CA-C-N 115.179 -0.918 . . . . 0.0 109.391 178.795 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.596 ' N ' HD12 ' A' ' 17' ' ' LEU . 4.5 mp -106.05 164.17 12.19 Favored 'General case' 0 N--CA 1.489 1.488 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 179.99 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 57.8 t -142.39 119.0 6.34 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.301 0 CA-C-O 118.962 -0.542 . . . . 0.0 109.904 179.527 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 53.2 m-85 -69.81 159.46 33.57 Favored 'General case' 0 N--CA 1.481 1.094 0 N-CA-C 107.491 -1.3 . . . . 0.0 107.491 177.186 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 11.7 t80 -171.68 -58.0 0.02 OUTLIER 'General case' 0 N--CA 1.487 1.417 0 CA-C-O 122.386 1.089 . . . . 0.0 109.815 179.65 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -39.32 89.73 0.0 OUTLIER 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 113.91 -1.496 . . . . 0.0 112.973 -178.03 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 37.1 tt0 -65.47 158.48 26.72 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.119 -0.946 . . . . 0.0 110.603 179.077 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 11.5 m-20 -140.74 137.63 33.57 Favored 'General case' 0 N--CA 1.479 0.994 0 C-N-CA 122.984 0.513 . . . . 0.0 110.249 179.702 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 17.7 t -91.7 -116.68 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.483 1.187 0 N-CA-C 108.64 -0.874 . . . . 0.0 108.64 179.576 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.404 ' O ' ' O ' ' B' ' 8' ' ' SER . . . -102.82 56.99 0.6 Allowed Glycine 0 N--CA 1.473 1.166 0 N-CA-C 110.954 -0.858 . . . . 0.0 110.954 179.997 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 79.6 p -85.25 124.74 32.23 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 178.068 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 61.7 t30 -64.58 100.88 0.41 Allowed 'General case' 0 N--CA 1.474 0.728 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 178.874 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 64.7 mttm -97.27 113.98 25.67 Favored 'General case' 0 N--CA 1.484 1.265 0 N-CA-C 110.011 -0.366 . . . . 0.0 110.011 -178.967 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.65 -134.26 0.01 OUTLIER Glycine 0 CA--C 1.534 1.235 0 N-CA-C 110.741 -0.944 . . . . 0.0 110.741 179.103 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -112.56 127.74 56.16 Favored 'General case' 0 N--CA 1.481 1.092 0 N-CA-C 109.155 -0.683 . . . . 0.0 109.155 178.997 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 65.0 mt -90.32 129.24 41.49 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.623 0 N-CA-C 107.532 -1.285 . . . . 0.0 107.532 178.755 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 12.4 mt -142.96 151.92 17.25 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.793 0 CA-C-N 116.2 -0.455 . . . . 0.0 109.943 -178.891 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 65.21 48.9 64.94 Favored Glycine 0 CA--C 1.524 0.632 0 CA-C-N 115.997 -0.547 . . . . 0.0 112.495 179.01 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.415 HD23 ' N ' ' A' ' 35' ' ' MET . 2.8 tt -99.03 121.1 40.52 Favored 'General case' 0 N--CA 1.479 1.009 0 N-CA-C 107.143 -1.429 . . . . 0.0 107.143 178.088 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 35' ' ' MET . . . . . 0.415 ' N ' HD23 ' A' ' 34' ' ' LEU . 27.5 ttt -153.24 158.08 41.16 Favored 'General case' 0 N--CA 1.47 0.539 0 N-CA-C 108.847 -0.797 . . . . 0.0 108.847 179.576 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.412 HG12 HE22 ' D' ' 15' ' ' GLN . 85.0 t -158.19 149.32 8.66 Favored 'Isoleucine or valine' 0 C--O 1.238 0.47 0 N-CA-C 106.868 -1.53 . . . . 0.0 106.868 -179.577 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 57.38 72.42 0.59 Allowed Glycine 0 C--N 1.315 -0.616 0 N-CA-C 111.318 -0.713 . . . . 0.0 111.318 178.342 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 172.74 -157.78 27.36 Favored Glycine 0 C--N 1.332 0.326 0 N-CA-C 110.804 -0.918 . . . . 0.0 110.804 -179.895 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 33.4 m -124.07 143.33 37.73 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.934 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 179.502 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 16.4 t . . . . . 0 CA--C 1.536 0.412 0 CA-C-O 118.056 -0.973 . . . . 0.0 111.062 179.152 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 21.4 m-85 . . . . . 0 N--CA 1.47 0.561 0 N-CA-C 109.4 -0.593 . . . . 0.0 109.4 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 32.2 mtp180 -67.94 129.8 41.01 Favored 'General case' 0 N--CA 1.47 0.529 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.214 -178.019 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 4.1 m-70 -99.81 131.79 45.57 Favored 'General case' 0 N--CA 1.476 0.854 0 N-CA-C 109.551 -0.537 . . . . 0.0 109.551 179.407 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 7' ' ' ASP . . . . . . . . . . . . . 13.2 m-20 -71.86 141.25 49.58 Favored 'General case' 0 CA--C 1.532 0.259 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.786 -179.688 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 8' ' ' SER . . . . . 0.404 ' O ' ' O ' ' A' ' 25' ' ' GLY . 8.7 t -143.54 -172.98 3.83 Favored 'General case' 0 N--CA 1.478 0.953 0 N-CA-C 109.017 -0.734 . . . . 0.0 109.017 178.417 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 117.45 11.79 8.53 Favored Glycine 0 N--CA 1.484 1.89 0 N-CA-C 112.513 -0.235 . . . . 0.0 112.513 179.241 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 47.4 p90 -59.33 128.09 35.36 Favored 'General case' 0 CA--C 1.54 0.583 0 N-CA-C 111.815 0.302 . . . . 0.0 111.815 -179.628 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 46.5 mt-10 -89.58 154.51 19.93 Favored 'General case' 0 N--CA 1.473 0.705 0 N-CA-C 109.418 -0.586 . . . . 0.0 109.418 178.552 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -153.48 128.31 1.47 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.286 0 N-CA-C 108.3 -1.0 . . . . 0.0 108.3 178.682 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 49.3 m-70 -134.89 147.35 49.82 Favored 'General case' 0 N--CA 1.489 1.514 0 CA-C-N 118.69 0.677 . . . . 0.0 111.044 -178.944 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 6.5 t60 -165.14 97.65 0.72 Allowed 'General case' 0 N--CA 1.481 1.125 0 CA-C-N 116.608 -0.269 . . . . 0.0 110.992 179.593 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 45.0 mt-30 -108.79 -172.79 2.12 Favored 'General case' 0 CA--C 1.501 -0.934 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 16' ' ' LYS . . . . . 0.401 ' C ' HD12 ' B' ' 17' ' ' LEU . 88.4 tttt -166.83 98.08 0.55 Allowed 'General case' 0 CA--C 1.541 0.616 0 CA-C-N 115.142 -0.935 . . . . 0.0 109.404 178.815 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 17' ' ' LEU . . . . . 0.595 ' N ' HD12 ' B' ' 17' ' ' LEU . 4.5 mp -106.2 164.2 12.19 Favored 'General case' 0 N--CA 1.487 1.41 0 N-CA-C 108.606 -0.887 . . . . 0.0 108.606 -179.948 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 58.9 t -142.52 118.46 5.65 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.258 0 CA-C-O 118.999 -0.524 . . . . 0.0 109.959 179.527 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 53.8 m-85 -70.04 159.55 33.62 Favored 'General case' 0 N--CA 1.478 0.942 0 N-CA-C 107.409 -1.33 . . . . 0.0 107.409 177.296 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 12.8 t80 -172.36 -56.98 0.02 OUTLIER 'General case' 0 N--CA 1.484 1.271 0 CA-C-O 122.233 1.016 . . . . 0.0 109.851 179.622 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -39.63 90.37 0.0 OUTLIER 'General case' 0 CA--C 1.529 0.138 0 CA-C-N 114.148 -1.387 . . . . 0.0 112.823 -178.163 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 36.9 tt0 -66.13 158.11 29.47 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 115.068 -0.969 . . . . 0.0 110.618 179.163 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 11.8 m-20 -140.18 138.38 35.12 Favored 'General case' 0 N--CA 1.48 1.058 0 C-N-CA 122.978 0.511 . . . . 0.0 110.127 179.697 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 17.9 t -92.73 -116.95 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.484 1.232 0 N-CA-C 108.707 -0.849 . . . . 0.0 108.707 179.543 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 25' ' ' GLY . . . . . 0.41 ' O ' ' O ' ' C' ' 8' ' ' SER . . . -101.89 56.43 0.68 Allowed Glycine 0 N--CA 1.474 1.191 0 N-CA-C 110.835 -0.906 . . . . 0.0 110.835 -179.959 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 78.9 p -85.23 124.82 32.31 Favored 'General case' 0 N--CA 1.466 0.354 0 N-CA-C 108.695 -0.854 . . . . 0.0 108.695 178.047 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 62.2 t30 -64.89 101.42 0.49 Allowed 'General case' 0 N--CA 1.473 0.701 0 N-CA-C 108.731 -0.84 . . . . 0.0 108.731 178.845 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 64.6 mttm -97.81 113.46 25.27 Favored 'General case' 0 N--CA 1.485 1.318 0 N-CA-C 110.029 -0.36 . . . . 0.0 110.029 -178.939 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.06 -134.16 0.01 OUTLIER Glycine 0 CA--C 1.534 1.255 0 N-CA-C 110.834 -0.907 . . . . 0.0 110.834 178.988 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -112.92 127.87 56.32 Favored 'General case' 0 N--CA 1.48 1.03 0 N-CA-C 109.114 -0.699 . . . . 0.0 109.114 179.02 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 64.4 mt -90.39 129.49 41.15 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.588 0 N-CA-C 107.52 -1.289 . . . . 0.0 107.52 178.768 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 12.0 mt -143.19 151.62 17.07 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.848 0 CA-C-N 116.06 -0.518 . . . . 0.0 109.905 -178.799 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 65.59 48.14 70.78 Favored Glycine 0 CA--C 1.526 0.722 0 CA-C-N 116.045 -0.525 . . . . 0.0 112.642 178.956 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 34' ' ' LEU . . . . . 0.4 HD23 ' N ' ' B' ' 35' ' ' MET . 2.9 tt -98.12 121.04 39.56 Favored 'General case' 0 N--CA 1.479 0.981 0 N-CA-C 107.269 -1.382 . . . . 0.0 107.269 177.951 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 35' ' ' MET . . . . . 0.4 ' N ' HD23 ' B' ' 34' ' ' LEU . 27.6 ttt -153.19 157.75 40.74 Favored 'General case' 0 N--CA 1.474 0.758 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 179.528 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 81.4 t -157.96 149.44 8.93 Favored 'Isoleucine or valine' 0 C--O 1.238 0.48 0 N-CA-C 106.676 -1.601 . . . . 0.0 106.676 -179.469 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.96 72.48 0.58 Allowed Glycine 0 C--N 1.314 -0.669 0 CA-C-N 115.621 -0.718 . . . . 0.0 111.394 178.331 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 172.86 -157.73 27.17 Favored Glycine 0 N--CA 1.459 0.233 0 N-CA-C 110.662 -0.975 . . . . 0.0 110.662 -179.946 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 33.5 m -124.06 143.3 37.83 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.933 0 C-N-CA 122.778 0.431 . . . . 0.0 109.891 179.402 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 16.2 t . . . . . 0 N--CA 1.468 0.439 0 CA-C-O 118.045 -0.979 . . . . 0.0 110.986 179.199 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 21.1 m-85 . . . . . 0 N--CA 1.47 0.548 0 N-CA-C 109.479 -0.563 . . . . 0.0 109.479 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 31.9 mtp180 -68.31 129.5 40.1 Favored 'General case' 0 N--CA 1.472 0.666 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.215 -178.001 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 4.1 m-70 -99.64 131.41 45.65 Favored 'General case' 0 N--CA 1.474 0.75 0 N-CA-C 109.467 -0.568 . . . . 0.0 109.467 179.455 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 7' ' ' ASP . . . . . . . . . . . . . 13.5 m-20 -71.63 141.0 49.95 Favored 'General case' 0 CA--C 1.531 0.232 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.848 -179.691 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 8' ' ' SER . . . . . 0.41 ' O ' ' O ' ' B' ' 25' ' ' GLY . 8.6 t -143.2 -173.19 3.86 Favored 'General case' 0 N--CA 1.479 1.01 0 N-CA-C 109.002 -0.74 . . . . 0.0 109.002 178.477 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 117.78 11.55 8.44 Favored Glycine 0 N--CA 1.486 1.981 0 N-CA-C 112.44 -0.264 . . . . 0.0 112.44 179.159 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 47.4 p90 -59.17 128.31 36.53 Favored 'General case' 0 CA--C 1.54 0.561 0 CA-C-N 116.907 0.353 . . . . 0.0 111.895 -179.626 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 46.3 mt-10 -89.59 154.68 19.79 Favored 'General case' 0 N--CA 1.473 0.704 0 N-CA-C 109.4 -0.593 . . . . 0.0 109.4 178.5 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -153.87 128.32 1.4 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.233 0 N-CA-C 108.254 -1.017 . . . . 0.0 108.254 178.61 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 49.8 m-70 -134.91 147.18 49.76 Favored 'General case' 0 N--CA 1.491 1.588 0 CA-C-N 118.603 0.638 . . . . 0.0 111.139 -178.89 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 6.4 t60 -165.1 98.03 0.73 Allowed 'General case' 0 N--CA 1.482 1.159 0 CA-C-N 116.601 -0.272 . . . . 0.0 111.094 179.575 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 44.6 mt-30 -109.29 -172.53 2.06 Favored 'General case' 0 CA--C 1.5 -0.955 0 N-CA-C 108.345 -0.983 . . . . 0.0 108.345 179.972 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 16' ' ' LYS . . . . . 0.402 ' C ' HD12 ' C' ' 17' ' ' LEU . 88.4 tttt -166.77 97.93 0.55 Allowed 'General case' 0 N--CA 1.471 0.59 0 CA-C-N 115.086 -0.961 . . . . 0.0 109.413 178.795 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 17' ' ' LEU . . . . . 0.594 ' N ' HD12 ' C' ' 17' ' ' LEU . 4.5 mp -105.91 163.87 12.4 Favored 'General case' 0 N--CA 1.488 1.462 0 N-CA-C 108.603 -0.888 . . . . 0.0 108.603 -179.969 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 59.8 t -142.28 118.65 6.29 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.305 0 CA-C-O 119.025 -0.512 . . . . 0.0 109.813 179.552 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 54.1 m-85 -70.17 159.47 33.89 Favored 'General case' 0 N--CA 1.479 0.986 0 N-CA-C 107.485 -1.302 . . . . 0.0 107.485 177.17 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 12.7 t80 -172.34 -57.05 0.02 OUTLIER 'General case' 0 N--CA 1.484 1.258 0 CA-C-O 122.209 1.004 . . . . 0.0 109.928 179.671 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -39.5 90.54 0.0 OUTLIER 'General case' 0 CA--C 1.53 0.187 0 CA-C-N 114.129 -1.396 . . . . 0.0 112.864 -178.221 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 37.1 tt0 -66.31 158.27 29.51 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.08 -0.964 . . . . 0.0 110.625 179.258 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 11.4 m-20 -140.4 138.18 34.58 Favored 'General case' 0 N--CA 1.478 0.967 0 C-N-CA 123.032 0.533 . . . . 0.0 110.175 179.797 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 18.1 t -92.47 -117.01 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.484 1.238 0 N-CA-C 108.721 -0.844 . . . . 0.0 108.721 179.545 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 25' ' ' GLY . . . . . 0.41 ' O ' ' O ' ' A' ' 8' ' ' SER . . . -101.94 56.65 0.67 Allowed Glycine 0 C--N 1.347 1.192 0 N-CA-C 110.927 -0.869 . . . . 0.0 110.927 -179.995 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 79.2 p -85.36 124.83 32.41 Favored 'General case' 0 N--CA 1.467 0.423 0 N-CA-C 108.683 -0.858 . . . . 0.0 108.683 178.149 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 61.9 t30 -64.88 101.16 0.46 Allowed 'General case' 0 N--CA 1.473 0.717 0 N-CA-C 108.73 -0.841 . . . . 0.0 108.73 178.809 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 28' ' ' LYS . . . . . 0.4 ' O ' ' O ' ' C' ' 29' ' ' GLY . 65.2 mttm -97.47 113.65 25.37 Favored 'General case' 0 N--CA 1.486 1.348 0 N-CA-C 110.064 -0.347 . . . . 0.0 110.064 -178.983 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 29' ' ' GLY . . . . . 0.4 ' O ' ' O ' ' C' ' 28' ' ' LYS . . . -60.2 -134.47 0.01 OUTLIER Glycine 0 CA--C 1.535 1.282 0 N-CA-C 110.798 -0.921 . . . . 0.0 110.798 178.982 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -112.5 128.0 56.21 Favored 'General case' 0 N--CA 1.48 1.075 0 N-CA-C 109.181 -0.674 . . . . 0.0 109.181 178.91 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 64.4 mt -90.6 129.26 41.7 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.674 0 N-CA-C 107.486 -1.301 . . . . 0.0 107.486 178.75 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 12.2 mt -142.96 152.12 17.2 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.806 0 CA-C-N 116.053 -0.521 . . . . 0.0 109.871 -178.88 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 65.04 48.37 71.62 Favored Glycine 0 CA--C 1.525 0.697 0 CA-C-N 116.012 -0.54 . . . . 0.0 112.63 178.982 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 34' ' ' LEU . . . . . 0.407 HD23 ' N ' ' C' ' 35' ' ' MET . 2.8 tt -98.46 121.0 39.84 Favored 'General case' 0 N--CA 1.478 0.955 0 N-CA-C 107.158 -1.423 . . . . 0.0 107.158 177.98 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 35' ' ' MET . . . . . 0.407 ' N ' HD23 ' C' ' 34' ' ' LEU . 27.7 ttt -153.07 158.12 41.46 Favored 'General case' 0 N--CA 1.471 0.584 0 N-CA-C 108.814 -0.81 . . . . 0.0 108.814 179.617 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 36' ' ' VAL . . . . . 0.411 HG12 HE22 ' F' ' 15' ' ' GLN . 78.3 t -158.38 149.46 8.3 Favored 'Isoleucine or valine' 0 C--O 1.237 0.432 0 N-CA-C 106.865 -1.531 . . . . 0.0 106.865 -179.526 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.94 72.54 0.57 Allowed Glycine 0 C--N 1.315 -0.616 0 CA-C-N 115.641 -0.709 . . . . 0.0 111.414 178.337 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 172.74 -157.45 26.79 Favored Glycine 0 N--CA 1.461 0.357 0 N-CA-C 110.659 -0.976 . . . . 0.0 110.659 -179.885 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 33.4 m -124.42 143.53 37.52 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.904 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 179.474 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 16.3 t . . . . . 0 N--CA 1.467 0.402 0 CA-C-O 118.118 -0.944 . . . . 0.0 111.082 179.285 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 23.1 m-85 . . . . . 0 N--CA 1.478 0.943 0 N-CA-C 107.913 -1.144 . . . . 0.0 107.913 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' D' D ' 5' ' ' ARG . . . . . . . . . . . . 0.297 39.3 mtp180 -76.43 133.58 39.82 Favored 'General case' 0 C--O 1.214 -0.812 0 N-CA-C 106.852 -1.536 . . . . 0.0 106.852 -168.536 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 4.2 m-70 -101.78 133.4 46.58 Favored 'General case' 0 C--N 1.363 1.167 0 CA-C-N 113.931 -1.486 . . . . 0.0 107.776 -176.422 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' D' D ' 7' ' ' ASP . . . . . . . . . . . . . 9.3 m-20 -64.69 124.05 20.91 Favored 'General case' 0 C--N 1.314 -0.964 0 C-N-CA 127.987 2.515 . . . . 0.0 115.331 176.692 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' D' D ' 8' ' ' SER . . . . . . . . . . . . . 8.2 t -133.3 -174.83 3.61 Favored 'General case' 0 N--CA 1.483 1.209 0 CA-C-N 119.928 1.24 . . . . 0.0 109.46 177.367 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 121.88 13.75 4.92 Favored Glycine 0 N--CA 1.483 1.79 0 N-CA-C 110.993 -0.843 . . . . 0.0 110.993 175.476 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 44.7 p90 -58.37 130.18 45.5 Favored 'General case' 0 CA--C 1.539 0.526 0 C-N-CA 120.938 -0.305 . . . . 0.0 111.71 -179.209 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 47.0 mt-10 -89.29 152.57 21.48 Favored 'General case' 0 N--CA 1.477 0.903 0 N-CA-C 110.063 -0.347 . . . . 0.0 110.063 176.679 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -149.54 129.99 4.33 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.522 0 N-CA-C 107.975 -1.12 . . . . 0.0 107.975 174.35 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 47.9 m-70 -129.86 150.31 51.21 Favored 'General case' 0 N--CA 1.482 1.17 0 CA-C-N 117.848 0.295 . . . . 0.0 111.567 176.611 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 6.6 t60 -165.05 104.65 0.78 Allowed 'General case' 0 N--CA 1.484 1.233 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 172.974 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' D' D ' 15' ' ' GLN . . . . . 0.412 HE22 HG12 ' A' ' 36' ' ' VAL . 44.2 mt-30 -112.46 -175.85 2.78 Favored 'General case' 0 CA--C 1.493 -1.222 0 N-CA-C 108.085 -1.079 . . . . 0.0 108.085 179.188 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' D' D ' 16' ' ' LYS . . . . . 0.452 ' C ' HD12 ' D' ' 17' ' ' LEU . 88.6 tttt -162.92 106.13 1.06 Allowed 'General case' 0 CA--C 1.536 0.419 0 N-CA-C 107.803 -1.184 . . . . 0.0 107.803 175.619 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' D' D ' 17' ' ' LEU . . . . . 0.542 ' N ' HD12 ' D' ' 17' ' ' LEU . 5.4 mp -112.47 162.86 15.14 Favored 'General case' 0 N--CA 1.488 1.442 0 N-CA-C 108.134 -1.061 . . . . 0.0 108.134 179.583 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 51.5 t -141.0 123.63 15.38 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.194 0 N-CA-C 109.01 -0.737 . . . . 0.0 109.01 175.962 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 78.5 m-85 -62.65 151.53 37.87 Favored 'General case' 0 C--N 1.349 0.569 0 C-N-CA 125.002 1.321 . . . . 0.0 110.395 170.485 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 8.3 t80 -170.17 -66.78 0.02 OUTLIER 'General case' 0 N--CA 1.476 0.831 0 N-CA-C 107.765 -1.198 . . . . 0.0 107.765 -179.584 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -37.94 95.74 0.01 OUTLIER 'General case' 0 CA--C 1.536 0.419 0 CA-C-N 113.889 -1.505 . . . . 0.0 111.706 -174.505 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 37.3 tt0 -68.32 158.97 32.3 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 113.587 -1.642 . . . . 0.0 110.308 178.654 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 11.5 m-20 -140.6 140.58 35.13 Favored 'General case' 0 N--CA 1.474 0.767 0 N-CA-C 109.646 -0.501 . . . . 0.0 109.646 178.795 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' D' D ' 24' ' ' VAL . . . . . . . . . . . . . 16.0 t -94.44 -120.65 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.381 0 N-CA-C 108.242 -1.021 . . . . 0.0 108.242 179.858 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . -104.65 61.93 0.38 Allowed Glycine 0 C--N 1.375 2.718 0 C-N-CA 117.791 -2.147 . . . . 0.0 109.555 178.866 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 90.9 p -71.57 121.07 18.09 Favored 'General case' 0 C--O 1.246 0.872 0 CA-C-O 115.949 -1.977 . . . . 0.0 112.537 168.01 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 64.7 t30 -60.69 102.06 0.17 Allowed 'General case' 0 N--CA 1.478 0.956 0 CA-C-N 122.278 2.308 . . . . 0.0 109.906 172.212 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' D' D ' 28' ' ' LYS . . . . . 0.403 ' O ' ' O ' ' D' ' 29' ' ' GLY . 64.6 mttm -100.95 116.16 32.14 Favored 'General case' 0 N--CA 1.493 1.714 0 CA-C-N 120.028 1.286 . . . . 0.0 109.157 179.461 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' D' D ' 29' ' ' GLY . . . . . 0.403 ' O ' ' O ' ' D' ' 28' ' ' LYS . . . -54.65 -134.6 0.0 OUTLIER Glycine 0 C--N 1.343 0.94 0 CA-C-N 115.51 -0.768 . . . . 0.0 113.433 176.203 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -112.95 132.58 55.28 Favored 'General case' 0 C--N 1.37 1.464 0 N-CA-C 108.46 -0.941 . . . . 0.0 108.46 174.435 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 66.7 mt -91.75 133.85 31.96 Favored 'Isoleucine or valine' 0 C--N 1.346 0.422 0 N-CA-C 106.888 -1.523 . . . . 0.0 106.888 176.682 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 14.2 mt -145.74 154.28 13.34 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.916 0 N-CA-C 109.092 -0.707 . . . . 0.0 109.092 179.276 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 64.09 47.65 83.26 Favored Glycine 0 C--O 1.246 0.877 0 CA-C-O 119.409 -0.662 . . . . 0.0 112.538 179.243 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 3.4 tt -97.81 132.53 43.34 Favored 'General case' 0 C--N 1.372 1.558 0 N-CA-C 104.593 -2.373 . . . . 0.0 104.593 176.44 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 28.2 ttt -155.96 165.32 36.81 Favored 'General case' 0 N--CA 1.475 0.812 0 N-CA-C 107.705 -1.22 . . . . 0.0 107.705 175.8 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 94.4 t -164.04 155.52 2.11 Favored 'Isoleucine or valine' 0 C--O 1.247 0.959 0 N-CA-C 105.204 -2.147 . . . . 0.0 105.204 175.016 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 61.22 65.15 3.46 Favored Glycine 0 CA--C 1.524 0.637 0 C-N-CA 117.97 -2.062 . . . . 0.0 113.042 176.686 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 168.83 -158.55 31.24 Favored Glycine 0 N--CA 1.465 0.633 0 CA-C-N 118.976 1.388 . . . . 0.0 111.58 -177.921 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 33.1 m -120.23 142.47 35.8 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.17 0 CA-C-N 118.426 1.113 . . . . 0.0 110.243 -178.534 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 13.9 t . . . . . 0 C--O 1.212 -0.916 0 N-CA-C 109.606 -0.516 . . . . 0.0 109.606 174.362 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 20.4 m-85 . . . . . 0 N--CA 1.472 0.665 0 N-CA-C 109.959 -0.386 . . . . 0.0 109.959 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' E' E ' 5' ' ' ARG . . . . . . . . . . . . . 30.6 mtp180 -67.7 130.32 42.64 Favored 'General case' 0 C--O 1.219 -0.517 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.503 -178.12 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 4.0 m-70 -100.4 131.02 46.56 Favored 'General case' 0 N--CA 1.475 0.802 0 N-CA-C 109.593 -0.521 . . . . 0.0 109.593 179.37 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' E' E ' 7' ' ' ASP . . . . . . . . . . . . . 17.0 m-20 -71.07 142.33 50.84 Favored 'General case' 0 N--CA 1.464 0.234 0 O-C-N 123.389 0.431 . . . . 0.0 110.979 -179.829 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' E' E ' 8' ' ' SER . . . . . . . . . . . . . 8.4 t -144.85 -172.9 3.93 Favored 'General case' 0 N--CA 1.478 0.938 0 N-CA-C 108.994 -0.743 . . . . 0.0 108.994 178.052 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 118.17 12.23 7.73 Favored Glycine 0 N--CA 1.482 1.742 0 N-CA-C 112.191 -0.364 . . . . 0.0 112.191 179.032 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 43.5 p90 -58.91 127.8 34.04 Favored 'General case' 0 CA--C 1.544 0.733 0 N-CA-C 112.107 0.41 . . . . 0.0 112.107 -179.366 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 46.8 mt-10 -88.46 155.16 19.83 Favored 'General case' 0 N--CA 1.476 0.838 0 N-CA-C 109.43 -0.581 . . . . 0.0 109.43 178.12 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -155.3 127.44 1.0 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.557 0 N-CA-C 108.344 -0.984 . . . . 0.0 108.344 178.539 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 48.0 m-70 -135.27 145.3 47.42 Favored 'General case' 0 N--CA 1.483 1.206 0 CA-C-O 120.704 0.287 . . . . 0.0 111.331 -177.826 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 6.3 t60 -164.0 97.53 0.83 Allowed 'General case' 0 N--CA 1.486 1.334 0 CA-C-N 116.752 -0.204 . . . . 0.0 111.048 179.693 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 44.1 mt-30 -108.35 -172.62 2.09 Favored 'General case' 0 CA--C 1.502 -0.902 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 -179.94 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -166.57 98.2 0.58 Allowed 'General case' 0 CA--C 1.541 0.621 0 CA-C-N 114.992 -1.004 . . . . 0.0 109.453 178.722 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' E' E ' 17' ' ' LEU . . . . . 0.589 ' N ' HD12 ' E' ' 17' ' ' LEU . 4.4 mp -106.14 163.1 13.06 Favored 'General case' 0 N--CA 1.49 1.565 0 N-CA-C 109.239 -0.652 . . . . 0.0 109.239 -179.693 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 42.1 t -142.15 118.14 6.11 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.418 0 C-N-CA 122.558 0.343 . . . . 0.0 110.554 179.158 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 52.8 m-85 -69.17 157.27 37.23 Favored 'General case' 0 C--N 1.356 0.867 0 N-CA-C 107.312 -1.366 . . . . 0.0 107.312 176.582 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 11.5 t80 -173.96 -54.7 0.01 OUTLIER 'General case' 0 N--CA 1.484 1.275 0 CA-C-O 121.717 0.77 . . . . 0.0 110.347 179.469 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.35 88.79 0.0 OUTLIER 'General case' 0 C--N 1.319 -0.751 0 CA-C-N 114.356 -1.293 . . . . 0.0 112.83 -178.974 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 37.4 tt0 -64.48 158.28 24.41 Favored 'General case' 0 N--CA 1.47 0.557 0 CA-C-N 114.944 -1.025 . . . . 0.0 110.681 179.702 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 11.0 m-20 -140.51 138.03 34.26 Favored 'General case' 0 N--CA 1.476 0.833 0 C-N-CA 122.985 0.514 . . . . 0.0 110.483 179.887 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 18.9 t -92.22 -116.79 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.288 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 179.587 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . -102.2 55.13 0.72 Allowed Glycine 0 N--CA 1.473 1.137 0 N-CA-C 111.226 -0.749 . . . . 0.0 111.226 -179.881 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 81.1 p -83.37 124.42 30.63 Favored 'General case' 0 N--CA 1.468 0.443 0 N-CA-C 109.205 -0.665 . . . . 0.0 109.205 177.819 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 62.9 t30 -64.58 101.42 0.46 Allowed 'General case' 0 N--CA 1.474 0.728 0 N-CA-C 108.307 -0.998 . . . . 0.0 108.307 178.725 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 64.3 mttm -98.07 113.32 25.16 Favored 'General case' 0 N--CA 1.488 1.469 0 N-CA-C 109.888 -0.412 . . . . 0.0 109.888 -178.603 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.06 -133.62 0.01 OUTLIER Glycine 0 CA--C 1.533 1.215 0 N-CA-C 111.471 -0.652 . . . . 0.0 111.471 178.894 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -113.19 126.87 55.9 Favored 'General case' 0 N--CA 1.477 0.907 0 N-CA-C 109.265 -0.642 . . . . 0.0 109.265 179.382 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 65.6 mt -90.13 130.24 39.72 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.279 0 N-CA-C 107.104 -1.443 . . . . 0.0 107.104 178.797 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 13.5 mt -142.99 153.42 16.99 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.825 0 N-CA-C 109.069 -0.715 . . . . 0.0 109.069 -179.42 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.71 49.94 65.13 Favored Glycine 0 CA--C 1.524 0.651 0 CA-C-N 116.432 -0.349 . . . . 0.0 113.153 179.022 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 2.9 tt -99.62 120.59 39.92 Favored 'General case' 0 N--CA 1.48 1.03 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 177.599 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 28.1 ttt -152.01 159.18 43.8 Favored 'General case' 0 N--CA 1.477 0.916 0 N-CA-C 108.373 -0.973 . . . . 0.0 108.373 179.578 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 95.7 t -159.49 149.23 6.93 Favored 'Isoleucine or valine' 0 C--O 1.237 0.419 0 N-CA-C 106.605 -1.628 . . . . 0.0 106.605 -179.816 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 57.32 72.19 0.62 Allowed Glycine 0 C--N 1.316 -0.579 0 CA-C-N 115.523 -0.762 . . . . 0.0 111.316 178.155 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 173.72 -155.66 22.45 Favored Glycine 0 C--O 1.219 -0.811 0 N-CA-C 111.123 -0.791 . . . . 0.0 111.123 -179.831 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 33.5 m -126.2 142.59 42.39 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.757 0 N-CA-C 109.203 -0.666 . . . . 0.0 109.203 179.379 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 15.1 t . . . . . 0 CA--C 1.538 0.509 0 CA-C-O 118.109 -0.948 . . . . 0.0 111.218 179.279 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 20.2 m-85 . . . . . 0 N--CA 1.474 0.734 0 CA-C-O 120.941 0.401 . . . . 0.0 109.971 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' F' F ' 5' ' ' ARG . . . . . . . . . . . . . 30.5 mtp180 -67.32 129.98 41.63 Favored 'General case' 0 C--O 1.217 -0.63 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.514 -178.162 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 4.0 m-70 -100.43 131.21 46.48 Favored 'General case' 0 N--CA 1.477 0.922 0 N-CA-C 109.572 -0.529 . . . . 0.0 109.572 179.358 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' F' F ' 7' ' ' ASP . . . . . . . . . . . . . 16.6 m-20 -71.37 142.02 50.36 Favored 'General case' 0 N--CA 1.464 0.26 0 O-C-N 123.422 0.451 . . . . 0.0 111.066 -179.786 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' F' F ' 8' ' ' SER . . . . . . . . . . . . . 8.4 t -144.67 -173.13 3.97 Favored 'General case' 0 N--CA 1.478 0.971 0 N-CA-C 108.958 -0.756 . . . . 0.0 108.958 178.002 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 118.6 11.73 7.73 Favored Glycine 0 N--CA 1.482 1.745 0 N-CA-C 112.126 -0.39 . . . . 0.0 112.126 179.072 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 43.4 p90 -58.64 128.22 36.08 Favored 'General case' 0 CA--C 1.544 0.738 0 N-CA-C 112.123 0.416 . . . . 0.0 112.123 -179.31 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 46.8 mt-10 -88.77 155.15 19.74 Favored 'General case' 0 N--CA 1.475 0.817 0 CA-C-O 121.303 0.573 . . . . 0.0 109.585 178.031 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -155.21 127.48 1.02 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.574 0 N-CA-C 108.338 -0.986 . . . . 0.0 108.338 178.505 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 48.0 m-70 -135.32 144.94 46.99 Favored 'General case' 0 N--CA 1.481 1.093 0 CA-C-O 120.681 0.277 . . . . 0.0 111.379 -177.923 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 6.3 t60 -163.78 98.16 0.86 Allowed 'General case' 0 N--CA 1.487 1.406 0 CA-C-N 116.697 -0.229 . . . . 0.0 111.145 179.645 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' F' F ' 15' ' ' GLN . . . . . 0.411 HE22 HG12 ' C' ' 36' ' ' VAL . 43.9 mt-30 -109.29 -171.97 1.95 Allowed 'General case' 0 CA--C 1.499 -1.015 0 N-CA-C 108.625 -0.88 . . . . 0.0 108.625 -179.911 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -166.84 98.57 0.55 Allowed 'General case' 0 CA--C 1.541 0.609 0 CA-C-N 114.895 -1.048 . . . . 0.0 109.483 178.778 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' F' F ' 17' ' ' LEU . . . . . 0.585 ' N ' HD12 ' F' ' 17' ' ' LEU . 4.4 mp -106.24 163.14 13.05 Favored 'General case' 0 N--CA 1.489 1.501 0 N-CA-C 109.141 -0.689 . . . . 0.0 109.141 -179.717 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 42.0 t -142.17 118.3 6.2 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.369 0 C-N-CA 122.507 0.323 . . . . 0.0 110.522 179.088 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 52.7 m-85 -69.27 157.17 37.51 Favored 'General case' 0 C--N 1.355 0.811 0 N-CA-C 107.151 -1.426 . . . . 0.0 107.151 176.563 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 12.3 t80 -173.75 -54.8 0.01 OUTLIER 'General case' 0 N--CA 1.486 1.344 0 CA-C-O 121.785 0.802 . . . . 0.0 109.752 179.688 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.35 88.68 0.0 OUTLIER 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 114.484 -1.234 . . . . 0.0 113.007 -178.893 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 37.0 tt0 -64.36 158.43 23.61 Favored 'General case' 0 N--CA 1.472 0.668 0 CA-C-N 114.999 -1.001 . . . . 0.0 110.895 179.481 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 11.8 m-20 -140.87 137.67 33.38 Favored 'General case' 0 N--CA 1.477 0.909 0 C-N-CA 122.893 0.477 . . . . 0.0 110.458 179.973 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' F' F ' 24' ' ' VAL . . . . . . . . . . . . . 18.6 t -91.88 -116.83 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.391 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 179.544 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -102.11 55.32 0.72 Allowed Glycine 0 N--CA 1.477 1.41 0 N-CA-C 110.953 -0.859 . . . . 0.0 110.953 -179.863 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 79.8 p -83.54 124.19 30.5 Favored 'General case' 0 N--CA 1.47 0.552 0 N-CA-C 109.012 -0.736 . . . . 0.0 109.012 177.726 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 62.3 t30 -64.44 101.47 0.45 Allowed 'General case' 0 N--CA 1.473 0.71 0 N-CA-C 108.375 -0.972 . . . . 0.0 108.375 178.684 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 64.3 mttm -98.04 113.26 25.08 Favored 'General case' 0 N--CA 1.488 1.46 0 N-CA-C 110.029 -0.36 . . . . 0.0 110.029 -178.648 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.07 -133.84 0.01 OUTLIER Glycine 0 CA--C 1.534 1.266 0 N-CA-C 111.559 -0.616 . . . . 0.0 111.559 178.901 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -112.69 127.17 56.05 Favored 'General case' 0 N--CA 1.477 0.885 0 N-CA-C 109.228 -0.656 . . . . 0.0 109.228 179.241 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 65.7 mt -90.53 130.15 40.22 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.286 0 N-CA-C 107.086 -1.45 . . . . 0.0 107.086 178.703 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 13.1 mt -142.9 153.6 17.18 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.763 0 N-CA-C 109.115 -0.698 . . . . 0.0 109.115 -179.33 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.59 49.73 67.14 Favored Glycine 0 CA--C 1.524 0.609 0 CA-C-N 116.486 -0.325 . . . . 0.0 113.141 179.098 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' F' F ' 34' ' ' LEU . . . . . 0.404 HD23 ' N ' ' F' ' 35' ' ' MET . 3.0 tt -99.48 120.79 40.2 Favored 'General case' 0 N--CA 1.478 0.944 0 N-CA-C 107.344 -1.354 . . . . 0.0 107.344 177.747 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' F' F ' 35' ' ' MET . . . . . 0.404 ' N ' HD23 ' F' ' 34' ' ' LEU . 28.1 ttt -152.68 159.86 43.17 Favored 'General case' 0 N--CA 1.472 0.667 0 N-CA-C 109.146 -0.687 . . . . 0.0 109.146 179.343 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' F' F ' 36' ' ' VAL . . . . . 0.407 HG12 HE22 ' I' ' 15' ' ' GLN . 95.4 t -159.75 149.4 6.6 Favored 'Isoleucine or valine' 0 C--O 1.237 0.429 0 N-CA-C 106.907 -1.516 . . . . 0.0 106.907 -179.586 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 57.26 72.68 0.55 Allowed Glycine 0 C--N 1.315 -0.596 0 CA-C-N 115.548 -0.751 . . . . 0.0 111.268 178.195 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 173.44 -155.29 22.04 Favored Glycine 0 C--O 1.219 -0.841 0 N-CA-C 111.119 -0.792 . . . . 0.0 111.119 -179.795 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 33.4 m -126.62 142.5 42.98 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.777 0 N-CA-C 109.206 -0.664 . . . . 0.0 109.206 179.372 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 15.3 t . . . . . 0 CA--C 1.539 0.521 0 CA-C-O 118.0 -1.0 . . . . 0.0 111.301 179.306 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 26.7 m-85 . . . . . 0 N--CA 1.473 0.695 0 CA-C-O 120.849 0.357 . . . . 0.0 110.226 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' G' G ' 5' ' ' ARG . . . . . . . . . . . . . 31.5 mtp180 -66.59 129.44 39.87 Favored 'General case' 0 N--CA 1.47 0.543 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.178 -178.297 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 4.1 m-70 -99.96 131.04 46.16 Favored 'General case' 0 N--CA 1.474 0.764 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 179.449 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 16.9 m-20 -72.21 137.85 47.15 Favored 'General case' 0 N--CA 1.466 0.358 0 O-C-N 123.638 0.586 . . . . 0.0 111.418 -179.488 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' G' G ' 8' ' ' SER . . . . . . . . . . . . . 8.0 t -142.16 -173.06 3.72 Favored 'General case' 0 N--CA 1.477 0.9 0 N-CA-C 109.114 -0.699 . . . . 0.0 109.114 178.038 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 119.13 12.97 6.66 Favored Glycine 0 N--CA 1.481 1.67 0 N-CA-C 111.725 -0.55 . . . . 0.0 111.725 179.075 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 47.4 p90 -59.52 128.25 36.09 Favored 'General case' 0 CA--C 1.541 0.604 0 N-CA-C 112.002 0.371 . . . . 0.0 112.002 -179.227 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 46.6 mt-10 -89.13 154.5 20.11 Favored 'General case' 0 N--CA 1.474 0.741 0 CA-C-O 121.208 0.528 . . . . 0.0 109.914 178.685 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 2.7 p -155.99 127.17 0.89 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.039 0 N-CA-C 108.334 -0.988 . . . . 0.0 108.334 178.765 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 51.4 m-70 -134.06 146.44 50.32 Favored 'General case' 0 N--CA 1.476 0.855 0 CA-C-N 115.289 -0.869 . . . . 0.0 110.997 -177.98 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 33.2 t-80 -165.41 97.47 0.69 Allowed 'General case' 0 N--CA 1.483 1.181 0 CA-C-N 116.542 -0.299 . . . . 0.0 110.691 179.064 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 43.7 mt-30 -108.62 -172.6 2.09 Favored 'General case' 0 CA--C 1.501 -0.928 0 N-CA-C 108.574 -0.898 . . . . 0.0 108.574 -179.787 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' G' G ' 16' ' ' LYS . . . . . 0.406 ' C ' HD12 ' G' ' 17' ' ' LEU . 88.5 tttt -166.47 98.69 0.59 Allowed 'General case' 0 CA--C 1.541 0.606 0 CA-C-N 115.018 -0.992 . . . . 0.0 109.383 178.714 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' G' G ' 17' ' ' LEU . . . . . 0.587 ' N ' HD12 ' G' ' 17' ' ' LEU . 5.1 mp -106.14 161.79 14.2 Favored 'General case' 0 N--CA 1.487 1.383 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 -179.581 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 40.8 t -142.53 118.74 5.83 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.052 0 CA-C-O 120.766 0.317 . . . . 0.0 110.449 178.724 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 45.8 m-85 -69.71 151.12 46.21 Favored 'General case' 0 C--N 1.369 1.417 0 N-CA-C 107.303 -1.369 . . . . 0.0 107.303 176.761 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 10.3 t80 -171.16 -55.1 0.02 OUTLIER 'General case' 0 N--CA 1.486 1.369 0 CA-C-N 118.006 0.367 . . . . 0.0 110.333 -179.662 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.65 90.25 0.0 OUTLIER 'General case' 0 C--N 1.326 -0.428 0 C-N-CA 123.716 0.807 . . . . 0.0 112.582 -179.819 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 37.1 tt0 -65.2 159.39 23.72 Favored 'General case' 0 N--CA 1.469 0.488 0 CA-C-N 114.669 -1.151 . . . . 0.0 110.086 179.076 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 12.0 m-20 -141.45 137.2 32.0 Favored 'General case' 0 N--CA 1.476 0.842 0 C-N-CA 122.905 0.482 . . . . 0.0 109.986 179.927 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' G' G ' 24' ' ' VAL . . . . . . . . . . . . . 15.8 t -92.31 -116.63 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.106 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 179.682 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -101.93 54.35 0.77 Allowed Glycine 0 N--CA 1.476 1.366 0 N-CA-C 111.581 -0.608 . . . . 0.0 111.581 -179.725 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 80.0 p -82.72 124.34 30.14 Favored 'General case' 0 N--CA 1.469 0.501 0 N-CA-C 108.952 -0.758 . . . . 0.0 108.952 177.864 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 59.1 t30 -64.77 101.35 0.47 Allowed 'General case' 0 N--CA 1.471 0.594 0 N-CA-C 108.585 -0.894 . . . . 0.0 108.585 178.586 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 64.7 mttm -97.32 114.43 26.2 Favored 'General case' 0 N--CA 1.486 1.373 0 N-CA-C 109.891 -0.411 . . . . 0.0 109.891 -178.955 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.69 -132.45 0.01 OUTLIER Glycine 0 CA--C 1.532 1.144 0 N-CA-C 110.767 -0.933 . . . . 0.0 110.767 179.045 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -112.81 126.24 55.22 Favored 'General case' 0 N--CA 1.469 0.508 0 C-N-CA 123.006 0.522 . . . . 0.0 109.661 179.602 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 68.7 mt -89.66 130.7 38.53 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.776 0 N-CA-C 107.263 -1.384 . . . . 0.0 107.263 178.555 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 15.9 mt -143.92 154.35 15.74 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.346 0 CA-C-N 118.945 0.793 . . . . 0.0 108.982 -179.91 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.8 49.02 71.24 Favored Glycine 0 CA--C 1.527 0.811 0 C-N-CA 121.803 -0.237 . . . . 0.0 112.75 179.155 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' G' G ' 34' ' ' LEU . . . . . 0.414 HD23 ' N ' ' G' ' 35' ' ' MET . 2.9 tt -98.93 121.96 41.57 Favored 'General case' 0 N--CA 1.479 0.982 0 N-CA-C 106.953 -1.499 . . . . 0.0 106.953 177.723 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' G' G ' 35' ' ' MET . . . . . 0.414 ' N ' HD23 ' G' ' 34' ' ' LEU . 28.2 ttt -153.76 159.83 42.07 Favored 'General case' 0 N--CA 1.48 1.048 0 N-CA-C 107.999 -1.111 . . . . 0.0 107.999 179.661 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 88.6 t -159.58 149.65 6.71 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 N-CA-C 106.231 -1.766 . . . . 0.0 106.231 -179.735 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 57.01 72.75 0.53 Allowed Glycine 0 C--N 1.314 -0.66 0 C-N-CA 121.055 -0.593 . . . . 0.0 111.781 177.921 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 172.15 -154.08 20.75 Favored Glycine 0 C--O 1.219 -0.838 0 N-CA-C 110.517 -1.033 . . . . 0.0 110.517 179.223 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 34.0 m -127.0 142.91 42.13 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.009 0 CA-C-N 117.041 0.421 . . . . 0.0 109.963 179.951 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 15.6 t . . . . . 0 N--CA 1.466 0.363 0 CA-C-O 118.193 -0.908 . . . . 0.0 111.382 179.631 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 26.2 m-85 . . . . . 0 N--CA 1.474 0.735 0 CA-C-O 120.912 0.387 . . . . 0.0 110.171 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' H' H ' 5' ' ' ARG . . . . . . . . . . . . . 31.0 mtp180 -66.46 129.43 39.81 Favored 'General case' 0 N--CA 1.469 0.477 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.309 -178.254 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 4.0 m-70 -100.0 131.17 46.12 Favored 'General case' 0 N--CA 1.474 0.773 0 N-CA-C 109.648 -0.501 . . . . 0.0 109.648 179.4 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 16.3 m-20 -72.42 137.7 46.66 Favored 'General case' 0 N--CA 1.466 0.35 0 O-C-N 123.526 0.517 . . . . 0.0 111.361 -179.484 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' H' H ' 8' ' ' SER . . . . . . . . . . . . . 8.4 t -141.86 -173.61 3.85 Favored 'General case' 0 N--CA 1.475 0.807 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 178.282 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 119.35 12.73 6.67 Favored Glycine 0 N--CA 1.484 1.888 0 N-CA-C 111.802 -0.519 . . . . 0.0 111.802 179.061 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 46.8 p90 -59.33 128.17 35.76 Favored 'General case' 0 CA--C 1.542 0.651 0 N-CA-C 112.042 0.386 . . . . 0.0 112.042 -179.338 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 46.6 mt-10 -88.96 154.34 20.3 Favored 'General case' 0 N--CA 1.475 0.78 0 CA-C-O 121.22 0.533 . . . . 0.0 109.892 178.694 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.7 p -155.77 127.2 0.92 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.009 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 178.712 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 50.8 m-70 -134.08 146.18 50.06 Favored 'General case' 0 N--CA 1.476 0.863 0 CA-C-N 115.313 -0.858 . . . . 0.0 111.203 -178.045 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 33.9 t-80 -165.08 97.58 0.73 Allowed 'General case' 0 N--CA 1.483 1.197 0 CA-C-N 116.583 -0.28 . . . . 0.0 110.716 179.039 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 43.8 mt-30 -108.57 -173.2 2.21 Favored 'General case' 0 CA--C 1.5 -0.966 0 N-CA-C 108.45 -0.945 . . . . 0.0 108.45 -179.787 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -166.12 98.39 0.63 Allowed 'General case' 0 N--CA 1.471 0.578 0 CA-C-N 114.984 -1.007 . . . . 0.0 109.341 178.727 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' H' H ' 17' ' ' LEU . . . . . 0.588 ' N ' HD12 ' H' ' 17' ' ' LEU . 5.1 mp -106.08 161.93 14.06 Favored 'General case' 0 N--CA 1.487 1.401 0 N-CA-C 109.394 -0.595 . . . . 0.0 109.394 -179.517 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 40.8 t -142.53 118.55 5.69 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.143 0 CA-C-O 120.775 0.321 . . . . 0.0 110.455 178.885 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 47.4 m-85 -69.85 151.44 45.71 Favored 'General case' 0 C--N 1.368 1.399 0 N-CA-C 107.334 -1.358 . . . . 0.0 107.334 176.59 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 10.9 t80 -172.37 -54.55 0.02 OUTLIER 'General case' 0 N--CA 1.484 1.246 0 CA-C-N 117.909 0.322 . . . . 0.0 110.21 -179.542 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.71 90.69 0.0 OUTLIER 'General case' 0 CA--C 1.534 0.356 0 C-N-CA 123.732 0.813 . . . . 0.0 112.298 -179.979 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 37.4 tt0 -65.74 159.29 25.45 Favored 'General case' 0 N--CA 1.47 0.537 0 CA-C-N 114.776 -1.102 . . . . 0.0 110.003 179.364 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 11.3 m-20 -141.29 137.55 32.54 Favored 'General case' 0 N--CA 1.476 0.837 0 C-N-CA 122.892 0.477 . . . . 0.0 109.919 179.861 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' H' H ' 24' ' ' VAL . . . . . . . . . . . . . 15.4 t -92.6 -116.94 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.09 0 N-CA-C 108.673 -0.862 . . . . 0.0 108.673 179.683 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . -101.48 54.25 0.8 Allowed Glycine 0 N--CA 1.479 1.538 0 N-CA-C 111.506 -0.638 . . . . 0.0 111.506 -179.742 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 80.3 p -82.85 124.54 30.41 Favored 'General case' 0 N--CA 1.469 0.497 0 N-CA-C 108.901 -0.778 . . . . 0.0 108.901 177.939 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 59.5 t30 -64.93 101.43 0.5 Allowed 'General case' 0 N--CA 1.472 0.664 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 178.679 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 65.1 mttm -97.33 114.11 25.84 Favored 'General case' 0 N--CA 1.485 1.321 0 N-CA-C 109.978 -0.378 . . . . 0.0 109.978 -179.021 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.42 -132.6 0.01 OUTLIER Glycine 0 CA--C 1.534 1.245 0 N-CA-C 110.845 -0.902 . . . . 0.0 110.845 179.053 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -112.72 126.28 55.24 Favored 'General case' 0 N--CA 1.471 0.603 0 C-N-CA 123.028 0.531 . . . . 0.0 109.662 179.59 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 68.0 mt -89.71 130.59 38.77 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.761 0 N-CA-C 107.35 -1.352 . . . . 0.0 107.35 178.506 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 16.3 mt -143.97 154.04 15.68 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.367 0 CA-C-N 118.922 0.783 . . . . 0.0 108.972 -179.74 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 64.09 49.01 69.75 Favored Glycine 0 CA--C 1.526 0.768 0 C-N-CA 121.717 -0.277 . . . . 0.0 112.81 179.184 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' H' H ' 34' ' ' LEU . . . . . 0.407 HD23 ' N ' ' H' ' 35' ' ' MET . 2.8 tt -99.02 121.66 41.26 Favored 'General case' 0 N--CA 1.477 0.914 0 N-CA-C 107.035 -1.469 . . . . 0.0 107.035 177.782 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' H' H ' 35' ' ' MET . . . . . 0.407 ' N ' HD23 ' H' ' 34' ' ' LEU . 28.2 ttt -153.4 159.75 42.47 Favored 'General case' 0 N--CA 1.48 1.036 0 N-CA-C 107.991 -1.115 . . . . 0.0 107.991 179.665 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 91.1 t -159.51 149.83 6.73 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 N-CA-C 106.278 -1.749 . . . . 0.0 106.278 -179.775 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.67 73.13 0.47 Allowed Glycine 0 C--N 1.313 -0.741 0 C-N-CA 120.982 -0.628 . . . . 0.0 111.727 178.117 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 171.65 -154.73 22.65 Favored Glycine 0 N--CA 1.468 0.806 0 N-CA-C 110.505 -1.038 . . . . 0.0 110.505 179.358 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 33.8 m -126.53 143.16 40.94 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.081 0 C-N-CA 122.663 0.385 . . . . 0.0 109.998 179.975 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 15.3 t . . . . . 0 N--CA 1.467 0.414 0 CA-C-O 118.137 -0.935 . . . . 0.0 111.293 179.544 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 25.9 m-85 . . . . . 0 N--CA 1.472 0.666 0 CA-C-O 120.843 0.354 . . . . 0.0 110.168 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' I' I ' 5' ' ' ARG . . . . . . . . . . . . . 31.0 mtp180 -66.72 129.13 38.85 Favored 'General case' 0 N--CA 1.471 0.625 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.293 -178.281 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 4.0 m-70 -99.72 130.97 45.98 Favored 'General case' 0 N--CA 1.474 0.768 0 N-CA-C 109.607 -0.516 . . . . 0.0 109.607 179.42 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 16.2 m-20 -72.05 138.02 47.57 Favored 'General case' 0 N--CA 1.466 0.336 0 O-C-N 123.539 0.525 . . . . 0.0 111.425 -179.546 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' I' I ' 8' ' ' SER . . . . . . . . . . . . . 8.5 t -142.26 -173.8 3.94 Favored 'General case' 0 N--CA 1.475 0.791 0 N-CA-C 109.078 -0.712 . . . . 0.0 109.078 178.388 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 119.46 12.66 6.65 Favored Glycine 0 N--CA 1.482 1.759 0 N-CA-C 111.864 -0.494 . . . . 0.0 111.864 179.185 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 47.5 p90 -59.15 128.38 36.86 Favored 'General case' 0 CA--C 1.541 0.625 0 N-CA-C 112.082 0.401 . . . . 0.0 112.082 -179.378 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 46.5 mt-10 -89.28 154.33 20.19 Favored 'General case' 0 N--CA 1.474 0.737 0 CA-C-O 121.101 0.477 . . . . 0.0 109.956 178.672 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 2.7 p -155.73 127.32 0.94 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.039 0 N-CA-C 108.373 -0.973 . . . . 0.0 108.373 178.722 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 50.2 m-70 -134.23 146.29 49.96 Favored 'General case' 0 N--CA 1.476 0.868 0 CA-C-N 115.276 -0.875 . . . . 0.0 111.145 -178.044 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 6.4 t60 -165.35 97.51 0.7 Allowed 'General case' 0 N--CA 1.484 1.244 0 CA-C-N 116.558 -0.292 . . . . 0.0 110.719 179.069 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' I' I ' 15' ' ' GLN . . . . . 0.407 HE22 HG12 ' F' ' 36' ' ' VAL . 44.2 mt-30 -108.57 -172.75 2.12 Favored 'General case' 0 CA--C 1.499 -1.002 0 N-CA-C 108.458 -0.941 . . . . 0.0 108.458 -179.737 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' I' I ' 16' ' ' LYS . . . . . 0.403 ' C ' HD12 ' I' ' 17' ' ' LEU . 88.4 tttt -166.48 98.45 0.59 Allowed 'General case' 0 CA--C 1.54 0.565 0 CA-C-N 114.921 -1.036 . . . . 0.0 109.29 178.803 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' I' I ' 17' ' ' LEU . . . . . 0.589 ' N ' HD12 ' I' ' 17' ' ' LEU . 5.1 mp -105.97 161.99 13.98 Favored 'General case' 0 N--CA 1.486 1.355 0 N-CA-C 109.448 -0.575 . . . . 0.0 109.448 -179.628 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 40.6 t -142.58 118.5 5.56 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.154 0 C-N-CA 122.494 0.318 . . . . 0.0 110.487 178.849 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 46.7 m-85 -69.92 151.34 45.76 Favored 'General case' 0 C--N 1.367 1.365 0 N-CA-C 107.31 -1.367 . . . . 0.0 107.31 176.712 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 10.9 t80 -172.17 -54.67 0.02 OUTLIER 'General case' 0 N--CA 1.485 1.296 0 CA-C-N 117.843 0.292 . . . . 0.0 110.218 -179.518 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.69 90.72 0.0 OUTLIER 'General case' 0 CA--C 1.536 0.408 0 C-N-CA 123.7 0.8 . . . . 0.0 112.251 -179.936 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 37.5 tt0 -65.69 159.31 25.26 Favored 'General case' 0 N--CA 1.47 0.549 0 CA-C-N 114.751 -1.113 . . . . 0.0 109.993 179.326 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 11.1 m-20 -141.34 137.5 32.42 Favored 'General case' 0 N--CA 1.476 0.836 0 C-N-CA 122.872 0.469 . . . . 0.0 110.034 179.839 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' I' I ' 24' ' ' VAL . . . . . . . . . . . . . 14.9 t -92.68 -116.77 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.112 0 N-CA-C 108.691 -0.855 . . . . 0.0 108.691 179.729 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . -101.51 54.45 0.79 Allowed Glycine 0 N--CA 1.476 1.357 0 CA-C-N 118.556 0.617 . . . . 0.0 111.585 -179.759 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 80.4 p -83.31 123.96 30.14 Favored 'General case' 0 N--CA 1.469 0.5 0 N-CA-C 108.916 -0.772 . . . . 0.0 108.916 178.059 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 59.7 t30 -64.53 101.63 0.47 Allowed 'General case' 0 N--CA 1.473 0.681 0 N-CA-C 108.588 -0.893 . . . . 0.0 108.588 178.618 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 64.7 mttm -97.57 114.28 26.16 Favored 'General case' 0 N--CA 1.486 1.354 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -178.952 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.45 -132.63 0.01 OUTLIER Glycine 0 CA--C 1.532 1.137 0 N-CA-C 110.803 -0.919 . . . . 0.0 110.803 179.093 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -112.73 126.09 55.02 Favored 'General case' 0 N--CA 1.471 0.586 0 C-N-CA 123.058 0.543 . . . . 0.0 109.614 179.601 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 68.3 mt -89.68 130.75 38.47 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.783 0 N-CA-C 107.264 -1.384 . . . . 0.0 107.264 178.61 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 16.2 mt -143.98 154.47 15.65 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.337 0 CA-C-N 118.892 0.769 . . . . 0.0 108.984 -179.807 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.75 48.84 73.19 Favored Glycine 0 CA--C 1.526 0.775 0 C-N-CA 121.678 -0.296 . . . . 0.0 112.792 179.134 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' I' I ' 34' ' ' LEU . . . . . 0.409 HD23 ' N ' ' I' ' 35' ' ' MET . 2.9 tt -98.84 121.94 41.43 Favored 'General case' 0 N--CA 1.478 0.947 0 N-CA-C 106.874 -1.528 . . . . 0.0 106.874 177.741 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' I' I ' 35' ' ' MET . . . . . 0.409 ' N ' HD23 ' I' ' 34' ' ' LEU . 28.2 ttt -153.53 159.72 42.3 Favored 'General case' 0 N--CA 1.478 0.963 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 179.616 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 90.9 t -159.54 149.75 6.73 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.224 0 N-CA-C 106.253 -1.758 . . . . 0.0 106.253 -179.804 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.94 72.79 0.53 Allowed Glycine 0 C--N 1.314 -0.69 0 C-N-CA 121.022 -0.609 . . . . 0.0 111.778 178.011 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 171.95 -154.4 21.66 Favored Glycine 0 N--CA 1.468 0.767 0 N-CA-C 110.529 -1.029 . . . . 0.0 110.529 179.257 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 33.8 m -126.61 142.84 42.0 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.064 0 C-N-CA 122.743 0.417 . . . . 0.0 109.994 179.943 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 15.5 t . . . . . 0 N--CA 1.465 0.306 0 CA-C-O 118.239 -0.886 . . . . 0.0 111.328 179.539 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 78.9 m-85 . . . . . 0 N--CA 1.475 0.818 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 71.9 mtp180 -143.84 141.28 30.26 Favored 'General case' 0 N--CA 1.481 1.102 0 N-CA-C 109.079 -0.712 . . . . 0.0 109.079 -179.879 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 76.7 m80 -149.53 119.92 7.37 Favored 'General case' 0 N--CA 1.469 0.502 0 N-CA-C 108.79 -0.819 . . . . 0.0 108.79 179.147 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 8.5 m-20 -68.02 149.95 49.06 Favored 'General case' 0 CA--C 1.53 0.196 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.16 -179.391 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 7.6 t -167.13 171.36 11.0 Favored 'General case' 0 N--CA 1.472 0.655 0 N-CA-C 109.551 -0.537 . . . . 0.0 109.551 178.581 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.48 23.65 2.31 Favored Glycine 0 N--CA 1.488 2.156 0 N-CA-C 112.209 -0.356 . . . . 0.0 112.209 179.37 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 42.8 p90 -56.64 128.37 36.02 Favored 'General case' 0 N--CA 1.475 0.815 0 N-CA-C 112.078 0.399 . . . . 0.0 112.078 -179.83 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 45.5 mt-10 -85.05 154.66 21.94 Favored 'General case' 0 C--N 1.344 0.358 0 N-CA-C 109.08 -0.711 . . . . 0.0 109.08 178.535 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -153.69 129.5 1.72 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.371 0 N-CA-C 108.151 -1.055 . . . . 0.0 108.151 178.928 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 48.6 m-70 -134.93 144.99 47.77 Favored 'General case' 0 N--CA 1.489 1.49 0 CA-C-N 118.683 0.674 . . . . 0.0 111.104 -179.116 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -165.9 98.31 0.65 Allowed 'General case' 0 N--CA 1.482 1.169 0 CA-C-N 116.603 -0.271 . . . . 0.0 110.984 179.628 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 40.0 mt-30 -108.54 -172.05 1.98 Allowed 'General case' 0 CA--C 1.503 -0.831 0 N-CA-C 108.174 -1.047 . . . . 0.0 108.174 -179.99 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -165.96 97.24 0.63 Allowed 'General case' 0 N--CA 1.471 0.613 0 CA-C-N 115.16 -0.927 . . . . 0.0 109.348 178.739 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.585 ' N ' HD12 ' A' ' 17' ' ' LEU . 4.7 mp -106.03 164.18 12.18 Favored 'General case' 0 N--CA 1.488 1.474 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 179.931 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 49.9 t -141.71 119.18 8.07 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.339 0 CA-C-O 118.888 -0.577 . . . . 0.0 109.98 179.657 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 50.9 m-85 -69.95 159.23 34.13 Favored 'General case' 0 N--CA 1.48 1.071 0 N-CA-C 107.573 -1.269 . . . . 0.0 107.573 177.287 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 12.9 t80 -171.44 -58.02 0.02 OUTLIER 'General case' 0 N--CA 1.485 1.305 0 CA-C-O 122.33 1.062 . . . . 0.0 109.772 179.481 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -38.83 90.48 0.0 OUTLIER 'General case' 0 C--O 1.232 0.165 0 CA-C-N 113.888 -1.505 . . . . 0.0 112.866 -177.929 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 54.4 tt0 -67.57 157.93 33.23 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 115.006 -0.997 . . . . 0.0 110.532 179.145 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 67.3 m-20 -140.02 137.72 34.87 Favored 'General case' 0 N--CA 1.481 1.112 0 C-N-CA 122.891 0.476 . . . . 0.0 110.339 179.762 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 17.2 t -84.42 -116.44 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.912 0 N-CA-C 108.51 -0.922 . . . . 0.0 108.51 179.541 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -110.67 54.5 0.54 Allowed Glycine 0 N--CA 1.473 1.137 0 N-CA-C 111.21 -0.756 . . . . 0.0 111.21 -179.935 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 70.5 p -80.12 126.24 30.83 Favored 'General case' 0 C--O 1.221 -0.434 0 N-CA-C 108.983 -0.747 . . . . 0.0 108.983 178.422 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 27' ' ' ASN . . . . . 0.459 HD21 ' HB3' ' D' ' 27' ' ' ASN . 2.1 t-20 -66.91 100.01 0.69 Allowed 'General case' 0 N--CA 1.472 0.644 0 N-CA-C 108.693 -0.854 . . . . 0.0 108.693 178.582 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 66.7 mttm -96.42 120.13 36.16 Favored 'General case' 0 N--CA 1.484 1.243 0 N-CA-C 110.087 -0.338 . . . . 0.0 110.087 -179.081 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.78 -126.36 0.01 OUTLIER Glycine 0 CA--C 1.532 1.154 0 N-CA-C 110.488 -1.045 . . . . 0.0 110.488 178.615 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -127.48 133.83 49.85 Favored 'General case' 0 N--CA 1.479 1.0 0 N-CA-C 109.294 -0.632 . . . . 0.0 109.294 179.112 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 66.9 mt -83.22 138.61 19.01 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.589 0 N-CA-C 107.136 -1.431 . . . . 0.0 107.136 178.54 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 18.7 mt -128.59 128.75 68.29 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.961 0 O-C-N 123.504 0.503 . . . . 0.0 110.123 -178.547 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 60.78 79.25 0.12 Allowed Glycine 0 CA--C 1.527 0.837 0 CA-C-N 116.003 -0.544 . . . . 0.0 112.95 178.898 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.402 HD23 ' N ' ' A' ' 35' ' ' MET . 2.0 tt -110.94 118.85 37.2 Favored 'General case' 0 N--CA 1.478 0.926 0 N-CA-C 106.932 -1.507 . . . . 0.0 106.932 177.432 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 35' ' ' MET . . . . . 0.402 ' N ' HD23 ' A' ' 34' ' ' LEU . 8.8 ttt -155.04 161.02 41.45 Favored 'General case' 0 N--CA 1.469 0.504 0 N-CA-C 109.077 -0.712 . . . . 0.0 109.077 179.339 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 93.6 t -157.96 150.73 8.14 Favored 'Isoleucine or valine' 0 C--O 1.234 0.277 0 N-CA-C 106.83 -1.545 . . . . 0.0 106.83 -179.598 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.6 75.17 0.25 Allowed Glycine 0 C--N 1.314 -0.689 0 CA-C-N 115.703 -0.68 . . . . 0.0 111.739 178.332 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 168.83 -148.72 12.65 Favored Glycine 0 CA--C 1.519 0.305 0 N-CA-C 110.692 -0.963 . . . . 0.0 110.692 179.742 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 21.1 m -132.9 142.47 42.2 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.887 0 N-CA-C 109.624 -0.509 . . . . 0.0 109.624 179.82 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 21.3 t . . . . . 0 N--CA 1.468 0.43 0 CA-C-O 117.851 -1.071 . . . . 0.0 110.725 179.225 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 79.8 m-85 . . . . . 0 N--CA 1.474 0.766 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 71.7 mtp180 -143.94 141.39 30.19 Favored 'General case' 0 N--CA 1.481 1.079 0 N-CA-C 109.136 -0.69 . . . . 0.0 109.136 -179.861 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 76.9 m80 -149.66 120.01 7.36 Favored 'General case' 0 N--CA 1.471 0.581 0 N-CA-C 108.772 -0.825 . . . . 0.0 108.772 179.117 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 7' ' ' ASP . . . . . . . . . . . . . 8.5 m-20 -67.96 149.45 49.75 Favored 'General case' 0 CA--C 1.531 0.217 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.226 -179.414 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 8' ' ' SER . . . . . . . . . . . . . 7.4 t -166.71 171.57 11.4 Favored 'General case' 0 N--CA 1.473 0.691 0 N-CA-C 109.583 -0.525 . . . . 0.0 109.583 178.501 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.26 23.94 2.31 Favored Glycine 0 N--CA 1.488 2.135 0 N-CA-C 112.122 -0.391 . . . . 0.0 112.122 179.425 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 42.4 p90 -56.9 128.11 35.18 Favored 'General case' 0 N--CA 1.473 0.681 0 N-CA-C 112.159 0.429 . . . . 0.0 112.159 -179.864 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 45.5 mt-10 -84.79 154.61 22.26 Favored 'General case' 0 N--CA 1.469 0.486 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 178.532 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -153.59 129.32 1.69 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.333 0 N-CA-C 108.268 -1.012 . . . . 0.0 108.268 178.914 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 48.6 m-70 -134.82 145.16 48.08 Favored 'General case' 0 N--CA 1.49 1.559 0 CA-C-N 118.556 0.616 . . . . 0.0 111.052 -179.062 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -166.11 98.33 0.63 Allowed 'General case' 0 N--CA 1.483 1.214 0 CA-C-N 116.607 -0.269 . . . . 0.0 110.96 179.654 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 39.8 mt-30 -108.56 -172.2 2.01 Favored 'General case' 0 CA--C 1.503 -0.854 0 N-CA-C 108.201 -1.037 . . . . 0.0 108.201 -179.901 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -165.95 96.95 0.63 Allowed 'General case' 0 CA--C 1.54 0.581 0 CA-C-N 115.121 -0.945 . . . . 0.0 109.337 178.817 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 17' ' ' LEU . . . . . 0.579 ' N ' HD12 ' B' ' 17' ' ' LEU . 4.9 mp -105.88 164.14 12.18 Favored 'General case' 0 N--CA 1.487 1.398 0 N-CA-C 108.611 -0.885 . . . . 0.0 108.611 179.868 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 53.9 t -141.69 119.16 8.08 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.269 0 CA-C-O 118.939 -0.553 . . . . 0.0 109.982 179.577 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 51.6 m-85 -70.41 159.3 34.45 Favored 'General case' 0 N--CA 1.479 0.983 0 N-CA-C 107.557 -1.275 . . . . 0.0 107.557 177.248 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 13.9 t80 -172.14 -57.25 0.02 OUTLIER 'General case' 0 N--CA 1.483 1.211 0 CA-C-O 122.2 1.0 . . . . 0.0 109.792 179.522 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -38.88 90.83 0.0 OUTLIER 'General case' 0 CA--C 1.529 0.159 0 CA-C-N 114.136 -1.393 . . . . 0.0 112.797 -178.005 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 54.2 tt0 -67.93 157.71 34.39 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 115.028 -0.987 . . . . 0.0 110.547 179.314 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 67.3 m-20 -139.86 137.75 35.16 Favored 'General case' 0 N--CA 1.481 1.082 0 C-N-CA 122.954 0.502 . . . . 0.0 110.287 179.71 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 18.1 t -84.66 -116.4 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.988 0 N-CA-C 108.577 -0.897 . . . . 0.0 108.577 179.665 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -110.13 54.37 0.55 Allowed Glycine 0 C--N 1.349 1.253 0 N-CA-C 111.167 -0.773 . . . . 0.0 111.167 -179.951 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 73.1 p -80.39 125.91 30.51 Favored 'General case' 0 C--O 1.221 -0.432 0 N-CA-C 109.037 -0.727 . . . . 0.0 109.037 178.434 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 27' ' ' ASN . . . . . 0.443 HD21 ' HB3' ' E' ' 27' ' ' ASN . 2.1 t-20 -66.73 100.41 0.7 Allowed 'General case' 0 N--CA 1.473 0.708 0 N-CA-C 108.657 -0.868 . . . . 0.0 108.657 178.613 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 66.7 mttm -96.81 120.04 36.41 Favored 'General case' 0 N--CA 1.483 1.205 0 N-CA-C 110.132 -0.321 . . . . 0.0 110.132 -179.035 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.57 -126.04 0.01 OUTLIER Glycine 0 CA--C 1.534 1.28 0 N-CA-C 110.453 -1.059 . . . . 0.0 110.453 178.618 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.13 133.75 49.02 Favored 'General case' 0 N--CA 1.48 1.026 0 N-CA-C 109.269 -0.641 . . . . 0.0 109.269 179.185 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 67.0 mt -83.15 138.6 19.04 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.476 0 N-CA-C 107.204 -1.406 . . . . 0.0 107.204 178.535 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 19.1 mt -128.53 128.42 68.02 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.928 0 O-C-N 123.537 0.523 . . . . 0.0 110.21 -178.412 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 60.96 78.98 0.13 Allowed Glycine 0 CA--C 1.526 0.777 0 CA-C-N 116.016 -0.538 . . . . 0.0 112.955 178.848 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 34' ' ' LEU . . . . . 0.401 HD23 ' N ' ' B' ' 35' ' ' MET . 2.0 tt -110.71 118.88 37.38 Favored 'General case' 0 N--CA 1.476 0.869 0 N-CA-C 106.94 -1.504 . . . . 0.0 106.94 177.386 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 35' ' ' MET . . . . . 0.401 ' N ' HD23 ' B' ' 34' ' ' LEU . 8.8 ttt -155.0 161.05 41.48 Favored 'General case' 0 N--CA 1.47 0.552 0 N-CA-C 109.096 -0.705 . . . . 0.0 109.096 179.247 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 92.9 t -158.04 150.73 8.06 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.192 0 N-CA-C 106.744 -1.576 . . . . 0.0 106.744 -179.555 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.44 75.31 0.25 Allowed Glycine 0 C--N 1.314 -0.654 0 CA-C-N 115.628 -0.714 . . . . 0.0 111.797 178.422 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 168.57 -149.14 13.4 Favored Glycine 0 CA--C 1.519 0.292 0 N-CA-C 110.686 -0.966 . . . . 0.0 110.686 179.76 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 21.5 m -132.36 142.7 41.97 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.834 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 179.65 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 21.3 t . . . . . 0 N--CA 1.467 0.41 0 CA-C-O 117.789 -1.101 . . . . 0.0 110.765 179.309 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 78.6 m-85 . . . . . 0 N--CA 1.475 0.797 0 N-CA-C 109.878 -0.416 . . . . 0.0 109.878 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 71.9 mtp180 -143.76 141.36 30.4 Favored 'General case' 0 N--CA 1.482 1.131 0 N-CA-C 109.077 -0.712 . . . . 0.0 109.077 -179.905 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 76.8 m80 -149.63 119.76 7.24 Favored 'General case' 0 N--CA 1.469 0.523 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 179.145 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 7' ' ' ASP . . . . . . . . . . . . . 8.2 m-20 -67.7 149.55 49.85 Favored 'General case' 0 N--CA 1.463 0.199 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.227 -179.41 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 8' ' ' SER . . . . . . . . . . . . . 7.6 t -166.97 171.14 11.44 Favored 'General case' 0 N--CA 1.473 0.682 0 N-CA-C 109.499 -0.556 . . . . 0.0 109.499 178.429 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.83 23.76 2.21 Favored Glycine 0 N--CA 1.487 2.093 0 N-CA-C 112.099 -0.4 . . . . 0.0 112.099 179.355 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 42.1 p90 -56.63 127.99 34.14 Favored 'General case' 0 N--CA 1.473 0.718 0 N-CA-C 112.125 0.417 . . . . 0.0 112.125 -179.847 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 45.8 mt-10 -84.74 154.73 22.24 Favored 'General case' 0 N--CA 1.468 0.448 0 N-CA-C 109.126 -0.694 . . . . 0.0 109.126 178.507 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -153.61 129.24 1.65 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.293 0 N-CA-C 108.274 -1.01 . . . . 0.0 108.274 178.863 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 48.7 m-70 -134.71 144.95 48.05 Favored 'General case' 0 N--CA 1.489 1.517 0 CA-C-N 118.635 0.652 . . . . 0.0 111.043 -179.012 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -165.95 98.51 0.64 Allowed 'General case' 0 N--CA 1.483 1.184 0 CA-C-N 116.578 -0.283 . . . . 0.0 111.013 179.665 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 39.7 mt-30 -108.91 -172.21 2.0 Favored 'General case' 0 CA--C 1.501 -0.939 0 N-CA-C 108.276 -1.009 . . . . 0.0 108.276 -179.959 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 16' ' ' LYS . . . . . 0.402 ' C ' HD12 ' C' ' 17' ' ' LEU . 88.4 tttt -165.87 97.38 0.64 Allowed 'General case' 0 CA--C 1.54 0.587 0 CA-C-N 115.104 -0.953 . . . . 0.0 109.348 178.749 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 17' ' ' LEU . . . . . 0.574 ' N ' HD12 ' C' ' 17' ' ' LEU . 4.8 mp -106.07 163.99 12.34 Favored 'General case' 0 N--CA 1.488 1.433 0 N-CA-C 108.577 -0.897 . . . . 0.0 108.577 179.937 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 53.7 t -141.62 119.19 8.28 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.283 0 CA-C-O 119.05 -0.5 . . . . 0.0 109.885 179.529 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 51.2 m-85 -70.47 159.28 34.54 Favored 'General case' 0 N--CA 1.478 0.964 0 N-CA-C 107.469 -1.308 . . . . 0.0 107.469 177.299 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 14.2 t80 -171.96 -57.33 0.02 OUTLIER 'General case' 0 N--CA 1.482 1.15 0 CA-C-O 122.24 1.019 . . . . 0.0 109.847 179.461 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -38.77 90.72 0.0 OUTLIER 'General case' 0 C--O 1.232 0.144 0 CA-C-N 114.129 -1.396 . . . . 0.0 112.804 -178.024 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 54.0 tt0 -67.88 157.7 34.31 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.122 -0.945 . . . . 0.0 110.595 179.254 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 67.4 m-20 -139.86 137.96 35.33 Favored 'General case' 0 N--CA 1.482 1.134 0 C-N-CA 122.854 0.462 . . . . 0.0 110.245 179.728 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 17.7 t -84.85 -116.44 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.985 0 N-CA-C 108.506 -0.924 . . . . 0.0 108.506 179.693 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -110.12 54.27 0.55 Allowed Glycine 0 N--CA 1.474 1.227 0 N-CA-C 111.175 -0.77 . . . . 0.0 111.175 -179.865 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 73.8 p -80.32 126.18 30.82 Favored 'General case' 0 C--O 1.22 -0.455 0 N-CA-C 109.07 -0.715 . . . . 0.0 109.07 178.414 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 27' ' ' ASN . . . . . 0.435 HD21 ' HB3' ' F' ' 27' ' ' ASN . 2.1 t-20 -66.94 100.28 0.72 Allowed 'General case' 0 N--CA 1.473 0.704 0 N-CA-C 108.673 -0.862 . . . . 0.0 108.673 178.563 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 66.9 mttm -96.79 119.68 35.72 Favored 'General case' 0 N--CA 1.482 1.172 0 N-CA-C 110.238 -0.282 . . . . 0.0 110.238 -179.169 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.31 -125.96 0.01 OUTLIER Glycine 0 CA--C 1.534 1.268 0 N-CA-C 110.534 -1.026 . . . . 0.0 110.534 178.727 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.01 133.7 49.17 Favored 'General case' 0 N--CA 1.482 1.14 0 N-CA-C 109.263 -0.643 . . . . 0.0 109.263 179.171 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 67.3 mt -83.12 138.54 19.15 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.456 0 N-CA-C 107.129 -1.434 . . . . 0.0 107.129 178.538 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 18.0 mt -128.5 128.74 68.44 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.987 0 O-C-N 123.626 0.579 . . . . 0.0 110.16 -178.519 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 60.67 78.93 0.13 Allowed Glycine 0 CA--C 1.527 0.797 0 CA-C-N 116.018 -0.537 . . . . 0.0 113.033 178.844 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 34' ' ' LEU . . . . . 0.4 HD23 ' N ' ' C' ' 35' ' ' MET . 2.0 tt -110.58 118.94 37.58 Favored 'General case' 0 N--CA 1.477 0.89 0 N-CA-C 106.902 -1.518 . . . . 0.0 106.902 177.37 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 35' ' ' MET . . . . . 0.4 ' N ' HD23 ' C' ' 34' ' ' LEU . 8.7 ttt -155.07 160.94 41.38 Favored 'General case' 0 N--CA 1.469 0.501 0 N-CA-C 109.125 -0.694 . . . . 0.0 109.125 179.185 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 93.0 t -157.93 150.57 8.28 Favored 'Isoleucine or valine' 0 C--O 1.233 0.203 0 N-CA-C 106.74 -1.578 . . . . 0.0 106.74 -179.566 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.7 75.32 0.25 Allowed Glycine 0 C--N 1.314 -0.649 0 CA-C-N 115.691 -0.686 . . . . 0.0 111.814 178.368 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 168.61 -148.78 12.84 Favored Glycine 0 CA--C 1.52 0.382 0 N-CA-C 110.631 -0.988 . . . . 0.0 110.631 179.862 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 21.5 m -132.89 142.56 41.97 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.814 0 N-CA-C 109.696 -0.483 . . . . 0.0 109.696 179.707 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 21.3 t . . . . . 0 N--CA 1.468 0.443 0 CA-C-O 117.772 -1.109 . . . . 0.0 110.801 179.376 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 87.7 m-85 . . . . . 0 N--CA 1.473 0.71 0 N-CA-C 108.283 -1.006 . . . . 0.0 108.283 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' D' D ' 5' ' ' ARG . . . . . . . . . . . . . 71.2 mtp180 -147.45 141.35 25.84 Favored 'General case' 0 N--CA 1.475 0.82 0 N-CA-C 108.961 -0.755 . . . . 0.0 108.961 179.746 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 77.1 m80 -149.17 123.6 9.67 Favored 'General case' 0 CA--C 1.538 0.51 0 N-CA-C 107.891 -1.152 . . . . 0.0 107.891 175.875 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 7' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -63.3 133.55 54.34 Favored 'General case' 0 C--N 1.321 -0.668 0 C-N-CA 127.049 2.139 . . . . 0.0 114.697 176.251 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 8' ' ' SER . . . . . . . . . . . . . 6.6 t -154.03 173.56 15.85 Favored 'General case' 0 N--CA 1.478 0.951 0 CA-C-N 118.533 0.606 . . . . 0.0 110.296 177.074 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 124.29 20.45 2.44 Favored Glycine 0 N--CA 1.485 1.917 0 N-CA-C 112.126 -0.39 . . . . 0.0 112.126 176.579 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 37.2 p90 -55.81 130.46 43.56 Favored 'General case' 0 CA--C 1.546 0.804 0 CA-C-O 121.126 0.489 . . . . 0.0 111.889 -177.355 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 46.0 mt-10 -85.26 152.42 23.33 Favored 'General case' 0 N--CA 1.473 0.694 0 N-CA-C 109.732 -0.469 . . . . 0.0 109.732 177.763 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -149.51 130.05 4.41 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.472 0 N-CA-C 108.222 -1.029 . . . . 0.0 108.222 175.593 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 46.9 m-70 -129.64 148.07 51.49 Favored 'General case' 0 N--CA 1.483 1.201 0 CA-C-N 118.009 0.368 . . . . 0.0 111.423 176.708 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -165.37 104.76 0.74 Allowed 'General case' 0 N--CA 1.483 1.207 0 N-CA-C 109.623 -0.51 . . . . 0.0 109.623 173.453 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 39.1 mt-30 -112.02 -175.66 2.74 Favored 'General case' 0 CA--C 1.493 -1.214 0 N-CA-C 108.019 -1.104 . . . . 0.0 108.019 179.348 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 16' ' ' LYS . . . . . 0.444 ' C ' HD12 ' D' ' 17' ' ' LEU . 88.7 tttt -162.09 105.9 1.19 Allowed 'General case' 0 CA--C 1.538 0.506 0 N-CA-C 107.603 -1.258 . . . . 0.0 107.603 175.386 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' D' D ' 17' ' ' LEU . . . . . 0.524 ' N ' HD12 ' D' ' 17' ' ' LEU . 5.7 mp -112.69 163.07 15.0 Favored 'General case' 0 N--CA 1.487 1.407 0 N-CA-C 108.095 -1.076 . . . . 0.0 108.095 179.536 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 48.1 t -140.92 123.59 15.56 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.072 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 176.158 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 76.1 m-85 -62.77 151.3 39.06 Favored 'General case' 0 C--N 1.351 0.652 0 C-N-CA 124.688 1.195 . . . . 0.0 110.386 170.774 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 9.0 t80 -169.86 -66.59 0.02 OUTLIER 'General case' 0 N--CA 1.476 0.827 0 N-CA-C 107.816 -1.179 . . . . 0.0 107.816 -179.707 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -37.83 96.11 0.01 OUTLIER 'General case' 0 CA--C 1.536 0.425 0 CA-C-N 113.919 -1.491 . . . . 0.0 111.583 -174.353 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 54.1 tt0 -69.98 158.52 35.48 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 113.459 -1.7 . . . . 0.0 110.17 178.767 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 68.1 m-20 -140.14 141.32 36.07 Favored 'General case' 0 N--CA 1.477 0.875 0 N-CA-C 109.496 -0.557 . . . . 0.0 109.496 178.581 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 24' ' ' VAL . . . . . . . . . . . . . 19.7 t -87.7 -119.19 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.486 1.372 0 N-CA-C 107.91 -1.144 . . . . 0.0 107.91 179.816 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . -113.93 61.98 0.33 Allowed Glycine 0 C--N 1.371 2.495 0 C-N-CA 118.073 -2.013 . . . . 0.0 109.441 178.612 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 89.1 p -70.54 121.37 17.7 Favored 'General case' 0 C--O 1.24 0.601 0 CA-C-O 116.521 -1.704 . . . . 0.0 112.184 169.162 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 27' ' ' ASN . . . . . 0.459 ' HB3' HD21 ' A' ' 27' ' ' ASN . 57.1 t30 -61.4 101.83 0.2 Allowed 'General case' 0 N--CA 1.475 0.788 0 CA-C-N 121.625 2.011 . . . . 0.0 109.489 172.464 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 66.5 mttm -100.17 121.44 41.44 Favored 'General case' 0 N--CA 1.488 1.453 0 CA-C-N 119.681 1.128 . . . . 0.0 109.378 178.673 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -53.96 -130.12 0.0 OUTLIER Glycine 0 CA--C 1.529 0.938 0 CA-C-N 115.535 -0.757 . . . . 0.0 112.284 175.008 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -125.23 139.84 53.38 Favored 'General case' 0 C--N 1.37 1.498 0 N-CA-C 108.666 -0.864 . . . . 0.0 108.666 174.278 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 66.4 mt -83.9 141.12 15.2 Favored 'Isoleucine or valine' 0 C--O 1.239 0.527 0 N-CA-C 107.145 -1.428 . . . . 0.0 107.145 176.29 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 25.6 mt -131.31 132.89 62.81 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.058 0 N-CA-C 108.59 -0.893 . . . . 0.0 108.59 178.253 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.88 77.16 0.21 Allowed Glycine 0 C--O 1.248 1.014 0 CA-C-O 118.351 -1.249 . . . . 0.0 112.618 178.791 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 2.5 tt -109.87 131.06 55.41 Favored 'General case' 0 C--N 1.376 1.756 0 N-CA-C 104.135 -2.543 . . . . 0.0 104.135 174.722 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 8.5 ttt -157.12 166.69 32.56 Favored 'General case' 0 C--O 1.219 -0.544 0 N-CA-C 108.794 -0.817 . . . . 0.0 108.794 176.44 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 88.8 t -163.57 154.78 2.45 Favored 'Isoleucine or valine' 0 C--O 1.24 0.566 0 N-CA-C 105.476 -2.046 . . . . 0.0 105.476 175.075 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 61.15 66.54 2.61 Favored Glycine 0 N--CA 1.444 -0.769 0 C-N-CA 117.875 -2.107 . . . . 0.0 113.674 177.125 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 166.82 -147.67 12.28 Favored Glycine 0 N--CA 1.466 0.688 0 CA-C-O 117.807 -1.552 . . . . 0.0 112.2 -179.045 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 22.4 m -130.11 142.88 42.64 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.112 0 CA-C-N 119.304 1.552 . . . . 0.0 109.429 -179.439 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 18.7 t . . . . . 0 C--O 1.214 -0.776 0 N-CA-C 109.169 -0.678 . . . . 0.0 109.169 174.944 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 79.2 m-85 . . . . . 0 N--CA 1.475 0.811 0 N-CA-C 109.949 -0.389 . . . . 0.0 109.949 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' E' E ' 5' ' ' ARG . . . . . . . . . . . . . 71.5 mtp180 -143.77 142.26 30.82 Favored 'General case' 0 N--CA 1.476 0.842 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 179.886 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 76.7 m80 -150.53 118.24 6.17 Favored 'General case' 0 N--CA 1.472 0.662 0 N-CA-C 108.926 -0.768 . . . . 0.0 108.926 179.129 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' E' E ' 7' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -66.16 149.63 50.01 Favored 'General case' 0 N--CA 1.465 0.289 0 O-C-N 123.542 0.526 . . . . 0.0 111.559 -179.606 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' E' E ' 8' ' ' SER . . . . . . . . . . . . . 6.7 t -167.12 172.53 9.94 Favored 'General case' 0 N--CA 1.477 0.891 0 CA-C-N 115.86 -0.609 . . . . 0.0 109.563 178.033 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.95 23.67 2.19 Favored Glycine 0 N--CA 1.482 1.716 0 N-CA-C 112.018 -0.433 . . . . 0.0 112.018 179.096 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 39.2 p90 -56.18 127.26 29.82 Favored 'General case' 0 N--CA 1.473 0.724 0 N-CA-C 112.639 0.607 . . . . 0.0 112.639 -179.149 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' E' E ' 11' ' ' GLU . . . . . 0.457 ' CG ' HD21 ' D' ' 27' ' ' ASN . 46.3 mt-10 -83.41 155.55 23.41 Favored 'General case' 0 N--CA 1.474 0.734 0 N-CA-C 109.302 -0.629 . . . . 0.0 109.302 178.033 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -155.67 128.34 1.09 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.534 0 N-CA-C 108.357 -0.979 . . . . 0.0 108.357 178.782 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 47.5 m-70 -135.17 143.18 46.33 Favored 'General case' 0 N--CA 1.48 1.074 0 CA-C-O 120.746 0.308 . . . . 0.0 111.329 -177.875 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -164.83 98.68 0.77 Allowed 'General case' 0 N--CA 1.488 1.472 0 CA-C-N 116.677 -0.238 . . . . 0.0 110.973 179.73 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 38.6 mt-30 -108.4 -171.91 1.95 Allowed 'General case' 0 CA--C 1.502 -0.883 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 -179.831 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -166.27 97.31 0.6 Allowed 'General case' 0 CA--C 1.541 0.629 0 CA-C-N 115.043 -0.98 . . . . 0.0 109.327 178.648 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' E' E ' 17' ' ' LEU . . . . . 0.568 ' N ' HD12 ' E' ' 17' ' ' LEU . 4.8 mp -105.85 163.56 12.63 Favored 'General case' 0 N--CA 1.49 1.545 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 -179.805 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 40.3 t -141.9 118.57 6.99 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.352 0 C-N-CA 122.612 0.365 . . . . 0.0 110.492 179.126 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 50.9 m-85 -69.49 156.77 38.35 Favored 'General case' 0 C--N 1.357 0.933 0 N-CA-C 107.336 -1.357 . . . . 0.0 107.336 176.56 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 12.4 t80 -173.41 -54.9 0.02 OUTLIER 'General case' 0 N--CA 1.485 1.28 0 CA-C-O 121.822 0.82 . . . . 0.0 110.288 179.457 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.96 89.31 0.0 OUTLIER 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 114.346 -1.297 . . . . 0.0 112.686 -178.783 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 54.7 tt0 -66.14 158.19 29.26 Favored 'General case' 0 N--CA 1.472 0.656 0 CA-C-N 114.823 -1.08 . . . . 0.0 110.651 179.651 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 66.0 m-20 -140.56 137.59 33.85 Favored 'General case' 0 N--CA 1.479 1.005 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.442 179.881 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 21.7 t -84.79 -115.45 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.039 0 N-CA-C 108.681 -0.859 . . . . 0.0 108.681 179.649 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . -110.61 54.16 0.55 Allowed Glycine 0 C--N 1.347 1.163 0 N-CA-C 111.457 -0.657 . . . . 0.0 111.457 -179.715 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 69.0 p -79.75 125.67 29.97 Favored 'General case' 0 N--CA 1.474 0.773 0 N-CA-C 109.384 -0.599 . . . . 0.0 109.384 178.078 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' E' E ' 27' ' ' ASN . . . . . 0.507 HD21 ' HB3' ' H' ' 27' ' ' ASN . 2.2 t-20 -66.72 99.5 0.61 Allowed 'General case' 0 N--CA 1.471 0.601 0 N-CA-C 108.081 -1.081 . . . . 0.0 108.081 178.382 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 66.4 mttm -96.44 119.3 34.66 Favored 'General case' 0 N--CA 1.484 1.252 0 N-CA-C 109.995 -0.372 . . . . 0.0 109.995 -178.748 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.57 -124.88 0.01 OUTLIER Glycine 0 CA--C 1.538 1.525 0 N-CA-C 110.95 -0.86 . . . . 0.0 110.95 178.601 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.74 133.33 48.08 Favored 'General case' 0 N--CA 1.482 1.158 0 N-CA-C 109.581 -0.526 . . . . 0.0 109.581 179.65 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 66.3 mt -82.65 138.97 18.5 Favored 'Isoleucine or valine' 0 C--O 1.237 0.405 0 N-CA-C 107.029 -1.471 . . . . 0.0 107.029 178.434 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 21.0 mt -128.32 129.06 69.05 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.865 0 N-CA-C 109.566 -0.531 . . . . 0.0 109.566 -179.433 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 60.97 80.28 0.1 Allowed Glycine 0 CA--C 1.524 0.641 0 CA-C-N 116.064 -0.516 . . . . 0.0 113.505 179.172 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 2.0 tt -111.77 118.86 36.74 Favored 'General case' 0 N--CA 1.477 0.916 0 N-CA-C 107.003 -1.481 . . . . 0.0 107.003 177.34 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 8.6 ttt -154.14 162.64 41.05 Favored 'General case' 0 C--O 1.211 -0.944 0 N-CA-C 108.744 -0.835 . . . . 0.0 108.744 179.203 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 84.1 t -159.71 150.53 6.33 Favored 'Isoleucine or valine' 0 C--O 1.239 0.509 0 N-CA-C 106.632 -1.618 . . . . 0.0 106.632 -179.864 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.61 74.94 0.27 Allowed Glycine 0 C--N 1.314 -0.662 0 CA-C-N 115.673 -0.694 . . . . 0.0 111.481 178.48 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 169.95 -147.7 11.08 Favored Glycine 0 C--O 1.222 -0.631 0 N-CA-C 111.321 -0.712 . . . . 0.0 111.321 179.965 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 20.3 m -133.93 141.38 44.12 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.872 0 N-CA-C 109.199 -0.667 . . . . 0.0 109.199 179.444 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 19.0 t . . . . . 0 CA--C 1.535 0.379 0 CA-C-O 117.722 -1.133 . . . . 0.0 110.895 179.453 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 79.4 m-85 . . . . . 0 N--CA 1.475 0.8 0 N-CA-C 109.873 -0.417 . . . . 0.0 109.873 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' F' F ' 5' ' ' ARG . . . . . . . . . . . . . 71.6 mtp180 -143.8 141.84 30.59 Favored 'General case' 0 N--CA 1.477 0.912 0 N-CA-C 109.261 -0.644 . . . . 0.0 109.261 179.998 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 76.9 m80 -150.28 118.41 6.34 Favored 'General case' 0 N--CA 1.473 0.688 0 N-CA-C 108.965 -0.754 . . . . 0.0 108.965 179.072 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' F' F ' 7' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -66.4 149.82 49.83 Favored 'General case' 0 N--CA 1.463 0.203 0 O-C-N 123.414 0.447 . . . . 0.0 111.636 -179.429 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' F' F ' 8' ' ' SER . . . . . . . . . . . . . 6.9 t -167.41 172.28 9.79 Favored 'General case' 0 N--CA 1.476 0.874 0 CA-C-N 115.991 -0.55 . . . . 0.0 109.56 178.04 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 123.19 23.25 2.21 Favored Glycine 0 N--CA 1.482 1.74 0 N-CA-C 112.04 -0.424 . . . . 0.0 112.04 179.109 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 38.7 p90 -55.87 127.72 31.63 Favored 'General case' 0 CA--C 1.543 0.694 0 N-CA-C 112.664 0.616 . . . . 0.0 112.664 -179.151 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 46.3 mt-10 -83.74 155.33 23.13 Favored 'General case' 0 N--CA 1.474 0.764 0 N-CA-C 109.436 -0.579 . . . . 0.0 109.436 178.023 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -155.34 128.19 1.11 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.587 0 N-CA-C 108.297 -1.001 . . . . 0.0 108.297 178.79 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 46.1 m-70 -135.01 143.22 46.68 Favored 'General case' 0 N--CA 1.483 1.196 0 CA-C-O 120.63 0.252 . . . . 0.0 111.329 -177.902 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -165.18 99.09 0.73 Allowed 'General case' 0 N--CA 1.487 1.422 0 CA-C-N 116.751 -0.204 . . . . 0.0 111.091 179.74 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 38.5 mt-30 -109.2 -171.51 1.86 Allowed 'General case' 0 CA--C 1.498 -1.034 0 N-CA-C 108.574 -0.899 . . . . 0.0 108.574 -179.826 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -166.11 97.57 0.62 Allowed 'General case' 0 CA--C 1.542 0.651 0 CA-C-N 114.93 -1.032 . . . . 0.0 109.406 178.769 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' F' F ' 17' ' ' LEU . . . . . 0.566 ' N ' HD12 ' F' ' 17' ' ' LEU . 4.7 mp -105.81 163.48 12.69 Favored 'General case' 0 N--CA 1.488 1.469 0 N-CA-C 109.213 -0.662 . . . . 0.0 109.213 -179.923 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 40.0 t -141.9 118.59 7.02 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.305 0 C-N-CA 122.644 0.378 . . . . 0.0 110.613 179.101 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 51.0 m-85 -69.53 156.66 38.54 Favored 'General case' 0 C--N 1.357 0.922 0 N-CA-C 107.221 -1.399 . . . . 0.0 107.221 176.548 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 13.2 t80 -173.19 -55.04 0.02 OUTLIER 'General case' 0 N--CA 1.486 1.372 0 CA-C-O 121.787 0.803 . . . . 0.0 109.85 179.458 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.73 88.99 0.0 OUTLIER 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 114.49 -1.232 . . . . 0.0 112.971 -178.876 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 54.4 tt0 -65.96 158.22 28.74 Favored 'General case' 0 N--CA 1.472 0.666 0 CA-C-N 114.894 -1.048 . . . . 0.0 110.799 179.541 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 66.7 m-20 -140.51 137.83 34.11 Favored 'General case' 0 N--CA 1.48 1.059 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.396 179.96 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' F' F ' 24' ' ' VAL . . . . . . . . . . . . . 21.7 t -85.09 -115.46 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.043 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 179.505 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -110.55 54.11 0.56 Allowed Glycine 0 N--CA 1.479 1.529 0 N-CA-C 111.383 -0.687 . . . . 0.0 111.383 -179.815 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 70.1 p -79.68 125.42 29.62 Favored 'General case' 0 N--CA 1.474 0.733 0 N-CA-C 109.335 -0.617 . . . . 0.0 109.335 177.948 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' F' F ' 27' ' ' ASN . . . . . 0.489 HD21 ' HB3' ' I' ' 27' ' ' ASN . 2.2 t-20 -66.5 99.23 0.55 Allowed 'General case' 0 N--CA 1.472 0.638 0 N-CA-C 108.115 -1.069 . . . . 0.0 108.115 178.382 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 66.4 mttm -96.26 119.17 34.27 Favored 'General case' 0 N--CA 1.483 1.19 0 N-CA-C 110.084 -0.339 . . . . 0.0 110.084 -178.804 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.55 -125.41 0.01 OUTLIER Glycine 0 CA--C 1.54 1.6 0 N-CA-C 110.964 -0.854 . . . . 0.0 110.964 178.617 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -127.91 133.08 49.25 Favored 'General case' 0 N--CA 1.484 1.249 0 N-CA-C 109.644 -0.502 . . . . 0.0 109.644 179.588 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 66.9 mt -82.65 138.81 18.77 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.273 0 N-CA-C 106.897 -1.52 . . . . 0.0 106.897 178.421 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 20.3 mt -128.22 129.08 69.22 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.891 0 N-CA-C 109.636 -0.505 . . . . 0.0 109.636 -179.357 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 60.86 80.27 0.1 Allowed Glycine 0 CA--C 1.525 0.688 0 CA-C-N 116.056 -0.52 . . . . 0.0 113.573 179.346 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 2.1 tt -111.85 118.82 36.59 Favored 'General case' 0 N--CA 1.479 0.981 0 N-CA-C 107.067 -1.457 . . . . 0.0 107.067 177.346 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 8.7 ttt -154.15 162.72 41.0 Favored 'General case' 0 C--O 1.209 -1.041 0 N-CA-C 109.009 -0.737 . . . . 0.0 109.009 179.143 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 85.1 t -159.7 150.57 6.32 Favored 'Isoleucine or valine' 0 C--O 1.237 0.402 0 N-CA-C 106.701 -1.592 . . . . 0.0 106.701 -179.823 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.8 74.67 0.3 Allowed Glycine 0 C--N 1.315 -0.632 0 CA-C-N 115.523 -0.762 . . . . 0.0 111.447 178.452 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 170.06 -147.82 11.14 Favored Glycine 0 C--O 1.221 -0.7 0 N-CA-C 111.233 -0.747 . . . . 0.0 111.233 179.839 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 20.2 m -133.72 141.37 44.35 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.841 0 N-CA-C 109.158 -0.682 . . . . 0.0 109.158 179.547 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 19.4 t . . . . . 0 CA--C 1.536 0.415 0 CA-C-O 117.746 -1.121 . . . . 0.0 110.75 179.389 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 79.0 m-85 . . . . . 0 N--CA 1.474 0.772 0 N-CA-C 109.644 -0.502 . . . . 0.0 109.644 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' G' G ' 5' ' ' ARG . . . . . . . . . . . . . 71.8 mtp180 -144.01 141.28 30.05 Favored 'General case' 0 N--CA 1.483 1.22 0 N-CA-C 109.178 -0.675 . . . . 0.0 109.178 -179.515 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 76.7 m80 -149.53 119.57 7.19 Favored 'General case' 0 N--CA 1.472 0.671 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 179.078 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 -68.41 145.28 54.27 Favored 'General case' 0 N--CA 1.47 0.526 0 O-C-N 123.505 0.503 . . . . 0.0 111.931 -179.328 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' G' G ' 8' ' ' SER . . . . . . . . . . . . . 5.7 t -163.81 173.54 12.64 Favored 'General case' 0 N--CA 1.47 0.566 0 N-CA-C 109.291 -0.633 . . . . 0.0 109.291 178.147 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.94 23.65 2.2 Favored Glycine 0 N--CA 1.479 1.519 0 N-CA-C 111.755 -0.538 . . . . 0.0 111.755 179.051 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 41.9 p90 -56.98 127.61 32.79 Favored 'General case' 0 N--CA 1.475 0.799 0 N-CA-C 112.437 0.532 . . . . 0.0 112.437 -178.648 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 45.2 mt-10 -83.93 154.34 23.43 Favored 'General case' 0 N--CA 1.471 0.618 0 CA-C-O 121.052 0.453 . . . . 0.0 109.852 178.686 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -155.4 128.51 1.15 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.968 0 N-CA-C 108.304 -0.999 . . . . 0.0 108.304 178.9 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 49.1 m-70 -134.19 144.38 48.44 Favored 'General case' 0 N--CA 1.476 0.865 0 CA-C-N 115.416 -0.811 . . . . 0.0 111.09 -178.136 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -166.35 98.2 0.6 Allowed 'General case' 0 N--CA 1.484 1.245 0 CA-C-N 116.642 -0.254 . . . . 0.0 110.572 179.219 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 39.1 mt-30 -108.32 -171.89 1.95 Allowed 'General case' 0 CA--C 1.503 -0.839 0 N-CA-C 108.635 -0.876 . . . . 0.0 108.635 -179.775 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -166.03 97.58 0.63 Allowed 'General case' 0 CA--C 1.541 0.618 0 CA-C-N 115.032 -0.985 . . . . 0.0 109.38 178.614 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' G' G ' 17' ' ' LEU . . . . . 0.573 ' N ' HD12 ' G' ' 17' ' ' LEU . 5.4 mp -105.73 162.33 13.63 Favored 'General case' 0 N--CA 1.487 1.423 0 N-CA-C 109.4 -0.593 . . . . 0.0 109.4 -179.717 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 39.0 t -142.45 118.83 6.08 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.082 0 CA-C-O 120.895 0.378 . . . . 0.0 110.352 178.773 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 44.9 m-85 -69.65 150.74 46.69 Favored 'General case' 0 C--N 1.369 1.444 0 N-CA-C 107.267 -1.383 . . . . 0.0 107.267 176.583 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 10.9 t80 -170.92 -54.84 0.02 OUTLIER 'General case' 0 N--CA 1.487 1.382 0 CA-C-N 117.847 0.294 . . . . 0.0 110.408 -179.73 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.45 90.27 0.0 OUTLIER 'General case' 0 C--N 1.325 -0.494 0 C-N-CA 123.866 0.866 . . . . 0.0 112.596 -179.918 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 53.8 tt0 -66.88 159.06 29.07 Favored 'General case' 0 N--CA 1.469 0.492 0 CA-C-N 114.634 -1.166 . . . . 0.0 109.923 179.189 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 66.2 m-20 -140.94 137.55 33.18 Favored 'General case' 0 N--CA 1.477 0.904 0 C-N-CA 122.822 0.449 . . . . 0.0 110.046 179.893 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' G' G ' 24' ' ' VAL . . . . . . . . . . . . . 21.4 t -85.42 -115.29 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.919 0 N-CA-C 108.521 -0.918 . . . . 0.0 108.521 179.608 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -110.53 53.97 0.56 Allowed Glycine 0 N--CA 1.477 1.425 0 N-CA-C 111.611 -0.596 . . . . 0.0 111.611 -179.712 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 70.4 p -80.08 126.27 30.85 Favored 'General case' 0 N--CA 1.467 0.393 0 N-CA-C 109.081 -0.711 . . . . 0.0 109.081 177.956 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 2.2 t-20 -67.23 99.99 0.75 Allowed 'General case' 0 CA--C 1.538 0.503 0 N-CA-C 108.401 -0.963 . . . . 0.0 108.401 178.434 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 66.9 mttm -96.33 119.91 35.68 Favored 'General case' 0 N--CA 1.482 1.147 0 N-CA-C 110.174 -0.306 . . . . 0.0 110.174 -179.182 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.02 -123.33 0.01 OUTLIER Glycine 0 CA--C 1.534 1.253 0 N-CA-C 110.54 -1.024 . . . . 0.0 110.54 178.787 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -129.58 132.78 46.89 Favored 'General case' 0 N--CA 1.47 0.557 0 N-CA-C 109.514 -0.55 . . . . 0.0 109.514 179.683 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 69.9 mt -81.54 140.91 15.85 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.654 0 N-CA-C 107.2 -1.407 . . . . 0.0 107.2 178.337 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 24.0 mt -130.2 130.52 65.74 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.46 0 CA-C-N 119.044 0.838 . . . . 0.0 109.435 179.785 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 60.96 79.82 0.11 Allowed Glycine 0 CA--C 1.528 0.888 0 CA-C-N 116.281 -0.418 . . . . 0.0 113.038 179.292 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' G' G ' 34' ' ' LEU . . . . . 0.404 HD23 ' N ' ' G' ' 35' ' ' MET . 1.9 tt -111.93 119.55 38.92 Favored 'General case' 0 N--CA 1.478 0.94 0 N-CA-C 106.961 -1.496 . . . . 0.0 106.961 177.479 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' G' G ' 35' ' ' MET . . . . . 0.404 ' N ' HD23 ' G' ' 34' ' ' LEU . 8.5 ttt -155.54 163.14 40.38 Favored 'General case' 0 N--CA 1.476 0.866 0 N-CA-C 108.192 -1.04 . . . . 0.0 108.192 179.503 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 98.6 t -159.8 150.85 6.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 N-CA-C 106.303 -1.74 . . . . 0.0 106.303 -179.899 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.1 74.74 0.29 Allowed Glycine 0 C--N 1.313 -0.706 0 CA-C-N 115.888 -0.596 . . . . 0.0 111.913 178.132 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 168.66 -146.42 10.34 Favored Glycine 0 N--CA 1.471 1.008 0 N-CA-C 110.636 -0.986 . . . . 0.0 110.636 179.231 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 23.1 m -134.23 141.62 43.17 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.906 0 CA-C-N 117.031 0.415 . . . . 0.0 109.984 179.881 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 19.2 t . . . . . 0 N--CA 1.47 0.548 0 CA-C-O 117.841 -1.076 . . . . 0.0 110.891 179.613 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 80.4 m-85 . . . . . 0 N--CA 1.475 0.805 0 N-CA-C 109.641 -0.503 . . . . 0.0 109.641 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' H' H ' 5' ' ' ARG . . . . . . . . . . . . . 71.5 mtp180 -144.29 141.4 29.77 Favored 'General case' 0 N--CA 1.48 1.055 0 N-CA-C 109.222 -0.658 . . . . 0.0 109.222 -179.625 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 76.8 m80 -149.72 119.29 6.96 Favored 'General case' 0 N--CA 1.473 0.698 0 N-CA-C 109.095 -0.705 . . . . 0.0 109.095 179.071 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 8.7 m-20 -68.08 145.35 54.5 Favored 'General case' 0 N--CA 1.468 0.45 0 O-C-N 123.466 0.479 . . . . 0.0 111.934 -179.393 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' H' H ' 8' ' ' SER . . . . . . . . . . . . . 7.0 t -163.9 172.83 13.45 Favored 'General case' 0 N--CA 1.468 0.474 0 N-CA-C 109.449 -0.574 . . . . 0.0 109.449 178.466 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 123.15 23.52 2.17 Favored Glycine 0 N--CA 1.481 1.684 0 N-CA-C 111.682 -0.567 . . . . 0.0 111.682 179.154 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 41.6 p90 -56.79 127.65 32.68 Favored 'General case' 0 N--CA 1.472 0.672 0 N-CA-C 112.443 0.534 . . . . 0.0 112.443 -178.763 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 45.4 mt-10 -83.96 154.4 23.36 Favored 'General case' 0 N--CA 1.473 0.679 0 CA-C-O 120.998 0.428 . . . . 0.0 109.893 178.739 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.6 p -155.58 128.11 1.07 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.016 0 N-CA-C 108.42 -0.955 . . . . 0.0 108.42 178.879 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 48.7 m-70 -133.91 144.4 48.83 Favored 'General case' 0 N--CA 1.478 0.947 0 CA-C-N 115.336 -0.847 . . . . 0.0 111.025 -178.072 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -166.29 98.54 0.61 Allowed 'General case' 0 N--CA 1.483 1.218 0 CA-C-N 116.568 -0.287 . . . . 0.0 110.617 179.166 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 38.9 mt-30 -108.64 -172.37 2.04 Favored 'General case' 0 CA--C 1.501 -0.931 0 N-CA-C 108.416 -0.957 . . . . 0.0 108.416 -179.656 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -165.73 97.35 0.65 Allowed 'General case' 0 CA--C 1.54 0.572 0 CA-C-N 114.951 -1.022 . . . . 0.0 109.364 178.716 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' H' H ' 17' ' ' LEU . . . . . 0.572 ' N ' HD12 ' H' ' 17' ' ' LEU . 5.4 mp -105.66 162.23 13.7 Favored 'General case' 0 N--CA 1.487 1.405 0 N-CA-C 109.362 -0.607 . . . . 0.0 109.362 -179.646 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 38.8 t -142.39 118.67 6.08 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.983 0 CA-C-O 120.97 0.414 . . . . 0.0 110.489 178.851 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 46.2 m-85 -69.8 151.07 46.18 Favored 'General case' 0 C--N 1.371 1.503 0 N-CA-C 107.355 -1.35 . . . . 0.0 107.355 176.653 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 11.4 t80 -172.15 -54.6 0.02 OUTLIER 'General case' 0 N--CA 1.485 1.295 0 N-CA-C 110.342 -0.244 . . . . 0.0 110.342 -179.635 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.39 90.41 0.0 OUTLIER 'General case' 0 CA--C 1.535 0.365 0 C-N-CA 123.815 0.846 . . . . 0.0 112.354 -179.958 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 54.0 tt0 -66.73 159.14 28.52 Favored 'General case' 0 N--CA 1.469 0.485 0 CA-C-N 114.69 -1.141 . . . . 0.0 110.012 179.34 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 67.5 m-20 -140.91 138.05 33.58 Favored 'General case' 0 N--CA 1.477 0.885 0 C-N-CA 122.821 0.448 . . . . 0.0 110.051 179.693 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' H' H ' 24' ' ' VAL . . . . . . . . . . . . . 21.4 t -85.93 -115.33 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 1.016 0 N-CA-C 108.609 -0.885 . . . . 0.0 108.609 179.602 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . -110.33 53.9 0.56 Allowed Glycine 0 N--CA 1.48 1.601 0 N-CA-C 111.471 -0.652 . . . . 0.0 111.471 -179.759 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 68.7 p -80.03 126.02 30.52 Favored 'General case' 0 N--CA 1.468 0.446 0 N-CA-C 109.053 -0.721 . . . . 0.0 109.053 178.067 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' H' H ' 27' ' ' ASN . . . . . 0.507 ' HB3' HD21 ' E' ' 27' ' ' ASN . 2.1 t-20 -67.31 100.1 0.78 Allowed 'General case' 0 N--CA 1.47 0.542 0 N-CA-C 108.409 -0.96 . . . . 0.0 108.409 178.492 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 67.0 mttm -96.41 119.76 35.49 Favored 'General case' 0 N--CA 1.484 1.236 0 N-CA-C 110.182 -0.303 . . . . 0.0 110.182 -179.131 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.89 -122.84 0.01 OUTLIER Glycine 0 CA--C 1.535 1.306 0 N-CA-C 110.606 -0.998 . . . . 0.0 110.606 178.735 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -129.95 133.0 46.54 Favored 'General case' 0 N--CA 1.471 0.62 0 C-N-CA 122.946 0.498 . . . . 0.0 109.663 179.709 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 69.5 mt -81.89 140.76 16.01 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.554 0 N-CA-C 107.128 -1.434 . . . . 0.0 107.128 178.446 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 25.1 mt -130.03 130.47 66.08 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.403 0 CA-C-N 119.021 0.828 . . . . 0.0 109.395 179.935 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 60.77 79.81 0.11 Allowed Glycine 0 CA--C 1.528 0.889 0 CA-C-N 116.382 -0.372 . . . . 0.0 113.067 179.193 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 1.9 tt -111.87 119.5 38.77 Favored 'General case' 0 N--CA 1.478 0.944 0 N-CA-C 106.944 -1.502 . . . . 0.0 106.944 177.426 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 8.4 ttt -155.19 163.19 40.54 Favored 'General case' 0 C--O 1.212 -0.91 0 N-CA-C 108.176 -1.046 . . . . 0.0 108.176 179.509 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 96.4 t -159.79 150.77 6.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 N-CA-C 106.254 -1.758 . . . . 0.0 106.254 -179.885 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.12 74.95 0.27 Allowed Glycine 0 C--N 1.313 -0.712 0 CA-C-N 115.914 -0.584 . . . . 0.0 111.914 178.124 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 168.32 -146.34 10.37 Favored Glycine 0 N--CA 1.469 0.866 0 N-CA-C 110.631 -0.988 . . . . 0.0 110.631 179.105 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 22.6 m -134.15 141.81 42.74 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.906 0 CA-C-N 116.998 0.399 . . . . 0.0 110.021 179.911 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 19.1 t . . . . . 0 N--CA 1.47 0.557 0 CA-C-O 117.789 -1.101 . . . . 0.0 110.932 179.539 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 79.9 m-85 . . . . . 0 N--CA 1.475 0.78 0 N-CA-C 109.599 -0.519 . . . . 0.0 109.599 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' I' I ' 5' ' ' ARG . . . . . . . . . . . . . 71.6 mtp180 -144.44 141.5 29.66 Favored 'General case' 0 N--CA 1.483 1.192 0 N-CA-C 109.187 -0.671 . . . . 0.0 109.187 -179.696 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 76.7 m80 -149.76 119.06 6.82 Favored 'General case' 0 N--CA 1.472 0.667 0 N-CA-C 109.126 -0.694 . . . . 0.0 109.126 179.082 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 8.6 m-20 -67.86 145.36 54.69 Favored 'General case' 0 N--CA 1.469 0.491 0 O-C-N 123.479 0.487 . . . . 0.0 111.935 -179.371 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' I' I ' 8' ' ' SER . . . . . . . . . . . . . 7.5 t -163.9 172.75 13.55 Favored 'General case' 0 N--CA 1.469 0.496 0 N-CA-C 109.429 -0.582 . . . . 0.0 109.429 178.465 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 123.2 23.77 2.12 Favored Glycine 0 N--CA 1.481 1.639 0 N-CA-C 111.78 -0.528 . . . . 0.0 111.78 179.118 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 41.5 p90 -56.95 127.52 32.27 Favored 'General case' 0 N--CA 1.474 0.737 0 N-CA-C 112.443 0.534 . . . . 0.0 112.443 -178.738 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 45.2 mt-10 -83.66 154.34 23.74 Favored 'General case' 0 N--CA 1.472 0.628 0 CA-C-O 120.998 0.427 . . . . 0.0 109.909 178.675 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -155.49 128.29 1.1 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.015 0 N-CA-C 108.313 -0.995 . . . . 0.0 108.313 178.848 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 49.5 m-70 -134.06 144.56 48.72 Favored 'General case' 0 N--CA 1.478 0.935 0 CA-C-N 115.337 -0.847 . . . . 0.0 111.13 -178.198 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -166.4 98.51 0.6 Allowed 'General case' 0 N--CA 1.484 1.255 0 CA-C-N 116.639 -0.255 . . . . 0.0 110.704 179.127 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 39.1 mt-30 -108.63 -172.45 2.06 Favored 'General case' 0 CA--C 1.498 -1.029 0 N-CA-C 108.461 -0.94 . . . . 0.0 108.461 -179.765 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -165.69 97.43 0.66 Allowed 'General case' 0 CA--C 1.541 0.61 0 CA-C-N 114.9 -1.046 . . . . 0.0 109.302 178.789 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' I' I ' 17' ' ' LEU . . . . . 0.569 ' N ' HD12 ' I' ' 17' ' ' LEU . 5.4 mp -105.68 162.51 13.46 Favored 'General case' 0 N--CA 1.487 1.402 0 N-CA-C 109.306 -0.627 . . . . 0.0 109.306 -179.609 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 39.2 t -142.5 118.81 5.95 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.006 0 CA-C-O 120.94 0.4 . . . . 0.0 110.471 178.851 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 45.8 m-85 -70.02 150.96 46.1 Favored 'General case' 0 C--N 1.369 1.431 0 N-CA-C 107.402 -1.332 . . . . 0.0 107.402 176.601 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 11.5 t80 -171.96 -54.72 0.02 OUTLIER 'General case' 0 N--CA 1.483 1.209 0 CA-C-N 117.765 0.257 . . . . 0.0 110.401 -179.561 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.34 90.22 0.0 OUTLIER 'General case' 0 CA--C 1.535 0.401 0 C-N-CA 123.743 0.817 . . . . 0.0 112.386 -179.942 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 54.1 tt0 -66.46 159.06 27.92 Favored 'General case' 0 N--CA 1.468 0.47 0 CA-C-N 114.667 -1.151 . . . . 0.0 110.061 179.272 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 67.2 m-20 -140.91 138.0 33.54 Favored 'General case' 0 N--CA 1.477 0.921 0 C-N-CA 122.775 0.43 . . . . 0.0 110.001 179.835 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' I' I ' 24' ' ' VAL . . . . . . . . . . . . . 21.3 t -85.99 -115.52 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.926 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 179.653 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . -110.16 53.6 0.58 Allowed Glycine 0 N--CA 1.479 1.501 0 N-CA-C 111.579 -0.609 . . . . 0.0 111.579 -179.702 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 68.7 p -79.74 126.24 30.7 Favored 'General case' 0 N--CA 1.467 0.411 0 N-CA-C 109.036 -0.727 . . . . 0.0 109.036 178.026 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' I' I ' 27' ' ' ASN . . . . . 0.489 ' HB3' HD21 ' F' ' 27' ' ' ASN . 2.2 t-20 -67.52 99.9 0.81 Allowed 'General case' 0 N--CA 1.47 0.527 0 N-CA-C 108.379 -0.971 . . . . 0.0 108.379 178.483 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 67.0 mttm -96.2 119.79 35.32 Favored 'General case' 0 N--CA 1.482 1.165 0 N-CA-C 110.216 -0.29 . . . . 0.0 110.216 -179.135 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.13 -123.23 0.01 OUTLIER Glycine 0 CA--C 1.534 1.254 0 N-CA-C 110.656 -0.978 . . . . 0.0 110.656 178.746 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -129.4 132.74 47.09 Favored 'General case' 0 N--CA 1.473 0.683 0 C-N-CA 122.962 0.505 . . . . 0.0 109.65 179.657 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 69.5 mt -81.75 140.68 16.16 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.637 0 N-CA-C 106.982 -1.488 . . . . 0.0 106.982 178.387 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 23.3 mt -129.89 130.44 66.37 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.383 0 CA-C-N 118.939 0.79 . . . . 0.0 109.361 179.868 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 60.63 80.04 0.11 Allowed Glycine 0 CA--C 1.528 0.846 0 CA-C-N 116.331 -0.395 . . . . 0.0 113.107 179.25 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 1.9 tt -112.0 119.6 39.02 Favored 'General case' 0 N--CA 1.478 0.949 0 N-CA-C 106.891 -1.522 . . . . 0.0 106.891 177.446 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 8.6 ttt -155.29 163.08 40.63 Favored 'General case' 0 N--CA 1.478 0.943 0 N-CA-C 108.256 -1.016 . . . . 0.0 108.256 179.518 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 97.7 t -159.76 150.94 6.17 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 N-CA-C 106.253 -1.758 . . . . 0.0 106.253 -179.915 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.14 74.45 0.33 Allowed Glycine 0 C--N 1.313 -0.739 0 CA-C-N 115.891 -0.595 . . . . 0.0 112.023 178.115 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 168.76 -146.4 10.31 Favored Glycine 0 N--CA 1.47 0.915 0 N-CA-C 110.602 -0.999 . . . . 0.0 110.602 179.268 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 22.8 m -134.06 141.79 42.88 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.873 0 CA-C-N 117.01 0.405 . . . . 0.0 109.981 179.921 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 19.2 t . . . . . 0 N--CA 1.469 0.506 0 CA-C-O 117.825 -1.083 . . . . 0.0 110.939 179.507 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 78.5 m-85 . . . . . 0 N--CA 1.475 0.795 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 72.2 mtp180 -143.62 141.17 30.5 Favored 'General case' 0 N--CA 1.481 1.116 0 N-CA-C 109.076 -0.713 . . . . 0.0 109.076 179.964 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 77.0 m80 -149.48 119.65 7.26 Favored 'General case' 0 N--CA 1.47 0.562 0 N-CA-C 108.806 -0.813 . . . . 0.0 108.806 179.136 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 7.4 m-20 -68.3 150.21 48.5 Favored 'General case' 0 CA--C 1.529 0.168 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.258 -179.437 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 8.5 t -166.95 172.27 10.41 Favored 'General case' 0 N--CA 1.472 0.63 0 N-CA-C 109.554 -0.536 . . . . 0.0 109.554 178.476 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.53 23.52 2.32 Favored Glycine 0 N--CA 1.487 2.097 0 N-CA-C 112.239 -0.344 . . . . 0.0 112.239 179.417 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 41.8 p90 -56.98 128.28 36.13 Favored 'General case' 0 N--CA 1.474 0.761 0 N-CA-C 112.088 0.403 . . . . 0.0 112.088 -179.912 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 57.4 mt-10 -85.66 155.38 21.12 Favored 'General case' 0 N--CA 1.469 0.504 0 N-CA-C 109.273 -0.64 . . . . 0.0 109.273 178.493 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -153.75 128.79 1.51 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 N-CA-C 108.107 -1.071 . . . . 0.0 108.107 178.839 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 49.5 m-70 -134.64 146.54 49.64 Favored 'General case' 0 N--CA 1.489 1.503 0 CA-C-N 118.641 0.655 . . . . 0.0 111.154 -179.024 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 6.4 t60 -164.96 97.91 0.74 Allowed 'General case' 0 N--CA 1.48 1.04 0 CA-C-N 116.502 -0.317 . . . . 0.0 111.055 179.582 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 35.0 mt-30 -106.06 -172.7 2.14 Favored 'General case' 0 CA--C 1.505 -0.762 0 N-CA-C 108.369 -0.974 . . . . 0.0 108.369 179.915 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 16' ' ' LYS . . . . . 0.403 ' C ' HD12 ' A' ' 17' ' ' LEU . 88.6 tttt -169.18 96.47 0.34 Allowed 'General case' 0 N--CA 1.472 0.629 0 CA-C-N 115.139 -0.937 . . . . 0.0 109.416 178.703 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.58 ' N ' HD12 ' A' ' 17' ' ' LEU . 4.8 mp -106.38 165.01 11.57 Favored 'General case' 0 N--CA 1.489 1.498 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 179.901 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 56.5 t -141.78 119.22 7.96 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.387 0 CA-C-O 118.934 -0.555 . . . . 0.0 109.897 179.68 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 52.4 m-85 -69.9 158.93 34.62 Favored 'General case' 0 N--CA 1.481 1.079 0 N-CA-C 107.592 -1.262 . . . . 0.0 107.592 177.392 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 13.1 t80 -171.22 -58.59 0.02 OUTLIER 'General case' 0 N--CA 1.485 1.324 0 CA-C-O 122.299 1.047 . . . . 0.0 109.73 179.485 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -38.82 90.11 0.0 OUTLIER 'General case' 0 C--O 1.232 0.142 0 CA-C-N 113.926 -1.488 . . . . 0.0 112.968 -177.985 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 37.0 tt0 -66.51 157.81 31.24 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 115.109 -0.95 . . . . 0.0 110.452 179.197 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 66.7 m-20 -139.98 137.38 34.66 Favored 'General case' 0 N--CA 1.48 1.071 0 C-N-CA 123.002 0.521 . . . . 0.0 110.344 179.866 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 17.9 t -84.49 -116.3 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.962 0 N-CA-C 108.444 -0.947 . . . . 0.0 108.444 179.501 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -110.37 54.63 0.54 Allowed Glycine 0 N--CA 1.475 1.265 0 N-CA-C 111.227 -0.749 . . . . 0.0 111.227 179.916 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 74.8 p -79.98 125.96 30.43 Favored 'General case' 0 C--O 1.221 -0.417 0 N-CA-C 108.969 -0.752 . . . . 0.0 108.969 178.378 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 41.9 t30 -66.6 100.42 0.67 Allowed 'General case' 0 N--CA 1.473 0.725 0 N-CA-C 108.576 -0.898 . . . . 0.0 108.576 178.704 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 66.6 mttm -96.85 120.34 37.01 Favored 'General case' 0 N--CA 1.483 1.182 0 N-CA-C 110.093 -0.336 . . . . 0.0 110.093 -179.157 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.58 -128.41 0.01 OUTLIER Glycine 0 CA--C 1.534 1.223 0 N-CA-C 110.525 -1.03 . . . . 0.0 110.525 178.779 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -126.05 133.86 51.59 Favored 'General case' 0 N--CA 1.48 1.052 0 N-CA-C 109.234 -0.654 . . . . 0.0 109.234 179.097 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 65.4 mt -83.21 137.81 20.34 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.538 0 N-CA-C 107.393 -1.336 . . . . 0.0 107.393 178.683 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 20.9 mt -129.44 129.25 66.95 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.976 0 O-C-N 123.495 0.497 . . . . 0.0 110.053 -178.424 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 60.43 79.05 0.13 Allowed Glycine 0 CA--C 1.525 0.685 0 CA-C-N 115.849 -0.614 . . . . 0.0 113.069 178.949 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.421 HD23 ' N ' ' A' ' 35' ' ' MET . 1.9 tt -110.94 119.48 39.21 Favored 'General case' 0 N--CA 1.477 0.915 0 N-CA-C 106.973 -1.492 . . . . 0.0 106.973 177.463 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 35' ' ' MET . . . . . 0.421 ' N ' HD23 ' A' ' 34' ' ' LEU . 8.6 ttt -154.91 161.08 41.54 Favored 'General case' 0 N--CA 1.468 0.443 0 N-CA-C 109.066 -0.716 . . . . 0.0 109.066 179.257 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 63.1 t -157.75 150.48 8.55 Favored 'Isoleucine or valine' 0 C--O 1.232 0.148 0 N-CA-C 106.897 -1.52 . . . . 0.0 106.897 -179.496 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.61 75.42 0.24 Allowed Glycine 0 C--N 1.315 -0.607 0 CA-C-N 115.671 -0.695 . . . . 0.0 111.777 178.201 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 168.83 -149.12 13.2 Favored Glycine 0 CA--C 1.519 0.3 0 N-CA-C 110.744 -0.943 . . . . 0.0 110.744 179.847 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 20.7 m -132.57 142.87 41.38 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.874 0 N-CA-C 109.598 -0.519 . . . . 0.0 109.598 179.658 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 21.2 t . . . . . 0 N--CA 1.467 0.399 0 CA-C-O 117.834 -1.079 . . . . 0.0 110.831 179.29 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 78.9 m-85 . . . . . 0 N--CA 1.474 0.726 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 72.2 mtp180 -143.68 141.14 30.41 Favored 'General case' 0 N--CA 1.481 1.108 0 N-CA-C 109.121 -0.696 . . . . 0.0 109.121 -179.931 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 76.7 m80 -149.51 119.6 7.22 Favored 'General case' 0 N--CA 1.471 0.615 0 N-CA-C 108.841 -0.8 . . . . 0.0 108.841 179.122 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 7' ' ' ASP . . . . . . . . . . . . . 8.5 m-20 -68.09 150.2 48.69 Favored 'General case' 0 CA--C 1.53 0.19 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.281 -179.453 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 8' ' ' SER . . . . . . . . . . . . . 8.4 t -166.98 172.2 10.43 Favored 'General case' 0 N--CA 1.472 0.631 0 N-CA-C 109.537 -0.542 . . . . 0.0 109.537 178.557 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.5 23.38 2.36 Favored Glycine 0 N--CA 1.487 2.051 0 N-CA-C 112.159 -0.377 . . . . 0.0 112.159 179.371 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 41.9 p90 -56.78 128.16 35.22 Favored 'General case' 0 N--CA 1.471 0.616 0 N-CA-C 112.166 0.432 . . . . 0.0 112.166 -179.983 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 57.4 mt-10 -85.58 155.64 21.07 Favored 'General case' 0 N--CA 1.471 0.58 0 N-CA-C 109.297 -0.631 . . . . 0.0 109.297 178.555 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -153.88 128.68 1.46 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 N-CA-C 108.186 -1.042 . . . . 0.0 108.186 178.816 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 50.1 m-70 -134.57 146.75 49.93 Favored 'General case' 0 N--CA 1.489 1.513 0 CA-C-N 118.481 0.582 . . . . 0.0 111.219 -179.018 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 6.5 t60 -165.32 97.82 0.7 Allowed 'General case' 0 N--CA 1.481 1.108 0 CA-C-N 116.519 -0.309 . . . . 0.0 111.022 179.627 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 35.2 mt-30 -105.96 -172.89 2.17 Favored 'General case' 0 CA--C 1.504 -0.789 0 N-CA-C 108.407 -0.96 . . . . 0.0 108.407 179.949 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 16' ' ' LYS . . . . . 0.408 ' C ' HD12 ' B' ' 17' ' ' LEU . 88.6 tttt -169.14 96.35 0.34 Allowed 'General case' 0 CA--C 1.54 0.592 0 CA-C-N 115.193 -0.912 . . . . 0.0 109.447 178.76 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 17' ' ' LEU . . . . . 0.578 ' N ' HD12 ' B' ' 17' ' ' LEU . 4.8 mp -106.41 164.82 11.73 Favored 'General case' 0 N--CA 1.488 1.461 0 N-CA-C 108.575 -0.898 . . . . 0.0 108.575 179.968 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 58.6 t -141.55 119.26 8.53 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.355 0 CA-C-O 118.957 -0.544 . . . . 0.0 109.9 179.566 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 53.3 m-85 -70.53 159.09 34.94 Favored 'General case' 0 N--CA 1.479 0.982 0 N-CA-C 107.52 -1.289 . . . . 0.0 107.52 177.316 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 14.4 t80 -171.84 -57.33 0.02 OUTLIER 'General case' 0 N--CA 1.482 1.138 0 CA-C-O 122.228 1.013 . . . . 0.0 109.838 179.452 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -39.39 90.37 0.0 OUTLIER 'General case' 0 C--O 1.232 0.152 0 CA-C-N 114.09 -1.413 . . . . 0.0 112.874 -178.052 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 36.6 tt0 -66.42 158.03 30.43 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 115.058 -0.973 . . . . 0.0 110.56 179.133 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 67.6 m-20 -140.37 137.42 34.04 Favored 'General case' 0 N--CA 1.481 1.089 0 C-N-CA 122.993 0.517 . . . . 0.0 110.251 179.805 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 17.5 t -84.59 -116.55 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 1.016 0 N-CA-C 108.65 -0.87 . . . . 0.0 108.65 179.482 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -109.46 54.01 0.56 Allowed Glycine 0 N--CA 1.476 1.331 0 N-CA-C 111.189 -0.764 . . . . 0.0 111.189 179.878 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 74.2 p -79.7 126.04 30.42 Favored 'General case' 0 C--O 1.221 -0.405 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 178.386 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 42.3 t30 -66.89 100.19 0.7 Allowed 'General case' 0 N--CA 1.474 0.761 0 N-CA-C 108.673 -0.862 . . . . 0.0 108.673 178.565 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 66.8 mttm -96.68 120.47 37.06 Favored 'General case' 0 N--CA 1.483 1.186 0 N-CA-C 110.118 -0.327 . . . . 0.0 110.118 -179.142 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.68 -127.73 0.01 OUTLIER Glycine 0 CA--C 1.534 1.246 0 N-CA-C 110.538 -1.025 . . . . 0.0 110.538 178.755 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -126.83 133.62 50.72 Favored 'General case' 0 N--CA 1.481 1.104 0 N-CA-C 109.165 -0.68 . . . . 0.0 109.165 179.252 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 64.4 mt -82.96 137.97 20.11 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.452 0 N-CA-C 107.363 -1.347 . . . . 0.0 107.363 178.59 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 21.6 mt -129.72 129.19 66.26 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.971 0 O-C-N 123.546 0.528 . . . . 0.0 109.941 -178.42 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 60.4 78.76 0.14 Allowed Glycine 0 CA--C 1.524 0.63 0 CA-C-N 115.828 -0.624 . . . . 0.0 113.094 178.915 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 34' ' ' LEU . . . . . 0.417 HD23 ' N ' ' B' ' 35' ' ' MET . 1.9 tt -110.39 119.61 39.77 Favored 'General case' 0 N--CA 1.478 0.953 0 N-CA-C 106.975 -1.491 . . . . 0.0 106.975 177.351 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 35' ' ' MET . . . . . 0.417 ' N ' HD23 ' B' ' 34' ' ' LEU . 8.7 ttt -154.89 160.79 41.43 Favored 'General case' 0 N--CA 1.47 0.562 0 N-CA-C 108.97 -0.752 . . . . 0.0 108.97 179.283 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 63.4 t -157.64 150.31 8.81 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.136 0 N-CA-C 106.825 -1.546 . . . . 0.0 106.825 -179.511 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.54 75.73 0.23 Allowed Glycine 0 C--N 1.314 -0.669 0 CA-C-N 115.659 -0.701 . . . . 0.0 111.771 178.169 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 168.52 -149.09 13.32 Favored Glycine 0 CA--C 1.519 0.306 0 N-CA-C 110.704 -0.958 . . . . 0.0 110.704 179.879 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 20.7 m -132.52 142.91 41.32 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.907 0 N-CA-C 109.643 -0.503 . . . . 0.0 109.643 179.676 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 21.2 t . . . . . 0 N--CA 1.467 0.405 0 CA-C-O 117.812 -1.089 . . . . 0.0 110.848 179.292 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 78.1 m-85 . . . . . 0 N--CA 1.474 0.737 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 72.4 mtp180 -143.61 141.07 30.46 Favored 'General case' 0 N--CA 1.482 1.136 0 N-CA-C 109.043 -0.725 . . . . 0.0 109.043 -179.857 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 76.5 m80 -149.47 119.64 7.26 Favored 'General case' 0 N--CA 1.47 0.571 0 N-CA-C 108.826 -0.805 . . . . 0.0 108.826 179.109 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' C' C ' 7' ' ' ASP . . . . . . . . . . . . . 7.6 m-20 -68.13 150.03 48.86 Favored 'General case' 0 CA--C 1.529 0.168 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.332 -179.381 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' C' C ' 8' ' ' SER . . . . . . . . . . . . . 8.5 t -166.71 172.73 10.27 Favored 'General case' 0 N--CA 1.471 0.618 0 N-CA-C 109.611 -0.514 . . . . 0.0 109.611 178.352 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.13 23.33 2.46 Favored Glycine 0 N--CA 1.487 2.042 0 N-CA-C 112.24 -0.344 . . . . 0.0 112.24 179.484 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 41.5 p90 -56.84 128.34 36.2 Favored 'General case' 0 N--CA 1.472 0.646 0 N-CA-C 112.088 0.403 . . . . 0.0 112.088 -179.896 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 57.5 mt-10 -85.79 155.27 21.08 Favored 'General case' 0 N--CA 1.47 0.556 0 N-CA-C 109.239 -0.652 . . . . 0.0 109.239 178.63 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -153.59 128.61 1.5 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 N-CA-C 108.181 -1.044 . . . . 0.0 108.181 178.853 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 49.5 m-70 -134.49 146.65 49.94 Favored 'General case' 0 N--CA 1.489 1.49 0 CA-C-N 118.541 0.609 . . . . 0.0 111.265 -179.105 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 6.4 t60 -165.15 98.04 0.72 Allowed 'General case' 0 N--CA 1.48 1.067 0 CA-C-N 116.572 -0.286 . . . . 0.0 111.085 179.596 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 35.1 mt-30 -106.36 -172.76 2.15 Favored 'General case' 0 CA--C 1.504 -0.807 0 N-CA-C 108.414 -0.958 . . . . 0.0 108.414 -179.99 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' C' C ' 16' ' ' LYS . . . . . 0.408 ' C ' HD12 ' C' ' 17' ' ' LEU . 88.7 tttt -169.18 96.45 0.34 Allowed 'General case' 0 CA--C 1.54 0.56 0 CA-C-N 115.12 -0.945 . . . . 0.0 109.451 178.751 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' C' C ' 17' ' ' LEU . . . . . 0.577 ' N ' HD12 ' C' ' 17' ' ' LEU . 4.8 mp -106.26 164.91 11.63 Favored 'General case' 0 N--CA 1.488 1.472 0 N-CA-C 108.584 -0.895 . . . . 0.0 108.584 179.968 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 58.5 t -141.71 118.94 7.76 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.341 0 CA-C-O 118.95 -0.548 . . . . 0.0 109.879 179.655 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 53.3 m-85 -70.25 159.0 34.84 Favored 'General case' 0 N--CA 1.478 0.956 0 N-CA-C 107.491 -1.3 . . . . 0.0 107.491 177.345 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 14.4 t80 -171.77 -57.41 0.02 OUTLIER 'General case' 0 N--CA 1.481 1.092 0 CA-C-O 122.183 0.992 . . . . 0.0 109.856 179.357 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -39.26 90.61 0.0 OUTLIER 'General case' 0 C--O 1.232 0.14 0 CA-C-N 114.125 -1.398 . . . . 0.0 112.849 -178.049 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 37.0 tt0 -66.74 158.05 31.21 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 115.096 -0.956 . . . . 0.0 110.513 179.219 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 67.2 m-20 -140.33 137.4 34.08 Favored 'General case' 0 N--CA 1.48 1.054 0 C-N-CA 122.944 0.498 . . . . 0.0 110.331 179.794 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 17.7 t -84.53 -116.42 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.967 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 179.588 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -109.86 54.35 0.55 Allowed Glycine 0 N--CA 1.475 1.275 0 N-CA-C 111.172 -0.771 . . . . 0.0 111.172 179.915 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 74.7 p -79.91 126.25 30.77 Favored 'General case' 0 C--O 1.222 -0.358 0 N-CA-C 109.004 -0.739 . . . . 0.0 109.004 178.417 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 42.6 t30 -66.99 100.37 0.73 Allowed 'General case' 0 N--CA 1.474 0.737 0 N-CA-C 108.682 -0.858 . . . . 0.0 108.682 178.606 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 66.8 mttm -96.86 120.09 36.54 Favored 'General case' 0 N--CA 1.484 1.251 0 N-CA-C 110.161 -0.311 . . . . 0.0 110.161 -179.138 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.34 -128.17 0.01 OUTLIER Glycine 0 CA--C 1.535 1.313 0 N-CA-C 110.529 -1.028 . . . . 0.0 110.529 178.76 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -126.33 133.75 51.29 Favored 'General case' 0 N--CA 1.48 1.073 0 N-CA-C 109.269 -0.641 . . . . 0.0 109.269 179.12 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 65.7 mt -83.06 137.82 20.35 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.525 0 N-CA-C 107.282 -1.377 . . . . 0.0 107.282 178.614 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 20.9 mt -129.59 128.81 66.27 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.935 0 O-C-N 123.545 0.528 . . . . 0.0 110.119 -178.507 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 60.84 78.55 0.15 Allowed Glycine 0 CA--C 1.524 0.654 0 CA-C-N 115.97 -0.559 . . . . 0.0 113.063 178.848 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' C' C ' 34' ' ' LEU . . . . . 0.413 HD23 ' N ' ' C' ' 35' ' ' MET . 1.9 tt -110.41 119.16 38.31 Favored 'General case' 0 N--CA 1.478 0.945 0 N-CA-C 107.021 -1.474 . . . . 0.0 107.021 177.463 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' C' C ' 35' ' ' MET . . . . . 0.413 ' N ' HD23 ' C' ' 34' ' ' LEU . 8.5 ttt -154.44 161.08 41.89 Favored 'General case' 0 N--CA 1.468 0.456 0 N-CA-C 108.976 -0.75 . . . . 0.0 108.976 179.356 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 63.4 t -158.03 150.13 8.42 Favored 'Isoleucine or valine' 0 C--O 1.232 0.158 0 N-CA-C 106.816 -1.55 . . . . 0.0 106.816 -179.393 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.68 75.54 0.24 Allowed Glycine 0 C--N 1.315 -0.635 0 CA-C-N 115.776 -0.647 . . . . 0.0 111.75 178.172 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 168.76 -148.95 12.95 Favored Glycine 0 CA--C 1.519 0.325 0 N-CA-C 110.639 -0.984 . . . . 0.0 110.639 179.88 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 20.1 m -132.79 142.7 41.67 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.875 0 N-CA-C 109.666 -0.494 . . . . 0.0 109.666 179.716 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 21.3 t . . . . . 0 N--CA 1.468 0.454 0 CA-C-O 117.726 -1.13 . . . . 0.0 110.718 179.244 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 86.9 m-85 . . . . . 0 N--CA 1.473 0.689 0 N-CA-C 108.275 -1.009 . . . . 0.0 108.275 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' D' D ' 5' ' ' ARG . . . . . . . . . . . . . 72.5 mtp180 -147.31 141.18 25.82 Favored 'General case' 0 N--CA 1.476 0.829 0 N-CA-C 108.896 -0.779 . . . . 0.0 108.896 179.757 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 77.1 m80 -149.22 123.43 9.53 Favored 'General case' 0 CA--C 1.539 0.527 0 N-CA-C 107.915 -1.143 . . . . 0.0 107.915 175.724 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' D' D ' 7' ' ' ASP . . . . . . . . . . . . . 5.6 m-20 -63.12 133.77 54.96 Favored 'General case' 0 C--N 1.319 -0.719 0 C-N-CA 127.188 2.195 . . . . 0.0 114.882 176.081 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' D' D ' 8' ' ' SER . . . . . . . . . . . . . 7.9 t -154.09 174.36 14.81 Favored 'General case' 0 N--CA 1.477 0.914 0 CA-C-N 118.751 0.705 . . . . 0.0 110.302 176.958 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 124.29 20.25 2.48 Favored Glycine 0 N--CA 1.483 1.787 0 N-CA-C 112.232 -0.347 . . . . 0.0 112.232 176.645 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 37.0 p90 -55.91 130.29 43.11 Favored 'General case' 0 CA--C 1.546 0.79 0 CA-C-O 121.07 0.462 . . . . 0.0 111.881 -177.494 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 57.3 mt-10 -85.71 152.83 22.76 Favored 'General case' 0 N--CA 1.474 0.759 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 177.681 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -149.38 129.97 4.45 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.455 0 N-CA-C 108.009 -1.108 . . . . 0.0 108.009 175.229 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 48.9 m-70 -129.74 149.7 51.38 Favored 'General case' 0 N--CA 1.482 1.128 0 CA-C-N 117.939 0.336 . . . . 0.0 111.503 176.727 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 6.6 t60 -164.81 104.66 0.8 Allowed 'General case' 0 N--CA 1.482 1.133 0 N-CA-C 109.539 -0.541 . . . . 0.0 109.539 173.203 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 35.2 mt-30 -109.32 -175.62 2.81 Favored 'General case' 0 CA--C 1.494 -1.18 0 N-CA-C 108.28 -1.007 . . . . 0.0 108.28 178.978 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' D' D ' 16' ' ' LYS . . . . . 0.453 ' C ' HD12 ' D' ' 17' ' ' LEU . 88.7 tttt -165.77 105.25 0.7 Allowed 'General case' 0 CA--C 1.538 0.504 0 N-CA-C 107.637 -1.246 . . . . 0.0 107.637 175.331 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' D' D ' 17' ' ' LEU . . . . . 0.522 ' N ' HD12 ' D' ' 17' ' ' LEU . 5.6 mp -113.2 163.2 15.07 Favored 'General case' 0 N--CA 1.488 1.454 0 N-CA-C 108.225 -1.028 . . . . 0.0 108.225 179.699 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 51.8 t -140.9 123.67 15.72 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.187 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 176.215 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 78.7 m-85 -62.43 151.2 37.84 Favored 'General case' 0 C--N 1.353 0.759 0 C-N-CA 124.726 1.21 . . . . 0.0 110.412 170.862 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 9.3 t80 -170.0 -66.64 0.02 OUTLIER 'General case' 0 N--CA 1.476 0.871 0 N-CA-C 107.81 -1.182 . . . . 0.0 107.81 -179.835 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -38.27 95.75 0.01 OUTLIER 'General case' 0 CA--C 1.535 0.39 0 CA-C-N 113.972 -1.467 . . . . 0.0 111.731 -174.603 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 37.2 tt0 -68.7 158.72 33.61 Favored 'General case' 0 N--CA 1.467 0.421 0 CA-C-N 113.36 -1.746 . . . . 0.0 110.243 178.65 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 67.8 m-20 -140.34 141.17 35.69 Favored 'General case' 0 N--CA 1.475 0.822 0 N-CA-C 109.517 -0.549 . . . . 0.0 109.517 178.585 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' D' D ' 24' ' ' VAL . . . . . . . . . . . . . 19.6 t -87.83 -119.62 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.486 1.368 0 N-CA-C 107.752 -1.203 . . . . 0.0 107.752 179.727 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . -113.31 61.85 0.32 Allowed Glycine 0 C--N 1.372 2.559 0 C-N-CA 118.005 -2.045 . . . . 0.0 109.313 178.81 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 90.9 p -70.35 121.44 17.69 Favored 'General case' 0 C--N 1.349 0.574 0 CA-C-O 116.647 -1.644 . . . . 0.0 112.016 169.276 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 43.7 t30 -61.36 101.67 0.18 Allowed 'General case' 0 N--CA 1.474 0.772 0 CA-C-N 121.558 1.981 . . . . 0.0 109.486 172.485 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 66.3 mttm -100.12 121.75 41.9 Favored 'General case' 0 N--CA 1.49 1.558 0 CA-C-N 119.64 1.109 . . . . 0.0 109.366 178.803 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -54.16 -130.2 0.0 OUTLIER Glycine 0 CA--C 1.529 0.961 0 CA-C-N 115.664 -0.698 . . . . 0.0 112.68 175.57 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -125.17 139.95 53.29 Favored 'General case' 0 C--N 1.373 1.614 0 N-CA-C 108.567 -0.901 . . . . 0.0 108.567 174.052 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 65.3 mt -84.13 140.29 16.35 Favored 'Isoleucine or valine' 0 C--O 1.239 0.506 0 N-CA-C 107.403 -1.332 . . . . 0.0 107.403 176.478 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 29.1 mt -131.89 132.95 61.51 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.017 0 N-CA-C 108.66 -0.866 . . . . 0.0 108.66 178.367 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.31 76.99 0.22 Allowed Glycine 0 C--O 1.248 0.994 0 CA-C-O 118.102 -1.388 . . . . 0.0 112.404 178.449 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' D' D ' 34' ' ' LEU . . . . . 0.406 HD23 ' N ' ' D' ' 35' ' ' MET . 2.4 tt -110.2 131.43 55.07 Favored 'General case' 0 C--N 1.372 1.562 0 N-CA-C 103.96 -2.607 . . . . 0.0 103.96 174.968 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' D' D ' 35' ' ' MET . . . . . 0.406 ' N ' HD23 ' D' ' 34' ' ' LEU . 8.3 ttt -156.85 166.7 32.63 Favored 'General case' 0 N--CA 1.471 0.594 0 N-CA-C 108.679 -0.86 . . . . 0.0 108.679 176.685 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 91.6 t -163.58 154.31 2.55 Favored 'Isoleucine or valine' 0 C--O 1.241 0.647 0 N-CA-C 105.545 -2.02 . . . . 0.0 105.545 175.379 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 61.39 66.51 2.61 Favored Glycine 0 N--CA 1.444 -0.782 0 C-N-CA 118.039 -2.029 . . . . 0.0 113.619 176.76 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 167.27 -148.39 13.05 Favored Glycine 0 N--CA 1.468 0.805 0 CA-C-O 118.163 -1.354 . . . . 0.0 111.859 -178.577 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 21.4 m -129.74 143.04 42.32 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.166 0 CA-C-N 118.896 1.348 . . . . 0.0 109.64 -179.944 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 18.8 t . . . . . 0 C--O 1.215 -0.745 0 N-CA-C 109.204 -0.665 . . . . 0.0 109.204 174.798 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 79.1 m-85 . . . . . 0 N--CA 1.476 0.829 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' E' E ' 5' ' ' ARG . . . . . . . . . . . . . 72.3 mtp180 -143.62 141.96 30.84 Favored 'General case' 0 N--CA 1.478 0.933 0 N-CA-C 109.392 -0.595 . . . . 0.0 109.392 179.893 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 76.8 m80 -150.37 118.23 6.24 Favored 'General case' 0 N--CA 1.473 0.692 0 N-CA-C 108.962 -0.755 . . . . 0.0 108.962 179.123 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' E' E ' 7' ' ' ASP . . . . . . . . . . . . . 7.5 m-20 -66.7 149.96 49.77 Favored 'General case' 0 N--CA 1.463 0.224 0 O-C-N 123.542 0.526 . . . . 0.0 111.639 -179.515 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' E' E ' 8' ' ' SER . . . . . . . . . . . . . 7.9 t -166.95 173.43 9.33 Favored 'General case' 0 N--CA 1.476 0.875 0 CA-C-N 115.965 -0.561 . . . . 0.0 109.549 178.003 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.85 23.59 2.23 Favored Glycine 0 N--CA 1.482 1.737 0 N-CA-C 111.908 -0.477 . . . . 0.0 111.908 179.163 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 38.2 p90 -56.64 127.49 31.65 Favored 'General case' 0 N--CA 1.473 0.676 0 N-CA-C 112.602 0.593 . . . . 0.0 112.602 -179.241 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 57.0 mt-10 -84.34 156.2 21.99 Favored 'General case' 0 N--CA 1.476 0.827 0 N-CA-C 109.482 -0.562 . . . . 0.0 109.482 178.045 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -155.62 127.9 1.03 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.512 0 N-CA-C 108.185 -1.042 . . . . 0.0 108.185 178.702 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 49.0 m-70 -135.08 144.81 47.4 Favored 'General case' 0 N--CA 1.48 1.073 0 CA-C-O 120.757 0.313 . . . . 0.0 111.38 -177.933 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 6.3 t60 -163.94 97.94 0.84 Allowed 'General case' 0 N--CA 1.487 1.379 0 CA-C-N 116.652 -0.249 . . . . 0.0 111.064 179.702 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 35.2 mt-30 -105.51 -172.45 2.1 Favored 'General case' 0 CA--C 1.502 -0.878 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 -179.951 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -169.45 96.56 0.32 Allowed 'General case' 0 CA--C 1.542 0.638 0 CA-C-N 115.018 -0.992 . . . . 0.0 109.402 178.658 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' E' E ' 17' ' ' LEU . . . . . 0.566 ' N ' HD12 ' E' ' 17' ' ' LEU . 4.8 mp -106.21 164.11 12.26 Favored 'General case' 0 N--CA 1.49 1.547 0 N-CA-C 109.233 -0.654 . . . . 0.0 109.233 -179.765 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 40.8 t -141.59 118.46 7.5 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 C-N-CA 122.563 0.345 . . . . 0.0 110.551 179.085 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 52.7 m-85 -69.45 156.54 38.69 Favored 'General case' 0 C--N 1.358 0.957 0 N-CA-C 107.397 -1.335 . . . . 0.0 107.397 176.696 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 12.7 t80 -173.28 -55.06 0.02 OUTLIER 'General case' 0 N--CA 1.485 1.299 0 CA-C-O 121.741 0.782 . . . . 0.0 110.368 179.472 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.23 89.1 0.0 OUTLIER 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 114.398 -1.274 . . . . 0.0 112.852 -179.009 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 37.0 tt0 -65.16 158.31 26.37 Favored 'General case' 0 N--CA 1.472 0.646 0 CA-C-N 114.876 -1.056 . . . . 0.0 110.698 179.604 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 66.1 m-20 -140.68 137.03 33.23 Favored 'General case' 0 N--CA 1.479 0.997 0 C-N-CA 122.853 0.461 . . . . 0.0 110.518 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 21.8 t -84.52 -115.5 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.066 0 N-CA-C 108.715 -0.846 . . . . 0.0 108.715 179.48 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . -110.09 54.38 0.55 Allowed Glycine 0 C--N 1.348 1.214 0 N-CA-C 111.362 -0.695 . . . . 0.0 111.362 -179.827 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 73.2 p -79.72 125.27 29.44 Favored 'General case' 0 N--CA 1.473 0.709 0 N-CA-C 109.34 -0.615 . . . . 0.0 109.34 178.059 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 45.3 t30 -66.27 99.88 0.58 Allowed 'General case' 0 N--CA 1.474 0.765 0 N-CA-C 108.063 -1.088 . . . . 0.0 108.063 178.386 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 65.9 mttm -96.99 119.45 35.5 Favored 'General case' 0 N--CA 1.485 1.293 0 N-CA-C 109.966 -0.383 . . . . 0.0 109.966 -178.744 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.28 -127.32 0.01 OUTLIER Glycine 0 CA--C 1.539 1.581 0 N-CA-C 110.988 -0.845 . . . . 0.0 110.988 178.724 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -126.9 133.2 50.73 Favored 'General case' 0 N--CA 1.481 1.102 0 N-CA-C 109.585 -0.524 . . . . 0.0 109.585 179.614 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 64.8 mt -82.38 138.17 19.88 Favored 'Isoleucine or valine' 0 C--O 1.236 0.35 0 N-CA-C 107.093 -1.447 . . . . 0.0 107.093 178.492 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 22.4 mt -129.3 129.49 67.35 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.858 0 N-CA-C 109.444 -0.576 . . . . 0.0 109.444 -179.426 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 60.65 80.27 0.1 Allowed Glycine 0 CA--C 1.523 0.554 0 CA-C-N 115.982 -0.554 . . . . 0.0 113.654 179.33 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 2.0 tt -111.98 118.99 36.99 Favored 'General case' 0 N--CA 1.479 0.992 0 N-CA-C 107.056 -1.461 . . . . 0.0 107.056 177.358 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 8.2 ttt -153.37 162.88 40.82 Favored 'General case' 0 C--O 1.209 -1.041 0 N-CA-C 108.696 -0.853 . . . . 0.0 108.696 179.202 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 78.0 t -159.65 150.27 6.46 Favored 'Isoleucine or valine' 0 C--O 1.236 0.351 0 N-CA-C 106.591 -1.633 . . . . 0.0 106.591 -179.748 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.53 74.97 0.27 Allowed Glycine 0 C--N 1.314 -0.656 0 CA-C-N 115.63 -0.714 . . . . 0.0 111.535 178.139 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 170.08 -148.14 11.44 Favored Glycine 0 C--O 1.222 -0.653 0 N-CA-C 111.248 -0.741 . . . . 0.0 111.248 -179.995 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 19.4 m -133.42 141.54 44.18 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.846 0 N-CA-C 109.188 -0.671 . . . . 0.0 109.188 179.498 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 19.0 t . . . . . 0 CA--C 1.535 0.372 0 CA-C-O 117.648 -1.168 . . . . 0.0 110.847 179.35 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 78.7 m-85 . . . . . 0 N--CA 1.475 0.798 0 N-CA-C 109.895 -0.409 . . . . 0.0 109.895 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' F' F ' 5' ' ' ARG . . . . . . . . . . . . . 72.4 mtp180 -143.43 141.62 30.91 Favored 'General case' 0 N--CA 1.477 0.878 0 N-CA-C 109.38 -0.6 . . . . 0.0 109.38 179.895 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 76.8 m80 -150.12 117.87 6.21 Favored 'General case' 0 N--CA 1.473 0.714 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 179.207 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' F' F ' 7' ' ' ASP . . . . . . . . . . . . . 7.5 m-20 -66.5 150.42 48.98 Favored 'General case' 0 N--CA 1.461 0.106 0 O-C-N 123.468 0.48 . . . . 0.0 111.711 -179.447 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' F' F ' 8' ' ' SER . . . . . . . . . . . . . 7.8 t -167.53 172.9 9.09 Favored 'General case' 0 N--CA 1.476 0.847 0 CA-C-N 116.015 -0.539 . . . . 0.0 109.568 178.065 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 123.34 23.63 2.12 Favored Glycine 0 N--CA 1.481 1.637 0 N-CA-C 111.997 -0.441 . . . . 0.0 111.997 179.064 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 36.6 p90 -56.74 127.97 34.18 Favored 'General case' 0 CA--C 1.542 0.671 0 N-CA-C 112.599 0.592 . . . . 0.0 112.599 -179.217 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 57.2 mt-10 -84.41 156.37 21.84 Favored 'General case' 0 N--CA 1.475 0.813 0 N-CA-C 109.457 -0.571 . . . . 0.0 109.457 178.063 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -155.77 127.53 0.96 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.586 0 N-CA-C 108.189 -1.041 . . . . 0.0 108.189 178.637 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 50.3 m-70 -134.76 144.73 47.87 Favored 'General case' 0 N--CA 1.481 1.078 0 CA-C-O 120.748 0.309 . . . . 0.0 111.341 -177.819 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 6.3 t60 -164.11 98.13 0.83 Allowed 'General case' 0 N--CA 1.486 1.356 0 CA-C-N 116.707 -0.224 . . . . 0.0 111.169 179.674 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 35.2 mt-30 -106.09 -172.36 2.07 Favored 'General case' 0 CA--C 1.498 -1.05 0 N-CA-C 108.787 -0.82 . . . . 0.0 108.787 179.989 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -169.23 96.87 0.34 Allowed 'General case' 0 CA--C 1.54 0.584 0 CA-C-N 114.891 -1.05 . . . . 0.0 109.443 178.687 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' F' F ' 17' ' ' LEU . . . . . 0.565 ' N ' HD12 ' F' ' 17' ' ' LEU . 4.7 mp -106.27 164.1 12.29 Favored 'General case' 0 N--CA 1.489 1.48 0 N-CA-C 109.209 -0.663 . . . . 0.0 109.209 -179.842 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 41.3 t -141.69 118.74 7.6 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.457 0 C-N-CA 122.55 0.34 . . . . 0.0 110.473 179.098 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 53.2 m-85 -69.56 156.49 38.82 Favored 'General case' 0 C--N 1.358 0.949 0 N-CA-C 107.253 -1.388 . . . . 0.0 107.253 176.612 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 13.1 t80 -173.15 -55.48 0.02 OUTLIER 'General case' 0 N--CA 1.484 1.267 0 CA-C-O 121.735 0.778 . . . . 0.0 109.904 179.484 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.73 88.89 0.0 OUTLIER 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 114.428 -1.26 . . . . 0.0 112.95 -179.047 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 36.7 tt0 -65.16 158.2 26.65 Favored 'General case' 0 N--CA 1.47 0.567 0 CA-C-N 114.952 -1.022 . . . . 0.0 110.786 179.504 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 66.5 m-20 -140.84 137.32 33.18 Favored 'General case' 0 N--CA 1.478 0.949 0 C-N-CA 122.813 0.445 . . . . 0.0 110.58 179.994 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' F' F ' 24' ' ' VAL . . . . . . . . . . . . . 21.5 t -84.84 -115.98 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.09 0 N-CA-C 108.811 -0.811 . . . . 0.0 108.811 179.523 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -109.48 54.08 0.56 Allowed Glycine 0 N--CA 1.479 1.511 0 N-CA-C 111.24 -0.744 . . . . 0.0 111.24 -179.836 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 75.6 p -79.46 125.04 29.04 Favored 'General case' 0 N--CA 1.472 0.668 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 177.883 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 45.1 t30 -66.19 99.71 0.55 Allowed 'General case' 0 N--CA 1.472 0.672 0 N-CA-C 108.125 -1.065 . . . . 0.0 108.125 178.457 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 66.1 mttm -96.78 119.29 34.98 Favored 'General case' 0 N--CA 1.484 1.269 0 N-CA-C 110.056 -0.35 . . . . 0.0 110.056 -178.711 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.19 -127.51 0.01 OUTLIER Glycine 0 CA--C 1.54 1.623 0 N-CA-C 111.093 -0.803 . . . . 0.0 111.093 178.796 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -126.35 133.14 51.43 Favored 'General case' 0 N--CA 1.482 1.161 0 N-CA-C 109.577 -0.527 . . . . 0.0 109.577 179.612 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 65.4 mt -82.73 138.07 19.98 Favored 'Isoleucine or valine' 0 C--O 1.236 0.345 0 N-CA-C 106.958 -1.497 . . . . 0.0 106.958 178.497 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 23.5 mt -129.22 129.61 67.59 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.811 0 N-CA-C 109.381 -0.6 . . . . 0.0 109.381 -179.365 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 60.51 80.17 0.1 Allowed Glycine 0 CA--C 1.522 0.518 0 CA-C-N 115.986 -0.552 . . . . 0.0 113.618 179.271 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' F' F ' 34' ' ' LEU . . . . . 0.407 HD23 ' N ' ' F' ' 35' ' ' MET . 2.0 tt -111.89 119.28 38.0 Favored 'General case' 0 N--CA 1.479 0.991 0 N-CA-C 106.971 -1.492 . . . . 0.0 106.971 177.472 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' F' F ' 35' ' ' MET . . . . . 0.407 ' N ' HD23 ' F' ' 34' ' ' LEU . 8.5 ttt -153.93 162.97 40.8 Favored 'General case' 0 C--O 1.209 -1.075 0 N-CA-C 108.81 -0.811 . . . . 0.0 108.81 179.212 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 81.2 t -159.61 150.64 6.4 Favored 'Isoleucine or valine' 0 C--O 1.237 0.412 0 N-CA-C 106.713 -1.588 . . . . 0.0 106.713 -179.651 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.34 75.0 0.26 Allowed Glycine 0 C--N 1.314 -0.644 0 CA-C-N 115.662 -0.699 . . . . 0.0 111.483 178.089 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 170.1 -147.89 11.19 Favored Glycine 0 C--O 1.221 -0.668 0 N-CA-C 111.226 -0.75 . . . . 0.0 111.226 -179.993 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 19.6 m -133.77 141.42 44.17 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.884 0 N-CA-C 109.203 -0.666 . . . . 0.0 109.203 179.442 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 19.3 t . . . . . 0 CA--C 1.533 0.313 0 CA-C-O 117.605 -1.188 . . . . 0.0 110.868 179.365 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 78.6 m-85 . . . . . 0 N--CA 1.476 0.836 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' G' G ' 5' ' ' ARG . . . . . . . . . . . . . 72.7 mtp180 -143.93 141.16 30.09 Favored 'General case' 0 N--CA 1.483 1.191 0 N-CA-C 109.282 -0.636 . . . . 0.0 109.282 -179.657 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 76.9 m80 -149.49 119.36 7.1 Favored 'General case' 0 N--CA 1.473 0.715 0 N-CA-C 109.05 -0.722 . . . . 0.0 109.05 179.116 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 8.0 m-20 -68.74 145.96 53.36 Favored 'General case' 0 CA--C 1.536 0.411 0 O-C-N 123.472 0.482 . . . . 0.0 111.942 -179.327 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' G' G ' 8' ' ' SER . . . . . . . . . . . . . 7.1 t -163.83 174.2 11.83 Favored 'General case' 0 N--CA 1.47 0.55 0 N-CA-C 109.443 -0.577 . . . . 0.0 109.443 178.171 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 123.06 23.34 2.23 Favored Glycine 0 N--CA 1.48 1.606 0 N-CA-C 111.643 -0.583 . . . . 0.0 111.643 178.89 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 40.8 p90 -56.86 127.86 33.82 Favored 'General case' 0 N--CA 1.473 0.68 0 N-CA-C 112.418 0.525 . . . . 0.0 112.418 -178.89 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 57.6 mt-10 -84.94 154.74 22.0 Favored 'General case' 0 N--CA 1.473 0.717 0 CA-C-O 121.054 0.454 . . . . 0.0 109.981 178.795 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -155.26 127.67 1.04 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.97 0 N-CA-C 108.246 -1.02 . . . . 0.0 108.246 178.847 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 51.6 m-70 -133.77 146.13 50.44 Favored 'General case' 0 N--CA 1.476 0.844 0 CA-C-N 115.443 -0.799 . . . . 0.0 111.09 -178.159 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 32.7 t-80 -165.57 97.74 0.68 Allowed 'General case' 0 N--CA 1.483 1.183 0 CA-C-N 116.511 -0.313 . . . . 0.0 110.656 179.123 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 35.8 mt-30 -105.7 -172.64 2.13 Favored 'General case' 0 CA--C 1.503 -0.862 0 N-CA-C 108.726 -0.842 . . . . 0.0 108.726 -179.849 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' G' G ' 16' ' ' LYS . . . . . 0.405 ' C ' HD12 ' G' ' 17' ' ' LEU . 88.5 tttt -169.2 97.07 0.35 Allowed 'General case' 0 CA--C 1.54 0.587 0 CA-C-N 115.0 -1.0 . . . . 0.0 109.444 178.629 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' G' G ' 17' ' ' LEU . . . . . 0.572 ' N ' HD12 ' G' ' 17' ' ' LEU . 5.4 mp -106.31 163.14 13.07 Favored 'General case' 0 N--CA 1.487 1.387 0 N-CA-C 109.427 -0.583 . . . . 0.0 109.427 -179.669 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 39.6 t -142.5 118.92 6.04 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.068 0 CA-C-O 120.886 0.374 . . . . 0.0 110.327 178.779 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 47.2 m-85 -69.79 150.32 47.0 Favored 'General case' 0 C--N 1.37 1.482 0 N-CA-C 107.357 -1.349 . . . . 0.0 107.357 176.737 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 10.7 t80 -170.73 -55.26 0.02 OUTLIER 'General case' 0 N--CA 1.486 1.359 0 CA-C-N 117.903 0.319 . . . . 0.0 110.356 -179.601 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.73 90.02 0.0 OUTLIER 'General case' 0 C--N 1.325 -0.477 0 C-N-CA 123.74 0.816 . . . . 0.0 112.574 -179.882 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 37.1 tt0 -65.54 159.3 24.87 Favored 'General case' 0 N--CA 1.468 0.462 0 CA-C-N 114.694 -1.139 . . . . 0.0 109.954 179.069 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 67.2 m-20 -141.23 137.35 32.51 Favored 'General case' 0 N--CA 1.476 0.873 0 C-N-CA 122.792 0.437 . . . . 0.0 109.993 179.962 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' G' G ' 24' ' ' VAL . . . . . . . . . . . . . 21.6 t -85.53 -115.41 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.99 0 N-CA-C 108.408 -0.96 . . . . 0.0 108.408 179.598 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -110.16 53.9 0.57 Allowed Glycine 0 N--CA 1.478 1.443 0 N-CA-C 111.612 -0.595 . . . . 0.0 111.612 -179.812 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 75.8 p -79.67 125.88 30.21 Favored 'General case' 0 N--CA 1.466 0.366 0 N-CA-C 109.119 -0.697 . . . . 0.0 109.119 178.026 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 43.5 t30 -66.87 100.5 0.73 Allowed 'General case' 0 CA--C 1.54 0.569 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 178.424 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 67.0 mttm -96.7 119.93 36.09 Favored 'General case' 0 N--CA 1.482 1.139 0 N-CA-C 110.085 -0.339 . . . . 0.0 110.085 -179.087 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.76 -125.52 0.01 OUTLIER Glycine 0 CA--C 1.533 1.21 0 N-CA-C 110.571 -1.012 . . . . 0.0 110.571 178.828 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -127.81 133.09 49.41 Favored 'General case' 0 N--CA 1.47 0.555 0 N-CA-C 109.579 -0.526 . . . . 0.0 109.579 179.684 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 68.2 mt -81.93 140.19 16.84 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.646 0 N-CA-C 107.22 -1.4 . . . . 0.0 107.22 178.475 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 27.6 mt -131.1 130.84 63.9 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 CA-C-N 119.057 0.844 . . . . 0.0 109.274 179.912 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 60.46 79.81 0.11 Allowed Glycine 0 CA--C 1.527 0.813 0 CA-C-N 116.269 -0.423 . . . . 0.0 113.127 179.273 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' G' G ' 34' ' ' LEU . . . . . 0.419 HD23 ' N ' ' G' ' 35' ' ' MET . 1.9 tt -111.87 120.29 41.46 Favored 'General case' 0 N--CA 1.479 1.011 0 N-CA-C 106.909 -1.515 . . . . 0.0 106.909 177.394 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' G' G ' 35' ' ' MET . . . . . 0.419 ' N ' HD23 ' G' ' 34' ' ' LEU . 8.4 ttt -155.35 163.08 40.58 Favored 'General case' 0 C--O 1.211 -0.945 0 N-CA-C 108.03 -1.1 . . . . 0.0 108.03 179.466 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 99.6 t -159.44 150.19 6.7 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 N-CA-C 106.295 -1.742 . . . . 0.0 106.295 -179.72 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.41 75.2 0.26 Allowed Glycine 0 C--N 1.312 -0.755 0 C-N-CA 121.093 -0.575 . . . . 0.0 111.956 177.801 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 168.51 -146.24 10.24 Favored Glycine 0 N--CA 1.47 0.928 0 N-CA-C 110.688 -0.965 . . . . 0.0 110.688 179.209 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 22.2 m -134.43 141.61 43.03 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.914 0 CA-C-N 117.039 0.42 . . . . 0.0 109.994 179.873 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 19.3 t . . . . . 0 N--CA 1.471 0.595 0 CA-C-O 117.678 -1.153 . . . . 0.0 110.914 179.541 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 79.4 m-85 . . . . . 0 N--CA 1.474 0.757 0 N-CA-C 109.662 -0.496 . . . . 0.0 109.662 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' H' H ' 5' ' ' ARG . . . . . . . . . . . . . 72.6 mtp180 -144.1 140.95 29.75 Favored 'General case' 0 N--CA 1.482 1.149 0 N-CA-C 109.219 -0.66 . . . . 0.0 109.219 -179.608 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 76.9 m80 -149.35 119.21 7.09 Favored 'General case' 0 N--CA 1.473 0.721 0 N-CA-C 109.076 -0.712 . . . . 0.0 109.076 179.07 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -68.33 145.87 53.79 Favored 'General case' 0 N--CA 1.468 0.431 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.951 -179.413 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' H' H ' 8' ' ' SER . . . . . . . . . . . . . 8.2 t -163.84 173.85 12.25 Favored 'General case' 0 N--CA 1.469 0.508 0 N-CA-C 109.373 -0.602 . . . . 0.0 109.373 178.321 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.89 23.09 2.31 Favored Glycine 0 N--CA 1.48 1.632 0 N-CA-C 111.828 -0.509 . . . . 0.0 111.828 179.125 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 40.4 p90 -56.64 127.81 33.26 Favored 'General case' 0 N--CA 1.474 0.735 0 N-CA-C 112.402 0.519 . . . . 0.0 112.402 -178.996 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 57.7 mt-10 -84.74 155.28 21.95 Favored 'General case' 0 N--CA 1.475 0.806 0 CA-C-O 121.121 0.486 . . . . 0.0 109.917 178.791 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -155.78 127.62 0.97 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.971 0 N-CA-C 108.263 -1.014 . . . . 0.0 108.263 178.847 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 51.3 m-70 -133.79 146.08 50.37 Favored 'General case' 0 N--CA 1.476 0.847 0 CA-C-N 115.423 -0.808 . . . . 0.0 111.239 -178.197 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 6.4 t60 -165.55 97.75 0.68 Allowed 'General case' 0 N--CA 1.482 1.146 0 CA-C-N 116.582 -0.281 . . . . 0.0 110.673 179.159 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 35.3 mt-30 -105.68 -173.04 2.21 Favored 'General case' 0 CA--C 1.501 -0.934 0 N-CA-C 108.549 -0.908 . . . . 0.0 108.549 -179.848 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' H' H ' 16' ' ' LYS . . . . . 0.404 ' C ' HD12 ' H' ' 17' ' ' LEU . 88.5 tttt -169.08 96.74 0.35 Allowed 'General case' 0 CA--C 1.54 0.562 0 CA-C-N 114.941 -1.027 . . . . 0.0 109.276 178.775 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' H' H ' 17' ' ' LEU . . . . . 0.57 ' N ' HD12 ' H' ' 17' ' ' LEU . 5.4 mp -106.21 163.29 12.92 Favored 'General case' 0 N--CA 1.487 1.382 0 N-CA-C 109.349 -0.612 . . . . 0.0 109.349 -179.553 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 40.1 t -142.63 118.48 5.44 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.037 0 CA-C-O 120.929 0.395 . . . . 0.0 110.479 178.895 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 48.0 m-85 -69.57 150.72 46.8 Favored 'General case' 0 C--N 1.37 1.483 0 N-CA-C 107.386 -1.338 . . . . 0.0 107.386 176.686 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 11.6 t80 -171.99 -54.66 0.02 OUTLIER 'General case' 0 N--CA 1.485 1.293 0 CA-C-N 117.837 0.289 . . . . 0.0 110.32 -179.537 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.94 90.39 0.0 OUTLIER 'General case' 0 CA--C 1.535 0.371 0 C-N-CA 123.685 0.794 . . . . 0.0 112.299 -179.974 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 37.2 tt0 -65.86 159.07 26.26 Favored 'General case' 0 N--CA 1.469 0.506 0 CA-C-N 114.784 -1.098 . . . . 0.0 110.006 179.254 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 67.0 m-20 -140.99 137.46 33.03 Favored 'General case' 0 N--CA 1.477 0.877 0 C-N-CA 122.845 0.458 . . . . 0.0 110.098 179.884 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' H' H ' 24' ' ' VAL . . . . . . . . . . . . . 21.4 t -85.8 -115.59 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.991 0 N-CA-C 108.531 -0.915 . . . . 0.0 108.531 179.601 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . -109.57 53.88 0.57 Allowed Glycine 0 N--CA 1.481 1.651 0 N-CA-C 111.379 -0.688 . . . . 0.0 111.379 -179.813 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 75.8 p -79.75 125.75 30.07 Favored 'General case' 0 N--CA 1.467 0.386 0 N-CA-C 108.958 -0.756 . . . . 0.0 108.958 178.034 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 43.5 t30 -66.95 100.59 0.75 Allowed 'General case' 0 N--CA 1.471 0.605 0 N-CA-C 108.352 -0.981 . . . . 0.0 108.352 178.51 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 66.6 mttm -96.79 119.6 35.57 Favored 'General case' 0 N--CA 1.483 1.189 0 N-CA-C 110.097 -0.334 . . . . 0.0 110.097 -179.076 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.41 -125.18 0.01 OUTLIER Glycine 0 CA--C 1.534 1.267 0 N-CA-C 110.738 -0.945 . . . . 0.0 110.738 178.71 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.11 132.81 48.95 Favored 'General case' 0 N--CA 1.47 0.569 0 N-CA-C 109.66 -0.496 . . . . 0.0 109.66 179.839 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 68.7 mt -81.95 139.96 17.18 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.587 0 N-CA-C 107.11 -1.441 . . . . 0.0 107.11 178.525 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 28.0 mt -130.98 130.75 64.17 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.417 0 CA-C-N 118.912 0.778 . . . . 0.0 109.273 -179.978 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 60.48 79.7 0.11 Allowed Glycine 0 CA--C 1.526 0.742 0 CA-C-N 116.301 -0.409 . . . . 0.0 113.126 179.231 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' H' H ' 34' ' ' LEU . . . . . 0.409 HD23 ' N ' ' H' ' 35' ' ' MET . 1.9 tt -111.84 120.05 40.64 Favored 'General case' 0 N--CA 1.479 1.018 0 N-CA-C 106.889 -1.523 . . . . 0.0 106.889 177.42 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' H' H ' 35' ' ' MET . . . . . 0.409 ' N ' HD23 ' H' ' 34' ' ' LEU . 8.5 ttt -154.97 163.18 40.67 Favored 'General case' 0 N--CA 1.479 0.982 0 N-CA-C 107.958 -1.127 . . . . 0.0 107.958 179.505 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 93.6 t -159.78 150.43 6.29 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.254 0 N-CA-C 106.275 -1.75 . . . . 0.0 106.275 -179.735 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.15 75.13 0.26 Allowed Glycine 0 C--N 1.313 -0.731 0 CA-C-N 115.942 -0.572 . . . . 0.0 111.922 177.959 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 168.42 -146.51 10.49 Favored Glycine 0 N--CA 1.471 0.992 0 N-CA-C 110.632 -0.987 . . . . 0.0 110.632 179.273 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 22.3 m -134.23 141.85 42.55 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.924 0 CA-C-N 116.977 0.389 . . . . 0.0 109.998 179.976 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 19.4 t . . . . . 0 N--CA 1.47 0.543 0 CA-C-O 117.768 -1.111 . . . . 0.0 110.918 179.489 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 78.3 m-85 . . . . . 0 N--CA 1.474 0.745 0 N-CA-C 109.651 -0.5 . . . . 0.0 109.651 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' I' I ' 5' ' ' ARG . . . . . . . . . . . . . 72.7 mtp180 -144.49 140.95 29.21 Favored 'General case' 0 N--CA 1.482 1.158 0 N-CA-C 109.232 -0.655 . . . . 0.0 109.232 -179.619 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 76.9 m80 -149.31 118.93 6.97 Favored 'General case' 0 N--CA 1.474 0.753 0 N-CA-C 109.11 -0.7 . . . . 0.0 109.11 179.095 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 8.0 m-20 -68.1 145.87 54.0 Favored 'General case' 0 N--CA 1.467 0.385 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.82 -179.361 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' I' I ' 8' ' ' SER . . . . . . . . . . . . . 8.3 t -163.91 173.7 12.36 Favored 'General case' 0 N--CA 1.47 0.555 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 178.34 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.97 23.32 2.25 Favored Glycine 0 N--CA 1.481 1.657 0 N-CA-C 111.845 -0.502 . . . . 0.0 111.845 179.156 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 41.0 p90 -56.81 128.03 34.61 Favored 'General case' 0 N--CA 1.473 0.683 0 N-CA-C 112.437 0.532 . . . . 0.0 112.437 -178.99 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 57.9 mt-10 -84.86 155.19 21.85 Favored 'General case' 0 N--CA 1.474 0.757 0 CA-C-O 121.074 0.464 . . . . 0.0 109.976 178.755 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -155.7 127.65 0.99 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.977 0 N-CA-C 108.236 -1.024 . . . . 0.0 108.236 178.777 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 51.2 m-70 -133.68 146.41 50.81 Favored 'General case' 0 N--CA 1.476 0.849 0 CA-C-N 115.372 -0.831 . . . . 0.0 111.119 -178.162 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 33.6 t-80 -165.99 97.89 0.63 Allowed 'General case' 0 N--CA 1.482 1.164 0 CA-C-N 116.556 -0.293 . . . . 0.0 110.696 179.026 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 35.3 mt-30 -105.85 -172.75 2.15 Favored 'General case' 0 CA--C 1.5 -0.948 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 -179.825 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' I' I ' 16' ' ' LYS . . . . . 0.403 ' C ' HD12 ' I' ' 17' ' ' LEU . 88.6 tttt -169.18 96.82 0.34 Allowed 'General case' 0 CA--C 1.539 0.543 0 CA-C-N 114.901 -1.045 . . . . 0.0 109.355 178.769 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' I' I ' 17' ' ' LEU . . . . . 0.566 ' N ' HD12 ' I' ' 17' ' ' LEU . 5.4 mp -106.19 163.15 13.03 Favored 'General case' 0 N--CA 1.488 1.43 0 N-CA-C 109.301 -0.629 . . . . 0.0 109.301 -179.555 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 40.1 t -142.48 118.37 5.66 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.015 0 CA-C-O 120.901 0.382 . . . . 0.0 110.387 178.933 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 48.6 m-85 -69.43 151.02 46.61 Favored 'General case' 0 C--N 1.372 1.553 0 N-CA-C 107.414 -1.328 . . . . 0.0 107.414 176.654 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 11.7 t80 -172.19 -54.98 0.02 OUTLIER 'General case' 0 N--CA 1.483 1.225 0 CA-C-N 117.822 0.283 . . . . 0.0 110.346 -179.587 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.81 90.29 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.465 0 C-N-CA 123.712 0.805 . . . . 0.0 112.327 -179.984 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 37.3 tt0 -65.68 159.15 25.57 Favored 'General case' 0 N--CA 1.468 0.464 0 CA-C-N 114.686 -1.143 . . . . 0.0 110.023 179.304 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 66.6 m-20 -140.92 137.21 32.97 Favored 'General case' 0 N--CA 1.476 0.834 0 C-N-CA 122.906 0.482 . . . . 0.0 110.122 179.835 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' I' I ' 24' ' ' VAL . . . . . . . . . . . . . 21.5 t -85.47 -115.35 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.034 0 N-CA-C 108.479 -0.934 . . . . 0.0 108.479 179.58 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . -109.84 53.44 0.59 Allowed Glycine 0 N--CA 1.48 1.584 0 N-CA-C 111.495 -0.642 . . . . 0.0 111.495 -179.761 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 77.0 p -79.29 125.79 29.95 Favored 'General case' 0 N--CA 1.467 0.388 0 N-CA-C 109.131 -0.692 . . . . 0.0 109.131 177.992 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 43.2 t30 -67.14 100.54 0.78 Allowed 'General case' 0 N--CA 1.471 0.625 0 N-CA-C 108.395 -0.965 . . . . 0.0 108.395 178.525 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 66.8 mttm -96.71 120.05 36.32 Favored 'General case' 0 N--CA 1.483 1.221 0 N-CA-C 110.129 -0.323 . . . . 0.0 110.129 -179.11 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.7 -125.36 0.01 OUTLIER Glycine 0 CA--C 1.535 1.319 0 N-CA-C 110.688 -0.965 . . . . 0.0 110.688 178.793 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -127.78 132.82 49.47 Favored 'General case' 0 N--CA 1.473 0.682 0 C-N-CA 123.023 0.529 . . . . 0.0 109.653 179.633 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 68.2 mt -81.92 139.91 17.24 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.582 0 N-CA-C 107.13 -1.433 . . . . 0.0 107.13 178.479 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 27.2 mt -130.99 130.87 64.22 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.373 0 CA-C-N 118.977 0.808 . . . . 0.0 109.282 -179.938 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 60.38 79.68 0.11 Allowed Glycine 0 CA--C 1.527 0.805 0 CA-C-N 116.285 -0.416 . . . . 0.0 113.079 179.261 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' I' I ' 34' ' ' LEU . . . . . 0.412 HD23 ' N ' ' I' ' 35' ' ' MET . 1.9 tt -111.9 120.07 40.67 Favored 'General case' 0 N--CA 1.48 1.038 0 N-CA-C 106.823 -1.547 . . . . 0.0 106.823 177.432 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' I' I ' 35' ' ' MET . . . . . 0.412 ' N ' HD23 ' I' ' 34' ' ' LEU . 8.5 ttt -154.9 163.28 40.51 Favored 'General case' 0 C--O 1.211 -0.958 0 N-CA-C 108.005 -1.109 . . . . 0.0 108.005 179.461 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 98.7 t -159.72 150.41 6.35 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.257 0 N-CA-C 106.273 -1.751 . . . . 0.0 106.273 -179.739 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.08 75.23 0.26 Allowed Glycine 0 C--N 1.315 -0.631 0 CA-C-N 115.893 -0.594 . . . . 0.0 111.951 177.907 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 168.46 -146.33 10.33 Favored Glycine 0 N--CA 1.469 0.886 0 N-CA-C 110.643 -0.983 . . . . 0.0 110.643 179.287 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 22.3 m -134.39 141.72 42.75 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.856 0 CA-C-N 116.985 0.392 . . . . 0.0 110.038 179.928 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 18.9 t . . . . . 0 N--CA 1.469 0.488 0 CA-C-O 117.765 -1.112 . . . . 0.0 110.92 179.434 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 55.1 m-85 . . . . . 0 N--CA 1.475 0.804 0 N-CA-C 110.241 -0.281 . . . . 0.0 110.241 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 -144.33 142.14 30.2 Favored 'General case' 0 N--CA 1.482 1.131 0 N-CA-C 110.01 -0.366 . . . . 0.0 110.01 179.713 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 41.7 t-80 -152.43 119.69 5.92 Favored 'General case' 0 N--CA 1.472 0.674 0 N-CA-C 109.23 -0.655 . . . . 0.0 109.23 179.098 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 7' ' ' ASP . . . . . 0.507 ' O ' ' OG ' ' D' ' 8' ' ' SER . 4.6 m-20 -69.02 148.68 49.73 Favored 'General case' 0 CA--C 1.535 0.383 0 CA-C-N 116.341 -0.39 . . . . 0.0 110.412 179.893 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 54.0 p -167.65 -173.58 2.21 Favored 'General case' 0 N--CA 1.481 1.084 0 CA-C-O 120.92 0.391 . . . . 0.0 110.698 179.217 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.26 47.45 1.32 Allowed Glycine 0 N--CA 1.482 1.742 0 CA-C-N 116.036 -0.529 . . . . 0.0 111.905 -179.941 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 49.7 p90 -66.03 133.03 49.93 Favored 'General case' 0 N--CA 1.473 0.695 0 CA-C-O 120.74 0.305 . . . . 0.0 111.618 179.814 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 84.2 mt-10 -91.82 152.19 20.24 Favored 'General case' 0 N--CA 1.477 0.91 0 N-CA-C 109.662 -0.496 . . . . 0.0 109.662 178.443 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -152.67 128.31 1.68 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.593 0 N-CA-C 107.884 -1.154 . . . . 0.0 107.884 178.074 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 43.7 m-70 -135.9 148.5 48.6 Favored 'General case' 0 N--CA 1.493 1.681 0 CA-C-N 119.025 0.829 . . . . 0.0 111.292 -178.986 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 6.6 t60 -164.82 98.47 0.76 Allowed 'General case' 0 N--CA 1.48 1.053 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.823 179.396 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -91.85 -177.38 4.72 Favored 'General case' 0 CA--C 1.514 -0.432 0 N-CA-C 108.851 -0.796 . . . . 0.0 108.851 -179.933 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -172.06 93.74 0.14 Allowed 'General case' 0 N--CA 1.469 0.489 0 CA-C-N 114.659 -1.155 . . . . 0.0 108.566 177.94 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 6.3 mp -124.77 155.98 38.46 Favored 'General case' 0 N--CA 1.497 1.896 0 CA-C-O 121.744 0.783 . . . . 0.0 110.989 -178.417 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 61.0 t -111.63 124.46 68.4 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.024 0 CA-C-O 117.825 -1.083 . . . . 0.0 108.469 177.77 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 29.4 m-85 -124.27 143.78 50.35 Favored 'General case' 0 N--CA 1.498 1.946 0 CA-C-N 120.177 1.353 . . . . 0.0 110.268 179.227 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 67.2 m-85 52.49 68.33 0.84 Allowed 'General case' 0 N--CA 1.472 0.637 0 CA-C-N 116.367 -0.378 . . . . 0.0 111.875 178.458 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -78.14 -84.62 0.08 Allowed 'General case' 0 C--N 1.361 1.097 0 CA-C-N 115.463 -0.79 . . . . 0.0 110.173 -179.829 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 41.2 tt0 -123.07 96.9 5.19 Favored 'General case' 0 C--N 1.323 -0.547 0 N-CA-C 108.089 -1.078 . . . . 0.0 108.089 179.7 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 4.1 p30 -158.97 143.67 15.78 Favored 'General case' 0 N--CA 1.484 1.261 0 O-C-N 122.313 -0.242 . . . . 0.0 111.102 179.092 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 61.6 t -61.38 162.66 1.36 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.784 0 N-CA-C 107.968 -1.123 . . . . 0.0 107.968 177.206 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.494 ' H ' ' HB ' ' D' ' 24' ' ' VAL . . . -117.71 48.96 0.89 Allowed Glycine 0 N--CA 1.476 1.328 0 N-CA-C 111.81 -0.516 . . . . 0.0 111.81 -179.377 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -61.84 -169.05 0.02 OUTLIER 'General case' 0 N--CA 1.469 0.522 0 O-C-N 123.722 0.307 . . . . 0.0 110.404 179.56 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 28.3 t-20 -69.52 80.35 0.4 Allowed 'General case' 0 N--CA 1.464 0.271 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.132 179.717 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -79.8 154.71 28.28 Favored 'General case' 0 N--CA 1.473 0.677 0 N-CA-C 108.883 -0.784 . . . . 0.0 108.883 179.059 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.0 -144.07 0.02 OUTLIER Glycine 0 CA--C 1.526 0.748 0 N-CA-C 109.749 -1.34 . . . . 0.0 109.749 178.496 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -136.89 120.3 16.97 Favored 'General case' 0 N--CA 1.479 0.976 0 CA-C-N 117.247 0.523 . . . . 0.0 109.755 179.38 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 69.5 mt -80.39 124.73 38.67 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.528 0 N-CA-C 106.741 -1.577 . . . . 0.0 106.741 178.339 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 32' ' ' ILE . . . . . 0.413 ' C ' ' H ' ' A' ' 34' ' ' LEU . 41.5 pt -151.34 162.71 2.93 Favored 'Isoleucine or valine' 0 C--N 1.358 0.958 0 CA-C-N 115.741 -0.663 . . . . 0.0 111.552 -178.805 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 64.88 0.44 5.24 Favored Glycine 0 CA--C 1.524 0.603 0 N-CA-C 111.008 -0.837 . . . . 0.0 111.008 179.611 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.413 ' H ' ' C ' ' A' ' 32' ' ' ILE . 7.8 tt -79.7 148.46 31.55 Favored 'General case' 0 N--CA 1.466 0.346 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 -179.989 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 28.6 ttt -159.89 140.68 12.21 Favored 'General case' 0 N--CA 1.473 0.68 0 N-CA-C 108.816 -0.809 . . . . 0.0 108.816 178.993 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 27.6 m -156.22 162.57 1.64 Allowed 'Isoleucine or valine' 0 C--N 1.347 0.495 0 N-CA-C 108.259 -1.015 . . . . 0.0 108.259 -179.756 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.63 67.55 2.15 Favored Glycine 0 C--N 1.308 -1.026 0 CA-C-N 115.773 -0.649 . . . . 0.0 111.967 178.6 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.91 172.49 17.98 Favored Glycine 0 N--CA 1.475 1.242 0 N-CA-C 110.649 -0.98 . . . . 0.0 110.649 179.28 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.56 ' H ' HG12 ' D' ' 39' ' ' VAL . 34.9 m -125.16 164.42 24.18 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.943 0 C-N-CA 123.549 0.739 . . . . 0.0 110.803 -179.546 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 25.0 t . . . . . 0 C--O 1.221 -0.437 0 CA-C-O 118.382 -0.818 . . . . 0.0 110.766 179.333 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 55.6 m-85 . . . . . 0 N--CA 1.476 0.843 0 N-CA-C 110.272 -0.269 . . . . 0.0 110.272 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 -144.22 142.09 30.28 Favored 'General case' 0 N--CA 1.481 1.124 0 N-CA-C 109.989 -0.375 . . . . 0.0 109.989 179.687 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 41.1 t-80 -152.34 119.46 5.87 Favored 'General case' 0 N--CA 1.473 0.686 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 179.146 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 7' ' ' ASP . . . . . 0.467 ' O ' ' OG ' ' E' ' 8' ' ' SER . 4.4 m-20 -69.01 148.31 50.29 Favored 'General case' 0 CA--C 1.536 0.436 0 CA-C-N 116.435 -0.348 . . . . 0.0 110.465 179.914 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 8' ' ' SER . . . . . . . . . . . . . 54.0 p -167.26 -173.35 2.25 Favored 'General case' 0 N--CA 1.48 1.048 0 CA-C-O 120.873 0.368 . . . . 0.0 110.645 179.214 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.08 47.37 1.35 Allowed Glycine 0 N--CA 1.482 1.762 0 CA-C-N 115.982 -0.554 . . . . 0.0 111.927 179.896 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 49.3 p90 -65.93 133.73 51.49 Favored 'General case' 0 N--CA 1.473 0.679 0 CA-C-O 120.751 0.31 . . . . 0.0 111.714 179.699 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 83.5 mt-10 -92.39 152.51 19.7 Favored 'General case' 0 N--CA 1.476 0.839 0 N-CA-C 109.666 -0.494 . . . . 0.0 109.666 178.398 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -153.14 128.42 1.56 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.609 0 N-CA-C 107.776 -1.194 . . . . 0.0 107.776 178.261 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 43.6 m-70 -136.27 148.35 47.96 Favored 'General case' 0 N--CA 1.492 1.655 0 CA-C-N 118.864 0.756 . . . . 0.0 111.37 -179.033 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 6.7 t60 -164.67 98.06 0.77 Allowed 'General case' 0 N--CA 1.481 1.093 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.694 179.512 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 5.1 pt20 -91.14 -176.86 4.73 Favored 'General case' 0 CA--C 1.515 -0.386 0 N-CA-C 108.74 -0.837 . . . . 0.0 108.74 -179.984 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -172.7 93.77 0.12 Allowed 'General case' 0 N--CA 1.469 0.505 0 CA-C-N 114.711 -1.131 . . . . 0.0 108.405 177.807 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 6.3 mp -124.71 156.1 38.18 Favored 'General case' 0 N--CA 1.497 1.918 0 CA-C-O 121.77 0.795 . . . . 0.0 110.985 -178.465 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 62.0 t -111.85 125.14 69.13 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.007 0 N-CA-C 108.297 -1.001 . . . . 0.0 108.297 177.645 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 29.6 m-85 -124.87 143.76 50.67 Favored 'General case' 0 N--CA 1.495 1.803 0 CA-C-N 119.813 1.188 . . . . 0.0 110.161 179.433 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 68.2 m-85 51.45 68.41 0.8 Allowed 'General case' 0 N--CA 1.468 0.452 0 CA-C-O 121.199 0.524 . . . . 0.0 111.994 178.48 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -78.09 -84.28 0.08 Allowed 'General case' 0 C--N 1.356 0.875 0 CA-C-N 115.198 -0.91 . . . . 0.0 110.055 -179.847 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 41.2 tt0 -123.14 97.42 5.42 Favored 'General case' 0 C--N 1.323 -0.583 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 179.682 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 4.0 p30 -159.34 143.5 15.1 Favored 'General case' 0 N--CA 1.483 1.206 0 O-C-N 122.342 -0.224 . . . . 0.0 111.083 179.103 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 61.9 t -61.17 162.65 1.31 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.89 0 N-CA-C 107.983 -1.117 . . . . 0.0 107.983 177.136 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 25' ' ' GLY . . . . . 0.495 ' H ' ' HB ' ' E' ' 24' ' ' VAL . . . -117.62 49.03 0.89 Allowed Glycine 0 N--CA 1.475 1.294 0 N-CA-C 111.725 -0.55 . . . . 0.0 111.725 -179.281 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -62.2 -168.78 0.02 OUTLIER 'General case' 0 N--CA 1.469 0.514 0 O-C-N 123.616 0.245 . . . . 0.0 110.374 179.598 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 27.9 t-20 -69.72 80.64 0.44 Allowed 'General case' 0 N--CA 1.465 0.312 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.043 179.773 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 97.9 mttt -80.2 154.41 27.96 Favored 'General case' 0 N--CA 1.472 0.633 0 N-CA-C 108.882 -0.784 . . . . 0.0 108.882 179.072 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.9 -144.5 0.02 OUTLIER Glycine 0 CA--C 1.526 0.738 0 N-CA-C 109.636 -1.386 . . . . 0.0 109.636 178.476 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -136.39 120.84 18.14 Favored 'General case' 0 N--CA 1.478 0.973 0 CA-C-N 117.142 0.471 . . . . 0.0 109.83 179.376 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 70.1 mt -80.65 124.98 39.12 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.524 0 N-CA-C 106.721 -1.585 . . . . 0.0 106.721 178.249 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 32' ' ' ILE . . . . . 0.408 ' C ' ' H ' ' B' ' 34' ' ' LEU . 41.3 pt -151.59 162.75 2.8 Favored 'Isoleucine or valine' 0 C--N 1.358 0.951 0 CA-C-N 115.836 -0.62 . . . . 0.0 111.491 -178.728 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 64.61 0.52 5.0 Favored Glycine 0 C--N 1.337 0.635 0 CA-C-N 115.507 -0.77 . . . . 0.0 111.177 179.716 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 34' ' ' LEU . . . . . 0.408 ' H ' ' C ' ' B' ' 32' ' ' ILE . 7.8 tt -79.85 148.15 31.47 Favored 'General case' 0 N--CA 1.465 0.292 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 -179.952 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 28.6 ttt -159.32 140.75 13.03 Favored 'General case' 0 N--CA 1.475 0.795 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 179.051 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 28.3 m -156.35 162.56 1.63 Allowed 'Isoleucine or valine' 0 C--N 1.346 0.422 0 N-CA-C 108.214 -1.032 . . . . 0.0 108.214 -179.796 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.67 67.45 2.2 Favored Glycine 0 C--N 1.306 -1.111 0 CA-C-N 115.756 -0.657 . . . . 0.0 111.932 178.558 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.86 172.8 18.27 Favored Glycine 0 N--CA 1.474 1.202 0 N-CA-C 110.678 -0.969 . . . . 0.0 110.678 179.208 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 39' ' ' VAL . . . . . 0.553 ' H ' HG12 ' E' ' 39' ' ' VAL . 35.2 m -125.3 164.29 24.67 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.082 0 C-N-CA 123.523 0.729 . . . . 0.0 110.819 -179.392 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 24.9 t . . . . . 0 N--CA 1.471 0.576 0 CA-C-O 118.237 -0.887 . . . . 0.0 110.636 179.164 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 54.9 m-85 . . . . . 0 N--CA 1.477 0.922 0 N-CA-C 110.238 -0.282 . . . . 0.0 110.238 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 -144.22 142.12 30.31 Favored 'General case' 0 N--CA 1.482 1.15 0 N-CA-C 109.974 -0.38 . . . . 0.0 109.974 179.645 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 40.8 t-80 -152.37 119.98 6.05 Favored 'General case' 0 N--CA 1.473 0.708 0 N-CA-C 109.251 -0.648 . . . . 0.0 109.251 179.152 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' C' C ' 7' ' ' ASP . . . . . 0.477 ' O ' ' OG ' ' F' ' 8' ' ' SER . 4.4 m-20 -69.45 148.39 49.63 Favored 'General case' 0 CA--C 1.535 0.397 0 CA-C-N 116.352 -0.385 . . . . 0.0 110.518 179.908 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' C' C ' 8' ' ' SER . . . . . . . . . . . . . 55.4 p -167.32 -173.51 2.29 Favored 'General case' 0 N--CA 1.48 1.029 0 CA-C-O 120.839 0.352 . . . . 0.0 110.656 179.272 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.18 47.58 1.31 Allowed Glycine 0 N--CA 1.483 1.795 0 CA-C-N 116.006 -0.543 . . . . 0.0 111.903 179.961 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 49.5 p90 -66.15 133.3 50.41 Favored 'General case' 0 N--CA 1.472 0.665 0 CA-C-N 116.783 0.292 . . . . 0.0 111.681 179.697 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 83.2 mt-10 -92.15 152.08 20.08 Favored 'General case' 0 N--CA 1.476 0.851 0 N-CA-C 109.696 -0.483 . . . . 0.0 109.696 178.4 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -152.61 128.35 1.71 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.588 0 N-CA-C 107.791 -1.189 . . . . 0.0 107.791 178.146 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 42.4 m-70 -136.03 148.38 48.35 Favored 'General case' 0 N--CA 1.492 1.663 0 CA-C-N 118.937 0.79 . . . . 0.0 111.286 -179.102 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 6.7 t60 -164.69 98.55 0.78 Allowed 'General case' 0 N--CA 1.481 1.105 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.685 179.475 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -91.91 -176.99 4.6 Favored 'General case' 0 CA--C 1.512 -0.484 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 -179.937 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -172.49 93.84 0.13 Allowed 'General case' 0 N--CA 1.47 0.533 0 CA-C-N 114.707 -1.133 . . . . 0.0 108.451 177.959 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 6.1 mp -124.93 155.7 39.15 Favored 'General case' 0 N--CA 1.496 1.842 0 CA-C-O 121.768 0.794 . . . . 0.0 111.096 -178.381 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 61.6 t -111.54 125.52 68.86 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.996 0 N-CA-C 108.238 -1.023 . . . . 0.0 108.238 177.754 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 29.3 m-85 -125.31 143.31 51.03 Favored 'General case' 0 N--CA 1.495 1.822 0 CA-C-N 119.673 1.124 . . . . 0.0 110.083 179.369 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 67.5 m-85 51.93 68.46 0.81 Allowed 'General case' 0 N--CA 1.47 0.534 0 CA-C-O 121.215 0.531 . . . . 0.0 111.975 178.501 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -78.09 -84.41 0.08 Allowed 'General case' 0 C--N 1.356 0.873 0 CA-C-N 115.186 -0.915 . . . . 0.0 110.071 -179.851 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 40.9 tt0 -123.14 96.97 5.21 Favored 'General case' 0 C--N 1.323 -0.546 0 N-CA-C 108.08 -1.081 . . . . 0.0 108.08 179.746 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 4.1 p30 -158.8 143.71 16.02 Favored 'General case' 0 N--CA 1.484 1.263 0 CA-C-O 119.672 -0.204 . . . . 0.0 111.118 179.002 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 59.9 t -61.43 162.38 1.45 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.849 0 N-CA-C 107.96 -1.126 . . . . 0.0 107.96 177.129 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' C' C ' 25' ' ' GLY . . . . . 0.481 ' H ' ' HB ' ' F' ' 24' ' ' VAL . . . -117.5 49.49 0.86 Allowed Glycine 0 N--CA 1.477 1.414 0 N-CA-C 111.726 -0.55 . . . . 0.0 111.726 -179.286 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -62.65 -168.51 0.02 OUTLIER 'General case' 0 N--CA 1.468 0.44 0 O-C-N 123.666 0.274 . . . . 0.0 110.443 179.64 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 27.8 t-20 -69.88 80.47 0.46 Allowed 'General case' 0 N--CA 1.465 0.322 0 N-CA-C 110.073 -0.343 . . . . 0.0 110.073 179.781 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -79.98 154.62 28.11 Favored 'General case' 0 N--CA 1.472 0.668 0 N-CA-C 108.915 -0.772 . . . . 0.0 108.915 179.111 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.89 -144.17 0.02 OUTLIER Glycine 0 CA--C 1.527 0.821 0 N-CA-C 109.769 -1.332 . . . . 0.0 109.769 178.488 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -136.78 120.47 17.28 Favored 'General case' 0 N--CA 1.481 1.083 0 CA-C-N 117.185 0.493 . . . . 0.0 109.719 179.258 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 70.0 mt -80.49 124.8 38.81 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.541 0 N-CA-C 106.762 -1.57 . . . . 0.0 106.762 178.254 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' C' C ' 32' ' ' ILE . . . . . 0.418 ' C ' ' H ' ' C' ' 34' ' ' LEU . 41.3 pt -151.39 162.53 2.97 Favored 'Isoleucine or valine' 0 C--N 1.359 0.991 0 CA-C-N 115.68 -0.691 . . . . 0.0 111.53 -178.634 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 64.89 0.68 5.5 Favored Glycine 0 N--CA 1.465 0.598 0 N-CA-C 110.973 -0.851 . . . . 0.0 110.973 179.606 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' C' C ' 34' ' ' LEU . . . . . 0.418 ' H ' ' C ' ' C' ' 32' ' ' ILE . 7.7 tt -79.87 148.12 31.45 Favored 'General case' 0 N--CA 1.465 0.302 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 179.955 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 28.6 ttt -159.29 140.85 13.16 Favored 'General case' 0 N--CA 1.474 0.742 0 N-CA-C 108.751 -0.833 . . . . 0.0 108.751 178.955 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 28.1 m -156.5 162.77 1.55 Allowed 'Isoleucine or valine' 0 C--N 1.348 0.511 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 -179.798 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.37 67.14 2.36 Favored Glycine 0 C--N 1.307 -1.07 0 CA-C-N 115.695 -0.684 . . . . 0.0 111.901 178.56 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 148.23 172.58 18.32 Favored Glycine 0 N--CA 1.474 1.218 0 N-CA-C 110.604 -0.998 . . . . 0.0 110.604 179.237 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' C' C ' 39' ' ' VAL . . . . . 0.55 ' H ' HG12 ' F' ' 39' ' ' VAL . 35.1 m -125.25 164.48 24.23 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.996 0 C-N-CA 123.518 0.727 . . . . 0.0 110.789 -179.415 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 25.4 t . . . . . 0 N--CA 1.469 0.484 0 CA-C-O 118.234 -0.889 . . . . 0.0 110.649 179.207 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 61.4 m-85 . . . . . 0 N--CA 1.474 0.765 0 N-CA-C 108.792 -0.818 . . . . 0.0 108.792 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' D' D ' 5' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 -146.43 140.49 26.33 Favored 'General case' 0 N--CA 1.476 0.85 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.236 -179.994 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 38.0 t-80 -149.82 124.02 9.5 Favored 'General case' 0 CA--C 1.545 0.781 0 N-CA-C 108.344 -0.984 . . . . 0.0 108.344 175.303 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' D' D ' 7' ' ' ASP . . . . . 0.57 ' O ' ' OG ' ' G' ' 8' ' ' SER . 3.3 m-20 -63.76 132.46 51.04 Favored 'General case' 0 C--N 1.322 -0.596 0 C-N-CA 126.885 2.074 . . . . 0.0 114.325 174.69 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' D' D ' 8' ' ' SER . . . . . 0.507 ' OG ' ' O ' ' A' ' 7' ' ' ASP . 54.2 p -154.63 -170.65 3.58 Favored 'General case' 0 N--CA 1.486 1.334 0 CA-C-N 119.77 1.168 . . . . 0.0 111.22 175.927 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.35 48.15 1.15 Allowed Glycine 0 N--CA 1.483 1.804 0 C-N-CA 124.562 1.077 . . . . 0.0 110.539 174.952 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 51.5 p90 -60.97 131.57 51.09 Favored 'General case' 0 N--CA 1.472 0.626 0 N-CA-C 112.908 0.707 . . . . 0.0 112.908 177.925 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 84.2 mt-10 -89.28 150.91 22.39 Favored 'General case' 0 N--CA 1.481 1.1 0 CA-C-N 117.974 0.352 . . . . 0.0 110.637 175.315 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.0 p -149.58 129.86 4.2 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.637 0 N-CA-C 107.416 -1.328 . . . . 0.0 107.416 173.066 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 38.3 m-70 -129.91 151.28 50.64 Favored 'General case' 0 N--CA 1.484 1.262 0 N-CA-C 112.329 0.492 . . . . 0.0 112.329 176.791 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 6.7 t60 -164.79 104.84 0.81 Allowed 'General case' 0 N--CA 1.482 1.145 0 N-CA-C 109.155 -0.683 . . . . 0.0 109.155 172.664 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' D' D ' 15' ' ' GLN . . . . . 0.401 ' OE1' ' N ' ' G' ' 37' ' ' GLY . 4.9 pt20 -94.96 -177.3 4.12 Favored 'General case' 0 CA--C 1.509 -0.631 0 N-CA-C 108.574 -0.898 . . . . 0.0 108.574 179.044 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -169.75 103.49 0.32 Allowed 'General case' 0 N--CA 1.465 0.308 0 N-CA-C 105.891 -1.892 . . . . 0.0 105.891 173.374 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 5.0 mp -132.19 153.44 50.57 Favored 'General case' 0 N--CA 1.498 1.97 0 CA-C-O 122.011 0.91 . . . . 0.0 110.214 178.912 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 35.8 t -101.12 129.01 52.79 Favored 'Isoleucine or valine' 0 C--O 1.266 1.943 0 CA-C-O 116.373 -1.775 . . . . 0.0 109.693 174.267 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 25.8 m-85 -126.63 149.25 49.59 Favored 'General case' 0 N--CA 1.49 1.562 0 CA-C-N 120.525 1.511 . . . . 0.0 109.472 172.329 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 66.7 m-85 55.14 63.64 2.05 Favored 'General case' 0 C--O 1.24 0.599 0 CA-C-O 118.518 -0.753 . . . . 0.0 111.555 175.097 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -79.99 -81.35 0.12 Allowed 'General case' 0 N--CA 1.474 0.741 0 CA-C-N 118.942 0.792 . . . . 0.0 109.967 -176.345 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 41.3 tt0 -124.91 101.81 7.24 Favored 'General case' 0 N--CA 1.479 0.999 0 N-CA-C 106.036 -1.838 . . . . 0.0 106.036 175.969 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 4.1 p30 -152.44 143.08 22.8 Favored 'General case' 0 N--CA 1.476 0.842 0 CA-C-O 116.792 -1.575 . . . . 0.0 113.624 177.592 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' D' D ' 24' ' ' VAL . . . . . 0.494 ' HB ' ' H ' ' A' ' 25' ' ' GLY . 67.1 t -63.58 165.26 1.29 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.366 0 CA-C-N 120.971 1.714 . . . . 0.0 107.824 174.538 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' D' D ' 25' ' ' GLY . . . . . 0.556 ' H ' ' HB ' ' G' ' 24' ' ' VAL . . . -116.84 51.3 0.74 Allowed Glycine 0 N--CA 1.48 1.613 0 CA-C-O 118.978 -0.901 . . . . 0.0 111.977 178.795 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -58.87 -171.23 0.01 OUTLIER 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 117.558 0.679 . . . . 0.0 111.533 176.88 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 28.5 t-20 -71.92 86.66 1.0 Allowed 'General case' 0 CA--C 1.537 0.468 0 N-CA-C 108.432 -0.951 . . . . 0.0 108.432 178.516 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 97.4 mttt -85.34 156.37 20.93 Favored 'General case' 0 N--CA 1.475 0.779 0 N-CA-C 108.124 -1.065 . . . . 0.0 108.124 179.031 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.39 -144.27 0.02 OUTLIER Glycine 0 C--N 1.335 0.488 0 N-CA-C 110.33 -1.108 . . . . 0.0 110.33 179.387 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -136.41 123.74 21.93 Favored 'General case' 0 N--CA 1.474 0.733 0 N-CA-C 109.159 -0.682 . . . . 0.0 109.159 177.648 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 76.4 mt -83.9 134.53 26.74 Favored 'Isoleucine or valine' 0 C--N 1.355 0.819 0 N-CA-C 104.846 -2.279 . . . . 0.0 104.846 178.776 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 46.0 pt -159.07 162.47 1.35 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.02 0 CA-C-O 121.407 0.622 . . . . 0.0 110.397 -178.37 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 64.83 0.17 4.89 Favored Glycine 0 CA--C 1.525 0.685 0 CA-C-N 115.46 -0.791 . . . . 0.0 111.186 -178.563 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 7.6 tt -79.25 150.04 31.69 Favored 'General case' 0 C--N 1.343 0.325 0 N-CA-C 109.345 -0.613 . . . . 0.0 109.345 -179.49 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 27.7 ttt -155.78 151.44 27.26 Favored 'General case' 0 N--CA 1.474 0.728 0 N-CA-C 107.509 -1.293 . . . . 0.0 107.509 174.348 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 29.7 m -164.52 163.65 0.73 Allowed 'Isoleucine or valine' 0 CA--C 1.513 -0.445 0 N-CA-C 107.661 -1.237 . . . . 0.0 107.661 176.901 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 60.32 63.75 4.75 Favored Glycine 0 CA--C 1.528 0.885 0 C-N-CA 119.584 -1.293 . . . . 0.0 112.359 177.88 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.92 173.2 15.2 Favored Glycine 0 N--CA 1.479 1.519 0 CA-C-N 118.451 1.125 . . . . 0.0 111.567 -177.851 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' D' D ' 39' ' ' VAL . . . . . 0.575 ' H ' HG12 ' G' ' 39' ' ' VAL . 34.6 m -128.14 160.16 38.41 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.061 0 C-N-CA 122.895 0.478 . . . . 0.0 110.422 -175.953 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 24.2 t . . . . . 0 C--N 1.331 -0.213 0 CA-C-O 116.386 -1.769 . . . . 0.0 109.855 177.694 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 53.7 m-85 . . . . . 0 N--CA 1.475 0.81 0 N-CA-C 110.348 -0.241 . . . . 0.0 110.348 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' E' E ' 5' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 -143.5 142.62 31.23 Favored 'General case' 0 N--CA 1.479 0.99 0 CA-C-O 120.794 0.33 . . . . 0.0 110.201 179.565 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 41.2 t-80 -152.46 119.54 5.85 Favored 'General case' 0 N--CA 1.474 0.725 0 N-CA-C 109.247 -0.649 . . . . 0.0 109.247 178.985 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' E' E ' 7' ' ' ASP . . . . . 0.435 ' O ' ' OG ' ' H' ' 8' ' ' SER . 4.3 m-20 -69.58 148.27 49.61 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-N 116.491 -0.322 . . . . 0.0 110.671 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' E' E ' 8' ' ' SER . . . . . 0.467 ' OG ' ' O ' ' B' ' 7' ' ' ASP . 52.5 p -167.92 -172.49 1.84 Allowed 'General case' 0 N--CA 1.486 1.328 0 CA-C-O 121.013 0.435 . . . . 0.0 110.87 178.952 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.87 47.66 1.24 Allowed Glycine 0 N--CA 1.48 1.595 0 N-CA-C 111.781 -0.528 . . . . 0.0 111.781 179.684 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 47.8 p90 -65.45 133.36 51.14 Favored 'General case' 0 N--CA 1.473 0.683 0 N-CA-C 112.06 0.392 . . . . 0.0 112.06 -179.846 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 85.1 mt-10 -91.4 152.68 20.31 Favored 'General case' 0 N--CA 1.479 1.002 0 N-CA-C 109.617 -0.512 . . . . 0.0 109.617 177.996 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -154.67 127.28 1.07 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.619 0 N-CA-C 107.816 -1.179 . . . . 0.0 107.816 178.067 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 40.8 m-70 -136.18 146.72 47.17 Favored 'General case' 0 N--CA 1.482 1.157 0 CA-C-O 120.851 0.357 . . . . 0.0 111.639 -178.047 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 6.6 t60 -163.64 98.39 0.88 Allowed 'General case' 0 N--CA 1.485 1.293 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.735 179.553 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 4.8 pt20 -91.36 -176.87 4.68 Favored 'General case' 0 CA--C 1.514 -0.43 0 N-CA-C 109.028 -0.73 . . . . 0.0 109.028 -179.925 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -172.31 92.72 0.12 Allowed 'General case' 0 N--CA 1.47 0.557 0 CA-C-N 114.77 -1.104 . . . . 0.0 108.693 177.929 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 6.0 mp -123.35 155.77 36.67 Favored 'General case' 0 N--CA 1.496 1.864 0 CA-C-O 121.443 0.64 . . . . 0.0 111.433 -177.901 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 48.0 t -113.33 122.57 67.72 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.198 0 N-CA-C 108.333 -0.988 . . . . 0.0 108.333 177.37 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 32.4 m-85 -122.76 142.51 50.65 Favored 'General case' 0 N--CA 1.491 1.594 0 CA-C-O 120.974 0.416 . . . . 0.0 110.649 -179.928 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 67.8 m-85 52.73 67.71 0.95 Allowed 'General case' 0 C--N 1.346 0.42 0 CA-C-N 115.767 -0.651 . . . . 0.0 111.614 178.245 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.15 -83.66 0.07 Allowed 'General case' 0 CA--C 1.541 0.605 0 N-CA-C 109.981 -0.377 . . . . 0.0 109.981 -179.464 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 41.0 tt0 -123.28 97.14 5.28 Favored 'General case' 0 C--N 1.32 -0.686 0 N-CA-C 108.14 -1.059 . . . . 0.0 108.14 179.938 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 4.1 p30 -158.35 143.46 16.44 Favored 'General case' 0 N--CA 1.48 1.057 0 O-C-N 122.422 -0.174 . . . . 0.0 111.33 179.062 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' E' E ' 24' ' ' VAL . . . . . 0.495 ' HB ' ' H ' ' B' ' 25' ' ' GLY . 57.9 t -59.53 167.42 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.954 0 N-CA-C 107.412 -1.329 . . . . 0.0 107.412 176.991 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' E' E ' 25' ' ' GLY . . . . . 0.461 ' H ' ' HB ' ' H' ' 24' ' ' VAL . . . -122.61 49.66 0.88 Allowed Glycine 0 N--CA 1.475 1.266 0 N-CA-C 110.915 -0.874 . . . . 0.0 110.915 -179.386 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -63.24 -168.54 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.639 0 CA-C-O 120.689 0.281 . . . . 0.0 110.572 179.946 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 28.4 t-20 -68.98 77.94 0.32 Allowed 'General case' 0 N--CA 1.465 0.281 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.261 179.946 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -78.12 155.28 30.59 Favored 'General case' 0 N--CA 1.475 0.779 0 N-CA-C 109.458 -0.571 . . . . 0.0 109.458 179.279 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.76 -144.74 0.02 OUTLIER Glycine 0 C--N 1.337 0.634 0 N-CA-C 110.34 -1.104 . . . . 0.0 110.34 178.022 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -137.12 117.25 13.42 Favored 'General case' 0 N--CA 1.476 0.831 0 CA-C-O 120.79 0.328 . . . . 0.0 110.286 179.723 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 67.0 mt -77.45 125.15 36.96 Favored 'Isoleucine or valine' 0 C--O 1.238 0.475 0 N-CA-C 107.011 -1.477 . . . . 0.0 107.011 178.411 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' E' E ' 32' ' ' ILE . . . . . 0.405 ' C ' ' H ' ' E' ' 34' ' ' LEU . 46.4 pt -150.96 164.47 2.64 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.085 0 CA-C-O 121.279 0.561 . . . . 0.0 111.019 -178.943 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.82 1.1 3.36 Favored Glycine 0 CA--C 1.529 0.911 0 CA-C-N 115.542 -0.753 . . . . 0.0 111.871 -179.643 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' E' E ' 34' ' ' LEU . . . . . 0.405 ' H ' ' C ' ' E' ' 32' ' ' ILE . 7.9 tt -79.31 148.18 32.2 Favored 'General case' 0 N--CA 1.468 0.462 0 C-N-CA 122.838 0.455 . . . . 0.0 109.832 -179.964 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 28.0 ttt -158.78 140.97 13.93 Favored 'General case' 0 N--CA 1.477 0.922 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 178.784 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 32.4 m -156.52 162.22 1.7 Allowed 'Isoleucine or valine' 0 C--N 1.344 0.368 0 N-CA-C 108.431 -0.951 . . . . 0.0 108.431 -179.598 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.5 67.36 2.25 Favored Glycine 0 C--N 1.308 -1.012 0 CA-C-N 115.975 -0.557 . . . . 0.0 111.894 178.494 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 148.33 173.06 18.87 Favored Glycine 0 N--CA 1.475 1.255 0 N-CA-C 110.875 -0.89 . . . . 0.0 110.875 179.222 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' E' E ' 39' ' ' VAL . . . . . 0.559 ' H ' HG12 ' H' ' 39' ' ' VAL . 32.9 m -126.18 163.08 28.71 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.909 0 C-N-CA 123.41 0.684 . . . . 0.0 111.016 -179.067 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 24.6 t . . . . . 0 N--CA 1.465 0.309 0 CA-C-O 118.253 -0.88 . . . . 0.0 110.466 178.972 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 53.7 m-85 . . . . . 0 N--CA 1.474 0.774 0 N-CA-C 110.234 -0.284 . . . . 0.0 110.234 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' F' F ' 5' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 -143.3 142.42 31.32 Favored 'General case' 0 N--CA 1.478 0.945 0 CA-C-O 120.803 0.335 . . . . 0.0 110.141 179.544 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 38.8 t-80 -152.42 119.3 5.77 Favored 'General case' 0 N--CA 1.472 0.674 0 N-CA-C 109.283 -0.636 . . . . 0.0 109.283 178.966 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' F' F ' 7' ' ' ASP . . . . . 0.465 ' O ' ' OG ' ' I' ' 8' ' ' SER . 4.2 m-20 -69.17 148.39 49.97 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-N 116.471 -0.331 . . . . 0.0 110.746 179.968 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' F' F ' 8' ' ' SER . . . . . 0.477 ' OG ' ' O ' ' C' ' 7' ' ' ASP . 52.6 p -168.01 -171.99 1.69 Allowed 'General case' 0 N--CA 1.486 1.335 0 CA-C-O 120.931 0.396 . . . . 0.0 111.012 178.74 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.35 47.32 1.32 Allowed Glycine 0 N--CA 1.48 1.591 0 N-CA-C 111.746 -0.542 . . . . 0.0 111.746 179.689 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 47.5 p90 -65.4 134.05 52.66 Favored 'General case' 0 N--CA 1.473 0.678 0 N-CA-C 111.981 0.363 . . . . 0.0 111.981 -179.856 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 85.7 mt-10 -91.8 152.88 19.93 Favored 'General case' 0 N--CA 1.479 0.987 0 N-CA-C 109.699 -0.482 . . . . 0.0 109.699 178.002 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -154.61 127.25 1.07 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.594 0 N-CA-C 107.823 -1.177 . . . . 0.0 107.823 178.029 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 42.2 m-70 -136.27 146.48 46.73 Favored 'General case' 0 N--CA 1.483 1.212 0 CA-C-O 120.833 0.349 . . . . 0.0 111.602 -177.948 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 6.5 t60 -163.51 98.74 0.9 Allowed 'General case' 0 N--CA 1.486 1.348 0 CA-C-N 116.343 -0.389 . . . . 0.0 110.736 179.609 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 4.8 pt20 -91.56 -176.95 4.66 Favored 'General case' 0 CA--C 1.51 -0.563 0 N-CA-C 109.109 -0.7 . . . . 0.0 109.109 179.934 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -172.3 92.38 0.12 Allowed 'General case' 0 C--O 1.219 -0.507 0 CA-C-N 114.777 -1.101 . . . . 0.0 108.591 177.961 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 6.0 mp -123.05 155.95 35.86 Favored 'General case' 0 N--CA 1.495 1.794 0 CA-C-O 121.581 0.705 . . . . 0.0 111.455 -177.983 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 48.2 t -113.52 122.5 67.77 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.141 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 177.362 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 32.6 m-85 -122.67 142.52 50.58 Favored 'General case' 0 N--CA 1.489 1.504 0 CA-C-O 120.955 0.407 . . . . 0.0 110.584 179.934 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 67.4 m-85 52.67 68.08 0.89 Allowed 'General case' 0 C--N 1.343 0.318 0 CA-C-N 115.866 -0.606 . . . . 0.0 111.918 178.474 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.42 -83.75 0.07 Allowed 'General case' 0 CA--C 1.54 0.57 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 -179.496 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 40.9 tt0 -123.22 97.68 5.53 Favored 'General case' 0 C--N 1.32 -0.689 0 N-CA-C 108.099 -1.074 . . . . 0.0 108.099 179.849 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 4.1 p30 -158.79 143.51 15.91 Favored 'General case' 0 N--CA 1.48 1.065 0 CA-C-O 119.692 -0.194 . . . . 0.0 111.277 179.059 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' F' F ' 24' ' ' VAL . . . . . 0.481 ' HB ' ' H ' ' C' ' 25' ' ' GLY . 58.0 t -59.95 166.82 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.96 0 N-CA-C 107.341 -1.355 . . . . 0.0 107.341 177.01 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' F' F ' 25' ' ' GLY . . . . . 0.443 ' H ' ' HB ' ' I' ' 24' ' ' VAL . . . -122.14 49.82 0.87 Allowed Glycine 0 N--CA 1.476 1.343 0 N-CA-C 111.039 -0.824 . . . . 0.0 111.039 -179.407 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -63.41 -168.43 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.526 0 CA-C-O 120.597 0.237 . . . . 0.0 110.505 179.938 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 28.4 t-20 -68.93 78.11 0.32 Allowed 'General case' 0 CA--C 1.534 0.359 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.23 -180.0 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -78.26 155.12 30.42 Favored 'General case' 0 N--CA 1.475 0.794 0 N-CA-C 109.408 -0.589 . . . . 0.0 109.408 179.248 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.56 -144.77 0.02 OUTLIER Glycine 0 C--N 1.338 0.679 0 N-CA-C 110.384 -1.087 . . . . 0.0 110.384 178.005 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -136.8 117.35 13.82 Favored 'General case' 0 N--CA 1.476 0.829 0 CA-C-O 120.751 0.31 . . . . 0.0 110.165 179.752 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 68.3 mt -77.69 125.42 37.35 Favored 'Isoleucine or valine' 0 C--O 1.238 0.45 0 N-CA-C 106.948 -1.501 . . . . 0.0 106.948 178.373 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' F' F ' 32' ' ' ILE . . . . . 0.419 ' C ' ' H ' ' F' ' 34' ' ' LEU . 45.8 pt -151.25 164.63 2.46 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.994 0 CA-C-O 121.154 0.502 . . . . 0.0 111.043 -179.018 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.64 1.43 3.53 Favored Glycine 0 CA--C 1.529 0.911 0 CA-C-N 115.583 -0.735 . . . . 0.0 111.864 -179.67 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' F' F ' 34' ' ' LEU . . . . . 0.419 ' H ' ' C ' ' F' ' 32' ' ' ILE . 7.9 tt -79.6 148.16 31.8 Favored 'General case' 0 N--CA 1.468 0.464 0 C-N-CA 122.837 0.455 . . . . 0.0 109.775 179.95 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 28.0 ttt -158.68 140.97 14.07 Favored 'General case' 0 N--CA 1.477 0.914 0 N-CA-C 108.806 -0.812 . . . . 0.0 108.806 178.725 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 32.2 m -156.59 161.86 1.78 Allowed 'Isoleucine or valine' 0 C--N 1.344 0.358 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 -179.611 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.0 67.22 2.33 Favored Glycine 0 C--N 1.307 -1.047 0 CA-C-N 115.962 -0.563 . . . . 0.0 111.887 178.458 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 148.46 173.82 19.63 Favored Glycine 0 N--CA 1.475 1.26 0 N-CA-C 110.943 -0.863 . . . . 0.0 110.943 179.192 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' F' F ' 39' ' ' VAL . . . . . 0.575 ' H ' HG12 ' I' ' 39' ' ' VAL . 33.1 m -126.82 163.08 30.06 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.935 0 C-N-CA 123.416 0.686 . . . . 0.0 110.899 -179.058 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 24.7 t . . . . . 0 C--O 1.223 -0.304 0 CA-C-O 118.29 -0.862 . . . . 0.0 110.435 178.89 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 56.4 m-85 . . . . . 0 N--CA 1.474 0.756 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' G' G ' 5' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 -143.67 142.58 31.06 Favored 'General case' 0 N--CA 1.482 1.131 0 C-N-CA 122.585 0.354 . . . . 0.0 110.301 179.813 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 40.0 t-80 -152.53 120.34 6.12 Favored 'General case' 0 N--CA 1.473 0.712 0 N-CA-C 109.46 -0.57 . . . . 0.0 109.46 179.016 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -71.16 143.88 50.38 Favored 'General case' 0 N--CA 1.471 0.584 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.12 -179.936 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' G' G ' 8' ' ' SER . . . . . 0.57 ' OG ' ' O ' ' D' ' 7' ' ' ASP . 49.1 p -164.54 -170.1 1.94 Allowed 'General case' 0 N--CA 1.475 0.783 0 CA-C-O 120.923 0.392 . . . . 0.0 110.52 178.506 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.11 47.32 1.35 Allowed Glycine 0 N--CA 1.48 1.571 0 N-CA-C 111.37 -0.692 . . . . 0.0 111.37 179.529 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 50.1 p90 -65.62 133.31 50.88 Favored 'General case' 0 CA--C 1.543 0.683 0 N-CA-C 111.875 0.324 . . . . 0.0 111.875 -179.497 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 83.0 mt-10 -91.6 151.89 20.51 Favored 'General case' 0 N--CA 1.478 0.974 0 CA-C-O 120.991 0.424 . . . . 0.0 110.076 178.555 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -154.78 127.41 1.07 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.014 0 N-CA-C 107.864 -1.161 . . . . 0.0 107.864 178.17 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 42.4 m-70 -135.42 148.21 49.24 Favored 'General case' 0 N--CA 1.479 1.004 0 CA-C-N 115.505 -0.77 . . . . 0.0 111.409 -178.258 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 32.8 t-80 -165.49 98.97 0.7 Allowed 'General case' 0 N--CA 1.484 1.263 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.307 179.012 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 27.5 pt20 -92.09 -176.73 4.48 Favored 'General case' 0 CA--C 1.513 -0.477 0 N-CA-C 108.901 -0.777 . . . . 0.0 108.901 -179.847 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -172.85 92.28 0.1 Allowed 'General case' 0 N--CA 1.47 0.565 0 CA-C-N 114.86 -1.064 . . . . 0.0 108.37 178.123 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 6.0 mp -123.19 154.77 38.27 Favored 'General case' 0 N--CA 1.498 1.955 0 CA-C-O 121.302 0.572 . . . . 0.0 111.668 -177.995 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 42.4 t -112.83 123.08 68.14 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.99 0 CA-C-N 114.747 -1.115 . . . . 0.0 108.394 176.866 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 34.8 m-85 -123.53 142.05 51.4 Favored 'General case' 0 C--N 1.367 1.35 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.691 -179.807 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 66.9 m-85 53.64 66.25 1.28 Allowed 'General case' 0 C--O 1.237 0.422 0 CA-C-N 115.742 -0.663 . . . . 0.0 111.584 178.192 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -76.02 -83.62 0.06 Allowed 'General case' 0 N--CA 1.471 0.586 0 N-CA-C 110.003 -0.369 . . . . 0.0 110.003 -179.076 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 41.3 tt0 -123.0 97.25 5.35 Favored 'General case' 0 C--N 1.321 -0.673 0 N-CA-C 107.829 -1.174 . . . . 0.0 107.829 -179.976 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 4.1 p30 -158.59 144.2 16.62 Favored 'General case' 0 N--CA 1.479 1.008 0 CA-C-O 120.463 0.173 . . . . 0.0 111.279 178.891 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' G' G ' 24' ' ' VAL . . . . . 0.556 ' HB ' ' H ' ' D' ' 25' ' ' GLY . 61.0 t -60.96 165.62 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.685 0 N-CA-C 107.617 -1.253 . . . . 0.0 107.617 177.347 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' G' G ' 25' ' ' GLY . . . . . 0.404 ' N ' HG12 ' G' ' 24' ' ' VAL . . . -120.36 50.34 0.83 Allowed Glycine 0 N--CA 1.482 1.711 0 N-CA-C 110.567 -1.013 . . . . 0.0 110.567 -179.561 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -64.06 -168.04 0.03 OUTLIER 'General case' 0 N--CA 1.472 0.647 0 CA-C-N 117.002 0.401 . . . . 0.0 109.963 179.875 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 28.3 t-20 -69.46 77.92 0.4 Allowed 'General case' 0 CA--C 1.537 0.459 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.444 179.954 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -77.2 155.22 32.37 Favored 'General case' 0 N--CA 1.475 0.788 0 N-CA-C 109.602 -0.518 . . . . 0.0 109.602 179.189 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.03 -142.53 0.02 OUTLIER Glycine 0 CA--C 1.527 0.792 0 N-CA-C 109.918 -1.273 . . . . 0.0 109.918 178.313 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -137.72 117.45 13.12 Favored 'General case' 0 N--CA 1.471 0.583 0 C-N-CA 122.624 0.37 . . . . 0.0 110.737 -179.915 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 71.7 mt -77.79 125.85 37.74 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.496 0 N-CA-C 107.007 -1.479 . . . . 0.0 107.007 178.382 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' G' G ' 32' ' ' ILE . . . . . 0.426 ' C ' ' H ' ' G' ' 34' ' ' LEU . 44.7 pt -152.31 164.95 1.96 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.755 0 CA-C-N 120.091 1.314 . . . . 0.0 110.032 -179.36 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.61 0.64 3.9 Favored Glycine 0 N--CA 1.468 0.779 0 N-CA-C 111.19 -0.764 . . . . 0.0 111.19 -179.912 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' G' G ' 34' ' ' LEU . . . . . 0.426 ' H ' ' C ' ' G' ' 32' ' ' ILE . 7.9 tt -79.71 148.34 31.58 Favored 'General case' 0 N--CA 1.465 0.303 0 C-N-CA 122.832 0.453 . . . . 0.0 109.841 179.855 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 27.1 ttt -159.14 141.98 14.27 Favored 'General case' 0 N--CA 1.476 0.837 0 N-CA-C 108.731 -0.84 . . . . 0.0 108.731 179.004 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 33.8 m -156.68 162.21 1.67 Allowed 'Isoleucine or valine' 0 C--N 1.345 0.412 0 N-CA-C 108.618 -0.882 . . . . 0.0 108.618 -179.492 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' G' G ' 37' ' ' GLY . . . . . 0.401 ' N ' ' OE1' ' D' ' 15' ' ' GLN . . . 54.95 67.86 1.98 Allowed Glycine 0 C--N 1.31 -0.879 0 CA-C-N 115.637 -0.71 . . . . 0.0 112.141 178.134 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 148.75 174.41 20.37 Favored Glycine 0 N--CA 1.475 1.296 0 N-CA-C 110.462 -1.055 . . . . 0.0 110.462 179.229 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' G' G ' 39' ' ' VAL . . . . . 0.575 HG12 ' H ' ' D' ' 39' ' ' VAL . 33.8 m -127.27 162.73 31.82 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.76 0 C-N-CA 123.1 0.56 . . . . 0.0 110.877 -179.308 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 28.1 t . . . . . 0 N--CA 1.469 0.493 0 CA-C-O 118.351 -0.833 . . . . 0.0 110.702 178.773 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 57.5 m-85 . . . . . 0 N--CA 1.473 0.705 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' H' H ' 5' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 -143.91 142.64 30.89 Favored 'General case' 0 N--CA 1.483 1.178 0 C-N-CA 122.551 0.341 . . . . 0.0 110.169 179.846 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 41.9 t-80 -152.55 120.38 6.13 Favored 'General case' 0 N--CA 1.474 0.737 0 N-CA-C 109.409 -0.589 . . . . 0.0 109.409 178.946 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -71.28 143.89 50.18 Favored 'General case' 0 N--CA 1.469 0.518 0 C-N-CA 122.699 0.399 . . . . 0.0 111.158 -179.913 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' H' H ' 8' ' ' SER . . . . . 0.435 ' OG ' ' O ' ' E' ' 7' ' ' ASP . 53.6 p -164.36 -170.42 2.06 Favored 'General case' 0 N--CA 1.474 0.759 0 CA-C-O 120.965 0.412 . . . . 0.0 110.422 178.766 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.95 47.97 1.3 Allowed Glycine 0 N--CA 1.48 1.586 0 N-CA-C 111.461 -0.655 . . . . 0.0 111.461 179.601 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 50.2 p90 -66.28 133.18 50.03 Favored 'General case' 0 N--CA 1.472 0.675 0 N-CA-C 112.046 0.387 . . . . 0.0 112.046 -179.605 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 83.4 mt-10 -91.42 151.66 20.72 Favored 'General case' 0 N--CA 1.478 0.957 0 CA-C-O 121.069 0.461 . . . . 0.0 110.195 178.576 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -154.73 127.41 1.08 Allowed 'Isoleucine or valine' 0 CA--C 1.553 1.059 0 N-CA-C 107.888 -1.153 . . . . 0.0 107.888 178.251 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 42.7 m-70 -135.46 148.2 49.17 Favored 'General case' 0 C--N 1.357 0.912 0 CA-C-N 115.461 -0.79 . . . . 0.0 111.444 -178.293 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 33.2 t-80 -165.43 98.75 0.7 Allowed 'General case' 0 N--CA 1.482 1.136 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.427 178.996 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 27.3 pt20 -91.88 -177.02 4.61 Favored 'General case' 0 CA--C 1.513 -0.468 0 N-CA-C 108.799 -0.815 . . . . 0.0 108.799 -179.814 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -172.7 92.13 0.11 Allowed 'General case' 0 N--CA 1.472 0.663 0 CA-C-N 114.707 -1.133 . . . . 0.0 108.239 178.142 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 6.0 mp -122.93 154.72 37.99 Favored 'General case' 0 N--CA 1.499 1.991 0 CA-C-O 121.224 0.535 . . . . 0.0 111.784 -178.064 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 41.5 t -112.72 123.25 68.21 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.947 0 CA-C-N 114.841 -1.072 . . . . 0.0 108.368 176.742 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 34.2 m-85 -123.66 141.58 51.88 Favored 'General case' 0 C--N 1.369 1.425 0 CA-C-N 115.427 -0.806 . . . . 0.0 110.598 -179.65 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 66.9 m-85 53.02 67.44 1.0 Allowed 'General case' 0 C--O 1.237 0.419 0 CA-C-N 115.623 -0.717 . . . . 0.0 111.674 178.389 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -76.66 -83.15 0.07 Allowed 'General case' 0 N--CA 1.469 0.504 0 N-CA-C 110.025 -0.361 . . . . 0.0 110.025 -179.168 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 41.1 tt0 -123.25 96.93 5.19 Favored 'General case' 0 C--N 1.319 -0.726 0 N-CA-C 107.891 -1.151 . . . . 0.0 107.891 -179.969 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 4.2 p30 -158.16 143.98 17.06 Favored 'General case' 0 N--CA 1.478 0.968 0 CA-C-O 120.423 0.154 . . . . 0.0 111.264 179.021 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' H' H ' 24' ' ' VAL . . . . . 0.461 ' HB ' ' H ' ' E' ' 25' ' ' GLY . 58.3 t -60.77 165.9 0.77 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.599 0 N-CA-C 107.61 -1.256 . . . . 0.0 107.61 177.285 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' H' H ' 25' ' ' GLY . . . . . 0.408 ' N ' HG12 ' H' ' 24' ' ' VAL . . . -120.47 49.7 0.86 Allowed Glycine 0 N--CA 1.479 1.518 0 N-CA-C 110.665 -0.974 . . . . 0.0 110.665 -179.472 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -63.71 -168.16 0.02 OUTLIER 'General case' 0 N--CA 1.471 0.625 0 CA-C-N 117.022 0.411 . . . . 0.0 110.125 179.926 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 28.1 t-20 -69.52 78.45 0.41 Allowed 'General case' 0 CA--C 1.536 0.413 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.41 179.987 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -77.86 155.44 30.98 Favored 'General case' 0 N--CA 1.474 0.768 0 N-CA-C 109.459 -0.571 . . . . 0.0 109.459 179.262 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.36 -142.76 0.02 OUTLIER Glycine 0 C--N 1.339 0.733 0 N-CA-C 109.798 -1.321 . . . . 0.0 109.798 178.386 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -137.67 117.38 13.09 Favored 'General case' 0 N--CA 1.469 0.522 0 C-N-CA 122.526 0.33 . . . . 0.0 110.758 -179.855 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 71.5 mt -77.49 125.73 37.42 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.506 0 N-CA-C 106.946 -1.502 . . . . 0.0 106.946 178.498 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' H' H ' 32' ' ' ILE . . . . . 0.418 ' C ' ' H ' ' H' ' 34' ' ' LEU . 44.7 pt -152.27 164.92 1.98 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 CA-C-N 120.094 1.316 . . . . 0.0 110.005 -179.452 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.91 0.3 3.97 Favored Glycine 0 CA--C 1.527 0.796 0 N-CA-C 111.202 -0.759 . . . . 0.0 111.202 -179.827 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' H' H ' 34' ' ' LEU . . . . . 0.418 ' H ' ' C ' ' H' ' 32' ' ' ILE . 7.9 tt -79.39 148.36 32.02 Favored 'General case' 0 N--CA 1.465 0.308 0 C-N-CA 122.84 0.456 . . . . 0.0 109.889 179.935 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 27.1 ttt -159.23 141.73 13.95 Favored 'General case' 0 N--CA 1.477 0.915 0 N-CA-C 108.709 -0.848 . . . . 0.0 108.709 178.999 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 35.9 m -156.69 162.13 1.7 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.416 0 N-CA-C 108.599 -0.889 . . . . 0.0 108.599 -179.39 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.04 67.79 2.02 Favored Glycine 0 C--N 1.31 -0.896 0 CA-C-N 115.638 -0.71 . . . . 0.0 112.086 178.239 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 149.01 174.89 20.98 Favored Glycine 0 N--CA 1.475 1.267 0 N-CA-C 110.571 -1.012 . . . . 0.0 110.571 179.19 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' H' H ' 39' ' ' VAL . . . . . 0.559 HG12 ' H ' ' E' ' 39' ' ' VAL . 33.9 m -127.65 162.53 33.09 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.799 0 C-N-CA 123.114 0.565 . . . . 0.0 110.923 -179.368 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 25.9 t . . . . . 0 N--CA 1.47 0.541 0 CA-C-O 118.402 -0.809 . . . . 0.0 110.707 178.74 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 56.3 m-85 . . . . . 0 N--CA 1.474 0.772 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' I' I ' 5' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 -143.93 142.37 30.72 Favored 'General case' 0 N--CA 1.483 1.199 0 C-N-CA 122.569 0.348 . . . . 0.0 110.108 179.827 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 40.7 t-80 -152.36 120.13 6.12 Favored 'General case' 0 N--CA 1.473 0.687 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 178.976 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -71.06 143.98 50.51 Favored 'General case' 0 N--CA 1.47 0.574 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.178 -179.856 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' I' I ' 8' ' ' SER . . . . . 0.465 ' OG ' ' O ' ' F' ' 7' ' ' ASP . 54.1 p -164.5 -170.43 2.04 Favored 'General case' 0 N--CA 1.475 0.781 0 CA-C-O 120.964 0.411 . . . . 0.0 110.456 178.707 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.19 47.24 1.35 Allowed Glycine 0 N--CA 1.48 1.611 0 N-CA-C 111.598 -0.601 . . . . 0.0 111.598 179.67 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 50.4 p90 -65.76 133.48 51.13 Favored 'General case' 0 N--CA 1.473 0.676 0 N-CA-C 112.0 0.37 . . . . 0.0 112.0 -179.566 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 82.6 mt-10 -91.81 151.71 20.47 Favored 'General case' 0 N--CA 1.476 0.871 0 CA-C-O 120.978 0.418 . . . . 0.0 110.184 178.639 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -154.67 127.48 1.1 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.033 0 N-CA-C 107.969 -1.123 . . . . 0.0 107.969 178.16 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 41.7 m-70 -135.5 148.1 49.07 Favored 'General case' 0 N--CA 1.477 0.922 0 CA-C-N 115.407 -0.815 . . . . 0.0 111.467 -178.248 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 33.2 t-80 -165.3 99.01 0.72 Allowed 'General case' 0 N--CA 1.483 1.192 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.383 179.013 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 27.4 pt20 -92.07 -176.92 4.54 Favored 'General case' 0 CA--C 1.511 -0.521 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 -179.848 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -172.83 92.08 0.1 Allowed 'General case' 0 N--CA 1.47 0.534 0 CA-C-N 114.74 -1.118 . . . . 0.0 108.291 178.199 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 6.0 mp -122.84 154.91 37.63 Favored 'General case' 0 N--CA 1.499 1.983 0 CA-C-O 121.223 0.535 . . . . 0.0 111.754 -178.054 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 41.3 t -113.09 123.42 68.72 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.927 0 CA-C-N 114.861 -1.063 . . . . 0.0 108.247 176.784 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 33.4 m-85 -123.96 141.18 52.27 Favored 'General case' 0 C--N 1.37 1.461 0 CA-C-N 115.413 -0.812 . . . . 0.0 110.636 -179.444 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 67.1 m-85 53.35 67.15 1.05 Allowed 'General case' 0 C--O 1.238 0.45 0 CA-C-N 115.69 -0.686 . . . . 0.0 111.537 178.41 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -76.32 -83.14 0.07 Allowed 'General case' 0 N--CA 1.47 0.541 0 N-CA-C 109.913 -0.402 . . . . 0.0 109.913 -179.148 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 41.3 tt0 -123.33 97.1 5.25 Favored 'General case' 0 C--N 1.32 -0.712 0 N-CA-C 107.868 -1.16 . . . . 0.0 107.868 -179.924 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 4.1 p30 -158.29 144.36 17.13 Favored 'General case' 0 N--CA 1.479 1.002 0 O-C-N 122.458 -0.151 . . . . 0.0 111.257 178.964 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' I' I ' 24' ' ' VAL . . . . . 0.443 ' HB ' ' H ' ' F' ' 25' ' ' GLY . 59.5 t -61.2 165.57 0.86 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.589 0 N-CA-C 107.63 -1.248 . . . . 0.0 107.63 177.345 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' I' I ' 25' ' ' GLY . . . . . 0.412 ' N ' HG12 ' I' ' 24' ' ' VAL . . . -120.24 49.95 0.85 Allowed Glycine 0 N--CA 1.481 1.661 0 N-CA-C 110.588 -1.005 . . . . 0.0 110.588 -179.383 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -63.8 -168.1 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.649 0 CA-C-N 116.991 0.395 . . . . 0.0 110.134 179.825 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 28.3 t-20 -69.56 78.3 0.41 Allowed 'General case' 0 CA--C 1.536 0.421 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.364 179.924 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -77.77 155.34 31.22 Favored 'General case' 0 N--CA 1.475 0.78 0 N-CA-C 109.504 -0.554 . . . . 0.0 109.504 179.263 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.28 -143.0 0.02 OUTLIER Glycine 0 CA--C 1.527 0.842 0 N-CA-C 109.813 -1.315 . . . . 0.0 109.813 178.39 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -137.3 117.36 13.38 Favored 'General case' 0 N--CA 1.471 0.597 0 C-N-CA 122.627 0.371 . . . . 0.0 110.778 -179.863 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 71.7 mt -77.57 125.89 37.6 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.488 0 N-CA-C 106.986 -1.487 . . . . 0.0 106.986 178.389 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' I' I ' 32' ' ' ILE . . . . . 0.429 ' C ' ' H ' ' I' ' 34' ' ' LEU . 44.9 pt -152.34 164.95 1.94 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 CA-C-N 120.143 1.338 . . . . 0.0 110.06 -179.436 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.64 0.98 4.22 Favored Glycine 0 N--CA 1.469 0.844 0 N-CA-C 111.127 -0.789 . . . . 0.0 111.127 -179.909 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' I' I ' 34' ' ' LEU . . . . . 0.429 ' H ' ' C ' ' I' ' 32' ' ' ILE . 8.1 tt -80.1 148.02 31.17 Favored 'General case' 0 CA--C 1.533 0.313 0 C-N-CA 122.845 0.458 . . . . 0.0 109.792 179.895 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 26.9 ttt -158.69 141.68 14.63 Favored 'General case' 0 N--CA 1.476 0.85 0 N-CA-C 108.611 -0.885 . . . . 0.0 108.611 179.086 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 35.9 m -156.65 162.06 1.72 Allowed 'Isoleucine or valine' 0 C--N 1.346 0.442 0 N-CA-C 108.523 -0.917 . . . . 0.0 108.523 -179.562 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.22 67.78 2.03 Favored Glycine 0 C--N 1.312 -0.798 0 CA-C-N 115.638 -0.71 . . . . 0.0 112.107 178.185 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 148.68 174.73 20.59 Favored Glycine 0 N--CA 1.474 1.217 0 N-CA-C 110.461 -1.056 . . . . 0.0 110.461 179.244 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' I' I ' 39' ' ' VAL . . . . . 0.575 HG12 ' H ' ' F' ' 39' ' ' VAL . 33.9 m -127.66 162.76 32.64 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.786 0 C-N-CA 123.1 0.56 . . . . 0.0 110.923 -179.259 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 27.1 t . . . . . 0 N--CA 1.47 0.544 0 CA-C-O 118.377 -0.821 . . . . 0.0 110.56 178.75 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 26.6 m-85 . . . . . 0 CA--C 1.537 0.478 0 N-CA-C 109.142 -0.688 . . . . 0.0 109.142 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 38.2 mtp180 -68.41 147.02 52.67 Favored 'General case' 0 C--O 1.201 -1.452 0 CA-C-N 115.821 -0.627 . . . . 0.0 111.293 -177.505 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 39.2 m80 -109.55 119.1 38.39 Favored 'General case' 0 N--CA 1.482 1.165 0 N-CA-C 108.953 -0.758 . . . . 0.0 108.953 178.289 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 7' ' ' ASP . . . . . 0.459 ' OD1' ' NH2' ' G' ' 5' ' ' ARG . 7.3 m-20 -67.52 140.7 57.01 Favored 'General case' 0 N--CA 1.469 0.502 0 CA-C-O 121.135 0.493 . . . . 0.0 111.795 -178.758 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 39.0 t -158.65 -169.49 2.74 Favored 'General case' 0 N--CA 1.467 0.376 0 CA-C-N 115.848 -0.615 . . . . 0.0 109.662 179.092 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 119.83 32.39 1.2 Allowed Glycine 0 N--CA 1.485 1.922 0 N-CA-C 111.574 -0.61 . . . . 0.0 111.574 179.61 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 46.9 p90 -57.2 130.43 46.16 Favored 'General case' 0 N--CA 1.471 0.61 0 CA-C-N 116.736 0.268 . . . . 0.0 111.49 179.971 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 11' ' ' GLU . . . . . 0.506 ' CG ' HD21 ' C' ' 27' ' ' ASN . 60.6 mt-10 -90.44 153.15 20.61 Favored 'General case' 0 N--CA 1.473 0.717 0 N-CA-C 109.329 -0.619 . . . . 0.0 109.329 178.69 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.6 p -153.48 126.55 1.15 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 N-CA-C 107.698 -1.223 . . . . 0.0 107.698 177.988 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 45.6 m-70 -136.91 162.06 34.3 Favored 'General case' 0 N--CA 1.49 1.537 0 CA-C-N 118.685 0.675 . . . . 0.0 110.879 -178.721 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 38.3 t60 -152.91 96.43 2.1 Favored 'General case' 0 N--CA 1.486 1.333 0 C-N-CA 122.634 0.374 . . . . 0.0 110.049 179.065 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 15' ' ' GLN . . . . . 0.539 HE22 ' C ' ' A' ' 38' ' ' GLY . 78.9 mt-30 -90.63 121.52 32.61 Favored 'General case' 0 N--CA 1.452 -0.371 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 -178.964 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -112.98 103.67 11.63 Favored 'General case' 0 N--CA 1.475 0.789 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 176.686 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 57.8 tp -133.34 150.43 51.85 Favored 'General case' 0 N--CA 1.486 1.347 0 N-CA-C 108.766 -0.827 . . . . 0.0 108.766 -179.391 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 84.5 t -145.42 123.13 4.65 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.969 0 CA-C-O 118.523 -0.751 . . . . 0.0 109.137 179.755 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 11.9 m-85 -70.74 158.67 35.89 Favored 'General case' 0 N--CA 1.485 1.324 0 N-CA-C 107.461 -1.311 . . . . 0.0 107.461 177.564 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 18.6 t80 -170.07 -58.44 0.02 OUTLIER 'General case' 0 N--CA 1.481 1.101 0 CA-C-O 122.425 1.107 . . . . 0.0 109.765 179.735 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -39.19 89.68 0.0 OUTLIER 'General case' 0 N--CA 1.456 -0.135 0 CA-C-N 113.807 -1.542 . . . . 0.0 112.844 -178.034 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 38.6 tt0 -64.49 159.59 21.2 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.175 -0.92 . . . . 0.0 110.552 179.245 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 9.6 m-20 -136.23 125.81 25.3 Favored 'General case' 0 N--CA 1.481 1.086 0 C-N-CA 123.297 0.639 . . . . 0.0 109.781 -179.897 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.861 HG12 ' H ' ' A' ' 25' ' ' GLY . 57.8 t -76.55 -170.44 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.591 0 N-CA-C 108.511 -0.922 . . . . 0.0 108.511 179.673 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.861 ' H ' HG12 ' A' ' 24' ' ' VAL . . . -69.11 48.86 0.52 Allowed Glycine 0 CA--C 1.53 1.003 0 CA-C-N 118.344 0.52 . . . . 0.0 112.313 -178.147 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 13.1 p -69.54 137.52 52.52 Favored 'General case' 0 C--O 1.217 -0.61 0 N-CA-C 109.596 -0.52 . . . . 0.0 109.596 178.66 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 27' ' ' ASN . . . . . 0.512 HD21 ' CG ' ' B' ' 11' ' ' GLU . 34.6 t30 -68.57 95.06 0.61 Allowed 'General case' 0 N--CA 1.47 0.553 0 N-CA-C 108.15 -1.055 . . . . 0.0 108.15 177.847 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 68.6 mttm -92.45 117.66 30.16 Favored 'General case' 0 N--CA 1.481 1.079 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 -179.221 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.33 -134.27 0.01 OUTLIER Glycine 0 CA--C 1.534 1.226 0 N-CA-C 110.771 -0.932 . . . . 0.0 110.771 179.044 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -115.65 127.16 54.98 Favored 'General case' 0 N--CA 1.477 0.897 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 179.12 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 66.1 mt -90.53 134.97 27.76 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.59 0 N-CA-C 107.673 -1.232 . . . . 0.0 107.673 179.012 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 30.3 mt -136.52 138.16 46.92 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.815 0 CA-C-N 115.982 -0.554 . . . . 0.0 109.606 -179.134 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.97 57.46 15.75 Favored Glycine 0 CA--C 1.527 0.842 0 CA-C-N 115.904 -0.589 . . . . 0.0 112.795 178.543 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 25.4 tp -106.11 132.77 51.79 Favored 'General case' 0 N--CA 1.488 1.474 0 N-CA-C 107.508 -1.293 . . . . 0.0 107.508 177.919 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 24.9 ttt -138.2 148.15 44.52 Favored 'General case' 0 N--CA 1.471 0.576 0 N-CA-C 107.769 -1.197 . . . . 0.0 107.769 179.136 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 60.4 t -156.64 160.45 2.25 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.587 0 N-CA-C 106.097 -1.816 . . . . 0.0 106.097 -178.855 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 53.55 74.48 0.3 Allowed Glycine 0 C--N 1.308 -0.993 0 C-N-CA 121.214 -0.517 . . . . 0.0 111.818 177.839 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 38' ' ' GLY . . . . . 0.539 ' C ' HE22 ' A' ' 15' ' ' GLN . . . 164.73 -168.51 39.02 Favored Glycine 0 N--CA 1.466 0.692 0 N-CA-C 111.042 -0.823 . . . . 0.0 111.042 179.352 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 24.5 m -126.67 148.9 31.38 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.855 0 C-N-CA 122.977 0.511 . . . . 0.0 109.847 179.665 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 9.7 t . . . . . 0 CA--C 1.535 0.385 0 CA-C-O 118.109 -0.948 . . . . 0.0 110.723 178.893 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 27.8 m-85 . . . . . 0 N--CA 1.468 0.435 0 N-CA-C 109.154 -0.684 . . . . 0.0 109.154 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 39.3 mtp180 -68.48 146.74 52.88 Favored 'General case' 0 C--O 1.201 -1.478 0 CA-C-N 115.708 -0.678 . . . . 0.0 111.3 -177.653 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 39.4 m80 -109.35 119.36 39.24 Favored 'General case' 0 N--CA 1.484 1.247 0 N-CA-C 108.995 -0.742 . . . . 0.0 108.995 178.282 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 7' ' ' ASP . . . . . 0.46 ' OD1' ' NH2' ' H' ' 5' ' ' ARG . 7.1 m-20 -67.66 141.02 56.84 Favored 'General case' 0 N--CA 1.469 0.501 0 CA-C-O 121.043 0.449 . . . . 0.0 111.76 -178.745 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 8' ' ' SER . . . . . . . . . . . . . 39.1 t -158.8 -169.45 2.7 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-N 115.814 -0.63 . . . . 0.0 109.634 179.099 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 119.75 32.37 1.21 Allowed Glycine 0 N--CA 1.485 1.92 0 N-CA-C 111.552 -0.619 . . . . 0.0 111.552 179.578 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 46.8 p90 -57.36 130.54 46.71 Favored 'General case' 0 N--CA 1.472 0.651 0 CA-C-O 120.64 0.257 . . . . 0.0 111.514 -179.996 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 11' ' ' GLU . . . . . 0.512 ' CG ' HD21 ' A' ' 27' ' ' ASN . 60.4 mt-10 -90.52 153.16 20.57 Favored 'General case' 0 N--CA 1.472 0.664 0 N-CA-C 109.357 -0.609 . . . . 0.0 109.357 178.857 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.6 p -153.53 126.14 1.09 Allowed 'Isoleucine or valine' 0 C--O 1.234 0.281 0 N-CA-C 107.846 -1.168 . . . . 0.0 107.846 178.086 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 45.6 m-70 -136.63 162.07 34.15 Favored 'General case' 0 N--CA 1.49 1.533 0 CA-C-N 118.648 0.658 . . . . 0.0 110.936 -178.567 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 38.4 t60 -152.86 96.44 2.1 Favored 'General case' 0 N--CA 1.487 1.422 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.087 179.057 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 15' ' ' GLN . . . . . 0.539 HE22 ' C ' ' B' ' 38' ' ' GLY . 78.9 mt-30 -90.48 121.16 32.2 Favored 'General case' 0 CA--C 1.517 -0.309 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 -179.01 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -112.63 103.49 11.53 Favored 'General case' 0 N--CA 1.474 0.742 0 N-CA-C 107.988 -1.115 . . . . 0.0 107.988 176.619 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 57.8 tp -133.34 150.25 51.86 Favored 'General case' 0 N--CA 1.486 1.369 0 N-CA-C 108.755 -0.831 . . . . 0.0 108.755 -179.368 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 84.6 t -145.41 122.48 4.28 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.011 0 CA-C-O 118.629 -0.7 . . . . 0.0 109.333 179.707 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 12.4 m-85 -70.52 158.91 35.26 Favored 'General case' 0 N--CA 1.486 1.334 0 N-CA-C 107.287 -1.375 . . . . 0.0 107.287 177.572 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 19.9 t80 -170.99 -57.67 0.02 OUTLIER 'General case' 0 N--CA 1.478 0.934 0 CA-C-O 122.22 1.009 . . . . 0.0 109.705 179.651 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -39.4 90.12 0.0 OUTLIER 'General case' 0 C--O 1.231 0.124 0 CA-C-N 113.959 -1.473 . . . . 0.0 112.721 -178.16 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 38.6 tt0 -64.85 159.55 22.35 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 115.1 -0.955 . . . . 0.0 110.559 179.298 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 9.7 m-20 -136.26 125.9 25.4 Favored 'General case' 0 N--CA 1.481 1.118 0 C-N-CA 123.217 0.607 . . . . 0.0 109.765 -179.876 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 24' ' ' VAL . . . . . 0.848 HG12 ' H ' ' B' ' 25' ' ' GLY . 56.9 t -76.7 -170.39 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.661 0 N-CA-C 108.586 -0.894 . . . . 0.0 108.586 179.722 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 25' ' ' GLY . . . . . 0.848 ' H ' HG12 ' B' ' 24' ' ' VAL . . . -68.71 48.42 0.45 Allowed Glycine 0 CA--C 1.531 1.087 0 CA-C-N 118.321 0.509 . . . . 0.0 112.208 -178.126 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 13.3 p -69.72 137.41 52.02 Favored 'General case' 0 C--O 1.219 -0.548 0 N-CA-C 109.591 -0.522 . . . . 0.0 109.591 178.706 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 27' ' ' ASN . . . . . 0.507 HD21 ' CG ' ' C' ' 11' ' ' GLU . 34.8 t30 -68.72 95.07 0.64 Allowed 'General case' 0 N--CA 1.47 0.543 0 N-CA-C 108.159 -1.052 . . . . 0.0 108.159 177.847 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 68.6 mttm -92.34 117.62 30.08 Favored 'General case' 0 N--CA 1.48 1.028 0 N-CA-C 109.997 -0.371 . . . . 0.0 109.997 -179.227 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.3 -134.17 0.01 OUTLIER Glycine 0 CA--C 1.532 1.128 0 N-CA-C 110.769 -0.932 . . . . 0.0 110.769 179.014 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -115.88 127.28 54.89 Favored 'General case' 0 N--CA 1.478 0.955 0 N-CA-C 109.428 -0.582 . . . . 0.0 109.428 179.149 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 66.0 mt -90.55 135.0 27.69 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.536 0 N-CA-C 107.676 -1.231 . . . . 0.0 107.676 179.035 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 30.2 mt -136.45 138.35 46.8 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.714 0 CA-C-N 115.933 -0.576 . . . . 0.0 109.567 -179.115 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.65 57.72 15.16 Favored Glycine 0 CA--C 1.527 0.829 0 CA-C-N 115.876 -0.602 . . . . 0.0 112.82 178.604 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 25.8 tp -106.3 132.83 51.88 Favored 'General case' 0 N--CA 1.486 1.375 0 N-CA-C 107.502 -1.296 . . . . 0.0 107.502 177.897 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 25.0 ttt -138.18 147.83 44.22 Favored 'General case' 0 N--CA 1.473 0.683 0 N-CA-C 107.778 -1.193 . . . . 0.0 107.778 179.216 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 36' ' ' VAL . . . . . 0.404 HG12 ' N ' ' B' ' 37' ' ' GLY . 60.8 t -156.67 159.98 2.45 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.625 0 N-CA-C 106.178 -1.786 . . . . 0.0 106.178 -178.928 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 37' ' ' GLY . . . . . 0.404 ' N ' HG12 ' B' ' 36' ' ' VAL . . . 54.12 74.26 0.33 Allowed Glycine 0 C--N 1.308 -0.973 0 N-CA-C 111.739 -0.544 . . . . 0.0 111.739 177.963 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 38' ' ' GLY . . . . . 0.539 ' C ' HE22 ' B' ' 15' ' ' GLN . . . 164.85 -168.44 39.07 Favored Glycine 0 N--CA 1.465 0.58 0 N-CA-C 111.124 -0.791 . . . . 0.0 111.124 179.266 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 24.5 m -126.62 148.89 31.33 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.808 0 C-N-CA 122.992 0.517 . . . . 0.0 109.955 179.601 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 9.7 t . . . . . 0 CA--C 1.535 0.392 0 CA-C-O 118.095 -0.955 . . . . 0.0 110.872 179.001 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 27.7 m-85 . . . . . 0 N--CA 1.468 0.429 0 N-CA-C 109.265 -0.643 . . . . 0.0 109.265 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 39.2 mtp180 -68.67 146.37 53.05 Favored 'General case' 0 C--O 1.201 -1.489 0 CA-C-N 115.849 -0.614 . . . . 0.0 111.221 -177.564 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 39.2 m80 -109.11 119.22 38.9 Favored 'General case' 0 N--CA 1.484 1.232 0 N-CA-C 108.978 -0.749 . . . . 0.0 108.978 178.269 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' C' C ' 7' ' ' ASP . . . . . 0.473 ' OD1' ' NH2' ' I' ' 5' ' ' ARG . 7.3 m-20 -67.64 141.11 56.83 Favored 'General case' 0 N--CA 1.468 0.448 0 CA-C-O 121.049 0.452 . . . . 0.0 111.79 -178.721 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' C' C ' 8' ' ' SER . . . . . . . . . . . . . 39.2 t -158.89 -169.49 2.71 Favored 'General case' 0 N--CA 1.466 0.37 0 CA-C-N 115.837 -0.62 . . . . 0.0 109.604 179.149 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 119.8 32.34 1.21 Allowed Glycine 0 N--CA 1.485 1.94 0 N-CA-C 111.506 -0.638 . . . . 0.0 111.506 179.543 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 46.8 p90 -57.32 130.42 46.15 Favored 'General case' 0 N--CA 1.471 0.587 0 CA-C-O 120.676 0.274 . . . . 0.0 111.53 179.951 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' C' C ' 11' ' ' GLU . . . . . 0.507 ' CG ' HD21 ' B' ' 27' ' ' ASN . 60.5 mt-10 -90.39 153.12 20.65 Favored 'General case' 0 N--CA 1.473 0.722 0 N-CA-C 109.368 -0.605 . . . . 0.0 109.368 178.792 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.6 p -153.47 126.16 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 N-CA-C 107.858 -1.164 . . . . 0.0 107.858 178.017 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 45.8 m-70 -136.59 162.16 33.9 Favored 'General case' 0 N--CA 1.491 1.589 0 CA-C-N 118.604 0.638 . . . . 0.0 110.958 -178.658 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 38.6 t60 -153.01 96.61 2.1 Favored 'General case' 0 N--CA 1.487 1.413 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.1 179.086 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' C' C ' 15' ' ' GLN . . . . . 0.523 HE22 ' C ' ' C' ' 38' ' ' GLY . 78.8 mt-30 -90.72 121.5 32.67 Favored 'General case' 0 CA--C 1.515 -0.381 0 N-CA-C 109.843 -0.429 . . . . 0.0 109.843 -178.99 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -112.92 103.49 11.46 Favored 'General case' 0 N--CA 1.473 0.677 0 N-CA-C 107.898 -1.149 . . . . 0.0 107.898 176.665 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 57.8 tp -133.28 150.23 51.92 Favored 'General case' 0 N--CA 1.486 1.337 0 N-CA-C 108.769 -0.826 . . . . 0.0 108.769 -179.435 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 85.3 t -145.38 122.59 4.37 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.013 0 CA-C-O 118.694 -0.67 . . . . 0.0 109.289 179.714 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 12.4 m-85 -70.63 158.88 35.41 Favored 'General case' 0 N--CA 1.487 1.39 0 N-CA-C 107.345 -1.354 . . . . 0.0 107.345 177.516 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 19.9 t80 -170.9 -57.72 0.02 OUTLIER 'General case' 0 N--CA 1.476 0.86 0 CA-C-O 122.29 1.043 . . . . 0.0 109.731 179.641 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -39.31 90.01 0.0 OUTLIER 'General case' 0 N--CA 1.457 -0.088 0 CA-C-N 113.986 -1.461 . . . . 0.0 112.711 -178.157 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 38.6 tt0 -64.84 159.64 22.11 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 115.183 -0.917 . . . . 0.0 110.593 179.343 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 9.6 m-20 -136.28 125.77 25.15 Favored 'General case' 0 N--CA 1.48 1.048 0 C-N-CA 123.315 0.646 . . . . 0.0 109.798 -179.838 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' C' C ' 24' ' ' VAL . . . . . 0.845 HG12 ' H ' ' C' ' 25' ' ' GLY . 57.1 t -76.66 -170.4 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.578 0 N-CA-C 108.609 -0.885 . . . . 0.0 108.609 179.708 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' C' C ' 25' ' ' GLY . . . . . 0.845 ' H ' HG12 ' C' ' 24' ' ' VAL . . . -68.8 48.56 0.47 Allowed Glycine 0 CA--C 1.533 1.18 0 CA-C-N 118.409 0.549 . . . . 0.0 112.249 -178.066 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 13.3 p -69.73 137.47 52.04 Favored 'General case' 0 C--O 1.22 -0.459 0 N-CA-C 109.646 -0.501 . . . . 0.0 109.646 178.716 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' C' C ' 27' ' ' ASN . . . . . 0.506 HD21 ' CG ' ' A' ' 11' ' ' GLU . 34.8 t30 -68.7 95.04 0.63 Allowed 'General case' 0 N--CA 1.469 0.485 0 N-CA-C 108.179 -1.045 . . . . 0.0 108.179 177.851 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 68.6 mttm -92.36 117.66 30.14 Favored 'General case' 0 N--CA 1.48 1.053 0 N-CA-C 109.988 -0.375 . . . . 0.0 109.988 -179.233 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.32 -134.2 0.01 OUTLIER Glycine 0 CA--C 1.533 1.16 0 N-CA-C 110.784 -0.926 . . . . 0.0 110.784 179.02 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -115.7 127.12 54.91 Favored 'General case' 0 N--CA 1.48 1.067 0 N-CA-C 109.314 -0.625 . . . . 0.0 109.314 179.203 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 66.2 mt -90.57 134.9 28.0 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.574 0 N-CA-C 107.666 -1.235 . . . . 0.0 107.666 178.845 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 30.4 mt -136.51 138.37 46.7 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.77 0 CA-C-N 115.937 -0.574 . . . . 0.0 109.545 -179.099 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.72 57.55 15.76 Favored Glycine 0 CA--C 1.528 0.887 0 CA-C-N 115.866 -0.606 . . . . 0.0 112.791 178.663 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 25.6 tp -106.13 132.75 51.83 Favored 'General case' 0 N--CA 1.486 1.353 0 N-CA-C 107.471 -1.307 . . . . 0.0 107.471 177.832 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 25.1 ttt -138.09 147.96 44.54 Favored 'General case' 0 N--CA 1.47 0.568 0 N-CA-C 107.591 -1.262 . . . . 0.0 107.591 179.315 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' C' C ' 36' ' ' VAL . . . . . 0.401 HG12 ' N ' ' C' ' 37' ' ' GLY . 60.6 t -156.81 160.05 2.4 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.546 0 N-CA-C 106.076 -1.824 . . . . 0.0 106.076 -178.959 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' C' C ' 37' ' ' GLY . . . . . 0.401 ' N ' HG12 ' C' ' 36' ' ' VAL . . . 54.1 74.12 0.34 Allowed Glycine 0 C--N 1.309 -0.925 0 C-N-CA 121.116 -0.564 . . . . 0.0 111.788 177.848 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' C' C ' 38' ' ' GLY . . . . . 0.523 ' C ' HE22 ' C' ' 15' ' ' GLN . . . 164.9 -168.36 39.07 Favored Glycine 0 N--CA 1.466 0.65 0 N-CA-C 111.104 -0.799 . . . . 0.0 111.104 179.349 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 24.2 m -126.71 148.88 31.43 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.858 0 C-N-CA 122.934 0.494 . . . . 0.0 109.935 179.716 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 9.8 t . . . . . 0 CA--C 1.534 0.364 0 CA-C-O 118.187 -0.911 . . . . 0.0 110.7 178.884 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 28.7 m-85 . . . . . 0 N--CA 1.475 0.789 0 N-CA-C 107.949 -1.13 . . . . 0.0 107.949 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' D' D ' 5' ' ' ARG . . . . . 0.772 HH12 HG13 ' C' ' 24' ' ' VAL 0.273 47.8 mtp180 -77.55 143.45 38.37 Favored 'General case' 0 C--O 1.207 -1.15 0 C-N-CA 123.595 0.758 . . . . 0.0 109.044 -169.708 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 40.5 m80 -107.79 124.44 50.05 Favored 'General case' 0 C--N 1.366 1.301 0 N-CA-C 106.87 -1.53 . . . . 0.0 106.87 -176.282 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' D' D ' 7' ' ' ASP . . . . . 0.468 ' OD2' HG11 ' I' ' 24' ' ' VAL . 7.9 m-20 -64.28 131.92 48.73 Favored 'General case' 0 CA--C 1.512 -0.485 0 CA-C-N 113.897 -1.501 . . . . 0.0 114.077 179.004 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' D' D ' 8' ' ' SER . . . . . . . . . . . . . 40.9 t -152.62 -167.8 2.86 Favored 'General case' 0 N--CA 1.482 1.152 0 C-N-CA 120.908 -0.317 . . . . 0.0 110.17 177.028 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 120.71 30.23 1.41 Allowed Glycine 0 N--CA 1.486 1.967 0 N-CA-C 111.35 -0.7 . . . . 0.0 111.35 177.862 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 44.9 p90 -54.46 131.13 41.87 Favored 'General case' 0 CA--C 1.545 0.785 0 CA-C-N 117.085 0.442 . . . . 0.0 111.591 -179.557 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' D' D ' 11' ' ' GLU . . . . . 0.435 ' CG ' HD21 ' F' ' 27' ' ' ASN . 60.3 mt-10 -89.7 151.2 21.98 Favored 'General case' 0 N--CA 1.475 0.808 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 177.324 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -149.66 129.07 3.53 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.529 0 N-CA-C 107.339 -1.356 . . . . 0.0 107.339 172.59 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 36.0 m-70 -130.29 162.59 28.67 Favored 'General case' 0 N--CA 1.48 1.054 0 C-N-CA 123.678 0.791 . . . . 0.0 112.902 178.205 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 41.5 t60 -153.96 104.31 2.65 Favored 'General case' 0 N--CA 1.486 1.35 0 N-CA-C 108.418 -0.956 . . . . 0.0 108.418 171.54 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' D' D ' 15' ' ' GLN . . . . . 0.522 HE22 ' C ' ' D' ' 38' ' ' GLY . 78.8 mt-30 -93.84 116.03 28.46 Favored 'General case' 0 CA--C 1.505 -0.762 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.325 -179.625 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -108.37 111.82 23.93 Favored 'General case' 0 C--N 1.359 0.99 0 N-CA-C 106.059 -1.83 . . . . 0.0 106.059 174.383 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 52.7 tp -134.32 150.73 50.98 Favored 'General case' 0 N--CA 1.484 1.238 0 N-CA-C 108.973 -0.751 . . . . 0.0 108.973 176.074 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 71.0 t -142.39 126.05 15.1 Favored 'Isoleucine or valine' 0 C--O 1.242 0.674 0 N-CA-C 109.141 -0.689 . . . . 0.0 109.141 173.863 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 26.8 m-85 -62.12 151.54 35.42 Favored 'General case' 0 N--CA 1.473 0.699 0 C-N-CA 124.284 1.034 . . . . 0.0 110.325 169.712 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 14.0 t80 -170.13 -66.86 0.02 OUTLIER 'General case' 0 C--N 1.318 -0.766 0 N-CA-C 107.765 -1.198 . . . . 0.0 107.765 -179.703 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -38.17 95.54 0.01 OUTLIER 'General case' 0 N--CA 1.449 -0.502 0 CA-C-N 114.207 -1.361 . . . . 0.0 111.798 -175.017 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 39.2 tt0 -67.51 161.12 26.19 Favored 'General case' 0 N--CA 1.468 0.458 0 CA-C-N 113.628 -1.624 . . . . 0.0 110.139 178.805 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 9.9 m-20 -137.22 126.52 24.79 Favored 'General case' 0 N--CA 1.479 1.019 0 C-N-CA 123.472 0.709 . . . . 0.0 109.942 -179.068 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' D' D ' 24' ' ' VAL . . . . . 0.943 HG12 ' H ' ' D' ' 25' ' ' GLY . 92.3 t -81.13 -165.64 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.482 1.169 0 N-CA-C 107.566 -1.272 . . . . 0.0 107.566 -178.098 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' D' D ' 25' ' ' GLY . . . . . 0.943 ' H ' HG12 ' D' ' 24' ' ' VAL . . . -79.27 56.62 4.4 Favored Glycine 0 C--N 1.362 1.997 0 C-N-CA 117.855 -2.117 . . . . 0.0 110.628 -174.263 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 21.8 p -61.34 132.83 54.82 Favored 'General case' 0 C--N 1.346 0.426 0 CA-C-N 113.545 -1.328 . . . . 0.0 111.965 170.648 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' D' D ' 27' ' ' ASN . . . . . 0.447 HD21 ' CG ' ' E' ' 11' ' ' GLU . 40.6 t30 -65.53 95.06 0.2 Allowed 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 119.908 1.231 . . . . 0.0 108.751 172.971 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 68.3 mttm -93.89 120.97 34.87 Favored 'General case' 0 N--CA 1.484 1.26 0 C-N-CA 119.521 -0.871 . . . . 0.0 108.908 179.756 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -57.45 -135.01 0.01 OUTLIER Glycine 0 C--N 1.341 0.806 0 CA-C-N 115.858 -0.61 . . . . 0.0 113.067 175.974 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -114.22 131.76 56.36 Favored 'General case' 0 C--N 1.367 1.357 0 N-CA-C 109.101 -0.703 . . . . 0.0 109.101 174.572 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 68.6 mt -91.79 138.43 19.82 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.298 0 N-CA-C 107.182 -1.414 . . . . 0.0 107.182 176.845 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 35.2 mt -138.7 140.85 38.4 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.879 0 N-CA-C 108.639 -0.875 . . . . 0.0 108.639 178.518 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.54 55.04 27.62 Favored Glycine 0 CA--C 1.529 0.911 0 CA-C-O 119.381 -0.677 . . . . 0.0 112.588 178.313 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 19.2 tp -102.84 141.59 35.39 Favored 'General case' 0 C--N 1.364 1.207 0 N-CA-C 106.333 -1.728 . . . . 0.0 106.333 176.536 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 23.9 ttt -142.07 156.95 45.42 Favored 'General case' 0 N--CA 1.472 0.664 0 N-CA-C 105.952 -1.87 . . . . 0.0 105.952 175.085 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 73.7 t -164.34 161.89 0.93 Allowed 'Isoleucine or valine' 0 CA--C 1.503 -0.835 0 N-CA-C 105.349 -2.093 . . . . 0.0 105.349 179.19 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' D' D ' 37' ' ' GLY . . . . . 0.422 ' O ' ' O ' ' G' ' 38' ' ' GLY . . . 60.21 64.44 4.15 Favored Glycine 0 N--CA 1.441 -1.004 0 C-N-CA 118.38 -1.867 . . . . 0.0 112.453 176.301 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' D' D ' 38' ' ' GLY . . . . . 0.522 ' C ' HE22 ' D' ' 15' ' ' GLN . . . 166.46 -163.86 37.23 Favored Glycine 0 C--O 1.215 -1.051 0 CA-C-N 119.308 1.554 . . . . 0.0 112.264 176.493 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 29.4 m -121.64 147.45 25.61 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.067 0 CA-C-O 118.041 -0.981 . . . . 0.0 112.259 179.35 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 7.5 t . . . . . 0 C--O 1.213 -0.864 0 N-CA-C 108.798 -0.815 . . . . 0.0 108.798 171.652 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 24.8 m-85 . . . . . 0 N--CA 1.471 0.579 0 N-CA-C 109.445 -0.576 . . . . 0.0 109.445 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' E' E ' 5' ' ' ARG . . . . . 0.756 HH12 HG13 ' A' ' 24' ' ' VAL . 34.9 mtp180 -68.13 148.15 51.31 Favored 'General case' 0 C--O 1.202 -1.419 0 CA-C-N 115.567 -0.742 . . . . 0.0 111.313 -178.012 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 39.2 m80 -109.9 118.97 37.89 Favored 'General case' 0 N--CA 1.483 1.181 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 177.889 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' E' E ' 7' ' ' ASP . . . . . 0.442 ' OD1' HG11 ' G' ' 24' ' ' VAL . 13.0 m-20 -66.31 140.28 58.1 Favored 'General case' 0 N--CA 1.466 0.37 0 CA-C-O 120.91 0.386 . . . . 0.0 112.02 -178.442 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' E' E ' 8' ' ' SER . . . . . . . . . . . . . 38.2 t -158.7 -169.87 2.86 Favored 'General case' 0 N--CA 1.487 1.378 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.194 178.924 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 120.33 32.84 1.09 Allowed Glycine 0 N--CA 1.484 1.867 0 N-CA-C 111.717 -0.553 . . . . 0.0 111.717 179.538 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 43.3 p90 -56.84 130.54 46.19 Favored 'General case' 0 CA--C 1.546 0.796 0 CA-C-N 116.948 0.374 . . . . 0.0 111.64 -179.963 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' E' E ' 11' ' ' GLU . . . . . 0.447 ' CG ' HD21 ' D' ' 27' ' ' ASN . 60.2 mt-10 -89.98 153.49 20.55 Favored 'General case' 0 N--CA 1.478 0.945 0 N-CA-C 109.404 -0.591 . . . . 0.0 109.404 178.606 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.8 p -155.15 124.78 0.74 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.575 0 N-CA-C 108.183 -1.043 . . . . 0.0 108.183 177.872 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 43.9 m-70 -136.04 160.95 37.07 Favored 'General case' 0 N--CA 1.481 1.113 0 CA-C-O 120.746 0.308 . . . . 0.0 111.115 -177.515 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 38.8 t60 -152.96 96.75 2.13 Favored 'General case' 0 N--CA 1.488 1.475 0 C-N-CA 122.687 0.395 . . . . 0.0 109.951 179.241 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' E' E ' 15' ' ' GLN . . . . . 0.49 HE22 ' C ' ' E' ' 38' ' ' GLY . 78.8 mt-30 -90.75 122.25 33.33 Favored 'General case' 0 C--N 1.329 -0.297 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 -179.064 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -113.78 103.5 11.27 Favored 'General case' 0 N--CA 1.474 0.726 0 N-CA-C 107.69 -1.226 . . . . 0.0 107.69 176.638 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 53.9 tp -132.19 149.1 52.47 Favored 'General case' 0 N--CA 1.486 1.343 0 C-N-CA 123.368 0.667 . . . . 0.0 109.269 -178.844 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 57.7 t -145.25 123.59 5.23 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.837 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 179.154 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 11.2 m-85 -71.4 156.35 39.58 Favored 'General case' 0 C--N 1.363 1.155 0 N-CA-C 106.911 -1.515 . . . . 0.0 106.911 176.937 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 17.8 t80 -172.13 -55.94 0.02 OUTLIER 'General case' 0 N--CA 1.481 1.084 0 CA-C-O 121.83 0.824 . . . . 0.0 110.238 179.733 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.99 88.26 0.0 OUTLIER 'General case' 0 C--N 1.319 -0.759 0 CA-C-N 114.107 -1.406 . . . . 0.0 112.87 -178.986 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 39.0 tt0 -63.26 159.72 17.24 Favored 'General case' 0 N--CA 1.471 0.625 0 CA-C-N 114.855 -1.066 . . . . 0.0 110.842 179.831 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 9.6 m-20 -136.56 125.52 24.29 Favored 'General case' 0 N--CA 1.482 1.162 0 C-N-CA 123.3 0.64 . . . . 0.0 110.23 -179.67 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' E' E ' 24' ' ' VAL . . . . . 0.873 HG12 ' H ' ' E' ' 25' ' ' GLY . 58.5 t -76.08 -170.35 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.484 1.252 0 N-CA-C 108.029 -1.1 . . . . 0.0 108.029 179.436 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' E' E ' 25' ' ' GLY . . . . . 0.873 ' H ' HG12 ' E' ' 24' ' ' VAL . . . -68.89 49.65 0.5 Allowed Glycine 0 CA--C 1.531 1.031 0 CA-C-N 118.079 0.4 . . . . 0.0 112.626 -178.132 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 8.1 p -69.16 136.79 52.65 Favored 'General case' 0 C--O 1.219 -0.514 0 N-CA-C 109.705 -0.48 . . . . 0.0 109.705 178.494 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' E' E ' 27' ' ' ASN . . . . . 0.445 HD21 ' CG ' ' F' ' 11' ' ' GLU . 36.2 t30 -68.3 95.5 0.6 Allowed 'General case' 0 N--CA 1.466 0.328 0 N-CA-C 107.481 -1.303 . . . . 0.0 107.481 177.388 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 68.1 mttm -93.33 117.09 29.66 Favored 'General case' 0 N--CA 1.482 1.136 0 N-CA-C 109.612 -0.514 . . . . 0.0 109.612 -178.858 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.16 -133.98 0.01 OUTLIER Glycine 0 CA--C 1.536 1.392 0 N-CA-C 111.308 -0.717 . . . . 0.0 111.308 178.877 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -115.66 126.42 54.13 Favored 'General case' 0 N--CA 1.481 1.081 0 N-CA-C 109.637 -0.505 . . . . 0.0 109.637 179.225 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 66.8 mt -89.35 135.02 27.02 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.213 0 N-CA-C 107.571 -1.27 . . . . 0.0 107.571 178.914 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 33.1 mt -136.21 137.83 47.85 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.867 0 N-CA-C 108.991 -0.744 . . . . 0.0 108.991 -179.768 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.37 59.68 8.54 Favored Glycine 0 CA--C 1.527 0.82 0 CA-C-N 116.047 -0.524 . . . . 0.0 112.947 178.835 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 22.0 tp -107.49 131.81 53.91 Favored 'General case' 0 N--CA 1.487 1.41 0 N-CA-C 107.454 -1.313 . . . . 0.0 107.454 177.741 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 23.6 ttt -137.26 147.82 45.99 Favored 'General case' 0 N--CA 1.472 0.66 0 N-CA-C 107.815 -1.18 . . . . 0.0 107.815 178.709 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' E' E ' 36' ' ' VAL . . . . . 0.407 HG12 ' N ' ' E' ' 37' ' ' GLY . 59.8 t -156.7 159.94 2.47 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.693 0 N-CA-C 106.457 -1.683 . . . . 0.0 106.457 -178.899 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' E' E ' 37' ' ' GLY . . . . . 0.407 ' N ' HG12 ' E' ' 36' ' ' VAL . . . 54.12 73.4 0.41 Allowed Glycine 0 C--N 1.31 -0.904 0 N-CA-C 111.801 -0.52 . . . . 0.0 111.801 177.787 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' E' E ' 38' ' ' GLY . . . . . 0.49 ' C ' HE22 ' E' ' 15' ' ' GLN . . . 165.83 -166.63 38.71 Favored Glycine 0 C--O 1.21 -1.395 0 N-CA-C 111.278 -0.729 . . . . 0.0 111.278 179.256 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 21.6 m -128.34 148.88 32.8 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.827 0 C-N-CA 122.833 0.453 . . . . 0.0 109.91 179.913 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 7.5 t . . . . . 0 CA--C 1.541 0.598 0 CA-C-O 118.202 -0.904 . . . . 0.0 110.473 178.85 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 25.7 m-85 . . . . . 0 N--CA 1.472 0.645 0 N-CA-C 109.572 -0.529 . . . . 0.0 109.572 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' F' F ' 5' ' ' ARG . . . . . 0.756 HH12 HG13 ' B' ' 24' ' ' VAL . 35.5 mtp180 -68.08 147.4 52.4 Favored 'General case' 0 C--O 1.201 -1.476 0 CA-C-N 115.499 -0.773 . . . . 0.0 111.468 -178.017 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 39.2 m80 -109.47 118.89 37.82 Favored 'General case' 0 N--CA 1.484 1.266 0 N-CA-C 109.094 -0.706 . . . . 0.0 109.094 177.815 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' F' F ' 7' ' ' ASP . . . . . 0.474 ' OD1' HG11 ' H' ' 24' ' ' VAL . 13.0 m-20 -66.32 140.27 58.09 Favored 'General case' 0 N--CA 1.466 0.341 0 N-CA-C 112.159 0.429 . . . . 0.0 112.159 -178.453 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' F' F ' 8' ' ' SER . . . . . . . . . . . . . 38.3 t -158.73 -169.81 2.84 Favored 'General case' 0 N--CA 1.486 1.365 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.18 178.9 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 120.33 32.84 1.09 Allowed Glycine 0 N--CA 1.483 1.808 0 N-CA-C 111.679 -0.568 . . . . 0.0 111.679 179.559 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 43.3 p90 -57.02 130.73 47.35 Favored 'General case' 0 CA--C 1.545 0.763 0 CA-C-N 116.945 0.372 . . . . 0.0 111.614 -179.952 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' F' F ' 11' ' ' GLU . . . . . 0.445 ' CG ' HD21 ' E' ' 27' ' ' ASN . 60.3 mt-10 -90.04 153.53 20.5 Favored 'General case' 0 N--CA 1.478 0.959 0 CA-C-O 121.306 0.574 . . . . 0.0 109.457 178.513 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.8 p -155.22 124.78 0.74 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.532 0 N-CA-C 108.071 -1.085 . . . . 0.0 108.071 177.942 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 44.4 m-70 -136.03 160.83 37.42 Favored 'General case' 0 N--CA 1.48 1.062 0 CA-C-O 120.668 0.271 . . . . 0.0 111.142 -177.645 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 39.0 t60 -152.93 97.13 2.17 Favored 'General case' 0 N--CA 1.487 1.406 0 C-N-CA 122.75 0.42 . . . . 0.0 110.06 179.278 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' F' F ' 15' ' ' GLN . . . . . 0.478 ' NE2' ' O ' ' F' ' 38' ' ' GLY . 78.8 mt-30 -91.21 122.87 34.21 Favored 'General case' 0 CA--C 1.513 -0.474 0 N-CA-C 110.174 -0.306 . . . . 0.0 110.174 -179.141 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -114.23 103.48 11.14 Favored 'General case' 0 N--CA 1.471 0.608 0 N-CA-C 107.808 -1.182 . . . . 0.0 107.808 176.694 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 54.2 tp -132.17 149.13 52.46 Favored 'General case' 0 N--CA 1.486 1.355 0 C-N-CA 123.388 0.675 . . . . 0.0 109.307 -179.041 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 58.7 t -145.24 123.69 5.32 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.805 0 N-CA-C 109.37 -0.604 . . . . 0.0 109.37 179.205 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 11.2 m-85 -71.5 156.14 39.77 Favored 'General case' 0 C--N 1.363 1.195 0 N-CA-C 106.795 -1.557 . . . . 0.0 106.795 176.92 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 18.5 t80 -171.87 -55.96 0.02 OUTLIER 'General case' 0 N--CA 1.481 1.105 0 CA-C-O 121.784 0.802 . . . . 0.0 109.873 179.799 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.02 88.24 0.0 OUTLIER 'General case' 0 C--N 1.319 -0.725 0 CA-C-N 114.235 -1.348 . . . . 0.0 112.968 -178.968 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 38.9 tt0 -63.22 159.91 16.74 Favored 'General case' 0 N--CA 1.472 0.638 0 CA-C-N 114.857 -1.065 . . . . 0.0 110.856 179.756 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 9.7 m-20 -136.82 125.77 24.27 Favored 'General case' 0 N--CA 1.481 1.122 0 C-N-CA 123.271 0.628 . . . . 0.0 110.252 -179.735 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' F' F ' 24' ' ' VAL . . . . . 0.848 HG12 ' H ' ' F' ' 25' ' ' GLY . 59.1 t -76.28 -170.1 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.484 1.267 0 N-CA-C 108.168 -1.049 . . . . 0.0 108.168 179.485 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' F' F ' 25' ' ' GLY . . . . . 0.848 ' H ' HG12 ' F' ' 24' ' ' VAL . . . -68.85 49.4 0.49 Allowed Glycine 0 CA--C 1.528 0.847 0 CA-C-N 118.264 0.484 . . . . 0.0 112.491 -178.305 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 8.1 p -68.96 136.66 52.85 Favored 'General case' 0 C--O 1.219 -0.535 0 N-CA-C 109.536 -0.542 . . . . 0.0 109.536 178.378 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' F' F ' 27' ' ' ASN . . . . . 0.435 HD21 ' CG ' ' D' ' 11' ' ' GLU . 35.4 t30 -68.38 95.73 0.63 Allowed 'General case' 0 CA--C 1.535 0.371 0 N-CA-C 107.35 -1.352 . . . . 0.0 107.35 177.464 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 68.1 mttm -93.41 116.96 29.5 Favored 'General case' 0 N--CA 1.48 1.073 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -178.931 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.13 -134.15 0.01 OUTLIER Glycine 0 CA--C 1.537 1.444 0 N-CA-C 111.383 -0.687 . . . . 0.0 111.383 178.997 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -115.19 125.99 54.05 Favored 'General case' 0 N--CA 1.485 1.277 0 C-N-CA 123.064 0.546 . . . . 0.0 109.615 179.212 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 66.9 mt -89.3 134.88 27.37 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.236 0 N-CA-C 107.457 -1.312 . . . . 0.0 107.457 178.816 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 32.9 mt -136.25 137.87 47.73 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.805 0 N-CA-C 108.984 -0.747 . . . . 0.0 108.984 -179.723 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.24 59.81 8.44 Favored Glycine 0 CA--C 1.525 0.663 0 CA-C-N 116.01 -0.541 . . . . 0.0 112.884 178.878 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 21.8 tp -107.78 132.04 53.81 Favored 'General case' 0 N--CA 1.487 1.376 0 N-CA-C 107.585 -1.265 . . . . 0.0 107.585 177.668 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 23.4 ttt -137.53 147.99 45.61 Favored 'General case' 0 N--CA 1.468 0.434 0 N-CA-C 108.324 -0.991 . . . . 0.0 108.324 178.733 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' F' F ' 36' ' ' VAL . . . . . 0.401 HG12 ' N ' ' F' ' 37' ' ' GLY . 60.8 t -156.63 160.03 2.44 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.772 0 N-CA-C 106.579 -1.637 . . . . 0.0 106.579 -178.741 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' F' F ' 37' ' ' GLY . . . . . 0.401 ' N ' HG12 ' F' ' 36' ' ' VAL . . . 54.05 73.37 0.42 Allowed Glycine 0 C--N 1.309 -0.964 0 CA-C-N 116.075 -0.512 . . . . 0.0 111.937 177.709 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' F' F ' 38' ' ' GLY . . . . . 0.478 ' O ' ' NE2' ' F' ' 15' ' ' GLN . . . 165.83 -166.58 38.68 Favored Glycine 0 C--O 1.209 -1.459 0 N-CA-C 111.264 -0.735 . . . . 0.0 111.264 179.315 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 21.1 m -128.46 148.76 32.9 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.811 0 C-N-CA 122.729 0.412 . . . . 0.0 109.906 179.935 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 6.8 t . . . . . 0 CA--C 1.54 0.565 0 CA-C-O 118.207 -0.901 . . . . 0.0 110.423 178.911 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 35.4 m-85 . . . . . 0 N--CA 1.469 0.499 0 CA-C-O 121.173 0.511 . . . . 0.0 109.833 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' G' G ' 5' ' ' ARG . . . . . 0.736 HH12 HG13 ' F' ' 24' ' ' VAL . 33.8 mtp180 -68.69 144.92 54.28 Favored 'General case' 0 N--CA 1.469 0.524 0 CA-C-N 115.415 -0.811 . . . . 0.0 111.146 -178.325 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 38.6 m80 -107.98 118.78 37.64 Favored 'General case' 0 N--CA 1.478 0.961 0 N-CA-C 109.226 -0.657 . . . . 0.0 109.226 178.095 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 10.5 m-20 -66.84 139.47 57.77 Favored 'General case' 0 N--CA 1.469 0.49 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.948 -179.061 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' G' G ' 8' ' ' SER . . . . . . . . . . . . . 37.8 t -158.09 -170.23 3.07 Favored 'General case' 0 N--CA 1.471 0.603 0 N-CA-C 109.666 -0.494 . . . . 0.0 109.666 179.024 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 120.37 31.97 1.2 Allowed Glycine 0 N--CA 1.484 1.869 0 N-CA-C 111.539 -0.624 . . . . 0.0 111.539 179.497 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 47.1 p90 -57.11 130.71 47.32 Favored 'General case' 0 N--CA 1.472 0.629 0 CA-C-N 116.825 0.313 . . . . 0.0 111.716 -179.822 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 60.4 mt-10 -90.34 152.58 20.96 Favored 'General case' 0 N--CA 1.474 0.758 0 CA-C-O 121.138 0.494 . . . . 0.0 109.807 179.082 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 3.5 p -155.47 124.83 0.72 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.058 0 N-CA-C 108.175 -1.046 . . . . 0.0 108.175 178.19 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 43.6 m-70 -135.86 160.73 37.68 Favored 'General case' 0 N--CA 1.475 0.781 0 CA-C-N 114.722 -1.126 . . . . 0.0 110.973 -177.619 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 39.6 t60 -153.39 96.93 2.09 Favored 'General case' 0 N--CA 1.484 1.231 0 CA-C-N 115.858 -0.61 . . . . 0.0 109.659 178.855 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' G' G ' 15' ' ' GLN . . . . . 0.507 HE22 ' C ' ' G' ' 38' ' ' GLY . 79.1 mt-30 -90.75 121.52 32.71 Favored 'General case' 0 N--CA 1.451 -0.406 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 -178.896 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -113.03 103.77 11.71 Favored 'General case' 0 N--CA 1.476 0.831 0 N-CA-C 107.694 -1.224 . . . . 0.0 107.694 176.65 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 56.6 tp -132.17 147.33 52.42 Favored 'General case' 0 N--CA 1.486 1.343 0 C-N-CA 123.336 0.654 . . . . 0.0 109.56 -179.288 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 61.3 t -144.99 123.3 5.31 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.861 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 178.664 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 9.6 m-85 -70.39 150.37 46.33 Favored 'General case' 0 C--N 1.376 1.728 0 N-CA-C 106.91 -1.515 . . . . 0.0 106.91 176.699 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 15.6 t80 -169.94 -55.4 0.02 OUTLIER 'General case' 0 N--CA 1.483 1.22 0 N-CA-C 110.248 -0.278 . . . . 0.0 110.248 -179.729 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.0 90.02 0.0 OUTLIER 'General case' 0 C--N 1.323 -0.545 0 C-N-CA 123.72 0.808 . . . . 0.0 112.471 -179.964 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 39.3 tt0 -64.4 160.76 18.36 Favored 'General case' 0 N--CA 1.468 0.467 0 CA-C-N 114.834 -1.076 . . . . 0.0 110.023 179.273 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 9.6 m-20 -137.26 125.38 22.99 Favored 'General case' 0 N--CA 1.48 1.072 0 C-N-CA 123.154 0.582 . . . . 0.0 109.721 -179.701 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' G' G ' 24' ' ' VAL . . . . . 0.857 HG12 ' H ' ' G' ' 25' ' ' GLY . 61.9 t -76.75 -169.97 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.827 0 N-CA-C 108.156 -1.053 . . . . 0.0 108.156 179.608 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' G' G ' 25' ' ' GLY . . . . . 0.857 ' H ' HG12 ' G' ' 24' ' ' VAL . . . -68.89 49.98 0.5 Allowed Glycine 0 CA--C 1.53 0.973 0 CA-C-N 118.48 0.582 . . . . 0.0 112.726 -178.467 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 8.4 p -69.51 137.63 52.67 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 109.157 -0.682 . . . . 0.0 109.157 177.748 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 34.2 t30 -69.49 94.72 0.77 Allowed 'General case' 0 CA--C 1.532 0.265 0 N-CA-C 107.618 -1.253 . . . . 0.0 107.618 177.562 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -91.63 117.81 30.07 Favored 'General case' 0 N--CA 1.478 0.953 0 N-CA-C 109.713 -0.477 . . . . 0.0 109.713 -179.396 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -62.37 -133.3 0.01 OUTLIER Glycine 0 CA--C 1.532 1.099 0 N-CA-C 110.547 -1.021 . . . . 0.0 110.547 178.927 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -115.19 126.83 55.05 Favored 'General case' 0 N--CA 1.475 0.808 0 N-CA-C 109.615 -0.513 . . . . 0.0 109.615 179.186 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 69.6 mt -89.64 136.14 24.41 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.671 0 N-CA-C 107.598 -1.26 . . . . 0.0 107.598 178.743 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 38.2 mt -137.46 139.18 43.98 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.249 0 CA-C-N 118.782 0.719 . . . . 0.0 109.158 179.721 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.1 57.98 13.56 Favored Glycine 0 CA--C 1.53 0.977 0 CA-C-N 116.11 -0.496 . . . . 0.0 112.624 178.99 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 23.1 tp -105.81 132.23 52.18 Favored 'General case' 0 N--CA 1.484 1.256 0 N-CA-C 107.6 -1.259 . . . . 0.0 107.6 177.775 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 22.1 ttt -137.63 147.97 45.4 Favored 'General case' 0 N--CA 1.474 0.727 0 N-CA-C 108.211 -1.033 . . . . 0.0 108.211 178.788 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 61.2 t -156.77 158.4 3.24 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 106.613 -1.625 . . . . 0.0 106.613 -179.095 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.57 71.74 0.68 Allowed Glycine 0 C--N 1.308 -0.973 0 CA-C-N 115.951 -0.568 . . . . 0.0 112.384 177.549 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' G' G ' 38' ' ' GLY . . . . . 0.507 ' C ' HE22 ' G' ' 15' ' ' GLN . . . 167.75 -165.22 38.55 Favored Glycine 0 C--O 1.212 -1.268 0 N-CA-C 110.747 -0.941 . . . . 0.0 110.747 178.631 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 18.7 m -128.64 148.14 33.07 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.93 0 C-N-CA 122.789 0.435 . . . . 0.0 109.93 179.911 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 8.6 t . . . . . 0 CA--C 1.534 0.337 0 CA-C-O 118.156 -0.926 . . . . 0.0 110.888 178.815 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 35.0 m-85 . . . . . 0 N--CA 1.47 0.557 0 CA-C-O 121.234 0.54 . . . . 0.0 109.756 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' H' H ' 5' ' ' ARG . . . . . 0.757 HH12 HG13 ' D' ' 24' ' ' VAL . 33.8 mtp180 -69.04 145.12 53.78 Favored 'General case' 0 N--CA 1.466 0.373 0 CA-C-N 115.387 -0.824 . . . . 0.0 111.229 -178.312 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 38.5 m80 -108.05 118.77 37.63 Favored 'General case' 0 N--CA 1.478 0.958 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 178.265 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 10.5 m-20 -66.91 139.58 57.73 Favored 'General case' 0 N--CA 1.468 0.441 0 CA-C-N 116.275 -0.421 . . . . 0.0 111.889 -179.066 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' H' H ' 8' ' ' SER . . . . . . . . . . . . . 37.9 t -158.12 -170.08 3.01 Favored 'General case' 0 N--CA 1.471 0.595 0 N-CA-C 109.73 -0.47 . . . . 0.0 109.73 178.985 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 120.11 32.09 1.21 Allowed Glycine 0 N--CA 1.483 1.829 0 N-CA-C 111.641 -0.583 . . . . 0.0 111.641 179.549 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 46.9 p90 -57.17 130.79 47.72 Favored 'General case' 0 CA--C 1.542 0.64 0 CA-C-N 116.715 0.258 . . . . 0.0 111.607 -179.777 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 60.5 mt-10 -90.3 152.54 20.99 Favored 'General case' 0 N--CA 1.474 0.771 0 CA-C-O 121.116 0.484 . . . . 0.0 109.859 179.023 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 3.4 p -155.53 124.95 0.72 Allowed 'Isoleucine or valine' 0 CA--C 1.553 1.089 0 N-CA-C 108.161 -1.051 . . . . 0.0 108.161 178.074 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 43.6 m-70 -135.93 160.78 37.55 Favored 'General case' 0 C--N 1.353 0.751 0 CA-C-N 114.627 -1.169 . . . . 0.0 111.072 -177.527 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 39.3 t60 -153.51 96.86 2.07 Favored 'General case' 0 N--CA 1.484 1.268 0 CA-C-N 115.868 -0.606 . . . . 0.0 109.773 178.911 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' H' H ' 15' ' ' GLN . . . . . 0.504 HE22 ' C ' ' H' ' 38' ' ' GLY . 79.0 mt-30 -90.71 121.37 32.55 Favored 'General case' 0 CA--C 1.514 -0.406 0 N-CA-C 109.711 -0.477 . . . . 0.0 109.711 -178.946 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -112.84 103.66 11.65 Favored 'General case' 0 N--CA 1.474 0.726 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 176.672 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 56.3 tp -132.14 147.37 52.42 Favored 'General case' 0 N--CA 1.486 1.374 0 C-N-CA 123.273 0.629 . . . . 0.0 109.488 -179.196 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 61.4 t -144.93 123.21 5.36 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.89 0 N-CA-C 109.368 -0.604 . . . . 0.0 109.368 178.667 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 9.5 m-85 -70.67 150.96 45.45 Favored 'General case' 0 C--N 1.376 1.741 0 N-CA-C 106.951 -1.5 . . . . 0.0 106.951 176.658 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 16.6 t80 -171.19 -55.13 0.02 OUTLIER 'General case' 0 N--CA 1.48 1.061 0 N-CA-C 110.216 -0.291 . . . . 0.0 110.216 -179.696 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.05 89.92 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.472 0 O-C-N 123.971 0.795 . . . . 0.0 112.269 -179.96 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 39.4 tt0 -64.12 160.76 17.56 Favored 'General case' 0 N--CA 1.469 0.487 0 CA-C-N 114.777 -1.102 . . . . 0.0 110.063 179.482 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 9.7 m-20 -137.11 125.43 23.27 Favored 'General case' 0 N--CA 1.481 1.077 0 C-N-CA 123.098 0.559 . . . . 0.0 109.869 -179.791 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' H' H ' 24' ' ' VAL . . . . . 0.836 HG12 ' H ' ' H' ' 25' ' ' GLY . 57.4 t -76.69 -170.0 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.475 0.806 0 N-CA-C 108.408 -0.96 . . . . 0.0 108.408 179.612 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' H' H ' 25' ' ' GLY . . . . . 0.836 ' H ' HG12 ' H' ' 24' ' ' VAL . . . -68.64 49.56 0.46 Allowed Glycine 0 CA--C 1.53 1.009 0 CA-C-N 118.627 0.649 . . . . 0.0 112.43 -178.468 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 8.5 p -69.56 137.47 52.44 Favored 'General case' 0 C--N 1.33 -0.266 0 N-CA-C 109.152 -0.684 . . . . 0.0 109.152 177.823 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 34.7 t30 -69.57 94.82 0.8 Allowed 'General case' 0 N--CA 1.464 0.258 0 N-CA-C 107.638 -1.245 . . . . 0.0 107.638 177.635 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -91.76 117.88 30.17 Favored 'General case' 0 N--CA 1.477 0.91 0 N-CA-C 109.708 -0.479 . . . . 0.0 109.708 -179.408 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -62.48 -133.15 0.01 OUTLIER Glycine 0 CA--C 1.532 1.107 0 N-CA-C 110.582 -1.007 . . . . 0.0 110.582 178.977 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -115.25 126.89 55.07 Favored 'General case' 0 N--CA 1.474 0.745 0 C-N-CA 122.984 0.514 . . . . 0.0 109.634 179.192 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 69.6 mt -89.67 136.03 24.68 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.621 0 N-CA-C 107.535 -1.283 . . . . 0.0 107.535 178.707 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 37.7 mt -137.4 139.24 44.01 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.263 0 N-CA-C 109.142 -0.688 . . . . 0.0 109.142 179.611 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.23 58.1 12.92 Favored Glycine 0 CA--C 1.529 0.964 0 CA-C-N 116.067 -0.515 . . . . 0.0 112.593 178.967 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 23.5 tp -105.85 131.81 52.73 Favored 'General case' 0 N--CA 1.484 1.256 0 N-CA-C 107.688 -1.227 . . . . 0.0 107.688 177.893 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 22.0 ttt -137.16 147.36 45.89 Favored 'General case' 0 N--CA 1.475 0.808 0 N-CA-C 108.135 -1.061 . . . . 0.0 108.135 178.924 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 61.7 t -156.5 158.14 3.45 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.487 0 N-CA-C 106.634 -1.617 . . . . 0.0 106.634 -179.109 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.68 71.53 0.71 Allowed Glycine 0 C--N 1.308 -0.992 0 CA-C-N 115.901 -0.59 . . . . 0.0 112.352 177.526 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' H' H ' 38' ' ' GLY . . . . . 0.504 ' C ' HE22 ' H' ' 15' ' ' GLN . . . 167.75 -165.75 38.91 Favored Glycine 0 C--O 1.212 -1.277 0 N-CA-C 110.6 -1.0 . . . . 0.0 110.6 178.693 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 18.9 m -128.2 148.45 32.72 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.023 0 C-N-CA 122.777 0.431 . . . . 0.0 109.926 179.966 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 8.6 t . . . . . 0 CA--C 1.535 0.369 0 CA-C-O 118.196 -0.907 . . . . 0.0 110.811 178.764 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 34.6 m-85 . . . . . 0 N--CA 1.47 0.537 0 CA-C-O 121.136 0.493 . . . . 0.0 109.827 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' I' I ' 5' ' ' ARG . . . . . 0.747 HH12 HG13 ' E' ' 24' ' ' VAL . 32.8 mtp180 -68.94 144.87 54.04 Favored 'General case' 0 N--CA 1.468 0.475 0 CA-C-N 115.473 -0.785 . . . . 0.0 111.206 -178.343 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 38.6 m80 -107.88 118.59 37.13 Favored 'General case' 0 N--CA 1.477 0.925 0 N-CA-C 109.195 -0.669 . . . . 0.0 109.195 178.314 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 10.5 m-20 -66.77 139.61 57.81 Favored 'General case' 0 N--CA 1.469 0.485 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.916 -179.059 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' I' I ' 8' ' ' SER . . . . . . . . . . . . . 37.8 t -158.08 -170.15 3.05 Favored 'General case' 0 N--CA 1.47 0.557 0 N-CA-C 109.688 -0.486 . . . . 0.0 109.688 178.996 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 120.29 32.0 1.2 Allowed Glycine 0 N--CA 1.483 1.809 0 N-CA-C 111.584 -0.606 . . . . 0.0 111.584 179.413 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 47.1 p90 -57.12 130.75 47.52 Favored 'General case' 0 N--CA 1.473 0.705 0 O-C-N 122.671 -0.311 . . . . 0.0 111.665 -179.815 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 60.5 mt-10 -90.3 152.5 21.01 Favored 'General case' 0 N--CA 1.475 0.813 0 CA-C-O 121.152 0.501 . . . . 0.0 109.865 179.013 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 3.5 p -155.46 124.87 0.73 Allowed 'Isoleucine or valine' 0 CA--C 1.554 1.125 0 N-CA-C 108.194 -1.039 . . . . 0.0 108.194 178.103 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 44.1 m-70 -135.82 160.85 37.29 Favored 'General case' 0 C--N 1.354 0.761 0 CA-C-N 114.6 -1.182 . . . . 0.0 111.0 -177.556 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 39.6 t60 -153.6 97.05 2.08 Favored 'General case' 0 N--CA 1.484 1.262 0 CA-C-N 115.841 -0.618 . . . . 0.0 109.761 178.841 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' I' I ' 15' ' ' GLN . . . . . 0.485 HE22 ' C ' ' I' ' 38' ' ' GLY . 79.0 mt-30 -90.79 121.37 32.6 Favored 'General case' 0 CA--C 1.514 -0.416 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 -178.95 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -112.86 103.69 11.68 Favored 'General case' 0 N--CA 1.473 0.709 0 N-CA-C 107.677 -1.231 . . . . 0.0 107.677 176.6 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 56.5 tp -132.18 147.26 52.41 Favored 'General case' 0 N--CA 1.485 1.296 0 C-N-CA 123.329 0.652 . . . . 0.0 109.436 -179.153 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 61.7 t -144.88 123.12 5.4 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.9 0 N-CA-C 109.425 -0.583 . . . . 0.0 109.425 178.642 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 9.4 m-85 -70.66 150.89 45.53 Favored 'General case' 0 C--N 1.374 1.642 0 N-CA-C 106.853 -1.536 . . . . 0.0 106.853 176.701 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 16.7 t80 -171.14 -55.26 0.02 OUTLIER 'General case' 0 N--CA 1.48 1.073 0 N-CA-C 110.212 -0.292 . . . . 0.0 110.212 -179.561 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.07 90.01 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.45 0 O-C-N 123.998 0.811 . . . . 0.0 112.327 -179.986 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 39.4 tt0 -64.22 160.77 17.85 Favored 'General case' 0 N--CA 1.469 0.511 0 CA-C-N 114.743 -1.117 . . . . 0.0 110.011 179.557 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 9.6 m-20 -137.01 125.31 23.25 Favored 'General case' 0 N--CA 1.481 1.082 0 C-N-CA 123.259 0.624 . . . . 0.0 109.891 -179.771 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' I' I ' 24' ' ' VAL . . . . . 0.846 HG12 ' H ' ' I' ' 25' ' ' GLY . 57.3 t -76.58 -169.96 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.757 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 179.568 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' I' I ' 25' ' ' GLY . . . . . 0.846 ' H ' HG12 ' I' ' 24' ' ' VAL . . . -68.81 49.72 0.49 Allowed Glycine 0 CA--C 1.531 1.054 0 CA-C-N 118.541 0.61 . . . . 0.0 112.485 -178.457 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 8.5 p -69.63 137.67 52.42 Favored 'General case' 0 C--N 1.33 -0.254 0 N-CA-C 109.166 -0.679 . . . . 0.0 109.166 177.856 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 35.0 t30 -69.57 94.74 0.79 Allowed 'General case' 0 CA--C 1.531 0.234 0 N-CA-C 107.676 -1.231 . . . . 0.0 107.676 177.534 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -91.8 117.84 30.15 Favored 'General case' 0 N--CA 1.478 0.936 0 N-CA-C 109.722 -0.473 . . . . 0.0 109.722 -179.395 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -62.37 -133.19 0.01 OUTLIER Glycine 0 CA--C 1.532 1.14 0 N-CA-C 110.613 -0.995 . . . . 0.0 110.613 178.96 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -115.22 126.54 54.68 Favored 'General case' 0 N--CA 1.474 0.737 0 C-N-CA 123.031 0.532 . . . . 0.0 109.697 179.246 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 69.5 mt -89.46 135.94 24.81 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.657 0 N-CA-C 107.552 -1.277 . . . . 0.0 107.552 178.784 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 37.7 mt -137.44 139.21 43.98 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.28 0 N-CA-C 109.004 -0.739 . . . . 0.0 109.004 179.739 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.24 57.99 13.3 Favored Glycine 0 CA--C 1.529 0.959 0 CA-C-N 115.978 -0.555 . . . . 0.0 112.562 178.908 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 23.1 tp -105.71 131.95 52.44 Favored 'General case' 0 N--CA 1.485 1.298 0 N-CA-C 107.531 -1.285 . . . . 0.0 107.531 177.839 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 22.1 ttt -137.3 147.53 45.72 Favored 'General case' 0 N--CA 1.475 0.783 0 N-CA-C 107.997 -1.112 . . . . 0.0 107.997 178.877 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 61.3 t -156.66 158.2 3.38 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.466 0 N-CA-C 106.623 -1.621 . . . . 0.0 106.623 -179.094 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.63 71.57 0.7 Allowed Glycine 0 C--N 1.308 -1.011 0 CA-C-N 115.953 -0.567 . . . . 0.0 112.376 177.556 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' I' I ' 38' ' ' GLY . . . . . 0.485 ' C ' HE22 ' I' ' 15' ' ' GLN . . . 167.72 -165.68 38.85 Favored Glycine 0 C--O 1.211 -1.337 0 N-CA-C 110.603 -0.999 . . . . 0.0 110.603 178.697 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 18.9 m -128.26 148.4 32.77 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.003 0 C-N-CA 122.831 0.452 . . . . 0.0 109.949 179.965 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 8.9 t . . . . . 0 CA--C 1.535 0.387 0 CA-C-O 118.104 -0.95 . . . . 0.0 110.738 178.824 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 76.6 m-85 . . . . . 0 N--CA 1.474 0.74 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 72.4 mtp180 -144.29 141.82 30.04 Favored 'General case' 0 N--CA 1.483 1.207 0 N-CA-C 109.035 -0.728 . . . . 0.0 109.035 179.866 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 77.2 m80 -149.72 118.51 6.62 Favored 'General case' 0 N--CA 1.472 0.655 0 N-CA-C 108.763 -0.828 . . . . 0.0 108.763 179.037 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 12.2 m-20 -66.83 149.5 50.49 Favored 'General case' 0 CA--C 1.531 0.242 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.193 -179.395 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 7.9 t -167.53 170.08 11.52 Favored 'General case' 0 N--CA 1.473 0.682 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 178.613 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 123.47 24.44 1.95 Allowed Glycine 0 N--CA 1.487 2.051 0 N-CA-C 112.089 -0.405 . . . . 0.0 112.089 179.466 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 41.0 p90 -56.59 128.26 35.4 Favored 'General case' 0 N--CA 1.473 0.714 0 N-CA-C 112.136 0.421 . . . . 0.0 112.136 -179.868 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 46.1 mt-10 -84.61 154.49 22.54 Favored 'General case' 0 N--CA 1.468 0.465 0 N-CA-C 108.847 -0.797 . . . . 0.0 108.847 178.256 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -154.03 129.18 1.54 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 N-CA-C 108.091 -1.077 . . . . 0.0 108.091 178.855 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 51.5 m-70 -134.5 144.77 48.24 Favored 'General case' 0 N--CA 1.487 1.409 0 CA-C-N 118.567 0.621 . . . . 0.0 110.729 -178.951 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 6.2 t60 -164.5 98.38 0.8 Allowed 'General case' 0 N--CA 1.482 1.172 0 CA-C-N 116.744 -0.207 . . . . 0.0 111.204 179.581 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 33.1 mt-30 -103.03 -172.65 2.15 Favored 'General case' 0 CA--C 1.506 -0.745 0 N-CA-C 108.191 -1.04 . . . . 0.0 108.191 179.338 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -167.25 98.17 0.51 Allowed 'General case' 0 N--CA 1.47 0.531 0 CA-C-N 115.084 -0.962 . . . . 0.0 109.366 178.766 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.564 HD12 ' N ' ' A' ' 17' ' ' LEU . 4.9 mp -106.69 162.44 13.76 Favored 'General case' 0 N--CA 1.485 1.303 0 N-CA-C 108.364 -0.976 . . . . 0.0 108.364 179.808 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 55.3 t -142.42 118.63 5.98 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.275 0 CA-C-O 118.804 -0.617 . . . . 0.0 109.899 179.29 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 54.2 m-85 -70.41 158.7 35.53 Favored 'General case' 0 N--CA 1.479 1.006 0 N-CA-C 107.812 -1.181 . . . . 0.0 107.812 177.07 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 15.0 t80 -171.0 -58.75 0.02 OUTLIER 'General case' 0 N--CA 1.483 1.198 0 CA-C-O 122.435 1.112 . . . . 0.0 109.546 179.244 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.33 90.56 0.0 OUTLIER 'General case' 0 N--CA 1.458 -0.073 0 CA-C-N 113.845 -1.525 . . . . 0.0 112.818 -178.113 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 53.6 tt0 -62.88 155.34 27.39 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 115.238 -0.892 . . . . 0.0 110.463 178.952 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 18.1 m-20 -136.51 134.71 37.85 Favored 'General case' 0 N--CA 1.48 1.071 0 C-N-CA 122.967 0.507 . . . . 0.0 109.983 179.851 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 16.2 t -84.74 -117.05 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.763 0 N-CA-C 108.173 -1.047 . . . . 0.0 108.173 179.296 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -107.4 53.27 0.61 Allowed Glycine 0 N--CA 1.474 1.172 0 N-CA-C 111.178 -0.769 . . . . 0.0 111.178 179.867 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 88.7 p -77.04 126.55 31.15 Favored 'General case' 0 N--CA 1.465 0.311 0 N-CA-C 109.023 -0.732 . . . . 0.0 109.023 178.398 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 1.8 t-20 -67.18 100.03 0.74 Allowed 'General case' 0 N--CA 1.472 0.656 0 N-CA-C 108.615 -0.883 . . . . 0.0 108.615 178.664 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 67.3 mttm -94.01 128.26 40.25 Favored 'General case' 0 N--CA 1.479 1.012 0 N-CA-C 109.634 -0.506 . . . . 0.0 109.634 -179.451 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.28 -133.26 0.01 OUTLIER Glycine 0 CA--C 1.53 0.985 0 N-CA-C 110.398 -1.081 . . . . 0.0 110.398 179.11 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.34 127.78 43.32 Favored 'General case' 0 N--CA 1.484 1.243 0 CA-C-N 117.096 0.448 . . . . 0.0 110.178 179.356 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 30.3 mt -91.9 160.52 2.68 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.648 0 N-CA-C 106.824 -1.547 . . . . 0.0 106.824 178.157 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 38.0 mt -138.27 94.14 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.766 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 -179.065 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 53.5 104.82 0.01 OUTLIER Glycine 0 CA--C 1.531 1.085 0 CA-C-N 115.899 -0.592 . . . . 0.0 114.192 176.621 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 91.1 mt -72.22 155.2 40.48 Favored 'General case' 0 N--CA 1.469 0.512 0 N-CA-C 107.502 -1.295 . . . . 0.0 107.502 176.51 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 2.2 ttp -143.84 139.3 29.21 Favored 'General case' 0 N--CA 1.473 0.725 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 178.943 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 59.1 t -159.23 150.05 6.96 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.261 0 N-CA-C 106.714 -1.587 . . . . 0.0 106.714 -179.229 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 54.78 75.15 0.25 Allowed Glycine 0 C--N 1.314 -0.667 0 N-CA-C 111.823 -0.511 . . . . 0.0 111.823 177.909 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 174.14 -148.97 10.33 Favored Glycine 0 CA--C 1.52 0.36 0 N-CA-C 110.974 -0.85 . . . . 0.0 110.974 179.928 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 30.9 m -134.81 146.0 31.44 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.906 0 C-N-CA 122.599 0.36 . . . . 0.0 110.373 -179.72 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 19.6 t . . . . . 0 C--O 1.221 -0.428 0 CA-C-O 117.59 -1.195 . . . . 0.0 110.986 179.153 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 77.1 m-85 . . . . . 0 N--CA 1.473 0.712 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 72.0 mtp180 -144.33 141.61 29.87 Favored 'General case' 0 N--CA 1.48 1.071 0 N-CA-C 108.999 -0.741 . . . . 0.0 108.999 179.955 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 77.2 m80 -149.51 118.65 6.77 Favored 'General case' 0 N--CA 1.474 0.742 0 N-CA-C 108.903 -0.777 . . . . 0.0 108.903 179.04 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 7' ' ' ASP . . . . . . . . . . . . . 12.4 m-20 -66.87 149.03 51.17 Favored 'General case' 0 CA--C 1.532 0.261 0 CA-C-N 116.411 -0.359 . . . . 0.0 111.236 -179.399 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 8' ' ' SER . . . . . . . . . . . . . 7.9 t -167.21 170.21 11.91 Favored 'General case' 0 N--CA 1.471 0.613 0 N-CA-C 109.288 -0.634 . . . . 0.0 109.288 178.459 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 123.43 24.4 1.97 Allowed Glycine 0 N--CA 1.486 2.023 0 N-CA-C 111.982 -0.447 . . . . 0.0 111.982 179.416 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 40.6 p90 -56.63 128.37 36.01 Favored 'General case' 0 N--CA 1.471 0.581 0 N-CA-C 112.091 0.404 . . . . 0.0 112.091 -179.775 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 46.1 mt-10 -84.69 154.54 22.41 Favored 'General case' 0 N--CA 1.469 0.498 0 N-CA-C 108.911 -0.774 . . . . 0.0 108.911 178.327 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -154.01 129.04 1.5 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 N-CA-C 108.173 -1.047 . . . . 0.0 108.173 178.861 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 51.4 m-70 -134.35 144.94 48.54 Favored 'General case' 0 N--CA 1.488 1.429 0 CA-C-N 118.475 0.579 . . . . 0.0 110.777 -178.95 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 6.2 t60 -164.66 98.16 0.78 Allowed 'General case' 0 N--CA 1.484 1.243 0 CA-C-N 116.697 -0.229 . . . . 0.0 111.189 179.596 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 33.1 mt-30 -102.84 -172.95 2.21 Favored 'General case' 0 CA--C 1.506 -0.743 0 N-CA-C 108.135 -1.061 . . . . 0.0 108.135 179.415 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -167.08 97.94 0.52 Allowed 'General case' 0 N--CA 1.47 0.558 0 CA-C-N 115.034 -0.984 . . . . 0.0 109.309 178.898 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 17' ' ' LEU . . . . . 0.571 ' N ' HD12 ' B' ' 17' ' ' LEU . 4.9 mp -106.63 162.19 13.97 Favored 'General case' 0 N--CA 1.486 1.329 0 N-CA-C 108.373 -0.973 . . . . 0.0 108.373 179.819 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 56.8 t -142.31 118.35 5.98 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.243 0 CA-C-O 118.873 -0.584 . . . . 0.0 109.924 179.309 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 56.0 m-85 -70.69 158.81 35.6 Favored 'General case' 0 N--CA 1.478 0.93 0 N-CA-C 107.671 -1.233 . . . . 0.0 107.671 177.036 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 16.0 t80 -171.73 -57.98 0.02 OUTLIER 'General case' 0 N--CA 1.481 1.102 0 CA-C-O 122.254 1.026 . . . . 0.0 109.541 179.233 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.54 90.8 0.0 OUTLIER 'General case' 0 C--O 1.231 0.103 0 CA-C-N 114.1 -1.409 . . . . 0.0 112.67 -178.169 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 53.5 tt0 -63.11 155.34 28.23 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 115.274 -0.875 . . . . 0.0 110.495 179.035 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 18.0 m-20 -136.46 134.91 38.16 Favored 'General case' 0 N--CA 1.481 1.088 0 C-N-CA 122.991 0.516 . . . . 0.0 110.007 179.875 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 16.1 t -85.21 -117.13 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.475 0.795 0 N-CA-C 108.331 -0.988 . . . . 0.0 108.331 179.282 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -106.66 52.74 0.66 Allowed Glycine 0 N--CA 1.476 1.306 0 N-CA-C 111.14 -0.784 . . . . 0.0 111.14 179.915 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 89.5 p -77.02 126.22 30.61 Favored 'General case' 0 N--CA 1.466 0.352 0 N-CA-C 109.207 -0.664 . . . . 0.0 109.207 178.421 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 1.8 t-20 -67.15 100.17 0.75 Allowed 'General case' 0 N--CA 1.473 0.676 0 N-CA-C 108.588 -0.893 . . . . 0.0 108.588 178.674 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 67.4 mttm -94.03 128.22 40.26 Favored 'General case' 0 N--CA 1.479 1.01 0 N-CA-C 109.684 -0.487 . . . . 0.0 109.684 -179.469 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.16 -132.94 0.01 OUTLIER Glycine 0 CA--C 1.53 0.991 0 N-CA-C 110.493 -1.043 . . . . 0.0 110.493 179.067 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.63 127.83 42.99 Favored 'General case' 0 N--CA 1.485 1.286 0 CA-C-N 117.192 0.496 . . . . 0.0 110.09 179.355 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 29.8 mt -92.03 160.3 2.7 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.69 0 N-CA-C 106.896 -1.52 . . . . 0.0 106.896 178.093 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 37.5 mt -138.0 94.05 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.684 0 N-CA-C 109.908 -0.405 . . . . 0.0 109.908 -178.969 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 53.47 104.91 0.01 OUTLIER Glycine 0 CA--C 1.53 1.02 0 CA-C-N 115.899 -0.591 . . . . 0.0 114.229 176.648 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 90.9 mt -72.29 155.26 40.38 Favored 'General case' 0 N--CA 1.471 0.578 0 N-CA-C 107.481 -1.303 . . . . 0.0 107.481 176.524 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 2.2 ttp -143.73 139.02 29.25 Favored 'General case' 0 N--CA 1.476 0.859 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 178.954 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 59.0 t -159.05 149.96 7.17 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.274 0 N-CA-C 106.58 -1.637 . . . . 0.0 106.58 -179.23 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 54.83 75.12 0.25 Allowed Glycine 0 C--N 1.314 -0.647 0 N-CA-C 111.786 -0.526 . . . . 0.0 111.786 177.778 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 174.06 -148.89 10.31 Favored Glycine 0 CA--C 1.521 0.452 0 N-CA-C 110.989 -0.844 . . . . 0.0 110.989 179.869 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 31.5 m -134.83 145.99 31.44 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.942 0 C-N-CA 122.566 0.346 . . . . 0.0 110.35 -179.717 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 20.0 t . . . . . 0 C--O 1.22 -0.448 0 CA-C-O 117.636 -1.173 . . . . 0.0 110.985 179.136 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 76.5 m-85 . . . . . 0 N--CA 1.473 0.72 0 N-CA-C 109.9 -0.407 . . . . 0.0 109.9 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 72.4 mtp180 -144.19 141.56 29.99 Favored 'General case' 0 N--CA 1.483 1.221 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 179.946 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 77.1 m80 -149.49 118.59 6.75 Favored 'General case' 0 N--CA 1.473 0.705 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 179.053 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' C' C ' 7' ' ' ASP . . . . . . . . . . . . . 11.7 m-20 -66.88 149.08 51.1 Favored 'General case' 0 N--CA 1.464 0.251 0 CA-C-N 116.337 -0.392 . . . . 0.0 111.25 -179.416 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' C' C ' 8' ' ' SER . . . . . . . . . . . . . 7.9 t -167.18 170.18 11.99 Favored 'General case' 0 N--CA 1.472 0.642 0 N-CA-C 109.188 -0.671 . . . . 0.0 109.188 178.493 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 123.45 24.42 1.96 Allowed Glycine 0 N--CA 1.486 2.023 0 N-CA-C 111.944 -0.462 . . . . 0.0 111.944 179.37 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 40.7 p90 -56.57 128.21 35.13 Favored 'General case' 0 N--CA 1.472 0.628 0 N-CA-C 112.066 0.395 . . . . 0.0 112.066 -179.836 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 46.0 mt-10 -84.54 154.54 22.59 Favored 'General case' 0 N--CA 1.469 0.51 0 N-CA-C 108.881 -0.785 . . . . 0.0 108.881 178.252 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -154.07 129.02 1.48 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 178.826 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 51.3 m-70 -134.24 144.96 48.71 Favored 'General case' 0 N--CA 1.487 1.411 0 CA-C-N 118.428 0.558 . . . . 0.0 110.827 -178.954 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 6.2 t60 -164.75 98.35 0.77 Allowed 'General case' 0 N--CA 1.484 1.259 0 CA-C-N 116.823 -0.171 . . . . 0.0 111.254 179.6 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 33.0 mt-30 -103.09 -172.73 2.16 Favored 'General case' 0 CA--C 1.503 -0.851 0 N-CA-C 108.244 -1.021 . . . . 0.0 108.244 179.322 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -167.18 98.11 0.51 Allowed 'General case' 0 CA--C 1.538 0.502 0 CA-C-N 114.973 -1.012 . . . . 0.0 109.333 178.861 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' C' C ' 17' ' ' LEU . . . . . 0.563 ' N ' HD12 ' C' ' 17' ' ' LEU . 4.9 mp -106.72 162.19 13.99 Favored 'General case' 0 N--CA 1.486 1.344 0 N-CA-C 108.291 -1.003 . . . . 0.0 108.291 179.76 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 57.5 t -142.24 118.41 6.18 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.296 0 CA-C-O 118.934 -0.555 . . . . 0.0 109.944 179.285 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 55.7 m-85 -70.64 158.82 35.53 Favored 'General case' 0 N--CA 1.478 0.946 0 N-CA-C 107.754 -1.202 . . . . 0.0 107.754 176.981 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 16.0 t80 -171.71 -57.94 0.02 OUTLIER 'General case' 0 N--CA 1.479 0.977 0 CA-C-O 122.299 1.047 . . . . 0.0 109.573 179.176 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.6 90.82 0.0 OUTLIER 'General case' 0 C--N 1.338 0.087 0 CA-C-N 114.137 -1.392 . . . . 0.0 112.653 -178.171 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 53.6 tt0 -63.11 155.34 28.24 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 115.226 -0.897 . . . . 0.0 110.462 179.04 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 17.9 m-20 -136.43 134.94 38.25 Favored 'General case' 0 N--CA 1.48 1.069 0 C-N-CA 122.898 0.479 . . . . 0.0 110.002 179.83 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 16.1 t -85.08 -117.23 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.475 0.796 0 N-CA-C 108.344 -0.984 . . . . 0.0 108.344 179.273 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -106.54 52.68 0.66 Allowed Glycine 0 N--CA 1.476 1.327 0 N-CA-C 111.144 -0.782 . . . . 0.0 111.144 179.852 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 89.3 p -77.1 126.45 30.98 Favored 'General case' 0 N--CA 1.466 0.364 0 N-CA-C 109.151 -0.685 . . . . 0.0 109.151 178.494 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 1.8 t-20 -67.24 100.17 0.77 Allowed 'General case' 0 N--CA 1.471 0.615 0 N-CA-C 108.627 -0.879 . . . . 0.0 108.627 178.619 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 67.3 mttm -94.09 128.23 40.35 Favored 'General case' 0 N--CA 1.479 1.016 0 N-CA-C 109.656 -0.498 . . . . 0.0 109.656 -179.41 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.29 -133.09 0.01 OUTLIER Glycine 0 CA--C 1.531 1.039 0 N-CA-C 110.481 -1.047 . . . . 0.0 110.481 179.139 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.37 127.52 42.79 Favored 'General case' 0 N--CA 1.486 1.332 0 CA-C-N 117.195 0.498 . . . . 0.0 110.177 179.379 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 29.6 mt -91.78 160.25 2.71 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.642 0 N-CA-C 106.887 -1.523 . . . . 0.0 106.887 178.063 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 36.9 mt -138.0 94.0 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.696 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 -178.964 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 53.52 104.93 0.01 OUTLIER Glycine 0 CA--C 1.531 1.067 0 CA-C-N 115.885 -0.598 . . . . 0.0 114.118 176.608 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 90.9 mt -72.21 155.17 40.52 Favored 'General case' 0 N--CA 1.47 0.563 0 N-CA-C 107.477 -1.305 . . . . 0.0 107.477 176.463 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 2.2 ttp -143.54 139.09 29.59 Favored 'General case' 0 N--CA 1.473 0.722 0 N-CA-C 108.812 -0.81 . . . . 0.0 108.812 178.9 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 59.3 t -159.2 150.08 6.98 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.258 0 N-CA-C 106.659 -1.608 . . . . 0.0 106.659 -179.279 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 54.84 75.04 0.25 Allowed Glycine 0 N--CA 1.465 0.633 0 N-CA-C 111.775 -0.53 . . . . 0.0 111.775 177.837 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 174.04 -148.9 10.32 Favored Glycine 0 CA--C 1.521 0.411 0 N-CA-C 110.967 -0.853 . . . . 0.0 110.967 179.8 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 31.3 m -134.8 145.97 31.5 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.97 0 C-N-CA 122.535 0.334 . . . . 0.0 110.481 -179.739 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 20.1 t . . . . . 0 C--O 1.222 -0.392 0 CA-C-O 117.616 -1.183 . . . . 0.0 110.873 179.116 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 84.5 m-85 . . . . . 0 N--CA 1.472 0.651 0 N-CA-C 108.346 -0.983 . . . . 0.0 108.346 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' D' D ' 5' ' ' ARG . . . . . . . . . . . . . 71.9 mtp180 -147.73 141.4 25.58 Favored 'General case' 0 N--CA 1.472 0.625 0 N-CA-C 109.037 -0.727 . . . . 0.0 109.037 179.779 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 77.5 m80 -149.2 123.46 9.57 Favored 'General case' 0 CA--C 1.541 0.627 0 N-CA-C 107.705 -1.22 . . . . 0.0 107.705 175.53 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' D' D ' 7' ' ' ASP . . . . . . . . . . . . . 7.9 m-20 -63.33 133.5 54.22 Favored 'General case' 0 C--N 1.322 -0.591 0 C-N-CA 126.813 2.045 . . . . 0.0 114.543 176.425 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' D' D ' 8' ' ' SER . . . . . . . . . . . . . 7.0 t -154.22 173.1 16.58 Favored 'General case' 0 N--CA 1.478 0.943 0 CA-C-N 118.468 0.576 . . . . 0.0 110.05 176.977 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 124.48 20.51 2.38 Favored Glycine 0 N--CA 1.484 1.874 0 N-CA-C 112.185 -0.366 . . . . 0.0 112.185 176.649 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 36.2 p90 -55.55 130.46 42.96 Favored 'General case' 0 CA--C 1.546 0.803 0 CA-C-O 121.089 0.471 . . . . 0.0 112.026 -177.341 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 46.2 mt-10 -84.89 152.25 23.69 Favored 'General case' 0 N--CA 1.474 0.755 0 N-CA-C 109.422 -0.584 . . . . 0.0 109.422 177.628 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -149.53 130.09 4.42 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.411 0 N-CA-C 108.158 -1.053 . . . . 0.0 108.158 175.389 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 49.4 m-70 -129.49 148.52 51.4 Favored 'General case' 0 N--CA 1.48 1.062 0 CA-C-N 118.016 0.371 . . . . 0.0 111.021 176.687 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 6.3 t60 -165.0 104.78 0.78 Allowed 'General case' 0 N--CA 1.484 1.256 0 N-CA-C 109.716 -0.476 . . . . 0.0 109.716 173.618 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 33.1 mt-30 -106.3 -175.7 2.87 Favored 'General case' 0 CA--C 1.498 -1.056 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 178.602 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' D' D ' 16' ' ' LYS . . . . . 0.414 ' C ' HD12 ' D' ' 17' ' ' LEU . 88.6 tttt -163.54 106.28 0.98 Allowed 'General case' 0 CA--C 1.536 0.423 0 N-CA-C 107.493 -1.299 . . . . 0.0 107.493 175.514 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' D' D ' 17' ' ' LEU . . . . . 0.498 ' N ' HD12 ' D' ' 17' ' ' LEU . 5.9 mp -112.94 162.18 16.14 Favored 'General case' 0 N--CA 1.487 1.381 0 N-CA-C 107.503 -1.295 . . . . 0.0 107.503 179.01 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 48.7 t -141.24 123.44 14.59 Favored 'Isoleucine or valine' 0 C--N 1.362 1.134 0 N-CA-C 109.084 -0.71 . . . . 0.0 109.084 175.344 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 80.4 m-85 -62.85 151.37 39.23 Favored 'General case' 0 C--N 1.349 0.582 0 C-N-CA 124.435 1.094 . . . . 0.0 110.703 170.11 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 11.4 t80 -170.23 -66.84 0.02 OUTLIER 'General case' 0 C--N 1.319 -0.723 0 N-CA-C 107.72 -1.215 . . . . 0.0 107.72 179.31 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -38.37 95.52 0.01 OUTLIER 'General case' 0 N--CA 1.451 -0.38 0 CA-C-N 113.964 -1.471 . . . . 0.0 111.672 -175.501 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 53.6 tt0 -65.39 156.03 33.53 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 114.072 -1.422 . . . . 0.0 110.104 178.587 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 17.9 m-20 -136.49 138.89 41.88 Favored 'General case' 0 N--CA 1.477 0.898 0 N-CA-C 109.256 -0.646 . . . . 0.0 109.256 178.501 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' D' D ' 24' ' ' VAL . . . . . . . . . . . . . 17.3 t -88.5 -120.4 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.482 1.168 0 N-CA-C 107.602 -1.259 . . . . 0.0 107.602 179.607 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . -110.35 61.77 0.3 Allowed Glycine 0 C--N 1.373 2.585 0 C-N-CA 117.706 -2.188 . . . . 0.0 109.162 178.44 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 94.5 p -67.91 121.74 16.67 Favored 'General case' 0 C--O 1.243 0.763 0 CA-C-O 116.524 -1.703 . . . . 0.0 112.307 168.7 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 1.9 t-20 -62.73 101.75 0.28 Allowed 'General case' 0 N--CA 1.476 0.845 0 CA-C-N 121.519 1.963 . . . . 0.0 109.476 172.984 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 67.1 mttm -95.95 127.37 41.91 Favored 'General case' 0 N--CA 1.485 1.277 0 CA-C-N 119.243 0.928 . . . . 0.0 109.102 178.377 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -55.84 -135.05 0.0 OUTLIER Glycine 0 CA--C 1.527 0.803 0 C-N-CA 123.573 0.606 . . . . 0.0 112.443 174.696 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.45 130.94 48.31 Favored 'General case' 0 C--N 1.373 1.62 0 CA-C-N 114.968 -0.616 . . . . 0.0 110.283 175.995 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 35.9 mt -92.08 162.32 2.43 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.455 0 N-CA-C 106.475 -1.676 . . . . 0.0 106.475 177.673 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . 0.267 41.6 mt -140.6 105.49 1.84 Allowed 'Isoleucine or valine' 0 C--N 1.359 1.015 0 N-CA-C 106.728 -1.582 . . . . 0.0 106.728 173.053 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.49 96.24 0.01 OUTLIER Glycine 0 CA--C 1.533 1.171 0 CA-C-O 115.935 -2.592 . . . . 0.0 112.682 169.063 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 95.2 mt -69.65 158.56 35.1 Favored 'General case' 0 N--CA 1.481 1.086 0 CA-C-N 122.731 3.265 . . . . 0.0 107.441 176.507 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 2.9 ttp -143.82 149.53 37.14 Favored 'General case' 0 N--CA 1.481 1.089 0 N-CA-C 106.352 -1.722 . . . . 0.0 106.352 174.293 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 89.6 t -165.18 154.09 1.91 Allowed 'Isoleucine or valine' 0 C--O 1.249 1.032 0 N-CA-C 105.41 -2.07 . . . . 0.0 105.41 177.601 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 60.83 66.74 2.5 Favored Glycine 0 N--CA 1.442 -0.953 0 C-N-CA 117.326 -2.369 . . . . 0.0 113.981 174.565 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 168.41 -147.85 11.88 Favored Glycine 0 N--CA 1.466 0.674 0 CA-C-O 117.0 -2.0 . . . . 0.0 112.492 -178.698 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 31.1 m -131.19 145.42 35.39 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.271 0 CA-C-N 119.958 1.879 . . . . 0.0 110.588 -176.988 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 18.0 t . . . . . 0 C--O 1.208 -1.128 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 173.591 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 77.1 m-85 . . . . . 0 N--CA 1.473 0.7 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' E' E ' 5' ' ' ARG . . . . . . . . . . . . . 71.8 mtp180 -144.27 142.32 30.38 Favored 'General case' 0 N--CA 1.476 0.826 0 N-CA-C 109.234 -0.654 . . . . 0.0 109.234 179.666 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 77.3 m80 -150.11 117.62 6.12 Favored 'General case' 0 N--CA 1.475 0.787 0 N-CA-C 109.049 -0.723 . . . . 0.0 109.049 179.073 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' E' E ' 7' ' ' ASP . . . . . . . . . . . . . 12.1 m-20 -65.85 149.19 50.58 Favored 'General case' 0 N--CA 1.463 0.205 0 O-C-N 123.276 0.36 . . . . 0.0 111.482 -179.409 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' E' E ' 8' ' ' SER . . . . . . . . . . . . . 7.2 t -167.6 171.34 10.34 Favored 'General case' 0 N--CA 1.476 0.836 0 N-CA-C 109.219 -0.66 . . . . 0.0 109.219 178.03 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 123.9 23.78 1.98 Allowed Glycine 0 N--CA 1.481 1.655 0 N-CA-C 111.876 -0.489 . . . . 0.0 111.876 179.024 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 37.1 p90 -55.82 127.53 30.64 Favored 'General case' 0 CA--C 1.543 0.694 0 N-CA-C 112.703 0.631 . . . . 0.0 112.703 -179.076 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 46.4 mt-10 -83.05 155.2 24.03 Favored 'General case' 0 N--CA 1.475 0.79 0 N-CA-C 109.234 -0.654 . . . . 0.0 109.234 177.774 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -155.69 127.88 1.02 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.498 0 N-CA-C 108.22 -1.03 . . . . 0.0 108.22 178.622 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 48.5 m-70 -134.29 143.1 47.54 Favored 'General case' 0 N--CA 1.478 0.97 0 C-N-CA 122.491 0.316 . . . . 0.0 111.099 -177.976 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 6.1 t60 -163.52 98.5 0.9 Allowed 'General case' 0 N--CA 1.486 1.359 0 CA-C-O 119.735 -0.174 . . . . 0.0 111.247 179.693 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 33.1 mt-30 -102.66 -172.7 2.17 Favored 'General case' 0 CA--C 1.506 -0.736 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 179.464 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -167.16 98.13 0.52 Allowed 'General case' 0 CA--C 1.54 0.59 0 CA-C-N 114.97 -1.014 . . . . 0.0 109.259 178.617 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' E' E ' 17' ' ' LEU . . . . . 0.537 ' N ' HD12 ' E' ' 17' ' ' LEU . 4.9 mp -106.43 161.44 14.58 Favored 'General case' 0 N--CA 1.487 1.411 0 N-CA-C 108.771 -0.826 . . . . 0.0 108.771 -179.95 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 42.0 t -142.4 117.82 5.39 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.379 0 C-N-CA 122.549 0.339 . . . . 0.0 110.463 178.896 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 54.9 m-85 -69.72 156.54 38.83 Favored 'General case' 0 C--N 1.356 0.891 0 N-CA-C 107.636 -1.246 . . . . 0.0 107.636 176.449 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 14.2 t80 -173.23 -56.16 0.02 OUTLIER 'General case' 0 N--CA 1.482 1.129 0 CA-C-O 121.731 0.777 . . . . 0.0 110.018 179.242 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.84 89.1 0.0 OUTLIER 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 114.364 -1.289 . . . . 0.0 112.689 -179.095 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 54.0 tt0 -61.69 155.08 23.55 Favored 'General case' 0 N--CA 1.47 0.55 0 CA-C-N 115.131 -0.94 . . . . 0.0 110.604 179.489 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 17.6 m-20 -136.46 134.54 37.77 Favored 'General case' 0 N--CA 1.479 0.978 0 C-N-CA 122.918 0.487 . . . . 0.0 110.301 -179.931 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 20.2 t -84.85 -116.64 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.873 0 N-CA-C 108.449 -0.945 . . . . 0.0 108.449 179.209 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . -106.84 52.98 0.64 Allowed Glycine 0 C--N 1.346 1.138 0 N-CA-C 111.255 -0.738 . . . . 0.0 111.255 -179.987 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 89.2 p -77.0 125.99 30.24 Favored 'General case' 0 N--CA 1.472 0.664 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 178.169 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 1.8 t-20 -66.66 100.22 0.67 Allowed 'General case' 0 N--CA 1.472 0.633 0 N-CA-C 108.108 -1.071 . . . . 0.0 108.108 178.528 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 66.6 mttm -94.31 127.15 40.01 Favored 'General case' 0 N--CA 1.481 1.101 0 N-CA-C 109.149 -0.685 . . . . 0.0 109.149 -179.463 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.84 -130.58 0.01 OUTLIER Glycine 0 CA--C 1.533 1.218 0 N-CA-C 110.454 -1.058 . . . . 0.0 110.454 179.31 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -129.25 127.56 41.49 Favored 'General case' 0 N--CA 1.484 1.265 0 CA-C-N 117.439 0.62 . . . . 0.0 111.324 -179.906 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 27.8 mt -90.91 161.01 2.65 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.499 0 N-CA-C 106.796 -1.557 . . . . 0.0 106.796 178.152 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 37.3 mt -138.75 94.5 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.479 0.979 0 N-CA-C 109.606 -0.516 . . . . 0.0 109.606 179.872 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 53.62 104.37 0.01 OUTLIER Glycine 0 CA--C 1.531 1.037 0 CA-C-N 116.101 -0.499 . . . . 0.0 114.204 176.791 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 93.8 mt -71.52 155.64 40.34 Favored 'General case' 0 N--CA 1.473 0.682 0 N-CA-C 107.49 -1.3 . . . . 0.0 107.49 176.516 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 2.4 ttp -143.81 139.99 29.62 Favored 'General case' 0 N--CA 1.479 1.019 0 N-CA-C 108.301 -1.0 . . . . 0.0 108.301 178.787 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 65.6 t -160.27 148.8 6.11 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.456 0 N-CA-C 106.618 -1.623 . . . . 0.0 106.618 -179.058 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.15 75.32 0.24 Allowed Glycine 0 N--CA 1.464 0.516 0 N-CA-C 111.815 -0.514 . . . . 0.0 111.815 178.118 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 174.77 -146.95 8.77 Favored Glycine 0 C--O 1.221 -0.663 0 N-CA-C 111.207 -0.757 . . . . 0.0 111.207 179.881 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 29.8 m -136.69 145.15 30.73 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.794 0 CA-C-N 117.104 0.452 . . . . 0.0 109.808 -179.647 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 19.0 t . . . . . 0 CA--C 1.537 0.449 0 CA-C-O 117.576 -1.202 . . . . 0.0 111.153 179.183 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 77.0 m-85 . . . . . 0 N--CA 1.474 0.75 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' F' F ' 5' ' ' ARG . . . . . . . . . . . . . 72.0 mtp180 -144.11 142.15 30.43 Favored 'General case' 0 N--CA 1.478 0.954 0 N-CA-C 109.092 -0.707 . . . . 0.0 109.092 179.755 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 77.2 m80 -150.14 117.43 6.04 Favored 'General case' 0 N--CA 1.476 0.843 0 N-CA-C 108.983 -0.747 . . . . 0.0 108.983 179.093 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' F' F ' 7' ' ' ASP . . . . . . . . . . . . . 11.5 m-20 -65.74 149.07 50.73 Favored 'General case' 0 N--CA 1.464 0.247 0 O-C-N 123.327 0.392 . . . . 0.0 111.662 -179.433 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' F' F ' 8' ' ' SER . . . . . . . . . . . . . 7.1 t -167.38 171.43 10.58 Favored 'General case' 0 N--CA 1.476 0.87 0 N-CA-C 109.253 -0.647 . . . . 0.0 109.253 178.056 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 123.79 23.71 2.01 Favored Glycine 0 N--CA 1.482 1.746 0 N-CA-C 111.901 -0.48 . . . . 0.0 111.901 179.008 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 37.4 p90 -55.9 127.75 31.81 Favored 'General case' 0 CA--C 1.542 0.647 0 N-CA-C 112.717 0.636 . . . . 0.0 112.717 -179.113 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 46.4 mt-10 -83.21 155.25 23.81 Favored 'General case' 0 N--CA 1.475 0.779 0 N-CA-C 109.2 -0.667 . . . . 0.0 109.2 177.756 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -155.74 127.94 1.02 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.538 0 N-CA-C 108.218 -1.03 . . . . 0.0 108.218 178.551 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 49.0 m-70 -134.29 143.16 47.58 Favored 'General case' 0 N--CA 1.479 1.024 0 C-N-CA 122.419 0.288 . . . . 0.0 110.996 -177.871 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 6.1 t60 -163.81 99.12 0.88 Allowed 'General case' 0 N--CA 1.487 1.38 0 CA-C-N 116.85 -0.159 . . . . 0.0 111.252 179.677 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 33.0 mt-30 -103.58 -171.91 2.02 Favored 'General case' 0 CA--C 1.501 -0.921 0 N-CA-C 108.388 -0.967 . . . . 0.0 108.388 179.384 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -167.6 98.3 0.48 Allowed 'General case' 0 CA--C 1.54 0.59 0 CA-C-N 114.842 -1.072 . . . . 0.0 109.322 178.775 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' F' F ' 17' ' ' LEU . . . . . 0.529 ' N ' HD12 ' F' ' 17' ' ' LEU . 4.9 mp -106.45 161.45 14.58 Favored 'General case' 0 N--CA 1.487 1.415 0 N-CA-C 108.721 -0.844 . . . . 0.0 108.721 -179.967 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 41.6 t -142.32 117.96 5.64 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.378 0 C-N-CA 122.638 0.375 . . . . 0.0 110.478 178.921 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 55.2 m-85 -69.82 156.47 38.99 Favored 'General case' 0 C--N 1.357 0.906 0 N-CA-C 107.455 -1.313 . . . . 0.0 107.455 176.363 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 15.0 t80 -173.11 -56.09 0.02 OUTLIER 'General case' 0 N--CA 1.482 1.164 0 CA-C-O 121.743 0.783 . . . . 0.0 109.606 179.233 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.99 89.09 0.0 OUTLIER 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 114.46 -1.245 . . . . 0.0 112.76 -179.02 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 53.9 tt0 -61.6 155.19 22.95 Favored 'General case' 0 N--CA 1.472 0.659 0 CA-C-N 115.151 -0.931 . . . . 0.0 110.641 179.346 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 17.5 m-20 -136.66 134.73 37.59 Favored 'General case' 0 N--CA 1.479 1.006 0 C-N-CA 122.925 0.49 . . . . 0.0 110.345 -179.986 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' F' F ' 24' ' ' VAL . . . . . . . . . . . . . 19.3 t -85.08 -116.69 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.93 0 N-CA-C 108.525 -0.917 . . . . 0.0 108.525 179.241 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -106.6 52.61 0.67 Allowed Glycine 0 N--CA 1.477 1.42 0 N-CA-C 111.172 -0.771 . . . . 0.0 111.172 179.974 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 89.3 p -76.78 125.86 29.99 Favored 'General case' 0 N--CA 1.472 0.655 0 N-CA-C 109.271 -0.64 . . . . 0.0 109.271 178.176 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 1.9 t-20 -66.83 100.35 0.71 Allowed 'General case' 0 N--CA 1.471 0.603 0 N-CA-C 108.134 -1.061 . . . . 0.0 108.134 178.587 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 66.7 mttm -94.31 126.96 39.89 Favored 'General case' 0 N--CA 1.481 1.123 0 N-CA-C 109.169 -0.678 . . . . 0.0 109.169 -179.389 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.81 -130.96 0.01 OUTLIER Glycine 0 CA--C 1.532 1.155 0 N-CA-C 110.591 -1.004 . . . . 0.0 110.591 179.212 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.55 126.94 41.38 Favored 'General case' 0 N--CA 1.488 1.433 0 CA-C-N 117.4 0.6 . . . . 0.0 111.348 -179.765 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 28.1 mt -90.62 160.92 2.68 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.547 0 N-CA-C 106.694 -1.595 . . . . 0.0 106.694 178.033 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 36.8 mt -138.87 94.57 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.093 0 N-CA-C 109.613 -0.514 . . . . 0.0 109.613 179.822 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 53.69 104.3 0.01 OUTLIER Glycine 0 CA--C 1.531 1.075 0 CA-C-N 116.039 -0.528 . . . . 0.0 114.145 176.752 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 94.1 mt -71.47 155.93 40.03 Favored 'General case' 0 N--CA 1.471 0.62 0 N-CA-C 107.524 -1.287 . . . . 0.0 107.524 176.588 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 2.3 ttp -144.13 140.01 29.15 Favored 'General case' 0 N--CA 1.478 0.957 0 N-CA-C 108.691 -0.855 . . . . 0.0 108.691 178.708 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 65.0 t -160.3 148.95 6.08 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.447 0 N-CA-C 106.703 -1.591 . . . . 0.0 106.703 -178.973 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.16 75.25 0.25 Allowed Glycine 0 N--CA 1.464 0.551 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.812 178.038 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 174.77 -146.94 8.76 Favored Glycine 0 C--O 1.22 -0.738 0 N-CA-C 111.22 -0.752 . . . . 0.0 111.22 179.845 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 30.3 m -136.7 145.05 30.88 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.757 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 -179.644 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 18.7 t . . . . . 0 C--O 1.221 -0.418 0 CA-C-O 117.621 -1.18 . . . . 0.0 111.157 179.215 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 77.1 m-85 . . . . . 0 N--CA 1.472 0.668 0 N-CA-C 109.594 -0.521 . . . . 0.0 109.594 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' G' G ' 5' ' ' ARG . . . . . . . . . . . . . 72.4 mtp180 -144.56 141.94 29.83 Favored 'General case' 0 N--CA 1.48 1.053 0 N-CA-C 109.088 -0.708 . . . . 0.0 109.088 -179.799 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 77.1 m80 -149.85 118.75 6.66 Favored 'General case' 0 N--CA 1.475 0.797 0 N-CA-C 108.979 -0.749 . . . . 0.0 108.979 179.072 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 12.1 m-20 -68.1 144.85 54.87 Favored 'General case' 0 CA--C 1.537 0.467 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.878 -179.2 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' G' G ' 8' ' ' SER . . . . . . . . . . . . . 6.1 t -163.58 173.1 13.44 Favored 'General case' 0 N--CA 1.47 0.552 0 N-CA-C 109.068 -0.715 . . . . 0.0 109.068 178.089 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 123.4 23.12 2.19 Favored Glycine 0 N--CA 1.481 1.644 0 N-CA-C 111.712 -0.555 . . . . 0.0 111.712 178.936 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 40.5 p90 -56.18 127.68 31.87 Favored 'General case' 0 N--CA 1.473 0.718 0 N-CA-C 112.682 0.623 . . . . 0.0 112.682 -178.705 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 46.2 mt-10 -83.44 154.1 24.14 Favored 'General case' 0 N--CA 1.47 0.561 0 N-CA-C 109.632 -0.507 . . . . 0.0 109.632 178.307 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -155.68 128.07 1.05 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.933 0 N-CA-C 108.036 -1.098 . . . . 0.0 108.036 178.846 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 50.2 m-70 -133.66 144.15 49.01 Favored 'General case' 0 N--CA 1.475 0.801 0 CA-C-N 115.353 -0.84 . . . . 0.0 110.773 -178.238 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 30.5 t-80 -164.82 98.83 0.77 Allowed 'General case' 0 N--CA 1.483 1.204 0 CA-C-N 116.635 -0.257 . . . . 0.0 110.786 179.033 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 33.3 mt-30 -103.18 -172.32 2.1 Favored 'General case' 0 CA--C 1.506 -0.737 0 N-CA-C 108.358 -0.979 . . . . 0.0 108.358 179.578 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -167.29 98.31 0.51 Allowed 'General case' 0 CA--C 1.539 0.546 0 CA-C-N 115.051 -0.977 . . . . 0.0 109.367 178.7 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' G' G ' 17' ' ' LEU . . . . . 0.55 ' N ' HD12 ' G' ' 17' ' ' LEU . 5.4 mp -106.2 160.81 15.05 Favored 'General case' 0 N--CA 1.486 1.335 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 -179.908 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 40.4 t -143.59 117.95 3.84 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.001 0 C-N-CA 122.573 0.349 . . . . 0.0 110.235 178.753 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 49.0 m-85 -69.7 150.84 46.53 Favored 'General case' 0 C--N 1.37 1.487 0 N-CA-C 107.404 -1.332 . . . . 0.0 107.404 176.477 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 12.4 t80 -171.03 -55.9 0.02 OUTLIER 'General case' 0 N--CA 1.485 1.29 0 N-CA-C 110.025 -0.361 . . . . 0.0 110.025 179.957 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.88 90.61 0.0 OUTLIER 'General case' 0 C--N 1.325 -0.481 0 O-C-N 123.938 0.774 . . . . 0.0 112.267 179.986 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 53.7 tt0 -62.81 155.84 25.68 Favored 'General case' 0 N--CA 1.469 0.475 0 CA-C-N 114.838 -1.074 . . . . 0.0 109.718 179.03 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 18.0 m-20 -136.71 134.71 37.48 Favored 'General case' 0 N--CA 1.478 0.96 0 C-N-CA 122.782 0.433 . . . . 0.0 109.87 -179.939 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' G' G ' 24' ' ' VAL . . . . . . . . . . . . . 19.6 t -85.5 -116.02 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.894 0 N-CA-C 108.293 -1.003 . . . . 0.0 108.293 179.289 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -107.28 53.06 0.63 Allowed Glycine 0 N--CA 1.476 1.311 0 N-CA-C 111.286 -0.726 . . . . 0.0 111.286 -179.947 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 89.3 p -77.48 126.2 30.53 Favored 'General case' 0 N--CA 1.466 0.37 0 N-CA-C 109.152 -0.684 . . . . 0.0 109.152 178.139 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 1.9 t-20 -67.16 99.82 0.72 Allowed 'General case' 0 N--CA 1.469 0.495 0 N-CA-C 108.604 -0.887 . . . . 0.0 108.604 178.81 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 67.3 mttm -93.51 127.09 39.01 Favored 'General case' 0 N--CA 1.481 1.081 0 N-CA-C 109.512 -0.551 . . . . 0.0 109.512 -179.662 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.87 -128.71 0.01 OUTLIER Glycine 0 CA--C 1.527 0.801 0 N-CA-C 110.576 -1.01 . . . . 0.0 110.576 179.27 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.84 126.09 35.36 Favored 'General case' 0 CA--C 1.54 0.567 0 C-N-CA 122.814 0.446 . . . . 0.0 110.933 -179.361 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 37.7 mt -90.53 162.26 2.49 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.842 0 N-CA-C 107.0 -1.482 . . . . 0.0 107.0 178.239 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 40.8 mt -139.04 95.96 0.96 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.437 0 CA-C-N 119.714 1.143 . . . . 0.0 110.068 178.173 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 53.64 103.92 0.01 OUTLIER Glycine 0 CA--C 1.53 1.019 0 CA-C-N 116.026 -0.534 . . . . 0.0 114.106 176.818 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 92.3 mt -71.34 154.96 41.19 Favored 'General case' 0 N--CA 1.47 0.57 0 N-CA-C 107.772 -1.196 . . . . 0.0 107.772 176.717 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 2.6 ttp -143.48 140.46 30.34 Favored 'General case' 0 N--CA 1.474 0.756 0 N-CA-C 108.555 -0.906 . . . . 0.0 108.555 178.897 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 69.2 t -160.36 149.11 5.98 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.256 0 N-CA-C 106.636 -1.616 . . . . 0.0 106.636 -179.329 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.5 75.12 0.26 Allowed Glycine 0 N--CA 1.466 0.637 0 C-N-CA 121.012 -0.613 . . . . 0.0 112.04 177.494 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 173.92 -146.17 8.59 Favored Glycine 0 C--O 1.221 -0.708 0 N-CA-C 110.581 -1.008 . . . . 0.0 110.581 179.339 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 32.9 m -136.76 145.9 29.42 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.923 0 CA-C-N 117.002 0.401 . . . . 0.0 110.185 -179.413 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 20.7 t . . . . . 0 C--O 1.22 -0.467 0 CA-C-O 117.603 -1.189 . . . . 0.0 111.417 179.091 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 77.6 m-85 . . . . . 0 N--CA 1.472 0.666 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' H' H ' 5' ' ' ARG . . . . . . . . . . . . . 72.3 mtp180 -144.6 141.86 29.73 Favored 'General case' 0 N--CA 1.48 1.062 0 N-CA-C 109.13 -0.693 . . . . 0.0 109.13 -179.859 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 77.1 m80 -149.84 118.3 6.49 Favored 'General case' 0 N--CA 1.476 0.831 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 179.096 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 11.9 m-20 -67.54 144.89 55.4 Favored 'General case' 0 N--CA 1.468 0.453 0 O-C-N 123.426 0.453 . . . . 0.0 111.931 -179.29 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' H' H ' 8' ' ' SER . . . . . . . . . . . . . 7.5 t -163.74 172.36 14.29 Favored 'General case' 0 N--CA 1.47 0.532 0 N-CA-C 109.174 -0.676 . . . . 0.0 109.174 178.261 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 123.52 23.36 2.13 Favored Glycine 0 N--CA 1.482 1.714 0 N-CA-C 111.817 -0.513 . . . . 0.0 111.817 179.084 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 40.5 p90 -56.17 127.82 32.56 Favored 'General case' 0 N--CA 1.473 0.714 0 N-CA-C 112.575 0.583 . . . . 0.0 112.575 -178.82 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 46.2 mt-10 -83.53 154.23 23.96 Favored 'General case' 0 N--CA 1.473 0.708 0 N-CA-C 109.597 -0.52 . . . . 0.0 109.597 178.297 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -155.85 127.99 1.02 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.943 0 N-CA-C 108.07 -1.085 . . . . 0.0 108.07 178.8 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 51.4 m-70 -133.54 144.33 49.28 Favored 'General case' 0 N--CA 1.476 0.825 0 CA-C-N 115.274 -0.875 . . . . 0.0 110.81 -178.214 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 6.2 t60 -164.96 98.5 0.75 Allowed 'General case' 0 N--CA 1.483 1.197 0 CA-C-N 116.709 -0.223 . . . . 0.0 110.85 179.034 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 33.0 mt-30 -102.8 -172.8 2.18 Favored 'General case' 0 CA--C 1.505 -0.77 0 N-CA-C 108.26 -1.015 . . . . 0.0 108.26 179.642 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -167.11 98.24 0.52 Allowed 'General case' 0 CA--C 1.539 0.524 0 CA-C-N 114.997 -1.001 . . . . 0.0 109.251 178.719 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' H' H ' 17' ' ' LEU . . . . . 0.56 HD12 ' N ' ' H' ' 17' ' ' LEU . 5.4 mp -106.17 160.84 15.02 Favored 'General case' 0 N--CA 1.485 1.279 0 N-CA-C 109.103 -0.702 . . . . 0.0 109.103 -179.823 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 40.4 t -143.52 117.77 3.81 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.089 0 C-N-CA 122.547 0.339 . . . . 0.0 110.25 178.744 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 50.2 m-85 -69.75 151.29 45.97 Favored 'General case' 0 C--N 1.369 1.426 0 N-CA-C 107.527 -1.286 . . . . 0.0 107.527 176.33 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 13.1 t80 -172.25 -55.58 0.02 OUTLIER 'General case' 0 N--CA 1.483 1.177 0 N-CA-C 110.069 -0.345 . . . . 0.0 110.069 180.0 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.96 90.71 0.0 OUTLIER 'General case' 0 CA--C 1.535 0.367 0 C-N-CA 123.517 0.727 . . . . 0.0 112.097 179.924 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 53.7 tt0 -62.61 155.83 24.99 Favored 'General case' 0 N--CA 1.469 0.512 0 CA-C-N 114.849 -1.069 . . . . 0.0 109.919 179.115 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 17.9 m-20 -136.55 134.86 37.93 Favored 'General case' 0 N--CA 1.48 1.025 0 C-N-CA 122.835 0.454 . . . . 0.0 109.917 -179.957 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' H' H ' 24' ' ' VAL . . . . . . . . . . . . . 19.6 t -85.85 -116.13 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.846 0 N-CA-C 108.358 -0.979 . . . . 0.0 108.358 179.364 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . -106.91 52.89 0.64 Allowed Glycine 0 N--CA 1.478 1.483 0 N-CA-C 111.099 -0.8 . . . . 0.0 111.099 -179.969 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 89.0 p -77.45 126.16 30.47 Favored 'General case' 0 N--CA 1.467 0.383 0 N-CA-C 109.006 -0.738 . . . . 0.0 109.006 178.304 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 1.9 t-20 -67.06 100.49 0.76 Allowed 'General case' 0 N--CA 1.469 0.5 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 178.667 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 67.3 mttm -94.39 127.12 40.07 Favored 'General case' 0 N--CA 1.481 1.084 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 -179.598 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.11 -128.54 0.01 OUTLIER Glycine 0 CA--C 1.527 0.783 0 N-CA-C 110.643 -0.983 . . . . 0.0 110.643 179.385 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.97 126.04 34.99 Favored 'General case' 0 N--CA 1.471 0.582 0 C-N-CA 122.853 0.461 . . . . 0.0 111.033 -179.251 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 35.8 mt -90.66 161.81 2.55 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.845 0 N-CA-C 107.014 -1.476 . . . . 0.0 107.014 178.228 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 40.4 mt -138.73 95.93 1.01 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.435 0 CA-C-N 119.511 1.051 . . . . 0.0 109.981 178.38 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 53.58 104.32 0.01 OUTLIER Glycine 0 CA--C 1.53 1.029 0 CA-C-N 116.101 -0.5 . . . . 0.0 114.144 176.832 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 92.1 mt -71.67 154.76 41.16 Favored 'General case' 0 N--CA 1.47 0.57 0 N-CA-C 107.673 -1.232 . . . . 0.0 107.673 176.716 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 2.6 ttp -143.09 140.09 30.74 Favored 'General case' 0 N--CA 1.477 0.889 0 N-CA-C 108.503 -0.925 . . . . 0.0 108.503 178.802 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 69.1 t -159.96 149.34 6.38 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.278 0 N-CA-C 106.525 -1.657 . . . . 0.0 106.525 -179.388 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.28 74.91 0.27 Allowed Glycine 0 C--N 1.314 -0.643 0 C-N-CA 120.989 -0.624 . . . . 0.0 112.155 177.489 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 173.97 -146.32 8.66 Favored Glycine 0 C--O 1.221 -0.675 0 N-CA-C 110.631 -0.988 . . . . 0.0 110.631 179.393 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 32.7 m -136.68 145.87 29.55 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.87 0 CA-C-N 116.98 0.39 . . . . 0.0 110.327 -179.423 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 21.1 t . . . . . 0 C--O 1.221 -0.4 0 CA-C-O 117.64 -1.171 . . . . 0.0 111.326 179.163 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 77.1 m-85 . . . . . 0 N--CA 1.473 0.704 0 N-CA-C 109.553 -0.536 . . . . 0.0 109.553 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' I' I ' 5' ' ' ARG . . . . . . . . . . . . . 72.3 mtp180 -144.78 141.9 29.56 Favored 'General case' 0 N--CA 1.481 1.094 0 N-CA-C 109.056 -0.72 . . . . 0.0 109.056 -179.834 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 77.1 m80 -149.83 118.34 6.51 Favored 'General case' 0 N--CA 1.476 0.838 0 N-CA-C 109.083 -0.71 . . . . 0.0 109.083 179.093 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 12.0 m-20 -67.62 144.76 55.39 Favored 'General case' 0 CA--C 1.535 0.396 0 CA-C-O 120.979 0.419 . . . . 0.0 111.927 -179.268 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' I' I ' 8' ' ' SER . . . . . . . . . . . . . 7.6 t -163.54 172.31 14.59 Favored 'General case' 0 N--CA 1.469 0.5 0 N-CA-C 109.152 -0.684 . . . . 0.0 109.152 178.276 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 123.7 23.26 2.1 Favored Glycine 0 N--CA 1.483 1.789 0 N-CA-C 111.747 -0.541 . . . . 0.0 111.747 179.027 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 40.3 p90 -56.08 127.82 32.43 Favored 'General case' 0 N--CA 1.474 0.75 0 N-CA-C 112.501 0.556 . . . . 0.0 112.501 -178.792 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 46.2 mt-10 -83.61 154.17 23.89 Favored 'General case' 0 N--CA 1.474 0.73 0 N-CA-C 109.644 -0.502 . . . . 0.0 109.644 178.203 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -155.74 128.01 1.03 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.927 0 N-CA-C 108.125 -1.065 . . . . 0.0 108.125 178.854 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 50.9 m-70 -133.58 144.33 49.24 Favored 'General case' 0 N--CA 1.476 0.832 0 CA-C-N 115.33 -0.85 . . . . 0.0 110.861 -178.236 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 30.6 t-80 -165.05 98.61 0.74 Allowed 'General case' 0 N--CA 1.485 1.297 0 CA-C-N 116.687 -0.233 . . . . 0.0 110.914 179.131 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 32.9 mt-30 -103.11 -172.55 2.13 Favored 'General case' 0 CA--C 1.503 -0.852 0 N-CA-C 108.328 -0.99 . . . . 0.0 108.328 179.598 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -167.26 98.23 0.51 Allowed 'General case' 0 CA--C 1.538 0.517 0 CA-C-N 114.977 -1.011 . . . . 0.0 109.279 178.82 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' I' I ' 17' ' ' LEU . . . . . 0.553 ' N ' HD12 ' I' ' 17' ' ' LEU . 5.4 mp -106.18 160.77 15.08 Favored 'General case' 0 N--CA 1.484 1.259 0 N-CA-C 109.089 -0.708 . . . . 0.0 109.089 -179.854 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 40.5 t -143.4 117.83 3.95 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.016 0 C-N-CA 122.542 0.337 . . . . 0.0 110.306 178.753 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 49.7 m-85 -69.83 151.3 45.88 Favored 'General case' 0 C--N 1.369 1.431 0 N-CA-C 107.486 -1.302 . . . . 0.0 107.486 176.423 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 13.2 t80 -172.25 -55.55 0.02 OUTLIER 'General case' 0 N--CA 1.481 1.093 0 N-CA-C 110.065 -0.346 . . . . 0.0 110.065 -179.999 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.98 90.8 0.0 OUTLIER 'General case' 0 CA--C 1.535 0.387 0 C-N-CA 123.496 0.718 . . . . 0.0 112.046 179.877 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 53.7 tt0 -62.69 155.96 24.91 Favored 'General case' 0 N--CA 1.469 0.5 0 CA-C-N 114.862 -1.063 . . . . 0.0 109.866 179.141 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 17.9 m-20 -136.69 134.85 37.66 Favored 'General case' 0 N--CA 1.479 0.987 0 C-N-CA 122.804 0.442 . . . . 0.0 109.867 -179.954 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' I' I ' 24' ' ' VAL . . . . . . . . . . . . . 19.4 t -85.76 -116.09 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.878 0 N-CA-C 108.337 -0.986 . . . . 0.0 108.337 179.39 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . -106.98 52.9 0.64 Allowed Glycine 0 N--CA 1.477 1.402 0 N-CA-C 111.225 -0.75 . . . . 0.0 111.225 179.991 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 89.3 p -77.46 126.2 30.53 Favored 'General case' 0 N--CA 1.466 0.372 0 N-CA-C 109.066 -0.716 . . . . 0.0 109.066 178.313 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 1.9 t-20 -67.03 100.4 0.74 Allowed 'General case' 0 N--CA 1.47 0.538 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 178.623 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 67.4 mttm -94.27 127.03 39.88 Favored 'General case' 0 N--CA 1.481 1.111 0 N-CA-C 109.452 -0.573 . . . . 0.0 109.452 -179.659 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.97 -128.78 0.01 OUTLIER Glycine 0 CA--C 1.527 0.831 0 N-CA-C 110.695 -0.962 . . . . 0.0 110.695 179.339 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.69 125.74 34.72 Favored 'General case' 0 N--CA 1.471 0.612 0 C-N-CA 122.957 0.503 . . . . 0.0 111.057 -179.299 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 36.2 mt -90.56 161.85 2.55 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.781 0 N-CA-C 106.933 -1.506 . . . . 0.0 106.933 178.201 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 40.4 mt -138.85 95.79 0.98 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 CA-C-N 119.485 1.039 . . . . 0.0 109.99 178.475 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 53.7 104.23 0.01 OUTLIER Glycine 0 CA--C 1.531 1.039 0 CA-C-N 116.103 -0.499 . . . . 0.0 114.093 176.818 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 91.9 mt -71.56 154.63 41.32 Favored 'General case' 0 N--CA 1.471 0.576 0 N-CA-C 107.683 -1.228 . . . . 0.0 107.683 176.687 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 2.6 ttp -143.03 140.03 30.8 Favored 'General case' 0 N--CA 1.475 0.815 0 N-CA-C 108.497 -0.927 . . . . 0.0 108.497 178.871 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 68.6 t -159.95 149.37 6.39 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.228 0 N-CA-C 106.567 -1.642 . . . . 0.0 106.567 -179.371 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.2 74.99 0.26 Allowed Glycine 0 N--CA 1.465 0.617 0 C-N-CA 120.942 -0.647 . . . . 0.0 112.152 177.517 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 173.95 -146.24 8.63 Favored Glycine 0 N--CA 1.465 0.633 0 N-CA-C 110.662 -0.975 . . . . 0.0 110.662 179.354 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 32.8 m -136.73 145.91 29.43 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.93 0 CA-C-N 117.013 0.406 . . . . 0.0 110.172 -179.369 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 20.9 t . . . . . 0 C--O 1.221 -0.42 0 CA-C-O 117.648 -1.168 . . . . 0.0 111.381 179.145 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 76.5 m-85 . . . . . 0 N--CA 1.475 0.791 0 N-CA-C 109.98 -0.378 . . . . 0.0 109.98 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 73.7 mtp180 -143.71 141.31 30.45 Favored 'General case' 0 N--CA 1.482 1.152 0 N-CA-C 109.045 -0.724 . . . . 0.0 109.045 -179.968 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 76.7 m80 -149.77 119.53 7.05 Favored 'General case' 0 N--CA 1.47 0.548 0 N-CA-C 108.781 -0.822 . . . . 0.0 108.781 179.137 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 -67.84 149.56 49.7 Favored 'General case' 0 N--CA 1.463 0.187 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.179 -179.62 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 7.0 t -167.22 171.28 10.94 Favored 'General case' 0 N--CA 1.473 0.698 0 N-CA-C 109.46 -0.57 . . . . 0.0 109.46 178.496 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.21 24.07 2.29 Favored Glycine 0 N--CA 1.487 2.065 0 N-CA-C 112.125 -0.39 . . . . 0.0 112.125 179.375 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 41.9 p90 -56.78 128.01 34.45 Favored 'General case' 0 N--CA 1.471 0.623 0 N-CA-C 112.106 0.41 . . . . 0.0 112.106 -179.889 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 46.1 mt-10 -84.86 156.09 21.44 Favored 'General case' 0 N--CA 1.468 0.443 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 178.544 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -154.86 124.48 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 N-CA-C 108.119 -1.067 . . . . 0.0 108.119 178.534 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 35.1 m80 -107.33 161.12 15.09 Favored 'General case' 0 N--CA 1.491 1.624 0 CA-C-N 118.455 0.57 . . . . 0.0 111.213 -178.767 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 57.1 t60 -164.66 99.14 0.79 Allowed 'General case' 0 N--CA 1.485 1.289 0 CA-C-N 116.766 -0.197 . . . . 0.0 111.06 179.63 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 15' ' ' GLN . . . . . 0.45 HE22 HG13 ' A' ' 36' ' ' VAL . 36.3 mt-30 -125.67 -175.15 3.26 Favored 'General case' 0 CA--C 1.491 -1.301 0 N-CA-C 107.862 -1.162 . . . . 0.0 107.862 -179.99 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -169.7 103.28 0.33 Allowed 'General case' 0 CA--C 1.542 0.644 0 CA-C-N 115.011 -0.995 . . . . 0.0 109.395 179.026 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 9.3 mp -110.75 151.35 27.88 Favored 'General case' 0 N--CA 1.489 1.515 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 -179.932 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 61.6 t -143.98 119.06 4.0 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.245 0 CA-C-O 118.69 -0.671 . . . . 0.0 109.543 179.084 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 17.3 m-85 -70.19 157.2 38.08 Favored 'General case' 0 N--CA 1.477 0.923 0 N-CA-C 107.727 -1.212 . . . . 0.0 107.727 177.542 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 14.6 t80 -170.99 -60.0 0.02 OUTLIER 'General case' 0 N--CA 1.482 1.156 0 CA-C-O 122.315 1.055 . . . . 0.0 109.482 179.278 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.0 89.64 0.0 OUTLIER 'General case' 0 N--CA 1.456 -0.152 0 CA-C-N 113.891 -1.504 . . . . 0.0 112.875 -177.973 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 43.4 mt-10 -61.42 158.22 15.14 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 115.166 -0.924 . . . . 0.0 110.782 179.037 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 12.0 m-20 -139.98 135.26 32.55 Favored 'General case' 0 N--CA 1.483 1.21 0 C-N-CA 122.769 0.427 . . . . 0.0 110.399 -179.956 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 18.1 t -84.34 -115.98 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.475 0.802 0 N-CA-C 108.35 -0.981 . . . . 0.0 108.35 179.355 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -109.32 54.25 0.55 Allowed Glycine 0 N--CA 1.473 1.112 0 N-CA-C 111.254 -0.738 . . . . 0.0 111.254 -179.986 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 82.8 p -77.49 126.96 31.72 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 109.0 -0.741 . . . . 0.0 109.0 178.469 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 27' ' ' ASN . . . . . 0.45 HD21 ' HB3' ' D' ' 27' ' ' ASN . 6.5 t-20 -66.7 100.92 0.74 Allowed 'General case' 0 N--CA 1.471 0.599 0 N-CA-C 108.611 -0.885 . . . . 0.0 108.611 178.593 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 67.2 mttm -95.3 128.88 42.51 Favored 'General case' 0 N--CA 1.481 1.089 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 -179.155 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.71 -132.12 0.01 OUTLIER Glycine 0 CA--C 1.533 1.203 0 N-CA-C 110.775 -0.93 . . . . 0.0 110.775 178.907 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.77 126.91 37.6 Favored 'General case' 0 N--CA 1.484 1.237 0 CA-C-N 117.097 0.448 . . . . 0.0 110.016 179.345 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 33.0 mt -91.31 159.17 2.83 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.496 0 N-CA-C 106.631 -1.618 . . . . 0.0 106.631 178.416 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 42.9 mt -138.25 92.86 0.83 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.468 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 -178.972 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 54.05 106.23 0.01 OUTLIER Glycine 0 CA--C 1.53 1.002 0 CA-C-N 115.933 -0.576 . . . . 0.0 114.162 177.239 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 97.9 mt -72.26 153.5 41.52 Favored 'General case' 0 CA--C 1.539 0.536 0 N-CA-C 107.27 -1.382 . . . . 0.0 107.27 176.703 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 27.2 ttt -147.07 138.34 24.01 Favored 'General case' 0 N--CA 1.477 0.879 0 N-CA-C 108.761 -0.829 . . . . 0.0 108.761 179.147 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.45 HG13 HE22 ' A' ' 15' ' ' GLN . 61.9 t -159.69 153.51 5.02 Favored 'Isoleucine or valine' 0 C--N 1.342 0.262 0 N-CA-C 106.596 -1.631 . . . . 0.0 106.596 -179.279 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.98 73.56 0.42 Allowed Glycine 0 C--N 1.313 -0.697 0 N-CA-C 111.663 -0.575 . . . . 0.0 111.663 177.987 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 174.65 -161.58 31.34 Favored Glycine 0 C--N 1.335 0.483 0 N-CA-C 111.086 -0.806 . . . . 0.0 111.086 -179.828 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 23.5 m -124.29 139.63 50.04 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.951 0 C-N-CA 122.762 0.425 . . . . 0.0 110.084 179.744 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 26.1 t . . . . . 0 C--O 1.221 -0.447 0 CA-C-O 117.635 -1.174 . . . . 0.0 111.108 179.37 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 77.0 m-85 . . . . . 0 N--CA 1.474 0.76 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 73.5 mtp180 -143.69 141.32 30.47 Favored 'General case' 0 N--CA 1.48 1.055 0 N-CA-C 109.092 -0.707 . . . . 0.0 109.092 -179.972 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 76.7 m80 -149.83 119.49 7.01 Favored 'General case' 0 N--CA 1.472 0.627 0 N-CA-C 108.93 -0.767 . . . . 0.0 108.93 179.104 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 7' ' ' ASP . . . . . . . . . . . . . 9.6 m-20 -67.77 149.4 49.97 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.196 -179.609 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 8' ' ' SER . . . . . . . . . . . . . 7.0 t -167.15 171.4 10.93 Favored 'General case' 0 N--CA 1.473 0.676 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 178.451 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.11 24.06 2.32 Favored Glycine 0 N--CA 1.487 2.072 0 N-CA-C 112.05 -0.42 . . . . 0.0 112.05 179.38 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 41.4 p90 -56.75 128.15 35.11 Favored 'General case' 0 N--CA 1.472 0.669 0 N-CA-C 112.071 0.397 . . . . 0.0 112.071 -179.834 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 45.7 mt-10 -84.99 155.63 21.49 Favored 'General case' 0 N--CA 1.47 0.557 0 N-CA-C 109.268 -0.642 . . . . 0.0 109.268 178.589 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -154.47 124.35 0.78 Allowed 'Isoleucine or valine' 0 C--O 1.234 0.249 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 178.538 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 34.2 m80 -107.27 161.2 15.0 Favored 'General case' 0 N--CA 1.491 1.585 0 CA-C-N 118.41 0.55 . . . . 0.0 111.155 -178.774 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 58.2 t60 -164.72 98.87 0.78 Allowed 'General case' 0 N--CA 1.485 1.301 0 CA-C-O 119.64 -0.219 . . . . 0.0 111.001 179.636 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 15' ' ' GLN . . . . . 0.456 HE22 HG13 ' B' ' 36' ' ' VAL . 36.2 mt-30 -125.19 -175.48 3.32 Favored 'General case' 0 CA--C 1.492 -1.275 0 N-CA-C 107.832 -1.173 . . . . 0.0 107.832 179.995 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -169.62 103.13 0.33 Allowed 'General case' 0 CA--C 1.541 0.6 0 CA-C-N 114.944 -1.025 . . . . 0.0 109.334 179.023 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 9.4 mp -110.67 151.23 27.94 Favored 'General case' 0 N--CA 1.489 1.507 0 N-CA-C 108.695 -0.854 . . . . 0.0 108.695 -179.951 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 61.9 t -143.92 118.77 3.91 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.139 0 CA-C-O 118.748 -0.644 . . . . 0.0 109.561 179.07 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 16.6 m-85 -70.45 157.17 38.31 Favored 'General case' 0 N--CA 1.475 0.798 0 N-CA-C 107.638 -1.245 . . . . 0.0 107.638 177.413 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 15.8 t80 -171.66 -59.06 0.02 OUTLIER 'General case' 0 N--CA 1.479 1.007 0 CA-C-O 122.261 1.029 . . . . 0.0 109.619 179.23 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.21 89.88 0.0 OUTLIER 'General case' 0 C--O 1.231 0.112 0 CA-C-N 114.051 -1.431 . . . . 0.0 112.764 -178.108 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 43.8 mt-10 -61.53 158.38 15.13 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 115.276 -0.875 . . . . 0.0 110.828 179.095 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 12.2 m-20 -140.25 135.6 32.48 Favored 'General case' 0 N--CA 1.483 1.196 0 C-N-CA 122.793 0.437 . . . . 0.0 110.416 179.955 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 18.1 t -84.97 -116.1 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.906 0 N-CA-C 108.408 -0.96 . . . . 0.0 108.408 179.499 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -108.45 53.65 0.59 Allowed Glycine 0 N--CA 1.476 1.366 0 N-CA-C 111.083 -0.807 . . . . 0.0 111.083 -179.909 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 86.0 p -77.35 126.58 31.15 Favored 'General case' 0 C--N 1.329 -0.294 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 178.409 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 27' ' ' ASN . . . . . 0.443 HD21 ' HB3' ' E' ' 27' ' ' ASN . 6.6 t-20 -66.74 100.98 0.75 Allowed 'General case' 0 N--CA 1.471 0.608 0 N-CA-C 108.593 -0.892 . . . . 0.0 108.593 178.672 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 67.1 mttm -95.3 128.91 42.52 Favored 'General case' 0 N--CA 1.481 1.121 0 N-CA-C 109.972 -0.381 . . . . 0.0 109.972 -179.226 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.77 -131.63 0.01 OUTLIER Glycine 0 CA--C 1.535 1.33 0 N-CA-C 110.746 -0.942 . . . . 0.0 110.746 178.904 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -131.18 127.12 37.31 Favored 'General case' 0 N--CA 1.485 1.304 0 C-N-CA 122.704 0.402 . . . . 0.0 110.081 179.431 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 32.8 mt -91.75 158.79 2.86 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.538 0 N-CA-C 106.602 -1.629 . . . . 0.0 106.602 178.516 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 43.1 mt -137.81 92.89 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.502 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 -178.816 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 53.85 106.17 0.01 OUTLIER Glycine 0 CA--C 1.53 0.993 0 CA-C-N 116.021 -0.536 . . . . 0.0 114.212 177.237 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 97.7 mt -72.12 153.4 41.69 Favored 'General case' 0 CA--C 1.539 0.53 0 N-CA-C 107.364 -1.346 . . . . 0.0 107.364 176.651 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 27.1 ttt -146.82 138.05 24.16 Favored 'General case' 0 N--CA 1.478 0.954 0 N-CA-C 108.701 -0.851 . . . . 0.0 108.701 179.21 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 36' ' ' VAL . . . . . 0.456 HG13 HE22 ' B' ' 15' ' ' GLN . 62.3 t -159.54 153.47 5.14 Favored 'Isoleucine or valine' 0 C--N 1.344 0.356 0 N-CA-C 106.52 -1.659 . . . . 0.0 106.52 -179.273 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.03 73.23 0.45 Allowed Glycine 0 C--N 1.313 -0.696 0 N-CA-C 111.686 -0.566 . . . . 0.0 111.686 178.005 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 174.98 -161.5 30.92 Favored Glycine 0 C--N 1.334 0.43 0 N-CA-C 111.056 -0.818 . . . . 0.0 111.056 -179.865 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 24.1 m -124.4 139.6 50.21 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.929 0 C-N-CA 122.751 0.421 . . . . 0.0 110.072 179.695 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 26.5 t . . . . . 0 C--O 1.219 -0.52 0 CA-C-O 117.651 -1.166 . . . . 0.0 111.054 179.381 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 77.1 m-85 . . . . . 0 N--CA 1.474 0.75 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 73.7 mtp180 -143.72 141.24 30.4 Favored 'General case' 0 N--CA 1.482 1.141 0 N-CA-C 109.005 -0.739 . . . . 0.0 109.005 -179.858 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 76.8 m80 -149.9 119.39 6.92 Favored 'General case' 0 N--CA 1.471 0.594 0 N-CA-C 108.798 -0.816 . . . . 0.0 108.798 179.159 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' C' C ' 7' ' ' ASP . . . . . . . . . . . . . 9.0 m-20 -67.71 149.29 50.17 Favored 'General case' 0 N--CA 1.463 0.218 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.244 -179.562 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' C' C ' 8' ' ' SER . . . . . . . . . . . . . 6.7 t -167.12 171.15 11.21 Favored 'General case' 0 N--CA 1.472 0.652 0 N-CA-C 109.502 -0.555 . . . . 0.0 109.502 178.424 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.49 23.92 2.26 Favored Glycine 0 N--CA 1.487 2.034 0 N-CA-C 111.968 -0.453 . . . . 0.0 111.968 179.38 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 41.5 p90 -56.61 128.16 34.93 Favored 'General case' 0 N--CA 1.471 0.614 0 N-CA-C 112.07 0.396 . . . . 0.0 112.07 -179.85 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 45.9 mt-10 -85.02 155.97 21.32 Favored 'General case' 0 N--CA 1.47 0.535 0 N-CA-C 109.24 -0.652 . . . . 0.0 109.24 178.592 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -154.76 124.54 0.76 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 N-CA-C 108.168 -1.049 . . . . 0.0 108.168 178.525 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 33.9 m80 -107.39 161.23 15.0 Favored 'General case' 0 N--CA 1.49 1.573 0 CA-C-N 118.397 0.544 . . . . 0.0 111.181 -178.717 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 57.3 t60 -164.83 99.22 0.77 Allowed 'General case' 0 N--CA 1.485 1.286 0 CA-C-N 116.77 -0.196 . . . . 0.0 111.094 179.651 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' C' C ' 15' ' ' GLN . . . . . 0.461 HE22 HG13 ' C' ' 36' ' ' VAL . 36.2 mt-30 -125.79 -175.34 3.32 Favored 'General case' 0 CA--C 1.489 -1.373 0 N-CA-C 107.904 -1.147 . . . . 0.0 107.904 -179.957 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -169.64 103.19 0.33 Allowed 'General case' 0 CA--C 1.541 0.624 0 CA-C-N 114.888 -1.051 . . . . 0.0 109.331 179.062 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 9.4 mp -110.67 150.92 28.32 Favored 'General case' 0 N--CA 1.488 1.441 0 N-CA-C 108.712 -0.848 . . . . 0.0 108.712 179.968 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 61.1 t -143.66 118.97 4.29 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.175 0 CA-C-O 118.765 -0.636 . . . . 0.0 109.61 179.029 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 16.6 m-85 -70.49 157.28 38.14 Favored 'General case' 0 N--CA 1.475 0.802 0 N-CA-C 107.664 -1.236 . . . . 0.0 107.664 177.436 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 15.4 t80 -171.59 -59.31 0.02 OUTLIER 'General case' 0 N--CA 1.478 0.953 0 CA-C-O 122.259 1.028 . . . . 0.0 109.642 179.195 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.12 89.96 0.0 OUTLIER 'General case' 0 C--O 1.231 0.11 0 CA-C-N 114.041 -1.436 . . . . 0.0 112.753 -178.076 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 43.9 mt-10 -61.6 158.23 15.68 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.219 -0.9 . . . . 0.0 110.833 179.047 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 12.3 m-20 -139.92 135.9 33.32 Favored 'General case' 0 N--CA 1.483 1.199 0 C-N-CA 122.861 0.464 . . . . 0.0 110.343 -179.977 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 18.2 t -85.27 -116.01 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.902 0 N-CA-C 108.414 -0.958 . . . . 0.0 108.414 179.444 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -108.58 53.42 0.6 Allowed Glycine 0 N--CA 1.475 1.257 0 N-CA-C 111.107 -0.797 . . . . 0.0 111.107 -179.918 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 85.9 p -77.3 126.73 31.4 Favored 'General case' 0 C--N 1.329 -0.32 0 N-CA-C 109.122 -0.695 . . . . 0.0 109.122 178.508 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' C' C ' 27' ' ' ASN . . . . . 0.463 HD21 ' HB3' ' F' ' 27' ' ' ASN . 6.4 t-20 -66.79 101.11 0.77 Allowed 'General case' 0 N--CA 1.471 0.582 0 N-CA-C 108.633 -0.877 . . . . 0.0 108.633 178.625 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 67.1 mttm -95.34 128.99 42.63 Favored 'General case' 0 N--CA 1.483 1.2 0 N-CA-C 109.886 -0.413 . . . . 0.0 109.886 -179.117 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.84 -131.85 0.01 OUTLIER Glycine 0 CA--C 1.535 1.293 0 N-CA-C 110.858 -0.897 . . . . 0.0 110.858 178.844 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.96 126.66 36.63 Favored 'General case' 0 N--CA 1.486 1.356 0 C-N-CA 122.822 0.449 . . . . 0.0 110.003 179.456 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 32.5 mt -91.33 158.81 2.86 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.525 0 N-CA-C 106.684 -1.599 . . . . 0.0 106.684 178.334 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 42.5 mt -137.99 92.89 0.86 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.505 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 -178.799 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 53.93 106.09 0.01 OUTLIER Glycine 0 CA--C 1.529 0.966 0 CA-C-N 115.921 -0.581 . . . . 0.0 114.257 177.229 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 97.6 mt -72.05 153.3 41.82 Favored 'General case' 0 CA--C 1.537 0.461 0 N-CA-C 107.328 -1.36 . . . . 0.0 107.328 176.655 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 27.3 ttt -146.63 138.09 24.42 Favored 'General case' 0 N--CA 1.477 0.891 0 N-CA-C 108.74 -0.837 . . . . 0.0 108.74 179.214 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' C' C ' 36' ' ' VAL . . . . . 0.461 HG13 HE22 ' C' ' 15' ' ' GLN . 61.1 t -159.57 153.56 5.07 Favored 'Isoleucine or valine' 0 C--N 1.345 0.372 0 N-CA-C 106.566 -1.642 . . . . 0.0 106.566 -179.251 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.89 73.15 0.46 Allowed Glycine 0 C--N 1.314 -0.671 0 N-CA-C 111.626 -0.59 . . . . 0.0 111.626 177.951 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 175.03 -161.75 31.24 Favored Glycine 0 C--N 1.335 0.479 0 N-CA-C 111.054 -0.818 . . . . 0.0 111.054 -179.865 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 23.5 m -124.2 139.67 49.88 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.923 0 C-N-CA 122.785 0.434 . . . . 0.0 110.054 179.727 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 27.7 t . . . . . 0 C--O 1.221 -0.424 0 CA-C-O 117.655 -1.164 . . . . 0.0 110.98 179.336 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 85.9 m-85 . . . . . 0 N--CA 1.473 0.705 0 N-CA-C 108.113 -1.069 . . . . 0.0 108.113 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' D' D ' 5' ' ' ARG . . . . . . . . . . . . . 73.9 mtp180 -147.52 141.05 25.45 Favored 'General case' 0 N--CA 1.473 0.7 0 N-CA-C 108.967 -0.753 . . . . 0.0 108.967 179.637 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 77.0 m80 -149.2 123.55 9.62 Favored 'General case' 0 CA--C 1.539 0.519 0 N-CA-C 107.926 -1.138 . . . . 0.0 107.926 175.967 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' D' D ' 7' ' ' ASP . . . . . . . . . . . . . 6.3 m-20 -63.42 133.41 53.94 Favored 'General case' 0 C--N 1.32 -0.688 0 C-N-CA 126.937 2.095 . . . . 0.0 114.798 176.152 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' D' D ' 8' ' ' SER . . . . . . . . . . . . . 5.9 t -154.04 173.52 15.91 Favored 'General case' 0 N--CA 1.477 0.925 0 CA-C-N 118.548 0.613 . . . . 0.0 110.443 176.799 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 124.23 20.38 2.47 Favored Glycine 0 N--CA 1.484 1.864 0 N-CA-C 111.99 -0.444 . . . . 0.0 111.99 176.203 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 37.2 p90 -55.67 130.32 42.67 Favored 'General case' 0 CA--C 1.545 0.753 0 CA-C-O 121.103 0.478 . . . . 0.0 111.914 -177.388 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 46.0 mt-10 -84.87 153.77 22.69 Favored 'General case' 0 N--CA 1.472 0.64 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 177.886 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.0 p -150.91 129.01 2.57 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.594 0 N-CA-C 106.937 -1.505 . . . . 0.0 106.937 172.73 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 24.6 m80 -100.86 161.98 13.22 Favored 'General case' 0 N--CA 1.481 1.116 0 C-N-CA 123.911 0.884 . . . . 0.0 113.168 176.722 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 61.0 t60 -165.0 105.27 0.79 Allowed 'General case' 0 N--CA 1.486 1.354 0 N-CA-C 109.694 -0.484 . . . . 0.0 109.694 172.242 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' D' D ' 15' ' ' GLN . . . . . 0.476 HE22 HG13 ' D' ' 36' ' ' VAL . 36.2 mt-30 -128.59 -176.33 3.8 Favored 'General case' 0 CA--C 1.485 -1.534 0 N-CA-C 107.255 -1.387 . . . . 0.0 107.255 178.892 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 88.8 tttt -166.87 109.51 0.7 Allowed 'General case' 0 C--O 1.238 0.487 0 N-CA-C 107.926 -1.139 . . . . 0.0 107.926 176.779 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 10.5 mp -115.69 153.16 31.85 Favored 'General case' 0 N--CA 1.489 1.502 0 N-CA-C 107.198 -1.408 . . . . 0.0 107.198 178.205 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 52.5 t -141.95 124.03 13.61 Favored 'Isoleucine or valine' 0 C--N 1.362 1.152 0 N-CA-C 108.668 -0.864 . . . . 0.0 108.668 174.283 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 16.0 m-85 -62.62 150.81 39.77 Favored 'General case' 0 C--N 1.348 0.513 0 C-N-CA 124.308 1.043 . . . . 0.0 110.719 169.695 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 11.3 t80 -170.51 -67.22 0.02 OUTLIER 'General case' 0 N--CA 1.475 0.788 0 N-CA-C 107.983 -1.117 . . . . 0.0 107.983 178.55 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -38.61 94.99 0.01 OUTLIER 'General case' 0 N--CA 1.451 -0.403 0 CA-C-N 113.855 -1.521 . . . . 0.0 111.586 -175.866 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 45.8 mt-10 -64.47 159.09 22.21 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 114.293 -1.321 . . . . 0.0 110.504 178.491 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 12.2 m-20 -139.87 139.47 36.27 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-O 121.253 0.549 . . . . 0.0 109.637 178.609 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' D' D ' 24' ' ' VAL . . . . . . . . . . . . . 19.4 t -88.17 -119.86 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.483 1.217 0 N-CA-C 107.597 -1.26 . . . . 0.0 107.597 179.58 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . -111.47 61.8 0.3 Allowed Glycine 0 C--N 1.368 2.359 0 C-N-CA 118.222 -1.942 . . . . 0.0 109.206 178.763 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 92.8 p -68.04 121.59 16.44 Favored 'General case' 0 C--O 1.24 0.595 0 CA-C-O 116.453 -1.737 . . . . 0.0 112.517 168.985 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' D' D ' 27' ' ' ASN . . . . . 0.467 HD21 ' HB3' ' G' ' 27' ' ' ASN . 6.5 t-20 -62.52 101.79 0.27 Allowed 'General case' 0 N--CA 1.474 0.765 0 CA-C-N 121.603 2.001 . . . . 0.0 109.453 173.65 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 66.8 mttm -96.84 128.28 43.64 Favored 'General case' 0 N--CA 1.487 1.387 0 CA-C-N 118.842 0.746 . . . . 0.0 109.35 178.996 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -55.21 -134.81 0.0 OUTLIER Glycine 0 CA--C 1.532 1.135 0 C-N-CA 123.793 0.711 . . . . 0.0 112.343 174.925 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -129.42 130.96 46.62 Favored 'General case' 0 C--N 1.371 1.507 0 CA-C-N 115.022 -0.589 . . . . 0.0 110.121 176.231 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 38.8 mt -91.64 161.75 2.52 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.338 0 N-CA-C 106.148 -1.797 . . . . 0.0 106.148 177.499 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . 0.28 43.1 mt -141.01 105.06 1.57 Allowed 'Isoleucine or valine' 0 C--N 1.363 1.191 0 N-CA-C 106.231 -1.766 . . . . 0.0 106.231 172.511 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.6 98.11 0.01 OUTLIER Glycine 0 CA--C 1.533 1.21 0 CA-C-O 116.312 -2.382 . . . . 0.0 112.198 169.074 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 97.0 mt -70.0 157.61 37.17 Favored 'General case' 0 CA--C 1.539 0.55 0 CA-C-N 122.355 3.078 . . . . 0.0 107.217 176.055 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 26.1 ttt -147.18 148.92 32.02 Favored 'General case' 0 N--CA 1.482 1.161 0 N-CA-C 106.373 -1.714 . . . . 0.0 106.373 174.269 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' D' D ' 36' ' ' VAL . . . . . 0.476 HG13 HE22 ' D' ' 15' ' ' GLN . 88.5 t -165.22 159.14 1.18 Allowed 'Isoleucine or valine' 0 C--O 1.248 1.004 0 N-CA-C 105.302 -2.11 . . . . 0.0 105.302 177.15 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 60.54 64.84 3.77 Favored Glycine 0 N--CA 1.442 -0.917 0 C-N-CA 117.24 -2.41 . . . . 0.0 113.756 174.581 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' D' D ' 38' ' ' GLY . . . . . 0.407 ' HA3' ' O ' ' G' ' 38' ' ' GLY . . . 169.8 -160.7 33.85 Favored Glycine 0 N--CA 1.47 0.956 0 CA-C-O 117.808 -1.551 . . . . 0.0 112.304 -178.987 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 23.2 m -120.37 139.31 48.06 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.256 0 CA-C-N 118.829 1.315 . . . . 0.0 110.348 -177.003 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 25.4 t . . . . . 0 C--O 1.203 -1.35 0 CA-C-N 118.211 0.46 . . . . 0.0 110.102 173.766 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 77.8 m-85 . . . . . 0 N--CA 1.475 0.812 0 N-CA-C 109.904 -0.406 . . . . 0.0 109.904 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' E' E ' 5' ' ' ARG . . . . . . . . . . . . . 74.1 mtp180 -143.55 141.72 30.81 Favored 'General case' 0 N--CA 1.476 0.837 0 N-CA-C 109.388 -0.597 . . . . 0.0 109.388 179.875 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 76.7 m80 -150.31 118.57 6.38 Favored 'General case' 0 N--CA 1.471 0.62 0 N-CA-C 108.994 -0.743 . . . . 0.0 108.994 179.215 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' E' E ' 7' ' ' ASP . . . . . . . . . . . . . 8.6 m-20 -66.82 149.48 50.51 Favored 'General case' 0 N--CA 1.464 0.24 0 O-C-N 123.388 0.43 . . . . 0.0 111.608 -179.552 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' E' E ' 8' ' ' SER . . . . . . . . . . . . . 6.0 t -167.63 171.72 9.98 Favored 'General case' 0 N--CA 1.477 0.878 0 CA-C-N 115.938 -0.574 . . . . 0.0 109.606 178.077 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 123.22 23.91 2.09 Favored Glycine 0 N--CA 1.482 1.754 0 N-CA-C 111.843 -0.503 . . . . 0.0 111.843 179.078 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 37.4 p90 -56.29 127.33 30.36 Favored 'General case' 0 N--CA 1.472 0.674 0 N-CA-C 112.621 0.6 . . . . 0.0 112.621 -179.283 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 46.0 mt-10 -83.36 156.77 22.83 Favored 'General case' 0 N--CA 1.476 0.856 0 N-CA-C 109.489 -0.56 . . . . 0.0 109.489 177.973 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -156.54 122.89 0.54 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.646 0 N-CA-C 108.324 -0.991 . . . . 0.0 108.324 178.257 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 36.5 m80 -106.88 160.24 15.66 Favored 'General case' 0 N--CA 1.482 1.135 0 C-N-CA 122.855 0.462 . . . . 0.0 111.238 -177.944 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 58.1 t60 -164.61 99.18 0.79 Allowed 'General case' 0 N--CA 1.487 1.38 0 CA-C-N 116.859 -0.155 . . . . 0.0 111.013 -179.842 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' E' E ' 15' ' ' GLN . . . . . 0.491 HE22 HG13 ' E' ' 36' ' ' VAL . 36.3 mt-30 -125.42 -175.06 3.22 Favored 'General case' 0 CA--C 1.492 -1.263 0 N-CA-C 107.835 -1.172 . . . . 0.0 107.835 -179.98 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -169.54 103.85 0.34 Allowed 'General case' 0 CA--C 1.54 0.591 0 CA-C-N 114.9 -1.045 . . . . 0.0 109.109 179.015 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 9.6 mp -111.03 150.16 29.7 Favored 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 -179.639 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 46.1 t -144.04 118.17 3.52 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.22 0 CA-C-O 118.928 -0.558 . . . . 0.0 109.903 178.646 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 19.7 m-85 -69.32 155.27 40.7 Favored 'General case' 0 C--N 1.357 0.908 0 N-CA-C 107.569 -1.271 . . . . 0.0 107.569 176.798 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 14.0 t80 -173.41 -56.94 0.02 OUTLIER 'General case' 0 N--CA 1.48 1.072 0 CA-C-O 121.624 0.726 . . . . 0.0 110.136 179.163 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -42.74 88.48 0.0 OUTLIER 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 114.425 -1.261 . . . . 0.0 112.76 -179.051 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 44.4 mt-10 -60.11 158.37 11.36 Favored 'General case' 0 N--CA 1.471 0.619 0 CA-C-N 115.039 -0.982 . . . . 0.0 110.944 179.535 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 11.7 m-20 -140.34 135.02 31.75 Favored 'General case' 0 N--CA 1.483 1.183 0 C-N-CA 122.653 0.381 . . . . 0.0 110.687 -179.829 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 21.4 t -84.55 -115.51 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.939 0 N-CA-C 108.61 -0.885 . . . . 0.0 108.61 179.416 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . -108.65 53.65 0.58 Allowed Glycine 0 C--N 1.347 1.139 0 N-CA-C 111.317 -0.713 . . . . 0.0 111.317 -179.91 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 86.1 p -77.15 126.37 30.84 Favored 'General case' 0 N--CA 1.471 0.577 0 N-CA-C 109.336 -0.616 . . . . 0.0 109.336 178.259 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' E' E ' 27' ' ' ASN . . . . . 0.458 HD21 ' HB3' ' H' ' 27' ' ' ASN . 7.1 t-20 -66.22 100.64 0.63 Allowed 'General case' 0 N--CA 1.471 0.612 0 N-CA-C 108.079 -1.082 . . . . 0.0 108.079 178.442 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 66.5 mttm -95.39 127.67 41.62 Favored 'General case' 0 N--CA 1.483 1.182 0 N-CA-C 109.305 -0.628 . . . . 0.0 109.305 -179.15 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.36 -128.93 0.01 OUTLIER Glycine 0 CA--C 1.537 1.462 0 N-CA-C 111.013 -0.835 . . . . 0.0 111.013 179.163 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -131.67 127.1 36.24 Favored 'General case' 0 N--CA 1.484 1.236 0 CA-C-N 117.307 0.554 . . . . 0.0 110.939 -179.62 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 31.2 mt -91.09 160.4 2.71 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.238 0 N-CA-C 106.338 -1.727 . . . . 0.0 106.338 178.306 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 41.6 mt -139.29 93.69 0.78 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.766 0 N-CA-C 109.653 -0.499 . . . . 0.0 109.653 179.879 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 53.54 105.96 0.01 OUTLIER Glycine 0 CA--C 1.531 1.053 0 CA-C-N 116.11 -0.495 . . . . 0.0 114.157 177.603 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 97.7 mt -72.03 153.72 41.58 Favored 'General case' 0 CA--C 1.542 0.636 0 N-CA-C 107.206 -1.405 . . . . 0.0 107.206 176.523 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 27.6 ttt -146.41 140.23 26.16 Favored 'General case' 0 N--CA 1.485 1.285 0 N-CA-C 108.005 -1.109 . . . . 0.0 108.005 178.841 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' E' E ' 36' ' ' VAL . . . . . 0.491 HG13 HE22 ' E' ' 15' ' ' GLN . 80.2 t -161.18 152.86 4.31 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.389 0 N-CA-C 106.358 -1.719 . . . . 0.0 106.358 -179.208 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.56 73.81 0.39 Allowed Glycine 0 C--N 1.316 -0.54 0 N-CA-C 111.633 -0.587 . . . . 0.0 111.633 178.199 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 175.91 -159.34 26.79 Favored Glycine 0 C--O 1.213 -1.166 0 N-CA-C 111.313 -0.715 . . . . 0.0 111.313 -179.708 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 23.7 m -127.16 138.81 53.71 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.83 0 N-CA-C 109.332 -0.618 . . . . 0.0 109.332 179.776 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 27.6 t . . . . . 0 CA--C 1.537 0.453 0 CA-C-O 117.986 -1.007 . . . . 0.0 111.106 179.739 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 77.7 m-85 . . . . . 0 N--CA 1.476 0.831 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' F' F ' 5' ' ' ARG . . . . . . . . . . . . . 74.2 mtp180 -143.54 141.39 30.68 Favored 'General case' 0 N--CA 1.479 1.023 0 N-CA-C 109.07 -0.715 . . . . 0.0 109.07 179.933 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 76.8 m80 -150.08 118.48 6.46 Favored 'General case' 0 N--CA 1.472 0.658 0 N-CA-C 108.957 -0.757 . . . . 0.0 108.957 179.139 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' F' F ' 7' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -66.97 149.79 50.14 Favored 'General case' 0 N--CA 1.463 0.21 0 O-C-N 123.434 0.459 . . . . 0.0 111.632 -179.366 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' F' F ' 8' ' ' SER . . . . . . . . . . . . . 6.1 t -167.73 172.27 9.37 Favored 'General case' 0 N--CA 1.476 0.869 0 CA-C-N 115.885 -0.598 . . . . 0.0 109.564 178.068 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.76 23.64 2.24 Favored Glycine 0 N--CA 1.483 1.789 0 N-CA-C 111.903 -0.479 . . . . 0.0 111.903 179.003 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 37.6 p90 -56.1 127.47 30.74 Favored 'General case' 0 N--CA 1.473 0.679 0 N-CA-C 112.615 0.598 . . . . 0.0 112.615 -179.296 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 45.9 mt-10 -83.45 156.79 22.72 Favored 'General case' 0 N--CA 1.477 0.875 0 N-CA-C 109.514 -0.55 . . . . 0.0 109.514 177.994 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -156.45 122.75 0.54 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.696 0 N-CA-C 108.297 -1.001 . . . . 0.0 108.297 178.274 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 37.5 m80 -106.65 160.36 15.51 Favored 'General case' 0 N--CA 1.483 1.218 0 C-N-CA 122.8 0.44 . . . . 0.0 111.294 -177.997 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 58.7 t60 -164.86 99.65 0.77 Allowed 'General case' 0 N--CA 1.486 1.374 0 CA-C-N 116.865 -0.152 . . . . 0.0 111.131 -179.775 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' F' F ' 15' ' ' GLN . . . . . 0.478 HE22 HG13 ' F' ' 36' ' ' VAL . 36.2 mt-30 -126.15 -174.68 3.16 Favored 'General case' 0 CA--C 1.488 -1.428 0 N-CA-C 108.02 -1.104 . . . . 0.0 108.02 -179.893 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -169.86 103.93 0.32 Allowed 'General case' 0 CA--C 1.541 0.61 0 CA-C-N 114.677 -1.147 . . . . 0.0 109.218 178.969 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 9.6 mp -110.93 149.92 29.96 Favored 'General case' 0 N--CA 1.489 1.518 0 N-CA-C 108.933 -0.766 . . . . 0.0 108.933 -179.704 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 46.3 t -143.85 118.32 3.77 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.223 0 CA-C-O 118.975 -0.536 . . . . 0.0 109.827 178.653 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 19.5 m-85 -69.4 155.15 40.92 Favored 'General case' 0 C--N 1.358 0.96 0 N-CA-C 107.506 -1.294 . . . . 0.0 107.506 176.721 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 14.9 t80 -173.13 -57.1 0.02 OUTLIER 'General case' 0 N--CA 1.483 1.198 0 CA-C-O 121.564 0.697 . . . . 0.0 109.613 179.245 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -42.52 88.47 0.0 OUTLIER 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 114.716 -1.129 . . . . 0.0 112.856 -179.015 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 44.1 mt-10 -60.28 158.2 12.1 Favored 'General case' 0 N--CA 1.472 0.643 0 CA-C-N 115.085 -0.961 . . . . 0.0 110.999 179.437 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 12.1 m-20 -140.2 134.97 31.9 Favored 'General case' 0 N--CA 1.482 1.132 0 C-N-CA 122.752 0.421 . . . . 0.0 110.784 -179.822 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' F' F ' 24' ' ' VAL . . . . . . . . . . . . . 21.3 t -84.51 -115.73 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.986 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 179.327 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -108.36 53.31 0.6 Allowed Glycine 0 N--CA 1.477 1.373 0 N-CA-C 111.154 -0.778 . . . . 0.0 111.154 -179.872 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 87.3 p -76.75 126.36 30.85 Favored 'General case' 0 N--CA 1.47 0.535 0 N-CA-C 109.313 -0.625 . . . . 0.0 109.313 178.141 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' F' F ' 27' ' ' ASN . . . . . 0.466 HD21 ' HB3' ' I' ' 27' ' ' ASN . 7.0 t-20 -66.48 100.7 0.68 Allowed 'General case' 0 N--CA 1.471 0.609 0 N-CA-C 108.195 -1.039 . . . . 0.0 108.195 178.412 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 66.6 mttm -95.39 127.65 41.61 Favored 'General case' 0 N--CA 1.483 1.221 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 -179.082 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.53 -129.15 0.01 OUTLIER Glycine 0 CA--C 1.539 1.576 0 N-CA-C 111.139 -0.784 . . . . 0.0 111.139 179.161 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -131.17 126.67 36.23 Favored 'General case' 0 N--CA 1.488 1.451 0 CA-C-N 117.308 0.554 . . . . 0.0 111.058 -179.668 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 32.2 mt -90.95 160.14 2.74 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.237 0 N-CA-C 106.236 -1.764 . . . . 0.0 106.236 178.265 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 41.0 mt -139.09 93.65 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.763 0 N-CA-C 109.671 -0.492 . . . . 0.0 109.671 179.864 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 53.61 106.0 0.01 OUTLIER Glycine 0 CA--C 1.532 1.114 0 CA-C-N 116.099 -0.5 . . . . 0.0 114.121 177.607 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 97.8 mt -72.0 153.94 41.47 Favored 'General case' 0 CA--C 1.54 0.561 0 N-CA-C 107.295 -1.372 . . . . 0.0 107.295 176.589 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 27.5 ttt -146.75 140.21 25.7 Favored 'General case' 0 N--CA 1.481 1.087 0 N-CA-C 108.408 -0.96 . . . . 0.0 108.408 178.819 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' F' F ' 36' ' ' VAL . . . . . 0.478 HG13 HE22 ' F' ' 15' ' ' GLN . 75.8 t -161.13 153.02 4.29 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.472 0 N-CA-C 106.452 -1.685 . . . . 0.0 106.452 -179.073 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.67 73.83 0.39 Allowed Glycine 0 C--N 1.316 -0.573 0 N-CA-C 111.543 -0.623 . . . . 0.0 111.543 178.049 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 175.5 -159.99 28.2 Favored Glycine 0 C--O 1.213 -1.195 0 N-CA-C 111.202 -0.759 . . . . 0.0 111.202 -179.723 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 23.3 m -126.36 139.01 52.89 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.824 0 N-CA-C 109.414 -0.588 . . . . 0.0 109.414 179.764 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 28.0 t . . . . . 0 CA--C 1.537 0.48 0 CA-C-O 117.957 -1.021 . . . . 0.0 111.181 179.703 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 77.4 m-85 . . . . . 0 N--CA 1.474 0.744 0 N-CA-C 109.583 -0.525 . . . . 0.0 109.583 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' G' G ' 5' ' ' ARG . . . . . . . . . . . . . 74.1 mtp180 -144.01 140.97 29.88 Favored 'General case' 0 N--CA 1.482 1.162 0 N-CA-C 109.178 -0.675 . . . . 0.0 109.178 -179.671 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 76.6 m80 -149.47 119.84 7.36 Favored 'General case' 0 N--CA 1.472 0.666 0 N-CA-C 109.04 -0.726 . . . . 0.0 109.04 179.016 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 8.7 m-20 -69.05 145.27 53.62 Favored 'General case' 0 CA--C 1.537 0.462 0 O-C-N 123.509 0.505 . . . . 0.0 112.062 -179.167 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' G' G ' 8' ' ' SER . . . . . . . . . . . . . 5.6 t -163.98 173.6 12.41 Favored 'General case' 0 N--CA 1.47 0.534 0 N-CA-C 109.474 -0.565 . . . . 0.0 109.474 178.2 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.47 23.33 2.37 Favored Glycine 0 N--CA 1.48 1.613 0 N-CA-C 111.731 -0.548 . . . . 0.0 111.731 178.942 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 41.7 p90 -56.55 127.68 32.46 Favored 'General case' 0 N--CA 1.475 0.8 0 N-CA-C 112.381 0.511 . . . . 0.0 112.381 -178.862 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 46.1 mt-10 -84.02 155.74 22.59 Favored 'General case' 0 N--CA 1.472 0.638 0 CA-C-O 121.05 0.452 . . . . 0.0 109.935 178.595 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -156.4 123.28 0.57 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.05 0 N-CA-C 108.277 -1.009 . . . . 0.0 108.277 178.545 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 35.3 m80 -106.36 160.21 15.55 Favored 'General case' 0 N--CA 1.481 1.093 0 CA-C-N 115.213 -0.903 . . . . 0.0 110.845 -178.419 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 59.2 t60 -165.64 99.27 0.68 Allowed 'General case' 0 N--CA 1.484 1.238 0 CA-C-N 116.453 -0.339 . . . . 0.0 110.777 179.51 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' G' G ' 15' ' ' GLN . . . . . 0.486 HE22 HG13 ' G' ' 36' ' ' VAL . 36.5 mt-30 -125.18 -175.0 3.19 Favored 'General case' 0 CA--C 1.493 -1.237 0 N-CA-C 108.031 -1.099 . . . . 0.0 108.031 -179.94 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -169.76 103.46 0.32 Allowed 'General case' 0 CA--C 1.541 0.624 0 CA-C-N 114.904 -1.043 . . . . 0.0 109.338 179.013 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 9.6 mp -109.89 149.5 29.79 Favored 'General case' 0 N--CA 1.49 1.533 0 N-CA-C 109.21 -0.663 . . . . 0.0 109.21 -179.793 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 43.9 t -145.24 117.64 2.31 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.841 0 N-CA-C 109.607 -0.516 . . . . 0.0 109.607 178.33 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 28.8 m-85 -68.11 149.45 49.6 Favored 'General case' 0 C--N 1.37 1.495 0 O-C-N 124.873 1.358 . . . . 0.0 107.842 176.653 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' G' G ' 20' ' ' PHE . . . . . 0.402 ' O ' ' N ' ' G' ' 22' ' ' GLU . 12.0 t80 -171.46 -56.15 0.02 OUTLIER 'General case' 0 N--CA 1.484 1.274 0 N-CA-C 110.205 -0.294 . . . . 0.0 110.205 179.943 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -42.99 90.01 0.0 OUTLIER 'General case' 0 C--N 1.325 -0.485 0 C-N-CA 123.521 0.729 . . . . 0.0 112.343 179.895 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' G' G ' 22' ' ' GLU . . . . . 0.402 ' N ' ' O ' ' G' ' 20' ' ' PHE . 46.1 mt-10 -61.44 158.65 14.28 Favored 'General case' 0 N--CA 1.468 0.43 0 CA-C-N 114.895 -1.048 . . . . 0.0 110.149 179.087 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 12.0 m-20 -140.11 135.49 32.59 Favored 'General case' 0 N--CA 1.481 1.103 0 C-N-CA 122.702 0.401 . . . . 0.0 110.3 -179.897 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' G' G ' 24' ' ' VAL . . . . . . . . . . . . . 21.4 t -85.63 -115.24 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.96 0 N-CA-C 108.331 -0.989 . . . . 0.0 108.331 179.356 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -108.8 53.87 0.57 Allowed Glycine 0 N--CA 1.477 1.43 0 N-CA-C 111.382 -0.687 . . . . 0.0 111.382 -179.883 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 86.8 p -77.32 126.6 31.19 Favored 'General case' 0 C--N 1.327 -0.413 0 N-CA-C 109.146 -0.686 . . . . 0.0 109.146 178.08 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' G' G ' 27' ' ' ASN . . . . . 0.467 ' HB3' HD21 ' D' ' 27' ' ' ASN . 6.4 t-20 -66.38 100.31 0.63 Allowed 'General case' 0 N--CA 1.469 0.504 0 N-CA-C 108.531 -0.915 . . . . 0.0 108.531 178.542 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 67.1 mttm -94.65 127.56 40.7 Favored 'General case' 0 N--CA 1.484 1.259 0 N-CA-C 109.646 -0.501 . . . . 0.0 109.646 -179.452 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -62.95 -127.11 0.01 OUTLIER Glycine 0 CA--C 1.529 0.962 0 N-CA-C 111.166 -0.774 . . . . 0.0 111.166 179.227 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -132.81 125.73 30.71 Favored 'General case' 0 N--CA 1.47 0.532 0 C-N-CA 122.874 0.47 . . . . 0.0 110.563 -179.141 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 40.9 mt -90.23 162.15 2.52 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.667 0 N-CA-C 106.477 -1.675 . . . . 0.0 106.477 178.356 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 45.0 mt -140.11 95.01 0.78 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.312 0 CA-C-N 119.756 1.162 . . . . 0.0 109.834 178.212 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 53.98 105.26 0.01 OUTLIER Glycine 0 CA--C 1.532 1.115 0 N-CA-C 114.07 0.388 . . . . 0.0 114.07 177.53 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 98.8 mt -71.93 152.85 42.23 Favored 'General case' 0 CA--C 1.539 0.536 0 N-CA-C 107.366 -1.346 . . . . 0.0 107.366 176.729 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 27.5 ttt -146.27 141.13 27.03 Favored 'General case' 0 N--CA 1.477 0.913 0 N-CA-C 107.996 -1.113 . . . . 0.0 107.996 179.084 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' G' G ' 36' ' ' VAL . . . . . 0.486 HG13 HE22 ' G' ' 15' ' ' GLN . 93.0 t -161.45 153.09 4.06 Favored 'Isoleucine or valine' 0 C--O 1.233 0.206 0 N-CA-C 106.553 -1.647 . . . . 0.0 106.553 -179.423 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.64 73.84 0.38 Allowed Glycine 0 C--N 1.313 -0.696 0 C-N-CA 121.035 -0.602 . . . . 0.0 111.951 177.701 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' G' G ' 38' ' ' GLY . . . . . 0.407 ' O ' ' HA3' ' D' ' 38' ' ' GLY . . . 174.75 -158.82 27.11 Favored Glycine 0 C--O 1.215 -1.067 0 N-CA-C 110.499 -1.04 . . . . 0.0 110.499 179.462 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 27.8 m -126.61 139.07 52.79 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.095 0 CA-C-N 117.249 0.525 . . . . 0.0 109.989 -179.824 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 36.3 t . . . . . 0 N--CA 1.469 0.503 0 CA-C-O 117.8 -1.095 . . . . 0.0 111.327 179.581 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 77.9 m-85 . . . . . 0 N--CA 1.474 0.765 0 N-CA-C 109.526 -0.546 . . . . 0.0 109.526 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' H' H ' 5' ' ' ARG . . . . . . . . . . . . . 74.2 mtp180 -144.22 140.87 29.54 Favored 'General case' 0 N--CA 1.481 1.103 0 N-CA-C 109.162 -0.681 . . . . 0.0 109.162 -179.65 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 76.9 m80 -149.46 119.79 7.34 Favored 'General case' 0 N--CA 1.475 0.79 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 179.07 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 8.8 m-20 -69.05 145.27 53.63 Favored 'General case' 0 N--CA 1.468 0.43 0 CA-C-N 116.203 -0.453 . . . . 0.0 112.092 -179.305 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' H' H ' 8' ' ' SER . . . . . . . . . . . . . 6.3 t -163.97 172.82 13.38 Favored 'General case' 0 N--CA 1.47 0.555 0 N-CA-C 109.458 -0.571 . . . . 0.0 109.458 178.555 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.69 23.5 2.29 Favored Glycine 0 N--CA 1.481 1.67 0 N-CA-C 111.77 -0.532 . . . . 0.0 111.77 179.008 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 40.8 p90 -56.49 127.58 31.9 Favored 'General case' 0 N--CA 1.472 0.674 0 N-CA-C 112.461 0.541 . . . . 0.0 112.461 -178.986 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 46.1 mt-10 -83.94 155.85 22.63 Favored 'General case' 0 N--CA 1.473 0.687 0 CA-C-O 121.086 0.469 . . . . 0.0 109.906 178.706 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -156.63 122.92 0.53 Allowed 'Isoleucine or valine' 0 CA--C 1.554 1.126 0 N-CA-C 108.335 -0.987 . . . . 0.0 108.335 178.649 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 34.1 m80 -106.08 160.45 15.3 Favored 'General case' 0 N--CA 1.48 1.047 0 CA-C-N 115.167 -0.924 . . . . 0.0 110.943 -178.385 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 58.1 t60 -165.86 99.43 0.66 Allowed 'General case' 0 N--CA 1.483 1.204 0 CA-C-N 116.532 -0.303 . . . . 0.0 110.854 179.533 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' H' H ' 15' ' ' GLN . . . . . 0.498 HE22 HG13 ' H' ' 36' ' ' VAL . 35.9 mt-30 -125.34 -175.33 3.29 Favored 'General case' 0 CA--C 1.49 -1.335 0 N-CA-C 107.834 -1.172 . . . . 0.0 107.834 -179.829 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -169.51 103.95 0.35 Allowed 'General case' 0 CA--C 1.541 0.623 0 CA-C-N 114.808 -1.087 . . . . 0.0 109.182 178.987 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 9.7 mp -110.34 149.15 30.64 Favored 'General case' 0 N--CA 1.489 1.502 0 N-CA-C 109.115 -0.698 . . . . 0.0 109.115 -179.746 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 43.7 t -144.99 117.51 2.38 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.818 0 N-CA-C 109.705 -0.48 . . . . 0.0 109.705 178.386 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 29.1 m-85 -68.64 149.74 48.78 Favored 'General case' 0 C--N 1.37 1.489 0 O-C-N 124.83 1.331 . . . . 0.0 107.855 176.741 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 12.5 t80 -172.45 -56.23 0.02 OUTLIER 'General case' 0 N--CA 1.482 1.162 0 N-CA-C 110.209 -0.293 . . . . 0.0 110.209 -179.882 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -42.88 90.2 0.0 OUTLIER 'General case' 0 CA--C 1.536 0.406 0 C-N-CA 123.429 0.692 . . . . 0.0 112.031 -179.971 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 46.0 mt-10 -61.34 158.95 13.34 Favored 'General case' 0 N--CA 1.469 0.522 0 CA-C-N 114.907 -1.042 . . . . 0.0 110.22 179.245 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 12.3 m-20 -140.14 135.74 32.79 Favored 'General case' 0 N--CA 1.482 1.148 0 C-N-CA 122.658 0.383 . . . . 0.0 110.301 -179.949 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' H' H ' 24' ' ' VAL . . . . . . . . . . . . . 21.3 t -85.81 -115.48 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.991 0 N-CA-C 108.467 -0.938 . . . . 0.0 108.467 179.366 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . -108.3 53.3 0.6 Allowed Glycine 0 N--CA 1.479 1.558 0 N-CA-C 111.138 -0.785 . . . . 0.0 111.138 -179.878 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 85.5 p -77.04 126.64 31.31 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 109.11 -0.7 . . . . 0.0 109.11 178.195 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' H' H ' 27' ' ' ASN . . . . . 0.458 ' HB3' HD21 ' E' ' 27' ' ' ASN . 6.5 t-20 -66.7 100.81 0.73 Allowed 'General case' 0 N--CA 1.469 0.516 0 N-CA-C 108.479 -0.934 . . . . 0.0 108.479 178.589 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 67.1 mttm -95.21 127.62 41.4 Favored 'General case' 0 N--CA 1.485 1.299 0 N-CA-C 109.605 -0.517 . . . . 0.0 109.605 -179.408 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.01 -126.85 0.01 OUTLIER Glycine 0 CA--C 1.528 0.877 0 N-CA-C 111.137 -0.785 . . . . 0.0 111.137 179.26 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -133.16 125.82 30.31 Favored 'General case' 0 N--CA 1.47 0.563 0 C-N-CA 122.824 0.45 . . . . 0.0 110.718 -179.126 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 40.1 mt -90.4 161.83 2.56 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.67 0 N-CA-C 106.496 -1.668 . . . . 0.0 106.496 178.369 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 46.0 mt -139.97 94.84 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.324 0 CA-C-N 119.533 1.06 . . . . 0.0 109.789 178.343 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 53.99 105.93 0.01 OUTLIER Glycine 0 CA--C 1.532 1.135 0 CA-C-N 116.291 -0.413 . . . . 0.0 114.042 177.617 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 99.1 mt -72.42 152.64 41.87 Favored 'General case' 0 CA--C 1.54 0.579 0 N-CA-C 107.255 -1.387 . . . . 0.0 107.255 176.706 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 27.6 ttt -145.94 140.82 27.22 Favored 'General case' 0 N--CA 1.478 0.975 0 N-CA-C 107.941 -1.133 . . . . 0.0 107.941 179.062 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' H' H ' 36' ' ' VAL . . . . . 0.498 HG13 HE22 ' H' ' 15' ' ' GLN . 90.1 t -161.24 153.22 4.15 Favored 'Isoleucine or valine' 0 C--O 1.233 0.216 0 N-CA-C 106.488 -1.671 . . . . 0.0 106.488 -179.39 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.42 73.78 0.39 Allowed Glycine 0 C--N 1.314 -0.679 0 C-N-CA 121.255 -0.498 . . . . 0.0 111.949 177.796 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 174.93 -158.63 26.59 Favored Glycine 0 C--O 1.215 -1.057 0 N-CA-C 110.527 -1.029 . . . . 0.0 110.527 179.469 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 27.0 m -126.81 138.97 53.16 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.161 0 CA-C-N 117.084 0.442 . . . . 0.0 109.964 -179.823 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 35.8 t . . . . . 0 N--CA 1.468 0.431 0 CA-C-O 117.801 -1.095 . . . . 0.0 111.436 179.61 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 77.4 m-85 . . . . . 0 N--CA 1.475 0.825 0 N-CA-C 109.54 -0.541 . . . . 0.0 109.54 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' I' I ' 5' ' ' ARG . . . . . . . . . . . . . 74.0 mtp180 -144.39 141.02 29.4 Favored 'General case' 0 N--CA 1.482 1.169 0 N-CA-C 109.079 -0.712 . . . . 0.0 109.079 -179.687 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 76.8 m80 -149.62 119.41 7.06 Favored 'General case' 0 N--CA 1.472 0.636 0 N-CA-C 109.017 -0.734 . . . . 0.0 109.017 179.17 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 8.6 m-20 -68.67 145.42 53.89 Favored 'General case' 0 N--CA 1.467 0.406 0 O-C-N 123.455 0.472 . . . . 0.0 112.024 -179.244 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' I' I ' 8' ' ' SER . . . . . . . . . . . . . 6.6 t -164.17 172.9 13.06 Favored 'General case' 0 N--CA 1.469 0.502 0 N-CA-C 109.529 -0.545 . . . . 0.0 109.529 178.435 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.68 23.48 2.29 Favored Glycine 0 N--CA 1.48 1.626 0 N-CA-C 111.76 -0.536 . . . . 0.0 111.76 179.052 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 40.9 p90 -56.54 127.57 31.92 Favored 'General case' 0 N--CA 1.474 0.744 0 N-CA-C 112.398 0.518 . . . . 0.0 112.398 -178.995 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 46.0 mt-10 -83.92 155.83 22.67 Favored 'General case' 0 N--CA 1.474 0.76 0 CA-C-O 121.096 0.474 . . . . 0.0 109.896 178.632 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -156.54 123.05 0.54 Allowed 'Isoleucine or valine' 0 CA--C 1.553 1.082 0 N-CA-C 108.299 -1.0 . . . . 0.0 108.299 178.586 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 35.0 m80 -106.04 160.08 15.57 Favored 'General case' 0 N--CA 1.481 1.081 0 CA-C-N 115.128 -0.942 . . . . 0.0 110.978 -178.336 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 58.4 t60 -165.65 99.38 0.68 Allowed 'General case' 0 N--CA 1.484 1.239 0 CA-C-N 116.563 -0.289 . . . . 0.0 110.943 179.459 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' I' I ' 15' ' ' GLN . . . . . 0.5 HE22 HG13 ' I' ' 36' ' ' VAL . 35.8 mt-30 -125.38 -175.12 3.23 Favored 'General case' 0 CA--C 1.489 -1.403 0 N-CA-C 107.905 -1.146 . . . . 0.0 107.905 -179.865 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -169.65 104.12 0.34 Allowed 'General case' 0 CA--C 1.541 0.615 0 CA-C-N 114.8 -1.091 . . . . 0.0 109.255 179.047 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 9.7 mp -110.43 149.34 30.42 Favored 'General case' 0 N--CA 1.488 1.465 0 N-CA-C 109.16 -0.682 . . . . 0.0 109.16 -179.763 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 43.7 t -145.2 117.57 2.3 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.863 0 N-CA-C 109.649 -0.5 . . . . 0.0 109.649 178.391 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 28.8 m-85 -68.7 149.79 48.66 Favored 'General case' 0 C--N 1.371 1.536 0 O-C-N 124.773 1.296 . . . . 0.0 107.817 176.72 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' I' I ' 20' ' ' PHE . . . . . 0.403 ' O ' ' N ' ' I' ' 22' ' ' GLU . 12.6 t80 -172.54 -56.14 0.02 OUTLIER 'General case' 0 N--CA 1.481 1.115 0 N-CA-C 110.205 -0.294 . . . . 0.0 110.205 -179.855 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -43.0 90.2 0.0 OUTLIER 'General case' 0 CA--C 1.535 0.381 0 C-N-CA 123.378 0.671 . . . . 0.0 112.06 -179.98 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' I' I ' 22' ' ' GLU . . . . . 0.403 ' N ' ' O ' ' I' ' 20' ' ' PHE . 46.1 mt-10 -61.17 158.93 12.88 Favored 'General case' 0 N--CA 1.47 0.528 0 CA-C-N 114.893 -1.049 . . . . 0.0 110.267 179.241 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 12.2 m-20 -140.22 135.68 32.61 Favored 'General case' 0 N--CA 1.482 1.143 0 C-N-CA 122.597 0.359 . . . . 0.0 110.304 -179.992 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' I' I ' 24' ' ' VAL . . . . . . . . . . . . . 21.2 t -85.8 -115.51 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.96 0 N-CA-C 108.463 -0.94 . . . . 0.0 108.463 179.386 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . -108.31 53.29 0.6 Allowed Glycine 0 N--CA 1.478 1.469 0 N-CA-C 111.249 -0.74 . . . . 0.0 111.249 -179.909 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 85.9 p -77.01 126.73 31.46 Favored 'General case' 0 C--N 1.329 -0.289 0 N-CA-C 109.202 -0.666 . . . . 0.0 109.202 178.148 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' I' I ' 27' ' ' ASN . . . . . 0.466 ' HB3' HD21 ' F' ' 27' ' ' ASN . 6.3 t-20 -66.67 100.97 0.74 Allowed 'General case' 0 N--CA 1.469 0.488 0 N-CA-C 108.474 -0.936 . . . . 0.0 108.474 178.56 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 67.2 mttm -95.38 127.52 41.5 Favored 'General case' 0 N--CA 1.483 1.224 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 -179.431 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -62.99 -127.4 0.01 OUTLIER Glycine 0 CA--C 1.53 0.969 0 N-CA-C 111.099 -0.8 . . . . 0.0 111.099 179.33 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -132.38 125.86 31.84 Favored 'General case' 0 N--CA 1.471 0.624 0 C-N-CA 122.906 0.482 . . . . 0.0 110.719 -179.109 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 39.8 mt -90.61 161.41 2.61 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.624 0 N-CA-C 106.458 -1.682 . . . . 0.0 106.458 178.233 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 47.0 mt -139.54 94.73 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.297 0 CA-C-N 119.586 1.085 . . . . 0.0 109.8 178.374 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 54.1 105.87 0.01 OUTLIER Glycine 0 CA--C 1.532 1.103 0 CA-C-N 116.32 -0.4 . . . . 0.0 114.011 177.568 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 98.7 mt -72.35 152.79 41.85 Favored 'General case' 0 CA--C 1.539 0.527 0 N-CA-C 107.295 -1.372 . . . . 0.0 107.295 176.721 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 27.6 ttt -146.02 140.77 27.06 Favored 'General case' 0 N--CA 1.478 0.956 0 N-CA-C 107.877 -1.157 . . . . 0.0 107.877 179.157 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' I' I ' 36' ' ' VAL . . . . . 0.5 HG13 HE22 ' I' ' 15' ' ' GLN . 94.9 t -161.12 153.46 4.13 Favored 'Isoleucine or valine' 0 C--O 1.233 0.193 0 N-CA-C 106.382 -1.71 . . . . 0.0 106.382 -179.45 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.08 73.95 0.37 Allowed Glycine 0 C--N 1.313 -0.724 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.894 177.762 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 174.95 -158.67 26.65 Favored Glycine 0 C--O 1.216 -1.012 0 N-CA-C 110.547 -1.021 . . . . 0.0 110.547 179.43 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 27.3 m -126.88 138.82 53.65 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.097 0 CA-C-N 117.186 0.493 . . . . 0.0 109.86 -179.722 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 36.8 t . . . . . 0 N--CA 1.469 0.517 0 CA-C-O 117.849 -1.072 . . . . 0.0 111.329 179.525 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 16.5 m-85 . . . . . 0 N--CA 1.469 0.498 0 N-CA-C 109.369 -0.604 . . . . 0.0 109.369 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 54.0 mtp180 -68.03 129.7 40.71 Favored 'General case' 0 N--CA 1.467 0.383 0 CA-C-N 115.868 -0.606 . . . . 0.0 110.533 -177.798 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 3.7 m-70 -96.1 125.59 40.74 Favored 'General case' 0 N--CA 1.473 0.691 0 N-CA-C 109.725 -0.472 . . . . 0.0 109.725 179.002 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 7' ' ' ASP . . . . . 0.495 ' OD1' HG11 ' F' ' 24' ' ' VAL . 10.0 m-20 -72.23 144.81 48.32 Favored 'General case' 0 CA--C 1.532 0.255 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.109 -179.81 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 23.0 t -160.72 179.47 8.51 Favored 'General case' 0 N--CA 1.471 0.615 0 N-CA-C 109.329 -0.619 . . . . 0.0 109.329 178.89 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 124.52 19.86 2.49 Favored Glycine 0 N--CA 1.487 2.064 0 N-CA-C 111.886 -0.486 . . . . 0.0 111.886 179.896 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 43.6 p90 -57.43 129.2 40.74 Favored 'General case' 0 N--CA 1.475 0.82 0 O-C-N 122.458 -0.436 . . . . 0.0 112.084 -179.707 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 46.7 mt-10 -85.54 154.7 21.57 Favored 'General case' 0 N--CA 1.469 0.512 0 N-CA-C 109.046 -0.724 . . . . 0.0 109.046 178.406 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -153.76 129.3 1.64 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 N-CA-C 108.046 -1.094 . . . . 0.0 108.046 178.895 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 51.3 m-70 -135.05 143.75 46.89 Favored 'General case' 0 N--CA 1.49 1.543 0 CA-C-N 118.803 0.729 . . . . 0.0 110.956 -179.218 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -165.98 98.21 0.64 Allowed 'General case' 0 N--CA 1.482 1.16 0 CA-C-N 116.688 -0.233 . . . . 0.0 111.099 179.673 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 45.4 mt-30 -108.06 -171.98 1.97 Allowed 'General case' 0 CA--C 1.503 -0.851 0 N-CA-C 108.176 -1.046 . . . . 0.0 108.176 179.712 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -164.34 97.86 0.8 Allowed 'General case' 0 N--CA 1.472 0.651 0 CA-C-N 115.243 -0.889 . . . . 0.0 109.516 178.686 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.582 ' N ' HD12 ' A' ' 17' ' ' LEU . 4.8 mp -107.02 163.85 12.64 Favored 'General case' 0 N--CA 1.488 1.44 0 N-CA-C 108.59 -0.893 . . . . 0.0 108.59 179.916 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 56.3 t -141.28 119.05 8.84 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.31 0 CA-C-O 118.772 -0.632 . . . . 0.0 109.847 179.433 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 54.5 m-85 -70.13 158.55 35.55 Favored 'General case' 0 N--CA 1.479 1.021 0 N-CA-C 107.706 -1.22 . . . . 0.0 107.706 177.275 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 13.8 t80 -171.03 -58.46 0.02 OUTLIER 'General case' 0 N--CA 1.483 1.217 0 CA-C-O 122.424 1.107 . . . . 0.0 109.672 179.333 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.42 90.05 0.0 OUTLIER 'General case' 0 N--CA 1.457 -0.092 0 CA-C-N 113.927 -1.488 . . . . 0.0 112.852 -178.078 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 37.7 tt0 -62.13 156.51 21.42 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 115.166 -0.925 . . . . 0.0 110.618 178.891 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 12.2 m-20 -138.09 129.75 28.09 Favored 'General case' 0 N--CA 1.482 1.132 0 C-N-CA 122.93 0.492 . . . . 0.0 110.246 -179.659 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.953 HG12 ' H ' ' A' ' 25' ' ' GLY . 39.6 t -79.6 -164.37 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 1.024 0 N-CA-C 108.518 -0.919 . . . . 0.0 108.518 179.583 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.953 ' H ' HG12 ' A' ' 24' ' ' VAL . . . -71.42 51.43 1.08 Allowed Glycine 0 CA--C 1.527 0.827 0 CA-C-N 118.399 0.545 . . . . 0.0 112.038 -179.086 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 27.1 p -72.36 136.45 46.14 Favored 'General case' 0 C--O 1.22 -0.488 0 N-CA-C 109.564 -0.532 . . . . 0.0 109.564 178.877 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 2.0 t-20 -68.66 95.5 0.66 Allowed 'General case' 0 N--CA 1.468 0.463 0 N-CA-C 108.479 -0.934 . . . . 0.0 108.479 178.139 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 67.8 mttm -93.34 119.26 32.27 Favored 'General case' 0 N--CA 1.481 1.108 0 N-CA-C 110.295 -0.261 . . . . 0.0 110.295 -179.104 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.12 -126.12 0.01 OUTLIER Glycine 0 CA--C 1.533 1.166 0 N-CA-C 110.485 -1.046 . . . . 0.0 110.485 178.639 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.24 134.23 48.94 Favored 'General case' 0 N--CA 1.48 1.035 0 N-CA-C 109.078 -0.712 . . . . 0.0 109.078 179.111 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 65.4 mt -83.3 138.05 19.95 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.467 0 N-CA-C 107.3 -1.37 . . . . 0.0 107.3 178.657 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 31.3 mt -130.46 127.71 62.8 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.914 0 O-C-N 123.472 0.483 . . . . 0.0 110.044 -178.592 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.27 78.9 0.14 Allowed Glycine 0 CA--C 1.524 0.653 0 CA-C-N 115.885 -0.598 . . . . 0.0 112.869 178.7 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.438 HD23 ' N ' ' A' ' 35' ' ' MET . 1.7 tt -109.94 120.82 43.67 Favored 'General case' 0 N--CA 1.481 1.077 0 N-CA-C 107.175 -1.417 . . . . 0.0 107.175 177.653 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 35' ' ' MET . . . . . 0.438 ' N ' HD23 ' A' ' 34' ' ' LEU . 8.8 mtp -154.08 161.24 42.05 Favored 'General case' 0 N--CA 1.472 0.647 0 N-CA-C 108.662 -0.866 . . . . 0.0 108.662 179.736 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.539 HG12 HE22 ' D' ' 15' ' ' GLN . 78.1 t -158.07 144.76 8.81 Favored 'Isoleucine or valine' 0 C--O 1.234 0.261 0 N-CA-C 106.774 -1.565 . . . . 0.0 106.774 -179.789 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.77 74.06 0.36 Allowed Glycine 0 C--N 1.315 -0.616 0 N-CA-C 111.511 -0.636 . . . . 0.0 111.511 178.675 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 169.99 -149.07 12.43 Favored Glycine 0 CA--C 1.519 0.324 0 N-CA-C 110.898 -0.881 . . . . 0.0 110.898 179.938 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 16.0 m -134.65 148.74 29.36 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.84 0 C-N-CA 122.675 0.39 . . . . 0.0 109.951 179.955 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 21.9 t . . . . . 0 C--O 1.22 -0.497 0 CA-C-O 117.81 -1.09 . . . . 0.0 111.043 178.931 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 17.3 m-85 . . . . . 0 N--CA 1.47 0.548 0 N-CA-C 109.404 -0.591 . . . . 0.0 109.404 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 54.3 mtp180 -68.36 129.61 40.45 Favored 'General case' 0 CA--C 1.534 0.349 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.525 -177.748 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 3.6 m-70 -95.99 125.6 40.65 Favored 'General case' 0 N--CA 1.473 0.703 0 N-CA-C 109.797 -0.446 . . . . 0.0 109.797 179.048 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 7' ' ' ASP . . . . . 0.513 ' OD1' HG11 ' D' ' 24' ' ' VAL . 10.0 m-20 -72.18 144.98 48.34 Favored 'General case' 0 CA--C 1.532 0.269 0 CA-C-N 116.464 -0.334 . . . . 0.0 111.163 -179.863 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 8' ' ' SER . . . . . . . . . . . . . 23.1 t -160.82 179.49 8.47 Favored 'General case' 0 N--CA 1.47 0.539 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 178.851 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 124.37 19.88 2.52 Favored Glycine 0 N--CA 1.487 2.081 0 N-CA-C 111.8 -0.52 . . . . 0.0 111.8 179.854 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 43.3 p90 -57.36 129.24 40.92 Favored 'General case' 0 N--CA 1.474 0.736 0 O-C-N 122.489 -0.418 . . . . 0.0 112.073 -179.788 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 46.6 mt-10 -85.55 154.79 21.51 Favored 'General case' 0 N--CA 1.47 0.557 0 N-CA-C 109.15 -0.685 . . . . 0.0 109.15 178.389 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -153.8 129.09 1.56 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.328 0 N-CA-C 108.188 -1.041 . . . . 0.0 108.188 178.839 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 50.9 m-70 -134.8 143.87 47.33 Favored 'General case' 0 N--CA 1.49 1.566 0 CA-C-N 118.79 0.723 . . . . 0.0 110.91 -179.089 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -166.02 98.23 0.63 Allowed 'General case' 0 N--CA 1.483 1.203 0 CA-C-N 116.616 -0.266 . . . . 0.0 111.117 179.619 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 45.5 mt-30 -108.09 -172.52 2.08 Favored 'General case' 0 CA--C 1.502 -0.896 0 N-CA-C 108.168 -1.049 . . . . 0.0 108.168 179.805 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 16' ' ' LYS . . . . . 0.401 ' C ' HD12 ' B' ' 17' ' ' LEU . 88.2 tttt -164.06 97.69 0.83 Allowed 'General case' 0 N--CA 1.473 0.698 0 CA-C-N 115.152 -0.931 . . . . 0.0 109.411 178.747 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 17' ' ' LEU . . . . . 0.584 ' N ' HD12 ' B' ' 17' ' ' LEU . 4.8 mp -106.97 163.91 12.58 Favored 'General case' 0 N--CA 1.488 1.427 0 N-CA-C 108.506 -0.924 . . . . 0.0 108.506 179.867 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 58.7 t -141.37 118.7 8.22 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.358 0 CA-C-O 118.957 -0.544 . . . . 0.0 109.821 179.512 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 56.0 m-85 -70.39 158.64 35.62 Favored 'General case' 0 N--CA 1.477 0.907 0 N-CA-C 107.614 -1.254 . . . . 0.0 107.614 177.25 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 14.5 t80 -171.64 -57.7 0.02 OUTLIER 'General case' 0 N--CA 1.482 1.164 0 CA-C-O 122.284 1.04 . . . . 0.0 109.764 179.288 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.56 90.49 0.0 OUTLIER 'General case' 0 C--O 1.232 0.156 0 CA-C-N 114.098 -1.41 . . . . 0.0 112.682 -178.126 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 37.6 tt0 -62.55 156.37 23.28 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 115.173 -0.921 . . . . 0.0 110.544 179.038 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 12.3 m-20 -138.0 130.16 28.88 Favored 'General case' 0 N--CA 1.483 1.196 0 C-N-CA 123.01 0.524 . . . . 0.0 110.193 -179.671 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 24' ' ' VAL . . . . . 0.983 HG12 ' H ' ' B' ' 25' ' ' GLY . 39.2 t -80.13 -163.89 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.037 0 N-CA-C 108.593 -0.891 . . . . 0.0 108.593 179.618 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 25' ' ' GLY . . . . . 0.983 ' H ' HG12 ' B' ' 24' ' ' VAL . . . -71.36 50.93 1.05 Allowed Glycine 0 C--N 1.342 0.897 0 CA-C-N 118.324 0.511 . . . . 0.0 112.045 -179.182 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 28.9 p -72.16 136.16 46.38 Favored 'General case' 0 C--O 1.22 -0.476 0 N-CA-C 109.644 -0.502 . . . . 0.0 109.644 178.798 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 2.0 t-20 -68.61 95.39 0.64 Allowed 'General case' 0 N--CA 1.469 0.5 0 N-CA-C 108.495 -0.928 . . . . 0.0 108.495 178.137 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 67.9 mttm -93.19 119.12 32.03 Favored 'General case' 0 N--CA 1.481 1.1 0 N-CA-C 110.358 -0.238 . . . . 0.0 110.358 -179.061 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.08 -125.67 0.01 OUTLIER Glycine 0 CA--C 1.534 1.28 0 N-CA-C 110.511 -1.036 . . . . 0.0 110.511 178.64 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.65 134.36 48.51 Favored 'General case' 0 N--CA 1.481 1.103 0 N-CA-C 109.159 -0.682 . . . . 0.0 109.159 179.141 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 65.6 mt -83.43 138.25 19.6 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.462 0 N-CA-C 107.288 -1.375 . . . . 0.0 107.288 178.626 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 29.9 mt -130.78 127.56 61.82 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.884 0 O-C-N 123.541 0.525 . . . . 0.0 110.012 -178.523 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.46 78.56 0.15 Allowed Glycine 0 CA--C 1.526 0.745 0 CA-C-N 115.898 -0.592 . . . . 0.0 112.888 178.642 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 34' ' ' LEU . . . . . 0.429 HD23 ' N ' ' B' ' 35' ' ' MET . 1.7 tt -109.6 120.65 43.14 Favored 'General case' 0 N--CA 1.48 1.061 0 N-CA-C 107.163 -1.421 . . . . 0.0 107.163 177.629 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 35' ' ' MET . . . . . 0.429 ' N ' HD23 ' B' ' 34' ' ' LEU . 8.9 mtp -153.81 161.07 42.37 Favored 'General case' 0 N--CA 1.473 0.682 0 N-CA-C 108.704 -0.85 . . . . 0.0 108.704 179.574 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 36' ' ' VAL . . . . . 0.53 HG12 HE22 ' E' ' 15' ' ' GLN . 72.8 t -157.93 144.65 9.0 Favored 'Isoleucine or valine' 0 C--O 1.233 0.201 0 N-CA-C 106.786 -1.561 . . . . 0.0 106.786 -179.739 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.71 74.08 0.36 Allowed Glycine 0 C--N 1.317 -0.526 0 N-CA-C 111.544 -0.622 . . . . 0.0 111.544 178.713 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 169.97 -148.9 12.23 Favored Glycine 0 CA--C 1.519 0.319 0 N-CA-C 110.796 -0.922 . . . . 0.0 110.796 179.886 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 16.1 m -134.69 148.73 29.32 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.823 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 -179.914 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 21.9 t . . . . . 0 N--CA 1.47 0.54 0 CA-C-O 117.717 -1.135 . . . . 0.0 110.959 178.801 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 17.4 m-85 . . . . . 0 N--CA 1.469 0.516 0 N-CA-C 109.473 -0.565 . . . . 0.0 109.473 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 54.4 mtp180 -68.37 129.25 39.36 Favored 'General case' 0 N--CA 1.468 0.469 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.481 -177.729 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 3.7 m-70 -95.74 125.66 40.47 Favored 'General case' 0 N--CA 1.474 0.733 0 N-CA-C 109.714 -0.476 . . . . 0.0 109.714 178.978 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' C' C ' 7' ' ' ASP . . . . . 0.516 ' OD1' HG11 ' E' ' 24' ' ' VAL . 10.1 m-20 -72.33 145.18 47.97 Favored 'General case' 0 CA--C 1.53 0.208 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.198 -179.842 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' C' C ' 8' ' ' SER . . . . . . . . . . . . . 22.9 t -160.91 179.53 8.4 Favored 'General case' 0 N--CA 1.469 0.506 0 N-CA-C 109.343 -0.614 . . . . 0.0 109.343 178.835 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 124.46 19.83 2.51 Favored Glycine 0 N--CA 1.487 2.055 0 N-CA-C 111.772 -0.531 . . . . 0.0 111.772 179.822 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 43.9 p90 -57.24 128.96 39.64 Favored 'General case' 0 N--CA 1.473 0.705 0 O-C-N 122.403 -0.469 . . . . 0.0 112.127 -179.767 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 46.5 mt-10 -85.35 154.95 21.54 Favored 'General case' 0 N--CA 1.47 0.553 0 N-CA-C 109.049 -0.723 . . . . 0.0 109.049 178.426 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -154.08 129.05 1.49 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 N-CA-C 108.174 -1.047 . . . . 0.0 108.174 178.802 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 50.7 m-70 -134.68 144.2 47.66 Favored 'General case' 0 N--CA 1.491 1.624 0 CA-C-N 118.716 0.689 . . . . 0.0 110.974 -179.117 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -166.38 98.16 0.6 Allowed 'General case' 0 N--CA 1.482 1.174 0 CA-C-N 116.674 -0.239 . . . . 0.0 111.161 179.753 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' C' C ' 15' ' ' GLN . . . . . 0.4 ' HB2' HE21 ' F' ' 15' ' ' GLN . 45.3 mt-30 -108.31 -172.12 2.0 Allowed 'General case' 0 CA--C 1.501 -0.941 0 N-CA-C 108.177 -1.046 . . . . 0.0 108.177 179.796 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' C' C ' 16' ' ' LYS . . . . . 0.406 ' C ' HD12 ' C' ' 17' ' ' LEU . 88.2 tttt -164.29 97.84 0.81 Allowed 'General case' 0 N--CA 1.472 0.626 0 CA-C-N 115.143 -0.935 . . . . 0.0 109.443 178.761 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' C' C ' 17' ' ' LEU . . . . . 0.581 ' N ' HD12 ' C' ' 17' ' ' LEU . 4.8 mp -106.96 163.81 12.65 Favored 'General case' 0 N--CA 1.487 1.406 0 N-CA-C 108.559 -0.904 . . . . 0.0 108.559 179.89 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 58.0 t -141.28 118.81 8.54 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.293 0 CA-C-O 118.917 -0.563 . . . . 0.0 109.805 179.48 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 55.1 m-85 -70.49 158.73 35.55 Favored 'General case' 0 N--CA 1.478 0.926 0 N-CA-C 107.529 -1.285 . . . . 0.0 107.529 177.317 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 14.7 t80 -171.63 -57.67 0.02 OUTLIER 'General case' 0 N--CA 1.481 1.104 0 CA-C-O 122.246 1.022 . . . . 0.0 109.857 179.21 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.59 90.4 0.0 OUTLIER 'General case' 0 C--O 1.231 0.107 0 CA-C-N 114.181 -1.372 . . . . 0.0 112.79 -178.168 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 38.0 tt0 -62.32 156.45 22.25 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.223 -0.899 . . . . 0.0 110.577 179.09 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 12.2 m-20 -138.05 129.93 28.42 Favored 'General case' 0 N--CA 1.482 1.156 0 C-N-CA 123.026 0.531 . . . . 0.0 110.255 -179.689 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' C' C ' 24' ' ' VAL . . . . . 0.967 HG12 ' H ' ' C' ' 25' ' ' GLY . 40.4 t -79.99 -164.08 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.035 0 N-CA-C 108.523 -0.917 . . . . 0.0 108.523 179.639 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' C' C ' 25' ' ' GLY . . . . . 0.967 ' H ' HG12 ' C' ' 24' ' ' VAL . . . -71.34 50.96 1.04 Allowed Glycine 0 CA--C 1.527 0.812 0 CA-C-N 118.363 0.529 . . . . 0.0 112.042 -179.019 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 27.3 p -72.13 136.43 46.52 Favored 'General case' 0 C--O 1.221 -0.414 0 N-CA-C 109.526 -0.546 . . . . 0.0 109.526 178.902 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 2.0 t-20 -68.87 95.65 0.7 Allowed 'General case' 0 N--CA 1.468 0.472 0 N-CA-C 108.419 -0.956 . . . . 0.0 108.419 178.107 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 67.9 mttm -93.46 119.07 32.11 Favored 'General case' 0 N--CA 1.481 1.105 0 N-CA-C 110.354 -0.239 . . . . 0.0 110.354 -179.092 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.93 -126.03 0.01 OUTLIER Glycine 0 CA--C 1.534 1.281 0 N-CA-C 110.563 -1.015 . . . . 0.0 110.563 178.606 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.28 134.12 48.89 Favored 'General case' 0 N--CA 1.481 1.102 0 N-CA-C 109.105 -0.702 . . . . 0.0 109.105 179.135 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 65.3 mt -83.26 138.0 20.02 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.451 0 N-CA-C 107.311 -1.366 . . . . 0.0 107.311 178.538 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 30.7 mt -130.41 127.79 63.03 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.931 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.015 -178.537 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.14 78.57 0.15 Allowed Glycine 0 CA--C 1.525 0.68 0 CA-C-N 115.908 -0.587 . . . . 0.0 112.933 178.677 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' C' C ' 34' ' ' LEU . . . . . 0.432 HD23 ' N ' ' C' ' 35' ' ' MET . 1.7 tt -109.49 120.77 43.51 Favored 'General case' 0 N--CA 1.48 1.035 0 N-CA-C 107.202 -1.407 . . . . 0.0 107.202 177.606 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' C' C ' 35' ' ' MET . . . . . 0.432 ' N ' HD23 ' C' ' 34' ' ' LEU . 8.8 mtp -153.93 161.22 42.16 Favored 'General case' 0 N--CA 1.469 0.524 0 N-CA-C 108.664 -0.865 . . . . 0.0 108.664 179.665 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' C' C ' 36' ' ' VAL . . . . . 0.532 HG12 HE22 ' F' ' 15' ' ' GLN . 79.2 t -158.05 144.86 8.89 Favored 'Isoleucine or valine' 0 C--O 1.233 0.232 0 N-CA-C 106.845 -1.539 . . . . 0.0 106.845 -179.832 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.65 74.03 0.37 Allowed Glycine 0 C--N 1.316 -0.535 0 CA-C-N 115.812 -0.631 . . . . 0.0 111.537 178.687 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 169.95 -149.12 12.54 Favored Glycine 0 CA--C 1.518 0.275 0 N-CA-C 110.815 -0.914 . . . . 0.0 110.815 179.941 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 16.4 m -134.58 148.85 29.41 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.872 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 -179.964 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 22.0 t . . . . . 0 N--CA 1.469 0.507 0 CA-C-O 117.717 -1.135 . . . . 0.0 110.952 178.916 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 18.7 m-85 . . . . . 0 N--CA 1.478 0.957 0 N-CA-C 107.9 -1.148 . . . . 0.0 107.9 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' D' D ' 5' ' ' ARG . . . . . 0.852 HH21 HG13 ' C' ' 24' ' ' VAL 0.344 64.5 mtp180 -77.03 133.52 39.09 Favored 'General case' 0 C--N 1.355 0.821 0 CA-C-O 123.248 1.499 . . . . 0.0 107.088 -167.987 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 3.7 m-70 -94.27 128.13 40.56 Favored 'General case' 0 C--N 1.365 1.273 0 CA-C-N 113.371 -1.741 . . . . 0.0 108.502 -177.669 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' D' D ' 7' ' ' ASP . . . . . 0.584 ' OD1' HG11 ' I' ' 24' ' ' VAL . 6.7 m-20 -66.35 130.48 43.37 Favored 'General case' 0 C--N 1.31 -1.134 0 C-N-CA 127.505 2.322 . . . . 0.0 115.117 175.029 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' D' D ' 8' ' ' SER . . . . . . . . . . . . . 22.9 t -152.11 -178.53 6.84 Favored 'General case' 0 N--CA 1.478 0.954 0 CA-C-N 119.168 0.895 . . . . 0.0 109.411 177.145 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 124.58 18.85 2.64 Favored Glycine 0 N--CA 1.485 1.914 0 N-CA-C 111.788 -0.525 . . . . 0.0 111.788 178.691 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 40.2 p90 -56.21 130.62 45.09 Favored 'General case' 0 CA--C 1.544 0.74 0 N-CA-C 112.134 0.42 . . . . 0.0 112.134 -179.209 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 46.7 mt-10 -85.6 152.5 23.08 Favored 'General case' 0 N--CA 1.475 0.78 0 N-CA-C 109.649 -0.5 . . . . 0.0 109.649 177.479 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -149.6 130.1 4.37 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.447 0 N-CA-C 108.1 -1.074 . . . . 0.0 108.1 175.357 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 48.5 m-70 -129.81 146.97 51.53 Favored 'General case' 0 N--CA 1.483 1.218 0 CA-C-N 117.867 0.303 . . . . 0.0 111.286 176.482 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -165.35 104.84 0.74 Allowed 'General case' 0 N--CA 1.483 1.209 0 N-CA-C 109.688 -0.486 . . . . 0.0 109.688 173.354 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' D' D ' 15' ' ' GLN . . . . . 0.539 HE22 HG12 ' A' ' 36' ' ' VAL . 44.1 mt-30 -111.62 -175.59 2.73 Favored 'General case' 0 CA--C 1.493 -1.249 0 N-CA-C 108.018 -1.104 . . . . 0.0 108.018 179.092 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' D' D ' 16' ' ' LYS . . . . . 0.451 ' C ' HD12 ' D' ' 17' ' ' LEU . 88.7 tttt -160.56 106.12 1.47 Allowed 'General case' 0 CA--C 1.538 0.5 0 N-CA-C 107.683 -1.228 . . . . 0.0 107.683 175.383 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' D' D ' 17' ' ' LEU . . . . . 0.528 ' N ' HD12 ' D' ' 17' ' ' LEU . 5.7 mp -113.38 163.03 15.38 Favored 'General case' 0 N--CA 1.488 1.456 0 N-CA-C 107.945 -1.132 . . . . 0.0 107.945 179.457 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 53.3 t -140.96 123.63 15.5 Favored 'Isoleucine or valine' 0 C--N 1.362 1.136 0 N-CA-C 108.753 -0.832 . . . . 0.0 108.753 175.964 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 79.1 m-85 -62.97 151.3 39.99 Favored 'General case' 0 C--N 1.355 0.82 0 C-N-CA 124.517 1.127 . . . . 0.0 110.515 170.967 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 9.9 t80 -170.11 -66.91 0.02 OUTLIER 'General case' 0 N--CA 1.475 0.789 0 N-CA-C 107.781 -1.192 . . . . 0.0 107.781 179.834 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -38.27 95.43 0.01 OUTLIER 'General case' 0 CA--C 1.535 0.39 0 CA-C-N 113.99 -1.459 . . . . 0.0 111.731 -175.293 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 38.3 tt0 -65.18 157.61 28.3 Favored 'General case' 0 N--CA 1.467 0.418 0 CA-C-N 113.919 -1.491 . . . . 0.0 110.122 178.469 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 12.0 m-20 -138.68 130.46 27.82 Favored 'General case' 0 N--CA 1.479 0.985 0 C-N-CA 123.181 0.592 . . . . 0.0 110.407 -178.969 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' D' D ' 24' ' ' VAL . . . . . 1.037 HG12 ' H ' ' D' ' 25' ' ' GLY . 48.7 t -84.42 -160.12 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.299 0 N-CA-C 107.742 -1.206 . . . . 0.0 107.742 -178.346 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' D' D ' 25' ' ' GLY . . . . . 1.037 ' H ' HG12 ' D' ' 24' ' ' VAL . . . -80.3 57.19 4.67 Favored Glycine 0 C--N 1.359 1.84 0 C-N-CA 118.198 -1.953 . . . . 0.0 110.695 -175.556 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 54.0 p -61.81 132.36 52.84 Favored 'General case' 0 C--N 1.346 0.431 0 CA-C-O 117.515 -1.231 . . . . 0.0 112.187 170.377 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 2.0 t-20 -65.53 95.32 0.21 Allowed 'General case' 0 C--O 1.242 0.666 0 CA-C-N 120.263 1.392 . . . . 0.0 109.044 172.049 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 67.6 mttm -95.0 122.17 37.37 Favored 'General case' 0 N--CA 1.483 1.219 0 C-N-CA 119.627 -0.829 . . . . 0.0 109.245 179.537 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -55.84 -130.18 0.01 OUTLIER Glycine 0 CA--C 1.528 0.893 0 C-N-CA 123.804 0.716 . . . . 0.0 112.045 174.717 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -125.33 139.97 53.23 Favored 'General case' 0 C--N 1.369 1.421 0 N-CA-C 108.669 -0.863 . . . . 0.0 108.669 174.602 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 65.2 mt -83.86 140.54 16.04 Favored 'Isoleucine or valine' 0 C--O 1.238 0.47 0 N-CA-C 107.374 -1.343 . . . . 0.0 107.374 176.342 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 42.1 mt -132.79 132.21 59.48 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.996 0 N-CA-C 108.329 -0.989 . . . . 0.0 108.329 178.079 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.22 76.96 0.22 Allowed Glycine 0 C--O 1.245 0.799 0 CA-C-O 118.552 -1.138 . . . . 0.0 112.519 178.351 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' D' D ' 34' ' ' LEU . . . . . 0.434 HD23 ' N ' ' D' ' 35' ' ' MET . 2.1 tt -109.32 132.17 54.38 Favored 'General case' 0 C--N 1.371 1.528 0 N-CA-C 104.73 -2.322 . . . . 0.0 104.73 175.275 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' D' D ' 35' ' ' MET . . . . . 0.434 ' N ' HD23 ' D' ' 34' ' ' LEU . 9.0 mtp -156.43 166.72 32.61 Favored 'General case' 0 N--CA 1.475 0.822 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 177.494 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' D' D ' 36' ' ' VAL . . . . . 0.523 HG12 HE22 ' G' ' 15' ' ' GLN . 93.2 t -163.73 150.72 3.06 Favored 'Isoleucine or valine' 0 C--O 1.237 0.401 0 N-CA-C 104.989 -2.226 . . . . 0.0 104.989 173.986 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 60.95 66.91 2.38 Favored Glycine 0 N--CA 1.444 -0.794 0 C-N-CA 118.509 -1.805 . . . . 0.0 112.129 177.13 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 166.8 -148.06 12.82 Favored Glycine 0 N--CA 1.468 0.767 0 CA-C-N 119.085 1.443 . . . . 0.0 112.296 -179.589 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 14.1 m -131.15 147.92 32.95 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.263 0 CA-C-N 119.009 1.405 . . . . 0.0 110.332 -178.908 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 21.2 t . . . . . 0 C--O 1.212 -0.897 0 N-CA-C 109.388 -0.597 . . . . 0.0 109.388 173.574 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 15.9 m-85 . . . . . 0 N--CA 1.472 0.631 0 CA-C-O 121.171 0.51 . . . . 0.0 109.864 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' E' E ' 5' ' ' ARG . . . . . 0.837 HH21 HG13 ' A' ' 24' ' ' VAL . 53.0 mtp180 -68.14 130.15 42.07 Favored 'General case' 0 CA--C 1.535 0.398 0 CA-C-N 115.579 -0.737 . . . . 0.0 110.585 -177.917 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 3.7 m-70 -96.42 125.3 40.81 Favored 'General case' 0 N--CA 1.476 0.854 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 178.958 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' E' E ' 7' ' ' ASP . . . . . 0.569 ' OD1' HG11 ' G' ' 24' ' ' VAL . 11.6 m-20 -71.75 145.24 48.89 Favored 'General case' 0 N--CA 1.465 0.31 0 O-C-N 123.286 0.366 . . . . 0.0 111.301 -179.823 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' E' E ' 8' ' ' SER . . . . . . . . . . . . . 22.6 t -161.05 179.88 8.07 Favored 'General case' 0 N--CA 1.473 0.702 0 N-CA-C 109.263 -0.643 . . . . 0.0 109.263 178.521 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 125.16 20.12 2.28 Favored Glycine 0 N--CA 1.482 1.754 0 N-CA-C 111.757 -0.537 . . . . 0.0 111.757 179.612 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 40.3 p90 -57.17 128.49 37.24 Favored 'General case' 0 N--CA 1.473 0.682 0 N-CA-C 112.607 0.595 . . . . 0.0 112.607 -179.214 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 45.8 mt-10 -84.37 155.08 22.48 Favored 'General case' 0 N--CA 1.475 0.813 0 N-CA-C 109.228 -0.656 . . . . 0.0 109.228 178.111 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -155.29 127.76 1.05 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.543 0 N-CA-C 108.367 -0.975 . . . . 0.0 108.367 178.764 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 47.4 m-70 -134.63 142.12 46.79 Favored 'General case' 0 N--CA 1.482 1.139 0 CA-C-O 120.591 0.234 . . . . 0.0 111.337 -177.995 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -165.17 98.38 0.73 Allowed 'General case' 0 N--CA 1.486 1.37 0 CA-C-N 116.688 -0.233 . . . . 0.0 111.127 179.711 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' E' E ' 15' ' ' GLN . . . . . 0.53 HE22 HG12 ' B' ' 36' ' ' VAL . 43.5 mt-30 -107.73 -172.2 2.02 Favored 'General case' 0 CA--C 1.501 -0.925 0 N-CA-C 108.393 -0.965 . . . . 0.0 108.393 179.81 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -164.34 97.88 0.8 Allowed 'General case' 0 CA--C 1.542 0.635 0 CA-C-N 115.007 -0.997 . . . . 0.0 109.337 178.697 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' E' E ' 17' ' ' LEU . . . . . 0.571 ' N ' HD12 ' E' ' 17' ' ' LEU . 4.7 mp -106.85 163.34 13.03 Favored 'General case' 0 N--CA 1.49 1.538 0 N-CA-C 109.075 -0.713 . . . . 0.0 109.075 -179.876 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 41.6 t -141.66 118.05 6.93 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.319 0 C-N-CA 122.684 0.394 . . . . 0.0 110.442 178.952 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 54.7 m-85 -69.43 156.31 39.05 Favored 'General case' 0 C--N 1.358 0.969 0 N-CA-C 107.489 -1.3 . . . . 0.0 107.489 176.621 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 13.1 t80 -173.29 -55.33 0.02 OUTLIER 'General case' 0 N--CA 1.484 1.244 0 CA-C-O 121.724 0.773 . . . . 0.0 110.292 179.333 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -42.35 88.94 0.0 OUTLIER 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 114.502 -1.226 . . . . 0.0 112.654 -179.036 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 37.7 tt0 -61.1 156.42 18.14 Favored 'General case' 0 N--CA 1.47 0.554 0 CA-C-N 115.014 -0.994 . . . . 0.0 110.733 179.416 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 12.0 m-20 -138.16 129.39 27.43 Favored 'General case' 0 N--CA 1.481 1.101 0 C-N-CA 123.003 0.521 . . . . 0.0 110.551 -179.52 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' E' E ' 24' ' ' VAL . . . . . 0.975 HG12 ' H ' ' E' ' 25' ' ' GLY . 40.4 t -79.94 -164.25 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.484 1.238 0 N-CA-C 108.164 -1.05 . . . . 0.0 108.164 179.557 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' E' E ' 25' ' ' GLY . . . . . 0.975 ' H ' HG12 ' E' ' 24' ' ' VAL . . . -70.79 52.25 0.92 Allowed Glycine 0 CA--C 1.529 0.928 0 CA-C-N 118.422 0.556 . . . . 0.0 112.534 -178.807 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 18.1 p -72.68 135.32 45.39 Favored 'General case' 0 C--O 1.219 -0.512 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 178.645 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 2.0 t-20 -68.36 95.33 0.6 Allowed 'General case' 0 CA--C 1.536 0.421 0 N-CA-C 107.681 -1.229 . . . . 0.0 107.681 177.866 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 67.4 mttm -93.74 118.38 31.34 Favored 'General case' 0 N--CA 1.483 1.187 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 -178.586 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.93 -124.97 0.01 OUTLIER Glycine 0 CA--C 1.539 1.587 0 N-CA-C 110.998 -0.841 . . . . 0.0 110.998 178.588 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -129.05 133.65 47.79 Favored 'General case' 0 N--CA 1.48 1.057 0 N-CA-C 109.511 -0.551 . . . . 0.0 109.511 179.493 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 65.3 mt -82.44 138.53 19.26 Favored 'Isoleucine or valine' 0 C--O 1.235 0.29 0 N-CA-C 107.158 -1.423 . . . . 0.0 107.158 178.617 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 36.2 mt -130.33 127.85 63.3 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.895 0 N-CA-C 109.437 -0.579 . . . . 0.0 109.437 -179.447 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.64 79.89 0.12 Allowed Glycine 0 CA--C 1.522 0.485 0 CA-C-N 115.914 -0.585 . . . . 0.0 113.299 179.021 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' E' E ' 34' ' ' LEU . . . . . 0.413 HD23 ' N ' ' E' ' 35' ' ' MET . 1.8 tt -110.56 120.26 41.83 Favored 'General case' 0 N--CA 1.48 1.044 0 N-CA-C 107.312 -1.366 . . . . 0.0 107.312 177.419 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' E' E ' 35' ' ' MET . . . . . 0.413 ' N ' HD23 ' E' ' 34' ' ' LEU . 8.7 mtp -152.4 163.23 39.92 Favored 'General case' 0 C--O 1.213 -0.864 0 N-CA-C 108.32 -0.992 . . . . 0.0 108.32 179.421 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' E' E ' 36' ' ' VAL . . . . . 0.546 HG12 HE22 ' H' ' 15' ' ' GLN . 97.5 t -159.85 145.3 6.17 Favored 'Isoleucine or valine' 0 C--O 1.233 0.235 0 N-CA-C 106.693 -1.595 . . . . 0.0 106.693 179.919 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.03 73.62 0.4 Allowed Glycine 0 C--N 1.316 -0.54 0 N-CA-C 111.202 -0.759 . . . . 0.0 111.202 178.769 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 171.03 -148.22 11.07 Favored Glycine 0 C--O 1.221 -0.688 0 C-N-CA 120.882 -0.675 . . . . 0.0 111.459 -179.807 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 14.0 m -136.04 147.89 27.97 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.918 0 N-CA-C 109.239 -0.652 . . . . 0.0 109.239 -179.833 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 21.5 t . . . . . 0 C--O 1.221 -0.395 0 CA-C-O 117.8 -1.095 . . . . 0.0 111.19 179.168 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 15.7 m-85 . . . . . 0 N--CA 1.473 0.691 0 CA-C-O 121.143 0.497 . . . . 0.0 110.015 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' F' F ' 5' ' ' ARG . . . . . 0.843 HH21 HG13 ' B' ' 24' ' ' VAL . 53.3 mtp180 -68.03 129.75 40.87 Favored 'General case' 0 CA--C 1.537 0.465 0 CA-C-N 115.422 -0.808 . . . . 0.0 110.602 -177.962 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 3.7 m-70 -96.39 125.33 40.81 Favored 'General case' 0 N--CA 1.476 0.874 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 178.885 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' F' F ' 7' ' ' ASP . . . . . 0.577 ' OD1' HG11 ' H' ' 24' ' ' VAL . 11.7 m-20 -71.72 145.05 49.06 Favored 'General case' 0 N--CA 1.465 0.307 0 O-C-N 123.293 0.37 . . . . 0.0 111.423 -179.842 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' F' F ' 8' ' ' SER . . . . . . . . . . . . . 22.8 t -161.06 179.35 8.5 Favored 'General case' 0 N--CA 1.473 0.685 0 N-CA-C 109.277 -0.638 . . . . 0.0 109.277 178.448 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 125.78 19.84 2.19 Favored Glycine 0 N--CA 1.482 1.742 0 N-CA-C 111.752 -0.539 . . . . 0.0 111.752 179.634 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 40.4 p90 -57.07 128.87 39.18 Favored 'General case' 0 N--CA 1.474 0.756 0 N-CA-C 112.528 0.566 . . . . 0.0 112.528 -179.18 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 45.8 mt-10 -84.49 155.34 22.22 Favored 'General case' 0 N--CA 1.474 0.732 0 N-CA-C 109.318 -0.623 . . . . 0.0 109.318 177.986 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -155.49 127.81 1.03 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.53 0 N-CA-C 108.31 -0.996 . . . . 0.0 108.31 178.742 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 48.6 m-70 -134.74 141.97 46.62 Favored 'General case' 0 N--CA 1.482 1.128 0 CA-C-O 120.606 0.241 . . . . 0.0 111.387 -178.034 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -165.19 99.14 0.73 Allowed 'General case' 0 N--CA 1.485 1.3 0 CA-C-N 116.811 -0.177 . . . . 0.0 111.191 179.702 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' F' F ' 15' ' ' GLN . . . . . 0.532 HE22 HG12 ' C' ' 36' ' ' VAL . 43.1 mt-30 -108.84 -171.44 1.85 Allowed 'General case' 0 CA--C 1.499 -0.981 0 N-CA-C 108.525 -0.917 . . . . 0.0 108.525 179.817 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -164.6 98.08 0.78 Allowed 'General case' 0 CA--C 1.54 0.58 0 CA-C-N 114.883 -1.053 . . . . 0.0 109.537 178.657 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' F' F ' 17' ' ' LEU . . . . . 0.569 ' N ' HD12 ' F' ' 17' ' ' LEU . 4.8 mp -106.78 163.14 13.18 Favored 'General case' 0 N--CA 1.49 1.573 0 N-CA-C 109.029 -0.73 . . . . 0.0 109.029 -179.899 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 42.4 t -141.54 118.19 7.31 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.308 0 C-N-CA 122.584 0.354 . . . . 0.0 110.361 179.071 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 55.1 m-85 -69.51 156.06 39.48 Favored 'General case' 0 C--N 1.357 0.932 0 N-CA-C 107.329 -1.36 . . . . 0.0 107.329 176.602 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 13.6 t80 -172.92 -55.69 0.02 OUTLIER 'General case' 0 N--CA 1.483 1.22 0 CA-C-O 121.868 0.842 . . . . 0.0 109.799 179.456 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -42.24 88.8 0.0 OUTLIER 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 114.534 -1.212 . . . . 0.0 112.789 -178.992 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 38.0 tt0 -61.12 156.33 18.4 Favored 'General case' 0 N--CA 1.471 0.617 0 CA-C-N 114.943 -1.026 . . . . 0.0 110.802 179.268 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 12.0 m-20 -138.1 129.63 27.89 Favored 'General case' 0 N--CA 1.482 1.134 0 C-N-CA 122.96 0.504 . . . . 0.0 110.637 -179.638 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' F' F ' 24' ' ' VAL . . . . . 0.963 HG12 ' H ' ' F' ' 25' ' ' GLY . 40.0 t -80.1 -164.07 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.283 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 179.613 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' F' F ' 25' ' ' GLY . . . . . 0.963 ' H ' HG12 ' F' ' 24' ' ' VAL . . . -70.82 52.25 0.93 Allowed Glycine 0 C--N 1.342 0.888 0 CA-C-N 118.608 0.64 . . . . 0.0 112.378 -178.779 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 19.8 p -72.79 134.97 45.17 Favored 'General case' 0 C--O 1.218 -0.558 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 178.525 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 2.0 t-20 -68.21 95.16 0.56 Allowed 'General case' 0 CA--C 1.536 0.422 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 177.967 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 67.4 mttm -93.56 118.21 31.07 Favored 'General case' 0 N--CA 1.482 1.134 0 N-CA-C 110.066 -0.346 . . . . 0.0 110.066 -178.657 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.8 -125.33 0.01 OUTLIER Glycine 0 CA--C 1.539 1.565 0 N-CA-C 111.022 -0.831 . . . . 0.0 111.022 178.629 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.49 133.46 48.47 Favored 'General case' 0 N--CA 1.483 1.193 0 N-CA-C 109.533 -0.543 . . . . 0.0 109.533 179.479 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 65.7 mt -82.47 138.64 19.07 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.306 0 N-CA-C 107.051 -1.463 . . . . 0.0 107.051 178.587 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 35.0 mt -130.34 127.82 63.23 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.833 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 -179.437 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.56 80.05 0.11 Allowed Glycine 0 CA--C 1.525 0.67 0 CA-C-N 115.929 -0.578 . . . . 0.0 113.241 179.023 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' F' F ' 34' ' ' LEU . . . . . 0.443 HD23 ' N ' ' F' ' 35' ' ' MET . 1.8 tt -110.65 121.23 44.81 Favored 'General case' 0 N--CA 1.48 1.067 0 N-CA-C 107.298 -1.371 . . . . 0.0 107.298 177.59 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' F' F ' 35' ' ' MET . . . . . 0.443 ' N ' HD23 ' F' ' 34' ' ' LEU . 8.7 mtp -153.83 163.85 39.35 Favored 'General case' 0 C--O 1.212 -0.894 0 N-CA-C 108.97 -0.752 . . . . 0.0 108.97 179.314 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' F' F ' 36' ' ' VAL . . . . . 0.54 HG12 HE22 ' I' ' 15' ' ' GLN . 98.3 t -160.19 145.48 5.79 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.27 0 N-CA-C 106.906 -1.516 . . . . 0.0 106.906 -179.857 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.15 73.84 0.38 Allowed Glycine 0 C--N 1.317 -0.507 0 N-CA-C 111.188 -0.765 . . . . 0.0 111.188 178.624 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 170.73 -148.17 11.16 Favored Glycine 0 C--O 1.222 -0.635 0 C-N-CA 120.832 -0.699 . . . . 0.0 111.493 -179.728 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 14.1 m -136.22 147.99 27.7 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.981 0 N-CA-C 109.119 -0.697 . . . . 0.0 109.119 -179.793 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 21.6 t . . . . . 0 C--O 1.221 -0.405 0 CA-C-O 117.722 -1.132 . . . . 0.0 111.129 179.138 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 21.7 m-85 . . . . . 0 N--CA 1.475 0.778 0 CA-C-O 120.991 0.424 . . . . 0.0 110.149 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' G' G ' 5' ' ' ARG . . . . . 0.746 HH21 HG13 ' F' ' 24' ' ' VAL . 55.0 mtp180 -67.13 129.1 38.79 Favored 'General case' 0 N--CA 1.469 0.512 0 CA-C-N 115.65 -0.705 . . . . 0.0 110.287 -178.152 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 3.6 m-70 -96.09 125.48 40.65 Favored 'General case' 0 N--CA 1.474 0.726 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 178.904 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 9.8 m-20 -72.37 141.5 48.74 Favored 'General case' 0 N--CA 1.468 0.437 0 O-C-N 123.742 0.652 . . . . 0.0 111.52 -179.698 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' G' G ' 8' ' ' SER . . . . . . . . . . . . . 23.2 t -158.58 -179.76 8.38 Favored 'General case' 0 N--CA 1.472 0.665 0 N-CA-C 109.196 -0.668 . . . . 0.0 109.196 178.408 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 125.02 20.16 2.31 Favored Glycine 0 N--CA 1.481 1.675 0 N-CA-C 111.617 -0.593 . . . . 0.0 111.617 179.477 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 43.1 p90 -57.75 128.7 38.41 Favored 'General case' 0 N--CA 1.474 0.727 0 N-CA-C 112.362 0.505 . . . . 0.0 112.362 -178.939 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 46.9 mt-10 -84.51 154.44 22.69 Favored 'General case' 0 N--CA 1.473 0.684 0 CA-C-O 121.055 0.455 . . . . 0.0 109.803 178.611 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 2.6 p -155.8 127.82 1.0 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.028 0 N-CA-C 108.353 -0.98 . . . . 0.0 108.353 178.926 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 50.2 m-70 -134.02 142.99 47.83 Favored 'General case' 0 N--CA 1.476 0.832 0 CA-C-N 115.154 -0.93 . . . . 0.0 111.077 -178.214 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -166.32 98.33 0.6 Allowed 'General case' 0 N--CA 1.484 1.227 0 CA-C-N 116.52 -0.309 . . . . 0.0 110.655 179.129 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' G' G ' 15' ' ' GLN . . . . . 0.523 HE22 HG12 ' D' ' 36' ' ' VAL . 43.3 mt-30 -107.92 -171.91 1.96 Allowed 'General case' 0 CA--C 1.5 -0.943 0 N-CA-C 108.544 -0.91 . . . . 0.0 108.544 179.959 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' G' G ' 16' ' ' LYS . . . . . 0.405 ' C ' HD12 ' G' ' 17' ' ' LEU . 88.1 tttt -164.35 98.18 0.81 Allowed 'General case' 0 N--CA 1.472 0.627 0 CA-C-N 115.083 -0.962 . . . . 0.0 109.441 178.567 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' G' G ' 17' ' ' LEU . . . . . 0.575 ' N ' HD12 ' G' ' 17' ' ' LEU . 5.3 mp -106.83 162.28 13.95 Favored 'General case' 0 N--CA 1.486 1.36 0 N-CA-C 109.33 -0.619 . . . . 0.0 109.33 -179.757 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 41.0 t -142.46 118.27 5.62 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.974 0 C-N-CA 122.601 0.361 . . . . 0.0 110.18 178.823 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 48.7 m-85 -69.33 150.49 47.29 Favored 'General case' 0 C--N 1.371 1.524 0 N-CA-C 107.454 -1.313 . . . . 0.0 107.454 176.709 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 11.4 t80 -171.09 -55.29 0.02 OUTLIER 'General case' 0 N--CA 1.486 1.351 0 CA-C-N 117.802 0.274 . . . . 0.0 110.263 -179.926 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.88 90.09 0.0 OUTLIER 'General case' 0 C--N 1.326 -0.446 0 C-N-CA 123.655 0.782 . . . . 0.0 112.339 179.925 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 38.4 tt0 -61.93 156.66 20.36 Favored 'General case' 0 N--CA 1.469 0.484 0 CA-C-N 114.855 -1.066 . . . . 0.0 110.029 178.886 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 12.1 m-20 -138.31 129.85 27.76 Favored 'General case' 0 N--CA 1.481 1.101 0 C-N-CA 122.958 0.503 . . . . 0.0 110.148 -179.557 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' G' G ' 24' ' ' VAL . . . . . 0.967 HG12 ' H ' ' G' ' 25' ' ' GLY . 39.5 t -81.03 -164.03 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.972 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 179.578 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' G' G ' 25' ' ' GLY . . . . . 0.967 ' H ' HG12 ' G' ' 24' ' ' VAL . . . -70.48 51.51 0.84 Allowed Glycine 0 CA--C 1.527 0.836 0 CA-C-N 118.383 0.538 . . . . 0.0 112.452 -179.016 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 18.0 p -72.34 135.9 46.03 Favored 'General case' 0 C--N 1.329 -0.294 0 N-CA-C 109.175 -0.676 . . . . 0.0 109.175 177.936 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 2.0 t-20 -69.1 94.5 0.67 Allowed 'General case' 0 CA--C 1.536 0.416 0 N-CA-C 107.902 -1.147 . . . . 0.0 107.902 177.814 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 68.0 mttm -92.14 118.94 31.32 Favored 'General case' 0 N--CA 1.482 1.134 0 N-CA-C 110.06 -0.348 . . . . 0.0 110.06 -179.2 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.45 -123.37 0.01 OUTLIER Glycine 0 CA--C 1.534 1.247 0 N-CA-C 110.517 -1.033 . . . . 0.0 110.517 178.608 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -129.91 133.54 46.92 Favored 'General case' 0 N--CA 1.47 0.547 0 N-CA-C 109.526 -0.546 . . . . 0.0 109.526 179.604 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 68.8 mt -81.9 140.23 16.78 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.664 0 N-CA-C 107.37 -1.344 . . . . 0.0 107.37 178.626 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 41.3 mt -131.81 129.27 60.94 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.402 0 CA-C-N 119.135 0.88 . . . . 0.0 109.375 179.698 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.47 79.41 0.13 Allowed Glycine 0 CA--C 1.527 0.816 0 CA-C-N 116.302 -0.408 . . . . 0.0 112.882 179.13 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' G' G ' 34' ' ' LEU . . . . . 0.441 HD23 ' N ' ' G' ' 35' ' ' MET . 1.7 tt -110.34 121.69 45.88 Favored 'General case' 0 N--CA 1.482 1.142 0 N-CA-C 107.146 -1.427 . . . . 0.0 107.146 177.616 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' G' G ' 35' ' ' MET . . . . . 0.441 ' N ' HD23 ' G' ' 34' ' ' LEU . 9.2 mtp -154.34 163.91 39.43 Favored 'General case' 0 N--CA 1.477 0.917 0 N-CA-C 107.94 -1.133 . . . . 0.0 107.94 179.583 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 91.6 t -160.03 145.22 5.92 Favored 'Isoleucine or valine' 0 C--O 1.232 0.167 0 N-CA-C 106.376 -1.713 . . . . 0.0 106.376 179.901 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.75 73.88 0.38 Allowed Glycine 0 C--N 1.316 -0.561 0 N-CA-C 111.58 -0.608 . . . . 0.0 111.58 178.355 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 169.69 -146.96 10.46 Favored Glycine 0 N--CA 1.469 0.886 0 N-CA-C 110.834 -0.907 . . . . 0.0 110.834 179.583 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 15.3 m -136.33 148.31 27.41 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.932 0 CA-C-N 117.042 0.421 . . . . 0.0 109.995 -179.768 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 21.2 t . . . . . 0 N--CA 1.472 0.649 0 CA-C-O 117.881 -1.057 . . . . 0.0 111.232 179.257 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 21.8 m-85 . . . . . 0 N--CA 1.473 0.7 0 CA-C-O 121.064 0.459 . . . . 0.0 110.105 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' H' H ' 5' ' ' ARG . . . . . 0.741 HH21 HG13 ' D' ' 24' ' ' VAL . 54.5 mtp180 -67.16 129.12 38.88 Favored 'General case' 0 N--CA 1.469 0.489 0 CA-C-N 115.591 -0.731 . . . . 0.0 110.382 -178.15 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 3.7 m-70 -96.13 125.27 40.55 Favored 'General case' 0 N--CA 1.474 0.772 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 179.0 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 9.7 m-20 -72.34 141.29 48.79 Favored 'General case' 0 N--CA 1.468 0.458 0 O-C-N 123.453 0.47 . . . . 0.0 111.506 -179.643 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' H' H ' 8' ' ' SER . . . . . . . . . . . . . 22.7 t -158.25 -179.83 8.47 Favored 'General case' 0 N--CA 1.472 0.642 0 N-CA-C 109.192 -0.669 . . . . 0.0 109.192 178.626 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 124.74 20.23 2.36 Favored Glycine 0 N--CA 1.481 1.645 0 N-CA-C 111.67 -0.572 . . . . 0.0 111.67 179.573 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 42.5 p90 -57.77 128.81 38.94 Favored 'General case' 0 N--CA 1.473 0.708 0 N-CA-C 112.344 0.498 . . . . 0.0 112.344 -179.038 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 46.9 mt-10 -84.48 154.36 22.77 Favored 'General case' 0 N--CA 1.475 0.795 0 CA-C-O 121.074 0.464 . . . . 0.0 109.839 178.571 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.6 p -155.69 128.03 1.04 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.048 0 N-CA-C 108.373 -0.973 . . . . 0.0 108.373 178.867 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 50.2 m-70 -134.11 143.27 47.88 Favored 'General case' 0 N--CA 1.476 0.851 0 CA-C-N 115.158 -0.928 . . . . 0.0 111.151 -178.171 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -166.75 98.32 0.56 Allowed 'General case' 0 N--CA 1.482 1.168 0 CA-C-N 116.65 -0.25 . . . . 0.0 110.726 179.131 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' H' H ' 15' ' ' GLN . . . . . 0.546 HE22 HG12 ' E' ' 36' ' ' VAL . 43.7 mt-30 -108.0 -172.39 2.05 Favored 'General case' 0 CA--C 1.499 -1.001 0 N-CA-C 108.42 -0.956 . . . . 0.0 108.42 -179.964 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -164.1 97.94 0.83 Allowed 'General case' 0 N--CA 1.471 0.582 0 CA-C-N 115.083 -0.962 . . . . 0.0 109.277 178.748 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' H' H ' 17' ' ' LEU . . . . . 0.578 ' N ' HD12 ' H' ' 17' ' ' LEU . 5.3 mp -106.67 162.24 13.94 Favored 'General case' 0 N--CA 1.486 1.354 0 N-CA-C 109.259 -0.645 . . . . 0.0 109.259 -179.774 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 41.0 t -142.35 118.15 5.73 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.032 0 C-N-CA 122.613 0.365 . . . . 0.0 110.209 178.899 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 49.1 m-85 -69.65 150.88 46.55 Favored 'General case' 0 C--N 1.371 1.502 0 N-CA-C 107.517 -1.29 . . . . 0.0 107.517 176.631 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 12.1 t80 -172.31 -54.88 0.02 OUTLIER 'General case' 0 N--CA 1.482 1.163 0 N-CA-C 110.213 -0.292 . . . . 0.0 110.213 -179.752 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -42.14 90.55 0.0 OUTLIER 'General case' 0 CA--C 1.534 0.352 0 C-N-CA 123.543 0.737 . . . . 0.0 112.095 179.942 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 38.5 tt0 -62.09 156.64 20.95 Favored 'General case' 0 N--CA 1.469 0.493 0 CA-C-N 114.815 -1.084 . . . . 0.0 110.105 179.087 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 12.0 m-20 -138.16 129.98 28.27 Favored 'General case' 0 N--CA 1.48 1.066 0 C-N-CA 122.968 0.507 . . . . 0.0 110.215 -179.536 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' H' H ' 24' ' ' VAL . . . . . 0.951 HG12 ' H ' ' H' ' 25' ' ' GLY . 39.4 t -81.3 -164.1 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.992 0 N-CA-C 108.376 -0.972 . . . . 0.0 108.376 179.664 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' H' H ' 25' ' ' GLY . . . . . 0.951 ' H ' HG12 ' H' ' 24' ' ' VAL . . . -70.18 51.32 0.77 Allowed Glycine 0 CA--C 1.529 0.932 0 CA-C-N 118.483 0.583 . . . . 0.0 112.268 -179.095 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 17.9 p -72.44 135.96 45.89 Favored 'General case' 0 C--N 1.33 -0.254 0 N-CA-C 109.3 -0.63 . . . . 0.0 109.3 177.945 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 2.0 t-20 -69.2 94.58 0.69 Allowed 'General case' 0 CA--C 1.535 0.368 0 N-CA-C 107.968 -1.123 . . . . 0.0 107.968 177.944 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 68.0 mttm -92.27 118.86 31.31 Favored 'General case' 0 N--CA 1.48 1.066 0 N-CA-C 110.111 -0.329 . . . . 0.0 110.111 -179.21 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.47 -123.02 0.01 OUTLIER Glycine 0 CA--C 1.535 1.291 0 N-CA-C 110.477 -1.049 . . . . 0.0 110.477 178.601 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.04 133.77 46.94 Favored 'General case' 0 N--CA 1.471 0.616 0 C-N-CA 123.0 0.52 . . . . 0.0 109.61 179.715 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 68.5 mt -82.2 140.1 16.93 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.591 0 N-CA-C 107.315 -1.365 . . . . 0.0 107.315 178.57 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 41.6 mt -131.74 129.46 61.26 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.278 0 CA-C-N 119.092 0.86 . . . . 0.0 109.317 179.826 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.14 79.48 0.12 Allowed Glycine 0 CA--C 1.527 0.788 0 CA-C-N 116.239 -0.437 . . . . 0.0 112.933 179.155 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' H' H ' 34' ' ' LEU . . . . . 0.432 HD23 ' N ' ' H' ' 35' ' ' MET . 1.7 tt -110.44 121.76 46.09 Favored 'General case' 0 N--CA 1.481 1.099 0 N-CA-C 107.082 -1.451 . . . . 0.0 107.082 177.592 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' H' H ' 35' ' ' MET . . . . . 0.432 ' N ' HD23 ' H' ' 34' ' ' LEU . 9.3 mtp -154.3 163.71 39.73 Favored 'General case' 0 N--CA 1.476 0.85 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 179.679 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 89.9 t -160.05 145.2 5.89 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.163 0 N-CA-C 106.415 -1.698 . . . . 0.0 106.415 179.838 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.75 73.77 0.39 Allowed Glycine 0 C--N 1.316 -0.537 0 N-CA-C 111.536 -0.625 . . . . 0.0 111.536 178.433 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 169.9 -147.19 10.6 Favored Glycine 0 N--CA 1.469 0.899 0 N-CA-C 110.779 -0.928 . . . . 0.0 110.779 179.641 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 15.1 m -136.25 148.18 27.57 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.918 0 CA-C-N 116.938 0.369 . . . . 0.0 110.033 -179.763 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 21.3 t . . . . . 0 N--CA 1.471 0.625 0 CA-C-O 117.864 -1.065 . . . . 0.0 111.138 179.227 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 21.8 m-85 . . . . . 0 N--CA 1.473 0.712 0 CA-C-O 120.981 0.42 . . . . 0.0 110.169 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' I' I ' 5' ' ' ARG . . . . . 0.725 HH21 HG13 ' E' ' 24' ' ' VAL . 54.6 mtp180 -67.18 128.89 38.07 Favored 'General case' 0 N--CA 1.468 0.455 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.378 -178.214 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 3.6 m-70 -95.87 125.22 40.27 Favored 'General case' 0 N--CA 1.475 0.777 0 N-CA-C 109.736 -0.468 . . . . 0.0 109.736 178.99 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 9.8 m-20 -72.21 141.76 49.0 Favored 'General case' 0 N--CA 1.468 0.442 0 O-C-N 123.484 0.49 . . . . 0.0 111.397 -179.682 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' I' I ' 8' ' ' SER . . . . . . . . . . . . . 22.7 t -158.65 179.94 8.65 Favored 'General case' 0 N--CA 1.472 0.63 0 N-CA-C 109.201 -0.666 . . . . 0.0 109.201 178.636 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 124.87 20.29 2.32 Favored Glycine 0 N--CA 1.482 1.739 0 N-CA-C 111.646 -0.582 . . . . 0.0 111.646 179.487 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 42.8 p90 -57.71 128.75 38.62 Favored 'General case' 0 N--CA 1.474 0.765 0 N-CA-C 112.342 0.497 . . . . 0.0 112.342 -179.053 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 46.8 mt-10 -84.39 154.48 22.8 Favored 'General case' 0 N--CA 1.474 0.773 0 CA-C-O 121.043 0.449 . . . . 0.0 109.806 178.538 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 2.6 p -155.82 128.04 1.03 Allowed 'Isoleucine or valine' 0 CA--C 1.553 1.062 0 N-CA-C 108.332 -0.988 . . . . 0.0 108.332 178.843 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 50.4 m-70 -134.17 143.27 47.81 Favored 'General case' 0 N--CA 1.476 0.848 0 CA-C-N 115.094 -0.957 . . . . 0.0 111.094 -178.182 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -166.75 98.37 0.56 Allowed 'General case' 0 N--CA 1.483 1.198 0 CA-C-N 116.626 -0.261 . . . . 0.0 110.795 179.125 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' I' I ' 15' ' ' GLN . . . . . 0.54 HE22 HG12 ' F' ' 36' ' ' VAL . 43.6 mt-30 -108.12 -172.15 2.01 Favored 'General case' 0 CA--C 1.499 -0.99 0 N-CA-C 108.441 -0.948 . . . . 0.0 108.441 -179.981 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' I' I ' 16' ' ' LYS . . . . . 0.403 ' C ' HD12 ' I' ' 17' ' ' LEU . 88.1 tttt -164.21 98.03 0.82 Allowed 'General case' 0 N--CA 1.471 0.606 0 CA-C-N 114.992 -1.004 . . . . 0.0 109.333 178.691 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' I' I ' 17' ' ' LEU . . . . . 0.576 ' N ' HD12 ' I' ' 17' ' ' LEU . 5.3 mp -106.64 162.21 13.96 Favored 'General case' 0 N--CA 1.487 1.388 0 N-CA-C 109.278 -0.638 . . . . 0.0 109.278 -179.749 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 40.7 t -142.24 118.12 5.93 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.059 0 C-N-CA 122.632 0.373 . . . . 0.0 110.223 178.851 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 49.2 m-85 -69.61 150.81 46.66 Favored 'General case' 0 C--N 1.37 1.494 0 N-CA-C 107.49 -1.3 . . . . 0.0 107.49 176.599 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 12.2 t80 -172.2 -55.0 0.02 OUTLIER 'General case' 0 N--CA 1.483 1.201 0 N-CA-C 110.231 -0.285 . . . . 0.0 110.231 -179.826 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -42.08 90.45 0.0 OUTLIER 'General case' 0 CA--C 1.535 0.389 0 C-N-CA 123.657 0.783 . . . . 0.0 112.084 179.958 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 38.3 tt0 -62.02 156.68 20.65 Favored 'General case' 0 N--CA 1.469 0.519 0 CA-C-N 114.793 -1.094 . . . . 0.0 110.043 179.147 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 12.3 m-20 -138.17 129.83 28.04 Favored 'General case' 0 N--CA 1.481 1.097 0 C-N-CA 122.973 0.509 . . . . 0.0 110.217 -179.624 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' I' I ' 24' ' ' VAL . . . . . 0.944 HG12 ' H ' ' I' ' 25' ' ' GLY . 38.8 t -80.96 -163.87 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 1.005 0 N-CA-C 108.381 -0.97 . . . . 0.0 108.381 179.618 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' I' I ' 25' ' ' GLY . . . . . 0.944 ' H ' HG12 ' I' ' 24' ' ' VAL . . . -70.57 51.33 0.85 Allowed Glycine 0 CA--C 1.528 0.895 0 CA-C-N 118.364 0.529 . . . . 0.0 112.376 -179.074 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 17.7 p -72.34 136.04 46.07 Favored 'General case' 0 C--N 1.33 -0.252 0 N-CA-C 109.252 -0.647 . . . . 0.0 109.252 177.947 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 2.0 t-20 -69.23 94.58 0.7 Allowed 'General case' 0 CA--C 1.535 0.371 0 N-CA-C 107.953 -1.128 . . . . 0.0 107.953 177.888 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 68.1 mttm -92.32 118.96 31.43 Favored 'General case' 0 N--CA 1.48 1.068 0 N-CA-C 110.15 -0.315 . . . . 0.0 110.15 -179.15 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.52 -123.31 0.01 OUTLIER Glycine 0 CA--C 1.534 1.249 0 N-CA-C 110.632 -0.987 . . . . 0.0 110.632 178.648 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -129.77 133.21 46.86 Favored 'General case' 0 N--CA 1.472 0.665 0 C-N-CA 123.047 0.539 . . . . 0.0 109.594 179.715 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 68.5 mt -81.86 139.99 17.15 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.555 0 N-CA-C 107.266 -1.383 . . . . 0.0 107.266 178.605 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 41.1 mt -131.62 129.48 61.62 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.359 0 CA-C-N 119.023 0.829 . . . . 0.0 109.318 179.807 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.13 79.36 0.13 Allowed Glycine 0 CA--C 1.527 0.814 0 CA-C-N 116.289 -0.414 . . . . 0.0 112.936 179.085 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' I' I ' 34' ' ' LEU . . . . . 0.436 HD23 ' N ' ' I' ' 35' ' ' MET . 1.7 tt -110.28 121.73 45.97 Favored 'General case' 0 N--CA 1.481 1.087 0 N-CA-C 107.163 -1.421 . . . . 0.0 107.163 177.55 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' I' I ' 35' ' ' MET . . . . . 0.436 ' N ' HD23 ' I' ' 34' ' ' LEU . 9.4 mtp -154.26 163.7 39.72 Favored 'General case' 0 N--CA 1.475 0.786 0 N-CA-C 107.971 -1.122 . . . . 0.0 107.971 179.786 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 89.5 t -160.04 145.31 5.94 Favored 'Isoleucine or valine' 0 C--O 1.232 0.162 0 N-CA-C 106.423 -1.695 . . . . 0.0 106.423 179.801 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.55 74.03 0.36 Allowed Glycine 0 C--N 1.315 -0.599 0 N-CA-C 111.573 -0.611 . . . . 0.0 111.573 178.484 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 169.68 -147.04 10.53 Favored Glycine 0 N--CA 1.469 0.877 0 N-CA-C 110.806 -0.918 . . . . 0.0 110.806 179.587 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 15.1 m -136.3 148.27 27.47 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.96 0 CA-C-N 116.979 0.389 . . . . 0.0 110.06 -179.79 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 21.4 t . . . . . 0 N--CA 1.471 0.61 0 CA-C-O 117.899 -1.048 . . . . 0.0 111.07 179.139 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 21.1 p90 . . . . . 0 N--CA 1.471 0.578 0 N-CA-C 110.384 -0.228 . . . . 0.0 110.384 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 99.0 mtt180 -136.73 153.18 50.93 Favored 'General case' 0 N--CA 1.482 1.137 0 N-CA-C 109.527 -0.546 . . . . 0.0 109.527 178.523 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 58.5 t-80 -113.98 114.82 26.69 Favored 'General case' 0 N--CA 1.477 0.9 0 C-N-CA 123.094 0.557 . . . . 0.0 109.627 179.493 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 7' ' ' ASP . . . . . 0.424 ' O ' ' OG ' ' D' ' 8' ' ' SER . 8.9 m-20 -72.99 156.36 38.91 Favored 'General case' 0 N--CA 1.465 0.307 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.062 179.053 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 9.5 p -166.17 -177.08 3.97 Favored 'General case' 0 N--CA 1.483 1.181 0 CA-C-O 120.913 0.387 . . . . 0.0 110.528 178.736 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.9 43.94 1.58 Allowed Glycine 0 N--CA 1.482 1.708 0 CA-C-N 115.747 -0.661 . . . . 0.0 112.19 179.427 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 51.2 p90 -65.32 131.86 47.54 Favored 'General case' 0 N--CA 1.473 0.715 0 CA-C-N 116.83 0.315 . . . . 0.0 111.479 179.751 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 84.4 mt-10 -94.3 153.52 17.97 Favored 'General case' 0 N--CA 1.476 0.853 0 N-CA-C 109.655 -0.498 . . . . 0.0 109.655 178.587 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -153.28 128.52 1.55 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.583 0 N-CA-C 107.781 -1.192 . . . . 0.0 107.781 178.126 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 50.9 m-70 -135.13 144.88 47.34 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 119.144 0.884 . . . . 0.0 111.221 -179.143 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 6.3 t60 -165.83 99.0 0.66 Allowed 'General case' 0 N--CA 1.48 1.061 0 CA-C-N 116.394 -0.366 . . . . 0.0 110.588 179.465 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 15' ' ' GLN . . . . . 0.451 HE22 ' H ' ' A' ' 37' ' ' GLY . 22.2 pt20 -124.41 155.33 39.01 Favored 'General case' 0 CA--C 1.501 -0.927 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 -179.609 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -124.99 106.02 9.64 Favored 'General case' 0 N--CA 1.478 0.974 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 177.986 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 6.1 mp -121.16 148.88 43.62 Favored 'General case' 0 N--CA 1.497 1.908 0 CA-C-O 121.412 0.625 . . . . 0.0 110.797 -178.528 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 30.8 t -107.57 123.77 63.12 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.018 0 N-CA-C 108.077 -1.083 . . . . 0.0 108.077 177.612 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.506 ' O ' ' N ' ' A' ' 21' ' ' ALA . 25.7 m-85 -119.57 -160.89 0.83 Allowed 'General case' 0 N--CA 1.498 1.962 0 CA-C-N 120.232 1.378 . . . . 0.0 109.178 -179.966 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.555 ' O ' ' HA ' ' D' ' 20' ' ' PHE . 78.7 m-85 -50.94 76.8 0.0 OUTLIER 'General case' 0 C--O 1.2 -1.511 0 C-N-CA 123.772 0.829 . . . . 0.0 111.318 -179.164 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 21' ' ' ALA . . . . . 0.506 ' N ' ' O ' ' A' ' 19' ' ' PHE . . . -88.47 -75.61 0.42 Allowed 'General case' 0 N--CA 1.471 0.597 0 CA-C-N 115.691 -0.686 . . . . 0.0 110.158 -179.614 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 40.4 tt0 -96.12 98.65 10.51 Favored 'General case' 0 N--CA 1.463 0.205 0 N-CA-C 108.461 -0.94 . . . . 0.0 108.461 179.349 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 4.1 p30 -159.45 145.03 15.91 Favored 'General case' 0 N--CA 1.484 1.242 0 O-C-N 122.334 -0.229 . . . . 0.0 110.828 179.598 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.405 HG12 ' N ' ' A' ' 25' ' ' GLY . 88.6 t -63.04 163.91 1.46 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.799 0 N-CA-C 107.619 -1.252 . . . . 0.0 107.619 176.998 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.5 ' H ' ' HB ' ' D' ' 24' ' ' VAL . . . -117.8 45.62 1.25 Allowed Glycine 0 N--CA 1.474 1.183 0 CA-C-O 119.649 -0.529 . . . . 0.0 111.927 -179.409 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -60.32 -165.21 0.01 OUTLIER 'General case' 0 N--CA 1.471 0.622 0 O-C-N 123.805 0.356 . . . . 0.0 110.461 179.618 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 24.0 t-20 -70.23 80.77 0.52 Allowed 'General case' 0 N--CA 1.463 0.197 0 CA-C-N 116.378 -0.373 . . . . 0.0 110.384 179.654 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 96.9 mttt -79.73 138.23 37.25 Favored 'General case' 0 N--CA 1.472 0.635 0 N-CA-C 109.195 -0.668 . . . . 0.0 109.195 179.365 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.84 -166.13 0.9 Allowed Glycine 0 C--N 1.337 0.621 0 N-CA-C 109.68 -1.368 . . . . 0.0 109.68 178.189 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.73 113.99 26.83 Favored 'General case' 0 N--CA 1.474 0.772 0 N-CA-C 109.546 -0.538 . . . . 0.0 109.546 179.505 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 76.5 mt -99.58 135.39 35.2 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.601 0 N-CA-C 107.054 -1.462 . . . . 0.0 107.054 178.734 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 32' ' ' ILE . . . . . 0.405 ' C ' ' H ' ' A' ' 34' ' ' LEU . 26.7 pt -150.78 -172.1 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.353 0.743 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.326 -179.27 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.57 2.53 6.0 Favored Glycine 0 CA--C 1.525 0.711 0 N-CA-C 110.864 -0.894 . . . . 0.0 110.864 -179.905 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.418 HD23 ' N ' ' A' ' 35' ' ' MET . 1.1 tt -74.66 133.58 42.1 Favored 'General case' 0 CA--C 1.544 0.735 0 N-CA-C 109.247 -0.649 . . . . 0.0 109.247 -179.611 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 35' ' ' MET . . . . . 0.418 ' N ' HD23 ' A' ' 34' ' ' LEU . 26.6 ttt -159.44 151.4 20.68 Favored 'General case' 0 N--CA 1.47 0.527 0 N-CA-C 108.297 -1.001 . . . . 0.0 108.297 178.924 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.473 HG12 ' N ' ' A' ' 37' ' ' GLY . 63.3 t -154.49 162.89 1.81 Allowed 'Isoleucine or valine' 0 C--N 1.344 0.353 0 N-CA-C 107.774 -1.195 . . . . 0.0 107.774 -179.52 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 37' ' ' GLY . . . . . 0.473 ' N ' HG12 ' A' ' 36' ' ' VAL . . . 57.57 67.32 2.27 Favored Glycine 0 C--N 1.306 -1.091 0 CA-C-N 115.606 -0.725 . . . . 0.0 112.133 178.717 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.7 177.83 22.44 Favored Glycine 0 N--CA 1.476 1.325 0 N-CA-C 111.045 -0.822 . . . . 0.0 111.045 178.717 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 33.4 m -109.69 152.71 11.66 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.612 0 C-N-CA 123.419 0.687 . . . . 0.0 110.217 -179.58 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 21.9 t . . . . . 0 C--O 1.216 -0.678 0 CA-C-O 118.319 -0.848 . . . . 0.0 110.531 179.615 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 20.5 p90 . . . . . 0 N--CA 1.47 0.549 0 N-CA-C 110.546 -0.168 . . . . 0.0 110.546 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 99.0 mtt180 -136.56 152.98 51.08 Favored 'General case' 0 N--CA 1.481 1.094 0 N-CA-C 109.517 -0.549 . . . . 0.0 109.517 178.534 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 58.4 t-80 -113.91 114.85 26.8 Favored 'General case' 0 N--CA 1.477 0.918 0 C-N-CA 123.156 0.582 . . . . 0.0 109.691 179.522 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 7' ' ' ASP . . . . . 0.419 ' O ' ' OG ' ' E' ' 8' ' ' SER . 8.4 m-20 -73.13 155.95 39.15 Favored 'General case' 0 N--CA 1.467 0.41 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.124 179.151 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 8' ' ' SER . . . . . . . . . . . . . 9.6 p -165.94 -176.93 4.0 Favored 'General case' 0 N--CA 1.481 1.105 0 CA-C-O 120.942 0.401 . . . . 0.0 110.567 178.847 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.67 44.08 1.6 Allowed Glycine 0 N--CA 1.483 1.779 0 CA-C-N 115.701 -0.681 . . . . 0.0 112.232 179.528 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 51.0 p90 -65.66 132.02 47.78 Favored 'General case' 0 N--CA 1.472 0.649 0 CA-C-O 120.688 0.28 . . . . 0.0 111.492 179.823 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 84.2 mt-10 -94.28 153.71 17.89 Favored 'General case' 0 N--CA 1.477 0.876 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 178.483 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -153.41 128.38 1.5 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.511 0 N-CA-C 107.738 -1.208 . . . . 0.0 107.738 178.119 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 49.9 m-70 -135.19 144.5 47.02 Favored 'General case' 0 N--CA 1.492 1.664 0 CA-C-N 119.042 0.837 . . . . 0.0 111.218 -179.091 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 6.3 t60 -165.45 98.71 0.7 Allowed 'General case' 0 N--CA 1.481 1.088 0 CA-C-N 116.461 -0.336 . . . . 0.0 110.482 179.573 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 15' ' ' GLN . . . . . 0.435 HE22 ' H ' ' B' ' 37' ' ' GLY . 22.2 pt20 -124.14 155.38 38.54 Favored 'General case' 0 CA--C 1.501 -0.909 0 N-CA-C 107.988 -1.116 . . . . 0.0 107.988 -179.694 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -124.99 106.13 9.73 Favored 'General case' 0 N--CA 1.479 1.016 0 N-CA-C 108.121 -1.066 . . . . 0.0 108.121 178.037 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 6.1 mp -121.25 148.82 43.77 Favored 'General case' 0 N--CA 1.497 1.901 0 CA-C-O 121.397 0.618 . . . . 0.0 110.809 -178.518 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 29.8 t -107.6 124.59 63.72 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.038 0 N-CA-C 107.949 -1.13 . . . . 0.0 107.949 177.502 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 19' ' ' PHE . . . . . 0.514 ' O ' ' N ' ' B' ' 21' ' ' ALA . 25.5 m-85 -120.65 -161.12 0.87 Allowed 'General case' 0 N--CA 1.496 1.842 0 CA-C-N 119.906 1.23 . . . . 0.0 109.09 -179.779 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 20' ' ' PHE . . . . . 0.512 ' O ' ' HA ' ' E' ' 20' ' ' PHE . 77.7 m-85 -51.1 76.56 0.0 OUTLIER 'General case' 0 C--O 1.202 -1.421 0 C-N-CA 123.684 0.794 . . . . 0.0 111.451 -179.129 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 21' ' ' ALA . . . . . 0.514 ' N ' ' O ' ' B' ' 19' ' ' PHE . . . -88.35 -75.9 0.41 Allowed 'General case' 0 N--CA 1.47 0.539 0 CA-C-N 115.628 -0.715 . . . . 0.0 110.1 -179.692 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 40.5 tt0 -95.9 98.95 10.8 Favored 'General case' 0 N--CA 1.464 0.231 0 N-CA-C 108.49 -0.929 . . . . 0.0 108.49 179.358 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 4.1 p30 -159.65 144.96 15.55 Favored 'General case' 0 N--CA 1.483 1.212 0 O-C-N 122.407 -0.183 . . . . 0.0 110.892 179.578 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 24' ' ' VAL . . . . . 0.402 HG12 ' N ' ' B' ' 25' ' ' GLY . 94.0 t -62.9 163.76 1.46 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.808 0 N-CA-C 107.609 -1.256 . . . . 0.0 107.609 177.088 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 25' ' ' GLY . . . . . 0.495 ' H ' ' HB ' ' E' ' 24' ' ' VAL . . . -117.54 45.67 1.24 Allowed Glycine 0 N--CA 1.474 1.231 0 N-CA-C 111.903 -0.479 . . . . 0.0 111.903 -179.371 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -60.67 -165.05 0.01 OUTLIER 'General case' 0 N--CA 1.472 0.643 0 O-C-N 123.62 0.247 . . . . 0.0 110.452 179.688 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 24.1 t-20 -70.4 80.93 0.55 Allowed 'General case' 0 N--CA 1.464 0.272 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.268 179.664 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 96.8 mttt -79.87 138.28 37.13 Favored 'General case' 0 N--CA 1.472 0.656 0 N-CA-C 109.187 -0.672 . . . . 0.0 109.187 179.373 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.82 -166.14 0.9 Allowed Glycine 0 C--N 1.337 0.602 0 N-CA-C 109.638 -1.385 . . . . 0.0 109.638 178.231 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.68 113.84 26.55 Favored 'General case' 0 N--CA 1.474 0.729 0 N-CA-C 109.639 -0.504 . . . . 0.0 109.639 179.475 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 76.0 mt -99.44 135.32 35.25 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.527 0 N-CA-C 107.054 -1.461 . . . . 0.0 107.054 178.733 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 32' ' ' ILE . . . . . 0.403 ' C ' ' H ' ' B' ' 34' ' ' LEU . 26.6 pt -150.73 -172.05 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.353 0.729 0 CA-C-O 121.185 0.517 . . . . 0.0 111.259 -179.278 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.67 2.35 5.94 Favored Glycine 0 CA--C 1.525 0.692 0 N-CA-C 110.776 -0.93 . . . . 0.0 110.776 -179.919 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 34' ' ' LEU . . . . . 0.403 ' H ' ' C ' ' B' ' 32' ' ' ILE . 1.1 tt -74.55 133.2 42.28 Favored 'General case' 0 CA--C 1.545 0.773 0 N-CA-C 109.209 -0.663 . . . . 0.0 109.209 -179.588 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 35' ' ' MET . . . . . 0.4 ' N ' HD23 ' B' ' 34' ' ' LEU . 26.6 ttt -159.04 150.76 20.68 Favored 'General case' 0 N--CA 1.47 0.562 0 N-CA-C 108.362 -0.977 . . . . 0.0 108.362 178.722 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 36' ' ' VAL . . . . . 0.472 HG12 ' N ' ' B' ' 37' ' ' GLY . 64.0 t -153.79 162.51 2.08 Favored 'Isoleucine or valine' 0 C--N 1.345 0.394 0 N-CA-C 107.838 -1.171 . . . . 0.0 107.838 -179.599 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 37' ' ' GLY . . . . . 0.472 ' N ' HG12 ' B' ' 36' ' ' VAL . . . 58.07 67.13 2.36 Favored Glycine 0 C--N 1.307 -1.043 0 CA-C-N 115.586 -0.734 . . . . 0.0 112.071 178.627 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.85 177.31 22.14 Favored Glycine 0 N--CA 1.475 1.298 0 N-CA-C 111.042 -0.823 . . . . 0.0 111.042 178.797 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 33.6 m -109.21 152.5 11.25 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.621 0 C-N-CA 123.37 0.668 . . . . 0.0 110.316 -179.599 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 22.0 t . . . . . 0 C--O 1.215 -0.758 0 CA-C-O 118.379 -0.82 . . . . 0.0 110.422 179.604 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 20.4 p90 . . . . . 0 N--CA 1.47 0.542 0 N-CA-C 110.566 -0.161 . . . . 0.0 110.566 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 99.0 mtt180 -136.68 153.09 50.99 Favored 'General case' 0 N--CA 1.481 1.089 0 N-CA-C 109.546 -0.539 . . . . 0.0 109.546 178.528 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 58.3 t-80 -113.86 115.06 27.14 Favored 'General case' 0 N--CA 1.478 0.951 0 C-N-CA 123.052 0.541 . . . . 0.0 109.6 179.634 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' C' C ' 7' ' ' ASP . . . . . . . . . . . . . 8.6 m-20 -73.38 155.75 39.04 Favored 'General case' 0 N--CA 1.467 0.385 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.167 179.086 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' C' C ' 8' ' ' SER . . . . . . . . . . . . . 9.5 p -165.67 -176.98 4.13 Favored 'General case' 0 N--CA 1.482 1.167 0 CA-C-O 120.909 0.385 . . . . 0.0 110.567 178.748 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.87 44.01 1.58 Allowed Glycine 0 N--CA 1.483 1.781 0 CA-C-N 115.728 -0.669 . . . . 0.0 112.284 179.49 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 51.0 p90 -65.49 132.0 47.83 Favored 'General case' 0 N--CA 1.473 0.724 0 O-C-N 122.653 -0.322 . . . . 0.0 111.465 179.789 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 83.7 mt-10 -94.27 153.78 17.86 Favored 'General case' 0 N--CA 1.476 0.84 0 N-CA-C 109.634 -0.506 . . . . 0.0 109.634 178.507 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -153.43 128.52 1.52 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.61 0 N-CA-C 107.757 -1.201 . . . . 0.0 107.757 178.135 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 50.0 m-70 -135.33 144.57 46.78 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 119.084 0.856 . . . . 0.0 111.142 -179.104 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 6.3 t60 -165.65 98.71 0.68 Allowed 'General case' 0 N--CA 1.48 1.066 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.458 179.549 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' C' C ' 15' ' ' GLN . . . . . 0.425 HE22 ' H ' ' C' ' 37' ' ' GLY . 21.9 pt20 -124.24 155.47 38.53 Favored 'General case' 0 CA--C 1.503 -0.859 0 N-CA-C 107.865 -1.161 . . . . 0.0 107.865 -179.66 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -124.97 106.31 9.87 Favored 'General case' 0 N--CA 1.479 1.004 0 N-CA-C 108.208 -1.034 . . . . 0.0 108.208 177.969 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 6.1 mp -121.34 148.88 43.76 Favored 'General case' 0 N--CA 1.498 1.966 0 CA-C-O 121.474 0.654 . . . . 0.0 110.796 -178.433 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 29.0 t -107.74 124.53 63.88 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.088 0 N-CA-C 107.968 -1.123 . . . . 0.0 107.968 177.51 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' C' C ' 19' ' ' PHE . . . . . 0.517 ' O ' ' N ' ' C' ' 21' ' ' ALA . 25.5 m-85 -120.55 -161.05 0.86 Allowed 'General case' 0 N--CA 1.496 1.857 0 CA-C-N 119.936 1.244 . . . . 0.0 109.13 -179.674 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' C' C ' 20' ' ' PHE . . . . . 0.514 ' O ' ' HA ' ' F' ' 20' ' ' PHE . 77.8 m-85 -51.25 76.46 0.0 OUTLIER 'General case' 0 C--O 1.202 -1.414 0 C-N-CA 123.716 0.807 . . . . 0.0 111.404 -179.186 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' C' C ' 21' ' ' ALA . . . . . 0.517 ' N ' ' O ' ' C' ' 19' ' ' PHE . . . -88.26 -75.89 0.41 Allowed 'General case' 0 N--CA 1.47 0.533 0 CA-C-N 115.604 -0.725 . . . . 0.0 110.142 -179.7 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 40.8 tt0 -95.74 98.62 10.6 Favored 'General case' 0 N--CA 1.464 0.265 0 N-CA-C 108.482 -0.933 . . . . 0.0 108.482 179.326 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 4.1 p30 -159.51 144.77 15.66 Favored 'General case' 0 N--CA 1.482 1.172 0 O-C-N 122.287 -0.258 . . . . 0.0 110.985 179.616 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' C' C ' 24' ' ' VAL . . . . . 0.41 HG12 ' N ' ' C' ' 25' ' ' GLY . 89.7 t -62.76 163.8 1.43 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.765 0 N-CA-C 107.681 -1.229 . . . . 0.0 107.681 177.067 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' C' C ' 25' ' ' GLY . . . . . 0.516 ' H ' ' HB ' ' F' ' 24' ' ' VAL . . . -117.65 45.72 1.24 Allowed Glycine 0 N--CA 1.476 1.364 0 N-CA-C 111.724 -0.55 . . . . 0.0 111.724 -179.377 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -60.47 -165.1 0.01 OUTLIER 'General case' 0 N--CA 1.472 0.647 0 CA-C-O 120.61 0.243 . . . . 0.0 110.421 179.616 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 24.1 t-20 -70.52 80.62 0.57 Allowed 'General case' 0 N--CA 1.464 0.258 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.308 179.684 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -79.41 138.5 37.65 Favored 'General case' 0 N--CA 1.472 0.639 0 N-CA-C 109.222 -0.659 . . . . 0.0 109.222 179.333 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.96 -165.68 0.87 Allowed Glycine 0 CA--C 1.523 0.588 0 N-CA-C 109.614 -1.394 . . . . 0.0 109.614 178.322 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.88 113.81 26.6 Favored 'General case' 0 N--CA 1.474 0.745 0 N-CA-C 109.617 -0.512 . . . . 0.0 109.617 179.459 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 76.0 mt -99.67 135.12 36.5 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.591 0 N-CA-C 107.041 -1.466 . . . . 0.0 107.041 178.83 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' C' C ' 32' ' ' ILE . . . . . 0.409 ' C ' ' H ' ' C' ' 34' ' ' LEU . 26.8 pt -150.61 -171.91 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.353 0.741 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.296 -179.305 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.59 2.24 5.67 Favored Glycine 0 CA--C 1.524 0.615 0 N-CA-C 110.808 -0.917 . . . . 0.0 110.808 -179.893 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' C' C ' 34' ' ' LEU . . . . . 0.413 HD23 ' N ' ' C' ' 35' ' ' MET . 1.1 tt -74.43 133.28 42.42 Favored 'General case' 0 CA--C 1.544 0.725 0 N-CA-C 109.275 -0.639 . . . . 0.0 109.275 -179.59 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' C' C ' 35' ' ' MET . . . . . 0.413 ' N ' HD23 ' C' ' 34' ' ' LEU . 26.6 ttt -159.03 150.69 20.65 Favored 'General case' 0 N--CA 1.47 0.557 0 N-CA-C 108.477 -0.934 . . . . 0.0 108.477 178.786 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' C' C ' 36' ' ' VAL . . . . . 0.478 HG12 ' N ' ' C' ' 37' ' ' GLY . 62.7 t -153.64 162.82 2.01 Favored 'Isoleucine or valine' 0 C--N 1.344 0.336 0 N-CA-C 107.78 -1.193 . . . . 0.0 107.78 -179.695 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' C' C ' 37' ' ' GLY . . . . . 0.478 ' N ' HG12 ' C' ' 36' ' ' VAL . . . 57.85 67.37 2.24 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-N 115.488 -0.778 . . . . 0.0 112.043 178.549 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.65 177.41 22.06 Favored Glycine 0 N--CA 1.475 1.271 0 N-CA-C 111.027 -0.829 . . . . 0.0 111.027 178.736 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' C' C ' 39' ' ' VAL . . . . . 0.401 ' H ' HG12 ' F' ' 39' ' ' VAL . 33.6 m -109.16 152.67 11.15 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.647 0 C-N-CA 123.303 0.641 . . . . 0.0 110.19 -179.601 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 22.0 t . . . . . 0 C--O 1.216 -0.687 0 CA-C-O 118.273 -0.87 . . . . 0.0 110.581 179.608 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 34.1 p90 . . . . . 0 C--O 1.221 -0.423 0 N-CA-C 108.43 -0.952 . . . . 0.0 108.43 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' D' D ' 5' ' ' ARG . . . . . . . . . . . . . 99.1 mtt180 -132.18 154.67 49.32 Favored 'General case' 0 N--CA 1.477 0.921 0 N-CA-C 109.163 -0.68 . . . . 0.0 109.163 -177.501 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 55.5 t-80 -115.78 121.65 43.06 Favored 'General case' 0 C--N 1.37 1.466 0 N-CA-C 107.827 -1.175 . . . . 0.0 107.827 176.283 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' D' D ' 7' ' ' ASP . . . . . 0.533 ' O ' ' OG ' ' G' ' 8' ' ' SER 0.279 5.0 m-20 -65.11 136.91 57.27 Favored 'General case' 0 C--N 1.313 -1.005 0 C-N-CA 129.589 3.155 . . . . 0.0 115.638 171.6 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' D' D ' 8' ' ' SER . . . . . 0.424 ' OG ' ' O ' ' A' ' 7' ' ' ASP . 7.0 p -153.4 -174.21 4.86 Favored 'General case' 0 N--CA 1.487 1.411 0 CA-C-N 120.825 1.648 . . . . 0.0 111.062 174.704 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 105.07 46.5 1.25 Allowed Glycine 0 N--CA 1.483 1.769 0 C-N-CA 125.071 1.319 . . . . 0.0 110.558 174.78 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 52.6 p90 -60.96 130.69 47.68 Favored 'General case' 0 N--CA 1.472 0.637 0 N-CA-C 112.543 0.572 . . . . 0.0 112.543 177.151 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 84.9 mt-10 -90.94 151.83 20.95 Favored 'General case' 0 N--CA 1.48 1.027 0 CA-C-N 118.029 0.377 . . . . 0.0 110.857 174.946 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -149.62 130.1 4.35 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.615 0 N-CA-C 107.355 -1.35 . . . . 0.0 107.355 172.829 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 47.0 m-70 -129.92 147.61 51.69 Favored 'General case' 0 N--CA 1.483 1.223 0 CA-C-N 118.102 0.41 . . . . 0.0 111.774 176.32 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 6.3 t60 -165.32 104.98 0.75 Allowed 'General case' 0 N--CA 1.485 1.303 0 N-CA-C 109.366 -0.605 . . . . 0.0 109.366 173.233 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' D' D ' 15' ' ' GLN . . . . . 0.461 HE22 ' H ' ' D' ' 37' ' ' GLY . 23.2 pt20 -128.59 148.38 50.78 Favored 'General case' 0 C--N 1.296 -1.726 0 C-N-CA 123.764 0.826 . . . . 0.0 108.879 -178.631 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -118.64 111.5 18.62 Favored 'General case' 0 N--CA 1.476 0.846 0 N-CA-C 107.486 -1.302 . . . . 0.0 107.486 177.054 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 5.0 mp -126.77 148.71 49.9 Favored 'General case' 0 N--CA 1.5 2.059 0 CA-C-O 122.068 0.937 . . . . 0.0 109.983 179.169 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 12.9 t -99.91 128.44 51.79 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.769 0 CA-C-O 116.37 -1.776 . . . . 0.0 109.691 174.939 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' D' D ' 19' ' ' PHE . . . . . 0.511 ' O ' ' N ' ' D' ' 21' ' ' ALA . 25.2 m-85 -127.43 -163.06 1.22 Allowed 'General case' 0 N--CA 1.499 1.977 0 CA-C-N 120.686 1.584 . . . . 0.0 107.681 -179.966 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' D' D ' 20' ' ' PHE . . . . . 0.555 ' HA ' ' O ' ' A' ' 20' ' ' PHE . 90.1 m-85 -53.22 70.73 0.0 OUTLIER 'General case' 0 C--O 1.198 -1.62 0 C-N-CA 126.344 1.857 . . . . 0.0 111.44 -174.517 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' D' D ' 21' ' ' ALA . . . . . 0.511 ' N ' ' O ' ' D' ' 19' ' ' PHE . . . -86.39 -74.18 0.43 Allowed 'General case' 0 C--N 1.362 1.117 0 CA-C-N 114.922 -1.036 . . . . 0.0 109.701 -175.945 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 41.1 tt0 -98.82 102.99 14.9 Favored 'General case' 0 N--CA 1.483 1.212 0 N-CA-C 106.577 -1.638 . . . . 0.0 106.577 178.108 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 4.2 p30 -152.4 143.92 23.43 Favored 'General case' 0 N--CA 1.476 0.872 0 CA-C-O 116.783 -1.58 . . . . 0.0 113.501 178.551 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' D' D ' 24' ' ' VAL . . . . . 0.5 ' HB ' ' H ' ' A' ' 25' ' ' GLY . 89.3 t -64.46 165.26 1.46 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.351 0 CA-C-N 120.952 1.705 . . . . 0.0 107.584 173.953 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' D' D ' 25' ' ' GLY . . . . . 0.581 ' H ' ' HB ' ' G' ' 24' ' ' VAL . . . -117.02 51.1 0.75 Allowed Glycine 0 N--CA 1.48 1.573 0 CA-C-O 118.885 -0.953 . . . . 0.0 111.575 177.849 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -57.87 -168.74 0.01 OUTLIER 'General case' 0 C--N 1.321 -0.655 0 C-N-CA 124.037 0.935 . . . . 0.0 111.491 175.509 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 25.7 t-20 -72.33 86.86 1.12 Allowed 'General case' 0 C--N 1.35 0.588 0 C-N-CA 119.003 -1.079 . . . . 0.0 108.598 178.455 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 96.4 mttt -83.47 141.19 31.84 Favored 'General case' 0 C--N 1.352 0.688 0 N-CA-C 108.181 -1.044 . . . . 0.0 108.181 178.596 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -62.47 -164.69 0.43 Allowed Glycine 0 C--N 1.333 0.394 0 N-CA-C 110.451 -1.06 . . . . 0.0 110.451 177.463 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -102.28 115.88 31.48 Favored 'General case' 0 N--CA 1.471 0.595 0 N-CA-C 108.727 -0.842 . . . . 0.0 108.727 178.735 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 82.9 mt -102.91 142.57 16.66 Favored 'Isoleucine or valine' 0 C--N 1.356 0.889 0 N-CA-C 104.949 -2.241 . . . . 0.0 104.949 179.215 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' D' D ' 32' ' ' ILE . . . . . 0.426 HG22 ' H ' ' G' ' 32' ' ' ILE . 27.4 pt -157.18 -172.41 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.109 0 CA-C-O 120.759 0.314 . . . . 0.0 110.219 -178.141 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.95 2.13 6.12 Favored Glycine 0 N--CA 1.465 0.615 0 N-CA-C 110.513 -1.035 . . . . 0.0 110.513 -178.706 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 1.3 tt -75.85 138.05 40.86 Favored 'General case' 0 C--N 1.354 0.777 0 N-CA-C 107.729 -1.211 . . . . 0.0 107.729 -178.311 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 25.3 ttt -156.5 160.73 39.8 Favored 'General case' 0 C--O 1.237 0.444 0 N-CA-C 107.877 -1.157 . . . . 0.0 107.877 175.009 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' D' D ' 36' ' ' VAL . . . . . 0.484 HG12 ' N ' ' D' ' 37' ' ' GLY . 97.0 t -163.2 163.83 0.8 Allowed 'Isoleucine or valine' 0 CA--C 1.517 -0.326 0 N-CA-C 107.021 -1.474 . . . . 0.0 107.021 177.03 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' D' D ' 37' ' ' GLY . . . . . 0.484 ' N ' HG12 ' D' ' 36' ' ' VAL . . . 60.61 63.55 4.89 Favored Glycine 0 CA--C 1.528 0.874 0 C-N-CA 120.075 -1.06 . . . . 0.0 112.888 179.869 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 146.24 178.63 21.81 Favored Glycine 0 N--CA 1.481 1.639 0 CA-C-N 117.801 0.8 . . . . 0.0 111.588 179.803 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 34.5 m -112.69 149.89 15.04 Favored 'Isoleucine or valine' 0 C--N 1.357 0.911 0 N-CA-C 109.432 -0.581 . . . . 0.0 109.432 -176.943 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 21.8 t . . . . . 0 CA--C 1.52 -0.179 0 CA-C-O 115.976 -1.964 . . . . 0.0 109.604 178.486 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 21.7 p90 . . . . . 0 C--O 1.217 -0.626 0 CA-C-O 119.475 -0.298 . . . . 0.0 110.662 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' E' E ' 5' ' ' ARG . . . . . . . . . . . . . 99.0 mtt180 -136.89 154.11 50.56 Favored 'General case' 0 N--CA 1.479 0.992 0 N-CA-C 109.433 -0.58 . . . . 0.0 109.433 178.539 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 58.4 t-80 -114.31 114.5 26.02 Favored 'General case' 0 N--CA 1.48 1.032 0 N-CA-C 109.68 -0.489 . . . . 0.0 109.68 179.581 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' E' E ' 7' ' ' ASP . . . . . 0.42 ' O ' ' OG ' ' H' ' 8' ' ' SER . 7.9 m-20 -73.27 156.29 38.63 Favored 'General case' 0 N--CA 1.466 0.352 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.173 179.095 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' E' E ' 8' ' ' SER . . . . . 0.419 ' OG ' ' O ' ' B' ' 7' ' ' ASP . 5.4 p -166.72 -175.06 2.98 Favored 'General case' 0 N--CA 1.485 1.31 0 CA-C-O 121.17 0.509 . . . . 0.0 110.727 178.388 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.48 44.12 1.61 Allowed Glycine 0 N--CA 1.48 1.59 0 CA-C-N 115.577 -0.738 . . . . 0.0 112.169 179.294 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 49.7 p90 -64.9 131.93 48.02 Favored 'General case' 0 CA--C 1.542 0.672 0 N-CA-C 111.769 0.285 . . . . 0.0 111.769 -179.922 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 86.8 mt-10 -93.55 153.81 18.22 Favored 'General case' 0 N--CA 1.48 1.027 0 CA-C-O 121.163 0.506 . . . . 0.0 109.654 178.074 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -154.72 127.24 1.05 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.546 0 N-CA-C 107.782 -1.192 . . . . 0.0 107.782 177.917 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 48.7 m-70 -135.09 142.61 46.3 Favored 'General case' 0 N--CA 1.483 1.185 0 CA-C-O 120.739 0.304 . . . . 0.0 111.473 -178.009 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 6.2 t60 -164.46 98.83 0.81 Allowed 'General case' 0 N--CA 1.486 1.364 0 CA-C-N 116.448 -0.342 . . . . 0.0 110.327 179.594 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' E' E ' 15' ' ' GLN . . . . . 0.441 HE22 ' H ' ' E' ' 37' ' ' GLY . 22.1 pt20 -123.63 155.57 37.46 Favored 'General case' 0 CA--C 1.503 -0.83 0 N-CA-C 108.243 -1.021 . . . . 0.0 108.243 -179.588 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -125.14 105.88 9.49 Favored 'General case' 0 N--CA 1.484 1.269 0 N-CA-C 108.216 -1.031 . . . . 0.0 108.216 178.145 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 6.0 mp -120.58 148.42 43.9 Favored 'General case' 0 N--CA 1.494 1.74 0 CA-C-O 121.123 0.487 . . . . 0.0 111.293 -178.063 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 21.8 t -109.62 120.53 60.97 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.146 0 N-CA-C 108.126 -1.065 . . . . 0.0 108.126 177.313 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' E' E ' 19' ' ' PHE . . . . . 0.54 ' O ' ' N ' ' E' ' 21' ' ' ALA . 28.5 m-85 -117.11 -162.98 0.89 Allowed 'General case' 0 N--CA 1.495 1.8 0 C-N-CA 122.911 0.485 . . . . 0.0 109.749 -179.365 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' E' E ' 20' ' ' PHE . . . . . 0.512 ' HA ' ' O ' ' B' ' 20' ' ' PHE . 77.2 m-85 -47.76 75.3 0.0 OUTLIER 'General case' 0 C--O 1.206 -1.202 0 C-N-CA 124.288 1.035 . . . . 0.0 111.551 -179.887 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' E' E ' 21' ' ' ALA . . . . . 0.54 ' N ' ' O ' ' E' ' 19' ' ' PHE . . . -87.82 -75.46 0.41 Allowed 'General case' 0 N--CA 1.469 0.52 0 C-N-CA 122.536 0.335 . . . . 0.0 110.399 -179.162 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 41.2 tt0 -96.78 98.92 10.54 Favored 'General case' 0 N--CA 1.463 0.197 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 179.469 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 4.1 p30 -158.58 144.59 16.9 Favored 'General case' 0 N--CA 1.481 1.078 0 O-C-N 122.356 -0.215 . . . . 0.0 111.166 179.821 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' E' E ' 24' ' ' VAL . . . . . 0.495 ' HB ' ' H ' ' B' ' 25' ' ' GLY . 89.5 t -61.8 167.32 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.944 0 N-CA-C 106.925 -1.509 . . . . 0.0 106.925 176.86 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' E' E ' 25' ' ' GLY . . . . . 0.491 ' H ' ' HB ' ' H' ' 24' ' ' VAL . . . -121.48 46.76 1.08 Allowed Glycine 0 N--CA 1.472 1.069 0 N-CA-C 111.163 -0.775 . . . . 0.0 111.163 -179.195 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -61.81 -164.43 0.01 OUTLIER 'General case' 0 N--CA 1.471 0.58 0 CA-C-N 116.943 0.371 . . . . 0.0 110.541 -179.948 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 24.6 t-20 -70.07 77.23 0.5 Allowed 'General case' 0 CA--C 1.533 0.319 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.693 -179.785 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 97.1 mttt -76.14 139.0 41.1 Favored 'General case' 0 N--CA 1.474 0.754 0 N-CA-C 109.715 -0.476 . . . . 0.0 109.715 179.394 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.64 -165.62 1.06 Allowed Glycine 0 C--N 1.335 0.486 0 N-CA-C 109.909 -1.276 . . . . 0.0 109.909 178.011 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.68 113.09 25.32 Favored 'General case' 0 N--CA 1.473 0.711 0 N-CA-C 109.805 -0.442 . . . . 0.0 109.805 179.494 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 75.9 mt -99.07 135.24 34.98 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.447 0 N-CA-C 106.893 -1.521 . . . . 0.0 106.893 178.768 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' E' E ' 32' ' ' ILE . . . . . 0.428 HG22 ' H ' ' H' ' 32' ' ' ILE . 28.3 pt -150.58 -170.31 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.099 0 CA-C-O 120.949 0.404 . . . . 0.0 110.755 -179.471 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.9 2.49 3.72 Favored Glycine 0 CA--C 1.529 0.92 0 N-CA-C 111.476 -0.65 . . . . 0.0 111.476 -179.59 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' E' E ' 34' ' ' LEU . . . . . 0.409 ' H ' ' C ' ' E' ' 32' ' ' ILE . 1.1 tt -73.89 133.73 43.15 Favored 'General case' 0 CA--C 1.545 0.78 0 N-CA-C 109.095 -0.706 . . . . 0.0 109.095 -179.7 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 25.0 ttt -159.34 149.56 19.12 Favored 'General case' 0 N--CA 1.473 0.69 0 N-CA-C 108.567 -0.901 . . . . 0.0 108.567 178.751 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' E' E ' 36' ' ' VAL . . . . . 0.476 HG12 ' N ' ' E' ' 37' ' ' GLY . 61.6 t -152.68 162.78 2.3 Favored 'Isoleucine or valine' 0 C--N 1.345 0.384 0 N-CA-C 108.228 -1.027 . . . . 0.0 108.228 -179.681 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' E' E ' 37' ' ' GLY . . . . . 0.476 ' N ' HG12 ' E' ' 36' ' ' VAL . . . 57.1 67.44 2.22 Favored Glycine 0 C--N 1.309 -0.93 0 CA-C-N 115.473 -0.785 . . . . 0.0 112.012 178.694 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.29 174.94 19.73 Favored Glycine 0 N--CA 1.476 1.325 0 N-CA-C 111.285 -0.726 . . . . 0.0 111.285 178.825 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 31.2 m -107.16 152.55 8.65 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.638 0 C-N-CA 123.475 0.71 . . . . 0.0 110.372 -179.079 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 21.9 t . . . . . 0 C--O 1.214 -0.784 0 O-C-N 124.222 0.951 . . . . 0.0 110.519 179.922 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 22.5 p90 . . . . . 0 C--O 1.218 -0.587 0 CA-C-O 119.582 -0.247 . . . . 0.0 110.575 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' F' F ' 5' ' ' ARG . . . . . . . . . . . . . 99.0 mtt180 -136.73 154.04 50.7 Favored 'General case' 0 N--CA 1.478 0.937 0 N-CA-C 109.409 -0.589 . . . . 0.0 109.409 178.49 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 58.1 t-80 -114.45 114.54 25.96 Favored 'General case' 0 N--CA 1.48 1.027 0 C-N-CA 122.909 0.483 . . . . 0.0 109.76 179.534 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' F' F ' 7' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -73.28 156.39 38.52 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.274 179.129 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' F' F ' 8' ' ' SER . . . . . 0.421 ' HA ' ' OG ' ' I' ' 8' ' ' SER . 5.4 p -166.87 -174.99 2.9 Favored 'General case' 0 N--CA 1.485 1.301 0 CA-C-O 121.023 0.439 . . . . 0.0 110.936 178.468 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.38 43.69 1.69 Allowed Glycine 0 N--CA 1.479 1.543 0 CA-C-N 115.757 -0.656 . . . . 0.0 112.149 179.199 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 49.9 p90 -64.4 132.31 49.69 Favored 'General case' 0 CA--C 1.544 0.724 0 O-C-N 122.632 -0.334 . . . . 0.0 111.813 -179.945 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 86.7 mt-10 -93.73 153.59 18.25 Favored 'General case' 0 N--CA 1.48 1.067 0 N-CA-C 109.636 -0.505 . . . . 0.0 109.636 178.085 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -154.57 127.18 1.07 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.545 0 N-CA-C 107.811 -1.181 . . . . 0.0 107.811 177.885 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 46.6 m-70 -135.06 142.77 46.4 Favored 'General case' 0 N--CA 1.483 1.215 0 CA-C-O 120.77 0.319 . . . . 0.0 111.515 -178.131 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 6.2 t60 -164.55 98.7 0.8 Allowed 'General case' 0 N--CA 1.485 1.302 0 CA-C-N 116.465 -0.334 . . . . 0.0 110.437 179.62 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' F' F ' 15' ' ' GLN . . . . . 0.426 HE22 ' H ' ' F' ' 37' ' ' GLY . 22.2 pt20 -123.52 155.61 37.23 Favored 'General case' 0 CA--C 1.501 -0.914 0 N-CA-C 108.225 -1.028 . . . . 0.0 108.225 -179.527 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -125.09 105.89 9.51 Favored 'General case' 0 N--CA 1.485 1.286 0 N-CA-C 108.245 -1.02 . . . . 0.0 108.245 178.104 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 6.0 mp -120.64 148.21 44.21 Favored 'General case' 0 N--CA 1.495 1.811 0 CA-C-O 121.168 0.509 . . . . 0.0 111.181 -178.009 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 21.7 t -109.45 120.3 60.42 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.167 0 N-CA-C 108.13 -1.063 . . . . 0.0 108.13 177.244 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' F' F ' 19' ' ' PHE . . . . . 0.539 ' O ' ' N ' ' F' ' 21' ' ' ALA . 28.4 m-85 -116.76 -162.7 0.87 Allowed 'General case' 0 N--CA 1.494 1.763 0 C-N-CA 122.919 0.487 . . . . 0.0 109.864 -179.436 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' F' F ' 20' ' ' PHE . . . . . 0.514 ' HA ' ' O ' ' C' ' 20' ' ' PHE . 78.3 m-85 -48.04 75.1 0.0 OUTLIER 'General case' 0 C--O 1.206 -1.229 0 C-N-CA 124.3 1.04 . . . . 0.0 111.466 -179.878 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' F' F ' 21' ' ' ALA . . . . . 0.539 ' N ' ' O ' ' F' ' 19' ' ' PHE . . . -87.38 -77.08 0.35 Allowed 'General case' 0 N--CA 1.466 0.369 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.044 -179.386 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 41.2 tt0 -95.21 99.29 11.27 Favored 'General case' 0 N--CA 1.462 0.173 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 179.49 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 4.1 p30 -158.8 144.8 16.73 Favored 'General case' 0 N--CA 1.481 1.097 0 CA-C-O 119.655 -0.212 . . . . 0.0 111.304 179.745 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' F' F ' 24' ' ' VAL . . . . . 0.516 ' HB ' ' H ' ' C' ' 25' ' ' GLY . 88.8 t -61.98 167.3 0.77 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.93 0 N-CA-C 106.933 -1.506 . . . . 0.0 106.933 176.894 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' F' F ' 25' ' ' GLY . . . . . 0.479 ' H ' ' HB ' ' I' ' 24' ' ' VAL . . . -121.67 46.88 1.07 Allowed Glycine 0 N--CA 1.478 1.44 0 N-CA-C 110.88 -0.888 . . . . 0.0 110.88 -179.239 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -61.89 -164.43 0.01 OUTLIER 'General case' 0 N--CA 1.471 0.612 0 CA-C-N 116.887 0.343 . . . . 0.0 110.436 -179.977 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 24.6 t-20 -69.88 77.11 0.47 Allowed 'General case' 0 CA--C 1.533 0.297 0 CA-C-N 116.319 -0.401 . . . . 0.0 110.752 -179.779 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -76.09 138.97 41.14 Favored 'General case' 0 N--CA 1.475 0.807 0 N-CA-C 109.638 -0.504 . . . . 0.0 109.638 179.451 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.47 -165.36 0.96 Allowed Glycine 0 C--N 1.335 0.484 0 N-CA-C 110.081 -1.207 . . . . 0.0 110.081 177.99 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.92 112.82 25.08 Favored 'General case' 0 N--CA 1.472 0.638 0 N-CA-C 109.695 -0.483 . . . . 0.0 109.695 179.511 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 76.1 mt -98.99 135.3 34.6 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.498 0 N-CA-C 106.882 -1.525 . . . . 0.0 106.882 178.84 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' F' F ' 32' ' ' ILE . . . . . 0.441 HG22 ' H ' ' I' ' 32' ' ' ILE . 28.2 pt -150.64 -170.19 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.128 0 CA-C-O 120.988 0.423 . . . . 0.0 110.777 -179.516 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.99 2.28 3.65 Favored Glycine 0 CA--C 1.53 1.006 0 N-CA-C 111.409 -0.676 . . . . 0.0 111.409 -179.673 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' F' F ' 34' ' ' LEU . . . . . 0.411 HD23 ' N ' ' F' ' 35' ' ' MET . 1.1 tt -73.91 133.72 43.13 Favored 'General case' 0 CA--C 1.546 0.798 0 N-CA-C 109.128 -0.693 . . . . 0.0 109.128 -179.654 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' F' F ' 35' ' ' MET . . . . . 0.411 ' N ' HD23 ' F' ' 34' ' ' LEU . 25.1 ttt -159.4 149.74 19.16 Favored 'General case' 0 N--CA 1.47 0.573 0 N-CA-C 108.563 -0.903 . . . . 0.0 108.563 178.832 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' F' F ' 36' ' ' VAL . . . . . 0.479 HG12 ' N ' ' F' ' 37' ' ' GLY . 62.2 t -152.83 162.84 2.21 Favored 'Isoleucine or valine' 0 C--N 1.345 0.37 0 N-CA-C 108.169 -1.049 . . . . 0.0 108.169 -179.667 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' F' F ' 37' ' ' GLY . . . . . 0.479 ' N ' HG12 ' F' ' 36' ' ' VAL . . . 57.1 67.44 2.22 Favored Glycine 0 C--N 1.308 -0.974 0 CA-C-N 115.433 -0.803 . . . . 0.0 112.004 178.626 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.34 175.04 19.85 Favored Glycine 0 N--CA 1.475 1.275 0 N-CA-C 111.248 -0.741 . . . . 0.0 111.248 178.848 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' F' F ' 39' ' ' VAL . . . . . 0.404 ' H ' HG12 ' I' ' 39' ' ' VAL . 31.4 m -107.27 152.41 8.85 Favored 'Isoleucine or valine' 0 C--N 1.35 0.597 0 C-N-CA 123.546 0.738 . . . . 0.0 110.361 -179.025 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 22.0 t . . . . . 0 C--O 1.213 -0.821 0 O-C-N 124.216 0.948 . . . . 0.0 110.385 179.804 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 20.1 p90 . . . . . 0 N--CA 1.472 0.625 0 N-CA-C 110.339 -0.245 . . . . 0.0 110.339 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' G' G ' 5' ' ' ARG . . . . . . . . . . . . . 99.1 mtt180 -136.54 154.04 50.83 Favored 'General case' 0 N--CA 1.482 1.13 0 N-CA-C 109.463 -0.569 . . . . 0.0 109.463 178.555 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 58.3 t-80 -114.1 115.54 27.7 Favored 'General case' 0 N--CA 1.483 1.207 0 C-N-CA 122.823 0.449 . . . . 0.0 109.891 179.649 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 -75.86 152.46 37.2 Favored 'General case' 0 N--CA 1.47 0.569 0 CA-C-N 116.0 -0.545 . . . . 0.0 110.772 179.279 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' G' G ' 8' ' ' SER . . . . . 0.533 ' OG ' ' O ' ' D' ' 7' ' ' ASP . 4.9 p -164.03 -172.39 2.78 Favored 'General case' 0 N--CA 1.475 0.775 0 CA-C-O 121.105 0.479 . . . . 0.0 110.596 178.621 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.12 43.6 1.87 Allowed Glycine 0 N--CA 1.479 1.563 0 CA-C-N 115.633 -0.712 . . . . 0.0 111.655 178.983 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 51.0 p90 -64.2 132.23 49.75 Favored 'General case' 0 CA--C 1.542 0.67 0 CA-C-O 120.648 0.261 . . . . 0.0 111.664 -179.772 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 84.1 mt-10 -94.01 152.88 18.49 Favored 'General case' 0 N--CA 1.479 1.008 0 CA-C-O 121.035 0.445 . . . . 0.0 110.057 178.644 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -155.21 127.55 1.03 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.016 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 178.179 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 49.9 m-70 -134.63 144.05 47.65 Favored 'General case' 0 N--CA 1.478 0.925 0 CA-C-N 115.416 -0.811 . . . . 0.0 111.405 -178.326 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 30.5 t-80 -166.12 98.74 0.63 Allowed 'General case' 0 N--CA 1.481 1.12 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.122 178.977 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' G' G ' 15' ' ' GLN . . . . . 0.436 HE22 ' H ' ' G' ' 37' ' ' GLY . 22.3 pt20 -123.91 154.95 38.99 Favored 'General case' 0 CA--C 1.497 -1.07 0 N-CA-C 107.998 -1.112 . . . . 0.0 107.998 -179.287 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -124.8 106.19 9.85 Favored 'General case' 0 N--CA 1.483 1.192 0 N-CA-C 108.04 -1.096 . . . . 0.0 108.04 178.151 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 6.0 mp -120.22 148.76 43.27 Favored 'General case' 0 N--CA 1.496 1.85 0 CA-C-O 121.091 0.472 . . . . 0.0 111.625 -178.244 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 20.4 t -111.11 120.21 61.29 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.043 0 N-CA-C 107.775 -1.194 . . . . 0.0 107.775 176.909 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' G' G ' 19' ' ' PHE . . . . . 0.556 ' O ' ' N ' ' G' ' 21' ' ' ALA . 28.1 m-85 -117.17 -164.58 1.0 Allowed 'General case' 0 N--CA 1.494 1.728 0 C-N-CA 124.372 1.069 . . . . 0.0 110.225 -178.846 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' G' G ' 20' ' ' PHE . . . . . 0.507 ' HA ' ' O ' ' D' ' 20' ' ' PHE . 78.4 m-85 -47.13 73.02 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.03 0 C-N-CA 124.522 1.129 . . . . 0.0 111.664 -179.83 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' G' G ' 21' ' ' ALA . . . . . 0.556 ' N ' ' O ' ' G' ' 19' ' ' PHE . . . -85.37 -78.23 0.27 Allowed 'General case' 0 N--CA 1.466 0.364 0 C-N-CA 122.715 0.406 . . . . 0.0 110.246 -178.901 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 41.0 tt0 -94.6 99.8 11.87 Favored 'General case' 0 N--CA 1.465 0.284 0 N-CA-C 108.284 -1.006 . . . . 0.0 108.284 179.364 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 4.1 p30 -159.17 144.83 16.23 Favored 'General case' 0 N--CA 1.477 0.91 0 O-C-N 122.313 -0.242 . . . . 0.0 111.226 179.745 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' G' G ' 24' ' ' VAL . . . . . 0.581 ' HB ' ' H ' ' D' ' 25' ' ' GLY . 92.4 t -62.48 165.74 1.02 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.655 0 N-CA-C 107.283 -1.377 . . . . 0.0 107.283 177.231 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' G' G ' 25' ' ' GLY . . . . . 0.408 ' N ' HG12 ' G' ' 24' ' ' VAL . . . -119.86 48.85 0.91 Allowed Glycine 0 N--CA 1.482 1.734 0 N-CA-C 110.587 -1.005 . . . . 0.0 110.587 -179.66 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -64.11 -164.65 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.669 0 CA-C-N 117.194 0.497 . . . . 0.0 109.752 179.787 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 24.8 t-20 -69.97 76.81 0.48 Allowed 'General case' 0 N--CA 1.467 0.415 0 CA-C-N 116.428 -0.351 . . . . 0.0 110.775 -179.699 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -75.2 139.02 42.35 Favored 'General case' 0 N--CA 1.474 0.759 0 N-CA-C 109.724 -0.473 . . . . 0.0 109.724 179.319 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.75 -164.48 0.9 Allowed Glycine 0 C--N 1.337 0.63 0 N-CA-C 109.679 -1.369 . . . . 0.0 109.679 178.185 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.71 113.04 25.25 Favored 'General case' 0 N--CA 1.467 0.412 0 C-N-CA 122.681 0.392 . . . . 0.0 110.204 179.627 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 77.8 mt -99.7 135.42 35.27 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.825 0 N-CA-C 106.932 -1.506 . . . . 0.0 106.932 178.789 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' G' G ' 32' ' ' ILE . . . . . 0.426 ' H ' HG22 ' D' ' 32' ' ' ILE . 30.4 pt -151.09 -169.13 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.745 0 CA-C-N 119.448 1.022 . . . . 0.0 109.946 179.963 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.98 2.42 3.76 Favored Glycine 0 CA--C 1.528 0.861 0 N-CA-C 111.253 -0.739 . . . . 0.0 111.253 -179.749 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' G' G ' 34' ' ' LEU . . . . . 0.415 HD23 ' N ' ' G' ' 35' ' ' MET . 1.1 tt -74.57 133.28 42.25 Favored 'General case' 0 CA--C 1.543 0.687 0 N-CA-C 109.156 -0.683 . . . . 0.0 109.156 -179.586 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' G' G ' 35' ' ' MET . . . . . 0.415 ' N ' HD23 ' G' ' 34' ' ' LEU . 23.8 ttt -159.04 150.27 20.26 Favored 'General case' 0 N--CA 1.469 0.486 0 N-CA-C 108.59 -0.893 . . . . 0.0 108.59 179.126 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' G' G ' 36' ' ' VAL . . . . . 0.445 HG12 ' N ' ' G' ' 37' ' ' GLY . 62.5 t -153.8 161.35 2.44 Favored 'Isoleucine or valine' 0 C--N 1.346 0.426 0 N-CA-C 108.05 -1.093 . . . . 0.0 108.05 -179.5 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' G' G ' 37' ' ' GLY . . . . . 0.445 ' N ' HG12 ' G' ' 36' ' ' VAL . . . 58.43 67.45 2.19 Favored Glycine 0 C--N 1.309 -0.957 0 CA-C-N 115.331 -0.85 . . . . 0.0 111.91 178.566 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.44 174.37 19.36 Favored Glycine 0 N--CA 1.477 1.383 0 N-CA-C 110.641 -0.983 . . . . 0.0 110.641 178.872 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 32.9 m -107.02 152.16 8.62 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.912 0 C-N-CA 123.256 0.622 . . . . 0.0 110.487 -179.453 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 22.7 t . . . . . 0 C--O 1.217 -0.63 0 CA-C-O 118.373 -0.822 . . . . 0.0 110.688 179.867 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 20.4 p90 . . . . . 0 N--CA 1.472 0.636 0 CA-C-O 119.549 -0.262 . . . . 0.0 110.313 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' H' H ' 5' ' ' ARG . . . . . . . . . . . . . 99.1 mtt180 -136.18 153.84 51.13 Favored 'General case' 0 N--CA 1.484 1.258 0 N-CA-C 109.398 -0.593 . . . . 0.0 109.398 178.571 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 58.4 t-80 -113.91 115.31 27.48 Favored 'General case' 0 N--CA 1.482 1.129 0 C-N-CA 122.829 0.452 . . . . 0.0 109.96 179.521 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -75.55 152.7 37.72 Favored 'General case' 0 N--CA 1.47 0.57 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.681 179.295 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' H' H ' 8' ' ' SER . . . . . 0.42 ' OG ' ' O ' ' E' ' 7' ' ' ASP . 6.9 p -164.17 -172.67 2.85 Favored 'General case' 0 N--CA 1.474 0.731 0 CA-C-O 121.113 0.482 . . . . 0.0 110.683 178.63 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.13 43.67 1.86 Allowed Glycine 0 N--CA 1.48 1.599 0 CA-C-N 115.79 -0.641 . . . . 0.0 111.765 179.157 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 51.0 p90 -64.44 132.28 49.56 Favored 'General case' 0 CA--C 1.541 0.61 0 O-C-N 122.68 -0.306 . . . . 0.0 111.709 -179.878 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 84.4 mt-10 -94.04 152.92 18.45 Favored 'General case' 0 N--CA 1.478 0.936 0 CA-C-O 121.095 0.474 . . . . 0.0 110.082 178.651 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -155.27 127.12 0.96 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.032 0 N-CA-C 108.03 -1.1 . . . . 0.0 108.03 178.176 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 48.9 m-70 -134.32 143.84 47.93 Favored 'General case' 0 N--CA 1.479 1.016 0 CA-C-N 115.415 -0.811 . . . . 0.0 111.348 -178.183 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 6.3 t60 -165.96 98.94 0.65 Allowed 'General case' 0 N--CA 1.484 1.227 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.012 178.958 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' H' H ' 15' ' ' GLN . . . . . 0.428 HE22 ' H ' ' H' ' 37' ' ' GLY . 22.5 pt20 -124.07 154.77 39.47 Favored 'General case' 0 CA--C 1.495 -1.135 0 N-CA-C 108.054 -1.091 . . . . 0.0 108.054 -179.339 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -124.52 106.06 9.87 Favored 'General case' 0 N--CA 1.483 1.204 0 N-CA-C 108.156 -1.054 . . . . 0.0 108.156 178.107 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 6.0 mp -120.17 148.58 43.46 Favored 'General case' 0 N--CA 1.496 1.868 0 CA-C-O 121.072 0.463 . . . . 0.0 111.567 -178.201 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 20.2 t -110.61 121.02 62.64 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.008 0 N-CA-C 107.777 -1.194 . . . . 0.0 107.777 176.776 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' H' H ' 19' ' ' PHE . . . . . 0.56 ' O ' ' N ' ' H' ' 21' ' ' ALA . 27.4 m-85 -117.95 -164.32 1.0 Allowed 'General case' 0 N--CA 1.492 1.675 0 C-N-CA 124.268 1.027 . . . . 0.0 110.127 -178.734 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' H' H ' 20' ' ' PHE . . . . . 0.485 ' HA ' ' O ' ' E' ' 20' ' ' PHE . 79.1 m-85 -47.53 73.03 0.0 OUTLIER 'General case' 0 N--CA 1.481 1.081 0 C-N-CA 124.425 1.09 . . . . 0.0 111.621 -179.78 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' H' H ' 21' ' ' ALA . . . . . 0.56 ' N ' ' O ' ' H' ' 19' ' ' PHE . . . -85.13 -77.8 0.27 Allowed 'General case' 0 N--CA 1.466 0.339 0 C-N-CA 122.744 0.417 . . . . 0.0 110.432 -179.018 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 41.1 tt0 -95.14 99.48 11.45 Favored 'General case' 0 N--CA 1.465 0.303 0 N-CA-C 108.313 -0.995 . . . . 0.0 108.313 179.439 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 4.2 p30 -158.76 145.06 16.97 Favored 'General case' 0 N--CA 1.478 0.938 0 O-C-N 122.475 -0.14 . . . . 0.0 111.188 179.874 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' H' H ' 24' ' ' VAL . . . . . 0.491 ' HB ' ' H ' ' E' ' 25' ' ' GLY . 88.8 t -62.65 165.45 1.09 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.594 0 N-CA-C 107.247 -1.39 . . . . 0.0 107.247 177.113 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' H' H ' 25' ' ' GLY . . . . . 0.41 ' N ' HG12 ' H' ' 24' ' ' VAL . . . -119.49 48.69 0.92 Allowed Glycine 0 N--CA 1.48 1.582 0 N-CA-C 110.625 -0.99 . . . . 0.0 110.625 -179.579 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -64.31 -164.83 0.02 OUTLIER 'General case' 0 N--CA 1.473 0.685 0 CA-C-N 117.233 0.517 . . . . 0.0 109.852 179.897 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 24.7 t-20 -69.68 76.95 0.44 Allowed 'General case' 0 N--CA 1.467 0.395 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.71 -179.733 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -75.57 139.29 42.02 Favored 'General case' 0 N--CA 1.472 0.672 0 N-CA-C 109.695 -0.483 . . . . 0.0 109.695 179.326 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -65.15 -164.65 1.07 Allowed Glycine 0 C--N 1.336 0.574 0 N-CA-C 109.651 -1.38 . . . . 0.0 109.651 178.27 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.56 112.92 25.07 Favored 'General case' 0 N--CA 1.468 0.443 0 C-N-CA 122.714 0.406 . . . . 0.0 110.22 179.761 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 76.6 mt -99.6 135.28 35.68 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.812 0 N-CA-C 106.986 -1.487 . . . . 0.0 106.986 178.774 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' H' H ' 32' ' ' ILE . . . . . 0.428 ' H ' HG22 ' E' ' 32' ' ' ILE . 30.5 pt -151.05 -169.16 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.707 0 CA-C-N 119.494 1.043 . . . . 0.0 109.836 -179.914 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.06 2.2 3.66 Favored Glycine 0 CA--C 1.528 0.852 0 N-CA-C 111.167 -0.773 . . . . 0.0 111.167 -179.834 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' H' H ' 34' ' ' LEU . . . . . 0.423 ' H ' ' C ' ' H' ' 32' ' ' ILE . 1.1 tt -74.28 133.13 42.61 Favored 'General case' 0 CA--C 1.544 0.733 0 N-CA-C 109.223 -0.658 . . . . 0.0 109.223 -179.58 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' H' H ' 35' ' ' MET . . . . . 0.404 ' N ' HD23 ' H' ' 34' ' ' LEU . 23.9 ttt -158.85 150.29 20.64 Favored 'General case' 0 N--CA 1.468 0.465 0 N-CA-C 108.644 -0.873 . . . . 0.0 108.644 179.066 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' H' H ' 36' ' ' VAL . . . . . 0.449 HG12 ' N ' ' H' ' 37' ' ' GLY . 59.9 t -153.83 161.38 2.43 Favored 'Isoleucine or valine' 0 C--N 1.346 0.425 0 N-CA-C 108.005 -1.109 . . . . 0.0 108.005 -179.438 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' H' H ' 37' ' ' GLY . . . . . 0.449 ' N ' HG12 ' H' ' 36' ' ' VAL . . . 58.35 67.35 2.24 Favored Glycine 0 C--N 1.309 -0.955 0 CA-C-N 115.349 -0.841 . . . . 0.0 111.902 178.52 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.29 173.8 18.75 Favored Glycine 0 N--CA 1.477 1.39 0 N-CA-C 110.708 -0.957 . . . . 0.0 110.708 178.907 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 32.7 m -106.35 152.08 8.12 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.914 0 C-N-CA 123.341 0.656 . . . . 0.0 110.554 -179.438 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 22.1 t . . . . . 0 C--O 1.218 -0.588 0 CA-C-O 118.321 -0.847 . . . . 0.0 110.644 179.843 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 20.4 p90 . . . . . 0 N--CA 1.471 0.615 0 CA-C-O 119.517 -0.278 . . . . 0.0 110.325 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' I' I ' 5' ' ' ARG . . . . . . . . . . . . . 99.1 mtt180 -136.11 153.92 51.15 Favored 'General case' 0 N--CA 1.483 1.213 0 N-CA-C 109.47 -0.566 . . . . 0.0 109.47 178.62 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 58.2 t-80 -114.12 115.53 27.68 Favored 'General case' 0 N--CA 1.482 1.153 0 C-N-CA 122.809 0.444 . . . . 0.0 109.863 179.545 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 8.0 m-20 -75.98 152.33 37.02 Favored 'General case' 0 N--CA 1.47 0.567 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.697 179.335 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' I' I ' 8' ' ' SER . . . . . 0.421 ' OG ' ' HA ' ' F' ' 8' ' ' SER . 6.7 p -163.89 -172.82 2.97 Favored 'General case' 0 N--CA 1.475 0.78 0 CA-C-O 121.124 0.487 . . . . 0.0 110.681 178.801 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.35 43.61 1.84 Allowed Glycine 0 N--CA 1.481 1.676 0 CA-C-N 115.773 -0.649 . . . . 0.0 111.71 179.105 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 51.1 p90 -64.32 132.38 50.03 Favored 'General case' 0 CA--C 1.541 0.622 0 O-C-N 122.681 -0.306 . . . . 0.0 111.722 -179.853 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 84.1 mt-10 -94.06 152.92 18.44 Favored 'General case' 0 N--CA 1.477 0.921 0 CA-C-O 121.11 0.481 . . . . 0.0 110.033 178.619 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -155.33 127.31 0.98 Allowed 'Isoleucine or valine' 0 CA--C 1.553 1.069 0 N-CA-C 107.978 -1.119 . . . . 0.0 107.978 178.098 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 50.3 m-70 -134.48 144.02 47.83 Favored 'General case' 0 N--CA 1.477 0.92 0 CA-C-N 115.387 -0.824 . . . . 0.0 111.391 -178.269 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 6.3 t60 -166.09 98.59 0.63 Allowed 'General case' 0 N--CA 1.483 1.183 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.06 179.094 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' I' I ' 15' ' ' GLN . . . . . 0.422 HE22 ' H ' ' I' ' 37' ' ' GLY . 22.6 pt20 -123.84 154.77 39.15 Favored 'General case' 0 CA--C 1.497 -1.082 0 N-CA-C 108.014 -1.106 . . . . 0.0 108.014 -179.323 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -124.54 106.07 9.87 Favored 'General case' 0 N--CA 1.483 1.199 0 N-CA-C 108.154 -1.054 . . . . 0.0 108.154 178.125 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 6.0 mp -120.25 148.61 43.47 Favored 'General case' 0 N--CA 1.495 1.819 0 CA-C-O 121.06 0.457 . . . . 0.0 111.593 -178.179 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 20.2 t -110.61 121.1 62.78 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.01 0 N-CA-C 107.799 -1.186 . . . . 0.0 107.799 176.87 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' I' I ' 19' ' ' PHE . . . . . 0.559 ' O ' ' N ' ' I' ' 21' ' ' ALA . 27.2 m-85 -118.11 -164.1 0.99 Allowed 'General case' 0 N--CA 1.495 1.776 0 C-N-CA 124.229 1.012 . . . . 0.0 110.095 -178.659 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' I' I ' 20' ' ' PHE . . . . . 0.485 ' HA ' ' O ' ' F' ' 20' ' ' PHE . 79.6 m-85 -47.61 72.97 0.0 OUTLIER 'General case' 0 N--CA 1.481 1.085 0 C-N-CA 124.54 1.136 . . . . 0.0 111.502 -179.771 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' I' I ' 21' ' ' ALA . . . . . 0.559 ' N ' ' O ' ' I' ' 19' ' ' PHE . . . -85.11 -78.82 0.24 Allowed 'General case' 0 N--CA 1.468 0.43 0 C-N-CA 122.76 0.424 . . . . 0.0 110.12 -178.935 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 41.3 tt0 -93.95 99.48 11.81 Favored 'General case' 0 N--CA 1.464 0.274 0 N-CA-C 108.469 -0.938 . . . . 0.0 108.469 179.247 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 4.2 p30 -158.87 145.26 16.94 Favored 'General case' 0 N--CA 1.478 0.928 0 O-C-N 122.388 -0.195 . . . . 0.0 111.214 179.616 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' I' I ' 24' ' ' VAL . . . . . 0.479 ' HB ' ' H ' ' F' ' 25' ' ' GLY . 92.1 t -62.78 165.71 1.07 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.606 0 N-CA-C 107.257 -1.386 . . . . 0.0 107.257 177.154 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' I' I ' 25' ' ' GLY . . . . . 0.419 ' N ' HG12 ' I' ' 24' ' ' VAL . . . -119.94 48.8 0.92 Allowed Glycine 0 N--CA 1.48 1.619 0 N-CA-C 110.546 -1.022 . . . . 0.0 110.546 -179.559 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -64.08 -164.37 0.02 OUTLIER 'General case' 0 N--CA 1.473 0.684 0 CA-C-N 117.168 0.484 . . . . 0.0 109.747 179.865 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 24.9 t-20 -70.27 77.2 0.53 Allowed 'General case' 0 CA--C 1.536 0.42 0 CA-C-N 116.394 -0.366 . . . . 0.0 110.63 -179.701 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -75.65 139.06 41.77 Favored 'General case' 0 N--CA 1.473 0.713 0 N-CA-C 109.62 -0.511 . . . . 0.0 109.62 179.367 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.83 -164.62 0.94 Allowed Glycine 0 C--N 1.337 0.59 0 N-CA-C 109.76 -1.336 . . . . 0.0 109.76 178.179 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.4 112.75 24.88 Favored 'General case' 0 CA--C 1.535 0.379 0 C-N-CA 122.723 0.409 . . . . 0.0 110.251 179.668 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 77.0 mt -99.52 135.21 35.84 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.852 0 N-CA-C 106.927 -1.508 . . . . 0.0 106.927 178.829 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' I' I ' 32' ' ' ILE . . . . . 0.441 ' H ' HG22 ' F' ' 32' ' ' ILE . 30.3 pt -151.05 -169.08 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 CA-C-N 119.487 1.039 . . . . 0.0 109.876 179.956 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.05 2.25 3.7 Favored Glycine 0 CA--C 1.527 0.827 0 N-CA-C 111.22 -0.752 . . . . 0.0 111.22 -179.751 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' I' I ' 34' ' ' LEU . . . . . 0.42 HD23 ' N ' ' I' ' 35' ' ' MET . 1.1 tt -74.27 133.2 42.62 Favored 'General case' 0 CA--C 1.545 0.761 0 N-CA-C 109.122 -0.696 . . . . 0.0 109.122 -179.598 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' I' I ' 35' ' ' MET . . . . . 0.42 ' N ' HD23 ' I' ' 34' ' ' LEU . 23.8 ttt -158.95 150.13 20.31 Favored 'General case' 0 N--CA 1.468 0.443 0 N-CA-C 108.612 -0.884 . . . . 0.0 108.612 179.04 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' I' I ' 36' ' ' VAL . . . . . 0.451 HG12 ' N ' ' I' ' 37' ' ' GLY . 60.4 t -153.79 161.24 2.48 Favored 'Isoleucine or valine' 0 C--N 1.345 0.396 0 N-CA-C 107.959 -1.126 . . . . 0.0 107.959 -179.46 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' I' I ' 37' ' ' GLY . . . . . 0.451 ' N ' HG12 ' I' ' 36' ' ' VAL . . . 58.45 67.41 2.21 Favored Glycine 0 C--N 1.311 -0.86 0 CA-C-N 115.275 -0.875 . . . . 0.0 111.935 178.564 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.28 173.92 18.84 Favored Glycine 0 N--CA 1.476 1.312 0 N-CA-C 110.674 -0.97 . . . . 0.0 110.674 178.841 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' I' I ' 39' ' ' VAL . . . . . 0.404 HG12 ' H ' ' F' ' 39' ' ' VAL . 32.8 m -106.51 151.98 8.28 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.923 0 C-N-CA 123.28 0.632 . . . . 0.0 110.643 -179.48 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 22.3 t . . . . . 0 C--O 1.217 -0.614 0 CA-C-O 118.413 -0.803 . . . . 0.0 110.752 179.908 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 77.9 m-85 . . . . . 0 N--CA 1.473 0.694 0 N-CA-C 109.658 -0.497 . . . . 0.0 109.658 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 35.6 mtp180 -142.43 143.03 32.45 Favored 'General case' 0 N--CA 1.48 1.059 0 N-CA-C 109.285 -0.635 . . . . 0.0 109.285 -179.951 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 74.4 m80 -150.29 117.84 6.13 Favored 'General case' 0 N--CA 1.472 0.64 0 N-CA-C 108.991 -0.744 . . . . 0.0 108.991 178.749 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 10.1 m-20 -68.31 149.4 49.47 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.822 -179.848 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 4.3 t -168.42 176.34 5.87 Favored 'General case' 0 N--CA 1.473 0.695 0 N-CA-C 109.643 -0.503 . . . . 0.0 109.643 178.592 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 105.08 51.54 0.88 Allowed Glycine 0 N--CA 1.484 1.884 0 N-CA-C 112.065 -0.414 . . . . 0.0 112.065 179.276 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 45.9 p90 -64.8 131.85 47.92 Favored 'General case' 0 N--CA 1.471 0.617 0 CA-C-O 120.51 0.195 . . . . 0.0 111.524 179.652 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 11' ' ' GLU . . . . . 0.424 ' OE2' ' ND2' ' F' ' 27' ' ' ASN . 43.2 mt-10 -82.78 150.49 26.61 Favored 'General case' 0 N--CA 1.472 0.669 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 177.756 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -154.17 128.98 1.45 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 N-CA-C 108.094 -1.076 . . . . 0.0 108.094 178.167 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 56.7 m-70 -133.39 145.22 50.12 Favored 'General case' 0 N--CA 1.488 1.451 0 CA-C-N 118.616 0.644 . . . . 0.0 110.806 -178.959 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 5.9 t60 -166.11 98.16 0.62 Allowed 'General case' 0 N--CA 1.482 1.141 0 N-CA-C 111.392 0.145 . . . . 0.0 111.392 179.476 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 48.1 mt-30 -107.44 -172.65 2.11 Favored 'General case' 0 CA--C 1.502 -0.886 0 N-CA-C 107.948 -1.13 . . . . 0.0 107.948 179.219 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -163.13 97.92 0.92 Allowed 'General case' 0 N--CA 1.471 0.576 0 CA-C-N 115.121 -0.945 . . . . 0.0 109.291 178.739 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.502 ' N ' HD12 ' A' ' 17' ' ' LEU . 6.2 mp -108.7 163.98 12.78 Favored 'General case' 0 N--CA 1.487 1.394 0 N-CA-C 108.05 -1.093 . . . . 0.0 108.05 179.792 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 55.3 t -141.84 120.25 9.18 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.395 0 CA-C-O 118.663 -0.684 . . . . 0.0 110.33 179.77 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 52.9 m-85 -72.97 158.07 36.19 Favored 'General case' 0 N--CA 1.482 1.172 0 N-CA-C 107.383 -1.34 . . . . 0.0 107.383 176.917 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 24.8 t80 -169.29 -58.22 0.02 OUTLIER 'General case' 0 N--CA 1.481 1.076 0 CA-C-O 122.553 1.168 . . . . 0.0 109.475 -179.82 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -39.76 91.12 0.0 OUTLIER 'General case' 0 N--CA 1.457 -0.092 0 CA-C-N 113.665 -1.607 . . . . 0.0 112.709 -178.115 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 36.4 tt0 -58.2 131.95 52.12 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-N 115.143 -0.935 . . . . 0.0 111.128 179.429 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 9.0 m-20 -80.45 162.89 24.18 Favored 'General case' 0 N--CA 1.478 0.961 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 179.772 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 98.3 t -161.2 -74.25 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.484 1.267 0 N-CA-C 107.609 -1.256 . . . . 0.0 107.609 -178.612 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -38.96 91.01 0.01 OUTLIER Glycine 0 N--CA 1.471 1.002 0 CA-C-N 115.385 -0.825 . . . . 0.0 111.981 -179.736 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 89.1 p -37.46 -99.91 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.917 0 C-N-CA 123.714 0.806 . . . . 0.0 112.9 -176.622 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 40.8 t30 -61.23 126.35 27.04 Favored 'General case' 0 CA--C 1.546 0.807 0 CA-C-N 119.495 1.043 . . . . 0.0 108.855 179.465 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 62.8 mttm -106.36 -178.95 3.8 Favored 'General case' 0 N--CA 1.484 1.259 0 N-CA-C 109.249 -0.648 . . . . 0.0 109.249 -179.728 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.83 -141.27 0.02 OUTLIER Glycine 0 CA--C 1.528 0.888 0 N-CA-C 109.39 -1.484 . . . . 0.0 109.39 177.967 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.79 119.42 22.25 Favored 'General case' 0 N--CA 1.477 0.922 0 N-CA-C 109.257 -0.645 . . . . 0.0 109.257 178.439 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 68.9 mt -100.76 146.3 9.61 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.876 0 N-CA-C 107.856 -1.164 . . . . 0.0 107.856 178.614 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 28.4 mt -146.07 124.59 4.87 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.745 0 N-CA-C 109.435 -0.579 . . . . 0.0 109.435 -177.877 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.55 83.91 0.07 OUTLIER Glycine 0 C--N 1.338 0.677 0 CA-C-N 116.138 -0.483 . . . . 0.0 112.93 178.08 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 14.6 tp -101.9 123.2 45.42 Favored 'General case' 0 N--CA 1.484 1.263 0 N-CA-C 107.112 -1.44 . . . . 0.0 107.112 177.394 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 13.5 ttt -158.37 158.06 33.55 Favored 'General case' 0 N--CA 1.468 0.452 0 N-CA-C 109.018 -0.734 . . . . 0.0 109.018 179.94 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 89.5 t -155.93 152.46 8.52 Favored 'Isoleucine or valine' 0 C--O 1.234 0.262 0 N-CA-C 107.37 -1.345 . . . . 0.0 107.37 -179.435 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 57.22 73.34 0.46 Allowed Glycine 0 C--N 1.31 -0.881 0 CA-C-N 115.569 -0.741 . . . . 0.0 111.834 178.398 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 169.84 -150.03 14.19 Favored Glycine 0 N--CA 1.462 0.394 0 N-CA-C 110.744 -0.942 . . . . 0.0 110.744 179.432 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 33.1 m -133.77 144.77 34.8 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.875 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 179.93 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 19.8 t . . . . . 0 C--O 1.222 -0.393 0 CA-C-O 117.787 -1.101 . . . . 0.0 110.924 179.753 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 78.1 m-85 . . . . . 0 N--CA 1.471 0.621 0 N-CA-C 109.656 -0.498 . . . . 0.0 109.656 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 35.7 mtp180 -142.58 143.15 32.31 Favored 'General case' 0 N--CA 1.479 1.015 0 N-CA-C 109.296 -0.631 . . . . 0.0 109.296 -179.93 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 74.5 m80 -150.38 118.04 6.16 Favored 'General case' 0 N--CA 1.473 0.701 0 N-CA-C 109.045 -0.724 . . . . 0.0 109.045 178.768 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 7' ' ' ASP . . . . . . . . . . . . . 10.0 m-20 -68.46 149.05 49.75 Favored 'General case' 0 N--CA 1.464 0.233 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.929 -179.884 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 8' ' ' SER . . . . . . . . . . . . . 4.3 t -168.14 176.44 6.04 Favored 'General case' 0 N--CA 1.472 0.666 0 N-CA-C 109.614 -0.513 . . . . 0.0 109.614 178.575 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 105.03 51.31 0.89 Allowed Glycine 0 N--CA 1.483 1.814 0 N-CA-C 112.042 -0.423 . . . . 0.0 112.042 179.296 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 46.7 p90 -64.49 131.9 48.43 Favored 'General case' 0 N--CA 1.471 0.618 0 CA-C-O 120.583 0.23 . . . . 0.0 111.538 179.596 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 11' ' ' GLU . . . . . 0.432 ' OE2' ' ND2' ' D' ' 27' ' ' ASN . 43.2 mt-10 -82.88 150.61 26.42 Favored 'General case' 0 N--CA 1.473 0.696 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 177.787 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -154.29 128.9 1.41 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 N-CA-C 108.214 -1.032 . . . . 0.0 108.214 178.162 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 56.8 m-70 -133.4 145.35 50.23 Favored 'General case' 0 N--CA 1.489 1.479 0 CA-C-N 118.458 0.572 . . . . 0.0 110.762 -178.84 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 5.9 t60 -166.25 97.91 0.61 Allowed 'General case' 0 N--CA 1.484 1.27 0 CA-C-O 119.694 -0.193 . . . . 0.0 111.236 179.554 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 48.3 mt-30 -107.21 -172.77 2.14 Favored 'General case' 0 CA--C 1.504 -0.803 0 N-CA-C 107.862 -1.162 . . . . 0.0 107.862 179.238 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -163.11 97.9 0.93 Allowed 'General case' 0 N--CA 1.471 0.625 0 CA-C-N 115.154 -0.93 . . . . 0.0 109.192 178.748 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 17' ' ' LEU . . . . . 0.502 ' N ' HD12 ' B' ' 17' ' ' LEU . 6.1 mp -108.77 163.96 12.81 Favored 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 108.075 -1.083 . . . . 0.0 108.075 179.784 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 57.6 t -141.98 119.92 8.39 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.31 0 CA-C-O 118.724 -0.655 . . . . 0.0 110.293 179.868 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 55.4 m-85 -73.14 158.29 35.58 Favored 'General case' 0 N--CA 1.48 1.036 0 N-CA-C 107.343 -1.355 . . . . 0.0 107.343 176.792 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 26.1 t80 -170.33 -57.25 0.02 OUTLIER 'General case' 0 N--CA 1.478 0.953 0 CA-C-O 122.354 1.073 . . . . 0.0 109.533 -179.962 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -39.87 91.07 0.0 OUTLIER 'General case' 0 C--N 1.34 0.161 0 CA-C-N 113.999 -1.455 . . . . 0.0 112.558 -178.314 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 36.1 tt0 -58.19 132.0 52.25 Favored 'General case' 0 C--N 1.317 -0.811 0 CA-C-N 115.142 -0.936 . . . . 0.0 111.219 179.545 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 -80.58 162.71 24.14 Favored 'General case' 0 N--CA 1.479 1.015 0 N-CA-C 109.491 -0.559 . . . . 0.0 109.491 179.776 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 98.5 t -160.99 -74.13 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.483 1.192 0 C-N-CA 124.76 1.224 . . . . 0.0 107.732 -178.526 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -39.38 91.04 0.01 OUTLIER Glycine 0 N--CA 1.473 1.154 0 CA-C-N 115.42 -0.809 . . . . 0.0 111.828 -179.709 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 92.4 p -37.08 -99.93 0.0 OUTLIER 'General case' 0 N--CA 1.481 1.107 0 C-N-CA 123.881 0.873 . . . . 0.0 112.615 -177.045 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 41.6 t30 -61.23 126.35 27.03 Favored 'General case' 0 CA--C 1.544 0.746 0 CA-C-N 119.547 1.067 . . . . 0.0 109.076 179.508 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 62.9 mttm -106.43 -179.03 3.82 Favored 'General case' 0 N--CA 1.483 1.178 0 N-CA-C 109.223 -0.658 . . . . 0.0 109.223 -179.703 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.85 -141.22 0.02 OUTLIER Glycine 0 CA--C 1.527 0.814 0 N-CA-C 109.411 -1.476 . . . . 0.0 109.411 177.924 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.77 119.36 22.18 Favored 'General case' 0 N--CA 1.478 0.962 0 N-CA-C 109.304 -0.628 . . . . 0.0 109.304 178.488 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 69.0 mt -100.84 146.03 10.13 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.901 0 N-CA-C 107.862 -1.162 . . . . 0.0 107.862 178.551 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 28.7 mt -145.9 124.59 5.1 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.755 0 N-CA-C 109.428 -0.582 . . . . 0.0 109.428 -177.817 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.87 83.87 0.07 OUTLIER Glycine 0 C--N 1.338 0.678 0 CA-C-N 116.119 -0.492 . . . . 0.0 112.872 178.005 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 15.0 tp -102.27 121.52 42.43 Favored 'General case' 0 N--CA 1.486 1.335 0 N-CA-C 107.386 -1.338 . . . . 0.0 107.386 177.441 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 13.3 ttt -156.75 158.18 36.41 Favored 'General case' 0 N--CA 1.466 0.327 0 N-CA-C 109.27 -0.641 . . . . 0.0 109.27 179.836 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 89.1 t -155.97 152.32 8.64 Favored 'Isoleucine or valine' 0 C--O 1.235 0.317 0 N-CA-C 107.256 -1.387 . . . . 0.0 107.256 -179.444 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 57.39 73.24 0.47 Allowed Glycine 0 C--N 1.312 -0.797 0 CA-C-N 115.525 -0.762 . . . . 0.0 111.789 178.332 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 169.79 -149.99 14.16 Favored Glycine 0 N--CA 1.462 0.412 0 N-CA-C 110.751 -0.94 . . . . 0.0 110.751 179.408 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 33.1 m -133.78 144.83 34.62 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.91 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 179.996 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 20.4 t . . . . . 0 C--O 1.221 -0.425 0 CA-C-O 117.766 -1.111 . . . . 0.0 110.877 179.708 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 78.2 m-85 . . . . . 0 N--CA 1.473 0.714 0 N-CA-C 109.605 -0.517 . . . . 0.0 109.605 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 35.7 mtp180 -142.66 143.11 32.2 Favored 'General case' 0 N--CA 1.48 1.057 0 N-CA-C 109.227 -0.657 . . . . 0.0 109.227 -179.93 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 74.6 m80 -150.44 118.08 6.15 Favored 'General case' 0 N--CA 1.472 0.641 0 N-CA-C 108.958 -0.756 . . . . 0.0 108.958 178.765 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' C' C ' 7' ' ' ASP . . . . . . . . . . . . . 10.0 m-20 -68.52 149.17 49.55 Favored 'General case' 0 N--CA 1.462 0.17 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.994 -179.92 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' C' C ' 8' ' ' SER . . . . . . . . . . . . . 4.3 t -168.22 176.49 5.95 Favored 'General case' 0 N--CA 1.472 0.655 0 N-CA-C 109.546 -0.539 . . . . 0.0 109.546 178.631 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 105.01 51.35 0.89 Allowed Glycine 0 N--CA 1.483 1.821 0 N-CA-C 112.006 -0.438 . . . . 0.0 112.006 179.275 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 46.1 p90 -64.64 131.82 48.02 Favored 'General case' 0 N--CA 1.471 0.602 0 CA-C-O 120.57 0.224 . . . . 0.0 111.509 179.648 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' C' C ' 11' ' ' GLU . . . . . 0.435 ' OE2' ' ND2' ' E' ' 27' ' ' ASN . 43.2 mt-10 -82.76 150.44 26.66 Favored 'General case' 0 N--CA 1.473 0.68 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 177.815 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -154.11 129.04 1.48 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 178.133 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 56.8 m-70 -133.44 145.41 50.22 Favored 'General case' 0 N--CA 1.489 1.507 0 CA-C-N 118.496 0.589 . . . . 0.0 110.81 -178.914 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 5.9 t60 -166.36 98.04 0.6 Allowed 'General case' 0 N--CA 1.483 1.204 0 CA-C-O 119.79 -0.148 . . . . 0.0 111.3 179.534 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 48.2 mt-30 -107.42 -172.69 2.12 Favored 'General case' 0 CA--C 1.5 -0.945 0 N-CA-C 107.999 -1.111 . . . . 0.0 107.999 179.246 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -163.15 97.86 0.92 Allowed 'General case' 0 N--CA 1.47 0.532 0 CA-C-N 115.181 -0.918 . . . . 0.0 109.308 178.782 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' C' C ' 17' ' ' LEU . . . . . 0.5 ' N ' HD12 ' C' ' 17' ' ' LEU . 6.1 mp -108.69 163.96 12.79 Favored 'General case' 0 N--CA 1.487 1.395 0 N-CA-C 108.037 -1.097 . . . . 0.0 108.037 179.879 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 57.3 t -141.93 119.97 8.59 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.365 0 CA-C-O 118.721 -0.657 . . . . 0.0 110.257 179.836 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 55.1 m-85 -73.14 158.28 35.61 Favored 'General case' 0 N--CA 1.479 1.016 0 N-CA-C 107.293 -1.373 . . . . 0.0 107.293 176.761 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 26.1 t80 -170.23 -57.21 0.02 OUTLIER 'General case' 0 N--CA 1.477 0.898 0 CA-C-O 122.358 1.075 . . . . 0.0 109.587 179.978 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -39.93 91.26 0.0 OUTLIER 'General case' 0 C--N 1.34 0.169 0 CA-C-N 114.028 -1.442 . . . . 0.0 112.549 -178.294 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 36.1 tt0 -58.3 131.88 51.96 Favored 'General case' 0 C--N 1.317 -0.847 0 CA-C-N 115.129 -0.941 . . . . 0.0 111.165 179.501 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 -80.45 162.76 24.25 Favored 'General case' 0 N--CA 1.479 0.994 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 179.722 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 98.2 t -161.07 -74.27 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.483 1.21 0 C-N-CA 124.753 1.221 . . . . 0.0 107.744 -178.556 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -39.46 91.09 0.01 OUTLIER Glycine 0 N--CA 1.473 1.105 0 CA-C-N 115.463 -0.79 . . . . 0.0 111.84 -179.68 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 91.1 p -37.03 -99.88 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.036 0 C-N-CA 123.831 0.852 . . . . 0.0 112.748 -177.0 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 41.6 t30 -61.17 126.37 27.12 Favored 'General case' 0 CA--C 1.545 0.752 0 CA-C-N 119.506 1.048 . . . . 0.0 109.061 179.484 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 62.9 mttm -106.46 -179.12 3.85 Favored 'General case' 0 N--CA 1.483 1.185 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 -179.713 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.79 -141.25 0.02 OUTLIER Glycine 0 CA--C 1.528 0.878 0 N-CA-C 109.362 -1.495 . . . . 0.0 109.362 177.996 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.73 119.34 22.21 Favored 'General case' 0 N--CA 1.477 0.882 0 N-CA-C 109.37 -0.604 . . . . 0.0 109.37 178.436 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 68.7 mt -100.81 146.01 10.15 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.945 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 178.598 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 28.6 mt -145.96 124.63 5.03 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.726 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 -177.793 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.74 83.78 0.07 OUTLIER Glycine 0 C--N 1.339 0.701 0 CA-C-N 116.127 -0.488 . . . . 0.0 112.92 178.05 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 15.2 tp -102.12 121.39 42.11 Favored 'General case' 0 N--CA 1.484 1.26 0 N-CA-C 107.485 -1.302 . . . . 0.0 107.485 177.349 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 13.4 ttt -156.62 158.23 36.67 Favored 'General case' 0 N--CA 1.465 0.32 0 N-CA-C 109.254 -0.647 . . . . 0.0 109.254 179.848 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 87.9 t -155.94 152.44 8.53 Favored 'Isoleucine or valine' 0 C--O 1.235 0.314 0 N-CA-C 107.331 -1.359 . . . . 0.0 107.331 -179.48 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 57.26 73.27 0.47 Allowed Glycine 0 C--N 1.311 -0.82 0 CA-C-N 115.535 -0.757 . . . . 0.0 111.812 178.384 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 169.78 -150.0 14.19 Favored Glycine 0 N--CA 1.462 0.433 0 N-CA-C 110.716 -0.954 . . . . 0.0 110.716 179.377 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 33.2 m -133.7 144.82 34.72 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.883 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 179.98 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 20.3 t . . . . . 0 N--CA 1.467 0.403 0 CA-C-O 117.747 -1.121 . . . . 0.0 110.864 179.667 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 85.5 m-85 . . . . . 0 N--CA 1.472 0.664 0 N-CA-C 108.142 -1.058 . . . . 0.0 108.142 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' D' D ' 5' ' ' ARG . . . . . 0.417 HH21 HG22 ' F' ' 24' ' ' VAL . 36.8 mtp180 -145.95 141.99 28.27 Favored 'General case' 0 N--CA 1.474 0.76 0 N-CA-C 109.365 -0.606 . . . . 0.0 109.365 -179.834 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 75.5 m80 -149.13 123.39 9.57 Favored 'General case' 0 CA--C 1.543 0.684 0 N-CA-C 107.815 -1.18 . . . . 0.0 107.815 174.618 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' D' D ' 7' ' ' ASP . . . . . . . . . . . . . 6.7 m-20 -63.71 133.13 53.02 Favored 'General case' 0 C--N 1.322 -0.615 0 C-N-CA 126.968 2.107 . . . . 0.0 114.675 175.231 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' D' D ' 8' ' ' SER . . . . . . . . . . . . . 3.5 t -154.59 -179.74 8.27 Favored 'General case' 0 N--CA 1.475 0.823 0 CA-C-N 119.081 0.855 . . . . 0.0 110.214 175.99 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.36 49.92 1.02 Allowed Glycine 0 N--CA 1.482 1.743 0 N-CA-C 112.047 -0.421 . . . . 0.0 112.047 175.194 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 46.4 p90 -61.49 132.31 52.98 Favored 'General case' 0 CA--C 1.54 0.575 0 N-CA-C 112.116 0.413 . . . . 0.0 112.116 179.505 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' D' D ' 11' ' ' GLU . . . . . 0.401 ' CG ' ' ND2' ' F' ' 27' ' ' ASN . 42.7 mt-10 -83.23 148.97 27.1 Favored 'General case' 0 N--CA 1.48 1.065 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 176.661 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -149.84 130.15 4.19 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.341 0 N-CA-C 108.325 -0.991 . . . . 0.0 108.325 174.876 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 54.7 m-70 -129.42 148.05 51.29 Favored 'General case' 0 N--CA 1.482 1.137 0 CA-C-N 118.158 0.436 . . . . 0.0 110.897 176.801 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' D' D ' 14' ' ' HIS . . . . . 0.41 ' ND1' ' O ' ' G' ' 14' ' ' HIS . 6.0 t60 -165.34 104.64 0.74 Allowed 'General case' 0 N--CA 1.484 1.246 0 CA-C-O 119.016 -0.516 . . . . 0.0 109.667 173.637 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 47.4 mt-30 -110.63 -175.72 2.79 Favored 'General case' 0 CA--C 1.492 -1.268 0 N-CA-C 107.551 -1.277 . . . . 0.0 107.551 178.285 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -159.54 105.88 1.67 Allowed 'General case' 0 CA--C 1.536 0.431 0 N-CA-C 107.679 -1.23 . . . . 0.0 107.679 175.619 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' D' D ' 17' ' ' LEU . . . . . 0.442 ' N ' HD12 ' D' ' 17' ' ' LEU . 6.9 mp -114.87 162.65 16.63 Favored 'General case' 0 N--CA 1.487 1.419 0 N-CA-C 107.638 -1.245 . . . . 0.0 107.638 179.401 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 48.1 t -140.99 123.78 15.58 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.147 0 N-CA-C 109.483 -0.562 . . . . 0.0 109.483 176.319 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 82.7 m-85 -63.25 151.08 41.53 Favored 'General case' 0 C--N 1.357 0.923 0 C-N-CA 124.569 1.147 . . . . 0.0 110.634 169.586 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 19.0 t80 -169.68 -66.85 0.02 OUTLIER 'General case' 0 C--N 1.315 -0.916 0 N-CA-C 107.456 -1.312 . . . . 0.0 107.456 -179.877 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -37.98 95.82 0.01 OUTLIER 'General case' 0 CA--C 1.536 0.42 0 CA-C-N 114.162 -1.381 . . . . 0.0 111.683 -175.407 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 36.6 tt0 -60.38 134.34 56.97 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 113.709 -1.587 . . . . 0.0 111.018 179.297 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' D' D ' 23' ' ' ASP . . . . . 0.469 ' O ' HG23 ' D' ' 24' ' ' VAL . 9.5 m-20 -82.57 168.27 17.52 Favored 'General case' 0 C--O 1.205 -1.285 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 179.558 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' D' D ' 24' ' ' VAL . . . . . 0.469 HG23 ' O ' ' D' ' 23' ' ' ASP 0.288 46.3 t -168.93 -94.15 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.505 2.291 0 N-CA-C 103.507 -2.775 . . . . 0.0 103.507 -164.215 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . -26.35 77.14 0.0 OUTLIER Glycine 0 C--N 1.259 -3.721 0 C-N-CA 129.754 3.549 . . . . 0.0 116.908 -179.957 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' D' D ' 26' ' ' SER . . . . . 0.459 ' OG ' ' N ' ' D' ' 27' ' ' ASN 0.51 75.0 p -59.05 -93.05 0.0 OUTLIER 'General case' 0 C--O 1.28 2.692 1 CA-C-O 107.247 -6.12 . . . . 0.0 104.856 -155.503 . . . . . . . . 4 3 . 1 . 018 nuclear build core ' D' D ' 27' ' ' ASN . . . . . 0.459 ' N ' ' OG ' ' D' ' 26' ' ' SER 0.293 32.8 t30 -62.98 135.82 57.5 Favored 'General case' 0 N--CA 1.491 1.581 1 CA-C-N 133.294 7.315 . . . . 0.0 108.193 -172.984 . . . . . . . . 4 3 . 1 . 018 nuclear build core ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 60.0 mttm -102.76 178.58 4.53 Favored 'General case' 0 N--CA 1.475 0.82 0 C-N-CA 125.3 1.44 . . . . 0.0 111.632 177.889 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.02 -145.83 0.01 OUTLIER Glycine 0 CA--C 1.537 1.447 0 N-CA-C 111.267 -0.733 . . . . 0.0 111.267 171.401 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -126.9 122.02 33.44 Favored 'General case' 0 C--N 1.369 1.421 0 N-CA-C 108.779 -0.823 . . . . 0.0 108.779 174.689 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 68.4 mt -97.81 152.27 4.17 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.758 0 N-CA-C 107.829 -1.174 . . . . 0.0 107.829 175.492 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 34.7 mt -152.04 128.68 1.99 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.006 0 N-CA-C 107.884 -1.154 . . . . 0.0 107.884 177.226 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 64.06 80.47 0.13 Allowed Glycine 0 C--N 1.35 1.344 0 CA-C-O 117.996 -1.447 . . . . 0.0 113.185 178.06 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 10.5 tp -101.42 131.98 47.24 Favored 'General case' 0 C--N 1.38 1.931 0 N-CA-C 104.792 -2.299 . . . . 0.0 104.792 176.402 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 12.5 ttt -157.3 165.69 35.15 Favored 'General case' 0 N--CA 1.467 0.395 0 N-CA-C 108.721 -0.844 . . . . 0.0 108.721 176.756 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 81.4 t -163.19 156.61 2.11 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.485 0 N-CA-C 106.145 -1.798 . . . . 0.0 106.145 175.089 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 61.25 66.17 2.83 Favored Glycine 0 N--CA 1.447 -0.633 0 C-N-CA 117.956 -2.068 . . . . 0.0 113.754 178.087 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 167.1 -148.95 13.88 Favored Glycine 0 N--CA 1.467 0.751 0 CA-C-O 118.011 -1.438 . . . . 0.0 112.105 179.982 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 33.0 m -130.67 144.47 37.81 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.225 0 CA-C-N 119.02 1.41 . . . . 0.0 109.956 -178.821 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 18.4 t . . . . . 0 C--O 1.214 -0.802 0 N-CA-C 109.2 -0.667 . . . . 0.0 109.2 174.99 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 77.6 m-85 . . . . . 0 N--CA 1.474 0.763 0 N-CA-C 109.703 -0.48 . . . . 0.0 109.703 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' E' E ' 5' ' ' ARG . . . . . 0.416 HH21 HG22 ' D' ' 24' ' ' VAL . 37.1 mtp180 -142.62 143.56 32.45 Favored 'General case' 0 N--CA 1.477 0.888 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 179.906 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 74.7 m80 -150.56 117.55 5.92 Favored 'General case' 0 N--CA 1.473 0.699 0 N-CA-C 109.136 -0.691 . . . . 0.0 109.136 178.653 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' E' E ' 7' ' ' ASP . . . . . . . . . . . . . 9.5 m-20 -68.06 149.18 49.98 Favored 'General case' 0 CA--C 1.529 0.171 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.043 -179.816 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' E' E ' 8' ' ' SER . . . . . . . . . . . . . 3.4 t -168.5 178.06 4.98 Favored 'General case' 0 N--CA 1.475 0.806 0 N-CA-C 109.574 -0.528 . . . . 0.0 109.574 178.224 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.85 50.9 0.92 Allowed Glycine 0 N--CA 1.477 1.385 0 N-CA-C 111.97 -0.452 . . . . 0.0 111.97 179.124 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 44.2 p90 -63.78 131.21 47.13 Favored 'General case' 0 CA--C 1.545 0.756 0 N-CA-C 111.895 0.332 . . . . 0.0 111.895 -179.861 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 41.4 mt-10 -81.78 151.42 27.43 Favored 'General case' 0 N--CA 1.479 1.008 0 N-CA-C 108.683 -0.858 . . . . 0.0 108.683 177.433 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.6 p -155.92 127.91 1.0 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.449 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 177.906 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 52.2 m-70 -133.5 143.51 48.82 Favored 'General case' 0 N--CA 1.48 1.034 0 O-C-N 122.259 -0.276 . . . . 0.0 111.073 -177.884 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 5.9 t60 -165.35 97.43 0.7 Allowed 'General case' 0 N--CA 1.488 1.437 0 CA-C-O 119.602 -0.237 . . . . 0.0 111.211 179.816 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 47.1 mt-30 -106.44 -172.29 2.06 Favored 'General case' 0 CA--C 1.505 -0.769 0 N-CA-C 107.969 -1.123 . . . . 0.0 107.969 179.228 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -163.23 98.0 0.92 Allowed 'General case' 0 N--CA 1.47 0.575 0 CA-C-N 115.135 -0.938 . . . . 0.0 109.241 178.634 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' E' E ' 17' ' ' LEU . . . . . 0.488 ' N ' HD12 ' E' ' 17' ' ' LEU . 6.2 mp -108.54 163.13 13.5 Favored 'General case' 0 N--CA 1.488 1.441 0 N-CA-C 108.636 -0.876 . . . . 0.0 108.636 -179.919 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 40.6 t -141.86 120.79 9.83 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.281 0 C-N-CA 122.465 0.306 . . . . 0.0 110.631 179.194 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 51.9 m-85 -73.64 155.6 38.87 Favored 'General case' 0 C--N 1.362 1.138 0 N-CA-C 106.823 -1.547 . . . . 0.0 106.823 176.349 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 23.6 t80 -171.78 -54.82 0.02 OUTLIER 'General case' 0 N--CA 1.479 1.01 0 CA-C-O 121.682 0.753 . . . . 0.0 110.161 -179.942 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.95 89.63 0.0 OUTLIER 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 114.426 -1.261 . . . . 0.0 112.634 -179.436 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 36.0 tt0 -56.2 133.47 52.4 Favored 'General case' 0 CA--C 1.539 0.536 0 CA-C-N 114.912 -1.04 . . . . 0.0 111.291 179.861 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 9.2 m-20 -81.72 162.25 23.05 Favored 'General case' 0 N--CA 1.475 0.779 0 N-CA-C 109.66 -0.496 . . . . 0.0 109.66 179.782 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' E' E ' 24' ' ' VAL . . . . . 0.429 HG22 HH21 ' F' ' 5' ' ' ARG . 95.0 t -160.7 -74.64 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.291 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 -179.003 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . -38.81 91.22 0.01 OUTLIER Glycine 0 CA--C 1.53 0.974 0 CA-C-N 115.263 -0.88 . . . . 0.0 112.403 -179.673 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 84.8 p -37.7 -101.33 0.0 OUTLIER 'General case' 0 N--CA 1.481 1.079 0 N-CA-C 113.725 1.009 . . . . 0.0 113.725 -177.429 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' E' E ' 27' ' ' ASN . . . . . 0.435 ' ND2' ' OE2' ' C' ' 11' ' ' GLU . 40.2 t30 -60.01 124.63 20.8 Favored 'General case' 0 CA--C 1.542 0.663 0 CA-C-N 119.482 1.037 . . . . 0.0 108.781 -179.89 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 62.8 mttm -105.38 -178.65 3.71 Favored 'General case' 0 N--CA 1.483 1.214 0 N-CA-C 108.889 -0.782 . . . . 0.0 108.889 -179.613 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -65.35 -141.45 0.03 OUTLIER Glycine 0 CA--C 1.532 1.102 0 N-CA-C 110.421 -1.072 . . . . 0.0 110.421 178.02 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.93 118.31 22.44 Favored 'General case' 0 C--N 1.349 0.582 0 C-N-CA 123.234 0.614 . . . . 0.0 109.46 178.471 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 71.6 mt -100.28 148.76 6.44 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.816 0 N-CA-C 106.88 -1.526 . . . . 0.0 106.88 178.103 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 34.1 mt -148.17 125.0 2.77 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.958 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 -179.434 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.76 85.49 0.05 OUTLIER Glycine 0 C--N 1.34 0.767 0 CA-C-N 115.966 -0.561 . . . . 0.0 112.827 178.493 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 13.2 tp -103.39 121.38 42.68 Favored 'General case' 0 N--CA 1.484 1.258 0 N-CA-C 106.97 -1.492 . . . . 0.0 106.97 177.371 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 12.6 ttt -156.08 158.93 38.6 Favored 'General case' 0 N--CA 1.476 0.859 0 N-CA-C 108.883 -0.784 . . . . 0.0 108.883 179.661 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 95.3 t -156.76 151.98 8.33 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.416 0 N-CA-C 107.493 -1.299 . . . . 0.0 107.493 -179.693 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 57.59 72.41 0.59 Allowed Glycine 0 C--N 1.313 -0.74 0 CA-C-N 115.397 -0.819 . . . . 0.0 111.481 178.168 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 171.62 -148.81 11.31 Favored Glycine 0 CA--C 1.524 0.624 0 N-CA-C 111.025 -0.83 . . . . 0.0 111.025 179.606 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 32.9 m -135.53 144.06 34.95 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.826 0 N-CA-C 109.095 -0.705 . . . . 0.0 109.095 179.906 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 19.5 t . . . . . 0 CA--C 1.537 0.471 0 CA-C-O 117.66 -1.162 . . . . 0.0 110.817 -179.988 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 77.6 m-85 . . . . . 0 N--CA 1.475 0.777 0 N-CA-C 109.625 -0.509 . . . . 0.0 109.625 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' F' F ' 5' ' ' ARG . . . . . 0.429 HH21 HG22 ' E' ' 24' ' ' VAL . 37.1 mtp180 -142.51 143.43 32.53 Favored 'General case' 0 N--CA 1.477 0.898 0 N-CA-C 109.396 -0.594 . . . . 0.0 109.396 179.979 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 74.8 m80 -150.59 117.65 5.94 Favored 'General case' 0 N--CA 1.474 0.744 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 178.626 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' F' F ' 7' ' ' ASP . . . . . . . . . . . . . 9.5 m-20 -68.05 149.11 50.08 Favored 'General case' 0 N--CA 1.463 0.21 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.057 -179.812 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' F' F ' 8' ' ' SER . . . . . . . . . . . . . 3.4 t -168.65 177.7 5.04 Favored 'General case' 0 N--CA 1.474 0.773 0 N-CA-C 109.521 -0.548 . . . . 0.0 109.521 178.153 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 105.13 50.95 0.9 Allowed Glycine 0 N--CA 1.478 1.496 0 N-CA-C 111.858 -0.497 . . . . 0.0 111.858 179.054 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 43.8 p90 -64.07 131.74 48.44 Favored 'General case' 0 CA--C 1.543 0.697 0 N-CA-C 112.0 0.37 . . . . 0.0 112.0 -179.867 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 41.5 mt-10 -82.01 151.56 27.07 Favored 'General case' 0 N--CA 1.479 0.994 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 177.448 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.6 p -156.0 127.88 0.98 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.46 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 177.921 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 52.3 m-70 -133.49 143.63 48.92 Favored 'General case' 0 N--CA 1.481 1.122 0 O-C-N 122.25 -0.281 . . . . 0.0 110.965 -177.856 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 5.9 t60 -165.44 97.73 0.69 Allowed 'General case' 0 N--CA 1.486 1.341 0 CA-C-O 119.604 -0.236 . . . . 0.0 111.386 179.777 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 46.9 mt-30 -106.75 -172.31 2.06 Favored 'General case' 0 CA--C 1.497 -1.064 0 N-CA-C 108.088 -1.078 . . . . 0.0 108.088 179.177 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -163.26 97.86 0.91 Allowed 'General case' 0 CA--C 1.539 0.551 0 CA-C-N 114.96 -1.018 . . . . 0.0 109.16 178.77 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' F' F ' 17' ' ' LEU . . . . . 0.483 ' N ' HD12 ' F' ' 17' ' ' LEU . 6.2 mp -108.46 163.14 13.48 Favored 'General case' 0 N--CA 1.489 1.488 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 -179.914 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 40.5 t -141.89 120.72 9.66 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.227 0 C-N-CA 122.549 0.339 . . . . 0.0 110.648 179.261 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 52.4 m-85 -73.59 155.43 39.11 Favored 'General case' 0 C--N 1.362 1.125 0 N-CA-C 106.765 -1.568 . . . . 0.0 106.765 176.219 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 24.3 t80 -171.48 -55.1 0.02 OUTLIER 'General case' 0 N--CA 1.481 1.084 0 CA-C-O 121.739 0.781 . . . . 0.0 109.75 -179.861 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.83 89.72 0.0 OUTLIER 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 114.49 -1.232 . . . . 0.0 112.693 -179.342 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 36.0 tt0 -56.4 133.4 52.99 Favored 'General case' 0 CA--C 1.54 0.586 0 CA-C-N 114.953 -1.021 . . . . 0.0 111.283 179.79 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 -81.7 162.39 23.01 Favored 'General case' 0 N--CA 1.475 0.793 0 N-CA-C 109.627 -0.508 . . . . 0.0 109.627 179.826 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' F' F ' 24' ' ' VAL . . . . . 0.417 HG22 HH21 ' D' ' 5' ' ' ARG . 95.8 t -160.7 -74.96 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.486 1.333 0 N-CA-C 107.095 -1.446 . . . . 0.0 107.095 -179.005 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -38.49 91.01 0.01 OUTLIER Glycine 0 CA--C 1.529 0.91 0 CA-C-N 115.305 -0.862 . . . . 0.0 112.451 -179.779 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 84.9 p -37.58 -100.97 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.067 0 N-CA-C 113.69 0.996 . . . . 0.0 113.69 -177.443 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' F' F ' 27' ' ' ASN . . . . . 0.424 ' ND2' ' OE2' ' A' ' 11' ' ' GLU . 39.9 t30 -60.18 124.91 21.7 Favored 'General case' 0 CA--C 1.542 0.642 0 CA-C-N 119.492 1.042 . . . . 0.0 108.769 -179.954 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 62.8 mttm -105.65 -178.6 3.7 Favored 'General case' 0 N--CA 1.483 1.197 0 N-CA-C 108.893 -0.78 . . . . 0.0 108.893 -179.737 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -65.29 -141.67 0.03 OUTLIER Glycine 0 CA--C 1.532 1.152 0 N-CA-C 110.463 -1.055 . . . . 0.0 110.463 178.008 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.65 117.79 21.8 Favored 'General case' 0 C--N 1.351 0.633 0 C-N-CA 123.351 0.66 . . . . 0.0 109.399 178.468 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 71.6 mt -99.81 148.86 6.15 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.871 0 N-CA-C 106.934 -1.506 . . . . 0.0 106.934 178.021 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 34.6 mt -148.15 124.99 2.78 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.912 0 N-CA-C 108.874 -0.787 . . . . 0.0 108.874 -179.399 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.71 85.5 0.05 OUTLIER Glycine 0 C--N 1.339 0.741 0 CA-C-N 115.967 -0.561 . . . . 0.0 112.793 178.526 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 13.1 tp -103.44 121.43 42.8 Favored 'General case' 0 N--CA 1.483 1.208 0 N-CA-C 106.945 -1.502 . . . . 0.0 106.945 177.43 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 12.5 ttt -156.17 159.01 38.6 Favored 'General case' 0 N--CA 1.474 0.771 0 N-CA-C 109.058 -0.719 . . . . 0.0 109.058 179.639 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 93.3 t -156.76 151.96 8.35 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.437 0 N-CA-C 107.615 -1.254 . . . . 0.0 107.615 -179.663 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 57.73 72.38 0.6 Allowed Glycine 0 C--N 1.312 -0.759 0 CA-C-N 115.491 -0.777 . . . . 0.0 111.508 178.162 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 171.57 -148.92 11.42 Favored Glycine 0 CA--C 1.523 0.578 0 N-CA-C 111.035 -0.826 . . . . 0.0 111.035 179.686 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 32.9 m -135.42 144.04 35.16 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.837 0 N-CA-C 109.054 -0.721 . . . . 0.0 109.054 179.932 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 19.6 t . . . . . 0 CA--C 1.537 0.454 0 CA-C-O 117.658 -1.163 . . . . 0.0 110.853 179.996 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 78.3 m-85 . . . . . 0 N--CA 1.473 0.691 0 N-CA-C 109.413 -0.588 . . . . 0.0 109.413 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' G' G ' 5' ' ' ARG . . . . . 0.414 HH21 HG22 ' I' ' 24' ' ' VAL . 37.0 mtp180 -142.79 143.37 32.15 Favored 'General case' 0 N--CA 1.481 1.113 0 N-CA-C 109.422 -0.585 . . . . 0.0 109.422 -179.635 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 74.7 m80 -150.41 118.81 6.43 Favored 'General case' 0 N--CA 1.473 0.711 0 N-CA-C 109.173 -0.677 . . . . 0.0 109.173 178.69 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 9.7 m-20 -70.0 144.41 52.3 Favored 'General case' 0 CA--C 1.538 0.482 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.642 -179.717 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' G' G ' 8' ' ' SER . . . . . . . . . . . . . 2.9 t -164.46 179.74 6.53 Favored 'General case' 0 N--CA 1.471 0.595 0 N-CA-C 109.465 -0.568 . . . . 0.0 109.465 177.998 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.3 50.7 0.97 Allowed Glycine 0 N--CA 1.476 1.327 0 N-CA-C 111.919 -0.472 . . . . 0.0 111.919 179.049 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 46.9 p90 -64.78 131.86 47.96 Favored 'General case' 0 N--CA 1.474 0.753 0 N-CA-C 112.097 0.406 . . . . 0.0 112.097 -179.484 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 44.0 mt-10 -82.08 150.39 27.54 Favored 'General case' 0 N--CA 1.474 0.748 0 N-CA-C 109.141 -0.688 . . . . 0.0 109.141 177.969 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 3.0 p -156.26 127.82 0.94 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.976 0 N-CA-C 108.285 -1.005 . . . . 0.0 108.285 178.168 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 55.9 m-70 -132.89 144.03 49.9 Favored 'General case' 0 N--CA 1.476 0.827 0 CA-C-N 115.392 -0.822 . . . . 0.0 110.718 -177.935 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' G' G ' 14' ' ' HIS . . . . . 0.41 ' O ' ' ND1' ' D' ' 14' ' ' HIS . 6.0 t60 -165.94 98.29 0.64 Allowed 'General case' 0 N--CA 1.483 1.19 0 CA-C-O 119.599 -0.239 . . . . 0.0 110.765 179.129 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 47.2 mt-30 -107.42 -172.24 2.03 Favored 'General case' 0 CA--C 1.503 -0.85 0 N-CA-C 108.194 -1.039 . . . . 0.0 108.194 179.306 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -163.19 98.27 0.93 Allowed 'General case' 0 N--CA 1.472 0.653 0 CA-C-N 115.05 -0.977 . . . . 0.0 109.281 178.718 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' G' G ' 17' ' ' LEU . . . . . 0.481 ' N ' HD12 ' G' ' 17' ' ' LEU . 6.6 mp -108.47 162.18 14.36 Favored 'General case' 0 N--CA 1.486 1.367 0 N-CA-C 108.946 -0.761 . . . . 0.0 108.946 -179.751 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 36.5 t -142.99 120.48 6.38 Favored 'Isoleucine or valine' 0 CA--C 1.551 1.019 0 CA-C-O 121.223 0.535 . . . . 0.0 110.435 178.973 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 47.3 m-85 -72.73 149.83 43.4 Favored 'General case' 0 C--N 1.375 1.71 0 N-CA-C 106.8 -1.555 . . . . 0.0 106.8 176.166 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 20.0 t80 -169.84 -54.23 0.02 OUTLIER 'General case' 0 N--CA 1.484 1.252 0 N-CA-C 110.194 -0.298 . . . . 0.0 110.194 -179.349 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -42.34 91.43 0.0 OUTLIER 'General case' 0 C--N 1.323 -0.571 0 O-C-N 123.942 0.776 . . . . 0.0 112.129 179.69 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 36.9 tt0 -57.83 133.67 55.62 Favored 'General case' 0 CA--C 1.539 0.542 0 CA-C-N 114.795 -1.093 . . . . 0.0 110.741 179.426 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 -81.08 161.51 24.12 Favored 'General case' 0 N--CA 1.474 0.749 0 N-CA-C 109.714 -0.476 . . . . 0.0 109.714 179.992 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' G' G ' 24' ' ' VAL . . . . . 0.423 HG22 HH21 ' H' ' 5' ' ' ARG . 94.8 t -159.44 -76.96 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.957 0 N-CA-C 106.839 -1.541 . . . . 0.0 106.839 -179.027 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -35.35 90.18 0.01 OUTLIER Glycine 0 C--O 1.225 -0.46 0 CA-C-N 114.876 -1.056 . . . . 0.0 112.765 179.381 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 94.2 p -37.78 -99.1 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.899 0 C-N-CA 123.626 0.771 . . . . 0.0 112.708 -176.861 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' G' G ' 27' ' ' ASN . . . . . 0.415 ' ND2' ' CG ' ' H' ' 11' ' ' GLU . 40.8 t30 -61.84 126.54 27.72 Favored 'General case' 0 CA--C 1.545 0.773 0 CA-C-N 119.474 1.034 . . . . 0.0 109.161 179.064 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 63.3 mttm -107.03 -179.09 3.83 Favored 'General case' 0 N--CA 1.483 1.184 0 N-CA-C 109.307 -0.627 . . . . 0.0 109.307 -179.76 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.97 -141.27 0.02 OUTLIER Glycine 0 N--CA 1.464 0.523 0 N-CA-C 109.848 -1.301 . . . . 0.0 109.848 178.422 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.96 115.2 17.45 Favored 'General case' 0 C--O 1.218 -0.558 0 C-N-CA 123.213 0.605 . . . . 0.0 109.413 179.572 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 74.5 mt -97.45 150.96 4.39 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.046 0 N-CA-C 106.92 -1.511 . . . . 0.0 106.92 178.1 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 35.8 mt -149.53 126.91 2.53 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.345 0 N-CA-C 108.876 -0.787 . . . . 0.0 108.876 178.405 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.28 85.95 0.04 OUTLIER Glycine 0 C--N 1.341 0.835 0 CA-C-N 115.957 -0.565 . . . . 0.0 112.823 178.559 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 14.4 tp -103.17 123.66 47.12 Favored 'General case' 0 N--CA 1.484 1.264 0 N-CA-C 107.029 -1.471 . . . . 0.0 107.029 177.271 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 11.9 ttt -158.75 158.57 33.88 Favored 'General case' 0 N--CA 1.469 0.494 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 179.973 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 94.5 t -156.47 153.13 7.42 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.289 0 N-CA-C 106.897 -1.519 . . . . 0.0 106.897 -179.663 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.89 73.18 0.47 Allowed Glycine 0 C--N 1.311 -0.811 0 CA-C-N 115.761 -0.654 . . . . 0.0 111.978 178.292 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 169.98 -148.05 11.4 Favored Glycine 0 N--CA 1.469 0.846 0 N-CA-C 110.703 -0.959 . . . . 0.0 110.703 179.019 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 33.5 m -135.48 144.03 35.11 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.009 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 -179.803 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 20.2 t . . . . . 0 N--CA 1.468 0.426 0 CA-C-O 117.776 -1.106 . . . . 0.0 110.838 179.914 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 78.7 m-85 . . . . . 0 N--CA 1.473 0.714 0 N-CA-C 109.362 -0.607 . . . . 0.0 109.362 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' H' H ' 5' ' ' ARG . . . . . 0.423 HH21 HG22 ' G' ' 24' ' ' VAL . 37.2 mtp180 -142.99 143.28 31.85 Favored 'General case' 0 N--CA 1.482 1.157 0 N-CA-C 109.302 -0.629 . . . . 0.0 109.302 -179.638 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 74.6 m80 -150.43 118.7 6.38 Favored 'General case' 0 N--CA 1.473 0.68 0 N-CA-C 109.252 -0.648 . . . . 0.0 109.252 178.642 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 9.4 m-20 -69.86 144.35 52.55 Favored 'General case' 0 N--CA 1.468 0.44 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.579 -179.693 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' H' H ' 8' ' ' SER . . . . . . . . . . . . . 3.6 t -164.38 179.09 6.99 Favored 'General case' 0 N--CA 1.47 0.538 0 N-CA-C 109.517 -0.549 . . . . 0.0 109.517 178.091 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.56 50.9 0.94 Allowed Glycine 0 N--CA 1.478 1.442 0 N-CA-C 111.948 -0.461 . . . . 0.0 111.948 179.054 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 46.7 p90 -64.79 131.87 48.0 Favored 'General case' 0 N--CA 1.474 0.765 0 N-CA-C 112.015 0.376 . . . . 0.0 112.015 -179.546 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' H' H ' 11' ' ' GLU . . . . . 0.415 ' CG ' ' ND2' ' G' ' 27' ' ' ASN . 44.0 mt-10 -82.05 150.38 27.59 Favored 'General case' 0 N--CA 1.474 0.749 0 N-CA-C 109.186 -0.672 . . . . 0.0 109.186 177.929 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 3.0 p -156.4 127.82 0.92 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.044 0 N-CA-C 108.291 -1.003 . . . . 0.0 108.291 178.108 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 56.0 m-70 -132.74 144.14 50.07 Favored 'General case' 0 N--CA 1.475 0.804 0 CA-C-N 115.22 -0.9 . . . . 0.0 110.731 -177.906 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 6.0 t60 -166.12 97.74 0.62 Allowed 'General case' 0 N--CA 1.482 1.163 0 CA-C-O 119.554 -0.26 . . . . 0.0 110.775 179.105 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 47.6 mt-30 -106.87 -172.56 2.1 Favored 'General case' 0 CA--C 1.505 -0.768 0 N-CA-C 108.099 -1.074 . . . . 0.0 108.099 179.403 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -163.0 98.24 0.94 Allowed 'General case' 0 N--CA 1.472 0.643 0 CA-C-N 115.268 -0.878 . . . . 0.0 109.218 178.679 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' H' H ' 17' ' ' LEU . . . . . 0.486 ' N ' HD12 ' H' ' 17' ' ' LEU . 6.6 mp -108.48 162.24 14.31 Favored 'General case' 0 N--CA 1.485 1.312 0 N-CA-C 108.978 -0.749 . . . . 0.0 108.978 -179.769 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 37.0 t -142.99 120.15 6.08 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.037 0 CA-C-O 121.16 0.505 . . . . 0.0 110.553 178.994 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 48.2 m-85 -72.76 150.41 42.84 Favored 'General case' 0 C--N 1.373 1.629 0 N-CA-C 106.909 -1.515 . . . . 0.0 106.909 176.182 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 21.3 t80 -171.25 -53.95 0.02 OUTLIER 'General case' 0 N--CA 1.481 1.093 0 N-CA-C 110.202 -0.295 . . . . 0.0 110.202 -179.361 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -42.26 91.6 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.463 0 O-C-N 123.872 0.732 . . . . 0.0 111.896 179.613 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 37.0 tt0 -57.81 133.89 55.8 Favored 'General case' 0 CA--C 1.54 0.564 0 CA-C-N 114.777 -1.102 . . . . 0.0 110.694 179.793 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 9.0 m-20 -81.24 161.44 23.96 Favored 'General case' 0 N--CA 1.474 0.768 0 N-CA-C 109.69 -0.485 . . . . 0.0 109.69 -179.986 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' H' H ' 24' ' ' VAL . . . . . 0.42 HG22 HH21 ' I' ' 5' ' ' ARG . 95.0 t -159.77 -77.03 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.99 0 N-CA-C 106.983 -1.488 . . . . 0.0 106.983 -179.037 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . -35.43 89.96 0.01 OUTLIER Glycine 0 N--CA 1.47 0.924 0 CA-C-N 115.086 -0.961 . . . . 0.0 112.245 179.547 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 97.5 p -37.47 -98.79 0.0 OUTLIER 'General case' 0 N--CA 1.478 0.954 0 C-N-CA 123.693 0.797 . . . . 0.0 112.739 -176.711 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' H' H ' 27' ' ' ASN . . . . . 0.409 ' ND2' ' CG ' ' I' ' 11' ' ' GLU . 40.1 t30 -61.62 126.69 28.23 Favored 'General case' 0 CA--C 1.543 0.689 0 CA-C-N 119.368 0.985 . . . . 0.0 109.144 179.01 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 63.3 mttm -106.97 -178.9 3.78 Favored 'General case' 0 N--CA 1.484 1.241 0 N-CA-C 109.365 -0.606 . . . . 0.0 109.365 -179.797 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.92 -141.19 0.02 OUTLIER Glycine 0 CA--C 1.522 0.521 0 N-CA-C 109.935 -1.266 . . . . 0.0 109.935 178.207 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -129.0 115.51 17.9 Favored 'General case' 0 C--O 1.217 -0.643 0 C-N-CA 123.263 0.625 . . . . 0.0 109.437 179.499 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 74.6 mt -97.86 150.6 4.65 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.027 0 N-CA-C 106.908 -1.515 . . . . 0.0 106.908 178.13 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 35.4 mt -149.32 126.89 2.62 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.309 0 N-CA-C 108.912 -0.773 . . . . 0.0 108.912 178.579 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.3 85.65 0.05 OUTLIER Glycine 0 C--N 1.34 0.801 0 CA-C-N 115.946 -0.57 . . . . 0.0 112.994 178.586 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 14.5 tp -102.97 123.28 46.29 Favored 'General case' 0 N--CA 1.482 1.158 0 N-CA-C 107.04 -1.466 . . . . 0.0 107.04 177.332 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 11.8 ttt -158.38 158.48 34.34 Favored 'General case' 0 N--CA 1.469 0.516 0 N-CA-C 108.585 -0.895 . . . . 0.0 108.585 -179.958 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 96.9 t -156.51 152.4 8.12 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.357 0 N-CA-C 107.076 -1.453 . . . . 0.0 107.076 -179.782 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 57.46 73.03 0.5 Allowed Glycine 0 C--N 1.313 -0.698 0 CA-C-N 115.644 -0.707 . . . . 0.0 112.028 178.169 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 169.98 -148.17 11.52 Favored Glycine 0 N--CA 1.468 0.792 0 N-CA-C 110.566 -1.014 . . . . 0.0 110.566 179.068 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 33.4 m -135.36 144.01 35.31 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.995 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.706 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 20.3 t . . . . . 0 C--O 1.222 -0.385 0 CA-C-O 117.852 -1.07 . . . . 0.0 110.916 179.99 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 79.0 m-85 . . . . . 0 N--CA 1.474 0.764 0 N-CA-C 109.323 -0.621 . . . . 0.0 109.323 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' I' I ' 5' ' ' ARG . . . . . 0.42 HH21 HG22 ' H' ' 24' ' ' VAL . 37.1 mtp180 -143.15 143.36 31.78 Favored 'General case' 0 N--CA 1.482 1.17 0 N-CA-C 109.273 -0.64 . . . . 0.0 109.273 -179.687 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 74.6 m80 -150.51 118.55 6.29 Favored 'General case' 0 N--CA 1.474 0.729 0 N-CA-C 109.243 -0.651 . . . . 0.0 109.243 178.691 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 9.5 m-20 -69.72 144.21 52.85 Favored 'General case' 0 CA--C 1.537 0.444 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.681 -179.696 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' I' I ' 8' ' ' SER . . . . . . . . . . . . . 3.6 t -164.23 179.11 7.06 Favored 'General case' 0 N--CA 1.469 0.514 0 N-CA-C 109.492 -0.558 . . . . 0.0 109.492 178.182 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.58 50.9 0.94 Allowed Glycine 0 N--CA 1.477 1.426 0 N-CA-C 111.929 -0.469 . . . . 0.0 111.929 179.047 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 47.1 p90 -64.85 131.91 48.01 Favored 'General case' 0 N--CA 1.474 0.734 0 N-CA-C 112.104 0.409 . . . . 0.0 112.104 -179.573 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' I' I ' 11' ' ' GLU . . . . . 0.409 ' CG ' ' ND2' ' H' ' 27' ' ' ASN . 43.9 mt-10 -82.14 150.39 27.48 Favored 'General case' 0 N--CA 1.473 0.71 0 N-CA-C 109.249 -0.648 . . . . 0.0 109.249 177.934 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 3.1 p -156.38 127.7 0.91 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.971 0 N-CA-C 108.366 -0.976 . . . . 0.0 108.366 178.209 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 55.5 m-70 -132.8 144.13 50.02 Favored 'General case' 0 N--CA 1.475 0.779 0 CA-C-N 115.24 -0.891 . . . . 0.0 110.735 -177.839 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 28.4 t-80 -166.21 97.98 0.61 Allowed 'General case' 0 N--CA 1.483 1.181 0 CA-C-N 116.664 -0.244 . . . . 0.0 110.818 179.228 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 47.3 mt-30 -107.11 -172.21 2.03 Favored 'General case' 0 CA--C 1.501 -0.918 0 N-CA-C 108.12 -1.067 . . . . 0.0 108.12 179.322 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -163.24 98.27 0.92 Allowed 'General case' 0 N--CA 1.47 0.563 0 CA-C-N 115.109 -0.95 . . . . 0.0 109.22 178.704 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' I' I ' 17' ' ' LEU . . . . . 0.48 ' N ' HD12 ' I' ' 17' ' ' LEU . 6.6 mp -108.45 162.12 14.41 Favored 'General case' 0 N--CA 1.485 1.323 0 N-CA-C 108.968 -0.753 . . . . 0.0 108.968 -179.751 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 37.7 t -142.9 120.18 6.35 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.048 0 CA-C-O 121.2 0.524 . . . . 0.0 110.483 178.987 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 47.7 m-85 -72.81 150.39 42.78 Favored 'General case' 0 C--N 1.374 1.645 0 N-CA-C 106.759 -1.571 . . . . 0.0 106.759 176.196 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 21.3 t80 -171.17 -54.15 0.02 OUTLIER 'General case' 0 N--CA 1.48 1.048 0 N-CA-C 110.217 -0.29 . . . . 0.0 110.217 -179.304 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -42.25 91.58 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.461 0 CA-C-O 121.632 0.729 . . . . 0.0 111.856 179.656 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 37.0 tt0 -57.75 133.82 55.7 Favored 'General case' 0 CA--C 1.539 0.558 0 CA-C-N 114.769 -1.105 . . . . 0.0 110.773 179.691 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 -81.09 161.38 24.16 Favored 'General case' 0 N--CA 1.473 0.716 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 179.936 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' I' I ' 24' ' ' VAL . . . . . 0.414 HG22 HH21 ' G' ' 5' ' ' ARG . 95.1 t -159.75 -77.11 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.04 0 N-CA-C 107.045 -1.465 . . . . 0.0 107.045 -179.095 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . -35.53 90.09 0.01 OUTLIER Glycine 0 C--N 1.34 0.804 0 CA-C-N 115.073 -0.967 . . . . 0.0 112.25 179.611 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 97.5 p -37.4 -98.95 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.875 0 C-N-CA 123.794 0.838 . . . . 0.0 112.82 -176.733 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 40.5 t30 -61.5 126.62 28.02 Favored 'General case' 0 CA--C 1.542 0.645 0 CA-C-N 119.431 1.014 . . . . 0.0 109.148 179.005 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 63.2 mttm -106.96 -178.95 3.79 Favored 'General case' 0 N--CA 1.484 1.275 0 N-CA-C 109.356 -0.609 . . . . 0.0 109.356 -179.791 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.92 -141.27 0.02 OUTLIER Glycine 0 CA--C 1.523 0.58 0 N-CA-C 109.906 -1.278 . . . . 0.0 109.906 178.254 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.86 115.46 17.93 Favored 'General case' 0 C--O 1.218 -0.584 0 C-N-CA 123.247 0.619 . . . . 0.0 109.434 179.537 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 74.6 mt -97.94 150.67 4.64 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.047 0 N-CA-C 106.878 -1.527 . . . . 0.0 106.878 178.186 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 35.7 mt -149.31 126.93 2.65 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.292 0 N-CA-C 108.863 -0.791 . . . . 0.0 108.863 178.646 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.28 85.69 0.05 OUTLIER Glycine 0 C--N 1.339 0.71 0 CA-C-N 115.986 -0.552 . . . . 0.0 112.919 178.571 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 14.6 tp -102.91 123.25 46.19 Favored 'General case' 0 N--CA 1.482 1.151 0 N-CA-C 107.008 -1.479 . . . . 0.0 107.008 177.208 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 11.8 ttt -158.31 158.51 34.51 Favored 'General case' 0 N--CA 1.469 0.489 0 N-CA-C 108.56 -0.904 . . . . 0.0 108.56 179.97 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 96.6 t -156.57 152.39 8.09 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.297 0 N-CA-C 107.007 -1.479 . . . . 0.0 107.007 -179.776 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 57.44 73.2 0.48 Allowed Glycine 0 C--N 1.313 -0.734 0 CA-C-N 115.661 -0.7 . . . . 0.0 111.932 178.141 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 169.9 -148.29 11.66 Favored Glycine 0 N--CA 1.467 0.719 0 N-CA-C 110.651 -0.979 . . . . 0.0 110.651 179.094 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 33.4 m -135.21 144.01 35.49 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.947 0 C-N-CA 122.765 0.426 . . . . 0.0 109.904 -179.83 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 20.3 t . . . . . 0 C--O 1.222 -0.378 0 CA-C-O 117.803 -1.094 . . . . 0.0 110.932 179.996 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 29.1 m-85 . . . . . 0 N--CA 1.476 0.864 0 N-CA-C 108.637 -0.875 . . . . 0.0 108.637 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 5' ' ' ARG . . . . . 0.897 HH12 HG11 ' C' ' 24' ' ' VAL . 6.2 ptm180 -165.06 146.65 7.73 Favored 'General case' 0 N--CA 1.478 0.954 0 N-CA-C 112.349 0.5 . . . . 0.0 112.349 -179.738 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 21.2 p80 -151.89 107.79 3.38 Favored 'General case' 0 N--CA 1.475 0.788 0 CA-C-O 120.884 0.374 . . . . 0.0 110.552 177.93 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -78.13 151.69 33.2 Favored 'General case' 0 N--CA 1.475 0.805 0 CA-C-O 121.03 0.443 . . . . 0.0 109.827 178.961 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 99.8 p -155.2 173.67 16.29 Favored 'General case' 0 N--CA 1.475 0.794 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.595 -179.766 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 125.13 78.99 0.35 Allowed Glycine 0 N--CA 1.481 1.692 0 N-CA-C 111.441 -0.664 . . . . 0.0 111.441 -179.969 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 23.6 p90 -55.14 156.05 4.33 Favored 'General case' 0 N--CA 1.478 0.954 0 C-N-CA 122.528 0.331 . . . . 0.0 110.698 178.982 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 65.7 mt-10 -119.65 127.21 52.7 Favored 'General case' 0 N--CA 1.486 1.366 0 N-CA-C 109.708 -0.479 . . . . 0.0 109.708 179.281 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 40.2 t -101.69 139.83 21.85 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.705 0 N-CA-C 109.194 -0.669 . . . . 0.0 109.194 178.815 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 88.4 m-70 -140.42 138.98 35.16 Favored 'General case' 0 N--CA 1.488 1.445 0 CA-C-N 118.762 0.71 . . . . 0.0 109.98 178.494 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 52.9 t-80 -167.55 97.31 0.48 Allowed 'General case' 0 N--CA 1.481 1.119 0 CA-C-O 119.745 -0.169 . . . . 0.0 110.632 178.979 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 55.2 mt-30 -100.55 116.48 32.6 Favored 'General case' 0 CA--C 1.512 -0.493 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 -179.484 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 64.4 tttp -104.32 105.95 16.27 Favored 'General case' 0 N--CA 1.48 1.07 0 N-CA-C 108.648 -0.871 . . . . 0.0 108.648 178.148 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 10.0 mp -122.63 165.17 16.92 Favored 'General case' 0 N--CA 1.487 1.412 0 N-CA-C 108.712 -0.847 . . . . 0.0 108.712 -179.55 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 62.1 t -142.57 111.28 2.19 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.09 0 N-CA-C 108.499 -0.926 . . . . 0.0 108.499 177.757 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 59.7 m-85 -101.24 164.92 11.55 Favored 'General case' 0 N--CA 1.475 0.821 0 N-CA-C 109.29 -0.633 . . . . 0.0 109.29 178.244 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.453 ' O ' ' O ' ' D' ' 21' ' ' ALA . 77.7 t80 -165.53 -83.46 0.02 OUTLIER 'General case' 0 C--O 1.209 -1.052 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 177.205 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -88.29 94.08 9.72 Favored 'General case' 0 C--N 1.353 0.726 0 N-CA-C 108.249 -1.019 . . . . 0.0 108.249 177.567 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 11.2 mm-40 -73.85 -170.13 0.84 Allowed 'General case' 0 N--CA 1.482 1.153 0 C-N-CA 120.344 -0.542 . . . . 0.0 110.771 179.812 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 8.2 m-20 -73.17 153.35 40.75 Favored 'General case' 0 N--CA 1.473 0.712 0 CA-C-O 121.886 0.85 . . . . 0.0 112.995 -177.637 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.917 HG11 HH12 ' B' ' 5' ' ' ARG . 71.2 t -155.23 94.35 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.466 0.369 0 CA-C-N 114.551 -1.204 . . . . 0.0 108.244 177.005 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -121.56 60.3 0.55 Allowed Glycine 0 N--CA 1.481 1.638 0 N-CA-C 110.995 -0.842 . . . . 0.0 110.995 179.038 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 15.3 m 47.32 -143.34 0.38 Allowed 'General case' 0 N--CA 1.484 1.261 0 CA-C-N 118.164 0.982 . . . . 0.0 110.479 -179.633 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 27' ' ' ASN . . . . . 0.443 ' ND2' ' O ' ' E' ' 9' ' ' GLY . 8.7 m120 -79.67 92.38 5.37 Favored 'General case' 0 N--CA 1.47 0.527 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 177.636 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 96.4 mttt -65.76 146.21 55.05 Favored 'General case' 0 CA--C 1.539 0.537 0 CA-C-O 121.264 0.554 . . . . 0.0 110.537 -178.559 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -70.17 -129.17 0.06 OUTLIER Glycine 0 CA--C 1.525 0.688 0 N-CA-C 109.445 -1.462 . . . . 0.0 109.445 178.533 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -85.01 131.35 34.48 Favored 'General case' 0 N--CA 1.465 0.3 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 179.69 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 18.3 tt -165.54 173.52 0.17 Allowed 'Isoleucine or valine' 0 C--O 1.215 -0.745 0 N-CA-C 108.815 -0.809 . . . . 0.0 108.815 -177.85 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 24.3 mt -140.27 145.21 26.41 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.487 0 N-CA-C 107.179 -1.415 . . . . 0.0 107.179 -179.288 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -52.0 168.17 0.71 Allowed Glycine 0 N--CA 1.473 1.14 0 C-N-CA 121.268 -0.491 . . . . 0.0 112.147 -179.328 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 2.7 pp -65.99 158.08 29.17 Favored 'General case' 0 N--CA 1.465 0.293 0 N-CA-C 109.671 -0.492 . . . . 0.0 109.671 179.741 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 21.3 ttt -142.57 154.76 44.72 Favored 'General case' 0 N--CA 1.473 0.676 0 N-CA-C 108.965 -0.754 . . . . 0.0 108.965 -179.919 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 41.3 t -149.49 139.33 16.03 Favored 'Isoleucine or valine' 0 C--O 1.235 0.318 0 N-CA-C 107.241 -1.392 . . . . 0.0 107.241 -179.695 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 60.54 67.44 2.14 Favored Glycine 0 C--N 1.318 -0.437 0 N-CA-C 109.006 -1.637 . . . . 0.0 109.006 -179.85 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -82.22 130.08 9.47 Favored Glycine 0 N--CA 1.468 0.788 0 N-CA-C 111.312 -0.715 . . . . 0.0 111.312 -178.818 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 1.9 t -146.71 113.43 1.05 Allowed 'Isoleucine or valine' 0 CA--C 1.561 1.373 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 179.257 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 19.1 t . . . . . 0 N--CA 1.497 1.899 0 CA-C-O 118.475 -0.774 . . . . 0.0 112.477 -177.877 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 29.0 m-85 . . . . . 0 N--CA 1.476 0.847 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' B' B ' 5' ' ' ARG . . . . . 0.917 HH12 HG11 ' A' ' 24' ' ' VAL . 6.3 ptm180 -165.39 146.59 7.31 Favored 'General case' 0 N--CA 1.474 0.773 0 C-N-CA 120.569 -0.452 . . . . 0.0 112.165 -179.698 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 20.9 p80 -151.79 108.07 3.43 Favored 'General case' 0 N--CA 1.476 0.838 0 CA-C-O 120.831 0.348 . . . . 0.0 110.562 177.867 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 7' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -78.56 151.1 32.64 Favored 'General case' 0 N--CA 1.476 0.834 0 CA-C-O 121.088 0.471 . . . . 0.0 109.889 179.042 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 8' ' ' SER . . . . . . . . . . . . . 99.3 p -154.54 173.72 15.92 Favored 'General case' 0 N--CA 1.473 0.718 0 CA-C-N 115.784 -0.643 . . . . 0.0 110.731 -179.759 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 125.2 78.91 0.34 Allowed Glycine 0 N--CA 1.48 1.621 0 N-CA-C 111.433 -0.667 . . . . 0.0 111.433 -179.972 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 23.9 p90 -55.28 156.05 4.55 Favored 'General case' 0 N--CA 1.478 0.927 0 C-N-CA 122.401 0.28 . . . . 0.0 110.742 179.054 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 65.6 mt-10 -119.55 127.43 52.98 Favored 'General case' 0 N--CA 1.486 1.367 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 179.288 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 40.0 t -102.04 139.66 22.55 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.708 0 N-CA-C 109.194 -0.669 . . . . 0.0 109.194 178.85 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 88.3 m-70 -140.41 139.09 35.2 Favored 'General case' 0 N--CA 1.484 1.272 0 CA-C-N 118.689 0.677 . . . . 0.0 110.011 178.729 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 52.5 t-80 -167.87 97.37 0.45 Allowed 'General case' 0 N--CA 1.482 1.165 0 N-CA-C 110.507 -0.183 . . . . 0.0 110.507 179.017 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 55.4 mt-30 -100.67 116.86 33.56 Favored 'General case' 0 CA--C 1.511 -0.546 0 N-CA-C 108.604 -0.887 . . . . 0.0 108.604 -179.533 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 64.6 tttp -104.51 105.97 16.29 Favored 'General case' 0 N--CA 1.479 1.014 0 N-CA-C 108.674 -0.861 . . . . 0.0 108.674 178.106 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 10.0 mp -122.83 165.05 17.26 Favored 'General case' 0 N--CA 1.489 1.516 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 -179.51 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 61.6 t -142.45 110.24 2.04 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.117 0 N-CA-C 108.743 -0.836 . . . . 0.0 108.743 177.838 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 61.1 m-85 -100.11 164.32 12.03 Favored 'General case' 0 N--CA 1.474 0.746 0 CA-C-N 118.745 0.702 . . . . 0.0 109.456 178.275 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 20' ' ' PHE . . . . . 0.433 ' O ' ' O ' ' E' ' 21' ' ' ALA . 76.4 t80 -164.38 -83.59 0.03 OUTLIER 'General case' 0 C--O 1.212 -0.881 0 N-CA-C 109.277 -0.638 . . . . 0.0 109.277 177.238 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -88.73 94.3 9.86 Favored 'General case' 0 C--N 1.35 0.59 0 N-CA-C 108.171 -1.048 . . . . 0.0 108.171 177.599 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 11.4 mm-40 -73.73 -170.24 0.84 Allowed 'General case' 0 N--CA 1.481 1.124 0 C-N-CA 120.487 -0.485 . . . . 0.0 110.791 179.881 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 23' ' ' ASP . . . . . 0.422 ' HB3' ' HZ1' ' B' ' 28' ' ' LYS . 8.2 m-20 -73.24 153.45 40.63 Favored 'General case' 0 N--CA 1.473 0.709 0 CA-C-O 121.943 0.878 . . . . 0.0 112.971 -177.598 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 24' ' ' VAL . . . . . 0.925 HG11 HH12 ' C' ' 5' ' ' ARG . 65.5 t -155.22 94.3 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.391 0 CA-C-N 114.586 -1.188 . . . . 0.0 108.166 177.013 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -121.35 60.16 0.55 Allowed Glycine 0 N--CA 1.479 1.547 0 N-CA-C 111.138 -0.785 . . . . 0.0 111.138 178.874 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 15.3 m 47.4 -143.72 0.36 Allowed 'General case' 0 N--CA 1.485 1.281 0 CA-C-N 118.209 1.005 . . . . 0.0 110.317 -179.574 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 27' ' ' ASN . . . . . 0.437 ' ND2' ' O ' ' F' ' 9' ' ' GLY . 8.8 m120 -79.43 92.45 5.23 Favored 'General case' 0 N--CA 1.469 0.497 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 177.661 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 28' ' ' LYS . . . . . 0.422 ' HZ1' ' HB3' ' B' ' 23' ' ' ASP . 96.4 mttt -65.87 146.47 54.71 Favored 'General case' 0 CA--C 1.54 0.569 0 CA-C-O 121.333 0.587 . . . . 0.0 110.42 -178.472 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -70.33 -129.11 0.06 OUTLIER Glycine 0 CA--C 1.526 0.745 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 178.523 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -85.0 131.32 34.48 Favored 'General case' 0 C--O 1.235 0.291 0 N-CA-C 109.413 -0.588 . . . . 0.0 109.413 179.628 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 18.3 tt -165.61 173.44 0.17 Allowed 'Isoleucine or valine' 0 C--O 1.215 -0.751 0 N-CA-C 108.753 -0.832 . . . . 0.0 108.753 -177.8 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 24.6 mt -140.25 145.14 26.53 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.475 0 N-CA-C 107.194 -1.41 . . . . 0.0 107.194 -179.24 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -51.94 168.25 0.68 Allowed Glycine 0 N--CA 1.472 1.078 0 C-N-CA 121.202 -0.523 . . . . 0.0 112.195 -179.372 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 2.7 pp -66.13 157.76 30.39 Favored 'General case' 0 N--CA 1.465 0.28 0 N-CA-C 109.646 -0.501 . . . . 0.0 109.646 179.79 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 21.3 ttt -142.25 154.93 45.16 Favored 'General case' 0 N--CA 1.473 0.677 0 N-CA-C 109.02 -0.733 . . . . 0.0 109.02 -179.975 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 41.0 t -149.46 139.51 16.21 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.313 0 N-CA-C 107.267 -1.382 . . . . 0.0 107.267 -179.638 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 60.1 67.41 2.17 Favored Glycine 0 C--N 1.318 -0.445 0 N-CA-C 109.152 -1.579 . . . . 0.0 109.152 -179.803 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . -82.16 129.98 9.41 Favored Glycine 0 CA--C 1.526 0.769 0 N-CA-C 111.284 -0.726 . . . . 0.0 111.284 -178.892 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 1.9 t -146.68 113.46 1.06 Allowed 'Isoleucine or valine' 0 CA--C 1.561 1.371 0 N-CA-C 108.459 -0.941 . . . . 0.0 108.459 179.192 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 19.8 t . . . . . 0 N--CA 1.498 1.937 0 CA-C-O 118.409 -0.805 . . . . 0.0 112.195 -177.997 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 28.6 m-85 . . . . . 0 N--CA 1.477 0.92 0 N-CA-C 108.653 -0.869 . . . . 0.0 108.653 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' C' C ' 5' ' ' ARG . . . . . 0.925 HH12 HG11 ' B' ' 24' ' ' VAL . 6.3 ptm180 -164.98 146.54 7.79 Favored 'General case' 0 N--CA 1.476 0.86 0 N-CA-C 112.231 0.456 . . . . 0.0 112.231 -179.706 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 21.2 p80 -151.78 107.92 3.42 Favored 'General case' 0 N--CA 1.476 0.868 0 CA-C-O 120.804 0.335 . . . . 0.0 110.554 177.883 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' C' C ' 7' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -78.51 150.91 32.81 Favored 'General case' 0 N--CA 1.476 0.862 0 CA-C-O 121.061 0.457 . . . . 0.0 109.861 179.038 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' C' C ' 8' ' ' SER . . . . . . . . . . . . . 99.3 p -154.38 173.86 15.64 Favored 'General case' 0 N--CA 1.475 0.796 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.711 -179.856 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 125.07 78.96 0.35 Allowed Glycine 0 N--CA 1.48 1.627 0 N-CA-C 111.447 -0.661 . . . . 0.0 111.447 179.984 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 24.3 p90 -55.24 156.01 4.53 Favored 'General case' 0 N--CA 1.478 0.925 0 C-N-CA 122.501 0.32 . . . . 0.0 110.757 178.959 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 65.5 mt-10 -119.49 127.33 52.94 Favored 'General case' 0 N--CA 1.485 1.325 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 179.326 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 39.9 t -101.87 139.59 22.61 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.717 0 N-CA-C 109.266 -0.642 . . . . 0.0 109.266 178.76 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 88.2 m-70 -140.41 138.92 35.12 Favored 'General case' 0 N--CA 1.486 1.366 0 CA-C-N 118.635 0.652 . . . . 0.0 110.009 178.662 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 52.1 t-80 -167.67 97.46 0.47 Allowed 'General case' 0 N--CA 1.481 1.109 0 N-CA-C 110.542 -0.17 . . . . 0.0 110.542 178.939 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 55.5 mt-30 -100.58 116.71 33.14 Favored 'General case' 0 CA--C 1.513 -0.474 0 N-CA-C 108.608 -0.886 . . . . 0.0 108.608 -179.491 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 64.6 tttp -104.39 106.07 16.43 Favored 'General case' 0 N--CA 1.481 1.111 0 N-CA-C 108.632 -0.877 . . . . 0.0 108.632 178.062 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 10.0 mp -122.91 164.88 17.63 Favored 'General case' 0 N--CA 1.488 1.452 0 N-CA-C 108.599 -0.889 . . . . 0.0 108.599 -179.567 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 60.8 t -142.21 110.31 2.19 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 N-CA-C 108.587 -0.894 . . . . 0.0 108.587 177.836 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 61.4 m-85 -100.09 164.3 12.04 Favored 'General case' 0 N--CA 1.476 0.839 0 CA-C-N 118.734 0.697 . . . . 0.0 109.426 178.202 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' C' C ' 20' ' ' PHE . . . . . 0.44 ' O ' ' O ' ' F' ' 21' ' ' ALA . 76.1 t80 -164.23 -83.66 0.03 OUTLIER 'General case' 0 C--O 1.211 -0.955 0 N-CA-C 109.441 -0.577 . . . . 0.0 109.441 177.132 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -88.61 94.27 9.83 Favored 'General case' 0 C--N 1.349 0.554 0 N-CA-C 108.124 -1.065 . . . . 0.0 108.124 177.633 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 11.3 mm-40 -73.81 -170.14 0.84 Allowed 'General case' 0 N--CA 1.48 1.074 0 C-N-CA 120.393 -0.523 . . . . 0.0 110.816 179.928 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 8.2 m-20 -73.2 153.41 40.69 Favored 'General case' 0 N--CA 1.474 0.76 0 CA-C-O 122.04 0.924 . . . . 0.0 112.864 -177.613 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' C' C ' 24' ' ' VAL . . . . . 0.897 HG11 HH12 ' A' ' 5' ' ' ARG . 65.5 t -155.31 94.43 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.39 0 CA-C-N 114.418 -1.264 . . . . 0.0 108.147 176.958 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -121.57 60.41 0.55 Allowed Glycine 0 N--CA 1.48 1.598 0 N-CA-C 110.984 -0.846 . . . . 0.0 110.984 178.96 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 15.4 m 47.23 -143.79 0.35 Allowed 'General case' 0 N--CA 1.484 1.265 0 CA-C-N 118.21 1.005 . . . . 0.0 110.456 -179.554 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' C' C ' 27' ' ' ASN . . . . . 0.447 ' ND2' ' O ' ' D' ' 9' ' ' GLY . 8.8 m120 -79.33 92.44 5.17 Favored 'General case' 0 N--CA 1.469 0.512 0 N-CA-C 108.71 -0.848 . . . . 0.0 108.71 177.613 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 96.4 mttt -65.87 146.2 55.03 Favored 'General case' 0 CA--C 1.541 0.603 0 CA-C-O 121.292 0.567 . . . . 0.0 110.502 -178.458 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -70.13 -129.0 0.06 OUTLIER Glycine 0 C--N 1.339 0.708 0 N-CA-C 109.591 -1.404 . . . . 0.0 109.591 178.483 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -85.01 131.25 34.49 Favored 'General case' 0 C--O 1.234 0.277 0 N-CA-C 109.423 -0.584 . . . . 0.0 109.423 179.65 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 18.3 tt -165.5 173.53 0.17 Allowed 'Isoleucine or valine' 0 C--O 1.215 -0.749 0 N-CA-C 108.832 -0.803 . . . . 0.0 108.832 -177.954 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 24.4 mt -140.25 145.22 26.43 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.466 0 N-CA-C 107.123 -1.436 . . . . 0.0 107.123 -179.22 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -52.01 168.19 0.71 Allowed Glycine 0 N--CA 1.473 1.113 0 C-N-CA 121.253 -0.499 . . . . 0.0 112.213 -179.442 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 2.7 pp -66.0 157.85 29.8 Favored 'General case' 0 N--CA 1.464 0.274 0 N-CA-C 109.679 -0.489 . . . . 0.0 109.679 179.736 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 21.4 ttt -142.28 154.79 45.01 Favored 'General case' 0 N--CA 1.473 0.68 0 N-CA-C 108.966 -0.753 . . . . 0.0 108.966 -179.939 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 41.1 t -149.4 139.65 16.37 Favored 'Isoleucine or valine' 0 C--O 1.234 0.288 0 N-CA-C 107.165 -1.42 . . . . 0.0 107.165 -179.71 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 60.01 67.3 2.22 Favored Glycine 0 C--N 1.32 -0.331 0 N-CA-C 109.173 -1.571 . . . . 0.0 109.173 -179.868 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . -81.97 130.04 9.45 Favored Glycine 0 CA--C 1.526 0.754 0 N-CA-C 111.264 -0.735 . . . . 0.0 111.264 -178.91 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 1.9 t -146.67 113.48 1.06 Allowed 'Isoleucine or valine' 0 CA--C 1.558 1.284 0 N-CA-C 108.47 -0.937 . . . . 0.0 108.47 179.131 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 19.9 t . . . . . 0 N--CA 1.495 1.789 0 CA-C-O 118.467 -0.778 . . . . 0.0 112.399 -177.894 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' D' D ' 4' ' ' PHE . . . . . 0.41 ' N ' ' CD1' ' D' ' 4' ' ' PHE 0.289 35.2 m-85 . . . . . 0 N--CA 1.486 1.339 0 N-CA-C 106.381 -1.711 . . . . 0.0 106.381 . . . . . . . . . 2 2 . 1 . 019 nuclear build core ' D' D ' 5' ' ' ARG . . . . . 0.916 HH12 HG11 ' F' ' 24' ' ' VAL . 6.0 ptm180 -154.59 150.01 27.26 Favored 'General case' 0 C--O 1.247 0.924 0 CA-C-O 116.565 -1.683 . . . . 0.0 113.175 176.423 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 15.4 p80 -150.75 117.98 5.99 Favored 'General case' 0 N--CA 1.481 1.102 0 CA-C-N 119.992 1.269 . . . . 0.0 107.882 163.217 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' D' D ' 7' ' ' ASP . . . . . . . . . . . . 0.367 0.7 OUTLIER -66.25 141.64 57.97 Favored 'General case' 0 C--N 1.324 -0.522 0 C-N-CA 128.565 2.746 . . . . 0.0 115.839 168.32 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' D' D ' 8' ' ' SER . . . . . . . . . . . . . 97.9 p -151.16 175.45 12.14 Favored 'General case' 0 N--CA 1.488 1.437 0 CA-C-N 119.452 1.024 . . . . 0.0 111.471 175.404 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' D' D ' 9' ' ' GLY . . . . . 0.447 ' O ' ' ND2' ' C' ' 27' ' ' ASN . . . 122.37 77.12 0.4 Allowed Glycine 0 N--CA 1.48 1.567 0 CA-C-N 116.056 -0.52 . . . . 0.0 112.762 179.594 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 25.9 p90 -50.98 152.25 2.26 Favored 'General case' 0 N--CA 1.48 1.053 0 C-N-CA 123.662 0.785 . . . . 0.0 111.967 177.768 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 64.9 mt-10 -117.39 131.13 56.83 Favored 'General case' 0 N--CA 1.49 1.568 0 C-N-CA 118.94 -1.104 . . . . 0.0 108.524 175.992 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 21.3 t -95.22 140.26 17.22 Favored 'Isoleucine or valine' 0 C--O 1.245 0.856 0 CA-C-O 117.678 -1.153 . . . . 0.0 111.083 173.673 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 86.5 m-70 -138.64 140.62 38.95 Favored 'General case' 0 N--CA 1.483 1.185 0 CA-C-N 119.543 1.065 . . . . 0.0 110.236 172.544 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 14.0 t60 -165.5 104.47 0.73 Allowed 'General case' 0 N--CA 1.48 1.066 0 N-CA-C 108.922 -0.77 . . . . 0.0 108.922 173.611 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 55.8 mt-30 -104.19 114.95 29.55 Favored 'General case' 0 C--N 1.311 -1.067 0 N-CA-C 108.698 -0.853 . . . . 0.0 108.698 179.15 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 64.6 tttp -102.49 112.89 25.82 Favored 'General case' 0 C--N 1.358 0.964 0 N-CA-C 107.677 -1.231 . . . . 0.0 107.677 177.073 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 9.3 mp -126.69 162.26 26.2 Favored 'General case' 0 N--CA 1.488 1.439 0 N-CA-C 108.409 -0.96 . . . . 0.0 108.409 179.499 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . 0.365 89.7 t -140.62 119.65 11.34 Favored 'Isoleucine or valine' 0 C--N 1.372 1.563 0 N-CA-C 105.636 -1.987 . . . . 0.0 105.636 168.099 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' D' D ' 19' ' ' PHE . . . . . . . . . . . . 0.69 57.8 m-85 -67.33 150.34 49.12 Favored 'General case' 0 N--CA 1.423 -1.794 1 C-N-CA 135.005 5.322 . . . . 0.0 121.46 159.418 . . . . . . . . 3 2 . 1 . 019 nuclear build core ' D' D ' 20' ' ' PHE . . . . . 0.403 ' O ' ' O ' ' G' ' 21' ' ' ALA 0.315 82.4 t80 -169.25 -67.79 0.02 OUTLIER 'General case' 0 N--CA 1.477 0.922 0 CA-C-O 114.713 -2.565 . . . . 0.0 113.794 152.691 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' D' D ' 21' ' ' ALA . . . . . 0.453 ' O ' ' O ' ' A' ' 20' ' ' PHE 0.354 . . -68.91 91.56 0.47 Allowed 'General case' 0 C--O 1.259 1.597 0 CA-C-O 113.016 -3.373 . . . . 0.0 113.057 160.959 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 11.8 mm-40 -76.88 -169.13 1.2 Allowed 'General case' 0 C--N 1.282 -2.34 1 CA-C-N 126.396 4.18 . . . . 0.0 111.316 177.061 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 9.7 m-20 -75.92 154.87 35.64 Favored 'General case' 0 C--O 1.241 0.625 0 CA-C-O 121.708 0.766 . . . . 0.0 111.233 -176.399 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' D' D ' 24' ' ' VAL . . . . . 0.927 HG11 HH12 ' E' ' 5' ' ' ARG 0.294 42.7 t -154.72 103.71 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.663 0 N-CA-C 104.002 -2.592 . . . . 0.0 104.002 170.27 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . -118.43 63.33 0.42 Allowed Glycine 0 C--N 1.361 1.929 0 CA-C-O 117.303 -1.831 . . . . 0.0 111.876 170.345 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 14.7 m 54.72 -143.15 0.76 Allowed 'General case' 0 N--CA 1.481 1.093 0 CA-C-N 121.411 2.606 . . . . 0.0 110.396 175.727 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' D' D ' 27' ' ' ASN . . . . . 0.449 ' ND2' ' O ' ' H' ' 9' ' ' GLY . 8.4 m120 -82.36 92.49 7.0 Favored 'General case' 0 N--CA 1.471 0.624 0 C-N-CA 123.78 0.832 . . . . 0.0 109.012 173.051 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 94.5 mttt -71.64 149.54 45.47 Favored 'General case' 0 CA--C 1.548 0.879 0 CA-C-O 122.601 1.191 . . . . 0.0 108.66 -175.815 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -70.01 -132.7 0.08 OUTLIER Glycine 0 N--CA 1.466 0.658 0 N-CA-C 107.804 -2.118 . . . . 0.0 107.804 179.481 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -89.42 132.89 34.78 Favored 'General case' 0 C--N 1.353 0.749 0 N-CA-C 106.923 -1.51 . . . . 0.0 106.923 -176.754 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' D' D ' 31' ' ' ILE . . . . . 0.409 ' N ' ' O ' ' E' ' 40' ' ' VAL . 18.9 tt -165.32 173.05 0.18 Allowed 'Isoleucine or valine' 0 C--O 1.218 -0.567 0 CA-C-N 113.21 -1.814 . . . . 0.0 109.085 -175.245 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 26.9 mt -141.65 145.49 24.37 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.623 0 N-CA-C 107.095 -1.446 . . . . 0.0 107.095 -179.659 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -52.33 169.15 0.66 Allowed Glycine 0 N--CA 1.473 1.115 0 C-N-CA 121.312 -0.471 . . . . 0.0 112.111 -178.581 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 2.5 pp -68.33 158.58 33.17 Favored 'General case' 0 N--CA 1.464 0.273 0 N-CA-C 109.34 -0.615 . . . . 0.0 109.34 -178.813 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 22.7 ttt -140.41 161.03 38.67 Favored 'General case' 0 N--CA 1.474 0.769 0 N-CA-C 107.98 -1.119 . . . . 0.0 107.98 179.168 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' D' D ' 36' ' ' VAL . . . . . . . . . . . . 0.284 62.0 t -155.71 147.05 12.5 Favored 'Isoleucine or valine' 0 C--N 1.349 0.573 0 N-CA-C 104.971 -2.233 . . . . 0.0 104.971 174.25 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 61.55 66.46 2.63 Favored Glycine 0 CA--C 1.535 1.326 0 N-CA-C 106.468 -2.653 . . . . 0.0 106.468 179.549 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . -80.74 129.9 9.37 Favored Glycine 0 C--N 1.313 -0.723 0 CA-C-N 118.683 1.242 . . . . 0.0 111.987 -179.077 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 2.4 t -148.74 122.74 1.8 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.789 0 N-CA-C 105.114 -2.18 . . . . 0.0 105.114 173.546 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 12.7 t . . . . . 0 N--CA 1.485 1.315 0 CA-C-O 116.567 -1.682 . . . . 0.0 113.769 179.317 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 27.3 m-85 . . . . . 0 N--CA 1.478 0.926 0 N-CA-C 108.379 -0.971 . . . . 0.0 108.379 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' E' E ' 5' ' ' ARG . . . . . 0.927 HH12 HG11 ' D' ' 24' ' ' VAL . 6.3 ptm180 -165.06 147.37 8.02 Favored 'General case' 0 C--O 1.217 -0.637 0 C-N-CA 120.365 -0.534 . . . . 0.0 112.166 -179.973 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 20.6 p80 -152.17 106.84 3.21 Favored 'General case' 0 N--CA 1.477 0.899 0 CA-C-O 120.839 0.352 . . . . 0.0 110.58 178.047 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' E' E ' 7' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -77.98 152.35 33.17 Favored 'General case' 0 N--CA 1.474 0.744 0 CA-C-O 121.556 0.693 . . . . 0.0 110.091 178.939 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' E' E ' 8' ' ' SER . . . . . . . . . . . . . 92.8 p -156.34 172.9 17.69 Favored 'General case' 0 N--CA 1.487 1.4 0 CA-C-N 115.07 -0.968 . . . . 0.0 111.377 -178.815 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' E' E ' 9' ' ' GLY . . . . . 0.443 ' O ' ' ND2' ' A' ' 27' ' ' ASN . . . 125.7 79.56 0.35 Allowed Glycine 0 N--CA 1.481 1.669 0 N-CA-C 111.441 -0.664 . . . . 0.0 111.441 179.543 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 18.4 p90 -53.48 157.65 2.03 Favored 'General case' 0 N--CA 1.479 0.986 0 C-N-CA 122.393 0.277 . . . . 0.0 111.125 179.298 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 65.6 mt-10 -120.11 126.96 52.03 Favored 'General case' 0 N--CA 1.49 1.551 0 N-CA-C 109.229 -0.656 . . . . 0.0 109.229 178.429 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 39.6 t -103.52 136.95 33.99 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.685 0 N-CA-C 109.014 -0.736 . . . . 0.0 109.014 178.255 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 84.3 m-70 -138.64 138.63 38.0 Favored 'General case' 0 N--CA 1.481 1.102 0 C-N-CA 122.326 0.25 . . . . 0.0 110.585 179.748 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 52.2 t-80 -167.96 97.45 0.45 Allowed 'General case' 0 N--CA 1.484 1.258 0 C-N-CA 122.239 0.215 . . . . 0.0 110.593 179.303 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 55.1 mt-30 -100.57 117.12 34.06 Favored 'General case' 0 CA--C 1.512 -0.509 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 -179.681 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 64.6 tttp -104.63 105.63 15.8 Favored 'General case' 0 N--CA 1.48 1.042 0 N-CA-C 108.657 -0.868 . . . . 0.0 108.657 178.225 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 9.9 mp -122.06 164.06 18.35 Favored 'General case' 0 N--CA 1.487 1.408 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 -179.239 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 54.8 t -142.58 113.22 2.75 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.848 0 N-CA-C 108.097 -1.075 . . . . 0.0 108.097 177.167 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 60.3 m-85 -102.86 163.46 12.2 Favored 'General case' 0 C--N 1.362 1.121 0 O-C-N 124.005 0.816 . . . . 0.0 109.459 178.12 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' E' E ' 20' ' ' PHE . . . . . 0.431 ' O ' ' O ' ' H' ' 21' ' ' ALA . 69.1 t80 -166.59 -84.41 0.02 OUTLIER 'General case' 0 C--O 1.215 -0.74 0 CA-C-N 115.907 -0.588 . . . . 0.0 109.726 177.335 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' E' E ' 21' ' ' ALA . . . . . 0.433 ' O ' ' O ' ' B' ' 20' ' ' PHE . . . -85.39 91.3 8.16 Favored 'General case' 0 N--CA 1.474 0.763 0 N-CA-C 108.28 -1.007 . . . . 0.0 108.28 178.498 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 11.2 mm-40 -70.89 -172.84 0.71 Allowed 'General case' 0 N--CA 1.481 1.086 0 C-N-CA 119.67 -0.812 . . . . 0.0 111.061 -179.932 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' E' E ' 23' ' ' ASP . . . . . 0.444 ' HB3' ' HZ1' ' E' ' 28' ' ' LYS . 8.5 m-20 -71.34 154.07 41.87 Favored 'General case' 0 N--CA 1.472 0.665 0 CA-C-O 121.749 0.785 . . . . 0.0 112.623 -177.405 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' E' E ' 24' ' ' VAL . . . . . 0.92 HG11 HH12 ' F' ' 5' ' ' ARG . 53.0 t -155.37 92.15 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.762 0 CA-C-N 114.733 -1.122 . . . . 0.0 108.072 177.274 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . -119.45 61.13 0.49 Allowed Glycine 0 N--CA 1.478 1.439 0 N-CA-C 110.87 -0.892 . . . . 0.0 110.87 178.798 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 15.8 m 45.95 -143.2 0.28 Allowed 'General case' 0 N--CA 1.485 1.294 0 CA-C-N 118.299 1.049 . . . . 0.0 110.701 -179.8 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' E' E ' 27' ' ' ASN . . . . . 0.436 ' ND2' ' O ' ' I' ' 9' ' ' GLY . 8.6 m120 -79.9 92.44 5.52 Favored 'General case' 0 N--CA 1.472 0.631 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 177.474 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' E' E ' 28' ' ' LYS . . . . . 0.444 ' HZ1' ' HB3' ' E' ' 23' ' ' ASP . 96.4 mttt -65.97 146.53 54.6 Favored 'General case' 0 CA--C 1.543 0.675 0 CA-C-O 121.193 0.52 . . . . 0.0 110.635 -178.565 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -71.29 -129.27 0.08 OUTLIER Glycine 0 CA--C 1.538 1.486 0 N-CA-C 109.912 -1.275 . . . . 0.0 109.912 178.492 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -82.22 131.28 35.23 Favored 'General case' 0 N--CA 1.439 -1.005 0 CA-C-N 117.637 0.719 . . . . 0.0 109.391 178.743 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 18.4 tt -165.28 173.31 0.18 Allowed 'Isoleucine or valine' 0 C--O 1.219 -0.532 0 N-CA-C 108.587 -0.894 . . . . 0.0 108.587 -178.737 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 25.5 mt -141.31 145.6 24.62 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.438 0 N-CA-C 107.106 -1.442 . . . . 0.0 107.106 179.674 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -51.63 167.93 0.64 Allowed Glycine 0 N--CA 1.474 1.209 0 C-N-CA 121.383 -0.437 . . . . 0.0 112.662 -179.333 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 2.7 pp -65.71 157.28 30.56 Favored 'General case' 0 N--CA 1.466 0.362 0 N-CA-C 109.97 -0.381 . . . . 0.0 109.97 179.746 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 23.0 ttt -142.37 154.24 44.47 Favored 'General case' 0 N--CA 1.478 0.949 0 N-CA-C 108.996 -0.742 . . . . 0.0 108.996 -179.956 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 40.3 t -149.41 138.54 15.42 Favored 'Isoleucine or valine' 0 C--O 1.238 0.458 0 N-CA-C 107.543 -1.28 . . . . 0.0 107.543 -179.57 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 60.94 67.96 1.89 Allowed Glycine 0 C--N 1.32 -0.336 0 N-CA-C 108.724 -1.751 . . . . 0.0 108.724 -179.882 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . -82.86 131.02 10.07 Favored Glycine 0 C--N 1.334 0.467 0 N-CA-C 111.286 -0.726 . . . . 0.0 111.286 -178.434 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 1.9 t -147.49 113.52 0.92 Allowed 'Isoleucine or valine' 0 N--CA 1.5 2.045 0 N-CA-C 108.447 -0.946 . . . . 0.0 108.447 179.389 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' E' E ' 40' ' ' VAL . . . . . 0.409 ' O ' ' N ' ' D' ' 31' ' ' ILE . 19.3 t . . . . . 0 N--CA 1.495 1.8 0 CA-C-O 118.074 -0.965 . . . . 0.0 112.127 -177.664 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 27.0 m-85 . . . . . 0 N--CA 1.476 0.873 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' F' F ' 5' ' ' ARG . . . . . 0.92 HH12 HG11 ' E' ' 24' ' ' VAL . 6.3 ptm180 -164.45 146.94 8.81 Favored 'General case' 0 N--CA 1.473 0.701 0 C-N-CA 120.291 -0.564 . . . . 0.0 112.063 -179.894 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 20.9 p80 -152.0 106.56 3.21 Favored 'General case' 0 N--CA 1.477 0.883 0 CA-C-O 120.793 0.33 . . . . 0.0 110.605 178.039 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' F' F ' 7' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -77.98 152.43 33.12 Favored 'General case' 0 N--CA 1.474 0.748 0 CA-C-O 121.573 0.701 . . . . 0.0 110.004 179.047 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' F' F ' 8' ' ' SER . . . . . . . . . . . . . 93.5 p -156.24 173.76 16.39 Favored 'General case' 0 N--CA 1.487 1.376 0 CA-C-N 114.933 -1.031 . . . . 0.0 111.488 -178.88 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' F' F ' 9' ' ' GLY . . . . . 0.437 ' O ' ' ND2' ' B' ' 27' ' ' ASN . . . 124.59 79.49 0.39 Allowed Glycine 0 N--CA 1.481 1.66 0 N-CA-C 111.424 -0.67 . . . . 0.0 111.424 179.669 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 18.3 p90 -53.89 158.11 2.16 Favored 'General case' 0 N--CA 1.479 0.996 0 C-N-CA 122.418 0.287 . . . . 0.0 111.136 179.252 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 65.3 mt-10 -120.23 126.97 51.95 Favored 'General case' 0 N--CA 1.489 1.483 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 178.506 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 39.3 t -103.44 136.87 34.24 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.687 0 N-CA-C 109.022 -0.733 . . . . 0.0 109.022 178.188 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 84.2 m-70 -138.52 138.52 38.11 Favored 'General case' 0 N--CA 1.481 1.075 0 C-N-CA 122.417 0.287 . . . . 0.0 110.591 179.757 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 51.6 t-80 -167.89 97.31 0.45 Allowed 'General case' 0 N--CA 1.483 1.191 0 C-N-CA 122.249 0.219 . . . . 0.0 110.626 179.198 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 55.3 mt-30 -100.29 117.24 34.09 Favored 'General case' 0 CA--C 1.513 -0.448 0 N-CA-C 108.399 -0.963 . . . . 0.0 108.399 -179.56 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 64.7 tttp -104.76 105.7 15.88 Favored 'General case' 0 N--CA 1.481 1.121 0 N-CA-C 108.558 -0.905 . . . . 0.0 108.558 178.104 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 9.9 mp -122.06 164.05 18.36 Favored 'General case' 0 N--CA 1.488 1.436 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 -179.398 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 55.2 t -142.39 112.75 2.76 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.911 0 N-CA-C 108.008 -1.108 . . . . 0.0 108.008 177.102 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 60.7 m-85 -102.09 163.68 12.11 Favored 'General case' 0 C--N 1.359 1.007 0 O-C-N 124.028 0.83 . . . . 0.0 109.107 177.779 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' F' F ' 20' ' ' PHE . . . . . 0.409 ' O ' ' O ' ' I' ' 21' ' ' ALA . 72.8 t80 -166.54 -84.12 0.02 OUTLIER 'General case' 0 C--O 1.215 -0.73 0 N-CA-C 109.399 -0.593 . . . . 0.0 109.399 177.173 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' F' F ' 21' ' ' ALA . . . . . 0.44 ' O ' ' O ' ' C' ' 20' ' ' PHE . . . -85.83 91.7 8.41 Favored 'General case' 0 N--CA 1.478 0.931 0 N-CA-C 108.302 -0.999 . . . . 0.0 108.302 178.547 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 11.1 mm-40 -71.14 -172.79 0.75 Allowed 'General case' 0 N--CA 1.481 1.124 0 C-N-CA 119.668 -0.813 . . . . 0.0 111.25 -179.842 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 8.5 m-20 -71.46 153.98 41.85 Favored 'General case' 0 N--CA 1.473 0.722 0 CA-C-O 121.847 0.832 . . . . 0.0 112.597 -177.334 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' F' F ' 24' ' ' VAL . . . . . 0.916 HG11 HH12 ' D' ' 5' ' ' ARG . 54.9 t -155.25 91.97 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.473 0.702 0 CA-C-N 114.65 -1.159 . . . . 0.0 108.261 177.302 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -119.51 61.33 0.49 Allowed Glycine 0 N--CA 1.482 1.703 0 N-CA-C 110.929 -0.868 . . . . 0.0 110.929 178.792 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 15.9 m 45.91 -143.18 0.28 Allowed 'General case' 0 N--CA 1.484 1.247 0 CA-C-N 118.206 1.003 . . . . 0.0 110.688 -179.973 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' F' F ' 27' ' ' ASN . . . . . 0.446 ' ND2' ' O ' ' G' ' 9' ' ' GLY . 8.5 m120 -79.86 92.5 5.5 Favored 'General case' 0 N--CA 1.472 0.637 0 N-CA-C 108.818 -0.808 . . . . 0.0 108.818 177.413 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 96.4 mttt -66.1 146.4 54.7 Favored 'General case' 0 CA--C 1.542 0.639 0 CA-C-O 121.229 0.538 . . . . 0.0 110.626 -178.582 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -71.26 -129.45 0.08 OUTLIER Glycine 0 CA--C 1.538 1.529 0 N-CA-C 109.874 -1.29 . . . . 0.0 109.874 178.578 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.97 131.31 35.25 Favored 'General case' 0 N--CA 1.436 -1.137 0 CA-C-N 117.528 0.664 . . . . 0.0 109.484 178.754 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 18.4 tt -165.22 173.65 0.17 Allowed 'Isoleucine or valine' 0 C--O 1.218 -0.553 0 N-CA-C 108.571 -0.9 . . . . 0.0 108.571 -178.756 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 25.9 mt -141.48 145.59 24.43 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.524 0 N-CA-C 107.016 -1.476 . . . . 0.0 107.016 179.665 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -51.78 167.9 0.69 Allowed Glycine 0 N--CA 1.476 1.354 0 C-N-CA 121.316 -0.469 . . . . 0.0 112.567 -179.38 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 2.6 pp -65.64 157.29 30.36 Favored 'General case' 0 N--CA 1.466 0.351 0 CA-C-O 120.834 0.35 . . . . 0.0 110.061 179.772 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 22.9 ttt -142.29 154.02 44.37 Favored 'General case' 0 N--CA 1.476 0.858 0 N-CA-C 109.111 -0.7 . . . . 0.0 109.111 -179.984 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 40.6 t -149.19 138.68 15.77 Favored 'Isoleucine or valine' 0 C--O 1.237 0.399 0 N-CA-C 107.559 -1.274 . . . . 0.0 107.559 -179.625 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 60.97 67.83 1.95 Allowed Glycine 0 C--N 1.321 -0.251 0 N-CA-C 108.721 -1.751 . . . . 0.0 108.721 -179.974 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -82.69 130.86 9.96 Favored Glycine 0 C--N 1.334 0.462 0 N-CA-C 111.335 -0.706 . . . . 0.0 111.335 -178.38 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 1.9 t -147.3 113.57 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.5 2.052 0 N-CA-C 108.494 -0.928 . . . . 0.0 108.494 179.324 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 19.4 t . . . . . 0 N--CA 1.492 1.653 0 CA-C-O 118.215 -0.898 . . . . 0.0 112.5 -177.474 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 31.9 m-85 . . . . . 0 N--CA 1.48 1.046 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' G' G ' 5' ' ' ARG . . . . . 0.9 HH12 HG11 ' I' ' 24' ' ' VAL . 6.1 ptm180 -165.07 148.81 8.58 Favored 'General case' 0 N--CA 1.47 0.555 0 C-N-CA 120.446 -0.502 . . . . 0.0 111.933 -179.907 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' G' G ' 6' ' ' HIS . . . . . 0.404 ' O ' ' ND1' ' G' ' 6' ' ' HIS . 21.8 p80 -153.81 106.71 2.89 Favored 'General case' 0 N--CA 1.474 0.767 0 CA-C-O 121.06 0.457 . . . . 0.0 110.719 178.224 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -77.39 152.11 34.52 Favored 'General case' 0 N--CA 1.474 0.727 0 CA-C-O 121.084 0.468 . . . . 0.0 110.276 179.008 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' G' G ' 8' ' ' SER . . . . . . . . . . . . . 99.2 p -155.7 174.5 15.2 Favored 'General case' 0 N--CA 1.474 0.75 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.846 179.996 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' G' G ' 9' ' ' GLY . . . . . 0.446 ' O ' ' ND2' ' F' ' 27' ' ' ASN . . . 124.61 78.87 0.37 Allowed Glycine 0 N--CA 1.478 1.466 0 N-CA-C 111.202 -0.759 . . . . 0.0 111.202 179.582 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 24.0 p90 -54.23 157.47 2.67 Favored 'General case' 0 N--CA 1.476 0.827 0 O-C-N 122.802 -0.234 . . . . 0.0 111.107 179.358 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 64.6 mt-10 -120.15 126.93 51.92 Favored 'General case' 0 N--CA 1.487 1.376 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 179.257 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 29.9 t -103.79 136.12 38.28 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.021 0 N-CA-C 109.158 -0.682 . . . . 0.0 109.158 178.658 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 86.2 m-70 -137.92 138.4 38.96 Favored 'General case' 0 N--CA 1.481 1.092 0 C-N-CA 122.827 0.451 . . . . 0.0 110.634 179.926 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 51.7 t-80 -168.26 97.4 0.42 Allowed 'General case' 0 N--CA 1.481 1.125 0 N-CA-C 110.355 -0.239 . . . . 0.0 110.355 178.727 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 55.3 mt-30 -100.4 117.53 34.77 Favored 'General case' 0 CA--C 1.512 -0.5 0 N-CA-C 108.476 -0.935 . . . . 0.0 108.476 -179.652 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 64.6 tttp -104.97 105.67 15.82 Favored 'General case' 0 N--CA 1.482 1.142 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 178.323 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 9.8 mp -121.71 161.97 21.62 Favored 'General case' 0 N--CA 1.486 1.345 0 C-N-CA 123.478 0.711 . . . . 0.0 109.413 -179.204 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 43.6 t -142.59 112.78 2.59 Favored 'Isoleucine or valine' 0 C--O 1.246 0.891 0 N-CA-C 108.269 -1.012 . . . . 0.0 108.269 176.734 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 61.4 m-85 -101.73 161.01 13.97 Favored 'General case' 0 C--N 1.371 1.539 0 O-C-N 125.566 1.791 . . . . 0.0 109.959 177.307 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 68.7 t80 -167.95 -82.5 0.02 OUTLIER 'General case' 0 CA--C 1.539 0.527 0 CA-C-N 115.7 -0.682 . . . . 0.0 109.36 177.389 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' G' G ' 21' ' ' ALA . . . . . 0.403 ' O ' ' O ' ' D' ' 20' ' ' PHE . . . -84.96 90.69 7.88 Favored 'General case' 0 N--CA 1.474 0.754 0 N-CA-C 108.302 -0.999 . . . . 0.0 108.302 179.184 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 11.6 mm-40 -70.36 -175.09 0.94 Allowed 'General case' 0 N--CA 1.483 1.177 0 C-N-CA 119.691 -0.803 . . . . 0.0 111.167 -179.935 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 8.9 m-20 -70.97 154.47 41.79 Favored 'General case' 0 N--CA 1.475 0.82 0 CA-C-O 121.3 0.571 . . . . 0.0 112.169 -177.218 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' G' G ' 24' ' ' VAL . . . . . 0.895 HG11 HH12 ' H' ' 5' ' ' ARG . 65.2 t -156.63 92.8 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.471 0.597 0 CA-C-N 114.951 -1.022 . . . . 0.0 108.323 177.085 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -119.34 61.38 0.48 Allowed Glycine 0 N--CA 1.477 1.43 0 N-CA-C 110.93 -0.868 . . . . 0.0 110.93 179.107 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 17.2 m 47.0 -139.02 0.62 Allowed 'General case' 0 N--CA 1.484 1.233 0 CA-C-N 118.23 1.015 . . . . 0.0 110.815 179.691 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 8.8 m120 -84.31 91.72 7.83 Favored 'General case' 0 N--CA 1.473 0.697 0 N-CA-C 108.087 -1.079 . . . . 0.0 108.087 177.511 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 96.5 mttt -65.3 146.61 54.7 Favored 'General case' 0 CA--C 1.539 0.539 0 CA-C-O 121.249 0.547 . . . . 0.0 110.576 -178.176 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -72.22 -127.84 0.09 OUTLIER Glycine 0 CA--C 1.526 0.779 0 N-CA-C 109.417 -1.473 . . . . 0.0 109.417 178.541 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.95 128.4 34.03 Favored 'General case' 0 CA--C 1.528 0.104 0 C-N-CA 122.66 0.384 . . . . 0.0 110.179 179.718 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 18.8 tt -164.41 172.88 0.21 Allowed 'Isoleucine or valine' 0 CA--C 1.506 -0.736 0 N-CA-C 109.53 -0.544 . . . . 0.0 109.53 -178.836 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 32.1 mt -139.42 146.9 24.87 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.092 0 N-CA-C 107.117 -1.438 . . . . 0.0 107.117 177.975 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -52.05 167.72 0.79 Allowed Glycine 0 N--CA 1.474 1.188 0 C-N-CA 121.489 -0.386 . . . . 0.0 112.187 -179.463 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 2.6 pp -65.87 157.61 30.1 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-O 120.793 0.33 . . . . 0.0 110.208 -179.935 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 22.8 ttt -142.74 154.54 44.37 Favored 'General case' 0 N--CA 1.472 0.669 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 -179.934 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 39.0 t -149.28 139.13 16.1 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.258 0 N-CA-C 107.712 -1.218 . . . . 0.0 107.712 -179.709 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 60.32 68.26 1.76 Allowed Glycine 0 C--N 1.319 -0.375 0 N-CA-C 108.956 -1.658 . . . . 0.0 108.956 179.963 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . -83.27 131.0 10.06 Favored Glycine 0 N--CA 1.465 0.599 0 N-CA-C 111.335 -0.706 . . . . 0.0 111.335 -178.703 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 2.1 t -146.97 113.2 0.96 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.91 0 N-CA-C 108.515 -0.92 . . . . 0.0 108.515 179.604 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 21.4 t . . . . . 0 N--CA 1.492 1.648 0 CA-C-O 118.205 -0.902 . . . . 0.0 111.958 -178.304 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 32.4 m-85 . . . . . 0 N--CA 1.48 1.068 0 N-CA-C 108.486 -0.931 . . . . 0.0 108.486 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' H' H ' 5' ' ' ARG . . . . . 0.895 HH12 HG11 ' G' ' 24' ' ' VAL . 6.1 ptm180 -165.33 148.78 8.23 Favored 'General case' 0 N--CA 1.47 0.558 0 C-N-CA 120.533 -0.467 . . . . 0.0 112.031 -179.968 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' H' H ' 6' ' ' HIS . . . . . 0.403 ' O ' ' ND1' ' H' ' 6' ' ' HIS . 21.7 p80 -153.89 106.76 2.88 Favored 'General case' 0 N--CA 1.475 0.79 0 CA-C-O 120.993 0.425 . . . . 0.0 110.645 178.204 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -77.58 151.75 34.28 Favored 'General case' 0 N--CA 1.474 0.745 0 CA-C-O 121.039 0.447 . . . . 0.0 110.261 179.016 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' H' H ' 8' ' ' SER . . . . . . . . . . . . . 99.3 p -155.22 174.89 14.57 Favored 'General case' 0 N--CA 1.475 0.808 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.839 179.99 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' H' H ' 9' ' ' GLY . . . . . 0.449 ' O ' ' ND2' ' D' ' 27' ' ' ASN . . . 124.15 78.89 0.39 Allowed Glycine 0 N--CA 1.478 1.472 0 N-CA-C 111.305 -0.718 . . . . 0.0 111.305 179.714 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 24.2 p90 -54.36 157.73 2.65 Favored 'General case' 0 N--CA 1.475 0.789 0 O-C-N 122.747 -0.267 . . . . 0.0 111.137 179.29 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 64.8 mt-10 -120.31 126.93 51.77 Favored 'General case' 0 N--CA 1.485 1.3 0 C-N-CA 122.694 0.397 . . . . 0.0 109.931 179.347 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 28.1 t -103.97 135.94 39.36 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.998 0 N-CA-C 109.153 -0.684 . . . . 0.0 109.153 178.683 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 86.4 m-70 -137.76 138.65 39.47 Favored 'General case' 0 N--CA 1.481 1.107 0 C-N-CA 122.981 0.512 . . . . 0.0 110.584 -179.949 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 51.7 t-80 -168.56 97.48 0.4 Allowed 'General case' 0 N--CA 1.482 1.127 0 N-CA-C 110.31 -0.256 . . . . 0.0 110.31 178.66 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 55.5 mt-30 -100.56 116.97 33.73 Favored 'General case' 0 CA--C 1.512 -0.49 0 N-CA-C 108.72 -0.845 . . . . 0.0 108.72 -179.619 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 64.5 tttp -104.35 105.72 15.96 Favored 'General case' 0 N--CA 1.482 1.136 0 N-CA-C 108.62 -0.882 . . . . 0.0 108.62 178.282 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 9.8 mp -121.91 162.29 21.29 Favored 'General case' 0 N--CA 1.487 1.386 0 C-N-CA 123.494 0.718 . . . . 0.0 109.224 -179.262 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 45.8 t -142.35 111.96 2.55 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.601 0 N-CA-C 108.372 -0.974 . . . . 0.0 108.372 176.921 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 61.1 m-85 -100.6 161.37 13.65 Favored 'General case' 0 C--N 1.364 1.228 0 O-C-N 124.724 1.265 . . . . 0.0 109.944 177.404 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 67.2 t80 -167.26 -83.15 0.02 OUTLIER 'General case' 0 N--CA 1.469 0.48 0 CA-C-N 115.696 -0.684 . . . . 0.0 109.572 177.214 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' H' H ' 21' ' ' ALA . . . . . 0.431 ' O ' ' O ' ' E' ' 20' ' ' PHE . . . -84.91 90.33 7.78 Favored 'General case' 0 N--CA 1.473 0.715 0 N-CA-C 108.406 -0.961 . . . . 0.0 108.406 179.22 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 11.7 mm-40 -69.76 -175.02 0.81 Allowed 'General case' 0 N--CA 1.483 1.176 0 C-N-CA 119.694 -0.803 . . . . 0.0 111.171 -179.872 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' H' H ' 23' ' ' ASP . . . . . 0.463 ' HB3' ' HZ1' ' H' ' 28' ' ' LYS . 8.8 m-20 -71.2 154.36 41.74 Favored 'General case' 0 N--CA 1.473 0.691 0 CA-C-O 121.333 0.587 . . . . 0.0 112.245 -177.093 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' H' H ' 24' ' ' VAL . . . . . 0.919 HG11 HH12 ' I' ' 5' ' ' ARG . 65.7 t -156.36 92.8 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.471 0.619 0 CA-C-N 114.943 -1.026 . . . . 0.0 108.407 177.095 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . -119.45 61.46 0.49 Allowed Glycine 0 N--CA 1.48 1.615 0 N-CA-C 110.961 -0.856 . . . . 0.0 110.961 179.226 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 17.2 m 46.82 -138.83 0.61 Allowed 'General case' 0 N--CA 1.485 1.296 0 CA-C-N 118.082 0.941 . . . . 0.0 110.832 -179.979 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 8.7 m120 -84.26 91.9 7.85 Favored 'General case' 0 N--CA 1.473 0.691 0 N-CA-C 108.027 -1.101 . . . . 0.0 108.027 177.417 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' H' H ' 28' ' ' LYS . . . . . 0.463 ' HZ1' ' HB3' ' H' ' 23' ' ' ASP . 96.4 mttt -65.47 146.75 54.48 Favored 'General case' 0 CA--C 1.539 0.549 0 CA-C-O 121.373 0.606 . . . . 0.0 110.487 -178.212 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -72.16 -127.87 0.09 OUTLIER Glycine 0 CA--C 1.528 0.856 0 N-CA-C 109.554 -1.419 . . . . 0.0 109.554 178.542 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.91 128.8 34.43 Favored 'General case' 0 C--O 1.231 0.086 0 N-CA-C 110.05 -0.352 . . . . 0.0 110.05 179.591 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 18.9 tt -164.73 172.57 0.21 Allowed 'Isoleucine or valine' 0 CA--C 1.505 -0.778 0 N-CA-C 109.578 -0.527 . . . . 0.0 109.578 -178.719 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 31.9 mt -139.34 147.01 24.78 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.038 0 N-CA-C 107.132 -1.433 . . . . 0.0 107.132 177.974 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -52.25 167.59 0.87 Allowed Glycine 0 N--CA 1.472 1.088 0 C-N-CA 121.505 -0.378 . . . . 0.0 112.267 -179.454 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 2.6 pp -65.5 157.84 28.52 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-O 120.937 0.399 . . . . 0.0 110.123 -179.95 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 22.8 ttt -142.97 154.48 44.08 Favored 'General case' 0 N--CA 1.473 0.712 0 N-CA-C 109.225 -0.657 . . . . 0.0 109.225 -179.859 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 39.2 t -149.54 139.11 15.82 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.216 0 N-CA-C 107.566 -1.272 . . . . 0.0 107.566 -179.578 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 60.19 67.88 1.94 Allowed Glycine 0 C--N 1.32 -0.335 0 N-CA-C 109.093 -1.603 . . . . 0.0 109.093 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . -83.02 131.17 10.17 Favored Glycine 0 N--CA 1.464 0.544 0 N-CA-C 111.45 -0.66 . . . . 0.0 111.45 -178.765 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 2.1 t -147.04 113.36 0.96 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.927 0 N-CA-C 108.324 -0.991 . . . . 0.0 108.324 179.539 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 21.7 t . . . . . 0 N--CA 1.491 1.589 0 CA-C-O 118.298 -0.858 . . . . 0.0 111.574 -178.358 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 32.8 m-85 . . . . . 0 N--CA 1.48 1.041 0 N-CA-C 108.46 -0.941 . . . . 0.0 108.46 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' I' I ' 5' ' ' ARG . . . . . 0.919 HH12 HG11 ' H' ' 24' ' ' VAL . 6.1 ptm180 -165.24 148.48 8.23 Favored 'General case' 0 N--CA 1.47 0.545 0 C-N-CA 120.567 -0.453 . . . . 0.0 112.017 -179.881 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' I' I ' 6' ' ' HIS . . . . . 0.401 ' ND1' ' O ' ' I' ' 6' ' ' HIS . 21.6 p80 -153.66 106.83 2.94 Favored 'General case' 0 N--CA 1.475 0.793 0 CA-C-O 121.008 0.432 . . . . 0.0 110.61 178.198 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -77.59 151.83 34.23 Favored 'General case' 0 N--CA 1.474 0.775 0 CA-C-O 121.072 0.463 . . . . 0.0 110.249 178.958 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' I' I ' 8' ' ' SER . . . . . . . . . . . . . 98.2 p -155.23 174.88 14.58 Favored 'General case' 0 N--CA 1.476 0.849 0 CA-C-N 115.945 -0.57 . . . . 0.0 110.854 179.915 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' I' I ' 9' ' ' GLY . . . . . 0.436 ' O ' ' ND2' ' E' ' 27' ' ' ASN . . . 124.23 78.92 0.39 Allowed Glycine 0 N--CA 1.479 1.56 0 N-CA-C 111.256 -0.738 . . . . 0.0 111.256 179.663 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 24.0 p90 -54.58 157.63 2.86 Favored 'General case' 0 N--CA 1.477 0.891 0 O-C-N 122.803 -0.234 . . . . 0.0 111.045 179.308 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 64.5 mt-10 -120.23 126.92 51.81 Favored 'General case' 0 N--CA 1.484 1.266 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 179.391 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 27.2 t -103.9 135.86 39.66 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.937 0 N-CA-C 109.16 -0.681 . . . . 0.0 109.16 178.679 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 86.2 m-70 -137.76 138.53 39.37 Favored 'General case' 0 N--CA 1.482 1.15 0 C-N-CA 122.966 0.506 . . . . 0.0 110.579 -179.943 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 51.3 t-80 -168.47 97.27 0.4 Allowed 'General case' 0 N--CA 1.482 1.136 0 N-CA-C 110.278 -0.267 . . . . 0.0 110.278 178.736 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 55.8 mt-30 -100.38 116.93 33.5 Favored 'General case' 0 C--N 1.326 -0.436 0 N-CA-C 108.611 -0.885 . . . . 0.0 108.611 -179.585 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 64.6 tttp -104.35 105.7 15.92 Favored 'General case' 0 N--CA 1.482 1.143 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 178.236 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 9.8 mp -121.88 162.35 21.14 Favored 'General case' 0 N--CA 1.487 1.416 0 C-N-CA 123.475 0.71 . . . . 0.0 109.21 -179.244 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 45.7 t -142.35 111.99 2.57 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.579 0 N-CA-C 108.32 -0.993 . . . . 0.0 108.32 176.937 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 60.8 m-85 -100.75 161.41 13.62 Favored 'General case' 0 C--N 1.364 1.208 0 O-C-N 124.79 1.306 . . . . 0.0 109.949 177.434 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 66.9 t80 -167.28 -83.39 0.02 OUTLIER 'General case' 0 N--CA 1.468 0.446 0 CA-C-N 115.629 -0.714 . . . . 0.0 109.649 177.267 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' I' I ' 21' ' ' ALA . . . . . 0.409 ' O ' ' O ' ' F' ' 20' ' ' PHE . . . -84.7 90.62 7.75 Favored 'General case' 0 N--CA 1.471 0.62 0 N-CA-C 108.274 -1.01 . . . . 0.0 108.274 179.243 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 11.7 mm-40 -70.16 -175.01 0.88 Allowed 'General case' 0 N--CA 1.482 1.17 0 C-N-CA 119.725 -0.79 . . . . 0.0 111.114 -179.836 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 8.8 m-20 -71.21 154.17 41.89 Favored 'General case' 0 N--CA 1.473 0.701 0 CA-C-O 121.296 0.57 . . . . 0.0 112.292 -177.067 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' I' I ' 24' ' ' VAL . . . . . 0.9 HG11 HH12 ' G' ' 5' ' ' ARG . 65.6 t -156.22 92.75 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.47 0.528 0 CA-C-N 115.023 -0.99 . . . . 0.0 108.396 177.08 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . -119.17 61.36 0.48 Allowed Glycine 0 N--CA 1.48 1.628 0 N-CA-C 110.981 -0.848 . . . . 0.0 110.981 179.148 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 17.4 m 46.81 -138.84 0.61 Allowed 'General case' 0 N--CA 1.486 1.36 0 CA-C-N 118.214 1.007 . . . . 0.0 110.707 179.948 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 8.7 m120 -84.29 91.97 7.88 Favored 'General case' 0 N--CA 1.472 0.665 0 N-CA-C 108.089 -1.078 . . . . 0.0 108.089 177.413 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 96.4 mttt -65.52 146.58 54.68 Favored 'General case' 0 CA--C 1.539 0.555 0 CA-C-O 121.378 0.608 . . . . 0.0 110.512 -178.195 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -71.92 -128.13 0.09 OUTLIER Glycine 0 CA--C 1.527 0.835 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 178.49 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.87 128.47 34.07 Favored 'General case' 0 CA--C 1.529 0.155 0 C-N-CA 122.709 0.404 . . . . 0.0 109.939 179.698 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 18.8 tt -164.38 172.64 0.22 Allowed 'Isoleucine or valine' 0 CA--C 1.506 -0.716 0 N-CA-C 109.553 -0.536 . . . . 0.0 109.553 -178.695 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 31.7 mt -139.31 146.99 24.85 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.101 0 N-CA-C 107.214 -1.402 . . . . 0.0 107.214 177.896 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -52.25 167.62 0.87 Allowed Glycine 0 N--CA 1.473 1.163 0 C-N-CA 121.528 -0.367 . . . . 0.0 112.234 -179.444 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 2.6 pp -65.59 157.59 29.41 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-O 120.892 0.377 . . . . 0.0 110.086 -179.956 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 22.9 ttt -142.73 154.17 44.03 Favored 'General case' 0 N--CA 1.472 0.655 0 N-CA-C 109.172 -0.677 . . . . 0.0 109.172 -179.827 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 39.6 t -149.26 139.27 16.23 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.252 0 N-CA-C 107.551 -1.277 . . . . 0.0 107.551 -179.719 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 60.09 67.93 1.92 Allowed Glycine 0 N--CA 1.461 0.344 0 N-CA-C 109.135 -1.586 . . . . 0.0 109.135 -179.921 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . -82.99 131.22 10.21 Favored Glycine 0 N--CA 1.464 0.564 0 N-CA-C 111.359 -0.697 . . . . 0.0 111.359 -178.702 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 2.1 t -147.16 113.39 0.95 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.908 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 179.527 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 21.6 t . . . . . 0 N--CA 1.489 1.521 0 CA-C-O 118.192 -0.909 . . . . 0.0 111.766 -178.315 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 29.8 m-85 . . . . . 0 N--CA 1.472 0.659 0 N-CA-C 109.426 -0.583 . . . . 0.0 109.426 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 77.1 mtt85 -139.85 145.58 38.26 Favored 'General case' 0 N--CA 1.478 0.925 0 CA-C-N 115.886 -0.597 . . . . 0.0 109.885 179.776 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 57.6 t-80 -150.51 116.96 5.73 Favored 'General case' 0 N--CA 1.476 0.863 0 N-CA-C 109.631 -0.507 . . . . 0.0 109.631 179.164 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 9.9 m-20 -66.94 144.6 56.13 Favored 'General case' 0 N--CA 1.474 0.75 0 C-N-CA 122.897 0.479 . . . . 0.0 111.83 -179.809 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 1.7 t -164.3 -176.89 4.64 Favored 'General case' 0 N--CA 1.471 0.597 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 177.986 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 85.54 70.46 1.33 Allowed Glycine 0 CA--C 1.53 1.029 0 CA-C-N 115.837 -0.62 . . . . 0.0 112.087 178.725 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 40.3 p90 -73.01 122.16 21.28 Favored 'General case' 0 N--CA 1.477 0.888 0 CA-C-N 117.255 0.527 . . . . 0.0 110.892 179.976 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 17.7 pt-20 -82.76 151.82 25.99 Favored 'General case' 0 N--CA 1.477 0.903 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 178.853 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 13.7 t -144.68 117.72 2.73 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.877 0 CA-C-O 121.578 0.704 . . . . 0.0 109.365 178.302 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 73.5 m80 -95.79 164.87 12.57 Favored 'General case' 0 C--N 1.358 0.941 0 CA-C-N 114.641 -1.163 . . . . 0.0 109.29 177.996 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 14' ' ' HIS . . . . . 0.449 ' NE2' ' NZ ' ' A' ' 16' ' ' LYS . 17.2 t60 -164.74 99.27 0.78 Allowed 'General case' 0 N--CA 1.476 0.855 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.12 179.223 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -91.66 111.58 23.15 Favored 'General case' 0 CA--C 1.517 -0.326 0 N-CA-C 108.386 -0.968 . . . . 0.0 108.386 179.668 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 16' ' ' LYS . . . . . 0.449 ' NZ ' ' NE2' ' A' ' 14' ' ' HIS . 8.5 ttmm -94.37 171.38 8.85 Favored 'General case' 0 N--CA 1.483 1.206 0 N-CA-C 108.893 -0.781 . . . . 0.0 108.893 179.926 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 17' ' ' LEU . . . . . 0.422 ' N ' HD12 ' A' ' 17' ' ' LEU . 9.6 mp -55.09 157.9 3.16 Favored 'General case' 0 N--CA 1.476 0.837 0 N-CA-C 110.002 -0.37 . . . . 0.0 110.002 -178.408 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 71.2 t -140.81 150.22 20.69 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.714 0 C-N-CA 123.206 0.602 . . . . 0.0 109.76 -177.798 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.69 ' HB3' ' O ' ' D' ' 18' ' ' VAL . 43.9 p90 -40.44 162.34 0.01 OUTLIER 'General case' 0 CA--C 1.542 0.666 0 N-CA-C 120.228 3.418 . . . . 0.0 120.228 -178.729 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.409 ' O ' ' CD2' ' A' ' 20' ' ' PHE . 20.9 p90 -119.75 69.82 0.85 Allowed 'General case' 0 CA--C 1.56 1.352 0 CA-C-N 112.033 -2.349 . . . . 0.0 109.449 173.552 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 21' ' ' ALA . . . . . 0.411 ' H ' ' HD1' ' A' ' 19' ' ' PHE . . . -62.97 95.04 0.07 Allowed 'General case' 0 C--N 1.325 -0.493 0 N-CA-C 108.38 -0.97 . . . . 0.0 108.38 176.767 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 77.5 mt-10 -49.61 123.73 8.3 Favored 'General case' 0 N--CA 1.475 0.813 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.517 -179.954 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 16.6 t70 -76.73 169.37 18.43 Favored 'General case' 0 N--CA 1.471 0.624 0 CA-C-O 120.983 0.42 . . . . 0.0 110.648 -178.901 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.548 HG13 ' H ' ' A' ' 25' ' ' GLY . 0.7 OUTLIER 178.28 -79.05 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.542 0.636 0 N-CA-C 107.298 -1.371 . . . . 0.0 107.298 -179.865 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.548 ' H ' HG13 ' A' ' 24' ' ' VAL . . . -34.03 84.4 0.0 OUTLIER Glycine 0 N--CA 1.473 1.166 0 C-N-CA 124.425 1.012 . . . . 0.0 113.461 178.546 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 26' ' ' SER . . . . . 0.438 ' N ' ' O ' ' A' ' 24' ' ' VAL . 87.9 p -41.25 -105.55 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.65 0 N-CA-C 113.676 0.991 . . . . 0.0 113.676 -177.401 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 16.8 p-10 -59.97 112.47 1.88 Allowed 'General case' 0 N--CA 1.469 0.488 0 CA-C-N 118.833 0.742 . . . . 0.0 110.417 -178.637 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 41.8 mttm -96.83 164.57 12.5 Favored 'General case' 0 N--CA 1.475 0.801 0 C-N-CA 123.31 0.644 . . . . 0.0 110.008 -179.564 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -72.95 -141.45 0.45 Allowed Glycine 0 N--CA 1.461 0.342 0 N-CA-C 107.876 -2.089 . . . . 0.0 107.876 176.548 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 30' ' ' ALA . . . . . 0.458 ' O ' ' O ' ' D' ' 31' ' ' ILE . . . -90.42 123.12 33.88 Favored 'General case' 0 C--O 1.208 -1.084 0 N-CA-C 106.836 -1.542 . . . . 0.0 106.836 176.524 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 16.7 tt -148.28 155.6 9.41 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.884 0 N-CA-C 107.996 -1.113 . . . . 0.0 107.996 179.192 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 20.5 pt -150.88 138.89 14.24 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 CA-C-N 119.042 0.837 . . . . 0.0 109.394 178.56 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -56.68 154.3 17.7 Favored Glycine 0 CA--C 1.533 1.167 0 CA-C-N 116.605 -0.27 . . . . 0.0 112.591 -178.537 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 2.5 pp -76.29 158.92 31.06 Favored 'General case' 0 N--CA 1.472 0.673 0 N-CA-C 109.68 -0.489 . . . . 0.0 109.68 179.242 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 11.9 ttp -102.84 151.59 22.25 Favored 'General case' 0 N--CA 1.481 1.08 0 N-CA-C 109.383 -0.599 . . . . 0.0 109.383 179.711 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 7.3 p -168.62 159.82 0.71 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.553 0 N-CA-C 108.044 -1.095 . . . . 0.0 108.044 179.772 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.41 69.86 1.14 Allowed Glycine 0 C--N 1.31 -0.862 0 N-CA-C 111.665 -0.574 . . . . 0.0 111.665 178.836 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 152.04 -177.49 29.84 Favored Glycine 0 N--CA 1.468 0.828 0 N-CA-C 110.214 -1.154 . . . . 0.0 110.214 179.659 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 4.6 t -124.99 139.14 51.99 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.758 0 N-CA-C 107.206 -1.405 . . . . 0.0 107.206 -179.502 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 72.7 t . . . . . 0 N--CA 1.481 1.081 0 CA-C-O 117.776 -1.107 . . . . 0.0 109.64 -177.501 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 30.1 m-85 . . . . . 0 N--CA 1.473 0.72 0 N-CA-C 109.531 -0.544 . . . . 0.0 109.531 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 77.1 mtt85 -140.05 145.61 37.93 Favored 'General case' 0 N--CA 1.477 0.92 0 CA-C-N 115.941 -0.572 . . . . 0.0 109.991 179.724 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 58.1 t-80 -150.43 117.29 5.87 Favored 'General case' 0 N--CA 1.475 0.814 0 N-CA-C 109.644 -0.502 . . . . 0.0 109.644 179.153 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 7' ' ' ASP . . . . . . . . . . . . . 9.8 m-20 -67.16 144.38 56.06 Favored 'General case' 0 N--CA 1.472 0.671 0 C-N-CA 122.863 0.465 . . . . 0.0 111.682 -179.713 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 8' ' ' SER . . . . . . . . . . . . . 2.2 t -163.96 -177.63 5.18 Favored 'General case' 0 N--CA 1.471 0.578 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 178.148 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 85.88 70.5 1.32 Allowed Glycine 0 CA--C 1.532 1.154 0 CA-C-N 115.916 -0.584 . . . . 0.0 112.158 178.775 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 40.1 p90 -72.81 121.99 20.83 Favored 'General case' 0 N--CA 1.478 0.931 0 CA-C-N 117.295 0.548 . . . . 0.0 110.87 179.833 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 17.7 pt-20 -82.67 151.92 26.06 Favored 'General case' 0 N--CA 1.479 0.986 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 178.828 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 13.1 t -144.75 117.81 2.71 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.842 0 CA-C-O 121.598 0.713 . . . . 0.0 109.318 178.362 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 73.5 m80 -96.02 164.66 12.61 Favored 'General case' 0 C--N 1.357 0.932 0 CA-C-N 114.616 -1.175 . . . . 0.0 109.333 177.919 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 14' ' ' HIS . . . . . 0.448 ' NE2' ' NZ ' ' B' ' 16' ' ' LYS . 17.2 t60 -164.59 99.25 0.8 Allowed 'General case' 0 N--CA 1.476 0.839 0 CA-C-N 116.471 -0.331 . . . . 0.0 110.113 179.224 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -91.44 111.54 23.08 Favored 'General case' 0 CA--C 1.515 -0.381 0 N-CA-C 108.441 -0.948 . . . . 0.0 108.441 179.585 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 16' ' ' LYS . . . . . 0.448 ' NZ ' ' NE2' ' B' ' 14' ' ' HIS . 8.5 ttmm -94.33 171.49 8.79 Favored 'General case' 0 N--CA 1.483 1.197 0 N-CA-C 108.899 -0.778 . . . . 0.0 108.899 179.995 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 17' ' ' LEU . . . . . 0.412 ' N ' HD12 ' B' ' 17' ' ' LEU . 9.7 mp -55.25 157.83 3.38 Favored 'General case' 0 N--CA 1.476 0.836 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 -178.41 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 71.3 t -140.87 150.46 20.49 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.763 0 C-N-CA 123.113 0.565 . . . . 0.0 109.652 -177.767 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 19' ' ' PHE . . . . . 0.704 ' HB3' ' O ' ' E' ' 18' ' ' VAL . 44.4 p90 -40.58 162.07 0.01 OUTLIER 'General case' 0 CA--C 1.543 0.7 0 N-CA-C 120.055 3.354 . . . . 0.0 120.055 -178.738 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 20' ' ' PHE . . . . . 0.418 ' CD2' ' O ' ' B' ' 20' ' ' PHE . 21.1 p90 -119.61 69.68 0.84 Allowed 'General case' 0 CA--C 1.561 1.371 0 CA-C-N 111.946 -2.388 . . . . 0.0 109.257 173.545 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 21' ' ' ALA . . . . . 0.42 ' H ' ' HD1' ' B' ' 19' ' ' PHE . . . -62.75 95.11 0.07 Allowed 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 108.409 -0.959 . . . . 0.0 108.409 176.759 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 77.2 mt-10 -49.62 123.73 8.3 Favored 'General case' 0 N--CA 1.476 0.849 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.421 -179.892 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 16.7 t70 -76.74 169.27 18.61 Favored 'General case' 0 N--CA 1.471 0.609 0 CA-C-O 121.007 0.432 . . . . 0.0 110.702 -179.044 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 24' ' ' VAL . . . . . 0.515 HG13 ' H ' ' B' ' 25' ' ' GLY . 0.7 OUTLIER 178.2 -79.11 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.545 0.755 0 N-CA-C 107.333 -1.358 . . . . 0.0 107.333 -179.608 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' B' B ' 25' ' ' GLY . . . . . 0.515 ' H ' HG13 ' B' ' 24' ' ' VAL . . . -34.1 84.12 0.0 OUTLIER Glycine 0 N--CA 1.48 1.633 0 C-N-CA 124.334 0.969 . . . . 0.0 113.258 178.7 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 26' ' ' SER . . . . . 0.453 ' N ' ' O ' ' B' ' 24' ' ' VAL . 88.0 p -41.02 -105.38 0.0 OUTLIER 'General case' 0 N--CA 1.475 0.817 0 N-CA-C 113.602 0.964 . . . . 0.0 113.602 -177.411 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 16.6 p-10 -60.02 112.27 1.81 Allowed 'General case' 0 N--CA 1.471 0.578 0 CA-C-N 118.83 0.741 . . . . 0.0 110.357 -178.631 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 41.6 mttm -96.53 164.43 12.62 Favored 'General case' 0 N--CA 1.474 0.773 0 C-N-CA 123.203 0.601 . . . . 0.0 110.195 -179.628 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -72.82 -141.03 0.42 Allowed Glycine 0 N--CA 1.461 0.365 0 N-CA-C 107.816 -2.114 . . . . 0.0 107.816 176.574 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 30' ' ' ALA . . . . . 0.491 ' O ' ' O ' ' E' ' 31' ' ' ILE . . . -91.05 123.4 34.48 Favored 'General case' 0 C--O 1.208 -1.128 0 N-CA-C 106.734 -1.58 . . . . 0.0 106.734 176.587 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 16.6 tt -148.35 155.6 9.33 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.829 0 N-CA-C 107.91 -1.144 . . . . 0.0 107.91 179.194 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 20.5 pt -150.79 138.92 14.37 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.469 0 CA-C-N 118.949 0.795 . . . . 0.0 109.246 178.664 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -56.81 154.29 18.32 Favored Glycine 0 CA--C 1.532 1.148 0 CA-C-N 116.598 -0.274 . . . . 0.0 112.63 -178.691 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 2.5 pp -76.18 158.81 31.3 Favored 'General case' 0 N--CA 1.472 0.635 0 C-N-CA 122.707 0.403 . . . . 0.0 109.971 179.161 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 11.8 ttp -102.73 151.21 22.66 Favored 'General case' 0 N--CA 1.481 1.078 0 N-CA-C 109.507 -0.553 . . . . 0.0 109.507 179.717 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 7.3 p -168.37 159.89 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.524 0 N-CA-C 108.035 -1.098 . . . . 0.0 108.035 179.826 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.42 69.6 1.22 Allowed Glycine 0 C--N 1.313 -0.746 0 N-CA-C 111.617 -0.593 . . . . 0.0 111.617 178.774 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 152.14 -177.75 29.77 Favored Glycine 0 N--CA 1.468 0.795 0 N-CA-C 110.217 -1.153 . . . . 0.0 110.217 179.696 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 4.4 t -124.69 139.05 52.05 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.717 0 N-CA-C 107.31 -1.367 . . . . 0.0 107.31 -179.515 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 74.2 t . . . . . 0 N--CA 1.481 1.115 0 CA-C-O 117.756 -1.116 . . . . 0.0 109.647 -177.522 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 29.9 m-85 . . . . . 0 N--CA 1.473 0.698 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 77.4 mtt85 -140.08 145.46 37.68 Favored 'General case' 0 N--CA 1.478 0.965 0 C-N-CA 122.999 0.52 . . . . 0.0 109.797 179.766 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 57.9 t-80 -150.37 116.94 5.78 Favored 'General case' 0 N--CA 1.476 0.864 0 N-CA-C 109.655 -0.498 . . . . 0.0 109.655 179.087 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' C' C ' 7' ' ' ASP . . . . . . . . . . . . . 9.9 m-20 -66.89 144.39 56.28 Favored 'General case' 0 N--CA 1.472 0.643 0 O-C-N 123.444 0.465 . . . . 0.0 111.777 -179.728 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' C' C ' 8' ' ' SER . . . . . . . . . . . . . 2.3 t -163.92 -177.68 5.22 Favored 'General case' 0 N--CA 1.471 0.589 0 N-CA-C 109.873 -0.417 . . . . 0.0 109.873 178.247 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 85.97 70.47 1.32 Allowed Glycine 0 CA--C 1.532 1.125 0 CA-C-N 115.904 -0.589 . . . . 0.0 112.165 178.736 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 40.4 p90 -72.92 122.17 21.22 Favored 'General case' 0 N--CA 1.477 0.882 0 CA-C-N 117.331 0.565 . . . . 0.0 110.882 179.886 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 17.7 pt-20 -82.8 151.9 25.9 Favored 'General case' 0 N--CA 1.478 0.962 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 178.859 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 13.0 t -144.69 117.87 2.78 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.889 0 CA-C-O 121.621 0.724 . . . . 0.0 109.361 178.343 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 73.6 m80 -96.07 164.76 12.56 Favored 'General case' 0 C--N 1.358 0.947 0 CA-C-N 114.623 -1.171 . . . . 0.0 109.263 177.96 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' C' C ' 14' ' ' HIS . . . . . 0.455 ' NE2' ' NZ ' ' C' ' 16' ' ' LYS . 17.1 t60 -164.68 99.38 0.79 Allowed 'General case' 0 N--CA 1.476 0.83 0 N-CA-C 110.038 -0.356 . . . . 0.0 110.038 179.221 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -91.74 111.72 23.36 Favored 'General case' 0 CA--C 1.516 -0.359 0 N-CA-C 108.381 -0.97 . . . . 0.0 108.381 179.574 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' C' C ' 16' ' ' LYS . . . . . 0.455 ' NZ ' ' NE2' ' C' ' 14' ' ' HIS . 8.5 ttmm -94.51 171.45 8.8 Favored 'General case' 0 N--CA 1.483 1.185 0 N-CA-C 108.831 -0.803 . . . . 0.0 108.831 -179.841 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' C' C ' 17' ' ' LEU . . . . . 0.413 HD12 ' N ' ' C' ' 17' ' ' LEU . 9.7 mp -55.11 157.75 3.25 Favored 'General case' 0 N--CA 1.475 0.809 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 -178.424 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 71.3 t -140.75 150.43 20.69 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 C-N-CA 123.188 0.595 . . . . 0.0 109.663 -177.769 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' C' C ' 19' ' ' PHE . . . . . 0.709 ' HB3' ' O ' ' F' ' 18' ' ' VAL . 44.5 p90 -40.67 162.2 0.01 OUTLIER 'General case' 0 CA--C 1.543 0.677 0 N-CA-C 120.081 3.363 . . . . 0.0 120.081 -178.675 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' C' C ' 20' ' ' PHE . . . . . 0.414 ' CD2' ' O ' ' C' ' 20' ' ' PHE . 20.8 p90 -119.65 69.65 0.84 Allowed 'General case' 0 CA--C 1.562 1.437 0 CA-C-N 112.048 -2.342 . . . . 0.0 109.299 173.568 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' C' C ' 21' ' ' ALA . . . . . 0.423 ' H ' ' HD1' ' C' ' 19' ' ' PHE . . . -62.85 95.19 0.07 Allowed 'General case' 0 C--N 1.326 -0.454 0 N-CA-C 108.42 -0.956 . . . . 0.0 108.42 176.824 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 77.3 mt-10 -49.7 123.76 8.45 Favored 'General case' 0 N--CA 1.475 0.814 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.495 -179.862 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 16.5 t70 -76.63 169.16 18.8 Favored 'General case' 0 N--CA 1.472 0.631 0 CA-C-O 121.002 0.43 . . . . 0.0 110.713 -179.009 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' C' C ' 24' ' ' VAL . . . . . 0.506 HG13 ' H ' ' C' ' 25' ' ' GLY . 0.7 OUTLIER 178.25 -79.28 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.544 0.729 0 N-CA-C 107.458 -1.312 . . . . 0.0 107.458 -179.658 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' C' C ' 25' ' ' GLY . . . . . 0.506 ' H ' HG13 ' C' ' 24' ' ' VAL . . . -34.09 84.25 0.0 OUTLIER Glycine 0 N--CA 1.48 1.62 0 C-N-CA 124.356 0.979 . . . . 0.0 113.254 178.591 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' C' C ' 26' ' ' SER . . . . . 0.451 ' N ' ' O ' ' C' ' 24' ' ' VAL . 88.7 p -41.15 -105.25 0.0 OUTLIER 'General case' 0 N--CA 1.473 0.702 0 N-CA-C 113.692 0.997 . . . . 0.0 113.692 -177.334 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 16.6 p-10 -59.98 112.21 1.78 Allowed 'General case' 0 N--CA 1.468 0.474 0 CA-C-N 118.874 0.761 . . . . 0.0 110.381 -178.632 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 41.7 mttm -96.55 164.51 12.58 Favored 'General case' 0 N--CA 1.475 0.78 0 C-N-CA 123.204 0.602 . . . . 0.0 110.113 -179.53 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -72.87 -141.31 0.44 Allowed Glycine 0 N--CA 1.462 0.398 0 N-CA-C 107.769 -2.132 . . . . 0.0 107.769 176.535 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' C' C ' 30' ' ' ALA . . . . . 0.489 ' O ' ' O ' ' F' ' 31' ' ' ILE . . . -90.68 123.16 34.07 Favored 'General case' 0 C--O 1.211 -0.968 0 N-CA-C 106.775 -1.565 . . . . 0.0 106.775 176.58 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 16.6 tt -148.08 155.59 9.7 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.889 0 N-CA-C 107.888 -1.153 . . . . 0.0 107.888 179.186 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 20.2 pt -150.79 138.85 14.28 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.469 0 CA-C-N 118.943 0.792 . . . . 0.0 109.266 178.674 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -56.78 154.3 18.17 Favored Glycine 0 CA--C 1.531 1.088 0 CA-C-N 116.606 -0.27 . . . . 0.0 112.56 -178.656 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 2.5 pp -76.32 158.76 31.19 Favored 'General case' 0 N--CA 1.472 0.644 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 179.232 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 11.6 ttp -102.58 151.47 22.3 Favored 'General case' 0 N--CA 1.481 1.091 0 N-CA-C 109.449 -0.574 . . . . 0.0 109.449 179.649 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 7.3 p -168.55 159.88 0.71 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.542 0 N-CA-C 108.038 -1.097 . . . . 0.0 108.038 179.764 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.45 69.69 1.19 Allowed Glycine 0 C--N 1.312 -0.774 0 N-CA-C 111.611 -0.596 . . . . 0.0 111.611 178.826 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 151.95 -177.82 29.57 Favored Glycine 0 N--CA 1.468 0.792 0 N-CA-C 110.25 -1.14 . . . . 0.0 110.25 179.669 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 4.4 t -124.57 138.8 52.81 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.722 0 N-CA-C 107.335 -1.358 . . . . 0.0 107.335 -179.445 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 74.3 t . . . . . 0 N--CA 1.48 1.032 0 CA-C-O 117.771 -1.109 . . . . 0.0 109.696 -177.589 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 30.0 m-85 . . . . . 0 N--CA 1.475 0.784 0 N-CA-C 109.117 -0.698 . . . . 0.0 109.117 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' D' D ' 5' ' ' ARG . . . . . . . . . . . . . 76.7 mtt85 -140.11 141.91 36.09 Favored 'General case' 0 N--CA 1.474 0.761 0 C-N-CA 123.974 0.909 . . . . 0.0 110.559 -178.702 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 54.3 t-80 -148.63 123.39 9.89 Favored 'General case' 0 CA--C 1.547 0.852 0 N-CA-C 107.86 -1.163 . . . . 0.0 107.86 174.848 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' D' D ' 7' ' ' ASP . . . . . . . . . . . . . 8.8 m-20 -63.47 133.17 53.45 Favored 'General case' 0 N--CA 1.469 0.496 0 C-N-CA 126.9 2.08 . . . . 0.0 114.15 176.313 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' D' D ' 8' ' ' SER . . . . . . . . . . . . . 2.4 t -154.35 -177.31 6.36 Favored 'General case' 0 N--CA 1.473 0.712 0 CA-C-N 118.895 0.771 . . . . 0.0 110.555 176.242 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 88.11 69.45 1.28 Allowed Glycine 0 N--CA 1.475 1.279 0 N-CA-C 111.33 -0.708 . . . . 0.0 111.33 174.523 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 35.2 p90 -70.82 124.34 24.09 Favored 'General case' 0 N--CA 1.476 0.837 0 CA-C-N 118.134 0.967 . . . . 0.0 110.507 -179.907 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 17.6 pt-20 -81.0 154.04 27.12 Favored 'General case' 0 C--N 1.363 1.162 0 C-N-CA 119.982 -0.687 . . . . 0.0 109.948 175.935 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 21.8 t -141.29 124.07 15.21 Favored 'Isoleucine or valine' 0 C--N 1.357 0.925 0 N-CA-C 107.945 -1.131 . . . . 0.0 107.945 171.011 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 61.5 m80 -89.03 164.37 15.1 Favored 'General case' 0 N--CA 1.472 0.657 0 C-N-CA 125.229 1.412 . . . . 0.0 112.607 171.865 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' D' D ' 14' ' ' HIS . . . . . 0.45 ' NE2' ' NZ ' ' D' ' 16' ' ' LYS . 17.1 t60 -163.82 104.91 0.92 Allowed 'General case' 0 N--CA 1.478 0.949 0 N-CA-C 109.0 -0.741 . . . . 0.0 109.0 171.671 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -95.24 111.45 23.3 Favored 'General case' 0 C--O 1.218 -0.59 0 N-CA-C 107.913 -1.143 . . . . 0.0 107.913 178.885 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' D' D ' 16' ' ' LYS . . . . . 0.45 ' NZ ' ' NE2' ' D' ' 14' ' ' HIS . 8.6 ttmm -95.49 169.93 9.7 Favored 'General case' 0 N--CA 1.487 1.409 0 C-N-CA 125.749 1.619 . . . . 0.0 108.715 -178.385 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 10.7 mp -65.79 156.23 33.82 Favored 'General case' 0 C--O 1.21 -0.975 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 -172.779 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' D' D ' 18' ' ' VAL . . . . . 0.69 ' O ' ' HB3' ' A' ' 19' ' ' PHE . 88.5 t -139.74 146.72 24.79 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.143 0 C-N-CA 126.183 1.793 . . . . 0.0 109.015 -168.808 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' D' D ' 19' ' ' PHE . . . . . 0.757 ' HB3' ' O ' ' G' ' 18' ' ' VAL 0.485 37.4 p90 -57.67 162.4 3.09 Favored 'General case' 0 C--N 1.391 2.403 0 N-CA-C 118.552 2.797 . . . . 0.0 118.552 -169.325 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' D' D ' 20' ' ' PHE . . . . . 0.404 ' O ' ' CD2' ' D' ' 20' ' ' PHE . 21.5 p90 -114.48 66.24 0.68 Allowed 'General case' 0 C--N 1.375 1.684 0 CA-C-N 112.958 -1.928 . . . . 0.0 110.608 -178.781 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' D' D ' 21' ' ' ALA . . . . . 0.45 ' H ' ' HD1' ' D' ' 19' ' ' PHE . . . -50.2 92.47 0.01 OUTLIER 'General case' 0 N--CA 1.441 -0.91 0 CA-C-N 113.448 -1.705 . . . . 0.0 110.669 173.675 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 77.0 mt-10 -52.69 125.53 16.98 Favored 'General case' 0 CA--C 1.547 0.843 0 CA-C-N 118.881 0.764 . . . . 0.0 110.306 -179.652 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 14.6 t70 -78.04 168.75 19.39 Favored 'General case' 0 N--CA 1.475 0.802 0 C-N-CA 122.764 0.426 . . . . 0.0 110.163 -179.747 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' D' D ' 24' ' ' VAL . . . . . 0.468 HG13 ' H ' ' D' ' 25' ' ' GLY 0.624 2.7 p -179.4 -100.54 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.203 -1.395 0 CA-C-O 125.938 2.78 . . . . 0.0 106.256 -164.685 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' D' D ' 25' ' ' GLY . . . . . 0.468 ' H ' HG13 ' D' ' 24' ' ' VAL . . . -24.32 71.59 0.0 OUTLIER Glycine 0 C--N 1.3 -1.46 0 C-N-CA 129.459 3.409 . . . . 0.0 116.907 178.476 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' D' D ' 26' ' ' SER . . . . . 0.412 ' OG ' ' N ' ' D' ' 27' ' ' ASN 0.381 78.9 p -52.69 -100.46 0.0 OUTLIER 'General case' 0 C--O 1.273 2.318 1 CA-C-O 110.787 -4.435 . . . . 0.0 107.203 -162.704 . . . . . . . . 4 3 . 1 . 020 nuclear build core ' D' D ' 27' ' ' ASN . . . . . 0.503 ' OD1' ' N ' ' D' ' 27' ' ' ASN 0.409 11.7 p-10 -70.38 121.87 18.53 Favored 'General case' 0 N--CA 1.481 1.109 1 CA-C-N 129.149 5.431 . . . . 0.0 108.818 -168.719 . . . . . . . . 4 3 . 1 . 020 nuclear build core ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 31.7 mttm -86.24 161.18 18.92 Favored 'General case' 0 C--N 1.364 1.23 0 CA-C-N 110.65 -2.977 . . . . 0.0 113.104 177.762 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -66.89 -145.13 0.07 OUTLIER Glycine 0 CA--C 1.535 1.331 0 N-CA-C 108.997 -1.641 . . . . 0.0 108.997 167.354 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' D' D ' 30' ' ' ALA . . . . . 0.489 ' O ' ' O ' ' G' ' 31' ' ' ILE . . . -92.12 123.45 35.47 Favored 'General case' 0 C--N 1.358 0.945 0 N-CA-C 106.708 -1.59 . . . . 0.0 106.708 174.207 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' D' D ' 31' ' ' ILE . . . . . 0.458 ' O ' ' O ' ' A' ' 30' ' ' ALA . 17.3 tt -144.73 155.42 14.42 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.451 0 N-CA-C 109.107 -0.701 . . . . 0.0 109.107 178.959 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 23.4 pt -150.99 135.31 8.94 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.912 0 CA-C-N 118.402 0.546 . . . . 0.0 110.035 178.939 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -52.85 153.9 6.47 Favored Glycine 0 N--CA 1.476 1.317 0 CA-C-N 116.32 -0.4 . . . . 0.0 112.891 -179.492 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 2.5 pp -76.46 159.85 30.05 Favored 'General case' 0 N--CA 1.473 0.677 0 N-CA-C 110.0 -0.37 . . . . 0.0 110.0 178.433 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 8.2 ttp -103.38 155.14 18.7 Favored 'General case' 0 N--CA 1.48 1.06 0 N-CA-C 108.655 -0.868 . . . . 0.0 108.655 178.781 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 6.7 p -167.04 163.73 0.58 Allowed 'Isoleucine or valine' 0 CA--C 1.507 -0.708 0 N-CA-C 107.456 -1.313 . . . . 0.0 107.456 177.054 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 59.32 63.9 4.74 Favored Glycine 0 C--N 1.319 -0.364 0 C-N-CA 118.733 -1.699 . . . . 0.0 113.143 174.397 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 148.4 179.73 24.58 Favored Glycine 0 N--CA 1.471 1.026 0 CA-C-N 118.0 0.9 . . . . 0.0 111.225 -177.175 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 5.5 t -122.2 138.42 52.47 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.86 0 N-CA-C 106.412 -1.699 . . . . 0.0 106.412 -177.546 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 77.1 t . . . . . 0 C--O 1.212 -0.887 0 N-CA-C 108.224 -1.028 . . . . 0.0 108.224 178.886 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 27.7 m-85 . . . . . 0 N--CA 1.474 0.727 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' E' E ' 5' ' ' ARG . . . . . . . . . . . . . 76.9 mtt85 -139.71 145.75 38.74 Favored 'General case' 0 N--CA 1.477 0.917 0 CA-C-N 115.978 -0.556 . . . . 0.0 110.015 179.378 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 57.9 t-80 -150.52 116.44 5.58 Favored 'General case' 0 N--CA 1.475 0.796 0 N-CA-C 109.472 -0.566 . . . . 0.0 109.472 179.239 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' E' E ' 7' ' ' ASP . . . . . . . . . . . . . 9.7 m-20 -66.11 148.64 51.51 Favored 'General case' 0 N--CA 1.47 0.549 0 O-C-N 123.259 0.349 . . . . 0.0 111.136 -179.825 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' E' E ' 8' ' ' SER . . . . . . . . . . . . . 2.2 t -167.45 -178.04 3.83 Favored 'General case' 0 N--CA 1.471 0.611 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 178.28 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 86.11 70.21 1.32 Allowed Glycine 0 CA--C 1.533 1.168 0 CA-C-N 115.964 -0.562 . . . . 0.0 112.089 178.779 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 34.2 p90 -71.65 121.87 19.58 Favored 'General case' 0 N--CA 1.479 1.008 0 CA-C-N 117.52 0.66 . . . . 0.0 110.771 179.704 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 17.4 pt-20 -83.01 152.77 25.27 Favored 'General case' 0 N--CA 1.482 1.159 0 N-CA-C 109.405 -0.591 . . . . 0.0 109.405 178.136 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 19.2 t -144.83 117.03 2.35 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.667 0 N-CA-C 109.478 -0.564 . . . . 0.0 109.478 178.831 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 73.8 m80 -95.33 165.89 12.16 Favored 'General case' 0 N--CA 1.475 0.794 0 N-CA-C 109.701 -0.481 . . . . 0.0 109.701 178.588 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' E' E ' 14' ' ' HIS . . . . . 0.447 ' NE2' ' NZ ' ' E' ' 16' ' ' LYS . 16.5 t60 -164.71 99.12 0.78 Allowed 'General case' 0 N--CA 1.478 0.971 0 N-CA-C 110.095 -0.335 . . . . 0.0 110.095 179.327 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -92.06 110.96 22.33 Favored 'General case' 0 CA--C 1.511 -0.548 0 N-CA-C 108.442 -0.948 . . . . 0.0 108.442 179.721 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' E' E ' 16' ' ' LYS . . . . . 0.447 ' NZ ' ' NE2' ' E' ' 14' ' ' HIS . 9.5 ttmm -93.53 172.04 8.52 Favored 'General case' 0 N--CA 1.485 1.303 0 N-CA-C 109.279 -0.638 . . . . 0.0 109.279 179.999 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' E' E ' 17' ' ' LEU . . . . . 0.438 ' N ' HD12 ' E' ' 17' ' ' LEU . 9.2 mp -55.11 155.98 4.32 Favored 'General case' 0 C--O 1.216 -0.693 0 N-CA-C 109.981 -0.377 . . . . 0.0 109.981 -178.599 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' E' E ' 18' ' ' VAL . . . . . 0.704 ' O ' ' HB3' ' B' ' 19' ' ' PHE . 79.5 t -141.48 150.61 19.62 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.966 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 -178.475 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' E' E ' 19' ' ' PHE . . . . . 0.735 ' HB3' ' O ' ' H' ' 18' ' ' VAL . 38.9 p90 -43.69 153.95 0.11 Allowed 'General case' 0 C--N 1.385 2.139 0 N-CA-C 120.387 3.477 . . . . 0.0 120.387 -177.216 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' E' E ' 20' ' ' PHE . . . . . 0.403 ' CD2' ' O ' ' E' ' 20' ' ' PHE . 20.8 p90 -111.62 66.95 0.64 Allowed 'General case' 0 N--CA 1.484 1.243 0 CA-C-N 113.938 -1.483 . . . . 0.0 111.495 175.007 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' E' E ' 21' ' ' ALA . . . . . 0.409 ' H ' ' HD1' ' E' ' 19' ' ' PHE . . . -58.64 93.96 0.02 OUTLIER 'General case' 0 N--CA 1.441 -0.919 0 CA-C-N 114.133 -1.394 . . . . 0.0 109.212 177.919 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 76.1 mt-10 -50.0 122.16 6.33 Favored 'General case' 0 N--CA 1.474 0.749 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.25 -179.712 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 18.4 t70 -75.03 173.51 10.62 Favored 'General case' 0 N--CA 1.466 0.349 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 -178.823 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' E' E ' 24' ' ' VAL . . . . . 0.526 HG13 ' H ' ' E' ' 25' ' ' GLY . 0.9 OUTLIER 173.71 -77.9 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.472 0.656 0 N-CA-C 107.896 -1.15 . . . . 0.0 107.896 -179.925 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' E' E ' 25' ' ' GLY . . . . . 0.526 ' H ' HG13 ' E' ' 24' ' ' VAL . . . -36.51 84.47 0.0 OUTLIER Glycine 0 CA--C 1.538 1.523 0 C-N-CA 124.102 0.858 . . . . 0.0 113.396 179.132 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' E' E ' 26' ' ' SER . . . . . 0.451 ' N ' ' O ' ' E' ' 24' ' ' VAL . 95.2 p -40.81 -107.11 0.0 OUTLIER 'General case' 0 N--CA 1.482 1.133 0 N-CA-C 114.25 1.204 . . . . 0.0 114.25 -177.544 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 16.5 p-10 -58.36 111.57 1.27 Allowed 'General case' 0 N--CA 1.473 0.688 0 CA-C-N 118.858 0.754 . . . . 0.0 110.067 -178.664 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 39.1 mttm -95.15 167.82 11.13 Favored 'General case' 0 N--CA 1.476 0.851 0 O-C-N 123.786 0.679 . . . . 0.0 109.588 -179.592 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -76.14 -140.17 0.94 Allowed Glycine 0 CA--C 1.524 0.652 0 N-CA-C 106.996 -2.441 . . . . 0.0 106.996 176.396 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' E' E ' 30' ' ' ALA . . . . . 0.458 ' O ' ' O ' ' H' ' 31' ' ' ILE . . . -91.82 126.34 36.87 Favored 'General case' 0 C--O 1.215 -0.723 0 N-CA-C 106.507 -1.664 . . . . 0.0 106.507 175.682 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' E' E ' 31' ' ' ILE . . . . . 0.491 ' O ' ' O ' ' B' ' 30' ' ' ALA . 16.6 tt -149.87 155.62 7.81 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.604 0 N-CA-C 108.077 -1.083 . . . . 0.0 108.077 179.07 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 19.2 pt -152.61 138.14 11.21 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.628 0 N-CA-C 109.096 -0.705 . . . . 0.0 109.096 -179.509 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -57.56 154.65 20.98 Favored Glycine 0 N--CA 1.474 1.174 0 CA-C-N 115.407 -0.815 . . . . 0.0 112.66 -177.851 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 2.5 pp -75.98 160.32 29.97 Favored 'General case' 0 N--CA 1.469 0.505 0 N-CA-C 109.64 -0.504 . . . . 0.0 109.64 179.244 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 7.7 ttp -104.91 151.95 23.24 Favored 'General case' 0 N--CA 1.48 1.052 0 N-CA-C 109.259 -0.645 . . . . 0.0 109.259 179.454 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 7.5 p -168.13 159.93 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.446 -0.641 0 N-CA-C 107.844 -1.169 . . . . 0.0 107.844 179.744 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 53.85 70.87 0.81 Allowed Glycine 0 C--N 1.313 -0.72 0 O-C-N 123.381 0.426 . . . . 0.0 112.328 179.365 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 153.06 -177.14 30.86 Favored Glycine 0 N--CA 1.461 0.367 0 N-CA-C 110.131 -1.188 . . . . 0.0 110.131 179.556 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 5.5 t -126.7 137.08 58.93 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.361 0 N-CA-C 106.259 -1.756 . . . . 0.0 106.259 -178.867 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 75.1 t . . . . . 0 N--CA 1.474 0.754 0 CA-C-O 117.649 -1.167 . . . . 0.0 109.504 -176.889 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 27.7 m-85 . . . . . 0 N--CA 1.472 0.672 0 N-CA-C 109.676 -0.49 . . . . 0.0 109.676 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' F' F ' 5' ' ' ARG . . . . . . . . . . . . . 76.8 mtt85 -139.61 145.34 38.4 Favored 'General case' 0 N--CA 1.479 0.98 0 CA-C-N 115.861 -0.609 . . . . 0.0 109.96 179.427 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 57.7 t-80 -150.33 116.31 5.61 Favored 'General case' 0 N--CA 1.475 0.776 0 N-CA-C 109.61 -0.515 . . . . 0.0 109.61 179.158 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' F' F ' 7' ' ' ASP . . . . . . . . . . . . . 9.8 m-20 -65.84 148.42 51.81 Favored 'General case' 0 N--CA 1.469 0.515 0 O-C-N 123.261 0.351 . . . . 0.0 111.301 -179.813 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' F' F ' 8' ' ' SER . . . . . . . . . . . . . 2.2 t -167.37 -178.0 3.85 Favored 'General case' 0 N--CA 1.471 0.59 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 178.214 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 86.25 70.15 1.32 Allowed Glycine 0 CA--C 1.532 1.143 0 CA-C-N 115.972 -0.558 . . . . 0.0 112.113 178.734 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 34.6 p90 -71.7 121.71 19.34 Favored 'General case' 0 N--CA 1.476 0.858 0 CA-C-N 117.514 0.657 . . . . 0.0 110.95 179.739 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 17.4 pt-20 -82.79 152.69 25.57 Favored 'General case' 0 N--CA 1.481 1.116 0 N-CA-C 109.399 -0.593 . . . . 0.0 109.399 178.156 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 19.3 t -144.83 117.02 2.35 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.635 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 178.795 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 73.8 m80 -95.3 165.94 12.14 Favored 'General case' 0 N--CA 1.476 0.871 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 178.534 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' F' F ' 14' ' ' HIS . . . . . 0.456 ' NE2' ' NZ ' ' F' ' 16' ' ' LYS . 16.4 t60 -164.66 98.86 0.79 Allowed 'General case' 0 N--CA 1.478 0.969 0 N-CA-C 110.224 -0.287 . . . . 0.0 110.224 179.394 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -91.74 110.93 22.27 Favored 'General case' 0 CA--C 1.507 -0.693 0 N-CA-C 108.376 -0.972 . . . . 0.0 108.376 179.655 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' F' F ' 16' ' ' LYS . . . . . 0.456 ' NZ ' ' NE2' ' F' ' 14' ' ' HIS . 9.7 ttmm -93.59 171.75 8.7 Favored 'General case' 0 N--CA 1.484 1.258 0 N-CA-C 109.224 -0.658 . . . . 0.0 109.224 179.919 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' F' F ' 17' ' ' LEU . . . . . 0.433 ' N ' HD12 ' F' ' 17' ' ' LEU . 9.2 mp -54.8 155.84 4.05 Favored 'General case' 0 N--CA 1.472 0.671 0 N-CA-C 110.044 -0.354 . . . . 0.0 110.044 -178.625 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' F' F ' 18' ' ' VAL . . . . . 0.709 ' O ' ' HB3' ' C' ' 19' ' ' PHE . 79.0 t -141.43 150.49 19.75 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.955 0 N-CA-C 107.929 -1.138 . . . . 0.0 107.929 -178.409 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' F' F ' 19' ' ' PHE . . . . . 0.745 ' HB3' ' O ' ' I' ' 18' ' ' VAL . 38.6 p90 -43.48 153.63 0.11 Allowed 'General case' 0 C--N 1.384 2.101 0 N-CA-C 120.41 3.485 . . . . 0.0 120.41 -177.232 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' F' F ' 20' ' ' PHE . . . . . 0.415 ' O ' ' CD2' ' F' ' 20' ' ' PHE . 20.1 p90 -111.46 67.25 0.64 Allowed 'General case' 0 N--CA 1.48 1.053 0 CA-C-N 113.947 -1.479 . . . . 0.0 111.538 175.029 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' F' F ' 21' ' ' ALA . . . . . 0.402 ' H ' ' HD1' ' F' ' 19' ' ' PHE . . . -58.82 94.27 0.02 OUTLIER 'General case' 0 C--N 1.317 -0.843 0 CA-C-N 114.211 -1.359 . . . . 0.0 109.262 178.074 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 76.5 mt-10 -50.29 122.28 6.71 Favored 'General case' 0 N--CA 1.476 0.85 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.296 -179.743 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 18.2 t70 -75.06 173.54 10.6 Favored 'General case' 0 N--CA 1.468 0.429 0 N-CA-C 110.031 -0.359 . . . . 0.0 110.031 -178.852 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' F' F ' 24' ' ' VAL . . . . . 0.527 HG13 ' H ' ' F' ' 25' ' ' GLY . 0.9 OUTLIER 173.83 -78.35 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.728 0 N-CA-C 107.934 -1.136 . . . . 0.0 107.934 -179.828 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' F' F ' 25' ' ' GLY . . . . . 0.527 ' H ' HG13 ' F' ' 24' ' ' VAL . . . -36.7 84.95 0.01 OUTLIER Glycine 0 CA--C 1.536 1.382 0 C-N-CA 124.045 0.831 . . . . 0.0 113.354 179.294 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' F' F ' 26' ' ' SER . . . . . 0.45 ' N ' ' O ' ' F' ' 24' ' ' VAL . 96.0 p -40.82 -107.11 0.0 OUTLIER 'General case' 0 N--CA 1.479 0.989 0 N-CA-C 114.19 1.181 . . . . 0.0 114.19 -177.696 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 16.6 p-10 -58.42 111.55 1.27 Allowed 'General case' 0 N--CA 1.472 0.654 0 CA-C-N 118.804 0.729 . . . . 0.0 110.171 -178.69 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 38.9 mttm -95.08 167.71 11.21 Favored 'General case' 0 N--CA 1.477 0.918 0 C-N-CA 123.392 0.677 . . . . 0.0 109.597 -179.553 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -76.03 -139.98 0.9 Allowed Glycine 0 CA--C 1.525 0.702 0 N-CA-C 107.113 -2.395 . . . . 0.0 107.113 176.403 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' F' F ' 30' ' ' ALA . . . . . 0.456 ' O ' ' O ' ' I' ' 31' ' ' ILE . . . -91.97 126.37 37.03 Favored 'General case' 0 N--CA 1.472 0.635 0 N-CA-C 106.227 -1.768 . . . . 0.0 106.227 175.706 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' F' F ' 31' ' ' ILE . . . . . 0.489 ' O ' ' O ' ' C' ' 30' ' ' ALA . 16.6 tt -150.01 155.29 8.01 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.619 0 N-CA-C 108.078 -1.082 . . . . 0.0 108.078 179.221 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 19.3 pt -152.48 138.34 11.7 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.651 0 N-CA-C 109.157 -0.683 . . . . 0.0 109.157 -179.482 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -57.63 154.54 21.62 Favored Glycine 0 N--CA 1.474 1.18 0 CA-C-N 115.421 -0.808 . . . . 0.0 112.622 -177.74 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 2.5 pp -75.96 160.51 29.8 Favored 'General case' 0 N--CA 1.47 0.543 0 N-CA-C 109.58 -0.526 . . . . 0.0 109.58 179.14 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 7.6 ttp -105.15 152.08 23.24 Favored 'General case' 0 N--CA 1.479 0.986 0 N-CA-C 109.313 -0.625 . . . . 0.0 109.313 179.528 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 7.5 p -168.19 160.23 0.72 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.625 0 N-CA-C 107.837 -1.172 . . . . 0.0 107.837 179.631 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 53.76 70.89 0.8 Allowed Glycine 0 C--N 1.313 -0.745 0 O-C-N 123.448 0.467 . . . . 0.0 112.425 179.4 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 152.97 -177.19 30.77 Favored Glycine 0 N--CA 1.461 0.364 0 N-CA-C 110.08 -1.208 . . . . 0.0 110.08 179.538 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 5.3 t -126.45 136.81 59.7 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.347 0 N-CA-C 106.242 -1.762 . . . . 0.0 106.242 -178.852 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 76.4 t . . . . . 0 N--CA 1.47 0.567 0 CA-C-O 117.597 -1.192 . . . . 0.0 109.692 -176.926 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 30.3 m-85 . . . . . 0 N--CA 1.474 0.748 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' G' G ' 5' ' ' ARG . . . . . . . . . . . . . 77.0 mtt85 -140.01 145.14 37.41 Favored 'General case' 0 N--CA 1.481 1.095 0 N-CA-C 109.688 -0.486 . . . . 0.0 109.688 179.515 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 58.7 t-80 -150.03 117.38 6.06 Favored 'General case' 0 N--CA 1.473 0.675 0 N-CA-C 109.209 -0.663 . . . . 0.0 109.209 179.217 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 12.4 m-20 -66.89 148.39 52.0 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.961 -179.83 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' G' G ' 8' ' ' SER . . . . . . . . . . . . . 3.5 t -166.93 -179.38 4.67 Favored 'General case' 0 N--CA 1.472 0.674 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.095 178.342 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 85.44 71.95 1.3 Allowed Glycine 0 N--CA 1.477 1.406 0 CA-C-N 116.144 -0.48 . . . . 0.0 112.247 179.015 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 38.5 p90 -72.84 122.03 20.92 Favored 'General case' 0 N--CA 1.477 0.887 0 CA-C-N 117.098 0.449 . . . . 0.0 110.76 179.353 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 17.7 pt-20 -83.28 153.16 24.8 Favored 'General case' 0 N--CA 1.478 0.932 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 178.263 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 22.0 t -143.76 117.64 3.53 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.006 0 CA-C-O 118.527 -0.749 . . . . 0.0 109.032 179.003 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 76.7 m80 -95.42 167.36 11.37 Favored 'General case' 0 N--CA 1.486 1.374 0 CA-C-N 119.569 1.077 . . . . 0.0 109.521 178.597 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' G' G ' 14' ' ' HIS . . . . . 0.442 ' NE2' ' NZ ' ' G' ' 16' ' ' LYS . 16.1 t60 -164.42 98.1 0.8 Allowed 'General case' 0 N--CA 1.479 1.014 0 N-CA-C 110.061 -0.348 . . . . 0.0 110.061 179.216 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -91.63 111.67 23.28 Favored 'General case' 0 CA--C 1.509 -0.6 0 N-CA-C 107.904 -1.146 . . . . 0.0 107.904 179.479 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' G' G ' 16' ' ' LYS . . . . . 0.442 ' NZ ' ' NE2' ' G' ' 14' ' ' HIS . 9.1 ttmm -93.61 171.97 8.56 Favored 'General case' 0 N--CA 1.485 1.315 0 N-CA-C 109.314 -0.624 . . . . 0.0 109.314 -179.86 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' G' G ' 17' ' ' LEU . . . . . 0.411 ' N ' HD12 ' G' ' 17' ' ' LEU . 9.5 mp -55.14 152.24 8.23 Favored 'General case' 0 N--CA 1.471 0.606 0 CA-C-O 121.147 0.498 . . . . 0.0 110.366 -178.829 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' G' G ' 18' ' ' VAL . . . . . 0.757 ' O ' ' HB3' ' D' ' 19' ' ' PHE . 87.0 t -138.13 150.9 24.77 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.622 0 N-CA-C 107.635 -1.246 . . . . 0.0 107.635 -179.166 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' G' G ' 19' ' ' PHE . . . . . 0.475 ' O ' ' CG ' ' D' ' 19' ' ' PHE . 29.3 p90 -44.26 149.22 0.38 Allowed 'General case' 0 C--N 1.406 3.034 0 O-C-N 128.483 3.615 . . . . 0.0 117.721 -175.283 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' G' G ' 20' ' ' PHE . . . . . 0.401 ' CD2' ' O ' ' G' ' 20' ' ' PHE . 23.0 p90 -109.77 62.54 0.6 Allowed 'General case' 0 N--CA 1.496 1.855 0 CA-C-O 122.787 1.28 . . . . 0.0 112.681 177.685 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -53.66 94.3 0.01 OUTLIER 'General case' 0 N--CA 1.445 -0.709 0 CA-C-N 113.928 -1.487 . . . . 0.0 110.303 179.933 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 74.5 mt-10 -51.3 120.3 4.9 Favored 'General case' 0 CA--C 1.541 0.612 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.274 179.912 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 19.2 t70 -73.47 173.66 9.31 Favored 'General case' 0 N--CA 1.468 0.443 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 -178.905 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' G' G ' 24' ' ' VAL . . . . . 0.526 HG13 ' H ' ' G' ' 25' ' ' GLY . 0.9 OUTLIER 174.18 -79.19 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.755 0 N-CA-C 108.221 -1.029 . . . . 0.0 108.221 -179.773 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' G' G ' 25' ' ' GLY . . . . . 0.526 ' H ' HG13 ' G' ' 24' ' ' VAL . . . -37.51 85.91 0.01 OUTLIER Glycine 0 N--CA 1.479 1.54 0 C-N-CA 123.698 0.666 . . . . 0.0 113.171 179.658 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' G' G ' 26' ' ' SER . . . . . 0.441 ' N ' ' O ' ' G' ' 24' ' ' VAL . 90.6 p -40.95 -105.81 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.882 0 N-CA-C 113.877 1.066 . . . . 0.0 113.877 -177.506 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 16.9 p-10 -59.46 110.38 1.1 Allowed 'General case' 0 N--CA 1.473 0.71 0 CA-C-N 118.908 0.776 . . . . 0.0 110.63 -178.795 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 41.7 mttm -93.27 167.82 11.49 Favored 'General case' 0 N--CA 1.47 0.542 0 CA-C-N 115.823 -0.626 . . . . 0.0 109.669 -179.728 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -75.76 -140.28 0.87 Allowed Glycine 0 CA--C 1.525 0.698 0 N-CA-C 106.209 -2.757 . . . . 0.0 106.209 176.236 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -93.64 125.95 38.54 Favored 'General case' 0 N--CA 1.469 0.489 0 N-CA-C 107.154 -1.425 . . . . 0.0 107.154 176.23 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' G' G ' 31' ' ' ILE . . . . . 0.489 ' O ' ' O ' ' D' ' 30' ' ' ALA . 16.4 tt -149.86 155.37 8.04 Favored 'Isoleucine or valine' 0 C--O 1.211 -0.936 0 N-CA-C 108.783 -0.821 . . . . 0.0 108.783 179.786 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 26.7 pt -151.42 136.33 10.21 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.434 0 N-CA-C 109.287 -0.634 . . . . 0.0 109.287 -177.588 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -56.58 154.3 17.24 Favored Glycine 0 CA--C 1.526 0.76 0 CA-C-N 116.147 -0.479 . . . . 0.0 112.179 -178.543 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 2.5 pp -75.63 160.7 29.82 Favored 'General case' 0 N--CA 1.466 0.369 0 N-CA-C 109.499 -0.556 . . . . 0.0 109.499 179.313 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 6.6 ttp -104.78 152.21 22.84 Favored 'General case' 0 N--CA 1.48 1.046 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 179.378 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 7.4 p -168.69 162.22 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 N-CA-C 107.343 -1.355 . . . . 0.0 107.343 179.632 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 54.08 68.93 1.4 Allowed Glycine 0 C--N 1.312 -0.774 0 N-CA-C 111.848 -0.501 . . . . 0.0 111.848 178.77 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 152.66 -178.31 29.88 Favored Glycine 0 N--CA 1.465 0.581 0 N-CA-C 110.473 -1.051 . . . . 0.0 110.473 179.7 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 4.3 t -124.67 138.59 53.55 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.844 0 N-CA-C 107.098 -1.445 . . . . 0.0 107.098 -180.0 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 74.1 t . . . . . 0 N--CA 1.482 1.135 0 CA-C-O 117.788 -1.101 . . . . 0.0 109.8 -177.213 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 31.6 m-85 . . . . . 0 N--CA 1.473 0.712 0 N-CA-C 109.641 -0.503 . . . . 0.0 109.641 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' H' H ' 5' ' ' ARG . . . . . . . . . . . . . 77.1 mtt85 -140.26 145.31 37.15 Favored 'General case' 0 N--CA 1.479 0.979 0 C-N-CA 122.86 0.464 . . . . 0.0 109.801 179.485 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 58.7 t-80 -150.28 117.59 6.04 Favored 'General case' 0 N--CA 1.475 0.786 0 N-CA-C 109.423 -0.584 . . . . 0.0 109.423 179.216 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 12.6 m-20 -67.02 148.17 52.29 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-N 116.386 -0.37 . . . . 0.0 111.078 -179.79 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' H' H ' 8' ' ' SER . . . . . . . . . . . . . 3.5 t -166.86 -179.29 4.66 Favored 'General case' 0 N--CA 1.471 0.598 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.151 178.326 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 85.36 71.68 1.31 Allowed Glycine 0 N--CA 1.477 1.406 0 CA-C-N 116.166 -0.47 . . . . 0.0 112.211 179.098 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 38.3 p90 -72.62 122.2 21.0 Favored 'General case' 0 N--CA 1.474 0.762 0 O-C-N 122.437 -0.449 . . . . 0.0 110.712 179.468 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 17.7 pt-20 -83.39 153.03 24.75 Favored 'General case' 0 N--CA 1.48 1.042 0 N-CA-C 109.294 -0.632 . . . . 0.0 109.294 178.37 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 21.8 t -143.81 116.83 3.12 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.029 0 CA-C-O 118.546 -0.74 . . . . 0.0 109.292 178.952 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 76.5 m80 -94.66 167.26 11.57 Favored 'General case' 0 N--CA 1.484 1.272 0 CA-C-N 119.441 1.018 . . . . 0.0 109.603 178.556 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' H' H ' 14' ' ' HIS . . . . . 0.442 ' NE2' ' NZ ' ' H' ' 16' ' ' LYS . 16.1 t60 -164.41 98.12 0.8 Allowed 'General case' 0 N--CA 1.479 0.979 0 N-CA-C 110.019 -0.363 . . . . 0.0 110.019 179.184 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -91.5 111.76 23.4 Favored 'General case' 0 CA--C 1.511 -0.544 0 N-CA-C 107.891 -1.151 . . . . 0.0 107.891 179.459 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' H' H ' 16' ' ' LYS . . . . . 0.442 ' NZ ' ' NE2' ' H' ' 14' ' ' HIS . 9.1 ttmm -93.72 172.06 8.49 Favored 'General case' 0 N--CA 1.486 1.338 0 N-CA-C 109.344 -0.613 . . . . 0.0 109.344 -179.768 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' H' H ' 17' ' ' LEU . . . . . 0.41 ' N ' HD12 ' H' ' 17' ' ' LEU . 9.4 mp -55.16 152.29 8.2 Favored 'General case' 0 N--CA 1.472 0.656 0 CA-C-O 121.152 0.501 . . . . 0.0 110.382 -178.921 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' H' H ' 18' ' ' VAL . . . . . 0.735 ' O ' ' HB3' ' E' ' 19' ' ' PHE . 89.0 t -138.23 151.15 24.71 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.711 0 N-CA-C 107.783 -1.191 . . . . 0.0 107.783 -179.158 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' H' H ' 19' ' ' PHE . . . . . 0.47 ' O ' ' CG ' ' E' ' 19' ' ' PHE . 29.5 p90 -44.73 149.0 0.45 Allowed 'General case' 0 C--N 1.406 3.033 0 O-C-N 128.487 3.617 . . . . 0.0 117.613 -175.055 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 23.3 p90 -109.56 62.45 0.6 Allowed 'General case' 0 N--CA 1.498 1.953 0 CA-C-O 122.758 1.266 . . . . 0.0 112.533 177.805 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -53.64 94.37 0.01 OUTLIER 'General case' 0 N--CA 1.446 -0.652 0 CA-C-N 113.954 -1.475 . . . . 0.0 110.211 179.947 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 74.8 mt-10 -51.45 120.18 4.85 Favored 'General case' 0 CA--C 1.541 0.62 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.297 179.91 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 19.0 t70 -73.47 173.34 9.77 Favored 'General case' 0 N--CA 1.466 0.355 0 N-CA-C 109.943 -0.391 . . . . 0.0 109.943 -178.897 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' H' H ' 24' ' ' VAL . . . . . 0.509 HG13 ' H ' ' H' ' 25' ' ' GLY . 0.9 OUTLIER 174.52 -79.16 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.542 0.661 0 N-CA-C 108.149 -1.056 . . . . 0.0 108.149 -179.693 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' H' H ' 25' ' ' GLY . . . . . 0.509 ' H ' HG13 ' H' ' 24' ' ' VAL . . . -37.33 85.74 0.01 OUTLIER Glycine 0 N--CA 1.478 1.455 0 C-N-CA 123.732 0.682 . . . . 0.0 113.269 179.646 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' H' H ' 26' ' ' SER . . . . . 0.437 ' N ' ' O ' ' H' ' 24' ' ' VAL . 89.5 p -40.64 -106.07 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.885 0 N-CA-C 113.614 0.968 . . . . 0.0 113.614 -177.789 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 17.0 p-10 -59.35 110.36 1.07 Allowed 'General case' 0 N--CA 1.473 0.686 0 CA-C-N 118.941 0.791 . . . . 0.0 110.68 -178.771 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 41.7 mttm -93.46 167.42 11.72 Favored 'General case' 0 N--CA 1.468 0.461 0 CA-C-N 115.757 -0.656 . . . . 0.0 109.701 -179.896 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -75.43 -140.22 0.79 Allowed Glycine 0 CA--C 1.524 0.645 0 N-CA-C 106.262 -2.735 . . . . 0.0 106.262 176.218 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -93.7 125.92 38.58 Favored 'General case' 0 N--CA 1.47 0.529 0 N-CA-C 107.14 -1.43 . . . . 0.0 107.14 176.342 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' H' H ' 31' ' ' ILE . . . . . 0.458 ' O ' ' O ' ' E' ' 30' ' ' ALA . 16.4 tt -150.02 155.32 7.97 Favored 'Isoleucine or valine' 0 C--O 1.213 -0.846 0 N-CA-C 108.658 -0.867 . . . . 0.0 108.658 179.673 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 27.3 pt -151.38 136.27 10.16 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.399 0 N-CA-C 109.243 -0.651 . . . . 0.0 109.243 -177.526 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -56.69 154.49 17.26 Favored Glycine 0 CA--C 1.528 0.854 0 CA-C-N 116.166 -0.47 . . . . 0.0 112.193 -178.442 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 2.5 pp -75.59 160.78 29.76 Favored 'General case' 0 N--CA 1.467 0.418 0 N-CA-C 109.515 -0.55 . . . . 0.0 109.515 179.37 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 6.5 ttp -104.83 152.17 22.93 Favored 'General case' 0 N--CA 1.48 1.027 0 N-CA-C 109.102 -0.703 . . . . 0.0 109.102 179.343 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 7.4 p -168.81 162.29 0.56 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.487 0 N-CA-C 107.209 -1.404 . . . . 0.0 107.209 179.639 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 54.14 68.87 1.43 Allowed Glycine 0 C--N 1.311 -0.828 0 N-CA-C 111.853 -0.499 . . . . 0.0 111.853 178.721 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 152.41 -178.26 29.7 Favored Glycine 0 N--CA 1.466 0.697 0 N-CA-C 110.564 -1.014 . . . . 0.0 110.564 179.781 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 4.4 t -124.58 138.58 53.54 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.788 0 N-CA-C 107.077 -1.453 . . . . 0.0 107.077 -179.931 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 75.2 t . . . . . 0 N--CA 1.483 1.217 0 CA-C-O 117.755 -1.117 . . . . 0.0 109.813 -177.254 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 31.0 m-85 . . . . . 0 N--CA 1.474 0.763 0 N-CA-C 109.7 -0.481 . . . . 0.0 109.7 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' I' I ' 5' ' ' ARG . . . . . . . . . . . . . 77.0 mtt85 -140.3 145.26 37.02 Favored 'General case' 0 N--CA 1.48 1.038 0 C-N-CA 122.896 0.478 . . . . 0.0 109.798 179.514 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 58.7 t-80 -150.25 117.4 5.98 Favored 'General case' 0 N--CA 1.474 0.746 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 179.226 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 12.3 m-20 -66.76 148.15 52.31 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-N 116.379 -0.373 . . . . 0.0 111.014 -179.848 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' I' I ' 8' ' ' SER . . . . . . . . . . . . . 3.5 t -166.81 -179.31 4.7 Favored 'General case' 0 N--CA 1.472 0.67 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.082 178.3 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 85.36 71.72 1.31 Allowed Glycine 0 N--CA 1.476 1.355 0 CA-C-N 116.14 -0.482 . . . . 0.0 112.232 179.086 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 38.0 p90 -72.48 121.95 20.46 Favored 'General case' 0 N--CA 1.476 0.837 0 O-C-N 122.356 -0.496 . . . . 0.0 110.745 179.38 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 17.7 pt-20 -83.2 153.02 24.96 Favored 'General case' 0 N--CA 1.478 0.959 0 N-CA-C 109.279 -0.638 . . . . 0.0 109.279 178.361 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 21.8 t -143.78 116.83 3.14 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.097 0 CA-C-O 118.584 -0.722 . . . . 0.0 109.326 178.928 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 76.5 m80 -94.69 167.24 11.58 Favored 'General case' 0 N--CA 1.485 1.317 0 CA-C-N 119.505 1.048 . . . . 0.0 109.574 178.603 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' I' I ' 14' ' ' HIS . . . . . 0.446 ' NE2' ' NZ ' ' I' ' 16' ' ' LYS . 15.9 t60 -164.41 98.01 0.8 Allowed 'General case' 0 N--CA 1.479 0.991 0 N-CA-C 110.181 -0.303 . . . . 0.0 110.181 179.149 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -91.43 111.63 23.21 Favored 'General case' 0 CA--C 1.509 -0.632 0 N-CA-C 107.94 -1.133 . . . . 0.0 107.94 179.49 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' I' I ' 16' ' ' LYS . . . . . 0.446 ' NZ ' ' NE2' ' I' ' 14' ' ' HIS . 9.1 ttmm -93.62 172.11 8.47 Favored 'General case' 0 N--CA 1.485 1.304 0 N-CA-C 109.362 -0.607 . . . . 0.0 109.362 -179.778 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' I' I ' 17' ' ' LEU . . . . . 0.405 ' N ' HD12 ' I' ' 17' ' ' LEU . 9.5 mp -55.17 152.29 8.24 Favored 'General case' 0 N--CA 1.472 0.652 0 CA-C-O 121.15 0.5 . . . . 0.0 110.3 -178.857 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' I' I ' 18' ' ' VAL . . . . . 0.745 ' O ' ' HB3' ' F' ' 19' ' ' PHE . 88.8 t -138.21 151.28 24.86 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.634 0 N-CA-C 107.683 -1.228 . . . . 0.0 107.683 -179.218 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' I' I ' 19' ' ' PHE . . . . . 0.466 ' O ' ' CG ' ' F' ' 19' ' ' PHE . 29.1 p90 -44.83 148.93 0.47 Allowed 'General case' 0 C--N 1.407 3.093 0 O-C-N 128.378 3.549 . . . . 0.0 117.57 -175.06 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 23.2 p90 -109.5 62.48 0.6 Allowed 'General case' 0 N--CA 1.497 1.904 0 CA-C-O 122.764 1.268 . . . . 0.0 112.522 177.763 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -53.65 94.42 0.01 OUTLIER 'General case' 0 N--CA 1.446 -0.673 0 CA-C-N 113.901 -1.499 . . . . 0.0 110.201 179.947 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 74.5 mt-10 -51.4 120.17 4.82 Favored 'General case' 0 CA--C 1.541 0.634 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.375 179.929 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 18.9 t70 -73.52 173.13 10.11 Favored 'General case' 0 N--CA 1.467 0.404 0 N-CA-C 109.98 -0.378 . . . . 0.0 109.98 -178.9 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' I' I ' 24' ' ' VAL . . . . . 0.511 HG13 ' H ' ' I' ' 25' ' ' GLY . 0.9 OUTLIER 174.61 -79.24 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.544 0.738 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 -179.745 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' I' I ' 25' ' ' GLY . . . . . 0.511 ' H ' HG13 ' I' ' 24' ' ' VAL . . . -37.29 85.87 0.01 OUTLIER Glycine 0 N--CA 1.48 1.63 0 C-N-CA 123.61 0.624 . . . . 0.0 113.229 179.636 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' I' I ' 26' ' ' SER . . . . . 0.44 ' N ' ' O ' ' I' ' 24' ' ' VAL . 87.7 p -40.77 -105.58 0.0 OUTLIER 'General case' 0 N--CA 1.478 0.949 0 N-CA-C 113.6 0.963 . . . . 0.0 113.6 -177.748 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 17.0 p-10 -59.68 110.4 1.13 Allowed 'General case' 0 N--CA 1.473 0.688 0 CA-C-N 118.993 0.815 . . . . 0.0 110.64 -178.754 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 41.6 mttm -93.53 167.53 11.63 Favored 'General case' 0 N--CA 1.469 0.517 0 CA-C-N 115.788 -0.642 . . . . 0.0 109.778 -179.912 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -75.39 -140.21 0.78 Allowed Glycine 0 CA--C 1.525 0.709 0 N-CA-C 106.361 -2.695 . . . . 0.0 106.361 176.289 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -93.65 125.82 38.47 Favored 'General case' 0 N--CA 1.469 0.508 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 176.242 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' I' I ' 31' ' ' ILE . . . . . 0.456 ' O ' ' O ' ' F' ' 30' ' ' ALA . 16.3 tt -149.91 155.24 8.12 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.806 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 179.688 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 27.5 pt -151.3 136.26 10.26 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.413 0 N-CA-C 109.311 -0.626 . . . . 0.0 109.311 -177.468 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -56.55 154.45 16.76 Favored Glycine 0 CA--C 1.526 0.762 0 CA-C-N 116.238 -0.437 . . . . 0.0 112.244 -178.468 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 2.5 pp -75.64 160.78 29.73 Favored 'General case' 0 N--CA 1.467 0.38 0 N-CA-C 109.448 -0.575 . . . . 0.0 109.448 179.338 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 6.5 ttp -104.78 152.32 22.7 Favored 'General case' 0 N--CA 1.48 1.045 0 N-CA-C 109.04 -0.726 . . . . 0.0 109.04 179.417 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 7.4 p -168.87 162.26 0.56 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.529 0 N-CA-C 107.324 -1.362 . . . . 0.0 107.324 179.582 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 54.04 68.95 1.39 Allowed Glycine 0 C--N 1.312 -0.795 0 N-CA-C 111.924 -0.471 . . . . 0.0 111.924 178.801 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 152.37 -178.25 29.67 Favored Glycine 0 N--CA 1.466 0.646 0 N-CA-C 110.525 -1.03 . . . . 0.0 110.525 179.716 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 4.2 t -124.49 138.34 54.29 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.803 0 N-CA-C 107.193 -1.41 . . . . 0.0 107.193 -179.967 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 74.0 t . . . . . 0 N--CA 1.481 1.125 0 CA-C-O 117.719 -1.134 . . . . 0.0 109.822 -177.304 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 15.8 m-20 . . . . . 0 N--CA 1.488 1.472 0 N-CA-C 108.785 -0.821 . . . . 0.0 108.785 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -76.93 129.37 36.08 Favored 'General case' 0 N--CA 1.466 0.345 0 N-CA-C 109.996 -0.372 . . . . 0.0 109.996 -179.864 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 45.0 mt-10 -119.56 107.39 13.22 Favored 'General case' 0 N--CA 1.478 0.937 0 C-N-CA 122.66 0.384 . . . . 0.0 110.25 179.676 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 22.6 m-85 -72.88 172.41 10.91 Favored 'General case' 0 N--CA 1.473 0.705 0 N-CA-C 109.589 -0.523 . . . . 0.0 109.589 179.391 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 87.5 mtt180 -68.87 133.01 47.67 Favored 'General case' 0 N--CA 1.473 0.698 0 CA-C-N 116.612 -0.267 . . . . 0.0 111.101 -178.211 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' HIS . . . . . 0.426 ' CE1' ' O ' ' A' ' 7' ' ' ASP . 1.6 t60 -98.71 127.77 44.75 Favored 'General case' 0 N--CA 1.474 0.732 0 N-CA-C 109.351 -0.611 . . . . 0.0 109.351 179.347 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 7' ' ' ASP . . . . . 0.426 ' O ' ' CE1' ' A' ' 6' ' ' HIS . 4.1 m-20 -72.68 139.89 47.54 Favored 'General case' 0 CA--C 1.538 0.487 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.406 178.545 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 28.0 p -163.24 -168.91 1.84 Allowed 'General case' 0 N--CA 1.481 1.102 0 C-N-CA 122.508 0.323 . . . . 0.0 110.694 179.37 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 105.03 44.39 1.51 Allowed Glycine 0 N--CA 1.483 1.798 0 N-CA-C 111.764 -0.534 . . . . 0.0 111.764 -179.475 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 49.0 p90 -64.11 132.79 51.53 Favored 'General case' 0 N--CA 1.472 0.65 0 O-C-N 122.641 -0.329 . . . . 0.0 111.698 -179.899 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 48.7 mt-10 -90.98 152.34 20.72 Favored 'General case' 0 N--CA 1.477 0.907 0 N-CA-C 109.705 -0.48 . . . . 0.0 109.705 178.37 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -152.98 128.07 1.52 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.655 0 N-CA-C 107.805 -1.183 . . . . 0.0 107.805 178.268 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 46.1 m-70 -135.25 147.4 49.26 Favored 'General case' 0 N--CA 1.492 1.672 0 CA-C-N 119.083 0.856 . . . . 0.0 111.388 -178.965 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 6.5 t60 -164.53 97.39 0.78 Allowed 'General case' 0 N--CA 1.481 1.102 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.733 179.191 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' GLN . . . . . 0.722 HE22 HG23 ' A' ' 36' ' ' VAL . 13.7 pt20 -102.15 -174.12 2.5 Favored 'General case' 0 CA--C 1.509 -0.634 0 N-CA-C 108.654 -0.869 . . . . 0.0 108.654 -179.755 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -169.77 95.68 0.29 Allowed 'General case' 0 N--CA 1.47 0.542 0 CA-C-N 114.565 -1.198 . . . . 0.0 108.345 178.351 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 6.3 mp -123.69 157.04 34.79 Favored 'General case' 0 N--CA 1.498 1.94 0 CA-C-O 121.882 0.848 . . . . 0.0 111.122 -178.151 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 60.2 t -111.92 127.11 69.3 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.099 0 CA-C-O 117.886 -1.054 . . . . 0.0 108.266 177.575 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 26.9 m-85 -126.91 123.05 36.33 Favored 'General case' 0 N--CA 1.497 1.903 0 CA-C-N 120.15 1.341 . . . . 0.0 110.418 179.559 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 66.0 m-85 53.45 74.83 0.29 Allowed 'General case' 0 N--CA 1.469 0.496 0 CA-C-O 121.483 0.659 . . . . 0.0 111.78 178.43 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -79.94 -77.77 0.18 Allowed 'General case' 0 C--N 1.352 0.703 0 CA-C-N 115.044 -0.98 . . . . 0.0 110.319 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 40.8 tt0 -113.96 100.79 8.68 Favored 'General case' 0 N--CA 1.47 0.527 0 N-CA-C 108.247 -1.02 . . . . 0.0 108.247 179.614 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 4.4 p30 -158.53 140.26 13.65 Favored 'General case' 0 N--CA 1.485 1.283 0 O-C-N 122.245 -0.284 . . . . 0.0 111.142 179.079 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.404 HG12 ' N ' ' A' ' 25' ' ' GLY . 60.4 t -59.72 163.58 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.865 0 N-CA-C 108.042 -1.096 . . . . 0.0 108.042 177.108 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.51 ' H ' ' HB ' ' D' ' 24' ' ' VAL . . . -117.87 47.52 1.02 Allowed Glycine 0 N--CA 1.475 1.299 0 N-CA-C 111.776 -0.53 . . . . 0.0 111.776 -179.372 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -61.19 -168.01 0.01 OUTLIER 'General case' 0 N--CA 1.469 0.479 0 O-C-N 123.762 0.331 . . . . 0.0 110.337 179.529 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 26.6 t-20 -70.59 80.7 0.59 Allowed 'General case' 0 N--CA 1.465 0.277 0 CA-C-N 116.401 -0.363 . . . . 0.0 110.17 179.596 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 97.9 mttt -78.03 143.91 37.09 Favored 'General case' 0 N--CA 1.472 0.642 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 179.216 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.81 -167.27 1.07 Allowed Glycine 0 CA--C 1.524 0.625 0 N-CA-C 109.872 -1.291 . . . . 0.0 109.872 178.737 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.83 114.68 28.03 Favored 'General case' 0 N--CA 1.478 0.971 0 N-CA-C 109.67 -0.493 . . . . 0.0 109.67 179.691 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 66.2 mt -98.45 135.83 31.72 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.608 0 N-CA-C 106.883 -1.525 . . . . 0.0 106.883 179.067 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 40.0 pt -152.44 -176.53 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.354 0.763 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.141 -178.765 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.35 4.85 9.61 Favored Glycine 0 CA--C 1.525 0.694 0 N-CA-C 110.861 -0.896 . . . . 0.0 110.861 179.956 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 1.6 tt -75.07 126.58 31.32 Favored 'General case' 0 CA--C 1.544 0.731 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 -179.614 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 28.0 ttt -163.05 150.33 13.05 Favored 'General case' 0 C--O 1.224 -0.253 0 N-CA-C 109.002 -0.74 . . . . 0.0 109.002 178.73 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.722 HG23 HE22 ' A' ' 15' ' ' GLN . 27.9 m -155.78 165.58 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.346 0.447 0 N-CA-C 108.193 -1.04 . . . . 0.0 108.193 179.587 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.92 66.9 2.51 Favored Glycine 0 C--N 1.306 -1.105 0 CA-C-N 115.714 -0.675 . . . . 0.0 112.145 178.693 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.78 -173.12 24.77 Favored Glycine 0 N--CA 1.475 1.276 0 N-CA-C 110.817 -0.913 . . . . 0.0 110.817 179.052 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.493 ' H ' HG12 ' D' ' 39' ' ' VAL . 35.3 m -125.55 157.51 34.83 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.819 0 C-N-CA 123.436 0.694 . . . . 0.0 110.419 -179.863 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 26.2 t . . . . . 0 C--O 1.218 -0.568 0 CA-C-O 118.451 -0.785 . . . . 0.0 110.758 179.775 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' B' B ' 1' ' ' ASP . . . . . . . . . . . . . 15.8 m-20 . . . . . 0 N--CA 1.489 1.52 0 N-CA-C 108.971 -0.752 . . . . 0.0 108.971 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' B' B ' 2' ' ' ALA . . . . . . . . . . . . . . . -76.44 128.66 35.23 Favored 'General case' 0 N--CA 1.466 0.375 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.07 -179.836 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 3' ' ' GLU . . . . . . . . . . . . . 44.6 mt-10 -118.76 107.2 13.36 Favored 'General case' 0 N--CA 1.479 0.987 0 C-N-CA 122.705 0.402 . . . . 0.0 110.277 179.691 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 24.4 m-85 -72.51 172.74 9.97 Favored 'General case' 0 N--CA 1.474 0.737 0 N-CA-C 109.699 -0.482 . . . . 0.0 109.699 179.461 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 87.9 mtt180 -69.06 132.16 46.17 Favored 'General case' 0 N--CA 1.474 0.767 0 CA-C-O 120.631 0.253 . . . . 0.0 110.995 -178.225 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 6' ' ' HIS . . . . . 0.415 ' CE1' ' O ' ' B' ' 7' ' ' ASP . 1.6 t60 -97.95 127.68 44.05 Favored 'General case' 0 N--CA 1.474 0.751 0 N-CA-C 109.298 -0.631 . . . . 0.0 109.298 179.312 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 7' ' ' ASP . . . . . 0.415 ' O ' ' CE1' ' B' ' 6' ' ' HIS . 4.1 m-20 -72.93 139.53 46.84 Favored 'General case' 0 CA--C 1.539 0.544 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.446 178.526 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 8' ' ' SER . . . . . . . . . . . . . 29.2 p -162.56 -168.51 1.84 Allowed 'General case' 0 N--CA 1.481 1.076 0 C-N-CA 122.52 0.328 . . . . 0.0 110.705 179.225 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.63 45.06 1.46 Allowed Glycine 0 N--CA 1.483 1.773 0 N-CA-C 111.732 -0.547 . . . . 0.0 111.732 -179.48 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 49.0 p90 -64.79 132.95 50.94 Favored 'General case' 0 N--CA 1.471 0.607 0 O-C-N 122.662 -0.316 . . . . 0.0 111.684 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 48.7 mt-10 -91.07 152.39 20.65 Favored 'General case' 0 N--CA 1.476 0.873 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 178.293 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -153.06 128.32 1.55 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.638 0 N-CA-C 107.734 -1.21 . . . . 0.0 107.734 178.335 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 45.6 m-70 -135.71 147.42 48.47 Favored 'General case' 0 N--CA 1.493 1.698 0 CA-C-N 118.917 0.78 . . . . 0.0 111.33 -178.958 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 6.5 t60 -164.65 97.33 0.76 Allowed 'General case' 0 N--CA 1.481 1.078 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.586 179.302 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 15' ' ' GLN . . . . . 0.722 HE22 HG23 ' B' ' 36' ' ' VAL . 13.5 pt20 -101.87 -173.68 2.41 Favored 'General case' 0 CA--C 1.51 -0.568 0 N-CA-C 108.639 -0.875 . . . . 0.0 108.639 -179.804 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -170.22 95.63 0.25 Allowed 'General case' 0 N--CA 1.471 0.591 0 CA-C-N 114.63 -1.168 . . . . 0.0 108.259 178.415 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 6.3 mp -123.71 157.05 34.79 Favored 'General case' 0 N--CA 1.497 1.896 0 CA-C-O 121.826 0.822 . . . . 0.0 111.123 -178.113 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 61.8 t -112.31 127.29 69.59 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.074 0 N-CA-C 108.016 -1.105 . . . . 0.0 108.016 177.501 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 27.0 m-85 -127.33 122.86 34.91 Favored 'General case' 0 N--CA 1.495 1.797 0 CA-C-N 119.667 1.121 . . . . 0.0 110.314 179.779 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 66.3 m-85 53.1 74.79 0.28 Allowed 'General case' 0 CA--C 1.539 0.547 0 CA-C-O 121.545 0.688 . . . . 0.0 111.859 178.397 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -79.98 -78.01 0.17 Allowed 'General case' 0 C--N 1.351 0.657 0 CA-C-N 115.016 -0.993 . . . . 0.0 110.278 179.966 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 40.5 tt0 -113.66 100.88 8.81 Favored 'General case' 0 N--CA 1.471 0.594 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 179.569 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 4.4 p30 -158.55 140.88 14.16 Favored 'General case' 0 N--CA 1.484 1.272 0 CA-C-O 119.494 -0.289 . . . . 0.0 111.151 179.021 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 59.0 t -60.13 163.81 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.91 0 N-CA-C 108.116 -1.068 . . . . 0.0 108.116 177.199 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 25' ' ' GLY . . . . . 0.516 ' H ' ' HB ' ' E' ' 24' ' ' VAL . . . -117.9 47.53 1.02 Allowed Glycine 0 N--CA 1.475 1.276 0 N-CA-C 111.739 -0.544 . . . . 0.0 111.739 -179.397 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -61.18 -167.74 0.01 OUTLIER 'General case' 0 N--CA 1.47 0.545 0 O-C-N 123.651 0.265 . . . . 0.0 110.379 179.396 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 26.9 t-20 -71.1 80.73 0.69 Allowed 'General case' 0 N--CA 1.466 0.348 0 N-CA-C 110.091 -0.337 . . . . 0.0 110.091 179.673 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -78.01 143.92 37.11 Favored 'General case' 0 N--CA 1.472 0.666 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 179.267 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.71 -166.7 0.94 Allowed Glycine 0 CA--C 1.524 0.628 0 N-CA-C 109.895 -1.282 . . . . 0.0 109.895 178.752 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -100.4 114.55 28.2 Favored 'General case' 0 N--CA 1.478 0.958 0 N-CA-C 109.668 -0.493 . . . . 0.0 109.668 179.628 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 65.5 mt -98.26 135.39 33.14 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.556 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 178.965 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 38.1 pt -151.73 -176.51 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.353 0.733 0 CA-C-N 115.962 -0.563 . . . . 0.0 111.151 -178.789 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.37 4.73 9.45 Favored Glycine 0 CA--C 1.525 0.703 0 N-CA-C 110.947 -0.861 . . . . 0.0 110.947 179.833 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 34' ' ' LEU . . . . . 0.412 HD23 ' N ' ' B' ' 35' ' ' MET . 1.6 tt -74.95 126.69 31.53 Favored 'General case' 0 CA--C 1.544 0.744 0 N-CA-C 109.37 -0.604 . . . . 0.0 109.37 -179.617 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 35' ' ' MET . . . . . 0.412 ' N ' HD23 ' B' ' 34' ' ' LEU . 27.4 ttt -163.04 150.17 12.96 Favored 'General case' 0 N--CA 1.467 0.378 0 N-CA-C 108.915 -0.772 . . . . 0.0 108.915 178.672 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 36' ' ' VAL . . . . . 0.722 HG23 HE22 ' B' ' 15' ' ' GLN . 27.8 m -155.8 165.26 1.15 Allowed 'Isoleucine or valine' 0 C--N 1.347 0.495 0 N-CA-C 108.155 -1.054 . . . . 0.0 108.155 179.6 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.09 67.16 2.36 Favored Glycine 0 C--N 1.307 -1.059 0 CA-C-N 115.674 -0.694 . . . . 0.0 112.098 178.649 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.54 -172.57 24.83 Favored Glycine 0 N--CA 1.476 1.318 0 N-CA-C 110.806 -0.917 . . . . 0.0 110.806 179.046 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 39' ' ' VAL . . . . . 0.513 ' H ' HG12 ' E' ' 39' ' ' VAL . 35.5 m -126.12 157.42 36.27 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.98 0 C-N-CA 123.448 0.699 . . . . 0.0 110.454 -179.651 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 26.0 t . . . . . 0 C--O 1.219 -0.509 0 CA-C-O 118.429 -0.796 . . . . 0.0 110.602 179.664 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' C' C ' 1' ' ' ASP . . . . . . . . . . . . . 14.9 m-20 . . . . . 0 N--CA 1.488 1.436 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' C' C ' 2' ' ' ALA . . . . . . . . . . . . . . . -76.92 128.75 35.11 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.035 -179.889 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 3' ' ' GLU . . . . . . . . . . . . . 45.3 mt-10 -119.03 107.27 13.31 Favored 'General case' 0 N--CA 1.479 0.991 0 C-N-CA 122.69 0.396 . . . . 0.0 110.255 179.713 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 23.9 m-85 -72.63 172.94 9.69 Favored 'General case' 0 N--CA 1.475 0.794 0 N-CA-C 109.683 -0.488 . . . . 0.0 109.683 179.343 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 87.4 mtt180 -69.28 131.91 45.62 Favored 'General case' 0 N--CA 1.477 0.904 0 CA-C-O 120.714 0.292 . . . . 0.0 110.955 -178.236 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 6' ' ' HIS . . . . . 0.427 ' CE1' ' O ' ' C' ' 7' ' ' ASP . 1.6 t60 -97.79 128.16 44.23 Favored 'General case' 0 N--CA 1.473 0.689 0 N-CA-C 109.262 -0.644 . . . . 0.0 109.262 179.215 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 7' ' ' ASP . . . . . 0.427 ' O ' ' CE1' ' C' ' 6' ' ' HIS . 4.1 m-20 -73.33 139.77 46.26 Favored 'General case' 0 CA--C 1.538 0.49 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.428 178.583 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 8' ' ' SER . . . . . . . . . . . . . 29.8 p -162.99 -168.71 1.83 Allowed 'General case' 0 N--CA 1.481 1.092 0 CA-C-O 120.828 0.347 . . . . 0.0 110.671 179.249 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.92 44.25 1.54 Allowed Glycine 0 N--CA 1.483 1.798 0 N-CA-C 111.759 -0.537 . . . . 0.0 111.759 -179.498 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 49.3 p90 -64.21 133.29 52.56 Favored 'General case' 0 N--CA 1.472 0.667 0 O-C-N 122.672 -0.311 . . . . 0.0 111.687 -179.935 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 48.3 mt-10 -91.4 152.28 20.47 Favored 'General case' 0 N--CA 1.476 0.858 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 178.356 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -152.83 128.15 1.59 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.598 0 N-CA-C 107.814 -1.18 . . . . 0.0 107.814 178.327 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 45.4 m-70 -135.43 147.69 49.05 Favored 'General case' 0 N--CA 1.493 1.695 0 CA-C-N 118.948 0.794 . . . . 0.0 111.306 -178.969 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 6.5 t60 -164.85 97.31 0.74 Allowed 'General case' 0 N--CA 1.481 1.101 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.646 179.293 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 15' ' ' GLN . . . . . 0.712 HE22 HG23 ' C' ' 36' ' ' VAL . 13.6 pt20 -102.05 -173.85 2.44 Favored 'General case' 0 CA--C 1.508 -0.645 0 N-CA-C 108.606 -0.887 . . . . 0.0 108.606 -179.735 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -170.06 95.81 0.27 Allowed 'General case' 0 N--CA 1.468 0.47 0 CA-C-N 114.623 -1.171 . . . . 0.0 108.292 178.298 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 6.4 mp -123.73 157.17 34.58 Favored 'General case' 0 N--CA 1.497 1.899 0 CA-C-O 121.808 0.813 . . . . 0.0 111.189 -178.194 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 61.7 t -112.32 127.63 69.41 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.057 0 N-CA-C 108.111 -1.07 . . . . 0.0 108.111 177.516 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 27.4 m-85 -127.58 122.77 34.09 Favored 'General case' 0 N--CA 1.493 1.723 0 CA-C-N 119.688 1.131 . . . . 0.0 110.305 179.861 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 66.6 m-85 53.28 74.77 0.28 Allowed 'General case' 0 CA--C 1.538 0.492 0 CA-C-O 121.488 0.661 . . . . 0.0 111.851 178.304 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -79.96 -78.23 0.17 Allowed 'General case' 0 C--N 1.35 0.621 0 CA-C-N 115.008 -0.996 . . . . 0.0 110.291 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 40.1 tt0 -113.58 100.66 8.67 Favored 'General case' 0 N--CA 1.471 0.591 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 179.629 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 4.4 p30 -158.29 140.41 14.09 Favored 'General case' 0 N--CA 1.484 1.229 0 O-C-N 122.264 -0.272 . . . . 0.0 111.117 179.183 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 24' ' ' VAL . . . . . 0.402 HG12 ' N ' ' C' ' 25' ' ' GLY . 59.4 t -59.88 163.51 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.868 0 N-CA-C 108.072 -1.084 . . . . 0.0 108.072 177.096 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 25' ' ' GLY . . . . . 0.501 ' H ' ' HB ' ' F' ' 24' ' ' VAL . . . -117.79 47.94 0.99 Allowed Glycine 0 N--CA 1.478 1.492 0 N-CA-C 111.597 -0.601 . . . . 0.0 111.597 -179.314 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -61.59 -168.18 0.01 OUTLIER 'General case' 0 N--CA 1.469 0.487 0 N-CA-C 110.268 -0.271 . . . . 0.0 110.268 179.447 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 26.7 t-20 -70.51 80.99 0.57 Allowed 'General case' 0 N--CA 1.466 0.332 0 N-CA-C 110.026 -0.361 . . . . 0.0 110.026 179.595 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -78.3 143.76 36.7 Favored 'General case' 0 N--CA 1.472 0.66 0 N-CA-C 109.089 -0.708 . . . . 0.0 109.089 179.312 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.45 -167.34 0.95 Allowed Glycine 0 CA--C 1.525 0.672 0 N-CA-C 109.937 -1.265 . . . . 0.0 109.937 178.689 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.86 113.97 26.86 Favored 'General case' 0 N--CA 1.48 1.028 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 179.657 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 66.0 mt -97.88 135.57 31.92 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.557 0 N-CA-C 106.942 -1.503 . . . . 0.0 106.942 178.992 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 38.8 pt -152.01 -176.42 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.354 0.768 0 CA-C-N 115.902 -0.59 . . . . 0.0 111.122 -178.791 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.45 4.52 9.36 Favored Glycine 0 CA--C 1.525 0.717 0 N-CA-C 110.907 -0.877 . . . . 0.0 110.907 179.882 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 34' ' ' LEU . . . . . 0.403 HD23 ' N ' ' C' ' 35' ' ' MET . 1.6 tt -74.75 126.34 30.68 Favored 'General case' 0 CA--C 1.543 0.692 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 -179.619 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 35' ' ' MET . . . . . 0.403 ' N ' HD23 ' C' ' 34' ' ' LEU . 27.5 ttt -162.57 150.36 13.97 Favored 'General case' 0 N--CA 1.466 0.349 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 178.763 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 36' ' ' VAL . . . . . 0.712 HG23 HE22 ' C' ' 15' ' ' GLN . 27.6 m -156.09 165.22 1.12 Allowed 'Isoleucine or valine' 0 C--N 1.347 0.48 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 179.543 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.14 66.74 2.63 Favored Glycine 0 C--N 1.306 -1.106 0 CA-C-N 115.721 -0.672 . . . . 0.0 112.072 178.548 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.84 -172.47 25.06 Favored Glycine 0 N--CA 1.476 1.308 0 N-CA-C 110.813 -0.915 . . . . 0.0 110.813 178.999 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 39' ' ' VAL . . . . . 0.505 ' H ' HG12 ' F' ' 39' ' ' VAL . 35.6 m -126.21 157.66 36.36 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.892 0 C-N-CA 123.429 0.692 . . . . 0.0 110.421 -179.667 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 27.2 t . . . . . 0 C--O 1.219 -0.512 0 CA-C-O 118.43 -0.795 . . . . 0.0 110.526 179.722 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' D' D ' 1' ' ' ASP . . . . . . . . . . . . . 14.8 m-20 . . . . . 0 N--CA 1.488 1.443 0 N-CA-C 109.228 -0.656 . . . . 0.0 109.228 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' D' D ' 2' ' ' ALA . . . . . . . . . . . . . . . -77.28 129.8 36.36 Favored 'General case' 0 C--O 1.239 0.506 0 N-CA-C 109.726 -0.472 . . . . 0.0 109.726 -179.568 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 3' ' ' GLU . . . . . . . . . . . . . 44.1 mt-10 -119.6 110.66 17.12 Favored 'General case' 0 C--O 1.208 -1.083 0 N-CA-C 109.523 -0.547 . . . . 0.0 109.523 -179.492 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 26.7 m-85 -77.33 166.98 22.46 Favored 'General case' 0 N--CA 1.485 1.276 0 C-N-CA 126.7 2.0 . . . . 0.0 108.304 -179.52 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 5' ' ' ARG . . . . . . . . . . . . 0.314 94.1 mtt180 -77.63 134.01 38.29 Favored 'General case' 0 N--CA 1.483 1.179 0 CA-C-O 123.01 1.386 . . . . 0.0 107.946 -169.394 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 6.2 t-160 -95.14 130.81 41.71 Favored 'General case' 0 C--N 1.364 1.231 0 CA-C-N 113.53 -1.668 . . . . 0.0 108.662 -177.259 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 7' ' ' ASP . . . . . 0.474 ' O ' ' OG ' ' G' ' 8' ' ' SER . 2.8 m-20 -66.29 125.44 25.59 Favored 'General case' 0 C--N 1.309 -1.161 0 C-N-CA 126.841 2.056 . . . . 0.0 114.989 173.304 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 8' ' ' SER . . . . . . . . . . . . . 27.6 p -153.35 -167.15 2.62 Favored 'General case' 0 N--CA 1.488 1.458 0 CA-C-N 120.187 1.358 . . . . 0.0 110.962 176.868 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.78 47.15 1.2 Allowed Glycine 0 N--CA 1.484 1.897 0 C-N-CA 124.797 1.189 . . . . 0.0 110.741 176.961 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 51.0 p90 -60.79 131.66 51.41 Favored 'General case' 0 N--CA 1.47 0.553 0 N-CA-C 112.838 0.681 . . . . 0.0 112.838 177.657 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 48.5 mt-10 -88.6 150.95 22.78 Favored 'General case' 0 N--CA 1.48 1.067 0 CA-C-N 117.862 0.301 . . . . 0.0 110.591 175.553 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -149.5 129.9 4.3 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.609 0 N-CA-C 107.377 -1.342 . . . . 0.0 107.377 173.464 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 42.4 m-70 -129.96 150.69 51.13 Favored 'General case' 0 N--CA 1.483 1.176 0 N-CA-C 112.05 0.389 . . . . 0.0 112.05 176.757 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 6.6 t60 -165.04 104.37 0.77 Allowed 'General case' 0 N--CA 1.483 1.194 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 172.32 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 15' ' ' GLN . . . . . 0.748 HE22 HG23 ' D' ' 36' ' ' VAL . 13.5 pt20 -105.48 -176.17 3.0 Favored 'General case' 0 CA--C 1.501 -0.908 0 N-CA-C 108.491 -0.929 . . . . 0.0 108.491 179.243 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -166.03 104.59 0.67 Allowed 'General case' 0 N--CA 1.466 0.327 0 N-CA-C 106.064 -1.828 . . . . 0.0 106.064 174.26 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 5.4 mp -130.87 153.86 48.68 Favored 'General case' 0 N--CA 1.499 1.988 0 CA-C-O 122.188 0.994 . . . . 0.0 110.604 179.563 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 35.8 t -101.29 131.79 48.35 Favored 'Isoleucine or valine' 0 C--O 1.259 1.57 0 CA-C-O 116.884 -1.531 . . . . 0.0 109.563 174.11 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 25.0 m-85 -130.45 126.3 36.62 Favored 'General case' 0 N--CA 1.49 1.544 0 CA-C-N 120.063 1.302 . . . . 0.0 109.591 173.9 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 66.3 m-85 55.65 71.69 0.53 Allowed 'General case' 0 C--N 1.348 0.535 0 CA-C-N 115.618 -0.719 . . . . 0.0 111.521 175.989 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -81.92 -73.03 0.41 Allowed 'General case' 0 C--N 1.35 0.607 0 CA-C-O 118.478 -0.772 . . . . 0.0 110.988 -177.647 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 40.9 tt0 -117.0 104.62 11.45 Favored 'General case' 0 N--CA 1.482 1.14 0 N-CA-C 106.404 -1.702 . . . . 0.0 106.404 176.32 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -152.06 140.43 20.51 Favored 'General case' 0 N--CA 1.476 0.865 0 CA-C-O 116.797 -1.573 . . . . 0.0 113.494 177.995 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 24' ' ' VAL . . . . . 0.51 ' HB ' ' H ' ' A' ' 25' ' ' GLY . 79.3 t -62.53 165.93 1.01 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.282 0 CA-C-N 121.063 1.756 . . . . 0.0 108.013 175.027 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 25' ' ' GLY . . . . . 0.571 ' H ' ' HB ' ' G' ' 24' ' ' VAL . . . -116.92 51.15 0.74 Allowed Glycine 0 N--CA 1.479 1.508 0 CA-C-O 119.003 -0.887 . . . . 0.0 111.78 178.196 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -57.72 -170.71 0.01 OUTLIER 'General case' 0 C--N 1.32 -0.689 0 C-N-CA 123.563 0.745 . . . . 0.0 111.643 176.042 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 28.2 t-20 -72.73 86.62 1.24 Allowed 'General case' 0 C--N 1.346 0.435 0 N-CA-C 108.421 -0.955 . . . . 0.0 108.421 177.952 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 97.4 mttt -83.27 146.21 28.67 Favored 'General case' 0 C--N 1.352 0.708 0 N-CA-C 108.063 -1.088 . . . . 0.0 108.063 179.138 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -62.8 -164.98 0.5 Allowed Glycine 0 C--N 1.337 0.592 0 N-CA-C 110.626 -0.99 . . . . 0.0 110.626 179.1 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -102.38 116.13 32.0 Favored 'General case' 0 N--CA 1.47 0.533 0 N-CA-C 109.155 -0.683 . . . . 0.0 109.155 179.394 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 73.9 mt -102.68 142.59 16.5 Favored 'Isoleucine or valine' 0 C--N 1.356 0.867 0 N-CA-C 104.505 -2.406 . . . . 0.0 104.505 -179.917 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 32' ' ' ILE . . . . . 0.431 HG22 ' H ' ' G' ' 32' ' ' ILE . 39.4 pt -158.25 -177.39 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.126 0 CA-C-O 120.939 0.4 . . . . 0.0 110.186 -177.075 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 64.32 4.64 13.06 Favored Glycine 0 C--O 1.241 0.562 0 N-CA-C 110.132 -1.187 . . . . 0.0 110.132 -178.828 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 2.1 tt -77.52 133.39 38.55 Favored 'General case' 0 C--N 1.369 1.438 0 C-N-CA 117.944 -1.502 . . . . 0.0 107.155 -177.801 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 35' ' ' MET . . . . . 0.415 ' O ' HG13 ' D' ' 36' ' ' VAL . 27.9 ttt -158.3 161.48 37.67 Favored 'General case' 0 CA--C 1.509 -0.62 0 CA-C-O 118.213 -0.899 . . . . 0.0 108.858 173.574 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 36' ' ' VAL . . . . . 0.748 HG23 HE22 ' D' ' 15' ' ' GLN . 27.7 m -164.63 164.36 0.66 Allowed 'Isoleucine or valine' 0 CA--C 1.517 -0.319 0 N-CA-C 108.064 -1.088 . . . . 0.0 108.064 175.62 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 60.18 64.05 4.5 Favored Glycine 0 C--N 1.313 -0.706 0 C-N-CA 119.759 -1.21 . . . . 0.0 112.883 178.318 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 140.68 -171.27 24.12 Favored Glycine 0 N--CA 1.48 1.581 0 CA-C-N 117.319 0.559 . . . . 0.0 111.769 -179.221 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 39' ' ' VAL . . . . . 0.522 ' H ' HG12 ' G' ' 39' ' ' VAL . 34.9 m -128.37 154.81 39.6 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.851 0 C-N-CA 122.716 0.406 . . . . 0.0 110.146 -176.877 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 25.3 t . . . . . 0 C--N 1.332 -0.16 0 CA-C-O 116.657 -1.64 . . . . 0.0 110.051 178.19 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' E' E ' 1' ' ' ASP . . . . . . . . . . . . . 14.1 m-20 . . . . . 0 N--CA 1.491 1.603 0 N-CA-C 109.365 -0.605 . . . . 0.0 109.365 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' E' E ' 2' ' ' ALA . . . . . . . . . . . . . . . -77.18 128.23 34.04 Favored 'General case' 0 N--CA 1.469 0.515 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.004 -179.732 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 3' ' ' GLU . . . . . . . . . . . . . 44.0 mt-10 -117.45 106.66 13.42 Favored 'General case' 0 N--CA 1.482 1.137 0 C-N-CA 122.312 0.245 . . . . 0.0 110.543 -179.806 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 24.0 m-85 -70.46 172.61 8.12 Favored 'General case' 0 N--CA 1.475 0.794 0 N-CA-C 109.962 -0.384 . . . . 0.0 109.962 179.322 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 5' ' ' ARG . . . . . . . . . . . . . 86.2 mtt180 -68.94 131.89 45.82 Favored 'General case' 0 N--CA 1.475 0.804 0 CA-C-N 116.423 -0.353 . . . . 0.0 111.153 -178.36 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 6' ' ' HIS . . . . . 0.418 ' CE1' ' O ' ' E' ' 7' ' ' ASP . 1.5 t60 -97.66 129.03 44.77 Favored 'General case' 0 N--CA 1.475 0.789 0 N-CA-C 109.194 -0.669 . . . . 0.0 109.194 179.08 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 7' ' ' ASP . . . . . 0.418 ' O ' ' CE1' ' E' ' 6' ' ' HIS . 4.2 m-20 -74.42 139.91 44.33 Favored 'General case' 0 N--CA 1.468 0.445 0 CA-C-N 116.513 -0.312 . . . . 0.0 110.531 178.725 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 8' ' ' SER . . . . . . . . . . . . . 24.8 p -163.68 -168.25 1.6 Allowed 'General case' 0 N--CA 1.485 1.301 0 CA-C-O 120.888 0.375 . . . . 0.0 110.886 178.922 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 105.57 44.84 1.39 Allowed Glycine 0 N--CA 1.482 1.732 0 N-CA-C 111.485 -0.646 . . . . 0.0 111.485 -179.682 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 47.0 p90 -63.84 133.45 53.4 Favored 'General case' 0 N--CA 1.475 0.783 0 N-CA-C 112.02 0.378 . . . . 0.0 112.02 -179.806 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 47.2 mt-10 -90.73 152.39 20.84 Favored 'General case' 0 N--CA 1.48 1.036 0 CA-C-O 121.111 0.481 . . . . 0.0 109.747 177.777 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -154.09 127.44 1.19 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.574 0 N-CA-C 107.795 -1.187 . . . . 0.0 107.795 178.003 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 45.0 m-70 -135.74 146.38 47.61 Favored 'General case' 0 N--CA 1.483 1.215 0 CA-C-O 120.869 0.366 . . . . 0.0 111.542 -178.025 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 6.5 t60 -164.32 97.15 0.79 Allowed 'General case' 0 N--CA 1.486 1.344 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.592 179.459 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 15' ' ' GLN . . . . . 0.762 HE22 HG23 ' E' ' 36' ' ' VAL . 13.6 pt20 -101.4 -173.83 2.46 Favored 'General case' 0 CA--C 1.51 -0.588 0 N-CA-C 108.924 -0.769 . . . . 0.0 108.924 -179.728 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -169.77 94.67 0.27 Allowed 'General case' 0 N--CA 1.472 0.647 0 CA-C-N 114.774 -1.103 . . . . 0.0 108.464 178.347 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 6.2 mp -122.4 156.72 33.41 Favored 'General case' 0 N--CA 1.495 1.787 0 CA-C-O 121.698 0.761 . . . . 0.0 111.641 -177.546 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 48.3 t -113.88 124.36 70.46 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.232 0 N-CA-C 108.212 -1.033 . . . . 0.0 108.212 177.245 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 29.8 m-85 -124.83 121.97 36.07 Favored 'General case' 0 N--CA 1.489 1.524 0 CA-C-O 120.907 0.384 . . . . 0.0 110.974 -179.563 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 67.2 m-85 54.47 73.57 0.39 Allowed 'General case' 0 N--CA 1.469 0.476 0 CA-C-N 115.892 -0.594 . . . . 0.0 111.53 177.931 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -78.27 -78.46 0.14 Allowed 'General case' 0 CA--C 1.535 0.377 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.258 -179.711 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 40.9 tt0 -113.02 101.56 9.58 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 108.319 -0.993 . . . . 0.0 108.319 179.683 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -158.15 140.58 14.41 Favored 'General case' 0 C--O 1.205 -1.285 0 CA-C-O 119.488 -0.292 . . . . 0.0 111.481 179.17 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 24' ' ' VAL . . . . . 0.516 ' HB ' ' H ' ' B' ' 25' ' ' GLY . 63.3 t -58.7 168.46 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.973 0 N-CA-C 107.629 -1.248 . . . . 0.0 107.629 177.034 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 25' ' ' GLY . . . . . 0.471 ' H ' ' HB ' ' H' ' 24' ' ' VAL . . . -122.57 47.68 1.0 Allowed Glycine 0 N--CA 1.475 1.264 0 N-CA-C 110.931 -0.867 . . . . 0.0 110.931 -179.347 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -61.81 -167.48 0.01 OUTLIER 'General case' 0 N--CA 1.47 0.548 0 CA-C-O 120.704 0.288 . . . . 0.0 110.469 179.808 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 27.2 t-20 -70.68 77.85 0.6 Allowed 'General case' 0 N--CA 1.467 0.377 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.393 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -75.48 144.56 42.0 Favored 'General case' 0 N--CA 1.475 0.817 0 N-CA-C 109.567 -0.531 . . . . 0.0 109.567 179.331 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.46 -166.4 1.14 Allowed Glycine 0 CA--C 1.522 0.474 0 N-CA-C 110.421 -1.072 . . . . 0.0 110.421 178.629 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -100.08 113.36 25.92 Favored 'General case' 0 N--CA 1.468 0.443 0 N-CA-C 109.961 -0.385 . . . . 0.0 109.961 179.659 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 66.3 mt -97.36 135.28 32.2 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.443 0 N-CA-C 106.752 -1.573 . . . . 0.0 106.752 179.146 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 32' ' ' ILE . . . . . 0.427 HG22 ' H ' ' H' ' 32' ' ' ILE . 39.2 pt -151.74 -174.73 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.123 0 CA-C-O 121.165 0.507 . . . . 0.0 110.682 -179.072 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.5 5.66 6.97 Favored Glycine 0 CA--C 1.53 1.03 0 CA-C-N 115.504 -0.771 . . . . 0.0 111.34 -179.674 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 34' ' ' LEU . . . . . 0.402 HD23 ' N ' ' E' ' 35' ' ' MET . 1.7 tt -74.86 126.62 31.34 Favored 'General case' 0 CA--C 1.545 0.787 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 -179.613 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 35' ' ' MET . . . . . 0.402 ' N ' HD23 ' E' ' 34' ' ' LEU . 28.2 ttt -162.14 151.11 15.41 Favored 'General case' 0 C--O 1.203 -1.348 0 N-CA-C 108.972 -0.751 . . . . 0.0 108.972 178.776 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 36' ' ' VAL . . . . . 0.762 HG23 HE22 ' E' ' 15' ' ' GLN . 32.9 m -157.04 165.22 1.01 Allowed 'Isoleucine or valine' 0 C--N 1.343 0.287 0 N-CA-C 108.434 -0.95 . . . . 0.0 108.434 179.596 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.61 67.08 2.39 Favored Glycine 0 C--N 1.306 -1.096 0 CA-C-N 115.762 -0.654 . . . . 0.0 111.95 178.774 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.88 -172.48 25.08 Favored Glycine 0 N--CA 1.476 1.362 0 N-CA-C 111.16 -0.776 . . . . 0.0 111.16 179.034 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 39' ' ' VAL . . . . . 0.53 ' H ' HG12 ' H' ' 39' ' ' VAL . 33.4 m -126.29 156.78 36.86 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.703 0 C-N-CA 123.452 0.701 . . . . 0.0 110.682 -179.402 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 26.1 t . . . . . 0 C--O 1.218 -0.56 0 CA-C-O 118.451 -0.785 . . . . 0.0 110.701 179.525 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' F' F ' 1' ' ' ASP . . . . . . . . . . . . . 14.9 m-20 . . . . . 0 N--CA 1.489 1.519 0 N-CA-C 109.263 -0.643 . . . . 0.0 109.263 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' F' F ' 2' ' ' ALA . . . . . . . . . . . . . . . -76.63 129.0 35.78 Favored 'General case' 0 N--CA 1.469 0.516 0 CA-C-N 116.298 -0.41 . . . . 0.0 109.984 -179.73 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 3' ' ' GLU . . . . . . . . . . . . . 43.9 mt-10 -118.33 106.81 13.15 Favored 'General case' 0 N--CA 1.483 1.189 0 N-CA-C 110.402 -0.222 . . . . 0.0 110.402 -179.78 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 24.0 m-85 -70.67 172.57 8.44 Favored 'General case' 0 N--CA 1.474 0.754 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 179.348 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 5' ' ' ARG . . . . . . . . . . . . . 87.2 mtt180 -69.0 132.66 47.02 Favored 'General case' 0 C--O 1.217 -0.634 0 CA-C-N 116.419 -0.355 . . . . 0.0 111.289 -178.244 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 6' ' ' HIS . . . . . 0.415 ' CE1' ' O ' ' F' ' 7' ' ' ASP . 1.5 t60 -98.31 128.69 44.86 Favored 'General case' 0 N--CA 1.477 0.889 0 N-CA-C 109.323 -0.621 . . . . 0.0 109.323 179.31 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 7' ' ' ASP . . . . . 0.415 ' O ' ' CE1' ' F' ' 6' ' ' HIS . 4.3 m-20 -74.1 139.54 44.66 Favored 'General case' 0 N--CA 1.467 0.42 0 CA-C-N 116.542 -0.299 . . . . 0.0 110.662 178.678 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 8' ' ' SER . . . . . . . . . . . . . 24.7 p -163.6 -168.33 1.63 Allowed 'General case' 0 N--CA 1.486 1.327 0 CA-C-O 120.963 0.411 . . . . 0.0 110.945 178.905 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 105.7 44.84 1.37 Allowed Glycine 0 N--CA 1.482 1.745 0 N-CA-C 111.459 -0.656 . . . . 0.0 111.459 -179.729 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 46.2 p90 -63.67 133.72 54.13 Favored 'General case' 0 CA--C 1.543 0.707 0 N-CA-C 112.094 0.405 . . . . 0.0 112.094 -179.639 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 47.2 mt-10 -90.89 152.24 20.82 Favored 'General case' 0 N--CA 1.481 1.085 0 CA-C-O 121.172 0.51 . . . . 0.0 109.74 177.794 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -153.92 127.19 1.18 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.601 0 N-CA-C 107.776 -1.194 . . . . 0.0 107.776 178.034 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 44.3 m-70 -135.53 145.93 47.54 Favored 'General case' 0 N--CA 1.484 1.232 0 CA-C-O 120.796 0.331 . . . . 0.0 111.635 -177.959 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 6.6 t60 -163.94 97.26 0.83 Allowed 'General case' 0 N--CA 1.486 1.335 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.697 179.442 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 15' ' ' GLN . . . . . 0.726 HE22 HG23 ' F' ' 36' ' ' VAL . 13.3 pt20 -101.68 -173.96 2.48 Favored 'General case' 0 CA--C 1.507 -0.698 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 -179.711 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -169.5 94.71 0.29 Allowed 'General case' 0 N--CA 1.471 0.597 0 CA-C-N 114.633 -1.167 . . . . 0.0 108.424 178.357 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 6.3 mp -122.16 156.84 32.83 Favored 'General case' 0 N--CA 1.495 1.817 0 CA-C-O 121.628 0.728 . . . . 0.0 111.623 -177.687 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 48.6 t -113.94 124.35 70.51 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.181 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 177.185 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 29.8 m-85 -124.72 121.69 35.37 Favored 'General case' 0 N--CA 1.489 1.49 0 CA-C-O 120.888 0.375 . . . . 0.0 110.984 -179.57 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 67.3 m-85 54.41 74.08 0.36 Allowed 'General case' 0 C--N 1.344 0.353 0 CA-C-N 115.917 -0.583 . . . . 0.0 111.68 178.032 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -78.4 -78.42 0.14 Allowed 'General case' 0 CA--C 1.535 0.375 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.282 -179.707 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 40.8 tt0 -113.19 101.39 9.38 Favored 'General case' 0 C--N 1.325 -0.477 0 N-CA-C 108.312 -0.996 . . . . 0.0 108.312 179.777 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -158.08 140.52 14.45 Favored 'General case' 0 C--O 1.204 -1.308 0 CA-C-O 119.537 -0.268 . . . . 0.0 111.419 179.045 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 24' ' ' VAL . . . . . 0.501 ' HB ' ' H ' ' C' ' 25' ' ' GLY . 60.6 t -58.61 168.61 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.962 0 N-CA-C 107.644 -1.243 . . . . 0.0 107.644 177.047 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 25' ' ' GLY . . . . . 0.467 ' H ' ' HB ' ' I' ' 24' ' ' VAL . . . -122.71 48.07 0.98 Allowed Glycine 0 N--CA 1.477 1.381 0 N-CA-C 110.822 -0.911 . . . . 0.0 110.822 -179.398 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -62.24 -167.63 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.559 0 CA-C-O 120.75 0.309 . . . . 0.0 110.417 179.807 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 27.2 t-20 -70.16 77.54 0.51 Allowed 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.432 -179.936 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -75.49 144.18 42.17 Favored 'General case' 0 N--CA 1.475 0.814 0 N-CA-C 109.551 -0.537 . . . . 0.0 109.551 179.489 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.14 -166.58 1.07 Allowed Glycine 0 CA--C 1.522 0.512 0 N-CA-C 110.55 -1.02 . . . . 0.0 110.55 178.596 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.72 113.69 26.33 Favored 'General case' 0 N--CA 1.471 0.589 0 N-CA-C 109.879 -0.415 . . . . 0.0 109.879 179.649 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 66.2 mt -97.85 135.22 33.15 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.43 0 N-CA-C 106.796 -1.557 . . . . 0.0 106.796 179.058 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 32' ' ' ILE . . . . . 0.43 HG22 ' H ' ' I' ' 32' ' ' ILE . 39.7 pt -151.65 -174.43 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.136 0 CA-C-O 121.208 0.527 . . . . 0.0 110.64 -179.049 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.11 6.0 6.59 Favored Glycine 0 CA--C 1.53 0.97 0 CA-C-N 115.426 -0.806 . . . . 0.0 111.345 -179.778 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 34' ' ' LEU . . . . . 0.422 HD23 ' N ' ' F' ' 35' ' ' MET . 1.7 tt -75.43 127.28 32.76 Favored 'General case' 0 N--CA 1.475 0.783 0 N-CA-C 109.31 -0.626 . . . . 0.0 109.31 -179.5 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 35' ' ' MET . . . . . 0.422 ' N ' HD23 ' F' ' 34' ' ' LEU . 28.2 ttt -163.18 152.02 14.45 Favored 'General case' 0 C--O 1.204 -1.306 0 N-CA-C 109.203 -0.665 . . . . 0.0 109.203 178.437 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 36' ' ' VAL . . . . . 0.726 HG23 HE22 ' F' ' 15' ' ' GLN . 32.6 m -157.21 165.69 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.342 0.26 0 N-CA-C 108.408 -0.96 . . . . 0.0 108.408 179.897 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.34 67.41 2.22 Favored Glycine 0 C--N 1.307 -1.081 0 CA-C-N 115.717 -0.674 . . . . 0.0 111.979 178.56 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.33 -172.33 24.78 Favored Glycine 0 N--CA 1.477 1.378 0 N-CA-C 111.084 -0.807 . . . . 0.0 111.084 178.992 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 39' ' ' VAL . . . . . 0.531 ' H ' HG12 ' I' ' 39' ' ' VAL . 33.3 m -126.39 157.01 37.17 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.685 0 C-N-CA 123.425 0.69 . . . . 0.0 110.688 -179.285 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 26.0 t . . . . . 0 C--O 1.22 -0.496 0 O-C-N 124.017 0.823 . . . . 0.0 110.599 179.358 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' G' G ' 1' ' ' ASP . . . . . . . . . . . . . 14.2 m-20 . . . . . 0 N--CA 1.491 1.608 0 N-CA-C 109.376 -0.602 . . . . 0.0 109.376 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' G' G ' 2' ' ' ALA . . . . . . . . . . . . . . . -76.54 130.3 37.71 Favored 'General case' 0 N--CA 1.473 0.705 0 CA-C-N 116.268 -0.424 . . . . 0.0 109.956 -179.858 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 3' ' ' GLU . . . . . . . . . . . . . 41.3 mt-10 -118.22 108.54 15.27 Favored 'General case' 0 N--CA 1.485 1.297 0 C-N-CA 122.203 0.201 . . . . 0.0 110.498 -179.517 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 29.4 m-85 -70.69 170.41 12.41 Favored 'General case' 0 N--CA 1.476 0.851 0 C-N-CA 122.71 0.404 . . . . 0.0 109.936 179.298 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 5' ' ' ARG . . . . . . . . . . . . . 86.5 mtt180 -67.53 132.18 47.07 Favored 'General case' 0 N--CA 1.473 0.723 0 CA-C-N 116.33 -0.396 . . . . 0.0 110.846 -178.615 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 6.4 t-160 -98.27 129.92 44.98 Favored 'General case' 0 N--CA 1.474 0.761 0 N-CA-C 109.415 -0.587 . . . . 0.0 109.415 179.108 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -75.92 135.73 40.09 Favored 'General case' 0 N--CA 1.47 0.554 0 C-N-CA 122.714 0.406 . . . . 0.0 111.097 179.006 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 8' ' ' SER . . . . . 0.474 ' OG ' ' O ' ' D' ' 7' ' ' ASP . 24.7 p -160.11 -166.23 1.65 Allowed 'General case' 0 N--CA 1.477 0.903 0 CA-C-O 120.971 0.415 . . . . 0.0 110.512 178.73 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.42 45.51 1.43 Allowed Glycine 0 N--CA 1.481 1.684 0 N-CA-C 111.211 -0.756 . . . . 0.0 111.211 179.866 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 48.9 p90 -64.59 133.43 52.28 Favored 'General case' 0 CA--C 1.542 0.641 0 N-CA-C 111.91 0.337 . . . . 0.0 111.91 -179.562 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 49.4 mt-10 -90.97 151.76 20.96 Favored 'General case' 0 N--CA 1.479 1.018 0 CA-C-O 121.006 0.432 . . . . 0.0 110.036 178.41 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -154.82 127.53 1.08 Allowed 'Isoleucine or valine' 0 CA--C 1.553 1.088 0 N-CA-C 107.845 -1.169 . . . . 0.0 107.845 178.359 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 46.0 m-70 -135.23 147.11 49.21 Favored 'General case' 0 N--CA 1.478 0.934 0 CA-C-N 115.433 -0.803 . . . . 0.0 111.471 -178.135 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 33.2 t-80 -165.22 97.63 0.71 Allowed 'General case' 0 N--CA 1.483 1.22 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.214 178.82 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 15' ' ' GLN . . . . . 0.777 HE22 HG23 ' G' ' 36' ' ' VAL . 13.7 pt20 -102.06 -173.81 2.43 Favored 'General case' 0 CA--C 1.507 -0.678 0 N-CA-C 108.688 -0.856 . . . . 0.0 108.688 -179.595 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -170.32 94.37 0.23 Allowed 'General case' 0 N--CA 1.471 0.624 0 CA-C-N 114.663 -1.153 . . . . 0.0 108.224 178.54 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 6.3 mp -121.86 155.94 34.32 Favored 'General case' 0 N--CA 1.498 1.935 0 CA-C-O 121.298 0.571 . . . . 0.0 111.881 -177.812 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 43.2 t -113.63 124.53 70.36 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.013 0 CA-C-N 114.746 -1.115 . . . . 0.0 108.156 176.617 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 31.5 m-85 -125.13 121.76 35.16 Favored 'General case' 0 C--N 1.366 1.314 0 C-N-CA 123.358 0.663 . . . . 0.0 111.01 -179.324 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 66.7 m-85 54.4 73.43 0.4 Allowed 'General case' 0 N--CA 1.467 0.407 0 CA-C-N 115.865 -0.607 . . . . 0.0 111.532 177.898 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.49 -77.86 0.14 Allowed 'General case' 0 N--CA 1.473 0.682 0 O-C-N 122.296 -0.252 . . . . 0.0 110.451 -179.426 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 40.9 tt0 -113.59 101.61 9.49 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 108.048 -1.093 . . . . 0.0 108.048 179.806 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -158.25 141.65 15.18 Favored 'General case' 0 N--CA 1.478 0.964 0 O-C-N 122.368 -0.207 . . . . 0.0 111.438 179.067 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 24' ' ' VAL . . . . . 0.571 ' HB ' ' H ' ' D' ' 25' ' ' GLY . 58.8 t -60.23 167.12 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.637 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 177.338 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 25' ' ' GLY . . . . . 0.426 ' N ' HG12 ' G' ' 24' ' ' VAL . . . -120.71 48.51 0.94 Allowed Glycine 0 N--CA 1.481 1.662 0 N-CA-C 110.548 -1.021 . . . . 0.0 110.548 -179.499 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -62.93 -167.73 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.648 0 CA-C-N 117.03 0.415 . . . . 0.0 109.943 179.825 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 27.6 t-20 -70.28 77.2 0.54 Allowed 'General case' 0 CA--C 1.536 0.413 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.456 -179.979 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 97.9 mttt -74.29 144.23 44.66 Favored 'General case' 0 N--CA 1.475 0.807 0 N-CA-C 109.642 -0.503 . . . . 0.0 109.642 179.292 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.56 -164.98 0.92 Allowed Glycine 0 C--N 1.337 0.609 0 N-CA-C 110.061 -1.216 . . . . 0.0 110.061 178.623 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -100.03 113.48 26.11 Favored 'General case' 0 N--CA 1.469 0.52 0 C-N-CA 122.737 0.415 . . . . 0.0 110.577 179.865 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 67.6 mt -98.33 135.51 32.81 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.838 0 N-CA-C 106.827 -1.546 . . . . 0.0 106.827 179.062 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 32' ' ' ILE . . . . . 0.431 ' H ' HG22 ' D' ' 32' ' ' ILE . 39.6 pt -152.27 -174.32 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.725 0 CA-C-N 119.784 1.174 . . . . 0.0 109.897 -179.473 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.06 5.63 8.14 Favored Glycine 0 CA--C 1.527 0.789 0 N-CA-C 111.03 -0.828 . . . . 0.0 111.03 -179.928 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 1.6 tt -75.71 125.46 29.09 Favored 'General case' 0 CA--C 1.544 0.733 0 N-CA-C 109.561 -0.533 . . . . 0.0 109.561 -179.574 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 28.1 ttt -161.04 152.91 19.67 Favored 'General case' 0 C--O 1.206 -1.194 0 N-CA-C 108.861 -0.792 . . . . 0.0 108.861 178.712 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 36' ' ' VAL . . . . . 0.777 HG23 HE22 ' G' ' 15' ' ' GLN . 30.4 m -157.8 164.28 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.343 0.293 0 N-CA-C 108.471 -0.937 . . . . 0.0 108.471 -179.836 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.42 67.63 2.11 Favored Glycine 0 C--N 1.309 -0.955 0 CA-C-N 115.602 -0.726 . . . . 0.0 112.207 178.457 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.89 -171.64 25.39 Favored Glycine 0 N--CA 1.478 1.438 0 N-CA-C 110.6 -1.0 . . . . 0.0 110.6 178.981 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 39' ' ' VAL . . . . . 0.522 HG12 ' H ' ' D' ' 39' ' ' VAL . 33.9 m -127.04 157.22 38.59 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.763 0 C-N-CA 123.138 0.575 . . . . 0.0 110.807 -179.43 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 28.0 t . . . . . 0 C--O 1.219 -0.51 0 O-C-N 123.976 0.797 . . . . 0.0 110.85 179.364 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' H' H ' 1' ' ' ASP . . . . . . . . . . . . . 15.2 m-20 . . . . . 0 N--CA 1.49 1.567 0 N-CA-C 109.438 -0.579 . . . . 0.0 109.438 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' H' H ' 2' ' ' ALA . . . . . . . . . . . . . . . -76.78 129.45 36.3 Favored 'General case' 0 N--CA 1.473 0.724 0 CA-C-N 116.22 -0.446 . . . . 0.0 109.942 -179.741 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 3' ' ' GLU . . . . . . . . . . . . . 41.7 mt-10 -117.38 108.79 16.0 Favored 'General case' 0 N--CA 1.483 1.217 0 C-N-CA 122.212 0.205 . . . . 0.0 110.525 -179.498 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 29.7 m-85 -70.97 170.74 12.11 Favored 'General case' 0 N--CA 1.476 0.833 0 C-N-CA 122.739 0.416 . . . . 0.0 109.963 179.209 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 5' ' ' ARG . . . . . . . . . . . . . 86.4 mtt180 -67.7 131.72 46.11 Favored 'General case' 0 N--CA 1.475 0.782 0 CA-C-N 116.421 -0.354 . . . . 0.0 110.798 -178.603 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 6.3 t-160 -98.09 129.5 44.91 Favored 'General case' 0 N--CA 1.475 0.78 0 N-CA-C 109.253 -0.647 . . . . 0.0 109.253 179.114 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -75.42 136.18 40.73 Favored 'General case' 0 N--CA 1.47 0.551 0 C-N-CA 122.666 0.386 . . . . 0.0 111.049 178.936 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 8' ' ' SER . . . . . . . . . . . . . 27.2 p -160.39 -166.52 1.68 Allowed 'General case' 0 N--CA 1.475 0.794 0 CA-C-O 120.85 0.357 . . . . 0.0 110.476 178.786 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.27 46.16 1.37 Allowed Glycine 0 N--CA 1.481 1.674 0 N-CA-C 111.292 -0.723 . . . . 0.0 111.292 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 48.6 p90 -65.46 133.73 51.92 Favored 'General case' 0 CA--C 1.542 0.665 0 N-CA-C 111.894 0.331 . . . . 0.0 111.894 -179.635 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 48.8 mt-10 -91.2 151.63 20.87 Favored 'General case' 0 N--CA 1.479 0.98 0 CA-C-O 121.0 0.429 . . . . 0.0 110.154 178.481 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -154.52 127.66 1.16 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.057 0 N-CA-C 107.874 -1.158 . . . . 0.0 107.874 178.267 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 45.9 m-70 -135.25 147.0 49.14 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.438 -0.801 . . . . 0.0 111.408 -178.073 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 32.0 t-80 -165.22 97.33 0.71 Allowed 'General case' 0 N--CA 1.483 1.192 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.264 178.837 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 15' ' ' GLN . . . . . 0.763 HE22 HG23 ' H' ' 36' ' ' VAL . 13.8 pt20 -101.64 -173.77 2.43 Favored 'General case' 0 CA--C 1.511 -0.555 0 N-CA-C 108.637 -0.875 . . . . 0.0 108.637 -179.592 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -170.31 94.22 0.23 Allowed 'General case' 0 N--CA 1.472 0.652 0 CA-C-N 114.664 -1.153 . . . . 0.0 108.116 178.503 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 6.3 mp -121.81 155.66 34.86 Favored 'General case' 0 N--CA 1.498 1.964 0 CA-C-O 121.29 0.567 . . . . 0.0 111.96 -177.778 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 42.2 t -113.33 124.74 70.27 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.044 0 CA-C-N 114.766 -1.106 . . . . 0.0 108.159 176.521 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 30.9 m-85 -125.4 121.06 32.78 Favored 'General case' 0 C--N 1.368 1.401 0 CA-C-N 115.524 -0.762 . . . . 0.0 110.904 -179.082 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 67.2 m-85 54.55 73.63 0.39 Allowed 'General case' 0 C--O 1.236 0.389 0 CA-C-N 115.815 -0.63 . . . . 0.0 111.535 177.9 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.33 -77.98 0.14 Allowed 'General case' 0 N--CA 1.472 0.634 0 O-C-N 122.248 -0.283 . . . . 0.0 110.611 -179.526 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 41.0 tt0 -113.4 101.34 9.29 Favored 'General case' 0 C--N 1.323 -0.578 0 N-CA-C 108.1 -1.074 . . . . 0.0 108.1 179.731 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -157.7 141.87 16.07 Favored 'General case' 0 N--CA 1.478 0.971 0 O-C-N 122.453 -0.155 . . . . 0.0 111.371 179.095 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 24' ' ' VAL . . . . . 0.471 ' HB ' ' H ' ' E' ' 25' ' ' GLY . 57.4 t -60.45 166.92 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.617 0 N-CA-C 107.632 -1.247 . . . . 0.0 107.632 177.246 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 25' ' ' GLY . . . . . 0.423 ' N ' HG12 ' H' ' 24' ' ' VAL . . . -120.6 49.36 0.88 Allowed Glycine 0 N--CA 1.48 1.603 0 N-CA-C 110.528 -1.029 . . . . 0.0 110.528 -179.592 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -63.77 -167.63 0.02 OUTLIER 'General case' 0 N--CA 1.473 0.697 0 CA-C-N 116.99 0.395 . . . . 0.0 110.028 179.812 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 27.4 t-20 -70.2 77.38 0.52 Allowed 'General case' 0 CA--C 1.536 0.41 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.445 179.883 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -74.8 144.21 43.62 Favored 'General case' 0 N--CA 1.474 0.754 0 N-CA-C 109.626 -0.509 . . . . 0.0 109.626 179.366 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.83 -165.42 1.08 Allowed Glycine 0 C--N 1.337 0.607 0 N-CA-C 109.978 -1.249 . . . . 0.0 109.978 178.731 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.66 113.57 26.1 Favored 'General case' 0 N--CA 1.468 0.431 0 C-N-CA 122.632 0.373 . . . . 0.0 110.593 179.902 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 66.6 mt -98.06 135.65 31.88 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.803 0 N-CA-C 106.81 -1.552 . . . . 0.0 106.81 178.964 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 32' ' ' ILE . . . . . 0.427 ' H ' HG22 ' E' ' 32' ' ' ILE . 39.1 pt -152.38 -174.31 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 CA-C-N 119.838 1.199 . . . . 0.0 109.832 -179.637 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.05 5.92 8.75 Favored Glycine 0 CA--C 1.528 0.86 0 N-CA-C 110.974 -0.85 . . . . 0.0 110.974 -179.929 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 34' ' ' LEU . . . . . 0.401 HD23 ' N ' ' H' ' 35' ' ' MET . 1.6 tt -75.84 125.19 28.6 Favored 'General case' 0 CA--C 1.545 0.761 0 N-CA-C 109.512 -0.551 . . . . 0.0 109.512 -179.602 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 35' ' ' MET . . . . . 0.401 ' N ' HD23 ' H' ' 34' ' ' LEU . 28.3 ttt -160.76 152.79 20.03 Favored 'General case' 0 C--O 1.207 -1.144 0 N-CA-C 108.925 -0.768 . . . . 0.0 108.925 178.595 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 36' ' ' VAL . . . . . 0.763 HG23 HE22 ' H' ' 15' ' ' GLN . 28.4 m -157.8 164.17 1.14 Allowed 'Isoleucine or valine' 0 C--N 1.343 0.294 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 -179.81 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.54 67.81 2.01 Favored Glycine 0 C--N 1.309 -0.964 0 CA-C-N 115.559 -0.746 . . . . 0.0 112.168 178.542 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.55 -171.59 25.2 Favored Glycine 0 N--CA 1.478 1.475 0 N-CA-C 110.621 -0.992 . . . . 0.0 110.621 179.05 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 39' ' ' VAL . . . . . 0.53 HG12 ' H ' ' E' ' 39' ' ' VAL . 33.8 m -126.99 157.71 38.23 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.82 0 C-N-CA 123.168 0.587 . . . . 0.0 110.795 -179.456 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 29.7 t . . . . . 0 N--CA 1.469 0.506 0 O-C-N 123.985 0.803 . . . . 0.0 110.745 179.281 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' I' I ' 1' ' ' ASP . . . . . . . . . . . . . 14.2 m-20 . . . . . 0 N--CA 1.491 1.611 0 N-CA-C 109.499 -0.556 . . . . 0.0 109.499 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' I' I ' 2' ' ' ALA . . . . . . . . . . . . . . . -76.19 129.82 37.31 Favored 'General case' 0 N--CA 1.473 0.714 0 CA-C-N 116.282 -0.417 . . . . 0.0 109.947 -179.819 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 3' ' ' GLU . . . . . . . . . . . . . 42.6 mt-10 -117.81 108.63 15.59 Favored 'General case' 0 N--CA 1.484 1.247 0 C-N-CA 122.207 0.203 . . . . 0.0 110.502 -179.565 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 29.3 m-85 -70.74 171.15 10.98 Favored 'General case' 0 N--CA 1.476 0.868 0 C-N-CA 122.733 0.413 . . . . 0.0 109.929 179.236 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 5' ' ' ARG . . . . . . . . . . . . . 86.5 mtt180 -68.18 131.72 45.9 Favored 'General case' 0 N--CA 1.476 0.837 0 CA-C-N 116.435 -0.348 . . . . 0.0 110.719 -178.569 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 6.4 t-160 -97.89 129.56 44.83 Favored 'General case' 0 N--CA 1.473 0.718 0 N-CA-C 109.333 -0.617 . . . . 0.0 109.333 179.051 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -75.48 135.98 40.66 Favored 'General case' 0 CA--C 1.539 0.533 0 C-N-CA 122.707 0.403 . . . . 0.0 111.003 178.955 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 8' ' ' SER . . . . . . . . . . . . . 25.0 p -160.41 -166.63 1.7 Allowed 'General case' 0 N--CA 1.476 0.833 0 CA-C-O 120.936 0.398 . . . . 0.0 110.494 178.841 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.37 45.97 1.38 Allowed Glycine 0 N--CA 1.481 1.693 0 N-CA-C 111.29 -0.724 . . . . 0.0 111.29 179.942 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 49.3 p90 -65.28 133.48 51.55 Favored 'General case' 0 N--CA 1.473 0.681 0 N-CA-C 111.942 0.349 . . . . 0.0 111.942 -179.599 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 49.1 mt-10 -90.93 151.71 21.0 Favored 'General case' 0 N--CA 1.478 0.949 0 CA-C-O 121.077 0.465 . . . . 0.0 110.165 178.463 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -154.72 127.55 1.1 Allowed 'Isoleucine or valine' 0 CA--C 1.553 1.073 0 N-CA-C 107.91 -1.144 . . . . 0.0 107.91 178.248 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 47.0 m-70 -135.22 146.84 49.04 Favored 'General case' 0 N--CA 1.477 0.915 0 CA-C-N 115.45 -0.796 . . . . 0.0 111.404 -178.002 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 31.8 t-80 -165.05 97.41 0.73 Allowed 'General case' 0 N--CA 1.483 1.207 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.27 178.884 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 15' ' ' GLN . . . . . 0.743 HE22 HG23 ' I' ' 36' ' ' VAL . 13.8 pt20 -101.82 -173.71 2.42 Favored 'General case' 0 CA--C 1.509 -0.627 0 N-CA-C 108.681 -0.859 . . . . 0.0 108.681 -179.612 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -170.36 94.02 0.22 Allowed 'General case' 0 N--CA 1.472 0.638 0 CA-C-N 114.628 -1.169 . . . . 0.0 108.128 178.607 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 6.3 mp -121.62 155.86 34.18 Favored 'General case' 0 N--CA 1.497 1.904 0 CA-C-O 121.257 0.551 . . . . 0.0 111.92 -177.751 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 42.1 t -113.53 125.09 70.75 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.997 0 CA-C-N 114.789 -1.096 . . . . 0.0 108.1 176.54 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 31.2 m-85 -125.73 121.41 33.31 Favored 'General case' 0 C--N 1.366 1.325 0 CA-C-N 115.61 -0.723 . . . . 0.0 110.945 -179.229 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 67.1 m-85 54.46 73.3 0.41 Allowed 'General case' 0 C--O 1.237 0.429 0 CA-C-N 115.911 -0.586 . . . . 0.0 111.482 177.885 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.15 -77.92 0.14 Allowed 'General case' 0 N--CA 1.473 0.702 0 O-C-N 122.272 -0.268 . . . . 0.0 110.5 -179.55 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 40.8 tt0 -113.4 101.54 9.48 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 108.069 -1.086 . . . . 0.0 108.069 179.692 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -157.91 141.59 15.56 Favored 'General case' 0 N--CA 1.479 1.004 0 O-C-N 122.42 -0.175 . . . . 0.0 111.361 179.087 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 24' ' ' VAL . . . . . 0.467 ' HB ' ' H ' ' F' ' 25' ' ' GLY . 59.0 t -60.26 167.27 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.631 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 177.22 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 25' ' ' GLY . . . . . 0.44 ' N ' HG12 ' I' ' 24' ' ' VAL . . . -120.89 49.3 0.89 Allowed Glycine 0 N--CA 1.481 1.683 0 N-CA-C 110.523 -1.031 . . . . 0.0 110.523 -179.572 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -63.75 -167.65 0.02 OUTLIER 'General case' 0 N--CA 1.473 0.682 0 CA-C-N 117.002 0.401 . . . . 0.0 109.949 179.768 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 27.6 t-20 -70.21 77.27 0.52 Allowed 'General case' 0 CA--C 1.535 0.401 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.411 179.913 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -74.66 143.92 44.04 Favored 'General case' 0 N--CA 1.475 0.8 0 N-CA-C 109.617 -0.512 . . . . 0.0 109.617 179.424 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.44 -165.8 1.03 Allowed Glycine 0 C--N 1.337 0.601 0 N-CA-C 110.009 -1.236 . . . . 0.0 110.009 178.653 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.26 113.7 26.13 Favored 'General case' 0 N--CA 1.468 0.471 0 C-N-CA 122.729 0.412 . . . . 0.0 110.583 179.991 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 66.9 mt -98.5 135.49 33.12 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.842 0 N-CA-C 106.833 -1.543 . . . . 0.0 106.833 178.98 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 32' ' ' ILE . . . . . 0.43 ' H ' HG22 ' F' ' 32' ' ' ILE . 39.2 pt -152.36 -174.3 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.725 0 CA-C-N 119.8 1.182 . . . . 0.0 109.84 -179.567 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.04 5.84 8.56 Favored Glycine 0 CA--C 1.527 0.819 0 N-CA-C 110.999 -0.84 . . . . 0.0 110.999 -179.874 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 34' ' ' LEU . . . . . 0.402 HD23 ' N ' ' I' ' 35' ' ' MET . 1.6 tt -75.82 125.42 29.05 Favored 'General case' 0 CA--C 1.545 0.753 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 -179.644 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 35' ' ' MET . . . . . 0.402 ' N ' HD23 ' I' ' 34' ' ' LEU . 28.3 ttt -160.88 152.59 19.57 Favored 'General case' 0 C--O 1.206 -1.186 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 178.723 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 36' ' ' VAL . . . . . 0.743 HG23 HE22 ' I' ' 15' ' ' GLN . 26.7 m -157.59 164.1 1.17 Allowed 'Isoleucine or valine' 0 C--N 1.342 0.262 0 N-CA-C 108.448 -0.945 . . . . 0.0 108.448 -179.988 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.57 67.91 1.96 Allowed Glycine 0 C--N 1.309 -0.951 0 CA-C-N 115.602 -0.727 . . . . 0.0 112.122 178.571 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.58 -171.86 25.11 Favored Glycine 0 N--CA 1.478 1.445 0 N-CA-C 110.644 -0.982 . . . . 0.0 110.644 178.97 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 39' ' ' VAL . . . . . 0.531 HG12 ' H ' ' F' ' 39' ' ' VAL . 33.9 m -126.82 157.26 38.07 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.792 0 C-N-CA 123.181 0.592 . . . . 0.0 110.832 -179.452 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 26.0 t . . . . . 0 C--O 1.22 -0.5 0 O-C-N 123.964 0.79 . . . . 0.0 110.825 179.347 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' ASP . . . . . 0.478 ' H1 ' ' CG ' ' D' ' 1' ' ' ASP . 16.2 m-20 . . . . . 0 N--CA 1.489 1.49 0 N-CA-C 108.939 -0.763 . . . . 0.0 108.939 . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -66.19 133.78 51.36 Favored 'General case' 0 CA--C 1.538 0.514 0 N-CA-C 110.075 -0.343 . . . . 0.0 110.075 -179.873 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.403 ' CD ' HH21 ' A' ' 5' ' ' ARG . 49.3 tt0 -169.65 106.08 0.36 Allowed 'General case' 0 N--CA 1.474 0.736 0 N-CA-C 109.961 -0.385 . . . . 0.0 109.961 -179.17 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 63.1 m-85 -83.97 145.68 28.41 Favored 'General case' 0 N--CA 1.474 0.769 0 N-CA-C 110.309 -0.256 . . . . 0.0 110.309 179.484 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' ARG . . . . . 0.403 HH21 ' CD ' ' A' ' 3' ' ' GLU . 99.5 mtt180 -144.45 142.51 30.34 Favored 'General case' 0 N--CA 1.483 1.221 0 N-CA-C 109.958 -0.386 . . . . 0.0 109.958 179.721 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 45.1 t-80 -152.61 118.77 5.51 Favored 'General case' 0 N--CA 1.469 0.524 0 N-CA-C 109.26 -0.645 . . . . 0.0 109.26 178.967 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' ASP . . . . . 0.51 ' O ' ' OG ' ' D' ' 8' ' ' SER . 4.0 m-20 -69.52 149.62 48.03 Favored 'General case' 0 CA--C 1.538 0.49 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.468 179.898 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 52.1 p -168.07 -173.24 2.0 Allowed 'General case' 0 N--CA 1.484 1.249 0 CA-C-O 121.075 0.464 . . . . 0.0 110.706 179.461 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.77 46.85 1.44 Allowed Glycine 0 N--CA 1.483 1.802 0 CA-C-N 115.962 -0.563 . . . . 0.0 111.941 179.808 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 47.8 p90 -65.27 132.56 49.37 Favored 'General case' 0 N--CA 1.471 0.616 0 CA-C-N 116.71 0.255 . . . . 0.0 111.62 179.764 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 48.1 mt-10 -91.87 151.77 20.4 Favored 'General case' 0 N--CA 1.478 0.935 0 N-CA-C 109.692 -0.484 . . . . 0.0 109.692 178.437 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.0 p -152.79 128.19 1.61 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.61 0 N-CA-C 107.894 -1.15 . . . . 0.0 107.894 178.239 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 45.3 m-70 -135.46 146.31 48.06 Favored 'General case' 0 N--CA 1.493 1.687 0 CA-C-N 118.993 0.815 . . . . 0.0 111.253 -178.916 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 6.0 t60 -165.8 96.78 0.64 Allowed 'General case' 0 N--CA 1.478 0.958 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.941 179.398 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' GLN . . . . . 0.708 HE22 ' H ' ' A' ' 37' ' ' GLY . 5.9 pt20 -108.27 -174.39 2.51 Favored 'General case' 0 CA--C 1.508 -0.645 0 N-CA-C 108.293 -1.003 . . . . 0.0 108.293 -179.781 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -164.22 98.79 0.83 Allowed 'General case' 0 N--CA 1.472 0.626 0 CA-C-N 114.477 -1.238 . . . . 0.0 108.285 178.38 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 6.5 mp -122.04 155.76 34.94 Favored 'General case' 0 N--CA 1.499 2.002 0 CA-C-O 121.837 0.827 . . . . 0.0 110.926 -178.341 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 60.2 t -111.55 126.73 68.97 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.093 0 CA-C-O 117.908 -1.044 . . . . 0.0 108.235 177.737 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 28.1 m-85 -126.43 122.99 36.87 Favored 'General case' 0 N--CA 1.497 1.902 0 CA-C-N 120.08 1.309 . . . . 0.0 110.477 179.203 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 67.0 m-85 54.08 73.79 0.37 Allowed 'General case' 0 N--CA 1.469 0.493 0 CA-C-O 121.306 0.574 . . . . 0.0 111.828 178.757 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -79.99 -77.97 0.18 Allowed 'General case' 0 C--N 1.351 0.665 0 CA-C-N 115.193 -0.912 . . . . 0.0 110.203 -179.752 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 40.6 tt0 -113.53 99.6 7.87 Favored 'General case' 0 N--CA 1.468 0.461 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 179.855 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -158.41 138.84 12.59 Favored 'General case' 0 C--O 1.206 -1.22 0 O-C-N 122.231 -0.293 . . . . 0.0 111.249 179.098 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.401 HG12 ' N ' ' A' ' 25' ' ' GLY . 59.8 t -59.53 163.37 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.921 0 N-CA-C 107.941 -1.133 . . . . 0.0 107.941 177.071 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.461 ' H ' ' HB ' ' D' ' 24' ' ' VAL . . . -116.88 47.61 1.02 Allowed Glycine 0 N--CA 1.476 1.359 0 N-CA-C 111.834 -0.506 . . . . 0.0 111.834 -179.417 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -60.61 -167.5 0.01 OUTLIER 'General case' 0 N--CA 1.469 0.478 0 O-C-N 123.786 0.345 . . . . 0.0 110.305 179.56 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 25.4 t-20 -71.02 80.46 0.66 Allowed 'General case' 0 N--CA 1.465 0.29 0 CA-C-N 116.45 -0.341 . . . . 0.0 110.246 179.539 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 97.7 mttt -77.45 142.95 38.92 Favored 'General case' 0 N--CA 1.474 0.744 0 N-CA-C 109.183 -0.673 . . . . 0.0 109.183 179.283 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.66 -167.89 1.12 Allowed Glycine 0 C--N 1.338 0.648 0 N-CA-C 109.957 -1.257 . . . . 0.0 109.957 178.757 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.44 115.12 28.54 Favored 'General case' 0 N--CA 1.478 0.951 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 179.727 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 71.0 mt -98.58 134.71 36.23 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.576 0 N-CA-C 107.202 -1.407 . . . . 0.0 107.202 178.722 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 31.1 pt -150.63 -171.43 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.352 0.696 0 CA-C-O 121.168 0.508 . . . . 0.0 111.122 -179.259 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.39 4.95 9.96 Favored Glycine 0 N--CA 1.466 0.636 0 N-CA-C 110.735 -0.946 . . . . 0.0 110.735 179.843 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.427 HD23 ' N ' ' A' ' 35' ' ' MET . 1.1 tt -75.38 135.21 40.81 Favored 'General case' 0 CA--C 1.545 0.77 0 N-CA-C 109.395 -0.594 . . . . 0.0 109.395 -179.727 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 35' ' ' MET . . . . . 0.427 ' N ' HD23 ' A' ' 34' ' ' LEU . 27.1 ttt -158.82 146.46 17.79 Favored 'General case' 0 N--CA 1.467 0.418 0 N-CA-C 108.619 -0.882 . . . . 0.0 108.619 178.608 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 1.9 m -148.9 165.65 4.01 Favored 'Isoleucine or valine' 0 C--N 1.348 0.517 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 -179.625 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 37' ' ' GLY . . . . . 0.708 ' H ' HE22 ' A' ' 15' ' ' GLN . . . 54.87 68.44 1.68 Allowed Glycine 0 C--N 1.306 -1.118 0 CA-C-N 115.49 -0.777 . . . . 0.0 112.32 177.518 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.53 176.59 21.3 Favored Glycine 0 N--CA 1.472 1.072 0 N-CA-C 111.11 -0.796 . . . . 0.0 111.11 178.7 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.439 ' H ' HG12 ' D' ' 39' ' ' VAL . 34.3 m -109.31 156.28 10.08 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.658 0 C-N-CA 123.385 0.674 . . . . 0.0 110.201 -179.689 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 24.4 t . . . . . 0 C--O 1.219 -0.55 0 CA-C-O 118.42 -0.8 . . . . 0.0 110.492 179.397 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' B' B ' 1' ' ' ASP . . . . . 0.428 ' H1 ' ' CG ' ' E' ' 1' ' ' ASP . 15.8 m-20 . . . . . 0 N--CA 1.49 1.529 0 N-CA-C 108.962 -0.755 . . . . 0.0 108.962 . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.72 133.23 50.63 Favored 'General case' 0 N--CA 1.47 0.547 0 CA-C-N 116.455 -0.339 . . . . 0.0 110.127 -179.845 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 3' ' ' GLU . . . . . . . . . . . . . 48.2 tt0 -169.11 105.55 0.4 Allowed 'General case' 0 N--CA 1.475 0.786 0 N-CA-C 110.077 -0.342 . . . . 0.0 110.077 -179.114 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 63.8 m-85 -83.39 145.4 29.03 Favored 'General case' 0 N--CA 1.473 0.678 0 N-CA-C 110.264 -0.272 . . . . 0.0 110.264 179.372 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -144.2 142.42 30.51 Favored 'General case' 0 N--CA 1.483 1.186 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 179.682 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 44.8 t-80 -152.45 118.63 5.53 Favored 'General case' 0 N--CA 1.471 0.582 0 N-CA-C 109.395 -0.594 . . . . 0.0 109.395 178.829 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 7' ' ' ASP . . . . . 0.457 ' O ' ' OG ' ' E' ' 8' ' ' SER . 3.8 m-20 -69.36 149.18 48.69 Favored 'General case' 0 CA--C 1.539 0.546 0 CA-C-N 116.4 -0.364 . . . . 0.0 110.622 179.896 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 8' ' ' SER . . . . . . . . . . . . . 52.7 p -167.52 -173.26 2.15 Favored 'General case' 0 N--CA 1.484 1.235 0 CA-C-O 121.033 0.444 . . . . 0.0 110.818 179.381 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.89 46.95 1.41 Allowed Glycine 0 N--CA 1.481 1.674 0 CA-C-N 115.966 -0.561 . . . . 0.0 112.015 179.661 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 47.7 p90 -65.79 132.53 48.94 Favored 'General case' 0 N--CA 1.472 0.652 0 CA-C-O 120.719 0.295 . . . . 0.0 111.649 179.837 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 47.9 mt-10 -91.65 151.86 20.49 Favored 'General case' 0 N--CA 1.477 0.894 0 N-CA-C 109.655 -0.498 . . . . 0.0 109.655 178.436 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -152.92 127.95 1.51 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.47 0 N-CA-C 107.972 -1.121 . . . . 0.0 107.972 178.13 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 43.5 m-70 -135.18 146.42 48.69 Favored 'General case' 0 N--CA 1.493 1.686 0 CA-C-N 118.869 0.759 . . . . 0.0 111.345 -178.93 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 6.1 t60 -165.79 97.02 0.65 Allowed 'General case' 0 N--CA 1.48 1.041 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.768 179.378 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 15' ' ' GLN . . . . . 0.715 HE22 ' H ' ' B' ' 37' ' ' GLY . 5.9 pt20 -108.37 -174.18 2.46 Favored 'General case' 0 CA--C 1.509 -0.603 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 -179.772 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -164.63 98.88 0.79 Allowed 'General case' 0 N--CA 1.474 0.755 0 CA-C-N 114.683 -1.144 . . . . 0.0 108.195 178.363 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 6.6 mp -122.04 156.04 34.35 Favored 'General case' 0 N--CA 1.497 1.925 0 CA-C-O 121.727 0.775 . . . . 0.0 111.012 -178.27 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 61.8 t -112.03 127.63 69.1 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.075 0 N-CA-C 108.028 -1.101 . . . . 0.0 108.028 177.605 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 28.2 m-85 -127.56 122.48 33.36 Favored 'General case' 0 N--CA 1.495 1.781 0 CA-C-N 119.678 1.126 . . . . 0.0 110.307 179.565 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 67.4 m-85 53.71 74.21 0.33 Allowed 'General case' 0 CA--C 1.538 0.504 0 CA-C-O 121.491 0.662 . . . . 0.0 111.846 178.792 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -80.55 -78.03 0.18 Allowed 'General case' 0 C--N 1.35 0.628 0 CA-C-N 115.065 -0.97 . . . . 0.0 110.116 -179.573 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 40.4 tt0 -113.15 99.57 7.93 Favored 'General case' 0 N--CA 1.47 0.543 0 N-CA-C 108.236 -1.024 . . . . 0.0 108.236 179.812 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -158.6 138.79 12.31 Favored 'General case' 0 C--O 1.205 -1.272 0 CA-C-O 119.524 -0.275 . . . . 0.0 111.236 179.1 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 24' ' ' VAL . . . . . 0.401 HG12 ' N ' ' B' ' 25' ' ' GLY . 57.1 t -59.41 163.8 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.857 0 N-CA-C 108.012 -1.107 . . . . 0.0 108.012 177.191 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 25' ' ' GLY . . . . . 0.471 ' H ' ' HB ' ' E' ' 24' ' ' VAL . . . -117.18 47.64 1.02 Allowed Glycine 0 N--CA 1.475 1.244 0 N-CA-C 111.773 -0.531 . . . . 0.0 111.773 -179.465 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -60.67 -167.62 0.01 OUTLIER 'General case' 0 N--CA 1.469 0.52 0 O-C-N 123.708 0.299 . . . . 0.0 110.202 179.457 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 4.1 t30 -71.1 81.12 0.69 Allowed 'General case' 0 N--CA 1.465 0.29 0 CA-C-N 116.481 -0.327 . . . . 0.0 110.186 179.548 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 97.8 mttt -78.07 142.55 38.08 Favored 'General case' 0 N--CA 1.474 0.762 0 N-CA-C 109.015 -0.735 . . . . 0.0 109.015 179.418 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.22 -167.76 0.92 Allowed Glycine 0 C--N 1.336 0.557 0 N-CA-C 109.917 -1.273 . . . . 0.0 109.917 178.659 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.54 115.53 29.56 Favored 'General case' 0 N--CA 1.478 0.959 0 N-CA-C 109.599 -0.519 . . . . 0.0 109.599 179.77 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 70.9 mt -98.96 134.68 36.96 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.505 0 N-CA-C 107.107 -1.442 . . . . 0.0 107.107 178.6 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 32' ' ' ILE . . . . . 0.405 HG22 ' H ' ' E' ' 32' ' ' ILE . 29.7 pt -150.77 -171.85 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.724 0 CA-C-O 121.141 0.496 . . . . 0.0 111.17 -179.022 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.76 4.58 10.68 Favored Glycine 0 C--N 1.337 0.595 0 N-CA-C 110.915 -0.874 . . . . 0.0 110.915 179.935 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 34' ' ' LEU . . . . . 0.42 HD23 ' N ' ' B' ' 35' ' ' MET . 1.1 tt -75.07 135.07 41.23 Favored 'General case' 0 CA--C 1.545 0.767 0 N-CA-C 109.497 -0.557 . . . . 0.0 109.497 -179.689 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 35' ' ' MET . . . . . 0.42 ' N ' HD23 ' B' ' 34' ' ' LEU . 27.0 ttt -158.54 146.42 18.18 Favored 'General case' 0 N--CA 1.471 0.582 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 178.64 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 1.9 m -149.08 165.54 3.83 Favored 'Isoleucine or valine' 0 C--N 1.347 0.48 0 N-CA-C 108.094 -1.076 . . . . 0.0 108.094 -179.642 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 37' ' ' GLY . . . . . 0.715 ' H ' HE22 ' B' ' 15' ' ' GLN . . . 55.19 68.21 1.81 Allowed Glycine 0 C--N 1.306 -1.097 0 CA-C-N 115.469 -0.787 . . . . 0.0 112.367 177.54 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.24 176.75 21.21 Favored Glycine 0 N--CA 1.473 1.105 0 N-CA-C 111.113 -0.795 . . . . 0.0 111.113 178.674 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 39' ' ' VAL . . . . . 0.438 ' H ' HG12 ' E' ' 39' ' ' VAL . 34.4 m -109.35 155.81 10.31 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.655 0 C-N-CA 123.376 0.67 . . . . 0.0 110.299 -179.546 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 25.1 t . . . . . 0 C--O 1.22 -0.497 0 O-C-N 123.99 0.806 . . . . 0.0 110.407 179.317 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' C' C ' 1' ' ' ASP . . . . . 0.417 ' H2 ' ' CB ' ' F' ' 1' ' ' ASP . 15.5 m-20 . . . . . 0 N--CA 1.489 1.492 0 N-CA-C 108.941 -0.763 . . . . 0.0 108.941 . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.72 133.47 51.13 Favored 'General case' 0 CA--C 1.538 0.509 0 CA-C-N 116.479 -0.328 . . . . 0.0 110.217 -179.756 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 3' ' ' GLU . . . . . 0.401 ' CD ' HH21 ' C' ' 5' ' ' ARG . 49.3 tt0 -169.38 105.92 0.38 Allowed 'General case' 0 N--CA 1.473 0.693 0 N-CA-C 110.038 -0.356 . . . . 0.0 110.038 -179.044 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 64.8 m-85 -83.85 145.42 28.65 Favored 'General case' 0 N--CA 1.474 0.767 0 N-CA-C 110.25 -0.278 . . . . 0.0 110.25 179.397 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 5' ' ' ARG . . . . . 0.401 HH21 ' CD ' ' C' ' 3' ' ' GLU . 99.5 mtt180 -144.22 142.4 30.48 Favored 'General case' 0 N--CA 1.484 1.244 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 179.769 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 45.2 t-80 -152.47 119.05 5.66 Favored 'General case' 0 N--CA 1.471 0.586 0 N-CA-C 109.397 -0.594 . . . . 0.0 109.397 179.013 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 7' ' ' ASP . . . . . 0.495 ' O ' ' OG ' ' F' ' 8' ' ' SER . 4.1 m-20 -70.1 149.03 48.04 Favored 'General case' 0 CA--C 1.538 0.493 0 CA-C-N 116.376 -0.375 . . . . 0.0 110.647 -179.983 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 8' ' ' SER . . . . . . . . . . . . . 54.0 p -167.28 -172.97 2.13 Favored 'General case' 0 N--CA 1.484 1.235 0 CA-C-O 121.061 0.457 . . . . 0.0 110.744 179.566 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.48 46.9 1.47 Allowed Glycine 0 N--CA 1.482 1.715 0 CA-C-N 115.945 -0.57 . . . . 0.0 112.035 179.688 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 47.7 p90 -65.78 132.35 48.51 Favored 'General case' 0 N--CA 1.471 0.591 0 O-C-N 122.745 -0.268 . . . . 0.0 111.686 179.826 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 47.7 mt-10 -91.41 151.82 20.66 Favored 'General case' 0 N--CA 1.475 0.782 0 N-CA-C 109.713 -0.477 . . . . 0.0 109.713 178.432 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -152.77 128.17 1.61 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.515 0 N-CA-C 107.833 -1.173 . . . . 0.0 107.833 177.999 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 41.7 m-70 -135.27 146.5 48.61 Favored 'General case' 0 N--CA 1.492 1.65 0 CA-C-N 118.916 0.78 . . . . 0.0 111.272 -179.056 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 6.0 t60 -165.88 96.84 0.63 Allowed 'General case' 0 N--CA 1.481 1.111 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.719 179.459 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 15' ' ' GLN . . . . . 0.69 HE22 ' H ' ' C' ' 37' ' ' GLY . 5.9 pt20 -108.39 -173.98 2.41 Favored 'General case' 0 CA--C 1.505 -0.77 0 N-CA-C 108.396 -0.965 . . . . 0.0 108.396 -179.898 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -164.63 98.85 0.79 Allowed 'General case' 0 N--CA 1.473 0.678 0 CA-C-N 114.617 -1.174 . . . . 0.0 108.223 178.502 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 6.6 mp -121.9 155.77 34.74 Favored 'General case' 0 N--CA 1.497 1.901 0 CA-C-O 121.84 0.828 . . . . 0.0 110.927 -178.35 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 61.2 t -111.68 127.55 68.77 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.117 0 N-CA-C 107.932 -1.136 . . . . 0.0 107.932 177.511 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 28.1 m-85 -127.51 123.06 35.0 Favored 'General case' 0 N--CA 1.495 1.782 0 CA-C-N 119.606 1.094 . . . . 0.0 110.272 179.395 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 67.0 m-85 53.08 74.12 0.32 Allowed 'General case' 0 N--CA 1.468 0.449 0 CA-C-O 121.558 0.694 . . . . 0.0 111.919 178.851 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -80.22 -78.29 0.17 Allowed 'General case' 0 C--N 1.35 0.62 0 CA-C-N 115.012 -0.994 . . . . 0.0 110.065 -179.595 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 40.4 tt0 -113.03 99.69 8.05 Favored 'General case' 0 N--CA 1.471 0.62 0 N-CA-C 108.153 -1.055 . . . . 0.0 108.153 179.899 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -158.45 139.15 12.8 Favored 'General case' 0 C--O 1.205 -1.246 0 O-C-N 122.309 -0.245 . . . . 0.0 111.203 179.131 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 60.7 t -59.94 163.3 0.96 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.878 0 N-CA-C 108.075 -1.083 . . . . 0.0 108.075 177.051 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 25' ' ' GLY . . . . . 0.479 ' H ' ' HB ' ' F' ' 24' ' ' VAL . . . -116.64 47.3 1.05 Allowed Glycine 0 N--CA 1.477 1.387 0 N-CA-C 111.722 -0.551 . . . . 0.0 111.722 -179.29 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -60.43 -167.38 0.01 OUTLIER 'General case' 0 N--CA 1.468 0.462 0 O-C-N 123.658 0.269 . . . . 0.0 110.284 179.539 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 4.3 t30 -71.29 80.69 0.74 Allowed 'General case' 0 N--CA 1.466 0.333 0 CA-C-N 116.442 -0.344 . . . . 0.0 110.132 179.495 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 97.7 mttt -77.53 143.06 38.69 Favored 'General case' 0 N--CA 1.474 0.741 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 179.253 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.83 -167.68 1.15 Allowed Glycine 0 CA--C 1.524 0.617 0 N-CA-C 109.994 -1.242 . . . . 0.0 109.994 178.705 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.49 115.11 28.55 Favored 'General case' 0 N--CA 1.482 1.144 0 N-CA-C 109.677 -0.49 . . . . 0.0 109.677 179.879 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 71.1 mt -98.78 134.21 38.45 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.48 0 N-CA-C 107.296 -1.372 . . . . 0.0 107.296 178.591 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 29.7 pt -150.3 -171.49 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.724 0 CA-C-O 121.227 0.537 . . . . 0.0 111.173 -179.107 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.31 5.11 10.05 Favored Glycine 0 CA--C 1.524 0.62 0 N-CA-C 110.838 -0.905 . . . . 0.0 110.838 179.881 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 34' ' ' LEU . . . . . 0.427 HD23 ' N ' ' C' ' 35' ' ' MET . 1.1 tt -75.46 134.77 40.77 Favored 'General case' 0 CA--C 1.546 0.813 0 N-CA-C 109.38 -0.6 . . . . 0.0 109.38 -179.703 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 35' ' ' MET . . . . . 0.427 ' N ' HD23 ' C' ' 34' ' ' LEU . 27.1 ttt -158.19 146.57 18.79 Favored 'General case' 0 N--CA 1.47 0.531 0 N-CA-C 108.426 -0.953 . . . . 0.0 108.426 178.686 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 1.7 m -149.33 165.28 3.72 Favored 'Isoleucine or valine' 0 C--N 1.348 0.532 0 N-CA-C 108.142 -1.059 . . . . 0.0 108.142 -179.556 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 37' ' ' GLY . . . . . 0.69 ' H ' HE22 ' C' ' 15' ' ' GLN . . . 54.77 68.7 1.55 Allowed Glycine 0 C--N 1.306 -1.096 0 CA-C-N 115.413 -0.812 . . . . 0.0 112.317 177.782 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.26 176.42 20.94 Favored Glycine 0 N--CA 1.473 1.101 0 N-CA-C 111.078 -0.809 . . . . 0.0 111.078 178.698 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 39' ' ' VAL . . . . . 0.444 ' H ' HG12 ' F' ' 39' ' ' VAL . 34.4 m -109.38 155.73 10.38 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.624 0 C-N-CA 123.328 0.651 . . . . 0.0 110.443 -179.641 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 25.1 t . . . . . 0 C--O 1.219 -0.538 0 O-C-N 124.009 0.818 . . . . 0.0 110.491 179.386 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' D' D ' 1' ' ' ASP . . . . . 0.478 ' CG ' ' H1 ' ' A' ' 1' ' ' ASP . 15.8 m-20 . . . . . 0 N--CA 1.49 1.559 0 N-CA-C 109.221 -0.659 . . . . 0.0 109.221 . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.44 131.34 46.88 Favored 'General case' 0 CA--C 1.536 0.439 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.429 179.796 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 3' ' ' GLU . . . . . 0.41 ' CD ' HH21 ' D' ' 5' ' ' ARG . 48.2 tt0 -169.26 108.91 0.44 Allowed 'General case' 0 N--CA 1.472 0.649 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 179.658 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 72.3 m-85 -87.93 151.59 22.7 Favored 'General case' 0 C--N 1.362 1.117 0 C-N-CA 119.361 -0.936 . . . . 0.0 108.948 179.643 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 5' ' ' ARG . . . . . 0.41 HH21 ' CD ' ' D' ' 3' ' ' GLU . 99.6 mtt180 -146.87 140.99 26.12 Favored 'General case' 0 N--CA 1.476 0.86 0 N-CA-C 110.059 -0.348 . . . . 0.0 110.059 179.764 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 41.6 t-80 -149.75 123.52 9.26 Favored 'General case' 0 CA--C 1.545 0.774 0 N-CA-C 108.499 -0.926 . . . . 0.0 108.499 174.468 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 7' ' ' ASP . . . . . 0.591 ' O ' ' OG ' ' G' ' 8' ' ' SER . 2.8 m-20 -63.81 133.32 53.2 Favored 'General case' 0 C--N 1.32 -0.688 0 C-N-CA 126.61 1.964 . . . . 0.0 114.339 174.029 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' D' D ' 8' ' ' SER . . . . . 0.51 ' OG ' ' O ' ' A' ' 7' ' ' ASP . 52.3 p -154.04 -170.53 3.59 Favored 'General case' 0 N--CA 1.488 1.438 0 CA-C-N 119.649 1.113 . . . . 0.0 111.131 175.534 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.43 48.05 1.16 Allowed Glycine 0 N--CA 1.484 1.88 0 N-CA-C 109.941 -1.264 . . . . 0.0 109.941 173.365 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 50.9 p90 -60.66 131.01 49.35 Favored 'General case' 0 N--CA 1.468 0.434 0 N-CA-C 113.155 0.798 . . . . 0.0 113.155 177.697 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 47.8 mt-10 -88.84 150.65 22.8 Favored 'General case' 0 N--CA 1.481 1.084 0 CA-C-N 118.175 0.443 . . . . 0.0 110.946 174.98 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.0 p -149.49 130.03 4.41 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.594 0 N-CA-C 107.423 -1.325 . . . . 0.0 107.423 173.128 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 40.9 m-70 -130.03 149.25 51.83 Favored 'General case' 0 N--CA 1.484 1.232 0 CA-C-N 118.03 0.377 . . . . 0.0 111.907 176.41 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 6.1 t60 -164.99 104.38 0.78 Allowed 'General case' 0 N--CA 1.48 1.035 0 N-CA-C 109.175 -0.676 . . . . 0.0 109.175 172.13 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 15' ' ' GLN . . . . . 0.65 HE22 ' H ' ' D' ' 37' ' ' GLY . 5.9 pt20 -111.97 -176.05 2.84 Favored 'General case' 0 CA--C 1.499 -1.002 0 N-CA-C 108.228 -1.027 . . . . 0.0 108.228 178.911 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -161.04 105.96 1.36 Allowed 'General case' 0 N--CA 1.468 0.433 0 N-CA-C 106.634 -1.617 . . . . 0.0 106.634 175.151 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 5.5 mp -128.38 153.22 47.3 Favored 'General case' 0 N--CA 1.498 1.945 0 CA-C-O 122.06 0.934 . . . . 0.0 110.582 179.662 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 35.8 t -100.97 131.82 47.88 Favored 'Isoleucine or valine' 0 C--O 1.262 1.761 0 CA-C-O 116.723 -1.608 . . . . 0.0 109.546 174.2 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 25.7 m-85 -130.49 126.35 36.66 Favored 'General case' 0 N--CA 1.491 1.583 0 CA-C-N 120.149 1.34 . . . . 0.0 109.528 173.366 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 68.2 m-85 55.85 71.53 0.55 Allowed 'General case' 0 C--O 1.241 0.651 0 CA-C-N 115.493 -0.776 . . . . 0.0 111.258 176.357 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -82.43 -73.18 0.41 Allowed 'General case' 0 N--CA 1.475 0.794 0 CA-C-O 118.52 -0.752 . . . . 0.0 111.106 -177.507 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 40.8 tt0 -116.52 103.81 10.79 Favored 'General case' 0 N--CA 1.482 1.174 0 N-CA-C 106.195 -1.78 . . . . 0.0 106.195 176.217 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -151.9 138.79 18.98 Favored 'General case' 0 N--CA 1.474 0.752 0 CA-C-O 116.686 -1.626 . . . . 0.0 113.738 177.697 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 24' ' ' VAL . . . . . 0.461 ' HB ' ' H ' ' A' ' 25' ' ' GLY . 64.1 t -62.27 166.23 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.206 0 CA-C-N 121.101 1.773 . . . . 0.0 107.834 175.184 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' D' D ' 25' ' ' GLY . . . . . 0.539 ' H ' ' HB ' ' G' ' 24' ' ' VAL . . . -116.79 51.14 0.74 Allowed Glycine 0 N--CA 1.478 1.46 0 CA-C-O 119.095 -0.836 . . . . 0.0 111.833 178.451 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -57.28 -170.42 0.01 OUTLIER 'General case' 0 C--N 1.322 -0.595 0 C-N-CA 123.706 0.802 . . . . 0.0 111.559 175.937 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 26.3 t-20 -72.89 86.69 1.29 Allowed 'General case' 0 C--N 1.347 0.466 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 177.976 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 97.2 mttt -82.87 145.56 29.38 Favored 'General case' 0 N--CA 1.476 0.84 0 N-CA-C 108.014 -1.106 . . . . 0.0 108.014 179.134 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.17 -165.34 0.61 Allowed Glycine 0 C--N 1.336 0.57 0 N-CA-C 110.45 -1.06 . . . . 0.0 110.45 179.171 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -102.35 116.11 31.95 Favored 'General case' 0 N--CA 1.476 0.851 0 N-CA-C 109.099 -0.704 . . . . 0.0 109.099 179.846 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 80.4 mt -102.52 142.24 17.07 Favored 'Isoleucine or valine' 0 C--N 1.358 0.941 0 N-CA-C 104.84 -2.281 . . . . 0.0 104.84 179.793 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 32' ' ' ILE . . . . . 0.45 HG22 ' H ' ' G' ' 32' ' ' ILE . 31.1 pt -157.43 -172.51 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.482 1.157 0 CA-C-O 120.84 0.353 . . . . 0.0 110.155 -177.332 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 64.27 4.55 12.59 Favored Glycine 0 N--CA 1.465 0.601 0 N-CA-C 110.387 -1.085 . . . . 0.0 110.387 -178.926 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 1.3 tt -76.52 140.47 41.17 Favored 'General case' 0 C--N 1.355 0.824 0 N-CA-C 107.787 -1.19 . . . . 0.0 107.787 -178.329 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 26.4 ttt -156.41 155.91 32.94 Favored 'General case' 0 C--O 1.247 0.955 0 N-CA-C 107.894 -1.15 . . . . 0.0 107.894 174.482 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 1.9 m -157.91 163.86 1.18 Allowed 'Isoleucine or valine' 0 CA--C 1.516 -0.334 0 N-CA-C 107.618 -1.252 . . . . 0.0 107.618 177.826 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 37' ' ' GLY . . . . . 0.65 ' H ' HE22 ' D' ' 15' ' ' GLN . . . 61.36 63.84 4.53 Favored Glycine 0 C--N 1.312 -0.76 0 C-N-CA 119.758 -1.211 . . . . 0.0 112.179 177.452 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 145.76 177.75 20.72 Favored Glycine 0 N--CA 1.476 1.365 0 CA-C-N 118.309 1.054 . . . . 0.0 111.776 179.756 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 39' ' ' VAL . . . . . 0.439 HG12 ' H ' ' A' ' 39' ' ' VAL . 35.2 m -112.5 152.76 14.24 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.895 0 N-CA-C 109.681 -0.489 . . . . 0.0 109.681 -176.824 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 25.2 t . . . . . 0 C--N 1.334 -0.066 0 CA-C-O 116.119 -1.896 . . . . 0.0 109.533 178.0 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' E' E ' 1' ' ' ASP . . . . . 0.43 ' H1 ' ' CG ' ' H' ' 1' ' ' ASP . 15.4 m-20 . . . . . 0 N--CA 1.49 1.543 0 N-CA-C 109.436 -0.579 . . . . 0.0 109.436 . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' E' E ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.07 131.24 46.95 Favored 'General case' 0 N--CA 1.469 0.517 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.414 179.926 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' E' E ' 3' ' ' GLU . . . . . 0.409 ' CD ' HH21 ' E' ' 5' ' ' ARG . 48.1 tt0 -168.52 105.71 0.45 Allowed 'General case' 0 N--CA 1.472 0.674 0 N-CA-C 110.544 -0.169 . . . . 0.0 110.544 -179.693 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 65.8 m-85 -84.39 145.06 28.4 Favored 'General case' 0 N--CA 1.474 0.756 0 O-C-N 122.247 -0.283 . . . . 0.0 110.257 179.177 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' E' E ' 5' ' ' ARG . . . . . 0.409 HH21 ' CD ' ' E' ' 3' ' ' GLU . 99.5 mtt180 -143.72 142.79 31.12 Favored 'General case' 0 N--CA 1.481 1.078 0 N-CA-C 110.113 -0.329 . . . . 0.0 110.113 179.458 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 45.1 t-80 -152.46 118.67 5.54 Favored 'General case' 0 N--CA 1.469 0.516 0 N-CA-C 109.294 -0.632 . . . . 0.0 109.294 178.86 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' E' E ' 7' ' ' ASP . . . . . 0.445 ' O ' ' OG ' ' H' ' 8' ' ' SER . 3.6 m-20 -70.14 149.14 47.87 Favored 'General case' 0 CA--C 1.535 0.391 0 CA-C-N 116.488 -0.324 . . . . 0.0 110.754 179.938 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' E' E ' 8' ' ' SER . . . . . 0.457 ' OG ' ' O ' ' B' ' 7' ' ' ASP . 43.7 p -168.26 -172.1 1.66 Allowed 'General case' 0 N--CA 1.486 1.33 0 CA-C-O 121.192 0.52 . . . . 0.0 110.854 179.18 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.24 47.7 1.3 Allowed Glycine 0 N--CA 1.478 1.485 0 CA-C-N 115.876 -0.602 . . . . 0.0 111.797 179.54 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 46.3 p90 -65.56 132.62 49.32 Favored 'General case' 0 N--CA 1.471 0.621 0 N-CA-C 112.064 0.394 . . . . 0.0 112.064 -179.891 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 49.0 mt-10 -90.98 152.29 20.74 Favored 'General case' 0 N--CA 1.481 1.123 0 CA-C-O 121.313 0.578 . . . . 0.0 109.575 177.954 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -154.65 127.07 1.04 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.588 0 N-CA-C 107.874 -1.158 . . . . 0.0 107.874 177.96 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 42.9 m-70 -135.42 144.4 46.49 Favored 'General case' 0 N--CA 1.482 1.149 0 CA-C-O 120.903 0.382 . . . . 0.0 111.478 -177.859 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 6.0 t60 -164.4 97.19 0.79 Allowed 'General case' 0 N--CA 1.484 1.237 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.694 179.419 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' E' E ' 15' ' ' GLN . . . . . 0.613 HE21 HD11 ' H' ' 17' ' ' LEU . 17.0 pt20 -108.21 -174.33 2.49 Favored 'General case' 0 CA--C 1.507 -0.686 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 -179.924 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -164.18 97.73 0.82 Allowed 'General case' 0 N--CA 1.476 0.839 0 CA-C-N 114.698 -1.137 . . . . 0.0 108.436 178.563 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 6.5 mp -120.52 155.66 33.17 Favored 'General case' 0 N--CA 1.494 1.775 0 CA-C-O 121.533 0.682 . . . . 0.0 111.588 -177.867 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 48.8 t -113.44 124.66 70.3 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.254 0 N-CA-C 108.176 -1.046 . . . . 0.0 108.176 177.131 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 30.8 m-85 -124.94 121.8 35.51 Favored 'General case' 0 N--CA 1.489 1.495 0 CA-C-O 120.836 0.351 . . . . 0.0 110.934 -179.891 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 68.8 m-85 54.79 73.29 0.42 Allowed 'General case' 0 N--CA 1.468 0.429 0 CA-C-N 115.92 -0.582 . . . . 0.0 111.478 178.34 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -78.83 -79.03 0.14 Allowed 'General case' 0 CA--C 1.537 0.459 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.03 -179.378 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 40.5 tt0 -112.1 100.02 8.52 Favored 'General case' 0 C--N 1.323 -0.548 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 -179.987 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -157.89 138.84 13.22 Favored 'General case' 0 C--O 1.201 -1.458 0 N-CA-C 111.621 0.23 . . . . 0.0 111.621 179.029 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' E' E ' 24' ' ' VAL . . . . . 0.471 ' HB ' ' H ' ' B' ' 25' ' ' GLY . 59.0 t -58.15 168.28 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.927 0 N-CA-C 107.403 -1.332 . . . . 0.0 107.403 177.056 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' E' E ' 25' ' ' GLY . . . . . 0.438 ' H ' ' HB ' ' H' ' 24' ' ' VAL . . . -122.0 48.63 0.94 Allowed Glycine 0 N--CA 1.473 1.157 0 N-CA-C 110.963 -0.855 . . . . 0.0 110.963 -179.38 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -62.12 -166.9 0.01 OUTLIER 'General case' 0 N--CA 1.47 0.541 0 CA-C-O 120.737 0.303 . . . . 0.0 110.482 179.892 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 5.1 t30 -70.68 76.88 0.6 Allowed 'General case' 0 C--O 1.222 -0.362 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.481 -179.956 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 97.9 mttt -74.36 143.67 44.75 Favored 'General case' 0 N--CA 1.476 0.873 0 N-CA-C 109.554 -0.536 . . . . 0.0 109.554 179.403 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.68 -167.38 1.43 Allowed Glycine 0 C--N 1.333 0.414 0 N-CA-C 110.408 -1.077 . . . . 0.0 110.408 178.534 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.54 113.99 26.72 Favored 'General case' 0 N--CA 1.476 0.834 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 179.953 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 72.0 mt -97.8 134.48 35.86 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.265 0 N-CA-C 106.986 -1.487 . . . . 0.0 106.986 178.768 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' E' E ' 32' ' ' ILE . . . . . 0.45 HG22 ' H ' ' H' ' 32' ' ' ILE . 31.4 pt -150.34 -169.7 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.174 0 CA-C-O 121.182 0.515 . . . . 0.0 110.753 -179.451 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.65 5.18 6.41 Favored Glycine 0 CA--C 1.527 0.834 0 CA-C-N 115.684 -0.689 . . . . 0.0 111.423 -179.796 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' E' E ' 34' ' ' LEU . . . . . 0.409 HD23 ' N ' ' E' ' 35' ' ' MET . 1.1 tt -74.75 135.26 41.77 Favored 'General case' 0 CA--C 1.549 0.941 0 N-CA-C 109.293 -0.632 . . . . 0.0 109.293 -179.616 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' E' E ' 35' ' ' MET . . . . . 0.409 ' N ' HD23 ' E' ' 34' ' ' LEU . 26.3 ttt -158.37 145.78 17.98 Favored 'General case' 0 N--CA 1.473 0.724 0 N-CA-C 108.611 -0.885 . . . . 0.0 108.611 178.466 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 1.5 m -148.65 165.08 4.56 Favored 'Isoleucine or valine' 0 C--N 1.347 0.48 0 N-CA-C 108.5 -0.926 . . . . 0.0 108.5 -179.447 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 54.28 68.56 1.6 Allowed Glycine 0 C--N 1.308 -1.024 0 CA-C-N 115.324 -0.853 . . . . 0.0 112.231 177.888 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 146.65 173.76 18.16 Favored Glycine 0 N--CA 1.473 1.11 0 N-CA-C 111.41 -0.676 . . . . 0.0 111.41 178.734 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' E' E ' 39' ' ' VAL . . . . . 0.438 HG12 ' H ' ' B' ' 39' ' ' VAL . 32.7 m -107.0 155.69 7.59 Favored 'Isoleucine or valine' 0 C--N 1.352 0.702 0 C-N-CA 123.629 0.772 . . . . 0.0 110.645 -178.711 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 25.4 t . . . . . 0 C--O 1.218 -0.599 0 O-C-N 124.18 0.925 . . . . 0.0 110.25 179.615 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' F' F ' 1' ' ' ASP . . . . . 0.417 ' CB ' ' H2 ' ' C' ' 1' ' ' ASP . 16.0 m-20 . . . . . 0 N--CA 1.49 1.56 0 N-CA-C 109.286 -0.635 . . . . 0.0 109.286 . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.19 131.54 47.72 Favored 'General case' 0 N--CA 1.467 0.41 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.46 179.886 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 3' ' ' GLU . . . . . 0.406 ' CD ' HH21 ' F' ' 5' ' ' ARG . 48.6 tt0 -168.6 105.82 0.45 Allowed 'General case' 0 C--O 1.215 -0.748 0 N-CA-C 110.397 -0.223 . . . . 0.0 110.397 -179.743 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 65.1 m-85 -84.61 144.81 28.38 Favored 'General case' 0 N--CA 1.474 0.77 0 O-C-N 122.233 -0.292 . . . . 0.0 110.235 179.266 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 5' ' ' ARG . . . . . 0.406 HH21 ' CD ' ' F' ' 3' ' ' GLU . 99.6 mtt180 -143.56 142.66 31.19 Favored 'General case' 0 N--CA 1.478 0.97 0 CA-C-O 120.838 0.351 . . . . 0.0 110.091 179.657 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 45.0 t-80 -152.45 119.26 5.75 Favored 'General case' 0 N--CA 1.471 0.614 0 N-CA-C 109.429 -0.582 . . . . 0.0 109.429 178.783 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 7' ' ' ASP . . . . . 0.486 ' O ' ' OG ' ' I' ' 8' ' ' SER . 3.7 m-20 -70.76 149.33 47.01 Favored 'General case' 0 CA--C 1.535 0.382 0 CA-C-N 116.418 -0.356 . . . . 0.0 110.844 -179.929 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' F' F ' 8' ' ' SER . . . . . 0.495 ' OG ' ' O ' ' C' ' 7' ' ' ASP . 43.2 p -168.56 -171.63 1.48 Allowed 'General case' 0 N--CA 1.484 1.262 0 CA-C-O 121.236 0.541 . . . . 0.0 110.935 179.169 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.95 46.82 1.42 Allowed Glycine 0 N--CA 1.478 1.492 0 CA-C-N 115.855 -0.611 . . . . 0.0 111.761 179.551 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 46.6 p90 -64.64 132.42 49.69 Favored 'General case' 0 CA--C 1.542 0.642 0 N-CA-C 112.01 0.374 . . . . 0.0 112.01 -179.886 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 48.6 mt-10 -91.04 152.29 20.71 Favored 'General case' 0 N--CA 1.482 1.13 0 CA-C-O 121.266 0.555 . . . . 0.0 109.685 177.89 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -154.49 126.98 1.05 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.67 0 N-CA-C 107.855 -1.165 . . . . 0.0 107.855 178.058 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 42.5 m-70 -135.24 144.81 47.09 Favored 'General case' 0 N--CA 1.483 1.179 0 CA-C-O 120.847 0.356 . . . . 0.0 111.522 -177.919 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 6.0 t60 -164.88 96.91 0.74 Allowed 'General case' 0 N--CA 1.484 1.27 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.805 179.539 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 15' ' ' GLN . . . . . 0.577 HE21 HD11 ' I' ' 17' ' ' LEU . 16.9 pt20 -108.02 -174.17 2.46 Favored 'General case' 0 CA--C 1.505 -0.751 0 N-CA-C 108.574 -0.899 . . . . 0.0 108.574 -179.875 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -164.17 97.79 0.82 Allowed 'General case' 0 N--CA 1.473 0.719 0 CA-C-N 114.578 -1.192 . . . . 0.0 108.397 178.561 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 6.4 mp -120.55 155.73 33.05 Favored 'General case' 0 N--CA 1.494 1.773 0 CA-C-O 121.667 0.746 . . . . 0.0 111.456 -177.727 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 48.4 t -113.64 124.38 70.23 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.25 0 N-CA-C 108.199 -1.037 . . . . 0.0 108.199 177.17 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 30.5 m-85 -124.7 121.19 33.97 Favored 'General case' 0 N--CA 1.488 1.439 0 CA-C-O 120.77 0.319 . . . . 0.0 111.015 -179.783 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 67.9 m-85 55.27 73.23 0.43 Allowed 'General case' 0 C--N 1.344 0.342 0 CA-C-N 115.953 -0.567 . . . . 0.0 111.733 178.322 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -78.92 -78.58 0.15 Allowed 'General case' 0 N--CA 1.467 0.419 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.147 -179.27 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 40.3 tt0 -112.66 99.99 8.36 Favored 'General case' 0 C--N 1.324 -0.524 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 -179.825 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -157.88 138.8 13.2 Favored 'General case' 0 C--O 1.203 -1.361 0 N-CA-C 111.681 0.252 . . . . 0.0 111.681 179.052 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 24' ' ' VAL . . . . . 0.479 ' HB ' ' H ' ' C' ' 25' ' ' GLY . 60.0 t -58.13 168.24 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.935 0 N-CA-C 107.398 -1.334 . . . . 0.0 107.398 177.116 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' F' F ' 25' ' ' GLY . . . . . 0.434 ' H ' ' HB ' ' I' ' 24' ' ' VAL . . . -121.92 48.53 0.94 Allowed Glycine 0 N--CA 1.476 1.35 0 N-CA-C 110.877 -0.889 . . . . 0.0 110.877 -179.394 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -62.11 -167.4 0.01 OUTLIER 'General case' 0 N--CA 1.47 0.565 0 CA-C-O 120.782 0.325 . . . . 0.0 110.285 179.895 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 4.9 t30 -70.1 77.0 0.51 Allowed 'General case' 0 N--CA 1.466 0.338 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.589 179.979 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 97.8 mttt -74.57 143.81 44.28 Favored 'General case' 0 N--CA 1.478 0.957 0 N-CA-C 109.483 -0.562 . . . . 0.0 109.483 179.524 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.39 -167.11 1.25 Allowed Glycine 0 C--N 1.334 0.425 0 N-CA-C 110.486 -1.046 . . . . 0.0 110.486 178.539 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.69 113.65 26.25 Favored 'General case' 0 N--CA 1.477 0.917 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 179.752 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 72.0 mt -97.71 134.59 35.28 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.285 0 N-CA-C 106.981 -1.489 . . . . 0.0 106.981 178.717 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 32' ' ' ILE . . . . . 0.446 HG22 ' H ' ' I' ' 32' ' ' ILE . 32.1 pt -150.74 -169.6 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.198 0 CA-C-O 121.126 0.489 . . . . 0.0 110.7 -179.476 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.64 5.12 6.29 Favored Glycine 0 CA--C 1.527 0.82 0 CA-C-N 115.688 -0.687 . . . . 0.0 111.407 -179.78 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 34' ' ' LEU . . . . . 0.419 HD23 ' N ' ' F' ' 35' ' ' MET . 1.1 tt -74.66 135.83 41.93 Favored 'General case' 0 CA--C 1.549 0.922 0 N-CA-C 109.18 -0.674 . . . . 0.0 109.18 -179.669 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' F' F ' 35' ' ' MET . . . . . 0.419 ' N ' HD23 ' F' ' 34' ' ' LEU . 26.0 ttt -158.72 145.92 17.58 Favored 'General case' 0 N--CA 1.47 0.561 0 N-CA-C 108.66 -0.867 . . . . 0.0 108.66 178.446 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 1.5 m -148.78 165.14 4.35 Favored 'Isoleucine or valine' 0 C--N 1.349 0.547 0 N-CA-C 108.425 -0.954 . . . . 0.0 108.425 -179.495 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 54.33 68.37 1.7 Allowed Glycine 0 C--N 1.306 -1.108 0 CA-C-N 115.328 -0.851 . . . . 0.0 112.331 177.808 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 146.97 174.09 18.74 Favored Glycine 0 N--CA 1.472 1.097 0 N-CA-C 111.415 -0.674 . . . . 0.0 111.415 178.645 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 39' ' ' VAL . . . . . 0.444 HG12 ' H ' ' C' ' 39' ' ' VAL . 33.1 m -107.22 155.54 7.88 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.714 0 C-N-CA 123.471 0.708 . . . . 0.0 110.588 -178.803 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 26.8 t . . . . . 0 C--O 1.219 -0.55 0 O-C-N 124.286 0.991 . . . . 0.0 110.3 179.601 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' G' G ' 1' ' ' ASP . . . . . 0.446 ' CB ' ' H2 ' ' D' ' 1' ' ' ASP . 15.0 m-20 . . . . . 0 N--CA 1.492 1.635 0 N-CA-C 109.303 -0.629 . . . . 0.0 109.303 . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' G' G ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.74 129.82 42.22 Favored 'General case' 0 N--CA 1.47 0.536 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.563 179.525 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' G' G ' 3' ' ' GLU . . . . . 0.414 ' CD ' HH21 ' G' ' 5' ' ' ARG . 46.9 tt0 -168.65 107.12 0.46 Allowed 'General case' 0 N--CA 1.475 0.821 0 N-CA-C 110.565 -0.161 . . . . 0.0 110.565 179.706 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 67.1 m-85 -86.52 144.61 27.15 Favored 'General case' 0 N--CA 1.473 0.692 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 179.169 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' G' G ' 5' ' ' ARG . . . . . 0.414 HH21 ' CD ' ' G' ' 3' ' ' GLU . 99.5 mtt180 -143.91 142.77 30.95 Favored 'General case' 0 N--CA 1.483 1.189 0 CA-C-O 120.828 0.347 . . . . 0.0 110.162 179.983 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 45.8 t-80 -152.31 119.5 5.9 Favored 'General case' 0 N--CA 1.473 0.682 0 N-CA-C 109.574 -0.528 . . . . 0.0 109.574 178.794 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 4.0 m-20 -71.82 144.49 49.11 Favored 'General case' 0 CA--C 1.538 0.519 0 C-N-CA 122.716 0.406 . . . . 0.0 111.176 -179.938 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' G' G ' 8' ' ' SER . . . . . 0.591 ' OG ' ' O ' ' D' ' 7' ' ' ASP . 35.5 p -164.77 -169.62 1.76 Allowed 'General case' 0 N--CA 1.476 0.86 0 CA-C-O 121.178 0.513 . . . . 0.0 110.512 178.672 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.21 47.73 1.41 Allowed Glycine 0 N--CA 1.48 1.63 0 N-CA-C 111.344 -0.703 . . . . 0.0 111.344 179.291 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 48.0 p90 -65.69 133.16 50.51 Favored 'General case' 0 CA--C 1.542 0.636 0 N-CA-C 111.872 0.323 . . . . 0.0 111.872 -179.627 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 47.9 mt-10 -91.76 151.48 20.6 Favored 'General case' 0 N--CA 1.479 1.022 0 CA-C-O 121.162 0.506 . . . . 0.0 110.0 178.576 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -154.99 127.28 1.01 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.004 0 N-CA-C 107.851 -1.166 . . . . 0.0 107.851 178.196 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 44.2 m-70 -134.67 146.06 49.14 Favored 'General case' 0 N--CA 1.48 1.05 0 CA-C-N 115.667 -0.697 . . . . 0.0 111.45 -178.363 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 28.5 t-80 -166.24 97.05 0.6 Allowed 'General case' 0 N--CA 1.481 1.115 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.385 178.946 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 17.0 pt20 -108.42 -174.51 2.54 Favored 'General case' 0 CA--C 1.508 -0.641 0 N-CA-C 108.31 -0.996 . . . . 0.0 108.31 -179.702 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -164.27 97.72 0.81 Allowed 'General case' 0 N--CA 1.475 0.802 0 CA-C-N 114.606 -1.179 . . . . 0.0 108.12 178.667 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 6.4 mp -120.4 154.8 34.64 Favored 'General case' 0 N--CA 1.498 1.934 0 CA-C-O 121.247 0.546 . . . . 0.0 111.774 -177.883 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 43.1 t -113.33 124.66 70.19 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.942 0 CA-C-N 114.777 -1.101 . . . . 0.0 108.186 176.55 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 32.1 m-85 -125.29 121.19 33.3 Favored 'General case' 0 C--N 1.367 1.349 0 C-N-CA 123.437 0.695 . . . . 0.0 110.979 -179.602 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 68.0 m-85 55.37 72.57 0.47 Allowed 'General case' 0 N--CA 1.467 0.393 0 CA-C-N 115.898 -0.592 . . . . 0.0 111.496 178.274 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.78 -77.99 0.14 Allowed 'General case' 0 N--CA 1.473 0.697 0 O-C-N 122.237 -0.289 . . . . 0.0 110.407 -178.932 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 41.1 tt0 -113.02 100.2 8.44 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 107.812 -1.181 . . . . 0.0 107.812 179.909 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -157.73 139.75 14.21 Favored 'General case' 0 N--CA 1.476 0.865 0 N-CA-C 111.649 0.24 . . . . 0.0 111.649 178.959 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' G' G ' 24' ' ' VAL . . . . . 0.539 ' HB ' ' H ' ' D' ' 25' ' ' GLY . 62.0 t -59.62 166.97 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.656 0 N-CA-C 107.564 -1.273 . . . . 0.0 107.564 177.353 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' G' G ' 25' ' ' GLY . . . . . 0.421 ' N ' HG12 ' G' ' 24' ' ' VAL . . . -120.13 49.32 0.88 Allowed Glycine 0 N--CA 1.479 1.538 0 N-CA-C 110.617 -0.993 . . . . 0.0 110.617 -179.507 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -63.45 -166.59 0.02 OUTLIER 'General case' 0 N--CA 1.471 0.62 0 N-CA-C 109.895 -0.409 . . . . 0.0 109.895 179.904 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 26.2 t-20 -70.99 76.96 0.65 Allowed 'General case' 0 CA--C 1.535 0.386 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.599 -179.89 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 97.9 mttt -73.95 143.14 45.81 Favored 'General case' 0 N--CA 1.475 0.808 0 N-CA-C 109.623 -0.51 . . . . 0.0 109.623 179.427 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.08 -166.17 0.98 Allowed Glycine 0 C--N 1.337 0.592 0 N-CA-C 110.019 -1.232 . . . . 0.0 110.019 178.642 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.57 114.28 27.2 Favored 'General case' 0 N--CA 1.472 0.659 0 C-N-CA 122.708 0.403 . . . . 0.0 110.138 -179.977 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 73.6 mt -98.51 135.02 34.97 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.649 0 N-CA-C 107.054 -1.461 . . . . 0.0 107.054 178.67 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' G' G ' 32' ' ' ILE . . . . . 0.45 ' H ' HG22 ' D' ' 32' ' ' ILE . 34.3 pt -151.5 -169.28 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 CA-C-N 119.723 1.147 . . . . 0.0 109.916 -179.813 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.28 4.78 6.85 Favored Glycine 0 N--CA 1.468 0.774 0 N-CA-C 111.132 -0.787 . . . . 0.0 111.132 -179.864 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' G' G ' 34' ' ' LEU . . . . . 0.433 HD23 ' N ' ' G' ' 35' ' ' MET . 1.1 tt -74.95 135.12 41.41 Favored 'General case' 0 CA--C 1.545 0.775 0 N-CA-C 109.295 -0.631 . . . . 0.0 109.295 -179.757 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' G' G ' 35' ' ' MET . . . . . 0.433 ' N ' HD23 ' G' ' 34' ' ' LEU . 25.0 ttt -158.28 146.06 18.31 Favored 'General case' 0 N--CA 1.47 0.566 0 N-CA-C 108.64 -0.874 . . . . 0.0 108.64 178.823 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 1.5 m -148.82 163.4 4.85 Favored 'Isoleucine or valine' 0 C--N 1.349 0.561 0 N-CA-C 108.587 -0.894 . . . . 0.0 108.587 -179.469 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.4 68.76 1.52 Allowed Glycine 0 C--N 1.308 -1.001 0 CA-C-N 115.226 -0.897 . . . . 0.0 112.293 177.596 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.39 172.35 17.46 Favored Glycine 0 N--CA 1.476 1.314 0 N-CA-C 110.569 -1.012 . . . . 0.0 110.569 178.892 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' G' G ' 39' ' ' VAL . . . . . 0.414 HG12 ' H ' ' D' ' 39' ' ' VAL . 33.9 m -106.01 155.64 6.92 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.923 0 C-N-CA 123.198 0.599 . . . . 0.0 110.452 -179.541 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 27.5 t . . . . . 0 C--O 1.22 -0.46 0 O-C-N 123.961 0.788 . . . . 0.0 110.563 179.371 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' H' H ' 1' ' ' ASP . . . . . 0.43 ' CG ' ' H1 ' ' E' ' 1' ' ' ASP . 16.4 m-20 . . . . . 0 N--CA 1.491 1.606 0 N-CA-C 109.445 -0.576 . . . . 0.0 109.445 . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' H' H ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.39 129.75 42.1 Favored 'General case' 0 N--CA 1.47 0.526 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.541 179.799 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' H' H ' 3' ' ' GLU . . . . . 0.407 ' CD ' HH21 ' H' ' 5' ' ' ARG . 47.3 tt0 -168.39 106.89 0.48 Allowed 'General case' 0 N--CA 1.472 0.635 0 CA-C-O 120.464 0.173 . . . . 0.0 110.634 179.697 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 68.8 m-85 -86.06 144.91 27.31 Favored 'General case' 0 N--CA 1.473 0.71 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 179.166 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' H' H ' 5' ' ' ARG . . . . . 0.407 HH21 ' CD ' ' H' ' 3' ' ' GLU . 99.5 mtt180 -144.21 142.92 30.81 Favored 'General case' 0 N--CA 1.483 1.217 0 N-CA-C 110.046 -0.353 . . . . 0.0 110.046 -179.98 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 46.6 t-80 -152.65 119.69 5.82 Favored 'General case' 0 N--CA 1.472 0.636 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 178.812 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 3.9 m-20 -72.19 144.56 48.47 Favored 'General case' 0 N--CA 1.469 0.481 0 CA-C-N 116.319 -0.401 . . . . 0.0 111.222 -179.781 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' H' H ' 8' ' ' SER . . . . . 0.445 ' OG ' ' O ' ' E' ' 7' ' ' ASP . 52.2 p -164.72 -170.07 1.9 Allowed 'General case' 0 N--CA 1.475 0.776 0 CA-C-O 121.129 0.49 . . . . 0.0 110.492 178.912 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.48 47.63 1.39 Allowed Glycine 0 N--CA 1.478 1.499 0 N-CA-C 111.557 -0.617 . . . . 0.0 111.557 179.409 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 48.4 p90 -65.97 133.14 50.22 Favored 'General case' 0 CA--C 1.54 0.584 0 N-CA-C 111.861 0.319 . . . . 0.0 111.861 -179.587 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 47.8 mt-10 -91.67 151.44 20.67 Favored 'General case' 0 N--CA 1.477 0.921 0 CA-C-O 121.064 0.459 . . . . 0.0 110.065 178.583 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -154.98 127.35 1.03 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.004 0 N-CA-C 107.92 -1.141 . . . . 0.0 107.92 178.13 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 43.5 m-70 -134.67 146.36 49.43 Favored 'General case' 0 N--CA 1.479 0.98 0 CA-C-N 115.694 -0.685 . . . . 0.0 111.311 -178.321 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 29.5 t-80 -166.43 96.71 0.57 Allowed 'General case' 0 N--CA 1.481 1.102 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.508 178.912 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 17.1 pt20 -107.97 -174.13 2.45 Favored 'General case' 0 CA--C 1.507 -0.681 0 N-CA-C 108.304 -0.999 . . . . 0.0 108.304 -179.624 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -164.68 97.5 0.76 Allowed 'General case' 0 N--CA 1.474 0.757 0 CA-C-N 114.584 -1.189 . . . . 0.0 108.127 178.61 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' H' H ' 17' ' ' LEU . . . . . 0.613 HD11 HE21 ' E' ' 15' ' ' GLN . 6.4 mp -120.21 154.92 34.16 Favored 'General case' 0 N--CA 1.496 1.857 0 CA-C-O 121.265 0.555 . . . . 0.0 111.838 -177.939 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 43.2 t -113.4 124.65 70.25 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.079 0 CA-C-N 114.817 -1.083 . . . . 0.0 108.158 176.668 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 32.2 m-85 -125.22 121.28 33.65 Favored 'General case' 0 C--N 1.366 1.313 0 C-N-CA 123.471 0.708 . . . . 0.0 110.885 -179.443 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 68.3 m-85 54.72 72.92 0.43 Allowed 'General case' 0 C--O 1.238 0.455 0 CA-C-N 115.698 -0.683 . . . . 0.0 111.672 178.342 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.68 -78.31 0.14 Allowed 'General case' 0 N--CA 1.473 0.676 0 O-C-N 122.154 -0.341 . . . . 0.0 110.349 -178.914 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 40.8 tt0 -112.85 99.77 8.15 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 107.878 -1.156 . . . . 0.0 107.878 -179.946 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -157.24 139.96 15.02 Favored 'General case' 0 N--CA 1.477 0.887 0 O-C-N 122.346 -0.221 . . . . 0.0 111.471 178.976 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' H' H ' 24' ' ' VAL . . . . . 0.438 ' HB ' ' H ' ' E' ' 25' ' ' GLY . 59.7 t -59.7 167.65 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.592 0 N-CA-C 107.458 -1.312 . . . . 0.0 107.458 177.313 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' H' H ' 25' ' ' GLY . . . . . 0.43 ' N ' HG12 ' H' ' 24' ' ' VAL . . . -120.63 49.27 0.89 Allowed Glycine 0 N--CA 1.479 1.5 0 N-CA-C 110.622 -0.991 . . . . 0.0 110.622 -179.581 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -63.6 -167.33 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.643 0 CA-C-N 117.033 0.417 . . . . 0.0 110.036 179.766 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 5.0 t30 -70.05 77.04 0.5 Allowed 'General case' 0 N--CA 1.465 0.318 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.587 -179.945 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 97.8 mttt -74.1 143.45 45.38 Favored 'General case' 0 N--CA 1.475 0.819 0 N-CA-C 109.5 -0.556 . . . . 0.0 109.5 179.41 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.67 -166.39 1.21 Allowed Glycine 0 C--N 1.338 0.669 0 N-CA-C 109.997 -1.241 . . . . 0.0 109.997 178.641 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.4 114.29 27.13 Favored 'General case' 0 N--CA 1.47 0.554 0 C-N-CA 122.683 0.393 . . . . 0.0 110.293 -179.995 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 74.0 mt -98.46 135.09 34.6 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.693 0 N-CA-C 106.992 -1.484 . . . . 0.0 106.992 178.672 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' H' H ' 32' ' ' ILE . . . . . 0.45 ' H ' HG22 ' E' ' 32' ' ' ILE . 34.8 pt -151.51 -169.02 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.759 0 CA-C-N 119.667 1.121 . . . . 0.0 109.826 -179.929 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.08 5.28 7.42 Favored Glycine 0 N--CA 1.467 0.706 0 N-CA-C 111.055 -0.818 . . . . 0.0 111.055 -179.979 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' H' H ' 34' ' ' LEU . . . . . 0.425 HD23 ' N ' ' H' ' 35' ' ' MET . 1.1 tt -75.44 135.24 40.73 Favored 'General case' 0 CA--C 1.545 0.784 0 N-CA-C 109.4 -0.593 . . . . 0.0 109.4 -179.744 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' H' H ' 35' ' ' MET . . . . . 0.425 ' N ' HD23 ' H' ' 34' ' ' LEU . 25.4 ttt -158.41 146.01 18.08 Favored 'General case' 0 N--CA 1.469 0.514 0 N-CA-C 108.698 -0.853 . . . . 0.0 108.698 178.882 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 1.5 m -148.91 163.83 4.57 Favored 'Isoleucine or valine' 0 C--N 1.35 0.594 0 N-CA-C 108.56 -0.904 . . . . 0.0 108.56 -179.467 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.29 68.29 1.76 Allowed Glycine 0 C--N 1.306 -1.087 0 CA-C-N 115.237 -0.892 . . . . 0.0 112.32 177.612 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.54 172.72 17.96 Favored Glycine 0 N--CA 1.475 1.24 0 N-CA-C 110.745 -0.942 . . . . 0.0 110.745 178.959 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' H' H ' 39' ' ' VAL . . . . . 0.43 HG12 ' H ' ' E' ' 39' ' ' VAL . 34.1 m -106.13 155.75 6.98 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.0 0 C-N-CA 123.32 0.648 . . . . 0.0 110.575 -179.497 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 25.9 t . . . . . 0 C--O 1.219 -0.533 0 O-C-N 123.991 0.807 . . . . 0.0 110.61 179.424 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' I' I ' 1' ' ' ASP . . . . . 0.417 ' CG ' ' H1 ' ' F' ' 1' ' ' ASP . 16.8 m-20 . . . . . 0 N--CA 1.491 1.615 0 N-CA-C 109.45 -0.574 . . . . 0.0 109.45 . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' I' I ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.3 129.63 41.59 Favored 'General case' 0 N--CA 1.469 0.52 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.573 179.716 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' I' I ' 3' ' ' GLU . . . . . 0.411 ' CD ' HH21 ' I' ' 5' ' ' ARG . 46.8 tt0 -168.42 107.07 0.48 Allowed 'General case' 0 N--CA 1.473 0.709 0 CA-C-O 120.484 0.183 . . . . 0.0 110.567 179.769 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 67.2 m-85 -86.46 144.81 27.1 Favored 'General case' 0 N--CA 1.475 0.788 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 179.226 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' I' I ' 5' ' ' ARG . . . . . 0.411 HH21 ' CD ' ' I' ' 3' ' ' GLU . 99.5 mtt180 -144.12 142.48 30.61 Favored 'General case' 0 N--CA 1.482 1.153 0 N-CA-C 110.023 -0.362 . . . . 0.0 110.023 -179.931 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 45.1 t-80 -152.28 119.61 5.95 Favored 'General case' 0 N--CA 1.472 0.629 0 N-CA-C 109.503 -0.554 . . . . 0.0 109.503 178.824 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -71.96 144.81 48.77 Favored 'General case' 0 N--CA 1.469 0.481 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.105 -179.758 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' I' I ' 8' ' ' SER . . . . . 0.486 ' OG ' ' O ' ' F' ' 7' ' ' ASP . 51.7 p -164.95 -170.21 1.89 Allowed 'General case' 0 N--CA 1.474 0.742 0 CA-C-O 121.139 0.495 . . . . 0.0 110.547 178.956 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.27 47.72 1.4 Allowed Glycine 0 N--CA 1.479 1.518 0 N-CA-C 111.592 -0.603 . . . . 0.0 111.592 179.544 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 47.5 p90 -65.89 132.9 49.76 Favored 'General case' 0 N--CA 1.471 0.586 0 N-CA-C 111.883 0.327 . . . . 0.0 111.883 -179.789 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 48.4 mt-10 -91.57 151.13 20.87 Favored 'General case' 0 N--CA 1.478 0.936 0 CA-C-O 121.149 0.499 . . . . 0.0 110.013 178.654 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -154.75 127.32 1.06 Allowed 'Isoleucine or valine' 0 CA--C 1.551 0.983 0 N-CA-C 107.979 -1.119 . . . . 0.0 107.979 178.252 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 44.0 m-70 -134.83 146.2 49.06 Favored 'General case' 0 N--CA 1.479 0.993 0 CA-C-N 115.68 -0.691 . . . . 0.0 111.384 -178.149 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 28.3 t-80 -166.31 96.87 0.59 Allowed 'General case' 0 N--CA 1.48 1.051 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.399 178.91 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 17.1 pt20 -108.17 -174.48 2.53 Favored 'General case' 0 CA--C 1.505 -0.762 0 N-CA-C 108.272 -1.01 . . . . 0.0 108.272 -179.731 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -164.3 97.84 0.81 Allowed 'General case' 0 N--CA 1.475 0.794 0 CA-C-N 114.58 -1.191 . . . . 0.0 108.043 178.698 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' I' I ' 17' ' ' LEU . . . . . 0.577 HD11 HE21 ' F' ' 15' ' ' GLN . 6.4 mp -120.65 154.34 35.64 Favored 'General case' 0 N--CA 1.497 1.902 0 CA-C-O 121.215 0.531 . . . . 0.0 111.837 -177.938 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 42.9 t -112.72 125.16 69.95 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.949 0 N-CA-C 108.067 -1.086 . . . . 0.0 108.067 176.595 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 30.7 m-85 -125.71 121.37 33.24 Favored 'General case' 0 C--N 1.367 1.341 0 CA-C-N 115.585 -0.734 . . . . 0.0 110.815 -179.285 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 68.9 m-85 54.59 72.52 0.46 Allowed 'General case' 0 C--N 1.345 0.38 0 CA-C-N 115.916 -0.584 . . . . 0.0 111.49 178.27 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.33 -78.25 0.13 Allowed 'General case' 0 N--CA 1.473 0.72 0 N-CA-C 110.294 -0.262 . . . . 0.0 110.294 -178.971 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 40.9 tt0 -112.77 99.86 8.24 Favored 'General case' 0 C--N 1.323 -0.566 0 N-CA-C 107.978 -1.119 . . . . 0.0 107.978 -179.959 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 4.7 p30 -157.31 139.91 14.88 Favored 'General case' 0 N--CA 1.477 0.891 0 N-CA-C 111.487 0.18 . . . . 0.0 111.487 178.978 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' I' I ' 24' ' ' VAL . . . . . 0.434 ' HB ' ' H ' ' F' ' 25' ' ' GLY . 61.2 t -59.76 167.26 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.56 0 N-CA-C 107.567 -1.271 . . . . 0.0 107.567 177.243 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' I' I ' 25' ' ' GLY . . . . . 0.428 ' N ' HG12 ' I' ' 24' ' ' VAL . . . -120.34 49.62 0.87 Allowed Glycine 0 N--CA 1.479 1.516 0 N-CA-C 110.669 -0.972 . . . . 0.0 110.669 -179.494 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -63.73 -166.89 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.572 0 N-CA-C 110.036 -0.357 . . . . 0.0 110.036 179.881 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 5.0 t30 -70.58 76.56 0.58 Allowed 'General case' 0 CA--C 1.533 0.294 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.584 179.983 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 97.9 mttt -73.65 143.63 46.2 Favored 'General case' 0 N--CA 1.475 0.816 0 N-CA-C 109.561 -0.533 . . . . 0.0 109.561 179.422 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.74 -166.31 1.22 Allowed Glycine 0 C--N 1.336 0.548 0 N-CA-C 110.016 -1.233 . . . . 0.0 110.016 178.647 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.24 114.11 26.74 Favored 'General case' 0 N--CA 1.473 0.721 0 C-N-CA 122.706 0.402 . . . . 0.0 110.315 179.937 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 75.1 mt -98.3 135.08 34.38 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.631 0 N-CA-C 106.94 -1.504 . . . . 0.0 106.94 178.695 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' I' I ' 32' ' ' ILE . . . . . 0.446 ' H ' HG22 ' F' ' 32' ' ' ILE . 35.1 pt -151.5 -169.16 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.831 0 CA-C-N 119.62 1.1 . . . . 0.0 109.771 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.36 5.11 7.53 Favored Glycine 0 N--CA 1.466 0.686 0 N-CA-C 111.054 -0.818 . . . . 0.0 111.054 -179.893 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' I' I ' 34' ' ' LEU . . . . . 0.425 HD23 ' N ' ' I' ' 35' ' ' MET . 1.1 tt -75.21 134.92 41.07 Favored 'General case' 0 N--CA 1.474 0.77 0 N-CA-C 109.336 -0.616 . . . . 0.0 109.336 -179.646 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' I' I ' 35' ' ' MET . . . . . 0.425 ' N ' HD23 ' I' ' 34' ' ' LEU . 24.7 ttt -158.06 145.97 18.55 Favored 'General case' 0 N--CA 1.47 0.555 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 178.906 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 1.5 m -149.08 163.67 4.41 Favored 'Isoleucine or valine' 0 C--N 1.35 0.616 0 N-CA-C 108.491 -0.929 . . . . 0.0 108.491 -179.455 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.25 68.58 1.61 Allowed Glycine 0 C--N 1.308 -1.015 0 CA-C-N 115.218 -0.901 . . . . 0.0 112.282 177.706 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.25 172.5 17.51 Favored Glycine 0 N--CA 1.475 1.234 0 N-CA-C 110.646 -0.982 . . . . 0.0 110.646 178.923 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' I' I ' 39' ' ' VAL . . . . . 0.443 HG12 ' H ' ' F' ' 39' ' ' VAL . 34.4 m -106.17 155.49 7.06 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.993 0 C-N-CA 123.185 0.594 . . . . 0.0 110.635 -179.382 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 25.9 t . . . . . 0 C--O 1.218 -0.559 0 O-C-N 123.955 0.784 . . . . 0.0 110.599 179.433 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' ASP . . . . . 0.486 ' H1 ' ' CG ' ' D' ' 1' ' ' ASP . 16.8 m-20 . . . . . 0 N--CA 1.49 1.532 0 N-CA-C 108.831 -0.803 . . . . 0.0 108.831 . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -66.27 133.65 51.02 Favored 'General case' 0 CA--C 1.539 0.537 0 CA-C-N 116.526 -0.306 . . . . 0.0 110.219 -179.773 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 48.8 tt0 -169.52 105.85 0.37 Allowed 'General case' 0 C--O 1.216 -0.696 0 N-CA-C 110.0 -0.37 . . . . 0.0 110.0 -179.296 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 64.9 m-85 -83.95 145.72 28.4 Favored 'General case' 0 N--CA 1.474 0.77 0 N-CA-C 110.173 -0.306 . . . . 0.0 110.173 179.54 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -144.11 142.94 30.89 Favored 'General case' 0 N--CA 1.481 1.098 0 CA-C-O 120.925 0.393 . . . . 0.0 110.031 179.417 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 46.7 t-80 -152.83 118.99 5.49 Favored 'General case' 0 N--CA 1.472 0.654 0 N-CA-C 109.157 -0.683 . . . . 0.0 109.157 179.19 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' ASP . . . . . 0.508 ' O ' ' OG ' ' D' ' 8' ' ' SER . 4.3 m-20 -69.58 149.59 48.0 Favored 'General case' 0 N--CA 1.467 0.406 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.331 179.794 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 52.4 p -168.03 -173.27 2.02 Favored 'General case' 0 N--CA 1.484 1.243 0 CA-C-O 121.006 0.431 . . . . 0.0 110.698 179.107 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.79 46.49 1.49 Allowed Glycine 0 N--CA 1.481 1.686 0 CA-C-N 116.009 -0.541 . . . . 0.0 112.11 -179.941 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 49.1 p90 -65.12 132.43 49.14 Favored 'General case' 0 N--CA 1.473 0.685 0 O-C-N 122.687 -0.302 . . . . 0.0 111.561 179.631 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 49.2 mt-10 -91.83 152.13 20.26 Favored 'General case' 0 N--CA 1.477 0.889 0 N-CA-C 109.87 -0.419 . . . . 0.0 109.87 178.297 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -152.73 128.45 1.69 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.592 0 N-CA-C 107.849 -1.167 . . . . 0.0 107.849 178.248 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 44.5 m-70 -135.54 145.94 47.54 Favored 'General case' 0 N--CA 1.491 1.617 0 CA-C-N 119.011 0.823 . . . . 0.0 111.374 -179.107 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -166.9 97.25 0.53 Allowed 'General case' 0 N--CA 1.481 1.107 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.635 179.571 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 14.7 pt20 -109.69 -174.01 2.4 Favored 'General case' 0 CA--C 1.505 -0.788 0 N-CA-C 108.36 -0.978 . . . . 0.0 108.36 179.887 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -162.71 98.98 1.0 Allowed 'General case' 0 N--CA 1.472 0.669 0 CA-C-N 114.59 -1.186 . . . . 0.0 108.309 178.274 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 6.7 mp -121.45 155.55 34.64 Favored 'General case' 0 N--CA 1.497 1.901 0 CA-C-O 121.832 0.825 . . . . 0.0 110.938 -178.347 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 58.3 t -111.59 126.47 68.98 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.046 0 CA-C-O 117.894 -1.05 . . . . 0.0 108.344 177.742 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 29.2 m-85 -126.27 122.9 36.84 Favored 'General case' 0 N--CA 1.496 1.862 0 CA-C-N 120.147 1.34 . . . . 0.0 110.284 179.281 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 68.1 m-85 54.02 74.02 0.35 Allowed 'General case' 0 N--CA 1.47 0.538 0 CA-C-O 121.398 0.618 . . . . 0.0 111.66 178.729 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -79.77 -78.29 0.16 Allowed 'General case' 0 C--N 1.353 0.734 0 CA-C-N 115.175 -0.92 . . . . 0.0 110.442 -179.902 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 40.8 tt0 -113.15 100.19 8.4 Favored 'General case' 0 N--CA 1.47 0.565 0 N-CA-C 108.327 -0.99 . . . . 0.0 108.327 179.603 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 4.4 p30 -158.74 138.72 12.09 Favored 'General case' 0 N--CA 1.485 1.282 0 CA-C-O 119.403 -0.332 . . . . 0.0 111.226 179.271 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.41 HG12 ' N ' ' A' ' 25' ' ' GLY . 57.4 t -59.83 163.9 0.87 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.783 0 N-CA-C 108.224 -1.028 . . . . 0.0 108.224 176.932 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.46 ' H ' ' HB ' ' D' ' 24' ' ' VAL . . . -117.06 47.15 1.06 Allowed Glycine 0 N--CA 1.477 1.39 0 N-CA-C 111.753 -0.539 . . . . 0.0 111.753 -179.219 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -60.11 -167.79 0.01 OUTLIER 'General case' 0 N--CA 1.469 0.512 0 O-C-N 123.852 0.384 . . . . 0.0 110.405 179.272 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 4.9 t30 -70.98 81.05 0.66 Allowed 'General case' 0 CA--C 1.531 0.219 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.212 179.6 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 97.7 mttt -77.93 143.16 37.9 Favored 'General case' 0 N--CA 1.471 0.582 0 N-CA-C 109.163 -0.68 . . . . 0.0 109.163 179.396 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.67 -167.51 1.06 Allowed Glycine 0 CA--C 1.525 0.707 0 N-CA-C 109.926 -1.269 . . . . 0.0 109.926 178.962 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.91 115.02 28.67 Favored 'General case' 0 N--CA 1.476 0.846 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 179.677 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 72.3 mt -98.68 134.46 37.34 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.518 0 N-CA-C 107.025 -1.472 . . . . 0.0 107.025 179.021 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 29.3 pt -150.68 -172.0 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.708 0 CA-C-O 121.209 0.528 . . . . 0.0 111.184 -179.14 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.63 4.73 10.5 Favored Glycine 0 CA--C 1.527 0.785 0 N-CA-C 110.699 -0.96 . . . . 0.0 110.699 179.882 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.431 HD23 ' N ' ' A' ' 35' ' ' MET . 1.1 tt -75.43 135.16 40.75 Favored 'General case' 0 CA--C 1.544 0.726 0 N-CA-C 109.405 -0.591 . . . . 0.0 109.405 -179.56 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 35' ' ' MET . . . . . 0.431 ' N ' HD23 ' A' ' 34' ' ' LEU . 27.2 ttt -158.54 146.64 18.33 Favored 'General case' 0 N--CA 1.47 0.546 0 N-CA-C 108.557 -0.905 . . . . 0.0 108.557 178.705 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 1.7 m -149.16 165.49 3.78 Favored 'Isoleucine or valine' 0 C--N 1.349 0.579 0 N-CA-C 108.056 -1.09 . . . . 0.0 108.056 -179.584 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.19 68.36 1.73 Allowed Glycine 0 C--N 1.305 -1.158 0 CA-C-N 115.521 -0.763 . . . . 0.0 112.316 177.581 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.32 177.32 21.73 Favored Glycine 0 N--CA 1.474 1.192 0 N-CA-C 111.008 -0.837 . . . . 0.0 111.008 178.514 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.437 ' H ' HG12 ' D' ' 39' ' ' VAL . 34.3 m -109.81 155.59 10.95 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.623 0 C-N-CA 123.432 0.693 . . . . 0.0 110.354 -179.643 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 23.4 t . . . . . 0 C--O 1.219 -0.501 0 O-C-N 124.031 0.832 . . . . 0.0 110.663 179.633 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' B' B ' 1' ' ' ASP . . . . . 0.431 ' H1 ' ' CG ' ' E' ' 1' ' ' ASP . 16.1 m-20 . . . . . 0 N--CA 1.489 1.475 0 N-CA-C 109.036 -0.727 . . . . 0.0 109.036 . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.98 133.4 50.77 Favored 'General case' 0 CA--C 1.54 0.575 0 N-CA-C 110.137 -0.319 . . . . 0.0 110.137 -179.788 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 3' ' ' GLU . . . . . . . . . . . . . 48.5 tt0 -169.38 105.68 0.38 Allowed 'General case' 0 N--CA 1.473 0.683 0 N-CA-C 110.055 -0.35 . . . . 0.0 110.055 -179.057 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 63.9 m-85 -83.78 145.65 28.58 Favored 'General case' 0 N--CA 1.475 0.804 0 N-CA-C 110.154 -0.313 . . . . 0.0 110.154 179.504 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -144.32 141.92 30.07 Favored 'General case' 0 N--CA 1.481 1.089 0 N-CA-C 109.881 -0.414 . . . . 0.0 109.881 179.513 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 47.2 t-80 -151.71 118.55 5.8 Favored 'General case' 0 N--CA 1.473 0.715 0 N-CA-C 109.319 -0.623 . . . . 0.0 109.319 178.989 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 7' ' ' ASP . . . . . 0.449 ' O ' ' OG ' ' E' ' 8' ' ' SER . 3.9 m-20 -69.2 148.9 49.21 Favored 'General case' 0 N--CA 1.469 0.485 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.525 179.761 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 8' ' ' SER . . . . . . . . . . . . . 49.4 p -167.52 -173.49 2.22 Favored 'General case' 0 N--CA 1.481 1.125 0 CA-C-O 120.974 0.416 . . . . 0.0 110.653 179.155 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.26 46.92 1.38 Allowed Glycine 0 N--CA 1.482 1.728 0 CA-C-N 116.007 -0.542 . . . . 0.0 112.158 179.987 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 48.7 p90 -65.74 132.33 48.48 Favored 'General case' 0 N--CA 1.472 0.668 0 O-C-N 122.733 -0.274 . . . . 0.0 111.618 179.663 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 48.6 mt-10 -91.52 152.32 20.37 Favored 'General case' 0 N--CA 1.475 0.819 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 178.167 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -153.05 128.25 1.54 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.581 0 N-CA-C 107.783 -1.191 . . . . 0.0 107.783 178.148 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 45.5 m-70 -135.4 145.86 47.72 Favored 'General case' 0 N--CA 1.493 1.692 0 CA-C-N 118.843 0.747 . . . . 0.0 111.37 -179.141 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -166.57 97.15 0.56 Allowed 'General case' 0 N--CA 1.48 1.05 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.651 179.485 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 14.9 pt20 -109.54 -173.62 2.3 Favored 'General case' 0 CA--C 1.507 -0.7 0 N-CA-C 108.324 -0.991 . . . . 0.0 108.324 179.854 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -163.2 98.82 0.94 Allowed 'General case' 0 N--CA 1.473 0.696 0 CA-C-N 114.699 -1.137 . . . . 0.0 108.279 178.357 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 6.6 mp -121.17 155.56 34.27 Favored 'General case' 0 N--CA 1.498 1.925 0 CA-C-O 121.894 0.854 . . . . 0.0 110.927 -178.298 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 60.4 t -111.77 127.69 68.78 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.082 0 N-CA-C 108.037 -1.097 . . . . 0.0 108.037 177.538 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 28.5 m-85 -127.66 122.34 32.78 Favored 'General case' 0 N--CA 1.495 1.821 0 CA-C-N 119.665 1.12 . . . . 0.0 110.161 179.566 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 67.4 m-85 53.96 73.65 0.37 Allowed 'General case' 0 CA--C 1.54 0.571 0 CA-C-O 121.505 0.669 . . . . 0.0 111.67 178.615 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -79.65 -78.0 0.17 Allowed 'General case' 0 C--N 1.351 0.649 0 CA-C-N 115.078 -0.965 . . . . 0.0 110.435 -179.917 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 41.0 tt0 -113.4 99.62 7.92 Favored 'General case' 0 N--CA 1.47 0.56 0 N-CA-C 108.499 -0.926 . . . . 0.0 108.499 179.624 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -157.99 139.15 13.35 Favored 'General case' 0 C--O 1.205 -1.266 0 CA-C-O 119.447 -0.311 . . . . 0.0 111.208 179.204 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 59.9 t -60.15 163.49 0.98 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.824 0 N-CA-C 108.212 -1.033 . . . . 0.0 108.212 176.976 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 25' ' ' GLY . . . . . 0.472 ' H ' ' HB ' ' E' ' 24' ' ' VAL . . . -116.42 47.63 1.02 Allowed Glycine 0 N--CA 1.476 1.357 0 N-CA-C 111.628 -0.589 . . . . 0.0 111.628 -179.167 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -60.69 -167.68 0.01 OUTLIER 'General case' 0 N--CA 1.468 0.46 0 O-C-N 123.782 0.342 . . . . 0.0 110.306 179.414 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 4.5 t30 -71.17 81.01 0.71 Allowed 'General case' 0 CA--C 1.532 0.27 0 N-CA-C 110.074 -0.343 . . . . 0.0 110.074 179.616 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 97.7 mttt -77.9 143.1 38.01 Favored 'General case' 0 N--CA 1.472 0.638 0 N-CA-C 109.105 -0.702 . . . . 0.0 109.105 179.442 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.49 -167.42 0.97 Allowed Glycine 0 C--N 1.337 0.618 0 N-CA-C 109.92 -1.272 . . . . 0.0 109.92 178.894 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -100.25 114.78 28.49 Favored 'General case' 0 N--CA 1.475 0.786 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 179.757 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 71.5 mt -98.46 134.51 36.8 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.501 0 N-CA-C 107.105 -1.443 . . . . 0.0 107.105 178.889 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 30.1 pt -150.31 -171.37 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.647 0 CA-C-O 121.115 0.484 . . . . 0.0 111.227 -179.166 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.1 4.57 8.11 Favored Glycine 0 CA--C 1.526 0.752 0 N-CA-C 110.835 -0.906 . . . . 0.0 110.835 179.748 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 34' ' ' LEU . . . . . 0.421 HD23 ' N ' ' B' ' 35' ' ' MET . 1.1 tt -75.11 135.08 41.18 Favored 'General case' 0 CA--C 1.544 0.726 0 N-CA-C 109.376 -0.601 . . . . 0.0 109.376 -179.554 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 35' ' ' MET . . . . . 0.421 ' N ' HD23 ' B' ' 34' ' ' LEU . 27.1 ttt -158.24 146.63 18.77 Favored 'General case' 0 N--CA 1.472 0.628 0 N-CA-C 108.57 -0.9 . . . . 0.0 108.57 178.547 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 1.6 m -149.29 165.45 3.7 Favored 'Isoleucine or valine' 0 C--N 1.347 0.48 0 N-CA-C 108.018 -1.105 . . . . 0.0 108.018 -179.503 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 54.81 68.67 1.56 Allowed Glycine 0 C--N 1.305 -1.158 0 CA-C-N 115.354 -0.839 . . . . 0.0 112.23 177.654 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 146.95 176.89 21.09 Favored Glycine 0 N--CA 1.474 1.194 0 N-CA-C 111.106 -0.797 . . . . 0.0 111.106 178.612 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 39' ' ' VAL . . . . . 0.436 ' H ' HG12 ' E' ' 39' ' ' VAL . 34.1 m -109.68 155.22 10.92 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.698 0 C-N-CA 123.412 0.685 . . . . 0.0 110.415 -179.501 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 23.2 t . . . . . 0 C--O 1.218 -0.569 0 O-C-N 123.991 0.807 . . . . 0.0 110.331 179.552 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' C' C ' 1' ' ' ASP . . . . . 0.432 ' H2 ' ' CB ' ' F' ' 1' ' ' ASP . 16.0 m-20 . . . . . 0 N--CA 1.49 1.543 0 N-CA-C 108.818 -0.808 . . . . 0.0 108.818 . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.91 132.86 49.65 Favored 'General case' 0 CA--C 1.54 0.569 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.248 -179.757 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 3' ' ' GLU . . . . . 0.406 ' CD ' HH21 ' C' ' 5' ' ' ARG . 49.4 tt0 -168.85 105.95 0.43 Allowed 'General case' 0 C--O 1.216 -0.667 0 N-CA-C 110.014 -0.365 . . . . 0.0 110.014 -179.274 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 62.0 m-85 -83.78 145.83 28.48 Favored 'General case' 0 N--CA 1.476 0.87 0 N-CA-C 110.179 -0.304 . . . . 0.0 110.179 179.449 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 5' ' ' ARG . . . . . 0.406 HH21 ' CD ' ' C' ' 3' ' ' GLU . 99.4 mtt180 -144.38 142.27 30.24 Favored 'General case' 0 N--CA 1.482 1.139 0 N-CA-C 109.994 -0.373 . . . . 0.0 109.994 179.426 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 46.7 t-80 -152.19 118.97 5.74 Favored 'General case' 0 N--CA 1.472 0.673 0 N-CA-C 109.216 -0.661 . . . . 0.0 109.216 179.216 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 7' ' ' ASP . . . . . 0.492 ' O ' ' OG ' ' F' ' 8' ' ' SER . 4.1 m-20 -69.69 149.11 48.41 Favored 'General case' 0 N--CA 1.467 0.423 0 CA-C-N 116.356 -0.384 . . . . 0.0 110.485 179.793 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 8' ' ' SER . . . . . . . . . . . . . 52.3 p -167.7 -173.18 2.08 Favored 'General case' 0 N--CA 1.483 1.192 0 CA-C-O 121.018 0.437 . . . . 0.0 110.604 179.051 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.01 46.8 1.42 Allowed Glycine 0 N--CA 1.481 1.651 0 CA-C-N 115.898 -0.592 . . . . 0.0 112.201 -179.978 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 48.4 p90 -65.81 132.34 48.47 Favored 'General case' 0 N--CA 1.474 0.737 0 CA-C-O 120.699 0.285 . . . . 0.0 111.532 179.805 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 48.2 mt-10 -91.4 152.4 20.42 Favored 'General case' 0 N--CA 1.474 0.759 0 CA-C-O 121.001 0.429 . . . . 0.0 109.871 178.141 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -152.96 128.29 1.57 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.514 0 N-CA-C 107.81 -1.181 . . . . 0.0 107.81 178.193 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 42.8 m-70 -135.42 145.87 47.68 Favored 'General case' 0 N--CA 1.492 1.647 0 CA-C-N 118.939 0.79 . . . . 0.0 111.309 -179.141 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -166.74 97.19 0.55 Allowed 'General case' 0 N--CA 1.481 1.09 0 CA-C-N 116.414 -0.357 . . . . 0.0 110.571 179.481 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 14.8 pt20 -109.58 -173.68 2.32 Favored 'General case' 0 CA--C 1.504 -0.799 0 N-CA-C 108.381 -0.97 . . . . 0.0 108.381 179.884 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -163.19 98.91 0.94 Allowed 'General case' 0 N--CA 1.471 0.601 0 CA-C-N 114.695 -1.139 . . . . 0.0 108.304 178.332 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 6.6 mp -121.37 155.35 34.98 Favored 'General case' 0 N--CA 1.497 1.906 0 CA-C-O 121.846 0.832 . . . . 0.0 111.0 -178.32 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 61.0 t -111.43 127.45 68.57 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.065 0 N-CA-C 108.183 -1.043 . . . . 0.0 108.183 177.532 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 28.5 m-85 -127.28 122.52 34.07 Favored 'General case' 0 N--CA 1.494 1.747 0 CA-C-N 119.674 1.125 . . . . 0.0 110.152 179.527 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 68.0 m-85 53.57 73.98 0.34 Allowed 'General case' 0 CA--C 1.539 0.545 0 CA-C-O 121.502 0.668 . . . . 0.0 111.745 178.615 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -79.88 -78.12 0.17 Allowed 'General case' 0 C--N 1.351 0.644 0 CA-C-N 114.999 -1.001 . . . . 0.0 110.342 -179.864 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 40.9 tt0 -113.24 99.86 8.13 Favored 'General case' 0 N--CA 1.47 0.556 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 179.675 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 4.4 p30 -158.41 138.73 12.51 Favored 'General case' 0 N--CA 1.484 1.236 0 CA-C-O 119.46 -0.305 . . . . 0.0 111.23 179.112 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 24' ' ' VAL . . . . . 0.405 HG12 ' N ' ' C' ' 25' ' ' GLY . 62.1 t -59.55 164.23 0.8 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.87 0 N-CA-C 108.124 -1.065 . . . . 0.0 108.124 177.107 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 25' ' ' GLY . . . . . 0.471 ' H ' ' HB ' ' F' ' 24' ' ' VAL . . . -117.14 47.3 1.05 Allowed Glycine 0 N--CA 1.477 1.368 0 N-CA-C 111.553 -0.619 . . . . 0.0 111.553 -179.298 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -60.31 -168.11 0.01 OUTLIER 'General case' 0 N--CA 1.468 0.465 0 O-C-N 123.747 0.322 . . . . 0.0 110.335 179.301 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 4.7 t30 -70.78 80.96 0.62 Allowed 'General case' 0 N--CA 1.465 0.317 0 N-CA-C 110.087 -0.338 . . . . 0.0 110.087 179.478 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 97.7 mttt -77.76 142.91 38.38 Favored 'General case' 0 N--CA 1.472 0.665 0 N-CA-C 109.151 -0.685 . . . . 0.0 109.151 179.32 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.51 -167.87 1.06 Allowed Glycine 0 CA--C 1.524 0.621 0 N-CA-C 109.938 -1.265 . . . . 0.0 109.938 178.826 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.5 114.84 28.06 Favored 'General case' 0 N--CA 1.477 0.894 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 179.708 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 71.5 mt -98.64 134.21 38.19 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.591 0 N-CA-C 106.98 -1.489 . . . . 0.0 106.98 178.85 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 29.9 pt -150.18 -171.57 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.352 0.713 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.21 -179.217 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.2 4.81 8.86 Favored Glycine 0 CA--C 1.526 0.767 0 N-CA-C 110.795 -0.922 . . . . 0.0 110.795 179.815 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 34' ' ' LEU . . . . . 0.429 HD23 ' N ' ' C' ' 35' ' ' MET . 1.1 tt -75.32 135.15 40.9 Favored 'General case' 0 CA--C 1.545 0.759 0 N-CA-C 109.273 -0.639 . . . . 0.0 109.273 -179.579 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 35' ' ' MET . . . . . 0.429 ' N ' HD23 ' C' ' 34' ' ' LEU . 27.3 ttt -158.41 146.4 18.35 Favored 'General case' 0 N--CA 1.471 0.585 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 178.734 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 1.6 m -149.25 165.44 3.73 Favored 'Isoleucine or valine' 0 C--N 1.348 0.506 0 N-CA-C 107.985 -1.117 . . . . 0.0 107.985 -179.476 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.08 68.56 1.62 Allowed Glycine 0 C--N 1.306 -1.13 0 CA-C-N 115.384 -0.825 . . . . 0.0 112.186 177.563 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.0 177.21 21.39 Favored Glycine 0 N--CA 1.473 1.132 0 N-CA-C 111.019 -0.832 . . . . 0.0 111.019 178.579 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 39' ' ' VAL . . . . . 0.437 ' H ' HG12 ' F' ' 39' ' ' VAL . 34.4 m -109.94 155.57 11.1 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.681 0 C-N-CA 123.401 0.68 . . . . 0.0 110.351 -179.523 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 23.6 t . . . . . 0 C--O 1.219 -0.514 0 O-C-N 124.021 0.826 . . . . 0.0 110.478 179.645 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' D' D ' 1' ' ' ASP . . . . . 0.486 ' CG ' ' H1 ' ' A' ' 1' ' ' ASP . 16.2 m-20 . . . . . 0 N--CA 1.49 1.559 0 N-CA-C 109.271 -0.64 . . . . 0.0 109.271 . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.29 131.18 46.55 Favored 'General case' 0 CA--C 1.534 0.358 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.569 179.82 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 3' ' ' GLU . . . . . 0.407 ' CD ' HH21 ' D' ' 5' ' ' ARG . 48.0 tt0 -169.28 108.86 0.44 Allowed 'General case' 0 N--CA 1.47 0.567 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 179.781 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 72.1 m-85 -88.45 151.95 22.21 Favored 'General case' 0 C--N 1.363 1.195 0 C-N-CA 119.196 -1.002 . . . . 0.0 108.608 179.829 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 5' ' ' ARG . . . . . 0.407 HH21 ' CD ' ' D' ' 3' ' ' GLU . 99.4 mtt180 -146.89 140.56 25.77 Favored 'General case' 0 N--CA 1.475 0.822 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.276 179.794 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 43.6 t-80 -149.78 123.69 9.33 Favored 'General case' 0 CA--C 1.545 0.78 0 N-CA-C 108.19 -1.041 . . . . 0.0 108.19 175.005 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 7' ' ' ASP . . . . . 0.593 ' O ' ' OG ' ' G' ' 8' ' ' SER . 2.9 m-20 -63.89 132.83 51.96 Favored 'General case' 0 C--N 1.321 -0.664 0 C-N-CA 127.068 2.147 . . . . 0.0 114.479 174.269 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' D' D ' 8' ' ' SER . . . . . 0.508 ' OG ' ' O ' ' A' ' 7' ' ' ASP . 51.9 p -154.8 -170.22 3.44 Favored 'General case' 0 N--CA 1.485 1.313 0 CA-C-N 120.046 1.294 . . . . 0.0 111.317 175.159 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.38 47.89 1.18 Allowed Glycine 0 N--CA 1.481 1.639 0 C-N-CA 124.553 1.073 . . . . 0.0 110.419 174.688 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 50.9 p90 -61.06 131.05 49.34 Favored 'General case' 0 N--CA 1.472 0.634 0 N-CA-C 112.725 0.639 . . . . 0.0 112.725 177.928 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 48.4 mt-10 -88.94 150.96 22.59 Favored 'General case' 0 N--CA 1.481 1.086 0 CA-C-N 117.961 0.346 . . . . 0.0 110.752 175.125 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -149.57 130.04 4.35 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.533 0 N-CA-C 107.518 -1.29 . . . . 0.0 107.518 173.119 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 40.9 m-70 -130.03 148.36 51.87 Favored 'General case' 0 N--CA 1.484 1.249 0 CA-C-N 118.098 0.408 . . . . 0.0 111.98 176.4 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -165.35 104.47 0.74 Allowed 'General case' 0 N--CA 1.481 1.098 0 N-CA-C 109.079 -0.711 . . . . 0.0 109.079 172.352 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 14.8 pt20 -113.36 -175.89 2.77 Favored 'General case' 0 CA--C 1.496 -1.127 0 N-CA-C 108.227 -1.027 . . . . 0.0 108.227 178.669 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -159.41 106.22 1.71 Allowed 'General case' 0 N--CA 1.468 0.444 0 N-CA-C 106.552 -1.648 . . . . 0.0 106.552 175.352 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 5.5 mp -128.01 152.87 47.4 Favored 'General case' 0 N--CA 1.499 2.008 0 CA-C-O 122.187 0.994 . . . . 0.0 110.396 179.795 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 38.4 t -101.01 131.66 48.24 Favored 'Isoleucine or valine' 0 C--O 1.258 1.518 0 CA-C-O 116.845 -1.55 . . . . 0.0 109.741 174.102 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 26.6 m-85 -130.27 126.39 37.15 Favored 'General case' 0 N--CA 1.491 1.617 0 CA-C-N 120.074 1.306 . . . . 0.0 109.417 173.61 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 68.5 m-85 55.27 71.67 0.53 Allowed 'General case' 0 C--N 1.35 0.597 0 CA-C-N 115.508 -0.769 . . . . 0.0 111.441 176.664 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -82.13 -73.21 0.4 Allowed 'General case' 0 C--N 1.353 0.721 0 CA-C-O 118.415 -0.803 . . . . 0.0 111.197 -177.693 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 41.1 tt0 -116.45 103.9 10.9 Favored 'General case' 0 N--CA 1.48 1.074 0 N-CA-C 106.434 -1.691 . . . . 0.0 106.434 176.124 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -151.82 138.5 18.79 Favored 'General case' 0 N--CA 1.477 0.896 0 CA-C-O 116.592 -1.671 . . . . 0.0 113.559 177.983 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 24' ' ' VAL . . . . . 0.46 ' HB ' ' H ' ' A' ' 25' ' ' GLY . 63.5 t -62.26 166.41 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.267 0 CA-C-N 121.264 1.847 . . . . 0.0 107.964 174.961 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' D' D ' 25' ' ' GLY . . . . . 0.531 ' H ' ' HB ' ' G' ' 24' ' ' VAL . . . -116.78 51.04 0.75 Allowed Glycine 0 N--CA 1.479 1.556 0 CA-C-O 118.964 -0.909 . . . . 0.0 111.654 178.593 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -57.1 -170.91 0.01 OUTLIER 'General case' 0 C--N 1.322 -0.627 0 C-N-CA 123.688 0.795 . . . . 0.0 111.639 175.768 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 5.6 t30 -72.54 86.81 1.19 Allowed 'General case' 0 C--N 1.347 0.475 0 C-N-CA 119.286 -0.965 . . . . 0.0 108.572 177.928 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 97.2 mttt -83.04 146.01 28.97 Favored 'General case' 0 N--CA 1.473 0.716 0 N-CA-C 107.948 -1.13 . . . . 0.0 107.948 179.281 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.45 -165.61 0.72 Allowed Glycine 0 C--N 1.337 0.609 0 N-CA-C 110.356 -1.098 . . . . 0.0 110.356 179.524 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -102.04 116.04 31.83 Favored 'General case' 0 N--CA 1.472 0.627 0 N-CA-C 109.36 -0.607 . . . . 0.0 109.36 179.594 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 80.8 mt -102.59 142.22 17.15 Favored 'Isoleucine or valine' 0 C--N 1.357 0.933 0 N-CA-C 104.568 -2.382 . . . . 0.0 104.568 179.979 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 32' ' ' ILE . . . . . 0.444 HG22 ' H ' ' G' ' 32' ' ' ILE . 30.0 pt -157.37 -172.59 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.482 1.148 0 CA-C-O 120.84 0.353 . . . . 0.0 110.189 -177.479 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 64.23 4.31 11.72 Favored Glycine 0 N--CA 1.466 0.668 0 N-CA-C 110.27 -1.132 . . . . 0.0 110.27 -178.917 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 1.3 tt -76.29 140.28 41.45 Favored 'General case' 0 CA--C 1.543 0.708 0 N-CA-C 107.797 -1.186 . . . . 0.0 107.797 -178.142 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 26.8 ttt -156.45 156.17 33.33 Favored 'General case' 0 C--O 1.244 0.782 0 N-CA-C 107.774 -1.195 . . . . 0.0 107.774 174.436 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 1.8 m -158.04 164.05 1.14 Allowed 'Isoleucine or valine' 0 CA--C 1.515 -0.399 0 N-CA-C 107.53 -1.285 . . . . 0.0 107.53 177.973 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 61.42 63.66 4.67 Favored Glycine 0 CA--C 1.526 0.742 0 C-N-CA 119.773 -1.203 . . . . 0.0 112.101 177.212 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 145.71 177.87 20.77 Favored Glycine 0 N--CA 1.478 1.469 0 CA-C-N 118.388 1.094 . . . . 0.0 111.665 179.885 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 39' ' ' VAL . . . . . 0.437 HG12 ' H ' ' A' ' 39' ' ' VAL . 35.2 m -112.64 152.36 14.43 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.881 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -176.89 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 23.5 t . . . . . 0 CA--C 1.522 -0.12 0 CA-C-O 116.166 -1.873 . . . . 0.0 109.597 178.315 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' E' E ' 1' ' ' ASP . . . . . 0.431 ' CG ' ' H1 ' ' B' ' 1' ' ' ASP . 15.7 m-20 . . . . . 0 N--CA 1.488 1.454 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' E' E ' 2' ' ' ALA . . . . . . . . . . . . . . . -63.95 131.65 48.3 Favored 'General case' 0 N--CA 1.469 0.501 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.43 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' E' E ' 3' ' ' GLU . . . . . 0.4 ' CD ' HH21 ' E' ' 5' ' ' ARG . 47.9 tt0 -169.04 105.72 0.41 Allowed 'General case' 0 C--O 1.215 -0.754 0 CA-C-N 116.825 -0.17 . . . . 0.0 110.632 -179.766 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 63.2 m-85 -84.51 145.09 28.29 Favored 'General case' 0 N--CA 1.477 0.902 0 N-CA-C 110.27 -0.27 . . . . 0.0 110.27 179.308 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' E' E ' 5' ' ' ARG . . . . . 0.4 HH21 ' CD ' ' E' ' 3' ' ' GLU . 99.5 mtt180 -143.6 142.69 31.17 Favored 'General case' 0 N--CA 1.48 1.039 0 CA-C-O 120.857 0.361 . . . . 0.0 110.163 179.356 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 45.7 t-80 -152.27 119.16 5.78 Favored 'General case' 0 N--CA 1.473 0.707 0 N-CA-C 109.194 -0.669 . . . . 0.0 109.194 179.027 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' E' E ' 7' ' ' ASP . . . . . 0.441 ' O ' ' OG ' ' H' ' 8' ' ' SER . 3.9 m-20 -70.23 149.26 47.66 Favored 'General case' 0 N--CA 1.469 0.501 0 CA-C-N 116.425 -0.352 . . . . 0.0 110.633 179.805 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' E' E ' 8' ' ' SER . . . . . 0.449 ' OG ' ' O ' ' B' ' 7' ' ' ASP . 44.5 p -168.68 -171.69 1.46 Allowed 'General case' 0 N--CA 1.484 1.234 0 CA-C-O 121.02 0.438 . . . . 0.0 110.842 178.591 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.05 47.02 1.38 Allowed Glycine 0 N--CA 1.478 1.476 0 CA-C-N 115.946 -0.57 . . . . 0.0 111.958 179.905 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 46.5 p90 -65.12 132.91 50.41 Favored 'General case' 0 N--CA 1.474 0.738 0 N-CA-C 111.881 0.326 . . . . 0.0 111.881 -179.873 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 48.9 mt-10 -91.45 152.71 20.26 Favored 'General case' 0 N--CA 1.479 0.989 0 CA-C-O 121.13 0.49 . . . . 0.0 109.75 177.885 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -154.58 127.59 1.13 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.538 0 N-CA-C 107.849 -1.167 . . . . 0.0 107.849 178.093 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 43.3 m-70 -135.89 143.97 45.3 Favored 'General case' 0 N--CA 1.482 1.135 0 CA-C-O 120.857 0.36 . . . . 0.0 111.609 -178.049 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -165.57 96.72 0.66 Allowed 'General case' 0 N--CA 1.484 1.256 0 CA-C-N 116.442 -0.345 . . . . 0.0 110.693 179.681 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 15.0 pt20 -108.71 -173.67 2.33 Favored 'General case' 0 CA--C 1.507 -0.688 0 N-CA-C 108.56 -0.904 . . . . 0.0 108.56 179.909 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -162.87 98.11 0.96 Allowed 'General case' 0 N--CA 1.477 0.903 0 CA-C-N 114.693 -1.139 . . . . 0.0 108.376 178.351 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 6.5 mp -120.07 155.48 32.87 Favored 'General case' 0 N--CA 1.495 1.78 0 CA-C-O 121.604 0.716 . . . . 0.0 111.5 -177.87 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 48.9 t -113.61 124.5 70.31 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.244 0 N-CA-C 108.249 -1.019 . . . . 0.0 108.249 177.167 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 31.3 m-85 -124.73 121.69 35.36 Favored 'General case' 0 N--CA 1.49 1.535 0 CA-C-O 120.921 0.391 . . . . 0.0 110.792 -179.769 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 70.0 m-85 54.75 73.21 0.42 Allowed 'General case' 0 N--CA 1.469 0.511 0 CA-C-N 115.969 -0.559 . . . . 0.0 111.281 178.219 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -78.39 -78.72 0.14 Allowed 'General case' 0 C--N 1.345 0.377 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.358 -179.594 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 40.4 tt0 -112.55 100.09 8.47 Favored 'General case' 0 C--N 1.325 -0.474 0 N-CA-C 108.467 -0.938 . . . . 0.0 108.467 179.758 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -157.31 138.5 13.6 Favored 'General case' 0 C--O 1.203 -1.369 0 CA-C-O 119.371 -0.347 . . . . 0.0 111.553 179.287 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' E' E ' 24' ' ' VAL . . . . . 0.472 ' HB ' ' H ' ' B' ' 25' ' ' GLY . 59.3 t -58.02 168.52 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.903 0 N-CA-C 107.663 -1.236 . . . . 0.0 107.663 176.615 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' E' E ' 25' ' ' GLY . . . . . 0.427 ' H ' ' HB ' ' H' ' 24' ' ' VAL . . . -122.05 48.44 0.95 Allowed Glycine 0 N--CA 1.476 1.325 0 N-CA-C 110.735 -0.946 . . . . 0.0 110.735 -179.104 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -61.93 -167.41 0.01 OUTLIER 'General case' 0 N--CA 1.47 0.559 0 CA-C-O 120.729 0.3 . . . . 0.0 110.514 179.74 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 5.7 t30 -70.34 77.33 0.55 Allowed 'General case' 0 N--CA 1.465 0.285 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.45 -179.939 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 97.8 mttt -74.69 143.55 44.16 Favored 'General case' 0 N--CA 1.474 0.765 0 N-CA-C 109.646 -0.502 . . . . 0.0 109.646 179.484 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.29 -167.44 1.29 Allowed Glycine 0 CA--C 1.522 0.496 0 N-CA-C 110.339 -1.105 . . . . 0.0 110.339 178.71 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.56 114.26 27.17 Favored 'General case' 0 N--CA 1.476 0.838 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 179.693 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 70.8 mt -98.32 134.23 37.64 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.35 0 N-CA-C 106.812 -1.551 . . . . 0.0 106.812 179.02 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' E' E ' 32' ' ' ILE . . . . . 0.439 HG22 ' H ' ' H' ' 32' ' ' ILE . 30.9 pt -150.24 -169.8 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.149 0 CA-C-O 120.998 0.428 . . . . 0.0 110.785 -179.313 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.41 5.2 6.02 Favored Glycine 0 CA--C 1.531 1.056 0 N-CA-C 111.288 -0.725 . . . . 0.0 111.288 -179.781 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' E' E ' 34' ' ' LEU . . . . . 0.419 HD23 ' N ' ' E' ' 35' ' ' MET . 1.1 tt -74.88 135.64 41.52 Favored 'General case' 0 CA--C 1.547 0.86 0 N-CA-C 109.304 -0.628 . . . . 0.0 109.304 -179.597 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' E' E ' 35' ' ' MET . . . . . 0.419 ' N ' HD23 ' E' ' 34' ' ' LEU . 26.6 ttt -158.82 145.57 17.22 Favored 'General case' 0 N--CA 1.474 0.734 0 N-CA-C 108.638 -0.875 . . . . 0.0 108.638 178.811 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 1.4 m -148.53 165.44 4.61 Favored 'Isoleucine or valine' 0 C--N 1.347 0.495 0 N-CA-C 108.388 -0.967 . . . . 0.0 108.388 -179.546 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 54.56 68.27 1.76 Allowed Glycine 0 C--N 1.308 -0.998 0 CA-C-N 115.266 -0.879 . . . . 0.0 112.1 177.573 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 146.81 174.28 18.77 Favored Glycine 0 N--CA 1.472 1.081 0 N-CA-C 111.381 -0.687 . . . . 0.0 111.381 178.685 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' E' E ' 39' ' ' VAL . . . . . 0.436 HG12 ' H ' ' B' ' 39' ' ' VAL . 33.1 m -107.58 154.97 8.47 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.768 0 C-N-CA 123.624 0.77 . . . . 0.0 110.568 -178.843 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 25.2 t . . . . . 0 C--O 1.219 -0.535 0 O-C-N 124.263 0.977 . . . . 0.0 110.263 179.802 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' F' F ' 1' ' ' ASP . . . . . 0.432 ' CB ' ' H2 ' ' C' ' 1' ' ' ASP . 15.5 m-20 . . . . . 0 N--CA 1.49 1.532 0 N-CA-C 109.316 -0.624 . . . . 0.0 109.316 . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' F' F ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.53 131.34 46.78 Favored 'General case' 0 N--CA 1.468 0.461 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.361 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' F' F ' 3' ' ' GLU . . . . . 0.403 ' CD ' HH21 ' F' ' 5' ' ' ARG . 47.9 tt0 -168.54 106.13 0.46 Allowed 'General case' 0 C--O 1.214 -0.808 0 N-CA-C 110.572 -0.159 . . . . 0.0 110.572 -179.789 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 63.8 m-85 -84.97 145.19 27.85 Favored 'General case' 0 N--CA 1.474 0.752 0 O-C-N 122.209 -0.307 . . . . 0.0 110.199 179.317 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' F' F ' 5' ' ' ARG . . . . . 0.403 HH21 ' CD ' ' F' ' 3' ' ' GLU . 99.5 mtt180 -143.51 143.26 31.48 Favored 'General case' 0 N--CA 1.477 0.908 0 CA-C-O 120.817 0.342 . . . . 0.0 110.195 179.318 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 46.1 t-80 -152.98 118.87 5.39 Favored 'General case' 0 N--CA 1.473 0.72 0 N-CA-C 109.275 -0.639 . . . . 0.0 109.275 179.055 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' F' F ' 7' ' ' ASP . . . . . 0.483 ' O ' ' OG ' ' I' ' 8' ' ' SER . 3.9 m-20 -70.2 149.03 47.92 Favored 'General case' 0 N--CA 1.468 0.447 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.68 179.981 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' F' F ' 8' ' ' SER . . . . . 0.492 ' OG ' ' O ' ' C' ' 7' ' ' ASP . 41.7 p -168.56 -171.74 1.5 Allowed 'General case' 0 N--CA 1.486 1.35 0 CA-C-O 121.039 0.447 . . . . 0.0 110.936 178.679 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.14 46.69 1.42 Allowed Glycine 0 N--CA 1.478 1.492 0 CA-C-N 115.951 -0.568 . . . . 0.0 111.984 179.955 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 46.3 p90 -64.65 132.74 50.57 Favored 'General case' 0 N--CA 1.474 0.734 0 O-C-N 122.623 -0.34 . . . . 0.0 111.913 -179.866 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 49.2 mt-10 -91.27 152.53 20.46 Favored 'General case' 0 N--CA 1.48 1.036 0 CA-C-O 121.158 0.504 . . . . 0.0 109.796 177.777 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -154.43 127.06 1.07 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.584 0 N-CA-C 107.828 -1.175 . . . . 0.0 107.828 178.13 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 42.0 m-70 -135.47 143.86 46.09 Favored 'General case' 0 N--CA 1.485 1.279 0 CA-C-O 120.849 0.357 . . . . 0.0 111.558 -178.045 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -165.32 97.11 0.69 Allowed 'General case' 0 N--CA 1.483 1.221 0 CA-C-N 116.43 -0.35 . . . . 0.0 110.771 179.754 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 15.0 pt20 -109.48 -174.17 2.44 Favored 'General case' 0 CA--C 1.503 -0.851 0 N-CA-C 108.629 -0.878 . . . . 0.0 108.629 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -162.22 98.46 1.04 Allowed 'General case' 0 N--CA 1.474 0.734 0 CA-C-N 114.694 -1.139 . . . . 0.0 108.401 178.384 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 6.4 mp -120.36 155.28 33.7 Favored 'General case' 0 N--CA 1.494 1.757 0 CA-C-O 121.532 0.682 . . . . 0.0 111.518 -177.854 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 50.2 t -113.41 124.2 69.81 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.246 0 N-CA-C 108.341 -0.985 . . . . 0.0 108.341 177.257 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 31.2 m-85 -124.56 121.58 35.18 Favored 'General case' 0 N--CA 1.489 1.49 0 CA-C-O 120.91 0.386 . . . . 0.0 110.796 -179.846 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 69.0 m-85 54.79 73.79 0.39 Allowed 'General case' 0 N--CA 1.468 0.437 0 CA-C-N 115.938 -0.574 . . . . 0.0 111.464 178.399 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -78.98 -78.31 0.15 Allowed 'General case' 0 C--N 1.344 0.359 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.537 -179.607 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 40.8 tt0 -112.76 100.09 8.42 Favored 'General case' 0 C--N 1.325 -0.471 0 N-CA-C 108.341 -0.985 . . . . 0.0 108.341 179.664 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -157.53 138.65 13.49 Favored 'General case' 0 C--O 1.205 -1.243 0 CA-C-O 119.422 -0.323 . . . . 0.0 111.532 179.282 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' F' F ' 24' ' ' VAL . . . . . 0.471 ' HB ' ' H ' ' C' ' 25' ' ' GLY . 59.6 t -58.46 168.35 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.94 0 N-CA-C 107.646 -1.242 . . . . 0.0 107.646 176.757 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' F' F ' 25' ' ' GLY . . . . . 0.435 ' H ' ' HB ' ' I' ' 24' ' ' VAL . . . -121.73 48.07 0.98 Allowed Glycine 0 N--CA 1.477 1.418 0 N-CA-C 110.789 -0.924 . . . . 0.0 110.789 -179.163 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -61.62 -167.05 0.01 OUTLIER 'General case' 0 N--CA 1.469 0.481 0 CA-C-N 116.768 0.284 . . . . 0.0 110.453 179.771 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 5.7 t30 -70.67 76.84 0.6 Allowed 'General case' 0 N--CA 1.466 0.367 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.441 -179.881 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -74.01 143.86 45.38 Favored 'General case' 0 N--CA 1.473 0.709 0 N-CA-C 109.691 -0.485 . . . . 0.0 109.691 179.242 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.57 -167.19 1.34 Allowed Glycine 0 CA--C 1.522 0.517 0 N-CA-C 110.426 -1.07 . . . . 0.0 110.426 178.712 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.6 113.81 26.47 Favored 'General case' 0 N--CA 1.472 0.662 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.837 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 72.0 mt -98.09 134.54 36.08 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.372 0 N-CA-C 106.84 -1.541 . . . . 0.0 106.84 179.038 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' F' F ' 32' ' ' ILE . . . . . 0.43 HG22 ' H ' ' I' ' 32' ' ' ILE . 31.8 pt -150.47 -169.83 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.118 0 CA-C-O 121.052 0.453 . . . . 0.0 110.751 -179.409 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.64 4.9 5.95 Favored Glycine 0 CA--C 1.53 1.015 0 N-CA-C 111.261 -0.736 . . . . 0.0 111.261 -179.87 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' F' F ' 34' ' ' LEU . . . . . 0.425 HD23 ' N ' ' F' ' 35' ' ' MET . 1.1 tt -74.77 135.82 41.72 Favored 'General case' 0 CA--C 1.546 0.822 0 N-CA-C 109.241 -0.652 . . . . 0.0 109.241 -179.612 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' F' F ' 35' ' ' MET . . . . . 0.425 ' N ' HD23 ' F' ' 34' ' ' LEU . 26.5 ttt -158.89 145.86 17.3 Favored 'General case' 0 N--CA 1.473 0.686 0 N-CA-C 108.494 -0.928 . . . . 0.0 108.494 178.804 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 1.5 m -148.72 165.33 4.38 Favored 'Isoleucine or valine' 0 C--N 1.348 0.537 0 N-CA-C 108.366 -0.976 . . . . 0.0 108.366 -179.449 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 54.33 68.61 1.58 Allowed Glycine 0 C--N 1.308 -1.021 0 CA-C-N 115.307 -0.861 . . . . 0.0 112.113 177.634 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 146.6 174.07 18.39 Favored Glycine 0 N--CA 1.473 1.118 0 N-CA-C 111.355 -0.698 . . . . 0.0 111.355 178.722 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' F' F ' 39' ' ' VAL . . . . . 0.437 HG12 ' H ' ' C' ' 39' ' ' VAL . 33.0 m -107.42 155.0 8.27 Favored 'Isoleucine or valine' 0 C--N 1.352 0.696 0 C-N-CA 123.528 0.731 . . . . 0.0 110.604 -178.773 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 25.9 t . . . . . 0 C--O 1.219 -0.543 0 O-C-N 124.365 1.041 . . . . 0.0 110.356 179.892 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' G' G ' 1' ' ' ASP . . . . . 0.442 ' CB ' ' H2 ' ' D' ' 1' ' ' ASP . 16.9 m-20 . . . . . 0 N--CA 1.491 1.601 0 N-CA-C 109.323 -0.621 . . . . 0.0 109.323 . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' G' G ' 2' ' ' ALA . . . . . . . . . . . . . . . -63.0 129.44 40.37 Favored 'General case' 0 N--CA 1.469 0.481 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.662 179.781 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' G' G ' 3' ' ' GLU . . . . . 0.411 ' CD ' HH21 ' G' ' 5' ' ' ARG . 46.6 tt0 -168.5 107.36 0.48 Allowed 'General case' 0 N--CA 1.471 0.613 0 CA-C-O 120.479 0.18 . . . . 0.0 110.745 179.638 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 64.8 m-85 -86.62 145.01 26.9 Favored 'General case' 0 N--CA 1.475 0.785 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 179.164 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' G' G ' 5' ' ' ARG . . . . . 0.411 HH21 ' CD ' ' G' ' 3' ' ' GLU . 99.4 mtt180 -144.09 142.09 30.42 Favored 'General case' 0 N--CA 1.481 1.091 0 CA-C-O 120.823 0.345 . . . . 0.0 110.205 179.726 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 46.8 t-80 -151.69 119.59 6.2 Favored 'General case' 0 N--CA 1.473 0.676 0 N-CA-C 109.46 -0.57 . . . . 0.0 109.46 179.016 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 4.1 m-20 -71.94 144.41 48.94 Favored 'General case' 0 N--CA 1.471 0.603 0 C-N-CA 122.763 0.425 . . . . 0.0 111.154 -179.833 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' G' G ' 8' ' ' SER . . . . . 0.593 ' OG ' ' O ' ' D' ' 7' ' ' ASP . 37.5 p -164.69 -169.24 1.68 Allowed 'General case' 0 N--CA 1.476 0.86 0 CA-C-O 121.049 0.452 . . . . 0.0 110.496 178.535 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 101.95 47.59 1.46 Allowed Glycine 0 N--CA 1.478 1.488 0 N-CA-C 111.529 -0.628 . . . . 0.0 111.529 179.553 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 48.6 p90 -65.93 132.71 49.27 Favored 'General case' 0 N--CA 1.473 0.692 0 N-CA-C 111.803 0.297 . . . . 0.0 111.803 -179.688 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 48.4 mt-10 -91.5 152.03 20.51 Favored 'General case' 0 N--CA 1.479 1.018 0 CA-C-O 121.043 0.449 . . . . 0.0 110.163 178.374 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -154.96 127.81 1.1 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.008 0 N-CA-C 107.864 -1.161 . . . . 0.0 107.864 178.221 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 44.9 m-70 -135.25 144.83 47.07 Favored 'General case' 0 N--CA 1.477 0.922 0 CA-C-N 115.702 -0.681 . . . . 0.0 111.407 -178.259 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -166.52 96.85 0.57 Allowed 'General case' 0 N--CA 1.483 1.181 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.288 179.132 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 15.0 pt20 -109.11 -173.75 2.34 Favored 'General case' 0 CA--C 1.503 -0.831 0 N-CA-C 108.391 -0.966 . . . . 0.0 108.391 179.88 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -163.15 98.03 0.93 Allowed 'General case' 0 N--CA 1.474 0.747 0 CA-C-N 114.701 -1.136 . . . . 0.0 108.132 178.558 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 6.4 mp -120.06 154.29 34.85 Favored 'General case' 0 N--CA 1.496 1.86 0 CA-C-O 121.204 0.526 . . . . 0.0 111.793 -177.935 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 44.5 t -112.83 125.39 70.09 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.968 0 CA-C-N 114.898 -1.046 . . . . 0.0 108.19 176.548 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 32.2 m-85 -125.88 121.15 32.38 Favored 'General case' 0 C--N 1.366 1.315 0 C-N-CA 123.39 0.676 . . . . 0.0 110.853 -179.532 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 69.3 m-85 55.13 72.76 0.45 Allowed 'General case' 0 N--CA 1.469 0.521 0 CA-C-N 115.882 -0.599 . . . . 0.0 111.292 178.24 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.67 -78.26 0.14 Allowed 'General case' 0 N--CA 1.471 0.583 0 O-C-N 122.244 -0.285 . . . . 0.0 110.55 -179.189 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 41.3 tt0 -112.57 100.43 8.73 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 108.124 -1.065 . . . . 0.0 108.124 179.646 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -157.86 139.78 14.08 Favored 'General case' 0 N--CA 1.478 0.949 0 N-CA-C 111.516 0.191 . . . . 0.0 111.516 179.153 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' G' G ' 24' ' ' VAL . . . . . 0.531 ' HB ' ' H ' ' D' ' 25' ' ' GLY . 61.4 t -59.96 167.25 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.624 0 N-CA-C 107.669 -1.234 . . . . 0.0 107.669 177.268 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' G' G ' 25' ' ' GLY . . . . . 0.428 ' N ' HG12 ' G' ' 24' ' ' VAL . . . -120.35 49.68 0.87 Allowed Glycine 0 N--CA 1.482 1.718 0 N-CA-C 110.313 -1.115 . . . . 0.0 110.313 -179.453 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -63.56 -167.51 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.658 0 CA-C-N 117.001 0.401 . . . . 0.0 109.953 179.484 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 5.3 t30 -70.11 76.69 0.51 Allowed 'General case' 0 CA--C 1.535 0.386 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.478 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 97.9 mttt -73.36 143.92 46.66 Favored 'General case' 0 N--CA 1.474 0.77 0 N-CA-C 109.701 -0.481 . . . . 0.0 109.701 179.209 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.64 -166.08 1.14 Allowed Glycine 0 C--N 1.337 0.593 0 N-CA-C 110.069 -1.212 . . . . 0.0 110.069 178.723 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.82 113.93 26.76 Favored 'General case' 0 N--CA 1.47 0.541 0 C-N-CA 122.723 0.409 . . . . 0.0 110.393 179.897 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 74.7 mt -98.61 134.77 36.05 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.773 0 N-CA-C 106.784 -1.562 . . . . 0.0 106.784 179.03 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' G' G ' 32' ' ' ILE . . . . . 0.444 ' H ' HG22 ' D' ' 32' ' ' ILE . 34.6 pt -151.11 -169.38 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 CA-C-N 119.657 1.117 . . . . 0.0 109.917 -179.826 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.18 4.79 6.71 Favored Glycine 0 CA--C 1.529 0.926 0 N-CA-C 111.052 -0.819 . . . . 0.0 111.052 179.933 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' G' G ' 34' ' ' LEU . . . . . 0.44 HD23 ' N ' ' G' ' 35' ' ' MET . 1.1 tt -74.95 135.74 41.38 Favored 'General case' 0 CA--C 1.544 0.745 0 N-CA-C 109.209 -0.663 . . . . 0.0 109.209 -179.635 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' G' G ' 35' ' ' MET . . . . . 0.44 ' N ' HD23 ' G' ' 34' ' ' LEU . 25.3 ttt -158.86 146.06 17.48 Favored 'General case' 0 N--CA 1.47 0.533 0 N-CA-C 108.695 -0.854 . . . . 0.0 108.695 178.801 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 1.4 m -148.8 163.89 4.72 Favored 'Isoleucine or valine' 0 C--N 1.349 0.566 0 N-CA-C 108.509 -0.922 . . . . 0.0 108.509 -179.293 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.13 68.67 1.57 Allowed Glycine 0 C--N 1.308 -0.997 0 CA-C-N 115.305 -0.862 . . . . 0.0 112.207 177.39 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.33 173.16 18.22 Favored Glycine 0 N--CA 1.475 1.274 0 N-CA-C 110.599 -1.0 . . . . 0.0 110.599 178.934 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' G' G ' 39' ' ' VAL . . . . . 0.405 HG12 ' H ' ' D' ' 39' ' ' VAL . 34.1 m -106.88 155.11 7.64 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.873 0 C-N-CA 123.222 0.609 . . . . 0.0 110.668 -179.346 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 25.8 t . . . . . 0 C--O 1.219 -0.532 0 O-C-N 124.035 0.835 . . . . 0.0 110.622 179.721 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' H' H ' 1' ' ' ASP . . . . . 0.417 ' CG ' ' H1 ' ' E' ' 1' ' ' ASP . 17.6 m-20 . . . . . 0 N--CA 1.491 1.602 0 N-CA-C 109.453 -0.573 . . . . 0.0 109.453 . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' H' H ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.76 129.69 41.6 Favored 'General case' 0 N--CA 1.469 0.494 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.517 179.72 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' H' H ' 3' ' ' GLU . . . . . . . . . . . . . 46.7 tt0 -168.58 107.39 0.48 Allowed 'General case' 0 N--CA 1.471 0.601 0 CA-C-O 120.449 0.166 . . . . 0.0 110.643 179.735 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 64.4 m-85 -86.9 144.67 26.87 Favored 'General case' 0 N--CA 1.473 0.712 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 179.181 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' H' H ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -143.72 142.71 31.07 Favored 'General case' 0 N--CA 1.482 1.133 0 C-N-CA 122.592 0.357 . . . . 0.0 110.1 179.712 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 47.7 t-80 -152.2 119.6 5.98 Favored 'General case' 0 N--CA 1.475 0.788 0 N-CA-C 109.326 -0.62 . . . . 0.0 109.326 178.991 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -71.57 144.44 49.54 Favored 'General case' 0 N--CA 1.469 0.497 0 C-N-CA 122.767 0.427 . . . . 0.0 111.164 179.89 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' H' H ' 8' ' ' SER . . . . . 0.441 ' OG ' ' O ' ' E' ' 7' ' ' ASP . 52.5 p -164.9 -170.37 1.94 Allowed 'General case' 0 N--CA 1.474 0.754 0 CA-C-O 120.935 0.398 . . . . 0.0 110.48 178.504 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.87 47.17 1.39 Allowed Glycine 0 N--CA 1.48 1.587 0 CA-C-N 115.971 -0.559 . . . . 0.0 111.709 179.604 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 48.2 p90 -65.61 132.67 49.41 Favored 'General case' 0 N--CA 1.473 0.707 0 N-CA-C 111.863 0.32 . . . . 0.0 111.863 -179.69 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 48.4 mt-10 -91.33 151.64 20.79 Favored 'General case' 0 N--CA 1.478 0.951 0 CA-C-O 121.036 0.446 . . . . 0.0 110.257 178.275 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -154.77 127.8 1.13 Allowed 'Isoleucine or valine' 0 CA--C 1.553 1.087 0 N-CA-C 107.815 -1.18 . . . . 0.0 107.815 178.286 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 45.0 m-70 -135.29 145.23 47.32 Favored 'General case' 0 N--CA 1.478 0.956 0 CA-C-N 115.596 -0.729 . . . . 0.0 111.373 -178.303 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -166.92 97.0 0.53 Allowed 'General case' 0 N--CA 1.481 1.116 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.312 179.151 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 15.1 pt20 -109.09 -173.43 2.26 Favored 'General case' 0 CA--C 1.505 -0.771 0 N-CA-C 108.417 -0.957 . . . . 0.0 108.417 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -163.5 97.98 0.89 Allowed 'General case' 0 N--CA 1.474 0.754 0 CA-C-N 114.718 -1.128 . . . . 0.0 108.1 178.565 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 6.4 mp -120.12 154.4 34.77 Favored 'General case' 0 N--CA 1.497 1.885 0 CA-C-O 121.263 0.554 . . . . 0.0 111.881 -177.981 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 43.9 t -113.02 124.79 70.01 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.978 0 CA-C-N 114.936 -1.029 . . . . 0.0 108.292 176.604 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 32.4 m-85 -125.17 121.16 33.39 Favored 'General case' 0 C--N 1.366 1.316 0 CA-C-N 115.56 -0.745 . . . . 0.0 110.735 -179.425 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 68.7 m-85 54.78 72.83 0.44 Allowed 'General case' 0 C--O 1.237 0.407 0 CA-C-N 115.868 -0.605 . . . . 0.0 111.425 178.173 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.31 -78.43 0.13 Allowed 'General case' 0 N--CA 1.469 0.522 0 O-C-N 122.229 -0.294 . . . . 0.0 110.591 -179.379 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 40.9 tt0 -112.62 100.34 8.65 Favored 'General case' 0 C--N 1.322 -0.589 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 179.792 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -157.6 139.47 14.12 Favored 'General case' 0 N--CA 1.477 0.909 0 O-C-N 122.403 -0.186 . . . . 0.0 111.498 179.272 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' H' H ' 24' ' ' VAL . . . . . 0.427 ' HB ' ' H ' ' E' ' 25' ' ' GLY . 62.0 t -59.73 167.4 0.56 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.521 0 N-CA-C 107.722 -1.214 . . . . 0.0 107.722 177.182 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' H' H ' 25' ' ' GLY . . . . . 0.425 ' N ' HG12 ' H' ' 24' ' ' VAL . . . -120.32 49.12 0.9 Allowed Glycine 0 N--CA 1.48 1.572 0 N-CA-C 110.491 -1.043 . . . . 0.0 110.491 -179.314 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -63.23 -166.99 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.675 0 CA-C-N 116.972 0.386 . . . . 0.0 110.092 179.748 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 5.3 t30 -70.63 76.46 0.59 Allowed 'General case' 0 CA--C 1.535 0.374 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.492 -179.85 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -73.44 143.88 46.53 Favored 'General case' 0 N--CA 1.473 0.685 0 N-CA-C 109.629 -0.508 . . . . 0.0 109.629 179.341 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -65.17 -166.14 1.37 Allowed Glycine 0 C--N 1.337 0.634 0 N-CA-C 109.936 -1.266 . . . . 0.0 109.936 178.889 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.44 114.28 27.12 Favored 'General case' 0 N--CA 1.467 0.408 0 C-N-CA 122.573 0.349 . . . . 0.0 110.617 179.85 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 74.5 mt -98.73 134.73 36.41 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.751 0 N-CA-C 106.8 -1.556 . . . . 0.0 106.8 178.974 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' H' H ' 32' ' ' ILE . . . . . 0.439 ' H ' HG22 ' E' ' 32' ' ' ILE . 34.2 pt -151.05 -169.24 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.687 0 CA-C-N 119.747 1.158 . . . . 0.0 109.917 -179.93 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.24 4.8 6.81 Favored Glycine 0 CA--C 1.529 0.919 0 N-CA-C 110.95 -0.86 . . . . 0.0 110.95 179.914 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' H' H ' 34' ' ' LEU . . . . . 0.431 HD23 ' N ' ' H' ' 35' ' ' MET . 1.1 tt -75.35 135.25 40.85 Favored 'General case' 0 CA--C 1.546 0.792 0 N-CA-C 109.412 -0.588 . . . . 0.0 109.412 -179.414 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' H' H ' 35' ' ' MET . . . . . 0.431 ' N ' HD23 ' H' ' 34' ' ' LEU . 25.2 ttt -158.52 146.15 18.03 Favored 'General case' 0 N--CA 1.472 0.641 0 N-CA-C 108.694 -0.854 . . . . 0.0 108.694 179.065 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 1.5 m -149.08 163.84 4.35 Favored 'Isoleucine or valine' 0 C--N 1.348 0.522 0 N-CA-C 108.449 -0.945 . . . . 0.0 108.449 -179.283 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.35 68.39 1.71 Allowed Glycine 0 C--N 1.309 -0.971 0 CA-C-N 115.16 -0.927 . . . . 0.0 112.064 177.451 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.27 172.35 17.37 Favored Glycine 0 N--CA 1.476 1.307 0 N-CA-C 110.639 -0.985 . . . . 0.0 110.639 178.959 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' H' H ' 39' ' ' VAL . . . . . 0.425 HG12 ' H ' ' E' ' 39' ' ' VAL . 33.8 m -106.1 154.93 7.13 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.927 0 C-N-CA 123.199 0.6 . . . . 0.0 110.715 -179.475 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 24.7 t . . . . . 0 C--O 1.219 -0.53 0 O-C-N 124.001 0.813 . . . . 0.0 110.709 179.699 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' I' I ' 1' ' ' ASP . . . . . 0.41 ' CG ' ' H1 ' ' F' ' 1' ' ' ASP . 16.4 m-20 . . . . . 0 N--CA 1.492 1.63 0 N-CA-C 109.487 -0.56 . . . . 0.0 109.487 . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' I' I ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.66 129.43 40.53 Favored 'General case' 0 N--CA 1.469 0.519 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.468 179.697 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' I' I ' 3' ' ' GLU . . . . . . . . . . . . . 46.9 tt0 -168.41 107.14 0.49 Allowed 'General case' 0 N--CA 1.472 0.646 0 CA-C-O 120.445 0.165 . . . . 0.0 110.597 179.737 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 66.3 m-85 -86.54 145.1 26.92 Favored 'General case' 0 N--CA 1.474 0.745 0 N-CA-C 109.736 -0.468 . . . . 0.0 109.736 179.264 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' I' I ' 5' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -144.13 142.47 30.6 Favored 'General case' 0 N--CA 1.484 1.23 0 C-N-CA 122.639 0.376 . . . . 0.0 110.194 179.81 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 47.6 t-80 -152.14 120.12 6.21 Favored 'General case' 0 N--CA 1.474 0.738 0 N-CA-C 109.361 -0.607 . . . . 0.0 109.361 179.007 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -72.32 144.16 48.41 Favored 'General case' 0 N--CA 1.471 0.605 0 C-N-CA 122.725 0.41 . . . . 0.0 111.084 -179.945 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' I' I ' 8' ' ' SER . . . . . 0.483 ' OG ' ' O ' ' F' ' 7' ' ' ASP . 50.8 p -164.73 -170.39 1.98 Allowed 'General case' 0 N--CA 1.475 0.782 0 CA-C-O 120.996 0.427 . . . . 0.0 110.488 178.586 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.82 47.47 1.36 Allowed Glycine 0 N--CA 1.48 1.628 0 N-CA-C 111.629 -0.589 . . . . 0.0 111.629 179.675 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 47.9 p90 -65.92 133.2 50.38 Favored 'General case' 0 N--CA 1.473 0.677 0 CA-C-O 120.803 0.335 . . . . 0.0 111.872 -179.649 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 48.4 mt-10 -91.77 151.7 20.49 Favored 'General case' 0 N--CA 1.478 0.95 0 CA-C-O 120.932 0.396 . . . . 0.0 110.311 178.348 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -154.99 126.92 0.96 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.057 0 N-CA-C 107.909 -1.145 . . . . 0.0 107.909 178.365 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 42.4 m-70 -134.52 144.88 48.27 Favored 'General case' 0 N--CA 1.478 0.967 0 CA-C-N 115.606 -0.724 . . . . 0.0 111.451 -178.382 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -166.43 97.09 0.58 Allowed 'General case' 0 N--CA 1.48 1.056 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.348 179.119 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 15.2 pt20 -109.3 -173.88 2.37 Favored 'General case' 0 CA--C 1.504 -0.797 0 N-CA-C 108.481 -0.933 . . . . 0.0 108.481 -179.99 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -163.08 98.11 0.93 Allowed 'General case' 0 N--CA 1.473 0.715 0 CA-C-N 114.701 -1.136 . . . . 0.0 108.07 178.514 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 6.4 mp -120.2 154.37 34.94 Favored 'General case' 0 N--CA 1.497 1.907 0 CA-C-O 121.24 0.543 . . . . 0.0 111.769 -177.91 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 44.8 t -113.0 125.07 70.2 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.028 0 CA-C-N 114.857 -1.065 . . . . 0.0 108.157 176.646 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 32.9 m-85 -125.57 121.11 32.69 Favored 'General case' 0 C--N 1.367 1.339 0 CA-C-N 115.582 -0.735 . . . . 0.0 110.815 -179.536 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 68.6 m-85 54.9 73.26 0.42 Allowed 'General case' 0 N--CA 1.469 0.51 0 CA-C-N 115.927 -0.579 . . . . 0.0 111.262 178.301 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.99 -78.01 0.15 Allowed 'General case' 0 N--CA 1.472 0.639 0 O-C-N 122.205 -0.309 . . . . 0.0 110.601 -179.268 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 40.9 tt0 -112.84 100.32 8.58 Favored 'General case' 0 C--N 1.323 -0.586 0 N-CA-C 108.088 -1.078 . . . . 0.0 108.088 179.614 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -157.71 139.26 13.8 Favored 'General case' 0 N--CA 1.479 0.983 0 O-C-N 122.344 -0.223 . . . . 0.0 111.433 179.396 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' I' I ' 24' ' ' VAL . . . . . 0.435 ' HB ' ' H ' ' F' ' 25' ' ' GLY . 62.0 t -59.48 167.26 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.54 0 N-CA-C 107.847 -1.168 . . . . 0.0 107.847 177.016 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' I' I ' 25' ' ' GLY . . . . . 0.432 ' N ' HG12 ' I' ' 24' ' ' VAL . . . -120.43 49.52 0.87 Allowed Glycine 0 N--CA 1.482 1.725 0 N-CA-C 110.411 -1.076 . . . . 0.0 110.411 -179.384 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -63.42 -166.9 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.656 0 CA-C-N 116.985 0.393 . . . . 0.0 110.064 179.59 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 5.5 t30 -70.68 76.71 0.6 Allowed 'General case' 0 N--CA 1.466 0.358 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.35 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 97.8 mttt -73.66 143.62 46.18 Favored 'General case' 0 N--CA 1.474 0.772 0 N-CA-C 109.64 -0.504 . . . . 0.0 109.64 179.284 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.59 -166.08 1.13 Allowed Glycine 0 C--N 1.339 0.703 0 N-CA-C 110.02 -1.232 . . . . 0.0 110.02 178.88 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.53 113.86 26.51 Favored 'General case' 0 N--CA 1.469 0.495 0 C-N-CA 122.691 0.396 . . . . 0.0 110.45 179.877 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 74.2 mt -98.37 135.04 34.66 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.836 0 N-CA-C 106.745 -1.576 . . . . 0.0 106.745 178.849 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' I' I ' 32' ' ' ILE . . . . . 0.43 ' H ' HG22 ' F' ' 32' ' ' ILE . 33.6 pt -151.38 -169.3 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 CA-C-N 119.698 1.135 . . . . 0.0 109.965 -179.987 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.22 4.71 6.68 Favored Glycine 0 CA--C 1.528 0.897 0 N-CA-C 110.952 -0.859 . . . . 0.0 110.952 179.962 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' I' I ' 34' ' ' LEU . . . . . 0.431 HD23 ' N ' ' I' ' 35' ' ' MET . 1.1 tt -74.85 135.29 41.58 Favored 'General case' 0 CA--C 1.544 0.738 0 N-CA-C 109.318 -0.623 . . . . 0.0 109.318 -179.602 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' I' I ' 35' ' ' MET . . . . . 0.431 ' N ' HD23 ' I' ' 34' ' ' LEU . 25.4 ttt -158.44 146.06 18.08 Favored 'General case' 0 N--CA 1.471 0.602 0 N-CA-C 108.53 -0.915 . . . . 0.0 108.53 178.982 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 1.4 m -149.02 163.78 4.41 Favored 'Isoleucine or valine' 0 C--N 1.35 0.616 0 N-CA-C 108.519 -0.919 . . . . 0.0 108.519 -179.401 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.08 68.5 1.65 Allowed Glycine 0 C--N 1.308 -0.991 0 CA-C-N 115.253 -0.885 . . . . 0.0 112.143 177.492 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.45 172.31 17.46 Favored Glycine 0 N--CA 1.474 1.224 0 N-CA-C 110.682 -0.967 . . . . 0.0 110.682 178.982 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' I' I ' 39' ' ' VAL . . . . . 0.426 HG12 ' H ' ' F' ' 39' ' ' VAL . 33.9 m -106.15 154.81 7.2 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.915 0 C-N-CA 123.236 0.614 . . . . 0.0 110.663 -179.467 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 25.3 t . . . . . 0 C--O 1.219 -0.524 0 O-C-N 124.06 0.85 . . . . 0.0 110.612 179.621 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 14.7 m-20 . . . . . 0 N--CA 1.491 1.587 0 N-CA-C 108.906 -0.776 . . . . 0.0 108.906 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.91 132.83 49.57 Favored 'General case' 0 CA--C 1.538 0.503 0 CA-C-N 116.548 -0.296 . . . . 0.0 110.24 -179.832 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 44.7 tt0 -168.21 105.4 0.47 Allowed 'General case' 0 C--O 1.215 -0.727 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 -179.295 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 42.0 m-85 -85.85 152.16 23.22 Favored 'General case' 0 N--CA 1.474 0.747 0 N-CA-C 110.118 -0.327 . . . . 0.0 110.118 179.589 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -143.45 140.62 30.47 Favored 'General case' 0 N--CA 1.481 1.085 0 CA-C-O 120.887 0.375 . . . . 0.0 110.03 179.711 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 42.3 t-80 -151.79 119.39 6.07 Favored 'General case' 0 N--CA 1.47 0.528 0 N-CA-C 109.231 -0.655 . . . . 0.0 109.231 179.176 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' ASP . . . . . 0.499 ' O ' ' OG ' ' D' ' 8' ' ' SER . 4.4 m-20 -68.98 148.77 49.65 Favored 'General case' 0 CA--C 1.537 0.471 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.516 179.816 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 53.2 p -167.58 -173.5 2.21 Favored 'General case' 0 N--CA 1.483 1.184 0 CA-C-O 121.054 0.454 . . . . 0.0 110.721 179.392 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.62 47.67 1.37 Allowed Glycine 0 N--CA 1.482 1.705 0 CA-C-N 115.966 -0.561 . . . . 0.0 112.08 179.785 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 48.7 p90 -65.86 132.72 49.35 Favored 'General case' 0 N--CA 1.474 0.735 0 O-C-N 122.755 -0.262 . . . . 0.0 111.496 179.712 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 46.0 mt-10 -92.17 152.08 20.06 Favored 'General case' 0 N--CA 1.479 0.986 0 N-CA-C 109.725 -0.472 . . . . 0.0 109.725 178.512 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.0 p -152.89 128.25 1.59 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.612 0 N-CA-C 107.868 -1.16 . . . . 0.0 107.868 178.238 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 47.2 m-70 -135.41 147.8 49.12 Favored 'General case' 0 N--CA 1.493 1.708 0 CA-C-N 119.044 0.838 . . . . 0.0 111.398 -179.013 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 6.4 t60 -165.1 97.02 0.72 Allowed 'General case' 0 N--CA 1.48 1.064 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.624 179.342 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' GLN . . . . . 0.731 HE22 HG23 ' A' ' 36' ' ' VAL . 13.9 pt20 -101.54 -174.16 2.53 Favored 'General case' 0 CA--C 1.507 -0.704 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 -179.82 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -169.9 95.81 0.28 Allowed 'General case' 0 N--CA 1.47 0.53 0 CA-C-N 114.608 -1.178 . . . . 0.0 108.389 178.38 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 6.5 mp -123.36 156.97 34.35 Favored 'General case' 0 N--CA 1.497 1.917 0 CA-C-O 121.794 0.807 . . . . 0.0 111.005 -178.14 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 60.1 t -111.79 126.86 69.22 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.135 0 CA-C-O 117.938 -1.029 . . . . 0.0 108.269 177.608 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 27.1 m-85 -126.89 123.09 36.44 Favored 'General case' 0 N--CA 1.497 1.912 0 CA-C-N 120.13 1.332 . . . . 0.0 110.474 179.5 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 67.9 m-85 53.66 74.71 0.3 Allowed 'General case' 0 CA--C 1.538 0.489 0 CA-C-O 121.414 0.626 . . . . 0.0 111.813 178.634 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -80.0 -78.28 0.17 Allowed 'General case' 0 C--N 1.353 0.727 0 CA-C-N 115.084 -0.962 . . . . 0.0 110.192 -179.922 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 38.2 tt0 -113.39 100.74 8.77 Favored 'General case' 0 N--CA 1.469 0.486 0 N-CA-C 108.191 -1.04 . . . . 0.0 108.191 179.725 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 4.4 p30 -159.18 139.79 12.43 Favored 'General case' 0 N--CA 1.483 1.178 0 O-C-N 122.31 -0.243 . . . . 0.0 111.219 179.147 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.405 HG12 ' N ' ' A' ' 25' ' ' GLY . 61.2 t -59.97 163.43 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.819 0 N-CA-C 108.104 -1.073 . . . . 0.0 108.104 177.106 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.469 ' H ' ' HB ' ' D' ' 24' ' ' VAL . . . -117.3 48.61 0.92 Allowed Glycine 0 N--CA 1.475 1.252 0 N-CA-C 111.755 -0.538 . . . . 0.0 111.755 -179.402 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -61.73 -167.83 0.01 OUTLIER 'General case' 0 N--CA 1.468 0.45 0 O-C-N 123.843 0.378 . . . . 0.0 110.412 179.522 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 3.7 t30 -71.06 80.4 0.67 Allowed 'General case' 0 N--CA 1.465 0.284 0 CA-C-N 116.492 -0.322 . . . . 0.0 110.176 179.557 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -77.85 143.76 37.55 Favored 'General case' 0 N--CA 1.473 0.704 0 N-CA-C 109.141 -0.689 . . . . 0.0 109.141 179.332 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.38 -167.51 0.94 Allowed Glycine 0 CA--C 1.525 0.664 0 N-CA-C 109.863 -1.295 . . . . 0.0 109.863 178.629 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.8 114.61 27.88 Favored 'General case' 0 N--CA 1.48 1.038 0 N-CA-C 109.696 -0.483 . . . . 0.0 109.696 179.839 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 64.9 mt -98.41 135.78 31.88 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.552 0 N-CA-C 107.078 -1.453 . . . . 0.0 107.078 178.982 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 34.1 pt -152.31 -176.14 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.734 0 CA-C-O 121.168 0.508 . . . . 0.0 111.18 -179.164 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.62 4.39 9.73 Favored Glycine 0 CA--C 1.524 0.597 0 N-CA-C 110.976 -0.85 . . . . 0.0 110.976 179.758 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 1.6 tt -74.28 127.18 32.33 Favored 'General case' 0 CA--C 1.545 0.767 0 N-CA-C 109.499 -0.556 . . . . 0.0 109.499 -179.604 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 28.5 ttt -163.75 149.81 11.43 Favored 'General case' 0 N--CA 1.465 0.279 0 N-CA-C 108.963 -0.755 . . . . 0.0 108.963 178.782 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.731 HG23 HE22 ' A' ' 15' ' ' GLN . 27.5 m -155.22 166.33 1.07 Allowed 'Isoleucine or valine' 0 C--N 1.347 0.482 0 N-CA-C 108.061 -1.088 . . . . 0.0 108.061 179.686 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.1 67.2 2.33 Favored Glycine 0 C--N 1.307 -1.045 0 CA-C-N 115.776 -0.647 . . . . 0.0 112.102 178.422 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.96 -173.23 24.85 Favored Glycine 0 N--CA 1.474 1.195 0 N-CA-C 110.85 -0.9 . . . . 0.0 110.85 179.089 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.561 ' H ' HG12 ' D' ' 39' ' ' VAL . 34.5 m -125.56 156.34 35.03 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.774 0 C-N-CA 123.393 0.677 . . . . 0.0 110.232 -179.645 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 27.1 t . . . . . 0 C--O 1.218 -0.589 0 CA-C-O 118.433 -0.794 . . . . 0.0 110.622 179.853 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' B' B ' 1' ' ' ASP . . . . . . . . . . . . . 14.4 m-20 . . . . . 0 N--CA 1.489 1.487 0 N-CA-C 109.084 -0.709 . . . . 0.0 109.084 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' B' B ' 2' ' ' ALA . . . . . . . . . . . . . . . -66.13 132.71 49.11 Favored 'General case' 0 CA--C 1.54 0.562 0 N-CA-C 110.075 -0.343 . . . . 0.0 110.075 -179.755 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 3' ' ' GLU . . . . . . . . . . . . . 44.7 tt0 -168.22 105.04 0.47 Allowed 'General case' 0 N--CA 1.475 0.8 0 N-CA-C 110.029 -0.36 . . . . 0.0 110.029 -179.245 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 38.9 m-85 -85.43 151.9 23.63 Favored 'General case' 0 N--CA 1.473 0.715 0 N-CA-C 110.13 -0.322 . . . . 0.0 110.13 179.513 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -143.06 140.44 30.94 Favored 'General case' 0 N--CA 1.483 1.198 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 179.574 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 41.9 t-80 -151.65 119.03 5.98 Favored 'General case' 0 N--CA 1.473 0.692 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 179.001 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 7' ' ' ASP . . . . . 0.448 ' O ' ' OG ' ' E' ' 8' ' ' SER . 4.3 m-20 -68.68 148.55 50.25 Favored 'General case' 0 CA--C 1.537 0.47 0 CA-C-N 116.343 -0.389 . . . . 0.0 110.677 179.907 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 8' ' ' SER . . . . . . . . . . . . . 53.8 p -167.59 -173.53 2.22 Favored 'General case' 0 N--CA 1.482 1.136 0 CA-C-O 120.966 0.412 . . . . 0.0 110.745 179.418 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.92 47.14 1.39 Allowed Glycine 0 N--CA 1.481 1.686 0 CA-C-N 115.985 -0.552 . . . . 0.0 112.126 179.758 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 48.8 p90 -65.57 132.88 49.96 Favored 'General case' 0 N--CA 1.472 0.644 0 CA-C-O 120.665 0.269 . . . . 0.0 111.562 179.819 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 45.3 mt-10 -92.14 152.22 20.01 Favored 'General case' 0 N--CA 1.475 0.824 0 C-N-CA 122.847 0.459 . . . . 0.0 109.816 178.475 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -153.15 128.13 1.5 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.547 0 N-CA-C 107.854 -1.165 . . . . 0.0 107.854 178.266 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 46.9 m-70 -135.46 147.71 49.0 Favored 'General case' 0 N--CA 1.492 1.65 0 CA-C-N 118.915 0.78 . . . . 0.0 111.379 -178.882 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 6.5 t60 -165.14 97.01 0.71 Allowed 'General case' 0 N--CA 1.48 1.052 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.604 179.345 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 15' ' ' GLN . . . . . 0.745 HE22 HG23 ' B' ' 36' ' ' VAL . 13.9 pt20 -101.51 -173.83 2.45 Favored 'General case' 0 CA--C 1.508 -0.638 0 N-CA-C 108.691 -0.855 . . . . 0.0 108.691 -179.764 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -170.22 95.82 0.25 Allowed 'General case' 0 N--CA 1.471 0.575 0 CA-C-N 114.727 -1.124 . . . . 0.0 108.321 178.324 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 6.5 mp -123.15 157.32 33.23 Favored 'General case' 0 N--CA 1.497 1.878 0 CA-C-O 121.73 0.776 . . . . 0.0 110.999 -178.134 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 60.9 t -112.37 127.65 69.46 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.098 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 177.44 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 27.0 m-85 -127.62 123.0 34.6 Favored 'General case' 0 N--CA 1.494 1.753 0 CA-C-N 119.707 1.14 . . . . 0.0 110.302 179.681 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 67.9 m-85 53.27 74.81 0.28 Allowed 'General case' 0 CA--C 1.537 0.476 0 CA-C-O 121.535 0.683 . . . . 0.0 111.919 178.475 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -80.48 -77.93 0.18 Allowed 'General case' 0 C--N 1.352 0.681 0 CA-C-N 115.004 -0.998 . . . . 0.0 110.218 -179.879 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 38.3 tt0 -113.53 100.45 8.52 Favored 'General case' 0 N--CA 1.47 0.565 0 N-CA-C 108.317 -0.994 . . . . 0.0 108.317 179.695 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -158.85 140.17 13.17 Favored 'General case' 0 N--CA 1.483 1.193 0 O-C-N 122.179 -0.326 . . . . 0.0 111.146 179.19 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 61.6 t -60.1 163.63 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.894 0 N-CA-C 108.121 -1.066 . . . . 0.0 108.121 177.072 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 25' ' ' GLY . . . . . 0.474 ' H ' ' HB ' ' E' ' 24' ' ' VAL . . . -117.23 48.32 0.95 Allowed Glycine 0 N--CA 1.476 1.309 0 N-CA-C 111.657 -0.577 . . . . 0.0 111.657 -179.353 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -61.87 -168.58 0.02 OUTLIER 'General case' 0 N--CA 1.469 0.505 0 O-C-N 123.783 0.343 . . . . 0.0 110.348 179.498 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 3.5 t30 -70.61 81.03 0.59 Allowed 'General case' 0 N--CA 1.467 0.377 0 N-CA-C 110.078 -0.342 . . . . 0.0 110.078 179.636 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -78.48 144.32 35.85 Favored 'General case' 0 N--CA 1.473 0.706 0 N-CA-C 109.077 -0.712 . . . . 0.0 109.077 179.394 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.47 -167.47 0.97 Allowed Glycine 0 C--N 1.336 0.569 0 N-CA-C 109.933 -1.267 . . . . 0.0 109.933 178.676 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.91 114.56 27.89 Favored 'General case' 0 N--CA 1.479 0.988 0 N-CA-C 109.677 -0.49 . . . . 0.0 109.677 179.644 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 64.3 mt -98.51 135.36 33.66 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.507 0 N-CA-C 107.073 -1.454 . . . . 0.0 107.073 178.9 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 32' ' ' ILE . . . . . 0.413 HG22 ' H ' ' E' ' 32' ' ' ILE . 33.7 pt -151.99 -176.63 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.353 0.722 0 CA-C-N 116.026 -0.534 . . . . 0.0 111.191 -178.975 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.73 4.76 10.99 Favored Glycine 0 CA--C 1.523 0.57 0 N-CA-C 110.925 -0.87 . . . . 0.0 110.925 179.718 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 1.6 tt -74.56 126.71 31.37 Favored 'General case' 0 CA--C 1.546 0.813 0 N-CA-C 109.438 -0.578 . . . . 0.0 109.438 -179.744 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 28.2 ttt -163.05 149.97 12.78 Favored 'General case' 0 N--CA 1.465 0.323 0 N-CA-C 108.935 -0.765 . . . . 0.0 108.935 178.82 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 36' ' ' VAL . . . . . 0.745 HG23 HE22 ' B' ' 15' ' ' GLN . 27.3 m -155.3 166.34 1.06 Allowed 'Isoleucine or valine' 0 C--N 1.348 0.508 0 N-CA-C 108.015 -1.105 . . . . 0.0 108.015 179.706 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.73 67.43 2.21 Favored Glycine 0 C--N 1.307 -1.069 0 CA-C-N 115.742 -0.663 . . . . 0.0 112.094 178.434 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.65 -173.52 24.51 Favored Glycine 0 N--CA 1.474 1.213 0 N-CA-C 110.94 -0.864 . . . . 0.0 110.94 179.034 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 39' ' ' VAL . . . . . 0.585 ' H ' HG12 ' E' ' 39' ' ' VAL . 35.0 m -125.27 156.26 34.34 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.818 0 C-N-CA 123.42 0.688 . . . . 0.0 110.309 -179.591 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 26.6 t . . . . . 0 C--O 1.219 -0.514 0 CA-C-O 118.54 -0.743 . . . . 0.0 110.436 179.758 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' C' C ' 1' ' ' ASP . . . . . . . . . . . . . 14.4 m-20 . . . . . 0 N--CA 1.49 1.563 0 N-CA-C 108.783 -0.821 . . . . 0.0 108.783 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' C' C ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.99 132.74 49.28 Favored 'General case' 0 CA--C 1.539 0.535 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.243 -179.841 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 3' ' ' GLU . . . . . . . . . . . . . 44.6 tt0 -168.3 105.48 0.47 Allowed 'General case' 0 N--CA 1.474 0.768 0 N-CA-C 109.984 -0.376 . . . . 0.0 109.984 -179.275 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 39.7 m-85 -85.88 152.12 23.23 Favored 'General case' 0 N--CA 1.474 0.774 0 N-CA-C 110.064 -0.347 . . . . 0.0 110.064 179.573 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -143.35 140.42 30.51 Favored 'General case' 0 N--CA 1.483 1.182 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 179.726 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 42.0 t-80 -151.72 119.51 6.15 Favored 'General case' 0 N--CA 1.472 0.648 0 N-CA-C 109.317 -0.623 . . . . 0.0 109.317 179.114 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 7' ' ' ASP . . . . . 0.49 ' O ' ' OG ' ' F' ' 8' ' ' SER . 4.3 m-20 -69.22 148.32 50.01 Favored 'General case' 0 CA--C 1.537 0.472 0 CA-C-N 116.328 -0.397 . . . . 0.0 110.648 179.978 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 8' ' ' SER . . . . . . . . . . . . . 53.5 p -167.31 -173.4 2.25 Favored 'General case' 0 N--CA 1.484 1.246 0 CA-C-O 121.028 0.442 . . . . 0.0 110.692 179.43 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.62 47.1 1.43 Allowed Glycine 0 N--CA 1.482 1.734 0 CA-C-N 115.899 -0.592 . . . . 0.0 112.076 179.787 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 49.1 p90 -65.44 133.06 50.5 Favored 'General case' 0 N--CA 1.473 0.709 0 CA-C-O 120.671 0.272 . . . . 0.0 111.489 179.617 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 46.0 mt-10 -92.48 152.49 19.64 Favored 'General case' 0 N--CA 1.476 0.826 0 CA-C-O 121.1 0.476 . . . . 0.0 109.787 178.436 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -153.21 128.48 1.56 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.545 0 N-CA-C 107.786 -1.19 . . . . 0.0 107.786 178.307 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 47.0 m-70 -135.71 147.56 48.53 Favored 'General case' 0 N--CA 1.492 1.632 0 CA-C-N 118.925 0.784 . . . . 0.0 111.355 -179.081 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 6.5 t60 -164.96 97.17 0.73 Allowed 'General case' 0 N--CA 1.482 1.149 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.507 179.312 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 15' ' ' GLN . . . . . 0.717 HE22 HG23 ' C' ' 36' ' ' VAL . 13.8 pt20 -101.64 -173.75 2.43 Favored 'General case' 0 CA--C 1.507 -0.701 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 -179.749 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -170.22 95.85 0.25 Allowed 'General case' 0 N--CA 1.47 0.553 0 CA-C-N 114.618 -1.174 . . . . 0.0 108.292 178.406 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 6.5 mp -123.37 157.08 34.12 Favored 'General case' 0 N--CA 1.497 1.918 0 CA-C-O 121.745 0.784 . . . . 0.0 111.07 -178.157 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 60.7 t -112.33 127.61 69.43 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.076 0 N-CA-C 108.059 -1.089 . . . . 0.0 108.059 177.53 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 27.7 m-85 -127.58 123.02 34.73 Favored 'General case' 0 N--CA 1.494 1.75 0 CA-C-N 119.6 1.091 . . . . 0.0 110.34 179.614 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 67.0 m-85 53.29 74.75 0.29 Allowed 'General case' 0 CA--C 1.538 0.495 0 CA-C-O 121.55 0.69 . . . . 0.0 111.975 178.441 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -80.34 -78.22 0.18 Allowed 'General case' 0 C--N 1.348 0.537 0 CA-C-N 114.911 -1.04 . . . . 0.0 110.197 -179.791 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 38.0 tt0 -113.31 100.39 8.52 Favored 'General case' 0 N--CA 1.47 0.56 0 N-CA-C 108.161 -1.051 . . . . 0.0 108.161 179.653 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 4.4 p30 -158.71 140.08 13.27 Favored 'General case' 0 N--CA 1.484 1.231 0 O-C-N 122.202 -0.311 . . . . 0.0 111.204 179.085 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 24' ' ' VAL . . . . . 0.401 HG12 ' N ' ' C' ' 25' ' ' GLY . 61.8 t -60.0 163.72 0.92 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.852 0 N-CA-C 108.153 -1.054 . . . . 0.0 108.153 177.082 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 25' ' ' GLY . . . . . 0.472 ' H ' ' HB ' ' F' ' 24' ' ' VAL . . . -117.38 48.31 0.95 Allowed Glycine 0 N--CA 1.477 1.385 0 N-CA-C 111.637 -0.585 . . . . 0.0 111.637 -179.336 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -61.81 -167.99 0.01 OUTLIER 'General case' 0 N--CA 1.468 0.427 0 O-C-N 123.79 0.347 . . . . 0.0 110.361 179.658 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 3.5 t30 -71.01 80.71 0.66 Allowed 'General case' 0 N--CA 1.465 0.304 0 N-CA-C 110.067 -0.345 . . . . 0.0 110.067 179.495 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -78.22 144.13 36.53 Favored 'General case' 0 N--CA 1.472 0.65 0 N-CA-C 109.117 -0.698 . . . . 0.0 109.117 179.415 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.55 -167.62 1.03 Allowed Glycine 0 CA--C 1.523 0.586 0 N-CA-C 109.965 -1.254 . . . . 0.0 109.965 178.788 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.6 114.34 27.31 Favored 'General case' 0 N--CA 1.48 1.071 0 N-CA-C 109.661 -0.496 . . . . 0.0 109.661 179.775 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 64.8 mt -98.42 135.45 33.16 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.546 0 N-CA-C 107.058 -1.46 . . . . 0.0 107.058 178.911 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 32' ' ' ILE . . . . . 0.414 HG22 ' H ' ' F' ' 32' ' ' ILE . 33.8 pt -152.01 -176.15 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.352 0.688 0 CA-C-N 115.998 -0.547 . . . . 0.0 111.189 -179.096 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.48 4.49 9.43 Favored Glycine 0 CA--C 1.524 0.615 0 N-CA-C 110.992 -0.843 . . . . 0.0 110.992 179.697 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 1.6 tt -74.27 127.27 32.57 Favored 'General case' 0 CA--C 1.547 0.831 0 N-CA-C 109.389 -0.597 . . . . 0.0 109.389 -179.776 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 28.3 ttt -163.52 150.06 12.02 Favored 'General case' 0 N--CA 1.467 0.397 0 N-CA-C 108.86 -0.792 . . . . 0.0 108.86 178.735 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 36' ' ' VAL . . . . . 0.717 HG23 HE22 ' C' ' 15' ' ' GLN . 27.3 m -155.59 166.05 1.07 Allowed 'Isoleucine or valine' 0 C--N 1.347 0.5 0 N-CA-C 108.06 -1.089 . . . . 0.0 108.06 179.657 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.06 67.23 2.32 Favored Glycine 0 C--N 1.307 -1.047 0 CA-C-N 115.721 -0.672 . . . . 0.0 112.077 178.503 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.71 -173.44 24.58 Favored Glycine 0 N--CA 1.473 1.139 0 N-CA-C 110.987 -0.845 . . . . 0.0 110.987 178.959 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 39' ' ' VAL . . . . . 0.587 ' H ' HG12 ' F' ' 39' ' ' VAL . 32.9 m -125.11 156.37 33.98 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.751 0 C-N-CA 123.386 0.674 . . . . 0.0 110.31 -179.572 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 25.6 t . . . . . 0 C--O 1.218 -0.576 0 CA-C-O 118.424 -0.798 . . . . 0.0 110.579 179.77 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' D' D ' 1' ' ' ASP . . . . . . . . . . . . . 14.7 m-20 . . . . . 0 N--CA 1.49 1.554 0 N-CA-C 109.216 -0.661 . . . . 0.0 109.216 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' D' D ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.28 131.05 46.21 Favored 'General case' 0 CA--C 1.535 0.388 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.541 179.804 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 3' ' ' GLU . . . . . . . . . . . . . 44.3 tt0 -169.31 107.98 0.42 Allowed 'General case' 0 N--CA 1.472 0.641 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 -179.953 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 41.4 m-85 -90.2 156.98 17.94 Favored 'General case' 0 C--N 1.358 0.971 0 N-CA-C 108.775 -0.824 . . . . 0.0 108.775 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -145.24 139.15 26.95 Favored 'General case' 0 N--CA 1.478 0.927 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.144 -179.846 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 38.7 t-80 -149.47 123.46 9.4 Favored 'General case' 0 CA--C 1.544 0.744 0 N-CA-C 108.42 -0.956 . . . . 0.0 108.42 175.352 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 7' ' ' ASP . . . . . 0.586 ' O ' ' OG ' ' G' ' 8' ' ' SER . 3.2 m-20 -63.79 133.02 52.69 Favored 'General case' 0 C--N 1.32 -0.702 0 C-N-CA 126.769 2.027 . . . . 0.0 113.965 174.817 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' D' D ' 8' ' ' SER . . . . . 0.499 ' OG ' ' O ' ' A' ' 7' ' ' ASP . 53.9 p -154.61 -170.57 3.56 Favored 'General case' 0 N--CA 1.487 1.41 0 CA-C-N 119.397 0.999 . . . . 0.0 111.12 175.622 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.2 47.77 1.2 Allowed Glycine 0 N--CA 1.481 1.651 0 N-CA-C 110.652 -0.979 . . . . 0.0 110.652 174.445 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 51.1 p90 -60.91 131.48 50.81 Favored 'General case' 0 N--CA 1.471 0.614 0 N-CA-C 112.804 0.668 . . . . 0.0 112.804 178.075 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 45.7 mt-10 -89.49 150.83 22.29 Favored 'General case' 0 N--CA 1.481 1.094 0 CA-C-N 117.825 0.284 . . . . 0.0 110.809 175.351 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.0 p -149.46 129.84 4.28 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.611 0 N-CA-C 107.49 -1.3 . . . . 0.0 107.49 173.417 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 42.9 m-70 -129.96 150.74 51.11 Favored 'General case' 0 N--CA 1.483 1.215 0 CA-C-N 118.198 0.454 . . . . 0.0 111.994 176.584 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 6.6 t60 -164.98 104.47 0.78 Allowed 'General case' 0 N--CA 1.483 1.186 0 N-CA-C 108.844 -0.799 . . . . 0.0 108.844 172.171 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 15' ' ' GLN . . . . . 0.764 HE22 HG23 ' D' ' 36' ' ' VAL . 13.7 pt20 -105.12 -176.1 2.98 Favored 'General case' 0 CA--C 1.502 -0.871 0 N-CA-C 108.487 -0.931 . . . . 0.0 108.487 179.177 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -166.23 104.52 0.64 Allowed 'General case' 0 N--CA 1.466 0.335 0 N-CA-C 106.205 -1.776 . . . . 0.0 106.205 174.131 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 5.4 mp -130.35 154.02 48.09 Favored 'General case' 0 N--CA 1.5 2.043 0 CA-C-O 122.062 0.934 . . . . 0.0 110.711 179.458 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 34.5 t -101.25 131.56 48.76 Favored 'Isoleucine or valine' 0 C--O 1.262 1.714 0 CA-C-O 116.779 -1.581 . . . . 0.0 109.686 174.097 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 26.2 m-85 -130.09 126.45 37.62 Favored 'General case' 0 N--CA 1.488 1.457 0 CA-C-N 120.126 1.33 . . . . 0.0 109.864 173.73 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 67.4 m-85 55.48 71.3 0.56 Allowed 'General case' 0 C--O 1.239 0.542 0 CA-C-N 115.712 -0.676 . . . . 0.0 111.837 176.206 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -81.6 -73.43 0.38 Allowed 'General case' 0 N--CA 1.473 0.718 0 CA-C-O 118.585 -0.721 . . . . 0.0 111.063 -177.61 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 38.6 tt0 -116.64 104.28 11.23 Favored 'General case' 0 N--CA 1.482 1.164 0 N-CA-C 106.361 -1.718 . . . . 0.0 106.361 176.324 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -152.15 139.92 19.9 Favored 'General case' 0 N--CA 1.474 0.756 0 CA-C-O 116.8 -1.571 . . . . 0.0 113.647 177.815 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 24' ' ' VAL . . . . . 0.469 ' HB ' ' H ' ' A' ' 25' ' ' GLY . 66.7 t -62.45 166.04 0.98 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.294 0 CA-C-N 121.037 1.744 . . . . 0.0 107.983 174.905 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' D' D ' 25' ' ' GLY . . . . . 0.526 ' H ' ' HB ' ' G' ' 24' ' ' VAL . . . -116.83 51.08 0.75 Allowed Glycine 0 N--CA 1.479 1.52 0 CA-C-O 119.081 -0.844 . . . . 0.0 111.738 178.536 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -57.75 -171.21 0.01 OUTLIER 'General case' 0 C--N 1.323 -0.58 0 C-N-CA 123.618 0.767 . . . . 0.0 111.722 176.054 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 4.5 t30 -72.11 86.52 1.05 Allowed 'General case' 0 C--N 1.346 0.435 0 N-CA-C 108.585 -0.894 . . . . 0.0 108.585 177.688 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 97.5 mttt -83.53 146.48 28.32 Favored 'General case' 0 N--CA 1.474 0.775 0 N-CA-C 108.056 -1.09 . . . . 0.0 108.056 179.196 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -62.95 -165.4 0.56 Allowed Glycine 0 C--N 1.335 0.476 0 N-CA-C 110.519 -1.032 . . . . 0.0 110.519 179.225 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -101.78 115.95 31.65 Favored 'General case' 0 N--CA 1.471 0.606 0 N-CA-C 109.235 -0.654 . . . . 0.0 109.235 179.594 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 72.6 mt -102.71 142.77 16.16 Favored 'Isoleucine or valine' 0 C--N 1.356 0.891 0 N-CA-C 104.544 -2.391 . . . . 0.0 104.544 179.838 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 32' ' ' ILE . . . . . 0.459 HG22 ' H ' ' G' ' 32' ' ' ILE . 34.8 pt -158.49 -176.96 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.209 0 CA-C-O 120.891 0.377 . . . . 0.0 110.152 -177.537 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 64.31 4.38 12.19 Favored Glycine 0 C--O 1.247 0.958 0 N-CA-C 110.087 -1.205 . . . . 0.0 110.087 -179.011 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 2.0 tt -76.37 132.94 40.02 Favored 'General case' 0 C--N 1.363 1.181 0 N-CA-C 107.185 -1.413 . . . . 0.0 107.185 -177.974 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 35' ' ' MET . . . . . 0.404 ' O ' HG13 ' D' ' 36' ' ' VAL . 28.2 ttt -158.52 161.53 37.36 Favored 'General case' 0 C--O 1.221 -0.419 0 CA-C-O 118.318 -0.849 . . . . 0.0 108.734 173.086 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' D' D ' 36' ' ' VAL . . . . . 0.764 HG23 HE22 ' D' ' 15' ' ' GLN . 27.6 m -164.74 165.07 0.61 Allowed 'Isoleucine or valine' 0 CA--C 1.519 -0.247 0 N-CA-C 107.624 -1.25 . . . . 0.0 107.624 175.835 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 60.36 64.1 4.43 Favored Glycine 0 CA--C 1.524 0.6 0 C-N-CA 119.576 -1.297 . . . . 0.0 113.006 178.572 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 140.95 -171.61 24.04 Favored Glycine 0 N--CA 1.476 1.361 0 CA-C-N 117.328 0.564 . . . . 0.0 111.95 -179.175 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 39' ' ' VAL . . . . . 0.587 ' H ' HG12 ' G' ' 39' ' ' VAL . 35.4 m -128.17 153.5 37.65 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.883 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -176.664 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 25.3 t . . . . . 0 C--O 1.225 -0.204 0 CA-C-O 116.686 -1.626 . . . . 0.0 109.773 178.118 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' E' E ' 1' ' ' ASP . . . . . . . . . . . . . 15.4 m-20 . . . . . 0 N--CA 1.488 1.457 0 N-CA-C 109.5 -0.555 . . . . 0.0 109.5 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' E' E ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.5 129.8 41.24 Favored 'General case' 0 N--CA 1.468 0.461 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.423 -179.892 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' E' E ' 3' ' ' GLU . . . . . . . . . . . . . 44.1 tt0 -167.14 105.29 0.56 Allowed 'General case' 0 C--O 1.213 -0.839 0 CA-C-N 116.775 -0.193 . . . . 0.0 110.634 -179.678 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 37.9 m-85 -86.62 151.76 23.16 Favored 'General case' 0 N--CA 1.475 0.825 0 N-CA-C 110.166 -0.309 . . . . 0.0 110.166 179.353 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' E' E ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -142.74 140.86 31.61 Favored 'General case' 0 N--CA 1.484 1.257 0 CA-C-O 120.952 0.405 . . . . 0.0 109.997 179.576 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 41.5 t-80 -151.68 119.21 6.05 Favored 'General case' 0 N--CA 1.472 0.625 0 N-CA-C 109.228 -0.656 . . . . 0.0 109.228 178.894 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' E' E ' 7' ' ' ASP . . . . . 0.432 ' O ' ' OG ' ' H' ' 8' ' ' SER . 4.0 m-20 -69.47 148.39 49.59 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 116.389 -0.368 . . . . 0.0 110.82 -179.982 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' E' E ' 8' ' ' SER . . . . . 0.448 ' OG ' ' O ' ' B' ' 7' ' ' ASP . 51.8 p -168.1 -172.13 1.71 Allowed 'General case' 0 N--CA 1.485 1.31 0 CA-C-O 121.153 0.501 . . . . 0.0 110.857 178.995 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.17 47.61 1.31 Allowed Glycine 0 N--CA 1.479 1.516 0 CA-C-N 115.879 -0.601 . . . . 0.0 111.942 179.622 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 46.8 p90 -65.2 133.16 50.91 Favored 'General case' 0 N--CA 1.474 0.762 0 N-CA-C 111.894 0.331 . . . . 0.0 111.894 -179.886 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 46.2 mt-10 -91.84 152.33 20.16 Favored 'General case' 0 N--CA 1.479 0.995 0 CA-C-O 121.211 0.529 . . . . 0.0 109.742 178.007 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -154.34 127.47 1.16 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.586 0 N-CA-C 107.799 -1.186 . . . . 0.0 107.799 178.103 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 44.8 m-70 -135.78 145.71 46.82 Favored 'General case' 0 N--CA 1.481 1.116 0 CA-C-O 120.768 0.318 . . . . 0.0 111.678 -177.861 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 6.4 t60 -163.94 97.1 0.83 Allowed 'General case' 0 N--CA 1.485 1.318 0 CA-C-N 116.374 -0.375 . . . . 0.0 110.61 179.531 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' E' E ' 15' ' ' GLN . . . . . 0.775 HE22 HG23 ' E' ' 36' ' ' VAL . 14.0 pt20 -101.3 -173.97 2.49 Favored 'General case' 0 CA--C 1.509 -0.634 0 N-CA-C 108.855 -0.794 . . . . 0.0 108.855 -179.77 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -169.85 94.95 0.27 Allowed 'General case' 0 N--CA 1.474 0.739 0 CA-C-N 114.702 -1.136 . . . . 0.0 108.423 178.468 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 6.4 mp -122.05 156.92 32.53 Favored 'General case' 0 N--CA 1.494 1.772 0 CA-C-O 121.649 0.738 . . . . 0.0 111.532 -177.641 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 48.0 t -113.9 124.35 70.47 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.231 0 N-CA-C 108.178 -1.045 . . . . 0.0 108.178 177.168 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 30.5 m-85 -124.83 121.78 35.54 Favored 'General case' 0 N--CA 1.488 1.427 0 CA-C-O 120.83 0.348 . . . . 0.0 111.086 -179.729 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 68.8 m-85 54.76 73.61 0.4 Allowed 'General case' 0 N--CA 1.467 0.407 0 CA-C-N 115.941 -0.572 . . . . 0.0 111.609 178.173 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -78.53 -78.6 0.14 Allowed 'General case' 0 CA--C 1.535 0.379 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.108 -179.615 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 38.5 tt0 -112.8 101.07 9.17 Favored 'General case' 0 C--N 1.324 -0.532 0 N-CA-C 108.257 -1.016 . . . . 0.0 108.257 179.905 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -158.39 140.12 13.71 Favored 'General case' 0 C--O 1.205 -1.274 0 O-C-N 122.282 -0.262 . . . . 0.0 111.5 178.97 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' E' E ' 24' ' ' VAL . . . . . 0.474 ' HB ' ' H ' ' B' ' 25' ' ' GLY . 57.6 t -58.65 168.53 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.867 0 N-CA-C 107.619 -1.252 . . . . 0.0 107.619 176.943 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' E' E ' 25' ' ' GLY . . . . . 0.432 ' H ' ' HB ' ' H' ' 24' ' ' VAL . . . -122.45 49.35 0.89 Allowed Glycine 0 N--CA 1.474 1.212 0 N-CA-C 110.783 -0.927 . . . . 0.0 110.783 -179.296 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -63.24 -167.83 0.02 OUTLIER 'General case' 0 N--CA 1.469 0.489 0 CA-C-O 120.763 0.316 . . . . 0.0 110.466 179.805 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 4.4 t30 -70.07 77.29 0.5 Allowed 'General case' 0 N--CA 1.466 0.365 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.422 179.961 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -75.17 144.45 42.73 Favored 'General case' 0 N--CA 1.476 0.855 0 N-CA-C 109.552 -0.536 . . . . 0.0 109.552 179.438 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.34 -166.9 1.19 Allowed Glycine 0 CA--C 1.521 0.454 0 N-CA-C 110.439 -1.064 . . . . 0.0 110.439 178.548 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.68 114.15 27.06 Favored 'General case' 0 N--CA 1.472 0.646 0 N-CA-C 109.848 -0.426 . . . . 0.0 109.848 179.769 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 65.6 mt -98.47 135.52 32.97 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.324 0 N-CA-C 106.832 -1.544 . . . . 0.0 106.832 178.979 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' E' E ' 32' ' ' ILE . . . . . 0.45 HG22 ' H ' ' H' ' 32' ' ' ILE . 36.2 pt -152.01 -174.05 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.208 0 CA-C-O 121.111 0.481 . . . . 0.0 110.713 -179.337 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.29 5.16 5.74 Favored Glycine 0 CA--C 1.529 0.942 0 CA-C-N 115.58 -0.736 . . . . 0.0 111.408 -179.731 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 1.6 tt -74.25 126.9 31.63 Favored 'General case' 0 CA--C 1.547 0.852 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 -179.559 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 28.5 ttt -162.74 151.09 14.26 Favored 'General case' 0 C--O 1.209 -1.05 0 N-CA-C 108.995 -0.742 . . . . 0.0 108.995 178.769 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' E' E ' 36' ' ' VAL . . . . . 0.775 HG23 HE22 ' E' ' 15' ' ' GLN . 35.4 m -156.62 166.23 0.94 Allowed 'Isoleucine or valine' 0 C--N 1.343 0.292 0 N-CA-C 108.354 -0.98 . . . . 0.0 108.354 179.747 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.72 66.87 2.53 Favored Glycine 0 C--N 1.307 -1.075 0 CA-C-N 115.576 -0.738 . . . . 0.0 111.997 178.442 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 144.1 -173.12 24.99 Favored Glycine 0 N--CA 1.475 1.281 0 N-CA-C 111.23 -0.748 . . . . 0.0 111.23 178.931 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' E' E ' 39' ' ' VAL . . . . . 0.596 ' H ' HG12 ' H' ' 39' ' ' VAL . 34.2 m -125.46 155.31 34.52 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.753 0 C-N-CA 123.405 0.682 . . . . 0.0 110.429 -179.138 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 26.4 t . . . . . 0 C--O 1.219 -0.526 0 O-C-N 124.062 0.851 . . . . 0.0 110.467 179.505 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' F' F ' 1' ' ' ASP . . . . . . . . . . . . . 14.5 m-20 . . . . . 0 N--CA 1.49 1.562 0 N-CA-C 109.302 -0.629 . . . . 0.0 109.302 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' F' F ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.58 130.19 42.72 Favored 'General case' 0 CA--C 1.536 0.42 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.354 179.982 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' F' F ' 3' ' ' GLU . . . . . . . . . . . . . 44.3 tt0 -167.53 106.05 0.54 Allowed 'General case' 0 C--O 1.213 -0.838 0 CA-C-N 116.71 -0.223 . . . . 0.0 110.505 -179.767 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 36.2 m-85 -87.49 151.77 22.76 Favored 'General case' 0 N--CA 1.474 0.75 0 N-CA-C 110.003 -0.369 . . . . 0.0 110.003 179.481 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' F' F ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -142.64 141.02 31.83 Favored 'General case' 0 N--CA 1.48 1.051 0 CA-C-O 120.884 0.373 . . . . 0.0 110.175 179.509 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 42.2 t-80 -151.9 118.95 5.85 Favored 'General case' 0 N--CA 1.472 0.639 0 N-CA-C 109.343 -0.614 . . . . 0.0 109.343 179.046 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' F' F ' 7' ' ' ASP . . . . . 0.478 ' O ' ' OG ' ' I' ' 8' ' ' SER . 4.0 m-20 -69.34 148.36 49.8 Favored 'General case' 0 N--CA 1.465 0.324 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.824 -179.902 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' F' F ' 8' ' ' SER . . . . . 0.49 ' OG ' ' O ' ' C' ' 7' ' ' ASP . 50.5 p -168.1 -172.03 1.68 Allowed 'General case' 0 N--CA 1.486 1.335 0 CA-C-O 121.119 0.485 . . . . 0.0 110.953 179.008 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.89 47.16 1.39 Allowed Glycine 0 N--CA 1.479 1.553 0 CA-C-N 115.884 -0.598 . . . . 0.0 111.953 179.629 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 46.2 p90 -64.73 133.4 52.0 Favored 'General case' 0 CA--C 1.543 0.68 0 N-CA-C 111.832 0.308 . . . . 0.0 111.832 -179.924 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 46.2 mt-10 -91.91 152.17 20.19 Favored 'General case' 0 N--CA 1.481 1.081 0 CA-C-O 121.19 0.519 . . . . 0.0 109.736 177.997 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -154.12 127.24 1.15 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.599 0 N-CA-C 107.838 -1.171 . . . . 0.0 107.838 178.131 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 44.5 m-70 -135.53 146.04 47.66 Favored 'General case' 0 N--CA 1.483 1.201 0 CA-C-O 120.88 0.372 . . . . 0.0 111.631 -177.916 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 6.4 t60 -164.07 96.94 0.81 Allowed 'General case' 0 N--CA 1.486 1.369 0 CA-C-N 116.436 -0.347 . . . . 0.0 110.674 179.385 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' F' F ' 15' ' ' GLN . . . . . 0.735 HE22 HG23 ' F' ' 36' ' ' VAL . 13.8 pt20 -101.18 -173.84 2.47 Favored 'General case' 0 CA--C 1.507 -0.698 0 N-CA-C 108.871 -0.789 . . . . 0.0 108.871 -179.814 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -169.87 94.93 0.27 Allowed 'General case' 0 N--CA 1.473 0.677 0 CA-C-N 114.609 -1.178 . . . . 0.0 108.443 178.42 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 6.3 mp -121.95 157.07 32.06 Favored 'General case' 0 N--CA 1.494 1.764 0 CA-C-O 121.685 0.755 . . . . 0.0 111.554 -177.676 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 48.1 t -114.02 124.27 70.5 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.217 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 177.162 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 30.0 m-85 -124.71 122.03 36.32 Favored 'General case' 0 N--CA 1.488 1.431 0 CA-C-O 120.863 0.364 . . . . 0.0 110.983 -179.741 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 68.9 m-85 54.61 74.18 0.36 Allowed 'General case' 0 C--N 1.344 0.362 0 CA-C-N 115.873 -0.603 . . . . 0.0 111.705 178.166 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -79.1 -78.5 0.15 Allowed 'General case' 0 CA--C 1.535 0.388 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.197 -179.56 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 38.4 tt0 -112.91 101.03 9.11 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 179.822 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -158.29 139.84 13.59 Favored 'General case' 0 C--O 1.208 -1.124 0 O-C-N 122.279 -0.263 . . . . 0.0 111.572 179.099 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' F' F ' 24' ' ' VAL . . . . . 0.472 ' HB ' ' H ' ' C' ' 25' ' ' GLY . 58.3 t -58.55 168.08 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.891 0 N-CA-C 107.507 -1.294 . . . . 0.0 107.507 177.037 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' F' F ' 25' ' ' GLY . . . . . 0.436 ' H ' ' HB ' ' I' ' 24' ' ' VAL . . . -122.14 49.48 0.89 Allowed Glycine 0 N--CA 1.477 1.43 0 N-CA-C 110.787 -0.925 . . . . 0.0 110.787 -179.427 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -63.27 -167.56 0.02 OUTLIER 'General case' 0 N--CA 1.469 0.509 0 CA-C-O 120.642 0.258 . . . . 0.0 110.441 179.796 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 4.3 t30 -70.26 77.12 0.53 Allowed 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.451 179.916 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -75.02 144.77 42.91 Favored 'General case' 0 N--CA 1.476 0.845 0 N-CA-C 109.579 -0.526 . . . . 0.0 109.579 179.335 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.46 -167.02 1.25 Allowed Glycine 0 CA--C 1.522 0.484 0 N-CA-C 110.494 -1.042 . . . . 0.0 110.494 178.64 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.17 113.96 26.47 Favored 'General case' 0 N--CA 1.473 0.711 0 N-CA-C 109.808 -0.442 . . . . 0.0 109.808 179.665 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 66.5 mt -98.43 135.27 33.89 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.388 0 N-CA-C 106.837 -1.542 . . . . 0.0 106.837 178.762 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' F' F ' 32' ' ' ILE . . . . . 0.445 HG22 ' H ' ' I' ' 32' ' ' ILE . 35.2 pt -151.87 -174.29 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.198 0 CA-C-O 121.248 0.547 . . . . 0.0 110.723 -179.373 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.35 5.45 6.31 Favored Glycine 0 CA--C 1.528 0.901 0 CA-C-N 115.55 -0.75 . . . . 0.0 111.443 -179.774 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 1.6 tt -74.42 127.05 32.07 Favored 'General case' 0 CA--C 1.549 0.913 0 N-CA-C 109.467 -0.568 . . . . 0.0 109.467 -179.741 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 28.4 ttt -162.69 151.32 14.62 Favored 'General case' 0 C--O 1.209 -1.045 0 N-CA-C 108.963 -0.755 . . . . 0.0 108.963 178.605 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' F' F ' 36' ' ' VAL . . . . . 0.735 HG23 HE22 ' F' ' 15' ' ' GLN . 35.4 m -156.82 166.13 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.344 0.347 0 N-CA-C 108.312 -0.995 . . . . 0.0 108.312 179.77 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.78 67.0 2.44 Favored Glycine 0 C--N 1.307 -1.038 0 CA-C-N 115.595 -0.729 . . . . 0.0 112.003 178.49 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.98 -173.0 24.96 Favored Glycine 0 N--CA 1.474 1.179 0 N-CA-C 111.251 -0.74 . . . . 0.0 111.251 178.992 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' F' F ' 39' ' ' VAL . . . . . 0.597 ' H ' HG12 ' I' ' 39' ' ' VAL . 34.2 m -125.62 155.51 34.93 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.729 0 C-N-CA 123.336 0.654 . . . . 0.0 110.365 -179.166 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 25.3 t . . . . . 0 C--O 1.219 -0.551 0 O-C-N 124.004 0.815 . . . . 0.0 110.423 179.593 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' G' G ' 1' ' ' ASP . . . . . . . . . . . . . 14.8 m-20 . . . . . 0 N--CA 1.492 1.664 0 N-CA-C 109.336 -0.616 . . . . 0.0 109.336 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' G' G ' 2' ' ' ALA . . . . . . . . . . . . . . . -63.34 128.64 36.77 Favored 'General case' 0 N--CA 1.468 0.473 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.666 179.692 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' G' G ' 3' ' ' GLU . . . . . . . . . . . . . 43.7 tt0 -167.86 107.0 0.53 Allowed 'General case' 0 N--CA 1.473 0.711 0 CA-C-O 120.495 0.188 . . . . 0.0 110.828 179.732 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 40.2 m-85 -89.19 151.51 22.12 Favored 'General case' 0 N--CA 1.474 0.768 0 N-CA-C 109.591 -0.522 . . . . 0.0 109.591 179.288 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' G' G ' 5' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -143.0 140.56 31.07 Favored 'General case' 0 N--CA 1.481 1.1 0 C-N-CA 122.498 0.319 . . . . 0.0 110.337 179.837 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 42.3 t-80 -151.27 120.22 6.66 Favored 'General case' 0 N--CA 1.474 0.739 0 N-CA-C 109.441 -0.578 . . . . 0.0 109.441 178.938 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -71.23 144.31 50.12 Favored 'General case' 0 N--CA 1.469 0.51 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.231 -179.829 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' G' G ' 8' ' ' SER . . . . . 0.586 ' OG ' ' O ' ' D' ' 7' ' ' ASP . 45.2 p -165.07 -170.52 1.95 Allowed 'General case' 0 N--CA 1.476 0.832 0 CA-C-O 121.037 0.446 . . . . 0.0 110.545 178.792 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.68 48.0 1.33 Allowed Glycine 0 N--CA 1.479 1.548 0 N-CA-C 111.485 -0.646 . . . . 0.0 111.485 179.468 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 48.8 p90 -65.77 133.43 50.99 Favored 'General case' 0 CA--C 1.543 0.676 0 N-CA-C 111.694 0.257 . . . . 0.0 111.694 -179.694 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 46.1 mt-10 -92.32 151.43 20.29 Favored 'General case' 0 N--CA 1.48 1.043 0 CA-C-O 121.146 0.498 . . . . 0.0 110.163 178.582 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -154.75 127.3 1.06 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.966 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 178.298 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 45.7 m-70 -134.74 147.34 50.01 Favored 'General case' 0 N--CA 1.478 0.965 0 CA-C-N 115.62 -0.718 . . . . 0.0 111.486 -178.291 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 32.7 t-80 -165.42 97.35 0.69 Allowed 'General case' 0 N--CA 1.483 1.204 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.242 178.83 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' G' G ' 15' ' ' GLN . . . . . 0.794 HE22 HG23 ' G' ' 36' ' ' VAL . 14.0 pt20 -101.59 -173.67 2.41 Favored 'General case' 0 CA--C 1.507 -0.699 0 N-CA-C 108.662 -0.866 . . . . 0.0 108.662 -179.58 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -170.55 94.22 0.21 Allowed 'General case' 0 N--CA 1.473 0.693 0 CA-C-N 114.654 -1.157 . . . . 0.0 108.076 178.637 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 6.3 mp -121.33 155.85 33.85 Favored 'General case' 0 N--CA 1.498 1.93 0 CA-C-O 121.237 0.541 . . . . 0.0 111.814 -177.8 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 42.9 t -113.43 125.15 70.65 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.011 0 CA-C-N 114.74 -1.118 . . . . 0.0 108.116 176.566 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 31.8 m-85 -125.96 121.54 33.38 Favored 'General case' 0 C--N 1.367 1.337 0 CA-C-N 115.664 -0.698 . . . . 0.0 111.083 -179.446 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 68.4 m-85 54.86 73.11 0.43 Allowed 'General case' 0 N--CA 1.467 0.416 0 CA-C-N 115.858 -0.61 . . . . 0.0 111.545 178.036 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.58 -77.95 0.14 Allowed 'General case' 0 N--CA 1.472 0.64 0 O-C-N 122.212 -0.305 . . . . 0.0 110.355 -179.25 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 38.4 tt0 -113.23 101.14 9.14 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 107.95 -1.13 . . . . 0.0 107.95 179.822 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -158.29 141.02 14.61 Favored 'General case' 0 N--CA 1.477 0.915 0 O-C-N 122.337 -0.227 . . . . 0.0 111.487 179.063 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' G' G ' 24' ' ' VAL . . . . . 0.526 ' HB ' ' H ' ' D' ' 25' ' ' GLY . 59.9 t -60.28 167.07 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.762 0 N-CA-C 107.641 -1.244 . . . . 0.0 107.641 177.26 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' G' G ' 25' ' ' GLY . . . . . 0.426 ' N ' HG12 ' G' ' 24' ' ' VAL . . . -120.45 49.61 0.87 Allowed Glycine 0 N--CA 1.479 1.566 0 N-CA-C 110.504 -1.038 . . . . 0.0 110.504 -179.452 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -64.02 -167.27 0.02 OUTLIER 'General case' 0 N--CA 1.471 0.598 0 CA-C-N 116.953 0.376 . . . . 0.0 110.061 179.829 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 4.3 t30 -70.45 77.12 0.56 Allowed 'General case' 0 CA--C 1.535 0.401 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.471 179.943 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -74.53 144.14 44.21 Favored 'General case' 0 N--CA 1.476 0.86 0 N-CA-C 109.653 -0.499 . . . . 0.0 109.653 179.361 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.39 -166.11 1.07 Allowed Glycine 0 C--N 1.337 0.619 0 N-CA-C 110.037 -1.225 . . . . 0.0 110.037 178.707 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -98.84 114.06 26.47 Favored 'General case' 0 N--CA 1.471 0.575 0 C-N-CA 122.672 0.389 . . . . 0.0 110.447 179.843 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 67.6 mt -99.16 135.51 34.02 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.698 0 N-CA-C 106.856 -1.535 . . . . 0.0 106.856 178.831 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' G' G ' 32' ' ' ILE . . . . . 0.459 ' H ' HG22 ' D' ' 32' ' ' ILE . 34.1 pt -152.48 -173.92 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 CA-C-N 119.891 1.223 . . . . 0.0 109.878 -179.725 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.15 5.31 7.61 Favored Glycine 0 N--CA 1.468 0.773 0 N-CA-C 111.061 -0.816 . . . . 0.0 111.061 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 1.6 tt -75.04 125.85 29.79 Favored 'General case' 0 CA--C 1.545 0.775 0 N-CA-C 109.524 -0.547 . . . . 0.0 109.524 -179.611 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 27.4 ttt -161.52 152.66 18.42 Favored 'General case' 0 C--O 1.21 -0.986 0 N-CA-C 108.775 -0.824 . . . . 0.0 108.775 178.503 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' G' G ' 36' ' ' VAL . . . . . 0.794 HG23 HE22 ' G' ' 15' ' ' GLN . 35.8 m -157.26 165.17 1.0 Allowed 'Isoleucine or valine' 0 C--N 1.346 0.429 0 N-CA-C 108.528 -0.916 . . . . 0.0 108.528 -179.675 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.39 67.99 1.92 Allowed Glycine 0 C--N 1.307 -1.031 0 CA-C-N 115.531 -0.759 . . . . 0.0 112.206 178.26 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.99 -171.66 25.45 Favored Glycine 0 N--CA 1.476 1.315 0 N-CA-C 110.621 -0.991 . . . . 0.0 110.621 178.998 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' G' G ' 39' ' ' VAL . . . . . 0.587 HG12 ' H ' ' D' ' 39' ' ' VAL . 34.7 m -126.93 156.03 38.04 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.911 0 C-N-CA 123.069 0.548 . . . . 0.0 110.631 -179.357 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 31.5 t . . . . . 0 C--O 1.219 -0.546 0 O-C-N 123.946 0.779 . . . . 0.0 110.737 179.218 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' H' H ' 1' ' ' ASP . . . . . . . . . . . . . 15.1 m-20 . . . . . 0 N--CA 1.49 1.567 0 N-CA-C 109.446 -0.575 . . . . 0.0 109.446 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' H' H ' 2' ' ' ALA . . . . . . . . . . . . . . . -63.0 128.63 36.74 Favored 'General case' 0 N--CA 1.469 0.487 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.587 179.766 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' H' H ' 3' ' ' GLU . . . . . . . . . . . . . 43.9 tt0 -167.82 106.41 0.53 Allowed 'General case' 0 N--CA 1.471 0.612 0 CA-C-O 120.581 0.229 . . . . 0.0 110.666 179.678 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 41.0 m-85 -88.57 151.5 22.46 Favored 'General case' 0 N--CA 1.473 0.706 0 N-CA-C 109.627 -0.508 . . . . 0.0 109.627 179.074 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' H' H ' 5' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -142.91 141.27 31.46 Favored 'General case' 0 N--CA 1.484 1.273 0 C-N-CA 122.585 0.354 . . . . 0.0 110.169 179.747 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 42.0 t-80 -151.98 120.1 6.28 Favored 'General case' 0 N--CA 1.474 0.731 0 N-CA-C 109.36 -0.607 . . . . 0.0 109.36 179.018 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -71.16 144.17 50.29 Favored 'General case' 0 N--CA 1.469 0.519 0 CA-C-N 116.321 -0.4 . . . . 0.0 111.303 -179.777 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' H' H ' 8' ' ' SER . . . . . 0.432 ' OG ' ' O ' ' E' ' 7' ' ' ASP . 53.1 p -164.77 -170.93 2.12 Favored 'General case' 0 N--CA 1.474 0.751 0 CA-C-O 121.06 0.457 . . . . 0.0 110.472 178.783 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.22 47.35 1.33 Allowed Glycine 0 N--CA 1.48 1.567 0 CA-C-N 115.848 -0.614 . . . . 0.0 111.713 179.47 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 49.2 p90 -65.47 133.09 50.53 Favored 'General case' 0 N--CA 1.471 0.594 0 N-CA-C 111.792 0.293 . . . . 0.0 111.792 -179.627 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 46.2 mt-10 -92.0 151.41 20.49 Favored 'General case' 0 N--CA 1.479 0.982 0 CA-C-O 121.115 0.483 . . . . 0.0 110.225 178.568 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -154.65 127.82 1.16 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.027 0 N-CA-C 107.851 -1.166 . . . . 0.0 107.851 178.233 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 46.6 m-70 -135.29 147.3 49.16 Favored 'General case' 0 N--CA 1.478 0.956 0 CA-C-N 115.653 -0.703 . . . . 0.0 111.409 -178.239 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 31.8 t-80 -165.47 97.31 0.68 Allowed 'General case' 0 N--CA 1.483 1.195 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.222 178.887 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' H' H ' 15' ' ' GLN . . . . . 0.781 HE22 HG23 ' H' ' 36' ' ' VAL . 13.9 pt20 -101.5 -173.46 2.37 Favored 'General case' 0 CA--C 1.507 -0.678 0 N-CA-C 108.636 -0.875 . . . . 0.0 108.636 -179.579 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -170.8 94.36 0.2 Allowed 'General case' 0 N--CA 1.472 0.652 0 CA-C-N 114.652 -1.158 . . . . 0.0 108.105 178.626 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 6.4 mp -121.43 155.57 34.57 Favored 'General case' 0 N--CA 1.497 1.911 0 CA-C-O 121.219 0.533 . . . . 0.0 111.938 -177.85 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 42.9 t -113.28 124.71 70.19 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.024 0 CA-C-N 114.782 -1.099 . . . . 0.0 108.134 176.568 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 31.3 m-85 -125.34 121.99 35.55 Favored 'General case' 0 C--N 1.367 1.351 0 CA-C-N 115.497 -0.774 . . . . 0.0 110.914 -179.252 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 68.1 m-85 54.05 73.34 0.39 Allowed 'General case' 0 C--O 1.237 0.436 0 CA-C-N 115.725 -0.67 . . . . 0.0 111.713 178.076 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.53 -78.03 0.14 Allowed 'General case' 0 N--CA 1.472 0.674 0 O-C-N 122.264 -0.273 . . . . 0.0 110.359 -179.218 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 38.3 tt0 -113.15 101.05 9.07 Favored 'General case' 0 C--N 1.322 -0.608 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 179.865 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -158.1 141.01 14.84 Favored 'General case' 0 N--CA 1.478 0.94 0 O-C-N 122.391 -0.193 . . . . 0.0 111.453 179.046 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' H' H ' 24' ' ' VAL . . . . . 0.432 ' HB ' ' H ' ' E' ' 25' ' ' GLY . 59.3 t -60.17 167.28 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.569 0 N-CA-C 107.655 -1.239 . . . . 0.0 107.655 177.209 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' H' H ' 25' ' ' GLY . . . . . 0.425 ' N ' HG12 ' H' ' 24' ' ' VAL . . . -120.65 49.65 0.87 Allowed Glycine 0 N--CA 1.478 1.499 0 N-CA-C 110.513 -1.035 . . . . 0.0 110.513 -179.463 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -64.26 -167.77 0.03 OUTLIER 'General case' 0 N--CA 1.473 0.701 0 CA-C-N 117.005 0.403 . . . . 0.0 110.1 179.755 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 4.5 t30 -70.01 77.15 0.49 Allowed 'General case' 0 CA--C 1.534 0.34 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.46 -179.974 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -74.65 144.5 43.81 Favored 'General case' 0 N--CA 1.476 0.846 0 N-CA-C 109.552 -0.536 . . . . 0.0 109.552 179.304 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.74 -165.23 1.01 Allowed Glycine 0 C--N 1.338 0.644 0 N-CA-C 109.936 -1.265 . . . . 0.0 109.936 178.833 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.94 113.71 26.46 Favored 'General case' 0 N--CA 1.47 0.54 0 C-N-CA 122.603 0.361 . . . . 0.0 110.548 -179.996 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 66.5 mt -98.6 135.78 32.15 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.758 0 N-CA-C 106.824 -1.547 . . . . 0.0 106.824 178.922 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' H' H ' 32' ' ' ILE . . . . . 0.45 ' H ' HG22 ' E' ' 32' ' ' ILE . 34.7 pt -152.81 -174.05 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 CA-C-N 119.853 1.206 . . . . 0.0 109.893 -179.797 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.15 5.61 8.3 Favored Glycine 0 N--CA 1.467 0.761 0 N-CA-C 111.004 -0.839 . . . . 0.0 111.004 179.971 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 1.6 tt -75.23 125.59 29.28 Favored 'General case' 0 CA--C 1.545 0.772 0 N-CA-C 109.588 -0.523 . . . . 0.0 109.588 -179.582 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 27.5 ttt -161.17 152.59 19.04 Favored 'General case' 0 C--O 1.212 -0.91 0 N-CA-C 108.886 -0.783 . . . . 0.0 108.886 178.61 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' H' H ' 36' ' ' VAL . . . . . 0.781 HG23 HE22 ' H' ' 15' ' ' GLN . 35.3 m -157.41 164.58 1.09 Allowed 'Isoleucine or valine' 0 C--N 1.347 0.458 0 N-CA-C 108.489 -0.93 . . . . 0.0 108.489 -179.582 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.78 67.91 1.96 Allowed Glycine 0 C--N 1.308 -0.997 0 CA-C-N 115.425 -0.807 . . . . 0.0 112.182 178.335 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 144.1 -171.89 25.43 Favored Glycine 0 N--CA 1.475 1.266 0 N-CA-C 110.682 -0.967 . . . . 0.0 110.682 179.11 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' H' H ' 39' ' ' VAL . . . . . 0.596 HG12 ' H ' ' E' ' 39' ' ' VAL . 35.0 m -126.8 155.75 37.65 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.94 0 C-N-CA 123.174 0.59 . . . . 0.0 110.663 -179.255 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 29.5 t . . . . . 0 C--O 1.217 -0.611 0 CA-C-O 118.433 -0.794 . . . . 0.0 110.759 179.341 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' I' I ' 1' ' ' ASP . . . . . . . . . . . . . 14.5 m-20 . . . . . 0 N--CA 1.492 1.665 0 N-CA-C 109.43 -0.581 . . . . 0.0 109.43 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' I' I ' 2' ' ' ALA . . . . . . . . . . . . . . . -63.18 128.62 36.68 Favored 'General case' 0 N--CA 1.469 0.483 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.595 179.801 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' I' I ' 3' ' ' GLU . . . . . . . . . . . . . 44.0 tt0 -167.68 107.03 0.55 Allowed 'General case' 0 N--CA 1.472 0.635 0 CA-C-O 120.516 0.198 . . . . 0.0 110.687 179.665 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 40.5 m-85 -89.04 151.89 22.0 Favored 'General case' 0 N--CA 1.474 0.749 0 N-CA-C 109.578 -0.527 . . . . 0.0 109.578 179.263 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' I' I ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -143.33 140.58 30.62 Favored 'General case' 0 N--CA 1.483 1.178 0 C-N-CA 122.513 0.325 . . . . 0.0 110.152 -179.987 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 41.6 t-80 -151.67 119.61 6.22 Favored 'General case' 0 N--CA 1.474 0.73 0 N-CA-C 109.435 -0.579 . . . . 0.0 109.435 179.058 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -70.7 144.61 50.94 Favored 'General case' 0 N--CA 1.468 0.472 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.203 -179.807 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' I' I ' 8' ' ' SER . . . . . 0.478 ' OG ' ' O ' ' F' ' 7' ' ' ASP . 52.8 p -165.08 -170.69 1.99 Allowed 'General case' 0 N--CA 1.474 0.752 0 CA-C-O 121.023 0.439 . . . . 0.0 110.521 178.752 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.71 47.77 1.35 Allowed Glycine 0 N--CA 1.481 1.638 0 CA-C-N 115.904 -0.589 . . . . 0.0 111.742 179.56 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 49.1 p90 -65.76 133.13 50.38 Favored 'General case' 0 N--CA 1.472 0.637 0 N-CA-C 111.834 0.309 . . . . 0.0 111.834 -179.771 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 46.2 mt-10 -92.0 151.19 20.6 Favored 'General case' 0 N--CA 1.477 0.923 0 C-N-CA 122.841 0.456 . . . . 0.0 110.249 178.615 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -154.6 127.68 1.15 Allowed 'Isoleucine or valine' 0 CA--C 1.551 0.997 0 N-CA-C 107.86 -1.163 . . . . 0.0 107.86 178.195 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 45.2 m-70 -135.02 147.33 49.63 Favored 'General case' 0 N--CA 1.477 0.918 0 CA-C-N 115.608 -0.724 . . . . 0.0 111.479 -178.252 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 32.1 t-80 -165.39 97.31 0.69 Allowed 'General case' 0 N--CA 1.483 1.179 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.218 178.82 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' I' I ' 15' ' ' GLN . . . . . 0.756 HE22 HG23 ' I' ' 36' ' ' VAL . 13.6 pt20 -101.59 -173.43 2.35 Favored 'General case' 0 CA--C 1.507 -0.696 0 N-CA-C 108.622 -0.881 . . . . 0.0 108.622 -179.524 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -170.83 94.48 0.2 Allowed 'General case' 0 N--CA 1.472 0.642 0 CA-C-N 114.631 -1.168 . . . . 0.0 108.076 178.677 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 6.3 mp -121.6 155.52 34.89 Favored 'General case' 0 N--CA 1.496 1.861 0 CA-C-O 121.229 0.538 . . . . 0.0 111.865 -177.851 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 42.0 t -113.09 125.22 70.32 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.015 0 CA-C-N 114.783 -1.099 . . . . 0.0 108.053 176.522 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 31.0 m-85 -125.98 121.63 33.62 Favored 'General case' 0 C--N 1.368 1.396 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.996 -179.17 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 68.2 m-85 54.38 73.05 0.42 Allowed 'General case' 0 N--CA 1.466 0.363 0 CA-C-N 115.836 -0.62 . . . . 0.0 111.584 178.085 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.34 -78.12 0.14 Allowed 'General case' 0 N--CA 1.473 0.712 0 N-CA-C 110.293 -0.262 . . . . 0.0 110.293 -179.218 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 38.6 tt0 -113.05 101.3 9.33 Favored 'General case' 0 C--N 1.323 -0.581 0 N-CA-C 107.994 -1.113 . . . . 0.0 107.994 179.811 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -158.34 141.1 14.61 Favored 'General case' 0 N--CA 1.476 0.867 0 O-C-N 122.368 -0.207 . . . . 0.0 111.444 179.021 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' I' I ' 24' ' ' VAL . . . . . 0.436 ' HB ' ' H ' ' F' ' 25' ' ' GLY . 59.6 t -60.31 166.85 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.348 0.534 0 N-CA-C 107.664 -1.236 . . . . 0.0 107.664 177.212 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' I' I ' 25' ' ' GLY . . . . . 0.43 ' N ' HG12 ' I' ' 24' ' ' VAL . . . -120.27 49.76 0.86 Allowed Glycine 0 N--CA 1.481 1.691 0 N-CA-C 110.542 -1.023 . . . . 0.0 110.542 -179.481 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -64.26 -167.85 0.03 OUTLIER 'General case' 0 N--CA 1.471 0.61 0 CA-C-N 116.922 0.361 . . . . 0.0 110.129 179.714 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 4.4 t30 -69.9 77.18 0.47 Allowed 'General case' 0 CA--C 1.534 0.345 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.419 -179.99 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -74.74 144.43 43.65 Favored 'General case' 0 N--CA 1.475 0.812 0 N-CA-C 109.641 -0.503 . . . . 0.0 109.641 179.387 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.66 -166.06 1.15 Allowed Glycine 0 C--N 1.337 0.607 0 N-CA-C 110.023 -1.231 . . . . 0.0 110.023 178.71 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.09 113.69 26.03 Favored 'General case' 0 N--CA 1.471 0.586 0 C-N-CA 122.674 0.39 . . . . 0.0 110.468 -179.887 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 67.2 mt -98.68 135.65 32.76 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.73 0 N-CA-C 106.895 -1.52 . . . . 0.0 106.895 178.889 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' I' I ' 32' ' ' ILE . . . . . 0.445 ' H ' HG22 ' F' ' 32' ' ' ILE . 35.0 pt -152.71 -173.92 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.774 0 CA-C-N 119.837 1.199 . . . . 0.0 109.826 -179.724 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.02 5.45 7.66 Favored Glycine 0 CA--C 1.527 0.811 0 N-CA-C 111.063 -0.815 . . . . 0.0 111.063 -179.942 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 1.6 tt -74.97 125.94 29.96 Favored 'General case' 0 CA--C 1.546 0.789 0 N-CA-C 109.549 -0.538 . . . . 0.0 109.549 -179.706 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 27.5 ttt -161.45 152.48 18.35 Favored 'General case' 0 C--O 1.21 -0.981 0 N-CA-C 108.794 -0.817 . . . . 0.0 108.794 178.625 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' I' I ' 36' ' ' VAL . . . . . 0.756 HG23 HE22 ' I' ' 15' ' ' GLN . 35.9 m -157.39 164.82 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.346 0.426 0 N-CA-C 108.468 -0.938 . . . . 0.0 108.468 -179.849 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.62 68.13 1.85 Allowed Glycine 0 C--N 1.308 -0.976 0 CA-C-N 115.501 -0.772 . . . . 0.0 112.137 178.294 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 144.01 -171.86 25.39 Favored Glycine 0 N--CA 1.476 1.302 0 N-CA-C 110.601 -1.0 . . . . 0.0 110.601 179.145 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' I' I ' 39' ' ' VAL . . . . . 0.597 HG12 ' H ' ' F' ' 39' ' ' VAL . 34.9 m -126.95 155.98 38.08 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.935 0 C-N-CA 123.118 0.567 . . . . 0.0 110.617 -179.359 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 31.8 t . . . . . 0 C--O 1.219 -0.542 0 O-C-N 123.953 0.783 . . . . 0.0 110.693 179.402 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 15.5 m-20 . . . . . 0 N--CA 1.49 1.531 0 N-CA-C 108.889 -0.782 . . . . 0.0 108.889 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.63 132.51 49.0 Favored 'General case' 0 CA--C 1.539 0.551 0 CA-C-N 116.55 -0.296 . . . . 0.0 110.276 -179.731 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 44.7 tt0 -168.05 106.29 0.5 Allowed 'General case' 0 C--O 1.213 -0.838 0 N-CA-C 109.879 -0.415 . . . . 0.0 109.879 -179.265 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 42.4 m-85 -85.48 151.33 24.05 Favored 'General case' 0 N--CA 1.474 0.758 0 N-CA-C 110.076 -0.342 . . . . 0.0 110.076 179.5 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -142.72 141.24 31.75 Favored 'General case' 0 N--CA 1.481 1.08 0 CA-C-O 120.861 0.363 . . . . 0.0 110.052 179.53 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 45.3 t-80 -152.11 119.03 5.79 Favored 'General case' 0 N--CA 1.471 0.613 0 N-CA-C 109.263 -0.643 . . . . 0.0 109.263 178.997 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' ASP . . . . . 0.488 ' O ' ' OG ' ' D' ' 8' ' ' SER . 4.5 m-20 -68.93 149.4 48.9 Favored 'General case' 0 CA--C 1.536 0.436 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.448 179.883 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 60.4 p -168.16 -173.78 2.13 Favored 'General case' 0 N--CA 1.484 1.228 0 CA-C-O 120.947 0.404 . . . . 0.0 110.635 179.224 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.37 46.85 1.37 Allowed Glycine 0 N--CA 1.482 1.721 0 CA-C-N 115.972 -0.558 . . . . 0.0 112.114 179.816 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 49.8 p90 -66.16 132.61 48.86 Favored 'General case' 0 N--CA 1.473 0.697 0 O-C-N 122.782 -0.246 . . . . 0.0 111.53 179.766 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 48.7 mt-10 -91.84 152.49 20.08 Favored 'General case' 0 N--CA 1.477 0.911 0 CA-C-O 121.066 0.46 . . . . 0.0 109.776 178.293 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.0 p -153.15 127.63 1.4 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.545 0 N-CA-C 107.915 -1.143 . . . . 0.0 107.915 178.363 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 44.1 m-70 -135.6 148.44 49.05 Favored 'General case' 0 N--CA 1.492 1.645 0 CA-C-N 119.09 0.859 . . . . 0.0 111.324 -179.064 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 7.0 t60 -163.67 97.81 0.87 Allowed 'General case' 0 N--CA 1.481 1.09 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.776 179.395 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' GLN . . . . . 0.531 HE22 ' H ' ' A' ' 37' ' ' GLY . 3.4 pt20 -107.63 -175.74 2.87 Favored 'General case' 0 CA--C 1.507 -0.68 0 N-CA-C 108.422 -0.955 . . . . 0.0 108.422 -179.98 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -169.63 100.56 0.32 Allowed 'General case' 0 CA--C 1.54 0.582 0 CA-C-N 114.629 -1.169 . . . . 0.0 108.466 179.029 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.547 ' H ' ' CD2' ' D' ' 17' ' ' LEU . 6.9 mt -125.46 153.17 43.91 Favored 'General case' 0 N--CA 1.492 1.675 0 CA-C-O 121.443 0.64 . . . . 0.0 110.975 -178.284 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 60.4 t -107.8 129.26 62.17 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.21 0 CA-C-O 117.896 -1.05 . . . . 0.0 108.392 178.039 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 45.3 m-85 -125.97 122.72 36.73 Favored 'General case' 0 N--CA 1.497 1.919 0 CA-C-N 120.099 1.318 . . . . 0.0 110.367 179.272 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 74.2 m-85 53.09 75.02 0.26 Allowed 'General case' 0 N--CA 1.471 0.594 0 CA-C-O 121.361 0.6 . . . . 0.0 111.935 178.469 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -79.52 -78.32 0.16 Allowed 'General case' 0 C--N 1.353 0.739 0 CA-C-N 115.097 -0.956 . . . . 0.0 110.283 -179.796 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 39.9 tt0 -112.58 100.57 8.83 Favored 'General case' 0 N--CA 1.47 0.564 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 179.805 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -159.33 140.54 12.86 Favored 'General case' 0 C--O 1.207 -1.163 0 O-C-N 122.283 -0.261 . . . . 0.0 111.161 179.175 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.417 HG12 ' N ' ' A' ' 25' ' ' GLY . 61.5 t -60.33 164.15 0.92 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.836 0 N-CA-C 108.154 -1.054 . . . . 0.0 108.154 177.174 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.444 ' H ' ' HB ' ' D' ' 24' ' ' VAL . . . -117.66 48.89 0.9 Allowed Glycine 0 N--CA 1.477 1.426 0 N-CA-C 111.657 -0.577 . . . . 0.0 111.657 -179.353 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -61.92 -168.23 0.02 OUTLIER 'General case' 0 N--CA 1.469 0.486 0 O-C-N 123.845 0.38 . . . . 0.0 110.371 179.532 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 3.1 t30 -70.17 81.11 0.51 Allowed 'General case' 0 N--CA 1.465 0.282 0 N-CA-C 110.144 -0.317 . . . . 0.0 110.144 179.792 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -79.65 146.43 32.49 Favored 'General case' 0 N--CA 1.472 0.627 0 N-CA-C 109.087 -0.708 . . . . 0.0 109.087 179.123 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -62.98 -168.54 0.93 Allowed Glycine 0 CA--C 1.524 0.653 0 N-CA-C 109.895 -1.282 . . . . 0.0 109.895 178.752 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -100.19 116.47 32.26 Favored 'General case' 0 N--CA 1.477 0.898 0 N-CA-C 109.685 -0.487 . . . . 0.0 109.685 179.723 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 69.4 mt -97.34 135.33 31.98 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.556 0 N-CA-C 107.102 -1.444 . . . . 0.0 107.102 179.003 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 44.1 pt -151.43 -178.17 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.713 0 CA-C-O 121.222 0.534 . . . . 0.0 111.11 -178.899 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 64.09 5.34 14.66 Favored Glycine 0 CA--C 1.526 0.728 0 N-CA-C 110.815 -0.914 . . . . 0.0 110.815 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.414 HD23 ' N ' ' A' ' 35' ' ' MET . 1.4 tt -73.79 128.7 36.2 Favored 'General case' 0 CA--C 1.545 0.776 0 N-CA-C 109.61 -0.515 . . . . 0.0 109.61 -179.714 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 35' ' ' MET . . . . . 0.414 ' N ' HD23 ' A' ' 34' ' ' LEU . 28.7 ttt -163.55 147.39 10.44 Favored 'General case' 0 N--CA 1.465 0.305 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 178.506 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.539 HG22 HG12 ' D' ' 36' ' ' VAL . 31.6 m -155.13 163.54 1.55 Allowed 'Isoleucine or valine' 0 C--N 1.347 0.488 0 N-CA-C 108.11 -1.07 . . . . 0.0 108.11 179.503 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 37' ' ' GLY . . . . . 0.531 ' H ' HE22 ' A' ' 15' ' ' GLN . . . 55.4 68.15 1.84 Allowed Glycine 0 C--N 1.306 -1.134 0 CA-C-N 115.89 -0.596 . . . . 0.0 112.078 178.706 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 141.09 175.35 14.71 Favored Glycine 0 N--CA 1.475 1.273 0 N-CA-C 110.821 -0.912 . . . . 0.0 110.821 179.164 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.512 ' H ' HG12 ' D' ' 39' ' ' VAL . 35.4 m -118.55 159.69 18.85 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.813 0 C-N-CA 123.364 0.666 . . . . 0.0 110.384 -179.998 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 22.1 t . . . . . 0 C--O 1.221 -0.441 0 CA-C-O 118.523 -0.751 . . . . 0.0 110.649 179.488 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' B' B ' 1' ' ' ASP . . . . . . . . . . . . . 13.9 m-20 . . . . . 0 N--CA 1.49 1.558 0 N-CA-C 109.091 -0.707 . . . . 0.0 109.091 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' B' B ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.06 132.7 49.89 Favored 'General case' 0 N--CA 1.47 0.547 0 N-CA-C 110.19 -0.3 . . . . 0.0 110.19 -179.76 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 3' ' ' GLU . . . . . . . . . . . . . 44.5 tt0 -168.33 105.5 0.46 Allowed 'General case' 0 C--O 1.214 -0.767 0 N-CA-C 110.011 -0.366 . . . . 0.0 110.011 -179.099 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 41.2 m-85 -84.82 151.22 24.48 Favored 'General case' 0 N--CA 1.474 0.751 0 N-CA-C 110.088 -0.338 . . . . 0.0 110.088 179.505 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -142.58 141.06 31.93 Favored 'General case' 0 N--CA 1.483 1.217 0 N-CA-C 109.98 -0.378 . . . . 0.0 109.98 179.437 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 44.4 t-80 -151.94 118.94 5.83 Favored 'General case' 0 N--CA 1.473 0.688 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 178.991 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 7' ' ' ASP . . . . . 0.441 ' O ' ' OG ' ' E' ' 8' ' ' SER . 4.3 m-20 -69.08 148.88 49.38 Favored 'General case' 0 CA--C 1.537 0.473 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.585 179.93 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 8' ' ' SER . . . . . . . . . . . . . 59.9 p -167.76 -173.73 2.23 Favored 'General case' 0 N--CA 1.482 1.144 0 CA-C-O 120.985 0.422 . . . . 0.0 110.644 179.336 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.23 46.72 1.41 Allowed Glycine 0 N--CA 1.482 1.753 0 CA-C-N 115.902 -0.59 . . . . 0.0 112.164 179.944 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 50.2 p90 -66.14 132.51 48.66 Favored 'General case' 0 N--CA 1.472 0.657 0 CA-C-O 120.624 0.25 . . . . 0.0 111.596 179.632 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 48.2 mt-10 -91.7 152.62 20.12 Favored 'General case' 0 N--CA 1.476 0.846 0 CA-C-O 121.076 0.465 . . . . 0.0 109.758 178.307 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.0 p -153.23 128.07 1.47 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.654 0 N-CA-C 107.772 -1.196 . . . . 0.0 107.772 178.167 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 43.6 m-70 -135.72 148.91 49.04 Favored 'General case' 0 N--CA 1.492 1.628 0 CA-C-N 118.837 0.744 . . . . 0.0 111.355 -179.145 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 7.2 t60 -164.3 97.62 0.8 Allowed 'General case' 0 N--CA 1.482 1.139 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.75 179.494 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 15' ' ' GLN . . . . . 0.532 HE22 ' H ' ' B' ' 37' ' ' GLY . 3.4 pt20 -107.41 -175.37 2.77 Favored 'General case' 0 CA--C 1.509 -0.623 0 N-CA-C 108.255 -1.017 . . . . 0.0 108.255 -179.921 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -169.96 100.18 0.3 Allowed 'General case' 0 N--CA 1.471 0.619 0 CA-C-N 114.667 -1.151 . . . . 0.0 108.415 178.995 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 17' ' ' LEU . . . . . 0.534 ' H ' ' CD2' ' E' ' 17' ' ' LEU . 6.9 mt -124.92 153.72 42.23 Favored 'General case' 0 N--CA 1.491 1.61 0 CA-C-O 121.506 0.669 . . . . 0.0 111.03 -178.39 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 61.3 t -108.4 130.33 61.25 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.221 0 N-CA-C 108.054 -1.091 . . . . 0.0 108.054 177.933 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 44.2 m-85 -127.24 122.06 32.92 Favored 'General case' 0 N--CA 1.494 1.766 0 CA-C-N 119.721 1.146 . . . . 0.0 110.221 179.524 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 74.7 m-85 52.89 75.28 0.25 Allowed 'General case' 0 CA--C 1.539 0.527 0 CA-C-O 121.427 0.632 . . . . 0.0 111.939 178.47 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -79.92 -78.06 0.17 Allowed 'General case' 0 C--N 1.351 0.666 0 CA-C-N 115.026 -0.988 . . . . 0.0 110.283 -179.839 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 40.2 tt0 -112.58 100.65 8.9 Favored 'General case' 0 N--CA 1.473 0.683 0 N-CA-C 108.349 -0.982 . . . . 0.0 108.349 179.73 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -159.34 141.24 13.4 Favored 'General case' 0 N--CA 1.484 1.235 0 O-C-N 122.222 -0.299 . . . . 0.0 111.144 179.193 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 61.4 t -61.0 163.9 1.05 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.852 0 N-CA-C 108.176 -1.046 . . . . 0.0 108.176 177.238 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 25' ' ' GLY . . . . . 0.466 ' H ' ' HB ' ' E' ' 24' ' ' VAL . . . -117.19 48.51 0.93 Allowed Glycine 0 N--CA 1.476 1.338 0 N-CA-C 111.581 -0.608 . . . . 0.0 111.581 -179.328 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -61.55 -167.43 0.01 OUTLIER 'General case' 0 N--CA 1.469 0.505 0 O-C-N 123.753 0.325 . . . . 0.0 110.364 179.494 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 3.1 t30 -71.24 81.18 0.73 Allowed 'General case' 0 N--CA 1.465 0.324 0 N-CA-C 110.076 -0.342 . . . . 0.0 110.076 179.863 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -79.75 146.47 32.33 Favored 'General case' 0 N--CA 1.473 0.69 0 N-CA-C 109.096 -0.705 . . . . 0.0 109.096 179.274 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.03 -168.7 0.97 Allowed Glycine 0 C--N 1.336 0.56 0 N-CA-C 109.914 -1.274 . . . . 0.0 109.914 178.735 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.97 116.76 32.77 Favored 'General case' 0 N--CA 1.476 0.87 0 N-CA-C 109.668 -0.493 . . . . 0.0 109.668 179.789 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 69.8 mt -97.65 135.07 33.37 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.537 0 N-CA-C 107.07 -1.456 . . . . 0.0 107.07 178.972 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 43.7 pt -151.1 -177.94 0.38 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.681 0 CA-C-O 121.299 0.571 . . . . 0.0 111.159 -178.753 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.42 5.94 13.46 Favored Glycine 0 CA--C 1.525 0.692 0 N-CA-C 110.884 -0.887 . . . . 0.0 110.884 -179.967 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 34' ' ' LEU . . . . . 0.4 HD23 ' N ' ' B' ' 35' ' ' MET . 1.4 tt -74.39 128.35 35.33 Favored 'General case' 0 CA--C 1.545 0.774 0 N-CA-C 109.528 -0.545 . . . . 0.0 109.528 -179.745 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 35' ' ' MET . . . . . 0.4 ' N ' HD23 ' B' ' 34' ' ' LEU . 28.6 ttt -162.95 147.76 11.6 Favored 'General case' 0 N--CA 1.468 0.427 0 N-CA-C 108.797 -0.816 . . . . 0.0 108.797 178.607 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 36' ' ' VAL . . . . . 0.497 HG22 HG12 ' E' ' 36' ' ' VAL . 29.9 m -155.68 163.31 1.53 Allowed 'Isoleucine or valine' 0 C--N 1.347 0.49 0 N-CA-C 108.096 -1.075 . . . . 0.0 108.096 179.516 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 37' ' ' GLY . . . . . 0.532 ' H ' HE22 ' B' ' 15' ' ' GLN . . . 55.67 67.74 2.05 Favored Glycine 0 C--N 1.306 -1.11 0 CA-C-N 115.881 -0.6 . . . . 0.0 112.014 178.676 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 141.17 175.65 14.97 Favored Glycine 0 N--CA 1.475 1.247 0 N-CA-C 110.891 -0.883 . . . . 0.0 110.891 179.079 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 39' ' ' VAL . . . . . 0.514 ' H ' HG12 ' E' ' 39' ' ' VAL . 35.5 m -118.56 159.87 18.73 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.89 0 C-N-CA 123.469 0.708 . . . . 0.0 110.476 -179.934 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 21.9 t . . . . . 0 N--CA 1.468 0.475 0 CA-C-O 118.364 -0.827 . . . . 0.0 110.468 179.362 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' C' C ' 1' ' ' ASP . . . . . . . . . . . . . 14.1 m-20 . . . . . 0 N--CA 1.49 1.553 0 N-CA-C 108.894 -0.78 . . . . 0.0 108.894 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' C' C ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.08 132.72 49.94 Favored 'General case' 0 CA--C 1.54 0.561 0 CA-C-N 116.509 -0.314 . . . . 0.0 110.229 -179.792 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 3' ' ' GLU . . . . . . . . . . . . . 44.6 tt0 -168.35 105.94 0.47 Allowed 'General case' 0 C--O 1.215 -0.749 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 -179.162 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 41.3 m-85 -85.07 151.89 23.82 Favored 'General case' 0 N--CA 1.475 0.775 0 N-CA-C 110.128 -0.323 . . . . 0.0 110.128 179.547 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -143.34 140.49 30.55 Favored 'General case' 0 N--CA 1.481 1.097 0 N-CA-C 110.126 -0.324 . . . . 0.0 110.126 179.608 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 45.4 t-80 -151.51 119.24 6.13 Favored 'General case' 0 N--CA 1.472 0.667 0 N-CA-C 109.286 -0.635 . . . . 0.0 109.286 178.984 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 7' ' ' ASP . . . . . 0.482 ' O ' ' OG ' ' F' ' 8' ' ' SER . 4.4 m-20 -69.32 148.76 49.27 Favored 'General case' 0 CA--C 1.537 0.471 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.591 179.891 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 8' ' ' SER . . . . . . . . . . . . . 59.6 p -167.63 -173.64 2.24 Favored 'General case' 0 N--CA 1.482 1.143 0 CA-C-O 121.04 0.448 . . . . 0.0 110.621 179.202 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.28 47.19 1.34 Allowed Glycine 0 N--CA 1.482 1.702 0 CA-C-N 115.995 -0.548 . . . . 0.0 112.11 179.892 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 49.6 p90 -66.62 132.49 48.29 Favored 'General case' 0 N--CA 1.473 0.713 0 CA-C-O 120.761 0.315 . . . . 0.0 111.571 179.655 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 48.4 mt-10 -91.45 152.63 20.29 Favored 'General case' 0 N--CA 1.475 0.806 0 N-CA-C 109.719 -0.474 . . . . 0.0 109.719 178.253 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -153.33 128.01 1.44 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.548 0 N-CA-C 107.873 -1.158 . . . . 0.0 107.873 178.183 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 43.7 m-70 -135.92 148.51 48.58 Favored 'General case' 0 N--CA 1.492 1.643 0 CA-C-N 118.932 0.787 . . . . 0.0 111.305 -179.055 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 7.1 t60 -163.86 97.56 0.85 Allowed 'General case' 0 N--CA 1.483 1.182 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.794 179.475 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 15' ' ' GLN . . . . . 0.539 HE22 ' H ' ' C' ' 37' ' ' GLY . 3.4 pt20 -107.43 -175.09 2.69 Favored 'General case' 0 CA--C 1.508 -0.662 0 N-CA-C 108.237 -1.023 . . . . 0.0 108.237 -179.96 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -170.29 100.27 0.27 Allowed 'General case' 0 N--CA 1.471 0.577 0 CA-C-N 114.59 -1.186 . . . . 0.0 108.415 179.192 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 17' ' ' LEU . . . . . 0.525 ' H ' ' CD2' ' F' ' 17' ' ' LEU . 6.9 mt -125.14 153.47 42.96 Favored 'General case' 0 N--CA 1.492 1.665 0 CA-C-O 121.52 0.676 . . . . 0.0 111.03 -178.217 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 61.2 t -108.07 130.22 60.97 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.188 0 N-CA-C 108.229 -1.026 . . . . 0.0 108.229 177.844 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 44.3 m-85 -127.16 121.99 32.89 Favored 'General case' 0 N--CA 1.493 1.68 0 CA-C-N 119.655 1.116 . . . . 0.0 110.349 179.454 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 74.2 m-85 52.84 75.22 0.25 Allowed 'General case' 0 N--CA 1.469 0.508 0 CA-C-O 121.518 0.675 . . . . 0.0 111.98 178.529 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -79.83 -77.97 0.17 Allowed 'General case' 0 C--N 1.35 0.6 0 CA-C-N 114.876 -1.056 . . . . 0.0 110.267 -179.814 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 39.8 tt0 -112.68 100.71 8.92 Favored 'General case' 0 N--CA 1.471 0.586 0 N-CA-C 108.3 -1.0 . . . . 0.0 108.3 179.736 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -159.41 140.83 12.98 Favored 'General case' 0 N--CA 1.483 1.178 0 O-C-N 122.22 -0.3 . . . . 0.0 111.226 179.124 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 24' ' ' VAL . . . . . 0.416 HG12 ' N ' ' C' ' 25' ' ' GLY . 60.2 t -60.39 164.34 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.871 0 N-CA-C 108.087 -1.079 . . . . 0.0 108.087 177.23 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 25' ' ' GLY . . . . . 0.447 ' H ' ' HB ' ' F' ' 24' ' ' VAL . . . -117.63 48.82 0.91 Allowed Glycine 0 N--CA 1.479 1.519 0 N-CA-C 111.45 -0.66 . . . . 0.0 111.45 -179.43 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -61.91 -167.92 0.01 OUTLIER 'General case' 0 N--CA 1.468 0.425 0 O-C-N 123.707 0.298 . . . . 0.0 110.386 179.547 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 3.2 t30 -70.54 80.9 0.58 Allowed 'General case' 0 N--CA 1.466 0.353 0 N-CA-C 110.113 -0.329 . . . . 0.0 110.113 179.692 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -79.51 146.57 32.61 Favored 'General case' 0 N--CA 1.473 0.698 0 N-CA-C 109.065 -0.717 . . . . 0.0 109.065 179.239 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.08 -168.76 1.0 Allowed Glycine 0 CA--C 1.525 0.699 0 N-CA-C 109.98 -1.248 . . . . 0.0 109.98 178.806 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.96 116.35 31.82 Favored 'General case' 0 N--CA 1.478 0.974 0 N-CA-C 109.657 -0.498 . . . . 0.0 109.657 179.757 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 69.3 mt -97.45 135.13 32.87 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.54 0 N-CA-C 107.16 -1.422 . . . . 0.0 107.16 179.034 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 43.9 pt -151.12 -177.91 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.649 0 CA-C-N 115.995 -0.548 . . . . 0.0 111.304 -178.691 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.59 5.58 13.11 Favored Glycine 0 CA--C 1.524 0.6 0 N-CA-C 110.853 -0.899 . . . . 0.0 110.853 -179.987 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 34' ' ' LEU . . . . . 0.413 HD23 ' N ' ' C' ' 35' ' ' MET . 1.4 tt -74.07 128.17 34.84 Favored 'General case' 0 CA--C 1.545 0.774 0 N-CA-C 109.626 -0.509 . . . . 0.0 109.626 -179.738 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 35' ' ' MET . . . . . 0.413 ' N ' HD23 ' C' ' 34' ' ' LEU . 28.5 ttt -162.94 147.38 11.44 Favored 'General case' 0 N--CA 1.466 0.364 0 N-CA-C 108.679 -0.86 . . . . 0.0 108.679 178.666 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 36' ' ' VAL . . . . . 0.521 HG22 HG12 ' F' ' 36' ' ' VAL . 33.7 m -155.25 163.38 1.57 Allowed 'Isoleucine or valine' 0 C--N 1.348 0.516 0 N-CA-C 108.125 -1.065 . . . . 0.0 108.125 179.49 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 37' ' ' GLY . . . . . 0.539 ' H ' HE22 ' C' ' 15' ' ' GLN . . . 55.32 67.85 1.99 Allowed Glycine 0 C--N 1.306 -1.135 0 CA-C-N 115.881 -0.6 . . . . 0.0 112.104 178.712 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 141.67 176.07 15.66 Favored Glycine 0 N--CA 1.475 1.248 0 N-CA-C 110.885 -0.886 . . . . 0.0 110.885 179.11 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 39' ' ' VAL . . . . . 0.505 ' H ' HG12 ' F' ' 39' ' ' VAL . 35.6 m -119.16 159.56 19.77 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.878 0 C-N-CA 123.349 0.66 . . . . 0.0 110.451 179.891 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 21.9 t . . . . . 0 N--CA 1.467 0.4 0 CA-C-O 118.45 -0.786 . . . . 0.0 110.473 179.443 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' D' D ' 1' ' ' ASP . . . . . . . . . . . . . 14.6 m-20 . . . . . 0 N--CA 1.49 1.534 0 N-CA-C 109.035 -0.728 . . . . 0.0 109.035 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' D' D ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.42 131.05 46.09 Favored 'General case' 0 CA--C 1.537 0.474 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.366 -179.824 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' D' D ' 3' ' ' GLU . . . . . . . . . . . . . 44.2 tt0 -169.23 108.01 0.43 Allowed 'General case' 0 C--O 1.217 -0.621 0 N-CA-C 110.028 -0.36 . . . . 0.0 110.028 -179.582 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 42.3 m-85 -89.17 156.12 18.99 Favored 'General case' 0 C--N 1.358 0.944 0 N-CA-C 108.941 -0.763 . . . . 0.0 108.941 -179.977 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' D' D ' 5' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -144.54 139.7 28.35 Favored 'General case' 0 N--CA 1.475 0.797 0 CA-C-N 116.374 -0.375 . . . . 0.0 110.214 179.869 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 41.0 t-80 -149.77 123.96 9.49 Favored 'General case' 0 CA--C 1.545 0.782 0 N-CA-C 108.142 -1.058 . . . . 0.0 108.142 174.72 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' D' D ' 7' ' ' ASP . . . . . 0.584 ' O ' ' OG ' ' G' ' 8' ' ' SER . 3.1 m-20 -63.6 132.98 52.89 Favored 'General case' 0 C--N 1.321 -0.647 0 C-N-CA 126.846 2.058 . . . . 0.0 114.209 174.62 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' D' D ' 8' ' ' SER . . . . . 0.488 ' OG ' ' O ' ' A' ' 7' ' ' ASP . 59.8 p -154.51 -170.8 3.64 Favored 'General case' 0 N--CA 1.488 1.454 0 CA-C-N 119.675 1.125 . . . . 0.0 111.255 175.246 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.39 47.91 1.17 Allowed Glycine 0 N--CA 1.481 1.666 0 C-N-CA 124.663 1.125 . . . . 0.0 110.632 174.321 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 51.5 p90 -60.99 131.56 51.02 Favored 'General case' 0 N--CA 1.47 0.526 0 N-CA-C 112.613 0.598 . . . . 0.0 112.613 177.559 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 48.3 mt-10 -89.64 151.01 22.11 Favored 'General case' 0 N--CA 1.479 1.025 0 CA-C-N 117.989 0.359 . . . . 0.0 110.662 174.982 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.0 p -149.64 129.95 4.22 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.662 0 N-CA-C 107.307 -1.368 . . . . 0.0 107.307 173.058 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 38.6 m-70 -129.79 151.63 50.16 Favored 'General case' 0 N--CA 1.483 1.182 0 N-CA-C 112.264 0.468 . . . . 0.0 112.264 176.639 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 7.3 t60 -164.68 104.75 0.82 Allowed 'General case' 0 N--CA 1.483 1.201 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 172.261 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' D' D ' 15' ' ' GLN . . . . . 0.482 HE22 ' H ' ' D' ' 37' ' ' GLY . 3.4 pt20 -111.05 -176.47 2.96 Favored 'General case' 0 CA--C 1.502 -0.884 0 N-CA-C 108.002 -1.11 . . . . 0.0 108.002 179.007 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -167.03 106.44 0.59 Allowed 'General case' 0 N--CA 1.466 0.337 0 N-CA-C 106.947 -1.501 . . . . 0.0 106.947 176.404 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' D' D ' 17' ' ' LEU . . . . . 0.554 ' H ' ' CD2' ' G' ' 17' ' ' LEU . 9.9 mt -130.57 152.35 50.04 Favored 'General case' 0 N--CA 1.493 1.702 0 CA-C-O 121.864 0.84 . . . . 0.0 110.493 179.651 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 38.6 t -99.65 133.09 43.73 Favored 'Isoleucine or valine' 0 C--O 1.259 1.596 0 CA-C-O 116.97 -1.49 . . . . 0.0 109.645 175.007 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 40.6 m-85 -130.04 125.97 36.54 Favored 'General case' 0 N--CA 1.489 1.523 0 CA-C-N 119.792 1.178 . . . . 0.0 109.357 174.144 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 74.1 m-85 55.87 71.87 0.53 Allowed 'General case' 0 C--N 1.352 0.693 0 CA-C-N 115.105 -0.952 . . . . 0.0 111.411 176.063 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -81.82 -73.0 0.41 Allowed 'General case' 0 N--CA 1.472 0.66 0 CA-C-O 118.369 -0.824 . . . . 0.0 111.005 -177.305 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 40.3 tt0 -115.98 104.17 11.33 Favored 'General case' 0 N--CA 1.484 1.262 0 N-CA-C 106.404 -1.702 . . . . 0.0 106.404 176.392 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -152.21 140.8 20.77 Favored 'General case' 0 N--CA 1.475 0.789 0 CA-C-O 116.748 -1.596 . . . . 0.0 113.634 177.867 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' D' D ' 24' ' ' VAL . . . . . 0.444 ' HB ' ' H ' ' A' ' 25' ' ' GLY . 66.7 t -62.95 166.57 0.97 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.237 0 CA-C-N 121.097 1.771 . . . . 0.0 107.979 174.782 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' D' D ' 25' ' ' GLY . . . . . 0.503 ' H ' ' HB ' ' G' ' 24' ' ' VAL . . . -116.67 51.07 0.75 Allowed Glycine 0 N--CA 1.481 1.667 0 CA-C-O 118.876 -0.958 . . . . 0.0 111.715 178.636 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -58.29 -170.73 0.01 OUTLIER 'General case' 0 C--N 1.322 -0.619 0 C-N-CA 123.38 0.672 . . . . 0.0 111.637 176.638 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 3.9 t30 -72.43 86.71 1.15 Allowed 'General case' 0 CA--C 1.537 0.453 0 N-CA-C 108.425 -0.954 . . . . 0.0 108.425 178.45 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 97.6 mttt -84.26 148.71 26.55 Favored 'General case' 0 N--CA 1.474 0.758 0 N-CA-C 108.155 -1.054 . . . . 0.0 108.155 178.884 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -62.7 -165.73 0.55 Allowed Glycine 0 C--N 1.337 0.614 0 N-CA-C 110.461 -1.056 . . . . 0.0 110.461 179.374 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -102.09 115.99 31.72 Favored 'General case' 0 N--CA 1.467 0.385 0 C-N-CA 123.186 0.595 . . . . 0.0 109.921 179.832 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 80.4 mt -102.41 142.46 16.6 Favored 'Isoleucine or valine' 0 C--N 1.355 0.836 0 N-CA-C 104.327 -2.472 . . . . 0.0 104.327 -178.908 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 38.6 pt -157.68 -179.05 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.241 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.118 -176.161 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 64.73 5.7 19.6 Favored Glycine 0 C--O 1.244 0.758 0 N-CA-C 110.003 -1.239 . . . . 0.0 110.003 -178.573 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 1.7 tt -76.42 134.14 39.68 Favored 'General case' 0 C--N 1.361 1.084 0 N-CA-C 107.244 -1.391 . . . . 0.0 107.244 -177.829 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' D' D ' 35' ' ' MET . . . . . 0.405 ' C ' HG13 ' D' ' 36' ' ' VAL . 28.2 ttt -157.91 159.99 37.15 Favored 'General case' 0 CA--C 1.517 -0.319 0 N-CA-C 108.225 -1.028 . . . . 0.0 108.225 172.577 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' D' D ' 36' ' ' VAL . . . . . 0.578 HG22 HG12 ' G' ' 36' ' ' VAL . 31.0 m -164.8 163.63 0.71 Allowed 'Isoleucine or valine' 0 C--O 1.223 -0.31 0 N-CA-C 107.765 -1.198 . . . . 0.0 107.765 174.232 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' D' D ' 37' ' ' GLY . . . . . 0.482 ' H ' HE22 ' D' ' 15' ' ' GLN . . . 59.9 63.71 4.84 Favored Glycine 0 CA--C 1.528 0.884 0 C-N-CA 120.435 -0.888 . . . . 0.0 111.335 178.024 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.18 179.66 20.01 Favored Glycine 0 N--CA 1.481 1.651 0 N-CA-C 111.057 -0.817 . . . . 0.0 111.057 178.352 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' D' D ' 39' ' ' VAL . . . . . 0.529 ' H ' HG12 ' G' ' 39' ' ' VAL . 33.9 m -120.54 157.02 23.56 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.822 0 C-N-CA 123.133 0.573 . . . . 0.0 110.94 179.461 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 22.0 t . . . . . 0 C--N 1.333 -0.14 0 CA-C-O 116.665 -1.636 . . . . 0.0 109.536 175.794 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' E' E ' 1' ' ' ASP . . . . . . . . . . . . . 14.6 m-20 . . . . . 0 N--CA 1.49 1.535 0 N-CA-C 109.427 -0.582 . . . . 0.0 109.427 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' E' E ' 2' ' ' ALA . . . . . . . . . . . . . . . -63.67 129.69 41.2 Favored 'General case' 0 N--CA 1.468 0.472 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.455 -179.939 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' E' E ' 3' ' ' GLU . . . . . . . . . . . . . 44.2 tt0 -167.26 106.03 0.57 Allowed 'General case' 0 C--O 1.213 -0.858 0 CA-C-N 116.732 -0.213 . . . . 0.0 110.648 -179.723 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 38.8 m-85 -86.04 151.43 23.72 Favored 'General case' 0 N--CA 1.475 0.806 0 N-CA-C 110.152 -0.314 . . . . 0.0 110.152 179.297 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' E' E ' 5' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -142.72 140.97 31.69 Favored 'General case' 0 N--CA 1.482 1.126 0 CA-C-O 120.904 0.383 . . . . 0.0 110.077 179.395 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 45.0 t-80 -151.4 118.8 6.0 Favored 'General case' 0 N--CA 1.472 0.669 0 N-CA-C 109.227 -0.657 . . . . 0.0 109.227 178.83 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' E' E ' 7' ' ' ASP . . . . . 0.441 ' O ' ' OG ' ' H' ' 8' ' ' SER . 4.2 m-20 -69.57 148.66 49.1 Favored 'General case' 0 N--CA 1.467 0.379 0 CA-C-N 116.435 -0.348 . . . . 0.0 110.745 179.941 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' E' E ' 8' ' ' SER . . . . . 0.441 ' OG ' ' O ' ' B' ' 7' ' ' ASP . 56.0 p -168.26 -172.51 1.76 Allowed 'General case' 0 N--CA 1.486 1.343 0 CA-C-O 121.099 0.476 . . . . 0.0 110.784 178.917 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.71 47.09 1.31 Allowed Glycine 0 N--CA 1.478 1.493 0 CA-C-N 115.912 -0.585 . . . . 0.0 112.101 179.807 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 47.7 p90 -65.82 133.22 50.51 Favored 'General case' 0 N--CA 1.473 0.721 0 N-CA-C 111.908 0.336 . . . . 0.0 111.908 -179.948 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 48.6 mt-10 -91.47 152.98 20.13 Favored 'General case' 0 N--CA 1.48 1.054 0 CA-C-O 121.245 0.545 . . . . 0.0 109.629 177.943 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -154.97 126.78 0.95 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.63 0 N-CA-C 107.739 -1.208 . . . . 0.0 107.739 178.135 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 42.2 m-70 -135.69 146.86 48.2 Favored 'General case' 0 N--CA 1.482 1.14 0 CA-C-O 120.849 0.357 . . . . 0.0 111.531 -178.126 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 7.1 t60 -163.0 97.64 0.93 Allowed 'General case' 0 N--CA 1.485 1.288 0 CA-C-N 116.365 -0.38 . . . . 0.0 110.717 179.506 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' E' E ' 15' ' ' GLN . . . . . 0.515 HE22 ' H ' ' E' ' 37' ' ' GLY . 3.4 pt20 -106.99 -175.22 2.73 Favored 'General case' 0 CA--C 1.51 -0.564 0 N-CA-C 108.521 -0.918 . . . . 0.0 108.521 -179.928 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -169.84 99.81 0.31 Allowed 'General case' 0 N--CA 1.473 0.713 0 CA-C-N 114.654 -1.157 . . . . 0.0 108.617 179.004 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' E' E ' 17' ' ' LEU . . . . . 0.563 ' H ' ' CD2' ' H' ' 17' ' ' LEU . 7.3 mt -123.9 153.89 40.5 Favored 'General case' 0 N--CA 1.49 1.549 0 CA-C-O 121.348 0.594 . . . . 0.0 111.505 -177.767 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 49.9 t -110.7 126.3 68.04 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.307 0 N-CA-C 108.205 -1.035 . . . . 0.0 108.205 177.604 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 46.6 m-85 -123.79 121.22 34.87 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 123.37 0.419 . . . . 0.0 111.038 -179.821 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 73.7 m-85 54.06 74.33 0.34 Allowed 'General case' 0 N--CA 1.47 0.542 0 CA-C-N 115.922 -0.581 . . . . 0.0 111.594 178.061 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -78.18 -78.96 0.13 Allowed 'General case' 0 CA--C 1.535 0.375 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.095 -179.488 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 39.9 tt0 -111.67 100.97 9.39 Favored 'General case' 0 N--CA 1.469 0.482 0 N-CA-C 108.438 -0.949 . . . . 0.0 108.438 -179.989 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -158.61 140.73 13.95 Favored 'General case' 0 C--O 1.204 -1.296 0 CA-C-O 119.581 -0.247 . . . . 0.0 111.535 179.147 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' E' E ' 24' ' ' VAL . . . . . 0.466 ' HB ' ' H ' ' B' ' 25' ' ' GLY . 57.6 t -58.86 169.03 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.851 0 N-CA-C 107.691 -1.225 . . . . 0.0 107.691 177.017 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' E' E ' 25' ' ' GLY . . . . . 0.432 ' N ' HG12 ' E' ' 24' ' ' VAL . . . -122.51 49.59 0.88 Allowed Glycine 0 N--CA 1.477 1.383 0 N-CA-C 110.674 -0.971 . . . . 0.0 110.674 -179.479 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -63.07 -167.57 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.553 0 CA-C-O 120.644 0.259 . . . . 0.0 110.601 179.774 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 4.0 t30 -69.93 78.12 0.48 Allowed 'General case' 0 N--CA 1.466 0.351 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.383 -179.944 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -77.32 146.73 36.58 Favored 'General case' 0 N--CA 1.475 0.81 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 179.28 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.39 -168.33 1.08 Allowed Glycine 0 CA--C 1.522 0.518 0 N-CA-C 110.522 -1.031 . . . . 0.0 110.522 178.623 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.74 115.45 29.55 Favored 'General case' 0 N--CA 1.468 0.461 0 N-CA-C 109.904 -0.406 . . . . 0.0 109.904 179.471 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 70.5 mt -96.38 135.09 31.6 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.282 0 N-CA-C 106.942 -1.503 . . . . 0.0 106.942 179.037 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 39.0 pt -151.1 -176.16 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.229 0 CA-C-O 121.164 0.506 . . . . 0.0 110.737 -179.157 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.2 5.97 9.25 Favored Glycine 0 CA--C 1.529 0.963 0 CA-C-N 115.322 -0.853 . . . . 0.0 111.243 -179.517 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 1.4 tt -73.8 128.68 36.16 Favored 'General case' 0 CA--C 1.548 0.884 0 N-CA-C 109.629 -0.508 . . . . 0.0 109.629 -179.544 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 28.4 ttt -162.93 148.79 12.11 Favored 'General case' 0 C--O 1.209 -1.056 0 N-CA-C 108.925 -0.769 . . . . 0.0 108.925 178.484 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' E' E ' 36' ' ' VAL . . . . . 0.572 HG22 HG12 ' H' ' 36' ' ' VAL . 34.0 m -156.97 162.73 1.5 Allowed 'Isoleucine or valine' 0 C--N 1.344 0.344 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 179.862 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' E' E ' 37' ' ' GLY . . . . . 0.515 ' H ' HE22 ' E' ' 15' ' ' GLN . . . 55.94 66.8 2.59 Favored Glycine 0 C--N 1.307 -1.06 0 CA-C-N 115.933 -0.576 . . . . 0.0 111.939 178.537 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 142.56 176.81 17.01 Favored Glycine 0 N--CA 1.477 1.382 0 N-CA-C 111.149 -0.78 . . . . 0.0 111.149 179.007 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' E' E ' 39' ' ' VAL . . . . . 0.544 ' H ' HG12 ' H' ' 39' ' ' VAL . 33.3 m -119.93 158.62 21.68 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.749 0 C-N-CA 123.392 0.677 . . . . 0.0 110.626 -179.595 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 22.6 t . . . . . 0 C--O 1.22 -0.478 0 CA-C-O 118.448 -0.787 . . . . 0.0 110.482 179.112 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' F' F ' 1' ' ' ASP . . . . . . . . . . . . . 15.0 m-20 . . . . . 0 N--CA 1.49 1.571 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' F' F ' 2' ' ' ALA . . . . . . . . . . . . . . . -63.68 130.01 42.48 Favored 'General case' 0 N--CA 1.467 0.422 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.504 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' F' F ' 3' ' ' GLU . . . . . . . . . . . . . 44.2 tt0 -167.49 106.12 0.55 Allowed 'General case' 0 C--O 1.212 -0.918 0 CA-C-N 116.743 -0.208 . . . . 0.0 110.466 -179.666 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 38.2 m-85 -86.29 151.29 23.72 Favored 'General case' 0 N--CA 1.474 0.75 0 N-CA-C 110.135 -0.32 . . . . 0.0 110.135 179.264 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' F' F ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -142.47 141.24 32.13 Favored 'General case' 0 N--CA 1.478 0.959 0 CA-C-O 120.805 0.336 . . . . 0.0 110.249 179.41 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 43.9 t-80 -151.92 118.74 5.78 Favored 'General case' 0 N--CA 1.472 0.659 0 N-CA-C 109.315 -0.624 . . . . 0.0 109.315 178.928 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' F' F ' 7' ' ' ASP . . . . . 0.477 ' O ' ' OG ' ' I' ' 8' ' ' SER . 4.3 m-20 -69.35 148.64 49.39 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 116.411 -0.359 . . . . 0.0 110.814 -179.96 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' F' F ' 8' ' ' SER . . . . . 0.482 ' OG ' ' O ' ' C' ' 7' ' ' ASP . 56.1 p -168.33 -172.79 1.81 Allowed 'General case' 0 N--CA 1.487 1.422 0 CA-C-O 121.111 0.482 . . . . 0.0 110.924 178.8 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.93 47.01 1.3 Allowed Glycine 0 N--CA 1.479 1.502 0 CA-C-N 115.978 -0.556 . . . . 0.0 112.064 179.877 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 47.7 p90 -65.57 133.03 50.32 Favored 'General case' 0 CA--C 1.543 0.673 0 N-CA-C 111.852 0.316 . . . . 0.0 111.852 -179.954 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 48.3 mt-10 -91.48 152.33 20.4 Favored 'General case' 0 N--CA 1.48 1.042 0 CA-C-O 121.195 0.521 . . . . 0.0 109.713 177.818 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -154.18 126.87 1.09 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.608 0 N-CA-C 107.825 -1.176 . . . . 0.0 107.825 177.997 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 41.9 m-70 -135.67 146.9 48.29 Favored 'General case' 0 N--CA 1.483 1.2 0 CA-C-O 120.936 0.398 . . . . 0.0 111.582 -178.142 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 7.1 t60 -162.98 97.49 0.93 Allowed 'General case' 0 N--CA 1.486 1.371 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.821 179.55 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' F' F ' 15' ' ' GLN . . . . . 0.526 HE22 ' H ' ' F' ' 37' ' ' GLY . 3.4 pt20 -107.06 -175.22 2.73 Favored 'General case' 0 CA--C 1.507 -0.675 0 N-CA-C 108.482 -0.932 . . . . 0.0 108.482 -179.939 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -169.77 99.86 0.31 Allowed 'General case' 0 N--CA 1.47 0.572 0 CA-C-N 114.712 -1.131 . . . . 0.0 108.606 179.052 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' F' F ' 17' ' ' LEU . . . . . 0.559 ' H ' ' CD2' ' I' ' 17' ' ' LEU . 7.2 mt -123.81 154.33 39.73 Favored 'General case' 0 N--CA 1.489 1.501 0 CA-C-O 121.273 0.558 . . . . 0.0 111.461 -177.735 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 51.8 t -111.07 126.21 68.45 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.325 0 N-CA-C 108.262 -1.014 . . . . 0.0 108.262 177.529 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 47.0 m-85 -123.71 121.15 34.76 Favored 'General case' 0 C--N 1.367 1.363 0 CA-C-O 120.972 0.415 . . . . 0.0 111.018 -179.819 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 74.1 m-85 54.23 74.31 0.34 Allowed 'General case' 0 N--CA 1.469 0.477 0 CA-C-N 115.871 -0.604 . . . . 0.0 111.743 178.054 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -78.15 -78.98 0.13 Allowed 'General case' 0 N--CA 1.465 0.32 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.228 -179.551 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 39.7 tt0 -111.71 101.19 9.58 Favored 'General case' 0 N--CA 1.469 0.5 0 N-CA-C 108.325 -0.991 . . . . 0.0 108.325 -179.986 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -158.86 140.6 13.53 Favored 'General case' 0 C--O 1.205 -1.277 0 CA-C-O 119.584 -0.246 . . . . 0.0 111.483 179.089 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' F' F ' 24' ' ' VAL . . . . . 0.447 ' HB ' ' H ' ' C' ' 25' ' ' GLY . 57.4 t -58.81 168.91 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.885 0 N-CA-C 107.591 -1.263 . . . . 0.0 107.591 177.057 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' F' F ' 25' ' ' GLY . . . . . 0.436 ' N ' HG12 ' F' ' 24' ' ' VAL . . . -122.31 49.4 0.89 Allowed Glycine 0 N--CA 1.477 1.402 0 N-CA-C 110.751 -0.94 . . . . 0.0 110.751 -179.478 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -63.16 -168.39 0.02 OUTLIER 'General case' 0 N--CA 1.469 0.489 0 CA-C-O 120.635 0.255 . . . . 0.0 110.447 -179.975 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 4.0 t30 -69.11 77.96 0.34 Allowed 'General case' 0 CA--C 1.533 0.292 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.484 -179.908 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -77.18 147.02 36.69 Favored 'General case' 0 N--CA 1.475 0.816 0 N-CA-C 109.468 -0.567 . . . . 0.0 109.468 179.239 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.44 -168.11 1.07 Allowed Glycine 0 CA--C 1.522 0.481 0 N-CA-C 110.612 -0.995 . . . . 0.0 110.612 178.569 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.54 114.85 28.1 Favored 'General case' 0 N--CA 1.469 0.504 0 N-CA-C 109.891 -0.411 . . . . 0.0 109.891 179.484 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 70.6 mt -96.16 135.02 31.59 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.298 0 N-CA-C 106.987 -1.486 . . . . 0.0 106.987 178.895 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 38.6 pt -151.16 -176.32 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.251 0 CA-C-O 121.191 0.519 . . . . 0.0 110.739 -179.184 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.39 6.0 9.79 Favored Glycine 0 CA--C 1.529 0.937 0 CA-C-N 115.29 -0.868 . . . . 0.0 111.186 -179.622 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' F' F ' 34' ' ' LEU . . . . . 0.403 HD23 ' N ' ' F' ' 35' ' ' MET . 1.3 tt -73.64 128.69 36.18 Favored 'General case' 0 CA--C 1.549 0.913 0 N-CA-C 109.538 -0.541 . . . . 0.0 109.538 -179.586 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' F' F ' 35' ' ' MET . . . . . 0.403 ' N ' HD23 ' F' ' 34' ' ' LEU . 28.4 ttt -162.96 148.73 12.03 Favored 'General case' 0 C--O 1.208 -1.094 0 N-CA-C 108.82 -0.807 . . . . 0.0 108.82 178.378 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' F' F ' 36' ' ' VAL . . . . . 0.575 HG22 HG12 ' I' ' 36' ' ' VAL . 34.1 m -156.75 163.0 1.46 Allowed 'Isoleucine or valine' 0 C--N 1.346 0.429 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 179.872 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' F' F ' 37' ' ' GLY . . . . . 0.526 ' H ' HE22 ' F' ' 15' ' ' GLN . . . 55.58 67.1 2.39 Favored Glycine 0 C--N 1.307 -1.061 0 CA-C-N 115.944 -0.571 . . . . 0.0 111.947 178.45 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 142.35 176.85 16.87 Favored Glycine 0 N--CA 1.476 1.325 0 N-CA-C 111.155 -0.778 . . . . 0.0 111.155 179.036 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' F' F ' 39' ' ' VAL . . . . . 0.531 ' H ' HG12 ' I' ' 39' ' ' VAL . 33.4 m -119.95 158.92 21.55 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.629 0 C-N-CA 123.374 0.67 . . . . 0.0 110.649 -179.675 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 23.6 t . . . . . 0 C--O 1.221 -0.417 0 CA-C-O 118.549 -0.738 . . . . 0.0 110.499 179.071 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' G' G ' 1' ' ' ASP . . . . . . . . . . . . . 14.2 m-20 . . . . . 0 N--CA 1.492 1.645 0 N-CA-C 109.392 -0.596 . . . . 0.0 109.392 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' G' G ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.81 128.84 37.77 Favored 'General case' 0 N--CA 1.468 0.448 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.637 179.642 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' G' G ' 3' ' ' GLU . . . . . . . . . . . . . 43.6 tt0 -168.1 107.01 0.51 Allowed 'General case' 0 N--CA 1.472 0.641 0 CA-C-O 120.52 0.2 . . . . 0.0 110.806 179.841 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 40.8 m-85 -87.98 151.22 22.94 Favored 'General case' 0 N--CA 1.473 0.719 0 N-CA-C 109.643 -0.503 . . . . 0.0 109.643 179.142 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' G' G ' 5' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -142.98 141.02 31.3 Favored 'General case' 0 N--CA 1.482 1.15 0 CA-C-O 120.816 0.341 . . . . 0.0 110.188 179.721 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 44.3 t-80 -151.53 119.48 6.22 Favored 'General case' 0 N--CA 1.474 0.743 0 N-CA-C 109.384 -0.599 . . . . 0.0 109.384 178.948 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -71.04 144.53 50.36 Favored 'General case' 0 N--CA 1.471 0.583 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.212 -179.822 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' G' G ' 8' ' ' SER . . . . . 0.584 ' OG ' ' O ' ' D' ' 7' ' ' ASP . 54.4 p -165.31 -171.22 2.1 Favored 'General case' 0 N--CA 1.476 0.861 0 CA-C-O 121.054 0.454 . . . . 0.0 110.436 178.644 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.88 46.76 1.33 Allowed Glycine 0 N--CA 1.479 1.566 0 CA-C-N 115.809 -0.632 . . . . 0.0 111.607 179.533 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 50.0 p90 -65.44 133.05 50.48 Favored 'General case' 0 N--CA 1.472 0.649 0 N-CA-C 111.835 0.309 . . . . 0.0 111.835 -179.795 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 49.1 mt-10 -91.88 151.89 20.34 Favored 'General case' 0 N--CA 1.479 1.001 0 CA-C-O 121.108 0.48 . . . . 0.0 110.062 178.401 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -155.08 127.04 0.97 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.021 0 N-CA-C 107.886 -1.153 . . . . 0.0 107.886 178.33 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 43.1 m-70 -135.01 148.39 49.94 Favored 'General case' 0 N--CA 1.478 0.944 0 CA-C-N 115.49 -0.777 . . . . 0.0 111.414 -178.399 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 35.5 t-80 -164.49 97.29 0.78 Allowed 'General case' 0 N--CA 1.484 1.227 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.486 178.907 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' G' G ' 15' ' ' GLN . . . . . 0.527 HE22 ' H ' ' G' ' 37' ' ' GLY . 3.5 pt20 -106.88 -175.67 2.86 Favored 'General case' 0 CA--C 1.508 -0.664 0 N-CA-C 108.364 -0.976 . . . . 0.0 108.364 -179.821 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -169.98 99.52 0.29 Allowed 'General case' 0 N--CA 1.473 0.691 0 CA-C-N 114.649 -1.159 . . . . 0.0 108.345 179.176 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' G' G ' 17' ' ' LEU . . . . . 0.554 ' CD2' ' H ' ' D' ' 17' ' ' LEU . 8.2 mt -123.4 153.94 39.69 Favored 'General case' 0 N--CA 1.495 1.786 0 CA-C-O 121.085 0.469 . . . . 0.0 111.789 -177.863 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 43.4 t -111.26 126.39 68.65 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.038 0 N-CA-C 108.1 -1.074 . . . . 0.0 108.1 177.021 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 48.0 m-85 -124.12 120.77 33.3 Favored 'General case' 0 C--N 1.367 1.346 0 CA-C-N 115.602 -0.726 . . . . 0.0 111.192 -179.539 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 73.8 m-85 54.46 73.66 0.39 Allowed 'General case' 0 N--CA 1.47 0.526 0 CA-C-N 115.896 -0.593 . . . . 0.0 111.594 178.008 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.04 -78.32 0.13 Allowed 'General case' 0 N--CA 1.471 0.59 0 O-C-N 122.282 -0.262 . . . . 0.0 110.446 -179.032 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 40.4 tt0 -112.25 101.07 9.32 Favored 'General case' 0 C--N 1.322 -0.629 0 N-CA-C 108.108 -1.071 . . . . 0.0 108.108 179.839 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -158.38 142.38 15.6 Favored 'General case' 0 N--CA 1.478 0.926 0 O-C-N 122.387 -0.195 . . . . 0.0 111.442 179.01 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' G' G ' 24' ' ' VAL . . . . . 0.503 ' HB ' ' H ' ' D' ' 25' ' ' GLY . 59.7 t -60.97 167.76 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.644 0 N-CA-C 107.67 -1.233 . . . . 0.0 107.67 177.384 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' G' G ' 25' ' ' GLY . . . . . 0.437 ' N ' HG12 ' G' ' 24' ' ' VAL . . . -120.64 49.95 0.85 Allowed Glycine 0 N--CA 1.482 1.755 0 N-CA-C 110.338 -1.105 . . . . 0.0 110.338 -179.58 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -63.78 -167.61 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.661 0 CA-C-N 116.984 0.392 . . . . 0.0 109.987 179.833 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 3.4 t30 -70.11 77.71 0.51 Allowed 'General case' 0 CA--C 1.536 0.407 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.451 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -76.16 146.72 38.98 Favored 'General case' 0 N--CA 1.475 0.818 0 N-CA-C 109.506 -0.553 . . . . 0.0 109.506 179.306 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.62 -167.01 0.95 Allowed Glycine 0 C--N 1.336 0.578 0 N-CA-C 110.076 -1.21 . . . . 0.0 110.076 178.721 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.58 115.26 28.98 Favored 'General case' 0 N--CA 1.469 0.516 0 C-N-CA 122.689 0.395 . . . . 0.0 110.438 179.841 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 72.1 mt -97.1 135.99 29.41 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.671 0 N-CA-C 106.87 -1.53 . . . . 0.0 106.87 178.931 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 36.8 pt -152.47 -176.01 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.71 0 CA-C-N 119.855 1.207 . . . . 0.0 109.95 -179.631 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.09 5.83 11.27 Favored Glycine 0 CA--C 1.527 0.811 0 N-CA-C 110.878 -0.889 . . . . 0.0 110.878 -179.763 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' G' G ' 34' ' ' LEU . . . . . 0.408 HD23 ' N ' ' G' ' 35' ' ' MET . 1.4 tt -74.3 127.4 32.89 Favored 'General case' 0 CA--C 1.546 0.796 0 N-CA-C 109.7 -0.482 . . . . 0.0 109.7 -179.503 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' G' G ' 35' ' ' MET . . . . . 0.408 ' N ' HD23 ' G' ' 34' ' ' LEU . 28.1 ttt -161.56 150.22 15.73 Favored 'General case' 0 C--O 1.212 -0.897 0 N-CA-C 108.844 -0.798 . . . . 0.0 108.844 178.533 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' G' G ' 36' ' ' VAL . . . . . 0.578 HG12 HG22 ' D' ' 36' ' ' VAL . 33.9 m -157.4 162.11 1.62 Allowed 'Isoleucine or valine' 0 C--N 1.346 0.451 0 N-CA-C 108.628 -0.878 . . . . 0.0 108.628 -179.819 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' G' G ' 37' ' ' GLY . . . . . 0.527 ' H ' HE22 ' G' ' 15' ' ' GLN . . . 55.61 67.01 2.43 Favored Glycine 0 C--N 1.312 -0.803 0 CA-C-N 115.599 -0.728 . . . . 0.0 112.299 178.111 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.33 178.3 19.02 Favored Glycine 0 N--CA 1.477 1.383 0 N-CA-C 110.569 -1.012 . . . . 0.0 110.569 178.925 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' G' G ' 39' ' ' VAL . . . . . 0.529 HG12 ' H ' ' D' ' 39' ' ' VAL . 34.2 m -121.34 158.37 24.3 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.837 0 C-N-CA 123.128 0.571 . . . . 0.0 110.6 -179.621 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 22.2 t . . . . . 0 N--CA 1.469 0.515 0 O-C-N 123.981 0.801 . . . . 0.0 110.752 179.163 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' H' H ' 1' ' ' ASP . . . . . . . . . . . . . 14.7 m-20 . . . . . 0 N--CA 1.491 1.612 0 N-CA-C 109.4 -0.593 . . . . 0.0 109.4 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' H' H ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.75 128.83 37.74 Favored 'General case' 0 N--CA 1.467 0.4 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.612 179.843 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' H' H ' 3' ' ' GLU . . . . . . . . . . . . . 43.7 tt0 -168.12 106.88 0.51 Allowed 'General case' 0 N--CA 1.471 0.603 0 CA-C-O 120.567 0.222 . . . . 0.0 110.736 179.819 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 42.2 m-85 -87.81 151.2 23.05 Favored 'General case' 0 N--CA 1.474 0.744 0 N-CA-C 109.603 -0.517 . . . . 0.0 109.603 179.136 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' H' H ' 5' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -142.91 141.35 31.48 Favored 'General case' 0 N--CA 1.484 1.263 0 N-CA-C 110.081 -0.34 . . . . 0.0 110.081 179.732 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 44.3 t-80 -151.89 119.54 6.09 Favored 'General case' 0 N--CA 1.474 0.745 0 N-CA-C 109.334 -0.617 . . . . 0.0 109.334 178.901 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -70.96 144.57 50.49 Favored 'General case' 0 N--CA 1.47 0.57 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.251 -179.884 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' H' H ' 8' ' ' SER . . . . . 0.441 ' OG ' ' O ' ' E' ' 7' ' ' ASP . 60.2 p -165.26 -171.55 2.22 Favored 'General case' 0 N--CA 1.474 0.758 0 CA-C-O 120.976 0.417 . . . . 0.0 110.485 178.751 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.83 46.62 1.36 Allowed Glycine 0 N--CA 1.481 1.645 0 CA-C-N 115.986 -0.552 . . . . 0.0 111.756 179.699 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 50.3 p90 -65.64 133.15 50.52 Favored 'General case' 0 N--CA 1.471 0.625 0 N-CA-C 111.798 0.295 . . . . 0.0 111.798 -179.835 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 48.5 mt-10 -91.75 152.25 20.25 Favored 'General case' 0 N--CA 1.477 0.911 0 CA-C-O 121.127 0.489 . . . . 0.0 110.128 178.446 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -155.2 127.49 1.02 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.049 0 N-CA-C 107.83 -1.174 . . . . 0.0 107.83 178.346 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 44.1 m-70 -135.53 148.01 48.99 Favored 'General case' 0 N--CA 1.477 0.909 0 CA-C-N 115.566 -0.743 . . . . 0.0 111.396 -178.307 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 7.1 t60 -164.32 97.26 0.8 Allowed 'General case' 0 N--CA 1.484 1.226 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.45 178.915 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' H' H ' 15' ' ' GLN . . . . . 0.512 HE22 ' H ' ' H' ' 37' ' ' GLY . 3.5 pt20 -106.8 -175.67 2.86 Favored 'General case' 0 CA--C 1.508 -0.666 0 N-CA-C 108.278 -1.008 . . . . 0.0 108.278 -179.872 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -169.81 99.64 0.31 Allowed 'General case' 0 N--CA 1.472 0.653 0 CA-C-N 114.72 -1.127 . . . . 0.0 108.358 179.124 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' H' H ' 17' ' ' LEU . . . . . 0.563 ' CD2' ' H ' ' E' ' 17' ' ' LEU . 8.6 mt -123.44 154.08 39.57 Favored 'General case' 0 N--CA 1.495 1.819 0 CA-C-O 121.118 0.485 . . . . 0.0 111.86 -177.757 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 43.0 t -111.65 126.05 69.01 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.111 0 N-CA-C 108.077 -1.082 . . . . 0.0 108.077 177.087 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 47.5 m-85 -123.83 120.45 32.63 Favored 'General case' 0 C--N 1.368 1.392 0 CA-C-N 115.456 -0.793 . . . . 0.0 110.981 -179.332 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 73.4 m-85 54.11 74.33 0.34 Allowed 'General case' 0 C--N 1.345 0.399 0 CA-C-N 115.776 -0.647 . . . . 0.0 111.697 178.02 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.25 -78.15 0.13 Allowed 'General case' 0 N--CA 1.472 0.655 0 O-C-N 122.4 -0.188 . . . . 0.0 110.519 -179.117 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 40.3 tt0 -112.41 100.95 9.18 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 108.024 -1.102 . . . . 0.0 108.024 179.899 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -158.31 141.95 15.34 Favored 'General case' 0 N--CA 1.478 0.946 0 O-C-N 122.384 -0.198 . . . . 0.0 111.458 179.104 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' H' H ' 24' ' ' VAL . . . . . 0.433 HG12 ' N ' ' H' ' 25' ' ' GLY . 59.6 t -60.63 167.89 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.561 0 N-CA-C 107.664 -1.236 . . . . 0.0 107.664 177.389 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' H' H ' 25' ' ' GLY . . . . . 0.433 ' N ' HG12 ' H' ' 24' ' ' VAL . . . -120.89 49.27 0.89 Allowed Glycine 0 N--CA 1.48 1.609 0 N-CA-C 110.482 -1.047 . . . . 0.0 110.482 -179.385 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -63.24 -167.56 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.642 0 CA-C-N 117.009 0.405 . . . . 0.0 110.201 179.881 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 3.5 t30 -69.93 78.11 0.48 Allowed 'General case' 0 CA--C 1.535 0.388 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.411 179.903 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -76.76 146.55 37.86 Favored 'General case' 0 N--CA 1.476 0.842 0 N-CA-C 109.501 -0.555 . . . . 0.0 109.501 179.314 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.74 -167.12 1.01 Allowed Glycine 0 C--N 1.336 0.578 0 N-CA-C 110.045 -1.222 . . . . 0.0 110.045 178.757 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.84 115.11 28.82 Favored 'General case' 0 N--CA 1.467 0.378 0 C-N-CA 122.6 0.36 . . . . 0.0 110.579 -179.938 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 71.6 mt -96.84 136.02 29.03 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.729 0 N-CA-C 106.866 -1.531 . . . . 0.0 106.866 179.094 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 36.6 pt -152.42 -175.87 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.761 0 CA-C-N 119.814 1.188 . . . . 0.0 109.898 -179.716 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.5 7.0 12.59 Favored Glycine 0 CA--C 1.526 0.78 0 N-CA-C 110.879 -0.889 . . . . 0.0 110.879 -179.755 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 1.3 tt -75.33 127.12 32.44 Favored 'General case' 0 CA--C 1.545 0.775 0 N-CA-C 109.69 -0.485 . . . . 0.0 109.69 -179.728 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 28.0 ttt -161.31 150.03 16.04 Favored 'General case' 0 C--O 1.212 -0.917 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 178.61 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' H' H ' 36' ' ' VAL . . . . . 0.572 HG12 HG22 ' E' ' 36' ' ' VAL . 34.0 m -157.24 161.74 1.73 Allowed 'Isoleucine or valine' 0 C--N 1.345 0.398 0 N-CA-C 108.742 -0.836 . . . . 0.0 108.742 -179.665 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' H' H ' 37' ' ' GLY . . . . . 0.512 ' H ' HE22 ' H' ' 15' ' ' GLN . . . 55.81 66.89 2.52 Favored Glycine 0 C--N 1.311 -0.833 0 CA-C-N 115.673 -0.694 . . . . 0.0 112.261 178.172 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.46 178.09 18.96 Favored Glycine 0 N--CA 1.477 1.396 0 N-CA-C 110.644 -0.982 . . . . 0.0 110.644 179.026 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' H' H ' 39' ' ' VAL . . . . . 0.544 HG12 ' H ' ' E' ' 39' ' ' VAL . 34.1 m -121.12 158.43 23.81 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.846 0 C-N-CA 123.191 0.597 . . . . 0.0 110.772 -179.646 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 23.7 t . . . . . 0 N--CA 1.47 0.529 0 O-C-N 123.936 0.772 . . . . 0.0 110.694 179.149 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' I' I ' 1' ' ' ASP . . . . . . . . . . . . . 14.7 m-20 . . . . . 0 N--CA 1.49 1.566 0 N-CA-C 109.465 -0.569 . . . . 0.0 109.465 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' I' I ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.96 128.78 37.46 Favored 'General case' 0 N--CA 1.468 0.468 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.578 179.91 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' I' I ' 3' ' ' GLU . . . . . . . . . . . . . 43.6 tt0 -167.91 107.01 0.53 Allowed 'General case' 0 N--CA 1.471 0.61 0 CA-C-O 120.501 0.191 . . . . 0.0 110.796 179.781 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 41.0 m-85 -88.0 151.13 23.0 Favored 'General case' 0 N--CA 1.474 0.767 0 N-CA-C 109.579 -0.526 . . . . 0.0 109.579 179.176 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' I' I ' 5' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -142.81 141.35 31.62 Favored 'General case' 0 N--CA 1.483 1.224 0 C-N-CA 122.596 0.359 . . . . 0.0 110.143 179.787 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 45.0 t-80 -151.93 119.46 6.04 Favored 'General case' 0 N--CA 1.473 0.708 0 N-CA-C 109.379 -0.6 . . . . 0.0 109.379 178.96 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -71.02 144.41 50.43 Favored 'General case' 0 N--CA 1.469 0.497 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.268 -179.859 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' I' I ' 8' ' ' SER . . . . . 0.477 ' OG ' ' O ' ' F' ' 7' ' ' ASP . 60.5 p -165.02 -171.47 2.24 Favored 'General case' 0 N--CA 1.474 0.771 0 CA-C-O 120.975 0.417 . . . . 0.0 110.469 178.839 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.66 47.03 1.32 Allowed Glycine 0 N--CA 1.479 1.525 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.777 179.598 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 50.0 p90 -66.18 132.8 49.29 Favored 'General case' 0 N--CA 1.472 0.626 0 N-CA-C 111.869 0.322 . . . . 0.0 111.869 -179.805 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 48.5 mt-10 -91.19 152.29 20.61 Favored 'General case' 0 N--CA 1.477 0.907 0 CA-C-O 121.155 0.502 . . . . 0.0 110.202 178.385 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -155.48 126.95 0.91 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.057 0 N-CA-C 107.887 -1.153 . . . . 0.0 107.887 178.201 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 42.9 m-70 -134.92 148.33 50.03 Favored 'General case' 0 N--CA 1.478 0.935 0 CA-C-N 115.488 -0.778 . . . . 0.0 111.432 -178.409 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 33.6 t-80 -164.49 97.33 0.78 Allowed 'General case' 0 N--CA 1.481 1.111 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.441 178.995 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' I' I ' 15' ' ' GLN . . . . . 0.534 HE22 ' H ' ' I' ' 37' ' ' GLY . 3.5 pt20 -106.84 -175.36 2.77 Favored 'General case' 0 CA--C 1.508 -0.666 0 N-CA-C 108.208 -1.034 . . . . 0.0 108.208 -179.815 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -170.18 99.53 0.28 Allowed 'General case' 0 N--CA 1.471 0.595 0 CA-C-N 114.592 -1.185 . . . . 0.0 108.25 179.159 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' I' I ' 17' ' ' LEU . . . . . 0.559 ' CD2' ' H ' ' F' ' 17' ' ' LEU . 8.4 mt -123.23 153.76 39.69 Favored 'General case' 0 N--CA 1.495 1.8 0 CA-C-O 121.042 0.449 . . . . 0.0 111.836 -177.829 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 43.8 t -111.3 126.44 68.69 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.02 0 N-CA-C 108.05 -1.093 . . . . 0.0 108.05 176.913 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 47.1 m-85 -124.16 120.77 33.27 Favored 'General case' 0 C--N 1.368 1.389 0 CA-C-N 115.511 -0.768 . . . . 0.0 111.002 -179.294 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 73.4 m-85 53.87 73.84 0.36 Allowed 'General case' 0 N--CA 1.469 0.495 0 CA-C-N 115.898 -0.592 . . . . 0.0 111.637 178.062 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -76.74 -78.43 0.12 Allowed 'General case' 0 N--CA 1.471 0.61 0 O-C-N 122.304 -0.247 . . . . 0.0 110.414 -179.209 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 40.1 tt0 -112.12 101.31 9.58 Favored 'General case' 0 C--N 1.324 -0.512 0 N-CA-C 108.075 -1.083 . . . . 0.0 108.075 179.938 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -158.53 142.4 15.42 Favored 'General case' 0 N--CA 1.477 0.903 0 O-C-N 122.42 -0.175 . . . . 0.0 111.467 179.063 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' I' I ' 24' ' ' VAL . . . . . 0.447 HG12 ' N ' ' I' ' 25' ' ' GLY . 59.0 t -61.06 167.82 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.561 0 N-CA-C 107.663 -1.236 . . . . 0.0 107.663 177.296 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' I' I ' 25' ' ' GLY . . . . . 0.447 ' N ' HG12 ' I' ' 24' ' ' VAL . . . -120.8 49.85 0.86 Allowed Glycine 0 N--CA 1.481 1.682 0 N-CA-C 110.45 -1.06 . . . . 0.0 110.45 -179.485 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -63.84 -167.57 0.02 OUTLIER 'General case' 0 N--CA 1.471 0.594 0 CA-C-N 116.927 0.364 . . . . 0.0 110.24 179.879 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 3.6 t30 -69.8 77.59 0.46 Allowed 'General case' 0 CA--C 1.535 0.37 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.445 179.883 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -76.39 146.66 38.55 Favored 'General case' 0 N--CA 1.474 0.755 0 N-CA-C 109.438 -0.578 . . . . 0.0 109.438 179.305 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.73 -166.79 0.96 Allowed Glycine 0 C--N 1.337 0.638 0 N-CA-C 110.074 -1.21 . . . . 0.0 110.074 178.76 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.84 114.88 28.37 Favored 'General case' 0 N--CA 1.469 0.501 0 C-N-CA 122.771 0.428 . . . . 0.0 110.582 179.913 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 72.0 mt -96.75 136.07 28.78 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.674 0 N-CA-C 106.883 -1.525 . . . . 0.0 106.883 178.981 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 37.5 pt -152.46 -175.94 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 CA-C-N 119.885 1.221 . . . . 0.0 109.907 -179.678 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.63 6.69 12.22 Favored Glycine 0 CA--C 1.526 0.763 0 N-CA-C 110.94 -0.864 . . . . 0.0 110.94 -179.776 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' I' I ' 34' ' ' LEU . . . . . 0.408 HD23 ' N ' ' I' ' 35' ' ' MET . 1.4 tt -75.04 127.13 32.51 Favored 'General case' 0 CA--C 1.547 0.83 0 N-CA-C 109.547 -0.538 . . . . 0.0 109.547 -179.64 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' I' I ' 35' ' ' MET . . . . . 0.408 ' N ' HD23 ' I' ' 34' ' ' LEU . 28.1 ttt -161.1 150.12 16.49 Favored 'General case' 0 C--O 1.211 -0.942 0 N-CA-C 108.738 -0.838 . . . . 0.0 108.738 178.564 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' I' I ' 36' ' ' VAL . . . . . 0.575 HG12 HG22 ' F' ' 36' ' ' VAL . 34.1 m -157.23 162.11 1.63 Allowed 'Isoleucine or valine' 0 C--N 1.347 0.459 0 N-CA-C 108.594 -0.891 . . . . 0.0 108.594 -179.747 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' I' I ' 37' ' ' GLY . . . . . 0.534 ' H ' HE22 ' I' ' 15' ' ' GLN . . . 55.34 67.2 2.33 Favored Glycine 0 C--N 1.311 -0.841 0 CA-C-N 115.643 -0.708 . . . . 0.0 112.241 178.122 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.18 178.28 18.88 Favored Glycine 0 N--CA 1.478 1.47 0 N-CA-C 110.568 -1.013 . . . . 0.0 110.568 178.875 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' I' I ' 39' ' ' VAL . . . . . 0.531 HG12 ' H ' ' F' ' 39' ' ' VAL . 33.9 m -121.33 158.31 24.33 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.856 0 C-N-CA 123.15 0.58 . . . . 0.0 110.723 -179.662 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 23.4 t . . . . . 0 N--CA 1.469 0.523 0 O-C-N 124.046 0.841 . . . . 0.0 110.699 179.041 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 13.4 m-20 . . . . . 0 N--CA 1.49 1.528 0 N-CA-C 108.942 -0.762 . . . . 0.0 108.942 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.89 132.93 49.83 Favored 'General case' 0 CA--C 1.538 0.518 0 N-CA-C 110.185 -0.302 . . . . 0.0 110.185 -179.785 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 44.1 tt0 -168.64 104.53 0.43 Allowed 'General case' 0 N--CA 1.473 0.703 0 N-CA-C 110.062 -0.347 . . . . 0.0 110.062 -179.152 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 35.1 m-85 -86.5 154.73 20.89 Favored 'General case' 0 N--CA 1.475 0.782 0 N-CA-C 110.082 -0.34 . . . . 0.0 110.082 179.697 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -144.31 139.65 28.69 Favored 'General case' 0 N--CA 1.481 1.115 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 179.563 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 42.1 t-80 -151.95 119.88 6.2 Favored 'General case' 0 N--CA 1.469 0.509 0 N-CA-C 109.264 -0.643 . . . . 0.0 109.264 179.257 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' ASP . . . . . 0.5 ' O ' ' OG ' ' D' ' 8' ' ' SER . 4.2 m-20 -69.04 148.68 49.72 Favored 'General case' 0 CA--C 1.537 0.476 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.498 179.876 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 53.9 p -168.2 -174.24 2.25 Favored 'General case' 0 N--CA 1.484 1.262 0 CA-C-O 121.035 0.445 . . . . 0.0 110.747 179.429 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.8 48.26 1.28 Allowed Glycine 0 N--CA 1.481 1.698 0 CA-C-N 115.911 -0.586 . . . . 0.0 111.83 179.725 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 49.7 p90 -64.6 132.39 49.67 Favored 'General case' 0 N--CA 1.473 0.691 0 O-C-N 122.761 -0.258 . . . . 0.0 111.425 179.732 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 83.3 mt-10 -91.71 152.25 20.28 Favored 'General case' 0 N--CA 1.48 1.047 0 C-N-CA 122.781 0.433 . . . . 0.0 109.839 178.379 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -153.23 128.42 1.54 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.617 0 N-CA-C 107.821 -1.177 . . . . 0.0 107.821 178.298 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 48.5 m-70 -135.25 145.98 48.13 Favored 'General case' 0 N--CA 1.492 1.666 0 CA-C-N 118.949 0.795 . . . . 0.0 111.388 -179.003 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 6.1 t60 -165.95 97.18 0.63 Allowed 'General case' 0 N--CA 1.48 1.058 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.848 179.5 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 3.6 pt20 -108.52 -174.69 2.58 Favored 'General case' 0 CA--C 1.506 -0.733 0 N-CA-C 108.432 -0.951 . . . . 0.0 108.432 -179.845 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -164.17 97.57 0.82 Allowed 'General case' 0 N--CA 1.472 0.651 0 CA-C-N 114.562 -1.199 . . . . 0.0 108.299 178.348 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 6.7 mp -122.27 157.78 30.94 Favored 'General case' 0 N--CA 1.497 1.924 0 CA-C-O 121.759 0.79 . . . . 0.0 110.91 -178.338 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 59.8 t -112.57 126.65 69.99 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.124 0 CA-C-O 117.984 -1.008 . . . . 0.0 108.316 177.702 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 28.7 m-85 -126.93 122.5 34.75 Favored 'General case' 0 N--CA 1.497 1.909 0 CA-C-N 120.017 1.28 . . . . 0.0 110.344 179.338 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 67.0 m-85 53.94 74.32 0.33 Allowed 'General case' 0 N--CA 1.47 0.572 0 CA-C-O 121.374 0.606 . . . . 0.0 111.745 178.751 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -80.55 -78.14 0.18 Allowed 'General case' 0 C--N 1.353 0.756 0 CA-C-N 115.139 -0.937 . . . . 0.0 110.334 -179.773 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 40.4 tt0 -112.21 101.59 9.82 Favored 'General case' 0 N--CA 1.469 0.502 0 N-CA-C 108.468 -0.938 . . . . 0.0 108.468 179.738 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 4.4 p30 -158.96 134.5 8.62 Favored 'General case' 0 N--CA 1.482 1.16 0 CA-C-O 119.512 -0.28 . . . . 0.0 111.211 178.936 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 58.7 t -58.05 163.07 0.71 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.853 0 N-CA-C 108.074 -1.084 . . . . 0.0 108.074 176.984 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.421 ' H ' ' HB ' ' D' ' 24' ' ' VAL . . . -115.76 47.95 0.99 Allowed Glycine 0 N--CA 1.477 1.383 0 N-CA-C 111.615 -0.594 . . . . 0.0 111.615 -179.474 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -61.85 -168.65 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.562 0 N-CA-C 110.152 -0.314 . . . . 0.0 110.152 179.338 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 2.8 t30 -72.05 79.97 0.94 Allowed 'General case' 0 N--CA 1.464 0.257 0 CA-C-N 116.428 -0.351 . . . . 0.0 110.082 179.164 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -73.46 140.32 46.39 Favored 'General case' 0 N--CA 1.476 0.837 0 N-CA-C 108.934 -0.765 . . . . 0.0 108.934 179.375 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.39 -149.76 0.03 OUTLIER Glycine 0 C--N 1.337 0.618 0 N-CA-C 110.183 -1.167 . . . . 0.0 110.183 179.282 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -93.76 128.07 39.8 Favored 'General case' 0 N--CA 1.476 0.825 0 N-CA-C 110.04 -0.356 . . . . 0.0 110.04 -179.905 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 74.8 mt -124.16 117.35 50.54 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.748 0 N-CA-C 106.653 -1.61 . . . . 0.0 106.653 178.876 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 39.2 pt -151.5 -169.78 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.354 0.804 0 CA-C-O 121.22 0.533 . . . . 0.0 111.246 -178.769 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.84 5.08 12.38 Favored Glycine 0 C--N 1.336 0.58 0 N-CA-C 110.797 -0.921 . . . . 0.0 110.797 179.587 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 1.5 tt -78.14 126.77 31.3 Favored 'General case' 0 CA--C 1.546 0.801 0 N-CA-C 109.558 -0.534 . . . . 0.0 109.558 -179.884 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 28.6 ttt -164.69 143.55 6.94 Favored 'General case' 0 N--CA 1.464 0.23 0 N-CA-C 108.871 -0.788 . . . . 0.0 108.871 178.266 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.426 HG22 HG12 ' D' ' 36' ' ' VAL . 35.6 m -155.27 162.71 1.73 Allowed 'Isoleucine or valine' 0 C--N 1.348 0.509 0 N-CA-C 108.042 -1.096 . . . . 0.0 108.042 179.327 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.61 66.33 2.93 Favored Glycine 0 C--N 1.307 -1.08 0 CA-C-N 115.834 -0.621 . . . . 0.0 111.874 178.429 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 145.7 172.97 16.53 Favored Glycine 0 N--CA 1.473 1.1 0 N-CA-C 110.994 -0.843 . . . . 0.0 110.994 179.095 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.583 ' H ' HG12 ' D' ' 39' ' ' VAL . 33.7 m -123.01 160.44 25.76 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.616 0 C-N-CA 123.405 0.682 . . . . 0.0 110.087 -179.691 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 23.7 t . . . . . 0 C--O 1.218 -0.556 0 CA-C-O 118.419 -0.8 . . . . 0.0 110.578 179.478 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' B' B ' 1' ' ' ASP . . . . . . . . . . . . . 12.5 m-20 . . . . . 0 N--CA 1.489 1.49 0 N-CA-C 108.992 -0.744 . . . . 0.0 108.992 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' B' B ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.48 132.61 49.35 Favored 'General case' 0 CA--C 1.539 0.554 0 N-CA-C 110.151 -0.315 . . . . 0.0 110.151 -179.704 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 3' ' ' GLU . . . . . . . . . . . . . 44.0 tt0 -168.33 104.47 0.45 Allowed 'General case' 0 N--CA 1.474 0.742 0 N-CA-C 110.085 -0.339 . . . . 0.0 110.085 -179.15 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 34.7 m-85 -86.39 154.69 20.99 Favored 'General case' 0 N--CA 1.474 0.752 0 N-CA-C 110.047 -0.353 . . . . 0.0 110.047 179.617 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -144.41 139.06 28.16 Favored 'General case' 0 N--CA 1.484 1.225 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 179.585 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 41.5 t-80 -151.24 119.63 6.41 Favored 'General case' 0 N--CA 1.472 0.638 0 N-CA-C 109.256 -0.646 . . . . 0.0 109.256 179.204 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 7' ' ' ASP . . . . . 0.507 ' O ' ' OG ' ' E' ' 8' ' ' SER . 4.0 m-20 -68.83 148.19 50.63 Favored 'General case' 0 CA--C 1.538 0.514 0 CA-C-N 116.295 -0.412 . . . . 0.0 110.721 179.828 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 8' ' ' SER . . . . . . . . . . . . . 54.1 p -167.58 -173.69 2.27 Favored 'General case' 0 N--CA 1.483 1.221 0 CA-C-O 121.045 0.45 . . . . 0.0 110.707 179.525 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.38 48.24 1.33 Allowed Glycine 0 N--CA 1.481 1.692 0 CA-C-N 115.908 -0.587 . . . . 0.0 111.949 179.55 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 50.2 p90 -64.94 132.89 50.55 Favored 'General case' 0 N--CA 1.473 0.687 0 CA-C-O 120.636 0.255 . . . . 0.0 111.496 179.871 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 84.2 mt-10 -92.02 152.75 19.84 Favored 'General case' 0 N--CA 1.478 0.93 0 CA-C-O 121.048 0.451 . . . . 0.0 109.823 178.456 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -153.61 128.39 1.46 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.495 0 N-CA-C 107.922 -1.14 . . . . 0.0 107.922 178.12 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 46.5 m-70 -135.32 145.67 47.69 Favored 'General case' 0 N--CA 1.493 1.723 0 CA-C-N 118.941 0.791 . . . . 0.0 111.289 -179.006 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 6.0 t60 -165.65 96.86 0.66 Allowed 'General case' 0 N--CA 1.48 1.035 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.739 179.38 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 3.6 pt20 -108.12 -174.74 2.59 Favored 'General case' 0 CA--C 1.507 -0.694 0 N-CA-C 108.411 -0.959 . . . . 0.0 108.411 -179.798 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -164.29 97.63 0.8 Allowed 'General case' 0 N--CA 1.473 0.699 0 CA-C-N 114.67 -1.15 . . . . 0.0 108.263 178.342 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 6.6 mp -122.27 157.69 31.13 Favored 'General case' 0 N--CA 1.497 1.906 0 CA-C-O 121.809 0.814 . . . . 0.0 111.023 -178.298 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 61.4 t -112.71 127.75 69.77 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.024 0 N-CA-C 108.069 -1.086 . . . . 0.0 108.069 177.595 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 28.6 m-85 -128.09 122.09 31.22 Favored 'General case' 0 N--CA 1.495 1.787 0 CA-C-N 119.726 1.148 . . . . 0.0 110.192 179.501 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 67.1 m-85 53.6 74.18 0.33 Allowed 'General case' 0 CA--C 1.54 0.581 0 CA-C-O 121.487 0.661 . . . . 0.0 111.799 178.622 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -80.35 -78.32 0.17 Allowed 'General case' 0 C--N 1.352 0.687 0 CA-C-N 115.001 -1.0 . . . . 0.0 110.275 -179.823 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 40.5 tt0 -112.02 101.73 10.0 Favored 'General case' 0 N--CA 1.471 0.613 0 N-CA-C 108.448 -0.945 . . . . 0.0 108.448 179.819 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 4.4 p30 -158.89 134.8 8.89 Favored 'General case' 0 N--CA 1.482 1.169 0 CA-C-O 119.54 -0.266 . . . . 0.0 111.155 178.913 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 58.5 t -58.26 163.2 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.874 0 N-CA-C 108.128 -1.064 . . . . 0.0 108.128 177.018 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 25' ' ' GLY . . . . . 0.436 ' H ' ' HB ' ' E' ' 24' ' ' VAL . . . -115.57 47.62 1.02 Allowed Glycine 0 N--CA 1.474 1.203 0 N-CA-C 111.65 -0.58 . . . . 0.0 111.65 -179.314 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -61.77 -168.59 0.01 OUTLIER 'General case' 0 N--CA 1.469 0.518 0 N-CA-C 110.25 -0.278 . . . . 0.0 110.25 179.45 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 24.6 t-20 -72.38 79.85 1.02 Allowed 'General case' 0 N--CA 1.468 0.426 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.318 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -73.19 140.6 47.1 Favored 'General case' 0 N--CA 1.477 0.898 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 179.565 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.56 -150.05 0.04 OUTLIER Glycine 0 C--N 1.338 0.639 0 N-CA-C 110.191 -1.163 . . . . 0.0 110.191 179.411 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -93.41 128.33 39.42 Favored 'General case' 0 N--CA 1.475 0.787 0 CA-C-N 116.938 0.369 . . . . 0.0 110.032 179.795 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 76.7 mt -124.46 117.26 50.02 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.658 0 N-CA-C 106.593 -1.632 . . . . 0.0 106.593 178.811 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 39.8 pt -151.19 -169.71 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.355 0.831 0 CA-C-N 115.986 -0.552 . . . . 0.0 111.255 -178.746 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.83 4.95 11.86 Favored Glycine 0 C--N 1.337 0.627 0 N-CA-C 110.945 -0.862 . . . . 0.0 110.945 179.479 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 1.5 tt -78.12 126.81 31.35 Favored 'General case' 0 CA--C 1.546 0.819 0 N-CA-C 109.57 -0.53 . . . . 0.0 109.57 -179.778 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 28.5 ttt -164.81 143.53 6.75 Favored 'General case' 0 N--CA 1.465 0.311 0 N-CA-C 108.801 -0.814 . . . . 0.0 108.801 178.225 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 35.4 m -155.37 162.41 1.8 Allowed 'Isoleucine or valine' 0 C--N 1.347 0.499 0 N-CA-C 108.0 -1.111 . . . . 0.0 108.0 179.471 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.71 66.9 2.52 Favored Glycine 0 C--N 1.307 -1.068 0 CA-C-N 115.742 -0.663 . . . . 0.0 111.784 178.415 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 144.97 172.65 15.58 Favored Glycine 0 N--CA 1.472 1.08 0 N-CA-C 110.869 -0.892 . . . . 0.0 110.869 179.179 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 39' ' ' VAL . . . . . 0.605 ' H ' HG12 ' E' ' 39' ' ' VAL . 32.5 m -123.09 159.95 26.49 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.711 0 C-N-CA 123.428 0.691 . . . . 0.0 110.209 -179.553 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 24.4 t . . . . . 0 N--CA 1.468 0.468 0 CA-C-O 118.316 -0.849 . . . . 0.0 110.441 179.475 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' C' C ' 1' ' ' ASP . . . . . . . . . . . . . 13.0 m-20 . . . . . 0 N--CA 1.489 1.525 0 N-CA-C 108.861 -0.792 . . . . 0.0 108.861 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' C' C ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.95 132.56 49.65 Favored 'General case' 0 CA--C 1.539 0.519 0 CA-C-N 116.421 -0.354 . . . . 0.0 110.298 -179.681 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 3' ' ' GLU . . . . . . . . . . . . . 44.1 tt0 -168.18 104.89 0.47 Allowed 'General case' 0 N--CA 1.473 0.7 0 N-CA-C 110.012 -0.366 . . . . 0.0 110.012 -179.303 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 34.6 m-85 -86.67 154.98 20.58 Favored 'General case' 0 N--CA 1.475 0.799 0 N-CA-C 110.023 -0.362 . . . . 0.0 110.023 179.608 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -144.75 138.85 27.47 Favored 'General case' 0 N--CA 1.482 1.165 0 N-CA-C 109.951 -0.389 . . . . 0.0 109.951 179.69 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 41.7 t-80 -151.16 119.7 6.48 Favored 'General case' 0 N--CA 1.471 0.582 0 N-CA-C 109.381 -0.599 . . . . 0.0 109.381 179.246 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 7' ' ' ASP . . . . . 0.482 ' O ' ' OG ' ' F' ' 8' ' ' SER . 4.3 m-20 -69.1 148.21 50.33 Favored 'General case' 0 CA--C 1.539 0.527 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.66 179.891 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 8' ' ' SER . . . . . . . . . . . . . 54.5 p -167.55 -173.95 2.36 Favored 'General case' 0 N--CA 1.484 1.271 0 CA-C-O 121.028 0.442 . . . . 0.0 110.764 179.455 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.81 48.19 1.29 Allowed Glycine 0 N--CA 1.48 1.616 0 CA-C-N 115.886 -0.597 . . . . 0.0 111.988 179.574 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 49.5 p90 -65.01 132.18 48.54 Favored 'General case' 0 N--CA 1.471 0.604 0 O-C-N 122.751 -0.264 . . . . 0.0 111.463 179.897 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 83.5 mt-10 -91.47 152.59 20.29 Favored 'General case' 0 N--CA 1.476 0.835 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 178.465 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -153.4 128.61 1.54 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.53 0 N-CA-C 107.778 -1.193 . . . . 0.0 107.778 178.237 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 46.8 m-70 -135.35 145.76 47.71 Favored 'General case' 0 N--CA 1.493 1.687 0 CA-C-N 118.986 0.812 . . . . 0.0 111.357 -179.099 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 6.0 t60 -165.69 97.33 0.66 Allowed 'General case' 0 N--CA 1.48 1.059 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.715 179.361 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 3.5 pt20 -108.74 -174.22 2.46 Favored 'General case' 0 CA--C 1.506 -0.722 0 N-CA-C 108.362 -0.977 . . . . 0.0 108.362 -179.891 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -164.66 97.7 0.77 Allowed 'General case' 0 N--CA 1.471 0.62 0 CA-C-N 114.573 -1.194 . . . . 0.0 108.269 178.55 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 6.6 mp -122.45 157.36 32.11 Favored 'General case' 0 N--CA 1.498 1.946 0 CA-C-O 121.883 0.849 . . . . 0.0 111.017 -178.208 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 58.8 t -112.41 127.28 69.71 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.091 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 177.655 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 29.2 m-85 -127.77 122.17 32.1 Favored 'General case' 0 N--CA 1.494 1.75 0 CA-C-N 119.686 1.13 . . . . 0.0 110.266 179.458 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 67.0 m-85 53.54 74.14 0.33 Allowed 'General case' 0 N--CA 1.468 0.448 0 CA-C-O 121.486 0.66 . . . . 0.0 111.915 178.588 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -80.56 -77.84 0.19 Allowed 'General case' 0 C--N 1.349 0.559 0 CA-C-N 114.969 -1.014 . . . . 0.0 110.373 -179.716 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 40.3 tt0 -112.38 101.32 9.52 Favored 'General case' 0 N--CA 1.47 0.535 0 N-CA-C 108.355 -0.98 . . . . 0.0 108.355 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -158.79 134.22 8.61 Favored 'General case' 0 N--CA 1.481 1.096 0 CA-C-O 119.466 -0.302 . . . . 0.0 111.205 178.965 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 59.3 t -57.55 163.55 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.805 0 N-CA-C 108.135 -1.061 . . . . 0.0 108.135 177.002 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 25' ' ' GLY . . . . . 0.437 ' H ' ' HB ' ' F' ' 24' ' ' VAL . . . -115.91 47.8 1.0 Allowed Glycine 0 N--CA 1.477 1.421 0 N-CA-C 111.519 -0.632 . . . . 0.0 111.519 -179.505 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -62.06 -169.23 0.02 OUTLIER 'General case' 0 N--CA 1.469 0.509 0 N-CA-C 110.17 -0.308 . . . . 0.0 110.17 179.348 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 24.7 t-20 -71.77 79.72 0.86 Allowed 'General case' 0 N--CA 1.468 0.425 0 N-CA-C 110.011 -0.366 . . . . 0.0 110.011 179.455 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -73.19 140.6 47.08 Favored 'General case' 0 N--CA 1.476 0.834 0 N-CA-C 109.011 -0.737 . . . . 0.0 109.011 179.442 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.7 -149.09 0.04 OUTLIER Glycine 0 C--N 1.337 0.594 0 N-CA-C 110.284 -1.126 . . . . 0.0 110.284 179.457 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -94.16 128.03 40.34 Favored 'General case' 0 N--CA 1.477 0.877 0 CA-C-N 116.931 0.365 . . . . 0.0 110.083 179.953 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 74.9 mt -124.28 117.23 50.06 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.697 0 N-CA-C 106.707 -1.59 . . . . 0.0 106.707 178.734 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 39.7 pt -151.3 -169.74 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.355 0.826 0 CA-C-N 115.978 -0.556 . . . . 0.0 111.231 -178.712 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.9 4.81 11.83 Favored Glycine 0 N--CA 1.465 0.609 0 N-CA-C 110.84 -0.904 . . . . 0.0 110.84 179.433 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 1.5 tt -77.96 126.66 31.17 Favored 'General case' 0 CA--C 1.546 0.826 0 N-CA-C 109.566 -0.531 . . . . 0.0 109.566 -179.803 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 28.6 ttt -164.49 143.33 7.13 Favored 'General case' 0 N--CA 1.465 0.298 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 178.298 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 35.5 m -155.19 162.58 1.77 Allowed 'Isoleucine or valine' 0 C--N 1.347 0.485 0 N-CA-C 107.989 -1.115 . . . . 0.0 107.989 179.373 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.64 66.45 2.84 Favored Glycine 0 C--N 1.306 -1.138 0 CA-C-N 115.808 -0.633 . . . . 0.0 111.88 178.422 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 145.46 173.33 16.62 Favored Glycine 0 N--CA 1.472 1.07 0 N-CA-C 111.024 -0.831 . . . . 0.0 111.024 178.946 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 39' ' ' VAL . . . . . 0.598 ' H ' HG12 ' F' ' 39' ' ' VAL . 33.0 m -123.17 160.39 26.18 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.658 0 C-N-CA 123.424 0.69 . . . . 0.0 110.192 -179.787 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 22.8 t . . . . . 0 C--O 1.219 -0.518 0 CA-C-O 118.406 -0.807 . . . . 0.0 110.46 179.546 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' D' D ' 1' ' ' ASP . . . . . . . . . . . . . 13.2 m-20 . . . . . 0 N--CA 1.49 1.528 0 N-CA-C 109.227 -0.657 . . . . 0.0 109.227 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' D' D ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.71 131.32 46.57 Favored 'General case' 0 CA--C 1.534 0.35 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.48 179.872 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 3' ' ' GLU . . . . . . . . . . . . . 43.7 tt0 -169.38 107.25 0.4 Allowed 'General case' 0 N--CA 1.471 0.59 0 N-CA-C 110.096 -0.335 . . . . 0.0 110.096 -179.962 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 35.1 m-85 -90.8 159.33 16.34 Favored 'General case' 0 C--N 1.355 0.843 0 N-CA-C 108.954 -0.758 . . . . 0.0 108.954 179.952 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 5' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -146.07 137.5 24.77 Favored 'General case' 0 N--CA 1.478 0.953 0 C-N-CA 122.814 0.445 . . . . 0.0 110.341 -179.888 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 37.7 t-80 -149.64 123.94 9.57 Favored 'General case' 0 CA--C 1.547 0.827 0 N-CA-C 108.188 -1.041 . . . . 0.0 108.188 175.182 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 7' ' ' ASP . . . . . 0.604 ' O ' ' OG ' ' G' ' 8' ' ' SER . 3.2 m-20 -63.69 132.52 51.33 Favored 'General case' 0 N--CA 1.466 0.363 0 C-N-CA 126.323 1.849 . . . . 0.0 114.361 174.856 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' D' D ' 8' ' ' SER . . . . . 0.5 ' OG ' ' O ' ' A' ' 7' ' ' ASP . 53.8 p -154.39 -171.35 3.83 Favored 'General case' 0 N--CA 1.487 1.385 0 CA-C-N 119.454 1.024 . . . . 0.0 111.255 176.266 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.28 49.0 1.09 Allowed Glycine 0 N--CA 1.483 1.8 0 N-CA-C 110.263 -1.135 . . . . 0.0 110.263 174.144 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 50.8 p90 -61.47 131.71 51.08 Favored 'General case' 0 N--CA 1.472 0.65 0 N-CA-C 112.338 0.495 . . . . 0.0 112.338 178.833 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 84.8 mt-10 -89.24 150.73 22.5 Favored 'General case' 0 N--CA 1.482 1.136 0 CA-C-O 120.564 0.221 . . . . 0.0 110.714 175.645 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.0 p -149.44 130.19 4.58 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.567 0 N-CA-C 107.492 -1.299 . . . . 0.0 107.492 173.114 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 43.2 m-70 -129.89 148.72 51.78 Favored 'General case' 0 N--CA 1.483 1.217 0 CA-C-N 118.074 0.397 . . . . 0.0 111.91 176.444 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 6.1 t60 -165.14 104.43 0.76 Allowed 'General case' 0 N--CA 1.481 1.083 0 N-CA-C 109.029 -0.73 . . . . 0.0 109.029 172.33 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 3.5 pt20 -111.84 -176.14 2.86 Favored 'General case' 0 CA--C 1.497 -1.089 0 N-CA-C 108.29 -1.004 . . . . 0.0 108.29 178.808 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -161.29 105.35 1.3 Allowed 'General case' 0 N--CA 1.469 0.5 0 N-CA-C 106.37 -1.715 . . . . 0.0 106.37 174.965 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 5.6 mp -129.15 154.07 47.08 Favored 'General case' 0 N--CA 1.499 1.989 0 CA-C-O 122.024 0.916 . . . . 0.0 110.581 179.732 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 33.1 t -101.29 131.39 49.14 Favored 'Isoleucine or valine' 0 C--O 1.262 1.75 0 CA-C-O 116.89 -1.529 . . . . 0.0 109.74 174.047 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 26.9 m-85 -130.24 126.63 37.8 Favored 'General case' 0 N--CA 1.491 1.618 0 CA-C-N 119.893 1.224 . . . . 0.0 109.497 173.19 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 67.3 m-85 55.22 71.3 0.55 Allowed 'General case' 0 C--O 1.241 0.658 0 CA-C-N 115.592 -0.731 . . . . 0.0 111.653 176.226 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -82.3 -73.42 0.39 Allowed 'General case' 0 N--CA 1.473 0.701 0 CA-C-O 118.601 -0.714 . . . . 0.0 111.259 -177.414 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 40.7 tt0 -115.35 105.37 12.77 Favored 'General case' 0 N--CA 1.48 1.046 0 N-CA-C 106.463 -1.68 . . . . 0.0 106.463 176.312 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 4.4 p30 -152.19 135.17 15.66 Favored 'General case' 0 N--CA 1.473 0.692 0 CA-C-O 116.67 -1.633 . . . . 0.0 113.493 177.301 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 24' ' ' VAL . . . . . 0.421 ' HB ' ' H ' ' A' ' 25' ' ' GLY . 87.7 t -61.35 166.27 0.81 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.218 0 CA-C-N 121.056 1.753 . . . . 0.0 107.759 175.529 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' D' D ' 25' ' ' GLY . . . . . 0.485 ' H ' ' HB ' ' G' ' 24' ' ' VAL . . . -116.38 50.99 0.75 Allowed Glycine 0 N--CA 1.478 1.476 0 CA-C-O 119.466 -0.63 . . . . 0.0 111.656 178.621 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -57.14 -171.03 0.01 OUTLIER 'General case' 0 N--CA 1.468 0.463 0 C-N-CA 123.414 0.685 . . . . 0.0 111.805 175.217 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 3.6 t30 -73.62 86.86 1.63 Allowed 'General case' 0 C--N 1.348 0.512 0 N-CA-C 108.44 -0.948 . . . . 0.0 108.44 176.753 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 97.6 mttt -81.09 143.26 32.56 Favored 'General case' 0 N--CA 1.481 1.101 0 N-CA-C 107.527 -1.286 . . . . 0.0 107.527 179.818 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.72 -144.78 0.02 OUTLIER Glycine 0 C--N 1.349 1.274 0 CA-C-N 114.928 -1.033 . . . . 0.0 111.705 -178.865 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -95.81 127.01 41.47 Favored 'General case' 0 C--O 1.241 0.619 0 N-CA-C 110.196 -0.298 . . . . 0.0 110.196 178.859 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 85.8 mt -125.98 127.61 71.23 Favored 'Isoleucine or valine' 0 C--N 1.354 0.77 0 N-CA-C 103.34 -2.837 . . . . 0.0 103.34 176.89 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 32' ' ' ILE . . . . . 0.408 HG22 ' H ' ' G' ' 32' ' ' ILE . 42.8 pt -159.61 -170.82 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.119 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.228 -177.696 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 64.12 4.83 12.78 Favored Glycine 0 C--O 1.243 0.685 0 N-CA-C 110.254 -1.138 . . . . 0.0 110.254 -179.251 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 34' ' ' LEU . . . . . . . . . . . . 0.265 2.0 tt -80.33 133.38 35.93 Favored 'General case' 0 C--N 1.377 1.798 0 C-N-CA 117.22 -1.792 . . . . 0.0 107.353 -178.729 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' D' D ' 35' ' ' MET . . . . . 0.406 ' C ' HG13 ' D' ' 36' ' ' VAL . 28.4 ttt -158.82 156.2 29.25 Favored 'General case' 0 C--O 1.25 1.081 0 CA-C-O 117.938 -1.03 . . . . 0.0 108.691 172.374 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' D' D ' 36' ' ' VAL . . . . . 0.488 HG22 HG12 ' G' ' 36' ' ' VAL . 35.5 m -164.74 163.7 0.71 Allowed 'Isoleucine or valine' 0 CA--C 1.516 -0.364 0 N-CA-C 107.643 -1.243 . . . . 0.0 107.643 174.273 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 60.5 63.03 5.35 Favored Glycine 0 CA--C 1.53 1.011 0 C-N-CA 120.216 -0.993 . . . . 0.0 111.509 177.578 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 144.03 175.53 17.24 Favored Glycine 0 N--CA 1.478 1.469 0 CA-C-N 118.443 1.122 . . . . 0.0 111.378 179.847 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 39' ' ' VAL . . . . . 0.624 ' H ' HG12 ' G' ' 39' ' ' VAL . 36.0 m -126.22 157.4 36.52 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.78 0 C-N-CA 122.937 0.495 . . . . 0.0 109.863 -177.737 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 24.0 t . . . . . 0 C--N 1.331 -0.211 0 CA-C-O 116.331 -1.795 . . . . 0.0 109.479 177.301 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' E' E ' 1' ' ' ASP . . . . . . . . . . . . . 13.1 m-20 . . . . . 0 N--CA 1.488 1.449 0 N-CA-C 109.58 -0.526 . . . . 0.0 109.58 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' E' E ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.1 130.02 42.32 Favored 'General case' 0 N--CA 1.468 0.458 0 CA-C-N 116.295 -0.412 . . . . 0.0 110.422 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' E' E ' 3' ' ' GLU . . . . . . . . . . . . . 43.7 tt0 -167.47 104.89 0.52 Allowed 'General case' 0 N--CA 1.472 0.64 0 CA-C-N 116.866 -0.152 . . . . 0.0 110.684 -179.808 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 31.8 m-85 -87.65 154.34 20.67 Favored 'General case' 0 N--CA 1.474 0.768 0 N-CA-C 110.135 -0.321 . . . . 0.0 110.135 179.351 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' E' E ' 5' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -143.69 139.82 29.71 Favored 'General case' 0 N--CA 1.484 1.256 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 179.374 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 41.3 t-80 -151.57 119.61 6.26 Favored 'General case' 0 N--CA 1.472 0.674 0 N-CA-C 109.276 -0.639 . . . . 0.0 109.276 178.953 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' E' E ' 7' ' ' ASP . . . . . 0.501 ' O ' ' OG ' ' H' ' 8' ' ' SER . 3.9 m-20 -69.6 147.81 50.21 Favored 'General case' 0 CA--C 1.534 0.334 0 CA-C-N 116.414 -0.357 . . . . 0.0 110.94 -179.951 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' E' E ' 8' ' ' SER . . . . . 0.507 ' OG ' ' O ' ' B' ' 7' ' ' ASP . 52.2 p -167.8 -172.72 1.93 Allowed 'General case' 0 N--CA 1.485 1.32 0 CA-C-O 121.18 0.514 . . . . 0.0 110.807 179.014 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.19 48.57 1.21 Allowed Glycine 0 N--CA 1.478 1.479 0 CA-C-N 115.702 -0.681 . . . . 0.0 111.82 179.475 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 47.8 p90 -64.66 133.11 51.49 Favored 'General case' 0 N--CA 1.473 0.688 0 N-CA-C 111.842 0.312 . . . . 0.0 111.842 -179.744 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 86.3 mt-10 -91.53 152.41 20.33 Favored 'General case' 0 N--CA 1.479 1.024 0 CA-C-O 121.175 0.512 . . . . 0.0 109.787 178.06 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -154.59 127.5 1.12 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.575 0 N-CA-C 107.735 -1.209 . . . . 0.0 107.735 178.053 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 46.6 m-70 -135.24 143.8 46.53 Favored 'General case' 0 N--CA 1.482 1.13 0 CA-C-O 120.846 0.355 . . . . 0.0 111.609 -177.942 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 6.1 t60 -164.31 97.25 0.8 Allowed 'General case' 0 N--CA 1.483 1.187 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.671 179.395 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 3.5 pt20 -108.07 -174.58 2.56 Favored 'General case' 0 CA--C 1.509 -0.63 0 N-CA-C 108.544 -0.909 . . . . 0.0 108.544 179.994 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -164.22 96.61 0.79 Allowed 'General case' 0 N--CA 1.477 0.906 0 CA-C-N 114.651 -1.158 . . . . 0.0 108.426 178.367 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' E' E ' 17' ' ' LEU . . . . . 0.412 ' H ' ' CD1' ' H' ' 17' ' ' LEU . 6.5 mp -120.91 157.31 30.15 Favored 'General case' 0 N--CA 1.495 1.788 0 CA-C-O 121.641 0.734 . . . . 0.0 111.557 -177.668 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 48.2 t -114.34 124.42 70.98 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.24 0 N-CA-C 108.277 -1.008 . . . . 0.0 108.277 177.266 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 31.7 m-85 -125.3 121.19 33.3 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 123.256 0.348 . . . . 0.0 110.909 -179.751 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 68.9 m-85 54.87 73.17 0.42 Allowed 'General case' 0 N--CA 1.469 0.504 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.392 178.196 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -78.73 -78.76 0.14 Allowed 'General case' 0 CA--C 1.536 0.419 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.201 -179.566 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 40.3 tt0 -111.5 102.2 10.57 Favored 'General case' 0 C--N 1.322 -0.588 0 N-CA-C 108.49 -0.93 . . . . 0.0 108.49 -179.996 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -158.27 134.62 9.42 Favored 'General case' 0 C--O 1.208 -1.1 0 CA-C-O 119.447 -0.311 . . . . 0.0 111.476 178.846 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' E' E ' 24' ' ' VAL . . . . . 0.436 ' HB ' ' H ' ' B' ' 25' ' ' GLY . 57.3 t -56.73 167.4 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.884 0 N-CA-C 107.564 -1.273 . . . . 0.0 107.564 176.791 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' E' E ' 25' ' ' GLY . . . . . 0.411 ' N ' HG12 ' E' ' 24' ' ' VAL . . . -120.37 48.96 0.91 Allowed Glycine 0 N--CA 1.472 1.091 0 N-CA-C 110.852 -0.899 . . . . 0.0 110.852 -179.389 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -63.37 -167.92 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.528 0 CA-C-O 120.767 0.318 . . . . 0.0 110.361 179.669 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 25.0 t-20 -71.71 76.35 0.84 Allowed 'General case' 0 N--CA 1.466 0.334 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.324 179.779 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -70.26 140.28 52.35 Favored 'General case' 0 N--CA 1.48 1.061 0 N-CA-C 109.438 -0.579 . . . . 0.0 109.438 179.462 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.47 -149.28 0.05 OUTLIER Glycine 0 C--N 1.335 0.49 0 N-CA-C 110.859 -0.896 . . . . 0.0 110.859 179.42 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -92.78 126.89 38.07 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-N 116.797 0.298 . . . . 0.0 110.402 179.713 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 76.8 mt -123.62 117.25 50.65 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.436 0 N-CA-C 106.365 -1.717 . . . . 0.0 106.365 178.591 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' E' E ' 32' ' ' ILE . . . . . 0.415 HG22 ' H ' ' H' ' 32' ' ' ILE . 44.2 pt -151.46 -168.19 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.17 0 CA-C-O 121.117 0.484 . . . . 0.0 110.882 -178.868 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.13 5.43 7.85 Favored Glycine 0 CA--C 1.527 0.839 0 N-CA-C 111.315 -0.714 . . . . 0.0 111.315 179.975 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 1.6 tt -77.74 127.23 32.1 Favored 'General case' 0 CA--C 1.548 0.88 0 N-CA-C 109.494 -0.558 . . . . 0.0 109.494 -179.886 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 28.6 ttt -164.7 144.52 7.34 Favored 'General case' 0 N--CA 1.469 0.51 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 178.267 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' E' E ' 36' ' ' VAL . . . . . 0.463 HG22 HG12 ' H' ' 36' ' ' VAL . 32.9 m -156.38 162.84 1.55 Allowed 'Isoleucine or valine' 0 C--N 1.348 0.523 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 179.675 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.05 66.13 3.06 Favored Glycine 0 C--N 1.307 -1.072 0 CA-C-N 115.599 -0.728 . . . . 0.0 111.799 178.34 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 145.97 174.31 18.02 Favored Glycine 0 N--CA 1.474 1.191 0 N-CA-C 111.256 -0.738 . . . . 0.0 111.256 178.8 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' E' E ' 39' ' ' VAL . . . . . 0.614 ' H ' HG12 ' H' ' 39' ' ' VAL . 34.3 m -124.15 159.87 29.1 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.709 0 C-N-CA 123.32 0.648 . . . . 0.0 110.297 -179.206 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 24.6 t . . . . . 0 C--O 1.218 -0.595 0 O-C-N 124.156 0.91 . . . . 0.0 110.43 179.394 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' F' F ' 1' ' ' ASP . . . . . . . . . . . . . 11.7 m-20 . . . . . 0 N--CA 1.491 1.619 0 N-CA-C 109.221 -0.659 . . . . 0.0 109.221 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' F' F ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.23 129.95 41.98 Favored 'General case' 0 N--CA 1.468 0.435 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.46 -179.89 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' F' F ' 3' ' ' GLU . . . . . . . . . . . . . 43.5 tt0 -167.26 105.22 0.55 Allowed 'General case' 0 C--O 1.216 -0.671 0 N-CA-C 110.552 -0.166 . . . . 0.0 110.552 -179.782 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 31.5 m-85 -87.88 154.67 20.35 Favored 'General case' 0 N--CA 1.475 0.813 0 N-CA-C 110.019 -0.363 . . . . 0.0 110.019 179.434 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' F' F ' 5' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -144.03 139.4 28.96 Favored 'General case' 0 N--CA 1.478 0.966 0 CA-C-O 120.759 0.314 . . . . 0.0 110.214 179.46 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 41.3 t-80 -151.48 119.73 6.35 Favored 'General case' 0 N--CA 1.473 0.695 0 N-CA-C 109.282 -0.636 . . . . 0.0 109.282 179.124 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' F' F ' 7' ' ' ASP . . . . . 0.465 ' O ' ' OG ' ' I' ' 8' ' ' SER . 3.9 m-20 -69.62 147.81 50.19 Favored 'General case' 0 CA--C 1.533 0.317 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.909 179.994 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' F' F ' 8' ' ' SER . . . . . 0.482 ' OG ' ' O ' ' C' ' 7' ' ' ASP . 51.7 p -168.09 -173.12 1.96 Allowed 'General case' 0 N--CA 1.485 1.321 0 CA-C-O 121.22 0.533 . . . . 0.0 110.923 178.977 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.49 48.3 1.22 Allowed Glycine 0 N--CA 1.478 1.457 0 CA-C-N 115.767 -0.651 . . . . 0.0 111.714 179.466 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 47.7 p90 -64.02 132.84 51.81 Favored 'General case' 0 N--CA 1.474 0.736 0 O-C-N 122.648 -0.325 . . . . 0.0 111.792 -179.888 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 86.8 mt-10 -91.28 152.42 20.49 Favored 'General case' 0 N--CA 1.481 1.103 0 CA-C-O 121.166 0.508 . . . . 0.0 109.877 177.873 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -154.57 127.61 1.14 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.627 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 178.008 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 44.4 m-70 -135.44 144.13 46.29 Favored 'General case' 0 N--CA 1.482 1.144 0 CA-C-O 120.807 0.337 . . . . 0.0 111.6 -178.079 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 6.0 t60 -164.57 96.82 0.76 Allowed 'General case' 0 N--CA 1.485 1.284 0 CA-C-N 116.431 -0.349 . . . . 0.0 110.788 179.478 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 3.5 pt20 -107.71 -174.06 2.44 Favored 'General case' 0 CA--C 1.505 -0.778 0 N-CA-C 108.637 -0.875 . . . . 0.0 108.637 -179.97 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -164.53 96.8 0.77 Allowed 'General case' 0 N--CA 1.475 0.802 0 CA-C-N 114.645 -1.161 . . . . 0.0 108.336 178.533 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' F' F ' 17' ' ' LEU . . . . . 0.406 ' H ' ' CD1' ' I' ' 17' ' ' LEU . 6.5 mp -121.01 157.17 30.57 Favored 'General case' 0 N--CA 1.494 1.766 0 CA-C-O 121.51 0.671 . . . . 0.0 111.483 -177.733 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 48.1 t -114.04 124.24 70.49 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.227 0 N-CA-C 108.288 -1.004 . . . . 0.0 108.288 177.11 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 31.6 m-85 -125.03 121.05 33.25 Favored 'General case' 0 N--CA 1.487 1.407 0 CA-C-O 120.787 0.327 . . . . 0.0 110.937 -179.855 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 68.7 m-85 55.2 73.32 0.42 Allowed 'General case' 0 C--N 1.345 0.386 0 CA-C-N 116.0 -0.545 . . . . 0.0 111.654 178.097 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -79.02 -78.65 0.15 Allowed 'General case' 0 C--N 1.345 0.379 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.345 -179.262 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 40.6 tt0 -111.74 102.01 10.33 Favored 'General case' 0 C--N 1.323 -0.555 0 N-CA-C 108.449 -0.945 . . . . 0.0 108.449 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -158.14 134.7 9.61 Favored 'General case' 0 C--O 1.209 -1.046 0 CA-C-O 119.571 -0.252 . . . . 0.0 111.448 178.975 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' F' F ' 24' ' ' VAL . . . . . 0.437 ' HB ' ' H ' ' C' ' 25' ' ' GLY . 63.6 t -57.13 166.89 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.885 0 N-CA-C 107.495 -1.298 . . . . 0.0 107.495 176.98 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' F' F ' 25' ' ' GLY . . . . . 0.413 ' H ' ' HB ' ' I' ' 24' ' ' VAL . . . -119.97 49.11 0.89 Allowed Glycine 0 N--CA 1.476 1.325 0 N-CA-C 110.792 -0.923 . . . . 0.0 110.792 -179.319 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -63.45 -167.77 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.549 0 CA-C-O 120.779 0.323 . . . . 0.0 110.221 179.579 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 24.8 t-20 -71.72 76.12 0.84 Allowed 'General case' 0 C--O 1.223 -0.321 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.378 179.761 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -70.18 140.49 52.55 Favored 'General case' 0 N--CA 1.478 0.967 0 N-CA-C 109.449 -0.574 . . . . 0.0 109.449 179.587 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.53 -149.8 0.05 OUTLIER Glycine 0 C--N 1.333 0.412 0 N-CA-C 110.852 -0.899 . . . . 0.0 110.852 179.443 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -92.16 126.68 37.34 Favored 'General case' 0 N--CA 1.47 0.573 0 N-CA-C 110.235 -0.283 . . . . 0.0 110.235 179.659 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 78.3 mt -123.65 116.98 49.8 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.512 0 N-CA-C 106.351 -1.722 . . . . 0.0 106.351 178.461 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' F' F ' 32' ' ' ILE . . . . . 0.42 HG22 ' H ' ' I' ' 32' ' ' ILE . 44.5 pt -151.31 -167.99 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.192 0 CA-C-O 121.061 0.458 . . . . 0.0 110.862 -178.882 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.98 5.66 8.05 Favored Glycine 0 CA--C 1.527 0.791 0 N-CA-C 111.373 -0.691 . . . . 0.0 111.373 -179.95 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 1.5 tt -77.9 127.18 31.97 Favored 'General case' 0 CA--C 1.548 0.886 0 N-CA-C 109.465 -0.569 . . . . 0.0 109.465 -179.897 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 28.4 ttt -164.45 144.44 7.69 Favored 'General case' 0 N--CA 1.469 0.493 0 N-CA-C 108.773 -0.825 . . . . 0.0 108.773 178.223 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' F' F ' 36' ' ' VAL . . . . . 0.473 HG22 HG12 ' I' ' 36' ' ' VAL . 32.9 m -156.26 162.75 1.59 Allowed 'Isoleucine or valine' 0 C--N 1.348 0.504 0 N-CA-C 108.292 -1.003 . . . . 0.0 108.292 179.566 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.16 66.28 2.96 Favored Glycine 0 C--N 1.307 -1.08 0 CA-C-N 115.691 -0.686 . . . . 0.0 111.854 178.366 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 145.79 174.42 17.95 Favored Glycine 0 N--CA 1.473 1.14 0 N-CA-C 111.313 -0.715 . . . . 0.0 111.313 178.863 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' F' F ' 39' ' ' VAL . . . . . 0.616 ' H ' HG12 ' I' ' 39' ' ' VAL . 34.4 m -124.47 159.78 30.0 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.669 0 C-N-CA 123.301 0.64 . . . . 0.0 110.224 -179.208 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 24.9 t . . . . . 0 C--O 1.218 -0.569 0 O-C-N 124.239 0.962 . . . . 0.0 110.517 179.507 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' G' G ' 1' ' ' ASP . . . . . . . . . . . . . 13.2 m-20 . . . . . 0 N--CA 1.491 1.598 0 N-CA-C 109.269 -0.641 . . . . 0.0 109.269 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' G' G ' 2' ' ' ALA . . . . . . . . . . . . . . . -63.17 128.84 37.7 Favored 'General case' 0 N--CA 1.468 0.426 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.69 179.67 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' G' G ' 3' ' ' GLU . . . . . . . . . . . . . 43.4 tt0 -168.06 106.36 0.5 Allowed 'General case' 0 N--CA 1.473 0.71 0 CA-C-O 120.424 0.154 . . . . 0.0 110.761 179.664 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 35.2 m-85 -89.79 154.69 19.71 Favored 'General case' 0 N--CA 1.474 0.736 0 N-CA-C 109.605 -0.517 . . . . 0.0 109.605 179.14 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' G' G ' 5' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -144.67 139.11 27.77 Favored 'General case' 0 N--CA 1.482 1.145 0 C-N-CA 122.544 0.338 . . . . 0.0 110.235 179.834 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 42.2 t-80 -150.8 120.87 7.19 Favored 'General case' 0 N--CA 1.474 0.726 0 N-CA-C 109.543 -0.54 . . . . 0.0 109.543 179.023 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -71.82 143.45 49.48 Favored 'General case' 0 N--CA 1.47 0.554 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.28 -179.766 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' G' G ' 8' ' ' SER . . . . . 0.604 ' OG ' ' O ' ' D' ' 7' ' ' ASP . 48.9 p -164.7 -170.93 2.13 Favored 'General case' 0 N--CA 1.476 0.828 0 CA-C-O 121.2 0.524 . . . . 0.0 110.534 178.83 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.52 49.01 1.23 Allowed Glycine 0 N--CA 1.479 1.528 0 N-CA-C 111.35 -0.7 . . . . 0.0 111.35 179.388 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 50.1 p90 -65.03 133.36 51.5 Favored 'General case' 0 N--CA 1.473 0.704 0 CA-C-O 120.673 0.273 . . . . 0.0 111.67 -179.719 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 83.3 mt-10 -92.1 151.64 20.32 Favored 'General case' 0 N--CA 1.48 1.031 0 CA-C-O 121.108 0.48 . . . . 0.0 110.142 178.665 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -154.89 127.45 1.06 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.973 0 N-CA-C 107.853 -1.165 . . . . 0.0 107.853 178.293 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 47.4 m-70 -134.6 144.73 48.08 Favored 'General case' 0 N--CA 1.479 1.005 0 CA-C-N 115.561 -0.745 . . . . 0.0 111.488 -178.298 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 29.5 t-80 -165.43 97.37 0.69 Allowed 'General case' 0 N--CA 1.482 1.131 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.377 178.989 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 3.6 pt20 -108.6 -174.72 2.58 Favored 'General case' 0 CA--C 1.506 -0.744 0 N-CA-C 108.433 -0.951 . . . . 0.0 108.433 -179.707 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -164.32 96.17 0.77 Allowed 'General case' 0 N--CA 1.474 0.758 0 CA-C-N 114.699 -1.137 . . . . 0.0 108.121 178.735 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 6.6 mp -120.58 155.61 33.34 Favored 'General case' 0 N--CA 1.497 1.924 0 CA-C-O 121.171 0.51 . . . . 0.0 111.771 -177.846 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 43.0 t -113.16 125.13 70.37 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.884 0 CA-C-N 114.757 -1.11 . . . . 0.0 108.128 176.477 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 33.1 m-85 -126.09 121.15 32.09 Favored 'General case' 0 C--N 1.369 1.424 0 CA-C-N 115.583 -0.735 . . . . 0.0 110.892 -179.699 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 67.2 m-85 54.8 72.95 0.43 Allowed 'General case' 0 C--O 1.238 0.459 0 CA-C-N 115.841 -0.618 . . . . 0.0 111.479 178.145 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -78.08 -77.96 0.15 Allowed 'General case' 0 N--CA 1.471 0.616 0 O-C-N 122.17 -0.331 . . . . 0.0 110.557 -178.939 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 40.4 tt0 -112.24 101.99 10.19 Favored 'General case' 0 C--N 1.323 -0.568 0 N-CA-C 108.093 -1.077 . . . . 0.0 108.093 179.917 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -157.88 135.91 10.8 Favored 'General case' 0 N--CA 1.476 0.867 0 O-C-N 122.401 -0.187 . . . . 0.0 111.488 178.826 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' G' G ' 24' ' ' VAL . . . . . 0.485 ' HB ' ' H ' ' D' ' 25' ' ' GLY . 57.3 t -58.27 166.47 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.647 0 N-CA-C 107.555 -1.276 . . . . 0.0 107.555 176.986 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' G' G ' 25' ' ' GLY . . . . . 0.413 ' N ' HG12 ' G' ' 24' ' ' VAL . . . -119.05 49.4 0.87 Allowed Glycine 0 N--CA 1.479 1.524 0 N-CA-C 110.456 -1.058 . . . . 0.0 110.456 -179.47 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -64.4 -168.09 0.03 OUTLIER 'General case' 0 N--CA 1.472 0.636 0 N-CA-C 109.904 -0.406 . . . . 0.0 109.904 179.645 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 3.3 t30 -71.62 76.09 0.82 Allowed 'General case' 0 CA--C 1.536 0.438 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.324 179.928 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -69.57 140.64 53.84 Favored 'General case' 0 N--CA 1.478 0.955 0 N-CA-C 109.562 -0.533 . . . . 0.0 109.562 179.604 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.99 -147.81 0.05 OUTLIER Glycine 0 C--N 1.337 0.587 0 N-CA-C 110.443 -1.063 . . . . 0.0 110.443 179.612 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -92.88 125.99 37.75 Favored 'General case' 0 N--CA 1.467 0.419 0 C-N-CA 122.65 0.38 . . . . 0.0 110.93 -179.824 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 76.6 mt -123.45 117.65 52.03 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.811 0 N-CA-C 106.417 -1.697 . . . . 0.0 106.417 178.238 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' G' G ' 32' ' ' ILE . . . . . 0.408 ' H ' HG22 ' D' ' 32' ' ' ILE . 44.0 pt -152.47 -167.61 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 CA-C-N 119.819 1.19 . . . . 0.0 110.031 -179.225 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.29 6.26 10.15 Favored Glycine 0 N--CA 1.466 0.671 0 N-CA-C 111.056 -0.818 . . . . 0.0 111.056 179.881 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 1.5 tt -79.49 125.7 29.91 Favored 'General case' 0 CA--C 1.545 0.773 0 N-CA-C 109.516 -0.55 . . . . 0.0 109.516 -179.702 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 27.7 ttt -162.86 146.17 10.97 Favored 'General case' 0 N--CA 1.47 0.553 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 178.534 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' G' G ' 36' ' ' VAL . . . . . 0.488 HG12 HG22 ' D' ' 36' ' ' VAL . 32.7 m -156.95 162.01 1.69 Allowed 'Isoleucine or valine' 0 C--N 1.35 0.603 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 -179.99 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.48 66.63 2.7 Favored Glycine 0 C--N 1.31 -0.913 0 CA-C-N 115.541 -0.754 . . . . 0.0 112.104 177.818 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 146.72 175.6 19.82 Favored Glycine 0 N--CA 1.475 1.251 0 N-CA-C 110.559 -1.016 . . . . 0.0 110.559 178.994 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' G' G ' 39' ' ' VAL . . . . . 0.624 HG12 ' H ' ' D' ' 39' ' ' VAL . 34.9 m -125.77 159.71 33.4 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.912 0 C-N-CA 123.092 0.557 . . . . 0.0 110.484 -179.408 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 26.3 t . . . . . 0 C--O 1.22 -0.488 0 CA-C-O 118.395 -0.812 . . . . 0.0 110.751 179.082 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' H' H ' 1' ' ' ASP . . . . . . . . . . . . . 13.3 m-20 . . . . . 0 N--CA 1.492 1.66 0 N-CA-C 109.343 -0.614 . . . . 0.0 109.343 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' H' H ' 2' ' ' ALA . . . . . . . . . . . . . . . -63.01 128.63 36.76 Favored 'General case' 0 N--CA 1.469 0.485 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.581 179.777 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' H' H ' 3' ' ' GLU . . . . . . . . . . . . . 43.2 tt0 -167.89 106.48 0.52 Allowed 'General case' 0 N--CA 1.471 0.586 0 CA-C-O 120.496 0.189 . . . . 0.0 110.722 179.642 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 34.9 m-85 -89.89 154.77 19.61 Favored 'General case' 0 N--CA 1.474 0.77 0 N-CA-C 109.518 -0.549 . . . . 0.0 109.518 179.263 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' H' H ' 5' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -144.74 139.68 28.04 Favored 'General case' 0 N--CA 1.485 1.313 0 N-CA-C 110.04 -0.355 . . . . 0.0 110.04 179.838 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 41.2 t-80 -151.58 120.7 6.72 Favored 'General case' 0 N--CA 1.474 0.76 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 179.068 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -71.65 143.82 49.62 Favored 'General case' 0 N--CA 1.469 0.511 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.308 -179.756 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' H' H ' 8' ' ' SER . . . . . 0.501 ' OG ' ' O ' ' E' ' 7' ' ' ASP . 52.2 p -164.81 -171.18 2.19 Favored 'General case' 0 N--CA 1.475 0.809 0 CA-C-O 121.126 0.489 . . . . 0.0 110.489 178.921 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.76 48.35 1.28 Allowed Glycine 0 N--CA 1.479 1.541 0 CA-C-N 115.783 -0.644 . . . . 0.0 111.551 179.336 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 50.1 p90 -64.51 133.06 51.64 Favored 'General case' 0 N--CA 1.471 0.624 0 N-CA-C 111.785 0.291 . . . . 0.0 111.785 -179.685 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 83.1 mt-10 -91.69 151.56 20.61 Favored 'General case' 0 N--CA 1.479 0.984 0 CA-C-O 121.068 0.461 . . . . 0.0 110.183 178.476 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -154.67 127.88 1.17 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.979 0 N-CA-C 107.885 -1.154 . . . . 0.0 107.885 178.08 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 47.3 m-70 -134.75 145.53 48.52 Favored 'General case' 0 N--CA 1.478 0.955 0 CA-C-N 115.676 -0.693 . . . . 0.0 111.359 -178.419 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 27.9 t-80 -166.24 97.37 0.6 Allowed 'General case' 0 N--CA 1.482 1.146 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.346 178.794 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 3.6 pt20 -108.33 -174.3 2.49 Favored 'General case' 0 CA--C 1.505 -0.757 0 N-CA-C 108.425 -0.954 . . . . 0.0 108.425 -179.728 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -164.84 96.22 0.72 Allowed 'General case' 0 N--CA 1.475 0.799 0 CA-C-N 114.647 -1.16 . . . . 0.0 108.018 178.66 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' H' H ' 17' ' ' LEU . . . . . 0.412 ' CD1' ' H ' ' E' ' 17' ' ' LEU . 6.5 mp -120.53 156.02 32.43 Favored 'General case' 0 N--CA 1.497 1.899 0 CA-C-O 121.239 0.543 . . . . 0.0 111.972 -177.949 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 41.4 t -113.7 124.73 70.63 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.07 0 CA-C-N 114.819 -1.082 . . . . 0.0 108.227 176.658 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 33.3 m-85 -125.73 121.31 33.04 Favored 'General case' 0 C--N 1.368 1.388 0 CA-C-N 115.459 -0.792 . . . . 0.0 110.863 -179.491 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 68.0 m-85 54.3 72.69 0.44 Allowed 'General case' 0 C--O 1.237 0.422 0 CA-C-N 115.858 -0.61 . . . . 0.0 111.587 178.11 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.63 -78.13 0.14 Allowed 'General case' 0 N--CA 1.471 0.622 0 O-C-N 122.203 -0.31 . . . . 0.0 110.571 -179.033 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 40.9 tt0 -112.12 101.99 10.22 Favored 'General case' 0 C--N 1.321 -0.632 0 N-CA-C 108.091 -1.077 . . . . 0.0 108.091 -179.99 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -157.97 135.78 10.61 Favored 'General case' 0 N--CA 1.477 0.913 0 N-CA-C 111.445 0.165 . . . . 0.0 111.445 178.863 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' H' H ' 24' ' ' VAL . . . . . 0.41 HG12 ' N ' ' H' ' 25' ' ' GLY . 59.2 t -58.3 166.35 0.51 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.606 0 N-CA-C 107.682 -1.229 . . . . 0.0 107.682 177.197 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' H' H ' 25' ' ' GLY . . . . . 0.41 ' N ' HG12 ' H' ' 24' ' ' VAL . . . -118.76 49.42 0.87 Allowed Glycine 0 N--CA 1.478 1.444 0 N-CA-C 110.653 -0.979 . . . . 0.0 110.653 -179.498 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -64.67 -167.85 0.03 OUTLIER 'General case' 0 N--CA 1.472 0.668 0 CA-C-N 116.97 0.385 . . . . 0.0 110.0 179.662 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 24.9 t-20 -71.77 76.39 0.86 Allowed 'General case' 0 CA--C 1.535 0.4 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.317 179.871 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -69.89 140.74 53.18 Favored 'General case' 0 N--CA 1.478 0.953 0 N-CA-C 109.552 -0.536 . . . . 0.0 109.552 179.483 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.96 -147.82 0.05 OUTLIER Glycine 0 C--N 1.338 0.653 0 N-CA-C 110.329 -1.108 . . . . 0.0 110.329 179.541 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -93.5 125.77 38.29 Favored 'General case' 0 N--CA 1.465 0.307 0 C-N-CA 122.58 0.352 . . . . 0.0 110.872 -179.61 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 76.1 mt -122.92 117.55 52.12 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.757 0 N-CA-C 106.431 -1.692 . . . . 0.0 106.431 178.315 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' H' H ' 32' ' ' ILE . . . . . 0.415 ' H ' HG22 ' E' ' 32' ' ' ILE . 44.8 pt -152.04 -167.84 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 CA-C-N 119.807 1.185 . . . . 0.0 109.98 -179.469 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.93 5.8 10.53 Favored Glycine 0 N--CA 1.466 0.661 0 N-CA-C 110.964 -0.854 . . . . 0.0 110.964 179.86 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 1.5 tt -79.04 124.95 28.77 Favored 'General case' 0 CA--C 1.544 0.744 0 N-CA-C 109.725 -0.472 . . . . 0.0 109.725 -179.515 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 27.8 ttt -162.19 145.97 12.01 Favored 'General case' 0 N--CA 1.469 0.502 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 178.635 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' H' H ' 36' ' ' VAL . . . . . 0.463 HG12 HG22 ' E' ' 36' ' ' VAL . 32.6 m -157.08 161.69 1.76 Allowed 'Isoleucine or valine' 0 C--N 1.349 0.566 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 -179.895 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.94 66.2 3.01 Favored Glycine 0 C--N 1.309 -0.93 0 CA-C-N 115.498 -0.773 . . . . 0.0 112.17 177.935 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 146.92 175.63 20.01 Favored Glycine 0 N--CA 1.474 1.197 0 N-CA-C 110.639 -0.984 . . . . 0.0 110.639 178.893 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' H' H ' 39' ' ' VAL . . . . . 0.614 HG12 ' H ' ' E' ' 39' ' ' VAL . 34.9 m -125.2 159.96 31.54 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.927 0 C-N-CA 123.173 0.589 . . . . 0.0 110.537 -179.487 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 25.1 t . . . . . 0 N--CA 1.47 0.54 0 CA-C-O 118.439 -0.791 . . . . 0.0 110.819 179.233 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' I' I ' 1' ' ' ASP . . . . . . . . . . . . . 13.0 m-20 . . . . . 0 N--CA 1.491 1.578 0 N-CA-C 109.461 -0.57 . . . . 0.0 109.461 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' I' I ' 2' ' ' ALA . . . . . . . . . . . . . . . -63.5 128.5 36.12 Favored 'General case' 0 N--CA 1.468 0.475 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.598 179.752 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' I' I ' 3' ' ' GLU . . . . . . . . . . . . . 43.3 tt0 -167.7 106.9 0.55 Allowed 'General case' 0 N--CA 1.471 0.61 0 CA-C-O 120.547 0.213 . . . . 0.0 110.704 179.709 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 35.9 m-85 -90.33 154.56 19.61 Favored 'General case' 0 N--CA 1.474 0.739 0 N-CA-C 109.538 -0.541 . . . . 0.0 109.538 179.152 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' I' I ' 5' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -144.51 139.17 28.08 Favored 'General case' 0 N--CA 1.484 1.255 0 N-CA-C 110.038 -0.356 . . . . 0.0 110.038 179.815 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 41.6 t-80 -150.81 120.73 7.12 Favored 'General case' 0 N--CA 1.473 0.679 0 N-CA-C 109.385 -0.598 . . . . 0.0 109.385 178.907 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 4.0 m-20 -71.48 143.94 49.86 Favored 'General case' 0 N--CA 1.47 0.531 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.141 -179.888 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' I' I ' 8' ' ' SER . . . . . 0.465 ' OG ' ' O ' ' F' ' 7' ' ' ASP . 52.5 p -165.05 -171.14 2.13 Favored 'General case' 0 N--CA 1.474 0.758 0 CA-C-O 121.081 0.467 . . . . 0.0 110.621 178.89 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.53 48.81 1.25 Allowed Glycine 0 N--CA 1.479 1.514 0 N-CA-C 111.502 -0.639 . . . . 0.0 111.502 179.348 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 50.2 p90 -65.12 132.94 50.49 Favored 'General case' 0 N--CA 1.472 0.663 0 N-CA-C 111.772 0.286 . . . . 0.0 111.772 -179.718 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 83.6 mt-10 -91.43 151.57 20.75 Favored 'General case' 0 N--CA 1.478 0.953 0 CA-C-O 121.045 0.45 . . . . 0.0 110.265 178.539 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -154.91 127.42 1.05 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.047 0 N-CA-C 107.91 -1.144 . . . . 0.0 107.91 178.198 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 46.9 m-70 -134.48 145.15 48.54 Favored 'General case' 0 N--CA 1.478 0.933 0 CA-C-N 115.61 -0.723 . . . . 0.0 111.407 -178.196 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 29.1 t-80 -165.75 97.25 0.65 Allowed 'General case' 0 N--CA 1.48 1.03 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.378 178.838 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 3.6 pt20 -108.39 -174.55 2.55 Favored 'General case' 0 CA--C 1.504 -0.809 0 N-CA-C 108.381 -0.97 . . . . 0.0 108.381 -179.757 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -164.54 96.33 0.75 Allowed 'General case' 0 N--CA 1.474 0.755 0 CA-C-N 114.608 -1.178 . . . . 0.0 108.116 178.641 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' I' I ' 17' ' ' LEU . . . . . 0.406 ' CD1' ' H ' ' F' ' 17' ' ' LEU . 6.4 mp -120.6 156.07 32.42 Favored 'General case' 0 N--CA 1.497 1.914 0 CA-C-O 121.232 0.539 . . . . 0.0 111.767 -177.882 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 41.4 t -113.77 125.06 70.98 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.884 0 CA-C-N 114.753 -1.112 . . . . 0.0 108.207 176.608 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 33.6 m-85 -126.0 121.38 32.86 Favored 'General case' 0 C--N 1.368 1.41 0 CA-C-N 115.502 -0.772 . . . . 0.0 110.829 -179.449 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 67.9 m-85 54.25 73.29 0.4 Allowed 'General case' 0 C--N 1.347 0.467 0 CA-C-N 115.925 -0.58 . . . . 0.0 111.464 178.136 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -78.18 -78.01 0.15 Allowed 'General case' 0 N--CA 1.475 0.802 0 O-C-N 122.296 -0.253 . . . . 0.0 110.453 -179.079 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 40.7 tt0 -112.02 102.12 10.36 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 108.088 -1.079 . . . . 0.0 108.088 179.802 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -157.88 135.92 10.81 Favored 'General case' 0 N--CA 1.478 0.97 0 N-CA-C 111.409 0.152 . . . . 0.0 111.409 178.784 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' I' I ' 24' ' ' VAL . . . . . 0.42 HG12 ' N ' ' I' ' 25' ' ' GLY . 59.5 t -58.57 166.32 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.573 0 N-CA-C 107.658 -1.238 . . . . 0.0 107.658 177.203 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' I' I ' 25' ' ' GLY . . . . . 0.42 ' N ' HG12 ' I' ' 24' ' ' VAL . . . -118.69 49.0 0.89 Allowed Glycine 0 N--CA 1.479 1.524 0 N-CA-C 110.556 -1.017 . . . . 0.0 110.556 -179.392 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -64.3 -167.87 0.03 OUTLIER 'General case' 0 N--CA 1.472 0.648 0 CA-C-N 116.951 0.376 . . . . 0.0 110.092 179.641 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 24.9 t-20 -71.74 76.45 0.85 Allowed 'General case' 0 CA--C 1.536 0.419 0 CA-C-N 116.07 -0.513 . . . . 0.0 110.219 179.884 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -70.08 140.86 52.81 Favored 'General case' 0 N--CA 1.478 0.961 0 N-CA-C 109.492 -0.559 . . . . 0.0 109.492 179.496 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -65.02 -147.67 0.05 OUTLIER Glycine 0 C--N 1.337 0.628 0 N-CA-C 110.416 -1.074 . . . . 0.0 110.416 179.577 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -93.3 125.89 38.14 Favored 'General case' 0 N--CA 1.469 0.496 0 C-N-CA 122.587 0.355 . . . . 0.0 110.924 -179.953 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 77.0 mt -123.2 117.3 51.15 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.708 0 N-CA-C 106.474 -1.676 . . . . 0.0 106.474 178.255 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' I' I ' 32' ' ' ILE . . . . . 0.42 ' H ' HG22 ' F' ' 32' ' ' ILE . 44.6 pt -152.13 -167.9 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 CA-C-N 119.851 1.205 . . . . 0.0 109.979 -179.284 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.07 5.52 10.2 Favored Glycine 0 N--CA 1.466 0.674 0 N-CA-C 110.969 -0.852 . . . . 0.0 110.969 179.86 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 1.5 tt -78.6 125.82 29.89 Favored 'General case' 0 CA--C 1.546 0.798 0 N-CA-C 109.6 -0.519 . . . . 0.0 109.6 -179.675 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 27.7 ttt -162.76 146.01 11.08 Favored 'General case' 0 N--CA 1.47 0.561 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 178.454 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' I' I ' 36' ' ' VAL . . . . . 0.473 HG12 HG22 ' F' ' 36' ' ' VAL . 32.5 m -157.08 161.78 1.73 Allowed 'Isoleucine or valine' 0 C--N 1.348 0.522 0 N-CA-C 108.6 -0.889 . . . . 0.0 108.6 179.928 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.76 66.42 2.86 Favored Glycine 0 C--N 1.308 -0.981 0 CA-C-N 115.557 -0.747 . . . . 0.0 112.114 177.863 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 146.64 175.76 19.88 Favored Glycine 0 N--CA 1.476 1.334 0 N-CA-C 110.57 -1.012 . . . . 0.0 110.57 178.95 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' I' I ' 39' ' ' VAL . . . . . 0.616 HG12 ' H ' ' F' ' 39' ' ' VAL . 35.0 m -125.69 160.11 32.64 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.915 0 C-N-CA 123.138 0.575 . . . . 0.0 110.53 -179.381 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 25.9 t . . . . . 0 C--O 1.218 -0.557 0 CA-C-O 118.449 -0.786 . . . . 0.0 110.713 179.216 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 9.3 m-20 . . . . . 0 N--CA 1.489 1.492 0 N-CA-C 108.992 -0.744 . . . . 0.0 108.992 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.85 132.42 48.64 Favored 'General case' 0 CA--C 1.539 0.529 0 N-CA-C 110.202 -0.295 . . . . 0.0 110.202 -179.754 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 44.7 tt0 -168.23 105.58 0.47 Allowed 'General case' 0 C--O 1.213 -0.843 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 -179.237 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 39.4 m-85 -85.66 152.67 22.92 Favored 'General case' 0 N--CA 1.477 0.882 0 N-CA-C 109.99 -0.374 . . . . 0.0 109.99 179.489 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -143.93 140.15 29.54 Favored 'General case' 0 N--CA 1.48 1.048 0 N-CA-C 110.016 -0.364 . . . . 0.0 110.016 179.67 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 43.3 t-80 -151.84 119.67 6.16 Favored 'General case' 0 N--CA 1.47 0.551 0 N-CA-C 109.224 -0.658 . . . . 0.0 109.224 179.291 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' ASP . . . . . 0.495 ' O ' ' OG ' ' D' ' 8' ' ' SER . 4.6 m-20 -69.14 148.9 49.27 Favored 'General case' 0 N--CA 1.466 0.34 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.466 179.879 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 54.8 p -168.21 -173.79 2.12 Favored 'General case' 0 N--CA 1.482 1.162 0 C-N-CA 122.669 0.388 . . . . 0.0 110.718 179.053 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.79 47.79 1.33 Allowed Glycine 0 N--CA 1.482 1.735 0 CA-C-N 116.013 -0.539 . . . . 0.0 112.147 -179.911 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 50.1 p90 -65.06 132.67 49.83 Favored 'General case' 0 N--CA 1.473 0.686 0 CA-C-O 120.716 0.293 . . . . 0.0 111.532 179.899 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 49.0 mt-10 -92.66 152.46 19.54 Favored 'General case' 0 N--CA 1.477 0.918 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 178.398 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.0 p -153.13 128.37 1.55 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.632 0 N-CA-C 107.847 -1.168 . . . . 0.0 107.847 178.382 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 47.2 m-70 -134.87 145.83 48.65 Favored 'General case' 0 N--CA 1.492 1.648 0 CA-C-N 119.096 0.862 . . . . 0.0 111.327 -179.127 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 6.1 t60 -165.73 97.51 0.66 Allowed 'General case' 0 N--CA 1.48 1.05 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.809 179.496 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 3.9 pt20 -111.9 -174.78 2.54 Favored 'General case' 0 CA--C 1.503 -0.86 0 N-CA-C 108.355 -0.98 . . . . 0.0 108.355 -179.849 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -163.27 99.13 0.94 Allowed 'General case' 0 N--CA 1.474 0.749 0 CA-C-N 114.527 -1.215 . . . . 0.0 108.347 178.582 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 6.9 mp -121.83 157.07 31.9 Favored 'General case' 0 N--CA 1.497 1.909 0 CA-C-O 121.945 0.879 . . . . 0.0 110.86 -178.338 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 60.0 t -112.54 126.84 69.98 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.179 0 CA-C-O 117.877 -1.058 . . . . 0.0 108.298 177.808 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 28.8 m-85 -127.11 122.52 34.49 Favored 'General case' 0 N--CA 1.496 1.859 0 CA-C-N 120.197 1.362 . . . . 0.0 110.336 179.302 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 68.3 m-85 53.95 73.98 0.35 Allowed 'General case' 0 N--CA 1.47 0.546 0 CA-C-O 121.544 0.687 . . . . 0.0 111.745 178.51 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -80.22 -78.13 0.18 Allowed 'General case' 0 C--N 1.353 0.758 0 CA-C-N 115.117 -0.947 . . . . 0.0 110.42 -179.739 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 40.3 tt0 -112.07 101.87 10.12 Favored 'General case' 0 N--CA 1.47 0.563 0 N-CA-C 108.493 -0.928 . . . . 0.0 108.493 179.927 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -158.69 134.65 9.0 Favored 'General case' 0 N--CA 1.481 1.092 0 CA-C-O 119.388 -0.339 . . . . 0.0 111.254 179.026 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 61.9 t -58.36 163.4 0.72 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.795 0 N-CA-C 108.227 -1.027 . . . . 0.0 108.227 177.173 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.422 ' H ' ' HB ' ' D' ' 24' ' ' VAL . . . -116.04 48.07 0.98 Allowed Glycine 0 N--CA 1.476 1.326 0 N-CA-C 111.759 -0.536 . . . . 0.0 111.759 -179.402 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -62.07 -168.59 0.02 OUTLIER 'General case' 0 N--CA 1.469 0.499 0 O-C-N 123.834 0.373 . . . . 0.0 110.218 179.284 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 2.8 t30 -72.43 79.83 1.04 Allowed 'General case' 0 N--CA 1.466 0.335 0 N-CA-C 110.048 -0.352 . . . . 0.0 110.048 179.221 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -73.28 140.32 46.73 Favored 'General case' 0 N--CA 1.471 0.625 0 N-CA-C 109.012 -0.736 . . . . 0.0 109.012 179.43 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.42 -148.9 0.03 OUTLIER Glycine 0 C--N 1.337 0.622 0 N-CA-C 110.383 -1.087 . . . . 0.0 110.383 179.443 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -93.94 128.54 40.31 Favored 'General case' 0 N--CA 1.471 0.604 0 N-CA-C 110.076 -0.342 . . . . 0.0 110.076 179.904 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 72.4 mt -125.0 116.77 48.13 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.874 0 N-CA-C 106.782 -1.562 . . . . 0.0 106.782 178.764 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 38.9 pt -151.01 -169.69 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.356 0.88 0 CA-C-N 115.857 -0.611 . . . . 0.0 111.206 -178.527 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.41 5.37 11.41 Favored Glycine 0 C--N 1.336 0.577 0 N-CA-C 110.912 -0.875 . . . . 0.0 110.912 179.673 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.403 HD23 ' N ' ' A' ' 35' ' ' MET . 1.5 tt -78.42 127.12 31.74 Favored 'General case' 0 CA--C 1.543 0.684 0 N-CA-C 109.44 -0.578 . . . . 0.0 109.44 -179.617 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 35' ' ' MET . . . . . 0.403 ' N ' HD23 ' A' ' 34' ' ' LEU . 28.6 ttt -164.59 143.86 7.22 Favored 'General case' 0 N--CA 1.466 0.368 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 178.404 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.403 HG22 HG12 ' D' ' 36' ' ' VAL . 35.3 m -155.92 163.28 1.51 Allowed 'Isoleucine or valine' 0 C--O 1.219 -0.525 0 N-CA-C 108.339 -0.985 . . . . 0.0 108.339 179.376 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.78 66.56 2.75 Favored Glycine 0 C--N 1.303 -1.292 0 CA-C-N 116.147 -0.479 . . . . 0.0 112.136 178.631 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 146.0 173.54 17.34 Favored Glycine 0 N--CA 1.475 1.243 0 N-CA-C 110.649 -0.98 . . . . 0.0 110.649 179.138 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.578 ' H ' HG12 ' D' ' 39' ' ' VAL . 35.6 m -123.96 159.98 28.53 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.861 0 C-N-CA 123.579 0.752 . . . . 0.0 110.552 -179.858 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 25.2 t . . . . . 0 C--O 1.22 -0.46 0 CA-C-O 118.323 -0.846 . . . . 0.0 110.78 179.568 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' B' B ' 1' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 . . . . . 0 N--CA 1.49 1.534 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' B' B ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.39 132.33 48.71 Favored 'General case' 0 CA--C 1.54 0.593 0 CA-C-N 116.56 -0.291 . . . . 0.0 110.229 -179.821 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 3' ' ' GLU . . . . . . . . . . . . . 44.6 tt0 -168.2 105.51 0.48 Allowed 'General case' 0 N--CA 1.474 0.728 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 -179.169 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 39.4 m-85 -85.59 152.47 23.11 Favored 'General case' 0 N--CA 1.475 0.807 0 N-CA-C 109.99 -0.374 . . . . 0.0 109.99 179.534 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -143.71 139.98 29.78 Favored 'General case' 0 N--CA 1.482 1.139 0 N-CA-C 109.977 -0.379 . . . . 0.0 109.977 179.693 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 40.5 t-80 -151.74 119.18 6.0 Favored 'General case' 0 N--CA 1.473 0.724 0 N-CA-C 109.238 -0.652 . . . . 0.0 109.238 179.216 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 7' ' ' ASP . . . . . 0.501 ' O ' ' OG ' ' E' ' 8' ' ' SER . 4.3 m-20 -68.89 148.15 50.64 Favored 'General case' 0 CA--C 1.535 0.385 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.639 179.865 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 8' ' ' SER . . . . . . . . . . . . . 54.3 p -167.44 -173.79 2.34 Favored 'General case' 0 N--CA 1.48 1.068 0 C-N-CA 122.575 0.35 . . . . 0.0 110.701 179.072 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.94 47.92 1.3 Allowed Glycine 0 N--CA 1.482 1.703 0 CA-C-N 115.991 -0.549 . . . . 0.0 112.178 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 50.1 p90 -65.18 132.7 49.8 Favored 'General case' 0 N--CA 1.472 0.633 0 O-C-N 122.716 -0.285 . . . . 0.0 111.663 179.782 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 48.5 mt-10 -92.55 152.77 19.45 Favored 'General case' 0 N--CA 1.477 0.913 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 178.331 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.0 p -153.43 128.45 1.51 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.587 0 N-CA-C 107.737 -1.209 . . . . 0.0 107.737 178.314 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 47.5 m-70 -135.0 145.81 48.45 Favored 'General case' 0 N--CA 1.492 1.639 0 CA-C-N 118.904 0.775 . . . . 0.0 111.303 -179.103 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 6.2 t60 -165.66 97.46 0.66 Allowed 'General case' 0 N--CA 1.482 1.133 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.648 179.452 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 3.9 pt20 -111.76 -174.34 2.44 Favored 'General case' 0 CA--C 1.506 -0.749 0 N-CA-C 108.362 -0.977 . . . . 0.0 108.362 -179.883 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -163.87 99.07 0.87 Allowed 'General case' 0 N--CA 1.474 0.77 0 CA-C-N 114.718 -1.128 . . . . 0.0 108.26 178.608 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 6.8 mp -121.62 157.0 31.77 Favored 'General case' 0 N--CA 1.497 1.916 0 CA-C-O 121.936 0.875 . . . . 0.0 110.998 -178.294 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 61.1 t -112.55 127.6 69.68 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.07 0 N-CA-C 108.122 -1.066 . . . . 0.0 108.122 177.574 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 29.0 m-85 -127.99 122.36 32.11 Favored 'General case' 0 N--CA 1.495 1.802 0 CA-C-N 119.638 1.108 . . . . 0.0 110.219 179.515 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 68.7 m-85 53.23 74.46 0.3 Allowed 'General case' 0 CA--C 1.54 0.566 0 CA-C-O 121.558 0.694 . . . . 0.0 111.735 178.573 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -80.71 -77.85 0.19 Allowed 'General case' 0 C--N 1.35 0.6 0 CA-C-N 115.075 -0.966 . . . . 0.0 110.45 -179.788 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 40.5 tt0 -112.22 101.9 10.1 Favored 'General case' 0 N--CA 1.471 0.615 0 N-CA-C 108.417 -0.957 . . . . 0.0 108.417 179.786 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -158.68 134.54 8.94 Favored 'General case' 0 N--CA 1.484 1.23 0 CA-C-O 119.444 -0.312 . . . . 0.0 111.16 178.85 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 24' ' ' VAL . . . . . 0.403 HG12 ' N ' ' B' ' 25' ' ' GLY . 61.1 t -57.98 163.82 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.806 0 N-CA-C 108.249 -1.019 . . . . 0.0 108.249 177.209 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 25' ' ' GLY . . . . . 0.437 ' H ' ' HB ' ' E' ' 24' ' ' VAL . . . -116.22 48.22 0.96 Allowed Glycine 0 N--CA 1.475 1.288 0 N-CA-C 111.625 -0.59 . . . . 0.0 111.625 -179.446 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -62.27 -169.06 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.531 0 O-C-N 123.76 0.33 . . . . 0.0 110.242 179.238 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 3.1 t30 -72.2 79.68 0.97 Allowed 'General case' 0 N--CA 1.467 0.393 0 N-CA-C 109.881 -0.414 . . . . 0.0 109.881 179.307 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -72.99 140.66 47.5 Favored 'General case' 0 N--CA 1.472 0.674 0 N-CA-C 109.105 -0.702 . . . . 0.0 109.105 179.417 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.86 -149.1 0.04 OUTLIER Glycine 0 C--N 1.338 0.645 0 N-CA-C 110.349 -1.1 . . . . 0.0 110.349 179.582 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -93.75 128.47 39.99 Favored 'General case' 0 N--CA 1.473 0.679 0 N-CA-C 110.036 -0.357 . . . . 0.0 110.036 179.882 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 72.5 mt -125.08 117.14 49.15 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.859 0 N-CA-C 106.723 -1.584 . . . . 0.0 106.723 178.768 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 39.6 pt -151.47 -169.94 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.356 0.887 0 CA-C-N 115.874 -0.603 . . . . 0.0 111.119 -178.364 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.68 5.26 12.31 Favored Glycine 0 C--N 1.337 0.614 0 N-CA-C 110.894 -0.882 . . . . 0.0 110.894 179.702 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 1.5 tt -78.42 126.67 31.09 Favored 'General case' 0 CA--C 1.545 0.76 0 N-CA-C 109.441 -0.577 . . . . 0.0 109.441 -179.521 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 28.5 ttt -164.12 143.66 7.83 Favored 'General case' 0 N--CA 1.467 0.378 0 N-CA-C 108.722 -0.844 . . . . 0.0 108.722 178.456 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 35.7 m -155.88 162.98 1.57 Allowed 'Isoleucine or valine' 0 C--O 1.22 -0.491 0 N-CA-C 108.343 -0.984 . . . . 0.0 108.343 179.519 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.81 66.95 2.47 Favored Glycine 0 C--N 1.303 -1.291 0 CA-C-N 116.183 -0.462 . . . . 0.0 112.076 178.591 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 145.33 173.24 16.41 Favored Glycine 0 N--CA 1.474 1.208 0 N-CA-C 110.69 -0.964 . . . . 0.0 110.69 179.181 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 39' ' ' VAL . . . . . 0.611 ' H ' HG12 ' E' ' 39' ' ' VAL . 35.7 m -123.65 159.84 27.95 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.934 0 C-N-CA 123.608 0.763 . . . . 0.0 110.713 -179.769 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 24.4 t . . . . . 0 N--CA 1.469 0.522 0 CA-C-O 118.339 -0.839 . . . . 0.0 110.599 179.53 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' C' C ' 1' ' ' ASP . . . . . . . . . . . . . 8.9 m-20 . . . . . 0 N--CA 1.49 1.548 0 N-CA-C 108.795 -0.817 . . . . 0.0 108.795 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' C' C ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.77 132.73 49.43 Favored 'General case' 0 CA--C 1.539 0.538 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.213 -179.745 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 3' ' ' GLU . . . . . . . . . . . . . 44.6 tt0 -168.5 105.61 0.45 Allowed 'General case' 0 C--O 1.214 -0.776 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 -179.192 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 40.3 m-85 -85.75 152.45 23.05 Favored 'General case' 0 N--CA 1.476 0.842 0 N-CA-C 110.031 -0.359 . . . . 0.0 110.031 179.532 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -143.63 139.98 29.89 Favored 'General case' 0 N--CA 1.482 1.134 0 CA-C-O 120.872 0.368 . . . . 0.0 110.05 179.762 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 42.1 t-80 -151.74 119.16 5.99 Favored 'General case' 0 N--CA 1.472 0.656 0 N-CA-C 109.26 -0.644 . . . . 0.0 109.26 179.173 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 7' ' ' ASP . . . . . 0.471 ' O ' ' OG ' ' F' ' 8' ' ' SER . 4.2 m-20 -68.77 148.47 50.28 Favored 'General case' 0 N--CA 1.468 0.443 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.52 179.783 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 8' ' ' SER . . . . . . . . . . . . . 54.2 p -167.97 -173.94 2.23 Favored 'General case' 0 N--CA 1.48 1.049 0 CA-C-O 120.874 0.368 . . . . 0.0 110.677 179.137 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.05 47.75 1.31 Allowed Glycine 0 N--CA 1.482 1.751 0 CA-C-N 115.968 -0.56 . . . . 0.0 112.072 -179.926 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 50.6 p90 -65.04 132.58 49.59 Favored 'General case' 0 N--CA 1.472 0.658 0 CA-C-O 120.778 0.323 . . . . 0.0 111.637 179.737 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 48.6 mt-10 -92.48 152.96 19.39 Favored 'General case' 0 N--CA 1.475 0.79 0 N-CA-C 109.738 -0.468 . . . . 0.0 109.738 178.395 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.0 p -153.65 128.62 1.5 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.523 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 178.263 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 46.1 m-70 -135.17 145.72 48.02 Favored 'General case' 0 N--CA 1.492 1.635 0 CA-C-N 118.931 0.787 . . . . 0.0 111.317 -179.057 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 6.2 t60 -165.52 97.52 0.68 Allowed 'General case' 0 N--CA 1.482 1.162 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.688 179.52 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 3.9 pt20 -112.0 -174.47 2.47 Favored 'General case' 0 CA--C 1.504 -0.825 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 -179.889 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -163.62 99.12 0.9 Allowed 'General case' 0 N--CA 1.473 0.677 0 CA-C-N 114.708 -1.133 . . . . 0.0 108.261 178.777 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 6.8 mp -121.71 157.07 31.74 Favored 'General case' 0 N--CA 1.497 1.902 0 CA-C-O 121.965 0.888 . . . . 0.0 110.994 -178.342 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 61.9 t -112.71 127.4 69.96 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.151 0 N-CA-C 108.146 -1.057 . . . . 0.0 108.146 177.612 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 28.9 m-85 -127.82 122.17 32.01 Favored 'General case' 0 N--CA 1.494 1.765 0 CA-C-N 119.673 1.124 . . . . 0.0 110.197 179.513 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 68.7 m-85 53.42 74.55 0.3 Allowed 'General case' 0 CA--C 1.539 0.523 0 CA-C-O 121.57 0.7 . . . . 0.0 111.787 178.612 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -80.62 -78.12 0.18 Allowed 'General case' 0 C--N 1.35 0.598 0 CA-C-N 114.961 -1.018 . . . . 0.0 110.379 -179.805 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 40.3 tt0 -112.02 102.05 10.3 Favored 'General case' 0 N--CA 1.469 0.522 0 N-CA-C 108.506 -0.924 . . . . 0.0 108.506 179.82 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -158.76 134.67 8.94 Favored 'General case' 0 N--CA 1.482 1.161 0 CA-C-O 119.385 -0.341 . . . . 0.0 111.185 178.906 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 61.0 t -58.14 163.74 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.843 0 N-CA-C 108.217 -1.031 . . . . 0.0 108.217 177.188 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 25' ' ' GLY . . . . . 0.443 ' H ' ' HB ' ' F' ' 24' ' ' VAL . . . -116.28 48.13 0.97 Allowed Glycine 0 N--CA 1.477 1.372 0 N-CA-C 111.617 -0.593 . . . . 0.0 111.617 -179.352 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -62.3 -169.11 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.532 0 O-C-N 123.726 0.309 . . . . 0.0 110.212 179.312 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 25.2 t-20 -71.98 79.98 0.92 Allowed 'General case' 0 N--CA 1.466 0.368 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.205 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -73.45 140.61 46.62 Favored 'General case' 0 N--CA 1.473 0.692 0 N-CA-C 109.015 -0.735 . . . . 0.0 109.015 179.369 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.71 -148.67 0.03 OUTLIER Glycine 0 C--N 1.338 0.661 0 N-CA-C 110.395 -1.082 . . . . 0.0 110.395 179.548 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -93.99 128.25 40.23 Favored 'General case' 0 N--CA 1.471 0.592 0 CA-C-N 116.866 0.333 . . . . 0.0 110.136 179.825 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 71.8 mt -124.94 116.71 48.02 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.834 0 N-CA-C 106.779 -1.563 . . . . 0.0 106.779 178.654 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 38.8 pt -150.97 -169.71 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.356 0.873 0 CA-C-N 115.903 -0.589 . . . . 0.0 111.183 -178.42 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.37 5.39 11.29 Favored Glycine 0 C--N 1.336 0.555 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 179.659 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 1.5 tt -78.53 126.44 30.76 Favored 'General case' 0 CA--C 1.544 0.744 0 N-CA-C 109.499 -0.556 . . . . 0.0 109.499 -179.613 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 28.6 ttt -163.65 143.76 8.55 Favored 'General case' 0 N--CA 1.468 0.427 0 N-CA-C 108.687 -0.857 . . . . 0.0 108.687 178.42 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 35.5 m -155.9 162.96 1.57 Allowed 'Isoleucine or valine' 0 C--O 1.219 -0.501 0 N-CA-C 108.292 -1.003 . . . . 0.0 108.292 179.384 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.93 66.9 2.51 Favored Glycine 0 C--N 1.303 -1.299 0 CA-C-N 116.195 -0.457 . . . . 0.0 112.058 178.565 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 145.53 173.67 17.01 Favored Glycine 0 N--CA 1.475 1.257 0 N-CA-C 110.663 -0.975 . . . . 0.0 110.663 179.061 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 39' ' ' VAL . . . . . 0.608 ' H ' HG12 ' F' ' 39' ' ' VAL . 35.9 m -124.02 159.87 28.81 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.868 0 C-N-CA 123.678 0.791 . . . . 0.0 110.592 -179.851 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 24.7 t . . . . . 0 C--O 1.219 -0.542 0 CA-C-O 118.355 -0.831 . . . . 0.0 110.611 179.496 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' D' D ' 1' ' ' ASP . . . . . . . . . . . . . 9.5 m-20 . . . . . 0 N--CA 1.491 1.6 0 N-CA-C 109.116 -0.698 . . . . 0.0 109.116 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' D' D ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.5 131.02 45.9 Favored 'General case' 0 CA--C 1.538 0.486 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.357 -179.897 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 3' ' ' GLU . . . . . . . . . . . . . 44.5 tt0 -169.34 107.97 0.42 Allowed 'General case' 0 N--CA 1.47 0.569 0 N-CA-C 109.978 -0.378 . . . . 0.0 109.978 -179.959 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 39.8 m-85 -89.68 157.33 18.04 Favored 'General case' 0 C--N 1.359 0.982 0 N-CA-C 108.898 -0.778 . . . . 0.0 108.898 179.862 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -145.9 138.11 25.38 Favored 'General case' 0 N--CA 1.476 0.848 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.396 -179.609 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 39.6 t-80 -149.29 123.69 9.65 Favored 'General case' 0 CA--C 1.546 0.79 0 N-CA-C 108.318 -0.993 . . . . 0.0 108.318 175.746 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 7' ' ' ASP . . . . . 0.598 ' O ' ' OG ' ' G' ' 8' ' ' SER . 3.3 m-20 -64.28 133.08 52.03 Favored 'General case' 0 C--N 1.324 -0.524 0 C-N-CA 126.477 1.911 . . . . 0.0 114.259 174.946 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' D' D ' 8' ' ' SER . . . . . 0.495 ' OG ' ' O ' ' A' ' 7' ' ' ASP . 54.0 p -154.93 -171.12 3.72 Favored 'General case' 0 N--CA 1.486 1.373 0 CA-C-N 119.566 1.075 . . . . 0.0 111.26 175.892 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.44 48.23 1.14 Allowed Glycine 0 N--CA 1.483 1.779 0 N-CA-C 110.517 -1.033 . . . . 0.0 110.517 174.559 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 51.4 p90 -61.0 131.19 49.85 Favored 'General case' 0 N--CA 1.471 0.594 0 N-CA-C 112.782 0.66 . . . . 0.0 112.782 178.433 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 48.5 mt-10 -89.44 151.04 22.23 Favored 'General case' 0 N--CA 1.48 1.07 0 C-N-CA 122.258 0.223 . . . . 0.0 110.826 175.581 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.0 p -149.58 130.01 4.32 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.599 0 N-CA-C 107.515 -1.291 . . . . 0.0 107.515 173.542 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 44.5 m-70 -130.07 148.63 51.94 Favored 'General case' 0 N--CA 1.483 1.212 0 CA-C-N 118.22 0.464 . . . . 0.0 111.78 176.379 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 6.2 t60 -164.96 104.38 0.78 Allowed 'General case' 0 N--CA 1.482 1.163 0 N-CA-C 109.141 -0.689 . . . . 0.0 109.141 172.859 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 3.9 pt20 -115.47 -176.18 2.87 Favored 'General case' 0 CA--C 1.496 -1.12 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 179.061 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -160.36 106.1 1.51 Allowed 'General case' 0 N--CA 1.469 0.506 0 N-CA-C 106.717 -1.586 . . . . 0.0 106.717 175.783 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 5.8 mp -128.17 153.68 46.62 Favored 'General case' 0 N--CA 1.497 1.909 0 CA-C-O 122.23 1.014 . . . . 0.0 110.586 179.989 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 36.1 t -101.29 131.58 48.76 Favored 'Isoleucine or valine' 0 C--O 1.26 1.631 0 CA-C-O 116.674 -1.632 . . . . 0.0 109.7 174.225 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 27.5 m-85 -130.44 126.12 36.16 Favored 'General case' 0 N--CA 1.49 1.547 0 CA-C-N 120.203 1.365 . . . . 0.0 109.552 173.359 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 69.7 m-85 55.53 71.52 0.54 Allowed 'General case' 0 C--O 1.239 0.517 0 CA-C-N 115.781 -0.645 . . . . 0.0 111.23 176.044 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -82.33 -73.28 0.4 Allowed 'General case' 0 N--CA 1.471 0.608 0 CA-C-O 118.555 -0.736 . . . . 0.0 111.171 -177.592 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 40.7 tt0 -115.37 105.67 13.11 Favored 'General case' 0 N--CA 1.481 1.12 0 N-CA-C 106.586 -1.635 . . . . 0.0 106.586 176.629 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 p-10 -152.02 135.13 15.78 Favored 'General case' 0 N--CA 1.474 0.756 0 CA-C-O 116.643 -1.646 . . . . 0.0 113.397 177.471 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 24' ' ' VAL . . . . . 0.422 ' HB ' ' H ' ' A' ' 25' ' ' GLY . 68.7 t -61.12 166.54 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.264 0 CA-C-N 121.351 1.887 . . . . 0.0 107.972 175.481 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' D' D ' 25' ' ' GLY . . . . . 0.496 ' H ' ' HB ' ' G' ' 24' ' ' VAL . . . -116.56 50.94 0.75 Allowed Glycine 0 N--CA 1.479 1.513 0 CA-C-O 119.203 -0.776 . . . . 0.0 111.489 178.814 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -57.57 -171.43 0.01 OUTLIER 'General case' 0 N--CA 1.468 0.465 0 C-N-CA 123.255 0.622 . . . . 0.0 111.888 175.556 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 3.9 t30 -73.08 86.43 1.35 Allowed 'General case' 0 C--N 1.347 0.464 0 N-CA-C 108.635 -0.876 . . . . 0.0 108.635 176.47 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 97.7 mttt -80.8 143.42 32.86 Favored 'General case' 0 N--CA 1.479 1.009 0 N-CA-C 107.712 -1.218 . . . . 0.0 107.712 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.27 -143.69 0.02 OUTLIER Glycine 0 C--N 1.348 1.212 0 C-N-CA 120.224 -0.989 . . . . 0.0 111.618 -178.266 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -95.46 126.42 40.74 Favored 'General case' 0 C--O 1.239 0.515 0 C-N-CA 123.031 0.532 . . . . 0.0 110.276 178.663 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 80.4 mt -125.44 126.86 71.25 Favored 'Isoleucine or valine' 0 C--N 1.358 0.944 0 N-CA-C 104.022 -2.584 . . . . 0.0 104.022 176.281 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 32' ' ' ILE . . . . . 0.421 HG22 ' H ' ' G' ' 32' ' ' ILE . 41.9 pt -159.14 -170.92 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.1 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.261 -177.927 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.91 5.04 12.53 Favored Glycine 0 C--O 1.239 0.463 0 N-CA-C 110.237 -1.145 . . . . 0.0 110.237 -178.957 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 1.9 tt -79.54 133.46 36.47 Favored 'General case' 0 C--N 1.369 1.451 0 C-N-CA 117.863 -1.535 . . . . 0.0 107.458 -178.968 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 35' ' ' MET . . . . . 0.4 ' C ' HG13 ' D' ' 36' ' ' VAL . 28.1 ttt -158.71 156.3 29.65 Favored 'General case' 0 CA--C 1.511 -0.52 0 N-CA-C 108.203 -1.036 . . . . 0.0 108.203 171.852 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' D' D ' 36' ' ' VAL . . . . . 0.464 HG22 HG12 ' G' ' 36' ' ' VAL . 35.7 m -164.72 163.77 0.7 Allowed 'Isoleucine or valine' 0 C--O 1.219 -0.506 0 N-CA-C 108.058 -1.09 . . . . 0.0 108.058 173.934 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 59.91 63.65 4.88 Favored Glycine 0 C--N 1.307 -1.066 0 C-N-CA 120.37 -0.919 . . . . 0.0 111.528 177.764 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 144.62 176.04 18.29 Favored Glycine 0 N--CA 1.48 1.6 0 CA-C-N 117.971 0.886 . . . . 0.0 111.145 179.368 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 39' ' ' VAL . . . . . 0.605 ' H ' HG12 ' G' ' 39' ' ' VAL . 34.3 m -125.43 157.08 34.82 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.861 0 C-N-CA 123.409 0.684 . . . . 0.0 111.119 -178.753 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 25.2 t . . . . . 0 C--N 1.329 -0.32 0 CA-C-O 116.333 -1.794 . . . . 0.0 109.748 176.588 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' E' E ' 1' ' ' ASP . . . . . . . . . . . . . 9.4 m-20 . . . . . 0 N--CA 1.488 1.451 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' E' E ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.34 129.73 41.04 Favored 'General case' 0 CA--C 1.538 0.504 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.486 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' E' E ' 3' ' ' GLU . . . . . . . . . . . . . 44.5 tt0 -167.5 105.85 0.54 Allowed 'General case' 0 C--O 1.213 -0.839 0 CA-C-N 116.755 -0.202 . . . . 0.0 110.636 -179.74 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 35.9 m-85 -86.63 152.55 22.48 Favored 'General case' 0 N--CA 1.475 0.82 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 179.257 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' E' E ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -143.53 140.04 30.07 Favored 'General case' 0 N--CA 1.48 1.045 0 CA-C-O 120.902 0.382 . . . . 0.0 110.15 179.583 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 43.3 t-80 -151.47 119.35 6.19 Favored 'General case' 0 N--CA 1.474 0.729 0 N-CA-C 109.167 -0.679 . . . . 0.0 109.167 179.085 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' E' E ' 7' ' ' ASP . . . . . 0.497 ' O ' ' OG ' ' H' ' 8' ' ' SER . 3.9 m-20 -69.65 148.15 49.69 Favored 'General case' 0 N--CA 1.466 0.349 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.838 179.998 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' E' E ' 8' ' ' SER . . . . . 0.501 ' OG ' ' O ' ' B' ' 7' ' ' ASP . 52.5 p -168.32 -172.6 1.77 Allowed 'General case' 0 N--CA 1.483 1.21 0 CA-C-O 121.015 0.436 . . . . 0.0 110.854 178.757 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.55 47.66 1.27 Allowed Glycine 0 N--CA 1.479 1.543 0 CA-C-N 116.033 -0.53 . . . . 0.0 111.965 179.917 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 49.1 p90 -64.26 132.53 50.54 Favored 'General case' 0 N--CA 1.473 0.706 0 N-CA-C 112.028 0.381 . . . . 0.0 112.028 -179.894 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 49.4 mt-10 -91.72 153.17 19.82 Favored 'General case' 0 N--CA 1.48 1.066 0 CA-C-O 121.158 0.504 . . . . 0.0 109.665 177.944 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -155.01 127.32 1.02 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.587 0 N-CA-C 107.882 -1.155 . . . . 0.0 107.882 177.968 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 45.1 m-70 -135.04 143.65 46.85 Favored 'General case' 0 N--CA 1.482 1.166 0 CA-C-O 120.787 0.327 . . . . 0.0 111.516 -177.958 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 6.0 t60 -164.26 97.6 0.81 Allowed 'General case' 0 N--CA 1.486 1.371 0 CA-C-N 116.356 -0.383 . . . . 0.0 110.634 179.593 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 3.9 pt20 -111.57 -174.63 2.51 Favored 'General case' 0 CA--C 1.505 -0.761 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 -179.805 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -163.27 98.61 0.93 Allowed 'General case' 0 N--CA 1.476 0.861 0 CA-C-N 114.75 -1.113 . . . . 0.0 108.49 178.633 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 6.5 mp -120.89 156.61 31.63 Favored 'General case' 0 N--CA 1.495 1.777 0 CA-C-O 121.786 0.803 . . . . 0.0 111.52 -177.682 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 48.4 t -114.06 124.62 70.88 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.216 0 N-CA-C 108.276 -1.009 . . . . 0.0 108.276 177.331 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 31.1 m-85 -125.51 121.41 33.65 Favored 'General case' 0 N--CA 1.489 1.51 0 CA-C-O 120.888 0.375 . . . . 0.0 110.846 -179.769 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 70.2 m-85 54.46 73.41 0.4 Allowed 'General case' 0 N--CA 1.469 0.508 0 CA-C-N 115.998 -0.547 . . . . 0.0 111.391 178.201 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -78.78 -78.95 0.14 Allowed 'General case' 0 C--N 1.344 0.348 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.268 -179.475 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 40.4 tt0 -111.2 102.72 11.12 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 -179.978 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -158.16 134.93 9.75 Favored 'General case' 0 C--O 1.208 -1.116 0 CA-C-O 119.484 -0.293 . . . . 0.0 111.378 178.829 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' E' E ' 24' ' ' VAL . . . . . 0.437 ' HB ' ' H ' ' B' ' 25' ' ' GLY . 58.5 t -56.97 167.72 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.941 0 N-CA-C 107.614 -1.254 . . . . 0.0 107.614 176.806 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' E' E ' 25' ' ' GLY . . . . . 0.413 ' N ' HG12 ' E' ' 24' ' ' VAL . . . -120.73 49.07 0.9 Allowed Glycine 0 N--CA 1.477 1.431 0 N-CA-C 110.765 -0.934 . . . . 0.0 110.765 -179.354 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -63.53 -168.32 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.542 0 CA-C-O 120.691 0.281 . . . . 0.0 110.25 179.622 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 3.6 t30 -71.7 76.42 0.84 Allowed 'General case' 0 N--CA 1.467 0.403 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.416 179.689 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -70.26 140.75 52.44 Favored 'General case' 0 N--CA 1.477 0.894 0 N-CA-C 109.497 -0.556 . . . . 0.0 109.497 179.557 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.6 -148.68 0.05 OUTLIER Glycine 0 CA--C 1.521 0.467 0 N-CA-C 110.895 -0.882 . . . . 0.0 110.895 179.519 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -92.81 127.18 38.22 Favored 'General case' 0 C--O 1.235 0.292 0 N-CA-C 110.268 -0.271 . . . . 0.0 110.268 179.577 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 74.2 mt -124.34 116.92 49.11 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.608 0 N-CA-C 106.491 -1.67 . . . . 0.0 106.491 178.439 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' E' E ' 32' ' ' ILE . . . . . 0.421 HG22 ' H ' ' H' ' 32' ' ' ILE . 43.7 pt -151.43 -168.46 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.182 0 CA-C-O 121.144 0.497 . . . . 0.0 110.622 -178.526 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.4 5.2 7.82 Favored Glycine 0 CA--C 1.528 0.873 0 N-CA-C 111.262 -0.735 . . . . 0.0 111.262 -179.954 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 1.5 tt -77.6 127.09 31.91 Favored 'General case' 0 CA--C 1.545 0.783 0 N-CA-C 109.491 -0.559 . . . . 0.0 109.491 -179.64 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 28.4 ttt -163.86 144.38 8.54 Favored 'General case' 0 N--CA 1.471 0.6 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 178.312 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' E' E ' 36' ' ' VAL . . . . . 0.444 HG22 HG12 ' H' ' 36' ' ' VAL . 32.8 m -156.73 162.62 1.56 Allowed 'Isoleucine or valine' 0 C--O 1.215 -0.712 0 N-CA-C 108.816 -0.809 . . . . 0.0 108.816 179.742 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.98 66.41 2.87 Favored Glycine 0 C--N 1.305 -1.194 0 N-CA-C 111.974 -0.45 . . . . 0.0 111.974 178.55 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 146.07 174.16 17.97 Favored Glycine 0 N--CA 1.477 1.374 0 N-CA-C 111.113 -0.795 . . . . 0.0 111.113 179.038 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' E' E ' 39' ' ' VAL . . . . . 0.611 HG12 ' H ' ' B' ' 39' ' ' VAL . 33.8 m -124.33 159.67 29.8 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.671 0 C-N-CA 123.478 0.711 . . . . 0.0 110.774 -179.566 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 25.8 t . . . . . 0 C--O 1.219 -0.518 0 CA-C-O 118.361 -0.828 . . . . 0.0 110.66 179.321 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' F' F ' 1' ' ' ASP . . . . . . . . . . . . . 9.5 m-20 . . . . . 0 N--CA 1.489 1.511 0 N-CA-C 109.293 -0.632 . . . . 0.0 109.293 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' F' F ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.02 129.85 41.67 Favored 'General case' 0 C--O 1.238 0.452 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.504 -179.968 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' F' F ' 3' ' ' GLU . . . . . . . . . . . . . 44.7 tt0 -167.54 106.03 0.54 Allowed 'General case' 0 C--O 1.213 -0.855 0 CA-C-N 116.733 -0.212 . . . . 0.0 110.511 -179.771 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 35.3 m-85 -86.77 152.56 22.4 Favored 'General case' 0 N--CA 1.475 0.8 0 N-CA-C 109.978 -0.378 . . . . 0.0 109.978 179.233 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' F' F ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -143.44 139.88 30.13 Favored 'General case' 0 N--CA 1.479 0.989 0 CA-C-O 120.872 0.368 . . . . 0.0 110.231 179.54 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 42.6 t-80 -151.35 119.02 6.09 Favored 'General case' 0 N--CA 1.474 0.761 0 N-CA-C 109.197 -0.668 . . . . 0.0 109.197 179.076 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' F' F ' 7' ' ' ASP . . . . . 0.463 ' O ' ' OG ' ' I' ' 8' ' ' SER . 4.0 m-20 -69.2 148.28 50.09 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.74 179.912 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' F' F ' 8' ' ' SER . . . . . 0.471 ' OG ' ' O ' ' C' ' 7' ' ' ASP . 52.1 p -168.65 -173.03 1.78 Allowed 'General case' 0 N--CA 1.486 1.329 0 CA-C-O 121.04 0.448 . . . . 0.0 110.858 178.749 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.79 47.55 1.26 Allowed Glycine 0 N--CA 1.479 1.529 0 CA-C-N 115.969 -0.559 . . . . 0.0 111.884 179.785 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 48.2 p90 -64.01 133.06 52.41 Favored 'General case' 0 CA--C 1.543 0.683 0 O-C-N 122.528 -0.395 . . . . 0.0 111.978 -179.821 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 49.2 mt-10 -92.02 152.94 19.74 Favored 'General case' 0 N--CA 1.48 1.056 0 CA-C-O 121.196 0.522 . . . . 0.0 109.727 177.841 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -154.78 127.0 1.01 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.572 0 N-CA-C 107.837 -1.172 . . . . 0.0 107.837 178.085 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 44.7 m-70 -134.71 143.65 47.31 Favored 'General case' 0 N--CA 1.484 1.228 0 CA-C-O 120.867 0.365 . . . . 0.0 111.563 -178.04 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 6.0 t60 -164.12 97.51 0.82 Allowed 'General case' 0 N--CA 1.487 1.391 0 CA-C-N 116.431 -0.349 . . . . 0.0 110.775 179.614 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 3.9 pt20 -111.71 -174.72 2.53 Favored 'General case' 0 CA--C 1.503 -0.847 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 -179.838 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -163.09 98.64 0.94 Allowed 'General case' 0 N--CA 1.473 0.711 0 CA-C-N 114.74 -1.118 . . . . 0.0 108.466 178.689 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 6.7 mp -120.76 156.97 30.7 Favored 'General case' 0 N--CA 1.495 1.795 0 CA-C-O 121.806 0.812 . . . . 0.0 111.498 -177.827 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 48.8 t -114.35 124.45 71.01 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.231 0 N-CA-C 108.186 -1.042 . . . . 0.0 108.186 177.321 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 32.2 m-85 -125.24 121.16 33.28 Favored 'General case' 0 N--CA 1.488 1.452 0 CA-C-O 120.893 0.377 . . . . 0.0 110.857 -179.911 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 70.4 m-85 54.67 73.78 0.38 Allowed 'General case' 0 N--CA 1.467 0.386 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.588 178.277 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -79.12 -78.53 0.15 Allowed 'General case' 0 C--N 1.344 0.354 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.406 -179.431 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 40.9 tt0 -111.71 102.58 10.87 Favored 'General case' 0 N--CA 1.47 0.527 0 N-CA-C 108.402 -0.962 . . . . 0.0 108.402 -179.929 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -158.02 134.77 9.78 Favored 'General case' 0 N--CA 1.481 1.081 0 CA-C-O 119.416 -0.326 . . . . 0.0 111.394 178.822 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' F' F ' 24' ' ' VAL . . . . . 0.443 ' HB ' ' H ' ' C' ' 25' ' ' GLY . 58.1 t -56.82 167.97 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.966 0 N-CA-C 107.641 -1.244 . . . . 0.0 107.641 176.938 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' F' F ' 25' ' ' GLY . . . . . 0.415 ' H ' ' HB ' ' I' ' 24' ' ' VAL . . . -120.97 49.2 0.89 Allowed Glycine 0 N--CA 1.478 1.48 0 N-CA-C 110.745 -0.942 . . . . 0.0 110.745 -179.344 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -63.72 -167.92 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.551 0 CA-C-O 120.731 0.301 . . . . 0.0 110.294 179.66 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 25.2 t-20 -71.92 76.51 0.9 Allowed 'General case' 0 N--CA 1.466 0.372 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.325 179.662 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -70.48 140.44 51.9 Favored 'General case' 0 N--CA 1.477 0.892 0 N-CA-C 109.525 -0.546 . . . . 0.0 109.525 179.562 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.17 -149.09 0.04 OUTLIER Glycine 0 CA--C 1.522 0.504 0 N-CA-C 110.898 -0.881 . . . . 0.0 110.898 179.441 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -92.34 127.14 37.71 Favored 'General case' 0 C--O 1.236 0.352 0 CA-C-O 120.676 0.274 . . . . 0.0 110.276 179.444 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 73.2 mt -124.26 116.93 49.2 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.572 0 N-CA-C 106.479 -1.674 . . . . 0.0 106.479 178.401 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' F' F ' 32' ' ' ILE . . . . . 0.417 HG22 ' H ' ' I' ' 32' ' ' ILE . 44.1 pt -151.6 -168.36 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.149 0 CA-C-O 121.071 0.462 . . . . 0.0 110.722 -178.543 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.13 5.54 8.1 Favored Glycine 0 CA--C 1.527 0.818 0 N-CA-C 111.274 -0.73 . . . . 0.0 111.274 -179.889 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 1.5 tt -77.76 126.88 31.54 Favored 'General case' 0 N--CA 1.476 0.839 0 N-CA-C 109.386 -0.598 . . . . 0.0 109.386 -179.689 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 28.4 ttt -163.62 144.36 8.9 Favored 'General case' 0 N--CA 1.471 0.591 0 N-CA-C 108.876 -0.787 . . . . 0.0 108.876 178.283 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' F' F ' 36' ' ' VAL . . . . . 0.455 HG22 HG12 ' I' ' 36' ' ' VAL . 32.8 m -156.63 162.81 1.53 Allowed 'Isoleucine or valine' 0 C--O 1.216 -0.709 0 N-CA-C 108.829 -0.804 . . . . 0.0 108.829 179.638 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.82 66.48 2.81 Favored Glycine 0 C--N 1.305 -1.169 0 N-CA-C 111.992 -0.443 . . . . 0.0 111.992 178.5 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 145.82 174.12 17.71 Favored Glycine 0 N--CA 1.477 1.419 0 N-CA-C 111.031 -0.828 . . . . 0.0 111.031 178.961 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' F' F ' 39' ' ' VAL . . . . . 0.608 HG12 ' H ' ' C' ' 39' ' ' VAL . 33.7 m -124.38 159.75 29.82 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.692 0 C-N-CA 123.366 0.666 . . . . 0.0 110.755 -179.488 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 26.3 t . . . . . 0 C--O 1.22 -0.476 0 CA-C-O 118.249 -0.881 . . . . 0.0 110.609 179.215 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' G' G ' 1' ' ' ASP . . . . . . . . . . . . . 9.6 m-20 . . . . . 0 N--CA 1.492 1.631 0 N-CA-C 109.344 -0.613 . . . . 0.0 109.344 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' G' G ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.77 128.25 35.04 Favored 'General case' 0 CA--C 1.537 0.444 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.693 179.664 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' G' G ' 3' ' ' GLU . . . . . . . . . . . . . 43.9 tt0 -167.84 106.79 0.53 Allowed 'General case' 0 N--CA 1.473 0.677 0 CA-C-O 120.518 0.199 . . . . 0.0 110.891 179.744 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 39.2 m-85 -88.58 152.31 21.93 Favored 'General case' 0 N--CA 1.474 0.736 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 179.12 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' G' G ' 5' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -143.79 140.3 29.81 Favored 'General case' 0 N--CA 1.482 1.168 0 CA-C-O 120.846 0.355 . . . . 0.0 110.311 179.825 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 43.3 t-80 -151.54 120.25 6.55 Favored 'General case' 0 N--CA 1.475 0.782 0 N-CA-C 109.342 -0.614 . . . . 0.0 109.342 179.125 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -71.22 144.19 50.19 Favored 'General case' 0 N--CA 1.47 0.547 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.17 -179.937 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' G' G ' 8' ' ' SER . . . . . 0.598 ' OG ' ' O ' ' D' ' 7' ' ' ASP . 47.8 p -165.4 -170.96 2.0 Allowed 'General case' 0 N--CA 1.474 0.767 0 CA-C-O 120.962 0.41 . . . . 0.0 110.589 178.585 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.01 47.92 1.29 Allowed Glycine 0 N--CA 1.48 1.611 0 N-CA-C 111.514 -0.635 . . . . 0.0 111.514 179.441 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 50.4 p90 -64.5 133.02 51.56 Favored 'General case' 0 N--CA 1.473 0.699 0 CA-C-O 120.753 0.311 . . . . 0.0 111.818 -179.544 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 48.6 mt-10 -92.62 151.63 20.01 Favored 'General case' 0 N--CA 1.479 0.982 0 CA-C-O 121.104 0.478 . . . . 0.0 110.105 178.484 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -154.74 127.6 1.11 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.016 0 N-CA-C 107.92 -1.141 . . . . 0.0 107.92 178.361 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 47.0 m-70 -134.49 145.04 48.43 Favored 'General case' 0 N--CA 1.478 0.956 0 CA-C-N 115.542 -0.754 . . . . 0.0 111.399 -178.348 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 30.3 t-80 -165.87 97.61 0.64 Allowed 'General case' 0 N--CA 1.483 1.206 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.301 178.963 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 3.9 pt20 -111.74 -174.3 2.43 Favored 'General case' 0 CA--C 1.503 -0.848 0 N-CA-C 108.37 -0.974 . . . . 0.0 108.37 -179.657 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -163.8 98.21 0.86 Allowed 'General case' 0 N--CA 1.474 0.774 0 CA-C-N 114.672 -1.149 . . . . 0.0 108.194 178.856 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 6.6 mp -120.51 155.15 34.2 Favored 'General case' 0 N--CA 1.497 1.896 0 CA-C-O 121.291 0.567 . . . . 0.0 111.74 -177.794 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 43.9 t -113.33 124.91 70.44 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.006 0 CA-C-N 114.804 -1.089 . . . . 0.0 108.234 176.713 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 33.5 m-85 -125.9 121.17 32.39 Favored 'General case' 0 C--N 1.366 1.299 0 C-N-CA 123.437 0.695 . . . . 0.0 110.934 -179.585 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 69.3 m-85 54.75 72.82 0.44 Allowed 'General case' 0 N--CA 1.468 0.462 0 CA-C-N 115.874 -0.603 . . . . 0.0 111.375 178.059 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.7 -78.37 0.14 Allowed 'General case' 0 N--CA 1.472 0.632 0 O-C-N 122.223 -0.298 . . . . 0.0 110.508 -178.981 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 40.7 tt0 -111.78 102.47 10.75 Favored 'General case' 0 C--N 1.321 -0.633 0 N-CA-C 108.212 -1.033 . . . . 0.0 108.212 179.942 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -157.7 136.05 11.1 Favored 'General case' 0 N--CA 1.479 0.98 0 O-C-N 122.43 -0.168 . . . . 0.0 111.415 178.748 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' G' G ' 24' ' ' VAL . . . . . 0.496 ' HB ' ' H ' ' D' ' 25' ' ' GLY . 59.9 t -58.35 167.11 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.639 0 N-CA-C 107.749 -1.204 . . . . 0.0 107.749 177.115 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' G' G ' 25' ' ' GLY . . . . . 0.42 ' N ' HG12 ' G' ' 24' ' ' VAL . . . -119.53 49.4 0.88 Allowed Glycine 0 N--CA 1.48 1.615 0 N-CA-C 110.479 -1.048 . . . . 0.0 110.479 -179.496 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -64.6 -168.66 0.03 OUTLIER 'General case' 0 N--CA 1.471 0.624 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 179.67 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 3.7 t30 -71.46 76.47 0.77 Allowed 'General case' 0 N--CA 1.468 0.435 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.385 179.796 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -69.82 140.55 53.3 Favored 'General case' 0 N--CA 1.474 0.765 0 N-CA-C 109.626 -0.509 . . . . 0.0 109.626 179.528 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.79 -147.01 0.04 OUTLIER Glycine 0 C--N 1.338 0.663 0 N-CA-C 110.517 -1.033 . . . . 0.0 110.517 179.637 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -93.36 126.12 38.32 Favored 'General case' 0 N--CA 1.468 0.43 0 C-N-CA 122.616 0.366 . . . . 0.0 110.663 -179.738 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 73.4 mt -123.76 117.3 50.7 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.771 0 N-CA-C 106.527 -1.657 . . . . 0.0 106.527 178.105 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' G' G ' 32' ' ' ILE . . . . . 0.421 ' H ' HG22 ' D' ' 32' ' ' ILE . 44.8 pt -152.27 -167.68 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 CA-C-N 119.839 1.2 . . . . 0.0 109.858 -179.046 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.37 6.2 10.23 Favored Glycine 0 CA--C 1.525 0.705 0 N-CA-C 110.998 -0.841 . . . . 0.0 110.998 179.824 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 1.5 tt -79.23 125.94 30.12 Favored 'General case' 0 CA--C 1.544 0.746 0 N-CA-C 109.492 -0.559 . . . . 0.0 109.492 -179.575 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 27.5 ttt -162.76 146.01 11.07 Favored 'General case' 0 N--CA 1.47 0.565 0 N-CA-C 108.757 -0.831 . . . . 0.0 108.757 178.418 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' G' G ' 36' ' ' VAL . . . . . 0.464 HG12 HG22 ' D' ' 36' ' ' VAL . 33.2 m -157.37 162.11 1.62 Allowed 'Isoleucine or valine' 0 C--N 1.347 0.461 0 N-CA-C 108.901 -0.777 . . . . 0.0 108.901 -179.959 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.37 66.8 2.58 Favored Glycine 0 C--N 1.312 -0.754 0 CA-C-N 115.712 -0.676 . . . . 0.0 112.271 178.213 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 146.53 175.17 19.29 Favored Glycine 0 N--CA 1.477 1.427 0 N-CA-C 110.516 -1.034 . . . . 0.0 110.516 178.988 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' G' G ' 39' ' ' VAL . . . . . 0.605 HG12 ' H ' ' D' ' 39' ' ' VAL . 34.6 m -125.34 159.94 31.94 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.867 0 C-N-CA 123.09 0.556 . . . . 0.0 110.73 -179.48 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 28.8 t . . . . . 0 N--CA 1.469 0.511 0 CA-C-O 118.388 -0.815 . . . . 0.0 110.796 179.025 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' H' H ' 1' ' ' ASP . . . . . . . . . . . . . 9.5 m-20 . . . . . 0 N--CA 1.491 1.58 0 N-CA-C 109.434 -0.58 . . . . 0.0 109.434 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' H' H ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.94 128.67 36.93 Favored 'General case' 0 CA--C 1.536 0.408 0 CA-C-N 115.949 -0.568 . . . . 0.0 110.613 179.77 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' H' H ' 3' ' ' GLU . . . . . . . . . . . . . 43.9 tt0 -168.27 106.89 0.49 Allowed 'General case' 0 N--CA 1.471 0.616 0 CA-C-O 120.529 0.204 . . . . 0.0 110.842 179.783 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 39.8 m-85 -88.57 152.15 22.03 Favored 'General case' 0 N--CA 1.473 0.697 0 N-CA-C 109.549 -0.537 . . . . 0.0 109.549 179.017 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' H' H ' 5' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -143.66 140.53 30.12 Favored 'General case' 0 N--CA 1.483 1.185 0 C-N-CA 122.583 0.353 . . . . 0.0 110.13 179.884 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 42.9 t-80 -151.77 120.4 6.5 Favored 'General case' 0 N--CA 1.473 0.701 0 N-CA-C 109.383 -0.599 . . . . 0.0 109.383 179.096 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -71.58 143.9 49.7 Favored 'General case' 0 N--CA 1.471 0.585 0 CA-C-N 116.323 -0.399 . . . . 0.0 111.178 -179.768 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' H' H ' 8' ' ' SER . . . . . 0.497 ' OG ' ' O ' ' E' ' 7' ' ' ASP . 53.7 p -165.07 -171.19 2.14 Favored 'General case' 0 N--CA 1.475 0.815 0 CA-C-O 120.94 0.4 . . . . 0.0 110.509 178.628 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.13 47.61 1.32 Allowed Glycine 0 N--CA 1.48 1.594 0 N-CA-C 111.683 -0.567 . . . . 0.0 111.683 179.642 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 50.4 p90 -64.51 133.13 51.77 Favored 'General case' 0 N--CA 1.472 0.659 0 N-CA-C 111.947 0.351 . . . . 0.0 111.947 -179.637 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 48.4 mt-10 -92.45 151.77 20.04 Favored 'General case' 0 N--CA 1.478 0.929 0 CA-C-O 121.013 0.435 . . . . 0.0 110.215 178.499 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -154.71 127.92 1.16 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.041 0 N-CA-C 107.854 -1.165 . . . . 0.0 107.854 178.251 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 46.4 m-70 -134.72 145.07 48.13 Favored 'General case' 0 N--CA 1.478 0.971 0 CA-C-N 115.5 -0.773 . . . . 0.0 111.394 -178.374 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 30.3 t-80 -165.93 97.29 0.63 Allowed 'General case' 0 N--CA 1.483 1.176 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.4 179.012 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 3.9 pt20 -111.39 -174.52 2.48 Favored 'General case' 0 CA--C 1.504 -0.826 0 N-CA-C 108.34 -0.985 . . . . 0.0 108.34 -179.652 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -163.72 98.29 0.87 Allowed 'General case' 0 N--CA 1.475 0.784 0 CA-C-N 114.671 -1.15 . . . . 0.0 108.093 178.757 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 6.7 mp -120.41 155.56 33.21 Favored 'General case' 0 N--CA 1.496 1.873 0 CA-C-O 121.233 0.539 . . . . 0.0 111.849 -177.82 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 42.6 t -113.64 125.23 70.88 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.01 0 CA-C-N 114.869 -1.06 . . . . 0.0 108.231 176.556 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 33.2 m-85 -126.24 121.07 31.66 Favored 'General case' 0 C--N 1.369 1.445 0 CA-C-N 115.518 -0.765 . . . . 0.0 110.775 -179.444 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 69.6 m-85 54.41 73.13 0.41 Allowed 'General case' 0 C--O 1.238 0.453 0 CA-C-N 115.814 -0.63 . . . . 0.0 111.399 178.107 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.75 -78.06 0.14 Allowed 'General case' 0 N--CA 1.472 0.657 0 O-C-N 122.201 -0.312 . . . . 0.0 110.661 -179.147 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 40.4 tt0 -112.09 102.57 10.77 Favored 'General case' 0 C--N 1.321 -0.641 0 N-CA-C 108.236 -1.024 . . . . 0.0 108.236 179.883 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -157.75 136.24 11.2 Favored 'General case' 0 N--CA 1.478 0.974 0 O-C-N 122.417 -0.177 . . . . 0.0 111.368 178.817 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' H' H ' 24' ' ' VAL . . . . . 0.418 HG12 ' N ' ' H' ' 25' ' ' GLY . 59.1 t -58.49 166.91 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.548 0 N-CA-C 107.71 -1.218 . . . . 0.0 107.71 177.18 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' H' H ' 25' ' ' GLY . . . . . 0.418 ' N ' HG12 ' H' ' 24' ' ' VAL . . . -119.25 49.2 0.89 Allowed Glycine 0 N--CA 1.479 1.551 0 N-CA-C 110.651 -0.98 . . . . 0.0 110.651 -179.573 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -64.68 -168.33 0.03 OUTLIER 'General case' 0 N--CA 1.472 0.661 0 N-CA-C 109.944 -0.391 . . . . 0.0 109.944 179.722 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 3.9 t30 -71.55 76.55 0.8 Allowed 'General case' 0 CA--C 1.537 0.472 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.316 179.809 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -70.15 140.56 52.61 Favored 'General case' 0 N--CA 1.474 0.775 0 N-CA-C 109.588 -0.523 . . . . 0.0 109.588 179.593 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.63 -147.69 0.04 OUTLIER Glycine 0 C--N 1.336 0.579 0 N-CA-C 110.376 -1.09 . . . . 0.0 110.376 179.549 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -93.05 126.31 38.07 Favored 'General case' 0 N--CA 1.465 0.298 0 C-N-CA 122.584 0.354 . . . . 0.0 110.781 -179.8 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 74.5 mt -123.87 117.23 50.41 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.776 0 N-CA-C 106.575 -1.639 . . . . 0.0 106.575 178.224 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' H' H ' 32' ' ' ILE . . . . . 0.421 ' H ' HG22 ' E' ' 32' ' ' ILE . 44.8 pt -152.11 -167.77 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 CA-C-N 119.761 1.164 . . . . 0.0 109.871 -179.026 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.71 5.76 9.9 Favored Glycine 0 CA--C 1.524 0.641 0 N-CA-C 110.935 -0.866 . . . . 0.0 110.935 179.845 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 1.4 tt -78.7 125.75 29.79 Favored 'General case' 0 CA--C 1.544 0.728 0 N-CA-C 109.555 -0.535 . . . . 0.0 109.555 -179.565 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 27.4 ttt -162.56 145.94 11.37 Favored 'General case' 0 N--CA 1.47 0.572 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 178.323 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' H' H ' 36' ' ' VAL . . . . . 0.444 HG12 HG22 ' E' ' 36' ' ' VAL . 33.2 m -157.35 162.18 1.6 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 N-CA-C 108.874 -0.788 . . . . 0.0 108.874 -179.935 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.25 67.06 2.4 Favored Glycine 0 C--N 1.311 -0.819 0 CA-C-N 115.781 -0.645 . . . . 0.0 112.149 178.286 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 146.42 175.76 19.69 Favored Glycine 0 N--CA 1.479 1.547 0 N-CA-C 110.577 -1.009 . . . . 0.0 110.577 178.892 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' H' H ' 39' ' ' VAL . . . . . 0.611 HG12 ' H ' ' E' ' 39' ' ' VAL . 34.6 m -125.97 159.85 33.75 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.82 0 C-N-CA 123.161 0.585 . . . . 0.0 110.708 -179.499 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 26.7 t . . . . . 0 C--O 1.219 -0.547 0 CA-C-O 118.346 -0.835 . . . . 0.0 110.79 179.263 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' I' I ' 1' ' ' ASP . . . . . . . . . . . . . 9.6 m-20 . . . . . 0 N--CA 1.492 1.647 0 N-CA-C 109.471 -0.566 . . . . 0.0 109.471 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' I' I ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.87 128.55 36.44 Favored 'General case' 0 CA--C 1.537 0.454 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.553 179.777 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' I' I ' 3' ' ' GLU . . . . . . . . . . . . . 43.8 tt0 -167.97 107.07 0.53 Allowed 'General case' 0 N--CA 1.472 0.648 0 CA-C-O 120.423 0.154 . . . . 0.0 110.803 179.756 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 39.7 m-85 -88.77 152.3 21.86 Favored 'General case' 0 N--CA 1.475 0.78 0 N-CA-C 109.473 -0.566 . . . . 0.0 109.473 179.063 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' I' I ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -143.72 140.28 29.91 Favored 'General case' 0 N--CA 1.482 1.167 0 C-N-CA 122.602 0.361 . . . . 0.0 110.15 179.894 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 43.1 t-80 -151.72 120.28 6.47 Favored 'General case' 0 N--CA 1.474 0.732 0 N-CA-C 109.358 -0.608 . . . . 0.0 109.358 179.04 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -71.23 143.87 50.27 Favored 'General case' 0 N--CA 1.469 0.503 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.234 -179.881 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' I' I ' 8' ' ' SER . . . . . 0.463 ' OG ' ' O ' ' F' ' 7' ' ' ASP . 53.3 p -164.87 -171.4 2.25 Favored 'General case' 0 N--CA 1.474 0.752 0 CA-C-O 120.857 0.36 . . . . 0.0 110.582 178.668 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.08 48.04 1.28 Allowed Glycine 0 N--CA 1.48 1.619 0 N-CA-C 111.693 -0.563 . . . . 0.0 111.693 179.63 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 50.4 p90 -65.1 132.52 49.39 Favored 'General case' 0 N--CA 1.472 0.632 0 N-CA-C 111.934 0.346 . . . . 0.0 111.934 -179.737 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 48.3 mt-10 -91.81 152.24 20.22 Favored 'General case' 0 N--CA 1.478 0.937 0 CA-C-O 121.033 0.445 . . . . 0.0 110.18 178.511 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -155.28 127.58 1.03 Allowed 'Isoleucine or valine' 0 CA--C 1.551 0.999 0 N-CA-C 107.848 -1.167 . . . . 0.0 107.848 178.349 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 46.1 m-70 -134.48 145.08 48.48 Favored 'General case' 0 N--CA 1.477 0.887 0 CA-C-N 115.572 -0.74 . . . . 0.0 111.436 -178.387 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 29.6 t-80 -165.61 97.47 0.67 Allowed 'General case' 0 N--CA 1.481 1.105 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.362 178.961 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 3.9 pt20 -111.79 -174.83 2.55 Favored 'General case' 0 CA--C 1.502 -0.894 0 N-CA-C 108.399 -0.963 . . . . 0.0 108.399 -179.689 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -163.39 98.41 0.91 Allowed 'General case' 0 N--CA 1.474 0.762 0 CA-C-N 114.647 -1.16 . . . . 0.0 108.172 178.87 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 6.7 mp -120.53 155.4 33.71 Favored 'General case' 0 N--CA 1.496 1.854 0 CA-C-O 121.266 0.555 . . . . 0.0 111.773 -177.829 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 41.6 t -113.56 125.35 70.82 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.998 0 CA-C-N 114.824 -1.08 . . . . 0.0 108.194 176.568 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 33.6 m-85 -126.32 121.32 32.24 Favored 'General case' 0 C--N 1.368 1.393 0 CA-C-N 115.61 -0.723 . . . . 0.0 110.876 -179.491 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 69.4 m-85 54.16 72.94 0.42 Allowed 'General case' 0 C--O 1.237 0.441 0 CA-C-N 115.918 -0.583 . . . . 0.0 111.375 178.165 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.63 -78.08 0.14 Allowed 'General case' 0 N--CA 1.472 0.657 0 O-C-N 122.302 -0.249 . . . . 0.0 110.598 -179.116 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 40.7 tt0 -112.01 102.73 10.93 Favored 'General case' 0 C--N 1.323 -0.573 0 N-CA-C 108.156 -1.053 . . . . 0.0 108.156 179.948 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -157.95 136.19 10.94 Favored 'General case' 0 N--CA 1.478 0.956 0 O-C-N 122.375 -0.203 . . . . 0.0 111.329 178.858 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' I' I ' 24' ' ' VAL . . . . . 0.425 HG12 ' N ' ' I' ' 25' ' ' GLY . 58.5 t -58.5 166.92 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.559 0 N-CA-C 107.779 -1.193 . . . . 0.0 107.779 177.134 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' I' I ' 25' ' ' GLY . . . . . 0.425 ' N ' HG12 ' I' ' 24' ' ' VAL . . . -119.42 49.22 0.88 Allowed Glycine 0 N--CA 1.481 1.661 0 N-CA-C 110.592 -1.003 . . . . 0.0 110.592 -179.404 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -64.54 -168.2 0.03 OUTLIER 'General case' 0 N--CA 1.471 0.602 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 179.702 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 25.5 t-20 -71.71 76.89 0.84 Allowed 'General case' 0 CA--C 1.536 0.439 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.259 179.675 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -70.45 140.6 52.0 Favored 'General case' 0 N--CA 1.475 0.807 0 N-CA-C 109.63 -0.507 . . . . 0.0 109.63 179.472 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.72 -147.32 0.04 OUTLIER Glycine 0 C--N 1.337 0.621 0 N-CA-C 110.496 -1.041 . . . . 0.0 110.496 179.588 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -93.26 125.86 38.07 Favored 'General case' 0 N--CA 1.465 0.314 0 C-N-CA 122.696 0.399 . . . . 0.0 110.752 -179.737 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 73.7 mt -123.47 117.33 51.03 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.768 0 N-CA-C 106.556 -1.646 . . . . 0.0 106.556 178.111 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' I' I ' 32' ' ' ILE . . . . . 0.417 ' H ' HG22 ' F' ' 32' ' ' ILE . 44.9 pt -152.17 -167.82 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 CA-C-N 119.758 1.163 . . . . 0.0 109.869 -179.05 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.71 5.86 10.18 Favored Glycine 0 CA--C 1.526 0.738 0 N-CA-C 110.95 -0.86 . . . . 0.0 110.95 179.768 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 1.4 tt -78.89 125.56 29.53 Favored 'General case' 0 CA--C 1.546 0.79 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 -179.593 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 27.4 ttt -162.25 145.79 11.83 Favored 'General case' 0 N--CA 1.47 0.542 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 178.559 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' I' I ' 36' ' ' VAL . . . . . 0.455 HG12 HG22 ' F' ' 36' ' ' VAL . 33.3 m -157.28 162.03 1.65 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.47 0 N-CA-C 108.845 -0.798 . . . . 0.0 108.845 -179.89 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.29 66.87 2.53 Favored Glycine 0 C--N 1.311 -0.85 0 CA-C-N 115.799 -0.637 . . . . 0.0 112.228 178.173 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 146.58 175.82 19.87 Favored Glycine 0 N--CA 1.478 1.497 0 N-CA-C 110.603 -0.999 . . . . 0.0 110.603 178.939 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' I' I ' 39' ' ' VAL . . . . . 0.603 HG12 ' H ' ' F' ' 39' ' ' VAL . 34.5 m -125.92 159.9 33.55 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.866 0 C-N-CA 123.131 0.572 . . . . 0.0 110.755 -179.488 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 29.8 t . . . . . 0 C--O 1.219 -0.513 0 CA-C-O 118.394 -0.812 . . . . 0.0 110.777 179.103 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 8.5 m-20 . . . . . 0 N--CA 1.489 1.513 0 N-CA-C 109.035 -0.728 . . . . 0.0 109.035 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.8 133.02 50.1 Favored 'General case' 0 CA--C 1.538 0.513 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.138 -179.924 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 54.8 tt0 -169.66 108.66 0.41 Allowed 'General case' 0 N--CA 1.47 0.544 0 N-CA-C 109.66 -0.496 . . . . 0.0 109.66 -179.158 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 78.8 m-85 -84.19 140.03 31.99 Favored 'General case' 0 N--CA 1.474 0.766 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 179.562 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 72.4 mtp180 -143.58 142.05 30.92 Favored 'General case' 0 N--CA 1.482 1.164 0 N-CA-C 109.134 -0.691 . . . . 0.0 109.134 -179.883 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 76.6 m80 -149.83 119.74 7.13 Favored 'General case' 0 N--CA 1.47 0.528 0 N-CA-C 108.759 -0.83 . . . . 0.0 108.759 179.102 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 8.5 m-20 -68.32 149.89 48.87 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.189 -179.385 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 7.9 t -167.65 171.16 10.42 Favored 'General case' 0 N--CA 1.473 0.706 0 N-CA-C 109.628 -0.508 . . . . 0.0 109.628 178.456 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.2 24.7 2.17 Favored Glycine 0 N--CA 1.488 2.127 0 N-CA-C 112.114 -0.394 . . . . 0.0 112.114 179.367 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 43.4 p90 -56.26 128.06 33.87 Favored 'General case' 0 N--CA 1.473 0.696 0 N-CA-C 112.175 0.435 . . . . 0.0 112.175 -179.866 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' GLU . . . . . 0.51 ' CG ' HD21 ' C' ' 27' ' ' ASN . 45.8 mt-10 -84.72 154.24 22.56 Favored 'General case' 0 N--CA 1.469 0.5 0 N-CA-C 109.082 -0.71 . . . . 0.0 109.082 178.445 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -153.25 129.29 1.75 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.341 0 N-CA-C 108.327 -0.99 . . . . 0.0 108.327 178.926 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 49.5 m-70 -134.03 144.72 48.86 Favored 'General case' 0 N--CA 1.489 1.507 0 CA-C-N 118.711 0.687 . . . . 0.0 110.993 -179.156 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 6.3 t60 -164.75 98.8 0.78 Allowed 'General case' 0 N--CA 1.479 0.978 0 CA-C-N 116.642 -0.254 . . . . 0.0 111.194 179.686 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 46.0 mt-30 -108.79 -172.26 2.02 Favored 'General case' 0 CA--C 1.502 -0.873 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 179.804 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -166.97 97.67 0.53 Allowed 'General case' 0 N--CA 1.473 0.689 0 CA-C-N 115.201 -0.909 . . . . 0.0 109.486 178.644 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.596 ' N ' HD12 ' A' ' 17' ' ' LEU . 4.5 mp -105.66 163.88 12.34 Favored 'General case' 0 N--CA 1.487 1.409 0 N-CA-C 108.543 -0.91 . . . . 0.0 108.543 179.901 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 48.9 t -142.15 118.92 6.79 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.354 0 CA-C-O 118.796 -0.621 . . . . 0.0 110.02 179.452 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 51.6 m-85 -69.98 159.24 34.13 Favored 'General case' 0 N--CA 1.48 1.055 0 N-CA-C 107.592 -1.262 . . . . 0.0 107.592 177.203 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 13.6 t80 -171.15 -58.52 0.02 OUTLIER 'General case' 0 N--CA 1.485 1.3 0 CA-C-O 122.365 1.079 . . . . 0.0 109.712 179.662 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -38.81 90.0 0.0 OUTLIER 'General case' 0 C--O 1.232 0.17 0 CA-C-N 113.782 -1.554 . . . . 0.0 112.938 -177.952 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 38.1 tt0 -66.16 157.65 30.75 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 115.05 -0.977 . . . . 0.0 110.565 179.118 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 66.8 m-20 -139.55 136.78 34.83 Favored 'General case' 0 N--CA 1.481 1.1 0 C-N-CA 123.008 0.523 . . . . 0.0 110.281 179.862 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 18.4 t -84.65 -116.46 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.982 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 179.469 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -109.15 54.81 0.53 Allowed Glycine 0 N--CA 1.474 1.211 0 N-CA-C 111.126 -0.79 . . . . 0.0 111.126 179.909 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 71.1 p -80.07 126.01 30.52 Favored 'General case' 0 C--N 1.328 -0.333 0 N-CA-C 108.799 -0.815 . . . . 0.0 108.799 178.184 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 27' ' ' ASN . . . . . 0.524 HD21 ' CG ' ' B' ' 11' ' ' GLU . 47.3 t30 -65.93 100.26 0.56 Allowed 'General case' 0 N--CA 1.473 0.719 0 N-CA-C 108.8 -0.815 . . . . 0.0 108.8 178.702 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 66.7 mttm -95.46 117.2 29.95 Favored 'General case' 0 N--CA 1.484 1.229 0 N-CA-C 110.01 -0.367 . . . . 0.0 110.01 -179.067 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.13 -133.55 0.01 OUTLIER Glycine 0 CA--C 1.532 1.12 0 N-CA-C 110.726 -0.95 . . . . 0.0 110.726 178.943 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -113.4 127.81 56.25 Favored 'General case' 0 N--CA 1.478 0.939 0 N-CA-C 109.29 -0.633 . . . . 0.0 109.29 178.934 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 66.7 mt -90.73 130.19 40.34 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.683 0 N-CA-C 107.606 -1.257 . . . . 0.0 107.606 178.715 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 18.1 mt -142.33 152.38 18.13 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.929 0 N-CA-C 109.838 -0.431 . . . . 0.0 109.838 -178.83 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 65.37 48.27 70.83 Favored Glycine 0 CA--C 1.524 0.63 0 CA-C-N 116.062 -0.517 . . . . 0.0 112.531 178.804 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.401 HD23 ' N ' ' A' ' 35' ' ' MET . 2.9 tt -98.88 120.39 39.24 Favored 'General case' 0 N--CA 1.478 0.934 0 N-CA-C 107.245 -1.391 . . . . 0.0 107.245 177.903 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 35' ' ' MET . . . . . 0.401 ' N ' HD23 ' A' ' 34' ' ' LEU . 28.1 ttt -152.71 158.26 42.09 Favored 'General case' 0 N--CA 1.471 0.579 0 N-CA-C 108.909 -0.774 . . . . 0.0 108.909 179.463 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.432 HG12 HE22 ' D' ' 15' ' ' GLN . 86.1 t -158.29 149.86 8.23 Favored 'Isoleucine or valine' 0 C--O 1.236 0.351 0 N-CA-C 107.012 -1.477 . . . . 0.0 107.012 -179.204 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.66 74.92 0.28 Allowed Glycine 0 C--N 1.313 -0.741 0 CA-C-N 115.622 -0.717 . . . . 0.0 111.658 178.181 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 170.96 -148.92 11.7 Favored Glycine 0 CA--C 1.519 0.299 0 N-CA-C 110.656 -0.978 . . . . 0.0 110.656 179.786 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 33.5 m -133.93 142.64 40.72 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.794 0 N-CA-C 109.688 -0.486 . . . . 0.0 109.688 179.744 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 16.3 t . . . . . 0 CA--C 1.535 0.392 0 CA-C-O 117.969 -1.015 . . . . 0.0 111.058 179.331 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' B' B ' 1' ' ' ASP . . . . . . . . . . . . . 7.6 m-20 . . . . . 0 N--CA 1.487 1.424 0 N-CA-C 109.14 -0.689 . . . . 0.0 109.14 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' B' B ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.46 132.63 49.43 Favored 'General case' 0 CA--C 1.538 0.507 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.172 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 3' ' ' GLU . . . . . . . . . . . . . 55.2 tt0 -169.32 108.83 0.44 Allowed 'General case' 0 N--CA 1.47 0.543 0 N-CA-C 109.541 -0.54 . . . . 0.0 109.541 -179.115 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 78.8 m-85 -84.17 140.52 31.68 Favored 'General case' 0 N--CA 1.474 0.729 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 179.489 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 71.9 mtp180 -144.09 141.82 30.26 Favored 'General case' 0 N--CA 1.481 1.11 0 N-CA-C 109.123 -0.695 . . . . 0.0 109.123 -179.815 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 76.7 m80 -149.7 119.64 7.15 Favored 'General case' 0 N--CA 1.471 0.611 0 N-CA-C 108.826 -0.805 . . . . 0.0 108.826 179.117 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 7' ' ' ASP . . . . . . . . . . . . . 8.6 m-20 -68.14 149.56 49.44 Favored 'General case' 0 CA--C 1.531 0.215 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.238 -179.439 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 8' ' ' SER . . . . . . . . . . . . . 8.1 t -167.36 171.87 10.21 Favored 'General case' 0 N--CA 1.473 0.685 0 N-CA-C 109.668 -0.493 . . . . 0.0 109.668 178.368 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 121.53 24.69 2.32 Favored Glycine 0 N--CA 1.488 2.135 0 N-CA-C 112.102 -0.399 . . . . 0.0 112.102 179.323 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 42.9 p90 -56.15 127.7 31.94 Favored 'General case' 0 N--CA 1.472 0.653 0 N-CA-C 112.236 0.458 . . . . 0.0 112.236 -179.87 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 11' ' ' GLU . . . . . 0.524 ' CG ' HD21 ' A' ' 27' ' ' ASN . 45.6 mt-10 -84.38 154.07 23.07 Favored 'General case' 0 N--CA 1.469 0.515 0 N-CA-C 109.223 -0.658 . . . . 0.0 109.223 178.442 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -153.17 129.65 1.9 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.328 0 N-CA-C 108.301 -1.0 . . . . 0.0 108.301 178.956 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 49.1 m-70 -134.34 145.34 48.92 Favored 'General case' 0 N--CA 1.49 1.552 0 CA-C-N 118.531 0.605 . . . . 0.0 110.975 -179.204 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 6.4 t60 -165.23 98.59 0.72 Allowed 'General case' 0 N--CA 1.482 1.125 0 CA-C-N 116.563 -0.29 . . . . 0.0 111.195 179.658 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 45.6 mt-30 -108.57 -172.81 2.13 Favored 'General case' 0 CA--C 1.502 -0.894 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 179.815 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -166.64 97.59 0.56 Allowed 'General case' 0 N--CA 1.472 0.63 0 CA-C-N 115.121 -0.945 . . . . 0.0 109.369 178.821 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 17' ' ' LEU . . . . . 0.596 ' N ' HD12 ' B' ' 17' ' ' LEU . 4.5 mp -105.87 163.88 12.38 Favored 'General case' 0 N--CA 1.487 1.394 0 N-CA-C 108.542 -0.91 . . . . 0.0 108.542 179.881 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 50.5 t -142.27 118.88 6.51 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.3 0 CA-C-O 118.959 -0.543 . . . . 0.0 109.96 179.58 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 53.0 m-85 -70.67 159.22 34.84 Favored 'General case' 0 N--CA 1.478 0.939 0 N-CA-C 107.53 -1.285 . . . . 0.0 107.53 177.248 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 14.9 t80 -171.83 -57.27 0.02 OUTLIER 'General case' 0 N--CA 1.482 1.168 0 CA-C-O 122.151 0.977 . . . . 0.0 109.769 179.631 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -39.1 90.38 0.0 OUTLIER 'General case' 0 CA--C 1.528 0.125 0 CA-C-N 114.125 -1.398 . . . . 0.0 112.768 -178.091 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 38.2 tt0 -66.45 157.45 31.99 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 115.089 -0.96 . . . . 0.0 110.52 179.19 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 67.4 m-20 -139.38 137.24 35.54 Favored 'General case' 0 N--CA 1.479 0.984 0 C-N-CA 123.083 0.553 . . . . 0.0 110.213 179.772 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 18.3 t -85.44 -116.71 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.048 0 N-CA-C 108.562 -0.903 . . . . 0.0 108.562 179.535 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -108.2 54.36 0.56 Allowed Glycine 0 N--CA 1.476 1.353 0 N-CA-C 111.049 -0.82 . . . . 0.0 111.049 179.929 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 71.8 p -80.13 125.55 29.96 Favored 'General case' 0 C--N 1.328 -0.351 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 178.242 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 27' ' ' ASN . . . . . 0.593 HD21 ' HB3' ' E' ' 27' ' ' ASN . 4.0 t-20 -65.69 100.4 0.53 Allowed 'General case' 0 N--CA 1.475 0.782 0 N-CA-C 108.812 -0.81 . . . . 0.0 108.812 178.649 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 66.6 mttm -95.58 117.0 29.64 Favored 'General case' 0 N--CA 1.485 1.298 0 N-CA-C 110.041 -0.355 . . . . 0.0 110.041 -179.179 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.85 -133.26 0.01 OUTLIER Glycine 0 CA--C 1.533 1.207 0 N-CA-C 110.723 -0.951 . . . . 0.0 110.723 178.927 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -113.88 127.9 56.18 Favored 'General case' 0 N--CA 1.479 0.981 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 179.031 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 66.6 mt -90.77 130.26 40.26 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.655 0 N-CA-C 107.532 -1.285 . . . . 0.0 107.532 178.692 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 17.8 mt -142.42 152.36 17.99 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.918 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 -178.852 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 65.52 47.55 77.02 Favored Glycine 0 CA--C 1.524 0.638 0 CA-C-N 116.085 -0.507 . . . . 0.0 112.667 178.793 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 2.9 tt -98.07 120.51 38.6 Favored 'General case' 0 N--CA 1.478 0.936 0 N-CA-C 107.25 -1.389 . . . . 0.0 107.25 177.85 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 28.0 ttt -152.81 157.97 41.55 Favored 'General case' 0 N--CA 1.472 0.627 0 N-CA-C 108.849 -0.797 . . . . 0.0 108.849 179.376 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 36' ' ' VAL . . . . . 0.416 HG12 HE22 ' E' ' 15' ' ' GLN . 82.1 t -158.15 149.77 8.47 Favored 'Isoleucine or valine' 0 C--O 1.235 0.306 0 N-CA-C 106.807 -1.553 . . . . 0.0 106.807 -179.147 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.67 75.28 0.26 Allowed Glycine 0 C--N 1.314 -0.689 0 CA-C-N 115.573 -0.74 . . . . 0.0 111.651 178.14 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 170.47 -149.07 12.14 Favored Glycine 0 CA--C 1.518 0.265 0 N-CA-C 110.698 -0.961 . . . . 0.0 110.698 179.772 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 33.8 m -133.59 142.76 40.73 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.842 0 N-CA-C 109.691 -0.485 . . . . 0.0 109.691 179.659 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 16.1 t . . . . . 0 C--O 1.222 -0.353 0 CA-C-O 117.993 -1.003 . . . . 0.0 111.111 179.319 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' C' C ' 1' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 . . . . . 0 N--CA 1.488 1.465 0 N-CA-C 109.106 -0.701 . . . . 0.0 109.106 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' C' C ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.51 132.66 49.46 Favored 'General case' 0 CA--C 1.538 0.517 0 CA-C-N 116.374 -0.375 . . . . 0.0 110.23 -179.921 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 3' ' ' GLU . . . . . . . . . . . . . 54.1 tt0 -169.35 108.59 0.43 Allowed 'General case' 0 N--CA 1.47 0.555 0 N-CA-C 109.637 -0.505 . . . . 0.0 109.637 -179.09 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 79.0 m-85 -83.95 140.43 31.93 Favored 'General case' 0 N--CA 1.475 0.784 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 179.515 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 72.4 mtp180 -144.11 141.48 30.03 Favored 'General case' 0 N--CA 1.482 1.157 0 N-CA-C 109.071 -0.714 . . . . 0.0 109.071 -179.834 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 76.8 m80 -149.41 119.67 7.3 Favored 'General case' 0 N--CA 1.471 0.597 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 179.089 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 7' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -68.05 149.5 49.6 Favored 'General case' 0 CA--C 1.53 0.197 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.281 -179.419 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 8' ' ' SER . . . . . . . . . . . . . 8.0 t -167.27 171.5 10.68 Favored 'General case' 0 N--CA 1.473 0.719 0 N-CA-C 109.564 -0.532 . . . . 0.0 109.564 178.419 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 121.79 24.79 2.24 Favored Glycine 0 N--CA 1.488 2.111 0 N-CA-C 112.105 -0.398 . . . . 0.0 112.105 179.304 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 42.4 p90 -56.41 128.28 35.19 Favored 'General case' 0 N--CA 1.472 0.669 0 N-CA-C 112.114 0.412 . . . . 0.0 112.114 -179.803 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 45.7 mt-10 -84.79 154.41 22.39 Favored 'General case' 0 N--CA 1.468 0.473 0 N-CA-C 109.113 -0.699 . . . . 0.0 109.113 178.504 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -153.54 129.36 1.71 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 N-CA-C 108.409 -0.96 . . . . 0.0 108.409 178.968 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 48.9 m-70 -134.22 144.97 48.74 Favored 'General case' 0 N--CA 1.489 1.518 0 CA-C-N 118.588 0.631 . . . . 0.0 110.968 -179.029 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 6.3 t60 -165.04 98.55 0.74 Allowed 'General case' 0 N--CA 1.481 1.099 0 CA-C-N 116.57 -0.286 . . . . 0.0 111.201 179.791 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 45.5 mt-30 -108.6 -172.05 1.98 Allowed 'General case' 0 CA--C 1.5 -0.954 0 N-CA-C 108.251 -1.018 . . . . 0.0 108.251 179.765 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -167.25 97.58 0.5 Allowed 'General case' 0 CA--C 1.54 0.58 0 CA-C-N 115.179 -0.918 . . . . 0.0 109.381 178.751 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 17' ' ' LEU . . . . . 0.599 ' N ' HD12 ' C' ' 17' ' ' LEU . 4.4 mp -105.66 163.64 12.53 Favored 'General case' 0 N--CA 1.487 1.392 0 N-CA-C 108.563 -0.903 . . . . 0.0 108.563 179.838 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 51.0 t -142.0 118.75 6.95 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.343 0 CA-C-O 119.032 -0.509 . . . . 0.0 109.959 179.495 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 52.6 m-85 -70.33 159.24 34.48 Favored 'General case' 0 N--CA 1.478 0.964 0 N-CA-C 107.502 -1.296 . . . . 0.0 107.502 177.247 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 14.8 t80 -171.82 -57.35 0.02 OUTLIER 'General case' 0 N--CA 1.482 1.153 0 CA-C-O 122.196 0.998 . . . . 0.0 109.777 179.49 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -39.21 90.75 0.0 OUTLIER 'General case' 0 CA--C 1.529 0.15 0 CA-C-N 114.193 -1.367 . . . . 0.0 112.785 -178.053 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 37.7 tt0 -66.77 157.4 32.95 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.063 -0.971 . . . . 0.0 110.539 179.247 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 66.8 m-20 -139.22 137.03 35.62 Favored 'General case' 0 N--CA 1.478 0.937 0 C-N-CA 123.138 0.575 . . . . 0.0 110.297 179.836 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 17.9 t -85.39 -116.67 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.064 0 N-CA-C 108.519 -0.919 . . . . 0.0 108.519 179.558 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -108.16 54.61 0.55 Allowed Glycine 0 N--CA 1.474 1.228 0 N-CA-C 111.1 -0.8 . . . . 0.0 111.1 179.96 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 73.2 p -80.42 125.47 29.96 Favored 'General case' 0 N--CA 1.466 0.336 0 N-CA-C 108.841 -0.8 . . . . 0.0 108.841 178.329 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 27' ' ' ASN . . . . . 0.51 HD21 ' CG ' ' A' ' 11' ' ' GLU . 48.3 t30 -65.64 100.55 0.53 Allowed 'General case' 0 N--CA 1.474 0.757 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 178.684 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 66.8 mttm -95.8 116.86 29.52 Favored 'General case' 0 N--CA 1.485 1.324 0 N-CA-C 109.977 -0.379 . . . . 0.0 109.977 -179.055 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.73 -133.32 0.01 OUTLIER Glycine 0 CA--C 1.534 1.248 0 N-CA-C 110.761 -0.936 . . . . 0.0 110.761 178.954 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -113.73 127.65 56.11 Favored 'General case' 0 N--CA 1.479 1.016 0 N-CA-C 109.231 -0.655 . . . . 0.0 109.231 178.981 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 66.7 mt -90.66 130.15 40.34 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.644 0 N-CA-C 107.492 -1.299 . . . . 0.0 107.492 178.746 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 17.8 mt -142.59 152.49 17.71 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.909 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -178.864 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 65.52 47.44 78.07 Favored Glycine 0 CA--C 1.524 0.604 0 CA-C-N 116.0 -0.545 . . . . 0.0 112.666 178.877 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 2.9 tt -98.16 120.38 38.46 Favored 'General case' 0 N--CA 1.477 0.92 0 N-CA-C 107.231 -1.396 . . . . 0.0 107.231 177.864 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 28.1 ttt -152.48 158.16 42.19 Favored 'General case' 0 N--CA 1.471 0.577 0 N-CA-C 108.834 -0.802 . . . . 0.0 108.834 179.401 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 36' ' ' VAL . . . . . 0.439 HG12 HE22 ' F' ' 15' ' ' GLN . 87.3 t -158.3 149.8 8.24 Favored 'Isoleucine or valine' 0 C--O 1.236 0.393 0 N-CA-C 106.856 -1.535 . . . . 0.0 106.856 -179.205 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.66 75.08 0.27 Allowed Glycine 0 C--N 1.313 -0.71 0 CA-C-N 115.608 -0.724 . . . . 0.0 111.675 178.101 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 170.55 -149.11 12.17 Favored Glycine 0 CA--C 1.519 0.336 0 N-CA-C 110.593 -1.003 . . . . 0.0 110.593 179.801 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 33.7 m -133.71 142.81 40.49 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.835 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 179.728 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 16.2 t . . . . . 0 CA--C 1.535 0.39 0 CA-C-O 117.888 -1.053 . . . . 0.0 110.983 179.34 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' D' D ' 1' ' ' ASP . . . . . . . . . . . . . 8.5 m-20 . . . . . 0 N--CA 1.492 1.626 0 N-CA-C 109.143 -0.688 . . . . 0.0 109.143 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' D' D ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.47 131.29 46.7 Favored 'General case' 0 CA--C 1.535 0.387 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.376 179.851 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' D' D ' 3' ' ' GLU . . . . . . . . . . . . . 54.1 tt0 -169.34 110.83 0.47 Allowed 'General case' 0 N--CA 1.47 0.525 0 N-CA-C 109.379 -0.601 . . . . 0.0 109.379 179.676 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 86.9 m-85 -87.46 147.69 25.29 Favored 'General case' 0 C--N 1.363 1.158 0 C-N-CA 118.671 -1.211 . . . . 0.0 108.261 179.771 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' D' D ' 5' ' ' ARG . . . . . . . . . . . . . 72.0 mtp180 -147.32 141.52 26.16 Favored 'General case' 0 N--CA 1.475 0.821 0 N-CA-C 109.13 -0.692 . . . . 0.0 109.13 179.888 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 76.9 m80 -149.14 123.68 9.74 Favored 'General case' 0 C--O 1.219 -0.541 0 N-CA-C 107.758 -1.201 . . . . 0.0 107.758 175.638 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' D' D ' 7' ' ' ASP . . . . . . . . . . . . . 6.1 m-20 -63.45 133.26 53.64 Favored 'General case' 0 C--N 1.322 -0.613 0 C-N-CA 127.036 2.134 . . . . 0.0 114.832 176.15 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' D' D ' 8' ' ' SER . . . . . . . . . . . . . 7.0 t -154.2 173.62 15.87 Favored 'General case' 0 N--CA 1.478 0.961 0 CA-C-N 118.609 0.64 . . . . 0.0 110.406 176.996 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 124.15 20.83 2.41 Favored Glycine 0 N--CA 1.484 1.842 0 N-CA-C 112.159 -0.377 . . . . 0.0 112.159 176.398 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 37.7 p90 -55.56 130.5 43.17 Favored 'General case' 0 CA--C 1.546 0.79 0 CA-C-O 121.176 0.513 . . . . 0.0 111.842 -176.771 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' D' D ' 11' ' ' GLU . . . . . 0.446 ' CG ' HD21 ' F' ' 27' ' ' ASN . 46.0 mt-10 -84.89 152.35 23.62 Favored 'General case' 0 N--CA 1.473 0.698 0 N-CA-C 109.703 -0.48 . . . . 0.0 109.703 177.663 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -149.56 130.13 4.42 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.426 0 N-CA-C 108.409 -0.96 . . . . 0.0 108.409 175.792 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 48.5 m-70 -129.53 148.34 51.42 Favored 'General case' 0 N--CA 1.483 1.184 0 CA-C-N 117.992 0.36 . . . . 0.0 111.116 176.84 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 6.5 t60 -165.02 104.85 0.78 Allowed 'General case' 0 N--CA 1.482 1.145 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 173.76 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' D' D ' 15' ' ' GLN . . . . . 0.432 HE22 HG12 ' A' ' 36' ' ' VAL . 44.9 mt-30 -111.78 -175.49 2.71 Favored 'General case' 0 CA--C 1.492 -1.255 0 N-CA-C 107.977 -1.12 . . . . 0.0 107.977 179.065 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' D' D ' 16' ' ' LYS . . . . . 0.437 ' C ' HD12 ' D' ' 17' ' ' LEU . 88.7 tttt -163.39 106.02 0.99 Allowed 'General case' 0 CA--C 1.536 0.433 0 N-CA-C 107.656 -1.239 . . . . 0.0 107.656 175.62 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' D' D ' 17' ' ' LEU . . . . . 0.539 ' N ' HD12 ' D' ' 17' ' ' LEU . 5.5 mp -112.42 162.73 15.25 Favored 'General case' 0 N--CA 1.488 1.447 0 N-CA-C 107.887 -1.153 . . . . 0.0 107.887 179.655 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 47.3 t -141.0 123.81 15.59 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.192 0 N-CA-C 109.053 -0.721 . . . . 0.0 109.053 175.834 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 78.3 m-85 -62.91 151.46 39.29 Favored 'General case' 0 C--N 1.352 0.685 0 C-N-CA 124.74 1.216 . . . . 0.0 110.396 170.501 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 9.8 t80 -170.1 -66.8 0.02 OUTLIER 'General case' 0 N--CA 1.477 0.903 0 N-CA-C 107.666 -1.235 . . . . 0.0 107.666 -179.629 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -37.91 95.66 0.01 OUTLIER 'General case' 0 CA--C 1.536 0.428 0 CA-C-N 114.019 -1.446 . . . . 0.0 111.663 -174.583 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 38.1 tt0 -68.35 158.19 34.07 Favored 'General case' 0 N--CA 1.467 0.388 0 CA-C-N 113.435 -1.711 . . . . 0.0 110.376 178.493 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 67.6 m-20 -139.54 140.65 37.19 Favored 'General case' 0 N--CA 1.476 0.834 0 N-CA-C 109.403 -0.592 . . . . 0.0 109.403 178.558 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' D' D ' 24' ' ' VAL . . . . . . . . . . . . . 19.5 t -88.28 -119.97 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.486 1.347 0 N-CA-C 107.779 -1.193 . . . . 0.0 107.779 179.699 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . -111.72 61.91 0.3 Allowed Glycine 0 C--N 1.371 2.478 0 C-N-CA 118.075 -2.012 . . . . 0.0 109.317 178.824 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 89.0 p -70.57 121.35 17.69 Favored 'General case' 0 C--O 1.243 0.713 0 CA-C-O 116.555 -1.688 . . . . 0.0 111.775 169.24 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' D' D ' 27' ' ' ASN . . . . . 0.44 HD21 ' CG ' ' E' ' 11' ' ' GLU . 54.6 t30 -61.2 101.8 0.18 Allowed 'General case' 0 N--CA 1.476 0.864 0 CA-C-N 121.558 1.981 . . . . 0.0 109.501 172.957 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 66.2 mttm -99.14 119.28 37.59 Favored 'General case' 0 N--CA 1.491 1.621 0 CA-C-N 119.427 1.012 . . . . 0.0 109.127 179.217 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -55.07 -134.39 0.0 OUTLIER Glycine 0 C--N 1.343 0.931 0 CA-C-N 115.607 -0.724 . . . . 0.0 113.379 175.931 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -113.19 132.65 55.41 Favored 'General case' 0 C--N 1.372 1.565 0 N-CA-C 108.591 -0.892 . . . . 0.0 108.591 174.145 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 68.2 mt -91.88 134.34 30.51 Favored 'Isoleucine or valine' 0 C--N 1.347 0.488 0 N-CA-C 106.929 -1.508 . . . . 0.0 106.929 176.459 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 20.0 mt -144.78 155.02 14.34 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.965 0 N-CA-C 109.2 -0.667 . . . . 0.0 109.2 179.137 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 64.11 46.86 90.03 Favored Glycine 0 C--O 1.245 0.841 0 CA-C-O 119.354 -0.692 . . . . 0.0 112.57 179.059 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 3.5 tt -97.7 132.27 43.49 Favored 'General case' 0 C--N 1.372 1.585 0 N-CA-C 104.569 -2.382 . . . . 0.0 104.569 176.408 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 28.3 ttt -155.9 165.23 37.1 Favored 'General case' 0 N--CA 1.474 0.752 0 N-CA-C 107.783 -1.192 . . . . 0.0 107.783 175.819 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' D' D ' 36' ' ' VAL . . . . . 0.41 HG12 HE22 ' G' ' 15' ' ' GLN . 96.3 t -164.1 154.69 2.26 Favored 'Isoleucine or valine' 0 C--O 1.247 0.973 0 N-CA-C 105.564 -2.013 . . . . 0.0 105.564 176.382 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 61.13 66.67 2.52 Favored Glycine 0 N--CA 1.445 -0.731 0 C-N-CA 117.446 -2.312 . . . . 0.0 113.974 176.577 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 167.64 -147.91 12.28 Favored Glycine 0 N--CA 1.466 0.644 0 CA-C-O 117.701 -1.61 . . . . 0.0 112.176 -179.117 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 33.7 m -130.4 142.69 43.07 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.088 0 CA-C-N 119.352 1.576 . . . . 0.0 109.886 -179.065 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 13.6 t . . . . . 0 C--O 1.212 -0.87 0 N-CA-C 109.54 -0.541 . . . . 0.0 109.54 174.466 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' E' E ' 1' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 . . . . . 0 N--CA 1.489 1.485 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' E' E ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.15 131.25 46.91 Favored 'General case' 0 CA--C 1.536 0.418 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.366 179.807 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' E' E ' 3' ' ' GLU . . . . . . . . . . . . . 54.5 tt0 -169.01 108.85 0.46 Allowed 'General case' 0 N--CA 1.469 0.486 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 -179.847 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 79.4 m-85 -84.88 140.52 31.08 Favored 'General case' 0 N--CA 1.474 0.771 0 N-CA-C 109.907 -0.405 . . . . 0.0 109.907 179.44 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' E' E ' 5' ' ' ARG . . . . . . . . . . . . . 72.5 mtp180 -143.92 142.52 30.81 Favored 'General case' 0 N--CA 1.476 0.842 0 N-CA-C 109.541 -0.54 . . . . 0.0 109.541 179.858 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 76.5 m80 -150.3 118.27 6.28 Favored 'General case' 0 N--CA 1.473 0.686 0 N-CA-C 108.929 -0.767 . . . . 0.0 108.929 179.169 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' E' E ' 7' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -66.69 149.86 49.9 Favored 'General case' 0 N--CA 1.464 0.236 0 O-C-N 123.541 0.526 . . . . 0.0 111.538 -179.5 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' E' E ' 8' ' ' SER . . . . . . . . . . . . . 7.1 t -167.92 172.4 9.01 Favored 'General case' 0 N--CA 1.476 0.839 0 N-CA-C 109.573 -0.528 . . . . 0.0 109.573 177.901 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.7 24.34 2.13 Favored Glycine 0 N--CA 1.482 1.731 0 N-CA-C 111.922 -0.471 . . . . 0.0 111.922 179.071 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 39.1 p90 -55.66 127.28 29.18 Favored 'General case' 0 N--CA 1.474 0.733 0 N-CA-C 112.627 0.602 . . . . 0.0 112.627 -179.091 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' E' E ' 11' ' ' GLU . . . . . 0.44 ' CG ' HD21 ' D' ' 27' ' ' ASN . 46.4 mt-10 -83.32 155.08 23.76 Favored 'General case' 0 N--CA 1.474 0.76 0 N-CA-C 109.388 -0.597 . . . . 0.0 109.388 177.938 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -155.18 128.77 1.22 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.494 0 N-CA-C 108.386 -0.968 . . . . 0.0 108.386 178.811 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 46.3 m-70 -134.77 143.21 46.99 Favored 'General case' 0 N--CA 1.481 1.095 0 O-C-N 122.324 -0.235 . . . . 0.0 111.225 -177.99 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 6.2 t60 -163.99 98.39 0.85 Allowed 'General case' 0 N--CA 1.486 1.352 0 CA-C-N 116.765 -0.198 . . . . 0.0 111.147 179.814 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' E' E ' 15' ' ' GLN . . . . . 0.416 HE22 HG12 ' B' ' 36' ' ' VAL . 44.5 mt-30 -107.82 -172.34 2.05 Favored 'General case' 0 CA--C 1.502 -0.9 0 N-CA-C 108.394 -0.965 . . . . 0.0 108.394 179.89 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -166.99 97.73 0.53 Allowed 'General case' 0 CA--C 1.543 0.686 0 CA-C-N 115.056 -0.975 . . . . 0.0 109.414 178.675 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' E' E ' 17' ' ' LEU . . . . . 0.583 ' N ' HD12 ' E' ' 17' ' ' LEU . 4.6 mp -105.69 163.32 12.79 Favored 'General case' 0 N--CA 1.49 1.558 0 N-CA-C 109.084 -0.709 . . . . 0.0 109.084 -179.796 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 39.0 t -142.32 118.39 6.0 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.38 0 C-N-CA 122.512 0.325 . . . . 0.0 110.52 179.078 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 51.0 m-85 -69.76 156.87 38.36 Favored 'General case' 0 C--N 1.358 0.964 0 N-CA-C 107.269 -1.382 . . . . 0.0 107.269 176.585 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 13.3 t80 -173.47 -54.96 0.02 OUTLIER 'General case' 0 N--CA 1.485 1.304 0 CA-C-O 121.606 0.717 . . . . 0.0 110.347 179.545 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.1 88.72 0.0 OUTLIER 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 114.396 -1.274 . . . . 0.0 112.843 -178.994 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 37.8 tt0 -64.62 157.88 25.88 Favored 'General case' 0 N--CA 1.471 0.581 0 CA-C-N 114.86 -1.064 . . . . 0.0 110.719 179.701 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 66.3 m-20 -139.97 136.68 34.03 Favored 'General case' 0 N--CA 1.477 0.883 0 C-N-CA 122.948 0.499 . . . . 0.0 110.399 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 21.8 t -85.23 -115.58 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.109 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 179.523 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . -108.97 54.66 0.54 Allowed Glycine 0 C--N 1.348 1.245 0 N-CA-C 111.237 -0.745 . . . . 0.0 111.237 -179.87 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 69.2 p -79.96 125.02 29.22 Favored 'General case' 0 N--CA 1.473 0.723 0 N-CA-C 109.111 -0.7 . . . . 0.0 109.111 177.947 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' E' E ' 27' ' ' ASN . . . . . 0.615 HD21 ' HB3' ' H' ' 27' ' ' ASN . 4.4 t-20 -65.37 100.04 0.45 Allowed 'General case' 0 N--CA 1.474 0.747 0 N-CA-C 108.236 -1.024 . . . . 0.0 108.236 178.552 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 66.2 mttm -95.69 116.74 29.3 Favored 'General case' 0 N--CA 1.486 1.351 0 N-CA-C 109.975 -0.38 . . . . 0.0 109.975 -178.708 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.02 -132.82 0.01 OUTLIER Glycine 0 CA--C 1.534 1.271 0 N-CA-C 111.38 -0.688 . . . . 0.0 111.38 178.858 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -114.02 127.09 55.79 Favored 'General case' 0 N--CA 1.477 0.896 0 N-CA-C 109.394 -0.595 . . . . 0.0 109.394 179.187 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 67.2 mt -90.38 131.19 38.21 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.233 0 N-CA-C 107.132 -1.432 . . . . 0.0 107.132 178.688 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 19.5 mt -142.4 154.44 18.3 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.907 0 N-CA-C 109.125 -0.694 . . . . 0.0 109.125 -179.341 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.39 48.86 74.96 Favored Glycine 0 CA--C 1.523 0.537 0 C-N-CA 121.702 -0.285 . . . . 0.0 113.291 178.944 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 3.0 tt -99.3 120.19 39.16 Favored 'General case' 0 N--CA 1.477 0.907 0 N-CA-C 107.143 -1.429 . . . . 0.0 107.143 177.617 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 28.5 ttt -151.68 159.55 43.96 Favored 'General case' 0 N--CA 1.479 1.019 0 N-CA-C 108.552 -0.907 . . . . 0.0 108.552 179.314 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' E' E ' 36' ' ' VAL . . . . . 0.416 HG12 HE22 ' H' ' 15' ' ' GLN . 96.9 t -159.64 149.85 6.59 Favored 'Isoleucine or valine' 0 C--O 1.236 0.384 0 N-CA-C 106.834 -1.543 . . . . 0.0 106.834 -179.504 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.71 74.53 0.32 Allowed Glycine 0 C--N 1.312 -0.751 0 CA-C-N 115.659 -0.701 . . . . 0.0 111.452 178.01 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 171.81 -147.24 9.96 Favored Glycine 0 C--O 1.223 -0.569 0 N-CA-C 111.08 -0.808 . . . . 0.0 111.08 179.67 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 33.2 m -135.28 141.85 41.46 Favored 'Isoleucine or valine' 0 C--N 1.353 0.731 0 N-CA-C 109.248 -0.649 . . . . 0.0 109.248 179.695 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 14.5 t . . . . . 0 CA--C 1.537 0.479 0 CA-C-O 117.916 -1.04 . . . . 0.0 111.24 179.383 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' F' F ' 1' ' ' ASP . . . . . . . . . . . . . 8.8 m-20 . . . . . 0 N--CA 1.491 1.602 0 N-CA-C 109.167 -0.679 . . . . 0.0 109.167 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' F' F ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.6 131.13 46.14 Favored 'General case' 0 N--CA 1.467 0.416 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.46 179.777 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' F' F ' 3' ' ' GLU . . . . . . . . . . . . . 55.0 tt0 -168.82 108.68 0.48 Allowed 'General case' 0 N--CA 1.469 0.524 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 -179.736 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 78.8 m-85 -84.68 140.55 31.23 Favored 'General case' 0 N--CA 1.475 0.796 0 N-CA-C 109.981 -0.377 . . . . 0.0 109.981 179.339 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' F' F ' 5' ' ' ARG . . . . . . . . . . . . . 72.2 mtp180 -143.88 142.36 30.77 Favored 'General case' 0 N--CA 1.477 0.911 0 N-CA-C 109.283 -0.636 . . . . 0.0 109.283 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 76.7 m80 -150.24 118.11 6.25 Favored 'General case' 0 N--CA 1.474 0.726 0 N-CA-C 108.936 -0.765 . . . . 0.0 108.936 179.045 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' F' F ' 7' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -66.72 149.94 49.8 Favored 'General case' 0 N--CA 1.464 0.252 0 O-C-N 123.386 0.428 . . . . 0.0 111.595 -179.424 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' F' F ' 8' ' ' SER . . . . . . . . . . . . . 7.2 t -167.96 172.51 8.86 Favored 'General case' 0 N--CA 1.475 0.815 0 CA-C-N 115.944 -0.571 . . . . 0.0 109.574 177.978 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.47 24.7 2.11 Favored Glycine 0 N--CA 1.483 1.776 0 N-CA-C 111.892 -0.483 . . . . 0.0 111.892 178.986 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 38.6 p90 -56.09 127.52 30.97 Favored 'General case' 0 N--CA 1.474 0.733 0 N-CA-C 112.637 0.606 . . . . 0.0 112.637 -179.061 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 46.0 mt-10 -83.25 155.03 23.86 Favored 'General case' 0 N--CA 1.474 0.746 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 177.897 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -155.13 128.61 1.2 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.503 0 N-CA-C 108.43 -0.952 . . . . 0.0 108.43 178.775 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 46.9 m-70 -134.7 143.11 47.02 Favored 'General case' 0 N--CA 1.48 1.051 0 O-C-N 122.275 -0.265 . . . . 0.0 111.194 -177.998 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 6.2 t60 -164.11 98.63 0.84 Allowed 'General case' 0 N--CA 1.486 1.342 0 CA-C-N 116.734 -0.212 . . . . 0.0 111.258 179.917 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' F' F ' 15' ' ' GLN . . . . . 0.439 HE22 HG12 ' C' ' 36' ' ' VAL . 44.3 mt-30 -108.36 -171.42 1.86 Allowed 'General case' 0 CA--C 1.499 -1.011 0 N-CA-C 108.544 -0.91 . . . . 0.0 108.544 179.885 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -167.53 98.01 0.49 Allowed 'General case' 0 CA--C 1.541 0.605 0 CA-C-N 114.933 -1.03 . . . . 0.0 109.484 178.667 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' F' F ' 17' ' ' LEU . . . . . 0.583 ' N ' HD12 ' F' ' 17' ' ' LEU . 4.5 mp -105.73 163.14 12.93 Favored 'General case' 0 N--CA 1.49 1.541 0 N-CA-C 109.151 -0.685 . . . . 0.0 109.151 -179.856 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 39.0 t -142.17 118.41 6.3 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.293 0 C-N-CA 122.573 0.349 . . . . 0.0 110.567 179.121 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 52.3 m-85 -69.78 156.7 38.63 Favored 'General case' 0 C--N 1.358 0.955 0 N-CA-C 107.121 -1.437 . . . . 0.0 107.121 176.482 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 13.9 t80 -173.0 -55.27 0.02 OUTLIER 'General case' 0 N--CA 1.485 1.293 0 CA-C-O 121.811 0.815 . . . . 0.0 109.826 179.645 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.86 88.89 0.0 OUTLIER 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 114.436 -1.256 . . . . 0.0 112.916 -178.938 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 37.8 tt0 -64.78 157.68 26.97 Favored 'General case' 0 N--CA 1.472 0.651 0 CA-C-N 114.935 -1.029 . . . . 0.0 110.784 179.464 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 66.1 m-20 -139.84 137.03 34.61 Favored 'General case' 0 N--CA 1.478 0.955 0 C-N-CA 122.944 0.497 . . . . 0.0 110.346 179.887 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' F' F ' 24' ' ' VAL . . . . . . . . . . . . . 21.6 t -85.62 -115.55 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.482 1.126 0 N-CA-C 108.706 -0.849 . . . . 0.0 108.706 179.502 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -108.8 54.06 0.57 Allowed Glycine 0 N--CA 1.477 1.371 0 N-CA-C 111.235 -0.746 . . . . 0.0 111.235 -179.869 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 69.8 p -79.5 125.04 29.05 Favored 'General case' 0 N--CA 1.473 0.675 0 N-CA-C 109.052 -0.721 . . . . 0.0 109.052 177.876 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' F' F ' 27' ' ' ASN . . . . . 0.446 HD21 ' CG ' ' D' ' 11' ' ' GLU . 48.2 t30 -65.46 100.15 0.47 Allowed 'General case' 0 N--CA 1.473 0.69 0 N-CA-C 108.328 -0.99 . . . . 0.0 108.328 178.533 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 66.1 mttm -95.66 116.82 29.41 Favored 'General case' 0 N--CA 1.485 1.281 0 N-CA-C 110.022 -0.362 . . . . 0.0 110.022 -178.669 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.17 -132.77 0.01 OUTLIER Glycine 0 CA--C 1.533 1.197 0 N-CA-C 111.491 -0.644 . . . . 0.0 111.491 178.916 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -113.85 126.37 55.11 Favored 'General case' 0 N--CA 1.478 0.954 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 179.278 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 67.2 mt -89.97 130.66 38.89 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.209 0 N-CA-C 107.175 -1.417 . . . . 0.0 107.175 178.632 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 19.4 mt -142.11 154.32 18.83 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.877 0 N-CA-C 109.106 -0.701 . . . . 0.0 109.106 -179.333 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.63 48.9 73.21 Favored Glycine 0 CA--C 1.524 0.596 0 CA-C-N 116.476 -0.329 . . . . 0.0 113.289 179.016 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 3.0 tt -99.41 120.26 39.31 Favored 'General case' 0 N--CA 1.478 0.946 0 N-CA-C 107.145 -1.428 . . . . 0.0 107.145 177.771 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 28.5 ttt -151.82 159.66 43.81 Favored 'General case' 0 N--CA 1.477 0.925 0 N-CA-C 108.673 -0.862 . . . . 0.0 108.673 179.437 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' F' F ' 36' ' ' VAL . . . . . 0.435 HG12 HE22 ' I' ' 15' ' ' GLN . 94.5 t -159.76 149.89 6.45 Favored 'Isoleucine or valine' 0 C--O 1.235 0.31 0 N-CA-C 106.865 -1.531 . . . . 0.0 106.865 -179.478 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.78 74.35 0.34 Allowed Glycine 0 C--N 1.313 -0.722 0 CA-C-N 115.549 -0.75 . . . . 0.0 111.512 177.904 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 171.91 -147.25 9.93 Favored Glycine 0 C--O 1.223 -0.534 0 N-CA-C 111.099 -0.8 . . . . 0.0 111.099 179.818 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 33.2 m -135.33 141.67 41.91 Favored 'Isoleucine or valine' 0 C--N 1.352 0.715 0 N-CA-C 109.27 -0.641 . . . . 0.0 109.27 179.712 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 15.2 t . . . . . 0 CA--C 1.537 0.473 0 CA-C-O 117.934 -1.031 . . . . 0.0 111.155 179.317 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' G' G ' 1' ' ' ASP . . . . . . . . . . . . . 8.6 m-20 . . . . . 0 N--CA 1.493 1.681 0 N-CA-C 109.521 -0.548 . . . . 0.0 109.521 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' G' G ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.59 129.36 40.24 Favored 'General case' 0 N--CA 1.469 0.481 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.544 179.616 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' G' G ' 3' ' ' GLU . . . . . . . . . . . . . 52.3 tt0 -168.64 108.71 0.5 Allowed 'General case' 0 N--CA 1.471 0.614 0 N-CA-C 110.104 -0.332 . . . . 0.0 110.104 179.742 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 79.4 m-85 -85.48 139.88 31.14 Favored 'General case' 0 N--CA 1.474 0.765 0 N-CA-C 109.543 -0.54 . . . . 0.0 109.543 179.333 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' G' G ' 5' ' ' ARG . . . . . . . . . . . . . 72.2 mtp180 -144.05 141.52 30.14 Favored 'General case' 0 N--CA 1.483 1.221 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 -179.612 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 76.8 m80 -149.24 119.29 7.18 Favored 'General case' 0 N--CA 1.473 0.679 0 N-CA-C 108.952 -0.759 . . . . 0.0 108.952 179.026 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 8.9 m-20 -68.55 145.46 53.97 Favored 'General case' 0 N--CA 1.468 0.462 0 O-C-N 123.578 0.549 . . . . 0.0 111.945 -179.319 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' G' G ' 8' ' ' SER . . . . . . . . . . . . . 6.0 t -164.64 173.52 11.83 Favored 'General case' 0 N--CA 1.468 0.461 0 N-CA-C 109.386 -0.598 . . . . 0.0 109.386 178.208 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.36 24.45 2.19 Favored Glycine 0 N--CA 1.48 1.584 0 N-CA-C 111.639 -0.584 . . . . 0.0 111.639 178.934 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 42.4 p90 -56.24 127.56 31.4 Favored 'General case' 0 N--CA 1.474 0.745 0 N-CA-C 112.516 0.562 . . . . 0.0 112.516 -178.757 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 45.7 mt-10 -83.61 154.24 23.86 Favored 'General case' 0 N--CA 1.471 0.601 0 CA-C-O 120.971 0.415 . . . . 0.0 109.882 178.638 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 2.6 p -155.5 128.51 1.13 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.959 0 N-CA-C 108.431 -0.951 . . . . 0.0 108.431 178.972 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 49.6 m-70 -133.6 144.64 49.41 Favored 'General case' 0 N--CA 1.477 0.876 0 CA-C-N 115.454 -0.793 . . . . 0.0 110.934 -178.177 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 32.2 t-80 -165.65 98.62 0.68 Allowed 'General case' 0 N--CA 1.483 1.2 0 CA-C-N 116.589 -0.278 . . . . 0.0 110.805 179.193 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' G' G ' 15' ' ' GLN . . . . . 0.41 HE22 HG12 ' D' ' 36' ' ' VAL . 45.0 mt-30 -108.49 -171.92 1.95 Allowed 'General case' 0 CA--C 1.501 -0.915 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 179.916 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -167.31 97.91 0.5 Allowed 'General case' 0 CA--C 1.542 0.641 0 CA-C-N 114.96 -1.018 . . . . 0.0 109.388 178.717 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' G' G ' 17' ' ' LEU . . . . . 0.589 ' N ' HD12 ' G' ' 17' ' ' LEU . 5.1 mp -105.38 162.41 13.47 Favored 'General case' 0 N--CA 1.487 1.402 0 N-CA-C 109.32 -0.622 . . . . 0.0 109.32 -179.685 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 36.5 t -143.13 118.52 4.6 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.009 0 CA-C-O 120.83 0.348 . . . . 0.0 110.442 178.851 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 46.5 m-85 -69.76 150.32 47.03 Favored 'General case' 0 C--N 1.37 1.481 0 N-CA-C 107.263 -1.384 . . . . 0.0 107.263 176.595 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 11.3 t80 -170.5 -55.06 0.02 OUTLIER 'General case' 0 N--CA 1.487 1.406 0 CA-C-N 117.953 0.342 . . . . 0.0 110.328 -179.583 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.68 89.9 0.0 OUTLIER 'General case' 0 C--N 1.325 -0.491 0 C-N-CA 123.774 0.83 . . . . 0.0 112.508 -179.839 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 38.0 tt0 -65.41 158.54 26.41 Favored 'General case' 0 N--CA 1.469 0.476 0 CA-C-N 114.714 -1.13 . . . . 0.0 109.954 179.146 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 67.4 m-20 -140.09 136.8 33.97 Favored 'General case' 0 N--CA 1.478 0.937 0 C-N-CA 122.874 0.469 . . . . 0.0 109.98 179.904 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' G' G ' 24' ' ' VAL . . . . . . . . . . . . . 21.5 t -85.95 -115.61 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 1.004 0 N-CA-C 108.506 -0.924 . . . . 0.0 108.506 179.555 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -108.61 54.04 0.57 Allowed Glycine 0 N--CA 1.477 1.397 0 N-CA-C 111.492 -0.643 . . . . 0.0 111.492 -179.868 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 72.6 p -79.96 125.57 29.92 Favored 'General case' 0 N--CA 1.467 0.389 0 N-CA-C 108.943 -0.762 . . . . 0.0 108.943 177.971 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 3.8 t-20 -65.76 100.98 0.59 Allowed 'General case' 0 N--CA 1.47 0.566 0 N-CA-C 108.567 -0.901 . . . . 0.0 108.567 178.525 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 66.6 mttm -95.76 117.2 30.09 Favored 'General case' 0 N--CA 1.485 1.309 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 -179.13 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.94 -131.95 0.01 OUTLIER Glycine 0 CA--C 1.53 1.005 0 N-CA-C 110.579 -1.008 . . . . 0.0 110.579 178.946 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -113.74 126.48 55.27 Favored 'General case' 0 N--CA 1.469 0.499 0 N-CA-C 109.522 -0.547 . . . . 0.0 109.522 179.542 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 69.3 mt -89.94 131.38 37.34 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.756 0 N-CA-C 107.327 -1.36 . . . . 0.0 107.327 178.495 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 22.7 mt -143.29 155.09 16.74 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.397 0 CA-C-N 118.982 0.81 . . . . 0.0 109.056 -179.751 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.74 48.2 79.29 Favored Glycine 0 CA--C 1.527 0.782 0 CA-C-N 116.659 -0.246 . . . . 0.0 112.835 179.053 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' G' G ' 34' ' ' LEU . . . . . 0.405 HD23 ' N ' ' G' ' 35' ' ' MET . 2.9 tt -98.87 121.19 40.5 Favored 'General case' 0 N--CA 1.478 0.955 0 N-CA-C 107.086 -1.449 . . . . 0.0 107.086 177.75 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' G' G ' 35' ' ' MET . . . . . 0.405 ' N ' HD23 ' G' ' 34' ' ' LEU . 28.7 ttt -153.08 160.21 42.9 Favored 'General case' 0 N--CA 1.477 0.882 0 N-CA-C 108.172 -1.047 . . . . 0.0 108.172 179.493 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 84.4 t -159.81 150.2 6.31 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.255 0 N-CA-C 106.419 -1.697 . . . . 0.0 106.419 -179.354 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.59 74.86 0.29 Allowed Glycine 0 C--N 1.312 -0.756 0 C-N-CA 120.975 -0.631 . . . . 0.0 112.049 177.727 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 170.28 -145.79 9.39 Favored Glycine 0 N--CA 1.467 0.702 0 N-CA-C 110.614 -0.995 . . . . 0.0 110.614 179.127 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 33.9 m -135.91 142.06 40.08 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.873 0 N-CA-C 109.911 -0.403 . . . . 0.0 109.911 -179.887 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 15.4 t . . . . . 0 N--CA 1.466 0.349 0 CA-C-O 118.046 -0.978 . . . . 0.0 111.304 179.463 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' H' H ' 1' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 . . . . . 0 N--CA 1.49 1.566 0 N-CA-C 109.669 -0.493 . . . . 0.0 109.669 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' H' H ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.56 129.48 40.8 Favored 'General case' 0 N--CA 1.468 0.466 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.472 179.597 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' H' H ' 3' ' ' GLU . . . . . . . . . . . . . 53.5 tt0 -168.66 108.52 0.49 Allowed 'General case' 0 N--CA 1.469 0.519 0 N-CA-C 110.099 -0.334 . . . . 0.0 110.099 179.804 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 80.1 m-85 -85.18 140.04 31.21 Favored 'General case' 0 N--CA 1.474 0.769 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 179.333 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' H' H ' 5' ' ' ARG . . . . . . . . . . . . . 72.3 mtp180 -144.11 141.85 30.26 Favored 'General case' 0 N--CA 1.483 1.191 0 N-CA-C 109.294 -0.632 . . . . 0.0 109.294 -179.635 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 76.9 m80 -149.67 118.87 6.78 Favored 'General case' 0 N--CA 1.473 0.695 0 N-CA-C 109.105 -0.702 . . . . 0.0 109.105 179.129 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 8.8 m-20 -68.25 145.2 54.48 Favored 'General case' 0 N--CA 1.469 0.48 0 O-C-N 123.469 0.481 . . . . 0.0 111.924 -179.309 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' H' H ' 8' ' ' SER . . . . . . . . . . . . . 7.5 t -164.36 172.96 12.77 Favored 'General case' 0 N--CA 1.469 0.507 0 N-CA-C 109.449 -0.575 . . . . 0.0 109.449 178.421 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.43 24.46 2.17 Favored Glycine 0 N--CA 1.481 1.665 0 N-CA-C 111.733 -0.547 . . . . 0.0 111.733 179.112 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 42.1 p90 -56.38 127.51 31.37 Favored 'General case' 0 N--CA 1.473 0.707 0 N-CA-C 112.428 0.529 . . . . 0.0 112.428 -178.795 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 45.4 mt-10 -83.51 154.2 24.0 Favored 'General case' 0 N--CA 1.473 0.676 0 CA-C-O 120.984 0.421 . . . . 0.0 109.874 178.62 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.6 p -155.41 128.41 1.13 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.975 0 N-CA-C 108.433 -0.951 . . . . 0.0 108.433 178.963 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 52.1 m-70 -133.42 144.63 49.65 Favored 'General case' 0 N--CA 1.476 0.863 0 CA-C-N 115.43 -0.804 . . . . 0.0 110.893 -178.16 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 6.4 t60 -165.61 98.48 0.68 Allowed 'General case' 0 N--CA 1.482 1.146 0 CA-C-N 116.527 -0.306 . . . . 0.0 110.839 179.146 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' H' H ' 15' ' ' GLN . . . . . 0.416 HE22 HG12 ' E' ' 36' ' ' VAL . 44.9 mt-30 -108.24 -172.45 2.06 Favored 'General case' 0 CA--C 1.5 -0.979 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 -179.921 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -167.01 97.78 0.52 Allowed 'General case' 0 CA--C 1.539 0.521 0 CA-C-N 114.989 -1.005 . . . . 0.0 109.402 178.73 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' H' H ' 17' ' ' LEU . . . . . 0.589 ' N ' HD12 ' H' ' 17' ' ' LEU . 5.1 mp -105.5 162.13 13.74 Favored 'General case' 0 N--CA 1.488 1.442 0 N-CA-C 109.292 -0.633 . . . . 0.0 109.292 -179.632 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 38.5 t -142.79 118.54 5.16 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.097 0 CA-C-O 120.905 0.383 . . . . 0.0 110.482 178.874 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 47.5 m-85 -70.14 150.89 46.06 Favored 'General case' 0 C--N 1.37 1.498 0 N-CA-C 107.391 -1.336 . . . . 0.0 107.391 176.585 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 11.9 t80 -171.88 -54.41 0.02 OUTLIER 'General case' 0 N--CA 1.485 1.28 0 CA-C-N 117.828 0.286 . . . . 0.0 110.323 -179.456 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.99 90.22 0.0 OUTLIER 'General case' 0 CA--C 1.536 0.437 0 C-N-CA 123.59 0.756 . . . . 0.0 112.262 -179.824 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 37.9 tt0 -65.38 158.63 26.09 Favored 'General case' 0 N--CA 1.468 0.465 0 CA-C-N 114.739 -1.118 . . . . 0.0 110.011 179.318 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 66.8 m-20 -140.18 136.98 34.01 Favored 'General case' 0 N--CA 1.477 0.899 0 C-N-CA 122.942 0.497 . . . . 0.0 109.972 179.872 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' H' H ' 24' ' ' VAL . . . . . . . . . . . . . 21.5 t -86.36 -115.55 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.049 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 179.605 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . -108.3 53.44 0.6 Allowed Glycine 0 N--CA 1.479 1.564 0 N-CA-C 111.395 -0.682 . . . . 0.0 111.395 -179.828 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 70.1 p -79.46 125.28 29.35 Favored 'General case' 0 N--CA 1.468 0.45 0 N-CA-C 108.893 -0.781 . . . . 0.0 108.893 178.004 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' H' H ' 27' ' ' ASN . . . . . 0.615 ' HB3' HD21 ' E' ' 27' ' ' ASN . 3.9 t-20 -65.69 100.91 0.57 Allowed 'General case' 0 N--CA 1.472 0.662 0 N-CA-C 108.497 -0.927 . . . . 0.0 108.497 178.5 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 66.6 mttm -95.89 117.09 29.93 Favored 'General case' 0 N--CA 1.485 1.283 0 N-CA-C 109.97 -0.382 . . . . 0.0 109.97 -179.146 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.66 -131.75 0.01 OUTLIER Glycine 0 CA--C 1.531 1.059 0 N-CA-C 110.802 -0.919 . . . . 0.0 110.802 178.921 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -114.0 126.24 54.91 Favored 'General case' 0 N--CA 1.471 0.604 0 N-CA-C 109.61 -0.515 . . . . 0.0 109.61 179.527 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 69.4 mt -89.79 131.13 37.82 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.701 0 N-CA-C 107.338 -1.356 . . . . 0.0 107.338 178.55 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 23.3 mt -143.11 155.05 17.02 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.339 0 CA-C-N 118.826 0.739 . . . . 0.0 109.024 -179.698 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.65 48.12 80.36 Favored Glycine 0 CA--C 1.524 0.626 0 CA-C-O 120.117 -0.269 . . . . 0.0 112.891 179.045 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 2.9 tt -98.75 121.09 40.25 Favored 'General case' 0 N--CA 1.478 0.969 0 N-CA-C 107.117 -1.438 . . . . 0.0 107.117 177.617 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 28.7 ttt -152.89 159.95 43.03 Favored 'General case' 0 N--CA 1.478 0.974 0 N-CA-C 108.07 -1.085 . . . . 0.0 108.07 179.61 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 87.2 t -159.66 150.34 6.43 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.261 0 N-CA-C 106.448 -1.686 . . . . 0.0 106.448 -179.51 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.35 74.96 0.27 Allowed Glycine 0 C--N 1.311 -0.811 0 C-N-CA 120.979 -0.629 . . . . 0.0 112.015 177.804 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 170.24 -146.2 9.7 Favored Glycine 0 N--CA 1.467 0.744 0 N-CA-C 110.539 -1.024 . . . . 0.0 110.539 179.129 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 34.0 m -135.57 142.02 40.64 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.815 0 N-CA-C 109.951 -0.388 . . . . 0.0 109.951 -179.875 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 15.9 t . . . . . 0 N--CA 1.467 0.4 0 CA-C-O 118.058 -0.973 . . . . 0.0 111.327 179.45 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' I' I ' 1' ' ' ASP . . . . . . . . . . . . . 8.7 m-20 . . . . . 0 N--CA 1.492 1.628 0 N-CA-C 109.572 -0.529 . . . . 0.0 109.572 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' I' I ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.85 129.62 41.26 Favored 'General case' 0 N--CA 1.468 0.456 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.403 179.625 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' I' I ' 3' ' ' GLU . . . . . . . . . . . . . 53.6 tt0 -168.75 108.31 0.48 Allowed 'General case' 0 N--CA 1.47 0.548 0 N-CA-C 110.166 -0.309 . . . . 0.0 110.166 179.773 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 79.6 m-85 -84.96 140.3 31.17 Favored 'General case' 0 N--CA 1.474 0.726 0 N-CA-C 109.643 -0.503 . . . . 0.0 109.643 179.333 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' I' I ' 5' ' ' ARG . . . . . . . . . . . . . 72.4 mtp180 -144.48 141.67 29.72 Favored 'General case' 0 N--CA 1.484 1.265 0 N-CA-C 109.224 -0.658 . . . . 0.0 109.224 -179.581 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 76.8 m80 -149.47 119.13 6.99 Favored 'General case' 0 N--CA 1.474 0.728 0 N-CA-C 109.08 -0.711 . . . . 0.0 109.08 178.999 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 8.9 m-20 -68.45 145.19 54.31 Favored 'General case' 0 N--CA 1.469 0.499 0 O-C-N 123.429 0.456 . . . . 0.0 111.866 -179.235 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' I' I ' 8' ' ' SER . . . . . . . . . . . . . 7.5 t -164.33 172.62 13.25 Favored 'General case' 0 N--CA 1.469 0.509 0 N-CA-C 109.463 -0.569 . . . . 0.0 109.463 178.368 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.92 24.62 2.03 Favored Glycine 0 N--CA 1.481 1.684 0 N-CA-C 111.7 -0.56 . . . . 0.0 111.7 179.104 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 42.4 p90 -56.52 127.53 31.69 Favored 'General case' 0 N--CA 1.474 0.762 0 N-CA-C 112.424 0.528 . . . . 0.0 112.424 -178.758 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 45.7 mt-10 -83.56 154.12 23.98 Favored 'General case' 0 N--CA 1.473 0.719 0 CA-C-O 121.071 0.463 . . . . 0.0 109.816 178.62 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 2.6 p -155.3 128.27 1.12 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.005 0 N-CA-C 108.389 -0.967 . . . . 0.0 108.389 178.956 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 50.9 m-70 -133.35 144.36 49.57 Favored 'General case' 0 N--CA 1.477 0.922 0 CA-C-N 115.45 -0.795 . . . . 0.0 110.966 -178.163 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 32.6 t-80 -165.45 98.71 0.7 Allowed 'General case' 0 N--CA 1.483 1.177 0 CA-C-N 116.559 -0.291 . . . . 0.0 110.794 179.203 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' I' I ' 15' ' ' GLN . . . . . 0.435 HE22 HG12 ' F' ' 36' ' ' VAL . 44.6 mt-30 -108.64 -172.46 2.06 Favored 'General case' 0 CA--C 1.499 -1.001 0 N-CA-C 108.405 -0.961 . . . . 0.0 108.405 179.979 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -166.78 98.02 0.55 Allowed 'General case' 0 CA--C 1.539 0.553 0 CA-C-N 114.933 -1.031 . . . . 0.0 109.423 178.745 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' I' I ' 17' ' ' LEU . . . . . 0.589 ' N ' HD12 ' I' ' 17' ' ' LEU . 5.1 mp -105.56 162.19 13.71 Favored 'General case' 0 N--CA 1.487 1.402 0 N-CA-C 109.327 -0.62 . . . . 0.0 109.327 -179.701 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 38.8 t -142.88 118.54 4.98 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.024 0 CA-C-O 120.987 0.423 . . . . 0.0 110.471 178.848 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 47.8 m-85 -70.01 150.89 46.18 Favored 'General case' 0 C--N 1.37 1.465 0 N-CA-C 107.306 -1.368 . . . . 0.0 107.306 176.567 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 12.0 t80 -171.94 -54.29 0.02 OUTLIER 'General case' 0 N--CA 1.483 1.206 0 CA-C-N 117.922 0.328 . . . . 0.0 110.408 -179.49 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.18 90.18 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.447 0 C-N-CA 123.713 0.805 . . . . 0.0 112.302 -179.893 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 38.2 tt0 -65.37 158.57 26.2 Favored 'General case' 0 N--CA 1.469 0.519 0 CA-C-N 114.738 -1.119 . . . . 0.0 110.045 179.254 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 66.3 m-20 -140.27 136.81 33.69 Favored 'General case' 0 N--CA 1.478 0.937 0 C-N-CA 122.859 0.464 . . . . 0.0 109.989 179.844 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' I' I ' 24' ' ' VAL . . . . . . . . . . . . . 21.3 t -86.04 -115.9 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.957 0 N-CA-C 108.542 -0.911 . . . . 0.0 108.542 179.559 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . -108.1 54.12 0.57 Allowed Glycine 0 N--CA 1.478 1.453 0 N-CA-C 111.384 -0.687 . . . . 0.0 111.384 -179.845 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 73.4 p -80.08 125.14 29.42 Favored 'General case' 0 N--CA 1.467 0.399 0 N-CA-C 108.962 -0.755 . . . . 0.0 108.962 177.889 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 3.9 t-20 -65.49 101.01 0.54 Allowed 'General case' 0 CA--C 1.54 0.583 0 N-CA-C 108.539 -0.911 . . . . 0.0 108.539 178.588 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 66.5 mttm -95.88 117.07 29.88 Favored 'General case' 0 N--CA 1.485 1.321 0 N-CA-C 109.98 -0.378 . . . . 0.0 109.98 -179.177 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.68 -132.1 0.01 OUTLIER Glycine 0 CA--C 1.533 1.186 0 N-CA-C 110.652 -0.979 . . . . 0.0 110.652 178.975 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -113.55 126.12 54.95 Favored 'General case' 0 N--CA 1.472 0.635 0 C-N-CA 123.009 0.524 . . . . 0.0 109.622 179.547 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 70.1 mt -89.81 131.51 36.89 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.752 0 N-CA-C 107.219 -1.401 . . . . 0.0 107.219 178.567 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 23.5 mt -143.49 155.12 16.42 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.36 0 CA-C-N 118.883 0.765 . . . . 0.0 108.994 -179.69 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.57 48.18 80.17 Favored Glycine 0 CA--C 1.525 0.661 0 CA-C-N 116.635 -0.257 . . . . 0.0 112.846 179.082 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 2.9 tt -98.78 121.19 40.41 Favored 'General case' 0 N--CA 1.478 0.956 0 N-CA-C 107.002 -1.481 . . . . 0.0 107.002 177.625 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 28.6 ttt -153.0 159.93 42.96 Favored 'General case' 0 N--CA 1.478 0.931 0 N-CA-C 108.057 -1.09 . . . . 0.0 108.057 179.543 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 86.9 t -159.67 150.33 6.42 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.243 0 N-CA-C 106.372 -1.714 . . . . 0.0 106.372 -179.518 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.52 74.61 0.31 Allowed Glycine 0 C--N 1.312 -0.762 0 C-N-CA 120.898 -0.668 . . . . 0.0 112.083 177.777 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 170.49 -146.12 9.57 Favored Glycine 0 N--CA 1.466 0.664 0 N-CA-C 110.599 -1.0 . . . . 0.0 110.599 179.131 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 34.0 m -135.67 141.99 40.57 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.807 0 N-CA-C 109.882 -0.414 . . . . 0.0 109.882 -179.834 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 16.2 t . . . . . 0 C--O 1.223 -0.315 0 CA-C-O 118.035 -0.984 . . . . 0.0 111.275 179.465 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 9.6 m-20 . . . . . 0 N--CA 1.49 1.538 0 N-CA-C 109.098 -0.704 . . . . 0.0 109.098 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -66.45 148.26 52.13 Favored 'General case' 0 N--CA 1.467 0.399 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.119 179.674 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 56.0 tt0 -162.14 104.17 1.14 Allowed 'General case' 0 N--CA 1.472 0.628 0 N-CA-C 110.035 -0.358 . . . . 0.0 110.035 179.641 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 20.2 m-85 -71.02 172.54 8.9 Favored 'General case' 0 N--CA 1.47 0.56 0 N-CA-C 109.495 -0.557 . . . . 0.0 109.495 179.533 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 31.9 mtp180 -67.96 130.38 42.79 Favored 'General case' 0 C--O 1.218 -0.602 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.154 -178.027 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 4.1 m-70 -100.34 131.54 46.22 Favored 'General case' 0 N--CA 1.474 0.733 0 N-CA-C 109.461 -0.57 . . . . 0.0 109.461 179.457 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 13.8 m-20 -71.42 141.03 50.31 Favored 'General case' 0 CA--C 1.53 0.19 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.819 -179.748 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' SER . . . . . 0.41 ' O ' ' O ' ' C' ' 25' ' ' GLY . 8.7 t -143.53 -173.35 3.93 Favored 'General case' 0 N--CA 1.48 1.032 0 N-CA-C 109.016 -0.735 . . . . 0.0 109.016 178.498 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 117.88 11.49 8.4 Favored Glycine 0 N--CA 1.486 1.993 0 N-CA-C 112.543 -0.223 . . . . 0.0 112.543 179.197 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 47.8 p90 -59.2 128.36 36.76 Favored 'General case' 0 N--CA 1.471 0.622 0 CA-C-O 120.768 0.318 . . . . 0.0 111.849 -179.593 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 46.6 mt-10 -89.8 154.67 19.73 Favored 'General case' 0 N--CA 1.471 0.598 0 N-CA-C 109.299 -0.63 . . . . 0.0 109.299 178.548 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -153.58 128.92 1.57 Allowed 'Isoleucine or valine' 0 C--O 1.235 0.297 0 N-CA-C 108.072 -1.084 . . . . 0.0 108.072 178.641 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 50.1 m-70 -135.37 147.04 48.95 Favored 'General case' 0 N--CA 1.49 1.565 0 CA-C-N 118.834 0.743 . . . . 0.0 111.114 -179.108 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 6.4 t60 -164.94 97.57 0.74 Allowed 'General case' 0 N--CA 1.48 1.056 0 CA-C-N 116.568 -0.287 . . . . 0.0 111.139 179.632 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 45.0 mt-30 -108.87 -172.49 2.06 Favored 'General case' 0 CA--C 1.503 -0.856 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 -179.969 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -166.81 98.0 0.55 Allowed 'General case' 0 N--CA 1.473 0.691 0 CA-C-N 115.179 -0.918 . . . . 0.0 109.391 178.795 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.596 ' N ' HD12 ' A' ' 17' ' ' LEU . 4.5 mp -106.05 164.17 12.19 Favored 'General case' 0 N--CA 1.489 1.488 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 179.99 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 57.8 t -142.39 119.0 6.34 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.301 0 CA-C-O 118.962 -0.542 . . . . 0.0 109.904 179.527 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 53.2 m-85 -69.81 159.46 33.57 Favored 'General case' 0 N--CA 1.481 1.094 0 N-CA-C 107.491 -1.3 . . . . 0.0 107.491 177.186 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 11.7 t80 -171.68 -58.0 0.02 OUTLIER 'General case' 0 N--CA 1.487 1.417 0 CA-C-O 122.386 1.089 . . . . 0.0 109.815 179.65 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -39.32 89.73 0.0 OUTLIER 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 113.91 -1.496 . . . . 0.0 112.973 -178.03 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 37.1 tt0 -65.47 158.48 26.72 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.119 -0.946 . . . . 0.0 110.603 179.077 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 11.5 m-20 -140.74 137.63 33.57 Favored 'General case' 0 N--CA 1.479 0.994 0 C-N-CA 122.984 0.513 . . . . 0.0 110.249 179.702 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 17.7 t -91.7 -116.68 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.483 1.187 0 N-CA-C 108.64 -0.874 . . . . 0.0 108.64 179.576 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.404 ' O ' ' O ' ' B' ' 8' ' ' SER . . . -102.82 56.99 0.6 Allowed Glycine 0 N--CA 1.473 1.166 0 N-CA-C 110.954 -0.858 . . . . 0.0 110.954 179.997 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 79.6 p -85.25 124.74 32.23 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 178.068 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 61.7 t30 -64.58 100.88 0.41 Allowed 'General case' 0 N--CA 1.474 0.728 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 178.874 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 64.7 mttm -97.27 113.98 25.67 Favored 'General case' 0 N--CA 1.484 1.265 0 N-CA-C 110.011 -0.366 . . . . 0.0 110.011 -178.967 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.65 -134.26 0.01 OUTLIER Glycine 0 CA--C 1.534 1.235 0 N-CA-C 110.741 -0.944 . . . . 0.0 110.741 179.103 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -112.56 127.74 56.16 Favored 'General case' 0 N--CA 1.481 1.092 0 N-CA-C 109.155 -0.683 . . . . 0.0 109.155 178.997 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 65.0 mt -90.32 129.24 41.49 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.623 0 N-CA-C 107.532 -1.285 . . . . 0.0 107.532 178.755 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 12.4 mt -142.96 151.92 17.25 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.793 0 CA-C-N 116.2 -0.455 . . . . 0.0 109.943 -178.891 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 65.21 48.9 64.94 Favored Glycine 0 CA--C 1.524 0.632 0 CA-C-N 115.997 -0.547 . . . . 0.0 112.495 179.01 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.415 HD23 ' N ' ' A' ' 35' ' ' MET . 2.8 tt -99.03 121.1 40.52 Favored 'General case' 0 N--CA 1.479 1.009 0 N-CA-C 107.143 -1.429 . . . . 0.0 107.143 178.088 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 35' ' ' MET . . . . . 0.415 ' N ' HD23 ' A' ' 34' ' ' LEU . 27.5 ttt -153.24 158.08 41.16 Favored 'General case' 0 N--CA 1.47 0.539 0 N-CA-C 108.847 -0.797 . . . . 0.0 108.847 179.576 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.412 HG12 HE22 ' D' ' 15' ' ' GLN . 85.0 t -158.19 149.32 8.66 Favored 'Isoleucine or valine' 0 C--O 1.238 0.47 0 N-CA-C 106.868 -1.53 . . . . 0.0 106.868 -179.577 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 57.38 72.42 0.59 Allowed Glycine 0 C--N 1.315 -0.616 0 N-CA-C 111.318 -0.713 . . . . 0.0 111.318 178.342 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 172.74 -157.78 27.36 Favored Glycine 0 C--N 1.332 0.326 0 N-CA-C 110.804 -0.918 . . . . 0.0 110.804 -179.895 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 33.4 m -124.07 143.33 37.73 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.934 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 179.502 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 16.4 t . . . . . 0 CA--C 1.536 0.412 0 CA-C-O 118.056 -0.973 . . . . 0.0 111.062 179.152 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' B' B ' 1' ' ' ASP . . . . . . . . . . . . . 9.5 m-20 . . . . . 0 N--CA 1.49 1.569 0 N-CA-C 109.107 -0.701 . . . . 0.0 109.107 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' B' B ' 2' ' ' ALA . . . . . . . . . . . . . . . -66.56 148.25 52.15 Favored 'General case' 0 N--CA 1.466 0.342 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.09 179.594 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 3' ' ' GLU . . . . . . . . . . . . . 56.3 tt0 -162.09 104.13 1.14 Allowed 'General case' 0 N--CA 1.472 0.644 0 N-CA-C 109.999 -0.371 . . . . 0.0 109.999 179.663 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 21.4 m-85 -71.04 172.49 9.01 Favored 'General case' 0 N--CA 1.47 0.561 0 N-CA-C 109.4 -0.593 . . . . 0.0 109.4 179.622 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 32.2 mtp180 -67.94 129.8 41.01 Favored 'General case' 0 N--CA 1.47 0.529 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.214 -178.019 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 4.1 m-70 -99.81 131.79 45.57 Favored 'General case' 0 N--CA 1.476 0.854 0 N-CA-C 109.551 -0.537 . . . . 0.0 109.551 179.407 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 7' ' ' ASP . . . . . . . . . . . . . 13.2 m-20 -71.86 141.25 49.58 Favored 'General case' 0 CA--C 1.532 0.259 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.786 -179.688 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 8' ' ' SER . . . . . 0.404 ' O ' ' O ' ' A' ' 25' ' ' GLY . 8.7 t -143.54 -172.98 3.83 Favored 'General case' 0 N--CA 1.478 0.953 0 N-CA-C 109.017 -0.734 . . . . 0.0 109.017 178.417 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 117.45 11.79 8.53 Favored Glycine 0 N--CA 1.484 1.89 0 N-CA-C 112.513 -0.235 . . . . 0.0 112.513 179.241 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 47.4 p90 -59.33 128.09 35.36 Favored 'General case' 0 CA--C 1.54 0.583 0 N-CA-C 111.815 0.302 . . . . 0.0 111.815 -179.628 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 46.5 mt-10 -89.58 154.51 19.93 Favored 'General case' 0 N--CA 1.473 0.705 0 N-CA-C 109.418 -0.586 . . . . 0.0 109.418 178.552 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -153.48 128.31 1.47 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.286 0 N-CA-C 108.3 -1.0 . . . . 0.0 108.3 178.682 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 49.3 m-70 -134.89 147.35 49.82 Favored 'General case' 0 N--CA 1.489 1.514 0 CA-C-N 118.69 0.677 . . . . 0.0 111.044 -178.944 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 6.5 t60 -165.14 97.65 0.72 Allowed 'General case' 0 N--CA 1.481 1.125 0 CA-C-N 116.608 -0.269 . . . . 0.0 110.992 179.593 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 45.0 mt-30 -108.79 -172.79 2.12 Favored 'General case' 0 CA--C 1.501 -0.934 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 16' ' ' LYS . . . . . 0.401 ' C ' HD12 ' B' ' 17' ' ' LEU . 88.4 tttt -166.83 98.08 0.55 Allowed 'General case' 0 CA--C 1.541 0.616 0 CA-C-N 115.142 -0.935 . . . . 0.0 109.404 178.815 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 17' ' ' LEU . . . . . 0.595 ' N ' HD12 ' B' ' 17' ' ' LEU . 4.5 mp -106.2 164.2 12.19 Favored 'General case' 0 N--CA 1.487 1.41 0 N-CA-C 108.606 -0.887 . . . . 0.0 108.606 -179.948 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 58.9 t -142.52 118.46 5.65 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.258 0 CA-C-O 118.999 -0.524 . . . . 0.0 109.959 179.527 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 53.8 m-85 -70.04 159.55 33.62 Favored 'General case' 0 N--CA 1.478 0.942 0 N-CA-C 107.409 -1.33 . . . . 0.0 107.409 177.296 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 12.8 t80 -172.36 -56.98 0.02 OUTLIER 'General case' 0 N--CA 1.484 1.271 0 CA-C-O 122.233 1.016 . . . . 0.0 109.851 179.622 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -39.63 90.37 0.0 OUTLIER 'General case' 0 CA--C 1.529 0.138 0 CA-C-N 114.148 -1.387 . . . . 0.0 112.823 -178.163 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 36.9 tt0 -66.13 158.11 29.47 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 115.068 -0.969 . . . . 0.0 110.618 179.163 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 11.8 m-20 -140.18 138.38 35.12 Favored 'General case' 0 N--CA 1.48 1.058 0 C-N-CA 122.978 0.511 . . . . 0.0 110.127 179.697 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 17.9 t -92.73 -116.95 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.484 1.232 0 N-CA-C 108.707 -0.849 . . . . 0.0 108.707 179.543 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 25' ' ' GLY . . . . . 0.41 ' O ' ' O ' ' C' ' 8' ' ' SER . . . -101.89 56.43 0.68 Allowed Glycine 0 N--CA 1.474 1.191 0 N-CA-C 110.835 -0.906 . . . . 0.0 110.835 -179.959 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 78.9 p -85.23 124.82 32.31 Favored 'General case' 0 N--CA 1.466 0.354 0 N-CA-C 108.695 -0.854 . . . . 0.0 108.695 178.047 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 62.2 t30 -64.89 101.42 0.49 Allowed 'General case' 0 N--CA 1.473 0.701 0 N-CA-C 108.731 -0.84 . . . . 0.0 108.731 178.845 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 64.6 mttm -97.81 113.46 25.27 Favored 'General case' 0 N--CA 1.485 1.318 0 N-CA-C 110.029 -0.36 . . . . 0.0 110.029 -178.939 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.06 -134.16 0.01 OUTLIER Glycine 0 CA--C 1.534 1.255 0 N-CA-C 110.834 -0.907 . . . . 0.0 110.834 178.988 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -112.92 127.87 56.32 Favored 'General case' 0 N--CA 1.48 1.03 0 N-CA-C 109.114 -0.699 . . . . 0.0 109.114 179.02 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 64.4 mt -90.39 129.49 41.15 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.588 0 N-CA-C 107.52 -1.289 . . . . 0.0 107.52 178.768 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 12.0 mt -143.19 151.62 17.07 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.848 0 CA-C-N 116.06 -0.518 . . . . 0.0 109.905 -178.799 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 65.59 48.14 70.78 Favored Glycine 0 CA--C 1.526 0.722 0 CA-C-N 116.045 -0.525 . . . . 0.0 112.642 178.956 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 34' ' ' LEU . . . . . 0.4 HD23 ' N ' ' B' ' 35' ' ' MET . 2.9 tt -98.12 121.04 39.56 Favored 'General case' 0 N--CA 1.479 0.981 0 N-CA-C 107.269 -1.382 . . . . 0.0 107.269 177.951 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 35' ' ' MET . . . . . 0.4 ' N ' HD23 ' B' ' 34' ' ' LEU . 27.6 ttt -153.19 157.75 40.74 Favored 'General case' 0 N--CA 1.474 0.758 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 179.528 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 81.4 t -157.96 149.44 8.93 Favored 'Isoleucine or valine' 0 C--O 1.238 0.48 0 N-CA-C 106.676 -1.601 . . . . 0.0 106.676 -179.469 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.96 72.48 0.58 Allowed Glycine 0 C--N 1.314 -0.669 0 CA-C-N 115.621 -0.718 . . . . 0.0 111.394 178.331 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 172.86 -157.73 27.17 Favored Glycine 0 N--CA 1.459 0.233 0 N-CA-C 110.662 -0.975 . . . . 0.0 110.662 -179.946 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 33.5 m -124.06 143.3 37.83 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.933 0 C-N-CA 122.778 0.431 . . . . 0.0 109.891 179.402 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 16.2 t . . . . . 0 N--CA 1.468 0.439 0 CA-C-O 118.045 -0.979 . . . . 0.0 110.986 179.199 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' C' C ' 1' ' ' ASP . . . . . . . . . . . . . 9.2 m-20 . . . . . 0 N--CA 1.489 1.497 0 N-CA-C 109.082 -0.71 . . . . 0.0 109.082 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' C' C ' 2' ' ' ALA . . . . . . . . . . . . . . . -66.65 148.25 52.16 Favored 'General case' 0 N--CA 1.467 0.411 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.121 179.639 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 3' ' ' GLU . . . . . . . . . . . . . 57.2 tt0 -162.11 104.48 1.15 Allowed 'General case' 0 N--CA 1.472 0.66 0 CA-C-N 116.411 -0.359 . . . . 0.0 110.058 179.661 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 21.1 m-85 -71.29 172.84 8.64 Favored 'General case' 0 N--CA 1.47 0.548 0 N-CA-C 109.479 -0.563 . . . . 0.0 109.479 179.548 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 31.9 mtp180 -68.31 129.5 40.1 Favored 'General case' 0 N--CA 1.472 0.666 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.215 -178.001 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 4.1 m-70 -99.64 131.41 45.65 Favored 'General case' 0 N--CA 1.474 0.75 0 N-CA-C 109.467 -0.568 . . . . 0.0 109.467 179.455 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 7' ' ' ASP . . . . . . . . . . . . . 13.5 m-20 -71.63 141.0 49.95 Favored 'General case' 0 CA--C 1.531 0.232 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.848 -179.691 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 8' ' ' SER . . . . . 0.41 ' O ' ' O ' ' B' ' 25' ' ' GLY . 8.6 t -143.2 -173.19 3.86 Favored 'General case' 0 N--CA 1.479 1.01 0 N-CA-C 109.002 -0.74 . . . . 0.0 109.002 178.477 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 117.78 11.55 8.44 Favored Glycine 0 N--CA 1.486 1.981 0 N-CA-C 112.44 -0.264 . . . . 0.0 112.44 179.159 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 47.4 p90 -59.17 128.31 36.53 Favored 'General case' 0 CA--C 1.54 0.561 0 CA-C-N 116.907 0.353 . . . . 0.0 111.895 -179.626 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 46.3 mt-10 -89.59 154.68 19.79 Favored 'General case' 0 N--CA 1.473 0.704 0 N-CA-C 109.4 -0.593 . . . . 0.0 109.4 178.5 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -153.87 128.32 1.4 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.233 0 N-CA-C 108.254 -1.017 . . . . 0.0 108.254 178.61 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 49.8 m-70 -134.91 147.18 49.76 Favored 'General case' 0 N--CA 1.491 1.588 0 CA-C-N 118.603 0.638 . . . . 0.0 111.139 -178.89 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 6.4 t60 -165.1 98.03 0.73 Allowed 'General case' 0 N--CA 1.482 1.159 0 CA-C-N 116.601 -0.272 . . . . 0.0 111.094 179.575 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 44.6 mt-30 -109.29 -172.53 2.06 Favored 'General case' 0 CA--C 1.5 -0.955 0 N-CA-C 108.345 -0.983 . . . . 0.0 108.345 179.972 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 16' ' ' LYS . . . . . 0.402 ' C ' HD12 ' C' ' 17' ' ' LEU . 88.4 tttt -166.77 97.93 0.55 Allowed 'General case' 0 N--CA 1.471 0.59 0 CA-C-N 115.086 -0.961 . . . . 0.0 109.413 178.795 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 17' ' ' LEU . . . . . 0.594 ' N ' HD12 ' C' ' 17' ' ' LEU . 4.5 mp -105.91 163.87 12.4 Favored 'General case' 0 N--CA 1.488 1.462 0 N-CA-C 108.603 -0.888 . . . . 0.0 108.603 -179.969 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 59.8 t -142.28 118.65 6.29 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.305 0 CA-C-O 119.025 -0.512 . . . . 0.0 109.813 179.552 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 54.1 m-85 -70.17 159.47 33.89 Favored 'General case' 0 N--CA 1.479 0.986 0 N-CA-C 107.485 -1.302 . . . . 0.0 107.485 177.17 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 12.7 t80 -172.34 -57.05 0.02 OUTLIER 'General case' 0 N--CA 1.484 1.258 0 CA-C-O 122.209 1.004 . . . . 0.0 109.928 179.671 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -39.5 90.54 0.0 OUTLIER 'General case' 0 CA--C 1.53 0.187 0 CA-C-N 114.129 -1.396 . . . . 0.0 112.864 -178.221 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 37.1 tt0 -66.31 158.27 29.51 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.08 -0.964 . . . . 0.0 110.625 179.258 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 11.4 m-20 -140.4 138.18 34.58 Favored 'General case' 0 N--CA 1.478 0.967 0 C-N-CA 123.032 0.533 . . . . 0.0 110.175 179.797 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 18.1 t -92.47 -117.01 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.484 1.238 0 N-CA-C 108.721 -0.844 . . . . 0.0 108.721 179.545 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 25' ' ' GLY . . . . . 0.41 ' O ' ' O ' ' A' ' 8' ' ' SER . . . -101.94 56.65 0.67 Allowed Glycine 0 C--N 1.347 1.192 0 N-CA-C 110.927 -0.869 . . . . 0.0 110.927 -179.995 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 79.2 p -85.36 124.83 32.41 Favored 'General case' 0 N--CA 1.467 0.423 0 N-CA-C 108.683 -0.858 . . . . 0.0 108.683 178.149 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 61.9 t30 -64.88 101.16 0.46 Allowed 'General case' 0 N--CA 1.473 0.717 0 N-CA-C 108.73 -0.841 . . . . 0.0 108.73 178.809 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 28' ' ' LYS . . . . . 0.4 ' O ' ' O ' ' C' ' 29' ' ' GLY . 65.2 mttm -97.47 113.65 25.37 Favored 'General case' 0 N--CA 1.486 1.348 0 N-CA-C 110.064 -0.347 . . . . 0.0 110.064 -178.983 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 29' ' ' GLY . . . . . 0.4 ' O ' ' O ' ' C' ' 28' ' ' LYS . . . -60.2 -134.47 0.01 OUTLIER Glycine 0 CA--C 1.535 1.282 0 N-CA-C 110.798 -0.921 . . . . 0.0 110.798 178.982 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -112.5 128.0 56.21 Favored 'General case' 0 N--CA 1.48 1.075 0 N-CA-C 109.181 -0.674 . . . . 0.0 109.181 178.91 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 64.4 mt -90.6 129.26 41.7 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.674 0 N-CA-C 107.486 -1.301 . . . . 0.0 107.486 178.75 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 12.2 mt -142.96 152.12 17.2 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.806 0 CA-C-N 116.053 -0.521 . . . . 0.0 109.871 -178.88 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 65.04 48.37 71.62 Favored Glycine 0 CA--C 1.525 0.697 0 CA-C-N 116.012 -0.54 . . . . 0.0 112.63 178.982 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 34' ' ' LEU . . . . . 0.407 HD23 ' N ' ' C' ' 35' ' ' MET . 2.8 tt -98.46 121.0 39.84 Favored 'General case' 0 N--CA 1.478 0.955 0 N-CA-C 107.158 -1.423 . . . . 0.0 107.158 177.98 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 35' ' ' MET . . . . . 0.407 ' N ' HD23 ' C' ' 34' ' ' LEU . 27.7 ttt -153.07 158.12 41.46 Favored 'General case' 0 N--CA 1.471 0.584 0 N-CA-C 108.814 -0.81 . . . . 0.0 108.814 179.617 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 36' ' ' VAL . . . . . 0.411 HG12 HE22 ' F' ' 15' ' ' GLN . 78.3 t -158.38 149.46 8.3 Favored 'Isoleucine or valine' 0 C--O 1.237 0.432 0 N-CA-C 106.865 -1.531 . . . . 0.0 106.865 -179.526 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.94 72.54 0.57 Allowed Glycine 0 C--N 1.315 -0.616 0 CA-C-N 115.641 -0.709 . . . . 0.0 111.414 178.337 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 172.74 -157.45 26.79 Favored Glycine 0 N--CA 1.461 0.357 0 N-CA-C 110.659 -0.976 . . . . 0.0 110.659 -179.885 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 33.4 m -124.42 143.53 37.52 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.904 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 179.474 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 16.3 t . . . . . 0 N--CA 1.467 0.402 0 CA-C-O 118.118 -0.944 . . . . 0.0 111.082 179.285 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' D' D ' 1' ' ' ASP . . . . . . . . . . . . . 8.9 m-20 . . . . . 0 N--CA 1.488 1.46 0 N-CA-C 109.096 -0.705 . . . . 0.0 109.096 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' D' D ' 2' ' ' ALA . . . . . . . . . . . . . . . -67.98 148.91 50.4 Favored 'General case' 0 N--CA 1.469 0.523 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.484 179.381 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 3' ' ' GLU . . . . . . . . . . . . . 57.1 tt0 -160.86 107.37 1.46 Allowed 'General case' 0 C--O 1.202 -1.398 0 N-CA-C 109.678 -0.489 . . . . 0.0 109.678 -179.956 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 23.1 m-85 -77.21 167.98 20.83 Favored 'General case' 0 C--N 1.302 -1.486 0 C-N-CA 126.137 1.775 . . . . 0.0 107.913 -179.073 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 5' ' ' ARG . . . . . . . . . . . . 0.297 39.3 mtp180 -76.43 133.58 39.82 Favored 'General case' 0 C--O 1.214 -0.812 0 N-CA-C 106.852 -1.536 . . . . 0.0 106.852 -168.536 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 4.2 m-70 -101.78 133.4 46.58 Favored 'General case' 0 C--N 1.363 1.167 0 CA-C-N 113.931 -1.486 . . . . 0.0 107.776 -176.422 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 7' ' ' ASP . . . . . . . . . . . . . 9.3 m-20 -64.69 124.05 20.91 Favored 'General case' 0 C--N 1.314 -0.964 0 C-N-CA 127.987 2.515 . . . . 0.0 115.331 176.692 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 8' ' ' SER . . . . . . . . . . . . . 8.2 t -133.3 -174.83 3.61 Favored 'General case' 0 N--CA 1.483 1.209 0 CA-C-N 119.928 1.24 . . . . 0.0 109.46 177.367 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 121.88 13.75 4.92 Favored Glycine 0 N--CA 1.483 1.79 0 N-CA-C 110.993 -0.843 . . . . 0.0 110.993 175.476 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 44.7 p90 -58.37 130.18 45.5 Favored 'General case' 0 CA--C 1.539 0.526 0 C-N-CA 120.938 -0.305 . . . . 0.0 111.71 -179.209 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 47.0 mt-10 -89.29 152.57 21.48 Favored 'General case' 0 N--CA 1.477 0.903 0 N-CA-C 110.063 -0.347 . . . . 0.0 110.063 176.679 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -149.54 129.99 4.33 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.522 0 N-CA-C 107.975 -1.12 . . . . 0.0 107.975 174.35 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 47.9 m-70 -129.86 150.31 51.21 Favored 'General case' 0 N--CA 1.482 1.17 0 CA-C-N 117.848 0.295 . . . . 0.0 111.567 176.611 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 6.6 t60 -165.05 104.65 0.78 Allowed 'General case' 0 N--CA 1.484 1.233 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 172.974 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 15' ' ' GLN . . . . . 0.412 HE22 HG12 ' A' ' 36' ' ' VAL . 44.2 mt-30 -112.46 -175.85 2.78 Favored 'General case' 0 CA--C 1.493 -1.222 0 N-CA-C 108.085 -1.079 . . . . 0.0 108.085 179.188 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' D' D ' 16' ' ' LYS . . . . . 0.452 ' C ' HD12 ' D' ' 17' ' ' LEU . 88.6 tttt -162.92 106.13 1.06 Allowed 'General case' 0 CA--C 1.536 0.419 0 N-CA-C 107.803 -1.184 . . . . 0.0 107.803 175.619 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' D' D ' 17' ' ' LEU . . . . . 0.542 ' N ' HD12 ' D' ' 17' ' ' LEU . 5.4 mp -112.47 162.86 15.14 Favored 'General case' 0 N--CA 1.488 1.442 0 N-CA-C 108.134 -1.061 . . . . 0.0 108.134 179.583 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 51.5 t -141.0 123.63 15.38 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.194 0 N-CA-C 109.01 -0.737 . . . . 0.0 109.01 175.962 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 78.5 m-85 -62.65 151.53 37.87 Favored 'General case' 0 C--N 1.349 0.569 0 C-N-CA 125.002 1.321 . . . . 0.0 110.395 170.485 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 8.3 t80 -170.17 -66.78 0.02 OUTLIER 'General case' 0 N--CA 1.476 0.831 0 N-CA-C 107.765 -1.198 . . . . 0.0 107.765 -179.584 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -37.94 95.74 0.01 OUTLIER 'General case' 0 CA--C 1.536 0.419 0 CA-C-N 113.889 -1.505 . . . . 0.0 111.706 -174.505 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 37.3 tt0 -68.32 158.97 32.3 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 113.587 -1.642 . . . . 0.0 110.308 178.654 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 11.5 m-20 -140.6 140.58 35.13 Favored 'General case' 0 N--CA 1.474 0.767 0 N-CA-C 109.646 -0.501 . . . . 0.0 109.646 178.795 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 24' ' ' VAL . . . . . . . . . . . . . 16.0 t -94.44 -120.65 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.381 0 N-CA-C 108.242 -1.021 . . . . 0.0 108.242 179.858 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . -104.65 61.93 0.38 Allowed Glycine 0 C--N 1.375 2.718 0 C-N-CA 117.791 -2.147 . . . . 0.0 109.555 178.866 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 90.9 p -71.57 121.07 18.09 Favored 'General case' 0 C--O 1.246 0.872 0 CA-C-O 115.949 -1.977 . . . . 0.0 112.537 168.01 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 64.7 t30 -60.69 102.06 0.17 Allowed 'General case' 0 N--CA 1.478 0.956 0 CA-C-N 122.278 2.308 . . . . 0.0 109.906 172.212 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 28' ' ' LYS . . . . . 0.403 ' O ' ' O ' ' D' ' 29' ' ' GLY . 64.6 mttm -100.95 116.16 32.14 Favored 'General case' 0 N--CA 1.493 1.714 0 CA-C-N 120.028 1.286 . . . . 0.0 109.157 179.461 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' D' D ' 29' ' ' GLY . . . . . 0.403 ' O ' ' O ' ' D' ' 28' ' ' LYS . . . -54.65 -134.6 0.0 OUTLIER Glycine 0 C--N 1.343 0.94 0 CA-C-N 115.51 -0.768 . . . . 0.0 113.433 176.203 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -112.95 132.58 55.28 Favored 'General case' 0 C--N 1.37 1.464 0 N-CA-C 108.46 -0.941 . . . . 0.0 108.46 174.435 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 66.7 mt -91.75 133.85 31.96 Favored 'Isoleucine or valine' 0 C--N 1.346 0.422 0 N-CA-C 106.888 -1.523 . . . . 0.0 106.888 176.682 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 14.2 mt -145.74 154.28 13.34 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.916 0 N-CA-C 109.092 -0.707 . . . . 0.0 109.092 179.276 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 64.09 47.65 83.26 Favored Glycine 0 C--O 1.246 0.877 0 CA-C-O 119.409 -0.662 . . . . 0.0 112.538 179.243 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 3.4 tt -97.81 132.53 43.34 Favored 'General case' 0 C--N 1.372 1.558 0 N-CA-C 104.593 -2.373 . . . . 0.0 104.593 176.44 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 28.2 ttt -155.96 165.32 36.81 Favored 'General case' 0 N--CA 1.475 0.812 0 N-CA-C 107.705 -1.22 . . . . 0.0 107.705 175.8 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 94.4 t -164.04 155.52 2.11 Favored 'Isoleucine or valine' 0 C--O 1.247 0.959 0 N-CA-C 105.204 -2.147 . . . . 0.0 105.204 175.016 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 61.22 65.15 3.46 Favored Glycine 0 CA--C 1.524 0.637 0 C-N-CA 117.97 -2.062 . . . . 0.0 113.042 176.686 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 168.83 -158.55 31.24 Favored Glycine 0 N--CA 1.465 0.633 0 CA-C-N 118.976 1.388 . . . . 0.0 111.58 -177.921 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 33.1 m -120.23 142.47 35.8 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.17 0 CA-C-N 118.426 1.113 . . . . 0.0 110.243 -178.534 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 13.9 t . . . . . 0 C--O 1.212 -0.916 0 N-CA-C 109.606 -0.516 . . . . 0.0 109.606 174.362 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' E' E ' 1' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 . . . . . 0 N--CA 1.487 1.419 0 N-CA-C 109.19 -0.67 . . . . 0.0 109.19 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' E' E ' 2' ' ' ALA . . . . . . . . . . . . . . . -67.76 149.4 49.99 Favored 'General case' 0 N--CA 1.468 0.456 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.321 179.557 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' E' E ' 3' ' ' GLU . . . . . . . . . . . . . 57.5 tt0 -162.58 102.31 1.05 Allowed 'General case' 0 C--O 1.211 -0.964 0 N-CA-C 110.075 -0.343 . . . . 0.0 110.075 -179.796 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 20.4 m-85 -68.12 172.48 5.66 Favored 'General case' 0 N--CA 1.472 0.665 0 N-CA-C 109.959 -0.386 . . . . 0.0 109.959 179.523 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' E' E ' 5' ' ' ARG . . . . . . . . . . . . . 30.6 mtp180 -67.7 130.32 42.64 Favored 'General case' 0 C--O 1.219 -0.517 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.503 -178.12 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 4.0 m-70 -100.4 131.02 46.56 Favored 'General case' 0 N--CA 1.475 0.802 0 N-CA-C 109.593 -0.521 . . . . 0.0 109.593 179.37 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' E' E ' 7' ' ' ASP . . . . . . . . . . . . . 17.0 m-20 -71.07 142.33 50.84 Favored 'General case' 0 N--CA 1.464 0.234 0 O-C-N 123.389 0.431 . . . . 0.0 110.979 -179.829 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' E' E ' 8' ' ' SER . . . . . . . . . . . . . 8.4 t -144.85 -172.9 3.93 Favored 'General case' 0 N--CA 1.478 0.938 0 N-CA-C 108.994 -0.743 . . . . 0.0 108.994 178.052 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 118.17 12.23 7.73 Favored Glycine 0 N--CA 1.482 1.742 0 N-CA-C 112.191 -0.364 . . . . 0.0 112.191 179.032 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 43.5 p90 -58.91 127.8 34.04 Favored 'General case' 0 CA--C 1.544 0.733 0 N-CA-C 112.107 0.41 . . . . 0.0 112.107 -179.366 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 46.8 mt-10 -88.46 155.16 19.83 Favored 'General case' 0 N--CA 1.476 0.838 0 N-CA-C 109.43 -0.581 . . . . 0.0 109.43 178.12 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -155.3 127.44 1.0 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.557 0 N-CA-C 108.344 -0.984 . . . . 0.0 108.344 178.539 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 48.0 m-70 -135.27 145.3 47.42 Favored 'General case' 0 N--CA 1.483 1.206 0 CA-C-O 120.704 0.287 . . . . 0.0 111.331 -177.826 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 6.3 t60 -164.0 97.53 0.83 Allowed 'General case' 0 N--CA 1.486 1.334 0 CA-C-N 116.752 -0.204 . . . . 0.0 111.048 179.693 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 44.1 mt-30 -108.35 -172.62 2.09 Favored 'General case' 0 CA--C 1.502 -0.902 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 -179.94 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -166.57 98.2 0.58 Allowed 'General case' 0 CA--C 1.541 0.621 0 CA-C-N 114.992 -1.004 . . . . 0.0 109.453 178.722 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' E' E ' 17' ' ' LEU . . . . . 0.589 ' N ' HD12 ' E' ' 17' ' ' LEU . 4.4 mp -106.14 163.1 13.06 Favored 'General case' 0 N--CA 1.49 1.565 0 N-CA-C 109.239 -0.652 . . . . 0.0 109.239 -179.693 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 42.1 t -142.15 118.14 6.11 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.418 0 C-N-CA 122.558 0.343 . . . . 0.0 110.554 179.158 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 52.8 m-85 -69.17 157.27 37.23 Favored 'General case' 0 C--N 1.356 0.867 0 N-CA-C 107.312 -1.366 . . . . 0.0 107.312 176.582 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 11.5 t80 -173.96 -54.7 0.01 OUTLIER 'General case' 0 N--CA 1.484 1.275 0 CA-C-O 121.717 0.77 . . . . 0.0 110.347 179.469 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.35 88.79 0.0 OUTLIER 'General case' 0 C--N 1.319 -0.751 0 CA-C-N 114.356 -1.293 . . . . 0.0 112.83 -178.974 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 37.4 tt0 -64.48 158.28 24.41 Favored 'General case' 0 N--CA 1.47 0.557 0 CA-C-N 114.944 -1.025 . . . . 0.0 110.681 179.702 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 11.0 m-20 -140.51 138.03 34.26 Favored 'General case' 0 N--CA 1.476 0.833 0 C-N-CA 122.985 0.514 . . . . 0.0 110.483 179.887 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 18.9 t -92.22 -116.79 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.288 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 179.587 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . -102.2 55.13 0.72 Allowed Glycine 0 N--CA 1.473 1.137 0 N-CA-C 111.226 -0.749 . . . . 0.0 111.226 -179.881 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 81.1 p -83.37 124.42 30.63 Favored 'General case' 0 N--CA 1.468 0.443 0 N-CA-C 109.205 -0.665 . . . . 0.0 109.205 177.819 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 62.9 t30 -64.58 101.42 0.46 Allowed 'General case' 0 N--CA 1.474 0.728 0 N-CA-C 108.307 -0.998 . . . . 0.0 108.307 178.725 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 64.3 mttm -98.07 113.32 25.16 Favored 'General case' 0 N--CA 1.488 1.469 0 N-CA-C 109.888 -0.412 . . . . 0.0 109.888 -178.603 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.06 -133.62 0.01 OUTLIER Glycine 0 CA--C 1.533 1.215 0 N-CA-C 111.471 -0.652 . . . . 0.0 111.471 178.894 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -113.19 126.87 55.9 Favored 'General case' 0 N--CA 1.477 0.907 0 N-CA-C 109.265 -0.642 . . . . 0.0 109.265 179.382 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 65.6 mt -90.13 130.24 39.72 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.279 0 N-CA-C 107.104 -1.443 . . . . 0.0 107.104 178.797 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 13.5 mt -142.99 153.42 16.99 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.825 0 N-CA-C 109.069 -0.715 . . . . 0.0 109.069 -179.42 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.71 49.94 65.13 Favored Glycine 0 CA--C 1.524 0.651 0 CA-C-N 116.432 -0.349 . . . . 0.0 113.153 179.022 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 2.9 tt -99.62 120.59 39.92 Favored 'General case' 0 N--CA 1.48 1.03 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 177.599 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 28.1 ttt -152.01 159.18 43.8 Favored 'General case' 0 N--CA 1.477 0.916 0 N-CA-C 108.373 -0.973 . . . . 0.0 108.373 179.578 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 95.7 t -159.49 149.23 6.93 Favored 'Isoleucine or valine' 0 C--O 1.237 0.419 0 N-CA-C 106.605 -1.628 . . . . 0.0 106.605 -179.816 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 57.32 72.19 0.62 Allowed Glycine 0 C--N 1.316 -0.579 0 CA-C-N 115.523 -0.762 . . . . 0.0 111.316 178.155 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 173.72 -155.66 22.45 Favored Glycine 0 C--O 1.219 -0.811 0 N-CA-C 111.123 -0.791 . . . . 0.0 111.123 -179.831 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 33.5 m -126.2 142.59 42.39 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.757 0 N-CA-C 109.203 -0.666 . . . . 0.0 109.203 179.379 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 15.1 t . . . . . 0 CA--C 1.538 0.509 0 CA-C-O 118.109 -0.948 . . . . 0.0 111.218 179.279 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' F' F ' 1' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 . . . . . 0 N--CA 1.488 1.432 0 N-CA-C 109.075 -0.713 . . . . 0.0 109.075 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' F' F ' 2' ' ' ALA . . . . . . . . . . . . . . . -68.19 149.82 49.08 Favored 'General case' 0 N--CA 1.47 0.529 0 CA-C-N 116.306 -0.407 . . . . 0.0 110.335 179.607 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' F' F ' 3' ' ' GLU . . . . . . . . . . . . . 57.4 tt0 -162.71 102.67 1.03 Allowed 'General case' 0 C--O 1.21 -1.003 0 CA-C-N 116.44 -0.346 . . . . 0.0 110.085 -179.845 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 20.2 m-85 -68.46 172.52 5.97 Favored 'General case' 0 N--CA 1.474 0.734 0 CA-C-O 120.941 0.401 . . . . 0.0 109.971 179.561 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' F' F ' 5' ' ' ARG . . . . . . . . . . . . . 30.5 mtp180 -67.32 129.98 41.63 Favored 'General case' 0 C--O 1.217 -0.63 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.514 -178.162 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 4.0 m-70 -100.43 131.21 46.48 Favored 'General case' 0 N--CA 1.477 0.922 0 N-CA-C 109.572 -0.529 . . . . 0.0 109.572 179.358 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' F' F ' 7' ' ' ASP . . . . . . . . . . . . . 16.6 m-20 -71.37 142.02 50.36 Favored 'General case' 0 N--CA 1.464 0.26 0 O-C-N 123.422 0.451 . . . . 0.0 111.066 -179.786 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' F' F ' 8' ' ' SER . . . . . . . . . . . . . 8.4 t -144.67 -173.13 3.97 Favored 'General case' 0 N--CA 1.478 0.971 0 N-CA-C 108.958 -0.756 . . . . 0.0 108.958 178.002 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 118.6 11.73 7.73 Favored Glycine 0 N--CA 1.482 1.745 0 N-CA-C 112.126 -0.39 . . . . 0.0 112.126 179.072 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 43.4 p90 -58.64 128.22 36.08 Favored 'General case' 0 CA--C 1.544 0.738 0 N-CA-C 112.123 0.416 . . . . 0.0 112.123 -179.31 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 46.8 mt-10 -88.77 155.15 19.74 Favored 'General case' 0 N--CA 1.475 0.817 0 CA-C-O 121.303 0.573 . . . . 0.0 109.585 178.031 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -155.21 127.48 1.02 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.574 0 N-CA-C 108.338 -0.986 . . . . 0.0 108.338 178.505 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 48.0 m-70 -135.32 144.94 46.99 Favored 'General case' 0 N--CA 1.481 1.093 0 CA-C-O 120.681 0.277 . . . . 0.0 111.379 -177.923 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 6.3 t60 -163.78 98.16 0.86 Allowed 'General case' 0 N--CA 1.487 1.406 0 CA-C-N 116.697 -0.229 . . . . 0.0 111.145 179.645 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' F' F ' 15' ' ' GLN . . . . . 0.411 HE22 HG12 ' C' ' 36' ' ' VAL . 43.9 mt-30 -109.29 -171.97 1.95 Allowed 'General case' 0 CA--C 1.499 -1.015 0 N-CA-C 108.625 -0.88 . . . . 0.0 108.625 -179.911 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -166.84 98.57 0.55 Allowed 'General case' 0 CA--C 1.541 0.609 0 CA-C-N 114.895 -1.048 . . . . 0.0 109.483 178.778 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' F' F ' 17' ' ' LEU . . . . . 0.585 ' N ' HD12 ' F' ' 17' ' ' LEU . 4.4 mp -106.24 163.14 13.05 Favored 'General case' 0 N--CA 1.489 1.501 0 N-CA-C 109.141 -0.689 . . . . 0.0 109.141 -179.717 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 42.0 t -142.17 118.3 6.2 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.369 0 C-N-CA 122.507 0.323 . . . . 0.0 110.522 179.088 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 52.7 m-85 -69.27 157.17 37.51 Favored 'General case' 0 C--N 1.355 0.811 0 N-CA-C 107.151 -1.426 . . . . 0.0 107.151 176.563 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 12.3 t80 -173.75 -54.8 0.01 OUTLIER 'General case' 0 N--CA 1.486 1.344 0 CA-C-O 121.785 0.802 . . . . 0.0 109.752 179.688 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.35 88.68 0.0 OUTLIER 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 114.484 -1.234 . . . . 0.0 113.007 -178.893 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 37.0 tt0 -64.36 158.43 23.61 Favored 'General case' 0 N--CA 1.472 0.668 0 CA-C-N 114.999 -1.001 . . . . 0.0 110.895 179.481 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 11.8 m-20 -140.87 137.67 33.38 Favored 'General case' 0 N--CA 1.477 0.909 0 C-N-CA 122.893 0.477 . . . . 0.0 110.458 179.973 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' F' F ' 24' ' ' VAL . . . . . . . . . . . . . 18.6 t -91.88 -116.83 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.391 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 179.544 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -102.11 55.32 0.72 Allowed Glycine 0 N--CA 1.477 1.41 0 N-CA-C 110.953 -0.859 . . . . 0.0 110.953 -179.863 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 79.8 p -83.54 124.19 30.5 Favored 'General case' 0 N--CA 1.47 0.552 0 N-CA-C 109.012 -0.736 . . . . 0.0 109.012 177.726 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 62.3 t30 -64.44 101.47 0.45 Allowed 'General case' 0 N--CA 1.473 0.71 0 N-CA-C 108.375 -0.972 . . . . 0.0 108.375 178.684 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 64.3 mttm -98.04 113.26 25.08 Favored 'General case' 0 N--CA 1.488 1.46 0 N-CA-C 110.029 -0.36 . . . . 0.0 110.029 -178.648 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.07 -133.84 0.01 OUTLIER Glycine 0 CA--C 1.534 1.266 0 N-CA-C 111.559 -0.616 . . . . 0.0 111.559 178.901 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -112.69 127.17 56.05 Favored 'General case' 0 N--CA 1.477 0.885 0 N-CA-C 109.228 -0.656 . . . . 0.0 109.228 179.241 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 65.7 mt -90.53 130.15 40.22 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.286 0 N-CA-C 107.086 -1.45 . . . . 0.0 107.086 178.703 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 13.1 mt -142.9 153.6 17.18 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.763 0 N-CA-C 109.115 -0.698 . . . . 0.0 109.115 -179.33 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.59 49.73 67.14 Favored Glycine 0 CA--C 1.524 0.609 0 CA-C-N 116.486 -0.325 . . . . 0.0 113.141 179.098 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' F' F ' 34' ' ' LEU . . . . . 0.404 HD23 ' N ' ' F' ' 35' ' ' MET . 3.0 tt -99.48 120.79 40.2 Favored 'General case' 0 N--CA 1.478 0.944 0 N-CA-C 107.344 -1.354 . . . . 0.0 107.344 177.747 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' F' F ' 35' ' ' MET . . . . . 0.404 ' N ' HD23 ' F' ' 34' ' ' LEU . 28.1 ttt -152.68 159.86 43.17 Favored 'General case' 0 N--CA 1.472 0.667 0 N-CA-C 109.146 -0.687 . . . . 0.0 109.146 179.343 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' F' F ' 36' ' ' VAL . . . . . 0.407 HG12 HE22 ' I' ' 15' ' ' GLN . 95.4 t -159.75 149.4 6.6 Favored 'Isoleucine or valine' 0 C--O 1.237 0.429 0 N-CA-C 106.907 -1.516 . . . . 0.0 106.907 -179.586 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 57.26 72.68 0.55 Allowed Glycine 0 C--N 1.315 -0.596 0 CA-C-N 115.548 -0.751 . . . . 0.0 111.268 178.195 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 173.44 -155.29 22.04 Favored Glycine 0 C--O 1.219 -0.841 0 N-CA-C 111.119 -0.792 . . . . 0.0 111.119 -179.795 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 33.4 m -126.62 142.5 42.98 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.777 0 N-CA-C 109.206 -0.664 . . . . 0.0 109.206 179.372 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 15.3 t . . . . . 0 CA--C 1.539 0.521 0 CA-C-O 118.0 -1.0 . . . . 0.0 111.301 179.306 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' G' G ' 1' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 . . . . . 0 N--CA 1.49 1.552 0 N-CA-C 109.434 -0.58 . . . . 0.0 109.434 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' G' G ' 2' ' ' ALA . . . . . . . . . . . . . . . -68.38 151.01 47.48 Favored 'General case' 0 CA--C 1.535 0.388 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.39 179.788 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 3' ' ' GLU . . . . . . . . . . . . . 57.3 tt0 -162.63 102.95 1.05 Allowed 'General case' 0 C--O 1.213 -0.845 0 N-CA-C 110.113 -0.329 . . . . 0.0 110.113 -179.382 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 26.7 m-85 -67.72 170.71 7.42 Favored 'General case' 0 N--CA 1.473 0.695 0 CA-C-O 120.849 0.357 . . . . 0.0 110.226 179.396 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 5' ' ' ARG . . . . . . . . . . . . . 31.5 mtp180 -66.59 129.44 39.87 Favored 'General case' 0 N--CA 1.47 0.543 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.178 -178.297 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 4.1 m-70 -99.96 131.04 46.16 Favored 'General case' 0 N--CA 1.474 0.764 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 179.449 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 16.9 m-20 -72.21 137.85 47.15 Favored 'General case' 0 N--CA 1.466 0.358 0 O-C-N 123.638 0.586 . . . . 0.0 111.418 -179.488 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 8' ' ' SER . . . . . . . . . . . . . 8.0 t -142.16 -173.06 3.72 Favored 'General case' 0 N--CA 1.477 0.9 0 N-CA-C 109.114 -0.699 . . . . 0.0 109.114 178.038 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 119.13 12.97 6.66 Favored Glycine 0 N--CA 1.481 1.67 0 N-CA-C 111.725 -0.55 . . . . 0.0 111.725 179.075 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 47.4 p90 -59.52 128.25 36.09 Favored 'General case' 0 CA--C 1.541 0.604 0 N-CA-C 112.002 0.371 . . . . 0.0 112.002 -179.227 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 46.6 mt-10 -89.13 154.5 20.11 Favored 'General case' 0 N--CA 1.474 0.741 0 CA-C-O 121.208 0.528 . . . . 0.0 109.914 178.685 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 2.7 p -155.99 127.17 0.89 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.039 0 N-CA-C 108.334 -0.988 . . . . 0.0 108.334 178.765 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 51.4 m-70 -134.06 146.44 50.32 Favored 'General case' 0 N--CA 1.476 0.855 0 CA-C-N 115.289 -0.869 . . . . 0.0 110.997 -177.98 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 33.2 t-80 -165.41 97.47 0.69 Allowed 'General case' 0 N--CA 1.483 1.181 0 CA-C-N 116.542 -0.299 . . . . 0.0 110.691 179.064 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 43.7 mt-30 -108.62 -172.6 2.09 Favored 'General case' 0 CA--C 1.501 -0.928 0 N-CA-C 108.574 -0.898 . . . . 0.0 108.574 -179.787 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 16' ' ' LYS . . . . . 0.406 ' C ' HD12 ' G' ' 17' ' ' LEU . 88.5 tttt -166.47 98.69 0.59 Allowed 'General case' 0 CA--C 1.541 0.606 0 CA-C-N 115.018 -0.992 . . . . 0.0 109.383 178.714 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' G' G ' 17' ' ' LEU . . . . . 0.587 ' N ' HD12 ' G' ' 17' ' ' LEU . 5.1 mp -106.14 161.79 14.2 Favored 'General case' 0 N--CA 1.487 1.383 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 -179.581 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 40.8 t -142.53 118.74 5.83 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.052 0 CA-C-O 120.766 0.317 . . . . 0.0 110.449 178.724 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 45.8 m-85 -69.71 151.12 46.21 Favored 'General case' 0 C--N 1.369 1.417 0 N-CA-C 107.303 -1.369 . . . . 0.0 107.303 176.761 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 10.3 t80 -171.16 -55.1 0.02 OUTLIER 'General case' 0 N--CA 1.486 1.369 0 CA-C-N 118.006 0.367 . . . . 0.0 110.333 -179.662 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.65 90.25 0.0 OUTLIER 'General case' 0 C--N 1.326 -0.428 0 C-N-CA 123.716 0.807 . . . . 0.0 112.582 -179.819 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 37.1 tt0 -65.2 159.39 23.72 Favored 'General case' 0 N--CA 1.469 0.488 0 CA-C-N 114.669 -1.151 . . . . 0.0 110.086 179.076 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 12.0 m-20 -141.45 137.2 32.0 Favored 'General case' 0 N--CA 1.476 0.842 0 C-N-CA 122.905 0.482 . . . . 0.0 109.986 179.927 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 24' ' ' VAL . . . . . . . . . . . . . 15.8 t -92.31 -116.63 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.106 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 179.682 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -101.93 54.35 0.77 Allowed Glycine 0 N--CA 1.476 1.366 0 N-CA-C 111.581 -0.608 . . . . 0.0 111.581 -179.725 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 80.0 p -82.72 124.34 30.14 Favored 'General case' 0 N--CA 1.469 0.501 0 N-CA-C 108.952 -0.758 . . . . 0.0 108.952 177.864 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 59.1 t30 -64.77 101.35 0.47 Allowed 'General case' 0 N--CA 1.471 0.594 0 N-CA-C 108.585 -0.894 . . . . 0.0 108.585 178.586 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 64.7 mttm -97.32 114.43 26.2 Favored 'General case' 0 N--CA 1.486 1.373 0 N-CA-C 109.891 -0.411 . . . . 0.0 109.891 -178.955 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.69 -132.45 0.01 OUTLIER Glycine 0 CA--C 1.532 1.144 0 N-CA-C 110.767 -0.933 . . . . 0.0 110.767 179.045 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -112.81 126.24 55.22 Favored 'General case' 0 N--CA 1.469 0.508 0 C-N-CA 123.006 0.522 . . . . 0.0 109.661 179.602 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 68.7 mt -89.66 130.7 38.53 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.776 0 N-CA-C 107.263 -1.384 . . . . 0.0 107.263 178.555 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 15.9 mt -143.92 154.35 15.74 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.346 0 CA-C-N 118.945 0.793 . . . . 0.0 108.982 -179.91 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.8 49.02 71.24 Favored Glycine 0 CA--C 1.527 0.811 0 C-N-CA 121.803 -0.237 . . . . 0.0 112.75 179.155 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 34' ' ' LEU . . . . . 0.414 HD23 ' N ' ' G' ' 35' ' ' MET . 2.9 tt -98.93 121.96 41.57 Favored 'General case' 0 N--CA 1.479 0.982 0 N-CA-C 106.953 -1.499 . . . . 0.0 106.953 177.723 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' G' G ' 35' ' ' MET . . . . . 0.414 ' N ' HD23 ' G' ' 34' ' ' LEU . 28.2 ttt -153.76 159.83 42.07 Favored 'General case' 0 N--CA 1.48 1.048 0 N-CA-C 107.999 -1.111 . . . . 0.0 107.999 179.661 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 88.6 t -159.58 149.65 6.71 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 N-CA-C 106.231 -1.766 . . . . 0.0 106.231 -179.735 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 57.01 72.75 0.53 Allowed Glycine 0 C--N 1.314 -0.66 0 C-N-CA 121.055 -0.593 . . . . 0.0 111.781 177.921 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 172.15 -154.08 20.75 Favored Glycine 0 C--O 1.219 -0.838 0 N-CA-C 110.517 -1.033 . . . . 0.0 110.517 179.223 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 34.0 m -127.0 142.91 42.13 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.009 0 CA-C-N 117.041 0.421 . . . . 0.0 109.963 179.951 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 15.6 t . . . . . 0 N--CA 1.466 0.363 0 CA-C-O 118.193 -0.908 . . . . 0.0 111.382 179.631 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' H' H ' 1' ' ' ASP . . . . . . . . . . . . . 7.9 m-20 . . . . . 0 N--CA 1.489 1.505 0 N-CA-C 109.481 -0.563 . . . . 0.0 109.481 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' H' H ' 2' ' ' ALA . . . . . . . . . . . . . . . -68.13 150.56 48.21 Favored 'General case' 0 N--CA 1.467 0.406 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.336 179.731 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' H' H ' 3' ' ' GLU . . . . . . . . . . . . . 57.2 tt0 -162.23 102.97 1.11 Allowed 'General case' 0 C--O 1.213 -0.823 0 N-CA-C 110.063 -0.347 . . . . 0.0 110.063 -179.346 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 26.2 m-85 -67.75 170.75 7.4 Favored 'General case' 0 N--CA 1.474 0.735 0 CA-C-O 120.912 0.387 . . . . 0.0 110.171 179.434 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' H' H ' 5' ' ' ARG . . . . . . . . . . . . . 31.0 mtp180 -66.46 129.43 39.81 Favored 'General case' 0 N--CA 1.469 0.477 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.309 -178.254 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 4.0 m-70 -100.0 131.17 46.12 Favored 'General case' 0 N--CA 1.474 0.773 0 N-CA-C 109.648 -0.501 . . . . 0.0 109.648 179.4 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 16.3 m-20 -72.42 137.7 46.66 Favored 'General case' 0 N--CA 1.466 0.35 0 O-C-N 123.526 0.517 . . . . 0.0 111.361 -179.484 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' H' H ' 8' ' ' SER . . . . . . . . . . . . . 8.4 t -141.86 -173.61 3.85 Favored 'General case' 0 N--CA 1.475 0.807 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 178.282 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 119.35 12.73 6.67 Favored Glycine 0 N--CA 1.484 1.888 0 N-CA-C 111.802 -0.519 . . . . 0.0 111.802 179.061 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 46.8 p90 -59.33 128.17 35.76 Favored 'General case' 0 CA--C 1.542 0.651 0 N-CA-C 112.042 0.386 . . . . 0.0 112.042 -179.338 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 46.6 mt-10 -88.96 154.34 20.3 Favored 'General case' 0 N--CA 1.475 0.78 0 CA-C-O 121.22 0.533 . . . . 0.0 109.892 178.694 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.7 p -155.77 127.2 0.92 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.009 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 178.712 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 50.8 m-70 -134.08 146.18 50.06 Favored 'General case' 0 N--CA 1.476 0.863 0 CA-C-N 115.313 -0.858 . . . . 0.0 111.203 -178.045 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 33.9 t-80 -165.08 97.58 0.73 Allowed 'General case' 0 N--CA 1.483 1.197 0 CA-C-N 116.583 -0.28 . . . . 0.0 110.716 179.039 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 43.8 mt-30 -108.57 -173.2 2.21 Favored 'General case' 0 CA--C 1.5 -0.966 0 N-CA-C 108.45 -0.945 . . . . 0.0 108.45 -179.787 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -166.12 98.39 0.63 Allowed 'General case' 0 N--CA 1.471 0.578 0 CA-C-N 114.984 -1.007 . . . . 0.0 109.341 178.727 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' H' H ' 17' ' ' LEU . . . . . 0.588 ' N ' HD12 ' H' ' 17' ' ' LEU . 5.1 mp -106.08 161.93 14.06 Favored 'General case' 0 N--CA 1.487 1.401 0 N-CA-C 109.394 -0.595 . . . . 0.0 109.394 -179.517 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 40.8 t -142.53 118.55 5.69 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.143 0 CA-C-O 120.775 0.321 . . . . 0.0 110.455 178.885 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 47.4 m-85 -69.85 151.44 45.71 Favored 'General case' 0 C--N 1.368 1.399 0 N-CA-C 107.334 -1.358 . . . . 0.0 107.334 176.59 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 10.9 t80 -172.37 -54.55 0.02 OUTLIER 'General case' 0 N--CA 1.484 1.246 0 CA-C-N 117.909 0.322 . . . . 0.0 110.21 -179.542 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.71 90.69 0.0 OUTLIER 'General case' 0 CA--C 1.534 0.356 0 C-N-CA 123.732 0.813 . . . . 0.0 112.298 -179.979 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 37.4 tt0 -65.74 159.29 25.45 Favored 'General case' 0 N--CA 1.47 0.537 0 CA-C-N 114.776 -1.102 . . . . 0.0 110.003 179.364 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 11.3 m-20 -141.29 137.55 32.54 Favored 'General case' 0 N--CA 1.476 0.837 0 C-N-CA 122.892 0.477 . . . . 0.0 109.919 179.861 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' H' H ' 24' ' ' VAL . . . . . . . . . . . . . 15.4 t -92.6 -116.94 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.09 0 N-CA-C 108.673 -0.862 . . . . 0.0 108.673 179.683 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . -101.48 54.25 0.8 Allowed Glycine 0 N--CA 1.479 1.538 0 N-CA-C 111.506 -0.638 . . . . 0.0 111.506 -179.742 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 80.3 p -82.85 124.54 30.41 Favored 'General case' 0 N--CA 1.469 0.497 0 N-CA-C 108.901 -0.778 . . . . 0.0 108.901 177.939 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 59.5 t30 -64.93 101.43 0.5 Allowed 'General case' 0 N--CA 1.472 0.664 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 178.679 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 65.1 mttm -97.33 114.11 25.84 Favored 'General case' 0 N--CA 1.485 1.321 0 N-CA-C 109.978 -0.378 . . . . 0.0 109.978 -179.021 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.42 -132.6 0.01 OUTLIER Glycine 0 CA--C 1.534 1.245 0 N-CA-C 110.845 -0.902 . . . . 0.0 110.845 179.053 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -112.72 126.28 55.24 Favored 'General case' 0 N--CA 1.471 0.603 0 C-N-CA 123.028 0.531 . . . . 0.0 109.662 179.59 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 68.0 mt -89.71 130.59 38.77 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.761 0 N-CA-C 107.35 -1.352 . . . . 0.0 107.35 178.506 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 16.3 mt -143.97 154.04 15.68 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.367 0 CA-C-N 118.922 0.783 . . . . 0.0 108.972 -179.74 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 64.09 49.01 69.75 Favored Glycine 0 CA--C 1.526 0.768 0 C-N-CA 121.717 -0.277 . . . . 0.0 112.81 179.184 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' H' H ' 34' ' ' LEU . . . . . 0.407 HD23 ' N ' ' H' ' 35' ' ' MET . 2.8 tt -99.02 121.66 41.26 Favored 'General case' 0 N--CA 1.477 0.914 0 N-CA-C 107.035 -1.469 . . . . 0.0 107.035 177.782 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' H' H ' 35' ' ' MET . . . . . 0.407 ' N ' HD23 ' H' ' 34' ' ' LEU . 28.2 ttt -153.4 159.75 42.47 Favored 'General case' 0 N--CA 1.48 1.036 0 N-CA-C 107.991 -1.115 . . . . 0.0 107.991 179.665 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 91.1 t -159.51 149.83 6.73 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 N-CA-C 106.278 -1.749 . . . . 0.0 106.278 -179.775 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.67 73.13 0.47 Allowed Glycine 0 C--N 1.313 -0.741 0 C-N-CA 120.982 -0.628 . . . . 0.0 111.727 178.117 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 171.65 -154.73 22.65 Favored Glycine 0 N--CA 1.468 0.806 0 N-CA-C 110.505 -1.038 . . . . 0.0 110.505 179.358 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 33.8 m -126.53 143.16 40.94 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.081 0 C-N-CA 122.663 0.385 . . . . 0.0 109.998 179.975 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 15.3 t . . . . . 0 N--CA 1.467 0.414 0 CA-C-O 118.137 -0.935 . . . . 0.0 111.293 179.544 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' I' I ' 1' ' ' ASP . . . . . . . . . . . . . 8.2 m-20 . . . . . 0 N--CA 1.489 1.506 0 N-CA-C 109.485 -0.561 . . . . 0.0 109.485 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' I' I ' 2' ' ' ALA . . . . . . . . . . . . . . . -68.61 151.19 47.06 Favored 'General case' 0 N--CA 1.466 0.358 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.324 179.675 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' I' I ' 3' ' ' GLU . . . . . . . . . . . . . 56.7 tt0 -162.76 102.87 1.03 Allowed 'General case' 0 C--O 1.213 -0.835 0 N-CA-C 110.09 -0.337 . . . . 0.0 110.09 -179.344 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 25.9 m-85 -67.68 170.91 7.03 Favored 'General case' 0 N--CA 1.472 0.666 0 CA-C-O 120.843 0.354 . . . . 0.0 110.168 179.461 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' I' I ' 5' ' ' ARG . . . . . . . . . . . . . 31.0 mtp180 -66.72 129.13 38.85 Favored 'General case' 0 N--CA 1.471 0.625 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.293 -178.281 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 4.0 m-70 -99.72 130.97 45.98 Favored 'General case' 0 N--CA 1.474 0.768 0 N-CA-C 109.607 -0.516 . . . . 0.0 109.607 179.42 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 16.2 m-20 -72.05 138.02 47.57 Favored 'General case' 0 N--CA 1.466 0.336 0 O-C-N 123.539 0.525 . . . . 0.0 111.425 -179.546 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' I' I ' 8' ' ' SER . . . . . . . . . . . . . 8.5 t -142.26 -173.8 3.94 Favored 'General case' 0 N--CA 1.475 0.791 0 N-CA-C 109.078 -0.712 . . . . 0.0 109.078 178.388 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 119.46 12.66 6.65 Favored Glycine 0 N--CA 1.482 1.759 0 N-CA-C 111.864 -0.494 . . . . 0.0 111.864 179.185 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 47.5 p90 -59.15 128.38 36.86 Favored 'General case' 0 CA--C 1.541 0.625 0 N-CA-C 112.082 0.401 . . . . 0.0 112.082 -179.378 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 46.5 mt-10 -89.28 154.33 20.19 Favored 'General case' 0 N--CA 1.474 0.737 0 CA-C-O 121.101 0.477 . . . . 0.0 109.956 178.672 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 2.7 p -155.73 127.32 0.94 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.039 0 N-CA-C 108.373 -0.973 . . . . 0.0 108.373 178.722 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 50.2 m-70 -134.23 146.29 49.96 Favored 'General case' 0 N--CA 1.476 0.868 0 CA-C-N 115.276 -0.875 . . . . 0.0 111.145 -178.044 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 6.4 t60 -165.35 97.51 0.7 Allowed 'General case' 0 N--CA 1.484 1.244 0 CA-C-N 116.558 -0.292 . . . . 0.0 110.719 179.069 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' I' I ' 15' ' ' GLN . . . . . 0.407 HE22 HG12 ' F' ' 36' ' ' VAL . 44.2 mt-30 -108.57 -172.75 2.12 Favored 'General case' 0 CA--C 1.499 -1.002 0 N-CA-C 108.458 -0.941 . . . . 0.0 108.458 -179.737 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' I' I ' 16' ' ' LYS . . . . . 0.403 ' C ' HD12 ' I' ' 17' ' ' LEU . 88.4 tttt -166.48 98.45 0.59 Allowed 'General case' 0 CA--C 1.54 0.565 0 CA-C-N 114.921 -1.036 . . . . 0.0 109.29 178.803 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' I' I ' 17' ' ' LEU . . . . . 0.589 ' N ' HD12 ' I' ' 17' ' ' LEU . 5.1 mp -105.97 161.99 13.98 Favored 'General case' 0 N--CA 1.486 1.355 0 N-CA-C 109.448 -0.575 . . . . 0.0 109.448 -179.628 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 40.6 t -142.58 118.5 5.56 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.154 0 C-N-CA 122.494 0.318 . . . . 0.0 110.487 178.849 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 46.7 m-85 -69.92 151.34 45.76 Favored 'General case' 0 C--N 1.367 1.365 0 N-CA-C 107.31 -1.367 . . . . 0.0 107.31 176.712 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 10.9 t80 -172.17 -54.67 0.02 OUTLIER 'General case' 0 N--CA 1.485 1.296 0 CA-C-N 117.843 0.292 . . . . 0.0 110.218 -179.518 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.69 90.72 0.0 OUTLIER 'General case' 0 CA--C 1.536 0.408 0 C-N-CA 123.7 0.8 . . . . 0.0 112.251 -179.936 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 37.5 tt0 -65.69 159.31 25.26 Favored 'General case' 0 N--CA 1.47 0.549 0 CA-C-N 114.751 -1.113 . . . . 0.0 109.993 179.326 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 11.1 m-20 -141.34 137.5 32.42 Favored 'General case' 0 N--CA 1.476 0.836 0 C-N-CA 122.872 0.469 . . . . 0.0 110.034 179.839 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' I' I ' 24' ' ' VAL . . . . . . . . . . . . . 14.9 t -92.68 -116.77 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.112 0 N-CA-C 108.691 -0.855 . . . . 0.0 108.691 179.729 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . -101.51 54.45 0.79 Allowed Glycine 0 N--CA 1.476 1.357 0 CA-C-N 118.556 0.617 . . . . 0.0 111.585 -179.759 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 80.4 p -83.31 123.96 30.14 Favored 'General case' 0 N--CA 1.469 0.5 0 N-CA-C 108.916 -0.772 . . . . 0.0 108.916 178.059 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 59.7 t30 -64.53 101.63 0.47 Allowed 'General case' 0 N--CA 1.473 0.681 0 N-CA-C 108.588 -0.893 . . . . 0.0 108.588 178.618 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 64.7 mttm -97.57 114.28 26.16 Favored 'General case' 0 N--CA 1.486 1.354 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -178.952 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.45 -132.63 0.01 OUTLIER Glycine 0 CA--C 1.532 1.137 0 N-CA-C 110.803 -0.919 . . . . 0.0 110.803 179.093 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -112.73 126.09 55.02 Favored 'General case' 0 N--CA 1.471 0.586 0 C-N-CA 123.058 0.543 . . . . 0.0 109.614 179.601 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 68.3 mt -89.68 130.75 38.47 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.783 0 N-CA-C 107.264 -1.384 . . . . 0.0 107.264 178.61 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 16.2 mt -143.98 154.47 15.65 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.337 0 CA-C-N 118.892 0.769 . . . . 0.0 108.984 -179.807 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.75 48.84 73.19 Favored Glycine 0 CA--C 1.526 0.775 0 C-N-CA 121.678 -0.296 . . . . 0.0 112.792 179.134 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' I' I ' 34' ' ' LEU . . . . . 0.409 HD23 ' N ' ' I' ' 35' ' ' MET . 2.9 tt -98.84 121.94 41.43 Favored 'General case' 0 N--CA 1.478 0.947 0 N-CA-C 106.874 -1.528 . . . . 0.0 106.874 177.741 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' I' I ' 35' ' ' MET . . . . . 0.409 ' N ' HD23 ' I' ' 34' ' ' LEU . 28.2 ttt -153.53 159.72 42.3 Favored 'General case' 0 N--CA 1.478 0.963 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 179.616 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 90.9 t -159.54 149.75 6.73 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.224 0 N-CA-C 106.253 -1.758 . . . . 0.0 106.253 -179.804 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.94 72.79 0.53 Allowed Glycine 0 C--N 1.314 -0.69 0 C-N-CA 121.022 -0.609 . . . . 0.0 111.778 178.011 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 171.95 -154.4 21.66 Favored Glycine 0 N--CA 1.468 0.767 0 N-CA-C 110.529 -1.029 . . . . 0.0 110.529 179.257 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 33.8 m -126.61 142.84 42.0 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.064 0 C-N-CA 122.743 0.417 . . . . 0.0 109.994 179.943 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 15.5 t . . . . . 0 N--CA 1.465 0.306 0 CA-C-O 118.239 -0.886 . . . . 0.0 111.328 179.539 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' ASP . . . . . 0.408 ' N ' ' CB ' ' D' ' 1' ' ' ASP . 9.1 m-20 . . . . . 0 N--CA 1.487 1.387 0 N-CA-C 108.963 -0.754 . . . . 0.0 108.963 . . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.47 132.47 49.0 Favored 'General case' 0 CA--C 1.539 0.552 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.207 -179.876 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 39.3 tt0 -169.7 108.85 0.41 Allowed 'General case' 0 N--CA 1.469 0.516 0 N-CA-C 109.598 -0.519 . . . . 0.0 109.598 -179.206 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 78.9 m-85 -83.87 140.22 32.13 Favored 'General case' 0 N--CA 1.475 0.818 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 179.464 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 71.9 mtp180 -143.84 141.28 30.26 Favored 'General case' 0 N--CA 1.481 1.102 0 N-CA-C 109.079 -0.712 . . . . 0.0 109.079 -179.879 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 76.7 m80 -149.53 119.92 7.37 Favored 'General case' 0 N--CA 1.469 0.502 0 N-CA-C 108.79 -0.819 . . . . 0.0 108.79 179.147 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 8.5 m-20 -68.02 149.95 49.06 Favored 'General case' 0 CA--C 1.53 0.196 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.16 -179.391 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 7.6 t -167.13 171.36 11.0 Favored 'General case' 0 N--CA 1.472 0.655 0 N-CA-C 109.551 -0.537 . . . . 0.0 109.551 178.581 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.48 23.65 2.31 Favored Glycine 0 N--CA 1.488 2.156 0 N-CA-C 112.209 -0.356 . . . . 0.0 112.209 179.37 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 42.8 p90 -56.64 128.37 36.02 Favored 'General case' 0 N--CA 1.475 0.815 0 N-CA-C 112.078 0.399 . . . . 0.0 112.078 -179.83 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 45.5 mt-10 -85.05 154.66 21.94 Favored 'General case' 0 C--N 1.344 0.358 0 N-CA-C 109.08 -0.711 . . . . 0.0 109.08 178.535 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -153.69 129.5 1.72 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.371 0 N-CA-C 108.151 -1.055 . . . . 0.0 108.151 178.928 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 48.6 m-70 -134.93 144.99 47.77 Favored 'General case' 0 N--CA 1.489 1.49 0 CA-C-N 118.683 0.674 . . . . 0.0 111.104 -179.116 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -165.9 98.31 0.65 Allowed 'General case' 0 N--CA 1.482 1.169 0 CA-C-N 116.603 -0.271 . . . . 0.0 110.984 179.628 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 40.0 mt-30 -108.54 -172.05 1.98 Allowed 'General case' 0 CA--C 1.503 -0.831 0 N-CA-C 108.174 -1.047 . . . . 0.0 108.174 -179.99 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -165.96 97.24 0.63 Allowed 'General case' 0 N--CA 1.471 0.613 0 CA-C-N 115.16 -0.927 . . . . 0.0 109.348 178.739 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.585 ' N ' HD12 ' A' ' 17' ' ' LEU . 4.7 mp -106.03 164.18 12.18 Favored 'General case' 0 N--CA 1.488 1.474 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 179.931 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 49.9 t -141.71 119.18 8.07 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.339 0 CA-C-O 118.888 -0.577 . . . . 0.0 109.98 179.657 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 50.9 m-85 -69.95 159.23 34.13 Favored 'General case' 0 N--CA 1.48 1.071 0 N-CA-C 107.573 -1.269 . . . . 0.0 107.573 177.287 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 12.9 t80 -171.44 -58.02 0.02 OUTLIER 'General case' 0 N--CA 1.485 1.305 0 CA-C-O 122.33 1.062 . . . . 0.0 109.772 179.481 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -38.83 90.48 0.0 OUTLIER 'General case' 0 C--O 1.232 0.165 0 CA-C-N 113.888 -1.505 . . . . 0.0 112.866 -177.929 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 54.4 tt0 -67.57 157.93 33.23 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 115.006 -0.997 . . . . 0.0 110.532 179.145 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 67.3 m-20 -140.02 137.72 34.87 Favored 'General case' 0 N--CA 1.481 1.112 0 C-N-CA 122.891 0.476 . . . . 0.0 110.339 179.762 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 17.2 t -84.42 -116.44 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.912 0 N-CA-C 108.51 -0.922 . . . . 0.0 108.51 179.541 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -110.67 54.5 0.54 Allowed Glycine 0 N--CA 1.473 1.137 0 N-CA-C 111.21 -0.756 . . . . 0.0 111.21 -179.935 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 70.5 p -80.12 126.24 30.83 Favored 'General case' 0 C--O 1.221 -0.434 0 N-CA-C 108.983 -0.747 . . . . 0.0 108.983 178.422 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' ASN . . . . . 0.459 HD21 ' HB3' ' D' ' 27' ' ' ASN . 2.1 t-20 -66.91 100.01 0.69 Allowed 'General case' 0 N--CA 1.472 0.644 0 N-CA-C 108.693 -0.854 . . . . 0.0 108.693 178.582 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 66.7 mttm -96.42 120.13 36.16 Favored 'General case' 0 N--CA 1.484 1.243 0 N-CA-C 110.087 -0.338 . . . . 0.0 110.087 -179.081 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.78 -126.36 0.01 OUTLIER Glycine 0 CA--C 1.532 1.154 0 N-CA-C 110.488 -1.045 . . . . 0.0 110.488 178.615 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -127.48 133.83 49.85 Favored 'General case' 0 N--CA 1.479 1.0 0 N-CA-C 109.294 -0.632 . . . . 0.0 109.294 179.112 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 66.9 mt -83.22 138.61 19.01 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.589 0 N-CA-C 107.136 -1.431 . . . . 0.0 107.136 178.54 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 18.7 mt -128.59 128.75 68.29 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.961 0 O-C-N 123.504 0.503 . . . . 0.0 110.123 -178.547 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 60.78 79.25 0.12 Allowed Glycine 0 CA--C 1.527 0.837 0 CA-C-N 116.003 -0.544 . . . . 0.0 112.95 178.898 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.402 HD23 ' N ' ' A' ' 35' ' ' MET . 2.0 tt -110.94 118.85 37.2 Favored 'General case' 0 N--CA 1.478 0.926 0 N-CA-C 106.932 -1.507 . . . . 0.0 106.932 177.432 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 35' ' ' MET . . . . . 0.402 ' N ' HD23 ' A' ' 34' ' ' LEU . 8.8 ttt -155.04 161.02 41.45 Favored 'General case' 0 N--CA 1.469 0.504 0 N-CA-C 109.077 -0.712 . . . . 0.0 109.077 179.339 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 93.6 t -157.96 150.73 8.14 Favored 'Isoleucine or valine' 0 C--O 1.234 0.277 0 N-CA-C 106.83 -1.545 . . . . 0.0 106.83 -179.598 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.6 75.17 0.25 Allowed Glycine 0 C--N 1.314 -0.689 0 CA-C-N 115.703 -0.68 . . . . 0.0 111.739 178.332 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 168.83 -148.72 12.65 Favored Glycine 0 CA--C 1.519 0.305 0 N-CA-C 110.692 -0.963 . . . . 0.0 110.692 179.742 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 21.1 m -132.9 142.47 42.2 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.887 0 N-CA-C 109.624 -0.509 . . . . 0.0 109.624 179.82 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 21.3 t . . . . . 0 N--CA 1.468 0.43 0 CA-C-O 117.851 -1.071 . . . . 0.0 110.725 179.225 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' B' B ' 1' ' ' ASP . . . . . 0.404 ' N ' ' CB ' ' E' ' 1' ' ' ASP . 9.3 m-20 . . . . . 0 N--CA 1.488 1.451 0 N-CA-C 109.112 -0.699 . . . . 0.0 109.112 . . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.5 132.35 48.69 Favored 'General case' 0 CA--C 1.538 0.517 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.218 -179.904 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 3' ' ' GLU . . . . . . . . . . . . . 39.2 tt0 -169.45 108.89 0.43 Allowed 'General case' 0 N--CA 1.47 0.531 0 N-CA-C 109.536 -0.542 . . . . 0.0 109.536 -179.107 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 79.8 m-85 -83.92 140.06 32.19 Favored 'General case' 0 N--CA 1.474 0.766 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 179.435 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 71.7 mtp180 -143.94 141.39 30.19 Favored 'General case' 0 N--CA 1.481 1.079 0 N-CA-C 109.136 -0.69 . . . . 0.0 109.136 -179.861 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 76.9 m80 -149.66 120.01 7.36 Favored 'General case' 0 N--CA 1.471 0.581 0 N-CA-C 108.772 -0.825 . . . . 0.0 108.772 179.117 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 7' ' ' ASP . . . . . . . . . . . . . 8.5 m-20 -67.96 149.45 49.75 Favored 'General case' 0 CA--C 1.531 0.217 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.226 -179.414 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 8' ' ' SER . . . . . . . . . . . . . 7.4 t -166.71 171.57 11.4 Favored 'General case' 0 N--CA 1.473 0.691 0 N-CA-C 109.583 -0.525 . . . . 0.0 109.583 178.501 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.26 23.94 2.31 Favored Glycine 0 N--CA 1.488 2.135 0 N-CA-C 112.122 -0.391 . . . . 0.0 112.122 179.425 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 42.4 p90 -56.9 128.11 35.18 Favored 'General case' 0 N--CA 1.473 0.681 0 N-CA-C 112.159 0.429 . . . . 0.0 112.159 -179.864 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 45.5 mt-10 -84.79 154.61 22.26 Favored 'General case' 0 N--CA 1.469 0.486 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 178.532 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -153.59 129.32 1.69 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.333 0 N-CA-C 108.268 -1.012 . . . . 0.0 108.268 178.914 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 48.6 m-70 -134.82 145.16 48.08 Favored 'General case' 0 N--CA 1.49 1.559 0 CA-C-N 118.556 0.616 . . . . 0.0 111.052 -179.062 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -166.11 98.33 0.63 Allowed 'General case' 0 N--CA 1.483 1.214 0 CA-C-N 116.607 -0.269 . . . . 0.0 110.96 179.654 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 39.8 mt-30 -108.56 -172.2 2.01 Favored 'General case' 0 CA--C 1.503 -0.854 0 N-CA-C 108.201 -1.037 . . . . 0.0 108.201 -179.901 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -165.95 96.95 0.63 Allowed 'General case' 0 CA--C 1.54 0.581 0 CA-C-N 115.121 -0.945 . . . . 0.0 109.337 178.817 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 17' ' ' LEU . . . . . 0.579 ' N ' HD12 ' B' ' 17' ' ' LEU . 4.9 mp -105.88 164.14 12.18 Favored 'General case' 0 N--CA 1.487 1.398 0 N-CA-C 108.611 -0.885 . . . . 0.0 108.611 179.868 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 53.9 t -141.69 119.16 8.08 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.269 0 CA-C-O 118.939 -0.553 . . . . 0.0 109.982 179.577 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 51.6 m-85 -70.41 159.3 34.45 Favored 'General case' 0 N--CA 1.479 0.983 0 N-CA-C 107.557 -1.275 . . . . 0.0 107.557 177.248 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 13.9 t80 -172.14 -57.25 0.02 OUTLIER 'General case' 0 N--CA 1.483 1.211 0 CA-C-O 122.2 1.0 . . . . 0.0 109.792 179.522 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -38.88 90.83 0.0 OUTLIER 'General case' 0 CA--C 1.529 0.159 0 CA-C-N 114.136 -1.393 . . . . 0.0 112.797 -178.005 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 54.2 tt0 -67.93 157.71 34.39 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 115.028 -0.987 . . . . 0.0 110.547 179.314 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 67.3 m-20 -139.86 137.75 35.16 Favored 'General case' 0 N--CA 1.481 1.082 0 C-N-CA 122.954 0.502 . . . . 0.0 110.287 179.71 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 18.1 t -84.66 -116.4 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.988 0 N-CA-C 108.577 -0.897 . . . . 0.0 108.577 179.665 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -110.13 54.37 0.55 Allowed Glycine 0 C--N 1.349 1.253 0 N-CA-C 111.167 -0.773 . . . . 0.0 111.167 -179.951 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 73.1 p -80.39 125.91 30.51 Favored 'General case' 0 C--O 1.221 -0.432 0 N-CA-C 109.037 -0.727 . . . . 0.0 109.037 178.434 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 27' ' ' ASN . . . . . 0.443 HD21 ' HB3' ' E' ' 27' ' ' ASN . 2.1 t-20 -66.73 100.41 0.7 Allowed 'General case' 0 N--CA 1.473 0.708 0 N-CA-C 108.657 -0.868 . . . . 0.0 108.657 178.613 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 66.7 mttm -96.81 120.04 36.41 Favored 'General case' 0 N--CA 1.483 1.205 0 N-CA-C 110.132 -0.321 . . . . 0.0 110.132 -179.035 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.57 -126.04 0.01 OUTLIER Glycine 0 CA--C 1.534 1.28 0 N-CA-C 110.453 -1.059 . . . . 0.0 110.453 178.618 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.13 133.75 49.02 Favored 'General case' 0 N--CA 1.48 1.026 0 N-CA-C 109.269 -0.641 . . . . 0.0 109.269 179.185 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 67.0 mt -83.15 138.6 19.04 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.476 0 N-CA-C 107.204 -1.406 . . . . 0.0 107.204 178.535 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 19.1 mt -128.53 128.42 68.02 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.928 0 O-C-N 123.537 0.523 . . . . 0.0 110.21 -178.412 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 60.96 78.98 0.13 Allowed Glycine 0 CA--C 1.526 0.777 0 CA-C-N 116.016 -0.538 . . . . 0.0 112.955 178.848 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 34' ' ' LEU . . . . . 0.401 HD23 ' N ' ' B' ' 35' ' ' MET . 2.0 tt -110.71 118.88 37.38 Favored 'General case' 0 N--CA 1.476 0.869 0 N-CA-C 106.94 -1.504 . . . . 0.0 106.94 177.386 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 35' ' ' MET . . . . . 0.401 ' N ' HD23 ' B' ' 34' ' ' LEU . 8.8 ttt -155.0 161.05 41.48 Favored 'General case' 0 N--CA 1.47 0.552 0 N-CA-C 109.096 -0.705 . . . . 0.0 109.096 179.247 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 92.9 t -158.04 150.73 8.06 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.192 0 N-CA-C 106.744 -1.576 . . . . 0.0 106.744 -179.555 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.44 75.31 0.25 Allowed Glycine 0 C--N 1.314 -0.654 0 CA-C-N 115.628 -0.714 . . . . 0.0 111.797 178.422 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 168.57 -149.14 13.4 Favored Glycine 0 CA--C 1.519 0.292 0 N-CA-C 110.686 -0.966 . . . . 0.0 110.686 179.76 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 21.5 m -132.36 142.7 41.97 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.834 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 179.65 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 21.3 t . . . . . 0 N--CA 1.467 0.41 0 CA-C-O 117.789 -1.101 . . . . 0.0 110.765 179.309 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' C' C ' 1' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 . . . . . 0 N--CA 1.487 1.423 0 N-CA-C 109.056 -0.72 . . . . 0.0 109.056 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' C' C ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.35 132.48 49.12 Favored 'General case' 0 CA--C 1.54 0.57 0 CA-C-N 116.367 -0.379 . . . . 0.0 110.162 -179.845 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 3' ' ' GLU . . . . . . . . . . . . . 39.5 tt0 -169.64 108.89 0.41 Allowed 'General case' 0 N--CA 1.47 0.554 0 N-CA-C 109.592 -0.522 . . . . 0.0 109.592 -179.274 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 78.6 m-85 -83.8 139.98 32.34 Favored 'General case' 0 N--CA 1.475 0.797 0 N-CA-C 109.878 -0.416 . . . . 0.0 109.878 179.459 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 71.9 mtp180 -143.76 141.36 30.4 Favored 'General case' 0 N--CA 1.482 1.131 0 N-CA-C 109.077 -0.712 . . . . 0.0 109.077 -179.905 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 76.8 m80 -149.63 119.76 7.24 Favored 'General case' 0 N--CA 1.469 0.523 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 179.145 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 7' ' ' ASP . . . . . . . . . . . . . 8.2 m-20 -67.7 149.55 49.85 Favored 'General case' 0 N--CA 1.463 0.199 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.227 -179.41 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 8' ' ' SER . . . . . . . . . . . . . 7.6 t -166.97 171.14 11.44 Favored 'General case' 0 N--CA 1.473 0.682 0 N-CA-C 109.499 -0.556 . . . . 0.0 109.499 178.429 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.83 23.76 2.21 Favored Glycine 0 N--CA 1.487 2.093 0 N-CA-C 112.099 -0.4 . . . . 0.0 112.099 179.355 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 42.1 p90 -56.63 127.99 34.14 Favored 'General case' 0 N--CA 1.473 0.718 0 N-CA-C 112.125 0.417 . . . . 0.0 112.125 -179.847 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 45.8 mt-10 -84.74 154.73 22.24 Favored 'General case' 0 N--CA 1.468 0.448 0 N-CA-C 109.126 -0.694 . . . . 0.0 109.126 178.507 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -153.61 129.24 1.65 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.293 0 N-CA-C 108.274 -1.01 . . . . 0.0 108.274 178.863 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 48.7 m-70 -134.71 144.95 48.05 Favored 'General case' 0 N--CA 1.489 1.517 0 CA-C-N 118.635 0.652 . . . . 0.0 111.043 -179.012 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -165.95 98.51 0.64 Allowed 'General case' 0 N--CA 1.483 1.184 0 CA-C-N 116.578 -0.283 . . . . 0.0 111.013 179.665 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 39.7 mt-30 -108.91 -172.21 2.0 Favored 'General case' 0 CA--C 1.501 -0.939 0 N-CA-C 108.276 -1.009 . . . . 0.0 108.276 -179.959 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 16' ' ' LYS . . . . . 0.402 ' C ' HD12 ' C' ' 17' ' ' LEU . 88.4 tttt -165.87 97.38 0.64 Allowed 'General case' 0 CA--C 1.54 0.587 0 CA-C-N 115.104 -0.953 . . . . 0.0 109.348 178.749 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 17' ' ' LEU . . . . . 0.574 ' N ' HD12 ' C' ' 17' ' ' LEU . 4.8 mp -106.07 163.99 12.34 Favored 'General case' 0 N--CA 1.488 1.433 0 N-CA-C 108.577 -0.897 . . . . 0.0 108.577 179.937 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 53.7 t -141.62 119.19 8.28 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.283 0 CA-C-O 119.05 -0.5 . . . . 0.0 109.885 179.529 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 51.2 m-85 -70.47 159.28 34.54 Favored 'General case' 0 N--CA 1.478 0.964 0 N-CA-C 107.469 -1.308 . . . . 0.0 107.469 177.299 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 14.2 t80 -171.96 -57.33 0.02 OUTLIER 'General case' 0 N--CA 1.482 1.15 0 CA-C-O 122.24 1.019 . . . . 0.0 109.847 179.461 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -38.77 90.72 0.0 OUTLIER 'General case' 0 C--O 1.232 0.144 0 CA-C-N 114.129 -1.396 . . . . 0.0 112.804 -178.024 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 54.0 tt0 -67.88 157.7 34.31 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.122 -0.945 . . . . 0.0 110.595 179.254 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 67.4 m-20 -139.86 137.96 35.33 Favored 'General case' 0 N--CA 1.482 1.134 0 C-N-CA 122.854 0.462 . . . . 0.0 110.245 179.728 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 17.7 t -84.85 -116.44 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.985 0 N-CA-C 108.506 -0.924 . . . . 0.0 108.506 179.693 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -110.12 54.27 0.55 Allowed Glycine 0 N--CA 1.474 1.227 0 N-CA-C 111.175 -0.77 . . . . 0.0 111.175 -179.865 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 73.8 p -80.32 126.18 30.82 Favored 'General case' 0 C--O 1.22 -0.455 0 N-CA-C 109.07 -0.715 . . . . 0.0 109.07 178.414 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 27' ' ' ASN . . . . . 0.435 HD21 ' HB3' ' F' ' 27' ' ' ASN . 2.1 t-20 -66.94 100.28 0.72 Allowed 'General case' 0 N--CA 1.473 0.704 0 N-CA-C 108.673 -0.862 . . . . 0.0 108.673 178.563 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 66.9 mttm -96.79 119.68 35.72 Favored 'General case' 0 N--CA 1.482 1.172 0 N-CA-C 110.238 -0.282 . . . . 0.0 110.238 -179.169 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.31 -125.96 0.01 OUTLIER Glycine 0 CA--C 1.534 1.268 0 N-CA-C 110.534 -1.026 . . . . 0.0 110.534 178.727 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.01 133.7 49.17 Favored 'General case' 0 N--CA 1.482 1.14 0 N-CA-C 109.263 -0.643 . . . . 0.0 109.263 179.171 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 67.3 mt -83.12 138.54 19.15 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.456 0 N-CA-C 107.129 -1.434 . . . . 0.0 107.129 178.538 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 18.0 mt -128.5 128.74 68.44 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.987 0 O-C-N 123.626 0.579 . . . . 0.0 110.16 -178.519 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 60.67 78.93 0.13 Allowed Glycine 0 CA--C 1.527 0.797 0 CA-C-N 116.018 -0.537 . . . . 0.0 113.033 178.844 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 34' ' ' LEU . . . . . 0.4 HD23 ' N ' ' C' ' 35' ' ' MET . 2.0 tt -110.58 118.94 37.58 Favored 'General case' 0 N--CA 1.477 0.89 0 N-CA-C 106.902 -1.518 . . . . 0.0 106.902 177.37 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 35' ' ' MET . . . . . 0.4 ' N ' HD23 ' C' ' 34' ' ' LEU . 8.7 ttt -155.07 160.94 41.38 Favored 'General case' 0 N--CA 1.469 0.501 0 N-CA-C 109.125 -0.694 . . . . 0.0 109.125 179.185 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 93.0 t -157.93 150.57 8.28 Favored 'Isoleucine or valine' 0 C--O 1.233 0.203 0 N-CA-C 106.74 -1.578 . . . . 0.0 106.74 -179.566 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.7 75.32 0.25 Allowed Glycine 0 C--N 1.314 -0.649 0 CA-C-N 115.691 -0.686 . . . . 0.0 111.814 178.368 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 168.61 -148.78 12.84 Favored Glycine 0 CA--C 1.52 0.382 0 N-CA-C 110.631 -0.988 . . . . 0.0 110.631 179.862 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 21.5 m -132.89 142.56 41.97 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.814 0 N-CA-C 109.696 -0.483 . . . . 0.0 109.696 179.707 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 21.3 t . . . . . 0 N--CA 1.468 0.443 0 CA-C-O 117.772 -1.109 . . . . 0.0 110.801 179.376 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' D' D ' 1' ' ' ASP . . . . . 0.408 ' CB ' ' N ' ' A' ' 1' ' ' ASP . 9.4 m-20 . . . . . 0 N--CA 1.491 1.588 0 N-CA-C 109.037 -0.727 . . . . 0.0 109.037 . . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.28 131.02 46.1 Favored 'General case' 0 CA--C 1.536 0.412 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.371 179.969 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 3' ' ' GLU . . . . . . . . . . . . . 39.2 tt0 -169.39 110.91 0.47 Allowed 'General case' 0 N--CA 1.469 0.494 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 179.698 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 87.7 m-85 -87.23 147.71 25.44 Favored 'General case' 0 C--N 1.363 1.155 0 C-N-CA 118.592 -1.243 . . . . 0.0 108.283 179.695 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 5' ' ' ARG . . . . . . . . . . . . . 71.2 mtp180 -147.45 141.35 25.84 Favored 'General case' 0 N--CA 1.475 0.82 0 N-CA-C 108.961 -0.755 . . . . 0.0 108.961 179.746 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 77.1 m80 -149.17 123.6 9.67 Favored 'General case' 0 CA--C 1.538 0.51 0 N-CA-C 107.891 -1.152 . . . . 0.0 107.891 175.875 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 7' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -63.3 133.55 54.34 Favored 'General case' 0 C--N 1.321 -0.668 0 C-N-CA 127.049 2.139 . . . . 0.0 114.697 176.251 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 8' ' ' SER . . . . . . . . . . . . . 6.6 t -154.03 173.56 15.85 Favored 'General case' 0 N--CA 1.478 0.951 0 CA-C-N 118.533 0.606 . . . . 0.0 110.296 177.074 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 124.29 20.45 2.44 Favored Glycine 0 N--CA 1.485 1.917 0 N-CA-C 112.126 -0.39 . . . . 0.0 112.126 176.579 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 37.2 p90 -55.81 130.46 43.56 Favored 'General case' 0 CA--C 1.546 0.804 0 CA-C-O 121.126 0.489 . . . . 0.0 111.889 -177.355 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 46.0 mt-10 -85.26 152.42 23.33 Favored 'General case' 0 N--CA 1.473 0.694 0 N-CA-C 109.732 -0.469 . . . . 0.0 109.732 177.763 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -149.51 130.05 4.41 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.472 0 N-CA-C 108.222 -1.029 . . . . 0.0 108.222 175.593 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 46.9 m-70 -129.64 148.07 51.49 Favored 'General case' 0 N--CA 1.483 1.201 0 CA-C-N 118.009 0.368 . . . . 0.0 111.423 176.708 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -165.37 104.76 0.74 Allowed 'General case' 0 N--CA 1.483 1.207 0 N-CA-C 109.623 -0.51 . . . . 0.0 109.623 173.453 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 39.1 mt-30 -112.02 -175.66 2.74 Favored 'General case' 0 CA--C 1.493 -1.214 0 N-CA-C 108.019 -1.104 . . . . 0.0 108.019 179.348 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 16' ' ' LYS . . . . . 0.444 ' C ' HD12 ' D' ' 17' ' ' LEU . 88.7 tttt -162.09 105.9 1.19 Allowed 'General case' 0 CA--C 1.538 0.506 0 N-CA-C 107.603 -1.258 . . . . 0.0 107.603 175.386 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' D' D ' 17' ' ' LEU . . . . . 0.524 ' N ' HD12 ' D' ' 17' ' ' LEU . 5.7 mp -112.69 163.07 15.0 Favored 'General case' 0 N--CA 1.487 1.407 0 N-CA-C 108.095 -1.076 . . . . 0.0 108.095 179.536 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 48.1 t -140.92 123.59 15.56 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.072 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 176.158 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 76.1 m-85 -62.77 151.3 39.06 Favored 'General case' 0 C--N 1.351 0.652 0 C-N-CA 124.688 1.195 . . . . 0.0 110.386 170.774 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 9.0 t80 -169.86 -66.59 0.02 OUTLIER 'General case' 0 N--CA 1.476 0.827 0 N-CA-C 107.816 -1.179 . . . . 0.0 107.816 -179.707 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -37.83 96.11 0.01 OUTLIER 'General case' 0 CA--C 1.536 0.425 0 CA-C-N 113.919 -1.491 . . . . 0.0 111.583 -174.353 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 54.1 tt0 -69.98 158.52 35.48 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 113.459 -1.7 . . . . 0.0 110.17 178.767 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 68.1 m-20 -140.14 141.32 36.07 Favored 'General case' 0 N--CA 1.477 0.875 0 N-CA-C 109.496 -0.557 . . . . 0.0 109.496 178.581 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 24' ' ' VAL . . . . . . . . . . . . . 19.7 t -87.7 -119.19 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.486 1.372 0 N-CA-C 107.91 -1.144 . . . . 0.0 107.91 179.816 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . -113.93 61.98 0.33 Allowed Glycine 0 C--N 1.371 2.495 0 C-N-CA 118.073 -2.013 . . . . 0.0 109.441 178.612 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 89.1 p -70.54 121.37 17.7 Favored 'General case' 0 C--O 1.24 0.601 0 CA-C-O 116.521 -1.704 . . . . 0.0 112.184 169.162 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 27' ' ' ASN . . . . . 0.459 ' HB3' HD21 ' A' ' 27' ' ' ASN . 57.1 t30 -61.4 101.83 0.2 Allowed 'General case' 0 N--CA 1.475 0.788 0 CA-C-N 121.625 2.011 . . . . 0.0 109.489 172.464 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 66.5 mttm -100.17 121.44 41.44 Favored 'General case' 0 N--CA 1.488 1.453 0 CA-C-N 119.681 1.128 . . . . 0.0 109.378 178.673 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -53.96 -130.12 0.0 OUTLIER Glycine 0 CA--C 1.529 0.938 0 CA-C-N 115.535 -0.757 . . . . 0.0 112.284 175.008 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -125.23 139.84 53.38 Favored 'General case' 0 C--N 1.37 1.498 0 N-CA-C 108.666 -0.864 . . . . 0.0 108.666 174.278 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 66.4 mt -83.9 141.12 15.2 Favored 'Isoleucine or valine' 0 C--O 1.239 0.527 0 N-CA-C 107.145 -1.428 . . . . 0.0 107.145 176.29 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 25.6 mt -131.31 132.89 62.81 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.058 0 N-CA-C 108.59 -0.893 . . . . 0.0 108.59 178.253 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.88 77.16 0.21 Allowed Glycine 0 C--O 1.248 1.014 0 CA-C-O 118.351 -1.249 . . . . 0.0 112.618 178.791 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 2.5 tt -109.87 131.06 55.41 Favored 'General case' 0 C--N 1.376 1.756 0 N-CA-C 104.135 -2.543 . . . . 0.0 104.135 174.722 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 8.5 ttt -157.12 166.69 32.56 Favored 'General case' 0 C--O 1.219 -0.544 0 N-CA-C 108.794 -0.817 . . . . 0.0 108.794 176.44 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 88.8 t -163.57 154.78 2.45 Favored 'Isoleucine or valine' 0 C--O 1.24 0.566 0 N-CA-C 105.476 -2.046 . . . . 0.0 105.476 175.075 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 61.15 66.54 2.61 Favored Glycine 0 N--CA 1.444 -0.769 0 C-N-CA 117.875 -2.107 . . . . 0.0 113.674 177.125 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 166.82 -147.67 12.28 Favored Glycine 0 N--CA 1.466 0.688 0 CA-C-O 117.807 -1.552 . . . . 0.0 112.2 -179.045 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 22.4 m -130.11 142.88 42.64 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.112 0 CA-C-N 119.304 1.552 . . . . 0.0 109.429 -179.439 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 18.7 t . . . . . 0 C--O 1.214 -0.776 0 N-CA-C 109.169 -0.678 . . . . 0.0 109.169 174.944 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' E' E ' 1' ' ' ASP . . . . . 0.404 ' CB ' ' N ' ' B' ' 1' ' ' ASP . 9.7 m-20 . . . . . 0 N--CA 1.49 1.545 0 N-CA-C 109.174 -0.676 . . . . 0.0 109.174 . . . . . . . . . 1 1 . 1 . 010 nuclear build full ' E' E ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.3 130.72 44.94 Favored 'General case' 0 CA--C 1.535 0.396 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.369 179.843 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' E' E ' 3' ' ' GLU . . . . . . . . . . . . . 39.4 tt0 -169.03 108.95 0.46 Allowed 'General case' 0 N--CA 1.47 0.557 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 -179.844 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 79.2 m-85 -84.64 140.28 31.46 Favored 'General case' 0 N--CA 1.475 0.811 0 N-CA-C 109.949 -0.389 . . . . 0.0 109.949 179.4 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' E' E ' 5' ' ' ARG . . . . . . . . . . . . . 71.5 mtp180 -143.77 142.26 30.82 Favored 'General case' 0 N--CA 1.476 0.842 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 179.886 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 76.7 m80 -150.53 118.24 6.17 Favored 'General case' 0 N--CA 1.472 0.662 0 N-CA-C 108.926 -0.768 . . . . 0.0 108.926 179.129 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' E' E ' 7' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -66.16 149.63 50.01 Favored 'General case' 0 N--CA 1.465 0.289 0 O-C-N 123.542 0.526 . . . . 0.0 111.559 -179.606 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' E' E ' 8' ' ' SER . . . . . . . . . . . . . 6.7 t -167.12 172.53 9.94 Favored 'General case' 0 N--CA 1.477 0.891 0 CA-C-N 115.86 -0.609 . . . . 0.0 109.563 178.033 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.95 23.67 2.19 Favored Glycine 0 N--CA 1.482 1.716 0 N-CA-C 112.018 -0.433 . . . . 0.0 112.018 179.096 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 39.2 p90 -56.18 127.26 29.82 Favored 'General case' 0 N--CA 1.473 0.724 0 N-CA-C 112.639 0.607 . . . . 0.0 112.639 -179.149 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' E' E ' 11' ' ' GLU . . . . . 0.457 ' CG ' HD21 ' D' ' 27' ' ' ASN . 46.3 mt-10 -83.41 155.55 23.41 Favored 'General case' 0 N--CA 1.474 0.734 0 N-CA-C 109.302 -0.629 . . . . 0.0 109.302 178.033 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -155.67 128.34 1.09 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.534 0 N-CA-C 108.357 -0.979 . . . . 0.0 108.357 178.782 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 47.5 m-70 -135.17 143.18 46.33 Favored 'General case' 0 N--CA 1.48 1.074 0 CA-C-O 120.746 0.308 . . . . 0.0 111.329 -177.875 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -164.83 98.68 0.77 Allowed 'General case' 0 N--CA 1.488 1.472 0 CA-C-N 116.677 -0.238 . . . . 0.0 110.973 179.73 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 38.6 mt-30 -108.4 -171.91 1.95 Allowed 'General case' 0 CA--C 1.502 -0.883 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 -179.831 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -166.27 97.31 0.6 Allowed 'General case' 0 CA--C 1.541 0.629 0 CA-C-N 115.043 -0.98 . . . . 0.0 109.327 178.648 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' E' E ' 17' ' ' LEU . . . . . 0.568 ' N ' HD12 ' E' ' 17' ' ' LEU . 4.8 mp -105.85 163.56 12.63 Favored 'General case' 0 N--CA 1.49 1.545 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 -179.805 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 40.3 t -141.9 118.57 6.99 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.352 0 C-N-CA 122.612 0.365 . . . . 0.0 110.492 179.126 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 50.9 m-85 -69.49 156.77 38.35 Favored 'General case' 0 C--N 1.357 0.933 0 N-CA-C 107.336 -1.357 . . . . 0.0 107.336 176.56 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 12.4 t80 -173.41 -54.9 0.02 OUTLIER 'General case' 0 N--CA 1.485 1.28 0 CA-C-O 121.822 0.82 . . . . 0.0 110.288 179.457 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.96 89.31 0.0 OUTLIER 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 114.346 -1.297 . . . . 0.0 112.686 -178.783 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 54.7 tt0 -66.14 158.19 29.26 Favored 'General case' 0 N--CA 1.472 0.656 0 CA-C-N 114.823 -1.08 . . . . 0.0 110.651 179.651 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 66.0 m-20 -140.56 137.59 33.85 Favored 'General case' 0 N--CA 1.479 1.005 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.442 179.881 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 21.7 t -84.79 -115.45 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.039 0 N-CA-C 108.681 -0.859 . . . . 0.0 108.681 179.649 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . -110.61 54.16 0.55 Allowed Glycine 0 C--N 1.347 1.163 0 N-CA-C 111.457 -0.657 . . . . 0.0 111.457 -179.715 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 69.0 p -79.75 125.67 29.97 Favored 'General case' 0 N--CA 1.474 0.773 0 N-CA-C 109.384 -0.599 . . . . 0.0 109.384 178.078 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' E' E ' 27' ' ' ASN . . . . . 0.507 HD21 ' HB3' ' H' ' 27' ' ' ASN . 2.2 t-20 -66.72 99.5 0.61 Allowed 'General case' 0 N--CA 1.471 0.601 0 N-CA-C 108.081 -1.081 . . . . 0.0 108.081 178.382 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 66.4 mttm -96.44 119.3 34.66 Favored 'General case' 0 N--CA 1.484 1.252 0 N-CA-C 109.995 -0.372 . . . . 0.0 109.995 -178.748 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.57 -124.88 0.01 OUTLIER Glycine 0 CA--C 1.538 1.525 0 N-CA-C 110.95 -0.86 . . . . 0.0 110.95 178.601 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.74 133.33 48.08 Favored 'General case' 0 N--CA 1.482 1.158 0 N-CA-C 109.581 -0.526 . . . . 0.0 109.581 179.65 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 66.3 mt -82.65 138.97 18.5 Favored 'Isoleucine or valine' 0 C--O 1.237 0.405 0 N-CA-C 107.029 -1.471 . . . . 0.0 107.029 178.434 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 21.0 mt -128.32 129.06 69.05 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.865 0 N-CA-C 109.566 -0.531 . . . . 0.0 109.566 -179.433 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 60.97 80.28 0.1 Allowed Glycine 0 CA--C 1.524 0.641 0 CA-C-N 116.064 -0.516 . . . . 0.0 113.505 179.172 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 2.0 tt -111.77 118.86 36.74 Favored 'General case' 0 N--CA 1.477 0.916 0 N-CA-C 107.003 -1.481 . . . . 0.0 107.003 177.34 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 8.6 ttt -154.14 162.64 41.05 Favored 'General case' 0 C--O 1.211 -0.944 0 N-CA-C 108.744 -0.835 . . . . 0.0 108.744 179.203 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 84.1 t -159.71 150.53 6.33 Favored 'Isoleucine or valine' 0 C--O 1.239 0.509 0 N-CA-C 106.632 -1.618 . . . . 0.0 106.632 -179.864 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.61 74.94 0.27 Allowed Glycine 0 C--N 1.314 -0.662 0 CA-C-N 115.673 -0.694 . . . . 0.0 111.481 178.48 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 169.95 -147.7 11.08 Favored Glycine 0 C--O 1.222 -0.631 0 N-CA-C 111.321 -0.712 . . . . 0.0 111.321 179.965 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 20.3 m -133.93 141.38 44.12 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.872 0 N-CA-C 109.199 -0.667 . . . . 0.0 109.199 179.444 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 19.0 t . . . . . 0 CA--C 1.535 0.379 0 CA-C-O 117.722 -1.133 . . . . 0.0 110.895 179.453 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' F' F ' 1' ' ' ASP . . . . . 0.408 ' H2 ' ' HB2' ' I' ' 1' ' ' ASP . 9.3 m-20 . . . . . 0 N--CA 1.489 1.525 0 N-CA-C 109.161 -0.681 . . . . 0.0 109.161 . . . . . . . . . 1 1 . 1 . 010 nuclear build full ' F' F ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.11 130.9 45.81 Favored 'General case' 0 CA--C 1.536 0.428 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.359 179.884 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' F' F ' 3' ' ' GLU . . . . . . . . . . . . . 39.3 tt0 -169.22 108.84 0.45 Allowed 'General case' 0 N--CA 1.468 0.473 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 -179.859 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 79.4 m-85 -84.56 140.45 31.4 Favored 'General case' 0 N--CA 1.475 0.8 0 N-CA-C 109.873 -0.417 . . . . 0.0 109.873 179.344 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' F' F ' 5' ' ' ARG . . . . . . . . . . . . . 71.6 mtp180 -143.8 141.84 30.59 Favored 'General case' 0 N--CA 1.477 0.912 0 N-CA-C 109.261 -0.644 . . . . 0.0 109.261 179.998 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 76.9 m80 -150.28 118.41 6.34 Favored 'General case' 0 N--CA 1.473 0.688 0 N-CA-C 108.965 -0.754 . . . . 0.0 108.965 179.072 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' F' F ' 7' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -66.4 149.82 49.83 Favored 'General case' 0 N--CA 1.463 0.203 0 O-C-N 123.414 0.447 . . . . 0.0 111.636 -179.429 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' F' F ' 8' ' ' SER . . . . . . . . . . . . . 6.9 t -167.41 172.28 9.79 Favored 'General case' 0 N--CA 1.476 0.874 0 CA-C-N 115.991 -0.55 . . . . 0.0 109.56 178.04 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 123.19 23.25 2.21 Favored Glycine 0 N--CA 1.482 1.74 0 N-CA-C 112.04 -0.424 . . . . 0.0 112.04 179.109 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 38.7 p90 -55.87 127.72 31.63 Favored 'General case' 0 CA--C 1.543 0.694 0 N-CA-C 112.664 0.616 . . . . 0.0 112.664 -179.151 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 46.3 mt-10 -83.74 155.33 23.13 Favored 'General case' 0 N--CA 1.474 0.764 0 N-CA-C 109.436 -0.579 . . . . 0.0 109.436 178.023 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -155.34 128.19 1.11 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.587 0 N-CA-C 108.297 -1.001 . . . . 0.0 108.297 178.79 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 46.1 m-70 -135.01 143.22 46.68 Favored 'General case' 0 N--CA 1.483 1.196 0 CA-C-O 120.63 0.252 . . . . 0.0 111.329 -177.902 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -165.18 99.09 0.73 Allowed 'General case' 0 N--CA 1.487 1.422 0 CA-C-N 116.751 -0.204 . . . . 0.0 111.091 179.74 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 38.5 mt-30 -109.2 -171.51 1.86 Allowed 'General case' 0 CA--C 1.498 -1.034 0 N-CA-C 108.574 -0.899 . . . . 0.0 108.574 -179.826 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -166.11 97.57 0.62 Allowed 'General case' 0 CA--C 1.542 0.651 0 CA-C-N 114.93 -1.032 . . . . 0.0 109.406 178.769 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' F' F ' 17' ' ' LEU . . . . . 0.566 ' N ' HD12 ' F' ' 17' ' ' LEU . 4.7 mp -105.81 163.48 12.69 Favored 'General case' 0 N--CA 1.488 1.469 0 N-CA-C 109.213 -0.662 . . . . 0.0 109.213 -179.923 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 40.0 t -141.9 118.59 7.02 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.305 0 C-N-CA 122.644 0.378 . . . . 0.0 110.613 179.101 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 51.0 m-85 -69.53 156.66 38.54 Favored 'General case' 0 C--N 1.357 0.922 0 N-CA-C 107.221 -1.399 . . . . 0.0 107.221 176.548 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 13.2 t80 -173.19 -55.04 0.02 OUTLIER 'General case' 0 N--CA 1.486 1.372 0 CA-C-O 121.787 0.803 . . . . 0.0 109.85 179.458 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.73 88.99 0.0 OUTLIER 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 114.49 -1.232 . . . . 0.0 112.971 -178.876 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 54.4 tt0 -65.96 158.22 28.74 Favored 'General case' 0 N--CA 1.472 0.666 0 CA-C-N 114.894 -1.048 . . . . 0.0 110.799 179.541 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 66.7 m-20 -140.51 137.83 34.11 Favored 'General case' 0 N--CA 1.48 1.059 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.396 179.96 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' F' F ' 24' ' ' VAL . . . . . . . . . . . . . 21.7 t -85.09 -115.46 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.043 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 179.505 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -110.55 54.11 0.56 Allowed Glycine 0 N--CA 1.479 1.529 0 N-CA-C 111.383 -0.687 . . . . 0.0 111.383 -179.815 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 70.1 p -79.68 125.42 29.62 Favored 'General case' 0 N--CA 1.474 0.733 0 N-CA-C 109.335 -0.617 . . . . 0.0 109.335 177.948 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' F' F ' 27' ' ' ASN . . . . . 0.489 HD21 ' HB3' ' I' ' 27' ' ' ASN . 2.2 t-20 -66.5 99.23 0.55 Allowed 'General case' 0 N--CA 1.472 0.638 0 N-CA-C 108.115 -1.069 . . . . 0.0 108.115 178.382 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 66.4 mttm -96.26 119.17 34.27 Favored 'General case' 0 N--CA 1.483 1.19 0 N-CA-C 110.084 -0.339 . . . . 0.0 110.084 -178.804 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.55 -125.41 0.01 OUTLIER Glycine 0 CA--C 1.54 1.6 0 N-CA-C 110.964 -0.854 . . . . 0.0 110.964 178.617 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -127.91 133.08 49.25 Favored 'General case' 0 N--CA 1.484 1.249 0 N-CA-C 109.644 -0.502 . . . . 0.0 109.644 179.588 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 66.9 mt -82.65 138.81 18.77 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.273 0 N-CA-C 106.897 -1.52 . . . . 0.0 106.897 178.421 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 20.3 mt -128.22 129.08 69.22 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.891 0 N-CA-C 109.636 -0.505 . . . . 0.0 109.636 -179.357 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 60.86 80.27 0.1 Allowed Glycine 0 CA--C 1.525 0.688 0 CA-C-N 116.056 -0.52 . . . . 0.0 113.573 179.346 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 2.1 tt -111.85 118.82 36.59 Favored 'General case' 0 N--CA 1.479 0.981 0 N-CA-C 107.067 -1.457 . . . . 0.0 107.067 177.346 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 8.7 ttt -154.15 162.72 41.0 Favored 'General case' 0 C--O 1.209 -1.041 0 N-CA-C 109.009 -0.737 . . . . 0.0 109.009 179.143 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 85.1 t -159.7 150.57 6.32 Favored 'Isoleucine or valine' 0 C--O 1.237 0.402 0 N-CA-C 106.701 -1.592 . . . . 0.0 106.701 -179.823 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.8 74.67 0.3 Allowed Glycine 0 C--N 1.315 -0.632 0 CA-C-N 115.523 -0.762 . . . . 0.0 111.447 178.452 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 170.06 -147.82 11.14 Favored Glycine 0 C--O 1.221 -0.7 0 N-CA-C 111.233 -0.747 . . . . 0.0 111.233 179.839 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 20.2 m -133.72 141.37 44.35 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.841 0 N-CA-C 109.158 -0.682 . . . . 0.0 109.158 179.547 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 19.4 t . . . . . 0 CA--C 1.536 0.415 0 CA-C-O 117.746 -1.121 . . . . 0.0 110.75 179.389 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' G' G ' 1' ' ' ASP . . . . . . . . . . . . . 8.7 m-20 . . . . . 0 N--CA 1.49 1.565 0 N-CA-C 109.723 -0.473 . . . . 0.0 109.723 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' G' G ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.44 129.27 39.9 Favored 'General case' 0 N--CA 1.469 0.514 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.44 179.636 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 3' ' ' GLU . . . . . . . . . . . . . 39.0 tt0 -169.08 108.59 0.45 Allowed 'General case' 0 N--CA 1.471 0.605 0 N-CA-C 110.117 -0.327 . . . . 0.0 110.117 179.758 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 79.0 m-85 -85.07 139.72 31.53 Favored 'General case' 0 N--CA 1.474 0.772 0 N-CA-C 109.644 -0.502 . . . . 0.0 109.644 179.199 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 5' ' ' ARG . . . . . . . . . . . . . 71.8 mtp180 -144.01 141.28 30.05 Favored 'General case' 0 N--CA 1.483 1.22 0 N-CA-C 109.178 -0.675 . . . . 0.0 109.178 -179.515 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 76.7 m80 -149.53 119.57 7.19 Favored 'General case' 0 N--CA 1.472 0.671 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 179.078 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 -68.41 145.28 54.27 Favored 'General case' 0 N--CA 1.47 0.526 0 O-C-N 123.505 0.503 . . . . 0.0 111.931 -179.328 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 8' ' ' SER . . . . . . . . . . . . . 5.7 t -163.81 173.54 12.64 Favored 'General case' 0 N--CA 1.47 0.566 0 N-CA-C 109.291 -0.633 . . . . 0.0 109.291 178.147 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.94 23.65 2.2 Favored Glycine 0 N--CA 1.479 1.519 0 N-CA-C 111.755 -0.538 . . . . 0.0 111.755 179.051 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 41.9 p90 -56.98 127.61 32.79 Favored 'General case' 0 N--CA 1.475 0.799 0 N-CA-C 112.437 0.532 . . . . 0.0 112.437 -178.648 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 45.2 mt-10 -83.93 154.34 23.43 Favored 'General case' 0 N--CA 1.471 0.618 0 CA-C-O 121.052 0.453 . . . . 0.0 109.852 178.686 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -155.4 128.51 1.15 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.968 0 N-CA-C 108.304 -0.999 . . . . 0.0 108.304 178.9 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 49.1 m-70 -134.19 144.38 48.44 Favored 'General case' 0 N--CA 1.476 0.865 0 CA-C-N 115.416 -0.811 . . . . 0.0 111.09 -178.136 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -166.35 98.2 0.6 Allowed 'General case' 0 N--CA 1.484 1.245 0 CA-C-N 116.642 -0.254 . . . . 0.0 110.572 179.219 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 39.1 mt-30 -108.32 -171.89 1.95 Allowed 'General case' 0 CA--C 1.503 -0.839 0 N-CA-C 108.635 -0.876 . . . . 0.0 108.635 -179.775 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -166.03 97.58 0.63 Allowed 'General case' 0 CA--C 1.541 0.618 0 CA-C-N 115.032 -0.985 . . . . 0.0 109.38 178.614 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 17' ' ' LEU . . . . . 0.573 ' N ' HD12 ' G' ' 17' ' ' LEU . 5.4 mp -105.73 162.33 13.63 Favored 'General case' 0 N--CA 1.487 1.423 0 N-CA-C 109.4 -0.593 . . . . 0.0 109.4 -179.717 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 39.0 t -142.45 118.83 6.08 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.082 0 CA-C-O 120.895 0.378 . . . . 0.0 110.352 178.773 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 44.9 m-85 -69.65 150.74 46.69 Favored 'General case' 0 C--N 1.369 1.444 0 N-CA-C 107.267 -1.383 . . . . 0.0 107.267 176.583 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 10.9 t80 -170.92 -54.84 0.02 OUTLIER 'General case' 0 N--CA 1.487 1.382 0 CA-C-N 117.847 0.294 . . . . 0.0 110.408 -179.73 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.45 90.27 0.0 OUTLIER 'General case' 0 C--N 1.325 -0.494 0 C-N-CA 123.866 0.866 . . . . 0.0 112.596 -179.918 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 53.8 tt0 -66.88 159.06 29.07 Favored 'General case' 0 N--CA 1.469 0.492 0 CA-C-N 114.634 -1.166 . . . . 0.0 109.923 179.189 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 66.2 m-20 -140.94 137.55 33.18 Favored 'General case' 0 N--CA 1.477 0.904 0 C-N-CA 122.822 0.449 . . . . 0.0 110.046 179.893 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 24' ' ' VAL . . . . . . . . . . . . . 21.4 t -85.42 -115.29 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.919 0 N-CA-C 108.521 -0.918 . . . . 0.0 108.521 179.608 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -110.53 53.97 0.56 Allowed Glycine 0 N--CA 1.477 1.425 0 N-CA-C 111.611 -0.596 . . . . 0.0 111.611 -179.712 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 70.4 p -80.08 126.27 30.85 Favored 'General case' 0 N--CA 1.467 0.393 0 N-CA-C 109.081 -0.711 . . . . 0.0 109.081 177.956 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 2.2 t-20 -67.23 99.99 0.75 Allowed 'General case' 0 CA--C 1.538 0.503 0 N-CA-C 108.401 -0.963 . . . . 0.0 108.401 178.434 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 66.9 mttm -96.33 119.91 35.68 Favored 'General case' 0 N--CA 1.482 1.147 0 N-CA-C 110.174 -0.306 . . . . 0.0 110.174 -179.182 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.02 -123.33 0.01 OUTLIER Glycine 0 CA--C 1.534 1.253 0 N-CA-C 110.54 -1.024 . . . . 0.0 110.54 178.787 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -129.58 132.78 46.89 Favored 'General case' 0 N--CA 1.47 0.557 0 N-CA-C 109.514 -0.55 . . . . 0.0 109.514 179.683 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 69.9 mt -81.54 140.91 15.85 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.654 0 N-CA-C 107.2 -1.407 . . . . 0.0 107.2 178.337 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 24.0 mt -130.2 130.52 65.74 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.46 0 CA-C-N 119.044 0.838 . . . . 0.0 109.435 179.785 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 60.96 79.82 0.11 Allowed Glycine 0 CA--C 1.528 0.888 0 CA-C-N 116.281 -0.418 . . . . 0.0 113.038 179.292 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 34' ' ' LEU . . . . . 0.404 HD23 ' N ' ' G' ' 35' ' ' MET . 1.9 tt -111.93 119.55 38.92 Favored 'General case' 0 N--CA 1.478 0.94 0 N-CA-C 106.961 -1.496 . . . . 0.0 106.961 177.479 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' G' G ' 35' ' ' MET . . . . . 0.404 ' N ' HD23 ' G' ' 34' ' ' LEU . 8.5 ttt -155.54 163.14 40.38 Favored 'General case' 0 N--CA 1.476 0.866 0 N-CA-C 108.192 -1.04 . . . . 0.0 108.192 179.503 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 98.6 t -159.8 150.85 6.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 N-CA-C 106.303 -1.74 . . . . 0.0 106.303 -179.899 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.1 74.74 0.29 Allowed Glycine 0 C--N 1.313 -0.706 0 CA-C-N 115.888 -0.596 . . . . 0.0 111.913 178.132 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 168.66 -146.42 10.34 Favored Glycine 0 N--CA 1.471 1.008 0 N-CA-C 110.636 -0.986 . . . . 0.0 110.636 179.231 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 23.1 m -134.23 141.62 43.17 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.906 0 CA-C-N 117.031 0.415 . . . . 0.0 109.984 179.881 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 19.2 t . . . . . 0 N--CA 1.47 0.548 0 CA-C-O 117.841 -1.076 . . . . 0.0 110.891 179.613 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' H' H ' 1' ' ' ASP . . . . . . . . . . . . . 9.7 m-20 . . . . . 0 N--CA 1.491 1.59 0 N-CA-C 109.661 -0.496 . . . . 0.0 109.661 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' H' H ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.56 129.07 38.95 Favored 'General case' 0 N--CA 1.468 0.473 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.491 179.716 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' H' H ' 3' ' ' GLU . . . . . . . . . . . . . 39.3 tt0 -168.96 108.58 0.46 Allowed 'General case' 0 N--CA 1.47 0.557 0 N-CA-C 110.114 -0.328 . . . . 0.0 110.114 179.745 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 80.4 m-85 -84.77 140.13 31.46 Favored 'General case' 0 N--CA 1.475 0.805 0 N-CA-C 109.641 -0.503 . . . . 0.0 109.641 179.342 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' H' H ' 5' ' ' ARG . . . . . . . . . . . . . 71.5 mtp180 -144.29 141.4 29.77 Favored 'General case' 0 N--CA 1.48 1.055 0 N-CA-C 109.222 -0.658 . . . . 0.0 109.222 -179.625 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 76.8 m80 -149.72 119.29 6.96 Favored 'General case' 0 N--CA 1.473 0.698 0 N-CA-C 109.095 -0.705 . . . . 0.0 109.095 179.071 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 8.7 m-20 -68.08 145.35 54.5 Favored 'General case' 0 N--CA 1.468 0.45 0 O-C-N 123.466 0.479 . . . . 0.0 111.934 -179.393 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' H' H ' 8' ' ' SER . . . . . . . . . . . . . 7.0 t -163.9 172.83 13.45 Favored 'General case' 0 N--CA 1.468 0.474 0 N-CA-C 109.449 -0.574 . . . . 0.0 109.449 178.466 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 123.15 23.52 2.17 Favored Glycine 0 N--CA 1.481 1.684 0 N-CA-C 111.682 -0.567 . . . . 0.0 111.682 179.154 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 41.6 p90 -56.79 127.65 32.68 Favored 'General case' 0 N--CA 1.472 0.672 0 N-CA-C 112.443 0.534 . . . . 0.0 112.443 -178.763 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 45.4 mt-10 -83.96 154.4 23.36 Favored 'General case' 0 N--CA 1.473 0.679 0 CA-C-O 120.998 0.428 . . . . 0.0 109.893 178.739 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.6 p -155.58 128.11 1.07 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.016 0 N-CA-C 108.42 -0.955 . . . . 0.0 108.42 178.879 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 48.7 m-70 -133.91 144.4 48.83 Favored 'General case' 0 N--CA 1.478 0.947 0 CA-C-N 115.336 -0.847 . . . . 0.0 111.025 -178.072 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -166.29 98.54 0.61 Allowed 'General case' 0 N--CA 1.483 1.218 0 CA-C-N 116.568 -0.287 . . . . 0.0 110.617 179.166 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 38.9 mt-30 -108.64 -172.37 2.04 Favored 'General case' 0 CA--C 1.501 -0.931 0 N-CA-C 108.416 -0.957 . . . . 0.0 108.416 -179.656 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -165.73 97.35 0.65 Allowed 'General case' 0 CA--C 1.54 0.572 0 CA-C-N 114.951 -1.022 . . . . 0.0 109.364 178.716 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' H' H ' 17' ' ' LEU . . . . . 0.572 ' N ' HD12 ' H' ' 17' ' ' LEU . 5.4 mp -105.66 162.23 13.7 Favored 'General case' 0 N--CA 1.487 1.405 0 N-CA-C 109.362 -0.607 . . . . 0.0 109.362 -179.646 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 38.8 t -142.39 118.67 6.08 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.983 0 CA-C-O 120.97 0.414 . . . . 0.0 110.489 178.851 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 46.2 m-85 -69.8 151.07 46.18 Favored 'General case' 0 C--N 1.371 1.503 0 N-CA-C 107.355 -1.35 . . . . 0.0 107.355 176.653 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 11.4 t80 -172.15 -54.6 0.02 OUTLIER 'General case' 0 N--CA 1.485 1.295 0 N-CA-C 110.342 -0.244 . . . . 0.0 110.342 -179.635 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.39 90.41 0.0 OUTLIER 'General case' 0 CA--C 1.535 0.365 0 C-N-CA 123.815 0.846 . . . . 0.0 112.354 -179.958 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 54.0 tt0 -66.73 159.14 28.52 Favored 'General case' 0 N--CA 1.469 0.485 0 CA-C-N 114.69 -1.141 . . . . 0.0 110.012 179.34 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 67.5 m-20 -140.91 138.05 33.58 Favored 'General case' 0 N--CA 1.477 0.885 0 C-N-CA 122.821 0.448 . . . . 0.0 110.051 179.693 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' H' H ' 24' ' ' VAL . . . . . . . . . . . . . 21.4 t -85.93 -115.33 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 1.016 0 N-CA-C 108.609 -0.885 . . . . 0.0 108.609 179.602 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . -110.33 53.9 0.56 Allowed Glycine 0 N--CA 1.48 1.601 0 N-CA-C 111.471 -0.652 . . . . 0.0 111.471 -179.759 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 68.7 p -80.03 126.02 30.52 Favored 'General case' 0 N--CA 1.468 0.446 0 N-CA-C 109.053 -0.721 . . . . 0.0 109.053 178.067 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' H' H ' 27' ' ' ASN . . . . . 0.507 ' HB3' HD21 ' E' ' 27' ' ' ASN . 2.1 t-20 -67.31 100.1 0.78 Allowed 'General case' 0 N--CA 1.47 0.542 0 N-CA-C 108.409 -0.96 . . . . 0.0 108.409 178.492 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 67.0 mttm -96.41 119.76 35.49 Favored 'General case' 0 N--CA 1.484 1.236 0 N-CA-C 110.182 -0.303 . . . . 0.0 110.182 -179.131 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.89 -122.84 0.01 OUTLIER Glycine 0 CA--C 1.535 1.306 0 N-CA-C 110.606 -0.998 . . . . 0.0 110.606 178.735 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -129.95 133.0 46.54 Favored 'General case' 0 N--CA 1.471 0.62 0 C-N-CA 122.946 0.498 . . . . 0.0 109.663 179.709 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 69.5 mt -81.89 140.76 16.01 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.554 0 N-CA-C 107.128 -1.434 . . . . 0.0 107.128 178.446 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 25.1 mt -130.03 130.47 66.08 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.403 0 CA-C-N 119.021 0.828 . . . . 0.0 109.395 179.935 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 60.77 79.81 0.11 Allowed Glycine 0 CA--C 1.528 0.889 0 CA-C-N 116.382 -0.372 . . . . 0.0 113.067 179.193 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 1.9 tt -111.87 119.5 38.77 Favored 'General case' 0 N--CA 1.478 0.944 0 N-CA-C 106.944 -1.502 . . . . 0.0 106.944 177.426 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 8.4 ttt -155.19 163.19 40.54 Favored 'General case' 0 C--O 1.212 -0.91 0 N-CA-C 108.176 -1.046 . . . . 0.0 108.176 179.509 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 96.4 t -159.79 150.77 6.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 N-CA-C 106.254 -1.758 . . . . 0.0 106.254 -179.885 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.12 74.95 0.27 Allowed Glycine 0 C--N 1.313 -0.712 0 CA-C-N 115.914 -0.584 . . . . 0.0 111.914 178.124 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 168.32 -146.34 10.37 Favored Glycine 0 N--CA 1.469 0.866 0 N-CA-C 110.631 -0.988 . . . . 0.0 110.631 179.105 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 22.6 m -134.15 141.81 42.74 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.906 0 CA-C-N 116.998 0.399 . . . . 0.0 110.021 179.911 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 19.1 t . . . . . 0 N--CA 1.47 0.557 0 CA-C-O 117.789 -1.101 . . . . 0.0 110.932 179.539 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' I' I ' 1' ' ' ASP . . . . . 0.408 ' HB2' ' H2 ' ' F' ' 1' ' ' ASP . 9.6 m-20 . . . . . 0 N--CA 1.491 1.589 0 N-CA-C 109.607 -0.516 . . . . 0.0 109.607 . . . . . . . . . 1 1 . 1 . 010 nuclear build full ' I' I ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.67 129.19 39.43 Favored 'General case' 0 N--CA 1.469 0.491 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.441 179.635 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' I' I ' 3' ' ' GLU . . . . . . . . . . . . . 39.0 tt0 -169.0 108.67 0.46 Allowed 'General case' 0 N--CA 1.47 0.563 0 N-CA-C 110.147 -0.316 . . . . 0.0 110.147 179.771 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 79.9 m-85 -84.96 140.32 31.16 Favored 'General case' 0 N--CA 1.475 0.78 0 N-CA-C 109.599 -0.519 . . . . 0.0 109.599 179.298 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' I' I ' 5' ' ' ARG . . . . . . . . . . . . . 71.6 mtp180 -144.44 141.5 29.66 Favored 'General case' 0 N--CA 1.483 1.192 0 N-CA-C 109.187 -0.671 . . . . 0.0 109.187 -179.696 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 76.7 m80 -149.76 119.06 6.82 Favored 'General case' 0 N--CA 1.472 0.667 0 N-CA-C 109.126 -0.694 . . . . 0.0 109.126 179.082 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 8.6 m-20 -67.86 145.36 54.69 Favored 'General case' 0 N--CA 1.469 0.491 0 O-C-N 123.479 0.487 . . . . 0.0 111.935 -179.371 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' I' I ' 8' ' ' SER . . . . . . . . . . . . . 7.5 t -163.9 172.75 13.55 Favored 'General case' 0 N--CA 1.469 0.496 0 N-CA-C 109.429 -0.582 . . . . 0.0 109.429 178.465 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 123.2 23.77 2.12 Favored Glycine 0 N--CA 1.481 1.639 0 N-CA-C 111.78 -0.528 . . . . 0.0 111.78 179.118 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 41.5 p90 -56.95 127.52 32.27 Favored 'General case' 0 N--CA 1.474 0.737 0 N-CA-C 112.443 0.534 . . . . 0.0 112.443 -178.738 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 45.2 mt-10 -83.66 154.34 23.74 Favored 'General case' 0 N--CA 1.472 0.628 0 CA-C-O 120.998 0.427 . . . . 0.0 109.909 178.675 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -155.49 128.29 1.1 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.015 0 N-CA-C 108.313 -0.995 . . . . 0.0 108.313 178.848 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 49.5 m-70 -134.06 144.56 48.72 Favored 'General case' 0 N--CA 1.478 0.935 0 CA-C-N 115.337 -0.847 . . . . 0.0 111.13 -178.198 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -166.4 98.51 0.6 Allowed 'General case' 0 N--CA 1.484 1.255 0 CA-C-N 116.639 -0.255 . . . . 0.0 110.704 179.127 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 39.1 mt-30 -108.63 -172.45 2.06 Favored 'General case' 0 CA--C 1.498 -1.029 0 N-CA-C 108.461 -0.94 . . . . 0.0 108.461 -179.765 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -165.69 97.43 0.66 Allowed 'General case' 0 CA--C 1.541 0.61 0 CA-C-N 114.9 -1.046 . . . . 0.0 109.302 178.789 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' I' I ' 17' ' ' LEU . . . . . 0.569 ' N ' HD12 ' I' ' 17' ' ' LEU . 5.4 mp -105.68 162.51 13.46 Favored 'General case' 0 N--CA 1.487 1.402 0 N-CA-C 109.306 -0.627 . . . . 0.0 109.306 -179.609 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 39.2 t -142.5 118.81 5.95 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.006 0 CA-C-O 120.94 0.4 . . . . 0.0 110.471 178.851 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 45.8 m-85 -70.02 150.96 46.1 Favored 'General case' 0 C--N 1.369 1.431 0 N-CA-C 107.402 -1.332 . . . . 0.0 107.402 176.601 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 11.5 t80 -171.96 -54.72 0.02 OUTLIER 'General case' 0 N--CA 1.483 1.209 0 CA-C-N 117.765 0.257 . . . . 0.0 110.401 -179.561 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.34 90.22 0.0 OUTLIER 'General case' 0 CA--C 1.535 0.401 0 C-N-CA 123.743 0.817 . . . . 0.0 112.386 -179.942 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 54.1 tt0 -66.46 159.06 27.92 Favored 'General case' 0 N--CA 1.468 0.47 0 CA-C-N 114.667 -1.151 . . . . 0.0 110.061 179.272 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 67.2 m-20 -140.91 138.0 33.54 Favored 'General case' 0 N--CA 1.477 0.921 0 C-N-CA 122.775 0.43 . . . . 0.0 110.001 179.835 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' I' I ' 24' ' ' VAL . . . . . . . . . . . . . 21.3 t -85.99 -115.52 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.926 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 179.653 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . -110.16 53.6 0.58 Allowed Glycine 0 N--CA 1.479 1.501 0 N-CA-C 111.579 -0.609 . . . . 0.0 111.579 -179.702 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 68.7 p -79.74 126.24 30.7 Favored 'General case' 0 N--CA 1.467 0.411 0 N-CA-C 109.036 -0.727 . . . . 0.0 109.036 178.026 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' I' I ' 27' ' ' ASN . . . . . 0.489 ' HB3' HD21 ' F' ' 27' ' ' ASN . 2.2 t-20 -67.52 99.9 0.81 Allowed 'General case' 0 N--CA 1.47 0.527 0 N-CA-C 108.379 -0.971 . . . . 0.0 108.379 178.483 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 67.0 mttm -96.2 119.79 35.32 Favored 'General case' 0 N--CA 1.482 1.165 0 N-CA-C 110.216 -0.29 . . . . 0.0 110.216 -179.135 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.13 -123.23 0.01 OUTLIER Glycine 0 CA--C 1.534 1.254 0 N-CA-C 110.656 -0.978 . . . . 0.0 110.656 178.746 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -129.4 132.74 47.09 Favored 'General case' 0 N--CA 1.473 0.683 0 C-N-CA 122.962 0.505 . . . . 0.0 109.65 179.657 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 69.5 mt -81.75 140.68 16.16 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.637 0 N-CA-C 106.982 -1.488 . . . . 0.0 106.982 178.387 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 23.3 mt -129.89 130.44 66.37 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.383 0 CA-C-N 118.939 0.79 . . . . 0.0 109.361 179.868 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 60.63 80.04 0.11 Allowed Glycine 0 CA--C 1.528 0.846 0 CA-C-N 116.331 -0.395 . . . . 0.0 113.107 179.25 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 1.9 tt -112.0 119.6 39.02 Favored 'General case' 0 N--CA 1.478 0.949 0 N-CA-C 106.891 -1.522 . . . . 0.0 106.891 177.446 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 8.6 ttt -155.29 163.08 40.63 Favored 'General case' 0 N--CA 1.478 0.943 0 N-CA-C 108.256 -1.016 . . . . 0.0 108.256 179.518 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 97.7 t -159.76 150.94 6.17 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 N-CA-C 106.253 -1.758 . . . . 0.0 106.253 -179.915 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.14 74.45 0.33 Allowed Glycine 0 C--N 1.313 -0.739 0 CA-C-N 115.891 -0.595 . . . . 0.0 112.023 178.115 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 168.76 -146.4 10.31 Favored Glycine 0 N--CA 1.47 0.915 0 N-CA-C 110.602 -0.999 . . . . 0.0 110.602 179.268 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 22.8 m -134.06 141.79 42.88 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.873 0 CA-C-N 117.01 0.405 . . . . 0.0 109.981 179.921 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 19.2 t . . . . . 0 N--CA 1.469 0.506 0 CA-C-O 117.825 -1.083 . . . . 0.0 110.939 179.507 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 8.6 m-20 . . . . . 0 N--CA 1.49 1.536 0 N-CA-C 109.048 -0.723 . . . . 0.0 109.048 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.95 132.72 49.29 Favored 'General case' 0 CA--C 1.538 0.491 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.201 -179.877 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 41.1 tt0 -169.33 108.32 0.43 Allowed 'General case' 0 N--CA 1.47 0.545 0 N-CA-C 109.693 -0.484 . . . . 0.0 109.693 -179.242 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 78.5 m-85 -83.56 140.52 32.2 Favored 'General case' 0 N--CA 1.475 0.795 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 179.469 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 72.2 mtp180 -143.62 141.17 30.5 Favored 'General case' 0 N--CA 1.481 1.116 0 N-CA-C 109.076 -0.713 . . . . 0.0 109.076 179.964 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 77.0 m80 -149.48 119.65 7.26 Favored 'General case' 0 N--CA 1.47 0.562 0 N-CA-C 108.806 -0.813 . . . . 0.0 108.806 179.136 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 7.4 m-20 -68.3 150.21 48.5 Favored 'General case' 0 CA--C 1.529 0.168 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.258 -179.437 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 8.5 t -166.95 172.27 10.41 Favored 'General case' 0 N--CA 1.472 0.63 0 N-CA-C 109.554 -0.536 . . . . 0.0 109.554 178.476 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.53 23.52 2.32 Favored Glycine 0 N--CA 1.487 2.097 0 N-CA-C 112.239 -0.344 . . . . 0.0 112.239 179.417 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 41.8 p90 -56.98 128.28 36.13 Favored 'General case' 0 N--CA 1.474 0.761 0 N-CA-C 112.088 0.403 . . . . 0.0 112.088 -179.912 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 57.4 mt-10 -85.66 155.38 21.12 Favored 'General case' 0 N--CA 1.469 0.504 0 N-CA-C 109.273 -0.64 . . . . 0.0 109.273 178.493 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -153.75 128.79 1.51 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 N-CA-C 108.107 -1.071 . . . . 0.0 108.107 178.839 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 49.5 m-70 -134.64 146.54 49.64 Favored 'General case' 0 N--CA 1.489 1.503 0 CA-C-N 118.641 0.655 . . . . 0.0 111.154 -179.024 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 6.4 t60 -164.96 97.91 0.74 Allowed 'General case' 0 N--CA 1.48 1.04 0 CA-C-N 116.502 -0.317 . . . . 0.0 111.055 179.582 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 35.0 mt-30 -106.06 -172.7 2.14 Favored 'General case' 0 CA--C 1.505 -0.762 0 N-CA-C 108.369 -0.974 . . . . 0.0 108.369 179.915 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 16' ' ' LYS . . . . . 0.403 ' C ' HD12 ' A' ' 17' ' ' LEU . 88.6 tttt -169.18 96.47 0.34 Allowed 'General case' 0 N--CA 1.472 0.629 0 CA-C-N 115.139 -0.937 . . . . 0.0 109.416 178.703 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.58 ' N ' HD12 ' A' ' 17' ' ' LEU . 4.8 mp -106.38 165.01 11.57 Favored 'General case' 0 N--CA 1.489 1.498 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 179.901 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 56.5 t -141.78 119.22 7.96 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.387 0 CA-C-O 118.934 -0.555 . . . . 0.0 109.897 179.68 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 52.4 m-85 -69.9 158.93 34.62 Favored 'General case' 0 N--CA 1.481 1.079 0 N-CA-C 107.592 -1.262 . . . . 0.0 107.592 177.392 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 13.1 t80 -171.22 -58.59 0.02 OUTLIER 'General case' 0 N--CA 1.485 1.324 0 CA-C-O 122.299 1.047 . . . . 0.0 109.73 179.485 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -38.82 90.11 0.0 OUTLIER 'General case' 0 C--O 1.232 0.142 0 CA-C-N 113.926 -1.488 . . . . 0.0 112.968 -177.985 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 37.0 tt0 -66.51 157.81 31.24 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 115.109 -0.95 . . . . 0.0 110.452 179.197 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 66.7 m-20 -139.98 137.38 34.66 Favored 'General case' 0 N--CA 1.48 1.071 0 C-N-CA 123.002 0.521 . . . . 0.0 110.344 179.866 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 17.9 t -84.49 -116.3 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.962 0 N-CA-C 108.444 -0.947 . . . . 0.0 108.444 179.501 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -110.37 54.63 0.54 Allowed Glycine 0 N--CA 1.475 1.265 0 N-CA-C 111.227 -0.749 . . . . 0.0 111.227 179.916 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 74.8 p -79.98 125.96 30.43 Favored 'General case' 0 C--O 1.221 -0.417 0 N-CA-C 108.969 -0.752 . . . . 0.0 108.969 178.378 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 41.9 t30 -66.6 100.42 0.67 Allowed 'General case' 0 N--CA 1.473 0.725 0 N-CA-C 108.576 -0.898 . . . . 0.0 108.576 178.704 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 66.6 mttm -96.85 120.34 37.01 Favored 'General case' 0 N--CA 1.483 1.182 0 N-CA-C 110.093 -0.336 . . . . 0.0 110.093 -179.157 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.58 -128.41 0.01 OUTLIER Glycine 0 CA--C 1.534 1.223 0 N-CA-C 110.525 -1.03 . . . . 0.0 110.525 178.779 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -126.05 133.86 51.59 Favored 'General case' 0 N--CA 1.48 1.052 0 N-CA-C 109.234 -0.654 . . . . 0.0 109.234 179.097 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 65.4 mt -83.21 137.81 20.34 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.538 0 N-CA-C 107.393 -1.336 . . . . 0.0 107.393 178.683 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 20.9 mt -129.44 129.25 66.95 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.976 0 O-C-N 123.495 0.497 . . . . 0.0 110.053 -178.424 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 60.43 79.05 0.13 Allowed Glycine 0 CA--C 1.525 0.685 0 CA-C-N 115.849 -0.614 . . . . 0.0 113.069 178.949 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.421 HD23 ' N ' ' A' ' 35' ' ' MET . 1.9 tt -110.94 119.48 39.21 Favored 'General case' 0 N--CA 1.477 0.915 0 N-CA-C 106.973 -1.492 . . . . 0.0 106.973 177.463 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 35' ' ' MET . . . . . 0.421 ' N ' HD23 ' A' ' 34' ' ' LEU . 8.6 ttt -154.91 161.08 41.54 Favored 'General case' 0 N--CA 1.468 0.443 0 N-CA-C 109.066 -0.716 . . . . 0.0 109.066 179.257 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 63.1 t -157.75 150.48 8.55 Favored 'Isoleucine or valine' 0 C--O 1.232 0.148 0 N-CA-C 106.897 -1.52 . . . . 0.0 106.897 -179.496 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.61 75.42 0.24 Allowed Glycine 0 C--N 1.315 -0.607 0 CA-C-N 115.671 -0.695 . . . . 0.0 111.777 178.201 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 168.83 -149.12 13.2 Favored Glycine 0 CA--C 1.519 0.3 0 N-CA-C 110.744 -0.943 . . . . 0.0 110.744 179.847 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 20.7 m -132.57 142.87 41.38 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.874 0 N-CA-C 109.598 -0.519 . . . . 0.0 109.598 179.658 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 21.2 t . . . . . 0 N--CA 1.467 0.399 0 CA-C-O 117.834 -1.079 . . . . 0.0 110.831 179.29 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' B' B ' 1' ' ' ASP . . . . . . . . . . . . . 9.2 m-20 . . . . . 0 N--CA 1.489 1.479 0 N-CA-C 109.124 -0.695 . . . . 0.0 109.124 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' B' B ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.68 132.83 49.75 Favored 'General case' 0 CA--C 1.538 0.483 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.204 -179.865 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 3' ' ' GLU . . . . . . . . . . . . . 41.4 tt0 -169.55 108.29 0.41 Allowed 'General case' 0 N--CA 1.471 0.589 0 N-CA-C 109.584 -0.525 . . . . 0.0 109.584 -179.125 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 78.9 m-85 -83.58 140.49 32.21 Favored 'General case' 0 N--CA 1.474 0.726 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 179.474 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 72.2 mtp180 -143.68 141.14 30.41 Favored 'General case' 0 N--CA 1.481 1.108 0 N-CA-C 109.121 -0.696 . . . . 0.0 109.121 -179.931 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 76.7 m80 -149.51 119.6 7.22 Favored 'General case' 0 N--CA 1.471 0.615 0 N-CA-C 108.841 -0.8 . . . . 0.0 108.841 179.122 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 7' ' ' ASP . . . . . . . . . . . . . 8.5 m-20 -68.09 150.2 48.69 Favored 'General case' 0 CA--C 1.53 0.19 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.281 -179.453 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 8' ' ' SER . . . . . . . . . . . . . 8.4 t -166.98 172.2 10.43 Favored 'General case' 0 N--CA 1.472 0.631 0 N-CA-C 109.537 -0.542 . . . . 0.0 109.537 178.557 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.5 23.38 2.36 Favored Glycine 0 N--CA 1.487 2.051 0 N-CA-C 112.159 -0.377 . . . . 0.0 112.159 179.371 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 41.9 p90 -56.78 128.16 35.22 Favored 'General case' 0 N--CA 1.471 0.616 0 N-CA-C 112.166 0.432 . . . . 0.0 112.166 -179.983 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 57.4 mt-10 -85.58 155.64 21.07 Favored 'General case' 0 N--CA 1.471 0.58 0 N-CA-C 109.297 -0.631 . . . . 0.0 109.297 178.555 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -153.88 128.68 1.46 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 N-CA-C 108.186 -1.042 . . . . 0.0 108.186 178.816 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 50.1 m-70 -134.57 146.75 49.93 Favored 'General case' 0 N--CA 1.489 1.513 0 CA-C-N 118.481 0.582 . . . . 0.0 111.219 -179.018 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 6.5 t60 -165.32 97.82 0.7 Allowed 'General case' 0 N--CA 1.481 1.108 0 CA-C-N 116.519 -0.309 . . . . 0.0 111.022 179.627 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 35.2 mt-30 -105.96 -172.89 2.17 Favored 'General case' 0 CA--C 1.504 -0.789 0 N-CA-C 108.407 -0.96 . . . . 0.0 108.407 179.949 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 16' ' ' LYS . . . . . 0.408 ' C ' HD12 ' B' ' 17' ' ' LEU . 88.6 tttt -169.14 96.35 0.34 Allowed 'General case' 0 CA--C 1.54 0.592 0 CA-C-N 115.193 -0.912 . . . . 0.0 109.447 178.76 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 17' ' ' LEU . . . . . 0.578 ' N ' HD12 ' B' ' 17' ' ' LEU . 4.8 mp -106.41 164.82 11.73 Favored 'General case' 0 N--CA 1.488 1.461 0 N-CA-C 108.575 -0.898 . . . . 0.0 108.575 179.968 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 58.6 t -141.55 119.26 8.53 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.355 0 CA-C-O 118.957 -0.544 . . . . 0.0 109.9 179.566 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 53.3 m-85 -70.53 159.09 34.94 Favored 'General case' 0 N--CA 1.479 0.982 0 N-CA-C 107.52 -1.289 . . . . 0.0 107.52 177.316 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 14.4 t80 -171.84 -57.33 0.02 OUTLIER 'General case' 0 N--CA 1.482 1.138 0 CA-C-O 122.228 1.013 . . . . 0.0 109.838 179.452 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -39.39 90.37 0.0 OUTLIER 'General case' 0 C--O 1.232 0.152 0 CA-C-N 114.09 -1.413 . . . . 0.0 112.874 -178.052 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 36.6 tt0 -66.42 158.03 30.43 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 115.058 -0.973 . . . . 0.0 110.56 179.133 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 67.6 m-20 -140.37 137.42 34.04 Favored 'General case' 0 N--CA 1.481 1.089 0 C-N-CA 122.993 0.517 . . . . 0.0 110.251 179.805 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 17.5 t -84.59 -116.55 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 1.016 0 N-CA-C 108.65 -0.87 . . . . 0.0 108.65 179.482 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -109.46 54.01 0.56 Allowed Glycine 0 N--CA 1.476 1.331 0 N-CA-C 111.189 -0.764 . . . . 0.0 111.189 179.878 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 74.2 p -79.7 126.04 30.42 Favored 'General case' 0 C--O 1.221 -0.405 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 178.386 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 42.3 t30 -66.89 100.19 0.7 Allowed 'General case' 0 N--CA 1.474 0.761 0 N-CA-C 108.673 -0.862 . . . . 0.0 108.673 178.565 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 66.8 mttm -96.68 120.47 37.06 Favored 'General case' 0 N--CA 1.483 1.186 0 N-CA-C 110.118 -0.327 . . . . 0.0 110.118 -179.142 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.68 -127.73 0.01 OUTLIER Glycine 0 CA--C 1.534 1.246 0 N-CA-C 110.538 -1.025 . . . . 0.0 110.538 178.755 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -126.83 133.62 50.72 Favored 'General case' 0 N--CA 1.481 1.104 0 N-CA-C 109.165 -0.68 . . . . 0.0 109.165 179.252 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 64.4 mt -82.96 137.97 20.11 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.452 0 N-CA-C 107.363 -1.347 . . . . 0.0 107.363 178.59 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 21.6 mt -129.72 129.19 66.26 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.971 0 O-C-N 123.546 0.528 . . . . 0.0 109.941 -178.42 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 60.4 78.76 0.14 Allowed Glycine 0 CA--C 1.524 0.63 0 CA-C-N 115.828 -0.624 . . . . 0.0 113.094 178.915 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 34' ' ' LEU . . . . . 0.417 HD23 ' N ' ' B' ' 35' ' ' MET . 1.9 tt -110.39 119.61 39.77 Favored 'General case' 0 N--CA 1.478 0.953 0 N-CA-C 106.975 -1.491 . . . . 0.0 106.975 177.351 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 35' ' ' MET . . . . . 0.417 ' N ' HD23 ' B' ' 34' ' ' LEU . 8.7 ttt -154.89 160.79 41.43 Favored 'General case' 0 N--CA 1.47 0.562 0 N-CA-C 108.97 -0.752 . . . . 0.0 108.97 179.283 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 63.4 t -157.64 150.31 8.81 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.136 0 N-CA-C 106.825 -1.546 . . . . 0.0 106.825 -179.511 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.54 75.73 0.23 Allowed Glycine 0 C--N 1.314 -0.669 0 CA-C-N 115.659 -0.701 . . . . 0.0 111.771 178.169 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 168.52 -149.09 13.32 Favored Glycine 0 CA--C 1.519 0.306 0 N-CA-C 110.704 -0.958 . . . . 0.0 110.704 179.879 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 20.7 m -132.52 142.91 41.32 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.907 0 N-CA-C 109.643 -0.503 . . . . 0.0 109.643 179.676 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 21.2 t . . . . . 0 N--CA 1.467 0.405 0 CA-C-O 117.812 -1.089 . . . . 0.0 110.848 179.292 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' C' C ' 1' ' ' ASP . . . . . . . . . . . . . 8.5 m-20 . . . . . 0 N--CA 1.487 1.419 0 N-CA-C 109.066 -0.716 . . . . 0.0 109.066 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' C' C ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.41 132.76 49.78 Favored 'General case' 0 CA--C 1.538 0.513 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.189 -179.935 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 3' ' ' GLU . . . . . . . . . . . . . 41.5 tt0 -169.56 108.38 0.41 Allowed 'General case' 0 N--CA 1.47 0.543 0 N-CA-C 109.588 -0.523 . . . . 0.0 109.588 -179.276 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 78.1 m-85 -83.65 140.42 32.19 Favored 'General case' 0 N--CA 1.474 0.737 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 179.433 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 72.4 mtp180 -143.61 141.07 30.46 Favored 'General case' 0 N--CA 1.482 1.136 0 N-CA-C 109.043 -0.725 . . . . 0.0 109.043 -179.857 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 76.5 m80 -149.47 119.64 7.26 Favored 'General case' 0 N--CA 1.47 0.571 0 N-CA-C 108.826 -0.805 . . . . 0.0 108.826 179.109 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 7' ' ' ASP . . . . . . . . . . . . . 7.6 m-20 -68.13 150.03 48.86 Favored 'General case' 0 CA--C 1.529 0.168 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.332 -179.381 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 8' ' ' SER . . . . . . . . . . . . . 8.5 t -166.71 172.73 10.27 Favored 'General case' 0 N--CA 1.471 0.618 0 N-CA-C 109.611 -0.514 . . . . 0.0 109.611 178.352 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.13 23.33 2.46 Favored Glycine 0 N--CA 1.487 2.042 0 N-CA-C 112.24 -0.344 . . . . 0.0 112.24 179.484 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 41.5 p90 -56.84 128.34 36.2 Favored 'General case' 0 N--CA 1.472 0.646 0 N-CA-C 112.088 0.403 . . . . 0.0 112.088 -179.896 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 57.5 mt-10 -85.79 155.27 21.08 Favored 'General case' 0 N--CA 1.47 0.556 0 N-CA-C 109.239 -0.652 . . . . 0.0 109.239 178.63 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -153.59 128.61 1.5 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 N-CA-C 108.181 -1.044 . . . . 0.0 108.181 178.853 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 49.5 m-70 -134.49 146.65 49.94 Favored 'General case' 0 N--CA 1.489 1.49 0 CA-C-N 118.541 0.609 . . . . 0.0 111.265 -179.105 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 6.4 t60 -165.15 98.04 0.72 Allowed 'General case' 0 N--CA 1.48 1.067 0 CA-C-N 116.572 -0.286 . . . . 0.0 111.085 179.596 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 35.1 mt-30 -106.36 -172.76 2.15 Favored 'General case' 0 CA--C 1.504 -0.807 0 N-CA-C 108.414 -0.958 . . . . 0.0 108.414 -179.99 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 16' ' ' LYS . . . . . 0.408 ' C ' HD12 ' C' ' 17' ' ' LEU . 88.7 tttt -169.18 96.45 0.34 Allowed 'General case' 0 CA--C 1.54 0.56 0 CA-C-N 115.12 -0.945 . . . . 0.0 109.451 178.751 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' C' C ' 17' ' ' LEU . . . . . 0.577 ' N ' HD12 ' C' ' 17' ' ' LEU . 4.8 mp -106.26 164.91 11.63 Favored 'General case' 0 N--CA 1.488 1.472 0 N-CA-C 108.584 -0.895 . . . . 0.0 108.584 179.968 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 58.5 t -141.71 118.94 7.76 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.341 0 CA-C-O 118.95 -0.548 . . . . 0.0 109.879 179.655 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 53.3 m-85 -70.25 159.0 34.84 Favored 'General case' 0 N--CA 1.478 0.956 0 N-CA-C 107.491 -1.3 . . . . 0.0 107.491 177.345 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 14.4 t80 -171.77 -57.41 0.02 OUTLIER 'General case' 0 N--CA 1.481 1.092 0 CA-C-O 122.183 0.992 . . . . 0.0 109.856 179.357 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -39.26 90.61 0.0 OUTLIER 'General case' 0 C--O 1.232 0.14 0 CA-C-N 114.125 -1.398 . . . . 0.0 112.849 -178.049 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 37.0 tt0 -66.74 158.05 31.21 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 115.096 -0.956 . . . . 0.0 110.513 179.219 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 67.2 m-20 -140.33 137.4 34.08 Favored 'General case' 0 N--CA 1.48 1.054 0 C-N-CA 122.944 0.498 . . . . 0.0 110.331 179.794 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 17.7 t -84.53 -116.42 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.967 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 179.588 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -109.86 54.35 0.55 Allowed Glycine 0 N--CA 1.475 1.275 0 N-CA-C 111.172 -0.771 . . . . 0.0 111.172 179.915 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 74.7 p -79.91 126.25 30.77 Favored 'General case' 0 C--O 1.222 -0.358 0 N-CA-C 109.004 -0.739 . . . . 0.0 109.004 178.417 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 42.6 t30 -66.99 100.37 0.73 Allowed 'General case' 0 N--CA 1.474 0.737 0 N-CA-C 108.682 -0.858 . . . . 0.0 108.682 178.606 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 66.8 mttm -96.86 120.09 36.54 Favored 'General case' 0 N--CA 1.484 1.251 0 N-CA-C 110.161 -0.311 . . . . 0.0 110.161 -179.138 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.34 -128.17 0.01 OUTLIER Glycine 0 CA--C 1.535 1.313 0 N-CA-C 110.529 -1.028 . . . . 0.0 110.529 178.76 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -126.33 133.75 51.29 Favored 'General case' 0 N--CA 1.48 1.073 0 N-CA-C 109.269 -0.641 . . . . 0.0 109.269 179.12 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 65.7 mt -83.06 137.82 20.35 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.525 0 N-CA-C 107.282 -1.377 . . . . 0.0 107.282 178.614 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 20.9 mt -129.59 128.81 66.27 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.935 0 O-C-N 123.545 0.528 . . . . 0.0 110.119 -178.507 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 60.84 78.55 0.15 Allowed Glycine 0 CA--C 1.524 0.654 0 CA-C-N 115.97 -0.559 . . . . 0.0 113.063 178.848 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 34' ' ' LEU . . . . . 0.413 HD23 ' N ' ' C' ' 35' ' ' MET . 1.9 tt -110.41 119.16 38.31 Favored 'General case' 0 N--CA 1.478 0.945 0 N-CA-C 107.021 -1.474 . . . . 0.0 107.021 177.463 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' C' C ' 35' ' ' MET . . . . . 0.413 ' N ' HD23 ' C' ' 34' ' ' LEU . 8.5 ttt -154.44 161.08 41.89 Favored 'General case' 0 N--CA 1.468 0.456 0 N-CA-C 108.976 -0.75 . . . . 0.0 108.976 179.356 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 63.4 t -158.03 150.13 8.42 Favored 'Isoleucine or valine' 0 C--O 1.232 0.158 0 N-CA-C 106.816 -1.55 . . . . 0.0 106.816 -179.393 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.68 75.54 0.24 Allowed Glycine 0 C--N 1.315 -0.635 0 CA-C-N 115.776 -0.647 . . . . 0.0 111.75 178.172 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 168.76 -148.95 12.95 Favored Glycine 0 CA--C 1.519 0.325 0 N-CA-C 110.639 -0.984 . . . . 0.0 110.639 179.88 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 20.1 m -132.79 142.7 41.67 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.875 0 N-CA-C 109.666 -0.494 . . . . 0.0 109.666 179.716 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 21.3 t . . . . . 0 N--CA 1.468 0.454 0 CA-C-O 117.726 -1.13 . . . . 0.0 110.718 179.244 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' D' D ' 1' ' ' ASP . . . . . . . . . . . . . 8.8 m-20 . . . . . 0 N--CA 1.49 1.543 0 N-CA-C 109.154 -0.684 . . . . 0.0 109.154 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' D' D ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.4 131.24 46.64 Favored 'General case' 0 CA--C 1.535 0.391 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.376 179.789 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' D' D ' 3' ' ' GLU . . . . . . . . . . . . . 41.0 tt0 -169.39 110.58 0.47 Allowed 'General case' 0 N--CA 1.47 0.533 0 N-CA-C 109.387 -0.597 . . . . 0.0 109.387 179.472 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 86.9 m-85 -87.04 148.2 25.38 Favored 'General case' 0 C--N 1.363 1.171 0 C-N-CA 118.526 -1.27 . . . . 0.0 108.275 179.768 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' D' D ' 5' ' ' ARG . . . . . . . . . . . . . 72.5 mtp180 -147.31 141.18 25.82 Favored 'General case' 0 N--CA 1.476 0.829 0 N-CA-C 108.896 -0.779 . . . . 0.0 108.896 179.757 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 77.1 m80 -149.22 123.43 9.53 Favored 'General case' 0 CA--C 1.539 0.527 0 N-CA-C 107.915 -1.143 . . . . 0.0 107.915 175.724 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' D' D ' 7' ' ' ASP . . . . . . . . . . . . . 5.6 m-20 -63.12 133.77 54.96 Favored 'General case' 0 C--N 1.319 -0.719 0 C-N-CA 127.188 2.195 . . . . 0.0 114.882 176.081 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' D' D ' 8' ' ' SER . . . . . . . . . . . . . 7.9 t -154.09 174.36 14.81 Favored 'General case' 0 N--CA 1.477 0.914 0 CA-C-N 118.751 0.705 . . . . 0.0 110.302 176.958 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 124.29 20.25 2.48 Favored Glycine 0 N--CA 1.483 1.787 0 N-CA-C 112.232 -0.347 . . . . 0.0 112.232 176.645 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 37.0 p90 -55.91 130.29 43.11 Favored 'General case' 0 CA--C 1.546 0.79 0 CA-C-O 121.07 0.462 . . . . 0.0 111.881 -177.494 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 57.3 mt-10 -85.71 152.83 22.76 Favored 'General case' 0 N--CA 1.474 0.759 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 177.681 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -149.38 129.97 4.45 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.455 0 N-CA-C 108.009 -1.108 . . . . 0.0 108.009 175.229 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 48.9 m-70 -129.74 149.7 51.38 Favored 'General case' 0 N--CA 1.482 1.128 0 CA-C-N 117.939 0.336 . . . . 0.0 111.503 176.727 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 6.6 t60 -164.81 104.66 0.8 Allowed 'General case' 0 N--CA 1.482 1.133 0 N-CA-C 109.539 -0.541 . . . . 0.0 109.539 173.203 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 35.2 mt-30 -109.32 -175.62 2.81 Favored 'General case' 0 CA--C 1.494 -1.18 0 N-CA-C 108.28 -1.007 . . . . 0.0 108.28 178.978 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' D' D ' 16' ' ' LYS . . . . . 0.453 ' C ' HD12 ' D' ' 17' ' ' LEU . 88.7 tttt -165.77 105.25 0.7 Allowed 'General case' 0 CA--C 1.538 0.504 0 N-CA-C 107.637 -1.246 . . . . 0.0 107.637 175.331 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' D' D ' 17' ' ' LEU . . . . . 0.522 ' N ' HD12 ' D' ' 17' ' ' LEU . 5.6 mp -113.2 163.2 15.07 Favored 'General case' 0 N--CA 1.488 1.454 0 N-CA-C 108.225 -1.028 . . . . 0.0 108.225 179.699 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 51.8 t -140.9 123.67 15.72 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.187 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 176.215 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 78.7 m-85 -62.43 151.2 37.84 Favored 'General case' 0 C--N 1.353 0.759 0 C-N-CA 124.726 1.21 . . . . 0.0 110.412 170.862 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 9.3 t80 -170.0 -66.64 0.02 OUTLIER 'General case' 0 N--CA 1.476 0.871 0 N-CA-C 107.81 -1.182 . . . . 0.0 107.81 -179.835 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -38.27 95.75 0.01 OUTLIER 'General case' 0 CA--C 1.535 0.39 0 CA-C-N 113.972 -1.467 . . . . 0.0 111.731 -174.603 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 37.2 tt0 -68.7 158.72 33.61 Favored 'General case' 0 N--CA 1.467 0.421 0 CA-C-N 113.36 -1.746 . . . . 0.0 110.243 178.65 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 67.8 m-20 -140.34 141.17 35.69 Favored 'General case' 0 N--CA 1.475 0.822 0 N-CA-C 109.517 -0.549 . . . . 0.0 109.517 178.585 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' D' D ' 24' ' ' VAL . . . . . . . . . . . . . 19.6 t -87.83 -119.62 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.486 1.368 0 N-CA-C 107.752 -1.203 . . . . 0.0 107.752 179.727 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . -113.31 61.85 0.32 Allowed Glycine 0 C--N 1.372 2.559 0 C-N-CA 118.005 -2.045 . . . . 0.0 109.313 178.81 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 90.9 p -70.35 121.44 17.69 Favored 'General case' 0 C--N 1.349 0.574 0 CA-C-O 116.647 -1.644 . . . . 0.0 112.016 169.276 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 43.7 t30 -61.36 101.67 0.18 Allowed 'General case' 0 N--CA 1.474 0.772 0 CA-C-N 121.558 1.981 . . . . 0.0 109.486 172.485 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 66.3 mttm -100.12 121.75 41.9 Favored 'General case' 0 N--CA 1.49 1.558 0 CA-C-N 119.64 1.109 . . . . 0.0 109.366 178.803 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -54.16 -130.2 0.0 OUTLIER Glycine 0 CA--C 1.529 0.961 0 CA-C-N 115.664 -0.698 . . . . 0.0 112.68 175.57 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -125.17 139.95 53.29 Favored 'General case' 0 C--N 1.373 1.614 0 N-CA-C 108.567 -0.901 . . . . 0.0 108.567 174.052 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 65.3 mt -84.13 140.29 16.35 Favored 'Isoleucine or valine' 0 C--O 1.239 0.506 0 N-CA-C 107.403 -1.332 . . . . 0.0 107.403 176.478 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 29.1 mt -131.89 132.95 61.51 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.017 0 N-CA-C 108.66 -0.866 . . . . 0.0 108.66 178.367 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.31 76.99 0.22 Allowed Glycine 0 C--O 1.248 0.994 0 CA-C-O 118.102 -1.388 . . . . 0.0 112.404 178.449 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' D' D ' 34' ' ' LEU . . . . . 0.406 HD23 ' N ' ' D' ' 35' ' ' MET . 2.4 tt -110.2 131.43 55.07 Favored 'General case' 0 C--N 1.372 1.562 0 N-CA-C 103.96 -2.607 . . . . 0.0 103.96 174.968 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' D' D ' 35' ' ' MET . . . . . 0.406 ' N ' HD23 ' D' ' 34' ' ' LEU . 8.3 ttt -156.85 166.7 32.63 Favored 'General case' 0 N--CA 1.471 0.594 0 N-CA-C 108.679 -0.86 . . . . 0.0 108.679 176.685 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 91.6 t -163.58 154.31 2.55 Favored 'Isoleucine or valine' 0 C--O 1.241 0.647 0 N-CA-C 105.545 -2.02 . . . . 0.0 105.545 175.379 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 61.39 66.51 2.61 Favored Glycine 0 N--CA 1.444 -0.782 0 C-N-CA 118.039 -2.029 . . . . 0.0 113.619 176.76 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 167.27 -148.39 13.05 Favored Glycine 0 N--CA 1.468 0.805 0 CA-C-O 118.163 -1.354 . . . . 0.0 111.859 -178.577 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 21.4 m -129.74 143.04 42.32 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.166 0 CA-C-N 118.896 1.348 . . . . 0.0 109.64 -179.944 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 18.8 t . . . . . 0 C--O 1.215 -0.745 0 N-CA-C 109.204 -0.665 . . . . 0.0 109.204 174.798 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' E' E ' 1' ' ' ASP . . . . . . . . . . . . . 8.5 m-20 . . . . . 0 N--CA 1.489 1.498 0 N-CA-C 109.225 -0.657 . . . . 0.0 109.225 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' E' E ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.46 131.18 46.4 Favored 'General case' 0 N--CA 1.468 0.443 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.371 179.927 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' E' E ' 3' ' ' GLU . . . . . . . . . . . . . 41.4 tt0 -168.83 108.53 0.48 Allowed 'General case' 0 N--CA 1.469 0.504 0 N-CA-C 109.978 -0.379 . . . . 0.0 109.978 -179.851 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 79.1 m-85 -84.5 140.69 31.29 Favored 'General case' 0 N--CA 1.476 0.829 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 179.434 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' E' E ' 5' ' ' ARG . . . . . . . . . . . . . 72.3 mtp180 -143.62 141.96 30.84 Favored 'General case' 0 N--CA 1.478 0.933 0 N-CA-C 109.392 -0.595 . . . . 0.0 109.392 179.893 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 76.8 m80 -150.37 118.23 6.24 Favored 'General case' 0 N--CA 1.473 0.692 0 N-CA-C 108.962 -0.755 . . . . 0.0 108.962 179.123 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' E' E ' 7' ' ' ASP . . . . . . . . . . . . . 7.5 m-20 -66.7 149.96 49.77 Favored 'General case' 0 N--CA 1.463 0.224 0 O-C-N 123.542 0.526 . . . . 0.0 111.639 -179.515 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' E' E ' 8' ' ' SER . . . . . . . . . . . . . 7.9 t -166.95 173.43 9.33 Favored 'General case' 0 N--CA 1.476 0.875 0 CA-C-N 115.965 -0.561 . . . . 0.0 109.549 178.003 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.85 23.59 2.23 Favored Glycine 0 N--CA 1.482 1.737 0 N-CA-C 111.908 -0.477 . . . . 0.0 111.908 179.163 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 38.2 p90 -56.64 127.49 31.65 Favored 'General case' 0 N--CA 1.473 0.676 0 N-CA-C 112.602 0.593 . . . . 0.0 112.602 -179.241 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 57.0 mt-10 -84.34 156.2 21.99 Favored 'General case' 0 N--CA 1.476 0.827 0 N-CA-C 109.482 -0.562 . . . . 0.0 109.482 178.045 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -155.62 127.9 1.03 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.512 0 N-CA-C 108.185 -1.042 . . . . 0.0 108.185 178.702 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 49.0 m-70 -135.08 144.81 47.4 Favored 'General case' 0 N--CA 1.48 1.073 0 CA-C-O 120.757 0.313 . . . . 0.0 111.38 -177.933 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 6.3 t60 -163.94 97.94 0.84 Allowed 'General case' 0 N--CA 1.487 1.379 0 CA-C-N 116.652 -0.249 . . . . 0.0 111.064 179.702 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 35.2 mt-30 -105.51 -172.45 2.1 Favored 'General case' 0 CA--C 1.502 -0.878 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 -179.951 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -169.45 96.56 0.32 Allowed 'General case' 0 CA--C 1.542 0.638 0 CA-C-N 115.018 -0.992 . . . . 0.0 109.402 178.658 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' E' E ' 17' ' ' LEU . . . . . 0.566 ' N ' HD12 ' E' ' 17' ' ' LEU . 4.8 mp -106.21 164.11 12.26 Favored 'General case' 0 N--CA 1.49 1.547 0 N-CA-C 109.233 -0.654 . . . . 0.0 109.233 -179.765 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 40.8 t -141.59 118.46 7.5 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 C-N-CA 122.563 0.345 . . . . 0.0 110.551 179.085 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 52.7 m-85 -69.45 156.54 38.69 Favored 'General case' 0 C--N 1.358 0.957 0 N-CA-C 107.397 -1.335 . . . . 0.0 107.397 176.696 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 12.7 t80 -173.28 -55.06 0.02 OUTLIER 'General case' 0 N--CA 1.485 1.299 0 CA-C-O 121.741 0.782 . . . . 0.0 110.368 179.472 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.23 89.1 0.0 OUTLIER 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 114.398 -1.274 . . . . 0.0 112.852 -179.009 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 37.0 tt0 -65.16 158.31 26.37 Favored 'General case' 0 N--CA 1.472 0.646 0 CA-C-N 114.876 -1.056 . . . . 0.0 110.698 179.604 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 66.1 m-20 -140.68 137.03 33.23 Favored 'General case' 0 N--CA 1.479 0.997 0 C-N-CA 122.853 0.461 . . . . 0.0 110.518 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 21.8 t -84.52 -115.5 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.066 0 N-CA-C 108.715 -0.846 . . . . 0.0 108.715 179.48 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . -110.09 54.38 0.55 Allowed Glycine 0 C--N 1.348 1.214 0 N-CA-C 111.362 -0.695 . . . . 0.0 111.362 -179.827 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 73.2 p -79.72 125.27 29.44 Favored 'General case' 0 N--CA 1.473 0.709 0 N-CA-C 109.34 -0.615 . . . . 0.0 109.34 178.059 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 45.3 t30 -66.27 99.88 0.58 Allowed 'General case' 0 N--CA 1.474 0.765 0 N-CA-C 108.063 -1.088 . . . . 0.0 108.063 178.386 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 65.9 mttm -96.99 119.45 35.5 Favored 'General case' 0 N--CA 1.485 1.293 0 N-CA-C 109.966 -0.383 . . . . 0.0 109.966 -178.744 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.28 -127.32 0.01 OUTLIER Glycine 0 CA--C 1.539 1.581 0 N-CA-C 110.988 -0.845 . . . . 0.0 110.988 178.724 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -126.9 133.2 50.73 Favored 'General case' 0 N--CA 1.481 1.102 0 N-CA-C 109.585 -0.524 . . . . 0.0 109.585 179.614 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 64.8 mt -82.38 138.17 19.88 Favored 'Isoleucine or valine' 0 C--O 1.236 0.35 0 N-CA-C 107.093 -1.447 . . . . 0.0 107.093 178.492 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 22.4 mt -129.3 129.49 67.35 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.858 0 N-CA-C 109.444 -0.576 . . . . 0.0 109.444 -179.426 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 60.65 80.27 0.1 Allowed Glycine 0 CA--C 1.523 0.554 0 CA-C-N 115.982 -0.554 . . . . 0.0 113.654 179.33 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 2.0 tt -111.98 118.99 36.99 Favored 'General case' 0 N--CA 1.479 0.992 0 N-CA-C 107.056 -1.461 . . . . 0.0 107.056 177.358 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 8.2 ttt -153.37 162.88 40.82 Favored 'General case' 0 C--O 1.209 -1.041 0 N-CA-C 108.696 -0.853 . . . . 0.0 108.696 179.202 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 78.0 t -159.65 150.27 6.46 Favored 'Isoleucine or valine' 0 C--O 1.236 0.351 0 N-CA-C 106.591 -1.633 . . . . 0.0 106.591 -179.748 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.53 74.97 0.27 Allowed Glycine 0 C--N 1.314 -0.656 0 CA-C-N 115.63 -0.714 . . . . 0.0 111.535 178.139 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 170.08 -148.14 11.44 Favored Glycine 0 C--O 1.222 -0.653 0 N-CA-C 111.248 -0.741 . . . . 0.0 111.248 -179.995 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 19.4 m -133.42 141.54 44.18 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.846 0 N-CA-C 109.188 -0.671 . . . . 0.0 109.188 179.498 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 19.0 t . . . . . 0 CA--C 1.535 0.372 0 CA-C-O 117.648 -1.168 . . . . 0.0 110.847 179.35 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' F' F ' 1' ' ' ASP . . . . . . . . . . . . . 9.0 m-20 . . . . . 0 N--CA 1.492 1.638 0 N-CA-C 109.131 -0.692 . . . . 0.0 109.131 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' F' F ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.67 131.38 46.78 Favored 'General case' 0 CA--C 1.535 0.386 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.402 179.792 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' F' F ' 3' ' ' GLU . . . . . . . . . . . . . 41.1 tt0 -169.15 108.65 0.45 Allowed 'General case' 0 N--CA 1.471 0.578 0 N-CA-C 109.907 -0.405 . . . . 0.0 109.907 -179.859 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 78.7 m-85 -84.61 140.59 31.26 Favored 'General case' 0 N--CA 1.475 0.798 0 O-C-N 122.031 -0.418 . . . . 0.0 109.895 179.347 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' F' F ' 5' ' ' ARG . . . . . . . . . . . . . 72.4 mtp180 -143.43 141.62 30.91 Favored 'General case' 0 N--CA 1.477 0.878 0 N-CA-C 109.38 -0.6 . . . . 0.0 109.38 179.895 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 76.8 m80 -150.12 117.87 6.21 Favored 'General case' 0 N--CA 1.473 0.714 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 179.207 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' F' F ' 7' ' ' ASP . . . . . . . . . . . . . 7.5 m-20 -66.5 150.42 48.98 Favored 'General case' 0 N--CA 1.461 0.106 0 O-C-N 123.468 0.48 . . . . 0.0 111.711 -179.447 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' F' F ' 8' ' ' SER . . . . . . . . . . . . . 7.8 t -167.53 172.9 9.09 Favored 'General case' 0 N--CA 1.476 0.847 0 CA-C-N 116.015 -0.539 . . . . 0.0 109.568 178.065 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 123.34 23.63 2.12 Favored Glycine 0 N--CA 1.481 1.637 0 N-CA-C 111.997 -0.441 . . . . 0.0 111.997 179.064 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 36.6 p90 -56.74 127.97 34.18 Favored 'General case' 0 CA--C 1.542 0.671 0 N-CA-C 112.599 0.592 . . . . 0.0 112.599 -179.217 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 57.2 mt-10 -84.41 156.37 21.84 Favored 'General case' 0 N--CA 1.475 0.813 0 N-CA-C 109.457 -0.571 . . . . 0.0 109.457 178.063 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -155.77 127.53 0.96 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.586 0 N-CA-C 108.189 -1.041 . . . . 0.0 108.189 178.637 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 50.3 m-70 -134.76 144.73 47.87 Favored 'General case' 0 N--CA 1.481 1.078 0 CA-C-O 120.748 0.309 . . . . 0.0 111.341 -177.819 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 6.3 t60 -164.11 98.13 0.83 Allowed 'General case' 0 N--CA 1.486 1.356 0 CA-C-N 116.707 -0.224 . . . . 0.0 111.169 179.674 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 35.2 mt-30 -106.09 -172.36 2.07 Favored 'General case' 0 CA--C 1.498 -1.05 0 N-CA-C 108.787 -0.82 . . . . 0.0 108.787 179.989 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -169.23 96.87 0.34 Allowed 'General case' 0 CA--C 1.54 0.584 0 CA-C-N 114.891 -1.05 . . . . 0.0 109.443 178.687 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' F' F ' 17' ' ' LEU . . . . . 0.565 ' N ' HD12 ' F' ' 17' ' ' LEU . 4.7 mp -106.27 164.1 12.29 Favored 'General case' 0 N--CA 1.489 1.48 0 N-CA-C 109.209 -0.663 . . . . 0.0 109.209 -179.842 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 41.3 t -141.69 118.74 7.6 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.457 0 C-N-CA 122.55 0.34 . . . . 0.0 110.473 179.098 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 53.2 m-85 -69.56 156.49 38.82 Favored 'General case' 0 C--N 1.358 0.949 0 N-CA-C 107.253 -1.388 . . . . 0.0 107.253 176.612 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 13.1 t80 -173.15 -55.48 0.02 OUTLIER 'General case' 0 N--CA 1.484 1.267 0 CA-C-O 121.735 0.778 . . . . 0.0 109.904 179.484 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.73 88.89 0.0 OUTLIER 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 114.428 -1.26 . . . . 0.0 112.95 -179.047 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 36.7 tt0 -65.16 158.2 26.65 Favored 'General case' 0 N--CA 1.47 0.567 0 CA-C-N 114.952 -1.022 . . . . 0.0 110.786 179.504 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 66.5 m-20 -140.84 137.32 33.18 Favored 'General case' 0 N--CA 1.478 0.949 0 C-N-CA 122.813 0.445 . . . . 0.0 110.58 179.994 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' F' F ' 24' ' ' VAL . . . . . . . . . . . . . 21.5 t -84.84 -115.98 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.09 0 N-CA-C 108.811 -0.811 . . . . 0.0 108.811 179.523 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -109.48 54.08 0.56 Allowed Glycine 0 N--CA 1.479 1.511 0 N-CA-C 111.24 -0.744 . . . . 0.0 111.24 -179.836 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 75.6 p -79.46 125.04 29.04 Favored 'General case' 0 N--CA 1.472 0.668 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 177.883 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 45.1 t30 -66.19 99.71 0.55 Allowed 'General case' 0 N--CA 1.472 0.672 0 N-CA-C 108.125 -1.065 . . . . 0.0 108.125 178.457 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 66.1 mttm -96.78 119.29 34.98 Favored 'General case' 0 N--CA 1.484 1.269 0 N-CA-C 110.056 -0.35 . . . . 0.0 110.056 -178.711 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.19 -127.51 0.01 OUTLIER Glycine 0 CA--C 1.54 1.623 0 N-CA-C 111.093 -0.803 . . . . 0.0 111.093 178.796 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -126.35 133.14 51.43 Favored 'General case' 0 N--CA 1.482 1.161 0 N-CA-C 109.577 -0.527 . . . . 0.0 109.577 179.612 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 65.4 mt -82.73 138.07 19.98 Favored 'Isoleucine or valine' 0 C--O 1.236 0.345 0 N-CA-C 106.958 -1.497 . . . . 0.0 106.958 178.497 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 23.5 mt -129.22 129.61 67.59 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.811 0 N-CA-C 109.381 -0.6 . . . . 0.0 109.381 -179.365 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 60.51 80.17 0.1 Allowed Glycine 0 CA--C 1.522 0.518 0 CA-C-N 115.986 -0.552 . . . . 0.0 113.618 179.271 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' F' F ' 34' ' ' LEU . . . . . 0.407 HD23 ' N ' ' F' ' 35' ' ' MET . 2.0 tt -111.89 119.28 38.0 Favored 'General case' 0 N--CA 1.479 0.991 0 N-CA-C 106.971 -1.492 . . . . 0.0 106.971 177.472 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' F' F ' 35' ' ' MET . . . . . 0.407 ' N ' HD23 ' F' ' 34' ' ' LEU . 8.5 ttt -153.93 162.97 40.8 Favored 'General case' 0 C--O 1.209 -1.075 0 N-CA-C 108.81 -0.811 . . . . 0.0 108.81 179.212 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 81.2 t -159.61 150.64 6.4 Favored 'Isoleucine or valine' 0 C--O 1.237 0.412 0 N-CA-C 106.713 -1.588 . . . . 0.0 106.713 -179.651 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.34 75.0 0.26 Allowed Glycine 0 C--N 1.314 -0.644 0 CA-C-N 115.662 -0.699 . . . . 0.0 111.483 178.089 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 170.1 -147.89 11.19 Favored Glycine 0 C--O 1.221 -0.668 0 N-CA-C 111.226 -0.75 . . . . 0.0 111.226 -179.993 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 19.6 m -133.77 141.42 44.17 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.884 0 N-CA-C 109.203 -0.666 . . . . 0.0 109.203 179.442 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 19.3 t . . . . . 0 CA--C 1.533 0.313 0 CA-C-O 117.605 -1.188 . . . . 0.0 110.868 179.365 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' G' G ' 1' ' ' ASP . . . . . . . . . . . . . 8.7 m-20 . . . . . 0 N--CA 1.491 1.608 0 N-CA-C 109.624 -0.509 . . . . 0.0 109.624 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' G' G ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.71 129.47 40.68 Favored 'General case' 0 N--CA 1.468 0.471 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.445 179.661 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' G' G ' 3' ' ' GLU . . . . . . . . . . . . . 40.7 tt0 -168.87 108.14 0.46 Allowed 'General case' 0 N--CA 1.469 0.512 0 N-CA-C 110.233 -0.284 . . . . 0.0 110.233 179.709 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 78.6 m-85 -84.87 140.19 31.33 Favored 'General case' 0 N--CA 1.476 0.836 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 179.227 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' G' G ' 5' ' ' ARG . . . . . . . . . . . . . 72.7 mtp180 -143.93 141.16 30.09 Favored 'General case' 0 N--CA 1.483 1.191 0 N-CA-C 109.282 -0.636 . . . . 0.0 109.282 -179.657 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 76.9 m80 -149.49 119.36 7.1 Favored 'General case' 0 N--CA 1.473 0.715 0 N-CA-C 109.05 -0.722 . . . . 0.0 109.05 179.116 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 8.0 m-20 -68.74 145.96 53.36 Favored 'General case' 0 CA--C 1.536 0.411 0 O-C-N 123.472 0.482 . . . . 0.0 111.942 -179.327 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' G' G ' 8' ' ' SER . . . . . . . . . . . . . 7.1 t -163.83 174.2 11.83 Favored 'General case' 0 N--CA 1.47 0.55 0 N-CA-C 109.443 -0.577 . . . . 0.0 109.443 178.171 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 123.06 23.34 2.23 Favored Glycine 0 N--CA 1.48 1.606 0 N-CA-C 111.643 -0.583 . . . . 0.0 111.643 178.89 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 40.8 p90 -56.86 127.86 33.82 Favored 'General case' 0 N--CA 1.473 0.68 0 N-CA-C 112.418 0.525 . . . . 0.0 112.418 -178.89 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 57.6 mt-10 -84.94 154.74 22.0 Favored 'General case' 0 N--CA 1.473 0.717 0 CA-C-O 121.054 0.454 . . . . 0.0 109.981 178.795 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -155.26 127.67 1.04 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.97 0 N-CA-C 108.246 -1.02 . . . . 0.0 108.246 178.847 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 51.6 m-70 -133.77 146.13 50.44 Favored 'General case' 0 N--CA 1.476 0.844 0 CA-C-N 115.443 -0.799 . . . . 0.0 111.09 -178.159 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 32.7 t-80 -165.57 97.74 0.68 Allowed 'General case' 0 N--CA 1.483 1.183 0 CA-C-N 116.511 -0.313 . . . . 0.0 110.656 179.123 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 35.8 mt-30 -105.7 -172.64 2.13 Favored 'General case' 0 CA--C 1.503 -0.862 0 N-CA-C 108.726 -0.842 . . . . 0.0 108.726 -179.849 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' G' G ' 16' ' ' LYS . . . . . 0.405 ' C ' HD12 ' G' ' 17' ' ' LEU . 88.5 tttt -169.2 97.07 0.35 Allowed 'General case' 0 CA--C 1.54 0.587 0 CA-C-N 115.0 -1.0 . . . . 0.0 109.444 178.629 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' G' G ' 17' ' ' LEU . . . . . 0.572 ' N ' HD12 ' G' ' 17' ' ' LEU . 5.4 mp -106.31 163.14 13.07 Favored 'General case' 0 N--CA 1.487 1.387 0 N-CA-C 109.427 -0.583 . . . . 0.0 109.427 -179.669 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 39.6 t -142.5 118.92 6.04 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.068 0 CA-C-O 120.886 0.374 . . . . 0.0 110.327 178.779 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 47.2 m-85 -69.79 150.32 47.0 Favored 'General case' 0 C--N 1.37 1.482 0 N-CA-C 107.357 -1.349 . . . . 0.0 107.357 176.737 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 10.7 t80 -170.73 -55.26 0.02 OUTLIER 'General case' 0 N--CA 1.486 1.359 0 CA-C-N 117.903 0.319 . . . . 0.0 110.356 -179.601 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.73 90.02 0.0 OUTLIER 'General case' 0 C--N 1.325 -0.477 0 C-N-CA 123.74 0.816 . . . . 0.0 112.574 -179.882 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 37.1 tt0 -65.54 159.3 24.87 Favored 'General case' 0 N--CA 1.468 0.462 0 CA-C-N 114.694 -1.139 . . . . 0.0 109.954 179.069 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 67.2 m-20 -141.23 137.35 32.51 Favored 'General case' 0 N--CA 1.476 0.873 0 C-N-CA 122.792 0.437 . . . . 0.0 109.993 179.962 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' G' G ' 24' ' ' VAL . . . . . . . . . . . . . 21.6 t -85.53 -115.41 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.99 0 N-CA-C 108.408 -0.96 . . . . 0.0 108.408 179.598 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -110.16 53.9 0.57 Allowed Glycine 0 N--CA 1.478 1.443 0 N-CA-C 111.612 -0.595 . . . . 0.0 111.612 -179.812 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 75.8 p -79.67 125.88 30.21 Favored 'General case' 0 N--CA 1.466 0.366 0 N-CA-C 109.119 -0.697 . . . . 0.0 109.119 178.026 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 43.5 t30 -66.87 100.5 0.73 Allowed 'General case' 0 CA--C 1.54 0.569 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 178.424 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 67.0 mttm -96.7 119.93 36.09 Favored 'General case' 0 N--CA 1.482 1.139 0 N-CA-C 110.085 -0.339 . . . . 0.0 110.085 -179.087 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.76 -125.52 0.01 OUTLIER Glycine 0 CA--C 1.533 1.21 0 N-CA-C 110.571 -1.012 . . . . 0.0 110.571 178.828 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -127.81 133.09 49.41 Favored 'General case' 0 N--CA 1.47 0.555 0 N-CA-C 109.579 -0.526 . . . . 0.0 109.579 179.684 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 68.2 mt -81.93 140.19 16.84 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.646 0 N-CA-C 107.22 -1.4 . . . . 0.0 107.22 178.475 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 27.6 mt -131.1 130.84 63.9 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 CA-C-N 119.057 0.844 . . . . 0.0 109.274 179.912 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 60.46 79.81 0.11 Allowed Glycine 0 CA--C 1.527 0.813 0 CA-C-N 116.269 -0.423 . . . . 0.0 113.127 179.273 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' G' G ' 34' ' ' LEU . . . . . 0.419 HD23 ' N ' ' G' ' 35' ' ' MET . 1.9 tt -111.87 120.29 41.46 Favored 'General case' 0 N--CA 1.479 1.011 0 N-CA-C 106.909 -1.515 . . . . 0.0 106.909 177.394 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' G' G ' 35' ' ' MET . . . . . 0.419 ' N ' HD23 ' G' ' 34' ' ' LEU . 8.4 ttt -155.35 163.08 40.58 Favored 'General case' 0 C--O 1.211 -0.945 0 N-CA-C 108.03 -1.1 . . . . 0.0 108.03 179.466 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 99.6 t -159.44 150.19 6.7 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 N-CA-C 106.295 -1.742 . . . . 0.0 106.295 -179.72 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.41 75.2 0.26 Allowed Glycine 0 C--N 1.312 -0.755 0 C-N-CA 121.093 -0.575 . . . . 0.0 111.956 177.801 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 168.51 -146.24 10.24 Favored Glycine 0 N--CA 1.47 0.928 0 N-CA-C 110.688 -0.965 . . . . 0.0 110.688 179.209 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 22.2 m -134.43 141.61 43.03 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.914 0 CA-C-N 117.039 0.42 . . . . 0.0 109.994 179.873 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 19.3 t . . . . . 0 N--CA 1.471 0.595 0 CA-C-O 117.678 -1.153 . . . . 0.0 110.914 179.541 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' H' H ' 1' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 . . . . . 0 N--CA 1.49 1.561 0 N-CA-C 109.654 -0.499 . . . . 0.0 109.654 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' H' H ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.79 129.26 39.7 Favored 'General case' 0 N--CA 1.468 0.442 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.453 179.578 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' H' H ' 3' ' ' GLU . . . . . . . . . . . . . 40.7 tt0 -168.6 108.4 0.5 Allowed 'General case' 0 N--CA 1.47 0.53 0 N-CA-C 110.146 -0.316 . . . . 0.0 110.146 179.775 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 79.4 m-85 -84.93 140.33 31.17 Favored 'General case' 0 N--CA 1.474 0.757 0 N-CA-C 109.662 -0.496 . . . . 0.0 109.662 179.233 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' H' H ' 5' ' ' ARG . . . . . . . . . . . . . 72.6 mtp180 -144.1 140.95 29.75 Favored 'General case' 0 N--CA 1.482 1.149 0 N-CA-C 109.219 -0.66 . . . . 0.0 109.219 -179.608 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 76.9 m80 -149.35 119.21 7.09 Favored 'General case' 0 N--CA 1.473 0.721 0 N-CA-C 109.076 -0.712 . . . . 0.0 109.076 179.07 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -68.33 145.87 53.79 Favored 'General case' 0 N--CA 1.468 0.431 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.951 -179.413 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' H' H ' 8' ' ' SER . . . . . . . . . . . . . 8.2 t -163.84 173.85 12.25 Favored 'General case' 0 N--CA 1.469 0.508 0 N-CA-C 109.373 -0.602 . . . . 0.0 109.373 178.321 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.89 23.09 2.31 Favored Glycine 0 N--CA 1.48 1.632 0 N-CA-C 111.828 -0.509 . . . . 0.0 111.828 179.125 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 40.4 p90 -56.64 127.81 33.26 Favored 'General case' 0 N--CA 1.474 0.735 0 N-CA-C 112.402 0.519 . . . . 0.0 112.402 -178.996 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 57.7 mt-10 -84.74 155.28 21.95 Favored 'General case' 0 N--CA 1.475 0.806 0 CA-C-O 121.121 0.486 . . . . 0.0 109.917 178.791 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -155.78 127.62 0.97 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.971 0 N-CA-C 108.263 -1.014 . . . . 0.0 108.263 178.847 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 51.3 m-70 -133.79 146.08 50.37 Favored 'General case' 0 N--CA 1.476 0.847 0 CA-C-N 115.423 -0.808 . . . . 0.0 111.239 -178.197 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 6.4 t60 -165.55 97.75 0.68 Allowed 'General case' 0 N--CA 1.482 1.146 0 CA-C-N 116.582 -0.281 . . . . 0.0 110.673 179.159 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 35.3 mt-30 -105.68 -173.04 2.21 Favored 'General case' 0 CA--C 1.501 -0.934 0 N-CA-C 108.549 -0.908 . . . . 0.0 108.549 -179.848 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' H' H ' 16' ' ' LYS . . . . . 0.404 ' C ' HD12 ' H' ' 17' ' ' LEU . 88.5 tttt -169.08 96.74 0.35 Allowed 'General case' 0 CA--C 1.54 0.562 0 CA-C-N 114.941 -1.027 . . . . 0.0 109.276 178.775 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' H' H ' 17' ' ' LEU . . . . . 0.57 ' N ' HD12 ' H' ' 17' ' ' LEU . 5.4 mp -106.21 163.29 12.92 Favored 'General case' 0 N--CA 1.487 1.382 0 N-CA-C 109.349 -0.612 . . . . 0.0 109.349 -179.553 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 40.1 t -142.63 118.48 5.44 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.037 0 CA-C-O 120.929 0.395 . . . . 0.0 110.479 178.895 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 48.0 m-85 -69.57 150.72 46.8 Favored 'General case' 0 C--N 1.37 1.483 0 N-CA-C 107.386 -1.338 . . . . 0.0 107.386 176.686 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 11.6 t80 -171.99 -54.66 0.02 OUTLIER 'General case' 0 N--CA 1.485 1.293 0 CA-C-N 117.837 0.289 . . . . 0.0 110.32 -179.537 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.94 90.39 0.0 OUTLIER 'General case' 0 CA--C 1.535 0.371 0 C-N-CA 123.685 0.794 . . . . 0.0 112.299 -179.974 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 37.2 tt0 -65.86 159.07 26.26 Favored 'General case' 0 N--CA 1.469 0.506 0 CA-C-N 114.784 -1.098 . . . . 0.0 110.006 179.254 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 67.0 m-20 -140.99 137.46 33.03 Favored 'General case' 0 N--CA 1.477 0.877 0 C-N-CA 122.845 0.458 . . . . 0.0 110.098 179.884 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' H' H ' 24' ' ' VAL . . . . . . . . . . . . . 21.4 t -85.8 -115.59 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.991 0 N-CA-C 108.531 -0.915 . . . . 0.0 108.531 179.601 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . -109.57 53.88 0.57 Allowed Glycine 0 N--CA 1.481 1.651 0 N-CA-C 111.379 -0.688 . . . . 0.0 111.379 -179.813 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 75.8 p -79.75 125.75 30.07 Favored 'General case' 0 N--CA 1.467 0.386 0 N-CA-C 108.958 -0.756 . . . . 0.0 108.958 178.034 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 43.5 t30 -66.95 100.59 0.75 Allowed 'General case' 0 N--CA 1.471 0.605 0 N-CA-C 108.352 -0.981 . . . . 0.0 108.352 178.51 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 66.6 mttm -96.79 119.6 35.57 Favored 'General case' 0 N--CA 1.483 1.189 0 N-CA-C 110.097 -0.334 . . . . 0.0 110.097 -179.076 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.41 -125.18 0.01 OUTLIER Glycine 0 CA--C 1.534 1.267 0 N-CA-C 110.738 -0.945 . . . . 0.0 110.738 178.71 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.11 132.81 48.95 Favored 'General case' 0 N--CA 1.47 0.569 0 N-CA-C 109.66 -0.496 . . . . 0.0 109.66 179.839 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 68.7 mt -81.95 139.96 17.18 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.587 0 N-CA-C 107.11 -1.441 . . . . 0.0 107.11 178.525 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 28.0 mt -130.98 130.75 64.17 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.417 0 CA-C-N 118.912 0.778 . . . . 0.0 109.273 -179.978 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 60.48 79.7 0.11 Allowed Glycine 0 CA--C 1.526 0.742 0 CA-C-N 116.301 -0.409 . . . . 0.0 113.126 179.231 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' H' H ' 34' ' ' LEU . . . . . 0.409 HD23 ' N ' ' H' ' 35' ' ' MET . 1.9 tt -111.84 120.05 40.64 Favored 'General case' 0 N--CA 1.479 1.018 0 N-CA-C 106.889 -1.523 . . . . 0.0 106.889 177.42 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' H' H ' 35' ' ' MET . . . . . 0.409 ' N ' HD23 ' H' ' 34' ' ' LEU . 8.5 ttt -154.97 163.18 40.67 Favored 'General case' 0 N--CA 1.479 0.982 0 N-CA-C 107.958 -1.127 . . . . 0.0 107.958 179.505 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 93.6 t -159.78 150.43 6.29 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.254 0 N-CA-C 106.275 -1.75 . . . . 0.0 106.275 -179.735 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.15 75.13 0.26 Allowed Glycine 0 C--N 1.313 -0.731 0 CA-C-N 115.942 -0.572 . . . . 0.0 111.922 177.959 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 168.42 -146.51 10.49 Favored Glycine 0 N--CA 1.471 0.992 0 N-CA-C 110.632 -0.987 . . . . 0.0 110.632 179.273 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 22.3 m -134.23 141.85 42.55 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.924 0 CA-C-N 116.977 0.389 . . . . 0.0 109.998 179.976 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 19.4 t . . . . . 0 N--CA 1.47 0.543 0 CA-C-O 117.768 -1.111 . . . . 0.0 110.918 179.489 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' I' I ' 1' ' ' ASP . . . . . . . . . . . . . 8.8 m-20 . . . . . 0 N--CA 1.491 1.606 0 N-CA-C 109.608 -0.516 . . . . 0.0 109.608 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' I' I ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.93 129.39 40.19 Favored 'General case' 0 N--CA 1.468 0.472 0 CA-C-N 115.903 -0.589 . . . . 0.0 110.381 179.669 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' I' I ' 3' ' ' GLU . . . . . . . . . . . . . 40.5 tt0 -168.76 107.98 0.47 Allowed 'General case' 0 N--CA 1.47 0.552 0 N-CA-C 110.221 -0.288 . . . . 0.0 110.221 179.765 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 78.3 m-85 -84.5 140.81 31.2 Favored 'General case' 0 N--CA 1.474 0.745 0 N-CA-C 109.651 -0.5 . . . . 0.0 109.651 179.253 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' I' I ' 5' ' ' ARG . . . . . . . . . . . . . 72.7 mtp180 -144.49 140.95 29.21 Favored 'General case' 0 N--CA 1.482 1.158 0 N-CA-C 109.232 -0.655 . . . . 0.0 109.232 -179.619 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 76.9 m80 -149.31 118.93 6.97 Favored 'General case' 0 N--CA 1.474 0.753 0 N-CA-C 109.11 -0.7 . . . . 0.0 109.11 179.095 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 8.0 m-20 -68.1 145.87 54.0 Favored 'General case' 0 N--CA 1.467 0.385 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.82 -179.361 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' I' I ' 8' ' ' SER . . . . . . . . . . . . . 8.3 t -163.91 173.7 12.36 Favored 'General case' 0 N--CA 1.47 0.555 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 178.34 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.97 23.32 2.25 Favored Glycine 0 N--CA 1.481 1.657 0 N-CA-C 111.845 -0.502 . . . . 0.0 111.845 179.156 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 41.0 p90 -56.81 128.03 34.61 Favored 'General case' 0 N--CA 1.473 0.683 0 N-CA-C 112.437 0.532 . . . . 0.0 112.437 -178.99 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 57.9 mt-10 -84.86 155.19 21.85 Favored 'General case' 0 N--CA 1.474 0.757 0 CA-C-O 121.074 0.464 . . . . 0.0 109.976 178.755 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -155.7 127.65 0.99 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.977 0 N-CA-C 108.236 -1.024 . . . . 0.0 108.236 178.777 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 51.2 m-70 -133.68 146.41 50.81 Favored 'General case' 0 N--CA 1.476 0.849 0 CA-C-N 115.372 -0.831 . . . . 0.0 111.119 -178.162 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 33.6 t-80 -165.99 97.89 0.63 Allowed 'General case' 0 N--CA 1.482 1.164 0 CA-C-N 116.556 -0.293 . . . . 0.0 110.696 179.026 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 35.3 mt-30 -105.85 -172.75 2.15 Favored 'General case' 0 CA--C 1.5 -0.948 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 -179.825 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' I' I ' 16' ' ' LYS . . . . . 0.403 ' C ' HD12 ' I' ' 17' ' ' LEU . 88.6 tttt -169.18 96.82 0.34 Allowed 'General case' 0 CA--C 1.539 0.543 0 CA-C-N 114.901 -1.045 . . . . 0.0 109.355 178.769 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' I' I ' 17' ' ' LEU . . . . . 0.566 ' N ' HD12 ' I' ' 17' ' ' LEU . 5.4 mp -106.19 163.15 13.03 Favored 'General case' 0 N--CA 1.488 1.43 0 N-CA-C 109.301 -0.629 . . . . 0.0 109.301 -179.555 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 40.1 t -142.48 118.37 5.66 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.015 0 CA-C-O 120.901 0.382 . . . . 0.0 110.387 178.933 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 48.6 m-85 -69.43 151.02 46.61 Favored 'General case' 0 C--N 1.372 1.553 0 N-CA-C 107.414 -1.328 . . . . 0.0 107.414 176.654 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 11.7 t80 -172.19 -54.98 0.02 OUTLIER 'General case' 0 N--CA 1.483 1.225 0 CA-C-N 117.822 0.283 . . . . 0.0 110.346 -179.587 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.81 90.29 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.465 0 C-N-CA 123.712 0.805 . . . . 0.0 112.327 -179.984 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 37.3 tt0 -65.68 159.15 25.57 Favored 'General case' 0 N--CA 1.468 0.464 0 CA-C-N 114.686 -1.143 . . . . 0.0 110.023 179.304 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 66.6 m-20 -140.92 137.21 32.97 Favored 'General case' 0 N--CA 1.476 0.834 0 C-N-CA 122.906 0.482 . . . . 0.0 110.122 179.835 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' I' I ' 24' ' ' VAL . . . . . . . . . . . . . 21.5 t -85.47 -115.35 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.034 0 N-CA-C 108.479 -0.934 . . . . 0.0 108.479 179.58 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . -109.84 53.44 0.59 Allowed Glycine 0 N--CA 1.48 1.584 0 N-CA-C 111.495 -0.642 . . . . 0.0 111.495 -179.761 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 77.0 p -79.29 125.79 29.95 Favored 'General case' 0 N--CA 1.467 0.388 0 N-CA-C 109.131 -0.692 . . . . 0.0 109.131 177.992 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 43.2 t30 -67.14 100.54 0.78 Allowed 'General case' 0 N--CA 1.471 0.625 0 N-CA-C 108.395 -0.965 . . . . 0.0 108.395 178.525 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 66.8 mttm -96.71 120.05 36.32 Favored 'General case' 0 N--CA 1.483 1.221 0 N-CA-C 110.129 -0.323 . . . . 0.0 110.129 -179.11 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.7 -125.36 0.01 OUTLIER Glycine 0 CA--C 1.535 1.319 0 N-CA-C 110.688 -0.965 . . . . 0.0 110.688 178.793 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -127.78 132.82 49.47 Favored 'General case' 0 N--CA 1.473 0.682 0 C-N-CA 123.023 0.529 . . . . 0.0 109.653 179.633 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 68.2 mt -81.92 139.91 17.24 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.582 0 N-CA-C 107.13 -1.433 . . . . 0.0 107.13 178.479 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 27.2 mt -130.99 130.87 64.22 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.373 0 CA-C-N 118.977 0.808 . . . . 0.0 109.282 -179.938 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 60.38 79.68 0.11 Allowed Glycine 0 CA--C 1.527 0.805 0 CA-C-N 116.285 -0.416 . . . . 0.0 113.079 179.261 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' I' I ' 34' ' ' LEU . . . . . 0.412 HD23 ' N ' ' I' ' 35' ' ' MET . 1.9 tt -111.9 120.07 40.67 Favored 'General case' 0 N--CA 1.48 1.038 0 N-CA-C 106.823 -1.547 . . . . 0.0 106.823 177.432 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' I' I ' 35' ' ' MET . . . . . 0.412 ' N ' HD23 ' I' ' 34' ' ' LEU . 8.5 ttt -154.9 163.28 40.51 Favored 'General case' 0 C--O 1.211 -0.958 0 N-CA-C 108.005 -1.109 . . . . 0.0 108.005 179.461 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 98.7 t -159.72 150.41 6.35 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.257 0 N-CA-C 106.273 -1.751 . . . . 0.0 106.273 -179.739 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.08 75.23 0.26 Allowed Glycine 0 C--N 1.315 -0.631 0 CA-C-N 115.893 -0.594 . . . . 0.0 111.951 177.907 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 168.46 -146.33 10.33 Favored Glycine 0 N--CA 1.469 0.886 0 N-CA-C 110.643 -0.983 . . . . 0.0 110.643 179.287 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 22.3 m -134.39 141.72 42.75 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.856 0 CA-C-N 116.985 0.392 . . . . 0.0 110.038 179.928 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 18.9 t . . . . . 0 N--CA 1.469 0.488 0 CA-C-O 117.765 -1.112 . . . . 0.0 110.92 179.434 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' ASP . . . . . 0.446 ' H1 ' ' CG ' ' D' ' 1' ' ' ASP . 65.9 m-20 . . . . . 0 N--CA 1.49 1.555 0 N-CA-C 108.808 -0.812 . . . . 0.0 108.808 . . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.31 133.2 50.9 Favored 'General case' 0 CA--C 1.539 0.537 0 CA-C-N 116.528 -0.306 . . . . 0.0 110.287 -179.743 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.403 ' CD ' HH21 ' A' ' 5' ' ' ARG . 43.2 tt0 -169.09 105.91 0.41 Allowed 'General case' 0 N--CA 1.472 0.646 0 N-CA-C 109.873 -0.417 . . . . 0.0 109.873 -179.197 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 55.1 m-85 -85.12 147.54 26.58 Favored 'General case' 0 N--CA 1.475 0.804 0 N-CA-C 110.241 -0.281 . . . . 0.0 110.241 179.573 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' ARG . . . . . 0.403 HH21 ' CD ' ' A' ' 3' ' ' GLU . 99.2 mtt180 -144.33 142.14 30.2 Favored 'General case' 0 N--CA 1.482 1.131 0 N-CA-C 110.01 -0.366 . . . . 0.0 110.01 179.713 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 41.7 t-80 -152.43 119.69 5.92 Favored 'General case' 0 N--CA 1.472 0.674 0 N-CA-C 109.23 -0.655 . . . . 0.0 109.23 179.098 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 7' ' ' ASP . . . . . 0.507 ' O ' ' OG ' ' D' ' 8' ' ' SER . 4.6 m-20 -69.02 148.68 49.73 Favored 'General case' 0 CA--C 1.535 0.383 0 CA-C-N 116.341 -0.39 . . . . 0.0 110.412 179.893 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 54.0 p -167.65 -173.58 2.21 Favored 'General case' 0 N--CA 1.481 1.084 0 CA-C-O 120.92 0.391 . . . . 0.0 110.698 179.217 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.26 47.45 1.32 Allowed Glycine 0 N--CA 1.482 1.742 0 CA-C-N 116.036 -0.529 . . . . 0.0 111.905 -179.941 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 49.7 p90 -66.03 133.03 49.93 Favored 'General case' 0 N--CA 1.473 0.695 0 CA-C-O 120.74 0.305 . . . . 0.0 111.618 179.814 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 84.2 mt-10 -91.82 152.19 20.24 Favored 'General case' 0 N--CA 1.477 0.91 0 N-CA-C 109.662 -0.496 . . . . 0.0 109.662 178.443 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -152.67 128.31 1.68 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.593 0 N-CA-C 107.884 -1.154 . . . . 0.0 107.884 178.074 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 43.7 m-70 -135.9 148.5 48.6 Favored 'General case' 0 N--CA 1.493 1.681 0 CA-C-N 119.025 0.829 . . . . 0.0 111.292 -178.986 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 6.6 t60 -164.82 98.47 0.76 Allowed 'General case' 0 N--CA 1.48 1.053 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.823 179.396 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -91.85 -177.38 4.72 Favored 'General case' 0 CA--C 1.514 -0.432 0 N-CA-C 108.851 -0.796 . . . . 0.0 108.851 -179.933 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -172.06 93.74 0.14 Allowed 'General case' 0 N--CA 1.469 0.489 0 CA-C-N 114.659 -1.155 . . . . 0.0 108.566 177.94 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 6.3 mp -124.77 155.98 38.46 Favored 'General case' 0 N--CA 1.497 1.896 0 CA-C-O 121.744 0.783 . . . . 0.0 110.989 -178.417 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 61.0 t -111.63 124.46 68.4 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.024 0 CA-C-O 117.825 -1.083 . . . . 0.0 108.469 177.77 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 29.4 m-85 -124.27 143.78 50.35 Favored 'General case' 0 N--CA 1.498 1.946 0 CA-C-N 120.177 1.353 . . . . 0.0 110.268 179.227 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 67.2 m-85 52.49 68.33 0.84 Allowed 'General case' 0 N--CA 1.472 0.637 0 CA-C-N 116.367 -0.378 . . . . 0.0 111.875 178.458 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -78.14 -84.62 0.08 Allowed 'General case' 0 C--N 1.361 1.097 0 CA-C-N 115.463 -0.79 . . . . 0.0 110.173 -179.829 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 41.2 tt0 -123.07 96.9 5.19 Favored 'General case' 0 C--N 1.323 -0.547 0 N-CA-C 108.089 -1.078 . . . . 0.0 108.089 179.7 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 4.1 p30 -158.97 143.67 15.78 Favored 'General case' 0 N--CA 1.484 1.261 0 O-C-N 122.313 -0.242 . . . . 0.0 111.102 179.092 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 61.6 t -61.38 162.66 1.36 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.784 0 N-CA-C 107.968 -1.123 . . . . 0.0 107.968 177.206 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.494 ' H ' ' HB ' ' D' ' 24' ' ' VAL . . . -117.71 48.96 0.89 Allowed Glycine 0 N--CA 1.476 1.328 0 N-CA-C 111.81 -0.516 . . . . 0.0 111.81 -179.377 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -61.84 -169.05 0.02 OUTLIER 'General case' 0 N--CA 1.469 0.522 0 O-C-N 123.722 0.307 . . . . 0.0 110.404 179.56 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 28.3 t-20 -69.52 80.35 0.4 Allowed 'General case' 0 N--CA 1.464 0.271 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.132 179.717 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -79.8 154.71 28.28 Favored 'General case' 0 N--CA 1.473 0.677 0 N-CA-C 108.883 -0.784 . . . . 0.0 108.883 179.059 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.0 -144.07 0.02 OUTLIER Glycine 0 CA--C 1.526 0.748 0 N-CA-C 109.749 -1.34 . . . . 0.0 109.749 178.496 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -136.89 120.3 16.97 Favored 'General case' 0 N--CA 1.479 0.976 0 CA-C-N 117.247 0.523 . . . . 0.0 109.755 179.38 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 69.5 mt -80.39 124.73 38.67 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.528 0 N-CA-C 106.741 -1.577 . . . . 0.0 106.741 178.339 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 32' ' ' ILE . . . . . 0.413 ' C ' ' H ' ' A' ' 34' ' ' LEU . 41.5 pt -151.34 162.71 2.93 Favored 'Isoleucine or valine' 0 C--N 1.358 0.958 0 CA-C-N 115.741 -0.663 . . . . 0.0 111.552 -178.805 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 64.88 0.44 5.24 Favored Glycine 0 CA--C 1.524 0.603 0 N-CA-C 111.008 -0.837 . . . . 0.0 111.008 179.611 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.413 ' H ' ' C ' ' A' ' 32' ' ' ILE . 7.8 tt -79.7 148.46 31.55 Favored 'General case' 0 N--CA 1.466 0.346 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 -179.989 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 28.6 ttt -159.89 140.68 12.21 Favored 'General case' 0 N--CA 1.473 0.68 0 N-CA-C 108.816 -0.809 . . . . 0.0 108.816 178.993 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 27.6 m -156.22 162.57 1.64 Allowed 'Isoleucine or valine' 0 C--N 1.347 0.495 0 N-CA-C 108.259 -1.015 . . . . 0.0 108.259 -179.756 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.63 67.55 2.15 Favored Glycine 0 C--N 1.308 -1.026 0 CA-C-N 115.773 -0.649 . . . . 0.0 111.967 178.6 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.91 172.49 17.98 Favored Glycine 0 N--CA 1.475 1.242 0 N-CA-C 110.649 -0.98 . . . . 0.0 110.649 179.28 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.56 ' H ' HG12 ' D' ' 39' ' ' VAL . 34.9 m -125.16 164.42 24.18 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.943 0 C-N-CA 123.549 0.739 . . . . 0.0 110.803 -179.546 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 25.0 t . . . . . 0 C--O 1.221 -0.437 0 CA-C-O 118.382 -0.818 . . . . 0.0 110.766 179.333 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' B' B ' 1' ' ' ASP . . . . . . . . . . . . . 65.7 m-20 . . . . . 0 N--CA 1.488 1.469 0 N-CA-C 108.989 -0.745 . . . . 0.0 108.989 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' B' B ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.61 133.1 50.45 Favored 'General case' 0 CA--C 1.539 0.552 0 CA-C-N 116.513 -0.312 . . . . 0.0 110.178 -179.752 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 3' ' ' GLU . . . . . . . . . . . . . 42.6 tt0 -169.1 105.73 0.4 Allowed 'General case' 0 N--CA 1.472 0.671 0 N-CA-C 109.971 -0.381 . . . . 0.0 109.971 -179.188 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 55.6 m-85 -84.89 147.49 26.74 Favored 'General case' 0 N--CA 1.476 0.843 0 N-CA-C 110.272 -0.269 . . . . 0.0 110.272 179.439 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 -144.22 142.09 30.28 Favored 'General case' 0 N--CA 1.481 1.124 0 N-CA-C 109.989 -0.375 . . . . 0.0 109.989 179.687 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 41.1 t-80 -152.34 119.46 5.87 Favored 'General case' 0 N--CA 1.473 0.686 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 179.146 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 7' ' ' ASP . . . . . 0.467 ' O ' ' OG ' ' E' ' 8' ' ' SER . 4.4 m-20 -69.01 148.31 50.29 Favored 'General case' 0 CA--C 1.536 0.436 0 CA-C-N 116.435 -0.348 . . . . 0.0 110.465 179.914 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 8' ' ' SER . . . . . . . . . . . . . 54.0 p -167.26 -173.35 2.25 Favored 'General case' 0 N--CA 1.48 1.048 0 CA-C-O 120.873 0.368 . . . . 0.0 110.645 179.214 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.08 47.37 1.35 Allowed Glycine 0 N--CA 1.482 1.762 0 CA-C-N 115.982 -0.554 . . . . 0.0 111.927 179.896 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 49.3 p90 -65.93 133.73 51.49 Favored 'General case' 0 N--CA 1.473 0.679 0 CA-C-O 120.751 0.31 . . . . 0.0 111.714 179.699 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 83.5 mt-10 -92.39 152.51 19.7 Favored 'General case' 0 N--CA 1.476 0.839 0 N-CA-C 109.666 -0.494 . . . . 0.0 109.666 178.398 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -153.14 128.42 1.56 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.609 0 N-CA-C 107.776 -1.194 . . . . 0.0 107.776 178.261 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 43.6 m-70 -136.27 148.35 47.96 Favored 'General case' 0 N--CA 1.492 1.655 0 CA-C-N 118.864 0.756 . . . . 0.0 111.37 -179.033 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 6.7 t60 -164.67 98.06 0.77 Allowed 'General case' 0 N--CA 1.481 1.093 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.694 179.512 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 5.1 pt20 -91.14 -176.86 4.73 Favored 'General case' 0 CA--C 1.515 -0.386 0 N-CA-C 108.74 -0.837 . . . . 0.0 108.74 -179.984 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -172.7 93.77 0.12 Allowed 'General case' 0 N--CA 1.469 0.505 0 CA-C-N 114.711 -1.131 . . . . 0.0 108.405 177.807 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 6.3 mp -124.71 156.1 38.18 Favored 'General case' 0 N--CA 1.497 1.918 0 CA-C-O 121.77 0.795 . . . . 0.0 110.985 -178.465 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 62.0 t -111.85 125.14 69.13 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.007 0 N-CA-C 108.297 -1.001 . . . . 0.0 108.297 177.645 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 29.6 m-85 -124.87 143.76 50.67 Favored 'General case' 0 N--CA 1.495 1.803 0 CA-C-N 119.813 1.188 . . . . 0.0 110.161 179.433 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 68.2 m-85 51.45 68.41 0.8 Allowed 'General case' 0 N--CA 1.468 0.452 0 CA-C-O 121.199 0.524 . . . . 0.0 111.994 178.48 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -78.09 -84.28 0.08 Allowed 'General case' 0 C--N 1.356 0.875 0 CA-C-N 115.198 -0.91 . . . . 0.0 110.055 -179.847 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 41.2 tt0 -123.14 97.42 5.42 Favored 'General case' 0 C--N 1.323 -0.583 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 179.682 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 4.0 p30 -159.34 143.5 15.1 Favored 'General case' 0 N--CA 1.483 1.206 0 O-C-N 122.342 -0.224 . . . . 0.0 111.083 179.103 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 61.9 t -61.17 162.65 1.31 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.89 0 N-CA-C 107.983 -1.117 . . . . 0.0 107.983 177.136 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 25' ' ' GLY . . . . . 0.495 ' H ' ' HB ' ' E' ' 24' ' ' VAL . . . -117.62 49.03 0.89 Allowed Glycine 0 N--CA 1.475 1.294 0 N-CA-C 111.725 -0.55 . . . . 0.0 111.725 -179.281 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -62.2 -168.78 0.02 OUTLIER 'General case' 0 N--CA 1.469 0.514 0 O-C-N 123.616 0.245 . . . . 0.0 110.374 179.598 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 27.9 t-20 -69.72 80.64 0.44 Allowed 'General case' 0 N--CA 1.465 0.312 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.043 179.773 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 97.9 mttt -80.2 154.41 27.96 Favored 'General case' 0 N--CA 1.472 0.633 0 N-CA-C 108.882 -0.784 . . . . 0.0 108.882 179.072 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.9 -144.5 0.02 OUTLIER Glycine 0 CA--C 1.526 0.738 0 N-CA-C 109.636 -1.386 . . . . 0.0 109.636 178.476 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -136.39 120.84 18.14 Favored 'General case' 0 N--CA 1.478 0.973 0 CA-C-N 117.142 0.471 . . . . 0.0 109.83 179.376 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 70.1 mt -80.65 124.98 39.12 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.524 0 N-CA-C 106.721 -1.585 . . . . 0.0 106.721 178.249 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 32' ' ' ILE . . . . . 0.408 ' C ' ' H ' ' B' ' 34' ' ' LEU . 41.3 pt -151.59 162.75 2.8 Favored 'Isoleucine or valine' 0 C--N 1.358 0.951 0 CA-C-N 115.836 -0.62 . . . . 0.0 111.491 -178.728 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 64.61 0.52 5.0 Favored Glycine 0 C--N 1.337 0.635 0 CA-C-N 115.507 -0.77 . . . . 0.0 111.177 179.716 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 34' ' ' LEU . . . . . 0.408 ' H ' ' C ' ' B' ' 32' ' ' ILE . 7.8 tt -79.85 148.15 31.47 Favored 'General case' 0 N--CA 1.465 0.292 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 -179.952 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 28.6 ttt -159.32 140.75 13.03 Favored 'General case' 0 N--CA 1.475 0.795 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 179.051 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 28.3 m -156.35 162.56 1.63 Allowed 'Isoleucine or valine' 0 C--N 1.346 0.422 0 N-CA-C 108.214 -1.032 . . . . 0.0 108.214 -179.796 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.67 67.45 2.2 Favored Glycine 0 C--N 1.306 -1.111 0 CA-C-N 115.756 -0.657 . . . . 0.0 111.932 178.558 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.86 172.8 18.27 Favored Glycine 0 N--CA 1.474 1.202 0 N-CA-C 110.678 -0.969 . . . . 0.0 110.678 179.208 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 39' ' ' VAL . . . . . 0.553 ' H ' HG12 ' E' ' 39' ' ' VAL . 35.2 m -125.3 164.29 24.67 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.082 0 C-N-CA 123.523 0.729 . . . . 0.0 110.819 -179.392 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 24.9 t . . . . . 0 N--CA 1.471 0.576 0 CA-C-O 118.237 -0.887 . . . . 0.0 110.636 179.164 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' C' C ' 1' ' ' ASP . . . . . 0.49 ' H1 ' ' CG ' ' F' ' 1' ' ' ASP . 66.2 m-20 . . . . . 0 N--CA 1.491 1.589 0 N-CA-C 108.86 -0.793 . . . . 0.0 108.86 . . . . . . . . . 1 1 . 1 . 012 nuclear build full ' C' C ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.4 133.13 50.68 Favored 'General case' 0 CA--C 1.54 0.562 0 CA-C-N 116.454 -0.339 . . . . 0.0 110.235 -179.782 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' C' C ' 3' ' ' GLU . . . . . . . . . . . . . 43.0 tt0 -169.19 105.71 0.4 Allowed 'General case' 0 N--CA 1.471 0.614 0 N-CA-C 109.884 -0.413 . . . . 0.0 109.884 -179.102 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 54.9 m-85 -84.98 147.41 26.71 Favored 'General case' 0 N--CA 1.477 0.922 0 N-CA-C 110.238 -0.282 . . . . 0.0 110.238 179.462 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 -144.22 142.12 30.31 Favored 'General case' 0 N--CA 1.482 1.15 0 N-CA-C 109.974 -0.38 . . . . 0.0 109.974 179.645 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 40.8 t-80 -152.37 119.98 6.05 Favored 'General case' 0 N--CA 1.473 0.708 0 N-CA-C 109.251 -0.648 . . . . 0.0 109.251 179.152 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' C' C ' 7' ' ' ASP . . . . . 0.477 ' O ' ' OG ' ' F' ' 8' ' ' SER . 4.4 m-20 -69.45 148.39 49.63 Favored 'General case' 0 CA--C 1.535 0.397 0 CA-C-N 116.352 -0.385 . . . . 0.0 110.518 179.908 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' C' C ' 8' ' ' SER . . . . . . . . . . . . . 55.4 p -167.32 -173.51 2.29 Favored 'General case' 0 N--CA 1.48 1.029 0 CA-C-O 120.839 0.352 . . . . 0.0 110.656 179.272 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.18 47.58 1.31 Allowed Glycine 0 N--CA 1.483 1.795 0 CA-C-N 116.006 -0.543 . . . . 0.0 111.903 179.961 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 49.5 p90 -66.15 133.3 50.41 Favored 'General case' 0 N--CA 1.472 0.665 0 CA-C-N 116.783 0.292 . . . . 0.0 111.681 179.697 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 83.2 mt-10 -92.15 152.08 20.08 Favored 'General case' 0 N--CA 1.476 0.851 0 N-CA-C 109.696 -0.483 . . . . 0.0 109.696 178.4 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -152.61 128.35 1.71 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.588 0 N-CA-C 107.791 -1.189 . . . . 0.0 107.791 178.146 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 42.4 m-70 -136.03 148.38 48.35 Favored 'General case' 0 N--CA 1.492 1.663 0 CA-C-N 118.937 0.79 . . . . 0.0 111.286 -179.102 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 6.7 t60 -164.69 98.55 0.78 Allowed 'General case' 0 N--CA 1.481 1.105 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.685 179.475 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -91.91 -176.99 4.6 Favored 'General case' 0 CA--C 1.512 -0.484 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 -179.937 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -172.49 93.84 0.13 Allowed 'General case' 0 N--CA 1.47 0.533 0 CA-C-N 114.707 -1.133 . . . . 0.0 108.451 177.959 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 6.1 mp -124.93 155.7 39.15 Favored 'General case' 0 N--CA 1.496 1.842 0 CA-C-O 121.768 0.794 . . . . 0.0 111.096 -178.381 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 61.6 t -111.54 125.52 68.86 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.996 0 N-CA-C 108.238 -1.023 . . . . 0.0 108.238 177.754 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 29.3 m-85 -125.31 143.31 51.03 Favored 'General case' 0 N--CA 1.495 1.822 0 CA-C-N 119.673 1.124 . . . . 0.0 110.083 179.369 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 67.5 m-85 51.93 68.46 0.81 Allowed 'General case' 0 N--CA 1.47 0.534 0 CA-C-O 121.215 0.531 . . . . 0.0 111.975 178.501 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -78.09 -84.41 0.08 Allowed 'General case' 0 C--N 1.356 0.873 0 CA-C-N 115.186 -0.915 . . . . 0.0 110.071 -179.851 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 40.9 tt0 -123.14 96.97 5.21 Favored 'General case' 0 C--N 1.323 -0.546 0 N-CA-C 108.08 -1.081 . . . . 0.0 108.08 179.746 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 4.1 p30 -158.8 143.71 16.02 Favored 'General case' 0 N--CA 1.484 1.263 0 CA-C-O 119.672 -0.204 . . . . 0.0 111.118 179.002 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 59.9 t -61.43 162.38 1.45 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.849 0 N-CA-C 107.96 -1.126 . . . . 0.0 107.96 177.129 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' C' C ' 25' ' ' GLY . . . . . 0.481 ' H ' ' HB ' ' F' ' 24' ' ' VAL . . . -117.5 49.49 0.86 Allowed Glycine 0 N--CA 1.477 1.414 0 N-CA-C 111.726 -0.55 . . . . 0.0 111.726 -179.286 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -62.65 -168.51 0.02 OUTLIER 'General case' 0 N--CA 1.468 0.44 0 O-C-N 123.666 0.274 . . . . 0.0 110.443 179.64 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 27.8 t-20 -69.88 80.47 0.46 Allowed 'General case' 0 N--CA 1.465 0.322 0 N-CA-C 110.073 -0.343 . . . . 0.0 110.073 179.781 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -79.98 154.62 28.11 Favored 'General case' 0 N--CA 1.472 0.668 0 N-CA-C 108.915 -0.772 . . . . 0.0 108.915 179.111 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.89 -144.17 0.02 OUTLIER Glycine 0 CA--C 1.527 0.821 0 N-CA-C 109.769 -1.332 . . . . 0.0 109.769 178.488 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -136.78 120.47 17.28 Favored 'General case' 0 N--CA 1.481 1.083 0 CA-C-N 117.185 0.493 . . . . 0.0 109.719 179.258 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 70.0 mt -80.49 124.8 38.81 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.541 0 N-CA-C 106.762 -1.57 . . . . 0.0 106.762 178.254 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' C' C ' 32' ' ' ILE . . . . . 0.418 ' C ' ' H ' ' C' ' 34' ' ' LEU . 41.3 pt -151.39 162.53 2.97 Favored 'Isoleucine or valine' 0 C--N 1.359 0.991 0 CA-C-N 115.68 -0.691 . . . . 0.0 111.53 -178.634 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 64.89 0.68 5.5 Favored Glycine 0 N--CA 1.465 0.598 0 N-CA-C 110.973 -0.851 . . . . 0.0 110.973 179.606 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' C' C ' 34' ' ' LEU . . . . . 0.418 ' H ' ' C ' ' C' ' 32' ' ' ILE . 7.7 tt -79.87 148.12 31.45 Favored 'General case' 0 N--CA 1.465 0.302 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 179.955 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 28.6 ttt -159.29 140.85 13.16 Favored 'General case' 0 N--CA 1.474 0.742 0 N-CA-C 108.751 -0.833 . . . . 0.0 108.751 178.955 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 28.1 m -156.5 162.77 1.55 Allowed 'Isoleucine or valine' 0 C--N 1.348 0.511 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 -179.798 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.37 67.14 2.36 Favored Glycine 0 C--N 1.307 -1.07 0 CA-C-N 115.695 -0.684 . . . . 0.0 111.901 178.56 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 148.23 172.58 18.32 Favored Glycine 0 N--CA 1.474 1.218 0 N-CA-C 110.604 -0.998 . . . . 0.0 110.604 179.237 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' C' C ' 39' ' ' VAL . . . . . 0.55 ' H ' HG12 ' F' ' 39' ' ' VAL . 35.1 m -125.25 164.48 24.23 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.996 0 C-N-CA 123.518 0.727 . . . . 0.0 110.789 -179.415 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 25.4 t . . . . . 0 N--CA 1.469 0.484 0 CA-C-O 118.234 -0.889 . . . . 0.0 110.649 179.207 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' D' D ' 1' ' ' ASP . . . . . 0.446 ' CG ' ' H1 ' ' A' ' 1' ' ' ASP . 66.4 m-20 . . . . . 0 N--CA 1.49 1.551 0 N-CA-C 109.084 -0.71 . . . . 0.0 109.084 . . . . . . . . . 1 1 . 1 . 012 nuclear build full ' D' D ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.14 131.14 46.59 Favored 'General case' 0 CA--C 1.535 0.38 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.535 179.902 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' D' D ' 3' ' ' GLU . . . . . 0.4 ' CD ' HH21 ' D' ' 5' ' ' ARG . 41.8 tt0 -169.22 108.49 0.44 Allowed 'General case' 0 N--CA 1.47 0.573 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 179.852 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 61.4 m-85 -89.42 153.05 21.14 Favored 'General case' 0 C--N 1.36 1.055 0 C-N-CA 119.473 -0.891 . . . . 0.0 108.792 179.729 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' D' D ' 5' ' ' ARG . . . . . 0.4 HH21 ' CD ' ' D' ' 3' ' ' GLU . 99.2 mtt180 -146.43 140.49 26.33 Favored 'General case' 0 N--CA 1.476 0.85 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.236 -179.994 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 38.0 t-80 -149.82 124.02 9.5 Favored 'General case' 0 CA--C 1.545 0.781 0 N-CA-C 108.344 -0.984 . . . . 0.0 108.344 175.303 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' D' D ' 7' ' ' ASP . . . . . 0.57 ' O ' ' OG ' ' G' ' 8' ' ' SER . 3.3 m-20 -63.76 132.46 51.04 Favored 'General case' 0 C--N 1.322 -0.596 0 C-N-CA 126.885 2.074 . . . . 0.0 114.325 174.69 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' D' D ' 8' ' ' SER . . . . . 0.507 ' OG ' ' O ' ' A' ' 7' ' ' ASP . 54.2 p -154.63 -170.65 3.58 Favored 'General case' 0 N--CA 1.486 1.334 0 CA-C-N 119.77 1.168 . . . . 0.0 111.22 175.927 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.35 48.15 1.15 Allowed Glycine 0 N--CA 1.483 1.804 0 C-N-CA 124.562 1.077 . . . . 0.0 110.539 174.952 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 51.5 p90 -60.97 131.57 51.09 Favored 'General case' 0 N--CA 1.472 0.626 0 N-CA-C 112.908 0.707 . . . . 0.0 112.908 177.925 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 84.2 mt-10 -89.28 150.91 22.39 Favored 'General case' 0 N--CA 1.481 1.1 0 CA-C-N 117.974 0.352 . . . . 0.0 110.637 175.315 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.0 p -149.58 129.86 4.2 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.637 0 N-CA-C 107.416 -1.328 . . . . 0.0 107.416 173.066 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 38.3 m-70 -129.91 151.28 50.64 Favored 'General case' 0 N--CA 1.484 1.262 0 N-CA-C 112.329 0.492 . . . . 0.0 112.329 176.791 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 6.7 t60 -164.79 104.84 0.81 Allowed 'General case' 0 N--CA 1.482 1.145 0 N-CA-C 109.155 -0.683 . . . . 0.0 109.155 172.664 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' D' D ' 15' ' ' GLN . . . . . 0.401 ' OE1' ' N ' ' G' ' 37' ' ' GLY . 4.9 pt20 -94.96 -177.3 4.12 Favored 'General case' 0 CA--C 1.509 -0.631 0 N-CA-C 108.574 -0.898 . . . . 0.0 108.574 179.044 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -169.75 103.49 0.32 Allowed 'General case' 0 N--CA 1.465 0.308 0 N-CA-C 105.891 -1.892 . . . . 0.0 105.891 173.374 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 5.0 mp -132.19 153.44 50.57 Favored 'General case' 0 N--CA 1.498 1.97 0 CA-C-O 122.011 0.91 . . . . 0.0 110.214 178.912 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 35.8 t -101.12 129.01 52.79 Favored 'Isoleucine or valine' 0 C--O 1.266 1.943 0 CA-C-O 116.373 -1.775 . . . . 0.0 109.693 174.267 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 25.8 m-85 -126.63 149.25 49.59 Favored 'General case' 0 N--CA 1.49 1.562 0 CA-C-N 120.525 1.511 . . . . 0.0 109.472 172.329 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 66.7 m-85 55.14 63.64 2.05 Favored 'General case' 0 C--O 1.24 0.599 0 CA-C-O 118.518 -0.753 . . . . 0.0 111.555 175.097 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -79.99 -81.35 0.12 Allowed 'General case' 0 N--CA 1.474 0.741 0 CA-C-N 118.942 0.792 . . . . 0.0 109.967 -176.345 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 41.3 tt0 -124.91 101.81 7.24 Favored 'General case' 0 N--CA 1.479 0.999 0 N-CA-C 106.036 -1.838 . . . . 0.0 106.036 175.969 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 4.1 p30 -152.44 143.08 22.8 Favored 'General case' 0 N--CA 1.476 0.842 0 CA-C-O 116.792 -1.575 . . . . 0.0 113.624 177.592 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' D' D ' 24' ' ' VAL . . . . . 0.494 ' HB ' ' H ' ' A' ' 25' ' ' GLY . 67.1 t -63.58 165.26 1.29 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.366 0 CA-C-N 120.971 1.714 . . . . 0.0 107.824 174.538 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' D' D ' 25' ' ' GLY . . . . . 0.556 ' H ' ' HB ' ' G' ' 24' ' ' VAL . . . -116.84 51.3 0.74 Allowed Glycine 0 N--CA 1.48 1.613 0 CA-C-O 118.978 -0.901 . . . . 0.0 111.977 178.795 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -58.87 -171.23 0.01 OUTLIER 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 117.558 0.679 . . . . 0.0 111.533 176.88 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 28.5 t-20 -71.92 86.66 1.0 Allowed 'General case' 0 CA--C 1.537 0.468 0 N-CA-C 108.432 -0.951 . . . . 0.0 108.432 178.516 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 97.4 mttt -85.34 156.37 20.93 Favored 'General case' 0 N--CA 1.475 0.779 0 N-CA-C 108.124 -1.065 . . . . 0.0 108.124 179.031 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.39 -144.27 0.02 OUTLIER Glycine 0 C--N 1.335 0.488 0 N-CA-C 110.33 -1.108 . . . . 0.0 110.33 179.387 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -136.41 123.74 21.93 Favored 'General case' 0 N--CA 1.474 0.733 0 N-CA-C 109.159 -0.682 . . . . 0.0 109.159 177.648 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 76.4 mt -83.9 134.53 26.74 Favored 'Isoleucine or valine' 0 C--N 1.355 0.819 0 N-CA-C 104.846 -2.279 . . . . 0.0 104.846 178.776 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 46.0 pt -159.07 162.47 1.35 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.02 0 CA-C-O 121.407 0.622 . . . . 0.0 110.397 -178.37 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 64.83 0.17 4.89 Favored Glycine 0 CA--C 1.525 0.685 0 CA-C-N 115.46 -0.791 . . . . 0.0 111.186 -178.563 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 7.6 tt -79.25 150.04 31.69 Favored 'General case' 0 C--N 1.343 0.325 0 N-CA-C 109.345 -0.613 . . . . 0.0 109.345 -179.49 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 27.7 ttt -155.78 151.44 27.26 Favored 'General case' 0 N--CA 1.474 0.728 0 N-CA-C 107.509 -1.293 . . . . 0.0 107.509 174.348 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 29.7 m -164.52 163.65 0.73 Allowed 'Isoleucine or valine' 0 CA--C 1.513 -0.445 0 N-CA-C 107.661 -1.237 . . . . 0.0 107.661 176.901 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 60.32 63.75 4.75 Favored Glycine 0 CA--C 1.528 0.885 0 C-N-CA 119.584 -1.293 . . . . 0.0 112.359 177.88 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.92 173.2 15.2 Favored Glycine 0 N--CA 1.479 1.519 0 CA-C-N 118.451 1.125 . . . . 0.0 111.567 -177.851 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' D' D ' 39' ' ' VAL . . . . . 0.575 ' H ' HG12 ' G' ' 39' ' ' VAL . 34.6 m -128.14 160.16 38.41 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.061 0 C-N-CA 122.895 0.478 . . . . 0.0 110.422 -175.953 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 24.2 t . . . . . 0 C--N 1.331 -0.213 0 CA-C-O 116.386 -1.769 . . . . 0.0 109.855 177.694 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' E' E ' 1' ' ' ASP . . . . . 0.415 ' H1 ' ' CG ' ' H' ' 1' ' ' ASP . 65.8 m-20 . . . . . 0 N--CA 1.489 1.485 0 N-CA-C 109.369 -0.604 . . . . 0.0 109.369 . . . . . . . . . 1 1 . 1 . 012 nuclear build full ' E' E ' 2' ' ' ALA . . . . . . . . . . . . . . . -63.76 131.06 46.69 Favored 'General case' 0 N--CA 1.468 0.449 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.414 179.966 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' E' E ' 3' ' ' GLU . . . . . . . . . . . . . 41.7 tt0 -168.71 105.78 0.44 Allowed 'General case' 0 C--O 1.215 -0.735 0 N-CA-C 110.477 -0.194 . . . . 0.0 110.477 -179.722 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 53.7 m-85 -85.94 146.94 26.47 Favored 'General case' 0 N--CA 1.475 0.81 0 N-CA-C 110.348 -0.241 . . . . 0.0 110.348 179.131 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' E' E ' 5' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 -143.5 142.62 31.23 Favored 'General case' 0 N--CA 1.479 0.99 0 CA-C-O 120.794 0.33 . . . . 0.0 110.201 179.565 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 41.2 t-80 -152.46 119.54 5.85 Favored 'General case' 0 N--CA 1.474 0.725 0 N-CA-C 109.247 -0.649 . . . . 0.0 109.247 178.985 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' E' E ' 7' ' ' ASP . . . . . 0.435 ' O ' ' OG ' ' H' ' 8' ' ' SER . 4.3 m-20 -69.58 148.27 49.61 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-N 116.491 -0.322 . . . . 0.0 110.671 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' E' E ' 8' ' ' SER . . . . . 0.467 ' OG ' ' O ' ' B' ' 7' ' ' ASP . 52.5 p -167.92 -172.49 1.84 Allowed 'General case' 0 N--CA 1.486 1.328 0 CA-C-O 121.013 0.435 . . . . 0.0 110.87 178.952 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.87 47.66 1.24 Allowed Glycine 0 N--CA 1.48 1.595 0 N-CA-C 111.781 -0.528 . . . . 0.0 111.781 179.684 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 47.8 p90 -65.45 133.36 51.14 Favored 'General case' 0 N--CA 1.473 0.683 0 N-CA-C 112.06 0.392 . . . . 0.0 112.06 -179.846 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 85.1 mt-10 -91.4 152.68 20.31 Favored 'General case' 0 N--CA 1.479 1.002 0 N-CA-C 109.617 -0.512 . . . . 0.0 109.617 177.996 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -154.67 127.28 1.07 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.619 0 N-CA-C 107.816 -1.179 . . . . 0.0 107.816 178.067 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 40.8 m-70 -136.18 146.72 47.17 Favored 'General case' 0 N--CA 1.482 1.157 0 CA-C-O 120.851 0.357 . . . . 0.0 111.639 -178.047 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 6.6 t60 -163.64 98.39 0.88 Allowed 'General case' 0 N--CA 1.485 1.293 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.735 179.553 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 4.8 pt20 -91.36 -176.87 4.68 Favored 'General case' 0 CA--C 1.514 -0.43 0 N-CA-C 109.028 -0.73 . . . . 0.0 109.028 -179.925 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -172.31 92.72 0.12 Allowed 'General case' 0 N--CA 1.47 0.557 0 CA-C-N 114.77 -1.104 . . . . 0.0 108.693 177.929 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 6.0 mp -123.35 155.77 36.67 Favored 'General case' 0 N--CA 1.496 1.864 0 CA-C-O 121.443 0.64 . . . . 0.0 111.433 -177.901 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 48.0 t -113.33 122.57 67.72 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.198 0 N-CA-C 108.333 -0.988 . . . . 0.0 108.333 177.37 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 32.4 m-85 -122.76 142.51 50.65 Favored 'General case' 0 N--CA 1.491 1.594 0 CA-C-O 120.974 0.416 . . . . 0.0 110.649 -179.928 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 67.8 m-85 52.73 67.71 0.95 Allowed 'General case' 0 C--N 1.346 0.42 0 CA-C-N 115.767 -0.651 . . . . 0.0 111.614 178.245 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.15 -83.66 0.07 Allowed 'General case' 0 CA--C 1.541 0.605 0 N-CA-C 109.981 -0.377 . . . . 0.0 109.981 -179.464 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 41.0 tt0 -123.28 97.14 5.28 Favored 'General case' 0 C--N 1.32 -0.686 0 N-CA-C 108.14 -1.059 . . . . 0.0 108.14 179.938 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 4.1 p30 -158.35 143.46 16.44 Favored 'General case' 0 N--CA 1.48 1.057 0 O-C-N 122.422 -0.174 . . . . 0.0 111.33 179.062 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' E' E ' 24' ' ' VAL . . . . . 0.495 ' HB ' ' H ' ' B' ' 25' ' ' GLY . 57.9 t -59.53 167.42 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.954 0 N-CA-C 107.412 -1.329 . . . . 0.0 107.412 176.991 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' E' E ' 25' ' ' GLY . . . . . 0.461 ' H ' ' HB ' ' H' ' 24' ' ' VAL . . . -122.61 49.66 0.88 Allowed Glycine 0 N--CA 1.475 1.266 0 N-CA-C 110.915 -0.874 . . . . 0.0 110.915 -179.386 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -63.24 -168.54 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.639 0 CA-C-O 120.689 0.281 . . . . 0.0 110.572 179.946 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 28.4 t-20 -68.98 77.94 0.32 Allowed 'General case' 0 N--CA 1.465 0.281 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.261 179.946 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -78.12 155.28 30.59 Favored 'General case' 0 N--CA 1.475 0.779 0 N-CA-C 109.458 -0.571 . . . . 0.0 109.458 179.279 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.76 -144.74 0.02 OUTLIER Glycine 0 C--N 1.337 0.634 0 N-CA-C 110.34 -1.104 . . . . 0.0 110.34 178.022 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -137.12 117.25 13.42 Favored 'General case' 0 N--CA 1.476 0.831 0 CA-C-O 120.79 0.328 . . . . 0.0 110.286 179.723 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 67.0 mt -77.45 125.15 36.96 Favored 'Isoleucine or valine' 0 C--O 1.238 0.475 0 N-CA-C 107.011 -1.477 . . . . 0.0 107.011 178.411 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' E' E ' 32' ' ' ILE . . . . . 0.405 ' C ' ' H ' ' E' ' 34' ' ' LEU . 46.4 pt -150.96 164.47 2.64 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.085 0 CA-C-O 121.279 0.561 . . . . 0.0 111.019 -178.943 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.82 1.1 3.36 Favored Glycine 0 CA--C 1.529 0.911 0 CA-C-N 115.542 -0.753 . . . . 0.0 111.871 -179.643 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' E' E ' 34' ' ' LEU . . . . . 0.405 ' H ' ' C ' ' E' ' 32' ' ' ILE . 7.9 tt -79.31 148.18 32.2 Favored 'General case' 0 N--CA 1.468 0.462 0 C-N-CA 122.838 0.455 . . . . 0.0 109.832 -179.964 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 28.0 ttt -158.78 140.97 13.93 Favored 'General case' 0 N--CA 1.477 0.922 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 178.784 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 32.4 m -156.52 162.22 1.7 Allowed 'Isoleucine or valine' 0 C--N 1.344 0.368 0 N-CA-C 108.431 -0.951 . . . . 0.0 108.431 -179.598 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.5 67.36 2.25 Favored Glycine 0 C--N 1.308 -1.012 0 CA-C-N 115.975 -0.557 . . . . 0.0 111.894 178.494 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 148.33 173.06 18.87 Favored Glycine 0 N--CA 1.475 1.255 0 N-CA-C 110.875 -0.89 . . . . 0.0 110.875 179.222 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' E' E ' 39' ' ' VAL . . . . . 0.559 ' H ' HG12 ' H' ' 39' ' ' VAL . 32.9 m -126.18 163.08 28.71 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.909 0 C-N-CA 123.41 0.684 . . . . 0.0 111.016 -179.067 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 24.6 t . . . . . 0 N--CA 1.465 0.309 0 CA-C-O 118.253 -0.88 . . . . 0.0 110.466 178.972 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' F' F ' 1' ' ' ASP . . . . . 0.49 ' CG ' ' H1 ' ' C' ' 1' ' ' ASP . 66.1 m-20 . . . . . 0 N--CA 1.49 1.561 0 N-CA-C 109.218 -0.66 . . . . 0.0 109.218 . . . . . . . . . 1 1 . 1 . 012 nuclear build full ' F' F ' 2' ' ' ALA . . . . . . . . . . . . . . . -63.78 131.0 46.48 Favored 'General case' 0 N--CA 1.468 0.456 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.487 179.97 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' F' F ' 3' ' ' GLU . . . . . 0.413 ' CD ' HH21 ' F' ' 5' ' ' ARG . 41.6 tt0 -168.52 105.74 0.45 Allowed 'General case' 0 C--O 1.215 -0.733 0 N-CA-C 110.467 -0.197 . . . . 0.0 110.467 -179.765 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 53.7 m-85 -85.95 146.69 26.57 Favored 'General case' 0 N--CA 1.474 0.774 0 N-CA-C 110.234 -0.284 . . . . 0.0 110.234 179.25 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' F' F ' 5' ' ' ARG . . . . . 0.413 HH21 ' CD ' ' F' ' 3' ' ' GLU . 99.2 mtt180 -143.3 142.42 31.32 Favored 'General case' 0 N--CA 1.478 0.945 0 CA-C-O 120.803 0.335 . . . . 0.0 110.141 179.544 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 38.8 t-80 -152.42 119.3 5.77 Favored 'General case' 0 N--CA 1.472 0.674 0 N-CA-C 109.283 -0.636 . . . . 0.0 109.283 178.966 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' F' F ' 7' ' ' ASP . . . . . 0.465 ' O ' ' OG ' ' I' ' 8' ' ' SER . 4.2 m-20 -69.17 148.39 49.97 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-N 116.471 -0.331 . . . . 0.0 110.746 179.968 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' F' F ' 8' ' ' SER . . . . . 0.477 ' OG ' ' O ' ' C' ' 7' ' ' ASP . 52.6 p -168.01 -171.99 1.69 Allowed 'General case' 0 N--CA 1.486 1.335 0 CA-C-O 120.931 0.396 . . . . 0.0 111.012 178.74 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.35 47.32 1.32 Allowed Glycine 0 N--CA 1.48 1.591 0 N-CA-C 111.746 -0.542 . . . . 0.0 111.746 179.689 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 47.5 p90 -65.4 134.05 52.66 Favored 'General case' 0 N--CA 1.473 0.678 0 N-CA-C 111.981 0.363 . . . . 0.0 111.981 -179.856 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 85.7 mt-10 -91.8 152.88 19.93 Favored 'General case' 0 N--CA 1.479 0.987 0 N-CA-C 109.699 -0.482 . . . . 0.0 109.699 178.002 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -154.61 127.25 1.07 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.594 0 N-CA-C 107.823 -1.177 . . . . 0.0 107.823 178.029 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 42.2 m-70 -136.27 146.48 46.73 Favored 'General case' 0 N--CA 1.483 1.212 0 CA-C-O 120.833 0.349 . . . . 0.0 111.602 -177.948 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 6.5 t60 -163.51 98.74 0.9 Allowed 'General case' 0 N--CA 1.486 1.348 0 CA-C-N 116.343 -0.389 . . . . 0.0 110.736 179.609 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 4.8 pt20 -91.56 -176.95 4.66 Favored 'General case' 0 CA--C 1.51 -0.563 0 N-CA-C 109.109 -0.7 . . . . 0.0 109.109 179.934 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -172.3 92.38 0.12 Allowed 'General case' 0 C--O 1.219 -0.507 0 CA-C-N 114.777 -1.101 . . . . 0.0 108.591 177.961 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 6.0 mp -123.05 155.95 35.86 Favored 'General case' 0 N--CA 1.495 1.794 0 CA-C-O 121.581 0.705 . . . . 0.0 111.455 -177.983 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 48.2 t -113.52 122.5 67.77 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.141 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 177.362 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 32.6 m-85 -122.67 142.52 50.58 Favored 'General case' 0 N--CA 1.489 1.504 0 CA-C-O 120.955 0.407 . . . . 0.0 110.584 179.934 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 67.4 m-85 52.67 68.08 0.89 Allowed 'General case' 0 C--N 1.343 0.318 0 CA-C-N 115.866 -0.606 . . . . 0.0 111.918 178.474 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.42 -83.75 0.07 Allowed 'General case' 0 CA--C 1.54 0.57 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 -179.496 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 40.9 tt0 -123.22 97.68 5.53 Favored 'General case' 0 C--N 1.32 -0.689 0 N-CA-C 108.099 -1.074 . . . . 0.0 108.099 179.849 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 4.1 p30 -158.79 143.51 15.91 Favored 'General case' 0 N--CA 1.48 1.065 0 CA-C-O 119.692 -0.194 . . . . 0.0 111.277 179.059 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' F' F ' 24' ' ' VAL . . . . . 0.481 ' HB ' ' H ' ' C' ' 25' ' ' GLY . 58.0 t -59.95 166.82 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.96 0 N-CA-C 107.341 -1.355 . . . . 0.0 107.341 177.01 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' F' F ' 25' ' ' GLY . . . . . 0.443 ' H ' ' HB ' ' I' ' 24' ' ' VAL . . . -122.14 49.82 0.87 Allowed Glycine 0 N--CA 1.476 1.343 0 N-CA-C 111.039 -0.824 . . . . 0.0 111.039 -179.407 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -63.41 -168.43 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.526 0 CA-C-O 120.597 0.237 . . . . 0.0 110.505 179.938 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 28.4 t-20 -68.93 78.11 0.32 Allowed 'General case' 0 CA--C 1.534 0.359 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.23 -180.0 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -78.26 155.12 30.42 Favored 'General case' 0 N--CA 1.475 0.794 0 N-CA-C 109.408 -0.589 . . . . 0.0 109.408 179.248 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.56 -144.77 0.02 OUTLIER Glycine 0 C--N 1.338 0.679 0 N-CA-C 110.384 -1.087 . . . . 0.0 110.384 178.005 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -136.8 117.35 13.82 Favored 'General case' 0 N--CA 1.476 0.829 0 CA-C-O 120.751 0.31 . . . . 0.0 110.165 179.752 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 68.3 mt -77.69 125.42 37.35 Favored 'Isoleucine or valine' 0 C--O 1.238 0.45 0 N-CA-C 106.948 -1.501 . . . . 0.0 106.948 178.373 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' F' F ' 32' ' ' ILE . . . . . 0.419 ' C ' ' H ' ' F' ' 34' ' ' LEU . 45.8 pt -151.25 164.63 2.46 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.994 0 CA-C-O 121.154 0.502 . . . . 0.0 111.043 -179.018 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.64 1.43 3.53 Favored Glycine 0 CA--C 1.529 0.911 0 CA-C-N 115.583 -0.735 . . . . 0.0 111.864 -179.67 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' F' F ' 34' ' ' LEU . . . . . 0.419 ' H ' ' C ' ' F' ' 32' ' ' ILE . 7.9 tt -79.6 148.16 31.8 Favored 'General case' 0 N--CA 1.468 0.464 0 C-N-CA 122.837 0.455 . . . . 0.0 109.775 179.95 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 28.0 ttt -158.68 140.97 14.07 Favored 'General case' 0 N--CA 1.477 0.914 0 N-CA-C 108.806 -0.812 . . . . 0.0 108.806 178.725 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 32.2 m -156.59 161.86 1.78 Allowed 'Isoleucine or valine' 0 C--N 1.344 0.358 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 -179.611 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.0 67.22 2.33 Favored Glycine 0 C--N 1.307 -1.047 0 CA-C-N 115.962 -0.563 . . . . 0.0 111.887 178.458 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 148.46 173.82 19.63 Favored Glycine 0 N--CA 1.475 1.26 0 N-CA-C 110.943 -0.863 . . . . 0.0 110.943 179.192 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' F' F ' 39' ' ' VAL . . . . . 0.575 ' H ' HG12 ' I' ' 39' ' ' VAL . 33.1 m -126.82 163.08 30.06 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.935 0 C-N-CA 123.416 0.686 . . . . 0.0 110.899 -179.058 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 24.7 t . . . . . 0 C--O 1.223 -0.304 0 CA-C-O 118.29 -0.862 . . . . 0.0 110.435 178.89 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' G' G ' 1' ' ' ASP . . . . . 0.429 ' CG ' ' H1 ' ' D' ' 1' ' ' ASP . 67.0 m-20 . . . . . 0 N--CA 1.491 1.62 0 N-CA-C 109.342 -0.614 . . . . 0.0 109.342 . . . . . . . . . 1 1 . 1 . 012 nuclear build full ' G' G ' 2' ' ' ALA . . . . . . . . . . . . . . . -61.79 129.21 39.92 Favored 'General case' 0 N--CA 1.468 0.46 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.632 179.687 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' G' G ' 3' ' ' GLU . . . . . . . . . . . . . 41.0 tt0 -168.62 106.78 0.46 Allowed 'General case' 0 N--CA 1.473 0.692 0 CA-C-O 120.398 0.142 . . . . 0.0 110.668 179.572 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 56.4 m-85 -87.62 146.45 25.73 Favored 'General case' 0 N--CA 1.474 0.756 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 179.215 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' G' G ' 5' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 -143.67 142.58 31.06 Favored 'General case' 0 N--CA 1.482 1.131 0 C-N-CA 122.585 0.354 . . . . 0.0 110.301 179.813 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 40.0 t-80 -152.53 120.34 6.12 Favored 'General case' 0 N--CA 1.473 0.712 0 N-CA-C 109.46 -0.57 . . . . 0.0 109.46 179.016 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -71.16 143.88 50.38 Favored 'General case' 0 N--CA 1.471 0.584 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.12 -179.936 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' G' G ' 8' ' ' SER . . . . . 0.57 ' OG ' ' O ' ' D' ' 7' ' ' ASP . 49.1 p -164.54 -170.1 1.94 Allowed 'General case' 0 N--CA 1.475 0.783 0 CA-C-O 120.923 0.392 . . . . 0.0 110.52 178.506 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.11 47.32 1.35 Allowed Glycine 0 N--CA 1.48 1.571 0 N-CA-C 111.37 -0.692 . . . . 0.0 111.37 179.529 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 50.1 p90 -65.62 133.31 50.88 Favored 'General case' 0 CA--C 1.543 0.683 0 N-CA-C 111.875 0.324 . . . . 0.0 111.875 -179.497 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 83.0 mt-10 -91.6 151.89 20.51 Favored 'General case' 0 N--CA 1.478 0.974 0 CA-C-O 120.991 0.424 . . . . 0.0 110.076 178.555 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -154.78 127.41 1.07 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.014 0 N-CA-C 107.864 -1.161 . . . . 0.0 107.864 178.17 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 42.4 m-70 -135.42 148.21 49.24 Favored 'General case' 0 N--CA 1.479 1.004 0 CA-C-N 115.505 -0.77 . . . . 0.0 111.409 -178.258 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 32.8 t-80 -165.49 98.97 0.7 Allowed 'General case' 0 N--CA 1.484 1.263 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.307 179.012 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 27.5 pt20 -92.09 -176.73 4.48 Favored 'General case' 0 CA--C 1.513 -0.477 0 N-CA-C 108.901 -0.777 . . . . 0.0 108.901 -179.847 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -172.85 92.28 0.1 Allowed 'General case' 0 N--CA 1.47 0.565 0 CA-C-N 114.86 -1.064 . . . . 0.0 108.37 178.123 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 6.0 mp -123.19 154.77 38.27 Favored 'General case' 0 N--CA 1.498 1.955 0 CA-C-O 121.302 0.572 . . . . 0.0 111.668 -177.995 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 42.4 t -112.83 123.08 68.14 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.99 0 CA-C-N 114.747 -1.115 . . . . 0.0 108.394 176.866 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 34.8 m-85 -123.53 142.05 51.4 Favored 'General case' 0 C--N 1.367 1.35 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.691 -179.807 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 66.9 m-85 53.64 66.25 1.28 Allowed 'General case' 0 C--O 1.237 0.422 0 CA-C-N 115.742 -0.663 . . . . 0.0 111.584 178.192 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -76.02 -83.62 0.06 Allowed 'General case' 0 N--CA 1.471 0.586 0 N-CA-C 110.003 -0.369 . . . . 0.0 110.003 -179.076 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 41.3 tt0 -123.0 97.25 5.35 Favored 'General case' 0 C--N 1.321 -0.673 0 N-CA-C 107.829 -1.174 . . . . 0.0 107.829 -179.976 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 4.1 p30 -158.59 144.2 16.62 Favored 'General case' 0 N--CA 1.479 1.008 0 CA-C-O 120.463 0.173 . . . . 0.0 111.279 178.891 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' G' G ' 24' ' ' VAL . . . . . 0.556 ' HB ' ' H ' ' D' ' 25' ' ' GLY . 61.0 t -60.96 165.62 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.685 0 N-CA-C 107.617 -1.253 . . . . 0.0 107.617 177.347 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' G' G ' 25' ' ' GLY . . . . . 0.404 ' N ' HG12 ' G' ' 24' ' ' VAL . . . -120.36 50.34 0.83 Allowed Glycine 0 N--CA 1.482 1.711 0 N-CA-C 110.567 -1.013 . . . . 0.0 110.567 -179.561 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -64.06 -168.04 0.03 OUTLIER 'General case' 0 N--CA 1.472 0.647 0 CA-C-N 117.002 0.401 . . . . 0.0 109.963 179.875 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 28.3 t-20 -69.46 77.92 0.4 Allowed 'General case' 0 CA--C 1.537 0.459 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.444 179.954 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -77.2 155.22 32.37 Favored 'General case' 0 N--CA 1.475 0.788 0 N-CA-C 109.602 -0.518 . . . . 0.0 109.602 179.189 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.03 -142.53 0.02 OUTLIER Glycine 0 CA--C 1.527 0.792 0 N-CA-C 109.918 -1.273 . . . . 0.0 109.918 178.313 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -137.72 117.45 13.12 Favored 'General case' 0 N--CA 1.471 0.583 0 C-N-CA 122.624 0.37 . . . . 0.0 110.737 -179.915 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 71.7 mt -77.79 125.85 37.74 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.496 0 N-CA-C 107.007 -1.479 . . . . 0.0 107.007 178.382 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' G' G ' 32' ' ' ILE . . . . . 0.426 ' C ' ' H ' ' G' ' 34' ' ' LEU . 44.7 pt -152.31 164.95 1.96 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.755 0 CA-C-N 120.091 1.314 . . . . 0.0 110.032 -179.36 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.61 0.64 3.9 Favored Glycine 0 N--CA 1.468 0.779 0 N-CA-C 111.19 -0.764 . . . . 0.0 111.19 -179.912 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' G' G ' 34' ' ' LEU . . . . . 0.426 ' H ' ' C ' ' G' ' 32' ' ' ILE . 7.9 tt -79.71 148.34 31.58 Favored 'General case' 0 N--CA 1.465 0.303 0 C-N-CA 122.832 0.453 . . . . 0.0 109.841 179.855 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 27.1 ttt -159.14 141.98 14.27 Favored 'General case' 0 N--CA 1.476 0.837 0 N-CA-C 108.731 -0.84 . . . . 0.0 108.731 179.004 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 33.8 m -156.68 162.21 1.67 Allowed 'Isoleucine or valine' 0 C--N 1.345 0.412 0 N-CA-C 108.618 -0.882 . . . . 0.0 108.618 -179.492 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' G' G ' 37' ' ' GLY . . . . . 0.401 ' N ' ' OE1' ' D' ' 15' ' ' GLN . . . 54.95 67.86 1.98 Allowed Glycine 0 C--N 1.31 -0.879 0 CA-C-N 115.637 -0.71 . . . . 0.0 112.141 178.134 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 148.75 174.41 20.37 Favored Glycine 0 N--CA 1.475 1.296 0 N-CA-C 110.462 -1.055 . . . . 0.0 110.462 179.229 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' G' G ' 39' ' ' VAL . . . . . 0.575 HG12 ' H ' ' D' ' 39' ' ' VAL . 33.8 m -127.27 162.73 31.82 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.76 0 C-N-CA 123.1 0.56 . . . . 0.0 110.877 -179.308 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 28.1 t . . . . . 0 N--CA 1.469 0.493 0 CA-C-O 118.351 -0.833 . . . . 0.0 110.702 178.773 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' H' H ' 1' ' ' ASP . . . . . 0.415 ' CG ' ' H1 ' ' E' ' 1' ' ' ASP . 67.0 m-20 . . . . . 0 N--CA 1.49 1.561 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 . . . . . . . . . 1 1 . 1 . 012 nuclear build full ' H' H ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.36 129.14 39.33 Favored 'General case' 0 N--CA 1.467 0.416 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.601 179.693 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' H' H ' 3' ' ' GLU . . . . . 0.404 ' CD ' HH21 ' H' ' 5' ' ' ARG . 41.1 tt0 -168.48 106.86 0.48 Allowed 'General case' 0 N--CA 1.471 0.617 0 CA-C-O 120.425 0.155 . . . . 0.0 110.705 179.711 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 57.5 m-85 -87.56 146.63 25.68 Favored 'General case' 0 N--CA 1.473 0.705 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 179.129 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' H' H ' 5' ' ' ARG . . . . . 0.404 HH21 ' CD ' ' H' ' 3' ' ' GLU . 99.2 mtt180 -143.91 142.64 30.89 Favored 'General case' 0 N--CA 1.483 1.178 0 C-N-CA 122.551 0.341 . . . . 0.0 110.169 179.846 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 41.9 t-80 -152.55 120.38 6.13 Favored 'General case' 0 N--CA 1.474 0.737 0 N-CA-C 109.409 -0.589 . . . . 0.0 109.409 178.946 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -71.28 143.89 50.18 Favored 'General case' 0 N--CA 1.469 0.518 0 C-N-CA 122.699 0.399 . . . . 0.0 111.158 -179.913 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' H' H ' 8' ' ' SER . . . . . 0.435 ' OG ' ' O ' ' E' ' 7' ' ' ASP . 53.6 p -164.36 -170.42 2.06 Favored 'General case' 0 N--CA 1.474 0.759 0 CA-C-O 120.965 0.412 . . . . 0.0 110.422 178.766 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.95 47.97 1.3 Allowed Glycine 0 N--CA 1.48 1.586 0 N-CA-C 111.461 -0.655 . . . . 0.0 111.461 179.601 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 50.2 p90 -66.28 133.18 50.03 Favored 'General case' 0 N--CA 1.472 0.675 0 N-CA-C 112.046 0.387 . . . . 0.0 112.046 -179.605 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 83.4 mt-10 -91.42 151.66 20.72 Favored 'General case' 0 N--CA 1.478 0.957 0 CA-C-O 121.069 0.461 . . . . 0.0 110.195 178.576 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -154.73 127.41 1.08 Allowed 'Isoleucine or valine' 0 CA--C 1.553 1.059 0 N-CA-C 107.888 -1.153 . . . . 0.0 107.888 178.251 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 42.7 m-70 -135.46 148.2 49.17 Favored 'General case' 0 C--N 1.357 0.912 0 CA-C-N 115.461 -0.79 . . . . 0.0 111.444 -178.293 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 33.2 t-80 -165.43 98.75 0.7 Allowed 'General case' 0 N--CA 1.482 1.136 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.427 178.996 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 27.3 pt20 -91.88 -177.02 4.61 Favored 'General case' 0 CA--C 1.513 -0.468 0 N-CA-C 108.799 -0.815 . . . . 0.0 108.799 -179.814 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -172.7 92.13 0.11 Allowed 'General case' 0 N--CA 1.472 0.663 0 CA-C-N 114.707 -1.133 . . . . 0.0 108.239 178.142 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 6.0 mp -122.93 154.72 37.99 Favored 'General case' 0 N--CA 1.499 1.991 0 CA-C-O 121.224 0.535 . . . . 0.0 111.784 -178.064 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 41.5 t -112.72 123.25 68.21 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.947 0 CA-C-N 114.841 -1.072 . . . . 0.0 108.368 176.742 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 34.2 m-85 -123.66 141.58 51.88 Favored 'General case' 0 C--N 1.369 1.425 0 CA-C-N 115.427 -0.806 . . . . 0.0 110.598 -179.65 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 66.9 m-85 53.02 67.44 1.0 Allowed 'General case' 0 C--O 1.237 0.419 0 CA-C-N 115.623 -0.717 . . . . 0.0 111.674 178.389 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -76.66 -83.15 0.07 Allowed 'General case' 0 N--CA 1.469 0.504 0 N-CA-C 110.025 -0.361 . . . . 0.0 110.025 -179.168 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 41.1 tt0 -123.25 96.93 5.19 Favored 'General case' 0 C--N 1.319 -0.726 0 N-CA-C 107.891 -1.151 . . . . 0.0 107.891 -179.969 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 4.2 p30 -158.16 143.98 17.06 Favored 'General case' 0 N--CA 1.478 0.968 0 CA-C-O 120.423 0.154 . . . . 0.0 111.264 179.021 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' H' H ' 24' ' ' VAL . . . . . 0.461 ' HB ' ' H ' ' E' ' 25' ' ' GLY . 58.3 t -60.77 165.9 0.77 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.599 0 N-CA-C 107.61 -1.256 . . . . 0.0 107.61 177.285 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' H' H ' 25' ' ' GLY . . . . . 0.408 ' N ' HG12 ' H' ' 24' ' ' VAL . . . -120.47 49.7 0.86 Allowed Glycine 0 N--CA 1.479 1.518 0 N-CA-C 110.665 -0.974 . . . . 0.0 110.665 -179.472 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -63.71 -168.16 0.02 OUTLIER 'General case' 0 N--CA 1.471 0.625 0 CA-C-N 117.022 0.411 . . . . 0.0 110.125 179.926 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 28.1 t-20 -69.52 78.45 0.41 Allowed 'General case' 0 CA--C 1.536 0.413 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.41 179.987 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -77.86 155.44 30.98 Favored 'General case' 0 N--CA 1.474 0.768 0 N-CA-C 109.459 -0.571 . . . . 0.0 109.459 179.262 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.36 -142.76 0.02 OUTLIER Glycine 0 C--N 1.339 0.733 0 N-CA-C 109.798 -1.321 . . . . 0.0 109.798 178.386 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -137.67 117.38 13.09 Favored 'General case' 0 N--CA 1.469 0.522 0 C-N-CA 122.526 0.33 . . . . 0.0 110.758 -179.855 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 71.5 mt -77.49 125.73 37.42 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.506 0 N-CA-C 106.946 -1.502 . . . . 0.0 106.946 178.498 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' H' H ' 32' ' ' ILE . . . . . 0.418 ' C ' ' H ' ' H' ' 34' ' ' LEU . 44.7 pt -152.27 164.92 1.98 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 CA-C-N 120.094 1.316 . . . . 0.0 110.005 -179.452 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.91 0.3 3.97 Favored Glycine 0 CA--C 1.527 0.796 0 N-CA-C 111.202 -0.759 . . . . 0.0 111.202 -179.827 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' H' H ' 34' ' ' LEU . . . . . 0.418 ' H ' ' C ' ' H' ' 32' ' ' ILE . 7.9 tt -79.39 148.36 32.02 Favored 'General case' 0 N--CA 1.465 0.308 0 C-N-CA 122.84 0.456 . . . . 0.0 109.889 179.935 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 27.1 ttt -159.23 141.73 13.95 Favored 'General case' 0 N--CA 1.477 0.915 0 N-CA-C 108.709 -0.848 . . . . 0.0 108.709 178.999 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 35.9 m -156.69 162.13 1.7 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.416 0 N-CA-C 108.599 -0.889 . . . . 0.0 108.599 -179.39 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.04 67.79 2.02 Favored Glycine 0 C--N 1.31 -0.896 0 CA-C-N 115.638 -0.71 . . . . 0.0 112.086 178.239 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 149.01 174.89 20.98 Favored Glycine 0 N--CA 1.475 1.267 0 N-CA-C 110.571 -1.012 . . . . 0.0 110.571 179.19 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' H' H ' 39' ' ' VAL . . . . . 0.559 HG12 ' H ' ' E' ' 39' ' ' VAL . 33.9 m -127.65 162.53 33.09 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.799 0 C-N-CA 123.114 0.565 . . . . 0.0 110.923 -179.368 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 25.9 t . . . . . 0 N--CA 1.47 0.541 0 CA-C-O 118.402 -0.809 . . . . 0.0 110.707 178.74 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' I' I ' 1' ' ' ASP . . . . . . . . . . . . . 66.4 m-20 . . . . . 0 N--CA 1.492 1.629 0 N-CA-C 109.442 -0.577 . . . . 0.0 109.442 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' I' I ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.15 129.27 40.02 Favored 'General case' 0 N--CA 1.468 0.436 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.617 179.685 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' I' I ' 3' ' ' GLU . . . . . 0.408 ' CD ' HH21 ' I' ' 5' ' ' ARG . 40.6 tt0 -168.6 106.91 0.47 Allowed 'General case' 0 N--CA 1.471 0.616 0 CA-C-O 120.397 0.142 . . . . 0.0 110.644 179.693 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 56.3 m-85 -87.66 146.69 25.59 Favored 'General case' 0 N--CA 1.474 0.772 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 179.054 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' I' I ' 5' ' ' ARG . . . . . 0.408 HH21 ' CD ' ' I' ' 3' ' ' GLU . 99.2 mtt180 -143.93 142.37 30.72 Favored 'General case' 0 N--CA 1.483 1.199 0 C-N-CA 122.569 0.348 . . . . 0.0 110.108 179.827 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 40.7 t-80 -152.36 120.13 6.12 Favored 'General case' 0 N--CA 1.473 0.687 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 178.976 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -71.06 143.98 50.51 Favored 'General case' 0 N--CA 1.47 0.574 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.178 -179.856 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' I' I ' 8' ' ' SER . . . . . 0.465 ' OG ' ' O ' ' F' ' 7' ' ' ASP . 54.1 p -164.5 -170.43 2.04 Favored 'General case' 0 N--CA 1.475 0.781 0 CA-C-O 120.964 0.411 . . . . 0.0 110.456 178.707 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.19 47.24 1.35 Allowed Glycine 0 N--CA 1.48 1.611 0 N-CA-C 111.598 -0.601 . . . . 0.0 111.598 179.67 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 50.4 p90 -65.76 133.48 51.13 Favored 'General case' 0 N--CA 1.473 0.676 0 N-CA-C 112.0 0.37 . . . . 0.0 112.0 -179.566 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 82.6 mt-10 -91.81 151.71 20.47 Favored 'General case' 0 N--CA 1.476 0.871 0 CA-C-O 120.978 0.418 . . . . 0.0 110.184 178.639 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -154.67 127.48 1.1 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.033 0 N-CA-C 107.969 -1.123 . . . . 0.0 107.969 178.16 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 41.7 m-70 -135.5 148.1 49.07 Favored 'General case' 0 N--CA 1.477 0.922 0 CA-C-N 115.407 -0.815 . . . . 0.0 111.467 -178.248 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 33.2 t-80 -165.3 99.01 0.72 Allowed 'General case' 0 N--CA 1.483 1.192 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.383 179.013 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 27.4 pt20 -92.07 -176.92 4.54 Favored 'General case' 0 CA--C 1.511 -0.521 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 -179.848 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -172.83 92.08 0.1 Allowed 'General case' 0 N--CA 1.47 0.534 0 CA-C-N 114.74 -1.118 . . . . 0.0 108.291 178.199 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 6.0 mp -122.84 154.91 37.63 Favored 'General case' 0 N--CA 1.499 1.983 0 CA-C-O 121.223 0.535 . . . . 0.0 111.754 -178.054 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 41.3 t -113.09 123.42 68.72 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.927 0 CA-C-N 114.861 -1.063 . . . . 0.0 108.247 176.784 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 33.4 m-85 -123.96 141.18 52.27 Favored 'General case' 0 C--N 1.37 1.461 0 CA-C-N 115.413 -0.812 . . . . 0.0 110.636 -179.444 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 67.1 m-85 53.35 67.15 1.05 Allowed 'General case' 0 C--O 1.238 0.45 0 CA-C-N 115.69 -0.686 . . . . 0.0 111.537 178.41 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -76.32 -83.14 0.07 Allowed 'General case' 0 N--CA 1.47 0.541 0 N-CA-C 109.913 -0.402 . . . . 0.0 109.913 -179.148 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 41.3 tt0 -123.33 97.1 5.25 Favored 'General case' 0 C--N 1.32 -0.712 0 N-CA-C 107.868 -1.16 . . . . 0.0 107.868 -179.924 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 4.1 p30 -158.29 144.36 17.13 Favored 'General case' 0 N--CA 1.479 1.002 0 O-C-N 122.458 -0.151 . . . . 0.0 111.257 178.964 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' I' I ' 24' ' ' VAL . . . . . 0.443 ' HB ' ' H ' ' F' ' 25' ' ' GLY . 59.5 t -61.2 165.57 0.86 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.589 0 N-CA-C 107.63 -1.248 . . . . 0.0 107.63 177.345 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' I' I ' 25' ' ' GLY . . . . . 0.412 ' N ' HG12 ' I' ' 24' ' ' VAL . . . -120.24 49.95 0.85 Allowed Glycine 0 N--CA 1.481 1.661 0 N-CA-C 110.588 -1.005 . . . . 0.0 110.588 -179.383 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -63.8 -168.1 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.649 0 CA-C-N 116.991 0.395 . . . . 0.0 110.134 179.825 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 28.3 t-20 -69.56 78.3 0.41 Allowed 'General case' 0 CA--C 1.536 0.421 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.364 179.924 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -77.77 155.34 31.22 Favored 'General case' 0 N--CA 1.475 0.78 0 N-CA-C 109.504 -0.554 . . . . 0.0 109.504 179.263 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.28 -143.0 0.02 OUTLIER Glycine 0 CA--C 1.527 0.842 0 N-CA-C 109.813 -1.315 . . . . 0.0 109.813 178.39 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -137.3 117.36 13.38 Favored 'General case' 0 N--CA 1.471 0.597 0 C-N-CA 122.627 0.371 . . . . 0.0 110.778 -179.863 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 71.7 mt -77.57 125.89 37.6 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.488 0 N-CA-C 106.986 -1.487 . . . . 0.0 106.986 178.389 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' I' I ' 32' ' ' ILE . . . . . 0.429 ' C ' ' H ' ' I' ' 34' ' ' LEU . 44.9 pt -152.34 164.95 1.94 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 CA-C-N 120.143 1.338 . . . . 0.0 110.06 -179.436 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.64 0.98 4.22 Favored Glycine 0 N--CA 1.469 0.844 0 N-CA-C 111.127 -0.789 . . . . 0.0 111.127 -179.909 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' I' I ' 34' ' ' LEU . . . . . 0.429 ' H ' ' C ' ' I' ' 32' ' ' ILE . 8.1 tt -80.1 148.02 31.17 Favored 'General case' 0 CA--C 1.533 0.313 0 C-N-CA 122.845 0.458 . . . . 0.0 109.792 179.895 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 26.9 ttt -158.69 141.68 14.63 Favored 'General case' 0 N--CA 1.476 0.85 0 N-CA-C 108.611 -0.885 . . . . 0.0 108.611 179.086 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 35.9 m -156.65 162.06 1.72 Allowed 'Isoleucine or valine' 0 C--N 1.346 0.442 0 N-CA-C 108.523 -0.917 . . . . 0.0 108.523 -179.562 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.22 67.78 2.03 Favored Glycine 0 C--N 1.312 -0.798 0 CA-C-N 115.638 -0.71 . . . . 0.0 112.107 178.185 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 148.68 174.73 20.59 Favored Glycine 0 N--CA 1.474 1.217 0 N-CA-C 110.461 -1.056 . . . . 0.0 110.461 179.244 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' I' I ' 39' ' ' VAL . . . . . 0.575 HG12 ' H ' ' F' ' 39' ' ' VAL . 33.9 m -127.66 162.76 32.64 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.786 0 C-N-CA 123.1 0.56 . . . . 0.0 110.923 -179.259 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 27.1 t . . . . . 0 N--CA 1.47 0.544 0 CA-C-O 118.377 -0.821 . . . . 0.0 110.56 178.75 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 9.4 m-20 . . . . . 0 N--CA 1.493 1.694 0 N-CA-C 109.835 -0.431 . . . . 0.0 109.835 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.35 129.74 42.1 Favored 'General case' 0 N--CA 1.47 0.529 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.228 179.473 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 38.6 tt0 -138.7 104.54 5.13 Favored 'General case' 0 N--CA 1.48 1.043 0 N-CA-C 109.555 -0.535 . . . . 0.0 109.555 179.427 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 26.6 m-85 -73.16 169.12 17.7 Favored 'General case' 0 CA--C 1.537 0.478 0 N-CA-C 109.142 -0.688 . . . . 0.0 109.142 179.512 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 38.2 mtp180 -68.41 147.02 52.67 Favored 'General case' 0 C--O 1.201 -1.452 0 CA-C-N 115.821 -0.627 . . . . 0.0 111.293 -177.505 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 39.2 m80 -109.55 119.1 38.39 Favored 'General case' 0 N--CA 1.482 1.165 0 N-CA-C 108.953 -0.758 . . . . 0.0 108.953 178.289 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 7' ' ' ASP . . . . . 0.459 ' OD1' ' NH2' ' G' ' 5' ' ' ARG . 7.3 m-20 -67.52 140.7 57.01 Favored 'General case' 0 N--CA 1.469 0.502 0 CA-C-O 121.135 0.493 . . . . 0.0 111.795 -178.758 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 39.0 t -158.65 -169.49 2.74 Favored 'General case' 0 N--CA 1.467 0.376 0 CA-C-N 115.848 -0.615 . . . . 0.0 109.662 179.092 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 119.83 32.39 1.2 Allowed Glycine 0 N--CA 1.485 1.922 0 N-CA-C 111.574 -0.61 . . . . 0.0 111.574 179.61 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 46.9 p90 -57.2 130.43 46.16 Favored 'General case' 0 N--CA 1.471 0.61 0 CA-C-N 116.736 0.268 . . . . 0.0 111.49 179.971 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 11' ' ' GLU . . . . . 0.506 ' CG ' HD21 ' C' ' 27' ' ' ASN . 60.6 mt-10 -90.44 153.15 20.61 Favored 'General case' 0 N--CA 1.473 0.717 0 N-CA-C 109.329 -0.619 . . . . 0.0 109.329 178.69 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.6 p -153.48 126.55 1.15 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 N-CA-C 107.698 -1.223 . . . . 0.0 107.698 177.988 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 45.6 m-70 -136.91 162.06 34.3 Favored 'General case' 0 N--CA 1.49 1.537 0 CA-C-N 118.685 0.675 . . . . 0.0 110.879 -178.721 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 38.3 t60 -152.91 96.43 2.1 Favored 'General case' 0 N--CA 1.486 1.333 0 C-N-CA 122.634 0.374 . . . . 0.0 110.049 179.065 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' GLN . . . . . 0.539 HE22 ' C ' ' A' ' 38' ' ' GLY . 78.9 mt-30 -90.63 121.52 32.61 Favored 'General case' 0 N--CA 1.452 -0.371 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 -178.964 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -112.98 103.67 11.63 Favored 'General case' 0 N--CA 1.475 0.789 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 176.686 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 57.8 tp -133.34 150.43 51.85 Favored 'General case' 0 N--CA 1.486 1.347 0 N-CA-C 108.766 -0.827 . . . . 0.0 108.766 -179.391 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 84.5 t -145.42 123.13 4.65 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.969 0 CA-C-O 118.523 -0.751 . . . . 0.0 109.137 179.755 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 11.9 m-85 -70.74 158.67 35.89 Favored 'General case' 0 N--CA 1.485 1.324 0 N-CA-C 107.461 -1.311 . . . . 0.0 107.461 177.564 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 18.6 t80 -170.07 -58.44 0.02 OUTLIER 'General case' 0 N--CA 1.481 1.101 0 CA-C-O 122.425 1.107 . . . . 0.0 109.765 179.735 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -39.19 89.68 0.0 OUTLIER 'General case' 0 N--CA 1.456 -0.135 0 CA-C-N 113.807 -1.542 . . . . 0.0 112.844 -178.034 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 38.6 tt0 -64.49 159.59 21.2 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.175 -0.92 . . . . 0.0 110.552 179.245 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 9.6 m-20 -136.23 125.81 25.3 Favored 'General case' 0 N--CA 1.481 1.086 0 C-N-CA 123.297 0.639 . . . . 0.0 109.781 -179.897 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.861 HG12 ' H ' ' A' ' 25' ' ' GLY . 57.8 t -76.55 -170.44 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.591 0 N-CA-C 108.511 -0.922 . . . . 0.0 108.511 179.673 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.861 ' H ' HG12 ' A' ' 24' ' ' VAL . . . -69.11 48.86 0.52 Allowed Glycine 0 CA--C 1.53 1.003 0 CA-C-N 118.344 0.52 . . . . 0.0 112.313 -178.147 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 13.1 p -69.54 137.52 52.52 Favored 'General case' 0 C--O 1.217 -0.61 0 N-CA-C 109.596 -0.52 . . . . 0.0 109.596 178.66 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 27' ' ' ASN . . . . . 0.512 HD21 ' CG ' ' B' ' 11' ' ' GLU . 34.6 t30 -68.57 95.06 0.61 Allowed 'General case' 0 N--CA 1.47 0.553 0 N-CA-C 108.15 -1.055 . . . . 0.0 108.15 177.847 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 68.6 mttm -92.45 117.66 30.16 Favored 'General case' 0 N--CA 1.481 1.079 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 -179.221 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.33 -134.27 0.01 OUTLIER Glycine 0 CA--C 1.534 1.226 0 N-CA-C 110.771 -0.932 . . . . 0.0 110.771 179.044 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -115.65 127.16 54.98 Favored 'General case' 0 N--CA 1.477 0.897 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 179.12 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 66.1 mt -90.53 134.97 27.76 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.59 0 N-CA-C 107.673 -1.232 . . . . 0.0 107.673 179.012 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 30.3 mt -136.52 138.16 46.92 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.815 0 CA-C-N 115.982 -0.554 . . . . 0.0 109.606 -179.134 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.97 57.46 15.75 Favored Glycine 0 CA--C 1.527 0.842 0 CA-C-N 115.904 -0.589 . . . . 0.0 112.795 178.543 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 25.4 tp -106.11 132.77 51.79 Favored 'General case' 0 N--CA 1.488 1.474 0 N-CA-C 107.508 -1.293 . . . . 0.0 107.508 177.919 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 24.9 ttt -138.2 148.15 44.52 Favored 'General case' 0 N--CA 1.471 0.576 0 N-CA-C 107.769 -1.197 . . . . 0.0 107.769 179.136 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 60.4 t -156.64 160.45 2.25 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.587 0 N-CA-C 106.097 -1.816 . . . . 0.0 106.097 -178.855 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 53.55 74.48 0.3 Allowed Glycine 0 C--N 1.308 -0.993 0 C-N-CA 121.214 -0.517 . . . . 0.0 111.818 177.839 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 38' ' ' GLY . . . . . 0.539 ' C ' HE22 ' A' ' 15' ' ' GLN . . . 164.73 -168.51 39.02 Favored Glycine 0 N--CA 1.466 0.692 0 N-CA-C 111.042 -0.823 . . . . 0.0 111.042 179.352 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 24.5 m -126.67 148.9 31.38 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.855 0 C-N-CA 122.977 0.511 . . . . 0.0 109.847 179.665 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 9.7 t . . . . . 0 CA--C 1.535 0.385 0 CA-C-O 118.109 -0.948 . . . . 0.0 110.723 178.893 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' B' B ' 1' ' ' ASP . . . . . . . . . . . . . 9.5 m-20 . . . . . 0 N--CA 1.494 1.74 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' B' B ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.28 129.85 42.65 Favored 'General case' 0 N--CA 1.47 0.544 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.238 179.47 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 3' ' ' GLU . . . . . . . . . . . . . 38.6 tt0 -138.77 104.59 5.13 Favored 'General case' 0 N--CA 1.48 1.029 0 N-CA-C 109.515 -0.55 . . . . 0.0 109.515 179.333 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 27.8 m-85 -72.9 169.03 17.7 Favored 'General case' 0 N--CA 1.468 0.435 0 N-CA-C 109.154 -0.684 . . . . 0.0 109.154 179.428 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 39.3 mtp180 -68.48 146.74 52.88 Favored 'General case' 0 C--O 1.201 -1.478 0 CA-C-N 115.708 -0.678 . . . . 0.0 111.3 -177.653 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 39.4 m80 -109.35 119.36 39.24 Favored 'General case' 0 N--CA 1.484 1.247 0 N-CA-C 108.995 -0.742 . . . . 0.0 108.995 178.282 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 7' ' ' ASP . . . . . 0.46 ' OD1' ' NH2' ' H' ' 5' ' ' ARG . 7.1 m-20 -67.66 141.02 56.84 Favored 'General case' 0 N--CA 1.469 0.501 0 CA-C-O 121.043 0.449 . . . . 0.0 111.76 -178.745 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 8' ' ' SER . . . . . . . . . . . . . 39.1 t -158.8 -169.45 2.7 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-N 115.814 -0.63 . . . . 0.0 109.634 179.099 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 119.75 32.37 1.21 Allowed Glycine 0 N--CA 1.485 1.92 0 N-CA-C 111.552 -0.619 . . . . 0.0 111.552 179.578 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 46.8 p90 -57.36 130.54 46.71 Favored 'General case' 0 N--CA 1.472 0.651 0 CA-C-O 120.64 0.257 . . . . 0.0 111.514 -179.996 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 11' ' ' GLU . . . . . 0.512 ' CG ' HD21 ' A' ' 27' ' ' ASN . 60.4 mt-10 -90.52 153.16 20.57 Favored 'General case' 0 N--CA 1.472 0.664 0 N-CA-C 109.357 -0.609 . . . . 0.0 109.357 178.857 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.6 p -153.53 126.14 1.09 Allowed 'Isoleucine or valine' 0 C--O 1.234 0.281 0 N-CA-C 107.846 -1.168 . . . . 0.0 107.846 178.086 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 45.6 m-70 -136.63 162.07 34.15 Favored 'General case' 0 N--CA 1.49 1.533 0 CA-C-N 118.648 0.658 . . . . 0.0 110.936 -178.567 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 38.4 t60 -152.86 96.44 2.1 Favored 'General case' 0 N--CA 1.487 1.422 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.087 179.057 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 15' ' ' GLN . . . . . 0.539 HE22 ' C ' ' B' ' 38' ' ' GLY . 78.9 mt-30 -90.48 121.16 32.2 Favored 'General case' 0 CA--C 1.517 -0.309 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 -179.01 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -112.63 103.49 11.53 Favored 'General case' 0 N--CA 1.474 0.742 0 N-CA-C 107.988 -1.115 . . . . 0.0 107.988 176.619 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 57.8 tp -133.34 150.25 51.86 Favored 'General case' 0 N--CA 1.486 1.369 0 N-CA-C 108.755 -0.831 . . . . 0.0 108.755 -179.368 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 84.6 t -145.41 122.48 4.28 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.011 0 CA-C-O 118.629 -0.7 . . . . 0.0 109.333 179.707 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 12.4 m-85 -70.52 158.91 35.26 Favored 'General case' 0 N--CA 1.486 1.334 0 N-CA-C 107.287 -1.375 . . . . 0.0 107.287 177.572 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 19.9 t80 -170.99 -57.67 0.02 OUTLIER 'General case' 0 N--CA 1.478 0.934 0 CA-C-O 122.22 1.009 . . . . 0.0 109.705 179.651 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -39.4 90.12 0.0 OUTLIER 'General case' 0 C--O 1.231 0.124 0 CA-C-N 113.959 -1.473 . . . . 0.0 112.721 -178.16 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 38.6 tt0 -64.85 159.55 22.35 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 115.1 -0.955 . . . . 0.0 110.559 179.298 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 9.7 m-20 -136.26 125.9 25.4 Favored 'General case' 0 N--CA 1.481 1.118 0 C-N-CA 123.217 0.607 . . . . 0.0 109.765 -179.876 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 24' ' ' VAL . . . . . 0.848 HG12 ' H ' ' B' ' 25' ' ' GLY . 56.9 t -76.7 -170.39 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.661 0 N-CA-C 108.586 -0.894 . . . . 0.0 108.586 179.722 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 25' ' ' GLY . . . . . 0.848 ' H ' HG12 ' B' ' 24' ' ' VAL . . . -68.71 48.42 0.45 Allowed Glycine 0 CA--C 1.531 1.087 0 CA-C-N 118.321 0.509 . . . . 0.0 112.208 -178.126 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 13.3 p -69.72 137.41 52.02 Favored 'General case' 0 C--O 1.219 -0.548 0 N-CA-C 109.591 -0.522 . . . . 0.0 109.591 178.706 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 27' ' ' ASN . . . . . 0.507 HD21 ' CG ' ' C' ' 11' ' ' GLU . 34.8 t30 -68.72 95.07 0.64 Allowed 'General case' 0 N--CA 1.47 0.543 0 N-CA-C 108.159 -1.052 . . . . 0.0 108.159 177.847 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 68.6 mttm -92.34 117.62 30.08 Favored 'General case' 0 N--CA 1.48 1.028 0 N-CA-C 109.997 -0.371 . . . . 0.0 109.997 -179.227 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.3 -134.17 0.01 OUTLIER Glycine 0 CA--C 1.532 1.128 0 N-CA-C 110.769 -0.932 . . . . 0.0 110.769 179.014 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -115.88 127.28 54.89 Favored 'General case' 0 N--CA 1.478 0.955 0 N-CA-C 109.428 -0.582 . . . . 0.0 109.428 179.149 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 66.0 mt -90.55 135.0 27.69 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.536 0 N-CA-C 107.676 -1.231 . . . . 0.0 107.676 179.035 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 30.2 mt -136.45 138.35 46.8 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.714 0 CA-C-N 115.933 -0.576 . . . . 0.0 109.567 -179.115 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.65 57.72 15.16 Favored Glycine 0 CA--C 1.527 0.829 0 CA-C-N 115.876 -0.602 . . . . 0.0 112.82 178.604 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 25.8 tp -106.3 132.83 51.88 Favored 'General case' 0 N--CA 1.486 1.375 0 N-CA-C 107.502 -1.296 . . . . 0.0 107.502 177.897 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 25.0 ttt -138.18 147.83 44.22 Favored 'General case' 0 N--CA 1.473 0.683 0 N-CA-C 107.778 -1.193 . . . . 0.0 107.778 179.216 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 36' ' ' VAL . . . . . 0.404 HG12 ' N ' ' B' ' 37' ' ' GLY . 60.8 t -156.67 159.98 2.45 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.625 0 N-CA-C 106.178 -1.786 . . . . 0.0 106.178 -178.928 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 37' ' ' GLY . . . . . 0.404 ' N ' HG12 ' B' ' 36' ' ' VAL . . . 54.12 74.26 0.33 Allowed Glycine 0 C--N 1.308 -0.973 0 N-CA-C 111.739 -0.544 . . . . 0.0 111.739 177.963 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 38' ' ' GLY . . . . . 0.539 ' C ' HE22 ' B' ' 15' ' ' GLN . . . 164.85 -168.44 39.07 Favored Glycine 0 N--CA 1.465 0.58 0 N-CA-C 111.124 -0.791 . . . . 0.0 111.124 179.266 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 24.5 m -126.62 148.89 31.33 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.808 0 C-N-CA 122.992 0.517 . . . . 0.0 109.955 179.601 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 9.7 t . . . . . 0 CA--C 1.535 0.392 0 CA-C-O 118.095 -0.955 . . . . 0.0 110.872 179.001 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' C' C ' 1' ' ' ASP . . . . . . . . . . . . . 9.5 m-20 . . . . . 0 N--CA 1.494 1.727 0 N-CA-C 109.703 -0.48 . . . . 0.0 109.703 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' C' C ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.4 129.73 42.02 Favored 'General case' 0 N--CA 1.47 0.538 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.29 179.4 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' C' C ' 3' ' ' GLU . . . . . . . . . . . . . 38.6 tt0 -138.64 104.6 5.16 Favored 'General case' 0 N--CA 1.48 1.062 0 N-CA-C 109.635 -0.506 . . . . 0.0 109.635 179.33 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 27.7 m-85 -72.93 169.23 17.32 Favored 'General case' 0 N--CA 1.468 0.429 0 N-CA-C 109.265 -0.643 . . . . 0.0 109.265 179.448 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 39.2 mtp180 -68.67 146.37 53.05 Favored 'General case' 0 C--O 1.201 -1.489 0 CA-C-N 115.849 -0.614 . . . . 0.0 111.221 -177.564 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 39.2 m80 -109.11 119.22 38.9 Favored 'General case' 0 N--CA 1.484 1.232 0 N-CA-C 108.978 -0.749 . . . . 0.0 108.978 178.269 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' C' C ' 7' ' ' ASP . . . . . 0.473 ' OD1' ' NH2' ' I' ' 5' ' ' ARG . 7.3 m-20 -67.64 141.11 56.83 Favored 'General case' 0 N--CA 1.468 0.448 0 CA-C-O 121.049 0.452 . . . . 0.0 111.79 -178.721 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' C' C ' 8' ' ' SER . . . . . . . . . . . . . 39.2 t -158.89 -169.49 2.71 Favored 'General case' 0 N--CA 1.466 0.37 0 CA-C-N 115.837 -0.62 . . . . 0.0 109.604 179.149 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 119.8 32.34 1.21 Allowed Glycine 0 N--CA 1.485 1.94 0 N-CA-C 111.506 -0.638 . . . . 0.0 111.506 179.543 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 46.8 p90 -57.32 130.42 46.15 Favored 'General case' 0 N--CA 1.471 0.587 0 CA-C-O 120.676 0.274 . . . . 0.0 111.53 179.951 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' C' C ' 11' ' ' GLU . . . . . 0.507 ' CG ' HD21 ' B' ' 27' ' ' ASN . 60.5 mt-10 -90.39 153.12 20.65 Favored 'General case' 0 N--CA 1.473 0.722 0 N-CA-C 109.368 -0.605 . . . . 0.0 109.368 178.792 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.6 p -153.47 126.16 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 N-CA-C 107.858 -1.164 . . . . 0.0 107.858 178.017 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 45.8 m-70 -136.59 162.16 33.9 Favored 'General case' 0 N--CA 1.491 1.589 0 CA-C-N 118.604 0.638 . . . . 0.0 110.958 -178.658 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 38.6 t60 -153.01 96.61 2.1 Favored 'General case' 0 N--CA 1.487 1.413 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.1 179.086 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' C' C ' 15' ' ' GLN . . . . . 0.523 HE22 ' C ' ' C' ' 38' ' ' GLY . 78.8 mt-30 -90.72 121.5 32.67 Favored 'General case' 0 CA--C 1.515 -0.381 0 N-CA-C 109.843 -0.429 . . . . 0.0 109.843 -178.99 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -112.92 103.49 11.46 Favored 'General case' 0 N--CA 1.473 0.677 0 N-CA-C 107.898 -1.149 . . . . 0.0 107.898 176.665 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 57.8 tp -133.28 150.23 51.92 Favored 'General case' 0 N--CA 1.486 1.337 0 N-CA-C 108.769 -0.826 . . . . 0.0 108.769 -179.435 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 85.3 t -145.38 122.59 4.37 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.013 0 CA-C-O 118.694 -0.67 . . . . 0.0 109.289 179.714 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 12.4 m-85 -70.63 158.88 35.41 Favored 'General case' 0 N--CA 1.487 1.39 0 N-CA-C 107.345 -1.354 . . . . 0.0 107.345 177.516 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 19.9 t80 -170.9 -57.72 0.02 OUTLIER 'General case' 0 N--CA 1.476 0.86 0 CA-C-O 122.29 1.043 . . . . 0.0 109.731 179.641 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -39.31 90.01 0.0 OUTLIER 'General case' 0 N--CA 1.457 -0.088 0 CA-C-N 113.986 -1.461 . . . . 0.0 112.711 -178.157 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 38.6 tt0 -64.84 159.64 22.11 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 115.183 -0.917 . . . . 0.0 110.593 179.343 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 9.6 m-20 -136.28 125.77 25.15 Favored 'General case' 0 N--CA 1.48 1.048 0 C-N-CA 123.315 0.646 . . . . 0.0 109.798 -179.838 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' C' C ' 24' ' ' VAL . . . . . 0.845 HG12 ' H ' ' C' ' 25' ' ' GLY . 57.1 t -76.66 -170.4 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.578 0 N-CA-C 108.609 -0.885 . . . . 0.0 108.609 179.708 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' C' C ' 25' ' ' GLY . . . . . 0.845 ' H ' HG12 ' C' ' 24' ' ' VAL . . . -68.8 48.56 0.47 Allowed Glycine 0 CA--C 1.533 1.18 0 CA-C-N 118.409 0.549 . . . . 0.0 112.249 -178.066 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 13.3 p -69.73 137.47 52.04 Favored 'General case' 0 C--O 1.22 -0.459 0 N-CA-C 109.646 -0.501 . . . . 0.0 109.646 178.716 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' C' C ' 27' ' ' ASN . . . . . 0.506 HD21 ' CG ' ' A' ' 11' ' ' GLU . 34.8 t30 -68.7 95.04 0.63 Allowed 'General case' 0 N--CA 1.469 0.485 0 N-CA-C 108.179 -1.045 . . . . 0.0 108.179 177.851 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 68.6 mttm -92.36 117.66 30.14 Favored 'General case' 0 N--CA 1.48 1.053 0 N-CA-C 109.988 -0.375 . . . . 0.0 109.988 -179.233 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.32 -134.2 0.01 OUTLIER Glycine 0 CA--C 1.533 1.16 0 N-CA-C 110.784 -0.926 . . . . 0.0 110.784 179.02 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -115.7 127.12 54.91 Favored 'General case' 0 N--CA 1.48 1.067 0 N-CA-C 109.314 -0.625 . . . . 0.0 109.314 179.203 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 66.2 mt -90.57 134.9 28.0 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.574 0 N-CA-C 107.666 -1.235 . . . . 0.0 107.666 178.845 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 30.4 mt -136.51 138.37 46.7 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.77 0 CA-C-N 115.937 -0.574 . . . . 0.0 109.545 -179.099 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.72 57.55 15.76 Favored Glycine 0 CA--C 1.528 0.887 0 CA-C-N 115.866 -0.606 . . . . 0.0 112.791 178.663 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 25.6 tp -106.13 132.75 51.83 Favored 'General case' 0 N--CA 1.486 1.353 0 N-CA-C 107.471 -1.307 . . . . 0.0 107.471 177.832 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 25.1 ttt -138.09 147.96 44.54 Favored 'General case' 0 N--CA 1.47 0.568 0 N-CA-C 107.591 -1.262 . . . . 0.0 107.591 179.315 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' C' C ' 36' ' ' VAL . . . . . 0.401 HG12 ' N ' ' C' ' 37' ' ' GLY . 60.6 t -156.81 160.05 2.4 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.546 0 N-CA-C 106.076 -1.824 . . . . 0.0 106.076 -178.959 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' C' C ' 37' ' ' GLY . . . . . 0.401 ' N ' HG12 ' C' ' 36' ' ' VAL . . . 54.1 74.12 0.34 Allowed Glycine 0 C--N 1.309 -0.925 0 C-N-CA 121.116 -0.564 . . . . 0.0 111.788 177.848 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' C' C ' 38' ' ' GLY . . . . . 0.523 ' C ' HE22 ' C' ' 15' ' ' GLN . . . 164.9 -168.36 39.07 Favored Glycine 0 N--CA 1.466 0.65 0 N-CA-C 111.104 -0.799 . . . . 0.0 111.104 179.349 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 24.2 m -126.71 148.88 31.43 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.858 0 C-N-CA 122.934 0.494 . . . . 0.0 109.935 179.716 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 9.8 t . . . . . 0 CA--C 1.534 0.364 0 CA-C-O 118.187 -0.911 . . . . 0.0 110.7 178.884 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' D' D ' 1' ' ' ASP . . . . . . . . . . . . . 9.5 m-20 . . . . . 0 N--CA 1.492 1.633 0 N-CA-C 108.994 -0.743 . . . . 0.0 108.994 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' D' D ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.18 130.94 45.16 Favored 'General case' 0 N--CA 1.468 0.449 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.289 -179.9 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' D' D ' 3' ' ' GLU . . . . . . . . . . . . . 38.8 tt0 -136.81 108.62 7.06 Favored 'General case' 0 C--O 1.212 -0.886 0 C-N-CA 123.14 0.576 . . . . 0.0 109.492 179.463 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 28.7 m-85 -77.57 165.4 24.36 Favored 'General case' 0 C--N 1.306 -1.294 0 C-N-CA 125.804 1.642 . . . . 0.0 107.949 179.843 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' D' D ' 5' ' ' ARG . . . . . 0.772 HH12 HG13 ' C' ' 24' ' ' VAL 0.273 47.8 mtp180 -77.55 143.45 38.37 Favored 'General case' 0 C--O 1.207 -1.15 0 C-N-CA 123.595 0.758 . . . . 0.0 109.044 -169.708 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 40.5 m80 -107.79 124.44 50.05 Favored 'General case' 0 C--N 1.366 1.301 0 N-CA-C 106.87 -1.53 . . . . 0.0 106.87 -176.282 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' D' D ' 7' ' ' ASP . . . . . 0.468 ' OD2' HG11 ' I' ' 24' ' ' VAL . 7.9 m-20 -64.28 131.92 48.73 Favored 'General case' 0 CA--C 1.512 -0.485 0 CA-C-N 113.897 -1.501 . . . . 0.0 114.077 179.004 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' D' D ' 8' ' ' SER . . . . . . . . . . . . . 40.9 t -152.62 -167.8 2.86 Favored 'General case' 0 N--CA 1.482 1.152 0 C-N-CA 120.908 -0.317 . . . . 0.0 110.17 177.028 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 120.71 30.23 1.41 Allowed Glycine 0 N--CA 1.486 1.967 0 N-CA-C 111.35 -0.7 . . . . 0.0 111.35 177.862 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 44.9 p90 -54.46 131.13 41.87 Favored 'General case' 0 CA--C 1.545 0.785 0 CA-C-N 117.085 0.442 . . . . 0.0 111.591 -179.557 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' D' D ' 11' ' ' GLU . . . . . 0.435 ' CG ' HD21 ' F' ' 27' ' ' ASN . 60.3 mt-10 -89.7 151.2 21.98 Favored 'General case' 0 N--CA 1.475 0.808 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 177.324 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -149.66 129.07 3.53 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.529 0 N-CA-C 107.339 -1.356 . . . . 0.0 107.339 172.59 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 36.0 m-70 -130.29 162.59 28.67 Favored 'General case' 0 N--CA 1.48 1.054 0 C-N-CA 123.678 0.791 . . . . 0.0 112.902 178.205 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 41.5 t60 -153.96 104.31 2.65 Favored 'General case' 0 N--CA 1.486 1.35 0 N-CA-C 108.418 -0.956 . . . . 0.0 108.418 171.54 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' D' D ' 15' ' ' GLN . . . . . 0.522 HE22 ' C ' ' D' ' 38' ' ' GLY . 78.8 mt-30 -93.84 116.03 28.46 Favored 'General case' 0 CA--C 1.505 -0.762 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.325 -179.625 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -108.37 111.82 23.93 Favored 'General case' 0 C--N 1.359 0.99 0 N-CA-C 106.059 -1.83 . . . . 0.0 106.059 174.383 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 52.7 tp -134.32 150.73 50.98 Favored 'General case' 0 N--CA 1.484 1.238 0 N-CA-C 108.973 -0.751 . . . . 0.0 108.973 176.074 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 71.0 t -142.39 126.05 15.1 Favored 'Isoleucine or valine' 0 C--O 1.242 0.674 0 N-CA-C 109.141 -0.689 . . . . 0.0 109.141 173.863 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 26.8 m-85 -62.12 151.54 35.42 Favored 'General case' 0 N--CA 1.473 0.699 0 C-N-CA 124.284 1.034 . . . . 0.0 110.325 169.712 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 14.0 t80 -170.13 -66.86 0.02 OUTLIER 'General case' 0 C--N 1.318 -0.766 0 N-CA-C 107.765 -1.198 . . . . 0.0 107.765 -179.703 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -38.17 95.54 0.01 OUTLIER 'General case' 0 N--CA 1.449 -0.502 0 CA-C-N 114.207 -1.361 . . . . 0.0 111.798 -175.017 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 39.2 tt0 -67.51 161.12 26.19 Favored 'General case' 0 N--CA 1.468 0.458 0 CA-C-N 113.628 -1.624 . . . . 0.0 110.139 178.805 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 9.9 m-20 -137.22 126.52 24.79 Favored 'General case' 0 N--CA 1.479 1.019 0 C-N-CA 123.472 0.709 . . . . 0.0 109.942 -179.068 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' D' D ' 24' ' ' VAL . . . . . 0.943 HG12 ' H ' ' D' ' 25' ' ' GLY . 92.3 t -81.13 -165.64 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.482 1.169 0 N-CA-C 107.566 -1.272 . . . . 0.0 107.566 -178.098 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' D' D ' 25' ' ' GLY . . . . . 0.943 ' H ' HG12 ' D' ' 24' ' ' VAL . . . -79.27 56.62 4.4 Favored Glycine 0 C--N 1.362 1.997 0 C-N-CA 117.855 -2.117 . . . . 0.0 110.628 -174.263 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 21.8 p -61.34 132.83 54.82 Favored 'General case' 0 C--N 1.346 0.426 0 CA-C-N 113.545 -1.328 . . . . 0.0 111.965 170.648 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' D' D ' 27' ' ' ASN . . . . . 0.447 HD21 ' CG ' ' E' ' 11' ' ' GLU . 40.6 t30 -65.53 95.06 0.2 Allowed 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 119.908 1.231 . . . . 0.0 108.751 172.971 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 68.3 mttm -93.89 120.97 34.87 Favored 'General case' 0 N--CA 1.484 1.26 0 C-N-CA 119.521 -0.871 . . . . 0.0 108.908 179.756 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -57.45 -135.01 0.01 OUTLIER Glycine 0 C--N 1.341 0.806 0 CA-C-N 115.858 -0.61 . . . . 0.0 113.067 175.974 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -114.22 131.76 56.36 Favored 'General case' 0 C--N 1.367 1.357 0 N-CA-C 109.101 -0.703 . . . . 0.0 109.101 174.572 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 68.6 mt -91.79 138.43 19.82 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.298 0 N-CA-C 107.182 -1.414 . . . . 0.0 107.182 176.845 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 35.2 mt -138.7 140.85 38.4 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.879 0 N-CA-C 108.639 -0.875 . . . . 0.0 108.639 178.518 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.54 55.04 27.62 Favored Glycine 0 CA--C 1.529 0.911 0 CA-C-O 119.381 -0.677 . . . . 0.0 112.588 178.313 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 19.2 tp -102.84 141.59 35.39 Favored 'General case' 0 C--N 1.364 1.207 0 N-CA-C 106.333 -1.728 . . . . 0.0 106.333 176.536 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 23.9 ttt -142.07 156.95 45.42 Favored 'General case' 0 N--CA 1.472 0.664 0 N-CA-C 105.952 -1.87 . . . . 0.0 105.952 175.085 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 73.7 t -164.34 161.89 0.93 Allowed 'Isoleucine or valine' 0 CA--C 1.503 -0.835 0 N-CA-C 105.349 -2.093 . . . . 0.0 105.349 179.19 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' D' D ' 37' ' ' GLY . . . . . 0.422 ' O ' ' O ' ' G' ' 38' ' ' GLY . . . 60.21 64.44 4.15 Favored Glycine 0 N--CA 1.441 -1.004 0 C-N-CA 118.38 -1.867 . . . . 0.0 112.453 176.301 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' D' D ' 38' ' ' GLY . . . . . 0.522 ' C ' HE22 ' D' ' 15' ' ' GLN . . . 166.46 -163.86 37.23 Favored Glycine 0 C--O 1.215 -1.051 0 CA-C-N 119.308 1.554 . . . . 0.0 112.264 176.493 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 29.4 m -121.64 147.45 25.61 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.067 0 CA-C-O 118.041 -0.981 . . . . 0.0 112.259 179.35 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 7.5 t . . . . . 0 C--O 1.213 -0.864 0 N-CA-C 108.798 -0.815 . . . . 0.0 108.798 171.652 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' E' E ' 1' ' ' ASP . . . . . . . . . . . . . 9.5 m-20 . . . . . 0 N--CA 1.491 1.585 0 N-CA-C 108.965 -0.754 . . . . 0.0 108.965 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' E' E ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.65 132.01 48.53 Favored 'General case' 0 N--CA 1.467 0.407 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.21 179.693 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' E' E ' 3' ' ' GLU . . . . . . . . . . . . . 38.8 tt0 -139.08 103.12 4.69 Favored 'General case' 0 N--CA 1.48 1.059 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 -179.794 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 24.8 m-85 -70.29 169.23 14.21 Favored 'General case' 0 N--CA 1.471 0.579 0 N-CA-C 109.445 -0.576 . . . . 0.0 109.445 179.354 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' E' E ' 5' ' ' ARG . . . . . 0.756 HH12 HG13 ' A' ' 24' ' ' VAL . 34.9 mtp180 -68.13 148.15 51.31 Favored 'General case' 0 C--O 1.202 -1.419 0 CA-C-N 115.567 -0.742 . . . . 0.0 111.313 -178.012 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 39.2 m80 -109.9 118.97 37.89 Favored 'General case' 0 N--CA 1.483 1.181 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 177.889 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' E' E ' 7' ' ' ASP . . . . . 0.442 ' OD1' HG11 ' G' ' 24' ' ' VAL . 13.0 m-20 -66.31 140.28 58.1 Favored 'General case' 0 N--CA 1.466 0.37 0 CA-C-O 120.91 0.386 . . . . 0.0 112.02 -178.442 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' E' E ' 8' ' ' SER . . . . . . . . . . . . . 38.2 t -158.7 -169.87 2.86 Favored 'General case' 0 N--CA 1.487 1.378 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.194 178.924 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 120.33 32.84 1.09 Allowed Glycine 0 N--CA 1.484 1.867 0 N-CA-C 111.717 -0.553 . . . . 0.0 111.717 179.538 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 43.3 p90 -56.84 130.54 46.19 Favored 'General case' 0 CA--C 1.546 0.796 0 CA-C-N 116.948 0.374 . . . . 0.0 111.64 -179.963 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' E' E ' 11' ' ' GLU . . . . . 0.447 ' CG ' HD21 ' D' ' 27' ' ' ASN . 60.2 mt-10 -89.98 153.49 20.55 Favored 'General case' 0 N--CA 1.478 0.945 0 N-CA-C 109.404 -0.591 . . . . 0.0 109.404 178.606 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.8 p -155.15 124.78 0.74 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.575 0 N-CA-C 108.183 -1.043 . . . . 0.0 108.183 177.872 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 43.9 m-70 -136.04 160.95 37.07 Favored 'General case' 0 N--CA 1.481 1.113 0 CA-C-O 120.746 0.308 . . . . 0.0 111.115 -177.515 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 38.8 t60 -152.96 96.75 2.13 Favored 'General case' 0 N--CA 1.488 1.475 0 C-N-CA 122.687 0.395 . . . . 0.0 109.951 179.241 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' E' E ' 15' ' ' GLN . . . . . 0.49 HE22 ' C ' ' E' ' 38' ' ' GLY . 78.8 mt-30 -90.75 122.25 33.33 Favored 'General case' 0 C--N 1.329 -0.297 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 -179.064 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -113.78 103.5 11.27 Favored 'General case' 0 N--CA 1.474 0.726 0 N-CA-C 107.69 -1.226 . . . . 0.0 107.69 176.638 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 53.9 tp -132.19 149.1 52.47 Favored 'General case' 0 N--CA 1.486 1.343 0 C-N-CA 123.368 0.667 . . . . 0.0 109.269 -178.844 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 57.7 t -145.25 123.59 5.23 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.837 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 179.154 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 11.2 m-85 -71.4 156.35 39.58 Favored 'General case' 0 C--N 1.363 1.155 0 N-CA-C 106.911 -1.515 . . . . 0.0 106.911 176.937 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 17.8 t80 -172.13 -55.94 0.02 OUTLIER 'General case' 0 N--CA 1.481 1.084 0 CA-C-O 121.83 0.824 . . . . 0.0 110.238 179.733 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.99 88.26 0.0 OUTLIER 'General case' 0 C--N 1.319 -0.759 0 CA-C-N 114.107 -1.406 . . . . 0.0 112.87 -178.986 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 39.0 tt0 -63.26 159.72 17.24 Favored 'General case' 0 N--CA 1.471 0.625 0 CA-C-N 114.855 -1.066 . . . . 0.0 110.842 179.831 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 9.6 m-20 -136.56 125.52 24.29 Favored 'General case' 0 N--CA 1.482 1.162 0 C-N-CA 123.3 0.64 . . . . 0.0 110.23 -179.67 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' E' E ' 24' ' ' VAL . . . . . 0.873 HG12 ' H ' ' E' ' 25' ' ' GLY . 58.5 t -76.08 -170.35 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.484 1.252 0 N-CA-C 108.029 -1.1 . . . . 0.0 108.029 179.436 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' E' E ' 25' ' ' GLY . . . . . 0.873 ' H ' HG12 ' E' ' 24' ' ' VAL . . . -68.89 49.65 0.5 Allowed Glycine 0 CA--C 1.531 1.031 0 CA-C-N 118.079 0.4 . . . . 0.0 112.626 -178.132 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 8.1 p -69.16 136.79 52.65 Favored 'General case' 0 C--O 1.219 -0.514 0 N-CA-C 109.705 -0.48 . . . . 0.0 109.705 178.494 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' E' E ' 27' ' ' ASN . . . . . 0.445 HD21 ' CG ' ' F' ' 11' ' ' GLU . 36.2 t30 -68.3 95.5 0.6 Allowed 'General case' 0 N--CA 1.466 0.328 0 N-CA-C 107.481 -1.303 . . . . 0.0 107.481 177.388 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 68.1 mttm -93.33 117.09 29.66 Favored 'General case' 0 N--CA 1.482 1.136 0 N-CA-C 109.612 -0.514 . . . . 0.0 109.612 -178.858 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.16 -133.98 0.01 OUTLIER Glycine 0 CA--C 1.536 1.392 0 N-CA-C 111.308 -0.717 . . . . 0.0 111.308 178.877 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -115.66 126.42 54.13 Favored 'General case' 0 N--CA 1.481 1.081 0 N-CA-C 109.637 -0.505 . . . . 0.0 109.637 179.225 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 66.8 mt -89.35 135.02 27.02 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.213 0 N-CA-C 107.571 -1.27 . . . . 0.0 107.571 178.914 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 33.1 mt -136.21 137.83 47.85 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.867 0 N-CA-C 108.991 -0.744 . . . . 0.0 108.991 -179.768 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.37 59.68 8.54 Favored Glycine 0 CA--C 1.527 0.82 0 CA-C-N 116.047 -0.524 . . . . 0.0 112.947 178.835 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 22.0 tp -107.49 131.81 53.91 Favored 'General case' 0 N--CA 1.487 1.41 0 N-CA-C 107.454 -1.313 . . . . 0.0 107.454 177.741 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 23.6 ttt -137.26 147.82 45.99 Favored 'General case' 0 N--CA 1.472 0.66 0 N-CA-C 107.815 -1.18 . . . . 0.0 107.815 178.709 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' E' E ' 36' ' ' VAL . . . . . 0.407 HG12 ' N ' ' E' ' 37' ' ' GLY . 59.8 t -156.7 159.94 2.47 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.693 0 N-CA-C 106.457 -1.683 . . . . 0.0 106.457 -178.899 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' E' E ' 37' ' ' GLY . . . . . 0.407 ' N ' HG12 ' E' ' 36' ' ' VAL . . . 54.12 73.4 0.41 Allowed Glycine 0 C--N 1.31 -0.904 0 N-CA-C 111.801 -0.52 . . . . 0.0 111.801 177.787 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' E' E ' 38' ' ' GLY . . . . . 0.49 ' C ' HE22 ' E' ' 15' ' ' GLN . . . 165.83 -166.63 38.71 Favored Glycine 0 C--O 1.21 -1.395 0 N-CA-C 111.278 -0.729 . . . . 0.0 111.278 179.256 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 21.6 m -128.34 148.88 32.8 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.827 0 C-N-CA 122.833 0.453 . . . . 0.0 109.91 179.913 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 7.5 t . . . . . 0 CA--C 1.541 0.598 0 CA-C-O 118.202 -0.904 . . . . 0.0 110.473 178.85 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' F' F ' 1' ' ' ASP . . . . . . . . . . . . . 9.6 m-20 . . . . . 0 N--CA 1.492 1.633 0 N-CA-C 108.88 -0.785 . . . . 0.0 108.88 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' F' F ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.71 132.11 48.75 Favored 'General case' 0 N--CA 1.468 0.449 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.191 179.692 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' F' F ' 3' ' ' GLU . . . . . . . . . . . . . 38.7 tt0 -139.16 103.08 4.67 Favored 'General case' 0 N--CA 1.482 1.157 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 -179.833 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 25.7 m-85 -70.2 169.52 13.48 Favored 'General case' 0 N--CA 1.472 0.645 0 N-CA-C 109.572 -0.529 . . . . 0.0 109.572 179.393 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' F' F ' 5' ' ' ARG . . . . . 0.756 HH12 HG13 ' B' ' 24' ' ' VAL . 35.5 mtp180 -68.08 147.4 52.4 Favored 'General case' 0 C--O 1.201 -1.476 0 CA-C-N 115.499 -0.773 . . . . 0.0 111.468 -178.017 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 39.2 m80 -109.47 118.89 37.82 Favored 'General case' 0 N--CA 1.484 1.266 0 N-CA-C 109.094 -0.706 . . . . 0.0 109.094 177.815 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' F' F ' 7' ' ' ASP . . . . . 0.474 ' OD1' HG11 ' H' ' 24' ' ' VAL . 13.0 m-20 -66.32 140.27 58.09 Favored 'General case' 0 N--CA 1.466 0.341 0 N-CA-C 112.159 0.429 . . . . 0.0 112.159 -178.453 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' F' F ' 8' ' ' SER . . . . . . . . . . . . . 38.3 t -158.73 -169.81 2.84 Favored 'General case' 0 N--CA 1.486 1.365 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.18 178.9 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 120.33 32.84 1.09 Allowed Glycine 0 N--CA 1.483 1.808 0 N-CA-C 111.679 -0.568 . . . . 0.0 111.679 179.559 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 43.3 p90 -57.02 130.73 47.35 Favored 'General case' 0 CA--C 1.545 0.763 0 CA-C-N 116.945 0.372 . . . . 0.0 111.614 -179.952 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' F' F ' 11' ' ' GLU . . . . . 0.445 ' CG ' HD21 ' E' ' 27' ' ' ASN . 60.3 mt-10 -90.04 153.53 20.5 Favored 'General case' 0 N--CA 1.478 0.959 0 CA-C-O 121.306 0.574 . . . . 0.0 109.457 178.513 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.8 p -155.22 124.78 0.74 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.532 0 N-CA-C 108.071 -1.085 . . . . 0.0 108.071 177.942 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 44.4 m-70 -136.03 160.83 37.42 Favored 'General case' 0 N--CA 1.48 1.062 0 CA-C-O 120.668 0.271 . . . . 0.0 111.142 -177.645 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 39.0 t60 -152.93 97.13 2.17 Favored 'General case' 0 N--CA 1.487 1.406 0 C-N-CA 122.75 0.42 . . . . 0.0 110.06 179.278 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' F' F ' 15' ' ' GLN . . . . . 0.478 ' NE2' ' O ' ' F' ' 38' ' ' GLY . 78.8 mt-30 -91.21 122.87 34.21 Favored 'General case' 0 CA--C 1.513 -0.474 0 N-CA-C 110.174 -0.306 . . . . 0.0 110.174 -179.141 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -114.23 103.48 11.14 Favored 'General case' 0 N--CA 1.471 0.608 0 N-CA-C 107.808 -1.182 . . . . 0.0 107.808 176.694 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 54.2 tp -132.17 149.13 52.46 Favored 'General case' 0 N--CA 1.486 1.355 0 C-N-CA 123.388 0.675 . . . . 0.0 109.307 -179.041 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 58.7 t -145.24 123.69 5.32 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.805 0 N-CA-C 109.37 -0.604 . . . . 0.0 109.37 179.205 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 11.2 m-85 -71.5 156.14 39.77 Favored 'General case' 0 C--N 1.363 1.195 0 N-CA-C 106.795 -1.557 . . . . 0.0 106.795 176.92 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 18.5 t80 -171.87 -55.96 0.02 OUTLIER 'General case' 0 N--CA 1.481 1.105 0 CA-C-O 121.784 0.802 . . . . 0.0 109.873 179.799 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.02 88.24 0.0 OUTLIER 'General case' 0 C--N 1.319 -0.725 0 CA-C-N 114.235 -1.348 . . . . 0.0 112.968 -178.968 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 38.9 tt0 -63.22 159.91 16.74 Favored 'General case' 0 N--CA 1.472 0.638 0 CA-C-N 114.857 -1.065 . . . . 0.0 110.856 179.756 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 9.7 m-20 -136.82 125.77 24.27 Favored 'General case' 0 N--CA 1.481 1.122 0 C-N-CA 123.271 0.628 . . . . 0.0 110.252 -179.735 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' F' F ' 24' ' ' VAL . . . . . 0.848 HG12 ' H ' ' F' ' 25' ' ' GLY . 59.1 t -76.28 -170.1 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.484 1.267 0 N-CA-C 108.168 -1.049 . . . . 0.0 108.168 179.485 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' F' F ' 25' ' ' GLY . . . . . 0.848 ' H ' HG12 ' F' ' 24' ' ' VAL . . . -68.85 49.4 0.49 Allowed Glycine 0 CA--C 1.528 0.847 0 CA-C-N 118.264 0.484 . . . . 0.0 112.491 -178.305 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 8.1 p -68.96 136.66 52.85 Favored 'General case' 0 C--O 1.219 -0.535 0 N-CA-C 109.536 -0.542 . . . . 0.0 109.536 178.378 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' F' F ' 27' ' ' ASN . . . . . 0.435 HD21 ' CG ' ' D' ' 11' ' ' GLU . 35.4 t30 -68.38 95.73 0.63 Allowed 'General case' 0 CA--C 1.535 0.371 0 N-CA-C 107.35 -1.352 . . . . 0.0 107.35 177.464 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 68.1 mttm -93.41 116.96 29.5 Favored 'General case' 0 N--CA 1.48 1.073 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -178.931 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.13 -134.15 0.01 OUTLIER Glycine 0 CA--C 1.537 1.444 0 N-CA-C 111.383 -0.687 . . . . 0.0 111.383 178.997 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -115.19 125.99 54.05 Favored 'General case' 0 N--CA 1.485 1.277 0 C-N-CA 123.064 0.546 . . . . 0.0 109.615 179.212 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 66.9 mt -89.3 134.88 27.37 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.236 0 N-CA-C 107.457 -1.312 . . . . 0.0 107.457 178.816 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 32.9 mt -136.25 137.87 47.73 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.805 0 N-CA-C 108.984 -0.747 . . . . 0.0 108.984 -179.723 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.24 59.81 8.44 Favored Glycine 0 CA--C 1.525 0.663 0 CA-C-N 116.01 -0.541 . . . . 0.0 112.884 178.878 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 21.8 tp -107.78 132.04 53.81 Favored 'General case' 0 N--CA 1.487 1.376 0 N-CA-C 107.585 -1.265 . . . . 0.0 107.585 177.668 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 23.4 ttt -137.53 147.99 45.61 Favored 'General case' 0 N--CA 1.468 0.434 0 N-CA-C 108.324 -0.991 . . . . 0.0 108.324 178.733 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' F' F ' 36' ' ' VAL . . . . . 0.401 HG12 ' N ' ' F' ' 37' ' ' GLY . 60.8 t -156.63 160.03 2.44 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.772 0 N-CA-C 106.579 -1.637 . . . . 0.0 106.579 -178.741 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' F' F ' 37' ' ' GLY . . . . . 0.401 ' N ' HG12 ' F' ' 36' ' ' VAL . . . 54.05 73.37 0.42 Allowed Glycine 0 C--N 1.309 -0.964 0 CA-C-N 116.075 -0.512 . . . . 0.0 111.937 177.709 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' F' F ' 38' ' ' GLY . . . . . 0.478 ' O ' ' NE2' ' F' ' 15' ' ' GLN . . . 165.83 -166.58 38.68 Favored Glycine 0 C--O 1.209 -1.459 0 N-CA-C 111.264 -0.735 . . . . 0.0 111.264 179.315 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 21.1 m -128.46 148.76 32.9 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.811 0 C-N-CA 122.729 0.412 . . . . 0.0 109.906 179.935 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 6.8 t . . . . . 0 CA--C 1.54 0.565 0 CA-C-O 118.207 -0.901 . . . . 0.0 110.423 178.911 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' G' G ' 1' ' ' ASP . . . . . . . . . . . . . 9.3 m-20 . . . . . 0 N--CA 1.487 1.404 0 N-CA-C 108.763 -0.829 . . . . 0.0 108.763 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' G' G ' 2' ' ' ALA . . . . . . . . . . . . . . . -66.63 133.82 51.06 Favored 'General case' 0 CA--C 1.538 0.486 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 -179.776 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' G' G ' 3' ' ' GLU . . . . . . . . . . . . . 38.9 tt0 -139.01 104.93 5.16 Favored 'General case' 0 N--CA 1.477 0.911 0 C-N-CA 123.097 0.559 . . . . 0.0 109.815 -178.969 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 35.4 m-85 -71.12 169.15 15.65 Favored 'General case' 0 N--CA 1.469 0.499 0 CA-C-O 121.173 0.511 . . . . 0.0 109.833 179.367 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' G' G ' 5' ' ' ARG . . . . . 0.736 HH12 HG13 ' F' ' 24' ' ' VAL . 33.8 mtp180 -68.69 144.92 54.28 Favored 'General case' 0 N--CA 1.469 0.524 0 CA-C-N 115.415 -0.811 . . . . 0.0 111.146 -178.325 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 38.6 m80 -107.98 118.78 37.64 Favored 'General case' 0 N--CA 1.478 0.961 0 N-CA-C 109.226 -0.657 . . . . 0.0 109.226 178.095 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 10.5 m-20 -66.84 139.47 57.77 Favored 'General case' 0 N--CA 1.469 0.49 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.948 -179.061 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' G' G ' 8' ' ' SER . . . . . . . . . . . . . 37.8 t -158.09 -170.23 3.07 Favored 'General case' 0 N--CA 1.471 0.603 0 N-CA-C 109.666 -0.494 . . . . 0.0 109.666 179.024 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 120.37 31.97 1.2 Allowed Glycine 0 N--CA 1.484 1.869 0 N-CA-C 111.539 -0.624 . . . . 0.0 111.539 179.497 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 47.1 p90 -57.11 130.71 47.32 Favored 'General case' 0 N--CA 1.472 0.629 0 CA-C-N 116.825 0.313 . . . . 0.0 111.716 -179.822 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 60.4 mt-10 -90.34 152.58 20.96 Favored 'General case' 0 N--CA 1.474 0.758 0 CA-C-O 121.138 0.494 . . . . 0.0 109.807 179.082 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 3.5 p -155.47 124.83 0.72 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.058 0 N-CA-C 108.175 -1.046 . . . . 0.0 108.175 178.19 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 43.6 m-70 -135.86 160.73 37.68 Favored 'General case' 0 N--CA 1.475 0.781 0 CA-C-N 114.722 -1.126 . . . . 0.0 110.973 -177.619 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 39.6 t60 -153.39 96.93 2.09 Favored 'General case' 0 N--CA 1.484 1.231 0 CA-C-N 115.858 -0.61 . . . . 0.0 109.659 178.855 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' G' G ' 15' ' ' GLN . . . . . 0.507 HE22 ' C ' ' G' ' 38' ' ' GLY . 79.1 mt-30 -90.75 121.52 32.71 Favored 'General case' 0 N--CA 1.451 -0.406 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 -178.896 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -113.03 103.77 11.71 Favored 'General case' 0 N--CA 1.476 0.831 0 N-CA-C 107.694 -1.224 . . . . 0.0 107.694 176.65 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 56.6 tp -132.17 147.33 52.42 Favored 'General case' 0 N--CA 1.486 1.343 0 C-N-CA 123.336 0.654 . . . . 0.0 109.56 -179.288 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 61.3 t -144.99 123.3 5.31 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.861 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 178.664 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 9.6 m-85 -70.39 150.37 46.33 Favored 'General case' 0 C--N 1.376 1.728 0 N-CA-C 106.91 -1.515 . . . . 0.0 106.91 176.699 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 15.6 t80 -169.94 -55.4 0.02 OUTLIER 'General case' 0 N--CA 1.483 1.22 0 N-CA-C 110.248 -0.278 . . . . 0.0 110.248 -179.729 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.0 90.02 0.0 OUTLIER 'General case' 0 C--N 1.323 -0.545 0 C-N-CA 123.72 0.808 . . . . 0.0 112.471 -179.964 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 39.3 tt0 -64.4 160.76 18.36 Favored 'General case' 0 N--CA 1.468 0.467 0 CA-C-N 114.834 -1.076 . . . . 0.0 110.023 179.273 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 9.6 m-20 -137.26 125.38 22.99 Favored 'General case' 0 N--CA 1.48 1.072 0 C-N-CA 123.154 0.582 . . . . 0.0 109.721 -179.701 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' G' G ' 24' ' ' VAL . . . . . 0.857 HG12 ' H ' ' G' ' 25' ' ' GLY . 61.9 t -76.75 -169.97 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.827 0 N-CA-C 108.156 -1.053 . . . . 0.0 108.156 179.608 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' G' G ' 25' ' ' GLY . . . . . 0.857 ' H ' HG12 ' G' ' 24' ' ' VAL . . . -68.89 49.98 0.5 Allowed Glycine 0 CA--C 1.53 0.973 0 CA-C-N 118.48 0.582 . . . . 0.0 112.726 -178.467 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 8.4 p -69.51 137.63 52.67 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 109.157 -0.682 . . . . 0.0 109.157 177.748 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 34.2 t30 -69.49 94.72 0.77 Allowed 'General case' 0 CA--C 1.532 0.265 0 N-CA-C 107.618 -1.253 . . . . 0.0 107.618 177.562 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -91.63 117.81 30.07 Favored 'General case' 0 N--CA 1.478 0.953 0 N-CA-C 109.713 -0.477 . . . . 0.0 109.713 -179.396 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -62.37 -133.3 0.01 OUTLIER Glycine 0 CA--C 1.532 1.099 0 N-CA-C 110.547 -1.021 . . . . 0.0 110.547 178.927 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -115.19 126.83 55.05 Favored 'General case' 0 N--CA 1.475 0.808 0 N-CA-C 109.615 -0.513 . . . . 0.0 109.615 179.186 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 69.6 mt -89.64 136.14 24.41 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.671 0 N-CA-C 107.598 -1.26 . . . . 0.0 107.598 178.743 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 38.2 mt -137.46 139.18 43.98 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.249 0 CA-C-N 118.782 0.719 . . . . 0.0 109.158 179.721 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.1 57.98 13.56 Favored Glycine 0 CA--C 1.53 0.977 0 CA-C-N 116.11 -0.496 . . . . 0.0 112.624 178.99 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 23.1 tp -105.81 132.23 52.18 Favored 'General case' 0 N--CA 1.484 1.256 0 N-CA-C 107.6 -1.259 . . . . 0.0 107.6 177.775 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 22.1 ttt -137.63 147.97 45.4 Favored 'General case' 0 N--CA 1.474 0.727 0 N-CA-C 108.211 -1.033 . . . . 0.0 108.211 178.788 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 61.2 t -156.77 158.4 3.24 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 106.613 -1.625 . . . . 0.0 106.613 -179.095 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.57 71.74 0.68 Allowed Glycine 0 C--N 1.308 -0.973 0 CA-C-N 115.951 -0.568 . . . . 0.0 112.384 177.549 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' G' G ' 38' ' ' GLY . . . . . 0.507 ' C ' HE22 ' G' ' 15' ' ' GLN . . . 167.75 -165.22 38.55 Favored Glycine 0 C--O 1.212 -1.268 0 N-CA-C 110.747 -0.941 . . . . 0.0 110.747 178.631 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 18.7 m -128.64 148.14 33.07 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.93 0 C-N-CA 122.789 0.435 . . . . 0.0 109.93 179.911 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 8.6 t . . . . . 0 CA--C 1.534 0.337 0 CA-C-O 118.156 -0.926 . . . . 0.0 110.888 178.815 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' H' H ' 1' ' ' ASP . . . . . . . . . . . . . 9.3 m-20 . . . . . 0 N--CA 1.488 1.43 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' H' H ' 2' ' ' ALA . . . . . . . . . . . . . . . -66.49 133.78 51.09 Favored 'General case' 0 CA--C 1.537 0.453 0 N-CA-C 109.886 -0.413 . . . . 0.0 109.886 -179.813 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' H' H ' 3' ' ' GLU . . . . . . . . . . . . . 38.9 tt0 -138.89 104.71 5.13 Favored 'General case' 0 N--CA 1.478 0.968 0 C-N-CA 123.064 0.546 . . . . 0.0 109.807 -178.855 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 35.0 m-85 -70.95 169.31 15.12 Favored 'General case' 0 N--CA 1.47 0.557 0 CA-C-O 121.234 0.54 . . . . 0.0 109.756 179.448 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' H' H ' 5' ' ' ARG . . . . . 0.757 HH12 HG13 ' D' ' 24' ' ' VAL . 33.8 mtp180 -69.04 145.12 53.78 Favored 'General case' 0 N--CA 1.466 0.373 0 CA-C-N 115.387 -0.824 . . . . 0.0 111.229 -178.312 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 38.5 m80 -108.05 118.77 37.63 Favored 'General case' 0 N--CA 1.478 0.958 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 178.265 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 10.5 m-20 -66.91 139.58 57.73 Favored 'General case' 0 N--CA 1.468 0.441 0 CA-C-N 116.275 -0.421 . . . . 0.0 111.889 -179.066 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' H' H ' 8' ' ' SER . . . . . . . . . . . . . 37.9 t -158.12 -170.08 3.01 Favored 'General case' 0 N--CA 1.471 0.595 0 N-CA-C 109.73 -0.47 . . . . 0.0 109.73 178.985 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 120.11 32.09 1.21 Allowed Glycine 0 N--CA 1.483 1.829 0 N-CA-C 111.641 -0.583 . . . . 0.0 111.641 179.549 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 46.9 p90 -57.17 130.79 47.72 Favored 'General case' 0 CA--C 1.542 0.64 0 CA-C-N 116.715 0.258 . . . . 0.0 111.607 -179.777 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 60.5 mt-10 -90.3 152.54 20.99 Favored 'General case' 0 N--CA 1.474 0.771 0 CA-C-O 121.116 0.484 . . . . 0.0 109.859 179.023 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 3.4 p -155.53 124.95 0.72 Allowed 'Isoleucine or valine' 0 CA--C 1.553 1.089 0 N-CA-C 108.161 -1.051 . . . . 0.0 108.161 178.074 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 43.6 m-70 -135.93 160.78 37.55 Favored 'General case' 0 C--N 1.353 0.751 0 CA-C-N 114.627 -1.169 . . . . 0.0 111.072 -177.527 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 39.3 t60 -153.51 96.86 2.07 Favored 'General case' 0 N--CA 1.484 1.268 0 CA-C-N 115.868 -0.606 . . . . 0.0 109.773 178.911 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' H' H ' 15' ' ' GLN . . . . . 0.504 HE22 ' C ' ' H' ' 38' ' ' GLY . 79.0 mt-30 -90.71 121.37 32.55 Favored 'General case' 0 CA--C 1.514 -0.406 0 N-CA-C 109.711 -0.477 . . . . 0.0 109.711 -178.946 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -112.84 103.66 11.65 Favored 'General case' 0 N--CA 1.474 0.726 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 176.672 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 56.3 tp -132.14 147.37 52.42 Favored 'General case' 0 N--CA 1.486 1.374 0 C-N-CA 123.273 0.629 . . . . 0.0 109.488 -179.196 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 61.4 t -144.93 123.21 5.36 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.89 0 N-CA-C 109.368 -0.604 . . . . 0.0 109.368 178.667 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 9.5 m-85 -70.67 150.96 45.45 Favored 'General case' 0 C--N 1.376 1.741 0 N-CA-C 106.951 -1.5 . . . . 0.0 106.951 176.658 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 16.6 t80 -171.19 -55.13 0.02 OUTLIER 'General case' 0 N--CA 1.48 1.061 0 N-CA-C 110.216 -0.291 . . . . 0.0 110.216 -179.696 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.05 89.92 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.472 0 O-C-N 123.971 0.795 . . . . 0.0 112.269 -179.96 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 39.4 tt0 -64.12 160.76 17.56 Favored 'General case' 0 N--CA 1.469 0.487 0 CA-C-N 114.777 -1.102 . . . . 0.0 110.063 179.482 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 9.7 m-20 -137.11 125.43 23.27 Favored 'General case' 0 N--CA 1.481 1.077 0 C-N-CA 123.098 0.559 . . . . 0.0 109.869 -179.791 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' H' H ' 24' ' ' VAL . . . . . 0.836 HG12 ' H ' ' H' ' 25' ' ' GLY . 57.4 t -76.69 -170.0 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.475 0.806 0 N-CA-C 108.408 -0.96 . . . . 0.0 108.408 179.612 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' H' H ' 25' ' ' GLY . . . . . 0.836 ' H ' HG12 ' H' ' 24' ' ' VAL . . . -68.64 49.56 0.46 Allowed Glycine 0 CA--C 1.53 1.009 0 CA-C-N 118.627 0.649 . . . . 0.0 112.43 -178.468 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 8.5 p -69.56 137.47 52.44 Favored 'General case' 0 C--N 1.33 -0.266 0 N-CA-C 109.152 -0.684 . . . . 0.0 109.152 177.823 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 34.7 t30 -69.57 94.82 0.8 Allowed 'General case' 0 N--CA 1.464 0.258 0 N-CA-C 107.638 -1.245 . . . . 0.0 107.638 177.635 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -91.76 117.88 30.17 Favored 'General case' 0 N--CA 1.477 0.91 0 N-CA-C 109.708 -0.479 . . . . 0.0 109.708 -179.408 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -62.48 -133.15 0.01 OUTLIER Glycine 0 CA--C 1.532 1.107 0 N-CA-C 110.582 -1.007 . . . . 0.0 110.582 178.977 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -115.25 126.89 55.07 Favored 'General case' 0 N--CA 1.474 0.745 0 C-N-CA 122.984 0.514 . . . . 0.0 109.634 179.192 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 69.6 mt -89.67 136.03 24.68 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.621 0 N-CA-C 107.535 -1.283 . . . . 0.0 107.535 178.707 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 37.7 mt -137.4 139.24 44.01 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.263 0 N-CA-C 109.142 -0.688 . . . . 0.0 109.142 179.611 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.23 58.1 12.92 Favored Glycine 0 CA--C 1.529 0.964 0 CA-C-N 116.067 -0.515 . . . . 0.0 112.593 178.967 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 23.5 tp -105.85 131.81 52.73 Favored 'General case' 0 N--CA 1.484 1.256 0 N-CA-C 107.688 -1.227 . . . . 0.0 107.688 177.893 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 22.0 ttt -137.16 147.36 45.89 Favored 'General case' 0 N--CA 1.475 0.808 0 N-CA-C 108.135 -1.061 . . . . 0.0 108.135 178.924 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 61.7 t -156.5 158.14 3.45 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.487 0 N-CA-C 106.634 -1.617 . . . . 0.0 106.634 -179.109 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.68 71.53 0.71 Allowed Glycine 0 C--N 1.308 -0.992 0 CA-C-N 115.901 -0.59 . . . . 0.0 112.352 177.526 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' H' H ' 38' ' ' GLY . . . . . 0.504 ' C ' HE22 ' H' ' 15' ' ' GLN . . . 167.75 -165.75 38.91 Favored Glycine 0 C--O 1.212 -1.277 0 N-CA-C 110.6 -1.0 . . . . 0.0 110.6 178.693 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 18.9 m -128.2 148.45 32.72 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.023 0 C-N-CA 122.777 0.431 . . . . 0.0 109.926 179.966 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 8.6 t . . . . . 0 CA--C 1.535 0.369 0 CA-C-O 118.196 -0.907 . . . . 0.0 110.811 178.764 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' I' I ' 1' ' ' ASP . . . . . . . . . . . . . 9.3 m-20 . . . . . 0 N--CA 1.487 1.414 0 N-CA-C 108.828 -0.804 . . . . 0.0 108.828 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' I' I ' 2' ' ' ALA . . . . . . . . . . . . . . . -66.56 133.91 51.29 Favored 'General case' 0 CA--C 1.538 0.499 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 -179.836 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' I' I ' 3' ' ' GLU . . . . . . . . . . . . . 38.9 tt0 -139.0 104.83 5.14 Favored 'General case' 0 N--CA 1.478 0.975 0 C-N-CA 123.062 0.545 . . . . 0.0 109.846 -178.909 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 34.6 m-85 -71.1 169.2 15.52 Favored 'General case' 0 N--CA 1.47 0.537 0 CA-C-O 121.136 0.493 . . . . 0.0 109.827 179.465 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' I' I ' 5' ' ' ARG . . . . . 0.747 HH12 HG13 ' E' ' 24' ' ' VAL . 32.8 mtp180 -68.94 144.87 54.04 Favored 'General case' 0 N--CA 1.468 0.475 0 CA-C-N 115.473 -0.785 . . . . 0.0 111.206 -178.343 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 38.6 m80 -107.88 118.59 37.13 Favored 'General case' 0 N--CA 1.477 0.925 0 N-CA-C 109.195 -0.669 . . . . 0.0 109.195 178.314 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 10.5 m-20 -66.77 139.61 57.81 Favored 'General case' 0 N--CA 1.469 0.485 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.916 -179.059 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' I' I ' 8' ' ' SER . . . . . . . . . . . . . 37.8 t -158.08 -170.15 3.05 Favored 'General case' 0 N--CA 1.47 0.557 0 N-CA-C 109.688 -0.486 . . . . 0.0 109.688 178.996 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 120.29 32.0 1.2 Allowed Glycine 0 N--CA 1.483 1.809 0 N-CA-C 111.584 -0.606 . . . . 0.0 111.584 179.413 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 47.1 p90 -57.12 130.75 47.52 Favored 'General case' 0 N--CA 1.473 0.705 0 O-C-N 122.671 -0.311 . . . . 0.0 111.665 -179.815 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 60.5 mt-10 -90.3 152.5 21.01 Favored 'General case' 0 N--CA 1.475 0.813 0 CA-C-O 121.152 0.501 . . . . 0.0 109.865 179.013 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 3.5 p -155.46 124.87 0.73 Allowed 'Isoleucine or valine' 0 CA--C 1.554 1.125 0 N-CA-C 108.194 -1.039 . . . . 0.0 108.194 178.103 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 44.1 m-70 -135.82 160.85 37.29 Favored 'General case' 0 C--N 1.354 0.761 0 CA-C-N 114.6 -1.182 . . . . 0.0 111.0 -177.556 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 39.6 t60 -153.6 97.05 2.08 Favored 'General case' 0 N--CA 1.484 1.262 0 CA-C-N 115.841 -0.618 . . . . 0.0 109.761 178.841 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' I' I ' 15' ' ' GLN . . . . . 0.485 HE22 ' C ' ' I' ' 38' ' ' GLY . 79.0 mt-30 -90.79 121.37 32.6 Favored 'General case' 0 CA--C 1.514 -0.416 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 -178.95 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -112.86 103.69 11.68 Favored 'General case' 0 N--CA 1.473 0.709 0 N-CA-C 107.677 -1.231 . . . . 0.0 107.677 176.6 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 56.5 tp -132.18 147.26 52.41 Favored 'General case' 0 N--CA 1.485 1.296 0 C-N-CA 123.329 0.652 . . . . 0.0 109.436 -179.153 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 61.7 t -144.88 123.12 5.4 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.9 0 N-CA-C 109.425 -0.583 . . . . 0.0 109.425 178.642 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 9.4 m-85 -70.66 150.89 45.53 Favored 'General case' 0 C--N 1.374 1.642 0 N-CA-C 106.853 -1.536 . . . . 0.0 106.853 176.701 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 16.7 t80 -171.14 -55.26 0.02 OUTLIER 'General case' 0 N--CA 1.48 1.073 0 N-CA-C 110.212 -0.292 . . . . 0.0 110.212 -179.561 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.07 90.01 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.45 0 O-C-N 123.998 0.811 . . . . 0.0 112.327 -179.986 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 39.4 tt0 -64.22 160.77 17.85 Favored 'General case' 0 N--CA 1.469 0.511 0 CA-C-N 114.743 -1.117 . . . . 0.0 110.011 179.557 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 9.6 m-20 -137.01 125.31 23.25 Favored 'General case' 0 N--CA 1.481 1.082 0 C-N-CA 123.259 0.624 . . . . 0.0 109.891 -179.771 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' I' I ' 24' ' ' VAL . . . . . 0.846 HG12 ' H ' ' I' ' 25' ' ' GLY . 57.3 t -76.58 -169.96 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.757 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 179.568 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' I' I ' 25' ' ' GLY . . . . . 0.846 ' H ' HG12 ' I' ' 24' ' ' VAL . . . -68.81 49.72 0.49 Allowed Glycine 0 CA--C 1.531 1.054 0 CA-C-N 118.541 0.61 . . . . 0.0 112.485 -178.457 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 8.5 p -69.63 137.67 52.42 Favored 'General case' 0 C--N 1.33 -0.254 0 N-CA-C 109.166 -0.679 . . . . 0.0 109.166 177.856 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 35.0 t30 -69.57 94.74 0.79 Allowed 'General case' 0 CA--C 1.531 0.234 0 N-CA-C 107.676 -1.231 . . . . 0.0 107.676 177.534 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -91.8 117.84 30.15 Favored 'General case' 0 N--CA 1.478 0.936 0 N-CA-C 109.722 -0.473 . . . . 0.0 109.722 -179.395 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -62.37 -133.19 0.01 OUTLIER Glycine 0 CA--C 1.532 1.14 0 N-CA-C 110.613 -0.995 . . . . 0.0 110.613 178.96 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -115.22 126.54 54.68 Favored 'General case' 0 N--CA 1.474 0.737 0 C-N-CA 123.031 0.532 . . . . 0.0 109.697 179.246 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 69.5 mt -89.46 135.94 24.81 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.657 0 N-CA-C 107.552 -1.277 . . . . 0.0 107.552 178.784 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 37.7 mt -137.44 139.21 43.98 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.28 0 N-CA-C 109.004 -0.739 . . . . 0.0 109.004 179.739 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.24 57.99 13.3 Favored Glycine 0 CA--C 1.529 0.959 0 CA-C-N 115.978 -0.555 . . . . 0.0 112.562 178.908 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 23.1 tp -105.71 131.95 52.44 Favored 'General case' 0 N--CA 1.485 1.298 0 N-CA-C 107.531 -1.285 . . . . 0.0 107.531 177.839 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 22.1 ttt -137.3 147.53 45.72 Favored 'General case' 0 N--CA 1.475 0.783 0 N-CA-C 107.997 -1.112 . . . . 0.0 107.997 178.877 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 61.3 t -156.66 158.2 3.38 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.466 0 N-CA-C 106.623 -1.621 . . . . 0.0 106.623 -179.094 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.63 71.57 0.7 Allowed Glycine 0 C--N 1.308 -1.011 0 CA-C-N 115.953 -0.567 . . . . 0.0 112.376 177.556 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' I' I ' 38' ' ' GLY . . . . . 0.485 ' C ' HE22 ' I' ' 15' ' ' GLN . . . 167.72 -165.68 38.85 Favored Glycine 0 C--O 1.211 -1.337 0 N-CA-C 110.603 -0.999 . . . . 0.0 110.603 178.697 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 18.9 m -128.26 148.4 32.77 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.003 0 C-N-CA 122.831 0.452 . . . . 0.0 109.949 179.965 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 8.9 t . . . . . 0 CA--C 1.535 0.387 0 CA-C-O 118.104 -0.95 . . . . 0.0 110.738 178.824 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 . . . . . 0 N--CA 1.49 1.537 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.55 132.44 48.89 Favored 'General case' 0 CA--C 1.54 0.58 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.215 -179.893 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 55.0 tt0 -169.45 108.16 0.42 Allowed 'General case' 0 N--CA 1.47 0.528 0 N-CA-C 109.621 -0.511 . . . . 0.0 109.621 -179.164 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 76.6 m-85 -83.51 141.22 31.8 Favored 'General case' 0 N--CA 1.474 0.74 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 179.516 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 72.4 mtp180 -144.29 141.82 30.04 Favored 'General case' 0 N--CA 1.483 1.207 0 N-CA-C 109.035 -0.728 . . . . 0.0 109.035 179.866 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 77.2 m80 -149.72 118.51 6.62 Favored 'General case' 0 N--CA 1.472 0.655 0 N-CA-C 108.763 -0.828 . . . . 0.0 108.763 179.037 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 12.2 m-20 -66.83 149.5 50.49 Favored 'General case' 0 CA--C 1.531 0.242 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.193 -179.395 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 7.9 t -167.53 170.08 11.52 Favored 'General case' 0 N--CA 1.473 0.682 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 178.613 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 123.47 24.44 1.95 Allowed Glycine 0 N--CA 1.487 2.051 0 N-CA-C 112.089 -0.405 . . . . 0.0 112.089 179.466 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 41.0 p90 -56.59 128.26 35.4 Favored 'General case' 0 N--CA 1.473 0.714 0 N-CA-C 112.136 0.421 . . . . 0.0 112.136 -179.868 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 46.1 mt-10 -84.61 154.49 22.54 Favored 'General case' 0 N--CA 1.468 0.465 0 N-CA-C 108.847 -0.797 . . . . 0.0 108.847 178.256 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -154.03 129.18 1.54 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 N-CA-C 108.091 -1.077 . . . . 0.0 108.091 178.855 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 51.5 m-70 -134.5 144.77 48.24 Favored 'General case' 0 N--CA 1.487 1.409 0 CA-C-N 118.567 0.621 . . . . 0.0 110.729 -178.951 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 6.2 t60 -164.5 98.38 0.8 Allowed 'General case' 0 N--CA 1.482 1.172 0 CA-C-N 116.744 -0.207 . . . . 0.0 111.204 179.581 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 33.1 mt-30 -103.03 -172.65 2.15 Favored 'General case' 0 CA--C 1.506 -0.745 0 N-CA-C 108.191 -1.04 . . . . 0.0 108.191 179.338 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -167.25 98.17 0.51 Allowed 'General case' 0 N--CA 1.47 0.531 0 CA-C-N 115.084 -0.962 . . . . 0.0 109.366 178.766 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.564 HD12 ' N ' ' A' ' 17' ' ' LEU . 4.9 mp -106.69 162.44 13.76 Favored 'General case' 0 N--CA 1.485 1.303 0 N-CA-C 108.364 -0.976 . . . . 0.0 108.364 179.808 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 55.3 t -142.42 118.63 5.98 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.275 0 CA-C-O 118.804 -0.617 . . . . 0.0 109.899 179.29 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 54.2 m-85 -70.41 158.7 35.53 Favored 'General case' 0 N--CA 1.479 1.006 0 N-CA-C 107.812 -1.181 . . . . 0.0 107.812 177.07 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 15.0 t80 -171.0 -58.75 0.02 OUTLIER 'General case' 0 N--CA 1.483 1.198 0 CA-C-O 122.435 1.112 . . . . 0.0 109.546 179.244 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.33 90.56 0.0 OUTLIER 'General case' 0 N--CA 1.458 -0.073 0 CA-C-N 113.845 -1.525 . . . . 0.0 112.818 -178.113 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 53.6 tt0 -62.88 155.34 27.39 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 115.238 -0.892 . . . . 0.0 110.463 178.952 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 18.1 m-20 -136.51 134.71 37.85 Favored 'General case' 0 N--CA 1.48 1.071 0 C-N-CA 122.967 0.507 . . . . 0.0 109.983 179.851 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 16.2 t -84.74 -117.05 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.763 0 N-CA-C 108.173 -1.047 . . . . 0.0 108.173 179.296 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -107.4 53.27 0.61 Allowed Glycine 0 N--CA 1.474 1.172 0 N-CA-C 111.178 -0.769 . . . . 0.0 111.178 179.867 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 88.7 p -77.04 126.55 31.15 Favored 'General case' 0 N--CA 1.465 0.311 0 N-CA-C 109.023 -0.732 . . . . 0.0 109.023 178.398 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 1.8 t-20 -67.18 100.03 0.74 Allowed 'General case' 0 N--CA 1.472 0.656 0 N-CA-C 108.615 -0.883 . . . . 0.0 108.615 178.664 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 67.3 mttm -94.01 128.26 40.25 Favored 'General case' 0 N--CA 1.479 1.012 0 N-CA-C 109.634 -0.506 . . . . 0.0 109.634 -179.451 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.28 -133.26 0.01 OUTLIER Glycine 0 CA--C 1.53 0.985 0 N-CA-C 110.398 -1.081 . . . . 0.0 110.398 179.11 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.34 127.78 43.32 Favored 'General case' 0 N--CA 1.484 1.243 0 CA-C-N 117.096 0.448 . . . . 0.0 110.178 179.356 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 30.3 mt -91.9 160.52 2.68 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.648 0 N-CA-C 106.824 -1.547 . . . . 0.0 106.824 178.157 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 38.0 mt -138.27 94.14 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.766 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 -179.065 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 53.5 104.82 0.01 OUTLIER Glycine 0 CA--C 1.531 1.085 0 CA-C-N 115.899 -0.592 . . . . 0.0 114.192 176.621 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 91.1 mt -72.22 155.2 40.48 Favored 'General case' 0 N--CA 1.469 0.512 0 N-CA-C 107.502 -1.295 . . . . 0.0 107.502 176.51 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 2.2 ttp -143.84 139.3 29.21 Favored 'General case' 0 N--CA 1.473 0.725 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 178.943 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 59.1 t -159.23 150.05 6.96 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.261 0 N-CA-C 106.714 -1.587 . . . . 0.0 106.714 -179.229 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 54.78 75.15 0.25 Allowed Glycine 0 C--N 1.314 -0.667 0 N-CA-C 111.823 -0.511 . . . . 0.0 111.823 177.909 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 174.14 -148.97 10.33 Favored Glycine 0 CA--C 1.52 0.36 0 N-CA-C 110.974 -0.85 . . . . 0.0 110.974 179.928 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 30.9 m -134.81 146.0 31.44 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.906 0 C-N-CA 122.599 0.36 . . . . 0.0 110.373 -179.72 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 19.6 t . . . . . 0 C--O 1.221 -0.428 0 CA-C-O 117.59 -1.195 . . . . 0.0 110.986 179.153 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' B' B ' 1' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 . . . . . 0 N--CA 1.489 1.497 0 N-CA-C 109.124 -0.695 . . . . 0.0 109.124 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' B' B ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.64 132.44 48.83 Favored 'General case' 0 CA--C 1.539 0.528 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.142 -179.877 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 3' ' ' GLU . . . . . . . . . . . . . 55.0 tt0 -169.45 108.21 0.42 Allowed 'General case' 0 N--CA 1.47 0.57 0 N-CA-C 109.608 -0.515 . . . . 0.0 109.608 -179.166 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 77.1 m-85 -83.53 141.22 31.78 Favored 'General case' 0 N--CA 1.473 0.712 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 179.531 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 72.0 mtp180 -144.33 141.61 29.87 Favored 'General case' 0 N--CA 1.48 1.071 0 N-CA-C 108.999 -0.741 . . . . 0.0 108.999 179.955 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 77.2 m80 -149.51 118.65 6.77 Favored 'General case' 0 N--CA 1.474 0.742 0 N-CA-C 108.903 -0.777 . . . . 0.0 108.903 179.04 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 7' ' ' ASP . . . . . . . . . . . . . 12.4 m-20 -66.87 149.03 51.17 Favored 'General case' 0 CA--C 1.532 0.261 0 CA-C-N 116.411 -0.359 . . . . 0.0 111.236 -179.399 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 8' ' ' SER . . . . . . . . . . . . . 7.9 t -167.21 170.21 11.91 Favored 'General case' 0 N--CA 1.471 0.613 0 N-CA-C 109.288 -0.634 . . . . 0.0 109.288 178.459 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 123.43 24.4 1.97 Allowed Glycine 0 N--CA 1.486 2.023 0 N-CA-C 111.982 -0.447 . . . . 0.0 111.982 179.416 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 40.6 p90 -56.63 128.37 36.01 Favored 'General case' 0 N--CA 1.471 0.581 0 N-CA-C 112.091 0.404 . . . . 0.0 112.091 -179.775 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 46.1 mt-10 -84.69 154.54 22.41 Favored 'General case' 0 N--CA 1.469 0.498 0 N-CA-C 108.911 -0.774 . . . . 0.0 108.911 178.327 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -154.01 129.04 1.5 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 N-CA-C 108.173 -1.047 . . . . 0.0 108.173 178.861 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 51.4 m-70 -134.35 144.94 48.54 Favored 'General case' 0 N--CA 1.488 1.429 0 CA-C-N 118.475 0.579 . . . . 0.0 110.777 -178.95 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 6.2 t60 -164.66 98.16 0.78 Allowed 'General case' 0 N--CA 1.484 1.243 0 CA-C-N 116.697 -0.229 . . . . 0.0 111.189 179.596 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 33.1 mt-30 -102.84 -172.95 2.21 Favored 'General case' 0 CA--C 1.506 -0.743 0 N-CA-C 108.135 -1.061 . . . . 0.0 108.135 179.415 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -167.08 97.94 0.52 Allowed 'General case' 0 N--CA 1.47 0.558 0 CA-C-N 115.034 -0.984 . . . . 0.0 109.309 178.898 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 17' ' ' LEU . . . . . 0.571 ' N ' HD12 ' B' ' 17' ' ' LEU . 4.9 mp -106.63 162.19 13.97 Favored 'General case' 0 N--CA 1.486 1.329 0 N-CA-C 108.373 -0.973 . . . . 0.0 108.373 179.819 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 56.8 t -142.31 118.35 5.98 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.243 0 CA-C-O 118.873 -0.584 . . . . 0.0 109.924 179.309 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 56.0 m-85 -70.69 158.81 35.6 Favored 'General case' 0 N--CA 1.478 0.93 0 N-CA-C 107.671 -1.233 . . . . 0.0 107.671 177.036 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 16.0 t80 -171.73 -57.98 0.02 OUTLIER 'General case' 0 N--CA 1.481 1.102 0 CA-C-O 122.254 1.026 . . . . 0.0 109.541 179.233 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.54 90.8 0.0 OUTLIER 'General case' 0 C--O 1.231 0.103 0 CA-C-N 114.1 -1.409 . . . . 0.0 112.67 -178.169 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 53.5 tt0 -63.11 155.34 28.23 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 115.274 -0.875 . . . . 0.0 110.495 179.035 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 18.0 m-20 -136.46 134.91 38.16 Favored 'General case' 0 N--CA 1.481 1.088 0 C-N-CA 122.991 0.516 . . . . 0.0 110.007 179.875 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 16.1 t -85.21 -117.13 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.475 0.795 0 N-CA-C 108.331 -0.988 . . . . 0.0 108.331 179.282 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -106.66 52.74 0.66 Allowed Glycine 0 N--CA 1.476 1.306 0 N-CA-C 111.14 -0.784 . . . . 0.0 111.14 179.915 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 89.5 p -77.02 126.22 30.61 Favored 'General case' 0 N--CA 1.466 0.352 0 N-CA-C 109.207 -0.664 . . . . 0.0 109.207 178.421 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 1.8 t-20 -67.15 100.17 0.75 Allowed 'General case' 0 N--CA 1.473 0.676 0 N-CA-C 108.588 -0.893 . . . . 0.0 108.588 178.674 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 67.4 mttm -94.03 128.22 40.26 Favored 'General case' 0 N--CA 1.479 1.01 0 N-CA-C 109.684 -0.487 . . . . 0.0 109.684 -179.469 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.16 -132.94 0.01 OUTLIER Glycine 0 CA--C 1.53 0.991 0 N-CA-C 110.493 -1.043 . . . . 0.0 110.493 179.067 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.63 127.83 42.99 Favored 'General case' 0 N--CA 1.485 1.286 0 CA-C-N 117.192 0.496 . . . . 0.0 110.09 179.355 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 29.8 mt -92.03 160.3 2.7 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.69 0 N-CA-C 106.896 -1.52 . . . . 0.0 106.896 178.093 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 37.5 mt -138.0 94.05 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.684 0 N-CA-C 109.908 -0.405 . . . . 0.0 109.908 -178.969 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 53.47 104.91 0.01 OUTLIER Glycine 0 CA--C 1.53 1.02 0 CA-C-N 115.899 -0.591 . . . . 0.0 114.229 176.648 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 90.9 mt -72.29 155.26 40.38 Favored 'General case' 0 N--CA 1.471 0.578 0 N-CA-C 107.481 -1.303 . . . . 0.0 107.481 176.524 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 2.2 ttp -143.73 139.02 29.25 Favored 'General case' 0 N--CA 1.476 0.859 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 178.954 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 59.0 t -159.05 149.96 7.17 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.274 0 N-CA-C 106.58 -1.637 . . . . 0.0 106.58 -179.23 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 54.83 75.12 0.25 Allowed Glycine 0 C--N 1.314 -0.647 0 N-CA-C 111.786 -0.526 . . . . 0.0 111.786 177.778 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 174.06 -148.89 10.31 Favored Glycine 0 CA--C 1.521 0.452 0 N-CA-C 110.989 -0.844 . . . . 0.0 110.989 179.869 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 31.5 m -134.83 145.99 31.44 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.942 0 C-N-CA 122.566 0.346 . . . . 0.0 110.35 -179.717 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 20.0 t . . . . . 0 C--O 1.22 -0.448 0 CA-C-O 117.636 -1.173 . . . . 0.0 110.985 179.136 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' C' C ' 1' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 . . . . . 0 N--CA 1.489 1.507 0 N-CA-C 109.013 -0.736 . . . . 0.0 109.013 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' C' C ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.51 132.41 48.83 Favored 'General case' 0 CA--C 1.539 0.535 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.202 -179.966 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 3' ' ' GLU . . . . . . . . . . . . . 55.0 tt0 -169.43 108.32 0.42 Allowed 'General case' 0 N--CA 1.471 0.62 0 N-CA-C 109.584 -0.524 . . . . 0.0 109.584 -179.247 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 76.5 m-85 -83.58 141.05 31.86 Favored 'General case' 0 N--CA 1.473 0.72 0 N-CA-C 109.9 -0.407 . . . . 0.0 109.9 179.472 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 72.4 mtp180 -144.19 141.56 29.99 Favored 'General case' 0 N--CA 1.483 1.221 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 179.946 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 77.1 m80 -149.49 118.59 6.75 Favored 'General case' 0 N--CA 1.473 0.705 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 179.053 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 7' ' ' ASP . . . . . . . . . . . . . 11.7 m-20 -66.88 149.08 51.1 Favored 'General case' 0 N--CA 1.464 0.251 0 CA-C-N 116.337 -0.392 . . . . 0.0 111.25 -179.416 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 8' ' ' SER . . . . . . . . . . . . . 7.9 t -167.18 170.18 11.99 Favored 'General case' 0 N--CA 1.472 0.642 0 N-CA-C 109.188 -0.671 . . . . 0.0 109.188 178.493 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 123.45 24.42 1.96 Allowed Glycine 0 N--CA 1.486 2.023 0 N-CA-C 111.944 -0.462 . . . . 0.0 111.944 179.37 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 40.7 p90 -56.57 128.21 35.13 Favored 'General case' 0 N--CA 1.472 0.628 0 N-CA-C 112.066 0.395 . . . . 0.0 112.066 -179.836 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 46.0 mt-10 -84.54 154.54 22.59 Favored 'General case' 0 N--CA 1.469 0.51 0 N-CA-C 108.881 -0.785 . . . . 0.0 108.881 178.252 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -154.07 129.02 1.48 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 178.826 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 51.3 m-70 -134.24 144.96 48.71 Favored 'General case' 0 N--CA 1.487 1.411 0 CA-C-N 118.428 0.558 . . . . 0.0 110.827 -178.954 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 6.2 t60 -164.75 98.35 0.77 Allowed 'General case' 0 N--CA 1.484 1.259 0 CA-C-N 116.823 -0.171 . . . . 0.0 111.254 179.6 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 33.0 mt-30 -103.09 -172.73 2.16 Favored 'General case' 0 CA--C 1.503 -0.851 0 N-CA-C 108.244 -1.021 . . . . 0.0 108.244 179.322 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -167.18 98.11 0.51 Allowed 'General case' 0 CA--C 1.538 0.502 0 CA-C-N 114.973 -1.012 . . . . 0.0 109.333 178.861 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 17' ' ' LEU . . . . . 0.563 ' N ' HD12 ' C' ' 17' ' ' LEU . 4.9 mp -106.72 162.19 13.99 Favored 'General case' 0 N--CA 1.486 1.344 0 N-CA-C 108.291 -1.003 . . . . 0.0 108.291 179.76 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 57.5 t -142.24 118.41 6.18 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.296 0 CA-C-O 118.934 -0.555 . . . . 0.0 109.944 179.285 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 55.7 m-85 -70.64 158.82 35.53 Favored 'General case' 0 N--CA 1.478 0.946 0 N-CA-C 107.754 -1.202 . . . . 0.0 107.754 176.981 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 16.0 t80 -171.71 -57.94 0.02 OUTLIER 'General case' 0 N--CA 1.479 0.977 0 CA-C-O 122.299 1.047 . . . . 0.0 109.573 179.176 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.6 90.82 0.0 OUTLIER 'General case' 0 C--N 1.338 0.087 0 CA-C-N 114.137 -1.392 . . . . 0.0 112.653 -178.171 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 53.6 tt0 -63.11 155.34 28.24 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 115.226 -0.897 . . . . 0.0 110.462 179.04 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 17.9 m-20 -136.43 134.94 38.25 Favored 'General case' 0 N--CA 1.48 1.069 0 C-N-CA 122.898 0.479 . . . . 0.0 110.002 179.83 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 16.1 t -85.08 -117.23 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.475 0.796 0 N-CA-C 108.344 -0.984 . . . . 0.0 108.344 179.273 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -106.54 52.68 0.66 Allowed Glycine 0 N--CA 1.476 1.327 0 N-CA-C 111.144 -0.782 . . . . 0.0 111.144 179.852 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 89.3 p -77.1 126.45 30.98 Favored 'General case' 0 N--CA 1.466 0.364 0 N-CA-C 109.151 -0.685 . . . . 0.0 109.151 178.494 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 1.8 t-20 -67.24 100.17 0.77 Allowed 'General case' 0 N--CA 1.471 0.615 0 N-CA-C 108.627 -0.879 . . . . 0.0 108.627 178.619 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 67.3 mttm -94.09 128.23 40.35 Favored 'General case' 0 N--CA 1.479 1.016 0 N-CA-C 109.656 -0.498 . . . . 0.0 109.656 -179.41 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.29 -133.09 0.01 OUTLIER Glycine 0 CA--C 1.531 1.039 0 N-CA-C 110.481 -1.047 . . . . 0.0 110.481 179.139 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.37 127.52 42.79 Favored 'General case' 0 N--CA 1.486 1.332 0 CA-C-N 117.195 0.498 . . . . 0.0 110.177 179.379 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 29.6 mt -91.78 160.25 2.71 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.642 0 N-CA-C 106.887 -1.523 . . . . 0.0 106.887 178.063 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 36.9 mt -138.0 94.0 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.696 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 -178.964 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 53.52 104.93 0.01 OUTLIER Glycine 0 CA--C 1.531 1.067 0 CA-C-N 115.885 -0.598 . . . . 0.0 114.118 176.608 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 90.9 mt -72.21 155.17 40.52 Favored 'General case' 0 N--CA 1.47 0.563 0 N-CA-C 107.477 -1.305 . . . . 0.0 107.477 176.463 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 2.2 ttp -143.54 139.09 29.59 Favored 'General case' 0 N--CA 1.473 0.722 0 N-CA-C 108.812 -0.81 . . . . 0.0 108.812 178.9 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 59.3 t -159.2 150.08 6.98 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.258 0 N-CA-C 106.659 -1.608 . . . . 0.0 106.659 -179.279 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 54.84 75.04 0.25 Allowed Glycine 0 N--CA 1.465 0.633 0 N-CA-C 111.775 -0.53 . . . . 0.0 111.775 177.837 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 174.04 -148.9 10.32 Favored Glycine 0 CA--C 1.521 0.411 0 N-CA-C 110.967 -0.853 . . . . 0.0 110.967 179.8 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 31.3 m -134.8 145.97 31.5 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.97 0 C-N-CA 122.535 0.334 . . . . 0.0 110.481 -179.739 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 20.1 t . . . . . 0 C--O 1.222 -0.392 0 CA-C-O 117.616 -1.183 . . . . 0.0 110.873 179.116 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' D' D ' 1' ' ' ASP . . . . . . . . . . . . . 8.6 m-20 . . . . . 0 N--CA 1.491 1.597 0 N-CA-C 109.075 -0.713 . . . . 0.0 109.075 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' D' D ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.29 131.1 46.33 Favored 'General case' 0 CA--C 1.536 0.427 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.431 179.769 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' D' D ' 3' ' ' GLU . . . . . . . . . . . . . 54.5 tt0 -169.36 110.52 0.47 Allowed 'General case' 0 N--CA 1.469 0.507 0 N-CA-C 109.333 -0.617 . . . . 0.0 109.333 179.51 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 84.5 m-85 -87.0 148.55 25.27 Favored 'General case' 0 C--N 1.361 1.103 0 C-N-CA 118.619 -1.232 . . . . 0.0 108.346 179.664 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' D' D ' 5' ' ' ARG . . . . . . . . . . . . . 71.9 mtp180 -147.73 141.4 25.58 Favored 'General case' 0 N--CA 1.472 0.625 0 N-CA-C 109.037 -0.727 . . . . 0.0 109.037 179.779 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 77.5 m80 -149.2 123.46 9.57 Favored 'General case' 0 CA--C 1.541 0.627 0 N-CA-C 107.705 -1.22 . . . . 0.0 107.705 175.53 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' D' D ' 7' ' ' ASP . . . . . . . . . . . . . 7.9 m-20 -63.33 133.5 54.22 Favored 'General case' 0 C--N 1.322 -0.591 0 C-N-CA 126.813 2.045 . . . . 0.0 114.543 176.425 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' D' D ' 8' ' ' SER . . . . . . . . . . . . . 7.0 t -154.22 173.1 16.58 Favored 'General case' 0 N--CA 1.478 0.943 0 CA-C-N 118.468 0.576 . . . . 0.0 110.05 176.977 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 124.48 20.51 2.38 Favored Glycine 0 N--CA 1.484 1.874 0 N-CA-C 112.185 -0.366 . . . . 0.0 112.185 176.649 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 36.2 p90 -55.55 130.46 42.96 Favored 'General case' 0 CA--C 1.546 0.803 0 CA-C-O 121.089 0.471 . . . . 0.0 112.026 -177.341 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 46.2 mt-10 -84.89 152.25 23.69 Favored 'General case' 0 N--CA 1.474 0.755 0 N-CA-C 109.422 -0.584 . . . . 0.0 109.422 177.628 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -149.53 130.09 4.42 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.411 0 N-CA-C 108.158 -1.053 . . . . 0.0 108.158 175.389 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 49.4 m-70 -129.49 148.52 51.4 Favored 'General case' 0 N--CA 1.48 1.062 0 CA-C-N 118.016 0.371 . . . . 0.0 111.021 176.687 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 6.3 t60 -165.0 104.78 0.78 Allowed 'General case' 0 N--CA 1.484 1.256 0 N-CA-C 109.716 -0.476 . . . . 0.0 109.716 173.618 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 33.1 mt-30 -106.3 -175.7 2.87 Favored 'General case' 0 CA--C 1.498 -1.056 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 178.602 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' D' D ' 16' ' ' LYS . . . . . 0.414 ' C ' HD12 ' D' ' 17' ' ' LEU . 88.6 tttt -163.54 106.28 0.98 Allowed 'General case' 0 CA--C 1.536 0.423 0 N-CA-C 107.493 -1.299 . . . . 0.0 107.493 175.514 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' D' D ' 17' ' ' LEU . . . . . 0.498 ' N ' HD12 ' D' ' 17' ' ' LEU . 5.9 mp -112.94 162.18 16.14 Favored 'General case' 0 N--CA 1.487 1.381 0 N-CA-C 107.503 -1.295 . . . . 0.0 107.503 179.01 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 48.7 t -141.24 123.44 14.59 Favored 'Isoleucine or valine' 0 C--N 1.362 1.134 0 N-CA-C 109.084 -0.71 . . . . 0.0 109.084 175.344 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 80.4 m-85 -62.85 151.37 39.23 Favored 'General case' 0 C--N 1.349 0.582 0 C-N-CA 124.435 1.094 . . . . 0.0 110.703 170.11 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 11.4 t80 -170.23 -66.84 0.02 OUTLIER 'General case' 0 C--N 1.319 -0.723 0 N-CA-C 107.72 -1.215 . . . . 0.0 107.72 179.31 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -38.37 95.52 0.01 OUTLIER 'General case' 0 N--CA 1.451 -0.38 0 CA-C-N 113.964 -1.471 . . . . 0.0 111.672 -175.501 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 53.6 tt0 -65.39 156.03 33.53 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 114.072 -1.422 . . . . 0.0 110.104 178.587 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 17.9 m-20 -136.49 138.89 41.88 Favored 'General case' 0 N--CA 1.477 0.898 0 N-CA-C 109.256 -0.646 . . . . 0.0 109.256 178.501 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' D' D ' 24' ' ' VAL . . . . . . . . . . . . . 17.3 t -88.5 -120.4 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.482 1.168 0 N-CA-C 107.602 -1.259 . . . . 0.0 107.602 179.607 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . -110.35 61.77 0.3 Allowed Glycine 0 C--N 1.373 2.585 0 C-N-CA 117.706 -2.188 . . . . 0.0 109.162 178.44 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 94.5 p -67.91 121.74 16.67 Favored 'General case' 0 C--O 1.243 0.763 0 CA-C-O 116.524 -1.703 . . . . 0.0 112.307 168.7 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 1.9 t-20 -62.73 101.75 0.28 Allowed 'General case' 0 N--CA 1.476 0.845 0 CA-C-N 121.519 1.963 . . . . 0.0 109.476 172.984 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 67.1 mttm -95.95 127.37 41.91 Favored 'General case' 0 N--CA 1.485 1.277 0 CA-C-N 119.243 0.928 . . . . 0.0 109.102 178.377 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -55.84 -135.05 0.0 OUTLIER Glycine 0 CA--C 1.527 0.803 0 C-N-CA 123.573 0.606 . . . . 0.0 112.443 174.696 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.45 130.94 48.31 Favored 'General case' 0 C--N 1.373 1.62 0 CA-C-N 114.968 -0.616 . . . . 0.0 110.283 175.995 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 35.9 mt -92.08 162.32 2.43 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.455 0 N-CA-C 106.475 -1.676 . . . . 0.0 106.475 177.673 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . 0.267 41.6 mt -140.6 105.49 1.84 Allowed 'Isoleucine or valine' 0 C--N 1.359 1.015 0 N-CA-C 106.728 -1.582 . . . . 0.0 106.728 173.053 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.49 96.24 0.01 OUTLIER Glycine 0 CA--C 1.533 1.171 0 CA-C-O 115.935 -2.592 . . . . 0.0 112.682 169.063 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 95.2 mt -69.65 158.56 35.1 Favored 'General case' 0 N--CA 1.481 1.086 0 CA-C-N 122.731 3.265 . . . . 0.0 107.441 176.507 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 2.9 ttp -143.82 149.53 37.14 Favored 'General case' 0 N--CA 1.481 1.089 0 N-CA-C 106.352 -1.722 . . . . 0.0 106.352 174.293 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 89.6 t -165.18 154.09 1.91 Allowed 'Isoleucine or valine' 0 C--O 1.249 1.032 0 N-CA-C 105.41 -2.07 . . . . 0.0 105.41 177.601 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 60.83 66.74 2.5 Favored Glycine 0 N--CA 1.442 -0.953 0 C-N-CA 117.326 -2.369 . . . . 0.0 113.981 174.565 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 168.41 -147.85 11.88 Favored Glycine 0 N--CA 1.466 0.674 0 CA-C-O 117.0 -2.0 . . . . 0.0 112.492 -178.698 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 31.1 m -131.19 145.42 35.39 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.271 0 CA-C-N 119.958 1.879 . . . . 0.0 110.588 -176.988 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 18.0 t . . . . . 0 C--O 1.208 -1.128 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 173.591 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' E' E ' 1' ' ' ASP . . . . . . . . . . . . . 8.6 m-20 . . . . . 0 N--CA 1.49 1.531 0 N-CA-C 109.196 -0.668 . . . . 0.0 109.196 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' E' E ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.3 131.14 46.44 Favored 'General case' 0 CA--C 1.536 0.416 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.373 179.866 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' E' E ' 3' ' ' GLU . . . . . . . . . . . . . 54.5 tt0 -169.14 108.32 0.44 Allowed 'General case' 0 N--CA 1.469 0.503 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 -179.784 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 77.1 m-85 -84.36 141.31 30.98 Favored 'General case' 0 N--CA 1.473 0.7 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 179.416 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' E' E ' 5' ' ' ARG . . . . . . . . . . . . . 71.8 mtp180 -144.27 142.32 30.38 Favored 'General case' 0 N--CA 1.476 0.826 0 N-CA-C 109.234 -0.654 . . . . 0.0 109.234 179.666 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 77.3 m80 -150.11 117.62 6.12 Favored 'General case' 0 N--CA 1.475 0.787 0 N-CA-C 109.049 -0.723 . . . . 0.0 109.049 179.073 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' E' E ' 7' ' ' ASP . . . . . . . . . . . . . 12.1 m-20 -65.85 149.19 50.58 Favored 'General case' 0 N--CA 1.463 0.205 0 O-C-N 123.276 0.36 . . . . 0.0 111.482 -179.409 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' E' E ' 8' ' ' SER . . . . . . . . . . . . . 7.2 t -167.6 171.34 10.34 Favored 'General case' 0 N--CA 1.476 0.836 0 N-CA-C 109.219 -0.66 . . . . 0.0 109.219 178.03 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 123.9 23.78 1.98 Allowed Glycine 0 N--CA 1.481 1.655 0 N-CA-C 111.876 -0.489 . . . . 0.0 111.876 179.024 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 37.1 p90 -55.82 127.53 30.64 Favored 'General case' 0 CA--C 1.543 0.694 0 N-CA-C 112.703 0.631 . . . . 0.0 112.703 -179.076 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 46.4 mt-10 -83.05 155.2 24.03 Favored 'General case' 0 N--CA 1.475 0.79 0 N-CA-C 109.234 -0.654 . . . . 0.0 109.234 177.774 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -155.69 127.88 1.02 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.498 0 N-CA-C 108.22 -1.03 . . . . 0.0 108.22 178.622 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 48.5 m-70 -134.29 143.1 47.54 Favored 'General case' 0 N--CA 1.478 0.97 0 C-N-CA 122.491 0.316 . . . . 0.0 111.099 -177.976 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 6.1 t60 -163.52 98.5 0.9 Allowed 'General case' 0 N--CA 1.486 1.359 0 CA-C-O 119.735 -0.174 . . . . 0.0 111.247 179.693 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 33.1 mt-30 -102.66 -172.7 2.17 Favored 'General case' 0 CA--C 1.506 -0.736 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 179.464 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -167.16 98.13 0.52 Allowed 'General case' 0 CA--C 1.54 0.59 0 CA-C-N 114.97 -1.014 . . . . 0.0 109.259 178.617 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' E' E ' 17' ' ' LEU . . . . . 0.537 ' N ' HD12 ' E' ' 17' ' ' LEU . 4.9 mp -106.43 161.44 14.58 Favored 'General case' 0 N--CA 1.487 1.411 0 N-CA-C 108.771 -0.826 . . . . 0.0 108.771 -179.95 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 42.0 t -142.4 117.82 5.39 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.379 0 C-N-CA 122.549 0.339 . . . . 0.0 110.463 178.896 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 54.9 m-85 -69.72 156.54 38.83 Favored 'General case' 0 C--N 1.356 0.891 0 N-CA-C 107.636 -1.246 . . . . 0.0 107.636 176.449 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 14.2 t80 -173.23 -56.16 0.02 OUTLIER 'General case' 0 N--CA 1.482 1.129 0 CA-C-O 121.731 0.777 . . . . 0.0 110.018 179.242 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.84 89.1 0.0 OUTLIER 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 114.364 -1.289 . . . . 0.0 112.689 -179.095 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 54.0 tt0 -61.69 155.08 23.55 Favored 'General case' 0 N--CA 1.47 0.55 0 CA-C-N 115.131 -0.94 . . . . 0.0 110.604 179.489 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 17.6 m-20 -136.46 134.54 37.77 Favored 'General case' 0 N--CA 1.479 0.978 0 C-N-CA 122.918 0.487 . . . . 0.0 110.301 -179.931 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 20.2 t -84.85 -116.64 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.873 0 N-CA-C 108.449 -0.945 . . . . 0.0 108.449 179.209 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . -106.84 52.98 0.64 Allowed Glycine 0 C--N 1.346 1.138 0 N-CA-C 111.255 -0.738 . . . . 0.0 111.255 -179.987 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 89.2 p -77.0 125.99 30.24 Favored 'General case' 0 N--CA 1.472 0.664 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 178.169 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 1.8 t-20 -66.66 100.22 0.67 Allowed 'General case' 0 N--CA 1.472 0.633 0 N-CA-C 108.108 -1.071 . . . . 0.0 108.108 178.528 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 66.6 mttm -94.31 127.15 40.01 Favored 'General case' 0 N--CA 1.481 1.101 0 N-CA-C 109.149 -0.685 . . . . 0.0 109.149 -179.463 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.84 -130.58 0.01 OUTLIER Glycine 0 CA--C 1.533 1.218 0 N-CA-C 110.454 -1.058 . . . . 0.0 110.454 179.31 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -129.25 127.56 41.49 Favored 'General case' 0 N--CA 1.484 1.265 0 CA-C-N 117.439 0.62 . . . . 0.0 111.324 -179.906 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 27.8 mt -90.91 161.01 2.65 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.499 0 N-CA-C 106.796 -1.557 . . . . 0.0 106.796 178.152 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 37.3 mt -138.75 94.5 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.479 0.979 0 N-CA-C 109.606 -0.516 . . . . 0.0 109.606 179.872 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 53.62 104.37 0.01 OUTLIER Glycine 0 CA--C 1.531 1.037 0 CA-C-N 116.101 -0.499 . . . . 0.0 114.204 176.791 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 93.8 mt -71.52 155.64 40.34 Favored 'General case' 0 N--CA 1.473 0.682 0 N-CA-C 107.49 -1.3 . . . . 0.0 107.49 176.516 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 2.4 ttp -143.81 139.99 29.62 Favored 'General case' 0 N--CA 1.479 1.019 0 N-CA-C 108.301 -1.0 . . . . 0.0 108.301 178.787 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 65.6 t -160.27 148.8 6.11 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.456 0 N-CA-C 106.618 -1.623 . . . . 0.0 106.618 -179.058 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.15 75.32 0.24 Allowed Glycine 0 N--CA 1.464 0.516 0 N-CA-C 111.815 -0.514 . . . . 0.0 111.815 178.118 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 174.77 -146.95 8.77 Favored Glycine 0 C--O 1.221 -0.663 0 N-CA-C 111.207 -0.757 . . . . 0.0 111.207 179.881 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 29.8 m -136.69 145.15 30.73 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.794 0 CA-C-N 117.104 0.452 . . . . 0.0 109.808 -179.647 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 19.0 t . . . . . 0 CA--C 1.537 0.449 0 CA-C-O 117.576 -1.202 . . . . 0.0 111.153 179.183 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' F' F ' 1' ' ' ASP . . . . . . . . . . . . . 8.6 m-20 . . . . . 0 N--CA 1.49 1.573 0 N-CA-C 109.177 -0.675 . . . . 0.0 109.177 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' F' F ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.31 131.16 46.49 Favored 'General case' 0 CA--C 1.536 0.441 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.382 179.832 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' F' F ' 3' ' ' GLU . . . . . . . . . . . . . 54.5 tt0 -169.19 108.34 0.44 Allowed 'General case' 0 N--CA 1.469 0.523 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 -179.824 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 77.0 m-85 -84.38 141.25 30.99 Favored 'General case' 0 N--CA 1.474 0.75 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 179.414 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' F' F ' 5' ' ' ARG . . . . . . . . . . . . . 72.0 mtp180 -144.11 142.15 30.43 Favored 'General case' 0 N--CA 1.478 0.954 0 N-CA-C 109.092 -0.707 . . . . 0.0 109.092 179.755 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 77.2 m80 -150.14 117.43 6.04 Favored 'General case' 0 N--CA 1.476 0.843 0 N-CA-C 108.983 -0.747 . . . . 0.0 108.983 179.093 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' F' F ' 7' ' ' ASP . . . . . . . . . . . . . 11.5 m-20 -65.74 149.07 50.73 Favored 'General case' 0 N--CA 1.464 0.247 0 O-C-N 123.327 0.392 . . . . 0.0 111.662 -179.433 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' F' F ' 8' ' ' SER . . . . . . . . . . . . . 7.1 t -167.38 171.43 10.58 Favored 'General case' 0 N--CA 1.476 0.87 0 N-CA-C 109.253 -0.647 . . . . 0.0 109.253 178.056 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 123.79 23.71 2.01 Favored Glycine 0 N--CA 1.482 1.746 0 N-CA-C 111.901 -0.48 . . . . 0.0 111.901 179.008 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 37.4 p90 -55.9 127.75 31.81 Favored 'General case' 0 CA--C 1.542 0.647 0 N-CA-C 112.717 0.636 . . . . 0.0 112.717 -179.113 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 46.4 mt-10 -83.21 155.25 23.81 Favored 'General case' 0 N--CA 1.475 0.779 0 N-CA-C 109.2 -0.667 . . . . 0.0 109.2 177.756 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -155.74 127.94 1.02 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.538 0 N-CA-C 108.218 -1.03 . . . . 0.0 108.218 178.551 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 49.0 m-70 -134.29 143.16 47.58 Favored 'General case' 0 N--CA 1.479 1.024 0 C-N-CA 122.419 0.288 . . . . 0.0 110.996 -177.871 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 6.1 t60 -163.81 99.12 0.88 Allowed 'General case' 0 N--CA 1.487 1.38 0 CA-C-N 116.85 -0.159 . . . . 0.0 111.252 179.677 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 33.0 mt-30 -103.58 -171.91 2.02 Favored 'General case' 0 CA--C 1.501 -0.921 0 N-CA-C 108.388 -0.967 . . . . 0.0 108.388 179.384 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -167.6 98.3 0.48 Allowed 'General case' 0 CA--C 1.54 0.59 0 CA-C-N 114.842 -1.072 . . . . 0.0 109.322 178.775 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' F' F ' 17' ' ' LEU . . . . . 0.529 ' N ' HD12 ' F' ' 17' ' ' LEU . 4.9 mp -106.45 161.45 14.58 Favored 'General case' 0 N--CA 1.487 1.415 0 N-CA-C 108.721 -0.844 . . . . 0.0 108.721 -179.967 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 41.6 t -142.32 117.96 5.64 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.378 0 C-N-CA 122.638 0.375 . . . . 0.0 110.478 178.921 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 55.2 m-85 -69.82 156.47 38.99 Favored 'General case' 0 C--N 1.357 0.906 0 N-CA-C 107.455 -1.313 . . . . 0.0 107.455 176.363 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 15.0 t80 -173.11 -56.09 0.02 OUTLIER 'General case' 0 N--CA 1.482 1.164 0 CA-C-O 121.743 0.783 . . . . 0.0 109.606 179.233 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.99 89.09 0.0 OUTLIER 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 114.46 -1.245 . . . . 0.0 112.76 -179.02 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 53.9 tt0 -61.6 155.19 22.95 Favored 'General case' 0 N--CA 1.472 0.659 0 CA-C-N 115.151 -0.931 . . . . 0.0 110.641 179.346 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 17.5 m-20 -136.66 134.73 37.59 Favored 'General case' 0 N--CA 1.479 1.006 0 C-N-CA 122.925 0.49 . . . . 0.0 110.345 -179.986 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' F' F ' 24' ' ' VAL . . . . . . . . . . . . . 19.3 t -85.08 -116.69 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.93 0 N-CA-C 108.525 -0.917 . . . . 0.0 108.525 179.241 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -106.6 52.61 0.67 Allowed Glycine 0 N--CA 1.477 1.42 0 N-CA-C 111.172 -0.771 . . . . 0.0 111.172 179.974 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 89.3 p -76.78 125.86 29.99 Favored 'General case' 0 N--CA 1.472 0.655 0 N-CA-C 109.271 -0.64 . . . . 0.0 109.271 178.176 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 1.9 t-20 -66.83 100.35 0.71 Allowed 'General case' 0 N--CA 1.471 0.603 0 N-CA-C 108.134 -1.061 . . . . 0.0 108.134 178.587 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 66.7 mttm -94.31 126.96 39.89 Favored 'General case' 0 N--CA 1.481 1.123 0 N-CA-C 109.169 -0.678 . . . . 0.0 109.169 -179.389 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.81 -130.96 0.01 OUTLIER Glycine 0 CA--C 1.532 1.155 0 N-CA-C 110.591 -1.004 . . . . 0.0 110.591 179.212 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.55 126.94 41.38 Favored 'General case' 0 N--CA 1.488 1.433 0 CA-C-N 117.4 0.6 . . . . 0.0 111.348 -179.765 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 28.1 mt -90.62 160.92 2.68 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.547 0 N-CA-C 106.694 -1.595 . . . . 0.0 106.694 178.033 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 36.8 mt -138.87 94.57 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.093 0 N-CA-C 109.613 -0.514 . . . . 0.0 109.613 179.822 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 53.69 104.3 0.01 OUTLIER Glycine 0 CA--C 1.531 1.075 0 CA-C-N 116.039 -0.528 . . . . 0.0 114.145 176.752 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 94.1 mt -71.47 155.93 40.03 Favored 'General case' 0 N--CA 1.471 0.62 0 N-CA-C 107.524 -1.287 . . . . 0.0 107.524 176.588 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 2.3 ttp -144.13 140.01 29.15 Favored 'General case' 0 N--CA 1.478 0.957 0 N-CA-C 108.691 -0.855 . . . . 0.0 108.691 178.708 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 65.0 t -160.3 148.95 6.08 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.447 0 N-CA-C 106.703 -1.591 . . . . 0.0 106.703 -178.973 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.16 75.25 0.25 Allowed Glycine 0 N--CA 1.464 0.551 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.812 178.038 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 174.77 -146.94 8.76 Favored Glycine 0 C--O 1.22 -0.738 0 N-CA-C 111.22 -0.752 . . . . 0.0 111.22 179.845 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 30.3 m -136.7 145.05 30.88 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.757 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 -179.644 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 18.7 t . . . . . 0 C--O 1.221 -0.418 0 CA-C-O 117.621 -1.18 . . . . 0.0 111.157 179.215 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' G' G ' 1' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 . . . . . 0 N--CA 1.492 1.643 0 N-CA-C 109.494 -0.558 . . . . 0.0 109.494 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' G' G ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.72 129.55 41.02 Favored 'General case' 0 N--CA 1.469 0.514 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.416 179.698 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' G' G ' 3' ' ' GLU . . . . . . . . . . . . . 53.7 tt0 -169.16 108.17 0.44 Allowed 'General case' 0 N--CA 1.47 0.53 0 N-CA-C 110.114 -0.328 . . . . 0.0 110.114 179.763 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 77.1 m-85 -84.88 140.85 30.83 Favored 'General case' 0 N--CA 1.472 0.668 0 N-CA-C 109.594 -0.521 . . . . 0.0 109.594 179.314 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' G' G ' 5' ' ' ARG . . . . . . . . . . . . . 72.4 mtp180 -144.56 141.94 29.83 Favored 'General case' 0 N--CA 1.48 1.053 0 N-CA-C 109.088 -0.708 . . . . 0.0 109.088 -179.799 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 77.1 m80 -149.85 118.75 6.66 Favored 'General case' 0 N--CA 1.475 0.797 0 N-CA-C 108.979 -0.749 . . . . 0.0 108.979 179.072 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 12.1 m-20 -68.1 144.85 54.87 Favored 'General case' 0 CA--C 1.537 0.467 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.878 -179.2 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' G' G ' 8' ' ' SER . . . . . . . . . . . . . 6.1 t -163.58 173.1 13.44 Favored 'General case' 0 N--CA 1.47 0.552 0 N-CA-C 109.068 -0.715 . . . . 0.0 109.068 178.089 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 123.4 23.12 2.19 Favored Glycine 0 N--CA 1.481 1.644 0 N-CA-C 111.712 -0.555 . . . . 0.0 111.712 178.936 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 40.5 p90 -56.18 127.68 31.87 Favored 'General case' 0 N--CA 1.473 0.718 0 N-CA-C 112.682 0.623 . . . . 0.0 112.682 -178.705 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 46.2 mt-10 -83.44 154.1 24.14 Favored 'General case' 0 N--CA 1.47 0.561 0 N-CA-C 109.632 -0.507 . . . . 0.0 109.632 178.307 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -155.68 128.07 1.05 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.933 0 N-CA-C 108.036 -1.098 . . . . 0.0 108.036 178.846 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 50.2 m-70 -133.66 144.15 49.01 Favored 'General case' 0 N--CA 1.475 0.801 0 CA-C-N 115.353 -0.84 . . . . 0.0 110.773 -178.238 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 30.5 t-80 -164.82 98.83 0.77 Allowed 'General case' 0 N--CA 1.483 1.204 0 CA-C-N 116.635 -0.257 . . . . 0.0 110.786 179.033 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 33.3 mt-30 -103.18 -172.32 2.1 Favored 'General case' 0 CA--C 1.506 -0.737 0 N-CA-C 108.358 -0.979 . . . . 0.0 108.358 179.578 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -167.29 98.31 0.51 Allowed 'General case' 0 CA--C 1.539 0.546 0 CA-C-N 115.051 -0.977 . . . . 0.0 109.367 178.7 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' G' G ' 17' ' ' LEU . . . . . 0.55 ' N ' HD12 ' G' ' 17' ' ' LEU . 5.4 mp -106.2 160.81 15.05 Favored 'General case' 0 N--CA 1.486 1.335 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 -179.908 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 40.4 t -143.59 117.95 3.84 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.001 0 C-N-CA 122.573 0.349 . . . . 0.0 110.235 178.753 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 49.0 m-85 -69.7 150.84 46.53 Favored 'General case' 0 C--N 1.37 1.487 0 N-CA-C 107.404 -1.332 . . . . 0.0 107.404 176.477 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 12.4 t80 -171.03 -55.9 0.02 OUTLIER 'General case' 0 N--CA 1.485 1.29 0 N-CA-C 110.025 -0.361 . . . . 0.0 110.025 179.957 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.88 90.61 0.0 OUTLIER 'General case' 0 C--N 1.325 -0.481 0 O-C-N 123.938 0.774 . . . . 0.0 112.267 179.986 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 53.7 tt0 -62.81 155.84 25.68 Favored 'General case' 0 N--CA 1.469 0.475 0 CA-C-N 114.838 -1.074 . . . . 0.0 109.718 179.03 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 18.0 m-20 -136.71 134.71 37.48 Favored 'General case' 0 N--CA 1.478 0.96 0 C-N-CA 122.782 0.433 . . . . 0.0 109.87 -179.939 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' G' G ' 24' ' ' VAL . . . . . . . . . . . . . 19.6 t -85.5 -116.02 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.894 0 N-CA-C 108.293 -1.003 . . . . 0.0 108.293 179.289 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -107.28 53.06 0.63 Allowed Glycine 0 N--CA 1.476 1.311 0 N-CA-C 111.286 -0.726 . . . . 0.0 111.286 -179.947 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 89.3 p -77.48 126.2 30.53 Favored 'General case' 0 N--CA 1.466 0.37 0 N-CA-C 109.152 -0.684 . . . . 0.0 109.152 178.139 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 1.9 t-20 -67.16 99.82 0.72 Allowed 'General case' 0 N--CA 1.469 0.495 0 N-CA-C 108.604 -0.887 . . . . 0.0 108.604 178.81 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 67.3 mttm -93.51 127.09 39.01 Favored 'General case' 0 N--CA 1.481 1.081 0 N-CA-C 109.512 -0.551 . . . . 0.0 109.512 -179.662 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.87 -128.71 0.01 OUTLIER Glycine 0 CA--C 1.527 0.801 0 N-CA-C 110.576 -1.01 . . . . 0.0 110.576 179.27 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.84 126.09 35.36 Favored 'General case' 0 CA--C 1.54 0.567 0 C-N-CA 122.814 0.446 . . . . 0.0 110.933 -179.361 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 37.7 mt -90.53 162.26 2.49 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.842 0 N-CA-C 107.0 -1.482 . . . . 0.0 107.0 178.239 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 40.8 mt -139.04 95.96 0.96 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.437 0 CA-C-N 119.714 1.143 . . . . 0.0 110.068 178.173 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 53.64 103.92 0.01 OUTLIER Glycine 0 CA--C 1.53 1.019 0 CA-C-N 116.026 -0.534 . . . . 0.0 114.106 176.818 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 92.3 mt -71.34 154.96 41.19 Favored 'General case' 0 N--CA 1.47 0.57 0 N-CA-C 107.772 -1.196 . . . . 0.0 107.772 176.717 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 2.6 ttp -143.48 140.46 30.34 Favored 'General case' 0 N--CA 1.474 0.756 0 N-CA-C 108.555 -0.906 . . . . 0.0 108.555 178.897 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 69.2 t -160.36 149.11 5.98 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.256 0 N-CA-C 106.636 -1.616 . . . . 0.0 106.636 -179.329 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.5 75.12 0.26 Allowed Glycine 0 N--CA 1.466 0.637 0 C-N-CA 121.012 -0.613 . . . . 0.0 112.04 177.494 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 173.92 -146.17 8.59 Favored Glycine 0 C--O 1.221 -0.708 0 N-CA-C 110.581 -1.008 . . . . 0.0 110.581 179.339 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 32.9 m -136.76 145.9 29.42 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.923 0 CA-C-N 117.002 0.401 . . . . 0.0 110.185 -179.413 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 20.7 t . . . . . 0 C--O 1.22 -0.467 0 CA-C-O 117.603 -1.189 . . . . 0.0 111.417 179.091 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' H' H ' 1' ' ' ASP . . . . . . . . . . . . . 8.5 m-20 . . . . . 0 N--CA 1.491 1.577 0 N-CA-C 109.568 -0.53 . . . . 0.0 109.568 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' H' H ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.83 129.47 40.59 Favored 'General case' 0 N--CA 1.469 0.5 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.381 179.711 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' H' H ' 3' ' ' GLU . . . . . . . . . . . . . 53.8 tt0 -169.04 108.12 0.45 Allowed 'General case' 0 N--CA 1.469 0.505 0 N-CA-C 110.137 -0.32 . . . . 0.0 110.137 179.78 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 77.6 m-85 -84.64 141.04 30.92 Favored 'General case' 0 N--CA 1.472 0.666 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 179.387 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' H' H ' 5' ' ' ARG . . . . . . . . . . . . . 72.3 mtp180 -144.6 141.86 29.73 Favored 'General case' 0 N--CA 1.48 1.062 0 N-CA-C 109.13 -0.693 . . . . 0.0 109.13 -179.859 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 77.1 m80 -149.84 118.3 6.49 Favored 'General case' 0 N--CA 1.476 0.831 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 179.096 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 11.9 m-20 -67.54 144.89 55.4 Favored 'General case' 0 N--CA 1.468 0.453 0 O-C-N 123.426 0.453 . . . . 0.0 111.931 -179.29 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' H' H ' 8' ' ' SER . . . . . . . . . . . . . 7.5 t -163.74 172.36 14.29 Favored 'General case' 0 N--CA 1.47 0.532 0 N-CA-C 109.174 -0.676 . . . . 0.0 109.174 178.261 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 123.52 23.36 2.13 Favored Glycine 0 N--CA 1.482 1.714 0 N-CA-C 111.817 -0.513 . . . . 0.0 111.817 179.084 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 40.5 p90 -56.17 127.82 32.56 Favored 'General case' 0 N--CA 1.473 0.714 0 N-CA-C 112.575 0.583 . . . . 0.0 112.575 -178.82 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 46.2 mt-10 -83.53 154.23 23.96 Favored 'General case' 0 N--CA 1.473 0.708 0 N-CA-C 109.597 -0.52 . . . . 0.0 109.597 178.297 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -155.85 127.99 1.02 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.943 0 N-CA-C 108.07 -1.085 . . . . 0.0 108.07 178.8 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 51.4 m-70 -133.54 144.33 49.28 Favored 'General case' 0 N--CA 1.476 0.825 0 CA-C-N 115.274 -0.875 . . . . 0.0 110.81 -178.214 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 6.2 t60 -164.96 98.5 0.75 Allowed 'General case' 0 N--CA 1.483 1.197 0 CA-C-N 116.709 -0.223 . . . . 0.0 110.85 179.034 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 33.0 mt-30 -102.8 -172.8 2.18 Favored 'General case' 0 CA--C 1.505 -0.77 0 N-CA-C 108.26 -1.015 . . . . 0.0 108.26 179.642 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -167.11 98.24 0.52 Allowed 'General case' 0 CA--C 1.539 0.524 0 CA-C-N 114.997 -1.001 . . . . 0.0 109.251 178.719 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' H' H ' 17' ' ' LEU . . . . . 0.56 HD12 ' N ' ' H' ' 17' ' ' LEU . 5.4 mp -106.17 160.84 15.02 Favored 'General case' 0 N--CA 1.485 1.279 0 N-CA-C 109.103 -0.702 . . . . 0.0 109.103 -179.823 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 40.4 t -143.52 117.77 3.81 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.089 0 C-N-CA 122.547 0.339 . . . . 0.0 110.25 178.744 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 50.2 m-85 -69.75 151.29 45.97 Favored 'General case' 0 C--N 1.369 1.426 0 N-CA-C 107.527 -1.286 . . . . 0.0 107.527 176.33 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 13.1 t80 -172.25 -55.58 0.02 OUTLIER 'General case' 0 N--CA 1.483 1.177 0 N-CA-C 110.069 -0.345 . . . . 0.0 110.069 180.0 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.96 90.71 0.0 OUTLIER 'General case' 0 CA--C 1.535 0.367 0 C-N-CA 123.517 0.727 . . . . 0.0 112.097 179.924 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 53.7 tt0 -62.61 155.83 24.99 Favored 'General case' 0 N--CA 1.469 0.512 0 CA-C-N 114.849 -1.069 . . . . 0.0 109.919 179.115 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 17.9 m-20 -136.55 134.86 37.93 Favored 'General case' 0 N--CA 1.48 1.025 0 C-N-CA 122.835 0.454 . . . . 0.0 109.917 -179.957 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' H' H ' 24' ' ' VAL . . . . . . . . . . . . . 19.6 t -85.85 -116.13 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.846 0 N-CA-C 108.358 -0.979 . . . . 0.0 108.358 179.364 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . -106.91 52.89 0.64 Allowed Glycine 0 N--CA 1.478 1.483 0 N-CA-C 111.099 -0.8 . . . . 0.0 111.099 -179.969 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 89.0 p -77.45 126.16 30.47 Favored 'General case' 0 N--CA 1.467 0.383 0 N-CA-C 109.006 -0.738 . . . . 0.0 109.006 178.304 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 1.9 t-20 -67.06 100.49 0.76 Allowed 'General case' 0 N--CA 1.469 0.5 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 178.667 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 67.3 mttm -94.39 127.12 40.07 Favored 'General case' 0 N--CA 1.481 1.084 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 -179.598 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.11 -128.54 0.01 OUTLIER Glycine 0 CA--C 1.527 0.783 0 N-CA-C 110.643 -0.983 . . . . 0.0 110.643 179.385 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.97 126.04 34.99 Favored 'General case' 0 N--CA 1.471 0.582 0 C-N-CA 122.853 0.461 . . . . 0.0 111.033 -179.251 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 35.8 mt -90.66 161.81 2.55 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.845 0 N-CA-C 107.014 -1.476 . . . . 0.0 107.014 178.228 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 40.4 mt -138.73 95.93 1.01 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.435 0 CA-C-N 119.511 1.051 . . . . 0.0 109.981 178.38 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 53.58 104.32 0.01 OUTLIER Glycine 0 CA--C 1.53 1.029 0 CA-C-N 116.101 -0.5 . . . . 0.0 114.144 176.832 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 92.1 mt -71.67 154.76 41.16 Favored 'General case' 0 N--CA 1.47 0.57 0 N-CA-C 107.673 -1.232 . . . . 0.0 107.673 176.716 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 2.6 ttp -143.09 140.09 30.74 Favored 'General case' 0 N--CA 1.477 0.889 0 N-CA-C 108.503 -0.925 . . . . 0.0 108.503 178.802 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 69.1 t -159.96 149.34 6.38 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.278 0 N-CA-C 106.525 -1.657 . . . . 0.0 106.525 -179.388 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.28 74.91 0.27 Allowed Glycine 0 C--N 1.314 -0.643 0 C-N-CA 120.989 -0.624 . . . . 0.0 112.155 177.489 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 173.97 -146.32 8.66 Favored Glycine 0 C--O 1.221 -0.675 0 N-CA-C 110.631 -0.988 . . . . 0.0 110.631 179.393 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 32.7 m -136.68 145.87 29.55 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.87 0 CA-C-N 116.98 0.39 . . . . 0.0 110.327 -179.423 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 21.1 t . . . . . 0 C--O 1.221 -0.4 0 CA-C-O 117.64 -1.171 . . . . 0.0 111.326 179.163 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' I' I ' 1' ' ' ASP . . . . . . . . . . . . . 8.5 m-20 . . . . . 0 N--CA 1.492 1.634 0 N-CA-C 109.435 -0.58 . . . . 0.0 109.435 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' I' I ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.77 129.43 40.44 Favored 'General case' 0 N--CA 1.469 0.502 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.478 179.672 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' I' I ' 3' ' ' GLU . . . . . . . . . . . . . 53.8 tt0 -169.02 108.2 0.45 Allowed 'General case' 0 N--CA 1.468 0.452 0 N-CA-C 110.13 -0.322 . . . . 0.0 110.13 179.833 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 77.1 m-85 -84.75 141.18 30.72 Favored 'General case' 0 N--CA 1.473 0.704 0 N-CA-C 109.553 -0.536 . . . . 0.0 109.553 179.377 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' I' I ' 5' ' ' ARG . . . . . . . . . . . . . 72.3 mtp180 -144.78 141.9 29.56 Favored 'General case' 0 N--CA 1.481 1.094 0 N-CA-C 109.056 -0.72 . . . . 0.0 109.056 -179.834 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 77.1 m80 -149.83 118.34 6.51 Favored 'General case' 0 N--CA 1.476 0.838 0 N-CA-C 109.083 -0.71 . . . . 0.0 109.083 179.093 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 12.0 m-20 -67.62 144.76 55.39 Favored 'General case' 0 CA--C 1.535 0.396 0 CA-C-O 120.979 0.419 . . . . 0.0 111.927 -179.268 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' I' I ' 8' ' ' SER . . . . . . . . . . . . . 7.6 t -163.54 172.31 14.59 Favored 'General case' 0 N--CA 1.469 0.5 0 N-CA-C 109.152 -0.684 . . . . 0.0 109.152 178.276 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 123.7 23.26 2.1 Favored Glycine 0 N--CA 1.483 1.789 0 N-CA-C 111.747 -0.541 . . . . 0.0 111.747 179.027 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 40.3 p90 -56.08 127.82 32.43 Favored 'General case' 0 N--CA 1.474 0.75 0 N-CA-C 112.501 0.556 . . . . 0.0 112.501 -178.792 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 46.2 mt-10 -83.61 154.17 23.89 Favored 'General case' 0 N--CA 1.474 0.73 0 N-CA-C 109.644 -0.502 . . . . 0.0 109.644 178.203 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -155.74 128.01 1.03 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.927 0 N-CA-C 108.125 -1.065 . . . . 0.0 108.125 178.854 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 50.9 m-70 -133.58 144.33 49.24 Favored 'General case' 0 N--CA 1.476 0.832 0 CA-C-N 115.33 -0.85 . . . . 0.0 110.861 -178.236 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 30.6 t-80 -165.05 98.61 0.74 Allowed 'General case' 0 N--CA 1.485 1.297 0 CA-C-N 116.687 -0.233 . . . . 0.0 110.914 179.131 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 32.9 mt-30 -103.11 -172.55 2.13 Favored 'General case' 0 CA--C 1.503 -0.852 0 N-CA-C 108.328 -0.99 . . . . 0.0 108.328 179.598 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -167.26 98.23 0.51 Allowed 'General case' 0 CA--C 1.538 0.517 0 CA-C-N 114.977 -1.011 . . . . 0.0 109.279 178.82 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' I' I ' 17' ' ' LEU . . . . . 0.553 ' N ' HD12 ' I' ' 17' ' ' LEU . 5.4 mp -106.18 160.77 15.08 Favored 'General case' 0 N--CA 1.484 1.259 0 N-CA-C 109.089 -0.708 . . . . 0.0 109.089 -179.854 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 40.5 t -143.4 117.83 3.95 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.016 0 C-N-CA 122.542 0.337 . . . . 0.0 110.306 178.753 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 49.7 m-85 -69.83 151.3 45.88 Favored 'General case' 0 C--N 1.369 1.431 0 N-CA-C 107.486 -1.302 . . . . 0.0 107.486 176.423 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 13.2 t80 -172.25 -55.55 0.02 OUTLIER 'General case' 0 N--CA 1.481 1.093 0 N-CA-C 110.065 -0.346 . . . . 0.0 110.065 -179.999 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.98 90.8 0.0 OUTLIER 'General case' 0 CA--C 1.535 0.387 0 C-N-CA 123.496 0.718 . . . . 0.0 112.046 179.877 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 53.7 tt0 -62.69 155.96 24.91 Favored 'General case' 0 N--CA 1.469 0.5 0 CA-C-N 114.862 -1.063 . . . . 0.0 109.866 179.141 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 17.9 m-20 -136.69 134.85 37.66 Favored 'General case' 0 N--CA 1.479 0.987 0 C-N-CA 122.804 0.442 . . . . 0.0 109.867 -179.954 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' I' I ' 24' ' ' VAL . . . . . . . . . . . . . 19.4 t -85.76 -116.09 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.878 0 N-CA-C 108.337 -0.986 . . . . 0.0 108.337 179.39 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . -106.98 52.9 0.64 Allowed Glycine 0 N--CA 1.477 1.402 0 N-CA-C 111.225 -0.75 . . . . 0.0 111.225 179.991 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 89.3 p -77.46 126.2 30.53 Favored 'General case' 0 N--CA 1.466 0.372 0 N-CA-C 109.066 -0.716 . . . . 0.0 109.066 178.313 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 1.9 t-20 -67.03 100.4 0.74 Allowed 'General case' 0 N--CA 1.47 0.538 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 178.623 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 67.4 mttm -94.27 127.03 39.88 Favored 'General case' 0 N--CA 1.481 1.111 0 N-CA-C 109.452 -0.573 . . . . 0.0 109.452 -179.659 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.97 -128.78 0.01 OUTLIER Glycine 0 CA--C 1.527 0.831 0 N-CA-C 110.695 -0.962 . . . . 0.0 110.695 179.339 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.69 125.74 34.72 Favored 'General case' 0 N--CA 1.471 0.612 0 C-N-CA 122.957 0.503 . . . . 0.0 111.057 -179.299 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 36.2 mt -90.56 161.85 2.55 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.781 0 N-CA-C 106.933 -1.506 . . . . 0.0 106.933 178.201 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 40.4 mt -138.85 95.79 0.98 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 CA-C-N 119.485 1.039 . . . . 0.0 109.99 178.475 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 53.7 104.23 0.01 OUTLIER Glycine 0 CA--C 1.531 1.039 0 CA-C-N 116.103 -0.499 . . . . 0.0 114.093 176.818 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 91.9 mt -71.56 154.63 41.32 Favored 'General case' 0 N--CA 1.471 0.576 0 N-CA-C 107.683 -1.228 . . . . 0.0 107.683 176.687 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 2.6 ttp -143.03 140.03 30.8 Favored 'General case' 0 N--CA 1.475 0.815 0 N-CA-C 108.497 -0.927 . . . . 0.0 108.497 178.871 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 68.6 t -159.95 149.37 6.39 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.228 0 N-CA-C 106.567 -1.642 . . . . 0.0 106.567 -179.371 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.2 74.99 0.26 Allowed Glycine 0 N--CA 1.465 0.617 0 C-N-CA 120.942 -0.647 . . . . 0.0 112.152 177.517 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 173.95 -146.24 8.63 Favored Glycine 0 N--CA 1.465 0.633 0 N-CA-C 110.662 -0.975 . . . . 0.0 110.662 179.354 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 32.8 m -136.73 145.91 29.43 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.93 0 CA-C-N 117.013 0.406 . . . . 0.0 110.172 -179.369 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 20.9 t . . . . . 0 C--O 1.221 -0.42 0 CA-C-O 117.648 -1.168 . . . . 0.0 111.381 179.145 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 8.6 m-20 . . . . . 0 N--CA 1.487 1.413 0 N-CA-C 109.04 -0.726 . . . . 0.0 109.04 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.49 132.45 48.95 Favored 'General case' 0 CA--C 1.539 0.528 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.18 -179.879 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 38.9 tt0 -169.44 108.27 0.42 Allowed 'General case' 0 N--CA 1.47 0.542 0 N-CA-C 109.558 -0.534 . . . . 0.0 109.558 -179.12 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 76.5 m-85 -83.59 140.78 32.02 Favored 'General case' 0 N--CA 1.475 0.791 0 N-CA-C 109.98 -0.378 . . . . 0.0 109.98 179.449 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 73.7 mtp180 -143.71 141.31 30.45 Favored 'General case' 0 N--CA 1.482 1.152 0 N-CA-C 109.045 -0.724 . . . . 0.0 109.045 -179.968 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 76.7 m80 -149.77 119.53 7.05 Favored 'General case' 0 N--CA 1.47 0.548 0 N-CA-C 108.781 -0.822 . . . . 0.0 108.781 179.137 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 -67.84 149.56 49.7 Favored 'General case' 0 N--CA 1.463 0.187 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.179 -179.62 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 7.0 t -167.22 171.28 10.94 Favored 'General case' 0 N--CA 1.473 0.698 0 N-CA-C 109.46 -0.57 . . . . 0.0 109.46 178.496 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.21 24.07 2.29 Favored Glycine 0 N--CA 1.487 2.065 0 N-CA-C 112.125 -0.39 . . . . 0.0 112.125 179.375 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 41.9 p90 -56.78 128.01 34.45 Favored 'General case' 0 N--CA 1.471 0.623 0 N-CA-C 112.106 0.41 . . . . 0.0 112.106 -179.889 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 46.1 mt-10 -84.86 156.09 21.44 Favored 'General case' 0 N--CA 1.468 0.443 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 178.544 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -154.86 124.48 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 N-CA-C 108.119 -1.067 . . . . 0.0 108.119 178.534 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 35.1 m80 -107.33 161.12 15.09 Favored 'General case' 0 N--CA 1.491 1.624 0 CA-C-N 118.455 0.57 . . . . 0.0 111.213 -178.767 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 57.1 t60 -164.66 99.14 0.79 Allowed 'General case' 0 N--CA 1.485 1.289 0 CA-C-N 116.766 -0.197 . . . . 0.0 111.06 179.63 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 15' ' ' GLN . . . . . 0.45 HE22 HG13 ' A' ' 36' ' ' VAL . 36.3 mt-30 -125.67 -175.15 3.26 Favored 'General case' 0 CA--C 1.491 -1.301 0 N-CA-C 107.862 -1.162 . . . . 0.0 107.862 -179.99 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -169.7 103.28 0.33 Allowed 'General case' 0 CA--C 1.542 0.644 0 CA-C-N 115.011 -0.995 . . . . 0.0 109.395 179.026 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 9.3 mp -110.75 151.35 27.88 Favored 'General case' 0 N--CA 1.489 1.515 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 -179.932 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 61.6 t -143.98 119.06 4.0 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.245 0 CA-C-O 118.69 -0.671 . . . . 0.0 109.543 179.084 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 17.3 m-85 -70.19 157.2 38.08 Favored 'General case' 0 N--CA 1.477 0.923 0 N-CA-C 107.727 -1.212 . . . . 0.0 107.727 177.542 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 14.6 t80 -170.99 -60.0 0.02 OUTLIER 'General case' 0 N--CA 1.482 1.156 0 CA-C-O 122.315 1.055 . . . . 0.0 109.482 179.278 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.0 89.64 0.0 OUTLIER 'General case' 0 N--CA 1.456 -0.152 0 CA-C-N 113.891 -1.504 . . . . 0.0 112.875 -177.973 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 43.4 mt-10 -61.42 158.22 15.14 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 115.166 -0.924 . . . . 0.0 110.782 179.037 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 12.0 m-20 -139.98 135.26 32.55 Favored 'General case' 0 N--CA 1.483 1.21 0 C-N-CA 122.769 0.427 . . . . 0.0 110.399 -179.956 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 18.1 t -84.34 -115.98 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.475 0.802 0 N-CA-C 108.35 -0.981 . . . . 0.0 108.35 179.355 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -109.32 54.25 0.55 Allowed Glycine 0 N--CA 1.473 1.112 0 N-CA-C 111.254 -0.738 . . . . 0.0 111.254 -179.986 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 82.8 p -77.49 126.96 31.72 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 109.0 -0.741 . . . . 0.0 109.0 178.469 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 27' ' ' ASN . . . . . 0.45 HD21 ' HB3' ' D' ' 27' ' ' ASN . 6.5 t-20 -66.7 100.92 0.74 Allowed 'General case' 0 N--CA 1.471 0.599 0 N-CA-C 108.611 -0.885 . . . . 0.0 108.611 178.593 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 67.2 mttm -95.3 128.88 42.51 Favored 'General case' 0 N--CA 1.481 1.089 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 -179.155 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.71 -132.12 0.01 OUTLIER Glycine 0 CA--C 1.533 1.203 0 N-CA-C 110.775 -0.93 . . . . 0.0 110.775 178.907 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.77 126.91 37.6 Favored 'General case' 0 N--CA 1.484 1.237 0 CA-C-N 117.097 0.448 . . . . 0.0 110.016 179.345 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 33.0 mt -91.31 159.17 2.83 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.496 0 N-CA-C 106.631 -1.618 . . . . 0.0 106.631 178.416 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 42.9 mt -138.25 92.86 0.83 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.468 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 -178.972 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 54.05 106.23 0.01 OUTLIER Glycine 0 CA--C 1.53 1.002 0 CA-C-N 115.933 -0.576 . . . . 0.0 114.162 177.239 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 97.9 mt -72.26 153.5 41.52 Favored 'General case' 0 CA--C 1.539 0.536 0 N-CA-C 107.27 -1.382 . . . . 0.0 107.27 176.703 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 27.2 ttt -147.07 138.34 24.01 Favored 'General case' 0 N--CA 1.477 0.879 0 N-CA-C 108.761 -0.829 . . . . 0.0 108.761 179.147 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.45 HG13 HE22 ' A' ' 15' ' ' GLN . 61.9 t -159.69 153.51 5.02 Favored 'Isoleucine or valine' 0 C--N 1.342 0.262 0 N-CA-C 106.596 -1.631 . . . . 0.0 106.596 -179.279 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.98 73.56 0.42 Allowed Glycine 0 C--N 1.313 -0.697 0 N-CA-C 111.663 -0.575 . . . . 0.0 111.663 177.987 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 174.65 -161.58 31.34 Favored Glycine 0 C--N 1.335 0.483 0 N-CA-C 111.086 -0.806 . . . . 0.0 111.086 -179.828 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 23.5 m -124.29 139.63 50.04 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.951 0 C-N-CA 122.762 0.425 . . . . 0.0 110.084 179.744 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 26.1 t . . . . . 0 C--O 1.221 -0.447 0 CA-C-O 117.635 -1.174 . . . . 0.0 111.108 179.37 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' B' B ' 1' ' ' ASP . . . . . . . . . . . . . 8.7 m-20 . . . . . 0 N--CA 1.488 1.461 0 N-CA-C 109.144 -0.687 . . . . 0.0 109.144 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' B' B ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.3 132.35 48.82 Favored 'General case' 0 CA--C 1.538 0.507 0 CA-C-N 116.385 -0.371 . . . . 0.0 110.234 -179.852 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 3' ' ' GLU . . . . . . . . . . . . . 39.1 tt0 -169.29 108.36 0.43 Allowed 'General case' 0 N--CA 1.469 0.509 0 N-CA-C 109.569 -0.53 . . . . 0.0 109.569 -179.153 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 77.0 m-85 -83.6 140.88 31.94 Favored 'General case' 0 N--CA 1.474 0.76 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 179.44 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 73.5 mtp180 -143.69 141.32 30.47 Favored 'General case' 0 N--CA 1.48 1.055 0 N-CA-C 109.092 -0.707 . . . . 0.0 109.092 -179.972 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 76.7 m80 -149.83 119.49 7.01 Favored 'General case' 0 N--CA 1.472 0.627 0 N-CA-C 108.93 -0.767 . . . . 0.0 108.93 179.104 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 7' ' ' ASP . . . . . . . . . . . . . 9.6 m-20 -67.77 149.4 49.97 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.196 -179.609 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 8' ' ' SER . . . . . . . . . . . . . 7.0 t -167.15 171.4 10.93 Favored 'General case' 0 N--CA 1.473 0.676 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 178.451 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.11 24.06 2.32 Favored Glycine 0 N--CA 1.487 2.072 0 N-CA-C 112.05 -0.42 . . . . 0.0 112.05 179.38 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 41.4 p90 -56.75 128.15 35.11 Favored 'General case' 0 N--CA 1.472 0.669 0 N-CA-C 112.071 0.397 . . . . 0.0 112.071 -179.834 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 45.7 mt-10 -84.99 155.63 21.49 Favored 'General case' 0 N--CA 1.47 0.557 0 N-CA-C 109.268 -0.642 . . . . 0.0 109.268 178.589 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -154.47 124.35 0.78 Allowed 'Isoleucine or valine' 0 C--O 1.234 0.249 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 178.538 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 34.2 m80 -107.27 161.2 15.0 Favored 'General case' 0 N--CA 1.491 1.585 0 CA-C-N 118.41 0.55 . . . . 0.0 111.155 -178.774 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 58.2 t60 -164.72 98.87 0.78 Allowed 'General case' 0 N--CA 1.485 1.301 0 CA-C-O 119.64 -0.219 . . . . 0.0 111.001 179.636 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 15' ' ' GLN . . . . . 0.456 HE22 HG13 ' B' ' 36' ' ' VAL . 36.2 mt-30 -125.19 -175.48 3.32 Favored 'General case' 0 CA--C 1.492 -1.275 0 N-CA-C 107.832 -1.173 . . . . 0.0 107.832 179.995 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -169.62 103.13 0.33 Allowed 'General case' 0 CA--C 1.541 0.6 0 CA-C-N 114.944 -1.025 . . . . 0.0 109.334 179.023 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 9.4 mp -110.67 151.23 27.94 Favored 'General case' 0 N--CA 1.489 1.507 0 N-CA-C 108.695 -0.854 . . . . 0.0 108.695 -179.951 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 61.9 t -143.92 118.77 3.91 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.139 0 CA-C-O 118.748 -0.644 . . . . 0.0 109.561 179.07 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 16.6 m-85 -70.45 157.17 38.31 Favored 'General case' 0 N--CA 1.475 0.798 0 N-CA-C 107.638 -1.245 . . . . 0.0 107.638 177.413 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 15.8 t80 -171.66 -59.06 0.02 OUTLIER 'General case' 0 N--CA 1.479 1.007 0 CA-C-O 122.261 1.029 . . . . 0.0 109.619 179.23 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.21 89.88 0.0 OUTLIER 'General case' 0 C--O 1.231 0.112 0 CA-C-N 114.051 -1.431 . . . . 0.0 112.764 -178.108 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 43.8 mt-10 -61.53 158.38 15.13 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 115.276 -0.875 . . . . 0.0 110.828 179.095 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 12.2 m-20 -140.25 135.6 32.48 Favored 'General case' 0 N--CA 1.483 1.196 0 C-N-CA 122.793 0.437 . . . . 0.0 110.416 179.955 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 18.1 t -84.97 -116.1 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.906 0 N-CA-C 108.408 -0.96 . . . . 0.0 108.408 179.499 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -108.45 53.65 0.59 Allowed Glycine 0 N--CA 1.476 1.366 0 N-CA-C 111.083 -0.807 . . . . 0.0 111.083 -179.909 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 86.0 p -77.35 126.58 31.15 Favored 'General case' 0 C--N 1.329 -0.294 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 178.409 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 27' ' ' ASN . . . . . 0.443 HD21 ' HB3' ' E' ' 27' ' ' ASN . 6.6 t-20 -66.74 100.98 0.75 Allowed 'General case' 0 N--CA 1.471 0.608 0 N-CA-C 108.593 -0.892 . . . . 0.0 108.593 178.672 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 67.1 mttm -95.3 128.91 42.52 Favored 'General case' 0 N--CA 1.481 1.121 0 N-CA-C 109.972 -0.381 . . . . 0.0 109.972 -179.226 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.77 -131.63 0.01 OUTLIER Glycine 0 CA--C 1.535 1.33 0 N-CA-C 110.746 -0.942 . . . . 0.0 110.746 178.904 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -131.18 127.12 37.31 Favored 'General case' 0 N--CA 1.485 1.304 0 C-N-CA 122.704 0.402 . . . . 0.0 110.081 179.431 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 32.8 mt -91.75 158.79 2.86 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.538 0 N-CA-C 106.602 -1.629 . . . . 0.0 106.602 178.516 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 43.1 mt -137.81 92.89 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.502 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 -178.816 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 53.85 106.17 0.01 OUTLIER Glycine 0 CA--C 1.53 0.993 0 CA-C-N 116.021 -0.536 . . . . 0.0 114.212 177.237 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 97.7 mt -72.12 153.4 41.69 Favored 'General case' 0 CA--C 1.539 0.53 0 N-CA-C 107.364 -1.346 . . . . 0.0 107.364 176.651 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 27.1 ttt -146.82 138.05 24.16 Favored 'General case' 0 N--CA 1.478 0.954 0 N-CA-C 108.701 -0.851 . . . . 0.0 108.701 179.21 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 36' ' ' VAL . . . . . 0.456 HG13 HE22 ' B' ' 15' ' ' GLN . 62.3 t -159.54 153.47 5.14 Favored 'Isoleucine or valine' 0 C--N 1.344 0.356 0 N-CA-C 106.52 -1.659 . . . . 0.0 106.52 -179.273 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.03 73.23 0.45 Allowed Glycine 0 C--N 1.313 -0.696 0 N-CA-C 111.686 -0.566 . . . . 0.0 111.686 178.005 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 174.98 -161.5 30.92 Favored Glycine 0 C--N 1.334 0.43 0 N-CA-C 111.056 -0.818 . . . . 0.0 111.056 -179.865 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 24.1 m -124.4 139.6 50.21 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.929 0 C-N-CA 122.751 0.421 . . . . 0.0 110.072 179.695 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 26.5 t . . . . . 0 C--O 1.219 -0.52 0 CA-C-O 117.651 -1.166 . . . . 0.0 111.054 179.381 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' C' C ' 1' ' ' ASP . . . . . . . . . . . . . 9.0 m-20 . . . . . 0 N--CA 1.489 1.5 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' C' C ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.28 132.42 49.01 Favored 'General case' 0 CA--C 1.538 0.519 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.181 -179.791 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 3' ' ' GLU . . . . . . . . . . . . . 39.0 tt0 -169.42 108.42 0.42 Allowed 'General case' 0 N--CA 1.47 0.55 0 N-CA-C 109.657 -0.497 . . . . 0.0 109.657 -179.2 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 77.1 m-85 -83.77 140.88 31.8 Favored 'General case' 0 N--CA 1.474 0.75 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 179.495 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 73.7 mtp180 -143.72 141.24 30.4 Favored 'General case' 0 N--CA 1.482 1.141 0 N-CA-C 109.005 -0.739 . . . . 0.0 109.005 -179.858 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 76.8 m80 -149.9 119.39 6.92 Favored 'General case' 0 N--CA 1.471 0.594 0 N-CA-C 108.798 -0.816 . . . . 0.0 108.798 179.159 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 7' ' ' ASP . . . . . . . . . . . . . 9.0 m-20 -67.71 149.29 50.17 Favored 'General case' 0 N--CA 1.463 0.218 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.244 -179.562 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 8' ' ' SER . . . . . . . . . . . . . 6.7 t -167.12 171.15 11.21 Favored 'General case' 0 N--CA 1.472 0.652 0 N-CA-C 109.502 -0.555 . . . . 0.0 109.502 178.424 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.49 23.92 2.26 Favored Glycine 0 N--CA 1.487 2.034 0 N-CA-C 111.968 -0.453 . . . . 0.0 111.968 179.38 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 41.5 p90 -56.61 128.16 34.93 Favored 'General case' 0 N--CA 1.471 0.614 0 N-CA-C 112.07 0.396 . . . . 0.0 112.07 -179.85 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 45.9 mt-10 -85.02 155.97 21.32 Favored 'General case' 0 N--CA 1.47 0.535 0 N-CA-C 109.24 -0.652 . . . . 0.0 109.24 178.592 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -154.76 124.54 0.76 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 N-CA-C 108.168 -1.049 . . . . 0.0 108.168 178.525 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 33.9 m80 -107.39 161.23 15.0 Favored 'General case' 0 N--CA 1.49 1.573 0 CA-C-N 118.397 0.544 . . . . 0.0 111.181 -178.717 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 57.3 t60 -164.83 99.22 0.77 Allowed 'General case' 0 N--CA 1.485 1.286 0 CA-C-N 116.77 -0.196 . . . . 0.0 111.094 179.651 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 15' ' ' GLN . . . . . 0.461 HE22 HG13 ' C' ' 36' ' ' VAL . 36.2 mt-30 -125.79 -175.34 3.32 Favored 'General case' 0 CA--C 1.489 -1.373 0 N-CA-C 107.904 -1.147 . . . . 0.0 107.904 -179.957 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -169.64 103.19 0.33 Allowed 'General case' 0 CA--C 1.541 0.624 0 CA-C-N 114.888 -1.051 . . . . 0.0 109.331 179.062 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 9.4 mp -110.67 150.92 28.32 Favored 'General case' 0 N--CA 1.488 1.441 0 N-CA-C 108.712 -0.848 . . . . 0.0 108.712 179.968 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 61.1 t -143.66 118.97 4.29 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.175 0 CA-C-O 118.765 -0.636 . . . . 0.0 109.61 179.029 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 16.6 m-85 -70.49 157.28 38.14 Favored 'General case' 0 N--CA 1.475 0.802 0 N-CA-C 107.664 -1.236 . . . . 0.0 107.664 177.436 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 15.4 t80 -171.59 -59.31 0.02 OUTLIER 'General case' 0 N--CA 1.478 0.953 0 CA-C-O 122.259 1.028 . . . . 0.0 109.642 179.195 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.12 89.96 0.0 OUTLIER 'General case' 0 C--O 1.231 0.11 0 CA-C-N 114.041 -1.436 . . . . 0.0 112.753 -178.076 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 43.9 mt-10 -61.6 158.23 15.68 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.219 -0.9 . . . . 0.0 110.833 179.047 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 12.3 m-20 -139.92 135.9 33.32 Favored 'General case' 0 N--CA 1.483 1.199 0 C-N-CA 122.861 0.464 . . . . 0.0 110.343 -179.977 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 18.2 t -85.27 -116.01 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.902 0 N-CA-C 108.414 -0.958 . . . . 0.0 108.414 179.444 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -108.58 53.42 0.6 Allowed Glycine 0 N--CA 1.475 1.257 0 N-CA-C 111.107 -0.797 . . . . 0.0 111.107 -179.918 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 85.9 p -77.3 126.73 31.4 Favored 'General case' 0 C--N 1.329 -0.32 0 N-CA-C 109.122 -0.695 . . . . 0.0 109.122 178.508 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 27' ' ' ASN . . . . . 0.463 HD21 ' HB3' ' F' ' 27' ' ' ASN . 6.4 t-20 -66.79 101.11 0.77 Allowed 'General case' 0 N--CA 1.471 0.582 0 N-CA-C 108.633 -0.877 . . . . 0.0 108.633 178.625 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 67.1 mttm -95.34 128.99 42.63 Favored 'General case' 0 N--CA 1.483 1.2 0 N-CA-C 109.886 -0.413 . . . . 0.0 109.886 -179.117 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.84 -131.85 0.01 OUTLIER Glycine 0 CA--C 1.535 1.293 0 N-CA-C 110.858 -0.897 . . . . 0.0 110.858 178.844 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.96 126.66 36.63 Favored 'General case' 0 N--CA 1.486 1.356 0 C-N-CA 122.822 0.449 . . . . 0.0 110.003 179.456 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 32.5 mt -91.33 158.81 2.86 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.525 0 N-CA-C 106.684 -1.599 . . . . 0.0 106.684 178.334 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 42.5 mt -137.99 92.89 0.86 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.505 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 -178.799 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 53.93 106.09 0.01 OUTLIER Glycine 0 CA--C 1.529 0.966 0 CA-C-N 115.921 -0.581 . . . . 0.0 114.257 177.229 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 97.6 mt -72.05 153.3 41.82 Favored 'General case' 0 CA--C 1.537 0.461 0 N-CA-C 107.328 -1.36 . . . . 0.0 107.328 176.655 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 27.3 ttt -146.63 138.09 24.42 Favored 'General case' 0 N--CA 1.477 0.891 0 N-CA-C 108.74 -0.837 . . . . 0.0 108.74 179.214 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 36' ' ' VAL . . . . . 0.461 HG13 HE22 ' C' ' 15' ' ' GLN . 61.1 t -159.57 153.56 5.07 Favored 'Isoleucine or valine' 0 C--N 1.345 0.372 0 N-CA-C 106.566 -1.642 . . . . 0.0 106.566 -179.251 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.89 73.15 0.46 Allowed Glycine 0 C--N 1.314 -0.671 0 N-CA-C 111.626 -0.59 . . . . 0.0 111.626 177.951 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 175.03 -161.75 31.24 Favored Glycine 0 C--N 1.335 0.479 0 N-CA-C 111.054 -0.818 . . . . 0.0 111.054 -179.865 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 23.5 m -124.2 139.67 49.88 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.923 0 C-N-CA 122.785 0.434 . . . . 0.0 110.054 179.727 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 27.7 t . . . . . 0 C--O 1.221 -0.424 0 CA-C-O 117.655 -1.164 . . . . 0.0 110.98 179.336 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' D' D ' 1' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 . . . . . 0 N--CA 1.49 1.565 0 N-CA-C 109.196 -0.668 . . . . 0.0 109.196 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' D' D ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.29 130.96 45.9 Favored 'General case' 0 CA--C 1.535 0.4 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.369 179.931 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' D' D ' 3' ' ' GLU . . . . . . . . . . . . . 38.7 tt0 -169.3 110.97 0.48 Allowed 'General case' 0 N--CA 1.47 0.534 0 N-CA-C 109.196 -0.668 . . . . 0.0 109.196 179.524 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 85.9 m-85 -87.31 148.61 24.99 Favored 'General case' 0 C--N 1.366 1.285 0 C-N-CA 118.584 -1.246 . . . . 0.0 108.113 179.765 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' D' D ' 5' ' ' ARG . . . . . . . . . . . . . 73.9 mtp180 -147.52 141.05 25.45 Favored 'General case' 0 N--CA 1.473 0.7 0 N-CA-C 108.967 -0.753 . . . . 0.0 108.967 179.637 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 77.0 m80 -149.2 123.55 9.62 Favored 'General case' 0 CA--C 1.539 0.519 0 N-CA-C 107.926 -1.138 . . . . 0.0 107.926 175.967 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' D' D ' 7' ' ' ASP . . . . . . . . . . . . . 6.3 m-20 -63.42 133.41 53.94 Favored 'General case' 0 C--N 1.32 -0.688 0 C-N-CA 126.937 2.095 . . . . 0.0 114.798 176.152 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' D' D ' 8' ' ' SER . . . . . . . . . . . . . 5.9 t -154.04 173.52 15.91 Favored 'General case' 0 N--CA 1.477 0.925 0 CA-C-N 118.548 0.613 . . . . 0.0 110.443 176.799 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 124.23 20.38 2.47 Favored Glycine 0 N--CA 1.484 1.864 0 N-CA-C 111.99 -0.444 . . . . 0.0 111.99 176.203 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 37.2 p90 -55.67 130.32 42.67 Favored 'General case' 0 CA--C 1.545 0.753 0 CA-C-O 121.103 0.478 . . . . 0.0 111.914 -177.388 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 46.0 mt-10 -84.87 153.77 22.69 Favored 'General case' 0 N--CA 1.472 0.64 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 177.886 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.0 p -150.91 129.01 2.57 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.594 0 N-CA-C 106.937 -1.505 . . . . 0.0 106.937 172.73 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 24.6 m80 -100.86 161.98 13.22 Favored 'General case' 0 N--CA 1.481 1.116 0 C-N-CA 123.911 0.884 . . . . 0.0 113.168 176.722 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 61.0 t60 -165.0 105.27 0.79 Allowed 'General case' 0 N--CA 1.486 1.354 0 N-CA-C 109.694 -0.484 . . . . 0.0 109.694 172.242 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' D' D ' 15' ' ' GLN . . . . . 0.476 HE22 HG13 ' D' ' 36' ' ' VAL . 36.2 mt-30 -128.59 -176.33 3.8 Favored 'General case' 0 CA--C 1.485 -1.534 0 N-CA-C 107.255 -1.387 . . . . 0.0 107.255 178.892 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 88.8 tttt -166.87 109.51 0.7 Allowed 'General case' 0 C--O 1.238 0.487 0 N-CA-C 107.926 -1.139 . . . . 0.0 107.926 176.779 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 10.5 mp -115.69 153.16 31.85 Favored 'General case' 0 N--CA 1.489 1.502 0 N-CA-C 107.198 -1.408 . . . . 0.0 107.198 178.205 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 52.5 t -141.95 124.03 13.61 Favored 'Isoleucine or valine' 0 C--N 1.362 1.152 0 N-CA-C 108.668 -0.864 . . . . 0.0 108.668 174.283 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 16.0 m-85 -62.62 150.81 39.77 Favored 'General case' 0 C--N 1.348 0.513 0 C-N-CA 124.308 1.043 . . . . 0.0 110.719 169.695 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 11.3 t80 -170.51 -67.22 0.02 OUTLIER 'General case' 0 N--CA 1.475 0.788 0 N-CA-C 107.983 -1.117 . . . . 0.0 107.983 178.55 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -38.61 94.99 0.01 OUTLIER 'General case' 0 N--CA 1.451 -0.403 0 CA-C-N 113.855 -1.521 . . . . 0.0 111.586 -175.866 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 45.8 mt-10 -64.47 159.09 22.21 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 114.293 -1.321 . . . . 0.0 110.504 178.491 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 12.2 m-20 -139.87 139.47 36.27 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-O 121.253 0.549 . . . . 0.0 109.637 178.609 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' D' D ' 24' ' ' VAL . . . . . . . . . . . . . 19.4 t -88.17 -119.86 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.483 1.217 0 N-CA-C 107.597 -1.26 . . . . 0.0 107.597 179.58 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . -111.47 61.8 0.3 Allowed Glycine 0 C--N 1.368 2.359 0 C-N-CA 118.222 -1.942 . . . . 0.0 109.206 178.763 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 92.8 p -68.04 121.59 16.44 Favored 'General case' 0 C--O 1.24 0.595 0 CA-C-O 116.453 -1.737 . . . . 0.0 112.517 168.985 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' D' D ' 27' ' ' ASN . . . . . 0.467 HD21 ' HB3' ' G' ' 27' ' ' ASN . 6.5 t-20 -62.52 101.79 0.27 Allowed 'General case' 0 N--CA 1.474 0.765 0 CA-C-N 121.603 2.001 . . . . 0.0 109.453 173.65 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 66.8 mttm -96.84 128.28 43.64 Favored 'General case' 0 N--CA 1.487 1.387 0 CA-C-N 118.842 0.746 . . . . 0.0 109.35 178.996 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -55.21 -134.81 0.0 OUTLIER Glycine 0 CA--C 1.532 1.135 0 C-N-CA 123.793 0.711 . . . . 0.0 112.343 174.925 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -129.42 130.96 46.62 Favored 'General case' 0 C--N 1.371 1.507 0 CA-C-N 115.022 -0.589 . . . . 0.0 110.121 176.231 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 38.8 mt -91.64 161.75 2.52 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.338 0 N-CA-C 106.148 -1.797 . . . . 0.0 106.148 177.499 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . 0.28 43.1 mt -141.01 105.06 1.57 Allowed 'Isoleucine or valine' 0 C--N 1.363 1.191 0 N-CA-C 106.231 -1.766 . . . . 0.0 106.231 172.511 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.6 98.11 0.01 OUTLIER Glycine 0 CA--C 1.533 1.21 0 CA-C-O 116.312 -2.382 . . . . 0.0 112.198 169.074 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 97.0 mt -70.0 157.61 37.17 Favored 'General case' 0 CA--C 1.539 0.55 0 CA-C-N 122.355 3.078 . . . . 0.0 107.217 176.055 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 26.1 ttt -147.18 148.92 32.02 Favored 'General case' 0 N--CA 1.482 1.161 0 N-CA-C 106.373 -1.714 . . . . 0.0 106.373 174.269 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' D' D ' 36' ' ' VAL . . . . . 0.476 HG13 HE22 ' D' ' 15' ' ' GLN . 88.5 t -165.22 159.14 1.18 Allowed 'Isoleucine or valine' 0 C--O 1.248 1.004 0 N-CA-C 105.302 -2.11 . . . . 0.0 105.302 177.15 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 60.54 64.84 3.77 Favored Glycine 0 N--CA 1.442 -0.917 0 C-N-CA 117.24 -2.41 . . . . 0.0 113.756 174.581 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' D' D ' 38' ' ' GLY . . . . . 0.407 ' HA3' ' O ' ' G' ' 38' ' ' GLY . . . 169.8 -160.7 33.85 Favored Glycine 0 N--CA 1.47 0.956 0 CA-C-O 117.808 -1.551 . . . . 0.0 112.304 -178.987 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 23.2 m -120.37 139.31 48.06 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.256 0 CA-C-N 118.829 1.315 . . . . 0.0 110.348 -177.003 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 25.4 t . . . . . 0 C--O 1.203 -1.35 0 CA-C-N 118.211 0.46 . . . . 0.0 110.102 173.766 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' E' E ' 1' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 . . . . . 0 N--CA 1.488 1.454 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' E' E ' 2' ' ' ALA . . . . . . . . . . . . . . . -63.86 131.1 46.72 Favored 'General case' 0 N--CA 1.468 0.468 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.375 179.862 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' E' E ' 3' ' ' GLU . . . . . . . . . . . . . 38.6 tt0 -169.04 108.43 0.45 Allowed 'General case' 0 N--CA 1.47 0.54 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 -179.811 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 77.8 m-85 -84.47 140.91 31.16 Favored 'General case' 0 N--CA 1.475 0.812 0 N-CA-C 109.904 -0.406 . . . . 0.0 109.904 179.451 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' E' E ' 5' ' ' ARG . . . . . . . . . . . . . 74.1 mtp180 -143.55 141.72 30.81 Favored 'General case' 0 N--CA 1.476 0.837 0 N-CA-C 109.388 -0.597 . . . . 0.0 109.388 179.875 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 76.7 m80 -150.31 118.57 6.38 Favored 'General case' 0 N--CA 1.471 0.62 0 N-CA-C 108.994 -0.743 . . . . 0.0 108.994 179.215 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' E' E ' 7' ' ' ASP . . . . . . . . . . . . . 8.6 m-20 -66.82 149.48 50.51 Favored 'General case' 0 N--CA 1.464 0.24 0 O-C-N 123.388 0.43 . . . . 0.0 111.608 -179.552 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' E' E ' 8' ' ' SER . . . . . . . . . . . . . 6.0 t -167.63 171.72 9.98 Favored 'General case' 0 N--CA 1.477 0.878 0 CA-C-N 115.938 -0.574 . . . . 0.0 109.606 178.077 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 123.22 23.91 2.09 Favored Glycine 0 N--CA 1.482 1.754 0 N-CA-C 111.843 -0.503 . . . . 0.0 111.843 179.078 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 37.4 p90 -56.29 127.33 30.36 Favored 'General case' 0 N--CA 1.472 0.674 0 N-CA-C 112.621 0.6 . . . . 0.0 112.621 -179.283 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 46.0 mt-10 -83.36 156.77 22.83 Favored 'General case' 0 N--CA 1.476 0.856 0 N-CA-C 109.489 -0.56 . . . . 0.0 109.489 177.973 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -156.54 122.89 0.54 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.646 0 N-CA-C 108.324 -0.991 . . . . 0.0 108.324 178.257 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 36.5 m80 -106.88 160.24 15.66 Favored 'General case' 0 N--CA 1.482 1.135 0 C-N-CA 122.855 0.462 . . . . 0.0 111.238 -177.944 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 58.1 t60 -164.61 99.18 0.79 Allowed 'General case' 0 N--CA 1.487 1.38 0 CA-C-N 116.859 -0.155 . . . . 0.0 111.013 -179.842 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' E' E ' 15' ' ' GLN . . . . . 0.491 HE22 HG13 ' E' ' 36' ' ' VAL . 36.3 mt-30 -125.42 -175.06 3.22 Favored 'General case' 0 CA--C 1.492 -1.263 0 N-CA-C 107.835 -1.172 . . . . 0.0 107.835 -179.98 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -169.54 103.85 0.34 Allowed 'General case' 0 CA--C 1.54 0.591 0 CA-C-N 114.9 -1.045 . . . . 0.0 109.109 179.015 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 9.6 mp -111.03 150.16 29.7 Favored 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 -179.639 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 46.1 t -144.04 118.17 3.52 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.22 0 CA-C-O 118.928 -0.558 . . . . 0.0 109.903 178.646 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 19.7 m-85 -69.32 155.27 40.7 Favored 'General case' 0 C--N 1.357 0.908 0 N-CA-C 107.569 -1.271 . . . . 0.0 107.569 176.798 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 14.0 t80 -173.41 -56.94 0.02 OUTLIER 'General case' 0 N--CA 1.48 1.072 0 CA-C-O 121.624 0.726 . . . . 0.0 110.136 179.163 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -42.74 88.48 0.0 OUTLIER 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 114.425 -1.261 . . . . 0.0 112.76 -179.051 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 44.4 mt-10 -60.11 158.37 11.36 Favored 'General case' 0 N--CA 1.471 0.619 0 CA-C-N 115.039 -0.982 . . . . 0.0 110.944 179.535 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 11.7 m-20 -140.34 135.02 31.75 Favored 'General case' 0 N--CA 1.483 1.183 0 C-N-CA 122.653 0.381 . . . . 0.0 110.687 -179.829 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 21.4 t -84.55 -115.51 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.939 0 N-CA-C 108.61 -0.885 . . . . 0.0 108.61 179.416 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . -108.65 53.65 0.58 Allowed Glycine 0 C--N 1.347 1.139 0 N-CA-C 111.317 -0.713 . . . . 0.0 111.317 -179.91 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 86.1 p -77.15 126.37 30.84 Favored 'General case' 0 N--CA 1.471 0.577 0 N-CA-C 109.336 -0.616 . . . . 0.0 109.336 178.259 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' E' E ' 27' ' ' ASN . . . . . 0.458 HD21 ' HB3' ' H' ' 27' ' ' ASN . 7.1 t-20 -66.22 100.64 0.63 Allowed 'General case' 0 N--CA 1.471 0.612 0 N-CA-C 108.079 -1.082 . . . . 0.0 108.079 178.442 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 66.5 mttm -95.39 127.67 41.62 Favored 'General case' 0 N--CA 1.483 1.182 0 N-CA-C 109.305 -0.628 . . . . 0.0 109.305 -179.15 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.36 -128.93 0.01 OUTLIER Glycine 0 CA--C 1.537 1.462 0 N-CA-C 111.013 -0.835 . . . . 0.0 111.013 179.163 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -131.67 127.1 36.24 Favored 'General case' 0 N--CA 1.484 1.236 0 CA-C-N 117.307 0.554 . . . . 0.0 110.939 -179.62 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 31.2 mt -91.09 160.4 2.71 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.238 0 N-CA-C 106.338 -1.727 . . . . 0.0 106.338 178.306 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 41.6 mt -139.29 93.69 0.78 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.766 0 N-CA-C 109.653 -0.499 . . . . 0.0 109.653 179.879 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 53.54 105.96 0.01 OUTLIER Glycine 0 CA--C 1.531 1.053 0 CA-C-N 116.11 -0.495 . . . . 0.0 114.157 177.603 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 97.7 mt -72.03 153.72 41.58 Favored 'General case' 0 CA--C 1.542 0.636 0 N-CA-C 107.206 -1.405 . . . . 0.0 107.206 176.523 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 27.6 ttt -146.41 140.23 26.16 Favored 'General case' 0 N--CA 1.485 1.285 0 N-CA-C 108.005 -1.109 . . . . 0.0 108.005 178.841 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' E' E ' 36' ' ' VAL . . . . . 0.491 HG13 HE22 ' E' ' 15' ' ' GLN . 80.2 t -161.18 152.86 4.31 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.389 0 N-CA-C 106.358 -1.719 . . . . 0.0 106.358 -179.208 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.56 73.81 0.39 Allowed Glycine 0 C--N 1.316 -0.54 0 N-CA-C 111.633 -0.587 . . . . 0.0 111.633 178.199 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 175.91 -159.34 26.79 Favored Glycine 0 C--O 1.213 -1.166 0 N-CA-C 111.313 -0.715 . . . . 0.0 111.313 -179.708 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 23.7 m -127.16 138.81 53.71 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.83 0 N-CA-C 109.332 -0.618 . . . . 0.0 109.332 179.776 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 27.6 t . . . . . 0 CA--C 1.537 0.453 0 CA-C-O 117.986 -1.007 . . . . 0.0 111.106 179.739 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' F' F ' 1' ' ' ASP . . . . . . . . . . . . . 9.3 m-20 . . . . . 0 N--CA 1.49 1.561 0 N-CA-C 109.106 -0.701 . . . . 0.0 109.106 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' F' F ' 2' ' ' ALA . . . . . . . . . . . . . . . -63.79 131.05 46.62 Favored 'General case' 0 N--CA 1.468 0.432 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.47 179.85 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' F' F ' 3' ' ' GLU . . . . . . . . . . . . . 38.7 tt0 -168.99 108.54 0.46 Allowed 'General case' 0 N--CA 1.469 0.513 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 -179.861 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 77.7 m-85 -84.53 140.85 31.15 Favored 'General case' 0 N--CA 1.476 0.831 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 179.353 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' F' F ' 5' ' ' ARG . . . . . . . . . . . . . 74.2 mtp180 -143.54 141.39 30.68 Favored 'General case' 0 N--CA 1.479 1.023 0 N-CA-C 109.07 -0.715 . . . . 0.0 109.07 179.933 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 76.8 m80 -150.08 118.48 6.46 Favored 'General case' 0 N--CA 1.472 0.658 0 N-CA-C 108.957 -0.757 . . . . 0.0 108.957 179.139 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' F' F ' 7' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -66.97 149.79 50.14 Favored 'General case' 0 N--CA 1.463 0.21 0 O-C-N 123.434 0.459 . . . . 0.0 111.632 -179.366 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' F' F ' 8' ' ' SER . . . . . . . . . . . . . 6.1 t -167.73 172.27 9.37 Favored 'General case' 0 N--CA 1.476 0.869 0 CA-C-N 115.885 -0.598 . . . . 0.0 109.564 178.068 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.76 23.64 2.24 Favored Glycine 0 N--CA 1.483 1.789 0 N-CA-C 111.903 -0.479 . . . . 0.0 111.903 179.003 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 37.6 p90 -56.1 127.47 30.74 Favored 'General case' 0 N--CA 1.473 0.679 0 N-CA-C 112.615 0.598 . . . . 0.0 112.615 -179.296 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 45.9 mt-10 -83.45 156.79 22.72 Favored 'General case' 0 N--CA 1.477 0.875 0 N-CA-C 109.514 -0.55 . . . . 0.0 109.514 177.994 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -156.45 122.75 0.54 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.696 0 N-CA-C 108.297 -1.001 . . . . 0.0 108.297 178.274 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 37.5 m80 -106.65 160.36 15.51 Favored 'General case' 0 N--CA 1.483 1.218 0 C-N-CA 122.8 0.44 . . . . 0.0 111.294 -177.997 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 58.7 t60 -164.86 99.65 0.77 Allowed 'General case' 0 N--CA 1.486 1.374 0 CA-C-N 116.865 -0.152 . . . . 0.0 111.131 -179.775 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' F' F ' 15' ' ' GLN . . . . . 0.478 HE22 HG13 ' F' ' 36' ' ' VAL . 36.2 mt-30 -126.15 -174.68 3.16 Favored 'General case' 0 CA--C 1.488 -1.428 0 N-CA-C 108.02 -1.104 . . . . 0.0 108.02 -179.893 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -169.86 103.93 0.32 Allowed 'General case' 0 CA--C 1.541 0.61 0 CA-C-N 114.677 -1.147 . . . . 0.0 109.218 178.969 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 9.6 mp -110.93 149.92 29.96 Favored 'General case' 0 N--CA 1.489 1.518 0 N-CA-C 108.933 -0.766 . . . . 0.0 108.933 -179.704 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 46.3 t -143.85 118.32 3.77 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.223 0 CA-C-O 118.975 -0.536 . . . . 0.0 109.827 178.653 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 19.5 m-85 -69.4 155.15 40.92 Favored 'General case' 0 C--N 1.358 0.96 0 N-CA-C 107.506 -1.294 . . . . 0.0 107.506 176.721 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 14.9 t80 -173.13 -57.1 0.02 OUTLIER 'General case' 0 N--CA 1.483 1.198 0 CA-C-O 121.564 0.697 . . . . 0.0 109.613 179.245 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -42.52 88.47 0.0 OUTLIER 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 114.716 -1.129 . . . . 0.0 112.856 -179.015 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 44.1 mt-10 -60.28 158.2 12.1 Favored 'General case' 0 N--CA 1.472 0.643 0 CA-C-N 115.085 -0.961 . . . . 0.0 110.999 179.437 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 12.1 m-20 -140.2 134.97 31.9 Favored 'General case' 0 N--CA 1.482 1.132 0 C-N-CA 122.752 0.421 . . . . 0.0 110.784 -179.822 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' F' F ' 24' ' ' VAL . . . . . . . . . . . . . 21.3 t -84.51 -115.73 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.986 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 179.327 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -108.36 53.31 0.6 Allowed Glycine 0 N--CA 1.477 1.373 0 N-CA-C 111.154 -0.778 . . . . 0.0 111.154 -179.872 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 87.3 p -76.75 126.36 30.85 Favored 'General case' 0 N--CA 1.47 0.535 0 N-CA-C 109.313 -0.625 . . . . 0.0 109.313 178.141 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' F' F ' 27' ' ' ASN . . . . . 0.466 HD21 ' HB3' ' I' ' 27' ' ' ASN . 7.0 t-20 -66.48 100.7 0.68 Allowed 'General case' 0 N--CA 1.471 0.609 0 N-CA-C 108.195 -1.039 . . . . 0.0 108.195 178.412 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 66.6 mttm -95.39 127.65 41.61 Favored 'General case' 0 N--CA 1.483 1.221 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 -179.082 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.53 -129.15 0.01 OUTLIER Glycine 0 CA--C 1.539 1.576 0 N-CA-C 111.139 -0.784 . . . . 0.0 111.139 179.161 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -131.17 126.67 36.23 Favored 'General case' 0 N--CA 1.488 1.451 0 CA-C-N 117.308 0.554 . . . . 0.0 111.058 -179.668 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 32.2 mt -90.95 160.14 2.74 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.237 0 N-CA-C 106.236 -1.764 . . . . 0.0 106.236 178.265 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 41.0 mt -139.09 93.65 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.763 0 N-CA-C 109.671 -0.492 . . . . 0.0 109.671 179.864 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 53.61 106.0 0.01 OUTLIER Glycine 0 CA--C 1.532 1.114 0 CA-C-N 116.099 -0.5 . . . . 0.0 114.121 177.607 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 97.8 mt -72.0 153.94 41.47 Favored 'General case' 0 CA--C 1.54 0.561 0 N-CA-C 107.295 -1.372 . . . . 0.0 107.295 176.589 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 27.5 ttt -146.75 140.21 25.7 Favored 'General case' 0 N--CA 1.481 1.087 0 N-CA-C 108.408 -0.96 . . . . 0.0 108.408 178.819 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' F' F ' 36' ' ' VAL . . . . . 0.478 HG13 HE22 ' F' ' 15' ' ' GLN . 75.8 t -161.13 153.02 4.29 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.472 0 N-CA-C 106.452 -1.685 . . . . 0.0 106.452 -179.073 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.67 73.83 0.39 Allowed Glycine 0 C--N 1.316 -0.573 0 N-CA-C 111.543 -0.623 . . . . 0.0 111.543 178.049 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 175.5 -159.99 28.2 Favored Glycine 0 C--O 1.213 -1.195 0 N-CA-C 111.202 -0.759 . . . . 0.0 111.202 -179.723 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 23.3 m -126.36 139.01 52.89 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.824 0 N-CA-C 109.414 -0.588 . . . . 0.0 109.414 179.764 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 28.0 t . . . . . 0 CA--C 1.537 0.48 0 CA-C-O 117.957 -1.021 . . . . 0.0 111.181 179.703 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' G' G ' 1' ' ' ASP . . . . . . . . . . . . . 8.8 m-20 . . . . . 0 N--CA 1.491 1.588 0 N-CA-C 109.514 -0.55 . . . . 0.0 109.514 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' G' G ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.42 129.33 40.17 Favored 'General case' 0 N--CA 1.47 0.531 0 CA-C-N 115.89 -0.596 . . . . 0.0 110.511 179.69 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' G' G ' 3' ' ' GLU . . . . . . . . . . . . . 38.3 tt0 -168.92 108.1 0.46 Allowed 'General case' 0 N--CA 1.471 0.576 0 N-CA-C 110.158 -0.312 . . . . 0.0 110.158 179.631 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 77.4 m-85 -84.72 140.55 31.2 Favored 'General case' 0 N--CA 1.474 0.744 0 N-CA-C 109.583 -0.525 . . . . 0.0 109.583 179.287 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' G' G ' 5' ' ' ARG . . . . . . . . . . . . . 74.1 mtp180 -144.01 140.97 29.88 Favored 'General case' 0 N--CA 1.482 1.162 0 N-CA-C 109.178 -0.675 . . . . 0.0 109.178 -179.671 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 76.6 m80 -149.47 119.84 7.36 Favored 'General case' 0 N--CA 1.472 0.666 0 N-CA-C 109.04 -0.726 . . . . 0.0 109.04 179.016 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 8.7 m-20 -69.05 145.27 53.62 Favored 'General case' 0 CA--C 1.537 0.462 0 O-C-N 123.509 0.505 . . . . 0.0 112.062 -179.167 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' G' G ' 8' ' ' SER . . . . . . . . . . . . . 5.6 t -163.98 173.6 12.41 Favored 'General case' 0 N--CA 1.47 0.534 0 N-CA-C 109.474 -0.565 . . . . 0.0 109.474 178.2 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.47 23.33 2.37 Favored Glycine 0 N--CA 1.48 1.613 0 N-CA-C 111.731 -0.548 . . . . 0.0 111.731 178.942 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 41.7 p90 -56.55 127.68 32.46 Favored 'General case' 0 N--CA 1.475 0.8 0 N-CA-C 112.381 0.511 . . . . 0.0 112.381 -178.862 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 46.1 mt-10 -84.02 155.74 22.59 Favored 'General case' 0 N--CA 1.472 0.638 0 CA-C-O 121.05 0.452 . . . . 0.0 109.935 178.595 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -156.4 123.28 0.57 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.05 0 N-CA-C 108.277 -1.009 . . . . 0.0 108.277 178.545 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 35.3 m80 -106.36 160.21 15.55 Favored 'General case' 0 N--CA 1.481 1.093 0 CA-C-N 115.213 -0.903 . . . . 0.0 110.845 -178.419 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 59.2 t60 -165.64 99.27 0.68 Allowed 'General case' 0 N--CA 1.484 1.238 0 CA-C-N 116.453 -0.339 . . . . 0.0 110.777 179.51 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' G' G ' 15' ' ' GLN . . . . . 0.486 HE22 HG13 ' G' ' 36' ' ' VAL . 36.5 mt-30 -125.18 -175.0 3.19 Favored 'General case' 0 CA--C 1.493 -1.237 0 N-CA-C 108.031 -1.099 . . . . 0.0 108.031 -179.94 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -169.76 103.46 0.32 Allowed 'General case' 0 CA--C 1.541 0.624 0 CA-C-N 114.904 -1.043 . . . . 0.0 109.338 179.013 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 9.6 mp -109.89 149.5 29.79 Favored 'General case' 0 N--CA 1.49 1.533 0 N-CA-C 109.21 -0.663 . . . . 0.0 109.21 -179.793 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 43.9 t -145.24 117.64 2.31 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.841 0 N-CA-C 109.607 -0.516 . . . . 0.0 109.607 178.33 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 28.8 m-85 -68.11 149.45 49.6 Favored 'General case' 0 C--N 1.37 1.495 0 O-C-N 124.873 1.358 . . . . 0.0 107.842 176.653 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' G' G ' 20' ' ' PHE . . . . . 0.402 ' O ' ' N ' ' G' ' 22' ' ' GLU . 12.0 t80 -171.46 -56.15 0.02 OUTLIER 'General case' 0 N--CA 1.484 1.274 0 N-CA-C 110.205 -0.294 . . . . 0.0 110.205 179.943 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -42.99 90.01 0.0 OUTLIER 'General case' 0 C--N 1.325 -0.485 0 C-N-CA 123.521 0.729 . . . . 0.0 112.343 179.895 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' G' G ' 22' ' ' GLU . . . . . 0.402 ' N ' ' O ' ' G' ' 20' ' ' PHE . 46.1 mt-10 -61.44 158.65 14.28 Favored 'General case' 0 N--CA 1.468 0.43 0 CA-C-N 114.895 -1.048 . . . . 0.0 110.149 179.087 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 12.0 m-20 -140.11 135.49 32.59 Favored 'General case' 0 N--CA 1.481 1.103 0 C-N-CA 122.702 0.401 . . . . 0.0 110.3 -179.897 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' G' G ' 24' ' ' VAL . . . . . . . . . . . . . 21.4 t -85.63 -115.24 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.96 0 N-CA-C 108.331 -0.989 . . . . 0.0 108.331 179.356 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -108.8 53.87 0.57 Allowed Glycine 0 N--CA 1.477 1.43 0 N-CA-C 111.382 -0.687 . . . . 0.0 111.382 -179.883 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 86.8 p -77.32 126.6 31.19 Favored 'General case' 0 C--N 1.327 -0.413 0 N-CA-C 109.146 -0.686 . . . . 0.0 109.146 178.08 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' G' G ' 27' ' ' ASN . . . . . 0.467 ' HB3' HD21 ' D' ' 27' ' ' ASN . 6.4 t-20 -66.38 100.31 0.63 Allowed 'General case' 0 N--CA 1.469 0.504 0 N-CA-C 108.531 -0.915 . . . . 0.0 108.531 178.542 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 67.1 mttm -94.65 127.56 40.7 Favored 'General case' 0 N--CA 1.484 1.259 0 N-CA-C 109.646 -0.501 . . . . 0.0 109.646 -179.452 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -62.95 -127.11 0.01 OUTLIER Glycine 0 CA--C 1.529 0.962 0 N-CA-C 111.166 -0.774 . . . . 0.0 111.166 179.227 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -132.81 125.73 30.71 Favored 'General case' 0 N--CA 1.47 0.532 0 C-N-CA 122.874 0.47 . . . . 0.0 110.563 -179.141 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 40.9 mt -90.23 162.15 2.52 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.667 0 N-CA-C 106.477 -1.675 . . . . 0.0 106.477 178.356 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 45.0 mt -140.11 95.01 0.78 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.312 0 CA-C-N 119.756 1.162 . . . . 0.0 109.834 178.212 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 53.98 105.26 0.01 OUTLIER Glycine 0 CA--C 1.532 1.115 0 N-CA-C 114.07 0.388 . . . . 0.0 114.07 177.53 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 98.8 mt -71.93 152.85 42.23 Favored 'General case' 0 CA--C 1.539 0.536 0 N-CA-C 107.366 -1.346 . . . . 0.0 107.366 176.729 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 27.5 ttt -146.27 141.13 27.03 Favored 'General case' 0 N--CA 1.477 0.913 0 N-CA-C 107.996 -1.113 . . . . 0.0 107.996 179.084 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' G' G ' 36' ' ' VAL . . . . . 0.486 HG13 HE22 ' G' ' 15' ' ' GLN . 93.0 t -161.45 153.09 4.06 Favored 'Isoleucine or valine' 0 C--O 1.233 0.206 0 N-CA-C 106.553 -1.647 . . . . 0.0 106.553 -179.423 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.64 73.84 0.38 Allowed Glycine 0 C--N 1.313 -0.696 0 C-N-CA 121.035 -0.602 . . . . 0.0 111.951 177.701 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' G' G ' 38' ' ' GLY . . . . . 0.407 ' O ' ' HA3' ' D' ' 38' ' ' GLY . . . 174.75 -158.82 27.11 Favored Glycine 0 C--O 1.215 -1.067 0 N-CA-C 110.499 -1.04 . . . . 0.0 110.499 179.462 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 27.8 m -126.61 139.07 52.79 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.095 0 CA-C-N 117.249 0.525 . . . . 0.0 109.989 -179.824 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 36.3 t . . . . . 0 N--CA 1.469 0.503 0 CA-C-O 117.8 -1.095 . . . . 0.0 111.327 179.581 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' H' H ' 1' ' ' ASP . . . . . . . . . . . . . 9.5 m-20 . . . . . 0 N--CA 1.49 1.571 0 N-CA-C 109.625 -0.509 . . . . 0.0 109.625 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' H' H ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.2 129.35 40.37 Favored 'General case' 0 N--CA 1.468 0.448 0 CA-C-N 115.947 -0.57 . . . . 0.0 110.491 179.607 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' H' H ' 3' ' ' GLU . . . . . . . . . . . . . 38.8 tt0 -168.98 107.88 0.45 Allowed 'General case' 0 N--CA 1.47 0.546 0 N-CA-C 110.047 -0.353 . . . . 0.0 110.047 179.8 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 77.9 m-85 -84.52 140.86 31.15 Favored 'General case' 0 N--CA 1.474 0.765 0 N-CA-C 109.526 -0.546 . . . . 0.0 109.526 179.313 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' H' H ' 5' ' ' ARG . . . . . . . . . . . . . 74.2 mtp180 -144.22 140.87 29.54 Favored 'General case' 0 N--CA 1.481 1.103 0 N-CA-C 109.162 -0.681 . . . . 0.0 109.162 -179.65 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 76.9 m80 -149.46 119.79 7.34 Favored 'General case' 0 N--CA 1.475 0.79 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 179.07 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 8.8 m-20 -69.05 145.27 53.63 Favored 'General case' 0 N--CA 1.468 0.43 0 CA-C-N 116.203 -0.453 . . . . 0.0 112.092 -179.305 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' H' H ' 8' ' ' SER . . . . . . . . . . . . . 6.3 t -163.97 172.82 13.38 Favored 'General case' 0 N--CA 1.47 0.555 0 N-CA-C 109.458 -0.571 . . . . 0.0 109.458 178.555 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.69 23.5 2.29 Favored Glycine 0 N--CA 1.481 1.67 0 N-CA-C 111.77 -0.532 . . . . 0.0 111.77 179.008 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 40.8 p90 -56.49 127.58 31.9 Favored 'General case' 0 N--CA 1.472 0.674 0 N-CA-C 112.461 0.541 . . . . 0.0 112.461 -178.986 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 46.1 mt-10 -83.94 155.85 22.63 Favored 'General case' 0 N--CA 1.473 0.687 0 CA-C-O 121.086 0.469 . . . . 0.0 109.906 178.706 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -156.63 122.92 0.53 Allowed 'Isoleucine or valine' 0 CA--C 1.554 1.126 0 N-CA-C 108.335 -0.987 . . . . 0.0 108.335 178.649 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 34.1 m80 -106.08 160.45 15.3 Favored 'General case' 0 N--CA 1.48 1.047 0 CA-C-N 115.167 -0.924 . . . . 0.0 110.943 -178.385 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 58.1 t60 -165.86 99.43 0.66 Allowed 'General case' 0 N--CA 1.483 1.204 0 CA-C-N 116.532 -0.303 . . . . 0.0 110.854 179.533 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' H' H ' 15' ' ' GLN . . . . . 0.498 HE22 HG13 ' H' ' 36' ' ' VAL . 35.9 mt-30 -125.34 -175.33 3.29 Favored 'General case' 0 CA--C 1.49 -1.335 0 N-CA-C 107.834 -1.172 . . . . 0.0 107.834 -179.829 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -169.51 103.95 0.35 Allowed 'General case' 0 CA--C 1.541 0.623 0 CA-C-N 114.808 -1.087 . . . . 0.0 109.182 178.987 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 9.7 mp -110.34 149.15 30.64 Favored 'General case' 0 N--CA 1.489 1.502 0 N-CA-C 109.115 -0.698 . . . . 0.0 109.115 -179.746 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 43.7 t -144.99 117.51 2.38 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.818 0 N-CA-C 109.705 -0.48 . . . . 0.0 109.705 178.386 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 29.1 m-85 -68.64 149.74 48.78 Favored 'General case' 0 C--N 1.37 1.489 0 O-C-N 124.83 1.331 . . . . 0.0 107.855 176.741 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 12.5 t80 -172.45 -56.23 0.02 OUTLIER 'General case' 0 N--CA 1.482 1.162 0 N-CA-C 110.209 -0.293 . . . . 0.0 110.209 -179.882 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -42.88 90.2 0.0 OUTLIER 'General case' 0 CA--C 1.536 0.406 0 C-N-CA 123.429 0.692 . . . . 0.0 112.031 -179.971 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 46.0 mt-10 -61.34 158.95 13.34 Favored 'General case' 0 N--CA 1.469 0.522 0 CA-C-N 114.907 -1.042 . . . . 0.0 110.22 179.245 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 12.3 m-20 -140.14 135.74 32.79 Favored 'General case' 0 N--CA 1.482 1.148 0 C-N-CA 122.658 0.383 . . . . 0.0 110.301 -179.949 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' H' H ' 24' ' ' VAL . . . . . . . . . . . . . 21.3 t -85.81 -115.48 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.991 0 N-CA-C 108.467 -0.938 . . . . 0.0 108.467 179.366 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . -108.3 53.3 0.6 Allowed Glycine 0 N--CA 1.479 1.558 0 N-CA-C 111.138 -0.785 . . . . 0.0 111.138 -179.878 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 85.5 p -77.04 126.64 31.31 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 109.11 -0.7 . . . . 0.0 109.11 178.195 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' H' H ' 27' ' ' ASN . . . . . 0.458 ' HB3' HD21 ' E' ' 27' ' ' ASN . 6.5 t-20 -66.7 100.81 0.73 Allowed 'General case' 0 N--CA 1.469 0.516 0 N-CA-C 108.479 -0.934 . . . . 0.0 108.479 178.589 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 67.1 mttm -95.21 127.62 41.4 Favored 'General case' 0 N--CA 1.485 1.299 0 N-CA-C 109.605 -0.517 . . . . 0.0 109.605 -179.408 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.01 -126.85 0.01 OUTLIER Glycine 0 CA--C 1.528 0.877 0 N-CA-C 111.137 -0.785 . . . . 0.0 111.137 179.26 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -133.16 125.82 30.31 Favored 'General case' 0 N--CA 1.47 0.563 0 C-N-CA 122.824 0.45 . . . . 0.0 110.718 -179.126 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 40.1 mt -90.4 161.83 2.56 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.67 0 N-CA-C 106.496 -1.668 . . . . 0.0 106.496 178.369 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 46.0 mt -139.97 94.84 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.324 0 CA-C-N 119.533 1.06 . . . . 0.0 109.789 178.343 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 53.99 105.93 0.01 OUTLIER Glycine 0 CA--C 1.532 1.135 0 CA-C-N 116.291 -0.413 . . . . 0.0 114.042 177.617 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 99.1 mt -72.42 152.64 41.87 Favored 'General case' 0 CA--C 1.54 0.579 0 N-CA-C 107.255 -1.387 . . . . 0.0 107.255 176.706 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 27.6 ttt -145.94 140.82 27.22 Favored 'General case' 0 N--CA 1.478 0.975 0 N-CA-C 107.941 -1.133 . . . . 0.0 107.941 179.062 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' H' H ' 36' ' ' VAL . . . . . 0.498 HG13 HE22 ' H' ' 15' ' ' GLN . 90.1 t -161.24 153.22 4.15 Favored 'Isoleucine or valine' 0 C--O 1.233 0.216 0 N-CA-C 106.488 -1.671 . . . . 0.0 106.488 -179.39 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.42 73.78 0.39 Allowed Glycine 0 C--N 1.314 -0.679 0 C-N-CA 121.255 -0.498 . . . . 0.0 111.949 177.796 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 174.93 -158.63 26.59 Favored Glycine 0 C--O 1.215 -1.057 0 N-CA-C 110.527 -1.029 . . . . 0.0 110.527 179.469 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 27.0 m -126.81 138.97 53.16 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.161 0 CA-C-N 117.084 0.442 . . . . 0.0 109.964 -179.823 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 35.8 t . . . . . 0 N--CA 1.468 0.431 0 CA-C-O 117.801 -1.095 . . . . 0.0 111.436 179.61 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' I' I ' 1' ' ' ASP . . . . . . . . . . . . . 9.4 m-20 . . . . . 0 N--CA 1.492 1.641 0 N-CA-C 109.488 -0.56 . . . . 0.0 109.488 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' I' I ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.69 129.29 39.88 Favored 'General case' 0 N--CA 1.469 0.509 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.448 179.677 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' I' I ' 3' ' ' GLU . . . . . . . . . . . . . 38.4 tt0 -168.92 108.07 0.46 Allowed 'General case' 0 N--CA 1.471 0.612 0 N-CA-C 110.076 -0.342 . . . . 0.0 110.076 179.8 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 77.4 m-85 -84.68 141.01 30.9 Favored 'General case' 0 N--CA 1.475 0.825 0 N-CA-C 109.54 -0.541 . . . . 0.0 109.54 179.277 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' I' I ' 5' ' ' ARG . . . . . . . . . . . . . 74.0 mtp180 -144.39 141.02 29.4 Favored 'General case' 0 N--CA 1.482 1.169 0 N-CA-C 109.079 -0.712 . . . . 0.0 109.079 -179.687 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 76.8 m80 -149.62 119.41 7.06 Favored 'General case' 0 N--CA 1.472 0.636 0 N-CA-C 109.017 -0.734 . . . . 0.0 109.017 179.17 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 8.6 m-20 -68.67 145.42 53.89 Favored 'General case' 0 N--CA 1.467 0.406 0 O-C-N 123.455 0.472 . . . . 0.0 112.024 -179.244 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' I' I ' 8' ' ' SER . . . . . . . . . . . . . 6.6 t -164.17 172.9 13.06 Favored 'General case' 0 N--CA 1.469 0.502 0 N-CA-C 109.529 -0.545 . . . . 0.0 109.529 178.435 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.68 23.48 2.29 Favored Glycine 0 N--CA 1.48 1.626 0 N-CA-C 111.76 -0.536 . . . . 0.0 111.76 179.052 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 40.9 p90 -56.54 127.57 31.92 Favored 'General case' 0 N--CA 1.474 0.744 0 N-CA-C 112.398 0.518 . . . . 0.0 112.398 -178.995 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 46.0 mt-10 -83.92 155.83 22.67 Favored 'General case' 0 N--CA 1.474 0.76 0 CA-C-O 121.096 0.474 . . . . 0.0 109.896 178.632 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -156.54 123.05 0.54 Allowed 'Isoleucine or valine' 0 CA--C 1.553 1.082 0 N-CA-C 108.299 -1.0 . . . . 0.0 108.299 178.586 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 35.0 m80 -106.04 160.08 15.57 Favored 'General case' 0 N--CA 1.481 1.081 0 CA-C-N 115.128 -0.942 . . . . 0.0 110.978 -178.336 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 58.4 t60 -165.65 99.38 0.68 Allowed 'General case' 0 N--CA 1.484 1.239 0 CA-C-N 116.563 -0.289 . . . . 0.0 110.943 179.459 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' I' I ' 15' ' ' GLN . . . . . 0.5 HE22 HG13 ' I' ' 36' ' ' VAL . 35.8 mt-30 -125.38 -175.12 3.23 Favored 'General case' 0 CA--C 1.489 -1.403 0 N-CA-C 107.905 -1.146 . . . . 0.0 107.905 -179.865 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -169.65 104.12 0.34 Allowed 'General case' 0 CA--C 1.541 0.615 0 CA-C-N 114.8 -1.091 . . . . 0.0 109.255 179.047 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 9.7 mp -110.43 149.34 30.42 Favored 'General case' 0 N--CA 1.488 1.465 0 N-CA-C 109.16 -0.682 . . . . 0.0 109.16 -179.763 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 43.7 t -145.2 117.57 2.3 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.863 0 N-CA-C 109.649 -0.5 . . . . 0.0 109.649 178.391 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 28.8 m-85 -68.7 149.79 48.66 Favored 'General case' 0 C--N 1.371 1.536 0 O-C-N 124.773 1.296 . . . . 0.0 107.817 176.72 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' I' I ' 20' ' ' PHE . . . . . 0.403 ' O ' ' N ' ' I' ' 22' ' ' GLU . 12.6 t80 -172.54 -56.14 0.02 OUTLIER 'General case' 0 N--CA 1.481 1.115 0 N-CA-C 110.205 -0.294 . . . . 0.0 110.205 -179.855 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -43.0 90.2 0.0 OUTLIER 'General case' 0 CA--C 1.535 0.381 0 C-N-CA 123.378 0.671 . . . . 0.0 112.06 -179.98 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' I' I ' 22' ' ' GLU . . . . . 0.403 ' N ' ' O ' ' I' ' 20' ' ' PHE . 46.1 mt-10 -61.17 158.93 12.88 Favored 'General case' 0 N--CA 1.47 0.528 0 CA-C-N 114.893 -1.049 . . . . 0.0 110.267 179.241 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 12.2 m-20 -140.22 135.68 32.61 Favored 'General case' 0 N--CA 1.482 1.143 0 C-N-CA 122.597 0.359 . . . . 0.0 110.304 -179.992 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' I' I ' 24' ' ' VAL . . . . . . . . . . . . . 21.2 t -85.8 -115.51 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.96 0 N-CA-C 108.463 -0.94 . . . . 0.0 108.463 179.386 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . -108.31 53.29 0.6 Allowed Glycine 0 N--CA 1.478 1.469 0 N-CA-C 111.249 -0.74 . . . . 0.0 111.249 -179.909 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 85.9 p -77.01 126.73 31.46 Favored 'General case' 0 C--N 1.329 -0.289 0 N-CA-C 109.202 -0.666 . . . . 0.0 109.202 178.148 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' I' I ' 27' ' ' ASN . . . . . 0.466 ' HB3' HD21 ' F' ' 27' ' ' ASN . 6.3 t-20 -66.67 100.97 0.74 Allowed 'General case' 0 N--CA 1.469 0.488 0 N-CA-C 108.474 -0.936 . . . . 0.0 108.474 178.56 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 67.2 mttm -95.38 127.52 41.5 Favored 'General case' 0 N--CA 1.483 1.224 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 -179.431 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -62.99 -127.4 0.01 OUTLIER Glycine 0 CA--C 1.53 0.969 0 N-CA-C 111.099 -0.8 . . . . 0.0 111.099 179.33 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -132.38 125.86 31.84 Favored 'General case' 0 N--CA 1.471 0.624 0 C-N-CA 122.906 0.482 . . . . 0.0 110.719 -179.109 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 39.8 mt -90.61 161.41 2.61 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.624 0 N-CA-C 106.458 -1.682 . . . . 0.0 106.458 178.233 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 47.0 mt -139.54 94.73 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.297 0 CA-C-N 119.586 1.085 . . . . 0.0 109.8 178.374 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 54.1 105.87 0.01 OUTLIER Glycine 0 CA--C 1.532 1.103 0 CA-C-N 116.32 -0.4 . . . . 0.0 114.011 177.568 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 98.7 mt -72.35 152.79 41.85 Favored 'General case' 0 CA--C 1.539 0.527 0 N-CA-C 107.295 -1.372 . . . . 0.0 107.295 176.721 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 27.6 ttt -146.02 140.77 27.06 Favored 'General case' 0 N--CA 1.478 0.956 0 N-CA-C 107.877 -1.157 . . . . 0.0 107.877 179.157 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' I' I ' 36' ' ' VAL . . . . . 0.5 HG13 HE22 ' I' ' 15' ' ' GLN . 94.9 t -161.12 153.46 4.13 Favored 'Isoleucine or valine' 0 C--O 1.233 0.193 0 N-CA-C 106.382 -1.71 . . . . 0.0 106.382 -179.45 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.08 73.95 0.37 Allowed Glycine 0 C--N 1.313 -0.724 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.894 177.762 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 174.95 -158.67 26.65 Favored Glycine 0 C--O 1.216 -1.012 0 N-CA-C 110.547 -1.021 . . . . 0.0 110.547 179.43 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 27.3 m -126.88 138.82 53.65 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.097 0 CA-C-N 117.186 0.493 . . . . 0.0 109.86 -179.722 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 36.8 t . . . . . 0 N--CA 1.469 0.517 0 CA-C-O 117.849 -1.072 . . . . 0.0 111.329 179.525 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 9.8 m-20 . . . . . 0 N--CA 1.491 1.592 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.78 147.74 52.89 Favored 'General case' 0 N--CA 1.47 0.555 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.045 179.6 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 39.5 tt0 -162.18 104.77 1.14 Allowed 'General case' 0 N--CA 1.472 0.646 0 N-CA-C 110.075 -0.343 . . . . 0.0 110.075 179.669 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 16.5 m-85 -71.32 172.3 9.62 Favored 'General case' 0 N--CA 1.469 0.498 0 N-CA-C 109.369 -0.604 . . . . 0.0 109.369 179.681 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 54.0 mtp180 -68.03 129.7 40.71 Favored 'General case' 0 N--CA 1.467 0.383 0 CA-C-N 115.868 -0.606 . . . . 0.0 110.533 -177.798 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 45.2 m170 -96.1 125.59 40.74 Favored 'General case' 0 N--CA 1.473 0.691 0 N-CA-C 109.725 -0.472 . . . . 0.0 109.725 179.002 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 7' ' ' ASP . . . . . 0.495 ' OD1' HG11 ' F' ' 24' ' ' VAL . 10.0 m-20 -72.23 144.81 48.32 Favored 'General case' 0 CA--C 1.532 0.255 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.109 -179.81 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 23.0 t -160.72 179.47 8.51 Favored 'General case' 0 N--CA 1.471 0.615 0 N-CA-C 109.329 -0.619 . . . . 0.0 109.329 178.89 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 124.52 19.86 2.49 Favored Glycine 0 N--CA 1.487 2.064 0 N-CA-C 111.886 -0.486 . . . . 0.0 111.886 179.896 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 43.6 p90 -57.43 129.2 40.74 Favored 'General case' 0 N--CA 1.475 0.82 0 O-C-N 122.458 -0.436 . . . . 0.0 112.084 -179.707 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 46.7 mt-10 -85.54 154.7 21.57 Favored 'General case' 0 N--CA 1.469 0.512 0 N-CA-C 109.046 -0.724 . . . . 0.0 109.046 178.406 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -153.76 129.3 1.64 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 N-CA-C 108.046 -1.094 . . . . 0.0 108.046 178.895 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 51.3 m-70 -135.05 143.75 46.89 Favored 'General case' 0 N--CA 1.49 1.543 0 CA-C-N 118.803 0.729 . . . . 0.0 110.956 -179.218 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -165.98 98.21 0.64 Allowed 'General case' 0 N--CA 1.482 1.16 0 CA-C-N 116.688 -0.233 . . . . 0.0 111.099 179.673 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 45.4 mt-30 -108.06 -171.98 1.97 Allowed 'General case' 0 CA--C 1.503 -0.851 0 N-CA-C 108.176 -1.046 . . . . 0.0 108.176 179.712 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -164.34 97.86 0.8 Allowed 'General case' 0 N--CA 1.472 0.651 0 CA-C-N 115.243 -0.889 . . . . 0.0 109.516 178.686 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.582 ' N ' HD12 ' A' ' 17' ' ' LEU . 4.8 mp -107.02 163.85 12.64 Favored 'General case' 0 N--CA 1.488 1.44 0 N-CA-C 108.59 -0.893 . . . . 0.0 108.59 179.916 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 56.3 t -141.28 119.05 8.84 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.31 0 CA-C-O 118.772 -0.632 . . . . 0.0 109.847 179.433 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 54.5 m-85 -70.13 158.55 35.55 Favored 'General case' 0 N--CA 1.479 1.021 0 N-CA-C 107.706 -1.22 . . . . 0.0 107.706 177.275 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 13.8 t80 -171.03 -58.46 0.02 OUTLIER 'General case' 0 N--CA 1.483 1.217 0 CA-C-O 122.424 1.107 . . . . 0.0 109.672 179.333 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.42 90.05 0.0 OUTLIER 'General case' 0 N--CA 1.457 -0.092 0 CA-C-N 113.927 -1.488 . . . . 0.0 112.852 -178.078 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 37.7 tt0 -62.13 156.51 21.42 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 115.166 -0.925 . . . . 0.0 110.618 178.891 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 12.2 m-20 -138.09 129.75 28.09 Favored 'General case' 0 N--CA 1.482 1.132 0 C-N-CA 122.93 0.492 . . . . 0.0 110.246 -179.659 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.953 HG12 ' H ' ' A' ' 25' ' ' GLY . 39.6 t -79.6 -164.37 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 1.024 0 N-CA-C 108.518 -0.919 . . . . 0.0 108.518 179.583 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.953 ' H ' HG12 ' A' ' 24' ' ' VAL . . . -71.42 51.43 1.08 Allowed Glycine 0 CA--C 1.527 0.827 0 CA-C-N 118.399 0.545 . . . . 0.0 112.038 -179.086 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 27.1 p -72.36 136.45 46.14 Favored 'General case' 0 C--O 1.22 -0.488 0 N-CA-C 109.564 -0.532 . . . . 0.0 109.564 178.877 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 2.0 t-20 -68.66 95.5 0.66 Allowed 'General case' 0 N--CA 1.468 0.463 0 N-CA-C 108.479 -0.934 . . . . 0.0 108.479 178.139 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 67.8 mttm -93.34 119.26 32.27 Favored 'General case' 0 N--CA 1.481 1.108 0 N-CA-C 110.295 -0.261 . . . . 0.0 110.295 -179.104 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.12 -126.12 0.01 OUTLIER Glycine 0 CA--C 1.533 1.166 0 N-CA-C 110.485 -1.046 . . . . 0.0 110.485 178.639 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.24 134.23 48.94 Favored 'General case' 0 N--CA 1.48 1.035 0 N-CA-C 109.078 -0.712 . . . . 0.0 109.078 179.111 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 65.4 mt -83.3 138.05 19.95 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.467 0 N-CA-C 107.3 -1.37 . . . . 0.0 107.3 178.657 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 31.3 mt -130.46 127.71 62.8 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.914 0 O-C-N 123.472 0.483 . . . . 0.0 110.044 -178.592 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.27 78.9 0.14 Allowed Glycine 0 CA--C 1.524 0.653 0 CA-C-N 115.885 -0.598 . . . . 0.0 112.869 178.7 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.438 HD23 ' N ' ' A' ' 35' ' ' MET . 1.7 tt -109.94 120.82 43.67 Favored 'General case' 0 N--CA 1.481 1.077 0 N-CA-C 107.175 -1.417 . . . . 0.0 107.175 177.653 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 35' ' ' MET . . . . . 0.438 ' N ' HD23 ' A' ' 34' ' ' LEU . 8.8 mtp -154.08 161.24 42.05 Favored 'General case' 0 N--CA 1.472 0.647 0 N-CA-C 108.662 -0.866 . . . . 0.0 108.662 179.736 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.539 HG12 HE22 ' D' ' 15' ' ' GLN . 78.1 t -158.07 144.76 8.81 Favored 'Isoleucine or valine' 0 C--O 1.234 0.261 0 N-CA-C 106.774 -1.565 . . . . 0.0 106.774 -179.789 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.77 74.06 0.36 Allowed Glycine 0 C--N 1.315 -0.616 0 N-CA-C 111.511 -0.636 . . . . 0.0 111.511 178.675 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 169.99 -149.07 12.43 Favored Glycine 0 CA--C 1.519 0.324 0 N-CA-C 110.898 -0.881 . . . . 0.0 110.898 179.938 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 16.0 m -134.65 148.74 29.36 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.84 0 C-N-CA 122.675 0.39 . . . . 0.0 109.951 179.955 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 21.9 t . . . . . 0 C--O 1.22 -0.497 0 CA-C-O 117.81 -1.09 . . . . 0.0 111.043 178.931 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' B' B ' 1' ' ' ASP . . . . . . . . . . . . . 9.2 m-20 . . . . . 0 N--CA 1.491 1.61 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' B' B ' 2' ' ' ALA . . . . . . . . . . . . . . . -66.16 147.83 52.75 Favored 'General case' 0 N--CA 1.47 0.537 0 CA-C-N 116.204 -0.453 . . . . 0.0 109.98 179.636 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 3' ' ' GLU . . . . . . . . . . . . . 39.8 tt0 -162.31 104.66 1.12 Allowed 'General case' 0 N--CA 1.473 0.718 0 N-CA-C 110.072 -0.344 . . . . 0.0 110.072 179.64 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 17.3 m-85 -71.11 172.51 9.05 Favored 'General case' 0 N--CA 1.47 0.548 0 N-CA-C 109.404 -0.591 . . . . 0.0 109.404 179.625 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 54.3 mtp180 -68.36 129.61 40.45 Favored 'General case' 0 CA--C 1.534 0.349 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.525 -177.748 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 44.0 m170 -95.99 125.6 40.65 Favored 'General case' 0 N--CA 1.473 0.703 0 N-CA-C 109.797 -0.446 . . . . 0.0 109.797 179.048 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 7' ' ' ASP . . . . . 0.513 ' OD1' HG11 ' D' ' 24' ' ' VAL . 10.0 m-20 -72.18 144.98 48.34 Favored 'General case' 0 CA--C 1.532 0.269 0 CA-C-N 116.464 -0.334 . . . . 0.0 111.163 -179.863 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 8' ' ' SER . . . . . . . . . . . . . 23.1 t -160.82 179.49 8.47 Favored 'General case' 0 N--CA 1.47 0.539 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 178.851 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 124.37 19.88 2.52 Favored Glycine 0 N--CA 1.487 2.081 0 N-CA-C 111.8 -0.52 . . . . 0.0 111.8 179.854 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 43.3 p90 -57.36 129.24 40.92 Favored 'General case' 0 N--CA 1.474 0.736 0 O-C-N 122.489 -0.418 . . . . 0.0 112.073 -179.788 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 46.6 mt-10 -85.55 154.79 21.51 Favored 'General case' 0 N--CA 1.47 0.557 0 N-CA-C 109.15 -0.685 . . . . 0.0 109.15 178.389 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -153.8 129.09 1.56 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.328 0 N-CA-C 108.188 -1.041 . . . . 0.0 108.188 178.839 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 50.9 m-70 -134.8 143.87 47.33 Favored 'General case' 0 N--CA 1.49 1.566 0 CA-C-N 118.79 0.723 . . . . 0.0 110.91 -179.089 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -166.02 98.23 0.63 Allowed 'General case' 0 N--CA 1.483 1.203 0 CA-C-N 116.616 -0.266 . . . . 0.0 111.117 179.619 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 45.5 mt-30 -108.09 -172.52 2.08 Favored 'General case' 0 CA--C 1.502 -0.896 0 N-CA-C 108.168 -1.049 . . . . 0.0 108.168 179.805 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 16' ' ' LYS . . . . . 0.401 ' C ' HD12 ' B' ' 17' ' ' LEU . 88.2 tttt -164.06 97.69 0.83 Allowed 'General case' 0 N--CA 1.473 0.698 0 CA-C-N 115.152 -0.931 . . . . 0.0 109.411 178.747 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 17' ' ' LEU . . . . . 0.584 ' N ' HD12 ' B' ' 17' ' ' LEU . 4.8 mp -106.97 163.91 12.58 Favored 'General case' 0 N--CA 1.488 1.427 0 N-CA-C 108.506 -0.924 . . . . 0.0 108.506 179.867 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 58.7 t -141.37 118.7 8.22 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.358 0 CA-C-O 118.957 -0.544 . . . . 0.0 109.821 179.512 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 56.0 m-85 -70.39 158.64 35.62 Favored 'General case' 0 N--CA 1.477 0.907 0 N-CA-C 107.614 -1.254 . . . . 0.0 107.614 177.25 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 14.5 t80 -171.64 -57.7 0.02 OUTLIER 'General case' 0 N--CA 1.482 1.164 0 CA-C-O 122.284 1.04 . . . . 0.0 109.764 179.288 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.56 90.49 0.0 OUTLIER 'General case' 0 C--O 1.232 0.156 0 CA-C-N 114.098 -1.41 . . . . 0.0 112.682 -178.126 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 37.6 tt0 -62.55 156.37 23.28 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 115.173 -0.921 . . . . 0.0 110.544 179.038 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 12.3 m-20 -138.0 130.16 28.88 Favored 'General case' 0 N--CA 1.483 1.196 0 C-N-CA 123.01 0.524 . . . . 0.0 110.193 -179.671 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 24' ' ' VAL . . . . . 0.983 HG12 ' H ' ' B' ' 25' ' ' GLY . 39.2 t -80.13 -163.89 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.037 0 N-CA-C 108.593 -0.891 . . . . 0.0 108.593 179.618 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 25' ' ' GLY . . . . . 0.983 ' H ' HG12 ' B' ' 24' ' ' VAL . . . -71.36 50.93 1.05 Allowed Glycine 0 C--N 1.342 0.897 0 CA-C-N 118.324 0.511 . . . . 0.0 112.045 -179.182 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 28.9 p -72.16 136.16 46.38 Favored 'General case' 0 C--O 1.22 -0.476 0 N-CA-C 109.644 -0.502 . . . . 0.0 109.644 178.798 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 2.0 t-20 -68.61 95.39 0.64 Allowed 'General case' 0 N--CA 1.469 0.5 0 N-CA-C 108.495 -0.928 . . . . 0.0 108.495 178.137 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 67.9 mttm -93.19 119.12 32.03 Favored 'General case' 0 N--CA 1.481 1.1 0 N-CA-C 110.358 -0.238 . . . . 0.0 110.358 -179.061 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.08 -125.67 0.01 OUTLIER Glycine 0 CA--C 1.534 1.28 0 N-CA-C 110.511 -1.036 . . . . 0.0 110.511 178.64 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.65 134.36 48.51 Favored 'General case' 0 N--CA 1.481 1.103 0 N-CA-C 109.159 -0.682 . . . . 0.0 109.159 179.141 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 65.6 mt -83.43 138.25 19.6 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.462 0 N-CA-C 107.288 -1.375 . . . . 0.0 107.288 178.626 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 29.9 mt -130.78 127.56 61.82 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.884 0 O-C-N 123.541 0.525 . . . . 0.0 110.012 -178.523 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.46 78.56 0.15 Allowed Glycine 0 CA--C 1.526 0.745 0 CA-C-N 115.898 -0.592 . . . . 0.0 112.888 178.642 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 34' ' ' LEU . . . . . 0.429 HD23 ' N ' ' B' ' 35' ' ' MET . 1.7 tt -109.6 120.65 43.14 Favored 'General case' 0 N--CA 1.48 1.061 0 N-CA-C 107.163 -1.421 . . . . 0.0 107.163 177.629 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 35' ' ' MET . . . . . 0.429 ' N ' HD23 ' B' ' 34' ' ' LEU . 8.9 mtp -153.81 161.07 42.37 Favored 'General case' 0 N--CA 1.473 0.682 0 N-CA-C 108.704 -0.85 . . . . 0.0 108.704 179.574 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 36' ' ' VAL . . . . . 0.53 HG12 HE22 ' E' ' 15' ' ' GLN . 72.8 t -157.93 144.65 9.0 Favored 'Isoleucine or valine' 0 C--O 1.233 0.201 0 N-CA-C 106.786 -1.561 . . . . 0.0 106.786 -179.739 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.71 74.08 0.36 Allowed Glycine 0 C--N 1.317 -0.526 0 N-CA-C 111.544 -0.622 . . . . 0.0 111.544 178.713 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 169.97 -148.9 12.23 Favored Glycine 0 CA--C 1.519 0.319 0 N-CA-C 110.796 -0.922 . . . . 0.0 110.796 179.886 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 16.1 m -134.69 148.73 29.32 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.823 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 -179.914 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 21.9 t . . . . . 0 N--CA 1.47 0.54 0 CA-C-O 117.717 -1.135 . . . . 0.0 110.959 178.801 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' C' C ' 1' ' ' ASP . . . . . . . . . . . . . 9.0 m-20 . . . . . 0 N--CA 1.49 1.551 0 N-CA-C 109.4 -0.593 . . . . 0.0 109.4 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' C' C ' 2' ' ' ALA . . . . . . . . . . . . . . . -66.0 147.69 52.96 Favored 'General case' 0 N--CA 1.469 0.491 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.128 179.562 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' C' C ' 3' ' ' GLU . . . . . . . . . . . . . 39.5 tt0 -162.14 104.83 1.15 Allowed 'General case' 0 N--CA 1.472 0.659 0 N-CA-C 110.145 -0.317 . . . . 0.0 110.145 179.69 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 17.4 m-85 -71.3 172.61 9.05 Favored 'General case' 0 N--CA 1.469 0.516 0 N-CA-C 109.473 -0.565 . . . . 0.0 109.473 179.677 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 54.4 mtp180 -68.37 129.25 39.36 Favored 'General case' 0 N--CA 1.468 0.469 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.481 -177.729 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 44.7 m170 -95.74 125.66 40.47 Favored 'General case' 0 N--CA 1.474 0.733 0 N-CA-C 109.714 -0.476 . . . . 0.0 109.714 178.978 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' C' C ' 7' ' ' ASP . . . . . 0.516 ' OD1' HG11 ' E' ' 24' ' ' VAL . 10.1 m-20 -72.33 145.18 47.97 Favored 'General case' 0 CA--C 1.53 0.208 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.198 -179.842 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' C' C ' 8' ' ' SER . . . . . . . . . . . . . 22.9 t -160.91 179.53 8.4 Favored 'General case' 0 N--CA 1.469 0.506 0 N-CA-C 109.343 -0.614 . . . . 0.0 109.343 178.835 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 124.46 19.83 2.51 Favored Glycine 0 N--CA 1.487 2.055 0 N-CA-C 111.772 -0.531 . . . . 0.0 111.772 179.822 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 43.9 p90 -57.24 128.96 39.64 Favored 'General case' 0 N--CA 1.473 0.705 0 O-C-N 122.403 -0.469 . . . . 0.0 112.127 -179.767 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 46.5 mt-10 -85.35 154.95 21.54 Favored 'General case' 0 N--CA 1.47 0.553 0 N-CA-C 109.049 -0.723 . . . . 0.0 109.049 178.426 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -154.08 129.05 1.49 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 N-CA-C 108.174 -1.047 . . . . 0.0 108.174 178.802 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 50.7 m-70 -134.68 144.2 47.66 Favored 'General case' 0 N--CA 1.491 1.624 0 CA-C-N 118.716 0.689 . . . . 0.0 110.974 -179.117 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -166.38 98.16 0.6 Allowed 'General case' 0 N--CA 1.482 1.174 0 CA-C-N 116.674 -0.239 . . . . 0.0 111.161 179.753 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' C' C ' 15' ' ' GLN . . . . . 0.4 ' HB2' HE21 ' F' ' 15' ' ' GLN . 45.3 mt-30 -108.31 -172.12 2.0 Allowed 'General case' 0 CA--C 1.501 -0.941 0 N-CA-C 108.177 -1.046 . . . . 0.0 108.177 179.796 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' C' C ' 16' ' ' LYS . . . . . 0.406 ' C ' HD12 ' C' ' 17' ' ' LEU . 88.2 tttt -164.29 97.84 0.81 Allowed 'General case' 0 N--CA 1.472 0.626 0 CA-C-N 115.143 -0.935 . . . . 0.0 109.443 178.761 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' C' C ' 17' ' ' LEU . . . . . 0.581 ' N ' HD12 ' C' ' 17' ' ' LEU . 4.8 mp -106.96 163.81 12.65 Favored 'General case' 0 N--CA 1.487 1.406 0 N-CA-C 108.559 -0.904 . . . . 0.0 108.559 179.89 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 58.0 t -141.28 118.81 8.54 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.293 0 CA-C-O 118.917 -0.563 . . . . 0.0 109.805 179.48 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 55.1 m-85 -70.49 158.73 35.55 Favored 'General case' 0 N--CA 1.478 0.926 0 N-CA-C 107.529 -1.285 . . . . 0.0 107.529 177.317 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 14.7 t80 -171.63 -57.67 0.02 OUTLIER 'General case' 0 N--CA 1.481 1.104 0 CA-C-O 122.246 1.022 . . . . 0.0 109.857 179.21 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.59 90.4 0.0 OUTLIER 'General case' 0 C--O 1.231 0.107 0 CA-C-N 114.181 -1.372 . . . . 0.0 112.79 -178.168 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 38.0 tt0 -62.32 156.45 22.25 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.223 -0.899 . . . . 0.0 110.577 179.09 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 12.2 m-20 -138.05 129.93 28.42 Favored 'General case' 0 N--CA 1.482 1.156 0 C-N-CA 123.026 0.531 . . . . 0.0 110.255 -179.689 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' C' C ' 24' ' ' VAL . . . . . 0.967 HG12 ' H ' ' C' ' 25' ' ' GLY . 40.4 t -79.99 -164.08 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.035 0 N-CA-C 108.523 -0.917 . . . . 0.0 108.523 179.639 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' C' C ' 25' ' ' GLY . . . . . 0.967 ' H ' HG12 ' C' ' 24' ' ' VAL . . . -71.34 50.96 1.04 Allowed Glycine 0 CA--C 1.527 0.812 0 CA-C-N 118.363 0.529 . . . . 0.0 112.042 -179.019 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 27.3 p -72.13 136.43 46.52 Favored 'General case' 0 C--O 1.221 -0.414 0 N-CA-C 109.526 -0.546 . . . . 0.0 109.526 178.902 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 2.0 t-20 -68.87 95.65 0.7 Allowed 'General case' 0 N--CA 1.468 0.472 0 N-CA-C 108.419 -0.956 . . . . 0.0 108.419 178.107 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 67.9 mttm -93.46 119.07 32.11 Favored 'General case' 0 N--CA 1.481 1.105 0 N-CA-C 110.354 -0.239 . . . . 0.0 110.354 -179.092 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.93 -126.03 0.01 OUTLIER Glycine 0 CA--C 1.534 1.281 0 N-CA-C 110.563 -1.015 . . . . 0.0 110.563 178.606 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.28 134.12 48.89 Favored 'General case' 0 N--CA 1.481 1.102 0 N-CA-C 109.105 -0.702 . . . . 0.0 109.105 179.135 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 65.3 mt -83.26 138.0 20.02 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.451 0 N-CA-C 107.311 -1.366 . . . . 0.0 107.311 178.538 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 30.7 mt -130.41 127.79 63.03 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.931 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.015 -178.537 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.14 78.57 0.15 Allowed Glycine 0 CA--C 1.525 0.68 0 CA-C-N 115.908 -0.587 . . . . 0.0 112.933 178.677 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' C' C ' 34' ' ' LEU . . . . . 0.432 HD23 ' N ' ' C' ' 35' ' ' MET . 1.7 tt -109.49 120.77 43.51 Favored 'General case' 0 N--CA 1.48 1.035 0 N-CA-C 107.202 -1.407 . . . . 0.0 107.202 177.606 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' C' C ' 35' ' ' MET . . . . . 0.432 ' N ' HD23 ' C' ' 34' ' ' LEU . 8.8 mtp -153.93 161.22 42.16 Favored 'General case' 0 N--CA 1.469 0.524 0 N-CA-C 108.664 -0.865 . . . . 0.0 108.664 179.665 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' C' C ' 36' ' ' VAL . . . . . 0.532 HG12 HE22 ' F' ' 15' ' ' GLN . 79.2 t -158.05 144.86 8.89 Favored 'Isoleucine or valine' 0 C--O 1.233 0.232 0 N-CA-C 106.845 -1.539 . . . . 0.0 106.845 -179.832 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.65 74.03 0.37 Allowed Glycine 0 C--N 1.316 -0.535 0 CA-C-N 115.812 -0.631 . . . . 0.0 111.537 178.687 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 169.95 -149.12 12.54 Favored Glycine 0 CA--C 1.518 0.275 0 N-CA-C 110.815 -0.914 . . . . 0.0 110.815 179.941 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 16.4 m -134.58 148.85 29.41 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.872 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 -179.964 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 22.0 t . . . . . 0 N--CA 1.469 0.507 0 CA-C-O 117.717 -1.135 . . . . 0.0 110.952 178.916 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' D' D ' 1' ' ' ASP . . . . . . . . . . . . . 9.2 m-20 . . . . . 0 N--CA 1.489 1.511 0 N-CA-C 109.0 -0.741 . . . . 0.0 109.0 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' D' D ' 2' ' ' ALA . . . . . . . . . . . . . . . -67.96 148.78 50.61 Favored 'General case' 0 N--CA 1.467 0.411 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.383 179.337 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' D' D ' 3' ' ' GLU . . . . . . . . . . . . . 40.0 tt0 -160.99 107.28 1.43 Allowed 'General case' 0 C--O 1.204 -1.291 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.005 -179.8 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 18.7 m-85 -77.12 167.66 21.4 Favored 'General case' 0 C--N 1.303 -1.428 0 C-N-CA 126.343 1.857 . . . . 0.0 107.9 -178.876 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' D' D ' 5' ' ' ARG . . . . . 0.852 HH21 HG13 ' C' ' 24' ' ' VAL 0.344 64.5 mtp180 -77.03 133.52 39.09 Favored 'General case' 0 C--N 1.355 0.821 0 CA-C-O 123.248 1.499 . . . . 0.0 107.088 -167.987 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 45.2 m170 -94.27 128.13 40.56 Favored 'General case' 0 C--N 1.365 1.273 0 CA-C-N 113.371 -1.741 . . . . 0.0 108.502 -177.669 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' D' D ' 7' ' ' ASP . . . . . 0.584 ' OD1' HG11 ' I' ' 24' ' ' VAL . 6.7 m-20 -66.35 130.48 43.37 Favored 'General case' 0 C--N 1.31 -1.134 0 C-N-CA 127.505 2.322 . . . . 0.0 115.117 175.029 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' D' D ' 8' ' ' SER . . . . . . . . . . . . . 22.9 t -152.11 -178.53 6.84 Favored 'General case' 0 N--CA 1.478 0.954 0 CA-C-N 119.168 0.895 . . . . 0.0 109.411 177.145 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 124.58 18.85 2.64 Favored Glycine 0 N--CA 1.485 1.914 0 N-CA-C 111.788 -0.525 . . . . 0.0 111.788 178.691 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 40.2 p90 -56.21 130.62 45.09 Favored 'General case' 0 CA--C 1.544 0.74 0 N-CA-C 112.134 0.42 . . . . 0.0 112.134 -179.209 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 46.7 mt-10 -85.6 152.5 23.08 Favored 'General case' 0 N--CA 1.475 0.78 0 N-CA-C 109.649 -0.5 . . . . 0.0 109.649 177.479 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -149.6 130.1 4.37 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.447 0 N-CA-C 108.1 -1.074 . . . . 0.0 108.1 175.357 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 48.5 m-70 -129.81 146.97 51.53 Favored 'General case' 0 N--CA 1.483 1.218 0 CA-C-N 117.867 0.303 . . . . 0.0 111.286 176.482 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -165.35 104.84 0.74 Allowed 'General case' 0 N--CA 1.483 1.209 0 N-CA-C 109.688 -0.486 . . . . 0.0 109.688 173.354 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' D' D ' 15' ' ' GLN . . . . . 0.539 HE22 HG12 ' A' ' 36' ' ' VAL . 44.1 mt-30 -111.62 -175.59 2.73 Favored 'General case' 0 CA--C 1.493 -1.249 0 N-CA-C 108.018 -1.104 . . . . 0.0 108.018 179.092 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' D' D ' 16' ' ' LYS . . . . . 0.451 ' C ' HD12 ' D' ' 17' ' ' LEU . 88.7 tttt -160.56 106.12 1.47 Allowed 'General case' 0 CA--C 1.538 0.5 0 N-CA-C 107.683 -1.228 . . . . 0.0 107.683 175.383 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' D' D ' 17' ' ' LEU . . . . . 0.528 ' N ' HD12 ' D' ' 17' ' ' LEU . 5.7 mp -113.38 163.03 15.38 Favored 'General case' 0 N--CA 1.488 1.456 0 N-CA-C 107.945 -1.132 . . . . 0.0 107.945 179.457 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 53.3 t -140.96 123.63 15.5 Favored 'Isoleucine or valine' 0 C--N 1.362 1.136 0 N-CA-C 108.753 -0.832 . . . . 0.0 108.753 175.964 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 79.1 m-85 -62.97 151.3 39.99 Favored 'General case' 0 C--N 1.355 0.82 0 C-N-CA 124.517 1.127 . . . . 0.0 110.515 170.967 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 9.9 t80 -170.11 -66.91 0.02 OUTLIER 'General case' 0 N--CA 1.475 0.789 0 N-CA-C 107.781 -1.192 . . . . 0.0 107.781 179.834 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -38.27 95.43 0.01 OUTLIER 'General case' 0 CA--C 1.535 0.39 0 CA-C-N 113.99 -1.459 . . . . 0.0 111.731 -175.293 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 38.3 tt0 -65.18 157.61 28.3 Favored 'General case' 0 N--CA 1.467 0.418 0 CA-C-N 113.919 -1.491 . . . . 0.0 110.122 178.469 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 12.0 m-20 -138.68 130.46 27.82 Favored 'General case' 0 N--CA 1.479 0.985 0 C-N-CA 123.181 0.592 . . . . 0.0 110.407 -178.969 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' D' D ' 24' ' ' VAL . . . . . 1.037 HG12 ' H ' ' D' ' 25' ' ' GLY . 48.7 t -84.42 -160.12 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.299 0 N-CA-C 107.742 -1.206 . . . . 0.0 107.742 -178.346 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' D' D ' 25' ' ' GLY . . . . . 1.037 ' H ' HG12 ' D' ' 24' ' ' VAL . . . -80.3 57.19 4.67 Favored Glycine 0 C--N 1.359 1.84 0 C-N-CA 118.198 -1.953 . . . . 0.0 110.695 -175.556 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 54.0 p -61.81 132.36 52.84 Favored 'General case' 0 C--N 1.346 0.431 0 CA-C-O 117.515 -1.231 . . . . 0.0 112.187 170.377 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 2.0 t-20 -65.53 95.32 0.21 Allowed 'General case' 0 C--O 1.242 0.666 0 CA-C-N 120.263 1.392 . . . . 0.0 109.044 172.049 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 67.6 mttm -95.0 122.17 37.37 Favored 'General case' 0 N--CA 1.483 1.219 0 C-N-CA 119.627 -0.829 . . . . 0.0 109.245 179.537 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -55.84 -130.18 0.01 OUTLIER Glycine 0 CA--C 1.528 0.893 0 C-N-CA 123.804 0.716 . . . . 0.0 112.045 174.717 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -125.33 139.97 53.23 Favored 'General case' 0 C--N 1.369 1.421 0 N-CA-C 108.669 -0.863 . . . . 0.0 108.669 174.602 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 65.2 mt -83.86 140.54 16.04 Favored 'Isoleucine or valine' 0 C--O 1.238 0.47 0 N-CA-C 107.374 -1.343 . . . . 0.0 107.374 176.342 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 42.1 mt -132.79 132.21 59.48 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.996 0 N-CA-C 108.329 -0.989 . . . . 0.0 108.329 178.079 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.22 76.96 0.22 Allowed Glycine 0 C--O 1.245 0.799 0 CA-C-O 118.552 -1.138 . . . . 0.0 112.519 178.351 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' D' D ' 34' ' ' LEU . . . . . 0.434 HD23 ' N ' ' D' ' 35' ' ' MET . 2.1 tt -109.32 132.17 54.38 Favored 'General case' 0 C--N 1.371 1.528 0 N-CA-C 104.73 -2.322 . . . . 0.0 104.73 175.275 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' D' D ' 35' ' ' MET . . . . . 0.434 ' N ' HD23 ' D' ' 34' ' ' LEU . 9.0 mtp -156.43 166.72 32.61 Favored 'General case' 0 N--CA 1.475 0.822 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 177.494 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' D' D ' 36' ' ' VAL . . . . . 0.523 HG12 HE22 ' G' ' 15' ' ' GLN . 93.2 t -163.73 150.72 3.06 Favored 'Isoleucine or valine' 0 C--O 1.237 0.401 0 N-CA-C 104.989 -2.226 . . . . 0.0 104.989 173.986 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 60.95 66.91 2.38 Favored Glycine 0 N--CA 1.444 -0.794 0 C-N-CA 118.509 -1.805 . . . . 0.0 112.129 177.13 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 166.8 -148.06 12.82 Favored Glycine 0 N--CA 1.468 0.767 0 CA-C-N 119.085 1.443 . . . . 0.0 112.296 -179.589 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 14.1 m -131.15 147.92 32.95 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.263 0 CA-C-N 119.009 1.405 . . . . 0.0 110.332 -178.908 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 21.2 t . . . . . 0 C--O 1.212 -0.897 0 N-CA-C 109.388 -0.597 . . . . 0.0 109.388 173.574 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' E' E ' 1' ' ' ASP . . . . . . . . . . . . . 9.7 m-20 . . . . . 0 N--CA 1.487 1.422 0 N-CA-C 109.204 -0.665 . . . . 0.0 109.204 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' E' E ' 2' ' ' ALA . . . . . . . . . . . . . . . -67.86 149.48 49.79 Favored 'General case' 0 N--CA 1.468 0.442 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.34 179.429 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' E' E ' 3' ' ' GLU . . . . . . . . . . . . . 39.9 tt0 -162.97 103.29 1.0 Allowed 'General case' 0 C--O 1.214 -0.801 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.182 -179.704 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 15.9 m-85 -68.41 172.84 5.5 Favored 'General case' 0 N--CA 1.472 0.631 0 CA-C-O 121.171 0.51 . . . . 0.0 109.864 179.479 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' E' E ' 5' ' ' ARG . . . . . 0.837 HH21 HG13 ' A' ' 24' ' ' VAL . 53.0 mtp180 -68.14 130.15 42.07 Favored 'General case' 0 CA--C 1.535 0.398 0 CA-C-N 115.579 -0.737 . . . . 0.0 110.585 -177.917 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 45.6 m170 -96.42 125.3 40.81 Favored 'General case' 0 N--CA 1.476 0.854 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 178.958 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' E' E ' 7' ' ' ASP . . . . . 0.569 ' OD1' HG11 ' G' ' 24' ' ' VAL . 11.6 m-20 -71.75 145.24 48.89 Favored 'General case' 0 N--CA 1.465 0.31 0 O-C-N 123.286 0.366 . . . . 0.0 111.301 -179.823 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' E' E ' 8' ' ' SER . . . . . . . . . . . . . 22.6 t -161.05 179.88 8.07 Favored 'General case' 0 N--CA 1.473 0.702 0 N-CA-C 109.263 -0.643 . . . . 0.0 109.263 178.521 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 125.16 20.12 2.28 Favored Glycine 0 N--CA 1.482 1.754 0 N-CA-C 111.757 -0.537 . . . . 0.0 111.757 179.612 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 40.3 p90 -57.17 128.49 37.24 Favored 'General case' 0 N--CA 1.473 0.682 0 N-CA-C 112.607 0.595 . . . . 0.0 112.607 -179.214 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 45.8 mt-10 -84.37 155.08 22.48 Favored 'General case' 0 N--CA 1.475 0.813 0 N-CA-C 109.228 -0.656 . . . . 0.0 109.228 178.111 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -155.29 127.76 1.05 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.543 0 N-CA-C 108.367 -0.975 . . . . 0.0 108.367 178.764 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 47.4 m-70 -134.63 142.12 46.79 Favored 'General case' 0 N--CA 1.482 1.139 0 CA-C-O 120.591 0.234 . . . . 0.0 111.337 -177.995 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -165.17 98.38 0.73 Allowed 'General case' 0 N--CA 1.486 1.37 0 CA-C-N 116.688 -0.233 . . . . 0.0 111.127 179.711 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' E' E ' 15' ' ' GLN . . . . . 0.53 HE22 HG12 ' B' ' 36' ' ' VAL . 43.5 mt-30 -107.73 -172.2 2.02 Favored 'General case' 0 CA--C 1.501 -0.925 0 N-CA-C 108.393 -0.965 . . . . 0.0 108.393 179.81 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -164.34 97.88 0.8 Allowed 'General case' 0 CA--C 1.542 0.635 0 CA-C-N 115.007 -0.997 . . . . 0.0 109.337 178.697 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' E' E ' 17' ' ' LEU . . . . . 0.571 ' N ' HD12 ' E' ' 17' ' ' LEU . 4.7 mp -106.85 163.34 13.03 Favored 'General case' 0 N--CA 1.49 1.538 0 N-CA-C 109.075 -0.713 . . . . 0.0 109.075 -179.876 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 41.6 t -141.66 118.05 6.93 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.319 0 C-N-CA 122.684 0.394 . . . . 0.0 110.442 178.952 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 54.7 m-85 -69.43 156.31 39.05 Favored 'General case' 0 C--N 1.358 0.969 0 N-CA-C 107.489 -1.3 . . . . 0.0 107.489 176.621 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 13.1 t80 -173.29 -55.33 0.02 OUTLIER 'General case' 0 N--CA 1.484 1.244 0 CA-C-O 121.724 0.773 . . . . 0.0 110.292 179.333 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -42.35 88.94 0.0 OUTLIER 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 114.502 -1.226 . . . . 0.0 112.654 -179.036 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 37.7 tt0 -61.1 156.42 18.14 Favored 'General case' 0 N--CA 1.47 0.554 0 CA-C-N 115.014 -0.994 . . . . 0.0 110.733 179.416 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 12.0 m-20 -138.16 129.39 27.43 Favored 'General case' 0 N--CA 1.481 1.101 0 C-N-CA 123.003 0.521 . . . . 0.0 110.551 -179.52 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' E' E ' 24' ' ' VAL . . . . . 0.975 HG12 ' H ' ' E' ' 25' ' ' GLY . 40.4 t -79.94 -164.25 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.484 1.238 0 N-CA-C 108.164 -1.05 . . . . 0.0 108.164 179.557 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' E' E ' 25' ' ' GLY . . . . . 0.975 ' H ' HG12 ' E' ' 24' ' ' VAL . . . -70.79 52.25 0.92 Allowed Glycine 0 CA--C 1.529 0.928 0 CA-C-N 118.422 0.556 . . . . 0.0 112.534 -178.807 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 18.1 p -72.68 135.32 45.39 Favored 'General case' 0 C--O 1.219 -0.512 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 178.645 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 2.0 t-20 -68.36 95.33 0.6 Allowed 'General case' 0 CA--C 1.536 0.421 0 N-CA-C 107.681 -1.229 . . . . 0.0 107.681 177.866 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 67.4 mttm -93.74 118.38 31.34 Favored 'General case' 0 N--CA 1.483 1.187 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 -178.586 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.93 -124.97 0.01 OUTLIER Glycine 0 CA--C 1.539 1.587 0 N-CA-C 110.998 -0.841 . . . . 0.0 110.998 178.588 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -129.05 133.65 47.79 Favored 'General case' 0 N--CA 1.48 1.057 0 N-CA-C 109.511 -0.551 . . . . 0.0 109.511 179.493 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 65.3 mt -82.44 138.53 19.26 Favored 'Isoleucine or valine' 0 C--O 1.235 0.29 0 N-CA-C 107.158 -1.423 . . . . 0.0 107.158 178.617 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 36.2 mt -130.33 127.85 63.3 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.895 0 N-CA-C 109.437 -0.579 . . . . 0.0 109.437 -179.447 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.64 79.89 0.12 Allowed Glycine 0 CA--C 1.522 0.485 0 CA-C-N 115.914 -0.585 . . . . 0.0 113.299 179.021 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' E' E ' 34' ' ' LEU . . . . . 0.413 HD23 ' N ' ' E' ' 35' ' ' MET . 1.8 tt -110.56 120.26 41.83 Favored 'General case' 0 N--CA 1.48 1.044 0 N-CA-C 107.312 -1.366 . . . . 0.0 107.312 177.419 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' E' E ' 35' ' ' MET . . . . . 0.413 ' N ' HD23 ' E' ' 34' ' ' LEU . 8.7 mtp -152.4 163.23 39.92 Favored 'General case' 0 C--O 1.213 -0.864 0 N-CA-C 108.32 -0.992 . . . . 0.0 108.32 179.421 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' E' E ' 36' ' ' VAL . . . . . 0.546 HG12 HE22 ' H' ' 15' ' ' GLN . 97.5 t -159.85 145.3 6.17 Favored 'Isoleucine or valine' 0 C--O 1.233 0.235 0 N-CA-C 106.693 -1.595 . . . . 0.0 106.693 179.919 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.03 73.62 0.4 Allowed Glycine 0 C--N 1.316 -0.54 0 N-CA-C 111.202 -0.759 . . . . 0.0 111.202 178.769 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 171.03 -148.22 11.07 Favored Glycine 0 C--O 1.221 -0.688 0 C-N-CA 120.882 -0.675 . . . . 0.0 111.459 -179.807 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 14.0 m -136.04 147.89 27.97 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.918 0 N-CA-C 109.239 -0.652 . . . . 0.0 109.239 -179.833 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 21.5 t . . . . . 0 C--O 1.221 -0.395 0 CA-C-O 117.8 -1.095 . . . . 0.0 111.19 179.168 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' F' F ' 1' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 . . . . . 0 N--CA 1.488 1.471 0 N-CA-C 109.166 -0.679 . . . . 0.0 109.166 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' F' F ' 2' ' ' ALA . . . . . . . . . . . . . . . -67.95 149.69 49.44 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-N 116.501 -0.318 . . . . 0.0 110.285 179.519 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' F' F ' 3' ' ' GLU . . . . . . . . . . . . . 40.2 tt0 -163.11 103.23 0.98 Allowed 'General case' 0 C--O 1.212 -0.89 0 CA-C-N 116.428 -0.351 . . . . 0.0 110.054 -179.679 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 15.7 m-85 -68.3 173.17 5.04 Favored 'General case' 0 N--CA 1.473 0.691 0 CA-C-O 121.143 0.497 . . . . 0.0 110.015 179.419 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' F' F ' 5' ' ' ARG . . . . . 0.843 HH21 HG13 ' B' ' 24' ' ' VAL . 53.3 mtp180 -68.03 129.75 40.87 Favored 'General case' 0 CA--C 1.537 0.465 0 CA-C-N 115.422 -0.808 . . . . 0.0 110.602 -177.962 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 45.4 m170 -96.39 125.33 40.81 Favored 'General case' 0 N--CA 1.476 0.874 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 178.885 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' F' F ' 7' ' ' ASP . . . . . 0.577 ' OD1' HG11 ' H' ' 24' ' ' VAL . 11.7 m-20 -71.72 145.05 49.06 Favored 'General case' 0 N--CA 1.465 0.307 0 O-C-N 123.293 0.37 . . . . 0.0 111.423 -179.842 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' F' F ' 8' ' ' SER . . . . . . . . . . . . . 22.8 t -161.06 179.35 8.5 Favored 'General case' 0 N--CA 1.473 0.685 0 N-CA-C 109.277 -0.638 . . . . 0.0 109.277 178.448 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 125.78 19.84 2.19 Favored Glycine 0 N--CA 1.482 1.742 0 N-CA-C 111.752 -0.539 . . . . 0.0 111.752 179.634 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 40.4 p90 -57.07 128.87 39.18 Favored 'General case' 0 N--CA 1.474 0.756 0 N-CA-C 112.528 0.566 . . . . 0.0 112.528 -179.18 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 45.8 mt-10 -84.49 155.34 22.22 Favored 'General case' 0 N--CA 1.474 0.732 0 N-CA-C 109.318 -0.623 . . . . 0.0 109.318 177.986 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -155.49 127.81 1.03 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.53 0 N-CA-C 108.31 -0.996 . . . . 0.0 108.31 178.742 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 48.6 m-70 -134.74 141.97 46.62 Favored 'General case' 0 N--CA 1.482 1.128 0 CA-C-O 120.606 0.241 . . . . 0.0 111.387 -178.034 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -165.19 99.14 0.73 Allowed 'General case' 0 N--CA 1.485 1.3 0 CA-C-N 116.811 -0.177 . . . . 0.0 111.191 179.702 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' F' F ' 15' ' ' GLN . . . . . 0.532 HE22 HG12 ' C' ' 36' ' ' VAL . 43.1 mt-30 -108.84 -171.44 1.85 Allowed 'General case' 0 CA--C 1.499 -0.981 0 N-CA-C 108.525 -0.917 . . . . 0.0 108.525 179.817 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -164.6 98.08 0.78 Allowed 'General case' 0 CA--C 1.54 0.58 0 CA-C-N 114.883 -1.053 . . . . 0.0 109.537 178.657 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' F' F ' 17' ' ' LEU . . . . . 0.569 ' N ' HD12 ' F' ' 17' ' ' LEU . 4.8 mp -106.78 163.14 13.18 Favored 'General case' 0 N--CA 1.49 1.573 0 N-CA-C 109.029 -0.73 . . . . 0.0 109.029 -179.899 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 42.4 t -141.54 118.19 7.31 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.308 0 C-N-CA 122.584 0.354 . . . . 0.0 110.361 179.071 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 55.1 m-85 -69.51 156.06 39.48 Favored 'General case' 0 C--N 1.357 0.932 0 N-CA-C 107.329 -1.36 . . . . 0.0 107.329 176.602 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 13.6 t80 -172.92 -55.69 0.02 OUTLIER 'General case' 0 N--CA 1.483 1.22 0 CA-C-O 121.868 0.842 . . . . 0.0 109.799 179.456 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -42.24 88.8 0.0 OUTLIER 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 114.534 -1.212 . . . . 0.0 112.789 -178.992 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 38.0 tt0 -61.12 156.33 18.4 Favored 'General case' 0 N--CA 1.471 0.617 0 CA-C-N 114.943 -1.026 . . . . 0.0 110.802 179.268 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 12.0 m-20 -138.1 129.63 27.89 Favored 'General case' 0 N--CA 1.482 1.134 0 C-N-CA 122.96 0.504 . . . . 0.0 110.637 -179.638 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' F' F ' 24' ' ' VAL . . . . . 0.963 HG12 ' H ' ' F' ' 25' ' ' GLY . 40.0 t -80.1 -164.07 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.283 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 179.613 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' F' F ' 25' ' ' GLY . . . . . 0.963 ' H ' HG12 ' F' ' 24' ' ' VAL . . . -70.82 52.25 0.93 Allowed Glycine 0 C--N 1.342 0.888 0 CA-C-N 118.608 0.64 . . . . 0.0 112.378 -178.779 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 19.8 p -72.79 134.97 45.17 Favored 'General case' 0 C--O 1.218 -0.558 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 178.525 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 2.0 t-20 -68.21 95.16 0.56 Allowed 'General case' 0 CA--C 1.536 0.422 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 177.967 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 67.4 mttm -93.56 118.21 31.07 Favored 'General case' 0 N--CA 1.482 1.134 0 N-CA-C 110.066 -0.346 . . . . 0.0 110.066 -178.657 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.8 -125.33 0.01 OUTLIER Glycine 0 CA--C 1.539 1.565 0 N-CA-C 111.022 -0.831 . . . . 0.0 111.022 178.629 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.49 133.46 48.47 Favored 'General case' 0 N--CA 1.483 1.193 0 N-CA-C 109.533 -0.543 . . . . 0.0 109.533 179.479 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 65.7 mt -82.47 138.64 19.07 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.306 0 N-CA-C 107.051 -1.463 . . . . 0.0 107.051 178.587 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 35.0 mt -130.34 127.82 63.23 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.833 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 -179.437 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.56 80.05 0.11 Allowed Glycine 0 CA--C 1.525 0.67 0 CA-C-N 115.929 -0.578 . . . . 0.0 113.241 179.023 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' F' F ' 34' ' ' LEU . . . . . 0.443 HD23 ' N ' ' F' ' 35' ' ' MET . 1.8 tt -110.65 121.23 44.81 Favored 'General case' 0 N--CA 1.48 1.067 0 N-CA-C 107.298 -1.371 . . . . 0.0 107.298 177.59 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' F' F ' 35' ' ' MET . . . . . 0.443 ' N ' HD23 ' F' ' 34' ' ' LEU . 8.7 mtp -153.83 163.85 39.35 Favored 'General case' 0 C--O 1.212 -0.894 0 N-CA-C 108.97 -0.752 . . . . 0.0 108.97 179.314 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' F' F ' 36' ' ' VAL . . . . . 0.54 HG12 HE22 ' I' ' 15' ' ' GLN . 98.3 t -160.19 145.48 5.79 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.27 0 N-CA-C 106.906 -1.516 . . . . 0.0 106.906 -179.857 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.15 73.84 0.38 Allowed Glycine 0 C--N 1.317 -0.507 0 N-CA-C 111.188 -0.765 . . . . 0.0 111.188 178.624 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 170.73 -148.17 11.16 Favored Glycine 0 C--O 1.222 -0.635 0 C-N-CA 120.832 -0.699 . . . . 0.0 111.493 -179.728 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 14.1 m -136.22 147.99 27.7 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.981 0 N-CA-C 109.119 -0.697 . . . . 0.0 109.119 -179.793 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 21.6 t . . . . . 0 C--O 1.221 -0.405 0 CA-C-O 117.722 -1.132 . . . . 0.0 111.129 179.138 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' G' G ' 1' ' ' ASP . . . . . . . . . . . . . 8.0 m-20 . . . . . 0 N--CA 1.487 1.41 0 N-CA-C 109.338 -0.616 . . . . 0.0 109.338 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' G' G ' 2' ' ' ALA . . . . . . . . . . . . . . . -68.85 151.1 47.03 Favored 'General case' 0 CA--C 1.533 0.291 0 CA-C-O 120.855 0.359 . . . . 0.0 110.243 179.779 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' G' G ' 3' ' ' GLU . . . . . . . . . . . . . 40.4 tt0 -162.89 103.89 1.02 Allowed 'General case' 0 C--O 1.216 -0.706 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.088 -179.286 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 21.7 m-85 -67.93 171.49 6.66 Favored 'General case' 0 N--CA 1.475 0.778 0 CA-C-O 120.991 0.424 . . . . 0.0 110.149 179.422 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' G' G ' 5' ' ' ARG . . . . . 0.746 HH21 HG13 ' F' ' 24' ' ' VAL . 55.0 mtp180 -67.13 129.1 38.79 Favored 'General case' 0 N--CA 1.469 0.512 0 CA-C-N 115.65 -0.705 . . . . 0.0 110.287 -178.152 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 44.2 m170 -96.09 125.48 40.65 Favored 'General case' 0 N--CA 1.474 0.726 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 178.904 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 9.8 m-20 -72.37 141.5 48.74 Favored 'General case' 0 N--CA 1.468 0.437 0 O-C-N 123.742 0.652 . . . . 0.0 111.52 -179.698 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' G' G ' 8' ' ' SER . . . . . . . . . . . . . 23.2 t -158.58 -179.76 8.38 Favored 'General case' 0 N--CA 1.472 0.665 0 N-CA-C 109.196 -0.668 . . . . 0.0 109.196 178.408 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 125.02 20.16 2.31 Favored Glycine 0 N--CA 1.481 1.675 0 N-CA-C 111.617 -0.593 . . . . 0.0 111.617 179.477 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 43.1 p90 -57.75 128.7 38.41 Favored 'General case' 0 N--CA 1.474 0.727 0 N-CA-C 112.362 0.505 . . . . 0.0 112.362 -178.939 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 46.9 mt-10 -84.51 154.44 22.69 Favored 'General case' 0 N--CA 1.473 0.684 0 CA-C-O 121.055 0.455 . . . . 0.0 109.803 178.611 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 2.6 p -155.8 127.82 1.0 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.028 0 N-CA-C 108.353 -0.98 . . . . 0.0 108.353 178.926 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 50.2 m-70 -134.02 142.99 47.83 Favored 'General case' 0 N--CA 1.476 0.832 0 CA-C-N 115.154 -0.93 . . . . 0.0 111.077 -178.214 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -166.32 98.33 0.6 Allowed 'General case' 0 N--CA 1.484 1.227 0 CA-C-N 116.52 -0.309 . . . . 0.0 110.655 179.129 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' G' G ' 15' ' ' GLN . . . . . 0.523 HE22 HG12 ' D' ' 36' ' ' VAL . 43.3 mt-30 -107.92 -171.91 1.96 Allowed 'General case' 0 CA--C 1.5 -0.943 0 N-CA-C 108.544 -0.91 . . . . 0.0 108.544 179.959 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' G' G ' 16' ' ' LYS . . . . . 0.405 ' C ' HD12 ' G' ' 17' ' ' LEU . 88.1 tttt -164.35 98.18 0.81 Allowed 'General case' 0 N--CA 1.472 0.627 0 CA-C-N 115.083 -0.962 . . . . 0.0 109.441 178.567 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' G' G ' 17' ' ' LEU . . . . . 0.575 ' N ' HD12 ' G' ' 17' ' ' LEU . 5.3 mp -106.83 162.28 13.95 Favored 'General case' 0 N--CA 1.486 1.36 0 N-CA-C 109.33 -0.619 . . . . 0.0 109.33 -179.757 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 41.0 t -142.46 118.27 5.62 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.974 0 C-N-CA 122.601 0.361 . . . . 0.0 110.18 178.823 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 48.7 m-85 -69.33 150.49 47.29 Favored 'General case' 0 C--N 1.371 1.524 0 N-CA-C 107.454 -1.313 . . . . 0.0 107.454 176.709 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 11.4 t80 -171.09 -55.29 0.02 OUTLIER 'General case' 0 N--CA 1.486 1.351 0 CA-C-N 117.802 0.274 . . . . 0.0 110.263 -179.926 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.88 90.09 0.0 OUTLIER 'General case' 0 C--N 1.326 -0.446 0 C-N-CA 123.655 0.782 . . . . 0.0 112.339 179.925 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 38.4 tt0 -61.93 156.66 20.36 Favored 'General case' 0 N--CA 1.469 0.484 0 CA-C-N 114.855 -1.066 . . . . 0.0 110.029 178.886 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 12.1 m-20 -138.31 129.85 27.76 Favored 'General case' 0 N--CA 1.481 1.101 0 C-N-CA 122.958 0.503 . . . . 0.0 110.148 -179.557 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' G' G ' 24' ' ' VAL . . . . . 0.967 HG12 ' H ' ' G' ' 25' ' ' GLY . 39.5 t -81.03 -164.03 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.972 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 179.578 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' G' G ' 25' ' ' GLY . . . . . 0.967 ' H ' HG12 ' G' ' 24' ' ' VAL . . . -70.48 51.51 0.84 Allowed Glycine 0 CA--C 1.527 0.836 0 CA-C-N 118.383 0.538 . . . . 0.0 112.452 -179.016 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 18.0 p -72.34 135.9 46.03 Favored 'General case' 0 C--N 1.329 -0.294 0 N-CA-C 109.175 -0.676 . . . . 0.0 109.175 177.936 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 2.0 t-20 -69.1 94.5 0.67 Allowed 'General case' 0 CA--C 1.536 0.416 0 N-CA-C 107.902 -1.147 . . . . 0.0 107.902 177.814 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 68.0 mttm -92.14 118.94 31.32 Favored 'General case' 0 N--CA 1.482 1.134 0 N-CA-C 110.06 -0.348 . . . . 0.0 110.06 -179.2 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.45 -123.37 0.01 OUTLIER Glycine 0 CA--C 1.534 1.247 0 N-CA-C 110.517 -1.033 . . . . 0.0 110.517 178.608 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -129.91 133.54 46.92 Favored 'General case' 0 N--CA 1.47 0.547 0 N-CA-C 109.526 -0.546 . . . . 0.0 109.526 179.604 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 68.8 mt -81.9 140.23 16.78 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.664 0 N-CA-C 107.37 -1.344 . . . . 0.0 107.37 178.626 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 41.3 mt -131.81 129.27 60.94 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.402 0 CA-C-N 119.135 0.88 . . . . 0.0 109.375 179.698 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.47 79.41 0.13 Allowed Glycine 0 CA--C 1.527 0.816 0 CA-C-N 116.302 -0.408 . . . . 0.0 112.882 179.13 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' G' G ' 34' ' ' LEU . . . . . 0.441 HD23 ' N ' ' G' ' 35' ' ' MET . 1.7 tt -110.34 121.69 45.88 Favored 'General case' 0 N--CA 1.482 1.142 0 N-CA-C 107.146 -1.427 . . . . 0.0 107.146 177.616 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' G' G ' 35' ' ' MET . . . . . 0.441 ' N ' HD23 ' G' ' 34' ' ' LEU . 9.2 mtp -154.34 163.91 39.43 Favored 'General case' 0 N--CA 1.477 0.917 0 N-CA-C 107.94 -1.133 . . . . 0.0 107.94 179.583 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 91.6 t -160.03 145.22 5.92 Favored 'Isoleucine or valine' 0 C--O 1.232 0.167 0 N-CA-C 106.376 -1.713 . . . . 0.0 106.376 179.901 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.75 73.88 0.38 Allowed Glycine 0 C--N 1.316 -0.561 0 N-CA-C 111.58 -0.608 . . . . 0.0 111.58 178.355 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 169.69 -146.96 10.46 Favored Glycine 0 N--CA 1.469 0.886 0 N-CA-C 110.834 -0.907 . . . . 0.0 110.834 179.583 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 15.3 m -136.33 148.31 27.41 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.932 0 CA-C-N 117.042 0.421 . . . . 0.0 109.995 -179.768 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 21.2 t . . . . . 0 N--CA 1.472 0.649 0 CA-C-O 117.881 -1.057 . . . . 0.0 111.232 179.257 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' H' H ' 1' ' ' ASP . . . . . . . . . . . . . 8.5 m-20 . . . . . 0 N--CA 1.488 1.468 0 N-CA-C 109.366 -0.605 . . . . 0.0 109.366 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' H' H ' 2' ' ' ALA . . . . . . . . . . . . . . . -68.85 150.96 47.2 Favored 'General case' 0 CA--C 1.532 0.286 0 CA-C-N 116.482 -0.326 . . . . 0.0 110.268 179.719 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' H' H ' 3' ' ' GLU . . . . . . . . . . . . . 39.9 tt0 -162.86 103.65 1.02 Allowed 'General case' 0 N--CA 1.472 0.673 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.16 -179.23 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 21.8 m-85 -67.82 171.56 6.43 Favored 'General case' 0 N--CA 1.473 0.7 0 CA-C-O 121.064 0.459 . . . . 0.0 110.105 179.489 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' H' H ' 5' ' ' ARG . . . . . 0.741 HH21 HG13 ' D' ' 24' ' ' VAL . 54.5 mtp180 -67.16 129.12 38.88 Favored 'General case' 0 N--CA 1.469 0.489 0 CA-C-N 115.591 -0.731 . . . . 0.0 110.382 -178.15 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 44.5 m170 -96.13 125.27 40.55 Favored 'General case' 0 N--CA 1.474 0.772 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 179.0 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 9.7 m-20 -72.34 141.29 48.79 Favored 'General case' 0 N--CA 1.468 0.458 0 O-C-N 123.453 0.47 . . . . 0.0 111.506 -179.643 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' H' H ' 8' ' ' SER . . . . . . . . . . . . . 22.7 t -158.25 -179.83 8.47 Favored 'General case' 0 N--CA 1.472 0.642 0 N-CA-C 109.192 -0.669 . . . . 0.0 109.192 178.626 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 124.74 20.23 2.36 Favored Glycine 0 N--CA 1.481 1.645 0 N-CA-C 111.67 -0.572 . . . . 0.0 111.67 179.573 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 42.5 p90 -57.77 128.81 38.94 Favored 'General case' 0 N--CA 1.473 0.708 0 N-CA-C 112.344 0.498 . . . . 0.0 112.344 -179.038 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 46.9 mt-10 -84.48 154.36 22.77 Favored 'General case' 0 N--CA 1.475 0.795 0 CA-C-O 121.074 0.464 . . . . 0.0 109.839 178.571 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.6 p -155.69 128.03 1.04 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.048 0 N-CA-C 108.373 -0.973 . . . . 0.0 108.373 178.867 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 50.2 m-70 -134.11 143.27 47.88 Favored 'General case' 0 N--CA 1.476 0.851 0 CA-C-N 115.158 -0.928 . . . . 0.0 111.151 -178.171 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -166.75 98.32 0.56 Allowed 'General case' 0 N--CA 1.482 1.168 0 CA-C-N 116.65 -0.25 . . . . 0.0 110.726 179.131 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' H' H ' 15' ' ' GLN . . . . . 0.546 HE22 HG12 ' E' ' 36' ' ' VAL . 43.7 mt-30 -108.0 -172.39 2.05 Favored 'General case' 0 CA--C 1.499 -1.001 0 N-CA-C 108.42 -0.956 . . . . 0.0 108.42 -179.964 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -164.1 97.94 0.83 Allowed 'General case' 0 N--CA 1.471 0.582 0 CA-C-N 115.083 -0.962 . . . . 0.0 109.277 178.748 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' H' H ' 17' ' ' LEU . . . . . 0.578 ' N ' HD12 ' H' ' 17' ' ' LEU . 5.3 mp -106.67 162.24 13.94 Favored 'General case' 0 N--CA 1.486 1.354 0 N-CA-C 109.259 -0.645 . . . . 0.0 109.259 -179.774 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 41.0 t -142.35 118.15 5.73 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.032 0 C-N-CA 122.613 0.365 . . . . 0.0 110.209 178.899 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 49.1 m-85 -69.65 150.88 46.55 Favored 'General case' 0 C--N 1.371 1.502 0 N-CA-C 107.517 -1.29 . . . . 0.0 107.517 176.631 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 12.1 t80 -172.31 -54.88 0.02 OUTLIER 'General case' 0 N--CA 1.482 1.163 0 N-CA-C 110.213 -0.292 . . . . 0.0 110.213 -179.752 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -42.14 90.55 0.0 OUTLIER 'General case' 0 CA--C 1.534 0.352 0 C-N-CA 123.543 0.737 . . . . 0.0 112.095 179.942 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 38.5 tt0 -62.09 156.64 20.95 Favored 'General case' 0 N--CA 1.469 0.493 0 CA-C-N 114.815 -1.084 . . . . 0.0 110.105 179.087 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 12.0 m-20 -138.16 129.98 28.27 Favored 'General case' 0 N--CA 1.48 1.066 0 C-N-CA 122.968 0.507 . . . . 0.0 110.215 -179.536 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' H' H ' 24' ' ' VAL . . . . . 0.951 HG12 ' H ' ' H' ' 25' ' ' GLY . 39.4 t -81.3 -164.1 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.992 0 N-CA-C 108.376 -0.972 . . . . 0.0 108.376 179.664 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' H' H ' 25' ' ' GLY . . . . . 0.951 ' H ' HG12 ' H' ' 24' ' ' VAL . . . -70.18 51.32 0.77 Allowed Glycine 0 CA--C 1.529 0.932 0 CA-C-N 118.483 0.583 . . . . 0.0 112.268 -179.095 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 17.9 p -72.44 135.96 45.89 Favored 'General case' 0 C--N 1.33 -0.254 0 N-CA-C 109.3 -0.63 . . . . 0.0 109.3 177.945 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 2.0 t-20 -69.2 94.58 0.69 Allowed 'General case' 0 CA--C 1.535 0.368 0 N-CA-C 107.968 -1.123 . . . . 0.0 107.968 177.944 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 68.0 mttm -92.27 118.86 31.31 Favored 'General case' 0 N--CA 1.48 1.066 0 N-CA-C 110.111 -0.329 . . . . 0.0 110.111 -179.21 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.47 -123.02 0.01 OUTLIER Glycine 0 CA--C 1.535 1.291 0 N-CA-C 110.477 -1.049 . . . . 0.0 110.477 178.601 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.04 133.77 46.94 Favored 'General case' 0 N--CA 1.471 0.616 0 C-N-CA 123.0 0.52 . . . . 0.0 109.61 179.715 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 68.5 mt -82.2 140.1 16.93 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.591 0 N-CA-C 107.315 -1.365 . . . . 0.0 107.315 178.57 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 41.6 mt -131.74 129.46 61.26 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.278 0 CA-C-N 119.092 0.86 . . . . 0.0 109.317 179.826 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.14 79.48 0.12 Allowed Glycine 0 CA--C 1.527 0.788 0 CA-C-N 116.239 -0.437 . . . . 0.0 112.933 179.155 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' H' H ' 34' ' ' LEU . . . . . 0.432 HD23 ' N ' ' H' ' 35' ' ' MET . 1.7 tt -110.44 121.76 46.09 Favored 'General case' 0 N--CA 1.481 1.099 0 N-CA-C 107.082 -1.451 . . . . 0.0 107.082 177.592 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' H' H ' 35' ' ' MET . . . . . 0.432 ' N ' HD23 ' H' ' 34' ' ' LEU . 9.3 mtp -154.3 163.71 39.73 Favored 'General case' 0 N--CA 1.476 0.85 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 179.679 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 89.9 t -160.05 145.2 5.89 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.163 0 N-CA-C 106.415 -1.698 . . . . 0.0 106.415 179.838 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.75 73.77 0.39 Allowed Glycine 0 C--N 1.316 -0.537 0 N-CA-C 111.536 -0.625 . . . . 0.0 111.536 178.433 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 169.9 -147.19 10.6 Favored Glycine 0 N--CA 1.469 0.899 0 N-CA-C 110.779 -0.928 . . . . 0.0 110.779 179.641 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 15.1 m -136.25 148.18 27.57 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.918 0 CA-C-N 116.938 0.369 . . . . 0.0 110.033 -179.763 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 21.3 t . . . . . 0 N--CA 1.471 0.625 0 CA-C-O 117.864 -1.065 . . . . 0.0 111.138 179.227 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' I' I ' 1' ' ' ASP . . . . . . . . . . . . . 8.5 m-20 . . . . . 0 N--CA 1.488 1.442 0 N-CA-C 109.306 -0.627 . . . . 0.0 109.306 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' I' I ' 2' ' ' ALA . . . . . . . . . . . . . . . -69.19 151.29 46.51 Favored 'General case' 0 CA--C 1.533 0.298 0 CA-C-O 120.956 0.407 . . . . 0.0 110.171 179.789 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' I' I ' 3' ' ' GLU . . . . . . . . . . . . . 40.4 tt0 -163.1 103.96 0.99 Allowed 'General case' 0 N--CA 1.471 0.624 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.105 -179.266 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 21.8 m-85 -67.97 171.48 6.72 Favored 'General case' 0 N--CA 1.473 0.712 0 CA-C-O 120.981 0.42 . . . . 0.0 110.169 179.433 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' I' I ' 5' ' ' ARG . . . . . 0.725 HH21 HG13 ' E' ' 24' ' ' VAL . 54.6 mtp180 -67.18 128.89 38.07 Favored 'General case' 0 N--CA 1.468 0.455 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.378 -178.214 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 44.3 m170 -95.87 125.22 40.27 Favored 'General case' 0 N--CA 1.475 0.777 0 N-CA-C 109.736 -0.468 . . . . 0.0 109.736 178.99 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 9.8 m-20 -72.21 141.76 49.0 Favored 'General case' 0 N--CA 1.468 0.442 0 O-C-N 123.484 0.49 . . . . 0.0 111.397 -179.682 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' I' I ' 8' ' ' SER . . . . . . . . . . . . . 22.7 t -158.65 179.94 8.65 Favored 'General case' 0 N--CA 1.472 0.63 0 N-CA-C 109.201 -0.666 . . . . 0.0 109.201 178.636 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 124.87 20.29 2.32 Favored Glycine 0 N--CA 1.482 1.739 0 N-CA-C 111.646 -0.582 . . . . 0.0 111.646 179.487 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 42.8 p90 -57.71 128.75 38.62 Favored 'General case' 0 N--CA 1.474 0.765 0 N-CA-C 112.342 0.497 . . . . 0.0 112.342 -179.053 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 46.8 mt-10 -84.39 154.48 22.8 Favored 'General case' 0 N--CA 1.474 0.773 0 CA-C-O 121.043 0.449 . . . . 0.0 109.806 178.538 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 2.6 p -155.82 128.04 1.03 Allowed 'Isoleucine or valine' 0 CA--C 1.553 1.062 0 N-CA-C 108.332 -0.988 . . . . 0.0 108.332 178.843 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 50.4 m-70 -134.17 143.27 47.81 Favored 'General case' 0 N--CA 1.476 0.848 0 CA-C-N 115.094 -0.957 . . . . 0.0 111.094 -178.182 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -166.75 98.37 0.56 Allowed 'General case' 0 N--CA 1.483 1.198 0 CA-C-N 116.626 -0.261 . . . . 0.0 110.795 179.125 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' I' I ' 15' ' ' GLN . . . . . 0.54 HE22 HG12 ' F' ' 36' ' ' VAL . 43.6 mt-30 -108.12 -172.15 2.01 Favored 'General case' 0 CA--C 1.499 -0.99 0 N-CA-C 108.441 -0.948 . . . . 0.0 108.441 -179.981 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' I' I ' 16' ' ' LYS . . . . . 0.403 ' C ' HD12 ' I' ' 17' ' ' LEU . 88.1 tttt -164.21 98.03 0.82 Allowed 'General case' 0 N--CA 1.471 0.606 0 CA-C-N 114.992 -1.004 . . . . 0.0 109.333 178.691 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' I' I ' 17' ' ' LEU . . . . . 0.576 ' N ' HD12 ' I' ' 17' ' ' LEU . 5.3 mp -106.64 162.21 13.96 Favored 'General case' 0 N--CA 1.487 1.388 0 N-CA-C 109.278 -0.638 . . . . 0.0 109.278 -179.749 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 40.7 t -142.24 118.12 5.93 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.059 0 C-N-CA 122.632 0.373 . . . . 0.0 110.223 178.851 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 49.2 m-85 -69.61 150.81 46.66 Favored 'General case' 0 C--N 1.37 1.494 0 N-CA-C 107.49 -1.3 . . . . 0.0 107.49 176.599 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 12.2 t80 -172.2 -55.0 0.02 OUTLIER 'General case' 0 N--CA 1.483 1.201 0 N-CA-C 110.231 -0.285 . . . . 0.0 110.231 -179.826 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -42.08 90.45 0.0 OUTLIER 'General case' 0 CA--C 1.535 0.389 0 C-N-CA 123.657 0.783 . . . . 0.0 112.084 179.958 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 38.3 tt0 -62.02 156.68 20.65 Favored 'General case' 0 N--CA 1.469 0.519 0 CA-C-N 114.793 -1.094 . . . . 0.0 110.043 179.147 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 12.3 m-20 -138.17 129.83 28.04 Favored 'General case' 0 N--CA 1.481 1.097 0 C-N-CA 122.973 0.509 . . . . 0.0 110.217 -179.624 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' I' I ' 24' ' ' VAL . . . . . 0.944 HG12 ' H ' ' I' ' 25' ' ' GLY . 38.8 t -80.96 -163.87 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 1.005 0 N-CA-C 108.381 -0.97 . . . . 0.0 108.381 179.618 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' I' I ' 25' ' ' GLY . . . . . 0.944 ' H ' HG12 ' I' ' 24' ' ' VAL . . . -70.57 51.33 0.85 Allowed Glycine 0 CA--C 1.528 0.895 0 CA-C-N 118.364 0.529 . . . . 0.0 112.376 -179.074 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 17.7 p -72.34 136.04 46.07 Favored 'General case' 0 C--N 1.33 -0.252 0 N-CA-C 109.252 -0.647 . . . . 0.0 109.252 177.947 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 2.0 t-20 -69.23 94.58 0.7 Allowed 'General case' 0 CA--C 1.535 0.371 0 N-CA-C 107.953 -1.128 . . . . 0.0 107.953 177.888 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 68.1 mttm -92.32 118.96 31.43 Favored 'General case' 0 N--CA 1.48 1.068 0 N-CA-C 110.15 -0.315 . . . . 0.0 110.15 -179.15 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.52 -123.31 0.01 OUTLIER Glycine 0 CA--C 1.534 1.249 0 N-CA-C 110.632 -0.987 . . . . 0.0 110.632 178.648 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -129.77 133.21 46.86 Favored 'General case' 0 N--CA 1.472 0.665 0 C-N-CA 123.047 0.539 . . . . 0.0 109.594 179.715 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 68.5 mt -81.86 139.99 17.15 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.555 0 N-CA-C 107.266 -1.383 . . . . 0.0 107.266 178.605 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 41.1 mt -131.62 129.48 61.62 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.359 0 CA-C-N 119.023 0.829 . . . . 0.0 109.318 179.807 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.13 79.36 0.13 Allowed Glycine 0 CA--C 1.527 0.814 0 CA-C-N 116.289 -0.414 . . . . 0.0 112.936 179.085 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' I' I ' 34' ' ' LEU . . . . . 0.436 HD23 ' N ' ' I' ' 35' ' ' MET . 1.7 tt -110.28 121.73 45.97 Favored 'General case' 0 N--CA 1.481 1.087 0 N-CA-C 107.163 -1.421 . . . . 0.0 107.163 177.55 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' I' I ' 35' ' ' MET . . . . . 0.436 ' N ' HD23 ' I' ' 34' ' ' LEU . 9.4 mtp -154.26 163.7 39.72 Favored 'General case' 0 N--CA 1.475 0.786 0 N-CA-C 107.971 -1.122 . . . . 0.0 107.971 179.786 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 89.5 t -160.04 145.31 5.94 Favored 'Isoleucine or valine' 0 C--O 1.232 0.162 0 N-CA-C 106.423 -1.695 . . . . 0.0 106.423 179.801 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.55 74.03 0.36 Allowed Glycine 0 C--N 1.315 -0.599 0 N-CA-C 111.573 -0.611 . . . . 0.0 111.573 178.484 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 169.68 -147.04 10.53 Favored Glycine 0 N--CA 1.469 0.877 0 N-CA-C 110.806 -0.918 . . . . 0.0 110.806 179.587 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 15.1 m -136.3 148.27 27.47 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.96 0 CA-C-N 116.979 0.389 . . . . 0.0 110.06 -179.79 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 21.4 t . . . . . 0 N--CA 1.471 0.61 0 CA-C-O 117.899 -1.048 . . . . 0.0 111.07 179.139 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 67.6 m-20 . . . . . 0 N--CA 1.49 1.573 0 N-CA-C 109.385 -0.598 . . . . 0.0 109.385 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -63.02 -170.59 0.03 OUTLIER 'General case' 0 N--CA 1.468 0.457 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.507 179.867 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 26.7 tt0 -153.21 165.98 33.97 Favored 'General case' 0 N--CA 1.475 0.798 0 N-CA-C 109.966 -0.383 . . . . 0.0 109.966 -179.904 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 21.1 p90 -67.45 137.44 55.87 Favored 'General case' 0 N--CA 1.471 0.578 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.384 -178.525 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 99.0 mtt180 -136.73 153.18 50.93 Favored 'General case' 0 N--CA 1.482 1.137 0 N-CA-C 109.527 -0.546 . . . . 0.0 109.527 178.523 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 58.5 t-80 -113.98 114.82 26.69 Favored 'General case' 0 N--CA 1.477 0.9 0 C-N-CA 123.094 0.557 . . . . 0.0 109.627 179.493 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 7' ' ' ASP . . . . . 0.424 ' O ' ' OG ' ' D' ' 8' ' ' SER . 8.9 m-20 -72.99 156.36 38.91 Favored 'General case' 0 N--CA 1.465 0.307 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.062 179.053 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 9.5 p -166.17 -177.08 3.97 Favored 'General case' 0 N--CA 1.483 1.181 0 CA-C-O 120.913 0.387 . . . . 0.0 110.528 178.736 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.9 43.94 1.58 Allowed Glycine 0 N--CA 1.482 1.708 0 CA-C-N 115.747 -0.661 . . . . 0.0 112.19 179.427 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 51.2 p90 -65.32 131.86 47.54 Favored 'General case' 0 N--CA 1.473 0.715 0 CA-C-N 116.83 0.315 . . . . 0.0 111.479 179.751 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 84.4 mt-10 -94.3 153.52 17.97 Favored 'General case' 0 N--CA 1.476 0.853 0 N-CA-C 109.655 -0.498 . . . . 0.0 109.655 178.587 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -153.28 128.52 1.55 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.583 0 N-CA-C 107.781 -1.192 . . . . 0.0 107.781 178.126 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 50.9 m-70 -135.13 144.88 47.34 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 119.144 0.884 . . . . 0.0 111.221 -179.143 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 6.3 t60 -165.83 99.0 0.66 Allowed 'General case' 0 N--CA 1.48 1.061 0 CA-C-N 116.394 -0.366 . . . . 0.0 110.588 179.465 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 15' ' ' GLN . . . . . 0.451 HE22 ' H ' ' A' ' 37' ' ' GLY . 22.2 pt20 -124.41 155.33 39.01 Favored 'General case' 0 CA--C 1.501 -0.927 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 -179.609 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -124.99 106.02 9.64 Favored 'General case' 0 N--CA 1.478 0.974 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 177.986 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 6.1 mp -121.16 148.88 43.62 Favored 'General case' 0 N--CA 1.497 1.908 0 CA-C-O 121.412 0.625 . . . . 0.0 110.797 -178.528 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 30.8 t -107.57 123.77 63.12 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.018 0 N-CA-C 108.077 -1.083 . . . . 0.0 108.077 177.612 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.506 ' O ' ' N ' ' A' ' 21' ' ' ALA . 25.7 m-85 -119.57 -160.89 0.83 Allowed 'General case' 0 N--CA 1.498 1.962 0 CA-C-N 120.232 1.378 . . . . 0.0 109.178 -179.966 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.555 ' O ' ' HA ' ' D' ' 20' ' ' PHE . 78.7 m-85 -50.94 76.8 0.0 OUTLIER 'General case' 0 C--O 1.2 -1.511 0 C-N-CA 123.772 0.829 . . . . 0.0 111.318 -179.164 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 21' ' ' ALA . . . . . 0.506 ' N ' ' O ' ' A' ' 19' ' ' PHE . . . -88.47 -75.61 0.42 Allowed 'General case' 0 N--CA 1.471 0.597 0 CA-C-N 115.691 -0.686 . . . . 0.0 110.158 -179.614 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 40.4 tt0 -96.12 98.65 10.51 Favored 'General case' 0 N--CA 1.463 0.205 0 N-CA-C 108.461 -0.94 . . . . 0.0 108.461 179.349 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 4.1 p30 -159.45 145.03 15.91 Favored 'General case' 0 N--CA 1.484 1.242 0 O-C-N 122.334 -0.229 . . . . 0.0 110.828 179.598 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.405 HG12 ' N ' ' A' ' 25' ' ' GLY . 88.6 t -63.04 163.91 1.46 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.799 0 N-CA-C 107.619 -1.252 . . . . 0.0 107.619 176.998 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.5 ' H ' ' HB ' ' D' ' 24' ' ' VAL . . . -117.8 45.62 1.25 Allowed Glycine 0 N--CA 1.474 1.183 0 CA-C-O 119.649 -0.529 . . . . 0.0 111.927 -179.409 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -60.32 -165.21 0.01 OUTLIER 'General case' 0 N--CA 1.471 0.622 0 O-C-N 123.805 0.356 . . . . 0.0 110.461 179.618 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 24.0 t-20 -70.23 80.77 0.52 Allowed 'General case' 0 N--CA 1.463 0.197 0 CA-C-N 116.378 -0.373 . . . . 0.0 110.384 179.654 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 96.9 mttt -79.73 138.23 37.25 Favored 'General case' 0 N--CA 1.472 0.635 0 N-CA-C 109.195 -0.668 . . . . 0.0 109.195 179.365 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.84 -166.13 0.9 Allowed Glycine 0 C--N 1.337 0.621 0 N-CA-C 109.68 -1.368 . . . . 0.0 109.68 178.189 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.73 113.99 26.83 Favored 'General case' 0 N--CA 1.474 0.772 0 N-CA-C 109.546 -0.538 . . . . 0.0 109.546 179.505 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 76.5 mt -99.58 135.39 35.2 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.601 0 N-CA-C 107.054 -1.462 . . . . 0.0 107.054 178.734 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 32' ' ' ILE . . . . . 0.405 ' C ' ' H ' ' A' ' 34' ' ' LEU . 26.7 pt -150.78 -172.1 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.353 0.743 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.326 -179.27 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.57 2.53 6.0 Favored Glycine 0 CA--C 1.525 0.711 0 N-CA-C 110.864 -0.894 . . . . 0.0 110.864 -179.905 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.418 HD23 ' N ' ' A' ' 35' ' ' MET . 1.1 tt -74.66 133.58 42.1 Favored 'General case' 0 CA--C 1.544 0.735 0 N-CA-C 109.247 -0.649 . . . . 0.0 109.247 -179.611 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 35' ' ' MET . . . . . 0.418 ' N ' HD23 ' A' ' 34' ' ' LEU . 26.6 ttt -159.44 151.4 20.68 Favored 'General case' 0 N--CA 1.47 0.527 0 N-CA-C 108.297 -1.001 . . . . 0.0 108.297 178.924 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.473 HG12 ' N ' ' A' ' 37' ' ' GLY . 63.3 t -154.49 162.89 1.81 Allowed 'Isoleucine or valine' 0 C--N 1.344 0.353 0 N-CA-C 107.774 -1.195 . . . . 0.0 107.774 -179.52 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 37' ' ' GLY . . . . . 0.473 ' N ' HG12 ' A' ' 36' ' ' VAL . . . 57.57 67.32 2.27 Favored Glycine 0 C--N 1.306 -1.091 0 CA-C-N 115.606 -0.725 . . . . 0.0 112.133 178.717 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.7 177.83 22.44 Favored Glycine 0 N--CA 1.476 1.325 0 N-CA-C 111.045 -0.822 . . . . 0.0 111.045 178.717 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 33.4 m -109.69 152.71 11.66 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.612 0 C-N-CA 123.419 0.687 . . . . 0.0 110.217 -179.58 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 21.9 t . . . . . 0 C--O 1.216 -0.678 0 CA-C-O 118.319 -0.848 . . . . 0.0 110.531 179.615 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' B' B ' 1' ' ' ASP . . . . . . . . . . . . . 67.0 m-20 . . . . . 0 N--CA 1.49 1.566 0 N-CA-C 109.403 -0.592 . . . . 0.0 109.403 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' B' B ' 2' ' ' ALA . . . . . . . . . . . . . . . -63.5 -170.34 0.03 OUTLIER 'General case' 0 N--CA 1.468 0.427 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.562 179.798 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 3' ' ' GLU . . . . . . . . . . . . . 26.7 tt0 -153.5 166.09 33.8 Favored 'General case' 0 N--CA 1.475 0.799 0 N-CA-C 110.005 -0.369 . . . . 0.0 110.005 -179.935 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 20.5 p90 -67.29 137.26 55.96 Favored 'General case' 0 N--CA 1.47 0.549 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.546 -178.564 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 99.0 mtt180 -136.56 152.98 51.08 Favored 'General case' 0 N--CA 1.481 1.094 0 N-CA-C 109.517 -0.549 . . . . 0.0 109.517 178.534 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 58.4 t-80 -113.91 114.85 26.8 Favored 'General case' 0 N--CA 1.477 0.918 0 C-N-CA 123.156 0.582 . . . . 0.0 109.691 179.522 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 7' ' ' ASP . . . . . 0.419 ' O ' ' OG ' ' E' ' 8' ' ' SER . 8.4 m-20 -73.13 155.95 39.15 Favored 'General case' 0 N--CA 1.467 0.41 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.124 179.151 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 8' ' ' SER . . . . . . . . . . . . . 9.6 p -165.94 -176.93 4.0 Favored 'General case' 0 N--CA 1.481 1.105 0 CA-C-O 120.942 0.401 . . . . 0.0 110.567 178.847 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.67 44.08 1.6 Allowed Glycine 0 N--CA 1.483 1.779 0 CA-C-N 115.701 -0.681 . . . . 0.0 112.232 179.528 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 51.0 p90 -65.66 132.02 47.78 Favored 'General case' 0 N--CA 1.472 0.649 0 CA-C-O 120.688 0.28 . . . . 0.0 111.492 179.823 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 84.2 mt-10 -94.28 153.71 17.89 Favored 'General case' 0 N--CA 1.477 0.876 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 178.483 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -153.41 128.38 1.5 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.511 0 N-CA-C 107.738 -1.208 . . . . 0.0 107.738 178.119 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 49.9 m-70 -135.19 144.5 47.02 Favored 'General case' 0 N--CA 1.492 1.664 0 CA-C-N 119.042 0.837 . . . . 0.0 111.218 -179.091 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 6.3 t60 -165.45 98.71 0.7 Allowed 'General case' 0 N--CA 1.481 1.088 0 CA-C-N 116.461 -0.336 . . . . 0.0 110.482 179.573 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 15' ' ' GLN . . . . . 0.435 HE22 ' H ' ' B' ' 37' ' ' GLY . 22.2 pt20 -124.14 155.38 38.54 Favored 'General case' 0 CA--C 1.501 -0.909 0 N-CA-C 107.988 -1.116 . . . . 0.0 107.988 -179.694 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -124.99 106.13 9.73 Favored 'General case' 0 N--CA 1.479 1.016 0 N-CA-C 108.121 -1.066 . . . . 0.0 108.121 178.037 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 6.1 mp -121.25 148.82 43.77 Favored 'General case' 0 N--CA 1.497 1.901 0 CA-C-O 121.397 0.618 . . . . 0.0 110.809 -178.518 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 29.8 t -107.6 124.59 63.72 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.038 0 N-CA-C 107.949 -1.13 . . . . 0.0 107.949 177.502 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 19' ' ' PHE . . . . . 0.514 ' O ' ' N ' ' B' ' 21' ' ' ALA . 25.5 m-85 -120.65 -161.12 0.87 Allowed 'General case' 0 N--CA 1.496 1.842 0 CA-C-N 119.906 1.23 . . . . 0.0 109.09 -179.779 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 20' ' ' PHE . . . . . 0.512 ' O ' ' HA ' ' E' ' 20' ' ' PHE . 77.7 m-85 -51.1 76.56 0.0 OUTLIER 'General case' 0 C--O 1.202 -1.421 0 C-N-CA 123.684 0.794 . . . . 0.0 111.451 -179.129 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 21' ' ' ALA . . . . . 0.514 ' N ' ' O ' ' B' ' 19' ' ' PHE . . . -88.35 -75.9 0.41 Allowed 'General case' 0 N--CA 1.47 0.539 0 CA-C-N 115.628 -0.715 . . . . 0.0 110.1 -179.692 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 40.5 tt0 -95.9 98.95 10.8 Favored 'General case' 0 N--CA 1.464 0.231 0 N-CA-C 108.49 -0.929 . . . . 0.0 108.49 179.358 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 4.1 p30 -159.65 144.96 15.55 Favored 'General case' 0 N--CA 1.483 1.212 0 O-C-N 122.407 -0.183 . . . . 0.0 110.892 179.578 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 24' ' ' VAL . . . . . 0.402 HG12 ' N ' ' B' ' 25' ' ' GLY . 94.0 t -62.9 163.76 1.46 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.808 0 N-CA-C 107.609 -1.256 . . . . 0.0 107.609 177.088 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 25' ' ' GLY . . . . . 0.495 ' H ' ' HB ' ' E' ' 24' ' ' VAL . . . -117.54 45.67 1.24 Allowed Glycine 0 N--CA 1.474 1.231 0 N-CA-C 111.903 -0.479 . . . . 0.0 111.903 -179.371 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -60.67 -165.05 0.01 OUTLIER 'General case' 0 N--CA 1.472 0.643 0 O-C-N 123.62 0.247 . . . . 0.0 110.452 179.688 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 24.1 t-20 -70.4 80.93 0.55 Allowed 'General case' 0 N--CA 1.464 0.272 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.268 179.664 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 96.8 mttt -79.87 138.28 37.13 Favored 'General case' 0 N--CA 1.472 0.656 0 N-CA-C 109.187 -0.672 . . . . 0.0 109.187 179.373 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.82 -166.14 0.9 Allowed Glycine 0 C--N 1.337 0.602 0 N-CA-C 109.638 -1.385 . . . . 0.0 109.638 178.231 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.68 113.84 26.55 Favored 'General case' 0 N--CA 1.474 0.729 0 N-CA-C 109.639 -0.504 . . . . 0.0 109.639 179.475 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 76.0 mt -99.44 135.32 35.25 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.527 0 N-CA-C 107.054 -1.461 . . . . 0.0 107.054 178.733 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 32' ' ' ILE . . . . . 0.403 ' C ' ' H ' ' B' ' 34' ' ' LEU . 26.6 pt -150.73 -172.05 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.353 0.729 0 CA-C-O 121.185 0.517 . . . . 0.0 111.259 -179.278 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.67 2.35 5.94 Favored Glycine 0 CA--C 1.525 0.692 0 N-CA-C 110.776 -0.93 . . . . 0.0 110.776 -179.919 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 34' ' ' LEU . . . . . 0.403 ' H ' ' C ' ' B' ' 32' ' ' ILE . 1.1 tt -74.55 133.2 42.28 Favored 'General case' 0 CA--C 1.545 0.773 0 N-CA-C 109.209 -0.663 . . . . 0.0 109.209 -179.588 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 35' ' ' MET . . . . . 0.4 ' N ' HD23 ' B' ' 34' ' ' LEU . 26.6 ttt -159.04 150.76 20.68 Favored 'General case' 0 N--CA 1.47 0.562 0 N-CA-C 108.362 -0.977 . . . . 0.0 108.362 178.722 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 36' ' ' VAL . . . . . 0.472 HG12 ' N ' ' B' ' 37' ' ' GLY . 64.0 t -153.79 162.51 2.08 Favored 'Isoleucine or valine' 0 C--N 1.345 0.394 0 N-CA-C 107.838 -1.171 . . . . 0.0 107.838 -179.599 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 37' ' ' GLY . . . . . 0.472 ' N ' HG12 ' B' ' 36' ' ' VAL . . . 58.07 67.13 2.36 Favored Glycine 0 C--N 1.307 -1.043 0 CA-C-N 115.586 -0.734 . . . . 0.0 112.071 178.627 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.85 177.31 22.14 Favored Glycine 0 N--CA 1.475 1.298 0 N-CA-C 111.042 -0.823 . . . . 0.0 111.042 178.797 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 33.6 m -109.21 152.5 11.25 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.621 0 C-N-CA 123.37 0.668 . . . . 0.0 110.316 -179.599 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 22.0 t . . . . . 0 C--O 1.215 -0.758 0 CA-C-O 118.379 -0.82 . . . . 0.0 110.422 179.604 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' C' C ' 1' ' ' ASP . . . . . . . . . . . . . 66.9 m-20 . . . . . 0 N--CA 1.491 1.596 0 N-CA-C 109.422 -0.584 . . . . 0.0 109.422 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' C' C ' 2' ' ' ALA . . . . . . . . . . . . . . . -63.45 -170.53 0.03 OUTLIER 'General case' 0 N--CA 1.466 0.374 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.437 179.906 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' C' C ' 3' ' ' GLU . . . . . . . . . . . . . 26.2 tt0 -153.25 166.38 32.76 Favored 'General case' 0 N--CA 1.474 0.763 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 -179.877 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 20.4 p90 -67.69 137.34 55.45 Favored 'General case' 0 N--CA 1.47 0.542 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.566 -178.58 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 99.0 mtt180 -136.68 153.09 50.99 Favored 'General case' 0 N--CA 1.481 1.089 0 N-CA-C 109.546 -0.539 . . . . 0.0 109.546 178.528 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 58.3 t-80 -113.86 115.06 27.14 Favored 'General case' 0 N--CA 1.478 0.951 0 C-N-CA 123.052 0.541 . . . . 0.0 109.6 179.634 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' C' C ' 7' ' ' ASP . . . . . . . . . . . . . 8.6 m-20 -73.38 155.75 39.04 Favored 'General case' 0 N--CA 1.467 0.385 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.167 179.086 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' C' C ' 8' ' ' SER . . . . . . . . . . . . . 9.5 p -165.67 -176.98 4.13 Favored 'General case' 0 N--CA 1.482 1.167 0 CA-C-O 120.909 0.385 . . . . 0.0 110.567 178.748 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.87 44.01 1.58 Allowed Glycine 0 N--CA 1.483 1.781 0 CA-C-N 115.728 -0.669 . . . . 0.0 112.284 179.49 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 51.0 p90 -65.49 132.0 47.83 Favored 'General case' 0 N--CA 1.473 0.724 0 O-C-N 122.653 -0.322 . . . . 0.0 111.465 179.789 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 83.7 mt-10 -94.27 153.78 17.86 Favored 'General case' 0 N--CA 1.476 0.84 0 N-CA-C 109.634 -0.506 . . . . 0.0 109.634 178.507 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -153.43 128.52 1.52 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.61 0 N-CA-C 107.757 -1.201 . . . . 0.0 107.757 178.135 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 50.0 m-70 -135.33 144.57 46.78 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 119.084 0.856 . . . . 0.0 111.142 -179.104 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 6.3 t60 -165.65 98.71 0.68 Allowed 'General case' 0 N--CA 1.48 1.066 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.458 179.549 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' C' C ' 15' ' ' GLN . . . . . 0.425 HE22 ' H ' ' C' ' 37' ' ' GLY . 21.9 pt20 -124.24 155.47 38.53 Favored 'General case' 0 CA--C 1.503 -0.859 0 N-CA-C 107.865 -1.161 . . . . 0.0 107.865 -179.66 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -124.97 106.31 9.87 Favored 'General case' 0 N--CA 1.479 1.004 0 N-CA-C 108.208 -1.034 . . . . 0.0 108.208 177.969 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 6.1 mp -121.34 148.88 43.76 Favored 'General case' 0 N--CA 1.498 1.966 0 CA-C-O 121.474 0.654 . . . . 0.0 110.796 -178.433 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 29.0 t -107.74 124.53 63.88 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.088 0 N-CA-C 107.968 -1.123 . . . . 0.0 107.968 177.51 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' C' C ' 19' ' ' PHE . . . . . 0.517 ' O ' ' N ' ' C' ' 21' ' ' ALA . 25.5 m-85 -120.55 -161.05 0.86 Allowed 'General case' 0 N--CA 1.496 1.857 0 CA-C-N 119.936 1.244 . . . . 0.0 109.13 -179.674 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' C' C ' 20' ' ' PHE . . . . . 0.514 ' O ' ' HA ' ' F' ' 20' ' ' PHE . 77.8 m-85 -51.25 76.46 0.0 OUTLIER 'General case' 0 C--O 1.202 -1.414 0 C-N-CA 123.716 0.807 . . . . 0.0 111.404 -179.186 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' C' C ' 21' ' ' ALA . . . . . 0.517 ' N ' ' O ' ' C' ' 19' ' ' PHE . . . -88.26 -75.89 0.41 Allowed 'General case' 0 N--CA 1.47 0.533 0 CA-C-N 115.604 -0.725 . . . . 0.0 110.142 -179.7 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 40.8 tt0 -95.74 98.62 10.6 Favored 'General case' 0 N--CA 1.464 0.265 0 N-CA-C 108.482 -0.933 . . . . 0.0 108.482 179.326 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 4.1 p30 -159.51 144.77 15.66 Favored 'General case' 0 N--CA 1.482 1.172 0 O-C-N 122.287 -0.258 . . . . 0.0 110.985 179.616 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' C' C ' 24' ' ' VAL . . . . . 0.41 HG12 ' N ' ' C' ' 25' ' ' GLY . 89.7 t -62.76 163.8 1.43 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.765 0 N-CA-C 107.681 -1.229 . . . . 0.0 107.681 177.067 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' C' C ' 25' ' ' GLY . . . . . 0.516 ' H ' ' HB ' ' F' ' 24' ' ' VAL . . . -117.65 45.72 1.24 Allowed Glycine 0 N--CA 1.476 1.364 0 N-CA-C 111.724 -0.55 . . . . 0.0 111.724 -179.377 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -60.47 -165.1 0.01 OUTLIER 'General case' 0 N--CA 1.472 0.647 0 CA-C-O 120.61 0.243 . . . . 0.0 110.421 179.616 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 24.1 t-20 -70.52 80.62 0.57 Allowed 'General case' 0 N--CA 1.464 0.258 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.308 179.684 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -79.41 138.5 37.65 Favored 'General case' 0 N--CA 1.472 0.639 0 N-CA-C 109.222 -0.659 . . . . 0.0 109.222 179.333 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.96 -165.68 0.87 Allowed Glycine 0 CA--C 1.523 0.588 0 N-CA-C 109.614 -1.394 . . . . 0.0 109.614 178.322 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.88 113.81 26.6 Favored 'General case' 0 N--CA 1.474 0.745 0 N-CA-C 109.617 -0.512 . . . . 0.0 109.617 179.459 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 76.0 mt -99.67 135.12 36.5 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.591 0 N-CA-C 107.041 -1.466 . . . . 0.0 107.041 178.83 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' C' C ' 32' ' ' ILE . . . . . 0.409 ' C ' ' H ' ' C' ' 34' ' ' LEU . 26.8 pt -150.61 -171.91 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.353 0.741 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.296 -179.305 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.59 2.24 5.67 Favored Glycine 0 CA--C 1.524 0.615 0 N-CA-C 110.808 -0.917 . . . . 0.0 110.808 -179.893 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' C' C ' 34' ' ' LEU . . . . . 0.413 HD23 ' N ' ' C' ' 35' ' ' MET . 1.1 tt -74.43 133.28 42.42 Favored 'General case' 0 CA--C 1.544 0.725 0 N-CA-C 109.275 -0.639 . . . . 0.0 109.275 -179.59 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' C' C ' 35' ' ' MET . . . . . 0.413 ' N ' HD23 ' C' ' 34' ' ' LEU . 26.6 ttt -159.03 150.69 20.65 Favored 'General case' 0 N--CA 1.47 0.557 0 N-CA-C 108.477 -0.934 . . . . 0.0 108.477 178.786 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' C' C ' 36' ' ' VAL . . . . . 0.478 HG12 ' N ' ' C' ' 37' ' ' GLY . 62.7 t -153.64 162.82 2.01 Favored 'Isoleucine or valine' 0 C--N 1.344 0.336 0 N-CA-C 107.78 -1.193 . . . . 0.0 107.78 -179.695 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' C' C ' 37' ' ' GLY . . . . . 0.478 ' N ' HG12 ' C' ' 36' ' ' VAL . . . 57.85 67.37 2.24 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-N 115.488 -0.778 . . . . 0.0 112.043 178.549 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.65 177.41 22.06 Favored Glycine 0 N--CA 1.475 1.271 0 N-CA-C 111.027 -0.829 . . . . 0.0 111.027 178.736 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' C' C ' 39' ' ' VAL . . . . . 0.401 ' H ' HG12 ' F' ' 39' ' ' VAL . 33.6 m -109.16 152.67 11.15 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.647 0 C-N-CA 123.303 0.641 . . . . 0.0 110.19 -179.601 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 22.0 t . . . . . 0 C--O 1.216 -0.687 0 CA-C-O 118.273 -0.87 . . . . 0.0 110.581 179.608 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' D' D ' 1' ' ' ASP . . . . . . . . . . . . . 65.2 m-20 . . . . . 0 N--CA 1.491 1.587 0 N-CA-C 109.35 -0.611 . . . . 0.0 109.35 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' D' D ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.91 -170.31 0.08 Allowed 'General case' 0 CA--C 1.533 0.305 0 C-N-CA 123.252 0.621 . . . . 0.0 109.797 179.373 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' D' D ' 3' ' ' GLU . . . . . . . . . . . . . 23.6 tt0 -156.45 161.93 40.03 Favored 'General case' 0 N--CA 1.473 0.676 0 C-N-CA 123.522 0.729 . . . . 0.0 110.37 -172.856 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 34.1 p90 -75.12 135.42 41.14 Favored 'General case' 0 C--O 1.221 -0.423 0 N-CA-C 108.43 -0.952 . . . . 0.0 108.43 -172.236 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' D' D ' 5' ' ' ARG . . . . . . . . . . . . . 99.1 mtt180 -132.18 154.67 49.32 Favored 'General case' 0 N--CA 1.477 0.921 0 N-CA-C 109.163 -0.68 . . . . 0.0 109.163 -177.501 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 55.5 t-80 -115.78 121.65 43.06 Favored 'General case' 0 C--N 1.37 1.466 0 N-CA-C 107.827 -1.175 . . . . 0.0 107.827 176.283 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' D' D ' 7' ' ' ASP . . . . . 0.533 ' O ' ' OG ' ' G' ' 8' ' ' SER 0.279 5.0 m-20 -65.11 136.91 57.27 Favored 'General case' 0 C--N 1.313 -1.005 0 C-N-CA 129.589 3.155 . . . . 0.0 115.638 171.6 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' D' D ' 8' ' ' SER . . . . . 0.424 ' OG ' ' O ' ' A' ' 7' ' ' ASP . 7.0 p -153.4 -174.21 4.86 Favored 'General case' 0 N--CA 1.487 1.411 0 CA-C-N 120.825 1.648 . . . . 0.0 111.062 174.704 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 105.07 46.5 1.25 Allowed Glycine 0 N--CA 1.483 1.769 0 C-N-CA 125.071 1.319 . . . . 0.0 110.558 174.78 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 52.6 p90 -60.96 130.69 47.68 Favored 'General case' 0 N--CA 1.472 0.637 0 N-CA-C 112.543 0.572 . . . . 0.0 112.543 177.151 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 84.9 mt-10 -90.94 151.83 20.95 Favored 'General case' 0 N--CA 1.48 1.027 0 CA-C-N 118.029 0.377 . . . . 0.0 110.857 174.946 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -149.62 130.1 4.35 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.615 0 N-CA-C 107.355 -1.35 . . . . 0.0 107.355 172.829 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 47.0 m-70 -129.92 147.61 51.69 Favored 'General case' 0 N--CA 1.483 1.223 0 CA-C-N 118.102 0.41 . . . . 0.0 111.774 176.32 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 6.3 t60 -165.32 104.98 0.75 Allowed 'General case' 0 N--CA 1.485 1.303 0 N-CA-C 109.366 -0.605 . . . . 0.0 109.366 173.233 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' D' D ' 15' ' ' GLN . . . . . 0.461 HE22 ' H ' ' D' ' 37' ' ' GLY . 23.2 pt20 -128.59 148.38 50.78 Favored 'General case' 0 C--N 1.296 -1.726 0 C-N-CA 123.764 0.826 . . . . 0.0 108.879 -178.631 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -118.64 111.5 18.62 Favored 'General case' 0 N--CA 1.476 0.846 0 N-CA-C 107.486 -1.302 . . . . 0.0 107.486 177.054 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 5.0 mp -126.77 148.71 49.9 Favored 'General case' 0 N--CA 1.5 2.059 0 CA-C-O 122.068 0.937 . . . . 0.0 109.983 179.169 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 12.9 t -99.91 128.44 51.79 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.769 0 CA-C-O 116.37 -1.776 . . . . 0.0 109.691 174.939 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' D' D ' 19' ' ' PHE . . . . . 0.511 ' O ' ' N ' ' D' ' 21' ' ' ALA . 25.2 m-85 -127.43 -163.06 1.22 Allowed 'General case' 0 N--CA 1.499 1.977 0 CA-C-N 120.686 1.584 . . . . 0.0 107.681 -179.966 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' D' D ' 20' ' ' PHE . . . . . 0.555 ' HA ' ' O ' ' A' ' 20' ' ' PHE . 90.1 m-85 -53.22 70.73 0.0 OUTLIER 'General case' 0 C--O 1.198 -1.62 0 C-N-CA 126.344 1.857 . . . . 0.0 111.44 -174.517 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' D' D ' 21' ' ' ALA . . . . . 0.511 ' N ' ' O ' ' D' ' 19' ' ' PHE . . . -86.39 -74.18 0.43 Allowed 'General case' 0 C--N 1.362 1.117 0 CA-C-N 114.922 -1.036 . . . . 0.0 109.701 -175.945 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 41.1 tt0 -98.82 102.99 14.9 Favored 'General case' 0 N--CA 1.483 1.212 0 N-CA-C 106.577 -1.638 . . . . 0.0 106.577 178.108 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 4.2 p30 -152.4 143.92 23.43 Favored 'General case' 0 N--CA 1.476 0.872 0 CA-C-O 116.783 -1.58 . . . . 0.0 113.501 178.551 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' D' D ' 24' ' ' VAL . . . . . 0.5 ' HB ' ' H ' ' A' ' 25' ' ' GLY . 89.3 t -64.46 165.26 1.46 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.351 0 CA-C-N 120.952 1.705 . . . . 0.0 107.584 173.953 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' D' D ' 25' ' ' GLY . . . . . 0.581 ' H ' ' HB ' ' G' ' 24' ' ' VAL . . . -117.02 51.1 0.75 Allowed Glycine 0 N--CA 1.48 1.573 0 CA-C-O 118.885 -0.953 . . . . 0.0 111.575 177.849 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -57.87 -168.74 0.01 OUTLIER 'General case' 0 C--N 1.321 -0.655 0 C-N-CA 124.037 0.935 . . . . 0.0 111.491 175.509 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 25.7 t-20 -72.33 86.86 1.12 Allowed 'General case' 0 C--N 1.35 0.588 0 C-N-CA 119.003 -1.079 . . . . 0.0 108.598 178.455 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 96.4 mttt -83.47 141.19 31.84 Favored 'General case' 0 C--N 1.352 0.688 0 N-CA-C 108.181 -1.044 . . . . 0.0 108.181 178.596 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -62.47 -164.69 0.43 Allowed Glycine 0 C--N 1.333 0.394 0 N-CA-C 110.451 -1.06 . . . . 0.0 110.451 177.463 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -102.28 115.88 31.48 Favored 'General case' 0 N--CA 1.471 0.595 0 N-CA-C 108.727 -0.842 . . . . 0.0 108.727 178.735 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 82.9 mt -102.91 142.57 16.66 Favored 'Isoleucine or valine' 0 C--N 1.356 0.889 0 N-CA-C 104.949 -2.241 . . . . 0.0 104.949 179.215 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' D' D ' 32' ' ' ILE . . . . . 0.426 HG22 ' H ' ' G' ' 32' ' ' ILE . 27.4 pt -157.18 -172.41 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.109 0 CA-C-O 120.759 0.314 . . . . 0.0 110.219 -178.141 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.95 2.13 6.12 Favored Glycine 0 N--CA 1.465 0.615 0 N-CA-C 110.513 -1.035 . . . . 0.0 110.513 -178.706 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 1.3 tt -75.85 138.05 40.86 Favored 'General case' 0 C--N 1.354 0.777 0 N-CA-C 107.729 -1.211 . . . . 0.0 107.729 -178.311 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 25.3 ttt -156.5 160.73 39.8 Favored 'General case' 0 C--O 1.237 0.444 0 N-CA-C 107.877 -1.157 . . . . 0.0 107.877 175.009 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' D' D ' 36' ' ' VAL . . . . . 0.484 HG12 ' N ' ' D' ' 37' ' ' GLY . 97.0 t -163.2 163.83 0.8 Allowed 'Isoleucine or valine' 0 CA--C 1.517 -0.326 0 N-CA-C 107.021 -1.474 . . . . 0.0 107.021 177.03 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' D' D ' 37' ' ' GLY . . . . . 0.484 ' N ' HG12 ' D' ' 36' ' ' VAL . . . 60.61 63.55 4.89 Favored Glycine 0 CA--C 1.528 0.874 0 C-N-CA 120.075 -1.06 . . . . 0.0 112.888 179.869 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 146.24 178.63 21.81 Favored Glycine 0 N--CA 1.481 1.639 0 CA-C-N 117.801 0.8 . . . . 0.0 111.588 179.803 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 34.5 m -112.69 149.89 15.04 Favored 'Isoleucine or valine' 0 C--N 1.357 0.911 0 N-CA-C 109.432 -0.581 . . . . 0.0 109.432 -176.943 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 21.8 t . . . . . 0 CA--C 1.52 -0.179 0 CA-C-O 115.976 -1.964 . . . . 0.0 109.604 178.486 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' E' E ' 1' ' ' ASP . . . . . . . . . . . . . 66.4 m-20 . . . . . 0 N--CA 1.491 1.575 0 N-CA-C 109.362 -0.607 . . . . 0.0 109.362 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' E' E ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.13 -168.6 0.04 OUTLIER 'General case' 0 N--CA 1.467 0.379 0 CA-C-N 116.319 -0.401 . . . . 0.0 110.74 -179.967 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' E' E ' 3' ' ' GLU . . . . . . . . . . . . . 25.0 tt0 -153.82 166.8 31.77 Favored 'General case' 0 N--CA 1.473 0.692 0 CA-C-N 116.508 -0.314 . . . . 0.0 110.37 -179.574 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 21.7 p90 -67.02 137.59 56.58 Favored 'General case' 0 C--O 1.217 -0.626 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.662 -178.476 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' E' E ' 5' ' ' ARG . . . . . . . . . . . . . 99.0 mtt180 -136.89 154.11 50.56 Favored 'General case' 0 N--CA 1.479 0.992 0 N-CA-C 109.433 -0.58 . . . . 0.0 109.433 178.539 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 58.4 t-80 -114.31 114.5 26.02 Favored 'General case' 0 N--CA 1.48 1.032 0 N-CA-C 109.68 -0.489 . . . . 0.0 109.68 179.581 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' E' E ' 7' ' ' ASP . . . . . 0.42 ' O ' ' OG ' ' H' ' 8' ' ' SER . 7.9 m-20 -73.27 156.29 38.63 Favored 'General case' 0 N--CA 1.466 0.352 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.173 179.095 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' E' E ' 8' ' ' SER . . . . . 0.419 ' OG ' ' O ' ' B' ' 7' ' ' ASP . 5.4 p -166.72 -175.06 2.98 Favored 'General case' 0 N--CA 1.485 1.31 0 CA-C-O 121.17 0.509 . . . . 0.0 110.727 178.388 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.48 44.12 1.61 Allowed Glycine 0 N--CA 1.48 1.59 0 CA-C-N 115.577 -0.738 . . . . 0.0 112.169 179.294 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 49.7 p90 -64.9 131.93 48.02 Favored 'General case' 0 CA--C 1.542 0.672 0 N-CA-C 111.769 0.285 . . . . 0.0 111.769 -179.922 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 86.8 mt-10 -93.55 153.81 18.22 Favored 'General case' 0 N--CA 1.48 1.027 0 CA-C-O 121.163 0.506 . . . . 0.0 109.654 178.074 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -154.72 127.24 1.05 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.546 0 N-CA-C 107.782 -1.192 . . . . 0.0 107.782 177.917 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 48.7 m-70 -135.09 142.61 46.3 Favored 'General case' 0 N--CA 1.483 1.185 0 CA-C-O 120.739 0.304 . . . . 0.0 111.473 -178.009 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 6.2 t60 -164.46 98.83 0.81 Allowed 'General case' 0 N--CA 1.486 1.364 0 CA-C-N 116.448 -0.342 . . . . 0.0 110.327 179.594 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' E' E ' 15' ' ' GLN . . . . . 0.441 HE22 ' H ' ' E' ' 37' ' ' GLY . 22.1 pt20 -123.63 155.57 37.46 Favored 'General case' 0 CA--C 1.503 -0.83 0 N-CA-C 108.243 -1.021 . . . . 0.0 108.243 -179.588 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -125.14 105.88 9.49 Favored 'General case' 0 N--CA 1.484 1.269 0 N-CA-C 108.216 -1.031 . . . . 0.0 108.216 178.145 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 6.0 mp -120.58 148.42 43.9 Favored 'General case' 0 N--CA 1.494 1.74 0 CA-C-O 121.123 0.487 . . . . 0.0 111.293 -178.063 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 21.8 t -109.62 120.53 60.97 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.146 0 N-CA-C 108.126 -1.065 . . . . 0.0 108.126 177.313 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' E' E ' 19' ' ' PHE . . . . . 0.54 ' O ' ' N ' ' E' ' 21' ' ' ALA . 28.5 m-85 -117.11 -162.98 0.89 Allowed 'General case' 0 N--CA 1.495 1.8 0 C-N-CA 122.911 0.485 . . . . 0.0 109.749 -179.365 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' E' E ' 20' ' ' PHE . . . . . 0.512 ' HA ' ' O ' ' B' ' 20' ' ' PHE . 77.2 m-85 -47.76 75.3 0.0 OUTLIER 'General case' 0 C--O 1.206 -1.202 0 C-N-CA 124.288 1.035 . . . . 0.0 111.551 -179.887 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' E' E ' 21' ' ' ALA . . . . . 0.54 ' N ' ' O ' ' E' ' 19' ' ' PHE . . . -87.82 -75.46 0.41 Allowed 'General case' 0 N--CA 1.469 0.52 0 C-N-CA 122.536 0.335 . . . . 0.0 110.399 -179.162 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 41.2 tt0 -96.78 98.92 10.54 Favored 'General case' 0 N--CA 1.463 0.197 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 179.469 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 4.1 p30 -158.58 144.59 16.9 Favored 'General case' 0 N--CA 1.481 1.078 0 O-C-N 122.356 -0.215 . . . . 0.0 111.166 179.821 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' E' E ' 24' ' ' VAL . . . . . 0.495 ' HB ' ' H ' ' B' ' 25' ' ' GLY . 89.5 t -61.8 167.32 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.944 0 N-CA-C 106.925 -1.509 . . . . 0.0 106.925 176.86 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' E' E ' 25' ' ' GLY . . . . . 0.491 ' H ' ' HB ' ' H' ' 24' ' ' VAL . . . -121.48 46.76 1.08 Allowed Glycine 0 N--CA 1.472 1.069 0 N-CA-C 111.163 -0.775 . . . . 0.0 111.163 -179.195 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -61.81 -164.43 0.01 OUTLIER 'General case' 0 N--CA 1.471 0.58 0 CA-C-N 116.943 0.371 . . . . 0.0 110.541 -179.948 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 24.6 t-20 -70.07 77.23 0.5 Allowed 'General case' 0 CA--C 1.533 0.319 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.693 -179.785 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 97.1 mttt -76.14 139.0 41.1 Favored 'General case' 0 N--CA 1.474 0.754 0 N-CA-C 109.715 -0.476 . . . . 0.0 109.715 179.394 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.64 -165.62 1.06 Allowed Glycine 0 C--N 1.335 0.486 0 N-CA-C 109.909 -1.276 . . . . 0.0 109.909 178.011 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.68 113.09 25.32 Favored 'General case' 0 N--CA 1.473 0.711 0 N-CA-C 109.805 -0.442 . . . . 0.0 109.805 179.494 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 75.9 mt -99.07 135.24 34.98 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.447 0 N-CA-C 106.893 -1.521 . . . . 0.0 106.893 178.768 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' E' E ' 32' ' ' ILE . . . . . 0.428 HG22 ' H ' ' H' ' 32' ' ' ILE . 28.3 pt -150.58 -170.31 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.099 0 CA-C-O 120.949 0.404 . . . . 0.0 110.755 -179.471 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.9 2.49 3.72 Favored Glycine 0 CA--C 1.529 0.92 0 N-CA-C 111.476 -0.65 . . . . 0.0 111.476 -179.59 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' E' E ' 34' ' ' LEU . . . . . 0.409 ' H ' ' C ' ' E' ' 32' ' ' ILE . 1.1 tt -73.89 133.73 43.15 Favored 'General case' 0 CA--C 1.545 0.78 0 N-CA-C 109.095 -0.706 . . . . 0.0 109.095 -179.7 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 25.0 ttt -159.34 149.56 19.12 Favored 'General case' 0 N--CA 1.473 0.69 0 N-CA-C 108.567 -0.901 . . . . 0.0 108.567 178.751 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' E' E ' 36' ' ' VAL . . . . . 0.476 HG12 ' N ' ' E' ' 37' ' ' GLY . 61.6 t -152.68 162.78 2.3 Favored 'Isoleucine or valine' 0 C--N 1.345 0.384 0 N-CA-C 108.228 -1.027 . . . . 0.0 108.228 -179.681 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' E' E ' 37' ' ' GLY . . . . . 0.476 ' N ' HG12 ' E' ' 36' ' ' VAL . . . 57.1 67.44 2.22 Favored Glycine 0 C--N 1.309 -0.93 0 CA-C-N 115.473 -0.785 . . . . 0.0 112.012 178.694 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.29 174.94 19.73 Favored Glycine 0 N--CA 1.476 1.325 0 N-CA-C 111.285 -0.726 . . . . 0.0 111.285 178.825 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 31.2 m -107.16 152.55 8.65 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.638 0 C-N-CA 123.475 0.71 . . . . 0.0 110.372 -179.079 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 21.9 t . . . . . 0 C--O 1.214 -0.784 0 O-C-N 124.222 0.951 . . . . 0.0 110.519 179.922 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' F' F ' 1' ' ' ASP . . . . . . . . . . . . . 66.1 m-20 . . . . . 0 N--CA 1.492 1.637 0 N-CA-C 109.327 -0.62 . . . . 0.0 109.327 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' F' F ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.75 -168.24 0.03 OUTLIER 'General case' 0 N--CA 1.467 0.394 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.602 -179.943 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' F' F ' 3' ' ' GLU . . . . . . . . . . . . . 24.8 tt0 -154.02 166.86 31.69 Favored 'General case' 0 N--CA 1.474 0.733 0 CA-C-N 116.429 -0.35 . . . . 0.0 110.291 -179.523 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 22.5 p90 -67.26 137.57 56.23 Favored 'General case' 0 C--O 1.218 -0.587 0 CA-C-N 116.251 -0.432 . . . . 0.0 110.575 -178.497 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' F' F ' 5' ' ' ARG . . . . . . . . . . . . . 99.0 mtt180 -136.73 154.04 50.7 Favored 'General case' 0 N--CA 1.478 0.937 0 N-CA-C 109.409 -0.589 . . . . 0.0 109.409 178.49 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 58.1 t-80 -114.45 114.54 25.96 Favored 'General case' 0 N--CA 1.48 1.027 0 C-N-CA 122.909 0.483 . . . . 0.0 109.76 179.534 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' F' F ' 7' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -73.28 156.39 38.52 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.274 179.129 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' F' F ' 8' ' ' SER . . . . . 0.421 ' HA ' ' OG ' ' I' ' 8' ' ' SER . 5.4 p -166.87 -174.99 2.9 Favored 'General case' 0 N--CA 1.485 1.301 0 CA-C-O 121.023 0.439 . . . . 0.0 110.936 178.468 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.38 43.69 1.69 Allowed Glycine 0 N--CA 1.479 1.543 0 CA-C-N 115.757 -0.656 . . . . 0.0 112.149 179.199 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 49.9 p90 -64.4 132.31 49.69 Favored 'General case' 0 CA--C 1.544 0.724 0 O-C-N 122.632 -0.334 . . . . 0.0 111.813 -179.945 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 86.7 mt-10 -93.73 153.59 18.25 Favored 'General case' 0 N--CA 1.48 1.067 0 N-CA-C 109.636 -0.505 . . . . 0.0 109.636 178.085 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -154.57 127.18 1.07 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.545 0 N-CA-C 107.811 -1.181 . . . . 0.0 107.811 177.885 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 46.6 m-70 -135.06 142.77 46.4 Favored 'General case' 0 N--CA 1.483 1.215 0 CA-C-O 120.77 0.319 . . . . 0.0 111.515 -178.131 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 6.2 t60 -164.55 98.7 0.8 Allowed 'General case' 0 N--CA 1.485 1.302 0 CA-C-N 116.465 -0.334 . . . . 0.0 110.437 179.62 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' F' F ' 15' ' ' GLN . . . . . 0.426 HE22 ' H ' ' F' ' 37' ' ' GLY . 22.2 pt20 -123.52 155.61 37.23 Favored 'General case' 0 CA--C 1.501 -0.914 0 N-CA-C 108.225 -1.028 . . . . 0.0 108.225 -179.527 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -125.09 105.89 9.51 Favored 'General case' 0 N--CA 1.485 1.286 0 N-CA-C 108.245 -1.02 . . . . 0.0 108.245 178.104 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 6.0 mp -120.64 148.21 44.21 Favored 'General case' 0 N--CA 1.495 1.811 0 CA-C-O 121.168 0.509 . . . . 0.0 111.181 -178.009 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 21.7 t -109.45 120.3 60.42 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.167 0 N-CA-C 108.13 -1.063 . . . . 0.0 108.13 177.244 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' F' F ' 19' ' ' PHE . . . . . 0.539 ' O ' ' N ' ' F' ' 21' ' ' ALA . 28.4 m-85 -116.76 -162.7 0.87 Allowed 'General case' 0 N--CA 1.494 1.763 0 C-N-CA 122.919 0.487 . . . . 0.0 109.864 -179.436 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' F' F ' 20' ' ' PHE . . . . . 0.514 ' HA ' ' O ' ' C' ' 20' ' ' PHE . 78.3 m-85 -48.04 75.1 0.0 OUTLIER 'General case' 0 C--O 1.206 -1.229 0 C-N-CA 124.3 1.04 . . . . 0.0 111.466 -179.878 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' F' F ' 21' ' ' ALA . . . . . 0.539 ' N ' ' O ' ' F' ' 19' ' ' PHE . . . -87.38 -77.08 0.35 Allowed 'General case' 0 N--CA 1.466 0.369 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.044 -179.386 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 41.2 tt0 -95.21 99.29 11.27 Favored 'General case' 0 N--CA 1.462 0.173 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 179.49 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 4.1 p30 -158.8 144.8 16.73 Favored 'General case' 0 N--CA 1.481 1.097 0 CA-C-O 119.655 -0.212 . . . . 0.0 111.304 179.745 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' F' F ' 24' ' ' VAL . . . . . 0.516 ' HB ' ' H ' ' C' ' 25' ' ' GLY . 88.8 t -61.98 167.3 0.77 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.93 0 N-CA-C 106.933 -1.506 . . . . 0.0 106.933 176.894 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' F' F ' 25' ' ' GLY . . . . . 0.479 ' H ' ' HB ' ' I' ' 24' ' ' VAL . . . -121.67 46.88 1.07 Allowed Glycine 0 N--CA 1.478 1.44 0 N-CA-C 110.88 -0.888 . . . . 0.0 110.88 -179.239 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -61.89 -164.43 0.01 OUTLIER 'General case' 0 N--CA 1.471 0.612 0 CA-C-N 116.887 0.343 . . . . 0.0 110.436 -179.977 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 24.6 t-20 -69.88 77.11 0.47 Allowed 'General case' 0 CA--C 1.533 0.297 0 CA-C-N 116.319 -0.401 . . . . 0.0 110.752 -179.779 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -76.09 138.97 41.14 Favored 'General case' 0 N--CA 1.475 0.807 0 N-CA-C 109.638 -0.504 . . . . 0.0 109.638 179.451 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.47 -165.36 0.96 Allowed Glycine 0 C--N 1.335 0.484 0 N-CA-C 110.081 -1.207 . . . . 0.0 110.081 177.99 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.92 112.82 25.08 Favored 'General case' 0 N--CA 1.472 0.638 0 N-CA-C 109.695 -0.483 . . . . 0.0 109.695 179.511 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 76.1 mt -98.99 135.3 34.6 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.498 0 N-CA-C 106.882 -1.525 . . . . 0.0 106.882 178.84 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' F' F ' 32' ' ' ILE . . . . . 0.441 HG22 ' H ' ' I' ' 32' ' ' ILE . 28.2 pt -150.64 -170.19 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.128 0 CA-C-O 120.988 0.423 . . . . 0.0 110.777 -179.516 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.99 2.28 3.65 Favored Glycine 0 CA--C 1.53 1.006 0 N-CA-C 111.409 -0.676 . . . . 0.0 111.409 -179.673 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' F' F ' 34' ' ' LEU . . . . . 0.411 HD23 ' N ' ' F' ' 35' ' ' MET . 1.1 tt -73.91 133.72 43.13 Favored 'General case' 0 CA--C 1.546 0.798 0 N-CA-C 109.128 -0.693 . . . . 0.0 109.128 -179.654 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' F' F ' 35' ' ' MET . . . . . 0.411 ' N ' HD23 ' F' ' 34' ' ' LEU . 25.1 ttt -159.4 149.74 19.16 Favored 'General case' 0 N--CA 1.47 0.573 0 N-CA-C 108.563 -0.903 . . . . 0.0 108.563 178.832 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' F' F ' 36' ' ' VAL . . . . . 0.479 HG12 ' N ' ' F' ' 37' ' ' GLY . 62.2 t -152.83 162.84 2.21 Favored 'Isoleucine or valine' 0 C--N 1.345 0.37 0 N-CA-C 108.169 -1.049 . . . . 0.0 108.169 -179.667 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' F' F ' 37' ' ' GLY . . . . . 0.479 ' N ' HG12 ' F' ' 36' ' ' VAL . . . 57.1 67.44 2.22 Favored Glycine 0 C--N 1.308 -0.974 0 CA-C-N 115.433 -0.803 . . . . 0.0 112.004 178.626 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.34 175.04 19.85 Favored Glycine 0 N--CA 1.475 1.275 0 N-CA-C 111.248 -0.741 . . . . 0.0 111.248 178.848 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' F' F ' 39' ' ' VAL . . . . . 0.404 ' H ' HG12 ' I' ' 39' ' ' VAL . 31.4 m -107.27 152.41 8.85 Favored 'Isoleucine or valine' 0 C--N 1.35 0.597 0 C-N-CA 123.546 0.738 . . . . 0.0 110.361 -179.025 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 22.0 t . . . . . 0 C--O 1.213 -0.821 0 O-C-N 124.216 0.948 . . . . 0.0 110.385 179.804 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' G' G ' 1' ' ' ASP . . . . . . . . . . . . . 65.3 m-20 . . . . . 0 N--CA 1.49 1.558 0 N-CA-C 109.029 -0.73 . . . . 0.0 109.029 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' G' G ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.78 -165.98 0.03 OUTLIER 'General case' 0 N--CA 1.467 0.4 0 CA-C-N 116.591 -0.277 . . . . 0.0 110.758 -179.814 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' G' G ' 3' ' ' GLU . . . . . . . . . . . . . 24.8 tt0 -154.87 166.95 31.9 Favored 'General case' 0 N--CA 1.474 0.74 0 CA-C-O 120.709 0.29 . . . . 0.0 110.632 -179.056 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 20.1 p90 -66.71 137.3 56.58 Favored 'General case' 0 N--CA 1.472 0.625 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.339 -178.643 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' G' G ' 5' ' ' ARG . . . . . . . . . . . . . 99.1 mtt180 -136.54 154.04 50.83 Favored 'General case' 0 N--CA 1.482 1.13 0 N-CA-C 109.463 -0.569 . . . . 0.0 109.463 178.555 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 58.3 t-80 -114.1 115.54 27.7 Favored 'General case' 0 N--CA 1.483 1.207 0 C-N-CA 122.823 0.449 . . . . 0.0 109.891 179.649 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 -75.86 152.46 37.2 Favored 'General case' 0 N--CA 1.47 0.569 0 CA-C-N 116.0 -0.545 . . . . 0.0 110.772 179.279 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' G' G ' 8' ' ' SER . . . . . 0.533 ' OG ' ' O ' ' D' ' 7' ' ' ASP . 4.9 p -164.03 -172.39 2.78 Favored 'General case' 0 N--CA 1.475 0.775 0 CA-C-O 121.105 0.479 . . . . 0.0 110.596 178.621 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.12 43.6 1.87 Allowed Glycine 0 N--CA 1.479 1.563 0 CA-C-N 115.633 -0.712 . . . . 0.0 111.655 178.983 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 51.0 p90 -64.2 132.23 49.75 Favored 'General case' 0 CA--C 1.542 0.67 0 CA-C-O 120.648 0.261 . . . . 0.0 111.664 -179.772 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 84.1 mt-10 -94.01 152.88 18.49 Favored 'General case' 0 N--CA 1.479 1.008 0 CA-C-O 121.035 0.445 . . . . 0.0 110.057 178.644 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -155.21 127.55 1.03 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.016 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 178.179 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 49.9 m-70 -134.63 144.05 47.65 Favored 'General case' 0 N--CA 1.478 0.925 0 CA-C-N 115.416 -0.811 . . . . 0.0 111.405 -178.326 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 30.5 t-80 -166.12 98.74 0.63 Allowed 'General case' 0 N--CA 1.481 1.12 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.122 178.977 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' G' G ' 15' ' ' GLN . . . . . 0.436 HE22 ' H ' ' G' ' 37' ' ' GLY . 22.3 pt20 -123.91 154.95 38.99 Favored 'General case' 0 CA--C 1.497 -1.07 0 N-CA-C 107.998 -1.112 . . . . 0.0 107.998 -179.287 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -124.8 106.19 9.85 Favored 'General case' 0 N--CA 1.483 1.192 0 N-CA-C 108.04 -1.096 . . . . 0.0 108.04 178.151 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 6.0 mp -120.22 148.76 43.27 Favored 'General case' 0 N--CA 1.496 1.85 0 CA-C-O 121.091 0.472 . . . . 0.0 111.625 -178.244 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 20.4 t -111.11 120.21 61.29 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.043 0 N-CA-C 107.775 -1.194 . . . . 0.0 107.775 176.909 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' G' G ' 19' ' ' PHE . . . . . 0.556 ' O ' ' N ' ' G' ' 21' ' ' ALA . 28.1 m-85 -117.17 -164.58 1.0 Allowed 'General case' 0 N--CA 1.494 1.728 0 C-N-CA 124.372 1.069 . . . . 0.0 110.225 -178.846 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' G' G ' 20' ' ' PHE . . . . . 0.507 ' HA ' ' O ' ' D' ' 20' ' ' PHE . 78.4 m-85 -47.13 73.02 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.03 0 C-N-CA 124.522 1.129 . . . . 0.0 111.664 -179.83 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' G' G ' 21' ' ' ALA . . . . . 0.556 ' N ' ' O ' ' G' ' 19' ' ' PHE . . . -85.37 -78.23 0.27 Allowed 'General case' 0 N--CA 1.466 0.364 0 C-N-CA 122.715 0.406 . . . . 0.0 110.246 -178.901 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 41.0 tt0 -94.6 99.8 11.87 Favored 'General case' 0 N--CA 1.465 0.284 0 N-CA-C 108.284 -1.006 . . . . 0.0 108.284 179.364 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 4.1 p30 -159.17 144.83 16.23 Favored 'General case' 0 N--CA 1.477 0.91 0 O-C-N 122.313 -0.242 . . . . 0.0 111.226 179.745 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' G' G ' 24' ' ' VAL . . . . . 0.581 ' HB ' ' H ' ' D' ' 25' ' ' GLY . 92.4 t -62.48 165.74 1.02 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.655 0 N-CA-C 107.283 -1.377 . . . . 0.0 107.283 177.231 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' G' G ' 25' ' ' GLY . . . . . 0.408 ' N ' HG12 ' G' ' 24' ' ' VAL . . . -119.86 48.85 0.91 Allowed Glycine 0 N--CA 1.482 1.734 0 N-CA-C 110.587 -1.005 . . . . 0.0 110.587 -179.66 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -64.11 -164.65 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.669 0 CA-C-N 117.194 0.497 . . . . 0.0 109.752 179.787 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 24.8 t-20 -69.97 76.81 0.48 Allowed 'General case' 0 N--CA 1.467 0.415 0 CA-C-N 116.428 -0.351 . . . . 0.0 110.775 -179.699 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -75.2 139.02 42.35 Favored 'General case' 0 N--CA 1.474 0.759 0 N-CA-C 109.724 -0.473 . . . . 0.0 109.724 179.319 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.75 -164.48 0.9 Allowed Glycine 0 C--N 1.337 0.63 0 N-CA-C 109.679 -1.369 . . . . 0.0 109.679 178.185 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.71 113.04 25.25 Favored 'General case' 0 N--CA 1.467 0.412 0 C-N-CA 122.681 0.392 . . . . 0.0 110.204 179.627 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 77.8 mt -99.7 135.42 35.27 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.825 0 N-CA-C 106.932 -1.506 . . . . 0.0 106.932 178.789 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' G' G ' 32' ' ' ILE . . . . . 0.426 ' H ' HG22 ' D' ' 32' ' ' ILE . 30.4 pt -151.09 -169.13 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.745 0 CA-C-N 119.448 1.022 . . . . 0.0 109.946 179.963 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.98 2.42 3.76 Favored Glycine 0 CA--C 1.528 0.861 0 N-CA-C 111.253 -0.739 . . . . 0.0 111.253 -179.749 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' G' G ' 34' ' ' LEU . . . . . 0.415 HD23 ' N ' ' G' ' 35' ' ' MET . 1.1 tt -74.57 133.28 42.25 Favored 'General case' 0 CA--C 1.543 0.687 0 N-CA-C 109.156 -0.683 . . . . 0.0 109.156 -179.586 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' G' G ' 35' ' ' MET . . . . . 0.415 ' N ' HD23 ' G' ' 34' ' ' LEU . 23.8 ttt -159.04 150.27 20.26 Favored 'General case' 0 N--CA 1.469 0.486 0 N-CA-C 108.59 -0.893 . . . . 0.0 108.59 179.126 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' G' G ' 36' ' ' VAL . . . . . 0.445 HG12 ' N ' ' G' ' 37' ' ' GLY . 62.5 t -153.8 161.35 2.44 Favored 'Isoleucine or valine' 0 C--N 1.346 0.426 0 N-CA-C 108.05 -1.093 . . . . 0.0 108.05 -179.5 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' G' G ' 37' ' ' GLY . . . . . 0.445 ' N ' HG12 ' G' ' 36' ' ' VAL . . . 58.43 67.45 2.19 Favored Glycine 0 C--N 1.309 -0.957 0 CA-C-N 115.331 -0.85 . . . . 0.0 111.91 178.566 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.44 174.37 19.36 Favored Glycine 0 N--CA 1.477 1.383 0 N-CA-C 110.641 -0.983 . . . . 0.0 110.641 178.872 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 32.9 m -107.02 152.16 8.62 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.912 0 C-N-CA 123.256 0.622 . . . . 0.0 110.487 -179.453 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 22.7 t . . . . . 0 C--O 1.217 -0.63 0 CA-C-O 118.373 -0.822 . . . . 0.0 110.688 179.867 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' H' H ' 1' ' ' ASP . . . . . . . . . . . . . 64.8 m-20 . . . . . 0 N--CA 1.49 1.57 0 N-CA-C 109.215 -0.661 . . . . 0.0 109.215 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' H' H ' 2' ' ' ALA . . . . . . . . . . . . . . . -66.07 -165.65 0.03 OUTLIER 'General case' 0 N--CA 1.466 0.339 0 CA-C-N 116.588 -0.278 . . . . 0.0 110.709 -179.758 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' H' H ' 3' ' ' GLU . . . . . . . . . . . . . 24.5 tt0 -155.22 166.91 32.09 Favored 'General case' 0 N--CA 1.473 0.694 0 CA-C-O 120.739 0.304 . . . . 0.0 110.588 -178.982 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 20.4 p90 -66.77 137.03 56.34 Favored 'General case' 0 N--CA 1.472 0.636 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.313 -178.592 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' H' H ' 5' ' ' ARG . . . . . . . . . . . . . 99.1 mtt180 -136.18 153.84 51.13 Favored 'General case' 0 N--CA 1.484 1.258 0 N-CA-C 109.398 -0.593 . . . . 0.0 109.398 178.571 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 58.4 t-80 -113.91 115.31 27.48 Favored 'General case' 0 N--CA 1.482 1.129 0 C-N-CA 122.829 0.452 . . . . 0.0 109.96 179.521 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -75.55 152.7 37.72 Favored 'General case' 0 N--CA 1.47 0.57 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.681 179.295 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' H' H ' 8' ' ' SER . . . . . 0.42 ' OG ' ' O ' ' E' ' 7' ' ' ASP . 6.9 p -164.17 -172.67 2.85 Favored 'General case' 0 N--CA 1.474 0.731 0 CA-C-O 121.113 0.482 . . . . 0.0 110.683 178.63 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.13 43.67 1.86 Allowed Glycine 0 N--CA 1.48 1.599 0 CA-C-N 115.79 -0.641 . . . . 0.0 111.765 179.157 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 51.0 p90 -64.44 132.28 49.56 Favored 'General case' 0 CA--C 1.541 0.61 0 O-C-N 122.68 -0.306 . . . . 0.0 111.709 -179.878 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 84.4 mt-10 -94.04 152.92 18.45 Favored 'General case' 0 N--CA 1.478 0.936 0 CA-C-O 121.095 0.474 . . . . 0.0 110.082 178.651 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -155.27 127.12 0.96 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.032 0 N-CA-C 108.03 -1.1 . . . . 0.0 108.03 178.176 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 48.9 m-70 -134.32 143.84 47.93 Favored 'General case' 0 N--CA 1.479 1.016 0 CA-C-N 115.415 -0.811 . . . . 0.0 111.348 -178.183 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 6.3 t60 -165.96 98.94 0.65 Allowed 'General case' 0 N--CA 1.484 1.227 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.012 178.958 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' H' H ' 15' ' ' GLN . . . . . 0.428 HE22 ' H ' ' H' ' 37' ' ' GLY . 22.5 pt20 -124.07 154.77 39.47 Favored 'General case' 0 CA--C 1.495 -1.135 0 N-CA-C 108.054 -1.091 . . . . 0.0 108.054 -179.339 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -124.52 106.06 9.87 Favored 'General case' 0 N--CA 1.483 1.204 0 N-CA-C 108.156 -1.054 . . . . 0.0 108.156 178.107 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 6.0 mp -120.17 148.58 43.46 Favored 'General case' 0 N--CA 1.496 1.868 0 CA-C-O 121.072 0.463 . . . . 0.0 111.567 -178.201 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 20.2 t -110.61 121.02 62.64 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.008 0 N-CA-C 107.777 -1.194 . . . . 0.0 107.777 176.776 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' H' H ' 19' ' ' PHE . . . . . 0.56 ' O ' ' N ' ' H' ' 21' ' ' ALA . 27.4 m-85 -117.95 -164.32 1.0 Allowed 'General case' 0 N--CA 1.492 1.675 0 C-N-CA 124.268 1.027 . . . . 0.0 110.127 -178.734 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' H' H ' 20' ' ' PHE . . . . . 0.485 ' HA ' ' O ' ' E' ' 20' ' ' PHE . 79.1 m-85 -47.53 73.03 0.0 OUTLIER 'General case' 0 N--CA 1.481 1.081 0 C-N-CA 124.425 1.09 . . . . 0.0 111.621 -179.78 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' H' H ' 21' ' ' ALA . . . . . 0.56 ' N ' ' O ' ' H' ' 19' ' ' PHE . . . -85.13 -77.8 0.27 Allowed 'General case' 0 N--CA 1.466 0.339 0 C-N-CA 122.744 0.417 . . . . 0.0 110.432 -179.018 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 41.1 tt0 -95.14 99.48 11.45 Favored 'General case' 0 N--CA 1.465 0.303 0 N-CA-C 108.313 -0.995 . . . . 0.0 108.313 179.439 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 4.2 p30 -158.76 145.06 16.97 Favored 'General case' 0 N--CA 1.478 0.938 0 O-C-N 122.475 -0.14 . . . . 0.0 111.188 179.874 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' H' H ' 24' ' ' VAL . . . . . 0.491 ' HB ' ' H ' ' E' ' 25' ' ' GLY . 88.8 t -62.65 165.45 1.09 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.594 0 N-CA-C 107.247 -1.39 . . . . 0.0 107.247 177.113 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' H' H ' 25' ' ' GLY . . . . . 0.41 ' N ' HG12 ' H' ' 24' ' ' VAL . . . -119.49 48.69 0.92 Allowed Glycine 0 N--CA 1.48 1.582 0 N-CA-C 110.625 -0.99 . . . . 0.0 110.625 -179.579 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -64.31 -164.83 0.02 OUTLIER 'General case' 0 N--CA 1.473 0.685 0 CA-C-N 117.233 0.517 . . . . 0.0 109.852 179.897 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 24.7 t-20 -69.68 76.95 0.44 Allowed 'General case' 0 N--CA 1.467 0.395 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.71 -179.733 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -75.57 139.29 42.02 Favored 'General case' 0 N--CA 1.472 0.672 0 N-CA-C 109.695 -0.483 . . . . 0.0 109.695 179.326 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -65.15 -164.65 1.07 Allowed Glycine 0 C--N 1.336 0.574 0 N-CA-C 109.651 -1.38 . . . . 0.0 109.651 178.27 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.56 112.92 25.07 Favored 'General case' 0 N--CA 1.468 0.443 0 C-N-CA 122.714 0.406 . . . . 0.0 110.22 179.761 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 76.6 mt -99.6 135.28 35.68 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.812 0 N-CA-C 106.986 -1.487 . . . . 0.0 106.986 178.774 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' H' H ' 32' ' ' ILE . . . . . 0.428 ' H ' HG22 ' E' ' 32' ' ' ILE . 30.5 pt -151.05 -169.16 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.707 0 CA-C-N 119.494 1.043 . . . . 0.0 109.836 -179.914 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.06 2.2 3.66 Favored Glycine 0 CA--C 1.528 0.852 0 N-CA-C 111.167 -0.773 . . . . 0.0 111.167 -179.834 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' H' H ' 34' ' ' LEU . . . . . 0.423 ' H ' ' C ' ' H' ' 32' ' ' ILE . 1.1 tt -74.28 133.13 42.61 Favored 'General case' 0 CA--C 1.544 0.733 0 N-CA-C 109.223 -0.658 . . . . 0.0 109.223 -179.58 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' H' H ' 35' ' ' MET . . . . . 0.404 ' N ' HD23 ' H' ' 34' ' ' LEU . 23.9 ttt -158.85 150.29 20.64 Favored 'General case' 0 N--CA 1.468 0.465 0 N-CA-C 108.644 -0.873 . . . . 0.0 108.644 179.066 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' H' H ' 36' ' ' VAL . . . . . 0.449 HG12 ' N ' ' H' ' 37' ' ' GLY . 59.9 t -153.83 161.38 2.43 Favored 'Isoleucine or valine' 0 C--N 1.346 0.425 0 N-CA-C 108.005 -1.109 . . . . 0.0 108.005 -179.438 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' H' H ' 37' ' ' GLY . . . . . 0.449 ' N ' HG12 ' H' ' 36' ' ' VAL . . . 58.35 67.35 2.24 Favored Glycine 0 C--N 1.309 -0.955 0 CA-C-N 115.349 -0.841 . . . . 0.0 111.902 178.52 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.29 173.8 18.75 Favored Glycine 0 N--CA 1.477 1.39 0 N-CA-C 110.708 -0.957 . . . . 0.0 110.708 178.907 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 32.7 m -106.35 152.08 8.12 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.914 0 C-N-CA 123.341 0.656 . . . . 0.0 110.554 -179.438 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 22.1 t . . . . . 0 C--O 1.218 -0.588 0 CA-C-O 118.321 -0.847 . . . . 0.0 110.644 179.843 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' I' I ' 1' ' ' ASP . . . . . . . . . . . . . 65.3 m-20 . . . . . 0 N--CA 1.49 1.552 0 N-CA-C 109.173 -0.677 . . . . 0.0 109.173 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' I' I ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.8 -166.05 0.03 OUTLIER 'General case' 0 N--CA 1.467 0.412 0 CA-C-N 116.577 -0.283 . . . . 0.0 110.77 -179.857 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' I' I ' 3' ' ' GLU . . . . . . . . . . . . . 24.3 tt0 -154.72 167.14 31.18 Favored 'General case' 0 N--CA 1.474 0.741 0 CA-C-O 120.704 0.287 . . . . 0.0 110.71 -179.058 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 20.4 p90 -66.97 137.0 56.19 Favored 'General case' 0 N--CA 1.471 0.615 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.325 -178.602 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' I' I ' 5' ' ' ARG . . . . . . . . . . . . . 99.1 mtt180 -136.11 153.92 51.15 Favored 'General case' 0 N--CA 1.483 1.213 0 N-CA-C 109.47 -0.566 . . . . 0.0 109.47 178.62 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 58.2 t-80 -114.12 115.53 27.68 Favored 'General case' 0 N--CA 1.482 1.153 0 C-N-CA 122.809 0.444 . . . . 0.0 109.863 179.545 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 8.0 m-20 -75.98 152.33 37.02 Favored 'General case' 0 N--CA 1.47 0.567 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.697 179.335 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' I' I ' 8' ' ' SER . . . . . 0.421 ' OG ' ' HA ' ' F' ' 8' ' ' SER . 6.7 p -163.89 -172.82 2.97 Favored 'General case' 0 N--CA 1.475 0.78 0 CA-C-O 121.124 0.487 . . . . 0.0 110.681 178.801 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.35 43.61 1.84 Allowed Glycine 0 N--CA 1.481 1.676 0 CA-C-N 115.773 -0.649 . . . . 0.0 111.71 179.105 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 51.1 p90 -64.32 132.38 50.03 Favored 'General case' 0 CA--C 1.541 0.622 0 O-C-N 122.681 -0.306 . . . . 0.0 111.722 -179.853 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 84.1 mt-10 -94.06 152.92 18.44 Favored 'General case' 0 N--CA 1.477 0.921 0 CA-C-O 121.11 0.481 . . . . 0.0 110.033 178.619 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -155.33 127.31 0.98 Allowed 'Isoleucine or valine' 0 CA--C 1.553 1.069 0 N-CA-C 107.978 -1.119 . . . . 0.0 107.978 178.098 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 50.3 m-70 -134.48 144.02 47.83 Favored 'General case' 0 N--CA 1.477 0.92 0 CA-C-N 115.387 -0.824 . . . . 0.0 111.391 -178.269 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 6.3 t60 -166.09 98.59 0.63 Allowed 'General case' 0 N--CA 1.483 1.183 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.06 179.094 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' I' I ' 15' ' ' GLN . . . . . 0.422 HE22 ' H ' ' I' ' 37' ' ' GLY . 22.6 pt20 -123.84 154.77 39.15 Favored 'General case' 0 CA--C 1.497 -1.082 0 N-CA-C 108.014 -1.106 . . . . 0.0 108.014 -179.323 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -124.54 106.07 9.87 Favored 'General case' 0 N--CA 1.483 1.199 0 N-CA-C 108.154 -1.054 . . . . 0.0 108.154 178.125 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 6.0 mp -120.25 148.61 43.47 Favored 'General case' 0 N--CA 1.495 1.819 0 CA-C-O 121.06 0.457 . . . . 0.0 111.593 -178.179 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 20.2 t -110.61 121.1 62.78 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.01 0 N-CA-C 107.799 -1.186 . . . . 0.0 107.799 176.87 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' I' I ' 19' ' ' PHE . . . . . 0.559 ' O ' ' N ' ' I' ' 21' ' ' ALA . 27.2 m-85 -118.11 -164.1 0.99 Allowed 'General case' 0 N--CA 1.495 1.776 0 C-N-CA 124.229 1.012 . . . . 0.0 110.095 -178.659 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' I' I ' 20' ' ' PHE . . . . . 0.485 ' HA ' ' O ' ' F' ' 20' ' ' PHE . 79.6 m-85 -47.61 72.97 0.0 OUTLIER 'General case' 0 N--CA 1.481 1.085 0 C-N-CA 124.54 1.136 . . . . 0.0 111.502 -179.771 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' I' I ' 21' ' ' ALA . . . . . 0.559 ' N ' ' O ' ' I' ' 19' ' ' PHE . . . -85.11 -78.82 0.24 Allowed 'General case' 0 N--CA 1.468 0.43 0 C-N-CA 122.76 0.424 . . . . 0.0 110.12 -178.935 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 41.3 tt0 -93.95 99.48 11.81 Favored 'General case' 0 N--CA 1.464 0.274 0 N-CA-C 108.469 -0.938 . . . . 0.0 108.469 179.247 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 4.2 p30 -158.87 145.26 16.94 Favored 'General case' 0 N--CA 1.478 0.928 0 O-C-N 122.388 -0.195 . . . . 0.0 111.214 179.616 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' I' I ' 24' ' ' VAL . . . . . 0.479 ' HB ' ' H ' ' F' ' 25' ' ' GLY . 92.1 t -62.78 165.71 1.07 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.606 0 N-CA-C 107.257 -1.386 . . . . 0.0 107.257 177.154 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' I' I ' 25' ' ' GLY . . . . . 0.419 ' N ' HG12 ' I' ' 24' ' ' VAL . . . -119.94 48.8 0.92 Allowed Glycine 0 N--CA 1.48 1.619 0 N-CA-C 110.546 -1.022 . . . . 0.0 110.546 -179.559 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -64.08 -164.37 0.02 OUTLIER 'General case' 0 N--CA 1.473 0.684 0 CA-C-N 117.168 0.484 . . . . 0.0 109.747 179.865 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 24.9 t-20 -70.27 77.2 0.53 Allowed 'General case' 0 CA--C 1.536 0.42 0 CA-C-N 116.394 -0.366 . . . . 0.0 110.63 -179.701 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -75.65 139.06 41.77 Favored 'General case' 0 N--CA 1.473 0.713 0 N-CA-C 109.62 -0.511 . . . . 0.0 109.62 179.367 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.83 -164.62 0.94 Allowed Glycine 0 C--N 1.337 0.59 0 N-CA-C 109.76 -1.336 . . . . 0.0 109.76 178.179 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.4 112.75 24.88 Favored 'General case' 0 CA--C 1.535 0.379 0 C-N-CA 122.723 0.409 . . . . 0.0 110.251 179.668 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 77.0 mt -99.52 135.21 35.84 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.852 0 N-CA-C 106.927 -1.508 . . . . 0.0 106.927 178.829 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' I' I ' 32' ' ' ILE . . . . . 0.441 ' H ' HG22 ' F' ' 32' ' ' ILE . 30.3 pt -151.05 -169.08 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 CA-C-N 119.487 1.039 . . . . 0.0 109.876 179.956 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.05 2.25 3.7 Favored Glycine 0 CA--C 1.527 0.827 0 N-CA-C 111.22 -0.752 . . . . 0.0 111.22 -179.751 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' I' I ' 34' ' ' LEU . . . . . 0.42 HD23 ' N ' ' I' ' 35' ' ' MET . 1.1 tt -74.27 133.2 42.62 Favored 'General case' 0 CA--C 1.545 0.761 0 N-CA-C 109.122 -0.696 . . . . 0.0 109.122 -179.598 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' I' I ' 35' ' ' MET . . . . . 0.42 ' N ' HD23 ' I' ' 34' ' ' LEU . 23.8 ttt -158.95 150.13 20.31 Favored 'General case' 0 N--CA 1.468 0.443 0 N-CA-C 108.612 -0.884 . . . . 0.0 108.612 179.04 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' I' I ' 36' ' ' VAL . . . . . 0.451 HG12 ' N ' ' I' ' 37' ' ' GLY . 60.4 t -153.79 161.24 2.48 Favored 'Isoleucine or valine' 0 C--N 1.345 0.396 0 N-CA-C 107.959 -1.126 . . . . 0.0 107.959 -179.46 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' I' I ' 37' ' ' GLY . . . . . 0.451 ' N ' HG12 ' I' ' 36' ' ' VAL . . . 58.45 67.41 2.21 Favored Glycine 0 C--N 1.311 -0.86 0 CA-C-N 115.275 -0.875 . . . . 0.0 111.935 178.564 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.28 173.92 18.84 Favored Glycine 0 N--CA 1.476 1.312 0 N-CA-C 110.674 -0.97 . . . . 0.0 110.674 178.841 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' I' I ' 39' ' ' VAL . . . . . 0.404 HG12 ' H ' ' F' ' 39' ' ' VAL . 32.8 m -106.51 151.98 8.28 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.923 0 C-N-CA 123.28 0.632 . . . . 0.0 110.643 -179.48 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 22.3 t . . . . . 0 C--O 1.217 -0.614 0 CA-C-O 118.413 -0.803 . . . . 0.0 110.752 179.908 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 1' ' ' ASP . . . . . 0.469 ' H2 ' ' HB2' ' D' ' 1' ' ' ASP . 9.0 m-20 . . . . . 0 N--CA 1.487 1.383 0 N-CA-C 109.126 -0.694 . . . . 0.0 109.126 . . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.15 132.27 48.7 Favored 'General case' 0 CA--C 1.539 0.526 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.108 -179.922 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 39.8 tt0 -169.4 108.84 0.43 Allowed 'General case' 0 N--CA 1.47 0.573 0 N-CA-C 109.556 -0.535 . . . . 0.0 109.556 -179.139 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 77.9 m-85 -83.75 141.38 31.47 Favored 'General case' 0 N--CA 1.473 0.694 0 N-CA-C 109.658 -0.497 . . . . 0.0 109.658 179.363 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 35.6 mtp180 -142.43 143.03 32.45 Favored 'General case' 0 N--CA 1.48 1.059 0 N-CA-C 109.285 -0.635 . . . . 0.0 109.285 -179.951 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 74.4 m80 -150.29 117.84 6.13 Favored 'General case' 0 N--CA 1.472 0.64 0 N-CA-C 108.991 -0.744 . . . . 0.0 108.991 178.749 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 10.1 m-20 -68.31 149.4 49.47 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.822 -179.848 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 4.3 t -168.42 176.34 5.87 Favored 'General case' 0 N--CA 1.473 0.695 0 N-CA-C 109.643 -0.503 . . . . 0.0 109.643 178.592 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 105.08 51.54 0.88 Allowed Glycine 0 N--CA 1.484 1.884 0 N-CA-C 112.065 -0.414 . . . . 0.0 112.065 179.276 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 45.9 p90 -64.8 131.85 47.92 Favored 'General case' 0 N--CA 1.471 0.617 0 CA-C-O 120.51 0.195 . . . . 0.0 111.524 179.652 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 11' ' ' GLU . . . . . 0.424 ' OE2' ' ND2' ' F' ' 27' ' ' ASN . 43.2 mt-10 -82.78 150.49 26.61 Favored 'General case' 0 N--CA 1.472 0.669 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 177.756 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -154.17 128.98 1.45 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 N-CA-C 108.094 -1.076 . . . . 0.0 108.094 178.167 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 56.7 m-70 -133.39 145.22 50.12 Favored 'General case' 0 N--CA 1.488 1.451 0 CA-C-N 118.616 0.644 . . . . 0.0 110.806 -178.959 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 5.9 t60 -166.11 98.16 0.62 Allowed 'General case' 0 N--CA 1.482 1.141 0 N-CA-C 111.392 0.145 . . . . 0.0 111.392 179.476 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 48.1 mt-30 -107.44 -172.65 2.11 Favored 'General case' 0 CA--C 1.502 -0.886 0 N-CA-C 107.948 -1.13 . . . . 0.0 107.948 179.219 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -163.13 97.92 0.92 Allowed 'General case' 0 N--CA 1.471 0.576 0 CA-C-N 115.121 -0.945 . . . . 0.0 109.291 178.739 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.502 ' N ' HD12 ' A' ' 17' ' ' LEU . 6.2 mp -108.7 163.98 12.78 Favored 'General case' 0 N--CA 1.487 1.394 0 N-CA-C 108.05 -1.093 . . . . 0.0 108.05 179.792 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 55.3 t -141.84 120.25 9.18 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.395 0 CA-C-O 118.663 -0.684 . . . . 0.0 110.33 179.77 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 52.9 m-85 -72.97 158.07 36.19 Favored 'General case' 0 N--CA 1.482 1.172 0 N-CA-C 107.383 -1.34 . . . . 0.0 107.383 176.917 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 24.8 t80 -169.29 -58.22 0.02 OUTLIER 'General case' 0 N--CA 1.481 1.076 0 CA-C-O 122.553 1.168 . . . . 0.0 109.475 -179.82 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -39.76 91.12 0.0 OUTLIER 'General case' 0 N--CA 1.457 -0.092 0 CA-C-N 113.665 -1.607 . . . . 0.0 112.709 -178.115 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 36.4 tt0 -58.2 131.95 52.12 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-N 115.143 -0.935 . . . . 0.0 111.128 179.429 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 9.0 m-20 -80.45 162.89 24.18 Favored 'General case' 0 N--CA 1.478 0.961 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 179.772 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 98.3 t -161.2 -74.25 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.484 1.267 0 N-CA-C 107.609 -1.256 . . . . 0.0 107.609 -178.612 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -38.96 91.01 0.01 OUTLIER Glycine 0 N--CA 1.471 1.002 0 CA-C-N 115.385 -0.825 . . . . 0.0 111.981 -179.736 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 89.1 p -37.46 -99.91 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.917 0 C-N-CA 123.714 0.806 . . . . 0.0 112.9 -176.622 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 40.8 t30 -61.23 126.35 27.04 Favored 'General case' 0 CA--C 1.546 0.807 0 CA-C-N 119.495 1.043 . . . . 0.0 108.855 179.465 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 62.8 mttm -106.36 -178.95 3.8 Favored 'General case' 0 N--CA 1.484 1.259 0 N-CA-C 109.249 -0.648 . . . . 0.0 109.249 -179.728 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.83 -141.27 0.02 OUTLIER Glycine 0 CA--C 1.528 0.888 0 N-CA-C 109.39 -1.484 . . . . 0.0 109.39 177.967 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.79 119.42 22.25 Favored 'General case' 0 N--CA 1.477 0.922 0 N-CA-C 109.257 -0.645 . . . . 0.0 109.257 178.439 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 68.9 mt -100.76 146.3 9.61 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.876 0 N-CA-C 107.856 -1.164 . . . . 0.0 107.856 178.614 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 28.4 mt -146.07 124.59 4.87 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.745 0 N-CA-C 109.435 -0.579 . . . . 0.0 109.435 -177.877 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.55 83.91 0.07 OUTLIER Glycine 0 C--N 1.338 0.677 0 CA-C-N 116.138 -0.483 . . . . 0.0 112.93 178.08 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 14.6 tp -101.9 123.2 45.42 Favored 'General case' 0 N--CA 1.484 1.263 0 N-CA-C 107.112 -1.44 . . . . 0.0 107.112 177.394 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 13.5 ttt -158.37 158.06 33.55 Favored 'General case' 0 N--CA 1.468 0.452 0 N-CA-C 109.018 -0.734 . . . . 0.0 109.018 179.94 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 89.5 t -155.93 152.46 8.52 Favored 'Isoleucine or valine' 0 C--O 1.234 0.262 0 N-CA-C 107.37 -1.345 . . . . 0.0 107.37 -179.435 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 57.22 73.34 0.46 Allowed Glycine 0 C--N 1.31 -0.881 0 CA-C-N 115.569 -0.741 . . . . 0.0 111.834 178.398 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 169.84 -150.03 14.19 Favored Glycine 0 N--CA 1.462 0.394 0 N-CA-C 110.744 -0.942 . . . . 0.0 110.744 179.432 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 33.1 m -133.77 144.77 34.8 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.875 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 179.93 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 19.8 t . . . . . 0 C--O 1.222 -0.393 0 CA-C-O 117.787 -1.101 . . . . 0.0 110.924 179.753 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' B' B ' 1' ' ' ASP . . . . . 0.405 ' N ' ' CB ' ' E' ' 1' ' ' ASP . 9.1 m-20 . . . . . 0 N--CA 1.488 1.441 0 N-CA-C 109.113 -0.699 . . . . 0.0 109.113 . . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.18 132.2 48.5 Favored 'General case' 0 CA--C 1.538 0.487 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.16 -179.945 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 3' ' ' GLU . . . . . . . . . . . . . 39.9 tt0 -169.35 108.77 0.43 Allowed 'General case' 0 N--CA 1.47 0.548 0 N-CA-C 109.519 -0.548 . . . . 0.0 109.519 -179.077 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 78.1 m-85 -83.67 141.52 31.43 Favored 'General case' 0 N--CA 1.471 0.621 0 N-CA-C 109.656 -0.498 . . . . 0.0 109.656 179.33 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 35.7 mtp180 -142.58 143.15 32.31 Favored 'General case' 0 N--CA 1.479 1.015 0 N-CA-C 109.296 -0.631 . . . . 0.0 109.296 -179.93 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 74.5 m80 -150.38 118.04 6.16 Favored 'General case' 0 N--CA 1.473 0.701 0 N-CA-C 109.045 -0.724 . . . . 0.0 109.045 178.768 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 7' ' ' ASP . . . . . . . . . . . . . 10.0 m-20 -68.46 149.05 49.75 Favored 'General case' 0 N--CA 1.464 0.233 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.929 -179.884 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 8' ' ' SER . . . . . . . . . . . . . 4.3 t -168.14 176.44 6.04 Favored 'General case' 0 N--CA 1.472 0.666 0 N-CA-C 109.614 -0.513 . . . . 0.0 109.614 178.575 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 105.03 51.31 0.89 Allowed Glycine 0 N--CA 1.483 1.814 0 N-CA-C 112.042 -0.423 . . . . 0.0 112.042 179.296 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 46.7 p90 -64.49 131.9 48.43 Favored 'General case' 0 N--CA 1.471 0.618 0 CA-C-O 120.583 0.23 . . . . 0.0 111.538 179.596 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 11' ' ' GLU . . . . . 0.432 ' OE2' ' ND2' ' D' ' 27' ' ' ASN . 43.2 mt-10 -82.88 150.61 26.42 Favored 'General case' 0 N--CA 1.473 0.696 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 177.787 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -154.29 128.9 1.41 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 N-CA-C 108.214 -1.032 . . . . 0.0 108.214 178.162 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 56.8 m-70 -133.4 145.35 50.23 Favored 'General case' 0 N--CA 1.489 1.479 0 CA-C-N 118.458 0.572 . . . . 0.0 110.762 -178.84 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 5.9 t60 -166.25 97.91 0.61 Allowed 'General case' 0 N--CA 1.484 1.27 0 CA-C-O 119.694 -0.193 . . . . 0.0 111.236 179.554 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 48.3 mt-30 -107.21 -172.77 2.14 Favored 'General case' 0 CA--C 1.504 -0.803 0 N-CA-C 107.862 -1.162 . . . . 0.0 107.862 179.238 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -163.11 97.9 0.93 Allowed 'General case' 0 N--CA 1.471 0.625 0 CA-C-N 115.154 -0.93 . . . . 0.0 109.192 178.748 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 17' ' ' LEU . . . . . 0.502 ' N ' HD12 ' B' ' 17' ' ' LEU . 6.1 mp -108.77 163.96 12.81 Favored 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 108.075 -1.083 . . . . 0.0 108.075 179.784 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 57.6 t -141.98 119.92 8.39 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.31 0 CA-C-O 118.724 -0.655 . . . . 0.0 110.293 179.868 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 55.4 m-85 -73.14 158.29 35.58 Favored 'General case' 0 N--CA 1.48 1.036 0 N-CA-C 107.343 -1.355 . . . . 0.0 107.343 176.792 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 26.1 t80 -170.33 -57.25 0.02 OUTLIER 'General case' 0 N--CA 1.478 0.953 0 CA-C-O 122.354 1.073 . . . . 0.0 109.533 -179.962 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -39.87 91.07 0.0 OUTLIER 'General case' 0 C--N 1.34 0.161 0 CA-C-N 113.999 -1.455 . . . . 0.0 112.558 -178.314 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 36.1 tt0 -58.19 132.0 52.25 Favored 'General case' 0 C--N 1.317 -0.811 0 CA-C-N 115.142 -0.936 . . . . 0.0 111.219 179.545 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 -80.58 162.71 24.14 Favored 'General case' 0 N--CA 1.479 1.015 0 N-CA-C 109.491 -0.559 . . . . 0.0 109.491 179.776 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 98.5 t -160.99 -74.13 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.483 1.192 0 C-N-CA 124.76 1.224 . . . . 0.0 107.732 -178.526 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -39.38 91.04 0.01 OUTLIER Glycine 0 N--CA 1.473 1.154 0 CA-C-N 115.42 -0.809 . . . . 0.0 111.828 -179.709 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 92.4 p -37.08 -99.93 0.0 OUTLIER 'General case' 0 N--CA 1.481 1.107 0 C-N-CA 123.881 0.873 . . . . 0.0 112.615 -177.045 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 41.6 t30 -61.23 126.35 27.03 Favored 'General case' 0 CA--C 1.544 0.746 0 CA-C-N 119.547 1.067 . . . . 0.0 109.076 179.508 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 62.9 mttm -106.43 -179.03 3.82 Favored 'General case' 0 N--CA 1.483 1.178 0 N-CA-C 109.223 -0.658 . . . . 0.0 109.223 -179.703 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.85 -141.22 0.02 OUTLIER Glycine 0 CA--C 1.527 0.814 0 N-CA-C 109.411 -1.476 . . . . 0.0 109.411 177.924 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.77 119.36 22.18 Favored 'General case' 0 N--CA 1.478 0.962 0 N-CA-C 109.304 -0.628 . . . . 0.0 109.304 178.488 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 69.0 mt -100.84 146.03 10.13 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.901 0 N-CA-C 107.862 -1.162 . . . . 0.0 107.862 178.551 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 28.7 mt -145.9 124.59 5.1 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.755 0 N-CA-C 109.428 -0.582 . . . . 0.0 109.428 -177.817 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.87 83.87 0.07 OUTLIER Glycine 0 C--N 1.338 0.678 0 CA-C-N 116.119 -0.492 . . . . 0.0 112.872 178.005 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 15.0 tp -102.27 121.52 42.43 Favored 'General case' 0 N--CA 1.486 1.335 0 N-CA-C 107.386 -1.338 . . . . 0.0 107.386 177.441 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 13.3 ttt -156.75 158.18 36.41 Favored 'General case' 0 N--CA 1.466 0.327 0 N-CA-C 109.27 -0.641 . . . . 0.0 109.27 179.836 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 89.1 t -155.97 152.32 8.64 Favored 'Isoleucine or valine' 0 C--O 1.235 0.317 0 N-CA-C 107.256 -1.387 . . . . 0.0 107.256 -179.444 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 57.39 73.24 0.47 Allowed Glycine 0 C--N 1.312 -0.797 0 CA-C-N 115.525 -0.762 . . . . 0.0 111.789 178.332 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 169.79 -149.99 14.16 Favored Glycine 0 N--CA 1.462 0.412 0 N-CA-C 110.751 -0.94 . . . . 0.0 110.751 179.408 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 33.1 m -133.78 144.83 34.62 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.91 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 179.996 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 20.4 t . . . . . 0 C--O 1.221 -0.425 0 CA-C-O 117.766 -1.111 . . . . 0.0 110.877 179.708 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' C' C ' 1' ' ' ASP . . . . . 0.407 ' N ' ' CB ' ' F' ' 1' ' ' ASP . 9.2 m-20 . . . . . 0 N--CA 1.489 1.494 0 N-CA-C 109.011 -0.737 . . . . 0.0 109.011 . . . . . . . . . 1 1 . 1 . 018 nuclear build full ' C' C ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.29 132.23 48.53 Favored 'General case' 0 CA--C 1.539 0.535 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.214 -179.896 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' C' C ' 3' ' ' GLU . . . . . . . . . . . . . 39.8 tt0 -169.42 108.92 0.43 Allowed 'General case' 0 N--CA 1.47 0.537 0 N-CA-C 109.553 -0.536 . . . . 0.0 109.553 -179.054 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 78.2 m-85 -83.74 141.59 31.32 Favored 'General case' 0 N--CA 1.473 0.714 0 N-CA-C 109.605 -0.517 . . . . 0.0 109.605 179.297 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 35.7 mtp180 -142.66 143.11 32.2 Favored 'General case' 0 N--CA 1.48 1.057 0 N-CA-C 109.227 -0.657 . . . . 0.0 109.227 -179.93 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 74.6 m80 -150.44 118.08 6.15 Favored 'General case' 0 N--CA 1.472 0.641 0 N-CA-C 108.958 -0.756 . . . . 0.0 108.958 178.765 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' C' C ' 7' ' ' ASP . . . . . . . . . . . . . 10.0 m-20 -68.52 149.17 49.55 Favored 'General case' 0 N--CA 1.462 0.17 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.994 -179.92 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' C' C ' 8' ' ' SER . . . . . . . . . . . . . 4.3 t -168.22 176.49 5.95 Favored 'General case' 0 N--CA 1.472 0.655 0 N-CA-C 109.546 -0.539 . . . . 0.0 109.546 178.631 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 105.01 51.35 0.89 Allowed Glycine 0 N--CA 1.483 1.821 0 N-CA-C 112.006 -0.438 . . . . 0.0 112.006 179.275 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 46.1 p90 -64.64 131.82 48.02 Favored 'General case' 0 N--CA 1.471 0.602 0 CA-C-O 120.57 0.224 . . . . 0.0 111.509 179.648 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' C' C ' 11' ' ' GLU . . . . . 0.435 ' OE2' ' ND2' ' E' ' 27' ' ' ASN . 43.2 mt-10 -82.76 150.44 26.66 Favored 'General case' 0 N--CA 1.473 0.68 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 177.815 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -154.11 129.04 1.48 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 178.133 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 56.8 m-70 -133.44 145.41 50.22 Favored 'General case' 0 N--CA 1.489 1.507 0 CA-C-N 118.496 0.589 . . . . 0.0 110.81 -178.914 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 5.9 t60 -166.36 98.04 0.6 Allowed 'General case' 0 N--CA 1.483 1.204 0 CA-C-O 119.79 -0.148 . . . . 0.0 111.3 179.534 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 48.2 mt-30 -107.42 -172.69 2.12 Favored 'General case' 0 CA--C 1.5 -0.945 0 N-CA-C 107.999 -1.111 . . . . 0.0 107.999 179.246 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -163.15 97.86 0.92 Allowed 'General case' 0 N--CA 1.47 0.532 0 CA-C-N 115.181 -0.918 . . . . 0.0 109.308 178.782 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' C' C ' 17' ' ' LEU . . . . . 0.5 ' N ' HD12 ' C' ' 17' ' ' LEU . 6.1 mp -108.69 163.96 12.79 Favored 'General case' 0 N--CA 1.487 1.395 0 N-CA-C 108.037 -1.097 . . . . 0.0 108.037 179.879 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 57.3 t -141.93 119.97 8.59 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.365 0 CA-C-O 118.721 -0.657 . . . . 0.0 110.257 179.836 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 55.1 m-85 -73.14 158.28 35.61 Favored 'General case' 0 N--CA 1.479 1.016 0 N-CA-C 107.293 -1.373 . . . . 0.0 107.293 176.761 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 26.1 t80 -170.23 -57.21 0.02 OUTLIER 'General case' 0 N--CA 1.477 0.898 0 CA-C-O 122.358 1.075 . . . . 0.0 109.587 179.978 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -39.93 91.26 0.0 OUTLIER 'General case' 0 C--N 1.34 0.169 0 CA-C-N 114.028 -1.442 . . . . 0.0 112.549 -178.294 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 36.1 tt0 -58.3 131.88 51.96 Favored 'General case' 0 C--N 1.317 -0.847 0 CA-C-N 115.129 -0.941 . . . . 0.0 111.165 179.501 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 -80.45 162.76 24.25 Favored 'General case' 0 N--CA 1.479 0.994 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 179.722 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 98.2 t -161.07 -74.27 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.483 1.21 0 C-N-CA 124.753 1.221 . . . . 0.0 107.744 -178.556 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -39.46 91.09 0.01 OUTLIER Glycine 0 N--CA 1.473 1.105 0 CA-C-N 115.463 -0.79 . . . . 0.0 111.84 -179.68 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 91.1 p -37.03 -99.88 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.036 0 C-N-CA 123.831 0.852 . . . . 0.0 112.748 -177.0 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 41.6 t30 -61.17 126.37 27.12 Favored 'General case' 0 CA--C 1.545 0.752 0 CA-C-N 119.506 1.048 . . . . 0.0 109.061 179.484 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 62.9 mttm -106.46 -179.12 3.85 Favored 'General case' 0 N--CA 1.483 1.185 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 -179.713 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.79 -141.25 0.02 OUTLIER Glycine 0 CA--C 1.528 0.878 0 N-CA-C 109.362 -1.495 . . . . 0.0 109.362 177.996 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.73 119.34 22.21 Favored 'General case' 0 N--CA 1.477 0.882 0 N-CA-C 109.37 -0.604 . . . . 0.0 109.37 178.436 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 68.7 mt -100.81 146.01 10.15 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.945 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 178.598 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 28.6 mt -145.96 124.63 5.03 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.726 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 -177.793 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.74 83.78 0.07 OUTLIER Glycine 0 C--N 1.339 0.701 0 CA-C-N 116.127 -0.488 . . . . 0.0 112.92 178.05 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 15.2 tp -102.12 121.39 42.11 Favored 'General case' 0 N--CA 1.484 1.26 0 N-CA-C 107.485 -1.302 . . . . 0.0 107.485 177.349 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 13.4 ttt -156.62 158.23 36.67 Favored 'General case' 0 N--CA 1.465 0.32 0 N-CA-C 109.254 -0.647 . . . . 0.0 109.254 179.848 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 87.9 t -155.94 152.44 8.53 Favored 'Isoleucine or valine' 0 C--O 1.235 0.314 0 N-CA-C 107.331 -1.359 . . . . 0.0 107.331 -179.48 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 57.26 73.27 0.47 Allowed Glycine 0 C--N 1.311 -0.82 0 CA-C-N 115.535 -0.757 . . . . 0.0 111.812 178.384 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 169.78 -150.0 14.19 Favored Glycine 0 N--CA 1.462 0.433 0 N-CA-C 110.716 -0.954 . . . . 0.0 110.716 179.377 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 33.2 m -133.7 144.82 34.72 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.883 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 179.98 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 20.3 t . . . . . 0 N--CA 1.467 0.403 0 CA-C-O 117.747 -1.121 . . . . 0.0 110.864 179.667 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' D' D ' 1' ' ' ASP . . . . . 0.469 ' HB2' ' H2 ' ' A' ' 1' ' ' ASP . 9.4 m-20 . . . . . 0 N--CA 1.489 1.477 0 N-CA-C 109.269 -0.641 . . . . 0.0 109.269 . . . . . . . . . 1 1 . 1 . 018 nuclear build full ' D' D ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.45 131.11 46.21 Favored 'General case' 0 CA--C 1.536 0.409 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.229 179.956 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' D' D ' 3' ' ' GLU . . . . . . . . . . . . . 39.6 tt0 -169.32 110.59 0.47 Allowed 'General case' 0 N--CA 1.469 0.487 0 N-CA-C 109.29 -0.633 . . . . 0.0 109.29 179.975 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 85.5 m-85 -86.8 148.82 25.23 Favored 'General case' 0 C--N 1.362 1.11 0 C-N-CA 118.68 -1.208 . . . . 0.0 108.142 179.59 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' D' D ' 5' ' ' ARG . . . . . 0.417 HH21 HG22 ' F' ' 24' ' ' VAL . 36.8 mtp180 -145.95 141.99 28.27 Favored 'General case' 0 N--CA 1.474 0.76 0 N-CA-C 109.365 -0.606 . . . . 0.0 109.365 -179.834 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 75.5 m80 -149.13 123.39 9.57 Favored 'General case' 0 CA--C 1.543 0.684 0 N-CA-C 107.815 -1.18 . . . . 0.0 107.815 174.618 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' D' D ' 7' ' ' ASP . . . . . . . . . . . . . 6.7 m-20 -63.71 133.13 53.02 Favored 'General case' 0 C--N 1.322 -0.615 0 C-N-CA 126.968 2.107 . . . . 0.0 114.675 175.231 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' D' D ' 8' ' ' SER . . . . . . . . . . . . . 3.5 t -154.59 -179.74 8.27 Favored 'General case' 0 N--CA 1.475 0.823 0 CA-C-N 119.081 0.855 . . . . 0.0 110.214 175.99 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.36 49.92 1.02 Allowed Glycine 0 N--CA 1.482 1.743 0 N-CA-C 112.047 -0.421 . . . . 0.0 112.047 175.194 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 46.4 p90 -61.49 132.31 52.98 Favored 'General case' 0 CA--C 1.54 0.575 0 N-CA-C 112.116 0.413 . . . . 0.0 112.116 179.505 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' D' D ' 11' ' ' GLU . . . . . 0.401 ' CG ' ' ND2' ' F' ' 27' ' ' ASN . 42.7 mt-10 -83.23 148.97 27.1 Favored 'General case' 0 N--CA 1.48 1.065 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 176.661 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -149.84 130.15 4.19 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.341 0 N-CA-C 108.325 -0.991 . . . . 0.0 108.325 174.876 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 54.7 m-70 -129.42 148.05 51.29 Favored 'General case' 0 N--CA 1.482 1.137 0 CA-C-N 118.158 0.436 . . . . 0.0 110.897 176.801 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' D' D ' 14' ' ' HIS . . . . . 0.41 ' ND1' ' O ' ' G' ' 14' ' ' HIS . 6.0 t60 -165.34 104.64 0.74 Allowed 'General case' 0 N--CA 1.484 1.246 0 CA-C-O 119.016 -0.516 . . . . 0.0 109.667 173.637 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 47.4 mt-30 -110.63 -175.72 2.79 Favored 'General case' 0 CA--C 1.492 -1.268 0 N-CA-C 107.551 -1.277 . . . . 0.0 107.551 178.285 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -159.54 105.88 1.67 Allowed 'General case' 0 CA--C 1.536 0.431 0 N-CA-C 107.679 -1.23 . . . . 0.0 107.679 175.619 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' D' D ' 17' ' ' LEU . . . . . 0.442 ' N ' HD12 ' D' ' 17' ' ' LEU . 6.9 mp -114.87 162.65 16.63 Favored 'General case' 0 N--CA 1.487 1.419 0 N-CA-C 107.638 -1.245 . . . . 0.0 107.638 179.401 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 48.1 t -140.99 123.78 15.58 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.147 0 N-CA-C 109.483 -0.562 . . . . 0.0 109.483 176.319 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 82.7 m-85 -63.25 151.08 41.53 Favored 'General case' 0 C--N 1.357 0.923 0 C-N-CA 124.569 1.147 . . . . 0.0 110.634 169.586 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 19.0 t80 -169.68 -66.85 0.02 OUTLIER 'General case' 0 C--N 1.315 -0.916 0 N-CA-C 107.456 -1.312 . . . . 0.0 107.456 -179.877 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -37.98 95.82 0.01 OUTLIER 'General case' 0 CA--C 1.536 0.42 0 CA-C-N 114.162 -1.381 . . . . 0.0 111.683 -175.407 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 36.6 tt0 -60.38 134.34 56.97 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 113.709 -1.587 . . . . 0.0 111.018 179.297 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' D' D ' 23' ' ' ASP . . . . . 0.469 ' O ' HG23 ' D' ' 24' ' ' VAL . 9.5 m-20 -82.57 168.27 17.52 Favored 'General case' 0 C--O 1.205 -1.285 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 179.558 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' D' D ' 24' ' ' VAL . . . . . 0.469 HG23 ' O ' ' D' ' 23' ' ' ASP 0.288 46.3 t -168.93 -94.15 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.505 2.291 0 N-CA-C 103.507 -2.775 . . . . 0.0 103.507 -164.215 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . -26.35 77.14 0.0 OUTLIER Glycine 0 C--N 1.259 -3.721 0 C-N-CA 129.754 3.549 . . . . 0.0 116.908 -179.957 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' D' D ' 26' ' ' SER . . . . . 0.459 ' OG ' ' N ' ' D' ' 27' ' ' ASN 0.51 75.0 p -59.05 -93.05 0.0 OUTLIER 'General case' 0 C--O 1.28 2.692 1 CA-C-O 107.247 -6.12 . . . . 0.0 104.856 -155.503 . . . . . . . . 4 3 . 1 . 018 nuclear build full ' D' D ' 27' ' ' ASN . . . . . 0.459 ' N ' ' OG ' ' D' ' 26' ' ' SER 0.293 32.8 t30 -62.98 135.82 57.5 Favored 'General case' 0 N--CA 1.491 1.581 1 CA-C-N 133.294 7.315 . . . . 0.0 108.193 -172.984 . . . . . . . . 4 3 . 1 . 018 nuclear build full ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 60.0 mttm -102.76 178.58 4.53 Favored 'General case' 0 N--CA 1.475 0.82 0 C-N-CA 125.3 1.44 . . . . 0.0 111.632 177.889 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.02 -145.83 0.01 OUTLIER Glycine 0 CA--C 1.537 1.447 0 N-CA-C 111.267 -0.733 . . . . 0.0 111.267 171.401 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -126.9 122.02 33.44 Favored 'General case' 0 C--N 1.369 1.421 0 N-CA-C 108.779 -0.823 . . . . 0.0 108.779 174.689 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 68.4 mt -97.81 152.27 4.17 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.758 0 N-CA-C 107.829 -1.174 . . . . 0.0 107.829 175.492 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 34.7 mt -152.04 128.68 1.99 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.006 0 N-CA-C 107.884 -1.154 . . . . 0.0 107.884 177.226 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 64.06 80.47 0.13 Allowed Glycine 0 C--N 1.35 1.344 0 CA-C-O 117.996 -1.447 . . . . 0.0 113.185 178.06 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 10.5 tp -101.42 131.98 47.24 Favored 'General case' 0 C--N 1.38 1.931 0 N-CA-C 104.792 -2.299 . . . . 0.0 104.792 176.402 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 12.5 ttt -157.3 165.69 35.15 Favored 'General case' 0 N--CA 1.467 0.395 0 N-CA-C 108.721 -0.844 . . . . 0.0 108.721 176.756 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 81.4 t -163.19 156.61 2.11 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.485 0 N-CA-C 106.145 -1.798 . . . . 0.0 106.145 175.089 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 61.25 66.17 2.83 Favored Glycine 0 N--CA 1.447 -0.633 0 C-N-CA 117.956 -2.068 . . . . 0.0 113.754 178.087 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 167.1 -148.95 13.88 Favored Glycine 0 N--CA 1.467 0.751 0 CA-C-O 118.011 -1.438 . . . . 0.0 112.105 179.982 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 33.0 m -130.67 144.47 37.81 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.225 0 CA-C-N 119.02 1.41 . . . . 0.0 109.956 -178.821 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 18.4 t . . . . . 0 C--O 1.214 -0.802 0 N-CA-C 109.2 -0.667 . . . . 0.0 109.2 174.99 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' E' E ' 1' ' ' ASP . . . . . 0.418 ' H2 ' ' HB2' ' H' ' 1' ' ' ASP . 9.3 m-20 . . . . . 0 N--CA 1.487 1.407 0 N-CA-C 109.323 -0.621 . . . . 0.0 109.323 . . . . . . . . . 1 1 . 1 . 018 nuclear build full ' E' E ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.12 130.98 46.11 Favored 'General case' 0 CA--C 1.536 0.405 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.27 179.83 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' E' E ' 3' ' ' GLU . . . . . . . . . . . . . 39.7 tt0 -169.11 108.62 0.45 Allowed 'General case' 0 N--CA 1.469 0.516 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 -179.665 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 77.6 m-85 -84.26 141.83 30.69 Favored 'General case' 0 N--CA 1.474 0.763 0 N-CA-C 109.703 -0.48 . . . . 0.0 109.703 179.235 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' E' E ' 5' ' ' ARG . . . . . 0.416 HH21 HG22 ' D' ' 24' ' ' VAL . 37.1 mtp180 -142.62 143.56 32.45 Favored 'General case' 0 N--CA 1.477 0.888 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 179.906 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 74.7 m80 -150.56 117.55 5.92 Favored 'General case' 0 N--CA 1.473 0.699 0 N-CA-C 109.136 -0.691 . . . . 0.0 109.136 178.653 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' E' E ' 7' ' ' ASP . . . . . . . . . . . . . 9.5 m-20 -68.06 149.18 49.98 Favored 'General case' 0 CA--C 1.529 0.171 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.043 -179.816 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' E' E ' 8' ' ' SER . . . . . . . . . . . . . 3.4 t -168.5 178.06 4.98 Favored 'General case' 0 N--CA 1.475 0.806 0 N-CA-C 109.574 -0.528 . . . . 0.0 109.574 178.224 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.85 50.9 0.92 Allowed Glycine 0 N--CA 1.477 1.385 0 N-CA-C 111.97 -0.452 . . . . 0.0 111.97 179.124 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 44.2 p90 -63.78 131.21 47.13 Favored 'General case' 0 CA--C 1.545 0.756 0 N-CA-C 111.895 0.332 . . . . 0.0 111.895 -179.861 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 41.4 mt-10 -81.78 151.42 27.43 Favored 'General case' 0 N--CA 1.479 1.008 0 N-CA-C 108.683 -0.858 . . . . 0.0 108.683 177.433 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.6 p -155.92 127.91 1.0 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.449 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 177.906 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 52.2 m-70 -133.5 143.51 48.82 Favored 'General case' 0 N--CA 1.48 1.034 0 O-C-N 122.259 -0.276 . . . . 0.0 111.073 -177.884 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 5.9 t60 -165.35 97.43 0.7 Allowed 'General case' 0 N--CA 1.488 1.437 0 CA-C-O 119.602 -0.237 . . . . 0.0 111.211 179.816 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 47.1 mt-30 -106.44 -172.29 2.06 Favored 'General case' 0 CA--C 1.505 -0.769 0 N-CA-C 107.969 -1.123 . . . . 0.0 107.969 179.228 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -163.23 98.0 0.92 Allowed 'General case' 0 N--CA 1.47 0.575 0 CA-C-N 115.135 -0.938 . . . . 0.0 109.241 178.634 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' E' E ' 17' ' ' LEU . . . . . 0.488 ' N ' HD12 ' E' ' 17' ' ' LEU . 6.2 mp -108.54 163.13 13.5 Favored 'General case' 0 N--CA 1.488 1.441 0 N-CA-C 108.636 -0.876 . . . . 0.0 108.636 -179.919 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 40.6 t -141.86 120.79 9.83 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.281 0 C-N-CA 122.465 0.306 . . . . 0.0 110.631 179.194 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 51.9 m-85 -73.64 155.6 38.87 Favored 'General case' 0 C--N 1.362 1.138 0 N-CA-C 106.823 -1.547 . . . . 0.0 106.823 176.349 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 23.6 t80 -171.78 -54.82 0.02 OUTLIER 'General case' 0 N--CA 1.479 1.01 0 CA-C-O 121.682 0.753 . . . . 0.0 110.161 -179.942 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.95 89.63 0.0 OUTLIER 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 114.426 -1.261 . . . . 0.0 112.634 -179.436 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 36.0 tt0 -56.2 133.47 52.4 Favored 'General case' 0 CA--C 1.539 0.536 0 CA-C-N 114.912 -1.04 . . . . 0.0 111.291 179.861 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 9.2 m-20 -81.72 162.25 23.05 Favored 'General case' 0 N--CA 1.475 0.779 0 N-CA-C 109.66 -0.496 . . . . 0.0 109.66 179.782 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' E' E ' 24' ' ' VAL . . . . . 0.429 HG22 HH21 ' F' ' 5' ' ' ARG . 95.0 t -160.7 -74.64 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.291 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 -179.003 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . -38.81 91.22 0.01 OUTLIER Glycine 0 CA--C 1.53 0.974 0 CA-C-N 115.263 -0.88 . . . . 0.0 112.403 -179.673 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 84.8 p -37.7 -101.33 0.0 OUTLIER 'General case' 0 N--CA 1.481 1.079 0 N-CA-C 113.725 1.009 . . . . 0.0 113.725 -177.429 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' E' E ' 27' ' ' ASN . . . . . 0.435 ' ND2' ' OE2' ' C' ' 11' ' ' GLU . 40.2 t30 -60.01 124.63 20.8 Favored 'General case' 0 CA--C 1.542 0.663 0 CA-C-N 119.482 1.037 . . . . 0.0 108.781 -179.89 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 62.8 mttm -105.38 -178.65 3.71 Favored 'General case' 0 N--CA 1.483 1.214 0 N-CA-C 108.889 -0.782 . . . . 0.0 108.889 -179.613 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -65.35 -141.45 0.03 OUTLIER Glycine 0 CA--C 1.532 1.102 0 N-CA-C 110.421 -1.072 . . . . 0.0 110.421 178.02 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.93 118.31 22.44 Favored 'General case' 0 C--N 1.349 0.582 0 C-N-CA 123.234 0.614 . . . . 0.0 109.46 178.471 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 71.6 mt -100.28 148.76 6.44 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.816 0 N-CA-C 106.88 -1.526 . . . . 0.0 106.88 178.103 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 34.1 mt -148.17 125.0 2.77 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.958 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 -179.434 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.76 85.49 0.05 OUTLIER Glycine 0 C--N 1.34 0.767 0 CA-C-N 115.966 -0.561 . . . . 0.0 112.827 178.493 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 13.2 tp -103.39 121.38 42.68 Favored 'General case' 0 N--CA 1.484 1.258 0 N-CA-C 106.97 -1.492 . . . . 0.0 106.97 177.371 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 12.6 ttt -156.08 158.93 38.6 Favored 'General case' 0 N--CA 1.476 0.859 0 N-CA-C 108.883 -0.784 . . . . 0.0 108.883 179.661 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 95.3 t -156.76 151.98 8.33 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.416 0 N-CA-C 107.493 -1.299 . . . . 0.0 107.493 -179.693 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 57.59 72.41 0.59 Allowed Glycine 0 C--N 1.313 -0.74 0 CA-C-N 115.397 -0.819 . . . . 0.0 111.481 178.168 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 171.62 -148.81 11.31 Favored Glycine 0 CA--C 1.524 0.624 0 N-CA-C 111.025 -0.83 . . . . 0.0 111.025 179.606 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 32.9 m -135.53 144.06 34.95 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.826 0 N-CA-C 109.095 -0.705 . . . . 0.0 109.095 179.906 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 19.5 t . . . . . 0 CA--C 1.537 0.471 0 CA-C-O 117.66 -1.162 . . . . 0.0 110.817 -179.988 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' F' F ' 1' ' ' ASP . . . . . 0.407 ' CB ' ' N ' ' C' ' 1' ' ' ASP . 9.4 m-20 . . . . . 0 N--CA 1.489 1.476 0 N-CA-C 109.286 -0.635 . . . . 0.0 109.286 . . . . . . . . . 1 1 . 1 . 018 nuclear build full ' F' F ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.13 131.05 46.34 Favored 'General case' 0 CA--C 1.536 0.421 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.322 179.804 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' F' F ' 3' ' ' GLU . . . . . . . . . . . . . 39.7 tt0 -169.1 108.56 0.45 Allowed 'General case' 0 N--CA 1.469 0.484 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 -179.632 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 77.6 m-85 -84.24 141.83 30.71 Favored 'General case' 0 N--CA 1.475 0.777 0 N-CA-C 109.625 -0.509 . . . . 0.0 109.625 179.228 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' F' F ' 5' ' ' ARG . . . . . 0.429 HH21 HG22 ' E' ' 24' ' ' VAL . 37.1 mtp180 -142.51 143.43 32.53 Favored 'General case' 0 N--CA 1.477 0.898 0 N-CA-C 109.396 -0.594 . . . . 0.0 109.396 179.979 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 74.8 m80 -150.59 117.65 5.94 Favored 'General case' 0 N--CA 1.474 0.744 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 178.626 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' F' F ' 7' ' ' ASP . . . . . . . . . . . . . 9.5 m-20 -68.05 149.11 50.08 Favored 'General case' 0 N--CA 1.463 0.21 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.057 -179.812 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' F' F ' 8' ' ' SER . . . . . . . . . . . . . 3.4 t -168.65 177.7 5.04 Favored 'General case' 0 N--CA 1.474 0.773 0 N-CA-C 109.521 -0.548 . . . . 0.0 109.521 178.153 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 105.13 50.95 0.9 Allowed Glycine 0 N--CA 1.478 1.496 0 N-CA-C 111.858 -0.497 . . . . 0.0 111.858 179.054 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 43.8 p90 -64.07 131.74 48.44 Favored 'General case' 0 CA--C 1.543 0.697 0 N-CA-C 112.0 0.37 . . . . 0.0 112.0 -179.867 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 41.5 mt-10 -82.01 151.56 27.07 Favored 'General case' 0 N--CA 1.479 0.994 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 177.448 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.6 p -156.0 127.88 0.98 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.46 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 177.921 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 52.3 m-70 -133.49 143.63 48.92 Favored 'General case' 0 N--CA 1.481 1.122 0 O-C-N 122.25 -0.281 . . . . 0.0 110.965 -177.856 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 5.9 t60 -165.44 97.73 0.69 Allowed 'General case' 0 N--CA 1.486 1.341 0 CA-C-O 119.604 -0.236 . . . . 0.0 111.386 179.777 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 46.9 mt-30 -106.75 -172.31 2.06 Favored 'General case' 0 CA--C 1.497 -1.064 0 N-CA-C 108.088 -1.078 . . . . 0.0 108.088 179.177 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -163.26 97.86 0.91 Allowed 'General case' 0 CA--C 1.539 0.551 0 CA-C-N 114.96 -1.018 . . . . 0.0 109.16 178.77 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' F' F ' 17' ' ' LEU . . . . . 0.483 ' N ' HD12 ' F' ' 17' ' ' LEU . 6.2 mp -108.46 163.14 13.48 Favored 'General case' 0 N--CA 1.489 1.488 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 -179.914 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 40.5 t -141.89 120.72 9.66 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.227 0 C-N-CA 122.549 0.339 . . . . 0.0 110.648 179.261 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 52.4 m-85 -73.59 155.43 39.11 Favored 'General case' 0 C--N 1.362 1.125 0 N-CA-C 106.765 -1.568 . . . . 0.0 106.765 176.219 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 24.3 t80 -171.48 -55.1 0.02 OUTLIER 'General case' 0 N--CA 1.481 1.084 0 CA-C-O 121.739 0.781 . . . . 0.0 109.75 -179.861 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.83 89.72 0.0 OUTLIER 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 114.49 -1.232 . . . . 0.0 112.693 -179.342 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 36.0 tt0 -56.4 133.4 52.99 Favored 'General case' 0 CA--C 1.54 0.586 0 CA-C-N 114.953 -1.021 . . . . 0.0 111.283 179.79 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 -81.7 162.39 23.01 Favored 'General case' 0 N--CA 1.475 0.793 0 N-CA-C 109.627 -0.508 . . . . 0.0 109.627 179.826 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' F' F ' 24' ' ' VAL . . . . . 0.417 HG22 HH21 ' D' ' 5' ' ' ARG . 95.8 t -160.7 -74.96 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.486 1.333 0 N-CA-C 107.095 -1.446 . . . . 0.0 107.095 -179.005 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -38.49 91.01 0.01 OUTLIER Glycine 0 CA--C 1.529 0.91 0 CA-C-N 115.305 -0.862 . . . . 0.0 112.451 -179.779 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 84.9 p -37.58 -100.97 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.067 0 N-CA-C 113.69 0.996 . . . . 0.0 113.69 -177.443 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' F' F ' 27' ' ' ASN . . . . . 0.424 ' ND2' ' OE2' ' A' ' 11' ' ' GLU . 39.9 t30 -60.18 124.91 21.7 Favored 'General case' 0 CA--C 1.542 0.642 0 CA-C-N 119.492 1.042 . . . . 0.0 108.769 -179.954 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 62.8 mttm -105.65 -178.6 3.7 Favored 'General case' 0 N--CA 1.483 1.197 0 N-CA-C 108.893 -0.78 . . . . 0.0 108.893 -179.737 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -65.29 -141.67 0.03 OUTLIER Glycine 0 CA--C 1.532 1.152 0 N-CA-C 110.463 -1.055 . . . . 0.0 110.463 178.008 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.65 117.79 21.8 Favored 'General case' 0 C--N 1.351 0.633 0 C-N-CA 123.351 0.66 . . . . 0.0 109.399 178.468 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 71.6 mt -99.81 148.86 6.15 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.871 0 N-CA-C 106.934 -1.506 . . . . 0.0 106.934 178.021 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 34.6 mt -148.15 124.99 2.78 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.912 0 N-CA-C 108.874 -0.787 . . . . 0.0 108.874 -179.399 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.71 85.5 0.05 OUTLIER Glycine 0 C--N 1.339 0.741 0 CA-C-N 115.967 -0.561 . . . . 0.0 112.793 178.526 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 13.1 tp -103.44 121.43 42.8 Favored 'General case' 0 N--CA 1.483 1.208 0 N-CA-C 106.945 -1.502 . . . . 0.0 106.945 177.43 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 12.5 ttt -156.17 159.01 38.6 Favored 'General case' 0 N--CA 1.474 0.771 0 N-CA-C 109.058 -0.719 . . . . 0.0 109.058 179.639 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 93.3 t -156.76 151.96 8.35 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.437 0 N-CA-C 107.615 -1.254 . . . . 0.0 107.615 -179.663 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 57.73 72.38 0.6 Allowed Glycine 0 C--N 1.312 -0.759 0 CA-C-N 115.491 -0.777 . . . . 0.0 111.508 178.162 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 171.57 -148.92 11.42 Favored Glycine 0 CA--C 1.523 0.578 0 N-CA-C 111.035 -0.826 . . . . 0.0 111.035 179.686 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 32.9 m -135.42 144.04 35.16 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.837 0 N-CA-C 109.054 -0.721 . . . . 0.0 109.054 179.932 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 19.6 t . . . . . 0 CA--C 1.537 0.454 0 CA-C-O 117.658 -1.163 . . . . 0.0 110.853 179.996 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' G' G ' 1' ' ' ASP . . . . . 0.433 ' HB2' ' H2 ' ' D' ' 1' ' ' ASP . 9.6 m-20 . . . . . 0 N--CA 1.49 1.569 0 N-CA-C 109.556 -0.535 . . . . 0.0 109.556 . . . . . . . . . 1 1 . 1 . 018 nuclear build full ' G' G ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.66 129.52 40.91 Favored 'General case' 0 N--CA 1.469 0.512 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.445 179.587 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' G' G ' 3' ' ' GLU . . . . . . . . . . . . . 39.5 tt0 -168.99 108.33 0.46 Allowed 'General case' 0 N--CA 1.47 0.557 0 N-CA-C 110.013 -0.365 . . . . 0.0 110.013 179.854 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 78.3 m-85 -84.51 141.17 30.94 Favored 'General case' 0 N--CA 1.473 0.691 0 N-CA-C 109.413 -0.588 . . . . 0.0 109.413 179.174 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' G' G ' 5' ' ' ARG . . . . . 0.414 HH21 HG22 ' I' ' 24' ' ' VAL . 37.0 mtp180 -142.79 143.37 32.15 Favored 'General case' 0 N--CA 1.481 1.113 0 N-CA-C 109.422 -0.585 . . . . 0.0 109.422 -179.635 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 74.7 m80 -150.41 118.81 6.43 Favored 'General case' 0 N--CA 1.473 0.711 0 N-CA-C 109.173 -0.677 . . . . 0.0 109.173 178.69 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 9.7 m-20 -70.0 144.41 52.3 Favored 'General case' 0 CA--C 1.538 0.482 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.642 -179.717 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' G' G ' 8' ' ' SER . . . . . . . . . . . . . 2.9 t -164.46 179.74 6.53 Favored 'General case' 0 N--CA 1.471 0.595 0 N-CA-C 109.465 -0.568 . . . . 0.0 109.465 177.998 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.3 50.7 0.97 Allowed Glycine 0 N--CA 1.476 1.327 0 N-CA-C 111.919 -0.472 . . . . 0.0 111.919 179.049 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 46.9 p90 -64.78 131.86 47.96 Favored 'General case' 0 N--CA 1.474 0.753 0 N-CA-C 112.097 0.406 . . . . 0.0 112.097 -179.484 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 44.0 mt-10 -82.08 150.39 27.54 Favored 'General case' 0 N--CA 1.474 0.748 0 N-CA-C 109.141 -0.688 . . . . 0.0 109.141 177.969 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 3.0 p -156.26 127.82 0.94 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.976 0 N-CA-C 108.285 -1.005 . . . . 0.0 108.285 178.168 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 55.9 m-70 -132.89 144.03 49.9 Favored 'General case' 0 N--CA 1.476 0.827 0 CA-C-N 115.392 -0.822 . . . . 0.0 110.718 -177.935 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' G' G ' 14' ' ' HIS . . . . . 0.41 ' O ' ' ND1' ' D' ' 14' ' ' HIS . 6.0 t60 -165.94 98.29 0.64 Allowed 'General case' 0 N--CA 1.483 1.19 0 CA-C-O 119.599 -0.239 . . . . 0.0 110.765 179.129 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 47.2 mt-30 -107.42 -172.24 2.03 Favored 'General case' 0 CA--C 1.503 -0.85 0 N-CA-C 108.194 -1.039 . . . . 0.0 108.194 179.306 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -163.19 98.27 0.93 Allowed 'General case' 0 N--CA 1.472 0.653 0 CA-C-N 115.05 -0.977 . . . . 0.0 109.281 178.718 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' G' G ' 17' ' ' LEU . . . . . 0.481 ' N ' HD12 ' G' ' 17' ' ' LEU . 6.6 mp -108.47 162.18 14.36 Favored 'General case' 0 N--CA 1.486 1.367 0 N-CA-C 108.946 -0.761 . . . . 0.0 108.946 -179.751 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 36.5 t -142.99 120.48 6.38 Favored 'Isoleucine or valine' 0 CA--C 1.551 1.019 0 CA-C-O 121.223 0.535 . . . . 0.0 110.435 178.973 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 47.3 m-85 -72.73 149.83 43.4 Favored 'General case' 0 C--N 1.375 1.71 0 N-CA-C 106.8 -1.555 . . . . 0.0 106.8 176.166 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 20.0 t80 -169.84 -54.23 0.02 OUTLIER 'General case' 0 N--CA 1.484 1.252 0 N-CA-C 110.194 -0.298 . . . . 0.0 110.194 -179.349 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -42.34 91.43 0.0 OUTLIER 'General case' 0 C--N 1.323 -0.571 0 O-C-N 123.942 0.776 . . . . 0.0 112.129 179.69 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 36.9 tt0 -57.83 133.67 55.62 Favored 'General case' 0 CA--C 1.539 0.542 0 CA-C-N 114.795 -1.093 . . . . 0.0 110.741 179.426 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 -81.08 161.51 24.12 Favored 'General case' 0 N--CA 1.474 0.749 0 N-CA-C 109.714 -0.476 . . . . 0.0 109.714 179.992 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' G' G ' 24' ' ' VAL . . . . . 0.423 HG22 HH21 ' H' ' 5' ' ' ARG . 94.8 t -159.44 -76.96 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.957 0 N-CA-C 106.839 -1.541 . . . . 0.0 106.839 -179.027 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -35.35 90.18 0.01 OUTLIER Glycine 0 C--O 1.225 -0.46 0 CA-C-N 114.876 -1.056 . . . . 0.0 112.765 179.381 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 94.2 p -37.78 -99.1 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.899 0 C-N-CA 123.626 0.771 . . . . 0.0 112.708 -176.861 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' G' G ' 27' ' ' ASN . . . . . 0.415 ' ND2' ' CG ' ' H' ' 11' ' ' GLU . 40.8 t30 -61.84 126.54 27.72 Favored 'General case' 0 CA--C 1.545 0.773 0 CA-C-N 119.474 1.034 . . . . 0.0 109.161 179.064 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 63.3 mttm -107.03 -179.09 3.83 Favored 'General case' 0 N--CA 1.483 1.184 0 N-CA-C 109.307 -0.627 . . . . 0.0 109.307 -179.76 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.97 -141.27 0.02 OUTLIER Glycine 0 N--CA 1.464 0.523 0 N-CA-C 109.848 -1.301 . . . . 0.0 109.848 178.422 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.96 115.2 17.45 Favored 'General case' 0 C--O 1.218 -0.558 0 C-N-CA 123.213 0.605 . . . . 0.0 109.413 179.572 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 74.5 mt -97.45 150.96 4.39 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.046 0 N-CA-C 106.92 -1.511 . . . . 0.0 106.92 178.1 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 35.8 mt -149.53 126.91 2.53 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.345 0 N-CA-C 108.876 -0.787 . . . . 0.0 108.876 178.405 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.28 85.95 0.04 OUTLIER Glycine 0 C--N 1.341 0.835 0 CA-C-N 115.957 -0.565 . . . . 0.0 112.823 178.559 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 14.4 tp -103.17 123.66 47.12 Favored 'General case' 0 N--CA 1.484 1.264 0 N-CA-C 107.029 -1.471 . . . . 0.0 107.029 177.271 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 11.9 ttt -158.75 158.57 33.88 Favored 'General case' 0 N--CA 1.469 0.494 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 179.973 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 94.5 t -156.47 153.13 7.42 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.289 0 N-CA-C 106.897 -1.519 . . . . 0.0 106.897 -179.663 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.89 73.18 0.47 Allowed Glycine 0 C--N 1.311 -0.811 0 CA-C-N 115.761 -0.654 . . . . 0.0 111.978 178.292 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 169.98 -148.05 11.4 Favored Glycine 0 N--CA 1.469 0.846 0 N-CA-C 110.703 -0.959 . . . . 0.0 110.703 179.019 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 33.5 m -135.48 144.03 35.11 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.009 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 -179.803 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 20.2 t . . . . . 0 N--CA 1.468 0.426 0 CA-C-O 117.776 -1.106 . . . . 0.0 110.838 179.914 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' H' H ' 1' ' ' ASP . . . . . 0.418 ' HB2' ' H2 ' ' E' ' 1' ' ' ASP . 9.7 m-20 . . . . . 0 N--CA 1.491 1.603 0 N-CA-C 109.591 -0.522 . . . . 0.0 109.591 . . . . . . . . . 1 1 . 1 . 018 nuclear build full ' H' H ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.75 129.5 40.79 Favored 'General case' 0 N--CA 1.469 0.494 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.374 179.641 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' H' H ' 3' ' ' GLU . . . . . . . . . . . . . 39.5 tt0 -168.91 108.28 0.46 Allowed 'General case' 0 N--CA 1.47 0.541 0 N-CA-C 109.981 -0.377 . . . . 0.0 109.981 179.845 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 78.7 m-85 -84.25 141.56 30.89 Favored 'General case' 0 N--CA 1.473 0.714 0 N-CA-C 109.362 -0.607 . . . . 0.0 109.362 179.183 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' H' H ' 5' ' ' ARG . . . . . 0.423 HH21 HG22 ' G' ' 24' ' ' VAL . 37.2 mtp180 -142.99 143.28 31.85 Favored 'General case' 0 N--CA 1.482 1.157 0 N-CA-C 109.302 -0.629 . . . . 0.0 109.302 -179.638 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 74.6 m80 -150.43 118.7 6.38 Favored 'General case' 0 N--CA 1.473 0.68 0 N-CA-C 109.252 -0.648 . . . . 0.0 109.252 178.642 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 9.4 m-20 -69.86 144.35 52.55 Favored 'General case' 0 N--CA 1.468 0.44 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.579 -179.693 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' H' H ' 8' ' ' SER . . . . . . . . . . . . . 3.6 t -164.38 179.09 6.99 Favored 'General case' 0 N--CA 1.47 0.538 0 N-CA-C 109.517 -0.549 . . . . 0.0 109.517 178.091 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.56 50.9 0.94 Allowed Glycine 0 N--CA 1.478 1.442 0 N-CA-C 111.948 -0.461 . . . . 0.0 111.948 179.054 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 46.7 p90 -64.79 131.87 48.0 Favored 'General case' 0 N--CA 1.474 0.765 0 N-CA-C 112.015 0.376 . . . . 0.0 112.015 -179.546 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' H' H ' 11' ' ' GLU . . . . . 0.415 ' CG ' ' ND2' ' G' ' 27' ' ' ASN . 44.0 mt-10 -82.05 150.38 27.59 Favored 'General case' 0 N--CA 1.474 0.749 0 N-CA-C 109.186 -0.672 . . . . 0.0 109.186 177.929 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 3.0 p -156.4 127.82 0.92 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.044 0 N-CA-C 108.291 -1.003 . . . . 0.0 108.291 178.108 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 56.0 m-70 -132.74 144.14 50.07 Favored 'General case' 0 N--CA 1.475 0.804 0 CA-C-N 115.22 -0.9 . . . . 0.0 110.731 -177.906 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 6.0 t60 -166.12 97.74 0.62 Allowed 'General case' 0 N--CA 1.482 1.163 0 CA-C-O 119.554 -0.26 . . . . 0.0 110.775 179.105 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 47.6 mt-30 -106.87 -172.56 2.1 Favored 'General case' 0 CA--C 1.505 -0.768 0 N-CA-C 108.099 -1.074 . . . . 0.0 108.099 179.403 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -163.0 98.24 0.94 Allowed 'General case' 0 N--CA 1.472 0.643 0 CA-C-N 115.268 -0.878 . . . . 0.0 109.218 178.679 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' H' H ' 17' ' ' LEU . . . . . 0.486 ' N ' HD12 ' H' ' 17' ' ' LEU . 6.6 mp -108.48 162.24 14.31 Favored 'General case' 0 N--CA 1.485 1.312 0 N-CA-C 108.978 -0.749 . . . . 0.0 108.978 -179.769 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 37.0 t -142.99 120.15 6.08 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.037 0 CA-C-O 121.16 0.505 . . . . 0.0 110.553 178.994 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 48.2 m-85 -72.76 150.41 42.84 Favored 'General case' 0 C--N 1.373 1.629 0 N-CA-C 106.909 -1.515 . . . . 0.0 106.909 176.182 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 21.3 t80 -171.25 -53.95 0.02 OUTLIER 'General case' 0 N--CA 1.481 1.093 0 N-CA-C 110.202 -0.295 . . . . 0.0 110.202 -179.361 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -42.26 91.6 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.463 0 O-C-N 123.872 0.732 . . . . 0.0 111.896 179.613 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 37.0 tt0 -57.81 133.89 55.8 Favored 'General case' 0 CA--C 1.54 0.564 0 CA-C-N 114.777 -1.102 . . . . 0.0 110.694 179.793 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 9.0 m-20 -81.24 161.44 23.96 Favored 'General case' 0 N--CA 1.474 0.768 0 N-CA-C 109.69 -0.485 . . . . 0.0 109.69 -179.986 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' H' H ' 24' ' ' VAL . . . . . 0.42 HG22 HH21 ' I' ' 5' ' ' ARG . 95.0 t -159.77 -77.03 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.99 0 N-CA-C 106.983 -1.488 . . . . 0.0 106.983 -179.037 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . -35.43 89.96 0.01 OUTLIER Glycine 0 N--CA 1.47 0.924 0 CA-C-N 115.086 -0.961 . . . . 0.0 112.245 179.547 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 97.5 p -37.47 -98.79 0.0 OUTLIER 'General case' 0 N--CA 1.478 0.954 0 C-N-CA 123.693 0.797 . . . . 0.0 112.739 -176.711 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' H' H ' 27' ' ' ASN . . . . . 0.409 ' ND2' ' CG ' ' I' ' 11' ' ' GLU . 40.1 t30 -61.62 126.69 28.23 Favored 'General case' 0 CA--C 1.543 0.689 0 CA-C-N 119.368 0.985 . . . . 0.0 109.144 179.01 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 63.3 mttm -106.97 -178.9 3.78 Favored 'General case' 0 N--CA 1.484 1.241 0 N-CA-C 109.365 -0.606 . . . . 0.0 109.365 -179.797 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.92 -141.19 0.02 OUTLIER Glycine 0 CA--C 1.522 0.521 0 N-CA-C 109.935 -1.266 . . . . 0.0 109.935 178.207 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -129.0 115.51 17.9 Favored 'General case' 0 C--O 1.217 -0.643 0 C-N-CA 123.263 0.625 . . . . 0.0 109.437 179.499 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 74.6 mt -97.86 150.6 4.65 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.027 0 N-CA-C 106.908 -1.515 . . . . 0.0 106.908 178.13 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 35.4 mt -149.32 126.89 2.62 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.309 0 N-CA-C 108.912 -0.773 . . . . 0.0 108.912 178.579 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.3 85.65 0.05 OUTLIER Glycine 0 C--N 1.34 0.801 0 CA-C-N 115.946 -0.57 . . . . 0.0 112.994 178.586 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 14.5 tp -102.97 123.28 46.29 Favored 'General case' 0 N--CA 1.482 1.158 0 N-CA-C 107.04 -1.466 . . . . 0.0 107.04 177.332 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 11.8 ttt -158.38 158.48 34.34 Favored 'General case' 0 N--CA 1.469 0.516 0 N-CA-C 108.585 -0.895 . . . . 0.0 108.585 -179.958 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 96.9 t -156.51 152.4 8.12 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.357 0 N-CA-C 107.076 -1.453 . . . . 0.0 107.076 -179.782 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 57.46 73.03 0.5 Allowed Glycine 0 C--N 1.313 -0.698 0 CA-C-N 115.644 -0.707 . . . . 0.0 112.028 178.169 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 169.98 -148.17 11.52 Favored Glycine 0 N--CA 1.468 0.792 0 N-CA-C 110.566 -1.014 . . . . 0.0 110.566 179.068 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 33.4 m -135.36 144.01 35.31 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.995 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.706 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 20.3 t . . . . . 0 C--O 1.222 -0.385 0 CA-C-O 117.852 -1.07 . . . . 0.0 110.916 179.99 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' I' I ' 1' ' ' ASP . . . . . . . . . . . . . 9.7 m-20 . . . . . 0 N--CA 1.491 1.603 0 N-CA-C 109.64 -0.504 . . . . 0.0 109.64 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' I' I ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.67 129.64 41.42 Favored 'General case' 0 N--CA 1.47 0.544 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.345 179.64 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' I' I ' 3' ' ' GLU . . . . . . . . . . . . . 39.4 tt0 -169.04 108.21 0.45 Allowed 'General case' 0 N--CA 1.47 0.527 0 N-CA-C 109.935 -0.394 . . . . 0.0 109.935 179.811 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 79.0 m-85 -84.27 141.63 30.82 Favored 'General case' 0 N--CA 1.474 0.764 0 N-CA-C 109.323 -0.621 . . . . 0.0 109.323 179.191 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' I' I ' 5' ' ' ARG . . . . . 0.42 HH21 HG22 ' H' ' 24' ' ' VAL . 37.1 mtp180 -143.15 143.36 31.78 Favored 'General case' 0 N--CA 1.482 1.17 0 N-CA-C 109.273 -0.64 . . . . 0.0 109.273 -179.687 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 74.6 m80 -150.51 118.55 6.29 Favored 'General case' 0 N--CA 1.474 0.729 0 N-CA-C 109.243 -0.651 . . . . 0.0 109.243 178.691 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 9.5 m-20 -69.72 144.21 52.85 Favored 'General case' 0 CA--C 1.537 0.444 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.681 -179.696 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' I' I ' 8' ' ' SER . . . . . . . . . . . . . 3.6 t -164.23 179.11 7.06 Favored 'General case' 0 N--CA 1.469 0.514 0 N-CA-C 109.492 -0.558 . . . . 0.0 109.492 178.182 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.58 50.9 0.94 Allowed Glycine 0 N--CA 1.477 1.426 0 N-CA-C 111.929 -0.469 . . . . 0.0 111.929 179.047 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 47.1 p90 -64.85 131.91 48.01 Favored 'General case' 0 N--CA 1.474 0.734 0 N-CA-C 112.104 0.409 . . . . 0.0 112.104 -179.573 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' I' I ' 11' ' ' GLU . . . . . 0.409 ' CG ' ' ND2' ' H' ' 27' ' ' ASN . 43.9 mt-10 -82.14 150.39 27.48 Favored 'General case' 0 N--CA 1.473 0.71 0 N-CA-C 109.249 -0.648 . . . . 0.0 109.249 177.934 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 3.1 p -156.38 127.7 0.91 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.971 0 N-CA-C 108.366 -0.976 . . . . 0.0 108.366 178.209 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 55.5 m-70 -132.8 144.13 50.02 Favored 'General case' 0 N--CA 1.475 0.779 0 CA-C-N 115.24 -0.891 . . . . 0.0 110.735 -177.839 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 28.4 t-80 -166.21 97.98 0.61 Allowed 'General case' 0 N--CA 1.483 1.181 0 CA-C-N 116.664 -0.244 . . . . 0.0 110.818 179.228 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 47.3 mt-30 -107.11 -172.21 2.03 Favored 'General case' 0 CA--C 1.501 -0.918 0 N-CA-C 108.12 -1.067 . . . . 0.0 108.12 179.322 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -163.24 98.27 0.92 Allowed 'General case' 0 N--CA 1.47 0.563 0 CA-C-N 115.109 -0.95 . . . . 0.0 109.22 178.704 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' I' I ' 17' ' ' LEU . . . . . 0.48 ' N ' HD12 ' I' ' 17' ' ' LEU . 6.6 mp -108.45 162.12 14.41 Favored 'General case' 0 N--CA 1.485 1.323 0 N-CA-C 108.968 -0.753 . . . . 0.0 108.968 -179.751 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 37.7 t -142.9 120.18 6.35 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.048 0 CA-C-O 121.2 0.524 . . . . 0.0 110.483 178.987 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 47.7 m-85 -72.81 150.39 42.78 Favored 'General case' 0 C--N 1.374 1.645 0 N-CA-C 106.759 -1.571 . . . . 0.0 106.759 176.196 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 21.3 t80 -171.17 -54.15 0.02 OUTLIER 'General case' 0 N--CA 1.48 1.048 0 N-CA-C 110.217 -0.29 . . . . 0.0 110.217 -179.304 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -42.25 91.58 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.461 0 CA-C-O 121.632 0.729 . . . . 0.0 111.856 179.656 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 37.0 tt0 -57.75 133.82 55.7 Favored 'General case' 0 CA--C 1.539 0.558 0 CA-C-N 114.769 -1.105 . . . . 0.0 110.773 179.691 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 -81.09 161.38 24.16 Favored 'General case' 0 N--CA 1.473 0.716 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 179.936 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' I' I ' 24' ' ' VAL . . . . . 0.414 HG22 HH21 ' G' ' 5' ' ' ARG . 95.1 t -159.75 -77.11 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.04 0 N-CA-C 107.045 -1.465 . . . . 0.0 107.045 -179.095 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . -35.53 90.09 0.01 OUTLIER Glycine 0 C--N 1.34 0.804 0 CA-C-N 115.073 -0.967 . . . . 0.0 112.25 179.611 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 97.5 p -37.4 -98.95 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.875 0 C-N-CA 123.794 0.838 . . . . 0.0 112.82 -176.733 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 40.5 t30 -61.5 126.62 28.02 Favored 'General case' 0 CA--C 1.542 0.645 0 CA-C-N 119.431 1.014 . . . . 0.0 109.148 179.005 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 63.2 mttm -106.96 -178.95 3.79 Favored 'General case' 0 N--CA 1.484 1.275 0 N-CA-C 109.356 -0.609 . . . . 0.0 109.356 -179.791 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.92 -141.27 0.02 OUTLIER Glycine 0 CA--C 1.523 0.58 0 N-CA-C 109.906 -1.278 . . . . 0.0 109.906 178.254 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.86 115.46 17.93 Favored 'General case' 0 C--O 1.218 -0.584 0 C-N-CA 123.247 0.619 . . . . 0.0 109.434 179.537 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 74.6 mt -97.94 150.67 4.64 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.047 0 N-CA-C 106.878 -1.527 . . . . 0.0 106.878 178.186 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 35.7 mt -149.31 126.93 2.65 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.292 0 N-CA-C 108.863 -0.791 . . . . 0.0 108.863 178.646 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.28 85.69 0.05 OUTLIER Glycine 0 C--N 1.339 0.71 0 CA-C-N 115.986 -0.552 . . . . 0.0 112.919 178.571 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 14.6 tp -102.91 123.25 46.19 Favored 'General case' 0 N--CA 1.482 1.151 0 N-CA-C 107.008 -1.479 . . . . 0.0 107.008 177.208 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 11.8 ttt -158.31 158.51 34.51 Favored 'General case' 0 N--CA 1.469 0.489 0 N-CA-C 108.56 -0.904 . . . . 0.0 108.56 179.97 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 96.6 t -156.57 152.39 8.09 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.297 0 N-CA-C 107.007 -1.479 . . . . 0.0 107.007 -179.776 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 57.44 73.2 0.48 Allowed Glycine 0 C--N 1.313 -0.734 0 CA-C-N 115.661 -0.7 . . . . 0.0 111.932 178.141 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 169.9 -148.29 11.66 Favored Glycine 0 N--CA 1.467 0.719 0 N-CA-C 110.651 -0.979 . . . . 0.0 110.651 179.094 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 33.4 m -135.21 144.01 35.49 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.947 0 C-N-CA 122.765 0.426 . . . . 0.0 109.904 -179.83 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 20.3 t . . . . . 0 C--O 1.222 -0.378 0 CA-C-O 117.803 -1.094 . . . . 0.0 110.932 179.996 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 8.8 m-20 . . . . . 0 N--CA 1.49 1.538 0 N-CA-C 108.49 -0.93 . . . . 0.0 108.49 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.82 132.54 49.76 Favored 'General case' 0 CA--C 1.541 0.614 0 CA-C-N 116.452 -0.34 . . . . 0.0 110.085 -179.943 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 54.6 tt0 -169.32 126.8 0.94 Allowed 'General case' 0 N--CA 1.472 0.653 0 N-CA-C 109.707 -0.479 . . . . 0.0 109.707 -179.133 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 29.1 m-85 -117.15 126.97 53.65 Favored 'General case' 0 N--CA 1.476 0.864 0 N-CA-C 108.637 -0.875 . . . . 0.0 108.637 179.578 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 5' ' ' ARG . . . . . 0.897 HH12 HG11 ' C' ' 24' ' ' VAL . 6.2 ptm180 -165.06 146.65 7.73 Favored 'General case' 0 N--CA 1.478 0.954 0 N-CA-C 112.349 0.5 . . . . 0.0 112.349 -179.738 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 21.2 p80 -151.89 107.79 3.38 Favored 'General case' 0 N--CA 1.475 0.788 0 CA-C-O 120.884 0.374 . . . . 0.0 110.552 177.93 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -78.13 151.69 33.2 Favored 'General case' 0 N--CA 1.475 0.805 0 CA-C-O 121.03 0.443 . . . . 0.0 109.827 178.961 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 99.8 p -155.2 173.67 16.29 Favored 'General case' 0 N--CA 1.475 0.794 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.595 -179.766 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 125.13 78.99 0.35 Allowed Glycine 0 N--CA 1.481 1.692 0 N-CA-C 111.441 -0.664 . . . . 0.0 111.441 -179.969 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 23.6 p90 -55.14 156.05 4.33 Favored 'General case' 0 N--CA 1.478 0.954 0 C-N-CA 122.528 0.331 . . . . 0.0 110.698 178.982 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 65.7 mt-10 -119.65 127.21 52.7 Favored 'General case' 0 N--CA 1.486 1.366 0 N-CA-C 109.708 -0.479 . . . . 0.0 109.708 179.281 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 40.2 t -101.69 139.83 21.85 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.705 0 N-CA-C 109.194 -0.669 . . . . 0.0 109.194 178.815 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 88.4 m-70 -140.42 138.98 35.16 Favored 'General case' 0 N--CA 1.488 1.445 0 CA-C-N 118.762 0.71 . . . . 0.0 109.98 178.494 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 52.9 t-80 -167.55 97.31 0.48 Allowed 'General case' 0 N--CA 1.481 1.119 0 CA-C-O 119.745 -0.169 . . . . 0.0 110.632 178.979 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 55.2 mt-30 -100.55 116.48 32.6 Favored 'General case' 0 CA--C 1.512 -0.493 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 -179.484 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 64.4 tttp -104.32 105.95 16.27 Favored 'General case' 0 N--CA 1.48 1.07 0 N-CA-C 108.648 -0.871 . . . . 0.0 108.648 178.148 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 10.0 mp -122.63 165.17 16.92 Favored 'General case' 0 N--CA 1.487 1.412 0 N-CA-C 108.712 -0.847 . . . . 0.0 108.712 -179.55 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 62.1 t -142.57 111.28 2.19 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.09 0 N-CA-C 108.499 -0.926 . . . . 0.0 108.499 177.757 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 59.7 m-85 -101.24 164.92 11.55 Favored 'General case' 0 N--CA 1.475 0.821 0 N-CA-C 109.29 -0.633 . . . . 0.0 109.29 178.244 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.453 ' O ' ' O ' ' D' ' 21' ' ' ALA . 77.7 t80 -165.53 -83.46 0.02 OUTLIER 'General case' 0 C--O 1.209 -1.052 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 177.205 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -88.29 94.08 9.72 Favored 'General case' 0 C--N 1.353 0.726 0 N-CA-C 108.249 -1.019 . . . . 0.0 108.249 177.567 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 11.2 mm-40 -73.85 -170.13 0.84 Allowed 'General case' 0 N--CA 1.482 1.153 0 C-N-CA 120.344 -0.542 . . . . 0.0 110.771 179.812 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 8.2 m-20 -73.17 153.35 40.75 Favored 'General case' 0 N--CA 1.473 0.712 0 CA-C-O 121.886 0.85 . . . . 0.0 112.995 -177.637 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.917 HG11 HH12 ' B' ' 5' ' ' ARG . 71.2 t -155.23 94.35 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.466 0.369 0 CA-C-N 114.551 -1.204 . . . . 0.0 108.244 177.005 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -121.56 60.3 0.55 Allowed Glycine 0 N--CA 1.481 1.638 0 N-CA-C 110.995 -0.842 . . . . 0.0 110.995 179.038 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 15.3 m 47.32 -143.34 0.38 Allowed 'General case' 0 N--CA 1.484 1.261 0 CA-C-N 118.164 0.982 . . . . 0.0 110.479 -179.633 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 27' ' ' ASN . . . . . 0.443 ' ND2' ' O ' ' E' ' 9' ' ' GLY . 8.7 m120 -79.67 92.38 5.37 Favored 'General case' 0 N--CA 1.47 0.527 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 177.636 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 96.4 mttt -65.76 146.21 55.05 Favored 'General case' 0 CA--C 1.539 0.537 0 CA-C-O 121.264 0.554 . . . . 0.0 110.537 -178.559 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -70.17 -129.17 0.06 OUTLIER Glycine 0 CA--C 1.525 0.688 0 N-CA-C 109.445 -1.462 . . . . 0.0 109.445 178.533 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -85.01 131.35 34.48 Favored 'General case' 0 N--CA 1.465 0.3 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 179.69 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 18.3 tt -165.54 173.52 0.17 Allowed 'Isoleucine or valine' 0 C--O 1.215 -0.745 0 N-CA-C 108.815 -0.809 . . . . 0.0 108.815 -177.85 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 24.3 mt -140.27 145.21 26.41 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.487 0 N-CA-C 107.179 -1.415 . . . . 0.0 107.179 -179.288 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -52.0 168.17 0.71 Allowed Glycine 0 N--CA 1.473 1.14 0 C-N-CA 121.268 -0.491 . . . . 0.0 112.147 -179.328 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 2.7 pp -65.99 158.08 29.17 Favored 'General case' 0 N--CA 1.465 0.293 0 N-CA-C 109.671 -0.492 . . . . 0.0 109.671 179.741 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 21.3 ttt -142.57 154.76 44.72 Favored 'General case' 0 N--CA 1.473 0.676 0 N-CA-C 108.965 -0.754 . . . . 0.0 108.965 -179.919 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 41.3 t -149.49 139.33 16.03 Favored 'Isoleucine or valine' 0 C--O 1.235 0.318 0 N-CA-C 107.241 -1.392 . . . . 0.0 107.241 -179.695 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 60.54 67.44 2.14 Favored Glycine 0 C--N 1.318 -0.437 0 N-CA-C 109.006 -1.637 . . . . 0.0 109.006 -179.85 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -82.22 130.08 9.47 Favored Glycine 0 N--CA 1.468 0.788 0 N-CA-C 111.312 -0.715 . . . . 0.0 111.312 -178.818 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 1.9 t -146.71 113.43 1.05 Allowed 'Isoleucine or valine' 0 CA--C 1.561 1.373 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 179.257 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 19.1 t . . . . . 0 N--CA 1.497 1.899 0 CA-C-O 118.475 -0.774 . . . . 0.0 112.477 -177.877 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' B' B ' 1' ' ' ASP . . . . . . . . . . . . . 8.5 m-20 . . . . . 0 N--CA 1.488 1.447 0 N-CA-C 108.799 -0.815 . . . . 0.0 108.799 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' B' B ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.87 132.33 49.14 Favored 'General case' 0 CA--C 1.54 0.582 0 N-CA-C 110.019 -0.363 . . . . 0.0 110.019 -179.906 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 3' ' ' GLU . . . . . . . . . . . . . 54.6 tt0 -169.28 126.62 0.94 Allowed 'General case' 0 CA--C 1.541 0.606 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 -179.056 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 29.0 m-85 -117.03 127.3 54.03 Favored 'General case' 0 N--CA 1.476 0.847 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 179.481 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 5' ' ' ARG . . . . . 0.917 HH12 HG11 ' A' ' 24' ' ' VAL . 6.3 ptm180 -165.39 146.59 7.31 Favored 'General case' 0 N--CA 1.474 0.773 0 C-N-CA 120.569 -0.452 . . . . 0.0 112.165 -179.698 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 20.9 p80 -151.79 108.07 3.43 Favored 'General case' 0 N--CA 1.476 0.838 0 CA-C-O 120.831 0.348 . . . . 0.0 110.562 177.867 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 7' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -78.56 151.1 32.64 Favored 'General case' 0 N--CA 1.476 0.834 0 CA-C-O 121.088 0.471 . . . . 0.0 109.889 179.042 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 8' ' ' SER . . . . . . . . . . . . . 99.3 p -154.54 173.72 15.92 Favored 'General case' 0 N--CA 1.473 0.718 0 CA-C-N 115.784 -0.643 . . . . 0.0 110.731 -179.759 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 125.2 78.91 0.34 Allowed Glycine 0 N--CA 1.48 1.621 0 N-CA-C 111.433 -0.667 . . . . 0.0 111.433 -179.972 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 23.9 p90 -55.28 156.05 4.55 Favored 'General case' 0 N--CA 1.478 0.927 0 C-N-CA 122.401 0.28 . . . . 0.0 110.742 179.054 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 65.6 mt-10 -119.55 127.43 52.98 Favored 'General case' 0 N--CA 1.486 1.367 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 179.288 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 40.0 t -102.04 139.66 22.55 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.708 0 N-CA-C 109.194 -0.669 . . . . 0.0 109.194 178.85 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 88.3 m-70 -140.41 139.09 35.2 Favored 'General case' 0 N--CA 1.484 1.272 0 CA-C-N 118.689 0.677 . . . . 0.0 110.011 178.729 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 52.5 t-80 -167.87 97.37 0.45 Allowed 'General case' 0 N--CA 1.482 1.165 0 N-CA-C 110.507 -0.183 . . . . 0.0 110.507 179.017 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 55.4 mt-30 -100.67 116.86 33.56 Favored 'General case' 0 CA--C 1.511 -0.546 0 N-CA-C 108.604 -0.887 . . . . 0.0 108.604 -179.533 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 64.6 tttp -104.51 105.97 16.29 Favored 'General case' 0 N--CA 1.479 1.014 0 N-CA-C 108.674 -0.861 . . . . 0.0 108.674 178.106 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 10.0 mp -122.83 165.05 17.26 Favored 'General case' 0 N--CA 1.489 1.516 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 -179.51 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 61.6 t -142.45 110.24 2.04 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.117 0 N-CA-C 108.743 -0.836 . . . . 0.0 108.743 177.838 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 61.1 m-85 -100.11 164.32 12.03 Favored 'General case' 0 N--CA 1.474 0.746 0 CA-C-N 118.745 0.702 . . . . 0.0 109.456 178.275 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 20' ' ' PHE . . . . . 0.433 ' O ' ' O ' ' E' ' 21' ' ' ALA . 76.4 t80 -164.38 -83.59 0.03 OUTLIER 'General case' 0 C--O 1.212 -0.881 0 N-CA-C 109.277 -0.638 . . . . 0.0 109.277 177.238 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -88.73 94.3 9.86 Favored 'General case' 0 C--N 1.35 0.59 0 N-CA-C 108.171 -1.048 . . . . 0.0 108.171 177.599 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 11.4 mm-40 -73.73 -170.24 0.84 Allowed 'General case' 0 N--CA 1.481 1.124 0 C-N-CA 120.487 -0.485 . . . . 0.0 110.791 179.881 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 23' ' ' ASP . . . . . 0.422 ' HB3' ' HZ1' ' B' ' 28' ' ' LYS . 8.2 m-20 -73.24 153.45 40.63 Favored 'General case' 0 N--CA 1.473 0.709 0 CA-C-O 121.943 0.878 . . . . 0.0 112.971 -177.598 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 24' ' ' VAL . . . . . 0.925 HG11 HH12 ' C' ' 5' ' ' ARG . 65.5 t -155.22 94.3 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.391 0 CA-C-N 114.586 -1.188 . . . . 0.0 108.166 177.013 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -121.35 60.16 0.55 Allowed Glycine 0 N--CA 1.479 1.547 0 N-CA-C 111.138 -0.785 . . . . 0.0 111.138 178.874 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 15.3 m 47.4 -143.72 0.36 Allowed 'General case' 0 N--CA 1.485 1.281 0 CA-C-N 118.209 1.005 . . . . 0.0 110.317 -179.574 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 27' ' ' ASN . . . . . 0.437 ' ND2' ' O ' ' F' ' 9' ' ' GLY . 8.8 m120 -79.43 92.45 5.23 Favored 'General case' 0 N--CA 1.469 0.497 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 177.661 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 28' ' ' LYS . . . . . 0.422 ' HZ1' ' HB3' ' B' ' 23' ' ' ASP . 96.4 mttt -65.87 146.47 54.71 Favored 'General case' 0 CA--C 1.54 0.569 0 CA-C-O 121.333 0.587 . . . . 0.0 110.42 -178.472 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -70.33 -129.11 0.06 OUTLIER Glycine 0 CA--C 1.526 0.745 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 178.523 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -85.0 131.32 34.48 Favored 'General case' 0 C--O 1.235 0.291 0 N-CA-C 109.413 -0.588 . . . . 0.0 109.413 179.628 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 18.3 tt -165.61 173.44 0.17 Allowed 'Isoleucine or valine' 0 C--O 1.215 -0.751 0 N-CA-C 108.753 -0.832 . . . . 0.0 108.753 -177.8 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 24.6 mt -140.25 145.14 26.53 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.475 0 N-CA-C 107.194 -1.41 . . . . 0.0 107.194 -179.24 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -51.94 168.25 0.68 Allowed Glycine 0 N--CA 1.472 1.078 0 C-N-CA 121.202 -0.523 . . . . 0.0 112.195 -179.372 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 2.7 pp -66.13 157.76 30.39 Favored 'General case' 0 N--CA 1.465 0.28 0 N-CA-C 109.646 -0.501 . . . . 0.0 109.646 179.79 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 21.3 ttt -142.25 154.93 45.16 Favored 'General case' 0 N--CA 1.473 0.677 0 N-CA-C 109.02 -0.733 . . . . 0.0 109.02 -179.975 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 41.0 t -149.46 139.51 16.21 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.313 0 N-CA-C 107.267 -1.382 . . . . 0.0 107.267 -179.638 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 60.1 67.41 2.17 Favored Glycine 0 C--N 1.318 -0.445 0 N-CA-C 109.152 -1.579 . . . . 0.0 109.152 -179.803 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . -82.16 129.98 9.41 Favored Glycine 0 CA--C 1.526 0.769 0 N-CA-C 111.284 -0.726 . . . . 0.0 111.284 -178.892 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 1.9 t -146.68 113.46 1.06 Allowed 'Isoleucine or valine' 0 CA--C 1.561 1.371 0 N-CA-C 108.459 -0.941 . . . . 0.0 108.459 179.192 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 19.8 t . . . . . 0 N--CA 1.498 1.937 0 CA-C-O 118.409 -0.805 . . . . 0.0 112.195 -177.997 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' C' C ' 1' ' ' ASP . . . . . . . . . . . . . 8.6 m-20 . . . . . 0 N--CA 1.488 1.436 0 N-CA-C 108.833 -0.802 . . . . 0.0 108.833 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' C' C ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.68 132.29 49.26 Favored 'General case' 0 CA--C 1.54 0.577 0 N-CA-C 110.109 -0.33 . . . . 0.0 110.109 -179.987 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' C' C ' 3' ' ' GLU . . . . . . . . . . . . . 54.5 tt0 -169.2 126.49 0.95 Allowed 'General case' 0 CA--C 1.541 0.596 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 -179.059 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 28.6 m-85 -116.88 126.99 53.83 Favored 'General case' 0 N--CA 1.477 0.92 0 N-CA-C 108.653 -0.869 . . . . 0.0 108.653 179.432 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' C' C ' 5' ' ' ARG . . . . . 0.925 HH12 HG11 ' B' ' 24' ' ' VAL . 6.3 ptm180 -164.98 146.54 7.79 Favored 'General case' 0 N--CA 1.476 0.86 0 N-CA-C 112.231 0.456 . . . . 0.0 112.231 -179.706 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 21.2 p80 -151.78 107.92 3.42 Favored 'General case' 0 N--CA 1.476 0.868 0 CA-C-O 120.804 0.335 . . . . 0.0 110.554 177.883 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' C' C ' 7' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -78.51 150.91 32.81 Favored 'General case' 0 N--CA 1.476 0.862 0 CA-C-O 121.061 0.457 . . . . 0.0 109.861 179.038 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' C' C ' 8' ' ' SER . . . . . . . . . . . . . 99.3 p -154.38 173.86 15.64 Favored 'General case' 0 N--CA 1.475 0.796 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.711 -179.856 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 125.07 78.96 0.35 Allowed Glycine 0 N--CA 1.48 1.627 0 N-CA-C 111.447 -0.661 . . . . 0.0 111.447 179.984 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 24.3 p90 -55.24 156.01 4.53 Favored 'General case' 0 N--CA 1.478 0.925 0 C-N-CA 122.501 0.32 . . . . 0.0 110.757 178.959 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 65.5 mt-10 -119.49 127.33 52.94 Favored 'General case' 0 N--CA 1.485 1.325 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 179.326 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 39.9 t -101.87 139.59 22.61 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.717 0 N-CA-C 109.266 -0.642 . . . . 0.0 109.266 178.76 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 88.2 m-70 -140.41 138.92 35.12 Favored 'General case' 0 N--CA 1.486 1.366 0 CA-C-N 118.635 0.652 . . . . 0.0 110.009 178.662 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 52.1 t-80 -167.67 97.46 0.47 Allowed 'General case' 0 N--CA 1.481 1.109 0 N-CA-C 110.542 -0.17 . . . . 0.0 110.542 178.939 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 55.5 mt-30 -100.58 116.71 33.14 Favored 'General case' 0 CA--C 1.513 -0.474 0 N-CA-C 108.608 -0.886 . . . . 0.0 108.608 -179.491 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 64.6 tttp -104.39 106.07 16.43 Favored 'General case' 0 N--CA 1.481 1.111 0 N-CA-C 108.632 -0.877 . . . . 0.0 108.632 178.062 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 10.0 mp -122.91 164.88 17.63 Favored 'General case' 0 N--CA 1.488 1.452 0 N-CA-C 108.599 -0.889 . . . . 0.0 108.599 -179.567 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 60.8 t -142.21 110.31 2.19 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 N-CA-C 108.587 -0.894 . . . . 0.0 108.587 177.836 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 61.4 m-85 -100.09 164.3 12.04 Favored 'General case' 0 N--CA 1.476 0.839 0 CA-C-N 118.734 0.697 . . . . 0.0 109.426 178.202 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' C' C ' 20' ' ' PHE . . . . . 0.44 ' O ' ' O ' ' F' ' 21' ' ' ALA . 76.1 t80 -164.23 -83.66 0.03 OUTLIER 'General case' 0 C--O 1.211 -0.955 0 N-CA-C 109.441 -0.577 . . . . 0.0 109.441 177.132 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -88.61 94.27 9.83 Favored 'General case' 0 C--N 1.349 0.554 0 N-CA-C 108.124 -1.065 . . . . 0.0 108.124 177.633 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 11.3 mm-40 -73.81 -170.14 0.84 Allowed 'General case' 0 N--CA 1.48 1.074 0 C-N-CA 120.393 -0.523 . . . . 0.0 110.816 179.928 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 8.2 m-20 -73.2 153.41 40.69 Favored 'General case' 0 N--CA 1.474 0.76 0 CA-C-O 122.04 0.924 . . . . 0.0 112.864 -177.613 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' C' C ' 24' ' ' VAL . . . . . 0.897 HG11 HH12 ' A' ' 5' ' ' ARG . 65.5 t -155.31 94.43 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.39 0 CA-C-N 114.418 -1.264 . . . . 0.0 108.147 176.958 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -121.57 60.41 0.55 Allowed Glycine 0 N--CA 1.48 1.598 0 N-CA-C 110.984 -0.846 . . . . 0.0 110.984 178.96 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 15.4 m 47.23 -143.79 0.35 Allowed 'General case' 0 N--CA 1.484 1.265 0 CA-C-N 118.21 1.005 . . . . 0.0 110.456 -179.554 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' C' C ' 27' ' ' ASN . . . . . 0.447 ' ND2' ' O ' ' D' ' 9' ' ' GLY . 8.8 m120 -79.33 92.44 5.17 Favored 'General case' 0 N--CA 1.469 0.512 0 N-CA-C 108.71 -0.848 . . . . 0.0 108.71 177.613 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 96.4 mttt -65.87 146.2 55.03 Favored 'General case' 0 CA--C 1.541 0.603 0 CA-C-O 121.292 0.567 . . . . 0.0 110.502 -178.458 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -70.13 -129.0 0.06 OUTLIER Glycine 0 C--N 1.339 0.708 0 N-CA-C 109.591 -1.404 . . . . 0.0 109.591 178.483 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -85.01 131.25 34.49 Favored 'General case' 0 C--O 1.234 0.277 0 N-CA-C 109.423 -0.584 . . . . 0.0 109.423 179.65 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 18.3 tt -165.5 173.53 0.17 Allowed 'Isoleucine or valine' 0 C--O 1.215 -0.749 0 N-CA-C 108.832 -0.803 . . . . 0.0 108.832 -177.954 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 24.4 mt -140.25 145.22 26.43 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.466 0 N-CA-C 107.123 -1.436 . . . . 0.0 107.123 -179.22 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -52.01 168.19 0.71 Allowed Glycine 0 N--CA 1.473 1.113 0 C-N-CA 121.253 -0.499 . . . . 0.0 112.213 -179.442 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 2.7 pp -66.0 157.85 29.8 Favored 'General case' 0 N--CA 1.464 0.274 0 N-CA-C 109.679 -0.489 . . . . 0.0 109.679 179.736 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 21.4 ttt -142.28 154.79 45.01 Favored 'General case' 0 N--CA 1.473 0.68 0 N-CA-C 108.966 -0.753 . . . . 0.0 108.966 -179.939 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 41.1 t -149.4 139.65 16.37 Favored 'Isoleucine or valine' 0 C--O 1.234 0.288 0 N-CA-C 107.165 -1.42 . . . . 0.0 107.165 -179.71 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 60.01 67.3 2.22 Favored Glycine 0 C--N 1.32 -0.331 0 N-CA-C 109.173 -1.571 . . . . 0.0 109.173 -179.868 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . -81.97 130.04 9.45 Favored Glycine 0 CA--C 1.526 0.754 0 N-CA-C 111.264 -0.735 . . . . 0.0 111.264 -178.91 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 1.9 t -146.67 113.48 1.06 Allowed 'Isoleucine or valine' 0 CA--C 1.558 1.284 0 N-CA-C 108.47 -0.937 . . . . 0.0 108.47 179.131 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 19.9 t . . . . . 0 N--CA 1.495 1.789 0 CA-C-O 118.467 -0.778 . . . . 0.0 112.399 -177.894 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' D' D ' 1' ' ' ASP . . . . . . . . . . . . . 8.6 m-20 . . . . . 0 N--CA 1.482 1.152 0 N-CA-C 109.707 -0.479 . . . . 0.0 109.707 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' D' D ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.13 131.36 47.26 Favored 'General case' 0 N--CA 1.472 0.625 0 CA-C-N 116.503 -0.317 . . . . 0.0 110.438 179.57 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' D' D ' 3' ' ' GLU . . . . . . . . . . . . . 53.6 tt0 -169.53 121.13 0.71 Allowed 'General case' 0 C--O 1.245 0.843 0 CA-C-O 119.124 -0.465 . . . . 0.0 111.062 -176.737 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' D' D ' 4' ' ' PHE . . . . . 0.41 ' N ' ' CD1' ' D' ' 4' ' ' PHE 0.289 35.2 m-85 -116.63 131.53 56.93 Favored 'General case' 0 C--N 1.379 1.88 0 N-CA-C 106.381 -1.711 . . . . 0.0 106.381 177.108 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' D' D ' 5' ' ' ARG . . . . . 0.916 HH12 HG11 ' F' ' 24' ' ' VAL . 6.0 ptm180 -154.59 150.01 27.26 Favored 'General case' 0 C--O 1.247 0.924 0 CA-C-O 116.565 -1.683 . . . . 0.0 113.175 176.423 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 15.4 p80 -150.75 117.98 5.99 Favored 'General case' 0 N--CA 1.481 1.102 0 CA-C-N 119.992 1.269 . . . . 0.0 107.882 163.217 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' D' D ' 7' ' ' ASP . . . . . . . . . . . . 0.367 0.7 OUTLIER -66.25 141.64 57.97 Favored 'General case' 0 C--N 1.324 -0.522 0 C-N-CA 128.565 2.746 . . . . 0.0 115.839 168.32 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' D' D ' 8' ' ' SER . . . . . . . . . . . . . 97.9 p -151.16 175.45 12.14 Favored 'General case' 0 N--CA 1.488 1.437 0 CA-C-N 119.452 1.024 . . . . 0.0 111.471 175.404 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' D' D ' 9' ' ' GLY . . . . . 0.447 ' O ' ' ND2' ' C' ' 27' ' ' ASN . . . 122.37 77.12 0.4 Allowed Glycine 0 N--CA 1.48 1.567 0 CA-C-N 116.056 -0.52 . . . . 0.0 112.762 179.594 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 25.9 p90 -50.98 152.25 2.26 Favored 'General case' 0 N--CA 1.48 1.053 0 C-N-CA 123.662 0.785 . . . . 0.0 111.967 177.768 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 64.9 mt-10 -117.39 131.13 56.83 Favored 'General case' 0 N--CA 1.49 1.568 0 C-N-CA 118.94 -1.104 . . . . 0.0 108.524 175.992 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 21.3 t -95.22 140.26 17.22 Favored 'Isoleucine or valine' 0 C--O 1.245 0.856 0 CA-C-O 117.678 -1.153 . . . . 0.0 111.083 173.673 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 86.5 m-70 -138.64 140.62 38.95 Favored 'General case' 0 N--CA 1.483 1.185 0 CA-C-N 119.543 1.065 . . . . 0.0 110.236 172.544 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 14.0 t60 -165.5 104.47 0.73 Allowed 'General case' 0 N--CA 1.48 1.066 0 N-CA-C 108.922 -0.77 . . . . 0.0 108.922 173.611 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 55.8 mt-30 -104.19 114.95 29.55 Favored 'General case' 0 C--N 1.311 -1.067 0 N-CA-C 108.698 -0.853 . . . . 0.0 108.698 179.15 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 64.6 tttp -102.49 112.89 25.82 Favored 'General case' 0 C--N 1.358 0.964 0 N-CA-C 107.677 -1.231 . . . . 0.0 107.677 177.073 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 9.3 mp -126.69 162.26 26.2 Favored 'General case' 0 N--CA 1.488 1.439 0 N-CA-C 108.409 -0.96 . . . . 0.0 108.409 179.499 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . 0.365 89.7 t -140.62 119.65 11.34 Favored 'Isoleucine or valine' 0 C--N 1.372 1.563 0 N-CA-C 105.636 -1.987 . . . . 0.0 105.636 168.099 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' D' D ' 19' ' ' PHE . . . . . . . . . . . . 0.69 57.8 m-85 -67.33 150.34 49.12 Favored 'General case' 0 N--CA 1.423 -1.794 1 C-N-CA 135.005 5.322 . . . . 0.0 121.46 159.418 . . . . . . . . 3 2 . 1 . 019 nuclear build full ' D' D ' 20' ' ' PHE . . . . . 0.403 ' O ' ' O ' ' G' ' 21' ' ' ALA 0.315 82.4 t80 -169.25 -67.79 0.02 OUTLIER 'General case' 0 N--CA 1.477 0.922 0 CA-C-O 114.713 -2.565 . . . . 0.0 113.794 152.691 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' D' D ' 21' ' ' ALA . . . . . 0.453 ' O ' ' O ' ' A' ' 20' ' ' PHE 0.354 . . -68.91 91.56 0.47 Allowed 'General case' 0 C--O 1.259 1.597 0 CA-C-O 113.016 -3.373 . . . . 0.0 113.057 160.959 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 11.8 mm-40 -76.88 -169.13 1.2 Allowed 'General case' 0 C--N 1.282 -2.34 1 CA-C-N 126.396 4.18 . . . . 0.0 111.316 177.061 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 9.7 m-20 -75.92 154.87 35.64 Favored 'General case' 0 C--O 1.241 0.625 0 CA-C-O 121.708 0.766 . . . . 0.0 111.233 -176.399 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' D' D ' 24' ' ' VAL . . . . . 0.927 HG11 HH12 ' E' ' 5' ' ' ARG 0.294 42.7 t -154.72 103.71 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.663 0 N-CA-C 104.002 -2.592 . . . . 0.0 104.002 170.27 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . -118.43 63.33 0.42 Allowed Glycine 0 C--N 1.361 1.929 0 CA-C-O 117.303 -1.831 . . . . 0.0 111.876 170.345 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 14.7 m 54.72 -143.15 0.76 Allowed 'General case' 0 N--CA 1.481 1.093 0 CA-C-N 121.411 2.606 . . . . 0.0 110.396 175.727 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' D' D ' 27' ' ' ASN . . . . . 0.449 ' ND2' ' O ' ' H' ' 9' ' ' GLY . 8.4 m120 -82.36 92.49 7.0 Favored 'General case' 0 N--CA 1.471 0.624 0 C-N-CA 123.78 0.832 . . . . 0.0 109.012 173.051 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 94.5 mttt -71.64 149.54 45.47 Favored 'General case' 0 CA--C 1.548 0.879 0 CA-C-O 122.601 1.191 . . . . 0.0 108.66 -175.815 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -70.01 -132.7 0.08 OUTLIER Glycine 0 N--CA 1.466 0.658 0 N-CA-C 107.804 -2.118 . . . . 0.0 107.804 179.481 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -89.42 132.89 34.78 Favored 'General case' 0 C--N 1.353 0.749 0 N-CA-C 106.923 -1.51 . . . . 0.0 106.923 -176.754 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' D' D ' 31' ' ' ILE . . . . . 0.409 ' N ' ' O ' ' E' ' 40' ' ' VAL . 18.9 tt -165.32 173.05 0.18 Allowed 'Isoleucine or valine' 0 C--O 1.218 -0.567 0 CA-C-N 113.21 -1.814 . . . . 0.0 109.085 -175.245 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 26.9 mt -141.65 145.49 24.37 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.623 0 N-CA-C 107.095 -1.446 . . . . 0.0 107.095 -179.659 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -52.33 169.15 0.66 Allowed Glycine 0 N--CA 1.473 1.115 0 C-N-CA 121.312 -0.471 . . . . 0.0 112.111 -178.581 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 2.5 pp -68.33 158.58 33.17 Favored 'General case' 0 N--CA 1.464 0.273 0 N-CA-C 109.34 -0.615 . . . . 0.0 109.34 -178.813 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 22.7 ttt -140.41 161.03 38.67 Favored 'General case' 0 N--CA 1.474 0.769 0 N-CA-C 107.98 -1.119 . . . . 0.0 107.98 179.168 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' D' D ' 36' ' ' VAL . . . . . . . . . . . . 0.284 62.0 t -155.71 147.05 12.5 Favored 'Isoleucine or valine' 0 C--N 1.349 0.573 0 N-CA-C 104.971 -2.233 . . . . 0.0 104.971 174.25 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 61.55 66.46 2.63 Favored Glycine 0 CA--C 1.535 1.326 0 N-CA-C 106.468 -2.653 . . . . 0.0 106.468 179.549 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . -80.74 129.9 9.37 Favored Glycine 0 C--N 1.313 -0.723 0 CA-C-N 118.683 1.242 . . . . 0.0 111.987 -179.077 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 2.4 t -148.74 122.74 1.8 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.789 0 N-CA-C 105.114 -2.18 . . . . 0.0 105.114 173.546 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 12.7 t . . . . . 0 N--CA 1.485 1.315 0 CA-C-O 116.567 -1.682 . . . . 0.0 113.769 179.317 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' E' E ' 1' ' ' ASP . . . . . . . . . . . . . 8.9 m-20 . . . . . 0 N--CA 1.485 1.323 0 N-CA-C 109.579 -0.526 . . . . 0.0 109.579 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' E' E ' 2' ' ' ALA . . . . . . . . . . . . . . . -63.66 131.17 47.12 Favored 'General case' 0 N--CA 1.469 0.515 0 N-CA-C 110.119 -0.326 . . . . 0.0 110.119 179.681 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' E' E ' 3' ' ' GLU . . . . . . . . . . . . . 54.0 tt0 -169.38 127.31 0.96 Allowed 'General case' 0 N--CA 1.47 0.562 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 -179.457 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 27.3 m-85 -118.24 127.74 54.02 Favored 'General case' 0 N--CA 1.478 0.926 0 N-CA-C 108.379 -0.971 . . . . 0.0 108.379 179.367 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' E' E ' 5' ' ' ARG . . . . . 0.927 HH12 HG11 ' D' ' 24' ' ' VAL . 6.3 ptm180 -165.06 147.37 8.02 Favored 'General case' 0 C--O 1.217 -0.637 0 C-N-CA 120.365 -0.534 . . . . 0.0 112.166 -179.973 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 20.6 p80 -152.17 106.84 3.21 Favored 'General case' 0 N--CA 1.477 0.899 0 CA-C-O 120.839 0.352 . . . . 0.0 110.58 178.047 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' E' E ' 7' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -77.98 152.35 33.17 Favored 'General case' 0 N--CA 1.474 0.744 0 CA-C-O 121.556 0.693 . . . . 0.0 110.091 178.939 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' E' E ' 8' ' ' SER . . . . . . . . . . . . . 92.8 p -156.34 172.9 17.69 Favored 'General case' 0 N--CA 1.487 1.4 0 CA-C-N 115.07 -0.968 . . . . 0.0 111.377 -178.815 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' E' E ' 9' ' ' GLY . . . . . 0.443 ' O ' ' ND2' ' A' ' 27' ' ' ASN . . . 125.7 79.56 0.35 Allowed Glycine 0 N--CA 1.481 1.669 0 N-CA-C 111.441 -0.664 . . . . 0.0 111.441 179.543 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 18.4 p90 -53.48 157.65 2.03 Favored 'General case' 0 N--CA 1.479 0.986 0 C-N-CA 122.393 0.277 . . . . 0.0 111.125 179.298 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 65.6 mt-10 -120.11 126.96 52.03 Favored 'General case' 0 N--CA 1.49 1.551 0 N-CA-C 109.229 -0.656 . . . . 0.0 109.229 178.429 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 39.6 t -103.52 136.95 33.99 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.685 0 N-CA-C 109.014 -0.736 . . . . 0.0 109.014 178.255 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 84.3 m-70 -138.64 138.63 38.0 Favored 'General case' 0 N--CA 1.481 1.102 0 C-N-CA 122.326 0.25 . . . . 0.0 110.585 179.748 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 52.2 t-80 -167.96 97.45 0.45 Allowed 'General case' 0 N--CA 1.484 1.258 0 C-N-CA 122.239 0.215 . . . . 0.0 110.593 179.303 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 55.1 mt-30 -100.57 117.12 34.06 Favored 'General case' 0 CA--C 1.512 -0.509 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 -179.681 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 64.6 tttp -104.63 105.63 15.8 Favored 'General case' 0 N--CA 1.48 1.042 0 N-CA-C 108.657 -0.868 . . . . 0.0 108.657 178.225 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 9.9 mp -122.06 164.06 18.35 Favored 'General case' 0 N--CA 1.487 1.408 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 -179.239 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 54.8 t -142.58 113.22 2.75 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.848 0 N-CA-C 108.097 -1.075 . . . . 0.0 108.097 177.167 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 60.3 m-85 -102.86 163.46 12.2 Favored 'General case' 0 C--N 1.362 1.121 0 O-C-N 124.005 0.816 . . . . 0.0 109.459 178.12 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' E' E ' 20' ' ' PHE . . . . . 0.431 ' O ' ' O ' ' H' ' 21' ' ' ALA . 69.1 t80 -166.59 -84.41 0.02 OUTLIER 'General case' 0 C--O 1.215 -0.74 0 CA-C-N 115.907 -0.588 . . . . 0.0 109.726 177.335 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' E' E ' 21' ' ' ALA . . . . . 0.433 ' O ' ' O ' ' B' ' 20' ' ' PHE . . . -85.39 91.3 8.16 Favored 'General case' 0 N--CA 1.474 0.763 0 N-CA-C 108.28 -1.007 . . . . 0.0 108.28 178.498 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 11.2 mm-40 -70.89 -172.84 0.71 Allowed 'General case' 0 N--CA 1.481 1.086 0 C-N-CA 119.67 -0.812 . . . . 0.0 111.061 -179.932 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' E' E ' 23' ' ' ASP . . . . . 0.444 ' HB3' ' HZ1' ' E' ' 28' ' ' LYS . 8.5 m-20 -71.34 154.07 41.87 Favored 'General case' 0 N--CA 1.472 0.665 0 CA-C-O 121.749 0.785 . . . . 0.0 112.623 -177.405 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' E' E ' 24' ' ' VAL . . . . . 0.92 HG11 HH12 ' F' ' 5' ' ' ARG . 53.0 t -155.37 92.15 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.762 0 CA-C-N 114.733 -1.122 . . . . 0.0 108.072 177.274 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . -119.45 61.13 0.49 Allowed Glycine 0 N--CA 1.478 1.439 0 N-CA-C 110.87 -0.892 . . . . 0.0 110.87 178.798 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 15.8 m 45.95 -143.2 0.28 Allowed 'General case' 0 N--CA 1.485 1.294 0 CA-C-N 118.299 1.049 . . . . 0.0 110.701 -179.8 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' E' E ' 27' ' ' ASN . . . . . 0.436 ' ND2' ' O ' ' I' ' 9' ' ' GLY . 8.6 m120 -79.9 92.44 5.52 Favored 'General case' 0 N--CA 1.472 0.631 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 177.474 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' E' E ' 28' ' ' LYS . . . . . 0.444 ' HZ1' ' HB3' ' E' ' 23' ' ' ASP . 96.4 mttt -65.97 146.53 54.6 Favored 'General case' 0 CA--C 1.543 0.675 0 CA-C-O 121.193 0.52 . . . . 0.0 110.635 -178.565 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -71.29 -129.27 0.08 OUTLIER Glycine 0 CA--C 1.538 1.486 0 N-CA-C 109.912 -1.275 . . . . 0.0 109.912 178.492 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -82.22 131.28 35.23 Favored 'General case' 0 N--CA 1.439 -1.005 0 CA-C-N 117.637 0.719 . . . . 0.0 109.391 178.743 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 18.4 tt -165.28 173.31 0.18 Allowed 'Isoleucine or valine' 0 C--O 1.219 -0.532 0 N-CA-C 108.587 -0.894 . . . . 0.0 108.587 -178.737 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 25.5 mt -141.31 145.6 24.62 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.438 0 N-CA-C 107.106 -1.442 . . . . 0.0 107.106 179.674 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -51.63 167.93 0.64 Allowed Glycine 0 N--CA 1.474 1.209 0 C-N-CA 121.383 -0.437 . . . . 0.0 112.662 -179.333 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 2.7 pp -65.71 157.28 30.56 Favored 'General case' 0 N--CA 1.466 0.362 0 N-CA-C 109.97 -0.381 . . . . 0.0 109.97 179.746 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 23.0 ttt -142.37 154.24 44.47 Favored 'General case' 0 N--CA 1.478 0.949 0 N-CA-C 108.996 -0.742 . . . . 0.0 108.996 -179.956 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 40.3 t -149.41 138.54 15.42 Favored 'Isoleucine or valine' 0 C--O 1.238 0.458 0 N-CA-C 107.543 -1.28 . . . . 0.0 107.543 -179.57 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 60.94 67.96 1.89 Allowed Glycine 0 C--N 1.32 -0.336 0 N-CA-C 108.724 -1.751 . . . . 0.0 108.724 -179.882 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . -82.86 131.02 10.07 Favored Glycine 0 C--N 1.334 0.467 0 N-CA-C 111.286 -0.726 . . . . 0.0 111.286 -178.434 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 1.9 t -147.49 113.52 0.92 Allowed 'Isoleucine or valine' 0 N--CA 1.5 2.045 0 N-CA-C 108.447 -0.946 . . . . 0.0 108.447 179.389 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' E' E ' 40' ' ' VAL . . . . . 0.409 ' O ' ' N ' ' D' ' 31' ' ' ILE . 19.3 t . . . . . 0 N--CA 1.495 1.8 0 CA-C-O 118.074 -0.965 . . . . 0.0 112.127 -177.664 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' F' F ' 1' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 . . . . . 0 N--CA 1.486 1.335 0 N-CA-C 109.434 -0.58 . . . . 0.0 109.434 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' F' F ' 2' ' ' ALA . . . . . . . . . . . . . . . -63.64 131.24 47.37 Favored 'General case' 0 N--CA 1.469 0.512 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.152 179.749 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' F' F ' 3' ' ' GLU . . . . . . . . . . . . . 53.8 tt0 -169.42 127.04 0.94 Allowed 'General case' 0 N--CA 1.469 0.52 0 N-CA-C 109.911 -0.403 . . . . 0.0 109.911 -179.474 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 27.0 m-85 -117.88 127.43 53.85 Favored 'General case' 0 N--CA 1.476 0.873 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 179.361 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' F' F ' 5' ' ' ARG . . . . . 0.92 HH12 HG11 ' E' ' 24' ' ' VAL . 6.3 ptm180 -164.45 146.94 8.81 Favored 'General case' 0 N--CA 1.473 0.701 0 C-N-CA 120.291 -0.564 . . . . 0.0 112.063 -179.894 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 20.9 p80 -152.0 106.56 3.21 Favored 'General case' 0 N--CA 1.477 0.883 0 CA-C-O 120.793 0.33 . . . . 0.0 110.605 178.039 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' F' F ' 7' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -77.98 152.43 33.12 Favored 'General case' 0 N--CA 1.474 0.748 0 CA-C-O 121.573 0.701 . . . . 0.0 110.004 179.047 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' F' F ' 8' ' ' SER . . . . . . . . . . . . . 93.5 p -156.24 173.76 16.39 Favored 'General case' 0 N--CA 1.487 1.376 0 CA-C-N 114.933 -1.031 . . . . 0.0 111.488 -178.88 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' F' F ' 9' ' ' GLY . . . . . 0.437 ' O ' ' ND2' ' B' ' 27' ' ' ASN . . . 124.59 79.49 0.39 Allowed Glycine 0 N--CA 1.481 1.66 0 N-CA-C 111.424 -0.67 . . . . 0.0 111.424 179.669 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 18.3 p90 -53.89 158.11 2.16 Favored 'General case' 0 N--CA 1.479 0.996 0 C-N-CA 122.418 0.287 . . . . 0.0 111.136 179.252 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 65.3 mt-10 -120.23 126.97 51.95 Favored 'General case' 0 N--CA 1.489 1.483 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 178.506 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 39.3 t -103.44 136.87 34.24 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.687 0 N-CA-C 109.022 -0.733 . . . . 0.0 109.022 178.188 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 84.2 m-70 -138.52 138.52 38.11 Favored 'General case' 0 N--CA 1.481 1.075 0 C-N-CA 122.417 0.287 . . . . 0.0 110.591 179.757 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 51.6 t-80 -167.89 97.31 0.45 Allowed 'General case' 0 N--CA 1.483 1.191 0 C-N-CA 122.249 0.219 . . . . 0.0 110.626 179.198 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 55.3 mt-30 -100.29 117.24 34.09 Favored 'General case' 0 CA--C 1.513 -0.448 0 N-CA-C 108.399 -0.963 . . . . 0.0 108.399 -179.56 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 64.7 tttp -104.76 105.7 15.88 Favored 'General case' 0 N--CA 1.481 1.121 0 N-CA-C 108.558 -0.905 . . . . 0.0 108.558 178.104 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 9.9 mp -122.06 164.05 18.36 Favored 'General case' 0 N--CA 1.488 1.436 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 -179.398 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 55.2 t -142.39 112.75 2.76 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.911 0 N-CA-C 108.008 -1.108 . . . . 0.0 108.008 177.102 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 60.7 m-85 -102.09 163.68 12.11 Favored 'General case' 0 C--N 1.359 1.007 0 O-C-N 124.028 0.83 . . . . 0.0 109.107 177.779 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' F' F ' 20' ' ' PHE . . . . . 0.409 ' O ' ' O ' ' I' ' 21' ' ' ALA . 72.8 t80 -166.54 -84.12 0.02 OUTLIER 'General case' 0 C--O 1.215 -0.73 0 N-CA-C 109.399 -0.593 . . . . 0.0 109.399 177.173 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' F' F ' 21' ' ' ALA . . . . . 0.44 ' O ' ' O ' ' C' ' 20' ' ' PHE . . . -85.83 91.7 8.41 Favored 'General case' 0 N--CA 1.478 0.931 0 N-CA-C 108.302 -0.999 . . . . 0.0 108.302 178.547 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 11.1 mm-40 -71.14 -172.79 0.75 Allowed 'General case' 0 N--CA 1.481 1.124 0 C-N-CA 119.668 -0.813 . . . . 0.0 111.25 -179.842 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 8.5 m-20 -71.46 153.98 41.85 Favored 'General case' 0 N--CA 1.473 0.722 0 CA-C-O 121.847 0.832 . . . . 0.0 112.597 -177.334 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' F' F ' 24' ' ' VAL . . . . . 0.916 HG11 HH12 ' D' ' 5' ' ' ARG . 54.9 t -155.25 91.97 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.473 0.702 0 CA-C-N 114.65 -1.159 . . . . 0.0 108.261 177.302 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -119.51 61.33 0.49 Allowed Glycine 0 N--CA 1.482 1.703 0 N-CA-C 110.929 -0.868 . . . . 0.0 110.929 178.792 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 15.9 m 45.91 -143.18 0.28 Allowed 'General case' 0 N--CA 1.484 1.247 0 CA-C-N 118.206 1.003 . . . . 0.0 110.688 -179.973 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' F' F ' 27' ' ' ASN . . . . . 0.446 ' ND2' ' O ' ' G' ' 9' ' ' GLY . 8.5 m120 -79.86 92.5 5.5 Favored 'General case' 0 N--CA 1.472 0.637 0 N-CA-C 108.818 -0.808 . . . . 0.0 108.818 177.413 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 96.4 mttt -66.1 146.4 54.7 Favored 'General case' 0 CA--C 1.542 0.639 0 CA-C-O 121.229 0.538 . . . . 0.0 110.626 -178.582 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -71.26 -129.45 0.08 OUTLIER Glycine 0 CA--C 1.538 1.529 0 N-CA-C 109.874 -1.29 . . . . 0.0 109.874 178.578 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.97 131.31 35.25 Favored 'General case' 0 N--CA 1.436 -1.137 0 CA-C-N 117.528 0.664 . . . . 0.0 109.484 178.754 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 18.4 tt -165.22 173.65 0.17 Allowed 'Isoleucine or valine' 0 C--O 1.218 -0.553 0 N-CA-C 108.571 -0.9 . . . . 0.0 108.571 -178.756 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 25.9 mt -141.48 145.59 24.43 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.524 0 N-CA-C 107.016 -1.476 . . . . 0.0 107.016 179.665 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -51.78 167.9 0.69 Allowed Glycine 0 N--CA 1.476 1.354 0 C-N-CA 121.316 -0.469 . . . . 0.0 112.567 -179.38 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 2.6 pp -65.64 157.29 30.36 Favored 'General case' 0 N--CA 1.466 0.351 0 CA-C-O 120.834 0.35 . . . . 0.0 110.061 179.772 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 22.9 ttt -142.29 154.02 44.37 Favored 'General case' 0 N--CA 1.476 0.858 0 N-CA-C 109.111 -0.7 . . . . 0.0 109.111 -179.984 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 40.6 t -149.19 138.68 15.77 Favored 'Isoleucine or valine' 0 C--O 1.237 0.399 0 N-CA-C 107.559 -1.274 . . . . 0.0 107.559 -179.625 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 60.97 67.83 1.95 Allowed Glycine 0 C--N 1.321 -0.251 0 N-CA-C 108.721 -1.751 . . . . 0.0 108.721 -179.974 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -82.69 130.86 9.96 Favored Glycine 0 C--N 1.334 0.462 0 N-CA-C 111.335 -0.706 . . . . 0.0 111.335 -178.38 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 1.9 t -147.3 113.57 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.5 2.052 0 N-CA-C 108.494 -0.928 . . . . 0.0 108.494 179.324 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 19.4 t . . . . . 0 N--CA 1.492 1.653 0 CA-C-O 118.215 -0.898 . . . . 0.0 112.5 -177.474 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' G' G ' 1' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 . . . . . 0 N--CA 1.491 1.596 0 N-CA-C 109.54 -0.541 . . . . 0.0 109.54 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' G' G ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.81 130.36 44.53 Favored 'General case' 0 N--CA 1.472 0.647 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.305 179.53 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' G' G ' 3' ' ' GLU . . . . . . . . . . . . . 53.6 tt0 -169.73 125.85 0.85 Allowed 'General case' 0 N--CA 1.471 0.575 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 -179.986 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 31.9 m-85 -117.63 127.93 54.43 Favored 'General case' 0 N--CA 1.48 1.046 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 179.317 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' G' G ' 5' ' ' ARG . . . . . 0.9 HH12 HG11 ' I' ' 24' ' ' VAL . 6.1 ptm180 -165.07 148.81 8.58 Favored 'General case' 0 N--CA 1.47 0.555 0 C-N-CA 120.446 -0.502 . . . . 0.0 111.933 -179.907 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' G' G ' 6' ' ' HIS . . . . . 0.404 ' O ' ' ND1' ' G' ' 6' ' ' HIS . 21.8 p80 -153.81 106.71 2.89 Favored 'General case' 0 N--CA 1.474 0.767 0 CA-C-O 121.06 0.457 . . . . 0.0 110.719 178.224 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -77.39 152.11 34.52 Favored 'General case' 0 N--CA 1.474 0.727 0 CA-C-O 121.084 0.468 . . . . 0.0 110.276 179.008 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' G' G ' 8' ' ' SER . . . . . . . . . . . . . 99.2 p -155.7 174.5 15.2 Favored 'General case' 0 N--CA 1.474 0.75 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.846 179.996 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' G' G ' 9' ' ' GLY . . . . . 0.446 ' O ' ' ND2' ' F' ' 27' ' ' ASN . . . 124.61 78.87 0.37 Allowed Glycine 0 N--CA 1.478 1.466 0 N-CA-C 111.202 -0.759 . . . . 0.0 111.202 179.582 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 24.0 p90 -54.23 157.47 2.67 Favored 'General case' 0 N--CA 1.476 0.827 0 O-C-N 122.802 -0.234 . . . . 0.0 111.107 179.358 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 64.6 mt-10 -120.15 126.93 51.92 Favored 'General case' 0 N--CA 1.487 1.376 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 179.257 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 29.9 t -103.79 136.12 38.28 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.021 0 N-CA-C 109.158 -0.682 . . . . 0.0 109.158 178.658 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 86.2 m-70 -137.92 138.4 38.96 Favored 'General case' 0 N--CA 1.481 1.092 0 C-N-CA 122.827 0.451 . . . . 0.0 110.634 179.926 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 51.7 t-80 -168.26 97.4 0.42 Allowed 'General case' 0 N--CA 1.481 1.125 0 N-CA-C 110.355 -0.239 . . . . 0.0 110.355 178.727 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 55.3 mt-30 -100.4 117.53 34.77 Favored 'General case' 0 CA--C 1.512 -0.5 0 N-CA-C 108.476 -0.935 . . . . 0.0 108.476 -179.652 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 64.6 tttp -104.97 105.67 15.82 Favored 'General case' 0 N--CA 1.482 1.142 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 178.323 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 9.8 mp -121.71 161.97 21.62 Favored 'General case' 0 N--CA 1.486 1.345 0 C-N-CA 123.478 0.711 . . . . 0.0 109.413 -179.204 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 43.6 t -142.59 112.78 2.59 Favored 'Isoleucine or valine' 0 C--O 1.246 0.891 0 N-CA-C 108.269 -1.012 . . . . 0.0 108.269 176.734 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 61.4 m-85 -101.73 161.01 13.97 Favored 'General case' 0 C--N 1.371 1.539 0 O-C-N 125.566 1.791 . . . . 0.0 109.959 177.307 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 68.7 t80 -167.95 -82.5 0.02 OUTLIER 'General case' 0 CA--C 1.539 0.527 0 CA-C-N 115.7 -0.682 . . . . 0.0 109.36 177.389 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' G' G ' 21' ' ' ALA . . . . . 0.403 ' O ' ' O ' ' D' ' 20' ' ' PHE . . . -84.96 90.69 7.88 Favored 'General case' 0 N--CA 1.474 0.754 0 N-CA-C 108.302 -0.999 . . . . 0.0 108.302 179.184 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 11.6 mm-40 -70.36 -175.09 0.94 Allowed 'General case' 0 N--CA 1.483 1.177 0 C-N-CA 119.691 -0.803 . . . . 0.0 111.167 -179.935 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 8.9 m-20 -70.97 154.47 41.79 Favored 'General case' 0 N--CA 1.475 0.82 0 CA-C-O 121.3 0.571 . . . . 0.0 112.169 -177.218 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' G' G ' 24' ' ' VAL . . . . . 0.895 HG11 HH12 ' H' ' 5' ' ' ARG . 65.2 t -156.63 92.8 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.471 0.597 0 CA-C-N 114.951 -1.022 . . . . 0.0 108.323 177.085 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -119.34 61.38 0.48 Allowed Glycine 0 N--CA 1.477 1.43 0 N-CA-C 110.93 -0.868 . . . . 0.0 110.93 179.107 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 17.2 m 47.0 -139.02 0.62 Allowed 'General case' 0 N--CA 1.484 1.233 0 CA-C-N 118.23 1.015 . . . . 0.0 110.815 179.691 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 8.8 m120 -84.31 91.72 7.83 Favored 'General case' 0 N--CA 1.473 0.697 0 N-CA-C 108.087 -1.079 . . . . 0.0 108.087 177.511 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 96.5 mttt -65.3 146.61 54.7 Favored 'General case' 0 CA--C 1.539 0.539 0 CA-C-O 121.249 0.547 . . . . 0.0 110.576 -178.176 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -72.22 -127.84 0.09 OUTLIER Glycine 0 CA--C 1.526 0.779 0 N-CA-C 109.417 -1.473 . . . . 0.0 109.417 178.541 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.95 128.4 34.03 Favored 'General case' 0 CA--C 1.528 0.104 0 C-N-CA 122.66 0.384 . . . . 0.0 110.179 179.718 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 18.8 tt -164.41 172.88 0.21 Allowed 'Isoleucine or valine' 0 CA--C 1.506 -0.736 0 N-CA-C 109.53 -0.544 . . . . 0.0 109.53 -178.836 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 32.1 mt -139.42 146.9 24.87 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.092 0 N-CA-C 107.117 -1.438 . . . . 0.0 107.117 177.975 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -52.05 167.72 0.79 Allowed Glycine 0 N--CA 1.474 1.188 0 C-N-CA 121.489 -0.386 . . . . 0.0 112.187 -179.463 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 2.6 pp -65.87 157.61 30.1 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-O 120.793 0.33 . . . . 0.0 110.208 -179.935 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 22.8 ttt -142.74 154.54 44.37 Favored 'General case' 0 N--CA 1.472 0.669 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 -179.934 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 39.0 t -149.28 139.13 16.1 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.258 0 N-CA-C 107.712 -1.218 . . . . 0.0 107.712 -179.709 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 60.32 68.26 1.76 Allowed Glycine 0 C--N 1.319 -0.375 0 N-CA-C 108.956 -1.658 . . . . 0.0 108.956 179.963 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . -83.27 131.0 10.06 Favored Glycine 0 N--CA 1.465 0.599 0 N-CA-C 111.335 -0.706 . . . . 0.0 111.335 -178.703 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 2.1 t -146.97 113.2 0.96 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.91 0 N-CA-C 108.515 -0.92 . . . . 0.0 108.515 179.604 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 21.4 t . . . . . 0 N--CA 1.492 1.648 0 CA-C-O 118.205 -0.902 . . . . 0.0 111.958 -178.304 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' H' H ' 1' ' ' ASP . . . . . . . . . . . . . 9.0 m-20 . . . . . 0 N--CA 1.491 1.576 0 N-CA-C 109.608 -0.516 . . . . 0.0 109.608 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' H' H ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.72 130.09 43.43 Favored 'General case' 0 N--CA 1.471 0.597 0 CA-C-N 116.284 -0.417 . . . . 0.0 110.315 179.455 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' H' H ' 3' ' ' GLU . . . . . . . . . . . . . 53.9 tt0 -169.61 125.7 0.86 Allowed 'General case' 0 N--CA 1.471 0.593 0 N-CA-C 110.009 -0.367 . . . . 0.0 110.009 179.948 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 32.4 m-85 -117.21 128.24 54.9 Favored 'General case' 0 N--CA 1.48 1.068 0 N-CA-C 108.486 -0.931 . . . . 0.0 108.486 179.22 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' H' H ' 5' ' ' ARG . . . . . 0.895 HH12 HG11 ' G' ' 24' ' ' VAL . 6.1 ptm180 -165.33 148.78 8.23 Favored 'General case' 0 N--CA 1.47 0.558 0 C-N-CA 120.533 -0.467 . . . . 0.0 112.031 -179.968 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' H' H ' 6' ' ' HIS . . . . . 0.403 ' O ' ' ND1' ' H' ' 6' ' ' HIS . 21.7 p80 -153.89 106.76 2.88 Favored 'General case' 0 N--CA 1.475 0.79 0 CA-C-O 120.993 0.425 . . . . 0.0 110.645 178.204 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -77.58 151.75 34.28 Favored 'General case' 0 N--CA 1.474 0.745 0 CA-C-O 121.039 0.447 . . . . 0.0 110.261 179.016 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' H' H ' 8' ' ' SER . . . . . . . . . . . . . 99.3 p -155.22 174.89 14.57 Favored 'General case' 0 N--CA 1.475 0.808 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.839 179.99 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' H' H ' 9' ' ' GLY . . . . . 0.449 ' O ' ' ND2' ' D' ' 27' ' ' ASN . . . 124.15 78.89 0.39 Allowed Glycine 0 N--CA 1.478 1.472 0 N-CA-C 111.305 -0.718 . . . . 0.0 111.305 179.714 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 24.2 p90 -54.36 157.73 2.65 Favored 'General case' 0 N--CA 1.475 0.789 0 O-C-N 122.747 -0.267 . . . . 0.0 111.137 179.29 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 64.8 mt-10 -120.31 126.93 51.77 Favored 'General case' 0 N--CA 1.485 1.3 0 C-N-CA 122.694 0.397 . . . . 0.0 109.931 179.347 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 28.1 t -103.97 135.94 39.36 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.998 0 N-CA-C 109.153 -0.684 . . . . 0.0 109.153 178.683 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 86.4 m-70 -137.76 138.65 39.47 Favored 'General case' 0 N--CA 1.481 1.107 0 C-N-CA 122.981 0.512 . . . . 0.0 110.584 -179.949 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 51.7 t-80 -168.56 97.48 0.4 Allowed 'General case' 0 N--CA 1.482 1.127 0 N-CA-C 110.31 -0.256 . . . . 0.0 110.31 178.66 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 55.5 mt-30 -100.56 116.97 33.73 Favored 'General case' 0 CA--C 1.512 -0.49 0 N-CA-C 108.72 -0.845 . . . . 0.0 108.72 -179.619 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 64.5 tttp -104.35 105.72 15.96 Favored 'General case' 0 N--CA 1.482 1.136 0 N-CA-C 108.62 -0.882 . . . . 0.0 108.62 178.282 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 9.8 mp -121.91 162.29 21.29 Favored 'General case' 0 N--CA 1.487 1.386 0 C-N-CA 123.494 0.718 . . . . 0.0 109.224 -179.262 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 45.8 t -142.35 111.96 2.55 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.601 0 N-CA-C 108.372 -0.974 . . . . 0.0 108.372 176.921 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 61.1 m-85 -100.6 161.37 13.65 Favored 'General case' 0 C--N 1.364 1.228 0 O-C-N 124.724 1.265 . . . . 0.0 109.944 177.404 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 67.2 t80 -167.26 -83.15 0.02 OUTLIER 'General case' 0 N--CA 1.469 0.48 0 CA-C-N 115.696 -0.684 . . . . 0.0 109.572 177.214 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' H' H ' 21' ' ' ALA . . . . . 0.431 ' O ' ' O ' ' E' ' 20' ' ' PHE . . . -84.91 90.33 7.78 Favored 'General case' 0 N--CA 1.473 0.715 0 N-CA-C 108.406 -0.961 . . . . 0.0 108.406 179.22 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 11.7 mm-40 -69.76 -175.02 0.81 Allowed 'General case' 0 N--CA 1.483 1.176 0 C-N-CA 119.694 -0.803 . . . . 0.0 111.171 -179.872 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' H' H ' 23' ' ' ASP . . . . . 0.463 ' HB3' ' HZ1' ' H' ' 28' ' ' LYS . 8.8 m-20 -71.2 154.36 41.74 Favored 'General case' 0 N--CA 1.473 0.691 0 CA-C-O 121.333 0.587 . . . . 0.0 112.245 -177.093 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' H' H ' 24' ' ' VAL . . . . . 0.919 HG11 HH12 ' I' ' 5' ' ' ARG . 65.7 t -156.36 92.8 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.471 0.619 0 CA-C-N 114.943 -1.026 . . . . 0.0 108.407 177.095 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . -119.45 61.46 0.49 Allowed Glycine 0 N--CA 1.48 1.615 0 N-CA-C 110.961 -0.856 . . . . 0.0 110.961 179.226 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 17.2 m 46.82 -138.83 0.61 Allowed 'General case' 0 N--CA 1.485 1.296 0 CA-C-N 118.082 0.941 . . . . 0.0 110.832 -179.979 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 8.7 m120 -84.26 91.9 7.85 Favored 'General case' 0 N--CA 1.473 0.691 0 N-CA-C 108.027 -1.101 . . . . 0.0 108.027 177.417 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' H' H ' 28' ' ' LYS . . . . . 0.463 ' HZ1' ' HB3' ' H' ' 23' ' ' ASP . 96.4 mttt -65.47 146.75 54.48 Favored 'General case' 0 CA--C 1.539 0.549 0 CA-C-O 121.373 0.606 . . . . 0.0 110.487 -178.212 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -72.16 -127.87 0.09 OUTLIER Glycine 0 CA--C 1.528 0.856 0 N-CA-C 109.554 -1.419 . . . . 0.0 109.554 178.542 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.91 128.8 34.43 Favored 'General case' 0 C--O 1.231 0.086 0 N-CA-C 110.05 -0.352 . . . . 0.0 110.05 179.591 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 18.9 tt -164.73 172.57 0.21 Allowed 'Isoleucine or valine' 0 CA--C 1.505 -0.778 0 N-CA-C 109.578 -0.527 . . . . 0.0 109.578 -178.719 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 31.9 mt -139.34 147.01 24.78 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.038 0 N-CA-C 107.132 -1.433 . . . . 0.0 107.132 177.974 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -52.25 167.59 0.87 Allowed Glycine 0 N--CA 1.472 1.088 0 C-N-CA 121.505 -0.378 . . . . 0.0 112.267 -179.454 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 2.6 pp -65.5 157.84 28.52 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-O 120.937 0.399 . . . . 0.0 110.123 -179.95 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 22.8 ttt -142.97 154.48 44.08 Favored 'General case' 0 N--CA 1.473 0.712 0 N-CA-C 109.225 -0.657 . . . . 0.0 109.225 -179.859 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 39.2 t -149.54 139.11 15.82 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.216 0 N-CA-C 107.566 -1.272 . . . . 0.0 107.566 -179.578 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 60.19 67.88 1.94 Allowed Glycine 0 C--N 1.32 -0.335 0 N-CA-C 109.093 -1.603 . . . . 0.0 109.093 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . -83.02 131.17 10.17 Favored Glycine 0 N--CA 1.464 0.544 0 N-CA-C 111.45 -0.66 . . . . 0.0 111.45 -178.765 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 2.1 t -147.04 113.36 0.96 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.927 0 N-CA-C 108.324 -0.991 . . . . 0.0 108.324 179.539 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 21.7 t . . . . . 0 N--CA 1.491 1.589 0 CA-C-O 118.298 -0.858 . . . . 0.0 111.574 -178.358 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' I' I ' 1' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 . . . . . 0 N--CA 1.491 1.613 0 N-CA-C 109.532 -0.544 . . . . 0.0 109.532 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' I' I ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.66 130.2 43.97 Favored 'General case' 0 N--CA 1.472 0.641 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.308 179.448 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' I' I ' 3' ' ' GLU . . . . . . . . . . . . . 53.7 tt0 -169.77 125.66 0.84 Allowed 'General case' 0 N--CA 1.47 0.559 0 N-CA-C 109.97 -0.382 . . . . 0.0 109.97 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 32.8 m-85 -117.32 128.15 54.77 Favored 'General case' 0 N--CA 1.48 1.041 0 N-CA-C 108.46 -0.941 . . . . 0.0 108.46 179.247 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' I' I ' 5' ' ' ARG . . . . . 0.919 HH12 HG11 ' H' ' 24' ' ' VAL . 6.1 ptm180 -165.24 148.48 8.23 Favored 'General case' 0 N--CA 1.47 0.545 0 C-N-CA 120.567 -0.453 . . . . 0.0 112.017 -179.881 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' I' I ' 6' ' ' HIS . . . . . 0.401 ' ND1' ' O ' ' I' ' 6' ' ' HIS . 21.6 p80 -153.66 106.83 2.94 Favored 'General case' 0 N--CA 1.475 0.793 0 CA-C-O 121.008 0.432 . . . . 0.0 110.61 178.198 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -77.59 151.83 34.23 Favored 'General case' 0 N--CA 1.474 0.775 0 CA-C-O 121.072 0.463 . . . . 0.0 110.249 178.958 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' I' I ' 8' ' ' SER . . . . . . . . . . . . . 98.2 p -155.23 174.88 14.58 Favored 'General case' 0 N--CA 1.476 0.849 0 CA-C-N 115.945 -0.57 . . . . 0.0 110.854 179.915 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' I' I ' 9' ' ' GLY . . . . . 0.436 ' O ' ' ND2' ' E' ' 27' ' ' ASN . . . 124.23 78.92 0.39 Allowed Glycine 0 N--CA 1.479 1.56 0 N-CA-C 111.256 -0.738 . . . . 0.0 111.256 179.663 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 24.0 p90 -54.58 157.63 2.86 Favored 'General case' 0 N--CA 1.477 0.891 0 O-C-N 122.803 -0.234 . . . . 0.0 111.045 179.308 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 64.5 mt-10 -120.23 126.92 51.81 Favored 'General case' 0 N--CA 1.484 1.266 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 179.391 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 27.2 t -103.9 135.86 39.66 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.937 0 N-CA-C 109.16 -0.681 . . . . 0.0 109.16 178.679 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 86.2 m-70 -137.76 138.53 39.37 Favored 'General case' 0 N--CA 1.482 1.15 0 C-N-CA 122.966 0.506 . . . . 0.0 110.579 -179.943 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 51.3 t-80 -168.47 97.27 0.4 Allowed 'General case' 0 N--CA 1.482 1.136 0 N-CA-C 110.278 -0.267 . . . . 0.0 110.278 178.736 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 55.8 mt-30 -100.38 116.93 33.5 Favored 'General case' 0 C--N 1.326 -0.436 0 N-CA-C 108.611 -0.885 . . . . 0.0 108.611 -179.585 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 64.6 tttp -104.35 105.7 15.92 Favored 'General case' 0 N--CA 1.482 1.143 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 178.236 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 9.8 mp -121.88 162.35 21.14 Favored 'General case' 0 N--CA 1.487 1.416 0 C-N-CA 123.475 0.71 . . . . 0.0 109.21 -179.244 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 45.7 t -142.35 111.99 2.57 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.579 0 N-CA-C 108.32 -0.993 . . . . 0.0 108.32 176.937 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 60.8 m-85 -100.75 161.41 13.62 Favored 'General case' 0 C--N 1.364 1.208 0 O-C-N 124.79 1.306 . . . . 0.0 109.949 177.434 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 66.9 t80 -167.28 -83.39 0.02 OUTLIER 'General case' 0 N--CA 1.468 0.446 0 CA-C-N 115.629 -0.714 . . . . 0.0 109.649 177.267 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' I' I ' 21' ' ' ALA . . . . . 0.409 ' O ' ' O ' ' F' ' 20' ' ' PHE . . . -84.7 90.62 7.75 Favored 'General case' 0 N--CA 1.471 0.62 0 N-CA-C 108.274 -1.01 . . . . 0.0 108.274 179.243 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 11.7 mm-40 -70.16 -175.01 0.88 Allowed 'General case' 0 N--CA 1.482 1.17 0 C-N-CA 119.725 -0.79 . . . . 0.0 111.114 -179.836 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 8.8 m-20 -71.21 154.17 41.89 Favored 'General case' 0 N--CA 1.473 0.701 0 CA-C-O 121.296 0.57 . . . . 0.0 112.292 -177.067 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' I' I ' 24' ' ' VAL . . . . . 0.9 HG11 HH12 ' G' ' 5' ' ' ARG . 65.6 t -156.22 92.75 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.47 0.528 0 CA-C-N 115.023 -0.99 . . . . 0.0 108.396 177.08 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . -119.17 61.36 0.48 Allowed Glycine 0 N--CA 1.48 1.628 0 N-CA-C 110.981 -0.848 . . . . 0.0 110.981 179.148 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 17.4 m 46.81 -138.84 0.61 Allowed 'General case' 0 N--CA 1.486 1.36 0 CA-C-N 118.214 1.007 . . . . 0.0 110.707 179.948 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 8.7 m120 -84.29 91.97 7.88 Favored 'General case' 0 N--CA 1.472 0.665 0 N-CA-C 108.089 -1.078 . . . . 0.0 108.089 177.413 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 96.4 mttt -65.52 146.58 54.68 Favored 'General case' 0 CA--C 1.539 0.555 0 CA-C-O 121.378 0.608 . . . . 0.0 110.512 -178.195 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -71.92 -128.13 0.09 OUTLIER Glycine 0 CA--C 1.527 0.835 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 178.49 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.87 128.47 34.07 Favored 'General case' 0 CA--C 1.529 0.155 0 C-N-CA 122.709 0.404 . . . . 0.0 109.939 179.698 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 18.8 tt -164.38 172.64 0.22 Allowed 'Isoleucine or valine' 0 CA--C 1.506 -0.716 0 N-CA-C 109.553 -0.536 . . . . 0.0 109.553 -178.695 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 31.7 mt -139.31 146.99 24.85 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.101 0 N-CA-C 107.214 -1.402 . . . . 0.0 107.214 177.896 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -52.25 167.62 0.87 Allowed Glycine 0 N--CA 1.473 1.163 0 C-N-CA 121.528 -0.367 . . . . 0.0 112.234 -179.444 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 2.6 pp -65.59 157.59 29.41 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-O 120.892 0.377 . . . . 0.0 110.086 -179.956 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 22.9 ttt -142.73 154.17 44.03 Favored 'General case' 0 N--CA 1.472 0.655 0 N-CA-C 109.172 -0.677 . . . . 0.0 109.172 -179.827 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 39.6 t -149.26 139.27 16.23 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.252 0 N-CA-C 107.551 -1.277 . . . . 0.0 107.551 -179.719 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 60.09 67.93 1.92 Allowed Glycine 0 N--CA 1.461 0.344 0 N-CA-C 109.135 -1.586 . . . . 0.0 109.135 -179.921 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . -82.99 131.22 10.21 Favored Glycine 0 N--CA 1.464 0.564 0 N-CA-C 111.359 -0.697 . . . . 0.0 111.359 -178.702 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 2.1 t -147.16 113.39 0.95 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.908 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 179.527 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 21.6 t . . . . . 0 N--CA 1.489 1.521 0 CA-C-O 118.192 -0.909 . . . . 0.0 111.766 -178.315 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 1' ' ' ASP . . . . . 0.408 ' HB3' ' H2 ' ' D' ' 1' ' ' ASP . 3.9 p-10 . . . . . 0 N--CA 1.49 1.574 0 N-CA-C 109.165 -0.68 . . . . 0.0 109.165 . . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.62 130.32 43.19 Favored 'General case' 0 N--CA 1.47 0.535 0 CA-C-N 116.378 -0.374 . . . . 0.0 111.406 -179.593 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 13.4 pt-20 -170.69 108.84 0.33 Allowed 'General case' 0 CA--C 1.545 0.781 0 CA-C-O 121.275 0.56 . . . . 0.0 110.143 179.08 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 29.8 m-85 -87.47 156.97 19.31 Favored 'General case' 0 N--CA 1.472 0.659 0 N-CA-C 109.426 -0.583 . . . . 0.0 109.426 -179.813 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 77.1 mtt85 -139.85 145.58 38.26 Favored 'General case' 0 N--CA 1.478 0.925 0 CA-C-N 115.886 -0.597 . . . . 0.0 109.885 179.776 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 57.6 t-80 -150.51 116.96 5.73 Favored 'General case' 0 N--CA 1.476 0.863 0 N-CA-C 109.631 -0.507 . . . . 0.0 109.631 179.164 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 9.9 m-20 -66.94 144.6 56.13 Favored 'General case' 0 N--CA 1.474 0.75 0 C-N-CA 122.897 0.479 . . . . 0.0 111.83 -179.809 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 1.7 t -164.3 -176.89 4.64 Favored 'General case' 0 N--CA 1.471 0.597 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 177.986 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 85.54 70.46 1.33 Allowed Glycine 0 CA--C 1.53 1.029 0 CA-C-N 115.837 -0.62 . . . . 0.0 112.087 178.725 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 40.3 p90 -73.01 122.16 21.28 Favored 'General case' 0 N--CA 1.477 0.888 0 CA-C-N 117.255 0.527 . . . . 0.0 110.892 179.976 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 17.7 pt-20 -82.76 151.82 25.99 Favored 'General case' 0 N--CA 1.477 0.903 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 178.853 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 13.7 t -144.68 117.72 2.73 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.877 0 CA-C-O 121.578 0.704 . . . . 0.0 109.365 178.302 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 73.5 m80 -95.79 164.87 12.57 Favored 'General case' 0 C--N 1.358 0.941 0 CA-C-N 114.641 -1.163 . . . . 0.0 109.29 177.996 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 14' ' ' HIS . . . . . 0.449 ' NE2' ' NZ ' ' A' ' 16' ' ' LYS . 17.2 t60 -164.74 99.27 0.78 Allowed 'General case' 0 N--CA 1.476 0.855 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.12 179.223 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -91.66 111.58 23.15 Favored 'General case' 0 CA--C 1.517 -0.326 0 N-CA-C 108.386 -0.968 . . . . 0.0 108.386 179.668 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 16' ' ' LYS . . . . . 0.449 ' NZ ' ' NE2' ' A' ' 14' ' ' HIS . 8.5 ttmm -94.37 171.38 8.85 Favored 'General case' 0 N--CA 1.483 1.206 0 N-CA-C 108.893 -0.781 . . . . 0.0 108.893 179.926 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 17' ' ' LEU . . . . . 0.422 ' N ' HD12 ' A' ' 17' ' ' LEU . 9.6 mp -55.09 157.9 3.16 Favored 'General case' 0 N--CA 1.476 0.837 0 N-CA-C 110.002 -0.37 . . . . 0.0 110.002 -178.408 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 71.2 t -140.81 150.22 20.69 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.714 0 C-N-CA 123.206 0.602 . . . . 0.0 109.76 -177.798 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.69 ' HB3' ' O ' ' D' ' 18' ' ' VAL . 43.9 p90 -40.44 162.34 0.01 OUTLIER 'General case' 0 CA--C 1.542 0.666 0 N-CA-C 120.228 3.418 . . . . 0.0 120.228 -178.729 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.409 ' O ' ' CD2' ' A' ' 20' ' ' PHE . 20.9 p90 -119.75 69.82 0.85 Allowed 'General case' 0 CA--C 1.56 1.352 0 CA-C-N 112.033 -2.349 . . . . 0.0 109.449 173.552 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 21' ' ' ALA . . . . . 0.411 ' H ' ' HD1' ' A' ' 19' ' ' PHE . . . -62.97 95.04 0.07 Allowed 'General case' 0 C--N 1.325 -0.493 0 N-CA-C 108.38 -0.97 . . . . 0.0 108.38 176.767 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 77.5 mt-10 -49.61 123.73 8.3 Favored 'General case' 0 N--CA 1.475 0.813 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.517 -179.954 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 16.6 t70 -76.73 169.37 18.43 Favored 'General case' 0 N--CA 1.471 0.624 0 CA-C-O 120.983 0.42 . . . . 0.0 110.648 -178.901 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.548 HG13 ' H ' ' A' ' 25' ' ' GLY . 0.7 OUTLIER 178.28 -79.05 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.542 0.636 0 N-CA-C 107.298 -1.371 . . . . 0.0 107.298 -179.865 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.548 ' H ' HG13 ' A' ' 24' ' ' VAL . . . -34.03 84.4 0.0 OUTLIER Glycine 0 N--CA 1.473 1.166 0 C-N-CA 124.425 1.012 . . . . 0.0 113.461 178.546 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 26' ' ' SER . . . . . 0.438 ' N ' ' O ' ' A' ' 24' ' ' VAL . 87.9 p -41.25 -105.55 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.65 0 N-CA-C 113.676 0.991 . . . . 0.0 113.676 -177.401 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 16.8 p-10 -59.97 112.47 1.88 Allowed 'General case' 0 N--CA 1.469 0.488 0 CA-C-N 118.833 0.742 . . . . 0.0 110.417 -178.637 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 41.8 mttm -96.83 164.57 12.5 Favored 'General case' 0 N--CA 1.475 0.801 0 C-N-CA 123.31 0.644 . . . . 0.0 110.008 -179.564 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -72.95 -141.45 0.45 Allowed Glycine 0 N--CA 1.461 0.342 0 N-CA-C 107.876 -2.089 . . . . 0.0 107.876 176.548 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 30' ' ' ALA . . . . . 0.458 ' O ' ' O ' ' D' ' 31' ' ' ILE . . . -90.42 123.12 33.88 Favored 'General case' 0 C--O 1.208 -1.084 0 N-CA-C 106.836 -1.542 . . . . 0.0 106.836 176.524 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 16.7 tt -148.28 155.6 9.41 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.884 0 N-CA-C 107.996 -1.113 . . . . 0.0 107.996 179.192 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 20.5 pt -150.88 138.89 14.24 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 CA-C-N 119.042 0.837 . . . . 0.0 109.394 178.56 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -56.68 154.3 17.7 Favored Glycine 0 CA--C 1.533 1.167 0 CA-C-N 116.605 -0.27 . . . . 0.0 112.591 -178.537 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 2.5 pp -76.29 158.92 31.06 Favored 'General case' 0 N--CA 1.472 0.673 0 N-CA-C 109.68 -0.489 . . . . 0.0 109.68 179.242 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 11.9 ttp -102.84 151.59 22.25 Favored 'General case' 0 N--CA 1.481 1.08 0 N-CA-C 109.383 -0.599 . . . . 0.0 109.383 179.711 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 7.3 p -168.62 159.82 0.71 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.553 0 N-CA-C 108.044 -1.095 . . . . 0.0 108.044 179.772 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.41 69.86 1.14 Allowed Glycine 0 C--N 1.31 -0.862 0 N-CA-C 111.665 -0.574 . . . . 0.0 111.665 178.836 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 152.04 -177.49 29.84 Favored Glycine 0 N--CA 1.468 0.828 0 N-CA-C 110.214 -1.154 . . . . 0.0 110.214 179.659 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 4.6 t -124.99 139.14 51.99 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.758 0 N-CA-C 107.206 -1.405 . . . . 0.0 107.206 -179.502 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 72.7 t . . . . . 0 N--CA 1.481 1.081 0 CA-C-O 117.776 -1.107 . . . . 0.0 109.64 -177.501 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' B' B ' 1' ' ' ASP . . . . . . . . . . . . . 3.9 p-10 . . . . . 0 N--CA 1.489 1.493 0 N-CA-C 109.194 -0.669 . . . . 0.0 109.194 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' B' B ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.52 130.19 42.74 Favored 'General case' 0 N--CA 1.469 0.496 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.403 -179.671 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 3' ' ' GLU . . . . . . . . . . . . . 13.3 pt-20 -170.69 108.86 0.33 Allowed 'General case' 0 CA--C 1.546 0.818 0 CA-C-O 121.334 0.588 . . . . 0.0 110.111 179.01 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 30.1 m-85 -87.29 157.16 19.36 Favored 'General case' 0 N--CA 1.473 0.72 0 N-CA-C 109.531 -0.544 . . . . 0.0 109.531 -179.808 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 77.1 mtt85 -140.05 145.61 37.93 Favored 'General case' 0 N--CA 1.477 0.92 0 CA-C-N 115.941 -0.572 . . . . 0.0 109.991 179.724 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 58.1 t-80 -150.43 117.29 5.87 Favored 'General case' 0 N--CA 1.475 0.814 0 N-CA-C 109.644 -0.502 . . . . 0.0 109.644 179.153 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 7' ' ' ASP . . . . . . . . . . . . . 9.8 m-20 -67.16 144.38 56.06 Favored 'General case' 0 N--CA 1.472 0.671 0 C-N-CA 122.863 0.465 . . . . 0.0 111.682 -179.713 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 8' ' ' SER . . . . . . . . . . . . . 2.2 t -163.96 -177.63 5.18 Favored 'General case' 0 N--CA 1.471 0.578 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 178.148 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 85.88 70.5 1.32 Allowed Glycine 0 CA--C 1.532 1.154 0 CA-C-N 115.916 -0.584 . . . . 0.0 112.158 178.775 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 40.1 p90 -72.81 121.99 20.83 Favored 'General case' 0 N--CA 1.478 0.931 0 CA-C-N 117.295 0.548 . . . . 0.0 110.87 179.833 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 17.7 pt-20 -82.67 151.92 26.06 Favored 'General case' 0 N--CA 1.479 0.986 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 178.828 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 13.1 t -144.75 117.81 2.71 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.842 0 CA-C-O 121.598 0.713 . . . . 0.0 109.318 178.362 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 73.5 m80 -96.02 164.66 12.61 Favored 'General case' 0 C--N 1.357 0.932 0 CA-C-N 114.616 -1.175 . . . . 0.0 109.333 177.919 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 14' ' ' HIS . . . . . 0.448 ' NE2' ' NZ ' ' B' ' 16' ' ' LYS . 17.2 t60 -164.59 99.25 0.8 Allowed 'General case' 0 N--CA 1.476 0.839 0 CA-C-N 116.471 -0.331 . . . . 0.0 110.113 179.224 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -91.44 111.54 23.08 Favored 'General case' 0 CA--C 1.515 -0.381 0 N-CA-C 108.441 -0.948 . . . . 0.0 108.441 179.585 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 16' ' ' LYS . . . . . 0.448 ' NZ ' ' NE2' ' B' ' 14' ' ' HIS . 8.5 ttmm -94.33 171.49 8.79 Favored 'General case' 0 N--CA 1.483 1.197 0 N-CA-C 108.899 -0.778 . . . . 0.0 108.899 179.995 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 17' ' ' LEU . . . . . 0.412 ' N ' HD12 ' B' ' 17' ' ' LEU . 9.7 mp -55.25 157.83 3.38 Favored 'General case' 0 N--CA 1.476 0.836 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 -178.41 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 71.3 t -140.87 150.46 20.49 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.763 0 C-N-CA 123.113 0.565 . . . . 0.0 109.652 -177.767 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 19' ' ' PHE . . . . . 0.704 ' HB3' ' O ' ' E' ' 18' ' ' VAL . 44.4 p90 -40.58 162.07 0.01 OUTLIER 'General case' 0 CA--C 1.543 0.7 0 N-CA-C 120.055 3.354 . . . . 0.0 120.055 -178.738 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 20' ' ' PHE . . . . . 0.418 ' CD2' ' O ' ' B' ' 20' ' ' PHE . 21.1 p90 -119.61 69.68 0.84 Allowed 'General case' 0 CA--C 1.561 1.371 0 CA-C-N 111.946 -2.388 . . . . 0.0 109.257 173.545 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 21' ' ' ALA . . . . . 0.42 ' H ' ' HD1' ' B' ' 19' ' ' PHE . . . -62.75 95.11 0.07 Allowed 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 108.409 -0.959 . . . . 0.0 108.409 176.759 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 77.2 mt-10 -49.62 123.73 8.3 Favored 'General case' 0 N--CA 1.476 0.849 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.421 -179.892 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 16.7 t70 -76.74 169.27 18.61 Favored 'General case' 0 N--CA 1.471 0.609 0 CA-C-O 121.007 0.432 . . . . 0.0 110.702 -179.044 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 24' ' ' VAL . . . . . 0.515 HG13 ' H ' ' B' ' 25' ' ' GLY . 0.7 OUTLIER 178.2 -79.11 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.545 0.755 0 N-CA-C 107.333 -1.358 . . . . 0.0 107.333 -179.608 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' B' B ' 25' ' ' GLY . . . . . 0.515 ' H ' HG13 ' B' ' 24' ' ' VAL . . . -34.1 84.12 0.0 OUTLIER Glycine 0 N--CA 1.48 1.633 0 C-N-CA 124.334 0.969 . . . . 0.0 113.258 178.7 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 26' ' ' SER . . . . . 0.453 ' N ' ' O ' ' B' ' 24' ' ' VAL . 88.0 p -41.02 -105.38 0.0 OUTLIER 'General case' 0 N--CA 1.475 0.817 0 N-CA-C 113.602 0.964 . . . . 0.0 113.602 -177.411 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 16.6 p-10 -60.02 112.27 1.81 Allowed 'General case' 0 N--CA 1.471 0.578 0 CA-C-N 118.83 0.741 . . . . 0.0 110.357 -178.631 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 41.6 mttm -96.53 164.43 12.62 Favored 'General case' 0 N--CA 1.474 0.773 0 C-N-CA 123.203 0.601 . . . . 0.0 110.195 -179.628 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -72.82 -141.03 0.42 Allowed Glycine 0 N--CA 1.461 0.365 0 N-CA-C 107.816 -2.114 . . . . 0.0 107.816 176.574 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 30' ' ' ALA . . . . . 0.491 ' O ' ' O ' ' E' ' 31' ' ' ILE . . . -91.05 123.4 34.48 Favored 'General case' 0 C--O 1.208 -1.128 0 N-CA-C 106.734 -1.58 . . . . 0.0 106.734 176.587 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 16.6 tt -148.35 155.6 9.33 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.829 0 N-CA-C 107.91 -1.144 . . . . 0.0 107.91 179.194 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 20.5 pt -150.79 138.92 14.37 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.469 0 CA-C-N 118.949 0.795 . . . . 0.0 109.246 178.664 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -56.81 154.29 18.32 Favored Glycine 0 CA--C 1.532 1.148 0 CA-C-N 116.598 -0.274 . . . . 0.0 112.63 -178.691 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 2.5 pp -76.18 158.81 31.3 Favored 'General case' 0 N--CA 1.472 0.635 0 C-N-CA 122.707 0.403 . . . . 0.0 109.971 179.161 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 11.8 ttp -102.73 151.21 22.66 Favored 'General case' 0 N--CA 1.481 1.078 0 N-CA-C 109.507 -0.553 . . . . 0.0 109.507 179.717 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 7.3 p -168.37 159.89 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.524 0 N-CA-C 108.035 -1.098 . . . . 0.0 108.035 179.826 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.42 69.6 1.22 Allowed Glycine 0 C--N 1.313 -0.746 0 N-CA-C 111.617 -0.593 . . . . 0.0 111.617 178.774 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 152.14 -177.75 29.77 Favored Glycine 0 N--CA 1.468 0.795 0 N-CA-C 110.217 -1.153 . . . . 0.0 110.217 179.696 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 4.4 t -124.69 139.05 52.05 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.717 0 N-CA-C 107.31 -1.367 . . . . 0.0 107.31 -179.515 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 74.2 t . . . . . 0 N--CA 1.481 1.115 0 CA-C-O 117.756 -1.116 . . . . 0.0 109.647 -177.522 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' C' C ' 1' ' ' ASP . . . . . 0.416 ' HB3' ' H2 ' ' F' ' 1' ' ' ASP . 3.9 p-10 . . . . . 0 N--CA 1.488 1.451 0 N-CA-C 109.317 -0.624 . . . . 0.0 109.317 . . . . . . . . . 1 1 . 1 . 020 nuclear build full ' C' C ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.22 130.46 43.98 Favored 'General case' 0 CA--C 1.538 0.493 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.368 -179.708 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' C' C ' 3' ' ' GLU . . . . . . . . . . . . . 13.4 pt-20 -171.01 108.87 0.3 Allowed 'General case' 0 CA--C 1.546 0.79 0 CA-C-O 121.267 0.555 . . . . 0.0 110.053 179.039 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 29.9 m-85 -87.29 157.23 19.34 Favored 'General case' 0 N--CA 1.473 0.698 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 -179.846 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 77.4 mtt85 -140.08 145.46 37.68 Favored 'General case' 0 N--CA 1.478 0.965 0 C-N-CA 122.999 0.52 . . . . 0.0 109.797 179.766 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 57.9 t-80 -150.37 116.94 5.78 Favored 'General case' 0 N--CA 1.476 0.864 0 N-CA-C 109.655 -0.498 . . . . 0.0 109.655 179.087 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' C' C ' 7' ' ' ASP . . . . . . . . . . . . . 9.9 m-20 -66.89 144.39 56.28 Favored 'General case' 0 N--CA 1.472 0.643 0 O-C-N 123.444 0.465 . . . . 0.0 111.777 -179.728 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' C' C ' 8' ' ' SER . . . . . . . . . . . . . 2.3 t -163.92 -177.68 5.22 Favored 'General case' 0 N--CA 1.471 0.589 0 N-CA-C 109.873 -0.417 . . . . 0.0 109.873 178.247 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 85.97 70.47 1.32 Allowed Glycine 0 CA--C 1.532 1.125 0 CA-C-N 115.904 -0.589 . . . . 0.0 112.165 178.736 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 40.4 p90 -72.92 122.17 21.22 Favored 'General case' 0 N--CA 1.477 0.882 0 CA-C-N 117.331 0.565 . . . . 0.0 110.882 179.886 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 17.7 pt-20 -82.8 151.9 25.9 Favored 'General case' 0 N--CA 1.478 0.962 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 178.859 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 13.0 t -144.69 117.87 2.78 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.889 0 CA-C-O 121.621 0.724 . . . . 0.0 109.361 178.343 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 73.6 m80 -96.07 164.76 12.56 Favored 'General case' 0 C--N 1.358 0.947 0 CA-C-N 114.623 -1.171 . . . . 0.0 109.263 177.96 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' C' C ' 14' ' ' HIS . . . . . 0.455 ' NE2' ' NZ ' ' C' ' 16' ' ' LYS . 17.1 t60 -164.68 99.38 0.79 Allowed 'General case' 0 N--CA 1.476 0.83 0 N-CA-C 110.038 -0.356 . . . . 0.0 110.038 179.221 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -91.74 111.72 23.36 Favored 'General case' 0 CA--C 1.516 -0.359 0 N-CA-C 108.381 -0.97 . . . . 0.0 108.381 179.574 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' C' C ' 16' ' ' LYS . . . . . 0.455 ' NZ ' ' NE2' ' C' ' 14' ' ' HIS . 8.5 ttmm -94.51 171.45 8.8 Favored 'General case' 0 N--CA 1.483 1.185 0 N-CA-C 108.831 -0.803 . . . . 0.0 108.831 -179.841 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' C' C ' 17' ' ' LEU . . . . . 0.413 HD12 ' N ' ' C' ' 17' ' ' LEU . 9.7 mp -55.11 157.75 3.25 Favored 'General case' 0 N--CA 1.475 0.809 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 -178.424 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 71.3 t -140.75 150.43 20.69 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 C-N-CA 123.188 0.595 . . . . 0.0 109.663 -177.769 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' C' C ' 19' ' ' PHE . . . . . 0.709 ' HB3' ' O ' ' F' ' 18' ' ' VAL . 44.5 p90 -40.67 162.2 0.01 OUTLIER 'General case' 0 CA--C 1.543 0.677 0 N-CA-C 120.081 3.363 . . . . 0.0 120.081 -178.675 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' C' C ' 20' ' ' PHE . . . . . 0.414 ' CD2' ' O ' ' C' ' 20' ' ' PHE . 20.8 p90 -119.65 69.65 0.84 Allowed 'General case' 0 CA--C 1.562 1.437 0 CA-C-N 112.048 -2.342 . . . . 0.0 109.299 173.568 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' C' C ' 21' ' ' ALA . . . . . 0.423 ' H ' ' HD1' ' C' ' 19' ' ' PHE . . . -62.85 95.19 0.07 Allowed 'General case' 0 C--N 1.326 -0.454 0 N-CA-C 108.42 -0.956 . . . . 0.0 108.42 176.824 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 77.3 mt-10 -49.7 123.76 8.45 Favored 'General case' 0 N--CA 1.475 0.814 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.495 -179.862 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 16.5 t70 -76.63 169.16 18.8 Favored 'General case' 0 N--CA 1.472 0.631 0 CA-C-O 121.002 0.43 . . . . 0.0 110.713 -179.009 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' C' C ' 24' ' ' VAL . . . . . 0.506 HG13 ' H ' ' C' ' 25' ' ' GLY . 0.7 OUTLIER 178.25 -79.28 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.544 0.729 0 N-CA-C 107.458 -1.312 . . . . 0.0 107.458 -179.658 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' C' C ' 25' ' ' GLY . . . . . 0.506 ' H ' HG13 ' C' ' 24' ' ' VAL . . . -34.09 84.25 0.0 OUTLIER Glycine 0 N--CA 1.48 1.62 0 C-N-CA 124.356 0.979 . . . . 0.0 113.254 178.591 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' C' C ' 26' ' ' SER . . . . . 0.451 ' N ' ' O ' ' C' ' 24' ' ' VAL . 88.7 p -41.15 -105.25 0.0 OUTLIER 'General case' 0 N--CA 1.473 0.702 0 N-CA-C 113.692 0.997 . . . . 0.0 113.692 -177.334 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 16.6 p-10 -59.98 112.21 1.78 Allowed 'General case' 0 N--CA 1.468 0.474 0 CA-C-N 118.874 0.761 . . . . 0.0 110.381 -178.632 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 41.7 mttm -96.55 164.51 12.58 Favored 'General case' 0 N--CA 1.475 0.78 0 C-N-CA 123.204 0.602 . . . . 0.0 110.113 -179.53 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -72.87 -141.31 0.44 Allowed Glycine 0 N--CA 1.462 0.398 0 N-CA-C 107.769 -2.132 . . . . 0.0 107.769 176.535 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' C' C ' 30' ' ' ALA . . . . . 0.489 ' O ' ' O ' ' F' ' 31' ' ' ILE . . . -90.68 123.16 34.07 Favored 'General case' 0 C--O 1.211 -0.968 0 N-CA-C 106.775 -1.565 . . . . 0.0 106.775 176.58 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 16.6 tt -148.08 155.59 9.7 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.889 0 N-CA-C 107.888 -1.153 . . . . 0.0 107.888 179.186 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 20.2 pt -150.79 138.85 14.28 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.469 0 CA-C-N 118.943 0.792 . . . . 0.0 109.266 178.674 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -56.78 154.3 18.17 Favored Glycine 0 CA--C 1.531 1.088 0 CA-C-N 116.606 -0.27 . . . . 0.0 112.56 -178.656 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 2.5 pp -76.32 158.76 31.19 Favored 'General case' 0 N--CA 1.472 0.644 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 179.232 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 11.6 ttp -102.58 151.47 22.3 Favored 'General case' 0 N--CA 1.481 1.091 0 N-CA-C 109.449 -0.574 . . . . 0.0 109.449 179.649 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 7.3 p -168.55 159.88 0.71 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.542 0 N-CA-C 108.038 -1.097 . . . . 0.0 108.038 179.764 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.45 69.69 1.19 Allowed Glycine 0 C--N 1.312 -0.774 0 N-CA-C 111.611 -0.596 . . . . 0.0 111.611 178.826 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 151.95 -177.82 29.57 Favored Glycine 0 N--CA 1.468 0.792 0 N-CA-C 110.25 -1.14 . . . . 0.0 110.25 179.669 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 4.4 t -124.57 138.8 52.81 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.722 0 N-CA-C 107.335 -1.358 . . . . 0.0 107.335 -179.445 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 74.3 t . . . . . 0 N--CA 1.48 1.032 0 CA-C-O 117.771 -1.109 . . . . 0.0 109.696 -177.589 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' D' D ' 1' ' ' ASP . . . . . 0.415 ' HB3' ' H2 ' ' G' ' 1' ' ' ASP . 3.9 p-10 . . . . . 0 N--CA 1.487 1.396 0 N-CA-C 109.013 -0.736 . . . . 0.0 109.013 . . . . . . . . . 1 1 . 1 . 020 nuclear build full ' D' D ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.62 131.75 47.86 Favored 'General case' 0 N--CA 1.469 0.485 0 CA-C-N 116.501 -0.318 . . . . 0.0 111.441 -179.675 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' D' D ' 3' ' ' GLU . . . . . . . . . . . . . 13.2 pt-20 -169.65 108.24 0.4 Allowed 'General case' 0 CA--C 1.542 0.646 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.208 179.114 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 30.0 m-85 -88.09 159.89 18.04 Favored 'General case' 0 N--CA 1.475 0.784 0 N-CA-C 109.117 -0.698 . . . . 0.0 109.117 -179.318 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' D' D ' 5' ' ' ARG . . . . . . . . . . . . . 76.7 mtt85 -140.11 141.91 36.09 Favored 'General case' 0 N--CA 1.474 0.761 0 C-N-CA 123.974 0.909 . . . . 0.0 110.559 -178.702 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 54.3 t-80 -148.63 123.39 9.89 Favored 'General case' 0 CA--C 1.547 0.852 0 N-CA-C 107.86 -1.163 . . . . 0.0 107.86 174.848 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' D' D ' 7' ' ' ASP . . . . . . . . . . . . . 8.8 m-20 -63.47 133.17 53.45 Favored 'General case' 0 N--CA 1.469 0.496 0 C-N-CA 126.9 2.08 . . . . 0.0 114.15 176.313 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' D' D ' 8' ' ' SER . . . . . . . . . . . . . 2.4 t -154.35 -177.31 6.36 Favored 'General case' 0 N--CA 1.473 0.712 0 CA-C-N 118.895 0.771 . . . . 0.0 110.555 176.242 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 88.11 69.45 1.28 Allowed Glycine 0 N--CA 1.475 1.279 0 N-CA-C 111.33 -0.708 . . . . 0.0 111.33 174.523 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 35.2 p90 -70.82 124.34 24.09 Favored 'General case' 0 N--CA 1.476 0.837 0 CA-C-N 118.134 0.967 . . . . 0.0 110.507 -179.907 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 17.6 pt-20 -81.0 154.04 27.12 Favored 'General case' 0 C--N 1.363 1.162 0 C-N-CA 119.982 -0.687 . . . . 0.0 109.948 175.935 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 21.8 t -141.29 124.07 15.21 Favored 'Isoleucine or valine' 0 C--N 1.357 0.925 0 N-CA-C 107.945 -1.131 . . . . 0.0 107.945 171.011 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 61.5 m80 -89.03 164.37 15.1 Favored 'General case' 0 N--CA 1.472 0.657 0 C-N-CA 125.229 1.412 . . . . 0.0 112.607 171.865 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' D' D ' 14' ' ' HIS . . . . . 0.45 ' NE2' ' NZ ' ' D' ' 16' ' ' LYS . 17.1 t60 -163.82 104.91 0.92 Allowed 'General case' 0 N--CA 1.478 0.949 0 N-CA-C 109.0 -0.741 . . . . 0.0 109.0 171.671 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -95.24 111.45 23.3 Favored 'General case' 0 C--O 1.218 -0.59 0 N-CA-C 107.913 -1.143 . . . . 0.0 107.913 178.885 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' D' D ' 16' ' ' LYS . . . . . 0.45 ' NZ ' ' NE2' ' D' ' 14' ' ' HIS . 8.6 ttmm -95.49 169.93 9.7 Favored 'General case' 0 N--CA 1.487 1.409 0 C-N-CA 125.749 1.619 . . . . 0.0 108.715 -178.385 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 10.7 mp -65.79 156.23 33.82 Favored 'General case' 0 C--O 1.21 -0.975 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 -172.779 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' D' D ' 18' ' ' VAL . . . . . 0.69 ' O ' ' HB3' ' A' ' 19' ' ' PHE . 88.5 t -139.74 146.72 24.79 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.143 0 C-N-CA 126.183 1.793 . . . . 0.0 109.015 -168.808 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' D' D ' 19' ' ' PHE . . . . . 0.757 ' HB3' ' O ' ' G' ' 18' ' ' VAL 0.485 37.4 p90 -57.67 162.4 3.09 Favored 'General case' 0 C--N 1.391 2.403 0 N-CA-C 118.552 2.797 . . . . 0.0 118.552 -169.325 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' D' D ' 20' ' ' PHE . . . . . 0.404 ' O ' ' CD2' ' D' ' 20' ' ' PHE . 21.5 p90 -114.48 66.24 0.68 Allowed 'General case' 0 C--N 1.375 1.684 0 CA-C-N 112.958 -1.928 . . . . 0.0 110.608 -178.781 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' D' D ' 21' ' ' ALA . . . . . 0.45 ' H ' ' HD1' ' D' ' 19' ' ' PHE . . . -50.2 92.47 0.01 OUTLIER 'General case' 0 N--CA 1.441 -0.91 0 CA-C-N 113.448 -1.705 . . . . 0.0 110.669 173.675 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 77.0 mt-10 -52.69 125.53 16.98 Favored 'General case' 0 CA--C 1.547 0.843 0 CA-C-N 118.881 0.764 . . . . 0.0 110.306 -179.652 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 14.6 t70 -78.04 168.75 19.39 Favored 'General case' 0 N--CA 1.475 0.802 0 C-N-CA 122.764 0.426 . . . . 0.0 110.163 -179.747 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' D' D ' 24' ' ' VAL . . . . . 0.468 HG13 ' H ' ' D' ' 25' ' ' GLY 0.624 2.7 p -179.4 -100.54 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.203 -1.395 0 CA-C-O 125.938 2.78 . . . . 0.0 106.256 -164.685 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' D' D ' 25' ' ' GLY . . . . . 0.468 ' H ' HG13 ' D' ' 24' ' ' VAL . . . -24.32 71.59 0.0 OUTLIER Glycine 0 C--N 1.3 -1.46 0 C-N-CA 129.459 3.409 . . . . 0.0 116.907 178.476 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' D' D ' 26' ' ' SER . . . . . 0.412 ' OG ' ' N ' ' D' ' 27' ' ' ASN 0.381 78.9 p -52.69 -100.46 0.0 OUTLIER 'General case' 0 C--O 1.273 2.318 1 CA-C-O 110.787 -4.435 . . . . 0.0 107.203 -162.704 . . . . . . . . 4 3 . 1 . 020 nuclear build full ' D' D ' 27' ' ' ASN . . . . . 0.503 ' OD1' ' N ' ' D' ' 27' ' ' ASN 0.409 11.7 p-10 -70.38 121.87 18.53 Favored 'General case' 0 N--CA 1.481 1.109 1 CA-C-N 129.149 5.431 . . . . 0.0 108.818 -168.719 . . . . . . . . 4 3 . 1 . 020 nuclear build full ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 31.7 mttm -86.24 161.18 18.92 Favored 'General case' 0 C--N 1.364 1.23 0 CA-C-N 110.65 -2.977 . . . . 0.0 113.104 177.762 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -66.89 -145.13 0.07 OUTLIER Glycine 0 CA--C 1.535 1.331 0 N-CA-C 108.997 -1.641 . . . . 0.0 108.997 167.354 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' D' D ' 30' ' ' ALA . . . . . 0.489 ' O ' ' O ' ' G' ' 31' ' ' ILE . . . -92.12 123.45 35.47 Favored 'General case' 0 C--N 1.358 0.945 0 N-CA-C 106.708 -1.59 . . . . 0.0 106.708 174.207 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' D' D ' 31' ' ' ILE . . . . . 0.458 ' O ' ' O ' ' A' ' 30' ' ' ALA . 17.3 tt -144.73 155.42 14.42 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.451 0 N-CA-C 109.107 -0.701 . . . . 0.0 109.107 178.959 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 23.4 pt -150.99 135.31 8.94 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.912 0 CA-C-N 118.402 0.546 . . . . 0.0 110.035 178.939 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -52.85 153.9 6.47 Favored Glycine 0 N--CA 1.476 1.317 0 CA-C-N 116.32 -0.4 . . . . 0.0 112.891 -179.492 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 2.5 pp -76.46 159.85 30.05 Favored 'General case' 0 N--CA 1.473 0.677 0 N-CA-C 110.0 -0.37 . . . . 0.0 110.0 178.433 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 8.2 ttp -103.38 155.14 18.7 Favored 'General case' 0 N--CA 1.48 1.06 0 N-CA-C 108.655 -0.868 . . . . 0.0 108.655 178.781 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 6.7 p -167.04 163.73 0.58 Allowed 'Isoleucine or valine' 0 CA--C 1.507 -0.708 0 N-CA-C 107.456 -1.313 . . . . 0.0 107.456 177.054 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 59.32 63.9 4.74 Favored Glycine 0 C--N 1.319 -0.364 0 C-N-CA 118.733 -1.699 . . . . 0.0 113.143 174.397 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 148.4 179.73 24.58 Favored Glycine 0 N--CA 1.471 1.026 0 CA-C-N 118.0 0.9 . . . . 0.0 111.225 -177.175 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 5.5 t -122.2 138.42 52.47 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.86 0 N-CA-C 106.412 -1.699 . . . . 0.0 106.412 -177.546 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 77.1 t . . . . . 0 C--O 1.212 -0.887 0 N-CA-C 108.224 -1.028 . . . . 0.0 108.224 178.886 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' E' E ' 1' ' ' ASP . . . . . . . . . . . . . 4.0 p-10 . . . . . 0 N--CA 1.485 1.321 0 N-CA-C 109.189 -0.671 . . . . 0.0 109.189 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' E' E ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.12 131.09 45.64 Favored 'General case' 0 CA--C 1.539 0.543 0 CA-C-O 120.835 0.35 . . . . 0.0 111.244 -179.265 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' E' E ' 3' ' ' GLU . . . . . . . . . . . . . 13.3 pt-20 -170.01 108.76 0.38 Allowed 'General case' 0 CA--C 1.543 0.709 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.059 179.397 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 27.7 m-85 -86.74 156.67 19.85 Favored 'General case' 0 N--CA 1.474 0.727 0 O-C-N 121.935 -0.478 . . . . 0.0 109.822 -179.696 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' E' E ' 5' ' ' ARG . . . . . . . . . . . . . 76.9 mtt85 -139.71 145.75 38.74 Favored 'General case' 0 N--CA 1.477 0.917 0 CA-C-N 115.978 -0.556 . . . . 0.0 110.015 179.378 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 57.9 t-80 -150.52 116.44 5.58 Favored 'General case' 0 N--CA 1.475 0.796 0 N-CA-C 109.472 -0.566 . . . . 0.0 109.472 179.239 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' E' E ' 7' ' ' ASP . . . . . . . . . . . . . 9.7 m-20 -66.11 148.64 51.51 Favored 'General case' 0 N--CA 1.47 0.549 0 O-C-N 123.259 0.349 . . . . 0.0 111.136 -179.825 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' E' E ' 8' ' ' SER . . . . . . . . . . . . . 2.2 t -167.45 -178.04 3.83 Favored 'General case' 0 N--CA 1.471 0.611 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 178.28 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 86.11 70.21 1.32 Allowed Glycine 0 CA--C 1.533 1.168 0 CA-C-N 115.964 -0.562 . . . . 0.0 112.089 178.779 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 34.2 p90 -71.65 121.87 19.58 Favored 'General case' 0 N--CA 1.479 1.008 0 CA-C-N 117.52 0.66 . . . . 0.0 110.771 179.704 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 17.4 pt-20 -83.01 152.77 25.27 Favored 'General case' 0 N--CA 1.482 1.159 0 N-CA-C 109.405 -0.591 . . . . 0.0 109.405 178.136 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 19.2 t -144.83 117.03 2.35 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.667 0 N-CA-C 109.478 -0.564 . . . . 0.0 109.478 178.831 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 73.8 m80 -95.33 165.89 12.16 Favored 'General case' 0 N--CA 1.475 0.794 0 N-CA-C 109.701 -0.481 . . . . 0.0 109.701 178.588 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' E' E ' 14' ' ' HIS . . . . . 0.447 ' NE2' ' NZ ' ' E' ' 16' ' ' LYS . 16.5 t60 -164.71 99.12 0.78 Allowed 'General case' 0 N--CA 1.478 0.971 0 N-CA-C 110.095 -0.335 . . . . 0.0 110.095 179.327 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -92.06 110.96 22.33 Favored 'General case' 0 CA--C 1.511 -0.548 0 N-CA-C 108.442 -0.948 . . . . 0.0 108.442 179.721 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' E' E ' 16' ' ' LYS . . . . . 0.447 ' NZ ' ' NE2' ' E' ' 14' ' ' HIS . 9.5 ttmm -93.53 172.04 8.52 Favored 'General case' 0 N--CA 1.485 1.303 0 N-CA-C 109.279 -0.638 . . . . 0.0 109.279 179.999 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' E' E ' 17' ' ' LEU . . . . . 0.438 ' N ' HD12 ' E' ' 17' ' ' LEU . 9.2 mp -55.11 155.98 4.32 Favored 'General case' 0 C--O 1.216 -0.693 0 N-CA-C 109.981 -0.377 . . . . 0.0 109.981 -178.599 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' E' E ' 18' ' ' VAL . . . . . 0.704 ' O ' ' HB3' ' B' ' 19' ' ' PHE . 79.5 t -141.48 150.61 19.62 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.966 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 -178.475 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' E' E ' 19' ' ' PHE . . . . . 0.735 ' HB3' ' O ' ' H' ' 18' ' ' VAL . 38.9 p90 -43.69 153.95 0.11 Allowed 'General case' 0 C--N 1.385 2.139 0 N-CA-C 120.387 3.477 . . . . 0.0 120.387 -177.216 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' E' E ' 20' ' ' PHE . . . . . 0.403 ' CD2' ' O ' ' E' ' 20' ' ' PHE . 20.8 p90 -111.62 66.95 0.64 Allowed 'General case' 0 N--CA 1.484 1.243 0 CA-C-N 113.938 -1.483 . . . . 0.0 111.495 175.007 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' E' E ' 21' ' ' ALA . . . . . 0.409 ' H ' ' HD1' ' E' ' 19' ' ' PHE . . . -58.64 93.96 0.02 OUTLIER 'General case' 0 N--CA 1.441 -0.919 0 CA-C-N 114.133 -1.394 . . . . 0.0 109.212 177.919 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 76.1 mt-10 -50.0 122.16 6.33 Favored 'General case' 0 N--CA 1.474 0.749 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.25 -179.712 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 18.4 t70 -75.03 173.51 10.62 Favored 'General case' 0 N--CA 1.466 0.349 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 -178.823 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' E' E ' 24' ' ' VAL . . . . . 0.526 HG13 ' H ' ' E' ' 25' ' ' GLY . 0.9 OUTLIER 173.71 -77.9 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.472 0.656 0 N-CA-C 107.896 -1.15 . . . . 0.0 107.896 -179.925 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' E' E ' 25' ' ' GLY . . . . . 0.526 ' H ' HG13 ' E' ' 24' ' ' VAL . . . -36.51 84.47 0.0 OUTLIER Glycine 0 CA--C 1.538 1.523 0 C-N-CA 124.102 0.858 . . . . 0.0 113.396 179.132 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' E' E ' 26' ' ' SER . . . . . 0.451 ' N ' ' O ' ' E' ' 24' ' ' VAL . 95.2 p -40.81 -107.11 0.0 OUTLIER 'General case' 0 N--CA 1.482 1.133 0 N-CA-C 114.25 1.204 . . . . 0.0 114.25 -177.544 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 16.5 p-10 -58.36 111.57 1.27 Allowed 'General case' 0 N--CA 1.473 0.688 0 CA-C-N 118.858 0.754 . . . . 0.0 110.067 -178.664 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 39.1 mttm -95.15 167.82 11.13 Favored 'General case' 0 N--CA 1.476 0.851 0 O-C-N 123.786 0.679 . . . . 0.0 109.588 -179.592 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -76.14 -140.17 0.94 Allowed Glycine 0 CA--C 1.524 0.652 0 N-CA-C 106.996 -2.441 . . . . 0.0 106.996 176.396 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' E' E ' 30' ' ' ALA . . . . . 0.458 ' O ' ' O ' ' H' ' 31' ' ' ILE . . . -91.82 126.34 36.87 Favored 'General case' 0 C--O 1.215 -0.723 0 N-CA-C 106.507 -1.664 . . . . 0.0 106.507 175.682 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' E' E ' 31' ' ' ILE . . . . . 0.491 ' O ' ' O ' ' B' ' 30' ' ' ALA . 16.6 tt -149.87 155.62 7.81 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.604 0 N-CA-C 108.077 -1.083 . . . . 0.0 108.077 179.07 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 19.2 pt -152.61 138.14 11.21 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.628 0 N-CA-C 109.096 -0.705 . . . . 0.0 109.096 -179.509 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -57.56 154.65 20.98 Favored Glycine 0 N--CA 1.474 1.174 0 CA-C-N 115.407 -0.815 . . . . 0.0 112.66 -177.851 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 2.5 pp -75.98 160.32 29.97 Favored 'General case' 0 N--CA 1.469 0.505 0 N-CA-C 109.64 -0.504 . . . . 0.0 109.64 179.244 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 7.7 ttp -104.91 151.95 23.24 Favored 'General case' 0 N--CA 1.48 1.052 0 N-CA-C 109.259 -0.645 . . . . 0.0 109.259 179.454 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 7.5 p -168.13 159.93 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.446 -0.641 0 N-CA-C 107.844 -1.169 . . . . 0.0 107.844 179.744 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 53.85 70.87 0.81 Allowed Glycine 0 C--N 1.313 -0.72 0 O-C-N 123.381 0.426 . . . . 0.0 112.328 179.365 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 153.06 -177.14 30.86 Favored Glycine 0 N--CA 1.461 0.367 0 N-CA-C 110.131 -1.188 . . . . 0.0 110.131 179.556 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 5.5 t -126.7 137.08 58.93 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.361 0 N-CA-C 106.259 -1.756 . . . . 0.0 106.259 -178.867 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 75.1 t . . . . . 0 N--CA 1.474 0.754 0 CA-C-O 117.649 -1.167 . . . . 0.0 109.504 -176.889 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' F' F ' 1' ' ' ASP . . . . . 0.416 ' H2 ' ' HB3' ' C' ' 1' ' ' ASP . 4.0 p-10 . . . . . 0 N--CA 1.487 1.398 0 N-CA-C 109.157 -0.682 . . . . 0.0 109.157 . . . . . . . . . 1 1 . 1 . 020 nuclear build full ' F' F ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.14 131.26 46.07 Favored 'General case' 0 CA--C 1.539 0.554 0 CA-C-O 120.808 0.337 . . . . 0.0 111.132 -179.206 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' F' F ' 3' ' ' GLU . . . . . . . . . . . . . 13.3 pt-20 -170.17 108.73 0.37 Allowed 'General case' 0 CA--C 1.545 0.767 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.002 179.436 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 27.7 m-85 -86.76 156.66 19.84 Favored 'General case' 0 N--CA 1.472 0.672 0 N-CA-C 109.676 -0.49 . . . . 0.0 109.676 -179.673 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' F' F ' 5' ' ' ARG . . . . . . . . . . . . . 76.8 mtt85 -139.61 145.34 38.4 Favored 'General case' 0 N--CA 1.479 0.98 0 CA-C-N 115.861 -0.609 . . . . 0.0 109.96 179.427 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 57.7 t-80 -150.33 116.31 5.61 Favored 'General case' 0 N--CA 1.475 0.776 0 N-CA-C 109.61 -0.515 . . . . 0.0 109.61 179.158 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' F' F ' 7' ' ' ASP . . . . . . . . . . . . . 9.8 m-20 -65.84 148.42 51.81 Favored 'General case' 0 N--CA 1.469 0.515 0 O-C-N 123.261 0.351 . . . . 0.0 111.301 -179.813 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' F' F ' 8' ' ' SER . . . . . . . . . . . . . 2.2 t -167.37 -178.0 3.85 Favored 'General case' 0 N--CA 1.471 0.59 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 178.214 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 86.25 70.15 1.32 Allowed Glycine 0 CA--C 1.532 1.143 0 CA-C-N 115.972 -0.558 . . . . 0.0 112.113 178.734 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 34.6 p90 -71.7 121.71 19.34 Favored 'General case' 0 N--CA 1.476 0.858 0 CA-C-N 117.514 0.657 . . . . 0.0 110.95 179.739 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 17.4 pt-20 -82.79 152.69 25.57 Favored 'General case' 0 N--CA 1.481 1.116 0 N-CA-C 109.399 -0.593 . . . . 0.0 109.399 178.156 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 19.3 t -144.83 117.02 2.35 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.635 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 178.795 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 73.8 m80 -95.3 165.94 12.14 Favored 'General case' 0 N--CA 1.476 0.871 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 178.534 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' F' F ' 14' ' ' HIS . . . . . 0.456 ' NE2' ' NZ ' ' F' ' 16' ' ' LYS . 16.4 t60 -164.66 98.86 0.79 Allowed 'General case' 0 N--CA 1.478 0.969 0 N-CA-C 110.224 -0.287 . . . . 0.0 110.224 179.394 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -91.74 110.93 22.27 Favored 'General case' 0 CA--C 1.507 -0.693 0 N-CA-C 108.376 -0.972 . . . . 0.0 108.376 179.655 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' F' F ' 16' ' ' LYS . . . . . 0.456 ' NZ ' ' NE2' ' F' ' 14' ' ' HIS . 9.7 ttmm -93.59 171.75 8.7 Favored 'General case' 0 N--CA 1.484 1.258 0 N-CA-C 109.224 -0.658 . . . . 0.0 109.224 179.919 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' F' F ' 17' ' ' LEU . . . . . 0.433 ' N ' HD12 ' F' ' 17' ' ' LEU . 9.2 mp -54.8 155.84 4.05 Favored 'General case' 0 N--CA 1.472 0.671 0 N-CA-C 110.044 -0.354 . . . . 0.0 110.044 -178.625 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' F' F ' 18' ' ' VAL . . . . . 0.709 ' O ' ' HB3' ' C' ' 19' ' ' PHE . 79.0 t -141.43 150.49 19.75 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.955 0 N-CA-C 107.929 -1.138 . . . . 0.0 107.929 -178.409 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' F' F ' 19' ' ' PHE . . . . . 0.745 ' HB3' ' O ' ' I' ' 18' ' ' VAL . 38.6 p90 -43.48 153.63 0.11 Allowed 'General case' 0 C--N 1.384 2.101 0 N-CA-C 120.41 3.485 . . . . 0.0 120.41 -177.232 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' F' F ' 20' ' ' PHE . . . . . 0.415 ' O ' ' CD2' ' F' ' 20' ' ' PHE . 20.1 p90 -111.46 67.25 0.64 Allowed 'General case' 0 N--CA 1.48 1.053 0 CA-C-N 113.947 -1.479 . . . . 0.0 111.538 175.029 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' F' F ' 21' ' ' ALA . . . . . 0.402 ' H ' ' HD1' ' F' ' 19' ' ' PHE . . . -58.82 94.27 0.02 OUTLIER 'General case' 0 C--N 1.317 -0.843 0 CA-C-N 114.211 -1.359 . . . . 0.0 109.262 178.074 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 76.5 mt-10 -50.29 122.28 6.71 Favored 'General case' 0 N--CA 1.476 0.85 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.296 -179.743 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 18.2 t70 -75.06 173.54 10.6 Favored 'General case' 0 N--CA 1.468 0.429 0 N-CA-C 110.031 -0.359 . . . . 0.0 110.031 -178.852 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' F' F ' 24' ' ' VAL . . . . . 0.527 HG13 ' H ' ' F' ' 25' ' ' GLY . 0.9 OUTLIER 173.83 -78.35 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.728 0 N-CA-C 107.934 -1.136 . . . . 0.0 107.934 -179.828 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' F' F ' 25' ' ' GLY . . . . . 0.527 ' H ' HG13 ' F' ' 24' ' ' VAL . . . -36.7 84.95 0.01 OUTLIER Glycine 0 CA--C 1.536 1.382 0 C-N-CA 124.045 0.831 . . . . 0.0 113.354 179.294 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' F' F ' 26' ' ' SER . . . . . 0.45 ' N ' ' O ' ' F' ' 24' ' ' VAL . 96.0 p -40.82 -107.11 0.0 OUTLIER 'General case' 0 N--CA 1.479 0.989 0 N-CA-C 114.19 1.181 . . . . 0.0 114.19 -177.696 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 16.6 p-10 -58.42 111.55 1.27 Allowed 'General case' 0 N--CA 1.472 0.654 0 CA-C-N 118.804 0.729 . . . . 0.0 110.171 -178.69 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 38.9 mttm -95.08 167.71 11.21 Favored 'General case' 0 N--CA 1.477 0.918 0 C-N-CA 123.392 0.677 . . . . 0.0 109.597 -179.553 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -76.03 -139.98 0.9 Allowed Glycine 0 CA--C 1.525 0.702 0 N-CA-C 107.113 -2.395 . . . . 0.0 107.113 176.403 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' F' F ' 30' ' ' ALA . . . . . 0.456 ' O ' ' O ' ' I' ' 31' ' ' ILE . . . -91.97 126.37 37.03 Favored 'General case' 0 N--CA 1.472 0.635 0 N-CA-C 106.227 -1.768 . . . . 0.0 106.227 175.706 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' F' F ' 31' ' ' ILE . . . . . 0.489 ' O ' ' O ' ' C' ' 30' ' ' ALA . 16.6 tt -150.01 155.29 8.01 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.619 0 N-CA-C 108.078 -1.082 . . . . 0.0 108.078 179.221 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 19.3 pt -152.48 138.34 11.7 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.651 0 N-CA-C 109.157 -0.683 . . . . 0.0 109.157 -179.482 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -57.63 154.54 21.62 Favored Glycine 0 N--CA 1.474 1.18 0 CA-C-N 115.421 -0.808 . . . . 0.0 112.622 -177.74 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 2.5 pp -75.96 160.51 29.8 Favored 'General case' 0 N--CA 1.47 0.543 0 N-CA-C 109.58 -0.526 . . . . 0.0 109.58 179.14 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 7.6 ttp -105.15 152.08 23.24 Favored 'General case' 0 N--CA 1.479 0.986 0 N-CA-C 109.313 -0.625 . . . . 0.0 109.313 179.528 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 7.5 p -168.19 160.23 0.72 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.625 0 N-CA-C 107.837 -1.172 . . . . 0.0 107.837 179.631 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 53.76 70.89 0.8 Allowed Glycine 0 C--N 1.313 -0.745 0 O-C-N 123.448 0.467 . . . . 0.0 112.425 179.4 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 152.97 -177.19 30.77 Favored Glycine 0 N--CA 1.461 0.364 0 N-CA-C 110.08 -1.208 . . . . 0.0 110.08 179.538 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 5.3 t -126.45 136.81 59.7 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.347 0 N-CA-C 106.242 -1.762 . . . . 0.0 106.242 -178.852 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 76.4 t . . . . . 0 N--CA 1.47 0.567 0 CA-C-O 117.597 -1.192 . . . . 0.0 109.692 -176.926 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' G' G ' 1' ' ' ASP . . . . . 0.415 ' H2 ' ' HB3' ' D' ' 1' ' ' ASP . 4.1 p-10 . . . . . 0 N--CA 1.486 1.337 0 N-CA-C 108.508 -0.923 . . . . 0.0 108.508 . . . . . . . . . 1 1 . 1 . 020 nuclear build full ' G' G ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.61 132.82 49.77 Favored 'General case' 0 CA--C 1.538 0.505 0 CA-C-O 120.828 0.347 . . . . 0.0 110.97 -178.906 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' G' G ' 3' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -170.2 108.74 0.37 Allowed 'General case' 0 CA--C 1.544 0.727 0 N-CA-C 109.636 -0.505 . . . . 0.0 109.636 179.63 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 30.3 m-85 -85.87 156.94 20.33 Favored 'General case' 0 N--CA 1.474 0.748 0 O-C-N 122.015 -0.428 . . . . 0.0 109.849 -179.342 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' G' G ' 5' ' ' ARG . . . . . . . . . . . . . 77.0 mtt85 -140.01 145.14 37.41 Favored 'General case' 0 N--CA 1.481 1.095 0 N-CA-C 109.688 -0.486 . . . . 0.0 109.688 179.515 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 58.7 t-80 -150.03 117.38 6.06 Favored 'General case' 0 N--CA 1.473 0.675 0 N-CA-C 109.209 -0.663 . . . . 0.0 109.209 179.217 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 12.4 m-20 -66.89 148.39 52.0 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.961 -179.83 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' G' G ' 8' ' ' SER . . . . . . . . . . . . . 3.5 t -166.93 -179.38 4.67 Favored 'General case' 0 N--CA 1.472 0.674 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.095 178.342 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 85.44 71.95 1.3 Allowed Glycine 0 N--CA 1.477 1.406 0 CA-C-N 116.144 -0.48 . . . . 0.0 112.247 179.015 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 38.5 p90 -72.84 122.03 20.92 Favored 'General case' 0 N--CA 1.477 0.887 0 CA-C-N 117.098 0.449 . . . . 0.0 110.76 179.353 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 17.7 pt-20 -83.28 153.16 24.8 Favored 'General case' 0 N--CA 1.478 0.932 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 178.263 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 22.0 t -143.76 117.64 3.53 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.006 0 CA-C-O 118.527 -0.749 . . . . 0.0 109.032 179.003 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 76.7 m80 -95.42 167.36 11.37 Favored 'General case' 0 N--CA 1.486 1.374 0 CA-C-N 119.569 1.077 . . . . 0.0 109.521 178.597 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' G' G ' 14' ' ' HIS . . . . . 0.442 ' NE2' ' NZ ' ' G' ' 16' ' ' LYS . 16.1 t60 -164.42 98.1 0.8 Allowed 'General case' 0 N--CA 1.479 1.014 0 N-CA-C 110.061 -0.348 . . . . 0.0 110.061 179.216 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -91.63 111.67 23.28 Favored 'General case' 0 CA--C 1.509 -0.6 0 N-CA-C 107.904 -1.146 . . . . 0.0 107.904 179.479 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' G' G ' 16' ' ' LYS . . . . . 0.442 ' NZ ' ' NE2' ' G' ' 14' ' ' HIS . 9.1 ttmm -93.61 171.97 8.56 Favored 'General case' 0 N--CA 1.485 1.315 0 N-CA-C 109.314 -0.624 . . . . 0.0 109.314 -179.86 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' G' G ' 17' ' ' LEU . . . . . 0.411 ' N ' HD12 ' G' ' 17' ' ' LEU . 9.5 mp -55.14 152.24 8.23 Favored 'General case' 0 N--CA 1.471 0.606 0 CA-C-O 121.147 0.498 . . . . 0.0 110.366 -178.829 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' G' G ' 18' ' ' VAL . . . . . 0.757 ' O ' ' HB3' ' D' ' 19' ' ' PHE . 87.0 t -138.13 150.9 24.77 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.622 0 N-CA-C 107.635 -1.246 . . . . 0.0 107.635 -179.166 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' G' G ' 19' ' ' PHE . . . . . 0.475 ' O ' ' CG ' ' D' ' 19' ' ' PHE . 29.3 p90 -44.26 149.22 0.38 Allowed 'General case' 0 C--N 1.406 3.034 0 O-C-N 128.483 3.615 . . . . 0.0 117.721 -175.283 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' G' G ' 20' ' ' PHE . . . . . 0.401 ' CD2' ' O ' ' G' ' 20' ' ' PHE . 23.0 p90 -109.77 62.54 0.6 Allowed 'General case' 0 N--CA 1.496 1.855 0 CA-C-O 122.787 1.28 . . . . 0.0 112.681 177.685 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -53.66 94.3 0.01 OUTLIER 'General case' 0 N--CA 1.445 -0.709 0 CA-C-N 113.928 -1.487 . . . . 0.0 110.303 179.933 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 74.5 mt-10 -51.3 120.3 4.9 Favored 'General case' 0 CA--C 1.541 0.612 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.274 179.912 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 19.2 t70 -73.47 173.66 9.31 Favored 'General case' 0 N--CA 1.468 0.443 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 -178.905 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' G' G ' 24' ' ' VAL . . . . . 0.526 HG13 ' H ' ' G' ' 25' ' ' GLY . 0.9 OUTLIER 174.18 -79.19 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.755 0 N-CA-C 108.221 -1.029 . . . . 0.0 108.221 -179.773 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' G' G ' 25' ' ' GLY . . . . . 0.526 ' H ' HG13 ' G' ' 24' ' ' VAL . . . -37.51 85.91 0.01 OUTLIER Glycine 0 N--CA 1.479 1.54 0 C-N-CA 123.698 0.666 . . . . 0.0 113.171 179.658 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' G' G ' 26' ' ' SER . . . . . 0.441 ' N ' ' O ' ' G' ' 24' ' ' VAL . 90.6 p -40.95 -105.81 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.882 0 N-CA-C 113.877 1.066 . . . . 0.0 113.877 -177.506 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 16.9 p-10 -59.46 110.38 1.1 Allowed 'General case' 0 N--CA 1.473 0.71 0 CA-C-N 118.908 0.776 . . . . 0.0 110.63 -178.795 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 41.7 mttm -93.27 167.82 11.49 Favored 'General case' 0 N--CA 1.47 0.542 0 CA-C-N 115.823 -0.626 . . . . 0.0 109.669 -179.728 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -75.76 -140.28 0.87 Allowed Glycine 0 CA--C 1.525 0.698 0 N-CA-C 106.209 -2.757 . . . . 0.0 106.209 176.236 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -93.64 125.95 38.54 Favored 'General case' 0 N--CA 1.469 0.489 0 N-CA-C 107.154 -1.425 . . . . 0.0 107.154 176.23 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' G' G ' 31' ' ' ILE . . . . . 0.489 ' O ' ' O ' ' D' ' 30' ' ' ALA . 16.4 tt -149.86 155.37 8.04 Favored 'Isoleucine or valine' 0 C--O 1.211 -0.936 0 N-CA-C 108.783 -0.821 . . . . 0.0 108.783 179.786 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 26.7 pt -151.42 136.33 10.21 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.434 0 N-CA-C 109.287 -0.634 . . . . 0.0 109.287 -177.588 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -56.58 154.3 17.24 Favored Glycine 0 CA--C 1.526 0.76 0 CA-C-N 116.147 -0.479 . . . . 0.0 112.179 -178.543 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 2.5 pp -75.63 160.7 29.82 Favored 'General case' 0 N--CA 1.466 0.369 0 N-CA-C 109.499 -0.556 . . . . 0.0 109.499 179.313 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 6.6 ttp -104.78 152.21 22.84 Favored 'General case' 0 N--CA 1.48 1.046 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 179.378 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 7.4 p -168.69 162.22 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 N-CA-C 107.343 -1.355 . . . . 0.0 107.343 179.632 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 54.08 68.93 1.4 Allowed Glycine 0 C--N 1.312 -0.774 0 N-CA-C 111.848 -0.501 . . . . 0.0 111.848 178.77 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 152.66 -178.31 29.88 Favored Glycine 0 N--CA 1.465 0.581 0 N-CA-C 110.473 -1.051 . . . . 0.0 110.473 179.7 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 4.3 t -124.67 138.59 53.55 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.844 0 N-CA-C 107.098 -1.445 . . . . 0.0 107.098 -180.0 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 74.1 t . . . . . 0 N--CA 1.482 1.135 0 CA-C-O 117.788 -1.101 . . . . 0.0 109.8 -177.213 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' H' H ' 1' ' ' ASP . . . . . . . . . . . . . 4.0 p-10 . . . . . 0 N--CA 1.487 1.421 0 N-CA-C 108.509 -0.923 . . . . 0.0 108.509 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' H' H ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.74 132.99 50.08 Favored 'General case' 0 N--CA 1.469 0.495 0 CA-C-O 120.904 0.383 . . . . 0.0 110.94 -179.035 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' H' H ' 3' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -170.24 108.77 0.36 Allowed 'General case' 0 CA--C 1.542 0.661 0 N-CA-C 109.552 -0.536 . . . . 0.0 109.552 179.662 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 31.6 m-85 -85.98 157.21 20.17 Favored 'General case' 0 N--CA 1.473 0.712 0 N-CA-C 109.641 -0.503 . . . . 0.0 109.641 -179.325 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' H' H ' 5' ' ' ARG . . . . . . . . . . . . . 77.1 mtt85 -140.26 145.31 37.15 Favored 'General case' 0 N--CA 1.479 0.979 0 C-N-CA 122.86 0.464 . . . . 0.0 109.801 179.485 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 58.7 t-80 -150.28 117.59 6.04 Favored 'General case' 0 N--CA 1.475 0.786 0 N-CA-C 109.423 -0.584 . . . . 0.0 109.423 179.216 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 12.6 m-20 -67.02 148.17 52.29 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-N 116.386 -0.37 . . . . 0.0 111.078 -179.79 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' H' H ' 8' ' ' SER . . . . . . . . . . . . . 3.5 t -166.86 -179.29 4.66 Favored 'General case' 0 N--CA 1.471 0.598 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.151 178.326 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 85.36 71.68 1.31 Allowed Glycine 0 N--CA 1.477 1.406 0 CA-C-N 116.166 -0.47 . . . . 0.0 112.211 179.098 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 38.3 p90 -72.62 122.2 21.0 Favored 'General case' 0 N--CA 1.474 0.762 0 O-C-N 122.437 -0.449 . . . . 0.0 110.712 179.468 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 17.7 pt-20 -83.39 153.03 24.75 Favored 'General case' 0 N--CA 1.48 1.042 0 N-CA-C 109.294 -0.632 . . . . 0.0 109.294 178.37 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 21.8 t -143.81 116.83 3.12 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.029 0 CA-C-O 118.546 -0.74 . . . . 0.0 109.292 178.952 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 76.5 m80 -94.66 167.26 11.57 Favored 'General case' 0 N--CA 1.484 1.272 0 CA-C-N 119.441 1.018 . . . . 0.0 109.603 178.556 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' H' H ' 14' ' ' HIS . . . . . 0.442 ' NE2' ' NZ ' ' H' ' 16' ' ' LYS . 16.1 t60 -164.41 98.12 0.8 Allowed 'General case' 0 N--CA 1.479 0.979 0 N-CA-C 110.019 -0.363 . . . . 0.0 110.019 179.184 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -91.5 111.76 23.4 Favored 'General case' 0 CA--C 1.511 -0.544 0 N-CA-C 107.891 -1.151 . . . . 0.0 107.891 179.459 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' H' H ' 16' ' ' LYS . . . . . 0.442 ' NZ ' ' NE2' ' H' ' 14' ' ' HIS . 9.1 ttmm -93.72 172.06 8.49 Favored 'General case' 0 N--CA 1.486 1.338 0 N-CA-C 109.344 -0.613 . . . . 0.0 109.344 -179.768 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' H' H ' 17' ' ' LEU . . . . . 0.41 ' N ' HD12 ' H' ' 17' ' ' LEU . 9.4 mp -55.16 152.29 8.2 Favored 'General case' 0 N--CA 1.472 0.656 0 CA-C-O 121.152 0.501 . . . . 0.0 110.382 -178.921 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' H' H ' 18' ' ' VAL . . . . . 0.735 ' O ' ' HB3' ' E' ' 19' ' ' PHE . 89.0 t -138.23 151.15 24.71 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.711 0 N-CA-C 107.783 -1.191 . . . . 0.0 107.783 -179.158 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' H' H ' 19' ' ' PHE . . . . . 0.47 ' O ' ' CG ' ' E' ' 19' ' ' PHE . 29.5 p90 -44.73 149.0 0.45 Allowed 'General case' 0 C--N 1.406 3.033 0 O-C-N 128.487 3.617 . . . . 0.0 117.613 -175.055 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 23.3 p90 -109.56 62.45 0.6 Allowed 'General case' 0 N--CA 1.498 1.953 0 CA-C-O 122.758 1.266 . . . . 0.0 112.533 177.805 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -53.64 94.37 0.01 OUTLIER 'General case' 0 N--CA 1.446 -0.652 0 CA-C-N 113.954 -1.475 . . . . 0.0 110.211 179.947 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 74.8 mt-10 -51.45 120.18 4.85 Favored 'General case' 0 CA--C 1.541 0.62 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.297 179.91 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 19.0 t70 -73.47 173.34 9.77 Favored 'General case' 0 N--CA 1.466 0.355 0 N-CA-C 109.943 -0.391 . . . . 0.0 109.943 -178.897 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' H' H ' 24' ' ' VAL . . . . . 0.509 HG13 ' H ' ' H' ' 25' ' ' GLY . 0.9 OUTLIER 174.52 -79.16 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.542 0.661 0 N-CA-C 108.149 -1.056 . . . . 0.0 108.149 -179.693 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' H' H ' 25' ' ' GLY . . . . . 0.509 ' H ' HG13 ' H' ' 24' ' ' VAL . . . -37.33 85.74 0.01 OUTLIER Glycine 0 N--CA 1.478 1.455 0 C-N-CA 123.732 0.682 . . . . 0.0 113.269 179.646 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' H' H ' 26' ' ' SER . . . . . 0.437 ' N ' ' O ' ' H' ' 24' ' ' VAL . 89.5 p -40.64 -106.07 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.885 0 N-CA-C 113.614 0.968 . . . . 0.0 113.614 -177.789 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 17.0 p-10 -59.35 110.36 1.07 Allowed 'General case' 0 N--CA 1.473 0.686 0 CA-C-N 118.941 0.791 . . . . 0.0 110.68 -178.771 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 41.7 mttm -93.46 167.42 11.72 Favored 'General case' 0 N--CA 1.468 0.461 0 CA-C-N 115.757 -0.656 . . . . 0.0 109.701 -179.896 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -75.43 -140.22 0.79 Allowed Glycine 0 CA--C 1.524 0.645 0 N-CA-C 106.262 -2.735 . . . . 0.0 106.262 176.218 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -93.7 125.92 38.58 Favored 'General case' 0 N--CA 1.47 0.529 0 N-CA-C 107.14 -1.43 . . . . 0.0 107.14 176.342 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' H' H ' 31' ' ' ILE . . . . . 0.458 ' O ' ' O ' ' E' ' 30' ' ' ALA . 16.4 tt -150.02 155.32 7.97 Favored 'Isoleucine or valine' 0 C--O 1.213 -0.846 0 N-CA-C 108.658 -0.867 . . . . 0.0 108.658 179.673 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 27.3 pt -151.38 136.27 10.16 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.399 0 N-CA-C 109.243 -0.651 . . . . 0.0 109.243 -177.526 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -56.69 154.49 17.26 Favored Glycine 0 CA--C 1.528 0.854 0 CA-C-N 116.166 -0.47 . . . . 0.0 112.193 -178.442 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 2.5 pp -75.59 160.78 29.76 Favored 'General case' 0 N--CA 1.467 0.418 0 N-CA-C 109.515 -0.55 . . . . 0.0 109.515 179.37 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 6.5 ttp -104.83 152.17 22.93 Favored 'General case' 0 N--CA 1.48 1.027 0 N-CA-C 109.102 -0.703 . . . . 0.0 109.102 179.343 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 7.4 p -168.81 162.29 0.56 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.487 0 N-CA-C 107.209 -1.404 . . . . 0.0 107.209 179.639 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 54.14 68.87 1.43 Allowed Glycine 0 C--N 1.311 -0.828 0 N-CA-C 111.853 -0.499 . . . . 0.0 111.853 178.721 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 152.41 -178.26 29.7 Favored Glycine 0 N--CA 1.466 0.697 0 N-CA-C 110.564 -1.014 . . . . 0.0 110.564 179.781 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 4.4 t -124.58 138.58 53.54 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.788 0 N-CA-C 107.077 -1.453 . . . . 0.0 107.077 -179.931 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 75.2 t . . . . . 0 N--CA 1.483 1.217 0 CA-C-O 117.755 -1.117 . . . . 0.0 109.813 -177.254 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' I' I ' 1' ' ' ASP . . . . . 0.408 ' H2 ' ' HB3' ' F' ' 1' ' ' ASP . 4.0 p-10 . . . . . 0 N--CA 1.487 1.414 0 N-CA-C 108.509 -0.923 . . . . 0.0 108.509 . . . . . . . . . 1 1 . 1 . 020 nuclear build full ' I' I ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.68 132.83 49.75 Favored 'General case' 0 CA--C 1.538 0.494 0 CA-C-O 120.916 0.388 . . . . 0.0 110.883 -178.955 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' I' I ' 3' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -170.16 108.61 0.37 Allowed 'General case' 0 CA--C 1.542 0.659 0 CA-C-N 116.068 -0.515 . . . . 0.0 109.613 179.684 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 31.0 m-85 -85.84 157.24 20.26 Favored 'General case' 0 N--CA 1.474 0.763 0 O-C-N 121.9 -0.5 . . . . 0.0 109.7 -179.293 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' I' I ' 5' ' ' ARG . . . . . . . . . . . . . 77.0 mtt85 -140.3 145.26 37.02 Favored 'General case' 0 N--CA 1.48 1.038 0 C-N-CA 122.896 0.478 . . . . 0.0 109.798 179.514 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 58.7 t-80 -150.25 117.4 5.98 Favored 'General case' 0 N--CA 1.474 0.746 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 179.226 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 12.3 m-20 -66.76 148.15 52.31 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-N 116.379 -0.373 . . . . 0.0 111.014 -179.848 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' I' I ' 8' ' ' SER . . . . . . . . . . . . . 3.5 t -166.81 -179.31 4.7 Favored 'General case' 0 N--CA 1.472 0.67 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.082 178.3 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 85.36 71.72 1.31 Allowed Glycine 0 N--CA 1.476 1.355 0 CA-C-N 116.14 -0.482 . . . . 0.0 112.232 179.086 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 38.0 p90 -72.48 121.95 20.46 Favored 'General case' 0 N--CA 1.476 0.837 0 O-C-N 122.356 -0.496 . . . . 0.0 110.745 179.38 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 17.7 pt-20 -83.2 153.02 24.96 Favored 'General case' 0 N--CA 1.478 0.959 0 N-CA-C 109.279 -0.638 . . . . 0.0 109.279 178.361 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 21.8 t -143.78 116.83 3.14 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.097 0 CA-C-O 118.584 -0.722 . . . . 0.0 109.326 178.928 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 76.5 m80 -94.69 167.24 11.58 Favored 'General case' 0 N--CA 1.485 1.317 0 CA-C-N 119.505 1.048 . . . . 0.0 109.574 178.603 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' I' I ' 14' ' ' HIS . . . . . 0.446 ' NE2' ' NZ ' ' I' ' 16' ' ' LYS . 15.9 t60 -164.41 98.01 0.8 Allowed 'General case' 0 N--CA 1.479 0.991 0 N-CA-C 110.181 -0.303 . . . . 0.0 110.181 179.149 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -91.43 111.63 23.21 Favored 'General case' 0 CA--C 1.509 -0.632 0 N-CA-C 107.94 -1.133 . . . . 0.0 107.94 179.49 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' I' I ' 16' ' ' LYS . . . . . 0.446 ' NZ ' ' NE2' ' I' ' 14' ' ' HIS . 9.1 ttmm -93.62 172.11 8.47 Favored 'General case' 0 N--CA 1.485 1.304 0 N-CA-C 109.362 -0.607 . . . . 0.0 109.362 -179.778 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' I' I ' 17' ' ' LEU . . . . . 0.405 ' N ' HD12 ' I' ' 17' ' ' LEU . 9.5 mp -55.17 152.29 8.24 Favored 'General case' 0 N--CA 1.472 0.652 0 CA-C-O 121.15 0.5 . . . . 0.0 110.3 -178.857 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' I' I ' 18' ' ' VAL . . . . . 0.745 ' O ' ' HB3' ' F' ' 19' ' ' PHE . 88.8 t -138.21 151.28 24.86 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.634 0 N-CA-C 107.683 -1.228 . . . . 0.0 107.683 -179.218 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' I' I ' 19' ' ' PHE . . . . . 0.466 ' O ' ' CG ' ' F' ' 19' ' ' PHE . 29.1 p90 -44.83 148.93 0.47 Allowed 'General case' 0 C--N 1.407 3.093 0 O-C-N 128.378 3.549 . . . . 0.0 117.57 -175.06 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 23.2 p90 -109.5 62.48 0.6 Allowed 'General case' 0 N--CA 1.497 1.904 0 CA-C-O 122.764 1.268 . . . . 0.0 112.522 177.763 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -53.65 94.42 0.01 OUTLIER 'General case' 0 N--CA 1.446 -0.673 0 CA-C-N 113.901 -1.499 . . . . 0.0 110.201 179.947 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 74.5 mt-10 -51.4 120.17 4.82 Favored 'General case' 0 CA--C 1.541 0.634 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.375 179.929 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 18.9 t70 -73.52 173.13 10.11 Favored 'General case' 0 N--CA 1.467 0.404 0 N-CA-C 109.98 -0.378 . . . . 0.0 109.98 -178.9 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' I' I ' 24' ' ' VAL . . . . . 0.511 HG13 ' H ' ' I' ' 25' ' ' GLY . 0.9 OUTLIER 174.61 -79.24 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.544 0.738 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 -179.745 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' I' I ' 25' ' ' GLY . . . . . 0.511 ' H ' HG13 ' I' ' 24' ' ' VAL . . . -37.29 85.87 0.01 OUTLIER Glycine 0 N--CA 1.48 1.63 0 C-N-CA 123.61 0.624 . . . . 0.0 113.229 179.636 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' I' I ' 26' ' ' SER . . . . . 0.44 ' N ' ' O ' ' I' ' 24' ' ' VAL . 87.7 p -40.77 -105.58 0.0 OUTLIER 'General case' 0 N--CA 1.478 0.949 0 N-CA-C 113.6 0.963 . . . . 0.0 113.6 -177.748 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 17.0 p-10 -59.68 110.4 1.13 Allowed 'General case' 0 N--CA 1.473 0.688 0 CA-C-N 118.993 0.815 . . . . 0.0 110.64 -178.754 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 41.6 mttm -93.53 167.53 11.63 Favored 'General case' 0 N--CA 1.469 0.517 0 CA-C-N 115.788 -0.642 . . . . 0.0 109.778 -179.912 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -75.39 -140.21 0.78 Allowed Glycine 0 CA--C 1.525 0.709 0 N-CA-C 106.361 -2.695 . . . . 0.0 106.361 176.289 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -93.65 125.82 38.47 Favored 'General case' 0 N--CA 1.469 0.508 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 176.242 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' I' I ' 31' ' ' ILE . . . . . 0.456 ' O ' ' O ' ' F' ' 30' ' ' ALA . 16.3 tt -149.91 155.24 8.12 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.806 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 179.688 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 27.5 pt -151.3 136.26 10.26 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.413 0 N-CA-C 109.311 -0.626 . . . . 0.0 109.311 -177.468 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -56.55 154.45 16.76 Favored Glycine 0 CA--C 1.526 0.762 0 CA-C-N 116.238 -0.437 . . . . 0.0 112.244 -178.468 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 2.5 pp -75.64 160.78 29.73 Favored 'General case' 0 N--CA 1.467 0.38 0 N-CA-C 109.448 -0.575 . . . . 0.0 109.448 179.338 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 6.5 ttp -104.78 152.32 22.7 Favored 'General case' 0 N--CA 1.48 1.045 0 N-CA-C 109.04 -0.726 . . . . 0.0 109.04 179.417 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 7.4 p -168.87 162.26 0.56 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.529 0 N-CA-C 107.324 -1.362 . . . . 0.0 107.324 179.582 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 54.04 68.95 1.39 Allowed Glycine 0 C--N 1.312 -0.795 0 N-CA-C 111.924 -0.471 . . . . 0.0 111.924 178.801 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 152.37 -178.25 29.67 Favored Glycine 0 N--CA 1.466 0.646 0 N-CA-C 110.525 -1.03 . . . . 0.0 110.525 179.716 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 4.2 t -124.49 138.34 54.29 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.803 0 N-CA-C 107.193 -1.41 . . . . 0.0 107.193 -179.967 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 74.0 t . . . . . 0 N--CA 1.481 1.125 0 CA-C-O 117.719 -1.134 . . . . 0.0 109.822 -177.304 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 22.6 m-85 . . . . . 0 N--CA 1.473 0.705 0 N-CA-C 109.589 -0.523 . . . . 0.0 109.589 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 87.5 mtt180 -68.87 133.01 47.67 Favored 'General case' 0 N--CA 1.473 0.698 0 CA-C-N 116.612 -0.267 . . . . 0.0 111.101 -178.211 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 6.9 t-160 -98.71 127.77 44.75 Favored 'General case' 0 N--CA 1.474 0.732 0 N-CA-C 109.351 -0.611 . . . . 0.0 109.351 179.347 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 4.1 m-20 -72.68 139.89 47.54 Favored 'General case' 0 CA--C 1.538 0.487 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.406 178.545 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 28.0 p -163.24 -168.91 1.84 Allowed 'General case' 0 N--CA 1.481 1.102 0 C-N-CA 122.508 0.323 . . . . 0.0 110.694 179.37 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 105.03 44.39 1.51 Allowed Glycine 0 N--CA 1.483 1.798 0 N-CA-C 111.764 -0.534 . . . . 0.0 111.764 -179.475 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 49.0 p90 -64.11 132.79 51.53 Favored 'General case' 0 N--CA 1.472 0.65 0 O-C-N 122.641 -0.329 . . . . 0.0 111.698 -179.899 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 48.7 mt-10 -90.98 152.34 20.72 Favored 'General case' 0 N--CA 1.477 0.907 0 N-CA-C 109.705 -0.48 . . . . 0.0 109.705 178.37 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -152.98 128.07 1.52 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.655 0 N-CA-C 107.805 -1.183 . . . . 0.0 107.805 178.268 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 46.1 m-70 -135.25 147.4 49.26 Favored 'General case' 0 N--CA 1.492 1.672 0 CA-C-N 119.083 0.856 . . . . 0.0 111.388 -178.965 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 6.5 t60 -164.53 97.39 0.78 Allowed 'General case' 0 N--CA 1.481 1.102 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.733 179.191 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . 0.478 HE22 HG23 ' A' ' 36' ' ' VAL . 3.9 pt20 -102.15 -174.12 2.5 Favored 'General case' 0 CA--C 1.509 -0.634 0 N-CA-C 108.654 -0.869 . . . . 0.0 108.654 -179.755 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -169.77 95.68 0.29 Allowed 'General case' 0 N--CA 1.47 0.542 0 CA-C-N 114.565 -1.198 . . . . 0.0 108.345 178.351 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 6.3 mp -123.69 157.04 34.79 Favored 'General case' 0 N--CA 1.498 1.94 0 CA-C-O 121.882 0.848 . . . . 0.0 111.122 -178.151 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 60.2 t -111.92 127.11 69.3 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.099 0 CA-C-O 117.886 -1.054 . . . . 0.0 108.266 177.575 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 26.9 m-85 -126.91 123.05 36.33 Favored 'General case' 0 N--CA 1.497 1.903 0 CA-C-N 120.15 1.341 . . . . 0.0 110.418 179.559 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 66.0 m-85 53.45 74.83 0.29 Allowed 'General case' 0 N--CA 1.469 0.496 0 CA-C-O 121.483 0.659 . . . . 0.0 111.78 178.43 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -79.94 -77.77 0.18 Allowed 'General case' 0 C--N 1.352 0.703 0 CA-C-N 115.044 -0.98 . . . . 0.0 110.319 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 40.8 tt0 -113.96 100.79 8.68 Favored 'General case' 0 N--CA 1.47 0.527 0 N-CA-C 108.247 -1.02 . . . . 0.0 108.247 179.614 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 4.4 p30 -158.53 140.26 13.65 Favored 'General case' 0 N--CA 1.485 1.283 0 O-C-N 122.245 -0.284 . . . . 0.0 111.142 179.079 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.404 HG12 ' N ' ' A' ' 25' ' ' GLY . 60.4 t -59.72 163.58 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.865 0 N-CA-C 108.042 -1.096 . . . . 0.0 108.042 177.108 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.51 ' H ' ' HB ' ' D' ' 24' ' ' VAL . . . -117.87 47.52 1.02 Allowed Glycine 0 N--CA 1.475 1.299 0 N-CA-C 111.776 -0.53 . . . . 0.0 111.776 -179.372 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -61.19 -168.01 0.01 OUTLIER 'General case' 0 N--CA 1.469 0.479 0 O-C-N 123.762 0.331 . . . . 0.0 110.337 179.529 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 26.6 t-20 -70.59 80.7 0.59 Allowed 'General case' 0 N--CA 1.465 0.277 0 CA-C-N 116.401 -0.363 . . . . 0.0 110.17 179.596 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 97.9 mttt -78.03 143.91 37.09 Favored 'General case' 0 N--CA 1.472 0.642 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 179.216 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.81 -167.27 1.07 Allowed Glycine 0 CA--C 1.524 0.625 0 N-CA-C 109.872 -1.291 . . . . 0.0 109.872 178.737 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.83 114.68 28.03 Favored 'General case' 0 N--CA 1.478 0.971 0 N-CA-C 109.67 -0.493 . . . . 0.0 109.67 179.691 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 66.2 mt -98.45 135.83 31.72 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.608 0 N-CA-C 106.883 -1.525 . . . . 0.0 106.883 179.067 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 40.0 pt -152.44 -176.53 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.354 0.763 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.141 -178.765 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.35 4.85 9.61 Favored Glycine 0 CA--C 1.525 0.694 0 N-CA-C 110.861 -0.896 . . . . 0.0 110.861 179.956 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 1.6 tt -75.07 126.58 31.32 Favored 'General case' 0 CA--C 1.544 0.731 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 -179.614 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 28.0 ttt -163.05 150.33 13.05 Favored 'General case' 0 C--O 1.224 -0.253 0 N-CA-C 109.002 -0.74 . . . . 0.0 109.002 178.73 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.569 HG22 HG12 ' D' ' 36' ' ' VAL . 27.9 m -155.78 165.58 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.346 0.447 0 N-CA-C 108.193 -1.04 . . . . 0.0 108.193 179.587 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.92 66.9 2.51 Favored Glycine 0 C--N 1.306 -1.105 0 CA-C-N 115.714 -0.675 . . . . 0.0 112.145 178.693 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.78 -173.12 24.77 Favored Glycine 0 N--CA 1.475 1.276 0 N-CA-C 110.817 -0.913 . . . . 0.0 110.817 179.052 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.493 ' H ' HG12 ' D' ' 39' ' ' VAL . 35.3 m -125.55 157.51 34.83 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.819 0 C-N-CA 123.436 0.694 . . . . 0.0 110.419 -179.863 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 26.2 t . . . . . 0 C--O 1.218 -0.568 0 CA-C-O 118.451 -0.785 . . . . 0.0 110.758 179.775 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 24.4 m-85 . . . . . 0 N--CA 1.474 0.737 0 N-CA-C 109.699 -0.482 . . . . 0.0 109.699 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 87.9 mtt180 -69.06 132.16 46.17 Favored 'General case' 0 N--CA 1.474 0.767 0 CA-C-O 120.631 0.253 . . . . 0.0 110.995 -178.225 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 6.8 t-160 -97.95 127.68 44.05 Favored 'General case' 0 N--CA 1.474 0.751 0 N-CA-C 109.298 -0.631 . . . . 0.0 109.298 179.312 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 7' ' ' ASP . . . . . . . . . . . . . 4.1 m-20 -72.93 139.53 46.84 Favored 'General case' 0 CA--C 1.539 0.544 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.446 178.526 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 8' ' ' SER . . . . . . . . . . . . . 29.2 p -162.56 -168.51 1.84 Allowed 'General case' 0 N--CA 1.481 1.076 0 C-N-CA 122.52 0.328 . . . . 0.0 110.705 179.225 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.63 45.06 1.46 Allowed Glycine 0 N--CA 1.483 1.773 0 N-CA-C 111.732 -0.547 . . . . 0.0 111.732 -179.48 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 49.0 p90 -64.79 132.95 50.94 Favored 'General case' 0 N--CA 1.471 0.607 0 O-C-N 122.662 -0.316 . . . . 0.0 111.684 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 48.7 mt-10 -91.07 152.39 20.65 Favored 'General case' 0 N--CA 1.476 0.873 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 178.293 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -153.06 128.32 1.55 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.638 0 N-CA-C 107.734 -1.21 . . . . 0.0 107.734 178.335 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 45.6 m-70 -135.71 147.42 48.47 Favored 'General case' 0 N--CA 1.493 1.698 0 CA-C-N 118.917 0.78 . . . . 0.0 111.33 -178.958 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 6.5 t60 -164.65 97.33 0.76 Allowed 'General case' 0 N--CA 1.481 1.078 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.586 179.302 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . 0.476 HE22 HG23 ' B' ' 36' ' ' VAL . 3.9 pt20 -101.87 -173.68 2.41 Favored 'General case' 0 CA--C 1.51 -0.568 0 N-CA-C 108.639 -0.875 . . . . 0.0 108.639 -179.804 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -170.22 95.63 0.25 Allowed 'General case' 0 N--CA 1.471 0.591 0 CA-C-N 114.63 -1.168 . . . . 0.0 108.259 178.415 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 6.3 mp -123.71 157.05 34.79 Favored 'General case' 0 N--CA 1.497 1.896 0 CA-C-O 121.826 0.822 . . . . 0.0 111.123 -178.113 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 61.8 t -112.31 127.29 69.59 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.074 0 N-CA-C 108.016 -1.105 . . . . 0.0 108.016 177.501 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 27.0 m-85 -127.33 122.86 34.91 Favored 'General case' 0 N--CA 1.495 1.797 0 CA-C-N 119.667 1.121 . . . . 0.0 110.314 179.779 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 66.3 m-85 53.1 74.79 0.28 Allowed 'General case' 0 CA--C 1.539 0.547 0 CA-C-O 121.545 0.688 . . . . 0.0 111.859 178.397 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -79.98 -78.01 0.17 Allowed 'General case' 0 C--N 1.351 0.657 0 CA-C-N 115.016 -0.993 . . . . 0.0 110.278 179.966 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 40.5 tt0 -113.66 100.88 8.81 Favored 'General case' 0 N--CA 1.471 0.594 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 179.569 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 4.4 p30 -158.55 140.88 14.16 Favored 'General case' 0 N--CA 1.484 1.272 0 CA-C-O 119.494 -0.289 . . . . 0.0 111.151 179.021 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 59.0 t -60.13 163.81 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.91 0 N-CA-C 108.116 -1.068 . . . . 0.0 108.116 177.199 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 25' ' ' GLY . . . . . 0.516 ' H ' ' HB ' ' E' ' 24' ' ' VAL . . . -117.9 47.53 1.02 Allowed Glycine 0 N--CA 1.475 1.276 0 N-CA-C 111.739 -0.544 . . . . 0.0 111.739 -179.397 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -61.18 -167.74 0.01 OUTLIER 'General case' 0 N--CA 1.47 0.545 0 O-C-N 123.651 0.265 . . . . 0.0 110.379 179.396 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 26.9 t-20 -71.1 80.73 0.69 Allowed 'General case' 0 N--CA 1.466 0.348 0 N-CA-C 110.091 -0.337 . . . . 0.0 110.091 179.673 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -78.01 143.92 37.11 Favored 'General case' 0 N--CA 1.472 0.666 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 179.267 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.71 -166.7 0.94 Allowed Glycine 0 CA--C 1.524 0.628 0 N-CA-C 109.895 -1.282 . . . . 0.0 109.895 178.752 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -100.4 114.55 28.2 Favored 'General case' 0 N--CA 1.478 0.958 0 N-CA-C 109.668 -0.493 . . . . 0.0 109.668 179.628 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 65.5 mt -98.26 135.39 33.14 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.556 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 178.965 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 38.1 pt -151.73 -176.51 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.353 0.733 0 CA-C-N 115.962 -0.563 . . . . 0.0 111.151 -178.789 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.37 4.73 9.45 Favored Glycine 0 CA--C 1.525 0.703 0 N-CA-C 110.947 -0.861 . . . . 0.0 110.947 179.833 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 34' ' ' LEU . . . . . 0.412 HD23 ' N ' ' B' ' 35' ' ' MET . 1.6 tt -74.95 126.69 31.53 Favored 'General case' 0 CA--C 1.544 0.744 0 N-CA-C 109.37 -0.604 . . . . 0.0 109.37 -179.617 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 35' ' ' MET . . . . . 0.412 ' N ' HD23 ' B' ' 34' ' ' LEU . 27.4 ttt -163.04 150.17 12.96 Favored 'General case' 0 N--CA 1.467 0.378 0 N-CA-C 108.915 -0.772 . . . . 0.0 108.915 178.672 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 36' ' ' VAL . . . . . 0.559 HG22 HG12 ' E' ' 36' ' ' VAL . 27.8 m -155.8 165.26 1.15 Allowed 'Isoleucine or valine' 0 C--N 1.347 0.495 0 N-CA-C 108.155 -1.054 . . . . 0.0 108.155 179.6 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.09 67.16 2.36 Favored Glycine 0 C--N 1.307 -1.059 0 CA-C-N 115.674 -0.694 . . . . 0.0 112.098 178.649 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.54 -172.57 24.83 Favored Glycine 0 N--CA 1.476 1.318 0 N-CA-C 110.806 -0.917 . . . . 0.0 110.806 179.046 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 39' ' ' VAL . . . . . 0.513 ' H ' HG12 ' E' ' 39' ' ' VAL . 35.5 m -126.12 157.42 36.27 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.98 0 C-N-CA 123.448 0.699 . . . . 0.0 110.454 -179.651 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 26.0 t . . . . . 0 C--O 1.219 -0.509 0 CA-C-O 118.429 -0.796 . . . . 0.0 110.602 179.664 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 23.9 m-85 . . . . . 0 N--CA 1.475 0.794 0 N-CA-C 109.683 -0.488 . . . . 0.0 109.683 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 87.4 mtt180 -69.28 131.91 45.62 Favored 'General case' 0 N--CA 1.477 0.904 0 CA-C-O 120.714 0.292 . . . . 0.0 110.955 -178.236 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 6.8 t-160 -97.79 128.16 44.23 Favored 'General case' 0 N--CA 1.473 0.689 0 N-CA-C 109.262 -0.644 . . . . 0.0 109.262 179.215 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 7' ' ' ASP . . . . . . . . . . . . . 4.1 m-20 -73.33 139.77 46.26 Favored 'General case' 0 CA--C 1.538 0.49 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.428 178.583 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 8' ' ' SER . . . . . . . . . . . . . 29.8 p -162.99 -168.71 1.83 Allowed 'General case' 0 N--CA 1.481 1.092 0 CA-C-O 120.828 0.347 . . . . 0.0 110.671 179.249 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.92 44.25 1.54 Allowed Glycine 0 N--CA 1.483 1.798 0 N-CA-C 111.759 -0.537 . . . . 0.0 111.759 -179.498 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 49.3 p90 -64.21 133.29 52.56 Favored 'General case' 0 N--CA 1.472 0.667 0 O-C-N 122.672 -0.311 . . . . 0.0 111.687 -179.935 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 48.3 mt-10 -91.4 152.28 20.47 Favored 'General case' 0 N--CA 1.476 0.858 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 178.356 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -152.83 128.15 1.59 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.598 0 N-CA-C 107.814 -1.18 . . . . 0.0 107.814 178.327 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 45.4 m-70 -135.43 147.69 49.05 Favored 'General case' 0 N--CA 1.493 1.695 0 CA-C-N 118.948 0.794 . . . . 0.0 111.306 -178.969 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 6.5 t60 -164.85 97.31 0.74 Allowed 'General case' 0 N--CA 1.481 1.101 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.646 179.293 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 15' ' ' GLN . . . . . 0.461 HE22 HG23 ' C' ' 36' ' ' VAL . 3.9 pt20 -102.05 -173.85 2.44 Favored 'General case' 0 CA--C 1.508 -0.645 0 N-CA-C 108.606 -0.887 . . . . 0.0 108.606 -179.735 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -170.06 95.81 0.27 Allowed 'General case' 0 N--CA 1.468 0.47 0 CA-C-N 114.623 -1.171 . . . . 0.0 108.292 178.298 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 6.4 mp -123.73 157.17 34.58 Favored 'General case' 0 N--CA 1.497 1.899 0 CA-C-O 121.808 0.813 . . . . 0.0 111.189 -178.194 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 61.7 t -112.32 127.63 69.41 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.057 0 N-CA-C 108.111 -1.07 . . . . 0.0 108.111 177.516 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 27.4 m-85 -127.58 122.77 34.09 Favored 'General case' 0 N--CA 1.493 1.723 0 CA-C-N 119.688 1.131 . . . . 0.0 110.305 179.861 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 66.6 m-85 53.28 74.77 0.28 Allowed 'General case' 0 CA--C 1.538 0.492 0 CA-C-O 121.488 0.661 . . . . 0.0 111.851 178.304 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -79.96 -78.23 0.17 Allowed 'General case' 0 C--N 1.35 0.621 0 CA-C-N 115.008 -0.996 . . . . 0.0 110.291 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 40.1 tt0 -113.58 100.66 8.67 Favored 'General case' 0 N--CA 1.471 0.591 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 179.629 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 4.4 p30 -158.29 140.41 14.09 Favored 'General case' 0 N--CA 1.484 1.229 0 O-C-N 122.264 -0.272 . . . . 0.0 111.117 179.183 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 24' ' ' VAL . . . . . 0.402 HG12 ' N ' ' C' ' 25' ' ' GLY . 59.4 t -59.88 163.51 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.868 0 N-CA-C 108.072 -1.084 . . . . 0.0 108.072 177.096 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 25' ' ' GLY . . . . . 0.501 ' H ' ' HB ' ' F' ' 24' ' ' VAL . . . -117.79 47.94 0.99 Allowed Glycine 0 N--CA 1.478 1.492 0 N-CA-C 111.597 -0.601 . . . . 0.0 111.597 -179.314 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -61.59 -168.18 0.01 OUTLIER 'General case' 0 N--CA 1.469 0.487 0 N-CA-C 110.268 -0.271 . . . . 0.0 110.268 179.447 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 26.7 t-20 -70.51 80.99 0.57 Allowed 'General case' 0 N--CA 1.466 0.332 0 N-CA-C 110.026 -0.361 . . . . 0.0 110.026 179.595 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -78.3 143.76 36.7 Favored 'General case' 0 N--CA 1.472 0.66 0 N-CA-C 109.089 -0.708 . . . . 0.0 109.089 179.312 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.45 -167.34 0.95 Allowed Glycine 0 CA--C 1.525 0.672 0 N-CA-C 109.937 -1.265 . . . . 0.0 109.937 178.689 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.86 113.97 26.86 Favored 'General case' 0 N--CA 1.48 1.028 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 179.657 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 66.0 mt -97.88 135.57 31.92 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.557 0 N-CA-C 106.942 -1.503 . . . . 0.0 106.942 178.992 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 38.8 pt -152.01 -176.42 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.354 0.768 0 CA-C-N 115.902 -0.59 . . . . 0.0 111.122 -178.791 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.45 4.52 9.36 Favored Glycine 0 CA--C 1.525 0.717 0 N-CA-C 110.907 -0.877 . . . . 0.0 110.907 179.882 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 34' ' ' LEU . . . . . 0.403 HD23 ' N ' ' C' ' 35' ' ' MET . 1.6 tt -74.75 126.34 30.68 Favored 'General case' 0 CA--C 1.543 0.692 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 -179.619 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 35' ' ' MET . . . . . 0.403 ' N ' HD23 ' C' ' 34' ' ' LEU . 27.5 ttt -162.57 150.36 13.97 Favored 'General case' 0 N--CA 1.466 0.349 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 178.763 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 36' ' ' VAL . . . . . 0.563 HG22 HG12 ' F' ' 36' ' ' VAL . 27.6 m -156.09 165.22 1.12 Allowed 'Isoleucine or valine' 0 C--N 1.347 0.48 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 179.543 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.14 66.74 2.63 Favored Glycine 0 C--N 1.306 -1.106 0 CA-C-N 115.721 -0.672 . . . . 0.0 112.072 178.548 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.84 -172.47 25.06 Favored Glycine 0 N--CA 1.476 1.308 0 N-CA-C 110.813 -0.915 . . . . 0.0 110.813 178.999 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 39' ' ' VAL . . . . . 0.505 ' H ' HG12 ' F' ' 39' ' ' VAL . 35.6 m -126.21 157.66 36.36 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.892 0 C-N-CA 123.429 0.692 . . . . 0.0 110.421 -179.667 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 27.2 t . . . . . 0 C--O 1.219 -0.512 0 CA-C-O 118.43 -0.795 . . . . 0.0 110.526 179.722 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 26.7 m-85 . . . . . 0 N--CA 1.485 1.276 0 N-CA-C 108.304 -0.998 . . . . 0.0 108.304 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' D' D ' 5' ' ' ARG . . . . . . . . . . . . 0.314 94.1 mtt180 -77.63 134.01 38.29 Favored 'General case' 0 N--CA 1.483 1.179 0 CA-C-O 123.01 1.386 . . . . 0.0 107.946 -169.394 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 6.2 t-160 -95.14 130.81 41.71 Favored 'General case' 0 C--N 1.364 1.231 0 CA-C-N 113.53 -1.668 . . . . 0.0 108.662 -177.259 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' D' D ' 7' ' ' ASP . . . . . 0.474 ' O ' ' OG ' ' G' ' 8' ' ' SER . 2.8 m-20 -66.29 125.44 25.59 Favored 'General case' 0 C--N 1.309 -1.161 0 C-N-CA 126.841 2.056 . . . . 0.0 114.989 173.304 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' D' D ' 8' ' ' SER . . . . . . . . . . . . . 27.6 p -153.35 -167.15 2.62 Favored 'General case' 0 N--CA 1.488 1.458 0 CA-C-N 120.187 1.358 . . . . 0.0 110.962 176.868 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.78 47.15 1.2 Allowed Glycine 0 N--CA 1.484 1.897 0 C-N-CA 124.797 1.189 . . . . 0.0 110.741 176.961 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 51.0 p90 -60.79 131.66 51.41 Favored 'General case' 0 N--CA 1.47 0.553 0 N-CA-C 112.838 0.681 . . . . 0.0 112.838 177.657 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 48.5 mt-10 -88.6 150.95 22.78 Favored 'General case' 0 N--CA 1.48 1.067 0 CA-C-N 117.862 0.301 . . . . 0.0 110.591 175.553 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -149.5 129.9 4.3 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.609 0 N-CA-C 107.377 -1.342 . . . . 0.0 107.377 173.464 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 42.4 m-70 -129.96 150.69 51.13 Favored 'General case' 0 N--CA 1.483 1.176 0 N-CA-C 112.05 0.389 . . . . 0.0 112.05 176.757 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 6.6 t60 -165.04 104.37 0.77 Allowed 'General case' 0 N--CA 1.483 1.194 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 172.32 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' D' D ' 15' ' ' GLN . . . . . 0.477 HE22 HG23 ' D' ' 36' ' ' VAL . 3.9 pt20 -105.48 -176.17 3.0 Favored 'General case' 0 CA--C 1.501 -0.908 0 N-CA-C 108.491 -0.929 . . . . 0.0 108.491 179.243 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -166.03 104.59 0.67 Allowed 'General case' 0 N--CA 1.466 0.327 0 N-CA-C 106.064 -1.828 . . . . 0.0 106.064 174.26 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 5.4 mp -130.87 153.86 48.68 Favored 'General case' 0 N--CA 1.499 1.988 0 CA-C-O 122.188 0.994 . . . . 0.0 110.604 179.563 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 35.8 t -101.29 131.79 48.35 Favored 'Isoleucine or valine' 0 C--O 1.259 1.57 0 CA-C-O 116.884 -1.531 . . . . 0.0 109.563 174.11 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 25.0 m-85 -130.45 126.3 36.62 Favored 'General case' 0 N--CA 1.49 1.544 0 CA-C-N 120.063 1.302 . . . . 0.0 109.591 173.9 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 66.3 m-85 55.65 71.69 0.53 Allowed 'General case' 0 C--N 1.348 0.535 0 CA-C-N 115.618 -0.719 . . . . 0.0 111.521 175.989 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -81.92 -73.03 0.41 Allowed 'General case' 0 C--N 1.35 0.607 0 CA-C-O 118.478 -0.772 . . . . 0.0 110.988 -177.647 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 40.9 tt0 -117.0 104.62 11.45 Favored 'General case' 0 N--CA 1.482 1.14 0 N-CA-C 106.404 -1.702 . . . . 0.0 106.404 176.32 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -152.06 140.43 20.51 Favored 'General case' 0 N--CA 1.476 0.865 0 CA-C-O 116.797 -1.573 . . . . 0.0 113.494 177.995 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' D' D ' 24' ' ' VAL . . . . . 0.51 ' HB ' ' H ' ' A' ' 25' ' ' GLY . 79.3 t -62.53 165.93 1.01 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.282 0 CA-C-N 121.063 1.756 . . . . 0.0 108.013 175.027 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' D' D ' 25' ' ' GLY . . . . . 0.571 ' H ' ' HB ' ' G' ' 24' ' ' VAL . . . -116.92 51.15 0.74 Allowed Glycine 0 N--CA 1.479 1.508 0 CA-C-O 119.003 -0.887 . . . . 0.0 111.78 178.196 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -57.72 -170.71 0.01 OUTLIER 'General case' 0 C--N 1.32 -0.689 0 C-N-CA 123.563 0.745 . . . . 0.0 111.643 176.042 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 28.2 t-20 -72.73 86.62 1.24 Allowed 'General case' 0 C--N 1.346 0.435 0 N-CA-C 108.421 -0.955 . . . . 0.0 108.421 177.952 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 97.4 mttt -83.27 146.21 28.67 Favored 'General case' 0 C--N 1.352 0.708 0 N-CA-C 108.063 -1.088 . . . . 0.0 108.063 179.138 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -62.8 -164.98 0.5 Allowed Glycine 0 C--N 1.337 0.592 0 N-CA-C 110.626 -0.99 . . . . 0.0 110.626 179.1 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -102.38 116.13 32.0 Favored 'General case' 0 N--CA 1.47 0.533 0 N-CA-C 109.155 -0.683 . . . . 0.0 109.155 179.394 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 73.9 mt -102.68 142.59 16.5 Favored 'Isoleucine or valine' 0 C--N 1.356 0.867 0 N-CA-C 104.505 -2.406 . . . . 0.0 104.505 -179.917 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' D' D ' 32' ' ' ILE . . . . . 0.431 HG22 ' H ' ' G' ' 32' ' ' ILE . 39.4 pt -158.25 -177.39 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.126 0 CA-C-O 120.939 0.4 . . . . 0.0 110.186 -177.075 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 64.32 4.64 13.06 Favored Glycine 0 C--O 1.241 0.562 0 N-CA-C 110.132 -1.187 . . . . 0.0 110.132 -178.828 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 2.1 tt -77.52 133.39 38.55 Favored 'General case' 0 C--N 1.369 1.438 0 C-N-CA 117.944 -1.502 . . . . 0.0 107.155 -177.801 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' D' D ' 35' ' ' MET . . . . . 0.415 ' O ' HG13 ' D' ' 36' ' ' VAL . 27.9 ttt -158.3 161.48 37.67 Favored 'General case' 0 CA--C 1.509 -0.62 0 CA-C-O 118.213 -0.899 . . . . 0.0 108.858 173.574 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' D' D ' 36' ' ' VAL . . . . . 0.607 HG22 HG12 ' G' ' 36' ' ' VAL . 27.7 m -164.63 164.36 0.66 Allowed 'Isoleucine or valine' 0 CA--C 1.517 -0.319 0 N-CA-C 108.064 -1.088 . . . . 0.0 108.064 175.62 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 60.18 64.05 4.5 Favored Glycine 0 C--N 1.313 -0.706 0 C-N-CA 119.759 -1.21 . . . . 0.0 112.883 178.318 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 140.68 -171.27 24.12 Favored Glycine 0 N--CA 1.48 1.581 0 CA-C-N 117.319 0.559 . . . . 0.0 111.769 -179.221 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' D' D ' 39' ' ' VAL . . . . . 0.522 ' H ' HG12 ' G' ' 39' ' ' VAL . 34.9 m -128.37 154.81 39.6 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.851 0 C-N-CA 122.716 0.406 . . . . 0.0 110.146 -176.877 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 25.3 t . . . . . 0 C--N 1.332 -0.16 0 CA-C-O 116.657 -1.64 . . . . 0.0 110.051 178.19 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 24.0 m-85 . . . . . 0 N--CA 1.475 0.794 0 N-CA-C 109.962 -0.384 . . . . 0.0 109.962 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' E' E ' 5' ' ' ARG . . . . . . . . . . . . . 86.2 mtt180 -68.94 131.89 45.82 Favored 'General case' 0 N--CA 1.475 0.804 0 CA-C-N 116.423 -0.353 . . . . 0.0 111.153 -178.36 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 6.5 t-160 -97.66 129.03 44.77 Favored 'General case' 0 N--CA 1.475 0.789 0 N-CA-C 109.194 -0.669 . . . . 0.0 109.194 179.08 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' E' E ' 7' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -74.42 139.91 44.33 Favored 'General case' 0 N--CA 1.468 0.445 0 CA-C-N 116.513 -0.312 . . . . 0.0 110.531 178.725 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' E' E ' 8' ' ' SER . . . . . . . . . . . . . 24.8 p -163.68 -168.25 1.6 Allowed 'General case' 0 N--CA 1.485 1.301 0 CA-C-O 120.888 0.375 . . . . 0.0 110.886 178.922 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 105.57 44.84 1.39 Allowed Glycine 0 N--CA 1.482 1.732 0 N-CA-C 111.485 -0.646 . . . . 0.0 111.485 -179.682 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 47.0 p90 -63.84 133.45 53.4 Favored 'General case' 0 N--CA 1.475 0.783 0 N-CA-C 112.02 0.378 . . . . 0.0 112.02 -179.806 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 47.2 mt-10 -90.73 152.39 20.84 Favored 'General case' 0 N--CA 1.48 1.036 0 CA-C-O 121.111 0.481 . . . . 0.0 109.747 177.777 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -154.09 127.44 1.19 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.574 0 N-CA-C 107.795 -1.187 . . . . 0.0 107.795 178.003 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 45.0 m-70 -135.74 146.38 47.61 Favored 'General case' 0 N--CA 1.483 1.215 0 CA-C-O 120.869 0.366 . . . . 0.0 111.542 -178.025 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 6.5 t60 -164.32 97.15 0.79 Allowed 'General case' 0 N--CA 1.486 1.344 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.592 179.459 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' E' E ' 15' ' ' GLN . . . . . 0.497 HE22 HG23 ' E' ' 36' ' ' VAL . 3.9 pt20 -101.4 -173.83 2.46 Favored 'General case' 0 CA--C 1.51 -0.588 0 N-CA-C 108.924 -0.769 . . . . 0.0 108.924 -179.728 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -169.77 94.67 0.27 Allowed 'General case' 0 N--CA 1.472 0.647 0 CA-C-N 114.774 -1.103 . . . . 0.0 108.464 178.347 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 6.2 mp -122.4 156.72 33.41 Favored 'General case' 0 N--CA 1.495 1.787 0 CA-C-O 121.698 0.761 . . . . 0.0 111.641 -177.546 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 48.3 t -113.88 124.36 70.46 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.232 0 N-CA-C 108.212 -1.033 . . . . 0.0 108.212 177.245 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 29.8 m-85 -124.83 121.97 36.07 Favored 'General case' 0 N--CA 1.489 1.524 0 CA-C-O 120.907 0.384 . . . . 0.0 110.974 -179.563 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 67.2 m-85 54.47 73.57 0.39 Allowed 'General case' 0 N--CA 1.469 0.476 0 CA-C-N 115.892 -0.594 . . . . 0.0 111.53 177.931 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -78.27 -78.46 0.14 Allowed 'General case' 0 CA--C 1.535 0.377 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.258 -179.711 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 40.9 tt0 -113.02 101.56 9.58 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 108.319 -0.993 . . . . 0.0 108.319 179.683 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -158.15 140.58 14.41 Favored 'General case' 0 C--O 1.205 -1.285 0 CA-C-O 119.488 -0.292 . . . . 0.0 111.481 179.17 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' E' E ' 24' ' ' VAL . . . . . 0.516 ' HB ' ' H ' ' B' ' 25' ' ' GLY . 63.3 t -58.7 168.46 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.973 0 N-CA-C 107.629 -1.248 . . . . 0.0 107.629 177.034 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' E' E ' 25' ' ' GLY . . . . . 0.471 ' H ' ' HB ' ' H' ' 24' ' ' VAL . . . -122.57 47.68 1.0 Allowed Glycine 0 N--CA 1.475 1.264 0 N-CA-C 110.931 -0.867 . . . . 0.0 110.931 -179.347 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -61.81 -167.48 0.01 OUTLIER 'General case' 0 N--CA 1.47 0.548 0 CA-C-O 120.704 0.288 . . . . 0.0 110.469 179.808 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 27.2 t-20 -70.68 77.85 0.6 Allowed 'General case' 0 N--CA 1.467 0.377 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.393 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -75.48 144.56 42.0 Favored 'General case' 0 N--CA 1.475 0.817 0 N-CA-C 109.567 -0.531 . . . . 0.0 109.567 179.331 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.46 -166.4 1.14 Allowed Glycine 0 CA--C 1.522 0.474 0 N-CA-C 110.421 -1.072 . . . . 0.0 110.421 178.629 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -100.08 113.36 25.92 Favored 'General case' 0 N--CA 1.468 0.443 0 N-CA-C 109.961 -0.385 . . . . 0.0 109.961 179.659 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 66.3 mt -97.36 135.28 32.2 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.443 0 N-CA-C 106.752 -1.573 . . . . 0.0 106.752 179.146 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' E' E ' 32' ' ' ILE . . . . . 0.427 HG22 ' H ' ' H' ' 32' ' ' ILE . 39.2 pt -151.74 -174.73 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.123 0 CA-C-O 121.165 0.507 . . . . 0.0 110.682 -179.072 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.5 5.66 6.97 Favored Glycine 0 CA--C 1.53 1.03 0 CA-C-N 115.504 -0.771 . . . . 0.0 111.34 -179.674 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' E' E ' 34' ' ' LEU . . . . . 0.402 HD23 ' N ' ' E' ' 35' ' ' MET . 1.7 tt -74.86 126.62 31.34 Favored 'General case' 0 CA--C 1.545 0.787 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 -179.613 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' E' E ' 35' ' ' MET . . . . . 0.402 ' N ' HD23 ' E' ' 34' ' ' LEU . 28.2 ttt -162.14 151.11 15.41 Favored 'General case' 0 C--O 1.203 -1.348 0 N-CA-C 108.972 -0.751 . . . . 0.0 108.972 178.776 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' E' E ' 36' ' ' VAL . . . . . 0.621 HG22 HG12 ' H' ' 36' ' ' VAL . 32.9 m -157.04 165.22 1.01 Allowed 'Isoleucine or valine' 0 C--N 1.343 0.287 0 N-CA-C 108.434 -0.95 . . . . 0.0 108.434 179.596 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.61 67.08 2.39 Favored Glycine 0 C--N 1.306 -1.096 0 CA-C-N 115.762 -0.654 . . . . 0.0 111.95 178.774 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.88 -172.48 25.08 Favored Glycine 0 N--CA 1.476 1.362 0 N-CA-C 111.16 -0.776 . . . . 0.0 111.16 179.034 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' E' E ' 39' ' ' VAL . . . . . 0.53 ' H ' HG12 ' H' ' 39' ' ' VAL . 33.4 m -126.29 156.78 36.86 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.703 0 C-N-CA 123.452 0.701 . . . . 0.0 110.682 -179.402 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 26.1 t . . . . . 0 C--O 1.218 -0.56 0 CA-C-O 118.451 -0.785 . . . . 0.0 110.701 179.525 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 24.0 m-85 . . . . . 0 N--CA 1.474 0.754 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' F' F ' 5' ' ' ARG . . . . . . . . . . . . . 87.2 mtt180 -69.0 132.66 47.02 Favored 'General case' 0 C--O 1.217 -0.634 0 CA-C-N 116.419 -0.355 . . . . 0.0 111.289 -178.244 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 6.6 t-160 -98.31 128.69 44.86 Favored 'General case' 0 N--CA 1.477 0.889 0 N-CA-C 109.323 -0.621 . . . . 0.0 109.323 179.31 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' F' F ' 7' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -74.1 139.54 44.66 Favored 'General case' 0 N--CA 1.467 0.42 0 CA-C-N 116.542 -0.299 . . . . 0.0 110.662 178.678 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' F' F ' 8' ' ' SER . . . . . . . . . . . . . 24.7 p -163.6 -168.33 1.63 Allowed 'General case' 0 N--CA 1.486 1.327 0 CA-C-O 120.963 0.411 . . . . 0.0 110.945 178.905 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 105.7 44.84 1.37 Allowed Glycine 0 N--CA 1.482 1.745 0 N-CA-C 111.459 -0.656 . . . . 0.0 111.459 -179.729 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 46.2 p90 -63.67 133.72 54.13 Favored 'General case' 0 CA--C 1.543 0.707 0 N-CA-C 112.094 0.405 . . . . 0.0 112.094 -179.639 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 47.2 mt-10 -90.89 152.24 20.82 Favored 'General case' 0 N--CA 1.481 1.085 0 CA-C-O 121.172 0.51 . . . . 0.0 109.74 177.794 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -153.92 127.19 1.18 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.601 0 N-CA-C 107.776 -1.194 . . . . 0.0 107.776 178.034 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 44.3 m-70 -135.53 145.93 47.54 Favored 'General case' 0 N--CA 1.484 1.232 0 CA-C-O 120.796 0.331 . . . . 0.0 111.635 -177.959 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 6.6 t60 -163.94 97.26 0.83 Allowed 'General case' 0 N--CA 1.486 1.335 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.697 179.442 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' F' F ' 15' ' ' GLN . . . . . 0.488 HE22 HG23 ' F' ' 36' ' ' VAL . 3.9 pt20 -101.68 -173.96 2.48 Favored 'General case' 0 CA--C 1.507 -0.698 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 -179.711 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -169.5 94.71 0.29 Allowed 'General case' 0 N--CA 1.471 0.597 0 CA-C-N 114.633 -1.167 . . . . 0.0 108.424 178.357 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 6.3 mp -122.16 156.84 32.83 Favored 'General case' 0 N--CA 1.495 1.817 0 CA-C-O 121.628 0.728 . . . . 0.0 111.623 -177.687 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 48.6 t -113.94 124.35 70.51 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.181 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 177.185 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 29.8 m-85 -124.72 121.69 35.37 Favored 'General case' 0 N--CA 1.489 1.49 0 CA-C-O 120.888 0.375 . . . . 0.0 110.984 -179.57 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 67.3 m-85 54.41 74.08 0.36 Allowed 'General case' 0 C--N 1.344 0.353 0 CA-C-N 115.917 -0.583 . . . . 0.0 111.68 178.032 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -78.4 -78.42 0.14 Allowed 'General case' 0 CA--C 1.535 0.375 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.282 -179.707 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 40.8 tt0 -113.19 101.39 9.38 Favored 'General case' 0 C--N 1.325 -0.477 0 N-CA-C 108.312 -0.996 . . . . 0.0 108.312 179.777 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -158.08 140.52 14.45 Favored 'General case' 0 C--O 1.204 -1.308 0 CA-C-O 119.537 -0.268 . . . . 0.0 111.419 179.045 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' F' F ' 24' ' ' VAL . . . . . 0.501 ' HB ' ' H ' ' C' ' 25' ' ' GLY . 60.6 t -58.61 168.61 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.962 0 N-CA-C 107.644 -1.243 . . . . 0.0 107.644 177.047 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' F' F ' 25' ' ' GLY . . . . . 0.467 ' H ' ' HB ' ' I' ' 24' ' ' VAL . . . -122.71 48.07 0.98 Allowed Glycine 0 N--CA 1.477 1.381 0 N-CA-C 110.822 -0.911 . . . . 0.0 110.822 -179.398 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -62.24 -167.63 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.559 0 CA-C-O 120.75 0.309 . . . . 0.0 110.417 179.807 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 27.2 t-20 -70.16 77.54 0.51 Allowed 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.432 -179.936 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -75.49 144.18 42.17 Favored 'General case' 0 N--CA 1.475 0.814 0 N-CA-C 109.551 -0.537 . . . . 0.0 109.551 179.489 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.14 -166.58 1.07 Allowed Glycine 0 CA--C 1.522 0.512 0 N-CA-C 110.55 -1.02 . . . . 0.0 110.55 178.596 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.72 113.69 26.33 Favored 'General case' 0 N--CA 1.471 0.589 0 N-CA-C 109.879 -0.415 . . . . 0.0 109.879 179.649 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 66.2 mt -97.85 135.22 33.15 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.43 0 N-CA-C 106.796 -1.557 . . . . 0.0 106.796 179.058 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' F' F ' 32' ' ' ILE . . . . . 0.43 HG22 ' H ' ' I' ' 32' ' ' ILE . 39.7 pt -151.65 -174.43 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.136 0 CA-C-O 121.208 0.527 . . . . 0.0 110.64 -179.049 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.11 6.0 6.59 Favored Glycine 0 CA--C 1.53 0.97 0 CA-C-N 115.426 -0.806 . . . . 0.0 111.345 -179.778 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' F' F ' 34' ' ' LEU . . . . . 0.422 HD23 ' N ' ' F' ' 35' ' ' MET . 1.7 tt -75.43 127.28 32.76 Favored 'General case' 0 N--CA 1.475 0.783 0 N-CA-C 109.31 -0.626 . . . . 0.0 109.31 -179.5 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' F' F ' 35' ' ' MET . . . . . 0.422 ' N ' HD23 ' F' ' 34' ' ' LEU . 28.2 ttt -163.18 152.02 14.45 Favored 'General case' 0 C--O 1.204 -1.306 0 N-CA-C 109.203 -0.665 . . . . 0.0 109.203 178.437 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' F' F ' 36' ' ' VAL . . . . . 0.618 HG22 HG12 ' I' ' 36' ' ' VAL . 32.6 m -157.21 165.69 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.342 0.26 0 N-CA-C 108.408 -0.96 . . . . 0.0 108.408 179.897 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.34 67.41 2.22 Favored Glycine 0 C--N 1.307 -1.081 0 CA-C-N 115.717 -0.674 . . . . 0.0 111.979 178.56 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.33 -172.33 24.78 Favored Glycine 0 N--CA 1.477 1.378 0 N-CA-C 111.084 -0.807 . . . . 0.0 111.084 178.992 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' F' F ' 39' ' ' VAL . . . . . 0.531 ' H ' HG12 ' I' ' 39' ' ' VAL . 33.3 m -126.39 157.01 37.17 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.685 0 C-N-CA 123.425 0.69 . . . . 0.0 110.688 -179.285 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 26.0 t . . . . . 0 C--O 1.22 -0.496 0 O-C-N 124.017 0.823 . . . . 0.0 110.599 179.358 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 29.4 m-85 . . . . . 0 N--CA 1.476 0.851 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' G' G ' 5' ' ' ARG . . . . . . . . . . . . . 86.5 mtt180 -67.53 132.18 47.07 Favored 'General case' 0 N--CA 1.473 0.723 0 CA-C-N 116.33 -0.396 . . . . 0.0 110.846 -178.615 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 6.4 t-160 -98.27 129.92 44.98 Favored 'General case' 0 N--CA 1.474 0.761 0 N-CA-C 109.415 -0.587 . . . . 0.0 109.415 179.108 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -75.92 135.73 40.09 Favored 'General case' 0 N--CA 1.47 0.554 0 C-N-CA 122.714 0.406 . . . . 0.0 111.097 179.006 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' G' G ' 8' ' ' SER . . . . . 0.474 ' OG ' ' O ' ' D' ' 7' ' ' ASP . 24.7 p -160.11 -166.23 1.65 Allowed 'General case' 0 N--CA 1.477 0.903 0 CA-C-O 120.971 0.415 . . . . 0.0 110.512 178.73 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.42 45.51 1.43 Allowed Glycine 0 N--CA 1.481 1.684 0 N-CA-C 111.211 -0.756 . . . . 0.0 111.211 179.866 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 48.9 p90 -64.59 133.43 52.28 Favored 'General case' 0 CA--C 1.542 0.641 0 N-CA-C 111.91 0.337 . . . . 0.0 111.91 -179.562 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 49.4 mt-10 -90.97 151.76 20.96 Favored 'General case' 0 N--CA 1.479 1.018 0 CA-C-O 121.006 0.432 . . . . 0.0 110.036 178.41 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -154.82 127.53 1.08 Allowed 'Isoleucine or valine' 0 CA--C 1.553 1.088 0 N-CA-C 107.845 -1.169 . . . . 0.0 107.845 178.359 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 46.0 m-70 -135.23 147.11 49.21 Favored 'General case' 0 N--CA 1.478 0.934 0 CA-C-N 115.433 -0.803 . . . . 0.0 111.471 -178.135 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 6.6 t60 -165.22 97.63 0.71 Allowed 'General case' 0 N--CA 1.483 1.22 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.214 178.82 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' G' G ' 15' ' ' GLN . . . . . 0.449 HE22 HG23 ' G' ' 36' ' ' VAL . 3.9 pt20 -102.06 -173.81 2.43 Favored 'General case' 0 CA--C 1.507 -0.678 0 N-CA-C 108.688 -0.856 . . . . 0.0 108.688 -179.595 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -170.32 94.37 0.23 Allowed 'General case' 0 N--CA 1.471 0.624 0 CA-C-N 114.663 -1.153 . . . . 0.0 108.224 178.54 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 6.3 mp -121.86 155.94 34.32 Favored 'General case' 0 N--CA 1.498 1.935 0 CA-C-O 121.298 0.571 . . . . 0.0 111.881 -177.812 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 43.2 t -113.63 124.53 70.36 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.013 0 CA-C-N 114.746 -1.115 . . . . 0.0 108.156 176.617 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 31.5 m-85 -125.13 121.76 35.16 Favored 'General case' 0 C--N 1.366 1.314 0 C-N-CA 123.358 0.663 . . . . 0.0 111.01 -179.324 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 66.7 m-85 54.4 73.43 0.4 Allowed 'General case' 0 N--CA 1.467 0.407 0 CA-C-N 115.865 -0.607 . . . . 0.0 111.532 177.898 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.49 -77.86 0.14 Allowed 'General case' 0 N--CA 1.473 0.682 0 O-C-N 122.296 -0.252 . . . . 0.0 110.451 -179.426 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 40.9 tt0 -113.59 101.61 9.49 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 108.048 -1.093 . . . . 0.0 108.048 179.806 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -158.25 141.65 15.18 Favored 'General case' 0 N--CA 1.478 0.964 0 O-C-N 122.368 -0.207 . . . . 0.0 111.438 179.067 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' G' G ' 24' ' ' VAL . . . . . 0.571 ' HB ' ' H ' ' D' ' 25' ' ' GLY . 58.8 t -60.23 167.12 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.637 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 177.338 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' G' G ' 25' ' ' GLY . . . . . 0.426 ' N ' HG12 ' G' ' 24' ' ' VAL . . . -120.71 48.51 0.94 Allowed Glycine 0 N--CA 1.481 1.662 0 N-CA-C 110.548 -1.021 . . . . 0.0 110.548 -179.499 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -62.93 -167.73 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.648 0 CA-C-N 117.03 0.415 . . . . 0.0 109.943 179.825 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 27.6 t-20 -70.28 77.2 0.54 Allowed 'General case' 0 CA--C 1.536 0.413 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.456 -179.979 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 97.9 mttt -74.29 144.23 44.66 Favored 'General case' 0 N--CA 1.475 0.807 0 N-CA-C 109.642 -0.503 . . . . 0.0 109.642 179.292 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.56 -164.98 0.92 Allowed Glycine 0 C--N 1.337 0.609 0 N-CA-C 110.061 -1.216 . . . . 0.0 110.061 178.623 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -100.03 113.48 26.11 Favored 'General case' 0 N--CA 1.469 0.52 0 C-N-CA 122.737 0.415 . . . . 0.0 110.577 179.865 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 67.6 mt -98.33 135.51 32.81 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.838 0 N-CA-C 106.827 -1.546 . . . . 0.0 106.827 179.062 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' G' G ' 32' ' ' ILE . . . . . 0.431 ' H ' HG22 ' D' ' 32' ' ' ILE . 39.6 pt -152.27 -174.32 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.725 0 CA-C-N 119.784 1.174 . . . . 0.0 109.897 -179.473 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.06 5.63 8.14 Favored Glycine 0 CA--C 1.527 0.789 0 N-CA-C 111.03 -0.828 . . . . 0.0 111.03 -179.928 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 1.6 tt -75.71 125.46 29.09 Favored 'General case' 0 CA--C 1.544 0.733 0 N-CA-C 109.561 -0.533 . . . . 0.0 109.561 -179.574 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 28.1 ttt -161.04 152.91 19.67 Favored 'General case' 0 C--O 1.206 -1.194 0 N-CA-C 108.861 -0.792 . . . . 0.0 108.861 178.712 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' G' G ' 36' ' ' VAL . . . . . 0.607 HG12 HG22 ' D' ' 36' ' ' VAL . 30.4 m -157.8 164.28 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.343 0.293 0 N-CA-C 108.471 -0.937 . . . . 0.0 108.471 -179.836 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.42 67.63 2.11 Favored Glycine 0 C--N 1.309 -0.955 0 CA-C-N 115.602 -0.726 . . . . 0.0 112.207 178.457 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.89 -171.64 25.39 Favored Glycine 0 N--CA 1.478 1.438 0 N-CA-C 110.6 -1.0 . . . . 0.0 110.6 178.981 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' G' G ' 39' ' ' VAL . . . . . 0.522 HG12 ' H ' ' D' ' 39' ' ' VAL . 33.9 m -127.04 157.22 38.59 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.763 0 C-N-CA 123.138 0.575 . . . . 0.0 110.807 -179.43 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 28.0 t . . . . . 0 C--O 1.219 -0.51 0 O-C-N 123.976 0.797 . . . . 0.0 110.85 179.364 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 29.7 m-85 . . . . . 0 N--CA 1.476 0.833 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' H' H ' 5' ' ' ARG . . . . . . . . . . . . . 86.4 mtt180 -67.7 131.72 46.11 Favored 'General case' 0 N--CA 1.475 0.782 0 CA-C-N 116.421 -0.354 . . . . 0.0 110.798 -178.603 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 6.3 t-160 -98.09 129.5 44.91 Favored 'General case' 0 N--CA 1.475 0.78 0 N-CA-C 109.253 -0.647 . . . . 0.0 109.253 179.114 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -75.42 136.18 40.73 Favored 'General case' 0 N--CA 1.47 0.551 0 C-N-CA 122.666 0.386 . . . . 0.0 111.049 178.936 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' H' H ' 8' ' ' SER . . . . . . . . . . . . . 27.2 p -160.39 -166.52 1.68 Allowed 'General case' 0 N--CA 1.475 0.794 0 CA-C-O 120.85 0.357 . . . . 0.0 110.476 178.786 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.27 46.16 1.37 Allowed Glycine 0 N--CA 1.481 1.674 0 N-CA-C 111.292 -0.723 . . . . 0.0 111.292 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 48.6 p90 -65.46 133.73 51.92 Favored 'General case' 0 CA--C 1.542 0.665 0 N-CA-C 111.894 0.331 . . . . 0.0 111.894 -179.635 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 48.8 mt-10 -91.2 151.63 20.87 Favored 'General case' 0 N--CA 1.479 0.98 0 CA-C-O 121.0 0.429 . . . . 0.0 110.154 178.481 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -154.52 127.66 1.16 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.057 0 N-CA-C 107.874 -1.158 . . . . 0.0 107.874 178.267 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 45.9 m-70 -135.25 147.0 49.14 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.438 -0.801 . . . . 0.0 111.408 -178.073 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 6.5 t60 -165.22 97.33 0.71 Allowed 'General case' 0 N--CA 1.483 1.192 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.264 178.837 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' H' H ' 15' ' ' GLN . . . . . 0.439 HE22 HG23 ' H' ' 36' ' ' VAL . 3.9 pt20 -101.64 -173.77 2.43 Favored 'General case' 0 CA--C 1.511 -0.555 0 N-CA-C 108.637 -0.875 . . . . 0.0 108.637 -179.592 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -170.31 94.22 0.23 Allowed 'General case' 0 N--CA 1.472 0.652 0 CA-C-N 114.664 -1.153 . . . . 0.0 108.116 178.503 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 6.3 mp -121.81 155.66 34.86 Favored 'General case' 0 N--CA 1.498 1.964 0 CA-C-O 121.29 0.567 . . . . 0.0 111.96 -177.778 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 42.2 t -113.33 124.74 70.27 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.044 0 CA-C-N 114.766 -1.106 . . . . 0.0 108.159 176.521 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 30.9 m-85 -125.4 121.06 32.78 Favored 'General case' 0 C--N 1.368 1.401 0 CA-C-N 115.524 -0.762 . . . . 0.0 110.904 -179.082 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 67.2 m-85 54.55 73.63 0.39 Allowed 'General case' 0 C--O 1.236 0.389 0 CA-C-N 115.815 -0.63 . . . . 0.0 111.535 177.9 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.33 -77.98 0.14 Allowed 'General case' 0 N--CA 1.472 0.634 0 O-C-N 122.248 -0.283 . . . . 0.0 110.611 -179.526 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 41.0 tt0 -113.4 101.34 9.29 Favored 'General case' 0 C--N 1.323 -0.578 0 N-CA-C 108.1 -1.074 . . . . 0.0 108.1 179.731 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -157.7 141.87 16.07 Favored 'General case' 0 N--CA 1.478 0.971 0 O-C-N 122.453 -0.155 . . . . 0.0 111.371 179.095 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' H' H ' 24' ' ' VAL . . . . . 0.471 ' HB ' ' H ' ' E' ' 25' ' ' GLY . 57.4 t -60.45 166.92 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.617 0 N-CA-C 107.632 -1.247 . . . . 0.0 107.632 177.246 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' H' H ' 25' ' ' GLY . . . . . 0.423 ' N ' HG12 ' H' ' 24' ' ' VAL . . . -120.6 49.36 0.88 Allowed Glycine 0 N--CA 1.48 1.603 0 N-CA-C 110.528 -1.029 . . . . 0.0 110.528 -179.592 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -63.77 -167.63 0.02 OUTLIER 'General case' 0 N--CA 1.473 0.697 0 CA-C-N 116.99 0.395 . . . . 0.0 110.028 179.812 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 27.4 t-20 -70.2 77.38 0.52 Allowed 'General case' 0 CA--C 1.536 0.41 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.445 179.883 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -74.8 144.21 43.62 Favored 'General case' 0 N--CA 1.474 0.754 0 N-CA-C 109.626 -0.509 . . . . 0.0 109.626 179.366 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.83 -165.42 1.08 Allowed Glycine 0 C--N 1.337 0.607 0 N-CA-C 109.978 -1.249 . . . . 0.0 109.978 178.731 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.66 113.57 26.1 Favored 'General case' 0 N--CA 1.468 0.431 0 C-N-CA 122.632 0.373 . . . . 0.0 110.593 179.902 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 66.6 mt -98.06 135.65 31.88 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.803 0 N-CA-C 106.81 -1.552 . . . . 0.0 106.81 178.964 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' H' H ' 32' ' ' ILE . . . . . 0.427 ' H ' HG22 ' E' ' 32' ' ' ILE . 39.1 pt -152.38 -174.31 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 CA-C-N 119.838 1.199 . . . . 0.0 109.832 -179.637 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.05 5.92 8.75 Favored Glycine 0 CA--C 1.528 0.86 0 N-CA-C 110.974 -0.85 . . . . 0.0 110.974 -179.929 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' H' H ' 34' ' ' LEU . . . . . 0.401 HD23 ' N ' ' H' ' 35' ' ' MET . 1.6 tt -75.84 125.19 28.6 Favored 'General case' 0 CA--C 1.545 0.761 0 N-CA-C 109.512 -0.551 . . . . 0.0 109.512 -179.602 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' H' H ' 35' ' ' MET . . . . . 0.401 ' N ' HD23 ' H' ' 34' ' ' LEU . 28.3 ttt -160.76 152.79 20.03 Favored 'General case' 0 C--O 1.207 -1.144 0 N-CA-C 108.925 -0.768 . . . . 0.0 108.925 178.595 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' H' H ' 36' ' ' VAL . . . . . 0.621 HG12 HG22 ' E' ' 36' ' ' VAL . 28.4 m -157.8 164.17 1.14 Allowed 'Isoleucine or valine' 0 C--N 1.343 0.294 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 -179.81 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.54 67.81 2.01 Favored Glycine 0 C--N 1.309 -0.964 0 CA-C-N 115.559 -0.746 . . . . 0.0 112.168 178.542 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.55 -171.59 25.2 Favored Glycine 0 N--CA 1.478 1.475 0 N-CA-C 110.621 -0.992 . . . . 0.0 110.621 179.05 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' H' H ' 39' ' ' VAL . . . . . 0.53 HG12 ' H ' ' E' ' 39' ' ' VAL . 33.8 m -126.99 157.71 38.23 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.82 0 C-N-CA 123.168 0.587 . . . . 0.0 110.795 -179.456 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 29.7 t . . . . . 0 N--CA 1.469 0.506 0 O-C-N 123.985 0.803 . . . . 0.0 110.745 179.281 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 29.3 m-85 . . . . . 0 N--CA 1.476 0.868 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' I' I ' 5' ' ' ARG . . . . . . . . . . . . . 86.5 mtt180 -68.18 131.72 45.9 Favored 'General case' 0 N--CA 1.476 0.837 0 CA-C-N 116.435 -0.348 . . . . 0.0 110.719 -178.569 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 6.4 t-160 -97.89 129.56 44.83 Favored 'General case' 0 N--CA 1.473 0.718 0 N-CA-C 109.333 -0.617 . . . . 0.0 109.333 179.051 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -75.48 135.98 40.66 Favored 'General case' 0 CA--C 1.539 0.533 0 C-N-CA 122.707 0.403 . . . . 0.0 111.003 178.955 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' I' I ' 8' ' ' SER . . . . . . . . . . . . . 25.0 p -160.41 -166.63 1.7 Allowed 'General case' 0 N--CA 1.476 0.833 0 CA-C-O 120.936 0.398 . . . . 0.0 110.494 178.841 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.37 45.97 1.38 Allowed Glycine 0 N--CA 1.481 1.693 0 N-CA-C 111.29 -0.724 . . . . 0.0 111.29 179.942 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 49.3 p90 -65.28 133.48 51.55 Favored 'General case' 0 N--CA 1.473 0.681 0 N-CA-C 111.942 0.349 . . . . 0.0 111.942 -179.599 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 49.1 mt-10 -90.93 151.71 21.0 Favored 'General case' 0 N--CA 1.478 0.949 0 CA-C-O 121.077 0.465 . . . . 0.0 110.165 178.463 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -154.72 127.55 1.1 Allowed 'Isoleucine or valine' 0 CA--C 1.553 1.073 0 N-CA-C 107.91 -1.144 . . . . 0.0 107.91 178.248 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 47.0 m-70 -135.22 146.84 49.04 Favored 'General case' 0 N--CA 1.477 0.915 0 CA-C-N 115.45 -0.796 . . . . 0.0 111.404 -178.002 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 6.5 t60 -165.05 97.41 0.73 Allowed 'General case' 0 N--CA 1.483 1.207 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.27 178.884 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' I' I ' 15' ' ' GLN . . . . . 0.421 HE22 HG23 ' I' ' 36' ' ' VAL . 3.9 pt20 -101.82 -173.71 2.42 Favored 'General case' 0 CA--C 1.509 -0.627 0 N-CA-C 108.681 -0.859 . . . . 0.0 108.681 -179.612 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -170.36 94.02 0.22 Allowed 'General case' 0 N--CA 1.472 0.638 0 CA-C-N 114.628 -1.169 . . . . 0.0 108.128 178.607 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 6.3 mp -121.62 155.86 34.18 Favored 'General case' 0 N--CA 1.497 1.904 0 CA-C-O 121.257 0.551 . . . . 0.0 111.92 -177.751 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 42.1 t -113.53 125.09 70.75 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.997 0 CA-C-N 114.789 -1.096 . . . . 0.0 108.1 176.54 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 31.2 m-85 -125.73 121.41 33.31 Favored 'General case' 0 C--N 1.366 1.325 0 CA-C-N 115.61 -0.723 . . . . 0.0 110.945 -179.229 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 67.1 m-85 54.46 73.3 0.41 Allowed 'General case' 0 C--O 1.237 0.429 0 CA-C-N 115.911 -0.586 . . . . 0.0 111.482 177.885 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.15 -77.92 0.14 Allowed 'General case' 0 N--CA 1.473 0.702 0 O-C-N 122.272 -0.268 . . . . 0.0 110.5 -179.55 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 40.8 tt0 -113.4 101.54 9.48 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 108.069 -1.086 . . . . 0.0 108.069 179.692 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -157.91 141.59 15.56 Favored 'General case' 0 N--CA 1.479 1.004 0 O-C-N 122.42 -0.175 . . . . 0.0 111.361 179.087 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' I' I ' 24' ' ' VAL . . . . . 0.467 ' HB ' ' H ' ' F' ' 25' ' ' GLY . 59.0 t -60.26 167.27 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.631 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 177.22 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' I' I ' 25' ' ' GLY . . . . . 0.44 ' N ' HG12 ' I' ' 24' ' ' VAL . . . -120.89 49.3 0.89 Allowed Glycine 0 N--CA 1.481 1.683 0 N-CA-C 110.523 -1.031 . . . . 0.0 110.523 -179.572 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -63.75 -167.65 0.02 OUTLIER 'General case' 0 N--CA 1.473 0.682 0 CA-C-N 117.002 0.401 . . . . 0.0 109.949 179.768 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 27.6 t-20 -70.21 77.27 0.52 Allowed 'General case' 0 CA--C 1.535 0.401 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.411 179.913 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -74.66 143.92 44.04 Favored 'General case' 0 N--CA 1.475 0.8 0 N-CA-C 109.617 -0.512 . . . . 0.0 109.617 179.424 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.44 -165.8 1.03 Allowed Glycine 0 C--N 1.337 0.601 0 N-CA-C 110.009 -1.236 . . . . 0.0 110.009 178.653 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.26 113.7 26.13 Favored 'General case' 0 N--CA 1.468 0.471 0 C-N-CA 122.729 0.412 . . . . 0.0 110.583 179.991 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 66.9 mt -98.5 135.49 33.12 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.842 0 N-CA-C 106.833 -1.543 . . . . 0.0 106.833 178.98 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' I' I ' 32' ' ' ILE . . . . . 0.43 ' H ' HG22 ' F' ' 32' ' ' ILE . 39.2 pt -152.36 -174.3 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.725 0 CA-C-N 119.8 1.182 . . . . 0.0 109.84 -179.567 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.04 5.84 8.56 Favored Glycine 0 CA--C 1.527 0.819 0 N-CA-C 110.999 -0.84 . . . . 0.0 110.999 -179.874 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' I' I ' 34' ' ' LEU . . . . . 0.402 HD23 ' N ' ' I' ' 35' ' ' MET . 1.6 tt -75.82 125.42 29.05 Favored 'General case' 0 CA--C 1.545 0.753 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 -179.644 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' I' I ' 35' ' ' MET . . . . . 0.402 ' N ' HD23 ' I' ' 34' ' ' LEU . 28.3 ttt -160.88 152.59 19.57 Favored 'General case' 0 C--O 1.206 -1.186 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 178.723 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' I' I ' 36' ' ' VAL . . . . . 0.618 HG12 HG22 ' F' ' 36' ' ' VAL . 26.7 m -157.59 164.1 1.17 Allowed 'Isoleucine or valine' 0 C--N 1.342 0.262 0 N-CA-C 108.448 -0.945 . . . . 0.0 108.448 -179.988 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.57 67.91 1.96 Allowed Glycine 0 C--N 1.309 -0.951 0 CA-C-N 115.602 -0.727 . . . . 0.0 112.122 178.571 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.58 -171.86 25.11 Favored Glycine 0 N--CA 1.478 1.445 0 N-CA-C 110.644 -0.982 . . . . 0.0 110.644 178.97 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' I' I ' 39' ' ' VAL . . . . . 0.531 HG12 ' H ' ' F' ' 39' ' ' VAL . 33.9 m -126.82 157.26 38.07 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.792 0 C-N-CA 123.181 0.592 . . . . 0.0 110.832 -179.452 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 26.0 t . . . . . 0 C--O 1.22 -0.5 0 O-C-N 123.964 0.79 . . . . 0.0 110.825 179.347 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 63.1 m-85 . . . . . 0 N--CA 1.474 0.769 0 N-CA-C 110.309 -0.256 . . . . 0.0 110.309 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -144.45 142.51 30.34 Favored 'General case' 0 N--CA 1.483 1.221 0 N-CA-C 109.958 -0.386 . . . . 0.0 109.958 179.721 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 45.1 t-80 -152.61 118.77 5.51 Favored 'General case' 0 N--CA 1.469 0.524 0 N-CA-C 109.26 -0.645 . . . . 0.0 109.26 178.967 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' ASP . . . . . 0.51 ' O ' ' OG ' ' D' ' 8' ' ' SER . 4.0 m-20 -69.52 149.62 48.03 Favored 'General case' 0 CA--C 1.538 0.49 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.468 179.898 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 52.1 p -168.07 -173.24 2.0 Allowed 'General case' 0 N--CA 1.484 1.249 0 CA-C-O 121.075 0.464 . . . . 0.0 110.706 179.461 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.77 46.85 1.44 Allowed Glycine 0 N--CA 1.483 1.802 0 CA-C-N 115.962 -0.563 . . . . 0.0 111.941 179.808 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 47.8 p90 -65.27 132.56 49.37 Favored 'General case' 0 N--CA 1.471 0.616 0 CA-C-N 116.71 0.255 . . . . 0.0 111.62 179.764 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 48.1 mt-10 -91.87 151.77 20.4 Favored 'General case' 0 N--CA 1.478 0.935 0 N-CA-C 109.692 -0.484 . . . . 0.0 109.692 178.437 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.0 p -152.79 128.19 1.61 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.61 0 N-CA-C 107.894 -1.15 . . . . 0.0 107.894 178.239 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 45.3 m-70 -135.46 146.31 48.06 Favored 'General case' 0 N--CA 1.493 1.687 0 CA-C-N 118.993 0.815 . . . . 0.0 111.253 -178.916 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 6.0 t60 -165.8 96.78 0.64 Allowed 'General case' 0 N--CA 1.478 0.958 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.941 179.398 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . 0.708 HE22 ' H ' ' A' ' 37' ' ' GLY . 5.9 pt20 -108.27 -174.39 2.51 Favored 'General case' 0 CA--C 1.508 -0.645 0 N-CA-C 108.293 -1.003 . . . . 0.0 108.293 -179.781 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -164.22 98.79 0.83 Allowed 'General case' 0 N--CA 1.472 0.626 0 CA-C-N 114.477 -1.238 . . . . 0.0 108.285 178.38 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 6.5 mp -122.04 155.76 34.94 Favored 'General case' 0 N--CA 1.499 2.002 0 CA-C-O 121.837 0.827 . . . . 0.0 110.926 -178.341 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 60.2 t -111.55 126.73 68.97 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.093 0 CA-C-O 117.908 -1.044 . . . . 0.0 108.235 177.737 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 28.1 m-85 -126.43 122.99 36.87 Favored 'General case' 0 N--CA 1.497 1.902 0 CA-C-N 120.08 1.309 . . . . 0.0 110.477 179.203 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 67.0 m-85 54.08 73.79 0.37 Allowed 'General case' 0 N--CA 1.469 0.493 0 CA-C-O 121.306 0.574 . . . . 0.0 111.828 178.757 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -79.99 -77.97 0.18 Allowed 'General case' 0 C--N 1.351 0.665 0 CA-C-N 115.193 -0.912 . . . . 0.0 110.203 -179.752 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 40.6 tt0 -113.53 99.6 7.87 Favored 'General case' 0 N--CA 1.468 0.461 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 179.855 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -158.41 138.84 12.59 Favored 'General case' 0 C--O 1.206 -1.22 0 O-C-N 122.231 -0.293 . . . . 0.0 111.249 179.098 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.401 HG12 ' N ' ' A' ' 25' ' ' GLY . 59.8 t -59.53 163.37 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.921 0 N-CA-C 107.941 -1.133 . . . . 0.0 107.941 177.071 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.461 ' H ' ' HB ' ' D' ' 24' ' ' VAL . . . -116.88 47.61 1.02 Allowed Glycine 0 N--CA 1.476 1.359 0 N-CA-C 111.834 -0.506 . . . . 0.0 111.834 -179.417 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -60.61 -167.5 0.01 OUTLIER 'General case' 0 N--CA 1.469 0.478 0 O-C-N 123.786 0.345 . . . . 0.0 110.305 179.56 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 25.4 t-20 -71.02 80.46 0.66 Allowed 'General case' 0 N--CA 1.465 0.29 0 CA-C-N 116.45 -0.341 . . . . 0.0 110.246 179.539 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 97.7 mttt -77.45 142.95 38.92 Favored 'General case' 0 N--CA 1.474 0.744 0 N-CA-C 109.183 -0.673 . . . . 0.0 109.183 179.283 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.66 -167.89 1.12 Allowed Glycine 0 C--N 1.338 0.648 0 N-CA-C 109.957 -1.257 . . . . 0.0 109.957 178.757 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.44 115.12 28.54 Favored 'General case' 0 N--CA 1.478 0.951 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 179.727 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 71.0 mt -98.58 134.71 36.23 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.576 0 N-CA-C 107.202 -1.407 . . . . 0.0 107.202 178.722 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 31.1 pt -150.63 -171.43 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.352 0.696 0 CA-C-O 121.168 0.508 . . . . 0.0 111.122 -179.259 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.39 4.95 9.96 Favored Glycine 0 N--CA 1.466 0.636 0 N-CA-C 110.735 -0.946 . . . . 0.0 110.735 179.843 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.427 HD23 ' N ' ' A' ' 35' ' ' MET . 1.1 tt -75.38 135.21 40.81 Favored 'General case' 0 CA--C 1.545 0.77 0 N-CA-C 109.395 -0.594 . . . . 0.0 109.395 -179.727 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' MET . . . . . 0.427 ' N ' HD23 ' A' ' 34' ' ' LEU . 27.1 ttt -158.82 146.46 17.79 Favored 'General case' 0 N--CA 1.467 0.418 0 N-CA-C 108.619 -0.882 . . . . 0.0 108.619 178.608 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 1.9 m -148.9 165.65 4.01 Favored 'Isoleucine or valine' 0 C--N 1.348 0.517 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 -179.625 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . 0.708 ' H ' HE22 ' A' ' 15' ' ' GLN . . . 54.87 68.44 1.68 Allowed Glycine 0 C--N 1.306 -1.118 0 CA-C-N 115.49 -0.777 . . . . 0.0 112.32 177.518 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.53 176.59 21.3 Favored Glycine 0 N--CA 1.472 1.072 0 N-CA-C 111.11 -0.796 . . . . 0.0 111.11 178.7 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.439 ' H ' HG12 ' D' ' 39' ' ' VAL . 34.3 m -109.31 156.28 10.08 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.658 0 C-N-CA 123.385 0.674 . . . . 0.0 110.201 -179.689 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 24.4 t . . . . . 0 C--O 1.219 -0.55 0 CA-C-O 118.42 -0.8 . . . . 0.0 110.492 179.397 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 63.8 m-85 . . . . . 0 N--CA 1.473 0.678 0 N-CA-C 110.264 -0.272 . . . . 0.0 110.264 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -144.2 142.42 30.51 Favored 'General case' 0 N--CA 1.483 1.186 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 179.682 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 44.8 t-80 -152.45 118.63 5.53 Favored 'General case' 0 N--CA 1.471 0.582 0 N-CA-C 109.395 -0.594 . . . . 0.0 109.395 178.829 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 7' ' ' ASP . . . . . 0.457 ' O ' ' OG ' ' E' ' 8' ' ' SER . 3.8 m-20 -69.36 149.18 48.69 Favored 'General case' 0 CA--C 1.539 0.546 0 CA-C-N 116.4 -0.364 . . . . 0.0 110.622 179.896 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 8' ' ' SER . . . . . . . . . . . . . 52.7 p -167.52 -173.26 2.15 Favored 'General case' 0 N--CA 1.484 1.235 0 CA-C-O 121.033 0.444 . . . . 0.0 110.818 179.381 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.89 46.95 1.41 Allowed Glycine 0 N--CA 1.481 1.674 0 CA-C-N 115.966 -0.561 . . . . 0.0 112.015 179.661 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 47.7 p90 -65.79 132.53 48.94 Favored 'General case' 0 N--CA 1.472 0.652 0 CA-C-O 120.719 0.295 . . . . 0.0 111.649 179.837 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 47.9 mt-10 -91.65 151.86 20.49 Favored 'General case' 0 N--CA 1.477 0.894 0 N-CA-C 109.655 -0.498 . . . . 0.0 109.655 178.436 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -152.92 127.95 1.51 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.47 0 N-CA-C 107.972 -1.121 . . . . 0.0 107.972 178.13 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 43.5 m-70 -135.18 146.42 48.69 Favored 'General case' 0 N--CA 1.493 1.686 0 CA-C-N 118.869 0.759 . . . . 0.0 111.345 -178.93 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 6.1 t60 -165.79 97.02 0.65 Allowed 'General case' 0 N--CA 1.48 1.041 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.768 179.378 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . 0.715 HE22 ' H ' ' B' ' 37' ' ' GLY . 5.9 pt20 -108.37 -174.18 2.46 Favored 'General case' 0 CA--C 1.509 -0.603 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 -179.772 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -164.63 98.88 0.79 Allowed 'General case' 0 N--CA 1.474 0.755 0 CA-C-N 114.683 -1.144 . . . . 0.0 108.195 178.363 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 6.6 mp -122.04 156.04 34.35 Favored 'General case' 0 N--CA 1.497 1.925 0 CA-C-O 121.727 0.775 . . . . 0.0 111.012 -178.27 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 61.8 t -112.03 127.63 69.1 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.075 0 N-CA-C 108.028 -1.101 . . . . 0.0 108.028 177.605 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 28.2 m-85 -127.56 122.48 33.36 Favored 'General case' 0 N--CA 1.495 1.781 0 CA-C-N 119.678 1.126 . . . . 0.0 110.307 179.565 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 67.4 m-85 53.71 74.21 0.33 Allowed 'General case' 0 CA--C 1.538 0.504 0 CA-C-O 121.491 0.662 . . . . 0.0 111.846 178.792 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -80.55 -78.03 0.18 Allowed 'General case' 0 C--N 1.35 0.628 0 CA-C-N 115.065 -0.97 . . . . 0.0 110.116 -179.573 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 40.4 tt0 -113.15 99.57 7.93 Favored 'General case' 0 N--CA 1.47 0.543 0 N-CA-C 108.236 -1.024 . . . . 0.0 108.236 179.812 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -158.6 138.79 12.31 Favored 'General case' 0 C--O 1.205 -1.272 0 CA-C-O 119.524 -0.275 . . . . 0.0 111.236 179.1 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 24' ' ' VAL . . . . . 0.401 HG12 ' N ' ' B' ' 25' ' ' GLY . 57.1 t -59.41 163.8 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.857 0 N-CA-C 108.012 -1.107 . . . . 0.0 108.012 177.191 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 25' ' ' GLY . . . . . 0.471 ' H ' ' HB ' ' E' ' 24' ' ' VAL . . . -117.18 47.64 1.02 Allowed Glycine 0 N--CA 1.475 1.244 0 N-CA-C 111.773 -0.531 . . . . 0.0 111.773 -179.465 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -60.67 -167.62 0.01 OUTLIER 'General case' 0 N--CA 1.469 0.52 0 O-C-N 123.708 0.299 . . . . 0.0 110.202 179.457 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 25.4 t-20 -71.1 81.12 0.69 Allowed 'General case' 0 N--CA 1.465 0.29 0 CA-C-N 116.481 -0.327 . . . . 0.0 110.186 179.548 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 97.8 mttt -78.07 142.55 38.08 Favored 'General case' 0 N--CA 1.474 0.762 0 N-CA-C 109.015 -0.735 . . . . 0.0 109.015 179.418 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.22 -167.76 0.92 Allowed Glycine 0 C--N 1.336 0.557 0 N-CA-C 109.917 -1.273 . . . . 0.0 109.917 178.659 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.54 115.53 29.56 Favored 'General case' 0 N--CA 1.478 0.959 0 N-CA-C 109.599 -0.519 . . . . 0.0 109.599 179.77 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 70.9 mt -98.96 134.68 36.96 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.505 0 N-CA-C 107.107 -1.442 . . . . 0.0 107.107 178.6 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . 0.405 HG22 ' H ' ' E' ' 32' ' ' ILE . 29.7 pt -150.77 -171.85 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.724 0 CA-C-O 121.141 0.496 . . . . 0.0 111.17 -179.022 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.76 4.58 10.68 Favored Glycine 0 C--N 1.337 0.595 0 N-CA-C 110.915 -0.874 . . . . 0.0 110.915 179.935 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 34' ' ' LEU . . . . . 0.42 HD23 ' N ' ' B' ' 35' ' ' MET . 1.1 tt -75.07 135.07 41.23 Favored 'General case' 0 CA--C 1.545 0.767 0 N-CA-C 109.497 -0.557 . . . . 0.0 109.497 -179.689 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 35' ' ' MET . . . . . 0.42 ' N ' HD23 ' B' ' 34' ' ' LEU . 27.0 ttt -158.54 146.42 18.18 Favored 'General case' 0 N--CA 1.471 0.582 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 178.64 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 1.9 m -149.08 165.54 3.83 Favored 'Isoleucine or valine' 0 C--N 1.347 0.48 0 N-CA-C 108.094 -1.076 . . . . 0.0 108.094 -179.642 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . 0.715 ' H ' HE22 ' B' ' 15' ' ' GLN . . . 55.19 68.21 1.81 Allowed Glycine 0 C--N 1.306 -1.097 0 CA-C-N 115.469 -0.787 . . . . 0.0 112.367 177.54 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.24 176.75 21.21 Favored Glycine 0 N--CA 1.473 1.105 0 N-CA-C 111.113 -0.795 . . . . 0.0 111.113 178.674 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 39' ' ' VAL . . . . . 0.438 ' H ' HG12 ' E' ' 39' ' ' VAL . 34.4 m -109.35 155.81 10.31 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.655 0 C-N-CA 123.376 0.67 . . . . 0.0 110.299 -179.546 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 25.1 t . . . . . 0 C--O 1.22 -0.497 0 O-C-N 123.99 0.806 . . . . 0.0 110.407 179.317 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 64.8 m-85 . . . . . 0 N--CA 1.474 0.767 0 N-CA-C 110.25 -0.278 . . . . 0.0 110.25 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -144.22 142.4 30.48 Favored 'General case' 0 N--CA 1.484 1.244 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 179.769 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 45.2 t-80 -152.47 119.05 5.66 Favored 'General case' 0 N--CA 1.471 0.586 0 N-CA-C 109.397 -0.594 . . . . 0.0 109.397 179.013 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 7' ' ' ASP . . . . . 0.495 ' O ' ' OG ' ' F' ' 8' ' ' SER . 4.1 m-20 -70.1 149.03 48.04 Favored 'General case' 0 CA--C 1.538 0.493 0 CA-C-N 116.376 -0.375 . . . . 0.0 110.647 -179.983 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 8' ' ' SER . . . . . . . . . . . . . 54.0 p -167.28 -172.97 2.13 Favored 'General case' 0 N--CA 1.484 1.235 0 CA-C-O 121.061 0.457 . . . . 0.0 110.744 179.566 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.48 46.9 1.47 Allowed Glycine 0 N--CA 1.482 1.715 0 CA-C-N 115.945 -0.57 . . . . 0.0 112.035 179.688 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 47.7 p90 -65.78 132.35 48.51 Favored 'General case' 0 N--CA 1.471 0.591 0 O-C-N 122.745 -0.268 . . . . 0.0 111.686 179.826 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 47.7 mt-10 -91.41 151.82 20.66 Favored 'General case' 0 N--CA 1.475 0.782 0 N-CA-C 109.713 -0.477 . . . . 0.0 109.713 178.432 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -152.77 128.17 1.61 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.515 0 N-CA-C 107.833 -1.173 . . . . 0.0 107.833 177.999 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 41.7 m-70 -135.27 146.5 48.61 Favored 'General case' 0 N--CA 1.492 1.65 0 CA-C-N 118.916 0.78 . . . . 0.0 111.272 -179.056 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 6.0 t60 -165.88 96.84 0.63 Allowed 'General case' 0 N--CA 1.481 1.111 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.719 179.459 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 15' ' ' GLN . . . . . 0.69 HE22 ' H ' ' C' ' 37' ' ' GLY . 5.9 pt20 -108.39 -173.98 2.41 Favored 'General case' 0 CA--C 1.505 -0.77 0 N-CA-C 108.396 -0.965 . . . . 0.0 108.396 -179.898 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -164.63 98.85 0.79 Allowed 'General case' 0 N--CA 1.473 0.678 0 CA-C-N 114.617 -1.174 . . . . 0.0 108.223 178.502 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 6.6 mp -121.9 155.77 34.74 Favored 'General case' 0 N--CA 1.497 1.901 0 CA-C-O 121.84 0.828 . . . . 0.0 110.927 -178.35 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 61.2 t -111.68 127.55 68.77 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.117 0 N-CA-C 107.932 -1.136 . . . . 0.0 107.932 177.511 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 28.1 m-85 -127.51 123.06 35.0 Favored 'General case' 0 N--CA 1.495 1.782 0 CA-C-N 119.606 1.094 . . . . 0.0 110.272 179.395 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 67.0 m-85 53.08 74.12 0.32 Allowed 'General case' 0 N--CA 1.468 0.449 0 CA-C-O 121.558 0.694 . . . . 0.0 111.919 178.851 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -80.22 -78.29 0.17 Allowed 'General case' 0 C--N 1.35 0.62 0 CA-C-N 115.012 -0.994 . . . . 0.0 110.065 -179.595 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 40.4 tt0 -113.03 99.69 8.05 Favored 'General case' 0 N--CA 1.471 0.62 0 N-CA-C 108.153 -1.055 . . . . 0.0 108.153 179.899 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -158.45 139.15 12.8 Favored 'General case' 0 C--O 1.205 -1.246 0 O-C-N 122.309 -0.245 . . . . 0.0 111.203 179.131 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 60.7 t -59.94 163.3 0.96 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.878 0 N-CA-C 108.075 -1.083 . . . . 0.0 108.075 177.051 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 25' ' ' GLY . . . . . 0.479 ' H ' ' HB ' ' F' ' 24' ' ' VAL . . . -116.64 47.3 1.05 Allowed Glycine 0 N--CA 1.477 1.387 0 N-CA-C 111.722 -0.551 . . . . 0.0 111.722 -179.29 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -60.43 -167.38 0.01 OUTLIER 'General case' 0 N--CA 1.468 0.462 0 O-C-N 123.658 0.269 . . . . 0.0 110.284 179.539 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 25.5 t-20 -71.29 80.69 0.74 Allowed 'General case' 0 N--CA 1.466 0.333 0 CA-C-N 116.442 -0.344 . . . . 0.0 110.132 179.495 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 97.7 mttt -77.53 143.06 38.69 Favored 'General case' 0 N--CA 1.474 0.741 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 179.253 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.83 -167.68 1.15 Allowed Glycine 0 CA--C 1.524 0.617 0 N-CA-C 109.994 -1.242 . . . . 0.0 109.994 178.705 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.49 115.11 28.55 Favored 'General case' 0 N--CA 1.482 1.144 0 N-CA-C 109.677 -0.49 . . . . 0.0 109.677 179.879 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 71.1 mt -98.78 134.21 38.45 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.48 0 N-CA-C 107.296 -1.372 . . . . 0.0 107.296 178.591 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 29.7 pt -150.3 -171.49 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.724 0 CA-C-O 121.227 0.537 . . . . 0.0 111.173 -179.107 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.31 5.11 10.05 Favored Glycine 0 CA--C 1.524 0.62 0 N-CA-C 110.838 -0.905 . . . . 0.0 110.838 179.881 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 34' ' ' LEU . . . . . 0.427 HD23 ' N ' ' C' ' 35' ' ' MET . 1.1 tt -75.46 134.77 40.77 Favored 'General case' 0 CA--C 1.546 0.813 0 N-CA-C 109.38 -0.6 . . . . 0.0 109.38 -179.703 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 35' ' ' MET . . . . . 0.427 ' N ' HD23 ' C' ' 34' ' ' LEU . 27.1 ttt -158.19 146.57 18.79 Favored 'General case' 0 N--CA 1.47 0.531 0 N-CA-C 108.426 -0.953 . . . . 0.0 108.426 178.686 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 1.7 m -149.33 165.28 3.72 Favored 'Isoleucine or valine' 0 C--N 1.348 0.532 0 N-CA-C 108.142 -1.059 . . . . 0.0 108.142 -179.556 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 37' ' ' GLY . . . . . 0.69 ' H ' HE22 ' C' ' 15' ' ' GLN . . . 54.77 68.7 1.55 Allowed Glycine 0 C--N 1.306 -1.096 0 CA-C-N 115.413 -0.812 . . . . 0.0 112.317 177.782 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.26 176.42 20.94 Favored Glycine 0 N--CA 1.473 1.101 0 N-CA-C 111.078 -0.809 . . . . 0.0 111.078 178.698 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 39' ' ' VAL . . . . . 0.444 ' H ' HG12 ' F' ' 39' ' ' VAL . 34.4 m -109.38 155.73 10.38 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.624 0 C-N-CA 123.328 0.651 . . . . 0.0 110.443 -179.641 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 25.1 t . . . . . 0 C--O 1.219 -0.538 0 O-C-N 124.009 0.818 . . . . 0.0 110.491 179.386 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 72.3 m-85 . . . . . 0 N--CA 1.471 0.599 0 N-CA-C 108.948 -0.76 . . . . 0.0 108.948 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' D' D ' 5' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -146.87 140.99 26.12 Favored 'General case' 0 N--CA 1.476 0.86 0 N-CA-C 110.059 -0.348 . . . . 0.0 110.059 179.764 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 41.6 t-80 -149.75 123.52 9.26 Favored 'General case' 0 CA--C 1.545 0.774 0 N-CA-C 108.499 -0.926 . . . . 0.0 108.499 174.468 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' D' D ' 7' ' ' ASP . . . . . 0.591 ' O ' ' OG ' ' G' ' 8' ' ' SER . 2.8 m-20 -63.81 133.32 53.2 Favored 'General case' 0 C--N 1.32 -0.688 0 C-N-CA 126.61 1.964 . . . . 0.0 114.339 174.029 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' D' D ' 8' ' ' SER . . . . . 0.51 ' OG ' ' O ' ' A' ' 7' ' ' ASP . 52.3 p -154.04 -170.53 3.59 Favored 'General case' 0 N--CA 1.488 1.438 0 CA-C-N 119.649 1.113 . . . . 0.0 111.131 175.534 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.43 48.05 1.16 Allowed Glycine 0 N--CA 1.484 1.88 0 N-CA-C 109.941 -1.264 . . . . 0.0 109.941 173.365 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 50.9 p90 -60.66 131.01 49.35 Favored 'General case' 0 N--CA 1.468 0.434 0 N-CA-C 113.155 0.798 . . . . 0.0 113.155 177.697 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 47.8 mt-10 -88.84 150.65 22.8 Favored 'General case' 0 N--CA 1.481 1.084 0 CA-C-N 118.175 0.443 . . . . 0.0 110.946 174.98 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.0 p -149.49 130.03 4.41 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.594 0 N-CA-C 107.423 -1.325 . . . . 0.0 107.423 173.128 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 40.9 m-70 -130.03 149.25 51.83 Favored 'General case' 0 N--CA 1.484 1.232 0 CA-C-N 118.03 0.377 . . . . 0.0 111.907 176.41 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 6.1 t60 -164.99 104.38 0.78 Allowed 'General case' 0 N--CA 1.48 1.035 0 N-CA-C 109.175 -0.676 . . . . 0.0 109.175 172.13 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' D' D ' 15' ' ' GLN . . . . . 0.65 HE22 ' H ' ' D' ' 37' ' ' GLY . 5.9 pt20 -111.97 -176.05 2.84 Favored 'General case' 0 CA--C 1.499 -1.002 0 N-CA-C 108.228 -1.027 . . . . 0.0 108.228 178.911 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -161.04 105.96 1.36 Allowed 'General case' 0 N--CA 1.468 0.433 0 N-CA-C 106.634 -1.617 . . . . 0.0 106.634 175.151 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 5.5 mp -128.38 153.22 47.3 Favored 'General case' 0 N--CA 1.498 1.945 0 CA-C-O 122.06 0.934 . . . . 0.0 110.582 179.662 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 35.8 t -100.97 131.82 47.88 Favored 'Isoleucine or valine' 0 C--O 1.262 1.761 0 CA-C-O 116.723 -1.608 . . . . 0.0 109.546 174.2 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 25.7 m-85 -130.49 126.35 36.66 Favored 'General case' 0 N--CA 1.491 1.583 0 CA-C-N 120.149 1.34 . . . . 0.0 109.528 173.366 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 68.2 m-85 55.85 71.53 0.55 Allowed 'General case' 0 C--O 1.241 0.651 0 CA-C-N 115.493 -0.776 . . . . 0.0 111.258 176.357 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -82.43 -73.18 0.41 Allowed 'General case' 0 N--CA 1.475 0.794 0 CA-C-O 118.52 -0.752 . . . . 0.0 111.106 -177.507 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 40.8 tt0 -116.52 103.81 10.79 Favored 'General case' 0 N--CA 1.482 1.174 0 N-CA-C 106.195 -1.78 . . . . 0.0 106.195 176.217 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -151.9 138.79 18.98 Favored 'General case' 0 N--CA 1.474 0.752 0 CA-C-O 116.686 -1.626 . . . . 0.0 113.738 177.697 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' D' D ' 24' ' ' VAL . . . . . 0.461 ' HB ' ' H ' ' A' ' 25' ' ' GLY . 64.1 t -62.27 166.23 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.206 0 CA-C-N 121.101 1.773 . . . . 0.0 107.834 175.184 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' D' D ' 25' ' ' GLY . . . . . 0.539 ' H ' ' HB ' ' G' ' 24' ' ' VAL . . . -116.79 51.14 0.74 Allowed Glycine 0 N--CA 1.478 1.46 0 CA-C-O 119.095 -0.836 . . . . 0.0 111.833 178.451 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -57.28 -170.42 0.01 OUTLIER 'General case' 0 C--N 1.322 -0.595 0 C-N-CA 123.706 0.802 . . . . 0.0 111.559 175.937 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 26.3 t-20 -72.89 86.69 1.29 Allowed 'General case' 0 C--N 1.347 0.466 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 177.976 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 97.2 mttt -82.87 145.56 29.38 Favored 'General case' 0 N--CA 1.476 0.84 0 N-CA-C 108.014 -1.106 . . . . 0.0 108.014 179.134 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.17 -165.34 0.61 Allowed Glycine 0 C--N 1.336 0.57 0 N-CA-C 110.45 -1.06 . . . . 0.0 110.45 179.171 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -102.35 116.11 31.95 Favored 'General case' 0 N--CA 1.476 0.851 0 N-CA-C 109.099 -0.704 . . . . 0.0 109.099 179.846 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 80.4 mt -102.52 142.24 17.07 Favored 'Isoleucine or valine' 0 C--N 1.358 0.941 0 N-CA-C 104.84 -2.281 . . . . 0.0 104.84 179.793 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' D' D ' 32' ' ' ILE . . . . . 0.45 HG22 ' H ' ' G' ' 32' ' ' ILE . 31.1 pt -157.43 -172.51 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.482 1.157 0 CA-C-O 120.84 0.353 . . . . 0.0 110.155 -177.332 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 64.27 4.55 12.59 Favored Glycine 0 N--CA 1.465 0.601 0 N-CA-C 110.387 -1.085 . . . . 0.0 110.387 -178.926 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 1.3 tt -76.52 140.47 41.17 Favored 'General case' 0 C--N 1.355 0.824 0 N-CA-C 107.787 -1.19 . . . . 0.0 107.787 -178.329 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 26.4 ttt -156.41 155.91 32.94 Favored 'General case' 0 C--O 1.247 0.955 0 N-CA-C 107.894 -1.15 . . . . 0.0 107.894 174.482 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 1.9 m -157.91 163.86 1.18 Allowed 'Isoleucine or valine' 0 CA--C 1.516 -0.334 0 N-CA-C 107.618 -1.252 . . . . 0.0 107.618 177.826 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' D' D ' 37' ' ' GLY . . . . . 0.65 ' H ' HE22 ' D' ' 15' ' ' GLN . . . 61.36 63.84 4.53 Favored Glycine 0 C--N 1.312 -0.76 0 C-N-CA 119.758 -1.211 . . . . 0.0 112.179 177.452 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 145.76 177.75 20.72 Favored Glycine 0 N--CA 1.476 1.365 0 CA-C-N 118.309 1.054 . . . . 0.0 111.776 179.756 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' D' D ' 39' ' ' VAL . . . . . 0.439 HG12 ' H ' ' A' ' 39' ' ' VAL . 35.2 m -112.5 152.76 14.24 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.895 0 N-CA-C 109.681 -0.489 . . . . 0.0 109.681 -176.824 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 25.2 t . . . . . 0 C--N 1.334 -0.066 0 CA-C-O 116.119 -1.896 . . . . 0.0 109.533 178.0 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 65.8 m-85 . . . . . 0 N--CA 1.474 0.756 0 N-CA-C 110.257 -0.275 . . . . 0.0 110.257 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' E' E ' 5' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -143.72 142.79 31.12 Favored 'General case' 0 N--CA 1.481 1.078 0 N-CA-C 110.113 -0.329 . . . . 0.0 110.113 179.458 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 45.1 t-80 -152.46 118.67 5.54 Favored 'General case' 0 N--CA 1.469 0.516 0 N-CA-C 109.294 -0.632 . . . . 0.0 109.294 178.86 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' E' E ' 7' ' ' ASP . . . . . 0.445 ' O ' ' OG ' ' H' ' 8' ' ' SER . 3.6 m-20 -70.14 149.14 47.87 Favored 'General case' 0 CA--C 1.535 0.391 0 CA-C-N 116.488 -0.324 . . . . 0.0 110.754 179.938 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' E' E ' 8' ' ' SER . . . . . 0.457 ' OG ' ' O ' ' B' ' 7' ' ' ASP . 43.7 p -168.26 -172.1 1.66 Allowed 'General case' 0 N--CA 1.486 1.33 0 CA-C-O 121.192 0.52 . . . . 0.0 110.854 179.18 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.24 47.7 1.3 Allowed Glycine 0 N--CA 1.478 1.485 0 CA-C-N 115.876 -0.602 . . . . 0.0 111.797 179.54 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 46.3 p90 -65.56 132.62 49.32 Favored 'General case' 0 N--CA 1.471 0.621 0 N-CA-C 112.064 0.394 . . . . 0.0 112.064 -179.891 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 49.0 mt-10 -90.98 152.29 20.74 Favored 'General case' 0 N--CA 1.481 1.123 0 CA-C-O 121.313 0.578 . . . . 0.0 109.575 177.954 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -154.65 127.07 1.04 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.588 0 N-CA-C 107.874 -1.158 . . . . 0.0 107.874 177.96 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 42.9 m-70 -135.42 144.4 46.49 Favored 'General case' 0 N--CA 1.482 1.149 0 CA-C-O 120.903 0.382 . . . . 0.0 111.478 -177.859 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 6.0 t60 -164.4 97.19 0.79 Allowed 'General case' 0 N--CA 1.484 1.237 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.694 179.419 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' E' E ' 15' ' ' GLN . . . . . 0.715 HE22 ' H ' ' E' ' 37' ' ' GLY . 6.0 pt20 -108.21 -174.33 2.49 Favored 'General case' 0 CA--C 1.507 -0.686 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 -179.924 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -164.18 97.73 0.82 Allowed 'General case' 0 N--CA 1.476 0.839 0 CA-C-N 114.698 -1.137 . . . . 0.0 108.436 178.563 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 6.5 mp -120.52 155.66 33.17 Favored 'General case' 0 N--CA 1.494 1.775 0 CA-C-O 121.533 0.682 . . . . 0.0 111.588 -177.867 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 48.8 t -113.44 124.66 70.3 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.254 0 N-CA-C 108.176 -1.046 . . . . 0.0 108.176 177.131 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 30.8 m-85 -124.94 121.8 35.51 Favored 'General case' 0 N--CA 1.489 1.495 0 CA-C-O 120.836 0.351 . . . . 0.0 110.934 -179.891 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 68.8 m-85 54.79 73.29 0.42 Allowed 'General case' 0 N--CA 1.468 0.429 0 CA-C-N 115.92 -0.582 . . . . 0.0 111.478 178.34 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -78.83 -79.03 0.14 Allowed 'General case' 0 CA--C 1.537 0.459 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.03 -179.378 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 40.5 tt0 -112.1 100.02 8.52 Favored 'General case' 0 C--N 1.323 -0.548 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 -179.987 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -157.89 138.84 13.22 Favored 'General case' 0 C--O 1.201 -1.458 0 N-CA-C 111.621 0.23 . . . . 0.0 111.621 179.029 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' E' E ' 24' ' ' VAL . . . . . 0.471 ' HB ' ' H ' ' B' ' 25' ' ' GLY . 59.0 t -58.15 168.28 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.927 0 N-CA-C 107.403 -1.332 . . . . 0.0 107.403 177.056 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' E' E ' 25' ' ' GLY . . . . . 0.438 ' H ' ' HB ' ' H' ' 24' ' ' VAL . . . -122.0 48.63 0.94 Allowed Glycine 0 N--CA 1.473 1.157 0 N-CA-C 110.963 -0.855 . . . . 0.0 110.963 -179.38 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -62.12 -166.9 0.01 OUTLIER 'General case' 0 N--CA 1.47 0.541 0 CA-C-O 120.737 0.303 . . . . 0.0 110.482 179.892 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 26.0 t-20 -70.68 76.88 0.6 Allowed 'General case' 0 C--O 1.222 -0.362 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.481 -179.956 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 97.9 mttt -74.36 143.67 44.75 Favored 'General case' 0 N--CA 1.476 0.873 0 N-CA-C 109.554 -0.536 . . . . 0.0 109.554 179.403 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.68 -167.38 1.43 Allowed Glycine 0 C--N 1.333 0.414 0 N-CA-C 110.408 -1.077 . . . . 0.0 110.408 178.534 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.54 113.99 26.72 Favored 'General case' 0 N--CA 1.476 0.834 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 179.953 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 72.0 mt -97.8 134.48 35.86 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.265 0 N-CA-C 106.986 -1.487 . . . . 0.0 106.986 178.768 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' E' E ' 32' ' ' ILE . . . . . 0.45 HG22 ' H ' ' H' ' 32' ' ' ILE . 31.4 pt -150.34 -169.7 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.174 0 CA-C-O 121.182 0.515 . . . . 0.0 110.753 -179.451 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.65 5.18 6.41 Favored Glycine 0 CA--C 1.527 0.834 0 CA-C-N 115.684 -0.689 . . . . 0.0 111.423 -179.796 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' E' E ' 34' ' ' LEU . . . . . 0.409 HD23 ' N ' ' E' ' 35' ' ' MET . 1.1 tt -74.75 135.26 41.77 Favored 'General case' 0 CA--C 1.549 0.941 0 N-CA-C 109.293 -0.632 . . . . 0.0 109.293 -179.616 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' E' E ' 35' ' ' MET . . . . . 0.409 ' N ' HD23 ' E' ' 34' ' ' LEU . 26.3 ttt -158.37 145.78 17.98 Favored 'General case' 0 N--CA 1.473 0.724 0 N-CA-C 108.611 -0.885 . . . . 0.0 108.611 178.466 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 1.5 m -148.65 165.08 4.56 Favored 'Isoleucine or valine' 0 C--N 1.347 0.48 0 N-CA-C 108.5 -0.926 . . . . 0.0 108.5 -179.447 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' E' E ' 37' ' ' GLY . . . . . 0.715 ' H ' HE22 ' E' ' 15' ' ' GLN . . . 54.28 68.56 1.6 Allowed Glycine 0 C--N 1.308 -1.024 0 CA-C-N 115.324 -0.853 . . . . 0.0 112.231 177.888 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 146.65 173.76 18.16 Favored Glycine 0 N--CA 1.473 1.11 0 N-CA-C 111.41 -0.676 . . . . 0.0 111.41 178.734 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' E' E ' 39' ' ' VAL . . . . . 0.438 HG12 ' H ' ' B' ' 39' ' ' VAL . 32.7 m -107.0 155.69 7.59 Favored 'Isoleucine or valine' 0 C--N 1.352 0.702 0 C-N-CA 123.629 0.772 . . . . 0.0 110.645 -178.711 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 25.4 t . . . . . 0 C--O 1.218 -0.599 0 O-C-N 124.18 0.925 . . . . 0.0 110.25 179.615 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 65.1 m-85 . . . . . 0 N--CA 1.474 0.77 0 N-CA-C 110.235 -0.283 . . . . 0.0 110.235 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' F' F ' 5' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -143.56 142.66 31.19 Favored 'General case' 0 N--CA 1.478 0.97 0 CA-C-O 120.838 0.351 . . . . 0.0 110.091 179.657 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 45.0 t-80 -152.45 119.26 5.75 Favored 'General case' 0 N--CA 1.471 0.614 0 N-CA-C 109.429 -0.582 . . . . 0.0 109.429 178.783 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' F' F ' 7' ' ' ASP . . . . . 0.486 ' O ' ' OG ' ' I' ' 8' ' ' SER . 3.7 m-20 -70.76 149.33 47.01 Favored 'General case' 0 CA--C 1.535 0.382 0 CA-C-N 116.418 -0.356 . . . . 0.0 110.844 -179.929 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' F' F ' 8' ' ' SER . . . . . 0.495 ' OG ' ' O ' ' C' ' 7' ' ' ASP . 43.2 p -168.56 -171.63 1.48 Allowed 'General case' 0 N--CA 1.484 1.262 0 CA-C-O 121.236 0.541 . . . . 0.0 110.935 179.169 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.95 46.82 1.42 Allowed Glycine 0 N--CA 1.478 1.492 0 CA-C-N 115.855 -0.611 . . . . 0.0 111.761 179.551 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 46.6 p90 -64.64 132.42 49.69 Favored 'General case' 0 CA--C 1.542 0.642 0 N-CA-C 112.01 0.374 . . . . 0.0 112.01 -179.886 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 48.6 mt-10 -91.04 152.29 20.71 Favored 'General case' 0 N--CA 1.482 1.13 0 CA-C-O 121.266 0.555 . . . . 0.0 109.685 177.89 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -154.49 126.98 1.05 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.67 0 N-CA-C 107.855 -1.165 . . . . 0.0 107.855 178.058 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 42.5 m-70 -135.24 144.81 47.09 Favored 'General case' 0 N--CA 1.483 1.179 0 CA-C-O 120.847 0.356 . . . . 0.0 111.522 -177.919 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 6.0 t60 -164.88 96.91 0.74 Allowed 'General case' 0 N--CA 1.484 1.27 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.805 179.539 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' F' F ' 15' ' ' GLN . . . . . 0.695 HE22 ' H ' ' F' ' 37' ' ' GLY . 6.0 pt20 -108.02 -174.17 2.46 Favored 'General case' 0 CA--C 1.505 -0.751 0 N-CA-C 108.574 -0.899 . . . . 0.0 108.574 -179.875 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -164.17 97.79 0.82 Allowed 'General case' 0 N--CA 1.473 0.719 0 CA-C-N 114.578 -1.192 . . . . 0.0 108.397 178.561 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 6.4 mp -120.55 155.73 33.05 Favored 'General case' 0 N--CA 1.494 1.773 0 CA-C-O 121.667 0.746 . . . . 0.0 111.456 -177.727 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 48.4 t -113.64 124.38 70.23 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.25 0 N-CA-C 108.199 -1.037 . . . . 0.0 108.199 177.17 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 30.5 m-85 -124.7 121.19 33.97 Favored 'General case' 0 N--CA 1.488 1.439 0 CA-C-O 120.77 0.319 . . . . 0.0 111.015 -179.783 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 67.9 m-85 55.27 73.23 0.43 Allowed 'General case' 0 C--N 1.344 0.342 0 CA-C-N 115.953 -0.567 . . . . 0.0 111.733 178.322 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -78.92 -78.58 0.15 Allowed 'General case' 0 N--CA 1.467 0.419 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.147 -179.27 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 40.3 tt0 -112.66 99.99 8.36 Favored 'General case' 0 C--N 1.324 -0.524 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 -179.825 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -157.88 138.8 13.2 Favored 'General case' 0 C--O 1.203 -1.361 0 N-CA-C 111.681 0.252 . . . . 0.0 111.681 179.052 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' F' F ' 24' ' ' VAL . . . . . 0.479 ' HB ' ' H ' ' C' ' 25' ' ' GLY . 60.0 t -58.13 168.24 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.935 0 N-CA-C 107.398 -1.334 . . . . 0.0 107.398 177.116 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' F' F ' 25' ' ' GLY . . . . . 0.434 ' H ' ' HB ' ' I' ' 24' ' ' VAL . . . -121.92 48.53 0.94 Allowed Glycine 0 N--CA 1.476 1.35 0 N-CA-C 110.877 -0.889 . . . . 0.0 110.877 -179.394 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -62.11 -167.4 0.01 OUTLIER 'General case' 0 N--CA 1.47 0.565 0 CA-C-O 120.782 0.325 . . . . 0.0 110.285 179.895 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 25.8 t-20 -70.1 77.0 0.51 Allowed 'General case' 0 N--CA 1.466 0.338 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.589 179.979 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 97.8 mttt -74.57 143.81 44.28 Favored 'General case' 0 N--CA 1.478 0.957 0 N-CA-C 109.483 -0.562 . . . . 0.0 109.483 179.524 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.39 -167.11 1.25 Allowed Glycine 0 C--N 1.334 0.425 0 N-CA-C 110.486 -1.046 . . . . 0.0 110.486 178.539 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.69 113.65 26.25 Favored 'General case' 0 N--CA 1.477 0.917 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 179.752 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 72.0 mt -97.71 134.59 35.28 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.285 0 N-CA-C 106.981 -1.489 . . . . 0.0 106.981 178.717 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' F' F ' 32' ' ' ILE . . . . . 0.446 HG22 ' H ' ' I' ' 32' ' ' ILE . 32.1 pt -150.74 -169.6 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.198 0 CA-C-O 121.126 0.489 . . . . 0.0 110.7 -179.476 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.64 5.12 6.29 Favored Glycine 0 CA--C 1.527 0.82 0 CA-C-N 115.688 -0.687 . . . . 0.0 111.407 -179.78 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' F' F ' 34' ' ' LEU . . . . . 0.419 HD23 ' N ' ' F' ' 35' ' ' MET . 1.1 tt -74.66 135.83 41.93 Favored 'General case' 0 CA--C 1.549 0.922 0 N-CA-C 109.18 -0.674 . . . . 0.0 109.18 -179.669 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' F' F ' 35' ' ' MET . . . . . 0.419 ' N ' HD23 ' F' ' 34' ' ' LEU . 26.0 ttt -158.72 145.92 17.58 Favored 'General case' 0 N--CA 1.47 0.561 0 N-CA-C 108.66 -0.867 . . . . 0.0 108.66 178.446 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 1.5 m -148.78 165.14 4.35 Favored 'Isoleucine or valine' 0 C--N 1.349 0.547 0 N-CA-C 108.425 -0.954 . . . . 0.0 108.425 -179.495 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' F' F ' 37' ' ' GLY . . . . . 0.695 ' H ' HE22 ' F' ' 15' ' ' GLN . . . 54.33 68.37 1.7 Allowed Glycine 0 C--N 1.306 -1.108 0 CA-C-N 115.328 -0.851 . . . . 0.0 112.331 177.808 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 146.97 174.09 18.74 Favored Glycine 0 N--CA 1.472 1.097 0 N-CA-C 111.415 -0.674 . . . . 0.0 111.415 178.645 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' F' F ' 39' ' ' VAL . . . . . 0.444 HG12 ' H ' ' C' ' 39' ' ' VAL . 33.1 m -107.22 155.54 7.88 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.714 0 C-N-CA 123.471 0.708 . . . . 0.0 110.588 -178.803 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 26.8 t . . . . . 0 C--O 1.219 -0.55 0 O-C-N 124.286 0.991 . . . . 0.0 110.3 179.601 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 67.1 m-85 . . . . . 0 N--CA 1.473 0.692 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' G' G ' 5' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -143.91 142.77 30.95 Favored 'General case' 0 N--CA 1.483 1.189 0 CA-C-O 120.828 0.347 . . . . 0.0 110.162 179.983 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 45.8 t-80 -152.31 119.5 5.9 Favored 'General case' 0 N--CA 1.473 0.682 0 N-CA-C 109.574 -0.528 . . . . 0.0 109.574 178.794 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 4.0 m-20 -71.82 144.49 49.11 Favored 'General case' 0 CA--C 1.538 0.519 0 C-N-CA 122.716 0.406 . . . . 0.0 111.176 -179.938 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' G' G ' 8' ' ' SER . . . . . 0.591 ' OG ' ' O ' ' D' ' 7' ' ' ASP . 35.5 p -164.77 -169.62 1.76 Allowed 'General case' 0 N--CA 1.476 0.86 0 CA-C-O 121.178 0.513 . . . . 0.0 110.512 178.672 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.21 47.73 1.41 Allowed Glycine 0 N--CA 1.48 1.63 0 N-CA-C 111.344 -0.703 . . . . 0.0 111.344 179.291 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 48.0 p90 -65.69 133.16 50.51 Favored 'General case' 0 CA--C 1.542 0.636 0 N-CA-C 111.872 0.323 . . . . 0.0 111.872 -179.627 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 47.9 mt-10 -91.76 151.48 20.6 Favored 'General case' 0 N--CA 1.479 1.022 0 CA-C-O 121.162 0.506 . . . . 0.0 110.0 178.576 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -154.99 127.28 1.01 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.004 0 N-CA-C 107.851 -1.166 . . . . 0.0 107.851 178.196 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 44.2 m-70 -134.67 146.06 49.14 Favored 'General case' 0 N--CA 1.48 1.05 0 CA-C-N 115.667 -0.697 . . . . 0.0 111.45 -178.363 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 6.0 t60 -166.24 97.05 0.6 Allowed 'General case' 0 N--CA 1.481 1.115 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.385 178.946 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' G' G ' 15' ' ' GLN . . . . . 0.704 HE22 ' H ' ' G' ' 37' ' ' GLY . 6.0 pt20 -108.42 -174.51 2.54 Favored 'General case' 0 CA--C 1.508 -0.641 0 N-CA-C 108.31 -0.996 . . . . 0.0 108.31 -179.702 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -164.27 97.72 0.81 Allowed 'General case' 0 N--CA 1.475 0.802 0 CA-C-N 114.606 -1.179 . . . . 0.0 108.12 178.667 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 6.4 mp -120.4 154.8 34.64 Favored 'General case' 0 N--CA 1.498 1.934 0 CA-C-O 121.247 0.546 . . . . 0.0 111.774 -177.883 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 43.1 t -113.33 124.66 70.19 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.942 0 CA-C-N 114.777 -1.101 . . . . 0.0 108.186 176.55 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 32.1 m-85 -125.29 121.19 33.3 Favored 'General case' 0 C--N 1.367 1.349 0 C-N-CA 123.437 0.695 . . . . 0.0 110.979 -179.602 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 68.0 m-85 55.37 72.57 0.47 Allowed 'General case' 0 N--CA 1.467 0.393 0 CA-C-N 115.898 -0.592 . . . . 0.0 111.496 178.274 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.78 -77.99 0.14 Allowed 'General case' 0 N--CA 1.473 0.697 0 O-C-N 122.237 -0.289 . . . . 0.0 110.407 -178.932 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 41.1 tt0 -113.02 100.2 8.44 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 107.812 -1.181 . . . . 0.0 107.812 179.909 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -157.73 139.75 14.21 Favored 'General case' 0 N--CA 1.476 0.865 0 N-CA-C 111.649 0.24 . . . . 0.0 111.649 178.959 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' G' G ' 24' ' ' VAL . . . . . 0.539 ' HB ' ' H ' ' D' ' 25' ' ' GLY . 62.0 t -59.62 166.97 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.656 0 N-CA-C 107.564 -1.273 . . . . 0.0 107.564 177.353 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' G' G ' 25' ' ' GLY . . . . . 0.421 ' N ' HG12 ' G' ' 24' ' ' VAL . . . -120.13 49.32 0.88 Allowed Glycine 0 N--CA 1.479 1.538 0 N-CA-C 110.617 -0.993 . . . . 0.0 110.617 -179.507 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -63.45 -166.59 0.02 OUTLIER 'General case' 0 N--CA 1.471 0.62 0 N-CA-C 109.895 -0.409 . . . . 0.0 109.895 179.904 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 26.2 t-20 -70.99 76.96 0.65 Allowed 'General case' 0 CA--C 1.535 0.386 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.599 -179.89 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 97.9 mttt -73.95 143.14 45.81 Favored 'General case' 0 N--CA 1.475 0.808 0 N-CA-C 109.623 -0.51 . . . . 0.0 109.623 179.427 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.08 -166.17 0.98 Allowed Glycine 0 C--N 1.337 0.592 0 N-CA-C 110.019 -1.232 . . . . 0.0 110.019 178.642 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.57 114.28 27.2 Favored 'General case' 0 N--CA 1.472 0.659 0 C-N-CA 122.708 0.403 . . . . 0.0 110.138 -179.977 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 73.6 mt -98.51 135.02 34.97 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.649 0 N-CA-C 107.054 -1.461 . . . . 0.0 107.054 178.67 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' G' G ' 32' ' ' ILE . . . . . 0.45 ' H ' HG22 ' D' ' 32' ' ' ILE . 34.3 pt -151.5 -169.28 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 CA-C-N 119.723 1.147 . . . . 0.0 109.916 -179.813 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.28 4.78 6.85 Favored Glycine 0 N--CA 1.468 0.774 0 N-CA-C 111.132 -0.787 . . . . 0.0 111.132 -179.864 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' G' G ' 34' ' ' LEU . . . . . 0.433 HD23 ' N ' ' G' ' 35' ' ' MET . 1.1 tt -74.95 135.12 41.41 Favored 'General case' 0 CA--C 1.545 0.775 0 N-CA-C 109.295 -0.631 . . . . 0.0 109.295 -179.757 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' G' G ' 35' ' ' MET . . . . . 0.433 ' N ' HD23 ' G' ' 34' ' ' LEU . 25.0 ttt -158.28 146.06 18.31 Favored 'General case' 0 N--CA 1.47 0.566 0 N-CA-C 108.64 -0.874 . . . . 0.0 108.64 178.823 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 1.5 m -148.82 163.4 4.85 Favored 'Isoleucine or valine' 0 C--N 1.349 0.561 0 N-CA-C 108.587 -0.894 . . . . 0.0 108.587 -179.469 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' G' G ' 37' ' ' GLY . . . . . 0.704 ' H ' HE22 ' G' ' 15' ' ' GLN . . . 55.4 68.76 1.52 Allowed Glycine 0 C--N 1.308 -1.001 0 CA-C-N 115.226 -0.897 . . . . 0.0 112.293 177.596 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.39 172.35 17.46 Favored Glycine 0 N--CA 1.476 1.314 0 N-CA-C 110.569 -1.012 . . . . 0.0 110.569 178.892 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' G' G ' 39' ' ' VAL . . . . . 0.414 HG12 ' H ' ' D' ' 39' ' ' VAL . 33.9 m -106.01 155.64 6.92 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.923 0 C-N-CA 123.198 0.599 . . . . 0.0 110.452 -179.541 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 27.5 t . . . . . 0 C--O 1.22 -0.46 0 O-C-N 123.961 0.788 . . . . 0.0 110.563 179.371 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 68.8 m-85 . . . . . 0 N--CA 1.473 0.71 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' H' H ' 5' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -144.21 142.92 30.81 Favored 'General case' 0 N--CA 1.483 1.217 0 N-CA-C 110.046 -0.353 . . . . 0.0 110.046 -179.98 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 46.6 t-80 -152.65 119.69 5.82 Favored 'General case' 0 N--CA 1.472 0.636 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 178.812 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 3.9 m-20 -72.19 144.56 48.47 Favored 'General case' 0 N--CA 1.469 0.481 0 CA-C-N 116.319 -0.401 . . . . 0.0 111.222 -179.781 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' H' H ' 8' ' ' SER . . . . . 0.445 ' OG ' ' O ' ' E' ' 7' ' ' ASP . 52.2 p -164.72 -170.07 1.9 Allowed 'General case' 0 N--CA 1.475 0.776 0 CA-C-O 121.129 0.49 . . . . 0.0 110.492 178.912 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.48 47.63 1.39 Allowed Glycine 0 N--CA 1.478 1.499 0 N-CA-C 111.557 -0.617 . . . . 0.0 111.557 179.409 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 48.4 p90 -65.97 133.14 50.22 Favored 'General case' 0 CA--C 1.54 0.584 0 N-CA-C 111.861 0.319 . . . . 0.0 111.861 -179.587 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 47.8 mt-10 -91.67 151.44 20.67 Favored 'General case' 0 N--CA 1.477 0.921 0 CA-C-O 121.064 0.459 . . . . 0.0 110.065 178.583 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -154.98 127.35 1.03 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.004 0 N-CA-C 107.92 -1.141 . . . . 0.0 107.92 178.13 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 43.5 m-70 -134.67 146.36 49.43 Favored 'General case' 0 N--CA 1.479 0.98 0 CA-C-N 115.694 -0.685 . . . . 0.0 111.311 -178.321 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 6.1 t60 -166.43 96.71 0.57 Allowed 'General case' 0 N--CA 1.481 1.102 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.508 178.912 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' H' H ' 15' ' ' GLN . . . . . 0.703 HE22 ' H ' ' H' ' 37' ' ' GLY . 5.9 pt20 -107.97 -174.13 2.45 Favored 'General case' 0 CA--C 1.507 -0.681 0 N-CA-C 108.304 -0.999 . . . . 0.0 108.304 -179.624 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -164.68 97.5 0.76 Allowed 'General case' 0 N--CA 1.474 0.757 0 CA-C-N 114.584 -1.189 . . . . 0.0 108.127 178.61 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 6.4 mp -120.21 154.92 34.16 Favored 'General case' 0 N--CA 1.496 1.857 0 CA-C-O 121.265 0.555 . . . . 0.0 111.838 -177.939 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 43.2 t -113.4 124.65 70.25 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.079 0 CA-C-N 114.817 -1.083 . . . . 0.0 108.158 176.668 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 32.2 m-85 -125.22 121.28 33.65 Favored 'General case' 0 C--N 1.366 1.313 0 C-N-CA 123.471 0.708 . . . . 0.0 110.885 -179.443 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 68.3 m-85 54.72 72.92 0.43 Allowed 'General case' 0 C--O 1.238 0.455 0 CA-C-N 115.698 -0.683 . . . . 0.0 111.672 178.342 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.68 -78.31 0.14 Allowed 'General case' 0 N--CA 1.473 0.676 0 O-C-N 122.154 -0.341 . . . . 0.0 110.349 -178.914 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 40.8 tt0 -112.85 99.77 8.15 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 107.878 -1.156 . . . . 0.0 107.878 -179.946 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -157.24 139.96 15.02 Favored 'General case' 0 N--CA 1.477 0.887 0 O-C-N 122.346 -0.221 . . . . 0.0 111.471 178.976 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' H' H ' 24' ' ' VAL . . . . . 0.438 ' HB ' ' H ' ' E' ' 25' ' ' GLY . 59.7 t -59.7 167.65 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.592 0 N-CA-C 107.458 -1.312 . . . . 0.0 107.458 177.313 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' H' H ' 25' ' ' GLY . . . . . 0.43 ' N ' HG12 ' H' ' 24' ' ' VAL . . . -120.63 49.27 0.89 Allowed Glycine 0 N--CA 1.479 1.5 0 N-CA-C 110.622 -0.991 . . . . 0.0 110.622 -179.581 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -63.6 -167.33 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.643 0 CA-C-N 117.033 0.417 . . . . 0.0 110.036 179.766 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 26.2 t-20 -70.05 77.04 0.5 Allowed 'General case' 0 N--CA 1.465 0.318 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.587 -179.945 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 97.8 mttt -74.1 143.45 45.38 Favored 'General case' 0 N--CA 1.475 0.819 0 N-CA-C 109.5 -0.556 . . . . 0.0 109.5 179.41 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.67 -166.39 1.21 Allowed Glycine 0 C--N 1.338 0.669 0 N-CA-C 109.997 -1.241 . . . . 0.0 109.997 178.641 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.4 114.29 27.13 Favored 'General case' 0 N--CA 1.47 0.554 0 C-N-CA 122.683 0.393 . . . . 0.0 110.293 -179.995 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 74.0 mt -98.46 135.09 34.6 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.693 0 N-CA-C 106.992 -1.484 . . . . 0.0 106.992 178.672 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' H' H ' 32' ' ' ILE . . . . . 0.45 ' H ' HG22 ' E' ' 32' ' ' ILE . 34.8 pt -151.51 -169.02 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.759 0 CA-C-N 119.667 1.121 . . . . 0.0 109.826 -179.929 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.08 5.28 7.42 Favored Glycine 0 N--CA 1.467 0.706 0 N-CA-C 111.055 -0.818 . . . . 0.0 111.055 -179.979 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' H' H ' 34' ' ' LEU . . . . . 0.425 HD23 ' N ' ' H' ' 35' ' ' MET . 1.1 tt -75.44 135.24 40.73 Favored 'General case' 0 CA--C 1.545 0.784 0 N-CA-C 109.4 -0.593 . . . . 0.0 109.4 -179.744 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' H' H ' 35' ' ' MET . . . . . 0.425 ' N ' HD23 ' H' ' 34' ' ' LEU . 25.4 ttt -158.41 146.01 18.08 Favored 'General case' 0 N--CA 1.469 0.514 0 N-CA-C 108.698 -0.853 . . . . 0.0 108.698 178.882 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 1.5 m -148.91 163.83 4.57 Favored 'Isoleucine or valine' 0 C--N 1.35 0.594 0 N-CA-C 108.56 -0.904 . . . . 0.0 108.56 -179.467 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' H' H ' 37' ' ' GLY . . . . . 0.703 ' H ' HE22 ' H' ' 15' ' ' GLN . . . 55.29 68.29 1.76 Allowed Glycine 0 C--N 1.306 -1.087 0 CA-C-N 115.237 -0.892 . . . . 0.0 112.32 177.612 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.54 172.72 17.96 Favored Glycine 0 N--CA 1.475 1.24 0 N-CA-C 110.745 -0.942 . . . . 0.0 110.745 178.959 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' H' H ' 39' ' ' VAL . . . . . 0.43 HG12 ' H ' ' E' ' 39' ' ' VAL . 34.1 m -106.13 155.75 6.98 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.0 0 C-N-CA 123.32 0.648 . . . . 0.0 110.575 -179.497 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 25.9 t . . . . . 0 C--O 1.219 -0.533 0 O-C-N 123.991 0.807 . . . . 0.0 110.61 179.424 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 67.2 m-85 . . . . . 0 N--CA 1.475 0.788 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' I' I ' 5' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -144.12 142.48 30.61 Favored 'General case' 0 N--CA 1.482 1.153 0 N-CA-C 110.023 -0.362 . . . . 0.0 110.023 -179.931 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 45.1 t-80 -152.28 119.61 5.95 Favored 'General case' 0 N--CA 1.472 0.629 0 N-CA-C 109.503 -0.554 . . . . 0.0 109.503 178.824 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -71.96 144.81 48.77 Favored 'General case' 0 N--CA 1.469 0.481 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.105 -179.758 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' I' I ' 8' ' ' SER . . . . . 0.486 ' OG ' ' O ' ' F' ' 7' ' ' ASP . 51.7 p -164.95 -170.21 1.89 Allowed 'General case' 0 N--CA 1.474 0.742 0 CA-C-O 121.139 0.495 . . . . 0.0 110.547 178.956 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.27 47.72 1.4 Allowed Glycine 0 N--CA 1.479 1.518 0 N-CA-C 111.592 -0.603 . . . . 0.0 111.592 179.544 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 47.5 p90 -65.89 132.9 49.76 Favored 'General case' 0 N--CA 1.471 0.586 0 N-CA-C 111.883 0.327 . . . . 0.0 111.883 -179.789 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 48.4 mt-10 -91.57 151.13 20.87 Favored 'General case' 0 N--CA 1.478 0.936 0 CA-C-O 121.149 0.499 . . . . 0.0 110.013 178.654 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -154.75 127.32 1.06 Allowed 'Isoleucine or valine' 0 CA--C 1.551 0.983 0 N-CA-C 107.979 -1.119 . . . . 0.0 107.979 178.252 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 44.0 m-70 -134.83 146.2 49.06 Favored 'General case' 0 N--CA 1.479 0.993 0 CA-C-N 115.68 -0.691 . . . . 0.0 111.384 -178.149 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 6.0 t60 -166.31 96.87 0.59 Allowed 'General case' 0 N--CA 1.48 1.051 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.399 178.91 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' I' I ' 15' ' ' GLN . . . . . 0.69 HE22 ' H ' ' I' ' 37' ' ' GLY . 5.9 pt20 -108.17 -174.48 2.53 Favored 'General case' 0 CA--C 1.505 -0.762 0 N-CA-C 108.272 -1.01 . . . . 0.0 108.272 -179.731 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -164.3 97.84 0.81 Allowed 'General case' 0 N--CA 1.475 0.794 0 CA-C-N 114.58 -1.191 . . . . 0.0 108.043 178.698 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 6.4 mp -120.65 154.34 35.64 Favored 'General case' 0 N--CA 1.497 1.902 0 CA-C-O 121.215 0.531 . . . . 0.0 111.837 -177.938 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 42.9 t -112.72 125.16 69.95 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.949 0 N-CA-C 108.067 -1.086 . . . . 0.0 108.067 176.595 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 30.7 m-85 -125.71 121.37 33.24 Favored 'General case' 0 C--N 1.367 1.341 0 CA-C-N 115.585 -0.734 . . . . 0.0 110.815 -179.285 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 68.9 m-85 54.59 72.52 0.46 Allowed 'General case' 0 C--N 1.345 0.38 0 CA-C-N 115.916 -0.584 . . . . 0.0 111.49 178.27 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.33 -78.25 0.13 Allowed 'General case' 0 N--CA 1.473 0.72 0 N-CA-C 110.294 -0.262 . . . . 0.0 110.294 -178.971 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 40.9 tt0 -112.77 99.86 8.24 Favored 'General case' 0 C--N 1.323 -0.566 0 N-CA-C 107.978 -1.119 . . . . 0.0 107.978 -179.959 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 4.7 p30 -157.31 139.91 14.88 Favored 'General case' 0 N--CA 1.477 0.891 0 N-CA-C 111.487 0.18 . . . . 0.0 111.487 178.978 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' I' I ' 24' ' ' VAL . . . . . 0.434 ' HB ' ' H ' ' F' ' 25' ' ' GLY . 61.2 t -59.76 167.26 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.56 0 N-CA-C 107.567 -1.271 . . . . 0.0 107.567 177.243 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' I' I ' 25' ' ' GLY . . . . . 0.428 ' N ' HG12 ' I' ' 24' ' ' VAL . . . -120.34 49.62 0.87 Allowed Glycine 0 N--CA 1.479 1.516 0 N-CA-C 110.669 -0.972 . . . . 0.0 110.669 -179.494 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -63.73 -166.89 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.572 0 N-CA-C 110.036 -0.357 . . . . 0.0 110.036 179.881 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 26.4 t-20 -70.58 76.56 0.58 Allowed 'General case' 0 CA--C 1.533 0.294 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.584 179.983 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 97.9 mttt -73.65 143.63 46.2 Favored 'General case' 0 N--CA 1.475 0.816 0 N-CA-C 109.561 -0.533 . . . . 0.0 109.561 179.422 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.74 -166.31 1.22 Allowed Glycine 0 C--N 1.336 0.548 0 N-CA-C 110.016 -1.233 . . . . 0.0 110.016 178.647 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.24 114.11 26.74 Favored 'General case' 0 N--CA 1.473 0.721 0 C-N-CA 122.706 0.402 . . . . 0.0 110.315 179.937 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 75.1 mt -98.3 135.08 34.38 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.631 0 N-CA-C 106.94 -1.504 . . . . 0.0 106.94 178.695 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' I' I ' 32' ' ' ILE . . . . . 0.446 ' H ' HG22 ' F' ' 32' ' ' ILE . 35.1 pt -151.5 -169.16 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.831 0 CA-C-N 119.62 1.1 . . . . 0.0 109.771 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.36 5.11 7.53 Favored Glycine 0 N--CA 1.466 0.686 0 N-CA-C 111.054 -0.818 . . . . 0.0 111.054 -179.893 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' I' I ' 34' ' ' LEU . . . . . 0.425 HD23 ' N ' ' I' ' 35' ' ' MET . 1.1 tt -75.21 134.92 41.07 Favored 'General case' 0 N--CA 1.474 0.77 0 N-CA-C 109.336 -0.616 . . . . 0.0 109.336 -179.646 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' I' I ' 35' ' ' MET . . . . . 0.425 ' N ' HD23 ' I' ' 34' ' ' LEU . 24.7 ttt -158.06 145.97 18.55 Favored 'General case' 0 N--CA 1.47 0.555 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 178.906 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 1.5 m -149.08 163.67 4.41 Favored 'Isoleucine or valine' 0 C--N 1.35 0.616 0 N-CA-C 108.491 -0.929 . . . . 0.0 108.491 -179.455 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' I' I ' 37' ' ' GLY . . . . . 0.69 ' H ' HE22 ' I' ' 15' ' ' GLN . . . 55.25 68.58 1.61 Allowed Glycine 0 C--N 1.308 -1.015 0 CA-C-N 115.218 -0.901 . . . . 0.0 112.282 177.706 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.25 172.5 17.51 Favored Glycine 0 N--CA 1.475 1.234 0 N-CA-C 110.646 -0.982 . . . . 0.0 110.646 178.923 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' I' I ' 39' ' ' VAL . . . . . 0.443 HG12 ' H ' ' F' ' 39' ' ' VAL . 34.4 m -106.17 155.49 7.06 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.993 0 C-N-CA 123.185 0.594 . . . . 0.0 110.635 -179.382 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 25.9 t . . . . . 0 C--O 1.218 -0.559 0 O-C-N 123.955 0.784 . . . . 0.0 110.599 179.433 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 64.9 m-85 . . . . . 0 N--CA 1.474 0.77 0 N-CA-C 110.173 -0.306 . . . . 0.0 110.173 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -144.11 142.94 30.89 Favored 'General case' 0 N--CA 1.481 1.098 0 CA-C-O 120.925 0.393 . . . . 0.0 110.031 179.417 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 46.7 t-80 -152.83 118.99 5.49 Favored 'General case' 0 N--CA 1.472 0.654 0 N-CA-C 109.157 -0.683 . . . . 0.0 109.157 179.19 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' ASP . . . . . 0.508 ' O ' ' OG ' ' D' ' 8' ' ' SER . 4.3 m-20 -69.58 149.59 48.0 Favored 'General case' 0 N--CA 1.467 0.406 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.331 179.794 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 52.4 p -168.03 -173.27 2.02 Favored 'General case' 0 N--CA 1.484 1.243 0 CA-C-O 121.006 0.431 . . . . 0.0 110.698 179.107 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.79 46.49 1.49 Allowed Glycine 0 N--CA 1.481 1.686 0 CA-C-N 116.009 -0.541 . . . . 0.0 112.11 -179.941 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 49.1 p90 -65.12 132.43 49.14 Favored 'General case' 0 N--CA 1.473 0.685 0 O-C-N 122.687 -0.302 . . . . 0.0 111.561 179.631 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 49.2 mt-10 -91.83 152.13 20.26 Favored 'General case' 0 N--CA 1.477 0.889 0 N-CA-C 109.87 -0.419 . . . . 0.0 109.87 178.297 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -152.73 128.45 1.69 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.592 0 N-CA-C 107.849 -1.167 . . . . 0.0 107.849 178.248 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 44.5 m-70 -135.54 145.94 47.54 Favored 'General case' 0 N--CA 1.491 1.617 0 CA-C-N 119.011 0.823 . . . . 0.0 111.374 -179.107 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -166.9 97.25 0.53 Allowed 'General case' 0 N--CA 1.481 1.107 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.635 179.571 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 14.7 pt20 -109.69 -174.01 2.4 Favored 'General case' 0 CA--C 1.505 -0.788 0 N-CA-C 108.36 -0.978 . . . . 0.0 108.36 179.887 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -162.71 98.98 1.0 Allowed 'General case' 0 N--CA 1.472 0.669 0 CA-C-N 114.59 -1.186 . . . . 0.0 108.309 178.274 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 6.7 mp -121.45 155.55 34.64 Favored 'General case' 0 N--CA 1.497 1.901 0 CA-C-O 121.832 0.825 . . . . 0.0 110.938 -178.347 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 58.3 t -111.59 126.47 68.98 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.046 0 CA-C-O 117.894 -1.05 . . . . 0.0 108.344 177.742 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 29.2 m-85 -126.27 122.9 36.84 Favored 'General case' 0 N--CA 1.496 1.862 0 CA-C-N 120.147 1.34 . . . . 0.0 110.284 179.281 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 68.1 m-85 54.02 74.02 0.35 Allowed 'General case' 0 N--CA 1.47 0.538 0 CA-C-O 121.398 0.618 . . . . 0.0 111.66 178.729 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -79.77 -78.29 0.16 Allowed 'General case' 0 C--N 1.353 0.734 0 CA-C-N 115.175 -0.92 . . . . 0.0 110.442 -179.902 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 40.8 tt0 -113.15 100.19 8.4 Favored 'General case' 0 N--CA 1.47 0.565 0 N-CA-C 108.327 -0.99 . . . . 0.0 108.327 179.603 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 4.4 p30 -158.74 138.72 12.09 Favored 'General case' 0 N--CA 1.485 1.282 0 CA-C-O 119.403 -0.332 . . . . 0.0 111.226 179.271 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.41 HG12 ' N ' ' A' ' 25' ' ' GLY . 57.4 t -59.83 163.9 0.87 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.783 0 N-CA-C 108.224 -1.028 . . . . 0.0 108.224 176.932 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.46 ' H ' ' HB ' ' D' ' 24' ' ' VAL . . . -117.06 47.15 1.06 Allowed Glycine 0 N--CA 1.477 1.39 0 N-CA-C 111.753 -0.539 . . . . 0.0 111.753 -179.219 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -60.11 -167.79 0.01 OUTLIER 'General case' 0 N--CA 1.469 0.512 0 O-C-N 123.852 0.384 . . . . 0.0 110.405 179.272 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 26.1 t-20 -70.98 81.05 0.66 Allowed 'General case' 0 CA--C 1.531 0.219 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.212 179.6 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 97.7 mttt -77.93 143.16 37.9 Favored 'General case' 0 N--CA 1.471 0.582 0 N-CA-C 109.163 -0.68 . . . . 0.0 109.163 179.396 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.67 -167.51 1.06 Allowed Glycine 0 CA--C 1.525 0.707 0 N-CA-C 109.926 -1.269 . . . . 0.0 109.926 178.962 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.91 115.02 28.67 Favored 'General case' 0 N--CA 1.476 0.846 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 179.677 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 72.3 mt -98.68 134.46 37.34 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.518 0 N-CA-C 107.025 -1.472 . . . . 0.0 107.025 179.021 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 29.3 pt -150.68 -172.0 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.708 0 CA-C-O 121.209 0.528 . . . . 0.0 111.184 -179.14 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.63 4.73 10.5 Favored Glycine 0 CA--C 1.527 0.785 0 N-CA-C 110.699 -0.96 . . . . 0.0 110.699 179.882 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.431 HD23 ' N ' ' A' ' 35' ' ' MET . 1.1 tt -75.43 135.16 40.75 Favored 'General case' 0 CA--C 1.544 0.726 0 N-CA-C 109.405 -0.591 . . . . 0.0 109.405 -179.56 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' MET . . . . . 0.431 ' N ' HD23 ' A' ' 34' ' ' LEU . 27.2 ttt -158.54 146.64 18.33 Favored 'General case' 0 N--CA 1.47 0.546 0 N-CA-C 108.557 -0.905 . . . . 0.0 108.557 178.705 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 1.7 m -149.16 165.49 3.78 Favored 'Isoleucine or valine' 0 C--N 1.349 0.579 0 N-CA-C 108.056 -1.09 . . . . 0.0 108.056 -179.584 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.19 68.36 1.73 Allowed Glycine 0 C--N 1.305 -1.158 0 CA-C-N 115.521 -0.763 . . . . 0.0 112.316 177.581 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.32 177.32 21.73 Favored Glycine 0 N--CA 1.474 1.192 0 N-CA-C 111.008 -0.837 . . . . 0.0 111.008 178.514 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.437 ' H ' HG12 ' D' ' 39' ' ' VAL . 34.3 m -109.81 155.59 10.95 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.623 0 C-N-CA 123.432 0.693 . . . . 0.0 110.354 -179.643 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 23.4 t . . . . . 0 C--O 1.219 -0.501 0 O-C-N 124.031 0.832 . . . . 0.0 110.663 179.633 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 63.9 m-85 . . . . . 0 N--CA 1.475 0.804 0 N-CA-C 110.154 -0.313 . . . . 0.0 110.154 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -144.32 141.92 30.07 Favored 'General case' 0 N--CA 1.481 1.089 0 N-CA-C 109.881 -0.414 . . . . 0.0 109.881 179.513 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 47.2 t-80 -151.71 118.55 5.8 Favored 'General case' 0 N--CA 1.473 0.715 0 N-CA-C 109.319 -0.623 . . . . 0.0 109.319 178.989 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 7' ' ' ASP . . . . . 0.449 ' O ' ' OG ' ' E' ' 8' ' ' SER . 3.9 m-20 -69.2 148.9 49.21 Favored 'General case' 0 N--CA 1.469 0.485 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.525 179.761 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 8' ' ' SER . . . . . . . . . . . . . 49.4 p -167.52 -173.49 2.22 Favored 'General case' 0 N--CA 1.481 1.125 0 CA-C-O 120.974 0.416 . . . . 0.0 110.653 179.155 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.26 46.92 1.38 Allowed Glycine 0 N--CA 1.482 1.728 0 CA-C-N 116.007 -0.542 . . . . 0.0 112.158 179.987 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 48.7 p90 -65.74 132.33 48.48 Favored 'General case' 0 N--CA 1.472 0.668 0 O-C-N 122.733 -0.274 . . . . 0.0 111.618 179.663 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 48.6 mt-10 -91.52 152.32 20.37 Favored 'General case' 0 N--CA 1.475 0.819 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 178.167 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -153.05 128.25 1.54 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.581 0 N-CA-C 107.783 -1.191 . . . . 0.0 107.783 178.148 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 45.5 m-70 -135.4 145.86 47.72 Favored 'General case' 0 N--CA 1.493 1.692 0 CA-C-N 118.843 0.747 . . . . 0.0 111.37 -179.141 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -166.57 97.15 0.56 Allowed 'General case' 0 N--CA 1.48 1.05 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.651 179.485 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 14.9 pt20 -109.54 -173.62 2.3 Favored 'General case' 0 CA--C 1.507 -0.7 0 N-CA-C 108.324 -0.991 . . . . 0.0 108.324 179.854 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -163.2 98.82 0.94 Allowed 'General case' 0 N--CA 1.473 0.696 0 CA-C-N 114.699 -1.137 . . . . 0.0 108.279 178.357 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 6.6 mp -121.17 155.56 34.27 Favored 'General case' 0 N--CA 1.498 1.925 0 CA-C-O 121.894 0.854 . . . . 0.0 110.927 -178.298 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 60.4 t -111.77 127.69 68.78 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.082 0 N-CA-C 108.037 -1.097 . . . . 0.0 108.037 177.538 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 28.5 m-85 -127.66 122.34 32.78 Favored 'General case' 0 N--CA 1.495 1.821 0 CA-C-N 119.665 1.12 . . . . 0.0 110.161 179.566 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 67.4 m-85 53.96 73.65 0.37 Allowed 'General case' 0 CA--C 1.54 0.571 0 CA-C-O 121.505 0.669 . . . . 0.0 111.67 178.615 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -79.65 -78.0 0.17 Allowed 'General case' 0 C--N 1.351 0.649 0 CA-C-N 115.078 -0.965 . . . . 0.0 110.435 -179.917 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 41.0 tt0 -113.4 99.62 7.92 Favored 'General case' 0 N--CA 1.47 0.56 0 N-CA-C 108.499 -0.926 . . . . 0.0 108.499 179.624 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -157.99 139.15 13.35 Favored 'General case' 0 C--O 1.205 -1.266 0 CA-C-O 119.447 -0.311 . . . . 0.0 111.208 179.204 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 59.9 t -60.15 163.49 0.98 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.824 0 N-CA-C 108.212 -1.033 . . . . 0.0 108.212 176.976 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 25' ' ' GLY . . . . . 0.472 ' H ' ' HB ' ' E' ' 24' ' ' VAL . . . -116.42 47.63 1.02 Allowed Glycine 0 N--CA 1.476 1.357 0 N-CA-C 111.628 -0.589 . . . . 0.0 111.628 -179.167 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -60.69 -167.68 0.01 OUTLIER 'General case' 0 N--CA 1.468 0.46 0 O-C-N 123.782 0.342 . . . . 0.0 110.306 179.414 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 26.0 t-20 -71.17 81.01 0.71 Allowed 'General case' 0 CA--C 1.532 0.27 0 N-CA-C 110.074 -0.343 . . . . 0.0 110.074 179.616 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 97.7 mttt -77.9 143.1 38.01 Favored 'General case' 0 N--CA 1.472 0.638 0 N-CA-C 109.105 -0.702 . . . . 0.0 109.105 179.442 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.49 -167.42 0.97 Allowed Glycine 0 C--N 1.337 0.618 0 N-CA-C 109.92 -1.272 . . . . 0.0 109.92 178.894 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -100.25 114.78 28.49 Favored 'General case' 0 N--CA 1.475 0.786 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 179.757 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 71.5 mt -98.46 134.51 36.8 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.501 0 N-CA-C 107.105 -1.443 . . . . 0.0 107.105 178.889 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 30.1 pt -150.31 -171.37 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.647 0 CA-C-O 121.115 0.484 . . . . 0.0 111.227 -179.166 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.1 4.57 8.11 Favored Glycine 0 CA--C 1.526 0.752 0 N-CA-C 110.835 -0.906 . . . . 0.0 110.835 179.748 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 34' ' ' LEU . . . . . 0.421 HD23 ' N ' ' B' ' 35' ' ' MET . 1.1 tt -75.11 135.08 41.18 Favored 'General case' 0 CA--C 1.544 0.726 0 N-CA-C 109.376 -0.601 . . . . 0.0 109.376 -179.554 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 35' ' ' MET . . . . . 0.421 ' N ' HD23 ' B' ' 34' ' ' LEU . 27.1 ttt -158.24 146.63 18.77 Favored 'General case' 0 N--CA 1.472 0.628 0 N-CA-C 108.57 -0.9 . . . . 0.0 108.57 178.547 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 1.6 m -149.29 165.45 3.7 Favored 'Isoleucine or valine' 0 C--N 1.347 0.48 0 N-CA-C 108.018 -1.105 . . . . 0.0 108.018 -179.503 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 54.81 68.67 1.56 Allowed Glycine 0 C--N 1.305 -1.158 0 CA-C-N 115.354 -0.839 . . . . 0.0 112.23 177.654 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 146.95 176.89 21.09 Favored Glycine 0 N--CA 1.474 1.194 0 N-CA-C 111.106 -0.797 . . . . 0.0 111.106 178.612 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 39' ' ' VAL . . . . . 0.436 ' H ' HG12 ' E' ' 39' ' ' VAL . 34.1 m -109.68 155.22 10.92 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.698 0 C-N-CA 123.412 0.685 . . . . 0.0 110.415 -179.501 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 23.2 t . . . . . 0 C--O 1.218 -0.569 0 O-C-N 123.991 0.807 . . . . 0.0 110.331 179.552 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 62.0 m-85 . . . . . 0 N--CA 1.476 0.87 0 N-CA-C 110.179 -0.304 . . . . 0.0 110.179 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -144.38 142.27 30.24 Favored 'General case' 0 N--CA 1.482 1.139 0 N-CA-C 109.994 -0.373 . . . . 0.0 109.994 179.426 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 46.7 t-80 -152.19 118.97 5.74 Favored 'General case' 0 N--CA 1.472 0.673 0 N-CA-C 109.216 -0.661 . . . . 0.0 109.216 179.216 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 7' ' ' ASP . . . . . 0.492 ' O ' ' OG ' ' F' ' 8' ' ' SER . 4.1 m-20 -69.69 149.11 48.41 Favored 'General case' 0 N--CA 1.467 0.423 0 CA-C-N 116.356 -0.384 . . . . 0.0 110.485 179.793 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 8' ' ' SER . . . . . . . . . . . . . 52.3 p -167.7 -173.18 2.08 Favored 'General case' 0 N--CA 1.483 1.192 0 CA-C-O 121.018 0.437 . . . . 0.0 110.604 179.051 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.01 46.8 1.42 Allowed Glycine 0 N--CA 1.481 1.651 0 CA-C-N 115.898 -0.592 . . . . 0.0 112.201 -179.978 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 48.4 p90 -65.81 132.34 48.47 Favored 'General case' 0 N--CA 1.474 0.737 0 CA-C-O 120.699 0.285 . . . . 0.0 111.532 179.805 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 48.2 mt-10 -91.4 152.4 20.42 Favored 'General case' 0 N--CA 1.474 0.759 0 CA-C-O 121.001 0.429 . . . . 0.0 109.871 178.141 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -152.96 128.29 1.57 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.514 0 N-CA-C 107.81 -1.181 . . . . 0.0 107.81 178.193 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 42.8 m-70 -135.42 145.87 47.68 Favored 'General case' 0 N--CA 1.492 1.647 0 CA-C-N 118.939 0.79 . . . . 0.0 111.309 -179.141 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -166.74 97.19 0.55 Allowed 'General case' 0 N--CA 1.481 1.09 0 CA-C-N 116.414 -0.357 . . . . 0.0 110.571 179.481 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 14.8 pt20 -109.58 -173.68 2.32 Favored 'General case' 0 CA--C 1.504 -0.799 0 N-CA-C 108.381 -0.97 . . . . 0.0 108.381 179.884 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -163.19 98.91 0.94 Allowed 'General case' 0 N--CA 1.471 0.601 0 CA-C-N 114.695 -1.139 . . . . 0.0 108.304 178.332 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 6.6 mp -121.37 155.35 34.98 Favored 'General case' 0 N--CA 1.497 1.906 0 CA-C-O 121.846 0.832 . . . . 0.0 111.0 -178.32 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 61.0 t -111.43 127.45 68.57 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.065 0 N-CA-C 108.183 -1.043 . . . . 0.0 108.183 177.532 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 28.5 m-85 -127.28 122.52 34.07 Favored 'General case' 0 N--CA 1.494 1.747 0 CA-C-N 119.674 1.125 . . . . 0.0 110.152 179.527 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 68.0 m-85 53.57 73.98 0.34 Allowed 'General case' 0 CA--C 1.539 0.545 0 CA-C-O 121.502 0.668 . . . . 0.0 111.745 178.615 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -79.88 -78.12 0.17 Allowed 'General case' 0 C--N 1.351 0.644 0 CA-C-N 114.999 -1.001 . . . . 0.0 110.342 -179.864 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 40.9 tt0 -113.24 99.86 8.13 Favored 'General case' 0 N--CA 1.47 0.556 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 179.675 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 4.4 p30 -158.41 138.73 12.51 Favored 'General case' 0 N--CA 1.484 1.236 0 CA-C-O 119.46 -0.305 . . . . 0.0 111.23 179.112 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 24' ' ' VAL . . . . . 0.405 HG12 ' N ' ' C' ' 25' ' ' GLY . 62.1 t -59.55 164.23 0.8 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.87 0 N-CA-C 108.124 -1.065 . . . . 0.0 108.124 177.107 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 25' ' ' GLY . . . . . 0.471 ' H ' ' HB ' ' F' ' 24' ' ' VAL . . . -117.14 47.3 1.05 Allowed Glycine 0 N--CA 1.477 1.368 0 N-CA-C 111.553 -0.619 . . . . 0.0 111.553 -179.298 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -60.31 -168.11 0.01 OUTLIER 'General case' 0 N--CA 1.468 0.465 0 O-C-N 123.747 0.322 . . . . 0.0 110.335 179.301 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 25.9 t-20 -70.78 80.96 0.62 Allowed 'General case' 0 N--CA 1.465 0.317 0 N-CA-C 110.087 -0.338 . . . . 0.0 110.087 179.478 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 97.7 mttt -77.76 142.91 38.38 Favored 'General case' 0 N--CA 1.472 0.665 0 N-CA-C 109.151 -0.685 . . . . 0.0 109.151 179.32 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.51 -167.87 1.06 Allowed Glycine 0 CA--C 1.524 0.621 0 N-CA-C 109.938 -1.265 . . . . 0.0 109.938 178.826 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.5 114.84 28.06 Favored 'General case' 0 N--CA 1.477 0.894 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 179.708 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 71.5 mt -98.64 134.21 38.19 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.591 0 N-CA-C 106.98 -1.489 . . . . 0.0 106.98 178.85 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 29.9 pt -150.18 -171.57 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.352 0.713 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.21 -179.217 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.2 4.81 8.86 Favored Glycine 0 CA--C 1.526 0.767 0 N-CA-C 110.795 -0.922 . . . . 0.0 110.795 179.815 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 34' ' ' LEU . . . . . 0.429 HD23 ' N ' ' C' ' 35' ' ' MET . 1.1 tt -75.32 135.15 40.9 Favored 'General case' 0 CA--C 1.545 0.759 0 N-CA-C 109.273 -0.639 . . . . 0.0 109.273 -179.579 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 35' ' ' MET . . . . . 0.429 ' N ' HD23 ' C' ' 34' ' ' LEU . 27.3 ttt -158.41 146.4 18.35 Favored 'General case' 0 N--CA 1.471 0.585 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 178.734 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 1.6 m -149.25 165.44 3.73 Favored 'Isoleucine or valine' 0 C--N 1.348 0.506 0 N-CA-C 107.985 -1.117 . . . . 0.0 107.985 -179.476 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.08 68.56 1.62 Allowed Glycine 0 C--N 1.306 -1.13 0 CA-C-N 115.384 -0.825 . . . . 0.0 112.186 177.563 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.0 177.21 21.39 Favored Glycine 0 N--CA 1.473 1.132 0 N-CA-C 111.019 -0.832 . . . . 0.0 111.019 178.579 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 39' ' ' VAL . . . . . 0.437 ' H ' HG12 ' F' ' 39' ' ' VAL . 34.4 m -109.94 155.57 11.1 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.681 0 C-N-CA 123.401 0.68 . . . . 0.0 110.351 -179.523 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 23.6 t . . . . . 0 C--O 1.219 -0.514 0 O-C-N 124.021 0.826 . . . . 0.0 110.478 179.645 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 72.1 m-85 . . . . . 0 N--CA 1.474 0.748 0 N-CA-C 108.608 -0.886 . . . . 0.0 108.608 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' D' D ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -146.89 140.56 25.77 Favored 'General case' 0 N--CA 1.475 0.822 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.276 179.794 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 43.6 t-80 -149.78 123.69 9.33 Favored 'General case' 0 CA--C 1.545 0.78 0 N-CA-C 108.19 -1.041 . . . . 0.0 108.19 175.005 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' D' D ' 7' ' ' ASP . . . . . 0.593 ' O ' ' OG ' ' G' ' 8' ' ' SER . 2.9 m-20 -63.89 132.83 51.96 Favored 'General case' 0 C--N 1.321 -0.664 0 C-N-CA 127.068 2.147 . . . . 0.0 114.479 174.269 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' D' D ' 8' ' ' SER . . . . . 0.508 ' OG ' ' O ' ' A' ' 7' ' ' ASP . 51.9 p -154.8 -170.22 3.44 Favored 'General case' 0 N--CA 1.485 1.313 0 CA-C-N 120.046 1.294 . . . . 0.0 111.317 175.159 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.38 47.89 1.18 Allowed Glycine 0 N--CA 1.481 1.639 0 C-N-CA 124.553 1.073 . . . . 0.0 110.419 174.688 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 50.9 p90 -61.06 131.05 49.34 Favored 'General case' 0 N--CA 1.472 0.634 0 N-CA-C 112.725 0.639 . . . . 0.0 112.725 177.928 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 48.4 mt-10 -88.94 150.96 22.59 Favored 'General case' 0 N--CA 1.481 1.086 0 CA-C-N 117.961 0.346 . . . . 0.0 110.752 175.125 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -149.57 130.04 4.35 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.533 0 N-CA-C 107.518 -1.29 . . . . 0.0 107.518 173.119 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 40.9 m-70 -130.03 148.36 51.87 Favored 'General case' 0 N--CA 1.484 1.249 0 CA-C-N 118.098 0.408 . . . . 0.0 111.98 176.4 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -165.35 104.47 0.74 Allowed 'General case' 0 N--CA 1.481 1.098 0 N-CA-C 109.079 -0.711 . . . . 0.0 109.079 172.352 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 14.8 pt20 -113.36 -175.89 2.77 Favored 'General case' 0 CA--C 1.496 -1.127 0 N-CA-C 108.227 -1.027 . . . . 0.0 108.227 178.669 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -159.41 106.22 1.71 Allowed 'General case' 0 N--CA 1.468 0.444 0 N-CA-C 106.552 -1.648 . . . . 0.0 106.552 175.352 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 5.5 mp -128.01 152.87 47.4 Favored 'General case' 0 N--CA 1.499 2.008 0 CA-C-O 122.187 0.994 . . . . 0.0 110.396 179.795 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 38.4 t -101.01 131.66 48.24 Favored 'Isoleucine or valine' 0 C--O 1.258 1.518 0 CA-C-O 116.845 -1.55 . . . . 0.0 109.741 174.102 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 26.6 m-85 -130.27 126.39 37.15 Favored 'General case' 0 N--CA 1.491 1.617 0 CA-C-N 120.074 1.306 . . . . 0.0 109.417 173.61 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 68.5 m-85 55.27 71.67 0.53 Allowed 'General case' 0 C--N 1.35 0.597 0 CA-C-N 115.508 -0.769 . . . . 0.0 111.441 176.664 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -82.13 -73.21 0.4 Allowed 'General case' 0 C--N 1.353 0.721 0 CA-C-O 118.415 -0.803 . . . . 0.0 111.197 -177.693 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 41.1 tt0 -116.45 103.9 10.9 Favored 'General case' 0 N--CA 1.48 1.074 0 N-CA-C 106.434 -1.691 . . . . 0.0 106.434 176.124 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -151.82 138.5 18.79 Favored 'General case' 0 N--CA 1.477 0.896 0 CA-C-O 116.592 -1.671 . . . . 0.0 113.559 177.983 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' D' D ' 24' ' ' VAL . . . . . 0.46 ' HB ' ' H ' ' A' ' 25' ' ' GLY . 63.5 t -62.26 166.41 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.267 0 CA-C-N 121.264 1.847 . . . . 0.0 107.964 174.961 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' D' D ' 25' ' ' GLY . . . . . 0.531 ' H ' ' HB ' ' G' ' 24' ' ' VAL . . . -116.78 51.04 0.75 Allowed Glycine 0 N--CA 1.479 1.556 0 CA-C-O 118.964 -0.909 . . . . 0.0 111.654 178.593 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -57.1 -170.91 0.01 OUTLIER 'General case' 0 C--N 1.322 -0.627 0 C-N-CA 123.688 0.795 . . . . 0.0 111.639 175.768 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 26.7 t-20 -72.54 86.81 1.19 Allowed 'General case' 0 C--N 1.347 0.475 0 C-N-CA 119.286 -0.965 . . . . 0.0 108.572 177.928 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 97.2 mttt -83.04 146.01 28.97 Favored 'General case' 0 N--CA 1.473 0.716 0 N-CA-C 107.948 -1.13 . . . . 0.0 107.948 179.281 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.45 -165.61 0.72 Allowed Glycine 0 C--N 1.337 0.609 0 N-CA-C 110.356 -1.098 . . . . 0.0 110.356 179.524 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -102.04 116.04 31.83 Favored 'General case' 0 N--CA 1.472 0.627 0 N-CA-C 109.36 -0.607 . . . . 0.0 109.36 179.594 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 80.8 mt -102.59 142.22 17.15 Favored 'Isoleucine or valine' 0 C--N 1.357 0.933 0 N-CA-C 104.568 -2.382 . . . . 0.0 104.568 179.979 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' D' D ' 32' ' ' ILE . . . . . 0.444 HG22 ' H ' ' G' ' 32' ' ' ILE . 30.0 pt -157.37 -172.59 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.482 1.148 0 CA-C-O 120.84 0.353 . . . . 0.0 110.189 -177.479 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 64.23 4.31 11.72 Favored Glycine 0 N--CA 1.466 0.668 0 N-CA-C 110.27 -1.132 . . . . 0.0 110.27 -178.917 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 1.3 tt -76.29 140.28 41.45 Favored 'General case' 0 CA--C 1.543 0.708 0 N-CA-C 107.797 -1.186 . . . . 0.0 107.797 -178.142 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 26.8 ttt -156.45 156.17 33.33 Favored 'General case' 0 C--O 1.244 0.782 0 N-CA-C 107.774 -1.195 . . . . 0.0 107.774 174.436 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 1.8 m -158.04 164.05 1.14 Allowed 'Isoleucine or valine' 0 CA--C 1.515 -0.399 0 N-CA-C 107.53 -1.285 . . . . 0.0 107.53 177.973 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 61.42 63.66 4.67 Favored Glycine 0 CA--C 1.526 0.742 0 C-N-CA 119.773 -1.203 . . . . 0.0 112.101 177.212 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 145.71 177.87 20.77 Favored Glycine 0 N--CA 1.478 1.469 0 CA-C-N 118.388 1.094 . . . . 0.0 111.665 179.885 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' D' D ' 39' ' ' VAL . . . . . 0.437 HG12 ' H ' ' A' ' 39' ' ' VAL . 35.2 m -112.64 152.36 14.43 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.881 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -176.89 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 23.5 t . . . . . 0 CA--C 1.522 -0.12 0 CA-C-O 116.166 -1.873 . . . . 0.0 109.597 178.315 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 63.2 m-85 . . . . . 0 N--CA 1.477 0.902 0 N-CA-C 110.27 -0.27 . . . . 0.0 110.27 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' E' E ' 5' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -143.6 142.69 31.17 Favored 'General case' 0 N--CA 1.48 1.039 0 CA-C-O 120.857 0.361 . . . . 0.0 110.163 179.356 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 45.7 t-80 -152.27 119.16 5.78 Favored 'General case' 0 N--CA 1.473 0.707 0 N-CA-C 109.194 -0.669 . . . . 0.0 109.194 179.027 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' E' E ' 7' ' ' ASP . . . . . 0.441 ' O ' ' OG ' ' H' ' 8' ' ' SER . 3.9 m-20 -70.23 149.26 47.66 Favored 'General case' 0 N--CA 1.469 0.501 0 CA-C-N 116.425 -0.352 . . . . 0.0 110.633 179.805 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' E' E ' 8' ' ' SER . . . . . 0.449 ' OG ' ' O ' ' B' ' 7' ' ' ASP . 44.5 p -168.68 -171.69 1.46 Allowed 'General case' 0 N--CA 1.484 1.234 0 CA-C-O 121.02 0.438 . . . . 0.0 110.842 178.591 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.05 47.02 1.38 Allowed Glycine 0 N--CA 1.478 1.476 0 CA-C-N 115.946 -0.57 . . . . 0.0 111.958 179.905 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 46.5 p90 -65.12 132.91 50.41 Favored 'General case' 0 N--CA 1.474 0.738 0 N-CA-C 111.881 0.326 . . . . 0.0 111.881 -179.873 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 48.9 mt-10 -91.45 152.71 20.26 Favored 'General case' 0 N--CA 1.479 0.989 0 CA-C-O 121.13 0.49 . . . . 0.0 109.75 177.885 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -154.58 127.59 1.13 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.538 0 N-CA-C 107.849 -1.167 . . . . 0.0 107.849 178.093 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 43.3 m-70 -135.89 143.97 45.3 Favored 'General case' 0 N--CA 1.482 1.135 0 CA-C-O 120.857 0.36 . . . . 0.0 111.609 -178.049 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -165.57 96.72 0.66 Allowed 'General case' 0 N--CA 1.484 1.256 0 CA-C-N 116.442 -0.345 . . . . 0.0 110.693 179.681 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 15.0 pt20 -108.71 -173.67 2.33 Favored 'General case' 0 CA--C 1.507 -0.688 0 N-CA-C 108.56 -0.904 . . . . 0.0 108.56 179.909 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -162.87 98.11 0.96 Allowed 'General case' 0 N--CA 1.477 0.903 0 CA-C-N 114.693 -1.139 . . . . 0.0 108.376 178.351 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 6.5 mp -120.07 155.48 32.87 Favored 'General case' 0 N--CA 1.495 1.78 0 CA-C-O 121.604 0.716 . . . . 0.0 111.5 -177.87 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 48.9 t -113.61 124.5 70.31 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.244 0 N-CA-C 108.249 -1.019 . . . . 0.0 108.249 177.167 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 31.3 m-85 -124.73 121.69 35.36 Favored 'General case' 0 N--CA 1.49 1.535 0 CA-C-O 120.921 0.391 . . . . 0.0 110.792 -179.769 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 70.0 m-85 54.75 73.21 0.42 Allowed 'General case' 0 N--CA 1.469 0.511 0 CA-C-N 115.969 -0.559 . . . . 0.0 111.281 178.219 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -78.39 -78.72 0.14 Allowed 'General case' 0 C--N 1.345 0.377 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.358 -179.594 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 40.4 tt0 -112.55 100.09 8.47 Favored 'General case' 0 C--N 1.325 -0.474 0 N-CA-C 108.467 -0.938 . . . . 0.0 108.467 179.758 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -157.31 138.5 13.6 Favored 'General case' 0 C--O 1.203 -1.369 0 CA-C-O 119.371 -0.347 . . . . 0.0 111.553 179.287 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' E' E ' 24' ' ' VAL . . . . . 0.472 ' HB ' ' H ' ' B' ' 25' ' ' GLY . 59.3 t -58.02 168.52 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.903 0 N-CA-C 107.663 -1.236 . . . . 0.0 107.663 176.615 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' E' E ' 25' ' ' GLY . . . . . 0.427 ' H ' ' HB ' ' H' ' 24' ' ' VAL . . . -122.05 48.44 0.95 Allowed Glycine 0 N--CA 1.476 1.325 0 N-CA-C 110.735 -0.946 . . . . 0.0 110.735 -179.104 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -61.93 -167.41 0.01 OUTLIER 'General case' 0 N--CA 1.47 0.559 0 CA-C-O 120.729 0.3 . . . . 0.0 110.514 179.74 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 26.6 t-20 -70.34 77.33 0.55 Allowed 'General case' 0 N--CA 1.465 0.285 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.45 -179.939 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 97.8 mttt -74.69 143.55 44.16 Favored 'General case' 0 N--CA 1.474 0.765 0 N-CA-C 109.646 -0.502 . . . . 0.0 109.646 179.484 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.29 -167.44 1.29 Allowed Glycine 0 CA--C 1.522 0.496 0 N-CA-C 110.339 -1.105 . . . . 0.0 110.339 178.71 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.56 114.26 27.17 Favored 'General case' 0 N--CA 1.476 0.838 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 179.693 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 70.8 mt -98.32 134.23 37.64 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.35 0 N-CA-C 106.812 -1.551 . . . . 0.0 106.812 179.02 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' E' E ' 32' ' ' ILE . . . . . 0.439 HG22 ' H ' ' H' ' 32' ' ' ILE . 30.9 pt -150.24 -169.8 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.149 0 CA-C-O 120.998 0.428 . . . . 0.0 110.785 -179.313 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.41 5.2 6.02 Favored Glycine 0 CA--C 1.531 1.056 0 N-CA-C 111.288 -0.725 . . . . 0.0 111.288 -179.781 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' E' E ' 34' ' ' LEU . . . . . 0.419 HD23 ' N ' ' E' ' 35' ' ' MET . 1.1 tt -74.88 135.64 41.52 Favored 'General case' 0 CA--C 1.547 0.86 0 N-CA-C 109.304 -0.628 . . . . 0.0 109.304 -179.597 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' E' E ' 35' ' ' MET . . . . . 0.419 ' N ' HD23 ' E' ' 34' ' ' LEU . 26.6 ttt -158.82 145.57 17.22 Favored 'General case' 0 N--CA 1.474 0.734 0 N-CA-C 108.638 -0.875 . . . . 0.0 108.638 178.811 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 1.4 m -148.53 165.44 4.61 Favored 'Isoleucine or valine' 0 C--N 1.347 0.495 0 N-CA-C 108.388 -0.967 . . . . 0.0 108.388 -179.546 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 54.56 68.27 1.76 Allowed Glycine 0 C--N 1.308 -0.998 0 CA-C-N 115.266 -0.879 . . . . 0.0 112.1 177.573 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 146.81 174.28 18.77 Favored Glycine 0 N--CA 1.472 1.081 0 N-CA-C 111.381 -0.687 . . . . 0.0 111.381 178.685 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' E' E ' 39' ' ' VAL . . . . . 0.436 HG12 ' H ' ' B' ' 39' ' ' VAL . 33.1 m -107.58 154.97 8.47 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.768 0 C-N-CA 123.624 0.77 . . . . 0.0 110.568 -178.843 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 25.2 t . . . . . 0 C--O 1.219 -0.535 0 O-C-N 124.263 0.977 . . . . 0.0 110.263 179.802 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 63.8 m-85 . . . . . 0 N--CA 1.474 0.752 0 N-CA-C 110.199 -0.297 . . . . 0.0 110.199 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' F' F ' 5' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -143.51 143.26 31.48 Favored 'General case' 0 N--CA 1.477 0.908 0 CA-C-O 120.817 0.342 . . . . 0.0 110.195 179.318 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 46.1 t-80 -152.98 118.87 5.39 Favored 'General case' 0 N--CA 1.473 0.72 0 N-CA-C 109.275 -0.639 . . . . 0.0 109.275 179.055 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' F' F ' 7' ' ' ASP . . . . . 0.483 ' O ' ' OG ' ' I' ' 8' ' ' SER . 3.9 m-20 -70.2 149.03 47.92 Favored 'General case' 0 N--CA 1.468 0.447 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.68 179.981 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' F' F ' 8' ' ' SER . . . . . 0.492 ' OG ' ' O ' ' C' ' 7' ' ' ASP . 41.7 p -168.56 -171.74 1.5 Allowed 'General case' 0 N--CA 1.486 1.35 0 CA-C-O 121.039 0.447 . . . . 0.0 110.936 178.679 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.14 46.69 1.42 Allowed Glycine 0 N--CA 1.478 1.492 0 CA-C-N 115.951 -0.568 . . . . 0.0 111.984 179.955 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 46.3 p90 -64.65 132.74 50.57 Favored 'General case' 0 N--CA 1.474 0.734 0 O-C-N 122.623 -0.34 . . . . 0.0 111.913 -179.866 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 49.2 mt-10 -91.27 152.53 20.46 Favored 'General case' 0 N--CA 1.48 1.036 0 CA-C-O 121.158 0.504 . . . . 0.0 109.796 177.777 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -154.43 127.06 1.07 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.584 0 N-CA-C 107.828 -1.175 . . . . 0.0 107.828 178.13 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 42.0 m-70 -135.47 143.86 46.09 Favored 'General case' 0 N--CA 1.485 1.279 0 CA-C-O 120.849 0.357 . . . . 0.0 111.558 -178.045 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -165.32 97.11 0.69 Allowed 'General case' 0 N--CA 1.483 1.221 0 CA-C-N 116.43 -0.35 . . . . 0.0 110.771 179.754 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 15.0 pt20 -109.48 -174.17 2.44 Favored 'General case' 0 CA--C 1.503 -0.851 0 N-CA-C 108.629 -0.878 . . . . 0.0 108.629 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -162.22 98.46 1.04 Allowed 'General case' 0 N--CA 1.474 0.734 0 CA-C-N 114.694 -1.139 . . . . 0.0 108.401 178.384 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 6.4 mp -120.36 155.28 33.7 Favored 'General case' 0 N--CA 1.494 1.757 0 CA-C-O 121.532 0.682 . . . . 0.0 111.518 -177.854 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 50.2 t -113.41 124.2 69.81 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.246 0 N-CA-C 108.341 -0.985 . . . . 0.0 108.341 177.257 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 31.2 m-85 -124.56 121.58 35.18 Favored 'General case' 0 N--CA 1.489 1.49 0 CA-C-O 120.91 0.386 . . . . 0.0 110.796 -179.846 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 69.0 m-85 54.79 73.79 0.39 Allowed 'General case' 0 N--CA 1.468 0.437 0 CA-C-N 115.938 -0.574 . . . . 0.0 111.464 178.399 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -78.98 -78.31 0.15 Allowed 'General case' 0 C--N 1.344 0.359 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.537 -179.607 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 40.8 tt0 -112.76 100.09 8.42 Favored 'General case' 0 C--N 1.325 -0.471 0 N-CA-C 108.341 -0.985 . . . . 0.0 108.341 179.664 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -157.53 138.65 13.49 Favored 'General case' 0 C--O 1.205 -1.243 0 CA-C-O 119.422 -0.323 . . . . 0.0 111.532 179.282 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' F' F ' 24' ' ' VAL . . . . . 0.471 ' HB ' ' H ' ' C' ' 25' ' ' GLY . 59.6 t -58.46 168.35 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.94 0 N-CA-C 107.646 -1.242 . . . . 0.0 107.646 176.757 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' F' F ' 25' ' ' GLY . . . . . 0.435 ' H ' ' HB ' ' I' ' 24' ' ' VAL . . . -121.73 48.07 0.98 Allowed Glycine 0 N--CA 1.477 1.418 0 N-CA-C 110.789 -0.924 . . . . 0.0 110.789 -179.163 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -61.62 -167.05 0.01 OUTLIER 'General case' 0 N--CA 1.469 0.481 0 CA-C-N 116.768 0.284 . . . . 0.0 110.453 179.771 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 26.7 t-20 -70.67 76.84 0.6 Allowed 'General case' 0 N--CA 1.466 0.367 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.441 -179.881 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -74.01 143.86 45.38 Favored 'General case' 0 N--CA 1.473 0.709 0 N-CA-C 109.691 -0.485 . . . . 0.0 109.691 179.242 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.57 -167.19 1.34 Allowed Glycine 0 CA--C 1.522 0.517 0 N-CA-C 110.426 -1.07 . . . . 0.0 110.426 178.712 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.6 113.81 26.47 Favored 'General case' 0 N--CA 1.472 0.662 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.837 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 72.0 mt -98.09 134.54 36.08 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.372 0 N-CA-C 106.84 -1.541 . . . . 0.0 106.84 179.038 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' F' F ' 32' ' ' ILE . . . . . 0.43 HG22 ' H ' ' I' ' 32' ' ' ILE . 31.8 pt -150.47 -169.83 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.118 0 CA-C-O 121.052 0.453 . . . . 0.0 110.751 -179.409 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.64 4.9 5.95 Favored Glycine 0 CA--C 1.53 1.015 0 N-CA-C 111.261 -0.736 . . . . 0.0 111.261 -179.87 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' F' F ' 34' ' ' LEU . . . . . 0.425 HD23 ' N ' ' F' ' 35' ' ' MET . 1.1 tt -74.77 135.82 41.72 Favored 'General case' 0 CA--C 1.546 0.822 0 N-CA-C 109.241 -0.652 . . . . 0.0 109.241 -179.612 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' F' F ' 35' ' ' MET . . . . . 0.425 ' N ' HD23 ' F' ' 34' ' ' LEU . 26.5 ttt -158.89 145.86 17.3 Favored 'General case' 0 N--CA 1.473 0.686 0 N-CA-C 108.494 -0.928 . . . . 0.0 108.494 178.804 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 1.5 m -148.72 165.33 4.38 Favored 'Isoleucine or valine' 0 C--N 1.348 0.537 0 N-CA-C 108.366 -0.976 . . . . 0.0 108.366 -179.449 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 54.33 68.61 1.58 Allowed Glycine 0 C--N 1.308 -1.021 0 CA-C-N 115.307 -0.861 . . . . 0.0 112.113 177.634 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 146.6 174.07 18.39 Favored Glycine 0 N--CA 1.473 1.118 0 N-CA-C 111.355 -0.698 . . . . 0.0 111.355 178.722 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' F' F ' 39' ' ' VAL . . . . . 0.437 HG12 ' H ' ' C' ' 39' ' ' VAL . 33.0 m -107.42 155.0 8.27 Favored 'Isoleucine or valine' 0 C--N 1.352 0.696 0 C-N-CA 123.528 0.731 . . . . 0.0 110.604 -178.773 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 25.9 t . . . . . 0 C--O 1.219 -0.543 0 O-C-N 124.365 1.041 . . . . 0.0 110.356 179.892 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 64.8 m-85 . . . . . 0 N--CA 1.475 0.785 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' G' G ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -144.09 142.09 30.42 Favored 'General case' 0 N--CA 1.481 1.091 0 CA-C-O 120.823 0.345 . . . . 0.0 110.205 179.726 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 46.8 t-80 -151.69 119.59 6.2 Favored 'General case' 0 N--CA 1.473 0.676 0 N-CA-C 109.46 -0.57 . . . . 0.0 109.46 179.016 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 4.1 m-20 -71.94 144.41 48.94 Favored 'General case' 0 N--CA 1.471 0.603 0 C-N-CA 122.763 0.425 . . . . 0.0 111.154 -179.833 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' G' G ' 8' ' ' SER . . . . . 0.593 ' OG ' ' O ' ' D' ' 7' ' ' ASP . 37.5 p -164.69 -169.24 1.68 Allowed 'General case' 0 N--CA 1.476 0.86 0 CA-C-O 121.049 0.452 . . . . 0.0 110.496 178.535 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 101.95 47.59 1.46 Allowed Glycine 0 N--CA 1.478 1.488 0 N-CA-C 111.529 -0.628 . . . . 0.0 111.529 179.553 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 48.6 p90 -65.93 132.71 49.27 Favored 'General case' 0 N--CA 1.473 0.692 0 N-CA-C 111.803 0.297 . . . . 0.0 111.803 -179.688 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 48.4 mt-10 -91.5 152.03 20.51 Favored 'General case' 0 N--CA 1.479 1.018 0 CA-C-O 121.043 0.449 . . . . 0.0 110.163 178.374 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -154.96 127.81 1.1 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.008 0 N-CA-C 107.864 -1.161 . . . . 0.0 107.864 178.221 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 44.9 m-70 -135.25 144.83 47.07 Favored 'General case' 0 N--CA 1.477 0.922 0 CA-C-N 115.702 -0.681 . . . . 0.0 111.407 -178.259 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -166.52 96.85 0.57 Allowed 'General case' 0 N--CA 1.483 1.181 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.288 179.132 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 15.0 pt20 -109.11 -173.75 2.34 Favored 'General case' 0 CA--C 1.503 -0.831 0 N-CA-C 108.391 -0.966 . . . . 0.0 108.391 179.88 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -163.15 98.03 0.93 Allowed 'General case' 0 N--CA 1.474 0.747 0 CA-C-N 114.701 -1.136 . . . . 0.0 108.132 178.558 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 6.4 mp -120.06 154.29 34.85 Favored 'General case' 0 N--CA 1.496 1.86 0 CA-C-O 121.204 0.526 . . . . 0.0 111.793 -177.935 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 44.5 t -112.83 125.39 70.09 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.968 0 CA-C-N 114.898 -1.046 . . . . 0.0 108.19 176.548 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 32.2 m-85 -125.88 121.15 32.38 Favored 'General case' 0 C--N 1.366 1.315 0 C-N-CA 123.39 0.676 . . . . 0.0 110.853 -179.532 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 69.3 m-85 55.13 72.76 0.45 Allowed 'General case' 0 N--CA 1.469 0.521 0 CA-C-N 115.882 -0.599 . . . . 0.0 111.292 178.24 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.67 -78.26 0.14 Allowed 'General case' 0 N--CA 1.471 0.583 0 O-C-N 122.244 -0.285 . . . . 0.0 110.55 -179.189 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 41.3 tt0 -112.57 100.43 8.73 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 108.124 -1.065 . . . . 0.0 108.124 179.646 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -157.86 139.78 14.08 Favored 'General case' 0 N--CA 1.478 0.949 0 N-CA-C 111.516 0.191 . . . . 0.0 111.516 179.153 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' G' G ' 24' ' ' VAL . . . . . 0.531 ' HB ' ' H ' ' D' ' 25' ' ' GLY . 61.4 t -59.96 167.25 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.624 0 N-CA-C 107.669 -1.234 . . . . 0.0 107.669 177.268 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' G' G ' 25' ' ' GLY . . . . . 0.428 ' N ' HG12 ' G' ' 24' ' ' VAL . . . -120.35 49.68 0.87 Allowed Glycine 0 N--CA 1.482 1.718 0 N-CA-C 110.313 -1.115 . . . . 0.0 110.313 -179.453 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -63.56 -167.51 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.658 0 CA-C-N 117.001 0.401 . . . . 0.0 109.953 179.484 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 26.6 t-20 -70.11 76.69 0.51 Allowed 'General case' 0 CA--C 1.535 0.386 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.478 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 97.9 mttt -73.36 143.92 46.66 Favored 'General case' 0 N--CA 1.474 0.77 0 N-CA-C 109.701 -0.481 . . . . 0.0 109.701 179.209 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.64 -166.08 1.14 Allowed Glycine 0 C--N 1.337 0.593 0 N-CA-C 110.069 -1.212 . . . . 0.0 110.069 178.723 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.82 113.93 26.76 Favored 'General case' 0 N--CA 1.47 0.541 0 C-N-CA 122.723 0.409 . . . . 0.0 110.393 179.897 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 74.7 mt -98.61 134.77 36.05 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.773 0 N-CA-C 106.784 -1.562 . . . . 0.0 106.784 179.03 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' G' G ' 32' ' ' ILE . . . . . 0.444 ' H ' HG22 ' D' ' 32' ' ' ILE . 34.6 pt -151.11 -169.38 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 CA-C-N 119.657 1.117 . . . . 0.0 109.917 -179.826 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.18 4.79 6.71 Favored Glycine 0 CA--C 1.529 0.926 0 N-CA-C 111.052 -0.819 . . . . 0.0 111.052 179.933 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' G' G ' 34' ' ' LEU . . . . . 0.44 HD23 ' N ' ' G' ' 35' ' ' MET . 1.1 tt -74.95 135.74 41.38 Favored 'General case' 0 CA--C 1.544 0.745 0 N-CA-C 109.209 -0.663 . . . . 0.0 109.209 -179.635 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' G' G ' 35' ' ' MET . . . . . 0.44 ' N ' HD23 ' G' ' 34' ' ' LEU . 25.3 ttt -158.86 146.06 17.48 Favored 'General case' 0 N--CA 1.47 0.533 0 N-CA-C 108.695 -0.854 . . . . 0.0 108.695 178.801 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 1.4 m -148.8 163.89 4.72 Favored 'Isoleucine or valine' 0 C--N 1.349 0.566 0 N-CA-C 108.509 -0.922 . . . . 0.0 108.509 -179.293 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.13 68.67 1.57 Allowed Glycine 0 C--N 1.308 -0.997 0 CA-C-N 115.305 -0.862 . . . . 0.0 112.207 177.39 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.33 173.16 18.22 Favored Glycine 0 N--CA 1.475 1.274 0 N-CA-C 110.599 -1.0 . . . . 0.0 110.599 178.934 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' G' G ' 39' ' ' VAL . . . . . 0.405 HG12 ' H ' ' D' ' 39' ' ' VAL . 34.1 m -106.88 155.11 7.64 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.873 0 C-N-CA 123.222 0.609 . . . . 0.0 110.668 -179.346 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 25.8 t . . . . . 0 C--O 1.219 -0.532 0 O-C-N 124.035 0.835 . . . . 0.0 110.622 179.721 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 64.4 m-85 . . . . . 0 N--CA 1.473 0.712 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' H' H ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -143.72 142.71 31.07 Favored 'General case' 0 N--CA 1.482 1.133 0 C-N-CA 122.592 0.357 . . . . 0.0 110.1 179.712 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 47.7 t-80 -152.2 119.6 5.98 Favored 'General case' 0 N--CA 1.475 0.788 0 N-CA-C 109.326 -0.62 . . . . 0.0 109.326 178.991 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -71.57 144.44 49.54 Favored 'General case' 0 N--CA 1.469 0.497 0 C-N-CA 122.767 0.427 . . . . 0.0 111.164 179.89 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' H' H ' 8' ' ' SER . . . . . 0.441 ' OG ' ' O ' ' E' ' 7' ' ' ASP . 52.5 p -164.9 -170.37 1.94 Allowed 'General case' 0 N--CA 1.474 0.754 0 CA-C-O 120.935 0.398 . . . . 0.0 110.48 178.504 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.87 47.17 1.39 Allowed Glycine 0 N--CA 1.48 1.587 0 CA-C-N 115.971 -0.559 . . . . 0.0 111.709 179.604 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 48.2 p90 -65.61 132.67 49.41 Favored 'General case' 0 N--CA 1.473 0.707 0 N-CA-C 111.863 0.32 . . . . 0.0 111.863 -179.69 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 48.4 mt-10 -91.33 151.64 20.79 Favored 'General case' 0 N--CA 1.478 0.951 0 CA-C-O 121.036 0.446 . . . . 0.0 110.257 178.275 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -154.77 127.8 1.13 Allowed 'Isoleucine or valine' 0 CA--C 1.553 1.087 0 N-CA-C 107.815 -1.18 . . . . 0.0 107.815 178.286 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 45.0 m-70 -135.29 145.23 47.32 Favored 'General case' 0 N--CA 1.478 0.956 0 CA-C-N 115.596 -0.729 . . . . 0.0 111.373 -178.303 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -166.92 97.0 0.53 Allowed 'General case' 0 N--CA 1.481 1.116 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.312 179.151 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 15.1 pt20 -109.09 -173.43 2.26 Favored 'General case' 0 CA--C 1.505 -0.771 0 N-CA-C 108.417 -0.957 . . . . 0.0 108.417 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -163.5 97.98 0.89 Allowed 'General case' 0 N--CA 1.474 0.754 0 CA-C-N 114.718 -1.128 . . . . 0.0 108.1 178.565 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 6.4 mp -120.12 154.4 34.77 Favored 'General case' 0 N--CA 1.497 1.885 0 CA-C-O 121.263 0.554 . . . . 0.0 111.881 -177.981 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 43.9 t -113.02 124.79 70.01 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.978 0 CA-C-N 114.936 -1.029 . . . . 0.0 108.292 176.604 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 32.4 m-85 -125.17 121.16 33.39 Favored 'General case' 0 C--N 1.366 1.316 0 CA-C-N 115.56 -0.745 . . . . 0.0 110.735 -179.425 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 68.7 m-85 54.78 72.83 0.44 Allowed 'General case' 0 C--O 1.237 0.407 0 CA-C-N 115.868 -0.605 . . . . 0.0 111.425 178.173 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.31 -78.43 0.13 Allowed 'General case' 0 N--CA 1.469 0.522 0 O-C-N 122.229 -0.294 . . . . 0.0 110.591 -179.379 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 40.9 tt0 -112.62 100.34 8.65 Favored 'General case' 0 C--N 1.322 -0.589 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 179.792 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -157.6 139.47 14.12 Favored 'General case' 0 N--CA 1.477 0.909 0 O-C-N 122.403 -0.186 . . . . 0.0 111.498 179.272 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' H' H ' 24' ' ' VAL . . . . . 0.427 ' HB ' ' H ' ' E' ' 25' ' ' GLY . 62.0 t -59.73 167.4 0.56 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.521 0 N-CA-C 107.722 -1.214 . . . . 0.0 107.722 177.182 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' H' H ' 25' ' ' GLY . . . . . 0.425 ' N ' HG12 ' H' ' 24' ' ' VAL . . . -120.32 49.12 0.9 Allowed Glycine 0 N--CA 1.48 1.572 0 N-CA-C 110.491 -1.043 . . . . 0.0 110.491 -179.314 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -63.23 -166.99 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.675 0 CA-C-N 116.972 0.386 . . . . 0.0 110.092 179.748 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 26.6 t-20 -70.63 76.46 0.59 Allowed 'General case' 0 CA--C 1.535 0.374 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.492 -179.85 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -73.44 143.88 46.53 Favored 'General case' 0 N--CA 1.473 0.685 0 N-CA-C 109.629 -0.508 . . . . 0.0 109.629 179.341 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -65.17 -166.14 1.37 Allowed Glycine 0 C--N 1.337 0.634 0 N-CA-C 109.936 -1.266 . . . . 0.0 109.936 178.889 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.44 114.28 27.12 Favored 'General case' 0 N--CA 1.467 0.408 0 C-N-CA 122.573 0.349 . . . . 0.0 110.617 179.85 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 74.5 mt -98.73 134.73 36.41 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.751 0 N-CA-C 106.8 -1.556 . . . . 0.0 106.8 178.974 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' H' H ' 32' ' ' ILE . . . . . 0.439 ' H ' HG22 ' E' ' 32' ' ' ILE . 34.2 pt -151.05 -169.24 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.687 0 CA-C-N 119.747 1.158 . . . . 0.0 109.917 -179.93 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.24 4.8 6.81 Favored Glycine 0 CA--C 1.529 0.919 0 N-CA-C 110.95 -0.86 . . . . 0.0 110.95 179.914 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' H' H ' 34' ' ' LEU . . . . . 0.431 HD23 ' N ' ' H' ' 35' ' ' MET . 1.1 tt -75.35 135.25 40.85 Favored 'General case' 0 CA--C 1.546 0.792 0 N-CA-C 109.412 -0.588 . . . . 0.0 109.412 -179.414 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' H' H ' 35' ' ' MET . . . . . 0.431 ' N ' HD23 ' H' ' 34' ' ' LEU . 25.2 ttt -158.52 146.15 18.03 Favored 'General case' 0 N--CA 1.472 0.641 0 N-CA-C 108.694 -0.854 . . . . 0.0 108.694 179.065 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 1.5 m -149.08 163.84 4.35 Favored 'Isoleucine or valine' 0 C--N 1.348 0.522 0 N-CA-C 108.449 -0.945 . . . . 0.0 108.449 -179.283 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.35 68.39 1.71 Allowed Glycine 0 C--N 1.309 -0.971 0 CA-C-N 115.16 -0.927 . . . . 0.0 112.064 177.451 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.27 172.35 17.37 Favored Glycine 0 N--CA 1.476 1.307 0 N-CA-C 110.639 -0.985 . . . . 0.0 110.639 178.959 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' H' H ' 39' ' ' VAL . . . . . 0.425 HG12 ' H ' ' E' ' 39' ' ' VAL . 33.8 m -106.1 154.93 7.13 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.927 0 C-N-CA 123.199 0.6 . . . . 0.0 110.715 -179.475 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 24.7 t . . . . . 0 C--O 1.219 -0.53 0 O-C-N 124.001 0.813 . . . . 0.0 110.709 179.699 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 66.3 m-85 . . . . . 0 N--CA 1.474 0.745 0 N-CA-C 109.736 -0.468 . . . . 0.0 109.736 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' I' I ' 5' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -144.13 142.47 30.6 Favored 'General case' 0 N--CA 1.484 1.23 0 C-N-CA 122.639 0.376 . . . . 0.0 110.194 179.81 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 47.6 t-80 -152.14 120.12 6.21 Favored 'General case' 0 N--CA 1.474 0.738 0 N-CA-C 109.361 -0.607 . . . . 0.0 109.361 179.007 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -72.32 144.16 48.41 Favored 'General case' 0 N--CA 1.471 0.605 0 C-N-CA 122.725 0.41 . . . . 0.0 111.084 -179.945 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' I' I ' 8' ' ' SER . . . . . 0.483 ' OG ' ' O ' ' F' ' 7' ' ' ASP . 50.8 p -164.73 -170.39 1.98 Allowed 'General case' 0 N--CA 1.475 0.782 0 CA-C-O 120.996 0.427 . . . . 0.0 110.488 178.586 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.82 47.47 1.36 Allowed Glycine 0 N--CA 1.48 1.628 0 N-CA-C 111.629 -0.589 . . . . 0.0 111.629 179.675 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 47.9 p90 -65.92 133.2 50.38 Favored 'General case' 0 N--CA 1.473 0.677 0 CA-C-O 120.803 0.335 . . . . 0.0 111.872 -179.649 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 48.4 mt-10 -91.77 151.7 20.49 Favored 'General case' 0 N--CA 1.478 0.95 0 CA-C-O 120.932 0.396 . . . . 0.0 110.311 178.348 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -154.99 126.92 0.96 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.057 0 N-CA-C 107.909 -1.145 . . . . 0.0 107.909 178.365 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 42.4 m-70 -134.52 144.88 48.27 Favored 'General case' 0 N--CA 1.478 0.967 0 CA-C-N 115.606 -0.724 . . . . 0.0 111.451 -178.382 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -166.43 97.09 0.58 Allowed 'General case' 0 N--CA 1.48 1.056 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.348 179.119 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 15.2 pt20 -109.3 -173.88 2.37 Favored 'General case' 0 CA--C 1.504 -0.797 0 N-CA-C 108.481 -0.933 . . . . 0.0 108.481 -179.99 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -163.08 98.11 0.93 Allowed 'General case' 0 N--CA 1.473 0.715 0 CA-C-N 114.701 -1.136 . . . . 0.0 108.07 178.514 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 6.4 mp -120.2 154.37 34.94 Favored 'General case' 0 N--CA 1.497 1.907 0 CA-C-O 121.24 0.543 . . . . 0.0 111.769 -177.91 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 44.8 t -113.0 125.07 70.2 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.028 0 CA-C-N 114.857 -1.065 . . . . 0.0 108.157 176.646 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 32.9 m-85 -125.57 121.11 32.69 Favored 'General case' 0 C--N 1.367 1.339 0 CA-C-N 115.582 -0.735 . . . . 0.0 110.815 -179.536 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 68.6 m-85 54.9 73.26 0.42 Allowed 'General case' 0 N--CA 1.469 0.51 0 CA-C-N 115.927 -0.579 . . . . 0.0 111.262 178.301 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.99 -78.01 0.15 Allowed 'General case' 0 N--CA 1.472 0.639 0 O-C-N 122.205 -0.309 . . . . 0.0 110.601 -179.268 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 40.9 tt0 -112.84 100.32 8.58 Favored 'General case' 0 C--N 1.323 -0.586 0 N-CA-C 108.088 -1.078 . . . . 0.0 108.088 179.614 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -157.71 139.26 13.8 Favored 'General case' 0 N--CA 1.479 0.983 0 O-C-N 122.344 -0.223 . . . . 0.0 111.433 179.396 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' I' I ' 24' ' ' VAL . . . . . 0.435 ' HB ' ' H ' ' F' ' 25' ' ' GLY . 62.0 t -59.48 167.26 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.54 0 N-CA-C 107.847 -1.168 . . . . 0.0 107.847 177.016 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' I' I ' 25' ' ' GLY . . . . . 0.432 ' N ' HG12 ' I' ' 24' ' ' VAL . . . -120.43 49.52 0.87 Allowed Glycine 0 N--CA 1.482 1.725 0 N-CA-C 110.411 -1.076 . . . . 0.0 110.411 -179.384 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -63.42 -166.9 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.656 0 CA-C-N 116.985 0.393 . . . . 0.0 110.064 179.59 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 26.8 t-20 -70.68 76.71 0.6 Allowed 'General case' 0 N--CA 1.466 0.358 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.35 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 97.8 mttt -73.66 143.62 46.18 Favored 'General case' 0 N--CA 1.474 0.772 0 N-CA-C 109.64 -0.504 . . . . 0.0 109.64 179.284 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.59 -166.08 1.13 Allowed Glycine 0 C--N 1.339 0.703 0 N-CA-C 110.02 -1.232 . . . . 0.0 110.02 178.88 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.53 113.86 26.51 Favored 'General case' 0 N--CA 1.469 0.495 0 C-N-CA 122.691 0.396 . . . . 0.0 110.45 179.877 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 74.2 mt -98.37 135.04 34.66 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.836 0 N-CA-C 106.745 -1.576 . . . . 0.0 106.745 178.849 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' I' I ' 32' ' ' ILE . . . . . 0.43 ' H ' HG22 ' F' ' 32' ' ' ILE . 33.6 pt -151.38 -169.3 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 CA-C-N 119.698 1.135 . . . . 0.0 109.965 -179.987 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.22 4.71 6.68 Favored Glycine 0 CA--C 1.528 0.897 0 N-CA-C 110.952 -0.859 . . . . 0.0 110.952 179.962 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' I' I ' 34' ' ' LEU . . . . . 0.431 HD23 ' N ' ' I' ' 35' ' ' MET . 1.1 tt -74.85 135.29 41.58 Favored 'General case' 0 CA--C 1.544 0.738 0 N-CA-C 109.318 -0.623 . . . . 0.0 109.318 -179.602 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' I' I ' 35' ' ' MET . . . . . 0.431 ' N ' HD23 ' I' ' 34' ' ' LEU . 25.4 ttt -158.44 146.06 18.08 Favored 'General case' 0 N--CA 1.471 0.602 0 N-CA-C 108.53 -0.915 . . . . 0.0 108.53 178.982 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 1.4 m -149.02 163.78 4.41 Favored 'Isoleucine or valine' 0 C--N 1.35 0.616 0 N-CA-C 108.519 -0.919 . . . . 0.0 108.519 -179.401 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.08 68.5 1.65 Allowed Glycine 0 C--N 1.308 -0.991 0 CA-C-N 115.253 -0.885 . . . . 0.0 112.143 177.492 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.45 172.31 17.46 Favored Glycine 0 N--CA 1.474 1.224 0 N-CA-C 110.682 -0.967 . . . . 0.0 110.682 178.982 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' I' I ' 39' ' ' VAL . . . . . 0.426 HG12 ' H ' ' F' ' 39' ' ' VAL . 33.9 m -106.15 154.81 7.2 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.915 0 C-N-CA 123.236 0.614 . . . . 0.0 110.663 -179.467 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 25.3 t . . . . . 0 C--O 1.219 -0.524 0 O-C-N 124.06 0.85 . . . . 0.0 110.612 179.621 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 42.0 m-85 . . . . . 0 N--CA 1.474 0.747 0 N-CA-C 110.118 -0.327 . . . . 0.0 110.118 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -143.45 140.62 30.47 Favored 'General case' 0 N--CA 1.481 1.085 0 CA-C-O 120.887 0.375 . . . . 0.0 110.03 179.711 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 42.3 t-80 -151.79 119.39 6.07 Favored 'General case' 0 N--CA 1.47 0.528 0 N-CA-C 109.231 -0.655 . . . . 0.0 109.231 179.176 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' ASP . . . . . 0.499 ' O ' ' OG ' ' D' ' 8' ' ' SER . 4.4 m-20 -68.98 148.77 49.65 Favored 'General case' 0 CA--C 1.537 0.471 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.516 179.816 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 53.2 p -167.58 -173.5 2.21 Favored 'General case' 0 N--CA 1.483 1.184 0 CA-C-O 121.054 0.454 . . . . 0.0 110.721 179.392 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.62 47.67 1.37 Allowed Glycine 0 N--CA 1.482 1.705 0 CA-C-N 115.966 -0.561 . . . . 0.0 112.08 179.785 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 48.7 p90 -65.86 132.72 49.35 Favored 'General case' 0 N--CA 1.474 0.735 0 O-C-N 122.755 -0.262 . . . . 0.0 111.496 179.712 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 46.0 mt-10 -92.17 152.08 20.06 Favored 'General case' 0 N--CA 1.479 0.986 0 N-CA-C 109.725 -0.472 . . . . 0.0 109.725 178.512 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.0 p -152.89 128.25 1.59 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.612 0 N-CA-C 107.868 -1.16 . . . . 0.0 107.868 178.238 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 47.2 m-70 -135.41 147.8 49.12 Favored 'General case' 0 N--CA 1.493 1.708 0 CA-C-N 119.044 0.838 . . . . 0.0 111.398 -179.013 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 6.4 t60 -165.1 97.02 0.72 Allowed 'General case' 0 N--CA 1.48 1.064 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.624 179.342 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . 0.479 HE22 HG23 ' A' ' 36' ' ' VAL . 3.9 pt20 -101.54 -174.16 2.53 Favored 'General case' 0 CA--C 1.507 -0.704 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 -179.82 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -169.9 95.81 0.28 Allowed 'General case' 0 N--CA 1.47 0.53 0 CA-C-N 114.608 -1.178 . . . . 0.0 108.389 178.38 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 6.5 mp -123.36 156.97 34.35 Favored 'General case' 0 N--CA 1.497 1.917 0 CA-C-O 121.794 0.807 . . . . 0.0 111.005 -178.14 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 60.1 t -111.79 126.86 69.22 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.135 0 CA-C-O 117.938 -1.029 . . . . 0.0 108.269 177.608 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 27.1 m-85 -126.89 123.09 36.44 Favored 'General case' 0 N--CA 1.497 1.912 0 CA-C-N 120.13 1.332 . . . . 0.0 110.474 179.5 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 67.9 m-85 53.66 74.71 0.3 Allowed 'General case' 0 CA--C 1.538 0.489 0 CA-C-O 121.414 0.626 . . . . 0.0 111.813 178.634 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -80.0 -78.28 0.17 Allowed 'General case' 0 C--N 1.353 0.727 0 CA-C-N 115.084 -0.962 . . . . 0.0 110.192 -179.922 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 38.2 tt0 -113.39 100.74 8.77 Favored 'General case' 0 N--CA 1.469 0.486 0 N-CA-C 108.191 -1.04 . . . . 0.0 108.191 179.725 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 4.4 p30 -159.18 139.79 12.43 Favored 'General case' 0 N--CA 1.483 1.178 0 O-C-N 122.31 -0.243 . . . . 0.0 111.219 179.147 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.405 HG12 ' N ' ' A' ' 25' ' ' GLY . 61.2 t -59.97 163.43 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.819 0 N-CA-C 108.104 -1.073 . . . . 0.0 108.104 177.106 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.469 ' H ' ' HB ' ' D' ' 24' ' ' VAL . . . -117.3 48.61 0.92 Allowed Glycine 0 N--CA 1.475 1.252 0 N-CA-C 111.755 -0.538 . . . . 0.0 111.755 -179.402 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -61.73 -167.83 0.01 OUTLIER 'General case' 0 N--CA 1.468 0.45 0 O-C-N 123.843 0.378 . . . . 0.0 110.412 179.522 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 25.1 t-20 -71.06 80.4 0.67 Allowed 'General case' 0 N--CA 1.465 0.284 0 CA-C-N 116.492 -0.322 . . . . 0.0 110.176 179.557 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -77.85 143.76 37.55 Favored 'General case' 0 N--CA 1.473 0.704 0 N-CA-C 109.141 -0.689 . . . . 0.0 109.141 179.332 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.38 -167.51 0.94 Allowed Glycine 0 CA--C 1.525 0.664 0 N-CA-C 109.863 -1.295 . . . . 0.0 109.863 178.629 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.8 114.61 27.88 Favored 'General case' 0 N--CA 1.48 1.038 0 N-CA-C 109.696 -0.483 . . . . 0.0 109.696 179.839 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 64.9 mt -98.41 135.78 31.88 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.552 0 N-CA-C 107.078 -1.453 . . . . 0.0 107.078 178.982 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 34.1 pt -152.31 -176.14 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.734 0 CA-C-O 121.168 0.508 . . . . 0.0 111.18 -179.164 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.62 4.39 9.73 Favored Glycine 0 CA--C 1.524 0.597 0 N-CA-C 110.976 -0.85 . . . . 0.0 110.976 179.758 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 1.6 tt -74.28 127.18 32.33 Favored 'General case' 0 CA--C 1.545 0.767 0 N-CA-C 109.499 -0.556 . . . . 0.0 109.499 -179.604 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 28.5 ttt -163.75 149.81 11.43 Favored 'General case' 0 N--CA 1.465 0.279 0 N-CA-C 108.963 -0.755 . . . . 0.0 108.963 178.782 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.596 HG22 HG12 ' D' ' 36' ' ' VAL . 27.5 m -155.22 166.33 1.07 Allowed 'Isoleucine or valine' 0 C--N 1.347 0.482 0 N-CA-C 108.061 -1.088 . . . . 0.0 108.061 179.686 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.1 67.2 2.33 Favored Glycine 0 C--N 1.307 -1.045 0 CA-C-N 115.776 -0.647 . . . . 0.0 112.102 178.422 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.96 -173.23 24.85 Favored Glycine 0 N--CA 1.474 1.195 0 N-CA-C 110.85 -0.9 . . . . 0.0 110.85 179.089 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.561 ' H ' HG12 ' D' ' 39' ' ' VAL . 34.5 m -125.56 156.34 35.03 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.774 0 C-N-CA 123.393 0.677 . . . . 0.0 110.232 -179.645 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 27.1 t . . . . . 0 C--O 1.218 -0.589 0 CA-C-O 118.433 -0.794 . . . . 0.0 110.622 179.853 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 38.9 m-85 . . . . . 0 N--CA 1.473 0.715 0 N-CA-C 110.13 -0.322 . . . . 0.0 110.13 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -143.06 140.44 30.94 Favored 'General case' 0 N--CA 1.483 1.198 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 179.574 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 41.9 t-80 -151.65 119.03 5.98 Favored 'General case' 0 N--CA 1.473 0.692 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 179.001 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 7' ' ' ASP . . . . . 0.448 ' O ' ' OG ' ' E' ' 8' ' ' SER . 4.3 m-20 -68.68 148.55 50.25 Favored 'General case' 0 CA--C 1.537 0.47 0 CA-C-N 116.343 -0.389 . . . . 0.0 110.677 179.907 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 8' ' ' SER . . . . . . . . . . . . . 53.8 p -167.59 -173.53 2.22 Favored 'General case' 0 N--CA 1.482 1.136 0 CA-C-O 120.966 0.412 . . . . 0.0 110.745 179.418 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.92 47.14 1.39 Allowed Glycine 0 N--CA 1.481 1.686 0 CA-C-N 115.985 -0.552 . . . . 0.0 112.126 179.758 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 48.8 p90 -65.57 132.88 49.96 Favored 'General case' 0 N--CA 1.472 0.644 0 CA-C-O 120.665 0.269 . . . . 0.0 111.562 179.819 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 45.3 mt-10 -92.14 152.22 20.01 Favored 'General case' 0 N--CA 1.475 0.824 0 C-N-CA 122.847 0.459 . . . . 0.0 109.816 178.475 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -153.15 128.13 1.5 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.547 0 N-CA-C 107.854 -1.165 . . . . 0.0 107.854 178.266 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 46.9 m-70 -135.46 147.71 49.0 Favored 'General case' 0 N--CA 1.492 1.65 0 CA-C-N 118.915 0.78 . . . . 0.0 111.379 -178.882 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 6.5 t60 -165.14 97.01 0.71 Allowed 'General case' 0 N--CA 1.48 1.052 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.604 179.345 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . 0.47 HE22 HG23 ' B' ' 36' ' ' VAL . 3.9 pt20 -101.51 -173.83 2.45 Favored 'General case' 0 CA--C 1.508 -0.638 0 N-CA-C 108.691 -0.855 . . . . 0.0 108.691 -179.764 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -170.22 95.82 0.25 Allowed 'General case' 0 N--CA 1.471 0.575 0 CA-C-N 114.727 -1.124 . . . . 0.0 108.321 178.324 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 6.5 mp -123.15 157.32 33.23 Favored 'General case' 0 N--CA 1.497 1.878 0 CA-C-O 121.73 0.776 . . . . 0.0 110.999 -178.134 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 60.9 t -112.37 127.65 69.46 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.098 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 177.44 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 27.0 m-85 -127.62 123.0 34.6 Favored 'General case' 0 N--CA 1.494 1.753 0 CA-C-N 119.707 1.14 . . . . 0.0 110.302 179.681 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 67.9 m-85 53.27 74.81 0.28 Allowed 'General case' 0 CA--C 1.537 0.476 0 CA-C-O 121.535 0.683 . . . . 0.0 111.919 178.475 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -80.48 -77.93 0.18 Allowed 'General case' 0 C--N 1.352 0.681 0 CA-C-N 115.004 -0.998 . . . . 0.0 110.218 -179.879 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 38.3 tt0 -113.53 100.45 8.52 Favored 'General case' 0 N--CA 1.47 0.565 0 N-CA-C 108.317 -0.994 . . . . 0.0 108.317 179.695 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -158.85 140.17 13.17 Favored 'General case' 0 N--CA 1.483 1.193 0 O-C-N 122.179 -0.326 . . . . 0.0 111.146 179.19 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 61.6 t -60.1 163.63 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.894 0 N-CA-C 108.121 -1.066 . . . . 0.0 108.121 177.072 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 25' ' ' GLY . . . . . 0.474 ' H ' ' HB ' ' E' ' 24' ' ' VAL . . . -117.23 48.32 0.95 Allowed Glycine 0 N--CA 1.476 1.309 0 N-CA-C 111.657 -0.577 . . . . 0.0 111.657 -179.353 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -61.87 -168.58 0.02 OUTLIER 'General case' 0 N--CA 1.469 0.505 0 O-C-N 123.783 0.343 . . . . 0.0 110.348 179.498 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 25.0 t-20 -70.61 81.03 0.59 Allowed 'General case' 0 N--CA 1.467 0.377 0 N-CA-C 110.078 -0.342 . . . . 0.0 110.078 179.636 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -78.48 144.32 35.85 Favored 'General case' 0 N--CA 1.473 0.706 0 N-CA-C 109.077 -0.712 . . . . 0.0 109.077 179.394 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.47 -167.47 0.97 Allowed Glycine 0 C--N 1.336 0.569 0 N-CA-C 109.933 -1.267 . . . . 0.0 109.933 178.676 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.91 114.56 27.89 Favored 'General case' 0 N--CA 1.479 0.988 0 N-CA-C 109.677 -0.49 . . . . 0.0 109.677 179.644 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 64.3 mt -98.51 135.36 33.66 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.507 0 N-CA-C 107.073 -1.454 . . . . 0.0 107.073 178.9 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . 0.413 HG22 ' H ' ' E' ' 32' ' ' ILE . 33.7 pt -151.99 -176.63 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.353 0.722 0 CA-C-N 116.026 -0.534 . . . . 0.0 111.191 -178.975 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.73 4.76 10.99 Favored Glycine 0 CA--C 1.523 0.57 0 N-CA-C 110.925 -0.87 . . . . 0.0 110.925 179.718 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 1.6 tt -74.56 126.71 31.37 Favored 'General case' 0 CA--C 1.546 0.813 0 N-CA-C 109.438 -0.578 . . . . 0.0 109.438 -179.744 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 28.2 ttt -163.05 149.97 12.78 Favored 'General case' 0 N--CA 1.465 0.323 0 N-CA-C 108.935 -0.765 . . . . 0.0 108.935 178.82 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 36' ' ' VAL . . . . . 0.599 HG22 HG12 ' E' ' 36' ' ' VAL . 27.3 m -155.3 166.34 1.06 Allowed 'Isoleucine or valine' 0 C--N 1.348 0.508 0 N-CA-C 108.015 -1.105 . . . . 0.0 108.015 179.706 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.73 67.43 2.21 Favored Glycine 0 C--N 1.307 -1.069 0 CA-C-N 115.742 -0.663 . . . . 0.0 112.094 178.434 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.65 -173.52 24.51 Favored Glycine 0 N--CA 1.474 1.213 0 N-CA-C 110.94 -0.864 . . . . 0.0 110.94 179.034 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 39' ' ' VAL . . . . . 0.585 ' H ' HG12 ' E' ' 39' ' ' VAL . 35.0 m -125.27 156.26 34.34 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.818 0 C-N-CA 123.42 0.688 . . . . 0.0 110.309 -179.591 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 26.6 t . . . . . 0 C--O 1.219 -0.514 0 CA-C-O 118.54 -0.743 . . . . 0.0 110.436 179.758 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 39.7 m-85 . . . . . 0 N--CA 1.474 0.774 0 N-CA-C 110.064 -0.347 . . . . 0.0 110.064 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -143.35 140.42 30.51 Favored 'General case' 0 N--CA 1.483 1.182 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 179.726 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 42.0 t-80 -151.72 119.51 6.15 Favored 'General case' 0 N--CA 1.472 0.648 0 N-CA-C 109.317 -0.623 . . . . 0.0 109.317 179.114 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 7' ' ' ASP . . . . . 0.49 ' O ' ' OG ' ' F' ' 8' ' ' SER . 4.3 m-20 -69.22 148.32 50.01 Favored 'General case' 0 CA--C 1.537 0.472 0 CA-C-N 116.328 -0.397 . . . . 0.0 110.648 179.978 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 8' ' ' SER . . . . . . . . . . . . . 53.5 p -167.31 -173.4 2.25 Favored 'General case' 0 N--CA 1.484 1.246 0 CA-C-O 121.028 0.442 . . . . 0.0 110.692 179.43 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.62 47.1 1.43 Allowed Glycine 0 N--CA 1.482 1.734 0 CA-C-N 115.899 -0.592 . . . . 0.0 112.076 179.787 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 49.1 p90 -65.44 133.06 50.5 Favored 'General case' 0 N--CA 1.473 0.709 0 CA-C-O 120.671 0.272 . . . . 0.0 111.489 179.617 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 46.0 mt-10 -92.48 152.49 19.64 Favored 'General case' 0 N--CA 1.476 0.826 0 CA-C-O 121.1 0.476 . . . . 0.0 109.787 178.436 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -153.21 128.48 1.56 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.545 0 N-CA-C 107.786 -1.19 . . . . 0.0 107.786 178.307 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 47.0 m-70 -135.71 147.56 48.53 Favored 'General case' 0 N--CA 1.492 1.632 0 CA-C-N 118.925 0.784 . . . . 0.0 111.355 -179.081 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 6.5 t60 -164.96 97.17 0.73 Allowed 'General case' 0 N--CA 1.482 1.149 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.507 179.312 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 15' ' ' GLN . . . . . 0.456 HE22 HG23 ' C' ' 36' ' ' VAL . 3.9 pt20 -101.64 -173.75 2.43 Favored 'General case' 0 CA--C 1.507 -0.701 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 -179.749 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -170.22 95.85 0.25 Allowed 'General case' 0 N--CA 1.47 0.553 0 CA-C-N 114.618 -1.174 . . . . 0.0 108.292 178.406 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 6.5 mp -123.37 157.08 34.12 Favored 'General case' 0 N--CA 1.497 1.918 0 CA-C-O 121.745 0.784 . . . . 0.0 111.07 -178.157 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 60.7 t -112.33 127.61 69.43 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.076 0 N-CA-C 108.059 -1.089 . . . . 0.0 108.059 177.53 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 27.7 m-85 -127.58 123.02 34.73 Favored 'General case' 0 N--CA 1.494 1.75 0 CA-C-N 119.6 1.091 . . . . 0.0 110.34 179.614 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 67.0 m-85 53.29 74.75 0.29 Allowed 'General case' 0 CA--C 1.538 0.495 0 CA-C-O 121.55 0.69 . . . . 0.0 111.975 178.441 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -80.34 -78.22 0.18 Allowed 'General case' 0 C--N 1.348 0.537 0 CA-C-N 114.911 -1.04 . . . . 0.0 110.197 -179.791 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 38.0 tt0 -113.31 100.39 8.52 Favored 'General case' 0 N--CA 1.47 0.56 0 N-CA-C 108.161 -1.051 . . . . 0.0 108.161 179.653 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 4.4 p30 -158.71 140.08 13.27 Favored 'General case' 0 N--CA 1.484 1.231 0 O-C-N 122.202 -0.311 . . . . 0.0 111.204 179.085 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 24' ' ' VAL . . . . . 0.401 HG12 ' N ' ' C' ' 25' ' ' GLY . 61.8 t -60.0 163.72 0.92 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.852 0 N-CA-C 108.153 -1.054 . . . . 0.0 108.153 177.082 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 25' ' ' GLY . . . . . 0.472 ' H ' ' HB ' ' F' ' 24' ' ' VAL . . . -117.38 48.31 0.95 Allowed Glycine 0 N--CA 1.477 1.385 0 N-CA-C 111.637 -0.585 . . . . 0.0 111.637 -179.336 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -61.81 -167.99 0.01 OUTLIER 'General case' 0 N--CA 1.468 0.427 0 O-C-N 123.79 0.347 . . . . 0.0 110.361 179.658 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 25.0 t-20 -71.01 80.71 0.66 Allowed 'General case' 0 N--CA 1.465 0.304 0 N-CA-C 110.067 -0.345 . . . . 0.0 110.067 179.495 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -78.22 144.13 36.53 Favored 'General case' 0 N--CA 1.472 0.65 0 N-CA-C 109.117 -0.698 . . . . 0.0 109.117 179.415 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.55 -167.62 1.03 Allowed Glycine 0 CA--C 1.523 0.586 0 N-CA-C 109.965 -1.254 . . . . 0.0 109.965 178.788 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.6 114.34 27.31 Favored 'General case' 0 N--CA 1.48 1.071 0 N-CA-C 109.661 -0.496 . . . . 0.0 109.661 179.775 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 64.8 mt -98.42 135.45 33.16 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.546 0 N-CA-C 107.058 -1.46 . . . . 0.0 107.058 178.911 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 32' ' ' ILE . . . . . 0.414 HG22 ' H ' ' F' ' 32' ' ' ILE . 33.8 pt -152.01 -176.15 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.352 0.688 0 CA-C-N 115.998 -0.547 . . . . 0.0 111.189 -179.096 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.48 4.49 9.43 Favored Glycine 0 CA--C 1.524 0.615 0 N-CA-C 110.992 -0.843 . . . . 0.0 110.992 179.697 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 1.6 tt -74.27 127.27 32.57 Favored 'General case' 0 CA--C 1.547 0.831 0 N-CA-C 109.389 -0.597 . . . . 0.0 109.389 -179.776 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 28.3 ttt -163.52 150.06 12.02 Favored 'General case' 0 N--CA 1.467 0.397 0 N-CA-C 108.86 -0.792 . . . . 0.0 108.86 178.735 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 36' ' ' VAL . . . . . 0.593 HG22 HG12 ' F' ' 36' ' ' VAL . 27.3 m -155.59 166.05 1.07 Allowed 'Isoleucine or valine' 0 C--N 1.347 0.5 0 N-CA-C 108.06 -1.089 . . . . 0.0 108.06 179.657 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.06 67.23 2.32 Favored Glycine 0 C--N 1.307 -1.047 0 CA-C-N 115.721 -0.672 . . . . 0.0 112.077 178.503 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.71 -173.44 24.58 Favored Glycine 0 N--CA 1.473 1.139 0 N-CA-C 110.987 -0.845 . . . . 0.0 110.987 178.959 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 39' ' ' VAL . . . . . 0.587 ' H ' HG12 ' F' ' 39' ' ' VAL . 32.9 m -125.11 156.37 33.98 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.751 0 C-N-CA 123.386 0.674 . . . . 0.0 110.31 -179.572 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 25.6 t . . . . . 0 C--O 1.218 -0.576 0 CA-C-O 118.424 -0.798 . . . . 0.0 110.579 179.77 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 41.4 m-85 . . . . . 0 N--CA 1.473 0.679 0 N-CA-C 108.775 -0.824 . . . . 0.0 108.775 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' D' D ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -145.24 139.15 26.95 Favored 'General case' 0 N--CA 1.478 0.927 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.144 -179.846 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 38.7 t-80 -149.47 123.46 9.4 Favored 'General case' 0 CA--C 1.544 0.744 0 N-CA-C 108.42 -0.956 . . . . 0.0 108.42 175.352 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' D' D ' 7' ' ' ASP . . . . . 0.586 ' O ' ' OG ' ' G' ' 8' ' ' SER . 3.2 m-20 -63.79 133.02 52.69 Favored 'General case' 0 C--N 1.32 -0.702 0 C-N-CA 126.769 2.027 . . . . 0.0 113.965 174.817 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' D' D ' 8' ' ' SER . . . . . 0.499 ' OG ' ' O ' ' A' ' 7' ' ' ASP . 53.9 p -154.61 -170.57 3.56 Favored 'General case' 0 N--CA 1.487 1.41 0 CA-C-N 119.397 0.999 . . . . 0.0 111.12 175.622 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.2 47.77 1.2 Allowed Glycine 0 N--CA 1.481 1.651 0 N-CA-C 110.652 -0.979 . . . . 0.0 110.652 174.445 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 51.1 p90 -60.91 131.48 50.81 Favored 'General case' 0 N--CA 1.471 0.614 0 N-CA-C 112.804 0.668 . . . . 0.0 112.804 178.075 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 45.7 mt-10 -89.49 150.83 22.29 Favored 'General case' 0 N--CA 1.481 1.094 0 CA-C-N 117.825 0.284 . . . . 0.0 110.809 175.351 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.0 p -149.46 129.84 4.28 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.611 0 N-CA-C 107.49 -1.3 . . . . 0.0 107.49 173.417 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 42.9 m-70 -129.96 150.74 51.11 Favored 'General case' 0 N--CA 1.483 1.215 0 CA-C-N 118.198 0.454 . . . . 0.0 111.994 176.584 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 6.6 t60 -164.98 104.47 0.78 Allowed 'General case' 0 N--CA 1.483 1.186 0 N-CA-C 108.844 -0.799 . . . . 0.0 108.844 172.171 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' D' D ' 15' ' ' GLN . . . . . 0.473 HE22 HG23 ' D' ' 36' ' ' VAL . 3.9 pt20 -105.12 -176.1 2.98 Favored 'General case' 0 CA--C 1.502 -0.871 0 N-CA-C 108.487 -0.931 . . . . 0.0 108.487 179.177 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -166.23 104.52 0.64 Allowed 'General case' 0 N--CA 1.466 0.335 0 N-CA-C 106.205 -1.776 . . . . 0.0 106.205 174.131 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 5.4 mp -130.35 154.02 48.09 Favored 'General case' 0 N--CA 1.5 2.043 0 CA-C-O 122.062 0.934 . . . . 0.0 110.711 179.458 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 34.5 t -101.25 131.56 48.76 Favored 'Isoleucine or valine' 0 C--O 1.262 1.714 0 CA-C-O 116.779 -1.581 . . . . 0.0 109.686 174.097 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 26.2 m-85 -130.09 126.45 37.62 Favored 'General case' 0 N--CA 1.488 1.457 0 CA-C-N 120.126 1.33 . . . . 0.0 109.864 173.73 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 67.4 m-85 55.48 71.3 0.56 Allowed 'General case' 0 C--O 1.239 0.542 0 CA-C-N 115.712 -0.676 . . . . 0.0 111.837 176.206 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -81.6 -73.43 0.38 Allowed 'General case' 0 N--CA 1.473 0.718 0 CA-C-O 118.585 -0.721 . . . . 0.0 111.063 -177.61 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 38.6 tt0 -116.64 104.28 11.23 Favored 'General case' 0 N--CA 1.482 1.164 0 N-CA-C 106.361 -1.718 . . . . 0.0 106.361 176.324 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -152.15 139.92 19.9 Favored 'General case' 0 N--CA 1.474 0.756 0 CA-C-O 116.8 -1.571 . . . . 0.0 113.647 177.815 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' D' D ' 24' ' ' VAL . . . . . 0.469 ' HB ' ' H ' ' A' ' 25' ' ' GLY . 66.7 t -62.45 166.04 0.98 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.294 0 CA-C-N 121.037 1.744 . . . . 0.0 107.983 174.905 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' D' D ' 25' ' ' GLY . . . . . 0.526 ' H ' ' HB ' ' G' ' 24' ' ' VAL . . . -116.83 51.08 0.75 Allowed Glycine 0 N--CA 1.479 1.52 0 CA-C-O 119.081 -0.844 . . . . 0.0 111.738 178.536 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -57.75 -171.21 0.01 OUTLIER 'General case' 0 C--N 1.323 -0.58 0 C-N-CA 123.618 0.767 . . . . 0.0 111.722 176.054 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 25.8 t-20 -72.11 86.52 1.05 Allowed 'General case' 0 C--N 1.346 0.435 0 N-CA-C 108.585 -0.894 . . . . 0.0 108.585 177.688 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 97.5 mttt -83.53 146.48 28.32 Favored 'General case' 0 N--CA 1.474 0.775 0 N-CA-C 108.056 -1.09 . . . . 0.0 108.056 179.196 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -62.95 -165.4 0.56 Allowed Glycine 0 C--N 1.335 0.476 0 N-CA-C 110.519 -1.032 . . . . 0.0 110.519 179.225 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -101.78 115.95 31.65 Favored 'General case' 0 N--CA 1.471 0.606 0 N-CA-C 109.235 -0.654 . . . . 0.0 109.235 179.594 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 72.6 mt -102.71 142.77 16.16 Favored 'Isoleucine or valine' 0 C--N 1.356 0.891 0 N-CA-C 104.544 -2.391 . . . . 0.0 104.544 179.838 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' D' D ' 32' ' ' ILE . . . . . 0.459 HG22 ' H ' ' G' ' 32' ' ' ILE . 34.8 pt -158.49 -176.96 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.209 0 CA-C-O 120.891 0.377 . . . . 0.0 110.152 -177.537 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 64.31 4.38 12.19 Favored Glycine 0 C--O 1.247 0.958 0 N-CA-C 110.087 -1.205 . . . . 0.0 110.087 -179.011 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 2.0 tt -76.37 132.94 40.02 Favored 'General case' 0 C--N 1.363 1.181 0 N-CA-C 107.185 -1.413 . . . . 0.0 107.185 -177.974 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' D' D ' 35' ' ' MET . . . . . 0.404 ' O ' HG13 ' D' ' 36' ' ' VAL . 28.2 ttt -158.52 161.53 37.36 Favored 'General case' 0 C--O 1.221 -0.419 0 CA-C-O 118.318 -0.849 . . . . 0.0 108.734 173.086 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' D' D ' 36' ' ' VAL . . . . . 0.635 HG22 HG12 ' G' ' 36' ' ' VAL . 27.6 m -164.74 165.07 0.61 Allowed 'Isoleucine or valine' 0 CA--C 1.519 -0.247 0 N-CA-C 107.624 -1.25 . . . . 0.0 107.624 175.835 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 60.36 64.1 4.43 Favored Glycine 0 CA--C 1.524 0.6 0 C-N-CA 119.576 -1.297 . . . . 0.0 113.006 178.572 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 140.95 -171.61 24.04 Favored Glycine 0 N--CA 1.476 1.361 0 CA-C-N 117.328 0.564 . . . . 0.0 111.95 -179.175 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' D' D ' 39' ' ' VAL . . . . . 0.587 ' H ' HG12 ' G' ' 39' ' ' VAL . 35.4 m -128.17 153.5 37.65 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.883 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -176.664 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 25.3 t . . . . . 0 C--O 1.225 -0.204 0 CA-C-O 116.686 -1.626 . . . . 0.0 109.773 178.118 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 37.9 m-85 . . . . . 0 N--CA 1.475 0.825 0 N-CA-C 110.166 -0.309 . . . . 0.0 110.166 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' E' E ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -142.74 140.86 31.61 Favored 'General case' 0 N--CA 1.484 1.257 0 CA-C-O 120.952 0.405 . . . . 0.0 109.997 179.576 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 41.5 t-80 -151.68 119.21 6.05 Favored 'General case' 0 N--CA 1.472 0.625 0 N-CA-C 109.228 -0.656 . . . . 0.0 109.228 178.894 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' E' E ' 7' ' ' ASP . . . . . 0.432 ' O ' ' OG ' ' H' ' 8' ' ' SER . 4.0 m-20 -69.47 148.39 49.59 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 116.389 -0.368 . . . . 0.0 110.82 -179.982 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' E' E ' 8' ' ' SER . . . . . 0.448 ' OG ' ' O ' ' B' ' 7' ' ' ASP . 51.8 p -168.1 -172.13 1.71 Allowed 'General case' 0 N--CA 1.485 1.31 0 CA-C-O 121.153 0.501 . . . . 0.0 110.857 178.995 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.17 47.61 1.31 Allowed Glycine 0 N--CA 1.479 1.516 0 CA-C-N 115.879 -0.601 . . . . 0.0 111.942 179.622 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 46.8 p90 -65.2 133.16 50.91 Favored 'General case' 0 N--CA 1.474 0.762 0 N-CA-C 111.894 0.331 . . . . 0.0 111.894 -179.886 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 46.2 mt-10 -91.84 152.33 20.16 Favored 'General case' 0 N--CA 1.479 0.995 0 CA-C-O 121.211 0.529 . . . . 0.0 109.742 178.007 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -154.34 127.47 1.16 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.586 0 N-CA-C 107.799 -1.186 . . . . 0.0 107.799 178.103 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 44.8 m-70 -135.78 145.71 46.82 Favored 'General case' 0 N--CA 1.481 1.116 0 CA-C-O 120.768 0.318 . . . . 0.0 111.678 -177.861 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 6.4 t60 -163.94 97.1 0.83 Allowed 'General case' 0 N--CA 1.485 1.318 0 CA-C-N 116.374 -0.375 . . . . 0.0 110.61 179.531 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' E' E ' 15' ' ' GLN . . . . . 0.502 HE22 HG23 ' E' ' 36' ' ' VAL . 3.9 pt20 -101.3 -173.97 2.49 Favored 'General case' 0 CA--C 1.509 -0.634 0 N-CA-C 108.855 -0.794 . . . . 0.0 108.855 -179.77 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -169.85 94.95 0.27 Allowed 'General case' 0 N--CA 1.474 0.739 0 CA-C-N 114.702 -1.136 . . . . 0.0 108.423 178.468 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 6.4 mp -122.05 156.92 32.53 Favored 'General case' 0 N--CA 1.494 1.772 0 CA-C-O 121.649 0.738 . . . . 0.0 111.532 -177.641 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 48.0 t -113.9 124.35 70.47 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.231 0 N-CA-C 108.178 -1.045 . . . . 0.0 108.178 177.168 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 30.5 m-85 -124.83 121.78 35.54 Favored 'General case' 0 N--CA 1.488 1.427 0 CA-C-O 120.83 0.348 . . . . 0.0 111.086 -179.729 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 68.8 m-85 54.76 73.61 0.4 Allowed 'General case' 0 N--CA 1.467 0.407 0 CA-C-N 115.941 -0.572 . . . . 0.0 111.609 178.173 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -78.53 -78.6 0.14 Allowed 'General case' 0 CA--C 1.535 0.379 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.108 -179.615 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 38.5 tt0 -112.8 101.07 9.17 Favored 'General case' 0 C--N 1.324 -0.532 0 N-CA-C 108.257 -1.016 . . . . 0.0 108.257 179.905 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -158.39 140.12 13.71 Favored 'General case' 0 C--O 1.205 -1.274 0 O-C-N 122.282 -0.262 . . . . 0.0 111.5 178.97 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' E' E ' 24' ' ' VAL . . . . . 0.474 ' HB ' ' H ' ' B' ' 25' ' ' GLY . 57.6 t -58.65 168.53 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.867 0 N-CA-C 107.619 -1.252 . . . . 0.0 107.619 176.943 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' E' E ' 25' ' ' GLY . . . . . 0.432 ' H ' ' HB ' ' H' ' 24' ' ' VAL . . . -122.45 49.35 0.89 Allowed Glycine 0 N--CA 1.474 1.212 0 N-CA-C 110.783 -0.927 . . . . 0.0 110.783 -179.296 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -63.24 -167.83 0.02 OUTLIER 'General case' 0 N--CA 1.469 0.489 0 CA-C-O 120.763 0.316 . . . . 0.0 110.466 179.805 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 25.4 t-20 -70.07 77.29 0.5 Allowed 'General case' 0 N--CA 1.466 0.365 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.422 179.961 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -75.17 144.45 42.73 Favored 'General case' 0 N--CA 1.476 0.855 0 N-CA-C 109.552 -0.536 . . . . 0.0 109.552 179.438 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.34 -166.9 1.19 Allowed Glycine 0 CA--C 1.521 0.454 0 N-CA-C 110.439 -1.064 . . . . 0.0 110.439 178.548 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.68 114.15 27.06 Favored 'General case' 0 N--CA 1.472 0.646 0 N-CA-C 109.848 -0.426 . . . . 0.0 109.848 179.769 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 65.6 mt -98.47 135.52 32.97 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.324 0 N-CA-C 106.832 -1.544 . . . . 0.0 106.832 178.979 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' E' E ' 32' ' ' ILE . . . . . 0.45 HG22 ' H ' ' H' ' 32' ' ' ILE . 36.2 pt -152.01 -174.05 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.208 0 CA-C-O 121.111 0.481 . . . . 0.0 110.713 -179.337 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.29 5.16 5.74 Favored Glycine 0 CA--C 1.529 0.942 0 CA-C-N 115.58 -0.736 . . . . 0.0 111.408 -179.731 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 1.6 tt -74.25 126.9 31.63 Favored 'General case' 0 CA--C 1.547 0.852 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 -179.559 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 28.5 ttt -162.74 151.09 14.26 Favored 'General case' 0 C--O 1.209 -1.05 0 N-CA-C 108.995 -0.742 . . . . 0.0 108.995 178.769 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' E' E ' 36' ' ' VAL . . . . . 0.661 HG22 HG12 ' H' ' 36' ' ' VAL . 35.4 m -156.62 166.23 0.94 Allowed 'Isoleucine or valine' 0 C--N 1.343 0.292 0 N-CA-C 108.354 -0.98 . . . . 0.0 108.354 179.747 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.72 66.87 2.53 Favored Glycine 0 C--N 1.307 -1.075 0 CA-C-N 115.576 -0.738 . . . . 0.0 111.997 178.442 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 144.1 -173.12 24.99 Favored Glycine 0 N--CA 1.475 1.281 0 N-CA-C 111.23 -0.748 . . . . 0.0 111.23 178.931 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' E' E ' 39' ' ' VAL . . . . . 0.596 ' H ' HG12 ' H' ' 39' ' ' VAL . 34.2 m -125.46 155.31 34.52 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.753 0 C-N-CA 123.405 0.682 . . . . 0.0 110.429 -179.138 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 26.4 t . . . . . 0 C--O 1.219 -0.526 0 O-C-N 124.062 0.851 . . . . 0.0 110.467 179.505 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 36.2 m-85 . . . . . 0 N--CA 1.474 0.75 0 N-CA-C 110.003 -0.369 . . . . 0.0 110.003 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' F' F ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -142.64 141.02 31.83 Favored 'General case' 0 N--CA 1.48 1.051 0 CA-C-O 120.884 0.373 . . . . 0.0 110.175 179.509 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 42.2 t-80 -151.9 118.95 5.85 Favored 'General case' 0 N--CA 1.472 0.639 0 N-CA-C 109.343 -0.614 . . . . 0.0 109.343 179.046 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' F' F ' 7' ' ' ASP . . . . . 0.478 ' O ' ' OG ' ' I' ' 8' ' ' SER . 4.0 m-20 -69.34 148.36 49.8 Favored 'General case' 0 N--CA 1.465 0.324 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.824 -179.902 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' F' F ' 8' ' ' SER . . . . . 0.49 ' OG ' ' O ' ' C' ' 7' ' ' ASP . 50.5 p -168.1 -172.03 1.68 Allowed 'General case' 0 N--CA 1.486 1.335 0 CA-C-O 121.119 0.485 . . . . 0.0 110.953 179.008 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.89 47.16 1.39 Allowed Glycine 0 N--CA 1.479 1.553 0 CA-C-N 115.884 -0.598 . . . . 0.0 111.953 179.629 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 46.2 p90 -64.73 133.4 52.0 Favored 'General case' 0 CA--C 1.543 0.68 0 N-CA-C 111.832 0.308 . . . . 0.0 111.832 -179.924 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 46.2 mt-10 -91.91 152.17 20.19 Favored 'General case' 0 N--CA 1.481 1.081 0 CA-C-O 121.19 0.519 . . . . 0.0 109.736 177.997 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -154.12 127.24 1.15 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.599 0 N-CA-C 107.838 -1.171 . . . . 0.0 107.838 178.131 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 44.5 m-70 -135.53 146.04 47.66 Favored 'General case' 0 N--CA 1.483 1.201 0 CA-C-O 120.88 0.372 . . . . 0.0 111.631 -177.916 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 6.4 t60 -164.07 96.94 0.81 Allowed 'General case' 0 N--CA 1.486 1.369 0 CA-C-N 116.436 -0.347 . . . . 0.0 110.674 179.385 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' F' F ' 15' ' ' GLN . . . . . 0.483 HE22 HG23 ' F' ' 36' ' ' VAL . 3.9 pt20 -101.18 -173.84 2.47 Favored 'General case' 0 CA--C 1.507 -0.698 0 N-CA-C 108.871 -0.789 . . . . 0.0 108.871 -179.814 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -169.87 94.93 0.27 Allowed 'General case' 0 N--CA 1.473 0.677 0 CA-C-N 114.609 -1.178 . . . . 0.0 108.443 178.42 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 6.3 mp -121.95 157.07 32.06 Favored 'General case' 0 N--CA 1.494 1.764 0 CA-C-O 121.685 0.755 . . . . 0.0 111.554 -177.676 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 48.1 t -114.02 124.27 70.5 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.217 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 177.162 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 30.0 m-85 -124.71 122.03 36.32 Favored 'General case' 0 N--CA 1.488 1.431 0 CA-C-O 120.863 0.364 . . . . 0.0 110.983 -179.741 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 68.9 m-85 54.61 74.18 0.36 Allowed 'General case' 0 C--N 1.344 0.362 0 CA-C-N 115.873 -0.603 . . . . 0.0 111.705 178.166 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -79.1 -78.5 0.15 Allowed 'General case' 0 CA--C 1.535 0.388 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.197 -179.56 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 38.4 tt0 -112.91 101.03 9.11 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 179.822 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -158.29 139.84 13.59 Favored 'General case' 0 C--O 1.208 -1.124 0 O-C-N 122.279 -0.263 . . . . 0.0 111.572 179.099 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' F' F ' 24' ' ' VAL . . . . . 0.472 ' HB ' ' H ' ' C' ' 25' ' ' GLY . 58.3 t -58.55 168.08 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.891 0 N-CA-C 107.507 -1.294 . . . . 0.0 107.507 177.037 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' F' F ' 25' ' ' GLY . . . . . 0.436 ' H ' ' HB ' ' I' ' 24' ' ' VAL . . . -122.14 49.48 0.89 Allowed Glycine 0 N--CA 1.477 1.43 0 N-CA-C 110.787 -0.925 . . . . 0.0 110.787 -179.427 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -63.27 -167.56 0.02 OUTLIER 'General case' 0 N--CA 1.469 0.509 0 CA-C-O 120.642 0.258 . . . . 0.0 110.441 179.796 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 25.5 t-20 -70.26 77.12 0.53 Allowed 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.451 179.916 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -75.02 144.77 42.91 Favored 'General case' 0 N--CA 1.476 0.845 0 N-CA-C 109.579 -0.526 . . . . 0.0 109.579 179.335 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.46 -167.02 1.25 Allowed Glycine 0 CA--C 1.522 0.484 0 N-CA-C 110.494 -1.042 . . . . 0.0 110.494 178.64 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.17 113.96 26.47 Favored 'General case' 0 N--CA 1.473 0.711 0 N-CA-C 109.808 -0.442 . . . . 0.0 109.808 179.665 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 66.5 mt -98.43 135.27 33.89 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.388 0 N-CA-C 106.837 -1.542 . . . . 0.0 106.837 178.762 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' F' F ' 32' ' ' ILE . . . . . 0.445 HG22 ' H ' ' I' ' 32' ' ' ILE . 35.2 pt -151.87 -174.29 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.198 0 CA-C-O 121.248 0.547 . . . . 0.0 110.723 -179.373 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.35 5.45 6.31 Favored Glycine 0 CA--C 1.528 0.901 0 CA-C-N 115.55 -0.75 . . . . 0.0 111.443 -179.774 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 1.6 tt -74.42 127.05 32.07 Favored 'General case' 0 CA--C 1.549 0.913 0 N-CA-C 109.467 -0.568 . . . . 0.0 109.467 -179.741 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 28.4 ttt -162.69 151.32 14.62 Favored 'General case' 0 C--O 1.209 -1.045 0 N-CA-C 108.963 -0.755 . . . . 0.0 108.963 178.605 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' F' F ' 36' ' ' VAL . . . . . 0.642 HG22 HG12 ' I' ' 36' ' ' VAL . 35.4 m -156.82 166.13 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.344 0.347 0 N-CA-C 108.312 -0.995 . . . . 0.0 108.312 179.77 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.78 67.0 2.44 Favored Glycine 0 C--N 1.307 -1.038 0 CA-C-N 115.595 -0.729 . . . . 0.0 112.003 178.49 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.98 -173.0 24.96 Favored Glycine 0 N--CA 1.474 1.179 0 N-CA-C 111.251 -0.74 . . . . 0.0 111.251 178.992 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' F' F ' 39' ' ' VAL . . . . . 0.597 ' H ' HG12 ' I' ' 39' ' ' VAL . 34.2 m -125.62 155.51 34.93 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.729 0 C-N-CA 123.336 0.654 . . . . 0.0 110.365 -179.166 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 25.3 t . . . . . 0 C--O 1.219 -0.551 0 O-C-N 124.004 0.815 . . . . 0.0 110.423 179.593 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 40.2 m-85 . . . . . 0 N--CA 1.474 0.768 0 N-CA-C 109.591 -0.522 . . . . 0.0 109.591 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' G' G ' 5' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -143.0 140.56 31.07 Favored 'General case' 0 N--CA 1.481 1.1 0 C-N-CA 122.498 0.319 . . . . 0.0 110.337 179.837 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 42.3 t-80 -151.27 120.22 6.66 Favored 'General case' 0 N--CA 1.474 0.739 0 N-CA-C 109.441 -0.578 . . . . 0.0 109.441 178.938 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -71.23 144.31 50.12 Favored 'General case' 0 N--CA 1.469 0.51 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.231 -179.829 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' G' G ' 8' ' ' SER . . . . . 0.586 ' OG ' ' O ' ' D' ' 7' ' ' ASP . 45.2 p -165.07 -170.52 1.95 Allowed 'General case' 0 N--CA 1.476 0.832 0 CA-C-O 121.037 0.446 . . . . 0.0 110.545 178.792 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.68 48.0 1.33 Allowed Glycine 0 N--CA 1.479 1.548 0 N-CA-C 111.485 -0.646 . . . . 0.0 111.485 179.468 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 48.8 p90 -65.77 133.43 50.99 Favored 'General case' 0 CA--C 1.543 0.676 0 N-CA-C 111.694 0.257 . . . . 0.0 111.694 -179.694 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 46.1 mt-10 -92.32 151.43 20.29 Favored 'General case' 0 N--CA 1.48 1.043 0 CA-C-O 121.146 0.498 . . . . 0.0 110.163 178.582 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -154.75 127.3 1.06 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.966 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 178.298 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 45.7 m-70 -134.74 147.34 50.01 Favored 'General case' 0 N--CA 1.478 0.965 0 CA-C-N 115.62 -0.718 . . . . 0.0 111.486 -178.291 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 6.6 t60 -165.42 97.35 0.69 Allowed 'General case' 0 N--CA 1.483 1.204 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.242 178.83 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' G' G ' 15' ' ' GLN . . . . . 0.44 HE22 HG23 ' G' ' 36' ' ' VAL . 3.9 pt20 -101.59 -173.67 2.41 Favored 'General case' 0 CA--C 1.507 -0.699 0 N-CA-C 108.662 -0.866 . . . . 0.0 108.662 -179.58 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -170.55 94.22 0.21 Allowed 'General case' 0 N--CA 1.473 0.693 0 CA-C-N 114.654 -1.157 . . . . 0.0 108.076 178.637 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 6.3 mp -121.33 155.85 33.85 Favored 'General case' 0 N--CA 1.498 1.93 0 CA-C-O 121.237 0.541 . . . . 0.0 111.814 -177.8 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 42.9 t -113.43 125.15 70.65 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.011 0 CA-C-N 114.74 -1.118 . . . . 0.0 108.116 176.566 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 31.8 m-85 -125.96 121.54 33.38 Favored 'General case' 0 C--N 1.367 1.337 0 CA-C-N 115.664 -0.698 . . . . 0.0 111.083 -179.446 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 68.4 m-85 54.86 73.11 0.43 Allowed 'General case' 0 N--CA 1.467 0.416 0 CA-C-N 115.858 -0.61 . . . . 0.0 111.545 178.036 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.58 -77.95 0.14 Allowed 'General case' 0 N--CA 1.472 0.64 0 O-C-N 122.212 -0.305 . . . . 0.0 110.355 -179.25 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 38.4 tt0 -113.23 101.14 9.14 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 107.95 -1.13 . . . . 0.0 107.95 179.822 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -158.29 141.02 14.61 Favored 'General case' 0 N--CA 1.477 0.915 0 O-C-N 122.337 -0.227 . . . . 0.0 111.487 179.063 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' G' G ' 24' ' ' VAL . . . . . 0.526 ' HB ' ' H ' ' D' ' 25' ' ' GLY . 59.9 t -60.28 167.07 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.762 0 N-CA-C 107.641 -1.244 . . . . 0.0 107.641 177.26 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' G' G ' 25' ' ' GLY . . . . . 0.426 ' N ' HG12 ' G' ' 24' ' ' VAL . . . -120.45 49.61 0.87 Allowed Glycine 0 N--CA 1.479 1.566 0 N-CA-C 110.504 -1.038 . . . . 0.0 110.504 -179.452 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -64.02 -167.27 0.02 OUTLIER 'General case' 0 N--CA 1.471 0.598 0 CA-C-N 116.953 0.376 . . . . 0.0 110.061 179.829 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 25.8 t-20 -70.45 77.12 0.56 Allowed 'General case' 0 CA--C 1.535 0.401 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.471 179.943 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -74.53 144.14 44.21 Favored 'General case' 0 N--CA 1.476 0.86 0 N-CA-C 109.653 -0.499 . . . . 0.0 109.653 179.361 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.39 -166.11 1.07 Allowed Glycine 0 C--N 1.337 0.619 0 N-CA-C 110.037 -1.225 . . . . 0.0 110.037 178.707 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -98.84 114.06 26.47 Favored 'General case' 0 N--CA 1.471 0.575 0 C-N-CA 122.672 0.389 . . . . 0.0 110.447 179.843 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 67.6 mt -99.16 135.51 34.02 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.698 0 N-CA-C 106.856 -1.535 . . . . 0.0 106.856 178.831 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' G' G ' 32' ' ' ILE . . . . . 0.459 ' H ' HG22 ' D' ' 32' ' ' ILE . 34.1 pt -152.48 -173.92 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 CA-C-N 119.891 1.223 . . . . 0.0 109.878 -179.725 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.15 5.31 7.61 Favored Glycine 0 N--CA 1.468 0.773 0 N-CA-C 111.061 -0.816 . . . . 0.0 111.061 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 1.6 tt -75.04 125.85 29.79 Favored 'General case' 0 CA--C 1.545 0.775 0 N-CA-C 109.524 -0.547 . . . . 0.0 109.524 -179.611 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 27.4 ttt -161.52 152.66 18.42 Favored 'General case' 0 C--O 1.21 -0.986 0 N-CA-C 108.775 -0.824 . . . . 0.0 108.775 178.503 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' G' G ' 36' ' ' VAL . . . . . 0.635 HG12 HG22 ' D' ' 36' ' ' VAL . 35.8 m -157.26 165.17 1.0 Allowed 'Isoleucine or valine' 0 C--N 1.346 0.429 0 N-CA-C 108.528 -0.916 . . . . 0.0 108.528 -179.675 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.39 67.99 1.92 Allowed Glycine 0 C--N 1.307 -1.031 0 CA-C-N 115.531 -0.759 . . . . 0.0 112.206 178.26 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.99 -171.66 25.45 Favored Glycine 0 N--CA 1.476 1.315 0 N-CA-C 110.621 -0.991 . . . . 0.0 110.621 178.998 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' G' G ' 39' ' ' VAL . . . . . 0.587 HG12 ' H ' ' D' ' 39' ' ' VAL . 34.7 m -126.93 156.03 38.04 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.911 0 C-N-CA 123.069 0.548 . . . . 0.0 110.631 -179.357 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 31.5 t . . . . . 0 C--O 1.219 -0.546 0 O-C-N 123.946 0.779 . . . . 0.0 110.737 179.218 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 41.0 m-85 . . . . . 0 N--CA 1.473 0.706 0 N-CA-C 109.627 -0.508 . . . . 0.0 109.627 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' H' H ' 5' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -142.91 141.27 31.46 Favored 'General case' 0 N--CA 1.484 1.273 0 C-N-CA 122.585 0.354 . . . . 0.0 110.169 179.747 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 42.0 t-80 -151.98 120.1 6.28 Favored 'General case' 0 N--CA 1.474 0.731 0 N-CA-C 109.36 -0.607 . . . . 0.0 109.36 179.018 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -71.16 144.17 50.29 Favored 'General case' 0 N--CA 1.469 0.519 0 CA-C-N 116.321 -0.4 . . . . 0.0 111.303 -179.777 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' H' H ' 8' ' ' SER . . . . . 0.432 ' OG ' ' O ' ' E' ' 7' ' ' ASP . 53.1 p -164.77 -170.93 2.12 Favored 'General case' 0 N--CA 1.474 0.751 0 CA-C-O 121.06 0.457 . . . . 0.0 110.472 178.783 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.22 47.35 1.33 Allowed Glycine 0 N--CA 1.48 1.567 0 CA-C-N 115.848 -0.614 . . . . 0.0 111.713 179.47 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 49.2 p90 -65.47 133.09 50.53 Favored 'General case' 0 N--CA 1.471 0.594 0 N-CA-C 111.792 0.293 . . . . 0.0 111.792 -179.627 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 46.2 mt-10 -92.0 151.41 20.49 Favored 'General case' 0 N--CA 1.479 0.982 0 CA-C-O 121.115 0.483 . . . . 0.0 110.225 178.568 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -154.65 127.82 1.16 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.027 0 N-CA-C 107.851 -1.166 . . . . 0.0 107.851 178.233 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 46.6 m-70 -135.29 147.3 49.16 Favored 'General case' 0 N--CA 1.478 0.956 0 CA-C-N 115.653 -0.703 . . . . 0.0 111.409 -178.239 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 6.5 t60 -165.47 97.31 0.68 Allowed 'General case' 0 N--CA 1.483 1.195 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.222 178.887 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' H' H ' 15' ' ' GLN . . . . . 0.431 HE22 HG23 ' H' ' 36' ' ' VAL . 3.9 pt20 -101.5 -173.46 2.37 Favored 'General case' 0 CA--C 1.507 -0.678 0 N-CA-C 108.636 -0.875 . . . . 0.0 108.636 -179.579 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -170.8 94.36 0.2 Allowed 'General case' 0 N--CA 1.472 0.652 0 CA-C-N 114.652 -1.158 . . . . 0.0 108.105 178.626 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 6.4 mp -121.43 155.57 34.57 Favored 'General case' 0 N--CA 1.497 1.911 0 CA-C-O 121.219 0.533 . . . . 0.0 111.938 -177.85 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 42.9 t -113.28 124.71 70.19 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.024 0 CA-C-N 114.782 -1.099 . . . . 0.0 108.134 176.568 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 31.3 m-85 -125.34 121.99 35.55 Favored 'General case' 0 C--N 1.367 1.351 0 CA-C-N 115.497 -0.774 . . . . 0.0 110.914 -179.252 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 68.1 m-85 54.05 73.34 0.39 Allowed 'General case' 0 C--O 1.237 0.436 0 CA-C-N 115.725 -0.67 . . . . 0.0 111.713 178.076 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.53 -78.03 0.14 Allowed 'General case' 0 N--CA 1.472 0.674 0 O-C-N 122.264 -0.273 . . . . 0.0 110.359 -179.218 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 38.3 tt0 -113.15 101.05 9.07 Favored 'General case' 0 C--N 1.322 -0.608 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 179.865 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -158.1 141.01 14.84 Favored 'General case' 0 N--CA 1.478 0.94 0 O-C-N 122.391 -0.193 . . . . 0.0 111.453 179.046 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' H' H ' 24' ' ' VAL . . . . . 0.432 ' HB ' ' H ' ' E' ' 25' ' ' GLY . 59.3 t -60.17 167.28 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.569 0 N-CA-C 107.655 -1.239 . . . . 0.0 107.655 177.209 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' H' H ' 25' ' ' GLY . . . . . 0.425 ' N ' HG12 ' H' ' 24' ' ' VAL . . . -120.65 49.65 0.87 Allowed Glycine 0 N--CA 1.478 1.499 0 N-CA-C 110.513 -1.035 . . . . 0.0 110.513 -179.463 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -64.26 -167.77 0.03 OUTLIER 'General case' 0 N--CA 1.473 0.701 0 CA-C-N 117.005 0.403 . . . . 0.0 110.1 179.755 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 25.9 t-20 -70.01 77.15 0.49 Allowed 'General case' 0 CA--C 1.534 0.34 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.46 -179.974 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -74.65 144.5 43.81 Favored 'General case' 0 N--CA 1.476 0.846 0 N-CA-C 109.552 -0.536 . . . . 0.0 109.552 179.304 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.74 -165.23 1.01 Allowed Glycine 0 C--N 1.338 0.644 0 N-CA-C 109.936 -1.265 . . . . 0.0 109.936 178.833 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.94 113.71 26.46 Favored 'General case' 0 N--CA 1.47 0.54 0 C-N-CA 122.603 0.361 . . . . 0.0 110.548 -179.996 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 66.5 mt -98.6 135.78 32.15 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.758 0 N-CA-C 106.824 -1.547 . . . . 0.0 106.824 178.922 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' H' H ' 32' ' ' ILE . . . . . 0.45 ' H ' HG22 ' E' ' 32' ' ' ILE . 34.7 pt -152.81 -174.05 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 CA-C-N 119.853 1.206 . . . . 0.0 109.893 -179.797 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.15 5.61 8.3 Favored Glycine 0 N--CA 1.467 0.761 0 N-CA-C 111.004 -0.839 . . . . 0.0 111.004 179.971 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 1.6 tt -75.23 125.59 29.28 Favored 'General case' 0 CA--C 1.545 0.772 0 N-CA-C 109.588 -0.523 . . . . 0.0 109.588 -179.582 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 27.5 ttt -161.17 152.59 19.04 Favored 'General case' 0 C--O 1.212 -0.91 0 N-CA-C 108.886 -0.783 . . . . 0.0 108.886 178.61 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' H' H ' 36' ' ' VAL . . . . . 0.661 HG12 HG22 ' E' ' 36' ' ' VAL . 35.3 m -157.41 164.58 1.09 Allowed 'Isoleucine or valine' 0 C--N 1.347 0.458 0 N-CA-C 108.489 -0.93 . . . . 0.0 108.489 -179.582 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.78 67.91 1.96 Allowed Glycine 0 C--N 1.308 -0.997 0 CA-C-N 115.425 -0.807 . . . . 0.0 112.182 178.335 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 144.1 -171.89 25.43 Favored Glycine 0 N--CA 1.475 1.266 0 N-CA-C 110.682 -0.967 . . . . 0.0 110.682 179.11 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' H' H ' 39' ' ' VAL . . . . . 0.596 HG12 ' H ' ' E' ' 39' ' ' VAL . 35.0 m -126.8 155.75 37.65 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.94 0 C-N-CA 123.174 0.59 . . . . 0.0 110.663 -179.255 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 29.5 t . . . . . 0 C--O 1.217 -0.611 0 CA-C-O 118.433 -0.794 . . . . 0.0 110.759 179.341 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 40.5 m-85 . . . . . 0 N--CA 1.474 0.749 0 N-CA-C 109.578 -0.527 . . . . 0.0 109.578 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' I' I ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -143.33 140.58 30.62 Favored 'General case' 0 N--CA 1.483 1.178 0 C-N-CA 122.513 0.325 . . . . 0.0 110.152 -179.987 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 41.6 t-80 -151.67 119.61 6.22 Favored 'General case' 0 N--CA 1.474 0.73 0 N-CA-C 109.435 -0.579 . . . . 0.0 109.435 179.058 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -70.7 144.61 50.94 Favored 'General case' 0 N--CA 1.468 0.472 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.203 -179.807 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' I' I ' 8' ' ' SER . . . . . 0.478 ' OG ' ' O ' ' F' ' 7' ' ' ASP . 52.8 p -165.08 -170.69 1.99 Allowed 'General case' 0 N--CA 1.474 0.752 0 CA-C-O 121.023 0.439 . . . . 0.0 110.521 178.752 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.71 47.77 1.35 Allowed Glycine 0 N--CA 1.481 1.638 0 CA-C-N 115.904 -0.589 . . . . 0.0 111.742 179.56 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 49.1 p90 -65.76 133.13 50.38 Favored 'General case' 0 N--CA 1.472 0.637 0 N-CA-C 111.834 0.309 . . . . 0.0 111.834 -179.771 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 46.2 mt-10 -92.0 151.19 20.6 Favored 'General case' 0 N--CA 1.477 0.923 0 C-N-CA 122.841 0.456 . . . . 0.0 110.249 178.615 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -154.6 127.68 1.15 Allowed 'Isoleucine or valine' 0 CA--C 1.551 0.997 0 N-CA-C 107.86 -1.163 . . . . 0.0 107.86 178.195 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 45.2 m-70 -135.02 147.33 49.63 Favored 'General case' 0 N--CA 1.477 0.918 0 CA-C-N 115.608 -0.724 . . . . 0.0 111.479 -178.252 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 6.5 t60 -165.39 97.31 0.69 Allowed 'General case' 0 N--CA 1.483 1.179 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.218 178.82 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' I' I ' 15' ' ' GLN . . . . . 0.43 HE22 HG23 ' I' ' 36' ' ' VAL . 3.9 pt20 -101.59 -173.43 2.35 Favored 'General case' 0 CA--C 1.507 -0.696 0 N-CA-C 108.622 -0.881 . . . . 0.0 108.622 -179.524 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -170.83 94.48 0.2 Allowed 'General case' 0 N--CA 1.472 0.642 0 CA-C-N 114.631 -1.168 . . . . 0.0 108.076 178.677 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 6.3 mp -121.6 155.52 34.89 Favored 'General case' 0 N--CA 1.496 1.861 0 CA-C-O 121.229 0.538 . . . . 0.0 111.865 -177.851 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 42.0 t -113.09 125.22 70.32 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.015 0 CA-C-N 114.783 -1.099 . . . . 0.0 108.053 176.522 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 31.0 m-85 -125.98 121.63 33.62 Favored 'General case' 0 C--N 1.368 1.396 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.996 -179.17 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 68.2 m-85 54.38 73.05 0.42 Allowed 'General case' 0 N--CA 1.466 0.363 0 CA-C-N 115.836 -0.62 . . . . 0.0 111.584 178.085 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.34 -78.12 0.14 Allowed 'General case' 0 N--CA 1.473 0.712 0 N-CA-C 110.293 -0.262 . . . . 0.0 110.293 -179.218 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 38.6 tt0 -113.05 101.3 9.33 Favored 'General case' 0 C--N 1.323 -0.581 0 N-CA-C 107.994 -1.113 . . . . 0.0 107.994 179.811 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -158.34 141.1 14.61 Favored 'General case' 0 N--CA 1.476 0.867 0 O-C-N 122.368 -0.207 . . . . 0.0 111.444 179.021 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' I' I ' 24' ' ' VAL . . . . . 0.436 ' HB ' ' H ' ' F' ' 25' ' ' GLY . 59.6 t -60.31 166.85 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.348 0.534 0 N-CA-C 107.664 -1.236 . . . . 0.0 107.664 177.212 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' I' I ' 25' ' ' GLY . . . . . 0.43 ' N ' HG12 ' I' ' 24' ' ' VAL . . . -120.27 49.76 0.86 Allowed Glycine 0 N--CA 1.481 1.691 0 N-CA-C 110.542 -1.023 . . . . 0.0 110.542 -179.481 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -64.26 -167.85 0.03 OUTLIER 'General case' 0 N--CA 1.471 0.61 0 CA-C-N 116.922 0.361 . . . . 0.0 110.129 179.714 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 25.7 t-20 -69.9 77.18 0.47 Allowed 'General case' 0 CA--C 1.534 0.345 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.419 -179.99 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -74.74 144.43 43.65 Favored 'General case' 0 N--CA 1.475 0.812 0 N-CA-C 109.641 -0.503 . . . . 0.0 109.641 179.387 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.66 -166.06 1.15 Allowed Glycine 0 C--N 1.337 0.607 0 N-CA-C 110.023 -1.231 . . . . 0.0 110.023 178.71 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.09 113.69 26.03 Favored 'General case' 0 N--CA 1.471 0.586 0 C-N-CA 122.674 0.39 . . . . 0.0 110.468 -179.887 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 67.2 mt -98.68 135.65 32.76 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.73 0 N-CA-C 106.895 -1.52 . . . . 0.0 106.895 178.889 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' I' I ' 32' ' ' ILE . . . . . 0.445 ' H ' HG22 ' F' ' 32' ' ' ILE . 35.0 pt -152.71 -173.92 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.774 0 CA-C-N 119.837 1.199 . . . . 0.0 109.826 -179.724 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.02 5.45 7.66 Favored Glycine 0 CA--C 1.527 0.811 0 N-CA-C 111.063 -0.815 . . . . 0.0 111.063 -179.942 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 1.6 tt -74.97 125.94 29.96 Favored 'General case' 0 CA--C 1.546 0.789 0 N-CA-C 109.549 -0.538 . . . . 0.0 109.549 -179.706 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 27.5 ttt -161.45 152.48 18.35 Favored 'General case' 0 C--O 1.21 -0.981 0 N-CA-C 108.794 -0.817 . . . . 0.0 108.794 178.625 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' I' I ' 36' ' ' VAL . . . . . 0.642 HG12 HG22 ' F' ' 36' ' ' VAL . 35.9 m -157.39 164.82 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.346 0.426 0 N-CA-C 108.468 -0.938 . . . . 0.0 108.468 -179.849 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.62 68.13 1.85 Allowed Glycine 0 C--N 1.308 -0.976 0 CA-C-N 115.501 -0.772 . . . . 0.0 112.137 178.294 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 144.01 -171.86 25.39 Favored Glycine 0 N--CA 1.476 1.302 0 N-CA-C 110.601 -1.0 . . . . 0.0 110.601 179.145 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' I' I ' 39' ' ' VAL . . . . . 0.597 HG12 ' H ' ' F' ' 39' ' ' VAL . 34.9 m -126.95 155.98 38.08 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.935 0 C-N-CA 123.118 0.567 . . . . 0.0 110.617 -179.359 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 31.8 t . . . . . 0 C--O 1.219 -0.542 0 O-C-N 123.953 0.783 . . . . 0.0 110.693 179.402 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 42.4 m-85 . . . . . 0 N--CA 1.474 0.758 0 N-CA-C 110.076 -0.342 . . . . 0.0 110.076 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -142.72 141.24 31.75 Favored 'General case' 0 N--CA 1.481 1.08 0 CA-C-O 120.861 0.363 . . . . 0.0 110.052 179.53 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 45.3 t-80 -152.11 119.03 5.79 Favored 'General case' 0 N--CA 1.471 0.613 0 N-CA-C 109.263 -0.643 . . . . 0.0 109.263 178.997 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' ASP . . . . . 0.488 ' O ' ' OG ' ' D' ' 8' ' ' SER . 4.5 m-20 -68.93 149.4 48.9 Favored 'General case' 0 CA--C 1.536 0.436 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.448 179.883 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 60.4 p -168.16 -173.78 2.13 Favored 'General case' 0 N--CA 1.484 1.228 0 CA-C-O 120.947 0.404 . . . . 0.0 110.635 179.224 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.37 46.85 1.37 Allowed Glycine 0 N--CA 1.482 1.721 0 CA-C-N 115.972 -0.558 . . . . 0.0 112.114 179.816 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 49.8 p90 -66.16 132.61 48.86 Favored 'General case' 0 N--CA 1.473 0.697 0 O-C-N 122.782 -0.246 . . . . 0.0 111.53 179.766 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 48.7 mt-10 -91.84 152.49 20.08 Favored 'General case' 0 N--CA 1.477 0.911 0 CA-C-O 121.066 0.46 . . . . 0.0 109.776 178.293 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.0 p -153.15 127.63 1.4 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.545 0 N-CA-C 107.915 -1.143 . . . . 0.0 107.915 178.363 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 44.1 m-70 -135.6 148.44 49.05 Favored 'General case' 0 N--CA 1.492 1.645 0 CA-C-N 119.09 0.859 . . . . 0.0 111.324 -179.064 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 7.0 t60 -163.67 97.81 0.87 Allowed 'General case' 0 N--CA 1.481 1.09 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.776 179.395 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . 0.531 HE22 ' H ' ' A' ' 37' ' ' GLY . 3.4 pt20 -107.63 -175.74 2.87 Favored 'General case' 0 CA--C 1.507 -0.68 0 N-CA-C 108.422 -0.955 . . . . 0.0 108.422 -179.98 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -169.63 100.56 0.32 Allowed 'General case' 0 CA--C 1.54 0.582 0 CA-C-N 114.629 -1.169 . . . . 0.0 108.466 179.029 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.547 ' H ' ' CD2' ' D' ' 17' ' ' LEU . 6.9 mt -125.46 153.17 43.91 Favored 'General case' 0 N--CA 1.492 1.675 0 CA-C-O 121.443 0.64 . . . . 0.0 110.975 -178.284 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 60.4 t -107.8 129.26 62.17 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.21 0 CA-C-O 117.896 -1.05 . . . . 0.0 108.392 178.039 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 45.3 m-85 -125.97 122.72 36.73 Favored 'General case' 0 N--CA 1.497 1.919 0 CA-C-N 120.099 1.318 . . . . 0.0 110.367 179.272 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 74.2 m-85 53.09 75.02 0.26 Allowed 'General case' 0 N--CA 1.471 0.594 0 CA-C-O 121.361 0.6 . . . . 0.0 111.935 178.469 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -79.52 -78.32 0.16 Allowed 'General case' 0 C--N 1.353 0.739 0 CA-C-N 115.097 -0.956 . . . . 0.0 110.283 -179.796 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 39.9 tt0 -112.58 100.57 8.83 Favored 'General case' 0 N--CA 1.47 0.564 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 179.805 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -159.33 140.54 12.86 Favored 'General case' 0 C--O 1.207 -1.163 0 O-C-N 122.283 -0.261 . . . . 0.0 111.161 179.175 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.417 HG12 ' N ' ' A' ' 25' ' ' GLY . 61.5 t -60.33 164.15 0.92 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.836 0 N-CA-C 108.154 -1.054 . . . . 0.0 108.154 177.174 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.444 ' H ' ' HB ' ' D' ' 24' ' ' VAL . . . -117.66 48.89 0.9 Allowed Glycine 0 N--CA 1.477 1.426 0 N-CA-C 111.657 -0.577 . . . . 0.0 111.657 -179.353 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -61.92 -168.23 0.02 OUTLIER 'General case' 0 N--CA 1.469 0.486 0 O-C-N 123.845 0.38 . . . . 0.0 110.371 179.532 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 24.7 t-20 -70.17 81.11 0.51 Allowed 'General case' 0 N--CA 1.465 0.282 0 N-CA-C 110.144 -0.317 . . . . 0.0 110.144 179.792 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -79.65 146.43 32.49 Favored 'General case' 0 N--CA 1.472 0.627 0 N-CA-C 109.087 -0.708 . . . . 0.0 109.087 179.123 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -62.98 -168.54 0.93 Allowed Glycine 0 CA--C 1.524 0.653 0 N-CA-C 109.895 -1.282 . . . . 0.0 109.895 178.752 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -100.19 116.47 32.26 Favored 'General case' 0 N--CA 1.477 0.898 0 N-CA-C 109.685 -0.487 . . . . 0.0 109.685 179.723 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 69.4 mt -97.34 135.33 31.98 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.556 0 N-CA-C 107.102 -1.444 . . . . 0.0 107.102 179.003 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 44.1 pt -151.43 -178.17 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.713 0 CA-C-O 121.222 0.534 . . . . 0.0 111.11 -178.899 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 64.09 5.34 14.66 Favored Glycine 0 CA--C 1.526 0.728 0 N-CA-C 110.815 -0.914 . . . . 0.0 110.815 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.414 HD23 ' N ' ' A' ' 35' ' ' MET . 1.4 tt -73.79 128.7 36.2 Favored 'General case' 0 CA--C 1.545 0.776 0 N-CA-C 109.61 -0.515 . . . . 0.0 109.61 -179.714 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' MET . . . . . 0.414 ' N ' HD23 ' A' ' 34' ' ' LEU . 28.7 ttt -163.55 147.39 10.44 Favored 'General case' 0 N--CA 1.465 0.305 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 178.506 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.539 HG22 HG12 ' D' ' 36' ' ' VAL . 31.6 m -155.13 163.54 1.55 Allowed 'Isoleucine or valine' 0 C--N 1.347 0.488 0 N-CA-C 108.11 -1.07 . . . . 0.0 108.11 179.503 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . 0.531 ' H ' HE22 ' A' ' 15' ' ' GLN . . . 55.4 68.15 1.84 Allowed Glycine 0 C--N 1.306 -1.134 0 CA-C-N 115.89 -0.596 . . . . 0.0 112.078 178.706 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 141.09 175.35 14.71 Favored Glycine 0 N--CA 1.475 1.273 0 N-CA-C 110.821 -0.912 . . . . 0.0 110.821 179.164 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.512 ' H ' HG12 ' D' ' 39' ' ' VAL . 35.4 m -118.55 159.69 18.85 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.813 0 C-N-CA 123.364 0.666 . . . . 0.0 110.384 -179.998 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 22.1 t . . . . . 0 C--O 1.221 -0.441 0 CA-C-O 118.523 -0.751 . . . . 0.0 110.649 179.488 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 41.2 m-85 . . . . . 0 N--CA 1.474 0.751 0 N-CA-C 110.088 -0.338 . . . . 0.0 110.088 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -142.58 141.06 31.93 Favored 'General case' 0 N--CA 1.483 1.217 0 N-CA-C 109.98 -0.378 . . . . 0.0 109.98 179.437 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 44.4 t-80 -151.94 118.94 5.83 Favored 'General case' 0 N--CA 1.473 0.688 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 178.991 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 7' ' ' ASP . . . . . 0.441 ' O ' ' OG ' ' E' ' 8' ' ' SER . 4.3 m-20 -69.08 148.88 49.38 Favored 'General case' 0 CA--C 1.537 0.473 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.585 179.93 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 8' ' ' SER . . . . . . . . . . . . . 59.9 p -167.76 -173.73 2.23 Favored 'General case' 0 N--CA 1.482 1.144 0 CA-C-O 120.985 0.422 . . . . 0.0 110.644 179.336 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.23 46.72 1.41 Allowed Glycine 0 N--CA 1.482 1.753 0 CA-C-N 115.902 -0.59 . . . . 0.0 112.164 179.944 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 50.2 p90 -66.14 132.51 48.66 Favored 'General case' 0 N--CA 1.472 0.657 0 CA-C-O 120.624 0.25 . . . . 0.0 111.596 179.632 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 48.2 mt-10 -91.7 152.62 20.12 Favored 'General case' 0 N--CA 1.476 0.846 0 CA-C-O 121.076 0.465 . . . . 0.0 109.758 178.307 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.0 p -153.23 128.07 1.47 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.654 0 N-CA-C 107.772 -1.196 . . . . 0.0 107.772 178.167 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 43.6 m-70 -135.72 148.91 49.04 Favored 'General case' 0 N--CA 1.492 1.628 0 CA-C-N 118.837 0.744 . . . . 0.0 111.355 -179.145 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 7.2 t60 -164.3 97.62 0.8 Allowed 'General case' 0 N--CA 1.482 1.139 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.75 179.494 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . 0.532 HE22 ' H ' ' B' ' 37' ' ' GLY . 3.4 pt20 -107.41 -175.37 2.77 Favored 'General case' 0 CA--C 1.509 -0.623 0 N-CA-C 108.255 -1.017 . . . . 0.0 108.255 -179.921 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -169.96 100.18 0.3 Allowed 'General case' 0 N--CA 1.471 0.619 0 CA-C-N 114.667 -1.151 . . . . 0.0 108.415 178.995 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . 0.534 ' H ' ' CD2' ' E' ' 17' ' ' LEU . 6.9 mt -124.92 153.72 42.23 Favored 'General case' 0 N--CA 1.491 1.61 0 CA-C-O 121.506 0.669 . . . . 0.0 111.03 -178.39 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 61.3 t -108.4 130.33 61.25 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.221 0 N-CA-C 108.054 -1.091 . . . . 0.0 108.054 177.933 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 44.2 m-85 -127.24 122.06 32.92 Favored 'General case' 0 N--CA 1.494 1.766 0 CA-C-N 119.721 1.146 . . . . 0.0 110.221 179.524 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 74.7 m-85 52.89 75.28 0.25 Allowed 'General case' 0 CA--C 1.539 0.527 0 CA-C-O 121.427 0.632 . . . . 0.0 111.939 178.47 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -79.92 -78.06 0.17 Allowed 'General case' 0 C--N 1.351 0.666 0 CA-C-N 115.026 -0.988 . . . . 0.0 110.283 -179.839 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 40.2 tt0 -112.58 100.65 8.9 Favored 'General case' 0 N--CA 1.473 0.683 0 N-CA-C 108.349 -0.982 . . . . 0.0 108.349 179.73 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -159.34 141.24 13.4 Favored 'General case' 0 N--CA 1.484 1.235 0 O-C-N 122.222 -0.299 . . . . 0.0 111.144 179.193 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 61.4 t -61.0 163.9 1.05 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.852 0 N-CA-C 108.176 -1.046 . . . . 0.0 108.176 177.238 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 25' ' ' GLY . . . . . 0.466 ' H ' ' HB ' ' E' ' 24' ' ' VAL . . . -117.19 48.51 0.93 Allowed Glycine 0 N--CA 1.476 1.338 0 N-CA-C 111.581 -0.608 . . . . 0.0 111.581 -179.328 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -61.55 -167.43 0.01 OUTLIER 'General case' 0 N--CA 1.469 0.505 0 O-C-N 123.753 0.325 . . . . 0.0 110.364 179.494 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 24.8 t-20 -71.24 81.18 0.73 Allowed 'General case' 0 N--CA 1.465 0.324 0 N-CA-C 110.076 -0.342 . . . . 0.0 110.076 179.863 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -79.75 146.47 32.33 Favored 'General case' 0 N--CA 1.473 0.69 0 N-CA-C 109.096 -0.705 . . . . 0.0 109.096 179.274 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.03 -168.7 0.97 Allowed Glycine 0 C--N 1.336 0.56 0 N-CA-C 109.914 -1.274 . . . . 0.0 109.914 178.735 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.97 116.76 32.77 Favored 'General case' 0 N--CA 1.476 0.87 0 N-CA-C 109.668 -0.493 . . . . 0.0 109.668 179.789 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 69.8 mt -97.65 135.07 33.37 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.537 0 N-CA-C 107.07 -1.456 . . . . 0.0 107.07 178.972 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 43.7 pt -151.1 -177.94 0.38 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.681 0 CA-C-O 121.299 0.571 . . . . 0.0 111.159 -178.753 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.42 5.94 13.46 Favored Glycine 0 CA--C 1.525 0.692 0 N-CA-C 110.884 -0.887 . . . . 0.0 110.884 -179.967 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 34' ' ' LEU . . . . . 0.4 HD23 ' N ' ' B' ' 35' ' ' MET . 1.4 tt -74.39 128.35 35.33 Favored 'General case' 0 CA--C 1.545 0.774 0 N-CA-C 109.528 -0.545 . . . . 0.0 109.528 -179.745 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 35' ' ' MET . . . . . 0.4 ' N ' HD23 ' B' ' 34' ' ' LEU . 28.6 ttt -162.95 147.76 11.6 Favored 'General case' 0 N--CA 1.468 0.427 0 N-CA-C 108.797 -0.816 . . . . 0.0 108.797 178.607 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 36' ' ' VAL . . . . . 0.497 HG22 HG12 ' E' ' 36' ' ' VAL . 29.9 m -155.68 163.31 1.53 Allowed 'Isoleucine or valine' 0 C--N 1.347 0.49 0 N-CA-C 108.096 -1.075 . . . . 0.0 108.096 179.516 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . 0.532 ' H ' HE22 ' B' ' 15' ' ' GLN . . . 55.67 67.74 2.05 Favored Glycine 0 C--N 1.306 -1.11 0 CA-C-N 115.881 -0.6 . . . . 0.0 112.014 178.676 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 141.17 175.65 14.97 Favored Glycine 0 N--CA 1.475 1.247 0 N-CA-C 110.891 -0.883 . . . . 0.0 110.891 179.079 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 39' ' ' VAL . . . . . 0.514 ' H ' HG12 ' E' ' 39' ' ' VAL . 35.5 m -118.56 159.87 18.73 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.89 0 C-N-CA 123.469 0.708 . . . . 0.0 110.476 -179.934 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 21.9 t . . . . . 0 N--CA 1.468 0.475 0 CA-C-O 118.364 -0.827 . . . . 0.0 110.468 179.362 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 41.3 m-85 . . . . . 0 N--CA 1.475 0.775 0 N-CA-C 110.128 -0.323 . . . . 0.0 110.128 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -143.34 140.49 30.55 Favored 'General case' 0 N--CA 1.481 1.097 0 N-CA-C 110.126 -0.324 . . . . 0.0 110.126 179.608 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 45.4 t-80 -151.51 119.24 6.13 Favored 'General case' 0 N--CA 1.472 0.667 0 N-CA-C 109.286 -0.635 . . . . 0.0 109.286 178.984 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 7' ' ' ASP . . . . . 0.482 ' O ' ' OG ' ' F' ' 8' ' ' SER . 4.4 m-20 -69.32 148.76 49.27 Favored 'General case' 0 CA--C 1.537 0.471 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.591 179.891 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 8' ' ' SER . . . . . . . . . . . . . 59.6 p -167.63 -173.64 2.24 Favored 'General case' 0 N--CA 1.482 1.143 0 CA-C-O 121.04 0.448 . . . . 0.0 110.621 179.202 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.28 47.19 1.34 Allowed Glycine 0 N--CA 1.482 1.702 0 CA-C-N 115.995 -0.548 . . . . 0.0 112.11 179.892 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 49.6 p90 -66.62 132.49 48.29 Favored 'General case' 0 N--CA 1.473 0.713 0 CA-C-O 120.761 0.315 . . . . 0.0 111.571 179.655 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 48.4 mt-10 -91.45 152.63 20.29 Favored 'General case' 0 N--CA 1.475 0.806 0 N-CA-C 109.719 -0.474 . . . . 0.0 109.719 178.253 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -153.33 128.01 1.44 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.548 0 N-CA-C 107.873 -1.158 . . . . 0.0 107.873 178.183 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 43.7 m-70 -135.92 148.51 48.58 Favored 'General case' 0 N--CA 1.492 1.643 0 CA-C-N 118.932 0.787 . . . . 0.0 111.305 -179.055 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 7.1 t60 -163.86 97.56 0.85 Allowed 'General case' 0 N--CA 1.483 1.182 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.794 179.475 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 15' ' ' GLN . . . . . 0.539 HE22 ' H ' ' C' ' 37' ' ' GLY . 3.4 pt20 -107.43 -175.09 2.69 Favored 'General case' 0 CA--C 1.508 -0.662 0 N-CA-C 108.237 -1.023 . . . . 0.0 108.237 -179.96 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -170.29 100.27 0.27 Allowed 'General case' 0 N--CA 1.471 0.577 0 CA-C-N 114.59 -1.186 . . . . 0.0 108.415 179.192 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 17' ' ' LEU . . . . . 0.525 ' H ' ' CD2' ' F' ' 17' ' ' LEU . 6.9 mt -125.14 153.47 42.96 Favored 'General case' 0 N--CA 1.492 1.665 0 CA-C-O 121.52 0.676 . . . . 0.0 111.03 -178.217 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 61.2 t -108.07 130.22 60.97 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.188 0 N-CA-C 108.229 -1.026 . . . . 0.0 108.229 177.844 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 44.3 m-85 -127.16 121.99 32.89 Favored 'General case' 0 N--CA 1.493 1.68 0 CA-C-N 119.655 1.116 . . . . 0.0 110.349 179.454 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 74.2 m-85 52.84 75.22 0.25 Allowed 'General case' 0 N--CA 1.469 0.508 0 CA-C-O 121.518 0.675 . . . . 0.0 111.98 178.529 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -79.83 -77.97 0.17 Allowed 'General case' 0 C--N 1.35 0.6 0 CA-C-N 114.876 -1.056 . . . . 0.0 110.267 -179.814 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 39.8 tt0 -112.68 100.71 8.92 Favored 'General case' 0 N--CA 1.471 0.586 0 N-CA-C 108.3 -1.0 . . . . 0.0 108.3 179.736 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -159.41 140.83 12.98 Favored 'General case' 0 N--CA 1.483 1.178 0 O-C-N 122.22 -0.3 . . . . 0.0 111.226 179.124 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 24' ' ' VAL . . . . . 0.416 HG12 ' N ' ' C' ' 25' ' ' GLY . 60.2 t -60.39 164.34 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.871 0 N-CA-C 108.087 -1.079 . . . . 0.0 108.087 177.23 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 25' ' ' GLY . . . . . 0.447 ' H ' ' HB ' ' F' ' 24' ' ' VAL . . . -117.63 48.82 0.91 Allowed Glycine 0 N--CA 1.479 1.519 0 N-CA-C 111.45 -0.66 . . . . 0.0 111.45 -179.43 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -61.91 -167.92 0.01 OUTLIER 'General case' 0 N--CA 1.468 0.425 0 O-C-N 123.707 0.298 . . . . 0.0 110.386 179.547 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 24.8 t-20 -70.54 80.9 0.58 Allowed 'General case' 0 N--CA 1.466 0.353 0 N-CA-C 110.113 -0.329 . . . . 0.0 110.113 179.692 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -79.51 146.57 32.61 Favored 'General case' 0 N--CA 1.473 0.698 0 N-CA-C 109.065 -0.717 . . . . 0.0 109.065 179.239 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.08 -168.76 1.0 Allowed Glycine 0 CA--C 1.525 0.699 0 N-CA-C 109.98 -1.248 . . . . 0.0 109.98 178.806 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.96 116.35 31.82 Favored 'General case' 0 N--CA 1.478 0.974 0 N-CA-C 109.657 -0.498 . . . . 0.0 109.657 179.757 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 69.3 mt -97.45 135.13 32.87 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.54 0 N-CA-C 107.16 -1.422 . . . . 0.0 107.16 179.034 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 43.9 pt -151.12 -177.91 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.649 0 CA-C-N 115.995 -0.548 . . . . 0.0 111.304 -178.691 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.59 5.58 13.11 Favored Glycine 0 CA--C 1.524 0.6 0 N-CA-C 110.853 -0.899 . . . . 0.0 110.853 -179.987 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 34' ' ' LEU . . . . . 0.413 HD23 ' N ' ' C' ' 35' ' ' MET . 1.4 tt -74.07 128.17 34.84 Favored 'General case' 0 CA--C 1.545 0.774 0 N-CA-C 109.626 -0.509 . . . . 0.0 109.626 -179.738 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 35' ' ' MET . . . . . 0.413 ' N ' HD23 ' C' ' 34' ' ' LEU . 28.5 ttt -162.94 147.38 11.44 Favored 'General case' 0 N--CA 1.466 0.364 0 N-CA-C 108.679 -0.86 . . . . 0.0 108.679 178.666 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 36' ' ' VAL . . . . . 0.521 HG22 HG12 ' F' ' 36' ' ' VAL . 33.7 m -155.25 163.38 1.57 Allowed 'Isoleucine or valine' 0 C--N 1.348 0.516 0 N-CA-C 108.125 -1.065 . . . . 0.0 108.125 179.49 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 37' ' ' GLY . . . . . 0.539 ' H ' HE22 ' C' ' 15' ' ' GLN . . . 55.32 67.85 1.99 Allowed Glycine 0 C--N 1.306 -1.135 0 CA-C-N 115.881 -0.6 . . . . 0.0 112.104 178.712 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 141.67 176.07 15.66 Favored Glycine 0 N--CA 1.475 1.248 0 N-CA-C 110.885 -0.886 . . . . 0.0 110.885 179.11 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 39' ' ' VAL . . . . . 0.505 ' H ' HG12 ' F' ' 39' ' ' VAL . 35.6 m -119.16 159.56 19.77 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.878 0 C-N-CA 123.349 0.66 . . . . 0.0 110.451 179.891 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 21.9 t . . . . . 0 N--CA 1.467 0.4 0 CA-C-O 118.45 -0.786 . . . . 0.0 110.473 179.443 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 42.3 m-85 . . . . . 0 N--CA 1.471 0.611 0 N-CA-C 108.941 -0.763 . . . . 0.0 108.941 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' D' D ' 5' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -144.54 139.7 28.35 Favored 'General case' 0 N--CA 1.475 0.797 0 CA-C-N 116.374 -0.375 . . . . 0.0 110.214 179.869 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 41.0 t-80 -149.77 123.96 9.49 Favored 'General case' 0 CA--C 1.545 0.782 0 N-CA-C 108.142 -1.058 . . . . 0.0 108.142 174.72 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' D' D ' 7' ' ' ASP . . . . . 0.584 ' O ' ' OG ' ' G' ' 8' ' ' SER . 3.1 m-20 -63.6 132.98 52.89 Favored 'General case' 0 C--N 1.321 -0.647 0 C-N-CA 126.846 2.058 . . . . 0.0 114.209 174.62 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' D' D ' 8' ' ' SER . . . . . 0.488 ' OG ' ' O ' ' A' ' 7' ' ' ASP . 59.8 p -154.51 -170.8 3.64 Favored 'General case' 0 N--CA 1.488 1.454 0 CA-C-N 119.675 1.125 . . . . 0.0 111.255 175.246 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.39 47.91 1.17 Allowed Glycine 0 N--CA 1.481 1.666 0 C-N-CA 124.663 1.125 . . . . 0.0 110.632 174.321 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 51.5 p90 -60.99 131.56 51.02 Favored 'General case' 0 N--CA 1.47 0.526 0 N-CA-C 112.613 0.598 . . . . 0.0 112.613 177.559 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 48.3 mt-10 -89.64 151.01 22.11 Favored 'General case' 0 N--CA 1.479 1.025 0 CA-C-N 117.989 0.359 . . . . 0.0 110.662 174.982 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.0 p -149.64 129.95 4.22 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.662 0 N-CA-C 107.307 -1.368 . . . . 0.0 107.307 173.058 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 38.6 m-70 -129.79 151.63 50.16 Favored 'General case' 0 N--CA 1.483 1.182 0 N-CA-C 112.264 0.468 . . . . 0.0 112.264 176.639 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 7.3 t60 -164.68 104.75 0.82 Allowed 'General case' 0 N--CA 1.483 1.201 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 172.261 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' D' D ' 15' ' ' GLN . . . . . 0.482 HE22 ' H ' ' D' ' 37' ' ' GLY . 3.4 pt20 -111.05 -176.47 2.96 Favored 'General case' 0 CA--C 1.502 -0.884 0 N-CA-C 108.002 -1.11 . . . . 0.0 108.002 179.007 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -167.03 106.44 0.59 Allowed 'General case' 0 N--CA 1.466 0.337 0 N-CA-C 106.947 -1.501 . . . . 0.0 106.947 176.404 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' D' D ' 17' ' ' LEU . . . . . 0.554 ' H ' ' CD2' ' G' ' 17' ' ' LEU . 9.9 mt -130.57 152.35 50.04 Favored 'General case' 0 N--CA 1.493 1.702 0 CA-C-O 121.864 0.84 . . . . 0.0 110.493 179.651 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 38.6 t -99.65 133.09 43.73 Favored 'Isoleucine or valine' 0 C--O 1.259 1.596 0 CA-C-O 116.97 -1.49 . . . . 0.0 109.645 175.007 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 40.6 m-85 -130.04 125.97 36.54 Favored 'General case' 0 N--CA 1.489 1.523 0 CA-C-N 119.792 1.178 . . . . 0.0 109.357 174.144 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 74.1 m-85 55.87 71.87 0.53 Allowed 'General case' 0 C--N 1.352 0.693 0 CA-C-N 115.105 -0.952 . . . . 0.0 111.411 176.063 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -81.82 -73.0 0.41 Allowed 'General case' 0 N--CA 1.472 0.66 0 CA-C-O 118.369 -0.824 . . . . 0.0 111.005 -177.305 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 40.3 tt0 -115.98 104.17 11.33 Favored 'General case' 0 N--CA 1.484 1.262 0 N-CA-C 106.404 -1.702 . . . . 0.0 106.404 176.392 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -152.21 140.8 20.77 Favored 'General case' 0 N--CA 1.475 0.789 0 CA-C-O 116.748 -1.596 . . . . 0.0 113.634 177.867 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' D' D ' 24' ' ' VAL . . . . . 0.444 ' HB ' ' H ' ' A' ' 25' ' ' GLY . 66.7 t -62.95 166.57 0.97 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.237 0 CA-C-N 121.097 1.771 . . . . 0.0 107.979 174.782 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' D' D ' 25' ' ' GLY . . . . . 0.503 ' H ' ' HB ' ' G' ' 24' ' ' VAL . . . -116.67 51.07 0.75 Allowed Glycine 0 N--CA 1.481 1.667 0 CA-C-O 118.876 -0.958 . . . . 0.0 111.715 178.636 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -58.29 -170.73 0.01 OUTLIER 'General case' 0 C--N 1.322 -0.619 0 C-N-CA 123.38 0.672 . . . . 0.0 111.637 176.638 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 25.4 t-20 -72.43 86.71 1.15 Allowed 'General case' 0 CA--C 1.537 0.453 0 N-CA-C 108.425 -0.954 . . . . 0.0 108.425 178.45 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 97.6 mttt -84.26 148.71 26.55 Favored 'General case' 0 N--CA 1.474 0.758 0 N-CA-C 108.155 -1.054 . . . . 0.0 108.155 178.884 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -62.7 -165.73 0.55 Allowed Glycine 0 C--N 1.337 0.614 0 N-CA-C 110.461 -1.056 . . . . 0.0 110.461 179.374 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -102.09 115.99 31.72 Favored 'General case' 0 N--CA 1.467 0.385 0 C-N-CA 123.186 0.595 . . . . 0.0 109.921 179.832 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 80.4 mt -102.41 142.46 16.6 Favored 'Isoleucine or valine' 0 C--N 1.355 0.836 0 N-CA-C 104.327 -2.472 . . . . 0.0 104.327 -178.908 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 38.6 pt -157.68 -179.05 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.241 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.118 -176.161 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 64.73 5.7 19.6 Favored Glycine 0 C--O 1.244 0.758 0 N-CA-C 110.003 -1.239 . . . . 0.0 110.003 -178.573 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 1.7 tt -76.42 134.14 39.68 Favored 'General case' 0 C--N 1.361 1.084 0 N-CA-C 107.244 -1.391 . . . . 0.0 107.244 -177.829 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' D' D ' 35' ' ' MET . . . . . 0.405 ' C ' HG13 ' D' ' 36' ' ' VAL . 28.2 ttt -157.91 159.99 37.15 Favored 'General case' 0 CA--C 1.517 -0.319 0 N-CA-C 108.225 -1.028 . . . . 0.0 108.225 172.577 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' D' D ' 36' ' ' VAL . . . . . 0.578 HG22 HG12 ' G' ' 36' ' ' VAL . 31.0 m -164.8 163.63 0.71 Allowed 'Isoleucine or valine' 0 C--O 1.223 -0.31 0 N-CA-C 107.765 -1.198 . . . . 0.0 107.765 174.232 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' D' D ' 37' ' ' GLY . . . . . 0.482 ' H ' HE22 ' D' ' 15' ' ' GLN . . . 59.9 63.71 4.84 Favored Glycine 0 CA--C 1.528 0.884 0 C-N-CA 120.435 -0.888 . . . . 0.0 111.335 178.024 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.18 179.66 20.01 Favored Glycine 0 N--CA 1.481 1.651 0 N-CA-C 111.057 -0.817 . . . . 0.0 111.057 178.352 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' D' D ' 39' ' ' VAL . . . . . 0.529 ' H ' HG12 ' G' ' 39' ' ' VAL . 33.9 m -120.54 157.02 23.56 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.822 0 C-N-CA 123.133 0.573 . . . . 0.0 110.94 179.461 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 22.0 t . . . . . 0 C--N 1.333 -0.14 0 CA-C-O 116.665 -1.636 . . . . 0.0 109.536 175.794 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 38.8 m-85 . . . . . 0 N--CA 1.475 0.806 0 N-CA-C 110.152 -0.314 . . . . 0.0 110.152 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' E' E ' 5' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -142.72 140.97 31.69 Favored 'General case' 0 N--CA 1.482 1.126 0 CA-C-O 120.904 0.383 . . . . 0.0 110.077 179.395 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 45.0 t-80 -151.4 118.8 6.0 Favored 'General case' 0 N--CA 1.472 0.669 0 N-CA-C 109.227 -0.657 . . . . 0.0 109.227 178.83 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' E' E ' 7' ' ' ASP . . . . . 0.441 ' O ' ' OG ' ' H' ' 8' ' ' SER . 4.2 m-20 -69.57 148.66 49.1 Favored 'General case' 0 N--CA 1.467 0.379 0 CA-C-N 116.435 -0.348 . . . . 0.0 110.745 179.941 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' E' E ' 8' ' ' SER . . . . . 0.441 ' OG ' ' O ' ' B' ' 7' ' ' ASP . 56.0 p -168.26 -172.51 1.76 Allowed 'General case' 0 N--CA 1.486 1.343 0 CA-C-O 121.099 0.476 . . . . 0.0 110.784 178.917 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.71 47.09 1.31 Allowed Glycine 0 N--CA 1.478 1.493 0 CA-C-N 115.912 -0.585 . . . . 0.0 112.101 179.807 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 47.7 p90 -65.82 133.22 50.51 Favored 'General case' 0 N--CA 1.473 0.721 0 N-CA-C 111.908 0.336 . . . . 0.0 111.908 -179.948 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 48.6 mt-10 -91.47 152.98 20.13 Favored 'General case' 0 N--CA 1.48 1.054 0 CA-C-O 121.245 0.545 . . . . 0.0 109.629 177.943 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -154.97 126.78 0.95 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.63 0 N-CA-C 107.739 -1.208 . . . . 0.0 107.739 178.135 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 42.2 m-70 -135.69 146.86 48.2 Favored 'General case' 0 N--CA 1.482 1.14 0 CA-C-O 120.849 0.357 . . . . 0.0 111.531 -178.126 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 7.1 t60 -163.0 97.64 0.93 Allowed 'General case' 0 N--CA 1.485 1.288 0 CA-C-N 116.365 -0.38 . . . . 0.0 110.717 179.506 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' E' E ' 15' ' ' GLN . . . . . 0.515 HE22 ' H ' ' E' ' 37' ' ' GLY . 3.4 pt20 -106.99 -175.22 2.73 Favored 'General case' 0 CA--C 1.51 -0.564 0 N-CA-C 108.521 -0.918 . . . . 0.0 108.521 -179.928 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -169.84 99.81 0.31 Allowed 'General case' 0 N--CA 1.473 0.713 0 CA-C-N 114.654 -1.157 . . . . 0.0 108.617 179.004 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' E' E ' 17' ' ' LEU . . . . . 0.563 ' H ' ' CD2' ' H' ' 17' ' ' LEU . 7.3 mt -123.9 153.89 40.5 Favored 'General case' 0 N--CA 1.49 1.549 0 CA-C-O 121.348 0.594 . . . . 0.0 111.505 -177.767 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 49.9 t -110.7 126.3 68.04 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.307 0 N-CA-C 108.205 -1.035 . . . . 0.0 108.205 177.604 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 46.6 m-85 -123.79 121.22 34.87 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 123.37 0.419 . . . . 0.0 111.038 -179.821 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 73.7 m-85 54.06 74.33 0.34 Allowed 'General case' 0 N--CA 1.47 0.542 0 CA-C-N 115.922 -0.581 . . . . 0.0 111.594 178.061 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -78.18 -78.96 0.13 Allowed 'General case' 0 CA--C 1.535 0.375 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.095 -179.488 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 39.9 tt0 -111.67 100.97 9.39 Favored 'General case' 0 N--CA 1.469 0.482 0 N-CA-C 108.438 -0.949 . . . . 0.0 108.438 -179.989 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -158.61 140.73 13.95 Favored 'General case' 0 C--O 1.204 -1.296 0 CA-C-O 119.581 -0.247 . . . . 0.0 111.535 179.147 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' E' E ' 24' ' ' VAL . . . . . 0.466 ' HB ' ' H ' ' B' ' 25' ' ' GLY . 57.6 t -58.86 169.03 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.851 0 N-CA-C 107.691 -1.225 . . . . 0.0 107.691 177.017 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' E' E ' 25' ' ' GLY . . . . . 0.432 ' N ' HG12 ' E' ' 24' ' ' VAL . . . -122.51 49.59 0.88 Allowed Glycine 0 N--CA 1.477 1.383 0 N-CA-C 110.674 -0.971 . . . . 0.0 110.674 -179.479 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -63.07 -167.57 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.553 0 CA-C-O 120.644 0.259 . . . . 0.0 110.601 179.774 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 25.1 t-20 -69.93 78.12 0.48 Allowed 'General case' 0 N--CA 1.466 0.351 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.383 -179.944 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -77.32 146.73 36.58 Favored 'General case' 0 N--CA 1.475 0.81 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 179.28 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.39 -168.33 1.08 Allowed Glycine 0 CA--C 1.522 0.518 0 N-CA-C 110.522 -1.031 . . . . 0.0 110.522 178.623 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.74 115.45 29.55 Favored 'General case' 0 N--CA 1.468 0.461 0 N-CA-C 109.904 -0.406 . . . . 0.0 109.904 179.471 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 70.5 mt -96.38 135.09 31.6 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.282 0 N-CA-C 106.942 -1.503 . . . . 0.0 106.942 179.037 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 39.0 pt -151.1 -176.16 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.229 0 CA-C-O 121.164 0.506 . . . . 0.0 110.737 -179.157 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.2 5.97 9.25 Favored Glycine 0 CA--C 1.529 0.963 0 CA-C-N 115.322 -0.853 . . . . 0.0 111.243 -179.517 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 1.4 tt -73.8 128.68 36.16 Favored 'General case' 0 CA--C 1.548 0.884 0 N-CA-C 109.629 -0.508 . . . . 0.0 109.629 -179.544 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 28.4 ttt -162.93 148.79 12.11 Favored 'General case' 0 C--O 1.209 -1.056 0 N-CA-C 108.925 -0.769 . . . . 0.0 108.925 178.484 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' E' E ' 36' ' ' VAL . . . . . 0.572 HG22 HG12 ' H' ' 36' ' ' VAL . 34.0 m -156.97 162.73 1.5 Allowed 'Isoleucine or valine' 0 C--N 1.344 0.344 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 179.862 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' E' E ' 37' ' ' GLY . . . . . 0.515 ' H ' HE22 ' E' ' 15' ' ' GLN . . . 55.94 66.8 2.59 Favored Glycine 0 C--N 1.307 -1.06 0 CA-C-N 115.933 -0.576 . . . . 0.0 111.939 178.537 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 142.56 176.81 17.01 Favored Glycine 0 N--CA 1.477 1.382 0 N-CA-C 111.149 -0.78 . . . . 0.0 111.149 179.007 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' E' E ' 39' ' ' VAL . . . . . 0.544 ' H ' HG12 ' H' ' 39' ' ' VAL . 33.3 m -119.93 158.62 21.68 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.749 0 C-N-CA 123.392 0.677 . . . . 0.0 110.626 -179.595 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 22.6 t . . . . . 0 C--O 1.22 -0.478 0 CA-C-O 118.448 -0.787 . . . . 0.0 110.482 179.112 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 38.2 m-85 . . . . . 0 N--CA 1.474 0.75 0 N-CA-C 110.135 -0.32 . . . . 0.0 110.135 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' F' F ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -142.47 141.24 32.13 Favored 'General case' 0 N--CA 1.478 0.959 0 CA-C-O 120.805 0.336 . . . . 0.0 110.249 179.41 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 43.9 t-80 -151.92 118.74 5.78 Favored 'General case' 0 N--CA 1.472 0.659 0 N-CA-C 109.315 -0.624 . . . . 0.0 109.315 178.928 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' F' F ' 7' ' ' ASP . . . . . 0.477 ' O ' ' OG ' ' I' ' 8' ' ' SER . 4.3 m-20 -69.35 148.64 49.39 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 116.411 -0.359 . . . . 0.0 110.814 -179.96 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' F' F ' 8' ' ' SER . . . . . 0.482 ' OG ' ' O ' ' C' ' 7' ' ' ASP . 56.1 p -168.33 -172.79 1.81 Allowed 'General case' 0 N--CA 1.487 1.422 0 CA-C-O 121.111 0.482 . . . . 0.0 110.924 178.8 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.93 47.01 1.3 Allowed Glycine 0 N--CA 1.479 1.502 0 CA-C-N 115.978 -0.556 . . . . 0.0 112.064 179.877 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 47.7 p90 -65.57 133.03 50.32 Favored 'General case' 0 CA--C 1.543 0.673 0 N-CA-C 111.852 0.316 . . . . 0.0 111.852 -179.954 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 48.3 mt-10 -91.48 152.33 20.4 Favored 'General case' 0 N--CA 1.48 1.042 0 CA-C-O 121.195 0.521 . . . . 0.0 109.713 177.818 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -154.18 126.87 1.09 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.608 0 N-CA-C 107.825 -1.176 . . . . 0.0 107.825 177.997 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 41.9 m-70 -135.67 146.9 48.29 Favored 'General case' 0 N--CA 1.483 1.2 0 CA-C-O 120.936 0.398 . . . . 0.0 111.582 -178.142 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 7.1 t60 -162.98 97.49 0.93 Allowed 'General case' 0 N--CA 1.486 1.371 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.821 179.55 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' F' F ' 15' ' ' GLN . . . . . 0.526 HE22 ' H ' ' F' ' 37' ' ' GLY . 3.4 pt20 -107.06 -175.22 2.73 Favored 'General case' 0 CA--C 1.507 -0.675 0 N-CA-C 108.482 -0.932 . . . . 0.0 108.482 -179.939 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -169.77 99.86 0.31 Allowed 'General case' 0 N--CA 1.47 0.572 0 CA-C-N 114.712 -1.131 . . . . 0.0 108.606 179.052 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' F' F ' 17' ' ' LEU . . . . . 0.559 ' H ' ' CD2' ' I' ' 17' ' ' LEU . 7.2 mt -123.81 154.33 39.73 Favored 'General case' 0 N--CA 1.489 1.501 0 CA-C-O 121.273 0.558 . . . . 0.0 111.461 -177.735 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 51.8 t -111.07 126.21 68.45 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.325 0 N-CA-C 108.262 -1.014 . . . . 0.0 108.262 177.529 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 47.0 m-85 -123.71 121.15 34.76 Favored 'General case' 0 C--N 1.367 1.363 0 CA-C-O 120.972 0.415 . . . . 0.0 111.018 -179.819 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 74.1 m-85 54.23 74.31 0.34 Allowed 'General case' 0 N--CA 1.469 0.477 0 CA-C-N 115.871 -0.604 . . . . 0.0 111.743 178.054 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -78.15 -78.98 0.13 Allowed 'General case' 0 N--CA 1.465 0.32 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.228 -179.551 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 39.7 tt0 -111.71 101.19 9.58 Favored 'General case' 0 N--CA 1.469 0.5 0 N-CA-C 108.325 -0.991 . . . . 0.0 108.325 -179.986 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -158.86 140.6 13.53 Favored 'General case' 0 C--O 1.205 -1.277 0 CA-C-O 119.584 -0.246 . . . . 0.0 111.483 179.089 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' F' F ' 24' ' ' VAL . . . . . 0.447 ' HB ' ' H ' ' C' ' 25' ' ' GLY . 57.4 t -58.81 168.91 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.885 0 N-CA-C 107.591 -1.263 . . . . 0.0 107.591 177.057 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' F' F ' 25' ' ' GLY . . . . . 0.436 ' N ' HG12 ' F' ' 24' ' ' VAL . . . -122.31 49.4 0.89 Allowed Glycine 0 N--CA 1.477 1.402 0 N-CA-C 110.751 -0.94 . . . . 0.0 110.751 -179.478 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -63.16 -168.39 0.02 OUTLIER 'General case' 0 N--CA 1.469 0.489 0 CA-C-O 120.635 0.255 . . . . 0.0 110.447 -179.975 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 25.1 t-20 -69.11 77.96 0.34 Allowed 'General case' 0 CA--C 1.533 0.292 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.484 -179.908 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -77.18 147.02 36.69 Favored 'General case' 0 N--CA 1.475 0.816 0 N-CA-C 109.468 -0.567 . . . . 0.0 109.468 179.239 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.44 -168.11 1.07 Allowed Glycine 0 CA--C 1.522 0.481 0 N-CA-C 110.612 -0.995 . . . . 0.0 110.612 178.569 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.54 114.85 28.1 Favored 'General case' 0 N--CA 1.469 0.504 0 N-CA-C 109.891 -0.411 . . . . 0.0 109.891 179.484 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 70.6 mt -96.16 135.02 31.59 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.298 0 N-CA-C 106.987 -1.486 . . . . 0.0 106.987 178.895 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 38.6 pt -151.16 -176.32 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.251 0 CA-C-O 121.191 0.519 . . . . 0.0 110.739 -179.184 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.39 6.0 9.79 Favored Glycine 0 CA--C 1.529 0.937 0 CA-C-N 115.29 -0.868 . . . . 0.0 111.186 -179.622 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' F' F ' 34' ' ' LEU . . . . . 0.403 HD23 ' N ' ' F' ' 35' ' ' MET . 1.3 tt -73.64 128.69 36.18 Favored 'General case' 0 CA--C 1.549 0.913 0 N-CA-C 109.538 -0.541 . . . . 0.0 109.538 -179.586 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' F' F ' 35' ' ' MET . . . . . 0.403 ' N ' HD23 ' F' ' 34' ' ' LEU . 28.4 ttt -162.96 148.73 12.03 Favored 'General case' 0 C--O 1.208 -1.094 0 N-CA-C 108.82 -0.807 . . . . 0.0 108.82 178.378 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' F' F ' 36' ' ' VAL . . . . . 0.575 HG22 HG12 ' I' ' 36' ' ' VAL . 34.1 m -156.75 163.0 1.46 Allowed 'Isoleucine or valine' 0 C--N 1.346 0.429 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 179.872 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' F' F ' 37' ' ' GLY . . . . . 0.526 ' H ' HE22 ' F' ' 15' ' ' GLN . . . 55.58 67.1 2.39 Favored Glycine 0 C--N 1.307 -1.061 0 CA-C-N 115.944 -0.571 . . . . 0.0 111.947 178.45 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 142.35 176.85 16.87 Favored Glycine 0 N--CA 1.476 1.325 0 N-CA-C 111.155 -0.778 . . . . 0.0 111.155 179.036 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' F' F ' 39' ' ' VAL . . . . . 0.531 ' H ' HG12 ' I' ' 39' ' ' VAL . 33.4 m -119.95 158.92 21.55 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.629 0 C-N-CA 123.374 0.67 . . . . 0.0 110.649 -179.675 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 23.6 t . . . . . 0 C--O 1.221 -0.417 0 CA-C-O 118.549 -0.738 . . . . 0.0 110.499 179.071 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 40.8 m-85 . . . . . 0 N--CA 1.473 0.719 0 N-CA-C 109.643 -0.503 . . . . 0.0 109.643 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' G' G ' 5' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -142.98 141.02 31.3 Favored 'General case' 0 N--CA 1.482 1.15 0 CA-C-O 120.816 0.341 . . . . 0.0 110.188 179.721 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 44.3 t-80 -151.53 119.48 6.22 Favored 'General case' 0 N--CA 1.474 0.743 0 N-CA-C 109.384 -0.599 . . . . 0.0 109.384 178.948 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -71.04 144.53 50.36 Favored 'General case' 0 N--CA 1.471 0.583 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.212 -179.822 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' G' G ' 8' ' ' SER . . . . . 0.584 ' OG ' ' O ' ' D' ' 7' ' ' ASP . 54.4 p -165.31 -171.22 2.1 Favored 'General case' 0 N--CA 1.476 0.861 0 CA-C-O 121.054 0.454 . . . . 0.0 110.436 178.644 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.88 46.76 1.33 Allowed Glycine 0 N--CA 1.479 1.566 0 CA-C-N 115.809 -0.632 . . . . 0.0 111.607 179.533 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 50.0 p90 -65.44 133.05 50.48 Favored 'General case' 0 N--CA 1.472 0.649 0 N-CA-C 111.835 0.309 . . . . 0.0 111.835 -179.795 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 49.1 mt-10 -91.88 151.89 20.34 Favored 'General case' 0 N--CA 1.479 1.001 0 CA-C-O 121.108 0.48 . . . . 0.0 110.062 178.401 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -155.08 127.04 0.97 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.021 0 N-CA-C 107.886 -1.153 . . . . 0.0 107.886 178.33 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 43.1 m-70 -135.01 148.39 49.94 Favored 'General case' 0 N--CA 1.478 0.944 0 CA-C-N 115.49 -0.777 . . . . 0.0 111.414 -178.399 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 7.2 t60 -164.49 97.29 0.78 Allowed 'General case' 0 N--CA 1.484 1.227 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.486 178.907 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' G' G ' 15' ' ' GLN . . . . . 0.527 HE22 ' H ' ' G' ' 37' ' ' GLY . 3.5 pt20 -106.88 -175.67 2.86 Favored 'General case' 0 CA--C 1.508 -0.664 0 N-CA-C 108.364 -0.976 . . . . 0.0 108.364 -179.821 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -169.98 99.52 0.29 Allowed 'General case' 0 N--CA 1.473 0.691 0 CA-C-N 114.649 -1.159 . . . . 0.0 108.345 179.176 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' G' G ' 17' ' ' LEU . . . . . 0.554 ' CD2' ' H ' ' D' ' 17' ' ' LEU . 8.2 mt -123.4 153.94 39.69 Favored 'General case' 0 N--CA 1.495 1.786 0 CA-C-O 121.085 0.469 . . . . 0.0 111.789 -177.863 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 43.4 t -111.26 126.39 68.65 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.038 0 N-CA-C 108.1 -1.074 . . . . 0.0 108.1 177.021 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 48.0 m-85 -124.12 120.77 33.3 Favored 'General case' 0 C--N 1.367 1.346 0 CA-C-N 115.602 -0.726 . . . . 0.0 111.192 -179.539 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 73.8 m-85 54.46 73.66 0.39 Allowed 'General case' 0 N--CA 1.47 0.526 0 CA-C-N 115.896 -0.593 . . . . 0.0 111.594 178.008 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.04 -78.32 0.13 Allowed 'General case' 0 N--CA 1.471 0.59 0 O-C-N 122.282 -0.262 . . . . 0.0 110.446 -179.032 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 40.4 tt0 -112.25 101.07 9.32 Favored 'General case' 0 C--N 1.322 -0.629 0 N-CA-C 108.108 -1.071 . . . . 0.0 108.108 179.839 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -158.38 142.38 15.6 Favored 'General case' 0 N--CA 1.478 0.926 0 O-C-N 122.387 -0.195 . . . . 0.0 111.442 179.01 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' G' G ' 24' ' ' VAL . . . . . 0.503 ' HB ' ' H ' ' D' ' 25' ' ' GLY . 59.7 t -60.97 167.76 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.644 0 N-CA-C 107.67 -1.233 . . . . 0.0 107.67 177.384 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' G' G ' 25' ' ' GLY . . . . . 0.437 ' N ' HG12 ' G' ' 24' ' ' VAL . . . -120.64 49.95 0.85 Allowed Glycine 0 N--CA 1.482 1.755 0 N-CA-C 110.338 -1.105 . . . . 0.0 110.338 -179.58 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -63.78 -167.61 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.661 0 CA-C-N 116.984 0.392 . . . . 0.0 109.987 179.833 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 25.2 t-20 -70.11 77.71 0.51 Allowed 'General case' 0 CA--C 1.536 0.407 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.451 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -76.16 146.72 38.98 Favored 'General case' 0 N--CA 1.475 0.818 0 N-CA-C 109.506 -0.553 . . . . 0.0 109.506 179.306 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.62 -167.01 0.95 Allowed Glycine 0 C--N 1.336 0.578 0 N-CA-C 110.076 -1.21 . . . . 0.0 110.076 178.721 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.58 115.26 28.98 Favored 'General case' 0 N--CA 1.469 0.516 0 C-N-CA 122.689 0.395 . . . . 0.0 110.438 179.841 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 72.1 mt -97.1 135.99 29.41 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.671 0 N-CA-C 106.87 -1.53 . . . . 0.0 106.87 178.931 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 36.8 pt -152.47 -176.01 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.71 0 CA-C-N 119.855 1.207 . . . . 0.0 109.95 -179.631 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.09 5.83 11.27 Favored Glycine 0 CA--C 1.527 0.811 0 N-CA-C 110.878 -0.889 . . . . 0.0 110.878 -179.763 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' G' G ' 34' ' ' LEU . . . . . 0.408 HD23 ' N ' ' G' ' 35' ' ' MET . 1.4 tt -74.3 127.4 32.89 Favored 'General case' 0 CA--C 1.546 0.796 0 N-CA-C 109.7 -0.482 . . . . 0.0 109.7 -179.503 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' G' G ' 35' ' ' MET . . . . . 0.408 ' N ' HD23 ' G' ' 34' ' ' LEU . 28.1 ttt -161.56 150.22 15.73 Favored 'General case' 0 C--O 1.212 -0.897 0 N-CA-C 108.844 -0.798 . . . . 0.0 108.844 178.533 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' G' G ' 36' ' ' VAL . . . . . 0.578 HG12 HG22 ' D' ' 36' ' ' VAL . 33.9 m -157.4 162.11 1.62 Allowed 'Isoleucine or valine' 0 C--N 1.346 0.451 0 N-CA-C 108.628 -0.878 . . . . 0.0 108.628 -179.819 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' G' G ' 37' ' ' GLY . . . . . 0.527 ' H ' HE22 ' G' ' 15' ' ' GLN . . . 55.61 67.01 2.43 Favored Glycine 0 C--N 1.312 -0.803 0 CA-C-N 115.599 -0.728 . . . . 0.0 112.299 178.111 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.33 178.3 19.02 Favored Glycine 0 N--CA 1.477 1.383 0 N-CA-C 110.569 -1.012 . . . . 0.0 110.569 178.925 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' G' G ' 39' ' ' VAL . . . . . 0.529 HG12 ' H ' ' D' ' 39' ' ' VAL . 34.2 m -121.34 158.37 24.3 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.837 0 C-N-CA 123.128 0.571 . . . . 0.0 110.6 -179.621 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 22.2 t . . . . . 0 N--CA 1.469 0.515 0 O-C-N 123.981 0.801 . . . . 0.0 110.752 179.163 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 42.2 m-85 . . . . . 0 N--CA 1.474 0.744 0 N-CA-C 109.603 -0.517 . . . . 0.0 109.603 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' H' H ' 5' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -142.91 141.35 31.48 Favored 'General case' 0 N--CA 1.484 1.263 0 N-CA-C 110.081 -0.34 . . . . 0.0 110.081 179.732 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 44.3 t-80 -151.89 119.54 6.09 Favored 'General case' 0 N--CA 1.474 0.745 0 N-CA-C 109.334 -0.617 . . . . 0.0 109.334 178.901 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -70.96 144.57 50.49 Favored 'General case' 0 N--CA 1.47 0.57 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.251 -179.884 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' H' H ' 8' ' ' SER . . . . . 0.441 ' OG ' ' O ' ' E' ' 7' ' ' ASP . 60.2 p -165.26 -171.55 2.22 Favored 'General case' 0 N--CA 1.474 0.758 0 CA-C-O 120.976 0.417 . . . . 0.0 110.485 178.751 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.83 46.62 1.36 Allowed Glycine 0 N--CA 1.481 1.645 0 CA-C-N 115.986 -0.552 . . . . 0.0 111.756 179.699 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 50.3 p90 -65.64 133.15 50.52 Favored 'General case' 0 N--CA 1.471 0.625 0 N-CA-C 111.798 0.295 . . . . 0.0 111.798 -179.835 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 48.5 mt-10 -91.75 152.25 20.25 Favored 'General case' 0 N--CA 1.477 0.911 0 CA-C-O 121.127 0.489 . . . . 0.0 110.128 178.446 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -155.2 127.49 1.02 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.049 0 N-CA-C 107.83 -1.174 . . . . 0.0 107.83 178.346 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 44.1 m-70 -135.53 148.01 48.99 Favored 'General case' 0 N--CA 1.477 0.909 0 CA-C-N 115.566 -0.743 . . . . 0.0 111.396 -178.307 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 7.1 t60 -164.32 97.26 0.8 Allowed 'General case' 0 N--CA 1.484 1.226 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.45 178.915 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' H' H ' 15' ' ' GLN . . . . . 0.512 HE22 ' H ' ' H' ' 37' ' ' GLY . 3.5 pt20 -106.8 -175.67 2.86 Favored 'General case' 0 CA--C 1.508 -0.666 0 N-CA-C 108.278 -1.008 . . . . 0.0 108.278 -179.872 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -169.81 99.64 0.31 Allowed 'General case' 0 N--CA 1.472 0.653 0 CA-C-N 114.72 -1.127 . . . . 0.0 108.358 179.124 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' H' H ' 17' ' ' LEU . . . . . 0.563 ' CD2' ' H ' ' E' ' 17' ' ' LEU . 8.6 mt -123.44 154.08 39.57 Favored 'General case' 0 N--CA 1.495 1.819 0 CA-C-O 121.118 0.485 . . . . 0.0 111.86 -177.757 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 43.0 t -111.65 126.05 69.01 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.111 0 N-CA-C 108.077 -1.082 . . . . 0.0 108.077 177.087 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 47.5 m-85 -123.83 120.45 32.63 Favored 'General case' 0 C--N 1.368 1.392 0 CA-C-N 115.456 -0.793 . . . . 0.0 110.981 -179.332 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 73.4 m-85 54.11 74.33 0.34 Allowed 'General case' 0 C--N 1.345 0.399 0 CA-C-N 115.776 -0.647 . . . . 0.0 111.697 178.02 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.25 -78.15 0.13 Allowed 'General case' 0 N--CA 1.472 0.655 0 O-C-N 122.4 -0.188 . . . . 0.0 110.519 -179.117 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 40.3 tt0 -112.41 100.95 9.18 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 108.024 -1.102 . . . . 0.0 108.024 179.899 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -158.31 141.95 15.34 Favored 'General case' 0 N--CA 1.478 0.946 0 O-C-N 122.384 -0.198 . . . . 0.0 111.458 179.104 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' H' H ' 24' ' ' VAL . . . . . 0.433 HG12 ' N ' ' H' ' 25' ' ' GLY . 59.6 t -60.63 167.89 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.561 0 N-CA-C 107.664 -1.236 . . . . 0.0 107.664 177.389 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' H' H ' 25' ' ' GLY . . . . . 0.433 ' N ' HG12 ' H' ' 24' ' ' VAL . . . -120.89 49.27 0.89 Allowed Glycine 0 N--CA 1.48 1.609 0 N-CA-C 110.482 -1.047 . . . . 0.0 110.482 -179.385 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -63.24 -167.56 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.642 0 CA-C-N 117.009 0.405 . . . . 0.0 110.201 179.881 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 25.2 t-20 -69.93 78.11 0.48 Allowed 'General case' 0 CA--C 1.535 0.388 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.411 179.903 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -76.76 146.55 37.86 Favored 'General case' 0 N--CA 1.476 0.842 0 N-CA-C 109.501 -0.555 . . . . 0.0 109.501 179.314 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.74 -167.12 1.01 Allowed Glycine 0 C--N 1.336 0.578 0 N-CA-C 110.045 -1.222 . . . . 0.0 110.045 178.757 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.84 115.11 28.82 Favored 'General case' 0 N--CA 1.467 0.378 0 C-N-CA 122.6 0.36 . . . . 0.0 110.579 -179.938 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 71.6 mt -96.84 136.02 29.03 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.729 0 N-CA-C 106.866 -1.531 . . . . 0.0 106.866 179.094 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 36.6 pt -152.42 -175.87 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.761 0 CA-C-N 119.814 1.188 . . . . 0.0 109.898 -179.716 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.5 7.0 12.59 Favored Glycine 0 CA--C 1.526 0.78 0 N-CA-C 110.879 -0.889 . . . . 0.0 110.879 -179.755 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 1.3 tt -75.33 127.12 32.44 Favored 'General case' 0 CA--C 1.545 0.775 0 N-CA-C 109.69 -0.485 . . . . 0.0 109.69 -179.728 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 28.0 ttt -161.31 150.03 16.04 Favored 'General case' 0 C--O 1.212 -0.917 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 178.61 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' H' H ' 36' ' ' VAL . . . . . 0.572 HG12 HG22 ' E' ' 36' ' ' VAL . 34.0 m -157.24 161.74 1.73 Allowed 'Isoleucine or valine' 0 C--N 1.345 0.398 0 N-CA-C 108.742 -0.836 . . . . 0.0 108.742 -179.665 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' H' H ' 37' ' ' GLY . . . . . 0.512 ' H ' HE22 ' H' ' 15' ' ' GLN . . . 55.81 66.89 2.52 Favored Glycine 0 C--N 1.311 -0.833 0 CA-C-N 115.673 -0.694 . . . . 0.0 112.261 178.172 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.46 178.09 18.96 Favored Glycine 0 N--CA 1.477 1.396 0 N-CA-C 110.644 -0.982 . . . . 0.0 110.644 179.026 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' H' H ' 39' ' ' VAL . . . . . 0.544 HG12 ' H ' ' E' ' 39' ' ' VAL . 34.1 m -121.12 158.43 23.81 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.846 0 C-N-CA 123.191 0.597 . . . . 0.0 110.772 -179.646 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 23.7 t . . . . . 0 N--CA 1.47 0.529 0 O-C-N 123.936 0.772 . . . . 0.0 110.694 179.149 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 41.0 m-85 . . . . . 0 N--CA 1.474 0.767 0 N-CA-C 109.579 -0.526 . . . . 0.0 109.579 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' I' I ' 5' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -142.81 141.35 31.62 Favored 'General case' 0 N--CA 1.483 1.224 0 C-N-CA 122.596 0.359 . . . . 0.0 110.143 179.787 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 45.0 t-80 -151.93 119.46 6.04 Favored 'General case' 0 N--CA 1.473 0.708 0 N-CA-C 109.379 -0.6 . . . . 0.0 109.379 178.96 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -71.02 144.41 50.43 Favored 'General case' 0 N--CA 1.469 0.497 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.268 -179.859 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' I' I ' 8' ' ' SER . . . . . 0.477 ' OG ' ' O ' ' F' ' 7' ' ' ASP . 60.5 p -165.02 -171.47 2.24 Favored 'General case' 0 N--CA 1.474 0.771 0 CA-C-O 120.975 0.417 . . . . 0.0 110.469 178.839 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.66 47.03 1.32 Allowed Glycine 0 N--CA 1.479 1.525 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.777 179.598 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 50.0 p90 -66.18 132.8 49.29 Favored 'General case' 0 N--CA 1.472 0.626 0 N-CA-C 111.869 0.322 . . . . 0.0 111.869 -179.805 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 48.5 mt-10 -91.19 152.29 20.61 Favored 'General case' 0 N--CA 1.477 0.907 0 CA-C-O 121.155 0.502 . . . . 0.0 110.202 178.385 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -155.48 126.95 0.91 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.057 0 N-CA-C 107.887 -1.153 . . . . 0.0 107.887 178.201 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 42.9 m-70 -134.92 148.33 50.03 Favored 'General case' 0 N--CA 1.478 0.935 0 CA-C-N 115.488 -0.778 . . . . 0.0 111.432 -178.409 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 7.1 t60 -164.49 97.33 0.78 Allowed 'General case' 0 N--CA 1.481 1.111 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.441 178.995 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' I' I ' 15' ' ' GLN . . . . . 0.534 HE22 ' H ' ' I' ' 37' ' ' GLY . 3.5 pt20 -106.84 -175.36 2.77 Favored 'General case' 0 CA--C 1.508 -0.666 0 N-CA-C 108.208 -1.034 . . . . 0.0 108.208 -179.815 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -170.18 99.53 0.28 Allowed 'General case' 0 N--CA 1.471 0.595 0 CA-C-N 114.592 -1.185 . . . . 0.0 108.25 179.159 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' I' I ' 17' ' ' LEU . . . . . 0.559 ' CD2' ' H ' ' F' ' 17' ' ' LEU . 8.4 mt -123.23 153.76 39.69 Favored 'General case' 0 N--CA 1.495 1.8 0 CA-C-O 121.042 0.449 . . . . 0.0 111.836 -177.829 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 43.8 t -111.3 126.44 68.69 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.02 0 N-CA-C 108.05 -1.093 . . . . 0.0 108.05 176.913 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 47.1 m-85 -124.16 120.77 33.27 Favored 'General case' 0 C--N 1.368 1.389 0 CA-C-N 115.511 -0.768 . . . . 0.0 111.002 -179.294 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 73.4 m-85 53.87 73.84 0.36 Allowed 'General case' 0 N--CA 1.469 0.495 0 CA-C-N 115.898 -0.592 . . . . 0.0 111.637 178.062 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -76.74 -78.43 0.12 Allowed 'General case' 0 N--CA 1.471 0.61 0 O-C-N 122.304 -0.247 . . . . 0.0 110.414 -179.209 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 40.1 tt0 -112.12 101.31 9.58 Favored 'General case' 0 C--N 1.324 -0.512 0 N-CA-C 108.075 -1.083 . . . . 0.0 108.075 179.938 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -158.53 142.4 15.42 Favored 'General case' 0 N--CA 1.477 0.903 0 O-C-N 122.42 -0.175 . . . . 0.0 111.467 179.063 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' I' I ' 24' ' ' VAL . . . . . 0.447 HG12 ' N ' ' I' ' 25' ' ' GLY . 59.0 t -61.06 167.82 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.561 0 N-CA-C 107.663 -1.236 . . . . 0.0 107.663 177.296 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' I' I ' 25' ' ' GLY . . . . . 0.447 ' N ' HG12 ' I' ' 24' ' ' VAL . . . -120.8 49.85 0.86 Allowed Glycine 0 N--CA 1.481 1.682 0 N-CA-C 110.45 -1.06 . . . . 0.0 110.45 -179.485 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -63.84 -167.57 0.02 OUTLIER 'General case' 0 N--CA 1.471 0.594 0 CA-C-N 116.927 0.364 . . . . 0.0 110.24 179.879 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 25.2 t-20 -69.8 77.59 0.46 Allowed 'General case' 0 CA--C 1.535 0.37 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.445 179.883 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -76.39 146.66 38.55 Favored 'General case' 0 N--CA 1.474 0.755 0 N-CA-C 109.438 -0.578 . . . . 0.0 109.438 179.305 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.73 -166.79 0.96 Allowed Glycine 0 C--N 1.337 0.638 0 N-CA-C 110.074 -1.21 . . . . 0.0 110.074 178.76 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.84 114.88 28.37 Favored 'General case' 0 N--CA 1.469 0.501 0 C-N-CA 122.771 0.428 . . . . 0.0 110.582 179.913 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 72.0 mt -96.75 136.07 28.78 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.674 0 N-CA-C 106.883 -1.525 . . . . 0.0 106.883 178.981 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 37.5 pt -152.46 -175.94 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 CA-C-N 119.885 1.221 . . . . 0.0 109.907 -179.678 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.63 6.69 12.22 Favored Glycine 0 CA--C 1.526 0.763 0 N-CA-C 110.94 -0.864 . . . . 0.0 110.94 -179.776 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' I' I ' 34' ' ' LEU . . . . . 0.408 HD23 ' N ' ' I' ' 35' ' ' MET . 1.4 tt -75.04 127.13 32.51 Favored 'General case' 0 CA--C 1.547 0.83 0 N-CA-C 109.547 -0.538 . . . . 0.0 109.547 -179.64 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' I' I ' 35' ' ' MET . . . . . 0.408 ' N ' HD23 ' I' ' 34' ' ' LEU . 28.1 ttt -161.1 150.12 16.49 Favored 'General case' 0 C--O 1.211 -0.942 0 N-CA-C 108.738 -0.838 . . . . 0.0 108.738 178.564 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' I' I ' 36' ' ' VAL . . . . . 0.575 HG12 HG22 ' F' ' 36' ' ' VAL . 34.1 m -157.23 162.11 1.63 Allowed 'Isoleucine or valine' 0 C--N 1.347 0.459 0 N-CA-C 108.594 -0.891 . . . . 0.0 108.594 -179.747 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' I' I ' 37' ' ' GLY . . . . . 0.534 ' H ' HE22 ' I' ' 15' ' ' GLN . . . 55.34 67.2 2.33 Favored Glycine 0 C--N 1.311 -0.841 0 CA-C-N 115.643 -0.708 . . . . 0.0 112.241 178.122 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.18 178.28 18.88 Favored Glycine 0 N--CA 1.478 1.47 0 N-CA-C 110.568 -1.013 . . . . 0.0 110.568 178.875 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' I' I ' 39' ' ' VAL . . . . . 0.531 HG12 ' H ' ' F' ' 39' ' ' VAL . 33.9 m -121.33 158.31 24.33 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.856 0 C-N-CA 123.15 0.58 . . . . 0.0 110.723 -179.662 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 23.4 t . . . . . 0 N--CA 1.469 0.523 0 O-C-N 124.046 0.841 . . . . 0.0 110.699 179.041 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 35.1 m-85 . . . . . 0 N--CA 1.475 0.782 0 N-CA-C 110.082 -0.34 . . . . 0.0 110.082 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -144.31 139.65 28.69 Favored 'General case' 0 N--CA 1.481 1.115 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 179.563 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 42.1 t-80 -151.95 119.88 6.2 Favored 'General case' 0 N--CA 1.469 0.509 0 N-CA-C 109.264 -0.643 . . . . 0.0 109.264 179.257 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' ASP . . . . . 0.5 ' O ' ' OG ' ' D' ' 8' ' ' SER . 4.2 m-20 -69.04 148.68 49.72 Favored 'General case' 0 CA--C 1.537 0.476 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.498 179.876 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 53.9 p -168.2 -174.24 2.25 Favored 'General case' 0 N--CA 1.484 1.262 0 CA-C-O 121.035 0.445 . . . . 0.0 110.747 179.429 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.8 48.26 1.28 Allowed Glycine 0 N--CA 1.481 1.698 0 CA-C-N 115.911 -0.586 . . . . 0.0 111.83 179.725 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 49.7 p90 -64.6 132.39 49.67 Favored 'General case' 0 N--CA 1.473 0.691 0 O-C-N 122.761 -0.258 . . . . 0.0 111.425 179.732 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 83.3 mt-10 -91.71 152.25 20.28 Favored 'General case' 0 N--CA 1.48 1.047 0 C-N-CA 122.781 0.433 . . . . 0.0 109.839 178.379 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -153.23 128.42 1.54 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.617 0 N-CA-C 107.821 -1.177 . . . . 0.0 107.821 178.298 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 48.5 m-70 -135.25 145.98 48.13 Favored 'General case' 0 N--CA 1.492 1.666 0 CA-C-N 118.949 0.795 . . . . 0.0 111.388 -179.003 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 6.1 t60 -165.95 97.18 0.63 Allowed 'General case' 0 N--CA 1.48 1.058 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.848 179.5 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 3.6 pt20 -108.52 -174.69 2.58 Favored 'General case' 0 CA--C 1.506 -0.733 0 N-CA-C 108.432 -0.951 . . . . 0.0 108.432 -179.845 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -164.17 97.57 0.82 Allowed 'General case' 0 N--CA 1.472 0.651 0 CA-C-N 114.562 -1.199 . . . . 0.0 108.299 178.348 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 6.7 mp -122.27 157.78 30.94 Favored 'General case' 0 N--CA 1.497 1.924 0 CA-C-O 121.759 0.79 . . . . 0.0 110.91 -178.338 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 59.8 t -112.57 126.65 69.99 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.124 0 CA-C-O 117.984 -1.008 . . . . 0.0 108.316 177.702 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 28.7 m-85 -126.93 122.5 34.75 Favored 'General case' 0 N--CA 1.497 1.909 0 CA-C-N 120.017 1.28 . . . . 0.0 110.344 179.338 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 67.0 m-85 53.94 74.32 0.33 Allowed 'General case' 0 N--CA 1.47 0.572 0 CA-C-O 121.374 0.606 . . . . 0.0 111.745 178.751 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -80.55 -78.14 0.18 Allowed 'General case' 0 C--N 1.353 0.756 0 CA-C-N 115.139 -0.937 . . . . 0.0 110.334 -179.773 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 40.4 tt0 -112.21 101.59 9.82 Favored 'General case' 0 N--CA 1.469 0.502 0 N-CA-C 108.468 -0.938 . . . . 0.0 108.468 179.738 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 4.4 p30 -158.96 134.5 8.62 Favored 'General case' 0 N--CA 1.482 1.16 0 CA-C-O 119.512 -0.28 . . . . 0.0 111.211 178.936 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 58.7 t -58.05 163.07 0.71 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.853 0 N-CA-C 108.074 -1.084 . . . . 0.0 108.074 176.984 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.421 ' H ' ' HB ' ' D' ' 24' ' ' VAL . . . -115.76 47.95 0.99 Allowed Glycine 0 N--CA 1.477 1.383 0 N-CA-C 111.615 -0.594 . . . . 0.0 111.615 -179.474 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -61.85 -168.65 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.562 0 N-CA-C 110.152 -0.314 . . . . 0.0 110.152 179.338 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 24.5 t-20 -72.05 79.97 0.94 Allowed 'General case' 0 N--CA 1.464 0.257 0 CA-C-N 116.428 -0.351 . . . . 0.0 110.082 179.164 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -73.46 140.32 46.39 Favored 'General case' 0 N--CA 1.476 0.837 0 N-CA-C 108.934 -0.765 . . . . 0.0 108.934 179.375 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.39 -149.76 0.03 OUTLIER Glycine 0 C--N 1.337 0.618 0 N-CA-C 110.183 -1.167 . . . . 0.0 110.183 179.282 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -93.76 128.07 39.8 Favored 'General case' 0 N--CA 1.476 0.825 0 N-CA-C 110.04 -0.356 . . . . 0.0 110.04 -179.905 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 74.8 mt -124.16 117.35 50.54 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.748 0 N-CA-C 106.653 -1.61 . . . . 0.0 106.653 178.876 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 39.2 pt -151.5 -169.78 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.354 0.804 0 CA-C-O 121.22 0.533 . . . . 0.0 111.246 -178.769 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.84 5.08 12.38 Favored Glycine 0 C--N 1.336 0.58 0 N-CA-C 110.797 -0.921 . . . . 0.0 110.797 179.587 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 1.5 tt -78.14 126.77 31.3 Favored 'General case' 0 CA--C 1.546 0.801 0 N-CA-C 109.558 -0.534 . . . . 0.0 109.558 -179.884 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 28.6 ttt -164.69 143.55 6.94 Favored 'General case' 0 N--CA 1.464 0.23 0 N-CA-C 108.871 -0.788 . . . . 0.0 108.871 178.266 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.426 HG22 HG12 ' D' ' 36' ' ' VAL . 35.6 m -155.27 162.71 1.73 Allowed 'Isoleucine or valine' 0 C--N 1.348 0.509 0 N-CA-C 108.042 -1.096 . . . . 0.0 108.042 179.327 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.61 66.33 2.93 Favored Glycine 0 C--N 1.307 -1.08 0 CA-C-N 115.834 -0.621 . . . . 0.0 111.874 178.429 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 145.7 172.97 16.53 Favored Glycine 0 N--CA 1.473 1.1 0 N-CA-C 110.994 -0.843 . . . . 0.0 110.994 179.095 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.583 ' H ' HG12 ' D' ' 39' ' ' VAL . 33.7 m -123.01 160.44 25.76 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.616 0 C-N-CA 123.405 0.682 . . . . 0.0 110.087 -179.691 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 23.7 t . . . . . 0 C--O 1.218 -0.556 0 CA-C-O 118.419 -0.8 . . . . 0.0 110.578 179.478 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 34.7 m-85 . . . . . 0 N--CA 1.474 0.752 0 N-CA-C 110.047 -0.353 . . . . 0.0 110.047 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -144.41 139.06 28.16 Favored 'General case' 0 N--CA 1.484 1.225 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 179.585 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 41.5 t-80 -151.24 119.63 6.41 Favored 'General case' 0 N--CA 1.472 0.638 0 N-CA-C 109.256 -0.646 . . . . 0.0 109.256 179.204 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 7' ' ' ASP . . . . . 0.507 ' O ' ' OG ' ' E' ' 8' ' ' SER . 4.0 m-20 -68.83 148.19 50.63 Favored 'General case' 0 CA--C 1.538 0.514 0 CA-C-N 116.295 -0.412 . . . . 0.0 110.721 179.828 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 8' ' ' SER . . . . . . . . . . . . . 54.1 p -167.58 -173.69 2.27 Favored 'General case' 0 N--CA 1.483 1.221 0 CA-C-O 121.045 0.45 . . . . 0.0 110.707 179.525 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.38 48.24 1.33 Allowed Glycine 0 N--CA 1.481 1.692 0 CA-C-N 115.908 -0.587 . . . . 0.0 111.949 179.55 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 50.2 p90 -64.94 132.89 50.55 Favored 'General case' 0 N--CA 1.473 0.687 0 CA-C-O 120.636 0.255 . . . . 0.0 111.496 179.871 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 84.2 mt-10 -92.02 152.75 19.84 Favored 'General case' 0 N--CA 1.478 0.93 0 CA-C-O 121.048 0.451 . . . . 0.0 109.823 178.456 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -153.61 128.39 1.46 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.495 0 N-CA-C 107.922 -1.14 . . . . 0.0 107.922 178.12 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 46.5 m-70 -135.32 145.67 47.69 Favored 'General case' 0 N--CA 1.493 1.723 0 CA-C-N 118.941 0.791 . . . . 0.0 111.289 -179.006 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 6.0 t60 -165.65 96.86 0.66 Allowed 'General case' 0 N--CA 1.48 1.035 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.739 179.38 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 3.6 pt20 -108.12 -174.74 2.59 Favored 'General case' 0 CA--C 1.507 -0.694 0 N-CA-C 108.411 -0.959 . . . . 0.0 108.411 -179.798 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -164.29 97.63 0.8 Allowed 'General case' 0 N--CA 1.473 0.699 0 CA-C-N 114.67 -1.15 . . . . 0.0 108.263 178.342 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 6.6 mp -122.27 157.69 31.13 Favored 'General case' 0 N--CA 1.497 1.906 0 CA-C-O 121.809 0.814 . . . . 0.0 111.023 -178.298 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 61.4 t -112.71 127.75 69.77 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.024 0 N-CA-C 108.069 -1.086 . . . . 0.0 108.069 177.595 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 28.6 m-85 -128.09 122.09 31.22 Favored 'General case' 0 N--CA 1.495 1.787 0 CA-C-N 119.726 1.148 . . . . 0.0 110.192 179.501 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 67.1 m-85 53.6 74.18 0.33 Allowed 'General case' 0 CA--C 1.54 0.581 0 CA-C-O 121.487 0.661 . . . . 0.0 111.799 178.622 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -80.35 -78.32 0.17 Allowed 'General case' 0 C--N 1.352 0.687 0 CA-C-N 115.001 -1.0 . . . . 0.0 110.275 -179.823 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 40.5 tt0 -112.02 101.73 10.0 Favored 'General case' 0 N--CA 1.471 0.613 0 N-CA-C 108.448 -0.945 . . . . 0.0 108.448 179.819 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 4.4 p30 -158.89 134.8 8.89 Favored 'General case' 0 N--CA 1.482 1.169 0 CA-C-O 119.54 -0.266 . . . . 0.0 111.155 178.913 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 58.5 t -58.26 163.2 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.874 0 N-CA-C 108.128 -1.064 . . . . 0.0 108.128 177.018 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 25' ' ' GLY . . . . . 0.436 ' H ' ' HB ' ' E' ' 24' ' ' VAL . . . -115.57 47.62 1.02 Allowed Glycine 0 N--CA 1.474 1.203 0 N-CA-C 111.65 -0.58 . . . . 0.0 111.65 -179.314 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -61.77 -168.59 0.01 OUTLIER 'General case' 0 N--CA 1.469 0.518 0 N-CA-C 110.25 -0.278 . . . . 0.0 110.25 179.45 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 24.6 t-20 -72.38 79.85 1.02 Allowed 'General case' 0 N--CA 1.468 0.426 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.318 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -73.19 140.6 47.1 Favored 'General case' 0 N--CA 1.477 0.898 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 179.565 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.56 -150.05 0.04 OUTLIER Glycine 0 C--N 1.338 0.639 0 N-CA-C 110.191 -1.163 . . . . 0.0 110.191 179.411 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -93.41 128.33 39.42 Favored 'General case' 0 N--CA 1.475 0.787 0 CA-C-N 116.938 0.369 . . . . 0.0 110.032 179.795 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 76.7 mt -124.46 117.26 50.02 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.658 0 N-CA-C 106.593 -1.632 . . . . 0.0 106.593 178.811 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 39.8 pt -151.19 -169.71 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.355 0.831 0 CA-C-N 115.986 -0.552 . . . . 0.0 111.255 -178.746 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.83 4.95 11.86 Favored Glycine 0 C--N 1.337 0.627 0 N-CA-C 110.945 -0.862 . . . . 0.0 110.945 179.479 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 1.5 tt -78.12 126.81 31.35 Favored 'General case' 0 CA--C 1.546 0.819 0 N-CA-C 109.57 -0.53 . . . . 0.0 109.57 -179.778 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 28.5 ttt -164.81 143.53 6.75 Favored 'General case' 0 N--CA 1.465 0.311 0 N-CA-C 108.801 -0.814 . . . . 0.0 108.801 178.225 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 35.4 m -155.37 162.41 1.8 Allowed 'Isoleucine or valine' 0 C--N 1.347 0.499 0 N-CA-C 108.0 -1.111 . . . . 0.0 108.0 179.471 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.71 66.9 2.52 Favored Glycine 0 C--N 1.307 -1.068 0 CA-C-N 115.742 -0.663 . . . . 0.0 111.784 178.415 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 144.97 172.65 15.58 Favored Glycine 0 N--CA 1.472 1.08 0 N-CA-C 110.869 -0.892 . . . . 0.0 110.869 179.179 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 39' ' ' VAL . . . . . 0.605 ' H ' HG12 ' E' ' 39' ' ' VAL . 32.5 m -123.09 159.95 26.49 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.711 0 C-N-CA 123.428 0.691 . . . . 0.0 110.209 -179.553 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 24.4 t . . . . . 0 N--CA 1.468 0.468 0 CA-C-O 118.316 -0.849 . . . . 0.0 110.441 179.475 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 34.6 m-85 . . . . . 0 N--CA 1.475 0.799 0 N-CA-C 110.023 -0.362 . . . . 0.0 110.023 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -144.75 138.85 27.47 Favored 'General case' 0 N--CA 1.482 1.165 0 N-CA-C 109.951 -0.389 . . . . 0.0 109.951 179.69 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 41.7 t-80 -151.16 119.7 6.48 Favored 'General case' 0 N--CA 1.471 0.582 0 N-CA-C 109.381 -0.599 . . . . 0.0 109.381 179.246 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 7' ' ' ASP . . . . . 0.482 ' O ' ' OG ' ' F' ' 8' ' ' SER . 4.3 m-20 -69.1 148.21 50.33 Favored 'General case' 0 CA--C 1.539 0.527 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.66 179.891 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 8' ' ' SER . . . . . . . . . . . . . 54.5 p -167.55 -173.95 2.36 Favored 'General case' 0 N--CA 1.484 1.271 0 CA-C-O 121.028 0.442 . . . . 0.0 110.764 179.455 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.81 48.19 1.29 Allowed Glycine 0 N--CA 1.48 1.616 0 CA-C-N 115.886 -0.597 . . . . 0.0 111.988 179.574 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 49.5 p90 -65.01 132.18 48.54 Favored 'General case' 0 N--CA 1.471 0.604 0 O-C-N 122.751 -0.264 . . . . 0.0 111.463 179.897 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 83.5 mt-10 -91.47 152.59 20.29 Favored 'General case' 0 N--CA 1.476 0.835 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 178.465 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -153.4 128.61 1.54 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.53 0 N-CA-C 107.778 -1.193 . . . . 0.0 107.778 178.237 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 46.8 m-70 -135.35 145.76 47.71 Favored 'General case' 0 N--CA 1.493 1.687 0 CA-C-N 118.986 0.812 . . . . 0.0 111.357 -179.099 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 6.0 t60 -165.69 97.33 0.66 Allowed 'General case' 0 N--CA 1.48 1.059 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.715 179.361 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 3.5 pt20 -108.74 -174.22 2.46 Favored 'General case' 0 CA--C 1.506 -0.722 0 N-CA-C 108.362 -0.977 . . . . 0.0 108.362 -179.891 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -164.66 97.7 0.77 Allowed 'General case' 0 N--CA 1.471 0.62 0 CA-C-N 114.573 -1.194 . . . . 0.0 108.269 178.55 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 6.6 mp -122.45 157.36 32.11 Favored 'General case' 0 N--CA 1.498 1.946 0 CA-C-O 121.883 0.849 . . . . 0.0 111.017 -178.208 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 58.8 t -112.41 127.28 69.71 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.091 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 177.655 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 29.2 m-85 -127.77 122.17 32.1 Favored 'General case' 0 N--CA 1.494 1.75 0 CA-C-N 119.686 1.13 . . . . 0.0 110.266 179.458 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 67.0 m-85 53.54 74.14 0.33 Allowed 'General case' 0 N--CA 1.468 0.448 0 CA-C-O 121.486 0.66 . . . . 0.0 111.915 178.588 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -80.56 -77.84 0.19 Allowed 'General case' 0 C--N 1.349 0.559 0 CA-C-N 114.969 -1.014 . . . . 0.0 110.373 -179.716 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 40.3 tt0 -112.38 101.32 9.52 Favored 'General case' 0 N--CA 1.47 0.535 0 N-CA-C 108.355 -0.98 . . . . 0.0 108.355 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -158.79 134.22 8.61 Favored 'General case' 0 N--CA 1.481 1.096 0 CA-C-O 119.466 -0.302 . . . . 0.0 111.205 178.965 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 59.3 t -57.55 163.55 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.805 0 N-CA-C 108.135 -1.061 . . . . 0.0 108.135 177.002 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 25' ' ' GLY . . . . . 0.437 ' H ' ' HB ' ' F' ' 24' ' ' VAL . . . -115.91 47.8 1.0 Allowed Glycine 0 N--CA 1.477 1.421 0 N-CA-C 111.519 -0.632 . . . . 0.0 111.519 -179.505 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -62.06 -169.23 0.02 OUTLIER 'General case' 0 N--CA 1.469 0.509 0 N-CA-C 110.17 -0.308 . . . . 0.0 110.17 179.348 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 24.7 t-20 -71.77 79.72 0.86 Allowed 'General case' 0 N--CA 1.468 0.425 0 N-CA-C 110.011 -0.366 . . . . 0.0 110.011 179.455 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -73.19 140.6 47.08 Favored 'General case' 0 N--CA 1.476 0.834 0 N-CA-C 109.011 -0.737 . . . . 0.0 109.011 179.442 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.7 -149.09 0.04 OUTLIER Glycine 0 C--N 1.337 0.594 0 N-CA-C 110.284 -1.126 . . . . 0.0 110.284 179.457 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -94.16 128.03 40.34 Favored 'General case' 0 N--CA 1.477 0.877 0 CA-C-N 116.931 0.365 . . . . 0.0 110.083 179.953 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 74.9 mt -124.28 117.23 50.06 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.697 0 N-CA-C 106.707 -1.59 . . . . 0.0 106.707 178.734 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 39.7 pt -151.3 -169.74 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.355 0.826 0 CA-C-N 115.978 -0.556 . . . . 0.0 111.231 -178.712 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.9 4.81 11.83 Favored Glycine 0 N--CA 1.465 0.609 0 N-CA-C 110.84 -0.904 . . . . 0.0 110.84 179.433 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 1.5 tt -77.96 126.66 31.17 Favored 'General case' 0 CA--C 1.546 0.826 0 N-CA-C 109.566 -0.531 . . . . 0.0 109.566 -179.803 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 28.6 ttt -164.49 143.33 7.13 Favored 'General case' 0 N--CA 1.465 0.298 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 178.298 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 35.5 m -155.19 162.58 1.77 Allowed 'Isoleucine or valine' 0 C--N 1.347 0.485 0 N-CA-C 107.989 -1.115 . . . . 0.0 107.989 179.373 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.64 66.45 2.84 Favored Glycine 0 C--N 1.306 -1.138 0 CA-C-N 115.808 -0.633 . . . . 0.0 111.88 178.422 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 145.46 173.33 16.62 Favored Glycine 0 N--CA 1.472 1.07 0 N-CA-C 111.024 -0.831 . . . . 0.0 111.024 178.946 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 39' ' ' VAL . . . . . 0.598 ' H ' HG12 ' F' ' 39' ' ' VAL . 33.0 m -123.17 160.39 26.18 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.658 0 C-N-CA 123.424 0.69 . . . . 0.0 110.192 -179.787 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 22.8 t . . . . . 0 C--O 1.219 -0.518 0 CA-C-O 118.406 -0.807 . . . . 0.0 110.46 179.546 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 35.1 m-85 . . . . . 0 N--CA 1.472 0.636 0 N-CA-C 108.954 -0.758 . . . . 0.0 108.954 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' D' D ' 5' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -146.07 137.5 24.77 Favored 'General case' 0 N--CA 1.478 0.953 0 C-N-CA 122.814 0.445 . . . . 0.0 110.341 -179.888 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 37.7 t-80 -149.64 123.94 9.57 Favored 'General case' 0 CA--C 1.547 0.827 0 N-CA-C 108.188 -1.041 . . . . 0.0 108.188 175.182 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' D' D ' 7' ' ' ASP . . . . . 0.604 ' O ' ' OG ' ' G' ' 8' ' ' SER . 3.2 m-20 -63.69 132.52 51.33 Favored 'General case' 0 N--CA 1.466 0.363 0 C-N-CA 126.323 1.849 . . . . 0.0 114.361 174.856 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' D' D ' 8' ' ' SER . . . . . 0.5 ' OG ' ' O ' ' A' ' 7' ' ' ASP . 53.8 p -154.39 -171.35 3.83 Favored 'General case' 0 N--CA 1.487 1.385 0 CA-C-N 119.454 1.024 . . . . 0.0 111.255 176.266 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.28 49.0 1.09 Allowed Glycine 0 N--CA 1.483 1.8 0 N-CA-C 110.263 -1.135 . . . . 0.0 110.263 174.144 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 50.8 p90 -61.47 131.71 51.08 Favored 'General case' 0 N--CA 1.472 0.65 0 N-CA-C 112.338 0.495 . . . . 0.0 112.338 178.833 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 84.8 mt-10 -89.24 150.73 22.5 Favored 'General case' 0 N--CA 1.482 1.136 0 CA-C-O 120.564 0.221 . . . . 0.0 110.714 175.645 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.0 p -149.44 130.19 4.58 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.567 0 N-CA-C 107.492 -1.299 . . . . 0.0 107.492 173.114 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 43.2 m-70 -129.89 148.72 51.78 Favored 'General case' 0 N--CA 1.483 1.217 0 CA-C-N 118.074 0.397 . . . . 0.0 111.91 176.444 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 6.1 t60 -165.14 104.43 0.76 Allowed 'General case' 0 N--CA 1.481 1.083 0 N-CA-C 109.029 -0.73 . . . . 0.0 109.029 172.33 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 3.5 pt20 -111.84 -176.14 2.86 Favored 'General case' 0 CA--C 1.497 -1.089 0 N-CA-C 108.29 -1.004 . . . . 0.0 108.29 178.808 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -161.29 105.35 1.3 Allowed 'General case' 0 N--CA 1.469 0.5 0 N-CA-C 106.37 -1.715 . . . . 0.0 106.37 174.965 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 5.6 mp -129.15 154.07 47.08 Favored 'General case' 0 N--CA 1.499 1.989 0 CA-C-O 122.024 0.916 . . . . 0.0 110.581 179.732 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 33.1 t -101.29 131.39 49.14 Favored 'Isoleucine or valine' 0 C--O 1.262 1.75 0 CA-C-O 116.89 -1.529 . . . . 0.0 109.74 174.047 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 26.9 m-85 -130.24 126.63 37.8 Favored 'General case' 0 N--CA 1.491 1.618 0 CA-C-N 119.893 1.224 . . . . 0.0 109.497 173.19 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 67.3 m-85 55.22 71.3 0.55 Allowed 'General case' 0 C--O 1.241 0.658 0 CA-C-N 115.592 -0.731 . . . . 0.0 111.653 176.226 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -82.3 -73.42 0.39 Allowed 'General case' 0 N--CA 1.473 0.701 0 CA-C-O 118.601 -0.714 . . . . 0.0 111.259 -177.414 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 40.7 tt0 -115.35 105.37 12.77 Favored 'General case' 0 N--CA 1.48 1.046 0 N-CA-C 106.463 -1.68 . . . . 0.0 106.463 176.312 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 4.4 p30 -152.19 135.17 15.66 Favored 'General case' 0 N--CA 1.473 0.692 0 CA-C-O 116.67 -1.633 . . . . 0.0 113.493 177.301 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' D' D ' 24' ' ' VAL . . . . . 0.421 ' HB ' ' H ' ' A' ' 25' ' ' GLY . 87.7 t -61.35 166.27 0.81 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.218 0 CA-C-N 121.056 1.753 . . . . 0.0 107.759 175.529 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' D' D ' 25' ' ' GLY . . . . . 0.485 ' H ' ' HB ' ' G' ' 24' ' ' VAL . . . -116.38 50.99 0.75 Allowed Glycine 0 N--CA 1.478 1.476 0 CA-C-O 119.466 -0.63 . . . . 0.0 111.656 178.621 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -57.14 -171.03 0.01 OUTLIER 'General case' 0 N--CA 1.468 0.463 0 C-N-CA 123.414 0.685 . . . . 0.0 111.805 175.217 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 25.4 t-20 -73.62 86.86 1.63 Allowed 'General case' 0 C--N 1.348 0.512 0 N-CA-C 108.44 -0.948 . . . . 0.0 108.44 176.753 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 97.6 mttt -81.09 143.26 32.56 Favored 'General case' 0 N--CA 1.481 1.101 0 N-CA-C 107.527 -1.286 . . . . 0.0 107.527 179.818 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.72 -144.78 0.02 OUTLIER Glycine 0 C--N 1.349 1.274 0 CA-C-N 114.928 -1.033 . . . . 0.0 111.705 -178.865 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -95.81 127.01 41.47 Favored 'General case' 0 C--O 1.241 0.619 0 N-CA-C 110.196 -0.298 . . . . 0.0 110.196 178.859 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 85.8 mt -125.98 127.61 71.23 Favored 'Isoleucine or valine' 0 C--N 1.354 0.77 0 N-CA-C 103.34 -2.837 . . . . 0.0 103.34 176.89 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' D' D ' 32' ' ' ILE . . . . . 0.408 HG22 ' H ' ' G' ' 32' ' ' ILE . 42.8 pt -159.61 -170.82 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.119 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.228 -177.696 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 64.12 4.83 12.78 Favored Glycine 0 C--O 1.243 0.685 0 N-CA-C 110.254 -1.138 . . . . 0.0 110.254 -179.251 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' D' D ' 34' ' ' LEU . . . . . . . . . . . . 0.265 2.0 tt -80.33 133.38 35.93 Favored 'General case' 0 C--N 1.377 1.798 0 C-N-CA 117.22 -1.792 . . . . 0.0 107.353 -178.729 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' D' D ' 35' ' ' MET . . . . . 0.406 ' C ' HG13 ' D' ' 36' ' ' VAL . 28.4 ttt -158.82 156.2 29.25 Favored 'General case' 0 C--O 1.25 1.081 0 CA-C-O 117.938 -1.03 . . . . 0.0 108.691 172.374 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' D' D ' 36' ' ' VAL . . . . . 0.488 HG22 HG12 ' G' ' 36' ' ' VAL . 35.5 m -164.74 163.7 0.71 Allowed 'Isoleucine or valine' 0 CA--C 1.516 -0.364 0 N-CA-C 107.643 -1.243 . . . . 0.0 107.643 174.273 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 60.5 63.03 5.35 Favored Glycine 0 CA--C 1.53 1.011 0 C-N-CA 120.216 -0.993 . . . . 0.0 111.509 177.578 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 144.03 175.53 17.24 Favored Glycine 0 N--CA 1.478 1.469 0 CA-C-N 118.443 1.122 . . . . 0.0 111.378 179.847 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' D' D ' 39' ' ' VAL . . . . . 0.624 ' H ' HG12 ' G' ' 39' ' ' VAL . 36.0 m -126.22 157.4 36.52 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.78 0 C-N-CA 122.937 0.495 . . . . 0.0 109.863 -177.737 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 24.0 t . . . . . 0 C--N 1.331 -0.211 0 CA-C-O 116.331 -1.795 . . . . 0.0 109.479 177.301 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 31.8 m-85 . . . . . 0 N--CA 1.474 0.768 0 N-CA-C 110.135 -0.321 . . . . 0.0 110.135 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' E' E ' 5' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -143.69 139.82 29.71 Favored 'General case' 0 N--CA 1.484 1.256 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 179.374 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 41.3 t-80 -151.57 119.61 6.26 Favored 'General case' 0 N--CA 1.472 0.674 0 N-CA-C 109.276 -0.639 . . . . 0.0 109.276 178.953 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' E' E ' 7' ' ' ASP . . . . . 0.501 ' O ' ' OG ' ' H' ' 8' ' ' SER . 3.9 m-20 -69.6 147.81 50.21 Favored 'General case' 0 CA--C 1.534 0.334 0 CA-C-N 116.414 -0.357 . . . . 0.0 110.94 -179.951 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' E' E ' 8' ' ' SER . . . . . 0.507 ' OG ' ' O ' ' B' ' 7' ' ' ASP . 52.2 p -167.8 -172.72 1.93 Allowed 'General case' 0 N--CA 1.485 1.32 0 CA-C-O 121.18 0.514 . . . . 0.0 110.807 179.014 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.19 48.57 1.21 Allowed Glycine 0 N--CA 1.478 1.479 0 CA-C-N 115.702 -0.681 . . . . 0.0 111.82 179.475 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 47.8 p90 -64.66 133.11 51.49 Favored 'General case' 0 N--CA 1.473 0.688 0 N-CA-C 111.842 0.312 . . . . 0.0 111.842 -179.744 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 86.3 mt-10 -91.53 152.41 20.33 Favored 'General case' 0 N--CA 1.479 1.024 0 CA-C-O 121.175 0.512 . . . . 0.0 109.787 178.06 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -154.59 127.5 1.12 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.575 0 N-CA-C 107.735 -1.209 . . . . 0.0 107.735 178.053 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 46.6 m-70 -135.24 143.8 46.53 Favored 'General case' 0 N--CA 1.482 1.13 0 CA-C-O 120.846 0.355 . . . . 0.0 111.609 -177.942 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 6.1 t60 -164.31 97.25 0.8 Allowed 'General case' 0 N--CA 1.483 1.187 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.671 179.395 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 3.5 pt20 -108.07 -174.58 2.56 Favored 'General case' 0 CA--C 1.509 -0.63 0 N-CA-C 108.544 -0.909 . . . . 0.0 108.544 179.994 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -164.22 96.61 0.79 Allowed 'General case' 0 N--CA 1.477 0.906 0 CA-C-N 114.651 -1.158 . . . . 0.0 108.426 178.367 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' E' E ' 17' ' ' LEU . . . . . 0.412 ' H ' ' CD1' ' H' ' 17' ' ' LEU . 6.5 mp -120.91 157.31 30.15 Favored 'General case' 0 N--CA 1.495 1.788 0 CA-C-O 121.641 0.734 . . . . 0.0 111.557 -177.668 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 48.2 t -114.34 124.42 70.98 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.24 0 N-CA-C 108.277 -1.008 . . . . 0.0 108.277 177.266 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 31.7 m-85 -125.3 121.19 33.3 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 123.256 0.348 . . . . 0.0 110.909 -179.751 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 68.9 m-85 54.87 73.17 0.42 Allowed 'General case' 0 N--CA 1.469 0.504 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.392 178.196 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -78.73 -78.76 0.14 Allowed 'General case' 0 CA--C 1.536 0.419 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.201 -179.566 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 40.3 tt0 -111.5 102.2 10.57 Favored 'General case' 0 C--N 1.322 -0.588 0 N-CA-C 108.49 -0.93 . . . . 0.0 108.49 -179.996 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -158.27 134.62 9.42 Favored 'General case' 0 C--O 1.208 -1.1 0 CA-C-O 119.447 -0.311 . . . . 0.0 111.476 178.846 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' E' E ' 24' ' ' VAL . . . . . 0.436 ' HB ' ' H ' ' B' ' 25' ' ' GLY . 57.3 t -56.73 167.4 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.884 0 N-CA-C 107.564 -1.273 . . . . 0.0 107.564 176.791 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' E' E ' 25' ' ' GLY . . . . . 0.411 ' N ' HG12 ' E' ' 24' ' ' VAL . . . -120.37 48.96 0.91 Allowed Glycine 0 N--CA 1.472 1.091 0 N-CA-C 110.852 -0.899 . . . . 0.0 110.852 -179.389 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -63.37 -167.92 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.528 0 CA-C-O 120.767 0.318 . . . . 0.0 110.361 179.669 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 25.0 t-20 -71.71 76.35 0.84 Allowed 'General case' 0 N--CA 1.466 0.334 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.324 179.779 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -70.26 140.28 52.35 Favored 'General case' 0 N--CA 1.48 1.061 0 N-CA-C 109.438 -0.579 . . . . 0.0 109.438 179.462 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.47 -149.28 0.05 OUTLIER Glycine 0 C--N 1.335 0.49 0 N-CA-C 110.859 -0.896 . . . . 0.0 110.859 179.42 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -92.78 126.89 38.07 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-N 116.797 0.298 . . . . 0.0 110.402 179.713 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 76.8 mt -123.62 117.25 50.65 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.436 0 N-CA-C 106.365 -1.717 . . . . 0.0 106.365 178.591 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' E' E ' 32' ' ' ILE . . . . . 0.415 HG22 ' H ' ' H' ' 32' ' ' ILE . 44.2 pt -151.46 -168.19 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.17 0 CA-C-O 121.117 0.484 . . . . 0.0 110.882 -178.868 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.13 5.43 7.85 Favored Glycine 0 CA--C 1.527 0.839 0 N-CA-C 111.315 -0.714 . . . . 0.0 111.315 179.975 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 1.6 tt -77.74 127.23 32.1 Favored 'General case' 0 CA--C 1.548 0.88 0 N-CA-C 109.494 -0.558 . . . . 0.0 109.494 -179.886 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 28.6 ttt -164.7 144.52 7.34 Favored 'General case' 0 N--CA 1.469 0.51 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 178.267 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' E' E ' 36' ' ' VAL . . . . . 0.463 HG22 HG12 ' H' ' 36' ' ' VAL . 32.9 m -156.38 162.84 1.55 Allowed 'Isoleucine or valine' 0 C--N 1.348 0.523 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 179.675 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.05 66.13 3.06 Favored Glycine 0 C--N 1.307 -1.072 0 CA-C-N 115.599 -0.728 . . . . 0.0 111.799 178.34 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 145.97 174.31 18.02 Favored Glycine 0 N--CA 1.474 1.191 0 N-CA-C 111.256 -0.738 . . . . 0.0 111.256 178.8 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' E' E ' 39' ' ' VAL . . . . . 0.614 ' H ' HG12 ' H' ' 39' ' ' VAL . 34.3 m -124.15 159.87 29.1 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.709 0 C-N-CA 123.32 0.648 . . . . 0.0 110.297 -179.206 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 24.6 t . . . . . 0 C--O 1.218 -0.595 0 O-C-N 124.156 0.91 . . . . 0.0 110.43 179.394 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 31.5 m-85 . . . . . 0 N--CA 1.475 0.813 0 N-CA-C 110.019 -0.363 . . . . 0.0 110.019 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' F' F ' 5' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -144.03 139.4 28.96 Favored 'General case' 0 N--CA 1.478 0.966 0 CA-C-O 120.759 0.314 . . . . 0.0 110.214 179.46 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 41.3 t-80 -151.48 119.73 6.35 Favored 'General case' 0 N--CA 1.473 0.695 0 N-CA-C 109.282 -0.636 . . . . 0.0 109.282 179.124 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' F' F ' 7' ' ' ASP . . . . . 0.465 ' O ' ' OG ' ' I' ' 8' ' ' SER . 3.9 m-20 -69.62 147.81 50.19 Favored 'General case' 0 CA--C 1.533 0.317 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.909 179.994 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' F' F ' 8' ' ' SER . . . . . 0.482 ' OG ' ' O ' ' C' ' 7' ' ' ASP . 51.7 p -168.09 -173.12 1.96 Allowed 'General case' 0 N--CA 1.485 1.321 0 CA-C-O 121.22 0.533 . . . . 0.0 110.923 178.977 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.49 48.3 1.22 Allowed Glycine 0 N--CA 1.478 1.457 0 CA-C-N 115.767 -0.651 . . . . 0.0 111.714 179.466 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 47.7 p90 -64.02 132.84 51.81 Favored 'General case' 0 N--CA 1.474 0.736 0 O-C-N 122.648 -0.325 . . . . 0.0 111.792 -179.888 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 86.8 mt-10 -91.28 152.42 20.49 Favored 'General case' 0 N--CA 1.481 1.103 0 CA-C-O 121.166 0.508 . . . . 0.0 109.877 177.873 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -154.57 127.61 1.14 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.627 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 178.008 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 44.4 m-70 -135.44 144.13 46.29 Favored 'General case' 0 N--CA 1.482 1.144 0 CA-C-O 120.807 0.337 . . . . 0.0 111.6 -178.079 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 6.0 t60 -164.57 96.82 0.76 Allowed 'General case' 0 N--CA 1.485 1.284 0 CA-C-N 116.431 -0.349 . . . . 0.0 110.788 179.478 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 3.5 pt20 -107.71 -174.06 2.44 Favored 'General case' 0 CA--C 1.505 -0.778 0 N-CA-C 108.637 -0.875 . . . . 0.0 108.637 -179.97 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -164.53 96.8 0.77 Allowed 'General case' 0 N--CA 1.475 0.802 0 CA-C-N 114.645 -1.161 . . . . 0.0 108.336 178.533 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' F' F ' 17' ' ' LEU . . . . . 0.406 ' H ' ' CD1' ' I' ' 17' ' ' LEU . 6.5 mp -121.01 157.17 30.57 Favored 'General case' 0 N--CA 1.494 1.766 0 CA-C-O 121.51 0.671 . . . . 0.0 111.483 -177.733 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 48.1 t -114.04 124.24 70.49 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.227 0 N-CA-C 108.288 -1.004 . . . . 0.0 108.288 177.11 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 31.6 m-85 -125.03 121.05 33.25 Favored 'General case' 0 N--CA 1.487 1.407 0 CA-C-O 120.787 0.327 . . . . 0.0 110.937 -179.855 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 68.7 m-85 55.2 73.32 0.42 Allowed 'General case' 0 C--N 1.345 0.386 0 CA-C-N 116.0 -0.545 . . . . 0.0 111.654 178.097 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -79.02 -78.65 0.15 Allowed 'General case' 0 C--N 1.345 0.379 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.345 -179.262 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 40.6 tt0 -111.74 102.01 10.33 Favored 'General case' 0 C--N 1.323 -0.555 0 N-CA-C 108.449 -0.945 . . . . 0.0 108.449 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -158.14 134.7 9.61 Favored 'General case' 0 C--O 1.209 -1.046 0 CA-C-O 119.571 -0.252 . . . . 0.0 111.448 178.975 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' F' F ' 24' ' ' VAL . . . . . 0.437 ' HB ' ' H ' ' C' ' 25' ' ' GLY . 63.6 t -57.13 166.89 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.885 0 N-CA-C 107.495 -1.298 . . . . 0.0 107.495 176.98 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' F' F ' 25' ' ' GLY . . . . . 0.413 ' H ' ' HB ' ' I' ' 24' ' ' VAL . . . -119.97 49.11 0.89 Allowed Glycine 0 N--CA 1.476 1.325 0 N-CA-C 110.792 -0.923 . . . . 0.0 110.792 -179.319 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -63.45 -167.77 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.549 0 CA-C-O 120.779 0.323 . . . . 0.0 110.221 179.579 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 24.8 t-20 -71.72 76.12 0.84 Allowed 'General case' 0 C--O 1.223 -0.321 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.378 179.761 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -70.18 140.49 52.55 Favored 'General case' 0 N--CA 1.478 0.967 0 N-CA-C 109.449 -0.574 . . . . 0.0 109.449 179.587 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.53 -149.8 0.05 OUTLIER Glycine 0 C--N 1.333 0.412 0 N-CA-C 110.852 -0.899 . . . . 0.0 110.852 179.443 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -92.16 126.68 37.34 Favored 'General case' 0 N--CA 1.47 0.573 0 N-CA-C 110.235 -0.283 . . . . 0.0 110.235 179.659 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 78.3 mt -123.65 116.98 49.8 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.512 0 N-CA-C 106.351 -1.722 . . . . 0.0 106.351 178.461 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' F' F ' 32' ' ' ILE . . . . . 0.42 HG22 ' H ' ' I' ' 32' ' ' ILE . 44.5 pt -151.31 -167.99 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.192 0 CA-C-O 121.061 0.458 . . . . 0.0 110.862 -178.882 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.98 5.66 8.05 Favored Glycine 0 CA--C 1.527 0.791 0 N-CA-C 111.373 -0.691 . . . . 0.0 111.373 -179.95 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 1.5 tt -77.9 127.18 31.97 Favored 'General case' 0 CA--C 1.548 0.886 0 N-CA-C 109.465 -0.569 . . . . 0.0 109.465 -179.897 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 28.4 ttt -164.45 144.44 7.69 Favored 'General case' 0 N--CA 1.469 0.493 0 N-CA-C 108.773 -0.825 . . . . 0.0 108.773 178.223 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' F' F ' 36' ' ' VAL . . . . . 0.473 HG22 HG12 ' I' ' 36' ' ' VAL . 32.9 m -156.26 162.75 1.59 Allowed 'Isoleucine or valine' 0 C--N 1.348 0.504 0 N-CA-C 108.292 -1.003 . . . . 0.0 108.292 179.566 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.16 66.28 2.96 Favored Glycine 0 C--N 1.307 -1.08 0 CA-C-N 115.691 -0.686 . . . . 0.0 111.854 178.366 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 145.79 174.42 17.95 Favored Glycine 0 N--CA 1.473 1.14 0 N-CA-C 111.313 -0.715 . . . . 0.0 111.313 178.863 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' F' F ' 39' ' ' VAL . . . . . 0.616 ' H ' HG12 ' I' ' 39' ' ' VAL . 34.4 m -124.47 159.78 30.0 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.669 0 C-N-CA 123.301 0.64 . . . . 0.0 110.224 -179.208 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 24.9 t . . . . . 0 C--O 1.218 -0.569 0 O-C-N 124.239 0.962 . . . . 0.0 110.517 179.507 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 35.2 m-85 . . . . . 0 N--CA 1.474 0.736 0 N-CA-C 109.605 -0.517 . . . . 0.0 109.605 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' G' G ' 5' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -144.67 139.11 27.77 Favored 'General case' 0 N--CA 1.482 1.145 0 C-N-CA 122.544 0.338 . . . . 0.0 110.235 179.834 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 42.2 t-80 -150.8 120.87 7.19 Favored 'General case' 0 N--CA 1.474 0.726 0 N-CA-C 109.543 -0.54 . . . . 0.0 109.543 179.023 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -71.82 143.45 49.48 Favored 'General case' 0 N--CA 1.47 0.554 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.28 -179.766 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' G' G ' 8' ' ' SER . . . . . 0.604 ' OG ' ' O ' ' D' ' 7' ' ' ASP . 48.9 p -164.7 -170.93 2.13 Favored 'General case' 0 N--CA 1.476 0.828 0 CA-C-O 121.2 0.524 . . . . 0.0 110.534 178.83 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.52 49.01 1.23 Allowed Glycine 0 N--CA 1.479 1.528 0 N-CA-C 111.35 -0.7 . . . . 0.0 111.35 179.388 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 50.1 p90 -65.03 133.36 51.5 Favored 'General case' 0 N--CA 1.473 0.704 0 CA-C-O 120.673 0.273 . . . . 0.0 111.67 -179.719 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 83.3 mt-10 -92.1 151.64 20.32 Favored 'General case' 0 N--CA 1.48 1.031 0 CA-C-O 121.108 0.48 . . . . 0.0 110.142 178.665 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -154.89 127.45 1.06 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.973 0 N-CA-C 107.853 -1.165 . . . . 0.0 107.853 178.293 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 47.4 m-70 -134.6 144.73 48.08 Favored 'General case' 0 N--CA 1.479 1.005 0 CA-C-N 115.561 -0.745 . . . . 0.0 111.488 -178.298 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 6.1 t60 -165.43 97.37 0.69 Allowed 'General case' 0 N--CA 1.482 1.131 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.377 178.989 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 3.6 pt20 -108.6 -174.72 2.58 Favored 'General case' 0 CA--C 1.506 -0.744 0 N-CA-C 108.433 -0.951 . . . . 0.0 108.433 -179.707 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -164.32 96.17 0.77 Allowed 'General case' 0 N--CA 1.474 0.758 0 CA-C-N 114.699 -1.137 . . . . 0.0 108.121 178.735 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 6.6 mp -120.58 155.61 33.34 Favored 'General case' 0 N--CA 1.497 1.924 0 CA-C-O 121.171 0.51 . . . . 0.0 111.771 -177.846 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 43.0 t -113.16 125.13 70.37 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.884 0 CA-C-N 114.757 -1.11 . . . . 0.0 108.128 176.477 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 33.1 m-85 -126.09 121.15 32.09 Favored 'General case' 0 C--N 1.369 1.424 0 CA-C-N 115.583 -0.735 . . . . 0.0 110.892 -179.699 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 67.2 m-85 54.8 72.95 0.43 Allowed 'General case' 0 C--O 1.238 0.459 0 CA-C-N 115.841 -0.618 . . . . 0.0 111.479 178.145 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -78.08 -77.96 0.15 Allowed 'General case' 0 N--CA 1.471 0.616 0 O-C-N 122.17 -0.331 . . . . 0.0 110.557 -178.939 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 40.4 tt0 -112.24 101.99 10.19 Favored 'General case' 0 C--N 1.323 -0.568 0 N-CA-C 108.093 -1.077 . . . . 0.0 108.093 179.917 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -157.88 135.91 10.8 Favored 'General case' 0 N--CA 1.476 0.867 0 O-C-N 122.401 -0.187 . . . . 0.0 111.488 178.826 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' G' G ' 24' ' ' VAL . . . . . 0.485 ' HB ' ' H ' ' D' ' 25' ' ' GLY . 57.3 t -58.27 166.47 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.647 0 N-CA-C 107.555 -1.276 . . . . 0.0 107.555 176.986 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' G' G ' 25' ' ' GLY . . . . . 0.413 ' N ' HG12 ' G' ' 24' ' ' VAL . . . -119.05 49.4 0.87 Allowed Glycine 0 N--CA 1.479 1.524 0 N-CA-C 110.456 -1.058 . . . . 0.0 110.456 -179.47 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -64.4 -168.09 0.03 OUTLIER 'General case' 0 N--CA 1.472 0.636 0 N-CA-C 109.904 -0.406 . . . . 0.0 109.904 179.645 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 25.1 t-20 -71.62 76.09 0.82 Allowed 'General case' 0 CA--C 1.536 0.438 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.324 179.928 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -69.57 140.64 53.84 Favored 'General case' 0 N--CA 1.478 0.955 0 N-CA-C 109.562 -0.533 . . . . 0.0 109.562 179.604 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.99 -147.81 0.05 OUTLIER Glycine 0 C--N 1.337 0.587 0 N-CA-C 110.443 -1.063 . . . . 0.0 110.443 179.612 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -92.88 125.99 37.75 Favored 'General case' 0 N--CA 1.467 0.419 0 C-N-CA 122.65 0.38 . . . . 0.0 110.93 -179.824 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 76.6 mt -123.45 117.65 52.03 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.811 0 N-CA-C 106.417 -1.697 . . . . 0.0 106.417 178.238 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' G' G ' 32' ' ' ILE . . . . . 0.408 ' H ' HG22 ' D' ' 32' ' ' ILE . 44.0 pt -152.47 -167.61 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 CA-C-N 119.819 1.19 . . . . 0.0 110.031 -179.225 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.29 6.26 10.15 Favored Glycine 0 N--CA 1.466 0.671 0 N-CA-C 111.056 -0.818 . . . . 0.0 111.056 179.881 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 1.5 tt -79.49 125.7 29.91 Favored 'General case' 0 CA--C 1.545 0.773 0 N-CA-C 109.516 -0.55 . . . . 0.0 109.516 -179.702 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 27.7 ttt -162.86 146.17 10.97 Favored 'General case' 0 N--CA 1.47 0.553 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 178.534 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' G' G ' 36' ' ' VAL . . . . . 0.488 HG12 HG22 ' D' ' 36' ' ' VAL . 32.7 m -156.95 162.01 1.69 Allowed 'Isoleucine or valine' 0 C--N 1.35 0.603 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 -179.99 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.48 66.63 2.7 Favored Glycine 0 C--N 1.31 -0.913 0 CA-C-N 115.541 -0.754 . . . . 0.0 112.104 177.818 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 146.72 175.6 19.82 Favored Glycine 0 N--CA 1.475 1.251 0 N-CA-C 110.559 -1.016 . . . . 0.0 110.559 178.994 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' G' G ' 39' ' ' VAL . . . . . 0.624 HG12 ' H ' ' D' ' 39' ' ' VAL . 34.9 m -125.77 159.71 33.4 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.912 0 C-N-CA 123.092 0.557 . . . . 0.0 110.484 -179.408 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 26.3 t . . . . . 0 C--O 1.22 -0.488 0 CA-C-O 118.395 -0.812 . . . . 0.0 110.751 179.082 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 34.9 m-85 . . . . . 0 N--CA 1.474 0.77 0 N-CA-C 109.518 -0.549 . . . . 0.0 109.518 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' H' H ' 5' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -144.74 139.68 28.04 Favored 'General case' 0 N--CA 1.485 1.313 0 N-CA-C 110.04 -0.355 . . . . 0.0 110.04 179.838 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 41.2 t-80 -151.58 120.7 6.72 Favored 'General case' 0 N--CA 1.474 0.76 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 179.068 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -71.65 143.82 49.62 Favored 'General case' 0 N--CA 1.469 0.511 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.308 -179.756 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' H' H ' 8' ' ' SER . . . . . 0.501 ' OG ' ' O ' ' E' ' 7' ' ' ASP . 52.2 p -164.81 -171.18 2.19 Favored 'General case' 0 N--CA 1.475 0.809 0 CA-C-O 121.126 0.489 . . . . 0.0 110.489 178.921 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.76 48.35 1.28 Allowed Glycine 0 N--CA 1.479 1.541 0 CA-C-N 115.783 -0.644 . . . . 0.0 111.551 179.336 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 50.1 p90 -64.51 133.06 51.64 Favored 'General case' 0 N--CA 1.471 0.624 0 N-CA-C 111.785 0.291 . . . . 0.0 111.785 -179.685 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 83.1 mt-10 -91.69 151.56 20.61 Favored 'General case' 0 N--CA 1.479 0.984 0 CA-C-O 121.068 0.461 . . . . 0.0 110.183 178.476 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -154.67 127.88 1.17 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.979 0 N-CA-C 107.885 -1.154 . . . . 0.0 107.885 178.08 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 47.3 m-70 -134.75 145.53 48.52 Favored 'General case' 0 N--CA 1.478 0.955 0 CA-C-N 115.676 -0.693 . . . . 0.0 111.359 -178.419 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 6.0 t60 -166.24 97.37 0.6 Allowed 'General case' 0 N--CA 1.482 1.146 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.346 178.794 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 3.6 pt20 -108.33 -174.3 2.49 Favored 'General case' 0 CA--C 1.505 -0.757 0 N-CA-C 108.425 -0.954 . . . . 0.0 108.425 -179.728 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -164.84 96.22 0.72 Allowed 'General case' 0 N--CA 1.475 0.799 0 CA-C-N 114.647 -1.16 . . . . 0.0 108.018 178.66 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' H' H ' 17' ' ' LEU . . . . . 0.412 ' CD1' ' H ' ' E' ' 17' ' ' LEU . 6.5 mp -120.53 156.02 32.43 Favored 'General case' 0 N--CA 1.497 1.899 0 CA-C-O 121.239 0.543 . . . . 0.0 111.972 -177.949 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 41.4 t -113.7 124.73 70.63 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.07 0 CA-C-N 114.819 -1.082 . . . . 0.0 108.227 176.658 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 33.3 m-85 -125.73 121.31 33.04 Favored 'General case' 0 C--N 1.368 1.388 0 CA-C-N 115.459 -0.792 . . . . 0.0 110.863 -179.491 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 68.0 m-85 54.3 72.69 0.44 Allowed 'General case' 0 C--O 1.237 0.422 0 CA-C-N 115.858 -0.61 . . . . 0.0 111.587 178.11 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.63 -78.13 0.14 Allowed 'General case' 0 N--CA 1.471 0.622 0 O-C-N 122.203 -0.31 . . . . 0.0 110.571 -179.033 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 40.9 tt0 -112.12 101.99 10.22 Favored 'General case' 0 C--N 1.321 -0.632 0 N-CA-C 108.091 -1.077 . . . . 0.0 108.091 -179.99 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -157.97 135.78 10.61 Favored 'General case' 0 N--CA 1.477 0.913 0 N-CA-C 111.445 0.165 . . . . 0.0 111.445 178.863 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' H' H ' 24' ' ' VAL . . . . . 0.41 HG12 ' N ' ' H' ' 25' ' ' GLY . 59.2 t -58.3 166.35 0.51 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.606 0 N-CA-C 107.682 -1.229 . . . . 0.0 107.682 177.197 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' H' H ' 25' ' ' GLY . . . . . 0.41 ' N ' HG12 ' H' ' 24' ' ' VAL . . . -118.76 49.42 0.87 Allowed Glycine 0 N--CA 1.478 1.444 0 N-CA-C 110.653 -0.979 . . . . 0.0 110.653 -179.498 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -64.67 -167.85 0.03 OUTLIER 'General case' 0 N--CA 1.472 0.668 0 CA-C-N 116.97 0.385 . . . . 0.0 110.0 179.662 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 24.9 t-20 -71.77 76.39 0.86 Allowed 'General case' 0 CA--C 1.535 0.4 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.317 179.871 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -69.89 140.74 53.18 Favored 'General case' 0 N--CA 1.478 0.953 0 N-CA-C 109.552 -0.536 . . . . 0.0 109.552 179.483 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.96 -147.82 0.05 OUTLIER Glycine 0 C--N 1.338 0.653 0 N-CA-C 110.329 -1.108 . . . . 0.0 110.329 179.541 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -93.5 125.77 38.29 Favored 'General case' 0 N--CA 1.465 0.307 0 C-N-CA 122.58 0.352 . . . . 0.0 110.872 -179.61 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 76.1 mt -122.92 117.55 52.12 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.757 0 N-CA-C 106.431 -1.692 . . . . 0.0 106.431 178.315 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' H' H ' 32' ' ' ILE . . . . . 0.415 ' H ' HG22 ' E' ' 32' ' ' ILE . 44.8 pt -152.04 -167.84 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 CA-C-N 119.807 1.185 . . . . 0.0 109.98 -179.469 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.93 5.8 10.53 Favored Glycine 0 N--CA 1.466 0.661 0 N-CA-C 110.964 -0.854 . . . . 0.0 110.964 179.86 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 1.5 tt -79.04 124.95 28.77 Favored 'General case' 0 CA--C 1.544 0.744 0 N-CA-C 109.725 -0.472 . . . . 0.0 109.725 -179.515 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 27.8 ttt -162.19 145.97 12.01 Favored 'General case' 0 N--CA 1.469 0.502 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 178.635 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' H' H ' 36' ' ' VAL . . . . . 0.463 HG12 HG22 ' E' ' 36' ' ' VAL . 32.6 m -157.08 161.69 1.76 Allowed 'Isoleucine or valine' 0 C--N 1.349 0.566 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 -179.895 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.94 66.2 3.01 Favored Glycine 0 C--N 1.309 -0.93 0 CA-C-N 115.498 -0.773 . . . . 0.0 112.17 177.935 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 146.92 175.63 20.01 Favored Glycine 0 N--CA 1.474 1.197 0 N-CA-C 110.639 -0.984 . . . . 0.0 110.639 178.893 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' H' H ' 39' ' ' VAL . . . . . 0.614 HG12 ' H ' ' E' ' 39' ' ' VAL . 34.9 m -125.2 159.96 31.54 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.927 0 C-N-CA 123.173 0.589 . . . . 0.0 110.537 -179.487 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 25.1 t . . . . . 0 N--CA 1.47 0.54 0 CA-C-O 118.439 -0.791 . . . . 0.0 110.819 179.233 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 35.9 m-85 . . . . . 0 N--CA 1.474 0.739 0 N-CA-C 109.538 -0.541 . . . . 0.0 109.538 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' I' I ' 5' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -144.51 139.17 28.08 Favored 'General case' 0 N--CA 1.484 1.255 0 N-CA-C 110.038 -0.356 . . . . 0.0 110.038 179.815 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 41.6 t-80 -150.81 120.73 7.12 Favored 'General case' 0 N--CA 1.473 0.679 0 N-CA-C 109.385 -0.598 . . . . 0.0 109.385 178.907 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 4.0 m-20 -71.48 143.94 49.86 Favored 'General case' 0 N--CA 1.47 0.531 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.141 -179.888 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' I' I ' 8' ' ' SER . . . . . 0.465 ' OG ' ' O ' ' F' ' 7' ' ' ASP . 52.5 p -165.05 -171.14 2.13 Favored 'General case' 0 N--CA 1.474 0.758 0 CA-C-O 121.081 0.467 . . . . 0.0 110.621 178.89 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.53 48.81 1.25 Allowed Glycine 0 N--CA 1.479 1.514 0 N-CA-C 111.502 -0.639 . . . . 0.0 111.502 179.348 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 50.2 p90 -65.12 132.94 50.49 Favored 'General case' 0 N--CA 1.472 0.663 0 N-CA-C 111.772 0.286 . . . . 0.0 111.772 -179.718 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 83.6 mt-10 -91.43 151.57 20.75 Favored 'General case' 0 N--CA 1.478 0.953 0 CA-C-O 121.045 0.45 . . . . 0.0 110.265 178.539 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -154.91 127.42 1.05 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.047 0 N-CA-C 107.91 -1.144 . . . . 0.0 107.91 178.198 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 46.9 m-70 -134.48 145.15 48.54 Favored 'General case' 0 N--CA 1.478 0.933 0 CA-C-N 115.61 -0.723 . . . . 0.0 111.407 -178.196 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 6.1 t60 -165.75 97.25 0.65 Allowed 'General case' 0 N--CA 1.48 1.03 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.378 178.838 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 3.6 pt20 -108.39 -174.55 2.55 Favored 'General case' 0 CA--C 1.504 -0.809 0 N-CA-C 108.381 -0.97 . . . . 0.0 108.381 -179.757 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -164.54 96.33 0.75 Allowed 'General case' 0 N--CA 1.474 0.755 0 CA-C-N 114.608 -1.178 . . . . 0.0 108.116 178.641 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' I' I ' 17' ' ' LEU . . . . . 0.406 ' CD1' ' H ' ' F' ' 17' ' ' LEU . 6.4 mp -120.6 156.07 32.42 Favored 'General case' 0 N--CA 1.497 1.914 0 CA-C-O 121.232 0.539 . . . . 0.0 111.767 -177.882 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 41.4 t -113.77 125.06 70.98 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.884 0 CA-C-N 114.753 -1.112 . . . . 0.0 108.207 176.608 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 33.6 m-85 -126.0 121.38 32.86 Favored 'General case' 0 C--N 1.368 1.41 0 CA-C-N 115.502 -0.772 . . . . 0.0 110.829 -179.449 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 67.9 m-85 54.25 73.29 0.4 Allowed 'General case' 0 C--N 1.347 0.467 0 CA-C-N 115.925 -0.58 . . . . 0.0 111.464 178.136 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -78.18 -78.01 0.15 Allowed 'General case' 0 N--CA 1.475 0.802 0 O-C-N 122.296 -0.253 . . . . 0.0 110.453 -179.079 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 40.7 tt0 -112.02 102.12 10.36 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 108.088 -1.079 . . . . 0.0 108.088 179.802 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -157.88 135.92 10.81 Favored 'General case' 0 N--CA 1.478 0.97 0 N-CA-C 111.409 0.152 . . . . 0.0 111.409 178.784 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' I' I ' 24' ' ' VAL . . . . . 0.42 HG12 ' N ' ' I' ' 25' ' ' GLY . 59.5 t -58.57 166.32 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.573 0 N-CA-C 107.658 -1.238 . . . . 0.0 107.658 177.203 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' I' I ' 25' ' ' GLY . . . . . 0.42 ' N ' HG12 ' I' ' 24' ' ' VAL . . . -118.69 49.0 0.89 Allowed Glycine 0 N--CA 1.479 1.524 0 N-CA-C 110.556 -1.017 . . . . 0.0 110.556 -179.392 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -64.3 -167.87 0.03 OUTLIER 'General case' 0 N--CA 1.472 0.648 0 CA-C-N 116.951 0.376 . . . . 0.0 110.092 179.641 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 24.9 t-20 -71.74 76.45 0.85 Allowed 'General case' 0 CA--C 1.536 0.419 0 CA-C-N 116.07 -0.513 . . . . 0.0 110.219 179.884 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -70.08 140.86 52.81 Favored 'General case' 0 N--CA 1.478 0.961 0 N-CA-C 109.492 -0.559 . . . . 0.0 109.492 179.496 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -65.02 -147.67 0.05 OUTLIER Glycine 0 C--N 1.337 0.628 0 N-CA-C 110.416 -1.074 . . . . 0.0 110.416 179.577 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -93.3 125.89 38.14 Favored 'General case' 0 N--CA 1.469 0.496 0 C-N-CA 122.587 0.355 . . . . 0.0 110.924 -179.953 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 77.0 mt -123.2 117.3 51.15 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.708 0 N-CA-C 106.474 -1.676 . . . . 0.0 106.474 178.255 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' I' I ' 32' ' ' ILE . . . . . 0.42 ' H ' HG22 ' F' ' 32' ' ' ILE . 44.6 pt -152.13 -167.9 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 CA-C-N 119.851 1.205 . . . . 0.0 109.979 -179.284 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.07 5.52 10.2 Favored Glycine 0 N--CA 1.466 0.674 0 N-CA-C 110.969 -0.852 . . . . 0.0 110.969 179.86 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 1.5 tt -78.6 125.82 29.89 Favored 'General case' 0 CA--C 1.546 0.798 0 N-CA-C 109.6 -0.519 . . . . 0.0 109.6 -179.675 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 27.7 ttt -162.76 146.01 11.08 Favored 'General case' 0 N--CA 1.47 0.561 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 178.454 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' I' I ' 36' ' ' VAL . . . . . 0.473 HG12 HG22 ' F' ' 36' ' ' VAL . 32.5 m -157.08 161.78 1.73 Allowed 'Isoleucine or valine' 0 C--N 1.348 0.522 0 N-CA-C 108.6 -0.889 . . . . 0.0 108.6 179.928 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.76 66.42 2.86 Favored Glycine 0 C--N 1.308 -0.981 0 CA-C-N 115.557 -0.747 . . . . 0.0 112.114 177.863 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 146.64 175.76 19.88 Favored Glycine 0 N--CA 1.476 1.334 0 N-CA-C 110.57 -1.012 . . . . 0.0 110.57 178.95 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' I' I ' 39' ' ' VAL . . . . . 0.616 HG12 ' H ' ' F' ' 39' ' ' VAL . 35.0 m -125.69 160.11 32.64 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.915 0 C-N-CA 123.138 0.575 . . . . 0.0 110.53 -179.381 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 25.9 t . . . . . 0 C--O 1.218 -0.557 0 CA-C-O 118.449 -0.786 . . . . 0.0 110.713 179.216 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 39.4 m-85 . . . . . 0 N--CA 1.477 0.882 0 N-CA-C 109.99 -0.374 . . . . 0.0 109.99 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -143.93 140.15 29.54 Favored 'General case' 0 N--CA 1.48 1.048 0 N-CA-C 110.016 -0.364 . . . . 0.0 110.016 179.67 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 43.3 t-80 -151.84 119.67 6.16 Favored 'General case' 0 N--CA 1.47 0.551 0 N-CA-C 109.224 -0.658 . . . . 0.0 109.224 179.291 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' ASP . . . . . 0.495 ' O ' ' OG ' ' D' ' 8' ' ' SER . 4.6 m-20 -69.14 148.9 49.27 Favored 'General case' 0 N--CA 1.466 0.34 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.466 179.879 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 54.8 p -168.21 -173.79 2.12 Favored 'General case' 0 N--CA 1.482 1.162 0 C-N-CA 122.669 0.388 . . . . 0.0 110.718 179.053 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.79 47.79 1.33 Allowed Glycine 0 N--CA 1.482 1.735 0 CA-C-N 116.013 -0.539 . . . . 0.0 112.147 -179.911 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 50.1 p90 -65.06 132.67 49.83 Favored 'General case' 0 N--CA 1.473 0.686 0 CA-C-O 120.716 0.293 . . . . 0.0 111.532 179.899 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 49.0 mt-10 -92.66 152.46 19.54 Favored 'General case' 0 N--CA 1.477 0.918 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 178.398 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.0 p -153.13 128.37 1.55 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.632 0 N-CA-C 107.847 -1.168 . . . . 0.0 107.847 178.382 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 47.2 m-70 -134.87 145.83 48.65 Favored 'General case' 0 N--CA 1.492 1.648 0 CA-C-N 119.096 0.862 . . . . 0.0 111.327 -179.127 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 6.1 t60 -165.73 97.51 0.66 Allowed 'General case' 0 N--CA 1.48 1.05 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.809 179.496 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . 0.501 HE22 HG23 ' A' ' 36' ' ' VAL . 11.9 pt20 -111.9 -174.78 2.54 Favored 'General case' 0 CA--C 1.503 -0.86 0 N-CA-C 108.355 -0.98 . . . . 0.0 108.355 -179.849 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -163.27 99.13 0.94 Allowed 'General case' 0 N--CA 1.474 0.749 0 CA-C-N 114.527 -1.215 . . . . 0.0 108.347 178.582 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 6.9 mp -121.83 157.07 31.9 Favored 'General case' 0 N--CA 1.497 1.909 0 CA-C-O 121.945 0.879 . . . . 0.0 110.86 -178.338 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 60.0 t -112.54 126.84 69.98 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.179 0 CA-C-O 117.877 -1.058 . . . . 0.0 108.298 177.808 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 28.8 m-85 -127.11 122.52 34.49 Favored 'General case' 0 N--CA 1.496 1.859 0 CA-C-N 120.197 1.362 . . . . 0.0 110.336 179.302 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 68.3 m-85 53.95 73.98 0.35 Allowed 'General case' 0 N--CA 1.47 0.546 0 CA-C-O 121.544 0.687 . . . . 0.0 111.745 178.51 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -80.22 -78.13 0.18 Allowed 'General case' 0 C--N 1.353 0.758 0 CA-C-N 115.117 -0.947 . . . . 0.0 110.42 -179.739 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 40.3 tt0 -112.07 101.87 10.12 Favored 'General case' 0 N--CA 1.47 0.563 0 N-CA-C 108.493 -0.928 . . . . 0.0 108.493 179.927 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -158.69 134.65 9.0 Favored 'General case' 0 N--CA 1.481 1.092 0 CA-C-O 119.388 -0.339 . . . . 0.0 111.254 179.026 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 61.9 t -58.36 163.4 0.72 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.795 0 N-CA-C 108.227 -1.027 . . . . 0.0 108.227 177.173 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.422 ' H ' ' HB ' ' D' ' 24' ' ' VAL . . . -116.04 48.07 0.98 Allowed Glycine 0 N--CA 1.476 1.326 0 N-CA-C 111.759 -0.536 . . . . 0.0 111.759 -179.402 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -62.07 -168.59 0.02 OUTLIER 'General case' 0 N--CA 1.469 0.499 0 O-C-N 123.834 0.373 . . . . 0.0 110.218 179.284 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 24.7 t-20 -72.43 79.83 1.04 Allowed 'General case' 0 N--CA 1.466 0.335 0 N-CA-C 110.048 -0.352 . . . . 0.0 110.048 179.221 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -73.28 140.32 46.73 Favored 'General case' 0 N--CA 1.471 0.625 0 N-CA-C 109.012 -0.736 . . . . 0.0 109.012 179.43 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.42 -148.9 0.03 OUTLIER Glycine 0 C--N 1.337 0.622 0 N-CA-C 110.383 -1.087 . . . . 0.0 110.383 179.443 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -93.94 128.54 40.31 Favored 'General case' 0 N--CA 1.471 0.604 0 N-CA-C 110.076 -0.342 . . . . 0.0 110.076 179.904 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 72.4 mt -125.0 116.77 48.13 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.874 0 N-CA-C 106.782 -1.562 . . . . 0.0 106.782 178.764 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 38.9 pt -151.01 -169.69 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.356 0.88 0 CA-C-N 115.857 -0.611 . . . . 0.0 111.206 -178.527 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.41 5.37 11.41 Favored Glycine 0 C--N 1.336 0.577 0 N-CA-C 110.912 -0.875 . . . . 0.0 110.912 179.673 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.403 HD23 ' N ' ' A' ' 35' ' ' MET . 1.5 tt -78.42 127.12 31.74 Favored 'General case' 0 CA--C 1.543 0.684 0 N-CA-C 109.44 -0.578 . . . . 0.0 109.44 -179.617 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' MET . . . . . 0.403 ' N ' HD23 ' A' ' 34' ' ' LEU . 28.6 ttt -164.59 143.86 7.22 Favored 'General case' 0 N--CA 1.466 0.368 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 178.404 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.501 HG23 HE22 ' A' ' 15' ' ' GLN . 35.3 m -155.92 163.28 1.51 Allowed 'Isoleucine or valine' 0 C--O 1.219 -0.525 0 N-CA-C 108.339 -0.985 . . . . 0.0 108.339 179.376 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.78 66.56 2.75 Favored Glycine 0 C--N 1.303 -1.292 0 CA-C-N 116.147 -0.479 . . . . 0.0 112.136 178.631 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 146.0 173.54 17.34 Favored Glycine 0 N--CA 1.475 1.243 0 N-CA-C 110.649 -0.98 . . . . 0.0 110.649 179.138 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.578 ' H ' HG12 ' D' ' 39' ' ' VAL . 35.6 m -123.96 159.98 28.53 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.861 0 C-N-CA 123.579 0.752 . . . . 0.0 110.552 -179.858 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 25.2 t . . . . . 0 C--O 1.22 -0.46 0 CA-C-O 118.323 -0.846 . . . . 0.0 110.78 179.568 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 39.4 m-85 . . . . . 0 N--CA 1.475 0.807 0 N-CA-C 109.99 -0.374 . . . . 0.0 109.99 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -143.71 139.98 29.78 Favored 'General case' 0 N--CA 1.482 1.139 0 N-CA-C 109.977 -0.379 . . . . 0.0 109.977 179.693 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 40.5 t-80 -151.74 119.18 6.0 Favored 'General case' 0 N--CA 1.473 0.724 0 N-CA-C 109.238 -0.652 . . . . 0.0 109.238 179.216 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 7' ' ' ASP . . . . . 0.501 ' O ' ' OG ' ' E' ' 8' ' ' SER . 4.3 m-20 -68.89 148.15 50.64 Favored 'General case' 0 CA--C 1.535 0.385 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.639 179.865 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 8' ' ' SER . . . . . . . . . . . . . 54.3 p -167.44 -173.79 2.34 Favored 'General case' 0 N--CA 1.48 1.068 0 C-N-CA 122.575 0.35 . . . . 0.0 110.701 179.072 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.94 47.92 1.3 Allowed Glycine 0 N--CA 1.482 1.703 0 CA-C-N 115.991 -0.549 . . . . 0.0 112.178 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 50.1 p90 -65.18 132.7 49.8 Favored 'General case' 0 N--CA 1.472 0.633 0 O-C-N 122.716 -0.285 . . . . 0.0 111.663 179.782 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 48.5 mt-10 -92.55 152.77 19.45 Favored 'General case' 0 N--CA 1.477 0.913 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 178.331 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.0 p -153.43 128.45 1.51 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.587 0 N-CA-C 107.737 -1.209 . . . . 0.0 107.737 178.314 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 47.5 m-70 -135.0 145.81 48.45 Favored 'General case' 0 N--CA 1.492 1.639 0 CA-C-N 118.904 0.775 . . . . 0.0 111.303 -179.103 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 6.2 t60 -165.66 97.46 0.66 Allowed 'General case' 0 N--CA 1.482 1.133 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.648 179.452 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . 0.494 HE22 HG23 ' B' ' 36' ' ' VAL . 12.0 pt20 -111.76 -174.34 2.44 Favored 'General case' 0 CA--C 1.506 -0.749 0 N-CA-C 108.362 -0.977 . . . . 0.0 108.362 -179.883 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -163.87 99.07 0.87 Allowed 'General case' 0 N--CA 1.474 0.77 0 CA-C-N 114.718 -1.128 . . . . 0.0 108.26 178.608 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 6.8 mp -121.62 157.0 31.77 Favored 'General case' 0 N--CA 1.497 1.916 0 CA-C-O 121.936 0.875 . . . . 0.0 110.998 -178.294 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 61.1 t -112.55 127.6 69.68 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.07 0 N-CA-C 108.122 -1.066 . . . . 0.0 108.122 177.574 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 29.0 m-85 -127.99 122.36 32.11 Favored 'General case' 0 N--CA 1.495 1.802 0 CA-C-N 119.638 1.108 . . . . 0.0 110.219 179.515 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 68.7 m-85 53.23 74.46 0.3 Allowed 'General case' 0 CA--C 1.54 0.566 0 CA-C-O 121.558 0.694 . . . . 0.0 111.735 178.573 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -80.71 -77.85 0.19 Allowed 'General case' 0 C--N 1.35 0.6 0 CA-C-N 115.075 -0.966 . . . . 0.0 110.45 -179.788 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 40.5 tt0 -112.22 101.9 10.1 Favored 'General case' 0 N--CA 1.471 0.615 0 N-CA-C 108.417 -0.957 . . . . 0.0 108.417 179.786 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -158.68 134.54 8.94 Favored 'General case' 0 N--CA 1.484 1.23 0 CA-C-O 119.444 -0.312 . . . . 0.0 111.16 178.85 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 24' ' ' VAL . . . . . 0.403 HG12 ' N ' ' B' ' 25' ' ' GLY . 61.1 t -57.98 163.82 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.806 0 N-CA-C 108.249 -1.019 . . . . 0.0 108.249 177.209 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 25' ' ' GLY . . . . . 0.437 ' H ' ' HB ' ' E' ' 24' ' ' VAL . . . -116.22 48.22 0.96 Allowed Glycine 0 N--CA 1.475 1.288 0 N-CA-C 111.625 -0.59 . . . . 0.0 111.625 -179.446 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -62.27 -169.06 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.531 0 O-C-N 123.76 0.33 . . . . 0.0 110.242 179.238 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 25.1 t-20 -72.2 79.68 0.97 Allowed 'General case' 0 N--CA 1.467 0.393 0 N-CA-C 109.881 -0.414 . . . . 0.0 109.881 179.307 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -72.99 140.66 47.5 Favored 'General case' 0 N--CA 1.472 0.674 0 N-CA-C 109.105 -0.702 . . . . 0.0 109.105 179.417 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.86 -149.1 0.04 OUTLIER Glycine 0 C--N 1.338 0.645 0 N-CA-C 110.349 -1.1 . . . . 0.0 110.349 179.582 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -93.75 128.47 39.99 Favored 'General case' 0 N--CA 1.473 0.679 0 N-CA-C 110.036 -0.357 . . . . 0.0 110.036 179.882 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 72.5 mt -125.08 117.14 49.15 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.859 0 N-CA-C 106.723 -1.584 . . . . 0.0 106.723 178.768 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 39.6 pt -151.47 -169.94 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.356 0.887 0 CA-C-N 115.874 -0.603 . . . . 0.0 111.119 -178.364 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.68 5.26 12.31 Favored Glycine 0 C--N 1.337 0.614 0 N-CA-C 110.894 -0.882 . . . . 0.0 110.894 179.702 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 1.5 tt -78.42 126.67 31.09 Favored 'General case' 0 CA--C 1.545 0.76 0 N-CA-C 109.441 -0.577 . . . . 0.0 109.441 -179.521 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 28.5 ttt -164.12 143.66 7.83 Favored 'General case' 0 N--CA 1.467 0.378 0 N-CA-C 108.722 -0.844 . . . . 0.0 108.722 178.456 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 36' ' ' VAL . . . . . 0.494 HG23 HE22 ' B' ' 15' ' ' GLN . 35.7 m -155.88 162.98 1.57 Allowed 'Isoleucine or valine' 0 C--O 1.22 -0.491 0 N-CA-C 108.343 -0.984 . . . . 0.0 108.343 179.519 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.81 66.95 2.47 Favored Glycine 0 C--N 1.303 -1.291 0 CA-C-N 116.183 -0.462 . . . . 0.0 112.076 178.591 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 145.33 173.24 16.41 Favored Glycine 0 N--CA 1.474 1.208 0 N-CA-C 110.69 -0.964 . . . . 0.0 110.69 179.181 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 39' ' ' VAL . . . . . 0.611 ' H ' HG12 ' E' ' 39' ' ' VAL . 35.7 m -123.65 159.84 27.95 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.934 0 C-N-CA 123.608 0.763 . . . . 0.0 110.713 -179.769 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 24.4 t . . . . . 0 N--CA 1.469 0.522 0 CA-C-O 118.339 -0.839 . . . . 0.0 110.599 179.53 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 40.3 m-85 . . . . . 0 N--CA 1.476 0.842 0 N-CA-C 110.031 -0.359 . . . . 0.0 110.031 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -143.63 139.98 29.89 Favored 'General case' 0 N--CA 1.482 1.134 0 CA-C-O 120.872 0.368 . . . . 0.0 110.05 179.762 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 42.1 t-80 -151.74 119.16 5.99 Favored 'General case' 0 N--CA 1.472 0.656 0 N-CA-C 109.26 -0.644 . . . . 0.0 109.26 179.173 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 7' ' ' ASP . . . . . 0.471 ' O ' ' OG ' ' F' ' 8' ' ' SER . 4.2 m-20 -68.77 148.47 50.28 Favored 'General case' 0 N--CA 1.468 0.443 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.52 179.783 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 8' ' ' SER . . . . . . . . . . . . . 54.2 p -167.97 -173.94 2.23 Favored 'General case' 0 N--CA 1.48 1.049 0 CA-C-O 120.874 0.368 . . . . 0.0 110.677 179.137 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.05 47.75 1.31 Allowed Glycine 0 N--CA 1.482 1.751 0 CA-C-N 115.968 -0.56 . . . . 0.0 112.072 -179.926 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 50.6 p90 -65.04 132.58 49.59 Favored 'General case' 0 N--CA 1.472 0.658 0 CA-C-O 120.778 0.323 . . . . 0.0 111.637 179.737 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 48.6 mt-10 -92.48 152.96 19.39 Favored 'General case' 0 N--CA 1.475 0.79 0 N-CA-C 109.738 -0.468 . . . . 0.0 109.738 178.395 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.0 p -153.65 128.62 1.5 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.523 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 178.263 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 46.1 m-70 -135.17 145.72 48.02 Favored 'General case' 0 N--CA 1.492 1.635 0 CA-C-N 118.931 0.787 . . . . 0.0 111.317 -179.057 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 6.2 t60 -165.52 97.52 0.68 Allowed 'General case' 0 N--CA 1.482 1.162 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.688 179.52 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 15' ' ' GLN . . . . . 0.503 HE22 HG23 ' C' ' 36' ' ' VAL . 12.0 pt20 -112.0 -174.47 2.47 Favored 'General case' 0 CA--C 1.504 -0.825 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 -179.889 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -163.62 99.12 0.9 Allowed 'General case' 0 N--CA 1.473 0.677 0 CA-C-N 114.708 -1.133 . . . . 0.0 108.261 178.777 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 6.8 mp -121.71 157.07 31.74 Favored 'General case' 0 N--CA 1.497 1.902 0 CA-C-O 121.965 0.888 . . . . 0.0 110.994 -178.342 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 61.9 t -112.71 127.4 69.96 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.151 0 N-CA-C 108.146 -1.057 . . . . 0.0 108.146 177.612 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 28.9 m-85 -127.82 122.17 32.01 Favored 'General case' 0 N--CA 1.494 1.765 0 CA-C-N 119.673 1.124 . . . . 0.0 110.197 179.513 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 68.7 m-85 53.42 74.55 0.3 Allowed 'General case' 0 CA--C 1.539 0.523 0 CA-C-O 121.57 0.7 . . . . 0.0 111.787 178.612 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -80.62 -78.12 0.18 Allowed 'General case' 0 C--N 1.35 0.598 0 CA-C-N 114.961 -1.018 . . . . 0.0 110.379 -179.805 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 40.3 tt0 -112.02 102.05 10.3 Favored 'General case' 0 N--CA 1.469 0.522 0 N-CA-C 108.506 -0.924 . . . . 0.0 108.506 179.82 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -158.76 134.67 8.94 Favored 'General case' 0 N--CA 1.482 1.161 0 CA-C-O 119.385 -0.341 . . . . 0.0 111.185 178.906 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 61.0 t -58.14 163.74 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.843 0 N-CA-C 108.217 -1.031 . . . . 0.0 108.217 177.188 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 25' ' ' GLY . . . . . 0.443 ' H ' ' HB ' ' F' ' 24' ' ' VAL . . . -116.28 48.13 0.97 Allowed Glycine 0 N--CA 1.477 1.372 0 N-CA-C 111.617 -0.593 . . . . 0.0 111.617 -179.352 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -62.3 -169.11 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.532 0 O-C-N 123.726 0.309 . . . . 0.0 110.212 179.312 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 25.2 t-20 -71.98 79.98 0.92 Allowed 'General case' 0 N--CA 1.466 0.368 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.205 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -73.45 140.61 46.62 Favored 'General case' 0 N--CA 1.473 0.692 0 N-CA-C 109.015 -0.735 . . . . 0.0 109.015 179.369 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.71 -148.67 0.03 OUTLIER Glycine 0 C--N 1.338 0.661 0 N-CA-C 110.395 -1.082 . . . . 0.0 110.395 179.548 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -93.99 128.25 40.23 Favored 'General case' 0 N--CA 1.471 0.592 0 CA-C-N 116.866 0.333 . . . . 0.0 110.136 179.825 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 71.8 mt -124.94 116.71 48.02 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.834 0 N-CA-C 106.779 -1.563 . . . . 0.0 106.779 178.654 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 38.8 pt -150.97 -169.71 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.356 0.873 0 CA-C-N 115.903 -0.589 . . . . 0.0 111.183 -178.42 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.37 5.39 11.29 Favored Glycine 0 C--N 1.336 0.555 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 179.659 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 1.5 tt -78.53 126.44 30.76 Favored 'General case' 0 CA--C 1.544 0.744 0 N-CA-C 109.499 -0.556 . . . . 0.0 109.499 -179.613 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 28.6 ttt -163.65 143.76 8.55 Favored 'General case' 0 N--CA 1.468 0.427 0 N-CA-C 108.687 -0.857 . . . . 0.0 108.687 178.42 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 36' ' ' VAL . . . . . 0.503 HG23 HE22 ' C' ' 15' ' ' GLN . 35.5 m -155.9 162.96 1.57 Allowed 'Isoleucine or valine' 0 C--O 1.219 -0.501 0 N-CA-C 108.292 -1.003 . . . . 0.0 108.292 179.384 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.93 66.9 2.51 Favored Glycine 0 C--N 1.303 -1.299 0 CA-C-N 116.195 -0.457 . . . . 0.0 112.058 178.565 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 145.53 173.67 17.01 Favored Glycine 0 N--CA 1.475 1.257 0 N-CA-C 110.663 -0.975 . . . . 0.0 110.663 179.061 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 39' ' ' VAL . . . . . 0.608 ' H ' HG12 ' F' ' 39' ' ' VAL . 35.9 m -124.02 159.87 28.81 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.868 0 C-N-CA 123.678 0.791 . . . . 0.0 110.592 -179.851 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 24.7 t . . . . . 0 C--O 1.219 -0.542 0 CA-C-O 118.355 -0.831 . . . . 0.0 110.611 179.496 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 39.8 m-85 . . . . . 0 N--CA 1.472 0.671 0 N-CA-C 108.898 -0.778 . . . . 0.0 108.898 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' D' D ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -145.9 138.11 25.38 Favored 'General case' 0 N--CA 1.476 0.848 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.396 -179.609 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 39.6 t-80 -149.29 123.69 9.65 Favored 'General case' 0 CA--C 1.546 0.79 0 N-CA-C 108.318 -0.993 . . . . 0.0 108.318 175.746 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' D' D ' 7' ' ' ASP . . . . . 0.598 ' O ' ' OG ' ' G' ' 8' ' ' SER . 3.3 m-20 -64.28 133.08 52.03 Favored 'General case' 0 C--N 1.324 -0.524 0 C-N-CA 126.477 1.911 . . . . 0.0 114.259 174.946 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' D' D ' 8' ' ' SER . . . . . 0.495 ' OG ' ' O ' ' A' ' 7' ' ' ASP . 54.0 p -154.93 -171.12 3.72 Favored 'General case' 0 N--CA 1.486 1.373 0 CA-C-N 119.566 1.075 . . . . 0.0 111.26 175.892 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.44 48.23 1.14 Allowed Glycine 0 N--CA 1.483 1.779 0 N-CA-C 110.517 -1.033 . . . . 0.0 110.517 174.559 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 51.4 p90 -61.0 131.19 49.85 Favored 'General case' 0 N--CA 1.471 0.594 0 N-CA-C 112.782 0.66 . . . . 0.0 112.782 178.433 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 48.5 mt-10 -89.44 151.04 22.23 Favored 'General case' 0 N--CA 1.48 1.07 0 C-N-CA 122.258 0.223 . . . . 0.0 110.826 175.581 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.0 p -149.58 130.01 4.32 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.599 0 N-CA-C 107.515 -1.291 . . . . 0.0 107.515 173.542 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 44.5 m-70 -130.07 148.63 51.94 Favored 'General case' 0 N--CA 1.483 1.212 0 CA-C-N 118.22 0.464 . . . . 0.0 111.78 176.379 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 6.2 t60 -164.96 104.38 0.78 Allowed 'General case' 0 N--CA 1.482 1.163 0 N-CA-C 109.141 -0.689 . . . . 0.0 109.141 172.859 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' D' D ' 15' ' ' GLN . . . . . 0.518 HE22 HG23 ' D' ' 36' ' ' VAL . 11.9 pt20 -115.47 -176.18 2.87 Favored 'General case' 0 CA--C 1.496 -1.12 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 179.061 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -160.36 106.1 1.51 Allowed 'General case' 0 N--CA 1.469 0.506 0 N-CA-C 106.717 -1.586 . . . . 0.0 106.717 175.783 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 5.8 mp -128.17 153.68 46.62 Favored 'General case' 0 N--CA 1.497 1.909 0 CA-C-O 122.23 1.014 . . . . 0.0 110.586 179.989 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 36.1 t -101.29 131.58 48.76 Favored 'Isoleucine or valine' 0 C--O 1.26 1.631 0 CA-C-O 116.674 -1.632 . . . . 0.0 109.7 174.225 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 27.5 m-85 -130.44 126.12 36.16 Favored 'General case' 0 N--CA 1.49 1.547 0 CA-C-N 120.203 1.365 . . . . 0.0 109.552 173.359 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 69.7 m-85 55.53 71.52 0.54 Allowed 'General case' 0 C--O 1.239 0.517 0 CA-C-N 115.781 -0.645 . . . . 0.0 111.23 176.044 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -82.33 -73.28 0.4 Allowed 'General case' 0 N--CA 1.471 0.608 0 CA-C-O 118.555 -0.736 . . . . 0.0 111.171 -177.592 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 40.7 tt0 -115.37 105.67 13.11 Favored 'General case' 0 N--CA 1.481 1.12 0 N-CA-C 106.586 -1.635 . . . . 0.0 106.586 176.629 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 p-10 -152.02 135.13 15.78 Favored 'General case' 0 N--CA 1.474 0.756 0 CA-C-O 116.643 -1.646 . . . . 0.0 113.397 177.471 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' D' D ' 24' ' ' VAL . . . . . 0.422 ' HB ' ' H ' ' A' ' 25' ' ' GLY . 68.7 t -61.12 166.54 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.264 0 CA-C-N 121.351 1.887 . . . . 0.0 107.972 175.481 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' D' D ' 25' ' ' GLY . . . . . 0.496 ' H ' ' HB ' ' G' ' 24' ' ' VAL . . . -116.56 50.94 0.75 Allowed Glycine 0 N--CA 1.479 1.513 0 CA-C-O 119.203 -0.776 . . . . 0.0 111.489 178.814 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -57.57 -171.43 0.01 OUTLIER 'General case' 0 N--CA 1.468 0.465 0 C-N-CA 123.255 0.622 . . . . 0.0 111.888 175.556 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 25.5 t-20 -73.08 86.43 1.35 Allowed 'General case' 0 C--N 1.347 0.464 0 N-CA-C 108.635 -0.876 . . . . 0.0 108.635 176.47 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 97.7 mttt -80.8 143.42 32.86 Favored 'General case' 0 N--CA 1.479 1.009 0 N-CA-C 107.712 -1.218 . . . . 0.0 107.712 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.27 -143.69 0.02 OUTLIER Glycine 0 C--N 1.348 1.212 0 C-N-CA 120.224 -0.989 . . . . 0.0 111.618 -178.266 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -95.46 126.42 40.74 Favored 'General case' 0 C--O 1.239 0.515 0 C-N-CA 123.031 0.532 . . . . 0.0 110.276 178.663 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 80.4 mt -125.44 126.86 71.25 Favored 'Isoleucine or valine' 0 C--N 1.358 0.944 0 N-CA-C 104.022 -2.584 . . . . 0.0 104.022 176.281 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' D' D ' 32' ' ' ILE . . . . . 0.421 HG22 ' H ' ' G' ' 32' ' ' ILE . 41.9 pt -159.14 -170.92 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.1 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.261 -177.927 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.91 5.04 12.53 Favored Glycine 0 C--O 1.239 0.463 0 N-CA-C 110.237 -1.145 . . . . 0.0 110.237 -178.957 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 1.9 tt -79.54 133.46 36.47 Favored 'General case' 0 C--N 1.369 1.451 0 C-N-CA 117.863 -1.535 . . . . 0.0 107.458 -178.968 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' D' D ' 35' ' ' MET . . . . . 0.4 ' C ' HG13 ' D' ' 36' ' ' VAL . 28.1 ttt -158.71 156.3 29.65 Favored 'General case' 0 CA--C 1.511 -0.52 0 N-CA-C 108.203 -1.036 . . . . 0.0 108.203 171.852 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' D' D ' 36' ' ' VAL . . . . . 0.518 HG23 HE22 ' D' ' 15' ' ' GLN . 35.7 m -164.72 163.77 0.7 Allowed 'Isoleucine or valine' 0 C--O 1.219 -0.506 0 N-CA-C 108.058 -1.09 . . . . 0.0 108.058 173.934 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 59.91 63.65 4.88 Favored Glycine 0 C--N 1.307 -1.066 0 C-N-CA 120.37 -0.919 . . . . 0.0 111.528 177.764 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 144.62 176.04 18.29 Favored Glycine 0 N--CA 1.48 1.6 0 CA-C-N 117.971 0.886 . . . . 0.0 111.145 179.368 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' D' D ' 39' ' ' VAL . . . . . 0.605 ' H ' HG12 ' G' ' 39' ' ' VAL . 34.3 m -125.43 157.08 34.82 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.861 0 C-N-CA 123.409 0.684 . . . . 0.0 111.119 -178.753 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 25.2 t . . . . . 0 C--N 1.329 -0.32 0 CA-C-O 116.333 -1.794 . . . . 0.0 109.748 176.588 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 35.9 m-85 . . . . . 0 N--CA 1.475 0.82 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' E' E ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -143.53 140.04 30.07 Favored 'General case' 0 N--CA 1.48 1.045 0 CA-C-O 120.902 0.382 . . . . 0.0 110.15 179.583 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 43.3 t-80 -151.47 119.35 6.19 Favored 'General case' 0 N--CA 1.474 0.729 0 N-CA-C 109.167 -0.679 . . . . 0.0 109.167 179.085 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' E' E ' 7' ' ' ASP . . . . . 0.497 ' O ' ' OG ' ' H' ' 8' ' ' SER . 3.9 m-20 -69.65 148.15 49.69 Favored 'General case' 0 N--CA 1.466 0.349 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.838 179.998 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' E' E ' 8' ' ' SER . . . . . 0.501 ' OG ' ' O ' ' B' ' 7' ' ' ASP . 52.5 p -168.32 -172.6 1.77 Allowed 'General case' 0 N--CA 1.483 1.21 0 CA-C-O 121.015 0.436 . . . . 0.0 110.854 178.757 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.55 47.66 1.27 Allowed Glycine 0 N--CA 1.479 1.543 0 CA-C-N 116.033 -0.53 . . . . 0.0 111.965 179.917 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 49.1 p90 -64.26 132.53 50.54 Favored 'General case' 0 N--CA 1.473 0.706 0 N-CA-C 112.028 0.381 . . . . 0.0 112.028 -179.894 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 49.4 mt-10 -91.72 153.17 19.82 Favored 'General case' 0 N--CA 1.48 1.066 0 CA-C-O 121.158 0.504 . . . . 0.0 109.665 177.944 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -155.01 127.32 1.02 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.587 0 N-CA-C 107.882 -1.155 . . . . 0.0 107.882 177.968 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 45.1 m-70 -135.04 143.65 46.85 Favored 'General case' 0 N--CA 1.482 1.166 0 CA-C-O 120.787 0.327 . . . . 0.0 111.516 -177.958 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 6.0 t60 -164.26 97.6 0.81 Allowed 'General case' 0 N--CA 1.486 1.371 0 CA-C-N 116.356 -0.383 . . . . 0.0 110.634 179.593 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' E' E ' 15' ' ' GLN . . . . . 0.527 HE22 HG23 ' E' ' 36' ' ' VAL . 12.0 pt20 -111.57 -174.63 2.51 Favored 'General case' 0 CA--C 1.505 -0.761 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 -179.805 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -163.27 98.61 0.93 Allowed 'General case' 0 N--CA 1.476 0.861 0 CA-C-N 114.75 -1.113 . . . . 0.0 108.49 178.633 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 6.5 mp -120.89 156.61 31.63 Favored 'General case' 0 N--CA 1.495 1.777 0 CA-C-O 121.786 0.803 . . . . 0.0 111.52 -177.682 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 48.4 t -114.06 124.62 70.88 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.216 0 N-CA-C 108.276 -1.009 . . . . 0.0 108.276 177.331 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 31.1 m-85 -125.51 121.41 33.65 Favored 'General case' 0 N--CA 1.489 1.51 0 CA-C-O 120.888 0.375 . . . . 0.0 110.846 -179.769 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 70.2 m-85 54.46 73.41 0.4 Allowed 'General case' 0 N--CA 1.469 0.508 0 CA-C-N 115.998 -0.547 . . . . 0.0 111.391 178.201 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -78.78 -78.95 0.14 Allowed 'General case' 0 C--N 1.344 0.348 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.268 -179.475 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 40.4 tt0 -111.2 102.72 11.12 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 -179.978 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -158.16 134.93 9.75 Favored 'General case' 0 C--O 1.208 -1.116 0 CA-C-O 119.484 -0.293 . . . . 0.0 111.378 178.829 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' E' E ' 24' ' ' VAL . . . . . 0.437 ' HB ' ' H ' ' B' ' 25' ' ' GLY . 58.5 t -56.97 167.72 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.941 0 N-CA-C 107.614 -1.254 . . . . 0.0 107.614 176.806 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' E' E ' 25' ' ' GLY . . . . . 0.413 ' N ' HG12 ' E' ' 24' ' ' VAL . . . -120.73 49.07 0.9 Allowed Glycine 0 N--CA 1.477 1.431 0 N-CA-C 110.765 -0.934 . . . . 0.0 110.765 -179.354 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -63.53 -168.32 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.542 0 CA-C-O 120.691 0.281 . . . . 0.0 110.25 179.622 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 25.2 t-20 -71.7 76.42 0.84 Allowed 'General case' 0 N--CA 1.467 0.403 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.416 179.689 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -70.26 140.75 52.44 Favored 'General case' 0 N--CA 1.477 0.894 0 N-CA-C 109.497 -0.556 . . . . 0.0 109.497 179.557 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.6 -148.68 0.05 OUTLIER Glycine 0 CA--C 1.521 0.467 0 N-CA-C 110.895 -0.882 . . . . 0.0 110.895 179.519 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -92.81 127.18 38.22 Favored 'General case' 0 C--O 1.235 0.292 0 N-CA-C 110.268 -0.271 . . . . 0.0 110.268 179.577 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 74.2 mt -124.34 116.92 49.11 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.608 0 N-CA-C 106.491 -1.67 . . . . 0.0 106.491 178.439 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' E' E ' 32' ' ' ILE . . . . . 0.421 HG22 ' H ' ' H' ' 32' ' ' ILE . 43.7 pt -151.43 -168.46 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.182 0 CA-C-O 121.144 0.497 . . . . 0.0 110.622 -178.526 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.4 5.2 7.82 Favored Glycine 0 CA--C 1.528 0.873 0 N-CA-C 111.262 -0.735 . . . . 0.0 111.262 -179.954 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 1.5 tt -77.6 127.09 31.91 Favored 'General case' 0 CA--C 1.545 0.783 0 N-CA-C 109.491 -0.559 . . . . 0.0 109.491 -179.64 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 28.4 ttt -163.86 144.38 8.54 Favored 'General case' 0 N--CA 1.471 0.6 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 178.312 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' E' E ' 36' ' ' VAL . . . . . 0.527 HG23 HE22 ' E' ' 15' ' ' GLN . 32.8 m -156.73 162.62 1.56 Allowed 'Isoleucine or valine' 0 C--O 1.215 -0.712 0 N-CA-C 108.816 -0.809 . . . . 0.0 108.816 179.742 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.98 66.41 2.87 Favored Glycine 0 C--N 1.305 -1.194 0 N-CA-C 111.974 -0.45 . . . . 0.0 111.974 178.55 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 146.07 174.16 17.97 Favored Glycine 0 N--CA 1.477 1.374 0 N-CA-C 111.113 -0.795 . . . . 0.0 111.113 179.038 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' E' E ' 39' ' ' VAL . . . . . 0.611 HG12 ' H ' ' B' ' 39' ' ' VAL . 33.8 m -124.33 159.67 29.8 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.671 0 C-N-CA 123.478 0.711 . . . . 0.0 110.774 -179.566 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 25.8 t . . . . . 0 C--O 1.219 -0.518 0 CA-C-O 118.361 -0.828 . . . . 0.0 110.66 179.321 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 35.3 m-85 . . . . . 0 N--CA 1.475 0.8 0 N-CA-C 109.978 -0.378 . . . . 0.0 109.978 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' F' F ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -143.44 139.88 30.13 Favored 'General case' 0 N--CA 1.479 0.989 0 CA-C-O 120.872 0.368 . . . . 0.0 110.231 179.54 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 42.6 t-80 -151.35 119.02 6.09 Favored 'General case' 0 N--CA 1.474 0.761 0 N-CA-C 109.197 -0.668 . . . . 0.0 109.197 179.076 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' F' F ' 7' ' ' ASP . . . . . 0.463 ' O ' ' OG ' ' I' ' 8' ' ' SER . 4.0 m-20 -69.2 148.28 50.09 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.74 179.912 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' F' F ' 8' ' ' SER . . . . . 0.471 ' OG ' ' O ' ' C' ' 7' ' ' ASP . 52.1 p -168.65 -173.03 1.78 Allowed 'General case' 0 N--CA 1.486 1.329 0 CA-C-O 121.04 0.448 . . . . 0.0 110.858 178.749 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.79 47.55 1.26 Allowed Glycine 0 N--CA 1.479 1.529 0 CA-C-N 115.969 -0.559 . . . . 0.0 111.884 179.785 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 48.2 p90 -64.01 133.06 52.41 Favored 'General case' 0 CA--C 1.543 0.683 0 O-C-N 122.528 -0.395 . . . . 0.0 111.978 -179.821 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 49.2 mt-10 -92.02 152.94 19.74 Favored 'General case' 0 N--CA 1.48 1.056 0 CA-C-O 121.196 0.522 . . . . 0.0 109.727 177.841 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -154.78 127.0 1.01 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.572 0 N-CA-C 107.837 -1.172 . . . . 0.0 107.837 178.085 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 44.7 m-70 -134.71 143.65 47.31 Favored 'General case' 0 N--CA 1.484 1.228 0 CA-C-O 120.867 0.365 . . . . 0.0 111.563 -178.04 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 6.0 t60 -164.12 97.51 0.82 Allowed 'General case' 0 N--CA 1.487 1.391 0 CA-C-N 116.431 -0.349 . . . . 0.0 110.775 179.614 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' F' F ' 15' ' ' GLN . . . . . 0.531 HE22 HG23 ' F' ' 36' ' ' VAL . 12.0 pt20 -111.71 -174.72 2.53 Favored 'General case' 0 CA--C 1.503 -0.847 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 -179.838 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -163.09 98.64 0.94 Allowed 'General case' 0 N--CA 1.473 0.711 0 CA-C-N 114.74 -1.118 . . . . 0.0 108.466 178.689 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 6.7 mp -120.76 156.97 30.7 Favored 'General case' 0 N--CA 1.495 1.795 0 CA-C-O 121.806 0.812 . . . . 0.0 111.498 -177.827 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 48.8 t -114.35 124.45 71.01 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.231 0 N-CA-C 108.186 -1.042 . . . . 0.0 108.186 177.321 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 32.2 m-85 -125.24 121.16 33.28 Favored 'General case' 0 N--CA 1.488 1.452 0 CA-C-O 120.893 0.377 . . . . 0.0 110.857 -179.911 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 70.4 m-85 54.67 73.78 0.38 Allowed 'General case' 0 N--CA 1.467 0.386 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.588 178.277 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -79.12 -78.53 0.15 Allowed 'General case' 0 C--N 1.344 0.354 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.406 -179.431 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 40.9 tt0 -111.71 102.58 10.87 Favored 'General case' 0 N--CA 1.47 0.527 0 N-CA-C 108.402 -0.962 . . . . 0.0 108.402 -179.929 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -158.02 134.77 9.78 Favored 'General case' 0 N--CA 1.481 1.081 0 CA-C-O 119.416 -0.326 . . . . 0.0 111.394 178.822 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' F' F ' 24' ' ' VAL . . . . . 0.443 ' HB ' ' H ' ' C' ' 25' ' ' GLY . 58.1 t -56.82 167.97 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.966 0 N-CA-C 107.641 -1.244 . . . . 0.0 107.641 176.938 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' F' F ' 25' ' ' GLY . . . . . 0.415 ' H ' ' HB ' ' I' ' 24' ' ' VAL . . . -120.97 49.2 0.89 Allowed Glycine 0 N--CA 1.478 1.48 0 N-CA-C 110.745 -0.942 . . . . 0.0 110.745 -179.344 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -63.72 -167.92 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.551 0 CA-C-O 120.731 0.301 . . . . 0.0 110.294 179.66 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 25.2 t-20 -71.92 76.51 0.9 Allowed 'General case' 0 N--CA 1.466 0.372 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.325 179.662 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -70.48 140.44 51.9 Favored 'General case' 0 N--CA 1.477 0.892 0 N-CA-C 109.525 -0.546 . . . . 0.0 109.525 179.562 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.17 -149.09 0.04 OUTLIER Glycine 0 CA--C 1.522 0.504 0 N-CA-C 110.898 -0.881 . . . . 0.0 110.898 179.441 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -92.34 127.14 37.71 Favored 'General case' 0 C--O 1.236 0.352 0 CA-C-O 120.676 0.274 . . . . 0.0 110.276 179.444 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 73.2 mt -124.26 116.93 49.2 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.572 0 N-CA-C 106.479 -1.674 . . . . 0.0 106.479 178.401 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' F' F ' 32' ' ' ILE . . . . . 0.417 HG22 ' H ' ' I' ' 32' ' ' ILE . 44.1 pt -151.6 -168.36 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.149 0 CA-C-O 121.071 0.462 . . . . 0.0 110.722 -178.543 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.13 5.54 8.1 Favored Glycine 0 CA--C 1.527 0.818 0 N-CA-C 111.274 -0.73 . . . . 0.0 111.274 -179.889 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 1.5 tt -77.76 126.88 31.54 Favored 'General case' 0 N--CA 1.476 0.839 0 N-CA-C 109.386 -0.598 . . . . 0.0 109.386 -179.689 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 28.4 ttt -163.62 144.36 8.9 Favored 'General case' 0 N--CA 1.471 0.591 0 N-CA-C 108.876 -0.787 . . . . 0.0 108.876 178.283 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' F' F ' 36' ' ' VAL . . . . . 0.531 HG23 HE22 ' F' ' 15' ' ' GLN . 32.8 m -156.63 162.81 1.53 Allowed 'Isoleucine or valine' 0 C--O 1.216 -0.709 0 N-CA-C 108.829 -0.804 . . . . 0.0 108.829 179.638 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.82 66.48 2.81 Favored Glycine 0 C--N 1.305 -1.169 0 N-CA-C 111.992 -0.443 . . . . 0.0 111.992 178.5 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 145.82 174.12 17.71 Favored Glycine 0 N--CA 1.477 1.419 0 N-CA-C 111.031 -0.828 . . . . 0.0 111.031 178.961 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' F' F ' 39' ' ' VAL . . . . . 0.608 HG12 ' H ' ' C' ' 39' ' ' VAL . 33.7 m -124.38 159.75 29.82 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.692 0 C-N-CA 123.366 0.666 . . . . 0.0 110.755 -179.488 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 26.3 t . . . . . 0 C--O 1.22 -0.476 0 CA-C-O 118.249 -0.881 . . . . 0.0 110.609 179.215 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 39.2 m-85 . . . . . 0 N--CA 1.474 0.736 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' G' G ' 5' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -143.79 140.3 29.81 Favored 'General case' 0 N--CA 1.482 1.168 0 CA-C-O 120.846 0.355 . . . . 0.0 110.311 179.825 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 43.3 t-80 -151.54 120.25 6.55 Favored 'General case' 0 N--CA 1.475 0.782 0 N-CA-C 109.342 -0.614 . . . . 0.0 109.342 179.125 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -71.22 144.19 50.19 Favored 'General case' 0 N--CA 1.47 0.547 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.17 -179.937 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' G' G ' 8' ' ' SER . . . . . 0.598 ' OG ' ' O ' ' D' ' 7' ' ' ASP . 47.8 p -165.4 -170.96 2.0 Allowed 'General case' 0 N--CA 1.474 0.767 0 CA-C-O 120.962 0.41 . . . . 0.0 110.589 178.585 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.01 47.92 1.29 Allowed Glycine 0 N--CA 1.48 1.611 0 N-CA-C 111.514 -0.635 . . . . 0.0 111.514 179.441 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 50.4 p90 -64.5 133.02 51.56 Favored 'General case' 0 N--CA 1.473 0.699 0 CA-C-O 120.753 0.311 . . . . 0.0 111.818 -179.544 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 48.6 mt-10 -92.62 151.63 20.01 Favored 'General case' 0 N--CA 1.479 0.982 0 CA-C-O 121.104 0.478 . . . . 0.0 110.105 178.484 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -154.74 127.6 1.11 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.016 0 N-CA-C 107.92 -1.141 . . . . 0.0 107.92 178.361 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 47.0 m-70 -134.49 145.04 48.43 Favored 'General case' 0 N--CA 1.478 0.956 0 CA-C-N 115.542 -0.754 . . . . 0.0 111.399 -178.348 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 6.2 t60 -165.87 97.61 0.64 Allowed 'General case' 0 N--CA 1.483 1.206 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.301 178.963 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' G' G ' 15' ' ' GLN . . . . . 0.508 HE22 HG23 ' G' ' 36' ' ' VAL . 12.1 pt20 -111.74 -174.3 2.43 Favored 'General case' 0 CA--C 1.503 -0.848 0 N-CA-C 108.37 -0.974 . . . . 0.0 108.37 -179.657 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -163.8 98.21 0.86 Allowed 'General case' 0 N--CA 1.474 0.774 0 CA-C-N 114.672 -1.149 . . . . 0.0 108.194 178.856 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 6.6 mp -120.51 155.15 34.2 Favored 'General case' 0 N--CA 1.497 1.896 0 CA-C-O 121.291 0.567 . . . . 0.0 111.74 -177.794 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 43.9 t -113.33 124.91 70.44 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.006 0 CA-C-N 114.804 -1.089 . . . . 0.0 108.234 176.713 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 33.5 m-85 -125.9 121.17 32.39 Favored 'General case' 0 C--N 1.366 1.299 0 C-N-CA 123.437 0.695 . . . . 0.0 110.934 -179.585 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 69.3 m-85 54.75 72.82 0.44 Allowed 'General case' 0 N--CA 1.468 0.462 0 CA-C-N 115.874 -0.603 . . . . 0.0 111.375 178.059 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.7 -78.37 0.14 Allowed 'General case' 0 N--CA 1.472 0.632 0 O-C-N 122.223 -0.298 . . . . 0.0 110.508 -178.981 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 40.7 tt0 -111.78 102.47 10.75 Favored 'General case' 0 C--N 1.321 -0.633 0 N-CA-C 108.212 -1.033 . . . . 0.0 108.212 179.942 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -157.7 136.05 11.1 Favored 'General case' 0 N--CA 1.479 0.98 0 O-C-N 122.43 -0.168 . . . . 0.0 111.415 178.748 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' G' G ' 24' ' ' VAL . . . . . 0.496 ' HB ' ' H ' ' D' ' 25' ' ' GLY . 59.9 t -58.35 167.11 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.639 0 N-CA-C 107.749 -1.204 . . . . 0.0 107.749 177.115 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' G' G ' 25' ' ' GLY . . . . . 0.42 ' N ' HG12 ' G' ' 24' ' ' VAL . . . -119.53 49.4 0.88 Allowed Glycine 0 N--CA 1.48 1.615 0 N-CA-C 110.479 -1.048 . . . . 0.0 110.479 -179.496 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -64.6 -168.66 0.03 OUTLIER 'General case' 0 N--CA 1.471 0.624 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 179.67 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 25.4 t-20 -71.46 76.47 0.77 Allowed 'General case' 0 N--CA 1.468 0.435 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.385 179.796 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -69.82 140.55 53.3 Favored 'General case' 0 N--CA 1.474 0.765 0 N-CA-C 109.626 -0.509 . . . . 0.0 109.626 179.528 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.79 -147.01 0.04 OUTLIER Glycine 0 C--N 1.338 0.663 0 N-CA-C 110.517 -1.033 . . . . 0.0 110.517 179.637 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -93.36 126.12 38.32 Favored 'General case' 0 N--CA 1.468 0.43 0 C-N-CA 122.616 0.366 . . . . 0.0 110.663 -179.738 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 73.4 mt -123.76 117.3 50.7 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.771 0 N-CA-C 106.527 -1.657 . . . . 0.0 106.527 178.105 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' G' G ' 32' ' ' ILE . . . . . 0.421 ' H ' HG22 ' D' ' 32' ' ' ILE . 44.8 pt -152.27 -167.68 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 CA-C-N 119.839 1.2 . . . . 0.0 109.858 -179.046 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.37 6.2 10.23 Favored Glycine 0 CA--C 1.525 0.705 0 N-CA-C 110.998 -0.841 . . . . 0.0 110.998 179.824 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 1.5 tt -79.23 125.94 30.12 Favored 'General case' 0 CA--C 1.544 0.746 0 N-CA-C 109.492 -0.559 . . . . 0.0 109.492 -179.575 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 27.5 ttt -162.76 146.01 11.07 Favored 'General case' 0 N--CA 1.47 0.565 0 N-CA-C 108.757 -0.831 . . . . 0.0 108.757 178.418 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' G' G ' 36' ' ' VAL . . . . . 0.508 HG23 HE22 ' G' ' 15' ' ' GLN . 33.2 m -157.37 162.11 1.62 Allowed 'Isoleucine or valine' 0 C--N 1.347 0.461 0 N-CA-C 108.901 -0.777 . . . . 0.0 108.901 -179.959 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.37 66.8 2.58 Favored Glycine 0 C--N 1.312 -0.754 0 CA-C-N 115.712 -0.676 . . . . 0.0 112.271 178.213 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 146.53 175.17 19.29 Favored Glycine 0 N--CA 1.477 1.427 0 N-CA-C 110.516 -1.034 . . . . 0.0 110.516 178.988 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' G' G ' 39' ' ' VAL . . . . . 0.605 HG12 ' H ' ' D' ' 39' ' ' VAL . 34.6 m -125.34 159.94 31.94 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.867 0 C-N-CA 123.09 0.556 . . . . 0.0 110.73 -179.48 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 28.8 t . . . . . 0 N--CA 1.469 0.511 0 CA-C-O 118.388 -0.815 . . . . 0.0 110.796 179.025 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 39.8 m-85 . . . . . 0 N--CA 1.473 0.697 0 N-CA-C 109.549 -0.537 . . . . 0.0 109.549 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' H' H ' 5' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -143.66 140.53 30.12 Favored 'General case' 0 N--CA 1.483 1.185 0 C-N-CA 122.583 0.353 . . . . 0.0 110.13 179.884 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 42.9 t-80 -151.77 120.4 6.5 Favored 'General case' 0 N--CA 1.473 0.701 0 N-CA-C 109.383 -0.599 . . . . 0.0 109.383 179.096 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -71.58 143.9 49.7 Favored 'General case' 0 N--CA 1.471 0.585 0 CA-C-N 116.323 -0.399 . . . . 0.0 111.178 -179.768 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' H' H ' 8' ' ' SER . . . . . 0.497 ' OG ' ' O ' ' E' ' 7' ' ' ASP . 53.7 p -165.07 -171.19 2.14 Favored 'General case' 0 N--CA 1.475 0.815 0 CA-C-O 120.94 0.4 . . . . 0.0 110.509 178.628 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.13 47.61 1.32 Allowed Glycine 0 N--CA 1.48 1.594 0 N-CA-C 111.683 -0.567 . . . . 0.0 111.683 179.642 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 50.4 p90 -64.51 133.13 51.77 Favored 'General case' 0 N--CA 1.472 0.659 0 N-CA-C 111.947 0.351 . . . . 0.0 111.947 -179.637 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 48.4 mt-10 -92.45 151.77 20.04 Favored 'General case' 0 N--CA 1.478 0.929 0 CA-C-O 121.013 0.435 . . . . 0.0 110.215 178.499 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -154.71 127.92 1.16 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.041 0 N-CA-C 107.854 -1.165 . . . . 0.0 107.854 178.251 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 46.4 m-70 -134.72 145.07 48.13 Favored 'General case' 0 N--CA 1.478 0.971 0 CA-C-N 115.5 -0.773 . . . . 0.0 111.394 -178.374 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 6.2 t60 -165.93 97.29 0.63 Allowed 'General case' 0 N--CA 1.483 1.176 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.4 179.012 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' H' H ' 15' ' ' GLN . . . . . 0.516 HE22 HG23 ' H' ' 36' ' ' VAL . 12.1 pt20 -111.39 -174.52 2.48 Favored 'General case' 0 CA--C 1.504 -0.826 0 N-CA-C 108.34 -0.985 . . . . 0.0 108.34 -179.652 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -163.72 98.29 0.87 Allowed 'General case' 0 N--CA 1.475 0.784 0 CA-C-N 114.671 -1.15 . . . . 0.0 108.093 178.757 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 6.7 mp -120.41 155.56 33.21 Favored 'General case' 0 N--CA 1.496 1.873 0 CA-C-O 121.233 0.539 . . . . 0.0 111.849 -177.82 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 42.6 t -113.64 125.23 70.88 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.01 0 CA-C-N 114.869 -1.06 . . . . 0.0 108.231 176.556 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 33.2 m-85 -126.24 121.07 31.66 Favored 'General case' 0 C--N 1.369 1.445 0 CA-C-N 115.518 -0.765 . . . . 0.0 110.775 -179.444 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 69.6 m-85 54.41 73.13 0.41 Allowed 'General case' 0 C--O 1.238 0.453 0 CA-C-N 115.814 -0.63 . . . . 0.0 111.399 178.107 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.75 -78.06 0.14 Allowed 'General case' 0 N--CA 1.472 0.657 0 O-C-N 122.201 -0.312 . . . . 0.0 110.661 -179.147 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 40.4 tt0 -112.09 102.57 10.77 Favored 'General case' 0 C--N 1.321 -0.641 0 N-CA-C 108.236 -1.024 . . . . 0.0 108.236 179.883 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -157.75 136.24 11.2 Favored 'General case' 0 N--CA 1.478 0.974 0 O-C-N 122.417 -0.177 . . . . 0.0 111.368 178.817 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' H' H ' 24' ' ' VAL . . . . . 0.418 HG12 ' N ' ' H' ' 25' ' ' GLY . 59.1 t -58.49 166.91 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.548 0 N-CA-C 107.71 -1.218 . . . . 0.0 107.71 177.18 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' H' H ' 25' ' ' GLY . . . . . 0.418 ' N ' HG12 ' H' ' 24' ' ' VAL . . . -119.25 49.2 0.89 Allowed Glycine 0 N--CA 1.479 1.551 0 N-CA-C 110.651 -0.98 . . . . 0.0 110.651 -179.573 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -64.68 -168.33 0.03 OUTLIER 'General case' 0 N--CA 1.472 0.661 0 N-CA-C 109.944 -0.391 . . . . 0.0 109.944 179.722 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 25.6 t-20 -71.55 76.55 0.8 Allowed 'General case' 0 CA--C 1.537 0.472 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.316 179.809 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -70.15 140.56 52.61 Favored 'General case' 0 N--CA 1.474 0.775 0 N-CA-C 109.588 -0.523 . . . . 0.0 109.588 179.593 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.63 -147.69 0.04 OUTLIER Glycine 0 C--N 1.336 0.579 0 N-CA-C 110.376 -1.09 . . . . 0.0 110.376 179.549 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -93.05 126.31 38.07 Favored 'General case' 0 N--CA 1.465 0.298 0 C-N-CA 122.584 0.354 . . . . 0.0 110.781 -179.8 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 74.5 mt -123.87 117.23 50.41 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.776 0 N-CA-C 106.575 -1.639 . . . . 0.0 106.575 178.224 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' H' H ' 32' ' ' ILE . . . . . 0.421 ' H ' HG22 ' E' ' 32' ' ' ILE . 44.8 pt -152.11 -167.77 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 CA-C-N 119.761 1.164 . . . . 0.0 109.871 -179.026 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.71 5.76 9.9 Favored Glycine 0 CA--C 1.524 0.641 0 N-CA-C 110.935 -0.866 . . . . 0.0 110.935 179.845 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 1.4 tt -78.7 125.75 29.79 Favored 'General case' 0 CA--C 1.544 0.728 0 N-CA-C 109.555 -0.535 . . . . 0.0 109.555 -179.565 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 27.4 ttt -162.56 145.94 11.37 Favored 'General case' 0 N--CA 1.47 0.572 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 178.323 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' H' H ' 36' ' ' VAL . . . . . 0.516 HG23 HE22 ' H' ' 15' ' ' GLN . 33.2 m -157.35 162.18 1.6 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 N-CA-C 108.874 -0.788 . . . . 0.0 108.874 -179.935 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.25 67.06 2.4 Favored Glycine 0 C--N 1.311 -0.819 0 CA-C-N 115.781 -0.645 . . . . 0.0 112.149 178.286 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 146.42 175.76 19.69 Favored Glycine 0 N--CA 1.479 1.547 0 N-CA-C 110.577 -1.009 . . . . 0.0 110.577 178.892 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' H' H ' 39' ' ' VAL . . . . . 0.611 HG12 ' H ' ' E' ' 39' ' ' VAL . 34.6 m -125.97 159.85 33.75 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.82 0 C-N-CA 123.161 0.585 . . . . 0.0 110.708 -179.499 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 26.7 t . . . . . 0 C--O 1.219 -0.547 0 CA-C-O 118.346 -0.835 . . . . 0.0 110.79 179.263 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 39.7 m-85 . . . . . 0 N--CA 1.475 0.78 0 N-CA-C 109.473 -0.566 . . . . 0.0 109.473 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' I' I ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -143.72 140.28 29.91 Favored 'General case' 0 N--CA 1.482 1.167 0 C-N-CA 122.602 0.361 . . . . 0.0 110.15 179.894 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 43.1 t-80 -151.72 120.28 6.47 Favored 'General case' 0 N--CA 1.474 0.732 0 N-CA-C 109.358 -0.608 . . . . 0.0 109.358 179.04 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -71.23 143.87 50.27 Favored 'General case' 0 N--CA 1.469 0.503 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.234 -179.881 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' I' I ' 8' ' ' SER . . . . . 0.463 ' OG ' ' O ' ' F' ' 7' ' ' ASP . 53.3 p -164.87 -171.4 2.25 Favored 'General case' 0 N--CA 1.474 0.752 0 CA-C-O 120.857 0.36 . . . . 0.0 110.582 178.668 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.08 48.04 1.28 Allowed Glycine 0 N--CA 1.48 1.619 0 N-CA-C 111.693 -0.563 . . . . 0.0 111.693 179.63 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 50.4 p90 -65.1 132.52 49.39 Favored 'General case' 0 N--CA 1.472 0.632 0 N-CA-C 111.934 0.346 . . . . 0.0 111.934 -179.737 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 48.3 mt-10 -91.81 152.24 20.22 Favored 'General case' 0 N--CA 1.478 0.937 0 CA-C-O 121.033 0.445 . . . . 0.0 110.18 178.511 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -155.28 127.58 1.03 Allowed 'Isoleucine or valine' 0 CA--C 1.551 0.999 0 N-CA-C 107.848 -1.167 . . . . 0.0 107.848 178.349 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 46.1 m-70 -134.48 145.08 48.48 Favored 'General case' 0 N--CA 1.477 0.887 0 CA-C-N 115.572 -0.74 . . . . 0.0 111.436 -178.387 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 6.1 t60 -165.61 97.47 0.67 Allowed 'General case' 0 N--CA 1.481 1.105 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.362 178.961 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' I' I ' 15' ' ' GLN . . . . . 0.486 HE22 HG23 ' I' ' 36' ' ' VAL . 12.3 pt20 -111.79 -174.83 2.55 Favored 'General case' 0 CA--C 1.502 -0.894 0 N-CA-C 108.399 -0.963 . . . . 0.0 108.399 -179.689 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -163.39 98.41 0.91 Allowed 'General case' 0 N--CA 1.474 0.762 0 CA-C-N 114.647 -1.16 . . . . 0.0 108.172 178.87 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 6.7 mp -120.53 155.4 33.71 Favored 'General case' 0 N--CA 1.496 1.854 0 CA-C-O 121.266 0.555 . . . . 0.0 111.773 -177.829 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 41.6 t -113.56 125.35 70.82 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.998 0 CA-C-N 114.824 -1.08 . . . . 0.0 108.194 176.568 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 33.6 m-85 -126.32 121.32 32.24 Favored 'General case' 0 C--N 1.368 1.393 0 CA-C-N 115.61 -0.723 . . . . 0.0 110.876 -179.491 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 69.4 m-85 54.16 72.94 0.42 Allowed 'General case' 0 C--O 1.237 0.441 0 CA-C-N 115.918 -0.583 . . . . 0.0 111.375 178.165 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.63 -78.08 0.14 Allowed 'General case' 0 N--CA 1.472 0.657 0 O-C-N 122.302 -0.249 . . . . 0.0 110.598 -179.116 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 40.7 tt0 -112.01 102.73 10.93 Favored 'General case' 0 C--N 1.323 -0.573 0 N-CA-C 108.156 -1.053 . . . . 0.0 108.156 179.948 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -157.95 136.19 10.94 Favored 'General case' 0 N--CA 1.478 0.956 0 O-C-N 122.375 -0.203 . . . . 0.0 111.329 178.858 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' I' I ' 24' ' ' VAL . . . . . 0.425 HG12 ' N ' ' I' ' 25' ' ' GLY . 58.5 t -58.5 166.92 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.559 0 N-CA-C 107.779 -1.193 . . . . 0.0 107.779 177.134 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' I' I ' 25' ' ' GLY . . . . . 0.425 ' N ' HG12 ' I' ' 24' ' ' VAL . . . -119.42 49.22 0.88 Allowed Glycine 0 N--CA 1.481 1.661 0 N-CA-C 110.592 -1.003 . . . . 0.0 110.592 -179.404 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -64.54 -168.2 0.03 OUTLIER 'General case' 0 N--CA 1.471 0.602 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 179.702 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 25.5 t-20 -71.71 76.89 0.84 Allowed 'General case' 0 CA--C 1.536 0.439 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.259 179.675 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -70.45 140.6 52.0 Favored 'General case' 0 N--CA 1.475 0.807 0 N-CA-C 109.63 -0.507 . . . . 0.0 109.63 179.472 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.72 -147.32 0.04 OUTLIER Glycine 0 C--N 1.337 0.621 0 N-CA-C 110.496 -1.041 . . . . 0.0 110.496 179.588 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -93.26 125.86 38.07 Favored 'General case' 0 N--CA 1.465 0.314 0 C-N-CA 122.696 0.399 . . . . 0.0 110.752 -179.737 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 73.7 mt -123.47 117.33 51.03 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.768 0 N-CA-C 106.556 -1.646 . . . . 0.0 106.556 178.111 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' I' I ' 32' ' ' ILE . . . . . 0.417 ' H ' HG22 ' F' ' 32' ' ' ILE . 44.9 pt -152.17 -167.82 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 CA-C-N 119.758 1.163 . . . . 0.0 109.869 -179.05 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.71 5.86 10.18 Favored Glycine 0 CA--C 1.526 0.738 0 N-CA-C 110.95 -0.86 . . . . 0.0 110.95 179.768 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 1.4 tt -78.89 125.56 29.53 Favored 'General case' 0 CA--C 1.546 0.79 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 -179.593 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 27.4 ttt -162.25 145.79 11.83 Favored 'General case' 0 N--CA 1.47 0.542 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 178.559 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' I' I ' 36' ' ' VAL . . . . . 0.486 HG23 HE22 ' I' ' 15' ' ' GLN . 33.3 m -157.28 162.03 1.65 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.47 0 N-CA-C 108.845 -0.798 . . . . 0.0 108.845 -179.89 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.29 66.87 2.53 Favored Glycine 0 C--N 1.311 -0.85 0 CA-C-N 115.799 -0.637 . . . . 0.0 112.228 178.173 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 146.58 175.82 19.87 Favored Glycine 0 N--CA 1.478 1.497 0 N-CA-C 110.603 -0.999 . . . . 0.0 110.603 178.939 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' I' I ' 39' ' ' VAL . . . . . 0.603 HG12 ' H ' ' F' ' 39' ' ' VAL . 34.5 m -125.92 159.9 33.55 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.866 0 C-N-CA 123.131 0.572 . . . . 0.0 110.755 -179.488 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 29.8 t . . . . . 0 C--O 1.219 -0.513 0 CA-C-O 118.394 -0.812 . . . . 0.0 110.777 179.103 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 78.8 m-85 . . . . . 0 N--CA 1.474 0.766 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 72.4 mtp180 -143.58 142.05 30.92 Favored 'General case' 0 N--CA 1.482 1.164 0 N-CA-C 109.134 -0.691 . . . . 0.0 109.134 -179.883 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 76.6 m80 -149.83 119.74 7.13 Favored 'General case' 0 N--CA 1.47 0.528 0 N-CA-C 108.759 -0.83 . . . . 0.0 108.759 179.102 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 8.5 m-20 -68.32 149.89 48.87 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.189 -179.385 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 7.9 t -167.65 171.16 10.42 Favored 'General case' 0 N--CA 1.473 0.706 0 N-CA-C 109.628 -0.508 . . . . 0.0 109.628 178.456 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.2 24.7 2.17 Favored Glycine 0 N--CA 1.488 2.127 0 N-CA-C 112.114 -0.394 . . . . 0.0 112.114 179.367 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 43.4 p90 -56.26 128.06 33.87 Favored 'General case' 0 N--CA 1.473 0.696 0 N-CA-C 112.175 0.435 . . . . 0.0 112.175 -179.866 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . 0.51 ' CG ' HD21 ' C' ' 27' ' ' ASN . 45.8 mt-10 -84.72 154.24 22.56 Favored 'General case' 0 N--CA 1.469 0.5 0 N-CA-C 109.082 -0.71 . . . . 0.0 109.082 178.445 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -153.25 129.29 1.75 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.341 0 N-CA-C 108.327 -0.99 . . . . 0.0 108.327 178.926 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 49.5 m-70 -134.03 144.72 48.86 Favored 'General case' 0 N--CA 1.489 1.507 0 CA-C-N 118.711 0.687 . . . . 0.0 110.993 -179.156 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 6.3 t60 -164.75 98.8 0.78 Allowed 'General case' 0 N--CA 1.479 0.978 0 CA-C-N 116.642 -0.254 . . . . 0.0 111.194 179.686 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . 0.56 HE22 ' H ' ' A' ' 37' ' ' GLY . 54.2 mt-30 -108.79 -172.26 2.02 Favored 'General case' 0 CA--C 1.502 -0.873 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 179.804 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -166.97 97.67 0.53 Allowed 'General case' 0 N--CA 1.473 0.689 0 CA-C-N 115.201 -0.909 . . . . 0.0 109.486 178.644 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.596 HD12 ' N ' ' A' ' 17' ' ' LEU . 4.5 mp -105.66 163.88 12.34 Favored 'General case' 0 N--CA 1.487 1.409 0 N-CA-C 108.543 -0.91 . . . . 0.0 108.543 179.901 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 48.9 t -142.15 118.92 6.79 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.354 0 CA-C-O 118.796 -0.621 . . . . 0.0 110.02 179.452 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 51.6 m-85 -69.98 159.24 34.13 Favored 'General case' 0 N--CA 1.48 1.055 0 N-CA-C 107.592 -1.262 . . . . 0.0 107.592 177.203 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 13.6 t80 -171.15 -58.52 0.02 OUTLIER 'General case' 0 N--CA 1.485 1.3 0 CA-C-O 122.365 1.079 . . . . 0.0 109.712 179.662 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -38.81 90.0 0.0 OUTLIER 'General case' 0 C--O 1.232 0.17 0 CA-C-N 113.782 -1.554 . . . . 0.0 112.938 -177.952 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 38.1 tt0 -66.16 157.65 30.75 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 115.05 -0.977 . . . . 0.0 110.565 179.118 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 66.8 m-20 -139.55 136.78 34.83 Favored 'General case' 0 N--CA 1.481 1.1 0 C-N-CA 123.008 0.523 . . . . 0.0 110.281 179.862 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 18.4 t -84.65 -116.46 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.982 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 179.469 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -109.15 54.81 0.53 Allowed Glycine 0 N--CA 1.474 1.211 0 N-CA-C 111.126 -0.79 . . . . 0.0 111.126 179.909 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 71.1 p -80.07 126.01 30.52 Favored 'General case' 0 C--N 1.328 -0.333 0 N-CA-C 108.799 -0.815 . . . . 0.0 108.799 178.184 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . 0.524 HD21 ' CG ' ' B' ' 11' ' ' GLU . 47.3 t30 -65.93 100.26 0.56 Allowed 'General case' 0 N--CA 1.473 0.719 0 N-CA-C 108.8 -0.815 . . . . 0.0 108.8 178.702 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 66.7 mttm -95.46 117.2 29.95 Favored 'General case' 0 N--CA 1.484 1.229 0 N-CA-C 110.01 -0.367 . . . . 0.0 110.01 -179.067 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.13 -133.55 0.01 OUTLIER Glycine 0 CA--C 1.532 1.12 0 N-CA-C 110.726 -0.95 . . . . 0.0 110.726 178.943 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -113.4 127.81 56.25 Favored 'General case' 0 N--CA 1.478 0.939 0 N-CA-C 109.29 -0.633 . . . . 0.0 109.29 178.934 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 66.7 mt -90.73 130.19 40.34 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.683 0 N-CA-C 107.606 -1.257 . . . . 0.0 107.606 178.715 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 18.1 mt -142.33 152.38 18.13 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.929 0 N-CA-C 109.838 -0.431 . . . . 0.0 109.838 -178.83 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 65.37 48.27 70.83 Favored Glycine 0 CA--C 1.524 0.63 0 CA-C-N 116.062 -0.517 . . . . 0.0 112.531 178.804 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.401 HD23 ' N ' ' A' ' 35' ' ' MET . 2.9 tt -98.88 120.39 39.24 Favored 'General case' 0 N--CA 1.478 0.934 0 N-CA-C 107.245 -1.391 . . . . 0.0 107.245 177.903 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' MET . . . . . 0.401 ' N ' HD23 ' A' ' 34' ' ' LEU . 28.1 ttt -152.71 158.26 42.09 Favored 'General case' 0 N--CA 1.471 0.579 0 N-CA-C 108.909 -0.774 . . . . 0.0 108.909 179.463 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 86.1 t -158.29 149.86 8.23 Favored 'Isoleucine or valine' 0 C--O 1.236 0.351 0 N-CA-C 107.012 -1.477 . . . . 0.0 107.012 -179.204 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . 0.56 ' H ' HE22 ' A' ' 15' ' ' GLN . . . 56.66 74.92 0.28 Allowed Glycine 0 C--N 1.313 -0.741 0 CA-C-N 115.622 -0.717 . . . . 0.0 111.658 178.181 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 170.96 -148.92 11.7 Favored Glycine 0 CA--C 1.519 0.299 0 N-CA-C 110.656 -0.978 . . . . 0.0 110.656 179.786 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 33.5 m -133.93 142.64 40.72 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.794 0 N-CA-C 109.688 -0.486 . . . . 0.0 109.688 179.744 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 16.3 t . . . . . 0 CA--C 1.535 0.392 0 CA-C-O 117.969 -1.015 . . . . 0.0 111.058 179.331 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 78.8 m-85 . . . . . 0 N--CA 1.474 0.729 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 71.9 mtp180 -144.09 141.82 30.26 Favored 'General case' 0 N--CA 1.481 1.11 0 N-CA-C 109.123 -0.695 . . . . 0.0 109.123 -179.815 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 76.7 m80 -149.7 119.64 7.15 Favored 'General case' 0 N--CA 1.471 0.611 0 N-CA-C 108.826 -0.805 . . . . 0.0 108.826 179.117 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 7' ' ' ASP . . . . . . . . . . . . . 8.6 m-20 -68.14 149.56 49.44 Favored 'General case' 0 CA--C 1.531 0.215 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.238 -179.439 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 8' ' ' SER . . . . . . . . . . . . . 8.1 t -167.36 171.87 10.21 Favored 'General case' 0 N--CA 1.473 0.685 0 N-CA-C 109.668 -0.493 . . . . 0.0 109.668 178.368 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 121.53 24.69 2.32 Favored Glycine 0 N--CA 1.488 2.135 0 N-CA-C 112.102 -0.399 . . . . 0.0 112.102 179.323 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 42.9 p90 -56.15 127.7 31.94 Favored 'General case' 0 N--CA 1.472 0.653 0 N-CA-C 112.236 0.458 . . . . 0.0 112.236 -179.87 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 11' ' ' GLU . . . . . 0.524 ' CG ' HD21 ' A' ' 27' ' ' ASN . 45.6 mt-10 -84.38 154.07 23.07 Favored 'General case' 0 N--CA 1.469 0.515 0 N-CA-C 109.223 -0.658 . . . . 0.0 109.223 178.442 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -153.17 129.65 1.9 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.328 0 N-CA-C 108.301 -1.0 . . . . 0.0 108.301 178.956 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 49.1 m-70 -134.34 145.34 48.92 Favored 'General case' 0 N--CA 1.49 1.552 0 CA-C-N 118.531 0.605 . . . . 0.0 110.975 -179.204 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 6.4 t60 -165.23 98.59 0.72 Allowed 'General case' 0 N--CA 1.482 1.125 0 CA-C-N 116.563 -0.29 . . . . 0.0 111.195 179.658 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . 0.548 HE22 ' H ' ' B' ' 37' ' ' GLY . 54.3 mt-30 -108.57 -172.81 2.13 Favored 'General case' 0 CA--C 1.502 -0.894 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 179.815 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -166.64 97.59 0.56 Allowed 'General case' 0 N--CA 1.472 0.63 0 CA-C-N 115.121 -0.945 . . . . 0.0 109.369 178.821 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . 0.596 ' N ' HD12 ' B' ' 17' ' ' LEU . 4.5 mp -105.87 163.88 12.38 Favored 'General case' 0 N--CA 1.487 1.394 0 N-CA-C 108.542 -0.91 . . . . 0.0 108.542 179.881 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 50.5 t -142.27 118.88 6.51 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.3 0 CA-C-O 118.959 -0.543 . . . . 0.0 109.96 179.58 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 53.0 m-85 -70.67 159.22 34.84 Favored 'General case' 0 N--CA 1.478 0.939 0 N-CA-C 107.53 -1.285 . . . . 0.0 107.53 177.248 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 14.9 t80 -171.83 -57.27 0.02 OUTLIER 'General case' 0 N--CA 1.482 1.168 0 CA-C-O 122.151 0.977 . . . . 0.0 109.769 179.631 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -39.1 90.38 0.0 OUTLIER 'General case' 0 CA--C 1.528 0.125 0 CA-C-N 114.125 -1.398 . . . . 0.0 112.768 -178.091 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 38.2 tt0 -66.45 157.45 31.99 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 115.089 -0.96 . . . . 0.0 110.52 179.19 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 67.4 m-20 -139.38 137.24 35.54 Favored 'General case' 0 N--CA 1.479 0.984 0 C-N-CA 123.083 0.553 . . . . 0.0 110.213 179.772 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 18.3 t -85.44 -116.71 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.048 0 N-CA-C 108.562 -0.903 . . . . 0.0 108.562 179.535 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -108.2 54.36 0.56 Allowed Glycine 0 N--CA 1.476 1.353 0 N-CA-C 111.049 -0.82 . . . . 0.0 111.049 179.929 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 71.8 p -80.13 125.55 29.96 Favored 'General case' 0 C--N 1.328 -0.351 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 178.242 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 27' ' ' ASN . . . . . 0.521 HD21 ' CG ' ' C' ' 11' ' ' GLU . 47.7 t30 -65.69 100.4 0.53 Allowed 'General case' 0 N--CA 1.475 0.782 0 N-CA-C 108.812 -0.81 . . . . 0.0 108.812 178.649 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 66.6 mttm -95.58 117.0 29.64 Favored 'General case' 0 N--CA 1.485 1.298 0 N-CA-C 110.041 -0.355 . . . . 0.0 110.041 -179.179 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.85 -133.26 0.01 OUTLIER Glycine 0 CA--C 1.533 1.207 0 N-CA-C 110.723 -0.951 . . . . 0.0 110.723 178.927 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -113.88 127.9 56.18 Favored 'General case' 0 N--CA 1.479 0.981 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 179.031 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 66.6 mt -90.77 130.26 40.26 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.655 0 N-CA-C 107.532 -1.285 . . . . 0.0 107.532 178.692 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 17.8 mt -142.42 152.36 17.99 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.918 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 -178.852 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 65.52 47.55 77.02 Favored Glycine 0 CA--C 1.524 0.638 0 CA-C-N 116.085 -0.507 . . . . 0.0 112.667 178.793 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 2.9 tt -98.07 120.51 38.6 Favored 'General case' 0 N--CA 1.478 0.936 0 N-CA-C 107.25 -1.389 . . . . 0.0 107.25 177.85 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 28.0 ttt -152.81 157.97 41.55 Favored 'General case' 0 N--CA 1.472 0.627 0 N-CA-C 108.849 -0.797 . . . . 0.0 108.849 179.376 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 82.1 t -158.15 149.77 8.47 Favored 'Isoleucine or valine' 0 C--O 1.235 0.306 0 N-CA-C 106.807 -1.553 . . . . 0.0 106.807 -179.147 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . 0.548 ' H ' HE22 ' B' ' 15' ' ' GLN . . . 56.67 75.28 0.26 Allowed Glycine 0 C--N 1.314 -0.689 0 CA-C-N 115.573 -0.74 . . . . 0.0 111.651 178.14 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 170.47 -149.07 12.14 Favored Glycine 0 CA--C 1.518 0.265 0 N-CA-C 110.698 -0.961 . . . . 0.0 110.698 179.772 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 33.8 m -133.59 142.76 40.73 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.842 0 N-CA-C 109.691 -0.485 . . . . 0.0 109.691 179.659 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 16.1 t . . . . . 0 C--O 1.222 -0.353 0 CA-C-O 117.993 -1.003 . . . . 0.0 111.111 179.319 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 79.0 m-85 . . . . . 0 N--CA 1.475 0.784 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 72.4 mtp180 -144.11 141.48 30.03 Favored 'General case' 0 N--CA 1.482 1.157 0 N-CA-C 109.071 -0.714 . . . . 0.0 109.071 -179.834 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 76.8 m80 -149.41 119.67 7.3 Favored 'General case' 0 N--CA 1.471 0.597 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 179.089 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 7' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -68.05 149.5 49.6 Favored 'General case' 0 CA--C 1.53 0.197 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.281 -179.419 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 8' ' ' SER . . . . . . . . . . . . . 8.0 t -167.27 171.5 10.68 Favored 'General case' 0 N--CA 1.473 0.719 0 N-CA-C 109.564 -0.532 . . . . 0.0 109.564 178.419 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 121.79 24.79 2.24 Favored Glycine 0 N--CA 1.488 2.111 0 N-CA-C 112.105 -0.398 . . . . 0.0 112.105 179.304 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 42.4 p90 -56.41 128.28 35.19 Favored 'General case' 0 N--CA 1.472 0.669 0 N-CA-C 112.114 0.412 . . . . 0.0 112.114 -179.803 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 11' ' ' GLU . . . . . 0.521 ' CG ' HD21 ' B' ' 27' ' ' ASN . 45.7 mt-10 -84.79 154.41 22.39 Favored 'General case' 0 N--CA 1.468 0.473 0 N-CA-C 109.113 -0.699 . . . . 0.0 109.113 178.504 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -153.54 129.36 1.71 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 N-CA-C 108.409 -0.96 . . . . 0.0 108.409 178.968 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 48.9 m-70 -134.22 144.97 48.74 Favored 'General case' 0 N--CA 1.489 1.518 0 CA-C-N 118.588 0.631 . . . . 0.0 110.968 -179.029 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 6.3 t60 -165.04 98.55 0.74 Allowed 'General case' 0 N--CA 1.481 1.099 0 CA-C-N 116.57 -0.286 . . . . 0.0 111.201 179.791 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 15' ' ' GLN . . . . . 0.57 HE22 ' H ' ' C' ' 37' ' ' GLY . 54.3 mt-30 -108.6 -172.05 1.98 Allowed 'General case' 0 CA--C 1.5 -0.954 0 N-CA-C 108.251 -1.018 . . . . 0.0 108.251 179.765 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -167.25 97.58 0.5 Allowed 'General case' 0 CA--C 1.54 0.58 0 CA-C-N 115.179 -0.918 . . . . 0.0 109.381 178.751 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 17' ' ' LEU . . . . . 0.599 HD12 ' N ' ' C' ' 17' ' ' LEU . 4.4 mp -105.66 163.64 12.53 Favored 'General case' 0 N--CA 1.487 1.392 0 N-CA-C 108.563 -0.903 . . . . 0.0 108.563 179.838 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 51.0 t -142.0 118.75 6.95 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.343 0 CA-C-O 119.032 -0.509 . . . . 0.0 109.959 179.495 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 52.6 m-85 -70.33 159.24 34.48 Favored 'General case' 0 N--CA 1.478 0.964 0 N-CA-C 107.502 -1.296 . . . . 0.0 107.502 177.247 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 14.8 t80 -171.82 -57.35 0.02 OUTLIER 'General case' 0 N--CA 1.482 1.153 0 CA-C-O 122.196 0.998 . . . . 0.0 109.777 179.49 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -39.21 90.75 0.0 OUTLIER 'General case' 0 CA--C 1.529 0.15 0 CA-C-N 114.193 -1.367 . . . . 0.0 112.785 -178.053 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 37.7 tt0 -66.77 157.4 32.95 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.063 -0.971 . . . . 0.0 110.539 179.247 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 66.8 m-20 -139.22 137.03 35.62 Favored 'General case' 0 N--CA 1.478 0.937 0 C-N-CA 123.138 0.575 . . . . 0.0 110.297 179.836 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 17.9 t -85.39 -116.67 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.064 0 N-CA-C 108.519 -0.919 . . . . 0.0 108.519 179.558 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -108.16 54.61 0.55 Allowed Glycine 0 N--CA 1.474 1.228 0 N-CA-C 111.1 -0.8 . . . . 0.0 111.1 179.96 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 73.2 p -80.42 125.47 29.96 Favored 'General case' 0 N--CA 1.466 0.336 0 N-CA-C 108.841 -0.8 . . . . 0.0 108.841 178.329 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 27' ' ' ASN . . . . . 0.51 HD21 ' CG ' ' A' ' 11' ' ' GLU . 48.3 t30 -65.64 100.55 0.53 Allowed 'General case' 0 N--CA 1.474 0.757 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 178.684 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 66.8 mttm -95.8 116.86 29.52 Favored 'General case' 0 N--CA 1.485 1.324 0 N-CA-C 109.977 -0.379 . . . . 0.0 109.977 -179.055 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.73 -133.32 0.01 OUTLIER Glycine 0 CA--C 1.534 1.248 0 N-CA-C 110.761 -0.936 . . . . 0.0 110.761 178.954 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -113.73 127.65 56.11 Favored 'General case' 0 N--CA 1.479 1.016 0 N-CA-C 109.231 -0.655 . . . . 0.0 109.231 178.981 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 66.7 mt -90.66 130.15 40.34 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.644 0 N-CA-C 107.492 -1.299 . . . . 0.0 107.492 178.746 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 17.8 mt -142.59 152.49 17.71 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.909 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -178.864 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 65.52 47.44 78.07 Favored Glycine 0 CA--C 1.524 0.604 0 CA-C-N 116.0 -0.545 . . . . 0.0 112.666 178.877 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 2.9 tt -98.16 120.38 38.46 Favored 'General case' 0 N--CA 1.477 0.92 0 N-CA-C 107.231 -1.396 . . . . 0.0 107.231 177.864 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 28.1 ttt -152.48 158.16 42.19 Favored 'General case' 0 N--CA 1.471 0.577 0 N-CA-C 108.834 -0.802 . . . . 0.0 108.834 179.401 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 87.3 t -158.3 149.8 8.24 Favored 'Isoleucine or valine' 0 C--O 1.236 0.393 0 N-CA-C 106.856 -1.535 . . . . 0.0 106.856 -179.205 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 37' ' ' GLY . . . . . 0.57 ' H ' HE22 ' C' ' 15' ' ' GLN . . . 56.66 75.08 0.27 Allowed Glycine 0 C--N 1.313 -0.71 0 CA-C-N 115.608 -0.724 . . . . 0.0 111.675 178.101 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 170.55 -149.11 12.17 Favored Glycine 0 CA--C 1.519 0.336 0 N-CA-C 110.593 -1.003 . . . . 0.0 110.593 179.801 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 33.7 m -133.71 142.81 40.49 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.835 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 179.728 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 16.2 t . . . . . 0 CA--C 1.535 0.39 0 CA-C-O 117.888 -1.053 . . . . 0.0 110.983 179.34 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 86.9 m-85 . . . . . 0 N--CA 1.473 0.698 0 N-CA-C 108.261 -1.014 . . . . 0.0 108.261 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' D' D ' 5' ' ' ARG . . . . . . . . . . . . . 72.0 mtp180 -147.32 141.52 26.16 Favored 'General case' 0 N--CA 1.475 0.821 0 N-CA-C 109.13 -0.692 . . . . 0.0 109.13 179.888 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 76.9 m80 -149.14 123.68 9.74 Favored 'General case' 0 C--O 1.219 -0.541 0 N-CA-C 107.758 -1.201 . . . . 0.0 107.758 175.638 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' D' D ' 7' ' ' ASP . . . . . . . . . . . . . 6.1 m-20 -63.45 133.26 53.64 Favored 'General case' 0 C--N 1.322 -0.613 0 C-N-CA 127.036 2.134 . . . . 0.0 114.832 176.15 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' D' D ' 8' ' ' SER . . . . . . . . . . . . . 7.0 t -154.2 173.62 15.87 Favored 'General case' 0 N--CA 1.478 0.961 0 CA-C-N 118.609 0.64 . . . . 0.0 110.406 176.996 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 124.15 20.83 2.41 Favored Glycine 0 N--CA 1.484 1.842 0 N-CA-C 112.159 -0.377 . . . . 0.0 112.159 176.398 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 37.7 p90 -55.56 130.5 43.17 Favored 'General case' 0 CA--C 1.546 0.79 0 CA-C-O 121.176 0.513 . . . . 0.0 111.842 -176.771 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' D' D ' 11' ' ' GLU . . . . . 0.446 ' CG ' HD21 ' F' ' 27' ' ' ASN . 46.0 mt-10 -84.89 152.35 23.62 Favored 'General case' 0 N--CA 1.473 0.698 0 N-CA-C 109.703 -0.48 . . . . 0.0 109.703 177.663 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -149.56 130.13 4.42 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.426 0 N-CA-C 108.409 -0.96 . . . . 0.0 108.409 175.792 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 48.5 m-70 -129.53 148.34 51.42 Favored 'General case' 0 N--CA 1.483 1.184 0 CA-C-N 117.992 0.36 . . . . 0.0 111.116 176.84 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 6.5 t60 -165.02 104.85 0.78 Allowed 'General case' 0 N--CA 1.482 1.145 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 173.76 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' D' D ' 15' ' ' GLN . . . . . 0.587 HE22 ' H ' ' D' ' 37' ' ' GLY . 54.3 mt-30 -111.78 -175.49 2.71 Favored 'General case' 0 CA--C 1.492 -1.255 0 N-CA-C 107.977 -1.12 . . . . 0.0 107.977 179.065 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' D' D ' 16' ' ' LYS . . . . . 0.437 ' C ' HD12 ' D' ' 17' ' ' LEU . 88.7 tttt -163.39 106.02 0.99 Allowed 'General case' 0 CA--C 1.536 0.433 0 N-CA-C 107.656 -1.239 . . . . 0.0 107.656 175.62 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' D' D ' 17' ' ' LEU . . . . . 0.539 HD12 ' N ' ' D' ' 17' ' ' LEU . 5.5 mp -112.42 162.73 15.25 Favored 'General case' 0 N--CA 1.488 1.447 0 N-CA-C 107.887 -1.153 . . . . 0.0 107.887 179.655 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 47.3 t -141.0 123.81 15.59 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.192 0 N-CA-C 109.053 -0.721 . . . . 0.0 109.053 175.834 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 78.3 m-85 -62.91 151.46 39.29 Favored 'General case' 0 C--N 1.352 0.685 0 C-N-CA 124.74 1.216 . . . . 0.0 110.396 170.501 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 9.8 t80 -170.1 -66.8 0.02 OUTLIER 'General case' 0 N--CA 1.477 0.903 0 N-CA-C 107.666 -1.235 . . . . 0.0 107.666 -179.629 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -37.91 95.66 0.01 OUTLIER 'General case' 0 CA--C 1.536 0.428 0 CA-C-N 114.019 -1.446 . . . . 0.0 111.663 -174.583 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 38.1 tt0 -68.35 158.19 34.07 Favored 'General case' 0 N--CA 1.467 0.388 0 CA-C-N 113.435 -1.711 . . . . 0.0 110.376 178.493 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 67.6 m-20 -139.54 140.65 37.19 Favored 'General case' 0 N--CA 1.476 0.834 0 N-CA-C 109.403 -0.592 . . . . 0.0 109.403 178.558 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' D' D ' 24' ' ' VAL . . . . . . . . . . . . . 19.5 t -88.28 -119.97 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.486 1.347 0 N-CA-C 107.779 -1.193 . . . . 0.0 107.779 179.699 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . -111.72 61.91 0.3 Allowed Glycine 0 C--N 1.371 2.478 0 C-N-CA 118.075 -2.012 . . . . 0.0 109.317 178.824 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 89.0 p -70.57 121.35 17.69 Favored 'General case' 0 C--O 1.243 0.713 0 CA-C-O 116.555 -1.688 . . . . 0.0 111.775 169.24 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' D' D ' 27' ' ' ASN . . . . . 0.44 HD21 ' CG ' ' E' ' 11' ' ' GLU . 54.6 t30 -61.2 101.8 0.18 Allowed 'General case' 0 N--CA 1.476 0.864 0 CA-C-N 121.558 1.981 . . . . 0.0 109.501 172.957 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 66.2 mttm -99.14 119.28 37.59 Favored 'General case' 0 N--CA 1.491 1.621 0 CA-C-N 119.427 1.012 . . . . 0.0 109.127 179.217 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -55.07 -134.39 0.0 OUTLIER Glycine 0 C--N 1.343 0.931 0 CA-C-N 115.607 -0.724 . . . . 0.0 113.379 175.931 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -113.19 132.65 55.41 Favored 'General case' 0 C--N 1.372 1.565 0 N-CA-C 108.591 -0.892 . . . . 0.0 108.591 174.145 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 68.2 mt -91.88 134.34 30.51 Favored 'Isoleucine or valine' 0 C--N 1.347 0.488 0 N-CA-C 106.929 -1.508 . . . . 0.0 106.929 176.459 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 20.0 mt -144.78 155.02 14.34 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.965 0 N-CA-C 109.2 -0.667 . . . . 0.0 109.2 179.137 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 64.11 46.86 90.03 Favored Glycine 0 C--O 1.245 0.841 0 CA-C-O 119.354 -0.692 . . . . 0.0 112.57 179.059 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 3.5 tt -97.7 132.27 43.49 Favored 'General case' 0 C--N 1.372 1.585 0 N-CA-C 104.569 -2.382 . . . . 0.0 104.569 176.408 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 28.3 ttt -155.9 165.23 37.1 Favored 'General case' 0 N--CA 1.474 0.752 0 N-CA-C 107.783 -1.192 . . . . 0.0 107.783 175.819 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 96.3 t -164.1 154.69 2.26 Favored 'Isoleucine or valine' 0 C--O 1.247 0.973 0 N-CA-C 105.564 -2.013 . . . . 0.0 105.564 176.382 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' D' D ' 37' ' ' GLY . . . . . 0.587 ' H ' HE22 ' D' ' 15' ' ' GLN . . . 61.13 66.67 2.52 Favored Glycine 0 N--CA 1.445 -0.731 0 C-N-CA 117.446 -2.312 . . . . 0.0 113.974 176.577 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 167.64 -147.91 12.28 Favored Glycine 0 N--CA 1.466 0.644 0 CA-C-O 117.701 -1.61 . . . . 0.0 112.176 -179.117 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 33.7 m -130.4 142.69 43.07 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.088 0 CA-C-N 119.352 1.576 . . . . 0.0 109.886 -179.065 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 13.6 t . . . . . 0 C--O 1.212 -0.87 0 N-CA-C 109.54 -0.541 . . . . 0.0 109.54 174.466 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 79.4 m-85 . . . . . 0 N--CA 1.474 0.771 0 N-CA-C 109.907 -0.405 . . . . 0.0 109.907 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' E' E ' 5' ' ' ARG . . . . . . . . . . . . . 72.5 mtp180 -143.92 142.52 30.81 Favored 'General case' 0 N--CA 1.476 0.842 0 N-CA-C 109.541 -0.54 . . . . 0.0 109.541 179.858 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 76.5 m80 -150.3 118.27 6.28 Favored 'General case' 0 N--CA 1.473 0.686 0 N-CA-C 108.929 -0.767 . . . . 0.0 108.929 179.169 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' E' E ' 7' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -66.69 149.86 49.9 Favored 'General case' 0 N--CA 1.464 0.236 0 O-C-N 123.541 0.526 . . . . 0.0 111.538 -179.5 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' E' E ' 8' ' ' SER . . . . . . . . . . . . . 7.1 t -167.92 172.4 9.01 Favored 'General case' 0 N--CA 1.476 0.839 0 N-CA-C 109.573 -0.528 . . . . 0.0 109.573 177.901 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.7 24.34 2.13 Favored Glycine 0 N--CA 1.482 1.731 0 N-CA-C 111.922 -0.471 . . . . 0.0 111.922 179.071 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 39.1 p90 -55.66 127.28 29.18 Favored 'General case' 0 N--CA 1.474 0.733 0 N-CA-C 112.627 0.602 . . . . 0.0 112.627 -179.091 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' E' E ' 11' ' ' GLU . . . . . 0.44 ' CG ' HD21 ' D' ' 27' ' ' ASN . 46.4 mt-10 -83.32 155.08 23.76 Favored 'General case' 0 N--CA 1.474 0.76 0 N-CA-C 109.388 -0.597 . . . . 0.0 109.388 177.938 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -155.18 128.77 1.22 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.494 0 N-CA-C 108.386 -0.968 . . . . 0.0 108.386 178.811 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 46.3 m-70 -134.77 143.21 46.99 Favored 'General case' 0 N--CA 1.481 1.095 0 O-C-N 122.324 -0.235 . . . . 0.0 111.225 -177.99 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 6.2 t60 -163.99 98.39 0.85 Allowed 'General case' 0 N--CA 1.486 1.352 0 CA-C-N 116.765 -0.198 . . . . 0.0 111.147 179.814 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' E' E ' 15' ' ' GLN . . . . . 0.537 HE22 ' H ' ' E' ' 37' ' ' GLY . 54.7 mt-30 -107.82 -172.34 2.05 Favored 'General case' 0 CA--C 1.502 -0.9 0 N-CA-C 108.394 -0.965 . . . . 0.0 108.394 179.89 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -166.99 97.73 0.53 Allowed 'General case' 0 CA--C 1.543 0.686 0 CA-C-N 115.056 -0.975 . . . . 0.0 109.414 178.675 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' E' E ' 17' ' ' LEU . . . . . 0.583 ' N ' HD12 ' E' ' 17' ' ' LEU . 4.6 mp -105.69 163.32 12.79 Favored 'General case' 0 N--CA 1.49 1.558 0 N-CA-C 109.084 -0.709 . . . . 0.0 109.084 -179.796 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 39.0 t -142.32 118.39 6.0 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.38 0 C-N-CA 122.512 0.325 . . . . 0.0 110.52 179.078 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 51.0 m-85 -69.76 156.87 38.36 Favored 'General case' 0 C--N 1.358 0.964 0 N-CA-C 107.269 -1.382 . . . . 0.0 107.269 176.585 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 13.3 t80 -173.47 -54.96 0.02 OUTLIER 'General case' 0 N--CA 1.485 1.304 0 CA-C-O 121.606 0.717 . . . . 0.0 110.347 179.545 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.1 88.72 0.0 OUTLIER 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 114.396 -1.274 . . . . 0.0 112.843 -178.994 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 37.8 tt0 -64.62 157.88 25.88 Favored 'General case' 0 N--CA 1.471 0.581 0 CA-C-N 114.86 -1.064 . . . . 0.0 110.719 179.701 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 66.3 m-20 -139.97 136.68 34.03 Favored 'General case' 0 N--CA 1.477 0.883 0 C-N-CA 122.948 0.499 . . . . 0.0 110.399 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 21.8 t -85.23 -115.58 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.109 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 179.523 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . -108.97 54.66 0.54 Allowed Glycine 0 C--N 1.348 1.245 0 N-CA-C 111.237 -0.745 . . . . 0.0 111.237 -179.87 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 69.2 p -79.96 125.02 29.22 Favored 'General case' 0 N--CA 1.473 0.723 0 N-CA-C 109.111 -0.7 . . . . 0.0 109.111 177.947 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' E' E ' 27' ' ' ASN . . . . . 0.459 HD21 ' CG ' ' F' ' 11' ' ' GLU . 48.4 t30 -65.37 100.04 0.45 Allowed 'General case' 0 N--CA 1.474 0.747 0 N-CA-C 108.236 -1.024 . . . . 0.0 108.236 178.552 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 66.2 mttm -95.69 116.74 29.3 Favored 'General case' 0 N--CA 1.486 1.351 0 N-CA-C 109.975 -0.38 . . . . 0.0 109.975 -178.708 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.02 -132.82 0.01 OUTLIER Glycine 0 CA--C 1.534 1.271 0 N-CA-C 111.38 -0.688 . . . . 0.0 111.38 178.858 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -114.02 127.09 55.79 Favored 'General case' 0 N--CA 1.477 0.896 0 N-CA-C 109.394 -0.595 . . . . 0.0 109.394 179.187 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 67.2 mt -90.38 131.19 38.21 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.233 0 N-CA-C 107.132 -1.432 . . . . 0.0 107.132 178.688 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 19.5 mt -142.4 154.44 18.3 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.907 0 N-CA-C 109.125 -0.694 . . . . 0.0 109.125 -179.341 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.39 48.86 74.96 Favored Glycine 0 CA--C 1.523 0.537 0 C-N-CA 121.702 -0.285 . . . . 0.0 113.291 178.944 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 3.0 tt -99.3 120.19 39.16 Favored 'General case' 0 N--CA 1.477 0.907 0 N-CA-C 107.143 -1.429 . . . . 0.0 107.143 177.617 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 28.5 ttt -151.68 159.55 43.96 Favored 'General case' 0 N--CA 1.479 1.019 0 N-CA-C 108.552 -0.907 . . . . 0.0 108.552 179.314 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 96.9 t -159.64 149.85 6.59 Favored 'Isoleucine or valine' 0 C--O 1.236 0.384 0 N-CA-C 106.834 -1.543 . . . . 0.0 106.834 -179.504 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' E' E ' 37' ' ' GLY . . . . . 0.537 ' H ' HE22 ' E' ' 15' ' ' GLN . . . 56.71 74.53 0.32 Allowed Glycine 0 C--N 1.312 -0.751 0 CA-C-N 115.659 -0.701 . . . . 0.0 111.452 178.01 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 171.81 -147.24 9.96 Favored Glycine 0 C--O 1.223 -0.569 0 N-CA-C 111.08 -0.808 . . . . 0.0 111.08 179.67 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 33.2 m -135.28 141.85 41.46 Favored 'Isoleucine or valine' 0 C--N 1.353 0.731 0 N-CA-C 109.248 -0.649 . . . . 0.0 109.248 179.695 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 14.5 t . . . . . 0 CA--C 1.537 0.479 0 CA-C-O 117.916 -1.04 . . . . 0.0 111.24 179.383 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 78.8 m-85 . . . . . 0 N--CA 1.475 0.796 0 N-CA-C 109.981 -0.377 . . . . 0.0 109.981 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' F' F ' 5' ' ' ARG . . . . . . . . . . . . . 72.2 mtp180 -143.88 142.36 30.77 Favored 'General case' 0 N--CA 1.477 0.911 0 N-CA-C 109.283 -0.636 . . . . 0.0 109.283 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 76.7 m80 -150.24 118.11 6.25 Favored 'General case' 0 N--CA 1.474 0.726 0 N-CA-C 108.936 -0.765 . . . . 0.0 108.936 179.045 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' F' F ' 7' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -66.72 149.94 49.8 Favored 'General case' 0 N--CA 1.464 0.252 0 O-C-N 123.386 0.428 . . . . 0.0 111.595 -179.424 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' F' F ' 8' ' ' SER . . . . . . . . . . . . . 7.2 t -167.96 172.51 8.86 Favored 'General case' 0 N--CA 1.475 0.815 0 CA-C-N 115.944 -0.571 . . . . 0.0 109.574 177.978 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.47 24.7 2.11 Favored Glycine 0 N--CA 1.483 1.776 0 N-CA-C 111.892 -0.483 . . . . 0.0 111.892 178.986 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 38.6 p90 -56.09 127.52 30.97 Favored 'General case' 0 N--CA 1.474 0.733 0 N-CA-C 112.637 0.606 . . . . 0.0 112.637 -179.061 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' F' F ' 11' ' ' GLU . . . . . 0.459 ' CG ' HD21 ' E' ' 27' ' ' ASN . 46.0 mt-10 -83.25 155.03 23.86 Favored 'General case' 0 N--CA 1.474 0.746 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 177.897 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -155.13 128.61 1.2 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.503 0 N-CA-C 108.43 -0.952 . . . . 0.0 108.43 178.775 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 46.9 m-70 -134.7 143.11 47.02 Favored 'General case' 0 N--CA 1.48 1.051 0 O-C-N 122.275 -0.265 . . . . 0.0 111.194 -177.998 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 6.2 t60 -164.11 98.63 0.84 Allowed 'General case' 0 N--CA 1.486 1.342 0 CA-C-N 116.734 -0.212 . . . . 0.0 111.258 179.917 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' F' F ' 15' ' ' GLN . . . . . 0.541 HE22 ' H ' ' F' ' 37' ' ' GLY . 55.0 mt-30 -108.36 -171.42 1.86 Allowed 'General case' 0 CA--C 1.499 -1.011 0 N-CA-C 108.544 -0.91 . . . . 0.0 108.544 179.885 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -167.53 98.01 0.49 Allowed 'General case' 0 CA--C 1.541 0.605 0 CA-C-N 114.933 -1.03 . . . . 0.0 109.484 178.667 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' F' F ' 17' ' ' LEU . . . . . 0.583 HD12 ' N ' ' F' ' 17' ' ' LEU . 4.5 mp -105.73 163.14 12.93 Favored 'General case' 0 N--CA 1.49 1.541 0 N-CA-C 109.151 -0.685 . . . . 0.0 109.151 -179.856 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 39.0 t -142.17 118.41 6.3 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.293 0 C-N-CA 122.573 0.349 . . . . 0.0 110.567 179.121 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 52.3 m-85 -69.78 156.7 38.63 Favored 'General case' 0 C--N 1.358 0.955 0 N-CA-C 107.121 -1.437 . . . . 0.0 107.121 176.482 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 13.9 t80 -173.0 -55.27 0.02 OUTLIER 'General case' 0 N--CA 1.485 1.293 0 CA-C-O 121.811 0.815 . . . . 0.0 109.826 179.645 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.86 88.89 0.0 OUTLIER 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 114.436 -1.256 . . . . 0.0 112.916 -178.938 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 37.8 tt0 -64.78 157.68 26.97 Favored 'General case' 0 N--CA 1.472 0.651 0 CA-C-N 114.935 -1.029 . . . . 0.0 110.784 179.464 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 66.1 m-20 -139.84 137.03 34.61 Favored 'General case' 0 N--CA 1.478 0.955 0 C-N-CA 122.944 0.497 . . . . 0.0 110.346 179.887 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' F' F ' 24' ' ' VAL . . . . . . . . . . . . . 21.6 t -85.62 -115.55 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.482 1.126 0 N-CA-C 108.706 -0.849 . . . . 0.0 108.706 179.502 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -108.8 54.06 0.57 Allowed Glycine 0 N--CA 1.477 1.371 0 N-CA-C 111.235 -0.746 . . . . 0.0 111.235 -179.869 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 69.8 p -79.5 125.04 29.05 Favored 'General case' 0 N--CA 1.473 0.675 0 N-CA-C 109.052 -0.721 . . . . 0.0 109.052 177.876 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' F' F ' 27' ' ' ASN . . . . . 0.446 HD21 ' CG ' ' D' ' 11' ' ' GLU . 48.2 t30 -65.46 100.15 0.47 Allowed 'General case' 0 N--CA 1.473 0.69 0 N-CA-C 108.328 -0.99 . . . . 0.0 108.328 178.533 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 66.1 mttm -95.66 116.82 29.41 Favored 'General case' 0 N--CA 1.485 1.281 0 N-CA-C 110.022 -0.362 . . . . 0.0 110.022 -178.669 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.17 -132.77 0.01 OUTLIER Glycine 0 CA--C 1.533 1.197 0 N-CA-C 111.491 -0.644 . . . . 0.0 111.491 178.916 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -113.85 126.37 55.11 Favored 'General case' 0 N--CA 1.478 0.954 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 179.278 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 67.2 mt -89.97 130.66 38.89 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.209 0 N-CA-C 107.175 -1.417 . . . . 0.0 107.175 178.632 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 19.4 mt -142.11 154.32 18.83 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.877 0 N-CA-C 109.106 -0.701 . . . . 0.0 109.106 -179.333 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.63 48.9 73.21 Favored Glycine 0 CA--C 1.524 0.596 0 CA-C-N 116.476 -0.329 . . . . 0.0 113.289 179.016 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 3.0 tt -99.41 120.26 39.31 Favored 'General case' 0 N--CA 1.478 0.946 0 N-CA-C 107.145 -1.428 . . . . 0.0 107.145 177.771 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 28.5 ttt -151.82 159.66 43.81 Favored 'General case' 0 N--CA 1.477 0.925 0 N-CA-C 108.673 -0.862 . . . . 0.0 108.673 179.437 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 94.5 t -159.76 149.89 6.45 Favored 'Isoleucine or valine' 0 C--O 1.235 0.31 0 N-CA-C 106.865 -1.531 . . . . 0.0 106.865 -179.478 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' F' F ' 37' ' ' GLY . . . . . 0.541 ' H ' HE22 ' F' ' 15' ' ' GLN . . . 56.78 74.35 0.34 Allowed Glycine 0 C--N 1.313 -0.722 0 CA-C-N 115.549 -0.75 . . . . 0.0 111.512 177.904 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 171.91 -147.25 9.93 Favored Glycine 0 C--O 1.223 -0.534 0 N-CA-C 111.099 -0.8 . . . . 0.0 111.099 179.818 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 33.2 m -135.33 141.67 41.91 Favored 'Isoleucine or valine' 0 C--N 1.352 0.715 0 N-CA-C 109.27 -0.641 . . . . 0.0 109.27 179.712 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 15.2 t . . . . . 0 CA--C 1.537 0.473 0 CA-C-O 117.934 -1.031 . . . . 0.0 111.155 179.317 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 79.4 m-85 . . . . . 0 N--CA 1.474 0.765 0 N-CA-C 109.543 -0.54 . . . . 0.0 109.543 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' G' G ' 5' ' ' ARG . . . . . . . . . . . . . 72.2 mtp180 -144.05 141.52 30.14 Favored 'General case' 0 N--CA 1.483 1.221 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 -179.612 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 76.8 m80 -149.24 119.29 7.18 Favored 'General case' 0 N--CA 1.473 0.679 0 N-CA-C 108.952 -0.759 . . . . 0.0 108.952 179.026 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 8.9 m-20 -68.55 145.46 53.97 Favored 'General case' 0 N--CA 1.468 0.462 0 O-C-N 123.578 0.549 . . . . 0.0 111.945 -179.319 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' G' G ' 8' ' ' SER . . . . . . . . . . . . . 6.0 t -164.64 173.52 11.83 Favored 'General case' 0 N--CA 1.468 0.461 0 N-CA-C 109.386 -0.598 . . . . 0.0 109.386 178.208 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.36 24.45 2.19 Favored Glycine 0 N--CA 1.48 1.584 0 N-CA-C 111.639 -0.584 . . . . 0.0 111.639 178.934 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 42.4 p90 -56.24 127.56 31.4 Favored 'General case' 0 N--CA 1.474 0.745 0 N-CA-C 112.516 0.562 . . . . 0.0 112.516 -178.757 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 45.7 mt-10 -83.61 154.24 23.86 Favored 'General case' 0 N--CA 1.471 0.601 0 CA-C-O 120.971 0.415 . . . . 0.0 109.882 178.638 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 2.6 p -155.5 128.51 1.13 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.959 0 N-CA-C 108.431 -0.951 . . . . 0.0 108.431 178.972 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 49.6 m-70 -133.6 144.64 49.41 Favored 'General case' 0 N--CA 1.477 0.876 0 CA-C-N 115.454 -0.793 . . . . 0.0 110.934 -178.177 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 6.3 t60 -165.65 98.62 0.68 Allowed 'General case' 0 N--CA 1.483 1.2 0 CA-C-N 116.589 -0.278 . . . . 0.0 110.805 179.193 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' G' G ' 15' ' ' GLN . . . . . 0.562 HE22 ' H ' ' G' ' 37' ' ' GLY . 54.5 mt-30 -108.49 -171.92 1.95 Allowed 'General case' 0 CA--C 1.501 -0.915 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 179.916 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -167.31 97.91 0.5 Allowed 'General case' 0 CA--C 1.542 0.641 0 CA-C-N 114.96 -1.018 . . . . 0.0 109.388 178.717 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' G' G ' 17' ' ' LEU . . . . . 0.589 ' N ' HD12 ' G' ' 17' ' ' LEU . 5.1 mp -105.38 162.41 13.47 Favored 'General case' 0 N--CA 1.487 1.402 0 N-CA-C 109.32 -0.622 . . . . 0.0 109.32 -179.685 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 36.5 t -143.13 118.52 4.6 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.009 0 CA-C-O 120.83 0.348 . . . . 0.0 110.442 178.851 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 46.5 m-85 -69.76 150.32 47.03 Favored 'General case' 0 C--N 1.37 1.481 0 N-CA-C 107.263 -1.384 . . . . 0.0 107.263 176.595 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 11.3 t80 -170.5 -55.06 0.02 OUTLIER 'General case' 0 N--CA 1.487 1.406 0 CA-C-N 117.953 0.342 . . . . 0.0 110.328 -179.583 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.68 89.9 0.0 OUTLIER 'General case' 0 C--N 1.325 -0.491 0 C-N-CA 123.774 0.83 . . . . 0.0 112.508 -179.839 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 38.0 tt0 -65.41 158.54 26.41 Favored 'General case' 0 N--CA 1.469 0.476 0 CA-C-N 114.714 -1.13 . . . . 0.0 109.954 179.146 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 67.4 m-20 -140.09 136.8 33.97 Favored 'General case' 0 N--CA 1.478 0.937 0 C-N-CA 122.874 0.469 . . . . 0.0 109.98 179.904 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' G' G ' 24' ' ' VAL . . . . . . . . . . . . . 21.5 t -85.95 -115.61 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 1.004 0 N-CA-C 108.506 -0.924 . . . . 0.0 108.506 179.555 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -108.61 54.04 0.57 Allowed Glycine 0 N--CA 1.477 1.397 0 N-CA-C 111.492 -0.643 . . . . 0.0 111.492 -179.868 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 72.6 p -79.96 125.57 29.92 Favored 'General case' 0 N--CA 1.467 0.389 0 N-CA-C 108.943 -0.762 . . . . 0.0 108.943 177.971 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 47.5 t30 -65.76 100.98 0.59 Allowed 'General case' 0 N--CA 1.47 0.566 0 N-CA-C 108.567 -0.901 . . . . 0.0 108.567 178.525 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 66.6 mttm -95.76 117.2 30.09 Favored 'General case' 0 N--CA 1.485 1.309 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 -179.13 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.94 -131.95 0.01 OUTLIER Glycine 0 CA--C 1.53 1.005 0 N-CA-C 110.579 -1.008 . . . . 0.0 110.579 178.946 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -113.74 126.48 55.27 Favored 'General case' 0 N--CA 1.469 0.499 0 N-CA-C 109.522 -0.547 . . . . 0.0 109.522 179.542 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 69.3 mt -89.94 131.38 37.34 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.756 0 N-CA-C 107.327 -1.36 . . . . 0.0 107.327 178.495 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 22.7 mt -143.29 155.09 16.74 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.397 0 CA-C-N 118.982 0.81 . . . . 0.0 109.056 -179.751 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.74 48.2 79.29 Favored Glycine 0 CA--C 1.527 0.782 0 CA-C-N 116.659 -0.246 . . . . 0.0 112.835 179.053 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' G' G ' 34' ' ' LEU . . . . . 0.405 HD23 ' N ' ' G' ' 35' ' ' MET . 2.9 tt -98.87 121.19 40.5 Favored 'General case' 0 N--CA 1.478 0.955 0 N-CA-C 107.086 -1.449 . . . . 0.0 107.086 177.75 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' G' G ' 35' ' ' MET . . . . . 0.405 ' N ' HD23 ' G' ' 34' ' ' LEU . 28.7 ttt -153.08 160.21 42.9 Favored 'General case' 0 N--CA 1.477 0.882 0 N-CA-C 108.172 -1.047 . . . . 0.0 108.172 179.493 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 84.4 t -159.81 150.2 6.31 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.255 0 N-CA-C 106.419 -1.697 . . . . 0.0 106.419 -179.354 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' G' G ' 37' ' ' GLY . . . . . 0.562 ' H ' HE22 ' G' ' 15' ' ' GLN . . . 56.59 74.86 0.29 Allowed Glycine 0 C--N 1.312 -0.756 0 C-N-CA 120.975 -0.631 . . . . 0.0 112.049 177.727 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 170.28 -145.79 9.39 Favored Glycine 0 N--CA 1.467 0.702 0 N-CA-C 110.614 -0.995 . . . . 0.0 110.614 179.127 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 33.9 m -135.91 142.06 40.08 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.873 0 N-CA-C 109.911 -0.403 . . . . 0.0 109.911 -179.887 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 15.4 t . . . . . 0 N--CA 1.466 0.349 0 CA-C-O 118.046 -0.978 . . . . 0.0 111.304 179.463 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 80.1 m-85 . . . . . 0 N--CA 1.474 0.769 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' H' H ' 5' ' ' ARG . . . . . . . . . . . . . 72.3 mtp180 -144.11 141.85 30.26 Favored 'General case' 0 N--CA 1.483 1.191 0 N-CA-C 109.294 -0.632 . . . . 0.0 109.294 -179.635 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 76.9 m80 -149.67 118.87 6.78 Favored 'General case' 0 N--CA 1.473 0.695 0 N-CA-C 109.105 -0.702 . . . . 0.0 109.105 179.129 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 8.8 m-20 -68.25 145.2 54.48 Favored 'General case' 0 N--CA 1.469 0.48 0 O-C-N 123.469 0.481 . . . . 0.0 111.924 -179.309 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' H' H ' 8' ' ' SER . . . . . . . . . . . . . 7.5 t -164.36 172.96 12.77 Favored 'General case' 0 N--CA 1.469 0.507 0 N-CA-C 109.449 -0.575 . . . . 0.0 109.449 178.421 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.43 24.46 2.17 Favored Glycine 0 N--CA 1.481 1.665 0 N-CA-C 111.733 -0.547 . . . . 0.0 111.733 179.112 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 42.1 p90 -56.38 127.51 31.37 Favored 'General case' 0 N--CA 1.473 0.707 0 N-CA-C 112.428 0.529 . . . . 0.0 112.428 -178.795 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 45.4 mt-10 -83.51 154.2 24.0 Favored 'General case' 0 N--CA 1.473 0.676 0 CA-C-O 120.984 0.421 . . . . 0.0 109.874 178.62 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.6 p -155.41 128.41 1.13 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.975 0 N-CA-C 108.433 -0.951 . . . . 0.0 108.433 178.963 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 52.1 m-70 -133.42 144.63 49.65 Favored 'General case' 0 N--CA 1.476 0.863 0 CA-C-N 115.43 -0.804 . . . . 0.0 110.893 -178.16 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 6.4 t60 -165.61 98.48 0.68 Allowed 'General case' 0 N--CA 1.482 1.146 0 CA-C-N 116.527 -0.306 . . . . 0.0 110.839 179.146 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' H' H ' 15' ' ' GLN . . . . . 0.552 HE22 ' H ' ' H' ' 37' ' ' GLY . 54.2 mt-30 -108.24 -172.45 2.06 Favored 'General case' 0 CA--C 1.5 -0.979 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 -179.921 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -167.01 97.78 0.52 Allowed 'General case' 0 CA--C 1.539 0.521 0 CA-C-N 114.989 -1.005 . . . . 0.0 109.402 178.73 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' H' H ' 17' ' ' LEU . . . . . 0.589 HD12 ' N ' ' H' ' 17' ' ' LEU . 5.1 mp -105.5 162.13 13.74 Favored 'General case' 0 N--CA 1.488 1.442 0 N-CA-C 109.292 -0.633 . . . . 0.0 109.292 -179.632 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 38.5 t -142.79 118.54 5.16 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.097 0 CA-C-O 120.905 0.383 . . . . 0.0 110.482 178.874 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 47.5 m-85 -70.14 150.89 46.06 Favored 'General case' 0 C--N 1.37 1.498 0 N-CA-C 107.391 -1.336 . . . . 0.0 107.391 176.585 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 11.9 t80 -171.88 -54.41 0.02 OUTLIER 'General case' 0 N--CA 1.485 1.28 0 CA-C-N 117.828 0.286 . . . . 0.0 110.323 -179.456 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.99 90.22 0.0 OUTLIER 'General case' 0 CA--C 1.536 0.437 0 C-N-CA 123.59 0.756 . . . . 0.0 112.262 -179.824 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 37.9 tt0 -65.38 158.63 26.09 Favored 'General case' 0 N--CA 1.468 0.465 0 CA-C-N 114.739 -1.118 . . . . 0.0 110.011 179.318 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 66.8 m-20 -140.18 136.98 34.01 Favored 'General case' 0 N--CA 1.477 0.899 0 C-N-CA 122.942 0.497 . . . . 0.0 109.972 179.872 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' H' H ' 24' ' ' VAL . . . . . . . . . . . . . 21.5 t -86.36 -115.55 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.049 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 179.605 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . -108.3 53.44 0.6 Allowed Glycine 0 N--CA 1.479 1.564 0 N-CA-C 111.395 -0.682 . . . . 0.0 111.395 -179.828 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 70.1 p -79.46 125.28 29.35 Favored 'General case' 0 N--CA 1.468 0.45 0 N-CA-C 108.893 -0.781 . . . . 0.0 108.893 178.004 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 47.5 t30 -65.69 100.91 0.57 Allowed 'General case' 0 N--CA 1.472 0.662 0 N-CA-C 108.497 -0.927 . . . . 0.0 108.497 178.5 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 66.6 mttm -95.89 117.09 29.93 Favored 'General case' 0 N--CA 1.485 1.283 0 N-CA-C 109.97 -0.382 . . . . 0.0 109.97 -179.146 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.66 -131.75 0.01 OUTLIER Glycine 0 CA--C 1.531 1.059 0 N-CA-C 110.802 -0.919 . . . . 0.0 110.802 178.921 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -114.0 126.24 54.91 Favored 'General case' 0 N--CA 1.471 0.604 0 N-CA-C 109.61 -0.515 . . . . 0.0 109.61 179.527 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 69.4 mt -89.79 131.13 37.82 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.701 0 N-CA-C 107.338 -1.356 . . . . 0.0 107.338 178.55 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 23.3 mt -143.11 155.05 17.02 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.339 0 CA-C-N 118.826 0.739 . . . . 0.0 109.024 -179.698 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.65 48.12 80.36 Favored Glycine 0 CA--C 1.524 0.626 0 CA-C-O 120.117 -0.269 . . . . 0.0 112.891 179.045 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 2.9 tt -98.75 121.09 40.25 Favored 'General case' 0 N--CA 1.478 0.969 0 N-CA-C 107.117 -1.438 . . . . 0.0 107.117 177.617 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 28.7 ttt -152.89 159.95 43.03 Favored 'General case' 0 N--CA 1.478 0.974 0 N-CA-C 108.07 -1.085 . . . . 0.0 108.07 179.61 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 87.2 t -159.66 150.34 6.43 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.261 0 N-CA-C 106.448 -1.686 . . . . 0.0 106.448 -179.51 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' H' H ' 37' ' ' GLY . . . . . 0.552 ' H ' HE22 ' H' ' 15' ' ' GLN . . . 56.35 74.96 0.27 Allowed Glycine 0 C--N 1.311 -0.811 0 C-N-CA 120.979 -0.629 . . . . 0.0 112.015 177.804 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 170.24 -146.2 9.7 Favored Glycine 0 N--CA 1.467 0.744 0 N-CA-C 110.539 -1.024 . . . . 0.0 110.539 179.129 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 34.0 m -135.57 142.02 40.64 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.815 0 N-CA-C 109.951 -0.388 . . . . 0.0 109.951 -179.875 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 15.9 t . . . . . 0 N--CA 1.467 0.4 0 CA-C-O 118.058 -0.973 . . . . 0.0 111.327 179.45 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 79.6 m-85 . . . . . 0 N--CA 1.474 0.726 0 N-CA-C 109.643 -0.503 . . . . 0.0 109.643 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' I' I ' 5' ' ' ARG . . . . . . . . . . . . . 72.4 mtp180 -144.48 141.67 29.72 Favored 'General case' 0 N--CA 1.484 1.265 0 N-CA-C 109.224 -0.658 . . . . 0.0 109.224 -179.581 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 76.8 m80 -149.47 119.13 6.99 Favored 'General case' 0 N--CA 1.474 0.728 0 N-CA-C 109.08 -0.711 . . . . 0.0 109.08 178.999 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 8.9 m-20 -68.45 145.19 54.31 Favored 'General case' 0 N--CA 1.469 0.499 0 O-C-N 123.429 0.456 . . . . 0.0 111.866 -179.235 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' I' I ' 8' ' ' SER . . . . . . . . . . . . . 7.5 t -164.33 172.62 13.25 Favored 'General case' 0 N--CA 1.469 0.509 0 N-CA-C 109.463 -0.569 . . . . 0.0 109.463 178.368 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.92 24.62 2.03 Favored Glycine 0 N--CA 1.481 1.684 0 N-CA-C 111.7 -0.56 . . . . 0.0 111.7 179.104 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 42.4 p90 -56.52 127.53 31.69 Favored 'General case' 0 N--CA 1.474 0.762 0 N-CA-C 112.424 0.528 . . . . 0.0 112.424 -178.758 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 45.7 mt-10 -83.56 154.12 23.98 Favored 'General case' 0 N--CA 1.473 0.719 0 CA-C-O 121.071 0.463 . . . . 0.0 109.816 178.62 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 2.6 p -155.3 128.27 1.12 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.005 0 N-CA-C 108.389 -0.967 . . . . 0.0 108.389 178.956 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 50.9 m-70 -133.35 144.36 49.57 Favored 'General case' 0 N--CA 1.477 0.922 0 CA-C-N 115.45 -0.795 . . . . 0.0 110.966 -178.163 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 6.4 t60 -165.45 98.71 0.7 Allowed 'General case' 0 N--CA 1.483 1.177 0 CA-C-N 116.559 -0.291 . . . . 0.0 110.794 179.203 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' I' I ' 15' ' ' GLN . . . . . 0.565 HE22 ' H ' ' I' ' 37' ' ' GLY . 54.4 mt-30 -108.64 -172.46 2.06 Favored 'General case' 0 CA--C 1.499 -1.001 0 N-CA-C 108.405 -0.961 . . . . 0.0 108.405 179.979 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -166.78 98.02 0.55 Allowed 'General case' 0 CA--C 1.539 0.553 0 CA-C-N 114.933 -1.031 . . . . 0.0 109.423 178.745 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' I' I ' 17' ' ' LEU . . . . . 0.589 HD12 ' N ' ' I' ' 17' ' ' LEU . 5.1 mp -105.56 162.19 13.71 Favored 'General case' 0 N--CA 1.487 1.402 0 N-CA-C 109.327 -0.62 . . . . 0.0 109.327 -179.701 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 38.8 t -142.88 118.54 4.98 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.024 0 CA-C-O 120.987 0.423 . . . . 0.0 110.471 178.848 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 47.8 m-85 -70.01 150.89 46.18 Favored 'General case' 0 C--N 1.37 1.465 0 N-CA-C 107.306 -1.368 . . . . 0.0 107.306 176.567 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 12.0 t80 -171.94 -54.29 0.02 OUTLIER 'General case' 0 N--CA 1.483 1.206 0 CA-C-N 117.922 0.328 . . . . 0.0 110.408 -179.49 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.18 90.18 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.447 0 C-N-CA 123.713 0.805 . . . . 0.0 112.302 -179.893 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 38.2 tt0 -65.37 158.57 26.2 Favored 'General case' 0 N--CA 1.469 0.519 0 CA-C-N 114.738 -1.119 . . . . 0.0 110.045 179.254 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 66.3 m-20 -140.27 136.81 33.69 Favored 'General case' 0 N--CA 1.478 0.937 0 C-N-CA 122.859 0.464 . . . . 0.0 109.989 179.844 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' I' I ' 24' ' ' VAL . . . . . . . . . . . . . 21.3 t -86.04 -115.9 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.957 0 N-CA-C 108.542 -0.911 . . . . 0.0 108.542 179.559 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . -108.1 54.12 0.57 Allowed Glycine 0 N--CA 1.478 1.453 0 N-CA-C 111.384 -0.687 . . . . 0.0 111.384 -179.845 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 73.4 p -80.08 125.14 29.42 Favored 'General case' 0 N--CA 1.467 0.399 0 N-CA-C 108.962 -0.755 . . . . 0.0 108.962 177.889 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 48.1 t30 -65.49 101.01 0.54 Allowed 'General case' 0 CA--C 1.54 0.583 0 N-CA-C 108.539 -0.911 . . . . 0.0 108.539 178.588 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 66.5 mttm -95.88 117.07 29.88 Favored 'General case' 0 N--CA 1.485 1.321 0 N-CA-C 109.98 -0.378 . . . . 0.0 109.98 -179.177 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.68 -132.1 0.01 OUTLIER Glycine 0 CA--C 1.533 1.186 0 N-CA-C 110.652 -0.979 . . . . 0.0 110.652 178.975 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -113.55 126.12 54.95 Favored 'General case' 0 N--CA 1.472 0.635 0 C-N-CA 123.009 0.524 . . . . 0.0 109.622 179.547 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 70.1 mt -89.81 131.51 36.89 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.752 0 N-CA-C 107.219 -1.401 . . . . 0.0 107.219 178.567 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 23.5 mt -143.49 155.12 16.42 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.36 0 CA-C-N 118.883 0.765 . . . . 0.0 108.994 -179.69 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.57 48.18 80.17 Favored Glycine 0 CA--C 1.525 0.661 0 CA-C-N 116.635 -0.257 . . . . 0.0 112.846 179.082 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 2.9 tt -98.78 121.19 40.41 Favored 'General case' 0 N--CA 1.478 0.956 0 N-CA-C 107.002 -1.481 . . . . 0.0 107.002 177.625 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 28.6 ttt -153.0 159.93 42.96 Favored 'General case' 0 N--CA 1.478 0.931 0 N-CA-C 108.057 -1.09 . . . . 0.0 108.057 179.543 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 86.9 t -159.67 150.33 6.42 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.243 0 N-CA-C 106.372 -1.714 . . . . 0.0 106.372 -179.518 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' I' I ' 37' ' ' GLY . . . . . 0.565 ' H ' HE22 ' I' ' 15' ' ' GLN . . . 56.52 74.61 0.31 Allowed Glycine 0 C--N 1.312 -0.762 0 C-N-CA 120.898 -0.668 . . . . 0.0 112.083 177.777 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 170.49 -146.12 9.57 Favored Glycine 0 N--CA 1.466 0.664 0 N-CA-C 110.599 -1.0 . . . . 0.0 110.599 179.131 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 34.0 m -135.67 141.99 40.57 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.807 0 N-CA-C 109.882 -0.414 . . . . 0.0 109.882 -179.834 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 16.2 t . . . . . 0 C--O 1.223 -0.315 0 CA-C-O 118.035 -0.984 . . . . 0.0 111.275 179.465 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 20.2 m-85 . . . . . 0 N--CA 1.47 0.56 0 N-CA-C 109.495 -0.557 . . . . 0.0 109.495 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 31.9 mtp180 -67.96 130.38 42.79 Favored 'General case' 0 C--O 1.218 -0.602 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.154 -178.027 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 48.0 m170 -100.34 131.54 46.22 Favored 'General case' 0 N--CA 1.474 0.733 0 N-CA-C 109.461 -0.57 . . . . 0.0 109.461 179.457 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 13.8 m-20 -71.42 141.03 50.31 Favored 'General case' 0 CA--C 1.53 0.19 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.819 -179.748 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' SER . . . . . 0.41 ' O ' ' O ' ' C' ' 25' ' ' GLY . 8.7 t -143.53 -173.35 3.93 Favored 'General case' 0 N--CA 1.48 1.032 0 N-CA-C 109.016 -0.735 . . . . 0.0 109.016 178.498 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 117.88 11.49 8.4 Favored Glycine 0 N--CA 1.486 1.993 0 N-CA-C 112.543 -0.223 . . . . 0.0 112.543 179.197 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 47.8 p90 -59.2 128.36 36.76 Favored 'General case' 0 N--CA 1.471 0.622 0 CA-C-O 120.768 0.318 . . . . 0.0 111.849 -179.593 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 46.6 mt-10 -89.8 154.67 19.73 Favored 'General case' 0 N--CA 1.471 0.598 0 N-CA-C 109.299 -0.63 . . . . 0.0 109.299 178.548 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -153.58 128.92 1.57 Allowed 'Isoleucine or valine' 0 C--O 1.235 0.297 0 N-CA-C 108.072 -1.084 . . . . 0.0 108.072 178.641 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 50.1 m-70 -135.37 147.04 48.95 Favored 'General case' 0 N--CA 1.49 1.565 0 CA-C-N 118.834 0.743 . . . . 0.0 111.114 -179.108 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 6.4 t60 -164.94 97.57 0.74 Allowed 'General case' 0 N--CA 1.48 1.056 0 CA-C-N 116.568 -0.287 . . . . 0.0 111.139 179.632 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . 0.547 HE22 ' H ' ' A' ' 37' ' ' GLY . 55.1 mt-30 -108.87 -172.49 2.06 Favored 'General case' 0 CA--C 1.503 -0.856 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 -179.969 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -166.81 98.0 0.55 Allowed 'General case' 0 N--CA 1.473 0.691 0 CA-C-N 115.179 -0.918 . . . . 0.0 109.391 178.795 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.596 HD12 ' N ' ' A' ' 17' ' ' LEU . 4.5 mp -106.05 164.17 12.19 Favored 'General case' 0 N--CA 1.489 1.488 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 179.99 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 57.8 t -142.39 119.0 6.34 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.301 0 CA-C-O 118.962 -0.542 . . . . 0.0 109.904 179.527 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 53.2 m-85 -69.81 159.46 33.57 Favored 'General case' 0 N--CA 1.481 1.094 0 N-CA-C 107.491 -1.3 . . . . 0.0 107.491 177.186 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 11.7 t80 -171.68 -58.0 0.02 OUTLIER 'General case' 0 N--CA 1.487 1.417 0 CA-C-O 122.386 1.089 . . . . 0.0 109.815 179.65 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -39.32 89.73 0.0 OUTLIER 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 113.91 -1.496 . . . . 0.0 112.973 -178.03 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 37.1 tt0 -65.47 158.48 26.72 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.119 -0.946 . . . . 0.0 110.603 179.077 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 11.5 m-20 -140.74 137.63 33.57 Favored 'General case' 0 N--CA 1.479 0.994 0 C-N-CA 122.984 0.513 . . . . 0.0 110.249 179.702 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 17.7 t -91.7 -116.68 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.483 1.187 0 N-CA-C 108.64 -0.874 . . . . 0.0 108.64 179.576 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.404 ' O ' ' O ' ' B' ' 8' ' ' SER . . . -102.82 56.99 0.6 Allowed Glycine 0 N--CA 1.473 1.166 0 N-CA-C 110.954 -0.858 . . . . 0.0 110.954 179.997 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 79.6 p -85.25 124.74 32.23 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 178.068 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 61.7 t30 -64.58 100.88 0.41 Allowed 'General case' 0 N--CA 1.474 0.728 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 178.874 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 64.7 mttm -97.27 113.98 25.67 Favored 'General case' 0 N--CA 1.484 1.265 0 N-CA-C 110.011 -0.366 . . . . 0.0 110.011 -178.967 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.65 -134.26 0.01 OUTLIER Glycine 0 CA--C 1.534 1.235 0 N-CA-C 110.741 -0.944 . . . . 0.0 110.741 179.103 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -112.56 127.74 56.16 Favored 'General case' 0 N--CA 1.481 1.092 0 N-CA-C 109.155 -0.683 . . . . 0.0 109.155 178.997 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 65.0 mt -90.32 129.24 41.49 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.623 0 N-CA-C 107.532 -1.285 . . . . 0.0 107.532 178.755 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 12.4 mt -142.96 151.92 17.25 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.793 0 CA-C-N 116.2 -0.455 . . . . 0.0 109.943 -178.891 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 65.21 48.9 64.94 Favored Glycine 0 CA--C 1.524 0.632 0 CA-C-N 115.997 -0.547 . . . . 0.0 112.495 179.01 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.415 HD23 ' N ' ' A' ' 35' ' ' MET . 2.8 tt -99.03 121.1 40.52 Favored 'General case' 0 N--CA 1.479 1.009 0 N-CA-C 107.143 -1.429 . . . . 0.0 107.143 178.088 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' MET . . . . . 0.415 ' N ' HD23 ' A' ' 34' ' ' LEU . 27.5 ttt -153.24 158.08 41.16 Favored 'General case' 0 N--CA 1.47 0.539 0 N-CA-C 108.847 -0.797 . . . . 0.0 108.847 179.576 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 85.0 t -158.19 149.32 8.66 Favored 'Isoleucine or valine' 0 C--O 1.238 0.47 0 N-CA-C 106.868 -1.53 . . . . 0.0 106.868 -179.577 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . 0.547 ' H ' HE22 ' A' ' 15' ' ' GLN . . . 57.38 72.42 0.59 Allowed Glycine 0 C--N 1.315 -0.616 0 N-CA-C 111.318 -0.713 . . . . 0.0 111.318 178.342 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 172.74 -157.78 27.36 Favored Glycine 0 C--N 1.332 0.326 0 N-CA-C 110.804 -0.918 . . . . 0.0 110.804 -179.895 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 33.4 m -124.07 143.33 37.73 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.934 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 179.502 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 16.4 t . . . . . 0 CA--C 1.536 0.412 0 CA-C-O 118.056 -0.973 . . . . 0.0 111.062 179.152 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 21.4 m-85 . . . . . 0 N--CA 1.47 0.561 0 N-CA-C 109.4 -0.593 . . . . 0.0 109.4 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 32.2 mtp180 -67.94 129.8 41.01 Favored 'General case' 0 N--CA 1.47 0.529 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.214 -178.019 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 47.7 m170 -99.81 131.79 45.57 Favored 'General case' 0 N--CA 1.476 0.854 0 N-CA-C 109.551 -0.537 . . . . 0.0 109.551 179.407 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 7' ' ' ASP . . . . . . . . . . . . . 13.2 m-20 -71.86 141.25 49.58 Favored 'General case' 0 CA--C 1.532 0.259 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.786 -179.688 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 8' ' ' SER . . . . . 0.404 ' O ' ' O ' ' A' ' 25' ' ' GLY . 8.7 t -143.54 -172.98 3.83 Favored 'General case' 0 N--CA 1.478 0.953 0 N-CA-C 109.017 -0.734 . . . . 0.0 109.017 178.417 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 117.45 11.79 8.53 Favored Glycine 0 N--CA 1.484 1.89 0 N-CA-C 112.513 -0.235 . . . . 0.0 112.513 179.241 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 47.4 p90 -59.33 128.09 35.36 Favored 'General case' 0 CA--C 1.54 0.583 0 N-CA-C 111.815 0.302 . . . . 0.0 111.815 -179.628 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 46.5 mt-10 -89.58 154.51 19.93 Favored 'General case' 0 N--CA 1.473 0.705 0 N-CA-C 109.418 -0.586 . . . . 0.0 109.418 178.552 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -153.48 128.31 1.47 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.286 0 N-CA-C 108.3 -1.0 . . . . 0.0 108.3 178.682 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 49.3 m-70 -134.89 147.35 49.82 Favored 'General case' 0 N--CA 1.489 1.514 0 CA-C-N 118.69 0.677 . . . . 0.0 111.044 -178.944 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 6.5 t60 -165.14 97.65 0.72 Allowed 'General case' 0 N--CA 1.481 1.125 0 CA-C-N 116.608 -0.269 . . . . 0.0 110.992 179.593 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . 0.543 HE22 ' H ' ' B' ' 37' ' ' GLY . 54.9 mt-30 -108.79 -172.79 2.12 Favored 'General case' 0 CA--C 1.501 -0.934 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 179.995 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 16' ' ' LYS . . . . . 0.401 ' C ' HD12 ' B' ' 17' ' ' LEU . 88.4 tttt -166.83 98.08 0.55 Allowed 'General case' 0 CA--C 1.541 0.616 0 CA-C-N 115.142 -0.935 . . . . 0.0 109.404 178.815 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . 0.595 ' N ' HD12 ' B' ' 17' ' ' LEU . 4.5 mp -106.2 164.2 12.19 Favored 'General case' 0 N--CA 1.487 1.41 0 N-CA-C 108.606 -0.887 . . . . 0.0 108.606 -179.948 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 58.9 t -142.52 118.46 5.65 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.258 0 CA-C-O 118.999 -0.524 . . . . 0.0 109.959 179.527 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 53.8 m-85 -70.04 159.55 33.62 Favored 'General case' 0 N--CA 1.478 0.942 0 N-CA-C 107.409 -1.33 . . . . 0.0 107.409 177.296 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 12.8 t80 -172.36 -56.98 0.02 OUTLIER 'General case' 0 N--CA 1.484 1.271 0 CA-C-O 122.233 1.016 . . . . 0.0 109.851 179.622 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -39.63 90.37 0.0 OUTLIER 'General case' 0 CA--C 1.529 0.138 0 CA-C-N 114.148 -1.387 . . . . 0.0 112.823 -178.163 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 36.9 tt0 -66.13 158.11 29.47 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 115.068 -0.969 . . . . 0.0 110.618 179.163 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 11.8 m-20 -140.18 138.38 35.12 Favored 'General case' 0 N--CA 1.48 1.058 0 C-N-CA 122.978 0.511 . . . . 0.0 110.127 179.697 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 17.9 t -92.73 -116.95 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.484 1.232 0 N-CA-C 108.707 -0.849 . . . . 0.0 108.707 179.543 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 25' ' ' GLY . . . . . 0.41 ' O ' ' O ' ' C' ' 8' ' ' SER . . . -101.89 56.43 0.68 Allowed Glycine 0 N--CA 1.474 1.191 0 N-CA-C 110.835 -0.906 . . . . 0.0 110.835 -179.959 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 78.9 p -85.23 124.82 32.31 Favored 'General case' 0 N--CA 1.466 0.354 0 N-CA-C 108.695 -0.854 . . . . 0.0 108.695 178.047 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 62.2 t30 -64.89 101.42 0.49 Allowed 'General case' 0 N--CA 1.473 0.701 0 N-CA-C 108.731 -0.84 . . . . 0.0 108.731 178.845 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 64.6 mttm -97.81 113.46 25.27 Favored 'General case' 0 N--CA 1.485 1.318 0 N-CA-C 110.029 -0.36 . . . . 0.0 110.029 -178.939 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.06 -134.16 0.01 OUTLIER Glycine 0 CA--C 1.534 1.255 0 N-CA-C 110.834 -0.907 . . . . 0.0 110.834 178.988 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -112.92 127.87 56.32 Favored 'General case' 0 N--CA 1.48 1.03 0 N-CA-C 109.114 -0.699 . . . . 0.0 109.114 179.02 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 64.4 mt -90.39 129.49 41.15 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.588 0 N-CA-C 107.52 -1.289 . . . . 0.0 107.52 178.768 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 12.0 mt -143.19 151.62 17.07 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.848 0 CA-C-N 116.06 -0.518 . . . . 0.0 109.905 -178.799 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 65.59 48.14 70.78 Favored Glycine 0 CA--C 1.526 0.722 0 CA-C-N 116.045 -0.525 . . . . 0.0 112.642 178.956 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 34' ' ' LEU . . . . . 0.4 HD23 ' N ' ' B' ' 35' ' ' MET . 2.9 tt -98.12 121.04 39.56 Favored 'General case' 0 N--CA 1.479 0.981 0 N-CA-C 107.269 -1.382 . . . . 0.0 107.269 177.951 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 35' ' ' MET . . . . . 0.4 ' N ' HD23 ' B' ' 34' ' ' LEU . 27.6 ttt -153.19 157.75 40.74 Favored 'General case' 0 N--CA 1.474 0.758 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 179.528 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 81.4 t -157.96 149.44 8.93 Favored 'Isoleucine or valine' 0 C--O 1.238 0.48 0 N-CA-C 106.676 -1.601 . . . . 0.0 106.676 -179.469 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . 0.543 ' H ' HE22 ' B' ' 15' ' ' GLN . . . 56.96 72.48 0.58 Allowed Glycine 0 C--N 1.314 -0.669 0 CA-C-N 115.621 -0.718 . . . . 0.0 111.394 178.331 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 172.86 -157.73 27.17 Favored Glycine 0 N--CA 1.459 0.233 0 N-CA-C 110.662 -0.975 . . . . 0.0 110.662 -179.946 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 33.5 m -124.06 143.3 37.83 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.933 0 C-N-CA 122.778 0.431 . . . . 0.0 109.891 179.402 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 16.2 t . . . . . 0 N--CA 1.468 0.439 0 CA-C-O 118.045 -0.979 . . . . 0.0 110.986 179.199 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 21.1 m-85 . . . . . 0 N--CA 1.47 0.548 0 N-CA-C 109.479 -0.563 . . . . 0.0 109.479 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 31.9 mtp180 -68.31 129.5 40.1 Favored 'General case' 0 N--CA 1.472 0.666 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.215 -178.001 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 47.4 m170 -99.64 131.41 45.65 Favored 'General case' 0 N--CA 1.474 0.75 0 N-CA-C 109.467 -0.568 . . . . 0.0 109.467 179.455 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 7' ' ' ASP . . . . . . . . . . . . . 13.5 m-20 -71.63 141.0 49.95 Favored 'General case' 0 CA--C 1.531 0.232 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.848 -179.691 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 8' ' ' SER . . . . . 0.41 ' O ' ' O ' ' B' ' 25' ' ' GLY . 8.6 t -143.2 -173.19 3.86 Favored 'General case' 0 N--CA 1.479 1.01 0 N-CA-C 109.002 -0.74 . . . . 0.0 109.002 178.477 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 117.78 11.55 8.44 Favored Glycine 0 N--CA 1.486 1.981 0 N-CA-C 112.44 -0.264 . . . . 0.0 112.44 179.159 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 47.4 p90 -59.17 128.31 36.53 Favored 'General case' 0 CA--C 1.54 0.561 0 CA-C-N 116.907 0.353 . . . . 0.0 111.895 -179.626 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 46.3 mt-10 -89.59 154.68 19.79 Favored 'General case' 0 N--CA 1.473 0.704 0 N-CA-C 109.4 -0.593 . . . . 0.0 109.4 178.5 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -153.87 128.32 1.4 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.233 0 N-CA-C 108.254 -1.017 . . . . 0.0 108.254 178.61 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 49.8 m-70 -134.91 147.18 49.76 Favored 'General case' 0 N--CA 1.491 1.588 0 CA-C-N 118.603 0.638 . . . . 0.0 111.139 -178.89 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 6.4 t60 -165.1 98.03 0.73 Allowed 'General case' 0 N--CA 1.482 1.159 0 CA-C-N 116.601 -0.272 . . . . 0.0 111.094 179.575 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 15' ' ' GLN . . . . . 0.557 HE22 ' H ' ' C' ' 37' ' ' GLY . 55.2 mt-30 -109.29 -172.53 2.06 Favored 'General case' 0 CA--C 1.5 -0.955 0 N-CA-C 108.345 -0.983 . . . . 0.0 108.345 179.972 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 16' ' ' LYS . . . . . 0.402 ' C ' HD12 ' C' ' 17' ' ' LEU . 88.4 tttt -166.77 97.93 0.55 Allowed 'General case' 0 N--CA 1.471 0.59 0 CA-C-N 115.086 -0.961 . . . . 0.0 109.413 178.795 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 17' ' ' LEU . . . . . 0.594 HD12 ' N ' ' C' ' 17' ' ' LEU . 4.5 mp -105.91 163.87 12.4 Favored 'General case' 0 N--CA 1.488 1.462 0 N-CA-C 108.603 -0.888 . . . . 0.0 108.603 -179.969 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 59.8 t -142.28 118.65 6.29 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.305 0 CA-C-O 119.025 -0.512 . . . . 0.0 109.813 179.552 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 54.1 m-85 -70.17 159.47 33.89 Favored 'General case' 0 N--CA 1.479 0.986 0 N-CA-C 107.485 -1.302 . . . . 0.0 107.485 177.17 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 12.7 t80 -172.34 -57.05 0.02 OUTLIER 'General case' 0 N--CA 1.484 1.258 0 CA-C-O 122.209 1.004 . . . . 0.0 109.928 179.671 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -39.5 90.54 0.0 OUTLIER 'General case' 0 CA--C 1.53 0.187 0 CA-C-N 114.129 -1.396 . . . . 0.0 112.864 -178.221 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 37.1 tt0 -66.31 158.27 29.51 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.08 -0.964 . . . . 0.0 110.625 179.258 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 11.4 m-20 -140.4 138.18 34.58 Favored 'General case' 0 N--CA 1.478 0.967 0 C-N-CA 123.032 0.533 . . . . 0.0 110.175 179.797 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 18.1 t -92.47 -117.01 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.484 1.238 0 N-CA-C 108.721 -0.844 . . . . 0.0 108.721 179.545 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 25' ' ' GLY . . . . . 0.41 ' O ' ' O ' ' A' ' 8' ' ' SER . . . -101.94 56.65 0.67 Allowed Glycine 0 C--N 1.347 1.192 0 N-CA-C 110.927 -0.869 . . . . 0.0 110.927 -179.995 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 79.2 p -85.36 124.83 32.41 Favored 'General case' 0 N--CA 1.467 0.423 0 N-CA-C 108.683 -0.858 . . . . 0.0 108.683 178.149 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 61.9 t30 -64.88 101.16 0.46 Allowed 'General case' 0 N--CA 1.473 0.717 0 N-CA-C 108.73 -0.841 . . . . 0.0 108.73 178.809 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 28' ' ' LYS . . . . . 0.4 ' O ' ' O ' ' C' ' 29' ' ' GLY . 65.2 mttm -97.47 113.65 25.37 Favored 'General case' 0 N--CA 1.486 1.348 0 N-CA-C 110.064 -0.347 . . . . 0.0 110.064 -178.983 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 29' ' ' GLY . . . . . 0.4 ' O ' ' O ' ' C' ' 28' ' ' LYS . . . -60.2 -134.47 0.01 OUTLIER Glycine 0 CA--C 1.535 1.282 0 N-CA-C 110.798 -0.921 . . . . 0.0 110.798 178.982 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -112.5 128.0 56.21 Favored 'General case' 0 N--CA 1.48 1.075 0 N-CA-C 109.181 -0.674 . . . . 0.0 109.181 178.91 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 64.4 mt -90.6 129.26 41.7 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.674 0 N-CA-C 107.486 -1.301 . . . . 0.0 107.486 178.75 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 12.2 mt -142.96 152.12 17.2 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.806 0 CA-C-N 116.053 -0.521 . . . . 0.0 109.871 -178.88 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 65.04 48.37 71.62 Favored Glycine 0 CA--C 1.525 0.697 0 CA-C-N 116.012 -0.54 . . . . 0.0 112.63 178.982 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 34' ' ' LEU . . . . . 0.407 HD23 ' N ' ' C' ' 35' ' ' MET . 2.8 tt -98.46 121.0 39.84 Favored 'General case' 0 N--CA 1.478 0.955 0 N-CA-C 107.158 -1.423 . . . . 0.0 107.158 177.98 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 35' ' ' MET . . . . . 0.407 ' N ' HD23 ' C' ' 34' ' ' LEU . 27.7 ttt -153.07 158.12 41.46 Favored 'General case' 0 N--CA 1.471 0.584 0 N-CA-C 108.814 -0.81 . . . . 0.0 108.814 179.617 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 78.3 t -158.38 149.46 8.3 Favored 'Isoleucine or valine' 0 C--O 1.237 0.432 0 N-CA-C 106.865 -1.531 . . . . 0.0 106.865 -179.526 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 37' ' ' GLY . . . . . 0.557 ' H ' HE22 ' C' ' 15' ' ' GLN . . . 56.94 72.54 0.57 Allowed Glycine 0 C--N 1.315 -0.616 0 CA-C-N 115.641 -0.709 . . . . 0.0 111.414 178.337 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 172.74 -157.45 26.79 Favored Glycine 0 N--CA 1.461 0.357 0 N-CA-C 110.659 -0.976 . . . . 0.0 110.659 -179.885 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 33.4 m -124.42 143.53 37.52 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.904 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 179.474 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 16.3 t . . . . . 0 N--CA 1.467 0.402 0 CA-C-O 118.118 -0.944 . . . . 0.0 111.082 179.285 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 23.1 m-85 . . . . . 0 N--CA 1.478 0.943 0 N-CA-C 107.913 -1.144 . . . . 0.0 107.913 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' D' D ' 5' ' ' ARG . . . . . . . . . . . . 0.297 39.3 mtp180 -76.43 133.58 39.82 Favored 'General case' 0 C--O 1.214 -0.812 0 N-CA-C 106.852 -1.536 . . . . 0.0 106.852 -168.536 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 51.4 m170 -101.78 133.4 46.58 Favored 'General case' 0 C--N 1.363 1.167 0 CA-C-N 113.931 -1.486 . . . . 0.0 107.776 -176.422 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' D' D ' 7' ' ' ASP . . . . . . . . . . . . . 9.3 m-20 -64.69 124.05 20.91 Favored 'General case' 0 C--N 1.314 -0.964 0 C-N-CA 127.987 2.515 . . . . 0.0 115.331 176.692 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' D' D ' 8' ' ' SER . . . . . . . . . . . . . 8.2 t -133.3 -174.83 3.61 Favored 'General case' 0 N--CA 1.483 1.209 0 CA-C-N 119.928 1.24 . . . . 0.0 109.46 177.367 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 121.88 13.75 4.92 Favored Glycine 0 N--CA 1.483 1.79 0 N-CA-C 110.993 -0.843 . . . . 0.0 110.993 175.476 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 44.7 p90 -58.37 130.18 45.5 Favored 'General case' 0 CA--C 1.539 0.526 0 C-N-CA 120.938 -0.305 . . . . 0.0 111.71 -179.209 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 47.0 mt-10 -89.29 152.57 21.48 Favored 'General case' 0 N--CA 1.477 0.903 0 N-CA-C 110.063 -0.347 . . . . 0.0 110.063 176.679 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -149.54 129.99 4.33 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.522 0 N-CA-C 107.975 -1.12 . . . . 0.0 107.975 174.35 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 47.9 m-70 -129.86 150.31 51.21 Favored 'General case' 0 N--CA 1.482 1.17 0 CA-C-N 117.848 0.295 . . . . 0.0 111.567 176.611 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 6.6 t60 -165.05 104.65 0.78 Allowed 'General case' 0 N--CA 1.484 1.233 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 172.974 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' D' D ' 15' ' ' GLN . . . . . 0.581 HE22 ' H ' ' D' ' 37' ' ' GLY . 55.2 mt-30 -112.46 -175.85 2.78 Favored 'General case' 0 CA--C 1.493 -1.222 0 N-CA-C 108.085 -1.079 . . . . 0.0 108.085 179.188 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' D' D ' 16' ' ' LYS . . . . . 0.452 ' C ' HD12 ' D' ' 17' ' ' LEU . 88.6 tttt -162.92 106.13 1.06 Allowed 'General case' 0 CA--C 1.536 0.419 0 N-CA-C 107.803 -1.184 . . . . 0.0 107.803 175.619 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' D' D ' 17' ' ' LEU . . . . . 0.542 HD12 ' N ' ' D' ' 17' ' ' LEU . 5.4 mp -112.47 162.86 15.14 Favored 'General case' 0 N--CA 1.488 1.442 0 N-CA-C 108.134 -1.061 . . . . 0.0 108.134 179.583 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 51.5 t -141.0 123.63 15.38 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.194 0 N-CA-C 109.01 -0.737 . . . . 0.0 109.01 175.962 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 78.5 m-85 -62.65 151.53 37.87 Favored 'General case' 0 C--N 1.349 0.569 0 C-N-CA 125.002 1.321 . . . . 0.0 110.395 170.485 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 8.3 t80 -170.17 -66.78 0.02 OUTLIER 'General case' 0 N--CA 1.476 0.831 0 N-CA-C 107.765 -1.198 . . . . 0.0 107.765 -179.584 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -37.94 95.74 0.01 OUTLIER 'General case' 0 CA--C 1.536 0.419 0 CA-C-N 113.889 -1.505 . . . . 0.0 111.706 -174.505 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 37.3 tt0 -68.32 158.97 32.3 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 113.587 -1.642 . . . . 0.0 110.308 178.654 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 11.5 m-20 -140.6 140.58 35.13 Favored 'General case' 0 N--CA 1.474 0.767 0 N-CA-C 109.646 -0.501 . . . . 0.0 109.646 178.795 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' D' D ' 24' ' ' VAL . . . . . . . . . . . . . 16.0 t -94.44 -120.65 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.381 0 N-CA-C 108.242 -1.021 . . . . 0.0 108.242 179.858 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . -104.65 61.93 0.38 Allowed Glycine 0 C--N 1.375 2.718 0 C-N-CA 117.791 -2.147 . . . . 0.0 109.555 178.866 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 90.9 p -71.57 121.07 18.09 Favored 'General case' 0 C--O 1.246 0.872 0 CA-C-O 115.949 -1.977 . . . . 0.0 112.537 168.01 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 64.7 t30 -60.69 102.06 0.17 Allowed 'General case' 0 N--CA 1.478 0.956 0 CA-C-N 122.278 2.308 . . . . 0.0 109.906 172.212 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' D' D ' 28' ' ' LYS . . . . . 0.403 ' O ' ' O ' ' D' ' 29' ' ' GLY . 64.6 mttm -100.95 116.16 32.14 Favored 'General case' 0 N--CA 1.493 1.714 0 CA-C-N 120.028 1.286 . . . . 0.0 109.157 179.461 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' D' D ' 29' ' ' GLY . . . . . 0.403 ' O ' ' O ' ' D' ' 28' ' ' LYS . . . -54.65 -134.6 0.0 OUTLIER Glycine 0 C--N 1.343 0.94 0 CA-C-N 115.51 -0.768 . . . . 0.0 113.433 176.203 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -112.95 132.58 55.28 Favored 'General case' 0 C--N 1.37 1.464 0 N-CA-C 108.46 -0.941 . . . . 0.0 108.46 174.435 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 66.7 mt -91.75 133.85 31.96 Favored 'Isoleucine or valine' 0 C--N 1.346 0.422 0 N-CA-C 106.888 -1.523 . . . . 0.0 106.888 176.682 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 14.2 mt -145.74 154.28 13.34 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.916 0 N-CA-C 109.092 -0.707 . . . . 0.0 109.092 179.276 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 64.09 47.65 83.26 Favored Glycine 0 C--O 1.246 0.877 0 CA-C-O 119.409 -0.662 . . . . 0.0 112.538 179.243 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 3.4 tt -97.81 132.53 43.34 Favored 'General case' 0 C--N 1.372 1.558 0 N-CA-C 104.593 -2.373 . . . . 0.0 104.593 176.44 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 28.2 ttt -155.96 165.32 36.81 Favored 'General case' 0 N--CA 1.475 0.812 0 N-CA-C 107.705 -1.22 . . . . 0.0 107.705 175.8 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 94.4 t -164.04 155.52 2.11 Favored 'Isoleucine or valine' 0 C--O 1.247 0.959 0 N-CA-C 105.204 -2.147 . . . . 0.0 105.204 175.016 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' D' D ' 37' ' ' GLY . . . . . 0.581 ' H ' HE22 ' D' ' 15' ' ' GLN . . . 61.22 65.15 3.46 Favored Glycine 0 CA--C 1.524 0.637 0 C-N-CA 117.97 -2.062 . . . . 0.0 113.042 176.686 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 168.83 -158.55 31.24 Favored Glycine 0 N--CA 1.465 0.633 0 CA-C-N 118.976 1.388 . . . . 0.0 111.58 -177.921 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 33.1 m -120.23 142.47 35.8 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.17 0 CA-C-N 118.426 1.113 . . . . 0.0 110.243 -178.534 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 13.9 t . . . . . 0 C--O 1.212 -0.916 0 N-CA-C 109.606 -0.516 . . . . 0.0 109.606 174.362 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 20.4 m-85 . . . . . 0 N--CA 1.472 0.665 0 N-CA-C 109.959 -0.386 . . . . 0.0 109.959 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' E' E ' 5' ' ' ARG . . . . . . . . . . . . . 30.6 mtp180 -67.7 130.32 42.64 Favored 'General case' 0 C--O 1.219 -0.517 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.503 -178.12 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 47.7 m170 -100.4 131.02 46.56 Favored 'General case' 0 N--CA 1.475 0.802 0 N-CA-C 109.593 -0.521 . . . . 0.0 109.593 179.37 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' E' E ' 7' ' ' ASP . . . . . . . . . . . . . 17.0 m-20 -71.07 142.33 50.84 Favored 'General case' 0 N--CA 1.464 0.234 0 O-C-N 123.389 0.431 . . . . 0.0 110.979 -179.829 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' E' E ' 8' ' ' SER . . . . . . . . . . . . . 8.4 t -144.85 -172.9 3.93 Favored 'General case' 0 N--CA 1.478 0.938 0 N-CA-C 108.994 -0.743 . . . . 0.0 108.994 178.052 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 118.17 12.23 7.73 Favored Glycine 0 N--CA 1.482 1.742 0 N-CA-C 112.191 -0.364 . . . . 0.0 112.191 179.032 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 43.5 p90 -58.91 127.8 34.04 Favored 'General case' 0 CA--C 1.544 0.733 0 N-CA-C 112.107 0.41 . . . . 0.0 112.107 -179.366 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 46.8 mt-10 -88.46 155.16 19.83 Favored 'General case' 0 N--CA 1.476 0.838 0 N-CA-C 109.43 -0.581 . . . . 0.0 109.43 178.12 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -155.3 127.44 1.0 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.557 0 N-CA-C 108.344 -0.984 . . . . 0.0 108.344 178.539 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 48.0 m-70 -135.27 145.3 47.42 Favored 'General case' 0 N--CA 1.483 1.206 0 CA-C-O 120.704 0.287 . . . . 0.0 111.331 -177.826 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 6.3 t60 -164.0 97.53 0.83 Allowed 'General case' 0 N--CA 1.486 1.334 0 CA-C-N 116.752 -0.204 . . . . 0.0 111.048 179.693 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' E' E ' 15' ' ' GLN . . . . . 0.53 HE22 ' H ' ' E' ' 37' ' ' GLY . 55.6 mt-30 -108.35 -172.62 2.09 Favored 'General case' 0 CA--C 1.502 -0.902 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 -179.94 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -166.57 98.2 0.58 Allowed 'General case' 0 CA--C 1.541 0.621 0 CA-C-N 114.992 -1.004 . . . . 0.0 109.453 178.722 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' E' E ' 17' ' ' LEU . . . . . 0.589 ' N ' HD12 ' E' ' 17' ' ' LEU . 4.4 mp -106.14 163.1 13.06 Favored 'General case' 0 N--CA 1.49 1.565 0 N-CA-C 109.239 -0.652 . . . . 0.0 109.239 -179.693 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 42.1 t -142.15 118.14 6.11 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.418 0 C-N-CA 122.558 0.343 . . . . 0.0 110.554 179.158 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 52.8 m-85 -69.17 157.27 37.23 Favored 'General case' 0 C--N 1.356 0.867 0 N-CA-C 107.312 -1.366 . . . . 0.0 107.312 176.582 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 11.5 t80 -173.96 -54.7 0.01 OUTLIER 'General case' 0 N--CA 1.484 1.275 0 CA-C-O 121.717 0.77 . . . . 0.0 110.347 179.469 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.35 88.79 0.0 OUTLIER 'General case' 0 C--N 1.319 -0.751 0 CA-C-N 114.356 -1.293 . . . . 0.0 112.83 -178.974 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 37.4 tt0 -64.48 158.28 24.41 Favored 'General case' 0 N--CA 1.47 0.557 0 CA-C-N 114.944 -1.025 . . . . 0.0 110.681 179.702 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 11.0 m-20 -140.51 138.03 34.26 Favored 'General case' 0 N--CA 1.476 0.833 0 C-N-CA 122.985 0.514 . . . . 0.0 110.483 179.887 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 18.9 t -92.22 -116.79 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.288 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 179.587 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . -102.2 55.13 0.72 Allowed Glycine 0 N--CA 1.473 1.137 0 N-CA-C 111.226 -0.749 . . . . 0.0 111.226 -179.881 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 81.1 p -83.37 124.42 30.63 Favored 'General case' 0 N--CA 1.468 0.443 0 N-CA-C 109.205 -0.665 . . . . 0.0 109.205 177.819 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 62.9 t30 -64.58 101.42 0.46 Allowed 'General case' 0 N--CA 1.474 0.728 0 N-CA-C 108.307 -0.998 . . . . 0.0 108.307 178.725 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 64.3 mttm -98.07 113.32 25.16 Favored 'General case' 0 N--CA 1.488 1.469 0 N-CA-C 109.888 -0.412 . . . . 0.0 109.888 -178.603 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.06 -133.62 0.01 OUTLIER Glycine 0 CA--C 1.533 1.215 0 N-CA-C 111.471 -0.652 . . . . 0.0 111.471 178.894 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -113.19 126.87 55.9 Favored 'General case' 0 N--CA 1.477 0.907 0 N-CA-C 109.265 -0.642 . . . . 0.0 109.265 179.382 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 65.6 mt -90.13 130.24 39.72 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.279 0 N-CA-C 107.104 -1.443 . . . . 0.0 107.104 178.797 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 13.5 mt -142.99 153.42 16.99 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.825 0 N-CA-C 109.069 -0.715 . . . . 0.0 109.069 -179.42 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.71 49.94 65.13 Favored Glycine 0 CA--C 1.524 0.651 0 CA-C-N 116.432 -0.349 . . . . 0.0 113.153 179.022 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 2.9 tt -99.62 120.59 39.92 Favored 'General case' 0 N--CA 1.48 1.03 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 177.599 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 28.1 ttt -152.01 159.18 43.8 Favored 'General case' 0 N--CA 1.477 0.916 0 N-CA-C 108.373 -0.973 . . . . 0.0 108.373 179.578 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 95.7 t -159.49 149.23 6.93 Favored 'Isoleucine or valine' 0 C--O 1.237 0.419 0 N-CA-C 106.605 -1.628 . . . . 0.0 106.605 -179.816 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' E' E ' 37' ' ' GLY . . . . . 0.53 ' H ' HE22 ' E' ' 15' ' ' GLN . . . 57.32 72.19 0.62 Allowed Glycine 0 C--N 1.316 -0.579 0 CA-C-N 115.523 -0.762 . . . . 0.0 111.316 178.155 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 173.72 -155.66 22.45 Favored Glycine 0 C--O 1.219 -0.811 0 N-CA-C 111.123 -0.791 . . . . 0.0 111.123 -179.831 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 33.5 m -126.2 142.59 42.39 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.757 0 N-CA-C 109.203 -0.666 . . . . 0.0 109.203 179.379 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 15.1 t . . . . . 0 CA--C 1.538 0.509 0 CA-C-O 118.109 -0.948 . . . . 0.0 111.218 179.279 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 20.2 m-85 . . . . . 0 N--CA 1.474 0.734 0 CA-C-O 120.941 0.401 . . . . 0.0 109.971 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' F' F ' 5' ' ' ARG . . . . . . . . . . . . . 30.5 mtp180 -67.32 129.98 41.63 Favored 'General case' 0 C--O 1.217 -0.63 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.514 -178.162 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 47.8 m170 -100.43 131.21 46.48 Favored 'General case' 0 N--CA 1.477 0.922 0 N-CA-C 109.572 -0.529 . . . . 0.0 109.572 179.358 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' F' F ' 7' ' ' ASP . . . . . . . . . . . . . 16.6 m-20 -71.37 142.02 50.36 Favored 'General case' 0 N--CA 1.464 0.26 0 O-C-N 123.422 0.451 . . . . 0.0 111.066 -179.786 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' F' F ' 8' ' ' SER . . . . . . . . . . . . . 8.4 t -144.67 -173.13 3.97 Favored 'General case' 0 N--CA 1.478 0.971 0 N-CA-C 108.958 -0.756 . . . . 0.0 108.958 178.002 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 118.6 11.73 7.73 Favored Glycine 0 N--CA 1.482 1.745 0 N-CA-C 112.126 -0.39 . . . . 0.0 112.126 179.072 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 43.4 p90 -58.64 128.22 36.08 Favored 'General case' 0 CA--C 1.544 0.738 0 N-CA-C 112.123 0.416 . . . . 0.0 112.123 -179.31 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 46.8 mt-10 -88.77 155.15 19.74 Favored 'General case' 0 N--CA 1.475 0.817 0 CA-C-O 121.303 0.573 . . . . 0.0 109.585 178.031 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -155.21 127.48 1.02 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.574 0 N-CA-C 108.338 -0.986 . . . . 0.0 108.338 178.505 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 48.0 m-70 -135.32 144.94 46.99 Favored 'General case' 0 N--CA 1.481 1.093 0 CA-C-O 120.681 0.277 . . . . 0.0 111.379 -177.923 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 6.3 t60 -163.78 98.16 0.86 Allowed 'General case' 0 N--CA 1.487 1.406 0 CA-C-N 116.697 -0.229 . . . . 0.0 111.145 179.645 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' F' F ' 15' ' ' GLN . . . . . 0.533 HE22 ' H ' ' F' ' 37' ' ' GLY . 55.8 mt-30 -109.29 -171.97 1.95 Allowed 'General case' 0 CA--C 1.499 -1.015 0 N-CA-C 108.625 -0.88 . . . . 0.0 108.625 -179.911 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -166.84 98.57 0.55 Allowed 'General case' 0 CA--C 1.541 0.609 0 CA-C-N 114.895 -1.048 . . . . 0.0 109.483 178.778 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' F' F ' 17' ' ' LEU . . . . . 0.585 HD12 ' N ' ' F' ' 17' ' ' LEU . 4.4 mp -106.24 163.14 13.05 Favored 'General case' 0 N--CA 1.489 1.501 0 N-CA-C 109.141 -0.689 . . . . 0.0 109.141 -179.717 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 42.0 t -142.17 118.3 6.2 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.369 0 C-N-CA 122.507 0.323 . . . . 0.0 110.522 179.088 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 52.7 m-85 -69.27 157.17 37.51 Favored 'General case' 0 C--N 1.355 0.811 0 N-CA-C 107.151 -1.426 . . . . 0.0 107.151 176.563 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 12.3 t80 -173.75 -54.8 0.01 OUTLIER 'General case' 0 N--CA 1.486 1.344 0 CA-C-O 121.785 0.802 . . . . 0.0 109.752 179.688 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.35 88.68 0.0 OUTLIER 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 114.484 -1.234 . . . . 0.0 113.007 -178.893 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 37.0 tt0 -64.36 158.43 23.61 Favored 'General case' 0 N--CA 1.472 0.668 0 CA-C-N 114.999 -1.001 . . . . 0.0 110.895 179.481 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 11.8 m-20 -140.87 137.67 33.38 Favored 'General case' 0 N--CA 1.477 0.909 0 C-N-CA 122.893 0.477 . . . . 0.0 110.458 179.973 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' F' F ' 24' ' ' VAL . . . . . . . . . . . . . 18.6 t -91.88 -116.83 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.391 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 179.544 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -102.11 55.32 0.72 Allowed Glycine 0 N--CA 1.477 1.41 0 N-CA-C 110.953 -0.859 . . . . 0.0 110.953 -179.863 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 79.8 p -83.54 124.19 30.5 Favored 'General case' 0 N--CA 1.47 0.552 0 N-CA-C 109.012 -0.736 . . . . 0.0 109.012 177.726 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 62.3 t30 -64.44 101.47 0.45 Allowed 'General case' 0 N--CA 1.473 0.71 0 N-CA-C 108.375 -0.972 . . . . 0.0 108.375 178.684 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 64.3 mttm -98.04 113.26 25.08 Favored 'General case' 0 N--CA 1.488 1.46 0 N-CA-C 110.029 -0.36 . . . . 0.0 110.029 -178.648 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.07 -133.84 0.01 OUTLIER Glycine 0 CA--C 1.534 1.266 0 N-CA-C 111.559 -0.616 . . . . 0.0 111.559 178.901 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -112.69 127.17 56.05 Favored 'General case' 0 N--CA 1.477 0.885 0 N-CA-C 109.228 -0.656 . . . . 0.0 109.228 179.241 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 65.7 mt -90.53 130.15 40.22 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.286 0 N-CA-C 107.086 -1.45 . . . . 0.0 107.086 178.703 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 13.1 mt -142.9 153.6 17.18 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.763 0 N-CA-C 109.115 -0.698 . . . . 0.0 109.115 -179.33 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.59 49.73 67.14 Favored Glycine 0 CA--C 1.524 0.609 0 CA-C-N 116.486 -0.325 . . . . 0.0 113.141 179.098 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' F' F ' 34' ' ' LEU . . . . . 0.404 HD23 ' N ' ' F' ' 35' ' ' MET . 3.0 tt -99.48 120.79 40.2 Favored 'General case' 0 N--CA 1.478 0.944 0 N-CA-C 107.344 -1.354 . . . . 0.0 107.344 177.747 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' F' F ' 35' ' ' MET . . . . . 0.404 ' N ' HD23 ' F' ' 34' ' ' LEU . 28.1 ttt -152.68 159.86 43.17 Favored 'General case' 0 N--CA 1.472 0.667 0 N-CA-C 109.146 -0.687 . . . . 0.0 109.146 179.343 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 95.4 t -159.75 149.4 6.6 Favored 'Isoleucine or valine' 0 C--O 1.237 0.429 0 N-CA-C 106.907 -1.516 . . . . 0.0 106.907 -179.586 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' F' F ' 37' ' ' GLY . . . . . 0.533 ' H ' HE22 ' F' ' 15' ' ' GLN . . . 57.26 72.68 0.55 Allowed Glycine 0 C--N 1.315 -0.596 0 CA-C-N 115.548 -0.751 . . . . 0.0 111.268 178.195 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 173.44 -155.29 22.04 Favored Glycine 0 C--O 1.219 -0.841 0 N-CA-C 111.119 -0.792 . . . . 0.0 111.119 -179.795 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 33.4 m -126.62 142.5 42.98 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.777 0 N-CA-C 109.206 -0.664 . . . . 0.0 109.206 179.372 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 15.3 t . . . . . 0 CA--C 1.539 0.521 0 CA-C-O 118.0 -1.0 . . . . 0.0 111.301 179.306 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 26.7 m-85 . . . . . 0 N--CA 1.473 0.695 0 CA-C-O 120.849 0.357 . . . . 0.0 110.226 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' G' G ' 5' ' ' ARG . . . . . . . . . . . . . 31.5 mtp180 -66.59 129.44 39.87 Favored 'General case' 0 N--CA 1.47 0.543 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.178 -178.297 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 47.1 m170 -99.96 131.04 46.16 Favored 'General case' 0 N--CA 1.474 0.764 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 179.449 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 16.9 m-20 -72.21 137.85 47.15 Favored 'General case' 0 N--CA 1.466 0.358 0 O-C-N 123.638 0.586 . . . . 0.0 111.418 -179.488 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' G' G ' 8' ' ' SER . . . . . . . . . . . . . 8.0 t -142.16 -173.06 3.72 Favored 'General case' 0 N--CA 1.477 0.9 0 N-CA-C 109.114 -0.699 . . . . 0.0 109.114 178.038 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 119.13 12.97 6.66 Favored Glycine 0 N--CA 1.481 1.67 0 N-CA-C 111.725 -0.55 . . . . 0.0 111.725 179.075 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 47.4 p90 -59.52 128.25 36.09 Favored 'General case' 0 CA--C 1.541 0.604 0 N-CA-C 112.002 0.371 . . . . 0.0 112.002 -179.227 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 46.6 mt-10 -89.13 154.5 20.11 Favored 'General case' 0 N--CA 1.474 0.741 0 CA-C-O 121.208 0.528 . . . . 0.0 109.914 178.685 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 2.7 p -155.99 127.17 0.89 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.039 0 N-CA-C 108.334 -0.988 . . . . 0.0 108.334 178.765 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 51.4 m-70 -134.06 146.44 50.32 Favored 'General case' 0 N--CA 1.476 0.855 0 CA-C-N 115.289 -0.869 . . . . 0.0 110.997 -177.98 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 6.3 t60 -165.41 97.47 0.69 Allowed 'General case' 0 N--CA 1.483 1.181 0 CA-C-N 116.542 -0.299 . . . . 0.0 110.691 179.064 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' G' G ' 15' ' ' GLN . . . . . 0.55 HE22 ' H ' ' G' ' 37' ' ' GLY . 55.6 mt-30 -108.62 -172.6 2.09 Favored 'General case' 0 CA--C 1.501 -0.928 0 N-CA-C 108.574 -0.898 . . . . 0.0 108.574 -179.787 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' G' G ' 16' ' ' LYS . . . . . 0.406 ' C ' HD12 ' G' ' 17' ' ' LEU . 88.5 tttt -166.47 98.69 0.59 Allowed 'General case' 0 CA--C 1.541 0.606 0 CA-C-N 115.018 -0.992 . . . . 0.0 109.383 178.714 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' G' G ' 17' ' ' LEU . . . . . 0.587 ' N ' HD12 ' G' ' 17' ' ' LEU . 5.1 mp -106.14 161.79 14.2 Favored 'General case' 0 N--CA 1.487 1.383 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 -179.581 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 40.8 t -142.53 118.74 5.83 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.052 0 CA-C-O 120.766 0.317 . . . . 0.0 110.449 178.724 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 45.8 m-85 -69.71 151.12 46.21 Favored 'General case' 0 C--N 1.369 1.417 0 N-CA-C 107.303 -1.369 . . . . 0.0 107.303 176.761 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 10.3 t80 -171.16 -55.1 0.02 OUTLIER 'General case' 0 N--CA 1.486 1.369 0 CA-C-N 118.006 0.367 . . . . 0.0 110.333 -179.662 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.65 90.25 0.0 OUTLIER 'General case' 0 C--N 1.326 -0.428 0 C-N-CA 123.716 0.807 . . . . 0.0 112.582 -179.819 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 37.1 tt0 -65.2 159.39 23.72 Favored 'General case' 0 N--CA 1.469 0.488 0 CA-C-N 114.669 -1.151 . . . . 0.0 110.086 179.076 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 12.0 m-20 -141.45 137.2 32.0 Favored 'General case' 0 N--CA 1.476 0.842 0 C-N-CA 122.905 0.482 . . . . 0.0 109.986 179.927 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' G' G ' 24' ' ' VAL . . . . . . . . . . . . . 15.8 t -92.31 -116.63 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.106 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 179.682 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -101.93 54.35 0.77 Allowed Glycine 0 N--CA 1.476 1.366 0 N-CA-C 111.581 -0.608 . . . . 0.0 111.581 -179.725 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 80.0 p -82.72 124.34 30.14 Favored 'General case' 0 N--CA 1.469 0.501 0 N-CA-C 108.952 -0.758 . . . . 0.0 108.952 177.864 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 59.1 t30 -64.77 101.35 0.47 Allowed 'General case' 0 N--CA 1.471 0.594 0 N-CA-C 108.585 -0.894 . . . . 0.0 108.585 178.586 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 64.7 mttm -97.32 114.43 26.2 Favored 'General case' 0 N--CA 1.486 1.373 0 N-CA-C 109.891 -0.411 . . . . 0.0 109.891 -178.955 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.69 -132.45 0.01 OUTLIER Glycine 0 CA--C 1.532 1.144 0 N-CA-C 110.767 -0.933 . . . . 0.0 110.767 179.045 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -112.81 126.24 55.22 Favored 'General case' 0 N--CA 1.469 0.508 0 C-N-CA 123.006 0.522 . . . . 0.0 109.661 179.602 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 68.7 mt -89.66 130.7 38.53 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.776 0 N-CA-C 107.263 -1.384 . . . . 0.0 107.263 178.555 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 15.9 mt -143.92 154.35 15.74 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.346 0 CA-C-N 118.945 0.793 . . . . 0.0 108.982 -179.91 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.8 49.02 71.24 Favored Glycine 0 CA--C 1.527 0.811 0 C-N-CA 121.803 -0.237 . . . . 0.0 112.75 179.155 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' G' G ' 34' ' ' LEU . . . . . 0.414 HD23 ' N ' ' G' ' 35' ' ' MET . 2.9 tt -98.93 121.96 41.57 Favored 'General case' 0 N--CA 1.479 0.982 0 N-CA-C 106.953 -1.499 . . . . 0.0 106.953 177.723 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' G' G ' 35' ' ' MET . . . . . 0.414 ' N ' HD23 ' G' ' 34' ' ' LEU . 28.2 ttt -153.76 159.83 42.07 Favored 'General case' 0 N--CA 1.48 1.048 0 N-CA-C 107.999 -1.111 . . . . 0.0 107.999 179.661 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 88.6 t -159.58 149.65 6.71 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 N-CA-C 106.231 -1.766 . . . . 0.0 106.231 -179.735 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' G' G ' 37' ' ' GLY . . . . . 0.55 ' H ' HE22 ' G' ' 15' ' ' GLN . . . 57.01 72.75 0.53 Allowed Glycine 0 C--N 1.314 -0.66 0 C-N-CA 121.055 -0.593 . . . . 0.0 111.781 177.921 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 172.15 -154.08 20.75 Favored Glycine 0 C--O 1.219 -0.838 0 N-CA-C 110.517 -1.033 . . . . 0.0 110.517 179.223 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 34.0 m -127.0 142.91 42.13 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.009 0 CA-C-N 117.041 0.421 . . . . 0.0 109.963 179.951 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 15.6 t . . . . . 0 N--CA 1.466 0.363 0 CA-C-O 118.193 -0.908 . . . . 0.0 111.382 179.631 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 26.2 m-85 . . . . . 0 N--CA 1.474 0.735 0 CA-C-O 120.912 0.387 . . . . 0.0 110.171 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' H' H ' 5' ' ' ARG . . . . . . . . . . . . . 31.0 mtp180 -66.46 129.43 39.81 Favored 'General case' 0 N--CA 1.469 0.477 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.309 -178.254 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 46.2 m170 -100.0 131.17 46.12 Favored 'General case' 0 N--CA 1.474 0.773 0 N-CA-C 109.648 -0.501 . . . . 0.0 109.648 179.4 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 16.3 m-20 -72.42 137.7 46.66 Favored 'General case' 0 N--CA 1.466 0.35 0 O-C-N 123.526 0.517 . . . . 0.0 111.361 -179.484 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' H' H ' 8' ' ' SER . . . . . . . . . . . . . 8.4 t -141.86 -173.61 3.85 Favored 'General case' 0 N--CA 1.475 0.807 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 178.282 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 119.35 12.73 6.67 Favored Glycine 0 N--CA 1.484 1.888 0 N-CA-C 111.802 -0.519 . . . . 0.0 111.802 179.061 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 46.8 p90 -59.33 128.17 35.76 Favored 'General case' 0 CA--C 1.542 0.651 0 N-CA-C 112.042 0.386 . . . . 0.0 112.042 -179.338 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 46.6 mt-10 -88.96 154.34 20.3 Favored 'General case' 0 N--CA 1.475 0.78 0 CA-C-O 121.22 0.533 . . . . 0.0 109.892 178.694 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.7 p -155.77 127.2 0.92 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.009 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 178.712 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 50.8 m-70 -134.08 146.18 50.06 Favored 'General case' 0 N--CA 1.476 0.863 0 CA-C-N 115.313 -0.858 . . . . 0.0 111.203 -178.045 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 6.4 t60 -165.08 97.58 0.73 Allowed 'General case' 0 N--CA 1.483 1.197 0 CA-C-N 116.583 -0.28 . . . . 0.0 110.716 179.039 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' H' H ' 15' ' ' GLN . . . . . 0.551 HE22 ' H ' ' H' ' 37' ' ' GLY . 55.3 mt-30 -108.57 -173.2 2.21 Favored 'General case' 0 CA--C 1.5 -0.966 0 N-CA-C 108.45 -0.945 . . . . 0.0 108.45 -179.787 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -166.12 98.39 0.63 Allowed 'General case' 0 N--CA 1.471 0.578 0 CA-C-N 114.984 -1.007 . . . . 0.0 109.341 178.727 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' H' H ' 17' ' ' LEU . . . . . 0.588 HD12 ' N ' ' H' ' 17' ' ' LEU . 5.1 mp -106.08 161.93 14.06 Favored 'General case' 0 N--CA 1.487 1.401 0 N-CA-C 109.394 -0.595 . . . . 0.0 109.394 -179.517 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 40.8 t -142.53 118.55 5.69 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.143 0 CA-C-O 120.775 0.321 . . . . 0.0 110.455 178.885 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 47.4 m-85 -69.85 151.44 45.71 Favored 'General case' 0 C--N 1.368 1.399 0 N-CA-C 107.334 -1.358 . . . . 0.0 107.334 176.59 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 10.9 t80 -172.37 -54.55 0.02 OUTLIER 'General case' 0 N--CA 1.484 1.246 0 CA-C-N 117.909 0.322 . . . . 0.0 110.21 -179.542 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.71 90.69 0.0 OUTLIER 'General case' 0 CA--C 1.534 0.356 0 C-N-CA 123.732 0.813 . . . . 0.0 112.298 -179.979 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 37.4 tt0 -65.74 159.29 25.45 Favored 'General case' 0 N--CA 1.47 0.537 0 CA-C-N 114.776 -1.102 . . . . 0.0 110.003 179.364 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 11.3 m-20 -141.29 137.55 32.54 Favored 'General case' 0 N--CA 1.476 0.837 0 C-N-CA 122.892 0.477 . . . . 0.0 109.919 179.861 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' H' H ' 24' ' ' VAL . . . . . . . . . . . . . 15.4 t -92.6 -116.94 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.09 0 N-CA-C 108.673 -0.862 . . . . 0.0 108.673 179.683 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . -101.48 54.25 0.8 Allowed Glycine 0 N--CA 1.479 1.538 0 N-CA-C 111.506 -0.638 . . . . 0.0 111.506 -179.742 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 80.3 p -82.85 124.54 30.41 Favored 'General case' 0 N--CA 1.469 0.497 0 N-CA-C 108.901 -0.778 . . . . 0.0 108.901 177.939 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 59.5 t30 -64.93 101.43 0.5 Allowed 'General case' 0 N--CA 1.472 0.664 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 178.679 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 65.1 mttm -97.33 114.11 25.84 Favored 'General case' 0 N--CA 1.485 1.321 0 N-CA-C 109.978 -0.378 . . . . 0.0 109.978 -179.021 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.42 -132.6 0.01 OUTLIER Glycine 0 CA--C 1.534 1.245 0 N-CA-C 110.845 -0.902 . . . . 0.0 110.845 179.053 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -112.72 126.28 55.24 Favored 'General case' 0 N--CA 1.471 0.603 0 C-N-CA 123.028 0.531 . . . . 0.0 109.662 179.59 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 68.0 mt -89.71 130.59 38.77 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.761 0 N-CA-C 107.35 -1.352 . . . . 0.0 107.35 178.506 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 16.3 mt -143.97 154.04 15.68 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.367 0 CA-C-N 118.922 0.783 . . . . 0.0 108.972 -179.74 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 64.09 49.01 69.75 Favored Glycine 0 CA--C 1.526 0.768 0 C-N-CA 121.717 -0.277 . . . . 0.0 112.81 179.184 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' H' H ' 34' ' ' LEU . . . . . 0.407 HD23 ' N ' ' H' ' 35' ' ' MET . 2.8 tt -99.02 121.66 41.26 Favored 'General case' 0 N--CA 1.477 0.914 0 N-CA-C 107.035 -1.469 . . . . 0.0 107.035 177.782 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' H' H ' 35' ' ' MET . . . . . 0.407 ' N ' HD23 ' H' ' 34' ' ' LEU . 28.2 ttt -153.4 159.75 42.47 Favored 'General case' 0 N--CA 1.48 1.036 0 N-CA-C 107.991 -1.115 . . . . 0.0 107.991 179.665 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 91.1 t -159.51 149.83 6.73 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 N-CA-C 106.278 -1.749 . . . . 0.0 106.278 -179.775 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' H' H ' 37' ' ' GLY . . . . . 0.551 ' H ' HE22 ' H' ' 15' ' ' GLN . . . 56.67 73.13 0.47 Allowed Glycine 0 C--N 1.313 -0.741 0 C-N-CA 120.982 -0.628 . . . . 0.0 111.727 178.117 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 171.65 -154.73 22.65 Favored Glycine 0 N--CA 1.468 0.806 0 N-CA-C 110.505 -1.038 . . . . 0.0 110.505 179.358 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 33.8 m -126.53 143.16 40.94 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.081 0 C-N-CA 122.663 0.385 . . . . 0.0 109.998 179.975 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 15.3 t . . . . . 0 N--CA 1.467 0.414 0 CA-C-O 118.137 -0.935 . . . . 0.0 111.293 179.544 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 25.9 m-85 . . . . . 0 N--CA 1.472 0.666 0 CA-C-O 120.843 0.354 . . . . 0.0 110.168 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' I' I ' 5' ' ' ARG . . . . . . . . . . . . . 31.0 mtp180 -66.72 129.13 38.85 Favored 'General case' 0 N--CA 1.471 0.625 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.293 -178.281 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 46.2 m170 -99.72 130.97 45.98 Favored 'General case' 0 N--CA 1.474 0.768 0 N-CA-C 109.607 -0.516 . . . . 0.0 109.607 179.42 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 16.2 m-20 -72.05 138.02 47.57 Favored 'General case' 0 N--CA 1.466 0.336 0 O-C-N 123.539 0.525 . . . . 0.0 111.425 -179.546 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' I' I ' 8' ' ' SER . . . . . . . . . . . . . 8.5 t -142.26 -173.8 3.94 Favored 'General case' 0 N--CA 1.475 0.791 0 N-CA-C 109.078 -0.712 . . . . 0.0 109.078 178.388 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 119.46 12.66 6.65 Favored Glycine 0 N--CA 1.482 1.759 0 N-CA-C 111.864 -0.494 . . . . 0.0 111.864 179.185 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 47.5 p90 -59.15 128.38 36.86 Favored 'General case' 0 CA--C 1.541 0.625 0 N-CA-C 112.082 0.401 . . . . 0.0 112.082 -179.378 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 46.5 mt-10 -89.28 154.33 20.19 Favored 'General case' 0 N--CA 1.474 0.737 0 CA-C-O 121.101 0.477 . . . . 0.0 109.956 178.672 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 2.7 p -155.73 127.32 0.94 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.039 0 N-CA-C 108.373 -0.973 . . . . 0.0 108.373 178.722 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 50.2 m-70 -134.23 146.29 49.96 Favored 'General case' 0 N--CA 1.476 0.868 0 CA-C-N 115.276 -0.875 . . . . 0.0 111.145 -178.044 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 6.4 t60 -165.35 97.51 0.7 Allowed 'General case' 0 N--CA 1.484 1.244 0 CA-C-N 116.558 -0.292 . . . . 0.0 110.719 179.069 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' I' I ' 15' ' ' GLN . . . . . 0.556 HE22 ' H ' ' I' ' 37' ' ' GLY . 55.3 mt-30 -108.57 -172.75 2.12 Favored 'General case' 0 CA--C 1.499 -1.002 0 N-CA-C 108.458 -0.941 . . . . 0.0 108.458 -179.737 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' I' I ' 16' ' ' LYS . . . . . 0.403 ' C ' HD12 ' I' ' 17' ' ' LEU . 88.4 tttt -166.48 98.45 0.59 Allowed 'General case' 0 CA--C 1.54 0.565 0 CA-C-N 114.921 -1.036 . . . . 0.0 109.29 178.803 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' I' I ' 17' ' ' LEU . . . . . 0.589 HD12 ' N ' ' I' ' 17' ' ' LEU . 5.1 mp -105.97 161.99 13.98 Favored 'General case' 0 N--CA 1.486 1.355 0 N-CA-C 109.448 -0.575 . . . . 0.0 109.448 -179.628 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 40.6 t -142.58 118.5 5.56 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.154 0 C-N-CA 122.494 0.318 . . . . 0.0 110.487 178.849 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 46.7 m-85 -69.92 151.34 45.76 Favored 'General case' 0 C--N 1.367 1.365 0 N-CA-C 107.31 -1.367 . . . . 0.0 107.31 176.712 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 10.9 t80 -172.17 -54.67 0.02 OUTLIER 'General case' 0 N--CA 1.485 1.296 0 CA-C-N 117.843 0.292 . . . . 0.0 110.218 -179.518 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.69 90.72 0.0 OUTLIER 'General case' 0 CA--C 1.536 0.408 0 C-N-CA 123.7 0.8 . . . . 0.0 112.251 -179.936 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 37.5 tt0 -65.69 159.31 25.26 Favored 'General case' 0 N--CA 1.47 0.549 0 CA-C-N 114.751 -1.113 . . . . 0.0 109.993 179.326 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 11.1 m-20 -141.34 137.5 32.42 Favored 'General case' 0 N--CA 1.476 0.836 0 C-N-CA 122.872 0.469 . . . . 0.0 110.034 179.839 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' I' I ' 24' ' ' VAL . . . . . . . . . . . . . 14.9 t -92.68 -116.77 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.112 0 N-CA-C 108.691 -0.855 . . . . 0.0 108.691 179.729 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . -101.51 54.45 0.79 Allowed Glycine 0 N--CA 1.476 1.357 0 CA-C-N 118.556 0.617 . . . . 0.0 111.585 -179.759 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 80.4 p -83.31 123.96 30.14 Favored 'General case' 0 N--CA 1.469 0.5 0 N-CA-C 108.916 -0.772 . . . . 0.0 108.916 178.059 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 59.7 t30 -64.53 101.63 0.47 Allowed 'General case' 0 N--CA 1.473 0.681 0 N-CA-C 108.588 -0.893 . . . . 0.0 108.588 178.618 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 64.7 mttm -97.57 114.28 26.16 Favored 'General case' 0 N--CA 1.486 1.354 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -178.952 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.45 -132.63 0.01 OUTLIER Glycine 0 CA--C 1.532 1.137 0 N-CA-C 110.803 -0.919 . . . . 0.0 110.803 179.093 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -112.73 126.09 55.02 Favored 'General case' 0 N--CA 1.471 0.586 0 C-N-CA 123.058 0.543 . . . . 0.0 109.614 179.601 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 68.3 mt -89.68 130.75 38.47 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.783 0 N-CA-C 107.264 -1.384 . . . . 0.0 107.264 178.61 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 16.2 mt -143.98 154.47 15.65 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.337 0 CA-C-N 118.892 0.769 . . . . 0.0 108.984 -179.807 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.75 48.84 73.19 Favored Glycine 0 CA--C 1.526 0.775 0 C-N-CA 121.678 -0.296 . . . . 0.0 112.792 179.134 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' I' I ' 34' ' ' LEU . . . . . 0.409 HD23 ' N ' ' I' ' 35' ' ' MET . 2.9 tt -98.84 121.94 41.43 Favored 'General case' 0 N--CA 1.478 0.947 0 N-CA-C 106.874 -1.528 . . . . 0.0 106.874 177.741 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' I' I ' 35' ' ' MET . . . . . 0.409 ' N ' HD23 ' I' ' 34' ' ' LEU . 28.2 ttt -153.53 159.72 42.3 Favored 'General case' 0 N--CA 1.478 0.963 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 179.616 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 90.9 t -159.54 149.75 6.73 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.224 0 N-CA-C 106.253 -1.758 . . . . 0.0 106.253 -179.804 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' I' I ' 37' ' ' GLY . . . . . 0.556 ' H ' HE22 ' I' ' 15' ' ' GLN . . . 56.94 72.79 0.53 Allowed Glycine 0 C--N 1.314 -0.69 0 C-N-CA 121.022 -0.609 . . . . 0.0 111.778 178.011 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 171.95 -154.4 21.66 Favored Glycine 0 N--CA 1.468 0.767 0 N-CA-C 110.529 -1.029 . . . . 0.0 110.529 179.257 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 33.8 m -126.61 142.84 42.0 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.064 0 C-N-CA 122.743 0.417 . . . . 0.0 109.994 179.943 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 15.5 t . . . . . 0 N--CA 1.465 0.306 0 CA-C-O 118.239 -0.886 . . . . 0.0 111.328 179.539 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 78.9 m-85 . . . . . 0 N--CA 1.475 0.818 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 71.9 mtp180 -143.84 141.28 30.26 Favored 'General case' 0 N--CA 1.481 1.102 0 N-CA-C 109.079 -0.712 . . . . 0.0 109.079 -179.879 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 76.7 m80 -149.53 119.92 7.37 Favored 'General case' 0 N--CA 1.469 0.502 0 N-CA-C 108.79 -0.819 . . . . 0.0 108.79 179.147 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 8.5 m-20 -68.02 149.95 49.06 Favored 'General case' 0 CA--C 1.53 0.196 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.16 -179.391 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 7.6 t -167.13 171.36 11.0 Favored 'General case' 0 N--CA 1.472 0.655 0 N-CA-C 109.551 -0.537 . . . . 0.0 109.551 178.581 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.48 23.65 2.31 Favored Glycine 0 N--CA 1.488 2.156 0 N-CA-C 112.209 -0.356 . . . . 0.0 112.209 179.37 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 42.8 p90 -56.64 128.37 36.02 Favored 'General case' 0 N--CA 1.475 0.815 0 N-CA-C 112.078 0.399 . . . . 0.0 112.078 -179.83 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . 0.506 ' CG ' HD21 ' C' ' 27' ' ' ASN . 45.5 mt-10 -85.05 154.66 21.94 Favored 'General case' 0 C--N 1.344 0.358 0 N-CA-C 109.08 -0.711 . . . . 0.0 109.08 178.535 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -153.69 129.5 1.72 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.371 0 N-CA-C 108.151 -1.055 . . . . 0.0 108.151 178.928 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 48.6 m-70 -134.93 144.99 47.77 Favored 'General case' 0 N--CA 1.489 1.49 0 CA-C-N 118.683 0.674 . . . . 0.0 111.104 -179.116 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -165.9 98.31 0.65 Allowed 'General case' 0 N--CA 1.482 1.169 0 CA-C-N 116.603 -0.271 . . . . 0.0 110.984 179.628 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . 0.548 HE22 ' H ' ' A' ' 37' ' ' GLY . 61.7 mt-30 -108.54 -172.05 1.98 Allowed 'General case' 0 CA--C 1.503 -0.831 0 N-CA-C 108.174 -1.047 . . . . 0.0 108.174 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -165.96 97.24 0.63 Allowed 'General case' 0 N--CA 1.471 0.613 0 CA-C-N 115.16 -0.927 . . . . 0.0 109.348 178.739 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.585 HD12 ' N ' ' A' ' 17' ' ' LEU . 4.7 mp -106.03 164.18 12.18 Favored 'General case' 0 N--CA 1.488 1.474 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 179.931 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 49.9 t -141.71 119.18 8.07 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.339 0 CA-C-O 118.888 -0.577 . . . . 0.0 109.98 179.657 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 50.9 m-85 -69.95 159.23 34.13 Favored 'General case' 0 N--CA 1.48 1.071 0 N-CA-C 107.573 -1.269 . . . . 0.0 107.573 177.287 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 12.9 t80 -171.44 -58.02 0.02 OUTLIER 'General case' 0 N--CA 1.485 1.305 0 CA-C-O 122.33 1.062 . . . . 0.0 109.772 179.481 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -38.83 90.48 0.0 OUTLIER 'General case' 0 C--O 1.232 0.165 0 CA-C-N 113.888 -1.505 . . . . 0.0 112.866 -177.929 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 54.4 tt0 -67.57 157.93 33.23 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 115.006 -0.997 . . . . 0.0 110.532 179.145 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 67.3 m-20 -140.02 137.72 34.87 Favored 'General case' 0 N--CA 1.481 1.112 0 C-N-CA 122.891 0.476 . . . . 0.0 110.339 179.762 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 17.2 t -84.42 -116.44 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.912 0 N-CA-C 108.51 -0.922 . . . . 0.0 108.51 179.541 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -110.67 54.5 0.54 Allowed Glycine 0 N--CA 1.473 1.137 0 N-CA-C 111.21 -0.756 . . . . 0.0 111.21 -179.935 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 70.5 p -80.12 126.24 30.83 Favored 'General case' 0 C--O 1.221 -0.434 0 N-CA-C 108.983 -0.747 . . . . 0.0 108.983 178.422 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . 0.52 HD21 ' CG ' ' B' ' 11' ' ' GLU . 50.0 t30 -66.91 100.01 0.69 Allowed 'General case' 0 N--CA 1.472 0.644 0 N-CA-C 108.693 -0.854 . . . . 0.0 108.693 178.582 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 66.7 mttm -96.42 120.13 36.16 Favored 'General case' 0 N--CA 1.484 1.243 0 N-CA-C 110.087 -0.338 . . . . 0.0 110.087 -179.081 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.78 -126.36 0.01 OUTLIER Glycine 0 CA--C 1.532 1.154 0 N-CA-C 110.488 -1.045 . . . . 0.0 110.488 178.615 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -127.48 133.83 49.85 Favored 'General case' 0 N--CA 1.479 1.0 0 N-CA-C 109.294 -0.632 . . . . 0.0 109.294 179.112 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 66.9 mt -83.22 138.61 19.01 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.589 0 N-CA-C 107.136 -1.431 . . . . 0.0 107.136 178.54 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 18.7 mt -128.59 128.75 68.29 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.961 0 O-C-N 123.504 0.503 . . . . 0.0 110.123 -178.547 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 60.78 79.25 0.12 Allowed Glycine 0 CA--C 1.527 0.837 0 CA-C-N 116.003 -0.544 . . . . 0.0 112.95 178.898 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.402 HD23 ' N ' ' A' ' 35' ' ' MET . 2.0 tt -110.94 118.85 37.2 Favored 'General case' 0 N--CA 1.478 0.926 0 N-CA-C 106.932 -1.507 . . . . 0.0 106.932 177.432 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' MET . . . . . 0.402 ' N ' HD23 ' A' ' 34' ' ' LEU . 8.8 ttt -155.04 161.02 41.45 Favored 'General case' 0 N--CA 1.469 0.504 0 N-CA-C 109.077 -0.712 . . . . 0.0 109.077 179.339 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 93.6 t -157.96 150.73 8.14 Favored 'Isoleucine or valine' 0 C--O 1.234 0.277 0 N-CA-C 106.83 -1.545 . . . . 0.0 106.83 -179.598 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . 0.548 ' H ' HE22 ' A' ' 15' ' ' GLN . . . 55.6 75.17 0.25 Allowed Glycine 0 C--N 1.314 -0.689 0 CA-C-N 115.703 -0.68 . . . . 0.0 111.739 178.332 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 168.83 -148.72 12.65 Favored Glycine 0 CA--C 1.519 0.305 0 N-CA-C 110.692 -0.963 . . . . 0.0 110.692 179.742 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 21.1 m -132.9 142.47 42.2 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.887 0 N-CA-C 109.624 -0.509 . . . . 0.0 109.624 179.82 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 21.3 t . . . . . 0 N--CA 1.468 0.43 0 CA-C-O 117.851 -1.071 . . . . 0.0 110.725 179.225 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 79.8 m-85 . . . . . 0 N--CA 1.474 0.766 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 71.7 mtp180 -143.94 141.39 30.19 Favored 'General case' 0 N--CA 1.481 1.079 0 N-CA-C 109.136 -0.69 . . . . 0.0 109.136 -179.861 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 76.9 m80 -149.66 120.01 7.36 Favored 'General case' 0 N--CA 1.471 0.581 0 N-CA-C 108.772 -0.825 . . . . 0.0 108.772 179.117 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 7' ' ' ASP . . . . . . . . . . . . . 8.5 m-20 -67.96 149.45 49.75 Favored 'General case' 0 CA--C 1.531 0.217 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.226 -179.414 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 8' ' ' SER . . . . . . . . . . . . . 7.4 t -166.71 171.57 11.4 Favored 'General case' 0 N--CA 1.473 0.691 0 N-CA-C 109.583 -0.525 . . . . 0.0 109.583 178.501 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.26 23.94 2.31 Favored Glycine 0 N--CA 1.488 2.135 0 N-CA-C 112.122 -0.391 . . . . 0.0 112.122 179.425 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 42.4 p90 -56.9 128.11 35.18 Favored 'General case' 0 N--CA 1.473 0.681 0 N-CA-C 112.159 0.429 . . . . 0.0 112.159 -179.864 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 11' ' ' GLU . . . . . 0.52 ' CG ' HD21 ' A' ' 27' ' ' ASN . 45.5 mt-10 -84.79 154.61 22.26 Favored 'General case' 0 N--CA 1.469 0.486 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 178.532 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -153.59 129.32 1.69 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.333 0 N-CA-C 108.268 -1.012 . . . . 0.0 108.268 178.914 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 48.6 m-70 -134.82 145.16 48.08 Favored 'General case' 0 N--CA 1.49 1.559 0 CA-C-N 118.556 0.616 . . . . 0.0 111.052 -179.062 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -166.11 98.33 0.63 Allowed 'General case' 0 N--CA 1.483 1.214 0 CA-C-N 116.607 -0.269 . . . . 0.0 110.96 179.654 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . 0.554 HE22 ' H ' ' B' ' 37' ' ' GLY . 61.9 mt-30 -108.56 -172.2 2.01 Favored 'General case' 0 CA--C 1.503 -0.854 0 N-CA-C 108.201 -1.037 . . . . 0.0 108.201 -179.901 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -165.95 96.95 0.63 Allowed 'General case' 0 CA--C 1.54 0.581 0 CA-C-N 115.121 -0.945 . . . . 0.0 109.337 178.817 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . 0.579 ' N ' HD12 ' B' ' 17' ' ' LEU . 4.9 mp -105.88 164.14 12.18 Favored 'General case' 0 N--CA 1.487 1.398 0 N-CA-C 108.611 -0.885 . . . . 0.0 108.611 179.868 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 53.9 t -141.69 119.16 8.08 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.269 0 CA-C-O 118.939 -0.553 . . . . 0.0 109.982 179.577 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 51.6 m-85 -70.41 159.3 34.45 Favored 'General case' 0 N--CA 1.479 0.983 0 N-CA-C 107.557 -1.275 . . . . 0.0 107.557 177.248 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 13.9 t80 -172.14 -57.25 0.02 OUTLIER 'General case' 0 N--CA 1.483 1.211 0 CA-C-O 122.2 1.0 . . . . 0.0 109.792 179.522 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -38.88 90.83 0.0 OUTLIER 'General case' 0 CA--C 1.529 0.159 0 CA-C-N 114.136 -1.393 . . . . 0.0 112.797 -178.005 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 54.2 tt0 -67.93 157.71 34.39 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 115.028 -0.987 . . . . 0.0 110.547 179.314 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 67.3 m-20 -139.86 137.75 35.16 Favored 'General case' 0 N--CA 1.481 1.082 0 C-N-CA 122.954 0.502 . . . . 0.0 110.287 179.71 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 18.1 t -84.66 -116.4 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.988 0 N-CA-C 108.577 -0.897 . . . . 0.0 108.577 179.665 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -110.13 54.37 0.55 Allowed Glycine 0 C--N 1.349 1.253 0 N-CA-C 111.167 -0.773 . . . . 0.0 111.167 -179.951 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 73.1 p -80.39 125.91 30.51 Favored 'General case' 0 C--O 1.221 -0.432 0 N-CA-C 109.037 -0.727 . . . . 0.0 109.037 178.434 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 27' ' ' ASN . . . . . 0.534 HD21 ' CG ' ' C' ' 11' ' ' GLU . 50.4 t30 -66.73 100.41 0.7 Allowed 'General case' 0 N--CA 1.473 0.708 0 N-CA-C 108.657 -0.868 . . . . 0.0 108.657 178.613 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 66.7 mttm -96.81 120.04 36.41 Favored 'General case' 0 N--CA 1.483 1.205 0 N-CA-C 110.132 -0.321 . . . . 0.0 110.132 -179.035 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.57 -126.04 0.01 OUTLIER Glycine 0 CA--C 1.534 1.28 0 N-CA-C 110.453 -1.059 . . . . 0.0 110.453 178.618 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.13 133.75 49.02 Favored 'General case' 0 N--CA 1.48 1.026 0 N-CA-C 109.269 -0.641 . . . . 0.0 109.269 179.185 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 67.0 mt -83.15 138.6 19.04 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.476 0 N-CA-C 107.204 -1.406 . . . . 0.0 107.204 178.535 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 19.1 mt -128.53 128.42 68.02 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.928 0 O-C-N 123.537 0.523 . . . . 0.0 110.21 -178.412 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 60.96 78.98 0.13 Allowed Glycine 0 CA--C 1.526 0.777 0 CA-C-N 116.016 -0.538 . . . . 0.0 112.955 178.848 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 34' ' ' LEU . . . . . 0.401 HD23 ' N ' ' B' ' 35' ' ' MET . 2.0 tt -110.71 118.88 37.38 Favored 'General case' 0 N--CA 1.476 0.869 0 N-CA-C 106.94 -1.504 . . . . 0.0 106.94 177.386 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 35' ' ' MET . . . . . 0.401 ' N ' HD23 ' B' ' 34' ' ' LEU . 8.8 ttt -155.0 161.05 41.48 Favored 'General case' 0 N--CA 1.47 0.552 0 N-CA-C 109.096 -0.705 . . . . 0.0 109.096 179.247 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 92.9 t -158.04 150.73 8.06 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.192 0 N-CA-C 106.744 -1.576 . . . . 0.0 106.744 -179.555 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . 0.554 ' H ' HE22 ' B' ' 15' ' ' GLN . . . 55.44 75.31 0.25 Allowed Glycine 0 C--N 1.314 -0.654 0 CA-C-N 115.628 -0.714 . . . . 0.0 111.797 178.422 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 168.57 -149.14 13.4 Favored Glycine 0 CA--C 1.519 0.292 0 N-CA-C 110.686 -0.966 . . . . 0.0 110.686 179.76 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 21.5 m -132.36 142.7 41.97 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.834 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 179.65 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 21.3 t . . . . . 0 N--CA 1.467 0.41 0 CA-C-O 117.789 -1.101 . . . . 0.0 110.765 179.309 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 78.6 m-85 . . . . . 0 N--CA 1.475 0.797 0 N-CA-C 109.878 -0.416 . . . . 0.0 109.878 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 71.9 mtp180 -143.76 141.36 30.4 Favored 'General case' 0 N--CA 1.482 1.131 0 N-CA-C 109.077 -0.712 . . . . 0.0 109.077 -179.905 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 76.8 m80 -149.63 119.76 7.24 Favored 'General case' 0 N--CA 1.469 0.523 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 179.145 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 7' ' ' ASP . . . . . . . . . . . . . 8.2 m-20 -67.7 149.55 49.85 Favored 'General case' 0 N--CA 1.463 0.199 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.227 -179.41 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 8' ' ' SER . . . . . . . . . . . . . 7.6 t -166.97 171.14 11.44 Favored 'General case' 0 N--CA 1.473 0.682 0 N-CA-C 109.499 -0.556 . . . . 0.0 109.499 178.429 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.83 23.76 2.21 Favored Glycine 0 N--CA 1.487 2.093 0 N-CA-C 112.099 -0.4 . . . . 0.0 112.099 179.355 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 42.1 p90 -56.63 127.99 34.14 Favored 'General case' 0 N--CA 1.473 0.718 0 N-CA-C 112.125 0.417 . . . . 0.0 112.125 -179.847 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 11' ' ' GLU . . . . . 0.534 ' CG ' HD21 ' B' ' 27' ' ' ASN . 45.8 mt-10 -84.74 154.73 22.24 Favored 'General case' 0 N--CA 1.468 0.448 0 N-CA-C 109.126 -0.694 . . . . 0.0 109.126 178.507 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -153.61 129.24 1.65 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.293 0 N-CA-C 108.274 -1.01 . . . . 0.0 108.274 178.863 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 48.7 m-70 -134.71 144.95 48.05 Favored 'General case' 0 N--CA 1.489 1.517 0 CA-C-N 118.635 0.652 . . . . 0.0 111.043 -179.012 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -165.95 98.51 0.64 Allowed 'General case' 0 N--CA 1.483 1.184 0 CA-C-N 116.578 -0.283 . . . . 0.0 111.013 179.665 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 15' ' ' GLN . . . . . 0.541 HE22 ' H ' ' C' ' 37' ' ' GLY . 62.3 mt-30 -108.91 -172.21 2.0 Favored 'General case' 0 CA--C 1.501 -0.939 0 N-CA-C 108.276 -1.009 . . . . 0.0 108.276 -179.959 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 16' ' ' LYS . . . . . 0.402 ' C ' HD12 ' C' ' 17' ' ' LEU . 88.4 tttt -165.87 97.38 0.64 Allowed 'General case' 0 CA--C 1.54 0.587 0 CA-C-N 115.104 -0.953 . . . . 0.0 109.348 178.749 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 17' ' ' LEU . . . . . 0.574 HD12 ' N ' ' C' ' 17' ' ' LEU . 4.8 mp -106.07 163.99 12.34 Favored 'General case' 0 N--CA 1.488 1.433 0 N-CA-C 108.577 -0.897 . . . . 0.0 108.577 179.937 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 53.7 t -141.62 119.19 8.28 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.283 0 CA-C-O 119.05 -0.5 . . . . 0.0 109.885 179.529 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 51.2 m-85 -70.47 159.28 34.54 Favored 'General case' 0 N--CA 1.478 0.964 0 N-CA-C 107.469 -1.308 . . . . 0.0 107.469 177.299 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 14.2 t80 -171.96 -57.33 0.02 OUTLIER 'General case' 0 N--CA 1.482 1.15 0 CA-C-O 122.24 1.019 . . . . 0.0 109.847 179.461 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -38.77 90.72 0.0 OUTLIER 'General case' 0 C--O 1.232 0.144 0 CA-C-N 114.129 -1.396 . . . . 0.0 112.804 -178.024 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 54.0 tt0 -67.88 157.7 34.31 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.122 -0.945 . . . . 0.0 110.595 179.254 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 67.4 m-20 -139.86 137.96 35.33 Favored 'General case' 0 N--CA 1.482 1.134 0 C-N-CA 122.854 0.462 . . . . 0.0 110.245 179.728 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 17.7 t -84.85 -116.44 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.985 0 N-CA-C 108.506 -0.924 . . . . 0.0 108.506 179.693 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -110.12 54.27 0.55 Allowed Glycine 0 N--CA 1.474 1.227 0 N-CA-C 111.175 -0.77 . . . . 0.0 111.175 -179.865 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 73.8 p -80.32 126.18 30.82 Favored 'General case' 0 C--O 1.22 -0.455 0 N-CA-C 109.07 -0.715 . . . . 0.0 109.07 178.414 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 27' ' ' ASN . . . . . 0.506 HD21 ' CG ' ' A' ' 11' ' ' GLU . 51.0 t30 -66.94 100.28 0.72 Allowed 'General case' 0 N--CA 1.473 0.704 0 N-CA-C 108.673 -0.862 . . . . 0.0 108.673 178.563 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 66.9 mttm -96.79 119.68 35.72 Favored 'General case' 0 N--CA 1.482 1.172 0 N-CA-C 110.238 -0.282 . . . . 0.0 110.238 -179.169 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.31 -125.96 0.01 OUTLIER Glycine 0 CA--C 1.534 1.268 0 N-CA-C 110.534 -1.026 . . . . 0.0 110.534 178.727 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.01 133.7 49.17 Favored 'General case' 0 N--CA 1.482 1.14 0 N-CA-C 109.263 -0.643 . . . . 0.0 109.263 179.171 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 67.3 mt -83.12 138.54 19.15 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.456 0 N-CA-C 107.129 -1.434 . . . . 0.0 107.129 178.538 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 18.0 mt -128.5 128.74 68.44 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.987 0 O-C-N 123.626 0.579 . . . . 0.0 110.16 -178.519 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 60.67 78.93 0.13 Allowed Glycine 0 CA--C 1.527 0.797 0 CA-C-N 116.018 -0.537 . . . . 0.0 113.033 178.844 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 34' ' ' LEU . . . . . 0.4 HD23 ' N ' ' C' ' 35' ' ' MET . 2.0 tt -110.58 118.94 37.58 Favored 'General case' 0 N--CA 1.477 0.89 0 N-CA-C 106.902 -1.518 . . . . 0.0 106.902 177.37 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 35' ' ' MET . . . . . 0.4 ' N ' HD23 ' C' ' 34' ' ' LEU . 8.7 ttt -155.07 160.94 41.38 Favored 'General case' 0 N--CA 1.469 0.501 0 N-CA-C 109.125 -0.694 . . . . 0.0 109.125 179.185 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 93.0 t -157.93 150.57 8.28 Favored 'Isoleucine or valine' 0 C--O 1.233 0.203 0 N-CA-C 106.74 -1.578 . . . . 0.0 106.74 -179.566 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 37' ' ' GLY . . . . . 0.541 ' H ' HE22 ' C' ' 15' ' ' GLN . . . 55.7 75.32 0.25 Allowed Glycine 0 C--N 1.314 -0.649 0 CA-C-N 115.691 -0.686 . . . . 0.0 111.814 178.368 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 168.61 -148.78 12.84 Favored Glycine 0 CA--C 1.52 0.382 0 N-CA-C 110.631 -0.988 . . . . 0.0 110.631 179.862 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 21.5 m -132.89 142.56 41.97 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.814 0 N-CA-C 109.696 -0.483 . . . . 0.0 109.696 179.707 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 21.3 t . . . . . 0 N--CA 1.468 0.443 0 CA-C-O 117.772 -1.109 . . . . 0.0 110.801 179.376 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 87.7 m-85 . . . . . 0 N--CA 1.473 0.71 0 N-CA-C 108.283 -1.006 . . . . 0.0 108.283 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' D' D ' 5' ' ' ARG . . . . . . . . . . . . . 71.2 mtp180 -147.45 141.35 25.84 Favored 'General case' 0 N--CA 1.475 0.82 0 N-CA-C 108.961 -0.755 . . . . 0.0 108.961 179.746 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 77.1 m80 -149.17 123.6 9.67 Favored 'General case' 0 CA--C 1.538 0.51 0 N-CA-C 107.891 -1.152 . . . . 0.0 107.891 175.875 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 7' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -63.3 133.55 54.34 Favored 'General case' 0 C--N 1.321 -0.668 0 C-N-CA 127.049 2.139 . . . . 0.0 114.697 176.251 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 8' ' ' SER . . . . . . . . . . . . . 6.6 t -154.03 173.56 15.85 Favored 'General case' 0 N--CA 1.478 0.951 0 CA-C-N 118.533 0.606 . . . . 0.0 110.296 177.074 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 124.29 20.45 2.44 Favored Glycine 0 N--CA 1.485 1.917 0 N-CA-C 112.126 -0.39 . . . . 0.0 112.126 176.579 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 37.2 p90 -55.81 130.46 43.56 Favored 'General case' 0 CA--C 1.546 0.804 0 CA-C-O 121.126 0.489 . . . . 0.0 111.889 -177.355 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 11' ' ' GLU . . . . . 0.478 ' CG ' HD21 ' F' ' 27' ' ' ASN . 46.0 mt-10 -85.26 152.42 23.33 Favored 'General case' 0 N--CA 1.473 0.694 0 N-CA-C 109.732 -0.469 . . . . 0.0 109.732 177.763 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -149.51 130.05 4.41 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.472 0 N-CA-C 108.222 -1.029 . . . . 0.0 108.222 175.593 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 46.9 m-70 -129.64 148.07 51.49 Favored 'General case' 0 N--CA 1.483 1.201 0 CA-C-N 118.009 0.368 . . . . 0.0 111.423 176.708 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -165.37 104.76 0.74 Allowed 'General case' 0 N--CA 1.483 1.207 0 N-CA-C 109.623 -0.51 . . . . 0.0 109.623 173.453 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' D' D ' 15' ' ' GLN . . . . . 0.555 HE22 ' H ' ' D' ' 37' ' ' GLY . 61.5 mt-30 -112.02 -175.66 2.74 Favored 'General case' 0 CA--C 1.493 -1.214 0 N-CA-C 108.019 -1.104 . . . . 0.0 108.019 179.348 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' D' D ' 16' ' ' LYS . . . . . 0.444 ' C ' HD12 ' D' ' 17' ' ' LEU . 88.7 tttt -162.09 105.9 1.19 Allowed 'General case' 0 CA--C 1.538 0.506 0 N-CA-C 107.603 -1.258 . . . . 0.0 107.603 175.386 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' D' D ' 17' ' ' LEU . . . . . 0.524 HD12 ' N ' ' D' ' 17' ' ' LEU . 5.7 mp -112.69 163.07 15.0 Favored 'General case' 0 N--CA 1.487 1.407 0 N-CA-C 108.095 -1.076 . . . . 0.0 108.095 179.536 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 48.1 t -140.92 123.59 15.56 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.072 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 176.158 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 76.1 m-85 -62.77 151.3 39.06 Favored 'General case' 0 C--N 1.351 0.652 0 C-N-CA 124.688 1.195 . . . . 0.0 110.386 170.774 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 9.0 t80 -169.86 -66.59 0.02 OUTLIER 'General case' 0 N--CA 1.476 0.827 0 N-CA-C 107.816 -1.179 . . . . 0.0 107.816 -179.707 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -37.83 96.11 0.01 OUTLIER 'General case' 0 CA--C 1.536 0.425 0 CA-C-N 113.919 -1.491 . . . . 0.0 111.583 -174.353 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 54.1 tt0 -69.98 158.52 35.48 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 113.459 -1.7 . . . . 0.0 110.17 178.767 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 68.1 m-20 -140.14 141.32 36.07 Favored 'General case' 0 N--CA 1.477 0.875 0 N-CA-C 109.496 -0.557 . . . . 0.0 109.496 178.581 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 24' ' ' VAL . . . . . . . . . . . . . 19.7 t -87.7 -119.19 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.486 1.372 0 N-CA-C 107.91 -1.144 . . . . 0.0 107.91 179.816 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . -113.93 61.98 0.33 Allowed Glycine 0 C--N 1.371 2.495 0 C-N-CA 118.073 -2.013 . . . . 0.0 109.441 178.612 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 89.1 p -70.54 121.37 17.7 Favored 'General case' 0 C--O 1.24 0.601 0 CA-C-O 116.521 -1.704 . . . . 0.0 112.184 169.162 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 27' ' ' ASN . . . . . 0.457 HD21 ' CG ' ' E' ' 11' ' ' GLU . 57.1 t30 -61.4 101.83 0.2 Allowed 'General case' 0 N--CA 1.475 0.788 0 CA-C-N 121.625 2.011 . . . . 0.0 109.489 172.464 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 66.5 mttm -100.17 121.44 41.44 Favored 'General case' 0 N--CA 1.488 1.453 0 CA-C-N 119.681 1.128 . . . . 0.0 109.378 178.673 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -53.96 -130.12 0.0 OUTLIER Glycine 0 CA--C 1.529 0.938 0 CA-C-N 115.535 -0.757 . . . . 0.0 112.284 175.008 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -125.23 139.84 53.38 Favored 'General case' 0 C--N 1.37 1.498 0 N-CA-C 108.666 -0.864 . . . . 0.0 108.666 174.278 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 66.4 mt -83.9 141.12 15.2 Favored 'Isoleucine or valine' 0 C--O 1.239 0.527 0 N-CA-C 107.145 -1.428 . . . . 0.0 107.145 176.29 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 25.6 mt -131.31 132.89 62.81 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.058 0 N-CA-C 108.59 -0.893 . . . . 0.0 108.59 178.253 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.88 77.16 0.21 Allowed Glycine 0 C--O 1.248 1.014 0 CA-C-O 118.351 -1.249 . . . . 0.0 112.618 178.791 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 2.5 tt -109.87 131.06 55.41 Favored 'General case' 0 C--N 1.376 1.756 0 N-CA-C 104.135 -2.543 . . . . 0.0 104.135 174.722 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 8.5 ttt -157.12 166.69 32.56 Favored 'General case' 0 C--O 1.219 -0.544 0 N-CA-C 108.794 -0.817 . . . . 0.0 108.794 176.44 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 88.8 t -163.57 154.78 2.45 Favored 'Isoleucine or valine' 0 C--O 1.24 0.566 0 N-CA-C 105.476 -2.046 . . . . 0.0 105.476 175.075 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 37' ' ' GLY . . . . . 0.555 ' H ' HE22 ' D' ' 15' ' ' GLN . . . 61.15 66.54 2.61 Favored Glycine 0 N--CA 1.444 -0.769 0 C-N-CA 117.875 -2.107 . . . . 0.0 113.674 177.125 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 166.82 -147.67 12.28 Favored Glycine 0 N--CA 1.466 0.688 0 CA-C-O 117.807 -1.552 . . . . 0.0 112.2 -179.045 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 22.4 m -130.11 142.88 42.64 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.112 0 CA-C-N 119.304 1.552 . . . . 0.0 109.429 -179.439 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 18.7 t . . . . . 0 C--O 1.214 -0.776 0 N-CA-C 109.169 -0.678 . . . . 0.0 109.169 174.944 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 79.2 m-85 . . . . . 0 N--CA 1.475 0.811 0 N-CA-C 109.949 -0.389 . . . . 0.0 109.949 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' E' E ' 5' ' ' ARG . . . . . . . . . . . . . 71.5 mtp180 -143.77 142.26 30.82 Favored 'General case' 0 N--CA 1.476 0.842 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 179.886 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 76.7 m80 -150.53 118.24 6.17 Favored 'General case' 0 N--CA 1.472 0.662 0 N-CA-C 108.926 -0.768 . . . . 0.0 108.926 179.129 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' E' E ' 7' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -66.16 149.63 50.01 Favored 'General case' 0 N--CA 1.465 0.289 0 O-C-N 123.542 0.526 . . . . 0.0 111.559 -179.606 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' E' E ' 8' ' ' SER . . . . . . . . . . . . . 6.7 t -167.12 172.53 9.94 Favored 'General case' 0 N--CA 1.477 0.891 0 CA-C-N 115.86 -0.609 . . . . 0.0 109.563 178.033 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.95 23.67 2.19 Favored Glycine 0 N--CA 1.482 1.716 0 N-CA-C 112.018 -0.433 . . . . 0.0 112.018 179.096 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 39.2 p90 -56.18 127.26 29.82 Favored 'General case' 0 N--CA 1.473 0.724 0 N-CA-C 112.639 0.607 . . . . 0.0 112.639 -179.149 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' E' E ' 11' ' ' GLU . . . . . 0.457 ' CG ' HD21 ' D' ' 27' ' ' ASN . 46.3 mt-10 -83.41 155.55 23.41 Favored 'General case' 0 N--CA 1.474 0.734 0 N-CA-C 109.302 -0.629 . . . . 0.0 109.302 178.033 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -155.67 128.34 1.09 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.534 0 N-CA-C 108.357 -0.979 . . . . 0.0 108.357 178.782 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 47.5 m-70 -135.17 143.18 46.33 Favored 'General case' 0 N--CA 1.48 1.074 0 CA-C-O 120.746 0.308 . . . . 0.0 111.329 -177.875 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -164.83 98.68 0.77 Allowed 'General case' 0 N--CA 1.488 1.472 0 CA-C-N 116.677 -0.238 . . . . 0.0 110.973 179.73 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' E' E ' 15' ' ' GLN . . . . . 0.546 HE22 ' H ' ' E' ' 37' ' ' GLY . 62.1 mt-30 -108.4 -171.91 1.95 Allowed 'General case' 0 CA--C 1.502 -0.883 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 -179.831 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -166.27 97.31 0.6 Allowed 'General case' 0 CA--C 1.541 0.629 0 CA-C-N 115.043 -0.98 . . . . 0.0 109.327 178.648 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' E' E ' 17' ' ' LEU . . . . . 0.568 ' N ' HD12 ' E' ' 17' ' ' LEU . 4.8 mp -105.85 163.56 12.63 Favored 'General case' 0 N--CA 1.49 1.545 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 -179.805 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 40.3 t -141.9 118.57 6.99 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.352 0 C-N-CA 122.612 0.365 . . . . 0.0 110.492 179.126 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 50.9 m-85 -69.49 156.77 38.35 Favored 'General case' 0 C--N 1.357 0.933 0 N-CA-C 107.336 -1.357 . . . . 0.0 107.336 176.56 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 12.4 t80 -173.41 -54.9 0.02 OUTLIER 'General case' 0 N--CA 1.485 1.28 0 CA-C-O 121.822 0.82 . . . . 0.0 110.288 179.457 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.96 89.31 0.0 OUTLIER 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 114.346 -1.297 . . . . 0.0 112.686 -178.783 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 54.7 tt0 -66.14 158.19 29.26 Favored 'General case' 0 N--CA 1.472 0.656 0 CA-C-N 114.823 -1.08 . . . . 0.0 110.651 179.651 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 66.0 m-20 -140.56 137.59 33.85 Favored 'General case' 0 N--CA 1.479 1.005 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.442 179.881 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 21.7 t -84.79 -115.45 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.039 0 N-CA-C 108.681 -0.859 . . . . 0.0 108.681 179.649 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . -110.61 54.16 0.55 Allowed Glycine 0 C--N 1.347 1.163 0 N-CA-C 111.457 -0.657 . . . . 0.0 111.457 -179.715 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 69.0 p -79.75 125.67 29.97 Favored 'General case' 0 N--CA 1.474 0.773 0 N-CA-C 109.384 -0.599 . . . . 0.0 109.384 178.078 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' E' E ' 27' ' ' ASN . . . . . 0.49 HD21 ' CG ' ' F' ' 11' ' ' GLU . 52.5 t30 -66.72 99.5 0.61 Allowed 'General case' 0 N--CA 1.471 0.601 0 N-CA-C 108.081 -1.081 . . . . 0.0 108.081 178.382 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 66.4 mttm -96.44 119.3 34.66 Favored 'General case' 0 N--CA 1.484 1.252 0 N-CA-C 109.995 -0.372 . . . . 0.0 109.995 -178.748 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.57 -124.88 0.01 OUTLIER Glycine 0 CA--C 1.538 1.525 0 N-CA-C 110.95 -0.86 . . . . 0.0 110.95 178.601 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.74 133.33 48.08 Favored 'General case' 0 N--CA 1.482 1.158 0 N-CA-C 109.581 -0.526 . . . . 0.0 109.581 179.65 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 66.3 mt -82.65 138.97 18.5 Favored 'Isoleucine or valine' 0 C--O 1.237 0.405 0 N-CA-C 107.029 -1.471 . . . . 0.0 107.029 178.434 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 21.0 mt -128.32 129.06 69.05 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.865 0 N-CA-C 109.566 -0.531 . . . . 0.0 109.566 -179.433 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 60.97 80.28 0.1 Allowed Glycine 0 CA--C 1.524 0.641 0 CA-C-N 116.064 -0.516 . . . . 0.0 113.505 179.172 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 2.0 tt -111.77 118.86 36.74 Favored 'General case' 0 N--CA 1.477 0.916 0 N-CA-C 107.003 -1.481 . . . . 0.0 107.003 177.34 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 8.6 ttt -154.14 162.64 41.05 Favored 'General case' 0 C--O 1.211 -0.944 0 N-CA-C 108.744 -0.835 . . . . 0.0 108.744 179.203 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 84.1 t -159.71 150.53 6.33 Favored 'Isoleucine or valine' 0 C--O 1.239 0.509 0 N-CA-C 106.632 -1.618 . . . . 0.0 106.632 -179.864 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' E' E ' 37' ' ' GLY . . . . . 0.546 ' H ' HE22 ' E' ' 15' ' ' GLN . . . 55.61 74.94 0.27 Allowed Glycine 0 C--N 1.314 -0.662 0 CA-C-N 115.673 -0.694 . . . . 0.0 111.481 178.48 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 169.95 -147.7 11.08 Favored Glycine 0 C--O 1.222 -0.631 0 N-CA-C 111.321 -0.712 . . . . 0.0 111.321 179.965 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 20.3 m -133.93 141.38 44.12 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.872 0 N-CA-C 109.199 -0.667 . . . . 0.0 109.199 179.444 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 19.0 t . . . . . 0 CA--C 1.535 0.379 0 CA-C-O 117.722 -1.133 . . . . 0.0 110.895 179.453 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 79.4 m-85 . . . . . 0 N--CA 1.475 0.8 0 N-CA-C 109.873 -0.417 . . . . 0.0 109.873 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' F' F ' 5' ' ' ARG . . . . . . . . . . . . . 71.6 mtp180 -143.8 141.84 30.59 Favored 'General case' 0 N--CA 1.477 0.912 0 N-CA-C 109.261 -0.644 . . . . 0.0 109.261 179.998 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 76.9 m80 -150.28 118.41 6.34 Favored 'General case' 0 N--CA 1.473 0.688 0 N-CA-C 108.965 -0.754 . . . . 0.0 108.965 179.072 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' F' F ' 7' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -66.4 149.82 49.83 Favored 'General case' 0 N--CA 1.463 0.203 0 O-C-N 123.414 0.447 . . . . 0.0 111.636 -179.429 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' F' F ' 8' ' ' SER . . . . . . . . . . . . . 6.9 t -167.41 172.28 9.79 Favored 'General case' 0 N--CA 1.476 0.874 0 CA-C-N 115.991 -0.55 . . . . 0.0 109.56 178.04 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 123.19 23.25 2.21 Favored Glycine 0 N--CA 1.482 1.74 0 N-CA-C 112.04 -0.424 . . . . 0.0 112.04 179.109 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 38.7 p90 -55.87 127.72 31.63 Favored 'General case' 0 CA--C 1.543 0.694 0 N-CA-C 112.664 0.616 . . . . 0.0 112.664 -179.151 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' F' F ' 11' ' ' GLU . . . . . 0.49 ' CG ' HD21 ' E' ' 27' ' ' ASN . 46.3 mt-10 -83.74 155.33 23.13 Favored 'General case' 0 N--CA 1.474 0.764 0 N-CA-C 109.436 -0.579 . . . . 0.0 109.436 178.023 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -155.34 128.19 1.11 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.587 0 N-CA-C 108.297 -1.001 . . . . 0.0 108.297 178.79 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 46.1 m-70 -135.01 143.22 46.68 Favored 'General case' 0 N--CA 1.483 1.196 0 CA-C-O 120.63 0.252 . . . . 0.0 111.329 -177.902 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -165.18 99.09 0.73 Allowed 'General case' 0 N--CA 1.487 1.422 0 CA-C-N 116.751 -0.204 . . . . 0.0 111.091 179.74 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' F' F ' 15' ' ' GLN . . . . . 0.541 HE22 ' H ' ' F' ' 37' ' ' GLY . 61.6 mt-30 -109.2 -171.51 1.86 Allowed 'General case' 0 CA--C 1.498 -1.034 0 N-CA-C 108.574 -0.899 . . . . 0.0 108.574 -179.826 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -166.11 97.57 0.62 Allowed 'General case' 0 CA--C 1.542 0.651 0 CA-C-N 114.93 -1.032 . . . . 0.0 109.406 178.769 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' F' F ' 17' ' ' LEU . . . . . 0.566 HD12 ' N ' ' F' ' 17' ' ' LEU . 4.7 mp -105.81 163.48 12.69 Favored 'General case' 0 N--CA 1.488 1.469 0 N-CA-C 109.213 -0.662 . . . . 0.0 109.213 -179.923 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 40.0 t -141.9 118.59 7.02 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.305 0 C-N-CA 122.644 0.378 . . . . 0.0 110.613 179.101 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 51.0 m-85 -69.53 156.66 38.54 Favored 'General case' 0 C--N 1.357 0.922 0 N-CA-C 107.221 -1.399 . . . . 0.0 107.221 176.548 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 13.2 t80 -173.19 -55.04 0.02 OUTLIER 'General case' 0 N--CA 1.486 1.372 0 CA-C-O 121.787 0.803 . . . . 0.0 109.85 179.458 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.73 88.99 0.0 OUTLIER 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 114.49 -1.232 . . . . 0.0 112.971 -178.876 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 54.4 tt0 -65.96 158.22 28.74 Favored 'General case' 0 N--CA 1.472 0.666 0 CA-C-N 114.894 -1.048 . . . . 0.0 110.799 179.541 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 66.7 m-20 -140.51 137.83 34.11 Favored 'General case' 0 N--CA 1.48 1.059 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.396 179.96 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' F' F ' 24' ' ' VAL . . . . . . . . . . . . . 21.7 t -85.09 -115.46 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.043 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 179.505 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -110.55 54.11 0.56 Allowed Glycine 0 N--CA 1.479 1.529 0 N-CA-C 111.383 -0.687 . . . . 0.0 111.383 -179.815 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 70.1 p -79.68 125.42 29.62 Favored 'General case' 0 N--CA 1.474 0.733 0 N-CA-C 109.335 -0.617 . . . . 0.0 109.335 177.948 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' F' F ' 27' ' ' ASN . . . . . 0.478 HD21 ' CG ' ' D' ' 11' ' ' GLU . 52.2 t30 -66.5 99.23 0.55 Allowed 'General case' 0 N--CA 1.472 0.638 0 N-CA-C 108.115 -1.069 . . . . 0.0 108.115 178.382 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 66.4 mttm -96.26 119.17 34.27 Favored 'General case' 0 N--CA 1.483 1.19 0 N-CA-C 110.084 -0.339 . . . . 0.0 110.084 -178.804 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.55 -125.41 0.01 OUTLIER Glycine 0 CA--C 1.54 1.6 0 N-CA-C 110.964 -0.854 . . . . 0.0 110.964 178.617 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -127.91 133.08 49.25 Favored 'General case' 0 N--CA 1.484 1.249 0 N-CA-C 109.644 -0.502 . . . . 0.0 109.644 179.588 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 66.9 mt -82.65 138.81 18.77 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.273 0 N-CA-C 106.897 -1.52 . . . . 0.0 106.897 178.421 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 20.3 mt -128.22 129.08 69.22 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.891 0 N-CA-C 109.636 -0.505 . . . . 0.0 109.636 -179.357 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 60.86 80.27 0.1 Allowed Glycine 0 CA--C 1.525 0.688 0 CA-C-N 116.056 -0.52 . . . . 0.0 113.573 179.346 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 2.1 tt -111.85 118.82 36.59 Favored 'General case' 0 N--CA 1.479 0.981 0 N-CA-C 107.067 -1.457 . . . . 0.0 107.067 177.346 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 8.7 ttt -154.15 162.72 41.0 Favored 'General case' 0 C--O 1.209 -1.041 0 N-CA-C 109.009 -0.737 . . . . 0.0 109.009 179.143 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 85.1 t -159.7 150.57 6.32 Favored 'Isoleucine or valine' 0 C--O 1.237 0.402 0 N-CA-C 106.701 -1.592 . . . . 0.0 106.701 -179.823 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' F' F ' 37' ' ' GLY . . . . . 0.541 ' H ' HE22 ' F' ' 15' ' ' GLN . . . 55.8 74.67 0.3 Allowed Glycine 0 C--N 1.315 -0.632 0 CA-C-N 115.523 -0.762 . . . . 0.0 111.447 178.452 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 170.06 -147.82 11.14 Favored Glycine 0 C--O 1.221 -0.7 0 N-CA-C 111.233 -0.747 . . . . 0.0 111.233 179.839 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 20.2 m -133.72 141.37 44.35 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.841 0 N-CA-C 109.158 -0.682 . . . . 0.0 109.158 179.547 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 19.4 t . . . . . 0 CA--C 1.536 0.415 0 CA-C-O 117.746 -1.121 . . . . 0.0 110.75 179.389 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 79.0 m-85 . . . . . 0 N--CA 1.474 0.772 0 N-CA-C 109.644 -0.502 . . . . 0.0 109.644 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' G' G ' 5' ' ' ARG . . . . . . . . . . . . . 71.8 mtp180 -144.01 141.28 30.05 Favored 'General case' 0 N--CA 1.483 1.22 0 N-CA-C 109.178 -0.675 . . . . 0.0 109.178 -179.515 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 76.7 m80 -149.53 119.57 7.19 Favored 'General case' 0 N--CA 1.472 0.671 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 179.078 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 -68.41 145.28 54.27 Favored 'General case' 0 N--CA 1.47 0.526 0 O-C-N 123.505 0.503 . . . . 0.0 111.931 -179.328 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' G' G ' 8' ' ' SER . . . . . . . . . . . . . 5.7 t -163.81 173.54 12.64 Favored 'General case' 0 N--CA 1.47 0.566 0 N-CA-C 109.291 -0.633 . . . . 0.0 109.291 178.147 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.94 23.65 2.2 Favored Glycine 0 N--CA 1.479 1.519 0 N-CA-C 111.755 -0.538 . . . . 0.0 111.755 179.051 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 41.9 p90 -56.98 127.61 32.79 Favored 'General case' 0 N--CA 1.475 0.799 0 N-CA-C 112.437 0.532 . . . . 0.0 112.437 -178.648 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 45.2 mt-10 -83.93 154.34 23.43 Favored 'General case' 0 N--CA 1.471 0.618 0 CA-C-O 121.052 0.453 . . . . 0.0 109.852 178.686 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -155.4 128.51 1.15 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.968 0 N-CA-C 108.304 -0.999 . . . . 0.0 108.304 178.9 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 49.1 m-70 -134.19 144.38 48.44 Favored 'General case' 0 N--CA 1.476 0.865 0 CA-C-N 115.416 -0.811 . . . . 0.0 111.09 -178.136 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -166.35 98.2 0.6 Allowed 'General case' 0 N--CA 1.484 1.245 0 CA-C-N 116.642 -0.254 . . . . 0.0 110.572 179.219 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' G' G ' 15' ' ' GLN . . . . . 0.541 HE22 ' H ' ' G' ' 37' ' ' GLY . 61.7 mt-30 -108.32 -171.89 1.95 Allowed 'General case' 0 CA--C 1.503 -0.839 0 N-CA-C 108.635 -0.876 . . . . 0.0 108.635 -179.775 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -166.03 97.58 0.63 Allowed 'General case' 0 CA--C 1.541 0.618 0 CA-C-N 115.032 -0.985 . . . . 0.0 109.38 178.614 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' G' G ' 17' ' ' LEU . . . . . 0.573 ' N ' HD12 ' G' ' 17' ' ' LEU . 5.4 mp -105.73 162.33 13.63 Favored 'General case' 0 N--CA 1.487 1.423 0 N-CA-C 109.4 -0.593 . . . . 0.0 109.4 -179.717 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 39.0 t -142.45 118.83 6.08 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.082 0 CA-C-O 120.895 0.378 . . . . 0.0 110.352 178.773 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 44.9 m-85 -69.65 150.74 46.69 Favored 'General case' 0 C--N 1.369 1.444 0 N-CA-C 107.267 -1.383 . . . . 0.0 107.267 176.583 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 10.9 t80 -170.92 -54.84 0.02 OUTLIER 'General case' 0 N--CA 1.487 1.382 0 CA-C-N 117.847 0.294 . . . . 0.0 110.408 -179.73 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.45 90.27 0.0 OUTLIER 'General case' 0 C--N 1.325 -0.494 0 C-N-CA 123.866 0.866 . . . . 0.0 112.596 -179.918 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 53.8 tt0 -66.88 159.06 29.07 Favored 'General case' 0 N--CA 1.469 0.492 0 CA-C-N 114.634 -1.166 . . . . 0.0 109.923 179.189 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 66.2 m-20 -140.94 137.55 33.18 Favored 'General case' 0 N--CA 1.477 0.904 0 C-N-CA 122.822 0.449 . . . . 0.0 110.046 179.893 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' G' G ' 24' ' ' VAL . . . . . . . . . . . . . 21.4 t -85.42 -115.29 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.919 0 N-CA-C 108.521 -0.918 . . . . 0.0 108.521 179.608 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -110.53 53.97 0.56 Allowed Glycine 0 N--CA 1.477 1.425 0 N-CA-C 111.611 -0.596 . . . . 0.0 111.611 -179.712 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 70.4 p -80.08 126.27 30.85 Favored 'General case' 0 N--CA 1.467 0.393 0 N-CA-C 109.081 -0.711 . . . . 0.0 109.081 177.956 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 50.4 t30 -67.23 99.99 0.75 Allowed 'General case' 0 CA--C 1.538 0.503 0 N-CA-C 108.401 -0.963 . . . . 0.0 108.401 178.434 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 66.9 mttm -96.33 119.91 35.68 Favored 'General case' 0 N--CA 1.482 1.147 0 N-CA-C 110.174 -0.306 . . . . 0.0 110.174 -179.182 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.02 -123.33 0.01 OUTLIER Glycine 0 CA--C 1.534 1.253 0 N-CA-C 110.54 -1.024 . . . . 0.0 110.54 178.787 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -129.58 132.78 46.89 Favored 'General case' 0 N--CA 1.47 0.557 0 N-CA-C 109.514 -0.55 . . . . 0.0 109.514 179.683 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 69.9 mt -81.54 140.91 15.85 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.654 0 N-CA-C 107.2 -1.407 . . . . 0.0 107.2 178.337 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 24.0 mt -130.2 130.52 65.74 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.46 0 CA-C-N 119.044 0.838 . . . . 0.0 109.435 179.785 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 60.96 79.82 0.11 Allowed Glycine 0 CA--C 1.528 0.888 0 CA-C-N 116.281 -0.418 . . . . 0.0 113.038 179.292 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' G' G ' 34' ' ' LEU . . . . . 0.404 HD23 ' N ' ' G' ' 35' ' ' MET . 1.9 tt -111.93 119.55 38.92 Favored 'General case' 0 N--CA 1.478 0.94 0 N-CA-C 106.961 -1.496 . . . . 0.0 106.961 177.479 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' G' G ' 35' ' ' MET . . . . . 0.404 ' N ' HD23 ' G' ' 34' ' ' LEU . 8.5 ttt -155.54 163.14 40.38 Favored 'General case' 0 N--CA 1.476 0.866 0 N-CA-C 108.192 -1.04 . . . . 0.0 108.192 179.503 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 98.6 t -159.8 150.85 6.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 N-CA-C 106.303 -1.74 . . . . 0.0 106.303 -179.899 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' G' G ' 37' ' ' GLY . . . . . 0.541 ' H ' HE22 ' G' ' 15' ' ' GLN . . . 56.1 74.74 0.29 Allowed Glycine 0 C--N 1.313 -0.706 0 CA-C-N 115.888 -0.596 . . . . 0.0 111.913 178.132 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 168.66 -146.42 10.34 Favored Glycine 0 N--CA 1.471 1.008 0 N-CA-C 110.636 -0.986 . . . . 0.0 110.636 179.231 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 23.1 m -134.23 141.62 43.17 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.906 0 CA-C-N 117.031 0.415 . . . . 0.0 109.984 179.881 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 19.2 t . . . . . 0 N--CA 1.47 0.548 0 CA-C-O 117.841 -1.076 . . . . 0.0 110.891 179.613 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 80.4 m-85 . . . . . 0 N--CA 1.475 0.805 0 N-CA-C 109.641 -0.503 . . . . 0.0 109.641 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' H' H ' 5' ' ' ARG . . . . . . . . . . . . . 71.5 mtp180 -144.29 141.4 29.77 Favored 'General case' 0 N--CA 1.48 1.055 0 N-CA-C 109.222 -0.658 . . . . 0.0 109.222 -179.625 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 76.8 m80 -149.72 119.29 6.96 Favored 'General case' 0 N--CA 1.473 0.698 0 N-CA-C 109.095 -0.705 . . . . 0.0 109.095 179.071 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 8.7 m-20 -68.08 145.35 54.5 Favored 'General case' 0 N--CA 1.468 0.45 0 O-C-N 123.466 0.479 . . . . 0.0 111.934 -179.393 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' H' H ' 8' ' ' SER . . . . . . . . . . . . . 7.0 t -163.9 172.83 13.45 Favored 'General case' 0 N--CA 1.468 0.474 0 N-CA-C 109.449 -0.574 . . . . 0.0 109.449 178.466 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 123.15 23.52 2.17 Favored Glycine 0 N--CA 1.481 1.684 0 N-CA-C 111.682 -0.567 . . . . 0.0 111.682 179.154 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 41.6 p90 -56.79 127.65 32.68 Favored 'General case' 0 N--CA 1.472 0.672 0 N-CA-C 112.443 0.534 . . . . 0.0 112.443 -178.763 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 45.4 mt-10 -83.96 154.4 23.36 Favored 'General case' 0 N--CA 1.473 0.679 0 CA-C-O 120.998 0.428 . . . . 0.0 109.893 178.739 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.6 p -155.58 128.11 1.07 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.016 0 N-CA-C 108.42 -0.955 . . . . 0.0 108.42 178.879 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 48.7 m-70 -133.91 144.4 48.83 Favored 'General case' 0 N--CA 1.478 0.947 0 CA-C-N 115.336 -0.847 . . . . 0.0 111.025 -178.072 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -166.29 98.54 0.61 Allowed 'General case' 0 N--CA 1.483 1.218 0 CA-C-N 116.568 -0.287 . . . . 0.0 110.617 179.166 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' H' H ' 15' ' ' GLN . . . . . 0.553 HE22 ' H ' ' H' ' 37' ' ' GLY . 61.6 mt-30 -108.64 -172.37 2.04 Favored 'General case' 0 CA--C 1.501 -0.931 0 N-CA-C 108.416 -0.957 . . . . 0.0 108.416 -179.656 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -165.73 97.35 0.65 Allowed 'General case' 0 CA--C 1.54 0.572 0 CA-C-N 114.951 -1.022 . . . . 0.0 109.364 178.716 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' H' H ' 17' ' ' LEU . . . . . 0.572 HD12 ' N ' ' H' ' 17' ' ' LEU . 5.4 mp -105.66 162.23 13.7 Favored 'General case' 0 N--CA 1.487 1.405 0 N-CA-C 109.362 -0.607 . . . . 0.0 109.362 -179.646 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 38.8 t -142.39 118.67 6.08 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.983 0 CA-C-O 120.97 0.414 . . . . 0.0 110.489 178.851 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 46.2 m-85 -69.8 151.07 46.18 Favored 'General case' 0 C--N 1.371 1.503 0 N-CA-C 107.355 -1.35 . . . . 0.0 107.355 176.653 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 11.4 t80 -172.15 -54.6 0.02 OUTLIER 'General case' 0 N--CA 1.485 1.295 0 N-CA-C 110.342 -0.244 . . . . 0.0 110.342 -179.635 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.39 90.41 0.0 OUTLIER 'General case' 0 CA--C 1.535 0.365 0 C-N-CA 123.815 0.846 . . . . 0.0 112.354 -179.958 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 54.0 tt0 -66.73 159.14 28.52 Favored 'General case' 0 N--CA 1.469 0.485 0 CA-C-N 114.69 -1.141 . . . . 0.0 110.012 179.34 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 67.5 m-20 -140.91 138.05 33.58 Favored 'General case' 0 N--CA 1.477 0.885 0 C-N-CA 122.821 0.448 . . . . 0.0 110.051 179.693 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' H' H ' 24' ' ' VAL . . . . . . . . . . . . . 21.4 t -85.93 -115.33 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 1.016 0 N-CA-C 108.609 -0.885 . . . . 0.0 108.609 179.602 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . -110.33 53.9 0.56 Allowed Glycine 0 N--CA 1.48 1.601 0 N-CA-C 111.471 -0.652 . . . . 0.0 111.471 -179.759 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 68.7 p -80.03 126.02 30.52 Favored 'General case' 0 N--CA 1.468 0.446 0 N-CA-C 109.053 -0.721 . . . . 0.0 109.053 178.067 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 50.6 t30 -67.31 100.1 0.78 Allowed 'General case' 0 N--CA 1.47 0.542 0 N-CA-C 108.409 -0.96 . . . . 0.0 108.409 178.492 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 67.0 mttm -96.41 119.76 35.49 Favored 'General case' 0 N--CA 1.484 1.236 0 N-CA-C 110.182 -0.303 . . . . 0.0 110.182 -179.131 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.89 -122.84 0.01 OUTLIER Glycine 0 CA--C 1.535 1.306 0 N-CA-C 110.606 -0.998 . . . . 0.0 110.606 178.735 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -129.95 133.0 46.54 Favored 'General case' 0 N--CA 1.471 0.62 0 C-N-CA 122.946 0.498 . . . . 0.0 109.663 179.709 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 69.5 mt -81.89 140.76 16.01 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.554 0 N-CA-C 107.128 -1.434 . . . . 0.0 107.128 178.446 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 25.1 mt -130.03 130.47 66.08 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.403 0 CA-C-N 119.021 0.828 . . . . 0.0 109.395 179.935 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 60.77 79.81 0.11 Allowed Glycine 0 CA--C 1.528 0.889 0 CA-C-N 116.382 -0.372 . . . . 0.0 113.067 179.193 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 1.9 tt -111.87 119.5 38.77 Favored 'General case' 0 N--CA 1.478 0.944 0 N-CA-C 106.944 -1.502 . . . . 0.0 106.944 177.426 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 8.4 ttt -155.19 163.19 40.54 Favored 'General case' 0 C--O 1.212 -0.91 0 N-CA-C 108.176 -1.046 . . . . 0.0 108.176 179.509 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 96.4 t -159.79 150.77 6.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 N-CA-C 106.254 -1.758 . . . . 0.0 106.254 -179.885 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' H' H ' 37' ' ' GLY . . . . . 0.553 ' H ' HE22 ' H' ' 15' ' ' GLN . . . 56.12 74.95 0.27 Allowed Glycine 0 C--N 1.313 -0.712 0 CA-C-N 115.914 -0.584 . . . . 0.0 111.914 178.124 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 168.32 -146.34 10.37 Favored Glycine 0 N--CA 1.469 0.866 0 N-CA-C 110.631 -0.988 . . . . 0.0 110.631 179.105 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 22.6 m -134.15 141.81 42.74 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.906 0 CA-C-N 116.998 0.399 . . . . 0.0 110.021 179.911 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 19.1 t . . . . . 0 N--CA 1.47 0.557 0 CA-C-O 117.789 -1.101 . . . . 0.0 110.932 179.539 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 79.9 m-85 . . . . . 0 N--CA 1.475 0.78 0 N-CA-C 109.599 -0.519 . . . . 0.0 109.599 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' I' I ' 5' ' ' ARG . . . . . . . . . . . . . 71.6 mtp180 -144.44 141.5 29.66 Favored 'General case' 0 N--CA 1.483 1.192 0 N-CA-C 109.187 -0.671 . . . . 0.0 109.187 -179.696 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 76.7 m80 -149.76 119.06 6.82 Favored 'General case' 0 N--CA 1.472 0.667 0 N-CA-C 109.126 -0.694 . . . . 0.0 109.126 179.082 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 8.6 m-20 -67.86 145.36 54.69 Favored 'General case' 0 N--CA 1.469 0.491 0 O-C-N 123.479 0.487 . . . . 0.0 111.935 -179.371 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' I' I ' 8' ' ' SER . . . . . . . . . . . . . 7.5 t -163.9 172.75 13.55 Favored 'General case' 0 N--CA 1.469 0.496 0 N-CA-C 109.429 -0.582 . . . . 0.0 109.429 178.465 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 123.2 23.77 2.12 Favored Glycine 0 N--CA 1.481 1.639 0 N-CA-C 111.78 -0.528 . . . . 0.0 111.78 179.118 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 41.5 p90 -56.95 127.52 32.27 Favored 'General case' 0 N--CA 1.474 0.737 0 N-CA-C 112.443 0.534 . . . . 0.0 112.443 -178.738 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 45.2 mt-10 -83.66 154.34 23.74 Favored 'General case' 0 N--CA 1.472 0.628 0 CA-C-O 120.998 0.427 . . . . 0.0 109.909 178.675 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -155.49 128.29 1.1 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.015 0 N-CA-C 108.313 -0.995 . . . . 0.0 108.313 178.848 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 49.5 m-70 -134.06 144.56 48.72 Favored 'General case' 0 N--CA 1.478 0.935 0 CA-C-N 115.337 -0.847 . . . . 0.0 111.13 -178.198 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -166.4 98.51 0.6 Allowed 'General case' 0 N--CA 1.484 1.255 0 CA-C-N 116.639 -0.255 . . . . 0.0 110.704 179.127 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' I' I ' 15' ' ' GLN . . . . . 0.551 HE22 ' H ' ' I' ' 37' ' ' GLY . 61.4 mt-30 -108.63 -172.45 2.06 Favored 'General case' 0 CA--C 1.498 -1.029 0 N-CA-C 108.461 -0.94 . . . . 0.0 108.461 -179.765 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -165.69 97.43 0.66 Allowed 'General case' 0 CA--C 1.541 0.61 0 CA-C-N 114.9 -1.046 . . . . 0.0 109.302 178.789 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' I' I ' 17' ' ' LEU . . . . . 0.569 HD12 ' N ' ' I' ' 17' ' ' LEU . 5.4 mp -105.68 162.51 13.46 Favored 'General case' 0 N--CA 1.487 1.402 0 N-CA-C 109.306 -0.627 . . . . 0.0 109.306 -179.609 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 39.2 t -142.5 118.81 5.95 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.006 0 CA-C-O 120.94 0.4 . . . . 0.0 110.471 178.851 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 45.8 m-85 -70.02 150.96 46.1 Favored 'General case' 0 C--N 1.369 1.431 0 N-CA-C 107.402 -1.332 . . . . 0.0 107.402 176.601 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 11.5 t80 -171.96 -54.72 0.02 OUTLIER 'General case' 0 N--CA 1.483 1.209 0 CA-C-N 117.765 0.257 . . . . 0.0 110.401 -179.561 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.34 90.22 0.0 OUTLIER 'General case' 0 CA--C 1.535 0.401 0 C-N-CA 123.743 0.817 . . . . 0.0 112.386 -179.942 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 54.1 tt0 -66.46 159.06 27.92 Favored 'General case' 0 N--CA 1.468 0.47 0 CA-C-N 114.667 -1.151 . . . . 0.0 110.061 179.272 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 67.2 m-20 -140.91 138.0 33.54 Favored 'General case' 0 N--CA 1.477 0.921 0 C-N-CA 122.775 0.43 . . . . 0.0 110.001 179.835 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' I' I ' 24' ' ' VAL . . . . . . . . . . . . . 21.3 t -85.99 -115.52 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.926 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 179.653 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . -110.16 53.6 0.58 Allowed Glycine 0 N--CA 1.479 1.501 0 N-CA-C 111.579 -0.609 . . . . 0.0 111.579 -179.702 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 68.7 p -79.74 126.24 30.7 Favored 'General case' 0 N--CA 1.467 0.411 0 N-CA-C 109.036 -0.727 . . . . 0.0 109.036 178.026 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 49.8 t30 -67.52 99.9 0.81 Allowed 'General case' 0 N--CA 1.47 0.527 0 N-CA-C 108.379 -0.971 . . . . 0.0 108.379 178.483 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 67.0 mttm -96.2 119.79 35.32 Favored 'General case' 0 N--CA 1.482 1.165 0 N-CA-C 110.216 -0.29 . . . . 0.0 110.216 -179.135 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.13 -123.23 0.01 OUTLIER Glycine 0 CA--C 1.534 1.254 0 N-CA-C 110.656 -0.978 . . . . 0.0 110.656 178.746 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -129.4 132.74 47.09 Favored 'General case' 0 N--CA 1.473 0.683 0 C-N-CA 122.962 0.505 . . . . 0.0 109.65 179.657 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 69.5 mt -81.75 140.68 16.16 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.637 0 N-CA-C 106.982 -1.488 . . . . 0.0 106.982 178.387 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 23.3 mt -129.89 130.44 66.37 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.383 0 CA-C-N 118.939 0.79 . . . . 0.0 109.361 179.868 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 60.63 80.04 0.11 Allowed Glycine 0 CA--C 1.528 0.846 0 CA-C-N 116.331 -0.395 . . . . 0.0 113.107 179.25 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 1.9 tt -112.0 119.6 39.02 Favored 'General case' 0 N--CA 1.478 0.949 0 N-CA-C 106.891 -1.522 . . . . 0.0 106.891 177.446 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 8.6 ttt -155.29 163.08 40.63 Favored 'General case' 0 N--CA 1.478 0.943 0 N-CA-C 108.256 -1.016 . . . . 0.0 108.256 179.518 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 97.7 t -159.76 150.94 6.17 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 N-CA-C 106.253 -1.758 . . . . 0.0 106.253 -179.915 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' I' I ' 37' ' ' GLY . . . . . 0.551 ' H ' HE22 ' I' ' 15' ' ' GLN . . . 56.14 74.45 0.33 Allowed Glycine 0 C--N 1.313 -0.739 0 CA-C-N 115.891 -0.595 . . . . 0.0 112.023 178.115 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 168.76 -146.4 10.31 Favored Glycine 0 N--CA 1.47 0.915 0 N-CA-C 110.602 -0.999 . . . . 0.0 110.602 179.268 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 22.8 m -134.06 141.79 42.88 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.873 0 CA-C-N 117.01 0.405 . . . . 0.0 109.981 179.921 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 19.2 t . . . . . 0 N--CA 1.469 0.506 0 CA-C-O 117.825 -1.083 . . . . 0.0 110.939 179.507 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 78.5 m-85 . . . . . 0 N--CA 1.475 0.795 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 72.2 mtp180 -143.62 141.17 30.5 Favored 'General case' 0 N--CA 1.481 1.116 0 N-CA-C 109.076 -0.713 . . . . 0.0 109.076 179.964 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 77.0 m80 -149.48 119.65 7.26 Favored 'General case' 0 N--CA 1.47 0.562 0 N-CA-C 108.806 -0.813 . . . . 0.0 108.806 179.136 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 7.4 m-20 -68.3 150.21 48.5 Favored 'General case' 0 CA--C 1.529 0.168 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.258 -179.437 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 8.5 t -166.95 172.27 10.41 Favored 'General case' 0 N--CA 1.472 0.63 0 N-CA-C 109.554 -0.536 . . . . 0.0 109.554 178.476 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.53 23.52 2.32 Favored Glycine 0 N--CA 1.487 2.097 0 N-CA-C 112.239 -0.344 . . . . 0.0 112.239 179.417 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 41.8 p90 -56.98 128.28 36.13 Favored 'General case' 0 N--CA 1.474 0.761 0 N-CA-C 112.088 0.403 . . . . 0.0 112.088 -179.912 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 57.4 mt-10 -85.66 155.38 21.12 Favored 'General case' 0 N--CA 1.469 0.504 0 N-CA-C 109.273 -0.64 . . . . 0.0 109.273 178.493 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -153.75 128.79 1.51 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 N-CA-C 108.107 -1.071 . . . . 0.0 108.107 178.839 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 49.5 m-70 -134.64 146.54 49.64 Favored 'General case' 0 N--CA 1.489 1.503 0 CA-C-N 118.641 0.655 . . . . 0.0 111.154 -179.024 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 6.4 t60 -164.96 97.91 0.74 Allowed 'General case' 0 N--CA 1.48 1.04 0 CA-C-N 116.502 -0.317 . . . . 0.0 111.055 179.582 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 35.0 mt-30 -106.06 -172.7 2.14 Favored 'General case' 0 CA--C 1.505 -0.762 0 N-CA-C 108.369 -0.974 . . . . 0.0 108.369 179.915 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . 0.403 ' C ' HD12 ' A' ' 17' ' ' LEU . 88.6 tttt -169.18 96.47 0.34 Allowed 'General case' 0 N--CA 1.472 0.629 0 CA-C-N 115.139 -0.937 . . . . 0.0 109.416 178.703 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.58 HD12 ' N ' ' A' ' 17' ' ' LEU . 4.8 mp -106.38 165.01 11.57 Favored 'General case' 0 N--CA 1.489 1.498 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 179.901 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 56.5 t -141.78 119.22 7.96 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.387 0 CA-C-O 118.934 -0.555 . . . . 0.0 109.897 179.68 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 52.4 m-85 -69.9 158.93 34.62 Favored 'General case' 0 N--CA 1.481 1.079 0 N-CA-C 107.592 -1.262 . . . . 0.0 107.592 177.392 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 13.1 t80 -171.22 -58.59 0.02 OUTLIER 'General case' 0 N--CA 1.485 1.324 0 CA-C-O 122.299 1.047 . . . . 0.0 109.73 179.485 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -38.82 90.11 0.0 OUTLIER 'General case' 0 C--O 1.232 0.142 0 CA-C-N 113.926 -1.488 . . . . 0.0 112.968 -177.985 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 37.0 tt0 -66.51 157.81 31.24 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 115.109 -0.95 . . . . 0.0 110.452 179.197 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 66.7 m-20 -139.98 137.38 34.66 Favored 'General case' 0 N--CA 1.48 1.071 0 C-N-CA 123.002 0.521 . . . . 0.0 110.344 179.866 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 17.9 t -84.49 -116.3 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.962 0 N-CA-C 108.444 -0.947 . . . . 0.0 108.444 179.501 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -110.37 54.63 0.54 Allowed Glycine 0 N--CA 1.475 1.265 0 N-CA-C 111.227 -0.749 . . . . 0.0 111.227 179.916 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 74.8 p -79.98 125.96 30.43 Favored 'General case' 0 C--O 1.221 -0.417 0 N-CA-C 108.969 -0.752 . . . . 0.0 108.969 178.378 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 19.9 t-20 -66.6 100.42 0.67 Allowed 'General case' 0 N--CA 1.473 0.725 0 N-CA-C 108.576 -0.898 . . . . 0.0 108.576 178.704 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 66.6 mttm -96.85 120.34 37.01 Favored 'General case' 0 N--CA 1.483 1.182 0 N-CA-C 110.093 -0.336 . . . . 0.0 110.093 -179.157 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.58 -128.41 0.01 OUTLIER Glycine 0 CA--C 1.534 1.223 0 N-CA-C 110.525 -1.03 . . . . 0.0 110.525 178.779 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -126.05 133.86 51.59 Favored 'General case' 0 N--CA 1.48 1.052 0 N-CA-C 109.234 -0.654 . . . . 0.0 109.234 179.097 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 65.4 mt -83.21 137.81 20.34 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.538 0 N-CA-C 107.393 -1.336 . . . . 0.0 107.393 178.683 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 20.9 mt -129.44 129.25 66.95 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.976 0 O-C-N 123.495 0.497 . . . . 0.0 110.053 -178.424 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 60.43 79.05 0.13 Allowed Glycine 0 CA--C 1.525 0.685 0 CA-C-N 115.849 -0.614 . . . . 0.0 113.069 178.949 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.421 HD23 ' N ' ' A' ' 35' ' ' MET . 1.9 tt -110.94 119.48 39.21 Favored 'General case' 0 N--CA 1.477 0.915 0 N-CA-C 106.973 -1.492 . . . . 0.0 106.973 177.463 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' MET . . . . . 0.421 ' N ' HD23 ' A' ' 34' ' ' LEU . 8.6 ttt -154.91 161.08 41.54 Favored 'General case' 0 N--CA 1.468 0.443 0 N-CA-C 109.066 -0.716 . . . . 0.0 109.066 179.257 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 63.1 t -157.75 150.48 8.55 Favored 'Isoleucine or valine' 0 C--O 1.232 0.148 0 N-CA-C 106.897 -1.52 . . . . 0.0 106.897 -179.496 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.61 75.42 0.24 Allowed Glycine 0 C--N 1.315 -0.607 0 CA-C-N 115.671 -0.695 . . . . 0.0 111.777 178.201 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 168.83 -149.12 13.2 Favored Glycine 0 CA--C 1.519 0.3 0 N-CA-C 110.744 -0.943 . . . . 0.0 110.744 179.847 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 20.7 m -132.57 142.87 41.38 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.874 0 N-CA-C 109.598 -0.519 . . . . 0.0 109.598 179.658 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 21.2 t . . . . . 0 N--CA 1.467 0.399 0 CA-C-O 117.834 -1.079 . . . . 0.0 110.831 179.29 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 78.9 m-85 . . . . . 0 N--CA 1.474 0.726 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 72.2 mtp180 -143.68 141.14 30.41 Favored 'General case' 0 N--CA 1.481 1.108 0 N-CA-C 109.121 -0.696 . . . . 0.0 109.121 -179.931 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 76.7 m80 -149.51 119.6 7.22 Favored 'General case' 0 N--CA 1.471 0.615 0 N-CA-C 108.841 -0.8 . . . . 0.0 108.841 179.122 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 7' ' ' ASP . . . . . . . . . . . . . 8.5 m-20 -68.09 150.2 48.69 Favored 'General case' 0 CA--C 1.53 0.19 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.281 -179.453 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 8' ' ' SER . . . . . . . . . . . . . 8.4 t -166.98 172.2 10.43 Favored 'General case' 0 N--CA 1.472 0.631 0 N-CA-C 109.537 -0.542 . . . . 0.0 109.537 178.557 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.5 23.38 2.36 Favored Glycine 0 N--CA 1.487 2.051 0 N-CA-C 112.159 -0.377 . . . . 0.0 112.159 179.371 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 41.9 p90 -56.78 128.16 35.22 Favored 'General case' 0 N--CA 1.471 0.616 0 N-CA-C 112.166 0.432 . . . . 0.0 112.166 -179.983 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 57.4 mt-10 -85.58 155.64 21.07 Favored 'General case' 0 N--CA 1.471 0.58 0 N-CA-C 109.297 -0.631 . . . . 0.0 109.297 178.555 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -153.88 128.68 1.46 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 N-CA-C 108.186 -1.042 . . . . 0.0 108.186 178.816 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 50.1 m-70 -134.57 146.75 49.93 Favored 'General case' 0 N--CA 1.489 1.513 0 CA-C-N 118.481 0.582 . . . . 0.0 111.219 -179.018 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 6.5 t60 -165.32 97.82 0.7 Allowed 'General case' 0 N--CA 1.481 1.108 0 CA-C-N 116.519 -0.309 . . . . 0.0 111.022 179.627 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 35.2 mt-30 -105.96 -172.89 2.17 Favored 'General case' 0 CA--C 1.504 -0.789 0 N-CA-C 108.407 -0.96 . . . . 0.0 108.407 179.949 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 16' ' ' LYS . . . . . 0.408 ' C ' HD12 ' B' ' 17' ' ' LEU . 88.6 tttt -169.14 96.35 0.34 Allowed 'General case' 0 CA--C 1.54 0.592 0 CA-C-N 115.193 -0.912 . . . . 0.0 109.447 178.76 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . 0.578 ' N ' HD12 ' B' ' 17' ' ' LEU . 4.8 mp -106.41 164.82 11.73 Favored 'General case' 0 N--CA 1.488 1.461 0 N-CA-C 108.575 -0.898 . . . . 0.0 108.575 179.968 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 58.6 t -141.55 119.26 8.53 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.355 0 CA-C-O 118.957 -0.544 . . . . 0.0 109.9 179.566 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 53.3 m-85 -70.53 159.09 34.94 Favored 'General case' 0 N--CA 1.479 0.982 0 N-CA-C 107.52 -1.289 . . . . 0.0 107.52 177.316 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 14.4 t80 -171.84 -57.33 0.02 OUTLIER 'General case' 0 N--CA 1.482 1.138 0 CA-C-O 122.228 1.013 . . . . 0.0 109.838 179.452 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -39.39 90.37 0.0 OUTLIER 'General case' 0 C--O 1.232 0.152 0 CA-C-N 114.09 -1.413 . . . . 0.0 112.874 -178.052 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 36.6 tt0 -66.42 158.03 30.43 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 115.058 -0.973 . . . . 0.0 110.56 179.133 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 67.6 m-20 -140.37 137.42 34.04 Favored 'General case' 0 N--CA 1.481 1.089 0 C-N-CA 122.993 0.517 . . . . 0.0 110.251 179.805 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 17.5 t -84.59 -116.55 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 1.016 0 N-CA-C 108.65 -0.87 . . . . 0.0 108.65 179.482 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -109.46 54.01 0.56 Allowed Glycine 0 N--CA 1.476 1.331 0 N-CA-C 111.189 -0.764 . . . . 0.0 111.189 179.878 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 74.2 p -79.7 126.04 30.42 Favored 'General case' 0 C--O 1.221 -0.405 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 178.386 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 19.7 t-20 -66.89 100.19 0.7 Allowed 'General case' 0 N--CA 1.474 0.761 0 N-CA-C 108.673 -0.862 . . . . 0.0 108.673 178.565 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 66.8 mttm -96.68 120.47 37.06 Favored 'General case' 0 N--CA 1.483 1.186 0 N-CA-C 110.118 -0.327 . . . . 0.0 110.118 -179.142 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.68 -127.73 0.01 OUTLIER Glycine 0 CA--C 1.534 1.246 0 N-CA-C 110.538 -1.025 . . . . 0.0 110.538 178.755 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -126.83 133.62 50.72 Favored 'General case' 0 N--CA 1.481 1.104 0 N-CA-C 109.165 -0.68 . . . . 0.0 109.165 179.252 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 64.4 mt -82.96 137.97 20.11 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.452 0 N-CA-C 107.363 -1.347 . . . . 0.0 107.363 178.59 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 21.6 mt -129.72 129.19 66.26 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.971 0 O-C-N 123.546 0.528 . . . . 0.0 109.941 -178.42 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 60.4 78.76 0.14 Allowed Glycine 0 CA--C 1.524 0.63 0 CA-C-N 115.828 -0.624 . . . . 0.0 113.094 178.915 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 34' ' ' LEU . . . . . 0.417 HD23 ' N ' ' B' ' 35' ' ' MET . 1.9 tt -110.39 119.61 39.77 Favored 'General case' 0 N--CA 1.478 0.953 0 N-CA-C 106.975 -1.491 . . . . 0.0 106.975 177.351 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 35' ' ' MET . . . . . 0.417 ' N ' HD23 ' B' ' 34' ' ' LEU . 8.7 ttt -154.89 160.79 41.43 Favored 'General case' 0 N--CA 1.47 0.562 0 N-CA-C 108.97 -0.752 . . . . 0.0 108.97 179.283 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 63.4 t -157.64 150.31 8.81 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.136 0 N-CA-C 106.825 -1.546 . . . . 0.0 106.825 -179.511 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.54 75.73 0.23 Allowed Glycine 0 C--N 1.314 -0.669 0 CA-C-N 115.659 -0.701 . . . . 0.0 111.771 178.169 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 168.52 -149.09 13.32 Favored Glycine 0 CA--C 1.519 0.306 0 N-CA-C 110.704 -0.958 . . . . 0.0 110.704 179.879 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 20.7 m -132.52 142.91 41.32 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.907 0 N-CA-C 109.643 -0.503 . . . . 0.0 109.643 179.676 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 21.2 t . . . . . 0 N--CA 1.467 0.405 0 CA-C-O 117.812 -1.089 . . . . 0.0 110.848 179.292 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 78.1 m-85 . . . . . 0 N--CA 1.474 0.737 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 72.4 mtp180 -143.61 141.07 30.46 Favored 'General case' 0 N--CA 1.482 1.136 0 N-CA-C 109.043 -0.725 . . . . 0.0 109.043 -179.857 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 76.5 m80 -149.47 119.64 7.26 Favored 'General case' 0 N--CA 1.47 0.571 0 N-CA-C 108.826 -0.805 . . . . 0.0 108.826 179.109 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' C' C ' 7' ' ' ASP . . . . . . . . . . . . . 7.6 m-20 -68.13 150.03 48.86 Favored 'General case' 0 CA--C 1.529 0.168 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.332 -179.381 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' C' C ' 8' ' ' SER . . . . . . . . . . . . . 8.5 t -166.71 172.73 10.27 Favored 'General case' 0 N--CA 1.471 0.618 0 N-CA-C 109.611 -0.514 . . . . 0.0 109.611 178.352 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.13 23.33 2.46 Favored Glycine 0 N--CA 1.487 2.042 0 N-CA-C 112.24 -0.344 . . . . 0.0 112.24 179.484 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 41.5 p90 -56.84 128.34 36.2 Favored 'General case' 0 N--CA 1.472 0.646 0 N-CA-C 112.088 0.403 . . . . 0.0 112.088 -179.896 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 57.5 mt-10 -85.79 155.27 21.08 Favored 'General case' 0 N--CA 1.47 0.556 0 N-CA-C 109.239 -0.652 . . . . 0.0 109.239 178.63 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -153.59 128.61 1.5 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 N-CA-C 108.181 -1.044 . . . . 0.0 108.181 178.853 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 49.5 m-70 -134.49 146.65 49.94 Favored 'General case' 0 N--CA 1.489 1.49 0 CA-C-N 118.541 0.609 . . . . 0.0 111.265 -179.105 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 6.4 t60 -165.15 98.04 0.72 Allowed 'General case' 0 N--CA 1.48 1.067 0 CA-C-N 116.572 -0.286 . . . . 0.0 111.085 179.596 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 35.1 mt-30 -106.36 -172.76 2.15 Favored 'General case' 0 CA--C 1.504 -0.807 0 N-CA-C 108.414 -0.958 . . . . 0.0 108.414 -179.99 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' C' C ' 16' ' ' LYS . . . . . 0.408 ' C ' HD12 ' C' ' 17' ' ' LEU . 88.7 tttt -169.18 96.45 0.34 Allowed 'General case' 0 CA--C 1.54 0.56 0 CA-C-N 115.12 -0.945 . . . . 0.0 109.451 178.751 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' C' C ' 17' ' ' LEU . . . . . 0.577 HD12 ' N ' ' C' ' 17' ' ' LEU . 4.8 mp -106.26 164.91 11.63 Favored 'General case' 0 N--CA 1.488 1.472 0 N-CA-C 108.584 -0.895 . . . . 0.0 108.584 179.968 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 58.5 t -141.71 118.94 7.76 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.341 0 CA-C-O 118.95 -0.548 . . . . 0.0 109.879 179.655 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 53.3 m-85 -70.25 159.0 34.84 Favored 'General case' 0 N--CA 1.478 0.956 0 N-CA-C 107.491 -1.3 . . . . 0.0 107.491 177.345 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 14.4 t80 -171.77 -57.41 0.02 OUTLIER 'General case' 0 N--CA 1.481 1.092 0 CA-C-O 122.183 0.992 . . . . 0.0 109.856 179.357 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -39.26 90.61 0.0 OUTLIER 'General case' 0 C--O 1.232 0.14 0 CA-C-N 114.125 -1.398 . . . . 0.0 112.849 -178.049 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 37.0 tt0 -66.74 158.05 31.21 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 115.096 -0.956 . . . . 0.0 110.513 179.219 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 67.2 m-20 -140.33 137.4 34.08 Favored 'General case' 0 N--CA 1.48 1.054 0 C-N-CA 122.944 0.498 . . . . 0.0 110.331 179.794 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 17.7 t -84.53 -116.42 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.967 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 179.588 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -109.86 54.35 0.55 Allowed Glycine 0 N--CA 1.475 1.275 0 N-CA-C 111.172 -0.771 . . . . 0.0 111.172 179.915 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 74.7 p -79.91 126.25 30.77 Favored 'General case' 0 C--O 1.222 -0.358 0 N-CA-C 109.004 -0.739 . . . . 0.0 109.004 178.417 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 19.4 t-20 -66.99 100.37 0.73 Allowed 'General case' 0 N--CA 1.474 0.737 0 N-CA-C 108.682 -0.858 . . . . 0.0 108.682 178.606 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 66.8 mttm -96.86 120.09 36.54 Favored 'General case' 0 N--CA 1.484 1.251 0 N-CA-C 110.161 -0.311 . . . . 0.0 110.161 -179.138 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.34 -128.17 0.01 OUTLIER Glycine 0 CA--C 1.535 1.313 0 N-CA-C 110.529 -1.028 . . . . 0.0 110.529 178.76 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -126.33 133.75 51.29 Favored 'General case' 0 N--CA 1.48 1.073 0 N-CA-C 109.269 -0.641 . . . . 0.0 109.269 179.12 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 65.7 mt -83.06 137.82 20.35 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.525 0 N-CA-C 107.282 -1.377 . . . . 0.0 107.282 178.614 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 20.9 mt -129.59 128.81 66.27 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.935 0 O-C-N 123.545 0.528 . . . . 0.0 110.119 -178.507 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 60.84 78.55 0.15 Allowed Glycine 0 CA--C 1.524 0.654 0 CA-C-N 115.97 -0.559 . . . . 0.0 113.063 178.848 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' C' C ' 34' ' ' LEU . . . . . 0.413 HD23 ' N ' ' C' ' 35' ' ' MET . 1.9 tt -110.41 119.16 38.31 Favored 'General case' 0 N--CA 1.478 0.945 0 N-CA-C 107.021 -1.474 . . . . 0.0 107.021 177.463 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' C' C ' 35' ' ' MET . . . . . 0.413 ' N ' HD23 ' C' ' 34' ' ' LEU . 8.5 ttt -154.44 161.08 41.89 Favored 'General case' 0 N--CA 1.468 0.456 0 N-CA-C 108.976 -0.75 . . . . 0.0 108.976 179.356 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 63.4 t -158.03 150.13 8.42 Favored 'Isoleucine or valine' 0 C--O 1.232 0.158 0 N-CA-C 106.816 -1.55 . . . . 0.0 106.816 -179.393 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.68 75.54 0.24 Allowed Glycine 0 C--N 1.315 -0.635 0 CA-C-N 115.776 -0.647 . . . . 0.0 111.75 178.172 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 168.76 -148.95 12.95 Favored Glycine 0 CA--C 1.519 0.325 0 N-CA-C 110.639 -0.984 . . . . 0.0 110.639 179.88 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 20.1 m -132.79 142.7 41.67 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.875 0 N-CA-C 109.666 -0.494 . . . . 0.0 109.666 179.716 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 21.3 t . . . . . 0 N--CA 1.468 0.454 0 CA-C-O 117.726 -1.13 . . . . 0.0 110.718 179.244 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 86.9 m-85 . . . . . 0 N--CA 1.473 0.689 0 N-CA-C 108.275 -1.009 . . . . 0.0 108.275 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' D' D ' 5' ' ' ARG . . . . . . . . . . . . . 72.5 mtp180 -147.31 141.18 25.82 Favored 'General case' 0 N--CA 1.476 0.829 0 N-CA-C 108.896 -0.779 . . . . 0.0 108.896 179.757 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 77.1 m80 -149.22 123.43 9.53 Favored 'General case' 0 CA--C 1.539 0.527 0 N-CA-C 107.915 -1.143 . . . . 0.0 107.915 175.724 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' D' D ' 7' ' ' ASP . . . . . . . . . . . . . 5.6 m-20 -63.12 133.77 54.96 Favored 'General case' 0 C--N 1.319 -0.719 0 C-N-CA 127.188 2.195 . . . . 0.0 114.882 176.081 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' D' D ' 8' ' ' SER . . . . . . . . . . . . . 7.9 t -154.09 174.36 14.81 Favored 'General case' 0 N--CA 1.477 0.914 0 CA-C-N 118.751 0.705 . . . . 0.0 110.302 176.958 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 124.29 20.25 2.48 Favored Glycine 0 N--CA 1.483 1.787 0 N-CA-C 112.232 -0.347 . . . . 0.0 112.232 176.645 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 37.0 p90 -55.91 130.29 43.11 Favored 'General case' 0 CA--C 1.546 0.79 0 CA-C-O 121.07 0.462 . . . . 0.0 111.881 -177.494 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 57.3 mt-10 -85.71 152.83 22.76 Favored 'General case' 0 N--CA 1.474 0.759 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 177.681 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -149.38 129.97 4.45 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.455 0 N-CA-C 108.009 -1.108 . . . . 0.0 108.009 175.229 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 48.9 m-70 -129.74 149.7 51.38 Favored 'General case' 0 N--CA 1.482 1.128 0 CA-C-N 117.939 0.336 . . . . 0.0 111.503 176.727 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 6.6 t60 -164.81 104.66 0.8 Allowed 'General case' 0 N--CA 1.482 1.133 0 N-CA-C 109.539 -0.541 . . . . 0.0 109.539 173.203 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 35.2 mt-30 -109.32 -175.62 2.81 Favored 'General case' 0 CA--C 1.494 -1.18 0 N-CA-C 108.28 -1.007 . . . . 0.0 108.28 178.978 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' D' D ' 16' ' ' LYS . . . . . 0.453 ' C ' HD12 ' D' ' 17' ' ' LEU . 88.7 tttt -165.77 105.25 0.7 Allowed 'General case' 0 CA--C 1.538 0.504 0 N-CA-C 107.637 -1.246 . . . . 0.0 107.637 175.331 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' D' D ' 17' ' ' LEU . . . . . 0.522 HD12 ' N ' ' D' ' 17' ' ' LEU . 5.6 mp -113.2 163.2 15.07 Favored 'General case' 0 N--CA 1.488 1.454 0 N-CA-C 108.225 -1.028 . . . . 0.0 108.225 179.699 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 51.8 t -140.9 123.67 15.72 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.187 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 176.215 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 78.7 m-85 -62.43 151.2 37.84 Favored 'General case' 0 C--N 1.353 0.759 0 C-N-CA 124.726 1.21 . . . . 0.0 110.412 170.862 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 9.3 t80 -170.0 -66.64 0.02 OUTLIER 'General case' 0 N--CA 1.476 0.871 0 N-CA-C 107.81 -1.182 . . . . 0.0 107.81 -179.835 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -38.27 95.75 0.01 OUTLIER 'General case' 0 CA--C 1.535 0.39 0 CA-C-N 113.972 -1.467 . . . . 0.0 111.731 -174.603 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 37.2 tt0 -68.7 158.72 33.61 Favored 'General case' 0 N--CA 1.467 0.421 0 CA-C-N 113.36 -1.746 . . . . 0.0 110.243 178.65 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 67.8 m-20 -140.34 141.17 35.69 Favored 'General case' 0 N--CA 1.475 0.822 0 N-CA-C 109.517 -0.549 . . . . 0.0 109.517 178.585 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' D' D ' 24' ' ' VAL . . . . . . . . . . . . . 19.6 t -87.83 -119.62 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.486 1.368 0 N-CA-C 107.752 -1.203 . . . . 0.0 107.752 179.727 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . -113.31 61.85 0.32 Allowed Glycine 0 C--N 1.372 2.559 0 C-N-CA 118.005 -2.045 . . . . 0.0 109.313 178.81 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 90.9 p -70.35 121.44 17.69 Favored 'General case' 0 C--N 1.349 0.574 0 CA-C-O 116.647 -1.644 . . . . 0.0 112.016 169.276 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 17.2 t-20 -61.36 101.67 0.18 Allowed 'General case' 0 N--CA 1.474 0.772 0 CA-C-N 121.558 1.981 . . . . 0.0 109.486 172.485 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 66.3 mttm -100.12 121.75 41.9 Favored 'General case' 0 N--CA 1.49 1.558 0 CA-C-N 119.64 1.109 . . . . 0.0 109.366 178.803 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -54.16 -130.2 0.0 OUTLIER Glycine 0 CA--C 1.529 0.961 0 CA-C-N 115.664 -0.698 . . . . 0.0 112.68 175.57 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -125.17 139.95 53.29 Favored 'General case' 0 C--N 1.373 1.614 0 N-CA-C 108.567 -0.901 . . . . 0.0 108.567 174.052 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 65.3 mt -84.13 140.29 16.35 Favored 'Isoleucine or valine' 0 C--O 1.239 0.506 0 N-CA-C 107.403 -1.332 . . . . 0.0 107.403 176.478 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 29.1 mt -131.89 132.95 61.51 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.017 0 N-CA-C 108.66 -0.866 . . . . 0.0 108.66 178.367 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.31 76.99 0.22 Allowed Glycine 0 C--O 1.248 0.994 0 CA-C-O 118.102 -1.388 . . . . 0.0 112.404 178.449 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' D' D ' 34' ' ' LEU . . . . . 0.406 HD23 ' N ' ' D' ' 35' ' ' MET . 2.4 tt -110.2 131.43 55.07 Favored 'General case' 0 C--N 1.372 1.562 0 N-CA-C 103.96 -2.607 . . . . 0.0 103.96 174.968 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' D' D ' 35' ' ' MET . . . . . 0.406 ' N ' HD23 ' D' ' 34' ' ' LEU . 8.3 ttt -156.85 166.7 32.63 Favored 'General case' 0 N--CA 1.471 0.594 0 N-CA-C 108.679 -0.86 . . . . 0.0 108.679 176.685 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 91.6 t -163.58 154.31 2.55 Favored 'Isoleucine or valine' 0 C--O 1.241 0.647 0 N-CA-C 105.545 -2.02 . . . . 0.0 105.545 175.379 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 61.39 66.51 2.61 Favored Glycine 0 N--CA 1.444 -0.782 0 C-N-CA 118.039 -2.029 . . . . 0.0 113.619 176.76 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 167.27 -148.39 13.05 Favored Glycine 0 N--CA 1.468 0.805 0 CA-C-O 118.163 -1.354 . . . . 0.0 111.859 -178.577 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 21.4 m -129.74 143.04 42.32 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.166 0 CA-C-N 118.896 1.348 . . . . 0.0 109.64 -179.944 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 18.8 t . . . . . 0 C--O 1.215 -0.745 0 N-CA-C 109.204 -0.665 . . . . 0.0 109.204 174.798 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 79.1 m-85 . . . . . 0 N--CA 1.476 0.829 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' E' E ' 5' ' ' ARG . . . . . . . . . . . . . 72.3 mtp180 -143.62 141.96 30.84 Favored 'General case' 0 N--CA 1.478 0.933 0 N-CA-C 109.392 -0.595 . . . . 0.0 109.392 179.893 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 76.8 m80 -150.37 118.23 6.24 Favored 'General case' 0 N--CA 1.473 0.692 0 N-CA-C 108.962 -0.755 . . . . 0.0 108.962 179.123 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' E' E ' 7' ' ' ASP . . . . . . . . . . . . . 7.5 m-20 -66.7 149.96 49.77 Favored 'General case' 0 N--CA 1.463 0.224 0 O-C-N 123.542 0.526 . . . . 0.0 111.639 -179.515 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' E' E ' 8' ' ' SER . . . . . . . . . . . . . 7.9 t -166.95 173.43 9.33 Favored 'General case' 0 N--CA 1.476 0.875 0 CA-C-N 115.965 -0.561 . . . . 0.0 109.549 178.003 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.85 23.59 2.23 Favored Glycine 0 N--CA 1.482 1.737 0 N-CA-C 111.908 -0.477 . . . . 0.0 111.908 179.163 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 38.2 p90 -56.64 127.49 31.65 Favored 'General case' 0 N--CA 1.473 0.676 0 N-CA-C 112.602 0.593 . . . . 0.0 112.602 -179.241 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 57.0 mt-10 -84.34 156.2 21.99 Favored 'General case' 0 N--CA 1.476 0.827 0 N-CA-C 109.482 -0.562 . . . . 0.0 109.482 178.045 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -155.62 127.9 1.03 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.512 0 N-CA-C 108.185 -1.042 . . . . 0.0 108.185 178.702 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 49.0 m-70 -135.08 144.81 47.4 Favored 'General case' 0 N--CA 1.48 1.073 0 CA-C-O 120.757 0.313 . . . . 0.0 111.38 -177.933 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 6.3 t60 -163.94 97.94 0.84 Allowed 'General case' 0 N--CA 1.487 1.379 0 CA-C-N 116.652 -0.249 . . . . 0.0 111.064 179.702 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 35.2 mt-30 -105.51 -172.45 2.1 Favored 'General case' 0 CA--C 1.502 -0.878 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 -179.951 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -169.45 96.56 0.32 Allowed 'General case' 0 CA--C 1.542 0.638 0 CA-C-N 115.018 -0.992 . . . . 0.0 109.402 178.658 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' E' E ' 17' ' ' LEU . . . . . 0.566 ' N ' HD12 ' E' ' 17' ' ' LEU . 4.8 mp -106.21 164.11 12.26 Favored 'General case' 0 N--CA 1.49 1.547 0 N-CA-C 109.233 -0.654 . . . . 0.0 109.233 -179.765 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 40.8 t -141.59 118.46 7.5 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 C-N-CA 122.563 0.345 . . . . 0.0 110.551 179.085 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 52.7 m-85 -69.45 156.54 38.69 Favored 'General case' 0 C--N 1.358 0.957 0 N-CA-C 107.397 -1.335 . . . . 0.0 107.397 176.696 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 12.7 t80 -173.28 -55.06 0.02 OUTLIER 'General case' 0 N--CA 1.485 1.299 0 CA-C-O 121.741 0.782 . . . . 0.0 110.368 179.472 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.23 89.1 0.0 OUTLIER 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 114.398 -1.274 . . . . 0.0 112.852 -179.009 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 37.0 tt0 -65.16 158.31 26.37 Favored 'General case' 0 N--CA 1.472 0.646 0 CA-C-N 114.876 -1.056 . . . . 0.0 110.698 179.604 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 66.1 m-20 -140.68 137.03 33.23 Favored 'General case' 0 N--CA 1.479 0.997 0 C-N-CA 122.853 0.461 . . . . 0.0 110.518 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 21.8 t -84.52 -115.5 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.066 0 N-CA-C 108.715 -0.846 . . . . 0.0 108.715 179.48 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . -110.09 54.38 0.55 Allowed Glycine 0 C--N 1.348 1.214 0 N-CA-C 111.362 -0.695 . . . . 0.0 111.362 -179.827 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 73.2 p -79.72 125.27 29.44 Favored 'General case' 0 N--CA 1.473 0.709 0 N-CA-C 109.34 -0.615 . . . . 0.0 109.34 178.059 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 18.4 t-20 -66.27 99.88 0.58 Allowed 'General case' 0 N--CA 1.474 0.765 0 N-CA-C 108.063 -1.088 . . . . 0.0 108.063 178.386 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 65.9 mttm -96.99 119.45 35.5 Favored 'General case' 0 N--CA 1.485 1.293 0 N-CA-C 109.966 -0.383 . . . . 0.0 109.966 -178.744 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.28 -127.32 0.01 OUTLIER Glycine 0 CA--C 1.539 1.581 0 N-CA-C 110.988 -0.845 . . . . 0.0 110.988 178.724 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -126.9 133.2 50.73 Favored 'General case' 0 N--CA 1.481 1.102 0 N-CA-C 109.585 -0.524 . . . . 0.0 109.585 179.614 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 64.8 mt -82.38 138.17 19.88 Favored 'Isoleucine or valine' 0 C--O 1.236 0.35 0 N-CA-C 107.093 -1.447 . . . . 0.0 107.093 178.492 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 22.4 mt -129.3 129.49 67.35 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.858 0 N-CA-C 109.444 -0.576 . . . . 0.0 109.444 -179.426 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 60.65 80.27 0.1 Allowed Glycine 0 CA--C 1.523 0.554 0 CA-C-N 115.982 -0.554 . . . . 0.0 113.654 179.33 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 2.0 tt -111.98 118.99 36.99 Favored 'General case' 0 N--CA 1.479 0.992 0 N-CA-C 107.056 -1.461 . . . . 0.0 107.056 177.358 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 8.2 ttt -153.37 162.88 40.82 Favored 'General case' 0 C--O 1.209 -1.041 0 N-CA-C 108.696 -0.853 . . . . 0.0 108.696 179.202 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 78.0 t -159.65 150.27 6.46 Favored 'Isoleucine or valine' 0 C--O 1.236 0.351 0 N-CA-C 106.591 -1.633 . . . . 0.0 106.591 -179.748 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.53 74.97 0.27 Allowed Glycine 0 C--N 1.314 -0.656 0 CA-C-N 115.63 -0.714 . . . . 0.0 111.535 178.139 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 170.08 -148.14 11.44 Favored Glycine 0 C--O 1.222 -0.653 0 N-CA-C 111.248 -0.741 . . . . 0.0 111.248 -179.995 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 19.4 m -133.42 141.54 44.18 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.846 0 N-CA-C 109.188 -0.671 . . . . 0.0 109.188 179.498 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 19.0 t . . . . . 0 CA--C 1.535 0.372 0 CA-C-O 117.648 -1.168 . . . . 0.0 110.847 179.35 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 78.7 m-85 . . . . . 0 N--CA 1.475 0.798 0 N-CA-C 109.895 -0.409 . . . . 0.0 109.895 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' F' F ' 5' ' ' ARG . . . . . . . . . . . . . 72.4 mtp180 -143.43 141.62 30.91 Favored 'General case' 0 N--CA 1.477 0.878 0 N-CA-C 109.38 -0.6 . . . . 0.0 109.38 179.895 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 76.8 m80 -150.12 117.87 6.21 Favored 'General case' 0 N--CA 1.473 0.714 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 179.207 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' F' F ' 7' ' ' ASP . . . . . . . . . . . . . 7.5 m-20 -66.5 150.42 48.98 Favored 'General case' 0 N--CA 1.461 0.106 0 O-C-N 123.468 0.48 . . . . 0.0 111.711 -179.447 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' F' F ' 8' ' ' SER . . . . . . . . . . . . . 7.8 t -167.53 172.9 9.09 Favored 'General case' 0 N--CA 1.476 0.847 0 CA-C-N 116.015 -0.539 . . . . 0.0 109.568 178.065 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 123.34 23.63 2.12 Favored Glycine 0 N--CA 1.481 1.637 0 N-CA-C 111.997 -0.441 . . . . 0.0 111.997 179.064 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 36.6 p90 -56.74 127.97 34.18 Favored 'General case' 0 CA--C 1.542 0.671 0 N-CA-C 112.599 0.592 . . . . 0.0 112.599 -179.217 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 57.2 mt-10 -84.41 156.37 21.84 Favored 'General case' 0 N--CA 1.475 0.813 0 N-CA-C 109.457 -0.571 . . . . 0.0 109.457 178.063 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -155.77 127.53 0.96 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.586 0 N-CA-C 108.189 -1.041 . . . . 0.0 108.189 178.637 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 50.3 m-70 -134.76 144.73 47.87 Favored 'General case' 0 N--CA 1.481 1.078 0 CA-C-O 120.748 0.309 . . . . 0.0 111.341 -177.819 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 6.3 t60 -164.11 98.13 0.83 Allowed 'General case' 0 N--CA 1.486 1.356 0 CA-C-N 116.707 -0.224 . . . . 0.0 111.169 179.674 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 35.2 mt-30 -106.09 -172.36 2.07 Favored 'General case' 0 CA--C 1.498 -1.05 0 N-CA-C 108.787 -0.82 . . . . 0.0 108.787 179.989 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -169.23 96.87 0.34 Allowed 'General case' 0 CA--C 1.54 0.584 0 CA-C-N 114.891 -1.05 . . . . 0.0 109.443 178.687 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' F' F ' 17' ' ' LEU . . . . . 0.565 HD12 ' N ' ' F' ' 17' ' ' LEU . 4.7 mp -106.27 164.1 12.29 Favored 'General case' 0 N--CA 1.489 1.48 0 N-CA-C 109.209 -0.663 . . . . 0.0 109.209 -179.842 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 41.3 t -141.69 118.74 7.6 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.457 0 C-N-CA 122.55 0.34 . . . . 0.0 110.473 179.098 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 53.2 m-85 -69.56 156.49 38.82 Favored 'General case' 0 C--N 1.358 0.949 0 N-CA-C 107.253 -1.388 . . . . 0.0 107.253 176.612 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 13.1 t80 -173.15 -55.48 0.02 OUTLIER 'General case' 0 N--CA 1.484 1.267 0 CA-C-O 121.735 0.778 . . . . 0.0 109.904 179.484 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.73 88.89 0.0 OUTLIER 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 114.428 -1.26 . . . . 0.0 112.95 -179.047 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 36.7 tt0 -65.16 158.2 26.65 Favored 'General case' 0 N--CA 1.47 0.567 0 CA-C-N 114.952 -1.022 . . . . 0.0 110.786 179.504 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 66.5 m-20 -140.84 137.32 33.18 Favored 'General case' 0 N--CA 1.478 0.949 0 C-N-CA 122.813 0.445 . . . . 0.0 110.58 179.994 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' F' F ' 24' ' ' VAL . . . . . . . . . . . . . 21.5 t -84.84 -115.98 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.09 0 N-CA-C 108.811 -0.811 . . . . 0.0 108.811 179.523 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -109.48 54.08 0.56 Allowed Glycine 0 N--CA 1.479 1.511 0 N-CA-C 111.24 -0.744 . . . . 0.0 111.24 -179.836 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 75.6 p -79.46 125.04 29.04 Favored 'General case' 0 N--CA 1.472 0.668 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 177.883 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 18.5 t-20 -66.19 99.71 0.55 Allowed 'General case' 0 N--CA 1.472 0.672 0 N-CA-C 108.125 -1.065 . . . . 0.0 108.125 178.457 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 66.1 mttm -96.78 119.29 34.98 Favored 'General case' 0 N--CA 1.484 1.269 0 N-CA-C 110.056 -0.35 . . . . 0.0 110.056 -178.711 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.19 -127.51 0.01 OUTLIER Glycine 0 CA--C 1.54 1.623 0 N-CA-C 111.093 -0.803 . . . . 0.0 111.093 178.796 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -126.35 133.14 51.43 Favored 'General case' 0 N--CA 1.482 1.161 0 N-CA-C 109.577 -0.527 . . . . 0.0 109.577 179.612 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 65.4 mt -82.73 138.07 19.98 Favored 'Isoleucine or valine' 0 C--O 1.236 0.345 0 N-CA-C 106.958 -1.497 . . . . 0.0 106.958 178.497 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 23.5 mt -129.22 129.61 67.59 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.811 0 N-CA-C 109.381 -0.6 . . . . 0.0 109.381 -179.365 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 60.51 80.17 0.1 Allowed Glycine 0 CA--C 1.522 0.518 0 CA-C-N 115.986 -0.552 . . . . 0.0 113.618 179.271 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' F' F ' 34' ' ' LEU . . . . . 0.407 HD23 ' N ' ' F' ' 35' ' ' MET . 2.0 tt -111.89 119.28 38.0 Favored 'General case' 0 N--CA 1.479 0.991 0 N-CA-C 106.971 -1.492 . . . . 0.0 106.971 177.472 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' F' F ' 35' ' ' MET . . . . . 0.407 ' N ' HD23 ' F' ' 34' ' ' LEU . 8.5 ttt -153.93 162.97 40.8 Favored 'General case' 0 C--O 1.209 -1.075 0 N-CA-C 108.81 -0.811 . . . . 0.0 108.81 179.212 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 81.2 t -159.61 150.64 6.4 Favored 'Isoleucine or valine' 0 C--O 1.237 0.412 0 N-CA-C 106.713 -1.588 . . . . 0.0 106.713 -179.651 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.34 75.0 0.26 Allowed Glycine 0 C--N 1.314 -0.644 0 CA-C-N 115.662 -0.699 . . . . 0.0 111.483 178.089 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 170.1 -147.89 11.19 Favored Glycine 0 C--O 1.221 -0.668 0 N-CA-C 111.226 -0.75 . . . . 0.0 111.226 -179.993 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 19.6 m -133.77 141.42 44.17 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.884 0 N-CA-C 109.203 -0.666 . . . . 0.0 109.203 179.442 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 19.3 t . . . . . 0 CA--C 1.533 0.313 0 CA-C-O 117.605 -1.188 . . . . 0.0 110.868 179.365 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 78.6 m-85 . . . . . 0 N--CA 1.476 0.836 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' G' G ' 5' ' ' ARG . . . . . . . . . . . . . 72.7 mtp180 -143.93 141.16 30.09 Favored 'General case' 0 N--CA 1.483 1.191 0 N-CA-C 109.282 -0.636 . . . . 0.0 109.282 -179.657 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 76.9 m80 -149.49 119.36 7.1 Favored 'General case' 0 N--CA 1.473 0.715 0 N-CA-C 109.05 -0.722 . . . . 0.0 109.05 179.116 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 8.0 m-20 -68.74 145.96 53.36 Favored 'General case' 0 CA--C 1.536 0.411 0 O-C-N 123.472 0.482 . . . . 0.0 111.942 -179.327 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' G' G ' 8' ' ' SER . . . . . . . . . . . . . 7.1 t -163.83 174.2 11.83 Favored 'General case' 0 N--CA 1.47 0.55 0 N-CA-C 109.443 -0.577 . . . . 0.0 109.443 178.171 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 123.06 23.34 2.23 Favored Glycine 0 N--CA 1.48 1.606 0 N-CA-C 111.643 -0.583 . . . . 0.0 111.643 178.89 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 40.8 p90 -56.86 127.86 33.82 Favored 'General case' 0 N--CA 1.473 0.68 0 N-CA-C 112.418 0.525 . . . . 0.0 112.418 -178.89 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 57.6 mt-10 -84.94 154.74 22.0 Favored 'General case' 0 N--CA 1.473 0.717 0 CA-C-O 121.054 0.454 . . . . 0.0 109.981 178.795 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -155.26 127.67 1.04 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.97 0 N-CA-C 108.246 -1.02 . . . . 0.0 108.246 178.847 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 51.6 m-70 -133.77 146.13 50.44 Favored 'General case' 0 N--CA 1.476 0.844 0 CA-C-N 115.443 -0.799 . . . . 0.0 111.09 -178.159 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 6.4 t60 -165.57 97.74 0.68 Allowed 'General case' 0 N--CA 1.483 1.183 0 CA-C-N 116.511 -0.313 . . . . 0.0 110.656 179.123 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 35.8 mt-30 -105.7 -172.64 2.13 Favored 'General case' 0 CA--C 1.503 -0.862 0 N-CA-C 108.726 -0.842 . . . . 0.0 108.726 -179.849 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' G' G ' 16' ' ' LYS . . . . . 0.405 ' C ' HD12 ' G' ' 17' ' ' LEU . 88.5 tttt -169.2 97.07 0.35 Allowed 'General case' 0 CA--C 1.54 0.587 0 CA-C-N 115.0 -1.0 . . . . 0.0 109.444 178.629 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' G' G ' 17' ' ' LEU . . . . . 0.572 ' N ' HD12 ' G' ' 17' ' ' LEU . 5.4 mp -106.31 163.14 13.07 Favored 'General case' 0 N--CA 1.487 1.387 0 N-CA-C 109.427 -0.583 . . . . 0.0 109.427 -179.669 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 39.6 t -142.5 118.92 6.04 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.068 0 CA-C-O 120.886 0.374 . . . . 0.0 110.327 178.779 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 47.2 m-85 -69.79 150.32 47.0 Favored 'General case' 0 C--N 1.37 1.482 0 N-CA-C 107.357 -1.349 . . . . 0.0 107.357 176.737 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 10.7 t80 -170.73 -55.26 0.02 OUTLIER 'General case' 0 N--CA 1.486 1.359 0 CA-C-N 117.903 0.319 . . . . 0.0 110.356 -179.601 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.73 90.02 0.0 OUTLIER 'General case' 0 C--N 1.325 -0.477 0 C-N-CA 123.74 0.816 . . . . 0.0 112.574 -179.882 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 37.1 tt0 -65.54 159.3 24.87 Favored 'General case' 0 N--CA 1.468 0.462 0 CA-C-N 114.694 -1.139 . . . . 0.0 109.954 179.069 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 67.2 m-20 -141.23 137.35 32.51 Favored 'General case' 0 N--CA 1.476 0.873 0 C-N-CA 122.792 0.437 . . . . 0.0 109.993 179.962 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' G' G ' 24' ' ' VAL . . . . . . . . . . . . . 21.6 t -85.53 -115.41 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.99 0 N-CA-C 108.408 -0.96 . . . . 0.0 108.408 179.598 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -110.16 53.9 0.57 Allowed Glycine 0 N--CA 1.478 1.443 0 N-CA-C 111.612 -0.595 . . . . 0.0 111.612 -179.812 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 75.8 p -79.67 125.88 30.21 Favored 'General case' 0 N--CA 1.466 0.366 0 N-CA-C 109.119 -0.697 . . . . 0.0 109.119 178.026 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 19.2 t-20 -66.87 100.5 0.73 Allowed 'General case' 0 CA--C 1.54 0.569 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 178.424 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 67.0 mttm -96.7 119.93 36.09 Favored 'General case' 0 N--CA 1.482 1.139 0 N-CA-C 110.085 -0.339 . . . . 0.0 110.085 -179.087 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.76 -125.52 0.01 OUTLIER Glycine 0 CA--C 1.533 1.21 0 N-CA-C 110.571 -1.012 . . . . 0.0 110.571 178.828 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -127.81 133.09 49.41 Favored 'General case' 0 N--CA 1.47 0.555 0 N-CA-C 109.579 -0.526 . . . . 0.0 109.579 179.684 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 68.2 mt -81.93 140.19 16.84 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.646 0 N-CA-C 107.22 -1.4 . . . . 0.0 107.22 178.475 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 27.6 mt -131.1 130.84 63.9 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 CA-C-N 119.057 0.844 . . . . 0.0 109.274 179.912 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 60.46 79.81 0.11 Allowed Glycine 0 CA--C 1.527 0.813 0 CA-C-N 116.269 -0.423 . . . . 0.0 113.127 179.273 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' G' G ' 34' ' ' LEU . . . . . 0.419 HD23 ' N ' ' G' ' 35' ' ' MET . 1.9 tt -111.87 120.29 41.46 Favored 'General case' 0 N--CA 1.479 1.011 0 N-CA-C 106.909 -1.515 . . . . 0.0 106.909 177.394 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' G' G ' 35' ' ' MET . . . . . 0.419 ' N ' HD23 ' G' ' 34' ' ' LEU . 8.4 ttt -155.35 163.08 40.58 Favored 'General case' 0 C--O 1.211 -0.945 0 N-CA-C 108.03 -1.1 . . . . 0.0 108.03 179.466 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 99.6 t -159.44 150.19 6.7 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 N-CA-C 106.295 -1.742 . . . . 0.0 106.295 -179.72 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.41 75.2 0.26 Allowed Glycine 0 C--N 1.312 -0.755 0 C-N-CA 121.093 -0.575 . . . . 0.0 111.956 177.801 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 168.51 -146.24 10.24 Favored Glycine 0 N--CA 1.47 0.928 0 N-CA-C 110.688 -0.965 . . . . 0.0 110.688 179.209 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 22.2 m -134.43 141.61 43.03 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.914 0 CA-C-N 117.039 0.42 . . . . 0.0 109.994 179.873 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 19.3 t . . . . . 0 N--CA 1.471 0.595 0 CA-C-O 117.678 -1.153 . . . . 0.0 110.914 179.541 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 79.4 m-85 . . . . . 0 N--CA 1.474 0.757 0 N-CA-C 109.662 -0.496 . . . . 0.0 109.662 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' H' H ' 5' ' ' ARG . . . . . . . . . . . . . 72.6 mtp180 -144.1 140.95 29.75 Favored 'General case' 0 N--CA 1.482 1.149 0 N-CA-C 109.219 -0.66 . . . . 0.0 109.219 -179.608 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 76.9 m80 -149.35 119.21 7.09 Favored 'General case' 0 N--CA 1.473 0.721 0 N-CA-C 109.076 -0.712 . . . . 0.0 109.076 179.07 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -68.33 145.87 53.79 Favored 'General case' 0 N--CA 1.468 0.431 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.951 -179.413 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' H' H ' 8' ' ' SER . . . . . . . . . . . . . 8.2 t -163.84 173.85 12.25 Favored 'General case' 0 N--CA 1.469 0.508 0 N-CA-C 109.373 -0.602 . . . . 0.0 109.373 178.321 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.89 23.09 2.31 Favored Glycine 0 N--CA 1.48 1.632 0 N-CA-C 111.828 -0.509 . . . . 0.0 111.828 179.125 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 40.4 p90 -56.64 127.81 33.26 Favored 'General case' 0 N--CA 1.474 0.735 0 N-CA-C 112.402 0.519 . . . . 0.0 112.402 -178.996 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 57.7 mt-10 -84.74 155.28 21.95 Favored 'General case' 0 N--CA 1.475 0.806 0 CA-C-O 121.121 0.486 . . . . 0.0 109.917 178.791 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -155.78 127.62 0.97 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.971 0 N-CA-C 108.263 -1.014 . . . . 0.0 108.263 178.847 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 51.3 m-70 -133.79 146.08 50.37 Favored 'General case' 0 N--CA 1.476 0.847 0 CA-C-N 115.423 -0.808 . . . . 0.0 111.239 -178.197 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 6.4 t60 -165.55 97.75 0.68 Allowed 'General case' 0 N--CA 1.482 1.146 0 CA-C-N 116.582 -0.281 . . . . 0.0 110.673 179.159 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 35.3 mt-30 -105.68 -173.04 2.21 Favored 'General case' 0 CA--C 1.501 -0.934 0 N-CA-C 108.549 -0.908 . . . . 0.0 108.549 -179.848 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' H' H ' 16' ' ' LYS . . . . . 0.404 ' C ' HD12 ' H' ' 17' ' ' LEU . 88.5 tttt -169.08 96.74 0.35 Allowed 'General case' 0 CA--C 1.54 0.562 0 CA-C-N 114.941 -1.027 . . . . 0.0 109.276 178.775 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' H' H ' 17' ' ' LEU . . . . . 0.57 HD12 ' N ' ' H' ' 17' ' ' LEU . 5.4 mp -106.21 163.29 12.92 Favored 'General case' 0 N--CA 1.487 1.382 0 N-CA-C 109.349 -0.612 . . . . 0.0 109.349 -179.553 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 40.1 t -142.63 118.48 5.44 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.037 0 CA-C-O 120.929 0.395 . . . . 0.0 110.479 178.895 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 48.0 m-85 -69.57 150.72 46.8 Favored 'General case' 0 C--N 1.37 1.483 0 N-CA-C 107.386 -1.338 . . . . 0.0 107.386 176.686 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 11.6 t80 -171.99 -54.66 0.02 OUTLIER 'General case' 0 N--CA 1.485 1.293 0 CA-C-N 117.837 0.289 . . . . 0.0 110.32 -179.537 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.94 90.39 0.0 OUTLIER 'General case' 0 CA--C 1.535 0.371 0 C-N-CA 123.685 0.794 . . . . 0.0 112.299 -179.974 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 37.2 tt0 -65.86 159.07 26.26 Favored 'General case' 0 N--CA 1.469 0.506 0 CA-C-N 114.784 -1.098 . . . . 0.0 110.006 179.254 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 67.0 m-20 -140.99 137.46 33.03 Favored 'General case' 0 N--CA 1.477 0.877 0 C-N-CA 122.845 0.458 . . . . 0.0 110.098 179.884 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' H' H ' 24' ' ' VAL . . . . . . . . . . . . . 21.4 t -85.8 -115.59 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.991 0 N-CA-C 108.531 -0.915 . . . . 0.0 108.531 179.601 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . -109.57 53.88 0.57 Allowed Glycine 0 N--CA 1.481 1.651 0 N-CA-C 111.379 -0.688 . . . . 0.0 111.379 -179.813 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 75.8 p -79.75 125.75 30.07 Favored 'General case' 0 N--CA 1.467 0.386 0 N-CA-C 108.958 -0.756 . . . . 0.0 108.958 178.034 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 19.3 t-20 -66.95 100.59 0.75 Allowed 'General case' 0 N--CA 1.471 0.605 0 N-CA-C 108.352 -0.981 . . . . 0.0 108.352 178.51 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 66.6 mttm -96.79 119.6 35.57 Favored 'General case' 0 N--CA 1.483 1.189 0 N-CA-C 110.097 -0.334 . . . . 0.0 110.097 -179.076 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.41 -125.18 0.01 OUTLIER Glycine 0 CA--C 1.534 1.267 0 N-CA-C 110.738 -0.945 . . . . 0.0 110.738 178.71 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.11 132.81 48.95 Favored 'General case' 0 N--CA 1.47 0.569 0 N-CA-C 109.66 -0.496 . . . . 0.0 109.66 179.839 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 68.7 mt -81.95 139.96 17.18 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.587 0 N-CA-C 107.11 -1.441 . . . . 0.0 107.11 178.525 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 28.0 mt -130.98 130.75 64.17 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.417 0 CA-C-N 118.912 0.778 . . . . 0.0 109.273 -179.978 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 60.48 79.7 0.11 Allowed Glycine 0 CA--C 1.526 0.742 0 CA-C-N 116.301 -0.409 . . . . 0.0 113.126 179.231 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' H' H ' 34' ' ' LEU . . . . . 0.409 HD23 ' N ' ' H' ' 35' ' ' MET . 1.9 tt -111.84 120.05 40.64 Favored 'General case' 0 N--CA 1.479 1.018 0 N-CA-C 106.889 -1.523 . . . . 0.0 106.889 177.42 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' H' H ' 35' ' ' MET . . . . . 0.409 ' N ' HD23 ' H' ' 34' ' ' LEU . 8.5 ttt -154.97 163.18 40.67 Favored 'General case' 0 N--CA 1.479 0.982 0 N-CA-C 107.958 -1.127 . . . . 0.0 107.958 179.505 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 93.6 t -159.78 150.43 6.29 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.254 0 N-CA-C 106.275 -1.75 . . . . 0.0 106.275 -179.735 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.15 75.13 0.26 Allowed Glycine 0 C--N 1.313 -0.731 0 CA-C-N 115.942 -0.572 . . . . 0.0 111.922 177.959 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 168.42 -146.51 10.49 Favored Glycine 0 N--CA 1.471 0.992 0 N-CA-C 110.632 -0.987 . . . . 0.0 110.632 179.273 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 22.3 m -134.23 141.85 42.55 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.924 0 CA-C-N 116.977 0.389 . . . . 0.0 109.998 179.976 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 19.4 t . . . . . 0 N--CA 1.47 0.543 0 CA-C-O 117.768 -1.111 . . . . 0.0 110.918 179.489 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 78.3 m-85 . . . . . 0 N--CA 1.474 0.745 0 N-CA-C 109.651 -0.5 . . . . 0.0 109.651 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' I' I ' 5' ' ' ARG . . . . . . . . . . . . . 72.7 mtp180 -144.49 140.95 29.21 Favored 'General case' 0 N--CA 1.482 1.158 0 N-CA-C 109.232 -0.655 . . . . 0.0 109.232 -179.619 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 76.9 m80 -149.31 118.93 6.97 Favored 'General case' 0 N--CA 1.474 0.753 0 N-CA-C 109.11 -0.7 . . . . 0.0 109.11 179.095 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 8.0 m-20 -68.1 145.87 54.0 Favored 'General case' 0 N--CA 1.467 0.385 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.82 -179.361 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' I' I ' 8' ' ' SER . . . . . . . . . . . . . 8.3 t -163.91 173.7 12.36 Favored 'General case' 0 N--CA 1.47 0.555 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 178.34 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.97 23.32 2.25 Favored Glycine 0 N--CA 1.481 1.657 0 N-CA-C 111.845 -0.502 . . . . 0.0 111.845 179.156 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 41.0 p90 -56.81 128.03 34.61 Favored 'General case' 0 N--CA 1.473 0.683 0 N-CA-C 112.437 0.532 . . . . 0.0 112.437 -178.99 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 57.9 mt-10 -84.86 155.19 21.85 Favored 'General case' 0 N--CA 1.474 0.757 0 CA-C-O 121.074 0.464 . . . . 0.0 109.976 178.755 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -155.7 127.65 0.99 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.977 0 N-CA-C 108.236 -1.024 . . . . 0.0 108.236 178.777 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 51.2 m-70 -133.68 146.41 50.81 Favored 'General case' 0 N--CA 1.476 0.849 0 CA-C-N 115.372 -0.831 . . . . 0.0 111.119 -178.162 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 6.5 t60 -165.99 97.89 0.63 Allowed 'General case' 0 N--CA 1.482 1.164 0 CA-C-N 116.556 -0.293 . . . . 0.0 110.696 179.026 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 35.3 mt-30 -105.85 -172.75 2.15 Favored 'General case' 0 CA--C 1.5 -0.948 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 -179.825 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' I' I ' 16' ' ' LYS . . . . . 0.403 ' C ' HD12 ' I' ' 17' ' ' LEU . 88.6 tttt -169.18 96.82 0.34 Allowed 'General case' 0 CA--C 1.539 0.543 0 CA-C-N 114.901 -1.045 . . . . 0.0 109.355 178.769 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' I' I ' 17' ' ' LEU . . . . . 0.566 HD12 ' N ' ' I' ' 17' ' ' LEU . 5.4 mp -106.19 163.15 13.03 Favored 'General case' 0 N--CA 1.488 1.43 0 N-CA-C 109.301 -0.629 . . . . 0.0 109.301 -179.555 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 40.1 t -142.48 118.37 5.66 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.015 0 CA-C-O 120.901 0.382 . . . . 0.0 110.387 178.933 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 48.6 m-85 -69.43 151.02 46.61 Favored 'General case' 0 C--N 1.372 1.553 0 N-CA-C 107.414 -1.328 . . . . 0.0 107.414 176.654 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 11.7 t80 -172.19 -54.98 0.02 OUTLIER 'General case' 0 N--CA 1.483 1.225 0 CA-C-N 117.822 0.283 . . . . 0.0 110.346 -179.587 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.81 90.29 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.465 0 C-N-CA 123.712 0.805 . . . . 0.0 112.327 -179.984 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 37.3 tt0 -65.68 159.15 25.57 Favored 'General case' 0 N--CA 1.468 0.464 0 CA-C-N 114.686 -1.143 . . . . 0.0 110.023 179.304 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 66.6 m-20 -140.92 137.21 32.97 Favored 'General case' 0 N--CA 1.476 0.834 0 C-N-CA 122.906 0.482 . . . . 0.0 110.122 179.835 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' I' I ' 24' ' ' VAL . . . . . . . . . . . . . 21.5 t -85.47 -115.35 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.034 0 N-CA-C 108.479 -0.934 . . . . 0.0 108.479 179.58 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . -109.84 53.44 0.59 Allowed Glycine 0 N--CA 1.48 1.584 0 N-CA-C 111.495 -0.642 . . . . 0.0 111.495 -179.761 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 77.0 p -79.29 125.79 29.95 Favored 'General case' 0 N--CA 1.467 0.388 0 N-CA-C 109.131 -0.692 . . . . 0.0 109.131 177.992 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 19.5 t-20 -67.14 100.54 0.78 Allowed 'General case' 0 N--CA 1.471 0.625 0 N-CA-C 108.395 -0.965 . . . . 0.0 108.395 178.525 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 66.8 mttm -96.71 120.05 36.32 Favored 'General case' 0 N--CA 1.483 1.221 0 N-CA-C 110.129 -0.323 . . . . 0.0 110.129 -179.11 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.7 -125.36 0.01 OUTLIER Glycine 0 CA--C 1.535 1.319 0 N-CA-C 110.688 -0.965 . . . . 0.0 110.688 178.793 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -127.78 132.82 49.47 Favored 'General case' 0 N--CA 1.473 0.682 0 C-N-CA 123.023 0.529 . . . . 0.0 109.653 179.633 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 68.2 mt -81.92 139.91 17.24 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.582 0 N-CA-C 107.13 -1.433 . . . . 0.0 107.13 178.479 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 27.2 mt -130.99 130.87 64.22 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.373 0 CA-C-N 118.977 0.808 . . . . 0.0 109.282 -179.938 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 60.38 79.68 0.11 Allowed Glycine 0 CA--C 1.527 0.805 0 CA-C-N 116.285 -0.416 . . . . 0.0 113.079 179.261 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' I' I ' 34' ' ' LEU . . . . . 0.412 HD23 ' N ' ' I' ' 35' ' ' MET . 1.9 tt -111.9 120.07 40.67 Favored 'General case' 0 N--CA 1.48 1.038 0 N-CA-C 106.823 -1.547 . . . . 0.0 106.823 177.432 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' I' I ' 35' ' ' MET . . . . . 0.412 ' N ' HD23 ' I' ' 34' ' ' LEU . 8.5 ttt -154.9 163.28 40.51 Favored 'General case' 0 C--O 1.211 -0.958 0 N-CA-C 108.005 -1.109 . . . . 0.0 108.005 179.461 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 98.7 t -159.72 150.41 6.35 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.257 0 N-CA-C 106.273 -1.751 . . . . 0.0 106.273 -179.739 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.08 75.23 0.26 Allowed Glycine 0 C--N 1.315 -0.631 0 CA-C-N 115.893 -0.594 . . . . 0.0 111.951 177.907 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 168.46 -146.33 10.33 Favored Glycine 0 N--CA 1.469 0.886 0 N-CA-C 110.643 -0.983 . . . . 0.0 110.643 179.287 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 22.3 m -134.39 141.72 42.75 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.856 0 CA-C-N 116.985 0.392 . . . . 0.0 110.038 179.928 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 18.9 t . . . . . 0 N--CA 1.469 0.488 0 CA-C-O 117.765 -1.112 . . . . 0.0 110.92 179.434 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 55.1 m-85 . . . . . 0 N--CA 1.475 0.804 0 N-CA-C 110.241 -0.281 . . . . 0.0 110.241 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 -144.33 142.14 30.2 Favored 'General case' 0 N--CA 1.482 1.131 0 N-CA-C 110.01 -0.366 . . . . 0.0 110.01 179.713 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 41.7 t-80 -152.43 119.69 5.92 Favored 'General case' 0 N--CA 1.472 0.674 0 N-CA-C 109.23 -0.655 . . . . 0.0 109.23 179.098 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' ASP . . . . . 0.507 ' O ' ' OG ' ' D' ' 8' ' ' SER . 4.6 m-20 -69.02 148.68 49.73 Favored 'General case' 0 CA--C 1.535 0.383 0 CA-C-N 116.341 -0.39 . . . . 0.0 110.412 179.893 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 54.0 p -167.65 -173.58 2.21 Favored 'General case' 0 N--CA 1.481 1.084 0 CA-C-O 120.92 0.391 . . . . 0.0 110.698 179.217 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.26 47.45 1.32 Allowed Glycine 0 N--CA 1.482 1.742 0 CA-C-N 116.036 -0.529 . . . . 0.0 111.905 -179.941 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 49.7 p90 -66.03 133.03 49.93 Favored 'General case' 0 N--CA 1.473 0.695 0 CA-C-O 120.74 0.305 . . . . 0.0 111.618 179.814 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 84.2 mt-10 -91.82 152.19 20.24 Favored 'General case' 0 N--CA 1.477 0.91 0 N-CA-C 109.662 -0.496 . . . . 0.0 109.662 178.443 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -152.67 128.31 1.68 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.593 0 N-CA-C 107.884 -1.154 . . . . 0.0 107.884 178.074 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 43.7 m-70 -135.9 148.5 48.6 Favored 'General case' 0 N--CA 1.493 1.681 0 CA-C-N 119.025 0.829 . . . . 0.0 111.292 -178.986 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 6.6 t60 -164.82 98.47 0.76 Allowed 'General case' 0 N--CA 1.48 1.053 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.823 179.396 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -91.85 -177.38 4.72 Favored 'General case' 0 CA--C 1.514 -0.432 0 N-CA-C 108.851 -0.796 . . . . 0.0 108.851 -179.933 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -172.06 93.74 0.14 Allowed 'General case' 0 N--CA 1.469 0.489 0 CA-C-N 114.659 -1.155 . . . . 0.0 108.566 177.94 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 6.3 mp -124.77 155.98 38.46 Favored 'General case' 0 N--CA 1.497 1.896 0 CA-C-O 121.744 0.783 . . . . 0.0 110.989 -178.417 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 61.0 t -111.63 124.46 68.4 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.024 0 CA-C-O 117.825 -1.083 . . . . 0.0 108.469 177.77 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 29.4 m-85 -124.27 143.78 50.35 Favored 'General case' 0 N--CA 1.498 1.946 0 CA-C-N 120.177 1.353 . . . . 0.0 110.268 179.227 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 67.2 m-85 52.49 68.33 0.84 Allowed 'General case' 0 N--CA 1.472 0.637 0 CA-C-N 116.367 -0.378 . . . . 0.0 111.875 178.458 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -78.14 -84.62 0.08 Allowed 'General case' 0 C--N 1.361 1.097 0 CA-C-N 115.463 -0.79 . . . . 0.0 110.173 -179.829 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 41.2 tt0 -123.07 96.9 5.19 Favored 'General case' 0 C--N 1.323 -0.547 0 N-CA-C 108.089 -1.078 . . . . 0.0 108.089 179.7 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 4.1 p30 -158.97 143.67 15.78 Favored 'General case' 0 N--CA 1.484 1.261 0 O-C-N 122.313 -0.242 . . . . 0.0 111.102 179.092 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 61.6 t -61.38 162.66 1.36 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.784 0 N-CA-C 107.968 -1.123 . . . . 0.0 107.968 177.206 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.494 ' H ' ' HB ' ' D' ' 24' ' ' VAL . . . -117.71 48.96 0.89 Allowed Glycine 0 N--CA 1.476 1.328 0 N-CA-C 111.81 -0.516 . . . . 0.0 111.81 -179.377 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -61.84 -169.05 0.02 OUTLIER 'General case' 0 N--CA 1.469 0.522 0 O-C-N 123.722 0.307 . . . . 0.0 110.404 179.56 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 15.1 t30 -69.52 80.35 0.4 Allowed 'General case' 0 N--CA 1.464 0.271 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.132 179.717 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -79.8 154.71 28.28 Favored 'General case' 0 N--CA 1.473 0.677 0 N-CA-C 108.883 -0.784 . . . . 0.0 108.883 179.059 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.0 -144.07 0.02 OUTLIER Glycine 0 CA--C 1.526 0.748 0 N-CA-C 109.749 -1.34 . . . . 0.0 109.749 178.496 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -136.89 120.3 16.97 Favored 'General case' 0 N--CA 1.479 0.976 0 CA-C-N 117.247 0.523 . . . . 0.0 109.755 179.38 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 69.5 mt -80.39 124.73 38.67 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.528 0 N-CA-C 106.741 -1.577 . . . . 0.0 106.741 178.339 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . 0.413 ' C ' ' H ' ' A' ' 34' ' ' LEU . 41.5 pt -151.34 162.71 2.93 Favored 'Isoleucine or valine' 0 C--N 1.358 0.958 0 CA-C-N 115.741 -0.663 . . . . 0.0 111.552 -178.805 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 64.88 0.44 5.24 Favored Glycine 0 CA--C 1.524 0.603 0 N-CA-C 111.008 -0.837 . . . . 0.0 111.008 179.611 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.413 ' H ' ' C ' ' A' ' 32' ' ' ILE . 7.8 tt -79.7 148.46 31.55 Favored 'General case' 0 N--CA 1.466 0.346 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 -179.989 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 28.6 ttt -159.89 140.68 12.21 Favored 'General case' 0 N--CA 1.473 0.68 0 N-CA-C 108.816 -0.809 . . . . 0.0 108.816 178.993 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 27.6 m -156.22 162.57 1.64 Allowed 'Isoleucine or valine' 0 C--N 1.347 0.495 0 N-CA-C 108.259 -1.015 . . . . 0.0 108.259 -179.756 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.63 67.55 2.15 Favored Glycine 0 C--N 1.308 -1.026 0 CA-C-N 115.773 -0.649 . . . . 0.0 111.967 178.6 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.91 172.49 17.98 Favored Glycine 0 N--CA 1.475 1.242 0 N-CA-C 110.649 -0.98 . . . . 0.0 110.649 179.28 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.56 ' H ' HG12 ' D' ' 39' ' ' VAL . 34.9 m -125.16 164.42 24.18 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.943 0 C-N-CA 123.549 0.739 . . . . 0.0 110.803 -179.546 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 25.0 t . . . . . 0 C--O 1.221 -0.437 0 CA-C-O 118.382 -0.818 . . . . 0.0 110.766 179.333 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 55.6 m-85 . . . . . 0 N--CA 1.476 0.843 0 N-CA-C 110.272 -0.269 . . . . 0.0 110.272 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 -144.22 142.09 30.28 Favored 'General case' 0 N--CA 1.481 1.124 0 N-CA-C 109.989 -0.375 . . . . 0.0 109.989 179.687 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 41.1 t-80 -152.34 119.46 5.87 Favored 'General case' 0 N--CA 1.473 0.686 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 179.146 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 7' ' ' ASP . . . . . 0.467 ' O ' ' OG ' ' E' ' 8' ' ' SER . 4.4 m-20 -69.01 148.31 50.29 Favored 'General case' 0 CA--C 1.536 0.436 0 CA-C-N 116.435 -0.348 . . . . 0.0 110.465 179.914 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 8' ' ' SER . . . . . . . . . . . . . 54.0 p -167.26 -173.35 2.25 Favored 'General case' 0 N--CA 1.48 1.048 0 CA-C-O 120.873 0.368 . . . . 0.0 110.645 179.214 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.08 47.37 1.35 Allowed Glycine 0 N--CA 1.482 1.762 0 CA-C-N 115.982 -0.554 . . . . 0.0 111.927 179.896 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 49.3 p90 -65.93 133.73 51.49 Favored 'General case' 0 N--CA 1.473 0.679 0 CA-C-O 120.751 0.31 . . . . 0.0 111.714 179.699 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 83.5 mt-10 -92.39 152.51 19.7 Favored 'General case' 0 N--CA 1.476 0.839 0 N-CA-C 109.666 -0.494 . . . . 0.0 109.666 178.398 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -153.14 128.42 1.56 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.609 0 N-CA-C 107.776 -1.194 . . . . 0.0 107.776 178.261 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 43.6 m-70 -136.27 148.35 47.96 Favored 'General case' 0 N--CA 1.492 1.655 0 CA-C-N 118.864 0.756 . . . . 0.0 111.37 -179.033 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 6.7 t60 -164.67 98.06 0.77 Allowed 'General case' 0 N--CA 1.481 1.093 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.694 179.512 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 5.1 pt20 -91.14 -176.86 4.73 Favored 'General case' 0 CA--C 1.515 -0.386 0 N-CA-C 108.74 -0.837 . . . . 0.0 108.74 -179.984 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -172.7 93.77 0.12 Allowed 'General case' 0 N--CA 1.469 0.505 0 CA-C-N 114.711 -1.131 . . . . 0.0 108.405 177.807 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 6.3 mp -124.71 156.1 38.18 Favored 'General case' 0 N--CA 1.497 1.918 0 CA-C-O 121.77 0.795 . . . . 0.0 110.985 -178.465 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 62.0 t -111.85 125.14 69.13 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.007 0 N-CA-C 108.297 -1.001 . . . . 0.0 108.297 177.645 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 29.6 m-85 -124.87 143.76 50.67 Favored 'General case' 0 N--CA 1.495 1.803 0 CA-C-N 119.813 1.188 . . . . 0.0 110.161 179.433 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 68.2 m-85 51.45 68.41 0.8 Allowed 'General case' 0 N--CA 1.468 0.452 0 CA-C-O 121.199 0.524 . . . . 0.0 111.994 178.48 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -78.09 -84.28 0.08 Allowed 'General case' 0 C--N 1.356 0.875 0 CA-C-N 115.198 -0.91 . . . . 0.0 110.055 -179.847 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 41.2 tt0 -123.14 97.42 5.42 Favored 'General case' 0 C--N 1.323 -0.583 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 179.682 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 4.0 p30 -159.34 143.5 15.1 Favored 'General case' 0 N--CA 1.483 1.206 0 O-C-N 122.342 -0.224 . . . . 0.0 111.083 179.103 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 61.9 t -61.17 162.65 1.31 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.89 0 N-CA-C 107.983 -1.117 . . . . 0.0 107.983 177.136 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 25' ' ' GLY . . . . . 0.495 ' H ' ' HB ' ' E' ' 24' ' ' VAL . . . -117.62 49.03 0.89 Allowed Glycine 0 N--CA 1.475 1.294 0 N-CA-C 111.725 -0.55 . . . . 0.0 111.725 -179.281 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -62.2 -168.78 0.02 OUTLIER 'General case' 0 N--CA 1.469 0.514 0 O-C-N 123.616 0.245 . . . . 0.0 110.374 179.598 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 14.9 t30 -69.72 80.64 0.44 Allowed 'General case' 0 N--CA 1.465 0.312 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.043 179.773 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 97.9 mttt -80.2 154.41 27.96 Favored 'General case' 0 N--CA 1.472 0.633 0 N-CA-C 108.882 -0.784 . . . . 0.0 108.882 179.072 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.9 -144.5 0.02 OUTLIER Glycine 0 CA--C 1.526 0.738 0 N-CA-C 109.636 -1.386 . . . . 0.0 109.636 178.476 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -136.39 120.84 18.14 Favored 'General case' 0 N--CA 1.478 0.973 0 CA-C-N 117.142 0.471 . . . . 0.0 109.83 179.376 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 70.1 mt -80.65 124.98 39.12 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.524 0 N-CA-C 106.721 -1.585 . . . . 0.0 106.721 178.249 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . 0.408 ' C ' ' H ' ' B' ' 34' ' ' LEU . 41.3 pt -151.59 162.75 2.8 Favored 'Isoleucine or valine' 0 C--N 1.358 0.951 0 CA-C-N 115.836 -0.62 . . . . 0.0 111.491 -178.728 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 64.61 0.52 5.0 Favored Glycine 0 C--N 1.337 0.635 0 CA-C-N 115.507 -0.77 . . . . 0.0 111.177 179.716 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 34' ' ' LEU . . . . . 0.408 ' H ' ' C ' ' B' ' 32' ' ' ILE . 7.8 tt -79.85 148.15 31.47 Favored 'General case' 0 N--CA 1.465 0.292 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 -179.952 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 28.6 ttt -159.32 140.75 13.03 Favored 'General case' 0 N--CA 1.475 0.795 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 179.051 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 28.3 m -156.35 162.56 1.63 Allowed 'Isoleucine or valine' 0 C--N 1.346 0.422 0 N-CA-C 108.214 -1.032 . . . . 0.0 108.214 -179.796 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.67 67.45 2.2 Favored Glycine 0 C--N 1.306 -1.111 0 CA-C-N 115.756 -0.657 . . . . 0.0 111.932 178.558 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.86 172.8 18.27 Favored Glycine 0 N--CA 1.474 1.202 0 N-CA-C 110.678 -0.969 . . . . 0.0 110.678 179.208 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 39' ' ' VAL . . . . . 0.553 ' H ' HG12 ' E' ' 39' ' ' VAL . 35.2 m -125.3 164.29 24.67 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.082 0 C-N-CA 123.523 0.729 . . . . 0.0 110.819 -179.392 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 24.9 t . . . . . 0 N--CA 1.471 0.576 0 CA-C-O 118.237 -0.887 . . . . 0.0 110.636 179.164 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 54.9 m-85 . . . . . 0 N--CA 1.477 0.922 0 N-CA-C 110.238 -0.282 . . . . 0.0 110.238 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 -144.22 142.12 30.31 Favored 'General case' 0 N--CA 1.482 1.15 0 N-CA-C 109.974 -0.38 . . . . 0.0 109.974 179.645 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 40.8 t-80 -152.37 119.98 6.05 Favored 'General case' 0 N--CA 1.473 0.708 0 N-CA-C 109.251 -0.648 . . . . 0.0 109.251 179.152 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' C' C ' 7' ' ' ASP . . . . . 0.477 ' O ' ' OG ' ' F' ' 8' ' ' SER . 4.4 m-20 -69.45 148.39 49.63 Favored 'General case' 0 CA--C 1.535 0.397 0 CA-C-N 116.352 -0.385 . . . . 0.0 110.518 179.908 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' C' C ' 8' ' ' SER . . . . . . . . . . . . . 55.4 p -167.32 -173.51 2.29 Favored 'General case' 0 N--CA 1.48 1.029 0 CA-C-O 120.839 0.352 . . . . 0.0 110.656 179.272 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.18 47.58 1.31 Allowed Glycine 0 N--CA 1.483 1.795 0 CA-C-N 116.006 -0.543 . . . . 0.0 111.903 179.961 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 49.5 p90 -66.15 133.3 50.41 Favored 'General case' 0 N--CA 1.472 0.665 0 CA-C-N 116.783 0.292 . . . . 0.0 111.681 179.697 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 83.2 mt-10 -92.15 152.08 20.08 Favored 'General case' 0 N--CA 1.476 0.851 0 N-CA-C 109.696 -0.483 . . . . 0.0 109.696 178.4 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -152.61 128.35 1.71 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.588 0 N-CA-C 107.791 -1.189 . . . . 0.0 107.791 178.146 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 42.4 m-70 -136.03 148.38 48.35 Favored 'General case' 0 N--CA 1.492 1.663 0 CA-C-N 118.937 0.79 . . . . 0.0 111.286 -179.102 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 6.7 t60 -164.69 98.55 0.78 Allowed 'General case' 0 N--CA 1.481 1.105 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.685 179.475 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -91.91 -176.99 4.6 Favored 'General case' 0 CA--C 1.512 -0.484 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 -179.937 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -172.49 93.84 0.13 Allowed 'General case' 0 N--CA 1.47 0.533 0 CA-C-N 114.707 -1.133 . . . . 0.0 108.451 177.959 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 6.1 mp -124.93 155.7 39.15 Favored 'General case' 0 N--CA 1.496 1.842 0 CA-C-O 121.768 0.794 . . . . 0.0 111.096 -178.381 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 61.6 t -111.54 125.52 68.86 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.996 0 N-CA-C 108.238 -1.023 . . . . 0.0 108.238 177.754 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 29.3 m-85 -125.31 143.31 51.03 Favored 'General case' 0 N--CA 1.495 1.822 0 CA-C-N 119.673 1.124 . . . . 0.0 110.083 179.369 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 67.5 m-85 51.93 68.46 0.81 Allowed 'General case' 0 N--CA 1.47 0.534 0 CA-C-O 121.215 0.531 . . . . 0.0 111.975 178.501 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -78.09 -84.41 0.08 Allowed 'General case' 0 C--N 1.356 0.873 0 CA-C-N 115.186 -0.915 . . . . 0.0 110.071 -179.851 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 40.9 tt0 -123.14 96.97 5.21 Favored 'General case' 0 C--N 1.323 -0.546 0 N-CA-C 108.08 -1.081 . . . . 0.0 108.08 179.746 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 4.1 p30 -158.8 143.71 16.02 Favored 'General case' 0 N--CA 1.484 1.263 0 CA-C-O 119.672 -0.204 . . . . 0.0 111.118 179.002 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 59.9 t -61.43 162.38 1.45 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.849 0 N-CA-C 107.96 -1.126 . . . . 0.0 107.96 177.129 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' C' C ' 25' ' ' GLY . . . . . 0.481 ' H ' ' HB ' ' F' ' 24' ' ' VAL . . . -117.5 49.49 0.86 Allowed Glycine 0 N--CA 1.477 1.414 0 N-CA-C 111.726 -0.55 . . . . 0.0 111.726 -179.286 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -62.65 -168.51 0.02 OUTLIER 'General case' 0 N--CA 1.468 0.44 0 O-C-N 123.666 0.274 . . . . 0.0 110.443 179.64 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 15.8 t30 -69.88 80.47 0.46 Allowed 'General case' 0 N--CA 1.465 0.322 0 N-CA-C 110.073 -0.343 . . . . 0.0 110.073 179.781 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -79.98 154.62 28.11 Favored 'General case' 0 N--CA 1.472 0.668 0 N-CA-C 108.915 -0.772 . . . . 0.0 108.915 179.111 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.89 -144.17 0.02 OUTLIER Glycine 0 CA--C 1.527 0.821 0 N-CA-C 109.769 -1.332 . . . . 0.0 109.769 178.488 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -136.78 120.47 17.28 Favored 'General case' 0 N--CA 1.481 1.083 0 CA-C-N 117.185 0.493 . . . . 0.0 109.719 179.258 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 70.0 mt -80.49 124.8 38.81 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.541 0 N-CA-C 106.762 -1.57 . . . . 0.0 106.762 178.254 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' C' C ' 32' ' ' ILE . . . . . 0.418 ' C ' ' H ' ' C' ' 34' ' ' LEU . 41.3 pt -151.39 162.53 2.97 Favored 'Isoleucine or valine' 0 C--N 1.359 0.991 0 CA-C-N 115.68 -0.691 . . . . 0.0 111.53 -178.634 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 64.89 0.68 5.5 Favored Glycine 0 N--CA 1.465 0.598 0 N-CA-C 110.973 -0.851 . . . . 0.0 110.973 179.606 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' C' C ' 34' ' ' LEU . . . . . 0.418 ' H ' ' C ' ' C' ' 32' ' ' ILE . 7.7 tt -79.87 148.12 31.45 Favored 'General case' 0 N--CA 1.465 0.302 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 179.955 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 28.6 ttt -159.29 140.85 13.16 Favored 'General case' 0 N--CA 1.474 0.742 0 N-CA-C 108.751 -0.833 . . . . 0.0 108.751 178.955 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 28.1 m -156.5 162.77 1.55 Allowed 'Isoleucine or valine' 0 C--N 1.348 0.511 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 -179.798 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.37 67.14 2.36 Favored Glycine 0 C--N 1.307 -1.07 0 CA-C-N 115.695 -0.684 . . . . 0.0 111.901 178.56 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 148.23 172.58 18.32 Favored Glycine 0 N--CA 1.474 1.218 0 N-CA-C 110.604 -0.998 . . . . 0.0 110.604 179.237 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' C' C ' 39' ' ' VAL . . . . . 0.55 ' H ' HG12 ' F' ' 39' ' ' VAL . 35.1 m -125.25 164.48 24.23 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.996 0 C-N-CA 123.518 0.727 . . . . 0.0 110.789 -179.415 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 25.4 t . . . . . 0 N--CA 1.469 0.484 0 CA-C-O 118.234 -0.889 . . . . 0.0 110.649 179.207 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 61.4 m-85 . . . . . 0 N--CA 1.474 0.765 0 N-CA-C 108.792 -0.818 . . . . 0.0 108.792 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' D' D ' 5' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 -146.43 140.49 26.33 Favored 'General case' 0 N--CA 1.476 0.85 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.236 -179.994 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 38.0 t-80 -149.82 124.02 9.5 Favored 'General case' 0 CA--C 1.545 0.781 0 N-CA-C 108.344 -0.984 . . . . 0.0 108.344 175.303 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' D' D ' 7' ' ' ASP . . . . . 0.57 ' O ' ' OG ' ' G' ' 8' ' ' SER . 3.3 m-20 -63.76 132.46 51.04 Favored 'General case' 0 C--N 1.322 -0.596 0 C-N-CA 126.885 2.074 . . . . 0.0 114.325 174.69 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' D' D ' 8' ' ' SER . . . . . 0.507 ' OG ' ' O ' ' A' ' 7' ' ' ASP . 54.2 p -154.63 -170.65 3.58 Favored 'General case' 0 N--CA 1.486 1.334 0 CA-C-N 119.77 1.168 . . . . 0.0 111.22 175.927 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.35 48.15 1.15 Allowed Glycine 0 N--CA 1.483 1.804 0 C-N-CA 124.562 1.077 . . . . 0.0 110.539 174.952 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 51.5 p90 -60.97 131.57 51.09 Favored 'General case' 0 N--CA 1.472 0.626 0 N-CA-C 112.908 0.707 . . . . 0.0 112.908 177.925 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 84.2 mt-10 -89.28 150.91 22.39 Favored 'General case' 0 N--CA 1.481 1.1 0 CA-C-N 117.974 0.352 . . . . 0.0 110.637 175.315 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.0 p -149.58 129.86 4.2 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.637 0 N-CA-C 107.416 -1.328 . . . . 0.0 107.416 173.066 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 38.3 m-70 -129.91 151.28 50.64 Favored 'General case' 0 N--CA 1.484 1.262 0 N-CA-C 112.329 0.492 . . . . 0.0 112.329 176.791 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 6.7 t60 -164.79 104.84 0.81 Allowed 'General case' 0 N--CA 1.482 1.145 0 N-CA-C 109.155 -0.683 . . . . 0.0 109.155 172.664 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' D' D ' 15' ' ' GLN . . . . . 0.401 ' OE1' ' N ' ' G' ' 37' ' ' GLY . 4.9 pt20 -94.96 -177.3 4.12 Favored 'General case' 0 CA--C 1.509 -0.631 0 N-CA-C 108.574 -0.898 . . . . 0.0 108.574 179.044 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -169.75 103.49 0.32 Allowed 'General case' 0 N--CA 1.465 0.308 0 N-CA-C 105.891 -1.892 . . . . 0.0 105.891 173.374 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 5.0 mp -132.19 153.44 50.57 Favored 'General case' 0 N--CA 1.498 1.97 0 CA-C-O 122.011 0.91 . . . . 0.0 110.214 178.912 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 35.8 t -101.12 129.01 52.79 Favored 'Isoleucine or valine' 0 C--O 1.266 1.943 0 CA-C-O 116.373 -1.775 . . . . 0.0 109.693 174.267 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 25.8 m-85 -126.63 149.25 49.59 Favored 'General case' 0 N--CA 1.49 1.562 0 CA-C-N 120.525 1.511 . . . . 0.0 109.472 172.329 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 66.7 m-85 55.14 63.64 2.05 Favored 'General case' 0 C--O 1.24 0.599 0 CA-C-O 118.518 -0.753 . . . . 0.0 111.555 175.097 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -79.99 -81.35 0.12 Allowed 'General case' 0 N--CA 1.474 0.741 0 CA-C-N 118.942 0.792 . . . . 0.0 109.967 -176.345 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 41.3 tt0 -124.91 101.81 7.24 Favored 'General case' 0 N--CA 1.479 0.999 0 N-CA-C 106.036 -1.838 . . . . 0.0 106.036 175.969 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 4.1 p30 -152.44 143.08 22.8 Favored 'General case' 0 N--CA 1.476 0.842 0 CA-C-O 116.792 -1.575 . . . . 0.0 113.624 177.592 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' D' D ' 24' ' ' VAL . . . . . 0.494 ' HB ' ' H ' ' A' ' 25' ' ' GLY . 67.1 t -63.58 165.26 1.29 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.366 0 CA-C-N 120.971 1.714 . . . . 0.0 107.824 174.538 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' D' D ' 25' ' ' GLY . . . . . 0.556 ' H ' ' HB ' ' G' ' 24' ' ' VAL . . . -116.84 51.3 0.74 Allowed Glycine 0 N--CA 1.48 1.613 0 CA-C-O 118.978 -0.901 . . . . 0.0 111.977 178.795 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -58.87 -171.23 0.01 OUTLIER 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 117.558 0.679 . . . . 0.0 111.533 176.88 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 15.7 t30 -71.92 86.66 1.0 Allowed 'General case' 0 CA--C 1.537 0.468 0 N-CA-C 108.432 -0.951 . . . . 0.0 108.432 178.516 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 97.4 mttt -85.34 156.37 20.93 Favored 'General case' 0 N--CA 1.475 0.779 0 N-CA-C 108.124 -1.065 . . . . 0.0 108.124 179.031 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.39 -144.27 0.02 OUTLIER Glycine 0 C--N 1.335 0.488 0 N-CA-C 110.33 -1.108 . . . . 0.0 110.33 179.387 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -136.41 123.74 21.93 Favored 'General case' 0 N--CA 1.474 0.733 0 N-CA-C 109.159 -0.682 . . . . 0.0 109.159 177.648 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 76.4 mt -83.9 134.53 26.74 Favored 'Isoleucine or valine' 0 C--N 1.355 0.819 0 N-CA-C 104.846 -2.279 . . . . 0.0 104.846 178.776 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 46.0 pt -159.07 162.47 1.35 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.02 0 CA-C-O 121.407 0.622 . . . . 0.0 110.397 -178.37 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 64.83 0.17 4.89 Favored Glycine 0 CA--C 1.525 0.685 0 CA-C-N 115.46 -0.791 . . . . 0.0 111.186 -178.563 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 7.6 tt -79.25 150.04 31.69 Favored 'General case' 0 C--N 1.343 0.325 0 N-CA-C 109.345 -0.613 . . . . 0.0 109.345 -179.49 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 27.7 ttt -155.78 151.44 27.26 Favored 'General case' 0 N--CA 1.474 0.728 0 N-CA-C 107.509 -1.293 . . . . 0.0 107.509 174.348 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 29.7 m -164.52 163.65 0.73 Allowed 'Isoleucine or valine' 0 CA--C 1.513 -0.445 0 N-CA-C 107.661 -1.237 . . . . 0.0 107.661 176.901 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 60.32 63.75 4.75 Favored Glycine 0 CA--C 1.528 0.885 0 C-N-CA 119.584 -1.293 . . . . 0.0 112.359 177.88 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.92 173.2 15.2 Favored Glycine 0 N--CA 1.479 1.519 0 CA-C-N 118.451 1.125 . . . . 0.0 111.567 -177.851 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' D' D ' 39' ' ' VAL . . . . . 0.575 ' H ' HG12 ' G' ' 39' ' ' VAL . 34.6 m -128.14 160.16 38.41 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.061 0 C-N-CA 122.895 0.478 . . . . 0.0 110.422 -175.953 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 24.2 t . . . . . 0 C--N 1.331 -0.213 0 CA-C-O 116.386 -1.769 . . . . 0.0 109.855 177.694 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 53.7 m-85 . . . . . 0 N--CA 1.475 0.81 0 N-CA-C 110.348 -0.241 . . . . 0.0 110.348 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' E' E ' 5' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 -143.5 142.62 31.23 Favored 'General case' 0 N--CA 1.479 0.99 0 CA-C-O 120.794 0.33 . . . . 0.0 110.201 179.565 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 41.2 t-80 -152.46 119.54 5.85 Favored 'General case' 0 N--CA 1.474 0.725 0 N-CA-C 109.247 -0.649 . . . . 0.0 109.247 178.985 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' E' E ' 7' ' ' ASP . . . . . 0.435 ' O ' ' OG ' ' H' ' 8' ' ' SER . 4.3 m-20 -69.58 148.27 49.61 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-N 116.491 -0.322 . . . . 0.0 110.671 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' E' E ' 8' ' ' SER . . . . . 0.467 ' OG ' ' O ' ' B' ' 7' ' ' ASP . 52.5 p -167.92 -172.49 1.84 Allowed 'General case' 0 N--CA 1.486 1.328 0 CA-C-O 121.013 0.435 . . . . 0.0 110.87 178.952 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.87 47.66 1.24 Allowed Glycine 0 N--CA 1.48 1.595 0 N-CA-C 111.781 -0.528 . . . . 0.0 111.781 179.684 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 47.8 p90 -65.45 133.36 51.14 Favored 'General case' 0 N--CA 1.473 0.683 0 N-CA-C 112.06 0.392 . . . . 0.0 112.06 -179.846 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 85.1 mt-10 -91.4 152.68 20.31 Favored 'General case' 0 N--CA 1.479 1.002 0 N-CA-C 109.617 -0.512 . . . . 0.0 109.617 177.996 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -154.67 127.28 1.07 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.619 0 N-CA-C 107.816 -1.179 . . . . 0.0 107.816 178.067 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 40.8 m-70 -136.18 146.72 47.17 Favored 'General case' 0 N--CA 1.482 1.157 0 CA-C-O 120.851 0.357 . . . . 0.0 111.639 -178.047 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 6.6 t60 -163.64 98.39 0.88 Allowed 'General case' 0 N--CA 1.485 1.293 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.735 179.553 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 4.8 pt20 -91.36 -176.87 4.68 Favored 'General case' 0 CA--C 1.514 -0.43 0 N-CA-C 109.028 -0.73 . . . . 0.0 109.028 -179.925 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -172.31 92.72 0.12 Allowed 'General case' 0 N--CA 1.47 0.557 0 CA-C-N 114.77 -1.104 . . . . 0.0 108.693 177.929 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 6.0 mp -123.35 155.77 36.67 Favored 'General case' 0 N--CA 1.496 1.864 0 CA-C-O 121.443 0.64 . . . . 0.0 111.433 -177.901 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 48.0 t -113.33 122.57 67.72 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.198 0 N-CA-C 108.333 -0.988 . . . . 0.0 108.333 177.37 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 32.4 m-85 -122.76 142.51 50.65 Favored 'General case' 0 N--CA 1.491 1.594 0 CA-C-O 120.974 0.416 . . . . 0.0 110.649 -179.928 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 67.8 m-85 52.73 67.71 0.95 Allowed 'General case' 0 C--N 1.346 0.42 0 CA-C-N 115.767 -0.651 . . . . 0.0 111.614 178.245 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.15 -83.66 0.07 Allowed 'General case' 0 CA--C 1.541 0.605 0 N-CA-C 109.981 -0.377 . . . . 0.0 109.981 -179.464 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 41.0 tt0 -123.28 97.14 5.28 Favored 'General case' 0 C--N 1.32 -0.686 0 N-CA-C 108.14 -1.059 . . . . 0.0 108.14 179.938 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 4.1 p30 -158.35 143.46 16.44 Favored 'General case' 0 N--CA 1.48 1.057 0 O-C-N 122.422 -0.174 . . . . 0.0 111.33 179.062 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' E' E ' 24' ' ' VAL . . . . . 0.495 ' HB ' ' H ' ' B' ' 25' ' ' GLY . 57.9 t -59.53 167.42 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.954 0 N-CA-C 107.412 -1.329 . . . . 0.0 107.412 176.991 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' E' E ' 25' ' ' GLY . . . . . 0.461 ' H ' ' HB ' ' H' ' 24' ' ' VAL . . . -122.61 49.66 0.88 Allowed Glycine 0 N--CA 1.475 1.266 0 N-CA-C 110.915 -0.874 . . . . 0.0 110.915 -179.386 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -63.24 -168.54 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.639 0 CA-C-O 120.689 0.281 . . . . 0.0 110.572 179.946 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 14.9 t30 -68.98 77.94 0.32 Allowed 'General case' 0 N--CA 1.465 0.281 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.261 179.946 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -78.12 155.28 30.59 Favored 'General case' 0 N--CA 1.475 0.779 0 N-CA-C 109.458 -0.571 . . . . 0.0 109.458 179.279 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.76 -144.74 0.02 OUTLIER Glycine 0 C--N 1.337 0.634 0 N-CA-C 110.34 -1.104 . . . . 0.0 110.34 178.022 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -137.12 117.25 13.42 Favored 'General case' 0 N--CA 1.476 0.831 0 CA-C-O 120.79 0.328 . . . . 0.0 110.286 179.723 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 67.0 mt -77.45 125.15 36.96 Favored 'Isoleucine or valine' 0 C--O 1.238 0.475 0 N-CA-C 107.011 -1.477 . . . . 0.0 107.011 178.411 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' E' E ' 32' ' ' ILE . . . . . 0.405 ' C ' ' H ' ' E' ' 34' ' ' LEU . 46.4 pt -150.96 164.47 2.64 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.085 0 CA-C-O 121.279 0.561 . . . . 0.0 111.019 -178.943 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.82 1.1 3.36 Favored Glycine 0 CA--C 1.529 0.911 0 CA-C-N 115.542 -0.753 . . . . 0.0 111.871 -179.643 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' E' E ' 34' ' ' LEU . . . . . 0.405 ' H ' ' C ' ' E' ' 32' ' ' ILE . 7.9 tt -79.31 148.18 32.2 Favored 'General case' 0 N--CA 1.468 0.462 0 C-N-CA 122.838 0.455 . . . . 0.0 109.832 -179.964 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 28.0 ttt -158.78 140.97 13.93 Favored 'General case' 0 N--CA 1.477 0.922 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 178.784 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 32.4 m -156.52 162.22 1.7 Allowed 'Isoleucine or valine' 0 C--N 1.344 0.368 0 N-CA-C 108.431 -0.951 . . . . 0.0 108.431 -179.598 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.5 67.36 2.25 Favored Glycine 0 C--N 1.308 -1.012 0 CA-C-N 115.975 -0.557 . . . . 0.0 111.894 178.494 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 148.33 173.06 18.87 Favored Glycine 0 N--CA 1.475 1.255 0 N-CA-C 110.875 -0.89 . . . . 0.0 110.875 179.222 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' E' E ' 39' ' ' VAL . . . . . 0.559 ' H ' HG12 ' H' ' 39' ' ' VAL . 32.9 m -126.18 163.08 28.71 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.909 0 C-N-CA 123.41 0.684 . . . . 0.0 111.016 -179.067 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 24.6 t . . . . . 0 N--CA 1.465 0.309 0 CA-C-O 118.253 -0.88 . . . . 0.0 110.466 178.972 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 53.7 m-85 . . . . . 0 N--CA 1.474 0.774 0 N-CA-C 110.234 -0.284 . . . . 0.0 110.234 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' F' F ' 5' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 -143.3 142.42 31.32 Favored 'General case' 0 N--CA 1.478 0.945 0 CA-C-O 120.803 0.335 . . . . 0.0 110.141 179.544 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 38.8 t-80 -152.42 119.3 5.77 Favored 'General case' 0 N--CA 1.472 0.674 0 N-CA-C 109.283 -0.636 . . . . 0.0 109.283 178.966 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' F' F ' 7' ' ' ASP . . . . . 0.465 ' O ' ' OG ' ' I' ' 8' ' ' SER . 4.2 m-20 -69.17 148.39 49.97 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-N 116.471 -0.331 . . . . 0.0 110.746 179.968 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' F' F ' 8' ' ' SER . . . . . 0.477 ' OG ' ' O ' ' C' ' 7' ' ' ASP . 52.6 p -168.01 -171.99 1.69 Allowed 'General case' 0 N--CA 1.486 1.335 0 CA-C-O 120.931 0.396 . . . . 0.0 111.012 178.74 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.35 47.32 1.32 Allowed Glycine 0 N--CA 1.48 1.591 0 N-CA-C 111.746 -0.542 . . . . 0.0 111.746 179.689 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 47.5 p90 -65.4 134.05 52.66 Favored 'General case' 0 N--CA 1.473 0.678 0 N-CA-C 111.981 0.363 . . . . 0.0 111.981 -179.856 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 85.7 mt-10 -91.8 152.88 19.93 Favored 'General case' 0 N--CA 1.479 0.987 0 N-CA-C 109.699 -0.482 . . . . 0.0 109.699 178.002 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -154.61 127.25 1.07 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.594 0 N-CA-C 107.823 -1.177 . . . . 0.0 107.823 178.029 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 42.2 m-70 -136.27 146.48 46.73 Favored 'General case' 0 N--CA 1.483 1.212 0 CA-C-O 120.833 0.349 . . . . 0.0 111.602 -177.948 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 6.5 t60 -163.51 98.74 0.9 Allowed 'General case' 0 N--CA 1.486 1.348 0 CA-C-N 116.343 -0.389 . . . . 0.0 110.736 179.609 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 4.8 pt20 -91.56 -176.95 4.66 Favored 'General case' 0 CA--C 1.51 -0.563 0 N-CA-C 109.109 -0.7 . . . . 0.0 109.109 179.934 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -172.3 92.38 0.12 Allowed 'General case' 0 C--O 1.219 -0.507 0 CA-C-N 114.777 -1.101 . . . . 0.0 108.591 177.961 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 6.0 mp -123.05 155.95 35.86 Favored 'General case' 0 N--CA 1.495 1.794 0 CA-C-O 121.581 0.705 . . . . 0.0 111.455 -177.983 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 48.2 t -113.52 122.5 67.77 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.141 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 177.362 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 32.6 m-85 -122.67 142.52 50.58 Favored 'General case' 0 N--CA 1.489 1.504 0 CA-C-O 120.955 0.407 . . . . 0.0 110.584 179.934 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 67.4 m-85 52.67 68.08 0.89 Allowed 'General case' 0 C--N 1.343 0.318 0 CA-C-N 115.866 -0.606 . . . . 0.0 111.918 178.474 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.42 -83.75 0.07 Allowed 'General case' 0 CA--C 1.54 0.57 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 -179.496 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 40.9 tt0 -123.22 97.68 5.53 Favored 'General case' 0 C--N 1.32 -0.689 0 N-CA-C 108.099 -1.074 . . . . 0.0 108.099 179.849 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 4.1 p30 -158.79 143.51 15.91 Favored 'General case' 0 N--CA 1.48 1.065 0 CA-C-O 119.692 -0.194 . . . . 0.0 111.277 179.059 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' F' F ' 24' ' ' VAL . . . . . 0.481 ' HB ' ' H ' ' C' ' 25' ' ' GLY . 58.0 t -59.95 166.82 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.96 0 N-CA-C 107.341 -1.355 . . . . 0.0 107.341 177.01 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' F' F ' 25' ' ' GLY . . . . . 0.443 ' H ' ' HB ' ' I' ' 24' ' ' VAL . . . -122.14 49.82 0.87 Allowed Glycine 0 N--CA 1.476 1.343 0 N-CA-C 111.039 -0.824 . . . . 0.0 111.039 -179.407 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -63.41 -168.43 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.526 0 CA-C-O 120.597 0.237 . . . . 0.0 110.505 179.938 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 14.4 t30 -68.93 78.11 0.32 Allowed 'General case' 0 CA--C 1.534 0.359 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.23 -180.0 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -78.26 155.12 30.42 Favored 'General case' 0 N--CA 1.475 0.794 0 N-CA-C 109.408 -0.589 . . . . 0.0 109.408 179.248 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.56 -144.77 0.02 OUTLIER Glycine 0 C--N 1.338 0.679 0 N-CA-C 110.384 -1.087 . . . . 0.0 110.384 178.005 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -136.8 117.35 13.82 Favored 'General case' 0 N--CA 1.476 0.829 0 CA-C-O 120.751 0.31 . . . . 0.0 110.165 179.752 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 68.3 mt -77.69 125.42 37.35 Favored 'Isoleucine or valine' 0 C--O 1.238 0.45 0 N-CA-C 106.948 -1.501 . . . . 0.0 106.948 178.373 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' F' F ' 32' ' ' ILE . . . . . 0.419 ' C ' ' H ' ' F' ' 34' ' ' LEU . 45.8 pt -151.25 164.63 2.46 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.994 0 CA-C-O 121.154 0.502 . . . . 0.0 111.043 -179.018 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.64 1.43 3.53 Favored Glycine 0 CA--C 1.529 0.911 0 CA-C-N 115.583 -0.735 . . . . 0.0 111.864 -179.67 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' F' F ' 34' ' ' LEU . . . . . 0.419 ' H ' ' C ' ' F' ' 32' ' ' ILE . 7.9 tt -79.6 148.16 31.8 Favored 'General case' 0 N--CA 1.468 0.464 0 C-N-CA 122.837 0.455 . . . . 0.0 109.775 179.95 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 28.0 ttt -158.68 140.97 14.07 Favored 'General case' 0 N--CA 1.477 0.914 0 N-CA-C 108.806 -0.812 . . . . 0.0 108.806 178.725 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 32.2 m -156.59 161.86 1.78 Allowed 'Isoleucine or valine' 0 C--N 1.344 0.358 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 -179.611 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.0 67.22 2.33 Favored Glycine 0 C--N 1.307 -1.047 0 CA-C-N 115.962 -0.563 . . . . 0.0 111.887 178.458 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 148.46 173.82 19.63 Favored Glycine 0 N--CA 1.475 1.26 0 N-CA-C 110.943 -0.863 . . . . 0.0 110.943 179.192 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' F' F ' 39' ' ' VAL . . . . . 0.575 ' H ' HG12 ' I' ' 39' ' ' VAL . 33.1 m -126.82 163.08 30.06 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.935 0 C-N-CA 123.416 0.686 . . . . 0.0 110.899 -179.058 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 24.7 t . . . . . 0 C--O 1.223 -0.304 0 CA-C-O 118.29 -0.862 . . . . 0.0 110.435 178.89 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 56.4 m-85 . . . . . 0 N--CA 1.474 0.756 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' G' G ' 5' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 -143.67 142.58 31.06 Favored 'General case' 0 N--CA 1.482 1.131 0 C-N-CA 122.585 0.354 . . . . 0.0 110.301 179.813 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 40.0 t-80 -152.53 120.34 6.12 Favored 'General case' 0 N--CA 1.473 0.712 0 N-CA-C 109.46 -0.57 . . . . 0.0 109.46 179.016 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -71.16 143.88 50.38 Favored 'General case' 0 N--CA 1.471 0.584 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.12 -179.936 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' G' G ' 8' ' ' SER . . . . . 0.57 ' OG ' ' O ' ' D' ' 7' ' ' ASP . 49.1 p -164.54 -170.1 1.94 Allowed 'General case' 0 N--CA 1.475 0.783 0 CA-C-O 120.923 0.392 . . . . 0.0 110.52 178.506 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.11 47.32 1.35 Allowed Glycine 0 N--CA 1.48 1.571 0 N-CA-C 111.37 -0.692 . . . . 0.0 111.37 179.529 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 50.1 p90 -65.62 133.31 50.88 Favored 'General case' 0 CA--C 1.543 0.683 0 N-CA-C 111.875 0.324 . . . . 0.0 111.875 -179.497 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 83.0 mt-10 -91.6 151.89 20.51 Favored 'General case' 0 N--CA 1.478 0.974 0 CA-C-O 120.991 0.424 . . . . 0.0 110.076 178.555 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -154.78 127.41 1.07 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.014 0 N-CA-C 107.864 -1.161 . . . . 0.0 107.864 178.17 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 42.4 m-70 -135.42 148.21 49.24 Favored 'General case' 0 N--CA 1.479 1.004 0 CA-C-N 115.505 -0.77 . . . . 0.0 111.409 -178.258 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 6.6 t60 -165.49 98.97 0.7 Allowed 'General case' 0 N--CA 1.484 1.263 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.307 179.012 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -92.09 -176.73 4.48 Favored 'General case' 0 CA--C 1.513 -0.477 0 N-CA-C 108.901 -0.777 . . . . 0.0 108.901 -179.847 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -172.85 92.28 0.1 Allowed 'General case' 0 N--CA 1.47 0.565 0 CA-C-N 114.86 -1.064 . . . . 0.0 108.37 178.123 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 6.0 mp -123.19 154.77 38.27 Favored 'General case' 0 N--CA 1.498 1.955 0 CA-C-O 121.302 0.572 . . . . 0.0 111.668 -177.995 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 42.4 t -112.83 123.08 68.14 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.99 0 CA-C-N 114.747 -1.115 . . . . 0.0 108.394 176.866 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 34.8 m-85 -123.53 142.05 51.4 Favored 'General case' 0 C--N 1.367 1.35 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.691 -179.807 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 66.9 m-85 53.64 66.25 1.28 Allowed 'General case' 0 C--O 1.237 0.422 0 CA-C-N 115.742 -0.663 . . . . 0.0 111.584 178.192 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -76.02 -83.62 0.06 Allowed 'General case' 0 N--CA 1.471 0.586 0 N-CA-C 110.003 -0.369 . . . . 0.0 110.003 -179.076 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 41.3 tt0 -123.0 97.25 5.35 Favored 'General case' 0 C--N 1.321 -0.673 0 N-CA-C 107.829 -1.174 . . . . 0.0 107.829 -179.976 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 4.1 p30 -158.59 144.2 16.62 Favored 'General case' 0 N--CA 1.479 1.008 0 CA-C-O 120.463 0.173 . . . . 0.0 111.279 178.891 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' G' G ' 24' ' ' VAL . . . . . 0.556 ' HB ' ' H ' ' D' ' 25' ' ' GLY . 61.0 t -60.96 165.62 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.685 0 N-CA-C 107.617 -1.253 . . . . 0.0 107.617 177.347 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' G' G ' 25' ' ' GLY . . . . . 0.404 ' N ' HG12 ' G' ' 24' ' ' VAL . . . -120.36 50.34 0.83 Allowed Glycine 0 N--CA 1.482 1.711 0 N-CA-C 110.567 -1.013 . . . . 0.0 110.567 -179.561 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -64.06 -168.04 0.03 OUTLIER 'General case' 0 N--CA 1.472 0.647 0 CA-C-N 117.002 0.401 . . . . 0.0 109.963 179.875 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 15.5 t30 -69.46 77.92 0.4 Allowed 'General case' 0 CA--C 1.537 0.459 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.444 179.954 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -77.2 155.22 32.37 Favored 'General case' 0 N--CA 1.475 0.788 0 N-CA-C 109.602 -0.518 . . . . 0.0 109.602 179.189 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.03 -142.53 0.02 OUTLIER Glycine 0 CA--C 1.527 0.792 0 N-CA-C 109.918 -1.273 . . . . 0.0 109.918 178.313 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -137.72 117.45 13.12 Favored 'General case' 0 N--CA 1.471 0.583 0 C-N-CA 122.624 0.37 . . . . 0.0 110.737 -179.915 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 71.7 mt -77.79 125.85 37.74 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.496 0 N-CA-C 107.007 -1.479 . . . . 0.0 107.007 178.382 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' G' G ' 32' ' ' ILE . . . . . 0.426 ' C ' ' H ' ' G' ' 34' ' ' LEU . 44.7 pt -152.31 164.95 1.96 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.755 0 CA-C-N 120.091 1.314 . . . . 0.0 110.032 -179.36 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.61 0.64 3.9 Favored Glycine 0 N--CA 1.468 0.779 0 N-CA-C 111.19 -0.764 . . . . 0.0 111.19 -179.912 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' G' G ' 34' ' ' LEU . . . . . 0.426 ' H ' ' C ' ' G' ' 32' ' ' ILE . 7.9 tt -79.71 148.34 31.58 Favored 'General case' 0 N--CA 1.465 0.303 0 C-N-CA 122.832 0.453 . . . . 0.0 109.841 179.855 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 27.1 ttt -159.14 141.98 14.27 Favored 'General case' 0 N--CA 1.476 0.837 0 N-CA-C 108.731 -0.84 . . . . 0.0 108.731 179.004 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 33.8 m -156.68 162.21 1.67 Allowed 'Isoleucine or valine' 0 C--N 1.345 0.412 0 N-CA-C 108.618 -0.882 . . . . 0.0 108.618 -179.492 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' G' G ' 37' ' ' GLY . . . . . 0.401 ' N ' ' OE1' ' D' ' 15' ' ' GLN . . . 54.95 67.86 1.98 Allowed Glycine 0 C--N 1.31 -0.879 0 CA-C-N 115.637 -0.71 . . . . 0.0 112.141 178.134 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 148.75 174.41 20.37 Favored Glycine 0 N--CA 1.475 1.296 0 N-CA-C 110.462 -1.055 . . . . 0.0 110.462 179.229 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' G' G ' 39' ' ' VAL . . . . . 0.575 HG12 ' H ' ' D' ' 39' ' ' VAL . 33.8 m -127.27 162.73 31.82 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.76 0 C-N-CA 123.1 0.56 . . . . 0.0 110.877 -179.308 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 28.1 t . . . . . 0 N--CA 1.469 0.493 0 CA-C-O 118.351 -0.833 . . . . 0.0 110.702 178.773 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 57.5 m-85 . . . . . 0 N--CA 1.473 0.705 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' H' H ' 5' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 -143.91 142.64 30.89 Favored 'General case' 0 N--CA 1.483 1.178 0 C-N-CA 122.551 0.341 . . . . 0.0 110.169 179.846 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 41.9 t-80 -152.55 120.38 6.13 Favored 'General case' 0 N--CA 1.474 0.737 0 N-CA-C 109.409 -0.589 . . . . 0.0 109.409 178.946 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -71.28 143.89 50.18 Favored 'General case' 0 N--CA 1.469 0.518 0 C-N-CA 122.699 0.399 . . . . 0.0 111.158 -179.913 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' H' H ' 8' ' ' SER . . . . . 0.435 ' OG ' ' O ' ' E' ' 7' ' ' ASP . 53.6 p -164.36 -170.42 2.06 Favored 'General case' 0 N--CA 1.474 0.759 0 CA-C-O 120.965 0.412 . . . . 0.0 110.422 178.766 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.95 47.97 1.3 Allowed Glycine 0 N--CA 1.48 1.586 0 N-CA-C 111.461 -0.655 . . . . 0.0 111.461 179.601 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 50.2 p90 -66.28 133.18 50.03 Favored 'General case' 0 N--CA 1.472 0.675 0 N-CA-C 112.046 0.387 . . . . 0.0 112.046 -179.605 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 83.4 mt-10 -91.42 151.66 20.72 Favored 'General case' 0 N--CA 1.478 0.957 0 CA-C-O 121.069 0.461 . . . . 0.0 110.195 178.576 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -154.73 127.41 1.08 Allowed 'Isoleucine or valine' 0 CA--C 1.553 1.059 0 N-CA-C 107.888 -1.153 . . . . 0.0 107.888 178.251 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 42.7 m-70 -135.46 148.2 49.17 Favored 'General case' 0 C--N 1.357 0.912 0 CA-C-N 115.461 -0.79 . . . . 0.0 111.444 -178.293 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 6.6 t60 -165.43 98.75 0.7 Allowed 'General case' 0 N--CA 1.482 1.136 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.427 178.996 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 4.9 pt20 -91.88 -177.02 4.61 Favored 'General case' 0 CA--C 1.513 -0.468 0 N-CA-C 108.799 -0.815 . . . . 0.0 108.799 -179.814 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -172.7 92.13 0.11 Allowed 'General case' 0 N--CA 1.472 0.663 0 CA-C-N 114.707 -1.133 . . . . 0.0 108.239 178.142 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 6.0 mp -122.93 154.72 37.99 Favored 'General case' 0 N--CA 1.499 1.991 0 CA-C-O 121.224 0.535 . . . . 0.0 111.784 -178.064 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 41.5 t -112.72 123.25 68.21 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.947 0 CA-C-N 114.841 -1.072 . . . . 0.0 108.368 176.742 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 34.2 m-85 -123.66 141.58 51.88 Favored 'General case' 0 C--N 1.369 1.425 0 CA-C-N 115.427 -0.806 . . . . 0.0 110.598 -179.65 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 66.9 m-85 53.02 67.44 1.0 Allowed 'General case' 0 C--O 1.237 0.419 0 CA-C-N 115.623 -0.717 . . . . 0.0 111.674 178.389 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -76.66 -83.15 0.07 Allowed 'General case' 0 N--CA 1.469 0.504 0 N-CA-C 110.025 -0.361 . . . . 0.0 110.025 -179.168 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 41.1 tt0 -123.25 96.93 5.19 Favored 'General case' 0 C--N 1.319 -0.726 0 N-CA-C 107.891 -1.151 . . . . 0.0 107.891 -179.969 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 4.2 p30 -158.16 143.98 17.06 Favored 'General case' 0 N--CA 1.478 0.968 0 CA-C-O 120.423 0.154 . . . . 0.0 111.264 179.021 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' H' H ' 24' ' ' VAL . . . . . 0.461 ' HB ' ' H ' ' E' ' 25' ' ' GLY . 58.3 t -60.77 165.9 0.77 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.599 0 N-CA-C 107.61 -1.256 . . . . 0.0 107.61 177.285 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' H' H ' 25' ' ' GLY . . . . . 0.408 ' N ' HG12 ' H' ' 24' ' ' VAL . . . -120.47 49.7 0.86 Allowed Glycine 0 N--CA 1.479 1.518 0 N-CA-C 110.665 -0.974 . . . . 0.0 110.665 -179.472 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -63.71 -168.16 0.02 OUTLIER 'General case' 0 N--CA 1.471 0.625 0 CA-C-N 117.022 0.411 . . . . 0.0 110.125 179.926 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 15.8 t30 -69.52 78.45 0.41 Allowed 'General case' 0 CA--C 1.536 0.413 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.41 179.987 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -77.86 155.44 30.98 Favored 'General case' 0 N--CA 1.474 0.768 0 N-CA-C 109.459 -0.571 . . . . 0.0 109.459 179.262 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.36 -142.76 0.02 OUTLIER Glycine 0 C--N 1.339 0.733 0 N-CA-C 109.798 -1.321 . . . . 0.0 109.798 178.386 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -137.67 117.38 13.09 Favored 'General case' 0 N--CA 1.469 0.522 0 C-N-CA 122.526 0.33 . . . . 0.0 110.758 -179.855 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 71.5 mt -77.49 125.73 37.42 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.506 0 N-CA-C 106.946 -1.502 . . . . 0.0 106.946 178.498 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' H' H ' 32' ' ' ILE . . . . . 0.418 ' C ' ' H ' ' H' ' 34' ' ' LEU . 44.7 pt -152.27 164.92 1.98 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 CA-C-N 120.094 1.316 . . . . 0.0 110.005 -179.452 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.91 0.3 3.97 Favored Glycine 0 CA--C 1.527 0.796 0 N-CA-C 111.202 -0.759 . . . . 0.0 111.202 -179.827 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' H' H ' 34' ' ' LEU . . . . . 0.418 ' H ' ' C ' ' H' ' 32' ' ' ILE . 7.9 tt -79.39 148.36 32.02 Favored 'General case' 0 N--CA 1.465 0.308 0 C-N-CA 122.84 0.456 . . . . 0.0 109.889 179.935 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 27.1 ttt -159.23 141.73 13.95 Favored 'General case' 0 N--CA 1.477 0.915 0 N-CA-C 108.709 -0.848 . . . . 0.0 108.709 178.999 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 35.9 m -156.69 162.13 1.7 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.416 0 N-CA-C 108.599 -0.889 . . . . 0.0 108.599 -179.39 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.04 67.79 2.02 Favored Glycine 0 C--N 1.31 -0.896 0 CA-C-N 115.638 -0.71 . . . . 0.0 112.086 178.239 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 149.01 174.89 20.98 Favored Glycine 0 N--CA 1.475 1.267 0 N-CA-C 110.571 -1.012 . . . . 0.0 110.571 179.19 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' H' H ' 39' ' ' VAL . . . . . 0.559 HG12 ' H ' ' E' ' 39' ' ' VAL . 33.9 m -127.65 162.53 33.09 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.799 0 C-N-CA 123.114 0.565 . . . . 0.0 110.923 -179.368 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 25.9 t . . . . . 0 N--CA 1.47 0.541 0 CA-C-O 118.402 -0.809 . . . . 0.0 110.707 178.74 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 56.3 m-85 . . . . . 0 N--CA 1.474 0.772 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' I' I ' 5' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 -143.93 142.37 30.72 Favored 'General case' 0 N--CA 1.483 1.199 0 C-N-CA 122.569 0.348 . . . . 0.0 110.108 179.827 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 40.7 t-80 -152.36 120.13 6.12 Favored 'General case' 0 N--CA 1.473 0.687 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 178.976 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -71.06 143.98 50.51 Favored 'General case' 0 N--CA 1.47 0.574 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.178 -179.856 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' I' I ' 8' ' ' SER . . . . . 0.465 ' OG ' ' O ' ' F' ' 7' ' ' ASP . 54.1 p -164.5 -170.43 2.04 Favored 'General case' 0 N--CA 1.475 0.781 0 CA-C-O 120.964 0.411 . . . . 0.0 110.456 178.707 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.19 47.24 1.35 Allowed Glycine 0 N--CA 1.48 1.611 0 N-CA-C 111.598 -0.601 . . . . 0.0 111.598 179.67 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 50.4 p90 -65.76 133.48 51.13 Favored 'General case' 0 N--CA 1.473 0.676 0 N-CA-C 112.0 0.37 . . . . 0.0 112.0 -179.566 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 82.6 mt-10 -91.81 151.71 20.47 Favored 'General case' 0 N--CA 1.476 0.871 0 CA-C-O 120.978 0.418 . . . . 0.0 110.184 178.639 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -154.67 127.48 1.1 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.033 0 N-CA-C 107.969 -1.123 . . . . 0.0 107.969 178.16 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 41.7 m-70 -135.5 148.1 49.07 Favored 'General case' 0 N--CA 1.477 0.922 0 CA-C-N 115.407 -0.815 . . . . 0.0 111.467 -178.248 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 6.6 t60 -165.3 99.01 0.72 Allowed 'General case' 0 N--CA 1.483 1.192 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.383 179.013 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -92.07 -176.92 4.54 Favored 'General case' 0 CA--C 1.511 -0.521 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 -179.848 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -172.83 92.08 0.1 Allowed 'General case' 0 N--CA 1.47 0.534 0 CA-C-N 114.74 -1.118 . . . . 0.0 108.291 178.199 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 6.0 mp -122.84 154.91 37.63 Favored 'General case' 0 N--CA 1.499 1.983 0 CA-C-O 121.223 0.535 . . . . 0.0 111.754 -178.054 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 41.3 t -113.09 123.42 68.72 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.927 0 CA-C-N 114.861 -1.063 . . . . 0.0 108.247 176.784 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 33.4 m-85 -123.96 141.18 52.27 Favored 'General case' 0 C--N 1.37 1.461 0 CA-C-N 115.413 -0.812 . . . . 0.0 110.636 -179.444 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 67.1 m-85 53.35 67.15 1.05 Allowed 'General case' 0 C--O 1.238 0.45 0 CA-C-N 115.69 -0.686 . . . . 0.0 111.537 178.41 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -76.32 -83.14 0.07 Allowed 'General case' 0 N--CA 1.47 0.541 0 N-CA-C 109.913 -0.402 . . . . 0.0 109.913 -179.148 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 41.3 tt0 -123.33 97.1 5.25 Favored 'General case' 0 C--N 1.32 -0.712 0 N-CA-C 107.868 -1.16 . . . . 0.0 107.868 -179.924 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 4.1 p30 -158.29 144.36 17.13 Favored 'General case' 0 N--CA 1.479 1.002 0 O-C-N 122.458 -0.151 . . . . 0.0 111.257 178.964 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' I' I ' 24' ' ' VAL . . . . . 0.443 ' HB ' ' H ' ' F' ' 25' ' ' GLY . 59.5 t -61.2 165.57 0.86 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.589 0 N-CA-C 107.63 -1.248 . . . . 0.0 107.63 177.345 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' I' I ' 25' ' ' GLY . . . . . 0.412 ' N ' HG12 ' I' ' 24' ' ' VAL . . . -120.24 49.95 0.85 Allowed Glycine 0 N--CA 1.481 1.661 0 N-CA-C 110.588 -1.005 . . . . 0.0 110.588 -179.383 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -63.8 -168.1 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.649 0 CA-C-N 116.991 0.395 . . . . 0.0 110.134 179.825 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 15.2 t30 -69.56 78.3 0.41 Allowed 'General case' 0 CA--C 1.536 0.421 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.364 179.924 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -77.77 155.34 31.22 Favored 'General case' 0 N--CA 1.475 0.78 0 N-CA-C 109.504 -0.554 . . . . 0.0 109.504 179.263 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.28 -143.0 0.02 OUTLIER Glycine 0 CA--C 1.527 0.842 0 N-CA-C 109.813 -1.315 . . . . 0.0 109.813 178.39 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -137.3 117.36 13.38 Favored 'General case' 0 N--CA 1.471 0.597 0 C-N-CA 122.627 0.371 . . . . 0.0 110.778 -179.863 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 71.7 mt -77.57 125.89 37.6 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.488 0 N-CA-C 106.986 -1.487 . . . . 0.0 106.986 178.389 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' I' I ' 32' ' ' ILE . . . . . 0.429 ' C ' ' H ' ' I' ' 34' ' ' LEU . 44.9 pt -152.34 164.95 1.94 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 CA-C-N 120.143 1.338 . . . . 0.0 110.06 -179.436 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.64 0.98 4.22 Favored Glycine 0 N--CA 1.469 0.844 0 N-CA-C 111.127 -0.789 . . . . 0.0 111.127 -179.909 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' I' I ' 34' ' ' LEU . . . . . 0.429 ' H ' ' C ' ' I' ' 32' ' ' ILE . 8.1 tt -80.1 148.02 31.17 Favored 'General case' 0 CA--C 1.533 0.313 0 C-N-CA 122.845 0.458 . . . . 0.0 109.792 179.895 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 26.9 ttt -158.69 141.68 14.63 Favored 'General case' 0 N--CA 1.476 0.85 0 N-CA-C 108.611 -0.885 . . . . 0.0 108.611 179.086 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 35.9 m -156.65 162.06 1.72 Allowed 'Isoleucine or valine' 0 C--N 1.346 0.442 0 N-CA-C 108.523 -0.917 . . . . 0.0 108.523 -179.562 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.22 67.78 2.03 Favored Glycine 0 C--N 1.312 -0.798 0 CA-C-N 115.638 -0.71 . . . . 0.0 112.107 178.185 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 148.68 174.73 20.59 Favored Glycine 0 N--CA 1.474 1.217 0 N-CA-C 110.461 -1.056 . . . . 0.0 110.461 179.244 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' I' I ' 39' ' ' VAL . . . . . 0.575 HG12 ' H ' ' F' ' 39' ' ' VAL . 33.9 m -127.66 162.76 32.64 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.786 0 C-N-CA 123.1 0.56 . . . . 0.0 110.923 -179.259 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 27.1 t . . . . . 0 N--CA 1.47 0.544 0 CA-C-O 118.377 -0.821 . . . . 0.0 110.56 178.75 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 26.6 m-85 . . . . . 0 CA--C 1.537 0.478 0 N-CA-C 109.142 -0.688 . . . . 0.0 109.142 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 38.2 mtp180 -68.41 147.02 52.67 Favored 'General case' 0 C--O 1.201 -1.452 0 CA-C-N 115.821 -0.627 . . . . 0.0 111.293 -177.505 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 39.2 m80 -109.55 119.1 38.39 Favored 'General case' 0 N--CA 1.482 1.165 0 N-CA-C 108.953 -0.758 . . . . 0.0 108.953 178.289 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' ASP . . . . . 0.459 ' OD1' ' NH2' ' G' ' 5' ' ' ARG . 7.3 m-20 -67.52 140.7 57.01 Favored 'General case' 0 N--CA 1.469 0.502 0 CA-C-O 121.135 0.493 . . . . 0.0 111.795 -178.758 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 39.0 t -158.65 -169.49 2.74 Favored 'General case' 0 N--CA 1.467 0.376 0 CA-C-N 115.848 -0.615 . . . . 0.0 109.662 179.092 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 119.83 32.39 1.2 Allowed Glycine 0 N--CA 1.485 1.922 0 N-CA-C 111.574 -0.61 . . . . 0.0 111.574 179.61 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 46.9 p90 -57.2 130.43 46.16 Favored 'General case' 0 N--CA 1.471 0.61 0 CA-C-N 116.736 0.268 . . . . 0.0 111.49 179.971 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . 0.506 ' CG ' HD21 ' C' ' 27' ' ' ASN . 60.6 mt-10 -90.44 153.15 20.61 Favored 'General case' 0 N--CA 1.473 0.717 0 N-CA-C 109.329 -0.619 . . . . 0.0 109.329 178.69 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.6 p -153.48 126.55 1.15 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 N-CA-C 107.698 -1.223 . . . . 0.0 107.698 177.988 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 45.6 m-70 -136.91 162.06 34.3 Favored 'General case' 0 N--CA 1.49 1.537 0 CA-C-N 118.685 0.675 . . . . 0.0 110.879 -178.721 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 38.3 t60 -152.91 96.43 2.1 Favored 'General case' 0 N--CA 1.486 1.333 0 C-N-CA 122.634 0.374 . . . . 0.0 110.049 179.065 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . 0.725 HE22 ' H ' ' A' ' 38' ' ' GLY . 28.3 mt-30 -90.63 121.52 32.61 Favored 'General case' 0 N--CA 1.452 -0.371 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 -178.964 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -112.98 103.67 11.63 Favored 'General case' 0 N--CA 1.475 0.789 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 176.686 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 57.8 tp -133.34 150.43 51.85 Favored 'General case' 0 N--CA 1.486 1.347 0 N-CA-C 108.766 -0.827 . . . . 0.0 108.766 -179.391 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 84.5 t -145.42 123.13 4.65 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.969 0 CA-C-O 118.523 -0.751 . . . . 0.0 109.137 179.755 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 11.9 m-85 -70.74 158.67 35.89 Favored 'General case' 0 N--CA 1.485 1.324 0 N-CA-C 107.461 -1.311 . . . . 0.0 107.461 177.564 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 18.6 t80 -170.07 -58.44 0.02 OUTLIER 'General case' 0 N--CA 1.481 1.101 0 CA-C-O 122.425 1.107 . . . . 0.0 109.765 179.735 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -39.19 89.68 0.0 OUTLIER 'General case' 0 N--CA 1.456 -0.135 0 CA-C-N 113.807 -1.542 . . . . 0.0 112.844 -178.034 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 38.6 tt0 -64.49 159.59 21.2 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.175 -0.92 . . . . 0.0 110.552 179.245 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 9.6 m-20 -136.23 125.81 25.3 Favored 'General case' 0 N--CA 1.481 1.086 0 C-N-CA 123.297 0.639 . . . . 0.0 109.781 -179.897 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.861 HG12 ' H ' ' A' ' 25' ' ' GLY . 57.8 t -76.55 -170.44 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.591 0 N-CA-C 108.511 -0.922 . . . . 0.0 108.511 179.673 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.861 ' H ' HG12 ' A' ' 24' ' ' VAL . . . -69.11 48.86 0.52 Allowed Glycine 0 CA--C 1.53 1.003 0 CA-C-N 118.344 0.52 . . . . 0.0 112.313 -178.147 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 13.1 p -69.54 137.52 52.52 Favored 'General case' 0 C--O 1.217 -0.61 0 N-CA-C 109.596 -0.52 . . . . 0.0 109.596 178.66 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . 0.512 HD21 ' CG ' ' B' ' 11' ' ' GLU . 34.6 t30 -68.57 95.06 0.61 Allowed 'General case' 0 N--CA 1.47 0.553 0 N-CA-C 108.15 -1.055 . . . . 0.0 108.15 177.847 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 68.6 mttm -92.45 117.66 30.16 Favored 'General case' 0 N--CA 1.481 1.079 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 -179.221 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.33 -134.27 0.01 OUTLIER Glycine 0 CA--C 1.534 1.226 0 N-CA-C 110.771 -0.932 . . . . 0.0 110.771 179.044 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -115.65 127.16 54.98 Favored 'General case' 0 N--CA 1.477 0.897 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 179.12 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 66.1 mt -90.53 134.97 27.76 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.59 0 N-CA-C 107.673 -1.232 . . . . 0.0 107.673 179.012 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 30.3 mt -136.52 138.16 46.92 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.815 0 CA-C-N 115.982 -0.554 . . . . 0.0 109.606 -179.134 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.97 57.46 15.75 Favored Glycine 0 CA--C 1.527 0.842 0 CA-C-N 115.904 -0.589 . . . . 0.0 112.795 178.543 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 25.4 tp -106.11 132.77 51.79 Favored 'General case' 0 N--CA 1.488 1.474 0 N-CA-C 107.508 -1.293 . . . . 0.0 107.508 177.919 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 24.9 ttt -138.2 148.15 44.52 Favored 'General case' 0 N--CA 1.471 0.576 0 N-CA-C 107.769 -1.197 . . . . 0.0 107.769 179.136 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 60.4 t -156.64 160.45 2.25 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.587 0 N-CA-C 106.097 -1.816 . . . . 0.0 106.097 -178.855 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . 0.455 ' O ' ' NE2' ' D' ' 15' ' ' GLN . . . 53.55 74.48 0.3 Allowed Glycine 0 C--N 1.308 -0.993 0 C-N-CA 121.214 -0.517 . . . . 0.0 111.818 177.839 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . 0.725 ' H ' HE22 ' A' ' 15' ' ' GLN . . . 164.73 -168.51 39.02 Favored Glycine 0 N--CA 1.466 0.692 0 N-CA-C 111.042 -0.823 . . . . 0.0 111.042 179.352 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 24.5 m -126.67 148.9 31.38 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.855 0 C-N-CA 122.977 0.511 . . . . 0.0 109.847 179.665 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 9.7 t . . . . . 0 CA--C 1.535 0.385 0 CA-C-O 118.109 -0.948 . . . . 0.0 110.723 178.893 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 27.8 m-85 . . . . . 0 N--CA 1.468 0.435 0 N-CA-C 109.154 -0.684 . . . . 0.0 109.154 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 39.3 mtp180 -68.48 146.74 52.88 Favored 'General case' 0 C--O 1.201 -1.478 0 CA-C-N 115.708 -0.678 . . . . 0.0 111.3 -177.653 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 39.4 m80 -109.35 119.36 39.24 Favored 'General case' 0 N--CA 1.484 1.247 0 N-CA-C 108.995 -0.742 . . . . 0.0 108.995 178.282 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 7' ' ' ASP . . . . . 0.46 ' OD1' ' NH2' ' H' ' 5' ' ' ARG . 7.1 m-20 -67.66 141.02 56.84 Favored 'General case' 0 N--CA 1.469 0.501 0 CA-C-O 121.043 0.449 . . . . 0.0 111.76 -178.745 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 8' ' ' SER . . . . . . . . . . . . . 39.1 t -158.8 -169.45 2.7 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-N 115.814 -0.63 . . . . 0.0 109.634 179.099 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 119.75 32.37 1.21 Allowed Glycine 0 N--CA 1.485 1.92 0 N-CA-C 111.552 -0.619 . . . . 0.0 111.552 179.578 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 46.8 p90 -57.36 130.54 46.71 Favored 'General case' 0 N--CA 1.472 0.651 0 CA-C-O 120.64 0.257 . . . . 0.0 111.514 -179.996 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 11' ' ' GLU . . . . . 0.512 ' CG ' HD21 ' A' ' 27' ' ' ASN . 60.4 mt-10 -90.52 153.16 20.57 Favored 'General case' 0 N--CA 1.472 0.664 0 N-CA-C 109.357 -0.609 . . . . 0.0 109.357 178.857 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.6 p -153.53 126.14 1.09 Allowed 'Isoleucine or valine' 0 C--O 1.234 0.281 0 N-CA-C 107.846 -1.168 . . . . 0.0 107.846 178.086 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 45.6 m-70 -136.63 162.07 34.15 Favored 'General case' 0 N--CA 1.49 1.533 0 CA-C-N 118.648 0.658 . . . . 0.0 110.936 -178.567 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 38.4 t60 -152.86 96.44 2.1 Favored 'General case' 0 N--CA 1.487 1.422 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.087 179.057 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . 0.721 HE22 ' H ' ' B' ' 38' ' ' GLY . 28.3 mt-30 -90.48 121.16 32.2 Favored 'General case' 0 CA--C 1.517 -0.309 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 -179.01 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -112.63 103.49 11.53 Favored 'General case' 0 N--CA 1.474 0.742 0 N-CA-C 107.988 -1.115 . . . . 0.0 107.988 176.619 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 57.8 tp -133.34 150.25 51.86 Favored 'General case' 0 N--CA 1.486 1.369 0 N-CA-C 108.755 -0.831 . . . . 0.0 108.755 -179.368 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 84.6 t -145.41 122.48 4.28 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.011 0 CA-C-O 118.629 -0.7 . . . . 0.0 109.333 179.707 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 12.4 m-85 -70.52 158.91 35.26 Favored 'General case' 0 N--CA 1.486 1.334 0 N-CA-C 107.287 -1.375 . . . . 0.0 107.287 177.572 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 19.9 t80 -170.99 -57.67 0.02 OUTLIER 'General case' 0 N--CA 1.478 0.934 0 CA-C-O 122.22 1.009 . . . . 0.0 109.705 179.651 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -39.4 90.12 0.0 OUTLIER 'General case' 0 C--O 1.231 0.124 0 CA-C-N 113.959 -1.473 . . . . 0.0 112.721 -178.16 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 38.6 tt0 -64.85 159.55 22.35 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 115.1 -0.955 . . . . 0.0 110.559 179.298 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 9.7 m-20 -136.26 125.9 25.4 Favored 'General case' 0 N--CA 1.481 1.118 0 C-N-CA 123.217 0.607 . . . . 0.0 109.765 -179.876 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 24' ' ' VAL . . . . . 0.848 HG12 ' H ' ' B' ' 25' ' ' GLY . 56.9 t -76.7 -170.39 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.661 0 N-CA-C 108.586 -0.894 . . . . 0.0 108.586 179.722 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 25' ' ' GLY . . . . . 0.848 ' H ' HG12 ' B' ' 24' ' ' VAL . . . -68.71 48.42 0.45 Allowed Glycine 0 CA--C 1.531 1.087 0 CA-C-N 118.321 0.509 . . . . 0.0 112.208 -178.126 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 13.3 p -69.72 137.41 52.02 Favored 'General case' 0 C--O 1.219 -0.548 0 N-CA-C 109.591 -0.522 . . . . 0.0 109.591 178.706 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 27' ' ' ASN . . . . . 0.507 HD21 ' CG ' ' C' ' 11' ' ' GLU . 34.8 t30 -68.72 95.07 0.64 Allowed 'General case' 0 N--CA 1.47 0.543 0 N-CA-C 108.159 -1.052 . . . . 0.0 108.159 177.847 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 68.6 mttm -92.34 117.62 30.08 Favored 'General case' 0 N--CA 1.48 1.028 0 N-CA-C 109.997 -0.371 . . . . 0.0 109.997 -179.227 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.3 -134.17 0.01 OUTLIER Glycine 0 CA--C 1.532 1.128 0 N-CA-C 110.769 -0.932 . . . . 0.0 110.769 179.014 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -115.88 127.28 54.89 Favored 'General case' 0 N--CA 1.478 0.955 0 N-CA-C 109.428 -0.582 . . . . 0.0 109.428 179.149 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 66.0 mt -90.55 135.0 27.69 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.536 0 N-CA-C 107.676 -1.231 . . . . 0.0 107.676 179.035 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 30.2 mt -136.45 138.35 46.8 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.714 0 CA-C-N 115.933 -0.576 . . . . 0.0 109.567 -179.115 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.65 57.72 15.16 Favored Glycine 0 CA--C 1.527 0.829 0 CA-C-N 115.876 -0.602 . . . . 0.0 112.82 178.604 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 25.8 tp -106.3 132.83 51.88 Favored 'General case' 0 N--CA 1.486 1.375 0 N-CA-C 107.502 -1.296 . . . . 0.0 107.502 177.897 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 25.0 ttt -138.18 147.83 44.22 Favored 'General case' 0 N--CA 1.473 0.683 0 N-CA-C 107.778 -1.193 . . . . 0.0 107.778 179.216 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 36' ' ' VAL . . . . . 0.404 HG12 ' N ' ' B' ' 37' ' ' GLY . 60.8 t -156.67 159.98 2.45 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.625 0 N-CA-C 106.178 -1.786 . . . . 0.0 106.178 -178.928 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . 0.464 ' O ' ' NE2' ' E' ' 15' ' ' GLN . . . 54.12 74.26 0.33 Allowed Glycine 0 C--N 1.308 -0.973 0 N-CA-C 111.739 -0.544 . . . . 0.0 111.739 177.963 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 38' ' ' GLY . . . . . 0.721 ' H ' HE22 ' B' ' 15' ' ' GLN . . . 164.85 -168.44 39.07 Favored Glycine 0 N--CA 1.465 0.58 0 N-CA-C 111.124 -0.791 . . . . 0.0 111.124 179.266 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 24.5 m -126.62 148.89 31.33 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.808 0 C-N-CA 122.992 0.517 . . . . 0.0 109.955 179.601 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 9.7 t . . . . . 0 CA--C 1.535 0.392 0 CA-C-O 118.095 -0.955 . . . . 0.0 110.872 179.001 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 27.7 m-85 . . . . . 0 N--CA 1.468 0.429 0 N-CA-C 109.265 -0.643 . . . . 0.0 109.265 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 39.2 mtp180 -68.67 146.37 53.05 Favored 'General case' 0 C--O 1.201 -1.489 0 CA-C-N 115.849 -0.614 . . . . 0.0 111.221 -177.564 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 39.2 m80 -109.11 119.22 38.9 Favored 'General case' 0 N--CA 1.484 1.232 0 N-CA-C 108.978 -0.749 . . . . 0.0 108.978 178.269 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' C' C ' 7' ' ' ASP . . . . . 0.473 ' OD1' ' NH2' ' I' ' 5' ' ' ARG . 7.3 m-20 -67.64 141.11 56.83 Favored 'General case' 0 N--CA 1.468 0.448 0 CA-C-O 121.049 0.452 . . . . 0.0 111.79 -178.721 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' C' C ' 8' ' ' SER . . . . . . . . . . . . . 39.2 t -158.89 -169.49 2.71 Favored 'General case' 0 N--CA 1.466 0.37 0 CA-C-N 115.837 -0.62 . . . . 0.0 109.604 179.149 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 119.8 32.34 1.21 Allowed Glycine 0 N--CA 1.485 1.94 0 N-CA-C 111.506 -0.638 . . . . 0.0 111.506 179.543 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 46.8 p90 -57.32 130.42 46.15 Favored 'General case' 0 N--CA 1.471 0.587 0 CA-C-O 120.676 0.274 . . . . 0.0 111.53 179.951 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' C' C ' 11' ' ' GLU . . . . . 0.507 ' CG ' HD21 ' B' ' 27' ' ' ASN . 60.5 mt-10 -90.39 153.12 20.65 Favored 'General case' 0 N--CA 1.473 0.722 0 N-CA-C 109.368 -0.605 . . . . 0.0 109.368 178.792 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.6 p -153.47 126.16 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 N-CA-C 107.858 -1.164 . . . . 0.0 107.858 178.017 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 45.8 m-70 -136.59 162.16 33.9 Favored 'General case' 0 N--CA 1.491 1.589 0 CA-C-N 118.604 0.638 . . . . 0.0 110.958 -178.658 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 38.6 t60 -153.01 96.61 2.1 Favored 'General case' 0 N--CA 1.487 1.413 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.1 179.086 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' C' C ' 15' ' ' GLN . . . . . 0.739 HE22 ' H ' ' C' ' 38' ' ' GLY . 28.3 mt-30 -90.72 121.5 32.67 Favored 'General case' 0 CA--C 1.515 -0.381 0 N-CA-C 109.843 -0.429 . . . . 0.0 109.843 -178.99 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -112.92 103.49 11.46 Favored 'General case' 0 N--CA 1.473 0.677 0 N-CA-C 107.898 -1.149 . . . . 0.0 107.898 176.665 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 57.8 tp -133.28 150.23 51.92 Favored 'General case' 0 N--CA 1.486 1.337 0 N-CA-C 108.769 -0.826 . . . . 0.0 108.769 -179.435 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 85.3 t -145.38 122.59 4.37 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.013 0 CA-C-O 118.694 -0.67 . . . . 0.0 109.289 179.714 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 12.4 m-85 -70.63 158.88 35.41 Favored 'General case' 0 N--CA 1.487 1.39 0 N-CA-C 107.345 -1.354 . . . . 0.0 107.345 177.516 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 19.9 t80 -170.9 -57.72 0.02 OUTLIER 'General case' 0 N--CA 1.476 0.86 0 CA-C-O 122.29 1.043 . . . . 0.0 109.731 179.641 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -39.31 90.01 0.0 OUTLIER 'General case' 0 N--CA 1.457 -0.088 0 CA-C-N 113.986 -1.461 . . . . 0.0 112.711 -178.157 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 38.6 tt0 -64.84 159.64 22.11 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 115.183 -0.917 . . . . 0.0 110.593 179.343 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 9.6 m-20 -136.28 125.77 25.15 Favored 'General case' 0 N--CA 1.48 1.048 0 C-N-CA 123.315 0.646 . . . . 0.0 109.798 -179.838 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' C' C ' 24' ' ' VAL . . . . . 0.845 HG12 ' H ' ' C' ' 25' ' ' GLY . 57.1 t -76.66 -170.4 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.578 0 N-CA-C 108.609 -0.885 . . . . 0.0 108.609 179.708 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' C' C ' 25' ' ' GLY . . . . . 0.845 ' H ' HG12 ' C' ' 24' ' ' VAL . . . -68.8 48.56 0.47 Allowed Glycine 0 CA--C 1.533 1.18 0 CA-C-N 118.409 0.549 . . . . 0.0 112.249 -178.066 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 13.3 p -69.73 137.47 52.04 Favored 'General case' 0 C--O 1.22 -0.459 0 N-CA-C 109.646 -0.501 . . . . 0.0 109.646 178.716 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' C' C ' 27' ' ' ASN . . . . . 0.506 HD21 ' CG ' ' A' ' 11' ' ' GLU . 34.8 t30 -68.7 95.04 0.63 Allowed 'General case' 0 N--CA 1.469 0.485 0 N-CA-C 108.179 -1.045 . . . . 0.0 108.179 177.851 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 68.6 mttm -92.36 117.66 30.14 Favored 'General case' 0 N--CA 1.48 1.053 0 N-CA-C 109.988 -0.375 . . . . 0.0 109.988 -179.233 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.32 -134.2 0.01 OUTLIER Glycine 0 CA--C 1.533 1.16 0 N-CA-C 110.784 -0.926 . . . . 0.0 110.784 179.02 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -115.7 127.12 54.91 Favored 'General case' 0 N--CA 1.48 1.067 0 N-CA-C 109.314 -0.625 . . . . 0.0 109.314 179.203 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 66.2 mt -90.57 134.9 28.0 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.574 0 N-CA-C 107.666 -1.235 . . . . 0.0 107.666 178.845 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 30.4 mt -136.51 138.37 46.7 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.77 0 CA-C-N 115.937 -0.574 . . . . 0.0 109.545 -179.099 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.72 57.55 15.76 Favored Glycine 0 CA--C 1.528 0.887 0 CA-C-N 115.866 -0.606 . . . . 0.0 112.791 178.663 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 25.6 tp -106.13 132.75 51.83 Favored 'General case' 0 N--CA 1.486 1.353 0 N-CA-C 107.471 -1.307 . . . . 0.0 107.471 177.832 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 25.1 ttt -138.09 147.96 44.54 Favored 'General case' 0 N--CA 1.47 0.568 0 N-CA-C 107.591 -1.262 . . . . 0.0 107.591 179.315 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' C' C ' 36' ' ' VAL . . . . . 0.401 HG12 ' N ' ' C' ' 37' ' ' GLY . 60.6 t -156.81 160.05 2.4 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.546 0 N-CA-C 106.076 -1.824 . . . . 0.0 106.076 -178.959 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' C' C ' 37' ' ' GLY . . . . . 0.46 ' O ' ' NE2' ' F' ' 15' ' ' GLN . . . 54.1 74.12 0.34 Allowed Glycine 0 C--N 1.309 -0.925 0 C-N-CA 121.116 -0.564 . . . . 0.0 111.788 177.848 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' C' C ' 38' ' ' GLY . . . . . 0.739 ' H ' HE22 ' C' ' 15' ' ' GLN . . . 164.9 -168.36 39.07 Favored Glycine 0 N--CA 1.466 0.65 0 N-CA-C 111.104 -0.799 . . . . 0.0 111.104 179.349 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 24.2 m -126.71 148.88 31.43 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.858 0 C-N-CA 122.934 0.494 . . . . 0.0 109.935 179.716 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 9.8 t . . . . . 0 CA--C 1.534 0.364 0 CA-C-O 118.187 -0.911 . . . . 0.0 110.7 178.884 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 28.7 m-85 . . . . . 0 N--CA 1.475 0.789 0 N-CA-C 107.949 -1.13 . . . . 0.0 107.949 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' D' D ' 5' ' ' ARG . . . . . 0.772 HH12 HG13 ' C' ' 24' ' ' VAL 0.273 47.8 mtp180 -77.55 143.45 38.37 Favored 'General case' 0 C--O 1.207 -1.15 0 C-N-CA 123.595 0.758 . . . . 0.0 109.044 -169.708 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 40.5 m80 -107.79 124.44 50.05 Favored 'General case' 0 C--N 1.366 1.301 0 N-CA-C 106.87 -1.53 . . . . 0.0 106.87 -176.282 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' D' D ' 7' ' ' ASP . . . . . 0.468 ' OD2' HG11 ' I' ' 24' ' ' VAL . 7.9 m-20 -64.28 131.92 48.73 Favored 'General case' 0 CA--C 1.512 -0.485 0 CA-C-N 113.897 -1.501 . . . . 0.0 114.077 179.004 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' D' D ' 8' ' ' SER . . . . . . . . . . . . . 40.9 t -152.62 -167.8 2.86 Favored 'General case' 0 N--CA 1.482 1.152 0 C-N-CA 120.908 -0.317 . . . . 0.0 110.17 177.028 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 120.71 30.23 1.41 Allowed Glycine 0 N--CA 1.486 1.967 0 N-CA-C 111.35 -0.7 . . . . 0.0 111.35 177.862 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 44.9 p90 -54.46 131.13 41.87 Favored 'General case' 0 CA--C 1.545 0.785 0 CA-C-N 117.085 0.442 . . . . 0.0 111.591 -179.557 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' D' D ' 11' ' ' GLU . . . . . 0.435 ' CG ' HD21 ' F' ' 27' ' ' ASN . 60.3 mt-10 -89.7 151.2 21.98 Favored 'General case' 0 N--CA 1.475 0.808 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 177.324 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -149.66 129.07 3.53 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.529 0 N-CA-C 107.339 -1.356 . . . . 0.0 107.339 172.59 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 36.0 m-70 -130.29 162.59 28.67 Favored 'General case' 0 N--CA 1.48 1.054 0 C-N-CA 123.678 0.791 . . . . 0.0 112.902 178.205 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 41.5 t60 -153.96 104.31 2.65 Favored 'General case' 0 N--CA 1.486 1.35 0 N-CA-C 108.418 -0.956 . . . . 0.0 108.418 171.54 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' D' D ' 15' ' ' GLN . . . . . 0.655 HE22 ' H ' ' D' ' 38' ' ' GLY . 28.1 mt-30 -93.84 116.03 28.46 Favored 'General case' 0 CA--C 1.505 -0.762 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.325 -179.625 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -108.37 111.82 23.93 Favored 'General case' 0 C--N 1.359 0.99 0 N-CA-C 106.059 -1.83 . . . . 0.0 106.059 174.383 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 52.7 tp -134.32 150.73 50.98 Favored 'General case' 0 N--CA 1.484 1.238 0 N-CA-C 108.973 -0.751 . . . . 0.0 108.973 176.074 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 71.0 t -142.39 126.05 15.1 Favored 'Isoleucine or valine' 0 C--O 1.242 0.674 0 N-CA-C 109.141 -0.689 . . . . 0.0 109.141 173.863 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 26.8 m-85 -62.12 151.54 35.42 Favored 'General case' 0 N--CA 1.473 0.699 0 C-N-CA 124.284 1.034 . . . . 0.0 110.325 169.712 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 14.0 t80 -170.13 -66.86 0.02 OUTLIER 'General case' 0 C--N 1.318 -0.766 0 N-CA-C 107.765 -1.198 . . . . 0.0 107.765 -179.703 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -38.17 95.54 0.01 OUTLIER 'General case' 0 N--CA 1.449 -0.502 0 CA-C-N 114.207 -1.361 . . . . 0.0 111.798 -175.017 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 39.2 tt0 -67.51 161.12 26.19 Favored 'General case' 0 N--CA 1.468 0.458 0 CA-C-N 113.628 -1.624 . . . . 0.0 110.139 178.805 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 9.9 m-20 -137.22 126.52 24.79 Favored 'General case' 0 N--CA 1.479 1.019 0 C-N-CA 123.472 0.709 . . . . 0.0 109.942 -179.068 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' D' D ' 24' ' ' VAL . . . . . 0.943 HG12 ' H ' ' D' ' 25' ' ' GLY . 92.3 t -81.13 -165.64 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.482 1.169 0 N-CA-C 107.566 -1.272 . . . . 0.0 107.566 -178.098 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' D' D ' 25' ' ' GLY . . . . . 0.943 ' H ' HG12 ' D' ' 24' ' ' VAL . . . -79.27 56.62 4.4 Favored Glycine 0 C--N 1.362 1.997 0 C-N-CA 117.855 -2.117 . . . . 0.0 110.628 -174.263 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 21.8 p -61.34 132.83 54.82 Favored 'General case' 0 C--N 1.346 0.426 0 CA-C-N 113.545 -1.328 . . . . 0.0 111.965 170.648 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' D' D ' 27' ' ' ASN . . . . . 0.447 HD21 ' CG ' ' E' ' 11' ' ' GLU . 40.6 t30 -65.53 95.06 0.2 Allowed 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 119.908 1.231 . . . . 0.0 108.751 172.971 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 68.3 mttm -93.89 120.97 34.87 Favored 'General case' 0 N--CA 1.484 1.26 0 C-N-CA 119.521 -0.871 . . . . 0.0 108.908 179.756 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -57.45 -135.01 0.01 OUTLIER Glycine 0 C--N 1.341 0.806 0 CA-C-N 115.858 -0.61 . . . . 0.0 113.067 175.974 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -114.22 131.76 56.36 Favored 'General case' 0 C--N 1.367 1.357 0 N-CA-C 109.101 -0.703 . . . . 0.0 109.101 174.572 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 68.6 mt -91.79 138.43 19.82 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.298 0 N-CA-C 107.182 -1.414 . . . . 0.0 107.182 176.845 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 35.2 mt -138.7 140.85 38.4 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.879 0 N-CA-C 108.639 -0.875 . . . . 0.0 108.639 178.518 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.54 55.04 27.62 Favored Glycine 0 CA--C 1.529 0.911 0 CA-C-O 119.381 -0.677 . . . . 0.0 112.588 178.313 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 19.2 tp -102.84 141.59 35.39 Favored 'General case' 0 C--N 1.364 1.207 0 N-CA-C 106.333 -1.728 . . . . 0.0 106.333 176.536 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 23.9 ttt -142.07 156.95 45.42 Favored 'General case' 0 N--CA 1.472 0.664 0 N-CA-C 105.952 -1.87 . . . . 0.0 105.952 175.085 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 73.7 t -164.34 161.89 0.93 Allowed 'Isoleucine or valine' 0 CA--C 1.503 -0.835 0 N-CA-C 105.349 -2.093 . . . . 0.0 105.349 179.19 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' D' D ' 37' ' ' GLY . . . . . 0.457 ' O ' ' NE2' ' G' ' 15' ' ' GLN . . . 60.21 64.44 4.15 Favored Glycine 0 N--CA 1.441 -1.004 0 C-N-CA 118.38 -1.867 . . . . 0.0 112.453 176.301 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' D' D ' 38' ' ' GLY . . . . . 0.655 ' H ' HE22 ' D' ' 15' ' ' GLN . . . 166.46 -163.86 37.23 Favored Glycine 0 C--O 1.215 -1.051 0 CA-C-N 119.308 1.554 . . . . 0.0 112.264 176.493 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 29.4 m -121.64 147.45 25.61 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.067 0 CA-C-O 118.041 -0.981 . . . . 0.0 112.259 179.35 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 7.5 t . . . . . 0 C--O 1.213 -0.864 0 N-CA-C 108.798 -0.815 . . . . 0.0 108.798 171.652 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 24.8 m-85 . . . . . 0 N--CA 1.471 0.579 0 N-CA-C 109.445 -0.576 . . . . 0.0 109.445 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' E' E ' 5' ' ' ARG . . . . . 0.756 HH12 HG13 ' A' ' 24' ' ' VAL . 34.9 mtp180 -68.13 148.15 51.31 Favored 'General case' 0 C--O 1.202 -1.419 0 CA-C-N 115.567 -0.742 . . . . 0.0 111.313 -178.012 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 39.2 m80 -109.9 118.97 37.89 Favored 'General case' 0 N--CA 1.483 1.181 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 177.889 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' E' E ' 7' ' ' ASP . . . . . 0.442 ' OD1' HG11 ' G' ' 24' ' ' VAL . 13.0 m-20 -66.31 140.28 58.1 Favored 'General case' 0 N--CA 1.466 0.37 0 CA-C-O 120.91 0.386 . . . . 0.0 112.02 -178.442 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' E' E ' 8' ' ' SER . . . . . . . . . . . . . 38.2 t -158.7 -169.87 2.86 Favored 'General case' 0 N--CA 1.487 1.378 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.194 178.924 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 120.33 32.84 1.09 Allowed Glycine 0 N--CA 1.484 1.867 0 N-CA-C 111.717 -0.553 . . . . 0.0 111.717 179.538 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 43.3 p90 -56.84 130.54 46.19 Favored 'General case' 0 CA--C 1.546 0.796 0 CA-C-N 116.948 0.374 . . . . 0.0 111.64 -179.963 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' E' E ' 11' ' ' GLU . . . . . 0.447 ' CG ' HD21 ' D' ' 27' ' ' ASN . 60.2 mt-10 -89.98 153.49 20.55 Favored 'General case' 0 N--CA 1.478 0.945 0 N-CA-C 109.404 -0.591 . . . . 0.0 109.404 178.606 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.8 p -155.15 124.78 0.74 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.575 0 N-CA-C 108.183 -1.043 . . . . 0.0 108.183 177.872 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 43.9 m-70 -136.04 160.95 37.07 Favored 'General case' 0 N--CA 1.481 1.113 0 CA-C-O 120.746 0.308 . . . . 0.0 111.115 -177.515 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 38.8 t60 -152.96 96.75 2.13 Favored 'General case' 0 N--CA 1.488 1.475 0 C-N-CA 122.687 0.395 . . . . 0.0 109.951 179.241 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' E' E ' 15' ' ' GLN . . . . . 0.648 HE22 ' H ' ' E' ' 38' ' ' GLY . 28.2 mt-30 -90.75 122.25 33.33 Favored 'General case' 0 C--N 1.329 -0.297 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 -179.064 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -113.78 103.5 11.27 Favored 'General case' 0 N--CA 1.474 0.726 0 N-CA-C 107.69 -1.226 . . . . 0.0 107.69 176.638 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 53.9 tp -132.19 149.1 52.47 Favored 'General case' 0 N--CA 1.486 1.343 0 C-N-CA 123.368 0.667 . . . . 0.0 109.269 -178.844 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 57.7 t -145.25 123.59 5.23 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.837 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 179.154 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 11.2 m-85 -71.4 156.35 39.58 Favored 'General case' 0 C--N 1.363 1.155 0 N-CA-C 106.911 -1.515 . . . . 0.0 106.911 176.937 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 17.8 t80 -172.13 -55.94 0.02 OUTLIER 'General case' 0 N--CA 1.481 1.084 0 CA-C-O 121.83 0.824 . . . . 0.0 110.238 179.733 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.99 88.26 0.0 OUTLIER 'General case' 0 C--N 1.319 -0.759 0 CA-C-N 114.107 -1.406 . . . . 0.0 112.87 -178.986 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 39.0 tt0 -63.26 159.72 17.24 Favored 'General case' 0 N--CA 1.471 0.625 0 CA-C-N 114.855 -1.066 . . . . 0.0 110.842 179.831 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 9.6 m-20 -136.56 125.52 24.29 Favored 'General case' 0 N--CA 1.482 1.162 0 C-N-CA 123.3 0.64 . . . . 0.0 110.23 -179.67 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' E' E ' 24' ' ' VAL . . . . . 0.873 HG12 ' H ' ' E' ' 25' ' ' GLY . 58.5 t -76.08 -170.35 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.484 1.252 0 N-CA-C 108.029 -1.1 . . . . 0.0 108.029 179.436 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' E' E ' 25' ' ' GLY . . . . . 0.873 ' H ' HG12 ' E' ' 24' ' ' VAL . . . -68.89 49.65 0.5 Allowed Glycine 0 CA--C 1.531 1.031 0 CA-C-N 118.079 0.4 . . . . 0.0 112.626 -178.132 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 8.1 p -69.16 136.79 52.65 Favored 'General case' 0 C--O 1.219 -0.514 0 N-CA-C 109.705 -0.48 . . . . 0.0 109.705 178.494 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' E' E ' 27' ' ' ASN . . . . . 0.445 HD21 ' CG ' ' F' ' 11' ' ' GLU . 36.2 t30 -68.3 95.5 0.6 Allowed 'General case' 0 N--CA 1.466 0.328 0 N-CA-C 107.481 -1.303 . . . . 0.0 107.481 177.388 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 68.1 mttm -93.33 117.09 29.66 Favored 'General case' 0 N--CA 1.482 1.136 0 N-CA-C 109.612 -0.514 . . . . 0.0 109.612 -178.858 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.16 -133.98 0.01 OUTLIER Glycine 0 CA--C 1.536 1.392 0 N-CA-C 111.308 -0.717 . . . . 0.0 111.308 178.877 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -115.66 126.42 54.13 Favored 'General case' 0 N--CA 1.481 1.081 0 N-CA-C 109.637 -0.505 . . . . 0.0 109.637 179.225 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 66.8 mt -89.35 135.02 27.02 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.213 0 N-CA-C 107.571 -1.27 . . . . 0.0 107.571 178.914 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 33.1 mt -136.21 137.83 47.85 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.867 0 N-CA-C 108.991 -0.744 . . . . 0.0 108.991 -179.768 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.37 59.68 8.54 Favored Glycine 0 CA--C 1.527 0.82 0 CA-C-N 116.047 -0.524 . . . . 0.0 112.947 178.835 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 22.0 tp -107.49 131.81 53.91 Favored 'General case' 0 N--CA 1.487 1.41 0 N-CA-C 107.454 -1.313 . . . . 0.0 107.454 177.741 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 23.6 ttt -137.26 147.82 45.99 Favored 'General case' 0 N--CA 1.472 0.66 0 N-CA-C 107.815 -1.18 . . . . 0.0 107.815 178.709 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' E' E ' 36' ' ' VAL . . . . . 0.407 HG12 ' N ' ' E' ' 37' ' ' GLY . 59.8 t -156.7 159.94 2.47 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.693 0 N-CA-C 106.457 -1.683 . . . . 0.0 106.457 -178.899 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' E' E ' 37' ' ' GLY . . . . . 0.425 ' O ' ' NE2' ' H' ' 15' ' ' GLN . . . 54.12 73.4 0.41 Allowed Glycine 0 C--N 1.31 -0.904 0 N-CA-C 111.801 -0.52 . . . . 0.0 111.801 177.787 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' E' E ' 38' ' ' GLY . . . . . 0.648 ' H ' HE22 ' E' ' 15' ' ' GLN . . . 165.83 -166.63 38.71 Favored Glycine 0 C--O 1.21 -1.395 0 N-CA-C 111.278 -0.729 . . . . 0.0 111.278 179.256 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 21.6 m -128.34 148.88 32.8 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.827 0 C-N-CA 122.833 0.453 . . . . 0.0 109.91 179.913 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 7.5 t . . . . . 0 CA--C 1.541 0.598 0 CA-C-O 118.202 -0.904 . . . . 0.0 110.473 178.85 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 25.7 m-85 . . . . . 0 N--CA 1.472 0.645 0 N-CA-C 109.572 -0.529 . . . . 0.0 109.572 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' F' F ' 5' ' ' ARG . . . . . 0.756 HH12 HG13 ' B' ' 24' ' ' VAL . 35.5 mtp180 -68.08 147.4 52.4 Favored 'General case' 0 C--O 1.201 -1.476 0 CA-C-N 115.499 -0.773 . . . . 0.0 111.468 -178.017 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 39.2 m80 -109.47 118.89 37.82 Favored 'General case' 0 N--CA 1.484 1.266 0 N-CA-C 109.094 -0.706 . . . . 0.0 109.094 177.815 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' F' F ' 7' ' ' ASP . . . . . 0.474 ' OD1' HG11 ' H' ' 24' ' ' VAL . 13.0 m-20 -66.32 140.27 58.09 Favored 'General case' 0 N--CA 1.466 0.341 0 N-CA-C 112.159 0.429 . . . . 0.0 112.159 -178.453 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' F' F ' 8' ' ' SER . . . . . . . . . . . . . 38.3 t -158.73 -169.81 2.84 Favored 'General case' 0 N--CA 1.486 1.365 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.18 178.9 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 120.33 32.84 1.09 Allowed Glycine 0 N--CA 1.483 1.808 0 N-CA-C 111.679 -0.568 . . . . 0.0 111.679 179.559 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 43.3 p90 -57.02 130.73 47.35 Favored 'General case' 0 CA--C 1.545 0.763 0 CA-C-N 116.945 0.372 . . . . 0.0 111.614 -179.952 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' F' F ' 11' ' ' GLU . . . . . 0.445 ' CG ' HD21 ' E' ' 27' ' ' ASN . 60.3 mt-10 -90.04 153.53 20.5 Favored 'General case' 0 N--CA 1.478 0.959 0 CA-C-O 121.306 0.574 . . . . 0.0 109.457 178.513 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.8 p -155.22 124.78 0.74 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.532 0 N-CA-C 108.071 -1.085 . . . . 0.0 108.071 177.942 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 44.4 m-70 -136.03 160.83 37.42 Favored 'General case' 0 N--CA 1.48 1.062 0 CA-C-O 120.668 0.271 . . . . 0.0 111.142 -177.645 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 39.0 t60 -152.93 97.13 2.17 Favored 'General case' 0 N--CA 1.487 1.406 0 C-N-CA 122.75 0.42 . . . . 0.0 110.06 179.278 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' F' F ' 15' ' ' GLN . . . . . 0.621 HE22 ' H ' ' F' ' 38' ' ' GLY . 28.2 mt-30 -91.21 122.87 34.21 Favored 'General case' 0 CA--C 1.513 -0.474 0 N-CA-C 110.174 -0.306 . . . . 0.0 110.174 -179.141 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -114.23 103.48 11.14 Favored 'General case' 0 N--CA 1.471 0.608 0 N-CA-C 107.808 -1.182 . . . . 0.0 107.808 176.694 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 54.2 tp -132.17 149.13 52.46 Favored 'General case' 0 N--CA 1.486 1.355 0 C-N-CA 123.388 0.675 . . . . 0.0 109.307 -179.041 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 58.7 t -145.24 123.69 5.32 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.805 0 N-CA-C 109.37 -0.604 . . . . 0.0 109.37 179.205 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 11.2 m-85 -71.5 156.14 39.77 Favored 'General case' 0 C--N 1.363 1.195 0 N-CA-C 106.795 -1.557 . . . . 0.0 106.795 176.92 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 18.5 t80 -171.87 -55.96 0.02 OUTLIER 'General case' 0 N--CA 1.481 1.105 0 CA-C-O 121.784 0.802 . . . . 0.0 109.873 179.799 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.02 88.24 0.0 OUTLIER 'General case' 0 C--N 1.319 -0.725 0 CA-C-N 114.235 -1.348 . . . . 0.0 112.968 -178.968 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 38.9 tt0 -63.22 159.91 16.74 Favored 'General case' 0 N--CA 1.472 0.638 0 CA-C-N 114.857 -1.065 . . . . 0.0 110.856 179.756 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 9.7 m-20 -136.82 125.77 24.27 Favored 'General case' 0 N--CA 1.481 1.122 0 C-N-CA 123.271 0.628 . . . . 0.0 110.252 -179.735 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' F' F ' 24' ' ' VAL . . . . . 0.848 HG12 ' H ' ' F' ' 25' ' ' GLY . 59.1 t -76.28 -170.1 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.484 1.267 0 N-CA-C 108.168 -1.049 . . . . 0.0 108.168 179.485 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' F' F ' 25' ' ' GLY . . . . . 0.848 ' H ' HG12 ' F' ' 24' ' ' VAL . . . -68.85 49.4 0.49 Allowed Glycine 0 CA--C 1.528 0.847 0 CA-C-N 118.264 0.484 . . . . 0.0 112.491 -178.305 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 8.1 p -68.96 136.66 52.85 Favored 'General case' 0 C--O 1.219 -0.535 0 N-CA-C 109.536 -0.542 . . . . 0.0 109.536 178.378 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' F' F ' 27' ' ' ASN . . . . . 0.435 HD21 ' CG ' ' D' ' 11' ' ' GLU . 35.4 t30 -68.38 95.73 0.63 Allowed 'General case' 0 CA--C 1.535 0.371 0 N-CA-C 107.35 -1.352 . . . . 0.0 107.35 177.464 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 68.1 mttm -93.41 116.96 29.5 Favored 'General case' 0 N--CA 1.48 1.073 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -178.931 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.13 -134.15 0.01 OUTLIER Glycine 0 CA--C 1.537 1.444 0 N-CA-C 111.383 -0.687 . . . . 0.0 111.383 178.997 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -115.19 125.99 54.05 Favored 'General case' 0 N--CA 1.485 1.277 0 C-N-CA 123.064 0.546 . . . . 0.0 109.615 179.212 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 66.9 mt -89.3 134.88 27.37 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.236 0 N-CA-C 107.457 -1.312 . . . . 0.0 107.457 178.816 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 32.9 mt -136.25 137.87 47.73 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.805 0 N-CA-C 108.984 -0.747 . . . . 0.0 108.984 -179.723 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.24 59.81 8.44 Favored Glycine 0 CA--C 1.525 0.663 0 CA-C-N 116.01 -0.541 . . . . 0.0 112.884 178.878 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 21.8 tp -107.78 132.04 53.81 Favored 'General case' 0 N--CA 1.487 1.376 0 N-CA-C 107.585 -1.265 . . . . 0.0 107.585 177.668 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 23.4 ttt -137.53 147.99 45.61 Favored 'General case' 0 N--CA 1.468 0.434 0 N-CA-C 108.324 -0.991 . . . . 0.0 108.324 178.733 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' F' F ' 36' ' ' VAL . . . . . 0.401 HG12 ' N ' ' F' ' 37' ' ' GLY . 60.8 t -156.63 160.03 2.44 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.772 0 N-CA-C 106.579 -1.637 . . . . 0.0 106.579 -178.741 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' F' F ' 37' ' ' GLY . . . . . 0.42 ' O ' ' NE2' ' I' ' 15' ' ' GLN . . . 54.05 73.37 0.42 Allowed Glycine 0 C--N 1.309 -0.964 0 CA-C-N 116.075 -0.512 . . . . 0.0 111.937 177.709 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' F' F ' 38' ' ' GLY . . . . . 0.621 ' H ' HE22 ' F' ' 15' ' ' GLN . . . 165.83 -166.58 38.68 Favored Glycine 0 C--O 1.209 -1.459 0 N-CA-C 111.264 -0.735 . . . . 0.0 111.264 179.315 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 21.1 m -128.46 148.76 32.9 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.811 0 C-N-CA 122.729 0.412 . . . . 0.0 109.906 179.935 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 6.8 t . . . . . 0 CA--C 1.54 0.565 0 CA-C-O 118.207 -0.901 . . . . 0.0 110.423 178.911 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 35.4 m-85 . . . . . 0 N--CA 1.469 0.499 0 CA-C-O 121.173 0.511 . . . . 0.0 109.833 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' G' G ' 5' ' ' ARG . . . . . 0.736 HH12 HG13 ' F' ' 24' ' ' VAL . 33.8 mtp180 -68.69 144.92 54.28 Favored 'General case' 0 N--CA 1.469 0.524 0 CA-C-N 115.415 -0.811 . . . . 0.0 111.146 -178.325 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 38.6 m80 -107.98 118.78 37.64 Favored 'General case' 0 N--CA 1.478 0.961 0 N-CA-C 109.226 -0.657 . . . . 0.0 109.226 178.095 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 10.5 m-20 -66.84 139.47 57.77 Favored 'General case' 0 N--CA 1.469 0.49 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.948 -179.061 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' G' G ' 8' ' ' SER . . . . . . . . . . . . . 37.8 t -158.09 -170.23 3.07 Favored 'General case' 0 N--CA 1.471 0.603 0 N-CA-C 109.666 -0.494 . . . . 0.0 109.666 179.024 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 120.37 31.97 1.2 Allowed Glycine 0 N--CA 1.484 1.869 0 N-CA-C 111.539 -0.624 . . . . 0.0 111.539 179.497 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 47.1 p90 -57.11 130.71 47.32 Favored 'General case' 0 N--CA 1.472 0.629 0 CA-C-N 116.825 0.313 . . . . 0.0 111.716 -179.822 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 60.4 mt-10 -90.34 152.58 20.96 Favored 'General case' 0 N--CA 1.474 0.758 0 CA-C-O 121.138 0.494 . . . . 0.0 109.807 179.082 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 3.5 p -155.47 124.83 0.72 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.058 0 N-CA-C 108.175 -1.046 . . . . 0.0 108.175 178.19 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 43.6 m-70 -135.86 160.73 37.68 Favored 'General case' 0 N--CA 1.475 0.781 0 CA-C-N 114.722 -1.126 . . . . 0.0 110.973 -177.619 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 39.6 t60 -153.39 96.93 2.09 Favored 'General case' 0 N--CA 1.484 1.231 0 CA-C-N 115.858 -0.61 . . . . 0.0 109.659 178.855 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' G' G ' 15' ' ' GLN . . . . . 0.681 HE22 ' H ' ' G' ' 38' ' ' GLY . 28.5 mt-30 -90.75 121.52 32.71 Favored 'General case' 0 N--CA 1.451 -0.406 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 -178.896 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -113.03 103.77 11.71 Favored 'General case' 0 N--CA 1.476 0.831 0 N-CA-C 107.694 -1.224 . . . . 0.0 107.694 176.65 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 56.6 tp -132.17 147.33 52.42 Favored 'General case' 0 N--CA 1.486 1.343 0 C-N-CA 123.336 0.654 . . . . 0.0 109.56 -179.288 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 61.3 t -144.99 123.3 5.31 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.861 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 178.664 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 9.6 m-85 -70.39 150.37 46.33 Favored 'General case' 0 C--N 1.376 1.728 0 N-CA-C 106.91 -1.515 . . . . 0.0 106.91 176.699 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 15.6 t80 -169.94 -55.4 0.02 OUTLIER 'General case' 0 N--CA 1.483 1.22 0 N-CA-C 110.248 -0.278 . . . . 0.0 110.248 -179.729 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.0 90.02 0.0 OUTLIER 'General case' 0 C--N 1.323 -0.545 0 C-N-CA 123.72 0.808 . . . . 0.0 112.471 -179.964 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 39.3 tt0 -64.4 160.76 18.36 Favored 'General case' 0 N--CA 1.468 0.467 0 CA-C-N 114.834 -1.076 . . . . 0.0 110.023 179.273 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 9.6 m-20 -137.26 125.38 22.99 Favored 'General case' 0 N--CA 1.48 1.072 0 C-N-CA 123.154 0.582 . . . . 0.0 109.721 -179.701 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' G' G ' 24' ' ' VAL . . . . . 0.857 HG12 ' H ' ' G' ' 25' ' ' GLY . 61.9 t -76.75 -169.97 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.827 0 N-CA-C 108.156 -1.053 . . . . 0.0 108.156 179.608 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' G' G ' 25' ' ' GLY . . . . . 0.857 ' H ' HG12 ' G' ' 24' ' ' VAL . . . -68.89 49.98 0.5 Allowed Glycine 0 CA--C 1.53 0.973 0 CA-C-N 118.48 0.582 . . . . 0.0 112.726 -178.467 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 8.4 p -69.51 137.63 52.67 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 109.157 -0.682 . . . . 0.0 109.157 177.748 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 34.2 t30 -69.49 94.72 0.77 Allowed 'General case' 0 CA--C 1.532 0.265 0 N-CA-C 107.618 -1.253 . . . . 0.0 107.618 177.562 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -91.63 117.81 30.07 Favored 'General case' 0 N--CA 1.478 0.953 0 N-CA-C 109.713 -0.477 . . . . 0.0 109.713 -179.396 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -62.37 -133.3 0.01 OUTLIER Glycine 0 CA--C 1.532 1.099 0 N-CA-C 110.547 -1.021 . . . . 0.0 110.547 178.927 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -115.19 126.83 55.05 Favored 'General case' 0 N--CA 1.475 0.808 0 N-CA-C 109.615 -0.513 . . . . 0.0 109.615 179.186 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 69.6 mt -89.64 136.14 24.41 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.671 0 N-CA-C 107.598 -1.26 . . . . 0.0 107.598 178.743 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 38.2 mt -137.46 139.18 43.98 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.249 0 CA-C-N 118.782 0.719 . . . . 0.0 109.158 179.721 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.1 57.98 13.56 Favored Glycine 0 CA--C 1.53 0.977 0 CA-C-N 116.11 -0.496 . . . . 0.0 112.624 178.99 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 23.1 tp -105.81 132.23 52.18 Favored 'General case' 0 N--CA 1.484 1.256 0 N-CA-C 107.6 -1.259 . . . . 0.0 107.6 177.775 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 22.1 ttt -137.63 147.97 45.4 Favored 'General case' 0 N--CA 1.474 0.727 0 N-CA-C 108.211 -1.033 . . . . 0.0 108.211 178.788 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 61.2 t -156.77 158.4 3.24 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 106.613 -1.625 . . . . 0.0 106.613 -179.095 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.57 71.74 0.68 Allowed Glycine 0 C--N 1.308 -0.973 0 CA-C-N 115.951 -0.568 . . . . 0.0 112.384 177.549 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' G' G ' 38' ' ' GLY . . . . . 0.681 ' H ' HE22 ' G' ' 15' ' ' GLN . . . 167.75 -165.22 38.55 Favored Glycine 0 C--O 1.212 -1.268 0 N-CA-C 110.747 -0.941 . . . . 0.0 110.747 178.631 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 18.7 m -128.64 148.14 33.07 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.93 0 C-N-CA 122.789 0.435 . . . . 0.0 109.93 179.911 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 8.6 t . . . . . 0 CA--C 1.534 0.337 0 CA-C-O 118.156 -0.926 . . . . 0.0 110.888 178.815 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 35.0 m-85 . . . . . 0 N--CA 1.47 0.557 0 CA-C-O 121.234 0.54 . . . . 0.0 109.756 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' H' H ' 5' ' ' ARG . . . . . 0.757 HH12 HG13 ' D' ' 24' ' ' VAL . 33.8 mtp180 -69.04 145.12 53.78 Favored 'General case' 0 N--CA 1.466 0.373 0 CA-C-N 115.387 -0.824 . . . . 0.0 111.229 -178.312 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 38.5 m80 -108.05 118.77 37.63 Favored 'General case' 0 N--CA 1.478 0.958 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 178.265 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 10.5 m-20 -66.91 139.58 57.73 Favored 'General case' 0 N--CA 1.468 0.441 0 CA-C-N 116.275 -0.421 . . . . 0.0 111.889 -179.066 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' H' H ' 8' ' ' SER . . . . . . . . . . . . . 37.9 t -158.12 -170.08 3.01 Favored 'General case' 0 N--CA 1.471 0.595 0 N-CA-C 109.73 -0.47 . . . . 0.0 109.73 178.985 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 120.11 32.09 1.21 Allowed Glycine 0 N--CA 1.483 1.829 0 N-CA-C 111.641 -0.583 . . . . 0.0 111.641 179.549 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 46.9 p90 -57.17 130.79 47.72 Favored 'General case' 0 CA--C 1.542 0.64 0 CA-C-N 116.715 0.258 . . . . 0.0 111.607 -179.777 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 60.5 mt-10 -90.3 152.54 20.99 Favored 'General case' 0 N--CA 1.474 0.771 0 CA-C-O 121.116 0.484 . . . . 0.0 109.859 179.023 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 3.4 p -155.53 124.95 0.72 Allowed 'Isoleucine or valine' 0 CA--C 1.553 1.089 0 N-CA-C 108.161 -1.051 . . . . 0.0 108.161 178.074 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 43.6 m-70 -135.93 160.78 37.55 Favored 'General case' 0 C--N 1.353 0.751 0 CA-C-N 114.627 -1.169 . . . . 0.0 111.072 -177.527 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 39.3 t60 -153.51 96.86 2.07 Favored 'General case' 0 N--CA 1.484 1.268 0 CA-C-N 115.868 -0.606 . . . . 0.0 109.773 178.911 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' H' H ' 15' ' ' GLN . . . . . 0.676 HE22 ' H ' ' H' ' 38' ' ' GLY . 28.3 mt-30 -90.71 121.37 32.55 Favored 'General case' 0 CA--C 1.514 -0.406 0 N-CA-C 109.711 -0.477 . . . . 0.0 109.711 -178.946 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -112.84 103.66 11.65 Favored 'General case' 0 N--CA 1.474 0.726 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 176.672 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 56.3 tp -132.14 147.37 52.42 Favored 'General case' 0 N--CA 1.486 1.374 0 C-N-CA 123.273 0.629 . . . . 0.0 109.488 -179.196 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 61.4 t -144.93 123.21 5.36 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.89 0 N-CA-C 109.368 -0.604 . . . . 0.0 109.368 178.667 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 9.5 m-85 -70.67 150.96 45.45 Favored 'General case' 0 C--N 1.376 1.741 0 N-CA-C 106.951 -1.5 . . . . 0.0 106.951 176.658 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 16.6 t80 -171.19 -55.13 0.02 OUTLIER 'General case' 0 N--CA 1.48 1.061 0 N-CA-C 110.216 -0.291 . . . . 0.0 110.216 -179.696 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.05 89.92 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.472 0 O-C-N 123.971 0.795 . . . . 0.0 112.269 -179.96 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 39.4 tt0 -64.12 160.76 17.56 Favored 'General case' 0 N--CA 1.469 0.487 0 CA-C-N 114.777 -1.102 . . . . 0.0 110.063 179.482 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 9.7 m-20 -137.11 125.43 23.27 Favored 'General case' 0 N--CA 1.481 1.077 0 C-N-CA 123.098 0.559 . . . . 0.0 109.869 -179.791 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' H' H ' 24' ' ' VAL . . . . . 0.836 HG12 ' H ' ' H' ' 25' ' ' GLY . 57.4 t -76.69 -170.0 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.475 0.806 0 N-CA-C 108.408 -0.96 . . . . 0.0 108.408 179.612 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' H' H ' 25' ' ' GLY . . . . . 0.836 ' H ' HG12 ' H' ' 24' ' ' VAL . . . -68.64 49.56 0.46 Allowed Glycine 0 CA--C 1.53 1.009 0 CA-C-N 118.627 0.649 . . . . 0.0 112.43 -178.468 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 8.5 p -69.56 137.47 52.44 Favored 'General case' 0 C--N 1.33 -0.266 0 N-CA-C 109.152 -0.684 . . . . 0.0 109.152 177.823 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 34.7 t30 -69.57 94.82 0.8 Allowed 'General case' 0 N--CA 1.464 0.258 0 N-CA-C 107.638 -1.245 . . . . 0.0 107.638 177.635 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -91.76 117.88 30.17 Favored 'General case' 0 N--CA 1.477 0.91 0 N-CA-C 109.708 -0.479 . . . . 0.0 109.708 -179.408 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -62.48 -133.15 0.01 OUTLIER Glycine 0 CA--C 1.532 1.107 0 N-CA-C 110.582 -1.007 . . . . 0.0 110.582 178.977 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -115.25 126.89 55.07 Favored 'General case' 0 N--CA 1.474 0.745 0 C-N-CA 122.984 0.514 . . . . 0.0 109.634 179.192 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 69.6 mt -89.67 136.03 24.68 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.621 0 N-CA-C 107.535 -1.283 . . . . 0.0 107.535 178.707 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 37.7 mt -137.4 139.24 44.01 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.263 0 N-CA-C 109.142 -0.688 . . . . 0.0 109.142 179.611 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.23 58.1 12.92 Favored Glycine 0 CA--C 1.529 0.964 0 CA-C-N 116.067 -0.515 . . . . 0.0 112.593 178.967 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 23.5 tp -105.85 131.81 52.73 Favored 'General case' 0 N--CA 1.484 1.256 0 N-CA-C 107.688 -1.227 . . . . 0.0 107.688 177.893 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 22.0 ttt -137.16 147.36 45.89 Favored 'General case' 0 N--CA 1.475 0.808 0 N-CA-C 108.135 -1.061 . . . . 0.0 108.135 178.924 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 61.7 t -156.5 158.14 3.45 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.487 0 N-CA-C 106.634 -1.617 . . . . 0.0 106.634 -179.109 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.68 71.53 0.71 Allowed Glycine 0 C--N 1.308 -0.992 0 CA-C-N 115.901 -0.59 . . . . 0.0 112.352 177.526 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' H' H ' 38' ' ' GLY . . . . . 0.676 ' H ' HE22 ' H' ' 15' ' ' GLN . . . 167.75 -165.75 38.91 Favored Glycine 0 C--O 1.212 -1.277 0 N-CA-C 110.6 -1.0 . . . . 0.0 110.6 178.693 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 18.9 m -128.2 148.45 32.72 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.023 0 C-N-CA 122.777 0.431 . . . . 0.0 109.926 179.966 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 8.6 t . . . . . 0 CA--C 1.535 0.369 0 CA-C-O 118.196 -0.907 . . . . 0.0 110.811 178.764 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 34.6 m-85 . . . . . 0 N--CA 1.47 0.537 0 CA-C-O 121.136 0.493 . . . . 0.0 109.827 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' I' I ' 5' ' ' ARG . . . . . 0.747 HH12 HG13 ' E' ' 24' ' ' VAL . 32.8 mtp180 -68.94 144.87 54.04 Favored 'General case' 0 N--CA 1.468 0.475 0 CA-C-N 115.473 -0.785 . . . . 0.0 111.206 -178.343 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 38.6 m80 -107.88 118.59 37.13 Favored 'General case' 0 N--CA 1.477 0.925 0 N-CA-C 109.195 -0.669 . . . . 0.0 109.195 178.314 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 10.5 m-20 -66.77 139.61 57.81 Favored 'General case' 0 N--CA 1.469 0.485 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.916 -179.059 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' I' I ' 8' ' ' SER . . . . . . . . . . . . . 37.8 t -158.08 -170.15 3.05 Favored 'General case' 0 N--CA 1.47 0.557 0 N-CA-C 109.688 -0.486 . . . . 0.0 109.688 178.996 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 120.29 32.0 1.2 Allowed Glycine 0 N--CA 1.483 1.809 0 N-CA-C 111.584 -0.606 . . . . 0.0 111.584 179.413 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 47.1 p90 -57.12 130.75 47.52 Favored 'General case' 0 N--CA 1.473 0.705 0 O-C-N 122.671 -0.311 . . . . 0.0 111.665 -179.815 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 60.5 mt-10 -90.3 152.5 21.01 Favored 'General case' 0 N--CA 1.475 0.813 0 CA-C-O 121.152 0.501 . . . . 0.0 109.865 179.013 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 3.5 p -155.46 124.87 0.73 Allowed 'Isoleucine or valine' 0 CA--C 1.554 1.125 0 N-CA-C 108.194 -1.039 . . . . 0.0 108.194 178.103 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 44.1 m-70 -135.82 160.85 37.29 Favored 'General case' 0 C--N 1.354 0.761 0 CA-C-N 114.6 -1.182 . . . . 0.0 111.0 -177.556 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 39.6 t60 -153.6 97.05 2.08 Favored 'General case' 0 N--CA 1.484 1.262 0 CA-C-N 115.841 -0.618 . . . . 0.0 109.761 178.841 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' I' I ' 15' ' ' GLN . . . . . 0.658 HE22 ' H ' ' I' ' 38' ' ' GLY . 28.4 mt-30 -90.79 121.37 32.6 Favored 'General case' 0 CA--C 1.514 -0.416 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 -178.95 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -112.86 103.69 11.68 Favored 'General case' 0 N--CA 1.473 0.709 0 N-CA-C 107.677 -1.231 . . . . 0.0 107.677 176.6 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 56.5 tp -132.18 147.26 52.41 Favored 'General case' 0 N--CA 1.485 1.296 0 C-N-CA 123.329 0.652 . . . . 0.0 109.436 -179.153 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 61.7 t -144.88 123.12 5.4 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.9 0 N-CA-C 109.425 -0.583 . . . . 0.0 109.425 178.642 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 9.4 m-85 -70.66 150.89 45.53 Favored 'General case' 0 C--N 1.374 1.642 0 N-CA-C 106.853 -1.536 . . . . 0.0 106.853 176.701 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 16.7 t80 -171.14 -55.26 0.02 OUTLIER 'General case' 0 N--CA 1.48 1.073 0 N-CA-C 110.212 -0.292 . . . . 0.0 110.212 -179.561 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.07 90.01 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.45 0 O-C-N 123.998 0.811 . . . . 0.0 112.327 -179.986 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 39.4 tt0 -64.22 160.77 17.85 Favored 'General case' 0 N--CA 1.469 0.511 0 CA-C-N 114.743 -1.117 . . . . 0.0 110.011 179.557 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 9.6 m-20 -137.01 125.31 23.25 Favored 'General case' 0 N--CA 1.481 1.082 0 C-N-CA 123.259 0.624 . . . . 0.0 109.891 -179.771 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' I' I ' 24' ' ' VAL . . . . . 0.846 HG12 ' H ' ' I' ' 25' ' ' GLY . 57.3 t -76.58 -169.96 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.757 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 179.568 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' I' I ' 25' ' ' GLY . . . . . 0.846 ' H ' HG12 ' I' ' 24' ' ' VAL . . . -68.81 49.72 0.49 Allowed Glycine 0 CA--C 1.531 1.054 0 CA-C-N 118.541 0.61 . . . . 0.0 112.485 -178.457 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 8.5 p -69.63 137.67 52.42 Favored 'General case' 0 C--N 1.33 -0.254 0 N-CA-C 109.166 -0.679 . . . . 0.0 109.166 177.856 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 35.0 t30 -69.57 94.74 0.79 Allowed 'General case' 0 CA--C 1.531 0.234 0 N-CA-C 107.676 -1.231 . . . . 0.0 107.676 177.534 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -91.8 117.84 30.15 Favored 'General case' 0 N--CA 1.478 0.936 0 N-CA-C 109.722 -0.473 . . . . 0.0 109.722 -179.395 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -62.37 -133.19 0.01 OUTLIER Glycine 0 CA--C 1.532 1.14 0 N-CA-C 110.613 -0.995 . . . . 0.0 110.613 178.96 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -115.22 126.54 54.68 Favored 'General case' 0 N--CA 1.474 0.737 0 C-N-CA 123.031 0.532 . . . . 0.0 109.697 179.246 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 69.5 mt -89.46 135.94 24.81 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.657 0 N-CA-C 107.552 -1.277 . . . . 0.0 107.552 178.784 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 37.7 mt -137.44 139.21 43.98 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.28 0 N-CA-C 109.004 -0.739 . . . . 0.0 109.004 179.739 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.24 57.99 13.3 Favored Glycine 0 CA--C 1.529 0.959 0 CA-C-N 115.978 -0.555 . . . . 0.0 112.562 178.908 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 23.1 tp -105.71 131.95 52.44 Favored 'General case' 0 N--CA 1.485 1.298 0 N-CA-C 107.531 -1.285 . . . . 0.0 107.531 177.839 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 22.1 ttt -137.3 147.53 45.72 Favored 'General case' 0 N--CA 1.475 0.783 0 N-CA-C 107.997 -1.112 . . . . 0.0 107.997 178.877 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 61.3 t -156.66 158.2 3.38 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.466 0 N-CA-C 106.623 -1.621 . . . . 0.0 106.623 -179.094 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.63 71.57 0.7 Allowed Glycine 0 C--N 1.308 -1.011 0 CA-C-N 115.953 -0.567 . . . . 0.0 112.376 177.556 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' I' I ' 38' ' ' GLY . . . . . 0.658 ' H ' HE22 ' I' ' 15' ' ' GLN . . . 167.72 -165.68 38.85 Favored Glycine 0 C--O 1.211 -1.337 0 N-CA-C 110.603 -0.999 . . . . 0.0 110.603 178.697 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 18.9 m -128.26 148.4 32.77 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.003 0 C-N-CA 122.831 0.452 . . . . 0.0 109.949 179.965 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 8.9 t . . . . . 0 CA--C 1.535 0.387 0 CA-C-O 118.104 -0.95 . . . . 0.0 110.738 178.824 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 76.6 m-85 . . . . . 0 N--CA 1.474 0.74 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 72.4 mtp180 -144.29 141.82 30.04 Favored 'General case' 0 N--CA 1.483 1.207 0 N-CA-C 109.035 -0.728 . . . . 0.0 109.035 179.866 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 77.2 m80 -149.72 118.51 6.62 Favored 'General case' 0 N--CA 1.472 0.655 0 N-CA-C 108.763 -0.828 . . . . 0.0 108.763 179.037 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 12.2 m-20 -66.83 149.5 50.49 Favored 'General case' 0 CA--C 1.531 0.242 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.193 -179.395 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 7.9 t -167.53 170.08 11.52 Favored 'General case' 0 N--CA 1.473 0.682 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 178.613 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 123.47 24.44 1.95 Allowed Glycine 0 N--CA 1.487 2.051 0 N-CA-C 112.089 -0.405 . . . . 0.0 112.089 179.466 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 41.0 p90 -56.59 128.26 35.4 Favored 'General case' 0 N--CA 1.473 0.714 0 N-CA-C 112.136 0.421 . . . . 0.0 112.136 -179.868 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 46.1 mt-10 -84.61 154.49 22.54 Favored 'General case' 0 N--CA 1.468 0.465 0 N-CA-C 108.847 -0.797 . . . . 0.0 108.847 178.256 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -154.03 129.18 1.54 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 N-CA-C 108.091 -1.077 . . . . 0.0 108.091 178.855 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 51.5 m-70 -134.5 144.77 48.24 Favored 'General case' 0 N--CA 1.487 1.409 0 CA-C-N 118.567 0.621 . . . . 0.0 110.729 -178.951 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 6.2 t60 -164.5 98.38 0.8 Allowed 'General case' 0 N--CA 1.482 1.172 0 CA-C-N 116.744 -0.207 . . . . 0.0 111.204 179.581 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . 0.642 ' NE2' ' H ' ' A' ' 37' ' ' GLY . 75.8 mt-30 -103.03 -172.65 2.15 Favored 'General case' 0 CA--C 1.506 -0.745 0 N-CA-C 108.191 -1.04 . . . . 0.0 108.191 179.338 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -167.25 98.17 0.51 Allowed 'General case' 0 N--CA 1.47 0.531 0 CA-C-N 115.084 -0.962 . . . . 0.0 109.366 178.766 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.564 HD12 ' N ' ' A' ' 17' ' ' LEU . 4.9 mp -106.69 162.44 13.76 Favored 'General case' 0 N--CA 1.485 1.303 0 N-CA-C 108.364 -0.976 . . . . 0.0 108.364 179.808 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 55.3 t -142.42 118.63 5.98 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.275 0 CA-C-O 118.804 -0.617 . . . . 0.0 109.899 179.29 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 54.2 m-85 -70.41 158.7 35.53 Favored 'General case' 0 N--CA 1.479 1.006 0 N-CA-C 107.812 -1.181 . . . . 0.0 107.812 177.07 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 15.0 t80 -171.0 -58.75 0.02 OUTLIER 'General case' 0 N--CA 1.483 1.198 0 CA-C-O 122.435 1.112 . . . . 0.0 109.546 179.244 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.33 90.56 0.0 OUTLIER 'General case' 0 N--CA 1.458 -0.073 0 CA-C-N 113.845 -1.525 . . . . 0.0 112.818 -178.113 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 53.6 tt0 -62.88 155.34 27.39 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 115.238 -0.892 . . . . 0.0 110.463 178.952 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 18.1 m-20 -136.51 134.71 37.85 Favored 'General case' 0 N--CA 1.48 1.071 0 C-N-CA 122.967 0.507 . . . . 0.0 109.983 179.851 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 16.2 t -84.74 -117.05 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.763 0 N-CA-C 108.173 -1.047 . . . . 0.0 108.173 179.296 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -107.4 53.27 0.61 Allowed Glycine 0 N--CA 1.474 1.172 0 N-CA-C 111.178 -0.769 . . . . 0.0 111.178 179.867 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 88.7 p -77.04 126.55 31.15 Favored 'General case' 0 N--CA 1.465 0.311 0 N-CA-C 109.023 -0.732 . . . . 0.0 109.023 178.398 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 1.8 t-20 -67.18 100.03 0.74 Allowed 'General case' 0 N--CA 1.472 0.656 0 N-CA-C 108.615 -0.883 . . . . 0.0 108.615 178.664 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 67.3 mttm -94.01 128.26 40.25 Favored 'General case' 0 N--CA 1.479 1.012 0 N-CA-C 109.634 -0.506 . . . . 0.0 109.634 -179.451 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.28 -133.26 0.01 OUTLIER Glycine 0 CA--C 1.53 0.985 0 N-CA-C 110.398 -1.081 . . . . 0.0 110.398 179.11 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.34 127.78 43.32 Favored 'General case' 0 N--CA 1.484 1.243 0 CA-C-N 117.096 0.448 . . . . 0.0 110.178 179.356 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 30.3 mt -91.9 160.52 2.68 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.648 0 N-CA-C 106.824 -1.547 . . . . 0.0 106.824 178.157 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 38.0 mt -138.27 94.14 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.766 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 -179.065 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 53.5 104.82 0.01 OUTLIER Glycine 0 CA--C 1.531 1.085 0 CA-C-N 115.899 -0.592 . . . . 0.0 114.192 176.621 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 91.1 mt -72.22 155.2 40.48 Favored 'General case' 0 N--CA 1.469 0.512 0 N-CA-C 107.502 -1.295 . . . . 0.0 107.502 176.51 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 2.2 ttp -143.84 139.3 29.21 Favored 'General case' 0 N--CA 1.473 0.725 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 178.943 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 59.1 t -159.23 150.05 6.96 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.261 0 N-CA-C 106.714 -1.587 . . . . 0.0 106.714 -179.229 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . 0.642 ' H ' ' NE2' ' A' ' 15' ' ' GLN . . . 54.78 75.15 0.25 Allowed Glycine 0 C--N 1.314 -0.667 0 N-CA-C 111.823 -0.511 . . . . 0.0 111.823 177.909 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 174.14 -148.97 10.33 Favored Glycine 0 CA--C 1.52 0.36 0 N-CA-C 110.974 -0.85 . . . . 0.0 110.974 179.928 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 30.9 m -134.81 146.0 31.44 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.906 0 C-N-CA 122.599 0.36 . . . . 0.0 110.373 -179.72 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 19.6 t . . . . . 0 C--O 1.221 -0.428 0 CA-C-O 117.59 -1.195 . . . . 0.0 110.986 179.153 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 77.1 m-85 . . . . . 0 N--CA 1.473 0.712 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 72.0 mtp180 -144.33 141.61 29.87 Favored 'General case' 0 N--CA 1.48 1.071 0 N-CA-C 108.999 -0.741 . . . . 0.0 108.999 179.955 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 77.2 m80 -149.51 118.65 6.77 Favored 'General case' 0 N--CA 1.474 0.742 0 N-CA-C 108.903 -0.777 . . . . 0.0 108.903 179.04 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 7' ' ' ASP . . . . . . . . . . . . . 12.4 m-20 -66.87 149.03 51.17 Favored 'General case' 0 CA--C 1.532 0.261 0 CA-C-N 116.411 -0.359 . . . . 0.0 111.236 -179.399 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 8' ' ' SER . . . . . . . . . . . . . 7.9 t -167.21 170.21 11.91 Favored 'General case' 0 N--CA 1.471 0.613 0 N-CA-C 109.288 -0.634 . . . . 0.0 109.288 178.459 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 123.43 24.4 1.97 Allowed Glycine 0 N--CA 1.486 2.023 0 N-CA-C 111.982 -0.447 . . . . 0.0 111.982 179.416 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 40.6 p90 -56.63 128.37 36.01 Favored 'General case' 0 N--CA 1.471 0.581 0 N-CA-C 112.091 0.404 . . . . 0.0 112.091 -179.775 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 46.1 mt-10 -84.69 154.54 22.41 Favored 'General case' 0 N--CA 1.469 0.498 0 N-CA-C 108.911 -0.774 . . . . 0.0 108.911 178.327 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -154.01 129.04 1.5 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 N-CA-C 108.173 -1.047 . . . . 0.0 108.173 178.861 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 51.4 m-70 -134.35 144.94 48.54 Favored 'General case' 0 N--CA 1.488 1.429 0 CA-C-N 118.475 0.579 . . . . 0.0 110.777 -178.95 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 6.2 t60 -164.66 98.16 0.78 Allowed 'General case' 0 N--CA 1.484 1.243 0 CA-C-N 116.697 -0.229 . . . . 0.0 111.189 179.596 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . 0.62 ' NE2' ' H ' ' B' ' 37' ' ' GLY . 75.8 mt-30 -102.84 -172.95 2.21 Favored 'General case' 0 CA--C 1.506 -0.743 0 N-CA-C 108.135 -1.061 . . . . 0.0 108.135 179.415 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -167.08 97.94 0.52 Allowed 'General case' 0 N--CA 1.47 0.558 0 CA-C-N 115.034 -0.984 . . . . 0.0 109.309 178.898 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . 0.571 ' N ' HD12 ' B' ' 17' ' ' LEU . 4.9 mp -106.63 162.19 13.97 Favored 'General case' 0 N--CA 1.486 1.329 0 N-CA-C 108.373 -0.973 . . . . 0.0 108.373 179.819 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 56.8 t -142.31 118.35 5.98 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.243 0 CA-C-O 118.873 -0.584 . . . . 0.0 109.924 179.309 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 56.0 m-85 -70.69 158.81 35.6 Favored 'General case' 0 N--CA 1.478 0.93 0 N-CA-C 107.671 -1.233 . . . . 0.0 107.671 177.036 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 16.0 t80 -171.73 -57.98 0.02 OUTLIER 'General case' 0 N--CA 1.481 1.102 0 CA-C-O 122.254 1.026 . . . . 0.0 109.541 179.233 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.54 90.8 0.0 OUTLIER 'General case' 0 C--O 1.231 0.103 0 CA-C-N 114.1 -1.409 . . . . 0.0 112.67 -178.169 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 53.5 tt0 -63.11 155.34 28.23 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 115.274 -0.875 . . . . 0.0 110.495 179.035 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 18.0 m-20 -136.46 134.91 38.16 Favored 'General case' 0 N--CA 1.481 1.088 0 C-N-CA 122.991 0.516 . . . . 0.0 110.007 179.875 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 16.1 t -85.21 -117.13 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.475 0.795 0 N-CA-C 108.331 -0.988 . . . . 0.0 108.331 179.282 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -106.66 52.74 0.66 Allowed Glycine 0 N--CA 1.476 1.306 0 N-CA-C 111.14 -0.784 . . . . 0.0 111.14 179.915 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 89.5 p -77.02 126.22 30.61 Favored 'General case' 0 N--CA 1.466 0.352 0 N-CA-C 109.207 -0.664 . . . . 0.0 109.207 178.421 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 1.8 t-20 -67.15 100.17 0.75 Allowed 'General case' 0 N--CA 1.473 0.676 0 N-CA-C 108.588 -0.893 . . . . 0.0 108.588 178.674 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 67.4 mttm -94.03 128.22 40.26 Favored 'General case' 0 N--CA 1.479 1.01 0 N-CA-C 109.684 -0.487 . . . . 0.0 109.684 -179.469 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.16 -132.94 0.01 OUTLIER Glycine 0 CA--C 1.53 0.991 0 N-CA-C 110.493 -1.043 . . . . 0.0 110.493 179.067 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.63 127.83 42.99 Favored 'General case' 0 N--CA 1.485 1.286 0 CA-C-N 117.192 0.496 . . . . 0.0 110.09 179.355 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 29.8 mt -92.03 160.3 2.7 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.69 0 N-CA-C 106.896 -1.52 . . . . 0.0 106.896 178.093 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 37.5 mt -138.0 94.05 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.684 0 N-CA-C 109.908 -0.405 . . . . 0.0 109.908 -178.969 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 53.47 104.91 0.01 OUTLIER Glycine 0 CA--C 1.53 1.02 0 CA-C-N 115.899 -0.591 . . . . 0.0 114.229 176.648 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 90.9 mt -72.29 155.26 40.38 Favored 'General case' 0 N--CA 1.471 0.578 0 N-CA-C 107.481 -1.303 . . . . 0.0 107.481 176.524 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 2.2 ttp -143.73 139.02 29.25 Favored 'General case' 0 N--CA 1.476 0.859 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 178.954 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 59.0 t -159.05 149.96 7.17 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.274 0 N-CA-C 106.58 -1.637 . . . . 0.0 106.58 -179.23 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . 0.62 ' H ' ' NE2' ' B' ' 15' ' ' GLN . . . 54.83 75.12 0.25 Allowed Glycine 0 C--N 1.314 -0.647 0 N-CA-C 111.786 -0.526 . . . . 0.0 111.786 177.778 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 174.06 -148.89 10.31 Favored Glycine 0 CA--C 1.521 0.452 0 N-CA-C 110.989 -0.844 . . . . 0.0 110.989 179.869 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 31.5 m -134.83 145.99 31.44 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.942 0 C-N-CA 122.566 0.346 . . . . 0.0 110.35 -179.717 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 20.0 t . . . . . 0 C--O 1.22 -0.448 0 CA-C-O 117.636 -1.173 . . . . 0.0 110.985 179.136 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 76.5 m-85 . . . . . 0 N--CA 1.473 0.72 0 N-CA-C 109.9 -0.407 . . . . 0.0 109.9 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 72.4 mtp180 -144.19 141.56 29.99 Favored 'General case' 0 N--CA 1.483 1.221 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 179.946 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 77.1 m80 -149.49 118.59 6.75 Favored 'General case' 0 N--CA 1.473 0.705 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 179.053 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' C' C ' 7' ' ' ASP . . . . . . . . . . . . . 11.7 m-20 -66.88 149.08 51.1 Favored 'General case' 0 N--CA 1.464 0.251 0 CA-C-N 116.337 -0.392 . . . . 0.0 111.25 -179.416 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' C' C ' 8' ' ' SER . . . . . . . . . . . . . 7.9 t -167.18 170.18 11.99 Favored 'General case' 0 N--CA 1.472 0.642 0 N-CA-C 109.188 -0.671 . . . . 0.0 109.188 178.493 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 123.45 24.42 1.96 Allowed Glycine 0 N--CA 1.486 2.023 0 N-CA-C 111.944 -0.462 . . . . 0.0 111.944 179.37 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 40.7 p90 -56.57 128.21 35.13 Favored 'General case' 0 N--CA 1.472 0.628 0 N-CA-C 112.066 0.395 . . . . 0.0 112.066 -179.836 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 46.0 mt-10 -84.54 154.54 22.59 Favored 'General case' 0 N--CA 1.469 0.51 0 N-CA-C 108.881 -0.785 . . . . 0.0 108.881 178.252 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -154.07 129.02 1.48 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 178.826 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 51.3 m-70 -134.24 144.96 48.71 Favored 'General case' 0 N--CA 1.487 1.411 0 CA-C-N 118.428 0.558 . . . . 0.0 110.827 -178.954 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 6.2 t60 -164.75 98.35 0.77 Allowed 'General case' 0 N--CA 1.484 1.259 0 CA-C-N 116.823 -0.171 . . . . 0.0 111.254 179.6 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' C' C ' 15' ' ' GLN . . . . . 0.634 ' NE2' ' H ' ' C' ' 37' ' ' GLY . 75.8 mt-30 -103.09 -172.73 2.16 Favored 'General case' 0 CA--C 1.503 -0.851 0 N-CA-C 108.244 -1.021 . . . . 0.0 108.244 179.322 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -167.18 98.11 0.51 Allowed 'General case' 0 CA--C 1.538 0.502 0 CA-C-N 114.973 -1.012 . . . . 0.0 109.333 178.861 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' C' C ' 17' ' ' LEU . . . . . 0.563 HD12 ' N ' ' C' ' 17' ' ' LEU . 4.9 mp -106.72 162.19 13.99 Favored 'General case' 0 N--CA 1.486 1.344 0 N-CA-C 108.291 -1.003 . . . . 0.0 108.291 179.76 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 57.5 t -142.24 118.41 6.18 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.296 0 CA-C-O 118.934 -0.555 . . . . 0.0 109.944 179.285 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 55.7 m-85 -70.64 158.82 35.53 Favored 'General case' 0 N--CA 1.478 0.946 0 N-CA-C 107.754 -1.202 . . . . 0.0 107.754 176.981 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 16.0 t80 -171.71 -57.94 0.02 OUTLIER 'General case' 0 N--CA 1.479 0.977 0 CA-C-O 122.299 1.047 . . . . 0.0 109.573 179.176 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.6 90.82 0.0 OUTLIER 'General case' 0 C--N 1.338 0.087 0 CA-C-N 114.137 -1.392 . . . . 0.0 112.653 -178.171 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 53.6 tt0 -63.11 155.34 28.24 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 115.226 -0.897 . . . . 0.0 110.462 179.04 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 17.9 m-20 -136.43 134.94 38.25 Favored 'General case' 0 N--CA 1.48 1.069 0 C-N-CA 122.898 0.479 . . . . 0.0 110.002 179.83 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 16.1 t -85.08 -117.23 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.475 0.796 0 N-CA-C 108.344 -0.984 . . . . 0.0 108.344 179.273 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -106.54 52.68 0.66 Allowed Glycine 0 N--CA 1.476 1.327 0 N-CA-C 111.144 -0.782 . . . . 0.0 111.144 179.852 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 89.3 p -77.1 126.45 30.98 Favored 'General case' 0 N--CA 1.466 0.364 0 N-CA-C 109.151 -0.685 . . . . 0.0 109.151 178.494 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 1.8 t-20 -67.24 100.17 0.77 Allowed 'General case' 0 N--CA 1.471 0.615 0 N-CA-C 108.627 -0.879 . . . . 0.0 108.627 178.619 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 67.3 mttm -94.09 128.23 40.35 Favored 'General case' 0 N--CA 1.479 1.016 0 N-CA-C 109.656 -0.498 . . . . 0.0 109.656 -179.41 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.29 -133.09 0.01 OUTLIER Glycine 0 CA--C 1.531 1.039 0 N-CA-C 110.481 -1.047 . . . . 0.0 110.481 179.139 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.37 127.52 42.79 Favored 'General case' 0 N--CA 1.486 1.332 0 CA-C-N 117.195 0.498 . . . . 0.0 110.177 179.379 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 29.6 mt -91.78 160.25 2.71 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.642 0 N-CA-C 106.887 -1.523 . . . . 0.0 106.887 178.063 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 36.9 mt -138.0 94.0 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.696 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 -178.964 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 53.52 104.93 0.01 OUTLIER Glycine 0 CA--C 1.531 1.067 0 CA-C-N 115.885 -0.598 . . . . 0.0 114.118 176.608 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 90.9 mt -72.21 155.17 40.52 Favored 'General case' 0 N--CA 1.47 0.563 0 N-CA-C 107.477 -1.305 . . . . 0.0 107.477 176.463 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 2.2 ttp -143.54 139.09 29.59 Favored 'General case' 0 N--CA 1.473 0.722 0 N-CA-C 108.812 -0.81 . . . . 0.0 108.812 178.9 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 59.3 t -159.2 150.08 6.98 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.258 0 N-CA-C 106.659 -1.608 . . . . 0.0 106.659 -179.279 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' C' C ' 37' ' ' GLY . . . . . 0.634 ' H ' ' NE2' ' C' ' 15' ' ' GLN . . . 54.84 75.04 0.25 Allowed Glycine 0 N--CA 1.465 0.633 0 N-CA-C 111.775 -0.53 . . . . 0.0 111.775 177.837 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 174.04 -148.9 10.32 Favored Glycine 0 CA--C 1.521 0.411 0 N-CA-C 110.967 -0.853 . . . . 0.0 110.967 179.8 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 31.3 m -134.8 145.97 31.5 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.97 0 C-N-CA 122.535 0.334 . . . . 0.0 110.481 -179.739 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 20.1 t . . . . . 0 C--O 1.222 -0.392 0 CA-C-O 117.616 -1.183 . . . . 0.0 110.873 179.116 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 84.5 m-85 . . . . . 0 N--CA 1.472 0.651 0 N-CA-C 108.346 -0.983 . . . . 0.0 108.346 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' D' D ' 5' ' ' ARG . . . . . . . . . . . . . 71.9 mtp180 -147.73 141.4 25.58 Favored 'General case' 0 N--CA 1.472 0.625 0 N-CA-C 109.037 -0.727 . . . . 0.0 109.037 179.779 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 77.5 m80 -149.2 123.46 9.57 Favored 'General case' 0 CA--C 1.541 0.627 0 N-CA-C 107.705 -1.22 . . . . 0.0 107.705 175.53 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' D' D ' 7' ' ' ASP . . . . . . . . . . . . . 7.9 m-20 -63.33 133.5 54.22 Favored 'General case' 0 C--N 1.322 -0.591 0 C-N-CA 126.813 2.045 . . . . 0.0 114.543 176.425 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' D' D ' 8' ' ' SER . . . . . . . . . . . . . 7.0 t -154.22 173.1 16.58 Favored 'General case' 0 N--CA 1.478 0.943 0 CA-C-N 118.468 0.576 . . . . 0.0 110.05 176.977 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 124.48 20.51 2.38 Favored Glycine 0 N--CA 1.484 1.874 0 N-CA-C 112.185 -0.366 . . . . 0.0 112.185 176.649 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 36.2 p90 -55.55 130.46 42.96 Favored 'General case' 0 CA--C 1.546 0.803 0 CA-C-O 121.089 0.471 . . . . 0.0 112.026 -177.341 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 46.2 mt-10 -84.89 152.25 23.69 Favored 'General case' 0 N--CA 1.474 0.755 0 N-CA-C 109.422 -0.584 . . . . 0.0 109.422 177.628 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -149.53 130.09 4.42 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.411 0 N-CA-C 108.158 -1.053 . . . . 0.0 108.158 175.389 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 49.4 m-70 -129.49 148.52 51.4 Favored 'General case' 0 N--CA 1.48 1.062 0 CA-C-N 118.016 0.371 . . . . 0.0 111.021 176.687 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 6.3 t60 -165.0 104.78 0.78 Allowed 'General case' 0 N--CA 1.484 1.256 0 N-CA-C 109.716 -0.476 . . . . 0.0 109.716 173.618 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' D' D ' 15' ' ' GLN . . . . . 0.659 ' NE2' ' H ' ' D' ' 37' ' ' GLY . 75.9 mt-30 -106.3 -175.7 2.87 Favored 'General case' 0 CA--C 1.498 -1.056 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 178.602 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' D' D ' 16' ' ' LYS . . . . . 0.414 ' C ' HD12 ' D' ' 17' ' ' LEU . 88.6 tttt -163.54 106.28 0.98 Allowed 'General case' 0 CA--C 1.536 0.423 0 N-CA-C 107.493 -1.299 . . . . 0.0 107.493 175.514 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' D' D ' 17' ' ' LEU . . . . . 0.498 HD12 ' N ' ' D' ' 17' ' ' LEU . 5.9 mp -112.94 162.18 16.14 Favored 'General case' 0 N--CA 1.487 1.381 0 N-CA-C 107.503 -1.295 . . . . 0.0 107.503 179.01 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 48.7 t -141.24 123.44 14.59 Favored 'Isoleucine or valine' 0 C--N 1.362 1.134 0 N-CA-C 109.084 -0.71 . . . . 0.0 109.084 175.344 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 80.4 m-85 -62.85 151.37 39.23 Favored 'General case' 0 C--N 1.349 0.582 0 C-N-CA 124.435 1.094 . . . . 0.0 110.703 170.11 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 11.4 t80 -170.23 -66.84 0.02 OUTLIER 'General case' 0 C--N 1.319 -0.723 0 N-CA-C 107.72 -1.215 . . . . 0.0 107.72 179.31 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -38.37 95.52 0.01 OUTLIER 'General case' 0 N--CA 1.451 -0.38 0 CA-C-N 113.964 -1.471 . . . . 0.0 111.672 -175.501 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 53.6 tt0 -65.39 156.03 33.53 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 114.072 -1.422 . . . . 0.0 110.104 178.587 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 17.9 m-20 -136.49 138.89 41.88 Favored 'General case' 0 N--CA 1.477 0.898 0 N-CA-C 109.256 -0.646 . . . . 0.0 109.256 178.501 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' D' D ' 24' ' ' VAL . . . . . . . . . . . . . 17.3 t -88.5 -120.4 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.482 1.168 0 N-CA-C 107.602 -1.259 . . . . 0.0 107.602 179.607 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . -110.35 61.77 0.3 Allowed Glycine 0 C--N 1.373 2.585 0 C-N-CA 117.706 -2.188 . . . . 0.0 109.162 178.44 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 94.5 p -67.91 121.74 16.67 Favored 'General case' 0 C--O 1.243 0.763 0 CA-C-O 116.524 -1.703 . . . . 0.0 112.307 168.7 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 1.9 t-20 -62.73 101.75 0.28 Allowed 'General case' 0 N--CA 1.476 0.845 0 CA-C-N 121.519 1.963 . . . . 0.0 109.476 172.984 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 67.1 mttm -95.95 127.37 41.91 Favored 'General case' 0 N--CA 1.485 1.277 0 CA-C-N 119.243 0.928 . . . . 0.0 109.102 178.377 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -55.84 -135.05 0.0 OUTLIER Glycine 0 CA--C 1.527 0.803 0 C-N-CA 123.573 0.606 . . . . 0.0 112.443 174.696 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.45 130.94 48.31 Favored 'General case' 0 C--N 1.373 1.62 0 CA-C-N 114.968 -0.616 . . . . 0.0 110.283 175.995 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 35.9 mt -92.08 162.32 2.43 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.455 0 N-CA-C 106.475 -1.676 . . . . 0.0 106.475 177.673 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . 0.267 41.6 mt -140.6 105.49 1.84 Allowed 'Isoleucine or valine' 0 C--N 1.359 1.015 0 N-CA-C 106.728 -1.582 . . . . 0.0 106.728 173.053 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.49 96.24 0.01 OUTLIER Glycine 0 CA--C 1.533 1.171 0 CA-C-O 115.935 -2.592 . . . . 0.0 112.682 169.063 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 95.2 mt -69.65 158.56 35.1 Favored 'General case' 0 N--CA 1.481 1.086 0 CA-C-N 122.731 3.265 . . . . 0.0 107.441 176.507 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 2.9 ttp -143.82 149.53 37.14 Favored 'General case' 0 N--CA 1.481 1.089 0 N-CA-C 106.352 -1.722 . . . . 0.0 106.352 174.293 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 89.6 t -165.18 154.09 1.91 Allowed 'Isoleucine or valine' 0 C--O 1.249 1.032 0 N-CA-C 105.41 -2.07 . . . . 0.0 105.41 177.601 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' D' D ' 37' ' ' GLY . . . . . 0.659 ' H ' ' NE2' ' D' ' 15' ' ' GLN . . . 60.83 66.74 2.5 Favored Glycine 0 N--CA 1.442 -0.953 0 C-N-CA 117.326 -2.369 . . . . 0.0 113.981 174.565 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 168.41 -147.85 11.88 Favored Glycine 0 N--CA 1.466 0.674 0 CA-C-O 117.0 -2.0 . . . . 0.0 112.492 -178.698 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 31.1 m -131.19 145.42 35.39 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.271 0 CA-C-N 119.958 1.879 . . . . 0.0 110.588 -176.988 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 18.0 t . . . . . 0 C--O 1.208 -1.128 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 173.591 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 77.1 m-85 . . . . . 0 N--CA 1.473 0.7 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' E' E ' 5' ' ' ARG . . . . . . . . . . . . . 71.8 mtp180 -144.27 142.32 30.38 Favored 'General case' 0 N--CA 1.476 0.826 0 N-CA-C 109.234 -0.654 . . . . 0.0 109.234 179.666 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 77.3 m80 -150.11 117.62 6.12 Favored 'General case' 0 N--CA 1.475 0.787 0 N-CA-C 109.049 -0.723 . . . . 0.0 109.049 179.073 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' E' E ' 7' ' ' ASP . . . . . . . . . . . . . 12.1 m-20 -65.85 149.19 50.58 Favored 'General case' 0 N--CA 1.463 0.205 0 O-C-N 123.276 0.36 . . . . 0.0 111.482 -179.409 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' E' E ' 8' ' ' SER . . . . . . . . . . . . . 7.2 t -167.6 171.34 10.34 Favored 'General case' 0 N--CA 1.476 0.836 0 N-CA-C 109.219 -0.66 . . . . 0.0 109.219 178.03 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 123.9 23.78 1.98 Allowed Glycine 0 N--CA 1.481 1.655 0 N-CA-C 111.876 -0.489 . . . . 0.0 111.876 179.024 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 37.1 p90 -55.82 127.53 30.64 Favored 'General case' 0 CA--C 1.543 0.694 0 N-CA-C 112.703 0.631 . . . . 0.0 112.703 -179.076 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 46.4 mt-10 -83.05 155.2 24.03 Favored 'General case' 0 N--CA 1.475 0.79 0 N-CA-C 109.234 -0.654 . . . . 0.0 109.234 177.774 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -155.69 127.88 1.02 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.498 0 N-CA-C 108.22 -1.03 . . . . 0.0 108.22 178.622 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 48.5 m-70 -134.29 143.1 47.54 Favored 'General case' 0 N--CA 1.478 0.97 0 C-N-CA 122.491 0.316 . . . . 0.0 111.099 -177.976 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 6.1 t60 -163.52 98.5 0.9 Allowed 'General case' 0 N--CA 1.486 1.359 0 CA-C-O 119.735 -0.174 . . . . 0.0 111.247 179.693 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' E' E ' 15' ' ' GLN . . . . . 0.611 ' NE2' ' H ' ' E' ' 37' ' ' GLY . 76.0 mt-30 -102.66 -172.7 2.17 Favored 'General case' 0 CA--C 1.506 -0.736 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 179.464 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -167.16 98.13 0.52 Allowed 'General case' 0 CA--C 1.54 0.59 0 CA-C-N 114.97 -1.014 . . . . 0.0 109.259 178.617 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' E' E ' 17' ' ' LEU . . . . . 0.537 ' N ' HD12 ' E' ' 17' ' ' LEU . 4.9 mp -106.43 161.44 14.58 Favored 'General case' 0 N--CA 1.487 1.411 0 N-CA-C 108.771 -0.826 . . . . 0.0 108.771 -179.95 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 42.0 t -142.4 117.82 5.39 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.379 0 C-N-CA 122.549 0.339 . . . . 0.0 110.463 178.896 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 54.9 m-85 -69.72 156.54 38.83 Favored 'General case' 0 C--N 1.356 0.891 0 N-CA-C 107.636 -1.246 . . . . 0.0 107.636 176.449 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 14.2 t80 -173.23 -56.16 0.02 OUTLIER 'General case' 0 N--CA 1.482 1.129 0 CA-C-O 121.731 0.777 . . . . 0.0 110.018 179.242 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.84 89.1 0.0 OUTLIER 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 114.364 -1.289 . . . . 0.0 112.689 -179.095 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 54.0 tt0 -61.69 155.08 23.55 Favored 'General case' 0 N--CA 1.47 0.55 0 CA-C-N 115.131 -0.94 . . . . 0.0 110.604 179.489 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 17.6 m-20 -136.46 134.54 37.77 Favored 'General case' 0 N--CA 1.479 0.978 0 C-N-CA 122.918 0.487 . . . . 0.0 110.301 -179.931 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 20.2 t -84.85 -116.64 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.873 0 N-CA-C 108.449 -0.945 . . . . 0.0 108.449 179.209 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . -106.84 52.98 0.64 Allowed Glycine 0 C--N 1.346 1.138 0 N-CA-C 111.255 -0.738 . . . . 0.0 111.255 -179.987 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 89.2 p -77.0 125.99 30.24 Favored 'General case' 0 N--CA 1.472 0.664 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 178.169 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 1.8 t-20 -66.66 100.22 0.67 Allowed 'General case' 0 N--CA 1.472 0.633 0 N-CA-C 108.108 -1.071 . . . . 0.0 108.108 178.528 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 66.6 mttm -94.31 127.15 40.01 Favored 'General case' 0 N--CA 1.481 1.101 0 N-CA-C 109.149 -0.685 . . . . 0.0 109.149 -179.463 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.84 -130.58 0.01 OUTLIER Glycine 0 CA--C 1.533 1.218 0 N-CA-C 110.454 -1.058 . . . . 0.0 110.454 179.31 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -129.25 127.56 41.49 Favored 'General case' 0 N--CA 1.484 1.265 0 CA-C-N 117.439 0.62 . . . . 0.0 111.324 -179.906 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 27.8 mt -90.91 161.01 2.65 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.499 0 N-CA-C 106.796 -1.557 . . . . 0.0 106.796 178.152 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 37.3 mt -138.75 94.5 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.479 0.979 0 N-CA-C 109.606 -0.516 . . . . 0.0 109.606 179.872 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 53.62 104.37 0.01 OUTLIER Glycine 0 CA--C 1.531 1.037 0 CA-C-N 116.101 -0.499 . . . . 0.0 114.204 176.791 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 93.8 mt -71.52 155.64 40.34 Favored 'General case' 0 N--CA 1.473 0.682 0 N-CA-C 107.49 -1.3 . . . . 0.0 107.49 176.516 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 2.4 ttp -143.81 139.99 29.62 Favored 'General case' 0 N--CA 1.479 1.019 0 N-CA-C 108.301 -1.0 . . . . 0.0 108.301 178.787 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 65.6 t -160.27 148.8 6.11 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.456 0 N-CA-C 106.618 -1.623 . . . . 0.0 106.618 -179.058 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' E' E ' 37' ' ' GLY . . . . . 0.611 ' H ' ' NE2' ' E' ' 15' ' ' GLN . . . 55.15 75.32 0.24 Allowed Glycine 0 N--CA 1.464 0.516 0 N-CA-C 111.815 -0.514 . . . . 0.0 111.815 178.118 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 174.77 -146.95 8.77 Favored Glycine 0 C--O 1.221 -0.663 0 N-CA-C 111.207 -0.757 . . . . 0.0 111.207 179.881 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 29.8 m -136.69 145.15 30.73 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.794 0 CA-C-N 117.104 0.452 . . . . 0.0 109.808 -179.647 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 19.0 t . . . . . 0 CA--C 1.537 0.449 0 CA-C-O 117.576 -1.202 . . . . 0.0 111.153 179.183 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 77.0 m-85 . . . . . 0 N--CA 1.474 0.75 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' F' F ' 5' ' ' ARG . . . . . . . . . . . . . 72.0 mtp180 -144.11 142.15 30.43 Favored 'General case' 0 N--CA 1.478 0.954 0 N-CA-C 109.092 -0.707 . . . . 0.0 109.092 179.755 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 77.2 m80 -150.14 117.43 6.04 Favored 'General case' 0 N--CA 1.476 0.843 0 N-CA-C 108.983 -0.747 . . . . 0.0 108.983 179.093 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' F' F ' 7' ' ' ASP . . . . . . . . . . . . . 11.5 m-20 -65.74 149.07 50.73 Favored 'General case' 0 N--CA 1.464 0.247 0 O-C-N 123.327 0.392 . . . . 0.0 111.662 -179.433 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' F' F ' 8' ' ' SER . . . . . . . . . . . . . 7.1 t -167.38 171.43 10.58 Favored 'General case' 0 N--CA 1.476 0.87 0 N-CA-C 109.253 -0.647 . . . . 0.0 109.253 178.056 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 123.79 23.71 2.01 Favored Glycine 0 N--CA 1.482 1.746 0 N-CA-C 111.901 -0.48 . . . . 0.0 111.901 179.008 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 37.4 p90 -55.9 127.75 31.81 Favored 'General case' 0 CA--C 1.542 0.647 0 N-CA-C 112.717 0.636 . . . . 0.0 112.717 -179.113 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 46.4 mt-10 -83.21 155.25 23.81 Favored 'General case' 0 N--CA 1.475 0.779 0 N-CA-C 109.2 -0.667 . . . . 0.0 109.2 177.756 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -155.74 127.94 1.02 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.538 0 N-CA-C 108.218 -1.03 . . . . 0.0 108.218 178.551 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 49.0 m-70 -134.29 143.16 47.58 Favored 'General case' 0 N--CA 1.479 1.024 0 C-N-CA 122.419 0.288 . . . . 0.0 110.996 -177.871 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 6.1 t60 -163.81 99.12 0.88 Allowed 'General case' 0 N--CA 1.487 1.38 0 CA-C-N 116.85 -0.159 . . . . 0.0 111.252 179.677 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' F' F ' 15' ' ' GLN . . . . . 0.625 ' NE2' ' H ' ' F' ' 37' ' ' GLY . 76.0 mt-30 -103.58 -171.91 2.02 Favored 'General case' 0 CA--C 1.501 -0.921 0 N-CA-C 108.388 -0.967 . . . . 0.0 108.388 179.384 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -167.6 98.3 0.48 Allowed 'General case' 0 CA--C 1.54 0.59 0 CA-C-N 114.842 -1.072 . . . . 0.0 109.322 178.775 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' F' F ' 17' ' ' LEU . . . . . 0.529 HD12 ' N ' ' F' ' 17' ' ' LEU . 4.9 mp -106.45 161.45 14.58 Favored 'General case' 0 N--CA 1.487 1.415 0 N-CA-C 108.721 -0.844 . . . . 0.0 108.721 -179.967 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 41.6 t -142.32 117.96 5.64 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.378 0 C-N-CA 122.638 0.375 . . . . 0.0 110.478 178.921 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 55.2 m-85 -69.82 156.47 38.99 Favored 'General case' 0 C--N 1.357 0.906 0 N-CA-C 107.455 -1.313 . . . . 0.0 107.455 176.363 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 15.0 t80 -173.11 -56.09 0.02 OUTLIER 'General case' 0 N--CA 1.482 1.164 0 CA-C-O 121.743 0.783 . . . . 0.0 109.606 179.233 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.99 89.09 0.0 OUTLIER 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 114.46 -1.245 . . . . 0.0 112.76 -179.02 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 53.9 tt0 -61.6 155.19 22.95 Favored 'General case' 0 N--CA 1.472 0.659 0 CA-C-N 115.151 -0.931 . . . . 0.0 110.641 179.346 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 17.5 m-20 -136.66 134.73 37.59 Favored 'General case' 0 N--CA 1.479 1.006 0 C-N-CA 122.925 0.49 . . . . 0.0 110.345 -179.986 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' F' F ' 24' ' ' VAL . . . . . . . . . . . . . 19.3 t -85.08 -116.69 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.93 0 N-CA-C 108.525 -0.917 . . . . 0.0 108.525 179.241 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -106.6 52.61 0.67 Allowed Glycine 0 N--CA 1.477 1.42 0 N-CA-C 111.172 -0.771 . . . . 0.0 111.172 179.974 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 89.3 p -76.78 125.86 29.99 Favored 'General case' 0 N--CA 1.472 0.655 0 N-CA-C 109.271 -0.64 . . . . 0.0 109.271 178.176 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 1.9 t-20 -66.83 100.35 0.71 Allowed 'General case' 0 N--CA 1.471 0.603 0 N-CA-C 108.134 -1.061 . . . . 0.0 108.134 178.587 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 66.7 mttm -94.31 126.96 39.89 Favored 'General case' 0 N--CA 1.481 1.123 0 N-CA-C 109.169 -0.678 . . . . 0.0 109.169 -179.389 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.81 -130.96 0.01 OUTLIER Glycine 0 CA--C 1.532 1.155 0 N-CA-C 110.591 -1.004 . . . . 0.0 110.591 179.212 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.55 126.94 41.38 Favored 'General case' 0 N--CA 1.488 1.433 0 CA-C-N 117.4 0.6 . . . . 0.0 111.348 -179.765 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 28.1 mt -90.62 160.92 2.68 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.547 0 N-CA-C 106.694 -1.595 . . . . 0.0 106.694 178.033 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 36.8 mt -138.87 94.57 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.093 0 N-CA-C 109.613 -0.514 . . . . 0.0 109.613 179.822 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 53.69 104.3 0.01 OUTLIER Glycine 0 CA--C 1.531 1.075 0 CA-C-N 116.039 -0.528 . . . . 0.0 114.145 176.752 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 94.1 mt -71.47 155.93 40.03 Favored 'General case' 0 N--CA 1.471 0.62 0 N-CA-C 107.524 -1.287 . . . . 0.0 107.524 176.588 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 2.3 ttp -144.13 140.01 29.15 Favored 'General case' 0 N--CA 1.478 0.957 0 N-CA-C 108.691 -0.855 . . . . 0.0 108.691 178.708 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 65.0 t -160.3 148.95 6.08 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.447 0 N-CA-C 106.703 -1.591 . . . . 0.0 106.703 -178.973 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' F' F ' 37' ' ' GLY . . . . . 0.625 ' H ' ' NE2' ' F' ' 15' ' ' GLN . . . 55.16 75.25 0.25 Allowed Glycine 0 N--CA 1.464 0.551 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.812 178.038 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 174.77 -146.94 8.76 Favored Glycine 0 C--O 1.22 -0.738 0 N-CA-C 111.22 -0.752 . . . . 0.0 111.22 179.845 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 30.3 m -136.7 145.05 30.88 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.757 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 -179.644 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 18.7 t . . . . . 0 C--O 1.221 -0.418 0 CA-C-O 117.621 -1.18 . . . . 0.0 111.157 179.215 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 77.1 m-85 . . . . . 0 N--CA 1.472 0.668 0 N-CA-C 109.594 -0.521 . . . . 0.0 109.594 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' G' G ' 5' ' ' ARG . . . . . . . . . . . . . 72.4 mtp180 -144.56 141.94 29.83 Favored 'General case' 0 N--CA 1.48 1.053 0 N-CA-C 109.088 -0.708 . . . . 0.0 109.088 -179.799 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 77.1 m80 -149.85 118.75 6.66 Favored 'General case' 0 N--CA 1.475 0.797 0 N-CA-C 108.979 -0.749 . . . . 0.0 108.979 179.072 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 12.1 m-20 -68.1 144.85 54.87 Favored 'General case' 0 CA--C 1.537 0.467 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.878 -179.2 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' G' G ' 8' ' ' SER . . . . . . . . . . . . . 6.1 t -163.58 173.1 13.44 Favored 'General case' 0 N--CA 1.47 0.552 0 N-CA-C 109.068 -0.715 . . . . 0.0 109.068 178.089 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 123.4 23.12 2.19 Favored Glycine 0 N--CA 1.481 1.644 0 N-CA-C 111.712 -0.555 . . . . 0.0 111.712 178.936 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 40.5 p90 -56.18 127.68 31.87 Favored 'General case' 0 N--CA 1.473 0.718 0 N-CA-C 112.682 0.623 . . . . 0.0 112.682 -178.705 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 46.2 mt-10 -83.44 154.1 24.14 Favored 'General case' 0 N--CA 1.47 0.561 0 N-CA-C 109.632 -0.507 . . . . 0.0 109.632 178.307 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -155.68 128.07 1.05 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.933 0 N-CA-C 108.036 -1.098 . . . . 0.0 108.036 178.846 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 50.2 m-70 -133.66 144.15 49.01 Favored 'General case' 0 N--CA 1.475 0.801 0 CA-C-N 115.353 -0.84 . . . . 0.0 110.773 -178.238 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 6.2 t60 -164.82 98.83 0.77 Allowed 'General case' 0 N--CA 1.483 1.204 0 CA-C-N 116.635 -0.257 . . . . 0.0 110.786 179.033 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' G' G ' 15' ' ' GLN . . . . . 0.637 ' NE2' ' H ' ' G' ' 37' ' ' GLY . 76.1 mt-30 -103.18 -172.32 2.1 Favored 'General case' 0 CA--C 1.506 -0.737 0 N-CA-C 108.358 -0.979 . . . . 0.0 108.358 179.578 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -167.29 98.31 0.51 Allowed 'General case' 0 CA--C 1.539 0.546 0 CA-C-N 115.051 -0.977 . . . . 0.0 109.367 178.7 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' G' G ' 17' ' ' LEU . . . . . 0.55 ' N ' HD12 ' G' ' 17' ' ' LEU . 5.4 mp -106.2 160.81 15.05 Favored 'General case' 0 N--CA 1.486 1.335 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 -179.908 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 40.4 t -143.59 117.95 3.84 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.001 0 C-N-CA 122.573 0.349 . . . . 0.0 110.235 178.753 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 49.0 m-85 -69.7 150.84 46.53 Favored 'General case' 0 C--N 1.37 1.487 0 N-CA-C 107.404 -1.332 . . . . 0.0 107.404 176.477 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 12.4 t80 -171.03 -55.9 0.02 OUTLIER 'General case' 0 N--CA 1.485 1.29 0 N-CA-C 110.025 -0.361 . . . . 0.0 110.025 179.957 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.88 90.61 0.0 OUTLIER 'General case' 0 C--N 1.325 -0.481 0 O-C-N 123.938 0.774 . . . . 0.0 112.267 179.986 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 53.7 tt0 -62.81 155.84 25.68 Favored 'General case' 0 N--CA 1.469 0.475 0 CA-C-N 114.838 -1.074 . . . . 0.0 109.718 179.03 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 18.0 m-20 -136.71 134.71 37.48 Favored 'General case' 0 N--CA 1.478 0.96 0 C-N-CA 122.782 0.433 . . . . 0.0 109.87 -179.939 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' G' G ' 24' ' ' VAL . . . . . . . . . . . . . 19.6 t -85.5 -116.02 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.894 0 N-CA-C 108.293 -1.003 . . . . 0.0 108.293 179.289 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -107.28 53.06 0.63 Allowed Glycine 0 N--CA 1.476 1.311 0 N-CA-C 111.286 -0.726 . . . . 0.0 111.286 -179.947 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 89.3 p -77.48 126.2 30.53 Favored 'General case' 0 N--CA 1.466 0.37 0 N-CA-C 109.152 -0.684 . . . . 0.0 109.152 178.139 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 1.9 t-20 -67.16 99.82 0.72 Allowed 'General case' 0 N--CA 1.469 0.495 0 N-CA-C 108.604 -0.887 . . . . 0.0 108.604 178.81 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 67.3 mttm -93.51 127.09 39.01 Favored 'General case' 0 N--CA 1.481 1.081 0 N-CA-C 109.512 -0.551 . . . . 0.0 109.512 -179.662 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.87 -128.71 0.01 OUTLIER Glycine 0 CA--C 1.527 0.801 0 N-CA-C 110.576 -1.01 . . . . 0.0 110.576 179.27 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.84 126.09 35.36 Favored 'General case' 0 CA--C 1.54 0.567 0 C-N-CA 122.814 0.446 . . . . 0.0 110.933 -179.361 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 37.7 mt -90.53 162.26 2.49 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.842 0 N-CA-C 107.0 -1.482 . . . . 0.0 107.0 178.239 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 40.8 mt -139.04 95.96 0.96 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.437 0 CA-C-N 119.714 1.143 . . . . 0.0 110.068 178.173 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 53.64 103.92 0.01 OUTLIER Glycine 0 CA--C 1.53 1.019 0 CA-C-N 116.026 -0.534 . . . . 0.0 114.106 176.818 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 92.3 mt -71.34 154.96 41.19 Favored 'General case' 0 N--CA 1.47 0.57 0 N-CA-C 107.772 -1.196 . . . . 0.0 107.772 176.717 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 2.6 ttp -143.48 140.46 30.34 Favored 'General case' 0 N--CA 1.474 0.756 0 N-CA-C 108.555 -0.906 . . . . 0.0 108.555 178.897 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 69.2 t -160.36 149.11 5.98 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.256 0 N-CA-C 106.636 -1.616 . . . . 0.0 106.636 -179.329 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' G' G ' 37' ' ' GLY . . . . . 0.637 ' H ' ' NE2' ' G' ' 15' ' ' GLN . . . 55.5 75.12 0.26 Allowed Glycine 0 N--CA 1.466 0.637 0 C-N-CA 121.012 -0.613 . . . . 0.0 112.04 177.494 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 173.92 -146.17 8.59 Favored Glycine 0 C--O 1.221 -0.708 0 N-CA-C 110.581 -1.008 . . . . 0.0 110.581 179.339 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 32.9 m -136.76 145.9 29.42 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.923 0 CA-C-N 117.002 0.401 . . . . 0.0 110.185 -179.413 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 20.7 t . . . . . 0 C--O 1.22 -0.467 0 CA-C-O 117.603 -1.189 . . . . 0.0 111.417 179.091 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 77.6 m-85 . . . . . 0 N--CA 1.472 0.666 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' H' H ' 5' ' ' ARG . . . . . . . . . . . . . 72.3 mtp180 -144.6 141.86 29.73 Favored 'General case' 0 N--CA 1.48 1.062 0 N-CA-C 109.13 -0.693 . . . . 0.0 109.13 -179.859 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 77.1 m80 -149.84 118.3 6.49 Favored 'General case' 0 N--CA 1.476 0.831 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 179.096 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 11.9 m-20 -67.54 144.89 55.4 Favored 'General case' 0 N--CA 1.468 0.453 0 O-C-N 123.426 0.453 . . . . 0.0 111.931 -179.29 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' H' H ' 8' ' ' SER . . . . . . . . . . . . . 7.5 t -163.74 172.36 14.29 Favored 'General case' 0 N--CA 1.47 0.532 0 N-CA-C 109.174 -0.676 . . . . 0.0 109.174 178.261 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 123.52 23.36 2.13 Favored Glycine 0 N--CA 1.482 1.714 0 N-CA-C 111.817 -0.513 . . . . 0.0 111.817 179.084 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 40.5 p90 -56.17 127.82 32.56 Favored 'General case' 0 N--CA 1.473 0.714 0 N-CA-C 112.575 0.583 . . . . 0.0 112.575 -178.82 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 46.2 mt-10 -83.53 154.23 23.96 Favored 'General case' 0 N--CA 1.473 0.708 0 N-CA-C 109.597 -0.52 . . . . 0.0 109.597 178.297 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -155.85 127.99 1.02 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.943 0 N-CA-C 108.07 -1.085 . . . . 0.0 108.07 178.8 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 51.4 m-70 -133.54 144.33 49.28 Favored 'General case' 0 N--CA 1.476 0.825 0 CA-C-N 115.274 -0.875 . . . . 0.0 110.81 -178.214 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 6.2 t60 -164.96 98.5 0.75 Allowed 'General case' 0 N--CA 1.483 1.197 0 CA-C-N 116.709 -0.223 . . . . 0.0 110.85 179.034 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' H' H ' 15' ' ' GLN . . . . . 0.62 ' NE2' ' H ' ' H' ' 37' ' ' GLY . 76.0 mt-30 -102.8 -172.8 2.18 Favored 'General case' 0 CA--C 1.505 -0.77 0 N-CA-C 108.26 -1.015 . . . . 0.0 108.26 179.642 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -167.11 98.24 0.52 Allowed 'General case' 0 CA--C 1.539 0.524 0 CA-C-N 114.997 -1.001 . . . . 0.0 109.251 178.719 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' H' H ' 17' ' ' LEU . . . . . 0.56 HD12 ' N ' ' H' ' 17' ' ' LEU . 5.4 mp -106.17 160.84 15.02 Favored 'General case' 0 N--CA 1.485 1.279 0 N-CA-C 109.103 -0.702 . . . . 0.0 109.103 -179.823 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 40.4 t -143.52 117.77 3.81 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.089 0 C-N-CA 122.547 0.339 . . . . 0.0 110.25 178.744 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 50.2 m-85 -69.75 151.29 45.97 Favored 'General case' 0 C--N 1.369 1.426 0 N-CA-C 107.527 -1.286 . . . . 0.0 107.527 176.33 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 13.1 t80 -172.25 -55.58 0.02 OUTLIER 'General case' 0 N--CA 1.483 1.177 0 N-CA-C 110.069 -0.345 . . . . 0.0 110.069 180.0 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.96 90.71 0.0 OUTLIER 'General case' 0 CA--C 1.535 0.367 0 C-N-CA 123.517 0.727 . . . . 0.0 112.097 179.924 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 53.7 tt0 -62.61 155.83 24.99 Favored 'General case' 0 N--CA 1.469 0.512 0 CA-C-N 114.849 -1.069 . . . . 0.0 109.919 179.115 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 17.9 m-20 -136.55 134.86 37.93 Favored 'General case' 0 N--CA 1.48 1.025 0 C-N-CA 122.835 0.454 . . . . 0.0 109.917 -179.957 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' H' H ' 24' ' ' VAL . . . . . . . . . . . . . 19.6 t -85.85 -116.13 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.846 0 N-CA-C 108.358 -0.979 . . . . 0.0 108.358 179.364 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . -106.91 52.89 0.64 Allowed Glycine 0 N--CA 1.478 1.483 0 N-CA-C 111.099 -0.8 . . . . 0.0 111.099 -179.969 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 89.0 p -77.45 126.16 30.47 Favored 'General case' 0 N--CA 1.467 0.383 0 N-CA-C 109.006 -0.738 . . . . 0.0 109.006 178.304 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 1.9 t-20 -67.06 100.49 0.76 Allowed 'General case' 0 N--CA 1.469 0.5 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 178.667 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 67.3 mttm -94.39 127.12 40.07 Favored 'General case' 0 N--CA 1.481 1.084 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 -179.598 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.11 -128.54 0.01 OUTLIER Glycine 0 CA--C 1.527 0.783 0 N-CA-C 110.643 -0.983 . . . . 0.0 110.643 179.385 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.97 126.04 34.99 Favored 'General case' 0 N--CA 1.471 0.582 0 C-N-CA 122.853 0.461 . . . . 0.0 111.033 -179.251 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 35.8 mt -90.66 161.81 2.55 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.845 0 N-CA-C 107.014 -1.476 . . . . 0.0 107.014 178.228 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 40.4 mt -138.73 95.93 1.01 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.435 0 CA-C-N 119.511 1.051 . . . . 0.0 109.981 178.38 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 53.58 104.32 0.01 OUTLIER Glycine 0 CA--C 1.53 1.029 0 CA-C-N 116.101 -0.5 . . . . 0.0 114.144 176.832 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 92.1 mt -71.67 154.76 41.16 Favored 'General case' 0 N--CA 1.47 0.57 0 N-CA-C 107.673 -1.232 . . . . 0.0 107.673 176.716 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 2.6 ttp -143.09 140.09 30.74 Favored 'General case' 0 N--CA 1.477 0.889 0 N-CA-C 108.503 -0.925 . . . . 0.0 108.503 178.802 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 69.1 t -159.96 149.34 6.38 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.278 0 N-CA-C 106.525 -1.657 . . . . 0.0 106.525 -179.388 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' H' H ' 37' ' ' GLY . . . . . 0.62 ' H ' ' NE2' ' H' ' 15' ' ' GLN . . . 55.28 74.91 0.27 Allowed Glycine 0 C--N 1.314 -0.643 0 C-N-CA 120.989 -0.624 . . . . 0.0 112.155 177.489 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 173.97 -146.32 8.66 Favored Glycine 0 C--O 1.221 -0.675 0 N-CA-C 110.631 -0.988 . . . . 0.0 110.631 179.393 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 32.7 m -136.68 145.87 29.55 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.87 0 CA-C-N 116.98 0.39 . . . . 0.0 110.327 -179.423 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 21.1 t . . . . . 0 C--O 1.221 -0.4 0 CA-C-O 117.64 -1.171 . . . . 0.0 111.326 179.163 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 77.1 m-85 . . . . . 0 N--CA 1.473 0.704 0 N-CA-C 109.553 -0.536 . . . . 0.0 109.553 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' I' I ' 5' ' ' ARG . . . . . . . . . . . . . 72.3 mtp180 -144.78 141.9 29.56 Favored 'General case' 0 N--CA 1.481 1.094 0 N-CA-C 109.056 -0.72 . . . . 0.0 109.056 -179.834 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 77.1 m80 -149.83 118.34 6.51 Favored 'General case' 0 N--CA 1.476 0.838 0 N-CA-C 109.083 -0.71 . . . . 0.0 109.083 179.093 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 12.0 m-20 -67.62 144.76 55.39 Favored 'General case' 0 CA--C 1.535 0.396 0 CA-C-O 120.979 0.419 . . . . 0.0 111.927 -179.268 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' I' I ' 8' ' ' SER . . . . . . . . . . . . . 7.6 t -163.54 172.31 14.59 Favored 'General case' 0 N--CA 1.469 0.5 0 N-CA-C 109.152 -0.684 . . . . 0.0 109.152 178.276 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 123.7 23.26 2.1 Favored Glycine 0 N--CA 1.483 1.789 0 N-CA-C 111.747 -0.541 . . . . 0.0 111.747 179.027 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 40.3 p90 -56.08 127.82 32.43 Favored 'General case' 0 N--CA 1.474 0.75 0 N-CA-C 112.501 0.556 . . . . 0.0 112.501 -178.792 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 46.2 mt-10 -83.61 154.17 23.89 Favored 'General case' 0 N--CA 1.474 0.73 0 N-CA-C 109.644 -0.502 . . . . 0.0 109.644 178.203 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -155.74 128.01 1.03 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.927 0 N-CA-C 108.125 -1.065 . . . . 0.0 108.125 178.854 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 50.9 m-70 -133.58 144.33 49.24 Favored 'General case' 0 N--CA 1.476 0.832 0 CA-C-N 115.33 -0.85 . . . . 0.0 110.861 -178.236 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 6.2 t60 -165.05 98.61 0.74 Allowed 'General case' 0 N--CA 1.485 1.297 0 CA-C-N 116.687 -0.233 . . . . 0.0 110.914 179.131 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' I' I ' 15' ' ' GLN . . . . . 0.632 ' NE2' ' H ' ' I' ' 37' ' ' GLY . 76.0 mt-30 -103.11 -172.55 2.13 Favored 'General case' 0 CA--C 1.503 -0.852 0 N-CA-C 108.328 -0.99 . . . . 0.0 108.328 179.598 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -167.26 98.23 0.51 Allowed 'General case' 0 CA--C 1.538 0.517 0 CA-C-N 114.977 -1.011 . . . . 0.0 109.279 178.82 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' I' I ' 17' ' ' LEU . . . . . 0.553 HD12 ' N ' ' I' ' 17' ' ' LEU . 5.4 mp -106.18 160.77 15.08 Favored 'General case' 0 N--CA 1.484 1.259 0 N-CA-C 109.089 -0.708 . . . . 0.0 109.089 -179.854 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 40.5 t -143.4 117.83 3.95 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.016 0 C-N-CA 122.542 0.337 . . . . 0.0 110.306 178.753 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 49.7 m-85 -69.83 151.3 45.88 Favored 'General case' 0 C--N 1.369 1.431 0 N-CA-C 107.486 -1.302 . . . . 0.0 107.486 176.423 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 13.2 t80 -172.25 -55.55 0.02 OUTLIER 'General case' 0 N--CA 1.481 1.093 0 N-CA-C 110.065 -0.346 . . . . 0.0 110.065 -179.999 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.98 90.8 0.0 OUTLIER 'General case' 0 CA--C 1.535 0.387 0 C-N-CA 123.496 0.718 . . . . 0.0 112.046 179.877 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 53.7 tt0 -62.69 155.96 24.91 Favored 'General case' 0 N--CA 1.469 0.5 0 CA-C-N 114.862 -1.063 . . . . 0.0 109.866 179.141 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 17.9 m-20 -136.69 134.85 37.66 Favored 'General case' 0 N--CA 1.479 0.987 0 C-N-CA 122.804 0.442 . . . . 0.0 109.867 -179.954 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' I' I ' 24' ' ' VAL . . . . . . . . . . . . . 19.4 t -85.76 -116.09 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.878 0 N-CA-C 108.337 -0.986 . . . . 0.0 108.337 179.39 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . -106.98 52.9 0.64 Allowed Glycine 0 N--CA 1.477 1.402 0 N-CA-C 111.225 -0.75 . . . . 0.0 111.225 179.991 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 89.3 p -77.46 126.2 30.53 Favored 'General case' 0 N--CA 1.466 0.372 0 N-CA-C 109.066 -0.716 . . . . 0.0 109.066 178.313 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 1.9 t-20 -67.03 100.4 0.74 Allowed 'General case' 0 N--CA 1.47 0.538 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 178.623 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 67.4 mttm -94.27 127.03 39.88 Favored 'General case' 0 N--CA 1.481 1.111 0 N-CA-C 109.452 -0.573 . . . . 0.0 109.452 -179.659 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.97 -128.78 0.01 OUTLIER Glycine 0 CA--C 1.527 0.831 0 N-CA-C 110.695 -0.962 . . . . 0.0 110.695 179.339 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.69 125.74 34.72 Favored 'General case' 0 N--CA 1.471 0.612 0 C-N-CA 122.957 0.503 . . . . 0.0 111.057 -179.299 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 36.2 mt -90.56 161.85 2.55 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.781 0 N-CA-C 106.933 -1.506 . . . . 0.0 106.933 178.201 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 40.4 mt -138.85 95.79 0.98 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 CA-C-N 119.485 1.039 . . . . 0.0 109.99 178.475 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 53.7 104.23 0.01 OUTLIER Glycine 0 CA--C 1.531 1.039 0 CA-C-N 116.103 -0.499 . . . . 0.0 114.093 176.818 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 91.9 mt -71.56 154.63 41.32 Favored 'General case' 0 N--CA 1.471 0.576 0 N-CA-C 107.683 -1.228 . . . . 0.0 107.683 176.687 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 2.6 ttp -143.03 140.03 30.8 Favored 'General case' 0 N--CA 1.475 0.815 0 N-CA-C 108.497 -0.927 . . . . 0.0 108.497 178.871 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 68.6 t -159.95 149.37 6.39 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.228 0 N-CA-C 106.567 -1.642 . . . . 0.0 106.567 -179.371 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' I' I ' 37' ' ' GLY . . . . . 0.632 ' H ' ' NE2' ' I' ' 15' ' ' GLN . . . 55.2 74.99 0.26 Allowed Glycine 0 N--CA 1.465 0.617 0 C-N-CA 120.942 -0.647 . . . . 0.0 112.152 177.517 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 173.95 -146.24 8.63 Favored Glycine 0 N--CA 1.465 0.633 0 N-CA-C 110.662 -0.975 . . . . 0.0 110.662 179.354 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 32.8 m -136.73 145.91 29.43 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.93 0 CA-C-N 117.013 0.406 . . . . 0.0 110.172 -179.369 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 20.9 t . . . . . 0 C--O 1.221 -0.42 0 CA-C-O 117.648 -1.168 . . . . 0.0 111.381 179.145 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 76.5 m-85 . . . . . 0 N--CA 1.475 0.791 0 N-CA-C 109.98 -0.378 . . . . 0.0 109.98 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 73.7 mtp180 -143.71 141.31 30.45 Favored 'General case' 0 N--CA 1.482 1.152 0 N-CA-C 109.045 -0.724 . . . . 0.0 109.045 -179.968 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 76.7 m80 -149.77 119.53 7.05 Favored 'General case' 0 N--CA 1.47 0.548 0 N-CA-C 108.781 -0.822 . . . . 0.0 108.781 179.137 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 -67.84 149.56 49.7 Favored 'General case' 0 N--CA 1.463 0.187 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.179 -179.62 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 7.0 t -167.22 171.28 10.94 Favored 'General case' 0 N--CA 1.473 0.698 0 N-CA-C 109.46 -0.57 . . . . 0.0 109.46 178.496 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.21 24.07 2.29 Favored Glycine 0 N--CA 1.487 2.065 0 N-CA-C 112.125 -0.39 . . . . 0.0 112.125 179.375 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 41.9 p90 -56.78 128.01 34.45 Favored 'General case' 0 N--CA 1.471 0.623 0 N-CA-C 112.106 0.41 . . . . 0.0 112.106 -179.889 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . 0.45 ' CD ' HD21 ' C' ' 27' ' ' ASN . 46.1 mt-10 -84.86 156.09 21.44 Favored 'General case' 0 N--CA 1.468 0.443 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 178.544 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -154.86 124.48 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 N-CA-C 108.119 -1.067 . . . . 0.0 108.119 178.534 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 35.1 m80 -107.33 161.12 15.09 Favored 'General case' 0 N--CA 1.491 1.624 0 CA-C-N 118.455 0.57 . . . . 0.0 111.213 -178.767 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 57.1 t60 -164.66 99.14 0.79 Allowed 'General case' 0 N--CA 1.485 1.289 0 CA-C-N 116.766 -0.197 . . . . 0.0 111.06 179.63 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . 0.694 HE22 ' H ' ' A' ' 37' ' ' GLY . 68.3 mt-30 -125.67 -175.15 3.26 Favored 'General case' 0 CA--C 1.491 -1.301 0 N-CA-C 107.862 -1.162 . . . . 0.0 107.862 -179.99 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -169.7 103.28 0.33 Allowed 'General case' 0 CA--C 1.542 0.644 0 CA-C-N 115.011 -0.995 . . . . 0.0 109.395 179.026 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 9.3 mp -110.75 151.35 27.88 Favored 'General case' 0 N--CA 1.489 1.515 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 -179.932 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 61.6 t -143.98 119.06 4.0 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.245 0 CA-C-O 118.69 -0.671 . . . . 0.0 109.543 179.084 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 17.3 m-85 -70.19 157.2 38.08 Favored 'General case' 0 N--CA 1.477 0.923 0 N-CA-C 107.727 -1.212 . . . . 0.0 107.727 177.542 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 14.6 t80 -170.99 -60.0 0.02 OUTLIER 'General case' 0 N--CA 1.482 1.156 0 CA-C-O 122.315 1.055 . . . . 0.0 109.482 179.278 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.0 89.64 0.0 OUTLIER 'General case' 0 N--CA 1.456 -0.152 0 CA-C-N 113.891 -1.504 . . . . 0.0 112.875 -177.973 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 43.4 mt-10 -61.42 158.22 15.14 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 115.166 -0.924 . . . . 0.0 110.782 179.037 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 12.0 m-20 -139.98 135.26 32.55 Favored 'General case' 0 N--CA 1.483 1.21 0 C-N-CA 122.769 0.427 . . . . 0.0 110.399 -179.956 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 18.1 t -84.34 -115.98 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.475 0.802 0 N-CA-C 108.35 -0.981 . . . . 0.0 108.35 179.355 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -109.32 54.25 0.55 Allowed Glycine 0 N--CA 1.473 1.112 0 N-CA-C 111.254 -0.738 . . . . 0.0 111.254 -179.986 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 82.8 p -77.49 126.96 31.72 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 109.0 -0.741 . . . . 0.0 109.0 178.469 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . 0.462 HD21 ' CD ' ' B' ' 11' ' ' GLU . 47.5 t30 -66.7 100.92 0.74 Allowed 'General case' 0 N--CA 1.471 0.599 0 N-CA-C 108.611 -0.885 . . . . 0.0 108.611 178.593 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 67.2 mttm -95.3 128.88 42.51 Favored 'General case' 0 N--CA 1.481 1.089 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 -179.155 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.71 -132.12 0.01 OUTLIER Glycine 0 CA--C 1.533 1.203 0 N-CA-C 110.775 -0.93 . . . . 0.0 110.775 178.907 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.77 126.91 37.6 Favored 'General case' 0 N--CA 1.484 1.237 0 CA-C-N 117.097 0.448 . . . . 0.0 110.016 179.345 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 33.0 mt -91.31 159.17 2.83 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.496 0 N-CA-C 106.631 -1.618 . . . . 0.0 106.631 178.416 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 42.9 mt -138.25 92.86 0.83 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.468 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 -178.972 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 54.05 106.23 0.01 OUTLIER Glycine 0 CA--C 1.53 1.002 0 CA-C-N 115.933 -0.576 . . . . 0.0 114.162 177.239 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 97.9 mt -72.26 153.5 41.52 Favored 'General case' 0 CA--C 1.539 0.536 0 N-CA-C 107.27 -1.382 . . . . 0.0 107.27 176.703 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 27.2 ttt -147.07 138.34 24.01 Favored 'General case' 0 N--CA 1.477 0.879 0 N-CA-C 108.761 -0.829 . . . . 0.0 108.761 179.147 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 61.9 t -159.69 153.51 5.02 Favored 'Isoleucine or valine' 0 C--N 1.342 0.262 0 N-CA-C 106.596 -1.631 . . . . 0.0 106.596 -179.279 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . 0.694 ' H ' HE22 ' A' ' 15' ' ' GLN . . . 55.98 73.56 0.42 Allowed Glycine 0 C--N 1.313 -0.697 0 N-CA-C 111.663 -0.575 . . . . 0.0 111.663 177.987 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 174.65 -161.58 31.34 Favored Glycine 0 C--N 1.335 0.483 0 N-CA-C 111.086 -0.806 . . . . 0.0 111.086 -179.828 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 23.5 m -124.29 139.63 50.04 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.951 0 C-N-CA 122.762 0.425 . . . . 0.0 110.084 179.744 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 26.1 t . . . . . 0 C--O 1.221 -0.447 0 CA-C-O 117.635 -1.174 . . . . 0.0 111.108 179.37 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 77.0 m-85 . . . . . 0 N--CA 1.474 0.76 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 73.5 mtp180 -143.69 141.32 30.47 Favored 'General case' 0 N--CA 1.48 1.055 0 N-CA-C 109.092 -0.707 . . . . 0.0 109.092 -179.972 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 76.7 m80 -149.83 119.49 7.01 Favored 'General case' 0 N--CA 1.472 0.627 0 N-CA-C 108.93 -0.767 . . . . 0.0 108.93 179.104 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 7' ' ' ASP . . . . . . . . . . . . . 9.6 m-20 -67.77 149.4 49.97 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.196 -179.609 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 8' ' ' SER . . . . . . . . . . . . . 7.0 t -167.15 171.4 10.93 Favored 'General case' 0 N--CA 1.473 0.676 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 178.451 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.11 24.06 2.32 Favored Glycine 0 N--CA 1.487 2.072 0 N-CA-C 112.05 -0.42 . . . . 0.0 112.05 179.38 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 41.4 p90 -56.75 128.15 35.11 Favored 'General case' 0 N--CA 1.472 0.669 0 N-CA-C 112.071 0.397 . . . . 0.0 112.071 -179.834 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 11' ' ' GLU . . . . . 0.462 ' CD ' HD21 ' A' ' 27' ' ' ASN . 45.7 mt-10 -84.99 155.63 21.49 Favored 'General case' 0 N--CA 1.47 0.557 0 N-CA-C 109.268 -0.642 . . . . 0.0 109.268 178.589 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -154.47 124.35 0.78 Allowed 'Isoleucine or valine' 0 C--O 1.234 0.249 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 178.538 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 34.2 m80 -107.27 161.2 15.0 Favored 'General case' 0 N--CA 1.491 1.585 0 CA-C-N 118.41 0.55 . . . . 0.0 111.155 -178.774 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 58.2 t60 -164.72 98.87 0.78 Allowed 'General case' 0 N--CA 1.485 1.301 0 CA-C-O 119.64 -0.219 . . . . 0.0 111.001 179.636 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . 0.717 HE22 ' H ' ' B' ' 37' ' ' GLY . 68.3 mt-30 -125.19 -175.48 3.32 Favored 'General case' 0 CA--C 1.492 -1.275 0 N-CA-C 107.832 -1.173 . . . . 0.0 107.832 179.995 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -169.62 103.13 0.33 Allowed 'General case' 0 CA--C 1.541 0.6 0 CA-C-N 114.944 -1.025 . . . . 0.0 109.334 179.023 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 9.4 mp -110.67 151.23 27.94 Favored 'General case' 0 N--CA 1.489 1.507 0 N-CA-C 108.695 -0.854 . . . . 0.0 108.695 -179.951 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 61.9 t -143.92 118.77 3.91 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.139 0 CA-C-O 118.748 -0.644 . . . . 0.0 109.561 179.07 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 16.6 m-85 -70.45 157.17 38.31 Favored 'General case' 0 N--CA 1.475 0.798 0 N-CA-C 107.638 -1.245 . . . . 0.0 107.638 177.413 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 15.8 t80 -171.66 -59.06 0.02 OUTLIER 'General case' 0 N--CA 1.479 1.007 0 CA-C-O 122.261 1.029 . . . . 0.0 109.619 179.23 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.21 89.88 0.0 OUTLIER 'General case' 0 C--O 1.231 0.112 0 CA-C-N 114.051 -1.431 . . . . 0.0 112.764 -178.108 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 43.8 mt-10 -61.53 158.38 15.13 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 115.276 -0.875 . . . . 0.0 110.828 179.095 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 12.2 m-20 -140.25 135.6 32.48 Favored 'General case' 0 N--CA 1.483 1.196 0 C-N-CA 122.793 0.437 . . . . 0.0 110.416 179.955 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 18.1 t -84.97 -116.1 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.906 0 N-CA-C 108.408 -0.96 . . . . 0.0 108.408 179.499 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -108.45 53.65 0.59 Allowed Glycine 0 N--CA 1.476 1.366 0 N-CA-C 111.083 -0.807 . . . . 0.0 111.083 -179.909 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 86.0 p -77.35 126.58 31.15 Favored 'General case' 0 C--N 1.329 -0.294 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 178.409 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 27' ' ' ASN . . . . . 0.459 HD21 ' CD ' ' C' ' 11' ' ' GLU . 47.5 t30 -66.74 100.98 0.75 Allowed 'General case' 0 N--CA 1.471 0.608 0 N-CA-C 108.593 -0.892 . . . . 0.0 108.593 178.672 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 67.1 mttm -95.3 128.91 42.52 Favored 'General case' 0 N--CA 1.481 1.121 0 N-CA-C 109.972 -0.381 . . . . 0.0 109.972 -179.226 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.77 -131.63 0.01 OUTLIER Glycine 0 CA--C 1.535 1.33 0 N-CA-C 110.746 -0.942 . . . . 0.0 110.746 178.904 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -131.18 127.12 37.31 Favored 'General case' 0 N--CA 1.485 1.304 0 C-N-CA 122.704 0.402 . . . . 0.0 110.081 179.431 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 32.8 mt -91.75 158.79 2.86 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.538 0 N-CA-C 106.602 -1.629 . . . . 0.0 106.602 178.516 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 43.1 mt -137.81 92.89 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.502 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 -178.816 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 53.85 106.17 0.01 OUTLIER Glycine 0 CA--C 1.53 0.993 0 CA-C-N 116.021 -0.536 . . . . 0.0 114.212 177.237 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 97.7 mt -72.12 153.4 41.69 Favored 'General case' 0 CA--C 1.539 0.53 0 N-CA-C 107.364 -1.346 . . . . 0.0 107.364 176.651 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 27.1 ttt -146.82 138.05 24.16 Favored 'General case' 0 N--CA 1.478 0.954 0 N-CA-C 108.701 -0.851 . . . . 0.0 108.701 179.21 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 62.3 t -159.54 153.47 5.14 Favored 'Isoleucine or valine' 0 C--N 1.344 0.356 0 N-CA-C 106.52 -1.659 . . . . 0.0 106.52 -179.273 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . 0.717 ' H ' HE22 ' B' ' 15' ' ' GLN . . . 56.03 73.23 0.45 Allowed Glycine 0 C--N 1.313 -0.696 0 N-CA-C 111.686 -0.566 . . . . 0.0 111.686 178.005 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 174.98 -161.5 30.92 Favored Glycine 0 C--N 1.334 0.43 0 N-CA-C 111.056 -0.818 . . . . 0.0 111.056 -179.865 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 24.1 m -124.4 139.6 50.21 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.929 0 C-N-CA 122.751 0.421 . . . . 0.0 110.072 179.695 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 26.5 t . . . . . 0 C--O 1.219 -0.52 0 CA-C-O 117.651 -1.166 . . . . 0.0 111.054 179.381 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 77.1 m-85 . . . . . 0 N--CA 1.474 0.75 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 73.7 mtp180 -143.72 141.24 30.4 Favored 'General case' 0 N--CA 1.482 1.141 0 N-CA-C 109.005 -0.739 . . . . 0.0 109.005 -179.858 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 76.8 m80 -149.9 119.39 6.92 Favored 'General case' 0 N--CA 1.471 0.594 0 N-CA-C 108.798 -0.816 . . . . 0.0 108.798 179.159 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' C' C ' 7' ' ' ASP . . . . . . . . . . . . . 9.0 m-20 -67.71 149.29 50.17 Favored 'General case' 0 N--CA 1.463 0.218 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.244 -179.562 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' C' C ' 8' ' ' SER . . . . . . . . . . . . . 6.7 t -167.12 171.15 11.21 Favored 'General case' 0 N--CA 1.472 0.652 0 N-CA-C 109.502 -0.555 . . . . 0.0 109.502 178.424 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.49 23.92 2.26 Favored Glycine 0 N--CA 1.487 2.034 0 N-CA-C 111.968 -0.453 . . . . 0.0 111.968 179.38 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 41.5 p90 -56.61 128.16 34.93 Favored 'General case' 0 N--CA 1.471 0.614 0 N-CA-C 112.07 0.396 . . . . 0.0 112.07 -179.85 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' C' C ' 11' ' ' GLU . . . . . 0.459 ' CD ' HD21 ' B' ' 27' ' ' ASN . 45.9 mt-10 -85.02 155.97 21.32 Favored 'General case' 0 N--CA 1.47 0.535 0 N-CA-C 109.24 -0.652 . . . . 0.0 109.24 178.592 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -154.76 124.54 0.76 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 N-CA-C 108.168 -1.049 . . . . 0.0 108.168 178.525 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 33.9 m80 -107.39 161.23 15.0 Favored 'General case' 0 N--CA 1.49 1.573 0 CA-C-N 118.397 0.544 . . . . 0.0 111.181 -178.717 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 57.3 t60 -164.83 99.22 0.77 Allowed 'General case' 0 N--CA 1.485 1.286 0 CA-C-N 116.77 -0.196 . . . . 0.0 111.094 179.651 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' C' C ' 15' ' ' GLN . . . . . 0.717 HE22 ' H ' ' C' ' 37' ' ' GLY . 68.1 mt-30 -125.79 -175.34 3.32 Favored 'General case' 0 CA--C 1.489 -1.373 0 N-CA-C 107.904 -1.147 . . . . 0.0 107.904 -179.957 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -169.64 103.19 0.33 Allowed 'General case' 0 CA--C 1.541 0.624 0 CA-C-N 114.888 -1.051 . . . . 0.0 109.331 179.062 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 9.4 mp -110.67 150.92 28.32 Favored 'General case' 0 N--CA 1.488 1.441 0 N-CA-C 108.712 -0.848 . . . . 0.0 108.712 179.968 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 61.1 t -143.66 118.97 4.29 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.175 0 CA-C-O 118.765 -0.636 . . . . 0.0 109.61 179.029 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 16.6 m-85 -70.49 157.28 38.14 Favored 'General case' 0 N--CA 1.475 0.802 0 N-CA-C 107.664 -1.236 . . . . 0.0 107.664 177.436 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 15.4 t80 -171.59 -59.31 0.02 OUTLIER 'General case' 0 N--CA 1.478 0.953 0 CA-C-O 122.259 1.028 . . . . 0.0 109.642 179.195 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.12 89.96 0.0 OUTLIER 'General case' 0 C--O 1.231 0.11 0 CA-C-N 114.041 -1.436 . . . . 0.0 112.753 -178.076 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 43.9 mt-10 -61.6 158.23 15.68 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.219 -0.9 . . . . 0.0 110.833 179.047 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 12.3 m-20 -139.92 135.9 33.32 Favored 'General case' 0 N--CA 1.483 1.199 0 C-N-CA 122.861 0.464 . . . . 0.0 110.343 -179.977 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 18.2 t -85.27 -116.01 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.902 0 N-CA-C 108.414 -0.958 . . . . 0.0 108.414 179.444 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -108.58 53.42 0.6 Allowed Glycine 0 N--CA 1.475 1.257 0 N-CA-C 111.107 -0.797 . . . . 0.0 111.107 -179.918 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 85.9 p -77.3 126.73 31.4 Favored 'General case' 0 C--N 1.329 -0.32 0 N-CA-C 109.122 -0.695 . . . . 0.0 109.122 178.508 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' C' C ' 27' ' ' ASN . . . . . 0.45 HD21 ' CD ' ' A' ' 11' ' ' GLU . 47.3 t30 -66.79 101.11 0.77 Allowed 'General case' 0 N--CA 1.471 0.582 0 N-CA-C 108.633 -0.877 . . . . 0.0 108.633 178.625 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 67.1 mttm -95.34 128.99 42.63 Favored 'General case' 0 N--CA 1.483 1.2 0 N-CA-C 109.886 -0.413 . . . . 0.0 109.886 -179.117 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.84 -131.85 0.01 OUTLIER Glycine 0 CA--C 1.535 1.293 0 N-CA-C 110.858 -0.897 . . . . 0.0 110.858 178.844 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.96 126.66 36.63 Favored 'General case' 0 N--CA 1.486 1.356 0 C-N-CA 122.822 0.449 . . . . 0.0 110.003 179.456 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 32.5 mt -91.33 158.81 2.86 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.525 0 N-CA-C 106.684 -1.599 . . . . 0.0 106.684 178.334 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 42.5 mt -137.99 92.89 0.86 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.505 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 -178.799 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 53.93 106.09 0.01 OUTLIER Glycine 0 CA--C 1.529 0.966 0 CA-C-N 115.921 -0.581 . . . . 0.0 114.257 177.229 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 97.6 mt -72.05 153.3 41.82 Favored 'General case' 0 CA--C 1.537 0.461 0 N-CA-C 107.328 -1.36 . . . . 0.0 107.328 176.655 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 27.3 ttt -146.63 138.09 24.42 Favored 'General case' 0 N--CA 1.477 0.891 0 N-CA-C 108.74 -0.837 . . . . 0.0 108.74 179.214 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 61.1 t -159.57 153.56 5.07 Favored 'Isoleucine or valine' 0 C--N 1.345 0.372 0 N-CA-C 106.566 -1.642 . . . . 0.0 106.566 -179.251 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' C' C ' 37' ' ' GLY . . . . . 0.717 ' H ' HE22 ' C' ' 15' ' ' GLN . . . 55.89 73.15 0.46 Allowed Glycine 0 C--N 1.314 -0.671 0 N-CA-C 111.626 -0.59 . . . . 0.0 111.626 177.951 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 175.03 -161.75 31.24 Favored Glycine 0 C--N 1.335 0.479 0 N-CA-C 111.054 -0.818 . . . . 0.0 111.054 -179.865 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 23.5 m -124.2 139.67 49.88 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.923 0 C-N-CA 122.785 0.434 . . . . 0.0 110.054 179.727 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 27.7 t . . . . . 0 C--O 1.221 -0.424 0 CA-C-O 117.655 -1.164 . . . . 0.0 110.98 179.336 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 85.9 m-85 . . . . . 0 N--CA 1.473 0.705 0 N-CA-C 108.113 -1.069 . . . . 0.0 108.113 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' D' D ' 5' ' ' ARG . . . . . . . . . . . . . 73.9 mtp180 -147.52 141.05 25.45 Favored 'General case' 0 N--CA 1.473 0.7 0 N-CA-C 108.967 -0.753 . . . . 0.0 108.967 179.637 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 77.0 m80 -149.2 123.55 9.62 Favored 'General case' 0 CA--C 1.539 0.519 0 N-CA-C 107.926 -1.138 . . . . 0.0 107.926 175.967 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' D' D ' 7' ' ' ASP . . . . . . . . . . . . . 6.3 m-20 -63.42 133.41 53.94 Favored 'General case' 0 C--N 1.32 -0.688 0 C-N-CA 126.937 2.095 . . . . 0.0 114.798 176.152 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' D' D ' 8' ' ' SER . . . . . . . . . . . . . 5.9 t -154.04 173.52 15.91 Favored 'General case' 0 N--CA 1.477 0.925 0 CA-C-N 118.548 0.613 . . . . 0.0 110.443 176.799 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 124.23 20.38 2.47 Favored Glycine 0 N--CA 1.484 1.864 0 N-CA-C 111.99 -0.444 . . . . 0.0 111.99 176.203 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 37.2 p90 -55.67 130.32 42.67 Favored 'General case' 0 CA--C 1.545 0.753 0 CA-C-O 121.103 0.478 . . . . 0.0 111.914 -177.388 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' D' D ' 11' ' ' GLU . . . . . 0.487 ' CG ' HD21 ' F' ' 27' ' ' ASN . 46.0 mt-10 -84.87 153.77 22.69 Favored 'General case' 0 N--CA 1.472 0.64 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 177.886 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.0 p -150.91 129.01 2.57 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.594 0 N-CA-C 106.937 -1.505 . . . . 0.0 106.937 172.73 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 24.6 m80 -100.86 161.98 13.22 Favored 'General case' 0 N--CA 1.481 1.116 0 C-N-CA 123.911 0.884 . . . . 0.0 113.168 176.722 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 61.0 t60 -165.0 105.27 0.79 Allowed 'General case' 0 N--CA 1.486 1.354 0 N-CA-C 109.694 -0.484 . . . . 0.0 109.694 172.242 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' D' D ' 15' ' ' GLN . . . . . 0.716 HE22 ' H ' ' D' ' 37' ' ' GLY . 69.1 mt-30 -128.59 -176.33 3.8 Favored 'General case' 0 CA--C 1.485 -1.534 0 N-CA-C 107.255 -1.387 . . . . 0.0 107.255 178.892 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 88.8 tttt -166.87 109.51 0.7 Allowed 'General case' 0 C--O 1.238 0.487 0 N-CA-C 107.926 -1.139 . . . . 0.0 107.926 176.779 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 10.5 mp -115.69 153.16 31.85 Favored 'General case' 0 N--CA 1.489 1.502 0 N-CA-C 107.198 -1.408 . . . . 0.0 107.198 178.205 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 52.5 t -141.95 124.03 13.61 Favored 'Isoleucine or valine' 0 C--N 1.362 1.152 0 N-CA-C 108.668 -0.864 . . . . 0.0 108.668 174.283 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 16.0 m-85 -62.62 150.81 39.77 Favored 'General case' 0 C--N 1.348 0.513 0 C-N-CA 124.308 1.043 . . . . 0.0 110.719 169.695 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 11.3 t80 -170.51 -67.22 0.02 OUTLIER 'General case' 0 N--CA 1.475 0.788 0 N-CA-C 107.983 -1.117 . . . . 0.0 107.983 178.55 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -38.61 94.99 0.01 OUTLIER 'General case' 0 N--CA 1.451 -0.403 0 CA-C-N 113.855 -1.521 . . . . 0.0 111.586 -175.866 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 45.8 mt-10 -64.47 159.09 22.21 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 114.293 -1.321 . . . . 0.0 110.504 178.491 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 12.2 m-20 -139.87 139.47 36.27 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-O 121.253 0.549 . . . . 0.0 109.637 178.609 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' D' D ' 24' ' ' VAL . . . . . . . . . . . . . 19.4 t -88.17 -119.86 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.483 1.217 0 N-CA-C 107.597 -1.26 . . . . 0.0 107.597 179.58 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . -111.47 61.8 0.3 Allowed Glycine 0 C--N 1.368 2.359 0 C-N-CA 118.222 -1.942 . . . . 0.0 109.206 178.763 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 92.8 p -68.04 121.59 16.44 Favored 'General case' 0 C--O 1.24 0.595 0 CA-C-O 116.453 -1.737 . . . . 0.0 112.517 168.985 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' D' D ' 27' ' ' ASN . . . . . 0.444 HD21 ' CG ' ' E' ' 11' ' ' GLU . 53.8 t30 -62.52 101.79 0.27 Allowed 'General case' 0 N--CA 1.474 0.765 0 CA-C-N 121.603 2.001 . . . . 0.0 109.453 173.65 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 66.8 mttm -96.84 128.28 43.64 Favored 'General case' 0 N--CA 1.487 1.387 0 CA-C-N 118.842 0.746 . . . . 0.0 109.35 178.996 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -55.21 -134.81 0.0 OUTLIER Glycine 0 CA--C 1.532 1.135 0 C-N-CA 123.793 0.711 . . . . 0.0 112.343 174.925 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -129.42 130.96 46.62 Favored 'General case' 0 C--N 1.371 1.507 0 CA-C-N 115.022 -0.589 . . . . 0.0 110.121 176.231 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 38.8 mt -91.64 161.75 2.52 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.338 0 N-CA-C 106.148 -1.797 . . . . 0.0 106.148 177.499 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . 0.28 43.1 mt -141.01 105.06 1.57 Allowed 'Isoleucine or valine' 0 C--N 1.363 1.191 0 N-CA-C 106.231 -1.766 . . . . 0.0 106.231 172.511 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.6 98.11 0.01 OUTLIER Glycine 0 CA--C 1.533 1.21 0 CA-C-O 116.312 -2.382 . . . . 0.0 112.198 169.074 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 97.0 mt -70.0 157.61 37.17 Favored 'General case' 0 CA--C 1.539 0.55 0 CA-C-N 122.355 3.078 . . . . 0.0 107.217 176.055 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 26.1 ttt -147.18 148.92 32.02 Favored 'General case' 0 N--CA 1.482 1.161 0 N-CA-C 106.373 -1.714 . . . . 0.0 106.373 174.269 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 88.5 t -165.22 159.14 1.18 Allowed 'Isoleucine or valine' 0 C--O 1.248 1.004 0 N-CA-C 105.302 -2.11 . . . . 0.0 105.302 177.15 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' D' D ' 37' ' ' GLY . . . . . 0.716 ' H ' HE22 ' D' ' 15' ' ' GLN . . . 60.54 64.84 3.77 Favored Glycine 0 N--CA 1.442 -0.917 0 C-N-CA 117.24 -2.41 . . . . 0.0 113.756 174.581 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' D' D ' 38' ' ' GLY . . . . . 0.407 ' HA3' ' O ' ' G' ' 38' ' ' GLY . . . 169.8 -160.7 33.85 Favored Glycine 0 N--CA 1.47 0.956 0 CA-C-O 117.808 -1.551 . . . . 0.0 112.304 -178.987 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 23.2 m -120.37 139.31 48.06 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.256 0 CA-C-N 118.829 1.315 . . . . 0.0 110.348 -177.003 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 25.4 t . . . . . 0 C--O 1.203 -1.35 0 CA-C-N 118.211 0.46 . . . . 0.0 110.102 173.766 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 77.8 m-85 . . . . . 0 N--CA 1.475 0.812 0 N-CA-C 109.904 -0.406 . . . . 0.0 109.904 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' E' E ' 5' ' ' ARG . . . . . . . . . . . . . 74.1 mtp180 -143.55 141.72 30.81 Favored 'General case' 0 N--CA 1.476 0.837 0 N-CA-C 109.388 -0.597 . . . . 0.0 109.388 179.875 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 76.7 m80 -150.31 118.57 6.38 Favored 'General case' 0 N--CA 1.471 0.62 0 N-CA-C 108.994 -0.743 . . . . 0.0 108.994 179.215 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' E' E ' 7' ' ' ASP . . . . . . . . . . . . . 8.6 m-20 -66.82 149.48 50.51 Favored 'General case' 0 N--CA 1.464 0.24 0 O-C-N 123.388 0.43 . . . . 0.0 111.608 -179.552 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' E' E ' 8' ' ' SER . . . . . . . . . . . . . 6.0 t -167.63 171.72 9.98 Favored 'General case' 0 N--CA 1.477 0.878 0 CA-C-N 115.938 -0.574 . . . . 0.0 109.606 178.077 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 123.22 23.91 2.09 Favored Glycine 0 N--CA 1.482 1.754 0 N-CA-C 111.843 -0.503 . . . . 0.0 111.843 179.078 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 37.4 p90 -56.29 127.33 30.36 Favored 'General case' 0 N--CA 1.472 0.674 0 N-CA-C 112.621 0.6 . . . . 0.0 112.621 -179.283 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' E' E ' 11' ' ' GLU . . . . . 0.444 ' CG ' HD21 ' D' ' 27' ' ' ASN . 46.0 mt-10 -83.36 156.77 22.83 Favored 'General case' 0 N--CA 1.476 0.856 0 N-CA-C 109.489 -0.56 . . . . 0.0 109.489 177.973 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -156.54 122.89 0.54 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.646 0 N-CA-C 108.324 -0.991 . . . . 0.0 108.324 178.257 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 36.5 m80 -106.88 160.24 15.66 Favored 'General case' 0 N--CA 1.482 1.135 0 C-N-CA 122.855 0.462 . . . . 0.0 111.238 -177.944 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 58.1 t60 -164.61 99.18 0.79 Allowed 'General case' 0 N--CA 1.487 1.38 0 CA-C-N 116.859 -0.155 . . . . 0.0 111.013 -179.842 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' E' E ' 15' ' ' GLN . . . . . 0.695 HE22 ' H ' ' E' ' 37' ' ' GLY . 69.3 mt-30 -125.42 -175.06 3.22 Favored 'General case' 0 CA--C 1.492 -1.263 0 N-CA-C 107.835 -1.172 . . . . 0.0 107.835 -179.98 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -169.54 103.85 0.34 Allowed 'General case' 0 CA--C 1.54 0.591 0 CA-C-N 114.9 -1.045 . . . . 0.0 109.109 179.015 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 9.6 mp -111.03 150.16 29.7 Favored 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 -179.639 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 46.1 t -144.04 118.17 3.52 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.22 0 CA-C-O 118.928 -0.558 . . . . 0.0 109.903 178.646 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 19.7 m-85 -69.32 155.27 40.7 Favored 'General case' 0 C--N 1.357 0.908 0 N-CA-C 107.569 -1.271 . . . . 0.0 107.569 176.798 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 14.0 t80 -173.41 -56.94 0.02 OUTLIER 'General case' 0 N--CA 1.48 1.072 0 CA-C-O 121.624 0.726 . . . . 0.0 110.136 179.163 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -42.74 88.48 0.0 OUTLIER 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 114.425 -1.261 . . . . 0.0 112.76 -179.051 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 44.4 mt-10 -60.11 158.37 11.36 Favored 'General case' 0 N--CA 1.471 0.619 0 CA-C-N 115.039 -0.982 . . . . 0.0 110.944 179.535 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 11.7 m-20 -140.34 135.02 31.75 Favored 'General case' 0 N--CA 1.483 1.183 0 C-N-CA 122.653 0.381 . . . . 0.0 110.687 -179.829 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 21.4 t -84.55 -115.51 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.939 0 N-CA-C 108.61 -0.885 . . . . 0.0 108.61 179.416 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . -108.65 53.65 0.58 Allowed Glycine 0 C--N 1.347 1.139 0 N-CA-C 111.317 -0.713 . . . . 0.0 111.317 -179.91 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 86.1 p -77.15 126.37 30.84 Favored 'General case' 0 N--CA 1.471 0.577 0 N-CA-C 109.336 -0.616 . . . . 0.0 109.336 178.259 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' E' E ' 27' ' ' ASN . . . . . 0.465 HD21 ' CG ' ' F' ' 11' ' ' GLU . 49.2 t30 -66.22 100.64 0.63 Allowed 'General case' 0 N--CA 1.471 0.612 0 N-CA-C 108.079 -1.082 . . . . 0.0 108.079 178.442 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 66.5 mttm -95.39 127.67 41.62 Favored 'General case' 0 N--CA 1.483 1.182 0 N-CA-C 109.305 -0.628 . . . . 0.0 109.305 -179.15 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.36 -128.93 0.01 OUTLIER Glycine 0 CA--C 1.537 1.462 0 N-CA-C 111.013 -0.835 . . . . 0.0 111.013 179.163 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -131.67 127.1 36.24 Favored 'General case' 0 N--CA 1.484 1.236 0 CA-C-N 117.307 0.554 . . . . 0.0 110.939 -179.62 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 31.2 mt -91.09 160.4 2.71 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.238 0 N-CA-C 106.338 -1.727 . . . . 0.0 106.338 178.306 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 41.6 mt -139.29 93.69 0.78 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.766 0 N-CA-C 109.653 -0.499 . . . . 0.0 109.653 179.879 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 53.54 105.96 0.01 OUTLIER Glycine 0 CA--C 1.531 1.053 0 CA-C-N 116.11 -0.495 . . . . 0.0 114.157 177.603 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 97.7 mt -72.03 153.72 41.58 Favored 'General case' 0 CA--C 1.542 0.636 0 N-CA-C 107.206 -1.405 . . . . 0.0 107.206 176.523 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 27.6 ttt -146.41 140.23 26.16 Favored 'General case' 0 N--CA 1.485 1.285 0 N-CA-C 108.005 -1.109 . . . . 0.0 108.005 178.841 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 80.2 t -161.18 152.86 4.31 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.389 0 N-CA-C 106.358 -1.719 . . . . 0.0 106.358 -179.208 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' E' E ' 37' ' ' GLY . . . . . 0.695 ' H ' HE22 ' E' ' 15' ' ' GLN . . . 55.56 73.81 0.39 Allowed Glycine 0 C--N 1.316 -0.54 0 N-CA-C 111.633 -0.587 . . . . 0.0 111.633 178.199 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 175.91 -159.34 26.79 Favored Glycine 0 C--O 1.213 -1.166 0 N-CA-C 111.313 -0.715 . . . . 0.0 111.313 -179.708 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 23.7 m -127.16 138.81 53.71 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.83 0 N-CA-C 109.332 -0.618 . . . . 0.0 109.332 179.776 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 27.6 t . . . . . 0 CA--C 1.537 0.453 0 CA-C-O 117.986 -1.007 . . . . 0.0 111.106 179.739 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 77.7 m-85 . . . . . 0 N--CA 1.476 0.831 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' F' F ' 5' ' ' ARG . . . . . . . . . . . . . 74.2 mtp180 -143.54 141.39 30.68 Favored 'General case' 0 N--CA 1.479 1.023 0 N-CA-C 109.07 -0.715 . . . . 0.0 109.07 179.933 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 76.8 m80 -150.08 118.48 6.46 Favored 'General case' 0 N--CA 1.472 0.658 0 N-CA-C 108.957 -0.757 . . . . 0.0 108.957 179.139 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' F' F ' 7' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -66.97 149.79 50.14 Favored 'General case' 0 N--CA 1.463 0.21 0 O-C-N 123.434 0.459 . . . . 0.0 111.632 -179.366 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' F' F ' 8' ' ' SER . . . . . . . . . . . . . 6.1 t -167.73 172.27 9.37 Favored 'General case' 0 N--CA 1.476 0.869 0 CA-C-N 115.885 -0.598 . . . . 0.0 109.564 178.068 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.76 23.64 2.24 Favored Glycine 0 N--CA 1.483 1.789 0 N-CA-C 111.903 -0.479 . . . . 0.0 111.903 179.003 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 37.6 p90 -56.1 127.47 30.74 Favored 'General case' 0 N--CA 1.473 0.679 0 N-CA-C 112.615 0.598 . . . . 0.0 112.615 -179.296 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' F' F ' 11' ' ' GLU . . . . . 0.465 ' CG ' HD21 ' E' ' 27' ' ' ASN . 45.9 mt-10 -83.45 156.79 22.72 Favored 'General case' 0 N--CA 1.477 0.875 0 N-CA-C 109.514 -0.55 . . . . 0.0 109.514 177.994 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -156.45 122.75 0.54 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.696 0 N-CA-C 108.297 -1.001 . . . . 0.0 108.297 178.274 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 37.5 m80 -106.65 160.36 15.51 Favored 'General case' 0 N--CA 1.483 1.218 0 C-N-CA 122.8 0.44 . . . . 0.0 111.294 -177.997 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 58.7 t60 -164.86 99.65 0.77 Allowed 'General case' 0 N--CA 1.486 1.374 0 CA-C-N 116.865 -0.152 . . . . 0.0 111.131 -179.775 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' F' F ' 15' ' ' GLN . . . . . 0.703 HE22 ' H ' ' F' ' 37' ' ' GLY . 69.3 mt-30 -126.15 -174.68 3.16 Favored 'General case' 0 CA--C 1.488 -1.428 0 N-CA-C 108.02 -1.104 . . . . 0.0 108.02 -179.893 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -169.86 103.93 0.32 Allowed 'General case' 0 CA--C 1.541 0.61 0 CA-C-N 114.677 -1.147 . . . . 0.0 109.218 178.969 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 9.6 mp -110.93 149.92 29.96 Favored 'General case' 0 N--CA 1.489 1.518 0 N-CA-C 108.933 -0.766 . . . . 0.0 108.933 -179.704 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 46.3 t -143.85 118.32 3.77 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.223 0 CA-C-O 118.975 -0.536 . . . . 0.0 109.827 178.653 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 19.5 m-85 -69.4 155.15 40.92 Favored 'General case' 0 C--N 1.358 0.96 0 N-CA-C 107.506 -1.294 . . . . 0.0 107.506 176.721 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 14.9 t80 -173.13 -57.1 0.02 OUTLIER 'General case' 0 N--CA 1.483 1.198 0 CA-C-O 121.564 0.697 . . . . 0.0 109.613 179.245 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -42.52 88.47 0.0 OUTLIER 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 114.716 -1.129 . . . . 0.0 112.856 -179.015 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 44.1 mt-10 -60.28 158.2 12.1 Favored 'General case' 0 N--CA 1.472 0.643 0 CA-C-N 115.085 -0.961 . . . . 0.0 110.999 179.437 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 12.1 m-20 -140.2 134.97 31.9 Favored 'General case' 0 N--CA 1.482 1.132 0 C-N-CA 122.752 0.421 . . . . 0.0 110.784 -179.822 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' F' F ' 24' ' ' VAL . . . . . . . . . . . . . 21.3 t -84.51 -115.73 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.986 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 179.327 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -108.36 53.31 0.6 Allowed Glycine 0 N--CA 1.477 1.373 0 N-CA-C 111.154 -0.778 . . . . 0.0 111.154 -179.872 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 87.3 p -76.75 126.36 30.85 Favored 'General case' 0 N--CA 1.47 0.535 0 N-CA-C 109.313 -0.625 . . . . 0.0 109.313 178.141 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' F' F ' 27' ' ' ASN . . . . . 0.487 HD21 ' CG ' ' D' ' 11' ' ' GLU . 48.7 t30 -66.48 100.7 0.68 Allowed 'General case' 0 N--CA 1.471 0.609 0 N-CA-C 108.195 -1.039 . . . . 0.0 108.195 178.412 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 66.6 mttm -95.39 127.65 41.61 Favored 'General case' 0 N--CA 1.483 1.221 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 -179.082 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.53 -129.15 0.01 OUTLIER Glycine 0 CA--C 1.539 1.576 0 N-CA-C 111.139 -0.784 . . . . 0.0 111.139 179.161 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -131.17 126.67 36.23 Favored 'General case' 0 N--CA 1.488 1.451 0 CA-C-N 117.308 0.554 . . . . 0.0 111.058 -179.668 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 32.2 mt -90.95 160.14 2.74 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.237 0 N-CA-C 106.236 -1.764 . . . . 0.0 106.236 178.265 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 41.0 mt -139.09 93.65 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.763 0 N-CA-C 109.671 -0.492 . . . . 0.0 109.671 179.864 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 53.61 106.0 0.01 OUTLIER Glycine 0 CA--C 1.532 1.114 0 CA-C-N 116.099 -0.5 . . . . 0.0 114.121 177.607 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 97.8 mt -72.0 153.94 41.47 Favored 'General case' 0 CA--C 1.54 0.561 0 N-CA-C 107.295 -1.372 . . . . 0.0 107.295 176.589 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 27.5 ttt -146.75 140.21 25.7 Favored 'General case' 0 N--CA 1.481 1.087 0 N-CA-C 108.408 -0.96 . . . . 0.0 108.408 178.819 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 75.8 t -161.13 153.02 4.29 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.472 0 N-CA-C 106.452 -1.685 . . . . 0.0 106.452 -179.073 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' F' F ' 37' ' ' GLY . . . . . 0.703 ' H ' HE22 ' F' ' 15' ' ' GLN . . . 55.67 73.83 0.39 Allowed Glycine 0 C--N 1.316 -0.573 0 N-CA-C 111.543 -0.623 . . . . 0.0 111.543 178.049 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 175.5 -159.99 28.2 Favored Glycine 0 C--O 1.213 -1.195 0 N-CA-C 111.202 -0.759 . . . . 0.0 111.202 -179.723 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 23.3 m -126.36 139.01 52.89 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.824 0 N-CA-C 109.414 -0.588 . . . . 0.0 109.414 179.764 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 28.0 t . . . . . 0 CA--C 1.537 0.48 0 CA-C-O 117.957 -1.021 . . . . 0.0 111.181 179.703 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 77.4 m-85 . . . . . 0 N--CA 1.474 0.744 0 N-CA-C 109.583 -0.525 . . . . 0.0 109.583 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' G' G ' 5' ' ' ARG . . . . . . . . . . . . . 74.1 mtp180 -144.01 140.97 29.88 Favored 'General case' 0 N--CA 1.482 1.162 0 N-CA-C 109.178 -0.675 . . . . 0.0 109.178 -179.671 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 76.6 m80 -149.47 119.84 7.36 Favored 'General case' 0 N--CA 1.472 0.666 0 N-CA-C 109.04 -0.726 . . . . 0.0 109.04 179.016 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 8.7 m-20 -69.05 145.27 53.62 Favored 'General case' 0 CA--C 1.537 0.462 0 O-C-N 123.509 0.505 . . . . 0.0 112.062 -179.167 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' G' G ' 8' ' ' SER . . . . . . . . . . . . . 5.6 t -163.98 173.6 12.41 Favored 'General case' 0 N--CA 1.47 0.534 0 N-CA-C 109.474 -0.565 . . . . 0.0 109.474 178.2 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.47 23.33 2.37 Favored Glycine 0 N--CA 1.48 1.613 0 N-CA-C 111.731 -0.548 . . . . 0.0 111.731 178.942 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 41.7 p90 -56.55 127.68 32.46 Favored 'General case' 0 N--CA 1.475 0.8 0 N-CA-C 112.381 0.511 . . . . 0.0 112.381 -178.862 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' G' G ' 11' ' ' GLU . . . . . 0.427 ' CG ' HD21 ' I' ' 27' ' ' ASN . 46.1 mt-10 -84.02 155.74 22.59 Favored 'General case' 0 N--CA 1.472 0.638 0 CA-C-O 121.05 0.452 . . . . 0.0 109.935 178.595 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -156.4 123.28 0.57 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.05 0 N-CA-C 108.277 -1.009 . . . . 0.0 108.277 178.545 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 35.3 m80 -106.36 160.21 15.55 Favored 'General case' 0 N--CA 1.481 1.093 0 CA-C-N 115.213 -0.903 . . . . 0.0 110.845 -178.419 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 59.2 t60 -165.64 99.27 0.68 Allowed 'General case' 0 N--CA 1.484 1.238 0 CA-C-N 116.453 -0.339 . . . . 0.0 110.777 179.51 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' G' G ' 15' ' ' GLN . . . . . 0.693 HE22 ' H ' ' G' ' 37' ' ' GLY . 69.4 mt-30 -125.18 -175.0 3.19 Favored 'General case' 0 CA--C 1.493 -1.237 0 N-CA-C 108.031 -1.099 . . . . 0.0 108.031 -179.94 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -169.76 103.46 0.32 Allowed 'General case' 0 CA--C 1.541 0.624 0 CA-C-N 114.904 -1.043 . . . . 0.0 109.338 179.013 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 9.6 mp -109.89 149.5 29.79 Favored 'General case' 0 N--CA 1.49 1.533 0 N-CA-C 109.21 -0.663 . . . . 0.0 109.21 -179.793 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 43.9 t -145.24 117.64 2.31 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.841 0 N-CA-C 109.607 -0.516 . . . . 0.0 109.607 178.33 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 28.8 m-85 -68.11 149.45 49.6 Favored 'General case' 0 C--N 1.37 1.495 0 O-C-N 124.873 1.358 . . . . 0.0 107.842 176.653 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' G' G ' 20' ' ' PHE . . . . . 0.402 ' O ' ' N ' ' G' ' 22' ' ' GLU . 12.0 t80 -171.46 -56.15 0.02 OUTLIER 'General case' 0 N--CA 1.484 1.274 0 N-CA-C 110.205 -0.294 . . . . 0.0 110.205 179.943 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -42.99 90.01 0.0 OUTLIER 'General case' 0 C--N 1.325 -0.485 0 C-N-CA 123.521 0.729 . . . . 0.0 112.343 179.895 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' G' G ' 22' ' ' GLU . . . . . 0.402 ' N ' ' O ' ' G' ' 20' ' ' PHE . 46.1 mt-10 -61.44 158.65 14.28 Favored 'General case' 0 N--CA 1.468 0.43 0 CA-C-N 114.895 -1.048 . . . . 0.0 110.149 179.087 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 12.0 m-20 -140.11 135.49 32.59 Favored 'General case' 0 N--CA 1.481 1.103 0 C-N-CA 122.702 0.401 . . . . 0.0 110.3 -179.897 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' G' G ' 24' ' ' VAL . . . . . . . . . . . . . 21.4 t -85.63 -115.24 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.96 0 N-CA-C 108.331 -0.989 . . . . 0.0 108.331 179.356 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -108.8 53.87 0.57 Allowed Glycine 0 N--CA 1.477 1.43 0 N-CA-C 111.382 -0.687 . . . . 0.0 111.382 -179.883 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 86.8 p -77.32 126.6 31.19 Favored 'General case' 0 C--N 1.327 -0.413 0 N-CA-C 109.146 -0.686 . . . . 0.0 109.146 178.08 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' G' G ' 27' ' ' ASN . . . . . 0.449 HD21 ' CG ' ' H' ' 11' ' ' GLU . 48.1 t30 -66.38 100.31 0.63 Allowed 'General case' 0 N--CA 1.469 0.504 0 N-CA-C 108.531 -0.915 . . . . 0.0 108.531 178.542 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 67.1 mttm -94.65 127.56 40.7 Favored 'General case' 0 N--CA 1.484 1.259 0 N-CA-C 109.646 -0.501 . . . . 0.0 109.646 -179.452 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -62.95 -127.11 0.01 OUTLIER Glycine 0 CA--C 1.529 0.962 0 N-CA-C 111.166 -0.774 . . . . 0.0 111.166 179.227 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -132.81 125.73 30.71 Favored 'General case' 0 N--CA 1.47 0.532 0 C-N-CA 122.874 0.47 . . . . 0.0 110.563 -179.141 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 40.9 mt -90.23 162.15 2.52 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.667 0 N-CA-C 106.477 -1.675 . . . . 0.0 106.477 178.356 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 45.0 mt -140.11 95.01 0.78 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.312 0 CA-C-N 119.756 1.162 . . . . 0.0 109.834 178.212 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 53.98 105.26 0.01 OUTLIER Glycine 0 CA--C 1.532 1.115 0 N-CA-C 114.07 0.388 . . . . 0.0 114.07 177.53 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 98.8 mt -71.93 152.85 42.23 Favored 'General case' 0 CA--C 1.539 0.536 0 N-CA-C 107.366 -1.346 . . . . 0.0 107.366 176.729 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 27.5 ttt -146.27 141.13 27.03 Favored 'General case' 0 N--CA 1.477 0.913 0 N-CA-C 107.996 -1.113 . . . . 0.0 107.996 179.084 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 93.0 t -161.45 153.09 4.06 Favored 'Isoleucine or valine' 0 C--O 1.233 0.206 0 N-CA-C 106.553 -1.647 . . . . 0.0 106.553 -179.423 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' G' G ' 37' ' ' GLY . . . . . 0.693 ' H ' HE22 ' G' ' 15' ' ' GLN . . . 55.64 73.84 0.38 Allowed Glycine 0 C--N 1.313 -0.696 0 C-N-CA 121.035 -0.602 . . . . 0.0 111.951 177.701 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' G' G ' 38' ' ' GLY . . . . . 0.407 ' O ' ' HA3' ' D' ' 38' ' ' GLY . . . 174.75 -158.82 27.11 Favored Glycine 0 C--O 1.215 -1.067 0 N-CA-C 110.499 -1.04 . . . . 0.0 110.499 179.462 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 27.8 m -126.61 139.07 52.79 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.095 0 CA-C-N 117.249 0.525 . . . . 0.0 109.989 -179.824 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 36.3 t . . . . . 0 N--CA 1.469 0.503 0 CA-C-O 117.8 -1.095 . . . . 0.0 111.327 179.581 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 77.9 m-85 . . . . . 0 N--CA 1.474 0.765 0 N-CA-C 109.526 -0.546 . . . . 0.0 109.526 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' H' H ' 5' ' ' ARG . . . . . . . . . . . . . 74.2 mtp180 -144.22 140.87 29.54 Favored 'General case' 0 N--CA 1.481 1.103 0 N-CA-C 109.162 -0.681 . . . . 0.0 109.162 -179.65 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 76.9 m80 -149.46 119.79 7.34 Favored 'General case' 0 N--CA 1.475 0.79 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 179.07 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 8.8 m-20 -69.05 145.27 53.63 Favored 'General case' 0 N--CA 1.468 0.43 0 CA-C-N 116.203 -0.453 . . . . 0.0 112.092 -179.305 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' H' H ' 8' ' ' SER . . . . . . . . . . . . . 6.3 t -163.97 172.82 13.38 Favored 'General case' 0 N--CA 1.47 0.555 0 N-CA-C 109.458 -0.571 . . . . 0.0 109.458 178.555 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.69 23.5 2.29 Favored Glycine 0 N--CA 1.481 1.67 0 N-CA-C 111.77 -0.532 . . . . 0.0 111.77 179.008 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 40.8 p90 -56.49 127.58 31.9 Favored 'General case' 0 N--CA 1.472 0.674 0 N-CA-C 112.461 0.541 . . . . 0.0 112.461 -178.986 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' H' H ' 11' ' ' GLU . . . . . 0.449 ' CG ' HD21 ' G' ' 27' ' ' ASN . 46.1 mt-10 -83.94 155.85 22.63 Favored 'General case' 0 N--CA 1.473 0.687 0 CA-C-O 121.086 0.469 . . . . 0.0 109.906 178.706 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -156.63 122.92 0.53 Allowed 'Isoleucine or valine' 0 CA--C 1.554 1.126 0 N-CA-C 108.335 -0.987 . . . . 0.0 108.335 178.649 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 34.1 m80 -106.08 160.45 15.3 Favored 'General case' 0 N--CA 1.48 1.047 0 CA-C-N 115.167 -0.924 . . . . 0.0 110.943 -178.385 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 58.1 t60 -165.86 99.43 0.66 Allowed 'General case' 0 N--CA 1.483 1.204 0 CA-C-N 116.532 -0.303 . . . . 0.0 110.854 179.533 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' H' H ' 15' ' ' GLN . . . . . 0.721 HE22 ' H ' ' H' ' 37' ' ' GLY . 70.0 mt-30 -125.34 -175.33 3.29 Favored 'General case' 0 CA--C 1.49 -1.335 0 N-CA-C 107.834 -1.172 . . . . 0.0 107.834 -179.829 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -169.51 103.95 0.35 Allowed 'General case' 0 CA--C 1.541 0.623 0 CA-C-N 114.808 -1.087 . . . . 0.0 109.182 178.987 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 9.7 mp -110.34 149.15 30.64 Favored 'General case' 0 N--CA 1.489 1.502 0 N-CA-C 109.115 -0.698 . . . . 0.0 109.115 -179.746 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 43.7 t -144.99 117.51 2.38 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.818 0 N-CA-C 109.705 -0.48 . . . . 0.0 109.705 178.386 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 29.1 m-85 -68.64 149.74 48.78 Favored 'General case' 0 C--N 1.37 1.489 0 O-C-N 124.83 1.331 . . . . 0.0 107.855 176.741 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 12.5 t80 -172.45 -56.23 0.02 OUTLIER 'General case' 0 N--CA 1.482 1.162 0 N-CA-C 110.209 -0.293 . . . . 0.0 110.209 -179.882 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -42.88 90.2 0.0 OUTLIER 'General case' 0 CA--C 1.536 0.406 0 C-N-CA 123.429 0.692 . . . . 0.0 112.031 -179.971 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 46.0 mt-10 -61.34 158.95 13.34 Favored 'General case' 0 N--CA 1.469 0.522 0 CA-C-N 114.907 -1.042 . . . . 0.0 110.22 179.245 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 12.3 m-20 -140.14 135.74 32.79 Favored 'General case' 0 N--CA 1.482 1.148 0 C-N-CA 122.658 0.383 . . . . 0.0 110.301 -179.949 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' H' H ' 24' ' ' VAL . . . . . . . . . . . . . 21.3 t -85.81 -115.48 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.991 0 N-CA-C 108.467 -0.938 . . . . 0.0 108.467 179.366 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . -108.3 53.3 0.6 Allowed Glycine 0 N--CA 1.479 1.558 0 N-CA-C 111.138 -0.785 . . . . 0.0 111.138 -179.878 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 85.5 p -77.04 126.64 31.31 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 109.11 -0.7 . . . . 0.0 109.11 178.195 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' H' H ' 27' ' ' ASN . . . . . 0.444 HD21 ' CG ' ' I' ' 11' ' ' GLU . 47.7 t30 -66.7 100.81 0.73 Allowed 'General case' 0 N--CA 1.469 0.516 0 N-CA-C 108.479 -0.934 . . . . 0.0 108.479 178.589 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 67.1 mttm -95.21 127.62 41.4 Favored 'General case' 0 N--CA 1.485 1.299 0 N-CA-C 109.605 -0.517 . . . . 0.0 109.605 -179.408 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.01 -126.85 0.01 OUTLIER Glycine 0 CA--C 1.528 0.877 0 N-CA-C 111.137 -0.785 . . . . 0.0 111.137 179.26 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -133.16 125.82 30.31 Favored 'General case' 0 N--CA 1.47 0.563 0 C-N-CA 122.824 0.45 . . . . 0.0 110.718 -179.126 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 40.1 mt -90.4 161.83 2.56 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.67 0 N-CA-C 106.496 -1.668 . . . . 0.0 106.496 178.369 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 46.0 mt -139.97 94.84 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.324 0 CA-C-N 119.533 1.06 . . . . 0.0 109.789 178.343 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 53.99 105.93 0.01 OUTLIER Glycine 0 CA--C 1.532 1.135 0 CA-C-N 116.291 -0.413 . . . . 0.0 114.042 177.617 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 99.1 mt -72.42 152.64 41.87 Favored 'General case' 0 CA--C 1.54 0.579 0 N-CA-C 107.255 -1.387 . . . . 0.0 107.255 176.706 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 27.6 ttt -145.94 140.82 27.22 Favored 'General case' 0 N--CA 1.478 0.975 0 N-CA-C 107.941 -1.133 . . . . 0.0 107.941 179.062 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 90.1 t -161.24 153.22 4.15 Favored 'Isoleucine or valine' 0 C--O 1.233 0.216 0 N-CA-C 106.488 -1.671 . . . . 0.0 106.488 -179.39 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' H' H ' 37' ' ' GLY . . . . . 0.721 ' H ' HE22 ' H' ' 15' ' ' GLN . . . 55.42 73.78 0.39 Allowed Glycine 0 C--N 1.314 -0.679 0 C-N-CA 121.255 -0.498 . . . . 0.0 111.949 177.796 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 174.93 -158.63 26.59 Favored Glycine 0 C--O 1.215 -1.057 0 N-CA-C 110.527 -1.029 . . . . 0.0 110.527 179.469 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 27.0 m -126.81 138.97 53.16 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.161 0 CA-C-N 117.084 0.442 . . . . 0.0 109.964 -179.823 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 35.8 t . . . . . 0 N--CA 1.468 0.431 0 CA-C-O 117.801 -1.095 . . . . 0.0 111.436 179.61 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 77.4 m-85 . . . . . 0 N--CA 1.475 0.825 0 N-CA-C 109.54 -0.541 . . . . 0.0 109.54 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' I' I ' 5' ' ' ARG . . . . . . . . . . . . . 74.0 mtp180 -144.39 141.02 29.4 Favored 'General case' 0 N--CA 1.482 1.169 0 N-CA-C 109.079 -0.712 . . . . 0.0 109.079 -179.687 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 76.8 m80 -149.62 119.41 7.06 Favored 'General case' 0 N--CA 1.472 0.636 0 N-CA-C 109.017 -0.734 . . . . 0.0 109.017 179.17 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 8.6 m-20 -68.67 145.42 53.89 Favored 'General case' 0 N--CA 1.467 0.406 0 O-C-N 123.455 0.472 . . . . 0.0 112.024 -179.244 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' I' I ' 8' ' ' SER . . . . . . . . . . . . . 6.6 t -164.17 172.9 13.06 Favored 'General case' 0 N--CA 1.469 0.502 0 N-CA-C 109.529 -0.545 . . . . 0.0 109.529 178.435 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.68 23.48 2.29 Favored Glycine 0 N--CA 1.48 1.626 0 N-CA-C 111.76 -0.536 . . . . 0.0 111.76 179.052 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 40.9 p90 -56.54 127.57 31.92 Favored 'General case' 0 N--CA 1.474 0.744 0 N-CA-C 112.398 0.518 . . . . 0.0 112.398 -178.995 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' I' I ' 11' ' ' GLU . . . . . 0.444 ' CG ' HD21 ' H' ' 27' ' ' ASN . 46.0 mt-10 -83.92 155.83 22.67 Favored 'General case' 0 N--CA 1.474 0.76 0 CA-C-O 121.096 0.474 . . . . 0.0 109.896 178.632 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -156.54 123.05 0.54 Allowed 'Isoleucine or valine' 0 CA--C 1.553 1.082 0 N-CA-C 108.299 -1.0 . . . . 0.0 108.299 178.586 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 35.0 m80 -106.04 160.08 15.57 Favored 'General case' 0 N--CA 1.481 1.081 0 CA-C-N 115.128 -0.942 . . . . 0.0 110.978 -178.336 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 58.4 t60 -165.65 99.38 0.68 Allowed 'General case' 0 N--CA 1.484 1.239 0 CA-C-N 116.563 -0.289 . . . . 0.0 110.943 179.459 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' I' I ' 15' ' ' GLN . . . . . 0.726 HE22 ' H ' ' I' ' 37' ' ' GLY . 70.0 mt-30 -125.38 -175.12 3.23 Favored 'General case' 0 CA--C 1.489 -1.403 0 N-CA-C 107.905 -1.146 . . . . 0.0 107.905 -179.865 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -169.65 104.12 0.34 Allowed 'General case' 0 CA--C 1.541 0.615 0 CA-C-N 114.8 -1.091 . . . . 0.0 109.255 179.047 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 9.7 mp -110.43 149.34 30.42 Favored 'General case' 0 N--CA 1.488 1.465 0 N-CA-C 109.16 -0.682 . . . . 0.0 109.16 -179.763 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 43.7 t -145.2 117.57 2.3 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.863 0 N-CA-C 109.649 -0.5 . . . . 0.0 109.649 178.391 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 28.8 m-85 -68.7 149.79 48.66 Favored 'General case' 0 C--N 1.371 1.536 0 O-C-N 124.773 1.296 . . . . 0.0 107.817 176.72 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' I' I ' 20' ' ' PHE . . . . . 0.403 ' O ' ' N ' ' I' ' 22' ' ' GLU . 12.6 t80 -172.54 -56.14 0.02 OUTLIER 'General case' 0 N--CA 1.481 1.115 0 N-CA-C 110.205 -0.294 . . . . 0.0 110.205 -179.855 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -43.0 90.2 0.0 OUTLIER 'General case' 0 CA--C 1.535 0.381 0 C-N-CA 123.378 0.671 . . . . 0.0 112.06 -179.98 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' I' I ' 22' ' ' GLU . . . . . 0.403 ' N ' ' O ' ' I' ' 20' ' ' PHE . 46.1 mt-10 -61.17 158.93 12.88 Favored 'General case' 0 N--CA 1.47 0.528 0 CA-C-N 114.893 -1.049 . . . . 0.0 110.267 179.241 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 12.2 m-20 -140.22 135.68 32.61 Favored 'General case' 0 N--CA 1.482 1.143 0 C-N-CA 122.597 0.359 . . . . 0.0 110.304 -179.992 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' I' I ' 24' ' ' VAL . . . . . . . . . . . . . 21.2 t -85.8 -115.51 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.96 0 N-CA-C 108.463 -0.94 . . . . 0.0 108.463 179.386 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . -108.31 53.29 0.6 Allowed Glycine 0 N--CA 1.478 1.469 0 N-CA-C 111.249 -0.74 . . . . 0.0 111.249 -179.909 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 85.9 p -77.01 126.73 31.46 Favored 'General case' 0 C--N 1.329 -0.289 0 N-CA-C 109.202 -0.666 . . . . 0.0 109.202 178.148 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' I' I ' 27' ' ' ASN . . . . . 0.427 HD21 ' CG ' ' G' ' 11' ' ' GLU . 47.9 t30 -66.67 100.97 0.74 Allowed 'General case' 0 N--CA 1.469 0.488 0 N-CA-C 108.474 -0.936 . . . . 0.0 108.474 178.56 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 67.2 mttm -95.38 127.52 41.5 Favored 'General case' 0 N--CA 1.483 1.224 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 -179.431 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -62.99 -127.4 0.01 OUTLIER Glycine 0 CA--C 1.53 0.969 0 N-CA-C 111.099 -0.8 . . . . 0.0 111.099 179.33 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -132.38 125.86 31.84 Favored 'General case' 0 N--CA 1.471 0.624 0 C-N-CA 122.906 0.482 . . . . 0.0 110.719 -179.109 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 39.8 mt -90.61 161.41 2.61 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.624 0 N-CA-C 106.458 -1.682 . . . . 0.0 106.458 178.233 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 47.0 mt -139.54 94.73 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.297 0 CA-C-N 119.586 1.085 . . . . 0.0 109.8 178.374 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 54.1 105.87 0.01 OUTLIER Glycine 0 CA--C 1.532 1.103 0 CA-C-N 116.32 -0.4 . . . . 0.0 114.011 177.568 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 98.7 mt -72.35 152.79 41.85 Favored 'General case' 0 CA--C 1.539 0.527 0 N-CA-C 107.295 -1.372 . . . . 0.0 107.295 176.721 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 27.6 ttt -146.02 140.77 27.06 Favored 'General case' 0 N--CA 1.478 0.956 0 N-CA-C 107.877 -1.157 . . . . 0.0 107.877 179.157 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 94.9 t -161.12 153.46 4.13 Favored 'Isoleucine or valine' 0 C--O 1.233 0.193 0 N-CA-C 106.382 -1.71 . . . . 0.0 106.382 -179.45 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' I' I ' 37' ' ' GLY . . . . . 0.726 ' H ' HE22 ' I' ' 15' ' ' GLN . . . 55.08 73.95 0.37 Allowed Glycine 0 C--N 1.313 -0.724 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.894 177.762 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 174.95 -158.67 26.65 Favored Glycine 0 C--O 1.216 -1.012 0 N-CA-C 110.547 -1.021 . . . . 0.0 110.547 179.43 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 27.3 m -126.88 138.82 53.65 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.097 0 CA-C-N 117.186 0.493 . . . . 0.0 109.86 -179.722 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 36.8 t . . . . . 0 N--CA 1.469 0.517 0 CA-C-O 117.849 -1.072 . . . . 0.0 111.329 179.525 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 16.5 m-85 . . . . . 0 N--CA 1.469 0.498 0 N-CA-C 109.369 -0.604 . . . . 0.0 109.369 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 54.0 mtp180 -68.03 129.7 40.71 Favored 'General case' 0 N--CA 1.467 0.383 0 CA-C-N 115.868 -0.606 . . . . 0.0 110.533 -177.798 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 45.2 m170 -96.1 125.59 40.74 Favored 'General case' 0 N--CA 1.473 0.691 0 N-CA-C 109.725 -0.472 . . . . 0.0 109.725 179.002 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' ASP . . . . . 0.495 ' OD1' HG11 ' F' ' 24' ' ' VAL . 10.0 m-20 -72.23 144.81 48.32 Favored 'General case' 0 CA--C 1.532 0.255 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.109 -179.81 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 23.0 t -160.72 179.47 8.51 Favored 'General case' 0 N--CA 1.471 0.615 0 N-CA-C 109.329 -0.619 . . . . 0.0 109.329 178.89 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 124.52 19.86 2.49 Favored Glycine 0 N--CA 1.487 2.064 0 N-CA-C 111.886 -0.486 . . . . 0.0 111.886 179.896 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 43.6 p90 -57.43 129.2 40.74 Favored 'General case' 0 N--CA 1.475 0.82 0 O-C-N 122.458 -0.436 . . . . 0.0 112.084 -179.707 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 46.7 mt-10 -85.54 154.7 21.57 Favored 'General case' 0 N--CA 1.469 0.512 0 N-CA-C 109.046 -0.724 . . . . 0.0 109.046 178.406 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -153.76 129.3 1.64 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 N-CA-C 108.046 -1.094 . . . . 0.0 108.046 178.895 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 51.3 m-70 -135.05 143.75 46.89 Favored 'General case' 0 N--CA 1.49 1.543 0 CA-C-N 118.803 0.729 . . . . 0.0 110.956 -179.218 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -165.98 98.21 0.64 Allowed 'General case' 0 N--CA 1.482 1.16 0 CA-C-N 116.688 -0.233 . . . . 0.0 111.099 179.673 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . 0.53 HE21 ' CA ' ' A' ' 37' ' ' GLY . 49.6 mt-30 -108.06 -171.98 1.97 Allowed 'General case' 0 CA--C 1.503 -0.851 0 N-CA-C 108.176 -1.046 . . . . 0.0 108.176 179.712 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -164.34 97.86 0.8 Allowed 'General case' 0 N--CA 1.472 0.651 0 CA-C-N 115.243 -0.889 . . . . 0.0 109.516 178.686 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.582 HD12 ' N ' ' A' ' 17' ' ' LEU . 4.8 mp -107.02 163.85 12.64 Favored 'General case' 0 N--CA 1.488 1.44 0 N-CA-C 108.59 -0.893 . . . . 0.0 108.59 179.916 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 56.3 t -141.28 119.05 8.84 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.31 0 CA-C-O 118.772 -0.632 . . . . 0.0 109.847 179.433 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 54.5 m-85 -70.13 158.55 35.55 Favored 'General case' 0 N--CA 1.479 1.021 0 N-CA-C 107.706 -1.22 . . . . 0.0 107.706 177.275 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 13.8 t80 -171.03 -58.46 0.02 OUTLIER 'General case' 0 N--CA 1.483 1.217 0 CA-C-O 122.424 1.107 . . . . 0.0 109.672 179.333 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.42 90.05 0.0 OUTLIER 'General case' 0 N--CA 1.457 -0.092 0 CA-C-N 113.927 -1.488 . . . . 0.0 112.852 -178.078 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 37.7 tt0 -62.13 156.51 21.42 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 115.166 -0.925 . . . . 0.0 110.618 178.891 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 12.2 m-20 -138.09 129.75 28.09 Favored 'General case' 0 N--CA 1.482 1.132 0 C-N-CA 122.93 0.492 . . . . 0.0 110.246 -179.659 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.953 HG12 ' H ' ' A' ' 25' ' ' GLY . 39.6 t -79.6 -164.37 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 1.024 0 N-CA-C 108.518 -0.919 . . . . 0.0 108.518 179.583 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.953 ' H ' HG12 ' A' ' 24' ' ' VAL . . . -71.42 51.43 1.08 Allowed Glycine 0 CA--C 1.527 0.827 0 CA-C-N 118.399 0.545 . . . . 0.0 112.038 -179.086 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 27.1 p -72.36 136.45 46.14 Favored 'General case' 0 C--O 1.22 -0.488 0 N-CA-C 109.564 -0.532 . . . . 0.0 109.564 178.877 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 2.0 t-20 -68.66 95.5 0.66 Allowed 'General case' 0 N--CA 1.468 0.463 0 N-CA-C 108.479 -0.934 . . . . 0.0 108.479 178.139 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 67.8 mttm -93.34 119.26 32.27 Favored 'General case' 0 N--CA 1.481 1.108 0 N-CA-C 110.295 -0.261 . . . . 0.0 110.295 -179.104 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.12 -126.12 0.01 OUTLIER Glycine 0 CA--C 1.533 1.166 0 N-CA-C 110.485 -1.046 . . . . 0.0 110.485 178.639 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.24 134.23 48.94 Favored 'General case' 0 N--CA 1.48 1.035 0 N-CA-C 109.078 -0.712 . . . . 0.0 109.078 179.111 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 65.4 mt -83.3 138.05 19.95 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.467 0 N-CA-C 107.3 -1.37 . . . . 0.0 107.3 178.657 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 31.3 mt -130.46 127.71 62.8 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.914 0 O-C-N 123.472 0.483 . . . . 0.0 110.044 -178.592 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.27 78.9 0.14 Allowed Glycine 0 CA--C 1.524 0.653 0 CA-C-N 115.885 -0.598 . . . . 0.0 112.869 178.7 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.438 HD23 ' N ' ' A' ' 35' ' ' MET . 1.7 tt -109.94 120.82 43.67 Favored 'General case' 0 N--CA 1.481 1.077 0 N-CA-C 107.175 -1.417 . . . . 0.0 107.175 177.653 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 35' ' ' MET . . . . . 0.438 ' N ' HD23 ' A' ' 34' ' ' LEU . 8.8 mtp -154.08 161.24 42.05 Favored 'General case' 0 N--CA 1.472 0.647 0 N-CA-C 108.662 -0.866 . . . . 0.0 108.662 179.736 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 78.1 t -158.07 144.76 8.81 Favored 'Isoleucine or valine' 0 C--O 1.234 0.261 0 N-CA-C 106.774 -1.565 . . . . 0.0 106.774 -179.789 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . 0.53 ' CA ' HE21 ' A' ' 15' ' ' GLN . . . 55.77 74.06 0.36 Allowed Glycine 0 C--N 1.315 -0.616 0 N-CA-C 111.511 -0.636 . . . . 0.0 111.511 178.675 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 169.99 -149.07 12.43 Favored Glycine 0 CA--C 1.519 0.324 0 N-CA-C 110.898 -0.881 . . . . 0.0 110.898 179.938 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 16.0 m -134.65 148.74 29.36 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.84 0 C-N-CA 122.675 0.39 . . . . 0.0 109.951 179.955 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 21.9 t . . . . . 0 C--O 1.22 -0.497 0 CA-C-O 117.81 -1.09 . . . . 0.0 111.043 178.931 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 17.3 m-85 . . . . . 0 N--CA 1.47 0.548 0 N-CA-C 109.404 -0.591 . . . . 0.0 109.404 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 54.3 mtp180 -68.36 129.61 40.45 Favored 'General case' 0 CA--C 1.534 0.349 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.525 -177.748 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 44.0 m170 -95.99 125.6 40.65 Favored 'General case' 0 N--CA 1.473 0.703 0 N-CA-C 109.797 -0.446 . . . . 0.0 109.797 179.048 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 7' ' ' ASP . . . . . 0.513 ' OD1' HG11 ' D' ' 24' ' ' VAL . 10.0 m-20 -72.18 144.98 48.34 Favored 'General case' 0 CA--C 1.532 0.269 0 CA-C-N 116.464 -0.334 . . . . 0.0 111.163 -179.863 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 8' ' ' SER . . . . . . . . . . . . . 23.1 t -160.82 179.49 8.47 Favored 'General case' 0 N--CA 1.47 0.539 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 178.851 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 124.37 19.88 2.52 Favored Glycine 0 N--CA 1.487 2.081 0 N-CA-C 111.8 -0.52 . . . . 0.0 111.8 179.854 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 43.3 p90 -57.36 129.24 40.92 Favored 'General case' 0 N--CA 1.474 0.736 0 O-C-N 122.489 -0.418 . . . . 0.0 112.073 -179.788 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 46.6 mt-10 -85.55 154.79 21.51 Favored 'General case' 0 N--CA 1.47 0.557 0 N-CA-C 109.15 -0.685 . . . . 0.0 109.15 178.389 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -153.8 129.09 1.56 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.328 0 N-CA-C 108.188 -1.041 . . . . 0.0 108.188 178.839 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 50.9 m-70 -134.8 143.87 47.33 Favored 'General case' 0 N--CA 1.49 1.566 0 CA-C-N 118.79 0.723 . . . . 0.0 110.91 -179.089 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -166.02 98.23 0.63 Allowed 'General case' 0 N--CA 1.483 1.203 0 CA-C-N 116.616 -0.266 . . . . 0.0 111.117 179.619 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . 0.521 HE21 ' CA ' ' B' ' 37' ' ' GLY . 49.7 mt-30 -108.09 -172.52 2.08 Favored 'General case' 0 CA--C 1.502 -0.896 0 N-CA-C 108.168 -1.049 . . . . 0.0 108.168 179.805 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 16' ' ' LYS . . . . . 0.401 ' C ' HD12 ' B' ' 17' ' ' LEU . 88.2 tttt -164.06 97.69 0.83 Allowed 'General case' 0 N--CA 1.473 0.698 0 CA-C-N 115.152 -0.931 . . . . 0.0 109.411 178.747 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . 0.584 ' N ' HD12 ' B' ' 17' ' ' LEU . 4.8 mp -106.97 163.91 12.58 Favored 'General case' 0 N--CA 1.488 1.427 0 N-CA-C 108.506 -0.924 . . . . 0.0 108.506 179.867 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 58.7 t -141.37 118.7 8.22 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.358 0 CA-C-O 118.957 -0.544 . . . . 0.0 109.821 179.512 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 56.0 m-85 -70.39 158.64 35.62 Favored 'General case' 0 N--CA 1.477 0.907 0 N-CA-C 107.614 -1.254 . . . . 0.0 107.614 177.25 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 14.5 t80 -171.64 -57.7 0.02 OUTLIER 'General case' 0 N--CA 1.482 1.164 0 CA-C-O 122.284 1.04 . . . . 0.0 109.764 179.288 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.56 90.49 0.0 OUTLIER 'General case' 0 C--O 1.232 0.156 0 CA-C-N 114.098 -1.41 . . . . 0.0 112.682 -178.126 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 37.6 tt0 -62.55 156.37 23.28 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 115.173 -0.921 . . . . 0.0 110.544 179.038 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 12.3 m-20 -138.0 130.16 28.88 Favored 'General case' 0 N--CA 1.483 1.196 0 C-N-CA 123.01 0.524 . . . . 0.0 110.193 -179.671 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 24' ' ' VAL . . . . . 0.983 HG12 ' H ' ' B' ' 25' ' ' GLY . 39.2 t -80.13 -163.89 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.037 0 N-CA-C 108.593 -0.891 . . . . 0.0 108.593 179.618 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 25' ' ' GLY . . . . . 0.983 ' H ' HG12 ' B' ' 24' ' ' VAL . . . -71.36 50.93 1.05 Allowed Glycine 0 C--N 1.342 0.897 0 CA-C-N 118.324 0.511 . . . . 0.0 112.045 -179.182 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 28.9 p -72.16 136.16 46.38 Favored 'General case' 0 C--O 1.22 -0.476 0 N-CA-C 109.644 -0.502 . . . . 0.0 109.644 178.798 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 2.0 t-20 -68.61 95.39 0.64 Allowed 'General case' 0 N--CA 1.469 0.5 0 N-CA-C 108.495 -0.928 . . . . 0.0 108.495 178.137 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 67.9 mttm -93.19 119.12 32.03 Favored 'General case' 0 N--CA 1.481 1.1 0 N-CA-C 110.358 -0.238 . . . . 0.0 110.358 -179.061 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.08 -125.67 0.01 OUTLIER Glycine 0 CA--C 1.534 1.28 0 N-CA-C 110.511 -1.036 . . . . 0.0 110.511 178.64 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.65 134.36 48.51 Favored 'General case' 0 N--CA 1.481 1.103 0 N-CA-C 109.159 -0.682 . . . . 0.0 109.159 179.141 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 65.6 mt -83.43 138.25 19.6 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.462 0 N-CA-C 107.288 -1.375 . . . . 0.0 107.288 178.626 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 29.9 mt -130.78 127.56 61.82 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.884 0 O-C-N 123.541 0.525 . . . . 0.0 110.012 -178.523 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.46 78.56 0.15 Allowed Glycine 0 CA--C 1.526 0.745 0 CA-C-N 115.898 -0.592 . . . . 0.0 112.888 178.642 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 34' ' ' LEU . . . . . 0.429 HD23 ' N ' ' B' ' 35' ' ' MET . 1.7 tt -109.6 120.65 43.14 Favored 'General case' 0 N--CA 1.48 1.061 0 N-CA-C 107.163 -1.421 . . . . 0.0 107.163 177.629 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 35' ' ' MET . . . . . 0.429 ' N ' HD23 ' B' ' 34' ' ' LEU . 8.9 mtp -153.81 161.07 42.37 Favored 'General case' 0 N--CA 1.473 0.682 0 N-CA-C 108.704 -0.85 . . . . 0.0 108.704 179.574 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 72.8 t -157.93 144.65 9.0 Favored 'Isoleucine or valine' 0 C--O 1.233 0.201 0 N-CA-C 106.786 -1.561 . . . . 0.0 106.786 -179.739 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . 0.521 ' CA ' HE21 ' B' ' 15' ' ' GLN . . . 55.71 74.08 0.36 Allowed Glycine 0 C--N 1.317 -0.526 0 N-CA-C 111.544 -0.622 . . . . 0.0 111.544 178.713 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 169.97 -148.9 12.23 Favored Glycine 0 CA--C 1.519 0.319 0 N-CA-C 110.796 -0.922 . . . . 0.0 110.796 179.886 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 16.1 m -134.69 148.73 29.32 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.823 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 -179.914 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 21.9 t . . . . . 0 N--CA 1.47 0.54 0 CA-C-O 117.717 -1.135 . . . . 0.0 110.959 178.801 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 17.4 m-85 . . . . . 0 N--CA 1.469 0.516 0 N-CA-C 109.473 -0.565 . . . . 0.0 109.473 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 54.4 mtp180 -68.37 129.25 39.36 Favored 'General case' 0 N--CA 1.468 0.469 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.481 -177.729 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 44.7 m170 -95.74 125.66 40.47 Favored 'General case' 0 N--CA 1.474 0.733 0 N-CA-C 109.714 -0.476 . . . . 0.0 109.714 178.978 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' C' C ' 7' ' ' ASP . . . . . 0.516 ' OD1' HG11 ' E' ' 24' ' ' VAL . 10.1 m-20 -72.33 145.18 47.97 Favored 'General case' 0 CA--C 1.53 0.208 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.198 -179.842 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' C' C ' 8' ' ' SER . . . . . . . . . . . . . 22.9 t -160.91 179.53 8.4 Favored 'General case' 0 N--CA 1.469 0.506 0 N-CA-C 109.343 -0.614 . . . . 0.0 109.343 178.835 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 124.46 19.83 2.51 Favored Glycine 0 N--CA 1.487 2.055 0 N-CA-C 111.772 -0.531 . . . . 0.0 111.772 179.822 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 43.9 p90 -57.24 128.96 39.64 Favored 'General case' 0 N--CA 1.473 0.705 0 O-C-N 122.403 -0.469 . . . . 0.0 112.127 -179.767 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 46.5 mt-10 -85.35 154.95 21.54 Favored 'General case' 0 N--CA 1.47 0.553 0 N-CA-C 109.049 -0.723 . . . . 0.0 109.049 178.426 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -154.08 129.05 1.49 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 N-CA-C 108.174 -1.047 . . . . 0.0 108.174 178.802 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 50.7 m-70 -134.68 144.2 47.66 Favored 'General case' 0 N--CA 1.491 1.624 0 CA-C-N 118.716 0.689 . . . . 0.0 110.974 -179.117 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -166.38 98.16 0.6 Allowed 'General case' 0 N--CA 1.482 1.174 0 CA-C-N 116.674 -0.239 . . . . 0.0 111.161 179.753 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' C' C ' 15' ' ' GLN . . . . . 0.528 HE21 ' CA ' ' C' ' 37' ' ' GLY . 49.7 mt-30 -108.31 -172.12 2.0 Allowed 'General case' 0 CA--C 1.501 -0.941 0 N-CA-C 108.177 -1.046 . . . . 0.0 108.177 179.796 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' C' C ' 16' ' ' LYS . . . . . 0.406 ' C ' HD12 ' C' ' 17' ' ' LEU . 88.2 tttt -164.29 97.84 0.81 Allowed 'General case' 0 N--CA 1.472 0.626 0 CA-C-N 115.143 -0.935 . . . . 0.0 109.443 178.761 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' C' C ' 17' ' ' LEU . . . . . 0.581 HD12 ' N ' ' C' ' 17' ' ' LEU . 4.8 mp -106.96 163.81 12.65 Favored 'General case' 0 N--CA 1.487 1.406 0 N-CA-C 108.559 -0.904 . . . . 0.0 108.559 179.89 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 58.0 t -141.28 118.81 8.54 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.293 0 CA-C-O 118.917 -0.563 . . . . 0.0 109.805 179.48 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 55.1 m-85 -70.49 158.73 35.55 Favored 'General case' 0 N--CA 1.478 0.926 0 N-CA-C 107.529 -1.285 . . . . 0.0 107.529 177.317 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 14.7 t80 -171.63 -57.67 0.02 OUTLIER 'General case' 0 N--CA 1.481 1.104 0 CA-C-O 122.246 1.022 . . . . 0.0 109.857 179.21 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.59 90.4 0.0 OUTLIER 'General case' 0 C--O 1.231 0.107 0 CA-C-N 114.181 -1.372 . . . . 0.0 112.79 -178.168 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 38.0 tt0 -62.32 156.45 22.25 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.223 -0.899 . . . . 0.0 110.577 179.09 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 12.2 m-20 -138.05 129.93 28.42 Favored 'General case' 0 N--CA 1.482 1.156 0 C-N-CA 123.026 0.531 . . . . 0.0 110.255 -179.689 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' C' C ' 24' ' ' VAL . . . . . 0.967 HG12 ' H ' ' C' ' 25' ' ' GLY . 40.4 t -79.99 -164.08 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.035 0 N-CA-C 108.523 -0.917 . . . . 0.0 108.523 179.639 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' C' C ' 25' ' ' GLY . . . . . 0.967 ' H ' HG12 ' C' ' 24' ' ' VAL . . . -71.34 50.96 1.04 Allowed Glycine 0 CA--C 1.527 0.812 0 CA-C-N 118.363 0.529 . . . . 0.0 112.042 -179.019 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 27.3 p -72.13 136.43 46.52 Favored 'General case' 0 C--O 1.221 -0.414 0 N-CA-C 109.526 -0.546 . . . . 0.0 109.526 178.902 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 2.0 t-20 -68.87 95.65 0.7 Allowed 'General case' 0 N--CA 1.468 0.472 0 N-CA-C 108.419 -0.956 . . . . 0.0 108.419 178.107 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 67.9 mttm -93.46 119.07 32.11 Favored 'General case' 0 N--CA 1.481 1.105 0 N-CA-C 110.354 -0.239 . . . . 0.0 110.354 -179.092 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.93 -126.03 0.01 OUTLIER Glycine 0 CA--C 1.534 1.281 0 N-CA-C 110.563 -1.015 . . . . 0.0 110.563 178.606 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.28 134.12 48.89 Favored 'General case' 0 N--CA 1.481 1.102 0 N-CA-C 109.105 -0.702 . . . . 0.0 109.105 179.135 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 65.3 mt -83.26 138.0 20.02 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.451 0 N-CA-C 107.311 -1.366 . . . . 0.0 107.311 178.538 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 30.7 mt -130.41 127.79 63.03 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.931 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.015 -178.537 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.14 78.57 0.15 Allowed Glycine 0 CA--C 1.525 0.68 0 CA-C-N 115.908 -0.587 . . . . 0.0 112.933 178.677 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' C' C ' 34' ' ' LEU . . . . . 0.432 HD23 ' N ' ' C' ' 35' ' ' MET . 1.7 tt -109.49 120.77 43.51 Favored 'General case' 0 N--CA 1.48 1.035 0 N-CA-C 107.202 -1.407 . . . . 0.0 107.202 177.606 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' C' C ' 35' ' ' MET . . . . . 0.432 ' N ' HD23 ' C' ' 34' ' ' LEU . 8.8 mtp -153.93 161.22 42.16 Favored 'General case' 0 N--CA 1.469 0.524 0 N-CA-C 108.664 -0.865 . . . . 0.0 108.664 179.665 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 79.2 t -158.05 144.86 8.89 Favored 'Isoleucine or valine' 0 C--O 1.233 0.232 0 N-CA-C 106.845 -1.539 . . . . 0.0 106.845 -179.832 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' C' C ' 37' ' ' GLY . . . . . 0.528 ' CA ' HE21 ' C' ' 15' ' ' GLN . . . 55.65 74.03 0.37 Allowed Glycine 0 C--N 1.316 -0.535 0 CA-C-N 115.812 -0.631 . . . . 0.0 111.537 178.687 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 169.95 -149.12 12.54 Favored Glycine 0 CA--C 1.518 0.275 0 N-CA-C 110.815 -0.914 . . . . 0.0 110.815 179.941 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 16.4 m -134.58 148.85 29.41 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.872 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 -179.964 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 22.0 t . . . . . 0 N--CA 1.469 0.507 0 CA-C-O 117.717 -1.135 . . . . 0.0 110.952 178.916 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 18.7 m-85 . . . . . 0 N--CA 1.478 0.957 0 N-CA-C 107.9 -1.148 . . . . 0.0 107.9 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' D' D ' 5' ' ' ARG . . . . . 0.852 HH21 HG13 ' C' ' 24' ' ' VAL 0.344 64.5 mtp180 -77.03 133.52 39.09 Favored 'General case' 0 C--N 1.355 0.821 0 CA-C-O 123.248 1.499 . . . . 0.0 107.088 -167.987 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 45.2 m170 -94.27 128.13 40.56 Favored 'General case' 0 C--N 1.365 1.273 0 CA-C-N 113.371 -1.741 . . . . 0.0 108.502 -177.669 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' D' D ' 7' ' ' ASP . . . . . 0.584 ' OD1' HG11 ' I' ' 24' ' ' VAL . 6.7 m-20 -66.35 130.48 43.37 Favored 'General case' 0 C--N 1.31 -1.134 0 C-N-CA 127.505 2.322 . . . . 0.0 115.117 175.029 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' D' D ' 8' ' ' SER . . . . . . . . . . . . . 22.9 t -152.11 -178.53 6.84 Favored 'General case' 0 N--CA 1.478 0.954 0 CA-C-N 119.168 0.895 . . . . 0.0 109.411 177.145 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 124.58 18.85 2.64 Favored Glycine 0 N--CA 1.485 1.914 0 N-CA-C 111.788 -0.525 . . . . 0.0 111.788 178.691 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 40.2 p90 -56.21 130.62 45.09 Favored 'General case' 0 CA--C 1.544 0.74 0 N-CA-C 112.134 0.42 . . . . 0.0 112.134 -179.209 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 46.7 mt-10 -85.6 152.5 23.08 Favored 'General case' 0 N--CA 1.475 0.78 0 N-CA-C 109.649 -0.5 . . . . 0.0 109.649 177.479 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -149.6 130.1 4.37 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.447 0 N-CA-C 108.1 -1.074 . . . . 0.0 108.1 175.357 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 48.5 m-70 -129.81 146.97 51.53 Favored 'General case' 0 N--CA 1.483 1.218 0 CA-C-N 117.867 0.303 . . . . 0.0 111.286 176.482 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -165.35 104.84 0.74 Allowed 'General case' 0 N--CA 1.483 1.209 0 N-CA-C 109.688 -0.486 . . . . 0.0 109.688 173.354 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' D' D ' 15' ' ' GLN . . . . . 0.538 HE21 ' CA ' ' D' ' 37' ' ' GLY . 49.1 mt-30 -111.62 -175.59 2.73 Favored 'General case' 0 CA--C 1.493 -1.249 0 N-CA-C 108.018 -1.104 . . . . 0.0 108.018 179.092 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' D' D ' 16' ' ' LYS . . . . . 0.451 ' C ' HD12 ' D' ' 17' ' ' LEU . 88.7 tttt -160.56 106.12 1.47 Allowed 'General case' 0 CA--C 1.538 0.5 0 N-CA-C 107.683 -1.228 . . . . 0.0 107.683 175.383 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' D' D ' 17' ' ' LEU . . . . . 0.528 HD12 ' N ' ' D' ' 17' ' ' LEU . 5.7 mp -113.38 163.03 15.38 Favored 'General case' 0 N--CA 1.488 1.456 0 N-CA-C 107.945 -1.132 . . . . 0.0 107.945 179.457 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 53.3 t -140.96 123.63 15.5 Favored 'Isoleucine or valine' 0 C--N 1.362 1.136 0 N-CA-C 108.753 -0.832 . . . . 0.0 108.753 175.964 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 79.1 m-85 -62.97 151.3 39.99 Favored 'General case' 0 C--N 1.355 0.82 0 C-N-CA 124.517 1.127 . . . . 0.0 110.515 170.967 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 9.9 t80 -170.11 -66.91 0.02 OUTLIER 'General case' 0 N--CA 1.475 0.789 0 N-CA-C 107.781 -1.192 . . . . 0.0 107.781 179.834 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -38.27 95.43 0.01 OUTLIER 'General case' 0 CA--C 1.535 0.39 0 CA-C-N 113.99 -1.459 . . . . 0.0 111.731 -175.293 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 38.3 tt0 -65.18 157.61 28.3 Favored 'General case' 0 N--CA 1.467 0.418 0 CA-C-N 113.919 -1.491 . . . . 0.0 110.122 178.469 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 12.0 m-20 -138.68 130.46 27.82 Favored 'General case' 0 N--CA 1.479 0.985 0 C-N-CA 123.181 0.592 . . . . 0.0 110.407 -178.969 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' D' D ' 24' ' ' VAL . . . . . 1.037 HG12 ' H ' ' D' ' 25' ' ' GLY . 48.7 t -84.42 -160.12 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.299 0 N-CA-C 107.742 -1.206 . . . . 0.0 107.742 -178.346 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' D' D ' 25' ' ' GLY . . . . . 1.037 ' H ' HG12 ' D' ' 24' ' ' VAL . . . -80.3 57.19 4.67 Favored Glycine 0 C--N 1.359 1.84 0 C-N-CA 118.198 -1.953 . . . . 0.0 110.695 -175.556 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 54.0 p -61.81 132.36 52.84 Favored 'General case' 0 C--N 1.346 0.431 0 CA-C-O 117.515 -1.231 . . . . 0.0 112.187 170.377 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 2.0 t-20 -65.53 95.32 0.21 Allowed 'General case' 0 C--O 1.242 0.666 0 CA-C-N 120.263 1.392 . . . . 0.0 109.044 172.049 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 67.6 mttm -95.0 122.17 37.37 Favored 'General case' 0 N--CA 1.483 1.219 0 C-N-CA 119.627 -0.829 . . . . 0.0 109.245 179.537 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -55.84 -130.18 0.01 OUTLIER Glycine 0 CA--C 1.528 0.893 0 C-N-CA 123.804 0.716 . . . . 0.0 112.045 174.717 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -125.33 139.97 53.23 Favored 'General case' 0 C--N 1.369 1.421 0 N-CA-C 108.669 -0.863 . . . . 0.0 108.669 174.602 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 65.2 mt -83.86 140.54 16.04 Favored 'Isoleucine or valine' 0 C--O 1.238 0.47 0 N-CA-C 107.374 -1.343 . . . . 0.0 107.374 176.342 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 42.1 mt -132.79 132.21 59.48 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.996 0 N-CA-C 108.329 -0.989 . . . . 0.0 108.329 178.079 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.22 76.96 0.22 Allowed Glycine 0 C--O 1.245 0.799 0 CA-C-O 118.552 -1.138 . . . . 0.0 112.519 178.351 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' D' D ' 34' ' ' LEU . . . . . 0.434 HD23 ' N ' ' D' ' 35' ' ' MET . 2.1 tt -109.32 132.17 54.38 Favored 'General case' 0 C--N 1.371 1.528 0 N-CA-C 104.73 -2.322 . . . . 0.0 104.73 175.275 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' D' D ' 35' ' ' MET . . . . . 0.434 ' N ' HD23 ' D' ' 34' ' ' LEU . 9.0 mtp -156.43 166.72 32.61 Favored 'General case' 0 N--CA 1.475 0.822 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 177.494 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 93.2 t -163.73 150.72 3.06 Favored 'Isoleucine or valine' 0 C--O 1.237 0.401 0 N-CA-C 104.989 -2.226 . . . . 0.0 104.989 173.986 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' D' D ' 37' ' ' GLY . . . . . 0.538 ' CA ' HE21 ' D' ' 15' ' ' GLN . . . 60.95 66.91 2.38 Favored Glycine 0 N--CA 1.444 -0.794 0 C-N-CA 118.509 -1.805 . . . . 0.0 112.129 177.13 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 166.8 -148.06 12.82 Favored Glycine 0 N--CA 1.468 0.767 0 CA-C-N 119.085 1.443 . . . . 0.0 112.296 -179.589 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 14.1 m -131.15 147.92 32.95 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.263 0 CA-C-N 119.009 1.405 . . . . 0.0 110.332 -178.908 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 21.2 t . . . . . 0 C--O 1.212 -0.897 0 N-CA-C 109.388 -0.597 . . . . 0.0 109.388 173.574 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 15.9 m-85 . . . . . 0 N--CA 1.472 0.631 0 CA-C-O 121.171 0.51 . . . . 0.0 109.864 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' E' E ' 5' ' ' ARG . . . . . 0.837 HH21 HG13 ' A' ' 24' ' ' VAL . 53.0 mtp180 -68.14 130.15 42.07 Favored 'General case' 0 CA--C 1.535 0.398 0 CA-C-N 115.579 -0.737 . . . . 0.0 110.585 -177.917 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 45.6 m170 -96.42 125.3 40.81 Favored 'General case' 0 N--CA 1.476 0.854 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 178.958 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' E' E ' 7' ' ' ASP . . . . . 0.569 ' OD1' HG11 ' G' ' 24' ' ' VAL . 11.6 m-20 -71.75 145.24 48.89 Favored 'General case' 0 N--CA 1.465 0.31 0 O-C-N 123.286 0.366 . . . . 0.0 111.301 -179.823 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' E' E ' 8' ' ' SER . . . . . . . . . . . . . 22.6 t -161.05 179.88 8.07 Favored 'General case' 0 N--CA 1.473 0.702 0 N-CA-C 109.263 -0.643 . . . . 0.0 109.263 178.521 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 125.16 20.12 2.28 Favored Glycine 0 N--CA 1.482 1.754 0 N-CA-C 111.757 -0.537 . . . . 0.0 111.757 179.612 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 40.3 p90 -57.17 128.49 37.24 Favored 'General case' 0 N--CA 1.473 0.682 0 N-CA-C 112.607 0.595 . . . . 0.0 112.607 -179.214 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 45.8 mt-10 -84.37 155.08 22.48 Favored 'General case' 0 N--CA 1.475 0.813 0 N-CA-C 109.228 -0.656 . . . . 0.0 109.228 178.111 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -155.29 127.76 1.05 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.543 0 N-CA-C 108.367 -0.975 . . . . 0.0 108.367 178.764 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 47.4 m-70 -134.63 142.12 46.79 Favored 'General case' 0 N--CA 1.482 1.139 0 CA-C-O 120.591 0.234 . . . . 0.0 111.337 -177.995 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -165.17 98.38 0.73 Allowed 'General case' 0 N--CA 1.486 1.37 0 CA-C-N 116.688 -0.233 . . . . 0.0 111.127 179.711 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' E' E ' 15' ' ' GLN . . . . . 0.537 HE21 ' CA ' ' E' ' 37' ' ' GLY . 49.2 mt-30 -107.73 -172.2 2.02 Favored 'General case' 0 CA--C 1.501 -0.925 0 N-CA-C 108.393 -0.965 . . . . 0.0 108.393 179.81 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -164.34 97.88 0.8 Allowed 'General case' 0 CA--C 1.542 0.635 0 CA-C-N 115.007 -0.997 . . . . 0.0 109.337 178.697 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' E' E ' 17' ' ' LEU . . . . . 0.571 ' N ' HD12 ' E' ' 17' ' ' LEU . 4.7 mp -106.85 163.34 13.03 Favored 'General case' 0 N--CA 1.49 1.538 0 N-CA-C 109.075 -0.713 . . . . 0.0 109.075 -179.876 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 41.6 t -141.66 118.05 6.93 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.319 0 C-N-CA 122.684 0.394 . . . . 0.0 110.442 178.952 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 54.7 m-85 -69.43 156.31 39.05 Favored 'General case' 0 C--N 1.358 0.969 0 N-CA-C 107.489 -1.3 . . . . 0.0 107.489 176.621 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 13.1 t80 -173.29 -55.33 0.02 OUTLIER 'General case' 0 N--CA 1.484 1.244 0 CA-C-O 121.724 0.773 . . . . 0.0 110.292 179.333 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -42.35 88.94 0.0 OUTLIER 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 114.502 -1.226 . . . . 0.0 112.654 -179.036 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 37.7 tt0 -61.1 156.42 18.14 Favored 'General case' 0 N--CA 1.47 0.554 0 CA-C-N 115.014 -0.994 . . . . 0.0 110.733 179.416 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 12.0 m-20 -138.16 129.39 27.43 Favored 'General case' 0 N--CA 1.481 1.101 0 C-N-CA 123.003 0.521 . . . . 0.0 110.551 -179.52 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' E' E ' 24' ' ' VAL . . . . . 0.975 HG12 ' H ' ' E' ' 25' ' ' GLY . 40.4 t -79.94 -164.25 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.484 1.238 0 N-CA-C 108.164 -1.05 . . . . 0.0 108.164 179.557 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' E' E ' 25' ' ' GLY . . . . . 0.975 ' H ' HG12 ' E' ' 24' ' ' VAL . . . -70.79 52.25 0.92 Allowed Glycine 0 CA--C 1.529 0.928 0 CA-C-N 118.422 0.556 . . . . 0.0 112.534 -178.807 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 18.1 p -72.68 135.32 45.39 Favored 'General case' 0 C--O 1.219 -0.512 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 178.645 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 2.0 t-20 -68.36 95.33 0.6 Allowed 'General case' 0 CA--C 1.536 0.421 0 N-CA-C 107.681 -1.229 . . . . 0.0 107.681 177.866 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 67.4 mttm -93.74 118.38 31.34 Favored 'General case' 0 N--CA 1.483 1.187 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 -178.586 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.93 -124.97 0.01 OUTLIER Glycine 0 CA--C 1.539 1.587 0 N-CA-C 110.998 -0.841 . . . . 0.0 110.998 178.588 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -129.05 133.65 47.79 Favored 'General case' 0 N--CA 1.48 1.057 0 N-CA-C 109.511 -0.551 . . . . 0.0 109.511 179.493 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 65.3 mt -82.44 138.53 19.26 Favored 'Isoleucine or valine' 0 C--O 1.235 0.29 0 N-CA-C 107.158 -1.423 . . . . 0.0 107.158 178.617 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 36.2 mt -130.33 127.85 63.3 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.895 0 N-CA-C 109.437 -0.579 . . . . 0.0 109.437 -179.447 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.64 79.89 0.12 Allowed Glycine 0 CA--C 1.522 0.485 0 CA-C-N 115.914 -0.585 . . . . 0.0 113.299 179.021 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' E' E ' 34' ' ' LEU . . . . . 0.413 HD23 ' N ' ' E' ' 35' ' ' MET . 1.8 tt -110.56 120.26 41.83 Favored 'General case' 0 N--CA 1.48 1.044 0 N-CA-C 107.312 -1.366 . . . . 0.0 107.312 177.419 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' E' E ' 35' ' ' MET . . . . . 0.413 ' N ' HD23 ' E' ' 34' ' ' LEU . 8.7 mtp -152.4 163.23 39.92 Favored 'General case' 0 C--O 1.213 -0.864 0 N-CA-C 108.32 -0.992 . . . . 0.0 108.32 179.421 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 97.5 t -159.85 145.3 6.17 Favored 'Isoleucine or valine' 0 C--O 1.233 0.235 0 N-CA-C 106.693 -1.595 . . . . 0.0 106.693 179.919 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' E' E ' 37' ' ' GLY . . . . . 0.537 ' CA ' HE21 ' E' ' 15' ' ' GLN . . . 55.03 73.62 0.4 Allowed Glycine 0 C--N 1.316 -0.54 0 N-CA-C 111.202 -0.759 . . . . 0.0 111.202 178.769 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 171.03 -148.22 11.07 Favored Glycine 0 C--O 1.221 -0.688 0 C-N-CA 120.882 -0.675 . . . . 0.0 111.459 -179.807 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 14.0 m -136.04 147.89 27.97 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.918 0 N-CA-C 109.239 -0.652 . . . . 0.0 109.239 -179.833 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 21.5 t . . . . . 0 C--O 1.221 -0.395 0 CA-C-O 117.8 -1.095 . . . . 0.0 111.19 179.168 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 15.7 m-85 . . . . . 0 N--CA 1.473 0.691 0 CA-C-O 121.143 0.497 . . . . 0.0 110.015 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' F' F ' 5' ' ' ARG . . . . . 0.843 HH21 HG13 ' B' ' 24' ' ' VAL . 53.3 mtp180 -68.03 129.75 40.87 Favored 'General case' 0 CA--C 1.537 0.465 0 CA-C-N 115.422 -0.808 . . . . 0.0 110.602 -177.962 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 45.4 m170 -96.39 125.33 40.81 Favored 'General case' 0 N--CA 1.476 0.874 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 178.885 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' F' F ' 7' ' ' ASP . . . . . 0.577 ' OD1' HG11 ' H' ' 24' ' ' VAL . 11.7 m-20 -71.72 145.05 49.06 Favored 'General case' 0 N--CA 1.465 0.307 0 O-C-N 123.293 0.37 . . . . 0.0 111.423 -179.842 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' F' F ' 8' ' ' SER . . . . . . . . . . . . . 22.8 t -161.06 179.35 8.5 Favored 'General case' 0 N--CA 1.473 0.685 0 N-CA-C 109.277 -0.638 . . . . 0.0 109.277 178.448 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 125.78 19.84 2.19 Favored Glycine 0 N--CA 1.482 1.742 0 N-CA-C 111.752 -0.539 . . . . 0.0 111.752 179.634 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 40.4 p90 -57.07 128.87 39.18 Favored 'General case' 0 N--CA 1.474 0.756 0 N-CA-C 112.528 0.566 . . . . 0.0 112.528 -179.18 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 45.8 mt-10 -84.49 155.34 22.22 Favored 'General case' 0 N--CA 1.474 0.732 0 N-CA-C 109.318 -0.623 . . . . 0.0 109.318 177.986 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -155.49 127.81 1.03 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.53 0 N-CA-C 108.31 -0.996 . . . . 0.0 108.31 178.742 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 48.6 m-70 -134.74 141.97 46.62 Favored 'General case' 0 N--CA 1.482 1.128 0 CA-C-O 120.606 0.241 . . . . 0.0 111.387 -178.034 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -165.19 99.14 0.73 Allowed 'General case' 0 N--CA 1.485 1.3 0 CA-C-N 116.811 -0.177 . . . . 0.0 111.191 179.702 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' F' F ' 15' ' ' GLN . . . . . 0.538 HE21 ' CA ' ' F' ' 37' ' ' GLY . 49.1 mt-30 -108.84 -171.44 1.85 Allowed 'General case' 0 CA--C 1.499 -0.981 0 N-CA-C 108.525 -0.917 . . . . 0.0 108.525 179.817 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -164.6 98.08 0.78 Allowed 'General case' 0 CA--C 1.54 0.58 0 CA-C-N 114.883 -1.053 . . . . 0.0 109.537 178.657 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' F' F ' 17' ' ' LEU . . . . . 0.569 HD12 ' N ' ' F' ' 17' ' ' LEU . 4.8 mp -106.78 163.14 13.18 Favored 'General case' 0 N--CA 1.49 1.573 0 N-CA-C 109.029 -0.73 . . . . 0.0 109.029 -179.899 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 42.4 t -141.54 118.19 7.31 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.308 0 C-N-CA 122.584 0.354 . . . . 0.0 110.361 179.071 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 55.1 m-85 -69.51 156.06 39.48 Favored 'General case' 0 C--N 1.357 0.932 0 N-CA-C 107.329 -1.36 . . . . 0.0 107.329 176.602 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 13.6 t80 -172.92 -55.69 0.02 OUTLIER 'General case' 0 N--CA 1.483 1.22 0 CA-C-O 121.868 0.842 . . . . 0.0 109.799 179.456 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -42.24 88.8 0.0 OUTLIER 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 114.534 -1.212 . . . . 0.0 112.789 -178.992 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 38.0 tt0 -61.12 156.33 18.4 Favored 'General case' 0 N--CA 1.471 0.617 0 CA-C-N 114.943 -1.026 . . . . 0.0 110.802 179.268 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 12.0 m-20 -138.1 129.63 27.89 Favored 'General case' 0 N--CA 1.482 1.134 0 C-N-CA 122.96 0.504 . . . . 0.0 110.637 -179.638 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' F' F ' 24' ' ' VAL . . . . . 0.963 HG12 ' H ' ' F' ' 25' ' ' GLY . 40.0 t -80.1 -164.07 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.283 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 179.613 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' F' F ' 25' ' ' GLY . . . . . 0.963 ' H ' HG12 ' F' ' 24' ' ' VAL . . . -70.82 52.25 0.93 Allowed Glycine 0 C--N 1.342 0.888 0 CA-C-N 118.608 0.64 . . . . 0.0 112.378 -178.779 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 19.8 p -72.79 134.97 45.17 Favored 'General case' 0 C--O 1.218 -0.558 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 178.525 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 2.0 t-20 -68.21 95.16 0.56 Allowed 'General case' 0 CA--C 1.536 0.422 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 177.967 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 67.4 mttm -93.56 118.21 31.07 Favored 'General case' 0 N--CA 1.482 1.134 0 N-CA-C 110.066 -0.346 . . . . 0.0 110.066 -178.657 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.8 -125.33 0.01 OUTLIER Glycine 0 CA--C 1.539 1.565 0 N-CA-C 111.022 -0.831 . . . . 0.0 111.022 178.629 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.49 133.46 48.47 Favored 'General case' 0 N--CA 1.483 1.193 0 N-CA-C 109.533 -0.543 . . . . 0.0 109.533 179.479 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 65.7 mt -82.47 138.64 19.07 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.306 0 N-CA-C 107.051 -1.463 . . . . 0.0 107.051 178.587 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 35.0 mt -130.34 127.82 63.23 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.833 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 -179.437 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.56 80.05 0.11 Allowed Glycine 0 CA--C 1.525 0.67 0 CA-C-N 115.929 -0.578 . . . . 0.0 113.241 179.023 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' F' F ' 34' ' ' LEU . . . . . 0.443 HD23 ' N ' ' F' ' 35' ' ' MET . 1.8 tt -110.65 121.23 44.81 Favored 'General case' 0 N--CA 1.48 1.067 0 N-CA-C 107.298 -1.371 . . . . 0.0 107.298 177.59 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' F' F ' 35' ' ' MET . . . . . 0.443 ' N ' HD23 ' F' ' 34' ' ' LEU . 8.7 mtp -153.83 163.85 39.35 Favored 'General case' 0 C--O 1.212 -0.894 0 N-CA-C 108.97 -0.752 . . . . 0.0 108.97 179.314 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 98.3 t -160.19 145.48 5.79 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.27 0 N-CA-C 106.906 -1.516 . . . . 0.0 106.906 -179.857 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' F' F ' 37' ' ' GLY . . . . . 0.538 ' CA ' HE21 ' F' ' 15' ' ' GLN . . . 55.15 73.84 0.38 Allowed Glycine 0 C--N 1.317 -0.507 0 N-CA-C 111.188 -0.765 . . . . 0.0 111.188 178.624 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 170.73 -148.17 11.16 Favored Glycine 0 C--O 1.222 -0.635 0 C-N-CA 120.832 -0.699 . . . . 0.0 111.493 -179.728 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 14.1 m -136.22 147.99 27.7 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.981 0 N-CA-C 109.119 -0.697 . . . . 0.0 109.119 -179.793 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 21.6 t . . . . . 0 C--O 1.221 -0.405 0 CA-C-O 117.722 -1.132 . . . . 0.0 111.129 179.138 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 21.7 m-85 . . . . . 0 N--CA 1.475 0.778 0 CA-C-O 120.991 0.424 . . . . 0.0 110.149 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' G' G ' 5' ' ' ARG . . . . . 0.746 HH21 HG13 ' F' ' 24' ' ' VAL . 55.0 mtp180 -67.13 129.1 38.79 Favored 'General case' 0 N--CA 1.469 0.512 0 CA-C-N 115.65 -0.705 . . . . 0.0 110.287 -178.152 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 44.2 m170 -96.09 125.48 40.65 Favored 'General case' 0 N--CA 1.474 0.726 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 178.904 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 9.8 m-20 -72.37 141.5 48.74 Favored 'General case' 0 N--CA 1.468 0.437 0 O-C-N 123.742 0.652 . . . . 0.0 111.52 -179.698 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' G' G ' 8' ' ' SER . . . . . . . . . . . . . 23.2 t -158.58 -179.76 8.38 Favored 'General case' 0 N--CA 1.472 0.665 0 N-CA-C 109.196 -0.668 . . . . 0.0 109.196 178.408 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 125.02 20.16 2.31 Favored Glycine 0 N--CA 1.481 1.675 0 N-CA-C 111.617 -0.593 . . . . 0.0 111.617 179.477 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 43.1 p90 -57.75 128.7 38.41 Favored 'General case' 0 N--CA 1.474 0.727 0 N-CA-C 112.362 0.505 . . . . 0.0 112.362 -178.939 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 46.9 mt-10 -84.51 154.44 22.69 Favored 'General case' 0 N--CA 1.473 0.684 0 CA-C-O 121.055 0.455 . . . . 0.0 109.803 178.611 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 2.6 p -155.8 127.82 1.0 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.028 0 N-CA-C 108.353 -0.98 . . . . 0.0 108.353 178.926 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 50.2 m-70 -134.02 142.99 47.83 Favored 'General case' 0 N--CA 1.476 0.832 0 CA-C-N 115.154 -0.93 . . . . 0.0 111.077 -178.214 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -166.32 98.33 0.6 Allowed 'General case' 0 N--CA 1.484 1.227 0 CA-C-N 116.52 -0.309 . . . . 0.0 110.655 179.129 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' G' G ' 15' ' ' GLN . . . . . 0.548 HE21 ' CA ' ' G' ' 37' ' ' GLY . 49.5 mt-30 -107.92 -171.91 1.96 Allowed 'General case' 0 CA--C 1.5 -0.943 0 N-CA-C 108.544 -0.91 . . . . 0.0 108.544 179.959 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' G' G ' 16' ' ' LYS . . . . . 0.405 ' C ' HD12 ' G' ' 17' ' ' LEU . 88.1 tttt -164.35 98.18 0.81 Allowed 'General case' 0 N--CA 1.472 0.627 0 CA-C-N 115.083 -0.962 . . . . 0.0 109.441 178.567 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' G' G ' 17' ' ' LEU . . . . . 0.575 ' N ' HD12 ' G' ' 17' ' ' LEU . 5.3 mp -106.83 162.28 13.95 Favored 'General case' 0 N--CA 1.486 1.36 0 N-CA-C 109.33 -0.619 . . . . 0.0 109.33 -179.757 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 41.0 t -142.46 118.27 5.62 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.974 0 C-N-CA 122.601 0.361 . . . . 0.0 110.18 178.823 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 48.7 m-85 -69.33 150.49 47.29 Favored 'General case' 0 C--N 1.371 1.524 0 N-CA-C 107.454 -1.313 . . . . 0.0 107.454 176.709 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 11.4 t80 -171.09 -55.29 0.02 OUTLIER 'General case' 0 N--CA 1.486 1.351 0 CA-C-N 117.802 0.274 . . . . 0.0 110.263 -179.926 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.88 90.09 0.0 OUTLIER 'General case' 0 C--N 1.326 -0.446 0 C-N-CA 123.655 0.782 . . . . 0.0 112.339 179.925 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 38.4 tt0 -61.93 156.66 20.36 Favored 'General case' 0 N--CA 1.469 0.484 0 CA-C-N 114.855 -1.066 . . . . 0.0 110.029 178.886 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 12.1 m-20 -138.31 129.85 27.76 Favored 'General case' 0 N--CA 1.481 1.101 0 C-N-CA 122.958 0.503 . . . . 0.0 110.148 -179.557 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' G' G ' 24' ' ' VAL . . . . . 0.967 HG12 ' H ' ' G' ' 25' ' ' GLY . 39.5 t -81.03 -164.03 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.972 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 179.578 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' G' G ' 25' ' ' GLY . . . . . 0.967 ' H ' HG12 ' G' ' 24' ' ' VAL . . . -70.48 51.51 0.84 Allowed Glycine 0 CA--C 1.527 0.836 0 CA-C-N 118.383 0.538 . . . . 0.0 112.452 -179.016 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 18.0 p -72.34 135.9 46.03 Favored 'General case' 0 C--N 1.329 -0.294 0 N-CA-C 109.175 -0.676 . . . . 0.0 109.175 177.936 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 2.0 t-20 -69.1 94.5 0.67 Allowed 'General case' 0 CA--C 1.536 0.416 0 N-CA-C 107.902 -1.147 . . . . 0.0 107.902 177.814 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 68.0 mttm -92.14 118.94 31.32 Favored 'General case' 0 N--CA 1.482 1.134 0 N-CA-C 110.06 -0.348 . . . . 0.0 110.06 -179.2 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.45 -123.37 0.01 OUTLIER Glycine 0 CA--C 1.534 1.247 0 N-CA-C 110.517 -1.033 . . . . 0.0 110.517 178.608 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -129.91 133.54 46.92 Favored 'General case' 0 N--CA 1.47 0.547 0 N-CA-C 109.526 -0.546 . . . . 0.0 109.526 179.604 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 68.8 mt -81.9 140.23 16.78 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.664 0 N-CA-C 107.37 -1.344 . . . . 0.0 107.37 178.626 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 41.3 mt -131.81 129.27 60.94 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.402 0 CA-C-N 119.135 0.88 . . . . 0.0 109.375 179.698 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.47 79.41 0.13 Allowed Glycine 0 CA--C 1.527 0.816 0 CA-C-N 116.302 -0.408 . . . . 0.0 112.882 179.13 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' G' G ' 34' ' ' LEU . . . . . 0.441 HD23 ' N ' ' G' ' 35' ' ' MET . 1.7 tt -110.34 121.69 45.88 Favored 'General case' 0 N--CA 1.482 1.142 0 N-CA-C 107.146 -1.427 . . . . 0.0 107.146 177.616 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' G' G ' 35' ' ' MET . . . . . 0.441 ' N ' HD23 ' G' ' 34' ' ' LEU . 9.2 mtp -154.34 163.91 39.43 Favored 'General case' 0 N--CA 1.477 0.917 0 N-CA-C 107.94 -1.133 . . . . 0.0 107.94 179.583 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 91.6 t -160.03 145.22 5.92 Favored 'Isoleucine or valine' 0 C--O 1.232 0.167 0 N-CA-C 106.376 -1.713 . . . . 0.0 106.376 179.901 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' G' G ' 37' ' ' GLY . . . . . 0.548 ' CA ' HE21 ' G' ' 15' ' ' GLN . . . 55.75 73.88 0.38 Allowed Glycine 0 C--N 1.316 -0.561 0 N-CA-C 111.58 -0.608 . . . . 0.0 111.58 178.355 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 169.69 -146.96 10.46 Favored Glycine 0 N--CA 1.469 0.886 0 N-CA-C 110.834 -0.907 . . . . 0.0 110.834 179.583 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 15.3 m -136.33 148.31 27.41 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.932 0 CA-C-N 117.042 0.421 . . . . 0.0 109.995 -179.768 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 21.2 t . . . . . 0 N--CA 1.472 0.649 0 CA-C-O 117.881 -1.057 . . . . 0.0 111.232 179.257 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 21.8 m-85 . . . . . 0 N--CA 1.473 0.7 0 CA-C-O 121.064 0.459 . . . . 0.0 110.105 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' H' H ' 5' ' ' ARG . . . . . 0.741 HH21 HG13 ' D' ' 24' ' ' VAL . 54.5 mtp180 -67.16 129.12 38.88 Favored 'General case' 0 N--CA 1.469 0.489 0 CA-C-N 115.591 -0.731 . . . . 0.0 110.382 -178.15 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 44.5 m170 -96.13 125.27 40.55 Favored 'General case' 0 N--CA 1.474 0.772 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 179.0 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 9.7 m-20 -72.34 141.29 48.79 Favored 'General case' 0 N--CA 1.468 0.458 0 O-C-N 123.453 0.47 . . . . 0.0 111.506 -179.643 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' H' H ' 8' ' ' SER . . . . . . . . . . . . . 22.7 t -158.25 -179.83 8.47 Favored 'General case' 0 N--CA 1.472 0.642 0 N-CA-C 109.192 -0.669 . . . . 0.0 109.192 178.626 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 124.74 20.23 2.36 Favored Glycine 0 N--CA 1.481 1.645 0 N-CA-C 111.67 -0.572 . . . . 0.0 111.67 179.573 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 42.5 p90 -57.77 128.81 38.94 Favored 'General case' 0 N--CA 1.473 0.708 0 N-CA-C 112.344 0.498 . . . . 0.0 112.344 -179.038 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 46.9 mt-10 -84.48 154.36 22.77 Favored 'General case' 0 N--CA 1.475 0.795 0 CA-C-O 121.074 0.464 . . . . 0.0 109.839 178.571 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.6 p -155.69 128.03 1.04 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.048 0 N-CA-C 108.373 -0.973 . . . . 0.0 108.373 178.867 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 50.2 m-70 -134.11 143.27 47.88 Favored 'General case' 0 N--CA 1.476 0.851 0 CA-C-N 115.158 -0.928 . . . . 0.0 111.151 -178.171 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -166.75 98.32 0.56 Allowed 'General case' 0 N--CA 1.482 1.168 0 CA-C-N 116.65 -0.25 . . . . 0.0 110.726 179.131 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' H' H ' 15' ' ' GLN . . . . . 0.537 HE21 ' CA ' ' H' ' 37' ' ' GLY . 49.0 mt-30 -108.0 -172.39 2.05 Favored 'General case' 0 CA--C 1.499 -1.001 0 N-CA-C 108.42 -0.956 . . . . 0.0 108.42 -179.964 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -164.1 97.94 0.83 Allowed 'General case' 0 N--CA 1.471 0.582 0 CA-C-N 115.083 -0.962 . . . . 0.0 109.277 178.748 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' H' H ' 17' ' ' LEU . . . . . 0.578 HD12 ' N ' ' H' ' 17' ' ' LEU . 5.3 mp -106.67 162.24 13.94 Favored 'General case' 0 N--CA 1.486 1.354 0 N-CA-C 109.259 -0.645 . . . . 0.0 109.259 -179.774 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 41.0 t -142.35 118.15 5.73 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.032 0 C-N-CA 122.613 0.365 . . . . 0.0 110.209 178.899 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 49.1 m-85 -69.65 150.88 46.55 Favored 'General case' 0 C--N 1.371 1.502 0 N-CA-C 107.517 -1.29 . . . . 0.0 107.517 176.631 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 12.1 t80 -172.31 -54.88 0.02 OUTLIER 'General case' 0 N--CA 1.482 1.163 0 N-CA-C 110.213 -0.292 . . . . 0.0 110.213 -179.752 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -42.14 90.55 0.0 OUTLIER 'General case' 0 CA--C 1.534 0.352 0 C-N-CA 123.543 0.737 . . . . 0.0 112.095 179.942 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 38.5 tt0 -62.09 156.64 20.95 Favored 'General case' 0 N--CA 1.469 0.493 0 CA-C-N 114.815 -1.084 . . . . 0.0 110.105 179.087 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 12.0 m-20 -138.16 129.98 28.27 Favored 'General case' 0 N--CA 1.48 1.066 0 C-N-CA 122.968 0.507 . . . . 0.0 110.215 -179.536 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' H' H ' 24' ' ' VAL . . . . . 0.951 HG12 ' H ' ' H' ' 25' ' ' GLY . 39.4 t -81.3 -164.1 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.992 0 N-CA-C 108.376 -0.972 . . . . 0.0 108.376 179.664 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' H' H ' 25' ' ' GLY . . . . . 0.951 ' H ' HG12 ' H' ' 24' ' ' VAL . . . -70.18 51.32 0.77 Allowed Glycine 0 CA--C 1.529 0.932 0 CA-C-N 118.483 0.583 . . . . 0.0 112.268 -179.095 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 17.9 p -72.44 135.96 45.89 Favored 'General case' 0 C--N 1.33 -0.254 0 N-CA-C 109.3 -0.63 . . . . 0.0 109.3 177.945 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 2.0 t-20 -69.2 94.58 0.69 Allowed 'General case' 0 CA--C 1.535 0.368 0 N-CA-C 107.968 -1.123 . . . . 0.0 107.968 177.944 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 68.0 mttm -92.27 118.86 31.31 Favored 'General case' 0 N--CA 1.48 1.066 0 N-CA-C 110.111 -0.329 . . . . 0.0 110.111 -179.21 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.47 -123.02 0.01 OUTLIER Glycine 0 CA--C 1.535 1.291 0 N-CA-C 110.477 -1.049 . . . . 0.0 110.477 178.601 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.04 133.77 46.94 Favored 'General case' 0 N--CA 1.471 0.616 0 C-N-CA 123.0 0.52 . . . . 0.0 109.61 179.715 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 68.5 mt -82.2 140.1 16.93 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.591 0 N-CA-C 107.315 -1.365 . . . . 0.0 107.315 178.57 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 41.6 mt -131.74 129.46 61.26 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.278 0 CA-C-N 119.092 0.86 . . . . 0.0 109.317 179.826 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.14 79.48 0.12 Allowed Glycine 0 CA--C 1.527 0.788 0 CA-C-N 116.239 -0.437 . . . . 0.0 112.933 179.155 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' H' H ' 34' ' ' LEU . . . . . 0.432 HD23 ' N ' ' H' ' 35' ' ' MET . 1.7 tt -110.44 121.76 46.09 Favored 'General case' 0 N--CA 1.481 1.099 0 N-CA-C 107.082 -1.451 . . . . 0.0 107.082 177.592 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' H' H ' 35' ' ' MET . . . . . 0.432 ' N ' HD23 ' H' ' 34' ' ' LEU . 9.3 mtp -154.3 163.71 39.73 Favored 'General case' 0 N--CA 1.476 0.85 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 179.679 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 89.9 t -160.05 145.2 5.89 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.163 0 N-CA-C 106.415 -1.698 . . . . 0.0 106.415 179.838 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' H' H ' 37' ' ' GLY . . . . . 0.537 ' CA ' HE21 ' H' ' 15' ' ' GLN . . . 55.75 73.77 0.39 Allowed Glycine 0 C--N 1.316 -0.537 0 N-CA-C 111.536 -0.625 . . . . 0.0 111.536 178.433 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 169.9 -147.19 10.6 Favored Glycine 0 N--CA 1.469 0.899 0 N-CA-C 110.779 -0.928 . . . . 0.0 110.779 179.641 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 15.1 m -136.25 148.18 27.57 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.918 0 CA-C-N 116.938 0.369 . . . . 0.0 110.033 -179.763 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 21.3 t . . . . . 0 N--CA 1.471 0.625 0 CA-C-O 117.864 -1.065 . . . . 0.0 111.138 179.227 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 21.8 m-85 . . . . . 0 N--CA 1.473 0.712 0 CA-C-O 120.981 0.42 . . . . 0.0 110.169 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' I' I ' 5' ' ' ARG . . . . . 0.725 HH21 HG13 ' E' ' 24' ' ' VAL . 54.6 mtp180 -67.18 128.89 38.07 Favored 'General case' 0 N--CA 1.468 0.455 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.378 -178.214 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 44.3 m170 -95.87 125.22 40.27 Favored 'General case' 0 N--CA 1.475 0.777 0 N-CA-C 109.736 -0.468 . . . . 0.0 109.736 178.99 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 9.8 m-20 -72.21 141.76 49.0 Favored 'General case' 0 N--CA 1.468 0.442 0 O-C-N 123.484 0.49 . . . . 0.0 111.397 -179.682 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' I' I ' 8' ' ' SER . . . . . . . . . . . . . 22.7 t -158.65 179.94 8.65 Favored 'General case' 0 N--CA 1.472 0.63 0 N-CA-C 109.201 -0.666 . . . . 0.0 109.201 178.636 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 124.87 20.29 2.32 Favored Glycine 0 N--CA 1.482 1.739 0 N-CA-C 111.646 -0.582 . . . . 0.0 111.646 179.487 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 42.8 p90 -57.71 128.75 38.62 Favored 'General case' 0 N--CA 1.474 0.765 0 N-CA-C 112.342 0.497 . . . . 0.0 112.342 -179.053 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 46.8 mt-10 -84.39 154.48 22.8 Favored 'General case' 0 N--CA 1.474 0.773 0 CA-C-O 121.043 0.449 . . . . 0.0 109.806 178.538 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 2.6 p -155.82 128.04 1.03 Allowed 'Isoleucine or valine' 0 CA--C 1.553 1.062 0 N-CA-C 108.332 -0.988 . . . . 0.0 108.332 178.843 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 50.4 m-70 -134.17 143.27 47.81 Favored 'General case' 0 N--CA 1.476 0.848 0 CA-C-N 115.094 -0.957 . . . . 0.0 111.094 -178.182 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -166.75 98.37 0.56 Allowed 'General case' 0 N--CA 1.483 1.198 0 CA-C-N 116.626 -0.261 . . . . 0.0 110.795 179.125 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' I' I ' 15' ' ' GLN . . . . . 0.548 HE21 ' CA ' ' I' ' 37' ' ' GLY . 48.9 mt-30 -108.12 -172.15 2.01 Favored 'General case' 0 CA--C 1.499 -0.99 0 N-CA-C 108.441 -0.948 . . . . 0.0 108.441 -179.981 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' I' I ' 16' ' ' LYS . . . . . 0.403 ' C ' HD12 ' I' ' 17' ' ' LEU . 88.1 tttt -164.21 98.03 0.82 Allowed 'General case' 0 N--CA 1.471 0.606 0 CA-C-N 114.992 -1.004 . . . . 0.0 109.333 178.691 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' I' I ' 17' ' ' LEU . . . . . 0.576 HD12 ' N ' ' I' ' 17' ' ' LEU . 5.3 mp -106.64 162.21 13.96 Favored 'General case' 0 N--CA 1.487 1.388 0 N-CA-C 109.278 -0.638 . . . . 0.0 109.278 -179.749 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 40.7 t -142.24 118.12 5.93 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.059 0 C-N-CA 122.632 0.373 . . . . 0.0 110.223 178.851 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 49.2 m-85 -69.61 150.81 46.66 Favored 'General case' 0 C--N 1.37 1.494 0 N-CA-C 107.49 -1.3 . . . . 0.0 107.49 176.599 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 12.2 t80 -172.2 -55.0 0.02 OUTLIER 'General case' 0 N--CA 1.483 1.201 0 N-CA-C 110.231 -0.285 . . . . 0.0 110.231 -179.826 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -42.08 90.45 0.0 OUTLIER 'General case' 0 CA--C 1.535 0.389 0 C-N-CA 123.657 0.783 . . . . 0.0 112.084 179.958 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 38.3 tt0 -62.02 156.68 20.65 Favored 'General case' 0 N--CA 1.469 0.519 0 CA-C-N 114.793 -1.094 . . . . 0.0 110.043 179.147 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 12.3 m-20 -138.17 129.83 28.04 Favored 'General case' 0 N--CA 1.481 1.097 0 C-N-CA 122.973 0.509 . . . . 0.0 110.217 -179.624 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' I' I ' 24' ' ' VAL . . . . . 0.944 HG12 ' H ' ' I' ' 25' ' ' GLY . 38.8 t -80.96 -163.87 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 1.005 0 N-CA-C 108.381 -0.97 . . . . 0.0 108.381 179.618 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' I' I ' 25' ' ' GLY . . . . . 0.944 ' H ' HG12 ' I' ' 24' ' ' VAL . . . -70.57 51.33 0.85 Allowed Glycine 0 CA--C 1.528 0.895 0 CA-C-N 118.364 0.529 . . . . 0.0 112.376 -179.074 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 17.7 p -72.34 136.04 46.07 Favored 'General case' 0 C--N 1.33 -0.252 0 N-CA-C 109.252 -0.647 . . . . 0.0 109.252 177.947 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 2.0 t-20 -69.23 94.58 0.7 Allowed 'General case' 0 CA--C 1.535 0.371 0 N-CA-C 107.953 -1.128 . . . . 0.0 107.953 177.888 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 68.1 mttm -92.32 118.96 31.43 Favored 'General case' 0 N--CA 1.48 1.068 0 N-CA-C 110.15 -0.315 . . . . 0.0 110.15 -179.15 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.52 -123.31 0.01 OUTLIER Glycine 0 CA--C 1.534 1.249 0 N-CA-C 110.632 -0.987 . . . . 0.0 110.632 178.648 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -129.77 133.21 46.86 Favored 'General case' 0 N--CA 1.472 0.665 0 C-N-CA 123.047 0.539 . . . . 0.0 109.594 179.715 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 68.5 mt -81.86 139.99 17.15 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.555 0 N-CA-C 107.266 -1.383 . . . . 0.0 107.266 178.605 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 41.1 mt -131.62 129.48 61.62 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.359 0 CA-C-N 119.023 0.829 . . . . 0.0 109.318 179.807 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.13 79.36 0.13 Allowed Glycine 0 CA--C 1.527 0.814 0 CA-C-N 116.289 -0.414 . . . . 0.0 112.936 179.085 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' I' I ' 34' ' ' LEU . . . . . 0.436 HD23 ' N ' ' I' ' 35' ' ' MET . 1.7 tt -110.28 121.73 45.97 Favored 'General case' 0 N--CA 1.481 1.087 0 N-CA-C 107.163 -1.421 . . . . 0.0 107.163 177.55 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' I' I ' 35' ' ' MET . . . . . 0.436 ' N ' HD23 ' I' ' 34' ' ' LEU . 9.4 mtp -154.26 163.7 39.72 Favored 'General case' 0 N--CA 1.475 0.786 0 N-CA-C 107.971 -1.122 . . . . 0.0 107.971 179.786 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 89.5 t -160.04 145.31 5.94 Favored 'Isoleucine or valine' 0 C--O 1.232 0.162 0 N-CA-C 106.423 -1.695 . . . . 0.0 106.423 179.801 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' I' I ' 37' ' ' GLY . . . . . 0.548 ' CA ' HE21 ' I' ' 15' ' ' GLN . . . 55.55 74.03 0.36 Allowed Glycine 0 C--N 1.315 -0.599 0 N-CA-C 111.573 -0.611 . . . . 0.0 111.573 178.484 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 169.68 -147.04 10.53 Favored Glycine 0 N--CA 1.469 0.877 0 N-CA-C 110.806 -0.918 . . . . 0.0 110.806 179.587 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 15.1 m -136.3 148.27 27.47 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.96 0 CA-C-N 116.979 0.389 . . . . 0.0 110.06 -179.79 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 21.4 t . . . . . 0 N--CA 1.471 0.61 0 CA-C-O 117.899 -1.048 . . . . 0.0 111.07 179.139 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 21.1 p90 . . . . . 0 N--CA 1.471 0.578 0 N-CA-C 110.384 -0.228 . . . . 0.0 110.384 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 99.0 mtt180 -136.73 153.18 50.93 Favored 'General case' 0 N--CA 1.482 1.137 0 N-CA-C 109.527 -0.546 . . . . 0.0 109.527 178.523 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 58.5 t-80 -113.98 114.82 26.69 Favored 'General case' 0 N--CA 1.477 0.9 0 C-N-CA 123.094 0.557 . . . . 0.0 109.627 179.493 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' ASP . . . . . 0.424 ' O ' ' OG ' ' D' ' 8' ' ' SER . 8.9 m-20 -72.99 156.36 38.91 Favored 'General case' 0 N--CA 1.465 0.307 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.062 179.053 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 9.5 p -166.17 -177.08 3.97 Favored 'General case' 0 N--CA 1.483 1.181 0 CA-C-O 120.913 0.387 . . . . 0.0 110.528 178.736 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.9 43.94 1.58 Allowed Glycine 0 N--CA 1.482 1.708 0 CA-C-N 115.747 -0.661 . . . . 0.0 112.19 179.427 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 51.2 p90 -65.32 131.86 47.54 Favored 'General case' 0 N--CA 1.473 0.715 0 CA-C-N 116.83 0.315 . . . . 0.0 111.479 179.751 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 84.4 mt-10 -94.3 153.52 17.97 Favored 'General case' 0 N--CA 1.476 0.853 0 N-CA-C 109.655 -0.498 . . . . 0.0 109.655 178.587 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -153.28 128.52 1.55 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.583 0 N-CA-C 107.781 -1.192 . . . . 0.0 107.781 178.126 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 50.9 m-70 -135.13 144.88 47.34 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 119.144 0.884 . . . . 0.0 111.221 -179.143 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 6.3 t60 -165.83 99.0 0.66 Allowed 'General case' 0 N--CA 1.48 1.061 0 CA-C-N 116.394 -0.366 . . . . 0.0 110.588 179.465 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . 0.451 HE22 ' H ' ' A' ' 37' ' ' GLY . 22.2 pt20 -124.41 155.33 39.01 Favored 'General case' 0 CA--C 1.501 -0.927 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 -179.609 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -124.99 106.02 9.64 Favored 'General case' 0 N--CA 1.478 0.974 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 177.986 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 6.1 mp -121.16 148.88 43.62 Favored 'General case' 0 N--CA 1.497 1.908 0 CA-C-O 121.412 0.625 . . . . 0.0 110.797 -178.528 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 30.8 t -107.57 123.77 63.12 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.018 0 N-CA-C 108.077 -1.083 . . . . 0.0 108.077 177.612 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.506 ' O ' ' N ' ' A' ' 21' ' ' ALA . 25.7 m-85 -119.57 -160.89 0.83 Allowed 'General case' 0 N--CA 1.498 1.962 0 CA-C-N 120.232 1.378 . . . . 0.0 109.178 -179.966 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.555 ' O ' ' HA ' ' D' ' 20' ' ' PHE . 78.7 m-85 -50.94 76.8 0.0 OUTLIER 'General case' 0 C--O 1.2 -1.511 0 C-N-CA 123.772 0.829 . . . . 0.0 111.318 -179.164 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . 0.506 ' N ' ' O ' ' A' ' 19' ' ' PHE . . . -88.47 -75.61 0.42 Allowed 'General case' 0 N--CA 1.471 0.597 0 CA-C-N 115.691 -0.686 . . . . 0.0 110.158 -179.614 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 40.4 tt0 -96.12 98.65 10.51 Favored 'General case' 0 N--CA 1.463 0.205 0 N-CA-C 108.461 -0.94 . . . . 0.0 108.461 179.349 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 4.1 p30 -159.45 145.03 15.91 Favored 'General case' 0 N--CA 1.484 1.242 0 O-C-N 122.334 -0.229 . . . . 0.0 110.828 179.598 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.405 HG12 ' N ' ' A' ' 25' ' ' GLY . 88.6 t -63.04 163.91 1.46 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.799 0 N-CA-C 107.619 -1.252 . . . . 0.0 107.619 176.998 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.5 ' H ' ' HB ' ' D' ' 24' ' ' VAL . . . -117.8 45.62 1.25 Allowed Glycine 0 N--CA 1.474 1.183 0 CA-C-O 119.649 -0.529 . . . . 0.0 111.927 -179.409 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -60.32 -165.21 0.01 OUTLIER 'General case' 0 N--CA 1.471 0.622 0 O-C-N 123.805 0.356 . . . . 0.0 110.461 179.618 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 24.0 t-20 -70.23 80.77 0.52 Allowed 'General case' 0 N--CA 1.463 0.197 0 CA-C-N 116.378 -0.373 . . . . 0.0 110.384 179.654 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 96.9 mttt -79.73 138.23 37.25 Favored 'General case' 0 N--CA 1.472 0.635 0 N-CA-C 109.195 -0.668 . . . . 0.0 109.195 179.365 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.84 -166.13 0.9 Allowed Glycine 0 C--N 1.337 0.621 0 N-CA-C 109.68 -1.368 . . . . 0.0 109.68 178.189 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.73 113.99 26.83 Favored 'General case' 0 N--CA 1.474 0.772 0 N-CA-C 109.546 -0.538 . . . . 0.0 109.546 179.505 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 76.5 mt -99.58 135.39 35.2 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.601 0 N-CA-C 107.054 -1.462 . . . . 0.0 107.054 178.734 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . 0.405 ' C ' ' H ' ' A' ' 34' ' ' LEU . 26.7 pt -150.78 -172.1 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.353 0.743 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.326 -179.27 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.57 2.53 6.0 Favored Glycine 0 CA--C 1.525 0.711 0 N-CA-C 110.864 -0.894 . . . . 0.0 110.864 -179.905 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.418 HD23 ' N ' ' A' ' 35' ' ' MET . 1.1 tt -74.66 133.58 42.1 Favored 'General case' 0 CA--C 1.544 0.735 0 N-CA-C 109.247 -0.649 . . . . 0.0 109.247 -179.611 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 35' ' ' MET . . . . . 0.418 ' N ' HD23 ' A' ' 34' ' ' LEU . 26.6 ttt -159.44 151.4 20.68 Favored 'General case' 0 N--CA 1.47 0.527 0 N-CA-C 108.297 -1.001 . . . . 0.0 108.297 178.924 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.473 HG12 ' N ' ' A' ' 37' ' ' GLY . 63.3 t -154.49 162.89 1.81 Allowed 'Isoleucine or valine' 0 C--N 1.344 0.353 0 N-CA-C 107.774 -1.195 . . . . 0.0 107.774 -179.52 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . 0.473 ' N ' HG12 ' A' ' 36' ' ' VAL . . . 57.57 67.32 2.27 Favored Glycine 0 C--N 1.306 -1.091 0 CA-C-N 115.606 -0.725 . . . . 0.0 112.133 178.717 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.7 177.83 22.44 Favored Glycine 0 N--CA 1.476 1.325 0 N-CA-C 111.045 -0.822 . . . . 0.0 111.045 178.717 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 33.4 m -109.69 152.71 11.66 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.612 0 C-N-CA 123.419 0.687 . . . . 0.0 110.217 -179.58 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 21.9 t . . . . . 0 C--O 1.216 -0.678 0 CA-C-O 118.319 -0.848 . . . . 0.0 110.531 179.615 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 20.5 p90 . . . . . 0 N--CA 1.47 0.549 0 N-CA-C 110.546 -0.168 . . . . 0.0 110.546 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 99.0 mtt180 -136.56 152.98 51.08 Favored 'General case' 0 N--CA 1.481 1.094 0 N-CA-C 109.517 -0.549 . . . . 0.0 109.517 178.534 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 58.4 t-80 -113.91 114.85 26.8 Favored 'General case' 0 N--CA 1.477 0.918 0 C-N-CA 123.156 0.582 . . . . 0.0 109.691 179.522 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 7' ' ' ASP . . . . . 0.419 ' O ' ' OG ' ' E' ' 8' ' ' SER . 8.4 m-20 -73.13 155.95 39.15 Favored 'General case' 0 N--CA 1.467 0.41 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.124 179.151 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 8' ' ' SER . . . . . . . . . . . . . 9.6 p -165.94 -176.93 4.0 Favored 'General case' 0 N--CA 1.481 1.105 0 CA-C-O 120.942 0.401 . . . . 0.0 110.567 178.847 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.67 44.08 1.6 Allowed Glycine 0 N--CA 1.483 1.779 0 CA-C-N 115.701 -0.681 . . . . 0.0 112.232 179.528 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 51.0 p90 -65.66 132.02 47.78 Favored 'General case' 0 N--CA 1.472 0.649 0 CA-C-O 120.688 0.28 . . . . 0.0 111.492 179.823 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 84.2 mt-10 -94.28 153.71 17.89 Favored 'General case' 0 N--CA 1.477 0.876 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 178.483 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -153.41 128.38 1.5 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.511 0 N-CA-C 107.738 -1.208 . . . . 0.0 107.738 178.119 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 49.9 m-70 -135.19 144.5 47.02 Favored 'General case' 0 N--CA 1.492 1.664 0 CA-C-N 119.042 0.837 . . . . 0.0 111.218 -179.091 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 6.3 t60 -165.45 98.71 0.7 Allowed 'General case' 0 N--CA 1.481 1.088 0 CA-C-N 116.461 -0.336 . . . . 0.0 110.482 179.573 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . 0.435 HE22 ' H ' ' B' ' 37' ' ' GLY . 22.2 pt20 -124.14 155.38 38.54 Favored 'General case' 0 CA--C 1.501 -0.909 0 N-CA-C 107.988 -1.116 . . . . 0.0 107.988 -179.694 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -124.99 106.13 9.73 Favored 'General case' 0 N--CA 1.479 1.016 0 N-CA-C 108.121 -1.066 . . . . 0.0 108.121 178.037 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 6.1 mp -121.25 148.82 43.77 Favored 'General case' 0 N--CA 1.497 1.901 0 CA-C-O 121.397 0.618 . . . . 0.0 110.809 -178.518 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 29.8 t -107.6 124.59 63.72 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.038 0 N-CA-C 107.949 -1.13 . . . . 0.0 107.949 177.502 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 19' ' ' PHE . . . . . 0.514 ' O ' ' N ' ' B' ' 21' ' ' ALA . 25.5 m-85 -120.65 -161.12 0.87 Allowed 'General case' 0 N--CA 1.496 1.842 0 CA-C-N 119.906 1.23 . . . . 0.0 109.09 -179.779 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . 0.512 ' O ' ' HA ' ' E' ' 20' ' ' PHE . 77.7 m-85 -51.1 76.56 0.0 OUTLIER 'General case' 0 C--O 1.202 -1.421 0 C-N-CA 123.684 0.794 . . . . 0.0 111.451 -179.129 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 21' ' ' ALA . . . . . 0.514 ' N ' ' O ' ' B' ' 19' ' ' PHE . . . -88.35 -75.9 0.41 Allowed 'General case' 0 N--CA 1.47 0.539 0 CA-C-N 115.628 -0.715 . . . . 0.0 110.1 -179.692 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 40.5 tt0 -95.9 98.95 10.8 Favored 'General case' 0 N--CA 1.464 0.231 0 N-CA-C 108.49 -0.929 . . . . 0.0 108.49 179.358 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 4.1 p30 -159.65 144.96 15.55 Favored 'General case' 0 N--CA 1.483 1.212 0 O-C-N 122.407 -0.183 . . . . 0.0 110.892 179.578 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 24' ' ' VAL . . . . . 0.402 HG12 ' N ' ' B' ' 25' ' ' GLY . 94.0 t -62.9 163.76 1.46 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.808 0 N-CA-C 107.609 -1.256 . . . . 0.0 107.609 177.088 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 25' ' ' GLY . . . . . 0.495 ' H ' ' HB ' ' E' ' 24' ' ' VAL . . . -117.54 45.67 1.24 Allowed Glycine 0 N--CA 1.474 1.231 0 N-CA-C 111.903 -0.479 . . . . 0.0 111.903 -179.371 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -60.67 -165.05 0.01 OUTLIER 'General case' 0 N--CA 1.472 0.643 0 O-C-N 123.62 0.247 . . . . 0.0 110.452 179.688 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 24.1 t-20 -70.4 80.93 0.55 Allowed 'General case' 0 N--CA 1.464 0.272 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.268 179.664 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 96.8 mttt -79.87 138.28 37.13 Favored 'General case' 0 N--CA 1.472 0.656 0 N-CA-C 109.187 -0.672 . . . . 0.0 109.187 179.373 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.82 -166.14 0.9 Allowed Glycine 0 C--N 1.337 0.602 0 N-CA-C 109.638 -1.385 . . . . 0.0 109.638 178.231 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.68 113.84 26.55 Favored 'General case' 0 N--CA 1.474 0.729 0 N-CA-C 109.639 -0.504 . . . . 0.0 109.639 179.475 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 76.0 mt -99.44 135.32 35.25 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.527 0 N-CA-C 107.054 -1.461 . . . . 0.0 107.054 178.733 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . 0.403 ' C ' ' H ' ' B' ' 34' ' ' LEU . 26.6 pt -150.73 -172.05 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.353 0.729 0 CA-C-O 121.185 0.517 . . . . 0.0 111.259 -179.278 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.67 2.35 5.94 Favored Glycine 0 CA--C 1.525 0.692 0 N-CA-C 110.776 -0.93 . . . . 0.0 110.776 -179.919 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 34' ' ' LEU . . . . . 0.403 ' H ' ' C ' ' B' ' 32' ' ' ILE . 1.1 tt -74.55 133.2 42.28 Favored 'General case' 0 CA--C 1.545 0.773 0 N-CA-C 109.209 -0.663 . . . . 0.0 109.209 -179.588 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 35' ' ' MET . . . . . 0.4 ' N ' HD23 ' B' ' 34' ' ' LEU . 26.6 ttt -159.04 150.76 20.68 Favored 'General case' 0 N--CA 1.47 0.562 0 N-CA-C 108.362 -0.977 . . . . 0.0 108.362 178.722 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 36' ' ' VAL . . . . . 0.472 HG12 ' N ' ' B' ' 37' ' ' GLY . 64.0 t -153.79 162.51 2.08 Favored 'Isoleucine or valine' 0 C--N 1.345 0.394 0 N-CA-C 107.838 -1.171 . . . . 0.0 107.838 -179.599 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . 0.472 ' N ' HG12 ' B' ' 36' ' ' VAL . . . 58.07 67.13 2.36 Favored Glycine 0 C--N 1.307 -1.043 0 CA-C-N 115.586 -0.734 . . . . 0.0 112.071 178.627 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.85 177.31 22.14 Favored Glycine 0 N--CA 1.475 1.298 0 N-CA-C 111.042 -0.823 . . . . 0.0 111.042 178.797 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 33.6 m -109.21 152.5 11.25 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.621 0 C-N-CA 123.37 0.668 . . . . 0.0 110.316 -179.599 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 22.0 t . . . . . 0 C--O 1.215 -0.758 0 CA-C-O 118.379 -0.82 . . . . 0.0 110.422 179.604 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 20.4 p90 . . . . . 0 N--CA 1.47 0.542 0 N-CA-C 110.566 -0.161 . . . . 0.0 110.566 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 99.0 mtt180 -136.68 153.09 50.99 Favored 'General case' 0 N--CA 1.481 1.089 0 N-CA-C 109.546 -0.539 . . . . 0.0 109.546 178.528 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 58.3 t-80 -113.86 115.06 27.14 Favored 'General case' 0 N--CA 1.478 0.951 0 C-N-CA 123.052 0.541 . . . . 0.0 109.6 179.634 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' C' C ' 7' ' ' ASP . . . . . . . . . . . . . 8.6 m-20 -73.38 155.75 39.04 Favored 'General case' 0 N--CA 1.467 0.385 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.167 179.086 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' C' C ' 8' ' ' SER . . . . . . . . . . . . . 9.5 p -165.67 -176.98 4.13 Favored 'General case' 0 N--CA 1.482 1.167 0 CA-C-O 120.909 0.385 . . . . 0.0 110.567 178.748 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.87 44.01 1.58 Allowed Glycine 0 N--CA 1.483 1.781 0 CA-C-N 115.728 -0.669 . . . . 0.0 112.284 179.49 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 51.0 p90 -65.49 132.0 47.83 Favored 'General case' 0 N--CA 1.473 0.724 0 O-C-N 122.653 -0.322 . . . . 0.0 111.465 179.789 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 83.7 mt-10 -94.27 153.78 17.86 Favored 'General case' 0 N--CA 1.476 0.84 0 N-CA-C 109.634 -0.506 . . . . 0.0 109.634 178.507 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -153.43 128.52 1.52 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.61 0 N-CA-C 107.757 -1.201 . . . . 0.0 107.757 178.135 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 50.0 m-70 -135.33 144.57 46.78 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 119.084 0.856 . . . . 0.0 111.142 -179.104 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 6.3 t60 -165.65 98.71 0.68 Allowed 'General case' 0 N--CA 1.48 1.066 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.458 179.549 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' C' C ' 15' ' ' GLN . . . . . 0.425 HE22 ' H ' ' C' ' 37' ' ' GLY . 21.9 pt20 -124.24 155.47 38.53 Favored 'General case' 0 CA--C 1.503 -0.859 0 N-CA-C 107.865 -1.161 . . . . 0.0 107.865 -179.66 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -124.97 106.31 9.87 Favored 'General case' 0 N--CA 1.479 1.004 0 N-CA-C 108.208 -1.034 . . . . 0.0 108.208 177.969 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 6.1 mp -121.34 148.88 43.76 Favored 'General case' 0 N--CA 1.498 1.966 0 CA-C-O 121.474 0.654 . . . . 0.0 110.796 -178.433 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 29.0 t -107.74 124.53 63.88 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.088 0 N-CA-C 107.968 -1.123 . . . . 0.0 107.968 177.51 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' C' C ' 19' ' ' PHE . . . . . 0.517 ' O ' ' N ' ' C' ' 21' ' ' ALA . 25.5 m-85 -120.55 -161.05 0.86 Allowed 'General case' 0 N--CA 1.496 1.857 0 CA-C-N 119.936 1.244 . . . . 0.0 109.13 -179.674 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' C' C ' 20' ' ' PHE . . . . . 0.514 ' O ' ' HA ' ' F' ' 20' ' ' PHE . 77.8 m-85 -51.25 76.46 0.0 OUTLIER 'General case' 0 C--O 1.202 -1.414 0 C-N-CA 123.716 0.807 . . . . 0.0 111.404 -179.186 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' C' C ' 21' ' ' ALA . . . . . 0.517 ' N ' ' O ' ' C' ' 19' ' ' PHE . . . -88.26 -75.89 0.41 Allowed 'General case' 0 N--CA 1.47 0.533 0 CA-C-N 115.604 -0.725 . . . . 0.0 110.142 -179.7 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 40.8 tt0 -95.74 98.62 10.6 Favored 'General case' 0 N--CA 1.464 0.265 0 N-CA-C 108.482 -0.933 . . . . 0.0 108.482 179.326 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 4.1 p30 -159.51 144.77 15.66 Favored 'General case' 0 N--CA 1.482 1.172 0 O-C-N 122.287 -0.258 . . . . 0.0 110.985 179.616 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' C' C ' 24' ' ' VAL . . . . . 0.41 HG12 ' N ' ' C' ' 25' ' ' GLY . 89.7 t -62.76 163.8 1.43 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.765 0 N-CA-C 107.681 -1.229 . . . . 0.0 107.681 177.067 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' C' C ' 25' ' ' GLY . . . . . 0.516 ' H ' ' HB ' ' F' ' 24' ' ' VAL . . . -117.65 45.72 1.24 Allowed Glycine 0 N--CA 1.476 1.364 0 N-CA-C 111.724 -0.55 . . . . 0.0 111.724 -179.377 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -60.47 -165.1 0.01 OUTLIER 'General case' 0 N--CA 1.472 0.647 0 CA-C-O 120.61 0.243 . . . . 0.0 110.421 179.616 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 24.1 t-20 -70.52 80.62 0.57 Allowed 'General case' 0 N--CA 1.464 0.258 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.308 179.684 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -79.41 138.5 37.65 Favored 'General case' 0 N--CA 1.472 0.639 0 N-CA-C 109.222 -0.659 . . . . 0.0 109.222 179.333 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.96 -165.68 0.87 Allowed Glycine 0 CA--C 1.523 0.588 0 N-CA-C 109.614 -1.394 . . . . 0.0 109.614 178.322 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.88 113.81 26.6 Favored 'General case' 0 N--CA 1.474 0.745 0 N-CA-C 109.617 -0.512 . . . . 0.0 109.617 179.459 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 76.0 mt -99.67 135.12 36.5 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.591 0 N-CA-C 107.041 -1.466 . . . . 0.0 107.041 178.83 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' C' C ' 32' ' ' ILE . . . . . 0.409 ' C ' ' H ' ' C' ' 34' ' ' LEU . 26.8 pt -150.61 -171.91 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.353 0.741 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.296 -179.305 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.59 2.24 5.67 Favored Glycine 0 CA--C 1.524 0.615 0 N-CA-C 110.808 -0.917 . . . . 0.0 110.808 -179.893 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' C' C ' 34' ' ' LEU . . . . . 0.413 HD23 ' N ' ' C' ' 35' ' ' MET . 1.1 tt -74.43 133.28 42.42 Favored 'General case' 0 CA--C 1.544 0.725 0 N-CA-C 109.275 -0.639 . . . . 0.0 109.275 -179.59 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' C' C ' 35' ' ' MET . . . . . 0.413 ' N ' HD23 ' C' ' 34' ' ' LEU . 26.6 ttt -159.03 150.69 20.65 Favored 'General case' 0 N--CA 1.47 0.557 0 N-CA-C 108.477 -0.934 . . . . 0.0 108.477 178.786 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' C' C ' 36' ' ' VAL . . . . . 0.478 HG12 ' N ' ' C' ' 37' ' ' GLY . 62.7 t -153.64 162.82 2.01 Favored 'Isoleucine or valine' 0 C--N 1.344 0.336 0 N-CA-C 107.78 -1.193 . . . . 0.0 107.78 -179.695 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' C' C ' 37' ' ' GLY . . . . . 0.478 ' N ' HG12 ' C' ' 36' ' ' VAL . . . 57.85 67.37 2.24 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-N 115.488 -0.778 . . . . 0.0 112.043 178.549 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.65 177.41 22.06 Favored Glycine 0 N--CA 1.475 1.271 0 N-CA-C 111.027 -0.829 . . . . 0.0 111.027 178.736 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' C' C ' 39' ' ' VAL . . . . . 0.401 ' H ' HG12 ' F' ' 39' ' ' VAL . 33.6 m -109.16 152.67 11.15 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.647 0 C-N-CA 123.303 0.641 . . . . 0.0 110.19 -179.601 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 22.0 t . . . . . 0 C--O 1.216 -0.687 0 CA-C-O 118.273 -0.87 . . . . 0.0 110.581 179.608 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 34.1 p90 . . . . . 0 C--O 1.221 -0.423 0 N-CA-C 108.43 -0.952 . . . . 0.0 108.43 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' D' D ' 5' ' ' ARG . . . . . . . . . . . . . 99.1 mtt180 -132.18 154.67 49.32 Favored 'General case' 0 N--CA 1.477 0.921 0 N-CA-C 109.163 -0.68 . . . . 0.0 109.163 -177.501 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 55.5 t-80 -115.78 121.65 43.06 Favored 'General case' 0 C--N 1.37 1.466 0 N-CA-C 107.827 -1.175 . . . . 0.0 107.827 176.283 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' D' D ' 7' ' ' ASP . . . . . 0.533 ' O ' ' OG ' ' G' ' 8' ' ' SER 0.279 5.0 m-20 -65.11 136.91 57.27 Favored 'General case' 0 C--N 1.313 -1.005 0 C-N-CA 129.589 3.155 . . . . 0.0 115.638 171.6 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' D' D ' 8' ' ' SER . . . . . 0.424 ' OG ' ' O ' ' A' ' 7' ' ' ASP . 7.0 p -153.4 -174.21 4.86 Favored 'General case' 0 N--CA 1.487 1.411 0 CA-C-N 120.825 1.648 . . . . 0.0 111.062 174.704 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 105.07 46.5 1.25 Allowed Glycine 0 N--CA 1.483 1.769 0 C-N-CA 125.071 1.319 . . . . 0.0 110.558 174.78 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 52.6 p90 -60.96 130.69 47.68 Favored 'General case' 0 N--CA 1.472 0.637 0 N-CA-C 112.543 0.572 . . . . 0.0 112.543 177.151 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 84.9 mt-10 -90.94 151.83 20.95 Favored 'General case' 0 N--CA 1.48 1.027 0 CA-C-N 118.029 0.377 . . . . 0.0 110.857 174.946 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -149.62 130.1 4.35 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.615 0 N-CA-C 107.355 -1.35 . . . . 0.0 107.355 172.829 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 47.0 m-70 -129.92 147.61 51.69 Favored 'General case' 0 N--CA 1.483 1.223 0 CA-C-N 118.102 0.41 . . . . 0.0 111.774 176.32 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 6.3 t60 -165.32 104.98 0.75 Allowed 'General case' 0 N--CA 1.485 1.303 0 N-CA-C 109.366 -0.605 . . . . 0.0 109.366 173.233 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' D' D ' 15' ' ' GLN . . . . . 0.461 HE22 ' H ' ' D' ' 37' ' ' GLY . 23.2 pt20 -128.59 148.38 50.78 Favored 'General case' 0 C--N 1.296 -1.726 0 C-N-CA 123.764 0.826 . . . . 0.0 108.879 -178.631 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -118.64 111.5 18.62 Favored 'General case' 0 N--CA 1.476 0.846 0 N-CA-C 107.486 -1.302 . . . . 0.0 107.486 177.054 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 5.0 mp -126.77 148.71 49.9 Favored 'General case' 0 N--CA 1.5 2.059 0 CA-C-O 122.068 0.937 . . . . 0.0 109.983 179.169 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 12.9 t -99.91 128.44 51.79 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.769 0 CA-C-O 116.37 -1.776 . . . . 0.0 109.691 174.939 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' D' D ' 19' ' ' PHE . . . . . 0.511 ' O ' ' N ' ' D' ' 21' ' ' ALA . 25.2 m-85 -127.43 -163.06 1.22 Allowed 'General case' 0 N--CA 1.499 1.977 0 CA-C-N 120.686 1.584 . . . . 0.0 107.681 -179.966 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' D' D ' 20' ' ' PHE . . . . . 0.555 ' HA ' ' O ' ' A' ' 20' ' ' PHE . 90.1 m-85 -53.22 70.73 0.0 OUTLIER 'General case' 0 C--O 1.198 -1.62 0 C-N-CA 126.344 1.857 . . . . 0.0 111.44 -174.517 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' D' D ' 21' ' ' ALA . . . . . 0.511 ' N ' ' O ' ' D' ' 19' ' ' PHE . . . -86.39 -74.18 0.43 Allowed 'General case' 0 C--N 1.362 1.117 0 CA-C-N 114.922 -1.036 . . . . 0.0 109.701 -175.945 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 41.1 tt0 -98.82 102.99 14.9 Favored 'General case' 0 N--CA 1.483 1.212 0 N-CA-C 106.577 -1.638 . . . . 0.0 106.577 178.108 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 4.2 p30 -152.4 143.92 23.43 Favored 'General case' 0 N--CA 1.476 0.872 0 CA-C-O 116.783 -1.58 . . . . 0.0 113.501 178.551 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' D' D ' 24' ' ' VAL . . . . . 0.5 ' HB ' ' H ' ' A' ' 25' ' ' GLY . 89.3 t -64.46 165.26 1.46 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.351 0 CA-C-N 120.952 1.705 . . . . 0.0 107.584 173.953 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' D' D ' 25' ' ' GLY . . . . . 0.581 ' H ' ' HB ' ' G' ' 24' ' ' VAL . . . -117.02 51.1 0.75 Allowed Glycine 0 N--CA 1.48 1.573 0 CA-C-O 118.885 -0.953 . . . . 0.0 111.575 177.849 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -57.87 -168.74 0.01 OUTLIER 'General case' 0 C--N 1.321 -0.655 0 C-N-CA 124.037 0.935 . . . . 0.0 111.491 175.509 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 25.7 t-20 -72.33 86.86 1.12 Allowed 'General case' 0 C--N 1.35 0.588 0 C-N-CA 119.003 -1.079 . . . . 0.0 108.598 178.455 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 96.4 mttt -83.47 141.19 31.84 Favored 'General case' 0 C--N 1.352 0.688 0 N-CA-C 108.181 -1.044 . . . . 0.0 108.181 178.596 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -62.47 -164.69 0.43 Allowed Glycine 0 C--N 1.333 0.394 0 N-CA-C 110.451 -1.06 . . . . 0.0 110.451 177.463 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -102.28 115.88 31.48 Favored 'General case' 0 N--CA 1.471 0.595 0 N-CA-C 108.727 -0.842 . . . . 0.0 108.727 178.735 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 82.9 mt -102.91 142.57 16.66 Favored 'Isoleucine or valine' 0 C--N 1.356 0.889 0 N-CA-C 104.949 -2.241 . . . . 0.0 104.949 179.215 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' D' D ' 32' ' ' ILE . . . . . 0.426 HG22 ' H ' ' G' ' 32' ' ' ILE . 27.4 pt -157.18 -172.41 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.109 0 CA-C-O 120.759 0.314 . . . . 0.0 110.219 -178.141 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.95 2.13 6.12 Favored Glycine 0 N--CA 1.465 0.615 0 N-CA-C 110.513 -1.035 . . . . 0.0 110.513 -178.706 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 1.3 tt -75.85 138.05 40.86 Favored 'General case' 0 C--N 1.354 0.777 0 N-CA-C 107.729 -1.211 . . . . 0.0 107.729 -178.311 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 25.3 ttt -156.5 160.73 39.8 Favored 'General case' 0 C--O 1.237 0.444 0 N-CA-C 107.877 -1.157 . . . . 0.0 107.877 175.009 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' D' D ' 36' ' ' VAL . . . . . 0.484 HG12 ' N ' ' D' ' 37' ' ' GLY . 97.0 t -163.2 163.83 0.8 Allowed 'Isoleucine or valine' 0 CA--C 1.517 -0.326 0 N-CA-C 107.021 -1.474 . . . . 0.0 107.021 177.03 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' D' D ' 37' ' ' GLY . . . . . 0.484 ' N ' HG12 ' D' ' 36' ' ' VAL . . . 60.61 63.55 4.89 Favored Glycine 0 CA--C 1.528 0.874 0 C-N-CA 120.075 -1.06 . . . . 0.0 112.888 179.869 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 146.24 178.63 21.81 Favored Glycine 0 N--CA 1.481 1.639 0 CA-C-N 117.801 0.8 . . . . 0.0 111.588 179.803 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 34.5 m -112.69 149.89 15.04 Favored 'Isoleucine or valine' 0 C--N 1.357 0.911 0 N-CA-C 109.432 -0.581 . . . . 0.0 109.432 -176.943 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 21.8 t . . . . . 0 CA--C 1.52 -0.179 0 CA-C-O 115.976 -1.964 . . . . 0.0 109.604 178.486 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 21.7 p90 . . . . . 0 C--O 1.217 -0.626 0 CA-C-O 119.475 -0.298 . . . . 0.0 110.662 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' E' E ' 5' ' ' ARG . . . . . . . . . . . . . 99.0 mtt180 -136.89 154.11 50.56 Favored 'General case' 0 N--CA 1.479 0.992 0 N-CA-C 109.433 -0.58 . . . . 0.0 109.433 178.539 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 58.4 t-80 -114.31 114.5 26.02 Favored 'General case' 0 N--CA 1.48 1.032 0 N-CA-C 109.68 -0.489 . . . . 0.0 109.68 179.581 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' E' E ' 7' ' ' ASP . . . . . 0.42 ' O ' ' OG ' ' H' ' 8' ' ' SER . 7.9 m-20 -73.27 156.29 38.63 Favored 'General case' 0 N--CA 1.466 0.352 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.173 179.095 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' E' E ' 8' ' ' SER . . . . . 0.419 ' OG ' ' O ' ' B' ' 7' ' ' ASP . 5.4 p -166.72 -175.06 2.98 Favored 'General case' 0 N--CA 1.485 1.31 0 CA-C-O 121.17 0.509 . . . . 0.0 110.727 178.388 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.48 44.12 1.61 Allowed Glycine 0 N--CA 1.48 1.59 0 CA-C-N 115.577 -0.738 . . . . 0.0 112.169 179.294 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 49.7 p90 -64.9 131.93 48.02 Favored 'General case' 0 CA--C 1.542 0.672 0 N-CA-C 111.769 0.285 . . . . 0.0 111.769 -179.922 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 86.8 mt-10 -93.55 153.81 18.22 Favored 'General case' 0 N--CA 1.48 1.027 0 CA-C-O 121.163 0.506 . . . . 0.0 109.654 178.074 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -154.72 127.24 1.05 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.546 0 N-CA-C 107.782 -1.192 . . . . 0.0 107.782 177.917 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 48.7 m-70 -135.09 142.61 46.3 Favored 'General case' 0 N--CA 1.483 1.185 0 CA-C-O 120.739 0.304 . . . . 0.0 111.473 -178.009 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 6.2 t60 -164.46 98.83 0.81 Allowed 'General case' 0 N--CA 1.486 1.364 0 CA-C-N 116.448 -0.342 . . . . 0.0 110.327 179.594 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' E' E ' 15' ' ' GLN . . . . . 0.441 HE22 ' H ' ' E' ' 37' ' ' GLY . 22.1 pt20 -123.63 155.57 37.46 Favored 'General case' 0 CA--C 1.503 -0.83 0 N-CA-C 108.243 -1.021 . . . . 0.0 108.243 -179.588 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -125.14 105.88 9.49 Favored 'General case' 0 N--CA 1.484 1.269 0 N-CA-C 108.216 -1.031 . . . . 0.0 108.216 178.145 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 6.0 mp -120.58 148.42 43.9 Favored 'General case' 0 N--CA 1.494 1.74 0 CA-C-O 121.123 0.487 . . . . 0.0 111.293 -178.063 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 21.8 t -109.62 120.53 60.97 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.146 0 N-CA-C 108.126 -1.065 . . . . 0.0 108.126 177.313 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' E' E ' 19' ' ' PHE . . . . . 0.54 ' O ' ' N ' ' E' ' 21' ' ' ALA . 28.5 m-85 -117.11 -162.98 0.89 Allowed 'General case' 0 N--CA 1.495 1.8 0 C-N-CA 122.911 0.485 . . . . 0.0 109.749 -179.365 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' E' E ' 20' ' ' PHE . . . . . 0.512 ' HA ' ' O ' ' B' ' 20' ' ' PHE . 77.2 m-85 -47.76 75.3 0.0 OUTLIER 'General case' 0 C--O 1.206 -1.202 0 C-N-CA 124.288 1.035 . . . . 0.0 111.551 -179.887 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' E' E ' 21' ' ' ALA . . . . . 0.54 ' N ' ' O ' ' E' ' 19' ' ' PHE . . . -87.82 -75.46 0.41 Allowed 'General case' 0 N--CA 1.469 0.52 0 C-N-CA 122.536 0.335 . . . . 0.0 110.399 -179.162 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 41.2 tt0 -96.78 98.92 10.54 Favored 'General case' 0 N--CA 1.463 0.197 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 179.469 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 4.1 p30 -158.58 144.59 16.9 Favored 'General case' 0 N--CA 1.481 1.078 0 O-C-N 122.356 -0.215 . . . . 0.0 111.166 179.821 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' E' E ' 24' ' ' VAL . . . . . 0.495 ' HB ' ' H ' ' B' ' 25' ' ' GLY . 89.5 t -61.8 167.32 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.944 0 N-CA-C 106.925 -1.509 . . . . 0.0 106.925 176.86 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' E' E ' 25' ' ' GLY . . . . . 0.491 ' H ' ' HB ' ' H' ' 24' ' ' VAL . . . -121.48 46.76 1.08 Allowed Glycine 0 N--CA 1.472 1.069 0 N-CA-C 111.163 -0.775 . . . . 0.0 111.163 -179.195 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -61.81 -164.43 0.01 OUTLIER 'General case' 0 N--CA 1.471 0.58 0 CA-C-N 116.943 0.371 . . . . 0.0 110.541 -179.948 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 24.6 t-20 -70.07 77.23 0.5 Allowed 'General case' 0 CA--C 1.533 0.319 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.693 -179.785 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 97.1 mttt -76.14 139.0 41.1 Favored 'General case' 0 N--CA 1.474 0.754 0 N-CA-C 109.715 -0.476 . . . . 0.0 109.715 179.394 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.64 -165.62 1.06 Allowed Glycine 0 C--N 1.335 0.486 0 N-CA-C 109.909 -1.276 . . . . 0.0 109.909 178.011 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.68 113.09 25.32 Favored 'General case' 0 N--CA 1.473 0.711 0 N-CA-C 109.805 -0.442 . . . . 0.0 109.805 179.494 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 75.9 mt -99.07 135.24 34.98 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.447 0 N-CA-C 106.893 -1.521 . . . . 0.0 106.893 178.768 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' E' E ' 32' ' ' ILE . . . . . 0.428 HG22 ' H ' ' H' ' 32' ' ' ILE . 28.3 pt -150.58 -170.31 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.099 0 CA-C-O 120.949 0.404 . . . . 0.0 110.755 -179.471 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.9 2.49 3.72 Favored Glycine 0 CA--C 1.529 0.92 0 N-CA-C 111.476 -0.65 . . . . 0.0 111.476 -179.59 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' E' E ' 34' ' ' LEU . . . . . 0.409 ' H ' ' C ' ' E' ' 32' ' ' ILE . 1.1 tt -73.89 133.73 43.15 Favored 'General case' 0 CA--C 1.545 0.78 0 N-CA-C 109.095 -0.706 . . . . 0.0 109.095 -179.7 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 25.0 ttt -159.34 149.56 19.12 Favored 'General case' 0 N--CA 1.473 0.69 0 N-CA-C 108.567 -0.901 . . . . 0.0 108.567 178.751 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' E' E ' 36' ' ' VAL . . . . . 0.476 HG12 ' N ' ' E' ' 37' ' ' GLY . 61.6 t -152.68 162.78 2.3 Favored 'Isoleucine or valine' 0 C--N 1.345 0.384 0 N-CA-C 108.228 -1.027 . . . . 0.0 108.228 -179.681 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' E' E ' 37' ' ' GLY . . . . . 0.476 ' N ' HG12 ' E' ' 36' ' ' VAL . . . 57.1 67.44 2.22 Favored Glycine 0 C--N 1.309 -0.93 0 CA-C-N 115.473 -0.785 . . . . 0.0 112.012 178.694 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.29 174.94 19.73 Favored Glycine 0 N--CA 1.476 1.325 0 N-CA-C 111.285 -0.726 . . . . 0.0 111.285 178.825 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 31.2 m -107.16 152.55 8.65 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.638 0 C-N-CA 123.475 0.71 . . . . 0.0 110.372 -179.079 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 21.9 t . . . . . 0 C--O 1.214 -0.784 0 O-C-N 124.222 0.951 . . . . 0.0 110.519 179.922 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 22.5 p90 . . . . . 0 C--O 1.218 -0.587 0 CA-C-O 119.582 -0.247 . . . . 0.0 110.575 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' F' F ' 5' ' ' ARG . . . . . . . . . . . . . 99.0 mtt180 -136.73 154.04 50.7 Favored 'General case' 0 N--CA 1.478 0.937 0 N-CA-C 109.409 -0.589 . . . . 0.0 109.409 178.49 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 58.1 t-80 -114.45 114.54 25.96 Favored 'General case' 0 N--CA 1.48 1.027 0 C-N-CA 122.909 0.483 . . . . 0.0 109.76 179.534 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' F' F ' 7' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -73.28 156.39 38.52 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.274 179.129 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' F' F ' 8' ' ' SER . . . . . 0.421 ' HA ' ' OG ' ' I' ' 8' ' ' SER . 5.4 p -166.87 -174.99 2.9 Favored 'General case' 0 N--CA 1.485 1.301 0 CA-C-O 121.023 0.439 . . . . 0.0 110.936 178.468 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.38 43.69 1.69 Allowed Glycine 0 N--CA 1.479 1.543 0 CA-C-N 115.757 -0.656 . . . . 0.0 112.149 179.199 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 49.9 p90 -64.4 132.31 49.69 Favored 'General case' 0 CA--C 1.544 0.724 0 O-C-N 122.632 -0.334 . . . . 0.0 111.813 -179.945 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 86.7 mt-10 -93.73 153.59 18.25 Favored 'General case' 0 N--CA 1.48 1.067 0 N-CA-C 109.636 -0.505 . . . . 0.0 109.636 178.085 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -154.57 127.18 1.07 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.545 0 N-CA-C 107.811 -1.181 . . . . 0.0 107.811 177.885 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 46.6 m-70 -135.06 142.77 46.4 Favored 'General case' 0 N--CA 1.483 1.215 0 CA-C-O 120.77 0.319 . . . . 0.0 111.515 -178.131 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 6.2 t60 -164.55 98.7 0.8 Allowed 'General case' 0 N--CA 1.485 1.302 0 CA-C-N 116.465 -0.334 . . . . 0.0 110.437 179.62 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' F' F ' 15' ' ' GLN . . . . . 0.426 HE22 ' H ' ' F' ' 37' ' ' GLY . 22.2 pt20 -123.52 155.61 37.23 Favored 'General case' 0 CA--C 1.501 -0.914 0 N-CA-C 108.225 -1.028 . . . . 0.0 108.225 -179.527 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -125.09 105.89 9.51 Favored 'General case' 0 N--CA 1.485 1.286 0 N-CA-C 108.245 -1.02 . . . . 0.0 108.245 178.104 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 6.0 mp -120.64 148.21 44.21 Favored 'General case' 0 N--CA 1.495 1.811 0 CA-C-O 121.168 0.509 . . . . 0.0 111.181 -178.009 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 21.7 t -109.45 120.3 60.42 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.167 0 N-CA-C 108.13 -1.063 . . . . 0.0 108.13 177.244 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' F' F ' 19' ' ' PHE . . . . . 0.539 ' O ' ' N ' ' F' ' 21' ' ' ALA . 28.4 m-85 -116.76 -162.7 0.87 Allowed 'General case' 0 N--CA 1.494 1.763 0 C-N-CA 122.919 0.487 . . . . 0.0 109.864 -179.436 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' F' F ' 20' ' ' PHE . . . . . 0.514 ' HA ' ' O ' ' C' ' 20' ' ' PHE . 78.3 m-85 -48.04 75.1 0.0 OUTLIER 'General case' 0 C--O 1.206 -1.229 0 C-N-CA 124.3 1.04 . . . . 0.0 111.466 -179.878 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' F' F ' 21' ' ' ALA . . . . . 0.539 ' N ' ' O ' ' F' ' 19' ' ' PHE . . . -87.38 -77.08 0.35 Allowed 'General case' 0 N--CA 1.466 0.369 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.044 -179.386 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 41.2 tt0 -95.21 99.29 11.27 Favored 'General case' 0 N--CA 1.462 0.173 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 179.49 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 4.1 p30 -158.8 144.8 16.73 Favored 'General case' 0 N--CA 1.481 1.097 0 CA-C-O 119.655 -0.212 . . . . 0.0 111.304 179.745 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' F' F ' 24' ' ' VAL . . . . . 0.516 ' HB ' ' H ' ' C' ' 25' ' ' GLY . 88.8 t -61.98 167.3 0.77 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.93 0 N-CA-C 106.933 -1.506 . . . . 0.0 106.933 176.894 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' F' F ' 25' ' ' GLY . . . . . 0.479 ' H ' ' HB ' ' I' ' 24' ' ' VAL . . . -121.67 46.88 1.07 Allowed Glycine 0 N--CA 1.478 1.44 0 N-CA-C 110.88 -0.888 . . . . 0.0 110.88 -179.239 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -61.89 -164.43 0.01 OUTLIER 'General case' 0 N--CA 1.471 0.612 0 CA-C-N 116.887 0.343 . . . . 0.0 110.436 -179.977 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 24.6 t-20 -69.88 77.11 0.47 Allowed 'General case' 0 CA--C 1.533 0.297 0 CA-C-N 116.319 -0.401 . . . . 0.0 110.752 -179.779 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -76.09 138.97 41.14 Favored 'General case' 0 N--CA 1.475 0.807 0 N-CA-C 109.638 -0.504 . . . . 0.0 109.638 179.451 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.47 -165.36 0.96 Allowed Glycine 0 C--N 1.335 0.484 0 N-CA-C 110.081 -1.207 . . . . 0.0 110.081 177.99 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.92 112.82 25.08 Favored 'General case' 0 N--CA 1.472 0.638 0 N-CA-C 109.695 -0.483 . . . . 0.0 109.695 179.511 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 76.1 mt -98.99 135.3 34.6 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.498 0 N-CA-C 106.882 -1.525 . . . . 0.0 106.882 178.84 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' F' F ' 32' ' ' ILE . . . . . 0.441 HG22 ' H ' ' I' ' 32' ' ' ILE . 28.2 pt -150.64 -170.19 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.128 0 CA-C-O 120.988 0.423 . . . . 0.0 110.777 -179.516 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.99 2.28 3.65 Favored Glycine 0 CA--C 1.53 1.006 0 N-CA-C 111.409 -0.676 . . . . 0.0 111.409 -179.673 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' F' F ' 34' ' ' LEU . . . . . 0.411 HD23 ' N ' ' F' ' 35' ' ' MET . 1.1 tt -73.91 133.72 43.13 Favored 'General case' 0 CA--C 1.546 0.798 0 N-CA-C 109.128 -0.693 . . . . 0.0 109.128 -179.654 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' F' F ' 35' ' ' MET . . . . . 0.411 ' N ' HD23 ' F' ' 34' ' ' LEU . 25.1 ttt -159.4 149.74 19.16 Favored 'General case' 0 N--CA 1.47 0.573 0 N-CA-C 108.563 -0.903 . . . . 0.0 108.563 178.832 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' F' F ' 36' ' ' VAL . . . . . 0.479 HG12 ' N ' ' F' ' 37' ' ' GLY . 62.2 t -152.83 162.84 2.21 Favored 'Isoleucine or valine' 0 C--N 1.345 0.37 0 N-CA-C 108.169 -1.049 . . . . 0.0 108.169 -179.667 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' F' F ' 37' ' ' GLY . . . . . 0.479 ' N ' HG12 ' F' ' 36' ' ' VAL . . . 57.1 67.44 2.22 Favored Glycine 0 C--N 1.308 -0.974 0 CA-C-N 115.433 -0.803 . . . . 0.0 112.004 178.626 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.34 175.04 19.85 Favored Glycine 0 N--CA 1.475 1.275 0 N-CA-C 111.248 -0.741 . . . . 0.0 111.248 178.848 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' F' F ' 39' ' ' VAL . . . . . 0.404 ' H ' HG12 ' I' ' 39' ' ' VAL . 31.4 m -107.27 152.41 8.85 Favored 'Isoleucine or valine' 0 C--N 1.35 0.597 0 C-N-CA 123.546 0.738 . . . . 0.0 110.361 -179.025 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 22.0 t . . . . . 0 C--O 1.213 -0.821 0 O-C-N 124.216 0.948 . . . . 0.0 110.385 179.804 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 20.1 p90 . . . . . 0 N--CA 1.472 0.625 0 N-CA-C 110.339 -0.245 . . . . 0.0 110.339 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' G' G ' 5' ' ' ARG . . . . . . . . . . . . . 99.1 mtt180 -136.54 154.04 50.83 Favored 'General case' 0 N--CA 1.482 1.13 0 N-CA-C 109.463 -0.569 . . . . 0.0 109.463 178.555 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 58.3 t-80 -114.1 115.54 27.7 Favored 'General case' 0 N--CA 1.483 1.207 0 C-N-CA 122.823 0.449 . . . . 0.0 109.891 179.649 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 -75.86 152.46 37.2 Favored 'General case' 0 N--CA 1.47 0.569 0 CA-C-N 116.0 -0.545 . . . . 0.0 110.772 179.279 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' G' G ' 8' ' ' SER . . . . . 0.533 ' OG ' ' O ' ' D' ' 7' ' ' ASP . 4.9 p -164.03 -172.39 2.78 Favored 'General case' 0 N--CA 1.475 0.775 0 CA-C-O 121.105 0.479 . . . . 0.0 110.596 178.621 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.12 43.6 1.87 Allowed Glycine 0 N--CA 1.479 1.563 0 CA-C-N 115.633 -0.712 . . . . 0.0 111.655 178.983 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 51.0 p90 -64.2 132.23 49.75 Favored 'General case' 0 CA--C 1.542 0.67 0 CA-C-O 120.648 0.261 . . . . 0.0 111.664 -179.772 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 84.1 mt-10 -94.01 152.88 18.49 Favored 'General case' 0 N--CA 1.479 1.008 0 CA-C-O 121.035 0.445 . . . . 0.0 110.057 178.644 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -155.21 127.55 1.03 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.016 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 178.179 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 49.9 m-70 -134.63 144.05 47.65 Favored 'General case' 0 N--CA 1.478 0.925 0 CA-C-N 115.416 -0.811 . . . . 0.0 111.405 -178.326 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 6.3 t60 -166.12 98.74 0.63 Allowed 'General case' 0 N--CA 1.481 1.12 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.122 178.977 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' G' G ' 15' ' ' GLN . . . . . 0.436 HE22 ' H ' ' G' ' 37' ' ' GLY . 22.3 pt20 -123.91 154.95 38.99 Favored 'General case' 0 CA--C 1.497 -1.07 0 N-CA-C 107.998 -1.112 . . . . 0.0 107.998 -179.287 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -124.8 106.19 9.85 Favored 'General case' 0 N--CA 1.483 1.192 0 N-CA-C 108.04 -1.096 . . . . 0.0 108.04 178.151 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 6.0 mp -120.22 148.76 43.27 Favored 'General case' 0 N--CA 1.496 1.85 0 CA-C-O 121.091 0.472 . . . . 0.0 111.625 -178.244 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 20.4 t -111.11 120.21 61.29 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.043 0 N-CA-C 107.775 -1.194 . . . . 0.0 107.775 176.909 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' G' G ' 19' ' ' PHE . . . . . 0.556 ' O ' ' N ' ' G' ' 21' ' ' ALA . 28.1 m-85 -117.17 -164.58 1.0 Allowed 'General case' 0 N--CA 1.494 1.728 0 C-N-CA 124.372 1.069 . . . . 0.0 110.225 -178.846 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' G' G ' 20' ' ' PHE . . . . . 0.507 ' HA ' ' O ' ' D' ' 20' ' ' PHE . 78.4 m-85 -47.13 73.02 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.03 0 C-N-CA 124.522 1.129 . . . . 0.0 111.664 -179.83 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' G' G ' 21' ' ' ALA . . . . . 0.556 ' N ' ' O ' ' G' ' 19' ' ' PHE . . . -85.37 -78.23 0.27 Allowed 'General case' 0 N--CA 1.466 0.364 0 C-N-CA 122.715 0.406 . . . . 0.0 110.246 -178.901 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 41.0 tt0 -94.6 99.8 11.87 Favored 'General case' 0 N--CA 1.465 0.284 0 N-CA-C 108.284 -1.006 . . . . 0.0 108.284 179.364 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 4.1 p30 -159.17 144.83 16.23 Favored 'General case' 0 N--CA 1.477 0.91 0 O-C-N 122.313 -0.242 . . . . 0.0 111.226 179.745 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' G' G ' 24' ' ' VAL . . . . . 0.581 ' HB ' ' H ' ' D' ' 25' ' ' GLY . 92.4 t -62.48 165.74 1.02 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.655 0 N-CA-C 107.283 -1.377 . . . . 0.0 107.283 177.231 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' G' G ' 25' ' ' GLY . . . . . 0.408 ' N ' HG12 ' G' ' 24' ' ' VAL . . . -119.86 48.85 0.91 Allowed Glycine 0 N--CA 1.482 1.734 0 N-CA-C 110.587 -1.005 . . . . 0.0 110.587 -179.66 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -64.11 -164.65 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.669 0 CA-C-N 117.194 0.497 . . . . 0.0 109.752 179.787 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 24.8 t-20 -69.97 76.81 0.48 Allowed 'General case' 0 N--CA 1.467 0.415 0 CA-C-N 116.428 -0.351 . . . . 0.0 110.775 -179.699 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -75.2 139.02 42.35 Favored 'General case' 0 N--CA 1.474 0.759 0 N-CA-C 109.724 -0.473 . . . . 0.0 109.724 179.319 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.75 -164.48 0.9 Allowed Glycine 0 C--N 1.337 0.63 0 N-CA-C 109.679 -1.369 . . . . 0.0 109.679 178.185 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.71 113.04 25.25 Favored 'General case' 0 N--CA 1.467 0.412 0 C-N-CA 122.681 0.392 . . . . 0.0 110.204 179.627 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 77.8 mt -99.7 135.42 35.27 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.825 0 N-CA-C 106.932 -1.506 . . . . 0.0 106.932 178.789 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' G' G ' 32' ' ' ILE . . . . . 0.426 ' H ' HG22 ' D' ' 32' ' ' ILE . 30.4 pt -151.09 -169.13 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.745 0 CA-C-N 119.448 1.022 . . . . 0.0 109.946 179.963 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.98 2.42 3.76 Favored Glycine 0 CA--C 1.528 0.861 0 N-CA-C 111.253 -0.739 . . . . 0.0 111.253 -179.749 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' G' G ' 34' ' ' LEU . . . . . 0.415 HD23 ' N ' ' G' ' 35' ' ' MET . 1.1 tt -74.57 133.28 42.25 Favored 'General case' 0 CA--C 1.543 0.687 0 N-CA-C 109.156 -0.683 . . . . 0.0 109.156 -179.586 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' G' G ' 35' ' ' MET . . . . . 0.415 ' N ' HD23 ' G' ' 34' ' ' LEU . 23.8 ttt -159.04 150.27 20.26 Favored 'General case' 0 N--CA 1.469 0.486 0 N-CA-C 108.59 -0.893 . . . . 0.0 108.59 179.126 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' G' G ' 36' ' ' VAL . . . . . 0.445 HG12 ' N ' ' G' ' 37' ' ' GLY . 62.5 t -153.8 161.35 2.44 Favored 'Isoleucine or valine' 0 C--N 1.346 0.426 0 N-CA-C 108.05 -1.093 . . . . 0.0 108.05 -179.5 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' G' G ' 37' ' ' GLY . . . . . 0.445 ' N ' HG12 ' G' ' 36' ' ' VAL . . . 58.43 67.45 2.19 Favored Glycine 0 C--N 1.309 -0.957 0 CA-C-N 115.331 -0.85 . . . . 0.0 111.91 178.566 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.44 174.37 19.36 Favored Glycine 0 N--CA 1.477 1.383 0 N-CA-C 110.641 -0.983 . . . . 0.0 110.641 178.872 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 32.9 m -107.02 152.16 8.62 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.912 0 C-N-CA 123.256 0.622 . . . . 0.0 110.487 -179.453 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 22.7 t . . . . . 0 C--O 1.217 -0.63 0 CA-C-O 118.373 -0.822 . . . . 0.0 110.688 179.867 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 20.4 p90 . . . . . 0 N--CA 1.472 0.636 0 CA-C-O 119.549 -0.262 . . . . 0.0 110.313 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' H' H ' 5' ' ' ARG . . . . . . . . . . . . . 99.1 mtt180 -136.18 153.84 51.13 Favored 'General case' 0 N--CA 1.484 1.258 0 N-CA-C 109.398 -0.593 . . . . 0.0 109.398 178.571 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 58.4 t-80 -113.91 115.31 27.48 Favored 'General case' 0 N--CA 1.482 1.129 0 C-N-CA 122.829 0.452 . . . . 0.0 109.96 179.521 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -75.55 152.7 37.72 Favored 'General case' 0 N--CA 1.47 0.57 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.681 179.295 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' H' H ' 8' ' ' SER . . . . . 0.42 ' OG ' ' O ' ' E' ' 7' ' ' ASP . 6.9 p -164.17 -172.67 2.85 Favored 'General case' 0 N--CA 1.474 0.731 0 CA-C-O 121.113 0.482 . . . . 0.0 110.683 178.63 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.13 43.67 1.86 Allowed Glycine 0 N--CA 1.48 1.599 0 CA-C-N 115.79 -0.641 . . . . 0.0 111.765 179.157 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 51.0 p90 -64.44 132.28 49.56 Favored 'General case' 0 CA--C 1.541 0.61 0 O-C-N 122.68 -0.306 . . . . 0.0 111.709 -179.878 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 84.4 mt-10 -94.04 152.92 18.45 Favored 'General case' 0 N--CA 1.478 0.936 0 CA-C-O 121.095 0.474 . . . . 0.0 110.082 178.651 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -155.27 127.12 0.96 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.032 0 N-CA-C 108.03 -1.1 . . . . 0.0 108.03 178.176 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 48.9 m-70 -134.32 143.84 47.93 Favored 'General case' 0 N--CA 1.479 1.016 0 CA-C-N 115.415 -0.811 . . . . 0.0 111.348 -178.183 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 6.3 t60 -165.96 98.94 0.65 Allowed 'General case' 0 N--CA 1.484 1.227 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.012 178.958 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' H' H ' 15' ' ' GLN . . . . . 0.428 HE22 ' H ' ' H' ' 37' ' ' GLY . 22.5 pt20 -124.07 154.77 39.47 Favored 'General case' 0 CA--C 1.495 -1.135 0 N-CA-C 108.054 -1.091 . . . . 0.0 108.054 -179.339 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -124.52 106.06 9.87 Favored 'General case' 0 N--CA 1.483 1.204 0 N-CA-C 108.156 -1.054 . . . . 0.0 108.156 178.107 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 6.0 mp -120.17 148.58 43.46 Favored 'General case' 0 N--CA 1.496 1.868 0 CA-C-O 121.072 0.463 . . . . 0.0 111.567 -178.201 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 20.2 t -110.61 121.02 62.64 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.008 0 N-CA-C 107.777 -1.194 . . . . 0.0 107.777 176.776 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' H' H ' 19' ' ' PHE . . . . . 0.56 ' O ' ' N ' ' H' ' 21' ' ' ALA . 27.4 m-85 -117.95 -164.32 1.0 Allowed 'General case' 0 N--CA 1.492 1.675 0 C-N-CA 124.268 1.027 . . . . 0.0 110.127 -178.734 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' H' H ' 20' ' ' PHE . . . . . 0.485 ' HA ' ' O ' ' E' ' 20' ' ' PHE . 79.1 m-85 -47.53 73.03 0.0 OUTLIER 'General case' 0 N--CA 1.481 1.081 0 C-N-CA 124.425 1.09 . . . . 0.0 111.621 -179.78 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' H' H ' 21' ' ' ALA . . . . . 0.56 ' N ' ' O ' ' H' ' 19' ' ' PHE . . . -85.13 -77.8 0.27 Allowed 'General case' 0 N--CA 1.466 0.339 0 C-N-CA 122.744 0.417 . . . . 0.0 110.432 -179.018 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 41.1 tt0 -95.14 99.48 11.45 Favored 'General case' 0 N--CA 1.465 0.303 0 N-CA-C 108.313 -0.995 . . . . 0.0 108.313 179.439 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 4.2 p30 -158.76 145.06 16.97 Favored 'General case' 0 N--CA 1.478 0.938 0 O-C-N 122.475 -0.14 . . . . 0.0 111.188 179.874 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' H' H ' 24' ' ' VAL . . . . . 0.491 ' HB ' ' H ' ' E' ' 25' ' ' GLY . 88.8 t -62.65 165.45 1.09 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.594 0 N-CA-C 107.247 -1.39 . . . . 0.0 107.247 177.113 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' H' H ' 25' ' ' GLY . . . . . 0.41 ' N ' HG12 ' H' ' 24' ' ' VAL . . . -119.49 48.69 0.92 Allowed Glycine 0 N--CA 1.48 1.582 0 N-CA-C 110.625 -0.99 . . . . 0.0 110.625 -179.579 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -64.31 -164.83 0.02 OUTLIER 'General case' 0 N--CA 1.473 0.685 0 CA-C-N 117.233 0.517 . . . . 0.0 109.852 179.897 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 24.7 t-20 -69.68 76.95 0.44 Allowed 'General case' 0 N--CA 1.467 0.395 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.71 -179.733 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -75.57 139.29 42.02 Favored 'General case' 0 N--CA 1.472 0.672 0 N-CA-C 109.695 -0.483 . . . . 0.0 109.695 179.326 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -65.15 -164.65 1.07 Allowed Glycine 0 C--N 1.336 0.574 0 N-CA-C 109.651 -1.38 . . . . 0.0 109.651 178.27 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.56 112.92 25.07 Favored 'General case' 0 N--CA 1.468 0.443 0 C-N-CA 122.714 0.406 . . . . 0.0 110.22 179.761 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 76.6 mt -99.6 135.28 35.68 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.812 0 N-CA-C 106.986 -1.487 . . . . 0.0 106.986 178.774 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' H' H ' 32' ' ' ILE . . . . . 0.428 ' H ' HG22 ' E' ' 32' ' ' ILE . 30.5 pt -151.05 -169.16 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.707 0 CA-C-N 119.494 1.043 . . . . 0.0 109.836 -179.914 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.06 2.2 3.66 Favored Glycine 0 CA--C 1.528 0.852 0 N-CA-C 111.167 -0.773 . . . . 0.0 111.167 -179.834 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' H' H ' 34' ' ' LEU . . . . . 0.423 ' H ' ' C ' ' H' ' 32' ' ' ILE . 1.1 tt -74.28 133.13 42.61 Favored 'General case' 0 CA--C 1.544 0.733 0 N-CA-C 109.223 -0.658 . . . . 0.0 109.223 -179.58 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' H' H ' 35' ' ' MET . . . . . 0.404 ' N ' HD23 ' H' ' 34' ' ' LEU . 23.9 ttt -158.85 150.29 20.64 Favored 'General case' 0 N--CA 1.468 0.465 0 N-CA-C 108.644 -0.873 . . . . 0.0 108.644 179.066 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' H' H ' 36' ' ' VAL . . . . . 0.449 HG12 ' N ' ' H' ' 37' ' ' GLY . 59.9 t -153.83 161.38 2.43 Favored 'Isoleucine or valine' 0 C--N 1.346 0.425 0 N-CA-C 108.005 -1.109 . . . . 0.0 108.005 -179.438 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' H' H ' 37' ' ' GLY . . . . . 0.449 ' N ' HG12 ' H' ' 36' ' ' VAL . . . 58.35 67.35 2.24 Favored Glycine 0 C--N 1.309 -0.955 0 CA-C-N 115.349 -0.841 . . . . 0.0 111.902 178.52 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.29 173.8 18.75 Favored Glycine 0 N--CA 1.477 1.39 0 N-CA-C 110.708 -0.957 . . . . 0.0 110.708 178.907 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 32.7 m -106.35 152.08 8.12 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.914 0 C-N-CA 123.341 0.656 . . . . 0.0 110.554 -179.438 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 22.1 t . . . . . 0 C--O 1.218 -0.588 0 CA-C-O 118.321 -0.847 . . . . 0.0 110.644 179.843 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 20.4 p90 . . . . . 0 N--CA 1.471 0.615 0 CA-C-O 119.517 -0.278 . . . . 0.0 110.325 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' I' I ' 5' ' ' ARG . . . . . . . . . . . . . 99.1 mtt180 -136.11 153.92 51.15 Favored 'General case' 0 N--CA 1.483 1.213 0 N-CA-C 109.47 -0.566 . . . . 0.0 109.47 178.62 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 58.2 t-80 -114.12 115.53 27.68 Favored 'General case' 0 N--CA 1.482 1.153 0 C-N-CA 122.809 0.444 . . . . 0.0 109.863 179.545 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 8.0 m-20 -75.98 152.33 37.02 Favored 'General case' 0 N--CA 1.47 0.567 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.697 179.335 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' I' I ' 8' ' ' SER . . . . . 0.421 ' OG ' ' HA ' ' F' ' 8' ' ' SER . 6.7 p -163.89 -172.82 2.97 Favored 'General case' 0 N--CA 1.475 0.78 0 CA-C-O 121.124 0.487 . . . . 0.0 110.681 178.801 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.35 43.61 1.84 Allowed Glycine 0 N--CA 1.481 1.676 0 CA-C-N 115.773 -0.649 . . . . 0.0 111.71 179.105 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 51.1 p90 -64.32 132.38 50.03 Favored 'General case' 0 CA--C 1.541 0.622 0 O-C-N 122.681 -0.306 . . . . 0.0 111.722 -179.853 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 84.1 mt-10 -94.06 152.92 18.44 Favored 'General case' 0 N--CA 1.477 0.921 0 CA-C-O 121.11 0.481 . . . . 0.0 110.033 178.619 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -155.33 127.31 0.98 Allowed 'Isoleucine or valine' 0 CA--C 1.553 1.069 0 N-CA-C 107.978 -1.119 . . . . 0.0 107.978 178.098 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 50.3 m-70 -134.48 144.02 47.83 Favored 'General case' 0 N--CA 1.477 0.92 0 CA-C-N 115.387 -0.824 . . . . 0.0 111.391 -178.269 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 6.3 t60 -166.09 98.59 0.63 Allowed 'General case' 0 N--CA 1.483 1.183 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.06 179.094 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' I' I ' 15' ' ' GLN . . . . . 0.422 HE22 ' H ' ' I' ' 37' ' ' GLY . 22.6 pt20 -123.84 154.77 39.15 Favored 'General case' 0 CA--C 1.497 -1.082 0 N-CA-C 108.014 -1.106 . . . . 0.0 108.014 -179.323 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -124.54 106.07 9.87 Favored 'General case' 0 N--CA 1.483 1.199 0 N-CA-C 108.154 -1.054 . . . . 0.0 108.154 178.125 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 6.0 mp -120.25 148.61 43.47 Favored 'General case' 0 N--CA 1.495 1.819 0 CA-C-O 121.06 0.457 . . . . 0.0 111.593 -178.179 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 20.2 t -110.61 121.1 62.78 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.01 0 N-CA-C 107.799 -1.186 . . . . 0.0 107.799 176.87 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' I' I ' 19' ' ' PHE . . . . . 0.559 ' O ' ' N ' ' I' ' 21' ' ' ALA . 27.2 m-85 -118.11 -164.1 0.99 Allowed 'General case' 0 N--CA 1.495 1.776 0 C-N-CA 124.229 1.012 . . . . 0.0 110.095 -178.659 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' I' I ' 20' ' ' PHE . . . . . 0.485 ' HA ' ' O ' ' F' ' 20' ' ' PHE . 79.6 m-85 -47.61 72.97 0.0 OUTLIER 'General case' 0 N--CA 1.481 1.085 0 C-N-CA 124.54 1.136 . . . . 0.0 111.502 -179.771 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' I' I ' 21' ' ' ALA . . . . . 0.559 ' N ' ' O ' ' I' ' 19' ' ' PHE . . . -85.11 -78.82 0.24 Allowed 'General case' 0 N--CA 1.468 0.43 0 C-N-CA 122.76 0.424 . . . . 0.0 110.12 -178.935 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 41.3 tt0 -93.95 99.48 11.81 Favored 'General case' 0 N--CA 1.464 0.274 0 N-CA-C 108.469 -0.938 . . . . 0.0 108.469 179.247 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 4.2 p30 -158.87 145.26 16.94 Favored 'General case' 0 N--CA 1.478 0.928 0 O-C-N 122.388 -0.195 . . . . 0.0 111.214 179.616 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' I' I ' 24' ' ' VAL . . . . . 0.479 ' HB ' ' H ' ' F' ' 25' ' ' GLY . 92.1 t -62.78 165.71 1.07 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.606 0 N-CA-C 107.257 -1.386 . . . . 0.0 107.257 177.154 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' I' I ' 25' ' ' GLY . . . . . 0.419 ' N ' HG12 ' I' ' 24' ' ' VAL . . . -119.94 48.8 0.92 Allowed Glycine 0 N--CA 1.48 1.619 0 N-CA-C 110.546 -1.022 . . . . 0.0 110.546 -179.559 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -64.08 -164.37 0.02 OUTLIER 'General case' 0 N--CA 1.473 0.684 0 CA-C-N 117.168 0.484 . . . . 0.0 109.747 179.865 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 24.9 t-20 -70.27 77.2 0.53 Allowed 'General case' 0 CA--C 1.536 0.42 0 CA-C-N 116.394 -0.366 . . . . 0.0 110.63 -179.701 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -75.65 139.06 41.77 Favored 'General case' 0 N--CA 1.473 0.713 0 N-CA-C 109.62 -0.511 . . . . 0.0 109.62 179.367 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.83 -164.62 0.94 Allowed Glycine 0 C--N 1.337 0.59 0 N-CA-C 109.76 -1.336 . . . . 0.0 109.76 178.179 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.4 112.75 24.88 Favored 'General case' 0 CA--C 1.535 0.379 0 C-N-CA 122.723 0.409 . . . . 0.0 110.251 179.668 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 77.0 mt -99.52 135.21 35.84 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.852 0 N-CA-C 106.927 -1.508 . . . . 0.0 106.927 178.829 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' I' I ' 32' ' ' ILE . . . . . 0.441 ' H ' HG22 ' F' ' 32' ' ' ILE . 30.3 pt -151.05 -169.08 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 CA-C-N 119.487 1.039 . . . . 0.0 109.876 179.956 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.05 2.25 3.7 Favored Glycine 0 CA--C 1.527 0.827 0 N-CA-C 111.22 -0.752 . . . . 0.0 111.22 -179.751 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' I' I ' 34' ' ' LEU . . . . . 0.42 HD23 ' N ' ' I' ' 35' ' ' MET . 1.1 tt -74.27 133.2 42.62 Favored 'General case' 0 CA--C 1.545 0.761 0 N-CA-C 109.122 -0.696 . . . . 0.0 109.122 -179.598 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' I' I ' 35' ' ' MET . . . . . 0.42 ' N ' HD23 ' I' ' 34' ' ' LEU . 23.8 ttt -158.95 150.13 20.31 Favored 'General case' 0 N--CA 1.468 0.443 0 N-CA-C 108.612 -0.884 . . . . 0.0 108.612 179.04 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' I' I ' 36' ' ' VAL . . . . . 0.451 HG12 ' N ' ' I' ' 37' ' ' GLY . 60.4 t -153.79 161.24 2.48 Favored 'Isoleucine or valine' 0 C--N 1.345 0.396 0 N-CA-C 107.959 -1.126 . . . . 0.0 107.959 -179.46 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' I' I ' 37' ' ' GLY . . . . . 0.451 ' N ' HG12 ' I' ' 36' ' ' VAL . . . 58.45 67.41 2.21 Favored Glycine 0 C--N 1.311 -0.86 0 CA-C-N 115.275 -0.875 . . . . 0.0 111.935 178.564 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.28 173.92 18.84 Favored Glycine 0 N--CA 1.476 1.312 0 N-CA-C 110.674 -0.97 . . . . 0.0 110.674 178.841 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' I' I ' 39' ' ' VAL . . . . . 0.404 HG12 ' H ' ' F' ' 39' ' ' VAL . 32.8 m -106.51 151.98 8.28 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.923 0 C-N-CA 123.28 0.632 . . . . 0.0 110.643 -179.48 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 22.3 t . . . . . 0 C--O 1.217 -0.614 0 CA-C-O 118.413 -0.803 . . . . 0.0 110.752 179.908 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 77.9 m-85 . . . . . 0 N--CA 1.473 0.694 0 N-CA-C 109.658 -0.497 . . . . 0.0 109.658 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 35.6 mtp180 -142.43 143.03 32.45 Favored 'General case' 0 N--CA 1.48 1.059 0 N-CA-C 109.285 -0.635 . . . . 0.0 109.285 -179.951 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 74.4 m80 -150.29 117.84 6.13 Favored 'General case' 0 N--CA 1.472 0.64 0 N-CA-C 108.991 -0.744 . . . . 0.0 108.991 178.749 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 10.1 m-20 -68.31 149.4 49.47 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.822 -179.848 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 4.3 t -168.42 176.34 5.87 Favored 'General case' 0 N--CA 1.473 0.695 0 N-CA-C 109.643 -0.503 . . . . 0.0 109.643 178.592 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 105.08 51.54 0.88 Allowed Glycine 0 N--CA 1.484 1.884 0 N-CA-C 112.065 -0.414 . . . . 0.0 112.065 179.276 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 45.9 p90 -64.8 131.85 47.92 Favored 'General case' 0 N--CA 1.471 0.617 0 CA-C-O 120.51 0.195 . . . . 0.0 111.524 179.652 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . 0.424 ' OE2' ' ND2' ' F' ' 27' ' ' ASN . 43.2 mt-10 -82.78 150.49 26.61 Favored 'General case' 0 N--CA 1.472 0.669 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 177.756 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -154.17 128.98 1.45 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 N-CA-C 108.094 -1.076 . . . . 0.0 108.094 178.167 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 56.7 m-70 -133.39 145.22 50.12 Favored 'General case' 0 N--CA 1.488 1.451 0 CA-C-N 118.616 0.644 . . . . 0.0 110.806 -178.959 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 5.9 t60 -166.11 98.16 0.62 Allowed 'General case' 0 N--CA 1.482 1.141 0 N-CA-C 111.392 0.145 . . . . 0.0 111.392 179.476 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . 0.515 HE22 ' H ' ' A' ' 37' ' ' GLY . 49.8 mt-30 -107.44 -172.65 2.11 Favored 'General case' 0 CA--C 1.502 -0.886 0 N-CA-C 107.948 -1.13 . . . . 0.0 107.948 179.219 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -163.13 97.92 0.92 Allowed 'General case' 0 N--CA 1.471 0.576 0 CA-C-N 115.121 -0.945 . . . . 0.0 109.291 178.739 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.502 HD12 ' N ' ' A' ' 17' ' ' LEU . 6.2 mp -108.7 163.98 12.78 Favored 'General case' 0 N--CA 1.487 1.394 0 N-CA-C 108.05 -1.093 . . . . 0.0 108.05 179.792 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 55.3 t -141.84 120.25 9.18 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.395 0 CA-C-O 118.663 -0.684 . . . . 0.0 110.33 179.77 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 52.9 m-85 -72.97 158.07 36.19 Favored 'General case' 0 N--CA 1.482 1.172 0 N-CA-C 107.383 -1.34 . . . . 0.0 107.383 176.917 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 24.8 t80 -169.29 -58.22 0.02 OUTLIER 'General case' 0 N--CA 1.481 1.076 0 CA-C-O 122.553 1.168 . . . . 0.0 109.475 -179.82 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -39.76 91.12 0.0 OUTLIER 'General case' 0 N--CA 1.457 -0.092 0 CA-C-N 113.665 -1.607 . . . . 0.0 112.709 -178.115 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 36.4 tt0 -58.2 131.95 52.12 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-N 115.143 -0.935 . . . . 0.0 111.128 179.429 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 9.0 m-20 -80.45 162.89 24.18 Favored 'General case' 0 N--CA 1.478 0.961 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 179.772 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 98.3 t -161.2 -74.25 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.484 1.267 0 N-CA-C 107.609 -1.256 . . . . 0.0 107.609 -178.612 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -38.96 91.01 0.01 OUTLIER Glycine 0 N--CA 1.471 1.002 0 CA-C-N 115.385 -0.825 . . . . 0.0 111.981 -179.736 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 89.1 p -37.46 -99.91 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.917 0 C-N-CA 123.714 0.806 . . . . 0.0 112.9 -176.622 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 40.8 t30 -61.23 126.35 27.04 Favored 'General case' 0 CA--C 1.546 0.807 0 CA-C-N 119.495 1.043 . . . . 0.0 108.855 179.465 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 62.8 mttm -106.36 -178.95 3.8 Favored 'General case' 0 N--CA 1.484 1.259 0 N-CA-C 109.249 -0.648 . . . . 0.0 109.249 -179.728 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.83 -141.27 0.02 OUTLIER Glycine 0 CA--C 1.528 0.888 0 N-CA-C 109.39 -1.484 . . . . 0.0 109.39 177.967 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.79 119.42 22.25 Favored 'General case' 0 N--CA 1.477 0.922 0 N-CA-C 109.257 -0.645 . . . . 0.0 109.257 178.439 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 68.9 mt -100.76 146.3 9.61 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.876 0 N-CA-C 107.856 -1.164 . . . . 0.0 107.856 178.614 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 28.4 mt -146.07 124.59 4.87 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.745 0 N-CA-C 109.435 -0.579 . . . . 0.0 109.435 -177.877 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.55 83.91 0.07 OUTLIER Glycine 0 C--N 1.338 0.677 0 CA-C-N 116.138 -0.483 . . . . 0.0 112.93 178.08 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 14.6 tp -101.9 123.2 45.42 Favored 'General case' 0 N--CA 1.484 1.263 0 N-CA-C 107.112 -1.44 . . . . 0.0 107.112 177.394 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 13.5 ttt -158.37 158.06 33.55 Favored 'General case' 0 N--CA 1.468 0.452 0 N-CA-C 109.018 -0.734 . . . . 0.0 109.018 179.94 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 89.5 t -155.93 152.46 8.52 Favored 'Isoleucine or valine' 0 C--O 1.234 0.262 0 N-CA-C 107.37 -1.345 . . . . 0.0 107.37 -179.435 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . 0.515 ' H ' HE22 ' A' ' 15' ' ' GLN . . . 57.22 73.34 0.46 Allowed Glycine 0 C--N 1.31 -0.881 0 CA-C-N 115.569 -0.741 . . . . 0.0 111.834 178.398 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 169.84 -150.03 14.19 Favored Glycine 0 N--CA 1.462 0.394 0 N-CA-C 110.744 -0.942 . . . . 0.0 110.744 179.432 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 33.1 m -133.77 144.77 34.8 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.875 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 179.93 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 19.8 t . . . . . 0 C--O 1.222 -0.393 0 CA-C-O 117.787 -1.101 . . . . 0.0 110.924 179.753 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 78.1 m-85 . . . . . 0 N--CA 1.471 0.621 0 N-CA-C 109.656 -0.498 . . . . 0.0 109.656 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 35.7 mtp180 -142.58 143.15 32.31 Favored 'General case' 0 N--CA 1.479 1.015 0 N-CA-C 109.296 -0.631 . . . . 0.0 109.296 -179.93 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 74.5 m80 -150.38 118.04 6.16 Favored 'General case' 0 N--CA 1.473 0.701 0 N-CA-C 109.045 -0.724 . . . . 0.0 109.045 178.768 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 7' ' ' ASP . . . . . . . . . . . . . 10.0 m-20 -68.46 149.05 49.75 Favored 'General case' 0 N--CA 1.464 0.233 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.929 -179.884 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 8' ' ' SER . . . . . . . . . . . . . 4.3 t -168.14 176.44 6.04 Favored 'General case' 0 N--CA 1.472 0.666 0 N-CA-C 109.614 -0.513 . . . . 0.0 109.614 178.575 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 105.03 51.31 0.89 Allowed Glycine 0 N--CA 1.483 1.814 0 N-CA-C 112.042 -0.423 . . . . 0.0 112.042 179.296 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 46.7 p90 -64.49 131.9 48.43 Favored 'General case' 0 N--CA 1.471 0.618 0 CA-C-O 120.583 0.23 . . . . 0.0 111.538 179.596 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 11' ' ' GLU . . . . . 0.432 ' OE2' ' ND2' ' D' ' 27' ' ' ASN . 43.2 mt-10 -82.88 150.61 26.42 Favored 'General case' 0 N--CA 1.473 0.696 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 177.787 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -154.29 128.9 1.41 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 N-CA-C 108.214 -1.032 . . . . 0.0 108.214 178.162 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 56.8 m-70 -133.4 145.35 50.23 Favored 'General case' 0 N--CA 1.489 1.479 0 CA-C-N 118.458 0.572 . . . . 0.0 110.762 -178.84 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 5.9 t60 -166.25 97.91 0.61 Allowed 'General case' 0 N--CA 1.484 1.27 0 CA-C-O 119.694 -0.193 . . . . 0.0 111.236 179.554 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . 0.514 HE22 ' H ' ' B' ' 37' ' ' GLY . 49.7 mt-30 -107.21 -172.77 2.14 Favored 'General case' 0 CA--C 1.504 -0.803 0 N-CA-C 107.862 -1.162 . . . . 0.0 107.862 179.238 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -163.11 97.9 0.93 Allowed 'General case' 0 N--CA 1.471 0.625 0 CA-C-N 115.154 -0.93 . . . . 0.0 109.192 178.748 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . 0.502 ' N ' HD12 ' B' ' 17' ' ' LEU . 6.1 mp -108.77 163.96 12.81 Favored 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 108.075 -1.083 . . . . 0.0 108.075 179.784 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 57.6 t -141.98 119.92 8.39 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.31 0 CA-C-O 118.724 -0.655 . . . . 0.0 110.293 179.868 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 55.4 m-85 -73.14 158.29 35.58 Favored 'General case' 0 N--CA 1.48 1.036 0 N-CA-C 107.343 -1.355 . . . . 0.0 107.343 176.792 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 26.1 t80 -170.33 -57.25 0.02 OUTLIER 'General case' 0 N--CA 1.478 0.953 0 CA-C-O 122.354 1.073 . . . . 0.0 109.533 -179.962 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -39.87 91.07 0.0 OUTLIER 'General case' 0 C--N 1.34 0.161 0 CA-C-N 113.999 -1.455 . . . . 0.0 112.558 -178.314 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 36.1 tt0 -58.19 132.0 52.25 Favored 'General case' 0 C--N 1.317 -0.811 0 CA-C-N 115.142 -0.936 . . . . 0.0 111.219 179.545 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 -80.58 162.71 24.14 Favored 'General case' 0 N--CA 1.479 1.015 0 N-CA-C 109.491 -0.559 . . . . 0.0 109.491 179.776 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 98.5 t -160.99 -74.13 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.483 1.192 0 C-N-CA 124.76 1.224 . . . . 0.0 107.732 -178.526 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -39.38 91.04 0.01 OUTLIER Glycine 0 N--CA 1.473 1.154 0 CA-C-N 115.42 -0.809 . . . . 0.0 111.828 -179.709 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 92.4 p -37.08 -99.93 0.0 OUTLIER 'General case' 0 N--CA 1.481 1.107 0 C-N-CA 123.881 0.873 . . . . 0.0 112.615 -177.045 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 41.6 t30 -61.23 126.35 27.03 Favored 'General case' 0 CA--C 1.544 0.746 0 CA-C-N 119.547 1.067 . . . . 0.0 109.076 179.508 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 62.9 mttm -106.43 -179.03 3.82 Favored 'General case' 0 N--CA 1.483 1.178 0 N-CA-C 109.223 -0.658 . . . . 0.0 109.223 -179.703 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.85 -141.22 0.02 OUTLIER Glycine 0 CA--C 1.527 0.814 0 N-CA-C 109.411 -1.476 . . . . 0.0 109.411 177.924 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.77 119.36 22.18 Favored 'General case' 0 N--CA 1.478 0.962 0 N-CA-C 109.304 -0.628 . . . . 0.0 109.304 178.488 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 69.0 mt -100.84 146.03 10.13 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.901 0 N-CA-C 107.862 -1.162 . . . . 0.0 107.862 178.551 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 28.7 mt -145.9 124.59 5.1 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.755 0 N-CA-C 109.428 -0.582 . . . . 0.0 109.428 -177.817 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.87 83.87 0.07 OUTLIER Glycine 0 C--N 1.338 0.678 0 CA-C-N 116.119 -0.492 . . . . 0.0 112.872 178.005 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 15.0 tp -102.27 121.52 42.43 Favored 'General case' 0 N--CA 1.486 1.335 0 N-CA-C 107.386 -1.338 . . . . 0.0 107.386 177.441 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 13.3 ttt -156.75 158.18 36.41 Favored 'General case' 0 N--CA 1.466 0.327 0 N-CA-C 109.27 -0.641 . . . . 0.0 109.27 179.836 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 89.1 t -155.97 152.32 8.64 Favored 'Isoleucine or valine' 0 C--O 1.235 0.317 0 N-CA-C 107.256 -1.387 . . . . 0.0 107.256 -179.444 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . 0.514 ' H ' HE22 ' B' ' 15' ' ' GLN . . . 57.39 73.24 0.47 Allowed Glycine 0 C--N 1.312 -0.797 0 CA-C-N 115.525 -0.762 . . . . 0.0 111.789 178.332 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 169.79 -149.99 14.16 Favored Glycine 0 N--CA 1.462 0.412 0 N-CA-C 110.751 -0.94 . . . . 0.0 110.751 179.408 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 33.1 m -133.78 144.83 34.62 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.91 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 179.996 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 20.4 t . . . . . 0 C--O 1.221 -0.425 0 CA-C-O 117.766 -1.111 . . . . 0.0 110.877 179.708 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 78.2 m-85 . . . . . 0 N--CA 1.473 0.714 0 N-CA-C 109.605 -0.517 . . . . 0.0 109.605 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 35.7 mtp180 -142.66 143.11 32.2 Favored 'General case' 0 N--CA 1.48 1.057 0 N-CA-C 109.227 -0.657 . . . . 0.0 109.227 -179.93 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 74.6 m80 -150.44 118.08 6.15 Favored 'General case' 0 N--CA 1.472 0.641 0 N-CA-C 108.958 -0.756 . . . . 0.0 108.958 178.765 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' C' C ' 7' ' ' ASP . . . . . . . . . . . . . 10.0 m-20 -68.52 149.17 49.55 Favored 'General case' 0 N--CA 1.462 0.17 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.994 -179.92 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' C' C ' 8' ' ' SER . . . . . . . . . . . . . 4.3 t -168.22 176.49 5.95 Favored 'General case' 0 N--CA 1.472 0.655 0 N-CA-C 109.546 -0.539 . . . . 0.0 109.546 178.631 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 105.01 51.35 0.89 Allowed Glycine 0 N--CA 1.483 1.821 0 N-CA-C 112.006 -0.438 . . . . 0.0 112.006 179.275 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 46.1 p90 -64.64 131.82 48.02 Favored 'General case' 0 N--CA 1.471 0.602 0 CA-C-O 120.57 0.224 . . . . 0.0 111.509 179.648 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' C' C ' 11' ' ' GLU . . . . . 0.435 ' OE2' ' ND2' ' E' ' 27' ' ' ASN . 43.2 mt-10 -82.76 150.44 26.66 Favored 'General case' 0 N--CA 1.473 0.68 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 177.815 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -154.11 129.04 1.48 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 178.133 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 56.8 m-70 -133.44 145.41 50.22 Favored 'General case' 0 N--CA 1.489 1.507 0 CA-C-N 118.496 0.589 . . . . 0.0 110.81 -178.914 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 5.9 t60 -166.36 98.04 0.6 Allowed 'General case' 0 N--CA 1.483 1.204 0 CA-C-O 119.79 -0.148 . . . . 0.0 111.3 179.534 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' C' C ' 15' ' ' GLN . . . . . 0.494 HE22 ' H ' ' C' ' 37' ' ' GLY . 49.7 mt-30 -107.42 -172.69 2.12 Favored 'General case' 0 CA--C 1.5 -0.945 0 N-CA-C 107.999 -1.111 . . . . 0.0 107.999 179.246 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -163.15 97.86 0.92 Allowed 'General case' 0 N--CA 1.47 0.532 0 CA-C-N 115.181 -0.918 . . . . 0.0 109.308 178.782 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' C' C ' 17' ' ' LEU . . . . . 0.5 HD12 ' N ' ' C' ' 17' ' ' LEU . 6.1 mp -108.69 163.96 12.79 Favored 'General case' 0 N--CA 1.487 1.395 0 N-CA-C 108.037 -1.097 . . . . 0.0 108.037 179.879 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 57.3 t -141.93 119.97 8.59 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.365 0 CA-C-O 118.721 -0.657 . . . . 0.0 110.257 179.836 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 55.1 m-85 -73.14 158.28 35.61 Favored 'General case' 0 N--CA 1.479 1.016 0 N-CA-C 107.293 -1.373 . . . . 0.0 107.293 176.761 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 26.1 t80 -170.23 -57.21 0.02 OUTLIER 'General case' 0 N--CA 1.477 0.898 0 CA-C-O 122.358 1.075 . . . . 0.0 109.587 179.978 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -39.93 91.26 0.0 OUTLIER 'General case' 0 C--N 1.34 0.169 0 CA-C-N 114.028 -1.442 . . . . 0.0 112.549 -178.294 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 36.1 tt0 -58.3 131.88 51.96 Favored 'General case' 0 C--N 1.317 -0.847 0 CA-C-N 115.129 -0.941 . . . . 0.0 111.165 179.501 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 -80.45 162.76 24.25 Favored 'General case' 0 N--CA 1.479 0.994 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 179.722 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 98.2 t -161.07 -74.27 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.483 1.21 0 C-N-CA 124.753 1.221 . . . . 0.0 107.744 -178.556 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -39.46 91.09 0.01 OUTLIER Glycine 0 N--CA 1.473 1.105 0 CA-C-N 115.463 -0.79 . . . . 0.0 111.84 -179.68 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 91.1 p -37.03 -99.88 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.036 0 C-N-CA 123.831 0.852 . . . . 0.0 112.748 -177.0 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 41.6 t30 -61.17 126.37 27.12 Favored 'General case' 0 CA--C 1.545 0.752 0 CA-C-N 119.506 1.048 . . . . 0.0 109.061 179.484 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 62.9 mttm -106.46 -179.12 3.85 Favored 'General case' 0 N--CA 1.483 1.185 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 -179.713 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.79 -141.25 0.02 OUTLIER Glycine 0 CA--C 1.528 0.878 0 N-CA-C 109.362 -1.495 . . . . 0.0 109.362 177.996 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.73 119.34 22.21 Favored 'General case' 0 N--CA 1.477 0.882 0 N-CA-C 109.37 -0.604 . . . . 0.0 109.37 178.436 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 68.7 mt -100.81 146.01 10.15 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.945 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 178.598 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 28.6 mt -145.96 124.63 5.03 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.726 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 -177.793 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.74 83.78 0.07 OUTLIER Glycine 0 C--N 1.339 0.701 0 CA-C-N 116.127 -0.488 . . . . 0.0 112.92 178.05 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 15.2 tp -102.12 121.39 42.11 Favored 'General case' 0 N--CA 1.484 1.26 0 N-CA-C 107.485 -1.302 . . . . 0.0 107.485 177.349 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 13.4 ttt -156.62 158.23 36.67 Favored 'General case' 0 N--CA 1.465 0.32 0 N-CA-C 109.254 -0.647 . . . . 0.0 109.254 179.848 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 87.9 t -155.94 152.44 8.53 Favored 'Isoleucine or valine' 0 C--O 1.235 0.314 0 N-CA-C 107.331 -1.359 . . . . 0.0 107.331 -179.48 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' C' C ' 37' ' ' GLY . . . . . 0.494 ' H ' HE22 ' C' ' 15' ' ' GLN . . . 57.26 73.27 0.47 Allowed Glycine 0 C--N 1.311 -0.82 0 CA-C-N 115.535 -0.757 . . . . 0.0 111.812 178.384 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 169.78 -150.0 14.19 Favored Glycine 0 N--CA 1.462 0.433 0 N-CA-C 110.716 -0.954 . . . . 0.0 110.716 179.377 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 33.2 m -133.7 144.82 34.72 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.883 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 179.98 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 20.3 t . . . . . 0 N--CA 1.467 0.403 0 CA-C-O 117.747 -1.121 . . . . 0.0 110.864 179.667 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 85.5 m-85 . . . . . 0 N--CA 1.472 0.664 0 N-CA-C 108.142 -1.058 . . . . 0.0 108.142 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' D' D ' 5' ' ' ARG . . . . . 0.417 HH21 HG22 ' F' ' 24' ' ' VAL . 36.8 mtp180 -145.95 141.99 28.27 Favored 'General case' 0 N--CA 1.474 0.76 0 N-CA-C 109.365 -0.606 . . . . 0.0 109.365 -179.834 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 75.5 m80 -149.13 123.39 9.57 Favored 'General case' 0 CA--C 1.543 0.684 0 N-CA-C 107.815 -1.18 . . . . 0.0 107.815 174.618 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' D' D ' 7' ' ' ASP . . . . . . . . . . . . . 6.7 m-20 -63.71 133.13 53.02 Favored 'General case' 0 C--N 1.322 -0.615 0 C-N-CA 126.968 2.107 . . . . 0.0 114.675 175.231 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' D' D ' 8' ' ' SER . . . . . . . . . . . . . 3.5 t -154.59 -179.74 8.27 Favored 'General case' 0 N--CA 1.475 0.823 0 CA-C-N 119.081 0.855 . . . . 0.0 110.214 175.99 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.36 49.92 1.02 Allowed Glycine 0 N--CA 1.482 1.743 0 N-CA-C 112.047 -0.421 . . . . 0.0 112.047 175.194 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 46.4 p90 -61.49 132.31 52.98 Favored 'General case' 0 CA--C 1.54 0.575 0 N-CA-C 112.116 0.413 . . . . 0.0 112.116 179.505 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' D' D ' 11' ' ' GLU . . . . . 0.401 ' CG ' ' ND2' ' F' ' 27' ' ' ASN . 42.7 mt-10 -83.23 148.97 27.1 Favored 'General case' 0 N--CA 1.48 1.065 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 176.661 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -149.84 130.15 4.19 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.341 0 N-CA-C 108.325 -0.991 . . . . 0.0 108.325 174.876 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 54.7 m-70 -129.42 148.05 51.29 Favored 'General case' 0 N--CA 1.482 1.137 0 CA-C-N 118.158 0.436 . . . . 0.0 110.897 176.801 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' D' D ' 14' ' ' HIS . . . . . 0.41 ' ND1' ' O ' ' G' ' 14' ' ' HIS . 6.0 t60 -165.34 104.64 0.74 Allowed 'General case' 0 N--CA 1.484 1.246 0 CA-C-O 119.016 -0.516 . . . . 0.0 109.667 173.637 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' D' D ' 15' ' ' GLN . . . . . 0.541 HE22 ' H ' ' D' ' 37' ' ' GLY . 49.7 mt-30 -110.63 -175.72 2.79 Favored 'General case' 0 CA--C 1.492 -1.268 0 N-CA-C 107.551 -1.277 . . . . 0.0 107.551 178.285 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -159.54 105.88 1.67 Allowed 'General case' 0 CA--C 1.536 0.431 0 N-CA-C 107.679 -1.23 . . . . 0.0 107.679 175.619 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' D' D ' 17' ' ' LEU . . . . . 0.442 HD12 ' N ' ' D' ' 17' ' ' LEU . 6.9 mp -114.87 162.65 16.63 Favored 'General case' 0 N--CA 1.487 1.419 0 N-CA-C 107.638 -1.245 . . . . 0.0 107.638 179.401 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 48.1 t -140.99 123.78 15.58 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.147 0 N-CA-C 109.483 -0.562 . . . . 0.0 109.483 176.319 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 82.7 m-85 -63.25 151.08 41.53 Favored 'General case' 0 C--N 1.357 0.923 0 C-N-CA 124.569 1.147 . . . . 0.0 110.634 169.586 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 19.0 t80 -169.68 -66.85 0.02 OUTLIER 'General case' 0 C--N 1.315 -0.916 0 N-CA-C 107.456 -1.312 . . . . 0.0 107.456 -179.877 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -37.98 95.82 0.01 OUTLIER 'General case' 0 CA--C 1.536 0.42 0 CA-C-N 114.162 -1.381 . . . . 0.0 111.683 -175.407 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 36.6 tt0 -60.38 134.34 56.97 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 113.709 -1.587 . . . . 0.0 111.018 179.297 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' D' D ' 23' ' ' ASP . . . . . 0.469 ' O ' HG23 ' D' ' 24' ' ' VAL . 9.5 m-20 -82.57 168.27 17.52 Favored 'General case' 0 C--O 1.205 -1.285 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 179.558 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' D' D ' 24' ' ' VAL . . . . . 0.469 HG23 ' O ' ' D' ' 23' ' ' ASP 0.288 46.3 t -168.93 -94.15 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.505 2.291 0 N-CA-C 103.507 -2.775 . . . . 0.0 103.507 -164.215 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . -26.35 77.14 0.0 OUTLIER Glycine 0 C--N 1.259 -3.721 0 C-N-CA 129.754 3.549 . . . . 0.0 116.908 -179.957 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' D' D ' 26' ' ' SER . . . . . 0.459 ' OG ' ' N ' ' D' ' 27' ' ' ASN 0.51 75.0 p -59.05 -93.05 0.0 OUTLIER 'General case' 0 C--O 1.28 2.692 1 CA-C-O 107.247 -6.12 . . . . 0.0 104.856 -155.503 . . . . . . . . 4 3 . 1 . 018 nuclear nobuild core ' D' D ' 27' ' ' ASN . . . . . 0.459 ' N ' ' OG ' ' D' ' 26' ' ' SER 0.293 32.8 t30 -62.98 135.82 57.5 Favored 'General case' 0 N--CA 1.491 1.581 1 CA-C-N 133.294 7.315 . . . . 0.0 108.193 -172.984 . . . . . . . . 4 3 . 1 . 018 nuclear nobuild core ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 60.0 mttm -102.76 178.58 4.53 Favored 'General case' 0 N--CA 1.475 0.82 0 C-N-CA 125.3 1.44 . . . . 0.0 111.632 177.889 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.02 -145.83 0.01 OUTLIER Glycine 0 CA--C 1.537 1.447 0 N-CA-C 111.267 -0.733 . . . . 0.0 111.267 171.401 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -126.9 122.02 33.44 Favored 'General case' 0 C--N 1.369 1.421 0 N-CA-C 108.779 -0.823 . . . . 0.0 108.779 174.689 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 68.4 mt -97.81 152.27 4.17 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.758 0 N-CA-C 107.829 -1.174 . . . . 0.0 107.829 175.492 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 34.7 mt -152.04 128.68 1.99 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.006 0 N-CA-C 107.884 -1.154 . . . . 0.0 107.884 177.226 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 64.06 80.47 0.13 Allowed Glycine 0 C--N 1.35 1.344 0 CA-C-O 117.996 -1.447 . . . . 0.0 113.185 178.06 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 10.5 tp -101.42 131.98 47.24 Favored 'General case' 0 C--N 1.38 1.931 0 N-CA-C 104.792 -2.299 . . . . 0.0 104.792 176.402 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 12.5 ttt -157.3 165.69 35.15 Favored 'General case' 0 N--CA 1.467 0.395 0 N-CA-C 108.721 -0.844 . . . . 0.0 108.721 176.756 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 81.4 t -163.19 156.61 2.11 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.485 0 N-CA-C 106.145 -1.798 . . . . 0.0 106.145 175.089 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' D' D ' 37' ' ' GLY . . . . . 0.541 ' H ' HE22 ' D' ' 15' ' ' GLN . . . 61.25 66.17 2.83 Favored Glycine 0 N--CA 1.447 -0.633 0 C-N-CA 117.956 -2.068 . . . . 0.0 113.754 178.087 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 167.1 -148.95 13.88 Favored Glycine 0 N--CA 1.467 0.751 0 CA-C-O 118.011 -1.438 . . . . 0.0 112.105 179.982 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 33.0 m -130.67 144.47 37.81 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.225 0 CA-C-N 119.02 1.41 . . . . 0.0 109.956 -178.821 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 18.4 t . . . . . 0 C--O 1.214 -0.802 0 N-CA-C 109.2 -0.667 . . . . 0.0 109.2 174.99 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 77.6 m-85 . . . . . 0 N--CA 1.474 0.763 0 N-CA-C 109.703 -0.48 . . . . 0.0 109.703 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' E' E ' 5' ' ' ARG . . . . . 0.416 HH21 HG22 ' D' ' 24' ' ' VAL . 37.1 mtp180 -142.62 143.56 32.45 Favored 'General case' 0 N--CA 1.477 0.888 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 179.906 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 74.7 m80 -150.56 117.55 5.92 Favored 'General case' 0 N--CA 1.473 0.699 0 N-CA-C 109.136 -0.691 . . . . 0.0 109.136 178.653 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' E' E ' 7' ' ' ASP . . . . . . . . . . . . . 9.5 m-20 -68.06 149.18 49.98 Favored 'General case' 0 CA--C 1.529 0.171 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.043 -179.816 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' E' E ' 8' ' ' SER . . . . . . . . . . . . . 3.4 t -168.5 178.06 4.98 Favored 'General case' 0 N--CA 1.475 0.806 0 N-CA-C 109.574 -0.528 . . . . 0.0 109.574 178.224 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.85 50.9 0.92 Allowed Glycine 0 N--CA 1.477 1.385 0 N-CA-C 111.97 -0.452 . . . . 0.0 111.97 179.124 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 44.2 p90 -63.78 131.21 47.13 Favored 'General case' 0 CA--C 1.545 0.756 0 N-CA-C 111.895 0.332 . . . . 0.0 111.895 -179.861 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 41.4 mt-10 -81.78 151.42 27.43 Favored 'General case' 0 N--CA 1.479 1.008 0 N-CA-C 108.683 -0.858 . . . . 0.0 108.683 177.433 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.6 p -155.92 127.91 1.0 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.449 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 177.906 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 52.2 m-70 -133.5 143.51 48.82 Favored 'General case' 0 N--CA 1.48 1.034 0 O-C-N 122.259 -0.276 . . . . 0.0 111.073 -177.884 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 5.9 t60 -165.35 97.43 0.7 Allowed 'General case' 0 N--CA 1.488 1.437 0 CA-C-O 119.602 -0.237 . . . . 0.0 111.211 179.816 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' E' E ' 15' ' ' GLN . . . . . 0.497 HE22 ' H ' ' E' ' 37' ' ' GLY . 50.0 mt-30 -106.44 -172.29 2.06 Favored 'General case' 0 CA--C 1.505 -0.769 0 N-CA-C 107.969 -1.123 . . . . 0.0 107.969 179.228 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -163.23 98.0 0.92 Allowed 'General case' 0 N--CA 1.47 0.575 0 CA-C-N 115.135 -0.938 . . . . 0.0 109.241 178.634 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' E' E ' 17' ' ' LEU . . . . . 0.488 ' N ' HD12 ' E' ' 17' ' ' LEU . 6.2 mp -108.54 163.13 13.5 Favored 'General case' 0 N--CA 1.488 1.441 0 N-CA-C 108.636 -0.876 . . . . 0.0 108.636 -179.919 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 40.6 t -141.86 120.79 9.83 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.281 0 C-N-CA 122.465 0.306 . . . . 0.0 110.631 179.194 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 51.9 m-85 -73.64 155.6 38.87 Favored 'General case' 0 C--N 1.362 1.138 0 N-CA-C 106.823 -1.547 . . . . 0.0 106.823 176.349 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 23.6 t80 -171.78 -54.82 0.02 OUTLIER 'General case' 0 N--CA 1.479 1.01 0 CA-C-O 121.682 0.753 . . . . 0.0 110.161 -179.942 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.95 89.63 0.0 OUTLIER 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 114.426 -1.261 . . . . 0.0 112.634 -179.436 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 36.0 tt0 -56.2 133.47 52.4 Favored 'General case' 0 CA--C 1.539 0.536 0 CA-C-N 114.912 -1.04 . . . . 0.0 111.291 179.861 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 9.2 m-20 -81.72 162.25 23.05 Favored 'General case' 0 N--CA 1.475 0.779 0 N-CA-C 109.66 -0.496 . . . . 0.0 109.66 179.782 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' E' E ' 24' ' ' VAL . . . . . 0.429 HG22 HH21 ' F' ' 5' ' ' ARG . 95.0 t -160.7 -74.64 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.291 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 -179.003 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . -38.81 91.22 0.01 OUTLIER Glycine 0 CA--C 1.53 0.974 0 CA-C-N 115.263 -0.88 . . . . 0.0 112.403 -179.673 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 84.8 p -37.7 -101.33 0.0 OUTLIER 'General case' 0 N--CA 1.481 1.079 0 N-CA-C 113.725 1.009 . . . . 0.0 113.725 -177.429 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' E' E ' 27' ' ' ASN . . . . . 0.435 ' ND2' ' OE2' ' C' ' 11' ' ' GLU . 40.2 t30 -60.01 124.63 20.8 Favored 'General case' 0 CA--C 1.542 0.663 0 CA-C-N 119.482 1.037 . . . . 0.0 108.781 -179.89 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 62.8 mttm -105.38 -178.65 3.71 Favored 'General case' 0 N--CA 1.483 1.214 0 N-CA-C 108.889 -0.782 . . . . 0.0 108.889 -179.613 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -65.35 -141.45 0.03 OUTLIER Glycine 0 CA--C 1.532 1.102 0 N-CA-C 110.421 -1.072 . . . . 0.0 110.421 178.02 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.93 118.31 22.44 Favored 'General case' 0 C--N 1.349 0.582 0 C-N-CA 123.234 0.614 . . . . 0.0 109.46 178.471 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 71.6 mt -100.28 148.76 6.44 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.816 0 N-CA-C 106.88 -1.526 . . . . 0.0 106.88 178.103 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 34.1 mt -148.17 125.0 2.77 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.958 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 -179.434 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.76 85.49 0.05 OUTLIER Glycine 0 C--N 1.34 0.767 0 CA-C-N 115.966 -0.561 . . . . 0.0 112.827 178.493 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 13.2 tp -103.39 121.38 42.68 Favored 'General case' 0 N--CA 1.484 1.258 0 N-CA-C 106.97 -1.492 . . . . 0.0 106.97 177.371 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 12.6 ttt -156.08 158.93 38.6 Favored 'General case' 0 N--CA 1.476 0.859 0 N-CA-C 108.883 -0.784 . . . . 0.0 108.883 179.661 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 95.3 t -156.76 151.98 8.33 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.416 0 N-CA-C 107.493 -1.299 . . . . 0.0 107.493 -179.693 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' E' E ' 37' ' ' GLY . . . . . 0.497 ' H ' HE22 ' E' ' 15' ' ' GLN . . . 57.59 72.41 0.59 Allowed Glycine 0 C--N 1.313 -0.74 0 CA-C-N 115.397 -0.819 . . . . 0.0 111.481 178.168 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 171.62 -148.81 11.31 Favored Glycine 0 CA--C 1.524 0.624 0 N-CA-C 111.025 -0.83 . . . . 0.0 111.025 179.606 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 32.9 m -135.53 144.06 34.95 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.826 0 N-CA-C 109.095 -0.705 . . . . 0.0 109.095 179.906 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 19.5 t . . . . . 0 CA--C 1.537 0.471 0 CA-C-O 117.66 -1.162 . . . . 0.0 110.817 -179.988 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 77.6 m-85 . . . . . 0 N--CA 1.475 0.777 0 N-CA-C 109.625 -0.509 . . . . 0.0 109.625 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' F' F ' 5' ' ' ARG . . . . . 0.429 HH21 HG22 ' E' ' 24' ' ' VAL . 37.1 mtp180 -142.51 143.43 32.53 Favored 'General case' 0 N--CA 1.477 0.898 0 N-CA-C 109.396 -0.594 . . . . 0.0 109.396 179.979 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 74.8 m80 -150.59 117.65 5.94 Favored 'General case' 0 N--CA 1.474 0.744 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 178.626 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' F' F ' 7' ' ' ASP . . . . . . . . . . . . . 9.5 m-20 -68.05 149.11 50.08 Favored 'General case' 0 N--CA 1.463 0.21 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.057 -179.812 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' F' F ' 8' ' ' SER . . . . . . . . . . . . . 3.4 t -168.65 177.7 5.04 Favored 'General case' 0 N--CA 1.474 0.773 0 N-CA-C 109.521 -0.548 . . . . 0.0 109.521 178.153 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 105.13 50.95 0.9 Allowed Glycine 0 N--CA 1.478 1.496 0 N-CA-C 111.858 -0.497 . . . . 0.0 111.858 179.054 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 43.8 p90 -64.07 131.74 48.44 Favored 'General case' 0 CA--C 1.543 0.697 0 N-CA-C 112.0 0.37 . . . . 0.0 112.0 -179.867 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 41.5 mt-10 -82.01 151.56 27.07 Favored 'General case' 0 N--CA 1.479 0.994 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 177.448 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.6 p -156.0 127.88 0.98 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.46 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 177.921 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 52.3 m-70 -133.49 143.63 48.92 Favored 'General case' 0 N--CA 1.481 1.122 0 O-C-N 122.25 -0.281 . . . . 0.0 110.965 -177.856 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 5.9 t60 -165.44 97.73 0.69 Allowed 'General case' 0 N--CA 1.486 1.341 0 CA-C-O 119.604 -0.236 . . . . 0.0 111.386 179.777 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' F' F ' 15' ' ' GLN . . . . . 0.468 HE22 ' H ' ' F' ' 37' ' ' GLY . 50.0 mt-30 -106.75 -172.31 2.06 Favored 'General case' 0 CA--C 1.497 -1.064 0 N-CA-C 108.088 -1.078 . . . . 0.0 108.088 179.177 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -163.26 97.86 0.91 Allowed 'General case' 0 CA--C 1.539 0.551 0 CA-C-N 114.96 -1.018 . . . . 0.0 109.16 178.77 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' F' F ' 17' ' ' LEU . . . . . 0.483 HD12 ' N ' ' F' ' 17' ' ' LEU . 6.2 mp -108.46 163.14 13.48 Favored 'General case' 0 N--CA 1.489 1.488 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 -179.914 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 40.5 t -141.89 120.72 9.66 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.227 0 C-N-CA 122.549 0.339 . . . . 0.0 110.648 179.261 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 52.4 m-85 -73.59 155.43 39.11 Favored 'General case' 0 C--N 1.362 1.125 0 N-CA-C 106.765 -1.568 . . . . 0.0 106.765 176.219 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 24.3 t80 -171.48 -55.1 0.02 OUTLIER 'General case' 0 N--CA 1.481 1.084 0 CA-C-O 121.739 0.781 . . . . 0.0 109.75 -179.861 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.83 89.72 0.0 OUTLIER 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 114.49 -1.232 . . . . 0.0 112.693 -179.342 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 36.0 tt0 -56.4 133.4 52.99 Favored 'General case' 0 CA--C 1.54 0.586 0 CA-C-N 114.953 -1.021 . . . . 0.0 111.283 179.79 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 -81.7 162.39 23.01 Favored 'General case' 0 N--CA 1.475 0.793 0 N-CA-C 109.627 -0.508 . . . . 0.0 109.627 179.826 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' F' F ' 24' ' ' VAL . . . . . 0.417 HG22 HH21 ' D' ' 5' ' ' ARG . 95.8 t -160.7 -74.96 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.486 1.333 0 N-CA-C 107.095 -1.446 . . . . 0.0 107.095 -179.005 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -38.49 91.01 0.01 OUTLIER Glycine 0 CA--C 1.529 0.91 0 CA-C-N 115.305 -0.862 . . . . 0.0 112.451 -179.779 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 84.9 p -37.58 -100.97 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.067 0 N-CA-C 113.69 0.996 . . . . 0.0 113.69 -177.443 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' F' F ' 27' ' ' ASN . . . . . 0.424 ' ND2' ' OE2' ' A' ' 11' ' ' GLU . 39.9 t30 -60.18 124.91 21.7 Favored 'General case' 0 CA--C 1.542 0.642 0 CA-C-N 119.492 1.042 . . . . 0.0 108.769 -179.954 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 62.8 mttm -105.65 -178.6 3.7 Favored 'General case' 0 N--CA 1.483 1.197 0 N-CA-C 108.893 -0.78 . . . . 0.0 108.893 -179.737 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -65.29 -141.67 0.03 OUTLIER Glycine 0 CA--C 1.532 1.152 0 N-CA-C 110.463 -1.055 . . . . 0.0 110.463 178.008 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.65 117.79 21.8 Favored 'General case' 0 C--N 1.351 0.633 0 C-N-CA 123.351 0.66 . . . . 0.0 109.399 178.468 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 71.6 mt -99.81 148.86 6.15 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.871 0 N-CA-C 106.934 -1.506 . . . . 0.0 106.934 178.021 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 34.6 mt -148.15 124.99 2.78 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.912 0 N-CA-C 108.874 -0.787 . . . . 0.0 108.874 -179.399 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.71 85.5 0.05 OUTLIER Glycine 0 C--N 1.339 0.741 0 CA-C-N 115.967 -0.561 . . . . 0.0 112.793 178.526 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 13.1 tp -103.44 121.43 42.8 Favored 'General case' 0 N--CA 1.483 1.208 0 N-CA-C 106.945 -1.502 . . . . 0.0 106.945 177.43 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 12.5 ttt -156.17 159.01 38.6 Favored 'General case' 0 N--CA 1.474 0.771 0 N-CA-C 109.058 -0.719 . . . . 0.0 109.058 179.639 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 93.3 t -156.76 151.96 8.35 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.437 0 N-CA-C 107.615 -1.254 . . . . 0.0 107.615 -179.663 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' F' F ' 37' ' ' GLY . . . . . 0.468 ' H ' HE22 ' F' ' 15' ' ' GLN . . . 57.73 72.38 0.6 Allowed Glycine 0 C--N 1.312 -0.759 0 CA-C-N 115.491 -0.777 . . . . 0.0 111.508 178.162 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 171.57 -148.92 11.42 Favored Glycine 0 CA--C 1.523 0.578 0 N-CA-C 111.035 -0.826 . . . . 0.0 111.035 179.686 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 32.9 m -135.42 144.04 35.16 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.837 0 N-CA-C 109.054 -0.721 . . . . 0.0 109.054 179.932 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 19.6 t . . . . . 0 CA--C 1.537 0.454 0 CA-C-O 117.658 -1.163 . . . . 0.0 110.853 179.996 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 78.3 m-85 . . . . . 0 N--CA 1.473 0.691 0 N-CA-C 109.413 -0.588 . . . . 0.0 109.413 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' G' G ' 5' ' ' ARG . . . . . 0.414 HH21 HG22 ' I' ' 24' ' ' VAL . 37.0 mtp180 -142.79 143.37 32.15 Favored 'General case' 0 N--CA 1.481 1.113 0 N-CA-C 109.422 -0.585 . . . . 0.0 109.422 -179.635 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 74.7 m80 -150.41 118.81 6.43 Favored 'General case' 0 N--CA 1.473 0.711 0 N-CA-C 109.173 -0.677 . . . . 0.0 109.173 178.69 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 9.7 m-20 -70.0 144.41 52.3 Favored 'General case' 0 CA--C 1.538 0.482 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.642 -179.717 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' G' G ' 8' ' ' SER . . . . . . . . . . . . . 2.9 t -164.46 179.74 6.53 Favored 'General case' 0 N--CA 1.471 0.595 0 N-CA-C 109.465 -0.568 . . . . 0.0 109.465 177.998 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.3 50.7 0.97 Allowed Glycine 0 N--CA 1.476 1.327 0 N-CA-C 111.919 -0.472 . . . . 0.0 111.919 179.049 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 46.9 p90 -64.78 131.86 47.96 Favored 'General case' 0 N--CA 1.474 0.753 0 N-CA-C 112.097 0.406 . . . . 0.0 112.097 -179.484 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 44.0 mt-10 -82.08 150.39 27.54 Favored 'General case' 0 N--CA 1.474 0.748 0 N-CA-C 109.141 -0.688 . . . . 0.0 109.141 177.969 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 3.0 p -156.26 127.82 0.94 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.976 0 N-CA-C 108.285 -1.005 . . . . 0.0 108.285 178.168 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 55.9 m-70 -132.89 144.03 49.9 Favored 'General case' 0 N--CA 1.476 0.827 0 CA-C-N 115.392 -0.822 . . . . 0.0 110.718 -177.935 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' G' G ' 14' ' ' HIS . . . . . 0.41 ' O ' ' ND1' ' D' ' 14' ' ' HIS . 6.0 t60 -165.94 98.29 0.64 Allowed 'General case' 0 N--CA 1.483 1.19 0 CA-C-O 119.599 -0.239 . . . . 0.0 110.765 179.129 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' G' G ' 15' ' ' GLN . . . . . 0.516 HE22 ' H ' ' G' ' 37' ' ' GLY . 50.0 mt-30 -107.42 -172.24 2.03 Favored 'General case' 0 CA--C 1.503 -0.85 0 N-CA-C 108.194 -1.039 . . . . 0.0 108.194 179.306 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -163.19 98.27 0.93 Allowed 'General case' 0 N--CA 1.472 0.653 0 CA-C-N 115.05 -0.977 . . . . 0.0 109.281 178.718 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' G' G ' 17' ' ' LEU . . . . . 0.481 ' N ' HD12 ' G' ' 17' ' ' LEU . 6.6 mp -108.47 162.18 14.36 Favored 'General case' 0 N--CA 1.486 1.367 0 N-CA-C 108.946 -0.761 . . . . 0.0 108.946 -179.751 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 36.5 t -142.99 120.48 6.38 Favored 'Isoleucine or valine' 0 CA--C 1.551 1.019 0 CA-C-O 121.223 0.535 . . . . 0.0 110.435 178.973 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 47.3 m-85 -72.73 149.83 43.4 Favored 'General case' 0 C--N 1.375 1.71 0 N-CA-C 106.8 -1.555 . . . . 0.0 106.8 176.166 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 20.0 t80 -169.84 -54.23 0.02 OUTLIER 'General case' 0 N--CA 1.484 1.252 0 N-CA-C 110.194 -0.298 . . . . 0.0 110.194 -179.349 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -42.34 91.43 0.0 OUTLIER 'General case' 0 C--N 1.323 -0.571 0 O-C-N 123.942 0.776 . . . . 0.0 112.129 179.69 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 36.9 tt0 -57.83 133.67 55.62 Favored 'General case' 0 CA--C 1.539 0.542 0 CA-C-N 114.795 -1.093 . . . . 0.0 110.741 179.426 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 -81.08 161.51 24.12 Favored 'General case' 0 N--CA 1.474 0.749 0 N-CA-C 109.714 -0.476 . . . . 0.0 109.714 179.992 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' G' G ' 24' ' ' VAL . . . . . 0.423 HG22 HH21 ' H' ' 5' ' ' ARG . 94.8 t -159.44 -76.96 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.957 0 N-CA-C 106.839 -1.541 . . . . 0.0 106.839 -179.027 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -35.35 90.18 0.01 OUTLIER Glycine 0 C--O 1.225 -0.46 0 CA-C-N 114.876 -1.056 . . . . 0.0 112.765 179.381 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 94.2 p -37.78 -99.1 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.899 0 C-N-CA 123.626 0.771 . . . . 0.0 112.708 -176.861 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' G' G ' 27' ' ' ASN . . . . . 0.415 ' ND2' ' CG ' ' H' ' 11' ' ' GLU . 40.8 t30 -61.84 126.54 27.72 Favored 'General case' 0 CA--C 1.545 0.773 0 CA-C-N 119.474 1.034 . . . . 0.0 109.161 179.064 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 63.3 mttm -107.03 -179.09 3.83 Favored 'General case' 0 N--CA 1.483 1.184 0 N-CA-C 109.307 -0.627 . . . . 0.0 109.307 -179.76 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.97 -141.27 0.02 OUTLIER Glycine 0 N--CA 1.464 0.523 0 N-CA-C 109.848 -1.301 . . . . 0.0 109.848 178.422 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.96 115.2 17.45 Favored 'General case' 0 C--O 1.218 -0.558 0 C-N-CA 123.213 0.605 . . . . 0.0 109.413 179.572 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 74.5 mt -97.45 150.96 4.39 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.046 0 N-CA-C 106.92 -1.511 . . . . 0.0 106.92 178.1 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 35.8 mt -149.53 126.91 2.53 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.345 0 N-CA-C 108.876 -0.787 . . . . 0.0 108.876 178.405 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.28 85.95 0.04 OUTLIER Glycine 0 C--N 1.341 0.835 0 CA-C-N 115.957 -0.565 . . . . 0.0 112.823 178.559 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 14.4 tp -103.17 123.66 47.12 Favored 'General case' 0 N--CA 1.484 1.264 0 N-CA-C 107.029 -1.471 . . . . 0.0 107.029 177.271 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 11.9 ttt -158.75 158.57 33.88 Favored 'General case' 0 N--CA 1.469 0.494 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 179.973 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 94.5 t -156.47 153.13 7.42 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.289 0 N-CA-C 106.897 -1.519 . . . . 0.0 106.897 -179.663 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' G' G ' 37' ' ' GLY . . . . . 0.516 ' H ' HE22 ' G' ' 15' ' ' GLN . . . 56.89 73.18 0.47 Allowed Glycine 0 C--N 1.311 -0.811 0 CA-C-N 115.761 -0.654 . . . . 0.0 111.978 178.292 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 169.98 -148.05 11.4 Favored Glycine 0 N--CA 1.469 0.846 0 N-CA-C 110.703 -0.959 . . . . 0.0 110.703 179.019 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 33.5 m -135.48 144.03 35.11 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.009 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 -179.803 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 20.2 t . . . . . 0 N--CA 1.468 0.426 0 CA-C-O 117.776 -1.106 . . . . 0.0 110.838 179.914 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 78.7 m-85 . . . . . 0 N--CA 1.473 0.714 0 N-CA-C 109.362 -0.607 . . . . 0.0 109.362 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' H' H ' 5' ' ' ARG . . . . . 0.423 HH21 HG22 ' G' ' 24' ' ' VAL . 37.2 mtp180 -142.99 143.28 31.85 Favored 'General case' 0 N--CA 1.482 1.157 0 N-CA-C 109.302 -0.629 . . . . 0.0 109.302 -179.638 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 74.6 m80 -150.43 118.7 6.38 Favored 'General case' 0 N--CA 1.473 0.68 0 N-CA-C 109.252 -0.648 . . . . 0.0 109.252 178.642 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 9.4 m-20 -69.86 144.35 52.55 Favored 'General case' 0 N--CA 1.468 0.44 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.579 -179.693 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' H' H ' 8' ' ' SER . . . . . . . . . . . . . 3.6 t -164.38 179.09 6.99 Favored 'General case' 0 N--CA 1.47 0.538 0 N-CA-C 109.517 -0.549 . . . . 0.0 109.517 178.091 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.56 50.9 0.94 Allowed Glycine 0 N--CA 1.478 1.442 0 N-CA-C 111.948 -0.461 . . . . 0.0 111.948 179.054 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 46.7 p90 -64.79 131.87 48.0 Favored 'General case' 0 N--CA 1.474 0.765 0 N-CA-C 112.015 0.376 . . . . 0.0 112.015 -179.546 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' H' H ' 11' ' ' GLU . . . . . 0.415 ' CG ' ' ND2' ' G' ' 27' ' ' ASN . 44.0 mt-10 -82.05 150.38 27.59 Favored 'General case' 0 N--CA 1.474 0.749 0 N-CA-C 109.186 -0.672 . . . . 0.0 109.186 177.929 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 3.0 p -156.4 127.82 0.92 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.044 0 N-CA-C 108.291 -1.003 . . . . 0.0 108.291 178.108 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 56.0 m-70 -132.74 144.14 50.07 Favored 'General case' 0 N--CA 1.475 0.804 0 CA-C-N 115.22 -0.9 . . . . 0.0 110.731 -177.906 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 6.0 t60 -166.12 97.74 0.62 Allowed 'General case' 0 N--CA 1.482 1.163 0 CA-C-O 119.554 -0.26 . . . . 0.0 110.775 179.105 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' H' H ' 15' ' ' GLN . . . . . 0.508 HE22 ' H ' ' H' ' 37' ' ' GLY . 49.9 mt-30 -106.87 -172.56 2.1 Favored 'General case' 0 CA--C 1.505 -0.768 0 N-CA-C 108.099 -1.074 . . . . 0.0 108.099 179.403 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -163.0 98.24 0.94 Allowed 'General case' 0 N--CA 1.472 0.643 0 CA-C-N 115.268 -0.878 . . . . 0.0 109.218 178.679 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' H' H ' 17' ' ' LEU . . . . . 0.486 HD12 ' N ' ' H' ' 17' ' ' LEU . 6.6 mp -108.48 162.24 14.31 Favored 'General case' 0 N--CA 1.485 1.312 0 N-CA-C 108.978 -0.749 . . . . 0.0 108.978 -179.769 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 37.0 t -142.99 120.15 6.08 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.037 0 CA-C-O 121.16 0.505 . . . . 0.0 110.553 178.994 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 48.2 m-85 -72.76 150.41 42.84 Favored 'General case' 0 C--N 1.373 1.629 0 N-CA-C 106.909 -1.515 . . . . 0.0 106.909 176.182 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 21.3 t80 -171.25 -53.95 0.02 OUTLIER 'General case' 0 N--CA 1.481 1.093 0 N-CA-C 110.202 -0.295 . . . . 0.0 110.202 -179.361 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -42.26 91.6 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.463 0 O-C-N 123.872 0.732 . . . . 0.0 111.896 179.613 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 37.0 tt0 -57.81 133.89 55.8 Favored 'General case' 0 CA--C 1.54 0.564 0 CA-C-N 114.777 -1.102 . . . . 0.0 110.694 179.793 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 9.0 m-20 -81.24 161.44 23.96 Favored 'General case' 0 N--CA 1.474 0.768 0 N-CA-C 109.69 -0.485 . . . . 0.0 109.69 -179.986 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' H' H ' 24' ' ' VAL . . . . . 0.42 HG22 HH21 ' I' ' 5' ' ' ARG . 95.0 t -159.77 -77.03 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.99 0 N-CA-C 106.983 -1.488 . . . . 0.0 106.983 -179.037 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . -35.43 89.96 0.01 OUTLIER Glycine 0 N--CA 1.47 0.924 0 CA-C-N 115.086 -0.961 . . . . 0.0 112.245 179.547 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 97.5 p -37.47 -98.79 0.0 OUTLIER 'General case' 0 N--CA 1.478 0.954 0 C-N-CA 123.693 0.797 . . . . 0.0 112.739 -176.711 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' H' H ' 27' ' ' ASN . . . . . 0.409 ' ND2' ' CG ' ' I' ' 11' ' ' GLU . 40.1 t30 -61.62 126.69 28.23 Favored 'General case' 0 CA--C 1.543 0.689 0 CA-C-N 119.368 0.985 . . . . 0.0 109.144 179.01 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 63.3 mttm -106.97 -178.9 3.78 Favored 'General case' 0 N--CA 1.484 1.241 0 N-CA-C 109.365 -0.606 . . . . 0.0 109.365 -179.797 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.92 -141.19 0.02 OUTLIER Glycine 0 CA--C 1.522 0.521 0 N-CA-C 109.935 -1.266 . . . . 0.0 109.935 178.207 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -129.0 115.51 17.9 Favored 'General case' 0 C--O 1.217 -0.643 0 C-N-CA 123.263 0.625 . . . . 0.0 109.437 179.499 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 74.6 mt -97.86 150.6 4.65 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.027 0 N-CA-C 106.908 -1.515 . . . . 0.0 106.908 178.13 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 35.4 mt -149.32 126.89 2.62 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.309 0 N-CA-C 108.912 -0.773 . . . . 0.0 108.912 178.579 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.3 85.65 0.05 OUTLIER Glycine 0 C--N 1.34 0.801 0 CA-C-N 115.946 -0.57 . . . . 0.0 112.994 178.586 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 14.5 tp -102.97 123.28 46.29 Favored 'General case' 0 N--CA 1.482 1.158 0 N-CA-C 107.04 -1.466 . . . . 0.0 107.04 177.332 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 11.8 ttt -158.38 158.48 34.34 Favored 'General case' 0 N--CA 1.469 0.516 0 N-CA-C 108.585 -0.895 . . . . 0.0 108.585 -179.958 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 96.9 t -156.51 152.4 8.12 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.357 0 N-CA-C 107.076 -1.453 . . . . 0.0 107.076 -179.782 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' H' H ' 37' ' ' GLY . . . . . 0.508 ' H ' HE22 ' H' ' 15' ' ' GLN . . . 57.46 73.03 0.5 Allowed Glycine 0 C--N 1.313 -0.698 0 CA-C-N 115.644 -0.707 . . . . 0.0 112.028 178.169 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 169.98 -148.17 11.52 Favored Glycine 0 N--CA 1.468 0.792 0 N-CA-C 110.566 -1.014 . . . . 0.0 110.566 179.068 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 33.4 m -135.36 144.01 35.31 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.995 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.706 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 20.3 t . . . . . 0 C--O 1.222 -0.385 0 CA-C-O 117.852 -1.07 . . . . 0.0 110.916 179.99 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 79.0 m-85 . . . . . 0 N--CA 1.474 0.764 0 N-CA-C 109.323 -0.621 . . . . 0.0 109.323 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' I' I ' 5' ' ' ARG . . . . . 0.42 HH21 HG22 ' H' ' 24' ' ' VAL . 37.1 mtp180 -143.15 143.36 31.78 Favored 'General case' 0 N--CA 1.482 1.17 0 N-CA-C 109.273 -0.64 . . . . 0.0 109.273 -179.687 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 74.6 m80 -150.51 118.55 6.29 Favored 'General case' 0 N--CA 1.474 0.729 0 N-CA-C 109.243 -0.651 . . . . 0.0 109.243 178.691 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 9.5 m-20 -69.72 144.21 52.85 Favored 'General case' 0 CA--C 1.537 0.444 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.681 -179.696 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' I' I ' 8' ' ' SER . . . . . . . . . . . . . 3.6 t -164.23 179.11 7.06 Favored 'General case' 0 N--CA 1.469 0.514 0 N-CA-C 109.492 -0.558 . . . . 0.0 109.492 178.182 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.58 50.9 0.94 Allowed Glycine 0 N--CA 1.477 1.426 0 N-CA-C 111.929 -0.469 . . . . 0.0 111.929 179.047 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 47.1 p90 -64.85 131.91 48.01 Favored 'General case' 0 N--CA 1.474 0.734 0 N-CA-C 112.104 0.409 . . . . 0.0 112.104 -179.573 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' I' I ' 11' ' ' GLU . . . . . 0.409 ' CG ' ' ND2' ' H' ' 27' ' ' ASN . 43.9 mt-10 -82.14 150.39 27.48 Favored 'General case' 0 N--CA 1.473 0.71 0 N-CA-C 109.249 -0.648 . . . . 0.0 109.249 177.934 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 3.1 p -156.38 127.7 0.91 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.971 0 N-CA-C 108.366 -0.976 . . . . 0.0 108.366 178.209 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 55.5 m-70 -132.8 144.13 50.02 Favored 'General case' 0 N--CA 1.475 0.779 0 CA-C-N 115.24 -0.891 . . . . 0.0 110.735 -177.839 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 6.0 t60 -166.21 97.98 0.61 Allowed 'General case' 0 N--CA 1.483 1.181 0 CA-C-N 116.664 -0.244 . . . . 0.0 110.818 179.228 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' I' I ' 15' ' ' GLN . . . . . 0.479 HE22 ' H ' ' I' ' 37' ' ' GLY . 49.8 mt-30 -107.11 -172.21 2.03 Favored 'General case' 0 CA--C 1.501 -0.918 0 N-CA-C 108.12 -1.067 . . . . 0.0 108.12 179.322 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -163.24 98.27 0.92 Allowed 'General case' 0 N--CA 1.47 0.563 0 CA-C-N 115.109 -0.95 . . . . 0.0 109.22 178.704 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' I' I ' 17' ' ' LEU . . . . . 0.48 HD12 ' N ' ' I' ' 17' ' ' LEU . 6.6 mp -108.45 162.12 14.41 Favored 'General case' 0 N--CA 1.485 1.323 0 N-CA-C 108.968 -0.753 . . . . 0.0 108.968 -179.751 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 37.7 t -142.9 120.18 6.35 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.048 0 CA-C-O 121.2 0.524 . . . . 0.0 110.483 178.987 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 47.7 m-85 -72.81 150.39 42.78 Favored 'General case' 0 C--N 1.374 1.645 0 N-CA-C 106.759 -1.571 . . . . 0.0 106.759 176.196 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 21.3 t80 -171.17 -54.15 0.02 OUTLIER 'General case' 0 N--CA 1.48 1.048 0 N-CA-C 110.217 -0.29 . . . . 0.0 110.217 -179.304 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -42.25 91.58 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.461 0 CA-C-O 121.632 0.729 . . . . 0.0 111.856 179.656 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 37.0 tt0 -57.75 133.82 55.7 Favored 'General case' 0 CA--C 1.539 0.558 0 CA-C-N 114.769 -1.105 . . . . 0.0 110.773 179.691 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 -81.09 161.38 24.16 Favored 'General case' 0 N--CA 1.473 0.716 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 179.936 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' I' I ' 24' ' ' VAL . . . . . 0.414 HG22 HH21 ' G' ' 5' ' ' ARG . 95.1 t -159.75 -77.11 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.04 0 N-CA-C 107.045 -1.465 . . . . 0.0 107.045 -179.095 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . -35.53 90.09 0.01 OUTLIER Glycine 0 C--N 1.34 0.804 0 CA-C-N 115.073 -0.967 . . . . 0.0 112.25 179.611 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 97.5 p -37.4 -98.95 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.875 0 C-N-CA 123.794 0.838 . . . . 0.0 112.82 -176.733 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 40.5 t30 -61.5 126.62 28.02 Favored 'General case' 0 CA--C 1.542 0.645 0 CA-C-N 119.431 1.014 . . . . 0.0 109.148 179.005 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 63.2 mttm -106.96 -178.95 3.79 Favored 'General case' 0 N--CA 1.484 1.275 0 N-CA-C 109.356 -0.609 . . . . 0.0 109.356 -179.791 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.92 -141.27 0.02 OUTLIER Glycine 0 CA--C 1.523 0.58 0 N-CA-C 109.906 -1.278 . . . . 0.0 109.906 178.254 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.86 115.46 17.93 Favored 'General case' 0 C--O 1.218 -0.584 0 C-N-CA 123.247 0.619 . . . . 0.0 109.434 179.537 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 74.6 mt -97.94 150.67 4.64 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.047 0 N-CA-C 106.878 -1.527 . . . . 0.0 106.878 178.186 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 35.7 mt -149.31 126.93 2.65 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.292 0 N-CA-C 108.863 -0.791 . . . . 0.0 108.863 178.646 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.28 85.69 0.05 OUTLIER Glycine 0 C--N 1.339 0.71 0 CA-C-N 115.986 -0.552 . . . . 0.0 112.919 178.571 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 14.6 tp -102.91 123.25 46.19 Favored 'General case' 0 N--CA 1.482 1.151 0 N-CA-C 107.008 -1.479 . . . . 0.0 107.008 177.208 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 11.8 ttt -158.31 158.51 34.51 Favored 'General case' 0 N--CA 1.469 0.489 0 N-CA-C 108.56 -0.904 . . . . 0.0 108.56 179.97 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 96.6 t -156.57 152.39 8.09 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.297 0 N-CA-C 107.007 -1.479 . . . . 0.0 107.007 -179.776 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' I' I ' 37' ' ' GLY . . . . . 0.479 ' H ' HE22 ' I' ' 15' ' ' GLN . . . 57.44 73.2 0.48 Allowed Glycine 0 C--N 1.313 -0.734 0 CA-C-N 115.661 -0.7 . . . . 0.0 111.932 178.141 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 169.9 -148.29 11.66 Favored Glycine 0 N--CA 1.467 0.719 0 N-CA-C 110.651 -0.979 . . . . 0.0 110.651 179.094 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 33.4 m -135.21 144.01 35.49 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.947 0 C-N-CA 122.765 0.426 . . . . 0.0 109.904 -179.83 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 20.3 t . . . . . 0 C--O 1.222 -0.378 0 CA-C-O 117.803 -1.094 . . . . 0.0 110.932 179.996 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 29.1 m-85 . . . . . 0 N--CA 1.476 0.864 0 N-CA-C 108.637 -0.875 . . . . 0.0 108.637 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 5' ' ' ARG . . . . . 0.897 HH12 HG11 ' C' ' 24' ' ' VAL . 6.2 ptm180 -165.06 146.65 7.73 Favored 'General case' 0 N--CA 1.478 0.954 0 N-CA-C 112.349 0.5 . . . . 0.0 112.349 -179.738 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 21.2 p80 -151.89 107.79 3.38 Favored 'General case' 0 N--CA 1.475 0.788 0 CA-C-O 120.884 0.374 . . . . 0.0 110.552 177.93 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -78.13 151.69 33.2 Favored 'General case' 0 N--CA 1.475 0.805 0 CA-C-O 121.03 0.443 . . . . 0.0 109.827 178.961 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 99.8 p -155.2 173.67 16.29 Favored 'General case' 0 N--CA 1.475 0.794 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.595 -179.766 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 125.13 78.99 0.35 Allowed Glycine 0 N--CA 1.481 1.692 0 N-CA-C 111.441 -0.664 . . . . 0.0 111.441 -179.969 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 23.6 p90 -55.14 156.05 4.33 Favored 'General case' 0 N--CA 1.478 0.954 0 C-N-CA 122.528 0.331 . . . . 0.0 110.698 178.982 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 65.7 mt-10 -119.65 127.21 52.7 Favored 'General case' 0 N--CA 1.486 1.366 0 N-CA-C 109.708 -0.479 . . . . 0.0 109.708 179.281 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 40.2 t -101.69 139.83 21.85 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.705 0 N-CA-C 109.194 -0.669 . . . . 0.0 109.194 178.815 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 42.3 m80 -140.42 138.98 35.16 Favored 'General case' 0 N--CA 1.488 1.445 0 CA-C-N 118.762 0.71 . . . . 0.0 109.98 178.494 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 13.0 t60 -167.55 97.31 0.48 Allowed 'General case' 0 N--CA 1.481 1.119 0 CA-C-O 119.745 -0.169 . . . . 0.0 110.632 178.979 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 55.2 mt-30 -100.55 116.48 32.6 Favored 'General case' 0 CA--C 1.512 -0.493 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 -179.484 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 64.4 tttp -104.32 105.95 16.27 Favored 'General case' 0 N--CA 1.48 1.07 0 N-CA-C 108.648 -0.871 . . . . 0.0 108.648 178.148 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 10.0 mp -122.63 165.17 16.92 Favored 'General case' 0 N--CA 1.487 1.412 0 N-CA-C 108.712 -0.847 . . . . 0.0 108.712 -179.55 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 62.1 t -142.57 111.28 2.19 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.09 0 N-CA-C 108.499 -0.926 . . . . 0.0 108.499 177.757 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 59.7 m-85 -101.24 164.92 11.55 Favored 'General case' 0 N--CA 1.475 0.821 0 N-CA-C 109.29 -0.633 . . . . 0.0 109.29 178.244 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.453 ' O ' ' O ' ' D' ' 21' ' ' ALA . 77.7 t80 -165.53 -83.46 0.02 OUTLIER 'General case' 0 C--O 1.209 -1.052 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 177.205 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -88.29 94.08 9.72 Favored 'General case' 0 C--N 1.353 0.726 0 N-CA-C 108.249 -1.019 . . . . 0.0 108.249 177.567 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 11.2 mm-40 -73.85 -170.13 0.84 Allowed 'General case' 0 N--CA 1.482 1.153 0 C-N-CA 120.344 -0.542 . . . . 0.0 110.771 179.812 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 8.2 m-20 -73.17 153.35 40.75 Favored 'General case' 0 N--CA 1.473 0.712 0 CA-C-O 121.886 0.85 . . . . 0.0 112.995 -177.637 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.917 HG11 HH12 ' B' ' 5' ' ' ARG . 71.2 t -155.23 94.35 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.466 0.369 0 CA-C-N 114.551 -1.204 . . . . 0.0 108.244 177.005 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -121.56 60.3 0.55 Allowed Glycine 0 N--CA 1.481 1.638 0 N-CA-C 110.995 -0.842 . . . . 0.0 110.995 179.038 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 15.3 m 47.32 -143.34 0.38 Allowed 'General case' 0 N--CA 1.484 1.261 0 CA-C-N 118.164 0.982 . . . . 0.0 110.479 -179.633 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 3.9 m-80 -79.67 92.38 5.37 Favored 'General case' 0 N--CA 1.47 0.527 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 177.636 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 96.4 mttt -65.76 146.21 55.05 Favored 'General case' 0 CA--C 1.539 0.537 0 CA-C-O 121.264 0.554 . . . . 0.0 110.537 -178.559 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -70.17 -129.17 0.06 OUTLIER Glycine 0 CA--C 1.525 0.688 0 N-CA-C 109.445 -1.462 . . . . 0.0 109.445 178.533 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -85.01 131.35 34.48 Favored 'General case' 0 N--CA 1.465 0.3 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 179.69 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 18.3 tt -165.54 173.52 0.17 Allowed 'Isoleucine or valine' 0 C--O 1.215 -0.745 0 N-CA-C 108.815 -0.809 . . . . 0.0 108.815 -177.85 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 24.3 mt -140.27 145.21 26.41 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.487 0 N-CA-C 107.179 -1.415 . . . . 0.0 107.179 -179.288 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -52.0 168.17 0.71 Allowed Glycine 0 N--CA 1.473 1.14 0 C-N-CA 121.268 -0.491 . . . . 0.0 112.147 -179.328 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 2.7 pp -65.99 158.08 29.17 Favored 'General case' 0 N--CA 1.465 0.293 0 N-CA-C 109.671 -0.492 . . . . 0.0 109.671 179.741 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 21.3 ttt -142.57 154.76 44.72 Favored 'General case' 0 N--CA 1.473 0.676 0 N-CA-C 108.965 -0.754 . . . . 0.0 108.965 -179.919 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 41.3 t -149.49 139.33 16.03 Favored 'Isoleucine or valine' 0 C--O 1.235 0.318 0 N-CA-C 107.241 -1.392 . . . . 0.0 107.241 -179.695 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 60.54 67.44 2.14 Favored Glycine 0 C--N 1.318 -0.437 0 N-CA-C 109.006 -1.637 . . . . 0.0 109.006 -179.85 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -82.22 130.08 9.47 Favored Glycine 0 N--CA 1.468 0.788 0 N-CA-C 111.312 -0.715 . . . . 0.0 111.312 -178.818 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 1.9 t -146.71 113.43 1.05 Allowed 'Isoleucine or valine' 0 CA--C 1.561 1.373 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 179.257 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 19.1 t . . . . . 0 N--CA 1.497 1.899 0 CA-C-O 118.475 -0.774 . . . . 0.0 112.477 -177.877 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 29.0 m-85 . . . . . 0 N--CA 1.476 0.847 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' B' B ' 5' ' ' ARG . . . . . 0.917 HH12 HG11 ' A' ' 24' ' ' VAL . 6.3 ptm180 -165.39 146.59 7.31 Favored 'General case' 0 N--CA 1.474 0.773 0 C-N-CA 120.569 -0.452 . . . . 0.0 112.165 -179.698 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 20.9 p80 -151.79 108.07 3.43 Favored 'General case' 0 N--CA 1.476 0.838 0 CA-C-O 120.831 0.348 . . . . 0.0 110.562 177.867 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 7' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -78.56 151.1 32.64 Favored 'General case' 0 N--CA 1.476 0.834 0 CA-C-O 121.088 0.471 . . . . 0.0 109.889 179.042 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 8' ' ' SER . . . . . . . . . . . . . 99.3 p -154.54 173.72 15.92 Favored 'General case' 0 N--CA 1.473 0.718 0 CA-C-N 115.784 -0.643 . . . . 0.0 110.731 -179.759 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 125.2 78.91 0.34 Allowed Glycine 0 N--CA 1.48 1.621 0 N-CA-C 111.433 -0.667 . . . . 0.0 111.433 -179.972 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 23.9 p90 -55.28 156.05 4.55 Favored 'General case' 0 N--CA 1.478 0.927 0 C-N-CA 122.401 0.28 . . . . 0.0 110.742 179.054 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 65.6 mt-10 -119.55 127.43 52.98 Favored 'General case' 0 N--CA 1.486 1.367 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 179.288 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 40.0 t -102.04 139.66 22.55 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.708 0 N-CA-C 109.194 -0.669 . . . . 0.0 109.194 178.85 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 41.9 m80 -140.41 139.09 35.2 Favored 'General case' 0 N--CA 1.484 1.272 0 CA-C-N 118.689 0.677 . . . . 0.0 110.011 178.729 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 13.2 t60 -167.87 97.37 0.45 Allowed 'General case' 0 N--CA 1.482 1.165 0 N-CA-C 110.507 -0.183 . . . . 0.0 110.507 179.017 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 55.4 mt-30 -100.67 116.86 33.56 Favored 'General case' 0 CA--C 1.511 -0.546 0 N-CA-C 108.604 -0.887 . . . . 0.0 108.604 -179.533 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 64.6 tttp -104.51 105.97 16.29 Favored 'General case' 0 N--CA 1.479 1.014 0 N-CA-C 108.674 -0.861 . . . . 0.0 108.674 178.106 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 10.0 mp -122.83 165.05 17.26 Favored 'General case' 0 N--CA 1.489 1.516 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 -179.51 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 61.6 t -142.45 110.24 2.04 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.117 0 N-CA-C 108.743 -0.836 . . . . 0.0 108.743 177.838 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 61.1 m-85 -100.11 164.32 12.03 Favored 'General case' 0 N--CA 1.474 0.746 0 CA-C-N 118.745 0.702 . . . . 0.0 109.456 178.275 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . 0.433 ' O ' ' O ' ' E' ' 21' ' ' ALA . 76.4 t80 -164.38 -83.59 0.03 OUTLIER 'General case' 0 C--O 1.212 -0.881 0 N-CA-C 109.277 -0.638 . . . . 0.0 109.277 177.238 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -88.73 94.3 9.86 Favored 'General case' 0 C--N 1.35 0.59 0 N-CA-C 108.171 -1.048 . . . . 0.0 108.171 177.599 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 11.4 mm-40 -73.73 -170.24 0.84 Allowed 'General case' 0 N--CA 1.481 1.124 0 C-N-CA 120.487 -0.485 . . . . 0.0 110.791 179.881 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 23' ' ' ASP . . . . . 0.422 ' HB3' ' HZ1' ' B' ' 28' ' ' LYS . 8.2 m-20 -73.24 153.45 40.63 Favored 'General case' 0 N--CA 1.473 0.709 0 CA-C-O 121.943 0.878 . . . . 0.0 112.971 -177.598 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 24' ' ' VAL . . . . . 0.925 HG11 HH12 ' C' ' 5' ' ' ARG . 65.5 t -155.22 94.3 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.391 0 CA-C-N 114.586 -1.188 . . . . 0.0 108.166 177.013 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -121.35 60.16 0.55 Allowed Glycine 0 N--CA 1.479 1.547 0 N-CA-C 111.138 -0.785 . . . . 0.0 111.138 178.874 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 15.3 m 47.4 -143.72 0.36 Allowed 'General case' 0 N--CA 1.485 1.281 0 CA-C-N 118.209 1.005 . . . . 0.0 110.317 -179.574 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 4.1 m-80 -79.43 92.45 5.23 Favored 'General case' 0 N--CA 1.469 0.497 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 177.661 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 28' ' ' LYS . . . . . 0.422 ' HZ1' ' HB3' ' B' ' 23' ' ' ASP . 96.4 mttt -65.87 146.47 54.71 Favored 'General case' 0 CA--C 1.54 0.569 0 CA-C-O 121.333 0.587 . . . . 0.0 110.42 -178.472 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -70.33 -129.11 0.06 OUTLIER Glycine 0 CA--C 1.526 0.745 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 178.523 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -85.0 131.32 34.48 Favored 'General case' 0 C--O 1.235 0.291 0 N-CA-C 109.413 -0.588 . . . . 0.0 109.413 179.628 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 18.3 tt -165.61 173.44 0.17 Allowed 'Isoleucine or valine' 0 C--O 1.215 -0.751 0 N-CA-C 108.753 -0.832 . . . . 0.0 108.753 -177.8 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 24.6 mt -140.25 145.14 26.53 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.475 0 N-CA-C 107.194 -1.41 . . . . 0.0 107.194 -179.24 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -51.94 168.25 0.68 Allowed Glycine 0 N--CA 1.472 1.078 0 C-N-CA 121.202 -0.523 . . . . 0.0 112.195 -179.372 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 2.7 pp -66.13 157.76 30.39 Favored 'General case' 0 N--CA 1.465 0.28 0 N-CA-C 109.646 -0.501 . . . . 0.0 109.646 179.79 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 21.3 ttt -142.25 154.93 45.16 Favored 'General case' 0 N--CA 1.473 0.677 0 N-CA-C 109.02 -0.733 . . . . 0.0 109.02 -179.975 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 41.0 t -149.46 139.51 16.21 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.313 0 N-CA-C 107.267 -1.382 . . . . 0.0 107.267 -179.638 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 60.1 67.41 2.17 Favored Glycine 0 C--N 1.318 -0.445 0 N-CA-C 109.152 -1.579 . . . . 0.0 109.152 -179.803 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . -82.16 129.98 9.41 Favored Glycine 0 CA--C 1.526 0.769 0 N-CA-C 111.284 -0.726 . . . . 0.0 111.284 -178.892 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 1.9 t -146.68 113.46 1.06 Allowed 'Isoleucine or valine' 0 CA--C 1.561 1.371 0 N-CA-C 108.459 -0.941 . . . . 0.0 108.459 179.192 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 19.8 t . . . . . 0 N--CA 1.498 1.937 0 CA-C-O 118.409 -0.805 . . . . 0.0 112.195 -177.997 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 28.6 m-85 . . . . . 0 N--CA 1.477 0.92 0 N-CA-C 108.653 -0.869 . . . . 0.0 108.653 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' C' C ' 5' ' ' ARG . . . . . 0.925 HH12 HG11 ' B' ' 24' ' ' VAL . 6.3 ptm180 -164.98 146.54 7.79 Favored 'General case' 0 N--CA 1.476 0.86 0 N-CA-C 112.231 0.456 . . . . 0.0 112.231 -179.706 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 21.2 p80 -151.78 107.92 3.42 Favored 'General case' 0 N--CA 1.476 0.868 0 CA-C-O 120.804 0.335 . . . . 0.0 110.554 177.883 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' C' C ' 7' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -78.51 150.91 32.81 Favored 'General case' 0 N--CA 1.476 0.862 0 CA-C-O 121.061 0.457 . . . . 0.0 109.861 179.038 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' C' C ' 8' ' ' SER . . . . . . . . . . . . . 99.3 p -154.38 173.86 15.64 Favored 'General case' 0 N--CA 1.475 0.796 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.711 -179.856 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 125.07 78.96 0.35 Allowed Glycine 0 N--CA 1.48 1.627 0 N-CA-C 111.447 -0.661 . . . . 0.0 111.447 179.984 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 24.3 p90 -55.24 156.01 4.53 Favored 'General case' 0 N--CA 1.478 0.925 0 C-N-CA 122.501 0.32 . . . . 0.0 110.757 178.959 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 65.5 mt-10 -119.49 127.33 52.94 Favored 'General case' 0 N--CA 1.485 1.325 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 179.326 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 39.9 t -101.87 139.59 22.61 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.717 0 N-CA-C 109.266 -0.642 . . . . 0.0 109.266 178.76 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 42.0 m80 -140.41 138.92 35.12 Favored 'General case' 0 N--CA 1.486 1.366 0 CA-C-N 118.635 0.652 . . . . 0.0 110.009 178.662 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 13.2 t60 -167.67 97.46 0.47 Allowed 'General case' 0 N--CA 1.481 1.109 0 N-CA-C 110.542 -0.17 . . . . 0.0 110.542 178.939 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 55.5 mt-30 -100.58 116.71 33.14 Favored 'General case' 0 CA--C 1.513 -0.474 0 N-CA-C 108.608 -0.886 . . . . 0.0 108.608 -179.491 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 64.6 tttp -104.39 106.07 16.43 Favored 'General case' 0 N--CA 1.481 1.111 0 N-CA-C 108.632 -0.877 . . . . 0.0 108.632 178.062 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 10.0 mp -122.91 164.88 17.63 Favored 'General case' 0 N--CA 1.488 1.452 0 N-CA-C 108.599 -0.889 . . . . 0.0 108.599 -179.567 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 60.8 t -142.21 110.31 2.19 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 N-CA-C 108.587 -0.894 . . . . 0.0 108.587 177.836 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 61.4 m-85 -100.09 164.3 12.04 Favored 'General case' 0 N--CA 1.476 0.839 0 CA-C-N 118.734 0.697 . . . . 0.0 109.426 178.202 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' C' C ' 20' ' ' PHE . . . . . 0.44 ' O ' ' O ' ' F' ' 21' ' ' ALA . 76.1 t80 -164.23 -83.66 0.03 OUTLIER 'General case' 0 C--O 1.211 -0.955 0 N-CA-C 109.441 -0.577 . . . . 0.0 109.441 177.132 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -88.61 94.27 9.83 Favored 'General case' 0 C--N 1.349 0.554 0 N-CA-C 108.124 -1.065 . . . . 0.0 108.124 177.633 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 11.3 mm-40 -73.81 -170.14 0.84 Allowed 'General case' 0 N--CA 1.48 1.074 0 C-N-CA 120.393 -0.523 . . . . 0.0 110.816 179.928 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 8.2 m-20 -73.2 153.41 40.69 Favored 'General case' 0 N--CA 1.474 0.76 0 CA-C-O 122.04 0.924 . . . . 0.0 112.864 -177.613 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' C' C ' 24' ' ' VAL . . . . . 0.897 HG11 HH12 ' A' ' 5' ' ' ARG . 65.5 t -155.31 94.43 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.39 0 CA-C-N 114.418 -1.264 . . . . 0.0 108.147 176.958 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -121.57 60.41 0.55 Allowed Glycine 0 N--CA 1.48 1.598 0 N-CA-C 110.984 -0.846 . . . . 0.0 110.984 178.96 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 15.4 m 47.23 -143.79 0.35 Allowed 'General case' 0 N--CA 1.484 1.265 0 CA-C-N 118.21 1.005 . . . . 0.0 110.456 -179.554 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 4.1 m-80 -79.33 92.44 5.17 Favored 'General case' 0 N--CA 1.469 0.512 0 N-CA-C 108.71 -0.848 . . . . 0.0 108.71 177.613 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 96.4 mttt -65.87 146.2 55.03 Favored 'General case' 0 CA--C 1.541 0.603 0 CA-C-O 121.292 0.567 . . . . 0.0 110.502 -178.458 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -70.13 -129.0 0.06 OUTLIER Glycine 0 C--N 1.339 0.708 0 N-CA-C 109.591 -1.404 . . . . 0.0 109.591 178.483 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -85.01 131.25 34.49 Favored 'General case' 0 C--O 1.234 0.277 0 N-CA-C 109.423 -0.584 . . . . 0.0 109.423 179.65 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 18.3 tt -165.5 173.53 0.17 Allowed 'Isoleucine or valine' 0 C--O 1.215 -0.749 0 N-CA-C 108.832 -0.803 . . . . 0.0 108.832 -177.954 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 24.4 mt -140.25 145.22 26.43 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.466 0 N-CA-C 107.123 -1.436 . . . . 0.0 107.123 -179.22 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -52.01 168.19 0.71 Allowed Glycine 0 N--CA 1.473 1.113 0 C-N-CA 121.253 -0.499 . . . . 0.0 112.213 -179.442 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 2.7 pp -66.0 157.85 29.8 Favored 'General case' 0 N--CA 1.464 0.274 0 N-CA-C 109.679 -0.489 . . . . 0.0 109.679 179.736 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 21.4 ttt -142.28 154.79 45.01 Favored 'General case' 0 N--CA 1.473 0.68 0 N-CA-C 108.966 -0.753 . . . . 0.0 108.966 -179.939 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 41.1 t -149.4 139.65 16.37 Favored 'Isoleucine or valine' 0 C--O 1.234 0.288 0 N-CA-C 107.165 -1.42 . . . . 0.0 107.165 -179.71 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 60.01 67.3 2.22 Favored Glycine 0 C--N 1.32 -0.331 0 N-CA-C 109.173 -1.571 . . . . 0.0 109.173 -179.868 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . -81.97 130.04 9.45 Favored Glycine 0 CA--C 1.526 0.754 0 N-CA-C 111.264 -0.735 . . . . 0.0 111.264 -178.91 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 1.9 t -146.67 113.48 1.06 Allowed 'Isoleucine or valine' 0 CA--C 1.558 1.284 0 N-CA-C 108.47 -0.937 . . . . 0.0 108.47 179.131 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 19.9 t . . . . . 0 N--CA 1.495 1.789 0 CA-C-O 118.467 -0.778 . . . . 0.0 112.399 -177.894 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' D' D ' 4' ' ' PHE . . . . . 0.41 ' N ' ' CD1' ' D' ' 4' ' ' PHE 0.289 35.2 m-85 . . . . . 0 N--CA 1.486 1.339 0 N-CA-C 106.381 -1.711 . . . . 0.0 106.381 . . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' D' D ' 5' ' ' ARG . . . . . 0.916 HH12 HG11 ' F' ' 24' ' ' VAL . 6.0 ptm180 -154.59 150.01 27.26 Favored 'General case' 0 C--O 1.247 0.924 0 CA-C-O 116.565 -1.683 . . . . 0.0 113.175 176.423 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 15.4 p80 -150.75 117.98 5.99 Favored 'General case' 0 N--CA 1.481 1.102 0 CA-C-N 119.992 1.269 . . . . 0.0 107.882 163.217 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' D' D ' 7' ' ' ASP . . . . . . . . . . . . 0.367 0.7 OUTLIER -66.25 141.64 57.97 Favored 'General case' 0 C--N 1.324 -0.522 0 C-N-CA 128.565 2.746 . . . . 0.0 115.839 168.32 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' D' D ' 8' ' ' SER . . . . . . . . . . . . . 97.9 p -151.16 175.45 12.14 Favored 'General case' 0 N--CA 1.488 1.437 0 CA-C-N 119.452 1.024 . . . . 0.0 111.471 175.404 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.37 77.12 0.4 Allowed Glycine 0 N--CA 1.48 1.567 0 CA-C-N 116.056 -0.52 . . . . 0.0 112.762 179.594 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 25.9 p90 -50.98 152.25 2.26 Favored 'General case' 0 N--CA 1.48 1.053 0 C-N-CA 123.662 0.785 . . . . 0.0 111.967 177.768 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 64.9 mt-10 -117.39 131.13 56.83 Favored 'General case' 0 N--CA 1.49 1.568 0 C-N-CA 118.94 -1.104 . . . . 0.0 108.524 175.992 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 21.3 t -95.22 140.26 17.22 Favored 'Isoleucine or valine' 0 C--O 1.245 0.856 0 CA-C-O 117.678 -1.153 . . . . 0.0 111.083 173.673 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 39.6 m80 -138.64 140.62 38.95 Favored 'General case' 0 N--CA 1.483 1.185 0 CA-C-N 119.543 1.065 . . . . 0.0 110.236 172.544 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 14.0 t60 -165.5 104.47 0.73 Allowed 'General case' 0 N--CA 1.48 1.066 0 N-CA-C 108.922 -0.77 . . . . 0.0 108.922 173.611 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 55.8 mt-30 -104.19 114.95 29.55 Favored 'General case' 0 C--N 1.311 -1.067 0 N-CA-C 108.698 -0.853 . . . . 0.0 108.698 179.15 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 64.6 tttp -102.49 112.89 25.82 Favored 'General case' 0 C--N 1.358 0.964 0 N-CA-C 107.677 -1.231 . . . . 0.0 107.677 177.073 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 9.3 mp -126.69 162.26 26.2 Favored 'General case' 0 N--CA 1.488 1.439 0 N-CA-C 108.409 -0.96 . . . . 0.0 108.409 179.499 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . 0.365 89.7 t -140.62 119.65 11.34 Favored 'Isoleucine or valine' 0 C--N 1.372 1.563 0 N-CA-C 105.636 -1.987 . . . . 0.0 105.636 168.099 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' D' D ' 19' ' ' PHE . . . . . . . . . . . . 0.69 57.8 m-85 -67.33 150.34 49.12 Favored 'General case' 0 N--CA 1.423 -1.794 1 C-N-CA 135.005 5.322 . . . . 0.0 121.46 159.418 . . . . . . . . 3 2 . 1 . 019 nuclear nobuild core ' D' D ' 20' ' ' PHE . . . . . 0.403 ' O ' ' O ' ' G' ' 21' ' ' ALA 0.315 82.4 t80 -169.25 -67.79 0.02 OUTLIER 'General case' 0 N--CA 1.477 0.922 0 CA-C-O 114.713 -2.565 . . . . 0.0 113.794 152.691 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' D' D ' 21' ' ' ALA . . . . . 0.453 ' O ' ' O ' ' A' ' 20' ' ' PHE 0.354 . . -68.91 91.56 0.47 Allowed 'General case' 0 C--O 1.259 1.597 0 CA-C-O 113.016 -3.373 . . . . 0.0 113.057 160.959 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 11.8 mm-40 -76.88 -169.13 1.2 Allowed 'General case' 0 C--N 1.282 -2.34 1 CA-C-N 126.396 4.18 . . . . 0.0 111.316 177.061 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 9.7 m-20 -75.92 154.87 35.64 Favored 'General case' 0 C--O 1.241 0.625 0 CA-C-O 121.708 0.766 . . . . 0.0 111.233 -176.399 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' D' D ' 24' ' ' VAL . . . . . 0.927 HG11 HH12 ' E' ' 5' ' ' ARG 0.294 42.7 t -154.72 103.71 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.663 0 N-CA-C 104.002 -2.592 . . . . 0.0 104.002 170.27 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . -118.43 63.33 0.42 Allowed Glycine 0 C--N 1.361 1.929 0 CA-C-O 117.303 -1.831 . . . . 0.0 111.876 170.345 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 14.7 m 54.72 -143.15 0.76 Allowed 'General case' 0 N--CA 1.481 1.093 0 CA-C-N 121.411 2.606 . . . . 0.0 110.396 175.727 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 3.5 m-80 -82.36 92.49 7.0 Favored 'General case' 0 N--CA 1.471 0.624 0 C-N-CA 123.78 0.832 . . . . 0.0 109.012 173.051 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 94.5 mttt -71.64 149.54 45.47 Favored 'General case' 0 CA--C 1.548 0.879 0 CA-C-O 122.601 1.191 . . . . 0.0 108.66 -175.815 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -70.01 -132.7 0.08 OUTLIER Glycine 0 N--CA 1.466 0.658 0 N-CA-C 107.804 -2.118 . . . . 0.0 107.804 179.481 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -89.42 132.89 34.78 Favored 'General case' 0 C--N 1.353 0.749 0 N-CA-C 106.923 -1.51 . . . . 0.0 106.923 -176.754 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' D' D ' 31' ' ' ILE . . . . . 0.409 ' N ' ' O ' ' E' ' 40' ' ' VAL . 18.9 tt -165.32 173.05 0.18 Allowed 'Isoleucine or valine' 0 C--O 1.218 -0.567 0 CA-C-N 113.21 -1.814 . . . . 0.0 109.085 -175.245 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 26.9 mt -141.65 145.49 24.37 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.623 0 N-CA-C 107.095 -1.446 . . . . 0.0 107.095 -179.659 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -52.33 169.15 0.66 Allowed Glycine 0 N--CA 1.473 1.115 0 C-N-CA 121.312 -0.471 . . . . 0.0 112.111 -178.581 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 2.5 pp -68.33 158.58 33.17 Favored 'General case' 0 N--CA 1.464 0.273 0 N-CA-C 109.34 -0.615 . . . . 0.0 109.34 -178.813 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 22.7 ttt -140.41 161.03 38.67 Favored 'General case' 0 N--CA 1.474 0.769 0 N-CA-C 107.98 -1.119 . . . . 0.0 107.98 179.168 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' D' D ' 36' ' ' VAL . . . . . . . . . . . . 0.284 62.0 t -155.71 147.05 12.5 Favored 'Isoleucine or valine' 0 C--N 1.349 0.573 0 N-CA-C 104.971 -2.233 . . . . 0.0 104.971 174.25 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 61.55 66.46 2.63 Favored Glycine 0 CA--C 1.535 1.326 0 N-CA-C 106.468 -2.653 . . . . 0.0 106.468 179.549 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . -80.74 129.9 9.37 Favored Glycine 0 C--N 1.313 -0.723 0 CA-C-N 118.683 1.242 . . . . 0.0 111.987 -179.077 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 2.4 t -148.74 122.74 1.8 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.789 0 N-CA-C 105.114 -2.18 . . . . 0.0 105.114 173.546 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 12.7 t . . . . . 0 N--CA 1.485 1.315 0 CA-C-O 116.567 -1.682 . . . . 0.0 113.769 179.317 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 27.3 m-85 . . . . . 0 N--CA 1.478 0.926 0 N-CA-C 108.379 -0.971 . . . . 0.0 108.379 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' E' E ' 5' ' ' ARG . . . . . 0.927 HH12 HG11 ' D' ' 24' ' ' VAL . 6.3 ptm180 -165.06 147.37 8.02 Favored 'General case' 0 C--O 1.217 -0.637 0 C-N-CA 120.365 -0.534 . . . . 0.0 112.166 -179.973 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 20.6 p80 -152.17 106.84 3.21 Favored 'General case' 0 N--CA 1.477 0.899 0 CA-C-O 120.839 0.352 . . . . 0.0 110.58 178.047 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' E' E ' 7' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -77.98 152.35 33.17 Favored 'General case' 0 N--CA 1.474 0.744 0 CA-C-O 121.556 0.693 . . . . 0.0 110.091 178.939 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' E' E ' 8' ' ' SER . . . . . . . . . . . . . 92.8 p -156.34 172.9 17.69 Favored 'General case' 0 N--CA 1.487 1.4 0 CA-C-N 115.07 -0.968 . . . . 0.0 111.377 -178.815 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 125.7 79.56 0.35 Allowed Glycine 0 N--CA 1.481 1.669 0 N-CA-C 111.441 -0.664 . . . . 0.0 111.441 179.543 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 18.4 p90 -53.48 157.65 2.03 Favored 'General case' 0 N--CA 1.479 0.986 0 C-N-CA 122.393 0.277 . . . . 0.0 111.125 179.298 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 65.6 mt-10 -120.11 126.96 52.03 Favored 'General case' 0 N--CA 1.49 1.551 0 N-CA-C 109.229 -0.656 . . . . 0.0 109.229 178.429 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 39.6 t -103.52 136.95 33.99 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.685 0 N-CA-C 109.014 -0.736 . . . . 0.0 109.014 178.255 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 35.9 m80 -138.64 138.63 38.0 Favored 'General case' 0 N--CA 1.481 1.102 0 C-N-CA 122.326 0.25 . . . . 0.0 110.585 179.748 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 13.2 t60 -167.96 97.45 0.45 Allowed 'General case' 0 N--CA 1.484 1.258 0 C-N-CA 122.239 0.215 . . . . 0.0 110.593 179.303 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 55.1 mt-30 -100.57 117.12 34.06 Favored 'General case' 0 CA--C 1.512 -0.509 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 -179.681 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 64.6 tttp -104.63 105.63 15.8 Favored 'General case' 0 N--CA 1.48 1.042 0 N-CA-C 108.657 -0.868 . . . . 0.0 108.657 178.225 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 9.9 mp -122.06 164.06 18.35 Favored 'General case' 0 N--CA 1.487 1.408 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 -179.239 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 54.8 t -142.58 113.22 2.75 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.848 0 N-CA-C 108.097 -1.075 . . . . 0.0 108.097 177.167 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 60.3 m-85 -102.86 163.46 12.2 Favored 'General case' 0 C--N 1.362 1.121 0 O-C-N 124.005 0.816 . . . . 0.0 109.459 178.12 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' E' E ' 20' ' ' PHE . . . . . 0.431 ' O ' ' O ' ' H' ' 21' ' ' ALA . 69.1 t80 -166.59 -84.41 0.02 OUTLIER 'General case' 0 C--O 1.215 -0.74 0 CA-C-N 115.907 -0.588 . . . . 0.0 109.726 177.335 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' E' E ' 21' ' ' ALA . . . . . 0.433 ' O ' ' O ' ' B' ' 20' ' ' PHE . . . -85.39 91.3 8.16 Favored 'General case' 0 N--CA 1.474 0.763 0 N-CA-C 108.28 -1.007 . . . . 0.0 108.28 178.498 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 11.2 mm-40 -70.89 -172.84 0.71 Allowed 'General case' 0 N--CA 1.481 1.086 0 C-N-CA 119.67 -0.812 . . . . 0.0 111.061 -179.932 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' E' E ' 23' ' ' ASP . . . . . 0.444 ' HB3' ' HZ1' ' E' ' 28' ' ' LYS . 8.5 m-20 -71.34 154.07 41.87 Favored 'General case' 0 N--CA 1.472 0.665 0 CA-C-O 121.749 0.785 . . . . 0.0 112.623 -177.405 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' E' E ' 24' ' ' VAL . . . . . 0.92 HG11 HH12 ' F' ' 5' ' ' ARG . 53.0 t -155.37 92.15 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.762 0 CA-C-N 114.733 -1.122 . . . . 0.0 108.072 177.274 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . -119.45 61.13 0.49 Allowed Glycine 0 N--CA 1.478 1.439 0 N-CA-C 110.87 -0.892 . . . . 0.0 110.87 178.798 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 15.8 m 45.95 -143.2 0.28 Allowed 'General case' 0 N--CA 1.485 1.294 0 CA-C-N 118.299 1.049 . . . . 0.0 110.701 -179.8 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' E' E ' 27' ' ' ASN . . . . . 0.4 HD22 ' H ' ' E' ' 27' ' ' ASN . 3.6 m-80 -79.9 92.44 5.52 Favored 'General case' 0 N--CA 1.472 0.631 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 177.474 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' E' E ' 28' ' ' LYS . . . . . 0.444 ' HZ1' ' HB3' ' E' ' 23' ' ' ASP . 96.4 mttt -65.97 146.53 54.6 Favored 'General case' 0 CA--C 1.543 0.675 0 CA-C-O 121.193 0.52 . . . . 0.0 110.635 -178.565 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -71.29 -129.27 0.08 OUTLIER Glycine 0 CA--C 1.538 1.486 0 N-CA-C 109.912 -1.275 . . . . 0.0 109.912 178.492 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -82.22 131.28 35.23 Favored 'General case' 0 N--CA 1.439 -1.005 0 CA-C-N 117.637 0.719 . . . . 0.0 109.391 178.743 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 18.4 tt -165.28 173.31 0.18 Allowed 'Isoleucine or valine' 0 C--O 1.219 -0.532 0 N-CA-C 108.587 -0.894 . . . . 0.0 108.587 -178.737 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 25.5 mt -141.31 145.6 24.62 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.438 0 N-CA-C 107.106 -1.442 . . . . 0.0 107.106 179.674 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -51.63 167.93 0.64 Allowed Glycine 0 N--CA 1.474 1.209 0 C-N-CA 121.383 -0.437 . . . . 0.0 112.662 -179.333 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 2.7 pp -65.71 157.28 30.56 Favored 'General case' 0 N--CA 1.466 0.362 0 N-CA-C 109.97 -0.381 . . . . 0.0 109.97 179.746 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 23.0 ttt -142.37 154.24 44.47 Favored 'General case' 0 N--CA 1.478 0.949 0 N-CA-C 108.996 -0.742 . . . . 0.0 108.996 -179.956 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 40.3 t -149.41 138.54 15.42 Favored 'Isoleucine or valine' 0 C--O 1.238 0.458 0 N-CA-C 107.543 -1.28 . . . . 0.0 107.543 -179.57 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 60.94 67.96 1.89 Allowed Glycine 0 C--N 1.32 -0.336 0 N-CA-C 108.724 -1.751 . . . . 0.0 108.724 -179.882 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . -82.86 131.02 10.07 Favored Glycine 0 C--N 1.334 0.467 0 N-CA-C 111.286 -0.726 . . . . 0.0 111.286 -178.434 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 1.9 t -147.49 113.52 0.92 Allowed 'Isoleucine or valine' 0 N--CA 1.5 2.045 0 N-CA-C 108.447 -0.946 . . . . 0.0 108.447 179.389 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' E' E ' 40' ' ' VAL . . . . . 0.409 ' O ' ' N ' ' D' ' 31' ' ' ILE . 19.3 t . . . . . 0 N--CA 1.495 1.8 0 CA-C-O 118.074 -0.965 . . . . 0.0 112.127 -177.664 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 27.0 m-85 . . . . . 0 N--CA 1.476 0.873 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' F' F ' 5' ' ' ARG . . . . . 0.92 HH12 HG11 ' E' ' 24' ' ' VAL . 6.3 ptm180 -164.45 146.94 8.81 Favored 'General case' 0 N--CA 1.473 0.701 0 C-N-CA 120.291 -0.564 . . . . 0.0 112.063 -179.894 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 20.9 p80 -152.0 106.56 3.21 Favored 'General case' 0 N--CA 1.477 0.883 0 CA-C-O 120.793 0.33 . . . . 0.0 110.605 178.039 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' F' F ' 7' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -77.98 152.43 33.12 Favored 'General case' 0 N--CA 1.474 0.748 0 CA-C-O 121.573 0.701 . . . . 0.0 110.004 179.047 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' F' F ' 8' ' ' SER . . . . . . . . . . . . . 93.5 p -156.24 173.76 16.39 Favored 'General case' 0 N--CA 1.487 1.376 0 CA-C-N 114.933 -1.031 . . . . 0.0 111.488 -178.88 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 124.59 79.49 0.39 Allowed Glycine 0 N--CA 1.481 1.66 0 N-CA-C 111.424 -0.67 . . . . 0.0 111.424 179.669 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 18.3 p90 -53.89 158.11 2.16 Favored 'General case' 0 N--CA 1.479 0.996 0 C-N-CA 122.418 0.287 . . . . 0.0 111.136 179.252 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 65.3 mt-10 -120.23 126.97 51.95 Favored 'General case' 0 N--CA 1.489 1.483 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 178.506 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 39.3 t -103.44 136.87 34.24 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.687 0 N-CA-C 109.022 -0.733 . . . . 0.0 109.022 178.188 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 35.8 m80 -138.52 138.52 38.11 Favored 'General case' 0 N--CA 1.481 1.075 0 C-N-CA 122.417 0.287 . . . . 0.0 110.591 179.757 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 13.1 t60 -167.89 97.31 0.45 Allowed 'General case' 0 N--CA 1.483 1.191 0 C-N-CA 122.249 0.219 . . . . 0.0 110.626 179.198 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 55.3 mt-30 -100.29 117.24 34.09 Favored 'General case' 0 CA--C 1.513 -0.448 0 N-CA-C 108.399 -0.963 . . . . 0.0 108.399 -179.56 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 64.7 tttp -104.76 105.7 15.88 Favored 'General case' 0 N--CA 1.481 1.121 0 N-CA-C 108.558 -0.905 . . . . 0.0 108.558 178.104 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 9.9 mp -122.06 164.05 18.36 Favored 'General case' 0 N--CA 1.488 1.436 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 -179.398 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 55.2 t -142.39 112.75 2.76 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.911 0 N-CA-C 108.008 -1.108 . . . . 0.0 108.008 177.102 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 60.7 m-85 -102.09 163.68 12.11 Favored 'General case' 0 C--N 1.359 1.007 0 O-C-N 124.028 0.83 . . . . 0.0 109.107 177.779 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' F' F ' 20' ' ' PHE . . . . . 0.409 ' O ' ' O ' ' I' ' 21' ' ' ALA . 72.8 t80 -166.54 -84.12 0.02 OUTLIER 'General case' 0 C--O 1.215 -0.73 0 N-CA-C 109.399 -0.593 . . . . 0.0 109.399 177.173 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' F' F ' 21' ' ' ALA . . . . . 0.44 ' O ' ' O ' ' C' ' 20' ' ' PHE . . . -85.83 91.7 8.41 Favored 'General case' 0 N--CA 1.478 0.931 0 N-CA-C 108.302 -0.999 . . . . 0.0 108.302 178.547 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 11.1 mm-40 -71.14 -172.79 0.75 Allowed 'General case' 0 N--CA 1.481 1.124 0 C-N-CA 119.668 -0.813 . . . . 0.0 111.25 -179.842 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 8.5 m-20 -71.46 153.98 41.85 Favored 'General case' 0 N--CA 1.473 0.722 0 CA-C-O 121.847 0.832 . . . . 0.0 112.597 -177.334 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' F' F ' 24' ' ' VAL . . . . . 0.916 HG11 HH12 ' D' ' 5' ' ' ARG . 54.9 t -155.25 91.97 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.473 0.702 0 CA-C-N 114.65 -1.159 . . . . 0.0 108.261 177.302 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -119.51 61.33 0.49 Allowed Glycine 0 N--CA 1.482 1.703 0 N-CA-C 110.929 -0.868 . . . . 0.0 110.929 178.792 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 15.9 m 45.91 -143.18 0.28 Allowed 'General case' 0 N--CA 1.484 1.247 0 CA-C-N 118.206 1.003 . . . . 0.0 110.688 -179.973 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' F' F ' 27' ' ' ASN . . . . . 0.413 ' H ' HD22 ' F' ' 27' ' ' ASN . 3.6 m-80 -79.86 92.5 5.5 Favored 'General case' 0 N--CA 1.472 0.637 0 N-CA-C 108.818 -0.808 . . . . 0.0 108.818 177.413 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 96.4 mttt -66.1 146.4 54.7 Favored 'General case' 0 CA--C 1.542 0.639 0 CA-C-O 121.229 0.538 . . . . 0.0 110.626 -178.582 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -71.26 -129.45 0.08 OUTLIER Glycine 0 CA--C 1.538 1.529 0 N-CA-C 109.874 -1.29 . . . . 0.0 109.874 178.578 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.97 131.31 35.25 Favored 'General case' 0 N--CA 1.436 -1.137 0 CA-C-N 117.528 0.664 . . . . 0.0 109.484 178.754 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 18.4 tt -165.22 173.65 0.17 Allowed 'Isoleucine or valine' 0 C--O 1.218 -0.553 0 N-CA-C 108.571 -0.9 . . . . 0.0 108.571 -178.756 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 25.9 mt -141.48 145.59 24.43 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.524 0 N-CA-C 107.016 -1.476 . . . . 0.0 107.016 179.665 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -51.78 167.9 0.69 Allowed Glycine 0 N--CA 1.476 1.354 0 C-N-CA 121.316 -0.469 . . . . 0.0 112.567 -179.38 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 2.6 pp -65.64 157.29 30.36 Favored 'General case' 0 N--CA 1.466 0.351 0 CA-C-O 120.834 0.35 . . . . 0.0 110.061 179.772 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 22.9 ttt -142.29 154.02 44.37 Favored 'General case' 0 N--CA 1.476 0.858 0 N-CA-C 109.111 -0.7 . . . . 0.0 109.111 -179.984 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 40.6 t -149.19 138.68 15.77 Favored 'Isoleucine or valine' 0 C--O 1.237 0.399 0 N-CA-C 107.559 -1.274 . . . . 0.0 107.559 -179.625 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 60.97 67.83 1.95 Allowed Glycine 0 C--N 1.321 -0.251 0 N-CA-C 108.721 -1.751 . . . . 0.0 108.721 -179.974 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -82.69 130.86 9.96 Favored Glycine 0 C--N 1.334 0.462 0 N-CA-C 111.335 -0.706 . . . . 0.0 111.335 -178.38 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 1.9 t -147.3 113.57 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.5 2.052 0 N-CA-C 108.494 -0.928 . . . . 0.0 108.494 179.324 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 19.4 t . . . . . 0 N--CA 1.492 1.653 0 CA-C-O 118.215 -0.898 . . . . 0.0 112.5 -177.474 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 31.9 m-85 . . . . . 0 N--CA 1.48 1.046 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' G' G ' 5' ' ' ARG . . . . . 0.9 HH12 HG11 ' I' ' 24' ' ' VAL . 6.1 ptm180 -165.07 148.81 8.58 Favored 'General case' 0 N--CA 1.47 0.555 0 C-N-CA 120.446 -0.502 . . . . 0.0 111.933 -179.907 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' G' G ' 6' ' ' HIS . . . . . 0.404 ' O ' ' ND1' ' G' ' 6' ' ' HIS . 21.8 p80 -153.81 106.71 2.89 Favored 'General case' 0 N--CA 1.474 0.767 0 CA-C-O 121.06 0.457 . . . . 0.0 110.719 178.224 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -77.39 152.11 34.52 Favored 'General case' 0 N--CA 1.474 0.727 0 CA-C-O 121.084 0.468 . . . . 0.0 110.276 179.008 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' G' G ' 8' ' ' SER . . . . . . . . . . . . . 99.2 p -155.7 174.5 15.2 Favored 'General case' 0 N--CA 1.474 0.75 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.846 179.996 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 124.61 78.87 0.37 Allowed Glycine 0 N--CA 1.478 1.466 0 N-CA-C 111.202 -0.759 . . . . 0.0 111.202 179.582 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 24.0 p90 -54.23 157.47 2.67 Favored 'General case' 0 N--CA 1.476 0.827 0 O-C-N 122.802 -0.234 . . . . 0.0 111.107 179.358 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 64.6 mt-10 -120.15 126.93 51.92 Favored 'General case' 0 N--CA 1.487 1.376 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 179.257 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 29.9 t -103.79 136.12 38.28 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.021 0 N-CA-C 109.158 -0.682 . . . . 0.0 109.158 178.658 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 38.6 m80 -137.92 138.4 38.96 Favored 'General case' 0 N--CA 1.481 1.092 0 C-N-CA 122.827 0.451 . . . . 0.0 110.634 179.926 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 13.1 t60 -168.26 97.4 0.42 Allowed 'General case' 0 N--CA 1.481 1.125 0 N-CA-C 110.355 -0.239 . . . . 0.0 110.355 178.727 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 55.3 mt-30 -100.4 117.53 34.77 Favored 'General case' 0 CA--C 1.512 -0.5 0 N-CA-C 108.476 -0.935 . . . . 0.0 108.476 -179.652 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 64.6 tttp -104.97 105.67 15.82 Favored 'General case' 0 N--CA 1.482 1.142 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 178.323 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 9.8 mp -121.71 161.97 21.62 Favored 'General case' 0 N--CA 1.486 1.345 0 C-N-CA 123.478 0.711 . . . . 0.0 109.413 -179.204 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 43.6 t -142.59 112.78 2.59 Favored 'Isoleucine or valine' 0 C--O 1.246 0.891 0 N-CA-C 108.269 -1.012 . . . . 0.0 108.269 176.734 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 61.4 m-85 -101.73 161.01 13.97 Favored 'General case' 0 C--N 1.371 1.539 0 O-C-N 125.566 1.791 . . . . 0.0 109.959 177.307 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 68.7 t80 -167.95 -82.5 0.02 OUTLIER 'General case' 0 CA--C 1.539 0.527 0 CA-C-N 115.7 -0.682 . . . . 0.0 109.36 177.389 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' G' G ' 21' ' ' ALA . . . . . 0.403 ' O ' ' O ' ' D' ' 20' ' ' PHE . . . -84.96 90.69 7.88 Favored 'General case' 0 N--CA 1.474 0.754 0 N-CA-C 108.302 -0.999 . . . . 0.0 108.302 179.184 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 11.6 mm-40 -70.36 -175.09 0.94 Allowed 'General case' 0 N--CA 1.483 1.177 0 C-N-CA 119.691 -0.803 . . . . 0.0 111.167 -179.935 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 8.9 m-20 -70.97 154.47 41.79 Favored 'General case' 0 N--CA 1.475 0.82 0 CA-C-O 121.3 0.571 . . . . 0.0 112.169 -177.218 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' G' G ' 24' ' ' VAL . . . . . 0.895 HG11 HH12 ' H' ' 5' ' ' ARG . 65.2 t -156.63 92.8 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.471 0.597 0 CA-C-N 114.951 -1.022 . . . . 0.0 108.323 177.085 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -119.34 61.38 0.48 Allowed Glycine 0 N--CA 1.477 1.43 0 N-CA-C 110.93 -0.868 . . . . 0.0 110.93 179.107 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 17.2 m 47.0 -139.02 0.62 Allowed 'General case' 0 N--CA 1.484 1.233 0 CA-C-N 118.23 1.015 . . . . 0.0 110.815 179.691 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 3.7 m-80 -84.31 91.72 7.83 Favored 'General case' 0 N--CA 1.473 0.697 0 N-CA-C 108.087 -1.079 . . . . 0.0 108.087 177.511 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 96.5 mttt -65.3 146.61 54.7 Favored 'General case' 0 CA--C 1.539 0.539 0 CA-C-O 121.249 0.547 . . . . 0.0 110.576 -178.176 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -72.22 -127.84 0.09 OUTLIER Glycine 0 CA--C 1.526 0.779 0 N-CA-C 109.417 -1.473 . . . . 0.0 109.417 178.541 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.95 128.4 34.03 Favored 'General case' 0 CA--C 1.528 0.104 0 C-N-CA 122.66 0.384 . . . . 0.0 110.179 179.718 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 18.8 tt -164.41 172.88 0.21 Allowed 'Isoleucine or valine' 0 CA--C 1.506 -0.736 0 N-CA-C 109.53 -0.544 . . . . 0.0 109.53 -178.836 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 32.1 mt -139.42 146.9 24.87 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.092 0 N-CA-C 107.117 -1.438 . . . . 0.0 107.117 177.975 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -52.05 167.72 0.79 Allowed Glycine 0 N--CA 1.474 1.188 0 C-N-CA 121.489 -0.386 . . . . 0.0 112.187 -179.463 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 2.6 pp -65.87 157.61 30.1 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-O 120.793 0.33 . . . . 0.0 110.208 -179.935 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 22.8 ttt -142.74 154.54 44.37 Favored 'General case' 0 N--CA 1.472 0.669 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 -179.934 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 39.0 t -149.28 139.13 16.1 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.258 0 N-CA-C 107.712 -1.218 . . . . 0.0 107.712 -179.709 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 60.32 68.26 1.76 Allowed Glycine 0 C--N 1.319 -0.375 0 N-CA-C 108.956 -1.658 . . . . 0.0 108.956 179.963 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . -83.27 131.0 10.06 Favored Glycine 0 N--CA 1.465 0.599 0 N-CA-C 111.335 -0.706 . . . . 0.0 111.335 -178.703 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 2.1 t -146.97 113.2 0.96 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.91 0 N-CA-C 108.515 -0.92 . . . . 0.0 108.515 179.604 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 21.4 t . . . . . 0 N--CA 1.492 1.648 0 CA-C-O 118.205 -0.902 . . . . 0.0 111.958 -178.304 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 32.4 m-85 . . . . . 0 N--CA 1.48 1.068 0 N-CA-C 108.486 -0.931 . . . . 0.0 108.486 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' H' H ' 5' ' ' ARG . . . . . 0.895 HH12 HG11 ' G' ' 24' ' ' VAL . 6.1 ptm180 -165.33 148.78 8.23 Favored 'General case' 0 N--CA 1.47 0.558 0 C-N-CA 120.533 -0.467 . . . . 0.0 112.031 -179.968 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' H' H ' 6' ' ' HIS . . . . . 0.403 ' O ' ' ND1' ' H' ' 6' ' ' HIS . 21.7 p80 -153.89 106.76 2.88 Favored 'General case' 0 N--CA 1.475 0.79 0 CA-C-O 120.993 0.425 . . . . 0.0 110.645 178.204 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -77.58 151.75 34.28 Favored 'General case' 0 N--CA 1.474 0.745 0 CA-C-O 121.039 0.447 . . . . 0.0 110.261 179.016 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' H' H ' 8' ' ' SER . . . . . . . . . . . . . 99.3 p -155.22 174.89 14.57 Favored 'General case' 0 N--CA 1.475 0.808 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.839 179.99 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 124.15 78.89 0.39 Allowed Glycine 0 N--CA 1.478 1.472 0 N-CA-C 111.305 -0.718 . . . . 0.0 111.305 179.714 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 24.2 p90 -54.36 157.73 2.65 Favored 'General case' 0 N--CA 1.475 0.789 0 O-C-N 122.747 -0.267 . . . . 0.0 111.137 179.29 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 64.8 mt-10 -120.31 126.93 51.77 Favored 'General case' 0 N--CA 1.485 1.3 0 C-N-CA 122.694 0.397 . . . . 0.0 109.931 179.347 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 28.1 t -103.97 135.94 39.36 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.998 0 N-CA-C 109.153 -0.684 . . . . 0.0 109.153 178.683 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 38.6 m80 -137.76 138.65 39.47 Favored 'General case' 0 N--CA 1.481 1.107 0 C-N-CA 122.981 0.512 . . . . 0.0 110.584 -179.949 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 13.2 t60 -168.56 97.48 0.4 Allowed 'General case' 0 N--CA 1.482 1.127 0 N-CA-C 110.31 -0.256 . . . . 0.0 110.31 178.66 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 55.5 mt-30 -100.56 116.97 33.73 Favored 'General case' 0 CA--C 1.512 -0.49 0 N-CA-C 108.72 -0.845 . . . . 0.0 108.72 -179.619 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 64.5 tttp -104.35 105.72 15.96 Favored 'General case' 0 N--CA 1.482 1.136 0 N-CA-C 108.62 -0.882 . . . . 0.0 108.62 178.282 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 9.8 mp -121.91 162.29 21.29 Favored 'General case' 0 N--CA 1.487 1.386 0 C-N-CA 123.494 0.718 . . . . 0.0 109.224 -179.262 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 45.8 t -142.35 111.96 2.55 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.601 0 N-CA-C 108.372 -0.974 . . . . 0.0 108.372 176.921 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 61.1 m-85 -100.6 161.37 13.65 Favored 'General case' 0 C--N 1.364 1.228 0 O-C-N 124.724 1.265 . . . . 0.0 109.944 177.404 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 67.2 t80 -167.26 -83.15 0.02 OUTLIER 'General case' 0 N--CA 1.469 0.48 0 CA-C-N 115.696 -0.684 . . . . 0.0 109.572 177.214 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' H' H ' 21' ' ' ALA . . . . . 0.431 ' O ' ' O ' ' E' ' 20' ' ' PHE . . . -84.91 90.33 7.78 Favored 'General case' 0 N--CA 1.473 0.715 0 N-CA-C 108.406 -0.961 . . . . 0.0 108.406 179.22 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 11.7 mm-40 -69.76 -175.02 0.81 Allowed 'General case' 0 N--CA 1.483 1.176 0 C-N-CA 119.694 -0.803 . . . . 0.0 111.171 -179.872 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' H' H ' 23' ' ' ASP . . . . . 0.463 ' HB3' ' HZ1' ' H' ' 28' ' ' LYS . 8.8 m-20 -71.2 154.36 41.74 Favored 'General case' 0 N--CA 1.473 0.691 0 CA-C-O 121.333 0.587 . . . . 0.0 112.245 -177.093 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' H' H ' 24' ' ' VAL . . . . . 0.919 HG11 HH12 ' I' ' 5' ' ' ARG . 65.7 t -156.36 92.8 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.471 0.619 0 CA-C-N 114.943 -1.026 . . . . 0.0 108.407 177.095 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . -119.45 61.46 0.49 Allowed Glycine 0 N--CA 1.48 1.615 0 N-CA-C 110.961 -0.856 . . . . 0.0 110.961 179.226 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 17.2 m 46.82 -138.83 0.61 Allowed 'General case' 0 N--CA 1.485 1.296 0 CA-C-N 118.082 0.941 . . . . 0.0 110.832 -179.979 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 3.4 m-80 -84.26 91.9 7.85 Favored 'General case' 0 N--CA 1.473 0.691 0 N-CA-C 108.027 -1.101 . . . . 0.0 108.027 177.417 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' H' H ' 28' ' ' LYS . . . . . 0.463 ' HZ1' ' HB3' ' H' ' 23' ' ' ASP . 96.4 mttt -65.47 146.75 54.48 Favored 'General case' 0 CA--C 1.539 0.549 0 CA-C-O 121.373 0.606 . . . . 0.0 110.487 -178.212 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -72.16 -127.87 0.09 OUTLIER Glycine 0 CA--C 1.528 0.856 0 N-CA-C 109.554 -1.419 . . . . 0.0 109.554 178.542 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.91 128.8 34.43 Favored 'General case' 0 C--O 1.231 0.086 0 N-CA-C 110.05 -0.352 . . . . 0.0 110.05 179.591 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 18.9 tt -164.73 172.57 0.21 Allowed 'Isoleucine or valine' 0 CA--C 1.505 -0.778 0 N-CA-C 109.578 -0.527 . . . . 0.0 109.578 -178.719 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 31.9 mt -139.34 147.01 24.78 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.038 0 N-CA-C 107.132 -1.433 . . . . 0.0 107.132 177.974 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -52.25 167.59 0.87 Allowed Glycine 0 N--CA 1.472 1.088 0 C-N-CA 121.505 -0.378 . . . . 0.0 112.267 -179.454 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 2.6 pp -65.5 157.84 28.52 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-O 120.937 0.399 . . . . 0.0 110.123 -179.95 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 22.8 ttt -142.97 154.48 44.08 Favored 'General case' 0 N--CA 1.473 0.712 0 N-CA-C 109.225 -0.657 . . . . 0.0 109.225 -179.859 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 39.2 t -149.54 139.11 15.82 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.216 0 N-CA-C 107.566 -1.272 . . . . 0.0 107.566 -179.578 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 60.19 67.88 1.94 Allowed Glycine 0 C--N 1.32 -0.335 0 N-CA-C 109.093 -1.603 . . . . 0.0 109.093 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . -83.02 131.17 10.17 Favored Glycine 0 N--CA 1.464 0.544 0 N-CA-C 111.45 -0.66 . . . . 0.0 111.45 -178.765 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 2.1 t -147.04 113.36 0.96 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.927 0 N-CA-C 108.324 -0.991 . . . . 0.0 108.324 179.539 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 21.7 t . . . . . 0 N--CA 1.491 1.589 0 CA-C-O 118.298 -0.858 . . . . 0.0 111.574 -178.358 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 32.8 m-85 . . . . . 0 N--CA 1.48 1.041 0 N-CA-C 108.46 -0.941 . . . . 0.0 108.46 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' I' I ' 5' ' ' ARG . . . . . 0.919 HH12 HG11 ' H' ' 24' ' ' VAL . 6.1 ptm180 -165.24 148.48 8.23 Favored 'General case' 0 N--CA 1.47 0.545 0 C-N-CA 120.567 -0.453 . . . . 0.0 112.017 -179.881 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' I' I ' 6' ' ' HIS . . . . . 0.401 ' ND1' ' O ' ' I' ' 6' ' ' HIS . 21.6 p80 -153.66 106.83 2.94 Favored 'General case' 0 N--CA 1.475 0.793 0 CA-C-O 121.008 0.432 . . . . 0.0 110.61 178.198 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -77.59 151.83 34.23 Favored 'General case' 0 N--CA 1.474 0.775 0 CA-C-O 121.072 0.463 . . . . 0.0 110.249 178.958 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' I' I ' 8' ' ' SER . . . . . . . . . . . . . 98.2 p -155.23 174.88 14.58 Favored 'General case' 0 N--CA 1.476 0.849 0 CA-C-N 115.945 -0.57 . . . . 0.0 110.854 179.915 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 124.23 78.92 0.39 Allowed Glycine 0 N--CA 1.479 1.56 0 N-CA-C 111.256 -0.738 . . . . 0.0 111.256 179.663 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 24.0 p90 -54.58 157.63 2.86 Favored 'General case' 0 N--CA 1.477 0.891 0 O-C-N 122.803 -0.234 . . . . 0.0 111.045 179.308 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 64.5 mt-10 -120.23 126.92 51.81 Favored 'General case' 0 N--CA 1.484 1.266 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 179.391 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 27.2 t -103.9 135.86 39.66 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.937 0 N-CA-C 109.16 -0.681 . . . . 0.0 109.16 178.679 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 38.5 m80 -137.76 138.53 39.37 Favored 'General case' 0 N--CA 1.482 1.15 0 C-N-CA 122.966 0.506 . . . . 0.0 110.579 -179.943 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 13.2 t60 -168.47 97.27 0.4 Allowed 'General case' 0 N--CA 1.482 1.136 0 N-CA-C 110.278 -0.267 . . . . 0.0 110.278 178.736 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 55.8 mt-30 -100.38 116.93 33.5 Favored 'General case' 0 C--N 1.326 -0.436 0 N-CA-C 108.611 -0.885 . . . . 0.0 108.611 -179.585 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 64.6 tttp -104.35 105.7 15.92 Favored 'General case' 0 N--CA 1.482 1.143 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 178.236 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 9.8 mp -121.88 162.35 21.14 Favored 'General case' 0 N--CA 1.487 1.416 0 C-N-CA 123.475 0.71 . . . . 0.0 109.21 -179.244 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 45.7 t -142.35 111.99 2.57 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.579 0 N-CA-C 108.32 -0.993 . . . . 0.0 108.32 176.937 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 60.8 m-85 -100.75 161.41 13.62 Favored 'General case' 0 C--N 1.364 1.208 0 O-C-N 124.79 1.306 . . . . 0.0 109.949 177.434 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 66.9 t80 -167.28 -83.39 0.02 OUTLIER 'General case' 0 N--CA 1.468 0.446 0 CA-C-N 115.629 -0.714 . . . . 0.0 109.649 177.267 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' I' I ' 21' ' ' ALA . . . . . 0.409 ' O ' ' O ' ' F' ' 20' ' ' PHE . . . -84.7 90.62 7.75 Favored 'General case' 0 N--CA 1.471 0.62 0 N-CA-C 108.274 -1.01 . . . . 0.0 108.274 179.243 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 11.7 mm-40 -70.16 -175.01 0.88 Allowed 'General case' 0 N--CA 1.482 1.17 0 C-N-CA 119.725 -0.79 . . . . 0.0 111.114 -179.836 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 8.8 m-20 -71.21 154.17 41.89 Favored 'General case' 0 N--CA 1.473 0.701 0 CA-C-O 121.296 0.57 . . . . 0.0 112.292 -177.067 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' I' I ' 24' ' ' VAL . . . . . 0.9 HG11 HH12 ' G' ' 5' ' ' ARG . 65.6 t -156.22 92.75 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.47 0.528 0 CA-C-N 115.023 -0.99 . . . . 0.0 108.396 177.08 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . -119.17 61.36 0.48 Allowed Glycine 0 N--CA 1.48 1.628 0 N-CA-C 110.981 -0.848 . . . . 0.0 110.981 179.148 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 17.4 m 46.81 -138.84 0.61 Allowed 'General case' 0 N--CA 1.486 1.36 0 CA-C-N 118.214 1.007 . . . . 0.0 110.707 179.948 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 3.3 m-80 -84.29 91.97 7.88 Favored 'General case' 0 N--CA 1.472 0.665 0 N-CA-C 108.089 -1.078 . . . . 0.0 108.089 177.413 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 96.4 mttt -65.52 146.58 54.68 Favored 'General case' 0 CA--C 1.539 0.555 0 CA-C-O 121.378 0.608 . . . . 0.0 110.512 -178.195 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -71.92 -128.13 0.09 OUTLIER Glycine 0 CA--C 1.527 0.835 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 178.49 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.87 128.47 34.07 Favored 'General case' 0 CA--C 1.529 0.155 0 C-N-CA 122.709 0.404 . . . . 0.0 109.939 179.698 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 18.8 tt -164.38 172.64 0.22 Allowed 'Isoleucine or valine' 0 CA--C 1.506 -0.716 0 N-CA-C 109.553 -0.536 . . . . 0.0 109.553 -178.695 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 31.7 mt -139.31 146.99 24.85 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.101 0 N-CA-C 107.214 -1.402 . . . . 0.0 107.214 177.896 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -52.25 167.62 0.87 Allowed Glycine 0 N--CA 1.473 1.163 0 C-N-CA 121.528 -0.367 . . . . 0.0 112.234 -179.444 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 2.6 pp -65.59 157.59 29.41 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-O 120.892 0.377 . . . . 0.0 110.086 -179.956 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 22.9 ttt -142.73 154.17 44.03 Favored 'General case' 0 N--CA 1.472 0.655 0 N-CA-C 109.172 -0.677 . . . . 0.0 109.172 -179.827 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 39.6 t -149.26 139.27 16.23 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.252 0 N-CA-C 107.551 -1.277 . . . . 0.0 107.551 -179.719 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 60.09 67.93 1.92 Allowed Glycine 0 N--CA 1.461 0.344 0 N-CA-C 109.135 -1.586 . . . . 0.0 109.135 -179.921 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . -82.99 131.22 10.21 Favored Glycine 0 N--CA 1.464 0.564 0 N-CA-C 111.359 -0.697 . . . . 0.0 111.359 -178.702 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 2.1 t -147.16 113.39 0.95 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.908 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 179.527 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 21.6 t . . . . . 0 N--CA 1.489 1.521 0 CA-C-O 118.192 -0.909 . . . . 0.0 111.766 -178.315 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 29.8 m-85 . . . . . 0 N--CA 1.472 0.659 0 N-CA-C 109.426 -0.583 . . . . 0.0 109.426 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 77.1 mtt85 -139.85 145.58 38.26 Favored 'General case' 0 N--CA 1.478 0.925 0 CA-C-N 115.886 -0.597 . . . . 0.0 109.885 179.776 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 57.6 t-80 -150.51 116.96 5.73 Favored 'General case' 0 N--CA 1.476 0.863 0 N-CA-C 109.631 -0.507 . . . . 0.0 109.631 179.164 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 9.9 m-20 -66.94 144.6 56.13 Favored 'General case' 0 N--CA 1.474 0.75 0 C-N-CA 122.897 0.479 . . . . 0.0 111.83 -179.809 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 1.7 t -164.3 -176.89 4.64 Favored 'General case' 0 N--CA 1.471 0.597 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 177.986 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 85.54 70.46 1.33 Allowed Glycine 0 CA--C 1.53 1.029 0 CA-C-N 115.837 -0.62 . . . . 0.0 112.087 178.725 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 40.3 p90 -73.01 122.16 21.28 Favored 'General case' 0 N--CA 1.477 0.888 0 CA-C-N 117.255 0.527 . . . . 0.0 110.892 179.976 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 17.7 pt-20 -82.76 151.82 25.99 Favored 'General case' 0 N--CA 1.477 0.903 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 178.853 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 13.7 t -144.68 117.72 2.73 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.877 0 CA-C-O 121.578 0.704 . . . . 0.0 109.365 178.302 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 73.5 m80 -95.79 164.87 12.57 Favored 'General case' 0 C--N 1.358 0.941 0 CA-C-N 114.641 -1.163 . . . . 0.0 109.29 177.996 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . 0.449 ' NE2' ' NZ ' ' A' ' 16' ' ' LYS . 17.2 t60 -164.74 99.27 0.78 Allowed 'General case' 0 N--CA 1.476 0.855 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.12 179.223 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -91.66 111.58 23.15 Favored 'General case' 0 CA--C 1.517 -0.326 0 N-CA-C 108.386 -0.968 . . . . 0.0 108.386 179.668 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . 0.449 ' NZ ' ' NE2' ' A' ' 14' ' ' HIS . 8.5 ttmm -94.37 171.38 8.85 Favored 'General case' 0 N--CA 1.483 1.206 0 N-CA-C 108.893 -0.781 . . . . 0.0 108.893 179.926 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.422 HD12 ' N ' ' A' ' 17' ' ' LEU . 9.6 mp -55.09 157.9 3.16 Favored 'General case' 0 N--CA 1.476 0.837 0 N-CA-C 110.002 -0.37 . . . . 0.0 110.002 -178.408 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 71.2 t -140.81 150.22 20.69 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.714 0 C-N-CA 123.206 0.602 . . . . 0.0 109.76 -177.798 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.69 ' HB3' ' O ' ' D' ' 18' ' ' VAL . 43.9 p90 -40.44 162.34 0.01 OUTLIER 'General case' 0 CA--C 1.542 0.666 0 N-CA-C 120.228 3.418 . . . . 0.0 120.228 -178.729 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.409 ' O ' ' CD2' ' A' ' 20' ' ' PHE . 20.9 p90 -119.75 69.82 0.85 Allowed 'General case' 0 CA--C 1.56 1.352 0 CA-C-N 112.033 -2.349 . . . . 0.0 109.449 173.552 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . 0.411 ' H ' ' HD1' ' A' ' 19' ' ' PHE . . . -62.97 95.04 0.07 Allowed 'General case' 0 C--N 1.325 -0.493 0 N-CA-C 108.38 -0.97 . . . . 0.0 108.38 176.767 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 77.5 mt-10 -49.61 123.73 8.3 Favored 'General case' 0 N--CA 1.475 0.813 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.517 -179.954 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 16.6 t70 -76.73 169.37 18.43 Favored 'General case' 0 N--CA 1.471 0.624 0 CA-C-O 120.983 0.42 . . . . 0.0 110.648 -178.901 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.548 HG13 ' H ' ' A' ' 25' ' ' GLY . 0.7 OUTLIER 178.28 -79.05 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.542 0.636 0 N-CA-C 107.298 -1.371 . . . . 0.0 107.298 -179.865 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.548 ' H ' HG13 ' A' ' 24' ' ' VAL . . . -34.03 84.4 0.0 OUTLIER Glycine 0 N--CA 1.473 1.166 0 C-N-CA 124.425 1.012 . . . . 0.0 113.461 178.546 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . 0.438 ' N ' ' O ' ' A' ' 24' ' ' VAL . 87.9 p -41.25 -105.55 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.65 0 N-CA-C 113.676 0.991 . . . . 0.0 113.676 -177.401 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 16.8 p-10 -59.97 112.47 1.88 Allowed 'General case' 0 N--CA 1.469 0.488 0 CA-C-N 118.833 0.742 . . . . 0.0 110.417 -178.637 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 41.8 mttm -96.83 164.57 12.5 Favored 'General case' 0 N--CA 1.475 0.801 0 C-N-CA 123.31 0.644 . . . . 0.0 110.008 -179.564 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -72.95 -141.45 0.45 Allowed Glycine 0 N--CA 1.461 0.342 0 N-CA-C 107.876 -2.089 . . . . 0.0 107.876 176.548 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . 0.458 ' O ' ' O ' ' D' ' 31' ' ' ILE . . . -90.42 123.12 33.88 Favored 'General case' 0 C--O 1.208 -1.084 0 N-CA-C 106.836 -1.542 . . . . 0.0 106.836 176.524 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 16.7 tt -148.28 155.6 9.41 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.884 0 N-CA-C 107.996 -1.113 . . . . 0.0 107.996 179.192 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 20.5 pt -150.88 138.89 14.24 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 CA-C-N 119.042 0.837 . . . . 0.0 109.394 178.56 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -56.68 154.3 17.7 Favored Glycine 0 CA--C 1.533 1.167 0 CA-C-N 116.605 -0.27 . . . . 0.0 112.591 -178.537 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 2.5 pp -76.29 158.92 31.06 Favored 'General case' 0 N--CA 1.472 0.673 0 N-CA-C 109.68 -0.489 . . . . 0.0 109.68 179.242 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 11.9 ttp -102.84 151.59 22.25 Favored 'General case' 0 N--CA 1.481 1.08 0 N-CA-C 109.383 -0.599 . . . . 0.0 109.383 179.711 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 7.3 p -168.62 159.82 0.71 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.553 0 N-CA-C 108.044 -1.095 . . . . 0.0 108.044 179.772 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.41 69.86 1.14 Allowed Glycine 0 C--N 1.31 -0.862 0 N-CA-C 111.665 -0.574 . . . . 0.0 111.665 178.836 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 152.04 -177.49 29.84 Favored Glycine 0 N--CA 1.468 0.828 0 N-CA-C 110.214 -1.154 . . . . 0.0 110.214 179.659 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 4.6 t -124.99 139.14 51.99 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.758 0 N-CA-C 107.206 -1.405 . . . . 0.0 107.206 -179.502 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 72.7 t . . . . . 0 N--CA 1.481 1.081 0 CA-C-O 117.776 -1.107 . . . . 0.0 109.64 -177.501 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 30.1 m-85 . . . . . 0 N--CA 1.473 0.72 0 N-CA-C 109.531 -0.544 . . . . 0.0 109.531 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 77.1 mtt85 -140.05 145.61 37.93 Favored 'General case' 0 N--CA 1.477 0.92 0 CA-C-N 115.941 -0.572 . . . . 0.0 109.991 179.724 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 58.1 t-80 -150.43 117.29 5.87 Favored 'General case' 0 N--CA 1.475 0.814 0 N-CA-C 109.644 -0.502 . . . . 0.0 109.644 179.153 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 7' ' ' ASP . . . . . . . . . . . . . 9.8 m-20 -67.16 144.38 56.06 Favored 'General case' 0 N--CA 1.472 0.671 0 C-N-CA 122.863 0.465 . . . . 0.0 111.682 -179.713 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 8' ' ' SER . . . . . . . . . . . . . 2.2 t -163.96 -177.63 5.18 Favored 'General case' 0 N--CA 1.471 0.578 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 178.148 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 85.88 70.5 1.32 Allowed Glycine 0 CA--C 1.532 1.154 0 CA-C-N 115.916 -0.584 . . . . 0.0 112.158 178.775 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 40.1 p90 -72.81 121.99 20.83 Favored 'General case' 0 N--CA 1.478 0.931 0 CA-C-N 117.295 0.548 . . . . 0.0 110.87 179.833 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 17.7 pt-20 -82.67 151.92 26.06 Favored 'General case' 0 N--CA 1.479 0.986 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 178.828 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 13.1 t -144.75 117.81 2.71 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.842 0 CA-C-O 121.598 0.713 . . . . 0.0 109.318 178.362 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 73.5 m80 -96.02 164.66 12.61 Favored 'General case' 0 C--N 1.357 0.932 0 CA-C-N 114.616 -1.175 . . . . 0.0 109.333 177.919 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 14' ' ' HIS . . . . . 0.448 ' NE2' ' NZ ' ' B' ' 16' ' ' LYS . 17.2 t60 -164.59 99.25 0.8 Allowed 'General case' 0 N--CA 1.476 0.839 0 CA-C-N 116.471 -0.331 . . . . 0.0 110.113 179.224 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -91.44 111.54 23.08 Favored 'General case' 0 CA--C 1.515 -0.381 0 N-CA-C 108.441 -0.948 . . . . 0.0 108.441 179.585 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 16' ' ' LYS . . . . . 0.448 ' NZ ' ' NE2' ' B' ' 14' ' ' HIS . 8.5 ttmm -94.33 171.49 8.79 Favored 'General case' 0 N--CA 1.483 1.197 0 N-CA-C 108.899 -0.778 . . . . 0.0 108.899 179.995 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . 0.412 ' N ' HD12 ' B' ' 17' ' ' LEU . 9.7 mp -55.25 157.83 3.38 Favored 'General case' 0 N--CA 1.476 0.836 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 -178.41 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 71.3 t -140.87 150.46 20.49 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.763 0 C-N-CA 123.113 0.565 . . . . 0.0 109.652 -177.767 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 19' ' ' PHE . . . . . 0.704 ' HB3' ' O ' ' E' ' 18' ' ' VAL . 44.4 p90 -40.58 162.07 0.01 OUTLIER 'General case' 0 CA--C 1.543 0.7 0 N-CA-C 120.055 3.354 . . . . 0.0 120.055 -178.738 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . 0.418 ' O ' ' CD2' ' B' ' 20' ' ' PHE . 21.1 p90 -119.61 69.68 0.84 Allowed 'General case' 0 CA--C 1.561 1.371 0 CA-C-N 111.946 -2.388 . . . . 0.0 109.257 173.545 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 21' ' ' ALA . . . . . 0.42 ' H ' ' HD1' ' B' ' 19' ' ' PHE . . . -62.75 95.11 0.07 Allowed 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 108.409 -0.959 . . . . 0.0 108.409 176.759 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 77.2 mt-10 -49.62 123.73 8.3 Favored 'General case' 0 N--CA 1.476 0.849 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.421 -179.892 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 16.7 t70 -76.74 169.27 18.61 Favored 'General case' 0 N--CA 1.471 0.609 0 CA-C-O 121.007 0.432 . . . . 0.0 110.702 -179.044 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 24' ' ' VAL . . . . . 0.515 HG13 ' H ' ' B' ' 25' ' ' GLY . 0.7 OUTLIER 178.2 -79.11 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.545 0.755 0 N-CA-C 107.333 -1.358 . . . . 0.0 107.333 -179.608 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' B' B ' 25' ' ' GLY . . . . . 0.515 ' H ' HG13 ' B' ' 24' ' ' VAL . . . -34.1 84.12 0.0 OUTLIER Glycine 0 N--CA 1.48 1.633 0 C-N-CA 124.334 0.969 . . . . 0.0 113.258 178.7 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 26' ' ' SER . . . . . 0.453 ' N ' ' O ' ' B' ' 24' ' ' VAL . 88.0 p -41.02 -105.38 0.0 OUTLIER 'General case' 0 N--CA 1.475 0.817 0 N-CA-C 113.602 0.964 . . . . 0.0 113.602 -177.411 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 16.6 p-10 -60.02 112.27 1.81 Allowed 'General case' 0 N--CA 1.471 0.578 0 CA-C-N 118.83 0.741 . . . . 0.0 110.357 -178.631 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 41.6 mttm -96.53 164.43 12.62 Favored 'General case' 0 N--CA 1.474 0.773 0 C-N-CA 123.203 0.601 . . . . 0.0 110.195 -179.628 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -72.82 -141.03 0.42 Allowed Glycine 0 N--CA 1.461 0.365 0 N-CA-C 107.816 -2.114 . . . . 0.0 107.816 176.574 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 30' ' ' ALA . . . . . 0.491 ' O ' ' O ' ' E' ' 31' ' ' ILE . . . -91.05 123.4 34.48 Favored 'General case' 0 C--O 1.208 -1.128 0 N-CA-C 106.734 -1.58 . . . . 0.0 106.734 176.587 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 16.6 tt -148.35 155.6 9.33 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.829 0 N-CA-C 107.91 -1.144 . . . . 0.0 107.91 179.194 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 20.5 pt -150.79 138.92 14.37 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.469 0 CA-C-N 118.949 0.795 . . . . 0.0 109.246 178.664 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -56.81 154.29 18.32 Favored Glycine 0 CA--C 1.532 1.148 0 CA-C-N 116.598 -0.274 . . . . 0.0 112.63 -178.691 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 2.5 pp -76.18 158.81 31.3 Favored 'General case' 0 N--CA 1.472 0.635 0 C-N-CA 122.707 0.403 . . . . 0.0 109.971 179.161 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 11.8 ttp -102.73 151.21 22.66 Favored 'General case' 0 N--CA 1.481 1.078 0 N-CA-C 109.507 -0.553 . . . . 0.0 109.507 179.717 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 7.3 p -168.37 159.89 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.524 0 N-CA-C 108.035 -1.098 . . . . 0.0 108.035 179.826 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.42 69.6 1.22 Allowed Glycine 0 C--N 1.313 -0.746 0 N-CA-C 111.617 -0.593 . . . . 0.0 111.617 178.774 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 152.14 -177.75 29.77 Favored Glycine 0 N--CA 1.468 0.795 0 N-CA-C 110.217 -1.153 . . . . 0.0 110.217 179.696 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 4.4 t -124.69 139.05 52.05 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.717 0 N-CA-C 107.31 -1.367 . . . . 0.0 107.31 -179.515 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 74.2 t . . . . . 0 N--CA 1.481 1.115 0 CA-C-O 117.756 -1.116 . . . . 0.0 109.647 -177.522 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 29.9 m-85 . . . . . 0 N--CA 1.473 0.698 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 77.4 mtt85 -140.08 145.46 37.68 Favored 'General case' 0 N--CA 1.478 0.965 0 C-N-CA 122.999 0.52 . . . . 0.0 109.797 179.766 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 57.9 t-80 -150.37 116.94 5.78 Favored 'General case' 0 N--CA 1.476 0.864 0 N-CA-C 109.655 -0.498 . . . . 0.0 109.655 179.087 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' C' C ' 7' ' ' ASP . . . . . . . . . . . . . 9.9 m-20 -66.89 144.39 56.28 Favored 'General case' 0 N--CA 1.472 0.643 0 O-C-N 123.444 0.465 . . . . 0.0 111.777 -179.728 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' C' C ' 8' ' ' SER . . . . . . . . . . . . . 2.3 t -163.92 -177.68 5.22 Favored 'General case' 0 N--CA 1.471 0.589 0 N-CA-C 109.873 -0.417 . . . . 0.0 109.873 178.247 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 85.97 70.47 1.32 Allowed Glycine 0 CA--C 1.532 1.125 0 CA-C-N 115.904 -0.589 . . . . 0.0 112.165 178.736 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 40.4 p90 -72.92 122.17 21.22 Favored 'General case' 0 N--CA 1.477 0.882 0 CA-C-N 117.331 0.565 . . . . 0.0 110.882 179.886 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 17.7 pt-20 -82.8 151.9 25.9 Favored 'General case' 0 N--CA 1.478 0.962 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 178.859 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 13.0 t -144.69 117.87 2.78 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.889 0 CA-C-O 121.621 0.724 . . . . 0.0 109.361 178.343 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 73.6 m80 -96.07 164.76 12.56 Favored 'General case' 0 C--N 1.358 0.947 0 CA-C-N 114.623 -1.171 . . . . 0.0 109.263 177.96 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' C' C ' 14' ' ' HIS . . . . . 0.455 ' NE2' ' NZ ' ' C' ' 16' ' ' LYS . 17.1 t60 -164.68 99.38 0.79 Allowed 'General case' 0 N--CA 1.476 0.83 0 N-CA-C 110.038 -0.356 . . . . 0.0 110.038 179.221 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -91.74 111.72 23.36 Favored 'General case' 0 CA--C 1.516 -0.359 0 N-CA-C 108.381 -0.97 . . . . 0.0 108.381 179.574 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' C' C ' 16' ' ' LYS . . . . . 0.455 ' NZ ' ' NE2' ' C' ' 14' ' ' HIS . 8.5 ttmm -94.51 171.45 8.8 Favored 'General case' 0 N--CA 1.483 1.185 0 N-CA-C 108.831 -0.803 . . . . 0.0 108.831 -179.841 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' C' C ' 17' ' ' LEU . . . . . 0.413 HD12 ' N ' ' C' ' 17' ' ' LEU . 9.7 mp -55.11 157.75 3.25 Favored 'General case' 0 N--CA 1.475 0.809 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 -178.424 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 71.3 t -140.75 150.43 20.69 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 C-N-CA 123.188 0.595 . . . . 0.0 109.663 -177.769 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' C' C ' 19' ' ' PHE . . . . . 0.709 ' HB3' ' O ' ' F' ' 18' ' ' VAL . 44.5 p90 -40.67 162.2 0.01 OUTLIER 'General case' 0 CA--C 1.543 0.677 0 N-CA-C 120.081 3.363 . . . . 0.0 120.081 -178.675 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' C' C ' 20' ' ' PHE . . . . . 0.414 ' O ' ' CD2' ' C' ' 20' ' ' PHE . 20.8 p90 -119.65 69.65 0.84 Allowed 'General case' 0 CA--C 1.562 1.437 0 CA-C-N 112.048 -2.342 . . . . 0.0 109.299 173.568 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' C' C ' 21' ' ' ALA . . . . . 0.423 ' H ' ' HD1' ' C' ' 19' ' ' PHE . . . -62.85 95.19 0.07 Allowed 'General case' 0 C--N 1.326 -0.454 0 N-CA-C 108.42 -0.956 . . . . 0.0 108.42 176.824 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 77.3 mt-10 -49.7 123.76 8.45 Favored 'General case' 0 N--CA 1.475 0.814 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.495 -179.862 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 16.5 t70 -76.63 169.16 18.8 Favored 'General case' 0 N--CA 1.472 0.631 0 CA-C-O 121.002 0.43 . . . . 0.0 110.713 -179.009 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' C' C ' 24' ' ' VAL . . . . . 0.506 HG13 ' H ' ' C' ' 25' ' ' GLY . 0.7 OUTLIER 178.25 -79.28 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.544 0.729 0 N-CA-C 107.458 -1.312 . . . . 0.0 107.458 -179.658 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' C' C ' 25' ' ' GLY . . . . . 0.506 ' H ' HG13 ' C' ' 24' ' ' VAL . . . -34.09 84.25 0.0 OUTLIER Glycine 0 N--CA 1.48 1.62 0 C-N-CA 124.356 0.979 . . . . 0.0 113.254 178.591 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' C' C ' 26' ' ' SER . . . . . 0.451 ' N ' ' O ' ' C' ' 24' ' ' VAL . 88.7 p -41.15 -105.25 0.0 OUTLIER 'General case' 0 N--CA 1.473 0.702 0 N-CA-C 113.692 0.997 . . . . 0.0 113.692 -177.334 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 16.6 p-10 -59.98 112.21 1.78 Allowed 'General case' 0 N--CA 1.468 0.474 0 CA-C-N 118.874 0.761 . . . . 0.0 110.381 -178.632 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 41.7 mttm -96.55 164.51 12.58 Favored 'General case' 0 N--CA 1.475 0.78 0 C-N-CA 123.204 0.602 . . . . 0.0 110.113 -179.53 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -72.87 -141.31 0.44 Allowed Glycine 0 N--CA 1.462 0.398 0 N-CA-C 107.769 -2.132 . . . . 0.0 107.769 176.535 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' C' C ' 30' ' ' ALA . . . . . 0.489 ' O ' ' O ' ' F' ' 31' ' ' ILE . . . -90.68 123.16 34.07 Favored 'General case' 0 C--O 1.211 -0.968 0 N-CA-C 106.775 -1.565 . . . . 0.0 106.775 176.58 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 16.6 tt -148.08 155.59 9.7 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.889 0 N-CA-C 107.888 -1.153 . . . . 0.0 107.888 179.186 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 20.2 pt -150.79 138.85 14.28 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.469 0 CA-C-N 118.943 0.792 . . . . 0.0 109.266 178.674 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -56.78 154.3 18.17 Favored Glycine 0 CA--C 1.531 1.088 0 CA-C-N 116.606 -0.27 . . . . 0.0 112.56 -178.656 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 2.5 pp -76.32 158.76 31.19 Favored 'General case' 0 N--CA 1.472 0.644 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 179.232 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 11.6 ttp -102.58 151.47 22.3 Favored 'General case' 0 N--CA 1.481 1.091 0 N-CA-C 109.449 -0.574 . . . . 0.0 109.449 179.649 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 7.3 p -168.55 159.88 0.71 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.542 0 N-CA-C 108.038 -1.097 . . . . 0.0 108.038 179.764 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.45 69.69 1.19 Allowed Glycine 0 C--N 1.312 -0.774 0 N-CA-C 111.611 -0.596 . . . . 0.0 111.611 178.826 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 151.95 -177.82 29.57 Favored Glycine 0 N--CA 1.468 0.792 0 N-CA-C 110.25 -1.14 . . . . 0.0 110.25 179.669 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 4.4 t -124.57 138.8 52.81 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.722 0 N-CA-C 107.335 -1.358 . . . . 0.0 107.335 -179.445 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 74.3 t . . . . . 0 N--CA 1.48 1.032 0 CA-C-O 117.771 -1.109 . . . . 0.0 109.696 -177.589 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 30.0 m-85 . . . . . 0 N--CA 1.475 0.784 0 N-CA-C 109.117 -0.698 . . . . 0.0 109.117 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' D' D ' 5' ' ' ARG . . . . . . . . . . . . . 76.7 mtt85 -140.11 141.91 36.09 Favored 'General case' 0 N--CA 1.474 0.761 0 C-N-CA 123.974 0.909 . . . . 0.0 110.559 -178.702 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 54.3 t-80 -148.63 123.39 9.89 Favored 'General case' 0 CA--C 1.547 0.852 0 N-CA-C 107.86 -1.163 . . . . 0.0 107.86 174.848 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' D' D ' 7' ' ' ASP . . . . . . . . . . . . . 8.8 m-20 -63.47 133.17 53.45 Favored 'General case' 0 N--CA 1.469 0.496 0 C-N-CA 126.9 2.08 . . . . 0.0 114.15 176.313 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' D' D ' 8' ' ' SER . . . . . . . . . . . . . 2.4 t -154.35 -177.31 6.36 Favored 'General case' 0 N--CA 1.473 0.712 0 CA-C-N 118.895 0.771 . . . . 0.0 110.555 176.242 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 88.11 69.45 1.28 Allowed Glycine 0 N--CA 1.475 1.279 0 N-CA-C 111.33 -0.708 . . . . 0.0 111.33 174.523 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 35.2 p90 -70.82 124.34 24.09 Favored 'General case' 0 N--CA 1.476 0.837 0 CA-C-N 118.134 0.967 . . . . 0.0 110.507 -179.907 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 17.6 pt-20 -81.0 154.04 27.12 Favored 'General case' 0 C--N 1.363 1.162 0 C-N-CA 119.982 -0.687 . . . . 0.0 109.948 175.935 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 21.8 t -141.29 124.07 15.21 Favored 'Isoleucine or valine' 0 C--N 1.357 0.925 0 N-CA-C 107.945 -1.131 . . . . 0.0 107.945 171.011 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 61.5 m80 -89.03 164.37 15.1 Favored 'General case' 0 N--CA 1.472 0.657 0 C-N-CA 125.229 1.412 . . . . 0.0 112.607 171.865 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' D' D ' 14' ' ' HIS . . . . . 0.45 ' NE2' ' NZ ' ' D' ' 16' ' ' LYS . 17.1 t60 -163.82 104.91 0.92 Allowed 'General case' 0 N--CA 1.478 0.949 0 N-CA-C 109.0 -0.741 . . . . 0.0 109.0 171.671 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -95.24 111.45 23.3 Favored 'General case' 0 C--O 1.218 -0.59 0 N-CA-C 107.913 -1.143 . . . . 0.0 107.913 178.885 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' D' D ' 16' ' ' LYS . . . . . 0.45 ' NZ ' ' NE2' ' D' ' 14' ' ' HIS . 8.6 ttmm -95.49 169.93 9.7 Favored 'General case' 0 N--CA 1.487 1.409 0 C-N-CA 125.749 1.619 . . . . 0.0 108.715 -178.385 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 10.7 mp -65.79 156.23 33.82 Favored 'General case' 0 C--O 1.21 -0.975 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 -172.779 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' D' D ' 18' ' ' VAL . . . . . 0.69 ' O ' ' HB3' ' A' ' 19' ' ' PHE . 88.5 t -139.74 146.72 24.79 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.143 0 C-N-CA 126.183 1.793 . . . . 0.0 109.015 -168.808 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' D' D ' 19' ' ' PHE . . . . . 0.757 ' HB3' ' O ' ' G' ' 18' ' ' VAL 0.485 37.4 p90 -57.67 162.4 3.09 Favored 'General case' 0 C--N 1.391 2.403 0 N-CA-C 118.552 2.797 . . . . 0.0 118.552 -169.325 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' D' D ' 20' ' ' PHE . . . . . 0.404 ' O ' ' CD2' ' D' ' 20' ' ' PHE . 21.5 p90 -114.48 66.24 0.68 Allowed 'General case' 0 C--N 1.375 1.684 0 CA-C-N 112.958 -1.928 . . . . 0.0 110.608 -178.781 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' D' D ' 21' ' ' ALA . . . . . 0.45 ' H ' ' HD1' ' D' ' 19' ' ' PHE . . . -50.2 92.47 0.01 OUTLIER 'General case' 0 N--CA 1.441 -0.91 0 CA-C-N 113.448 -1.705 . . . . 0.0 110.669 173.675 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 77.0 mt-10 -52.69 125.53 16.98 Favored 'General case' 0 CA--C 1.547 0.843 0 CA-C-N 118.881 0.764 . . . . 0.0 110.306 -179.652 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 14.6 t70 -78.04 168.75 19.39 Favored 'General case' 0 N--CA 1.475 0.802 0 C-N-CA 122.764 0.426 . . . . 0.0 110.163 -179.747 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' D' D ' 24' ' ' VAL . . . . . 0.468 HG13 ' H ' ' D' ' 25' ' ' GLY 0.624 2.7 p -179.4 -100.54 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.203 -1.395 0 CA-C-O 125.938 2.78 . . . . 0.0 106.256 -164.685 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' D' D ' 25' ' ' GLY . . . . . 0.468 ' H ' HG13 ' D' ' 24' ' ' VAL . . . -24.32 71.59 0.0 OUTLIER Glycine 0 C--N 1.3 -1.46 0 C-N-CA 129.459 3.409 . . . . 0.0 116.907 178.476 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' D' D ' 26' ' ' SER . . . . . 0.412 ' OG ' ' N ' ' D' ' 27' ' ' ASN 0.381 78.9 p -52.69 -100.46 0.0 OUTLIER 'General case' 0 C--O 1.273 2.318 1 CA-C-O 110.787 -4.435 . . . . 0.0 107.203 -162.704 . . . . . . . . 4 3 . 1 . 020 nuclear nobuild core ' D' D ' 27' ' ' ASN . . . . . 0.503 ' OD1' ' N ' ' D' ' 27' ' ' ASN 0.409 11.7 p-10 -70.38 121.87 18.53 Favored 'General case' 0 N--CA 1.481 1.109 1 CA-C-N 129.149 5.431 . . . . 0.0 108.818 -168.719 . . . . . . . . 4 3 . 1 . 020 nuclear nobuild core ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 31.7 mttm -86.24 161.18 18.92 Favored 'General case' 0 C--N 1.364 1.23 0 CA-C-N 110.65 -2.977 . . . . 0.0 113.104 177.762 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -66.89 -145.13 0.07 OUTLIER Glycine 0 CA--C 1.535 1.331 0 N-CA-C 108.997 -1.641 . . . . 0.0 108.997 167.354 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' D' D ' 30' ' ' ALA . . . . . 0.489 ' O ' ' O ' ' G' ' 31' ' ' ILE . . . -92.12 123.45 35.47 Favored 'General case' 0 C--N 1.358 0.945 0 N-CA-C 106.708 -1.59 . . . . 0.0 106.708 174.207 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' D' D ' 31' ' ' ILE . . . . . 0.458 ' O ' ' O ' ' A' ' 30' ' ' ALA . 17.3 tt -144.73 155.42 14.42 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.451 0 N-CA-C 109.107 -0.701 . . . . 0.0 109.107 178.959 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 23.4 pt -150.99 135.31 8.94 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.912 0 CA-C-N 118.402 0.546 . . . . 0.0 110.035 178.939 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -52.85 153.9 6.47 Favored Glycine 0 N--CA 1.476 1.317 0 CA-C-N 116.32 -0.4 . . . . 0.0 112.891 -179.492 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 2.5 pp -76.46 159.85 30.05 Favored 'General case' 0 N--CA 1.473 0.677 0 N-CA-C 110.0 -0.37 . . . . 0.0 110.0 178.433 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 8.2 ttp -103.38 155.14 18.7 Favored 'General case' 0 N--CA 1.48 1.06 0 N-CA-C 108.655 -0.868 . . . . 0.0 108.655 178.781 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 6.7 p -167.04 163.73 0.58 Allowed 'Isoleucine or valine' 0 CA--C 1.507 -0.708 0 N-CA-C 107.456 -1.313 . . . . 0.0 107.456 177.054 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 59.32 63.9 4.74 Favored Glycine 0 C--N 1.319 -0.364 0 C-N-CA 118.733 -1.699 . . . . 0.0 113.143 174.397 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 148.4 179.73 24.58 Favored Glycine 0 N--CA 1.471 1.026 0 CA-C-N 118.0 0.9 . . . . 0.0 111.225 -177.175 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 5.5 t -122.2 138.42 52.47 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.86 0 N-CA-C 106.412 -1.699 . . . . 0.0 106.412 -177.546 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 77.1 t . . . . . 0 C--O 1.212 -0.887 0 N-CA-C 108.224 -1.028 . . . . 0.0 108.224 178.886 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 27.7 m-85 . . . . . 0 N--CA 1.474 0.727 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' E' E ' 5' ' ' ARG . . . . . . . . . . . . . 76.9 mtt85 -139.71 145.75 38.74 Favored 'General case' 0 N--CA 1.477 0.917 0 CA-C-N 115.978 -0.556 . . . . 0.0 110.015 179.378 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 57.9 t-80 -150.52 116.44 5.58 Favored 'General case' 0 N--CA 1.475 0.796 0 N-CA-C 109.472 -0.566 . . . . 0.0 109.472 179.239 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' E' E ' 7' ' ' ASP . . . . . . . . . . . . . 9.7 m-20 -66.11 148.64 51.51 Favored 'General case' 0 N--CA 1.47 0.549 0 O-C-N 123.259 0.349 . . . . 0.0 111.136 -179.825 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' E' E ' 8' ' ' SER . . . . . . . . . . . . . 2.2 t -167.45 -178.04 3.83 Favored 'General case' 0 N--CA 1.471 0.611 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 178.28 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 86.11 70.21 1.32 Allowed Glycine 0 CA--C 1.533 1.168 0 CA-C-N 115.964 -0.562 . . . . 0.0 112.089 178.779 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 34.2 p90 -71.65 121.87 19.58 Favored 'General case' 0 N--CA 1.479 1.008 0 CA-C-N 117.52 0.66 . . . . 0.0 110.771 179.704 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 17.4 pt-20 -83.01 152.77 25.27 Favored 'General case' 0 N--CA 1.482 1.159 0 N-CA-C 109.405 -0.591 . . . . 0.0 109.405 178.136 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 19.2 t -144.83 117.03 2.35 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.667 0 N-CA-C 109.478 -0.564 . . . . 0.0 109.478 178.831 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 73.8 m80 -95.33 165.89 12.16 Favored 'General case' 0 N--CA 1.475 0.794 0 N-CA-C 109.701 -0.481 . . . . 0.0 109.701 178.588 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' E' E ' 14' ' ' HIS . . . . . 0.447 ' NE2' ' NZ ' ' E' ' 16' ' ' LYS . 16.5 t60 -164.71 99.12 0.78 Allowed 'General case' 0 N--CA 1.478 0.971 0 N-CA-C 110.095 -0.335 . . . . 0.0 110.095 179.327 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -92.06 110.96 22.33 Favored 'General case' 0 CA--C 1.511 -0.548 0 N-CA-C 108.442 -0.948 . . . . 0.0 108.442 179.721 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' E' E ' 16' ' ' LYS . . . . . 0.447 ' NZ ' ' NE2' ' E' ' 14' ' ' HIS . 9.5 ttmm -93.53 172.04 8.52 Favored 'General case' 0 N--CA 1.485 1.303 0 N-CA-C 109.279 -0.638 . . . . 0.0 109.279 179.999 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' E' E ' 17' ' ' LEU . . . . . 0.438 ' N ' HD12 ' E' ' 17' ' ' LEU . 9.2 mp -55.11 155.98 4.32 Favored 'General case' 0 C--O 1.216 -0.693 0 N-CA-C 109.981 -0.377 . . . . 0.0 109.981 -178.599 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' E' E ' 18' ' ' VAL . . . . . 0.704 ' O ' ' HB3' ' B' ' 19' ' ' PHE . 79.5 t -141.48 150.61 19.62 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.966 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 -178.475 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' E' E ' 19' ' ' PHE . . . . . 0.735 ' HB3' ' O ' ' H' ' 18' ' ' VAL . 38.9 p90 -43.69 153.95 0.11 Allowed 'General case' 0 C--N 1.385 2.139 0 N-CA-C 120.387 3.477 . . . . 0.0 120.387 -177.216 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' E' E ' 20' ' ' PHE . . . . . 0.403 ' CD2' ' O ' ' E' ' 20' ' ' PHE . 20.8 p90 -111.62 66.95 0.64 Allowed 'General case' 0 N--CA 1.484 1.243 0 CA-C-N 113.938 -1.483 . . . . 0.0 111.495 175.007 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' E' E ' 21' ' ' ALA . . . . . 0.409 ' H ' ' HD1' ' E' ' 19' ' ' PHE . . . -58.64 93.96 0.02 OUTLIER 'General case' 0 N--CA 1.441 -0.919 0 CA-C-N 114.133 -1.394 . . . . 0.0 109.212 177.919 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 76.1 mt-10 -50.0 122.16 6.33 Favored 'General case' 0 N--CA 1.474 0.749 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.25 -179.712 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 18.4 t70 -75.03 173.51 10.62 Favored 'General case' 0 N--CA 1.466 0.349 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 -178.823 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' E' E ' 24' ' ' VAL . . . . . 0.526 HG13 ' H ' ' E' ' 25' ' ' GLY . 0.9 OUTLIER 173.71 -77.9 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.472 0.656 0 N-CA-C 107.896 -1.15 . . . . 0.0 107.896 -179.925 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' E' E ' 25' ' ' GLY . . . . . 0.526 ' H ' HG13 ' E' ' 24' ' ' VAL . . . -36.51 84.47 0.0 OUTLIER Glycine 0 CA--C 1.538 1.523 0 C-N-CA 124.102 0.858 . . . . 0.0 113.396 179.132 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' E' E ' 26' ' ' SER . . . . . 0.451 ' N ' ' O ' ' E' ' 24' ' ' VAL . 95.2 p -40.81 -107.11 0.0 OUTLIER 'General case' 0 N--CA 1.482 1.133 0 N-CA-C 114.25 1.204 . . . . 0.0 114.25 -177.544 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 16.5 p-10 -58.36 111.57 1.27 Allowed 'General case' 0 N--CA 1.473 0.688 0 CA-C-N 118.858 0.754 . . . . 0.0 110.067 -178.664 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 39.1 mttm -95.15 167.82 11.13 Favored 'General case' 0 N--CA 1.476 0.851 0 O-C-N 123.786 0.679 . . . . 0.0 109.588 -179.592 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -76.14 -140.17 0.94 Allowed Glycine 0 CA--C 1.524 0.652 0 N-CA-C 106.996 -2.441 . . . . 0.0 106.996 176.396 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' E' E ' 30' ' ' ALA . . . . . 0.458 ' O ' ' O ' ' H' ' 31' ' ' ILE . . . -91.82 126.34 36.87 Favored 'General case' 0 C--O 1.215 -0.723 0 N-CA-C 106.507 -1.664 . . . . 0.0 106.507 175.682 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' E' E ' 31' ' ' ILE . . . . . 0.491 ' O ' ' O ' ' B' ' 30' ' ' ALA . 16.6 tt -149.87 155.62 7.81 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.604 0 N-CA-C 108.077 -1.083 . . . . 0.0 108.077 179.07 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 19.2 pt -152.61 138.14 11.21 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.628 0 N-CA-C 109.096 -0.705 . . . . 0.0 109.096 -179.509 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -57.56 154.65 20.98 Favored Glycine 0 N--CA 1.474 1.174 0 CA-C-N 115.407 -0.815 . . . . 0.0 112.66 -177.851 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 2.5 pp -75.98 160.32 29.97 Favored 'General case' 0 N--CA 1.469 0.505 0 N-CA-C 109.64 -0.504 . . . . 0.0 109.64 179.244 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 7.7 ttp -104.91 151.95 23.24 Favored 'General case' 0 N--CA 1.48 1.052 0 N-CA-C 109.259 -0.645 . . . . 0.0 109.259 179.454 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 7.5 p -168.13 159.93 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.446 -0.641 0 N-CA-C 107.844 -1.169 . . . . 0.0 107.844 179.744 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 53.85 70.87 0.81 Allowed Glycine 0 C--N 1.313 -0.72 0 O-C-N 123.381 0.426 . . . . 0.0 112.328 179.365 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 153.06 -177.14 30.86 Favored Glycine 0 N--CA 1.461 0.367 0 N-CA-C 110.131 -1.188 . . . . 0.0 110.131 179.556 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 5.5 t -126.7 137.08 58.93 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.361 0 N-CA-C 106.259 -1.756 . . . . 0.0 106.259 -178.867 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 75.1 t . . . . . 0 N--CA 1.474 0.754 0 CA-C-O 117.649 -1.167 . . . . 0.0 109.504 -176.889 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 27.7 m-85 . . . . . 0 N--CA 1.472 0.672 0 N-CA-C 109.676 -0.49 . . . . 0.0 109.676 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' F' F ' 5' ' ' ARG . . . . . . . . . . . . . 76.8 mtt85 -139.61 145.34 38.4 Favored 'General case' 0 N--CA 1.479 0.98 0 CA-C-N 115.861 -0.609 . . . . 0.0 109.96 179.427 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 57.7 t-80 -150.33 116.31 5.61 Favored 'General case' 0 N--CA 1.475 0.776 0 N-CA-C 109.61 -0.515 . . . . 0.0 109.61 179.158 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' F' F ' 7' ' ' ASP . . . . . . . . . . . . . 9.8 m-20 -65.84 148.42 51.81 Favored 'General case' 0 N--CA 1.469 0.515 0 O-C-N 123.261 0.351 . . . . 0.0 111.301 -179.813 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' F' F ' 8' ' ' SER . . . . . . . . . . . . . 2.2 t -167.37 -178.0 3.85 Favored 'General case' 0 N--CA 1.471 0.59 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 178.214 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 86.25 70.15 1.32 Allowed Glycine 0 CA--C 1.532 1.143 0 CA-C-N 115.972 -0.558 . . . . 0.0 112.113 178.734 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 34.6 p90 -71.7 121.71 19.34 Favored 'General case' 0 N--CA 1.476 0.858 0 CA-C-N 117.514 0.657 . . . . 0.0 110.95 179.739 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 17.4 pt-20 -82.79 152.69 25.57 Favored 'General case' 0 N--CA 1.481 1.116 0 N-CA-C 109.399 -0.593 . . . . 0.0 109.399 178.156 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 19.3 t -144.83 117.02 2.35 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.635 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 178.795 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 73.8 m80 -95.3 165.94 12.14 Favored 'General case' 0 N--CA 1.476 0.871 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 178.534 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' F' F ' 14' ' ' HIS . . . . . 0.456 ' NE2' ' NZ ' ' F' ' 16' ' ' LYS . 16.4 t60 -164.66 98.86 0.79 Allowed 'General case' 0 N--CA 1.478 0.969 0 N-CA-C 110.224 -0.287 . . . . 0.0 110.224 179.394 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -91.74 110.93 22.27 Favored 'General case' 0 CA--C 1.507 -0.693 0 N-CA-C 108.376 -0.972 . . . . 0.0 108.376 179.655 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' F' F ' 16' ' ' LYS . . . . . 0.456 ' NZ ' ' NE2' ' F' ' 14' ' ' HIS . 9.7 ttmm -93.59 171.75 8.7 Favored 'General case' 0 N--CA 1.484 1.258 0 N-CA-C 109.224 -0.658 . . . . 0.0 109.224 179.919 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' F' F ' 17' ' ' LEU . . . . . 0.433 HD12 ' N ' ' F' ' 17' ' ' LEU . 9.2 mp -54.8 155.84 4.05 Favored 'General case' 0 N--CA 1.472 0.671 0 N-CA-C 110.044 -0.354 . . . . 0.0 110.044 -178.625 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' F' F ' 18' ' ' VAL . . . . . 0.709 ' O ' ' HB3' ' C' ' 19' ' ' PHE . 79.0 t -141.43 150.49 19.75 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.955 0 N-CA-C 107.929 -1.138 . . . . 0.0 107.929 -178.409 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' F' F ' 19' ' ' PHE . . . . . 0.745 ' HB3' ' O ' ' I' ' 18' ' ' VAL . 38.6 p90 -43.48 153.63 0.11 Allowed 'General case' 0 C--N 1.384 2.101 0 N-CA-C 120.41 3.485 . . . . 0.0 120.41 -177.232 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' F' F ' 20' ' ' PHE . . . . . 0.415 ' O ' ' CD2' ' F' ' 20' ' ' PHE . 20.1 p90 -111.46 67.25 0.64 Allowed 'General case' 0 N--CA 1.48 1.053 0 CA-C-N 113.947 -1.479 . . . . 0.0 111.538 175.029 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' F' F ' 21' ' ' ALA . . . . . 0.402 ' H ' ' HD1' ' F' ' 19' ' ' PHE . . . -58.82 94.27 0.02 OUTLIER 'General case' 0 C--N 1.317 -0.843 0 CA-C-N 114.211 -1.359 . . . . 0.0 109.262 178.074 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 76.5 mt-10 -50.29 122.28 6.71 Favored 'General case' 0 N--CA 1.476 0.85 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.296 -179.743 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 18.2 t70 -75.06 173.54 10.6 Favored 'General case' 0 N--CA 1.468 0.429 0 N-CA-C 110.031 -0.359 . . . . 0.0 110.031 -178.852 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' F' F ' 24' ' ' VAL . . . . . 0.527 HG13 ' H ' ' F' ' 25' ' ' GLY . 0.9 OUTLIER 173.83 -78.35 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.728 0 N-CA-C 107.934 -1.136 . . . . 0.0 107.934 -179.828 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' F' F ' 25' ' ' GLY . . . . . 0.527 ' H ' HG13 ' F' ' 24' ' ' VAL . . . -36.7 84.95 0.01 OUTLIER Glycine 0 CA--C 1.536 1.382 0 C-N-CA 124.045 0.831 . . . . 0.0 113.354 179.294 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' F' F ' 26' ' ' SER . . . . . 0.45 ' N ' ' O ' ' F' ' 24' ' ' VAL . 96.0 p -40.82 -107.11 0.0 OUTLIER 'General case' 0 N--CA 1.479 0.989 0 N-CA-C 114.19 1.181 . . . . 0.0 114.19 -177.696 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 16.6 p-10 -58.42 111.55 1.27 Allowed 'General case' 0 N--CA 1.472 0.654 0 CA-C-N 118.804 0.729 . . . . 0.0 110.171 -178.69 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 38.9 mttm -95.08 167.71 11.21 Favored 'General case' 0 N--CA 1.477 0.918 0 C-N-CA 123.392 0.677 . . . . 0.0 109.597 -179.553 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -76.03 -139.98 0.9 Allowed Glycine 0 CA--C 1.525 0.702 0 N-CA-C 107.113 -2.395 . . . . 0.0 107.113 176.403 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' F' F ' 30' ' ' ALA . . . . . 0.456 ' O ' ' O ' ' I' ' 31' ' ' ILE . . . -91.97 126.37 37.03 Favored 'General case' 0 N--CA 1.472 0.635 0 N-CA-C 106.227 -1.768 . . . . 0.0 106.227 175.706 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' F' F ' 31' ' ' ILE . . . . . 0.489 ' O ' ' O ' ' C' ' 30' ' ' ALA . 16.6 tt -150.01 155.29 8.01 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.619 0 N-CA-C 108.078 -1.082 . . . . 0.0 108.078 179.221 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 19.3 pt -152.48 138.34 11.7 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.651 0 N-CA-C 109.157 -0.683 . . . . 0.0 109.157 -179.482 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -57.63 154.54 21.62 Favored Glycine 0 N--CA 1.474 1.18 0 CA-C-N 115.421 -0.808 . . . . 0.0 112.622 -177.74 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 2.5 pp -75.96 160.51 29.8 Favored 'General case' 0 N--CA 1.47 0.543 0 N-CA-C 109.58 -0.526 . . . . 0.0 109.58 179.14 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 7.6 ttp -105.15 152.08 23.24 Favored 'General case' 0 N--CA 1.479 0.986 0 N-CA-C 109.313 -0.625 . . . . 0.0 109.313 179.528 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 7.5 p -168.19 160.23 0.72 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.625 0 N-CA-C 107.837 -1.172 . . . . 0.0 107.837 179.631 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 53.76 70.89 0.8 Allowed Glycine 0 C--N 1.313 -0.745 0 O-C-N 123.448 0.467 . . . . 0.0 112.425 179.4 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 152.97 -177.19 30.77 Favored Glycine 0 N--CA 1.461 0.364 0 N-CA-C 110.08 -1.208 . . . . 0.0 110.08 179.538 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 5.3 t -126.45 136.81 59.7 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.347 0 N-CA-C 106.242 -1.762 . . . . 0.0 106.242 -178.852 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 76.4 t . . . . . 0 N--CA 1.47 0.567 0 CA-C-O 117.597 -1.192 . . . . 0.0 109.692 -176.926 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 30.3 m-85 . . . . . 0 N--CA 1.474 0.748 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' G' G ' 5' ' ' ARG . . . . . . . . . . . . . 77.0 mtt85 -140.01 145.14 37.41 Favored 'General case' 0 N--CA 1.481 1.095 0 N-CA-C 109.688 -0.486 . . . . 0.0 109.688 179.515 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 58.7 t-80 -150.03 117.38 6.06 Favored 'General case' 0 N--CA 1.473 0.675 0 N-CA-C 109.209 -0.663 . . . . 0.0 109.209 179.217 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 12.4 m-20 -66.89 148.39 52.0 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.961 -179.83 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' G' G ' 8' ' ' SER . . . . . . . . . . . . . 3.5 t -166.93 -179.38 4.67 Favored 'General case' 0 N--CA 1.472 0.674 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.095 178.342 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 85.44 71.95 1.3 Allowed Glycine 0 N--CA 1.477 1.406 0 CA-C-N 116.144 -0.48 . . . . 0.0 112.247 179.015 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 38.5 p90 -72.84 122.03 20.92 Favored 'General case' 0 N--CA 1.477 0.887 0 CA-C-N 117.098 0.449 . . . . 0.0 110.76 179.353 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 17.7 pt-20 -83.28 153.16 24.8 Favored 'General case' 0 N--CA 1.478 0.932 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 178.263 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 22.0 t -143.76 117.64 3.53 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.006 0 CA-C-O 118.527 -0.749 . . . . 0.0 109.032 179.003 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 76.7 m80 -95.42 167.36 11.37 Favored 'General case' 0 N--CA 1.486 1.374 0 CA-C-N 119.569 1.077 . . . . 0.0 109.521 178.597 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' G' G ' 14' ' ' HIS . . . . . 0.442 ' NE2' ' NZ ' ' G' ' 16' ' ' LYS . 16.1 t60 -164.42 98.1 0.8 Allowed 'General case' 0 N--CA 1.479 1.014 0 N-CA-C 110.061 -0.348 . . . . 0.0 110.061 179.216 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -91.63 111.67 23.28 Favored 'General case' 0 CA--C 1.509 -0.6 0 N-CA-C 107.904 -1.146 . . . . 0.0 107.904 179.479 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' G' G ' 16' ' ' LYS . . . . . 0.442 ' NZ ' ' NE2' ' G' ' 14' ' ' HIS . 9.1 ttmm -93.61 171.97 8.56 Favored 'General case' 0 N--CA 1.485 1.315 0 N-CA-C 109.314 -0.624 . . . . 0.0 109.314 -179.86 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' G' G ' 17' ' ' LEU . . . . . 0.411 ' N ' HD12 ' G' ' 17' ' ' LEU . 9.5 mp -55.14 152.24 8.23 Favored 'General case' 0 N--CA 1.471 0.606 0 CA-C-O 121.147 0.498 . . . . 0.0 110.366 -178.829 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' G' G ' 18' ' ' VAL . . . . . 0.757 ' O ' ' HB3' ' D' ' 19' ' ' PHE . 87.0 t -138.13 150.9 24.77 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.622 0 N-CA-C 107.635 -1.246 . . . . 0.0 107.635 -179.166 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' G' G ' 19' ' ' PHE . . . . . 0.475 ' O ' ' CG ' ' D' ' 19' ' ' PHE . 29.3 p90 -44.26 149.22 0.38 Allowed 'General case' 0 C--N 1.406 3.034 0 O-C-N 128.483 3.615 . . . . 0.0 117.721 -175.283 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' G' G ' 20' ' ' PHE . . . . . 0.401 ' CD2' ' O ' ' G' ' 20' ' ' PHE . 23.0 p90 -109.77 62.54 0.6 Allowed 'General case' 0 N--CA 1.496 1.855 0 CA-C-O 122.787 1.28 . . . . 0.0 112.681 177.685 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -53.66 94.3 0.01 OUTLIER 'General case' 0 N--CA 1.445 -0.709 0 CA-C-N 113.928 -1.487 . . . . 0.0 110.303 179.933 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 74.5 mt-10 -51.3 120.3 4.9 Favored 'General case' 0 CA--C 1.541 0.612 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.274 179.912 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 19.2 t70 -73.47 173.66 9.31 Favored 'General case' 0 N--CA 1.468 0.443 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 -178.905 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' G' G ' 24' ' ' VAL . . . . . 0.526 HG13 ' H ' ' G' ' 25' ' ' GLY . 0.9 OUTLIER 174.18 -79.19 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.755 0 N-CA-C 108.221 -1.029 . . . . 0.0 108.221 -179.773 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' G' G ' 25' ' ' GLY . . . . . 0.526 ' H ' HG13 ' G' ' 24' ' ' VAL . . . -37.51 85.91 0.01 OUTLIER Glycine 0 N--CA 1.479 1.54 0 C-N-CA 123.698 0.666 . . . . 0.0 113.171 179.658 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' G' G ' 26' ' ' SER . . . . . 0.441 ' N ' ' O ' ' G' ' 24' ' ' VAL . 90.6 p -40.95 -105.81 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.882 0 N-CA-C 113.877 1.066 . . . . 0.0 113.877 -177.506 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 16.9 p-10 -59.46 110.38 1.1 Allowed 'General case' 0 N--CA 1.473 0.71 0 CA-C-N 118.908 0.776 . . . . 0.0 110.63 -178.795 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 41.7 mttm -93.27 167.82 11.49 Favored 'General case' 0 N--CA 1.47 0.542 0 CA-C-N 115.823 -0.626 . . . . 0.0 109.669 -179.728 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -75.76 -140.28 0.87 Allowed Glycine 0 CA--C 1.525 0.698 0 N-CA-C 106.209 -2.757 . . . . 0.0 106.209 176.236 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -93.64 125.95 38.54 Favored 'General case' 0 N--CA 1.469 0.489 0 N-CA-C 107.154 -1.425 . . . . 0.0 107.154 176.23 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' G' G ' 31' ' ' ILE . . . . . 0.489 ' O ' ' O ' ' D' ' 30' ' ' ALA . 16.4 tt -149.86 155.37 8.04 Favored 'Isoleucine or valine' 0 C--O 1.211 -0.936 0 N-CA-C 108.783 -0.821 . . . . 0.0 108.783 179.786 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 26.7 pt -151.42 136.33 10.21 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.434 0 N-CA-C 109.287 -0.634 . . . . 0.0 109.287 -177.588 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -56.58 154.3 17.24 Favored Glycine 0 CA--C 1.526 0.76 0 CA-C-N 116.147 -0.479 . . . . 0.0 112.179 -178.543 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 2.5 pp -75.63 160.7 29.82 Favored 'General case' 0 N--CA 1.466 0.369 0 N-CA-C 109.499 -0.556 . . . . 0.0 109.499 179.313 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 6.6 ttp -104.78 152.21 22.84 Favored 'General case' 0 N--CA 1.48 1.046 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 179.378 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 7.4 p -168.69 162.22 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 N-CA-C 107.343 -1.355 . . . . 0.0 107.343 179.632 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 54.08 68.93 1.4 Allowed Glycine 0 C--N 1.312 -0.774 0 N-CA-C 111.848 -0.501 . . . . 0.0 111.848 178.77 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 152.66 -178.31 29.88 Favored Glycine 0 N--CA 1.465 0.581 0 N-CA-C 110.473 -1.051 . . . . 0.0 110.473 179.7 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 4.3 t -124.67 138.59 53.55 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.844 0 N-CA-C 107.098 -1.445 . . . . 0.0 107.098 -180.0 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 74.1 t . . . . . 0 N--CA 1.482 1.135 0 CA-C-O 117.788 -1.101 . . . . 0.0 109.8 -177.213 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 31.6 m-85 . . . . . 0 N--CA 1.473 0.712 0 N-CA-C 109.641 -0.503 . . . . 0.0 109.641 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' H' H ' 5' ' ' ARG . . . . . . . . . . . . . 77.1 mtt85 -140.26 145.31 37.15 Favored 'General case' 0 N--CA 1.479 0.979 0 C-N-CA 122.86 0.464 . . . . 0.0 109.801 179.485 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 58.7 t-80 -150.28 117.59 6.04 Favored 'General case' 0 N--CA 1.475 0.786 0 N-CA-C 109.423 -0.584 . . . . 0.0 109.423 179.216 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 12.6 m-20 -67.02 148.17 52.29 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-N 116.386 -0.37 . . . . 0.0 111.078 -179.79 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' H' H ' 8' ' ' SER . . . . . . . . . . . . . 3.5 t -166.86 -179.29 4.66 Favored 'General case' 0 N--CA 1.471 0.598 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.151 178.326 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 85.36 71.68 1.31 Allowed Glycine 0 N--CA 1.477 1.406 0 CA-C-N 116.166 -0.47 . . . . 0.0 112.211 179.098 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 38.3 p90 -72.62 122.2 21.0 Favored 'General case' 0 N--CA 1.474 0.762 0 O-C-N 122.437 -0.449 . . . . 0.0 110.712 179.468 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 17.7 pt-20 -83.39 153.03 24.75 Favored 'General case' 0 N--CA 1.48 1.042 0 N-CA-C 109.294 -0.632 . . . . 0.0 109.294 178.37 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 21.8 t -143.81 116.83 3.12 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.029 0 CA-C-O 118.546 -0.74 . . . . 0.0 109.292 178.952 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 76.5 m80 -94.66 167.26 11.57 Favored 'General case' 0 N--CA 1.484 1.272 0 CA-C-N 119.441 1.018 . . . . 0.0 109.603 178.556 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' H' H ' 14' ' ' HIS . . . . . 0.442 ' NE2' ' NZ ' ' H' ' 16' ' ' LYS . 16.1 t60 -164.41 98.12 0.8 Allowed 'General case' 0 N--CA 1.479 0.979 0 N-CA-C 110.019 -0.363 . . . . 0.0 110.019 179.184 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -91.5 111.76 23.4 Favored 'General case' 0 CA--C 1.511 -0.544 0 N-CA-C 107.891 -1.151 . . . . 0.0 107.891 179.459 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' H' H ' 16' ' ' LYS . . . . . 0.442 ' NZ ' ' NE2' ' H' ' 14' ' ' HIS . 9.1 ttmm -93.72 172.06 8.49 Favored 'General case' 0 N--CA 1.486 1.338 0 N-CA-C 109.344 -0.613 . . . . 0.0 109.344 -179.768 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' H' H ' 17' ' ' LEU . . . . . 0.41 HD12 ' N ' ' H' ' 17' ' ' LEU . 9.4 mp -55.16 152.29 8.2 Favored 'General case' 0 N--CA 1.472 0.656 0 CA-C-O 121.152 0.501 . . . . 0.0 110.382 -178.921 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' H' H ' 18' ' ' VAL . . . . . 0.735 ' O ' ' HB3' ' E' ' 19' ' ' PHE . 89.0 t -138.23 151.15 24.71 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.711 0 N-CA-C 107.783 -1.191 . . . . 0.0 107.783 -179.158 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' H' H ' 19' ' ' PHE . . . . . 0.47 ' O ' ' CG ' ' E' ' 19' ' ' PHE . 29.5 p90 -44.73 149.0 0.45 Allowed 'General case' 0 C--N 1.406 3.033 0 O-C-N 128.487 3.617 . . . . 0.0 117.613 -175.055 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 23.3 p90 -109.56 62.45 0.6 Allowed 'General case' 0 N--CA 1.498 1.953 0 CA-C-O 122.758 1.266 . . . . 0.0 112.533 177.805 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -53.64 94.37 0.01 OUTLIER 'General case' 0 N--CA 1.446 -0.652 0 CA-C-N 113.954 -1.475 . . . . 0.0 110.211 179.947 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 74.8 mt-10 -51.45 120.18 4.85 Favored 'General case' 0 CA--C 1.541 0.62 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.297 179.91 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 19.0 t70 -73.47 173.34 9.77 Favored 'General case' 0 N--CA 1.466 0.355 0 N-CA-C 109.943 -0.391 . . . . 0.0 109.943 -178.897 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' H' H ' 24' ' ' VAL . . . . . 0.509 HG13 ' H ' ' H' ' 25' ' ' GLY . 0.9 OUTLIER 174.52 -79.16 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.542 0.661 0 N-CA-C 108.149 -1.056 . . . . 0.0 108.149 -179.693 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' H' H ' 25' ' ' GLY . . . . . 0.509 ' H ' HG13 ' H' ' 24' ' ' VAL . . . -37.33 85.74 0.01 OUTLIER Glycine 0 N--CA 1.478 1.455 0 C-N-CA 123.732 0.682 . . . . 0.0 113.269 179.646 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' H' H ' 26' ' ' SER . . . . . 0.437 ' N ' ' O ' ' H' ' 24' ' ' VAL . 89.5 p -40.64 -106.07 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.885 0 N-CA-C 113.614 0.968 . . . . 0.0 113.614 -177.789 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 17.0 p-10 -59.35 110.36 1.07 Allowed 'General case' 0 N--CA 1.473 0.686 0 CA-C-N 118.941 0.791 . . . . 0.0 110.68 -178.771 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 41.7 mttm -93.46 167.42 11.72 Favored 'General case' 0 N--CA 1.468 0.461 0 CA-C-N 115.757 -0.656 . . . . 0.0 109.701 -179.896 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -75.43 -140.22 0.79 Allowed Glycine 0 CA--C 1.524 0.645 0 N-CA-C 106.262 -2.735 . . . . 0.0 106.262 176.218 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -93.7 125.92 38.58 Favored 'General case' 0 N--CA 1.47 0.529 0 N-CA-C 107.14 -1.43 . . . . 0.0 107.14 176.342 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' H' H ' 31' ' ' ILE . . . . . 0.458 ' O ' ' O ' ' E' ' 30' ' ' ALA . 16.4 tt -150.02 155.32 7.97 Favored 'Isoleucine or valine' 0 C--O 1.213 -0.846 0 N-CA-C 108.658 -0.867 . . . . 0.0 108.658 179.673 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 27.3 pt -151.38 136.27 10.16 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.399 0 N-CA-C 109.243 -0.651 . . . . 0.0 109.243 -177.526 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -56.69 154.49 17.26 Favored Glycine 0 CA--C 1.528 0.854 0 CA-C-N 116.166 -0.47 . . . . 0.0 112.193 -178.442 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 2.5 pp -75.59 160.78 29.76 Favored 'General case' 0 N--CA 1.467 0.418 0 N-CA-C 109.515 -0.55 . . . . 0.0 109.515 179.37 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 6.5 ttp -104.83 152.17 22.93 Favored 'General case' 0 N--CA 1.48 1.027 0 N-CA-C 109.102 -0.703 . . . . 0.0 109.102 179.343 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 7.4 p -168.81 162.29 0.56 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.487 0 N-CA-C 107.209 -1.404 . . . . 0.0 107.209 179.639 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 54.14 68.87 1.43 Allowed Glycine 0 C--N 1.311 -0.828 0 N-CA-C 111.853 -0.499 . . . . 0.0 111.853 178.721 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 152.41 -178.26 29.7 Favored Glycine 0 N--CA 1.466 0.697 0 N-CA-C 110.564 -1.014 . . . . 0.0 110.564 179.781 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 4.4 t -124.58 138.58 53.54 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.788 0 N-CA-C 107.077 -1.453 . . . . 0.0 107.077 -179.931 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 75.2 t . . . . . 0 N--CA 1.483 1.217 0 CA-C-O 117.755 -1.117 . . . . 0.0 109.813 -177.254 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 31.0 m-85 . . . . . 0 N--CA 1.474 0.763 0 N-CA-C 109.7 -0.481 . . . . 0.0 109.7 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' I' I ' 5' ' ' ARG . . . . . . . . . . . . . 77.0 mtt85 -140.3 145.26 37.02 Favored 'General case' 0 N--CA 1.48 1.038 0 C-N-CA 122.896 0.478 . . . . 0.0 109.798 179.514 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 58.7 t-80 -150.25 117.4 5.98 Favored 'General case' 0 N--CA 1.474 0.746 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 179.226 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 12.3 m-20 -66.76 148.15 52.31 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-N 116.379 -0.373 . . . . 0.0 111.014 -179.848 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' I' I ' 8' ' ' SER . . . . . . . . . . . . . 3.5 t -166.81 -179.31 4.7 Favored 'General case' 0 N--CA 1.472 0.67 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.082 178.3 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 85.36 71.72 1.31 Allowed Glycine 0 N--CA 1.476 1.355 0 CA-C-N 116.14 -0.482 . . . . 0.0 112.232 179.086 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 38.0 p90 -72.48 121.95 20.46 Favored 'General case' 0 N--CA 1.476 0.837 0 O-C-N 122.356 -0.496 . . . . 0.0 110.745 179.38 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 17.7 pt-20 -83.2 153.02 24.96 Favored 'General case' 0 N--CA 1.478 0.959 0 N-CA-C 109.279 -0.638 . . . . 0.0 109.279 178.361 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 21.8 t -143.78 116.83 3.14 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.097 0 CA-C-O 118.584 -0.722 . . . . 0.0 109.326 178.928 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 76.5 m80 -94.69 167.24 11.58 Favored 'General case' 0 N--CA 1.485 1.317 0 CA-C-N 119.505 1.048 . . . . 0.0 109.574 178.603 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' I' I ' 14' ' ' HIS . . . . . 0.446 ' NE2' ' NZ ' ' I' ' 16' ' ' LYS . 15.9 t60 -164.41 98.01 0.8 Allowed 'General case' 0 N--CA 1.479 0.991 0 N-CA-C 110.181 -0.303 . . . . 0.0 110.181 179.149 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -91.43 111.63 23.21 Favored 'General case' 0 CA--C 1.509 -0.632 0 N-CA-C 107.94 -1.133 . . . . 0.0 107.94 179.49 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' I' I ' 16' ' ' LYS . . . . . 0.446 ' NZ ' ' NE2' ' I' ' 14' ' ' HIS . 9.1 ttmm -93.62 172.11 8.47 Favored 'General case' 0 N--CA 1.485 1.304 0 N-CA-C 109.362 -0.607 . . . . 0.0 109.362 -179.778 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' I' I ' 17' ' ' LEU . . . . . 0.405 HD12 ' N ' ' I' ' 17' ' ' LEU . 9.5 mp -55.17 152.29 8.24 Favored 'General case' 0 N--CA 1.472 0.652 0 CA-C-O 121.15 0.5 . . . . 0.0 110.3 -178.857 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' I' I ' 18' ' ' VAL . . . . . 0.745 ' O ' ' HB3' ' F' ' 19' ' ' PHE . 88.8 t -138.21 151.28 24.86 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.634 0 N-CA-C 107.683 -1.228 . . . . 0.0 107.683 -179.218 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' I' I ' 19' ' ' PHE . . . . . 0.466 ' O ' ' CG ' ' F' ' 19' ' ' PHE . 29.1 p90 -44.83 148.93 0.47 Allowed 'General case' 0 C--N 1.407 3.093 0 O-C-N 128.378 3.549 . . . . 0.0 117.57 -175.06 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 23.2 p90 -109.5 62.48 0.6 Allowed 'General case' 0 N--CA 1.497 1.904 0 CA-C-O 122.764 1.268 . . . . 0.0 112.522 177.763 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -53.65 94.42 0.01 OUTLIER 'General case' 0 N--CA 1.446 -0.673 0 CA-C-N 113.901 -1.499 . . . . 0.0 110.201 179.947 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 74.5 mt-10 -51.4 120.17 4.82 Favored 'General case' 0 CA--C 1.541 0.634 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.375 179.929 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 18.9 t70 -73.52 173.13 10.11 Favored 'General case' 0 N--CA 1.467 0.404 0 N-CA-C 109.98 -0.378 . . . . 0.0 109.98 -178.9 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' I' I ' 24' ' ' VAL . . . . . 0.511 HG13 ' H ' ' I' ' 25' ' ' GLY . 0.9 OUTLIER 174.61 -79.24 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.544 0.738 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 -179.745 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' I' I ' 25' ' ' GLY . . . . . 0.511 ' H ' HG13 ' I' ' 24' ' ' VAL . . . -37.29 85.87 0.01 OUTLIER Glycine 0 N--CA 1.48 1.63 0 C-N-CA 123.61 0.624 . . . . 0.0 113.229 179.636 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' I' I ' 26' ' ' SER . . . . . 0.44 ' N ' ' O ' ' I' ' 24' ' ' VAL . 87.7 p -40.77 -105.58 0.0 OUTLIER 'General case' 0 N--CA 1.478 0.949 0 N-CA-C 113.6 0.963 . . . . 0.0 113.6 -177.748 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 17.0 p-10 -59.68 110.4 1.13 Allowed 'General case' 0 N--CA 1.473 0.688 0 CA-C-N 118.993 0.815 . . . . 0.0 110.64 -178.754 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 41.6 mttm -93.53 167.53 11.63 Favored 'General case' 0 N--CA 1.469 0.517 0 CA-C-N 115.788 -0.642 . . . . 0.0 109.778 -179.912 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -75.39 -140.21 0.78 Allowed Glycine 0 CA--C 1.525 0.709 0 N-CA-C 106.361 -2.695 . . . . 0.0 106.361 176.289 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -93.65 125.82 38.47 Favored 'General case' 0 N--CA 1.469 0.508 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 176.242 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' I' I ' 31' ' ' ILE . . . . . 0.456 ' O ' ' O ' ' F' ' 30' ' ' ALA . 16.3 tt -149.91 155.24 8.12 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.806 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 179.688 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 27.5 pt -151.3 136.26 10.26 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.413 0 N-CA-C 109.311 -0.626 . . . . 0.0 109.311 -177.468 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -56.55 154.45 16.76 Favored Glycine 0 CA--C 1.526 0.762 0 CA-C-N 116.238 -0.437 . . . . 0.0 112.244 -178.468 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 2.5 pp -75.64 160.78 29.73 Favored 'General case' 0 N--CA 1.467 0.38 0 N-CA-C 109.448 -0.575 . . . . 0.0 109.448 179.338 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 6.5 ttp -104.78 152.32 22.7 Favored 'General case' 0 N--CA 1.48 1.045 0 N-CA-C 109.04 -0.726 . . . . 0.0 109.04 179.417 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 7.4 p -168.87 162.26 0.56 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.529 0 N-CA-C 107.324 -1.362 . . . . 0.0 107.324 179.582 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 54.04 68.95 1.39 Allowed Glycine 0 C--N 1.312 -0.795 0 N-CA-C 111.924 -0.471 . . . . 0.0 111.924 178.801 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 152.37 -178.25 29.67 Favored Glycine 0 N--CA 1.466 0.646 0 N-CA-C 110.525 -1.03 . . . . 0.0 110.525 179.716 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 4.2 t -124.49 138.34 54.29 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.803 0 N-CA-C 107.193 -1.41 . . . . 0.0 107.193 -179.967 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 74.0 t . . . . . 0 N--CA 1.481 1.125 0 CA-C-O 117.719 -1.134 . . . . 0.0 109.822 -177.304 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 15.8 m-20 . . . . . 0 N--CA 1.488 1.472 0 N-CA-C 108.785 -0.821 . . . . 0.0 108.785 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -76.93 129.37 36.08 Favored 'General case' 0 N--CA 1.466 0.345 0 N-CA-C 109.996 -0.372 . . . . 0.0 109.996 -179.864 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 45.0 mt-10 -119.56 107.39 13.22 Favored 'General case' 0 N--CA 1.478 0.937 0 C-N-CA 122.66 0.384 . . . . 0.0 110.25 179.676 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 22.6 m-85 -72.88 172.41 10.91 Favored 'General case' 0 N--CA 1.473 0.705 0 N-CA-C 109.589 -0.523 . . . . 0.0 109.589 179.391 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 87.5 mtt180 -68.87 133.01 47.67 Favored 'General case' 0 N--CA 1.473 0.698 0 CA-C-N 116.612 -0.267 . . . . 0.0 111.101 -178.211 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 6.9 t-160 -98.71 127.77 44.75 Favored 'General case' 0 N--CA 1.474 0.732 0 N-CA-C 109.351 -0.611 . . . . 0.0 109.351 179.347 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 4.1 m-20 -72.68 139.89 47.54 Favored 'General case' 0 CA--C 1.538 0.487 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.406 178.545 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 28.0 p -163.24 -168.91 1.84 Allowed 'General case' 0 N--CA 1.481 1.102 0 C-N-CA 122.508 0.323 . . . . 0.0 110.694 179.37 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 105.03 44.39 1.51 Allowed Glycine 0 N--CA 1.483 1.798 0 N-CA-C 111.764 -0.534 . . . . 0.0 111.764 -179.475 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 49.0 p90 -64.11 132.79 51.53 Favored 'General case' 0 N--CA 1.472 0.65 0 O-C-N 122.641 -0.329 . . . . 0.0 111.698 -179.899 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 48.7 mt-10 -90.98 152.34 20.72 Favored 'General case' 0 N--CA 1.477 0.907 0 N-CA-C 109.705 -0.48 . . . . 0.0 109.705 178.37 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -152.98 128.07 1.52 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.655 0 N-CA-C 107.805 -1.183 . . . . 0.0 107.805 178.268 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 46.1 m-70 -135.25 147.4 49.26 Favored 'General case' 0 N--CA 1.492 1.672 0 CA-C-N 119.083 0.856 . . . . 0.0 111.388 -178.965 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 6.5 t60 -164.53 97.39 0.78 Allowed 'General case' 0 N--CA 1.481 1.102 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.733 179.191 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . 0.478 HE22 HG23 ' A' ' 36' ' ' VAL . 3.9 pt20 -102.15 -174.12 2.5 Favored 'General case' 0 CA--C 1.509 -0.634 0 N-CA-C 108.654 -0.869 . . . . 0.0 108.654 -179.755 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -169.77 95.68 0.29 Allowed 'General case' 0 N--CA 1.47 0.542 0 CA-C-N 114.565 -1.198 . . . . 0.0 108.345 178.351 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 6.3 mp -123.69 157.04 34.79 Favored 'General case' 0 N--CA 1.498 1.94 0 CA-C-O 121.882 0.848 . . . . 0.0 111.122 -178.151 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 60.2 t -111.92 127.11 69.3 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.099 0 CA-C-O 117.886 -1.054 . . . . 0.0 108.266 177.575 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 26.9 m-85 -126.91 123.05 36.33 Favored 'General case' 0 N--CA 1.497 1.903 0 CA-C-N 120.15 1.341 . . . . 0.0 110.418 179.559 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 66.0 m-85 53.45 74.83 0.29 Allowed 'General case' 0 N--CA 1.469 0.496 0 CA-C-O 121.483 0.659 . . . . 0.0 111.78 178.43 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -79.94 -77.77 0.18 Allowed 'General case' 0 C--N 1.352 0.703 0 CA-C-N 115.044 -0.98 . . . . 0.0 110.319 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 40.8 tt0 -113.96 100.79 8.68 Favored 'General case' 0 N--CA 1.47 0.527 0 N-CA-C 108.247 -1.02 . . . . 0.0 108.247 179.614 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 4.4 p30 -158.53 140.26 13.65 Favored 'General case' 0 N--CA 1.485 1.283 0 O-C-N 122.245 -0.284 . . . . 0.0 111.142 179.079 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.404 HG12 ' N ' ' A' ' 25' ' ' GLY . 60.4 t -59.72 163.58 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.865 0 N-CA-C 108.042 -1.096 . . . . 0.0 108.042 177.108 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.51 ' H ' ' HB ' ' D' ' 24' ' ' VAL . . . -117.87 47.52 1.02 Allowed Glycine 0 N--CA 1.475 1.299 0 N-CA-C 111.776 -0.53 . . . . 0.0 111.776 -179.372 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -61.19 -168.01 0.01 OUTLIER 'General case' 0 N--CA 1.469 0.479 0 O-C-N 123.762 0.331 . . . . 0.0 110.337 179.529 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 26.6 t-20 -70.59 80.7 0.59 Allowed 'General case' 0 N--CA 1.465 0.277 0 CA-C-N 116.401 -0.363 . . . . 0.0 110.17 179.596 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 97.9 mttt -78.03 143.91 37.09 Favored 'General case' 0 N--CA 1.472 0.642 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 179.216 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.81 -167.27 1.07 Allowed Glycine 0 CA--C 1.524 0.625 0 N-CA-C 109.872 -1.291 . . . . 0.0 109.872 178.737 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.83 114.68 28.03 Favored 'General case' 0 N--CA 1.478 0.971 0 N-CA-C 109.67 -0.493 . . . . 0.0 109.67 179.691 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 66.2 mt -98.45 135.83 31.72 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.608 0 N-CA-C 106.883 -1.525 . . . . 0.0 106.883 179.067 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 40.0 pt -152.44 -176.53 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.354 0.763 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.141 -178.765 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.35 4.85 9.61 Favored Glycine 0 CA--C 1.525 0.694 0 N-CA-C 110.861 -0.896 . . . . 0.0 110.861 179.956 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 1.6 tt -75.07 126.58 31.32 Favored 'General case' 0 CA--C 1.544 0.731 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 -179.614 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 28.0 ttt -163.05 150.33 13.05 Favored 'General case' 0 C--O 1.224 -0.253 0 N-CA-C 109.002 -0.74 . . . . 0.0 109.002 178.73 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.569 HG22 HG12 ' D' ' 36' ' ' VAL . 27.9 m -155.78 165.58 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.346 0.447 0 N-CA-C 108.193 -1.04 . . . . 0.0 108.193 179.587 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.92 66.9 2.51 Favored Glycine 0 C--N 1.306 -1.105 0 CA-C-N 115.714 -0.675 . . . . 0.0 112.145 178.693 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.78 -173.12 24.77 Favored Glycine 0 N--CA 1.475 1.276 0 N-CA-C 110.817 -0.913 . . . . 0.0 110.817 179.052 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.493 ' H ' HG12 ' D' ' 39' ' ' VAL . 35.3 m -125.55 157.51 34.83 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.819 0 C-N-CA 123.436 0.694 . . . . 0.0 110.419 -179.863 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 26.2 t . . . . . 0 C--O 1.218 -0.568 0 CA-C-O 118.451 -0.785 . . . . 0.0 110.758 179.775 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' B' B ' 1' ' ' ASP . . . . . . . . . . . . . 15.8 m-20 . . . . . 0 N--CA 1.489 1.52 0 N-CA-C 108.971 -0.752 . . . . 0.0 108.971 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' B' B ' 2' ' ' ALA . . . . . . . . . . . . . . . -76.44 128.66 35.23 Favored 'General case' 0 N--CA 1.466 0.375 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.07 -179.836 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 3' ' ' GLU . . . . . . . . . . . . . 44.6 mt-10 -118.76 107.2 13.36 Favored 'General case' 0 N--CA 1.479 0.987 0 C-N-CA 122.705 0.402 . . . . 0.0 110.277 179.691 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 24.4 m-85 -72.51 172.74 9.97 Favored 'General case' 0 N--CA 1.474 0.737 0 N-CA-C 109.699 -0.482 . . . . 0.0 109.699 179.461 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 87.9 mtt180 -69.06 132.16 46.17 Favored 'General case' 0 N--CA 1.474 0.767 0 CA-C-O 120.631 0.253 . . . . 0.0 110.995 -178.225 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 6.8 t-160 -97.95 127.68 44.05 Favored 'General case' 0 N--CA 1.474 0.751 0 N-CA-C 109.298 -0.631 . . . . 0.0 109.298 179.312 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 7' ' ' ASP . . . . . . . . . . . . . 4.1 m-20 -72.93 139.53 46.84 Favored 'General case' 0 CA--C 1.539 0.544 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.446 178.526 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 8' ' ' SER . . . . . . . . . . . . . 29.2 p -162.56 -168.51 1.84 Allowed 'General case' 0 N--CA 1.481 1.076 0 C-N-CA 122.52 0.328 . . . . 0.0 110.705 179.225 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.63 45.06 1.46 Allowed Glycine 0 N--CA 1.483 1.773 0 N-CA-C 111.732 -0.547 . . . . 0.0 111.732 -179.48 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 49.0 p90 -64.79 132.95 50.94 Favored 'General case' 0 N--CA 1.471 0.607 0 O-C-N 122.662 -0.316 . . . . 0.0 111.684 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 48.7 mt-10 -91.07 152.39 20.65 Favored 'General case' 0 N--CA 1.476 0.873 0 N-CA-C 109.733 -0.469 . . . . 0.0 109.733 178.293 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -153.06 128.32 1.55 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.638 0 N-CA-C 107.734 -1.21 . . . . 0.0 107.734 178.335 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 45.6 m-70 -135.71 147.42 48.47 Favored 'General case' 0 N--CA 1.493 1.698 0 CA-C-N 118.917 0.78 . . . . 0.0 111.33 -178.958 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 6.5 t60 -164.65 97.33 0.76 Allowed 'General case' 0 N--CA 1.481 1.078 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.586 179.302 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . 0.476 HE22 HG23 ' B' ' 36' ' ' VAL . 3.9 pt20 -101.87 -173.68 2.41 Favored 'General case' 0 CA--C 1.51 -0.568 0 N-CA-C 108.639 -0.875 . . . . 0.0 108.639 -179.804 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -170.22 95.63 0.25 Allowed 'General case' 0 N--CA 1.471 0.591 0 CA-C-N 114.63 -1.168 . . . . 0.0 108.259 178.415 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 6.3 mp -123.71 157.05 34.79 Favored 'General case' 0 N--CA 1.497 1.896 0 CA-C-O 121.826 0.822 . . . . 0.0 111.123 -178.113 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 61.8 t -112.31 127.29 69.59 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.074 0 N-CA-C 108.016 -1.105 . . . . 0.0 108.016 177.501 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 27.0 m-85 -127.33 122.86 34.91 Favored 'General case' 0 N--CA 1.495 1.797 0 CA-C-N 119.667 1.121 . . . . 0.0 110.314 179.779 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 66.3 m-85 53.1 74.79 0.28 Allowed 'General case' 0 CA--C 1.539 0.547 0 CA-C-O 121.545 0.688 . . . . 0.0 111.859 178.397 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -79.98 -78.01 0.17 Allowed 'General case' 0 C--N 1.351 0.657 0 CA-C-N 115.016 -0.993 . . . . 0.0 110.278 179.966 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 40.5 tt0 -113.66 100.88 8.81 Favored 'General case' 0 N--CA 1.471 0.594 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 179.569 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 4.4 p30 -158.55 140.88 14.16 Favored 'General case' 0 N--CA 1.484 1.272 0 CA-C-O 119.494 -0.289 . . . . 0.0 111.151 179.021 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 59.0 t -60.13 163.81 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.91 0 N-CA-C 108.116 -1.068 . . . . 0.0 108.116 177.199 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . 0.516 ' H ' ' HB ' ' E' ' 24' ' ' VAL . . . -117.9 47.53 1.02 Allowed Glycine 0 N--CA 1.475 1.276 0 N-CA-C 111.739 -0.544 . . . . 0.0 111.739 -179.397 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -61.18 -167.74 0.01 OUTLIER 'General case' 0 N--CA 1.47 0.545 0 O-C-N 123.651 0.265 . . . . 0.0 110.379 179.396 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 26.9 t-20 -71.1 80.73 0.69 Allowed 'General case' 0 N--CA 1.466 0.348 0 N-CA-C 110.091 -0.337 . . . . 0.0 110.091 179.673 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -78.01 143.92 37.11 Favored 'General case' 0 N--CA 1.472 0.666 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 179.267 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.71 -166.7 0.94 Allowed Glycine 0 CA--C 1.524 0.628 0 N-CA-C 109.895 -1.282 . . . . 0.0 109.895 178.752 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -100.4 114.55 28.2 Favored 'General case' 0 N--CA 1.478 0.958 0 N-CA-C 109.668 -0.493 . . . . 0.0 109.668 179.628 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 65.5 mt -98.26 135.39 33.14 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.556 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 178.965 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 38.1 pt -151.73 -176.51 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.353 0.733 0 CA-C-N 115.962 -0.563 . . . . 0.0 111.151 -178.789 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.37 4.73 9.45 Favored Glycine 0 CA--C 1.525 0.703 0 N-CA-C 110.947 -0.861 . . . . 0.0 110.947 179.833 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 34' ' ' LEU . . . . . 0.412 HD23 ' N ' ' B' ' 35' ' ' MET . 1.6 tt -74.95 126.69 31.53 Favored 'General case' 0 CA--C 1.544 0.744 0 N-CA-C 109.37 -0.604 . . . . 0.0 109.37 -179.617 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 35' ' ' MET . . . . . 0.412 ' N ' HD23 ' B' ' 34' ' ' LEU . 27.4 ttt -163.04 150.17 12.96 Favored 'General case' 0 N--CA 1.467 0.378 0 N-CA-C 108.915 -0.772 . . . . 0.0 108.915 178.672 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 36' ' ' VAL . . . . . 0.559 HG22 HG12 ' E' ' 36' ' ' VAL . 27.8 m -155.8 165.26 1.15 Allowed 'Isoleucine or valine' 0 C--N 1.347 0.495 0 N-CA-C 108.155 -1.054 . . . . 0.0 108.155 179.6 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.09 67.16 2.36 Favored Glycine 0 C--N 1.307 -1.059 0 CA-C-N 115.674 -0.694 . . . . 0.0 112.098 178.649 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.54 -172.57 24.83 Favored Glycine 0 N--CA 1.476 1.318 0 N-CA-C 110.806 -0.917 . . . . 0.0 110.806 179.046 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 39' ' ' VAL . . . . . 0.513 ' H ' HG12 ' E' ' 39' ' ' VAL . 35.5 m -126.12 157.42 36.27 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.98 0 C-N-CA 123.448 0.699 . . . . 0.0 110.454 -179.651 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 26.0 t . . . . . 0 C--O 1.219 -0.509 0 CA-C-O 118.429 -0.796 . . . . 0.0 110.602 179.664 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' C' C ' 1' ' ' ASP . . . . . . . . . . . . . 14.9 m-20 . . . . . 0 N--CA 1.488 1.436 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' C' C ' 2' ' ' ALA . . . . . . . . . . . . . . . -76.92 128.75 35.11 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.035 -179.889 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 3' ' ' GLU . . . . . . . . . . . . . 45.3 mt-10 -119.03 107.27 13.31 Favored 'General case' 0 N--CA 1.479 0.991 0 C-N-CA 122.69 0.396 . . . . 0.0 110.255 179.713 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 23.9 m-85 -72.63 172.94 9.69 Favored 'General case' 0 N--CA 1.475 0.794 0 N-CA-C 109.683 -0.488 . . . . 0.0 109.683 179.343 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 87.4 mtt180 -69.28 131.91 45.62 Favored 'General case' 0 N--CA 1.477 0.904 0 CA-C-O 120.714 0.292 . . . . 0.0 110.955 -178.236 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 6.8 t-160 -97.79 128.16 44.23 Favored 'General case' 0 N--CA 1.473 0.689 0 N-CA-C 109.262 -0.644 . . . . 0.0 109.262 179.215 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 7' ' ' ASP . . . . . . . . . . . . . 4.1 m-20 -73.33 139.77 46.26 Favored 'General case' 0 CA--C 1.538 0.49 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.428 178.583 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 8' ' ' SER . . . . . . . . . . . . . 29.8 p -162.99 -168.71 1.83 Allowed 'General case' 0 N--CA 1.481 1.092 0 CA-C-O 120.828 0.347 . . . . 0.0 110.671 179.249 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.92 44.25 1.54 Allowed Glycine 0 N--CA 1.483 1.798 0 N-CA-C 111.759 -0.537 . . . . 0.0 111.759 -179.498 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 49.3 p90 -64.21 133.29 52.56 Favored 'General case' 0 N--CA 1.472 0.667 0 O-C-N 122.672 -0.311 . . . . 0.0 111.687 -179.935 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 48.3 mt-10 -91.4 152.28 20.47 Favored 'General case' 0 N--CA 1.476 0.858 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 178.356 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -152.83 128.15 1.59 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.598 0 N-CA-C 107.814 -1.18 . . . . 0.0 107.814 178.327 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 45.4 m-70 -135.43 147.69 49.05 Favored 'General case' 0 N--CA 1.493 1.695 0 CA-C-N 118.948 0.794 . . . . 0.0 111.306 -178.969 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 6.5 t60 -164.85 97.31 0.74 Allowed 'General case' 0 N--CA 1.481 1.101 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.646 179.293 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 15' ' ' GLN . . . . . 0.461 HE22 HG23 ' C' ' 36' ' ' VAL . 3.9 pt20 -102.05 -173.85 2.44 Favored 'General case' 0 CA--C 1.508 -0.645 0 N-CA-C 108.606 -0.887 . . . . 0.0 108.606 -179.735 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -170.06 95.81 0.27 Allowed 'General case' 0 N--CA 1.468 0.47 0 CA-C-N 114.623 -1.171 . . . . 0.0 108.292 178.298 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 6.4 mp -123.73 157.17 34.58 Favored 'General case' 0 N--CA 1.497 1.899 0 CA-C-O 121.808 0.813 . . . . 0.0 111.189 -178.194 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 61.7 t -112.32 127.63 69.41 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.057 0 N-CA-C 108.111 -1.07 . . . . 0.0 108.111 177.516 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 27.4 m-85 -127.58 122.77 34.09 Favored 'General case' 0 N--CA 1.493 1.723 0 CA-C-N 119.688 1.131 . . . . 0.0 110.305 179.861 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 66.6 m-85 53.28 74.77 0.28 Allowed 'General case' 0 CA--C 1.538 0.492 0 CA-C-O 121.488 0.661 . . . . 0.0 111.851 178.304 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -79.96 -78.23 0.17 Allowed 'General case' 0 C--N 1.35 0.621 0 CA-C-N 115.008 -0.996 . . . . 0.0 110.291 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 40.1 tt0 -113.58 100.66 8.67 Favored 'General case' 0 N--CA 1.471 0.591 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 179.629 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 4.4 p30 -158.29 140.41 14.09 Favored 'General case' 0 N--CA 1.484 1.229 0 O-C-N 122.264 -0.272 . . . . 0.0 111.117 179.183 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 24' ' ' VAL . . . . . 0.402 HG12 ' N ' ' C' ' 25' ' ' GLY . 59.4 t -59.88 163.51 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.868 0 N-CA-C 108.072 -1.084 . . . . 0.0 108.072 177.096 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 25' ' ' GLY . . . . . 0.501 ' H ' ' HB ' ' F' ' 24' ' ' VAL . . . -117.79 47.94 0.99 Allowed Glycine 0 N--CA 1.478 1.492 0 N-CA-C 111.597 -0.601 . . . . 0.0 111.597 -179.314 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -61.59 -168.18 0.01 OUTLIER 'General case' 0 N--CA 1.469 0.487 0 N-CA-C 110.268 -0.271 . . . . 0.0 110.268 179.447 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 26.7 t-20 -70.51 80.99 0.57 Allowed 'General case' 0 N--CA 1.466 0.332 0 N-CA-C 110.026 -0.361 . . . . 0.0 110.026 179.595 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -78.3 143.76 36.7 Favored 'General case' 0 N--CA 1.472 0.66 0 N-CA-C 109.089 -0.708 . . . . 0.0 109.089 179.312 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.45 -167.34 0.95 Allowed Glycine 0 CA--C 1.525 0.672 0 N-CA-C 109.937 -1.265 . . . . 0.0 109.937 178.689 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.86 113.97 26.86 Favored 'General case' 0 N--CA 1.48 1.028 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 179.657 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 66.0 mt -97.88 135.57 31.92 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.557 0 N-CA-C 106.942 -1.503 . . . . 0.0 106.942 178.992 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 38.8 pt -152.01 -176.42 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.354 0.768 0 CA-C-N 115.902 -0.59 . . . . 0.0 111.122 -178.791 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.45 4.52 9.36 Favored Glycine 0 CA--C 1.525 0.717 0 N-CA-C 110.907 -0.877 . . . . 0.0 110.907 179.882 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 34' ' ' LEU . . . . . 0.403 HD23 ' N ' ' C' ' 35' ' ' MET . 1.6 tt -74.75 126.34 30.68 Favored 'General case' 0 CA--C 1.543 0.692 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 -179.619 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 35' ' ' MET . . . . . 0.403 ' N ' HD23 ' C' ' 34' ' ' LEU . 27.5 ttt -162.57 150.36 13.97 Favored 'General case' 0 N--CA 1.466 0.349 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 178.763 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 36' ' ' VAL . . . . . 0.563 HG22 HG12 ' F' ' 36' ' ' VAL . 27.6 m -156.09 165.22 1.12 Allowed 'Isoleucine or valine' 0 C--N 1.347 0.48 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 179.543 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.14 66.74 2.63 Favored Glycine 0 C--N 1.306 -1.106 0 CA-C-N 115.721 -0.672 . . . . 0.0 112.072 178.548 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.84 -172.47 25.06 Favored Glycine 0 N--CA 1.476 1.308 0 N-CA-C 110.813 -0.915 . . . . 0.0 110.813 178.999 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 39' ' ' VAL . . . . . 0.505 ' H ' HG12 ' F' ' 39' ' ' VAL . 35.6 m -126.21 157.66 36.36 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.892 0 C-N-CA 123.429 0.692 . . . . 0.0 110.421 -179.667 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 27.2 t . . . . . 0 C--O 1.219 -0.512 0 CA-C-O 118.43 -0.795 . . . . 0.0 110.526 179.722 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' D' D ' 1' ' ' ASP . . . . . . . . . . . . . 14.8 m-20 . . . . . 0 N--CA 1.488 1.443 0 N-CA-C 109.228 -0.656 . . . . 0.0 109.228 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' D' D ' 2' ' ' ALA . . . . . . . . . . . . . . . -77.28 129.8 36.36 Favored 'General case' 0 C--O 1.239 0.506 0 N-CA-C 109.726 -0.472 . . . . 0.0 109.726 -179.568 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 3' ' ' GLU . . . . . . . . . . . . . 44.1 mt-10 -119.6 110.66 17.12 Favored 'General case' 0 C--O 1.208 -1.083 0 N-CA-C 109.523 -0.547 . . . . 0.0 109.523 -179.492 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 26.7 m-85 -77.33 166.98 22.46 Favored 'General case' 0 N--CA 1.485 1.276 0 C-N-CA 126.7 2.0 . . . . 0.0 108.304 -179.52 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 5' ' ' ARG . . . . . . . . . . . . 0.314 94.1 mtt180 -77.63 134.01 38.29 Favored 'General case' 0 N--CA 1.483 1.179 0 CA-C-O 123.01 1.386 . . . . 0.0 107.946 -169.394 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 6.2 t-160 -95.14 130.81 41.71 Favored 'General case' 0 C--N 1.364 1.231 0 CA-C-N 113.53 -1.668 . . . . 0.0 108.662 -177.259 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 7' ' ' ASP . . . . . 0.474 ' O ' ' OG ' ' G' ' 8' ' ' SER . 2.8 m-20 -66.29 125.44 25.59 Favored 'General case' 0 C--N 1.309 -1.161 0 C-N-CA 126.841 2.056 . . . . 0.0 114.989 173.304 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 8' ' ' SER . . . . . . . . . . . . . 27.6 p -153.35 -167.15 2.62 Favored 'General case' 0 N--CA 1.488 1.458 0 CA-C-N 120.187 1.358 . . . . 0.0 110.962 176.868 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.78 47.15 1.2 Allowed Glycine 0 N--CA 1.484 1.897 0 C-N-CA 124.797 1.189 . . . . 0.0 110.741 176.961 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 51.0 p90 -60.79 131.66 51.41 Favored 'General case' 0 N--CA 1.47 0.553 0 N-CA-C 112.838 0.681 . . . . 0.0 112.838 177.657 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 48.5 mt-10 -88.6 150.95 22.78 Favored 'General case' 0 N--CA 1.48 1.067 0 CA-C-N 117.862 0.301 . . . . 0.0 110.591 175.553 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -149.5 129.9 4.3 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.609 0 N-CA-C 107.377 -1.342 . . . . 0.0 107.377 173.464 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 42.4 m-70 -129.96 150.69 51.13 Favored 'General case' 0 N--CA 1.483 1.176 0 N-CA-C 112.05 0.389 . . . . 0.0 112.05 176.757 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 6.6 t60 -165.04 104.37 0.77 Allowed 'General case' 0 N--CA 1.483 1.194 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 172.32 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 15' ' ' GLN . . . . . 0.477 HE22 HG23 ' D' ' 36' ' ' VAL . 3.9 pt20 -105.48 -176.17 3.0 Favored 'General case' 0 CA--C 1.501 -0.908 0 N-CA-C 108.491 -0.929 . . . . 0.0 108.491 179.243 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -166.03 104.59 0.67 Allowed 'General case' 0 N--CA 1.466 0.327 0 N-CA-C 106.064 -1.828 . . . . 0.0 106.064 174.26 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 5.4 mp -130.87 153.86 48.68 Favored 'General case' 0 N--CA 1.499 1.988 0 CA-C-O 122.188 0.994 . . . . 0.0 110.604 179.563 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 35.8 t -101.29 131.79 48.35 Favored 'Isoleucine or valine' 0 C--O 1.259 1.57 0 CA-C-O 116.884 -1.531 . . . . 0.0 109.563 174.11 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 25.0 m-85 -130.45 126.3 36.62 Favored 'General case' 0 N--CA 1.49 1.544 0 CA-C-N 120.063 1.302 . . . . 0.0 109.591 173.9 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 66.3 m-85 55.65 71.69 0.53 Allowed 'General case' 0 C--N 1.348 0.535 0 CA-C-N 115.618 -0.719 . . . . 0.0 111.521 175.989 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -81.92 -73.03 0.41 Allowed 'General case' 0 C--N 1.35 0.607 0 CA-C-O 118.478 -0.772 . . . . 0.0 110.988 -177.647 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 40.9 tt0 -117.0 104.62 11.45 Favored 'General case' 0 N--CA 1.482 1.14 0 N-CA-C 106.404 -1.702 . . . . 0.0 106.404 176.32 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -152.06 140.43 20.51 Favored 'General case' 0 N--CA 1.476 0.865 0 CA-C-O 116.797 -1.573 . . . . 0.0 113.494 177.995 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 24' ' ' VAL . . . . . 0.51 ' HB ' ' H ' ' A' ' 25' ' ' GLY . 79.3 t -62.53 165.93 1.01 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.282 0 CA-C-N 121.063 1.756 . . . . 0.0 108.013 175.027 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 25' ' ' GLY . . . . . 0.571 ' H ' ' HB ' ' G' ' 24' ' ' VAL . . . -116.92 51.15 0.74 Allowed Glycine 0 N--CA 1.479 1.508 0 CA-C-O 119.003 -0.887 . . . . 0.0 111.78 178.196 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -57.72 -170.71 0.01 OUTLIER 'General case' 0 C--N 1.32 -0.689 0 C-N-CA 123.563 0.745 . . . . 0.0 111.643 176.042 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 28.2 t-20 -72.73 86.62 1.24 Allowed 'General case' 0 C--N 1.346 0.435 0 N-CA-C 108.421 -0.955 . . . . 0.0 108.421 177.952 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 97.4 mttt -83.27 146.21 28.67 Favored 'General case' 0 C--N 1.352 0.708 0 N-CA-C 108.063 -1.088 . . . . 0.0 108.063 179.138 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -62.8 -164.98 0.5 Allowed Glycine 0 C--N 1.337 0.592 0 N-CA-C 110.626 -0.99 . . . . 0.0 110.626 179.1 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -102.38 116.13 32.0 Favored 'General case' 0 N--CA 1.47 0.533 0 N-CA-C 109.155 -0.683 . . . . 0.0 109.155 179.394 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 73.9 mt -102.68 142.59 16.5 Favored 'Isoleucine or valine' 0 C--N 1.356 0.867 0 N-CA-C 104.505 -2.406 . . . . 0.0 104.505 -179.917 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 32' ' ' ILE . . . . . 0.431 HG22 ' H ' ' G' ' 32' ' ' ILE . 39.4 pt -158.25 -177.39 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.126 0 CA-C-O 120.939 0.4 . . . . 0.0 110.186 -177.075 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 64.32 4.64 13.06 Favored Glycine 0 C--O 1.241 0.562 0 N-CA-C 110.132 -1.187 . . . . 0.0 110.132 -178.828 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 2.1 tt -77.52 133.39 38.55 Favored 'General case' 0 C--N 1.369 1.438 0 C-N-CA 117.944 -1.502 . . . . 0.0 107.155 -177.801 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 35' ' ' MET . . . . . 0.415 ' O ' HG13 ' D' ' 36' ' ' VAL . 27.9 ttt -158.3 161.48 37.67 Favored 'General case' 0 CA--C 1.509 -0.62 0 CA-C-O 118.213 -0.899 . . . . 0.0 108.858 173.574 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 36' ' ' VAL . . . . . 0.607 HG22 HG12 ' G' ' 36' ' ' VAL . 27.7 m -164.63 164.36 0.66 Allowed 'Isoleucine or valine' 0 CA--C 1.517 -0.319 0 N-CA-C 108.064 -1.088 . . . . 0.0 108.064 175.62 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 60.18 64.05 4.5 Favored Glycine 0 C--N 1.313 -0.706 0 C-N-CA 119.759 -1.21 . . . . 0.0 112.883 178.318 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 140.68 -171.27 24.12 Favored Glycine 0 N--CA 1.48 1.581 0 CA-C-N 117.319 0.559 . . . . 0.0 111.769 -179.221 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 39' ' ' VAL . . . . . 0.522 ' H ' HG12 ' G' ' 39' ' ' VAL . 34.9 m -128.37 154.81 39.6 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.851 0 C-N-CA 122.716 0.406 . . . . 0.0 110.146 -176.877 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 25.3 t . . . . . 0 C--N 1.332 -0.16 0 CA-C-O 116.657 -1.64 . . . . 0.0 110.051 178.19 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' E' E ' 1' ' ' ASP . . . . . . . . . . . . . 14.1 m-20 . . . . . 0 N--CA 1.491 1.603 0 N-CA-C 109.365 -0.605 . . . . 0.0 109.365 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' E' E ' 2' ' ' ALA . . . . . . . . . . . . . . . -77.18 128.23 34.04 Favored 'General case' 0 N--CA 1.469 0.515 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.004 -179.732 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 3' ' ' GLU . . . . . . . . . . . . . 44.0 mt-10 -117.45 106.66 13.42 Favored 'General case' 0 N--CA 1.482 1.137 0 C-N-CA 122.312 0.245 . . . . 0.0 110.543 -179.806 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 24.0 m-85 -70.46 172.61 8.12 Favored 'General case' 0 N--CA 1.475 0.794 0 N-CA-C 109.962 -0.384 . . . . 0.0 109.962 179.322 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 5' ' ' ARG . . . . . . . . . . . . . 86.2 mtt180 -68.94 131.89 45.82 Favored 'General case' 0 N--CA 1.475 0.804 0 CA-C-N 116.423 -0.353 . . . . 0.0 111.153 -178.36 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 6.5 t-160 -97.66 129.03 44.77 Favored 'General case' 0 N--CA 1.475 0.789 0 N-CA-C 109.194 -0.669 . . . . 0.0 109.194 179.08 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 7' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -74.42 139.91 44.33 Favored 'General case' 0 N--CA 1.468 0.445 0 CA-C-N 116.513 -0.312 . . . . 0.0 110.531 178.725 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 8' ' ' SER . . . . . . . . . . . . . 24.8 p -163.68 -168.25 1.6 Allowed 'General case' 0 N--CA 1.485 1.301 0 CA-C-O 120.888 0.375 . . . . 0.0 110.886 178.922 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 105.57 44.84 1.39 Allowed Glycine 0 N--CA 1.482 1.732 0 N-CA-C 111.485 -0.646 . . . . 0.0 111.485 -179.682 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 47.0 p90 -63.84 133.45 53.4 Favored 'General case' 0 N--CA 1.475 0.783 0 N-CA-C 112.02 0.378 . . . . 0.0 112.02 -179.806 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 47.2 mt-10 -90.73 152.39 20.84 Favored 'General case' 0 N--CA 1.48 1.036 0 CA-C-O 121.111 0.481 . . . . 0.0 109.747 177.777 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -154.09 127.44 1.19 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.574 0 N-CA-C 107.795 -1.187 . . . . 0.0 107.795 178.003 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 45.0 m-70 -135.74 146.38 47.61 Favored 'General case' 0 N--CA 1.483 1.215 0 CA-C-O 120.869 0.366 . . . . 0.0 111.542 -178.025 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 6.5 t60 -164.32 97.15 0.79 Allowed 'General case' 0 N--CA 1.486 1.344 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.592 179.459 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 15' ' ' GLN . . . . . 0.497 HE22 HG23 ' E' ' 36' ' ' VAL . 3.9 pt20 -101.4 -173.83 2.46 Favored 'General case' 0 CA--C 1.51 -0.588 0 N-CA-C 108.924 -0.769 . . . . 0.0 108.924 -179.728 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -169.77 94.67 0.27 Allowed 'General case' 0 N--CA 1.472 0.647 0 CA-C-N 114.774 -1.103 . . . . 0.0 108.464 178.347 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 6.2 mp -122.4 156.72 33.41 Favored 'General case' 0 N--CA 1.495 1.787 0 CA-C-O 121.698 0.761 . . . . 0.0 111.641 -177.546 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 48.3 t -113.88 124.36 70.46 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.232 0 N-CA-C 108.212 -1.033 . . . . 0.0 108.212 177.245 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 29.8 m-85 -124.83 121.97 36.07 Favored 'General case' 0 N--CA 1.489 1.524 0 CA-C-O 120.907 0.384 . . . . 0.0 110.974 -179.563 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 67.2 m-85 54.47 73.57 0.39 Allowed 'General case' 0 N--CA 1.469 0.476 0 CA-C-N 115.892 -0.594 . . . . 0.0 111.53 177.931 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -78.27 -78.46 0.14 Allowed 'General case' 0 CA--C 1.535 0.377 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.258 -179.711 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 40.9 tt0 -113.02 101.56 9.58 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 108.319 -0.993 . . . . 0.0 108.319 179.683 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -158.15 140.58 14.41 Favored 'General case' 0 C--O 1.205 -1.285 0 CA-C-O 119.488 -0.292 . . . . 0.0 111.481 179.17 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 24' ' ' VAL . . . . . 0.516 ' HB ' ' H ' ' B' ' 25' ' ' GLY . 63.3 t -58.7 168.46 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.973 0 N-CA-C 107.629 -1.248 . . . . 0.0 107.629 177.034 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 25' ' ' GLY . . . . . 0.471 ' H ' ' HB ' ' H' ' 24' ' ' VAL . . . -122.57 47.68 1.0 Allowed Glycine 0 N--CA 1.475 1.264 0 N-CA-C 110.931 -0.867 . . . . 0.0 110.931 -179.347 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -61.81 -167.48 0.01 OUTLIER 'General case' 0 N--CA 1.47 0.548 0 CA-C-O 120.704 0.288 . . . . 0.0 110.469 179.808 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 27.2 t-20 -70.68 77.85 0.6 Allowed 'General case' 0 N--CA 1.467 0.377 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.393 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -75.48 144.56 42.0 Favored 'General case' 0 N--CA 1.475 0.817 0 N-CA-C 109.567 -0.531 . . . . 0.0 109.567 179.331 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.46 -166.4 1.14 Allowed Glycine 0 CA--C 1.522 0.474 0 N-CA-C 110.421 -1.072 . . . . 0.0 110.421 178.629 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -100.08 113.36 25.92 Favored 'General case' 0 N--CA 1.468 0.443 0 N-CA-C 109.961 -0.385 . . . . 0.0 109.961 179.659 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 66.3 mt -97.36 135.28 32.2 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.443 0 N-CA-C 106.752 -1.573 . . . . 0.0 106.752 179.146 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 32' ' ' ILE . . . . . 0.427 HG22 ' H ' ' H' ' 32' ' ' ILE . 39.2 pt -151.74 -174.73 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.123 0 CA-C-O 121.165 0.507 . . . . 0.0 110.682 -179.072 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.5 5.66 6.97 Favored Glycine 0 CA--C 1.53 1.03 0 CA-C-N 115.504 -0.771 . . . . 0.0 111.34 -179.674 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 34' ' ' LEU . . . . . 0.402 HD23 ' N ' ' E' ' 35' ' ' MET . 1.7 tt -74.86 126.62 31.34 Favored 'General case' 0 CA--C 1.545 0.787 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 -179.613 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 35' ' ' MET . . . . . 0.402 ' N ' HD23 ' E' ' 34' ' ' LEU . 28.2 ttt -162.14 151.11 15.41 Favored 'General case' 0 C--O 1.203 -1.348 0 N-CA-C 108.972 -0.751 . . . . 0.0 108.972 178.776 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 36' ' ' VAL . . . . . 0.621 HG22 HG12 ' H' ' 36' ' ' VAL . 32.9 m -157.04 165.22 1.01 Allowed 'Isoleucine or valine' 0 C--N 1.343 0.287 0 N-CA-C 108.434 -0.95 . . . . 0.0 108.434 179.596 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.61 67.08 2.39 Favored Glycine 0 C--N 1.306 -1.096 0 CA-C-N 115.762 -0.654 . . . . 0.0 111.95 178.774 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.88 -172.48 25.08 Favored Glycine 0 N--CA 1.476 1.362 0 N-CA-C 111.16 -0.776 . . . . 0.0 111.16 179.034 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 39' ' ' VAL . . . . . 0.53 ' H ' HG12 ' H' ' 39' ' ' VAL . 33.4 m -126.29 156.78 36.86 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.703 0 C-N-CA 123.452 0.701 . . . . 0.0 110.682 -179.402 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 26.1 t . . . . . 0 C--O 1.218 -0.56 0 CA-C-O 118.451 -0.785 . . . . 0.0 110.701 179.525 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' F' F ' 1' ' ' ASP . . . . . . . . . . . . . 14.9 m-20 . . . . . 0 N--CA 1.489 1.519 0 N-CA-C 109.263 -0.643 . . . . 0.0 109.263 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' F' F ' 2' ' ' ALA . . . . . . . . . . . . . . . -76.63 129.0 35.78 Favored 'General case' 0 N--CA 1.469 0.516 0 CA-C-N 116.298 -0.41 . . . . 0.0 109.984 -179.73 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 3' ' ' GLU . . . . . . . . . . . . . 43.9 mt-10 -118.33 106.81 13.15 Favored 'General case' 0 N--CA 1.483 1.189 0 N-CA-C 110.402 -0.222 . . . . 0.0 110.402 -179.78 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 24.0 m-85 -70.67 172.57 8.44 Favored 'General case' 0 N--CA 1.474 0.754 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 179.348 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 5' ' ' ARG . . . . . . . . . . . . . 87.2 mtt180 -69.0 132.66 47.02 Favored 'General case' 0 C--O 1.217 -0.634 0 CA-C-N 116.419 -0.355 . . . . 0.0 111.289 -178.244 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 6.6 t-160 -98.31 128.69 44.86 Favored 'General case' 0 N--CA 1.477 0.889 0 N-CA-C 109.323 -0.621 . . . . 0.0 109.323 179.31 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 7' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -74.1 139.54 44.66 Favored 'General case' 0 N--CA 1.467 0.42 0 CA-C-N 116.542 -0.299 . . . . 0.0 110.662 178.678 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 8' ' ' SER . . . . . . . . . . . . . 24.7 p -163.6 -168.33 1.63 Allowed 'General case' 0 N--CA 1.486 1.327 0 CA-C-O 120.963 0.411 . . . . 0.0 110.945 178.905 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 105.7 44.84 1.37 Allowed Glycine 0 N--CA 1.482 1.745 0 N-CA-C 111.459 -0.656 . . . . 0.0 111.459 -179.729 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 46.2 p90 -63.67 133.72 54.13 Favored 'General case' 0 CA--C 1.543 0.707 0 N-CA-C 112.094 0.405 . . . . 0.0 112.094 -179.639 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 47.2 mt-10 -90.89 152.24 20.82 Favored 'General case' 0 N--CA 1.481 1.085 0 CA-C-O 121.172 0.51 . . . . 0.0 109.74 177.794 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -153.92 127.19 1.18 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.601 0 N-CA-C 107.776 -1.194 . . . . 0.0 107.776 178.034 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 44.3 m-70 -135.53 145.93 47.54 Favored 'General case' 0 N--CA 1.484 1.232 0 CA-C-O 120.796 0.331 . . . . 0.0 111.635 -177.959 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 6.6 t60 -163.94 97.26 0.83 Allowed 'General case' 0 N--CA 1.486 1.335 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.697 179.442 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 15' ' ' GLN . . . . . 0.488 HE22 HG23 ' F' ' 36' ' ' VAL . 3.9 pt20 -101.68 -173.96 2.48 Favored 'General case' 0 CA--C 1.507 -0.698 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 -179.711 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -169.5 94.71 0.29 Allowed 'General case' 0 N--CA 1.471 0.597 0 CA-C-N 114.633 -1.167 . . . . 0.0 108.424 178.357 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 6.3 mp -122.16 156.84 32.83 Favored 'General case' 0 N--CA 1.495 1.817 0 CA-C-O 121.628 0.728 . . . . 0.0 111.623 -177.687 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 48.6 t -113.94 124.35 70.51 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.181 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 177.185 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 29.8 m-85 -124.72 121.69 35.37 Favored 'General case' 0 N--CA 1.489 1.49 0 CA-C-O 120.888 0.375 . . . . 0.0 110.984 -179.57 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 67.3 m-85 54.41 74.08 0.36 Allowed 'General case' 0 C--N 1.344 0.353 0 CA-C-N 115.917 -0.583 . . . . 0.0 111.68 178.032 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -78.4 -78.42 0.14 Allowed 'General case' 0 CA--C 1.535 0.375 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.282 -179.707 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 40.8 tt0 -113.19 101.39 9.38 Favored 'General case' 0 C--N 1.325 -0.477 0 N-CA-C 108.312 -0.996 . . . . 0.0 108.312 179.777 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -158.08 140.52 14.45 Favored 'General case' 0 C--O 1.204 -1.308 0 CA-C-O 119.537 -0.268 . . . . 0.0 111.419 179.045 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 24' ' ' VAL . . . . . 0.501 ' HB ' ' H ' ' C' ' 25' ' ' GLY . 60.6 t -58.61 168.61 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.962 0 N-CA-C 107.644 -1.243 . . . . 0.0 107.644 177.047 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 25' ' ' GLY . . . . . 0.467 ' H ' ' HB ' ' I' ' 24' ' ' VAL . . . -122.71 48.07 0.98 Allowed Glycine 0 N--CA 1.477 1.381 0 N-CA-C 110.822 -0.911 . . . . 0.0 110.822 -179.398 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -62.24 -167.63 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.559 0 CA-C-O 120.75 0.309 . . . . 0.0 110.417 179.807 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 27.2 t-20 -70.16 77.54 0.51 Allowed 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.432 -179.936 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -75.49 144.18 42.17 Favored 'General case' 0 N--CA 1.475 0.814 0 N-CA-C 109.551 -0.537 . . . . 0.0 109.551 179.489 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.14 -166.58 1.07 Allowed Glycine 0 CA--C 1.522 0.512 0 N-CA-C 110.55 -1.02 . . . . 0.0 110.55 178.596 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.72 113.69 26.33 Favored 'General case' 0 N--CA 1.471 0.589 0 N-CA-C 109.879 -0.415 . . . . 0.0 109.879 179.649 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 66.2 mt -97.85 135.22 33.15 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.43 0 N-CA-C 106.796 -1.557 . . . . 0.0 106.796 179.058 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 32' ' ' ILE . . . . . 0.43 HG22 ' H ' ' I' ' 32' ' ' ILE . 39.7 pt -151.65 -174.43 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.136 0 CA-C-O 121.208 0.527 . . . . 0.0 110.64 -179.049 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.11 6.0 6.59 Favored Glycine 0 CA--C 1.53 0.97 0 CA-C-N 115.426 -0.806 . . . . 0.0 111.345 -179.778 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 34' ' ' LEU . . . . . 0.422 HD23 ' N ' ' F' ' 35' ' ' MET . 1.7 tt -75.43 127.28 32.76 Favored 'General case' 0 N--CA 1.475 0.783 0 N-CA-C 109.31 -0.626 . . . . 0.0 109.31 -179.5 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 35' ' ' MET . . . . . 0.422 ' N ' HD23 ' F' ' 34' ' ' LEU . 28.2 ttt -163.18 152.02 14.45 Favored 'General case' 0 C--O 1.204 -1.306 0 N-CA-C 109.203 -0.665 . . . . 0.0 109.203 178.437 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 36' ' ' VAL . . . . . 0.618 HG22 HG12 ' I' ' 36' ' ' VAL . 32.6 m -157.21 165.69 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.342 0.26 0 N-CA-C 108.408 -0.96 . . . . 0.0 108.408 179.897 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.34 67.41 2.22 Favored Glycine 0 C--N 1.307 -1.081 0 CA-C-N 115.717 -0.674 . . . . 0.0 111.979 178.56 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.33 -172.33 24.78 Favored Glycine 0 N--CA 1.477 1.378 0 N-CA-C 111.084 -0.807 . . . . 0.0 111.084 178.992 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 39' ' ' VAL . . . . . 0.531 ' H ' HG12 ' I' ' 39' ' ' VAL . 33.3 m -126.39 157.01 37.17 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.685 0 C-N-CA 123.425 0.69 . . . . 0.0 110.688 -179.285 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 26.0 t . . . . . 0 C--O 1.22 -0.496 0 O-C-N 124.017 0.823 . . . . 0.0 110.599 179.358 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' G' G ' 1' ' ' ASP . . . . . . . . . . . . . 14.2 m-20 . . . . . 0 N--CA 1.491 1.608 0 N-CA-C 109.376 -0.602 . . . . 0.0 109.376 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' G' G ' 2' ' ' ALA . . . . . . . . . . . . . . . -76.54 130.3 37.71 Favored 'General case' 0 N--CA 1.473 0.705 0 CA-C-N 116.268 -0.424 . . . . 0.0 109.956 -179.858 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 3' ' ' GLU . . . . . . . . . . . . . 41.3 mt-10 -118.22 108.54 15.27 Favored 'General case' 0 N--CA 1.485 1.297 0 C-N-CA 122.203 0.201 . . . . 0.0 110.498 -179.517 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 29.4 m-85 -70.69 170.41 12.41 Favored 'General case' 0 N--CA 1.476 0.851 0 C-N-CA 122.71 0.404 . . . . 0.0 109.936 179.298 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 5' ' ' ARG . . . . . . . . . . . . . 86.5 mtt180 -67.53 132.18 47.07 Favored 'General case' 0 N--CA 1.473 0.723 0 CA-C-N 116.33 -0.396 . . . . 0.0 110.846 -178.615 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 6.4 t-160 -98.27 129.92 44.98 Favored 'General case' 0 N--CA 1.474 0.761 0 N-CA-C 109.415 -0.587 . . . . 0.0 109.415 179.108 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -75.92 135.73 40.09 Favored 'General case' 0 N--CA 1.47 0.554 0 C-N-CA 122.714 0.406 . . . . 0.0 111.097 179.006 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 8' ' ' SER . . . . . 0.474 ' OG ' ' O ' ' D' ' 7' ' ' ASP . 24.7 p -160.11 -166.23 1.65 Allowed 'General case' 0 N--CA 1.477 0.903 0 CA-C-O 120.971 0.415 . . . . 0.0 110.512 178.73 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.42 45.51 1.43 Allowed Glycine 0 N--CA 1.481 1.684 0 N-CA-C 111.211 -0.756 . . . . 0.0 111.211 179.866 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 48.9 p90 -64.59 133.43 52.28 Favored 'General case' 0 CA--C 1.542 0.641 0 N-CA-C 111.91 0.337 . . . . 0.0 111.91 -179.562 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 49.4 mt-10 -90.97 151.76 20.96 Favored 'General case' 0 N--CA 1.479 1.018 0 CA-C-O 121.006 0.432 . . . . 0.0 110.036 178.41 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -154.82 127.53 1.08 Allowed 'Isoleucine or valine' 0 CA--C 1.553 1.088 0 N-CA-C 107.845 -1.169 . . . . 0.0 107.845 178.359 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 46.0 m-70 -135.23 147.11 49.21 Favored 'General case' 0 N--CA 1.478 0.934 0 CA-C-N 115.433 -0.803 . . . . 0.0 111.471 -178.135 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 6.6 t60 -165.22 97.63 0.71 Allowed 'General case' 0 N--CA 1.483 1.22 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.214 178.82 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 15' ' ' GLN . . . . . 0.449 HE22 HG23 ' G' ' 36' ' ' VAL . 3.9 pt20 -102.06 -173.81 2.43 Favored 'General case' 0 CA--C 1.507 -0.678 0 N-CA-C 108.688 -0.856 . . . . 0.0 108.688 -179.595 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -170.32 94.37 0.23 Allowed 'General case' 0 N--CA 1.471 0.624 0 CA-C-N 114.663 -1.153 . . . . 0.0 108.224 178.54 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 6.3 mp -121.86 155.94 34.32 Favored 'General case' 0 N--CA 1.498 1.935 0 CA-C-O 121.298 0.571 . . . . 0.0 111.881 -177.812 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 43.2 t -113.63 124.53 70.36 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.013 0 CA-C-N 114.746 -1.115 . . . . 0.0 108.156 176.617 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 31.5 m-85 -125.13 121.76 35.16 Favored 'General case' 0 C--N 1.366 1.314 0 C-N-CA 123.358 0.663 . . . . 0.0 111.01 -179.324 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 66.7 m-85 54.4 73.43 0.4 Allowed 'General case' 0 N--CA 1.467 0.407 0 CA-C-N 115.865 -0.607 . . . . 0.0 111.532 177.898 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.49 -77.86 0.14 Allowed 'General case' 0 N--CA 1.473 0.682 0 O-C-N 122.296 -0.252 . . . . 0.0 110.451 -179.426 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 40.9 tt0 -113.59 101.61 9.49 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 108.048 -1.093 . . . . 0.0 108.048 179.806 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -158.25 141.65 15.18 Favored 'General case' 0 N--CA 1.478 0.964 0 O-C-N 122.368 -0.207 . . . . 0.0 111.438 179.067 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 24' ' ' VAL . . . . . 0.571 ' HB ' ' H ' ' D' ' 25' ' ' GLY . 58.8 t -60.23 167.12 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.637 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 177.338 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 25' ' ' GLY . . . . . 0.426 ' N ' HG12 ' G' ' 24' ' ' VAL . . . -120.71 48.51 0.94 Allowed Glycine 0 N--CA 1.481 1.662 0 N-CA-C 110.548 -1.021 . . . . 0.0 110.548 -179.499 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -62.93 -167.73 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.648 0 CA-C-N 117.03 0.415 . . . . 0.0 109.943 179.825 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 27.6 t-20 -70.28 77.2 0.54 Allowed 'General case' 0 CA--C 1.536 0.413 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.456 -179.979 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 97.9 mttt -74.29 144.23 44.66 Favored 'General case' 0 N--CA 1.475 0.807 0 N-CA-C 109.642 -0.503 . . . . 0.0 109.642 179.292 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.56 -164.98 0.92 Allowed Glycine 0 C--N 1.337 0.609 0 N-CA-C 110.061 -1.216 . . . . 0.0 110.061 178.623 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -100.03 113.48 26.11 Favored 'General case' 0 N--CA 1.469 0.52 0 C-N-CA 122.737 0.415 . . . . 0.0 110.577 179.865 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 67.6 mt -98.33 135.51 32.81 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.838 0 N-CA-C 106.827 -1.546 . . . . 0.0 106.827 179.062 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 32' ' ' ILE . . . . . 0.431 ' H ' HG22 ' D' ' 32' ' ' ILE . 39.6 pt -152.27 -174.32 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.725 0 CA-C-N 119.784 1.174 . . . . 0.0 109.897 -179.473 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.06 5.63 8.14 Favored Glycine 0 CA--C 1.527 0.789 0 N-CA-C 111.03 -0.828 . . . . 0.0 111.03 -179.928 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 1.6 tt -75.71 125.46 29.09 Favored 'General case' 0 CA--C 1.544 0.733 0 N-CA-C 109.561 -0.533 . . . . 0.0 109.561 -179.574 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 28.1 ttt -161.04 152.91 19.67 Favored 'General case' 0 C--O 1.206 -1.194 0 N-CA-C 108.861 -0.792 . . . . 0.0 108.861 178.712 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 36' ' ' VAL . . . . . 0.607 HG12 HG22 ' D' ' 36' ' ' VAL . 30.4 m -157.8 164.28 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.343 0.293 0 N-CA-C 108.471 -0.937 . . . . 0.0 108.471 -179.836 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.42 67.63 2.11 Favored Glycine 0 C--N 1.309 -0.955 0 CA-C-N 115.602 -0.726 . . . . 0.0 112.207 178.457 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.89 -171.64 25.39 Favored Glycine 0 N--CA 1.478 1.438 0 N-CA-C 110.6 -1.0 . . . . 0.0 110.6 178.981 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 39' ' ' VAL . . . . . 0.522 HG12 ' H ' ' D' ' 39' ' ' VAL . 33.9 m -127.04 157.22 38.59 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.763 0 C-N-CA 123.138 0.575 . . . . 0.0 110.807 -179.43 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 28.0 t . . . . . 0 C--O 1.219 -0.51 0 O-C-N 123.976 0.797 . . . . 0.0 110.85 179.364 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' H' H ' 1' ' ' ASP . . . . . . . . . . . . . 15.2 m-20 . . . . . 0 N--CA 1.49 1.567 0 N-CA-C 109.438 -0.579 . . . . 0.0 109.438 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' H' H ' 2' ' ' ALA . . . . . . . . . . . . . . . -76.78 129.45 36.3 Favored 'General case' 0 N--CA 1.473 0.724 0 CA-C-N 116.22 -0.446 . . . . 0.0 109.942 -179.741 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 3' ' ' GLU . . . . . . . . . . . . . 41.7 mt-10 -117.38 108.79 16.0 Favored 'General case' 0 N--CA 1.483 1.217 0 C-N-CA 122.212 0.205 . . . . 0.0 110.525 -179.498 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 29.7 m-85 -70.97 170.74 12.11 Favored 'General case' 0 N--CA 1.476 0.833 0 C-N-CA 122.739 0.416 . . . . 0.0 109.963 179.209 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 5' ' ' ARG . . . . . . . . . . . . . 86.4 mtt180 -67.7 131.72 46.11 Favored 'General case' 0 N--CA 1.475 0.782 0 CA-C-N 116.421 -0.354 . . . . 0.0 110.798 -178.603 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 6.3 t-160 -98.09 129.5 44.91 Favored 'General case' 0 N--CA 1.475 0.78 0 N-CA-C 109.253 -0.647 . . . . 0.0 109.253 179.114 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -75.42 136.18 40.73 Favored 'General case' 0 N--CA 1.47 0.551 0 C-N-CA 122.666 0.386 . . . . 0.0 111.049 178.936 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 8' ' ' SER . . . . . . . . . . . . . 27.2 p -160.39 -166.52 1.68 Allowed 'General case' 0 N--CA 1.475 0.794 0 CA-C-O 120.85 0.357 . . . . 0.0 110.476 178.786 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.27 46.16 1.37 Allowed Glycine 0 N--CA 1.481 1.674 0 N-CA-C 111.292 -0.723 . . . . 0.0 111.292 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 48.6 p90 -65.46 133.73 51.92 Favored 'General case' 0 CA--C 1.542 0.665 0 N-CA-C 111.894 0.331 . . . . 0.0 111.894 -179.635 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 48.8 mt-10 -91.2 151.63 20.87 Favored 'General case' 0 N--CA 1.479 0.98 0 CA-C-O 121.0 0.429 . . . . 0.0 110.154 178.481 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -154.52 127.66 1.16 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.057 0 N-CA-C 107.874 -1.158 . . . . 0.0 107.874 178.267 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 45.9 m-70 -135.25 147.0 49.14 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.438 -0.801 . . . . 0.0 111.408 -178.073 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 6.5 t60 -165.22 97.33 0.71 Allowed 'General case' 0 N--CA 1.483 1.192 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.264 178.837 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 15' ' ' GLN . . . . . 0.439 HE22 HG23 ' H' ' 36' ' ' VAL . 3.9 pt20 -101.64 -173.77 2.43 Favored 'General case' 0 CA--C 1.511 -0.555 0 N-CA-C 108.637 -0.875 . . . . 0.0 108.637 -179.592 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -170.31 94.22 0.23 Allowed 'General case' 0 N--CA 1.472 0.652 0 CA-C-N 114.664 -1.153 . . . . 0.0 108.116 178.503 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 6.3 mp -121.81 155.66 34.86 Favored 'General case' 0 N--CA 1.498 1.964 0 CA-C-O 121.29 0.567 . . . . 0.0 111.96 -177.778 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 42.2 t -113.33 124.74 70.27 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.044 0 CA-C-N 114.766 -1.106 . . . . 0.0 108.159 176.521 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 30.9 m-85 -125.4 121.06 32.78 Favored 'General case' 0 C--N 1.368 1.401 0 CA-C-N 115.524 -0.762 . . . . 0.0 110.904 -179.082 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 67.2 m-85 54.55 73.63 0.39 Allowed 'General case' 0 C--O 1.236 0.389 0 CA-C-N 115.815 -0.63 . . . . 0.0 111.535 177.9 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.33 -77.98 0.14 Allowed 'General case' 0 N--CA 1.472 0.634 0 O-C-N 122.248 -0.283 . . . . 0.0 110.611 -179.526 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 41.0 tt0 -113.4 101.34 9.29 Favored 'General case' 0 C--N 1.323 -0.578 0 N-CA-C 108.1 -1.074 . . . . 0.0 108.1 179.731 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -157.7 141.87 16.07 Favored 'General case' 0 N--CA 1.478 0.971 0 O-C-N 122.453 -0.155 . . . . 0.0 111.371 179.095 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 24' ' ' VAL . . . . . 0.471 ' HB ' ' H ' ' E' ' 25' ' ' GLY . 57.4 t -60.45 166.92 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.617 0 N-CA-C 107.632 -1.247 . . . . 0.0 107.632 177.246 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 25' ' ' GLY . . . . . 0.423 ' N ' HG12 ' H' ' 24' ' ' VAL . . . -120.6 49.36 0.88 Allowed Glycine 0 N--CA 1.48 1.603 0 N-CA-C 110.528 -1.029 . . . . 0.0 110.528 -179.592 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -63.77 -167.63 0.02 OUTLIER 'General case' 0 N--CA 1.473 0.697 0 CA-C-N 116.99 0.395 . . . . 0.0 110.028 179.812 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 27.4 t-20 -70.2 77.38 0.52 Allowed 'General case' 0 CA--C 1.536 0.41 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.445 179.883 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -74.8 144.21 43.62 Favored 'General case' 0 N--CA 1.474 0.754 0 N-CA-C 109.626 -0.509 . . . . 0.0 109.626 179.366 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.83 -165.42 1.08 Allowed Glycine 0 C--N 1.337 0.607 0 N-CA-C 109.978 -1.249 . . . . 0.0 109.978 178.731 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.66 113.57 26.1 Favored 'General case' 0 N--CA 1.468 0.431 0 C-N-CA 122.632 0.373 . . . . 0.0 110.593 179.902 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 66.6 mt -98.06 135.65 31.88 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.803 0 N-CA-C 106.81 -1.552 . . . . 0.0 106.81 178.964 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 32' ' ' ILE . . . . . 0.427 ' H ' HG22 ' E' ' 32' ' ' ILE . 39.1 pt -152.38 -174.31 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 CA-C-N 119.838 1.199 . . . . 0.0 109.832 -179.637 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.05 5.92 8.75 Favored Glycine 0 CA--C 1.528 0.86 0 N-CA-C 110.974 -0.85 . . . . 0.0 110.974 -179.929 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 34' ' ' LEU . . . . . 0.401 HD23 ' N ' ' H' ' 35' ' ' MET . 1.6 tt -75.84 125.19 28.6 Favored 'General case' 0 CA--C 1.545 0.761 0 N-CA-C 109.512 -0.551 . . . . 0.0 109.512 -179.602 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 35' ' ' MET . . . . . 0.401 ' N ' HD23 ' H' ' 34' ' ' LEU . 28.3 ttt -160.76 152.79 20.03 Favored 'General case' 0 C--O 1.207 -1.144 0 N-CA-C 108.925 -0.768 . . . . 0.0 108.925 178.595 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 36' ' ' VAL . . . . . 0.621 HG12 HG22 ' E' ' 36' ' ' VAL . 28.4 m -157.8 164.17 1.14 Allowed 'Isoleucine or valine' 0 C--N 1.343 0.294 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 -179.81 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.54 67.81 2.01 Favored Glycine 0 C--N 1.309 -0.964 0 CA-C-N 115.559 -0.746 . . . . 0.0 112.168 178.542 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.55 -171.59 25.2 Favored Glycine 0 N--CA 1.478 1.475 0 N-CA-C 110.621 -0.992 . . . . 0.0 110.621 179.05 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 39' ' ' VAL . . . . . 0.53 HG12 ' H ' ' E' ' 39' ' ' VAL . 33.8 m -126.99 157.71 38.23 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.82 0 C-N-CA 123.168 0.587 . . . . 0.0 110.795 -179.456 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 29.7 t . . . . . 0 N--CA 1.469 0.506 0 O-C-N 123.985 0.803 . . . . 0.0 110.745 179.281 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' I' I ' 1' ' ' ASP . . . . . . . . . . . . . 14.2 m-20 . . . . . 0 N--CA 1.491 1.611 0 N-CA-C 109.499 -0.556 . . . . 0.0 109.499 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' I' I ' 2' ' ' ALA . . . . . . . . . . . . . . . -76.19 129.82 37.31 Favored 'General case' 0 N--CA 1.473 0.714 0 CA-C-N 116.282 -0.417 . . . . 0.0 109.947 -179.819 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 3' ' ' GLU . . . . . . . . . . . . . 42.6 mt-10 -117.81 108.63 15.59 Favored 'General case' 0 N--CA 1.484 1.247 0 C-N-CA 122.207 0.203 . . . . 0.0 110.502 -179.565 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 29.3 m-85 -70.74 171.15 10.98 Favored 'General case' 0 N--CA 1.476 0.868 0 C-N-CA 122.733 0.413 . . . . 0.0 109.929 179.236 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 5' ' ' ARG . . . . . . . . . . . . . 86.5 mtt180 -68.18 131.72 45.9 Favored 'General case' 0 N--CA 1.476 0.837 0 CA-C-N 116.435 -0.348 . . . . 0.0 110.719 -178.569 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 6.4 t-160 -97.89 129.56 44.83 Favored 'General case' 0 N--CA 1.473 0.718 0 N-CA-C 109.333 -0.617 . . . . 0.0 109.333 179.051 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -75.48 135.98 40.66 Favored 'General case' 0 CA--C 1.539 0.533 0 C-N-CA 122.707 0.403 . . . . 0.0 111.003 178.955 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 8' ' ' SER . . . . . . . . . . . . . 25.0 p -160.41 -166.63 1.7 Allowed 'General case' 0 N--CA 1.476 0.833 0 CA-C-O 120.936 0.398 . . . . 0.0 110.494 178.841 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.37 45.97 1.38 Allowed Glycine 0 N--CA 1.481 1.693 0 N-CA-C 111.29 -0.724 . . . . 0.0 111.29 179.942 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 49.3 p90 -65.28 133.48 51.55 Favored 'General case' 0 N--CA 1.473 0.681 0 N-CA-C 111.942 0.349 . . . . 0.0 111.942 -179.599 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 49.1 mt-10 -90.93 151.71 21.0 Favored 'General case' 0 N--CA 1.478 0.949 0 CA-C-O 121.077 0.465 . . . . 0.0 110.165 178.463 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -154.72 127.55 1.1 Allowed 'Isoleucine or valine' 0 CA--C 1.553 1.073 0 N-CA-C 107.91 -1.144 . . . . 0.0 107.91 178.248 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 47.0 m-70 -135.22 146.84 49.04 Favored 'General case' 0 N--CA 1.477 0.915 0 CA-C-N 115.45 -0.796 . . . . 0.0 111.404 -178.002 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 6.5 t60 -165.05 97.41 0.73 Allowed 'General case' 0 N--CA 1.483 1.207 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.27 178.884 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 15' ' ' GLN . . . . . 0.421 HE22 HG23 ' I' ' 36' ' ' VAL . 3.9 pt20 -101.82 -173.71 2.42 Favored 'General case' 0 CA--C 1.509 -0.627 0 N-CA-C 108.681 -0.859 . . . . 0.0 108.681 -179.612 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -170.36 94.02 0.22 Allowed 'General case' 0 N--CA 1.472 0.638 0 CA-C-N 114.628 -1.169 . . . . 0.0 108.128 178.607 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 6.3 mp -121.62 155.86 34.18 Favored 'General case' 0 N--CA 1.497 1.904 0 CA-C-O 121.257 0.551 . . . . 0.0 111.92 -177.751 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 42.1 t -113.53 125.09 70.75 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.997 0 CA-C-N 114.789 -1.096 . . . . 0.0 108.1 176.54 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 31.2 m-85 -125.73 121.41 33.31 Favored 'General case' 0 C--N 1.366 1.325 0 CA-C-N 115.61 -0.723 . . . . 0.0 110.945 -179.229 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 67.1 m-85 54.46 73.3 0.41 Allowed 'General case' 0 C--O 1.237 0.429 0 CA-C-N 115.911 -0.586 . . . . 0.0 111.482 177.885 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.15 -77.92 0.14 Allowed 'General case' 0 N--CA 1.473 0.702 0 O-C-N 122.272 -0.268 . . . . 0.0 110.5 -179.55 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 40.8 tt0 -113.4 101.54 9.48 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 108.069 -1.086 . . . . 0.0 108.069 179.692 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -157.91 141.59 15.56 Favored 'General case' 0 N--CA 1.479 1.004 0 O-C-N 122.42 -0.175 . . . . 0.0 111.361 179.087 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 24' ' ' VAL . . . . . 0.467 ' HB ' ' H ' ' F' ' 25' ' ' GLY . 59.0 t -60.26 167.27 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.631 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 177.22 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 25' ' ' GLY . . . . . 0.44 ' N ' HG12 ' I' ' 24' ' ' VAL . . . -120.89 49.3 0.89 Allowed Glycine 0 N--CA 1.481 1.683 0 N-CA-C 110.523 -1.031 . . . . 0.0 110.523 -179.572 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -63.75 -167.65 0.02 OUTLIER 'General case' 0 N--CA 1.473 0.682 0 CA-C-N 117.002 0.401 . . . . 0.0 109.949 179.768 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 27.6 t-20 -70.21 77.27 0.52 Allowed 'General case' 0 CA--C 1.535 0.401 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.411 179.913 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -74.66 143.92 44.04 Favored 'General case' 0 N--CA 1.475 0.8 0 N-CA-C 109.617 -0.512 . . . . 0.0 109.617 179.424 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.44 -165.8 1.03 Allowed Glycine 0 C--N 1.337 0.601 0 N-CA-C 110.009 -1.236 . . . . 0.0 110.009 178.653 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.26 113.7 26.13 Favored 'General case' 0 N--CA 1.468 0.471 0 C-N-CA 122.729 0.412 . . . . 0.0 110.583 179.991 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 66.9 mt -98.5 135.49 33.12 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.842 0 N-CA-C 106.833 -1.543 . . . . 0.0 106.833 178.98 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 32' ' ' ILE . . . . . 0.43 ' H ' HG22 ' F' ' 32' ' ' ILE . 39.2 pt -152.36 -174.3 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.725 0 CA-C-N 119.8 1.182 . . . . 0.0 109.84 -179.567 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.04 5.84 8.56 Favored Glycine 0 CA--C 1.527 0.819 0 N-CA-C 110.999 -0.84 . . . . 0.0 110.999 -179.874 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 34' ' ' LEU . . . . . 0.402 HD23 ' N ' ' I' ' 35' ' ' MET . 1.6 tt -75.82 125.42 29.05 Favored 'General case' 0 CA--C 1.545 0.753 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 -179.644 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 35' ' ' MET . . . . . 0.402 ' N ' HD23 ' I' ' 34' ' ' LEU . 28.3 ttt -160.88 152.59 19.57 Favored 'General case' 0 C--O 1.206 -1.186 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 178.723 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 36' ' ' VAL . . . . . 0.618 HG12 HG22 ' F' ' 36' ' ' VAL . 26.7 m -157.59 164.1 1.17 Allowed 'Isoleucine or valine' 0 C--N 1.342 0.262 0 N-CA-C 108.448 -0.945 . . . . 0.0 108.448 -179.988 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.57 67.91 1.96 Allowed Glycine 0 C--N 1.309 -0.951 0 CA-C-N 115.602 -0.727 . . . . 0.0 112.122 178.571 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.58 -171.86 25.11 Favored Glycine 0 N--CA 1.478 1.445 0 N-CA-C 110.644 -0.982 . . . . 0.0 110.644 178.97 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 39' ' ' VAL . . . . . 0.531 HG12 ' H ' ' F' ' 39' ' ' VAL . 33.9 m -126.82 157.26 38.07 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.792 0 C-N-CA 123.181 0.592 . . . . 0.0 110.832 -179.452 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 26.0 t . . . . . 0 C--O 1.22 -0.5 0 O-C-N 123.964 0.79 . . . . 0.0 110.825 179.347 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . 0.478 ' H1 ' ' CG ' ' D' ' 1' ' ' ASP . 16.2 m-20 . . . . . 0 N--CA 1.489 1.49 0 N-CA-C 108.939 -0.763 . . . . 0.0 108.939 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -66.19 133.78 51.36 Favored 'General case' 0 CA--C 1.538 0.514 0 N-CA-C 110.075 -0.343 . . . . 0.0 110.075 -179.873 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.403 ' CD ' HH21 ' A' ' 5' ' ' ARG . 49.3 tt0 -169.65 106.08 0.36 Allowed 'General case' 0 N--CA 1.474 0.736 0 N-CA-C 109.961 -0.385 . . . . 0.0 109.961 -179.17 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 63.1 m-85 -83.97 145.68 28.41 Favored 'General case' 0 N--CA 1.474 0.769 0 N-CA-C 110.309 -0.256 . . . . 0.0 110.309 179.484 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' ARG . . . . . 0.403 HH21 ' CD ' ' A' ' 3' ' ' GLU . 99.5 mtt180 -144.45 142.51 30.34 Favored 'General case' 0 N--CA 1.483 1.221 0 N-CA-C 109.958 -0.386 . . . . 0.0 109.958 179.721 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 45.1 t-80 -152.61 118.77 5.51 Favored 'General case' 0 N--CA 1.469 0.524 0 N-CA-C 109.26 -0.645 . . . . 0.0 109.26 178.967 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' ASP . . . . . 0.51 ' O ' ' OG ' ' D' ' 8' ' ' SER . 4.0 m-20 -69.52 149.62 48.03 Favored 'General case' 0 CA--C 1.538 0.49 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.468 179.898 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 52.1 p -168.07 -173.24 2.0 Allowed 'General case' 0 N--CA 1.484 1.249 0 CA-C-O 121.075 0.464 . . . . 0.0 110.706 179.461 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.77 46.85 1.44 Allowed Glycine 0 N--CA 1.483 1.802 0 CA-C-N 115.962 -0.563 . . . . 0.0 111.941 179.808 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 47.8 p90 -65.27 132.56 49.37 Favored 'General case' 0 N--CA 1.471 0.616 0 CA-C-N 116.71 0.255 . . . . 0.0 111.62 179.764 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 48.1 mt-10 -91.87 151.77 20.4 Favored 'General case' 0 N--CA 1.478 0.935 0 N-CA-C 109.692 -0.484 . . . . 0.0 109.692 178.437 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.0 p -152.79 128.19 1.61 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.61 0 N-CA-C 107.894 -1.15 . . . . 0.0 107.894 178.239 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 45.3 m-70 -135.46 146.31 48.06 Favored 'General case' 0 N--CA 1.493 1.687 0 CA-C-N 118.993 0.815 . . . . 0.0 111.253 -178.916 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 6.0 t60 -165.8 96.78 0.64 Allowed 'General case' 0 N--CA 1.478 0.958 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.941 179.398 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . 0.708 HE22 ' H ' ' A' ' 37' ' ' GLY . 5.9 pt20 -108.27 -174.39 2.51 Favored 'General case' 0 CA--C 1.508 -0.645 0 N-CA-C 108.293 -1.003 . . . . 0.0 108.293 -179.781 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -164.22 98.79 0.83 Allowed 'General case' 0 N--CA 1.472 0.626 0 CA-C-N 114.477 -1.238 . . . . 0.0 108.285 178.38 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 6.5 mp -122.04 155.76 34.94 Favored 'General case' 0 N--CA 1.499 2.002 0 CA-C-O 121.837 0.827 . . . . 0.0 110.926 -178.341 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 60.2 t -111.55 126.73 68.97 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.093 0 CA-C-O 117.908 -1.044 . . . . 0.0 108.235 177.737 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 28.1 m-85 -126.43 122.99 36.87 Favored 'General case' 0 N--CA 1.497 1.902 0 CA-C-N 120.08 1.309 . . . . 0.0 110.477 179.203 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 67.0 m-85 54.08 73.79 0.37 Allowed 'General case' 0 N--CA 1.469 0.493 0 CA-C-O 121.306 0.574 . . . . 0.0 111.828 178.757 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -79.99 -77.97 0.18 Allowed 'General case' 0 C--N 1.351 0.665 0 CA-C-N 115.193 -0.912 . . . . 0.0 110.203 -179.752 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 40.6 tt0 -113.53 99.6 7.87 Favored 'General case' 0 N--CA 1.468 0.461 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 179.855 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -158.41 138.84 12.59 Favored 'General case' 0 C--O 1.206 -1.22 0 O-C-N 122.231 -0.293 . . . . 0.0 111.249 179.098 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.401 HG12 ' N ' ' A' ' 25' ' ' GLY . 59.8 t -59.53 163.37 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.921 0 N-CA-C 107.941 -1.133 . . . . 0.0 107.941 177.071 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.461 ' H ' ' HB ' ' D' ' 24' ' ' VAL . . . -116.88 47.61 1.02 Allowed Glycine 0 N--CA 1.476 1.359 0 N-CA-C 111.834 -0.506 . . . . 0.0 111.834 -179.417 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -60.61 -167.5 0.01 OUTLIER 'General case' 0 N--CA 1.469 0.478 0 O-C-N 123.786 0.345 . . . . 0.0 110.305 179.56 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 25.4 t-20 -71.02 80.46 0.66 Allowed 'General case' 0 N--CA 1.465 0.29 0 CA-C-N 116.45 -0.341 . . . . 0.0 110.246 179.539 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 97.7 mttt -77.45 142.95 38.92 Favored 'General case' 0 N--CA 1.474 0.744 0 N-CA-C 109.183 -0.673 . . . . 0.0 109.183 179.283 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.66 -167.89 1.12 Allowed Glycine 0 C--N 1.338 0.648 0 N-CA-C 109.957 -1.257 . . . . 0.0 109.957 178.757 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.44 115.12 28.54 Favored 'General case' 0 N--CA 1.478 0.951 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 179.727 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 71.0 mt -98.58 134.71 36.23 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.576 0 N-CA-C 107.202 -1.407 . . . . 0.0 107.202 178.722 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 31.1 pt -150.63 -171.43 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.352 0.696 0 CA-C-O 121.168 0.508 . . . . 0.0 111.122 -179.259 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.39 4.95 9.96 Favored Glycine 0 N--CA 1.466 0.636 0 N-CA-C 110.735 -0.946 . . . . 0.0 110.735 179.843 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.427 HD23 ' N ' ' A' ' 35' ' ' MET . 1.1 tt -75.38 135.21 40.81 Favored 'General case' 0 CA--C 1.545 0.77 0 N-CA-C 109.395 -0.594 . . . . 0.0 109.395 -179.727 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' MET . . . . . 0.427 ' N ' HD23 ' A' ' 34' ' ' LEU . 27.1 ttt -158.82 146.46 17.79 Favored 'General case' 0 N--CA 1.467 0.418 0 N-CA-C 108.619 -0.882 . . . . 0.0 108.619 178.608 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 1.9 m -148.9 165.65 4.01 Favored 'Isoleucine or valine' 0 C--N 1.348 0.517 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 -179.625 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . 0.708 ' H ' HE22 ' A' ' 15' ' ' GLN . . . 54.87 68.44 1.68 Allowed Glycine 0 C--N 1.306 -1.118 0 CA-C-N 115.49 -0.777 . . . . 0.0 112.32 177.518 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.53 176.59 21.3 Favored Glycine 0 N--CA 1.472 1.072 0 N-CA-C 111.11 -0.796 . . . . 0.0 111.11 178.7 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.439 ' H ' HG12 ' D' ' 39' ' ' VAL . 34.3 m -109.31 156.28 10.08 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.658 0 C-N-CA 123.385 0.674 . . . . 0.0 110.201 -179.689 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 24.4 t . . . . . 0 C--O 1.219 -0.55 0 CA-C-O 118.42 -0.8 . . . . 0.0 110.492 179.397 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' B' B ' 1' ' ' ASP . . . . . 0.428 ' H1 ' ' CG ' ' E' ' 1' ' ' ASP . 15.8 m-20 . . . . . 0 N--CA 1.49 1.529 0 N-CA-C 108.962 -0.755 . . . . 0.0 108.962 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.72 133.23 50.63 Favored 'General case' 0 N--CA 1.47 0.547 0 CA-C-N 116.455 -0.339 . . . . 0.0 110.127 -179.845 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 3' ' ' GLU . . . . . . . . . . . . . 48.2 tt0 -169.11 105.55 0.4 Allowed 'General case' 0 N--CA 1.475 0.786 0 N-CA-C 110.077 -0.342 . . . . 0.0 110.077 -179.114 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 63.8 m-85 -83.39 145.4 29.03 Favored 'General case' 0 N--CA 1.473 0.678 0 N-CA-C 110.264 -0.272 . . . . 0.0 110.264 179.372 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -144.2 142.42 30.51 Favored 'General case' 0 N--CA 1.483 1.186 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 179.682 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 44.8 t-80 -152.45 118.63 5.53 Favored 'General case' 0 N--CA 1.471 0.582 0 N-CA-C 109.395 -0.594 . . . . 0.0 109.395 178.829 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 7' ' ' ASP . . . . . 0.457 ' O ' ' OG ' ' E' ' 8' ' ' SER . 3.8 m-20 -69.36 149.18 48.69 Favored 'General case' 0 CA--C 1.539 0.546 0 CA-C-N 116.4 -0.364 . . . . 0.0 110.622 179.896 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 8' ' ' SER . . . . . . . . . . . . . 52.7 p -167.52 -173.26 2.15 Favored 'General case' 0 N--CA 1.484 1.235 0 CA-C-O 121.033 0.444 . . . . 0.0 110.818 179.381 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.89 46.95 1.41 Allowed Glycine 0 N--CA 1.481 1.674 0 CA-C-N 115.966 -0.561 . . . . 0.0 112.015 179.661 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 47.7 p90 -65.79 132.53 48.94 Favored 'General case' 0 N--CA 1.472 0.652 0 CA-C-O 120.719 0.295 . . . . 0.0 111.649 179.837 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 47.9 mt-10 -91.65 151.86 20.49 Favored 'General case' 0 N--CA 1.477 0.894 0 N-CA-C 109.655 -0.498 . . . . 0.0 109.655 178.436 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -152.92 127.95 1.51 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.47 0 N-CA-C 107.972 -1.121 . . . . 0.0 107.972 178.13 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 43.5 m-70 -135.18 146.42 48.69 Favored 'General case' 0 N--CA 1.493 1.686 0 CA-C-N 118.869 0.759 . . . . 0.0 111.345 -178.93 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 6.1 t60 -165.79 97.02 0.65 Allowed 'General case' 0 N--CA 1.48 1.041 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.768 179.378 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . 0.715 HE22 ' H ' ' B' ' 37' ' ' GLY . 5.9 pt20 -108.37 -174.18 2.46 Favored 'General case' 0 CA--C 1.509 -0.603 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 -179.772 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -164.63 98.88 0.79 Allowed 'General case' 0 N--CA 1.474 0.755 0 CA-C-N 114.683 -1.144 . . . . 0.0 108.195 178.363 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 6.6 mp -122.04 156.04 34.35 Favored 'General case' 0 N--CA 1.497 1.925 0 CA-C-O 121.727 0.775 . . . . 0.0 111.012 -178.27 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 61.8 t -112.03 127.63 69.1 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.075 0 N-CA-C 108.028 -1.101 . . . . 0.0 108.028 177.605 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 28.2 m-85 -127.56 122.48 33.36 Favored 'General case' 0 N--CA 1.495 1.781 0 CA-C-N 119.678 1.126 . . . . 0.0 110.307 179.565 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 67.4 m-85 53.71 74.21 0.33 Allowed 'General case' 0 CA--C 1.538 0.504 0 CA-C-O 121.491 0.662 . . . . 0.0 111.846 178.792 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -80.55 -78.03 0.18 Allowed 'General case' 0 C--N 1.35 0.628 0 CA-C-N 115.065 -0.97 . . . . 0.0 110.116 -179.573 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 40.4 tt0 -113.15 99.57 7.93 Favored 'General case' 0 N--CA 1.47 0.543 0 N-CA-C 108.236 -1.024 . . . . 0.0 108.236 179.812 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -158.6 138.79 12.31 Favored 'General case' 0 C--O 1.205 -1.272 0 CA-C-O 119.524 -0.275 . . . . 0.0 111.236 179.1 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . 0.401 HG12 ' N ' ' B' ' 25' ' ' GLY . 57.1 t -59.41 163.8 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.857 0 N-CA-C 108.012 -1.107 . . . . 0.0 108.012 177.191 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . 0.471 ' H ' ' HB ' ' E' ' 24' ' ' VAL . . . -117.18 47.64 1.02 Allowed Glycine 0 N--CA 1.475 1.244 0 N-CA-C 111.773 -0.531 . . . . 0.0 111.773 -179.465 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -60.67 -167.62 0.01 OUTLIER 'General case' 0 N--CA 1.469 0.52 0 O-C-N 123.708 0.299 . . . . 0.0 110.202 179.457 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 25.4 t-20 -71.1 81.12 0.69 Allowed 'General case' 0 N--CA 1.465 0.29 0 CA-C-N 116.481 -0.327 . . . . 0.0 110.186 179.548 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 97.8 mttt -78.07 142.55 38.08 Favored 'General case' 0 N--CA 1.474 0.762 0 N-CA-C 109.015 -0.735 . . . . 0.0 109.015 179.418 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.22 -167.76 0.92 Allowed Glycine 0 C--N 1.336 0.557 0 N-CA-C 109.917 -1.273 . . . . 0.0 109.917 178.659 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.54 115.53 29.56 Favored 'General case' 0 N--CA 1.478 0.959 0 N-CA-C 109.599 -0.519 . . . . 0.0 109.599 179.77 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 70.9 mt -98.96 134.68 36.96 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.505 0 N-CA-C 107.107 -1.442 . . . . 0.0 107.107 178.6 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . 0.405 HG22 ' H ' ' E' ' 32' ' ' ILE . 29.7 pt -150.77 -171.85 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.724 0 CA-C-O 121.141 0.496 . . . . 0.0 111.17 -179.022 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.76 4.58 10.68 Favored Glycine 0 C--N 1.337 0.595 0 N-CA-C 110.915 -0.874 . . . . 0.0 110.915 179.935 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 34' ' ' LEU . . . . . 0.42 HD23 ' N ' ' B' ' 35' ' ' MET . 1.1 tt -75.07 135.07 41.23 Favored 'General case' 0 CA--C 1.545 0.767 0 N-CA-C 109.497 -0.557 . . . . 0.0 109.497 -179.689 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 35' ' ' MET . . . . . 0.42 ' N ' HD23 ' B' ' 34' ' ' LEU . 27.0 ttt -158.54 146.42 18.18 Favored 'General case' 0 N--CA 1.471 0.582 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 178.64 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 1.9 m -149.08 165.54 3.83 Favored 'Isoleucine or valine' 0 C--N 1.347 0.48 0 N-CA-C 108.094 -1.076 . . . . 0.0 108.094 -179.642 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . 0.715 ' H ' HE22 ' B' ' 15' ' ' GLN . . . 55.19 68.21 1.81 Allowed Glycine 0 C--N 1.306 -1.097 0 CA-C-N 115.469 -0.787 . . . . 0.0 112.367 177.54 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.24 176.75 21.21 Favored Glycine 0 N--CA 1.473 1.105 0 N-CA-C 111.113 -0.795 . . . . 0.0 111.113 178.674 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 39' ' ' VAL . . . . . 0.438 ' H ' HG12 ' E' ' 39' ' ' VAL . 34.4 m -109.35 155.81 10.31 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.655 0 C-N-CA 123.376 0.67 . . . . 0.0 110.299 -179.546 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 25.1 t . . . . . 0 C--O 1.22 -0.497 0 O-C-N 123.99 0.806 . . . . 0.0 110.407 179.317 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' C' C ' 1' ' ' ASP . . . . . 0.417 ' H2 ' ' CB ' ' F' ' 1' ' ' ASP . 15.5 m-20 . . . . . 0 N--CA 1.489 1.492 0 N-CA-C 108.941 -0.763 . . . . 0.0 108.941 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.72 133.47 51.13 Favored 'General case' 0 CA--C 1.538 0.509 0 CA-C-N 116.479 -0.328 . . . . 0.0 110.217 -179.756 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 3' ' ' GLU . . . . . 0.401 ' CD ' HH21 ' C' ' 5' ' ' ARG . 49.3 tt0 -169.38 105.92 0.38 Allowed 'General case' 0 N--CA 1.473 0.693 0 N-CA-C 110.038 -0.356 . . . . 0.0 110.038 -179.044 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 64.8 m-85 -83.85 145.42 28.65 Favored 'General case' 0 N--CA 1.474 0.767 0 N-CA-C 110.25 -0.278 . . . . 0.0 110.25 179.397 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 5' ' ' ARG . . . . . 0.401 HH21 ' CD ' ' C' ' 3' ' ' GLU . 99.5 mtt180 -144.22 142.4 30.48 Favored 'General case' 0 N--CA 1.484 1.244 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 179.769 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 45.2 t-80 -152.47 119.05 5.66 Favored 'General case' 0 N--CA 1.471 0.586 0 N-CA-C 109.397 -0.594 . . . . 0.0 109.397 179.013 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 7' ' ' ASP . . . . . 0.495 ' O ' ' OG ' ' F' ' 8' ' ' SER . 4.1 m-20 -70.1 149.03 48.04 Favored 'General case' 0 CA--C 1.538 0.493 0 CA-C-N 116.376 -0.375 . . . . 0.0 110.647 -179.983 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 8' ' ' SER . . . . . . . . . . . . . 54.0 p -167.28 -172.97 2.13 Favored 'General case' 0 N--CA 1.484 1.235 0 CA-C-O 121.061 0.457 . . . . 0.0 110.744 179.566 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.48 46.9 1.47 Allowed Glycine 0 N--CA 1.482 1.715 0 CA-C-N 115.945 -0.57 . . . . 0.0 112.035 179.688 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 47.7 p90 -65.78 132.35 48.51 Favored 'General case' 0 N--CA 1.471 0.591 0 O-C-N 122.745 -0.268 . . . . 0.0 111.686 179.826 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 47.7 mt-10 -91.41 151.82 20.66 Favored 'General case' 0 N--CA 1.475 0.782 0 N-CA-C 109.713 -0.477 . . . . 0.0 109.713 178.432 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -152.77 128.17 1.61 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.515 0 N-CA-C 107.833 -1.173 . . . . 0.0 107.833 177.999 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 41.7 m-70 -135.27 146.5 48.61 Favored 'General case' 0 N--CA 1.492 1.65 0 CA-C-N 118.916 0.78 . . . . 0.0 111.272 -179.056 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 6.0 t60 -165.88 96.84 0.63 Allowed 'General case' 0 N--CA 1.481 1.111 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.719 179.459 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 15' ' ' GLN . . . . . 0.69 HE22 ' H ' ' C' ' 37' ' ' GLY . 5.9 pt20 -108.39 -173.98 2.41 Favored 'General case' 0 CA--C 1.505 -0.77 0 N-CA-C 108.396 -0.965 . . . . 0.0 108.396 -179.898 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -164.63 98.85 0.79 Allowed 'General case' 0 N--CA 1.473 0.678 0 CA-C-N 114.617 -1.174 . . . . 0.0 108.223 178.502 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 6.6 mp -121.9 155.77 34.74 Favored 'General case' 0 N--CA 1.497 1.901 0 CA-C-O 121.84 0.828 . . . . 0.0 110.927 -178.35 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 61.2 t -111.68 127.55 68.77 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.117 0 N-CA-C 107.932 -1.136 . . . . 0.0 107.932 177.511 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 28.1 m-85 -127.51 123.06 35.0 Favored 'General case' 0 N--CA 1.495 1.782 0 CA-C-N 119.606 1.094 . . . . 0.0 110.272 179.395 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 67.0 m-85 53.08 74.12 0.32 Allowed 'General case' 0 N--CA 1.468 0.449 0 CA-C-O 121.558 0.694 . . . . 0.0 111.919 178.851 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -80.22 -78.29 0.17 Allowed 'General case' 0 C--N 1.35 0.62 0 CA-C-N 115.012 -0.994 . . . . 0.0 110.065 -179.595 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 40.4 tt0 -113.03 99.69 8.05 Favored 'General case' 0 N--CA 1.471 0.62 0 N-CA-C 108.153 -1.055 . . . . 0.0 108.153 179.899 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -158.45 139.15 12.8 Favored 'General case' 0 C--O 1.205 -1.246 0 O-C-N 122.309 -0.245 . . . . 0.0 111.203 179.131 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 60.7 t -59.94 163.3 0.96 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.878 0 N-CA-C 108.075 -1.083 . . . . 0.0 108.075 177.051 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 25' ' ' GLY . . . . . 0.479 ' H ' ' HB ' ' F' ' 24' ' ' VAL . . . -116.64 47.3 1.05 Allowed Glycine 0 N--CA 1.477 1.387 0 N-CA-C 111.722 -0.551 . . . . 0.0 111.722 -179.29 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -60.43 -167.38 0.01 OUTLIER 'General case' 0 N--CA 1.468 0.462 0 O-C-N 123.658 0.269 . . . . 0.0 110.284 179.539 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 25.5 t-20 -71.29 80.69 0.74 Allowed 'General case' 0 N--CA 1.466 0.333 0 CA-C-N 116.442 -0.344 . . . . 0.0 110.132 179.495 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 97.7 mttt -77.53 143.06 38.69 Favored 'General case' 0 N--CA 1.474 0.741 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 179.253 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.83 -167.68 1.15 Allowed Glycine 0 CA--C 1.524 0.617 0 N-CA-C 109.994 -1.242 . . . . 0.0 109.994 178.705 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.49 115.11 28.55 Favored 'General case' 0 N--CA 1.482 1.144 0 N-CA-C 109.677 -0.49 . . . . 0.0 109.677 179.879 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 71.1 mt -98.78 134.21 38.45 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.48 0 N-CA-C 107.296 -1.372 . . . . 0.0 107.296 178.591 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 29.7 pt -150.3 -171.49 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.724 0 CA-C-O 121.227 0.537 . . . . 0.0 111.173 -179.107 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.31 5.11 10.05 Favored Glycine 0 CA--C 1.524 0.62 0 N-CA-C 110.838 -0.905 . . . . 0.0 110.838 179.881 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 34' ' ' LEU . . . . . 0.427 HD23 ' N ' ' C' ' 35' ' ' MET . 1.1 tt -75.46 134.77 40.77 Favored 'General case' 0 CA--C 1.546 0.813 0 N-CA-C 109.38 -0.6 . . . . 0.0 109.38 -179.703 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 35' ' ' MET . . . . . 0.427 ' N ' HD23 ' C' ' 34' ' ' LEU . 27.1 ttt -158.19 146.57 18.79 Favored 'General case' 0 N--CA 1.47 0.531 0 N-CA-C 108.426 -0.953 . . . . 0.0 108.426 178.686 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 1.7 m -149.33 165.28 3.72 Favored 'Isoleucine or valine' 0 C--N 1.348 0.532 0 N-CA-C 108.142 -1.059 . . . . 0.0 108.142 -179.556 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 37' ' ' GLY . . . . . 0.69 ' H ' HE22 ' C' ' 15' ' ' GLN . . . 54.77 68.7 1.55 Allowed Glycine 0 C--N 1.306 -1.096 0 CA-C-N 115.413 -0.812 . . . . 0.0 112.317 177.782 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.26 176.42 20.94 Favored Glycine 0 N--CA 1.473 1.101 0 N-CA-C 111.078 -0.809 . . . . 0.0 111.078 178.698 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 39' ' ' VAL . . . . . 0.444 ' H ' HG12 ' F' ' 39' ' ' VAL . 34.4 m -109.38 155.73 10.38 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.624 0 C-N-CA 123.328 0.651 . . . . 0.0 110.443 -179.641 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 25.1 t . . . . . 0 C--O 1.219 -0.538 0 O-C-N 124.009 0.818 . . . . 0.0 110.491 179.386 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' D' D ' 1' ' ' ASP . . . . . 0.478 ' CG ' ' H1 ' ' A' ' 1' ' ' ASP . 15.8 m-20 . . . . . 0 N--CA 1.49 1.559 0 N-CA-C 109.221 -0.659 . . . . 0.0 109.221 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.44 131.34 46.88 Favored 'General case' 0 CA--C 1.536 0.439 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.429 179.796 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 3' ' ' GLU . . . . . 0.41 ' CD ' HH21 ' D' ' 5' ' ' ARG . 48.2 tt0 -169.26 108.91 0.44 Allowed 'General case' 0 N--CA 1.472 0.649 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 179.658 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 72.3 m-85 -87.93 151.59 22.7 Favored 'General case' 0 C--N 1.362 1.117 0 C-N-CA 119.361 -0.936 . . . . 0.0 108.948 179.643 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 5' ' ' ARG . . . . . 0.41 HH21 ' CD ' ' D' ' 3' ' ' GLU . 99.6 mtt180 -146.87 140.99 26.12 Favored 'General case' 0 N--CA 1.476 0.86 0 N-CA-C 110.059 -0.348 . . . . 0.0 110.059 179.764 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 41.6 t-80 -149.75 123.52 9.26 Favored 'General case' 0 CA--C 1.545 0.774 0 N-CA-C 108.499 -0.926 . . . . 0.0 108.499 174.468 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 7' ' ' ASP . . . . . 0.591 ' O ' ' OG ' ' G' ' 8' ' ' SER . 2.8 m-20 -63.81 133.32 53.2 Favored 'General case' 0 C--N 1.32 -0.688 0 C-N-CA 126.61 1.964 . . . . 0.0 114.339 174.029 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' D' D ' 8' ' ' SER . . . . . 0.51 ' OG ' ' O ' ' A' ' 7' ' ' ASP . 52.3 p -154.04 -170.53 3.59 Favored 'General case' 0 N--CA 1.488 1.438 0 CA-C-N 119.649 1.113 . . . . 0.0 111.131 175.534 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.43 48.05 1.16 Allowed Glycine 0 N--CA 1.484 1.88 0 N-CA-C 109.941 -1.264 . . . . 0.0 109.941 173.365 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 50.9 p90 -60.66 131.01 49.35 Favored 'General case' 0 N--CA 1.468 0.434 0 N-CA-C 113.155 0.798 . . . . 0.0 113.155 177.697 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 47.8 mt-10 -88.84 150.65 22.8 Favored 'General case' 0 N--CA 1.481 1.084 0 CA-C-N 118.175 0.443 . . . . 0.0 110.946 174.98 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.0 p -149.49 130.03 4.41 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.594 0 N-CA-C 107.423 -1.325 . . . . 0.0 107.423 173.128 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 40.9 m-70 -130.03 149.25 51.83 Favored 'General case' 0 N--CA 1.484 1.232 0 CA-C-N 118.03 0.377 . . . . 0.0 111.907 176.41 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 6.1 t60 -164.99 104.38 0.78 Allowed 'General case' 0 N--CA 1.48 1.035 0 N-CA-C 109.175 -0.676 . . . . 0.0 109.175 172.13 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 15' ' ' GLN . . . . . 0.65 HE22 ' H ' ' D' ' 37' ' ' GLY . 5.9 pt20 -111.97 -176.05 2.84 Favored 'General case' 0 CA--C 1.499 -1.002 0 N-CA-C 108.228 -1.027 . . . . 0.0 108.228 178.911 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -161.04 105.96 1.36 Allowed 'General case' 0 N--CA 1.468 0.433 0 N-CA-C 106.634 -1.617 . . . . 0.0 106.634 175.151 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 5.5 mp -128.38 153.22 47.3 Favored 'General case' 0 N--CA 1.498 1.945 0 CA-C-O 122.06 0.934 . . . . 0.0 110.582 179.662 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 35.8 t -100.97 131.82 47.88 Favored 'Isoleucine or valine' 0 C--O 1.262 1.761 0 CA-C-O 116.723 -1.608 . . . . 0.0 109.546 174.2 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 25.7 m-85 -130.49 126.35 36.66 Favored 'General case' 0 N--CA 1.491 1.583 0 CA-C-N 120.149 1.34 . . . . 0.0 109.528 173.366 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 68.2 m-85 55.85 71.53 0.55 Allowed 'General case' 0 C--O 1.241 0.651 0 CA-C-N 115.493 -0.776 . . . . 0.0 111.258 176.357 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -82.43 -73.18 0.41 Allowed 'General case' 0 N--CA 1.475 0.794 0 CA-C-O 118.52 -0.752 . . . . 0.0 111.106 -177.507 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 40.8 tt0 -116.52 103.81 10.79 Favored 'General case' 0 N--CA 1.482 1.174 0 N-CA-C 106.195 -1.78 . . . . 0.0 106.195 176.217 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -151.9 138.79 18.98 Favored 'General case' 0 N--CA 1.474 0.752 0 CA-C-O 116.686 -1.626 . . . . 0.0 113.738 177.697 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 24' ' ' VAL . . . . . 0.461 ' HB ' ' H ' ' A' ' 25' ' ' GLY . 64.1 t -62.27 166.23 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.206 0 CA-C-N 121.101 1.773 . . . . 0.0 107.834 175.184 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' D' D ' 25' ' ' GLY . . . . . 0.539 ' H ' ' HB ' ' G' ' 24' ' ' VAL . . . -116.79 51.14 0.74 Allowed Glycine 0 N--CA 1.478 1.46 0 CA-C-O 119.095 -0.836 . . . . 0.0 111.833 178.451 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -57.28 -170.42 0.01 OUTLIER 'General case' 0 C--N 1.322 -0.595 0 C-N-CA 123.706 0.802 . . . . 0.0 111.559 175.937 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 26.3 t-20 -72.89 86.69 1.29 Allowed 'General case' 0 C--N 1.347 0.466 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 177.976 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 97.2 mttt -82.87 145.56 29.38 Favored 'General case' 0 N--CA 1.476 0.84 0 N-CA-C 108.014 -1.106 . . . . 0.0 108.014 179.134 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.17 -165.34 0.61 Allowed Glycine 0 C--N 1.336 0.57 0 N-CA-C 110.45 -1.06 . . . . 0.0 110.45 179.171 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -102.35 116.11 31.95 Favored 'General case' 0 N--CA 1.476 0.851 0 N-CA-C 109.099 -0.704 . . . . 0.0 109.099 179.846 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 80.4 mt -102.52 142.24 17.07 Favored 'Isoleucine or valine' 0 C--N 1.358 0.941 0 N-CA-C 104.84 -2.281 . . . . 0.0 104.84 179.793 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 32' ' ' ILE . . . . . 0.45 HG22 ' H ' ' G' ' 32' ' ' ILE . 31.1 pt -157.43 -172.51 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.482 1.157 0 CA-C-O 120.84 0.353 . . . . 0.0 110.155 -177.332 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 64.27 4.55 12.59 Favored Glycine 0 N--CA 1.465 0.601 0 N-CA-C 110.387 -1.085 . . . . 0.0 110.387 -178.926 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 1.3 tt -76.52 140.47 41.17 Favored 'General case' 0 C--N 1.355 0.824 0 N-CA-C 107.787 -1.19 . . . . 0.0 107.787 -178.329 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 26.4 ttt -156.41 155.91 32.94 Favored 'General case' 0 C--O 1.247 0.955 0 N-CA-C 107.894 -1.15 . . . . 0.0 107.894 174.482 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 1.9 m -157.91 163.86 1.18 Allowed 'Isoleucine or valine' 0 CA--C 1.516 -0.334 0 N-CA-C 107.618 -1.252 . . . . 0.0 107.618 177.826 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 37' ' ' GLY . . . . . 0.65 ' H ' HE22 ' D' ' 15' ' ' GLN . . . 61.36 63.84 4.53 Favored Glycine 0 C--N 1.312 -0.76 0 C-N-CA 119.758 -1.211 . . . . 0.0 112.179 177.452 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 145.76 177.75 20.72 Favored Glycine 0 N--CA 1.476 1.365 0 CA-C-N 118.309 1.054 . . . . 0.0 111.776 179.756 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 39' ' ' VAL . . . . . 0.439 HG12 ' H ' ' A' ' 39' ' ' VAL . 35.2 m -112.5 152.76 14.24 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.895 0 N-CA-C 109.681 -0.489 . . . . 0.0 109.681 -176.824 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 25.2 t . . . . . 0 C--N 1.334 -0.066 0 CA-C-O 116.119 -1.896 . . . . 0.0 109.533 178.0 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' E' E ' 1' ' ' ASP . . . . . 0.43 ' H1 ' ' CG ' ' H' ' 1' ' ' ASP . 15.4 m-20 . . . . . 0 N--CA 1.49 1.543 0 N-CA-C 109.436 -0.579 . . . . 0.0 109.436 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' E' E ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.07 131.24 46.95 Favored 'General case' 0 N--CA 1.469 0.517 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.414 179.926 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' E' E ' 3' ' ' GLU . . . . . 0.409 ' CD ' HH21 ' E' ' 5' ' ' ARG . 48.1 tt0 -168.52 105.71 0.45 Allowed 'General case' 0 N--CA 1.472 0.674 0 N-CA-C 110.544 -0.169 . . . . 0.0 110.544 -179.693 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 65.8 m-85 -84.39 145.06 28.4 Favored 'General case' 0 N--CA 1.474 0.756 0 O-C-N 122.247 -0.283 . . . . 0.0 110.257 179.177 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' E' E ' 5' ' ' ARG . . . . . 0.409 HH21 ' CD ' ' E' ' 3' ' ' GLU . 99.5 mtt180 -143.72 142.79 31.12 Favored 'General case' 0 N--CA 1.481 1.078 0 N-CA-C 110.113 -0.329 . . . . 0.0 110.113 179.458 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 45.1 t-80 -152.46 118.67 5.54 Favored 'General case' 0 N--CA 1.469 0.516 0 N-CA-C 109.294 -0.632 . . . . 0.0 109.294 178.86 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' E' E ' 7' ' ' ASP . . . . . 0.445 ' O ' ' OG ' ' H' ' 8' ' ' SER . 3.6 m-20 -70.14 149.14 47.87 Favored 'General case' 0 CA--C 1.535 0.391 0 CA-C-N 116.488 -0.324 . . . . 0.0 110.754 179.938 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' E' E ' 8' ' ' SER . . . . . 0.457 ' OG ' ' O ' ' B' ' 7' ' ' ASP . 43.7 p -168.26 -172.1 1.66 Allowed 'General case' 0 N--CA 1.486 1.33 0 CA-C-O 121.192 0.52 . . . . 0.0 110.854 179.18 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.24 47.7 1.3 Allowed Glycine 0 N--CA 1.478 1.485 0 CA-C-N 115.876 -0.602 . . . . 0.0 111.797 179.54 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 46.3 p90 -65.56 132.62 49.32 Favored 'General case' 0 N--CA 1.471 0.621 0 N-CA-C 112.064 0.394 . . . . 0.0 112.064 -179.891 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 49.0 mt-10 -90.98 152.29 20.74 Favored 'General case' 0 N--CA 1.481 1.123 0 CA-C-O 121.313 0.578 . . . . 0.0 109.575 177.954 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -154.65 127.07 1.04 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.588 0 N-CA-C 107.874 -1.158 . . . . 0.0 107.874 177.96 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 42.9 m-70 -135.42 144.4 46.49 Favored 'General case' 0 N--CA 1.482 1.149 0 CA-C-O 120.903 0.382 . . . . 0.0 111.478 -177.859 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 6.0 t60 -164.4 97.19 0.79 Allowed 'General case' 0 N--CA 1.484 1.237 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.694 179.419 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' E' E ' 15' ' ' GLN . . . . . 0.715 HE22 ' H ' ' E' ' 37' ' ' GLY . 6.0 pt20 -108.21 -174.33 2.49 Favored 'General case' 0 CA--C 1.507 -0.686 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 -179.924 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -164.18 97.73 0.82 Allowed 'General case' 0 N--CA 1.476 0.839 0 CA-C-N 114.698 -1.137 . . . . 0.0 108.436 178.563 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 6.5 mp -120.52 155.66 33.17 Favored 'General case' 0 N--CA 1.494 1.775 0 CA-C-O 121.533 0.682 . . . . 0.0 111.588 -177.867 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 48.8 t -113.44 124.66 70.3 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.254 0 N-CA-C 108.176 -1.046 . . . . 0.0 108.176 177.131 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 30.8 m-85 -124.94 121.8 35.51 Favored 'General case' 0 N--CA 1.489 1.495 0 CA-C-O 120.836 0.351 . . . . 0.0 110.934 -179.891 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 68.8 m-85 54.79 73.29 0.42 Allowed 'General case' 0 N--CA 1.468 0.429 0 CA-C-N 115.92 -0.582 . . . . 0.0 111.478 178.34 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -78.83 -79.03 0.14 Allowed 'General case' 0 CA--C 1.537 0.459 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.03 -179.378 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 40.5 tt0 -112.1 100.02 8.52 Favored 'General case' 0 C--N 1.323 -0.548 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 -179.987 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -157.89 138.84 13.22 Favored 'General case' 0 C--O 1.201 -1.458 0 N-CA-C 111.621 0.23 . . . . 0.0 111.621 179.029 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' E' E ' 24' ' ' VAL . . . . . 0.471 ' HB ' ' H ' ' B' ' 25' ' ' GLY . 59.0 t -58.15 168.28 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.927 0 N-CA-C 107.403 -1.332 . . . . 0.0 107.403 177.056 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' E' E ' 25' ' ' GLY . . . . . 0.438 ' H ' ' HB ' ' H' ' 24' ' ' VAL . . . -122.0 48.63 0.94 Allowed Glycine 0 N--CA 1.473 1.157 0 N-CA-C 110.963 -0.855 . . . . 0.0 110.963 -179.38 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -62.12 -166.9 0.01 OUTLIER 'General case' 0 N--CA 1.47 0.541 0 CA-C-O 120.737 0.303 . . . . 0.0 110.482 179.892 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 26.0 t-20 -70.68 76.88 0.6 Allowed 'General case' 0 C--O 1.222 -0.362 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.481 -179.956 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 97.9 mttt -74.36 143.67 44.75 Favored 'General case' 0 N--CA 1.476 0.873 0 N-CA-C 109.554 -0.536 . . . . 0.0 109.554 179.403 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.68 -167.38 1.43 Allowed Glycine 0 C--N 1.333 0.414 0 N-CA-C 110.408 -1.077 . . . . 0.0 110.408 178.534 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.54 113.99 26.72 Favored 'General case' 0 N--CA 1.476 0.834 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 179.953 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 72.0 mt -97.8 134.48 35.86 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.265 0 N-CA-C 106.986 -1.487 . . . . 0.0 106.986 178.768 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' E' E ' 32' ' ' ILE . . . . . 0.45 HG22 ' H ' ' H' ' 32' ' ' ILE . 31.4 pt -150.34 -169.7 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.174 0 CA-C-O 121.182 0.515 . . . . 0.0 110.753 -179.451 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.65 5.18 6.41 Favored Glycine 0 CA--C 1.527 0.834 0 CA-C-N 115.684 -0.689 . . . . 0.0 111.423 -179.796 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' E' E ' 34' ' ' LEU . . . . . 0.409 HD23 ' N ' ' E' ' 35' ' ' MET . 1.1 tt -74.75 135.26 41.77 Favored 'General case' 0 CA--C 1.549 0.941 0 N-CA-C 109.293 -0.632 . . . . 0.0 109.293 -179.616 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' E' E ' 35' ' ' MET . . . . . 0.409 ' N ' HD23 ' E' ' 34' ' ' LEU . 26.3 ttt -158.37 145.78 17.98 Favored 'General case' 0 N--CA 1.473 0.724 0 N-CA-C 108.611 -0.885 . . . . 0.0 108.611 178.466 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 1.5 m -148.65 165.08 4.56 Favored 'Isoleucine or valine' 0 C--N 1.347 0.48 0 N-CA-C 108.5 -0.926 . . . . 0.0 108.5 -179.447 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' E' E ' 37' ' ' GLY . . . . . 0.715 ' H ' HE22 ' E' ' 15' ' ' GLN . . . 54.28 68.56 1.6 Allowed Glycine 0 C--N 1.308 -1.024 0 CA-C-N 115.324 -0.853 . . . . 0.0 112.231 177.888 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 146.65 173.76 18.16 Favored Glycine 0 N--CA 1.473 1.11 0 N-CA-C 111.41 -0.676 . . . . 0.0 111.41 178.734 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' E' E ' 39' ' ' VAL . . . . . 0.438 HG12 ' H ' ' B' ' 39' ' ' VAL . 32.7 m -107.0 155.69 7.59 Favored 'Isoleucine or valine' 0 C--N 1.352 0.702 0 C-N-CA 123.629 0.772 . . . . 0.0 110.645 -178.711 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 25.4 t . . . . . 0 C--O 1.218 -0.599 0 O-C-N 124.18 0.925 . . . . 0.0 110.25 179.615 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' F' F ' 1' ' ' ASP . . . . . 0.417 ' CB ' ' H2 ' ' C' ' 1' ' ' ASP . 16.0 m-20 . . . . . 0 N--CA 1.49 1.56 0 N-CA-C 109.286 -0.635 . . . . 0.0 109.286 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' F' F ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.19 131.54 47.72 Favored 'General case' 0 N--CA 1.467 0.41 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.46 179.886 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' F' F ' 3' ' ' GLU . . . . . 0.406 ' CD ' HH21 ' F' ' 5' ' ' ARG . 48.6 tt0 -168.6 105.82 0.45 Allowed 'General case' 0 C--O 1.215 -0.748 0 N-CA-C 110.397 -0.223 . . . . 0.0 110.397 -179.743 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 65.1 m-85 -84.61 144.81 28.38 Favored 'General case' 0 N--CA 1.474 0.77 0 O-C-N 122.233 -0.292 . . . . 0.0 110.235 179.266 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' F' F ' 5' ' ' ARG . . . . . 0.406 HH21 ' CD ' ' F' ' 3' ' ' GLU . 99.6 mtt180 -143.56 142.66 31.19 Favored 'General case' 0 N--CA 1.478 0.97 0 CA-C-O 120.838 0.351 . . . . 0.0 110.091 179.657 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 45.0 t-80 -152.45 119.26 5.75 Favored 'General case' 0 N--CA 1.471 0.614 0 N-CA-C 109.429 -0.582 . . . . 0.0 109.429 178.783 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' F' F ' 7' ' ' ASP . . . . . 0.486 ' O ' ' OG ' ' I' ' 8' ' ' SER . 3.7 m-20 -70.76 149.33 47.01 Favored 'General case' 0 CA--C 1.535 0.382 0 CA-C-N 116.418 -0.356 . . . . 0.0 110.844 -179.929 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' F' F ' 8' ' ' SER . . . . . 0.495 ' OG ' ' O ' ' C' ' 7' ' ' ASP . 43.2 p -168.56 -171.63 1.48 Allowed 'General case' 0 N--CA 1.484 1.262 0 CA-C-O 121.236 0.541 . . . . 0.0 110.935 179.169 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.95 46.82 1.42 Allowed Glycine 0 N--CA 1.478 1.492 0 CA-C-N 115.855 -0.611 . . . . 0.0 111.761 179.551 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 46.6 p90 -64.64 132.42 49.69 Favored 'General case' 0 CA--C 1.542 0.642 0 N-CA-C 112.01 0.374 . . . . 0.0 112.01 -179.886 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 48.6 mt-10 -91.04 152.29 20.71 Favored 'General case' 0 N--CA 1.482 1.13 0 CA-C-O 121.266 0.555 . . . . 0.0 109.685 177.89 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -154.49 126.98 1.05 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.67 0 N-CA-C 107.855 -1.165 . . . . 0.0 107.855 178.058 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 42.5 m-70 -135.24 144.81 47.09 Favored 'General case' 0 N--CA 1.483 1.179 0 CA-C-O 120.847 0.356 . . . . 0.0 111.522 -177.919 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 6.0 t60 -164.88 96.91 0.74 Allowed 'General case' 0 N--CA 1.484 1.27 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.805 179.539 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' F' F ' 15' ' ' GLN . . . . . 0.695 HE22 ' H ' ' F' ' 37' ' ' GLY . 6.0 pt20 -108.02 -174.17 2.46 Favored 'General case' 0 CA--C 1.505 -0.751 0 N-CA-C 108.574 -0.899 . . . . 0.0 108.574 -179.875 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -164.17 97.79 0.82 Allowed 'General case' 0 N--CA 1.473 0.719 0 CA-C-N 114.578 -1.192 . . . . 0.0 108.397 178.561 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 6.4 mp -120.55 155.73 33.05 Favored 'General case' 0 N--CA 1.494 1.773 0 CA-C-O 121.667 0.746 . . . . 0.0 111.456 -177.727 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 48.4 t -113.64 124.38 70.23 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.25 0 N-CA-C 108.199 -1.037 . . . . 0.0 108.199 177.17 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 30.5 m-85 -124.7 121.19 33.97 Favored 'General case' 0 N--CA 1.488 1.439 0 CA-C-O 120.77 0.319 . . . . 0.0 111.015 -179.783 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 67.9 m-85 55.27 73.23 0.43 Allowed 'General case' 0 C--N 1.344 0.342 0 CA-C-N 115.953 -0.567 . . . . 0.0 111.733 178.322 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -78.92 -78.58 0.15 Allowed 'General case' 0 N--CA 1.467 0.419 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.147 -179.27 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 40.3 tt0 -112.66 99.99 8.36 Favored 'General case' 0 C--N 1.324 -0.524 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 -179.825 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -157.88 138.8 13.2 Favored 'General case' 0 C--O 1.203 -1.361 0 N-CA-C 111.681 0.252 . . . . 0.0 111.681 179.052 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' F' F ' 24' ' ' VAL . . . . . 0.479 ' HB ' ' H ' ' C' ' 25' ' ' GLY . 60.0 t -58.13 168.24 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.935 0 N-CA-C 107.398 -1.334 . . . . 0.0 107.398 177.116 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' F' F ' 25' ' ' GLY . . . . . 0.434 ' H ' ' HB ' ' I' ' 24' ' ' VAL . . . -121.92 48.53 0.94 Allowed Glycine 0 N--CA 1.476 1.35 0 N-CA-C 110.877 -0.889 . . . . 0.0 110.877 -179.394 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -62.11 -167.4 0.01 OUTLIER 'General case' 0 N--CA 1.47 0.565 0 CA-C-O 120.782 0.325 . . . . 0.0 110.285 179.895 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 25.8 t-20 -70.1 77.0 0.51 Allowed 'General case' 0 N--CA 1.466 0.338 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.589 179.979 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 97.8 mttt -74.57 143.81 44.28 Favored 'General case' 0 N--CA 1.478 0.957 0 N-CA-C 109.483 -0.562 . . . . 0.0 109.483 179.524 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.39 -167.11 1.25 Allowed Glycine 0 C--N 1.334 0.425 0 N-CA-C 110.486 -1.046 . . . . 0.0 110.486 178.539 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.69 113.65 26.25 Favored 'General case' 0 N--CA 1.477 0.917 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 179.752 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 72.0 mt -97.71 134.59 35.28 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.285 0 N-CA-C 106.981 -1.489 . . . . 0.0 106.981 178.717 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' F' F ' 32' ' ' ILE . . . . . 0.446 HG22 ' H ' ' I' ' 32' ' ' ILE . 32.1 pt -150.74 -169.6 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.198 0 CA-C-O 121.126 0.489 . . . . 0.0 110.7 -179.476 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.64 5.12 6.29 Favored Glycine 0 CA--C 1.527 0.82 0 CA-C-N 115.688 -0.687 . . . . 0.0 111.407 -179.78 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' F' F ' 34' ' ' LEU . . . . . 0.419 HD23 ' N ' ' F' ' 35' ' ' MET . 1.1 tt -74.66 135.83 41.93 Favored 'General case' 0 CA--C 1.549 0.922 0 N-CA-C 109.18 -0.674 . . . . 0.0 109.18 -179.669 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' F' F ' 35' ' ' MET . . . . . 0.419 ' N ' HD23 ' F' ' 34' ' ' LEU . 26.0 ttt -158.72 145.92 17.58 Favored 'General case' 0 N--CA 1.47 0.561 0 N-CA-C 108.66 -0.867 . . . . 0.0 108.66 178.446 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 1.5 m -148.78 165.14 4.35 Favored 'Isoleucine or valine' 0 C--N 1.349 0.547 0 N-CA-C 108.425 -0.954 . . . . 0.0 108.425 -179.495 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' F' F ' 37' ' ' GLY . . . . . 0.695 ' H ' HE22 ' F' ' 15' ' ' GLN . . . 54.33 68.37 1.7 Allowed Glycine 0 C--N 1.306 -1.108 0 CA-C-N 115.328 -0.851 . . . . 0.0 112.331 177.808 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 146.97 174.09 18.74 Favored Glycine 0 N--CA 1.472 1.097 0 N-CA-C 111.415 -0.674 . . . . 0.0 111.415 178.645 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' F' F ' 39' ' ' VAL . . . . . 0.444 HG12 ' H ' ' C' ' 39' ' ' VAL . 33.1 m -107.22 155.54 7.88 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.714 0 C-N-CA 123.471 0.708 . . . . 0.0 110.588 -178.803 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 26.8 t . . . . . 0 C--O 1.219 -0.55 0 O-C-N 124.286 0.991 . . . . 0.0 110.3 179.601 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' G' G ' 1' ' ' ASP . . . . . 0.446 ' CB ' ' H2 ' ' D' ' 1' ' ' ASP . 15.0 m-20 . . . . . 0 N--CA 1.492 1.635 0 N-CA-C 109.303 -0.629 . . . . 0.0 109.303 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' G' G ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.74 129.82 42.22 Favored 'General case' 0 N--CA 1.47 0.536 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.563 179.525 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' G' G ' 3' ' ' GLU . . . . . 0.414 ' CD ' HH21 ' G' ' 5' ' ' ARG . 46.9 tt0 -168.65 107.12 0.46 Allowed 'General case' 0 N--CA 1.475 0.821 0 N-CA-C 110.565 -0.161 . . . . 0.0 110.565 179.706 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 67.1 m-85 -86.52 144.61 27.15 Favored 'General case' 0 N--CA 1.473 0.692 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 179.169 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' G' G ' 5' ' ' ARG . . . . . 0.414 HH21 ' CD ' ' G' ' 3' ' ' GLU . 99.5 mtt180 -143.91 142.77 30.95 Favored 'General case' 0 N--CA 1.483 1.189 0 CA-C-O 120.828 0.347 . . . . 0.0 110.162 179.983 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 45.8 t-80 -152.31 119.5 5.9 Favored 'General case' 0 N--CA 1.473 0.682 0 N-CA-C 109.574 -0.528 . . . . 0.0 109.574 178.794 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 4.0 m-20 -71.82 144.49 49.11 Favored 'General case' 0 CA--C 1.538 0.519 0 C-N-CA 122.716 0.406 . . . . 0.0 111.176 -179.938 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' G' G ' 8' ' ' SER . . . . . 0.591 ' OG ' ' O ' ' D' ' 7' ' ' ASP . 35.5 p -164.77 -169.62 1.76 Allowed 'General case' 0 N--CA 1.476 0.86 0 CA-C-O 121.178 0.513 . . . . 0.0 110.512 178.672 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.21 47.73 1.41 Allowed Glycine 0 N--CA 1.48 1.63 0 N-CA-C 111.344 -0.703 . . . . 0.0 111.344 179.291 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 48.0 p90 -65.69 133.16 50.51 Favored 'General case' 0 CA--C 1.542 0.636 0 N-CA-C 111.872 0.323 . . . . 0.0 111.872 -179.627 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 47.9 mt-10 -91.76 151.48 20.6 Favored 'General case' 0 N--CA 1.479 1.022 0 CA-C-O 121.162 0.506 . . . . 0.0 110.0 178.576 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -154.99 127.28 1.01 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.004 0 N-CA-C 107.851 -1.166 . . . . 0.0 107.851 178.196 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 44.2 m-70 -134.67 146.06 49.14 Favored 'General case' 0 N--CA 1.48 1.05 0 CA-C-N 115.667 -0.697 . . . . 0.0 111.45 -178.363 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 6.0 t60 -166.24 97.05 0.6 Allowed 'General case' 0 N--CA 1.481 1.115 0 CA-C-N 116.101 -0.499 . . . . 0.0 110.385 178.946 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' G' G ' 15' ' ' GLN . . . . . 0.704 HE22 ' H ' ' G' ' 37' ' ' GLY . 6.0 pt20 -108.42 -174.51 2.54 Favored 'General case' 0 CA--C 1.508 -0.641 0 N-CA-C 108.31 -0.996 . . . . 0.0 108.31 -179.702 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -164.27 97.72 0.81 Allowed 'General case' 0 N--CA 1.475 0.802 0 CA-C-N 114.606 -1.179 . . . . 0.0 108.12 178.667 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 6.4 mp -120.4 154.8 34.64 Favored 'General case' 0 N--CA 1.498 1.934 0 CA-C-O 121.247 0.546 . . . . 0.0 111.774 -177.883 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 43.1 t -113.33 124.66 70.19 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.942 0 CA-C-N 114.777 -1.101 . . . . 0.0 108.186 176.55 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 32.1 m-85 -125.29 121.19 33.3 Favored 'General case' 0 C--N 1.367 1.349 0 C-N-CA 123.437 0.695 . . . . 0.0 110.979 -179.602 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 68.0 m-85 55.37 72.57 0.47 Allowed 'General case' 0 N--CA 1.467 0.393 0 CA-C-N 115.898 -0.592 . . . . 0.0 111.496 178.274 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.78 -77.99 0.14 Allowed 'General case' 0 N--CA 1.473 0.697 0 O-C-N 122.237 -0.289 . . . . 0.0 110.407 -178.932 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 41.1 tt0 -113.02 100.2 8.44 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 107.812 -1.181 . . . . 0.0 107.812 179.909 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -157.73 139.75 14.21 Favored 'General case' 0 N--CA 1.476 0.865 0 N-CA-C 111.649 0.24 . . . . 0.0 111.649 178.959 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' G' G ' 24' ' ' VAL . . . . . 0.539 ' HB ' ' H ' ' D' ' 25' ' ' GLY . 62.0 t -59.62 166.97 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.656 0 N-CA-C 107.564 -1.273 . . . . 0.0 107.564 177.353 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' G' G ' 25' ' ' GLY . . . . . 0.421 ' N ' HG12 ' G' ' 24' ' ' VAL . . . -120.13 49.32 0.88 Allowed Glycine 0 N--CA 1.479 1.538 0 N-CA-C 110.617 -0.993 . . . . 0.0 110.617 -179.507 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -63.45 -166.59 0.02 OUTLIER 'General case' 0 N--CA 1.471 0.62 0 N-CA-C 109.895 -0.409 . . . . 0.0 109.895 179.904 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 26.2 t-20 -70.99 76.96 0.65 Allowed 'General case' 0 CA--C 1.535 0.386 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.599 -179.89 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 97.9 mttt -73.95 143.14 45.81 Favored 'General case' 0 N--CA 1.475 0.808 0 N-CA-C 109.623 -0.51 . . . . 0.0 109.623 179.427 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.08 -166.17 0.98 Allowed Glycine 0 C--N 1.337 0.592 0 N-CA-C 110.019 -1.232 . . . . 0.0 110.019 178.642 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.57 114.28 27.2 Favored 'General case' 0 N--CA 1.472 0.659 0 C-N-CA 122.708 0.403 . . . . 0.0 110.138 -179.977 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 73.6 mt -98.51 135.02 34.97 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.649 0 N-CA-C 107.054 -1.461 . . . . 0.0 107.054 178.67 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' G' G ' 32' ' ' ILE . . . . . 0.45 ' H ' HG22 ' D' ' 32' ' ' ILE . 34.3 pt -151.5 -169.28 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 CA-C-N 119.723 1.147 . . . . 0.0 109.916 -179.813 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.28 4.78 6.85 Favored Glycine 0 N--CA 1.468 0.774 0 N-CA-C 111.132 -0.787 . . . . 0.0 111.132 -179.864 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' G' G ' 34' ' ' LEU . . . . . 0.433 HD23 ' N ' ' G' ' 35' ' ' MET . 1.1 tt -74.95 135.12 41.41 Favored 'General case' 0 CA--C 1.545 0.775 0 N-CA-C 109.295 -0.631 . . . . 0.0 109.295 -179.757 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' G' G ' 35' ' ' MET . . . . . 0.433 ' N ' HD23 ' G' ' 34' ' ' LEU . 25.0 ttt -158.28 146.06 18.31 Favored 'General case' 0 N--CA 1.47 0.566 0 N-CA-C 108.64 -0.874 . . . . 0.0 108.64 178.823 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 1.5 m -148.82 163.4 4.85 Favored 'Isoleucine or valine' 0 C--N 1.349 0.561 0 N-CA-C 108.587 -0.894 . . . . 0.0 108.587 -179.469 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' G' G ' 37' ' ' GLY . . . . . 0.704 ' H ' HE22 ' G' ' 15' ' ' GLN . . . 55.4 68.76 1.52 Allowed Glycine 0 C--N 1.308 -1.001 0 CA-C-N 115.226 -0.897 . . . . 0.0 112.293 177.596 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.39 172.35 17.46 Favored Glycine 0 N--CA 1.476 1.314 0 N-CA-C 110.569 -1.012 . . . . 0.0 110.569 178.892 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' G' G ' 39' ' ' VAL . . . . . 0.414 HG12 ' H ' ' D' ' 39' ' ' VAL . 33.9 m -106.01 155.64 6.92 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.923 0 C-N-CA 123.198 0.599 . . . . 0.0 110.452 -179.541 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 27.5 t . . . . . 0 C--O 1.22 -0.46 0 O-C-N 123.961 0.788 . . . . 0.0 110.563 179.371 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' H' H ' 1' ' ' ASP . . . . . 0.43 ' CG ' ' H1 ' ' E' ' 1' ' ' ASP . 16.4 m-20 . . . . . 0 N--CA 1.491 1.606 0 N-CA-C 109.445 -0.576 . . . . 0.0 109.445 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' H' H ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.39 129.75 42.1 Favored 'General case' 0 N--CA 1.47 0.526 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.541 179.799 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' H' H ' 3' ' ' GLU . . . . . 0.407 ' CD ' HH21 ' H' ' 5' ' ' ARG . 47.3 tt0 -168.39 106.89 0.48 Allowed 'General case' 0 N--CA 1.472 0.635 0 CA-C-O 120.464 0.173 . . . . 0.0 110.634 179.697 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 68.8 m-85 -86.06 144.91 27.31 Favored 'General case' 0 N--CA 1.473 0.71 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 179.166 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' H' H ' 5' ' ' ARG . . . . . 0.407 HH21 ' CD ' ' H' ' 3' ' ' GLU . 99.5 mtt180 -144.21 142.92 30.81 Favored 'General case' 0 N--CA 1.483 1.217 0 N-CA-C 110.046 -0.353 . . . . 0.0 110.046 -179.98 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 46.6 t-80 -152.65 119.69 5.82 Favored 'General case' 0 N--CA 1.472 0.636 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 178.812 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 3.9 m-20 -72.19 144.56 48.47 Favored 'General case' 0 N--CA 1.469 0.481 0 CA-C-N 116.319 -0.401 . . . . 0.0 111.222 -179.781 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' H' H ' 8' ' ' SER . . . . . 0.445 ' OG ' ' O ' ' E' ' 7' ' ' ASP . 52.2 p -164.72 -170.07 1.9 Allowed 'General case' 0 N--CA 1.475 0.776 0 CA-C-O 121.129 0.49 . . . . 0.0 110.492 178.912 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.48 47.63 1.39 Allowed Glycine 0 N--CA 1.478 1.499 0 N-CA-C 111.557 -0.617 . . . . 0.0 111.557 179.409 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 48.4 p90 -65.97 133.14 50.22 Favored 'General case' 0 CA--C 1.54 0.584 0 N-CA-C 111.861 0.319 . . . . 0.0 111.861 -179.587 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 47.8 mt-10 -91.67 151.44 20.67 Favored 'General case' 0 N--CA 1.477 0.921 0 CA-C-O 121.064 0.459 . . . . 0.0 110.065 178.583 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -154.98 127.35 1.03 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.004 0 N-CA-C 107.92 -1.141 . . . . 0.0 107.92 178.13 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 43.5 m-70 -134.67 146.36 49.43 Favored 'General case' 0 N--CA 1.479 0.98 0 CA-C-N 115.694 -0.685 . . . . 0.0 111.311 -178.321 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 6.1 t60 -166.43 96.71 0.57 Allowed 'General case' 0 N--CA 1.481 1.102 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.508 178.912 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' H' H ' 15' ' ' GLN . . . . . 0.703 HE22 ' H ' ' H' ' 37' ' ' GLY . 5.9 pt20 -107.97 -174.13 2.45 Favored 'General case' 0 CA--C 1.507 -0.681 0 N-CA-C 108.304 -0.999 . . . . 0.0 108.304 -179.624 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -164.68 97.5 0.76 Allowed 'General case' 0 N--CA 1.474 0.757 0 CA-C-N 114.584 -1.189 . . . . 0.0 108.127 178.61 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 6.4 mp -120.21 154.92 34.16 Favored 'General case' 0 N--CA 1.496 1.857 0 CA-C-O 121.265 0.555 . . . . 0.0 111.838 -177.939 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 43.2 t -113.4 124.65 70.25 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.079 0 CA-C-N 114.817 -1.083 . . . . 0.0 108.158 176.668 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 32.2 m-85 -125.22 121.28 33.65 Favored 'General case' 0 C--N 1.366 1.313 0 C-N-CA 123.471 0.708 . . . . 0.0 110.885 -179.443 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 68.3 m-85 54.72 72.92 0.43 Allowed 'General case' 0 C--O 1.238 0.455 0 CA-C-N 115.698 -0.683 . . . . 0.0 111.672 178.342 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.68 -78.31 0.14 Allowed 'General case' 0 N--CA 1.473 0.676 0 O-C-N 122.154 -0.341 . . . . 0.0 110.349 -178.914 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 40.8 tt0 -112.85 99.77 8.15 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 107.878 -1.156 . . . . 0.0 107.878 -179.946 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -157.24 139.96 15.02 Favored 'General case' 0 N--CA 1.477 0.887 0 O-C-N 122.346 -0.221 . . . . 0.0 111.471 178.976 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' H' H ' 24' ' ' VAL . . . . . 0.438 ' HB ' ' H ' ' E' ' 25' ' ' GLY . 59.7 t -59.7 167.65 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.592 0 N-CA-C 107.458 -1.312 . . . . 0.0 107.458 177.313 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' H' H ' 25' ' ' GLY . . . . . 0.43 ' N ' HG12 ' H' ' 24' ' ' VAL . . . -120.63 49.27 0.89 Allowed Glycine 0 N--CA 1.479 1.5 0 N-CA-C 110.622 -0.991 . . . . 0.0 110.622 -179.581 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -63.6 -167.33 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.643 0 CA-C-N 117.033 0.417 . . . . 0.0 110.036 179.766 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 26.2 t-20 -70.05 77.04 0.5 Allowed 'General case' 0 N--CA 1.465 0.318 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.587 -179.945 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 97.8 mttt -74.1 143.45 45.38 Favored 'General case' 0 N--CA 1.475 0.819 0 N-CA-C 109.5 -0.556 . . . . 0.0 109.5 179.41 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.67 -166.39 1.21 Allowed Glycine 0 C--N 1.338 0.669 0 N-CA-C 109.997 -1.241 . . . . 0.0 109.997 178.641 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.4 114.29 27.13 Favored 'General case' 0 N--CA 1.47 0.554 0 C-N-CA 122.683 0.393 . . . . 0.0 110.293 -179.995 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 74.0 mt -98.46 135.09 34.6 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.693 0 N-CA-C 106.992 -1.484 . . . . 0.0 106.992 178.672 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' H' H ' 32' ' ' ILE . . . . . 0.45 ' H ' HG22 ' E' ' 32' ' ' ILE . 34.8 pt -151.51 -169.02 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.759 0 CA-C-N 119.667 1.121 . . . . 0.0 109.826 -179.929 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.08 5.28 7.42 Favored Glycine 0 N--CA 1.467 0.706 0 N-CA-C 111.055 -0.818 . . . . 0.0 111.055 -179.979 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' H' H ' 34' ' ' LEU . . . . . 0.425 HD23 ' N ' ' H' ' 35' ' ' MET . 1.1 tt -75.44 135.24 40.73 Favored 'General case' 0 CA--C 1.545 0.784 0 N-CA-C 109.4 -0.593 . . . . 0.0 109.4 -179.744 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' H' H ' 35' ' ' MET . . . . . 0.425 ' N ' HD23 ' H' ' 34' ' ' LEU . 25.4 ttt -158.41 146.01 18.08 Favored 'General case' 0 N--CA 1.469 0.514 0 N-CA-C 108.698 -0.853 . . . . 0.0 108.698 178.882 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 1.5 m -148.91 163.83 4.57 Favored 'Isoleucine or valine' 0 C--N 1.35 0.594 0 N-CA-C 108.56 -0.904 . . . . 0.0 108.56 -179.467 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' H' H ' 37' ' ' GLY . . . . . 0.703 ' H ' HE22 ' H' ' 15' ' ' GLN . . . 55.29 68.29 1.76 Allowed Glycine 0 C--N 1.306 -1.087 0 CA-C-N 115.237 -0.892 . . . . 0.0 112.32 177.612 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.54 172.72 17.96 Favored Glycine 0 N--CA 1.475 1.24 0 N-CA-C 110.745 -0.942 . . . . 0.0 110.745 178.959 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' H' H ' 39' ' ' VAL . . . . . 0.43 HG12 ' H ' ' E' ' 39' ' ' VAL . 34.1 m -106.13 155.75 6.98 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.0 0 C-N-CA 123.32 0.648 . . . . 0.0 110.575 -179.497 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 25.9 t . . . . . 0 C--O 1.219 -0.533 0 O-C-N 123.991 0.807 . . . . 0.0 110.61 179.424 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' I' I ' 1' ' ' ASP . . . . . 0.417 ' CG ' ' H1 ' ' F' ' 1' ' ' ASP . 16.8 m-20 . . . . . 0 N--CA 1.491 1.615 0 N-CA-C 109.45 -0.574 . . . . 0.0 109.45 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' I' I ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.3 129.63 41.59 Favored 'General case' 0 N--CA 1.469 0.52 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.573 179.716 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' I' I ' 3' ' ' GLU . . . . . 0.411 ' CD ' HH21 ' I' ' 5' ' ' ARG . 46.8 tt0 -168.42 107.07 0.48 Allowed 'General case' 0 N--CA 1.473 0.709 0 CA-C-O 120.484 0.183 . . . . 0.0 110.567 179.769 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 67.2 m-85 -86.46 144.81 27.1 Favored 'General case' 0 N--CA 1.475 0.788 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 179.226 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' I' I ' 5' ' ' ARG . . . . . 0.411 HH21 ' CD ' ' I' ' 3' ' ' GLU . 99.5 mtt180 -144.12 142.48 30.61 Favored 'General case' 0 N--CA 1.482 1.153 0 N-CA-C 110.023 -0.362 . . . . 0.0 110.023 -179.931 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 45.1 t-80 -152.28 119.61 5.95 Favored 'General case' 0 N--CA 1.472 0.629 0 N-CA-C 109.503 -0.554 . . . . 0.0 109.503 178.824 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -71.96 144.81 48.77 Favored 'General case' 0 N--CA 1.469 0.481 0 CA-C-N 116.253 -0.43 . . . . 0.0 111.105 -179.758 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' I' I ' 8' ' ' SER . . . . . 0.486 ' OG ' ' O ' ' F' ' 7' ' ' ASP . 51.7 p -164.95 -170.21 1.89 Allowed 'General case' 0 N--CA 1.474 0.742 0 CA-C-O 121.139 0.495 . . . . 0.0 110.547 178.956 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.27 47.72 1.4 Allowed Glycine 0 N--CA 1.479 1.518 0 N-CA-C 111.592 -0.603 . . . . 0.0 111.592 179.544 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 47.5 p90 -65.89 132.9 49.76 Favored 'General case' 0 N--CA 1.471 0.586 0 N-CA-C 111.883 0.327 . . . . 0.0 111.883 -179.789 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 48.4 mt-10 -91.57 151.13 20.87 Favored 'General case' 0 N--CA 1.478 0.936 0 CA-C-O 121.149 0.499 . . . . 0.0 110.013 178.654 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -154.75 127.32 1.06 Allowed 'Isoleucine or valine' 0 CA--C 1.551 0.983 0 N-CA-C 107.979 -1.119 . . . . 0.0 107.979 178.252 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 44.0 m-70 -134.83 146.2 49.06 Favored 'General case' 0 N--CA 1.479 0.993 0 CA-C-N 115.68 -0.691 . . . . 0.0 111.384 -178.149 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 6.0 t60 -166.31 96.87 0.59 Allowed 'General case' 0 N--CA 1.48 1.051 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.399 178.91 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' I' I ' 15' ' ' GLN . . . . . 0.69 HE22 ' H ' ' I' ' 37' ' ' GLY . 5.9 pt20 -108.17 -174.48 2.53 Favored 'General case' 0 CA--C 1.505 -0.762 0 N-CA-C 108.272 -1.01 . . . . 0.0 108.272 -179.731 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -164.3 97.84 0.81 Allowed 'General case' 0 N--CA 1.475 0.794 0 CA-C-N 114.58 -1.191 . . . . 0.0 108.043 178.698 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 6.4 mp -120.65 154.34 35.64 Favored 'General case' 0 N--CA 1.497 1.902 0 CA-C-O 121.215 0.531 . . . . 0.0 111.837 -177.938 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 42.9 t -112.72 125.16 69.95 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.949 0 N-CA-C 108.067 -1.086 . . . . 0.0 108.067 176.595 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 30.7 m-85 -125.71 121.37 33.24 Favored 'General case' 0 C--N 1.367 1.341 0 CA-C-N 115.585 -0.734 . . . . 0.0 110.815 -179.285 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 68.9 m-85 54.59 72.52 0.46 Allowed 'General case' 0 C--N 1.345 0.38 0 CA-C-N 115.916 -0.584 . . . . 0.0 111.49 178.27 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.33 -78.25 0.13 Allowed 'General case' 0 N--CA 1.473 0.72 0 N-CA-C 110.294 -0.262 . . . . 0.0 110.294 -178.971 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 40.9 tt0 -112.77 99.86 8.24 Favored 'General case' 0 C--N 1.323 -0.566 0 N-CA-C 107.978 -1.119 . . . . 0.0 107.978 -179.959 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 4.7 p30 -157.31 139.91 14.88 Favored 'General case' 0 N--CA 1.477 0.891 0 N-CA-C 111.487 0.18 . . . . 0.0 111.487 178.978 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' I' I ' 24' ' ' VAL . . . . . 0.434 ' HB ' ' H ' ' F' ' 25' ' ' GLY . 61.2 t -59.76 167.26 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.56 0 N-CA-C 107.567 -1.271 . . . . 0.0 107.567 177.243 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' I' I ' 25' ' ' GLY . . . . . 0.428 ' N ' HG12 ' I' ' 24' ' ' VAL . . . -120.34 49.62 0.87 Allowed Glycine 0 N--CA 1.479 1.516 0 N-CA-C 110.669 -0.972 . . . . 0.0 110.669 -179.494 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -63.73 -166.89 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.572 0 N-CA-C 110.036 -0.357 . . . . 0.0 110.036 179.881 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 26.4 t-20 -70.58 76.56 0.58 Allowed 'General case' 0 CA--C 1.533 0.294 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.584 179.983 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 97.9 mttt -73.65 143.63 46.2 Favored 'General case' 0 N--CA 1.475 0.816 0 N-CA-C 109.561 -0.533 . . . . 0.0 109.561 179.422 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.74 -166.31 1.22 Allowed Glycine 0 C--N 1.336 0.548 0 N-CA-C 110.016 -1.233 . . . . 0.0 110.016 178.647 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.24 114.11 26.74 Favored 'General case' 0 N--CA 1.473 0.721 0 C-N-CA 122.706 0.402 . . . . 0.0 110.315 179.937 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 75.1 mt -98.3 135.08 34.38 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.631 0 N-CA-C 106.94 -1.504 . . . . 0.0 106.94 178.695 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' I' I ' 32' ' ' ILE . . . . . 0.446 ' H ' HG22 ' F' ' 32' ' ' ILE . 35.1 pt -151.5 -169.16 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.831 0 CA-C-N 119.62 1.1 . . . . 0.0 109.771 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.36 5.11 7.53 Favored Glycine 0 N--CA 1.466 0.686 0 N-CA-C 111.054 -0.818 . . . . 0.0 111.054 -179.893 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' I' I ' 34' ' ' LEU . . . . . 0.425 HD23 ' N ' ' I' ' 35' ' ' MET . 1.1 tt -75.21 134.92 41.07 Favored 'General case' 0 N--CA 1.474 0.77 0 N-CA-C 109.336 -0.616 . . . . 0.0 109.336 -179.646 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' I' I ' 35' ' ' MET . . . . . 0.425 ' N ' HD23 ' I' ' 34' ' ' LEU . 24.7 ttt -158.06 145.97 18.55 Favored 'General case' 0 N--CA 1.47 0.555 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 178.906 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 1.5 m -149.08 163.67 4.41 Favored 'Isoleucine or valine' 0 C--N 1.35 0.616 0 N-CA-C 108.491 -0.929 . . . . 0.0 108.491 -179.455 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' I' I ' 37' ' ' GLY . . . . . 0.69 ' H ' HE22 ' I' ' 15' ' ' GLN . . . 55.25 68.58 1.61 Allowed Glycine 0 C--N 1.308 -1.015 0 CA-C-N 115.218 -0.901 . . . . 0.0 112.282 177.706 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.25 172.5 17.51 Favored Glycine 0 N--CA 1.475 1.234 0 N-CA-C 110.646 -0.982 . . . . 0.0 110.646 178.923 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' I' I ' 39' ' ' VAL . . . . . 0.443 HG12 ' H ' ' F' ' 39' ' ' VAL . 34.4 m -106.17 155.49 7.06 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.993 0 C-N-CA 123.185 0.594 . . . . 0.0 110.635 -179.382 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 25.9 t . . . . . 0 C--O 1.218 -0.559 0 O-C-N 123.955 0.784 . . . . 0.0 110.599 179.433 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . 0.486 ' H1 ' ' CG ' ' D' ' 1' ' ' ASP . 16.8 m-20 . . . . . 0 N--CA 1.49 1.532 0 N-CA-C 108.831 -0.803 . . . . 0.0 108.831 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -66.27 133.65 51.02 Favored 'General case' 0 CA--C 1.539 0.537 0 CA-C-N 116.526 -0.306 . . . . 0.0 110.219 -179.773 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 48.8 tt0 -169.52 105.85 0.37 Allowed 'General case' 0 C--O 1.216 -0.696 0 N-CA-C 110.0 -0.37 . . . . 0.0 110.0 -179.296 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 64.9 m-85 -83.95 145.72 28.4 Favored 'General case' 0 N--CA 1.474 0.77 0 N-CA-C 110.173 -0.306 . . . . 0.0 110.173 179.54 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -144.11 142.94 30.89 Favored 'General case' 0 N--CA 1.481 1.098 0 CA-C-O 120.925 0.393 . . . . 0.0 110.031 179.417 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 46.7 t-80 -152.83 118.99 5.49 Favored 'General case' 0 N--CA 1.472 0.654 0 N-CA-C 109.157 -0.683 . . . . 0.0 109.157 179.19 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' ASP . . . . . 0.508 ' O ' ' OG ' ' D' ' 8' ' ' SER . 4.3 m-20 -69.58 149.59 48.0 Favored 'General case' 0 N--CA 1.467 0.406 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.331 179.794 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 52.4 p -168.03 -173.27 2.02 Favored 'General case' 0 N--CA 1.484 1.243 0 CA-C-O 121.006 0.431 . . . . 0.0 110.698 179.107 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.79 46.49 1.49 Allowed Glycine 0 N--CA 1.481 1.686 0 CA-C-N 116.009 -0.541 . . . . 0.0 112.11 -179.941 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 49.1 p90 -65.12 132.43 49.14 Favored 'General case' 0 N--CA 1.473 0.685 0 O-C-N 122.687 -0.302 . . . . 0.0 111.561 179.631 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 49.2 mt-10 -91.83 152.13 20.26 Favored 'General case' 0 N--CA 1.477 0.889 0 N-CA-C 109.87 -0.419 . . . . 0.0 109.87 178.297 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -152.73 128.45 1.69 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.592 0 N-CA-C 107.849 -1.167 . . . . 0.0 107.849 178.248 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 44.5 m-70 -135.54 145.94 47.54 Favored 'General case' 0 N--CA 1.491 1.617 0 CA-C-N 119.011 0.823 . . . . 0.0 111.374 -179.107 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -166.9 97.25 0.53 Allowed 'General case' 0 N--CA 1.481 1.107 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.635 179.571 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 14.7 pt20 -109.69 -174.01 2.4 Favored 'General case' 0 CA--C 1.505 -0.788 0 N-CA-C 108.36 -0.978 . . . . 0.0 108.36 179.887 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -162.71 98.98 1.0 Allowed 'General case' 0 N--CA 1.472 0.669 0 CA-C-N 114.59 -1.186 . . . . 0.0 108.309 178.274 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 6.7 mp -121.45 155.55 34.64 Favored 'General case' 0 N--CA 1.497 1.901 0 CA-C-O 121.832 0.825 . . . . 0.0 110.938 -178.347 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 58.3 t -111.59 126.47 68.98 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.046 0 CA-C-O 117.894 -1.05 . . . . 0.0 108.344 177.742 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 29.2 m-85 -126.27 122.9 36.84 Favored 'General case' 0 N--CA 1.496 1.862 0 CA-C-N 120.147 1.34 . . . . 0.0 110.284 179.281 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 68.1 m-85 54.02 74.02 0.35 Allowed 'General case' 0 N--CA 1.47 0.538 0 CA-C-O 121.398 0.618 . . . . 0.0 111.66 178.729 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -79.77 -78.29 0.16 Allowed 'General case' 0 C--N 1.353 0.734 0 CA-C-N 115.175 -0.92 . . . . 0.0 110.442 -179.902 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 40.8 tt0 -113.15 100.19 8.4 Favored 'General case' 0 N--CA 1.47 0.565 0 N-CA-C 108.327 -0.99 . . . . 0.0 108.327 179.603 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 4.4 p30 -158.74 138.72 12.09 Favored 'General case' 0 N--CA 1.485 1.282 0 CA-C-O 119.403 -0.332 . . . . 0.0 111.226 179.271 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.41 HG12 ' N ' ' A' ' 25' ' ' GLY . 57.4 t -59.83 163.9 0.87 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.783 0 N-CA-C 108.224 -1.028 . . . . 0.0 108.224 176.932 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.46 ' H ' ' HB ' ' D' ' 24' ' ' VAL . . . -117.06 47.15 1.06 Allowed Glycine 0 N--CA 1.477 1.39 0 N-CA-C 111.753 -0.539 . . . . 0.0 111.753 -179.219 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -60.11 -167.79 0.01 OUTLIER 'General case' 0 N--CA 1.469 0.512 0 O-C-N 123.852 0.384 . . . . 0.0 110.405 179.272 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 26.1 t-20 -70.98 81.05 0.66 Allowed 'General case' 0 CA--C 1.531 0.219 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.212 179.6 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 97.7 mttt -77.93 143.16 37.9 Favored 'General case' 0 N--CA 1.471 0.582 0 N-CA-C 109.163 -0.68 . . . . 0.0 109.163 179.396 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.67 -167.51 1.06 Allowed Glycine 0 CA--C 1.525 0.707 0 N-CA-C 109.926 -1.269 . . . . 0.0 109.926 178.962 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.91 115.02 28.67 Favored 'General case' 0 N--CA 1.476 0.846 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 179.677 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 72.3 mt -98.68 134.46 37.34 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.518 0 N-CA-C 107.025 -1.472 . . . . 0.0 107.025 179.021 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 29.3 pt -150.68 -172.0 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.708 0 CA-C-O 121.209 0.528 . . . . 0.0 111.184 -179.14 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.63 4.73 10.5 Favored Glycine 0 CA--C 1.527 0.785 0 N-CA-C 110.699 -0.96 . . . . 0.0 110.699 179.882 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.431 HD23 ' N ' ' A' ' 35' ' ' MET . 1.1 tt -75.43 135.16 40.75 Favored 'General case' 0 CA--C 1.544 0.726 0 N-CA-C 109.405 -0.591 . . . . 0.0 109.405 -179.56 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' MET . . . . . 0.431 ' N ' HD23 ' A' ' 34' ' ' LEU . 27.2 ttt -158.54 146.64 18.33 Favored 'General case' 0 N--CA 1.47 0.546 0 N-CA-C 108.557 -0.905 . . . . 0.0 108.557 178.705 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 1.7 m -149.16 165.49 3.78 Favored 'Isoleucine or valine' 0 C--N 1.349 0.579 0 N-CA-C 108.056 -1.09 . . . . 0.0 108.056 -179.584 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.19 68.36 1.73 Allowed Glycine 0 C--N 1.305 -1.158 0 CA-C-N 115.521 -0.763 . . . . 0.0 112.316 177.581 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.32 177.32 21.73 Favored Glycine 0 N--CA 1.474 1.192 0 N-CA-C 111.008 -0.837 . . . . 0.0 111.008 178.514 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.437 ' H ' HG12 ' D' ' 39' ' ' VAL . 34.3 m -109.81 155.59 10.95 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.623 0 C-N-CA 123.432 0.693 . . . . 0.0 110.354 -179.643 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 23.4 t . . . . . 0 C--O 1.219 -0.501 0 O-C-N 124.031 0.832 . . . . 0.0 110.663 179.633 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' B' B ' 1' ' ' ASP . . . . . 0.431 ' H1 ' ' CG ' ' E' ' 1' ' ' ASP . 16.1 m-20 . . . . . 0 N--CA 1.489 1.475 0 N-CA-C 109.036 -0.727 . . . . 0.0 109.036 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.98 133.4 50.77 Favored 'General case' 0 CA--C 1.54 0.575 0 N-CA-C 110.137 -0.319 . . . . 0.0 110.137 -179.788 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 3' ' ' GLU . . . . . . . . . . . . . 48.5 tt0 -169.38 105.68 0.38 Allowed 'General case' 0 N--CA 1.473 0.683 0 N-CA-C 110.055 -0.35 . . . . 0.0 110.055 -179.057 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 63.9 m-85 -83.78 145.65 28.58 Favored 'General case' 0 N--CA 1.475 0.804 0 N-CA-C 110.154 -0.313 . . . . 0.0 110.154 179.504 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -144.32 141.92 30.07 Favored 'General case' 0 N--CA 1.481 1.089 0 N-CA-C 109.881 -0.414 . . . . 0.0 109.881 179.513 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 47.2 t-80 -151.71 118.55 5.8 Favored 'General case' 0 N--CA 1.473 0.715 0 N-CA-C 109.319 -0.623 . . . . 0.0 109.319 178.989 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 7' ' ' ASP . . . . . 0.449 ' O ' ' OG ' ' E' ' 8' ' ' SER . 3.9 m-20 -69.2 148.9 49.21 Favored 'General case' 0 N--CA 1.469 0.485 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.525 179.761 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 8' ' ' SER . . . . . . . . . . . . . 49.4 p -167.52 -173.49 2.22 Favored 'General case' 0 N--CA 1.481 1.125 0 CA-C-O 120.974 0.416 . . . . 0.0 110.653 179.155 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.26 46.92 1.38 Allowed Glycine 0 N--CA 1.482 1.728 0 CA-C-N 116.007 -0.542 . . . . 0.0 112.158 179.987 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 48.7 p90 -65.74 132.33 48.48 Favored 'General case' 0 N--CA 1.472 0.668 0 O-C-N 122.733 -0.274 . . . . 0.0 111.618 179.663 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 48.6 mt-10 -91.52 152.32 20.37 Favored 'General case' 0 N--CA 1.475 0.819 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 178.167 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -153.05 128.25 1.54 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.581 0 N-CA-C 107.783 -1.191 . . . . 0.0 107.783 178.148 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 45.5 m-70 -135.4 145.86 47.72 Favored 'General case' 0 N--CA 1.493 1.692 0 CA-C-N 118.843 0.747 . . . . 0.0 111.37 -179.141 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -166.57 97.15 0.56 Allowed 'General case' 0 N--CA 1.48 1.05 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.651 179.485 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 14.9 pt20 -109.54 -173.62 2.3 Favored 'General case' 0 CA--C 1.507 -0.7 0 N-CA-C 108.324 -0.991 . . . . 0.0 108.324 179.854 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -163.2 98.82 0.94 Allowed 'General case' 0 N--CA 1.473 0.696 0 CA-C-N 114.699 -1.137 . . . . 0.0 108.279 178.357 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 6.6 mp -121.17 155.56 34.27 Favored 'General case' 0 N--CA 1.498 1.925 0 CA-C-O 121.894 0.854 . . . . 0.0 110.927 -178.298 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 60.4 t -111.77 127.69 68.78 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.082 0 N-CA-C 108.037 -1.097 . . . . 0.0 108.037 177.538 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 28.5 m-85 -127.66 122.34 32.78 Favored 'General case' 0 N--CA 1.495 1.821 0 CA-C-N 119.665 1.12 . . . . 0.0 110.161 179.566 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 67.4 m-85 53.96 73.65 0.37 Allowed 'General case' 0 CA--C 1.54 0.571 0 CA-C-O 121.505 0.669 . . . . 0.0 111.67 178.615 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -79.65 -78.0 0.17 Allowed 'General case' 0 C--N 1.351 0.649 0 CA-C-N 115.078 -0.965 . . . . 0.0 110.435 -179.917 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 41.0 tt0 -113.4 99.62 7.92 Favored 'General case' 0 N--CA 1.47 0.56 0 N-CA-C 108.499 -0.926 . . . . 0.0 108.499 179.624 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -157.99 139.15 13.35 Favored 'General case' 0 C--O 1.205 -1.266 0 CA-C-O 119.447 -0.311 . . . . 0.0 111.208 179.204 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 59.9 t -60.15 163.49 0.98 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.824 0 N-CA-C 108.212 -1.033 . . . . 0.0 108.212 176.976 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . 0.472 ' H ' ' HB ' ' E' ' 24' ' ' VAL . . . -116.42 47.63 1.02 Allowed Glycine 0 N--CA 1.476 1.357 0 N-CA-C 111.628 -0.589 . . . . 0.0 111.628 -179.167 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -60.69 -167.68 0.01 OUTLIER 'General case' 0 N--CA 1.468 0.46 0 O-C-N 123.782 0.342 . . . . 0.0 110.306 179.414 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 26.0 t-20 -71.17 81.01 0.71 Allowed 'General case' 0 CA--C 1.532 0.27 0 N-CA-C 110.074 -0.343 . . . . 0.0 110.074 179.616 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 97.7 mttt -77.9 143.1 38.01 Favored 'General case' 0 N--CA 1.472 0.638 0 N-CA-C 109.105 -0.702 . . . . 0.0 109.105 179.442 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.49 -167.42 0.97 Allowed Glycine 0 C--N 1.337 0.618 0 N-CA-C 109.92 -1.272 . . . . 0.0 109.92 178.894 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -100.25 114.78 28.49 Favored 'General case' 0 N--CA 1.475 0.786 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 179.757 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 71.5 mt -98.46 134.51 36.8 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.501 0 N-CA-C 107.105 -1.443 . . . . 0.0 107.105 178.889 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 30.1 pt -150.31 -171.37 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.647 0 CA-C-O 121.115 0.484 . . . . 0.0 111.227 -179.166 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.1 4.57 8.11 Favored Glycine 0 CA--C 1.526 0.752 0 N-CA-C 110.835 -0.906 . . . . 0.0 110.835 179.748 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 34' ' ' LEU . . . . . 0.421 HD23 ' N ' ' B' ' 35' ' ' MET . 1.1 tt -75.11 135.08 41.18 Favored 'General case' 0 CA--C 1.544 0.726 0 N-CA-C 109.376 -0.601 . . . . 0.0 109.376 -179.554 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 35' ' ' MET . . . . . 0.421 ' N ' HD23 ' B' ' 34' ' ' LEU . 27.1 ttt -158.24 146.63 18.77 Favored 'General case' 0 N--CA 1.472 0.628 0 N-CA-C 108.57 -0.9 . . . . 0.0 108.57 178.547 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 1.6 m -149.29 165.45 3.7 Favored 'Isoleucine or valine' 0 C--N 1.347 0.48 0 N-CA-C 108.018 -1.105 . . . . 0.0 108.018 -179.503 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 54.81 68.67 1.56 Allowed Glycine 0 C--N 1.305 -1.158 0 CA-C-N 115.354 -0.839 . . . . 0.0 112.23 177.654 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 146.95 176.89 21.09 Favored Glycine 0 N--CA 1.474 1.194 0 N-CA-C 111.106 -0.797 . . . . 0.0 111.106 178.612 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 39' ' ' VAL . . . . . 0.436 ' H ' HG12 ' E' ' 39' ' ' VAL . 34.1 m -109.68 155.22 10.92 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.698 0 C-N-CA 123.412 0.685 . . . . 0.0 110.415 -179.501 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 23.2 t . . . . . 0 C--O 1.218 -0.569 0 O-C-N 123.991 0.807 . . . . 0.0 110.331 179.552 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' C' C ' 1' ' ' ASP . . . . . 0.432 ' H2 ' ' CB ' ' F' ' 1' ' ' ASP . 16.0 m-20 . . . . . 0 N--CA 1.49 1.543 0 N-CA-C 108.818 -0.808 . . . . 0.0 108.818 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.91 132.86 49.65 Favored 'General case' 0 CA--C 1.54 0.569 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.248 -179.757 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 3' ' ' GLU . . . . . 0.406 ' CD ' HH21 ' C' ' 5' ' ' ARG . 49.4 tt0 -168.85 105.95 0.43 Allowed 'General case' 0 C--O 1.216 -0.667 0 N-CA-C 110.014 -0.365 . . . . 0.0 110.014 -179.274 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 62.0 m-85 -83.78 145.83 28.48 Favored 'General case' 0 N--CA 1.476 0.87 0 N-CA-C 110.179 -0.304 . . . . 0.0 110.179 179.449 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 5' ' ' ARG . . . . . 0.406 HH21 ' CD ' ' C' ' 3' ' ' GLU . 99.4 mtt180 -144.38 142.27 30.24 Favored 'General case' 0 N--CA 1.482 1.139 0 N-CA-C 109.994 -0.373 . . . . 0.0 109.994 179.426 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 46.7 t-80 -152.19 118.97 5.74 Favored 'General case' 0 N--CA 1.472 0.673 0 N-CA-C 109.216 -0.661 . . . . 0.0 109.216 179.216 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 7' ' ' ASP . . . . . 0.492 ' O ' ' OG ' ' F' ' 8' ' ' SER . 4.1 m-20 -69.69 149.11 48.41 Favored 'General case' 0 N--CA 1.467 0.423 0 CA-C-N 116.356 -0.384 . . . . 0.0 110.485 179.793 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 8' ' ' SER . . . . . . . . . . . . . 52.3 p -167.7 -173.18 2.08 Favored 'General case' 0 N--CA 1.483 1.192 0 CA-C-O 121.018 0.437 . . . . 0.0 110.604 179.051 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.01 46.8 1.42 Allowed Glycine 0 N--CA 1.481 1.651 0 CA-C-N 115.898 -0.592 . . . . 0.0 112.201 -179.978 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 48.4 p90 -65.81 132.34 48.47 Favored 'General case' 0 N--CA 1.474 0.737 0 CA-C-O 120.699 0.285 . . . . 0.0 111.532 179.805 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 48.2 mt-10 -91.4 152.4 20.42 Favored 'General case' 0 N--CA 1.474 0.759 0 CA-C-O 121.001 0.429 . . . . 0.0 109.871 178.141 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -152.96 128.29 1.57 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.514 0 N-CA-C 107.81 -1.181 . . . . 0.0 107.81 178.193 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 42.8 m-70 -135.42 145.87 47.68 Favored 'General case' 0 N--CA 1.492 1.647 0 CA-C-N 118.939 0.79 . . . . 0.0 111.309 -179.141 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -166.74 97.19 0.55 Allowed 'General case' 0 N--CA 1.481 1.09 0 CA-C-N 116.414 -0.357 . . . . 0.0 110.571 179.481 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 14.8 pt20 -109.58 -173.68 2.32 Favored 'General case' 0 CA--C 1.504 -0.799 0 N-CA-C 108.381 -0.97 . . . . 0.0 108.381 179.884 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -163.19 98.91 0.94 Allowed 'General case' 0 N--CA 1.471 0.601 0 CA-C-N 114.695 -1.139 . . . . 0.0 108.304 178.332 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 6.6 mp -121.37 155.35 34.98 Favored 'General case' 0 N--CA 1.497 1.906 0 CA-C-O 121.846 0.832 . . . . 0.0 111.0 -178.32 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 61.0 t -111.43 127.45 68.57 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.065 0 N-CA-C 108.183 -1.043 . . . . 0.0 108.183 177.532 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 28.5 m-85 -127.28 122.52 34.07 Favored 'General case' 0 N--CA 1.494 1.747 0 CA-C-N 119.674 1.125 . . . . 0.0 110.152 179.527 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 68.0 m-85 53.57 73.98 0.34 Allowed 'General case' 0 CA--C 1.539 0.545 0 CA-C-O 121.502 0.668 . . . . 0.0 111.745 178.615 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -79.88 -78.12 0.17 Allowed 'General case' 0 C--N 1.351 0.644 0 CA-C-N 114.999 -1.001 . . . . 0.0 110.342 -179.864 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 40.9 tt0 -113.24 99.86 8.13 Favored 'General case' 0 N--CA 1.47 0.556 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 179.675 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 4.4 p30 -158.41 138.73 12.51 Favored 'General case' 0 N--CA 1.484 1.236 0 CA-C-O 119.46 -0.305 . . . . 0.0 111.23 179.112 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 24' ' ' VAL . . . . . 0.405 HG12 ' N ' ' C' ' 25' ' ' GLY . 62.1 t -59.55 164.23 0.8 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.87 0 N-CA-C 108.124 -1.065 . . . . 0.0 108.124 177.107 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 25' ' ' GLY . . . . . 0.471 ' H ' ' HB ' ' F' ' 24' ' ' VAL . . . -117.14 47.3 1.05 Allowed Glycine 0 N--CA 1.477 1.368 0 N-CA-C 111.553 -0.619 . . . . 0.0 111.553 -179.298 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -60.31 -168.11 0.01 OUTLIER 'General case' 0 N--CA 1.468 0.465 0 O-C-N 123.747 0.322 . . . . 0.0 110.335 179.301 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 25.9 t-20 -70.78 80.96 0.62 Allowed 'General case' 0 N--CA 1.465 0.317 0 N-CA-C 110.087 -0.338 . . . . 0.0 110.087 179.478 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 97.7 mttt -77.76 142.91 38.38 Favored 'General case' 0 N--CA 1.472 0.665 0 N-CA-C 109.151 -0.685 . . . . 0.0 109.151 179.32 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.51 -167.87 1.06 Allowed Glycine 0 CA--C 1.524 0.621 0 N-CA-C 109.938 -1.265 . . . . 0.0 109.938 178.826 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.5 114.84 28.06 Favored 'General case' 0 N--CA 1.477 0.894 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 179.708 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 71.5 mt -98.64 134.21 38.19 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.591 0 N-CA-C 106.98 -1.489 . . . . 0.0 106.98 178.85 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 29.9 pt -150.18 -171.57 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.352 0.713 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.21 -179.217 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.2 4.81 8.86 Favored Glycine 0 CA--C 1.526 0.767 0 N-CA-C 110.795 -0.922 . . . . 0.0 110.795 179.815 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 34' ' ' LEU . . . . . 0.429 HD23 ' N ' ' C' ' 35' ' ' MET . 1.1 tt -75.32 135.15 40.9 Favored 'General case' 0 CA--C 1.545 0.759 0 N-CA-C 109.273 -0.639 . . . . 0.0 109.273 -179.579 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 35' ' ' MET . . . . . 0.429 ' N ' HD23 ' C' ' 34' ' ' LEU . 27.3 ttt -158.41 146.4 18.35 Favored 'General case' 0 N--CA 1.471 0.585 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 178.734 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 1.6 m -149.25 165.44 3.73 Favored 'Isoleucine or valine' 0 C--N 1.348 0.506 0 N-CA-C 107.985 -1.117 . . . . 0.0 107.985 -179.476 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.08 68.56 1.62 Allowed Glycine 0 C--N 1.306 -1.13 0 CA-C-N 115.384 -0.825 . . . . 0.0 112.186 177.563 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.0 177.21 21.39 Favored Glycine 0 N--CA 1.473 1.132 0 N-CA-C 111.019 -0.832 . . . . 0.0 111.019 178.579 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 39' ' ' VAL . . . . . 0.437 ' H ' HG12 ' F' ' 39' ' ' VAL . 34.4 m -109.94 155.57 11.1 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.681 0 C-N-CA 123.401 0.68 . . . . 0.0 110.351 -179.523 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 23.6 t . . . . . 0 C--O 1.219 -0.514 0 O-C-N 124.021 0.826 . . . . 0.0 110.478 179.645 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' D' D ' 1' ' ' ASP . . . . . 0.486 ' CG ' ' H1 ' ' A' ' 1' ' ' ASP . 16.2 m-20 . . . . . 0 N--CA 1.49 1.559 0 N-CA-C 109.271 -0.64 . . . . 0.0 109.271 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.29 131.18 46.55 Favored 'General case' 0 CA--C 1.534 0.358 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.569 179.82 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 3' ' ' GLU . . . . . 0.407 ' CD ' HH21 ' D' ' 5' ' ' ARG . 48.0 tt0 -169.28 108.86 0.44 Allowed 'General case' 0 N--CA 1.47 0.567 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 179.781 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 72.1 m-85 -88.45 151.95 22.21 Favored 'General case' 0 C--N 1.363 1.195 0 C-N-CA 119.196 -1.002 . . . . 0.0 108.608 179.829 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 5' ' ' ARG . . . . . 0.407 HH21 ' CD ' ' D' ' 3' ' ' GLU . 99.4 mtt180 -146.89 140.56 25.77 Favored 'General case' 0 N--CA 1.475 0.822 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.276 179.794 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 43.6 t-80 -149.78 123.69 9.33 Favored 'General case' 0 CA--C 1.545 0.78 0 N-CA-C 108.19 -1.041 . . . . 0.0 108.19 175.005 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 7' ' ' ASP . . . . . 0.593 ' O ' ' OG ' ' G' ' 8' ' ' SER . 2.9 m-20 -63.89 132.83 51.96 Favored 'General case' 0 C--N 1.321 -0.664 0 C-N-CA 127.068 2.147 . . . . 0.0 114.479 174.269 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' D' D ' 8' ' ' SER . . . . . 0.508 ' OG ' ' O ' ' A' ' 7' ' ' ASP . 51.9 p -154.8 -170.22 3.44 Favored 'General case' 0 N--CA 1.485 1.313 0 CA-C-N 120.046 1.294 . . . . 0.0 111.317 175.159 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.38 47.89 1.18 Allowed Glycine 0 N--CA 1.481 1.639 0 C-N-CA 124.553 1.073 . . . . 0.0 110.419 174.688 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 50.9 p90 -61.06 131.05 49.34 Favored 'General case' 0 N--CA 1.472 0.634 0 N-CA-C 112.725 0.639 . . . . 0.0 112.725 177.928 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 48.4 mt-10 -88.94 150.96 22.59 Favored 'General case' 0 N--CA 1.481 1.086 0 CA-C-N 117.961 0.346 . . . . 0.0 110.752 175.125 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -149.57 130.04 4.35 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.533 0 N-CA-C 107.518 -1.29 . . . . 0.0 107.518 173.119 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 40.9 m-70 -130.03 148.36 51.87 Favored 'General case' 0 N--CA 1.484 1.249 0 CA-C-N 118.098 0.408 . . . . 0.0 111.98 176.4 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -165.35 104.47 0.74 Allowed 'General case' 0 N--CA 1.481 1.098 0 N-CA-C 109.079 -0.711 . . . . 0.0 109.079 172.352 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 14.8 pt20 -113.36 -175.89 2.77 Favored 'General case' 0 CA--C 1.496 -1.127 0 N-CA-C 108.227 -1.027 . . . . 0.0 108.227 178.669 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -159.41 106.22 1.71 Allowed 'General case' 0 N--CA 1.468 0.444 0 N-CA-C 106.552 -1.648 . . . . 0.0 106.552 175.352 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 5.5 mp -128.01 152.87 47.4 Favored 'General case' 0 N--CA 1.499 2.008 0 CA-C-O 122.187 0.994 . . . . 0.0 110.396 179.795 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 38.4 t -101.01 131.66 48.24 Favored 'Isoleucine or valine' 0 C--O 1.258 1.518 0 CA-C-O 116.845 -1.55 . . . . 0.0 109.741 174.102 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 26.6 m-85 -130.27 126.39 37.15 Favored 'General case' 0 N--CA 1.491 1.617 0 CA-C-N 120.074 1.306 . . . . 0.0 109.417 173.61 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 68.5 m-85 55.27 71.67 0.53 Allowed 'General case' 0 C--N 1.35 0.597 0 CA-C-N 115.508 -0.769 . . . . 0.0 111.441 176.664 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -82.13 -73.21 0.4 Allowed 'General case' 0 C--N 1.353 0.721 0 CA-C-O 118.415 -0.803 . . . . 0.0 111.197 -177.693 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 41.1 tt0 -116.45 103.9 10.9 Favored 'General case' 0 N--CA 1.48 1.074 0 N-CA-C 106.434 -1.691 . . . . 0.0 106.434 176.124 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -151.82 138.5 18.79 Favored 'General case' 0 N--CA 1.477 0.896 0 CA-C-O 116.592 -1.671 . . . . 0.0 113.559 177.983 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 24' ' ' VAL . . . . . 0.46 ' HB ' ' H ' ' A' ' 25' ' ' GLY . 63.5 t -62.26 166.41 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.267 0 CA-C-N 121.264 1.847 . . . . 0.0 107.964 174.961 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' D' D ' 25' ' ' GLY . . . . . 0.531 ' H ' ' HB ' ' G' ' 24' ' ' VAL . . . -116.78 51.04 0.75 Allowed Glycine 0 N--CA 1.479 1.556 0 CA-C-O 118.964 -0.909 . . . . 0.0 111.654 178.593 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -57.1 -170.91 0.01 OUTLIER 'General case' 0 C--N 1.322 -0.627 0 C-N-CA 123.688 0.795 . . . . 0.0 111.639 175.768 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 26.7 t-20 -72.54 86.81 1.19 Allowed 'General case' 0 C--N 1.347 0.475 0 C-N-CA 119.286 -0.965 . . . . 0.0 108.572 177.928 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 97.2 mttt -83.04 146.01 28.97 Favored 'General case' 0 N--CA 1.473 0.716 0 N-CA-C 107.948 -1.13 . . . . 0.0 107.948 179.281 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.45 -165.61 0.72 Allowed Glycine 0 C--N 1.337 0.609 0 N-CA-C 110.356 -1.098 . . . . 0.0 110.356 179.524 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -102.04 116.04 31.83 Favored 'General case' 0 N--CA 1.472 0.627 0 N-CA-C 109.36 -0.607 . . . . 0.0 109.36 179.594 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 80.8 mt -102.59 142.22 17.15 Favored 'Isoleucine or valine' 0 C--N 1.357 0.933 0 N-CA-C 104.568 -2.382 . . . . 0.0 104.568 179.979 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 32' ' ' ILE . . . . . 0.444 HG22 ' H ' ' G' ' 32' ' ' ILE . 30.0 pt -157.37 -172.59 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.482 1.148 0 CA-C-O 120.84 0.353 . . . . 0.0 110.189 -177.479 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 64.23 4.31 11.72 Favored Glycine 0 N--CA 1.466 0.668 0 N-CA-C 110.27 -1.132 . . . . 0.0 110.27 -178.917 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 1.3 tt -76.29 140.28 41.45 Favored 'General case' 0 CA--C 1.543 0.708 0 N-CA-C 107.797 -1.186 . . . . 0.0 107.797 -178.142 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 26.8 ttt -156.45 156.17 33.33 Favored 'General case' 0 C--O 1.244 0.782 0 N-CA-C 107.774 -1.195 . . . . 0.0 107.774 174.436 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 1.8 m -158.04 164.05 1.14 Allowed 'Isoleucine or valine' 0 CA--C 1.515 -0.399 0 N-CA-C 107.53 -1.285 . . . . 0.0 107.53 177.973 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 61.42 63.66 4.67 Favored Glycine 0 CA--C 1.526 0.742 0 C-N-CA 119.773 -1.203 . . . . 0.0 112.101 177.212 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 145.71 177.87 20.77 Favored Glycine 0 N--CA 1.478 1.469 0 CA-C-N 118.388 1.094 . . . . 0.0 111.665 179.885 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 39' ' ' VAL . . . . . 0.437 HG12 ' H ' ' A' ' 39' ' ' VAL . 35.2 m -112.64 152.36 14.43 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.881 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 -176.89 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 23.5 t . . . . . 0 CA--C 1.522 -0.12 0 CA-C-O 116.166 -1.873 . . . . 0.0 109.597 178.315 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' E' E ' 1' ' ' ASP . . . . . 0.431 ' CG ' ' H1 ' ' B' ' 1' ' ' ASP . 15.7 m-20 . . . . . 0 N--CA 1.488 1.454 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' E' E ' 2' ' ' ALA . . . . . . . . . . . . . . . -63.95 131.65 48.3 Favored 'General case' 0 N--CA 1.469 0.501 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.43 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' E' E ' 3' ' ' GLU . . . . . 0.4 ' CD ' HH21 ' E' ' 5' ' ' ARG . 47.9 tt0 -169.04 105.72 0.41 Allowed 'General case' 0 C--O 1.215 -0.754 0 CA-C-N 116.825 -0.17 . . . . 0.0 110.632 -179.766 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 63.2 m-85 -84.51 145.09 28.29 Favored 'General case' 0 N--CA 1.477 0.902 0 N-CA-C 110.27 -0.27 . . . . 0.0 110.27 179.308 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' E' E ' 5' ' ' ARG . . . . . 0.4 HH21 ' CD ' ' E' ' 3' ' ' GLU . 99.5 mtt180 -143.6 142.69 31.17 Favored 'General case' 0 N--CA 1.48 1.039 0 CA-C-O 120.857 0.361 . . . . 0.0 110.163 179.356 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 45.7 t-80 -152.27 119.16 5.78 Favored 'General case' 0 N--CA 1.473 0.707 0 N-CA-C 109.194 -0.669 . . . . 0.0 109.194 179.027 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' E' E ' 7' ' ' ASP . . . . . 0.441 ' O ' ' OG ' ' H' ' 8' ' ' SER . 3.9 m-20 -70.23 149.26 47.66 Favored 'General case' 0 N--CA 1.469 0.501 0 CA-C-N 116.425 -0.352 . . . . 0.0 110.633 179.805 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' E' E ' 8' ' ' SER . . . . . 0.449 ' OG ' ' O ' ' B' ' 7' ' ' ASP . 44.5 p -168.68 -171.69 1.46 Allowed 'General case' 0 N--CA 1.484 1.234 0 CA-C-O 121.02 0.438 . . . . 0.0 110.842 178.591 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.05 47.02 1.38 Allowed Glycine 0 N--CA 1.478 1.476 0 CA-C-N 115.946 -0.57 . . . . 0.0 111.958 179.905 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 46.5 p90 -65.12 132.91 50.41 Favored 'General case' 0 N--CA 1.474 0.738 0 N-CA-C 111.881 0.326 . . . . 0.0 111.881 -179.873 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 48.9 mt-10 -91.45 152.71 20.26 Favored 'General case' 0 N--CA 1.479 0.989 0 CA-C-O 121.13 0.49 . . . . 0.0 109.75 177.885 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -154.58 127.59 1.13 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.538 0 N-CA-C 107.849 -1.167 . . . . 0.0 107.849 178.093 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 43.3 m-70 -135.89 143.97 45.3 Favored 'General case' 0 N--CA 1.482 1.135 0 CA-C-O 120.857 0.36 . . . . 0.0 111.609 -178.049 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -165.57 96.72 0.66 Allowed 'General case' 0 N--CA 1.484 1.256 0 CA-C-N 116.442 -0.345 . . . . 0.0 110.693 179.681 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 15.0 pt20 -108.71 -173.67 2.33 Favored 'General case' 0 CA--C 1.507 -0.688 0 N-CA-C 108.56 -0.904 . . . . 0.0 108.56 179.909 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -162.87 98.11 0.96 Allowed 'General case' 0 N--CA 1.477 0.903 0 CA-C-N 114.693 -1.139 . . . . 0.0 108.376 178.351 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 6.5 mp -120.07 155.48 32.87 Favored 'General case' 0 N--CA 1.495 1.78 0 CA-C-O 121.604 0.716 . . . . 0.0 111.5 -177.87 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 48.9 t -113.61 124.5 70.31 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.244 0 N-CA-C 108.249 -1.019 . . . . 0.0 108.249 177.167 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 31.3 m-85 -124.73 121.69 35.36 Favored 'General case' 0 N--CA 1.49 1.535 0 CA-C-O 120.921 0.391 . . . . 0.0 110.792 -179.769 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 70.0 m-85 54.75 73.21 0.42 Allowed 'General case' 0 N--CA 1.469 0.511 0 CA-C-N 115.969 -0.559 . . . . 0.0 111.281 178.219 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -78.39 -78.72 0.14 Allowed 'General case' 0 C--N 1.345 0.377 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.358 -179.594 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 40.4 tt0 -112.55 100.09 8.47 Favored 'General case' 0 C--N 1.325 -0.474 0 N-CA-C 108.467 -0.938 . . . . 0.0 108.467 179.758 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -157.31 138.5 13.6 Favored 'General case' 0 C--O 1.203 -1.369 0 CA-C-O 119.371 -0.347 . . . . 0.0 111.553 179.287 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' E' E ' 24' ' ' VAL . . . . . 0.472 ' HB ' ' H ' ' B' ' 25' ' ' GLY . 59.3 t -58.02 168.52 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.903 0 N-CA-C 107.663 -1.236 . . . . 0.0 107.663 176.615 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' E' E ' 25' ' ' GLY . . . . . 0.427 ' H ' ' HB ' ' H' ' 24' ' ' VAL . . . -122.05 48.44 0.95 Allowed Glycine 0 N--CA 1.476 1.325 0 N-CA-C 110.735 -0.946 . . . . 0.0 110.735 -179.104 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -61.93 -167.41 0.01 OUTLIER 'General case' 0 N--CA 1.47 0.559 0 CA-C-O 120.729 0.3 . . . . 0.0 110.514 179.74 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 26.6 t-20 -70.34 77.33 0.55 Allowed 'General case' 0 N--CA 1.465 0.285 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.45 -179.939 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 97.8 mttt -74.69 143.55 44.16 Favored 'General case' 0 N--CA 1.474 0.765 0 N-CA-C 109.646 -0.502 . . . . 0.0 109.646 179.484 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.29 -167.44 1.29 Allowed Glycine 0 CA--C 1.522 0.496 0 N-CA-C 110.339 -1.105 . . . . 0.0 110.339 178.71 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.56 114.26 27.17 Favored 'General case' 0 N--CA 1.476 0.838 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 179.693 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 70.8 mt -98.32 134.23 37.64 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.35 0 N-CA-C 106.812 -1.551 . . . . 0.0 106.812 179.02 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' E' E ' 32' ' ' ILE . . . . . 0.439 HG22 ' H ' ' H' ' 32' ' ' ILE . 30.9 pt -150.24 -169.8 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.149 0 CA-C-O 120.998 0.428 . . . . 0.0 110.785 -179.313 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.41 5.2 6.02 Favored Glycine 0 CA--C 1.531 1.056 0 N-CA-C 111.288 -0.725 . . . . 0.0 111.288 -179.781 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' E' E ' 34' ' ' LEU . . . . . 0.419 HD23 ' N ' ' E' ' 35' ' ' MET . 1.1 tt -74.88 135.64 41.52 Favored 'General case' 0 CA--C 1.547 0.86 0 N-CA-C 109.304 -0.628 . . . . 0.0 109.304 -179.597 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' E' E ' 35' ' ' MET . . . . . 0.419 ' N ' HD23 ' E' ' 34' ' ' LEU . 26.6 ttt -158.82 145.57 17.22 Favored 'General case' 0 N--CA 1.474 0.734 0 N-CA-C 108.638 -0.875 . . . . 0.0 108.638 178.811 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 1.4 m -148.53 165.44 4.61 Favored 'Isoleucine or valine' 0 C--N 1.347 0.495 0 N-CA-C 108.388 -0.967 . . . . 0.0 108.388 -179.546 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 54.56 68.27 1.76 Allowed Glycine 0 C--N 1.308 -0.998 0 CA-C-N 115.266 -0.879 . . . . 0.0 112.1 177.573 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 146.81 174.28 18.77 Favored Glycine 0 N--CA 1.472 1.081 0 N-CA-C 111.381 -0.687 . . . . 0.0 111.381 178.685 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' E' E ' 39' ' ' VAL . . . . . 0.436 HG12 ' H ' ' B' ' 39' ' ' VAL . 33.1 m -107.58 154.97 8.47 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.768 0 C-N-CA 123.624 0.77 . . . . 0.0 110.568 -178.843 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 25.2 t . . . . . 0 C--O 1.219 -0.535 0 O-C-N 124.263 0.977 . . . . 0.0 110.263 179.802 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' F' F ' 1' ' ' ASP . . . . . 0.432 ' CB ' ' H2 ' ' C' ' 1' ' ' ASP . 15.5 m-20 . . . . . 0 N--CA 1.49 1.532 0 N-CA-C 109.316 -0.624 . . . . 0.0 109.316 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' F' F ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.53 131.34 46.78 Favored 'General case' 0 N--CA 1.468 0.461 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.361 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' F' F ' 3' ' ' GLU . . . . . 0.403 ' CD ' HH21 ' F' ' 5' ' ' ARG . 47.9 tt0 -168.54 106.13 0.46 Allowed 'General case' 0 C--O 1.214 -0.808 0 N-CA-C 110.572 -0.159 . . . . 0.0 110.572 -179.789 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 63.8 m-85 -84.97 145.19 27.85 Favored 'General case' 0 N--CA 1.474 0.752 0 O-C-N 122.209 -0.307 . . . . 0.0 110.199 179.317 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' F' F ' 5' ' ' ARG . . . . . 0.403 HH21 ' CD ' ' F' ' 3' ' ' GLU . 99.5 mtt180 -143.51 143.26 31.48 Favored 'General case' 0 N--CA 1.477 0.908 0 CA-C-O 120.817 0.342 . . . . 0.0 110.195 179.318 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 46.1 t-80 -152.98 118.87 5.39 Favored 'General case' 0 N--CA 1.473 0.72 0 N-CA-C 109.275 -0.639 . . . . 0.0 109.275 179.055 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' F' F ' 7' ' ' ASP . . . . . 0.483 ' O ' ' OG ' ' I' ' 8' ' ' SER . 3.9 m-20 -70.2 149.03 47.92 Favored 'General case' 0 N--CA 1.468 0.447 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.68 179.981 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' F' F ' 8' ' ' SER . . . . . 0.492 ' OG ' ' O ' ' C' ' 7' ' ' ASP . 41.7 p -168.56 -171.74 1.5 Allowed 'General case' 0 N--CA 1.486 1.35 0 CA-C-O 121.039 0.447 . . . . 0.0 110.936 178.679 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.14 46.69 1.42 Allowed Glycine 0 N--CA 1.478 1.492 0 CA-C-N 115.951 -0.568 . . . . 0.0 111.984 179.955 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 46.3 p90 -64.65 132.74 50.57 Favored 'General case' 0 N--CA 1.474 0.734 0 O-C-N 122.623 -0.34 . . . . 0.0 111.913 -179.866 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 49.2 mt-10 -91.27 152.53 20.46 Favored 'General case' 0 N--CA 1.48 1.036 0 CA-C-O 121.158 0.504 . . . . 0.0 109.796 177.777 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -154.43 127.06 1.07 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.584 0 N-CA-C 107.828 -1.175 . . . . 0.0 107.828 178.13 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 42.0 m-70 -135.47 143.86 46.09 Favored 'General case' 0 N--CA 1.485 1.279 0 CA-C-O 120.849 0.357 . . . . 0.0 111.558 -178.045 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -165.32 97.11 0.69 Allowed 'General case' 0 N--CA 1.483 1.221 0 CA-C-N 116.43 -0.35 . . . . 0.0 110.771 179.754 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 15.0 pt20 -109.48 -174.17 2.44 Favored 'General case' 0 CA--C 1.503 -0.851 0 N-CA-C 108.629 -0.878 . . . . 0.0 108.629 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -162.22 98.46 1.04 Allowed 'General case' 0 N--CA 1.474 0.734 0 CA-C-N 114.694 -1.139 . . . . 0.0 108.401 178.384 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 6.4 mp -120.36 155.28 33.7 Favored 'General case' 0 N--CA 1.494 1.757 0 CA-C-O 121.532 0.682 . . . . 0.0 111.518 -177.854 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 50.2 t -113.41 124.2 69.81 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.246 0 N-CA-C 108.341 -0.985 . . . . 0.0 108.341 177.257 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 31.2 m-85 -124.56 121.58 35.18 Favored 'General case' 0 N--CA 1.489 1.49 0 CA-C-O 120.91 0.386 . . . . 0.0 110.796 -179.846 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 69.0 m-85 54.79 73.79 0.39 Allowed 'General case' 0 N--CA 1.468 0.437 0 CA-C-N 115.938 -0.574 . . . . 0.0 111.464 178.399 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -78.98 -78.31 0.15 Allowed 'General case' 0 C--N 1.344 0.359 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.537 -179.607 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 40.8 tt0 -112.76 100.09 8.42 Favored 'General case' 0 C--N 1.325 -0.471 0 N-CA-C 108.341 -0.985 . . . . 0.0 108.341 179.664 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -157.53 138.65 13.49 Favored 'General case' 0 C--O 1.205 -1.243 0 CA-C-O 119.422 -0.323 . . . . 0.0 111.532 179.282 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' F' F ' 24' ' ' VAL . . . . . 0.471 ' HB ' ' H ' ' C' ' 25' ' ' GLY . 59.6 t -58.46 168.35 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.94 0 N-CA-C 107.646 -1.242 . . . . 0.0 107.646 176.757 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' F' F ' 25' ' ' GLY . . . . . 0.435 ' H ' ' HB ' ' I' ' 24' ' ' VAL . . . -121.73 48.07 0.98 Allowed Glycine 0 N--CA 1.477 1.418 0 N-CA-C 110.789 -0.924 . . . . 0.0 110.789 -179.163 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -61.62 -167.05 0.01 OUTLIER 'General case' 0 N--CA 1.469 0.481 0 CA-C-N 116.768 0.284 . . . . 0.0 110.453 179.771 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 26.7 t-20 -70.67 76.84 0.6 Allowed 'General case' 0 N--CA 1.466 0.367 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.441 -179.881 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -74.01 143.86 45.38 Favored 'General case' 0 N--CA 1.473 0.709 0 N-CA-C 109.691 -0.485 . . . . 0.0 109.691 179.242 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.57 -167.19 1.34 Allowed Glycine 0 CA--C 1.522 0.517 0 N-CA-C 110.426 -1.07 . . . . 0.0 110.426 178.712 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.6 113.81 26.47 Favored 'General case' 0 N--CA 1.472 0.662 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.837 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 72.0 mt -98.09 134.54 36.08 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.372 0 N-CA-C 106.84 -1.541 . . . . 0.0 106.84 179.038 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' F' F ' 32' ' ' ILE . . . . . 0.43 HG22 ' H ' ' I' ' 32' ' ' ILE . 31.8 pt -150.47 -169.83 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.118 0 CA-C-O 121.052 0.453 . . . . 0.0 110.751 -179.409 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.64 4.9 5.95 Favored Glycine 0 CA--C 1.53 1.015 0 N-CA-C 111.261 -0.736 . . . . 0.0 111.261 -179.87 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' F' F ' 34' ' ' LEU . . . . . 0.425 HD23 ' N ' ' F' ' 35' ' ' MET . 1.1 tt -74.77 135.82 41.72 Favored 'General case' 0 CA--C 1.546 0.822 0 N-CA-C 109.241 -0.652 . . . . 0.0 109.241 -179.612 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' F' F ' 35' ' ' MET . . . . . 0.425 ' N ' HD23 ' F' ' 34' ' ' LEU . 26.5 ttt -158.89 145.86 17.3 Favored 'General case' 0 N--CA 1.473 0.686 0 N-CA-C 108.494 -0.928 . . . . 0.0 108.494 178.804 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 1.5 m -148.72 165.33 4.38 Favored 'Isoleucine or valine' 0 C--N 1.348 0.537 0 N-CA-C 108.366 -0.976 . . . . 0.0 108.366 -179.449 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 54.33 68.61 1.58 Allowed Glycine 0 C--N 1.308 -1.021 0 CA-C-N 115.307 -0.861 . . . . 0.0 112.113 177.634 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 146.6 174.07 18.39 Favored Glycine 0 N--CA 1.473 1.118 0 N-CA-C 111.355 -0.698 . . . . 0.0 111.355 178.722 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' F' F ' 39' ' ' VAL . . . . . 0.437 HG12 ' H ' ' C' ' 39' ' ' VAL . 33.0 m -107.42 155.0 8.27 Favored 'Isoleucine or valine' 0 C--N 1.352 0.696 0 C-N-CA 123.528 0.731 . . . . 0.0 110.604 -178.773 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 25.9 t . . . . . 0 C--O 1.219 -0.543 0 O-C-N 124.365 1.041 . . . . 0.0 110.356 179.892 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' G' G ' 1' ' ' ASP . . . . . 0.442 ' CB ' ' H2 ' ' D' ' 1' ' ' ASP . 16.9 m-20 . . . . . 0 N--CA 1.491 1.601 0 N-CA-C 109.323 -0.621 . . . . 0.0 109.323 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' G' G ' 2' ' ' ALA . . . . . . . . . . . . . . . -63.0 129.44 40.37 Favored 'General case' 0 N--CA 1.469 0.481 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.662 179.781 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' G' G ' 3' ' ' GLU . . . . . 0.411 ' CD ' HH21 ' G' ' 5' ' ' ARG . 46.6 tt0 -168.5 107.36 0.48 Allowed 'General case' 0 N--CA 1.471 0.613 0 CA-C-O 120.479 0.18 . . . . 0.0 110.745 179.638 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 64.8 m-85 -86.62 145.01 26.9 Favored 'General case' 0 N--CA 1.475 0.785 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 179.164 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' G' G ' 5' ' ' ARG . . . . . 0.411 HH21 ' CD ' ' G' ' 3' ' ' GLU . 99.4 mtt180 -144.09 142.09 30.42 Favored 'General case' 0 N--CA 1.481 1.091 0 CA-C-O 120.823 0.345 . . . . 0.0 110.205 179.726 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 46.8 t-80 -151.69 119.59 6.2 Favored 'General case' 0 N--CA 1.473 0.676 0 N-CA-C 109.46 -0.57 . . . . 0.0 109.46 179.016 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 4.1 m-20 -71.94 144.41 48.94 Favored 'General case' 0 N--CA 1.471 0.603 0 C-N-CA 122.763 0.425 . . . . 0.0 111.154 -179.833 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' G' G ' 8' ' ' SER . . . . . 0.593 ' OG ' ' O ' ' D' ' 7' ' ' ASP . 37.5 p -164.69 -169.24 1.68 Allowed 'General case' 0 N--CA 1.476 0.86 0 CA-C-O 121.049 0.452 . . . . 0.0 110.496 178.535 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 101.95 47.59 1.46 Allowed Glycine 0 N--CA 1.478 1.488 0 N-CA-C 111.529 -0.628 . . . . 0.0 111.529 179.553 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 48.6 p90 -65.93 132.71 49.27 Favored 'General case' 0 N--CA 1.473 0.692 0 N-CA-C 111.803 0.297 . . . . 0.0 111.803 -179.688 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 48.4 mt-10 -91.5 152.03 20.51 Favored 'General case' 0 N--CA 1.479 1.018 0 CA-C-O 121.043 0.449 . . . . 0.0 110.163 178.374 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -154.96 127.81 1.1 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.008 0 N-CA-C 107.864 -1.161 . . . . 0.0 107.864 178.221 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 44.9 m-70 -135.25 144.83 47.07 Favored 'General case' 0 N--CA 1.477 0.922 0 CA-C-N 115.702 -0.681 . . . . 0.0 111.407 -178.259 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -166.52 96.85 0.57 Allowed 'General case' 0 N--CA 1.483 1.181 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.288 179.132 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 15.0 pt20 -109.11 -173.75 2.34 Favored 'General case' 0 CA--C 1.503 -0.831 0 N-CA-C 108.391 -0.966 . . . . 0.0 108.391 179.88 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -163.15 98.03 0.93 Allowed 'General case' 0 N--CA 1.474 0.747 0 CA-C-N 114.701 -1.136 . . . . 0.0 108.132 178.558 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 6.4 mp -120.06 154.29 34.85 Favored 'General case' 0 N--CA 1.496 1.86 0 CA-C-O 121.204 0.526 . . . . 0.0 111.793 -177.935 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 44.5 t -112.83 125.39 70.09 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.968 0 CA-C-N 114.898 -1.046 . . . . 0.0 108.19 176.548 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 32.2 m-85 -125.88 121.15 32.38 Favored 'General case' 0 C--N 1.366 1.315 0 C-N-CA 123.39 0.676 . . . . 0.0 110.853 -179.532 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 69.3 m-85 55.13 72.76 0.45 Allowed 'General case' 0 N--CA 1.469 0.521 0 CA-C-N 115.882 -0.599 . . . . 0.0 111.292 178.24 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.67 -78.26 0.14 Allowed 'General case' 0 N--CA 1.471 0.583 0 O-C-N 122.244 -0.285 . . . . 0.0 110.55 -179.189 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 41.3 tt0 -112.57 100.43 8.73 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 108.124 -1.065 . . . . 0.0 108.124 179.646 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -157.86 139.78 14.08 Favored 'General case' 0 N--CA 1.478 0.949 0 N-CA-C 111.516 0.191 . . . . 0.0 111.516 179.153 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' G' G ' 24' ' ' VAL . . . . . 0.531 ' HB ' ' H ' ' D' ' 25' ' ' GLY . 61.4 t -59.96 167.25 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.624 0 N-CA-C 107.669 -1.234 . . . . 0.0 107.669 177.268 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' G' G ' 25' ' ' GLY . . . . . 0.428 ' N ' HG12 ' G' ' 24' ' ' VAL . . . -120.35 49.68 0.87 Allowed Glycine 0 N--CA 1.482 1.718 0 N-CA-C 110.313 -1.115 . . . . 0.0 110.313 -179.453 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -63.56 -167.51 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.658 0 CA-C-N 117.001 0.401 . . . . 0.0 109.953 179.484 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 26.6 t-20 -70.11 76.69 0.51 Allowed 'General case' 0 CA--C 1.535 0.386 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.478 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 97.9 mttt -73.36 143.92 46.66 Favored 'General case' 0 N--CA 1.474 0.77 0 N-CA-C 109.701 -0.481 . . . . 0.0 109.701 179.209 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.64 -166.08 1.14 Allowed Glycine 0 C--N 1.337 0.593 0 N-CA-C 110.069 -1.212 . . . . 0.0 110.069 178.723 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.82 113.93 26.76 Favored 'General case' 0 N--CA 1.47 0.541 0 C-N-CA 122.723 0.409 . . . . 0.0 110.393 179.897 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 74.7 mt -98.61 134.77 36.05 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.773 0 N-CA-C 106.784 -1.562 . . . . 0.0 106.784 179.03 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' G' G ' 32' ' ' ILE . . . . . 0.444 ' H ' HG22 ' D' ' 32' ' ' ILE . 34.6 pt -151.11 -169.38 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 CA-C-N 119.657 1.117 . . . . 0.0 109.917 -179.826 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.18 4.79 6.71 Favored Glycine 0 CA--C 1.529 0.926 0 N-CA-C 111.052 -0.819 . . . . 0.0 111.052 179.933 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' G' G ' 34' ' ' LEU . . . . . 0.44 HD23 ' N ' ' G' ' 35' ' ' MET . 1.1 tt -74.95 135.74 41.38 Favored 'General case' 0 CA--C 1.544 0.745 0 N-CA-C 109.209 -0.663 . . . . 0.0 109.209 -179.635 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' G' G ' 35' ' ' MET . . . . . 0.44 ' N ' HD23 ' G' ' 34' ' ' LEU . 25.3 ttt -158.86 146.06 17.48 Favored 'General case' 0 N--CA 1.47 0.533 0 N-CA-C 108.695 -0.854 . . . . 0.0 108.695 178.801 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 1.4 m -148.8 163.89 4.72 Favored 'Isoleucine or valine' 0 C--N 1.349 0.566 0 N-CA-C 108.509 -0.922 . . . . 0.0 108.509 -179.293 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.13 68.67 1.57 Allowed Glycine 0 C--N 1.308 -0.997 0 CA-C-N 115.305 -0.862 . . . . 0.0 112.207 177.39 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.33 173.16 18.22 Favored Glycine 0 N--CA 1.475 1.274 0 N-CA-C 110.599 -1.0 . . . . 0.0 110.599 178.934 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' G' G ' 39' ' ' VAL . . . . . 0.405 HG12 ' H ' ' D' ' 39' ' ' VAL . 34.1 m -106.88 155.11 7.64 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.873 0 C-N-CA 123.222 0.609 . . . . 0.0 110.668 -179.346 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 25.8 t . . . . . 0 C--O 1.219 -0.532 0 O-C-N 124.035 0.835 . . . . 0.0 110.622 179.721 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' H' H ' 1' ' ' ASP . . . . . 0.417 ' CG ' ' H1 ' ' E' ' 1' ' ' ASP . 17.6 m-20 . . . . . 0 N--CA 1.491 1.602 0 N-CA-C 109.453 -0.573 . . . . 0.0 109.453 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' H' H ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.76 129.69 41.6 Favored 'General case' 0 N--CA 1.469 0.494 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.517 179.72 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' H' H ' 3' ' ' GLU . . . . . . . . . . . . . 46.7 tt0 -168.58 107.39 0.48 Allowed 'General case' 0 N--CA 1.471 0.601 0 CA-C-O 120.449 0.166 . . . . 0.0 110.643 179.735 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 64.4 m-85 -86.9 144.67 26.87 Favored 'General case' 0 N--CA 1.473 0.712 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 179.181 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' H' H ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -143.72 142.71 31.07 Favored 'General case' 0 N--CA 1.482 1.133 0 C-N-CA 122.592 0.357 . . . . 0.0 110.1 179.712 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 47.7 t-80 -152.2 119.6 5.98 Favored 'General case' 0 N--CA 1.475 0.788 0 N-CA-C 109.326 -0.62 . . . . 0.0 109.326 178.991 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -71.57 144.44 49.54 Favored 'General case' 0 N--CA 1.469 0.497 0 C-N-CA 122.767 0.427 . . . . 0.0 111.164 179.89 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' H' H ' 8' ' ' SER . . . . . 0.441 ' OG ' ' O ' ' E' ' 7' ' ' ASP . 52.5 p -164.9 -170.37 1.94 Allowed 'General case' 0 N--CA 1.474 0.754 0 CA-C-O 120.935 0.398 . . . . 0.0 110.48 178.504 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.87 47.17 1.39 Allowed Glycine 0 N--CA 1.48 1.587 0 CA-C-N 115.971 -0.559 . . . . 0.0 111.709 179.604 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 48.2 p90 -65.61 132.67 49.41 Favored 'General case' 0 N--CA 1.473 0.707 0 N-CA-C 111.863 0.32 . . . . 0.0 111.863 -179.69 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 48.4 mt-10 -91.33 151.64 20.79 Favored 'General case' 0 N--CA 1.478 0.951 0 CA-C-O 121.036 0.446 . . . . 0.0 110.257 178.275 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -154.77 127.8 1.13 Allowed 'Isoleucine or valine' 0 CA--C 1.553 1.087 0 N-CA-C 107.815 -1.18 . . . . 0.0 107.815 178.286 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 45.0 m-70 -135.29 145.23 47.32 Favored 'General case' 0 N--CA 1.478 0.956 0 CA-C-N 115.596 -0.729 . . . . 0.0 111.373 -178.303 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -166.92 97.0 0.53 Allowed 'General case' 0 N--CA 1.481 1.116 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.312 179.151 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 15.1 pt20 -109.09 -173.43 2.26 Favored 'General case' 0 CA--C 1.505 -0.771 0 N-CA-C 108.417 -0.957 . . . . 0.0 108.417 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -163.5 97.98 0.89 Allowed 'General case' 0 N--CA 1.474 0.754 0 CA-C-N 114.718 -1.128 . . . . 0.0 108.1 178.565 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 6.4 mp -120.12 154.4 34.77 Favored 'General case' 0 N--CA 1.497 1.885 0 CA-C-O 121.263 0.554 . . . . 0.0 111.881 -177.981 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 43.9 t -113.02 124.79 70.01 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.978 0 CA-C-N 114.936 -1.029 . . . . 0.0 108.292 176.604 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 32.4 m-85 -125.17 121.16 33.39 Favored 'General case' 0 C--N 1.366 1.316 0 CA-C-N 115.56 -0.745 . . . . 0.0 110.735 -179.425 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 68.7 m-85 54.78 72.83 0.44 Allowed 'General case' 0 C--O 1.237 0.407 0 CA-C-N 115.868 -0.605 . . . . 0.0 111.425 178.173 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.31 -78.43 0.13 Allowed 'General case' 0 N--CA 1.469 0.522 0 O-C-N 122.229 -0.294 . . . . 0.0 110.591 -179.379 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 40.9 tt0 -112.62 100.34 8.65 Favored 'General case' 0 C--N 1.322 -0.589 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 179.792 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -157.6 139.47 14.12 Favored 'General case' 0 N--CA 1.477 0.909 0 O-C-N 122.403 -0.186 . . . . 0.0 111.498 179.272 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' H' H ' 24' ' ' VAL . . . . . 0.427 ' HB ' ' H ' ' E' ' 25' ' ' GLY . 62.0 t -59.73 167.4 0.56 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.521 0 N-CA-C 107.722 -1.214 . . . . 0.0 107.722 177.182 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' H' H ' 25' ' ' GLY . . . . . 0.425 ' N ' HG12 ' H' ' 24' ' ' VAL . . . -120.32 49.12 0.9 Allowed Glycine 0 N--CA 1.48 1.572 0 N-CA-C 110.491 -1.043 . . . . 0.0 110.491 -179.314 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -63.23 -166.99 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.675 0 CA-C-N 116.972 0.386 . . . . 0.0 110.092 179.748 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 26.6 t-20 -70.63 76.46 0.59 Allowed 'General case' 0 CA--C 1.535 0.374 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.492 -179.85 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -73.44 143.88 46.53 Favored 'General case' 0 N--CA 1.473 0.685 0 N-CA-C 109.629 -0.508 . . . . 0.0 109.629 179.341 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -65.17 -166.14 1.37 Allowed Glycine 0 C--N 1.337 0.634 0 N-CA-C 109.936 -1.266 . . . . 0.0 109.936 178.889 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.44 114.28 27.12 Favored 'General case' 0 N--CA 1.467 0.408 0 C-N-CA 122.573 0.349 . . . . 0.0 110.617 179.85 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 74.5 mt -98.73 134.73 36.41 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.751 0 N-CA-C 106.8 -1.556 . . . . 0.0 106.8 178.974 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' H' H ' 32' ' ' ILE . . . . . 0.439 ' H ' HG22 ' E' ' 32' ' ' ILE . 34.2 pt -151.05 -169.24 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.687 0 CA-C-N 119.747 1.158 . . . . 0.0 109.917 -179.93 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.24 4.8 6.81 Favored Glycine 0 CA--C 1.529 0.919 0 N-CA-C 110.95 -0.86 . . . . 0.0 110.95 179.914 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' H' H ' 34' ' ' LEU . . . . . 0.431 HD23 ' N ' ' H' ' 35' ' ' MET . 1.1 tt -75.35 135.25 40.85 Favored 'General case' 0 CA--C 1.546 0.792 0 N-CA-C 109.412 -0.588 . . . . 0.0 109.412 -179.414 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' H' H ' 35' ' ' MET . . . . . 0.431 ' N ' HD23 ' H' ' 34' ' ' LEU . 25.2 ttt -158.52 146.15 18.03 Favored 'General case' 0 N--CA 1.472 0.641 0 N-CA-C 108.694 -0.854 . . . . 0.0 108.694 179.065 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 1.5 m -149.08 163.84 4.35 Favored 'Isoleucine or valine' 0 C--N 1.348 0.522 0 N-CA-C 108.449 -0.945 . . . . 0.0 108.449 -179.283 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.35 68.39 1.71 Allowed Glycine 0 C--N 1.309 -0.971 0 CA-C-N 115.16 -0.927 . . . . 0.0 112.064 177.451 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.27 172.35 17.37 Favored Glycine 0 N--CA 1.476 1.307 0 N-CA-C 110.639 -0.985 . . . . 0.0 110.639 178.959 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' H' H ' 39' ' ' VAL . . . . . 0.425 HG12 ' H ' ' E' ' 39' ' ' VAL . 33.8 m -106.1 154.93 7.13 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.927 0 C-N-CA 123.199 0.6 . . . . 0.0 110.715 -179.475 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 24.7 t . . . . . 0 C--O 1.219 -0.53 0 O-C-N 124.001 0.813 . . . . 0.0 110.709 179.699 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' I' I ' 1' ' ' ASP . . . . . 0.41 ' CG ' ' H1 ' ' F' ' 1' ' ' ASP . 16.4 m-20 . . . . . 0 N--CA 1.492 1.63 0 N-CA-C 109.487 -0.56 . . . . 0.0 109.487 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' I' I ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.66 129.43 40.53 Favored 'General case' 0 N--CA 1.469 0.519 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.468 179.697 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' I' I ' 3' ' ' GLU . . . . . . . . . . . . . 46.9 tt0 -168.41 107.14 0.49 Allowed 'General case' 0 N--CA 1.472 0.646 0 CA-C-O 120.445 0.165 . . . . 0.0 110.597 179.737 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 66.3 m-85 -86.54 145.1 26.92 Favored 'General case' 0 N--CA 1.474 0.745 0 N-CA-C 109.736 -0.468 . . . . 0.0 109.736 179.264 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' I' I ' 5' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -144.13 142.47 30.6 Favored 'General case' 0 N--CA 1.484 1.23 0 C-N-CA 122.639 0.376 . . . . 0.0 110.194 179.81 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 47.6 t-80 -152.14 120.12 6.21 Favored 'General case' 0 N--CA 1.474 0.738 0 N-CA-C 109.361 -0.607 . . . . 0.0 109.361 179.007 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -72.32 144.16 48.41 Favored 'General case' 0 N--CA 1.471 0.605 0 C-N-CA 122.725 0.41 . . . . 0.0 111.084 -179.945 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' I' I ' 8' ' ' SER . . . . . 0.483 ' OG ' ' O ' ' F' ' 7' ' ' ASP . 50.8 p -164.73 -170.39 1.98 Allowed 'General case' 0 N--CA 1.475 0.782 0 CA-C-O 120.996 0.427 . . . . 0.0 110.488 178.586 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.82 47.47 1.36 Allowed Glycine 0 N--CA 1.48 1.628 0 N-CA-C 111.629 -0.589 . . . . 0.0 111.629 179.675 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 47.9 p90 -65.92 133.2 50.38 Favored 'General case' 0 N--CA 1.473 0.677 0 CA-C-O 120.803 0.335 . . . . 0.0 111.872 -179.649 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 48.4 mt-10 -91.77 151.7 20.49 Favored 'General case' 0 N--CA 1.478 0.95 0 CA-C-O 120.932 0.396 . . . . 0.0 110.311 178.348 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -154.99 126.92 0.96 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.057 0 N-CA-C 107.909 -1.145 . . . . 0.0 107.909 178.365 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 42.4 m-70 -134.52 144.88 48.27 Favored 'General case' 0 N--CA 1.478 0.967 0 CA-C-N 115.606 -0.724 . . . . 0.0 111.451 -178.382 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -166.43 97.09 0.58 Allowed 'General case' 0 N--CA 1.48 1.056 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.348 179.119 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 15.2 pt20 -109.3 -173.88 2.37 Favored 'General case' 0 CA--C 1.504 -0.797 0 N-CA-C 108.481 -0.933 . . . . 0.0 108.481 -179.99 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -163.08 98.11 0.93 Allowed 'General case' 0 N--CA 1.473 0.715 0 CA-C-N 114.701 -1.136 . . . . 0.0 108.07 178.514 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 6.4 mp -120.2 154.37 34.94 Favored 'General case' 0 N--CA 1.497 1.907 0 CA-C-O 121.24 0.543 . . . . 0.0 111.769 -177.91 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 44.8 t -113.0 125.07 70.2 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.028 0 CA-C-N 114.857 -1.065 . . . . 0.0 108.157 176.646 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 32.9 m-85 -125.57 121.11 32.69 Favored 'General case' 0 C--N 1.367 1.339 0 CA-C-N 115.582 -0.735 . . . . 0.0 110.815 -179.536 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 68.6 m-85 54.9 73.26 0.42 Allowed 'General case' 0 N--CA 1.469 0.51 0 CA-C-N 115.927 -0.579 . . . . 0.0 111.262 178.301 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.99 -78.01 0.15 Allowed 'General case' 0 N--CA 1.472 0.639 0 O-C-N 122.205 -0.309 . . . . 0.0 110.601 -179.268 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 40.9 tt0 -112.84 100.32 8.58 Favored 'General case' 0 C--N 1.323 -0.586 0 N-CA-C 108.088 -1.078 . . . . 0.0 108.088 179.614 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -157.71 139.26 13.8 Favored 'General case' 0 N--CA 1.479 0.983 0 O-C-N 122.344 -0.223 . . . . 0.0 111.433 179.396 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' I' I ' 24' ' ' VAL . . . . . 0.435 ' HB ' ' H ' ' F' ' 25' ' ' GLY . 62.0 t -59.48 167.26 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.54 0 N-CA-C 107.847 -1.168 . . . . 0.0 107.847 177.016 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' I' I ' 25' ' ' GLY . . . . . 0.432 ' N ' HG12 ' I' ' 24' ' ' VAL . . . -120.43 49.52 0.87 Allowed Glycine 0 N--CA 1.482 1.725 0 N-CA-C 110.411 -1.076 . . . . 0.0 110.411 -179.384 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -63.42 -166.9 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.656 0 CA-C-N 116.985 0.393 . . . . 0.0 110.064 179.59 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 26.8 t-20 -70.68 76.71 0.6 Allowed 'General case' 0 N--CA 1.466 0.358 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.35 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 97.8 mttt -73.66 143.62 46.18 Favored 'General case' 0 N--CA 1.474 0.772 0 N-CA-C 109.64 -0.504 . . . . 0.0 109.64 179.284 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.59 -166.08 1.13 Allowed Glycine 0 C--N 1.339 0.703 0 N-CA-C 110.02 -1.232 . . . . 0.0 110.02 178.88 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.53 113.86 26.51 Favored 'General case' 0 N--CA 1.469 0.495 0 C-N-CA 122.691 0.396 . . . . 0.0 110.45 179.877 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 74.2 mt -98.37 135.04 34.66 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.836 0 N-CA-C 106.745 -1.576 . . . . 0.0 106.745 178.849 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' I' I ' 32' ' ' ILE . . . . . 0.43 ' H ' HG22 ' F' ' 32' ' ' ILE . 33.6 pt -151.38 -169.3 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 CA-C-N 119.698 1.135 . . . . 0.0 109.965 -179.987 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.22 4.71 6.68 Favored Glycine 0 CA--C 1.528 0.897 0 N-CA-C 110.952 -0.859 . . . . 0.0 110.952 179.962 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' I' I ' 34' ' ' LEU . . . . . 0.431 HD23 ' N ' ' I' ' 35' ' ' MET . 1.1 tt -74.85 135.29 41.58 Favored 'General case' 0 CA--C 1.544 0.738 0 N-CA-C 109.318 -0.623 . . . . 0.0 109.318 -179.602 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' I' I ' 35' ' ' MET . . . . . 0.431 ' N ' HD23 ' I' ' 34' ' ' LEU . 25.4 ttt -158.44 146.06 18.08 Favored 'General case' 0 N--CA 1.471 0.602 0 N-CA-C 108.53 -0.915 . . . . 0.0 108.53 178.982 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 1.4 m -149.02 163.78 4.41 Favored 'Isoleucine or valine' 0 C--N 1.35 0.616 0 N-CA-C 108.519 -0.919 . . . . 0.0 108.519 -179.401 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.08 68.5 1.65 Allowed Glycine 0 C--N 1.308 -0.991 0 CA-C-N 115.253 -0.885 . . . . 0.0 112.143 177.492 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.45 172.31 17.46 Favored Glycine 0 N--CA 1.474 1.224 0 N-CA-C 110.682 -0.967 . . . . 0.0 110.682 178.982 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' I' I ' 39' ' ' VAL . . . . . 0.426 HG12 ' H ' ' F' ' 39' ' ' VAL . 33.9 m -106.15 154.81 7.2 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.915 0 C-N-CA 123.236 0.614 . . . . 0.0 110.663 -179.467 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 25.3 t . . . . . 0 C--O 1.219 -0.524 0 O-C-N 124.06 0.85 . . . . 0.0 110.612 179.621 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 14.7 m-20 . . . . . 0 N--CA 1.491 1.587 0 N-CA-C 108.906 -0.776 . . . . 0.0 108.906 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.91 132.83 49.57 Favored 'General case' 0 CA--C 1.538 0.503 0 CA-C-N 116.548 -0.296 . . . . 0.0 110.24 -179.832 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 44.7 tt0 -168.21 105.4 0.47 Allowed 'General case' 0 C--O 1.215 -0.727 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 -179.295 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 42.0 m-85 -85.85 152.16 23.22 Favored 'General case' 0 N--CA 1.474 0.747 0 N-CA-C 110.118 -0.327 . . . . 0.0 110.118 179.589 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -143.45 140.62 30.47 Favored 'General case' 0 N--CA 1.481 1.085 0 CA-C-O 120.887 0.375 . . . . 0.0 110.03 179.711 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 42.3 t-80 -151.79 119.39 6.07 Favored 'General case' 0 N--CA 1.47 0.528 0 N-CA-C 109.231 -0.655 . . . . 0.0 109.231 179.176 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' ASP . . . . . 0.499 ' O ' ' OG ' ' D' ' 8' ' ' SER . 4.4 m-20 -68.98 148.77 49.65 Favored 'General case' 0 CA--C 1.537 0.471 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.516 179.816 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 53.2 p -167.58 -173.5 2.21 Favored 'General case' 0 N--CA 1.483 1.184 0 CA-C-O 121.054 0.454 . . . . 0.0 110.721 179.392 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.62 47.67 1.37 Allowed Glycine 0 N--CA 1.482 1.705 0 CA-C-N 115.966 -0.561 . . . . 0.0 112.08 179.785 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 48.7 p90 -65.86 132.72 49.35 Favored 'General case' 0 N--CA 1.474 0.735 0 O-C-N 122.755 -0.262 . . . . 0.0 111.496 179.712 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 46.0 mt-10 -92.17 152.08 20.06 Favored 'General case' 0 N--CA 1.479 0.986 0 N-CA-C 109.725 -0.472 . . . . 0.0 109.725 178.512 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.0 p -152.89 128.25 1.59 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.612 0 N-CA-C 107.868 -1.16 . . . . 0.0 107.868 178.238 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 47.2 m-70 -135.41 147.8 49.12 Favored 'General case' 0 N--CA 1.493 1.708 0 CA-C-N 119.044 0.838 . . . . 0.0 111.398 -179.013 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 6.4 t60 -165.1 97.02 0.72 Allowed 'General case' 0 N--CA 1.48 1.064 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.624 179.342 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . 0.479 HE22 HG23 ' A' ' 36' ' ' VAL . 3.9 pt20 -101.54 -174.16 2.53 Favored 'General case' 0 CA--C 1.507 -0.704 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 -179.82 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -169.9 95.81 0.28 Allowed 'General case' 0 N--CA 1.47 0.53 0 CA-C-N 114.608 -1.178 . . . . 0.0 108.389 178.38 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 6.5 mp -123.36 156.97 34.35 Favored 'General case' 0 N--CA 1.497 1.917 0 CA-C-O 121.794 0.807 . . . . 0.0 111.005 -178.14 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 60.1 t -111.79 126.86 69.22 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.135 0 CA-C-O 117.938 -1.029 . . . . 0.0 108.269 177.608 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 27.1 m-85 -126.89 123.09 36.44 Favored 'General case' 0 N--CA 1.497 1.912 0 CA-C-N 120.13 1.332 . . . . 0.0 110.474 179.5 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 67.9 m-85 53.66 74.71 0.3 Allowed 'General case' 0 CA--C 1.538 0.489 0 CA-C-O 121.414 0.626 . . . . 0.0 111.813 178.634 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -80.0 -78.28 0.17 Allowed 'General case' 0 C--N 1.353 0.727 0 CA-C-N 115.084 -0.962 . . . . 0.0 110.192 -179.922 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 38.2 tt0 -113.39 100.74 8.77 Favored 'General case' 0 N--CA 1.469 0.486 0 N-CA-C 108.191 -1.04 . . . . 0.0 108.191 179.725 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 4.4 p30 -159.18 139.79 12.43 Favored 'General case' 0 N--CA 1.483 1.178 0 O-C-N 122.31 -0.243 . . . . 0.0 111.219 179.147 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.405 HG12 ' N ' ' A' ' 25' ' ' GLY . 61.2 t -59.97 163.43 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.819 0 N-CA-C 108.104 -1.073 . . . . 0.0 108.104 177.106 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.469 ' H ' ' HB ' ' D' ' 24' ' ' VAL . . . -117.3 48.61 0.92 Allowed Glycine 0 N--CA 1.475 1.252 0 N-CA-C 111.755 -0.538 . . . . 0.0 111.755 -179.402 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -61.73 -167.83 0.01 OUTLIER 'General case' 0 N--CA 1.468 0.45 0 O-C-N 123.843 0.378 . . . . 0.0 110.412 179.522 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 25.1 t-20 -71.06 80.4 0.67 Allowed 'General case' 0 N--CA 1.465 0.284 0 CA-C-N 116.492 -0.322 . . . . 0.0 110.176 179.557 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -77.85 143.76 37.55 Favored 'General case' 0 N--CA 1.473 0.704 0 N-CA-C 109.141 -0.689 . . . . 0.0 109.141 179.332 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.38 -167.51 0.94 Allowed Glycine 0 CA--C 1.525 0.664 0 N-CA-C 109.863 -1.295 . . . . 0.0 109.863 178.629 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.8 114.61 27.88 Favored 'General case' 0 N--CA 1.48 1.038 0 N-CA-C 109.696 -0.483 . . . . 0.0 109.696 179.839 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 64.9 mt -98.41 135.78 31.88 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.552 0 N-CA-C 107.078 -1.453 . . . . 0.0 107.078 178.982 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 34.1 pt -152.31 -176.14 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.734 0 CA-C-O 121.168 0.508 . . . . 0.0 111.18 -179.164 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.62 4.39 9.73 Favored Glycine 0 CA--C 1.524 0.597 0 N-CA-C 110.976 -0.85 . . . . 0.0 110.976 179.758 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 1.6 tt -74.28 127.18 32.33 Favored 'General case' 0 CA--C 1.545 0.767 0 N-CA-C 109.499 -0.556 . . . . 0.0 109.499 -179.604 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 28.5 ttt -163.75 149.81 11.43 Favored 'General case' 0 N--CA 1.465 0.279 0 N-CA-C 108.963 -0.755 . . . . 0.0 108.963 178.782 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.596 HG22 HG12 ' D' ' 36' ' ' VAL . 27.5 m -155.22 166.33 1.07 Allowed 'Isoleucine or valine' 0 C--N 1.347 0.482 0 N-CA-C 108.061 -1.088 . . . . 0.0 108.061 179.686 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.1 67.2 2.33 Favored Glycine 0 C--N 1.307 -1.045 0 CA-C-N 115.776 -0.647 . . . . 0.0 112.102 178.422 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.96 -173.23 24.85 Favored Glycine 0 N--CA 1.474 1.195 0 N-CA-C 110.85 -0.9 . . . . 0.0 110.85 179.089 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.561 ' H ' HG12 ' D' ' 39' ' ' VAL . 34.5 m -125.56 156.34 35.03 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.774 0 C-N-CA 123.393 0.677 . . . . 0.0 110.232 -179.645 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 27.1 t . . . . . 0 C--O 1.218 -0.589 0 CA-C-O 118.433 -0.794 . . . . 0.0 110.622 179.853 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' B' B ' 1' ' ' ASP . . . . . . . . . . . . . 14.4 m-20 . . . . . 0 N--CA 1.489 1.487 0 N-CA-C 109.084 -0.709 . . . . 0.0 109.084 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' B' B ' 2' ' ' ALA . . . . . . . . . . . . . . . -66.13 132.71 49.11 Favored 'General case' 0 CA--C 1.54 0.562 0 N-CA-C 110.075 -0.343 . . . . 0.0 110.075 -179.755 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 3' ' ' GLU . . . . . . . . . . . . . 44.7 tt0 -168.22 105.04 0.47 Allowed 'General case' 0 N--CA 1.475 0.8 0 N-CA-C 110.029 -0.36 . . . . 0.0 110.029 -179.245 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 38.9 m-85 -85.43 151.9 23.63 Favored 'General case' 0 N--CA 1.473 0.715 0 N-CA-C 110.13 -0.322 . . . . 0.0 110.13 179.513 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -143.06 140.44 30.94 Favored 'General case' 0 N--CA 1.483 1.198 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 179.574 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 41.9 t-80 -151.65 119.03 5.98 Favored 'General case' 0 N--CA 1.473 0.692 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 179.001 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 7' ' ' ASP . . . . . 0.448 ' O ' ' OG ' ' E' ' 8' ' ' SER . 4.3 m-20 -68.68 148.55 50.25 Favored 'General case' 0 CA--C 1.537 0.47 0 CA-C-N 116.343 -0.389 . . . . 0.0 110.677 179.907 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 8' ' ' SER . . . . . . . . . . . . . 53.8 p -167.59 -173.53 2.22 Favored 'General case' 0 N--CA 1.482 1.136 0 CA-C-O 120.966 0.412 . . . . 0.0 110.745 179.418 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.92 47.14 1.39 Allowed Glycine 0 N--CA 1.481 1.686 0 CA-C-N 115.985 -0.552 . . . . 0.0 112.126 179.758 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 48.8 p90 -65.57 132.88 49.96 Favored 'General case' 0 N--CA 1.472 0.644 0 CA-C-O 120.665 0.269 . . . . 0.0 111.562 179.819 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 45.3 mt-10 -92.14 152.22 20.01 Favored 'General case' 0 N--CA 1.475 0.824 0 C-N-CA 122.847 0.459 . . . . 0.0 109.816 178.475 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -153.15 128.13 1.5 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.547 0 N-CA-C 107.854 -1.165 . . . . 0.0 107.854 178.266 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 46.9 m-70 -135.46 147.71 49.0 Favored 'General case' 0 N--CA 1.492 1.65 0 CA-C-N 118.915 0.78 . . . . 0.0 111.379 -178.882 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 6.5 t60 -165.14 97.01 0.71 Allowed 'General case' 0 N--CA 1.48 1.052 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.604 179.345 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . 0.47 HE22 HG23 ' B' ' 36' ' ' VAL . 3.9 pt20 -101.51 -173.83 2.45 Favored 'General case' 0 CA--C 1.508 -0.638 0 N-CA-C 108.691 -0.855 . . . . 0.0 108.691 -179.764 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -170.22 95.82 0.25 Allowed 'General case' 0 N--CA 1.471 0.575 0 CA-C-N 114.727 -1.124 . . . . 0.0 108.321 178.324 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 6.5 mp -123.15 157.32 33.23 Favored 'General case' 0 N--CA 1.497 1.878 0 CA-C-O 121.73 0.776 . . . . 0.0 110.999 -178.134 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 60.9 t -112.37 127.65 69.46 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.098 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 177.44 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 27.0 m-85 -127.62 123.0 34.6 Favored 'General case' 0 N--CA 1.494 1.753 0 CA-C-N 119.707 1.14 . . . . 0.0 110.302 179.681 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 67.9 m-85 53.27 74.81 0.28 Allowed 'General case' 0 CA--C 1.537 0.476 0 CA-C-O 121.535 0.683 . . . . 0.0 111.919 178.475 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -80.48 -77.93 0.18 Allowed 'General case' 0 C--N 1.352 0.681 0 CA-C-N 115.004 -0.998 . . . . 0.0 110.218 -179.879 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 38.3 tt0 -113.53 100.45 8.52 Favored 'General case' 0 N--CA 1.47 0.565 0 N-CA-C 108.317 -0.994 . . . . 0.0 108.317 179.695 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -158.85 140.17 13.17 Favored 'General case' 0 N--CA 1.483 1.193 0 O-C-N 122.179 -0.326 . . . . 0.0 111.146 179.19 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 61.6 t -60.1 163.63 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.894 0 N-CA-C 108.121 -1.066 . . . . 0.0 108.121 177.072 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . 0.474 ' H ' ' HB ' ' E' ' 24' ' ' VAL . . . -117.23 48.32 0.95 Allowed Glycine 0 N--CA 1.476 1.309 0 N-CA-C 111.657 -0.577 . . . . 0.0 111.657 -179.353 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -61.87 -168.58 0.02 OUTLIER 'General case' 0 N--CA 1.469 0.505 0 O-C-N 123.783 0.343 . . . . 0.0 110.348 179.498 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 25.0 t-20 -70.61 81.03 0.59 Allowed 'General case' 0 N--CA 1.467 0.377 0 N-CA-C 110.078 -0.342 . . . . 0.0 110.078 179.636 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -78.48 144.32 35.85 Favored 'General case' 0 N--CA 1.473 0.706 0 N-CA-C 109.077 -0.712 . . . . 0.0 109.077 179.394 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.47 -167.47 0.97 Allowed Glycine 0 C--N 1.336 0.569 0 N-CA-C 109.933 -1.267 . . . . 0.0 109.933 178.676 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.91 114.56 27.89 Favored 'General case' 0 N--CA 1.479 0.988 0 N-CA-C 109.677 -0.49 . . . . 0.0 109.677 179.644 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 64.3 mt -98.51 135.36 33.66 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.507 0 N-CA-C 107.073 -1.454 . . . . 0.0 107.073 178.9 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . 0.413 HG22 ' H ' ' E' ' 32' ' ' ILE . 33.7 pt -151.99 -176.63 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.353 0.722 0 CA-C-N 116.026 -0.534 . . . . 0.0 111.191 -178.975 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.73 4.76 10.99 Favored Glycine 0 CA--C 1.523 0.57 0 N-CA-C 110.925 -0.87 . . . . 0.0 110.925 179.718 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 1.6 tt -74.56 126.71 31.37 Favored 'General case' 0 CA--C 1.546 0.813 0 N-CA-C 109.438 -0.578 . . . . 0.0 109.438 -179.744 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 28.2 ttt -163.05 149.97 12.78 Favored 'General case' 0 N--CA 1.465 0.323 0 N-CA-C 108.935 -0.765 . . . . 0.0 108.935 178.82 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 36' ' ' VAL . . . . . 0.599 HG22 HG12 ' E' ' 36' ' ' VAL . 27.3 m -155.3 166.34 1.06 Allowed 'Isoleucine or valine' 0 C--N 1.348 0.508 0 N-CA-C 108.015 -1.105 . . . . 0.0 108.015 179.706 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.73 67.43 2.21 Favored Glycine 0 C--N 1.307 -1.069 0 CA-C-N 115.742 -0.663 . . . . 0.0 112.094 178.434 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.65 -173.52 24.51 Favored Glycine 0 N--CA 1.474 1.213 0 N-CA-C 110.94 -0.864 . . . . 0.0 110.94 179.034 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 39' ' ' VAL . . . . . 0.585 ' H ' HG12 ' E' ' 39' ' ' VAL . 35.0 m -125.27 156.26 34.34 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.818 0 C-N-CA 123.42 0.688 . . . . 0.0 110.309 -179.591 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 26.6 t . . . . . 0 C--O 1.219 -0.514 0 CA-C-O 118.54 -0.743 . . . . 0.0 110.436 179.758 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' C' C ' 1' ' ' ASP . . . . . . . . . . . . . 14.4 m-20 . . . . . 0 N--CA 1.49 1.563 0 N-CA-C 108.783 -0.821 . . . . 0.0 108.783 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' C' C ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.99 132.74 49.28 Favored 'General case' 0 CA--C 1.539 0.535 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.243 -179.841 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 3' ' ' GLU . . . . . . . . . . . . . 44.6 tt0 -168.3 105.48 0.47 Allowed 'General case' 0 N--CA 1.474 0.768 0 N-CA-C 109.984 -0.376 . . . . 0.0 109.984 -179.275 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 39.7 m-85 -85.88 152.12 23.23 Favored 'General case' 0 N--CA 1.474 0.774 0 N-CA-C 110.064 -0.347 . . . . 0.0 110.064 179.573 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -143.35 140.42 30.51 Favored 'General case' 0 N--CA 1.483 1.182 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 179.726 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 42.0 t-80 -151.72 119.51 6.15 Favored 'General case' 0 N--CA 1.472 0.648 0 N-CA-C 109.317 -0.623 . . . . 0.0 109.317 179.114 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 7' ' ' ASP . . . . . 0.49 ' O ' ' OG ' ' F' ' 8' ' ' SER . 4.3 m-20 -69.22 148.32 50.01 Favored 'General case' 0 CA--C 1.537 0.472 0 CA-C-N 116.328 -0.397 . . . . 0.0 110.648 179.978 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 8' ' ' SER . . . . . . . . . . . . . 53.5 p -167.31 -173.4 2.25 Favored 'General case' 0 N--CA 1.484 1.246 0 CA-C-O 121.028 0.442 . . . . 0.0 110.692 179.43 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.62 47.1 1.43 Allowed Glycine 0 N--CA 1.482 1.734 0 CA-C-N 115.899 -0.592 . . . . 0.0 112.076 179.787 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 49.1 p90 -65.44 133.06 50.5 Favored 'General case' 0 N--CA 1.473 0.709 0 CA-C-O 120.671 0.272 . . . . 0.0 111.489 179.617 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 46.0 mt-10 -92.48 152.49 19.64 Favored 'General case' 0 N--CA 1.476 0.826 0 CA-C-O 121.1 0.476 . . . . 0.0 109.787 178.436 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -153.21 128.48 1.56 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.545 0 N-CA-C 107.786 -1.19 . . . . 0.0 107.786 178.307 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 47.0 m-70 -135.71 147.56 48.53 Favored 'General case' 0 N--CA 1.492 1.632 0 CA-C-N 118.925 0.784 . . . . 0.0 111.355 -179.081 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 6.5 t60 -164.96 97.17 0.73 Allowed 'General case' 0 N--CA 1.482 1.149 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.507 179.312 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 15' ' ' GLN . . . . . 0.456 HE22 HG23 ' C' ' 36' ' ' VAL . 3.9 pt20 -101.64 -173.75 2.43 Favored 'General case' 0 CA--C 1.507 -0.701 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 -179.749 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -170.22 95.85 0.25 Allowed 'General case' 0 N--CA 1.47 0.553 0 CA-C-N 114.618 -1.174 . . . . 0.0 108.292 178.406 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 6.5 mp -123.37 157.08 34.12 Favored 'General case' 0 N--CA 1.497 1.918 0 CA-C-O 121.745 0.784 . . . . 0.0 111.07 -178.157 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 60.7 t -112.33 127.61 69.43 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.076 0 N-CA-C 108.059 -1.089 . . . . 0.0 108.059 177.53 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 27.7 m-85 -127.58 123.02 34.73 Favored 'General case' 0 N--CA 1.494 1.75 0 CA-C-N 119.6 1.091 . . . . 0.0 110.34 179.614 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 67.0 m-85 53.29 74.75 0.29 Allowed 'General case' 0 CA--C 1.538 0.495 0 CA-C-O 121.55 0.69 . . . . 0.0 111.975 178.441 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -80.34 -78.22 0.18 Allowed 'General case' 0 C--N 1.348 0.537 0 CA-C-N 114.911 -1.04 . . . . 0.0 110.197 -179.791 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 38.0 tt0 -113.31 100.39 8.52 Favored 'General case' 0 N--CA 1.47 0.56 0 N-CA-C 108.161 -1.051 . . . . 0.0 108.161 179.653 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 4.4 p30 -158.71 140.08 13.27 Favored 'General case' 0 N--CA 1.484 1.231 0 O-C-N 122.202 -0.311 . . . . 0.0 111.204 179.085 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 24' ' ' VAL . . . . . 0.401 HG12 ' N ' ' C' ' 25' ' ' GLY . 61.8 t -60.0 163.72 0.92 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.852 0 N-CA-C 108.153 -1.054 . . . . 0.0 108.153 177.082 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 25' ' ' GLY . . . . . 0.472 ' H ' ' HB ' ' F' ' 24' ' ' VAL . . . -117.38 48.31 0.95 Allowed Glycine 0 N--CA 1.477 1.385 0 N-CA-C 111.637 -0.585 . . . . 0.0 111.637 -179.336 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -61.81 -167.99 0.01 OUTLIER 'General case' 0 N--CA 1.468 0.427 0 O-C-N 123.79 0.347 . . . . 0.0 110.361 179.658 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 25.0 t-20 -71.01 80.71 0.66 Allowed 'General case' 0 N--CA 1.465 0.304 0 N-CA-C 110.067 -0.345 . . . . 0.0 110.067 179.495 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -78.22 144.13 36.53 Favored 'General case' 0 N--CA 1.472 0.65 0 N-CA-C 109.117 -0.698 . . . . 0.0 109.117 179.415 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.55 -167.62 1.03 Allowed Glycine 0 CA--C 1.523 0.586 0 N-CA-C 109.965 -1.254 . . . . 0.0 109.965 178.788 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.6 114.34 27.31 Favored 'General case' 0 N--CA 1.48 1.071 0 N-CA-C 109.661 -0.496 . . . . 0.0 109.661 179.775 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 64.8 mt -98.42 135.45 33.16 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.546 0 N-CA-C 107.058 -1.46 . . . . 0.0 107.058 178.911 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 32' ' ' ILE . . . . . 0.414 HG22 ' H ' ' F' ' 32' ' ' ILE . 33.8 pt -152.01 -176.15 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.352 0.688 0 CA-C-N 115.998 -0.547 . . . . 0.0 111.189 -179.096 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.48 4.49 9.43 Favored Glycine 0 CA--C 1.524 0.615 0 N-CA-C 110.992 -0.843 . . . . 0.0 110.992 179.697 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 1.6 tt -74.27 127.27 32.57 Favored 'General case' 0 CA--C 1.547 0.831 0 N-CA-C 109.389 -0.597 . . . . 0.0 109.389 -179.776 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 28.3 ttt -163.52 150.06 12.02 Favored 'General case' 0 N--CA 1.467 0.397 0 N-CA-C 108.86 -0.792 . . . . 0.0 108.86 178.735 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 36' ' ' VAL . . . . . 0.593 HG22 HG12 ' F' ' 36' ' ' VAL . 27.3 m -155.59 166.05 1.07 Allowed 'Isoleucine or valine' 0 C--N 1.347 0.5 0 N-CA-C 108.06 -1.089 . . . . 0.0 108.06 179.657 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.06 67.23 2.32 Favored Glycine 0 C--N 1.307 -1.047 0 CA-C-N 115.721 -0.672 . . . . 0.0 112.077 178.503 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.71 -173.44 24.58 Favored Glycine 0 N--CA 1.473 1.139 0 N-CA-C 110.987 -0.845 . . . . 0.0 110.987 178.959 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 39' ' ' VAL . . . . . 0.587 ' H ' HG12 ' F' ' 39' ' ' VAL . 32.9 m -125.11 156.37 33.98 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.751 0 C-N-CA 123.386 0.674 . . . . 0.0 110.31 -179.572 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 25.6 t . . . . . 0 C--O 1.218 -0.576 0 CA-C-O 118.424 -0.798 . . . . 0.0 110.579 179.77 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' D' D ' 1' ' ' ASP . . . . . . . . . . . . . 14.7 m-20 . . . . . 0 N--CA 1.49 1.554 0 N-CA-C 109.216 -0.661 . . . . 0.0 109.216 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' D' D ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.28 131.05 46.21 Favored 'General case' 0 CA--C 1.535 0.388 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.541 179.804 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 3' ' ' GLU . . . . . . . . . . . . . 44.3 tt0 -169.31 107.98 0.42 Allowed 'General case' 0 N--CA 1.472 0.641 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 -179.953 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 41.4 m-85 -90.2 156.98 17.94 Favored 'General case' 0 C--N 1.358 0.971 0 N-CA-C 108.775 -0.824 . . . . 0.0 108.775 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -145.24 139.15 26.95 Favored 'General case' 0 N--CA 1.478 0.927 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.144 -179.846 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 38.7 t-80 -149.47 123.46 9.4 Favored 'General case' 0 CA--C 1.544 0.744 0 N-CA-C 108.42 -0.956 . . . . 0.0 108.42 175.352 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 7' ' ' ASP . . . . . 0.586 ' O ' ' OG ' ' G' ' 8' ' ' SER . 3.2 m-20 -63.79 133.02 52.69 Favored 'General case' 0 C--N 1.32 -0.702 0 C-N-CA 126.769 2.027 . . . . 0.0 113.965 174.817 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' D' D ' 8' ' ' SER . . . . . 0.499 ' OG ' ' O ' ' A' ' 7' ' ' ASP . 53.9 p -154.61 -170.57 3.56 Favored 'General case' 0 N--CA 1.487 1.41 0 CA-C-N 119.397 0.999 . . . . 0.0 111.12 175.622 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.2 47.77 1.2 Allowed Glycine 0 N--CA 1.481 1.651 0 N-CA-C 110.652 -0.979 . . . . 0.0 110.652 174.445 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 51.1 p90 -60.91 131.48 50.81 Favored 'General case' 0 N--CA 1.471 0.614 0 N-CA-C 112.804 0.668 . . . . 0.0 112.804 178.075 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 45.7 mt-10 -89.49 150.83 22.29 Favored 'General case' 0 N--CA 1.481 1.094 0 CA-C-N 117.825 0.284 . . . . 0.0 110.809 175.351 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.0 p -149.46 129.84 4.28 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.611 0 N-CA-C 107.49 -1.3 . . . . 0.0 107.49 173.417 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 42.9 m-70 -129.96 150.74 51.11 Favored 'General case' 0 N--CA 1.483 1.215 0 CA-C-N 118.198 0.454 . . . . 0.0 111.994 176.584 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 6.6 t60 -164.98 104.47 0.78 Allowed 'General case' 0 N--CA 1.483 1.186 0 N-CA-C 108.844 -0.799 . . . . 0.0 108.844 172.171 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 15' ' ' GLN . . . . . 0.473 HE22 HG23 ' D' ' 36' ' ' VAL . 3.9 pt20 -105.12 -176.1 2.98 Favored 'General case' 0 CA--C 1.502 -0.871 0 N-CA-C 108.487 -0.931 . . . . 0.0 108.487 179.177 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -166.23 104.52 0.64 Allowed 'General case' 0 N--CA 1.466 0.335 0 N-CA-C 106.205 -1.776 . . . . 0.0 106.205 174.131 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 5.4 mp -130.35 154.02 48.09 Favored 'General case' 0 N--CA 1.5 2.043 0 CA-C-O 122.062 0.934 . . . . 0.0 110.711 179.458 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 34.5 t -101.25 131.56 48.76 Favored 'Isoleucine or valine' 0 C--O 1.262 1.714 0 CA-C-O 116.779 -1.581 . . . . 0.0 109.686 174.097 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 26.2 m-85 -130.09 126.45 37.62 Favored 'General case' 0 N--CA 1.488 1.457 0 CA-C-N 120.126 1.33 . . . . 0.0 109.864 173.73 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 67.4 m-85 55.48 71.3 0.56 Allowed 'General case' 0 C--O 1.239 0.542 0 CA-C-N 115.712 -0.676 . . . . 0.0 111.837 176.206 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -81.6 -73.43 0.38 Allowed 'General case' 0 N--CA 1.473 0.718 0 CA-C-O 118.585 -0.721 . . . . 0.0 111.063 -177.61 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 38.6 tt0 -116.64 104.28 11.23 Favored 'General case' 0 N--CA 1.482 1.164 0 N-CA-C 106.361 -1.718 . . . . 0.0 106.361 176.324 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -152.15 139.92 19.9 Favored 'General case' 0 N--CA 1.474 0.756 0 CA-C-O 116.8 -1.571 . . . . 0.0 113.647 177.815 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 24' ' ' VAL . . . . . 0.469 ' HB ' ' H ' ' A' ' 25' ' ' GLY . 66.7 t -62.45 166.04 0.98 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.294 0 CA-C-N 121.037 1.744 . . . . 0.0 107.983 174.905 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' D' D ' 25' ' ' GLY . . . . . 0.526 ' H ' ' HB ' ' G' ' 24' ' ' VAL . . . -116.83 51.08 0.75 Allowed Glycine 0 N--CA 1.479 1.52 0 CA-C-O 119.081 -0.844 . . . . 0.0 111.738 178.536 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -57.75 -171.21 0.01 OUTLIER 'General case' 0 C--N 1.323 -0.58 0 C-N-CA 123.618 0.767 . . . . 0.0 111.722 176.054 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 25.8 t-20 -72.11 86.52 1.05 Allowed 'General case' 0 C--N 1.346 0.435 0 N-CA-C 108.585 -0.894 . . . . 0.0 108.585 177.688 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 97.5 mttt -83.53 146.48 28.32 Favored 'General case' 0 N--CA 1.474 0.775 0 N-CA-C 108.056 -1.09 . . . . 0.0 108.056 179.196 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -62.95 -165.4 0.56 Allowed Glycine 0 C--N 1.335 0.476 0 N-CA-C 110.519 -1.032 . . . . 0.0 110.519 179.225 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -101.78 115.95 31.65 Favored 'General case' 0 N--CA 1.471 0.606 0 N-CA-C 109.235 -0.654 . . . . 0.0 109.235 179.594 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 72.6 mt -102.71 142.77 16.16 Favored 'Isoleucine or valine' 0 C--N 1.356 0.891 0 N-CA-C 104.544 -2.391 . . . . 0.0 104.544 179.838 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 32' ' ' ILE . . . . . 0.459 HG22 ' H ' ' G' ' 32' ' ' ILE . 34.8 pt -158.49 -176.96 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.209 0 CA-C-O 120.891 0.377 . . . . 0.0 110.152 -177.537 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 64.31 4.38 12.19 Favored Glycine 0 C--O 1.247 0.958 0 N-CA-C 110.087 -1.205 . . . . 0.0 110.087 -179.011 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 2.0 tt -76.37 132.94 40.02 Favored 'General case' 0 C--N 1.363 1.181 0 N-CA-C 107.185 -1.413 . . . . 0.0 107.185 -177.974 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 35' ' ' MET . . . . . 0.404 ' O ' HG13 ' D' ' 36' ' ' VAL . 28.2 ttt -158.52 161.53 37.36 Favored 'General case' 0 C--O 1.221 -0.419 0 CA-C-O 118.318 -0.849 . . . . 0.0 108.734 173.086 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' D' D ' 36' ' ' VAL . . . . . 0.635 HG22 HG12 ' G' ' 36' ' ' VAL . 27.6 m -164.74 165.07 0.61 Allowed 'Isoleucine or valine' 0 CA--C 1.519 -0.247 0 N-CA-C 107.624 -1.25 . . . . 0.0 107.624 175.835 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 60.36 64.1 4.43 Favored Glycine 0 CA--C 1.524 0.6 0 C-N-CA 119.576 -1.297 . . . . 0.0 113.006 178.572 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 140.95 -171.61 24.04 Favored Glycine 0 N--CA 1.476 1.361 0 CA-C-N 117.328 0.564 . . . . 0.0 111.95 -179.175 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 39' ' ' VAL . . . . . 0.587 ' H ' HG12 ' G' ' 39' ' ' VAL . 35.4 m -128.17 153.5 37.65 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.883 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 -176.664 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 25.3 t . . . . . 0 C--O 1.225 -0.204 0 CA-C-O 116.686 -1.626 . . . . 0.0 109.773 178.118 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' E' E ' 1' ' ' ASP . . . . . . . . . . . . . 15.4 m-20 . . . . . 0 N--CA 1.488 1.457 0 N-CA-C 109.5 -0.555 . . . . 0.0 109.5 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' E' E ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.5 129.8 41.24 Favored 'General case' 0 N--CA 1.468 0.461 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.423 -179.892 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' E' E ' 3' ' ' GLU . . . . . . . . . . . . . 44.1 tt0 -167.14 105.29 0.56 Allowed 'General case' 0 C--O 1.213 -0.839 0 CA-C-N 116.775 -0.193 . . . . 0.0 110.634 -179.678 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 37.9 m-85 -86.62 151.76 23.16 Favored 'General case' 0 N--CA 1.475 0.825 0 N-CA-C 110.166 -0.309 . . . . 0.0 110.166 179.353 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' E' E ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -142.74 140.86 31.61 Favored 'General case' 0 N--CA 1.484 1.257 0 CA-C-O 120.952 0.405 . . . . 0.0 109.997 179.576 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 41.5 t-80 -151.68 119.21 6.05 Favored 'General case' 0 N--CA 1.472 0.625 0 N-CA-C 109.228 -0.656 . . . . 0.0 109.228 178.894 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' E' E ' 7' ' ' ASP . . . . . 0.432 ' O ' ' OG ' ' H' ' 8' ' ' SER . 4.0 m-20 -69.47 148.39 49.59 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 116.389 -0.368 . . . . 0.0 110.82 -179.982 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' E' E ' 8' ' ' SER . . . . . 0.448 ' OG ' ' O ' ' B' ' 7' ' ' ASP . 51.8 p -168.1 -172.13 1.71 Allowed 'General case' 0 N--CA 1.485 1.31 0 CA-C-O 121.153 0.501 . . . . 0.0 110.857 178.995 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.17 47.61 1.31 Allowed Glycine 0 N--CA 1.479 1.516 0 CA-C-N 115.879 -0.601 . . . . 0.0 111.942 179.622 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 46.8 p90 -65.2 133.16 50.91 Favored 'General case' 0 N--CA 1.474 0.762 0 N-CA-C 111.894 0.331 . . . . 0.0 111.894 -179.886 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 46.2 mt-10 -91.84 152.33 20.16 Favored 'General case' 0 N--CA 1.479 0.995 0 CA-C-O 121.211 0.529 . . . . 0.0 109.742 178.007 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -154.34 127.47 1.16 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.586 0 N-CA-C 107.799 -1.186 . . . . 0.0 107.799 178.103 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 44.8 m-70 -135.78 145.71 46.82 Favored 'General case' 0 N--CA 1.481 1.116 0 CA-C-O 120.768 0.318 . . . . 0.0 111.678 -177.861 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 6.4 t60 -163.94 97.1 0.83 Allowed 'General case' 0 N--CA 1.485 1.318 0 CA-C-N 116.374 -0.375 . . . . 0.0 110.61 179.531 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' E' E ' 15' ' ' GLN . . . . . 0.502 HE22 HG23 ' E' ' 36' ' ' VAL . 3.9 pt20 -101.3 -173.97 2.49 Favored 'General case' 0 CA--C 1.509 -0.634 0 N-CA-C 108.855 -0.794 . . . . 0.0 108.855 -179.77 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -169.85 94.95 0.27 Allowed 'General case' 0 N--CA 1.474 0.739 0 CA-C-N 114.702 -1.136 . . . . 0.0 108.423 178.468 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 6.4 mp -122.05 156.92 32.53 Favored 'General case' 0 N--CA 1.494 1.772 0 CA-C-O 121.649 0.738 . . . . 0.0 111.532 -177.641 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 48.0 t -113.9 124.35 70.47 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.231 0 N-CA-C 108.178 -1.045 . . . . 0.0 108.178 177.168 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 30.5 m-85 -124.83 121.78 35.54 Favored 'General case' 0 N--CA 1.488 1.427 0 CA-C-O 120.83 0.348 . . . . 0.0 111.086 -179.729 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 68.8 m-85 54.76 73.61 0.4 Allowed 'General case' 0 N--CA 1.467 0.407 0 CA-C-N 115.941 -0.572 . . . . 0.0 111.609 178.173 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -78.53 -78.6 0.14 Allowed 'General case' 0 CA--C 1.535 0.379 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.108 -179.615 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 38.5 tt0 -112.8 101.07 9.17 Favored 'General case' 0 C--N 1.324 -0.532 0 N-CA-C 108.257 -1.016 . . . . 0.0 108.257 179.905 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -158.39 140.12 13.71 Favored 'General case' 0 C--O 1.205 -1.274 0 O-C-N 122.282 -0.262 . . . . 0.0 111.5 178.97 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' E' E ' 24' ' ' VAL . . . . . 0.474 ' HB ' ' H ' ' B' ' 25' ' ' GLY . 57.6 t -58.65 168.53 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.867 0 N-CA-C 107.619 -1.252 . . . . 0.0 107.619 176.943 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' E' E ' 25' ' ' GLY . . . . . 0.432 ' H ' ' HB ' ' H' ' 24' ' ' VAL . . . -122.45 49.35 0.89 Allowed Glycine 0 N--CA 1.474 1.212 0 N-CA-C 110.783 -0.927 . . . . 0.0 110.783 -179.296 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -63.24 -167.83 0.02 OUTLIER 'General case' 0 N--CA 1.469 0.489 0 CA-C-O 120.763 0.316 . . . . 0.0 110.466 179.805 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 25.4 t-20 -70.07 77.29 0.5 Allowed 'General case' 0 N--CA 1.466 0.365 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.422 179.961 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -75.17 144.45 42.73 Favored 'General case' 0 N--CA 1.476 0.855 0 N-CA-C 109.552 -0.536 . . . . 0.0 109.552 179.438 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.34 -166.9 1.19 Allowed Glycine 0 CA--C 1.521 0.454 0 N-CA-C 110.439 -1.064 . . . . 0.0 110.439 178.548 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.68 114.15 27.06 Favored 'General case' 0 N--CA 1.472 0.646 0 N-CA-C 109.848 -0.426 . . . . 0.0 109.848 179.769 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 65.6 mt -98.47 135.52 32.97 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.324 0 N-CA-C 106.832 -1.544 . . . . 0.0 106.832 178.979 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' E' E ' 32' ' ' ILE . . . . . 0.45 HG22 ' H ' ' H' ' 32' ' ' ILE . 36.2 pt -152.01 -174.05 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.208 0 CA-C-O 121.111 0.481 . . . . 0.0 110.713 -179.337 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.29 5.16 5.74 Favored Glycine 0 CA--C 1.529 0.942 0 CA-C-N 115.58 -0.736 . . . . 0.0 111.408 -179.731 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 1.6 tt -74.25 126.9 31.63 Favored 'General case' 0 CA--C 1.547 0.852 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 -179.559 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 28.5 ttt -162.74 151.09 14.26 Favored 'General case' 0 C--O 1.209 -1.05 0 N-CA-C 108.995 -0.742 . . . . 0.0 108.995 178.769 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' E' E ' 36' ' ' VAL . . . . . 0.661 HG22 HG12 ' H' ' 36' ' ' VAL . 35.4 m -156.62 166.23 0.94 Allowed 'Isoleucine or valine' 0 C--N 1.343 0.292 0 N-CA-C 108.354 -0.98 . . . . 0.0 108.354 179.747 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.72 66.87 2.53 Favored Glycine 0 C--N 1.307 -1.075 0 CA-C-N 115.576 -0.738 . . . . 0.0 111.997 178.442 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 144.1 -173.12 24.99 Favored Glycine 0 N--CA 1.475 1.281 0 N-CA-C 111.23 -0.748 . . . . 0.0 111.23 178.931 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' E' E ' 39' ' ' VAL . . . . . 0.596 ' H ' HG12 ' H' ' 39' ' ' VAL . 34.2 m -125.46 155.31 34.52 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.753 0 C-N-CA 123.405 0.682 . . . . 0.0 110.429 -179.138 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 26.4 t . . . . . 0 C--O 1.219 -0.526 0 O-C-N 124.062 0.851 . . . . 0.0 110.467 179.505 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' F' F ' 1' ' ' ASP . . . . . . . . . . . . . 14.5 m-20 . . . . . 0 N--CA 1.49 1.562 0 N-CA-C 109.302 -0.629 . . . . 0.0 109.302 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' F' F ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.58 130.19 42.72 Favored 'General case' 0 CA--C 1.536 0.42 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.354 179.982 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' F' F ' 3' ' ' GLU . . . . . . . . . . . . . 44.3 tt0 -167.53 106.05 0.54 Allowed 'General case' 0 C--O 1.213 -0.838 0 CA-C-N 116.71 -0.223 . . . . 0.0 110.505 -179.767 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 36.2 m-85 -87.49 151.77 22.76 Favored 'General case' 0 N--CA 1.474 0.75 0 N-CA-C 110.003 -0.369 . . . . 0.0 110.003 179.481 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' F' F ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -142.64 141.02 31.83 Favored 'General case' 0 N--CA 1.48 1.051 0 CA-C-O 120.884 0.373 . . . . 0.0 110.175 179.509 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 42.2 t-80 -151.9 118.95 5.85 Favored 'General case' 0 N--CA 1.472 0.639 0 N-CA-C 109.343 -0.614 . . . . 0.0 109.343 179.046 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' F' F ' 7' ' ' ASP . . . . . 0.478 ' O ' ' OG ' ' I' ' 8' ' ' SER . 4.0 m-20 -69.34 148.36 49.8 Favored 'General case' 0 N--CA 1.465 0.324 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.824 -179.902 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' F' F ' 8' ' ' SER . . . . . 0.49 ' OG ' ' O ' ' C' ' 7' ' ' ASP . 50.5 p -168.1 -172.03 1.68 Allowed 'General case' 0 N--CA 1.486 1.335 0 CA-C-O 121.119 0.485 . . . . 0.0 110.953 179.008 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.89 47.16 1.39 Allowed Glycine 0 N--CA 1.479 1.553 0 CA-C-N 115.884 -0.598 . . . . 0.0 111.953 179.629 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 46.2 p90 -64.73 133.4 52.0 Favored 'General case' 0 CA--C 1.543 0.68 0 N-CA-C 111.832 0.308 . . . . 0.0 111.832 -179.924 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 46.2 mt-10 -91.91 152.17 20.19 Favored 'General case' 0 N--CA 1.481 1.081 0 CA-C-O 121.19 0.519 . . . . 0.0 109.736 177.997 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -154.12 127.24 1.15 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.599 0 N-CA-C 107.838 -1.171 . . . . 0.0 107.838 178.131 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 44.5 m-70 -135.53 146.04 47.66 Favored 'General case' 0 N--CA 1.483 1.201 0 CA-C-O 120.88 0.372 . . . . 0.0 111.631 -177.916 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 6.4 t60 -164.07 96.94 0.81 Allowed 'General case' 0 N--CA 1.486 1.369 0 CA-C-N 116.436 -0.347 . . . . 0.0 110.674 179.385 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' F' F ' 15' ' ' GLN . . . . . 0.483 HE22 HG23 ' F' ' 36' ' ' VAL . 3.9 pt20 -101.18 -173.84 2.47 Favored 'General case' 0 CA--C 1.507 -0.698 0 N-CA-C 108.871 -0.789 . . . . 0.0 108.871 -179.814 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -169.87 94.93 0.27 Allowed 'General case' 0 N--CA 1.473 0.677 0 CA-C-N 114.609 -1.178 . . . . 0.0 108.443 178.42 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 6.3 mp -121.95 157.07 32.06 Favored 'General case' 0 N--CA 1.494 1.764 0 CA-C-O 121.685 0.755 . . . . 0.0 111.554 -177.676 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 48.1 t -114.02 124.27 70.5 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.217 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 177.162 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 30.0 m-85 -124.71 122.03 36.32 Favored 'General case' 0 N--CA 1.488 1.431 0 CA-C-O 120.863 0.364 . . . . 0.0 110.983 -179.741 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 68.9 m-85 54.61 74.18 0.36 Allowed 'General case' 0 C--N 1.344 0.362 0 CA-C-N 115.873 -0.603 . . . . 0.0 111.705 178.166 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -79.1 -78.5 0.15 Allowed 'General case' 0 CA--C 1.535 0.388 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.197 -179.56 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 38.4 tt0 -112.91 101.03 9.11 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 179.822 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -158.29 139.84 13.59 Favored 'General case' 0 C--O 1.208 -1.124 0 O-C-N 122.279 -0.263 . . . . 0.0 111.572 179.099 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' F' F ' 24' ' ' VAL . . . . . 0.472 ' HB ' ' H ' ' C' ' 25' ' ' GLY . 58.3 t -58.55 168.08 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.891 0 N-CA-C 107.507 -1.294 . . . . 0.0 107.507 177.037 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' F' F ' 25' ' ' GLY . . . . . 0.436 ' H ' ' HB ' ' I' ' 24' ' ' VAL . . . -122.14 49.48 0.89 Allowed Glycine 0 N--CA 1.477 1.43 0 N-CA-C 110.787 -0.925 . . . . 0.0 110.787 -179.427 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -63.27 -167.56 0.02 OUTLIER 'General case' 0 N--CA 1.469 0.509 0 CA-C-O 120.642 0.258 . . . . 0.0 110.441 179.796 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 25.5 t-20 -70.26 77.12 0.53 Allowed 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.451 179.916 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -75.02 144.77 42.91 Favored 'General case' 0 N--CA 1.476 0.845 0 N-CA-C 109.579 -0.526 . . . . 0.0 109.579 179.335 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.46 -167.02 1.25 Allowed Glycine 0 CA--C 1.522 0.484 0 N-CA-C 110.494 -1.042 . . . . 0.0 110.494 178.64 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.17 113.96 26.47 Favored 'General case' 0 N--CA 1.473 0.711 0 N-CA-C 109.808 -0.442 . . . . 0.0 109.808 179.665 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 66.5 mt -98.43 135.27 33.89 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.388 0 N-CA-C 106.837 -1.542 . . . . 0.0 106.837 178.762 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' F' F ' 32' ' ' ILE . . . . . 0.445 HG22 ' H ' ' I' ' 32' ' ' ILE . 35.2 pt -151.87 -174.29 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.198 0 CA-C-O 121.248 0.547 . . . . 0.0 110.723 -179.373 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.35 5.45 6.31 Favored Glycine 0 CA--C 1.528 0.901 0 CA-C-N 115.55 -0.75 . . . . 0.0 111.443 -179.774 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 1.6 tt -74.42 127.05 32.07 Favored 'General case' 0 CA--C 1.549 0.913 0 N-CA-C 109.467 -0.568 . . . . 0.0 109.467 -179.741 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 28.4 ttt -162.69 151.32 14.62 Favored 'General case' 0 C--O 1.209 -1.045 0 N-CA-C 108.963 -0.755 . . . . 0.0 108.963 178.605 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' F' F ' 36' ' ' VAL . . . . . 0.642 HG22 HG12 ' I' ' 36' ' ' VAL . 35.4 m -156.82 166.13 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.344 0.347 0 N-CA-C 108.312 -0.995 . . . . 0.0 108.312 179.77 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.78 67.0 2.44 Favored Glycine 0 C--N 1.307 -1.038 0 CA-C-N 115.595 -0.729 . . . . 0.0 112.003 178.49 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.98 -173.0 24.96 Favored Glycine 0 N--CA 1.474 1.179 0 N-CA-C 111.251 -0.74 . . . . 0.0 111.251 178.992 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' F' F ' 39' ' ' VAL . . . . . 0.597 ' H ' HG12 ' I' ' 39' ' ' VAL . 34.2 m -125.62 155.51 34.93 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.729 0 C-N-CA 123.336 0.654 . . . . 0.0 110.365 -179.166 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 25.3 t . . . . . 0 C--O 1.219 -0.551 0 O-C-N 124.004 0.815 . . . . 0.0 110.423 179.593 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' G' G ' 1' ' ' ASP . . . . . . . . . . . . . 14.8 m-20 . . . . . 0 N--CA 1.492 1.664 0 N-CA-C 109.336 -0.616 . . . . 0.0 109.336 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' G' G ' 2' ' ' ALA . . . . . . . . . . . . . . . -63.34 128.64 36.77 Favored 'General case' 0 N--CA 1.468 0.473 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.666 179.692 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' G' G ' 3' ' ' GLU . . . . . . . . . . . . . 43.7 tt0 -167.86 107.0 0.53 Allowed 'General case' 0 N--CA 1.473 0.711 0 CA-C-O 120.495 0.188 . . . . 0.0 110.828 179.732 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 40.2 m-85 -89.19 151.51 22.12 Favored 'General case' 0 N--CA 1.474 0.768 0 N-CA-C 109.591 -0.522 . . . . 0.0 109.591 179.288 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' G' G ' 5' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -143.0 140.56 31.07 Favored 'General case' 0 N--CA 1.481 1.1 0 C-N-CA 122.498 0.319 . . . . 0.0 110.337 179.837 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 42.3 t-80 -151.27 120.22 6.66 Favored 'General case' 0 N--CA 1.474 0.739 0 N-CA-C 109.441 -0.578 . . . . 0.0 109.441 178.938 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -71.23 144.31 50.12 Favored 'General case' 0 N--CA 1.469 0.51 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.231 -179.829 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' G' G ' 8' ' ' SER . . . . . 0.586 ' OG ' ' O ' ' D' ' 7' ' ' ASP . 45.2 p -165.07 -170.52 1.95 Allowed 'General case' 0 N--CA 1.476 0.832 0 CA-C-O 121.037 0.446 . . . . 0.0 110.545 178.792 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.68 48.0 1.33 Allowed Glycine 0 N--CA 1.479 1.548 0 N-CA-C 111.485 -0.646 . . . . 0.0 111.485 179.468 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 48.8 p90 -65.77 133.43 50.99 Favored 'General case' 0 CA--C 1.543 0.676 0 N-CA-C 111.694 0.257 . . . . 0.0 111.694 -179.694 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 46.1 mt-10 -92.32 151.43 20.29 Favored 'General case' 0 N--CA 1.48 1.043 0 CA-C-O 121.146 0.498 . . . . 0.0 110.163 178.582 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -154.75 127.3 1.06 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.966 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 178.298 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 45.7 m-70 -134.74 147.34 50.01 Favored 'General case' 0 N--CA 1.478 0.965 0 CA-C-N 115.62 -0.718 . . . . 0.0 111.486 -178.291 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 6.6 t60 -165.42 97.35 0.69 Allowed 'General case' 0 N--CA 1.483 1.204 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.242 178.83 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' G' G ' 15' ' ' GLN . . . . . 0.44 HE22 HG23 ' G' ' 36' ' ' VAL . 3.9 pt20 -101.59 -173.67 2.41 Favored 'General case' 0 CA--C 1.507 -0.699 0 N-CA-C 108.662 -0.866 . . . . 0.0 108.662 -179.58 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -170.55 94.22 0.21 Allowed 'General case' 0 N--CA 1.473 0.693 0 CA-C-N 114.654 -1.157 . . . . 0.0 108.076 178.637 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 6.3 mp -121.33 155.85 33.85 Favored 'General case' 0 N--CA 1.498 1.93 0 CA-C-O 121.237 0.541 . . . . 0.0 111.814 -177.8 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 42.9 t -113.43 125.15 70.65 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.011 0 CA-C-N 114.74 -1.118 . . . . 0.0 108.116 176.566 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 31.8 m-85 -125.96 121.54 33.38 Favored 'General case' 0 C--N 1.367 1.337 0 CA-C-N 115.664 -0.698 . . . . 0.0 111.083 -179.446 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 68.4 m-85 54.86 73.11 0.43 Allowed 'General case' 0 N--CA 1.467 0.416 0 CA-C-N 115.858 -0.61 . . . . 0.0 111.545 178.036 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.58 -77.95 0.14 Allowed 'General case' 0 N--CA 1.472 0.64 0 O-C-N 122.212 -0.305 . . . . 0.0 110.355 -179.25 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 38.4 tt0 -113.23 101.14 9.14 Favored 'General case' 0 C--N 1.323 -0.549 0 N-CA-C 107.95 -1.13 . . . . 0.0 107.95 179.822 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -158.29 141.02 14.61 Favored 'General case' 0 N--CA 1.477 0.915 0 O-C-N 122.337 -0.227 . . . . 0.0 111.487 179.063 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' G' G ' 24' ' ' VAL . . . . . 0.526 ' HB ' ' H ' ' D' ' 25' ' ' GLY . 59.9 t -60.28 167.07 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.762 0 N-CA-C 107.641 -1.244 . . . . 0.0 107.641 177.26 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' G' G ' 25' ' ' GLY . . . . . 0.426 ' N ' HG12 ' G' ' 24' ' ' VAL . . . -120.45 49.61 0.87 Allowed Glycine 0 N--CA 1.479 1.566 0 N-CA-C 110.504 -1.038 . . . . 0.0 110.504 -179.452 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -64.02 -167.27 0.02 OUTLIER 'General case' 0 N--CA 1.471 0.598 0 CA-C-N 116.953 0.376 . . . . 0.0 110.061 179.829 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 25.8 t-20 -70.45 77.12 0.56 Allowed 'General case' 0 CA--C 1.535 0.401 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.471 179.943 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -74.53 144.14 44.21 Favored 'General case' 0 N--CA 1.476 0.86 0 N-CA-C 109.653 -0.499 . . . . 0.0 109.653 179.361 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.39 -166.11 1.07 Allowed Glycine 0 C--N 1.337 0.619 0 N-CA-C 110.037 -1.225 . . . . 0.0 110.037 178.707 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -98.84 114.06 26.47 Favored 'General case' 0 N--CA 1.471 0.575 0 C-N-CA 122.672 0.389 . . . . 0.0 110.447 179.843 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 67.6 mt -99.16 135.51 34.02 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.698 0 N-CA-C 106.856 -1.535 . . . . 0.0 106.856 178.831 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' G' G ' 32' ' ' ILE . . . . . 0.459 ' H ' HG22 ' D' ' 32' ' ' ILE . 34.1 pt -152.48 -173.92 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 CA-C-N 119.891 1.223 . . . . 0.0 109.878 -179.725 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.15 5.31 7.61 Favored Glycine 0 N--CA 1.468 0.773 0 N-CA-C 111.061 -0.816 . . . . 0.0 111.061 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 1.6 tt -75.04 125.85 29.79 Favored 'General case' 0 CA--C 1.545 0.775 0 N-CA-C 109.524 -0.547 . . . . 0.0 109.524 -179.611 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 27.4 ttt -161.52 152.66 18.42 Favored 'General case' 0 C--O 1.21 -0.986 0 N-CA-C 108.775 -0.824 . . . . 0.0 108.775 178.503 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' G' G ' 36' ' ' VAL . . . . . 0.635 HG12 HG22 ' D' ' 36' ' ' VAL . 35.8 m -157.26 165.17 1.0 Allowed 'Isoleucine or valine' 0 C--N 1.346 0.429 0 N-CA-C 108.528 -0.916 . . . . 0.0 108.528 -179.675 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.39 67.99 1.92 Allowed Glycine 0 C--N 1.307 -1.031 0 CA-C-N 115.531 -0.759 . . . . 0.0 112.206 178.26 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.99 -171.66 25.45 Favored Glycine 0 N--CA 1.476 1.315 0 N-CA-C 110.621 -0.991 . . . . 0.0 110.621 178.998 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' G' G ' 39' ' ' VAL . . . . . 0.587 HG12 ' H ' ' D' ' 39' ' ' VAL . 34.7 m -126.93 156.03 38.04 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.911 0 C-N-CA 123.069 0.548 . . . . 0.0 110.631 -179.357 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 31.5 t . . . . . 0 C--O 1.219 -0.546 0 O-C-N 123.946 0.779 . . . . 0.0 110.737 179.218 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' H' H ' 1' ' ' ASP . . . . . . . . . . . . . 15.1 m-20 . . . . . 0 N--CA 1.49 1.567 0 N-CA-C 109.446 -0.575 . . . . 0.0 109.446 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' H' H ' 2' ' ' ALA . . . . . . . . . . . . . . . -63.0 128.63 36.74 Favored 'General case' 0 N--CA 1.469 0.487 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.587 179.766 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' H' H ' 3' ' ' GLU . . . . . . . . . . . . . 43.9 tt0 -167.82 106.41 0.53 Allowed 'General case' 0 N--CA 1.471 0.612 0 CA-C-O 120.581 0.229 . . . . 0.0 110.666 179.678 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 41.0 m-85 -88.57 151.5 22.46 Favored 'General case' 0 N--CA 1.473 0.706 0 N-CA-C 109.627 -0.508 . . . . 0.0 109.627 179.074 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' H' H ' 5' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -142.91 141.27 31.46 Favored 'General case' 0 N--CA 1.484 1.273 0 C-N-CA 122.585 0.354 . . . . 0.0 110.169 179.747 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 42.0 t-80 -151.98 120.1 6.28 Favored 'General case' 0 N--CA 1.474 0.731 0 N-CA-C 109.36 -0.607 . . . . 0.0 109.36 179.018 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -71.16 144.17 50.29 Favored 'General case' 0 N--CA 1.469 0.519 0 CA-C-N 116.321 -0.4 . . . . 0.0 111.303 -179.777 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' H' H ' 8' ' ' SER . . . . . 0.432 ' OG ' ' O ' ' E' ' 7' ' ' ASP . 53.1 p -164.77 -170.93 2.12 Favored 'General case' 0 N--CA 1.474 0.751 0 CA-C-O 121.06 0.457 . . . . 0.0 110.472 178.783 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.22 47.35 1.33 Allowed Glycine 0 N--CA 1.48 1.567 0 CA-C-N 115.848 -0.614 . . . . 0.0 111.713 179.47 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 49.2 p90 -65.47 133.09 50.53 Favored 'General case' 0 N--CA 1.471 0.594 0 N-CA-C 111.792 0.293 . . . . 0.0 111.792 -179.627 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 46.2 mt-10 -92.0 151.41 20.49 Favored 'General case' 0 N--CA 1.479 0.982 0 CA-C-O 121.115 0.483 . . . . 0.0 110.225 178.568 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -154.65 127.82 1.16 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.027 0 N-CA-C 107.851 -1.166 . . . . 0.0 107.851 178.233 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 46.6 m-70 -135.29 147.3 49.16 Favored 'General case' 0 N--CA 1.478 0.956 0 CA-C-N 115.653 -0.703 . . . . 0.0 111.409 -178.239 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 6.5 t60 -165.47 97.31 0.68 Allowed 'General case' 0 N--CA 1.483 1.195 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.222 178.887 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' H' H ' 15' ' ' GLN . . . . . 0.431 HE22 HG23 ' H' ' 36' ' ' VAL . 3.9 pt20 -101.5 -173.46 2.37 Favored 'General case' 0 CA--C 1.507 -0.678 0 N-CA-C 108.636 -0.875 . . . . 0.0 108.636 -179.579 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -170.8 94.36 0.2 Allowed 'General case' 0 N--CA 1.472 0.652 0 CA-C-N 114.652 -1.158 . . . . 0.0 108.105 178.626 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 6.4 mp -121.43 155.57 34.57 Favored 'General case' 0 N--CA 1.497 1.911 0 CA-C-O 121.219 0.533 . . . . 0.0 111.938 -177.85 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 42.9 t -113.28 124.71 70.19 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.024 0 CA-C-N 114.782 -1.099 . . . . 0.0 108.134 176.568 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 31.3 m-85 -125.34 121.99 35.55 Favored 'General case' 0 C--N 1.367 1.351 0 CA-C-N 115.497 -0.774 . . . . 0.0 110.914 -179.252 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 68.1 m-85 54.05 73.34 0.39 Allowed 'General case' 0 C--O 1.237 0.436 0 CA-C-N 115.725 -0.67 . . . . 0.0 111.713 178.076 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.53 -78.03 0.14 Allowed 'General case' 0 N--CA 1.472 0.674 0 O-C-N 122.264 -0.273 . . . . 0.0 110.359 -179.218 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 38.3 tt0 -113.15 101.05 9.07 Favored 'General case' 0 C--N 1.322 -0.608 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 179.865 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -158.1 141.01 14.84 Favored 'General case' 0 N--CA 1.478 0.94 0 O-C-N 122.391 -0.193 . . . . 0.0 111.453 179.046 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' H' H ' 24' ' ' VAL . . . . . 0.432 ' HB ' ' H ' ' E' ' 25' ' ' GLY . 59.3 t -60.17 167.28 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.569 0 N-CA-C 107.655 -1.239 . . . . 0.0 107.655 177.209 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' H' H ' 25' ' ' GLY . . . . . 0.425 ' N ' HG12 ' H' ' 24' ' ' VAL . . . -120.65 49.65 0.87 Allowed Glycine 0 N--CA 1.478 1.499 0 N-CA-C 110.513 -1.035 . . . . 0.0 110.513 -179.463 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -64.26 -167.77 0.03 OUTLIER 'General case' 0 N--CA 1.473 0.701 0 CA-C-N 117.005 0.403 . . . . 0.0 110.1 179.755 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 25.9 t-20 -70.01 77.15 0.49 Allowed 'General case' 0 CA--C 1.534 0.34 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.46 -179.974 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -74.65 144.5 43.81 Favored 'General case' 0 N--CA 1.476 0.846 0 N-CA-C 109.552 -0.536 . . . . 0.0 109.552 179.304 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.74 -165.23 1.01 Allowed Glycine 0 C--N 1.338 0.644 0 N-CA-C 109.936 -1.265 . . . . 0.0 109.936 178.833 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.94 113.71 26.46 Favored 'General case' 0 N--CA 1.47 0.54 0 C-N-CA 122.603 0.361 . . . . 0.0 110.548 -179.996 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 66.5 mt -98.6 135.78 32.15 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.758 0 N-CA-C 106.824 -1.547 . . . . 0.0 106.824 178.922 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' H' H ' 32' ' ' ILE . . . . . 0.45 ' H ' HG22 ' E' ' 32' ' ' ILE . 34.7 pt -152.81 -174.05 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 CA-C-N 119.853 1.206 . . . . 0.0 109.893 -179.797 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.15 5.61 8.3 Favored Glycine 0 N--CA 1.467 0.761 0 N-CA-C 111.004 -0.839 . . . . 0.0 111.004 179.971 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 1.6 tt -75.23 125.59 29.28 Favored 'General case' 0 CA--C 1.545 0.772 0 N-CA-C 109.588 -0.523 . . . . 0.0 109.588 -179.582 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 27.5 ttt -161.17 152.59 19.04 Favored 'General case' 0 C--O 1.212 -0.91 0 N-CA-C 108.886 -0.783 . . . . 0.0 108.886 178.61 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' H' H ' 36' ' ' VAL . . . . . 0.661 HG12 HG22 ' E' ' 36' ' ' VAL . 35.3 m -157.41 164.58 1.09 Allowed 'Isoleucine or valine' 0 C--N 1.347 0.458 0 N-CA-C 108.489 -0.93 . . . . 0.0 108.489 -179.582 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.78 67.91 1.96 Allowed Glycine 0 C--N 1.308 -0.997 0 CA-C-N 115.425 -0.807 . . . . 0.0 112.182 178.335 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 144.1 -171.89 25.43 Favored Glycine 0 N--CA 1.475 1.266 0 N-CA-C 110.682 -0.967 . . . . 0.0 110.682 179.11 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' H' H ' 39' ' ' VAL . . . . . 0.596 HG12 ' H ' ' E' ' 39' ' ' VAL . 35.0 m -126.8 155.75 37.65 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.94 0 C-N-CA 123.174 0.59 . . . . 0.0 110.663 -179.255 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 29.5 t . . . . . 0 C--O 1.217 -0.611 0 CA-C-O 118.433 -0.794 . . . . 0.0 110.759 179.341 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' I' I ' 1' ' ' ASP . . . . . . . . . . . . . 14.5 m-20 . . . . . 0 N--CA 1.492 1.665 0 N-CA-C 109.43 -0.581 . . . . 0.0 109.43 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' I' I ' 2' ' ' ALA . . . . . . . . . . . . . . . -63.18 128.62 36.68 Favored 'General case' 0 N--CA 1.469 0.483 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.595 179.801 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' I' I ' 3' ' ' GLU . . . . . . . . . . . . . 44.0 tt0 -167.68 107.03 0.55 Allowed 'General case' 0 N--CA 1.472 0.635 0 CA-C-O 120.516 0.198 . . . . 0.0 110.687 179.665 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 40.5 m-85 -89.04 151.89 22.0 Favored 'General case' 0 N--CA 1.474 0.749 0 N-CA-C 109.578 -0.527 . . . . 0.0 109.578 179.263 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' I' I ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -143.33 140.58 30.62 Favored 'General case' 0 N--CA 1.483 1.178 0 C-N-CA 122.513 0.325 . . . . 0.0 110.152 -179.987 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 41.6 t-80 -151.67 119.61 6.22 Favored 'General case' 0 N--CA 1.474 0.73 0 N-CA-C 109.435 -0.579 . . . . 0.0 109.435 179.058 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -70.7 144.61 50.94 Favored 'General case' 0 N--CA 1.468 0.472 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.203 -179.807 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' I' I ' 8' ' ' SER . . . . . 0.478 ' OG ' ' O ' ' F' ' 7' ' ' ASP . 52.8 p -165.08 -170.69 1.99 Allowed 'General case' 0 N--CA 1.474 0.752 0 CA-C-O 121.023 0.439 . . . . 0.0 110.521 178.752 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.71 47.77 1.35 Allowed Glycine 0 N--CA 1.481 1.638 0 CA-C-N 115.904 -0.589 . . . . 0.0 111.742 179.56 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 49.1 p90 -65.76 133.13 50.38 Favored 'General case' 0 N--CA 1.472 0.637 0 N-CA-C 111.834 0.309 . . . . 0.0 111.834 -179.771 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 46.2 mt-10 -92.0 151.19 20.6 Favored 'General case' 0 N--CA 1.477 0.923 0 C-N-CA 122.841 0.456 . . . . 0.0 110.249 178.615 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -154.6 127.68 1.15 Allowed 'Isoleucine or valine' 0 CA--C 1.551 0.997 0 N-CA-C 107.86 -1.163 . . . . 0.0 107.86 178.195 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 45.2 m-70 -135.02 147.33 49.63 Favored 'General case' 0 N--CA 1.477 0.918 0 CA-C-N 115.608 -0.724 . . . . 0.0 111.479 -178.252 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 6.5 t60 -165.39 97.31 0.69 Allowed 'General case' 0 N--CA 1.483 1.179 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.218 178.82 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' I' I ' 15' ' ' GLN . . . . . 0.43 HE22 HG23 ' I' ' 36' ' ' VAL . 3.9 pt20 -101.59 -173.43 2.35 Favored 'General case' 0 CA--C 1.507 -0.696 0 N-CA-C 108.622 -0.881 . . . . 0.0 108.622 -179.524 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -170.83 94.48 0.2 Allowed 'General case' 0 N--CA 1.472 0.642 0 CA-C-N 114.631 -1.168 . . . . 0.0 108.076 178.677 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 6.3 mp -121.6 155.52 34.89 Favored 'General case' 0 N--CA 1.496 1.861 0 CA-C-O 121.229 0.538 . . . . 0.0 111.865 -177.851 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 42.0 t -113.09 125.22 70.32 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.015 0 CA-C-N 114.783 -1.099 . . . . 0.0 108.053 176.522 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 31.0 m-85 -125.98 121.63 33.62 Favored 'General case' 0 C--N 1.368 1.396 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.996 -179.17 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 68.2 m-85 54.38 73.05 0.42 Allowed 'General case' 0 N--CA 1.466 0.363 0 CA-C-N 115.836 -0.62 . . . . 0.0 111.584 178.085 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.34 -78.12 0.14 Allowed 'General case' 0 N--CA 1.473 0.712 0 N-CA-C 110.293 -0.262 . . . . 0.0 110.293 -179.218 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 38.6 tt0 -113.05 101.3 9.33 Favored 'General case' 0 C--N 1.323 -0.581 0 N-CA-C 107.994 -1.113 . . . . 0.0 107.994 179.811 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -158.34 141.1 14.61 Favored 'General case' 0 N--CA 1.476 0.867 0 O-C-N 122.368 -0.207 . . . . 0.0 111.444 179.021 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' I' I ' 24' ' ' VAL . . . . . 0.436 ' HB ' ' H ' ' F' ' 25' ' ' GLY . 59.6 t -60.31 166.85 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.348 0.534 0 N-CA-C 107.664 -1.236 . . . . 0.0 107.664 177.212 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' I' I ' 25' ' ' GLY . . . . . 0.43 ' N ' HG12 ' I' ' 24' ' ' VAL . . . -120.27 49.76 0.86 Allowed Glycine 0 N--CA 1.481 1.691 0 N-CA-C 110.542 -1.023 . . . . 0.0 110.542 -179.481 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -64.26 -167.85 0.03 OUTLIER 'General case' 0 N--CA 1.471 0.61 0 CA-C-N 116.922 0.361 . . . . 0.0 110.129 179.714 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 25.7 t-20 -69.9 77.18 0.47 Allowed 'General case' 0 CA--C 1.534 0.345 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.419 -179.99 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -74.74 144.43 43.65 Favored 'General case' 0 N--CA 1.475 0.812 0 N-CA-C 109.641 -0.503 . . . . 0.0 109.641 179.387 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.66 -166.06 1.15 Allowed Glycine 0 C--N 1.337 0.607 0 N-CA-C 110.023 -1.231 . . . . 0.0 110.023 178.71 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.09 113.69 26.03 Favored 'General case' 0 N--CA 1.471 0.586 0 C-N-CA 122.674 0.39 . . . . 0.0 110.468 -179.887 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 67.2 mt -98.68 135.65 32.76 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.73 0 N-CA-C 106.895 -1.52 . . . . 0.0 106.895 178.889 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' I' I ' 32' ' ' ILE . . . . . 0.445 ' H ' HG22 ' F' ' 32' ' ' ILE . 35.0 pt -152.71 -173.92 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.774 0 CA-C-N 119.837 1.199 . . . . 0.0 109.826 -179.724 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.02 5.45 7.66 Favored Glycine 0 CA--C 1.527 0.811 0 N-CA-C 111.063 -0.815 . . . . 0.0 111.063 -179.942 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 1.6 tt -74.97 125.94 29.96 Favored 'General case' 0 CA--C 1.546 0.789 0 N-CA-C 109.549 -0.538 . . . . 0.0 109.549 -179.706 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 27.5 ttt -161.45 152.48 18.35 Favored 'General case' 0 C--O 1.21 -0.981 0 N-CA-C 108.794 -0.817 . . . . 0.0 108.794 178.625 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' I' I ' 36' ' ' VAL . . . . . 0.642 HG12 HG22 ' F' ' 36' ' ' VAL . 35.9 m -157.39 164.82 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.346 0.426 0 N-CA-C 108.468 -0.938 . . . . 0.0 108.468 -179.849 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.62 68.13 1.85 Allowed Glycine 0 C--N 1.308 -0.976 0 CA-C-N 115.501 -0.772 . . . . 0.0 112.137 178.294 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 144.01 -171.86 25.39 Favored Glycine 0 N--CA 1.476 1.302 0 N-CA-C 110.601 -1.0 . . . . 0.0 110.601 179.145 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' I' I ' 39' ' ' VAL . . . . . 0.597 HG12 ' H ' ' F' ' 39' ' ' VAL . 34.9 m -126.95 155.98 38.08 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.935 0 C-N-CA 123.118 0.567 . . . . 0.0 110.617 -179.359 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 31.8 t . . . . . 0 C--O 1.219 -0.542 0 O-C-N 123.953 0.783 . . . . 0.0 110.693 179.402 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 15.5 m-20 . . . . . 0 N--CA 1.49 1.531 0 N-CA-C 108.889 -0.782 . . . . 0.0 108.889 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.63 132.51 49.0 Favored 'General case' 0 CA--C 1.539 0.551 0 CA-C-N 116.55 -0.296 . . . . 0.0 110.276 -179.731 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 44.7 tt0 -168.05 106.29 0.5 Allowed 'General case' 0 C--O 1.213 -0.838 0 N-CA-C 109.879 -0.415 . . . . 0.0 109.879 -179.265 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 42.4 m-85 -85.48 151.33 24.05 Favored 'General case' 0 N--CA 1.474 0.758 0 N-CA-C 110.076 -0.342 . . . . 0.0 110.076 179.5 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -142.72 141.24 31.75 Favored 'General case' 0 N--CA 1.481 1.08 0 CA-C-O 120.861 0.363 . . . . 0.0 110.052 179.53 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 45.3 t-80 -152.11 119.03 5.79 Favored 'General case' 0 N--CA 1.471 0.613 0 N-CA-C 109.263 -0.643 . . . . 0.0 109.263 178.997 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' ASP . . . . . 0.488 ' O ' ' OG ' ' D' ' 8' ' ' SER . 4.5 m-20 -68.93 149.4 48.9 Favored 'General case' 0 CA--C 1.536 0.436 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.448 179.883 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 60.4 p -168.16 -173.78 2.13 Favored 'General case' 0 N--CA 1.484 1.228 0 CA-C-O 120.947 0.404 . . . . 0.0 110.635 179.224 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.37 46.85 1.37 Allowed Glycine 0 N--CA 1.482 1.721 0 CA-C-N 115.972 -0.558 . . . . 0.0 112.114 179.816 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 49.8 p90 -66.16 132.61 48.86 Favored 'General case' 0 N--CA 1.473 0.697 0 O-C-N 122.782 -0.246 . . . . 0.0 111.53 179.766 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 48.7 mt-10 -91.84 152.49 20.08 Favored 'General case' 0 N--CA 1.477 0.911 0 CA-C-O 121.066 0.46 . . . . 0.0 109.776 178.293 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.0 p -153.15 127.63 1.4 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.545 0 N-CA-C 107.915 -1.143 . . . . 0.0 107.915 178.363 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 44.1 m-70 -135.6 148.44 49.05 Favored 'General case' 0 N--CA 1.492 1.645 0 CA-C-N 119.09 0.859 . . . . 0.0 111.324 -179.064 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 7.0 t60 -163.67 97.81 0.87 Allowed 'General case' 0 N--CA 1.481 1.09 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.776 179.395 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . 0.531 HE22 ' H ' ' A' ' 37' ' ' GLY . 3.4 pt20 -107.63 -175.74 2.87 Favored 'General case' 0 CA--C 1.507 -0.68 0 N-CA-C 108.422 -0.955 . . . . 0.0 108.422 -179.98 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -169.63 100.56 0.32 Allowed 'General case' 0 CA--C 1.54 0.582 0 CA-C-N 114.629 -1.169 . . . . 0.0 108.466 179.029 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.547 ' H ' ' CD2' ' D' ' 17' ' ' LEU . 6.9 mt -125.46 153.17 43.91 Favored 'General case' 0 N--CA 1.492 1.675 0 CA-C-O 121.443 0.64 . . . . 0.0 110.975 -178.284 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 60.4 t -107.8 129.26 62.17 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.21 0 CA-C-O 117.896 -1.05 . . . . 0.0 108.392 178.039 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 45.3 m-85 -125.97 122.72 36.73 Favored 'General case' 0 N--CA 1.497 1.919 0 CA-C-N 120.099 1.318 . . . . 0.0 110.367 179.272 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 74.2 m-85 53.09 75.02 0.26 Allowed 'General case' 0 N--CA 1.471 0.594 0 CA-C-O 121.361 0.6 . . . . 0.0 111.935 178.469 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -79.52 -78.32 0.16 Allowed 'General case' 0 C--N 1.353 0.739 0 CA-C-N 115.097 -0.956 . . . . 0.0 110.283 -179.796 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 39.9 tt0 -112.58 100.57 8.83 Favored 'General case' 0 N--CA 1.47 0.564 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 179.805 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -159.33 140.54 12.86 Favored 'General case' 0 C--O 1.207 -1.163 0 O-C-N 122.283 -0.261 . . . . 0.0 111.161 179.175 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.417 HG12 ' N ' ' A' ' 25' ' ' GLY . 61.5 t -60.33 164.15 0.92 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.836 0 N-CA-C 108.154 -1.054 . . . . 0.0 108.154 177.174 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.444 ' H ' ' HB ' ' D' ' 24' ' ' VAL . . . -117.66 48.89 0.9 Allowed Glycine 0 N--CA 1.477 1.426 0 N-CA-C 111.657 -0.577 . . . . 0.0 111.657 -179.353 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -61.92 -168.23 0.02 OUTLIER 'General case' 0 N--CA 1.469 0.486 0 O-C-N 123.845 0.38 . . . . 0.0 110.371 179.532 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 24.7 t-20 -70.17 81.11 0.51 Allowed 'General case' 0 N--CA 1.465 0.282 0 N-CA-C 110.144 -0.317 . . . . 0.0 110.144 179.792 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -79.65 146.43 32.49 Favored 'General case' 0 N--CA 1.472 0.627 0 N-CA-C 109.087 -0.708 . . . . 0.0 109.087 179.123 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -62.98 -168.54 0.93 Allowed Glycine 0 CA--C 1.524 0.653 0 N-CA-C 109.895 -1.282 . . . . 0.0 109.895 178.752 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -100.19 116.47 32.26 Favored 'General case' 0 N--CA 1.477 0.898 0 N-CA-C 109.685 -0.487 . . . . 0.0 109.685 179.723 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 69.4 mt -97.34 135.33 31.98 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.556 0 N-CA-C 107.102 -1.444 . . . . 0.0 107.102 179.003 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 44.1 pt -151.43 -178.17 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.713 0 CA-C-O 121.222 0.534 . . . . 0.0 111.11 -178.899 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 64.09 5.34 14.66 Favored Glycine 0 CA--C 1.526 0.728 0 N-CA-C 110.815 -0.914 . . . . 0.0 110.815 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.414 HD23 ' N ' ' A' ' 35' ' ' MET . 1.4 tt -73.79 128.7 36.2 Favored 'General case' 0 CA--C 1.545 0.776 0 N-CA-C 109.61 -0.515 . . . . 0.0 109.61 -179.714 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' MET . . . . . 0.414 ' N ' HD23 ' A' ' 34' ' ' LEU . 28.7 ttt -163.55 147.39 10.44 Favored 'General case' 0 N--CA 1.465 0.305 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 178.506 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.539 HG22 HG12 ' D' ' 36' ' ' VAL . 31.6 m -155.13 163.54 1.55 Allowed 'Isoleucine or valine' 0 C--N 1.347 0.488 0 N-CA-C 108.11 -1.07 . . . . 0.0 108.11 179.503 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . 0.531 ' H ' HE22 ' A' ' 15' ' ' GLN . . . 55.4 68.15 1.84 Allowed Glycine 0 C--N 1.306 -1.134 0 CA-C-N 115.89 -0.596 . . . . 0.0 112.078 178.706 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 141.09 175.35 14.71 Favored Glycine 0 N--CA 1.475 1.273 0 N-CA-C 110.821 -0.912 . . . . 0.0 110.821 179.164 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.512 ' H ' HG12 ' D' ' 39' ' ' VAL . 35.4 m -118.55 159.69 18.85 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.813 0 C-N-CA 123.364 0.666 . . . . 0.0 110.384 -179.998 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 22.1 t . . . . . 0 C--O 1.221 -0.441 0 CA-C-O 118.523 -0.751 . . . . 0.0 110.649 179.488 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' B' B ' 1' ' ' ASP . . . . . . . . . . . . . 13.9 m-20 . . . . . 0 N--CA 1.49 1.558 0 N-CA-C 109.091 -0.707 . . . . 0.0 109.091 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' B' B ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.06 132.7 49.89 Favored 'General case' 0 N--CA 1.47 0.547 0 N-CA-C 110.19 -0.3 . . . . 0.0 110.19 -179.76 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 3' ' ' GLU . . . . . . . . . . . . . 44.5 tt0 -168.33 105.5 0.46 Allowed 'General case' 0 C--O 1.214 -0.767 0 N-CA-C 110.011 -0.366 . . . . 0.0 110.011 -179.099 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 41.2 m-85 -84.82 151.22 24.48 Favored 'General case' 0 N--CA 1.474 0.751 0 N-CA-C 110.088 -0.338 . . . . 0.0 110.088 179.505 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -142.58 141.06 31.93 Favored 'General case' 0 N--CA 1.483 1.217 0 N-CA-C 109.98 -0.378 . . . . 0.0 109.98 179.437 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 44.4 t-80 -151.94 118.94 5.83 Favored 'General case' 0 N--CA 1.473 0.688 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 178.991 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 7' ' ' ASP . . . . . 0.441 ' O ' ' OG ' ' E' ' 8' ' ' SER . 4.3 m-20 -69.08 148.88 49.38 Favored 'General case' 0 CA--C 1.537 0.473 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.585 179.93 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 8' ' ' SER . . . . . . . . . . . . . 59.9 p -167.76 -173.73 2.23 Favored 'General case' 0 N--CA 1.482 1.144 0 CA-C-O 120.985 0.422 . . . . 0.0 110.644 179.336 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.23 46.72 1.41 Allowed Glycine 0 N--CA 1.482 1.753 0 CA-C-N 115.902 -0.59 . . . . 0.0 112.164 179.944 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 50.2 p90 -66.14 132.51 48.66 Favored 'General case' 0 N--CA 1.472 0.657 0 CA-C-O 120.624 0.25 . . . . 0.0 111.596 179.632 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 48.2 mt-10 -91.7 152.62 20.12 Favored 'General case' 0 N--CA 1.476 0.846 0 CA-C-O 121.076 0.465 . . . . 0.0 109.758 178.307 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.0 p -153.23 128.07 1.47 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.654 0 N-CA-C 107.772 -1.196 . . . . 0.0 107.772 178.167 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 43.6 m-70 -135.72 148.91 49.04 Favored 'General case' 0 N--CA 1.492 1.628 0 CA-C-N 118.837 0.744 . . . . 0.0 111.355 -179.145 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 7.2 t60 -164.3 97.62 0.8 Allowed 'General case' 0 N--CA 1.482 1.139 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.75 179.494 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . 0.532 HE22 ' H ' ' B' ' 37' ' ' GLY . 3.4 pt20 -107.41 -175.37 2.77 Favored 'General case' 0 CA--C 1.509 -0.623 0 N-CA-C 108.255 -1.017 . . . . 0.0 108.255 -179.921 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -169.96 100.18 0.3 Allowed 'General case' 0 N--CA 1.471 0.619 0 CA-C-N 114.667 -1.151 . . . . 0.0 108.415 178.995 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . 0.534 ' H ' ' CD2' ' E' ' 17' ' ' LEU . 6.9 mt -124.92 153.72 42.23 Favored 'General case' 0 N--CA 1.491 1.61 0 CA-C-O 121.506 0.669 . . . . 0.0 111.03 -178.39 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 61.3 t -108.4 130.33 61.25 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.221 0 N-CA-C 108.054 -1.091 . . . . 0.0 108.054 177.933 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 44.2 m-85 -127.24 122.06 32.92 Favored 'General case' 0 N--CA 1.494 1.766 0 CA-C-N 119.721 1.146 . . . . 0.0 110.221 179.524 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 74.7 m-85 52.89 75.28 0.25 Allowed 'General case' 0 CA--C 1.539 0.527 0 CA-C-O 121.427 0.632 . . . . 0.0 111.939 178.47 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -79.92 -78.06 0.17 Allowed 'General case' 0 C--N 1.351 0.666 0 CA-C-N 115.026 -0.988 . . . . 0.0 110.283 -179.839 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 40.2 tt0 -112.58 100.65 8.9 Favored 'General case' 0 N--CA 1.473 0.683 0 N-CA-C 108.349 -0.982 . . . . 0.0 108.349 179.73 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -159.34 141.24 13.4 Favored 'General case' 0 N--CA 1.484 1.235 0 O-C-N 122.222 -0.299 . . . . 0.0 111.144 179.193 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 61.4 t -61.0 163.9 1.05 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.852 0 N-CA-C 108.176 -1.046 . . . . 0.0 108.176 177.238 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . 0.466 ' H ' ' HB ' ' E' ' 24' ' ' VAL . . . -117.19 48.51 0.93 Allowed Glycine 0 N--CA 1.476 1.338 0 N-CA-C 111.581 -0.608 . . . . 0.0 111.581 -179.328 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -61.55 -167.43 0.01 OUTLIER 'General case' 0 N--CA 1.469 0.505 0 O-C-N 123.753 0.325 . . . . 0.0 110.364 179.494 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 24.8 t-20 -71.24 81.18 0.73 Allowed 'General case' 0 N--CA 1.465 0.324 0 N-CA-C 110.076 -0.342 . . . . 0.0 110.076 179.863 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -79.75 146.47 32.33 Favored 'General case' 0 N--CA 1.473 0.69 0 N-CA-C 109.096 -0.705 . . . . 0.0 109.096 179.274 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.03 -168.7 0.97 Allowed Glycine 0 C--N 1.336 0.56 0 N-CA-C 109.914 -1.274 . . . . 0.0 109.914 178.735 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.97 116.76 32.77 Favored 'General case' 0 N--CA 1.476 0.87 0 N-CA-C 109.668 -0.493 . . . . 0.0 109.668 179.789 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 69.8 mt -97.65 135.07 33.37 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.537 0 N-CA-C 107.07 -1.456 . . . . 0.0 107.07 178.972 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 43.7 pt -151.1 -177.94 0.38 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.681 0 CA-C-O 121.299 0.571 . . . . 0.0 111.159 -178.753 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.42 5.94 13.46 Favored Glycine 0 CA--C 1.525 0.692 0 N-CA-C 110.884 -0.887 . . . . 0.0 110.884 -179.967 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 34' ' ' LEU . . . . . 0.4 HD23 ' N ' ' B' ' 35' ' ' MET . 1.4 tt -74.39 128.35 35.33 Favored 'General case' 0 CA--C 1.545 0.774 0 N-CA-C 109.528 -0.545 . . . . 0.0 109.528 -179.745 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 35' ' ' MET . . . . . 0.4 ' N ' HD23 ' B' ' 34' ' ' LEU . 28.6 ttt -162.95 147.76 11.6 Favored 'General case' 0 N--CA 1.468 0.427 0 N-CA-C 108.797 -0.816 . . . . 0.0 108.797 178.607 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 36' ' ' VAL . . . . . 0.497 HG22 HG12 ' E' ' 36' ' ' VAL . 29.9 m -155.68 163.31 1.53 Allowed 'Isoleucine or valine' 0 C--N 1.347 0.49 0 N-CA-C 108.096 -1.075 . . . . 0.0 108.096 179.516 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . 0.532 ' H ' HE22 ' B' ' 15' ' ' GLN . . . 55.67 67.74 2.05 Favored Glycine 0 C--N 1.306 -1.11 0 CA-C-N 115.881 -0.6 . . . . 0.0 112.014 178.676 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 141.17 175.65 14.97 Favored Glycine 0 N--CA 1.475 1.247 0 N-CA-C 110.891 -0.883 . . . . 0.0 110.891 179.079 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 39' ' ' VAL . . . . . 0.514 ' H ' HG12 ' E' ' 39' ' ' VAL . 35.5 m -118.56 159.87 18.73 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.89 0 C-N-CA 123.469 0.708 . . . . 0.0 110.476 -179.934 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 21.9 t . . . . . 0 N--CA 1.468 0.475 0 CA-C-O 118.364 -0.827 . . . . 0.0 110.468 179.362 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' C' C ' 1' ' ' ASP . . . . . . . . . . . . . 14.1 m-20 . . . . . 0 N--CA 1.49 1.553 0 N-CA-C 108.894 -0.78 . . . . 0.0 108.894 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' C' C ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.08 132.72 49.94 Favored 'General case' 0 CA--C 1.54 0.561 0 CA-C-N 116.509 -0.314 . . . . 0.0 110.229 -179.792 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 3' ' ' GLU . . . . . . . . . . . . . 44.6 tt0 -168.35 105.94 0.47 Allowed 'General case' 0 C--O 1.215 -0.749 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 -179.162 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 41.3 m-85 -85.07 151.89 23.82 Favored 'General case' 0 N--CA 1.475 0.775 0 N-CA-C 110.128 -0.323 . . . . 0.0 110.128 179.547 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -143.34 140.49 30.55 Favored 'General case' 0 N--CA 1.481 1.097 0 N-CA-C 110.126 -0.324 . . . . 0.0 110.126 179.608 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 45.4 t-80 -151.51 119.24 6.13 Favored 'General case' 0 N--CA 1.472 0.667 0 N-CA-C 109.286 -0.635 . . . . 0.0 109.286 178.984 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 7' ' ' ASP . . . . . 0.482 ' O ' ' OG ' ' F' ' 8' ' ' SER . 4.4 m-20 -69.32 148.76 49.27 Favored 'General case' 0 CA--C 1.537 0.471 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.591 179.891 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 8' ' ' SER . . . . . . . . . . . . . 59.6 p -167.63 -173.64 2.24 Favored 'General case' 0 N--CA 1.482 1.143 0 CA-C-O 121.04 0.448 . . . . 0.0 110.621 179.202 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.28 47.19 1.34 Allowed Glycine 0 N--CA 1.482 1.702 0 CA-C-N 115.995 -0.548 . . . . 0.0 112.11 179.892 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 49.6 p90 -66.62 132.49 48.29 Favored 'General case' 0 N--CA 1.473 0.713 0 CA-C-O 120.761 0.315 . . . . 0.0 111.571 179.655 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 48.4 mt-10 -91.45 152.63 20.29 Favored 'General case' 0 N--CA 1.475 0.806 0 N-CA-C 109.719 -0.474 . . . . 0.0 109.719 178.253 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -153.33 128.01 1.44 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.548 0 N-CA-C 107.873 -1.158 . . . . 0.0 107.873 178.183 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 43.7 m-70 -135.92 148.51 48.58 Favored 'General case' 0 N--CA 1.492 1.643 0 CA-C-N 118.932 0.787 . . . . 0.0 111.305 -179.055 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 7.1 t60 -163.86 97.56 0.85 Allowed 'General case' 0 N--CA 1.483 1.182 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.794 179.475 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 15' ' ' GLN . . . . . 0.539 HE22 ' H ' ' C' ' 37' ' ' GLY . 3.4 pt20 -107.43 -175.09 2.69 Favored 'General case' 0 CA--C 1.508 -0.662 0 N-CA-C 108.237 -1.023 . . . . 0.0 108.237 -179.96 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -170.29 100.27 0.27 Allowed 'General case' 0 N--CA 1.471 0.577 0 CA-C-N 114.59 -1.186 . . . . 0.0 108.415 179.192 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 17' ' ' LEU . . . . . 0.525 ' H ' ' CD2' ' F' ' 17' ' ' LEU . 6.9 mt -125.14 153.47 42.96 Favored 'General case' 0 N--CA 1.492 1.665 0 CA-C-O 121.52 0.676 . . . . 0.0 111.03 -178.217 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 61.2 t -108.07 130.22 60.97 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.188 0 N-CA-C 108.229 -1.026 . . . . 0.0 108.229 177.844 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 44.3 m-85 -127.16 121.99 32.89 Favored 'General case' 0 N--CA 1.493 1.68 0 CA-C-N 119.655 1.116 . . . . 0.0 110.349 179.454 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 74.2 m-85 52.84 75.22 0.25 Allowed 'General case' 0 N--CA 1.469 0.508 0 CA-C-O 121.518 0.675 . . . . 0.0 111.98 178.529 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -79.83 -77.97 0.17 Allowed 'General case' 0 C--N 1.35 0.6 0 CA-C-N 114.876 -1.056 . . . . 0.0 110.267 -179.814 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 39.8 tt0 -112.68 100.71 8.92 Favored 'General case' 0 N--CA 1.471 0.586 0 N-CA-C 108.3 -1.0 . . . . 0.0 108.3 179.736 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -159.41 140.83 12.98 Favored 'General case' 0 N--CA 1.483 1.178 0 O-C-N 122.22 -0.3 . . . . 0.0 111.226 179.124 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 24' ' ' VAL . . . . . 0.416 HG12 ' N ' ' C' ' 25' ' ' GLY . 60.2 t -60.39 164.34 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.871 0 N-CA-C 108.087 -1.079 . . . . 0.0 108.087 177.23 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 25' ' ' GLY . . . . . 0.447 ' H ' ' HB ' ' F' ' 24' ' ' VAL . . . -117.63 48.82 0.91 Allowed Glycine 0 N--CA 1.479 1.519 0 N-CA-C 111.45 -0.66 . . . . 0.0 111.45 -179.43 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -61.91 -167.92 0.01 OUTLIER 'General case' 0 N--CA 1.468 0.425 0 O-C-N 123.707 0.298 . . . . 0.0 110.386 179.547 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 24.8 t-20 -70.54 80.9 0.58 Allowed 'General case' 0 N--CA 1.466 0.353 0 N-CA-C 110.113 -0.329 . . . . 0.0 110.113 179.692 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -79.51 146.57 32.61 Favored 'General case' 0 N--CA 1.473 0.698 0 N-CA-C 109.065 -0.717 . . . . 0.0 109.065 179.239 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.08 -168.76 1.0 Allowed Glycine 0 CA--C 1.525 0.699 0 N-CA-C 109.98 -1.248 . . . . 0.0 109.98 178.806 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.96 116.35 31.82 Favored 'General case' 0 N--CA 1.478 0.974 0 N-CA-C 109.657 -0.498 . . . . 0.0 109.657 179.757 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 69.3 mt -97.45 135.13 32.87 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.54 0 N-CA-C 107.16 -1.422 . . . . 0.0 107.16 179.034 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 43.9 pt -151.12 -177.91 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.649 0 CA-C-N 115.995 -0.548 . . . . 0.0 111.304 -178.691 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.59 5.58 13.11 Favored Glycine 0 CA--C 1.524 0.6 0 N-CA-C 110.853 -0.899 . . . . 0.0 110.853 -179.987 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 34' ' ' LEU . . . . . 0.413 HD23 ' N ' ' C' ' 35' ' ' MET . 1.4 tt -74.07 128.17 34.84 Favored 'General case' 0 CA--C 1.545 0.774 0 N-CA-C 109.626 -0.509 . . . . 0.0 109.626 -179.738 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 35' ' ' MET . . . . . 0.413 ' N ' HD23 ' C' ' 34' ' ' LEU . 28.5 ttt -162.94 147.38 11.44 Favored 'General case' 0 N--CA 1.466 0.364 0 N-CA-C 108.679 -0.86 . . . . 0.0 108.679 178.666 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 36' ' ' VAL . . . . . 0.521 HG22 HG12 ' F' ' 36' ' ' VAL . 33.7 m -155.25 163.38 1.57 Allowed 'Isoleucine or valine' 0 C--N 1.348 0.516 0 N-CA-C 108.125 -1.065 . . . . 0.0 108.125 179.49 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 37' ' ' GLY . . . . . 0.539 ' H ' HE22 ' C' ' 15' ' ' GLN . . . 55.32 67.85 1.99 Allowed Glycine 0 C--N 1.306 -1.135 0 CA-C-N 115.881 -0.6 . . . . 0.0 112.104 178.712 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 141.67 176.07 15.66 Favored Glycine 0 N--CA 1.475 1.248 0 N-CA-C 110.885 -0.886 . . . . 0.0 110.885 179.11 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 39' ' ' VAL . . . . . 0.505 ' H ' HG12 ' F' ' 39' ' ' VAL . 35.6 m -119.16 159.56 19.77 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.878 0 C-N-CA 123.349 0.66 . . . . 0.0 110.451 179.891 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 21.9 t . . . . . 0 N--CA 1.467 0.4 0 CA-C-O 118.45 -0.786 . . . . 0.0 110.473 179.443 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' D' D ' 1' ' ' ASP . . . . . . . . . . . . . 14.6 m-20 . . . . . 0 N--CA 1.49 1.534 0 N-CA-C 109.035 -0.728 . . . . 0.0 109.035 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' D' D ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.42 131.05 46.09 Favored 'General case' 0 CA--C 1.537 0.474 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.366 -179.824 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' D' D ' 3' ' ' GLU . . . . . . . . . . . . . 44.2 tt0 -169.23 108.01 0.43 Allowed 'General case' 0 C--O 1.217 -0.621 0 N-CA-C 110.028 -0.36 . . . . 0.0 110.028 -179.582 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 42.3 m-85 -89.17 156.12 18.99 Favored 'General case' 0 C--N 1.358 0.944 0 N-CA-C 108.941 -0.763 . . . . 0.0 108.941 -179.977 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' D' D ' 5' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -144.54 139.7 28.35 Favored 'General case' 0 N--CA 1.475 0.797 0 CA-C-N 116.374 -0.375 . . . . 0.0 110.214 179.869 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 41.0 t-80 -149.77 123.96 9.49 Favored 'General case' 0 CA--C 1.545 0.782 0 N-CA-C 108.142 -1.058 . . . . 0.0 108.142 174.72 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' D' D ' 7' ' ' ASP . . . . . 0.584 ' O ' ' OG ' ' G' ' 8' ' ' SER . 3.1 m-20 -63.6 132.98 52.89 Favored 'General case' 0 C--N 1.321 -0.647 0 C-N-CA 126.846 2.058 . . . . 0.0 114.209 174.62 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' D' D ' 8' ' ' SER . . . . . 0.488 ' OG ' ' O ' ' A' ' 7' ' ' ASP . 59.8 p -154.51 -170.8 3.64 Favored 'General case' 0 N--CA 1.488 1.454 0 CA-C-N 119.675 1.125 . . . . 0.0 111.255 175.246 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.39 47.91 1.17 Allowed Glycine 0 N--CA 1.481 1.666 0 C-N-CA 124.663 1.125 . . . . 0.0 110.632 174.321 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 51.5 p90 -60.99 131.56 51.02 Favored 'General case' 0 N--CA 1.47 0.526 0 N-CA-C 112.613 0.598 . . . . 0.0 112.613 177.559 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 48.3 mt-10 -89.64 151.01 22.11 Favored 'General case' 0 N--CA 1.479 1.025 0 CA-C-N 117.989 0.359 . . . . 0.0 110.662 174.982 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.0 p -149.64 129.95 4.22 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.662 0 N-CA-C 107.307 -1.368 . . . . 0.0 107.307 173.058 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 38.6 m-70 -129.79 151.63 50.16 Favored 'General case' 0 N--CA 1.483 1.182 0 N-CA-C 112.264 0.468 . . . . 0.0 112.264 176.639 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 7.3 t60 -164.68 104.75 0.82 Allowed 'General case' 0 N--CA 1.483 1.201 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 172.261 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' D' D ' 15' ' ' GLN . . . . . 0.482 HE22 ' H ' ' D' ' 37' ' ' GLY . 3.4 pt20 -111.05 -176.47 2.96 Favored 'General case' 0 CA--C 1.502 -0.884 0 N-CA-C 108.002 -1.11 . . . . 0.0 108.002 179.007 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -167.03 106.44 0.59 Allowed 'General case' 0 N--CA 1.466 0.337 0 N-CA-C 106.947 -1.501 . . . . 0.0 106.947 176.404 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' D' D ' 17' ' ' LEU . . . . . 0.554 ' H ' ' CD2' ' G' ' 17' ' ' LEU . 9.9 mt -130.57 152.35 50.04 Favored 'General case' 0 N--CA 1.493 1.702 0 CA-C-O 121.864 0.84 . . . . 0.0 110.493 179.651 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 38.6 t -99.65 133.09 43.73 Favored 'Isoleucine or valine' 0 C--O 1.259 1.596 0 CA-C-O 116.97 -1.49 . . . . 0.0 109.645 175.007 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 40.6 m-85 -130.04 125.97 36.54 Favored 'General case' 0 N--CA 1.489 1.523 0 CA-C-N 119.792 1.178 . . . . 0.0 109.357 174.144 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 74.1 m-85 55.87 71.87 0.53 Allowed 'General case' 0 C--N 1.352 0.693 0 CA-C-N 115.105 -0.952 . . . . 0.0 111.411 176.063 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -81.82 -73.0 0.41 Allowed 'General case' 0 N--CA 1.472 0.66 0 CA-C-O 118.369 -0.824 . . . . 0.0 111.005 -177.305 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 40.3 tt0 -115.98 104.17 11.33 Favored 'General case' 0 N--CA 1.484 1.262 0 N-CA-C 106.404 -1.702 . . . . 0.0 106.404 176.392 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -152.21 140.8 20.77 Favored 'General case' 0 N--CA 1.475 0.789 0 CA-C-O 116.748 -1.596 . . . . 0.0 113.634 177.867 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' D' D ' 24' ' ' VAL . . . . . 0.444 ' HB ' ' H ' ' A' ' 25' ' ' GLY . 66.7 t -62.95 166.57 0.97 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.237 0 CA-C-N 121.097 1.771 . . . . 0.0 107.979 174.782 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' D' D ' 25' ' ' GLY . . . . . 0.503 ' H ' ' HB ' ' G' ' 24' ' ' VAL . . . -116.67 51.07 0.75 Allowed Glycine 0 N--CA 1.481 1.667 0 CA-C-O 118.876 -0.958 . . . . 0.0 111.715 178.636 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -58.29 -170.73 0.01 OUTLIER 'General case' 0 C--N 1.322 -0.619 0 C-N-CA 123.38 0.672 . . . . 0.0 111.637 176.638 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 25.4 t-20 -72.43 86.71 1.15 Allowed 'General case' 0 CA--C 1.537 0.453 0 N-CA-C 108.425 -0.954 . . . . 0.0 108.425 178.45 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 97.6 mttt -84.26 148.71 26.55 Favored 'General case' 0 N--CA 1.474 0.758 0 N-CA-C 108.155 -1.054 . . . . 0.0 108.155 178.884 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -62.7 -165.73 0.55 Allowed Glycine 0 C--N 1.337 0.614 0 N-CA-C 110.461 -1.056 . . . . 0.0 110.461 179.374 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -102.09 115.99 31.72 Favored 'General case' 0 N--CA 1.467 0.385 0 C-N-CA 123.186 0.595 . . . . 0.0 109.921 179.832 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 80.4 mt -102.41 142.46 16.6 Favored 'Isoleucine or valine' 0 C--N 1.355 0.836 0 N-CA-C 104.327 -2.472 . . . . 0.0 104.327 -178.908 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 38.6 pt -157.68 -179.05 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.241 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.118 -176.161 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 64.73 5.7 19.6 Favored Glycine 0 C--O 1.244 0.758 0 N-CA-C 110.003 -1.239 . . . . 0.0 110.003 -178.573 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 1.7 tt -76.42 134.14 39.68 Favored 'General case' 0 C--N 1.361 1.084 0 N-CA-C 107.244 -1.391 . . . . 0.0 107.244 -177.829 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' D' D ' 35' ' ' MET . . . . . 0.405 ' C ' HG13 ' D' ' 36' ' ' VAL . 28.2 ttt -157.91 159.99 37.15 Favored 'General case' 0 CA--C 1.517 -0.319 0 N-CA-C 108.225 -1.028 . . . . 0.0 108.225 172.577 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' D' D ' 36' ' ' VAL . . . . . 0.578 HG22 HG12 ' G' ' 36' ' ' VAL . 31.0 m -164.8 163.63 0.71 Allowed 'Isoleucine or valine' 0 C--O 1.223 -0.31 0 N-CA-C 107.765 -1.198 . . . . 0.0 107.765 174.232 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' D' D ' 37' ' ' GLY . . . . . 0.482 ' H ' HE22 ' D' ' 15' ' ' GLN . . . 59.9 63.71 4.84 Favored Glycine 0 CA--C 1.528 0.884 0 C-N-CA 120.435 -0.888 . . . . 0.0 111.335 178.024 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.18 179.66 20.01 Favored Glycine 0 N--CA 1.481 1.651 0 N-CA-C 111.057 -0.817 . . . . 0.0 111.057 178.352 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' D' D ' 39' ' ' VAL . . . . . 0.529 ' H ' HG12 ' G' ' 39' ' ' VAL . 33.9 m -120.54 157.02 23.56 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.822 0 C-N-CA 123.133 0.573 . . . . 0.0 110.94 179.461 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 22.0 t . . . . . 0 C--N 1.333 -0.14 0 CA-C-O 116.665 -1.636 . . . . 0.0 109.536 175.794 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' E' E ' 1' ' ' ASP . . . . . . . . . . . . . 14.6 m-20 . . . . . 0 N--CA 1.49 1.535 0 N-CA-C 109.427 -0.582 . . . . 0.0 109.427 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' E' E ' 2' ' ' ALA . . . . . . . . . . . . . . . -63.67 129.69 41.2 Favored 'General case' 0 N--CA 1.468 0.472 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.455 -179.939 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' E' E ' 3' ' ' GLU . . . . . . . . . . . . . 44.2 tt0 -167.26 106.03 0.57 Allowed 'General case' 0 C--O 1.213 -0.858 0 CA-C-N 116.732 -0.213 . . . . 0.0 110.648 -179.723 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 38.8 m-85 -86.04 151.43 23.72 Favored 'General case' 0 N--CA 1.475 0.806 0 N-CA-C 110.152 -0.314 . . . . 0.0 110.152 179.297 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' E' E ' 5' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -142.72 140.97 31.69 Favored 'General case' 0 N--CA 1.482 1.126 0 CA-C-O 120.904 0.383 . . . . 0.0 110.077 179.395 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 45.0 t-80 -151.4 118.8 6.0 Favored 'General case' 0 N--CA 1.472 0.669 0 N-CA-C 109.227 -0.657 . . . . 0.0 109.227 178.83 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' E' E ' 7' ' ' ASP . . . . . 0.441 ' O ' ' OG ' ' H' ' 8' ' ' SER . 4.2 m-20 -69.57 148.66 49.1 Favored 'General case' 0 N--CA 1.467 0.379 0 CA-C-N 116.435 -0.348 . . . . 0.0 110.745 179.941 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' E' E ' 8' ' ' SER . . . . . 0.441 ' OG ' ' O ' ' B' ' 7' ' ' ASP . 56.0 p -168.26 -172.51 1.76 Allowed 'General case' 0 N--CA 1.486 1.343 0 CA-C-O 121.099 0.476 . . . . 0.0 110.784 178.917 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.71 47.09 1.31 Allowed Glycine 0 N--CA 1.478 1.493 0 CA-C-N 115.912 -0.585 . . . . 0.0 112.101 179.807 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 47.7 p90 -65.82 133.22 50.51 Favored 'General case' 0 N--CA 1.473 0.721 0 N-CA-C 111.908 0.336 . . . . 0.0 111.908 -179.948 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 48.6 mt-10 -91.47 152.98 20.13 Favored 'General case' 0 N--CA 1.48 1.054 0 CA-C-O 121.245 0.545 . . . . 0.0 109.629 177.943 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -154.97 126.78 0.95 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.63 0 N-CA-C 107.739 -1.208 . . . . 0.0 107.739 178.135 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 42.2 m-70 -135.69 146.86 48.2 Favored 'General case' 0 N--CA 1.482 1.14 0 CA-C-O 120.849 0.357 . . . . 0.0 111.531 -178.126 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 7.1 t60 -163.0 97.64 0.93 Allowed 'General case' 0 N--CA 1.485 1.288 0 CA-C-N 116.365 -0.38 . . . . 0.0 110.717 179.506 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' E' E ' 15' ' ' GLN . . . . . 0.515 HE22 ' H ' ' E' ' 37' ' ' GLY . 3.4 pt20 -106.99 -175.22 2.73 Favored 'General case' 0 CA--C 1.51 -0.564 0 N-CA-C 108.521 -0.918 . . . . 0.0 108.521 -179.928 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -169.84 99.81 0.31 Allowed 'General case' 0 N--CA 1.473 0.713 0 CA-C-N 114.654 -1.157 . . . . 0.0 108.617 179.004 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' E' E ' 17' ' ' LEU . . . . . 0.563 ' H ' ' CD2' ' H' ' 17' ' ' LEU . 7.3 mt -123.9 153.89 40.5 Favored 'General case' 0 N--CA 1.49 1.549 0 CA-C-O 121.348 0.594 . . . . 0.0 111.505 -177.767 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 49.9 t -110.7 126.3 68.04 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.307 0 N-CA-C 108.205 -1.035 . . . . 0.0 108.205 177.604 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 46.6 m-85 -123.79 121.22 34.87 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 123.37 0.419 . . . . 0.0 111.038 -179.821 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 73.7 m-85 54.06 74.33 0.34 Allowed 'General case' 0 N--CA 1.47 0.542 0 CA-C-N 115.922 -0.581 . . . . 0.0 111.594 178.061 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -78.18 -78.96 0.13 Allowed 'General case' 0 CA--C 1.535 0.375 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.095 -179.488 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 39.9 tt0 -111.67 100.97 9.39 Favored 'General case' 0 N--CA 1.469 0.482 0 N-CA-C 108.438 -0.949 . . . . 0.0 108.438 -179.989 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -158.61 140.73 13.95 Favored 'General case' 0 C--O 1.204 -1.296 0 CA-C-O 119.581 -0.247 . . . . 0.0 111.535 179.147 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' E' E ' 24' ' ' VAL . . . . . 0.466 ' HB ' ' H ' ' B' ' 25' ' ' GLY . 57.6 t -58.86 169.03 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.851 0 N-CA-C 107.691 -1.225 . . . . 0.0 107.691 177.017 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' E' E ' 25' ' ' GLY . . . . . 0.432 ' N ' HG12 ' E' ' 24' ' ' VAL . . . -122.51 49.59 0.88 Allowed Glycine 0 N--CA 1.477 1.383 0 N-CA-C 110.674 -0.971 . . . . 0.0 110.674 -179.479 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -63.07 -167.57 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.553 0 CA-C-O 120.644 0.259 . . . . 0.0 110.601 179.774 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 25.1 t-20 -69.93 78.12 0.48 Allowed 'General case' 0 N--CA 1.466 0.351 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.383 -179.944 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -77.32 146.73 36.58 Favored 'General case' 0 N--CA 1.475 0.81 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 179.28 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.39 -168.33 1.08 Allowed Glycine 0 CA--C 1.522 0.518 0 N-CA-C 110.522 -1.031 . . . . 0.0 110.522 178.623 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.74 115.45 29.55 Favored 'General case' 0 N--CA 1.468 0.461 0 N-CA-C 109.904 -0.406 . . . . 0.0 109.904 179.471 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 70.5 mt -96.38 135.09 31.6 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.282 0 N-CA-C 106.942 -1.503 . . . . 0.0 106.942 179.037 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 39.0 pt -151.1 -176.16 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.229 0 CA-C-O 121.164 0.506 . . . . 0.0 110.737 -179.157 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.2 5.97 9.25 Favored Glycine 0 CA--C 1.529 0.963 0 CA-C-N 115.322 -0.853 . . . . 0.0 111.243 -179.517 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 1.4 tt -73.8 128.68 36.16 Favored 'General case' 0 CA--C 1.548 0.884 0 N-CA-C 109.629 -0.508 . . . . 0.0 109.629 -179.544 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 28.4 ttt -162.93 148.79 12.11 Favored 'General case' 0 C--O 1.209 -1.056 0 N-CA-C 108.925 -0.769 . . . . 0.0 108.925 178.484 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' E' E ' 36' ' ' VAL . . . . . 0.572 HG22 HG12 ' H' ' 36' ' ' VAL . 34.0 m -156.97 162.73 1.5 Allowed 'Isoleucine or valine' 0 C--N 1.344 0.344 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 179.862 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' E' E ' 37' ' ' GLY . . . . . 0.515 ' H ' HE22 ' E' ' 15' ' ' GLN . . . 55.94 66.8 2.59 Favored Glycine 0 C--N 1.307 -1.06 0 CA-C-N 115.933 -0.576 . . . . 0.0 111.939 178.537 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 142.56 176.81 17.01 Favored Glycine 0 N--CA 1.477 1.382 0 N-CA-C 111.149 -0.78 . . . . 0.0 111.149 179.007 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' E' E ' 39' ' ' VAL . . . . . 0.544 ' H ' HG12 ' H' ' 39' ' ' VAL . 33.3 m -119.93 158.62 21.68 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.749 0 C-N-CA 123.392 0.677 . . . . 0.0 110.626 -179.595 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 22.6 t . . . . . 0 C--O 1.22 -0.478 0 CA-C-O 118.448 -0.787 . . . . 0.0 110.482 179.112 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' F' F ' 1' ' ' ASP . . . . . . . . . . . . . 15.0 m-20 . . . . . 0 N--CA 1.49 1.571 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' F' F ' 2' ' ' ALA . . . . . . . . . . . . . . . -63.68 130.01 42.48 Favored 'General case' 0 N--CA 1.467 0.422 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.504 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' F' F ' 3' ' ' GLU . . . . . . . . . . . . . 44.2 tt0 -167.49 106.12 0.55 Allowed 'General case' 0 C--O 1.212 -0.918 0 CA-C-N 116.743 -0.208 . . . . 0.0 110.466 -179.666 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 38.2 m-85 -86.29 151.29 23.72 Favored 'General case' 0 N--CA 1.474 0.75 0 N-CA-C 110.135 -0.32 . . . . 0.0 110.135 179.264 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' F' F ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -142.47 141.24 32.13 Favored 'General case' 0 N--CA 1.478 0.959 0 CA-C-O 120.805 0.336 . . . . 0.0 110.249 179.41 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 43.9 t-80 -151.92 118.74 5.78 Favored 'General case' 0 N--CA 1.472 0.659 0 N-CA-C 109.315 -0.624 . . . . 0.0 109.315 178.928 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' F' F ' 7' ' ' ASP . . . . . 0.477 ' O ' ' OG ' ' I' ' 8' ' ' SER . 4.3 m-20 -69.35 148.64 49.39 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 116.411 -0.359 . . . . 0.0 110.814 -179.96 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' F' F ' 8' ' ' SER . . . . . 0.482 ' OG ' ' O ' ' C' ' 7' ' ' ASP . 56.1 p -168.33 -172.79 1.81 Allowed 'General case' 0 N--CA 1.487 1.422 0 CA-C-O 121.111 0.482 . . . . 0.0 110.924 178.8 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.93 47.01 1.3 Allowed Glycine 0 N--CA 1.479 1.502 0 CA-C-N 115.978 -0.556 . . . . 0.0 112.064 179.877 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 47.7 p90 -65.57 133.03 50.32 Favored 'General case' 0 CA--C 1.543 0.673 0 N-CA-C 111.852 0.316 . . . . 0.0 111.852 -179.954 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 48.3 mt-10 -91.48 152.33 20.4 Favored 'General case' 0 N--CA 1.48 1.042 0 CA-C-O 121.195 0.521 . . . . 0.0 109.713 177.818 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -154.18 126.87 1.09 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.608 0 N-CA-C 107.825 -1.176 . . . . 0.0 107.825 177.997 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 41.9 m-70 -135.67 146.9 48.29 Favored 'General case' 0 N--CA 1.483 1.2 0 CA-C-O 120.936 0.398 . . . . 0.0 111.582 -178.142 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 7.1 t60 -162.98 97.49 0.93 Allowed 'General case' 0 N--CA 1.486 1.371 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.821 179.55 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' F' F ' 15' ' ' GLN . . . . . 0.526 HE22 ' H ' ' F' ' 37' ' ' GLY . 3.4 pt20 -107.06 -175.22 2.73 Favored 'General case' 0 CA--C 1.507 -0.675 0 N-CA-C 108.482 -0.932 . . . . 0.0 108.482 -179.939 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -169.77 99.86 0.31 Allowed 'General case' 0 N--CA 1.47 0.572 0 CA-C-N 114.712 -1.131 . . . . 0.0 108.606 179.052 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' F' F ' 17' ' ' LEU . . . . . 0.559 ' H ' ' CD2' ' I' ' 17' ' ' LEU . 7.2 mt -123.81 154.33 39.73 Favored 'General case' 0 N--CA 1.489 1.501 0 CA-C-O 121.273 0.558 . . . . 0.0 111.461 -177.735 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 51.8 t -111.07 126.21 68.45 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.325 0 N-CA-C 108.262 -1.014 . . . . 0.0 108.262 177.529 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 47.0 m-85 -123.71 121.15 34.76 Favored 'General case' 0 C--N 1.367 1.363 0 CA-C-O 120.972 0.415 . . . . 0.0 111.018 -179.819 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 74.1 m-85 54.23 74.31 0.34 Allowed 'General case' 0 N--CA 1.469 0.477 0 CA-C-N 115.871 -0.604 . . . . 0.0 111.743 178.054 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -78.15 -78.98 0.13 Allowed 'General case' 0 N--CA 1.465 0.32 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.228 -179.551 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 39.7 tt0 -111.71 101.19 9.58 Favored 'General case' 0 N--CA 1.469 0.5 0 N-CA-C 108.325 -0.991 . . . . 0.0 108.325 -179.986 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -158.86 140.6 13.53 Favored 'General case' 0 C--O 1.205 -1.277 0 CA-C-O 119.584 -0.246 . . . . 0.0 111.483 179.089 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' F' F ' 24' ' ' VAL . . . . . 0.447 ' HB ' ' H ' ' C' ' 25' ' ' GLY . 57.4 t -58.81 168.91 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.885 0 N-CA-C 107.591 -1.263 . . . . 0.0 107.591 177.057 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' F' F ' 25' ' ' GLY . . . . . 0.436 ' N ' HG12 ' F' ' 24' ' ' VAL . . . -122.31 49.4 0.89 Allowed Glycine 0 N--CA 1.477 1.402 0 N-CA-C 110.751 -0.94 . . . . 0.0 110.751 -179.478 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -63.16 -168.39 0.02 OUTLIER 'General case' 0 N--CA 1.469 0.489 0 CA-C-O 120.635 0.255 . . . . 0.0 110.447 -179.975 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 25.1 t-20 -69.11 77.96 0.34 Allowed 'General case' 0 CA--C 1.533 0.292 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.484 -179.908 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -77.18 147.02 36.69 Favored 'General case' 0 N--CA 1.475 0.816 0 N-CA-C 109.468 -0.567 . . . . 0.0 109.468 179.239 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.44 -168.11 1.07 Allowed Glycine 0 CA--C 1.522 0.481 0 N-CA-C 110.612 -0.995 . . . . 0.0 110.612 178.569 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.54 114.85 28.1 Favored 'General case' 0 N--CA 1.469 0.504 0 N-CA-C 109.891 -0.411 . . . . 0.0 109.891 179.484 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 70.6 mt -96.16 135.02 31.59 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.298 0 N-CA-C 106.987 -1.486 . . . . 0.0 106.987 178.895 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 38.6 pt -151.16 -176.32 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.251 0 CA-C-O 121.191 0.519 . . . . 0.0 110.739 -179.184 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.39 6.0 9.79 Favored Glycine 0 CA--C 1.529 0.937 0 CA-C-N 115.29 -0.868 . . . . 0.0 111.186 -179.622 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' F' F ' 34' ' ' LEU . . . . . 0.403 HD23 ' N ' ' F' ' 35' ' ' MET . 1.3 tt -73.64 128.69 36.18 Favored 'General case' 0 CA--C 1.549 0.913 0 N-CA-C 109.538 -0.541 . . . . 0.0 109.538 -179.586 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' F' F ' 35' ' ' MET . . . . . 0.403 ' N ' HD23 ' F' ' 34' ' ' LEU . 28.4 ttt -162.96 148.73 12.03 Favored 'General case' 0 C--O 1.208 -1.094 0 N-CA-C 108.82 -0.807 . . . . 0.0 108.82 178.378 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' F' F ' 36' ' ' VAL . . . . . 0.575 HG22 HG12 ' I' ' 36' ' ' VAL . 34.1 m -156.75 163.0 1.46 Allowed 'Isoleucine or valine' 0 C--N 1.346 0.429 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 179.872 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' F' F ' 37' ' ' GLY . . . . . 0.526 ' H ' HE22 ' F' ' 15' ' ' GLN . . . 55.58 67.1 2.39 Favored Glycine 0 C--N 1.307 -1.061 0 CA-C-N 115.944 -0.571 . . . . 0.0 111.947 178.45 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 142.35 176.85 16.87 Favored Glycine 0 N--CA 1.476 1.325 0 N-CA-C 111.155 -0.778 . . . . 0.0 111.155 179.036 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' F' F ' 39' ' ' VAL . . . . . 0.531 ' H ' HG12 ' I' ' 39' ' ' VAL . 33.4 m -119.95 158.92 21.55 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.629 0 C-N-CA 123.374 0.67 . . . . 0.0 110.649 -179.675 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 23.6 t . . . . . 0 C--O 1.221 -0.417 0 CA-C-O 118.549 -0.738 . . . . 0.0 110.499 179.071 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' G' G ' 1' ' ' ASP . . . . . . . . . . . . . 14.2 m-20 . . . . . 0 N--CA 1.492 1.645 0 N-CA-C 109.392 -0.596 . . . . 0.0 109.392 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' G' G ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.81 128.84 37.77 Favored 'General case' 0 N--CA 1.468 0.448 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.637 179.642 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' G' G ' 3' ' ' GLU . . . . . . . . . . . . . 43.6 tt0 -168.1 107.01 0.51 Allowed 'General case' 0 N--CA 1.472 0.641 0 CA-C-O 120.52 0.2 . . . . 0.0 110.806 179.841 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 40.8 m-85 -87.98 151.22 22.94 Favored 'General case' 0 N--CA 1.473 0.719 0 N-CA-C 109.643 -0.503 . . . . 0.0 109.643 179.142 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' G' G ' 5' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -142.98 141.02 31.3 Favored 'General case' 0 N--CA 1.482 1.15 0 CA-C-O 120.816 0.341 . . . . 0.0 110.188 179.721 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 44.3 t-80 -151.53 119.48 6.22 Favored 'General case' 0 N--CA 1.474 0.743 0 N-CA-C 109.384 -0.599 . . . . 0.0 109.384 178.948 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -71.04 144.53 50.36 Favored 'General case' 0 N--CA 1.471 0.583 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.212 -179.822 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' G' G ' 8' ' ' SER . . . . . 0.584 ' OG ' ' O ' ' D' ' 7' ' ' ASP . 54.4 p -165.31 -171.22 2.1 Favored 'General case' 0 N--CA 1.476 0.861 0 CA-C-O 121.054 0.454 . . . . 0.0 110.436 178.644 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.88 46.76 1.33 Allowed Glycine 0 N--CA 1.479 1.566 0 CA-C-N 115.809 -0.632 . . . . 0.0 111.607 179.533 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 50.0 p90 -65.44 133.05 50.48 Favored 'General case' 0 N--CA 1.472 0.649 0 N-CA-C 111.835 0.309 . . . . 0.0 111.835 -179.795 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 49.1 mt-10 -91.88 151.89 20.34 Favored 'General case' 0 N--CA 1.479 1.001 0 CA-C-O 121.108 0.48 . . . . 0.0 110.062 178.401 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -155.08 127.04 0.97 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.021 0 N-CA-C 107.886 -1.153 . . . . 0.0 107.886 178.33 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 43.1 m-70 -135.01 148.39 49.94 Favored 'General case' 0 N--CA 1.478 0.944 0 CA-C-N 115.49 -0.777 . . . . 0.0 111.414 -178.399 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 7.2 t60 -164.49 97.29 0.78 Allowed 'General case' 0 N--CA 1.484 1.227 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.486 178.907 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' G' G ' 15' ' ' GLN . . . . . 0.527 HE22 ' H ' ' G' ' 37' ' ' GLY . 3.5 pt20 -106.88 -175.67 2.86 Favored 'General case' 0 CA--C 1.508 -0.664 0 N-CA-C 108.364 -0.976 . . . . 0.0 108.364 -179.821 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -169.98 99.52 0.29 Allowed 'General case' 0 N--CA 1.473 0.691 0 CA-C-N 114.649 -1.159 . . . . 0.0 108.345 179.176 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' G' G ' 17' ' ' LEU . . . . . 0.554 ' CD2' ' H ' ' D' ' 17' ' ' LEU . 8.2 mt -123.4 153.94 39.69 Favored 'General case' 0 N--CA 1.495 1.786 0 CA-C-O 121.085 0.469 . . . . 0.0 111.789 -177.863 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 43.4 t -111.26 126.39 68.65 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.038 0 N-CA-C 108.1 -1.074 . . . . 0.0 108.1 177.021 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 48.0 m-85 -124.12 120.77 33.3 Favored 'General case' 0 C--N 1.367 1.346 0 CA-C-N 115.602 -0.726 . . . . 0.0 111.192 -179.539 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 73.8 m-85 54.46 73.66 0.39 Allowed 'General case' 0 N--CA 1.47 0.526 0 CA-C-N 115.896 -0.593 . . . . 0.0 111.594 178.008 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.04 -78.32 0.13 Allowed 'General case' 0 N--CA 1.471 0.59 0 O-C-N 122.282 -0.262 . . . . 0.0 110.446 -179.032 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 40.4 tt0 -112.25 101.07 9.32 Favored 'General case' 0 C--N 1.322 -0.629 0 N-CA-C 108.108 -1.071 . . . . 0.0 108.108 179.839 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -158.38 142.38 15.6 Favored 'General case' 0 N--CA 1.478 0.926 0 O-C-N 122.387 -0.195 . . . . 0.0 111.442 179.01 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' G' G ' 24' ' ' VAL . . . . . 0.503 ' HB ' ' H ' ' D' ' 25' ' ' GLY . 59.7 t -60.97 167.76 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.644 0 N-CA-C 107.67 -1.233 . . . . 0.0 107.67 177.384 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' G' G ' 25' ' ' GLY . . . . . 0.437 ' N ' HG12 ' G' ' 24' ' ' VAL . . . -120.64 49.95 0.85 Allowed Glycine 0 N--CA 1.482 1.755 0 N-CA-C 110.338 -1.105 . . . . 0.0 110.338 -179.58 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -63.78 -167.61 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.661 0 CA-C-N 116.984 0.392 . . . . 0.0 109.987 179.833 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 25.2 t-20 -70.11 77.71 0.51 Allowed 'General case' 0 CA--C 1.536 0.407 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.451 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -76.16 146.72 38.98 Favored 'General case' 0 N--CA 1.475 0.818 0 N-CA-C 109.506 -0.553 . . . . 0.0 109.506 179.306 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.62 -167.01 0.95 Allowed Glycine 0 C--N 1.336 0.578 0 N-CA-C 110.076 -1.21 . . . . 0.0 110.076 178.721 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.58 115.26 28.98 Favored 'General case' 0 N--CA 1.469 0.516 0 C-N-CA 122.689 0.395 . . . . 0.0 110.438 179.841 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 72.1 mt -97.1 135.99 29.41 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.671 0 N-CA-C 106.87 -1.53 . . . . 0.0 106.87 178.931 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 36.8 pt -152.47 -176.01 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.71 0 CA-C-N 119.855 1.207 . . . . 0.0 109.95 -179.631 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.09 5.83 11.27 Favored Glycine 0 CA--C 1.527 0.811 0 N-CA-C 110.878 -0.889 . . . . 0.0 110.878 -179.763 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' G' G ' 34' ' ' LEU . . . . . 0.408 HD23 ' N ' ' G' ' 35' ' ' MET . 1.4 tt -74.3 127.4 32.89 Favored 'General case' 0 CA--C 1.546 0.796 0 N-CA-C 109.7 -0.482 . . . . 0.0 109.7 -179.503 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' G' G ' 35' ' ' MET . . . . . 0.408 ' N ' HD23 ' G' ' 34' ' ' LEU . 28.1 ttt -161.56 150.22 15.73 Favored 'General case' 0 C--O 1.212 -0.897 0 N-CA-C 108.844 -0.798 . . . . 0.0 108.844 178.533 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' G' G ' 36' ' ' VAL . . . . . 0.578 HG12 HG22 ' D' ' 36' ' ' VAL . 33.9 m -157.4 162.11 1.62 Allowed 'Isoleucine or valine' 0 C--N 1.346 0.451 0 N-CA-C 108.628 -0.878 . . . . 0.0 108.628 -179.819 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' G' G ' 37' ' ' GLY . . . . . 0.527 ' H ' HE22 ' G' ' 15' ' ' GLN . . . 55.61 67.01 2.43 Favored Glycine 0 C--N 1.312 -0.803 0 CA-C-N 115.599 -0.728 . . . . 0.0 112.299 178.111 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.33 178.3 19.02 Favored Glycine 0 N--CA 1.477 1.383 0 N-CA-C 110.569 -1.012 . . . . 0.0 110.569 178.925 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' G' G ' 39' ' ' VAL . . . . . 0.529 HG12 ' H ' ' D' ' 39' ' ' VAL . 34.2 m -121.34 158.37 24.3 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.837 0 C-N-CA 123.128 0.571 . . . . 0.0 110.6 -179.621 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 22.2 t . . . . . 0 N--CA 1.469 0.515 0 O-C-N 123.981 0.801 . . . . 0.0 110.752 179.163 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' H' H ' 1' ' ' ASP . . . . . . . . . . . . . 14.7 m-20 . . . . . 0 N--CA 1.491 1.612 0 N-CA-C 109.4 -0.593 . . . . 0.0 109.4 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' H' H ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.75 128.83 37.74 Favored 'General case' 0 N--CA 1.467 0.4 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.612 179.843 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' H' H ' 3' ' ' GLU . . . . . . . . . . . . . 43.7 tt0 -168.12 106.88 0.51 Allowed 'General case' 0 N--CA 1.471 0.603 0 CA-C-O 120.567 0.222 . . . . 0.0 110.736 179.819 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 42.2 m-85 -87.81 151.2 23.05 Favored 'General case' 0 N--CA 1.474 0.744 0 N-CA-C 109.603 -0.517 . . . . 0.0 109.603 179.136 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' H' H ' 5' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -142.91 141.35 31.48 Favored 'General case' 0 N--CA 1.484 1.263 0 N-CA-C 110.081 -0.34 . . . . 0.0 110.081 179.732 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 44.3 t-80 -151.89 119.54 6.09 Favored 'General case' 0 N--CA 1.474 0.745 0 N-CA-C 109.334 -0.617 . . . . 0.0 109.334 178.901 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -70.96 144.57 50.49 Favored 'General case' 0 N--CA 1.47 0.57 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.251 -179.884 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' H' H ' 8' ' ' SER . . . . . 0.441 ' OG ' ' O ' ' E' ' 7' ' ' ASP . 60.2 p -165.26 -171.55 2.22 Favored 'General case' 0 N--CA 1.474 0.758 0 CA-C-O 120.976 0.417 . . . . 0.0 110.485 178.751 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.83 46.62 1.36 Allowed Glycine 0 N--CA 1.481 1.645 0 CA-C-N 115.986 -0.552 . . . . 0.0 111.756 179.699 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 50.3 p90 -65.64 133.15 50.52 Favored 'General case' 0 N--CA 1.471 0.625 0 N-CA-C 111.798 0.295 . . . . 0.0 111.798 -179.835 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 48.5 mt-10 -91.75 152.25 20.25 Favored 'General case' 0 N--CA 1.477 0.911 0 CA-C-O 121.127 0.489 . . . . 0.0 110.128 178.446 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -155.2 127.49 1.02 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.049 0 N-CA-C 107.83 -1.174 . . . . 0.0 107.83 178.346 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 44.1 m-70 -135.53 148.01 48.99 Favored 'General case' 0 N--CA 1.477 0.909 0 CA-C-N 115.566 -0.743 . . . . 0.0 111.396 -178.307 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 7.1 t60 -164.32 97.26 0.8 Allowed 'General case' 0 N--CA 1.484 1.226 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.45 178.915 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' H' H ' 15' ' ' GLN . . . . . 0.512 HE22 ' H ' ' H' ' 37' ' ' GLY . 3.5 pt20 -106.8 -175.67 2.86 Favored 'General case' 0 CA--C 1.508 -0.666 0 N-CA-C 108.278 -1.008 . . . . 0.0 108.278 -179.872 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -169.81 99.64 0.31 Allowed 'General case' 0 N--CA 1.472 0.653 0 CA-C-N 114.72 -1.127 . . . . 0.0 108.358 179.124 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' H' H ' 17' ' ' LEU . . . . . 0.563 ' CD2' ' H ' ' E' ' 17' ' ' LEU . 8.6 mt -123.44 154.08 39.57 Favored 'General case' 0 N--CA 1.495 1.819 0 CA-C-O 121.118 0.485 . . . . 0.0 111.86 -177.757 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 43.0 t -111.65 126.05 69.01 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.111 0 N-CA-C 108.077 -1.082 . . . . 0.0 108.077 177.087 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 47.5 m-85 -123.83 120.45 32.63 Favored 'General case' 0 C--N 1.368 1.392 0 CA-C-N 115.456 -0.793 . . . . 0.0 110.981 -179.332 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 73.4 m-85 54.11 74.33 0.34 Allowed 'General case' 0 C--N 1.345 0.399 0 CA-C-N 115.776 -0.647 . . . . 0.0 111.697 178.02 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.25 -78.15 0.13 Allowed 'General case' 0 N--CA 1.472 0.655 0 O-C-N 122.4 -0.188 . . . . 0.0 110.519 -179.117 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 40.3 tt0 -112.41 100.95 9.18 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 108.024 -1.102 . . . . 0.0 108.024 179.899 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -158.31 141.95 15.34 Favored 'General case' 0 N--CA 1.478 0.946 0 O-C-N 122.384 -0.198 . . . . 0.0 111.458 179.104 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' H' H ' 24' ' ' VAL . . . . . 0.433 HG12 ' N ' ' H' ' 25' ' ' GLY . 59.6 t -60.63 167.89 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.561 0 N-CA-C 107.664 -1.236 . . . . 0.0 107.664 177.389 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' H' H ' 25' ' ' GLY . . . . . 0.433 ' N ' HG12 ' H' ' 24' ' ' VAL . . . -120.89 49.27 0.89 Allowed Glycine 0 N--CA 1.48 1.609 0 N-CA-C 110.482 -1.047 . . . . 0.0 110.482 -179.385 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -63.24 -167.56 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.642 0 CA-C-N 117.009 0.405 . . . . 0.0 110.201 179.881 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 25.2 t-20 -69.93 78.11 0.48 Allowed 'General case' 0 CA--C 1.535 0.388 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.411 179.903 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -76.76 146.55 37.86 Favored 'General case' 0 N--CA 1.476 0.842 0 N-CA-C 109.501 -0.555 . . . . 0.0 109.501 179.314 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.74 -167.12 1.01 Allowed Glycine 0 C--N 1.336 0.578 0 N-CA-C 110.045 -1.222 . . . . 0.0 110.045 178.757 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.84 115.11 28.82 Favored 'General case' 0 N--CA 1.467 0.378 0 C-N-CA 122.6 0.36 . . . . 0.0 110.579 -179.938 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 71.6 mt -96.84 136.02 29.03 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.729 0 N-CA-C 106.866 -1.531 . . . . 0.0 106.866 179.094 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 36.6 pt -152.42 -175.87 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.761 0 CA-C-N 119.814 1.188 . . . . 0.0 109.898 -179.716 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.5 7.0 12.59 Favored Glycine 0 CA--C 1.526 0.78 0 N-CA-C 110.879 -0.889 . . . . 0.0 110.879 -179.755 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 1.3 tt -75.33 127.12 32.44 Favored 'General case' 0 CA--C 1.545 0.775 0 N-CA-C 109.69 -0.485 . . . . 0.0 109.69 -179.728 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 28.0 ttt -161.31 150.03 16.04 Favored 'General case' 0 C--O 1.212 -0.917 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 178.61 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' H' H ' 36' ' ' VAL . . . . . 0.572 HG12 HG22 ' E' ' 36' ' ' VAL . 34.0 m -157.24 161.74 1.73 Allowed 'Isoleucine or valine' 0 C--N 1.345 0.398 0 N-CA-C 108.742 -0.836 . . . . 0.0 108.742 -179.665 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' H' H ' 37' ' ' GLY . . . . . 0.512 ' H ' HE22 ' H' ' 15' ' ' GLN . . . 55.81 66.89 2.52 Favored Glycine 0 C--N 1.311 -0.833 0 CA-C-N 115.673 -0.694 . . . . 0.0 112.261 178.172 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.46 178.09 18.96 Favored Glycine 0 N--CA 1.477 1.396 0 N-CA-C 110.644 -0.982 . . . . 0.0 110.644 179.026 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' H' H ' 39' ' ' VAL . . . . . 0.544 HG12 ' H ' ' E' ' 39' ' ' VAL . 34.1 m -121.12 158.43 23.81 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.846 0 C-N-CA 123.191 0.597 . . . . 0.0 110.772 -179.646 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 23.7 t . . . . . 0 N--CA 1.47 0.529 0 O-C-N 123.936 0.772 . . . . 0.0 110.694 179.149 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' I' I ' 1' ' ' ASP . . . . . . . . . . . . . 14.7 m-20 . . . . . 0 N--CA 1.49 1.566 0 N-CA-C 109.465 -0.569 . . . . 0.0 109.465 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' I' I ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.96 128.78 37.46 Favored 'General case' 0 N--CA 1.468 0.468 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.578 179.91 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' I' I ' 3' ' ' GLU . . . . . . . . . . . . . 43.6 tt0 -167.91 107.01 0.53 Allowed 'General case' 0 N--CA 1.471 0.61 0 CA-C-O 120.501 0.191 . . . . 0.0 110.796 179.781 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 41.0 m-85 -88.0 151.13 23.0 Favored 'General case' 0 N--CA 1.474 0.767 0 N-CA-C 109.579 -0.526 . . . . 0.0 109.579 179.176 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' I' I ' 5' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -142.81 141.35 31.62 Favored 'General case' 0 N--CA 1.483 1.224 0 C-N-CA 122.596 0.359 . . . . 0.0 110.143 179.787 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 45.0 t-80 -151.93 119.46 6.04 Favored 'General case' 0 N--CA 1.473 0.708 0 N-CA-C 109.379 -0.6 . . . . 0.0 109.379 178.96 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -71.02 144.41 50.43 Favored 'General case' 0 N--CA 1.469 0.497 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.268 -179.859 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' I' I ' 8' ' ' SER . . . . . 0.477 ' OG ' ' O ' ' F' ' 7' ' ' ASP . 60.5 p -165.02 -171.47 2.24 Favored 'General case' 0 N--CA 1.474 0.771 0 CA-C-O 120.975 0.417 . . . . 0.0 110.469 178.839 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.66 47.03 1.32 Allowed Glycine 0 N--CA 1.479 1.525 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.777 179.598 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 50.0 p90 -66.18 132.8 49.29 Favored 'General case' 0 N--CA 1.472 0.626 0 N-CA-C 111.869 0.322 . . . . 0.0 111.869 -179.805 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 48.5 mt-10 -91.19 152.29 20.61 Favored 'General case' 0 N--CA 1.477 0.907 0 CA-C-O 121.155 0.502 . . . . 0.0 110.202 178.385 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -155.48 126.95 0.91 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.057 0 N-CA-C 107.887 -1.153 . . . . 0.0 107.887 178.201 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 42.9 m-70 -134.92 148.33 50.03 Favored 'General case' 0 N--CA 1.478 0.935 0 CA-C-N 115.488 -0.778 . . . . 0.0 111.432 -178.409 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 7.1 t60 -164.49 97.33 0.78 Allowed 'General case' 0 N--CA 1.481 1.111 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.441 178.995 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' I' I ' 15' ' ' GLN . . . . . 0.534 HE22 ' H ' ' I' ' 37' ' ' GLY . 3.5 pt20 -106.84 -175.36 2.77 Favored 'General case' 0 CA--C 1.508 -0.666 0 N-CA-C 108.208 -1.034 . . . . 0.0 108.208 -179.815 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -170.18 99.53 0.28 Allowed 'General case' 0 N--CA 1.471 0.595 0 CA-C-N 114.592 -1.185 . . . . 0.0 108.25 179.159 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' I' I ' 17' ' ' LEU . . . . . 0.559 ' CD2' ' H ' ' F' ' 17' ' ' LEU . 8.4 mt -123.23 153.76 39.69 Favored 'General case' 0 N--CA 1.495 1.8 0 CA-C-O 121.042 0.449 . . . . 0.0 111.836 -177.829 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 43.8 t -111.3 126.44 68.69 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.02 0 N-CA-C 108.05 -1.093 . . . . 0.0 108.05 176.913 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 47.1 m-85 -124.16 120.77 33.27 Favored 'General case' 0 C--N 1.368 1.389 0 CA-C-N 115.511 -0.768 . . . . 0.0 111.002 -179.294 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 73.4 m-85 53.87 73.84 0.36 Allowed 'General case' 0 N--CA 1.469 0.495 0 CA-C-N 115.898 -0.592 . . . . 0.0 111.637 178.062 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -76.74 -78.43 0.12 Allowed 'General case' 0 N--CA 1.471 0.61 0 O-C-N 122.304 -0.247 . . . . 0.0 110.414 -179.209 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 40.1 tt0 -112.12 101.31 9.58 Favored 'General case' 0 C--N 1.324 -0.512 0 N-CA-C 108.075 -1.083 . . . . 0.0 108.075 179.938 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -158.53 142.4 15.42 Favored 'General case' 0 N--CA 1.477 0.903 0 O-C-N 122.42 -0.175 . . . . 0.0 111.467 179.063 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' I' I ' 24' ' ' VAL . . . . . 0.447 HG12 ' N ' ' I' ' 25' ' ' GLY . 59.0 t -61.06 167.82 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.561 0 N-CA-C 107.663 -1.236 . . . . 0.0 107.663 177.296 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' I' I ' 25' ' ' GLY . . . . . 0.447 ' N ' HG12 ' I' ' 24' ' ' VAL . . . -120.8 49.85 0.86 Allowed Glycine 0 N--CA 1.481 1.682 0 N-CA-C 110.45 -1.06 . . . . 0.0 110.45 -179.485 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -63.84 -167.57 0.02 OUTLIER 'General case' 0 N--CA 1.471 0.594 0 CA-C-N 116.927 0.364 . . . . 0.0 110.24 179.879 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 25.2 t-20 -69.8 77.59 0.46 Allowed 'General case' 0 CA--C 1.535 0.37 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.445 179.883 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -76.39 146.66 38.55 Favored 'General case' 0 N--CA 1.474 0.755 0 N-CA-C 109.438 -0.578 . . . . 0.0 109.438 179.305 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.73 -166.79 0.96 Allowed Glycine 0 C--N 1.337 0.638 0 N-CA-C 110.074 -1.21 . . . . 0.0 110.074 178.76 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.84 114.88 28.37 Favored 'General case' 0 N--CA 1.469 0.501 0 C-N-CA 122.771 0.428 . . . . 0.0 110.582 179.913 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 72.0 mt -96.75 136.07 28.78 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.674 0 N-CA-C 106.883 -1.525 . . . . 0.0 106.883 178.981 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 37.5 pt -152.46 -175.94 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 CA-C-N 119.885 1.221 . . . . 0.0 109.907 -179.678 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.63 6.69 12.22 Favored Glycine 0 CA--C 1.526 0.763 0 N-CA-C 110.94 -0.864 . . . . 0.0 110.94 -179.776 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' I' I ' 34' ' ' LEU . . . . . 0.408 HD23 ' N ' ' I' ' 35' ' ' MET . 1.4 tt -75.04 127.13 32.51 Favored 'General case' 0 CA--C 1.547 0.83 0 N-CA-C 109.547 -0.538 . . . . 0.0 109.547 -179.64 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' I' I ' 35' ' ' MET . . . . . 0.408 ' N ' HD23 ' I' ' 34' ' ' LEU . 28.1 ttt -161.1 150.12 16.49 Favored 'General case' 0 C--O 1.211 -0.942 0 N-CA-C 108.738 -0.838 . . . . 0.0 108.738 178.564 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' I' I ' 36' ' ' VAL . . . . . 0.575 HG12 HG22 ' F' ' 36' ' ' VAL . 34.1 m -157.23 162.11 1.63 Allowed 'Isoleucine or valine' 0 C--N 1.347 0.459 0 N-CA-C 108.594 -0.891 . . . . 0.0 108.594 -179.747 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' I' I ' 37' ' ' GLY . . . . . 0.534 ' H ' HE22 ' I' ' 15' ' ' GLN . . . 55.34 67.2 2.33 Favored Glycine 0 C--N 1.311 -0.841 0 CA-C-N 115.643 -0.708 . . . . 0.0 112.241 178.122 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.18 178.28 18.88 Favored Glycine 0 N--CA 1.478 1.47 0 N-CA-C 110.568 -1.013 . . . . 0.0 110.568 178.875 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' I' I ' 39' ' ' VAL . . . . . 0.531 HG12 ' H ' ' F' ' 39' ' ' VAL . 33.9 m -121.33 158.31 24.33 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.856 0 C-N-CA 123.15 0.58 . . . . 0.0 110.723 -179.662 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 23.4 t . . . . . 0 N--CA 1.469 0.523 0 O-C-N 124.046 0.841 . . . . 0.0 110.699 179.041 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 13.4 m-20 . . . . . 0 N--CA 1.49 1.528 0 N-CA-C 108.942 -0.762 . . . . 0.0 108.942 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.89 132.93 49.83 Favored 'General case' 0 CA--C 1.538 0.518 0 N-CA-C 110.185 -0.302 . . . . 0.0 110.185 -179.785 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 44.1 tt0 -168.64 104.53 0.43 Allowed 'General case' 0 N--CA 1.473 0.703 0 N-CA-C 110.062 -0.347 . . . . 0.0 110.062 -179.152 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 35.1 m-85 -86.5 154.73 20.89 Favored 'General case' 0 N--CA 1.475 0.782 0 N-CA-C 110.082 -0.34 . . . . 0.0 110.082 179.697 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -144.31 139.65 28.69 Favored 'General case' 0 N--CA 1.481 1.115 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 179.563 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 42.1 t-80 -151.95 119.88 6.2 Favored 'General case' 0 N--CA 1.469 0.509 0 N-CA-C 109.264 -0.643 . . . . 0.0 109.264 179.257 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' ASP . . . . . 0.5 ' O ' ' OG ' ' D' ' 8' ' ' SER . 4.2 m-20 -69.04 148.68 49.72 Favored 'General case' 0 CA--C 1.537 0.476 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.498 179.876 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 53.9 p -168.2 -174.24 2.25 Favored 'General case' 0 N--CA 1.484 1.262 0 CA-C-O 121.035 0.445 . . . . 0.0 110.747 179.429 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.8 48.26 1.28 Allowed Glycine 0 N--CA 1.481 1.698 0 CA-C-N 115.911 -0.586 . . . . 0.0 111.83 179.725 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 49.7 p90 -64.6 132.39 49.67 Favored 'General case' 0 N--CA 1.473 0.691 0 O-C-N 122.761 -0.258 . . . . 0.0 111.425 179.732 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 83.3 mt-10 -91.71 152.25 20.28 Favored 'General case' 0 N--CA 1.48 1.047 0 C-N-CA 122.781 0.433 . . . . 0.0 109.839 178.379 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -153.23 128.42 1.54 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.617 0 N-CA-C 107.821 -1.177 . . . . 0.0 107.821 178.298 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 48.5 m-70 -135.25 145.98 48.13 Favored 'General case' 0 N--CA 1.492 1.666 0 CA-C-N 118.949 0.795 . . . . 0.0 111.388 -179.003 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 6.1 t60 -165.95 97.18 0.63 Allowed 'General case' 0 N--CA 1.48 1.058 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.848 179.5 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 3.6 pt20 -108.52 -174.69 2.58 Favored 'General case' 0 CA--C 1.506 -0.733 0 N-CA-C 108.432 -0.951 . . . . 0.0 108.432 -179.845 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -164.17 97.57 0.82 Allowed 'General case' 0 N--CA 1.472 0.651 0 CA-C-N 114.562 -1.199 . . . . 0.0 108.299 178.348 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 6.7 mp -122.27 157.78 30.94 Favored 'General case' 0 N--CA 1.497 1.924 0 CA-C-O 121.759 0.79 . . . . 0.0 110.91 -178.338 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 59.8 t -112.57 126.65 69.99 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.124 0 CA-C-O 117.984 -1.008 . . . . 0.0 108.316 177.702 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 28.7 m-85 -126.93 122.5 34.75 Favored 'General case' 0 N--CA 1.497 1.909 0 CA-C-N 120.017 1.28 . . . . 0.0 110.344 179.338 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 67.0 m-85 53.94 74.32 0.33 Allowed 'General case' 0 N--CA 1.47 0.572 0 CA-C-O 121.374 0.606 . . . . 0.0 111.745 178.751 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -80.55 -78.14 0.18 Allowed 'General case' 0 C--N 1.353 0.756 0 CA-C-N 115.139 -0.937 . . . . 0.0 110.334 -179.773 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 40.4 tt0 -112.21 101.59 9.82 Favored 'General case' 0 N--CA 1.469 0.502 0 N-CA-C 108.468 -0.938 . . . . 0.0 108.468 179.738 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 4.4 p30 -158.96 134.5 8.62 Favored 'General case' 0 N--CA 1.482 1.16 0 CA-C-O 119.512 -0.28 . . . . 0.0 111.211 178.936 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 58.7 t -58.05 163.07 0.71 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.853 0 N-CA-C 108.074 -1.084 . . . . 0.0 108.074 176.984 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.421 ' H ' ' HB ' ' D' ' 24' ' ' VAL . . . -115.76 47.95 0.99 Allowed Glycine 0 N--CA 1.477 1.383 0 N-CA-C 111.615 -0.594 . . . . 0.0 111.615 -179.474 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -61.85 -168.65 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.562 0 N-CA-C 110.152 -0.314 . . . . 0.0 110.152 179.338 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 24.5 t-20 -72.05 79.97 0.94 Allowed 'General case' 0 N--CA 1.464 0.257 0 CA-C-N 116.428 -0.351 . . . . 0.0 110.082 179.164 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -73.46 140.32 46.39 Favored 'General case' 0 N--CA 1.476 0.837 0 N-CA-C 108.934 -0.765 . . . . 0.0 108.934 179.375 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.39 -149.76 0.03 OUTLIER Glycine 0 C--N 1.337 0.618 0 N-CA-C 110.183 -1.167 . . . . 0.0 110.183 179.282 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -93.76 128.07 39.8 Favored 'General case' 0 N--CA 1.476 0.825 0 N-CA-C 110.04 -0.356 . . . . 0.0 110.04 -179.905 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 74.8 mt -124.16 117.35 50.54 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.748 0 N-CA-C 106.653 -1.61 . . . . 0.0 106.653 178.876 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 39.2 pt -151.5 -169.78 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.354 0.804 0 CA-C-O 121.22 0.533 . . . . 0.0 111.246 -178.769 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.84 5.08 12.38 Favored Glycine 0 C--N 1.336 0.58 0 N-CA-C 110.797 -0.921 . . . . 0.0 110.797 179.587 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 1.5 tt -78.14 126.77 31.3 Favored 'General case' 0 CA--C 1.546 0.801 0 N-CA-C 109.558 -0.534 . . . . 0.0 109.558 -179.884 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 28.6 ttt -164.69 143.55 6.94 Favored 'General case' 0 N--CA 1.464 0.23 0 N-CA-C 108.871 -0.788 . . . . 0.0 108.871 178.266 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.426 HG22 HG12 ' D' ' 36' ' ' VAL . 35.6 m -155.27 162.71 1.73 Allowed 'Isoleucine or valine' 0 C--N 1.348 0.509 0 N-CA-C 108.042 -1.096 . . . . 0.0 108.042 179.327 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.61 66.33 2.93 Favored Glycine 0 C--N 1.307 -1.08 0 CA-C-N 115.834 -0.621 . . . . 0.0 111.874 178.429 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 145.7 172.97 16.53 Favored Glycine 0 N--CA 1.473 1.1 0 N-CA-C 110.994 -0.843 . . . . 0.0 110.994 179.095 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.583 ' H ' HG12 ' D' ' 39' ' ' VAL . 33.7 m -123.01 160.44 25.76 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.616 0 C-N-CA 123.405 0.682 . . . . 0.0 110.087 -179.691 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 23.7 t . . . . . 0 C--O 1.218 -0.556 0 CA-C-O 118.419 -0.8 . . . . 0.0 110.578 179.478 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' B' B ' 1' ' ' ASP . . . . . . . . . . . . . 12.5 m-20 . . . . . 0 N--CA 1.489 1.49 0 N-CA-C 108.992 -0.744 . . . . 0.0 108.992 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' B' B ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.48 132.61 49.35 Favored 'General case' 0 CA--C 1.539 0.554 0 N-CA-C 110.151 -0.315 . . . . 0.0 110.151 -179.704 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 3' ' ' GLU . . . . . . . . . . . . . 44.0 tt0 -168.33 104.47 0.45 Allowed 'General case' 0 N--CA 1.474 0.742 0 N-CA-C 110.085 -0.339 . . . . 0.0 110.085 -179.15 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 34.7 m-85 -86.39 154.69 20.99 Favored 'General case' 0 N--CA 1.474 0.752 0 N-CA-C 110.047 -0.353 . . . . 0.0 110.047 179.617 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -144.41 139.06 28.16 Favored 'General case' 0 N--CA 1.484 1.225 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 179.585 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 41.5 t-80 -151.24 119.63 6.41 Favored 'General case' 0 N--CA 1.472 0.638 0 N-CA-C 109.256 -0.646 . . . . 0.0 109.256 179.204 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 7' ' ' ASP . . . . . 0.507 ' O ' ' OG ' ' E' ' 8' ' ' SER . 4.0 m-20 -68.83 148.19 50.63 Favored 'General case' 0 CA--C 1.538 0.514 0 CA-C-N 116.295 -0.412 . . . . 0.0 110.721 179.828 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 8' ' ' SER . . . . . . . . . . . . . 54.1 p -167.58 -173.69 2.27 Favored 'General case' 0 N--CA 1.483 1.221 0 CA-C-O 121.045 0.45 . . . . 0.0 110.707 179.525 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.38 48.24 1.33 Allowed Glycine 0 N--CA 1.481 1.692 0 CA-C-N 115.908 -0.587 . . . . 0.0 111.949 179.55 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 50.2 p90 -64.94 132.89 50.55 Favored 'General case' 0 N--CA 1.473 0.687 0 CA-C-O 120.636 0.255 . . . . 0.0 111.496 179.871 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 84.2 mt-10 -92.02 152.75 19.84 Favored 'General case' 0 N--CA 1.478 0.93 0 CA-C-O 121.048 0.451 . . . . 0.0 109.823 178.456 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -153.61 128.39 1.46 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.495 0 N-CA-C 107.922 -1.14 . . . . 0.0 107.922 178.12 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 46.5 m-70 -135.32 145.67 47.69 Favored 'General case' 0 N--CA 1.493 1.723 0 CA-C-N 118.941 0.791 . . . . 0.0 111.289 -179.006 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 6.0 t60 -165.65 96.86 0.66 Allowed 'General case' 0 N--CA 1.48 1.035 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.739 179.38 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 3.6 pt20 -108.12 -174.74 2.59 Favored 'General case' 0 CA--C 1.507 -0.694 0 N-CA-C 108.411 -0.959 . . . . 0.0 108.411 -179.798 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -164.29 97.63 0.8 Allowed 'General case' 0 N--CA 1.473 0.699 0 CA-C-N 114.67 -1.15 . . . . 0.0 108.263 178.342 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 6.6 mp -122.27 157.69 31.13 Favored 'General case' 0 N--CA 1.497 1.906 0 CA-C-O 121.809 0.814 . . . . 0.0 111.023 -178.298 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 61.4 t -112.71 127.75 69.77 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.024 0 N-CA-C 108.069 -1.086 . . . . 0.0 108.069 177.595 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 28.6 m-85 -128.09 122.09 31.22 Favored 'General case' 0 N--CA 1.495 1.787 0 CA-C-N 119.726 1.148 . . . . 0.0 110.192 179.501 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 67.1 m-85 53.6 74.18 0.33 Allowed 'General case' 0 CA--C 1.54 0.581 0 CA-C-O 121.487 0.661 . . . . 0.0 111.799 178.622 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -80.35 -78.32 0.17 Allowed 'General case' 0 C--N 1.352 0.687 0 CA-C-N 115.001 -1.0 . . . . 0.0 110.275 -179.823 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 40.5 tt0 -112.02 101.73 10.0 Favored 'General case' 0 N--CA 1.471 0.613 0 N-CA-C 108.448 -0.945 . . . . 0.0 108.448 179.819 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 4.4 p30 -158.89 134.8 8.89 Favored 'General case' 0 N--CA 1.482 1.169 0 CA-C-O 119.54 -0.266 . . . . 0.0 111.155 178.913 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 58.5 t -58.26 163.2 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.874 0 N-CA-C 108.128 -1.064 . . . . 0.0 108.128 177.018 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . 0.436 ' H ' ' HB ' ' E' ' 24' ' ' VAL . . . -115.57 47.62 1.02 Allowed Glycine 0 N--CA 1.474 1.203 0 N-CA-C 111.65 -0.58 . . . . 0.0 111.65 -179.314 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -61.77 -168.59 0.01 OUTLIER 'General case' 0 N--CA 1.469 0.518 0 N-CA-C 110.25 -0.278 . . . . 0.0 110.25 179.45 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 24.6 t-20 -72.38 79.85 1.02 Allowed 'General case' 0 N--CA 1.468 0.426 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.318 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -73.19 140.6 47.1 Favored 'General case' 0 N--CA 1.477 0.898 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 179.565 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.56 -150.05 0.04 OUTLIER Glycine 0 C--N 1.338 0.639 0 N-CA-C 110.191 -1.163 . . . . 0.0 110.191 179.411 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -93.41 128.33 39.42 Favored 'General case' 0 N--CA 1.475 0.787 0 CA-C-N 116.938 0.369 . . . . 0.0 110.032 179.795 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 76.7 mt -124.46 117.26 50.02 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.658 0 N-CA-C 106.593 -1.632 . . . . 0.0 106.593 178.811 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 39.8 pt -151.19 -169.71 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.355 0.831 0 CA-C-N 115.986 -0.552 . . . . 0.0 111.255 -178.746 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.83 4.95 11.86 Favored Glycine 0 C--N 1.337 0.627 0 N-CA-C 110.945 -0.862 . . . . 0.0 110.945 179.479 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 1.5 tt -78.12 126.81 31.35 Favored 'General case' 0 CA--C 1.546 0.819 0 N-CA-C 109.57 -0.53 . . . . 0.0 109.57 -179.778 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 28.5 ttt -164.81 143.53 6.75 Favored 'General case' 0 N--CA 1.465 0.311 0 N-CA-C 108.801 -0.814 . . . . 0.0 108.801 178.225 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 35.4 m -155.37 162.41 1.8 Allowed 'Isoleucine or valine' 0 C--N 1.347 0.499 0 N-CA-C 108.0 -1.111 . . . . 0.0 108.0 179.471 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.71 66.9 2.52 Favored Glycine 0 C--N 1.307 -1.068 0 CA-C-N 115.742 -0.663 . . . . 0.0 111.784 178.415 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 144.97 172.65 15.58 Favored Glycine 0 N--CA 1.472 1.08 0 N-CA-C 110.869 -0.892 . . . . 0.0 110.869 179.179 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 39' ' ' VAL . . . . . 0.605 ' H ' HG12 ' E' ' 39' ' ' VAL . 32.5 m -123.09 159.95 26.49 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.711 0 C-N-CA 123.428 0.691 . . . . 0.0 110.209 -179.553 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 24.4 t . . . . . 0 N--CA 1.468 0.468 0 CA-C-O 118.316 -0.849 . . . . 0.0 110.441 179.475 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' C' C ' 1' ' ' ASP . . . . . . . . . . . . . 13.0 m-20 . . . . . 0 N--CA 1.489 1.525 0 N-CA-C 108.861 -0.792 . . . . 0.0 108.861 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' C' C ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.95 132.56 49.65 Favored 'General case' 0 CA--C 1.539 0.519 0 CA-C-N 116.421 -0.354 . . . . 0.0 110.298 -179.681 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 3' ' ' GLU . . . . . . . . . . . . . 44.1 tt0 -168.18 104.89 0.47 Allowed 'General case' 0 N--CA 1.473 0.7 0 N-CA-C 110.012 -0.366 . . . . 0.0 110.012 -179.303 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 34.6 m-85 -86.67 154.98 20.58 Favored 'General case' 0 N--CA 1.475 0.799 0 N-CA-C 110.023 -0.362 . . . . 0.0 110.023 179.608 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -144.75 138.85 27.47 Favored 'General case' 0 N--CA 1.482 1.165 0 N-CA-C 109.951 -0.389 . . . . 0.0 109.951 179.69 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 41.7 t-80 -151.16 119.7 6.48 Favored 'General case' 0 N--CA 1.471 0.582 0 N-CA-C 109.381 -0.599 . . . . 0.0 109.381 179.246 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 7' ' ' ASP . . . . . 0.482 ' O ' ' OG ' ' F' ' 8' ' ' SER . 4.3 m-20 -69.1 148.21 50.33 Favored 'General case' 0 CA--C 1.539 0.527 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.66 179.891 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 8' ' ' SER . . . . . . . . . . . . . 54.5 p -167.55 -173.95 2.36 Favored 'General case' 0 N--CA 1.484 1.271 0 CA-C-O 121.028 0.442 . . . . 0.0 110.764 179.455 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.81 48.19 1.29 Allowed Glycine 0 N--CA 1.48 1.616 0 CA-C-N 115.886 -0.597 . . . . 0.0 111.988 179.574 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 49.5 p90 -65.01 132.18 48.54 Favored 'General case' 0 N--CA 1.471 0.604 0 O-C-N 122.751 -0.264 . . . . 0.0 111.463 179.897 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 83.5 mt-10 -91.47 152.59 20.29 Favored 'General case' 0 N--CA 1.476 0.835 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 178.465 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -153.4 128.61 1.54 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.53 0 N-CA-C 107.778 -1.193 . . . . 0.0 107.778 178.237 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 46.8 m-70 -135.35 145.76 47.71 Favored 'General case' 0 N--CA 1.493 1.687 0 CA-C-N 118.986 0.812 . . . . 0.0 111.357 -179.099 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 6.0 t60 -165.69 97.33 0.66 Allowed 'General case' 0 N--CA 1.48 1.059 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.715 179.361 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 3.5 pt20 -108.74 -174.22 2.46 Favored 'General case' 0 CA--C 1.506 -0.722 0 N-CA-C 108.362 -0.977 . . . . 0.0 108.362 -179.891 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -164.66 97.7 0.77 Allowed 'General case' 0 N--CA 1.471 0.62 0 CA-C-N 114.573 -1.194 . . . . 0.0 108.269 178.55 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 6.6 mp -122.45 157.36 32.11 Favored 'General case' 0 N--CA 1.498 1.946 0 CA-C-O 121.883 0.849 . . . . 0.0 111.017 -178.208 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 58.8 t -112.41 127.28 69.71 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.091 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 177.655 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 29.2 m-85 -127.77 122.17 32.1 Favored 'General case' 0 N--CA 1.494 1.75 0 CA-C-N 119.686 1.13 . . . . 0.0 110.266 179.458 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 67.0 m-85 53.54 74.14 0.33 Allowed 'General case' 0 N--CA 1.468 0.448 0 CA-C-O 121.486 0.66 . . . . 0.0 111.915 178.588 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -80.56 -77.84 0.19 Allowed 'General case' 0 C--N 1.349 0.559 0 CA-C-N 114.969 -1.014 . . . . 0.0 110.373 -179.716 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 40.3 tt0 -112.38 101.32 9.52 Favored 'General case' 0 N--CA 1.47 0.535 0 N-CA-C 108.355 -0.98 . . . . 0.0 108.355 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -158.79 134.22 8.61 Favored 'General case' 0 N--CA 1.481 1.096 0 CA-C-O 119.466 -0.302 . . . . 0.0 111.205 178.965 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 59.3 t -57.55 163.55 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.805 0 N-CA-C 108.135 -1.061 . . . . 0.0 108.135 177.002 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 25' ' ' GLY . . . . . 0.437 ' H ' ' HB ' ' F' ' 24' ' ' VAL . . . -115.91 47.8 1.0 Allowed Glycine 0 N--CA 1.477 1.421 0 N-CA-C 111.519 -0.632 . . . . 0.0 111.519 -179.505 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -62.06 -169.23 0.02 OUTLIER 'General case' 0 N--CA 1.469 0.509 0 N-CA-C 110.17 -0.308 . . . . 0.0 110.17 179.348 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 24.7 t-20 -71.77 79.72 0.86 Allowed 'General case' 0 N--CA 1.468 0.425 0 N-CA-C 110.011 -0.366 . . . . 0.0 110.011 179.455 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -73.19 140.6 47.08 Favored 'General case' 0 N--CA 1.476 0.834 0 N-CA-C 109.011 -0.737 . . . . 0.0 109.011 179.442 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.7 -149.09 0.04 OUTLIER Glycine 0 C--N 1.337 0.594 0 N-CA-C 110.284 -1.126 . . . . 0.0 110.284 179.457 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -94.16 128.03 40.34 Favored 'General case' 0 N--CA 1.477 0.877 0 CA-C-N 116.931 0.365 . . . . 0.0 110.083 179.953 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 74.9 mt -124.28 117.23 50.06 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.697 0 N-CA-C 106.707 -1.59 . . . . 0.0 106.707 178.734 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 39.7 pt -151.3 -169.74 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.355 0.826 0 CA-C-N 115.978 -0.556 . . . . 0.0 111.231 -178.712 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.9 4.81 11.83 Favored Glycine 0 N--CA 1.465 0.609 0 N-CA-C 110.84 -0.904 . . . . 0.0 110.84 179.433 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 1.5 tt -77.96 126.66 31.17 Favored 'General case' 0 CA--C 1.546 0.826 0 N-CA-C 109.566 -0.531 . . . . 0.0 109.566 -179.803 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 28.6 ttt -164.49 143.33 7.13 Favored 'General case' 0 N--CA 1.465 0.298 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 178.298 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 35.5 m -155.19 162.58 1.77 Allowed 'Isoleucine or valine' 0 C--N 1.347 0.485 0 N-CA-C 107.989 -1.115 . . . . 0.0 107.989 179.373 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.64 66.45 2.84 Favored Glycine 0 C--N 1.306 -1.138 0 CA-C-N 115.808 -0.633 . . . . 0.0 111.88 178.422 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 145.46 173.33 16.62 Favored Glycine 0 N--CA 1.472 1.07 0 N-CA-C 111.024 -0.831 . . . . 0.0 111.024 178.946 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 39' ' ' VAL . . . . . 0.598 ' H ' HG12 ' F' ' 39' ' ' VAL . 33.0 m -123.17 160.39 26.18 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.658 0 C-N-CA 123.424 0.69 . . . . 0.0 110.192 -179.787 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 22.8 t . . . . . 0 C--O 1.219 -0.518 0 CA-C-O 118.406 -0.807 . . . . 0.0 110.46 179.546 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' D' D ' 1' ' ' ASP . . . . . . . . . . . . . 13.2 m-20 . . . . . 0 N--CA 1.49 1.528 0 N-CA-C 109.227 -0.657 . . . . 0.0 109.227 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' D' D ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.71 131.32 46.57 Favored 'General case' 0 CA--C 1.534 0.35 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.48 179.872 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 3' ' ' GLU . . . . . . . . . . . . . 43.7 tt0 -169.38 107.25 0.4 Allowed 'General case' 0 N--CA 1.471 0.59 0 N-CA-C 110.096 -0.335 . . . . 0.0 110.096 -179.962 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 35.1 m-85 -90.8 159.33 16.34 Favored 'General case' 0 C--N 1.355 0.843 0 N-CA-C 108.954 -0.758 . . . . 0.0 108.954 179.952 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 5' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -146.07 137.5 24.77 Favored 'General case' 0 N--CA 1.478 0.953 0 C-N-CA 122.814 0.445 . . . . 0.0 110.341 -179.888 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 37.7 t-80 -149.64 123.94 9.57 Favored 'General case' 0 CA--C 1.547 0.827 0 N-CA-C 108.188 -1.041 . . . . 0.0 108.188 175.182 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 7' ' ' ASP . . . . . 0.604 ' O ' ' OG ' ' G' ' 8' ' ' SER . 3.2 m-20 -63.69 132.52 51.33 Favored 'General case' 0 N--CA 1.466 0.363 0 C-N-CA 126.323 1.849 . . . . 0.0 114.361 174.856 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' D' D ' 8' ' ' SER . . . . . 0.5 ' OG ' ' O ' ' A' ' 7' ' ' ASP . 53.8 p -154.39 -171.35 3.83 Favored 'General case' 0 N--CA 1.487 1.385 0 CA-C-N 119.454 1.024 . . . . 0.0 111.255 176.266 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.28 49.0 1.09 Allowed Glycine 0 N--CA 1.483 1.8 0 N-CA-C 110.263 -1.135 . . . . 0.0 110.263 174.144 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 50.8 p90 -61.47 131.71 51.08 Favored 'General case' 0 N--CA 1.472 0.65 0 N-CA-C 112.338 0.495 . . . . 0.0 112.338 178.833 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 84.8 mt-10 -89.24 150.73 22.5 Favored 'General case' 0 N--CA 1.482 1.136 0 CA-C-O 120.564 0.221 . . . . 0.0 110.714 175.645 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.0 p -149.44 130.19 4.58 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.567 0 N-CA-C 107.492 -1.299 . . . . 0.0 107.492 173.114 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 43.2 m-70 -129.89 148.72 51.78 Favored 'General case' 0 N--CA 1.483 1.217 0 CA-C-N 118.074 0.397 . . . . 0.0 111.91 176.444 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 6.1 t60 -165.14 104.43 0.76 Allowed 'General case' 0 N--CA 1.481 1.083 0 N-CA-C 109.029 -0.73 . . . . 0.0 109.029 172.33 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 3.5 pt20 -111.84 -176.14 2.86 Favored 'General case' 0 CA--C 1.497 -1.089 0 N-CA-C 108.29 -1.004 . . . . 0.0 108.29 178.808 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -161.29 105.35 1.3 Allowed 'General case' 0 N--CA 1.469 0.5 0 N-CA-C 106.37 -1.715 . . . . 0.0 106.37 174.965 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 5.6 mp -129.15 154.07 47.08 Favored 'General case' 0 N--CA 1.499 1.989 0 CA-C-O 122.024 0.916 . . . . 0.0 110.581 179.732 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 33.1 t -101.29 131.39 49.14 Favored 'Isoleucine or valine' 0 C--O 1.262 1.75 0 CA-C-O 116.89 -1.529 . . . . 0.0 109.74 174.047 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 26.9 m-85 -130.24 126.63 37.8 Favored 'General case' 0 N--CA 1.491 1.618 0 CA-C-N 119.893 1.224 . . . . 0.0 109.497 173.19 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 67.3 m-85 55.22 71.3 0.55 Allowed 'General case' 0 C--O 1.241 0.658 0 CA-C-N 115.592 -0.731 . . . . 0.0 111.653 176.226 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -82.3 -73.42 0.39 Allowed 'General case' 0 N--CA 1.473 0.701 0 CA-C-O 118.601 -0.714 . . . . 0.0 111.259 -177.414 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 40.7 tt0 -115.35 105.37 12.77 Favored 'General case' 0 N--CA 1.48 1.046 0 N-CA-C 106.463 -1.68 . . . . 0.0 106.463 176.312 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 4.4 p30 -152.19 135.17 15.66 Favored 'General case' 0 N--CA 1.473 0.692 0 CA-C-O 116.67 -1.633 . . . . 0.0 113.493 177.301 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 24' ' ' VAL . . . . . 0.421 ' HB ' ' H ' ' A' ' 25' ' ' GLY . 87.7 t -61.35 166.27 0.81 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.218 0 CA-C-N 121.056 1.753 . . . . 0.0 107.759 175.529 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' D' D ' 25' ' ' GLY . . . . . 0.485 ' H ' ' HB ' ' G' ' 24' ' ' VAL . . . -116.38 50.99 0.75 Allowed Glycine 0 N--CA 1.478 1.476 0 CA-C-O 119.466 -0.63 . . . . 0.0 111.656 178.621 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -57.14 -171.03 0.01 OUTLIER 'General case' 0 N--CA 1.468 0.463 0 C-N-CA 123.414 0.685 . . . . 0.0 111.805 175.217 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 25.4 t-20 -73.62 86.86 1.63 Allowed 'General case' 0 C--N 1.348 0.512 0 N-CA-C 108.44 -0.948 . . . . 0.0 108.44 176.753 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 97.6 mttt -81.09 143.26 32.56 Favored 'General case' 0 N--CA 1.481 1.101 0 N-CA-C 107.527 -1.286 . . . . 0.0 107.527 179.818 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.72 -144.78 0.02 OUTLIER Glycine 0 C--N 1.349 1.274 0 CA-C-N 114.928 -1.033 . . . . 0.0 111.705 -178.865 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -95.81 127.01 41.47 Favored 'General case' 0 C--O 1.241 0.619 0 N-CA-C 110.196 -0.298 . . . . 0.0 110.196 178.859 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 85.8 mt -125.98 127.61 71.23 Favored 'Isoleucine or valine' 0 C--N 1.354 0.77 0 N-CA-C 103.34 -2.837 . . . . 0.0 103.34 176.89 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 32' ' ' ILE . . . . . 0.408 HG22 ' H ' ' G' ' 32' ' ' ILE . 42.8 pt -159.61 -170.82 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.119 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.228 -177.696 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 64.12 4.83 12.78 Favored Glycine 0 C--O 1.243 0.685 0 N-CA-C 110.254 -1.138 . . . . 0.0 110.254 -179.251 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 34' ' ' LEU . . . . . . . . . . . . 0.265 2.0 tt -80.33 133.38 35.93 Favored 'General case' 0 C--N 1.377 1.798 0 C-N-CA 117.22 -1.792 . . . . 0.0 107.353 -178.729 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' D' D ' 35' ' ' MET . . . . . 0.406 ' C ' HG13 ' D' ' 36' ' ' VAL . 28.4 ttt -158.82 156.2 29.25 Favored 'General case' 0 C--O 1.25 1.081 0 CA-C-O 117.938 -1.03 . . . . 0.0 108.691 172.374 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' D' D ' 36' ' ' VAL . . . . . 0.488 HG22 HG12 ' G' ' 36' ' ' VAL . 35.5 m -164.74 163.7 0.71 Allowed 'Isoleucine or valine' 0 CA--C 1.516 -0.364 0 N-CA-C 107.643 -1.243 . . . . 0.0 107.643 174.273 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 60.5 63.03 5.35 Favored Glycine 0 CA--C 1.53 1.011 0 C-N-CA 120.216 -0.993 . . . . 0.0 111.509 177.578 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 144.03 175.53 17.24 Favored Glycine 0 N--CA 1.478 1.469 0 CA-C-N 118.443 1.122 . . . . 0.0 111.378 179.847 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 39' ' ' VAL . . . . . 0.624 ' H ' HG12 ' G' ' 39' ' ' VAL . 36.0 m -126.22 157.4 36.52 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.78 0 C-N-CA 122.937 0.495 . . . . 0.0 109.863 -177.737 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 24.0 t . . . . . 0 C--N 1.331 -0.211 0 CA-C-O 116.331 -1.795 . . . . 0.0 109.479 177.301 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' E' E ' 1' ' ' ASP . . . . . . . . . . . . . 13.1 m-20 . . . . . 0 N--CA 1.488 1.449 0 N-CA-C 109.58 -0.526 . . . . 0.0 109.58 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' E' E ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.1 130.02 42.32 Favored 'General case' 0 N--CA 1.468 0.458 0 CA-C-N 116.295 -0.412 . . . . 0.0 110.422 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' E' E ' 3' ' ' GLU . . . . . . . . . . . . . 43.7 tt0 -167.47 104.89 0.52 Allowed 'General case' 0 N--CA 1.472 0.64 0 CA-C-N 116.866 -0.152 . . . . 0.0 110.684 -179.808 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 31.8 m-85 -87.65 154.34 20.67 Favored 'General case' 0 N--CA 1.474 0.768 0 N-CA-C 110.135 -0.321 . . . . 0.0 110.135 179.351 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' E' E ' 5' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -143.69 139.82 29.71 Favored 'General case' 0 N--CA 1.484 1.256 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 179.374 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 41.3 t-80 -151.57 119.61 6.26 Favored 'General case' 0 N--CA 1.472 0.674 0 N-CA-C 109.276 -0.639 . . . . 0.0 109.276 178.953 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' E' E ' 7' ' ' ASP . . . . . 0.501 ' O ' ' OG ' ' H' ' 8' ' ' SER . 3.9 m-20 -69.6 147.81 50.21 Favored 'General case' 0 CA--C 1.534 0.334 0 CA-C-N 116.414 -0.357 . . . . 0.0 110.94 -179.951 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' E' E ' 8' ' ' SER . . . . . 0.507 ' OG ' ' O ' ' B' ' 7' ' ' ASP . 52.2 p -167.8 -172.72 1.93 Allowed 'General case' 0 N--CA 1.485 1.32 0 CA-C-O 121.18 0.514 . . . . 0.0 110.807 179.014 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.19 48.57 1.21 Allowed Glycine 0 N--CA 1.478 1.479 0 CA-C-N 115.702 -0.681 . . . . 0.0 111.82 179.475 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 47.8 p90 -64.66 133.11 51.49 Favored 'General case' 0 N--CA 1.473 0.688 0 N-CA-C 111.842 0.312 . . . . 0.0 111.842 -179.744 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 86.3 mt-10 -91.53 152.41 20.33 Favored 'General case' 0 N--CA 1.479 1.024 0 CA-C-O 121.175 0.512 . . . . 0.0 109.787 178.06 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -154.59 127.5 1.12 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.575 0 N-CA-C 107.735 -1.209 . . . . 0.0 107.735 178.053 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 46.6 m-70 -135.24 143.8 46.53 Favored 'General case' 0 N--CA 1.482 1.13 0 CA-C-O 120.846 0.355 . . . . 0.0 111.609 -177.942 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 6.1 t60 -164.31 97.25 0.8 Allowed 'General case' 0 N--CA 1.483 1.187 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.671 179.395 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 3.5 pt20 -108.07 -174.58 2.56 Favored 'General case' 0 CA--C 1.509 -0.63 0 N-CA-C 108.544 -0.909 . . . . 0.0 108.544 179.994 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -164.22 96.61 0.79 Allowed 'General case' 0 N--CA 1.477 0.906 0 CA-C-N 114.651 -1.158 . . . . 0.0 108.426 178.367 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' E' E ' 17' ' ' LEU . . . . . 0.412 ' H ' ' CD1' ' H' ' 17' ' ' LEU . 6.5 mp -120.91 157.31 30.15 Favored 'General case' 0 N--CA 1.495 1.788 0 CA-C-O 121.641 0.734 . . . . 0.0 111.557 -177.668 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 48.2 t -114.34 124.42 70.98 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.24 0 N-CA-C 108.277 -1.008 . . . . 0.0 108.277 177.266 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 31.7 m-85 -125.3 121.19 33.3 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 123.256 0.348 . . . . 0.0 110.909 -179.751 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 68.9 m-85 54.87 73.17 0.42 Allowed 'General case' 0 N--CA 1.469 0.504 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.392 178.196 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -78.73 -78.76 0.14 Allowed 'General case' 0 CA--C 1.536 0.419 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.201 -179.566 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 40.3 tt0 -111.5 102.2 10.57 Favored 'General case' 0 C--N 1.322 -0.588 0 N-CA-C 108.49 -0.93 . . . . 0.0 108.49 -179.996 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -158.27 134.62 9.42 Favored 'General case' 0 C--O 1.208 -1.1 0 CA-C-O 119.447 -0.311 . . . . 0.0 111.476 178.846 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' E' E ' 24' ' ' VAL . . . . . 0.436 ' HB ' ' H ' ' B' ' 25' ' ' GLY . 57.3 t -56.73 167.4 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.884 0 N-CA-C 107.564 -1.273 . . . . 0.0 107.564 176.791 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' E' E ' 25' ' ' GLY . . . . . 0.411 ' N ' HG12 ' E' ' 24' ' ' VAL . . . -120.37 48.96 0.91 Allowed Glycine 0 N--CA 1.472 1.091 0 N-CA-C 110.852 -0.899 . . . . 0.0 110.852 -179.389 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -63.37 -167.92 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.528 0 CA-C-O 120.767 0.318 . . . . 0.0 110.361 179.669 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 25.0 t-20 -71.71 76.35 0.84 Allowed 'General case' 0 N--CA 1.466 0.334 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.324 179.779 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -70.26 140.28 52.35 Favored 'General case' 0 N--CA 1.48 1.061 0 N-CA-C 109.438 -0.579 . . . . 0.0 109.438 179.462 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.47 -149.28 0.05 OUTLIER Glycine 0 C--N 1.335 0.49 0 N-CA-C 110.859 -0.896 . . . . 0.0 110.859 179.42 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -92.78 126.89 38.07 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-N 116.797 0.298 . . . . 0.0 110.402 179.713 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 76.8 mt -123.62 117.25 50.65 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.436 0 N-CA-C 106.365 -1.717 . . . . 0.0 106.365 178.591 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' E' E ' 32' ' ' ILE . . . . . 0.415 HG22 ' H ' ' H' ' 32' ' ' ILE . 44.2 pt -151.46 -168.19 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.17 0 CA-C-O 121.117 0.484 . . . . 0.0 110.882 -178.868 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.13 5.43 7.85 Favored Glycine 0 CA--C 1.527 0.839 0 N-CA-C 111.315 -0.714 . . . . 0.0 111.315 179.975 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 1.6 tt -77.74 127.23 32.1 Favored 'General case' 0 CA--C 1.548 0.88 0 N-CA-C 109.494 -0.558 . . . . 0.0 109.494 -179.886 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 28.6 ttt -164.7 144.52 7.34 Favored 'General case' 0 N--CA 1.469 0.51 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 178.267 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' E' E ' 36' ' ' VAL . . . . . 0.463 HG22 HG12 ' H' ' 36' ' ' VAL . 32.9 m -156.38 162.84 1.55 Allowed 'Isoleucine or valine' 0 C--N 1.348 0.523 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 179.675 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.05 66.13 3.06 Favored Glycine 0 C--N 1.307 -1.072 0 CA-C-N 115.599 -0.728 . . . . 0.0 111.799 178.34 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 145.97 174.31 18.02 Favored Glycine 0 N--CA 1.474 1.191 0 N-CA-C 111.256 -0.738 . . . . 0.0 111.256 178.8 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' E' E ' 39' ' ' VAL . . . . . 0.614 ' H ' HG12 ' H' ' 39' ' ' VAL . 34.3 m -124.15 159.87 29.1 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.709 0 C-N-CA 123.32 0.648 . . . . 0.0 110.297 -179.206 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 24.6 t . . . . . 0 C--O 1.218 -0.595 0 O-C-N 124.156 0.91 . . . . 0.0 110.43 179.394 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' F' F ' 1' ' ' ASP . . . . . . . . . . . . . 11.7 m-20 . . . . . 0 N--CA 1.491 1.619 0 N-CA-C 109.221 -0.659 . . . . 0.0 109.221 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' F' F ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.23 129.95 41.98 Favored 'General case' 0 N--CA 1.468 0.435 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.46 -179.89 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' F' F ' 3' ' ' GLU . . . . . . . . . . . . . 43.5 tt0 -167.26 105.22 0.55 Allowed 'General case' 0 C--O 1.216 -0.671 0 N-CA-C 110.552 -0.166 . . . . 0.0 110.552 -179.782 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 31.5 m-85 -87.88 154.67 20.35 Favored 'General case' 0 N--CA 1.475 0.813 0 N-CA-C 110.019 -0.363 . . . . 0.0 110.019 179.434 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' F' F ' 5' ' ' ARG . . . . . . . . . . . . . 99.6 mtt180 -144.03 139.4 28.96 Favored 'General case' 0 N--CA 1.478 0.966 0 CA-C-O 120.759 0.314 . . . . 0.0 110.214 179.46 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 41.3 t-80 -151.48 119.73 6.35 Favored 'General case' 0 N--CA 1.473 0.695 0 N-CA-C 109.282 -0.636 . . . . 0.0 109.282 179.124 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' F' F ' 7' ' ' ASP . . . . . 0.465 ' O ' ' OG ' ' I' ' 8' ' ' SER . 3.9 m-20 -69.62 147.81 50.19 Favored 'General case' 0 CA--C 1.533 0.317 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.909 179.994 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' F' F ' 8' ' ' SER . . . . . 0.482 ' OG ' ' O ' ' C' ' 7' ' ' ASP . 51.7 p -168.09 -173.12 1.96 Allowed 'General case' 0 N--CA 1.485 1.321 0 CA-C-O 121.22 0.533 . . . . 0.0 110.923 178.977 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.49 48.3 1.22 Allowed Glycine 0 N--CA 1.478 1.457 0 CA-C-N 115.767 -0.651 . . . . 0.0 111.714 179.466 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 47.7 p90 -64.02 132.84 51.81 Favored 'General case' 0 N--CA 1.474 0.736 0 O-C-N 122.648 -0.325 . . . . 0.0 111.792 -179.888 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 86.8 mt-10 -91.28 152.42 20.49 Favored 'General case' 0 N--CA 1.481 1.103 0 CA-C-O 121.166 0.508 . . . . 0.0 109.877 177.873 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -154.57 127.61 1.14 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.627 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 178.008 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 44.4 m-70 -135.44 144.13 46.29 Favored 'General case' 0 N--CA 1.482 1.144 0 CA-C-O 120.807 0.337 . . . . 0.0 111.6 -178.079 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 6.0 t60 -164.57 96.82 0.76 Allowed 'General case' 0 N--CA 1.485 1.284 0 CA-C-N 116.431 -0.349 . . . . 0.0 110.788 179.478 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 3.5 pt20 -107.71 -174.06 2.44 Favored 'General case' 0 CA--C 1.505 -0.778 0 N-CA-C 108.637 -0.875 . . . . 0.0 108.637 -179.97 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -164.53 96.8 0.77 Allowed 'General case' 0 N--CA 1.475 0.802 0 CA-C-N 114.645 -1.161 . . . . 0.0 108.336 178.533 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' F' F ' 17' ' ' LEU . . . . . 0.406 ' H ' ' CD1' ' I' ' 17' ' ' LEU . 6.5 mp -121.01 157.17 30.57 Favored 'General case' 0 N--CA 1.494 1.766 0 CA-C-O 121.51 0.671 . . . . 0.0 111.483 -177.733 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 48.1 t -114.04 124.24 70.49 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.227 0 N-CA-C 108.288 -1.004 . . . . 0.0 108.288 177.11 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 31.6 m-85 -125.03 121.05 33.25 Favored 'General case' 0 N--CA 1.487 1.407 0 CA-C-O 120.787 0.327 . . . . 0.0 110.937 -179.855 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 68.7 m-85 55.2 73.32 0.42 Allowed 'General case' 0 C--N 1.345 0.386 0 CA-C-N 116.0 -0.545 . . . . 0.0 111.654 178.097 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -79.02 -78.65 0.15 Allowed 'General case' 0 C--N 1.345 0.379 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.345 -179.262 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 40.6 tt0 -111.74 102.01 10.33 Favored 'General case' 0 C--N 1.323 -0.555 0 N-CA-C 108.449 -0.945 . . . . 0.0 108.449 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 p30 -158.14 134.7 9.61 Favored 'General case' 0 C--O 1.209 -1.046 0 CA-C-O 119.571 -0.252 . . . . 0.0 111.448 178.975 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' F' F ' 24' ' ' VAL . . . . . 0.437 ' HB ' ' H ' ' C' ' 25' ' ' GLY . 63.6 t -57.13 166.89 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.885 0 N-CA-C 107.495 -1.298 . . . . 0.0 107.495 176.98 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' F' F ' 25' ' ' GLY . . . . . 0.413 ' H ' ' HB ' ' I' ' 24' ' ' VAL . . . -119.97 49.11 0.89 Allowed Glycine 0 N--CA 1.476 1.325 0 N-CA-C 110.792 -0.923 . . . . 0.0 110.792 -179.319 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -63.45 -167.77 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.549 0 CA-C-O 120.779 0.323 . . . . 0.0 110.221 179.579 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 24.8 t-20 -71.72 76.12 0.84 Allowed 'General case' 0 C--O 1.223 -0.321 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.378 179.761 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -70.18 140.49 52.55 Favored 'General case' 0 N--CA 1.478 0.967 0 N-CA-C 109.449 -0.574 . . . . 0.0 109.449 179.587 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.53 -149.8 0.05 OUTLIER Glycine 0 C--N 1.333 0.412 0 N-CA-C 110.852 -0.899 . . . . 0.0 110.852 179.443 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -92.16 126.68 37.34 Favored 'General case' 0 N--CA 1.47 0.573 0 N-CA-C 110.235 -0.283 . . . . 0.0 110.235 179.659 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 78.3 mt -123.65 116.98 49.8 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.512 0 N-CA-C 106.351 -1.722 . . . . 0.0 106.351 178.461 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' F' F ' 32' ' ' ILE . . . . . 0.42 HG22 ' H ' ' I' ' 32' ' ' ILE . 44.5 pt -151.31 -167.99 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.192 0 CA-C-O 121.061 0.458 . . . . 0.0 110.862 -178.882 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.98 5.66 8.05 Favored Glycine 0 CA--C 1.527 0.791 0 N-CA-C 111.373 -0.691 . . . . 0.0 111.373 -179.95 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 1.5 tt -77.9 127.18 31.97 Favored 'General case' 0 CA--C 1.548 0.886 0 N-CA-C 109.465 -0.569 . . . . 0.0 109.465 -179.897 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 28.4 ttt -164.45 144.44 7.69 Favored 'General case' 0 N--CA 1.469 0.493 0 N-CA-C 108.773 -0.825 . . . . 0.0 108.773 178.223 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' F' F ' 36' ' ' VAL . . . . . 0.473 HG22 HG12 ' I' ' 36' ' ' VAL . 32.9 m -156.26 162.75 1.59 Allowed 'Isoleucine or valine' 0 C--N 1.348 0.504 0 N-CA-C 108.292 -1.003 . . . . 0.0 108.292 179.566 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.16 66.28 2.96 Favored Glycine 0 C--N 1.307 -1.08 0 CA-C-N 115.691 -0.686 . . . . 0.0 111.854 178.366 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 145.79 174.42 17.95 Favored Glycine 0 N--CA 1.473 1.14 0 N-CA-C 111.313 -0.715 . . . . 0.0 111.313 178.863 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' F' F ' 39' ' ' VAL . . . . . 0.616 ' H ' HG12 ' I' ' 39' ' ' VAL . 34.4 m -124.47 159.78 30.0 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.669 0 C-N-CA 123.301 0.64 . . . . 0.0 110.224 -179.208 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 24.9 t . . . . . 0 C--O 1.218 -0.569 0 O-C-N 124.239 0.962 . . . . 0.0 110.517 179.507 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' G' G ' 1' ' ' ASP . . . . . . . . . . . . . 13.2 m-20 . . . . . 0 N--CA 1.491 1.598 0 N-CA-C 109.269 -0.641 . . . . 0.0 109.269 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' G' G ' 2' ' ' ALA . . . . . . . . . . . . . . . -63.17 128.84 37.7 Favored 'General case' 0 N--CA 1.468 0.426 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.69 179.67 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' G' G ' 3' ' ' GLU . . . . . . . . . . . . . 43.4 tt0 -168.06 106.36 0.5 Allowed 'General case' 0 N--CA 1.473 0.71 0 CA-C-O 120.424 0.154 . . . . 0.0 110.761 179.664 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 35.2 m-85 -89.79 154.69 19.71 Favored 'General case' 0 N--CA 1.474 0.736 0 N-CA-C 109.605 -0.517 . . . . 0.0 109.605 179.14 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' G' G ' 5' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -144.67 139.11 27.77 Favored 'General case' 0 N--CA 1.482 1.145 0 C-N-CA 122.544 0.338 . . . . 0.0 110.235 179.834 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 42.2 t-80 -150.8 120.87 7.19 Favored 'General case' 0 N--CA 1.474 0.726 0 N-CA-C 109.543 -0.54 . . . . 0.0 109.543 179.023 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -71.82 143.45 49.48 Favored 'General case' 0 N--CA 1.47 0.554 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.28 -179.766 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' G' G ' 8' ' ' SER . . . . . 0.604 ' OG ' ' O ' ' D' ' 7' ' ' ASP . 48.9 p -164.7 -170.93 2.13 Favored 'General case' 0 N--CA 1.476 0.828 0 CA-C-O 121.2 0.524 . . . . 0.0 110.534 178.83 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.52 49.01 1.23 Allowed Glycine 0 N--CA 1.479 1.528 0 N-CA-C 111.35 -0.7 . . . . 0.0 111.35 179.388 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 50.1 p90 -65.03 133.36 51.5 Favored 'General case' 0 N--CA 1.473 0.704 0 CA-C-O 120.673 0.273 . . . . 0.0 111.67 -179.719 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 83.3 mt-10 -92.1 151.64 20.32 Favored 'General case' 0 N--CA 1.48 1.031 0 CA-C-O 121.108 0.48 . . . . 0.0 110.142 178.665 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -154.89 127.45 1.06 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.973 0 N-CA-C 107.853 -1.165 . . . . 0.0 107.853 178.293 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 47.4 m-70 -134.6 144.73 48.08 Favored 'General case' 0 N--CA 1.479 1.005 0 CA-C-N 115.561 -0.745 . . . . 0.0 111.488 -178.298 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 6.1 t60 -165.43 97.37 0.69 Allowed 'General case' 0 N--CA 1.482 1.131 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.377 178.989 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 3.6 pt20 -108.6 -174.72 2.58 Favored 'General case' 0 CA--C 1.506 -0.744 0 N-CA-C 108.433 -0.951 . . . . 0.0 108.433 -179.707 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -164.32 96.17 0.77 Allowed 'General case' 0 N--CA 1.474 0.758 0 CA-C-N 114.699 -1.137 . . . . 0.0 108.121 178.735 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 6.6 mp -120.58 155.61 33.34 Favored 'General case' 0 N--CA 1.497 1.924 0 CA-C-O 121.171 0.51 . . . . 0.0 111.771 -177.846 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 43.0 t -113.16 125.13 70.37 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.884 0 CA-C-N 114.757 -1.11 . . . . 0.0 108.128 176.477 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 33.1 m-85 -126.09 121.15 32.09 Favored 'General case' 0 C--N 1.369 1.424 0 CA-C-N 115.583 -0.735 . . . . 0.0 110.892 -179.699 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 67.2 m-85 54.8 72.95 0.43 Allowed 'General case' 0 C--O 1.238 0.459 0 CA-C-N 115.841 -0.618 . . . . 0.0 111.479 178.145 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -78.08 -77.96 0.15 Allowed 'General case' 0 N--CA 1.471 0.616 0 O-C-N 122.17 -0.331 . . . . 0.0 110.557 -178.939 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 40.4 tt0 -112.24 101.99 10.19 Favored 'General case' 0 C--N 1.323 -0.568 0 N-CA-C 108.093 -1.077 . . . . 0.0 108.093 179.917 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -157.88 135.91 10.8 Favored 'General case' 0 N--CA 1.476 0.867 0 O-C-N 122.401 -0.187 . . . . 0.0 111.488 178.826 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' G' G ' 24' ' ' VAL . . . . . 0.485 ' HB ' ' H ' ' D' ' 25' ' ' GLY . 57.3 t -58.27 166.47 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.647 0 N-CA-C 107.555 -1.276 . . . . 0.0 107.555 176.986 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' G' G ' 25' ' ' GLY . . . . . 0.413 ' N ' HG12 ' G' ' 24' ' ' VAL . . . -119.05 49.4 0.87 Allowed Glycine 0 N--CA 1.479 1.524 0 N-CA-C 110.456 -1.058 . . . . 0.0 110.456 -179.47 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -64.4 -168.09 0.03 OUTLIER 'General case' 0 N--CA 1.472 0.636 0 N-CA-C 109.904 -0.406 . . . . 0.0 109.904 179.645 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 25.1 t-20 -71.62 76.09 0.82 Allowed 'General case' 0 CA--C 1.536 0.438 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.324 179.928 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -69.57 140.64 53.84 Favored 'General case' 0 N--CA 1.478 0.955 0 N-CA-C 109.562 -0.533 . . . . 0.0 109.562 179.604 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.99 -147.81 0.05 OUTLIER Glycine 0 C--N 1.337 0.587 0 N-CA-C 110.443 -1.063 . . . . 0.0 110.443 179.612 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -92.88 125.99 37.75 Favored 'General case' 0 N--CA 1.467 0.419 0 C-N-CA 122.65 0.38 . . . . 0.0 110.93 -179.824 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 76.6 mt -123.45 117.65 52.03 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.811 0 N-CA-C 106.417 -1.697 . . . . 0.0 106.417 178.238 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' G' G ' 32' ' ' ILE . . . . . 0.408 ' H ' HG22 ' D' ' 32' ' ' ILE . 44.0 pt -152.47 -167.61 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 CA-C-N 119.819 1.19 . . . . 0.0 110.031 -179.225 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.29 6.26 10.15 Favored Glycine 0 N--CA 1.466 0.671 0 N-CA-C 111.056 -0.818 . . . . 0.0 111.056 179.881 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 1.5 tt -79.49 125.7 29.91 Favored 'General case' 0 CA--C 1.545 0.773 0 N-CA-C 109.516 -0.55 . . . . 0.0 109.516 -179.702 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 27.7 ttt -162.86 146.17 10.97 Favored 'General case' 0 N--CA 1.47 0.553 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 178.534 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' G' G ' 36' ' ' VAL . . . . . 0.488 HG12 HG22 ' D' ' 36' ' ' VAL . 32.7 m -156.95 162.01 1.69 Allowed 'Isoleucine or valine' 0 C--N 1.35 0.603 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 -179.99 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.48 66.63 2.7 Favored Glycine 0 C--N 1.31 -0.913 0 CA-C-N 115.541 -0.754 . . . . 0.0 112.104 177.818 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 146.72 175.6 19.82 Favored Glycine 0 N--CA 1.475 1.251 0 N-CA-C 110.559 -1.016 . . . . 0.0 110.559 178.994 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' G' G ' 39' ' ' VAL . . . . . 0.624 HG12 ' H ' ' D' ' 39' ' ' VAL . 34.9 m -125.77 159.71 33.4 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.912 0 C-N-CA 123.092 0.557 . . . . 0.0 110.484 -179.408 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 26.3 t . . . . . 0 C--O 1.22 -0.488 0 CA-C-O 118.395 -0.812 . . . . 0.0 110.751 179.082 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' H' H ' 1' ' ' ASP . . . . . . . . . . . . . 13.3 m-20 . . . . . 0 N--CA 1.492 1.66 0 N-CA-C 109.343 -0.614 . . . . 0.0 109.343 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' H' H ' 2' ' ' ALA . . . . . . . . . . . . . . . -63.01 128.63 36.76 Favored 'General case' 0 N--CA 1.469 0.485 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.581 179.777 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' H' H ' 3' ' ' GLU . . . . . . . . . . . . . 43.2 tt0 -167.89 106.48 0.52 Allowed 'General case' 0 N--CA 1.471 0.586 0 CA-C-O 120.496 0.189 . . . . 0.0 110.722 179.642 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 34.9 m-85 -89.89 154.77 19.61 Favored 'General case' 0 N--CA 1.474 0.77 0 N-CA-C 109.518 -0.549 . . . . 0.0 109.518 179.263 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' H' H ' 5' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -144.74 139.68 28.04 Favored 'General case' 0 N--CA 1.485 1.313 0 N-CA-C 110.04 -0.355 . . . . 0.0 110.04 179.838 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 41.2 t-80 -151.58 120.7 6.72 Favored 'General case' 0 N--CA 1.474 0.76 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 179.068 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -71.65 143.82 49.62 Favored 'General case' 0 N--CA 1.469 0.511 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.308 -179.756 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' H' H ' 8' ' ' SER . . . . . 0.501 ' OG ' ' O ' ' E' ' 7' ' ' ASP . 52.2 p -164.81 -171.18 2.19 Favored 'General case' 0 N--CA 1.475 0.809 0 CA-C-O 121.126 0.489 . . . . 0.0 110.489 178.921 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.76 48.35 1.28 Allowed Glycine 0 N--CA 1.479 1.541 0 CA-C-N 115.783 -0.644 . . . . 0.0 111.551 179.336 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 50.1 p90 -64.51 133.06 51.64 Favored 'General case' 0 N--CA 1.471 0.624 0 N-CA-C 111.785 0.291 . . . . 0.0 111.785 -179.685 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 83.1 mt-10 -91.69 151.56 20.61 Favored 'General case' 0 N--CA 1.479 0.984 0 CA-C-O 121.068 0.461 . . . . 0.0 110.183 178.476 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -154.67 127.88 1.17 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.979 0 N-CA-C 107.885 -1.154 . . . . 0.0 107.885 178.08 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 47.3 m-70 -134.75 145.53 48.52 Favored 'General case' 0 N--CA 1.478 0.955 0 CA-C-N 115.676 -0.693 . . . . 0.0 111.359 -178.419 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 6.0 t60 -166.24 97.37 0.6 Allowed 'General case' 0 N--CA 1.482 1.146 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.346 178.794 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 3.6 pt20 -108.33 -174.3 2.49 Favored 'General case' 0 CA--C 1.505 -0.757 0 N-CA-C 108.425 -0.954 . . . . 0.0 108.425 -179.728 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -164.84 96.22 0.72 Allowed 'General case' 0 N--CA 1.475 0.799 0 CA-C-N 114.647 -1.16 . . . . 0.0 108.018 178.66 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' H' H ' 17' ' ' LEU . . . . . 0.412 ' CD1' ' H ' ' E' ' 17' ' ' LEU . 6.5 mp -120.53 156.02 32.43 Favored 'General case' 0 N--CA 1.497 1.899 0 CA-C-O 121.239 0.543 . . . . 0.0 111.972 -177.949 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 41.4 t -113.7 124.73 70.63 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.07 0 CA-C-N 114.819 -1.082 . . . . 0.0 108.227 176.658 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 33.3 m-85 -125.73 121.31 33.04 Favored 'General case' 0 C--N 1.368 1.388 0 CA-C-N 115.459 -0.792 . . . . 0.0 110.863 -179.491 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 68.0 m-85 54.3 72.69 0.44 Allowed 'General case' 0 C--O 1.237 0.422 0 CA-C-N 115.858 -0.61 . . . . 0.0 111.587 178.11 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.63 -78.13 0.14 Allowed 'General case' 0 N--CA 1.471 0.622 0 O-C-N 122.203 -0.31 . . . . 0.0 110.571 -179.033 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 40.9 tt0 -112.12 101.99 10.22 Favored 'General case' 0 C--N 1.321 -0.632 0 N-CA-C 108.091 -1.077 . . . . 0.0 108.091 -179.99 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -157.97 135.78 10.61 Favored 'General case' 0 N--CA 1.477 0.913 0 N-CA-C 111.445 0.165 . . . . 0.0 111.445 178.863 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' H' H ' 24' ' ' VAL . . . . . 0.41 HG12 ' N ' ' H' ' 25' ' ' GLY . 59.2 t -58.3 166.35 0.51 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.606 0 N-CA-C 107.682 -1.229 . . . . 0.0 107.682 177.197 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' H' H ' 25' ' ' GLY . . . . . 0.41 ' N ' HG12 ' H' ' 24' ' ' VAL . . . -118.76 49.42 0.87 Allowed Glycine 0 N--CA 1.478 1.444 0 N-CA-C 110.653 -0.979 . . . . 0.0 110.653 -179.498 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -64.67 -167.85 0.03 OUTLIER 'General case' 0 N--CA 1.472 0.668 0 CA-C-N 116.97 0.385 . . . . 0.0 110.0 179.662 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 24.9 t-20 -71.77 76.39 0.86 Allowed 'General case' 0 CA--C 1.535 0.4 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.317 179.871 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -69.89 140.74 53.18 Favored 'General case' 0 N--CA 1.478 0.953 0 N-CA-C 109.552 -0.536 . . . . 0.0 109.552 179.483 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.96 -147.82 0.05 OUTLIER Glycine 0 C--N 1.338 0.653 0 N-CA-C 110.329 -1.108 . . . . 0.0 110.329 179.541 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -93.5 125.77 38.29 Favored 'General case' 0 N--CA 1.465 0.307 0 C-N-CA 122.58 0.352 . . . . 0.0 110.872 -179.61 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 76.1 mt -122.92 117.55 52.12 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.757 0 N-CA-C 106.431 -1.692 . . . . 0.0 106.431 178.315 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' H' H ' 32' ' ' ILE . . . . . 0.415 ' H ' HG22 ' E' ' 32' ' ' ILE . 44.8 pt -152.04 -167.84 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 CA-C-N 119.807 1.185 . . . . 0.0 109.98 -179.469 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.93 5.8 10.53 Favored Glycine 0 N--CA 1.466 0.661 0 N-CA-C 110.964 -0.854 . . . . 0.0 110.964 179.86 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 1.5 tt -79.04 124.95 28.77 Favored 'General case' 0 CA--C 1.544 0.744 0 N-CA-C 109.725 -0.472 . . . . 0.0 109.725 -179.515 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 27.8 ttt -162.19 145.97 12.01 Favored 'General case' 0 N--CA 1.469 0.502 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 178.635 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' H' H ' 36' ' ' VAL . . . . . 0.463 HG12 HG22 ' E' ' 36' ' ' VAL . 32.6 m -157.08 161.69 1.76 Allowed 'Isoleucine or valine' 0 C--N 1.349 0.566 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 -179.895 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.94 66.2 3.01 Favored Glycine 0 C--N 1.309 -0.93 0 CA-C-N 115.498 -0.773 . . . . 0.0 112.17 177.935 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 146.92 175.63 20.01 Favored Glycine 0 N--CA 1.474 1.197 0 N-CA-C 110.639 -0.984 . . . . 0.0 110.639 178.893 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' H' H ' 39' ' ' VAL . . . . . 0.614 HG12 ' H ' ' E' ' 39' ' ' VAL . 34.9 m -125.2 159.96 31.54 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.927 0 C-N-CA 123.173 0.589 . . . . 0.0 110.537 -179.487 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 25.1 t . . . . . 0 N--CA 1.47 0.54 0 CA-C-O 118.439 -0.791 . . . . 0.0 110.819 179.233 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' I' I ' 1' ' ' ASP . . . . . . . . . . . . . 13.0 m-20 . . . . . 0 N--CA 1.491 1.578 0 N-CA-C 109.461 -0.57 . . . . 0.0 109.461 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' I' I ' 2' ' ' ALA . . . . . . . . . . . . . . . -63.5 128.5 36.12 Favored 'General case' 0 N--CA 1.468 0.475 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.598 179.752 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' I' I ' 3' ' ' GLU . . . . . . . . . . . . . 43.3 tt0 -167.7 106.9 0.55 Allowed 'General case' 0 N--CA 1.471 0.61 0 CA-C-O 120.547 0.213 . . . . 0.0 110.704 179.709 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 35.9 m-85 -90.33 154.56 19.61 Favored 'General case' 0 N--CA 1.474 0.739 0 N-CA-C 109.538 -0.541 . . . . 0.0 109.538 179.152 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' I' I ' 5' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -144.51 139.17 28.08 Favored 'General case' 0 N--CA 1.484 1.255 0 N-CA-C 110.038 -0.356 . . . . 0.0 110.038 179.815 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 41.6 t-80 -150.81 120.73 7.12 Favored 'General case' 0 N--CA 1.473 0.679 0 N-CA-C 109.385 -0.598 . . . . 0.0 109.385 178.907 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 4.0 m-20 -71.48 143.94 49.86 Favored 'General case' 0 N--CA 1.47 0.531 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.141 -179.888 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' I' I ' 8' ' ' SER . . . . . 0.465 ' OG ' ' O ' ' F' ' 7' ' ' ASP . 52.5 p -165.05 -171.14 2.13 Favored 'General case' 0 N--CA 1.474 0.758 0 CA-C-O 121.081 0.467 . . . . 0.0 110.621 178.89 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.53 48.81 1.25 Allowed Glycine 0 N--CA 1.479 1.514 0 N-CA-C 111.502 -0.639 . . . . 0.0 111.502 179.348 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 50.2 p90 -65.12 132.94 50.49 Favored 'General case' 0 N--CA 1.472 0.663 0 N-CA-C 111.772 0.286 . . . . 0.0 111.772 -179.718 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 83.6 mt-10 -91.43 151.57 20.75 Favored 'General case' 0 N--CA 1.478 0.953 0 CA-C-O 121.045 0.45 . . . . 0.0 110.265 178.539 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -154.91 127.42 1.05 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.047 0 N-CA-C 107.91 -1.144 . . . . 0.0 107.91 178.198 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 46.9 m-70 -134.48 145.15 48.54 Favored 'General case' 0 N--CA 1.478 0.933 0 CA-C-N 115.61 -0.723 . . . . 0.0 111.407 -178.196 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 6.1 t60 -165.75 97.25 0.65 Allowed 'General case' 0 N--CA 1.48 1.03 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.378 178.838 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 3.6 pt20 -108.39 -174.55 2.55 Favored 'General case' 0 CA--C 1.504 -0.809 0 N-CA-C 108.381 -0.97 . . . . 0.0 108.381 -179.757 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -164.54 96.33 0.75 Allowed 'General case' 0 N--CA 1.474 0.755 0 CA-C-N 114.608 -1.178 . . . . 0.0 108.116 178.641 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' I' I ' 17' ' ' LEU . . . . . 0.406 ' CD1' ' H ' ' F' ' 17' ' ' LEU . 6.4 mp -120.6 156.07 32.42 Favored 'General case' 0 N--CA 1.497 1.914 0 CA-C-O 121.232 0.539 . . . . 0.0 111.767 -177.882 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 41.4 t -113.77 125.06 70.98 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.884 0 CA-C-N 114.753 -1.112 . . . . 0.0 108.207 176.608 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 33.6 m-85 -126.0 121.38 32.86 Favored 'General case' 0 C--N 1.368 1.41 0 CA-C-N 115.502 -0.772 . . . . 0.0 110.829 -179.449 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 67.9 m-85 54.25 73.29 0.4 Allowed 'General case' 0 C--N 1.347 0.467 0 CA-C-N 115.925 -0.58 . . . . 0.0 111.464 178.136 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -78.18 -78.01 0.15 Allowed 'General case' 0 N--CA 1.475 0.802 0 O-C-N 122.296 -0.253 . . . . 0.0 110.453 -179.079 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 40.7 tt0 -112.02 102.12 10.36 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 108.088 -1.079 . . . . 0.0 108.088 179.802 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -157.88 135.92 10.81 Favored 'General case' 0 N--CA 1.478 0.97 0 N-CA-C 111.409 0.152 . . . . 0.0 111.409 178.784 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' I' I ' 24' ' ' VAL . . . . . 0.42 HG12 ' N ' ' I' ' 25' ' ' GLY . 59.5 t -58.57 166.32 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.573 0 N-CA-C 107.658 -1.238 . . . . 0.0 107.658 177.203 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' I' I ' 25' ' ' GLY . . . . . 0.42 ' N ' HG12 ' I' ' 24' ' ' VAL . . . -118.69 49.0 0.89 Allowed Glycine 0 N--CA 1.479 1.524 0 N-CA-C 110.556 -1.017 . . . . 0.0 110.556 -179.392 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -64.3 -167.87 0.03 OUTLIER 'General case' 0 N--CA 1.472 0.648 0 CA-C-N 116.951 0.376 . . . . 0.0 110.092 179.641 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 24.9 t-20 -71.74 76.45 0.85 Allowed 'General case' 0 CA--C 1.536 0.419 0 CA-C-N 116.07 -0.513 . . . . 0.0 110.219 179.884 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -70.08 140.86 52.81 Favored 'General case' 0 N--CA 1.478 0.961 0 N-CA-C 109.492 -0.559 . . . . 0.0 109.492 179.496 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -65.02 -147.67 0.05 OUTLIER Glycine 0 C--N 1.337 0.628 0 N-CA-C 110.416 -1.074 . . . . 0.0 110.416 179.577 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -93.3 125.89 38.14 Favored 'General case' 0 N--CA 1.469 0.496 0 C-N-CA 122.587 0.355 . . . . 0.0 110.924 -179.953 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 77.0 mt -123.2 117.3 51.15 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.708 0 N-CA-C 106.474 -1.676 . . . . 0.0 106.474 178.255 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' I' I ' 32' ' ' ILE . . . . . 0.42 ' H ' HG22 ' F' ' 32' ' ' ILE . 44.6 pt -152.13 -167.9 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 CA-C-N 119.851 1.205 . . . . 0.0 109.979 -179.284 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.07 5.52 10.2 Favored Glycine 0 N--CA 1.466 0.674 0 N-CA-C 110.969 -0.852 . . . . 0.0 110.969 179.86 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 1.5 tt -78.6 125.82 29.89 Favored 'General case' 0 CA--C 1.546 0.798 0 N-CA-C 109.6 -0.519 . . . . 0.0 109.6 -179.675 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 27.7 ttt -162.76 146.01 11.08 Favored 'General case' 0 N--CA 1.47 0.561 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 178.454 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' I' I ' 36' ' ' VAL . . . . . 0.473 HG12 HG22 ' F' ' 36' ' ' VAL . 32.5 m -157.08 161.78 1.73 Allowed 'Isoleucine or valine' 0 C--N 1.348 0.522 0 N-CA-C 108.6 -0.889 . . . . 0.0 108.6 179.928 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.76 66.42 2.86 Favored Glycine 0 C--N 1.308 -0.981 0 CA-C-N 115.557 -0.747 . . . . 0.0 112.114 177.863 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 146.64 175.76 19.88 Favored Glycine 0 N--CA 1.476 1.334 0 N-CA-C 110.57 -1.012 . . . . 0.0 110.57 178.95 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' I' I ' 39' ' ' VAL . . . . . 0.616 HG12 ' H ' ' F' ' 39' ' ' VAL . 35.0 m -125.69 160.11 32.64 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.915 0 C-N-CA 123.138 0.575 . . . . 0.0 110.53 -179.381 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 25.9 t . . . . . 0 C--O 1.218 -0.557 0 CA-C-O 118.449 -0.786 . . . . 0.0 110.713 179.216 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 9.3 m-20 . . . . . 0 N--CA 1.489 1.492 0 N-CA-C 108.992 -0.744 . . . . 0.0 108.992 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.85 132.42 48.64 Favored 'General case' 0 CA--C 1.539 0.529 0 N-CA-C 110.202 -0.295 . . . . 0.0 110.202 -179.754 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 44.7 tt0 -168.23 105.58 0.47 Allowed 'General case' 0 C--O 1.213 -0.843 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 -179.237 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 39.4 m-85 -85.66 152.67 22.92 Favored 'General case' 0 N--CA 1.477 0.882 0 N-CA-C 109.99 -0.374 . . . . 0.0 109.99 179.489 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -143.93 140.15 29.54 Favored 'General case' 0 N--CA 1.48 1.048 0 N-CA-C 110.016 -0.364 . . . . 0.0 110.016 179.67 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 43.3 t-80 -151.84 119.67 6.16 Favored 'General case' 0 N--CA 1.47 0.551 0 N-CA-C 109.224 -0.658 . . . . 0.0 109.224 179.291 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' ASP . . . . . 0.495 ' O ' ' OG ' ' D' ' 8' ' ' SER . 4.6 m-20 -69.14 148.9 49.27 Favored 'General case' 0 N--CA 1.466 0.34 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.466 179.879 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 54.8 p -168.21 -173.79 2.12 Favored 'General case' 0 N--CA 1.482 1.162 0 C-N-CA 122.669 0.388 . . . . 0.0 110.718 179.053 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.79 47.79 1.33 Allowed Glycine 0 N--CA 1.482 1.735 0 CA-C-N 116.013 -0.539 . . . . 0.0 112.147 -179.911 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 50.1 p90 -65.06 132.67 49.83 Favored 'General case' 0 N--CA 1.473 0.686 0 CA-C-O 120.716 0.293 . . . . 0.0 111.532 179.899 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 49.0 mt-10 -92.66 152.46 19.54 Favored 'General case' 0 N--CA 1.477 0.918 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 178.398 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.0 p -153.13 128.37 1.55 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.632 0 N-CA-C 107.847 -1.168 . . . . 0.0 107.847 178.382 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 47.2 m-70 -134.87 145.83 48.65 Favored 'General case' 0 N--CA 1.492 1.648 0 CA-C-N 119.096 0.862 . . . . 0.0 111.327 -179.127 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 6.1 t60 -165.73 97.51 0.66 Allowed 'General case' 0 N--CA 1.48 1.05 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.809 179.496 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . 0.501 HE22 HG23 ' A' ' 36' ' ' VAL . 11.9 pt20 -111.9 -174.78 2.54 Favored 'General case' 0 CA--C 1.503 -0.86 0 N-CA-C 108.355 -0.98 . . . . 0.0 108.355 -179.849 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -163.27 99.13 0.94 Allowed 'General case' 0 N--CA 1.474 0.749 0 CA-C-N 114.527 -1.215 . . . . 0.0 108.347 178.582 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 6.9 mp -121.83 157.07 31.9 Favored 'General case' 0 N--CA 1.497 1.909 0 CA-C-O 121.945 0.879 . . . . 0.0 110.86 -178.338 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 60.0 t -112.54 126.84 69.98 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.179 0 CA-C-O 117.877 -1.058 . . . . 0.0 108.298 177.808 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 28.8 m-85 -127.11 122.52 34.49 Favored 'General case' 0 N--CA 1.496 1.859 0 CA-C-N 120.197 1.362 . . . . 0.0 110.336 179.302 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 68.3 m-85 53.95 73.98 0.35 Allowed 'General case' 0 N--CA 1.47 0.546 0 CA-C-O 121.544 0.687 . . . . 0.0 111.745 178.51 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -80.22 -78.13 0.18 Allowed 'General case' 0 C--N 1.353 0.758 0 CA-C-N 115.117 -0.947 . . . . 0.0 110.42 -179.739 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 40.3 tt0 -112.07 101.87 10.12 Favored 'General case' 0 N--CA 1.47 0.563 0 N-CA-C 108.493 -0.928 . . . . 0.0 108.493 179.927 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -158.69 134.65 9.0 Favored 'General case' 0 N--CA 1.481 1.092 0 CA-C-O 119.388 -0.339 . . . . 0.0 111.254 179.026 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 61.9 t -58.36 163.4 0.72 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.795 0 N-CA-C 108.227 -1.027 . . . . 0.0 108.227 177.173 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.422 ' H ' ' HB ' ' D' ' 24' ' ' VAL . . . -116.04 48.07 0.98 Allowed Glycine 0 N--CA 1.476 1.326 0 N-CA-C 111.759 -0.536 . . . . 0.0 111.759 -179.402 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -62.07 -168.59 0.02 OUTLIER 'General case' 0 N--CA 1.469 0.499 0 O-C-N 123.834 0.373 . . . . 0.0 110.218 179.284 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 24.7 t-20 -72.43 79.83 1.04 Allowed 'General case' 0 N--CA 1.466 0.335 0 N-CA-C 110.048 -0.352 . . . . 0.0 110.048 179.221 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -73.28 140.32 46.73 Favored 'General case' 0 N--CA 1.471 0.625 0 N-CA-C 109.012 -0.736 . . . . 0.0 109.012 179.43 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.42 -148.9 0.03 OUTLIER Glycine 0 C--N 1.337 0.622 0 N-CA-C 110.383 -1.087 . . . . 0.0 110.383 179.443 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -93.94 128.54 40.31 Favored 'General case' 0 N--CA 1.471 0.604 0 N-CA-C 110.076 -0.342 . . . . 0.0 110.076 179.904 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 72.4 mt -125.0 116.77 48.13 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.874 0 N-CA-C 106.782 -1.562 . . . . 0.0 106.782 178.764 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 38.9 pt -151.01 -169.69 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.356 0.88 0 CA-C-N 115.857 -0.611 . . . . 0.0 111.206 -178.527 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.41 5.37 11.41 Favored Glycine 0 C--N 1.336 0.577 0 N-CA-C 110.912 -0.875 . . . . 0.0 110.912 179.673 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.403 HD23 ' N ' ' A' ' 35' ' ' MET . 1.5 tt -78.42 127.12 31.74 Favored 'General case' 0 CA--C 1.543 0.684 0 N-CA-C 109.44 -0.578 . . . . 0.0 109.44 -179.617 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' MET . . . . . 0.403 ' N ' HD23 ' A' ' 34' ' ' LEU . 28.6 ttt -164.59 143.86 7.22 Favored 'General case' 0 N--CA 1.466 0.368 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 178.404 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.501 HG23 HE22 ' A' ' 15' ' ' GLN . 35.3 m -155.92 163.28 1.51 Allowed 'Isoleucine or valine' 0 C--O 1.219 -0.525 0 N-CA-C 108.339 -0.985 . . . . 0.0 108.339 179.376 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.78 66.56 2.75 Favored Glycine 0 C--N 1.303 -1.292 0 CA-C-N 116.147 -0.479 . . . . 0.0 112.136 178.631 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 146.0 173.54 17.34 Favored Glycine 0 N--CA 1.475 1.243 0 N-CA-C 110.649 -0.98 . . . . 0.0 110.649 179.138 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.578 ' H ' HG12 ' D' ' 39' ' ' VAL . 35.6 m -123.96 159.98 28.53 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.861 0 C-N-CA 123.579 0.752 . . . . 0.0 110.552 -179.858 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 25.2 t . . . . . 0 C--O 1.22 -0.46 0 CA-C-O 118.323 -0.846 . . . . 0.0 110.78 179.568 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' B' B ' 1' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 . . . . . 0 N--CA 1.49 1.534 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' B' B ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.39 132.33 48.71 Favored 'General case' 0 CA--C 1.54 0.593 0 CA-C-N 116.56 -0.291 . . . . 0.0 110.229 -179.821 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 3' ' ' GLU . . . . . . . . . . . . . 44.6 tt0 -168.2 105.51 0.48 Allowed 'General case' 0 N--CA 1.474 0.728 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 -179.169 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 39.4 m-85 -85.59 152.47 23.11 Favored 'General case' 0 N--CA 1.475 0.807 0 N-CA-C 109.99 -0.374 . . . . 0.0 109.99 179.534 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -143.71 139.98 29.78 Favored 'General case' 0 N--CA 1.482 1.139 0 N-CA-C 109.977 -0.379 . . . . 0.0 109.977 179.693 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 40.5 t-80 -151.74 119.18 6.0 Favored 'General case' 0 N--CA 1.473 0.724 0 N-CA-C 109.238 -0.652 . . . . 0.0 109.238 179.216 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 7' ' ' ASP . . . . . 0.501 ' O ' ' OG ' ' E' ' 8' ' ' SER . 4.3 m-20 -68.89 148.15 50.64 Favored 'General case' 0 CA--C 1.535 0.385 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.639 179.865 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 8' ' ' SER . . . . . . . . . . . . . 54.3 p -167.44 -173.79 2.34 Favored 'General case' 0 N--CA 1.48 1.068 0 C-N-CA 122.575 0.35 . . . . 0.0 110.701 179.072 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.94 47.92 1.3 Allowed Glycine 0 N--CA 1.482 1.703 0 CA-C-N 115.991 -0.549 . . . . 0.0 112.178 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 50.1 p90 -65.18 132.7 49.8 Favored 'General case' 0 N--CA 1.472 0.633 0 O-C-N 122.716 -0.285 . . . . 0.0 111.663 179.782 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 48.5 mt-10 -92.55 152.77 19.45 Favored 'General case' 0 N--CA 1.477 0.913 0 N-CA-C 109.764 -0.458 . . . . 0.0 109.764 178.331 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.0 p -153.43 128.45 1.51 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.587 0 N-CA-C 107.737 -1.209 . . . . 0.0 107.737 178.314 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 47.5 m-70 -135.0 145.81 48.45 Favored 'General case' 0 N--CA 1.492 1.639 0 CA-C-N 118.904 0.775 . . . . 0.0 111.303 -179.103 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 6.2 t60 -165.66 97.46 0.66 Allowed 'General case' 0 N--CA 1.482 1.133 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.648 179.452 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . 0.494 HE22 HG23 ' B' ' 36' ' ' VAL . 12.0 pt20 -111.76 -174.34 2.44 Favored 'General case' 0 CA--C 1.506 -0.749 0 N-CA-C 108.362 -0.977 . . . . 0.0 108.362 -179.883 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -163.87 99.07 0.87 Allowed 'General case' 0 N--CA 1.474 0.77 0 CA-C-N 114.718 -1.128 . . . . 0.0 108.26 178.608 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 6.8 mp -121.62 157.0 31.77 Favored 'General case' 0 N--CA 1.497 1.916 0 CA-C-O 121.936 0.875 . . . . 0.0 110.998 -178.294 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 61.1 t -112.55 127.6 69.68 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.07 0 N-CA-C 108.122 -1.066 . . . . 0.0 108.122 177.574 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 29.0 m-85 -127.99 122.36 32.11 Favored 'General case' 0 N--CA 1.495 1.802 0 CA-C-N 119.638 1.108 . . . . 0.0 110.219 179.515 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 68.7 m-85 53.23 74.46 0.3 Allowed 'General case' 0 CA--C 1.54 0.566 0 CA-C-O 121.558 0.694 . . . . 0.0 111.735 178.573 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -80.71 -77.85 0.19 Allowed 'General case' 0 C--N 1.35 0.6 0 CA-C-N 115.075 -0.966 . . . . 0.0 110.45 -179.788 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 40.5 tt0 -112.22 101.9 10.1 Favored 'General case' 0 N--CA 1.471 0.615 0 N-CA-C 108.417 -0.957 . . . . 0.0 108.417 179.786 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -158.68 134.54 8.94 Favored 'General case' 0 N--CA 1.484 1.23 0 CA-C-O 119.444 -0.312 . . . . 0.0 111.16 178.85 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . 0.403 HG12 ' N ' ' B' ' 25' ' ' GLY . 61.1 t -57.98 163.82 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.806 0 N-CA-C 108.249 -1.019 . . . . 0.0 108.249 177.209 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . 0.437 ' H ' ' HB ' ' E' ' 24' ' ' VAL . . . -116.22 48.22 0.96 Allowed Glycine 0 N--CA 1.475 1.288 0 N-CA-C 111.625 -0.59 . . . . 0.0 111.625 -179.446 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -62.27 -169.06 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.531 0 O-C-N 123.76 0.33 . . . . 0.0 110.242 179.238 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 25.1 t-20 -72.2 79.68 0.97 Allowed 'General case' 0 N--CA 1.467 0.393 0 N-CA-C 109.881 -0.414 . . . . 0.0 109.881 179.307 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -72.99 140.66 47.5 Favored 'General case' 0 N--CA 1.472 0.674 0 N-CA-C 109.105 -0.702 . . . . 0.0 109.105 179.417 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.86 -149.1 0.04 OUTLIER Glycine 0 C--N 1.338 0.645 0 N-CA-C 110.349 -1.1 . . . . 0.0 110.349 179.582 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -93.75 128.47 39.99 Favored 'General case' 0 N--CA 1.473 0.679 0 N-CA-C 110.036 -0.357 . . . . 0.0 110.036 179.882 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 72.5 mt -125.08 117.14 49.15 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.859 0 N-CA-C 106.723 -1.584 . . . . 0.0 106.723 178.768 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 39.6 pt -151.47 -169.94 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.356 0.887 0 CA-C-N 115.874 -0.603 . . . . 0.0 111.119 -178.364 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.68 5.26 12.31 Favored Glycine 0 C--N 1.337 0.614 0 N-CA-C 110.894 -0.882 . . . . 0.0 110.894 179.702 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 1.5 tt -78.42 126.67 31.09 Favored 'General case' 0 CA--C 1.545 0.76 0 N-CA-C 109.441 -0.577 . . . . 0.0 109.441 -179.521 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 28.5 ttt -164.12 143.66 7.83 Favored 'General case' 0 N--CA 1.467 0.378 0 N-CA-C 108.722 -0.844 . . . . 0.0 108.722 178.456 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 36' ' ' VAL . . . . . 0.494 HG23 HE22 ' B' ' 15' ' ' GLN . 35.7 m -155.88 162.98 1.57 Allowed 'Isoleucine or valine' 0 C--O 1.22 -0.491 0 N-CA-C 108.343 -0.984 . . . . 0.0 108.343 179.519 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.81 66.95 2.47 Favored Glycine 0 C--N 1.303 -1.291 0 CA-C-N 116.183 -0.462 . . . . 0.0 112.076 178.591 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 145.33 173.24 16.41 Favored Glycine 0 N--CA 1.474 1.208 0 N-CA-C 110.69 -0.964 . . . . 0.0 110.69 179.181 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 39' ' ' VAL . . . . . 0.611 ' H ' HG12 ' E' ' 39' ' ' VAL . 35.7 m -123.65 159.84 27.95 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.934 0 C-N-CA 123.608 0.763 . . . . 0.0 110.713 -179.769 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 24.4 t . . . . . 0 N--CA 1.469 0.522 0 CA-C-O 118.339 -0.839 . . . . 0.0 110.599 179.53 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' C' C ' 1' ' ' ASP . . . . . . . . . . . . . 8.9 m-20 . . . . . 0 N--CA 1.49 1.548 0 N-CA-C 108.795 -0.817 . . . . 0.0 108.795 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' C' C ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.77 132.73 49.43 Favored 'General case' 0 CA--C 1.539 0.538 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.213 -179.745 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 3' ' ' GLU . . . . . . . . . . . . . 44.6 tt0 -168.5 105.61 0.45 Allowed 'General case' 0 C--O 1.214 -0.776 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 -179.192 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 40.3 m-85 -85.75 152.45 23.05 Favored 'General case' 0 N--CA 1.476 0.842 0 N-CA-C 110.031 -0.359 . . . . 0.0 110.031 179.532 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -143.63 139.98 29.89 Favored 'General case' 0 N--CA 1.482 1.134 0 CA-C-O 120.872 0.368 . . . . 0.0 110.05 179.762 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 42.1 t-80 -151.74 119.16 5.99 Favored 'General case' 0 N--CA 1.472 0.656 0 N-CA-C 109.26 -0.644 . . . . 0.0 109.26 179.173 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 7' ' ' ASP . . . . . 0.471 ' O ' ' OG ' ' F' ' 8' ' ' SER . 4.2 m-20 -68.77 148.47 50.28 Favored 'General case' 0 N--CA 1.468 0.443 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.52 179.783 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 8' ' ' SER . . . . . . . . . . . . . 54.2 p -167.97 -173.94 2.23 Favored 'General case' 0 N--CA 1.48 1.049 0 CA-C-O 120.874 0.368 . . . . 0.0 110.677 179.137 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.05 47.75 1.31 Allowed Glycine 0 N--CA 1.482 1.751 0 CA-C-N 115.968 -0.56 . . . . 0.0 112.072 -179.926 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 50.6 p90 -65.04 132.58 49.59 Favored 'General case' 0 N--CA 1.472 0.658 0 CA-C-O 120.778 0.323 . . . . 0.0 111.637 179.737 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 48.6 mt-10 -92.48 152.96 19.39 Favored 'General case' 0 N--CA 1.475 0.79 0 N-CA-C 109.738 -0.468 . . . . 0.0 109.738 178.395 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.0 p -153.65 128.62 1.5 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.523 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 178.263 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 46.1 m-70 -135.17 145.72 48.02 Favored 'General case' 0 N--CA 1.492 1.635 0 CA-C-N 118.931 0.787 . . . . 0.0 111.317 -179.057 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 6.2 t60 -165.52 97.52 0.68 Allowed 'General case' 0 N--CA 1.482 1.162 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.688 179.52 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 15' ' ' GLN . . . . . 0.503 HE22 HG23 ' C' ' 36' ' ' VAL . 12.0 pt20 -112.0 -174.47 2.47 Favored 'General case' 0 CA--C 1.504 -0.825 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 -179.889 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -163.62 99.12 0.9 Allowed 'General case' 0 N--CA 1.473 0.677 0 CA-C-N 114.708 -1.133 . . . . 0.0 108.261 178.777 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 6.8 mp -121.71 157.07 31.74 Favored 'General case' 0 N--CA 1.497 1.902 0 CA-C-O 121.965 0.888 . . . . 0.0 110.994 -178.342 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 61.9 t -112.71 127.4 69.96 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.151 0 N-CA-C 108.146 -1.057 . . . . 0.0 108.146 177.612 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 28.9 m-85 -127.82 122.17 32.01 Favored 'General case' 0 N--CA 1.494 1.765 0 CA-C-N 119.673 1.124 . . . . 0.0 110.197 179.513 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 68.7 m-85 53.42 74.55 0.3 Allowed 'General case' 0 CA--C 1.539 0.523 0 CA-C-O 121.57 0.7 . . . . 0.0 111.787 178.612 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -80.62 -78.12 0.18 Allowed 'General case' 0 C--N 1.35 0.598 0 CA-C-N 114.961 -1.018 . . . . 0.0 110.379 -179.805 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 40.3 tt0 -112.02 102.05 10.3 Favored 'General case' 0 N--CA 1.469 0.522 0 N-CA-C 108.506 -0.924 . . . . 0.0 108.506 179.82 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -158.76 134.67 8.94 Favored 'General case' 0 N--CA 1.482 1.161 0 CA-C-O 119.385 -0.341 . . . . 0.0 111.185 178.906 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 61.0 t -58.14 163.74 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.843 0 N-CA-C 108.217 -1.031 . . . . 0.0 108.217 177.188 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 25' ' ' GLY . . . . . 0.443 ' H ' ' HB ' ' F' ' 24' ' ' VAL . . . -116.28 48.13 0.97 Allowed Glycine 0 N--CA 1.477 1.372 0 N-CA-C 111.617 -0.593 . . . . 0.0 111.617 -179.352 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -62.3 -169.11 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.532 0 O-C-N 123.726 0.309 . . . . 0.0 110.212 179.312 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 25.2 t-20 -71.98 79.98 0.92 Allowed 'General case' 0 N--CA 1.466 0.368 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.205 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -73.45 140.61 46.62 Favored 'General case' 0 N--CA 1.473 0.692 0 N-CA-C 109.015 -0.735 . . . . 0.0 109.015 179.369 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.71 -148.67 0.03 OUTLIER Glycine 0 C--N 1.338 0.661 0 N-CA-C 110.395 -1.082 . . . . 0.0 110.395 179.548 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -93.99 128.25 40.23 Favored 'General case' 0 N--CA 1.471 0.592 0 CA-C-N 116.866 0.333 . . . . 0.0 110.136 179.825 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 71.8 mt -124.94 116.71 48.02 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.834 0 N-CA-C 106.779 -1.563 . . . . 0.0 106.779 178.654 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 38.8 pt -150.97 -169.71 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.356 0.873 0 CA-C-N 115.903 -0.589 . . . . 0.0 111.183 -178.42 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.37 5.39 11.29 Favored Glycine 0 C--N 1.336 0.555 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 179.659 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 1.5 tt -78.53 126.44 30.76 Favored 'General case' 0 CA--C 1.544 0.744 0 N-CA-C 109.499 -0.556 . . . . 0.0 109.499 -179.613 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 28.6 ttt -163.65 143.76 8.55 Favored 'General case' 0 N--CA 1.468 0.427 0 N-CA-C 108.687 -0.857 . . . . 0.0 108.687 178.42 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 36' ' ' VAL . . . . . 0.503 HG23 HE22 ' C' ' 15' ' ' GLN . 35.5 m -155.9 162.96 1.57 Allowed 'Isoleucine or valine' 0 C--O 1.219 -0.501 0 N-CA-C 108.292 -1.003 . . . . 0.0 108.292 179.384 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.93 66.9 2.51 Favored Glycine 0 C--N 1.303 -1.299 0 CA-C-N 116.195 -0.457 . . . . 0.0 112.058 178.565 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 145.53 173.67 17.01 Favored Glycine 0 N--CA 1.475 1.257 0 N-CA-C 110.663 -0.975 . . . . 0.0 110.663 179.061 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 39' ' ' VAL . . . . . 0.608 ' H ' HG12 ' F' ' 39' ' ' VAL . 35.9 m -124.02 159.87 28.81 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.868 0 C-N-CA 123.678 0.791 . . . . 0.0 110.592 -179.851 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 24.7 t . . . . . 0 C--O 1.219 -0.542 0 CA-C-O 118.355 -0.831 . . . . 0.0 110.611 179.496 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' D' D ' 1' ' ' ASP . . . . . . . . . . . . . 9.5 m-20 . . . . . 0 N--CA 1.491 1.6 0 N-CA-C 109.116 -0.698 . . . . 0.0 109.116 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' D' D ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.5 131.02 45.9 Favored 'General case' 0 CA--C 1.538 0.486 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.357 -179.897 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 3' ' ' GLU . . . . . . . . . . . . . 44.5 tt0 -169.34 107.97 0.42 Allowed 'General case' 0 N--CA 1.47 0.569 0 N-CA-C 109.978 -0.378 . . . . 0.0 109.978 -179.959 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 39.8 m-85 -89.68 157.33 18.04 Favored 'General case' 0 C--N 1.359 0.982 0 N-CA-C 108.898 -0.778 . . . . 0.0 108.898 179.862 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -145.9 138.11 25.38 Favored 'General case' 0 N--CA 1.476 0.848 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.396 -179.609 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 39.6 t-80 -149.29 123.69 9.65 Favored 'General case' 0 CA--C 1.546 0.79 0 N-CA-C 108.318 -0.993 . . . . 0.0 108.318 175.746 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 7' ' ' ASP . . . . . 0.598 ' O ' ' OG ' ' G' ' 8' ' ' SER . 3.3 m-20 -64.28 133.08 52.03 Favored 'General case' 0 C--N 1.324 -0.524 0 C-N-CA 126.477 1.911 . . . . 0.0 114.259 174.946 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' D' D ' 8' ' ' SER . . . . . 0.495 ' OG ' ' O ' ' A' ' 7' ' ' ASP . 54.0 p -154.93 -171.12 3.72 Favored 'General case' 0 N--CA 1.486 1.373 0 CA-C-N 119.566 1.075 . . . . 0.0 111.26 175.892 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.44 48.23 1.14 Allowed Glycine 0 N--CA 1.483 1.779 0 N-CA-C 110.517 -1.033 . . . . 0.0 110.517 174.559 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 51.4 p90 -61.0 131.19 49.85 Favored 'General case' 0 N--CA 1.471 0.594 0 N-CA-C 112.782 0.66 . . . . 0.0 112.782 178.433 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 48.5 mt-10 -89.44 151.04 22.23 Favored 'General case' 0 N--CA 1.48 1.07 0 C-N-CA 122.258 0.223 . . . . 0.0 110.826 175.581 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.0 p -149.58 130.01 4.32 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.599 0 N-CA-C 107.515 -1.291 . . . . 0.0 107.515 173.542 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 44.5 m-70 -130.07 148.63 51.94 Favored 'General case' 0 N--CA 1.483 1.212 0 CA-C-N 118.22 0.464 . . . . 0.0 111.78 176.379 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 6.2 t60 -164.96 104.38 0.78 Allowed 'General case' 0 N--CA 1.482 1.163 0 N-CA-C 109.141 -0.689 . . . . 0.0 109.141 172.859 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 15' ' ' GLN . . . . . 0.518 HE22 HG23 ' D' ' 36' ' ' VAL . 11.9 pt20 -115.47 -176.18 2.87 Favored 'General case' 0 CA--C 1.496 -1.12 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 179.061 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -160.36 106.1 1.51 Allowed 'General case' 0 N--CA 1.469 0.506 0 N-CA-C 106.717 -1.586 . . . . 0.0 106.717 175.783 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 5.8 mp -128.17 153.68 46.62 Favored 'General case' 0 N--CA 1.497 1.909 0 CA-C-O 122.23 1.014 . . . . 0.0 110.586 179.989 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 36.1 t -101.29 131.58 48.76 Favored 'Isoleucine or valine' 0 C--O 1.26 1.631 0 CA-C-O 116.674 -1.632 . . . . 0.0 109.7 174.225 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 27.5 m-85 -130.44 126.12 36.16 Favored 'General case' 0 N--CA 1.49 1.547 0 CA-C-N 120.203 1.365 . . . . 0.0 109.552 173.359 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 69.7 m-85 55.53 71.52 0.54 Allowed 'General case' 0 C--O 1.239 0.517 0 CA-C-N 115.781 -0.645 . . . . 0.0 111.23 176.044 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -82.33 -73.28 0.4 Allowed 'General case' 0 N--CA 1.471 0.608 0 CA-C-O 118.555 -0.736 . . . . 0.0 111.171 -177.592 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 40.7 tt0 -115.37 105.67 13.11 Favored 'General case' 0 N--CA 1.481 1.12 0 N-CA-C 106.586 -1.635 . . . . 0.0 106.586 176.629 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 4.6 p-10 -152.02 135.13 15.78 Favored 'General case' 0 N--CA 1.474 0.756 0 CA-C-O 116.643 -1.646 . . . . 0.0 113.397 177.471 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 24' ' ' VAL . . . . . 0.422 ' HB ' ' H ' ' A' ' 25' ' ' GLY . 68.7 t -61.12 166.54 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.264 0 CA-C-N 121.351 1.887 . . . . 0.0 107.972 175.481 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' D' D ' 25' ' ' GLY . . . . . 0.496 ' H ' ' HB ' ' G' ' 24' ' ' VAL . . . -116.56 50.94 0.75 Allowed Glycine 0 N--CA 1.479 1.513 0 CA-C-O 119.203 -0.776 . . . . 0.0 111.489 178.814 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -57.57 -171.43 0.01 OUTLIER 'General case' 0 N--CA 1.468 0.465 0 C-N-CA 123.255 0.622 . . . . 0.0 111.888 175.556 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 25.5 t-20 -73.08 86.43 1.35 Allowed 'General case' 0 C--N 1.347 0.464 0 N-CA-C 108.635 -0.876 . . . . 0.0 108.635 176.47 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 97.7 mttt -80.8 143.42 32.86 Favored 'General case' 0 N--CA 1.479 1.009 0 N-CA-C 107.712 -1.218 . . . . 0.0 107.712 179.973 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.27 -143.69 0.02 OUTLIER Glycine 0 C--N 1.348 1.212 0 C-N-CA 120.224 -0.989 . . . . 0.0 111.618 -178.266 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -95.46 126.42 40.74 Favored 'General case' 0 C--O 1.239 0.515 0 C-N-CA 123.031 0.532 . . . . 0.0 110.276 178.663 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 80.4 mt -125.44 126.86 71.25 Favored 'Isoleucine or valine' 0 C--N 1.358 0.944 0 N-CA-C 104.022 -2.584 . . . . 0.0 104.022 176.281 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 32' ' ' ILE . . . . . 0.421 HG22 ' H ' ' G' ' 32' ' ' ILE . 41.9 pt -159.14 -170.92 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.1 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.261 -177.927 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.91 5.04 12.53 Favored Glycine 0 C--O 1.239 0.463 0 N-CA-C 110.237 -1.145 . . . . 0.0 110.237 -178.957 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 1.9 tt -79.54 133.46 36.47 Favored 'General case' 0 C--N 1.369 1.451 0 C-N-CA 117.863 -1.535 . . . . 0.0 107.458 -178.968 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 35' ' ' MET . . . . . 0.4 ' C ' HG13 ' D' ' 36' ' ' VAL . 28.1 ttt -158.71 156.3 29.65 Favored 'General case' 0 CA--C 1.511 -0.52 0 N-CA-C 108.203 -1.036 . . . . 0.0 108.203 171.852 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' D' D ' 36' ' ' VAL . . . . . 0.518 HG23 HE22 ' D' ' 15' ' ' GLN . 35.7 m -164.72 163.77 0.7 Allowed 'Isoleucine or valine' 0 C--O 1.219 -0.506 0 N-CA-C 108.058 -1.09 . . . . 0.0 108.058 173.934 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 59.91 63.65 4.88 Favored Glycine 0 C--N 1.307 -1.066 0 C-N-CA 120.37 -0.919 . . . . 0.0 111.528 177.764 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 144.62 176.04 18.29 Favored Glycine 0 N--CA 1.48 1.6 0 CA-C-N 117.971 0.886 . . . . 0.0 111.145 179.368 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 39' ' ' VAL . . . . . 0.605 ' H ' HG12 ' G' ' 39' ' ' VAL . 34.3 m -125.43 157.08 34.82 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.861 0 C-N-CA 123.409 0.684 . . . . 0.0 111.119 -178.753 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 25.2 t . . . . . 0 C--N 1.329 -0.32 0 CA-C-O 116.333 -1.794 . . . . 0.0 109.748 176.588 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' E' E ' 1' ' ' ASP . . . . . . . . . . . . . 9.4 m-20 . . . . . 0 N--CA 1.488 1.451 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' E' E ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.34 129.73 41.04 Favored 'General case' 0 CA--C 1.538 0.504 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.486 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' E' E ' 3' ' ' GLU . . . . . . . . . . . . . 44.5 tt0 -167.5 105.85 0.54 Allowed 'General case' 0 C--O 1.213 -0.839 0 CA-C-N 116.755 -0.202 . . . . 0.0 110.636 -179.74 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 35.9 m-85 -86.63 152.55 22.48 Favored 'General case' 0 N--CA 1.475 0.82 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 179.257 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' E' E ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -143.53 140.04 30.07 Favored 'General case' 0 N--CA 1.48 1.045 0 CA-C-O 120.902 0.382 . . . . 0.0 110.15 179.583 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 43.3 t-80 -151.47 119.35 6.19 Favored 'General case' 0 N--CA 1.474 0.729 0 N-CA-C 109.167 -0.679 . . . . 0.0 109.167 179.085 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' E' E ' 7' ' ' ASP . . . . . 0.497 ' O ' ' OG ' ' H' ' 8' ' ' SER . 3.9 m-20 -69.65 148.15 49.69 Favored 'General case' 0 N--CA 1.466 0.349 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.838 179.998 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' E' E ' 8' ' ' SER . . . . . 0.501 ' OG ' ' O ' ' B' ' 7' ' ' ASP . 52.5 p -168.32 -172.6 1.77 Allowed 'General case' 0 N--CA 1.483 1.21 0 CA-C-O 121.015 0.436 . . . . 0.0 110.854 178.757 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.55 47.66 1.27 Allowed Glycine 0 N--CA 1.479 1.543 0 CA-C-N 116.033 -0.53 . . . . 0.0 111.965 179.917 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 49.1 p90 -64.26 132.53 50.54 Favored 'General case' 0 N--CA 1.473 0.706 0 N-CA-C 112.028 0.381 . . . . 0.0 112.028 -179.894 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 49.4 mt-10 -91.72 153.17 19.82 Favored 'General case' 0 N--CA 1.48 1.066 0 CA-C-O 121.158 0.504 . . . . 0.0 109.665 177.944 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -155.01 127.32 1.02 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.587 0 N-CA-C 107.882 -1.155 . . . . 0.0 107.882 177.968 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 45.1 m-70 -135.04 143.65 46.85 Favored 'General case' 0 N--CA 1.482 1.166 0 CA-C-O 120.787 0.327 . . . . 0.0 111.516 -177.958 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 6.0 t60 -164.26 97.6 0.81 Allowed 'General case' 0 N--CA 1.486 1.371 0 CA-C-N 116.356 -0.383 . . . . 0.0 110.634 179.593 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' E' E ' 15' ' ' GLN . . . . . 0.527 HE22 HG23 ' E' ' 36' ' ' VAL . 12.0 pt20 -111.57 -174.63 2.51 Favored 'General case' 0 CA--C 1.505 -0.761 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 -179.805 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -163.27 98.61 0.93 Allowed 'General case' 0 N--CA 1.476 0.861 0 CA-C-N 114.75 -1.113 . . . . 0.0 108.49 178.633 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 6.5 mp -120.89 156.61 31.63 Favored 'General case' 0 N--CA 1.495 1.777 0 CA-C-O 121.786 0.803 . . . . 0.0 111.52 -177.682 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 48.4 t -114.06 124.62 70.88 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.216 0 N-CA-C 108.276 -1.009 . . . . 0.0 108.276 177.331 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 31.1 m-85 -125.51 121.41 33.65 Favored 'General case' 0 N--CA 1.489 1.51 0 CA-C-O 120.888 0.375 . . . . 0.0 110.846 -179.769 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 70.2 m-85 54.46 73.41 0.4 Allowed 'General case' 0 N--CA 1.469 0.508 0 CA-C-N 115.998 -0.547 . . . . 0.0 111.391 178.201 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -78.78 -78.95 0.14 Allowed 'General case' 0 C--N 1.344 0.348 0 CA-C-N 116.345 -0.389 . . . . 0.0 110.268 -179.475 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 40.4 tt0 -111.2 102.72 11.12 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 -179.978 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -158.16 134.93 9.75 Favored 'General case' 0 C--O 1.208 -1.116 0 CA-C-O 119.484 -0.293 . . . . 0.0 111.378 178.829 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' E' E ' 24' ' ' VAL . . . . . 0.437 ' HB ' ' H ' ' B' ' 25' ' ' GLY . 58.5 t -56.97 167.72 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.941 0 N-CA-C 107.614 -1.254 . . . . 0.0 107.614 176.806 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' E' E ' 25' ' ' GLY . . . . . 0.413 ' N ' HG12 ' E' ' 24' ' ' VAL . . . -120.73 49.07 0.9 Allowed Glycine 0 N--CA 1.477 1.431 0 N-CA-C 110.765 -0.934 . . . . 0.0 110.765 -179.354 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -63.53 -168.32 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.542 0 CA-C-O 120.691 0.281 . . . . 0.0 110.25 179.622 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 25.2 t-20 -71.7 76.42 0.84 Allowed 'General case' 0 N--CA 1.467 0.403 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.416 179.689 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -70.26 140.75 52.44 Favored 'General case' 0 N--CA 1.477 0.894 0 N-CA-C 109.497 -0.556 . . . . 0.0 109.497 179.557 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.6 -148.68 0.05 OUTLIER Glycine 0 CA--C 1.521 0.467 0 N-CA-C 110.895 -0.882 . . . . 0.0 110.895 179.519 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -92.81 127.18 38.22 Favored 'General case' 0 C--O 1.235 0.292 0 N-CA-C 110.268 -0.271 . . . . 0.0 110.268 179.577 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 74.2 mt -124.34 116.92 49.11 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.608 0 N-CA-C 106.491 -1.67 . . . . 0.0 106.491 178.439 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' E' E ' 32' ' ' ILE . . . . . 0.421 HG22 ' H ' ' H' ' 32' ' ' ILE . 43.7 pt -151.43 -168.46 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.182 0 CA-C-O 121.144 0.497 . . . . 0.0 110.622 -178.526 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.4 5.2 7.82 Favored Glycine 0 CA--C 1.528 0.873 0 N-CA-C 111.262 -0.735 . . . . 0.0 111.262 -179.954 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 1.5 tt -77.6 127.09 31.91 Favored 'General case' 0 CA--C 1.545 0.783 0 N-CA-C 109.491 -0.559 . . . . 0.0 109.491 -179.64 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 28.4 ttt -163.86 144.38 8.54 Favored 'General case' 0 N--CA 1.471 0.6 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 178.312 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' E' E ' 36' ' ' VAL . . . . . 0.527 HG23 HE22 ' E' ' 15' ' ' GLN . 32.8 m -156.73 162.62 1.56 Allowed 'Isoleucine or valine' 0 C--O 1.215 -0.712 0 N-CA-C 108.816 -0.809 . . . . 0.0 108.816 179.742 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.98 66.41 2.87 Favored Glycine 0 C--N 1.305 -1.194 0 N-CA-C 111.974 -0.45 . . . . 0.0 111.974 178.55 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 146.07 174.16 17.97 Favored Glycine 0 N--CA 1.477 1.374 0 N-CA-C 111.113 -0.795 . . . . 0.0 111.113 179.038 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' E' E ' 39' ' ' VAL . . . . . 0.611 HG12 ' H ' ' B' ' 39' ' ' VAL . 33.8 m -124.33 159.67 29.8 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.671 0 C-N-CA 123.478 0.711 . . . . 0.0 110.774 -179.566 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 25.8 t . . . . . 0 C--O 1.219 -0.518 0 CA-C-O 118.361 -0.828 . . . . 0.0 110.66 179.321 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' F' F ' 1' ' ' ASP . . . . . . . . . . . . . 9.5 m-20 . . . . . 0 N--CA 1.489 1.511 0 N-CA-C 109.293 -0.632 . . . . 0.0 109.293 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' F' F ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.02 129.85 41.67 Favored 'General case' 0 C--O 1.238 0.452 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.504 -179.968 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' F' F ' 3' ' ' GLU . . . . . . . . . . . . . 44.7 tt0 -167.54 106.03 0.54 Allowed 'General case' 0 C--O 1.213 -0.855 0 CA-C-N 116.733 -0.212 . . . . 0.0 110.511 -179.771 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 35.3 m-85 -86.77 152.56 22.4 Favored 'General case' 0 N--CA 1.475 0.8 0 N-CA-C 109.978 -0.378 . . . . 0.0 109.978 179.233 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' F' F ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -143.44 139.88 30.13 Favored 'General case' 0 N--CA 1.479 0.989 0 CA-C-O 120.872 0.368 . . . . 0.0 110.231 179.54 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 42.6 t-80 -151.35 119.02 6.09 Favored 'General case' 0 N--CA 1.474 0.761 0 N-CA-C 109.197 -0.668 . . . . 0.0 109.197 179.076 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' F' F ' 7' ' ' ASP . . . . . 0.463 ' O ' ' OG ' ' I' ' 8' ' ' SER . 4.0 m-20 -69.2 148.28 50.09 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.74 179.912 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' F' F ' 8' ' ' SER . . . . . 0.471 ' OG ' ' O ' ' C' ' 7' ' ' ASP . 52.1 p -168.65 -173.03 1.78 Allowed 'General case' 0 N--CA 1.486 1.329 0 CA-C-O 121.04 0.448 . . . . 0.0 110.858 178.749 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.79 47.55 1.26 Allowed Glycine 0 N--CA 1.479 1.529 0 CA-C-N 115.969 -0.559 . . . . 0.0 111.884 179.785 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 48.2 p90 -64.01 133.06 52.41 Favored 'General case' 0 CA--C 1.543 0.683 0 O-C-N 122.528 -0.395 . . . . 0.0 111.978 -179.821 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 49.2 mt-10 -92.02 152.94 19.74 Favored 'General case' 0 N--CA 1.48 1.056 0 CA-C-O 121.196 0.522 . . . . 0.0 109.727 177.841 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -154.78 127.0 1.01 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.572 0 N-CA-C 107.837 -1.172 . . . . 0.0 107.837 178.085 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 44.7 m-70 -134.71 143.65 47.31 Favored 'General case' 0 N--CA 1.484 1.228 0 CA-C-O 120.867 0.365 . . . . 0.0 111.563 -178.04 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 6.0 t60 -164.12 97.51 0.82 Allowed 'General case' 0 N--CA 1.487 1.391 0 CA-C-N 116.431 -0.349 . . . . 0.0 110.775 179.614 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' F' F ' 15' ' ' GLN . . . . . 0.531 HE22 HG23 ' F' ' 36' ' ' VAL . 12.0 pt20 -111.71 -174.72 2.53 Favored 'General case' 0 CA--C 1.503 -0.847 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 -179.838 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -163.09 98.64 0.94 Allowed 'General case' 0 N--CA 1.473 0.711 0 CA-C-N 114.74 -1.118 . . . . 0.0 108.466 178.689 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 6.7 mp -120.76 156.97 30.7 Favored 'General case' 0 N--CA 1.495 1.795 0 CA-C-O 121.806 0.812 . . . . 0.0 111.498 -177.827 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 48.8 t -114.35 124.45 71.01 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.231 0 N-CA-C 108.186 -1.042 . . . . 0.0 108.186 177.321 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 32.2 m-85 -125.24 121.16 33.28 Favored 'General case' 0 N--CA 1.488 1.452 0 CA-C-O 120.893 0.377 . . . . 0.0 110.857 -179.911 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 70.4 m-85 54.67 73.78 0.38 Allowed 'General case' 0 N--CA 1.467 0.386 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.588 178.277 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -79.12 -78.53 0.15 Allowed 'General case' 0 C--N 1.344 0.354 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.406 -179.431 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 40.9 tt0 -111.71 102.58 10.87 Favored 'General case' 0 N--CA 1.47 0.527 0 N-CA-C 108.402 -0.962 . . . . 0.0 108.402 -179.929 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -158.02 134.77 9.78 Favored 'General case' 0 N--CA 1.481 1.081 0 CA-C-O 119.416 -0.326 . . . . 0.0 111.394 178.822 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' F' F ' 24' ' ' VAL . . . . . 0.443 ' HB ' ' H ' ' C' ' 25' ' ' GLY . 58.1 t -56.82 167.97 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.966 0 N-CA-C 107.641 -1.244 . . . . 0.0 107.641 176.938 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' F' F ' 25' ' ' GLY . . . . . 0.415 ' H ' ' HB ' ' I' ' 24' ' ' VAL . . . -120.97 49.2 0.89 Allowed Glycine 0 N--CA 1.478 1.48 0 N-CA-C 110.745 -0.942 . . . . 0.0 110.745 -179.344 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -63.72 -167.92 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.551 0 CA-C-O 120.731 0.301 . . . . 0.0 110.294 179.66 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 25.2 t-20 -71.92 76.51 0.9 Allowed 'General case' 0 N--CA 1.466 0.372 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.325 179.662 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -70.48 140.44 51.9 Favored 'General case' 0 N--CA 1.477 0.892 0 N-CA-C 109.525 -0.546 . . . . 0.0 109.525 179.562 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.17 -149.09 0.04 OUTLIER Glycine 0 CA--C 1.522 0.504 0 N-CA-C 110.898 -0.881 . . . . 0.0 110.898 179.441 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -92.34 127.14 37.71 Favored 'General case' 0 C--O 1.236 0.352 0 CA-C-O 120.676 0.274 . . . . 0.0 110.276 179.444 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 73.2 mt -124.26 116.93 49.2 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.572 0 N-CA-C 106.479 -1.674 . . . . 0.0 106.479 178.401 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' F' F ' 32' ' ' ILE . . . . . 0.417 HG22 ' H ' ' I' ' 32' ' ' ILE . 44.1 pt -151.6 -168.36 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.149 0 CA-C-O 121.071 0.462 . . . . 0.0 110.722 -178.543 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.13 5.54 8.1 Favored Glycine 0 CA--C 1.527 0.818 0 N-CA-C 111.274 -0.73 . . . . 0.0 111.274 -179.889 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 1.5 tt -77.76 126.88 31.54 Favored 'General case' 0 N--CA 1.476 0.839 0 N-CA-C 109.386 -0.598 . . . . 0.0 109.386 -179.689 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 28.4 ttt -163.62 144.36 8.9 Favored 'General case' 0 N--CA 1.471 0.591 0 N-CA-C 108.876 -0.787 . . . . 0.0 108.876 178.283 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' F' F ' 36' ' ' VAL . . . . . 0.531 HG23 HE22 ' F' ' 15' ' ' GLN . 32.8 m -156.63 162.81 1.53 Allowed 'Isoleucine or valine' 0 C--O 1.216 -0.709 0 N-CA-C 108.829 -0.804 . . . . 0.0 108.829 179.638 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.82 66.48 2.81 Favored Glycine 0 C--N 1.305 -1.169 0 N-CA-C 111.992 -0.443 . . . . 0.0 111.992 178.5 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 145.82 174.12 17.71 Favored Glycine 0 N--CA 1.477 1.419 0 N-CA-C 111.031 -0.828 . . . . 0.0 111.031 178.961 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' F' F ' 39' ' ' VAL . . . . . 0.608 HG12 ' H ' ' C' ' 39' ' ' VAL . 33.7 m -124.38 159.75 29.82 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.692 0 C-N-CA 123.366 0.666 . . . . 0.0 110.755 -179.488 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 26.3 t . . . . . 0 C--O 1.22 -0.476 0 CA-C-O 118.249 -0.881 . . . . 0.0 110.609 179.215 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' G' G ' 1' ' ' ASP . . . . . . . . . . . . . 9.6 m-20 . . . . . 0 N--CA 1.492 1.631 0 N-CA-C 109.344 -0.613 . . . . 0.0 109.344 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' G' G ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.77 128.25 35.04 Favored 'General case' 0 CA--C 1.537 0.444 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.693 179.664 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' G' G ' 3' ' ' GLU . . . . . . . . . . . . . 43.9 tt0 -167.84 106.79 0.53 Allowed 'General case' 0 N--CA 1.473 0.677 0 CA-C-O 120.518 0.199 . . . . 0.0 110.891 179.744 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 39.2 m-85 -88.58 152.31 21.93 Favored 'General case' 0 N--CA 1.474 0.736 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 179.12 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' G' G ' 5' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -143.79 140.3 29.81 Favored 'General case' 0 N--CA 1.482 1.168 0 CA-C-O 120.846 0.355 . . . . 0.0 110.311 179.825 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 43.3 t-80 -151.54 120.25 6.55 Favored 'General case' 0 N--CA 1.475 0.782 0 N-CA-C 109.342 -0.614 . . . . 0.0 109.342 179.125 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -71.22 144.19 50.19 Favored 'General case' 0 N--CA 1.47 0.547 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.17 -179.937 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' G' G ' 8' ' ' SER . . . . . 0.598 ' OG ' ' O ' ' D' ' 7' ' ' ASP . 47.8 p -165.4 -170.96 2.0 Allowed 'General case' 0 N--CA 1.474 0.767 0 CA-C-O 120.962 0.41 . . . . 0.0 110.589 178.585 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.01 47.92 1.29 Allowed Glycine 0 N--CA 1.48 1.611 0 N-CA-C 111.514 -0.635 . . . . 0.0 111.514 179.441 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 50.4 p90 -64.5 133.02 51.56 Favored 'General case' 0 N--CA 1.473 0.699 0 CA-C-O 120.753 0.311 . . . . 0.0 111.818 -179.544 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 48.6 mt-10 -92.62 151.63 20.01 Favored 'General case' 0 N--CA 1.479 0.982 0 CA-C-O 121.104 0.478 . . . . 0.0 110.105 178.484 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -154.74 127.6 1.11 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.016 0 N-CA-C 107.92 -1.141 . . . . 0.0 107.92 178.361 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 47.0 m-70 -134.49 145.04 48.43 Favored 'General case' 0 N--CA 1.478 0.956 0 CA-C-N 115.542 -0.754 . . . . 0.0 111.399 -178.348 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 6.2 t60 -165.87 97.61 0.64 Allowed 'General case' 0 N--CA 1.483 1.206 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.301 178.963 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' G' G ' 15' ' ' GLN . . . . . 0.508 HE22 HG23 ' G' ' 36' ' ' VAL . 12.1 pt20 -111.74 -174.3 2.43 Favored 'General case' 0 CA--C 1.503 -0.848 0 N-CA-C 108.37 -0.974 . . . . 0.0 108.37 -179.657 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -163.8 98.21 0.86 Allowed 'General case' 0 N--CA 1.474 0.774 0 CA-C-N 114.672 -1.149 . . . . 0.0 108.194 178.856 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 6.6 mp -120.51 155.15 34.2 Favored 'General case' 0 N--CA 1.497 1.896 0 CA-C-O 121.291 0.567 . . . . 0.0 111.74 -177.794 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 43.9 t -113.33 124.91 70.44 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.006 0 CA-C-N 114.804 -1.089 . . . . 0.0 108.234 176.713 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 33.5 m-85 -125.9 121.17 32.39 Favored 'General case' 0 C--N 1.366 1.299 0 C-N-CA 123.437 0.695 . . . . 0.0 110.934 -179.585 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 69.3 m-85 54.75 72.82 0.44 Allowed 'General case' 0 N--CA 1.468 0.462 0 CA-C-N 115.874 -0.603 . . . . 0.0 111.375 178.059 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.7 -78.37 0.14 Allowed 'General case' 0 N--CA 1.472 0.632 0 O-C-N 122.223 -0.298 . . . . 0.0 110.508 -178.981 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 40.7 tt0 -111.78 102.47 10.75 Favored 'General case' 0 C--N 1.321 -0.633 0 N-CA-C 108.212 -1.033 . . . . 0.0 108.212 179.942 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -157.7 136.05 11.1 Favored 'General case' 0 N--CA 1.479 0.98 0 O-C-N 122.43 -0.168 . . . . 0.0 111.415 178.748 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' G' G ' 24' ' ' VAL . . . . . 0.496 ' HB ' ' H ' ' D' ' 25' ' ' GLY . 59.9 t -58.35 167.11 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.639 0 N-CA-C 107.749 -1.204 . . . . 0.0 107.749 177.115 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' G' G ' 25' ' ' GLY . . . . . 0.42 ' N ' HG12 ' G' ' 24' ' ' VAL . . . -119.53 49.4 0.88 Allowed Glycine 0 N--CA 1.48 1.615 0 N-CA-C 110.479 -1.048 . . . . 0.0 110.479 -179.496 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -64.6 -168.66 0.03 OUTLIER 'General case' 0 N--CA 1.471 0.624 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 179.67 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 25.4 t-20 -71.46 76.47 0.77 Allowed 'General case' 0 N--CA 1.468 0.435 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.385 179.796 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -69.82 140.55 53.3 Favored 'General case' 0 N--CA 1.474 0.765 0 N-CA-C 109.626 -0.509 . . . . 0.0 109.626 179.528 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.79 -147.01 0.04 OUTLIER Glycine 0 C--N 1.338 0.663 0 N-CA-C 110.517 -1.033 . . . . 0.0 110.517 179.637 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -93.36 126.12 38.32 Favored 'General case' 0 N--CA 1.468 0.43 0 C-N-CA 122.616 0.366 . . . . 0.0 110.663 -179.738 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 73.4 mt -123.76 117.3 50.7 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.771 0 N-CA-C 106.527 -1.657 . . . . 0.0 106.527 178.105 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' G' G ' 32' ' ' ILE . . . . . 0.421 ' H ' HG22 ' D' ' 32' ' ' ILE . 44.8 pt -152.27 -167.68 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 CA-C-N 119.839 1.2 . . . . 0.0 109.858 -179.046 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.37 6.2 10.23 Favored Glycine 0 CA--C 1.525 0.705 0 N-CA-C 110.998 -0.841 . . . . 0.0 110.998 179.824 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 1.5 tt -79.23 125.94 30.12 Favored 'General case' 0 CA--C 1.544 0.746 0 N-CA-C 109.492 -0.559 . . . . 0.0 109.492 -179.575 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 27.5 ttt -162.76 146.01 11.07 Favored 'General case' 0 N--CA 1.47 0.565 0 N-CA-C 108.757 -0.831 . . . . 0.0 108.757 178.418 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' G' G ' 36' ' ' VAL . . . . . 0.508 HG23 HE22 ' G' ' 15' ' ' GLN . 33.2 m -157.37 162.11 1.62 Allowed 'Isoleucine or valine' 0 C--N 1.347 0.461 0 N-CA-C 108.901 -0.777 . . . . 0.0 108.901 -179.959 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.37 66.8 2.58 Favored Glycine 0 C--N 1.312 -0.754 0 CA-C-N 115.712 -0.676 . . . . 0.0 112.271 178.213 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 146.53 175.17 19.29 Favored Glycine 0 N--CA 1.477 1.427 0 N-CA-C 110.516 -1.034 . . . . 0.0 110.516 178.988 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' G' G ' 39' ' ' VAL . . . . . 0.605 HG12 ' H ' ' D' ' 39' ' ' VAL . 34.6 m -125.34 159.94 31.94 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.867 0 C-N-CA 123.09 0.556 . . . . 0.0 110.73 -179.48 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 28.8 t . . . . . 0 N--CA 1.469 0.511 0 CA-C-O 118.388 -0.815 . . . . 0.0 110.796 179.025 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' H' H ' 1' ' ' ASP . . . . . . . . . . . . . 9.5 m-20 . . . . . 0 N--CA 1.491 1.58 0 N-CA-C 109.434 -0.58 . . . . 0.0 109.434 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' H' H ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.94 128.67 36.93 Favored 'General case' 0 CA--C 1.536 0.408 0 CA-C-N 115.949 -0.568 . . . . 0.0 110.613 179.77 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' H' H ' 3' ' ' GLU . . . . . . . . . . . . . 43.9 tt0 -168.27 106.89 0.49 Allowed 'General case' 0 N--CA 1.471 0.616 0 CA-C-O 120.529 0.204 . . . . 0.0 110.842 179.783 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 39.8 m-85 -88.57 152.15 22.03 Favored 'General case' 0 N--CA 1.473 0.697 0 N-CA-C 109.549 -0.537 . . . . 0.0 109.549 179.017 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' H' H ' 5' ' ' ARG . . . . . . . . . . . . . 99.3 mtt180 -143.66 140.53 30.12 Favored 'General case' 0 N--CA 1.483 1.185 0 C-N-CA 122.583 0.353 . . . . 0.0 110.13 179.884 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 42.9 t-80 -151.77 120.4 6.5 Favored 'General case' 0 N--CA 1.473 0.701 0 N-CA-C 109.383 -0.599 . . . . 0.0 109.383 179.096 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -71.58 143.9 49.7 Favored 'General case' 0 N--CA 1.471 0.585 0 CA-C-N 116.323 -0.399 . . . . 0.0 111.178 -179.768 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' H' H ' 8' ' ' SER . . . . . 0.497 ' OG ' ' O ' ' E' ' 7' ' ' ASP . 53.7 p -165.07 -171.19 2.14 Favored 'General case' 0 N--CA 1.475 0.815 0 CA-C-O 120.94 0.4 . . . . 0.0 110.509 178.628 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.13 47.61 1.32 Allowed Glycine 0 N--CA 1.48 1.594 0 N-CA-C 111.683 -0.567 . . . . 0.0 111.683 179.642 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 50.4 p90 -64.51 133.13 51.77 Favored 'General case' 0 N--CA 1.472 0.659 0 N-CA-C 111.947 0.351 . . . . 0.0 111.947 -179.637 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 48.4 mt-10 -92.45 151.77 20.04 Favored 'General case' 0 N--CA 1.478 0.929 0 CA-C-O 121.013 0.435 . . . . 0.0 110.215 178.499 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -154.71 127.92 1.16 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.041 0 N-CA-C 107.854 -1.165 . . . . 0.0 107.854 178.251 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 46.4 m-70 -134.72 145.07 48.13 Favored 'General case' 0 N--CA 1.478 0.971 0 CA-C-N 115.5 -0.773 . . . . 0.0 111.394 -178.374 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 6.2 t60 -165.93 97.29 0.63 Allowed 'General case' 0 N--CA 1.483 1.176 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.4 179.012 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' H' H ' 15' ' ' GLN . . . . . 0.516 HE22 HG23 ' H' ' 36' ' ' VAL . 12.1 pt20 -111.39 -174.52 2.48 Favored 'General case' 0 CA--C 1.504 -0.826 0 N-CA-C 108.34 -0.985 . . . . 0.0 108.34 -179.652 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -163.72 98.29 0.87 Allowed 'General case' 0 N--CA 1.475 0.784 0 CA-C-N 114.671 -1.15 . . . . 0.0 108.093 178.757 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 6.7 mp -120.41 155.56 33.21 Favored 'General case' 0 N--CA 1.496 1.873 0 CA-C-O 121.233 0.539 . . . . 0.0 111.849 -177.82 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 42.6 t -113.64 125.23 70.88 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.01 0 CA-C-N 114.869 -1.06 . . . . 0.0 108.231 176.556 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 33.2 m-85 -126.24 121.07 31.66 Favored 'General case' 0 C--N 1.369 1.445 0 CA-C-N 115.518 -0.765 . . . . 0.0 110.775 -179.444 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 69.6 m-85 54.41 73.13 0.41 Allowed 'General case' 0 C--O 1.238 0.453 0 CA-C-N 115.814 -0.63 . . . . 0.0 111.399 178.107 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.75 -78.06 0.14 Allowed 'General case' 0 N--CA 1.472 0.657 0 O-C-N 122.201 -0.312 . . . . 0.0 110.661 -179.147 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 40.4 tt0 -112.09 102.57 10.77 Favored 'General case' 0 C--N 1.321 -0.641 0 N-CA-C 108.236 -1.024 . . . . 0.0 108.236 179.883 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -157.75 136.24 11.2 Favored 'General case' 0 N--CA 1.478 0.974 0 O-C-N 122.417 -0.177 . . . . 0.0 111.368 178.817 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' H' H ' 24' ' ' VAL . . . . . 0.418 HG12 ' N ' ' H' ' 25' ' ' GLY . 59.1 t -58.49 166.91 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.548 0 N-CA-C 107.71 -1.218 . . . . 0.0 107.71 177.18 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' H' H ' 25' ' ' GLY . . . . . 0.418 ' N ' HG12 ' H' ' 24' ' ' VAL . . . -119.25 49.2 0.89 Allowed Glycine 0 N--CA 1.479 1.551 0 N-CA-C 110.651 -0.98 . . . . 0.0 110.651 -179.573 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -64.68 -168.33 0.03 OUTLIER 'General case' 0 N--CA 1.472 0.661 0 N-CA-C 109.944 -0.391 . . . . 0.0 109.944 179.722 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 25.6 t-20 -71.55 76.55 0.8 Allowed 'General case' 0 CA--C 1.537 0.472 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.316 179.809 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -70.15 140.56 52.61 Favored 'General case' 0 N--CA 1.474 0.775 0 N-CA-C 109.588 -0.523 . . . . 0.0 109.588 179.593 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.63 -147.69 0.04 OUTLIER Glycine 0 C--N 1.336 0.579 0 N-CA-C 110.376 -1.09 . . . . 0.0 110.376 179.549 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -93.05 126.31 38.07 Favored 'General case' 0 N--CA 1.465 0.298 0 C-N-CA 122.584 0.354 . . . . 0.0 110.781 -179.8 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 74.5 mt -123.87 117.23 50.41 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.776 0 N-CA-C 106.575 -1.639 . . . . 0.0 106.575 178.224 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' H' H ' 32' ' ' ILE . . . . . 0.421 ' H ' HG22 ' E' ' 32' ' ' ILE . 44.8 pt -152.11 -167.77 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 CA-C-N 119.761 1.164 . . . . 0.0 109.871 -179.026 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.71 5.76 9.9 Favored Glycine 0 CA--C 1.524 0.641 0 N-CA-C 110.935 -0.866 . . . . 0.0 110.935 179.845 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 1.4 tt -78.7 125.75 29.79 Favored 'General case' 0 CA--C 1.544 0.728 0 N-CA-C 109.555 -0.535 . . . . 0.0 109.555 -179.565 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 27.4 ttt -162.56 145.94 11.37 Favored 'General case' 0 N--CA 1.47 0.572 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 178.323 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' H' H ' 36' ' ' VAL . . . . . 0.516 HG23 HE22 ' H' ' 15' ' ' GLN . 33.2 m -157.35 162.18 1.6 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 N-CA-C 108.874 -0.788 . . . . 0.0 108.874 -179.935 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.25 67.06 2.4 Favored Glycine 0 C--N 1.311 -0.819 0 CA-C-N 115.781 -0.645 . . . . 0.0 112.149 178.286 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 146.42 175.76 19.69 Favored Glycine 0 N--CA 1.479 1.547 0 N-CA-C 110.577 -1.009 . . . . 0.0 110.577 178.892 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' H' H ' 39' ' ' VAL . . . . . 0.611 HG12 ' H ' ' E' ' 39' ' ' VAL . 34.6 m -125.97 159.85 33.75 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.82 0 C-N-CA 123.161 0.585 . . . . 0.0 110.708 -179.499 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 26.7 t . . . . . 0 C--O 1.219 -0.547 0 CA-C-O 118.346 -0.835 . . . . 0.0 110.79 179.263 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' I' I ' 1' ' ' ASP . . . . . . . . . . . . . 9.6 m-20 . . . . . 0 N--CA 1.492 1.647 0 N-CA-C 109.471 -0.566 . . . . 0.0 109.471 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' I' I ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.87 128.55 36.44 Favored 'General case' 0 CA--C 1.537 0.454 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.553 179.777 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' I' I ' 3' ' ' GLU . . . . . . . . . . . . . 43.8 tt0 -167.97 107.07 0.53 Allowed 'General case' 0 N--CA 1.472 0.648 0 CA-C-O 120.423 0.154 . . . . 0.0 110.803 179.756 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 39.7 m-85 -88.77 152.3 21.86 Favored 'General case' 0 N--CA 1.475 0.78 0 N-CA-C 109.473 -0.566 . . . . 0.0 109.473 179.063 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' I' I ' 5' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -143.72 140.28 29.91 Favored 'General case' 0 N--CA 1.482 1.167 0 C-N-CA 122.602 0.361 . . . . 0.0 110.15 179.894 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 43.1 t-80 -151.72 120.28 6.47 Favored 'General case' 0 N--CA 1.474 0.732 0 N-CA-C 109.358 -0.608 . . . . 0.0 109.358 179.04 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -71.23 143.87 50.27 Favored 'General case' 0 N--CA 1.469 0.503 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.234 -179.881 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' I' I ' 8' ' ' SER . . . . . 0.463 ' OG ' ' O ' ' F' ' 7' ' ' ASP . 53.3 p -164.87 -171.4 2.25 Favored 'General case' 0 N--CA 1.474 0.752 0 CA-C-O 120.857 0.36 . . . . 0.0 110.582 178.668 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.08 48.04 1.28 Allowed Glycine 0 N--CA 1.48 1.619 0 N-CA-C 111.693 -0.563 . . . . 0.0 111.693 179.63 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 50.4 p90 -65.1 132.52 49.39 Favored 'General case' 0 N--CA 1.472 0.632 0 N-CA-C 111.934 0.346 . . . . 0.0 111.934 -179.737 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 48.3 mt-10 -91.81 152.24 20.22 Favored 'General case' 0 N--CA 1.478 0.937 0 CA-C-O 121.033 0.445 . . . . 0.0 110.18 178.511 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -155.28 127.58 1.03 Allowed 'Isoleucine or valine' 0 CA--C 1.551 0.999 0 N-CA-C 107.848 -1.167 . . . . 0.0 107.848 178.349 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 46.1 m-70 -134.48 145.08 48.48 Favored 'General case' 0 N--CA 1.477 0.887 0 CA-C-N 115.572 -0.74 . . . . 0.0 111.436 -178.387 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 6.1 t60 -165.61 97.47 0.67 Allowed 'General case' 0 N--CA 1.481 1.105 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.362 178.961 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' I' I ' 15' ' ' GLN . . . . . 0.486 HE22 HG23 ' I' ' 36' ' ' VAL . 12.3 pt20 -111.79 -174.83 2.55 Favored 'General case' 0 CA--C 1.502 -0.894 0 N-CA-C 108.399 -0.963 . . . . 0.0 108.399 -179.689 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -163.39 98.41 0.91 Allowed 'General case' 0 N--CA 1.474 0.762 0 CA-C-N 114.647 -1.16 . . . . 0.0 108.172 178.87 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 6.7 mp -120.53 155.4 33.71 Favored 'General case' 0 N--CA 1.496 1.854 0 CA-C-O 121.266 0.555 . . . . 0.0 111.773 -177.829 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 41.6 t -113.56 125.35 70.82 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.998 0 CA-C-N 114.824 -1.08 . . . . 0.0 108.194 176.568 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 33.6 m-85 -126.32 121.32 32.24 Favored 'General case' 0 C--N 1.368 1.393 0 CA-C-N 115.61 -0.723 . . . . 0.0 110.876 -179.491 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 69.4 m-85 54.16 72.94 0.42 Allowed 'General case' 0 C--O 1.237 0.441 0 CA-C-N 115.918 -0.583 . . . . 0.0 111.375 178.165 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.63 -78.08 0.14 Allowed 'General case' 0 N--CA 1.472 0.657 0 O-C-N 122.302 -0.249 . . . . 0.0 110.598 -179.116 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 40.7 tt0 -112.01 102.73 10.93 Favored 'General case' 0 C--N 1.323 -0.573 0 N-CA-C 108.156 -1.053 . . . . 0.0 108.156 179.948 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -157.95 136.19 10.94 Favored 'General case' 0 N--CA 1.478 0.956 0 O-C-N 122.375 -0.203 . . . . 0.0 111.329 178.858 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' I' I ' 24' ' ' VAL . . . . . 0.425 HG12 ' N ' ' I' ' 25' ' ' GLY . 58.5 t -58.5 166.92 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.559 0 N-CA-C 107.779 -1.193 . . . . 0.0 107.779 177.134 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' I' I ' 25' ' ' GLY . . . . . 0.425 ' N ' HG12 ' I' ' 24' ' ' VAL . . . -119.42 49.22 0.88 Allowed Glycine 0 N--CA 1.481 1.661 0 N-CA-C 110.592 -1.003 . . . . 0.0 110.592 -179.404 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -64.54 -168.2 0.03 OUTLIER 'General case' 0 N--CA 1.471 0.602 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 179.702 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 25.5 t-20 -71.71 76.89 0.84 Allowed 'General case' 0 CA--C 1.536 0.439 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.259 179.675 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -70.45 140.6 52.0 Favored 'General case' 0 N--CA 1.475 0.807 0 N-CA-C 109.63 -0.507 . . . . 0.0 109.63 179.472 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.72 -147.32 0.04 OUTLIER Glycine 0 C--N 1.337 0.621 0 N-CA-C 110.496 -1.041 . . . . 0.0 110.496 179.588 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -93.26 125.86 38.07 Favored 'General case' 0 N--CA 1.465 0.314 0 C-N-CA 122.696 0.399 . . . . 0.0 110.752 -179.737 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 73.7 mt -123.47 117.33 51.03 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.768 0 N-CA-C 106.556 -1.646 . . . . 0.0 106.556 178.111 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' I' I ' 32' ' ' ILE . . . . . 0.417 ' H ' HG22 ' F' ' 32' ' ' ILE . 44.9 pt -152.17 -167.82 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 CA-C-N 119.758 1.163 . . . . 0.0 109.869 -179.05 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.71 5.86 10.18 Favored Glycine 0 CA--C 1.526 0.738 0 N-CA-C 110.95 -0.86 . . . . 0.0 110.95 179.768 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 1.4 tt -78.89 125.56 29.53 Favored 'General case' 0 CA--C 1.546 0.79 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 -179.593 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 27.4 ttt -162.25 145.79 11.83 Favored 'General case' 0 N--CA 1.47 0.542 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 178.559 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' I' I ' 36' ' ' VAL . . . . . 0.486 HG23 HE22 ' I' ' 15' ' ' GLN . 33.3 m -157.28 162.03 1.65 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.47 0 N-CA-C 108.845 -0.798 . . . . 0.0 108.845 -179.89 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.29 66.87 2.53 Favored Glycine 0 C--N 1.311 -0.85 0 CA-C-N 115.799 -0.637 . . . . 0.0 112.228 178.173 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 146.58 175.82 19.87 Favored Glycine 0 N--CA 1.478 1.497 0 N-CA-C 110.603 -0.999 . . . . 0.0 110.603 178.939 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' I' I ' 39' ' ' VAL . . . . . 0.603 HG12 ' H ' ' F' ' 39' ' ' VAL . 34.5 m -125.92 159.9 33.55 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.866 0 C-N-CA 123.131 0.572 . . . . 0.0 110.755 -179.488 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 29.8 t . . . . . 0 C--O 1.219 -0.513 0 CA-C-O 118.394 -0.812 . . . . 0.0 110.777 179.103 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 8.5 m-20 . . . . . 0 N--CA 1.489 1.513 0 N-CA-C 109.035 -0.728 . . . . 0.0 109.035 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.8 133.02 50.1 Favored 'General case' 0 CA--C 1.538 0.513 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.138 -179.924 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 54.8 tt0 -169.66 108.66 0.41 Allowed 'General case' 0 N--CA 1.47 0.544 0 N-CA-C 109.66 -0.496 . . . . 0.0 109.66 -179.158 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 78.8 m-85 -84.19 140.03 31.99 Favored 'General case' 0 N--CA 1.474 0.766 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 179.562 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 72.4 mtp180 -143.58 142.05 30.92 Favored 'General case' 0 N--CA 1.482 1.164 0 N-CA-C 109.134 -0.691 . . . . 0.0 109.134 -179.883 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 76.6 m80 -149.83 119.74 7.13 Favored 'General case' 0 N--CA 1.47 0.528 0 N-CA-C 108.759 -0.83 . . . . 0.0 108.759 179.102 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 8.5 m-20 -68.32 149.89 48.87 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.189 -179.385 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 7.9 t -167.65 171.16 10.42 Favored 'General case' 0 N--CA 1.473 0.706 0 N-CA-C 109.628 -0.508 . . . . 0.0 109.628 178.456 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.2 24.7 2.17 Favored Glycine 0 N--CA 1.488 2.127 0 N-CA-C 112.114 -0.394 . . . . 0.0 112.114 179.367 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 43.4 p90 -56.26 128.06 33.87 Favored 'General case' 0 N--CA 1.473 0.696 0 N-CA-C 112.175 0.435 . . . . 0.0 112.175 -179.866 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.51 ' CG ' HD21 ' C' ' 27' ' ' ASN . 45.8 mt-10 -84.72 154.24 22.56 Favored 'General case' 0 N--CA 1.469 0.5 0 N-CA-C 109.082 -0.71 . . . . 0.0 109.082 178.445 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -153.25 129.29 1.75 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.341 0 N-CA-C 108.327 -0.99 . . . . 0.0 108.327 178.926 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 49.5 m-70 -134.03 144.72 48.86 Favored 'General case' 0 N--CA 1.489 1.507 0 CA-C-N 118.711 0.687 . . . . 0.0 110.993 -179.156 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 6.3 t60 -164.75 98.8 0.78 Allowed 'General case' 0 N--CA 1.479 0.978 0 CA-C-N 116.642 -0.254 . . . . 0.0 111.194 179.686 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . 0.56 HE22 ' H ' ' A' ' 37' ' ' GLY . 54.2 mt-30 -108.79 -172.26 2.02 Favored 'General case' 0 CA--C 1.502 -0.873 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 179.804 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -166.97 97.67 0.53 Allowed 'General case' 0 N--CA 1.473 0.689 0 CA-C-N 115.201 -0.909 . . . . 0.0 109.486 178.644 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.596 HD12 ' N ' ' A' ' 17' ' ' LEU . 4.5 mp -105.66 163.88 12.34 Favored 'General case' 0 N--CA 1.487 1.409 0 N-CA-C 108.543 -0.91 . . . . 0.0 108.543 179.901 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 48.9 t -142.15 118.92 6.79 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.354 0 CA-C-O 118.796 -0.621 . . . . 0.0 110.02 179.452 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 51.6 m-85 -69.98 159.24 34.13 Favored 'General case' 0 N--CA 1.48 1.055 0 N-CA-C 107.592 -1.262 . . . . 0.0 107.592 177.203 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 13.6 t80 -171.15 -58.52 0.02 OUTLIER 'General case' 0 N--CA 1.485 1.3 0 CA-C-O 122.365 1.079 . . . . 0.0 109.712 179.662 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -38.81 90.0 0.0 OUTLIER 'General case' 0 C--O 1.232 0.17 0 CA-C-N 113.782 -1.554 . . . . 0.0 112.938 -177.952 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 38.1 tt0 -66.16 157.65 30.75 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 115.05 -0.977 . . . . 0.0 110.565 179.118 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 66.8 m-20 -139.55 136.78 34.83 Favored 'General case' 0 N--CA 1.481 1.1 0 C-N-CA 123.008 0.523 . . . . 0.0 110.281 179.862 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 18.4 t -84.65 -116.46 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.982 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 179.469 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -109.15 54.81 0.53 Allowed Glycine 0 N--CA 1.474 1.211 0 N-CA-C 111.126 -0.79 . . . . 0.0 111.126 179.909 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 71.1 p -80.07 126.01 30.52 Favored 'General case' 0 C--N 1.328 -0.333 0 N-CA-C 108.799 -0.815 . . . . 0.0 108.799 178.184 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . 0.524 HD21 ' CG ' ' B' ' 11' ' ' GLU . 47.3 t30 -65.93 100.26 0.56 Allowed 'General case' 0 N--CA 1.473 0.719 0 N-CA-C 108.8 -0.815 . . . . 0.0 108.8 178.702 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 66.7 mttm -95.46 117.2 29.95 Favored 'General case' 0 N--CA 1.484 1.229 0 N-CA-C 110.01 -0.367 . . . . 0.0 110.01 -179.067 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.13 -133.55 0.01 OUTLIER Glycine 0 CA--C 1.532 1.12 0 N-CA-C 110.726 -0.95 . . . . 0.0 110.726 178.943 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -113.4 127.81 56.25 Favored 'General case' 0 N--CA 1.478 0.939 0 N-CA-C 109.29 -0.633 . . . . 0.0 109.29 178.934 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 66.7 mt -90.73 130.19 40.34 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.683 0 N-CA-C 107.606 -1.257 . . . . 0.0 107.606 178.715 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 18.1 mt -142.33 152.38 18.13 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.929 0 N-CA-C 109.838 -0.431 . . . . 0.0 109.838 -178.83 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 65.37 48.27 70.83 Favored Glycine 0 CA--C 1.524 0.63 0 CA-C-N 116.062 -0.517 . . . . 0.0 112.531 178.804 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.401 HD23 ' N ' ' A' ' 35' ' ' MET . 2.9 tt -98.88 120.39 39.24 Favored 'General case' 0 N--CA 1.478 0.934 0 N-CA-C 107.245 -1.391 . . . . 0.0 107.245 177.903 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' MET . . . . . 0.401 ' N ' HD23 ' A' ' 34' ' ' LEU . 28.1 ttt -152.71 158.26 42.09 Favored 'General case' 0 N--CA 1.471 0.579 0 N-CA-C 108.909 -0.774 . . . . 0.0 108.909 179.463 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 86.1 t -158.29 149.86 8.23 Favored 'Isoleucine or valine' 0 C--O 1.236 0.351 0 N-CA-C 107.012 -1.477 . . . . 0.0 107.012 -179.204 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . 0.56 ' H ' HE22 ' A' ' 15' ' ' GLN . . . 56.66 74.92 0.28 Allowed Glycine 0 C--N 1.313 -0.741 0 CA-C-N 115.622 -0.717 . . . . 0.0 111.658 178.181 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 170.96 -148.92 11.7 Favored Glycine 0 CA--C 1.519 0.299 0 N-CA-C 110.656 -0.978 . . . . 0.0 110.656 179.786 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 33.5 m -133.93 142.64 40.72 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.794 0 N-CA-C 109.688 -0.486 . . . . 0.0 109.688 179.744 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 16.3 t . . . . . 0 CA--C 1.535 0.392 0 CA-C-O 117.969 -1.015 . . . . 0.0 111.058 179.331 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' B' B ' 1' ' ' ASP . . . . . . . . . . . . . 7.6 m-20 . . . . . 0 N--CA 1.487 1.424 0 N-CA-C 109.14 -0.689 . . . . 0.0 109.14 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' B' B ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.46 132.63 49.43 Favored 'General case' 0 CA--C 1.538 0.507 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.172 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 3' ' ' GLU . . . . . . . . . . . . . 55.2 tt0 -169.32 108.83 0.44 Allowed 'General case' 0 N--CA 1.47 0.543 0 N-CA-C 109.541 -0.54 . . . . 0.0 109.541 -179.115 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 78.8 m-85 -84.17 140.52 31.68 Favored 'General case' 0 N--CA 1.474 0.729 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 179.489 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 71.9 mtp180 -144.09 141.82 30.26 Favored 'General case' 0 N--CA 1.481 1.11 0 N-CA-C 109.123 -0.695 . . . . 0.0 109.123 -179.815 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 76.7 m80 -149.7 119.64 7.15 Favored 'General case' 0 N--CA 1.471 0.611 0 N-CA-C 108.826 -0.805 . . . . 0.0 108.826 179.117 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 7' ' ' ASP . . . . . . . . . . . . . 8.6 m-20 -68.14 149.56 49.44 Favored 'General case' 0 CA--C 1.531 0.215 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.238 -179.439 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 8' ' ' SER . . . . . . . . . . . . . 8.1 t -167.36 171.87 10.21 Favored 'General case' 0 N--CA 1.473 0.685 0 N-CA-C 109.668 -0.493 . . . . 0.0 109.668 178.368 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 121.53 24.69 2.32 Favored Glycine 0 N--CA 1.488 2.135 0 N-CA-C 112.102 -0.399 . . . . 0.0 112.102 179.323 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 42.9 p90 -56.15 127.7 31.94 Favored 'General case' 0 N--CA 1.472 0.653 0 N-CA-C 112.236 0.458 . . . . 0.0 112.236 -179.87 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 11' ' ' GLU . . . . . 0.524 ' CG ' HD21 ' A' ' 27' ' ' ASN . 45.6 mt-10 -84.38 154.07 23.07 Favored 'General case' 0 N--CA 1.469 0.515 0 N-CA-C 109.223 -0.658 . . . . 0.0 109.223 178.442 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -153.17 129.65 1.9 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.328 0 N-CA-C 108.301 -1.0 . . . . 0.0 108.301 178.956 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 49.1 m-70 -134.34 145.34 48.92 Favored 'General case' 0 N--CA 1.49 1.552 0 CA-C-N 118.531 0.605 . . . . 0.0 110.975 -179.204 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 6.4 t60 -165.23 98.59 0.72 Allowed 'General case' 0 N--CA 1.482 1.125 0 CA-C-N 116.563 -0.29 . . . . 0.0 111.195 179.658 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . 0.548 HE22 ' H ' ' B' ' 37' ' ' GLY . 54.3 mt-30 -108.57 -172.81 2.13 Favored 'General case' 0 CA--C 1.502 -0.894 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 179.815 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -166.64 97.59 0.56 Allowed 'General case' 0 N--CA 1.472 0.63 0 CA-C-N 115.121 -0.945 . . . . 0.0 109.369 178.821 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . 0.596 ' N ' HD12 ' B' ' 17' ' ' LEU . 4.5 mp -105.87 163.88 12.38 Favored 'General case' 0 N--CA 1.487 1.394 0 N-CA-C 108.542 -0.91 . . . . 0.0 108.542 179.881 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 50.5 t -142.27 118.88 6.51 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.3 0 CA-C-O 118.959 -0.543 . . . . 0.0 109.96 179.58 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 53.0 m-85 -70.67 159.22 34.84 Favored 'General case' 0 N--CA 1.478 0.939 0 N-CA-C 107.53 -1.285 . . . . 0.0 107.53 177.248 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 14.9 t80 -171.83 -57.27 0.02 OUTLIER 'General case' 0 N--CA 1.482 1.168 0 CA-C-O 122.151 0.977 . . . . 0.0 109.769 179.631 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -39.1 90.38 0.0 OUTLIER 'General case' 0 CA--C 1.528 0.125 0 CA-C-N 114.125 -1.398 . . . . 0.0 112.768 -178.091 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 38.2 tt0 -66.45 157.45 31.99 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 115.089 -0.96 . . . . 0.0 110.52 179.19 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 67.4 m-20 -139.38 137.24 35.54 Favored 'General case' 0 N--CA 1.479 0.984 0 C-N-CA 123.083 0.553 . . . . 0.0 110.213 179.772 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 18.3 t -85.44 -116.71 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.048 0 N-CA-C 108.562 -0.903 . . . . 0.0 108.562 179.535 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -108.2 54.36 0.56 Allowed Glycine 0 N--CA 1.476 1.353 0 N-CA-C 111.049 -0.82 . . . . 0.0 111.049 179.929 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 71.8 p -80.13 125.55 29.96 Favored 'General case' 0 C--N 1.328 -0.351 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 178.242 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 27' ' ' ASN . . . . . 0.521 HD21 ' CG ' ' C' ' 11' ' ' GLU . 47.7 t30 -65.69 100.4 0.53 Allowed 'General case' 0 N--CA 1.475 0.782 0 N-CA-C 108.812 -0.81 . . . . 0.0 108.812 178.649 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 66.6 mttm -95.58 117.0 29.64 Favored 'General case' 0 N--CA 1.485 1.298 0 N-CA-C 110.041 -0.355 . . . . 0.0 110.041 -179.179 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.85 -133.26 0.01 OUTLIER Glycine 0 CA--C 1.533 1.207 0 N-CA-C 110.723 -0.951 . . . . 0.0 110.723 178.927 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -113.88 127.9 56.18 Favored 'General case' 0 N--CA 1.479 0.981 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 179.031 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 66.6 mt -90.77 130.26 40.26 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.655 0 N-CA-C 107.532 -1.285 . . . . 0.0 107.532 178.692 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 17.8 mt -142.42 152.36 17.99 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.918 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 -178.852 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 65.52 47.55 77.02 Favored Glycine 0 CA--C 1.524 0.638 0 CA-C-N 116.085 -0.507 . . . . 0.0 112.667 178.793 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 2.9 tt -98.07 120.51 38.6 Favored 'General case' 0 N--CA 1.478 0.936 0 N-CA-C 107.25 -1.389 . . . . 0.0 107.25 177.85 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 28.0 ttt -152.81 157.97 41.55 Favored 'General case' 0 N--CA 1.472 0.627 0 N-CA-C 108.849 -0.797 . . . . 0.0 108.849 179.376 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 82.1 t -158.15 149.77 8.47 Favored 'Isoleucine or valine' 0 C--O 1.235 0.306 0 N-CA-C 106.807 -1.553 . . . . 0.0 106.807 -179.147 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . 0.548 ' H ' HE22 ' B' ' 15' ' ' GLN . . . 56.67 75.28 0.26 Allowed Glycine 0 C--N 1.314 -0.689 0 CA-C-N 115.573 -0.74 . . . . 0.0 111.651 178.14 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 170.47 -149.07 12.14 Favored Glycine 0 CA--C 1.518 0.265 0 N-CA-C 110.698 -0.961 . . . . 0.0 110.698 179.772 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 33.8 m -133.59 142.76 40.73 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.842 0 N-CA-C 109.691 -0.485 . . . . 0.0 109.691 179.659 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 16.1 t . . . . . 0 C--O 1.222 -0.353 0 CA-C-O 117.993 -1.003 . . . . 0.0 111.111 179.319 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' C' C ' 1' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 . . . . . 0 N--CA 1.488 1.465 0 N-CA-C 109.106 -0.701 . . . . 0.0 109.106 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' C' C ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.51 132.66 49.46 Favored 'General case' 0 CA--C 1.538 0.517 0 CA-C-N 116.374 -0.375 . . . . 0.0 110.23 -179.921 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 3' ' ' GLU . . . . . . . . . . . . . 54.1 tt0 -169.35 108.59 0.43 Allowed 'General case' 0 N--CA 1.47 0.555 0 N-CA-C 109.637 -0.505 . . . . 0.0 109.637 -179.09 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 79.0 m-85 -83.95 140.43 31.93 Favored 'General case' 0 N--CA 1.475 0.784 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 179.515 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 72.4 mtp180 -144.11 141.48 30.03 Favored 'General case' 0 N--CA 1.482 1.157 0 N-CA-C 109.071 -0.714 . . . . 0.0 109.071 -179.834 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 76.8 m80 -149.41 119.67 7.3 Favored 'General case' 0 N--CA 1.471 0.597 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 179.089 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 7' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -68.05 149.5 49.6 Favored 'General case' 0 CA--C 1.53 0.197 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.281 -179.419 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 8' ' ' SER . . . . . . . . . . . . . 8.0 t -167.27 171.5 10.68 Favored 'General case' 0 N--CA 1.473 0.719 0 N-CA-C 109.564 -0.532 . . . . 0.0 109.564 178.419 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 121.79 24.79 2.24 Favored Glycine 0 N--CA 1.488 2.111 0 N-CA-C 112.105 -0.398 . . . . 0.0 112.105 179.304 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 42.4 p90 -56.41 128.28 35.19 Favored 'General case' 0 N--CA 1.472 0.669 0 N-CA-C 112.114 0.412 . . . . 0.0 112.114 -179.803 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 11' ' ' GLU . . . . . 0.521 ' CG ' HD21 ' B' ' 27' ' ' ASN . 45.7 mt-10 -84.79 154.41 22.39 Favored 'General case' 0 N--CA 1.468 0.473 0 N-CA-C 109.113 -0.699 . . . . 0.0 109.113 178.504 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -153.54 129.36 1.71 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 N-CA-C 108.409 -0.96 . . . . 0.0 108.409 178.968 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 48.9 m-70 -134.22 144.97 48.74 Favored 'General case' 0 N--CA 1.489 1.518 0 CA-C-N 118.588 0.631 . . . . 0.0 110.968 -179.029 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 6.3 t60 -165.04 98.55 0.74 Allowed 'General case' 0 N--CA 1.481 1.099 0 CA-C-N 116.57 -0.286 . . . . 0.0 111.201 179.791 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 15' ' ' GLN . . . . . 0.57 HE22 ' H ' ' C' ' 37' ' ' GLY . 54.3 mt-30 -108.6 -172.05 1.98 Allowed 'General case' 0 CA--C 1.5 -0.954 0 N-CA-C 108.251 -1.018 . . . . 0.0 108.251 179.765 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -167.25 97.58 0.5 Allowed 'General case' 0 CA--C 1.54 0.58 0 CA-C-N 115.179 -0.918 . . . . 0.0 109.381 178.751 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 17' ' ' LEU . . . . . 0.599 HD12 ' N ' ' C' ' 17' ' ' LEU . 4.4 mp -105.66 163.64 12.53 Favored 'General case' 0 N--CA 1.487 1.392 0 N-CA-C 108.563 -0.903 . . . . 0.0 108.563 179.838 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 51.0 t -142.0 118.75 6.95 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.343 0 CA-C-O 119.032 -0.509 . . . . 0.0 109.959 179.495 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 52.6 m-85 -70.33 159.24 34.48 Favored 'General case' 0 N--CA 1.478 0.964 0 N-CA-C 107.502 -1.296 . . . . 0.0 107.502 177.247 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 14.8 t80 -171.82 -57.35 0.02 OUTLIER 'General case' 0 N--CA 1.482 1.153 0 CA-C-O 122.196 0.998 . . . . 0.0 109.777 179.49 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -39.21 90.75 0.0 OUTLIER 'General case' 0 CA--C 1.529 0.15 0 CA-C-N 114.193 -1.367 . . . . 0.0 112.785 -178.053 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 37.7 tt0 -66.77 157.4 32.95 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.063 -0.971 . . . . 0.0 110.539 179.247 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 66.8 m-20 -139.22 137.03 35.62 Favored 'General case' 0 N--CA 1.478 0.937 0 C-N-CA 123.138 0.575 . . . . 0.0 110.297 179.836 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 17.9 t -85.39 -116.67 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.064 0 N-CA-C 108.519 -0.919 . . . . 0.0 108.519 179.558 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -108.16 54.61 0.55 Allowed Glycine 0 N--CA 1.474 1.228 0 N-CA-C 111.1 -0.8 . . . . 0.0 111.1 179.96 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 73.2 p -80.42 125.47 29.96 Favored 'General case' 0 N--CA 1.466 0.336 0 N-CA-C 108.841 -0.8 . . . . 0.0 108.841 178.329 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 27' ' ' ASN . . . . . 0.51 HD21 ' CG ' ' A' ' 11' ' ' GLU . 48.3 t30 -65.64 100.55 0.53 Allowed 'General case' 0 N--CA 1.474 0.757 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 178.684 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 66.8 mttm -95.8 116.86 29.52 Favored 'General case' 0 N--CA 1.485 1.324 0 N-CA-C 109.977 -0.379 . . . . 0.0 109.977 -179.055 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.73 -133.32 0.01 OUTLIER Glycine 0 CA--C 1.534 1.248 0 N-CA-C 110.761 -0.936 . . . . 0.0 110.761 178.954 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -113.73 127.65 56.11 Favored 'General case' 0 N--CA 1.479 1.016 0 N-CA-C 109.231 -0.655 . . . . 0.0 109.231 178.981 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 66.7 mt -90.66 130.15 40.34 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.644 0 N-CA-C 107.492 -1.299 . . . . 0.0 107.492 178.746 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 17.8 mt -142.59 152.49 17.71 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.909 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -178.864 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 65.52 47.44 78.07 Favored Glycine 0 CA--C 1.524 0.604 0 CA-C-N 116.0 -0.545 . . . . 0.0 112.666 178.877 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 2.9 tt -98.16 120.38 38.46 Favored 'General case' 0 N--CA 1.477 0.92 0 N-CA-C 107.231 -1.396 . . . . 0.0 107.231 177.864 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 28.1 ttt -152.48 158.16 42.19 Favored 'General case' 0 N--CA 1.471 0.577 0 N-CA-C 108.834 -0.802 . . . . 0.0 108.834 179.401 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 87.3 t -158.3 149.8 8.24 Favored 'Isoleucine or valine' 0 C--O 1.236 0.393 0 N-CA-C 106.856 -1.535 . . . . 0.0 106.856 -179.205 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 37' ' ' GLY . . . . . 0.57 ' H ' HE22 ' C' ' 15' ' ' GLN . . . 56.66 75.08 0.27 Allowed Glycine 0 C--N 1.313 -0.71 0 CA-C-N 115.608 -0.724 . . . . 0.0 111.675 178.101 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 170.55 -149.11 12.17 Favored Glycine 0 CA--C 1.519 0.336 0 N-CA-C 110.593 -1.003 . . . . 0.0 110.593 179.801 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 33.7 m -133.71 142.81 40.49 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.835 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 179.728 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 16.2 t . . . . . 0 CA--C 1.535 0.39 0 CA-C-O 117.888 -1.053 . . . . 0.0 110.983 179.34 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' D' D ' 1' ' ' ASP . . . . . . . . . . . . . 8.5 m-20 . . . . . 0 N--CA 1.492 1.626 0 N-CA-C 109.143 -0.688 . . . . 0.0 109.143 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' D' D ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.47 131.29 46.7 Favored 'General case' 0 CA--C 1.535 0.387 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.376 179.851 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' D' D ' 3' ' ' GLU . . . . . . . . . . . . . 54.1 tt0 -169.34 110.83 0.47 Allowed 'General case' 0 N--CA 1.47 0.525 0 N-CA-C 109.379 -0.601 . . . . 0.0 109.379 179.676 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 86.9 m-85 -87.46 147.69 25.29 Favored 'General case' 0 C--N 1.363 1.158 0 C-N-CA 118.671 -1.211 . . . . 0.0 108.261 179.771 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' D' D ' 5' ' ' ARG . . . . . . . . . . . . . 72.0 mtp180 -147.32 141.52 26.16 Favored 'General case' 0 N--CA 1.475 0.821 0 N-CA-C 109.13 -0.692 . . . . 0.0 109.13 179.888 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 76.9 m80 -149.14 123.68 9.74 Favored 'General case' 0 C--O 1.219 -0.541 0 N-CA-C 107.758 -1.201 . . . . 0.0 107.758 175.638 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' D' D ' 7' ' ' ASP . . . . . . . . . . . . . 6.1 m-20 -63.45 133.26 53.64 Favored 'General case' 0 C--N 1.322 -0.613 0 C-N-CA 127.036 2.134 . . . . 0.0 114.832 176.15 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' D' D ' 8' ' ' SER . . . . . . . . . . . . . 7.0 t -154.2 173.62 15.87 Favored 'General case' 0 N--CA 1.478 0.961 0 CA-C-N 118.609 0.64 . . . . 0.0 110.406 176.996 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 124.15 20.83 2.41 Favored Glycine 0 N--CA 1.484 1.842 0 N-CA-C 112.159 -0.377 . . . . 0.0 112.159 176.398 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 37.7 p90 -55.56 130.5 43.17 Favored 'General case' 0 CA--C 1.546 0.79 0 CA-C-O 121.176 0.513 . . . . 0.0 111.842 -176.771 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' D' D ' 11' ' ' GLU . . . . . 0.446 ' CG ' HD21 ' F' ' 27' ' ' ASN . 46.0 mt-10 -84.89 152.35 23.62 Favored 'General case' 0 N--CA 1.473 0.698 0 N-CA-C 109.703 -0.48 . . . . 0.0 109.703 177.663 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -149.56 130.13 4.42 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.426 0 N-CA-C 108.409 -0.96 . . . . 0.0 108.409 175.792 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 48.5 m-70 -129.53 148.34 51.42 Favored 'General case' 0 N--CA 1.483 1.184 0 CA-C-N 117.992 0.36 . . . . 0.0 111.116 176.84 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 6.5 t60 -165.02 104.85 0.78 Allowed 'General case' 0 N--CA 1.482 1.145 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 173.76 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' D' D ' 15' ' ' GLN . . . . . 0.587 HE22 ' H ' ' D' ' 37' ' ' GLY . 54.3 mt-30 -111.78 -175.49 2.71 Favored 'General case' 0 CA--C 1.492 -1.255 0 N-CA-C 107.977 -1.12 . . . . 0.0 107.977 179.065 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' D' D ' 16' ' ' LYS . . . . . 0.437 ' C ' HD12 ' D' ' 17' ' ' LEU . 88.7 tttt -163.39 106.02 0.99 Allowed 'General case' 0 CA--C 1.536 0.433 0 N-CA-C 107.656 -1.239 . . . . 0.0 107.656 175.62 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' D' D ' 17' ' ' LEU . . . . . 0.539 HD12 ' N ' ' D' ' 17' ' ' LEU . 5.5 mp -112.42 162.73 15.25 Favored 'General case' 0 N--CA 1.488 1.447 0 N-CA-C 107.887 -1.153 . . . . 0.0 107.887 179.655 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 47.3 t -141.0 123.81 15.59 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.192 0 N-CA-C 109.053 -0.721 . . . . 0.0 109.053 175.834 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 78.3 m-85 -62.91 151.46 39.29 Favored 'General case' 0 C--N 1.352 0.685 0 C-N-CA 124.74 1.216 . . . . 0.0 110.396 170.501 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 9.8 t80 -170.1 -66.8 0.02 OUTLIER 'General case' 0 N--CA 1.477 0.903 0 N-CA-C 107.666 -1.235 . . . . 0.0 107.666 -179.629 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -37.91 95.66 0.01 OUTLIER 'General case' 0 CA--C 1.536 0.428 0 CA-C-N 114.019 -1.446 . . . . 0.0 111.663 -174.583 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 38.1 tt0 -68.35 158.19 34.07 Favored 'General case' 0 N--CA 1.467 0.388 0 CA-C-N 113.435 -1.711 . . . . 0.0 110.376 178.493 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 67.6 m-20 -139.54 140.65 37.19 Favored 'General case' 0 N--CA 1.476 0.834 0 N-CA-C 109.403 -0.592 . . . . 0.0 109.403 178.558 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' D' D ' 24' ' ' VAL . . . . . . . . . . . . . 19.5 t -88.28 -119.97 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.486 1.347 0 N-CA-C 107.779 -1.193 . . . . 0.0 107.779 179.699 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . -111.72 61.91 0.3 Allowed Glycine 0 C--N 1.371 2.478 0 C-N-CA 118.075 -2.012 . . . . 0.0 109.317 178.824 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 89.0 p -70.57 121.35 17.69 Favored 'General case' 0 C--O 1.243 0.713 0 CA-C-O 116.555 -1.688 . . . . 0.0 111.775 169.24 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' D' D ' 27' ' ' ASN . . . . . 0.44 HD21 ' CG ' ' E' ' 11' ' ' GLU . 54.6 t30 -61.2 101.8 0.18 Allowed 'General case' 0 N--CA 1.476 0.864 0 CA-C-N 121.558 1.981 . . . . 0.0 109.501 172.957 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 66.2 mttm -99.14 119.28 37.59 Favored 'General case' 0 N--CA 1.491 1.621 0 CA-C-N 119.427 1.012 . . . . 0.0 109.127 179.217 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -55.07 -134.39 0.0 OUTLIER Glycine 0 C--N 1.343 0.931 0 CA-C-N 115.607 -0.724 . . . . 0.0 113.379 175.931 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -113.19 132.65 55.41 Favored 'General case' 0 C--N 1.372 1.565 0 N-CA-C 108.591 -0.892 . . . . 0.0 108.591 174.145 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 68.2 mt -91.88 134.34 30.51 Favored 'Isoleucine or valine' 0 C--N 1.347 0.488 0 N-CA-C 106.929 -1.508 . . . . 0.0 106.929 176.459 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 20.0 mt -144.78 155.02 14.34 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.965 0 N-CA-C 109.2 -0.667 . . . . 0.0 109.2 179.137 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 64.11 46.86 90.03 Favored Glycine 0 C--O 1.245 0.841 0 CA-C-O 119.354 -0.692 . . . . 0.0 112.57 179.059 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 3.5 tt -97.7 132.27 43.49 Favored 'General case' 0 C--N 1.372 1.585 0 N-CA-C 104.569 -2.382 . . . . 0.0 104.569 176.408 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 28.3 ttt -155.9 165.23 37.1 Favored 'General case' 0 N--CA 1.474 0.752 0 N-CA-C 107.783 -1.192 . . . . 0.0 107.783 175.819 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 96.3 t -164.1 154.69 2.26 Favored 'Isoleucine or valine' 0 C--O 1.247 0.973 0 N-CA-C 105.564 -2.013 . . . . 0.0 105.564 176.382 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' D' D ' 37' ' ' GLY . . . . . 0.587 ' H ' HE22 ' D' ' 15' ' ' GLN . . . 61.13 66.67 2.52 Favored Glycine 0 N--CA 1.445 -0.731 0 C-N-CA 117.446 -2.312 . . . . 0.0 113.974 176.577 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 167.64 -147.91 12.28 Favored Glycine 0 N--CA 1.466 0.644 0 CA-C-O 117.701 -1.61 . . . . 0.0 112.176 -179.117 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 33.7 m -130.4 142.69 43.07 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.088 0 CA-C-N 119.352 1.576 . . . . 0.0 109.886 -179.065 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 13.6 t . . . . . 0 C--O 1.212 -0.87 0 N-CA-C 109.54 -0.541 . . . . 0.0 109.54 174.466 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' E' E ' 1' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 . . . . . 0 N--CA 1.489 1.485 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' E' E ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.15 131.25 46.91 Favored 'General case' 0 CA--C 1.536 0.418 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.366 179.807 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' E' E ' 3' ' ' GLU . . . . . . . . . . . . . 54.5 tt0 -169.01 108.85 0.46 Allowed 'General case' 0 N--CA 1.469 0.486 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 -179.847 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 79.4 m-85 -84.88 140.52 31.08 Favored 'General case' 0 N--CA 1.474 0.771 0 N-CA-C 109.907 -0.405 . . . . 0.0 109.907 179.44 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' E' E ' 5' ' ' ARG . . . . . . . . . . . . . 72.5 mtp180 -143.92 142.52 30.81 Favored 'General case' 0 N--CA 1.476 0.842 0 N-CA-C 109.541 -0.54 . . . . 0.0 109.541 179.858 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 76.5 m80 -150.3 118.27 6.28 Favored 'General case' 0 N--CA 1.473 0.686 0 N-CA-C 108.929 -0.767 . . . . 0.0 108.929 179.169 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' E' E ' 7' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -66.69 149.86 49.9 Favored 'General case' 0 N--CA 1.464 0.236 0 O-C-N 123.541 0.526 . . . . 0.0 111.538 -179.5 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' E' E ' 8' ' ' SER . . . . . . . . . . . . . 7.1 t -167.92 172.4 9.01 Favored 'General case' 0 N--CA 1.476 0.839 0 N-CA-C 109.573 -0.528 . . . . 0.0 109.573 177.901 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.7 24.34 2.13 Favored Glycine 0 N--CA 1.482 1.731 0 N-CA-C 111.922 -0.471 . . . . 0.0 111.922 179.071 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 39.1 p90 -55.66 127.28 29.18 Favored 'General case' 0 N--CA 1.474 0.733 0 N-CA-C 112.627 0.602 . . . . 0.0 112.627 -179.091 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' E' E ' 11' ' ' GLU . . . . . 0.44 ' CG ' HD21 ' D' ' 27' ' ' ASN . 46.4 mt-10 -83.32 155.08 23.76 Favored 'General case' 0 N--CA 1.474 0.76 0 N-CA-C 109.388 -0.597 . . . . 0.0 109.388 177.938 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -155.18 128.77 1.22 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.494 0 N-CA-C 108.386 -0.968 . . . . 0.0 108.386 178.811 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 46.3 m-70 -134.77 143.21 46.99 Favored 'General case' 0 N--CA 1.481 1.095 0 O-C-N 122.324 -0.235 . . . . 0.0 111.225 -177.99 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 6.2 t60 -163.99 98.39 0.85 Allowed 'General case' 0 N--CA 1.486 1.352 0 CA-C-N 116.765 -0.198 . . . . 0.0 111.147 179.814 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' E' E ' 15' ' ' GLN . . . . . 0.537 HE22 ' H ' ' E' ' 37' ' ' GLY . 54.7 mt-30 -107.82 -172.34 2.05 Favored 'General case' 0 CA--C 1.502 -0.9 0 N-CA-C 108.394 -0.965 . . . . 0.0 108.394 179.89 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -166.99 97.73 0.53 Allowed 'General case' 0 CA--C 1.543 0.686 0 CA-C-N 115.056 -0.975 . . . . 0.0 109.414 178.675 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' E' E ' 17' ' ' LEU . . . . . 0.583 ' N ' HD12 ' E' ' 17' ' ' LEU . 4.6 mp -105.69 163.32 12.79 Favored 'General case' 0 N--CA 1.49 1.558 0 N-CA-C 109.084 -0.709 . . . . 0.0 109.084 -179.796 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 39.0 t -142.32 118.39 6.0 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.38 0 C-N-CA 122.512 0.325 . . . . 0.0 110.52 179.078 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 51.0 m-85 -69.76 156.87 38.36 Favored 'General case' 0 C--N 1.358 0.964 0 N-CA-C 107.269 -1.382 . . . . 0.0 107.269 176.585 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 13.3 t80 -173.47 -54.96 0.02 OUTLIER 'General case' 0 N--CA 1.485 1.304 0 CA-C-O 121.606 0.717 . . . . 0.0 110.347 179.545 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.1 88.72 0.0 OUTLIER 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 114.396 -1.274 . . . . 0.0 112.843 -178.994 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 37.8 tt0 -64.62 157.88 25.88 Favored 'General case' 0 N--CA 1.471 0.581 0 CA-C-N 114.86 -1.064 . . . . 0.0 110.719 179.701 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 66.3 m-20 -139.97 136.68 34.03 Favored 'General case' 0 N--CA 1.477 0.883 0 C-N-CA 122.948 0.499 . . . . 0.0 110.399 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 21.8 t -85.23 -115.58 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.109 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 179.523 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . -108.97 54.66 0.54 Allowed Glycine 0 C--N 1.348 1.245 0 N-CA-C 111.237 -0.745 . . . . 0.0 111.237 -179.87 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 69.2 p -79.96 125.02 29.22 Favored 'General case' 0 N--CA 1.473 0.723 0 N-CA-C 109.111 -0.7 . . . . 0.0 109.111 177.947 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' E' E ' 27' ' ' ASN . . . . . 0.459 HD21 ' CG ' ' F' ' 11' ' ' GLU . 48.4 t30 -65.37 100.04 0.45 Allowed 'General case' 0 N--CA 1.474 0.747 0 N-CA-C 108.236 -1.024 . . . . 0.0 108.236 178.552 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 66.2 mttm -95.69 116.74 29.3 Favored 'General case' 0 N--CA 1.486 1.351 0 N-CA-C 109.975 -0.38 . . . . 0.0 109.975 -178.708 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.02 -132.82 0.01 OUTLIER Glycine 0 CA--C 1.534 1.271 0 N-CA-C 111.38 -0.688 . . . . 0.0 111.38 178.858 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -114.02 127.09 55.79 Favored 'General case' 0 N--CA 1.477 0.896 0 N-CA-C 109.394 -0.595 . . . . 0.0 109.394 179.187 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 67.2 mt -90.38 131.19 38.21 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.233 0 N-CA-C 107.132 -1.432 . . . . 0.0 107.132 178.688 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 19.5 mt -142.4 154.44 18.3 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.907 0 N-CA-C 109.125 -0.694 . . . . 0.0 109.125 -179.341 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.39 48.86 74.96 Favored Glycine 0 CA--C 1.523 0.537 0 C-N-CA 121.702 -0.285 . . . . 0.0 113.291 178.944 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 3.0 tt -99.3 120.19 39.16 Favored 'General case' 0 N--CA 1.477 0.907 0 N-CA-C 107.143 -1.429 . . . . 0.0 107.143 177.617 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 28.5 ttt -151.68 159.55 43.96 Favored 'General case' 0 N--CA 1.479 1.019 0 N-CA-C 108.552 -0.907 . . . . 0.0 108.552 179.314 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 96.9 t -159.64 149.85 6.59 Favored 'Isoleucine or valine' 0 C--O 1.236 0.384 0 N-CA-C 106.834 -1.543 . . . . 0.0 106.834 -179.504 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' E' E ' 37' ' ' GLY . . . . . 0.537 ' H ' HE22 ' E' ' 15' ' ' GLN . . . 56.71 74.53 0.32 Allowed Glycine 0 C--N 1.312 -0.751 0 CA-C-N 115.659 -0.701 . . . . 0.0 111.452 178.01 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 171.81 -147.24 9.96 Favored Glycine 0 C--O 1.223 -0.569 0 N-CA-C 111.08 -0.808 . . . . 0.0 111.08 179.67 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 33.2 m -135.28 141.85 41.46 Favored 'Isoleucine or valine' 0 C--N 1.353 0.731 0 N-CA-C 109.248 -0.649 . . . . 0.0 109.248 179.695 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 14.5 t . . . . . 0 CA--C 1.537 0.479 0 CA-C-O 117.916 -1.04 . . . . 0.0 111.24 179.383 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' F' F ' 1' ' ' ASP . . . . . . . . . . . . . 8.8 m-20 . . . . . 0 N--CA 1.491 1.602 0 N-CA-C 109.167 -0.679 . . . . 0.0 109.167 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' F' F ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.6 131.13 46.14 Favored 'General case' 0 N--CA 1.467 0.416 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.46 179.777 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' F' F ' 3' ' ' GLU . . . . . . . . . . . . . 55.0 tt0 -168.82 108.68 0.48 Allowed 'General case' 0 N--CA 1.469 0.524 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 -179.736 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 78.8 m-85 -84.68 140.55 31.23 Favored 'General case' 0 N--CA 1.475 0.796 0 N-CA-C 109.981 -0.377 . . . . 0.0 109.981 179.339 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' F' F ' 5' ' ' ARG . . . . . . . . . . . . . 72.2 mtp180 -143.88 142.36 30.77 Favored 'General case' 0 N--CA 1.477 0.911 0 N-CA-C 109.283 -0.636 . . . . 0.0 109.283 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 76.7 m80 -150.24 118.11 6.25 Favored 'General case' 0 N--CA 1.474 0.726 0 N-CA-C 108.936 -0.765 . . . . 0.0 108.936 179.045 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' F' F ' 7' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -66.72 149.94 49.8 Favored 'General case' 0 N--CA 1.464 0.252 0 O-C-N 123.386 0.428 . . . . 0.0 111.595 -179.424 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' F' F ' 8' ' ' SER . . . . . . . . . . . . . 7.2 t -167.96 172.51 8.86 Favored 'General case' 0 N--CA 1.475 0.815 0 CA-C-N 115.944 -0.571 . . . . 0.0 109.574 177.978 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.47 24.7 2.11 Favored Glycine 0 N--CA 1.483 1.776 0 N-CA-C 111.892 -0.483 . . . . 0.0 111.892 178.986 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 38.6 p90 -56.09 127.52 30.97 Favored 'General case' 0 N--CA 1.474 0.733 0 N-CA-C 112.637 0.606 . . . . 0.0 112.637 -179.061 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' F' F ' 11' ' ' GLU . . . . . 0.459 ' CG ' HD21 ' E' ' 27' ' ' ASN . 46.0 mt-10 -83.25 155.03 23.86 Favored 'General case' 0 N--CA 1.474 0.746 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 177.897 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -155.13 128.61 1.2 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.503 0 N-CA-C 108.43 -0.952 . . . . 0.0 108.43 178.775 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 46.9 m-70 -134.7 143.11 47.02 Favored 'General case' 0 N--CA 1.48 1.051 0 O-C-N 122.275 -0.265 . . . . 0.0 111.194 -177.998 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 6.2 t60 -164.11 98.63 0.84 Allowed 'General case' 0 N--CA 1.486 1.342 0 CA-C-N 116.734 -0.212 . . . . 0.0 111.258 179.917 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' F' F ' 15' ' ' GLN . . . . . 0.541 HE22 ' H ' ' F' ' 37' ' ' GLY . 55.0 mt-30 -108.36 -171.42 1.86 Allowed 'General case' 0 CA--C 1.499 -1.011 0 N-CA-C 108.544 -0.91 . . . . 0.0 108.544 179.885 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -167.53 98.01 0.49 Allowed 'General case' 0 CA--C 1.541 0.605 0 CA-C-N 114.933 -1.03 . . . . 0.0 109.484 178.667 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' F' F ' 17' ' ' LEU . . . . . 0.583 HD12 ' N ' ' F' ' 17' ' ' LEU . 4.5 mp -105.73 163.14 12.93 Favored 'General case' 0 N--CA 1.49 1.541 0 N-CA-C 109.151 -0.685 . . . . 0.0 109.151 -179.856 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 39.0 t -142.17 118.41 6.3 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.293 0 C-N-CA 122.573 0.349 . . . . 0.0 110.567 179.121 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 52.3 m-85 -69.78 156.7 38.63 Favored 'General case' 0 C--N 1.358 0.955 0 N-CA-C 107.121 -1.437 . . . . 0.0 107.121 176.482 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 13.9 t80 -173.0 -55.27 0.02 OUTLIER 'General case' 0 N--CA 1.485 1.293 0 CA-C-O 121.811 0.815 . . . . 0.0 109.826 179.645 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.86 88.89 0.0 OUTLIER 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 114.436 -1.256 . . . . 0.0 112.916 -178.938 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 37.8 tt0 -64.78 157.68 26.97 Favored 'General case' 0 N--CA 1.472 0.651 0 CA-C-N 114.935 -1.029 . . . . 0.0 110.784 179.464 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 66.1 m-20 -139.84 137.03 34.61 Favored 'General case' 0 N--CA 1.478 0.955 0 C-N-CA 122.944 0.497 . . . . 0.0 110.346 179.887 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' F' F ' 24' ' ' VAL . . . . . . . . . . . . . 21.6 t -85.62 -115.55 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.482 1.126 0 N-CA-C 108.706 -0.849 . . . . 0.0 108.706 179.502 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -108.8 54.06 0.57 Allowed Glycine 0 N--CA 1.477 1.371 0 N-CA-C 111.235 -0.746 . . . . 0.0 111.235 -179.869 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 69.8 p -79.5 125.04 29.05 Favored 'General case' 0 N--CA 1.473 0.675 0 N-CA-C 109.052 -0.721 . . . . 0.0 109.052 177.876 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' F' F ' 27' ' ' ASN . . . . . 0.446 HD21 ' CG ' ' D' ' 11' ' ' GLU . 48.2 t30 -65.46 100.15 0.47 Allowed 'General case' 0 N--CA 1.473 0.69 0 N-CA-C 108.328 -0.99 . . . . 0.0 108.328 178.533 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 66.1 mttm -95.66 116.82 29.41 Favored 'General case' 0 N--CA 1.485 1.281 0 N-CA-C 110.022 -0.362 . . . . 0.0 110.022 -178.669 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.17 -132.77 0.01 OUTLIER Glycine 0 CA--C 1.533 1.197 0 N-CA-C 111.491 -0.644 . . . . 0.0 111.491 178.916 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -113.85 126.37 55.11 Favored 'General case' 0 N--CA 1.478 0.954 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 179.278 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 67.2 mt -89.97 130.66 38.89 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.209 0 N-CA-C 107.175 -1.417 . . . . 0.0 107.175 178.632 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 19.4 mt -142.11 154.32 18.83 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.877 0 N-CA-C 109.106 -0.701 . . . . 0.0 109.106 -179.333 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.63 48.9 73.21 Favored Glycine 0 CA--C 1.524 0.596 0 CA-C-N 116.476 -0.329 . . . . 0.0 113.289 179.016 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 3.0 tt -99.41 120.26 39.31 Favored 'General case' 0 N--CA 1.478 0.946 0 N-CA-C 107.145 -1.428 . . . . 0.0 107.145 177.771 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 28.5 ttt -151.82 159.66 43.81 Favored 'General case' 0 N--CA 1.477 0.925 0 N-CA-C 108.673 -0.862 . . . . 0.0 108.673 179.437 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 94.5 t -159.76 149.89 6.45 Favored 'Isoleucine or valine' 0 C--O 1.235 0.31 0 N-CA-C 106.865 -1.531 . . . . 0.0 106.865 -179.478 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' F' F ' 37' ' ' GLY . . . . . 0.541 ' H ' HE22 ' F' ' 15' ' ' GLN . . . 56.78 74.35 0.34 Allowed Glycine 0 C--N 1.313 -0.722 0 CA-C-N 115.549 -0.75 . . . . 0.0 111.512 177.904 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 171.91 -147.25 9.93 Favored Glycine 0 C--O 1.223 -0.534 0 N-CA-C 111.099 -0.8 . . . . 0.0 111.099 179.818 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 33.2 m -135.33 141.67 41.91 Favored 'Isoleucine or valine' 0 C--N 1.352 0.715 0 N-CA-C 109.27 -0.641 . . . . 0.0 109.27 179.712 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 15.2 t . . . . . 0 CA--C 1.537 0.473 0 CA-C-O 117.934 -1.031 . . . . 0.0 111.155 179.317 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' G' G ' 1' ' ' ASP . . . . . . . . . . . . . 8.6 m-20 . . . . . 0 N--CA 1.493 1.681 0 N-CA-C 109.521 -0.548 . . . . 0.0 109.521 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' G' G ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.59 129.36 40.24 Favored 'General case' 0 N--CA 1.469 0.481 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.544 179.616 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' G' G ' 3' ' ' GLU . . . . . . . . . . . . . 52.3 tt0 -168.64 108.71 0.5 Allowed 'General case' 0 N--CA 1.471 0.614 0 N-CA-C 110.104 -0.332 . . . . 0.0 110.104 179.742 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 79.4 m-85 -85.48 139.88 31.14 Favored 'General case' 0 N--CA 1.474 0.765 0 N-CA-C 109.543 -0.54 . . . . 0.0 109.543 179.333 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' G' G ' 5' ' ' ARG . . . . . . . . . . . . . 72.2 mtp180 -144.05 141.52 30.14 Favored 'General case' 0 N--CA 1.483 1.221 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 -179.612 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 76.8 m80 -149.24 119.29 7.18 Favored 'General case' 0 N--CA 1.473 0.679 0 N-CA-C 108.952 -0.759 . . . . 0.0 108.952 179.026 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 8.9 m-20 -68.55 145.46 53.97 Favored 'General case' 0 N--CA 1.468 0.462 0 O-C-N 123.578 0.549 . . . . 0.0 111.945 -179.319 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' G' G ' 8' ' ' SER . . . . . . . . . . . . . 6.0 t -164.64 173.52 11.83 Favored 'General case' 0 N--CA 1.468 0.461 0 N-CA-C 109.386 -0.598 . . . . 0.0 109.386 178.208 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.36 24.45 2.19 Favored Glycine 0 N--CA 1.48 1.584 0 N-CA-C 111.639 -0.584 . . . . 0.0 111.639 178.934 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 42.4 p90 -56.24 127.56 31.4 Favored 'General case' 0 N--CA 1.474 0.745 0 N-CA-C 112.516 0.562 . . . . 0.0 112.516 -178.757 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 45.7 mt-10 -83.61 154.24 23.86 Favored 'General case' 0 N--CA 1.471 0.601 0 CA-C-O 120.971 0.415 . . . . 0.0 109.882 178.638 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 2.6 p -155.5 128.51 1.13 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.959 0 N-CA-C 108.431 -0.951 . . . . 0.0 108.431 178.972 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 49.6 m-70 -133.6 144.64 49.41 Favored 'General case' 0 N--CA 1.477 0.876 0 CA-C-N 115.454 -0.793 . . . . 0.0 110.934 -178.177 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 6.3 t60 -165.65 98.62 0.68 Allowed 'General case' 0 N--CA 1.483 1.2 0 CA-C-N 116.589 -0.278 . . . . 0.0 110.805 179.193 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' G' G ' 15' ' ' GLN . . . . . 0.562 HE22 ' H ' ' G' ' 37' ' ' GLY . 54.5 mt-30 -108.49 -171.92 1.95 Allowed 'General case' 0 CA--C 1.501 -0.915 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 179.916 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -167.31 97.91 0.5 Allowed 'General case' 0 CA--C 1.542 0.641 0 CA-C-N 114.96 -1.018 . . . . 0.0 109.388 178.717 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' G' G ' 17' ' ' LEU . . . . . 0.589 ' N ' HD12 ' G' ' 17' ' ' LEU . 5.1 mp -105.38 162.41 13.47 Favored 'General case' 0 N--CA 1.487 1.402 0 N-CA-C 109.32 -0.622 . . . . 0.0 109.32 -179.685 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 36.5 t -143.13 118.52 4.6 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.009 0 CA-C-O 120.83 0.348 . . . . 0.0 110.442 178.851 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 46.5 m-85 -69.76 150.32 47.03 Favored 'General case' 0 C--N 1.37 1.481 0 N-CA-C 107.263 -1.384 . . . . 0.0 107.263 176.595 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 11.3 t80 -170.5 -55.06 0.02 OUTLIER 'General case' 0 N--CA 1.487 1.406 0 CA-C-N 117.953 0.342 . . . . 0.0 110.328 -179.583 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.68 89.9 0.0 OUTLIER 'General case' 0 C--N 1.325 -0.491 0 C-N-CA 123.774 0.83 . . . . 0.0 112.508 -179.839 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 38.0 tt0 -65.41 158.54 26.41 Favored 'General case' 0 N--CA 1.469 0.476 0 CA-C-N 114.714 -1.13 . . . . 0.0 109.954 179.146 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 67.4 m-20 -140.09 136.8 33.97 Favored 'General case' 0 N--CA 1.478 0.937 0 C-N-CA 122.874 0.469 . . . . 0.0 109.98 179.904 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' G' G ' 24' ' ' VAL . . . . . . . . . . . . . 21.5 t -85.95 -115.61 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 1.004 0 N-CA-C 108.506 -0.924 . . . . 0.0 108.506 179.555 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -108.61 54.04 0.57 Allowed Glycine 0 N--CA 1.477 1.397 0 N-CA-C 111.492 -0.643 . . . . 0.0 111.492 -179.868 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 72.6 p -79.96 125.57 29.92 Favored 'General case' 0 N--CA 1.467 0.389 0 N-CA-C 108.943 -0.762 . . . . 0.0 108.943 177.971 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 47.5 t30 -65.76 100.98 0.59 Allowed 'General case' 0 N--CA 1.47 0.566 0 N-CA-C 108.567 -0.901 . . . . 0.0 108.567 178.525 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 66.6 mttm -95.76 117.2 30.09 Favored 'General case' 0 N--CA 1.485 1.309 0 N-CA-C 109.883 -0.414 . . . . 0.0 109.883 -179.13 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.94 -131.95 0.01 OUTLIER Glycine 0 CA--C 1.53 1.005 0 N-CA-C 110.579 -1.008 . . . . 0.0 110.579 178.946 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -113.74 126.48 55.27 Favored 'General case' 0 N--CA 1.469 0.499 0 N-CA-C 109.522 -0.547 . . . . 0.0 109.522 179.542 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 69.3 mt -89.94 131.38 37.34 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.756 0 N-CA-C 107.327 -1.36 . . . . 0.0 107.327 178.495 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 22.7 mt -143.29 155.09 16.74 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.397 0 CA-C-N 118.982 0.81 . . . . 0.0 109.056 -179.751 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.74 48.2 79.29 Favored Glycine 0 CA--C 1.527 0.782 0 CA-C-N 116.659 -0.246 . . . . 0.0 112.835 179.053 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' G' G ' 34' ' ' LEU . . . . . 0.405 HD23 ' N ' ' G' ' 35' ' ' MET . 2.9 tt -98.87 121.19 40.5 Favored 'General case' 0 N--CA 1.478 0.955 0 N-CA-C 107.086 -1.449 . . . . 0.0 107.086 177.75 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' G' G ' 35' ' ' MET . . . . . 0.405 ' N ' HD23 ' G' ' 34' ' ' LEU . 28.7 ttt -153.08 160.21 42.9 Favored 'General case' 0 N--CA 1.477 0.882 0 N-CA-C 108.172 -1.047 . . . . 0.0 108.172 179.493 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 84.4 t -159.81 150.2 6.31 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.255 0 N-CA-C 106.419 -1.697 . . . . 0.0 106.419 -179.354 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' G' G ' 37' ' ' GLY . . . . . 0.562 ' H ' HE22 ' G' ' 15' ' ' GLN . . . 56.59 74.86 0.29 Allowed Glycine 0 C--N 1.312 -0.756 0 C-N-CA 120.975 -0.631 . . . . 0.0 112.049 177.727 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 170.28 -145.79 9.39 Favored Glycine 0 N--CA 1.467 0.702 0 N-CA-C 110.614 -0.995 . . . . 0.0 110.614 179.127 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 33.9 m -135.91 142.06 40.08 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.873 0 N-CA-C 109.911 -0.403 . . . . 0.0 109.911 -179.887 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 15.4 t . . . . . 0 N--CA 1.466 0.349 0 CA-C-O 118.046 -0.978 . . . . 0.0 111.304 179.463 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' H' H ' 1' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 . . . . . 0 N--CA 1.49 1.566 0 N-CA-C 109.669 -0.493 . . . . 0.0 109.669 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' H' H ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.56 129.48 40.8 Favored 'General case' 0 N--CA 1.468 0.466 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.472 179.597 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' H' H ' 3' ' ' GLU . . . . . . . . . . . . . 53.5 tt0 -168.66 108.52 0.49 Allowed 'General case' 0 N--CA 1.469 0.519 0 N-CA-C 110.099 -0.334 . . . . 0.0 110.099 179.804 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 80.1 m-85 -85.18 140.04 31.21 Favored 'General case' 0 N--CA 1.474 0.769 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 179.333 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' H' H ' 5' ' ' ARG . . . . . . . . . . . . . 72.3 mtp180 -144.11 141.85 30.26 Favored 'General case' 0 N--CA 1.483 1.191 0 N-CA-C 109.294 -0.632 . . . . 0.0 109.294 -179.635 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 76.9 m80 -149.67 118.87 6.78 Favored 'General case' 0 N--CA 1.473 0.695 0 N-CA-C 109.105 -0.702 . . . . 0.0 109.105 179.129 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 8.8 m-20 -68.25 145.2 54.48 Favored 'General case' 0 N--CA 1.469 0.48 0 O-C-N 123.469 0.481 . . . . 0.0 111.924 -179.309 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' H' H ' 8' ' ' SER . . . . . . . . . . . . . 7.5 t -164.36 172.96 12.77 Favored 'General case' 0 N--CA 1.469 0.507 0 N-CA-C 109.449 -0.575 . . . . 0.0 109.449 178.421 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.43 24.46 2.17 Favored Glycine 0 N--CA 1.481 1.665 0 N-CA-C 111.733 -0.547 . . . . 0.0 111.733 179.112 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 42.1 p90 -56.38 127.51 31.37 Favored 'General case' 0 N--CA 1.473 0.707 0 N-CA-C 112.428 0.529 . . . . 0.0 112.428 -178.795 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 45.4 mt-10 -83.51 154.2 24.0 Favored 'General case' 0 N--CA 1.473 0.676 0 CA-C-O 120.984 0.421 . . . . 0.0 109.874 178.62 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.6 p -155.41 128.41 1.13 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.975 0 N-CA-C 108.433 -0.951 . . . . 0.0 108.433 178.963 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 52.1 m-70 -133.42 144.63 49.65 Favored 'General case' 0 N--CA 1.476 0.863 0 CA-C-N 115.43 -0.804 . . . . 0.0 110.893 -178.16 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 6.4 t60 -165.61 98.48 0.68 Allowed 'General case' 0 N--CA 1.482 1.146 0 CA-C-N 116.527 -0.306 . . . . 0.0 110.839 179.146 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' H' H ' 15' ' ' GLN . . . . . 0.552 HE22 ' H ' ' H' ' 37' ' ' GLY . 54.2 mt-30 -108.24 -172.45 2.06 Favored 'General case' 0 CA--C 1.5 -0.979 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 -179.921 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -167.01 97.78 0.52 Allowed 'General case' 0 CA--C 1.539 0.521 0 CA-C-N 114.989 -1.005 . . . . 0.0 109.402 178.73 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' H' H ' 17' ' ' LEU . . . . . 0.589 HD12 ' N ' ' H' ' 17' ' ' LEU . 5.1 mp -105.5 162.13 13.74 Favored 'General case' 0 N--CA 1.488 1.442 0 N-CA-C 109.292 -0.633 . . . . 0.0 109.292 -179.632 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 38.5 t -142.79 118.54 5.16 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.097 0 CA-C-O 120.905 0.383 . . . . 0.0 110.482 178.874 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 47.5 m-85 -70.14 150.89 46.06 Favored 'General case' 0 C--N 1.37 1.498 0 N-CA-C 107.391 -1.336 . . . . 0.0 107.391 176.585 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 11.9 t80 -171.88 -54.41 0.02 OUTLIER 'General case' 0 N--CA 1.485 1.28 0 CA-C-N 117.828 0.286 . . . . 0.0 110.323 -179.456 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.99 90.22 0.0 OUTLIER 'General case' 0 CA--C 1.536 0.437 0 C-N-CA 123.59 0.756 . . . . 0.0 112.262 -179.824 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 37.9 tt0 -65.38 158.63 26.09 Favored 'General case' 0 N--CA 1.468 0.465 0 CA-C-N 114.739 -1.118 . . . . 0.0 110.011 179.318 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 66.8 m-20 -140.18 136.98 34.01 Favored 'General case' 0 N--CA 1.477 0.899 0 C-N-CA 122.942 0.497 . . . . 0.0 109.972 179.872 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' H' H ' 24' ' ' VAL . . . . . . . . . . . . . 21.5 t -86.36 -115.55 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.049 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 179.605 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . -108.3 53.44 0.6 Allowed Glycine 0 N--CA 1.479 1.564 0 N-CA-C 111.395 -0.682 . . . . 0.0 111.395 -179.828 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 70.1 p -79.46 125.28 29.35 Favored 'General case' 0 N--CA 1.468 0.45 0 N-CA-C 108.893 -0.781 . . . . 0.0 108.893 178.004 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 47.5 t30 -65.69 100.91 0.57 Allowed 'General case' 0 N--CA 1.472 0.662 0 N-CA-C 108.497 -0.927 . . . . 0.0 108.497 178.5 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 66.6 mttm -95.89 117.09 29.93 Favored 'General case' 0 N--CA 1.485 1.283 0 N-CA-C 109.97 -0.382 . . . . 0.0 109.97 -179.146 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.66 -131.75 0.01 OUTLIER Glycine 0 CA--C 1.531 1.059 0 N-CA-C 110.802 -0.919 . . . . 0.0 110.802 178.921 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -114.0 126.24 54.91 Favored 'General case' 0 N--CA 1.471 0.604 0 N-CA-C 109.61 -0.515 . . . . 0.0 109.61 179.527 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 69.4 mt -89.79 131.13 37.82 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.701 0 N-CA-C 107.338 -1.356 . . . . 0.0 107.338 178.55 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 23.3 mt -143.11 155.05 17.02 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.339 0 CA-C-N 118.826 0.739 . . . . 0.0 109.024 -179.698 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.65 48.12 80.36 Favored Glycine 0 CA--C 1.524 0.626 0 CA-C-O 120.117 -0.269 . . . . 0.0 112.891 179.045 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 2.9 tt -98.75 121.09 40.25 Favored 'General case' 0 N--CA 1.478 0.969 0 N-CA-C 107.117 -1.438 . . . . 0.0 107.117 177.617 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 28.7 ttt -152.89 159.95 43.03 Favored 'General case' 0 N--CA 1.478 0.974 0 N-CA-C 108.07 -1.085 . . . . 0.0 108.07 179.61 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 87.2 t -159.66 150.34 6.43 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.261 0 N-CA-C 106.448 -1.686 . . . . 0.0 106.448 -179.51 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' H' H ' 37' ' ' GLY . . . . . 0.552 ' H ' HE22 ' H' ' 15' ' ' GLN . . . 56.35 74.96 0.27 Allowed Glycine 0 C--N 1.311 -0.811 0 C-N-CA 120.979 -0.629 . . . . 0.0 112.015 177.804 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 170.24 -146.2 9.7 Favored Glycine 0 N--CA 1.467 0.744 0 N-CA-C 110.539 -1.024 . . . . 0.0 110.539 179.129 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 34.0 m -135.57 142.02 40.64 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.815 0 N-CA-C 109.951 -0.388 . . . . 0.0 109.951 -179.875 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 15.9 t . . . . . 0 N--CA 1.467 0.4 0 CA-C-O 118.058 -0.973 . . . . 0.0 111.327 179.45 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' I' I ' 1' ' ' ASP . . . . . . . . . . . . . 8.7 m-20 . . . . . 0 N--CA 1.492 1.628 0 N-CA-C 109.572 -0.529 . . . . 0.0 109.572 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' I' I ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.85 129.62 41.26 Favored 'General case' 0 N--CA 1.468 0.456 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.403 179.625 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' I' I ' 3' ' ' GLU . . . . . . . . . . . . . 53.6 tt0 -168.75 108.31 0.48 Allowed 'General case' 0 N--CA 1.47 0.548 0 N-CA-C 110.166 -0.309 . . . . 0.0 110.166 179.773 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 79.6 m-85 -84.96 140.3 31.17 Favored 'General case' 0 N--CA 1.474 0.726 0 N-CA-C 109.643 -0.503 . . . . 0.0 109.643 179.333 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' I' I ' 5' ' ' ARG . . . . . . . . . . . . . 72.4 mtp180 -144.48 141.67 29.72 Favored 'General case' 0 N--CA 1.484 1.265 0 N-CA-C 109.224 -0.658 . . . . 0.0 109.224 -179.581 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 76.8 m80 -149.47 119.13 6.99 Favored 'General case' 0 N--CA 1.474 0.728 0 N-CA-C 109.08 -0.711 . . . . 0.0 109.08 178.999 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 8.9 m-20 -68.45 145.19 54.31 Favored 'General case' 0 N--CA 1.469 0.499 0 O-C-N 123.429 0.456 . . . . 0.0 111.866 -179.235 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' I' I ' 8' ' ' SER . . . . . . . . . . . . . 7.5 t -164.33 172.62 13.25 Favored 'General case' 0 N--CA 1.469 0.509 0 N-CA-C 109.463 -0.569 . . . . 0.0 109.463 178.368 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.92 24.62 2.03 Favored Glycine 0 N--CA 1.481 1.684 0 N-CA-C 111.7 -0.56 . . . . 0.0 111.7 179.104 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 42.4 p90 -56.52 127.53 31.69 Favored 'General case' 0 N--CA 1.474 0.762 0 N-CA-C 112.424 0.528 . . . . 0.0 112.424 -178.758 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 45.7 mt-10 -83.56 154.12 23.98 Favored 'General case' 0 N--CA 1.473 0.719 0 CA-C-O 121.071 0.463 . . . . 0.0 109.816 178.62 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 2.6 p -155.3 128.27 1.12 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.005 0 N-CA-C 108.389 -0.967 . . . . 0.0 108.389 178.956 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 50.9 m-70 -133.35 144.36 49.57 Favored 'General case' 0 N--CA 1.477 0.922 0 CA-C-N 115.45 -0.795 . . . . 0.0 110.966 -178.163 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 6.4 t60 -165.45 98.71 0.7 Allowed 'General case' 0 N--CA 1.483 1.177 0 CA-C-N 116.559 -0.291 . . . . 0.0 110.794 179.203 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' I' I ' 15' ' ' GLN . . . . . 0.565 HE22 ' H ' ' I' ' 37' ' ' GLY . 54.4 mt-30 -108.64 -172.46 2.06 Favored 'General case' 0 CA--C 1.499 -1.001 0 N-CA-C 108.405 -0.961 . . . . 0.0 108.405 179.979 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -166.78 98.02 0.55 Allowed 'General case' 0 CA--C 1.539 0.553 0 CA-C-N 114.933 -1.031 . . . . 0.0 109.423 178.745 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' I' I ' 17' ' ' LEU . . . . . 0.589 HD12 ' N ' ' I' ' 17' ' ' LEU . 5.1 mp -105.56 162.19 13.71 Favored 'General case' 0 N--CA 1.487 1.402 0 N-CA-C 109.327 -0.62 . . . . 0.0 109.327 -179.701 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 38.8 t -142.88 118.54 4.98 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.024 0 CA-C-O 120.987 0.423 . . . . 0.0 110.471 178.848 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 47.8 m-85 -70.01 150.89 46.18 Favored 'General case' 0 C--N 1.37 1.465 0 N-CA-C 107.306 -1.368 . . . . 0.0 107.306 176.567 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 12.0 t80 -171.94 -54.29 0.02 OUTLIER 'General case' 0 N--CA 1.483 1.206 0 CA-C-N 117.922 0.328 . . . . 0.0 110.408 -179.49 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.18 90.18 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.447 0 C-N-CA 123.713 0.805 . . . . 0.0 112.302 -179.893 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 38.2 tt0 -65.37 158.57 26.2 Favored 'General case' 0 N--CA 1.469 0.519 0 CA-C-N 114.738 -1.119 . . . . 0.0 110.045 179.254 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 66.3 m-20 -140.27 136.81 33.69 Favored 'General case' 0 N--CA 1.478 0.937 0 C-N-CA 122.859 0.464 . . . . 0.0 109.989 179.844 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' I' I ' 24' ' ' VAL . . . . . . . . . . . . . 21.3 t -86.04 -115.9 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.957 0 N-CA-C 108.542 -0.911 . . . . 0.0 108.542 179.559 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . -108.1 54.12 0.57 Allowed Glycine 0 N--CA 1.478 1.453 0 N-CA-C 111.384 -0.687 . . . . 0.0 111.384 -179.845 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 73.4 p -80.08 125.14 29.42 Favored 'General case' 0 N--CA 1.467 0.399 0 N-CA-C 108.962 -0.755 . . . . 0.0 108.962 177.889 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 48.1 t30 -65.49 101.01 0.54 Allowed 'General case' 0 CA--C 1.54 0.583 0 N-CA-C 108.539 -0.911 . . . . 0.0 108.539 178.588 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 66.5 mttm -95.88 117.07 29.88 Favored 'General case' 0 N--CA 1.485 1.321 0 N-CA-C 109.98 -0.378 . . . . 0.0 109.98 -179.177 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.68 -132.1 0.01 OUTLIER Glycine 0 CA--C 1.533 1.186 0 N-CA-C 110.652 -0.979 . . . . 0.0 110.652 178.975 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -113.55 126.12 54.95 Favored 'General case' 0 N--CA 1.472 0.635 0 C-N-CA 123.009 0.524 . . . . 0.0 109.622 179.547 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 70.1 mt -89.81 131.51 36.89 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.752 0 N-CA-C 107.219 -1.401 . . . . 0.0 107.219 178.567 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 23.5 mt -143.49 155.12 16.42 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.36 0 CA-C-N 118.883 0.765 . . . . 0.0 108.994 -179.69 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.57 48.18 80.17 Favored Glycine 0 CA--C 1.525 0.661 0 CA-C-N 116.635 -0.257 . . . . 0.0 112.846 179.082 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 2.9 tt -98.78 121.19 40.41 Favored 'General case' 0 N--CA 1.478 0.956 0 N-CA-C 107.002 -1.481 . . . . 0.0 107.002 177.625 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 28.6 ttt -153.0 159.93 42.96 Favored 'General case' 0 N--CA 1.478 0.931 0 N-CA-C 108.057 -1.09 . . . . 0.0 108.057 179.543 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 86.9 t -159.67 150.33 6.42 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.243 0 N-CA-C 106.372 -1.714 . . . . 0.0 106.372 -179.518 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' I' I ' 37' ' ' GLY . . . . . 0.565 ' H ' HE22 ' I' ' 15' ' ' GLN . . . 56.52 74.61 0.31 Allowed Glycine 0 C--N 1.312 -0.762 0 C-N-CA 120.898 -0.668 . . . . 0.0 112.083 177.777 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 170.49 -146.12 9.57 Favored Glycine 0 N--CA 1.466 0.664 0 N-CA-C 110.599 -1.0 . . . . 0.0 110.599 179.131 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 34.0 m -135.67 141.99 40.57 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.807 0 N-CA-C 109.882 -0.414 . . . . 0.0 109.882 -179.834 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 16.2 t . . . . . 0 C--O 1.223 -0.315 0 CA-C-O 118.035 -0.984 . . . . 0.0 111.275 179.465 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 9.6 m-20 . . . . . 0 N--CA 1.49 1.538 0 N-CA-C 109.098 -0.704 . . . . 0.0 109.098 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -66.45 148.26 52.13 Favored 'General case' 0 N--CA 1.467 0.399 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.119 179.674 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 56.0 tt0 -162.14 104.17 1.14 Allowed 'General case' 0 N--CA 1.472 0.628 0 N-CA-C 110.035 -0.358 . . . . 0.0 110.035 179.641 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 20.2 m-85 -71.02 172.54 8.9 Favored 'General case' 0 N--CA 1.47 0.56 0 N-CA-C 109.495 -0.557 . . . . 0.0 109.495 179.533 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 31.9 mtp180 -67.96 130.38 42.79 Favored 'General case' 0 C--O 1.218 -0.602 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.154 -178.027 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 48.0 m170 -100.34 131.54 46.22 Favored 'General case' 0 N--CA 1.474 0.733 0 N-CA-C 109.461 -0.57 . . . . 0.0 109.461 179.457 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 13.8 m-20 -71.42 141.03 50.31 Favored 'General case' 0 CA--C 1.53 0.19 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.819 -179.748 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . 0.41 ' O ' ' O ' ' C' ' 25' ' ' GLY . 8.7 t -143.53 -173.35 3.93 Favored 'General case' 0 N--CA 1.48 1.032 0 N-CA-C 109.016 -0.735 . . . . 0.0 109.016 178.498 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 117.88 11.49 8.4 Favored Glycine 0 N--CA 1.486 1.993 0 N-CA-C 112.543 -0.223 . . . . 0.0 112.543 179.197 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 47.8 p90 -59.2 128.36 36.76 Favored 'General case' 0 N--CA 1.471 0.622 0 CA-C-O 120.768 0.318 . . . . 0.0 111.849 -179.593 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 46.6 mt-10 -89.8 154.67 19.73 Favored 'General case' 0 N--CA 1.471 0.598 0 N-CA-C 109.299 -0.63 . . . . 0.0 109.299 178.548 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -153.58 128.92 1.57 Allowed 'Isoleucine or valine' 0 C--O 1.235 0.297 0 N-CA-C 108.072 -1.084 . . . . 0.0 108.072 178.641 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 50.1 m-70 -135.37 147.04 48.95 Favored 'General case' 0 N--CA 1.49 1.565 0 CA-C-N 118.834 0.743 . . . . 0.0 111.114 -179.108 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 6.4 t60 -164.94 97.57 0.74 Allowed 'General case' 0 N--CA 1.48 1.056 0 CA-C-N 116.568 -0.287 . . . . 0.0 111.139 179.632 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . 0.547 HE22 ' H ' ' A' ' 37' ' ' GLY . 55.1 mt-30 -108.87 -172.49 2.06 Favored 'General case' 0 CA--C 1.503 -0.856 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 -179.969 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -166.81 98.0 0.55 Allowed 'General case' 0 N--CA 1.473 0.691 0 CA-C-N 115.179 -0.918 . . . . 0.0 109.391 178.795 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.596 HD12 ' N ' ' A' ' 17' ' ' LEU . 4.5 mp -106.05 164.17 12.19 Favored 'General case' 0 N--CA 1.489 1.488 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 179.99 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 57.8 t -142.39 119.0 6.34 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.301 0 CA-C-O 118.962 -0.542 . . . . 0.0 109.904 179.527 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 53.2 m-85 -69.81 159.46 33.57 Favored 'General case' 0 N--CA 1.481 1.094 0 N-CA-C 107.491 -1.3 . . . . 0.0 107.491 177.186 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 11.7 t80 -171.68 -58.0 0.02 OUTLIER 'General case' 0 N--CA 1.487 1.417 0 CA-C-O 122.386 1.089 . . . . 0.0 109.815 179.65 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -39.32 89.73 0.0 OUTLIER 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 113.91 -1.496 . . . . 0.0 112.973 -178.03 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 37.1 tt0 -65.47 158.48 26.72 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.119 -0.946 . . . . 0.0 110.603 179.077 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 11.5 m-20 -140.74 137.63 33.57 Favored 'General case' 0 N--CA 1.479 0.994 0 C-N-CA 122.984 0.513 . . . . 0.0 110.249 179.702 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 17.7 t -91.7 -116.68 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.483 1.187 0 N-CA-C 108.64 -0.874 . . . . 0.0 108.64 179.576 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.404 ' O ' ' O ' ' B' ' 8' ' ' SER . . . -102.82 56.99 0.6 Allowed Glycine 0 N--CA 1.473 1.166 0 N-CA-C 110.954 -0.858 . . . . 0.0 110.954 179.997 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 79.6 p -85.25 124.74 32.23 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 178.068 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 61.7 t30 -64.58 100.88 0.41 Allowed 'General case' 0 N--CA 1.474 0.728 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 178.874 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 64.7 mttm -97.27 113.98 25.67 Favored 'General case' 0 N--CA 1.484 1.265 0 N-CA-C 110.011 -0.366 . . . . 0.0 110.011 -178.967 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.65 -134.26 0.01 OUTLIER Glycine 0 CA--C 1.534 1.235 0 N-CA-C 110.741 -0.944 . . . . 0.0 110.741 179.103 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -112.56 127.74 56.16 Favored 'General case' 0 N--CA 1.481 1.092 0 N-CA-C 109.155 -0.683 . . . . 0.0 109.155 178.997 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 65.0 mt -90.32 129.24 41.49 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.623 0 N-CA-C 107.532 -1.285 . . . . 0.0 107.532 178.755 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 12.4 mt -142.96 151.92 17.25 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.793 0 CA-C-N 116.2 -0.455 . . . . 0.0 109.943 -178.891 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 65.21 48.9 64.94 Favored Glycine 0 CA--C 1.524 0.632 0 CA-C-N 115.997 -0.547 . . . . 0.0 112.495 179.01 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.415 HD23 ' N ' ' A' ' 35' ' ' MET . 2.8 tt -99.03 121.1 40.52 Favored 'General case' 0 N--CA 1.479 1.009 0 N-CA-C 107.143 -1.429 . . . . 0.0 107.143 178.088 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' MET . . . . . 0.415 ' N ' HD23 ' A' ' 34' ' ' LEU . 27.5 ttt -153.24 158.08 41.16 Favored 'General case' 0 N--CA 1.47 0.539 0 N-CA-C 108.847 -0.797 . . . . 0.0 108.847 179.576 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 85.0 t -158.19 149.32 8.66 Favored 'Isoleucine or valine' 0 C--O 1.238 0.47 0 N-CA-C 106.868 -1.53 . . . . 0.0 106.868 -179.577 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . 0.547 ' H ' HE22 ' A' ' 15' ' ' GLN . . . 57.38 72.42 0.59 Allowed Glycine 0 C--N 1.315 -0.616 0 N-CA-C 111.318 -0.713 . . . . 0.0 111.318 178.342 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 172.74 -157.78 27.36 Favored Glycine 0 C--N 1.332 0.326 0 N-CA-C 110.804 -0.918 . . . . 0.0 110.804 -179.895 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 33.4 m -124.07 143.33 37.73 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.934 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 179.502 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 16.4 t . . . . . 0 CA--C 1.536 0.412 0 CA-C-O 118.056 -0.973 . . . . 0.0 111.062 179.152 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' B' B ' 1' ' ' ASP . . . . . . . . . . . . . 9.5 m-20 . . . . . 0 N--CA 1.49 1.569 0 N-CA-C 109.107 -0.701 . . . . 0.0 109.107 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' B' B ' 2' ' ' ALA . . . . . . . . . . . . . . . -66.56 148.25 52.15 Favored 'General case' 0 N--CA 1.466 0.342 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.09 179.594 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 3' ' ' GLU . . . . . . . . . . . . . 56.3 tt0 -162.09 104.13 1.14 Allowed 'General case' 0 N--CA 1.472 0.644 0 N-CA-C 109.999 -0.371 . . . . 0.0 109.999 179.663 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 21.4 m-85 -71.04 172.49 9.01 Favored 'General case' 0 N--CA 1.47 0.561 0 N-CA-C 109.4 -0.593 . . . . 0.0 109.4 179.622 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 32.2 mtp180 -67.94 129.8 41.01 Favored 'General case' 0 N--CA 1.47 0.529 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.214 -178.019 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 47.7 m170 -99.81 131.79 45.57 Favored 'General case' 0 N--CA 1.476 0.854 0 N-CA-C 109.551 -0.537 . . . . 0.0 109.551 179.407 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 7' ' ' ASP . . . . . . . . . . . . . 13.2 m-20 -71.86 141.25 49.58 Favored 'General case' 0 CA--C 1.532 0.259 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.786 -179.688 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 8' ' ' SER . . . . . 0.404 ' O ' ' O ' ' A' ' 25' ' ' GLY . 8.7 t -143.54 -172.98 3.83 Favored 'General case' 0 N--CA 1.478 0.953 0 N-CA-C 109.017 -0.734 . . . . 0.0 109.017 178.417 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 117.45 11.79 8.53 Favored Glycine 0 N--CA 1.484 1.89 0 N-CA-C 112.513 -0.235 . . . . 0.0 112.513 179.241 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 47.4 p90 -59.33 128.09 35.36 Favored 'General case' 0 CA--C 1.54 0.583 0 N-CA-C 111.815 0.302 . . . . 0.0 111.815 -179.628 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 46.5 mt-10 -89.58 154.51 19.93 Favored 'General case' 0 N--CA 1.473 0.705 0 N-CA-C 109.418 -0.586 . . . . 0.0 109.418 178.552 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -153.48 128.31 1.47 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.286 0 N-CA-C 108.3 -1.0 . . . . 0.0 108.3 178.682 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 49.3 m-70 -134.89 147.35 49.82 Favored 'General case' 0 N--CA 1.489 1.514 0 CA-C-N 118.69 0.677 . . . . 0.0 111.044 -178.944 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 6.5 t60 -165.14 97.65 0.72 Allowed 'General case' 0 N--CA 1.481 1.125 0 CA-C-N 116.608 -0.269 . . . . 0.0 110.992 179.593 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . 0.543 HE22 ' H ' ' B' ' 37' ' ' GLY . 54.9 mt-30 -108.79 -172.79 2.12 Favored 'General case' 0 CA--C 1.501 -0.934 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 179.995 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 16' ' ' LYS . . . . . 0.401 ' C ' HD12 ' B' ' 17' ' ' LEU . 88.4 tttt -166.83 98.08 0.55 Allowed 'General case' 0 CA--C 1.541 0.616 0 CA-C-N 115.142 -0.935 . . . . 0.0 109.404 178.815 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . 0.595 ' N ' HD12 ' B' ' 17' ' ' LEU . 4.5 mp -106.2 164.2 12.19 Favored 'General case' 0 N--CA 1.487 1.41 0 N-CA-C 108.606 -0.887 . . . . 0.0 108.606 -179.948 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 58.9 t -142.52 118.46 5.65 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.258 0 CA-C-O 118.999 -0.524 . . . . 0.0 109.959 179.527 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 53.8 m-85 -70.04 159.55 33.62 Favored 'General case' 0 N--CA 1.478 0.942 0 N-CA-C 107.409 -1.33 . . . . 0.0 107.409 177.296 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 12.8 t80 -172.36 -56.98 0.02 OUTLIER 'General case' 0 N--CA 1.484 1.271 0 CA-C-O 122.233 1.016 . . . . 0.0 109.851 179.622 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -39.63 90.37 0.0 OUTLIER 'General case' 0 CA--C 1.529 0.138 0 CA-C-N 114.148 -1.387 . . . . 0.0 112.823 -178.163 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 36.9 tt0 -66.13 158.11 29.47 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 115.068 -0.969 . . . . 0.0 110.618 179.163 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 11.8 m-20 -140.18 138.38 35.12 Favored 'General case' 0 N--CA 1.48 1.058 0 C-N-CA 122.978 0.511 . . . . 0.0 110.127 179.697 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 17.9 t -92.73 -116.95 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.484 1.232 0 N-CA-C 108.707 -0.849 . . . . 0.0 108.707 179.543 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . 0.41 ' O ' ' O ' ' C' ' 8' ' ' SER . . . -101.89 56.43 0.68 Allowed Glycine 0 N--CA 1.474 1.191 0 N-CA-C 110.835 -0.906 . . . . 0.0 110.835 -179.959 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 78.9 p -85.23 124.82 32.31 Favored 'General case' 0 N--CA 1.466 0.354 0 N-CA-C 108.695 -0.854 . . . . 0.0 108.695 178.047 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 62.2 t30 -64.89 101.42 0.49 Allowed 'General case' 0 N--CA 1.473 0.701 0 N-CA-C 108.731 -0.84 . . . . 0.0 108.731 178.845 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 64.6 mttm -97.81 113.46 25.27 Favored 'General case' 0 N--CA 1.485 1.318 0 N-CA-C 110.029 -0.36 . . . . 0.0 110.029 -178.939 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.06 -134.16 0.01 OUTLIER Glycine 0 CA--C 1.534 1.255 0 N-CA-C 110.834 -0.907 . . . . 0.0 110.834 178.988 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -112.92 127.87 56.32 Favored 'General case' 0 N--CA 1.48 1.03 0 N-CA-C 109.114 -0.699 . . . . 0.0 109.114 179.02 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 64.4 mt -90.39 129.49 41.15 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.588 0 N-CA-C 107.52 -1.289 . . . . 0.0 107.52 178.768 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 12.0 mt -143.19 151.62 17.07 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.848 0 CA-C-N 116.06 -0.518 . . . . 0.0 109.905 -178.799 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 65.59 48.14 70.78 Favored Glycine 0 CA--C 1.526 0.722 0 CA-C-N 116.045 -0.525 . . . . 0.0 112.642 178.956 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 34' ' ' LEU . . . . . 0.4 HD23 ' N ' ' B' ' 35' ' ' MET . 2.9 tt -98.12 121.04 39.56 Favored 'General case' 0 N--CA 1.479 0.981 0 N-CA-C 107.269 -1.382 . . . . 0.0 107.269 177.951 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 35' ' ' MET . . . . . 0.4 ' N ' HD23 ' B' ' 34' ' ' LEU . 27.6 ttt -153.19 157.75 40.74 Favored 'General case' 0 N--CA 1.474 0.758 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 179.528 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 81.4 t -157.96 149.44 8.93 Favored 'Isoleucine or valine' 0 C--O 1.238 0.48 0 N-CA-C 106.676 -1.601 . . . . 0.0 106.676 -179.469 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . 0.543 ' H ' HE22 ' B' ' 15' ' ' GLN . . . 56.96 72.48 0.58 Allowed Glycine 0 C--N 1.314 -0.669 0 CA-C-N 115.621 -0.718 . . . . 0.0 111.394 178.331 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 172.86 -157.73 27.17 Favored Glycine 0 N--CA 1.459 0.233 0 N-CA-C 110.662 -0.975 . . . . 0.0 110.662 -179.946 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 33.5 m -124.06 143.3 37.83 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.933 0 C-N-CA 122.778 0.431 . . . . 0.0 109.891 179.402 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 16.2 t . . . . . 0 N--CA 1.468 0.439 0 CA-C-O 118.045 -0.979 . . . . 0.0 110.986 179.199 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' C' C ' 1' ' ' ASP . . . . . . . . . . . . . 9.2 m-20 . . . . . 0 N--CA 1.489 1.497 0 N-CA-C 109.082 -0.71 . . . . 0.0 109.082 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' C' C ' 2' ' ' ALA . . . . . . . . . . . . . . . -66.65 148.25 52.16 Favored 'General case' 0 N--CA 1.467 0.411 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.121 179.639 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 3' ' ' GLU . . . . . . . . . . . . . 57.2 tt0 -162.11 104.48 1.15 Allowed 'General case' 0 N--CA 1.472 0.66 0 CA-C-N 116.411 -0.359 . . . . 0.0 110.058 179.661 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 21.1 m-85 -71.29 172.84 8.64 Favored 'General case' 0 N--CA 1.47 0.548 0 N-CA-C 109.479 -0.563 . . . . 0.0 109.479 179.548 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 31.9 mtp180 -68.31 129.5 40.1 Favored 'General case' 0 N--CA 1.472 0.666 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.215 -178.001 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 47.4 m170 -99.64 131.41 45.65 Favored 'General case' 0 N--CA 1.474 0.75 0 N-CA-C 109.467 -0.568 . . . . 0.0 109.467 179.455 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 7' ' ' ASP . . . . . . . . . . . . . 13.5 m-20 -71.63 141.0 49.95 Favored 'General case' 0 CA--C 1.531 0.232 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.848 -179.691 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 8' ' ' SER . . . . . 0.41 ' O ' ' O ' ' B' ' 25' ' ' GLY . 8.6 t -143.2 -173.19 3.86 Favored 'General case' 0 N--CA 1.479 1.01 0 N-CA-C 109.002 -0.74 . . . . 0.0 109.002 178.477 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 117.78 11.55 8.44 Favored Glycine 0 N--CA 1.486 1.981 0 N-CA-C 112.44 -0.264 . . . . 0.0 112.44 179.159 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 47.4 p90 -59.17 128.31 36.53 Favored 'General case' 0 CA--C 1.54 0.561 0 CA-C-N 116.907 0.353 . . . . 0.0 111.895 -179.626 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 46.3 mt-10 -89.59 154.68 19.79 Favored 'General case' 0 N--CA 1.473 0.704 0 N-CA-C 109.4 -0.593 . . . . 0.0 109.4 178.5 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -153.87 128.32 1.4 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.233 0 N-CA-C 108.254 -1.017 . . . . 0.0 108.254 178.61 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 49.8 m-70 -134.91 147.18 49.76 Favored 'General case' 0 N--CA 1.491 1.588 0 CA-C-N 118.603 0.638 . . . . 0.0 111.139 -178.89 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 6.4 t60 -165.1 98.03 0.73 Allowed 'General case' 0 N--CA 1.482 1.159 0 CA-C-N 116.601 -0.272 . . . . 0.0 111.094 179.575 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 15' ' ' GLN . . . . . 0.557 HE22 ' H ' ' C' ' 37' ' ' GLY . 55.2 mt-30 -109.29 -172.53 2.06 Favored 'General case' 0 CA--C 1.5 -0.955 0 N-CA-C 108.345 -0.983 . . . . 0.0 108.345 179.972 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 16' ' ' LYS . . . . . 0.402 ' C ' HD12 ' C' ' 17' ' ' LEU . 88.4 tttt -166.77 97.93 0.55 Allowed 'General case' 0 N--CA 1.471 0.59 0 CA-C-N 115.086 -0.961 . . . . 0.0 109.413 178.795 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 17' ' ' LEU . . . . . 0.594 HD12 ' N ' ' C' ' 17' ' ' LEU . 4.5 mp -105.91 163.87 12.4 Favored 'General case' 0 N--CA 1.488 1.462 0 N-CA-C 108.603 -0.888 . . . . 0.0 108.603 -179.969 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 59.8 t -142.28 118.65 6.29 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.305 0 CA-C-O 119.025 -0.512 . . . . 0.0 109.813 179.552 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 54.1 m-85 -70.17 159.47 33.89 Favored 'General case' 0 N--CA 1.479 0.986 0 N-CA-C 107.485 -1.302 . . . . 0.0 107.485 177.17 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 12.7 t80 -172.34 -57.05 0.02 OUTLIER 'General case' 0 N--CA 1.484 1.258 0 CA-C-O 122.209 1.004 . . . . 0.0 109.928 179.671 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -39.5 90.54 0.0 OUTLIER 'General case' 0 CA--C 1.53 0.187 0 CA-C-N 114.129 -1.396 . . . . 0.0 112.864 -178.221 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 37.1 tt0 -66.31 158.27 29.51 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.08 -0.964 . . . . 0.0 110.625 179.258 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 11.4 m-20 -140.4 138.18 34.58 Favored 'General case' 0 N--CA 1.478 0.967 0 C-N-CA 123.032 0.533 . . . . 0.0 110.175 179.797 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 18.1 t -92.47 -117.01 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.484 1.238 0 N-CA-C 108.721 -0.844 . . . . 0.0 108.721 179.545 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 25' ' ' GLY . . . . . 0.41 ' O ' ' O ' ' A' ' 8' ' ' SER . . . -101.94 56.65 0.67 Allowed Glycine 0 C--N 1.347 1.192 0 N-CA-C 110.927 -0.869 . . . . 0.0 110.927 -179.995 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 79.2 p -85.36 124.83 32.41 Favored 'General case' 0 N--CA 1.467 0.423 0 N-CA-C 108.683 -0.858 . . . . 0.0 108.683 178.149 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 61.9 t30 -64.88 101.16 0.46 Allowed 'General case' 0 N--CA 1.473 0.717 0 N-CA-C 108.73 -0.841 . . . . 0.0 108.73 178.809 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 28' ' ' LYS . . . . . 0.4 ' O ' ' O ' ' C' ' 29' ' ' GLY . 65.2 mttm -97.47 113.65 25.37 Favored 'General case' 0 N--CA 1.486 1.348 0 N-CA-C 110.064 -0.347 . . . . 0.0 110.064 -178.983 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 29' ' ' GLY . . . . . 0.4 ' O ' ' O ' ' C' ' 28' ' ' LYS . . . -60.2 -134.47 0.01 OUTLIER Glycine 0 CA--C 1.535 1.282 0 N-CA-C 110.798 -0.921 . . . . 0.0 110.798 178.982 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -112.5 128.0 56.21 Favored 'General case' 0 N--CA 1.48 1.075 0 N-CA-C 109.181 -0.674 . . . . 0.0 109.181 178.91 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 64.4 mt -90.6 129.26 41.7 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.674 0 N-CA-C 107.486 -1.301 . . . . 0.0 107.486 178.75 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 12.2 mt -142.96 152.12 17.2 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.806 0 CA-C-N 116.053 -0.521 . . . . 0.0 109.871 -178.88 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 65.04 48.37 71.62 Favored Glycine 0 CA--C 1.525 0.697 0 CA-C-N 116.012 -0.54 . . . . 0.0 112.63 178.982 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 34' ' ' LEU . . . . . 0.407 HD23 ' N ' ' C' ' 35' ' ' MET . 2.8 tt -98.46 121.0 39.84 Favored 'General case' 0 N--CA 1.478 0.955 0 N-CA-C 107.158 -1.423 . . . . 0.0 107.158 177.98 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 35' ' ' MET . . . . . 0.407 ' N ' HD23 ' C' ' 34' ' ' LEU . 27.7 ttt -153.07 158.12 41.46 Favored 'General case' 0 N--CA 1.471 0.584 0 N-CA-C 108.814 -0.81 . . . . 0.0 108.814 179.617 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 78.3 t -158.38 149.46 8.3 Favored 'Isoleucine or valine' 0 C--O 1.237 0.432 0 N-CA-C 106.865 -1.531 . . . . 0.0 106.865 -179.526 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 37' ' ' GLY . . . . . 0.557 ' H ' HE22 ' C' ' 15' ' ' GLN . . . 56.94 72.54 0.57 Allowed Glycine 0 C--N 1.315 -0.616 0 CA-C-N 115.641 -0.709 . . . . 0.0 111.414 178.337 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 172.74 -157.45 26.79 Favored Glycine 0 N--CA 1.461 0.357 0 N-CA-C 110.659 -0.976 . . . . 0.0 110.659 -179.885 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 33.4 m -124.42 143.53 37.52 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.904 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 179.474 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 16.3 t . . . . . 0 N--CA 1.467 0.402 0 CA-C-O 118.118 -0.944 . . . . 0.0 111.082 179.285 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' D' D ' 1' ' ' ASP . . . . . . . . . . . . . 8.9 m-20 . . . . . 0 N--CA 1.488 1.46 0 N-CA-C 109.096 -0.705 . . . . 0.0 109.096 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' D' D ' 2' ' ' ALA . . . . . . . . . . . . . . . -67.98 148.91 50.4 Favored 'General case' 0 N--CA 1.469 0.523 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.484 179.381 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' D' D ' 3' ' ' GLU . . . . . . . . . . . . . 57.1 tt0 -160.86 107.37 1.46 Allowed 'General case' 0 C--O 1.202 -1.398 0 N-CA-C 109.678 -0.489 . . . . 0.0 109.678 -179.956 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 23.1 m-85 -77.21 167.98 20.83 Favored 'General case' 0 C--N 1.302 -1.486 0 C-N-CA 126.137 1.775 . . . . 0.0 107.913 -179.073 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' D' D ' 5' ' ' ARG . . . . . . . . . . . . 0.297 39.3 mtp180 -76.43 133.58 39.82 Favored 'General case' 0 C--O 1.214 -0.812 0 N-CA-C 106.852 -1.536 . . . . 0.0 106.852 -168.536 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 51.4 m170 -101.78 133.4 46.58 Favored 'General case' 0 C--N 1.363 1.167 0 CA-C-N 113.931 -1.486 . . . . 0.0 107.776 -176.422 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' D' D ' 7' ' ' ASP . . . . . . . . . . . . . 9.3 m-20 -64.69 124.05 20.91 Favored 'General case' 0 C--N 1.314 -0.964 0 C-N-CA 127.987 2.515 . . . . 0.0 115.331 176.692 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' D' D ' 8' ' ' SER . . . . . . . . . . . . . 8.2 t -133.3 -174.83 3.61 Favored 'General case' 0 N--CA 1.483 1.209 0 CA-C-N 119.928 1.24 . . . . 0.0 109.46 177.367 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 121.88 13.75 4.92 Favored Glycine 0 N--CA 1.483 1.79 0 N-CA-C 110.993 -0.843 . . . . 0.0 110.993 175.476 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 44.7 p90 -58.37 130.18 45.5 Favored 'General case' 0 CA--C 1.539 0.526 0 C-N-CA 120.938 -0.305 . . . . 0.0 111.71 -179.209 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 47.0 mt-10 -89.29 152.57 21.48 Favored 'General case' 0 N--CA 1.477 0.903 0 N-CA-C 110.063 -0.347 . . . . 0.0 110.063 176.679 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -149.54 129.99 4.33 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.522 0 N-CA-C 107.975 -1.12 . . . . 0.0 107.975 174.35 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 47.9 m-70 -129.86 150.31 51.21 Favored 'General case' 0 N--CA 1.482 1.17 0 CA-C-N 117.848 0.295 . . . . 0.0 111.567 176.611 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 6.6 t60 -165.05 104.65 0.78 Allowed 'General case' 0 N--CA 1.484 1.233 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 172.974 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' D' D ' 15' ' ' GLN . . . . . 0.581 HE22 ' H ' ' D' ' 37' ' ' GLY . 55.2 mt-30 -112.46 -175.85 2.78 Favored 'General case' 0 CA--C 1.493 -1.222 0 N-CA-C 108.085 -1.079 . . . . 0.0 108.085 179.188 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' D' D ' 16' ' ' LYS . . . . . 0.452 ' C ' HD12 ' D' ' 17' ' ' LEU . 88.6 tttt -162.92 106.13 1.06 Allowed 'General case' 0 CA--C 1.536 0.419 0 N-CA-C 107.803 -1.184 . . . . 0.0 107.803 175.619 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' D' D ' 17' ' ' LEU . . . . . 0.542 HD12 ' N ' ' D' ' 17' ' ' LEU . 5.4 mp -112.47 162.86 15.14 Favored 'General case' 0 N--CA 1.488 1.442 0 N-CA-C 108.134 -1.061 . . . . 0.0 108.134 179.583 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 51.5 t -141.0 123.63 15.38 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.194 0 N-CA-C 109.01 -0.737 . . . . 0.0 109.01 175.962 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 78.5 m-85 -62.65 151.53 37.87 Favored 'General case' 0 C--N 1.349 0.569 0 C-N-CA 125.002 1.321 . . . . 0.0 110.395 170.485 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 8.3 t80 -170.17 -66.78 0.02 OUTLIER 'General case' 0 N--CA 1.476 0.831 0 N-CA-C 107.765 -1.198 . . . . 0.0 107.765 -179.584 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -37.94 95.74 0.01 OUTLIER 'General case' 0 CA--C 1.536 0.419 0 CA-C-N 113.889 -1.505 . . . . 0.0 111.706 -174.505 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 37.3 tt0 -68.32 158.97 32.3 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 113.587 -1.642 . . . . 0.0 110.308 178.654 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 11.5 m-20 -140.6 140.58 35.13 Favored 'General case' 0 N--CA 1.474 0.767 0 N-CA-C 109.646 -0.501 . . . . 0.0 109.646 178.795 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' D' D ' 24' ' ' VAL . . . . . . . . . . . . . 16.0 t -94.44 -120.65 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.381 0 N-CA-C 108.242 -1.021 . . . . 0.0 108.242 179.858 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . -104.65 61.93 0.38 Allowed Glycine 0 C--N 1.375 2.718 0 C-N-CA 117.791 -2.147 . . . . 0.0 109.555 178.866 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 90.9 p -71.57 121.07 18.09 Favored 'General case' 0 C--O 1.246 0.872 0 CA-C-O 115.949 -1.977 . . . . 0.0 112.537 168.01 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 64.7 t30 -60.69 102.06 0.17 Allowed 'General case' 0 N--CA 1.478 0.956 0 CA-C-N 122.278 2.308 . . . . 0.0 109.906 172.212 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' D' D ' 28' ' ' LYS . . . . . 0.403 ' O ' ' O ' ' D' ' 29' ' ' GLY . 64.6 mttm -100.95 116.16 32.14 Favored 'General case' 0 N--CA 1.493 1.714 0 CA-C-N 120.028 1.286 . . . . 0.0 109.157 179.461 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' D' D ' 29' ' ' GLY . . . . . 0.403 ' O ' ' O ' ' D' ' 28' ' ' LYS . . . -54.65 -134.6 0.0 OUTLIER Glycine 0 C--N 1.343 0.94 0 CA-C-N 115.51 -0.768 . . . . 0.0 113.433 176.203 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -112.95 132.58 55.28 Favored 'General case' 0 C--N 1.37 1.464 0 N-CA-C 108.46 -0.941 . . . . 0.0 108.46 174.435 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 66.7 mt -91.75 133.85 31.96 Favored 'Isoleucine or valine' 0 C--N 1.346 0.422 0 N-CA-C 106.888 -1.523 . . . . 0.0 106.888 176.682 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 14.2 mt -145.74 154.28 13.34 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.916 0 N-CA-C 109.092 -0.707 . . . . 0.0 109.092 179.276 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 64.09 47.65 83.26 Favored Glycine 0 C--O 1.246 0.877 0 CA-C-O 119.409 -0.662 . . . . 0.0 112.538 179.243 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 3.4 tt -97.81 132.53 43.34 Favored 'General case' 0 C--N 1.372 1.558 0 N-CA-C 104.593 -2.373 . . . . 0.0 104.593 176.44 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 28.2 ttt -155.96 165.32 36.81 Favored 'General case' 0 N--CA 1.475 0.812 0 N-CA-C 107.705 -1.22 . . . . 0.0 107.705 175.8 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 94.4 t -164.04 155.52 2.11 Favored 'Isoleucine or valine' 0 C--O 1.247 0.959 0 N-CA-C 105.204 -2.147 . . . . 0.0 105.204 175.016 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' D' D ' 37' ' ' GLY . . . . . 0.581 ' H ' HE22 ' D' ' 15' ' ' GLN . . . 61.22 65.15 3.46 Favored Glycine 0 CA--C 1.524 0.637 0 C-N-CA 117.97 -2.062 . . . . 0.0 113.042 176.686 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 168.83 -158.55 31.24 Favored Glycine 0 N--CA 1.465 0.633 0 CA-C-N 118.976 1.388 . . . . 0.0 111.58 -177.921 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 33.1 m -120.23 142.47 35.8 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.17 0 CA-C-N 118.426 1.113 . . . . 0.0 110.243 -178.534 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 13.9 t . . . . . 0 C--O 1.212 -0.916 0 N-CA-C 109.606 -0.516 . . . . 0.0 109.606 174.362 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' E' E ' 1' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 . . . . . 0 N--CA 1.487 1.419 0 N-CA-C 109.19 -0.67 . . . . 0.0 109.19 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' E' E ' 2' ' ' ALA . . . . . . . . . . . . . . . -67.76 149.4 49.99 Favored 'General case' 0 N--CA 1.468 0.456 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.321 179.557 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' E' E ' 3' ' ' GLU . . . . . . . . . . . . . 57.5 tt0 -162.58 102.31 1.05 Allowed 'General case' 0 C--O 1.211 -0.964 0 N-CA-C 110.075 -0.343 . . . . 0.0 110.075 -179.796 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 20.4 m-85 -68.12 172.48 5.66 Favored 'General case' 0 N--CA 1.472 0.665 0 N-CA-C 109.959 -0.386 . . . . 0.0 109.959 179.523 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' E' E ' 5' ' ' ARG . . . . . . . . . . . . . 30.6 mtp180 -67.7 130.32 42.64 Favored 'General case' 0 C--O 1.219 -0.517 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.503 -178.12 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 47.7 m170 -100.4 131.02 46.56 Favored 'General case' 0 N--CA 1.475 0.802 0 N-CA-C 109.593 -0.521 . . . . 0.0 109.593 179.37 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' E' E ' 7' ' ' ASP . . . . . . . . . . . . . 17.0 m-20 -71.07 142.33 50.84 Favored 'General case' 0 N--CA 1.464 0.234 0 O-C-N 123.389 0.431 . . . . 0.0 110.979 -179.829 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' E' E ' 8' ' ' SER . . . . . . . . . . . . . 8.4 t -144.85 -172.9 3.93 Favored 'General case' 0 N--CA 1.478 0.938 0 N-CA-C 108.994 -0.743 . . . . 0.0 108.994 178.052 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 118.17 12.23 7.73 Favored Glycine 0 N--CA 1.482 1.742 0 N-CA-C 112.191 -0.364 . . . . 0.0 112.191 179.032 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 43.5 p90 -58.91 127.8 34.04 Favored 'General case' 0 CA--C 1.544 0.733 0 N-CA-C 112.107 0.41 . . . . 0.0 112.107 -179.366 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 46.8 mt-10 -88.46 155.16 19.83 Favored 'General case' 0 N--CA 1.476 0.838 0 N-CA-C 109.43 -0.581 . . . . 0.0 109.43 178.12 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -155.3 127.44 1.0 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.557 0 N-CA-C 108.344 -0.984 . . . . 0.0 108.344 178.539 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 48.0 m-70 -135.27 145.3 47.42 Favored 'General case' 0 N--CA 1.483 1.206 0 CA-C-O 120.704 0.287 . . . . 0.0 111.331 -177.826 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 6.3 t60 -164.0 97.53 0.83 Allowed 'General case' 0 N--CA 1.486 1.334 0 CA-C-N 116.752 -0.204 . . . . 0.0 111.048 179.693 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' E' E ' 15' ' ' GLN . . . . . 0.53 HE22 ' H ' ' E' ' 37' ' ' GLY . 55.6 mt-30 -108.35 -172.62 2.09 Favored 'General case' 0 CA--C 1.502 -0.902 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 -179.94 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -166.57 98.2 0.58 Allowed 'General case' 0 CA--C 1.541 0.621 0 CA-C-N 114.992 -1.004 . . . . 0.0 109.453 178.722 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' E' E ' 17' ' ' LEU . . . . . 0.589 ' N ' HD12 ' E' ' 17' ' ' LEU . 4.4 mp -106.14 163.1 13.06 Favored 'General case' 0 N--CA 1.49 1.565 0 N-CA-C 109.239 -0.652 . . . . 0.0 109.239 -179.693 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 42.1 t -142.15 118.14 6.11 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.418 0 C-N-CA 122.558 0.343 . . . . 0.0 110.554 179.158 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 52.8 m-85 -69.17 157.27 37.23 Favored 'General case' 0 C--N 1.356 0.867 0 N-CA-C 107.312 -1.366 . . . . 0.0 107.312 176.582 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 11.5 t80 -173.96 -54.7 0.01 OUTLIER 'General case' 0 N--CA 1.484 1.275 0 CA-C-O 121.717 0.77 . . . . 0.0 110.347 179.469 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.35 88.79 0.0 OUTLIER 'General case' 0 C--N 1.319 -0.751 0 CA-C-N 114.356 -1.293 . . . . 0.0 112.83 -178.974 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 37.4 tt0 -64.48 158.28 24.41 Favored 'General case' 0 N--CA 1.47 0.557 0 CA-C-N 114.944 -1.025 . . . . 0.0 110.681 179.702 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 11.0 m-20 -140.51 138.03 34.26 Favored 'General case' 0 N--CA 1.476 0.833 0 C-N-CA 122.985 0.514 . . . . 0.0 110.483 179.887 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 18.9 t -92.22 -116.79 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.288 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 179.587 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . -102.2 55.13 0.72 Allowed Glycine 0 N--CA 1.473 1.137 0 N-CA-C 111.226 -0.749 . . . . 0.0 111.226 -179.881 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 81.1 p -83.37 124.42 30.63 Favored 'General case' 0 N--CA 1.468 0.443 0 N-CA-C 109.205 -0.665 . . . . 0.0 109.205 177.819 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 62.9 t30 -64.58 101.42 0.46 Allowed 'General case' 0 N--CA 1.474 0.728 0 N-CA-C 108.307 -0.998 . . . . 0.0 108.307 178.725 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 64.3 mttm -98.07 113.32 25.16 Favored 'General case' 0 N--CA 1.488 1.469 0 N-CA-C 109.888 -0.412 . . . . 0.0 109.888 -178.603 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.06 -133.62 0.01 OUTLIER Glycine 0 CA--C 1.533 1.215 0 N-CA-C 111.471 -0.652 . . . . 0.0 111.471 178.894 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -113.19 126.87 55.9 Favored 'General case' 0 N--CA 1.477 0.907 0 N-CA-C 109.265 -0.642 . . . . 0.0 109.265 179.382 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 65.6 mt -90.13 130.24 39.72 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.279 0 N-CA-C 107.104 -1.443 . . . . 0.0 107.104 178.797 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 13.5 mt -142.99 153.42 16.99 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.825 0 N-CA-C 109.069 -0.715 . . . . 0.0 109.069 -179.42 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.71 49.94 65.13 Favored Glycine 0 CA--C 1.524 0.651 0 CA-C-N 116.432 -0.349 . . . . 0.0 113.153 179.022 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 2.9 tt -99.62 120.59 39.92 Favored 'General case' 0 N--CA 1.48 1.03 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 177.599 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 28.1 ttt -152.01 159.18 43.8 Favored 'General case' 0 N--CA 1.477 0.916 0 N-CA-C 108.373 -0.973 . . . . 0.0 108.373 179.578 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 95.7 t -159.49 149.23 6.93 Favored 'Isoleucine or valine' 0 C--O 1.237 0.419 0 N-CA-C 106.605 -1.628 . . . . 0.0 106.605 -179.816 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' E' E ' 37' ' ' GLY . . . . . 0.53 ' H ' HE22 ' E' ' 15' ' ' GLN . . . 57.32 72.19 0.62 Allowed Glycine 0 C--N 1.316 -0.579 0 CA-C-N 115.523 -0.762 . . . . 0.0 111.316 178.155 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 173.72 -155.66 22.45 Favored Glycine 0 C--O 1.219 -0.811 0 N-CA-C 111.123 -0.791 . . . . 0.0 111.123 -179.831 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 33.5 m -126.2 142.59 42.39 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.757 0 N-CA-C 109.203 -0.666 . . . . 0.0 109.203 179.379 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 15.1 t . . . . . 0 CA--C 1.538 0.509 0 CA-C-O 118.109 -0.948 . . . . 0.0 111.218 179.279 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' F' F ' 1' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 . . . . . 0 N--CA 1.488 1.432 0 N-CA-C 109.075 -0.713 . . . . 0.0 109.075 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' F' F ' 2' ' ' ALA . . . . . . . . . . . . . . . -68.19 149.82 49.08 Favored 'General case' 0 N--CA 1.47 0.529 0 CA-C-N 116.306 -0.407 . . . . 0.0 110.335 179.607 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' F' F ' 3' ' ' GLU . . . . . . . . . . . . . 57.4 tt0 -162.71 102.67 1.03 Allowed 'General case' 0 C--O 1.21 -1.003 0 CA-C-N 116.44 -0.346 . . . . 0.0 110.085 -179.845 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 20.2 m-85 -68.46 172.52 5.97 Favored 'General case' 0 N--CA 1.474 0.734 0 CA-C-O 120.941 0.401 . . . . 0.0 109.971 179.561 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' F' F ' 5' ' ' ARG . . . . . . . . . . . . . 30.5 mtp180 -67.32 129.98 41.63 Favored 'General case' 0 C--O 1.217 -0.63 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.514 -178.162 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 47.8 m170 -100.43 131.21 46.48 Favored 'General case' 0 N--CA 1.477 0.922 0 N-CA-C 109.572 -0.529 . . . . 0.0 109.572 179.358 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' F' F ' 7' ' ' ASP . . . . . . . . . . . . . 16.6 m-20 -71.37 142.02 50.36 Favored 'General case' 0 N--CA 1.464 0.26 0 O-C-N 123.422 0.451 . . . . 0.0 111.066 -179.786 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' F' F ' 8' ' ' SER . . . . . . . . . . . . . 8.4 t -144.67 -173.13 3.97 Favored 'General case' 0 N--CA 1.478 0.971 0 N-CA-C 108.958 -0.756 . . . . 0.0 108.958 178.002 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 118.6 11.73 7.73 Favored Glycine 0 N--CA 1.482 1.745 0 N-CA-C 112.126 -0.39 . . . . 0.0 112.126 179.072 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 43.4 p90 -58.64 128.22 36.08 Favored 'General case' 0 CA--C 1.544 0.738 0 N-CA-C 112.123 0.416 . . . . 0.0 112.123 -179.31 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 46.8 mt-10 -88.77 155.15 19.74 Favored 'General case' 0 N--CA 1.475 0.817 0 CA-C-O 121.303 0.573 . . . . 0.0 109.585 178.031 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -155.21 127.48 1.02 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.574 0 N-CA-C 108.338 -0.986 . . . . 0.0 108.338 178.505 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 48.0 m-70 -135.32 144.94 46.99 Favored 'General case' 0 N--CA 1.481 1.093 0 CA-C-O 120.681 0.277 . . . . 0.0 111.379 -177.923 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 6.3 t60 -163.78 98.16 0.86 Allowed 'General case' 0 N--CA 1.487 1.406 0 CA-C-N 116.697 -0.229 . . . . 0.0 111.145 179.645 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' F' F ' 15' ' ' GLN . . . . . 0.533 HE22 ' H ' ' F' ' 37' ' ' GLY . 55.8 mt-30 -109.29 -171.97 1.95 Allowed 'General case' 0 CA--C 1.499 -1.015 0 N-CA-C 108.625 -0.88 . . . . 0.0 108.625 -179.911 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -166.84 98.57 0.55 Allowed 'General case' 0 CA--C 1.541 0.609 0 CA-C-N 114.895 -1.048 . . . . 0.0 109.483 178.778 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' F' F ' 17' ' ' LEU . . . . . 0.585 HD12 ' N ' ' F' ' 17' ' ' LEU . 4.4 mp -106.24 163.14 13.05 Favored 'General case' 0 N--CA 1.489 1.501 0 N-CA-C 109.141 -0.689 . . . . 0.0 109.141 -179.717 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 42.0 t -142.17 118.3 6.2 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.369 0 C-N-CA 122.507 0.323 . . . . 0.0 110.522 179.088 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 52.7 m-85 -69.27 157.17 37.51 Favored 'General case' 0 C--N 1.355 0.811 0 N-CA-C 107.151 -1.426 . . . . 0.0 107.151 176.563 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 12.3 t80 -173.75 -54.8 0.01 OUTLIER 'General case' 0 N--CA 1.486 1.344 0 CA-C-O 121.785 0.802 . . . . 0.0 109.752 179.688 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.35 88.68 0.0 OUTLIER 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 114.484 -1.234 . . . . 0.0 113.007 -178.893 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 37.0 tt0 -64.36 158.43 23.61 Favored 'General case' 0 N--CA 1.472 0.668 0 CA-C-N 114.999 -1.001 . . . . 0.0 110.895 179.481 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 11.8 m-20 -140.87 137.67 33.38 Favored 'General case' 0 N--CA 1.477 0.909 0 C-N-CA 122.893 0.477 . . . . 0.0 110.458 179.973 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' F' F ' 24' ' ' VAL . . . . . . . . . . . . . 18.6 t -91.88 -116.83 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.391 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 179.544 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -102.11 55.32 0.72 Allowed Glycine 0 N--CA 1.477 1.41 0 N-CA-C 110.953 -0.859 . . . . 0.0 110.953 -179.863 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 79.8 p -83.54 124.19 30.5 Favored 'General case' 0 N--CA 1.47 0.552 0 N-CA-C 109.012 -0.736 . . . . 0.0 109.012 177.726 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 62.3 t30 -64.44 101.47 0.45 Allowed 'General case' 0 N--CA 1.473 0.71 0 N-CA-C 108.375 -0.972 . . . . 0.0 108.375 178.684 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 64.3 mttm -98.04 113.26 25.08 Favored 'General case' 0 N--CA 1.488 1.46 0 N-CA-C 110.029 -0.36 . . . . 0.0 110.029 -178.648 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.07 -133.84 0.01 OUTLIER Glycine 0 CA--C 1.534 1.266 0 N-CA-C 111.559 -0.616 . . . . 0.0 111.559 178.901 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -112.69 127.17 56.05 Favored 'General case' 0 N--CA 1.477 0.885 0 N-CA-C 109.228 -0.656 . . . . 0.0 109.228 179.241 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 65.7 mt -90.53 130.15 40.22 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.286 0 N-CA-C 107.086 -1.45 . . . . 0.0 107.086 178.703 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 13.1 mt -142.9 153.6 17.18 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.763 0 N-CA-C 109.115 -0.698 . . . . 0.0 109.115 -179.33 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.59 49.73 67.14 Favored Glycine 0 CA--C 1.524 0.609 0 CA-C-N 116.486 -0.325 . . . . 0.0 113.141 179.098 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' F' F ' 34' ' ' LEU . . . . . 0.404 HD23 ' N ' ' F' ' 35' ' ' MET . 3.0 tt -99.48 120.79 40.2 Favored 'General case' 0 N--CA 1.478 0.944 0 N-CA-C 107.344 -1.354 . . . . 0.0 107.344 177.747 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' F' F ' 35' ' ' MET . . . . . 0.404 ' N ' HD23 ' F' ' 34' ' ' LEU . 28.1 ttt -152.68 159.86 43.17 Favored 'General case' 0 N--CA 1.472 0.667 0 N-CA-C 109.146 -0.687 . . . . 0.0 109.146 179.343 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 95.4 t -159.75 149.4 6.6 Favored 'Isoleucine or valine' 0 C--O 1.237 0.429 0 N-CA-C 106.907 -1.516 . . . . 0.0 106.907 -179.586 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' F' F ' 37' ' ' GLY . . . . . 0.533 ' H ' HE22 ' F' ' 15' ' ' GLN . . . 57.26 72.68 0.55 Allowed Glycine 0 C--N 1.315 -0.596 0 CA-C-N 115.548 -0.751 . . . . 0.0 111.268 178.195 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 173.44 -155.29 22.04 Favored Glycine 0 C--O 1.219 -0.841 0 N-CA-C 111.119 -0.792 . . . . 0.0 111.119 -179.795 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 33.4 m -126.62 142.5 42.98 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.777 0 N-CA-C 109.206 -0.664 . . . . 0.0 109.206 179.372 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 15.3 t . . . . . 0 CA--C 1.539 0.521 0 CA-C-O 118.0 -1.0 . . . . 0.0 111.301 179.306 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' G' G ' 1' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 . . . . . 0 N--CA 1.49 1.552 0 N-CA-C 109.434 -0.58 . . . . 0.0 109.434 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' G' G ' 2' ' ' ALA . . . . . . . . . . . . . . . -68.38 151.01 47.48 Favored 'General case' 0 CA--C 1.535 0.388 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.39 179.788 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' G' G ' 3' ' ' GLU . . . . . . . . . . . . . 57.3 tt0 -162.63 102.95 1.05 Allowed 'General case' 0 C--O 1.213 -0.845 0 N-CA-C 110.113 -0.329 . . . . 0.0 110.113 -179.382 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 26.7 m-85 -67.72 170.71 7.42 Favored 'General case' 0 N--CA 1.473 0.695 0 CA-C-O 120.849 0.357 . . . . 0.0 110.226 179.396 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' G' G ' 5' ' ' ARG . . . . . . . . . . . . . 31.5 mtp180 -66.59 129.44 39.87 Favored 'General case' 0 N--CA 1.47 0.543 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.178 -178.297 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 47.1 m170 -99.96 131.04 46.16 Favored 'General case' 0 N--CA 1.474 0.764 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 179.449 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 16.9 m-20 -72.21 137.85 47.15 Favored 'General case' 0 N--CA 1.466 0.358 0 O-C-N 123.638 0.586 . . . . 0.0 111.418 -179.488 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' G' G ' 8' ' ' SER . . . . . . . . . . . . . 8.0 t -142.16 -173.06 3.72 Favored 'General case' 0 N--CA 1.477 0.9 0 N-CA-C 109.114 -0.699 . . . . 0.0 109.114 178.038 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 119.13 12.97 6.66 Favored Glycine 0 N--CA 1.481 1.67 0 N-CA-C 111.725 -0.55 . . . . 0.0 111.725 179.075 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 47.4 p90 -59.52 128.25 36.09 Favored 'General case' 0 CA--C 1.541 0.604 0 N-CA-C 112.002 0.371 . . . . 0.0 112.002 -179.227 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 46.6 mt-10 -89.13 154.5 20.11 Favored 'General case' 0 N--CA 1.474 0.741 0 CA-C-O 121.208 0.528 . . . . 0.0 109.914 178.685 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 2.7 p -155.99 127.17 0.89 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.039 0 N-CA-C 108.334 -0.988 . . . . 0.0 108.334 178.765 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 51.4 m-70 -134.06 146.44 50.32 Favored 'General case' 0 N--CA 1.476 0.855 0 CA-C-N 115.289 -0.869 . . . . 0.0 110.997 -177.98 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 6.3 t60 -165.41 97.47 0.69 Allowed 'General case' 0 N--CA 1.483 1.181 0 CA-C-N 116.542 -0.299 . . . . 0.0 110.691 179.064 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' G' G ' 15' ' ' GLN . . . . . 0.55 HE22 ' H ' ' G' ' 37' ' ' GLY . 55.6 mt-30 -108.62 -172.6 2.09 Favored 'General case' 0 CA--C 1.501 -0.928 0 N-CA-C 108.574 -0.898 . . . . 0.0 108.574 -179.787 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' G' G ' 16' ' ' LYS . . . . . 0.406 ' C ' HD12 ' G' ' 17' ' ' LEU . 88.5 tttt -166.47 98.69 0.59 Allowed 'General case' 0 CA--C 1.541 0.606 0 CA-C-N 115.018 -0.992 . . . . 0.0 109.383 178.714 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' G' G ' 17' ' ' LEU . . . . . 0.587 ' N ' HD12 ' G' ' 17' ' ' LEU . 5.1 mp -106.14 161.79 14.2 Favored 'General case' 0 N--CA 1.487 1.383 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 -179.581 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 40.8 t -142.53 118.74 5.83 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.052 0 CA-C-O 120.766 0.317 . . . . 0.0 110.449 178.724 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 45.8 m-85 -69.71 151.12 46.21 Favored 'General case' 0 C--N 1.369 1.417 0 N-CA-C 107.303 -1.369 . . . . 0.0 107.303 176.761 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 10.3 t80 -171.16 -55.1 0.02 OUTLIER 'General case' 0 N--CA 1.486 1.369 0 CA-C-N 118.006 0.367 . . . . 0.0 110.333 -179.662 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.65 90.25 0.0 OUTLIER 'General case' 0 C--N 1.326 -0.428 0 C-N-CA 123.716 0.807 . . . . 0.0 112.582 -179.819 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 37.1 tt0 -65.2 159.39 23.72 Favored 'General case' 0 N--CA 1.469 0.488 0 CA-C-N 114.669 -1.151 . . . . 0.0 110.086 179.076 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 12.0 m-20 -141.45 137.2 32.0 Favored 'General case' 0 N--CA 1.476 0.842 0 C-N-CA 122.905 0.482 . . . . 0.0 109.986 179.927 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' G' G ' 24' ' ' VAL . . . . . . . . . . . . . 15.8 t -92.31 -116.63 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.106 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 179.682 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -101.93 54.35 0.77 Allowed Glycine 0 N--CA 1.476 1.366 0 N-CA-C 111.581 -0.608 . . . . 0.0 111.581 -179.725 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 80.0 p -82.72 124.34 30.14 Favored 'General case' 0 N--CA 1.469 0.501 0 N-CA-C 108.952 -0.758 . . . . 0.0 108.952 177.864 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 59.1 t30 -64.77 101.35 0.47 Allowed 'General case' 0 N--CA 1.471 0.594 0 N-CA-C 108.585 -0.894 . . . . 0.0 108.585 178.586 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 64.7 mttm -97.32 114.43 26.2 Favored 'General case' 0 N--CA 1.486 1.373 0 N-CA-C 109.891 -0.411 . . . . 0.0 109.891 -178.955 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.69 -132.45 0.01 OUTLIER Glycine 0 CA--C 1.532 1.144 0 N-CA-C 110.767 -0.933 . . . . 0.0 110.767 179.045 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -112.81 126.24 55.22 Favored 'General case' 0 N--CA 1.469 0.508 0 C-N-CA 123.006 0.522 . . . . 0.0 109.661 179.602 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 68.7 mt -89.66 130.7 38.53 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.776 0 N-CA-C 107.263 -1.384 . . . . 0.0 107.263 178.555 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 15.9 mt -143.92 154.35 15.74 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.346 0 CA-C-N 118.945 0.793 . . . . 0.0 108.982 -179.91 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.8 49.02 71.24 Favored Glycine 0 CA--C 1.527 0.811 0 C-N-CA 121.803 -0.237 . . . . 0.0 112.75 179.155 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' G' G ' 34' ' ' LEU . . . . . 0.414 HD23 ' N ' ' G' ' 35' ' ' MET . 2.9 tt -98.93 121.96 41.57 Favored 'General case' 0 N--CA 1.479 0.982 0 N-CA-C 106.953 -1.499 . . . . 0.0 106.953 177.723 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' G' G ' 35' ' ' MET . . . . . 0.414 ' N ' HD23 ' G' ' 34' ' ' LEU . 28.2 ttt -153.76 159.83 42.07 Favored 'General case' 0 N--CA 1.48 1.048 0 N-CA-C 107.999 -1.111 . . . . 0.0 107.999 179.661 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 88.6 t -159.58 149.65 6.71 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 N-CA-C 106.231 -1.766 . . . . 0.0 106.231 -179.735 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' G' G ' 37' ' ' GLY . . . . . 0.55 ' H ' HE22 ' G' ' 15' ' ' GLN . . . 57.01 72.75 0.53 Allowed Glycine 0 C--N 1.314 -0.66 0 C-N-CA 121.055 -0.593 . . . . 0.0 111.781 177.921 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 172.15 -154.08 20.75 Favored Glycine 0 C--O 1.219 -0.838 0 N-CA-C 110.517 -1.033 . . . . 0.0 110.517 179.223 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 34.0 m -127.0 142.91 42.13 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.009 0 CA-C-N 117.041 0.421 . . . . 0.0 109.963 179.951 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 15.6 t . . . . . 0 N--CA 1.466 0.363 0 CA-C-O 118.193 -0.908 . . . . 0.0 111.382 179.631 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' H' H ' 1' ' ' ASP . . . . . . . . . . . . . 7.9 m-20 . . . . . 0 N--CA 1.489 1.505 0 N-CA-C 109.481 -0.563 . . . . 0.0 109.481 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' H' H ' 2' ' ' ALA . . . . . . . . . . . . . . . -68.13 150.56 48.21 Favored 'General case' 0 N--CA 1.467 0.406 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.336 179.731 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' H' H ' 3' ' ' GLU . . . . . . . . . . . . . 57.2 tt0 -162.23 102.97 1.11 Allowed 'General case' 0 C--O 1.213 -0.823 0 N-CA-C 110.063 -0.347 . . . . 0.0 110.063 -179.346 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 26.2 m-85 -67.75 170.75 7.4 Favored 'General case' 0 N--CA 1.474 0.735 0 CA-C-O 120.912 0.387 . . . . 0.0 110.171 179.434 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' H' H ' 5' ' ' ARG . . . . . . . . . . . . . 31.0 mtp180 -66.46 129.43 39.81 Favored 'General case' 0 N--CA 1.469 0.477 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.309 -178.254 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 46.2 m170 -100.0 131.17 46.12 Favored 'General case' 0 N--CA 1.474 0.773 0 N-CA-C 109.648 -0.501 . . . . 0.0 109.648 179.4 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 16.3 m-20 -72.42 137.7 46.66 Favored 'General case' 0 N--CA 1.466 0.35 0 O-C-N 123.526 0.517 . . . . 0.0 111.361 -179.484 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' H' H ' 8' ' ' SER . . . . . . . . . . . . . 8.4 t -141.86 -173.61 3.85 Favored 'General case' 0 N--CA 1.475 0.807 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 178.282 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 119.35 12.73 6.67 Favored Glycine 0 N--CA 1.484 1.888 0 N-CA-C 111.802 -0.519 . . . . 0.0 111.802 179.061 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 46.8 p90 -59.33 128.17 35.76 Favored 'General case' 0 CA--C 1.542 0.651 0 N-CA-C 112.042 0.386 . . . . 0.0 112.042 -179.338 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 46.6 mt-10 -88.96 154.34 20.3 Favored 'General case' 0 N--CA 1.475 0.78 0 CA-C-O 121.22 0.533 . . . . 0.0 109.892 178.694 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.7 p -155.77 127.2 0.92 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.009 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 178.712 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 50.8 m-70 -134.08 146.18 50.06 Favored 'General case' 0 N--CA 1.476 0.863 0 CA-C-N 115.313 -0.858 . . . . 0.0 111.203 -178.045 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 6.4 t60 -165.08 97.58 0.73 Allowed 'General case' 0 N--CA 1.483 1.197 0 CA-C-N 116.583 -0.28 . . . . 0.0 110.716 179.039 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' H' H ' 15' ' ' GLN . . . . . 0.551 HE22 ' H ' ' H' ' 37' ' ' GLY . 55.3 mt-30 -108.57 -173.2 2.21 Favored 'General case' 0 CA--C 1.5 -0.966 0 N-CA-C 108.45 -0.945 . . . . 0.0 108.45 -179.787 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -166.12 98.39 0.63 Allowed 'General case' 0 N--CA 1.471 0.578 0 CA-C-N 114.984 -1.007 . . . . 0.0 109.341 178.727 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' H' H ' 17' ' ' LEU . . . . . 0.588 HD12 ' N ' ' H' ' 17' ' ' LEU . 5.1 mp -106.08 161.93 14.06 Favored 'General case' 0 N--CA 1.487 1.401 0 N-CA-C 109.394 -0.595 . . . . 0.0 109.394 -179.517 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 40.8 t -142.53 118.55 5.69 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.143 0 CA-C-O 120.775 0.321 . . . . 0.0 110.455 178.885 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 47.4 m-85 -69.85 151.44 45.71 Favored 'General case' 0 C--N 1.368 1.399 0 N-CA-C 107.334 -1.358 . . . . 0.0 107.334 176.59 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 10.9 t80 -172.37 -54.55 0.02 OUTLIER 'General case' 0 N--CA 1.484 1.246 0 CA-C-N 117.909 0.322 . . . . 0.0 110.21 -179.542 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.71 90.69 0.0 OUTLIER 'General case' 0 CA--C 1.534 0.356 0 C-N-CA 123.732 0.813 . . . . 0.0 112.298 -179.979 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 37.4 tt0 -65.74 159.29 25.45 Favored 'General case' 0 N--CA 1.47 0.537 0 CA-C-N 114.776 -1.102 . . . . 0.0 110.003 179.364 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 11.3 m-20 -141.29 137.55 32.54 Favored 'General case' 0 N--CA 1.476 0.837 0 C-N-CA 122.892 0.477 . . . . 0.0 109.919 179.861 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' H' H ' 24' ' ' VAL . . . . . . . . . . . . . 15.4 t -92.6 -116.94 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.09 0 N-CA-C 108.673 -0.862 . . . . 0.0 108.673 179.683 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . -101.48 54.25 0.8 Allowed Glycine 0 N--CA 1.479 1.538 0 N-CA-C 111.506 -0.638 . . . . 0.0 111.506 -179.742 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 80.3 p -82.85 124.54 30.41 Favored 'General case' 0 N--CA 1.469 0.497 0 N-CA-C 108.901 -0.778 . . . . 0.0 108.901 177.939 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 59.5 t30 -64.93 101.43 0.5 Allowed 'General case' 0 N--CA 1.472 0.664 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 178.679 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 65.1 mttm -97.33 114.11 25.84 Favored 'General case' 0 N--CA 1.485 1.321 0 N-CA-C 109.978 -0.378 . . . . 0.0 109.978 -179.021 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.42 -132.6 0.01 OUTLIER Glycine 0 CA--C 1.534 1.245 0 N-CA-C 110.845 -0.902 . . . . 0.0 110.845 179.053 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -112.72 126.28 55.24 Favored 'General case' 0 N--CA 1.471 0.603 0 C-N-CA 123.028 0.531 . . . . 0.0 109.662 179.59 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 68.0 mt -89.71 130.59 38.77 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.761 0 N-CA-C 107.35 -1.352 . . . . 0.0 107.35 178.506 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 16.3 mt -143.97 154.04 15.68 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.367 0 CA-C-N 118.922 0.783 . . . . 0.0 108.972 -179.74 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 64.09 49.01 69.75 Favored Glycine 0 CA--C 1.526 0.768 0 C-N-CA 121.717 -0.277 . . . . 0.0 112.81 179.184 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' H' H ' 34' ' ' LEU . . . . . 0.407 HD23 ' N ' ' H' ' 35' ' ' MET . 2.8 tt -99.02 121.66 41.26 Favored 'General case' 0 N--CA 1.477 0.914 0 N-CA-C 107.035 -1.469 . . . . 0.0 107.035 177.782 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' H' H ' 35' ' ' MET . . . . . 0.407 ' N ' HD23 ' H' ' 34' ' ' LEU . 28.2 ttt -153.4 159.75 42.47 Favored 'General case' 0 N--CA 1.48 1.036 0 N-CA-C 107.991 -1.115 . . . . 0.0 107.991 179.665 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 91.1 t -159.51 149.83 6.73 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 N-CA-C 106.278 -1.749 . . . . 0.0 106.278 -179.775 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' H' H ' 37' ' ' GLY . . . . . 0.551 ' H ' HE22 ' H' ' 15' ' ' GLN . . . 56.67 73.13 0.47 Allowed Glycine 0 C--N 1.313 -0.741 0 C-N-CA 120.982 -0.628 . . . . 0.0 111.727 178.117 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 171.65 -154.73 22.65 Favored Glycine 0 N--CA 1.468 0.806 0 N-CA-C 110.505 -1.038 . . . . 0.0 110.505 179.358 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 33.8 m -126.53 143.16 40.94 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.081 0 C-N-CA 122.663 0.385 . . . . 0.0 109.998 179.975 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 15.3 t . . . . . 0 N--CA 1.467 0.414 0 CA-C-O 118.137 -0.935 . . . . 0.0 111.293 179.544 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' I' I ' 1' ' ' ASP . . . . . . . . . . . . . 8.2 m-20 . . . . . 0 N--CA 1.489 1.506 0 N-CA-C 109.485 -0.561 . . . . 0.0 109.485 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' I' I ' 2' ' ' ALA . . . . . . . . . . . . . . . -68.61 151.19 47.06 Favored 'General case' 0 N--CA 1.466 0.358 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.324 179.675 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' I' I ' 3' ' ' GLU . . . . . . . . . . . . . 56.7 tt0 -162.76 102.87 1.03 Allowed 'General case' 0 C--O 1.213 -0.835 0 N-CA-C 110.09 -0.337 . . . . 0.0 110.09 -179.344 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 25.9 m-85 -67.68 170.91 7.03 Favored 'General case' 0 N--CA 1.472 0.666 0 CA-C-O 120.843 0.354 . . . . 0.0 110.168 179.461 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' I' I ' 5' ' ' ARG . . . . . . . . . . . . . 31.0 mtp180 -66.72 129.13 38.85 Favored 'General case' 0 N--CA 1.471 0.625 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.293 -178.281 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 46.2 m170 -99.72 130.97 45.98 Favored 'General case' 0 N--CA 1.474 0.768 0 N-CA-C 109.607 -0.516 . . . . 0.0 109.607 179.42 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 16.2 m-20 -72.05 138.02 47.57 Favored 'General case' 0 N--CA 1.466 0.336 0 O-C-N 123.539 0.525 . . . . 0.0 111.425 -179.546 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' I' I ' 8' ' ' SER . . . . . . . . . . . . . 8.5 t -142.26 -173.8 3.94 Favored 'General case' 0 N--CA 1.475 0.791 0 N-CA-C 109.078 -0.712 . . . . 0.0 109.078 178.388 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 119.46 12.66 6.65 Favored Glycine 0 N--CA 1.482 1.759 0 N-CA-C 111.864 -0.494 . . . . 0.0 111.864 179.185 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 47.5 p90 -59.15 128.38 36.86 Favored 'General case' 0 CA--C 1.541 0.625 0 N-CA-C 112.082 0.401 . . . . 0.0 112.082 -179.378 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 46.5 mt-10 -89.28 154.33 20.19 Favored 'General case' 0 N--CA 1.474 0.737 0 CA-C-O 121.101 0.477 . . . . 0.0 109.956 178.672 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 2.7 p -155.73 127.32 0.94 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.039 0 N-CA-C 108.373 -0.973 . . . . 0.0 108.373 178.722 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 50.2 m-70 -134.23 146.29 49.96 Favored 'General case' 0 N--CA 1.476 0.868 0 CA-C-N 115.276 -0.875 . . . . 0.0 111.145 -178.044 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 6.4 t60 -165.35 97.51 0.7 Allowed 'General case' 0 N--CA 1.484 1.244 0 CA-C-N 116.558 -0.292 . . . . 0.0 110.719 179.069 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' I' I ' 15' ' ' GLN . . . . . 0.556 HE22 ' H ' ' I' ' 37' ' ' GLY . 55.3 mt-30 -108.57 -172.75 2.12 Favored 'General case' 0 CA--C 1.499 -1.002 0 N-CA-C 108.458 -0.941 . . . . 0.0 108.458 -179.737 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' I' I ' 16' ' ' LYS . . . . . 0.403 ' C ' HD12 ' I' ' 17' ' ' LEU . 88.4 tttt -166.48 98.45 0.59 Allowed 'General case' 0 CA--C 1.54 0.565 0 CA-C-N 114.921 -1.036 . . . . 0.0 109.29 178.803 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' I' I ' 17' ' ' LEU . . . . . 0.589 HD12 ' N ' ' I' ' 17' ' ' LEU . 5.1 mp -105.97 161.99 13.98 Favored 'General case' 0 N--CA 1.486 1.355 0 N-CA-C 109.448 -0.575 . . . . 0.0 109.448 -179.628 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 40.6 t -142.58 118.5 5.56 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.154 0 C-N-CA 122.494 0.318 . . . . 0.0 110.487 178.849 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 46.7 m-85 -69.92 151.34 45.76 Favored 'General case' 0 C--N 1.367 1.365 0 N-CA-C 107.31 -1.367 . . . . 0.0 107.31 176.712 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 10.9 t80 -172.17 -54.67 0.02 OUTLIER 'General case' 0 N--CA 1.485 1.296 0 CA-C-N 117.843 0.292 . . . . 0.0 110.218 -179.518 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.69 90.72 0.0 OUTLIER 'General case' 0 CA--C 1.536 0.408 0 C-N-CA 123.7 0.8 . . . . 0.0 112.251 -179.936 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 37.5 tt0 -65.69 159.31 25.26 Favored 'General case' 0 N--CA 1.47 0.549 0 CA-C-N 114.751 -1.113 . . . . 0.0 109.993 179.326 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 11.1 m-20 -141.34 137.5 32.42 Favored 'General case' 0 N--CA 1.476 0.836 0 C-N-CA 122.872 0.469 . . . . 0.0 110.034 179.839 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' I' I ' 24' ' ' VAL . . . . . . . . . . . . . 14.9 t -92.68 -116.77 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.112 0 N-CA-C 108.691 -0.855 . . . . 0.0 108.691 179.729 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . -101.51 54.45 0.79 Allowed Glycine 0 N--CA 1.476 1.357 0 CA-C-N 118.556 0.617 . . . . 0.0 111.585 -179.759 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 80.4 p -83.31 123.96 30.14 Favored 'General case' 0 N--CA 1.469 0.5 0 N-CA-C 108.916 -0.772 . . . . 0.0 108.916 178.059 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 59.7 t30 -64.53 101.63 0.47 Allowed 'General case' 0 N--CA 1.473 0.681 0 N-CA-C 108.588 -0.893 . . . . 0.0 108.588 178.618 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 64.7 mttm -97.57 114.28 26.16 Favored 'General case' 0 N--CA 1.486 1.354 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 -178.952 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.45 -132.63 0.01 OUTLIER Glycine 0 CA--C 1.532 1.137 0 N-CA-C 110.803 -0.919 . . . . 0.0 110.803 179.093 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -112.73 126.09 55.02 Favored 'General case' 0 N--CA 1.471 0.586 0 C-N-CA 123.058 0.543 . . . . 0.0 109.614 179.601 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 68.3 mt -89.68 130.75 38.47 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.783 0 N-CA-C 107.264 -1.384 . . . . 0.0 107.264 178.61 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 16.2 mt -143.98 154.47 15.65 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.337 0 CA-C-N 118.892 0.769 . . . . 0.0 108.984 -179.807 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.75 48.84 73.19 Favored Glycine 0 CA--C 1.526 0.775 0 C-N-CA 121.678 -0.296 . . . . 0.0 112.792 179.134 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' I' I ' 34' ' ' LEU . . . . . 0.409 HD23 ' N ' ' I' ' 35' ' ' MET . 2.9 tt -98.84 121.94 41.43 Favored 'General case' 0 N--CA 1.478 0.947 0 N-CA-C 106.874 -1.528 . . . . 0.0 106.874 177.741 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' I' I ' 35' ' ' MET . . . . . 0.409 ' N ' HD23 ' I' ' 34' ' ' LEU . 28.2 ttt -153.53 159.72 42.3 Favored 'General case' 0 N--CA 1.478 0.963 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 179.616 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 90.9 t -159.54 149.75 6.73 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.224 0 N-CA-C 106.253 -1.758 . . . . 0.0 106.253 -179.804 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' I' I ' 37' ' ' GLY . . . . . 0.556 ' H ' HE22 ' I' ' 15' ' ' GLN . . . 56.94 72.79 0.53 Allowed Glycine 0 C--N 1.314 -0.69 0 C-N-CA 121.022 -0.609 . . . . 0.0 111.778 178.011 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 171.95 -154.4 21.66 Favored Glycine 0 N--CA 1.468 0.767 0 N-CA-C 110.529 -1.029 . . . . 0.0 110.529 179.257 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 33.8 m -126.61 142.84 42.0 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.064 0 C-N-CA 122.743 0.417 . . . . 0.0 109.994 179.943 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 15.5 t . . . . . 0 N--CA 1.465 0.306 0 CA-C-O 118.239 -0.886 . . . . 0.0 111.328 179.539 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . 0.408 ' N ' ' CB ' ' D' ' 1' ' ' ASP . 9.1 m-20 . . . . . 0 N--CA 1.487 1.387 0 N-CA-C 108.963 -0.754 . . . . 0.0 108.963 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.47 132.47 49.0 Favored 'General case' 0 CA--C 1.539 0.552 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.207 -179.876 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 39.3 tt0 -169.7 108.85 0.41 Allowed 'General case' 0 N--CA 1.469 0.516 0 N-CA-C 109.598 -0.519 . . . . 0.0 109.598 -179.206 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 78.9 m-85 -83.87 140.22 32.13 Favored 'General case' 0 N--CA 1.475 0.818 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 179.464 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 71.9 mtp180 -143.84 141.28 30.26 Favored 'General case' 0 N--CA 1.481 1.102 0 N-CA-C 109.079 -0.712 . . . . 0.0 109.079 -179.879 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 76.7 m80 -149.53 119.92 7.37 Favored 'General case' 0 N--CA 1.469 0.502 0 N-CA-C 108.79 -0.819 . . . . 0.0 108.79 179.147 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 8.5 m-20 -68.02 149.95 49.06 Favored 'General case' 0 CA--C 1.53 0.196 0 CA-C-N 116.279 -0.419 . . . . 0.0 111.16 -179.391 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 7.6 t -167.13 171.36 11.0 Favored 'General case' 0 N--CA 1.472 0.655 0 N-CA-C 109.551 -0.537 . . . . 0.0 109.551 178.581 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.48 23.65 2.31 Favored Glycine 0 N--CA 1.488 2.156 0 N-CA-C 112.209 -0.356 . . . . 0.0 112.209 179.37 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 42.8 p90 -56.64 128.37 36.02 Favored 'General case' 0 N--CA 1.475 0.815 0 N-CA-C 112.078 0.399 . . . . 0.0 112.078 -179.83 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.506 ' CG ' HD21 ' C' ' 27' ' ' ASN . 45.5 mt-10 -85.05 154.66 21.94 Favored 'General case' 0 C--N 1.344 0.358 0 N-CA-C 109.08 -0.711 . . . . 0.0 109.08 178.535 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -153.69 129.5 1.72 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.371 0 N-CA-C 108.151 -1.055 . . . . 0.0 108.151 178.928 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 48.6 m-70 -134.93 144.99 47.77 Favored 'General case' 0 N--CA 1.489 1.49 0 CA-C-N 118.683 0.674 . . . . 0.0 111.104 -179.116 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -165.9 98.31 0.65 Allowed 'General case' 0 N--CA 1.482 1.169 0 CA-C-N 116.603 -0.271 . . . . 0.0 110.984 179.628 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . 0.548 HE22 ' H ' ' A' ' 37' ' ' GLY . 61.7 mt-30 -108.54 -172.05 1.98 Allowed 'General case' 0 CA--C 1.503 -0.831 0 N-CA-C 108.174 -1.047 . . . . 0.0 108.174 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -165.96 97.24 0.63 Allowed 'General case' 0 N--CA 1.471 0.613 0 CA-C-N 115.16 -0.927 . . . . 0.0 109.348 178.739 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.585 HD12 ' N ' ' A' ' 17' ' ' LEU . 4.7 mp -106.03 164.18 12.18 Favored 'General case' 0 N--CA 1.488 1.474 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 179.931 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 49.9 t -141.71 119.18 8.07 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.339 0 CA-C-O 118.888 -0.577 . . . . 0.0 109.98 179.657 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 50.9 m-85 -69.95 159.23 34.13 Favored 'General case' 0 N--CA 1.48 1.071 0 N-CA-C 107.573 -1.269 . . . . 0.0 107.573 177.287 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 12.9 t80 -171.44 -58.02 0.02 OUTLIER 'General case' 0 N--CA 1.485 1.305 0 CA-C-O 122.33 1.062 . . . . 0.0 109.772 179.481 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -38.83 90.48 0.0 OUTLIER 'General case' 0 C--O 1.232 0.165 0 CA-C-N 113.888 -1.505 . . . . 0.0 112.866 -177.929 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 54.4 tt0 -67.57 157.93 33.23 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-N 115.006 -0.997 . . . . 0.0 110.532 179.145 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 67.3 m-20 -140.02 137.72 34.87 Favored 'General case' 0 N--CA 1.481 1.112 0 C-N-CA 122.891 0.476 . . . . 0.0 110.339 179.762 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 17.2 t -84.42 -116.44 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.912 0 N-CA-C 108.51 -0.922 . . . . 0.0 108.51 179.541 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -110.67 54.5 0.54 Allowed Glycine 0 N--CA 1.473 1.137 0 N-CA-C 111.21 -0.756 . . . . 0.0 111.21 -179.935 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 70.5 p -80.12 126.24 30.83 Favored 'General case' 0 C--O 1.221 -0.434 0 N-CA-C 108.983 -0.747 . . . . 0.0 108.983 178.422 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . 0.52 HD21 ' CG ' ' B' ' 11' ' ' GLU . 50.0 t30 -66.91 100.01 0.69 Allowed 'General case' 0 N--CA 1.472 0.644 0 N-CA-C 108.693 -0.854 . . . . 0.0 108.693 178.582 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 66.7 mttm -96.42 120.13 36.16 Favored 'General case' 0 N--CA 1.484 1.243 0 N-CA-C 110.087 -0.338 . . . . 0.0 110.087 -179.081 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.78 -126.36 0.01 OUTLIER Glycine 0 CA--C 1.532 1.154 0 N-CA-C 110.488 -1.045 . . . . 0.0 110.488 178.615 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -127.48 133.83 49.85 Favored 'General case' 0 N--CA 1.479 1.0 0 N-CA-C 109.294 -0.632 . . . . 0.0 109.294 179.112 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 66.9 mt -83.22 138.61 19.01 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.589 0 N-CA-C 107.136 -1.431 . . . . 0.0 107.136 178.54 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 18.7 mt -128.59 128.75 68.29 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.961 0 O-C-N 123.504 0.503 . . . . 0.0 110.123 -178.547 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 60.78 79.25 0.12 Allowed Glycine 0 CA--C 1.527 0.837 0 CA-C-N 116.003 -0.544 . . . . 0.0 112.95 178.898 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.402 HD23 ' N ' ' A' ' 35' ' ' MET . 2.0 tt -110.94 118.85 37.2 Favored 'General case' 0 N--CA 1.478 0.926 0 N-CA-C 106.932 -1.507 . . . . 0.0 106.932 177.432 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' MET . . . . . 0.402 ' N ' HD23 ' A' ' 34' ' ' LEU . 8.8 ttt -155.04 161.02 41.45 Favored 'General case' 0 N--CA 1.469 0.504 0 N-CA-C 109.077 -0.712 . . . . 0.0 109.077 179.339 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 93.6 t -157.96 150.73 8.14 Favored 'Isoleucine or valine' 0 C--O 1.234 0.277 0 N-CA-C 106.83 -1.545 . . . . 0.0 106.83 -179.598 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . 0.548 ' H ' HE22 ' A' ' 15' ' ' GLN . . . 55.6 75.17 0.25 Allowed Glycine 0 C--N 1.314 -0.689 0 CA-C-N 115.703 -0.68 . . . . 0.0 111.739 178.332 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 168.83 -148.72 12.65 Favored Glycine 0 CA--C 1.519 0.305 0 N-CA-C 110.692 -0.963 . . . . 0.0 110.692 179.742 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 21.1 m -132.9 142.47 42.2 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.887 0 N-CA-C 109.624 -0.509 . . . . 0.0 109.624 179.82 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 21.3 t . . . . . 0 N--CA 1.468 0.43 0 CA-C-O 117.851 -1.071 . . . . 0.0 110.725 179.225 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' B' B ' 1' ' ' ASP . . . . . 0.404 ' N ' ' CB ' ' E' ' 1' ' ' ASP . 9.3 m-20 . . . . . 0 N--CA 1.488 1.451 0 N-CA-C 109.112 -0.699 . . . . 0.0 109.112 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.5 132.35 48.69 Favored 'General case' 0 CA--C 1.538 0.517 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.218 -179.904 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 3' ' ' GLU . . . . . . . . . . . . . 39.2 tt0 -169.45 108.89 0.43 Allowed 'General case' 0 N--CA 1.47 0.531 0 N-CA-C 109.536 -0.542 . . . . 0.0 109.536 -179.107 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 79.8 m-85 -83.92 140.06 32.19 Favored 'General case' 0 N--CA 1.474 0.766 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 179.435 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 71.7 mtp180 -143.94 141.39 30.19 Favored 'General case' 0 N--CA 1.481 1.079 0 N-CA-C 109.136 -0.69 . . . . 0.0 109.136 -179.861 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 76.9 m80 -149.66 120.01 7.36 Favored 'General case' 0 N--CA 1.471 0.581 0 N-CA-C 108.772 -0.825 . . . . 0.0 108.772 179.117 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 7' ' ' ASP . . . . . . . . . . . . . 8.5 m-20 -67.96 149.45 49.75 Favored 'General case' 0 CA--C 1.531 0.217 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.226 -179.414 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 8' ' ' SER . . . . . . . . . . . . . 7.4 t -166.71 171.57 11.4 Favored 'General case' 0 N--CA 1.473 0.691 0 N-CA-C 109.583 -0.525 . . . . 0.0 109.583 178.501 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.26 23.94 2.31 Favored Glycine 0 N--CA 1.488 2.135 0 N-CA-C 112.122 -0.391 . . . . 0.0 112.122 179.425 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 42.4 p90 -56.9 128.11 35.18 Favored 'General case' 0 N--CA 1.473 0.681 0 N-CA-C 112.159 0.429 . . . . 0.0 112.159 -179.864 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 11' ' ' GLU . . . . . 0.52 ' CG ' HD21 ' A' ' 27' ' ' ASN . 45.5 mt-10 -84.79 154.61 22.26 Favored 'General case' 0 N--CA 1.469 0.486 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 178.532 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -153.59 129.32 1.69 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.333 0 N-CA-C 108.268 -1.012 . . . . 0.0 108.268 178.914 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 48.6 m-70 -134.82 145.16 48.08 Favored 'General case' 0 N--CA 1.49 1.559 0 CA-C-N 118.556 0.616 . . . . 0.0 111.052 -179.062 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -166.11 98.33 0.63 Allowed 'General case' 0 N--CA 1.483 1.214 0 CA-C-N 116.607 -0.269 . . . . 0.0 110.96 179.654 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . 0.554 HE22 ' H ' ' B' ' 37' ' ' GLY . 61.9 mt-30 -108.56 -172.2 2.01 Favored 'General case' 0 CA--C 1.503 -0.854 0 N-CA-C 108.201 -1.037 . . . . 0.0 108.201 -179.901 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -165.95 96.95 0.63 Allowed 'General case' 0 CA--C 1.54 0.581 0 CA-C-N 115.121 -0.945 . . . . 0.0 109.337 178.817 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . 0.579 ' N ' HD12 ' B' ' 17' ' ' LEU . 4.9 mp -105.88 164.14 12.18 Favored 'General case' 0 N--CA 1.487 1.398 0 N-CA-C 108.611 -0.885 . . . . 0.0 108.611 179.868 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 53.9 t -141.69 119.16 8.08 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.269 0 CA-C-O 118.939 -0.553 . . . . 0.0 109.982 179.577 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 51.6 m-85 -70.41 159.3 34.45 Favored 'General case' 0 N--CA 1.479 0.983 0 N-CA-C 107.557 -1.275 . . . . 0.0 107.557 177.248 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 13.9 t80 -172.14 -57.25 0.02 OUTLIER 'General case' 0 N--CA 1.483 1.211 0 CA-C-O 122.2 1.0 . . . . 0.0 109.792 179.522 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -38.88 90.83 0.0 OUTLIER 'General case' 0 CA--C 1.529 0.159 0 CA-C-N 114.136 -1.393 . . . . 0.0 112.797 -178.005 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 54.2 tt0 -67.93 157.71 34.39 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 115.028 -0.987 . . . . 0.0 110.547 179.314 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 67.3 m-20 -139.86 137.75 35.16 Favored 'General case' 0 N--CA 1.481 1.082 0 C-N-CA 122.954 0.502 . . . . 0.0 110.287 179.71 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 18.1 t -84.66 -116.4 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.988 0 N-CA-C 108.577 -0.897 . . . . 0.0 108.577 179.665 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -110.13 54.37 0.55 Allowed Glycine 0 C--N 1.349 1.253 0 N-CA-C 111.167 -0.773 . . . . 0.0 111.167 -179.951 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 73.1 p -80.39 125.91 30.51 Favored 'General case' 0 C--O 1.221 -0.432 0 N-CA-C 109.037 -0.727 . . . . 0.0 109.037 178.434 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 27' ' ' ASN . . . . . 0.534 HD21 ' CG ' ' C' ' 11' ' ' GLU . 50.4 t30 -66.73 100.41 0.7 Allowed 'General case' 0 N--CA 1.473 0.708 0 N-CA-C 108.657 -0.868 . . . . 0.0 108.657 178.613 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 66.7 mttm -96.81 120.04 36.41 Favored 'General case' 0 N--CA 1.483 1.205 0 N-CA-C 110.132 -0.321 . . . . 0.0 110.132 -179.035 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.57 -126.04 0.01 OUTLIER Glycine 0 CA--C 1.534 1.28 0 N-CA-C 110.453 -1.059 . . . . 0.0 110.453 178.618 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.13 133.75 49.02 Favored 'General case' 0 N--CA 1.48 1.026 0 N-CA-C 109.269 -0.641 . . . . 0.0 109.269 179.185 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 67.0 mt -83.15 138.6 19.04 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.476 0 N-CA-C 107.204 -1.406 . . . . 0.0 107.204 178.535 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 19.1 mt -128.53 128.42 68.02 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.928 0 O-C-N 123.537 0.523 . . . . 0.0 110.21 -178.412 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 60.96 78.98 0.13 Allowed Glycine 0 CA--C 1.526 0.777 0 CA-C-N 116.016 -0.538 . . . . 0.0 112.955 178.848 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 34' ' ' LEU . . . . . 0.401 HD23 ' N ' ' B' ' 35' ' ' MET . 2.0 tt -110.71 118.88 37.38 Favored 'General case' 0 N--CA 1.476 0.869 0 N-CA-C 106.94 -1.504 . . . . 0.0 106.94 177.386 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 35' ' ' MET . . . . . 0.401 ' N ' HD23 ' B' ' 34' ' ' LEU . 8.8 ttt -155.0 161.05 41.48 Favored 'General case' 0 N--CA 1.47 0.552 0 N-CA-C 109.096 -0.705 . . . . 0.0 109.096 179.247 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 92.9 t -158.04 150.73 8.06 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.192 0 N-CA-C 106.744 -1.576 . . . . 0.0 106.744 -179.555 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . 0.554 ' H ' HE22 ' B' ' 15' ' ' GLN . . . 55.44 75.31 0.25 Allowed Glycine 0 C--N 1.314 -0.654 0 CA-C-N 115.628 -0.714 . . . . 0.0 111.797 178.422 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 168.57 -149.14 13.4 Favored Glycine 0 CA--C 1.519 0.292 0 N-CA-C 110.686 -0.966 . . . . 0.0 110.686 179.76 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 21.5 m -132.36 142.7 41.97 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.834 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 179.65 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 21.3 t . . . . . 0 N--CA 1.467 0.41 0 CA-C-O 117.789 -1.101 . . . . 0.0 110.765 179.309 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' C' C ' 1' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 . . . . . 0 N--CA 1.487 1.423 0 N-CA-C 109.056 -0.72 . . . . 0.0 109.056 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' C' C ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.35 132.48 49.12 Favored 'General case' 0 CA--C 1.54 0.57 0 CA-C-N 116.367 -0.379 . . . . 0.0 110.162 -179.845 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 3' ' ' GLU . . . . . . . . . . . . . 39.5 tt0 -169.64 108.89 0.41 Allowed 'General case' 0 N--CA 1.47 0.554 0 N-CA-C 109.592 -0.522 . . . . 0.0 109.592 -179.274 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 78.6 m-85 -83.8 139.98 32.34 Favored 'General case' 0 N--CA 1.475 0.797 0 N-CA-C 109.878 -0.416 . . . . 0.0 109.878 179.459 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 71.9 mtp180 -143.76 141.36 30.4 Favored 'General case' 0 N--CA 1.482 1.131 0 N-CA-C 109.077 -0.712 . . . . 0.0 109.077 -179.905 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 76.8 m80 -149.63 119.76 7.24 Favored 'General case' 0 N--CA 1.469 0.523 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 179.145 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 7' ' ' ASP . . . . . . . . . . . . . 8.2 m-20 -67.7 149.55 49.85 Favored 'General case' 0 N--CA 1.463 0.199 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.227 -179.41 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 8' ' ' SER . . . . . . . . . . . . . 7.6 t -166.97 171.14 11.44 Favored 'General case' 0 N--CA 1.473 0.682 0 N-CA-C 109.499 -0.556 . . . . 0.0 109.499 178.429 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.83 23.76 2.21 Favored Glycine 0 N--CA 1.487 2.093 0 N-CA-C 112.099 -0.4 . . . . 0.0 112.099 179.355 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 42.1 p90 -56.63 127.99 34.14 Favored 'General case' 0 N--CA 1.473 0.718 0 N-CA-C 112.125 0.417 . . . . 0.0 112.125 -179.847 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 11' ' ' GLU . . . . . 0.534 ' CG ' HD21 ' B' ' 27' ' ' ASN . 45.8 mt-10 -84.74 154.73 22.24 Favored 'General case' 0 N--CA 1.468 0.448 0 N-CA-C 109.126 -0.694 . . . . 0.0 109.126 178.507 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -153.61 129.24 1.65 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.293 0 N-CA-C 108.274 -1.01 . . . . 0.0 108.274 178.863 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 48.7 m-70 -134.71 144.95 48.05 Favored 'General case' 0 N--CA 1.489 1.517 0 CA-C-N 118.635 0.652 . . . . 0.0 111.043 -179.012 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -165.95 98.51 0.64 Allowed 'General case' 0 N--CA 1.483 1.184 0 CA-C-N 116.578 -0.283 . . . . 0.0 111.013 179.665 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 15' ' ' GLN . . . . . 0.541 HE22 ' H ' ' C' ' 37' ' ' GLY . 62.3 mt-30 -108.91 -172.21 2.0 Favored 'General case' 0 CA--C 1.501 -0.939 0 N-CA-C 108.276 -1.009 . . . . 0.0 108.276 -179.959 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 16' ' ' LYS . . . . . 0.402 ' C ' HD12 ' C' ' 17' ' ' LEU . 88.4 tttt -165.87 97.38 0.64 Allowed 'General case' 0 CA--C 1.54 0.587 0 CA-C-N 115.104 -0.953 . . . . 0.0 109.348 178.749 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 17' ' ' LEU . . . . . 0.574 HD12 ' N ' ' C' ' 17' ' ' LEU . 4.8 mp -106.07 163.99 12.34 Favored 'General case' 0 N--CA 1.488 1.433 0 N-CA-C 108.577 -0.897 . . . . 0.0 108.577 179.937 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 53.7 t -141.62 119.19 8.28 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.283 0 CA-C-O 119.05 -0.5 . . . . 0.0 109.885 179.529 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 51.2 m-85 -70.47 159.28 34.54 Favored 'General case' 0 N--CA 1.478 0.964 0 N-CA-C 107.469 -1.308 . . . . 0.0 107.469 177.299 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 14.2 t80 -171.96 -57.33 0.02 OUTLIER 'General case' 0 N--CA 1.482 1.15 0 CA-C-O 122.24 1.019 . . . . 0.0 109.847 179.461 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -38.77 90.72 0.0 OUTLIER 'General case' 0 C--O 1.232 0.144 0 CA-C-N 114.129 -1.396 . . . . 0.0 112.804 -178.024 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 54.0 tt0 -67.88 157.7 34.31 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.122 -0.945 . . . . 0.0 110.595 179.254 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 67.4 m-20 -139.86 137.96 35.33 Favored 'General case' 0 N--CA 1.482 1.134 0 C-N-CA 122.854 0.462 . . . . 0.0 110.245 179.728 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 17.7 t -84.85 -116.44 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.985 0 N-CA-C 108.506 -0.924 . . . . 0.0 108.506 179.693 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -110.12 54.27 0.55 Allowed Glycine 0 N--CA 1.474 1.227 0 N-CA-C 111.175 -0.77 . . . . 0.0 111.175 -179.865 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 73.8 p -80.32 126.18 30.82 Favored 'General case' 0 C--O 1.22 -0.455 0 N-CA-C 109.07 -0.715 . . . . 0.0 109.07 178.414 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 27' ' ' ASN . . . . . 0.506 HD21 ' CG ' ' A' ' 11' ' ' GLU . 51.0 t30 -66.94 100.28 0.72 Allowed 'General case' 0 N--CA 1.473 0.704 0 N-CA-C 108.673 -0.862 . . . . 0.0 108.673 178.563 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 66.9 mttm -96.79 119.68 35.72 Favored 'General case' 0 N--CA 1.482 1.172 0 N-CA-C 110.238 -0.282 . . . . 0.0 110.238 -179.169 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.31 -125.96 0.01 OUTLIER Glycine 0 CA--C 1.534 1.268 0 N-CA-C 110.534 -1.026 . . . . 0.0 110.534 178.727 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.01 133.7 49.17 Favored 'General case' 0 N--CA 1.482 1.14 0 N-CA-C 109.263 -0.643 . . . . 0.0 109.263 179.171 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 67.3 mt -83.12 138.54 19.15 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.456 0 N-CA-C 107.129 -1.434 . . . . 0.0 107.129 178.538 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 18.0 mt -128.5 128.74 68.44 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.987 0 O-C-N 123.626 0.579 . . . . 0.0 110.16 -178.519 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 60.67 78.93 0.13 Allowed Glycine 0 CA--C 1.527 0.797 0 CA-C-N 116.018 -0.537 . . . . 0.0 113.033 178.844 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 34' ' ' LEU . . . . . 0.4 HD23 ' N ' ' C' ' 35' ' ' MET . 2.0 tt -110.58 118.94 37.58 Favored 'General case' 0 N--CA 1.477 0.89 0 N-CA-C 106.902 -1.518 . . . . 0.0 106.902 177.37 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 35' ' ' MET . . . . . 0.4 ' N ' HD23 ' C' ' 34' ' ' LEU . 8.7 ttt -155.07 160.94 41.38 Favored 'General case' 0 N--CA 1.469 0.501 0 N-CA-C 109.125 -0.694 . . . . 0.0 109.125 179.185 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 93.0 t -157.93 150.57 8.28 Favored 'Isoleucine or valine' 0 C--O 1.233 0.203 0 N-CA-C 106.74 -1.578 . . . . 0.0 106.74 -179.566 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 37' ' ' GLY . . . . . 0.541 ' H ' HE22 ' C' ' 15' ' ' GLN . . . 55.7 75.32 0.25 Allowed Glycine 0 C--N 1.314 -0.649 0 CA-C-N 115.691 -0.686 . . . . 0.0 111.814 178.368 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 168.61 -148.78 12.84 Favored Glycine 0 CA--C 1.52 0.382 0 N-CA-C 110.631 -0.988 . . . . 0.0 110.631 179.862 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 21.5 m -132.89 142.56 41.97 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.814 0 N-CA-C 109.696 -0.483 . . . . 0.0 109.696 179.707 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 21.3 t . . . . . 0 N--CA 1.468 0.443 0 CA-C-O 117.772 -1.109 . . . . 0.0 110.801 179.376 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' D' D ' 1' ' ' ASP . . . . . 0.408 ' CB ' ' N ' ' A' ' 1' ' ' ASP . 9.4 m-20 . . . . . 0 N--CA 1.491 1.588 0 N-CA-C 109.037 -0.727 . . . . 0.0 109.037 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.28 131.02 46.1 Favored 'General case' 0 CA--C 1.536 0.412 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.371 179.969 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 3' ' ' GLU . . . . . . . . . . . . . 39.2 tt0 -169.39 110.91 0.47 Allowed 'General case' 0 N--CA 1.469 0.494 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 179.698 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 87.7 m-85 -87.23 147.71 25.44 Favored 'General case' 0 C--N 1.363 1.155 0 C-N-CA 118.592 -1.243 . . . . 0.0 108.283 179.695 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 5' ' ' ARG . . . . . . . . . . . . . 71.2 mtp180 -147.45 141.35 25.84 Favored 'General case' 0 N--CA 1.475 0.82 0 N-CA-C 108.961 -0.755 . . . . 0.0 108.961 179.746 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 77.1 m80 -149.17 123.6 9.67 Favored 'General case' 0 CA--C 1.538 0.51 0 N-CA-C 107.891 -1.152 . . . . 0.0 107.891 175.875 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 7' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -63.3 133.55 54.34 Favored 'General case' 0 C--N 1.321 -0.668 0 C-N-CA 127.049 2.139 . . . . 0.0 114.697 176.251 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 8' ' ' SER . . . . . . . . . . . . . 6.6 t -154.03 173.56 15.85 Favored 'General case' 0 N--CA 1.478 0.951 0 CA-C-N 118.533 0.606 . . . . 0.0 110.296 177.074 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 124.29 20.45 2.44 Favored Glycine 0 N--CA 1.485 1.917 0 N-CA-C 112.126 -0.39 . . . . 0.0 112.126 176.579 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 37.2 p90 -55.81 130.46 43.56 Favored 'General case' 0 CA--C 1.546 0.804 0 CA-C-O 121.126 0.489 . . . . 0.0 111.889 -177.355 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 11' ' ' GLU . . . . . 0.478 ' CG ' HD21 ' F' ' 27' ' ' ASN . 46.0 mt-10 -85.26 152.42 23.33 Favored 'General case' 0 N--CA 1.473 0.694 0 N-CA-C 109.732 -0.469 . . . . 0.0 109.732 177.763 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -149.51 130.05 4.41 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.472 0 N-CA-C 108.222 -1.029 . . . . 0.0 108.222 175.593 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 46.9 m-70 -129.64 148.07 51.49 Favored 'General case' 0 N--CA 1.483 1.201 0 CA-C-N 118.009 0.368 . . . . 0.0 111.423 176.708 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -165.37 104.76 0.74 Allowed 'General case' 0 N--CA 1.483 1.207 0 N-CA-C 109.623 -0.51 . . . . 0.0 109.623 173.453 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' D' D ' 15' ' ' GLN . . . . . 0.555 HE22 ' H ' ' D' ' 37' ' ' GLY . 61.5 mt-30 -112.02 -175.66 2.74 Favored 'General case' 0 CA--C 1.493 -1.214 0 N-CA-C 108.019 -1.104 . . . . 0.0 108.019 179.348 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' D' D ' 16' ' ' LYS . . . . . 0.444 ' C ' HD12 ' D' ' 17' ' ' LEU . 88.7 tttt -162.09 105.9 1.19 Allowed 'General case' 0 CA--C 1.538 0.506 0 N-CA-C 107.603 -1.258 . . . . 0.0 107.603 175.386 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' D' D ' 17' ' ' LEU . . . . . 0.524 HD12 ' N ' ' D' ' 17' ' ' LEU . 5.7 mp -112.69 163.07 15.0 Favored 'General case' 0 N--CA 1.487 1.407 0 N-CA-C 108.095 -1.076 . . . . 0.0 108.095 179.536 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 48.1 t -140.92 123.59 15.56 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.072 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 176.158 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 76.1 m-85 -62.77 151.3 39.06 Favored 'General case' 0 C--N 1.351 0.652 0 C-N-CA 124.688 1.195 . . . . 0.0 110.386 170.774 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 9.0 t80 -169.86 -66.59 0.02 OUTLIER 'General case' 0 N--CA 1.476 0.827 0 N-CA-C 107.816 -1.179 . . . . 0.0 107.816 -179.707 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -37.83 96.11 0.01 OUTLIER 'General case' 0 CA--C 1.536 0.425 0 CA-C-N 113.919 -1.491 . . . . 0.0 111.583 -174.353 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 54.1 tt0 -69.98 158.52 35.48 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 113.459 -1.7 . . . . 0.0 110.17 178.767 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 68.1 m-20 -140.14 141.32 36.07 Favored 'General case' 0 N--CA 1.477 0.875 0 N-CA-C 109.496 -0.557 . . . . 0.0 109.496 178.581 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 24' ' ' VAL . . . . . . . . . . . . . 19.7 t -87.7 -119.19 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.486 1.372 0 N-CA-C 107.91 -1.144 . . . . 0.0 107.91 179.816 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . -113.93 61.98 0.33 Allowed Glycine 0 C--N 1.371 2.495 0 C-N-CA 118.073 -2.013 . . . . 0.0 109.441 178.612 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 89.1 p -70.54 121.37 17.7 Favored 'General case' 0 C--O 1.24 0.601 0 CA-C-O 116.521 -1.704 . . . . 0.0 112.184 169.162 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 27' ' ' ASN . . . . . 0.457 HD21 ' CG ' ' E' ' 11' ' ' GLU . 57.1 t30 -61.4 101.83 0.2 Allowed 'General case' 0 N--CA 1.475 0.788 0 CA-C-N 121.625 2.011 . . . . 0.0 109.489 172.464 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 66.5 mttm -100.17 121.44 41.44 Favored 'General case' 0 N--CA 1.488 1.453 0 CA-C-N 119.681 1.128 . . . . 0.0 109.378 178.673 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -53.96 -130.12 0.0 OUTLIER Glycine 0 CA--C 1.529 0.938 0 CA-C-N 115.535 -0.757 . . . . 0.0 112.284 175.008 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -125.23 139.84 53.38 Favored 'General case' 0 C--N 1.37 1.498 0 N-CA-C 108.666 -0.864 . . . . 0.0 108.666 174.278 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 66.4 mt -83.9 141.12 15.2 Favored 'Isoleucine or valine' 0 C--O 1.239 0.527 0 N-CA-C 107.145 -1.428 . . . . 0.0 107.145 176.29 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 25.6 mt -131.31 132.89 62.81 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.058 0 N-CA-C 108.59 -0.893 . . . . 0.0 108.59 178.253 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.88 77.16 0.21 Allowed Glycine 0 C--O 1.248 1.014 0 CA-C-O 118.351 -1.249 . . . . 0.0 112.618 178.791 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 2.5 tt -109.87 131.06 55.41 Favored 'General case' 0 C--N 1.376 1.756 0 N-CA-C 104.135 -2.543 . . . . 0.0 104.135 174.722 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 8.5 ttt -157.12 166.69 32.56 Favored 'General case' 0 C--O 1.219 -0.544 0 N-CA-C 108.794 -0.817 . . . . 0.0 108.794 176.44 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 88.8 t -163.57 154.78 2.45 Favored 'Isoleucine or valine' 0 C--O 1.24 0.566 0 N-CA-C 105.476 -2.046 . . . . 0.0 105.476 175.075 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 37' ' ' GLY . . . . . 0.555 ' H ' HE22 ' D' ' 15' ' ' GLN . . . 61.15 66.54 2.61 Favored Glycine 0 N--CA 1.444 -0.769 0 C-N-CA 117.875 -2.107 . . . . 0.0 113.674 177.125 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 166.82 -147.67 12.28 Favored Glycine 0 N--CA 1.466 0.688 0 CA-C-O 117.807 -1.552 . . . . 0.0 112.2 -179.045 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 22.4 m -130.11 142.88 42.64 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.112 0 CA-C-N 119.304 1.552 . . . . 0.0 109.429 -179.439 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 18.7 t . . . . . 0 C--O 1.214 -0.776 0 N-CA-C 109.169 -0.678 . . . . 0.0 109.169 174.944 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' E' E ' 1' ' ' ASP . . . . . 0.404 ' CB ' ' N ' ' B' ' 1' ' ' ASP . 9.7 m-20 . . . . . 0 N--CA 1.49 1.545 0 N-CA-C 109.174 -0.676 . . . . 0.0 109.174 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' E' E ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.3 130.72 44.94 Favored 'General case' 0 CA--C 1.535 0.396 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.369 179.843 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' E' E ' 3' ' ' GLU . . . . . . . . . . . . . 39.4 tt0 -169.03 108.95 0.46 Allowed 'General case' 0 N--CA 1.47 0.557 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 -179.844 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 79.2 m-85 -84.64 140.28 31.46 Favored 'General case' 0 N--CA 1.475 0.811 0 N-CA-C 109.949 -0.389 . . . . 0.0 109.949 179.4 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' E' E ' 5' ' ' ARG . . . . . . . . . . . . . 71.5 mtp180 -143.77 142.26 30.82 Favored 'General case' 0 N--CA 1.476 0.842 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 179.886 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 76.7 m80 -150.53 118.24 6.17 Favored 'General case' 0 N--CA 1.472 0.662 0 N-CA-C 108.926 -0.768 . . . . 0.0 108.926 179.129 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' E' E ' 7' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -66.16 149.63 50.01 Favored 'General case' 0 N--CA 1.465 0.289 0 O-C-N 123.542 0.526 . . . . 0.0 111.559 -179.606 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' E' E ' 8' ' ' SER . . . . . . . . . . . . . 6.7 t -167.12 172.53 9.94 Favored 'General case' 0 N--CA 1.477 0.891 0 CA-C-N 115.86 -0.609 . . . . 0.0 109.563 178.033 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.95 23.67 2.19 Favored Glycine 0 N--CA 1.482 1.716 0 N-CA-C 112.018 -0.433 . . . . 0.0 112.018 179.096 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 39.2 p90 -56.18 127.26 29.82 Favored 'General case' 0 N--CA 1.473 0.724 0 N-CA-C 112.639 0.607 . . . . 0.0 112.639 -179.149 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' E' E ' 11' ' ' GLU . . . . . 0.457 ' CG ' HD21 ' D' ' 27' ' ' ASN . 46.3 mt-10 -83.41 155.55 23.41 Favored 'General case' 0 N--CA 1.474 0.734 0 N-CA-C 109.302 -0.629 . . . . 0.0 109.302 178.033 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -155.67 128.34 1.09 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.534 0 N-CA-C 108.357 -0.979 . . . . 0.0 108.357 178.782 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 47.5 m-70 -135.17 143.18 46.33 Favored 'General case' 0 N--CA 1.48 1.074 0 CA-C-O 120.746 0.308 . . . . 0.0 111.329 -177.875 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -164.83 98.68 0.77 Allowed 'General case' 0 N--CA 1.488 1.472 0 CA-C-N 116.677 -0.238 . . . . 0.0 110.973 179.73 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' E' E ' 15' ' ' GLN . . . . . 0.546 HE22 ' H ' ' E' ' 37' ' ' GLY . 62.1 mt-30 -108.4 -171.91 1.95 Allowed 'General case' 0 CA--C 1.502 -0.883 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 -179.831 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -166.27 97.31 0.6 Allowed 'General case' 0 CA--C 1.541 0.629 0 CA-C-N 115.043 -0.98 . . . . 0.0 109.327 178.648 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' E' E ' 17' ' ' LEU . . . . . 0.568 ' N ' HD12 ' E' ' 17' ' ' LEU . 4.8 mp -105.85 163.56 12.63 Favored 'General case' 0 N--CA 1.49 1.545 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 -179.805 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 40.3 t -141.9 118.57 6.99 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.352 0 C-N-CA 122.612 0.365 . . . . 0.0 110.492 179.126 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 50.9 m-85 -69.49 156.77 38.35 Favored 'General case' 0 C--N 1.357 0.933 0 N-CA-C 107.336 -1.357 . . . . 0.0 107.336 176.56 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 12.4 t80 -173.41 -54.9 0.02 OUTLIER 'General case' 0 N--CA 1.485 1.28 0 CA-C-O 121.822 0.82 . . . . 0.0 110.288 179.457 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.96 89.31 0.0 OUTLIER 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 114.346 -1.297 . . . . 0.0 112.686 -178.783 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 54.7 tt0 -66.14 158.19 29.26 Favored 'General case' 0 N--CA 1.472 0.656 0 CA-C-N 114.823 -1.08 . . . . 0.0 110.651 179.651 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 66.0 m-20 -140.56 137.59 33.85 Favored 'General case' 0 N--CA 1.479 1.005 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.442 179.881 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 21.7 t -84.79 -115.45 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.039 0 N-CA-C 108.681 -0.859 . . . . 0.0 108.681 179.649 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . -110.61 54.16 0.55 Allowed Glycine 0 C--N 1.347 1.163 0 N-CA-C 111.457 -0.657 . . . . 0.0 111.457 -179.715 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 69.0 p -79.75 125.67 29.97 Favored 'General case' 0 N--CA 1.474 0.773 0 N-CA-C 109.384 -0.599 . . . . 0.0 109.384 178.078 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' E' E ' 27' ' ' ASN . . . . . 0.49 HD21 ' CG ' ' F' ' 11' ' ' GLU . 52.5 t30 -66.72 99.5 0.61 Allowed 'General case' 0 N--CA 1.471 0.601 0 N-CA-C 108.081 -1.081 . . . . 0.0 108.081 178.382 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 66.4 mttm -96.44 119.3 34.66 Favored 'General case' 0 N--CA 1.484 1.252 0 N-CA-C 109.995 -0.372 . . . . 0.0 109.995 -178.748 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.57 -124.88 0.01 OUTLIER Glycine 0 CA--C 1.538 1.525 0 N-CA-C 110.95 -0.86 . . . . 0.0 110.95 178.601 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.74 133.33 48.08 Favored 'General case' 0 N--CA 1.482 1.158 0 N-CA-C 109.581 -0.526 . . . . 0.0 109.581 179.65 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 66.3 mt -82.65 138.97 18.5 Favored 'Isoleucine or valine' 0 C--O 1.237 0.405 0 N-CA-C 107.029 -1.471 . . . . 0.0 107.029 178.434 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 21.0 mt -128.32 129.06 69.05 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.865 0 N-CA-C 109.566 -0.531 . . . . 0.0 109.566 -179.433 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 60.97 80.28 0.1 Allowed Glycine 0 CA--C 1.524 0.641 0 CA-C-N 116.064 -0.516 . . . . 0.0 113.505 179.172 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 2.0 tt -111.77 118.86 36.74 Favored 'General case' 0 N--CA 1.477 0.916 0 N-CA-C 107.003 -1.481 . . . . 0.0 107.003 177.34 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 8.6 ttt -154.14 162.64 41.05 Favored 'General case' 0 C--O 1.211 -0.944 0 N-CA-C 108.744 -0.835 . . . . 0.0 108.744 179.203 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 84.1 t -159.71 150.53 6.33 Favored 'Isoleucine or valine' 0 C--O 1.239 0.509 0 N-CA-C 106.632 -1.618 . . . . 0.0 106.632 -179.864 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' E' E ' 37' ' ' GLY . . . . . 0.546 ' H ' HE22 ' E' ' 15' ' ' GLN . . . 55.61 74.94 0.27 Allowed Glycine 0 C--N 1.314 -0.662 0 CA-C-N 115.673 -0.694 . . . . 0.0 111.481 178.48 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 169.95 -147.7 11.08 Favored Glycine 0 C--O 1.222 -0.631 0 N-CA-C 111.321 -0.712 . . . . 0.0 111.321 179.965 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 20.3 m -133.93 141.38 44.12 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.872 0 N-CA-C 109.199 -0.667 . . . . 0.0 109.199 179.444 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 19.0 t . . . . . 0 CA--C 1.535 0.379 0 CA-C-O 117.722 -1.133 . . . . 0.0 110.895 179.453 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' F' F ' 1' ' ' ASP . . . . . 0.408 ' H2 ' ' HB2' ' I' ' 1' ' ' ASP . 9.3 m-20 . . . . . 0 N--CA 1.489 1.525 0 N-CA-C 109.161 -0.681 . . . . 0.0 109.161 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' F' F ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.11 130.9 45.81 Favored 'General case' 0 CA--C 1.536 0.428 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.359 179.884 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' F' F ' 3' ' ' GLU . . . . . . . . . . . . . 39.3 tt0 -169.22 108.84 0.45 Allowed 'General case' 0 N--CA 1.468 0.473 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 -179.859 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 79.4 m-85 -84.56 140.45 31.4 Favored 'General case' 0 N--CA 1.475 0.8 0 N-CA-C 109.873 -0.417 . . . . 0.0 109.873 179.344 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' F' F ' 5' ' ' ARG . . . . . . . . . . . . . 71.6 mtp180 -143.8 141.84 30.59 Favored 'General case' 0 N--CA 1.477 0.912 0 N-CA-C 109.261 -0.644 . . . . 0.0 109.261 179.998 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 76.9 m80 -150.28 118.41 6.34 Favored 'General case' 0 N--CA 1.473 0.688 0 N-CA-C 108.965 -0.754 . . . . 0.0 108.965 179.072 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' F' F ' 7' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -66.4 149.82 49.83 Favored 'General case' 0 N--CA 1.463 0.203 0 O-C-N 123.414 0.447 . . . . 0.0 111.636 -179.429 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' F' F ' 8' ' ' SER . . . . . . . . . . . . . 6.9 t -167.41 172.28 9.79 Favored 'General case' 0 N--CA 1.476 0.874 0 CA-C-N 115.991 -0.55 . . . . 0.0 109.56 178.04 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 123.19 23.25 2.21 Favored Glycine 0 N--CA 1.482 1.74 0 N-CA-C 112.04 -0.424 . . . . 0.0 112.04 179.109 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 38.7 p90 -55.87 127.72 31.63 Favored 'General case' 0 CA--C 1.543 0.694 0 N-CA-C 112.664 0.616 . . . . 0.0 112.664 -179.151 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' F' F ' 11' ' ' GLU . . . . . 0.49 ' CG ' HD21 ' E' ' 27' ' ' ASN . 46.3 mt-10 -83.74 155.33 23.13 Favored 'General case' 0 N--CA 1.474 0.764 0 N-CA-C 109.436 -0.579 . . . . 0.0 109.436 178.023 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -155.34 128.19 1.11 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.587 0 N-CA-C 108.297 -1.001 . . . . 0.0 108.297 178.79 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 46.1 m-70 -135.01 143.22 46.68 Favored 'General case' 0 N--CA 1.483 1.196 0 CA-C-O 120.63 0.252 . . . . 0.0 111.329 -177.902 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -165.18 99.09 0.73 Allowed 'General case' 0 N--CA 1.487 1.422 0 CA-C-N 116.751 -0.204 . . . . 0.0 111.091 179.74 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' F' F ' 15' ' ' GLN . . . . . 0.541 HE22 ' H ' ' F' ' 37' ' ' GLY . 61.6 mt-30 -109.2 -171.51 1.86 Allowed 'General case' 0 CA--C 1.498 -1.034 0 N-CA-C 108.574 -0.899 . . . . 0.0 108.574 -179.826 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -166.11 97.57 0.62 Allowed 'General case' 0 CA--C 1.542 0.651 0 CA-C-N 114.93 -1.032 . . . . 0.0 109.406 178.769 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' F' F ' 17' ' ' LEU . . . . . 0.566 HD12 ' N ' ' F' ' 17' ' ' LEU . 4.7 mp -105.81 163.48 12.69 Favored 'General case' 0 N--CA 1.488 1.469 0 N-CA-C 109.213 -0.662 . . . . 0.0 109.213 -179.923 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 40.0 t -141.9 118.59 7.02 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.305 0 C-N-CA 122.644 0.378 . . . . 0.0 110.613 179.101 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 51.0 m-85 -69.53 156.66 38.54 Favored 'General case' 0 C--N 1.357 0.922 0 N-CA-C 107.221 -1.399 . . . . 0.0 107.221 176.548 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 13.2 t80 -173.19 -55.04 0.02 OUTLIER 'General case' 0 N--CA 1.486 1.372 0 CA-C-O 121.787 0.803 . . . . 0.0 109.85 179.458 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.73 88.99 0.0 OUTLIER 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 114.49 -1.232 . . . . 0.0 112.971 -178.876 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 54.4 tt0 -65.96 158.22 28.74 Favored 'General case' 0 N--CA 1.472 0.666 0 CA-C-N 114.894 -1.048 . . . . 0.0 110.799 179.541 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 66.7 m-20 -140.51 137.83 34.11 Favored 'General case' 0 N--CA 1.48 1.059 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.396 179.96 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' F' F ' 24' ' ' VAL . . . . . . . . . . . . . 21.7 t -85.09 -115.46 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.043 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 179.505 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -110.55 54.11 0.56 Allowed Glycine 0 N--CA 1.479 1.529 0 N-CA-C 111.383 -0.687 . . . . 0.0 111.383 -179.815 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 70.1 p -79.68 125.42 29.62 Favored 'General case' 0 N--CA 1.474 0.733 0 N-CA-C 109.335 -0.617 . . . . 0.0 109.335 177.948 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' F' F ' 27' ' ' ASN . . . . . 0.478 HD21 ' CG ' ' D' ' 11' ' ' GLU . 52.2 t30 -66.5 99.23 0.55 Allowed 'General case' 0 N--CA 1.472 0.638 0 N-CA-C 108.115 -1.069 . . . . 0.0 108.115 178.382 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 66.4 mttm -96.26 119.17 34.27 Favored 'General case' 0 N--CA 1.483 1.19 0 N-CA-C 110.084 -0.339 . . . . 0.0 110.084 -178.804 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.55 -125.41 0.01 OUTLIER Glycine 0 CA--C 1.54 1.6 0 N-CA-C 110.964 -0.854 . . . . 0.0 110.964 178.617 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -127.91 133.08 49.25 Favored 'General case' 0 N--CA 1.484 1.249 0 N-CA-C 109.644 -0.502 . . . . 0.0 109.644 179.588 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 66.9 mt -82.65 138.81 18.77 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.273 0 N-CA-C 106.897 -1.52 . . . . 0.0 106.897 178.421 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 20.3 mt -128.22 129.08 69.22 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.891 0 N-CA-C 109.636 -0.505 . . . . 0.0 109.636 -179.357 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 60.86 80.27 0.1 Allowed Glycine 0 CA--C 1.525 0.688 0 CA-C-N 116.056 -0.52 . . . . 0.0 113.573 179.346 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 2.1 tt -111.85 118.82 36.59 Favored 'General case' 0 N--CA 1.479 0.981 0 N-CA-C 107.067 -1.457 . . . . 0.0 107.067 177.346 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 8.7 ttt -154.15 162.72 41.0 Favored 'General case' 0 C--O 1.209 -1.041 0 N-CA-C 109.009 -0.737 . . . . 0.0 109.009 179.143 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 85.1 t -159.7 150.57 6.32 Favored 'Isoleucine or valine' 0 C--O 1.237 0.402 0 N-CA-C 106.701 -1.592 . . . . 0.0 106.701 -179.823 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' F' F ' 37' ' ' GLY . . . . . 0.541 ' H ' HE22 ' F' ' 15' ' ' GLN . . . 55.8 74.67 0.3 Allowed Glycine 0 C--N 1.315 -0.632 0 CA-C-N 115.523 -0.762 . . . . 0.0 111.447 178.452 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 170.06 -147.82 11.14 Favored Glycine 0 C--O 1.221 -0.7 0 N-CA-C 111.233 -0.747 . . . . 0.0 111.233 179.839 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 20.2 m -133.72 141.37 44.35 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.841 0 N-CA-C 109.158 -0.682 . . . . 0.0 109.158 179.547 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 19.4 t . . . . . 0 CA--C 1.536 0.415 0 CA-C-O 117.746 -1.121 . . . . 0.0 110.75 179.389 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' G' G ' 1' ' ' ASP . . . . . . . . . . . . . 8.7 m-20 . . . . . 0 N--CA 1.49 1.565 0 N-CA-C 109.723 -0.473 . . . . 0.0 109.723 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' G' G ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.44 129.27 39.9 Favored 'General case' 0 N--CA 1.469 0.514 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.44 179.636 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 3' ' ' GLU . . . . . . . . . . . . . 39.0 tt0 -169.08 108.59 0.45 Allowed 'General case' 0 N--CA 1.471 0.605 0 N-CA-C 110.117 -0.327 . . . . 0.0 110.117 179.758 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 79.0 m-85 -85.07 139.72 31.53 Favored 'General case' 0 N--CA 1.474 0.772 0 N-CA-C 109.644 -0.502 . . . . 0.0 109.644 179.199 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 5' ' ' ARG . . . . . . . . . . . . . 71.8 mtp180 -144.01 141.28 30.05 Favored 'General case' 0 N--CA 1.483 1.22 0 N-CA-C 109.178 -0.675 . . . . 0.0 109.178 -179.515 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 76.7 m80 -149.53 119.57 7.19 Favored 'General case' 0 N--CA 1.472 0.671 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 179.078 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 -68.41 145.28 54.27 Favored 'General case' 0 N--CA 1.47 0.526 0 O-C-N 123.505 0.503 . . . . 0.0 111.931 -179.328 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 8' ' ' SER . . . . . . . . . . . . . 5.7 t -163.81 173.54 12.64 Favored 'General case' 0 N--CA 1.47 0.566 0 N-CA-C 109.291 -0.633 . . . . 0.0 109.291 178.147 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.94 23.65 2.2 Favored Glycine 0 N--CA 1.479 1.519 0 N-CA-C 111.755 -0.538 . . . . 0.0 111.755 179.051 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 41.9 p90 -56.98 127.61 32.79 Favored 'General case' 0 N--CA 1.475 0.799 0 N-CA-C 112.437 0.532 . . . . 0.0 112.437 -178.648 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 45.2 mt-10 -83.93 154.34 23.43 Favored 'General case' 0 N--CA 1.471 0.618 0 CA-C-O 121.052 0.453 . . . . 0.0 109.852 178.686 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -155.4 128.51 1.15 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.968 0 N-CA-C 108.304 -0.999 . . . . 0.0 108.304 178.9 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 49.1 m-70 -134.19 144.38 48.44 Favored 'General case' 0 N--CA 1.476 0.865 0 CA-C-N 115.416 -0.811 . . . . 0.0 111.09 -178.136 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -166.35 98.2 0.6 Allowed 'General case' 0 N--CA 1.484 1.245 0 CA-C-N 116.642 -0.254 . . . . 0.0 110.572 179.219 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' G' G ' 15' ' ' GLN . . . . . 0.541 HE22 ' H ' ' G' ' 37' ' ' GLY . 61.7 mt-30 -108.32 -171.89 1.95 Allowed 'General case' 0 CA--C 1.503 -0.839 0 N-CA-C 108.635 -0.876 . . . . 0.0 108.635 -179.775 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -166.03 97.58 0.63 Allowed 'General case' 0 CA--C 1.541 0.618 0 CA-C-N 115.032 -0.985 . . . . 0.0 109.38 178.614 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 17' ' ' LEU . . . . . 0.573 ' N ' HD12 ' G' ' 17' ' ' LEU . 5.4 mp -105.73 162.33 13.63 Favored 'General case' 0 N--CA 1.487 1.423 0 N-CA-C 109.4 -0.593 . . . . 0.0 109.4 -179.717 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 39.0 t -142.45 118.83 6.08 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.082 0 CA-C-O 120.895 0.378 . . . . 0.0 110.352 178.773 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 44.9 m-85 -69.65 150.74 46.69 Favored 'General case' 0 C--N 1.369 1.444 0 N-CA-C 107.267 -1.383 . . . . 0.0 107.267 176.583 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 10.9 t80 -170.92 -54.84 0.02 OUTLIER 'General case' 0 N--CA 1.487 1.382 0 CA-C-N 117.847 0.294 . . . . 0.0 110.408 -179.73 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.45 90.27 0.0 OUTLIER 'General case' 0 C--N 1.325 -0.494 0 C-N-CA 123.866 0.866 . . . . 0.0 112.596 -179.918 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 53.8 tt0 -66.88 159.06 29.07 Favored 'General case' 0 N--CA 1.469 0.492 0 CA-C-N 114.634 -1.166 . . . . 0.0 109.923 179.189 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 66.2 m-20 -140.94 137.55 33.18 Favored 'General case' 0 N--CA 1.477 0.904 0 C-N-CA 122.822 0.449 . . . . 0.0 110.046 179.893 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 24' ' ' VAL . . . . . . . . . . . . . 21.4 t -85.42 -115.29 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.919 0 N-CA-C 108.521 -0.918 . . . . 0.0 108.521 179.608 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -110.53 53.97 0.56 Allowed Glycine 0 N--CA 1.477 1.425 0 N-CA-C 111.611 -0.596 . . . . 0.0 111.611 -179.712 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 70.4 p -80.08 126.27 30.85 Favored 'General case' 0 N--CA 1.467 0.393 0 N-CA-C 109.081 -0.711 . . . . 0.0 109.081 177.956 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 50.4 t30 -67.23 99.99 0.75 Allowed 'General case' 0 CA--C 1.538 0.503 0 N-CA-C 108.401 -0.963 . . . . 0.0 108.401 178.434 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 66.9 mttm -96.33 119.91 35.68 Favored 'General case' 0 N--CA 1.482 1.147 0 N-CA-C 110.174 -0.306 . . . . 0.0 110.174 -179.182 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.02 -123.33 0.01 OUTLIER Glycine 0 CA--C 1.534 1.253 0 N-CA-C 110.54 -1.024 . . . . 0.0 110.54 178.787 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -129.58 132.78 46.89 Favored 'General case' 0 N--CA 1.47 0.557 0 N-CA-C 109.514 -0.55 . . . . 0.0 109.514 179.683 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 69.9 mt -81.54 140.91 15.85 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.654 0 N-CA-C 107.2 -1.407 . . . . 0.0 107.2 178.337 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 24.0 mt -130.2 130.52 65.74 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.46 0 CA-C-N 119.044 0.838 . . . . 0.0 109.435 179.785 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 60.96 79.82 0.11 Allowed Glycine 0 CA--C 1.528 0.888 0 CA-C-N 116.281 -0.418 . . . . 0.0 113.038 179.292 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 34' ' ' LEU . . . . . 0.404 HD23 ' N ' ' G' ' 35' ' ' MET . 1.9 tt -111.93 119.55 38.92 Favored 'General case' 0 N--CA 1.478 0.94 0 N-CA-C 106.961 -1.496 . . . . 0.0 106.961 177.479 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' G' G ' 35' ' ' MET . . . . . 0.404 ' N ' HD23 ' G' ' 34' ' ' LEU . 8.5 ttt -155.54 163.14 40.38 Favored 'General case' 0 N--CA 1.476 0.866 0 N-CA-C 108.192 -1.04 . . . . 0.0 108.192 179.503 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 98.6 t -159.8 150.85 6.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 N-CA-C 106.303 -1.74 . . . . 0.0 106.303 -179.899 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 37' ' ' GLY . . . . . 0.541 ' H ' HE22 ' G' ' 15' ' ' GLN . . . 56.1 74.74 0.29 Allowed Glycine 0 C--N 1.313 -0.706 0 CA-C-N 115.888 -0.596 . . . . 0.0 111.913 178.132 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 168.66 -146.42 10.34 Favored Glycine 0 N--CA 1.471 1.008 0 N-CA-C 110.636 -0.986 . . . . 0.0 110.636 179.231 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 23.1 m -134.23 141.62 43.17 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.906 0 CA-C-N 117.031 0.415 . . . . 0.0 109.984 179.881 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 19.2 t . . . . . 0 N--CA 1.47 0.548 0 CA-C-O 117.841 -1.076 . . . . 0.0 110.891 179.613 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' H' H ' 1' ' ' ASP . . . . . . . . . . . . . 9.7 m-20 . . . . . 0 N--CA 1.491 1.59 0 N-CA-C 109.661 -0.496 . . . . 0.0 109.661 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' H' H ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.56 129.07 38.95 Favored 'General case' 0 N--CA 1.468 0.473 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.491 179.716 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' H' H ' 3' ' ' GLU . . . . . . . . . . . . . 39.3 tt0 -168.96 108.58 0.46 Allowed 'General case' 0 N--CA 1.47 0.557 0 N-CA-C 110.114 -0.328 . . . . 0.0 110.114 179.745 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 80.4 m-85 -84.77 140.13 31.46 Favored 'General case' 0 N--CA 1.475 0.805 0 N-CA-C 109.641 -0.503 . . . . 0.0 109.641 179.342 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' H' H ' 5' ' ' ARG . . . . . . . . . . . . . 71.5 mtp180 -144.29 141.4 29.77 Favored 'General case' 0 N--CA 1.48 1.055 0 N-CA-C 109.222 -0.658 . . . . 0.0 109.222 -179.625 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 76.8 m80 -149.72 119.29 6.96 Favored 'General case' 0 N--CA 1.473 0.698 0 N-CA-C 109.095 -0.705 . . . . 0.0 109.095 179.071 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 8.7 m-20 -68.08 145.35 54.5 Favored 'General case' 0 N--CA 1.468 0.45 0 O-C-N 123.466 0.479 . . . . 0.0 111.934 -179.393 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' H' H ' 8' ' ' SER . . . . . . . . . . . . . 7.0 t -163.9 172.83 13.45 Favored 'General case' 0 N--CA 1.468 0.474 0 N-CA-C 109.449 -0.574 . . . . 0.0 109.449 178.466 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 123.15 23.52 2.17 Favored Glycine 0 N--CA 1.481 1.684 0 N-CA-C 111.682 -0.567 . . . . 0.0 111.682 179.154 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 41.6 p90 -56.79 127.65 32.68 Favored 'General case' 0 N--CA 1.472 0.672 0 N-CA-C 112.443 0.534 . . . . 0.0 112.443 -178.763 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 45.4 mt-10 -83.96 154.4 23.36 Favored 'General case' 0 N--CA 1.473 0.679 0 CA-C-O 120.998 0.428 . . . . 0.0 109.893 178.739 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.6 p -155.58 128.11 1.07 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.016 0 N-CA-C 108.42 -0.955 . . . . 0.0 108.42 178.879 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 48.7 m-70 -133.91 144.4 48.83 Favored 'General case' 0 N--CA 1.478 0.947 0 CA-C-N 115.336 -0.847 . . . . 0.0 111.025 -178.072 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -166.29 98.54 0.61 Allowed 'General case' 0 N--CA 1.483 1.218 0 CA-C-N 116.568 -0.287 . . . . 0.0 110.617 179.166 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' H' H ' 15' ' ' GLN . . . . . 0.553 HE22 ' H ' ' H' ' 37' ' ' GLY . 61.6 mt-30 -108.64 -172.37 2.04 Favored 'General case' 0 CA--C 1.501 -0.931 0 N-CA-C 108.416 -0.957 . . . . 0.0 108.416 -179.656 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -165.73 97.35 0.65 Allowed 'General case' 0 CA--C 1.54 0.572 0 CA-C-N 114.951 -1.022 . . . . 0.0 109.364 178.716 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' H' H ' 17' ' ' LEU . . . . . 0.572 HD12 ' N ' ' H' ' 17' ' ' LEU . 5.4 mp -105.66 162.23 13.7 Favored 'General case' 0 N--CA 1.487 1.405 0 N-CA-C 109.362 -0.607 . . . . 0.0 109.362 -179.646 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 38.8 t -142.39 118.67 6.08 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.983 0 CA-C-O 120.97 0.414 . . . . 0.0 110.489 178.851 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 46.2 m-85 -69.8 151.07 46.18 Favored 'General case' 0 C--N 1.371 1.503 0 N-CA-C 107.355 -1.35 . . . . 0.0 107.355 176.653 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 11.4 t80 -172.15 -54.6 0.02 OUTLIER 'General case' 0 N--CA 1.485 1.295 0 N-CA-C 110.342 -0.244 . . . . 0.0 110.342 -179.635 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.39 90.41 0.0 OUTLIER 'General case' 0 CA--C 1.535 0.365 0 C-N-CA 123.815 0.846 . . . . 0.0 112.354 -179.958 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 54.0 tt0 -66.73 159.14 28.52 Favored 'General case' 0 N--CA 1.469 0.485 0 CA-C-N 114.69 -1.141 . . . . 0.0 110.012 179.34 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 67.5 m-20 -140.91 138.05 33.58 Favored 'General case' 0 N--CA 1.477 0.885 0 C-N-CA 122.821 0.448 . . . . 0.0 110.051 179.693 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' H' H ' 24' ' ' VAL . . . . . . . . . . . . . 21.4 t -85.93 -115.33 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 1.016 0 N-CA-C 108.609 -0.885 . . . . 0.0 108.609 179.602 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . -110.33 53.9 0.56 Allowed Glycine 0 N--CA 1.48 1.601 0 N-CA-C 111.471 -0.652 . . . . 0.0 111.471 -179.759 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 68.7 p -80.03 126.02 30.52 Favored 'General case' 0 N--CA 1.468 0.446 0 N-CA-C 109.053 -0.721 . . . . 0.0 109.053 178.067 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 50.6 t30 -67.31 100.1 0.78 Allowed 'General case' 0 N--CA 1.47 0.542 0 N-CA-C 108.409 -0.96 . . . . 0.0 108.409 178.492 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 67.0 mttm -96.41 119.76 35.49 Favored 'General case' 0 N--CA 1.484 1.236 0 N-CA-C 110.182 -0.303 . . . . 0.0 110.182 -179.131 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.89 -122.84 0.01 OUTLIER Glycine 0 CA--C 1.535 1.306 0 N-CA-C 110.606 -0.998 . . . . 0.0 110.606 178.735 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -129.95 133.0 46.54 Favored 'General case' 0 N--CA 1.471 0.62 0 C-N-CA 122.946 0.498 . . . . 0.0 109.663 179.709 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 69.5 mt -81.89 140.76 16.01 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.554 0 N-CA-C 107.128 -1.434 . . . . 0.0 107.128 178.446 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 25.1 mt -130.03 130.47 66.08 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.403 0 CA-C-N 119.021 0.828 . . . . 0.0 109.395 179.935 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 60.77 79.81 0.11 Allowed Glycine 0 CA--C 1.528 0.889 0 CA-C-N 116.382 -0.372 . . . . 0.0 113.067 179.193 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 1.9 tt -111.87 119.5 38.77 Favored 'General case' 0 N--CA 1.478 0.944 0 N-CA-C 106.944 -1.502 . . . . 0.0 106.944 177.426 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 8.4 ttt -155.19 163.19 40.54 Favored 'General case' 0 C--O 1.212 -0.91 0 N-CA-C 108.176 -1.046 . . . . 0.0 108.176 179.509 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 96.4 t -159.79 150.77 6.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 N-CA-C 106.254 -1.758 . . . . 0.0 106.254 -179.885 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' H' H ' 37' ' ' GLY . . . . . 0.553 ' H ' HE22 ' H' ' 15' ' ' GLN . . . 56.12 74.95 0.27 Allowed Glycine 0 C--N 1.313 -0.712 0 CA-C-N 115.914 -0.584 . . . . 0.0 111.914 178.124 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 168.32 -146.34 10.37 Favored Glycine 0 N--CA 1.469 0.866 0 N-CA-C 110.631 -0.988 . . . . 0.0 110.631 179.105 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 22.6 m -134.15 141.81 42.74 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.906 0 CA-C-N 116.998 0.399 . . . . 0.0 110.021 179.911 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 19.1 t . . . . . 0 N--CA 1.47 0.557 0 CA-C-O 117.789 -1.101 . . . . 0.0 110.932 179.539 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' I' I ' 1' ' ' ASP . . . . . 0.408 ' HB2' ' H2 ' ' F' ' 1' ' ' ASP . 9.6 m-20 . . . . . 0 N--CA 1.491 1.589 0 N-CA-C 109.607 -0.516 . . . . 0.0 109.607 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' I' I ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.67 129.19 39.43 Favored 'General case' 0 N--CA 1.469 0.491 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.441 179.635 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' I' I ' 3' ' ' GLU . . . . . . . . . . . . . 39.0 tt0 -169.0 108.67 0.46 Allowed 'General case' 0 N--CA 1.47 0.563 0 N-CA-C 110.147 -0.316 . . . . 0.0 110.147 179.771 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 79.9 m-85 -84.96 140.32 31.16 Favored 'General case' 0 N--CA 1.475 0.78 0 N-CA-C 109.599 -0.519 . . . . 0.0 109.599 179.298 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' I' I ' 5' ' ' ARG . . . . . . . . . . . . . 71.6 mtp180 -144.44 141.5 29.66 Favored 'General case' 0 N--CA 1.483 1.192 0 N-CA-C 109.187 -0.671 . . . . 0.0 109.187 -179.696 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 76.7 m80 -149.76 119.06 6.82 Favored 'General case' 0 N--CA 1.472 0.667 0 N-CA-C 109.126 -0.694 . . . . 0.0 109.126 179.082 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 8.6 m-20 -67.86 145.36 54.69 Favored 'General case' 0 N--CA 1.469 0.491 0 O-C-N 123.479 0.487 . . . . 0.0 111.935 -179.371 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' I' I ' 8' ' ' SER . . . . . . . . . . . . . 7.5 t -163.9 172.75 13.55 Favored 'General case' 0 N--CA 1.469 0.496 0 N-CA-C 109.429 -0.582 . . . . 0.0 109.429 178.465 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 123.2 23.77 2.12 Favored Glycine 0 N--CA 1.481 1.639 0 N-CA-C 111.78 -0.528 . . . . 0.0 111.78 179.118 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 41.5 p90 -56.95 127.52 32.27 Favored 'General case' 0 N--CA 1.474 0.737 0 N-CA-C 112.443 0.534 . . . . 0.0 112.443 -178.738 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 45.2 mt-10 -83.66 154.34 23.74 Favored 'General case' 0 N--CA 1.472 0.628 0 CA-C-O 120.998 0.427 . . . . 0.0 109.909 178.675 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -155.49 128.29 1.1 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.015 0 N-CA-C 108.313 -0.995 . . . . 0.0 108.313 178.848 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 49.5 m-70 -134.06 144.56 48.72 Favored 'General case' 0 N--CA 1.478 0.935 0 CA-C-N 115.337 -0.847 . . . . 0.0 111.13 -178.198 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -166.4 98.51 0.6 Allowed 'General case' 0 N--CA 1.484 1.255 0 CA-C-N 116.639 -0.255 . . . . 0.0 110.704 179.127 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' I' I ' 15' ' ' GLN . . . . . 0.551 HE22 ' H ' ' I' ' 37' ' ' GLY . 61.4 mt-30 -108.63 -172.45 2.06 Favored 'General case' 0 CA--C 1.498 -1.029 0 N-CA-C 108.461 -0.94 . . . . 0.0 108.461 -179.765 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -165.69 97.43 0.66 Allowed 'General case' 0 CA--C 1.541 0.61 0 CA-C-N 114.9 -1.046 . . . . 0.0 109.302 178.789 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' I' I ' 17' ' ' LEU . . . . . 0.569 HD12 ' N ' ' I' ' 17' ' ' LEU . 5.4 mp -105.68 162.51 13.46 Favored 'General case' 0 N--CA 1.487 1.402 0 N-CA-C 109.306 -0.627 . . . . 0.0 109.306 -179.609 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 39.2 t -142.5 118.81 5.95 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.006 0 CA-C-O 120.94 0.4 . . . . 0.0 110.471 178.851 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 45.8 m-85 -70.02 150.96 46.1 Favored 'General case' 0 C--N 1.369 1.431 0 N-CA-C 107.402 -1.332 . . . . 0.0 107.402 176.601 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 11.5 t80 -171.96 -54.72 0.02 OUTLIER 'General case' 0 N--CA 1.483 1.209 0 CA-C-N 117.765 0.257 . . . . 0.0 110.401 -179.561 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.34 90.22 0.0 OUTLIER 'General case' 0 CA--C 1.535 0.401 0 C-N-CA 123.743 0.817 . . . . 0.0 112.386 -179.942 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 54.1 tt0 -66.46 159.06 27.92 Favored 'General case' 0 N--CA 1.468 0.47 0 CA-C-N 114.667 -1.151 . . . . 0.0 110.061 179.272 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 67.2 m-20 -140.91 138.0 33.54 Favored 'General case' 0 N--CA 1.477 0.921 0 C-N-CA 122.775 0.43 . . . . 0.0 110.001 179.835 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' I' I ' 24' ' ' VAL . . . . . . . . . . . . . 21.3 t -85.99 -115.52 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.926 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 179.653 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . -110.16 53.6 0.58 Allowed Glycine 0 N--CA 1.479 1.501 0 N-CA-C 111.579 -0.609 . . . . 0.0 111.579 -179.702 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 68.7 p -79.74 126.24 30.7 Favored 'General case' 0 N--CA 1.467 0.411 0 N-CA-C 109.036 -0.727 . . . . 0.0 109.036 178.026 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 49.8 t30 -67.52 99.9 0.81 Allowed 'General case' 0 N--CA 1.47 0.527 0 N-CA-C 108.379 -0.971 . . . . 0.0 108.379 178.483 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 67.0 mttm -96.2 119.79 35.32 Favored 'General case' 0 N--CA 1.482 1.165 0 N-CA-C 110.216 -0.29 . . . . 0.0 110.216 -179.135 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.13 -123.23 0.01 OUTLIER Glycine 0 CA--C 1.534 1.254 0 N-CA-C 110.656 -0.978 . . . . 0.0 110.656 178.746 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -129.4 132.74 47.09 Favored 'General case' 0 N--CA 1.473 0.683 0 C-N-CA 122.962 0.505 . . . . 0.0 109.65 179.657 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 69.5 mt -81.75 140.68 16.16 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.637 0 N-CA-C 106.982 -1.488 . . . . 0.0 106.982 178.387 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 23.3 mt -129.89 130.44 66.37 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.383 0 CA-C-N 118.939 0.79 . . . . 0.0 109.361 179.868 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 60.63 80.04 0.11 Allowed Glycine 0 CA--C 1.528 0.846 0 CA-C-N 116.331 -0.395 . . . . 0.0 113.107 179.25 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 1.9 tt -112.0 119.6 39.02 Favored 'General case' 0 N--CA 1.478 0.949 0 N-CA-C 106.891 -1.522 . . . . 0.0 106.891 177.446 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 8.6 ttt -155.29 163.08 40.63 Favored 'General case' 0 N--CA 1.478 0.943 0 N-CA-C 108.256 -1.016 . . . . 0.0 108.256 179.518 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 97.7 t -159.76 150.94 6.17 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 N-CA-C 106.253 -1.758 . . . . 0.0 106.253 -179.915 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' I' I ' 37' ' ' GLY . . . . . 0.551 ' H ' HE22 ' I' ' 15' ' ' GLN . . . 56.14 74.45 0.33 Allowed Glycine 0 C--N 1.313 -0.739 0 CA-C-N 115.891 -0.595 . . . . 0.0 112.023 178.115 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 168.76 -146.4 10.31 Favored Glycine 0 N--CA 1.47 0.915 0 N-CA-C 110.602 -0.999 . . . . 0.0 110.602 179.268 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 22.8 m -134.06 141.79 42.88 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.873 0 CA-C-N 117.01 0.405 . . . . 0.0 109.981 179.921 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 19.2 t . . . . . 0 N--CA 1.469 0.506 0 CA-C-O 117.825 -1.083 . . . . 0.0 110.939 179.507 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 8.6 m-20 . . . . . 0 N--CA 1.49 1.536 0 N-CA-C 109.048 -0.723 . . . . 0.0 109.048 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.95 132.72 49.29 Favored 'General case' 0 CA--C 1.538 0.491 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.201 -179.877 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 41.1 tt0 -169.33 108.32 0.43 Allowed 'General case' 0 N--CA 1.47 0.545 0 N-CA-C 109.693 -0.484 . . . . 0.0 109.693 -179.242 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 78.5 m-85 -83.56 140.52 32.2 Favored 'General case' 0 N--CA 1.475 0.795 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 179.469 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 72.2 mtp180 -143.62 141.17 30.5 Favored 'General case' 0 N--CA 1.481 1.116 0 N-CA-C 109.076 -0.713 . . . . 0.0 109.076 179.964 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 77.0 m80 -149.48 119.65 7.26 Favored 'General case' 0 N--CA 1.47 0.562 0 N-CA-C 108.806 -0.813 . . . . 0.0 108.806 179.136 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 7.4 m-20 -68.3 150.21 48.5 Favored 'General case' 0 CA--C 1.529 0.168 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.258 -179.437 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 8.5 t -166.95 172.27 10.41 Favored 'General case' 0 N--CA 1.472 0.63 0 N-CA-C 109.554 -0.536 . . . . 0.0 109.554 178.476 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.53 23.52 2.32 Favored Glycine 0 N--CA 1.487 2.097 0 N-CA-C 112.239 -0.344 . . . . 0.0 112.239 179.417 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 41.8 p90 -56.98 128.28 36.13 Favored 'General case' 0 N--CA 1.474 0.761 0 N-CA-C 112.088 0.403 . . . . 0.0 112.088 -179.912 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 57.4 mt-10 -85.66 155.38 21.12 Favored 'General case' 0 N--CA 1.469 0.504 0 N-CA-C 109.273 -0.64 . . . . 0.0 109.273 178.493 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -153.75 128.79 1.51 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 N-CA-C 108.107 -1.071 . . . . 0.0 108.107 178.839 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 49.5 m-70 -134.64 146.54 49.64 Favored 'General case' 0 N--CA 1.489 1.503 0 CA-C-N 118.641 0.655 . . . . 0.0 111.154 -179.024 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 6.4 t60 -164.96 97.91 0.74 Allowed 'General case' 0 N--CA 1.48 1.04 0 CA-C-N 116.502 -0.317 . . . . 0.0 111.055 179.582 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 35.0 mt-30 -106.06 -172.7 2.14 Favored 'General case' 0 CA--C 1.505 -0.762 0 N-CA-C 108.369 -0.974 . . . . 0.0 108.369 179.915 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . 0.403 ' C ' HD12 ' A' ' 17' ' ' LEU . 88.6 tttt -169.18 96.47 0.34 Allowed 'General case' 0 N--CA 1.472 0.629 0 CA-C-N 115.139 -0.937 . . . . 0.0 109.416 178.703 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.58 HD12 ' N ' ' A' ' 17' ' ' LEU . 4.8 mp -106.38 165.01 11.57 Favored 'General case' 0 N--CA 1.489 1.498 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 179.901 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 56.5 t -141.78 119.22 7.96 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.387 0 CA-C-O 118.934 -0.555 . . . . 0.0 109.897 179.68 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 52.4 m-85 -69.9 158.93 34.62 Favored 'General case' 0 N--CA 1.481 1.079 0 N-CA-C 107.592 -1.262 . . . . 0.0 107.592 177.392 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 13.1 t80 -171.22 -58.59 0.02 OUTLIER 'General case' 0 N--CA 1.485 1.324 0 CA-C-O 122.299 1.047 . . . . 0.0 109.73 179.485 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -38.82 90.11 0.0 OUTLIER 'General case' 0 C--O 1.232 0.142 0 CA-C-N 113.926 -1.488 . . . . 0.0 112.968 -177.985 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 37.0 tt0 -66.51 157.81 31.24 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-N 115.109 -0.95 . . . . 0.0 110.452 179.197 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 66.7 m-20 -139.98 137.38 34.66 Favored 'General case' 0 N--CA 1.48 1.071 0 C-N-CA 123.002 0.521 . . . . 0.0 110.344 179.866 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 17.9 t -84.49 -116.3 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.962 0 N-CA-C 108.444 -0.947 . . . . 0.0 108.444 179.501 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -110.37 54.63 0.54 Allowed Glycine 0 N--CA 1.475 1.265 0 N-CA-C 111.227 -0.749 . . . . 0.0 111.227 179.916 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 74.8 p -79.98 125.96 30.43 Favored 'General case' 0 C--O 1.221 -0.417 0 N-CA-C 108.969 -0.752 . . . . 0.0 108.969 178.378 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 19.9 t-20 -66.6 100.42 0.67 Allowed 'General case' 0 N--CA 1.473 0.725 0 N-CA-C 108.576 -0.898 . . . . 0.0 108.576 178.704 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 66.6 mttm -96.85 120.34 37.01 Favored 'General case' 0 N--CA 1.483 1.182 0 N-CA-C 110.093 -0.336 . . . . 0.0 110.093 -179.157 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.58 -128.41 0.01 OUTLIER Glycine 0 CA--C 1.534 1.223 0 N-CA-C 110.525 -1.03 . . . . 0.0 110.525 178.779 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -126.05 133.86 51.59 Favored 'General case' 0 N--CA 1.48 1.052 0 N-CA-C 109.234 -0.654 . . . . 0.0 109.234 179.097 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 65.4 mt -83.21 137.81 20.34 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.538 0 N-CA-C 107.393 -1.336 . . . . 0.0 107.393 178.683 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 20.9 mt -129.44 129.25 66.95 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.976 0 O-C-N 123.495 0.497 . . . . 0.0 110.053 -178.424 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 60.43 79.05 0.13 Allowed Glycine 0 CA--C 1.525 0.685 0 CA-C-N 115.849 -0.614 . . . . 0.0 113.069 178.949 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.421 HD23 ' N ' ' A' ' 35' ' ' MET . 1.9 tt -110.94 119.48 39.21 Favored 'General case' 0 N--CA 1.477 0.915 0 N-CA-C 106.973 -1.492 . . . . 0.0 106.973 177.463 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' MET . . . . . 0.421 ' N ' HD23 ' A' ' 34' ' ' LEU . 8.6 ttt -154.91 161.08 41.54 Favored 'General case' 0 N--CA 1.468 0.443 0 N-CA-C 109.066 -0.716 . . . . 0.0 109.066 179.257 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 63.1 t -157.75 150.48 8.55 Favored 'Isoleucine or valine' 0 C--O 1.232 0.148 0 N-CA-C 106.897 -1.52 . . . . 0.0 106.897 -179.496 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.61 75.42 0.24 Allowed Glycine 0 C--N 1.315 -0.607 0 CA-C-N 115.671 -0.695 . . . . 0.0 111.777 178.201 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 168.83 -149.12 13.2 Favored Glycine 0 CA--C 1.519 0.3 0 N-CA-C 110.744 -0.943 . . . . 0.0 110.744 179.847 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 20.7 m -132.57 142.87 41.38 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.874 0 N-CA-C 109.598 -0.519 . . . . 0.0 109.598 179.658 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 21.2 t . . . . . 0 N--CA 1.467 0.399 0 CA-C-O 117.834 -1.079 . . . . 0.0 110.831 179.29 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' B' B ' 1' ' ' ASP . . . . . . . . . . . . . 9.2 m-20 . . . . . 0 N--CA 1.489 1.479 0 N-CA-C 109.124 -0.695 . . . . 0.0 109.124 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' B' B ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.68 132.83 49.75 Favored 'General case' 0 CA--C 1.538 0.483 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.204 -179.865 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 3' ' ' GLU . . . . . . . . . . . . . 41.4 tt0 -169.55 108.29 0.41 Allowed 'General case' 0 N--CA 1.471 0.589 0 N-CA-C 109.584 -0.525 . . . . 0.0 109.584 -179.125 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 78.9 m-85 -83.58 140.49 32.21 Favored 'General case' 0 N--CA 1.474 0.726 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 179.474 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 72.2 mtp180 -143.68 141.14 30.41 Favored 'General case' 0 N--CA 1.481 1.108 0 N-CA-C 109.121 -0.696 . . . . 0.0 109.121 -179.931 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 76.7 m80 -149.51 119.6 7.22 Favored 'General case' 0 N--CA 1.471 0.615 0 N-CA-C 108.841 -0.8 . . . . 0.0 108.841 179.122 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 7' ' ' ASP . . . . . . . . . . . . . 8.5 m-20 -68.09 150.2 48.69 Favored 'General case' 0 CA--C 1.53 0.19 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.281 -179.453 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 8' ' ' SER . . . . . . . . . . . . . 8.4 t -166.98 172.2 10.43 Favored 'General case' 0 N--CA 1.472 0.631 0 N-CA-C 109.537 -0.542 . . . . 0.0 109.537 178.557 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.5 23.38 2.36 Favored Glycine 0 N--CA 1.487 2.051 0 N-CA-C 112.159 -0.377 . . . . 0.0 112.159 179.371 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 41.9 p90 -56.78 128.16 35.22 Favored 'General case' 0 N--CA 1.471 0.616 0 N-CA-C 112.166 0.432 . . . . 0.0 112.166 -179.983 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 57.4 mt-10 -85.58 155.64 21.07 Favored 'General case' 0 N--CA 1.471 0.58 0 N-CA-C 109.297 -0.631 . . . . 0.0 109.297 178.555 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -153.88 128.68 1.46 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 N-CA-C 108.186 -1.042 . . . . 0.0 108.186 178.816 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 50.1 m-70 -134.57 146.75 49.93 Favored 'General case' 0 N--CA 1.489 1.513 0 CA-C-N 118.481 0.582 . . . . 0.0 111.219 -179.018 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 6.5 t60 -165.32 97.82 0.7 Allowed 'General case' 0 N--CA 1.481 1.108 0 CA-C-N 116.519 -0.309 . . . . 0.0 111.022 179.627 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 35.2 mt-30 -105.96 -172.89 2.17 Favored 'General case' 0 CA--C 1.504 -0.789 0 N-CA-C 108.407 -0.96 . . . . 0.0 108.407 179.949 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 16' ' ' LYS . . . . . 0.408 ' C ' HD12 ' B' ' 17' ' ' LEU . 88.6 tttt -169.14 96.35 0.34 Allowed 'General case' 0 CA--C 1.54 0.592 0 CA-C-N 115.193 -0.912 . . . . 0.0 109.447 178.76 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . 0.578 ' N ' HD12 ' B' ' 17' ' ' LEU . 4.8 mp -106.41 164.82 11.73 Favored 'General case' 0 N--CA 1.488 1.461 0 N-CA-C 108.575 -0.898 . . . . 0.0 108.575 179.968 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 58.6 t -141.55 119.26 8.53 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.355 0 CA-C-O 118.957 -0.544 . . . . 0.0 109.9 179.566 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 53.3 m-85 -70.53 159.09 34.94 Favored 'General case' 0 N--CA 1.479 0.982 0 N-CA-C 107.52 -1.289 . . . . 0.0 107.52 177.316 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 14.4 t80 -171.84 -57.33 0.02 OUTLIER 'General case' 0 N--CA 1.482 1.138 0 CA-C-O 122.228 1.013 . . . . 0.0 109.838 179.452 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -39.39 90.37 0.0 OUTLIER 'General case' 0 C--O 1.232 0.152 0 CA-C-N 114.09 -1.413 . . . . 0.0 112.874 -178.052 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 36.6 tt0 -66.42 158.03 30.43 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 115.058 -0.973 . . . . 0.0 110.56 179.133 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 67.6 m-20 -140.37 137.42 34.04 Favored 'General case' 0 N--CA 1.481 1.089 0 C-N-CA 122.993 0.517 . . . . 0.0 110.251 179.805 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 17.5 t -84.59 -116.55 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 1.016 0 N-CA-C 108.65 -0.87 . . . . 0.0 108.65 179.482 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -109.46 54.01 0.56 Allowed Glycine 0 N--CA 1.476 1.331 0 N-CA-C 111.189 -0.764 . . . . 0.0 111.189 179.878 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 74.2 p -79.7 126.04 30.42 Favored 'General case' 0 C--O 1.221 -0.405 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 178.386 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 19.7 t-20 -66.89 100.19 0.7 Allowed 'General case' 0 N--CA 1.474 0.761 0 N-CA-C 108.673 -0.862 . . . . 0.0 108.673 178.565 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 66.8 mttm -96.68 120.47 37.06 Favored 'General case' 0 N--CA 1.483 1.186 0 N-CA-C 110.118 -0.327 . . . . 0.0 110.118 -179.142 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.68 -127.73 0.01 OUTLIER Glycine 0 CA--C 1.534 1.246 0 N-CA-C 110.538 -1.025 . . . . 0.0 110.538 178.755 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -126.83 133.62 50.72 Favored 'General case' 0 N--CA 1.481 1.104 0 N-CA-C 109.165 -0.68 . . . . 0.0 109.165 179.252 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 64.4 mt -82.96 137.97 20.11 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.452 0 N-CA-C 107.363 -1.347 . . . . 0.0 107.363 178.59 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 21.6 mt -129.72 129.19 66.26 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.971 0 O-C-N 123.546 0.528 . . . . 0.0 109.941 -178.42 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 60.4 78.76 0.14 Allowed Glycine 0 CA--C 1.524 0.63 0 CA-C-N 115.828 -0.624 . . . . 0.0 113.094 178.915 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 34' ' ' LEU . . . . . 0.417 HD23 ' N ' ' B' ' 35' ' ' MET . 1.9 tt -110.39 119.61 39.77 Favored 'General case' 0 N--CA 1.478 0.953 0 N-CA-C 106.975 -1.491 . . . . 0.0 106.975 177.351 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 35' ' ' MET . . . . . 0.417 ' N ' HD23 ' B' ' 34' ' ' LEU . 8.7 ttt -154.89 160.79 41.43 Favored 'General case' 0 N--CA 1.47 0.562 0 N-CA-C 108.97 -0.752 . . . . 0.0 108.97 179.283 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 63.4 t -157.64 150.31 8.81 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.136 0 N-CA-C 106.825 -1.546 . . . . 0.0 106.825 -179.511 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.54 75.73 0.23 Allowed Glycine 0 C--N 1.314 -0.669 0 CA-C-N 115.659 -0.701 . . . . 0.0 111.771 178.169 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 168.52 -149.09 13.32 Favored Glycine 0 CA--C 1.519 0.306 0 N-CA-C 110.704 -0.958 . . . . 0.0 110.704 179.879 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 20.7 m -132.52 142.91 41.32 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.907 0 N-CA-C 109.643 -0.503 . . . . 0.0 109.643 179.676 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 21.2 t . . . . . 0 N--CA 1.467 0.405 0 CA-C-O 117.812 -1.089 . . . . 0.0 110.848 179.292 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' C' C ' 1' ' ' ASP . . . . . . . . . . . . . 8.5 m-20 . . . . . 0 N--CA 1.487 1.419 0 N-CA-C 109.066 -0.716 . . . . 0.0 109.066 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' C' C ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.41 132.76 49.78 Favored 'General case' 0 CA--C 1.538 0.513 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.189 -179.935 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 3' ' ' GLU . . . . . . . . . . . . . 41.5 tt0 -169.56 108.38 0.41 Allowed 'General case' 0 N--CA 1.47 0.543 0 N-CA-C 109.588 -0.523 . . . . 0.0 109.588 -179.276 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 78.1 m-85 -83.65 140.42 32.19 Favored 'General case' 0 N--CA 1.474 0.737 0 N-CA-C 109.939 -0.393 . . . . 0.0 109.939 179.433 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 72.4 mtp180 -143.61 141.07 30.46 Favored 'General case' 0 N--CA 1.482 1.136 0 N-CA-C 109.043 -0.725 . . . . 0.0 109.043 -179.857 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 76.5 m80 -149.47 119.64 7.26 Favored 'General case' 0 N--CA 1.47 0.571 0 N-CA-C 108.826 -0.805 . . . . 0.0 108.826 179.109 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 7' ' ' ASP . . . . . . . . . . . . . 7.6 m-20 -68.13 150.03 48.86 Favored 'General case' 0 CA--C 1.529 0.168 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.332 -179.381 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 8' ' ' SER . . . . . . . . . . . . . 8.5 t -166.71 172.73 10.27 Favored 'General case' 0 N--CA 1.471 0.618 0 N-CA-C 109.611 -0.514 . . . . 0.0 109.611 178.352 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.13 23.33 2.46 Favored Glycine 0 N--CA 1.487 2.042 0 N-CA-C 112.24 -0.344 . . . . 0.0 112.24 179.484 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 41.5 p90 -56.84 128.34 36.2 Favored 'General case' 0 N--CA 1.472 0.646 0 N-CA-C 112.088 0.403 . . . . 0.0 112.088 -179.896 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 57.5 mt-10 -85.79 155.27 21.08 Favored 'General case' 0 N--CA 1.47 0.556 0 N-CA-C 109.239 -0.652 . . . . 0.0 109.239 178.63 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -153.59 128.61 1.5 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 N-CA-C 108.181 -1.044 . . . . 0.0 108.181 178.853 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 49.5 m-70 -134.49 146.65 49.94 Favored 'General case' 0 N--CA 1.489 1.49 0 CA-C-N 118.541 0.609 . . . . 0.0 111.265 -179.105 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 6.4 t60 -165.15 98.04 0.72 Allowed 'General case' 0 N--CA 1.48 1.067 0 CA-C-N 116.572 -0.286 . . . . 0.0 111.085 179.596 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 35.1 mt-30 -106.36 -172.76 2.15 Favored 'General case' 0 CA--C 1.504 -0.807 0 N-CA-C 108.414 -0.958 . . . . 0.0 108.414 -179.99 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 16' ' ' LYS . . . . . 0.408 ' C ' HD12 ' C' ' 17' ' ' LEU . 88.7 tttt -169.18 96.45 0.34 Allowed 'General case' 0 CA--C 1.54 0.56 0 CA-C-N 115.12 -0.945 . . . . 0.0 109.451 178.751 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' C' C ' 17' ' ' LEU . . . . . 0.577 HD12 ' N ' ' C' ' 17' ' ' LEU . 4.8 mp -106.26 164.91 11.63 Favored 'General case' 0 N--CA 1.488 1.472 0 N-CA-C 108.584 -0.895 . . . . 0.0 108.584 179.968 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 58.5 t -141.71 118.94 7.76 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.341 0 CA-C-O 118.95 -0.548 . . . . 0.0 109.879 179.655 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 53.3 m-85 -70.25 159.0 34.84 Favored 'General case' 0 N--CA 1.478 0.956 0 N-CA-C 107.491 -1.3 . . . . 0.0 107.491 177.345 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 14.4 t80 -171.77 -57.41 0.02 OUTLIER 'General case' 0 N--CA 1.481 1.092 0 CA-C-O 122.183 0.992 . . . . 0.0 109.856 179.357 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -39.26 90.61 0.0 OUTLIER 'General case' 0 C--O 1.232 0.14 0 CA-C-N 114.125 -1.398 . . . . 0.0 112.849 -178.049 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 37.0 tt0 -66.74 158.05 31.21 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 115.096 -0.956 . . . . 0.0 110.513 179.219 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 67.2 m-20 -140.33 137.4 34.08 Favored 'General case' 0 N--CA 1.48 1.054 0 C-N-CA 122.944 0.498 . . . . 0.0 110.331 179.794 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 17.7 t -84.53 -116.42 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.967 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 179.588 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -109.86 54.35 0.55 Allowed Glycine 0 N--CA 1.475 1.275 0 N-CA-C 111.172 -0.771 . . . . 0.0 111.172 179.915 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 74.7 p -79.91 126.25 30.77 Favored 'General case' 0 C--O 1.222 -0.358 0 N-CA-C 109.004 -0.739 . . . . 0.0 109.004 178.417 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 19.4 t-20 -66.99 100.37 0.73 Allowed 'General case' 0 N--CA 1.474 0.737 0 N-CA-C 108.682 -0.858 . . . . 0.0 108.682 178.606 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 66.8 mttm -96.86 120.09 36.54 Favored 'General case' 0 N--CA 1.484 1.251 0 N-CA-C 110.161 -0.311 . . . . 0.0 110.161 -179.138 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.34 -128.17 0.01 OUTLIER Glycine 0 CA--C 1.535 1.313 0 N-CA-C 110.529 -1.028 . . . . 0.0 110.529 178.76 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -126.33 133.75 51.29 Favored 'General case' 0 N--CA 1.48 1.073 0 N-CA-C 109.269 -0.641 . . . . 0.0 109.269 179.12 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 65.7 mt -83.06 137.82 20.35 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.525 0 N-CA-C 107.282 -1.377 . . . . 0.0 107.282 178.614 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 20.9 mt -129.59 128.81 66.27 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.935 0 O-C-N 123.545 0.528 . . . . 0.0 110.119 -178.507 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 60.84 78.55 0.15 Allowed Glycine 0 CA--C 1.524 0.654 0 CA-C-N 115.97 -0.559 . . . . 0.0 113.063 178.848 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 34' ' ' LEU . . . . . 0.413 HD23 ' N ' ' C' ' 35' ' ' MET . 1.9 tt -110.41 119.16 38.31 Favored 'General case' 0 N--CA 1.478 0.945 0 N-CA-C 107.021 -1.474 . . . . 0.0 107.021 177.463 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' C' C ' 35' ' ' MET . . . . . 0.413 ' N ' HD23 ' C' ' 34' ' ' LEU . 8.5 ttt -154.44 161.08 41.89 Favored 'General case' 0 N--CA 1.468 0.456 0 N-CA-C 108.976 -0.75 . . . . 0.0 108.976 179.356 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 63.4 t -158.03 150.13 8.42 Favored 'Isoleucine or valine' 0 C--O 1.232 0.158 0 N-CA-C 106.816 -1.55 . . . . 0.0 106.816 -179.393 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.68 75.54 0.24 Allowed Glycine 0 C--N 1.315 -0.635 0 CA-C-N 115.776 -0.647 . . . . 0.0 111.75 178.172 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 168.76 -148.95 12.95 Favored Glycine 0 CA--C 1.519 0.325 0 N-CA-C 110.639 -0.984 . . . . 0.0 110.639 179.88 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 20.1 m -132.79 142.7 41.67 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.875 0 N-CA-C 109.666 -0.494 . . . . 0.0 109.666 179.716 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 21.3 t . . . . . 0 N--CA 1.468 0.454 0 CA-C-O 117.726 -1.13 . . . . 0.0 110.718 179.244 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' D' D ' 1' ' ' ASP . . . . . . . . . . . . . 8.8 m-20 . . . . . 0 N--CA 1.49 1.543 0 N-CA-C 109.154 -0.684 . . . . 0.0 109.154 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' D' D ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.4 131.24 46.64 Favored 'General case' 0 CA--C 1.535 0.391 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.376 179.789 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' D' D ' 3' ' ' GLU . . . . . . . . . . . . . 41.0 tt0 -169.39 110.58 0.47 Allowed 'General case' 0 N--CA 1.47 0.533 0 N-CA-C 109.387 -0.597 . . . . 0.0 109.387 179.472 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 86.9 m-85 -87.04 148.2 25.38 Favored 'General case' 0 C--N 1.363 1.171 0 C-N-CA 118.526 -1.27 . . . . 0.0 108.275 179.768 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' D' D ' 5' ' ' ARG . . . . . . . . . . . . . 72.5 mtp180 -147.31 141.18 25.82 Favored 'General case' 0 N--CA 1.476 0.829 0 N-CA-C 108.896 -0.779 . . . . 0.0 108.896 179.757 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 77.1 m80 -149.22 123.43 9.53 Favored 'General case' 0 CA--C 1.539 0.527 0 N-CA-C 107.915 -1.143 . . . . 0.0 107.915 175.724 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' D' D ' 7' ' ' ASP . . . . . . . . . . . . . 5.6 m-20 -63.12 133.77 54.96 Favored 'General case' 0 C--N 1.319 -0.719 0 C-N-CA 127.188 2.195 . . . . 0.0 114.882 176.081 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' D' D ' 8' ' ' SER . . . . . . . . . . . . . 7.9 t -154.09 174.36 14.81 Favored 'General case' 0 N--CA 1.477 0.914 0 CA-C-N 118.751 0.705 . . . . 0.0 110.302 176.958 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 124.29 20.25 2.48 Favored Glycine 0 N--CA 1.483 1.787 0 N-CA-C 112.232 -0.347 . . . . 0.0 112.232 176.645 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 37.0 p90 -55.91 130.29 43.11 Favored 'General case' 0 CA--C 1.546 0.79 0 CA-C-O 121.07 0.462 . . . . 0.0 111.881 -177.494 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 57.3 mt-10 -85.71 152.83 22.76 Favored 'General case' 0 N--CA 1.474 0.759 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 177.681 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -149.38 129.97 4.45 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.455 0 N-CA-C 108.009 -1.108 . . . . 0.0 108.009 175.229 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 48.9 m-70 -129.74 149.7 51.38 Favored 'General case' 0 N--CA 1.482 1.128 0 CA-C-N 117.939 0.336 . . . . 0.0 111.503 176.727 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 6.6 t60 -164.81 104.66 0.8 Allowed 'General case' 0 N--CA 1.482 1.133 0 N-CA-C 109.539 -0.541 . . . . 0.0 109.539 173.203 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 35.2 mt-30 -109.32 -175.62 2.81 Favored 'General case' 0 CA--C 1.494 -1.18 0 N-CA-C 108.28 -1.007 . . . . 0.0 108.28 178.978 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' D' D ' 16' ' ' LYS . . . . . 0.453 ' C ' HD12 ' D' ' 17' ' ' LEU . 88.7 tttt -165.77 105.25 0.7 Allowed 'General case' 0 CA--C 1.538 0.504 0 N-CA-C 107.637 -1.246 . . . . 0.0 107.637 175.331 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' D' D ' 17' ' ' LEU . . . . . 0.522 HD12 ' N ' ' D' ' 17' ' ' LEU . 5.6 mp -113.2 163.2 15.07 Favored 'General case' 0 N--CA 1.488 1.454 0 N-CA-C 108.225 -1.028 . . . . 0.0 108.225 179.699 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 51.8 t -140.9 123.67 15.72 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.187 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 176.215 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 78.7 m-85 -62.43 151.2 37.84 Favored 'General case' 0 C--N 1.353 0.759 0 C-N-CA 124.726 1.21 . . . . 0.0 110.412 170.862 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 9.3 t80 -170.0 -66.64 0.02 OUTLIER 'General case' 0 N--CA 1.476 0.871 0 N-CA-C 107.81 -1.182 . . . . 0.0 107.81 -179.835 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -38.27 95.75 0.01 OUTLIER 'General case' 0 CA--C 1.535 0.39 0 CA-C-N 113.972 -1.467 . . . . 0.0 111.731 -174.603 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 37.2 tt0 -68.7 158.72 33.61 Favored 'General case' 0 N--CA 1.467 0.421 0 CA-C-N 113.36 -1.746 . . . . 0.0 110.243 178.65 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 67.8 m-20 -140.34 141.17 35.69 Favored 'General case' 0 N--CA 1.475 0.822 0 N-CA-C 109.517 -0.549 . . . . 0.0 109.517 178.585 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' D' D ' 24' ' ' VAL . . . . . . . . . . . . . 19.6 t -87.83 -119.62 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.486 1.368 0 N-CA-C 107.752 -1.203 . . . . 0.0 107.752 179.727 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . -113.31 61.85 0.32 Allowed Glycine 0 C--N 1.372 2.559 0 C-N-CA 118.005 -2.045 . . . . 0.0 109.313 178.81 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 90.9 p -70.35 121.44 17.69 Favored 'General case' 0 C--N 1.349 0.574 0 CA-C-O 116.647 -1.644 . . . . 0.0 112.016 169.276 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 17.2 t-20 -61.36 101.67 0.18 Allowed 'General case' 0 N--CA 1.474 0.772 0 CA-C-N 121.558 1.981 . . . . 0.0 109.486 172.485 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 66.3 mttm -100.12 121.75 41.9 Favored 'General case' 0 N--CA 1.49 1.558 0 CA-C-N 119.64 1.109 . . . . 0.0 109.366 178.803 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -54.16 -130.2 0.0 OUTLIER Glycine 0 CA--C 1.529 0.961 0 CA-C-N 115.664 -0.698 . . . . 0.0 112.68 175.57 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -125.17 139.95 53.29 Favored 'General case' 0 C--N 1.373 1.614 0 N-CA-C 108.567 -0.901 . . . . 0.0 108.567 174.052 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 65.3 mt -84.13 140.29 16.35 Favored 'Isoleucine or valine' 0 C--O 1.239 0.506 0 N-CA-C 107.403 -1.332 . . . . 0.0 107.403 176.478 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 29.1 mt -131.89 132.95 61.51 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.017 0 N-CA-C 108.66 -0.866 . . . . 0.0 108.66 178.367 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.31 76.99 0.22 Allowed Glycine 0 C--O 1.248 0.994 0 CA-C-O 118.102 -1.388 . . . . 0.0 112.404 178.449 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' D' D ' 34' ' ' LEU . . . . . 0.406 HD23 ' N ' ' D' ' 35' ' ' MET . 2.4 tt -110.2 131.43 55.07 Favored 'General case' 0 C--N 1.372 1.562 0 N-CA-C 103.96 -2.607 . . . . 0.0 103.96 174.968 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' D' D ' 35' ' ' MET . . . . . 0.406 ' N ' HD23 ' D' ' 34' ' ' LEU . 8.3 ttt -156.85 166.7 32.63 Favored 'General case' 0 N--CA 1.471 0.594 0 N-CA-C 108.679 -0.86 . . . . 0.0 108.679 176.685 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 91.6 t -163.58 154.31 2.55 Favored 'Isoleucine or valine' 0 C--O 1.241 0.647 0 N-CA-C 105.545 -2.02 . . . . 0.0 105.545 175.379 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 61.39 66.51 2.61 Favored Glycine 0 N--CA 1.444 -0.782 0 C-N-CA 118.039 -2.029 . . . . 0.0 113.619 176.76 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 167.27 -148.39 13.05 Favored Glycine 0 N--CA 1.468 0.805 0 CA-C-O 118.163 -1.354 . . . . 0.0 111.859 -178.577 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 21.4 m -129.74 143.04 42.32 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.166 0 CA-C-N 118.896 1.348 . . . . 0.0 109.64 -179.944 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 18.8 t . . . . . 0 C--O 1.215 -0.745 0 N-CA-C 109.204 -0.665 . . . . 0.0 109.204 174.798 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' E' E ' 1' ' ' ASP . . . . . . . . . . . . . 8.5 m-20 . . . . . 0 N--CA 1.489 1.498 0 N-CA-C 109.225 -0.657 . . . . 0.0 109.225 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' E' E ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.46 131.18 46.4 Favored 'General case' 0 N--CA 1.468 0.443 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.371 179.927 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' E' E ' 3' ' ' GLU . . . . . . . . . . . . . 41.4 tt0 -168.83 108.53 0.48 Allowed 'General case' 0 N--CA 1.469 0.504 0 N-CA-C 109.978 -0.379 . . . . 0.0 109.978 -179.851 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 79.1 m-85 -84.5 140.69 31.29 Favored 'General case' 0 N--CA 1.476 0.829 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 179.434 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' E' E ' 5' ' ' ARG . . . . . . . . . . . . . 72.3 mtp180 -143.62 141.96 30.84 Favored 'General case' 0 N--CA 1.478 0.933 0 N-CA-C 109.392 -0.595 . . . . 0.0 109.392 179.893 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 76.8 m80 -150.37 118.23 6.24 Favored 'General case' 0 N--CA 1.473 0.692 0 N-CA-C 108.962 -0.755 . . . . 0.0 108.962 179.123 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' E' E ' 7' ' ' ASP . . . . . . . . . . . . . 7.5 m-20 -66.7 149.96 49.77 Favored 'General case' 0 N--CA 1.463 0.224 0 O-C-N 123.542 0.526 . . . . 0.0 111.639 -179.515 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' E' E ' 8' ' ' SER . . . . . . . . . . . . . 7.9 t -166.95 173.43 9.33 Favored 'General case' 0 N--CA 1.476 0.875 0 CA-C-N 115.965 -0.561 . . . . 0.0 109.549 178.003 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.85 23.59 2.23 Favored Glycine 0 N--CA 1.482 1.737 0 N-CA-C 111.908 -0.477 . . . . 0.0 111.908 179.163 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 38.2 p90 -56.64 127.49 31.65 Favored 'General case' 0 N--CA 1.473 0.676 0 N-CA-C 112.602 0.593 . . . . 0.0 112.602 -179.241 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 57.0 mt-10 -84.34 156.2 21.99 Favored 'General case' 0 N--CA 1.476 0.827 0 N-CA-C 109.482 -0.562 . . . . 0.0 109.482 178.045 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -155.62 127.9 1.03 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.512 0 N-CA-C 108.185 -1.042 . . . . 0.0 108.185 178.702 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 49.0 m-70 -135.08 144.81 47.4 Favored 'General case' 0 N--CA 1.48 1.073 0 CA-C-O 120.757 0.313 . . . . 0.0 111.38 -177.933 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 6.3 t60 -163.94 97.94 0.84 Allowed 'General case' 0 N--CA 1.487 1.379 0 CA-C-N 116.652 -0.249 . . . . 0.0 111.064 179.702 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 35.2 mt-30 -105.51 -172.45 2.1 Favored 'General case' 0 CA--C 1.502 -0.878 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 -179.951 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -169.45 96.56 0.32 Allowed 'General case' 0 CA--C 1.542 0.638 0 CA-C-N 115.018 -0.992 . . . . 0.0 109.402 178.658 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' E' E ' 17' ' ' LEU . . . . . 0.566 ' N ' HD12 ' E' ' 17' ' ' LEU . 4.8 mp -106.21 164.11 12.26 Favored 'General case' 0 N--CA 1.49 1.547 0 N-CA-C 109.233 -0.654 . . . . 0.0 109.233 -179.765 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 40.8 t -141.59 118.46 7.5 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 C-N-CA 122.563 0.345 . . . . 0.0 110.551 179.085 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 52.7 m-85 -69.45 156.54 38.69 Favored 'General case' 0 C--N 1.358 0.957 0 N-CA-C 107.397 -1.335 . . . . 0.0 107.397 176.696 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 12.7 t80 -173.28 -55.06 0.02 OUTLIER 'General case' 0 N--CA 1.485 1.299 0 CA-C-O 121.741 0.782 . . . . 0.0 110.368 179.472 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.23 89.1 0.0 OUTLIER 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 114.398 -1.274 . . . . 0.0 112.852 -179.009 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 37.0 tt0 -65.16 158.31 26.37 Favored 'General case' 0 N--CA 1.472 0.646 0 CA-C-N 114.876 -1.056 . . . . 0.0 110.698 179.604 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 66.1 m-20 -140.68 137.03 33.23 Favored 'General case' 0 N--CA 1.479 0.997 0 C-N-CA 122.853 0.461 . . . . 0.0 110.518 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 21.8 t -84.52 -115.5 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.066 0 N-CA-C 108.715 -0.846 . . . . 0.0 108.715 179.48 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . -110.09 54.38 0.55 Allowed Glycine 0 C--N 1.348 1.214 0 N-CA-C 111.362 -0.695 . . . . 0.0 111.362 -179.827 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 73.2 p -79.72 125.27 29.44 Favored 'General case' 0 N--CA 1.473 0.709 0 N-CA-C 109.34 -0.615 . . . . 0.0 109.34 178.059 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 18.4 t-20 -66.27 99.88 0.58 Allowed 'General case' 0 N--CA 1.474 0.765 0 N-CA-C 108.063 -1.088 . . . . 0.0 108.063 178.386 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 65.9 mttm -96.99 119.45 35.5 Favored 'General case' 0 N--CA 1.485 1.293 0 N-CA-C 109.966 -0.383 . . . . 0.0 109.966 -178.744 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.28 -127.32 0.01 OUTLIER Glycine 0 CA--C 1.539 1.581 0 N-CA-C 110.988 -0.845 . . . . 0.0 110.988 178.724 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -126.9 133.2 50.73 Favored 'General case' 0 N--CA 1.481 1.102 0 N-CA-C 109.585 -0.524 . . . . 0.0 109.585 179.614 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 64.8 mt -82.38 138.17 19.88 Favored 'Isoleucine or valine' 0 C--O 1.236 0.35 0 N-CA-C 107.093 -1.447 . . . . 0.0 107.093 178.492 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 22.4 mt -129.3 129.49 67.35 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.858 0 N-CA-C 109.444 -0.576 . . . . 0.0 109.444 -179.426 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 60.65 80.27 0.1 Allowed Glycine 0 CA--C 1.523 0.554 0 CA-C-N 115.982 -0.554 . . . . 0.0 113.654 179.33 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 2.0 tt -111.98 118.99 36.99 Favored 'General case' 0 N--CA 1.479 0.992 0 N-CA-C 107.056 -1.461 . . . . 0.0 107.056 177.358 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 8.2 ttt -153.37 162.88 40.82 Favored 'General case' 0 C--O 1.209 -1.041 0 N-CA-C 108.696 -0.853 . . . . 0.0 108.696 179.202 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 78.0 t -159.65 150.27 6.46 Favored 'Isoleucine or valine' 0 C--O 1.236 0.351 0 N-CA-C 106.591 -1.633 . . . . 0.0 106.591 -179.748 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.53 74.97 0.27 Allowed Glycine 0 C--N 1.314 -0.656 0 CA-C-N 115.63 -0.714 . . . . 0.0 111.535 178.139 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 170.08 -148.14 11.44 Favored Glycine 0 C--O 1.222 -0.653 0 N-CA-C 111.248 -0.741 . . . . 0.0 111.248 -179.995 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 19.4 m -133.42 141.54 44.18 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.846 0 N-CA-C 109.188 -0.671 . . . . 0.0 109.188 179.498 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 19.0 t . . . . . 0 CA--C 1.535 0.372 0 CA-C-O 117.648 -1.168 . . . . 0.0 110.847 179.35 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' F' F ' 1' ' ' ASP . . . . . . . . . . . . . 9.0 m-20 . . . . . 0 N--CA 1.492 1.638 0 N-CA-C 109.131 -0.692 . . . . 0.0 109.131 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' F' F ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.67 131.38 46.78 Favored 'General case' 0 CA--C 1.535 0.386 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.402 179.792 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' F' F ' 3' ' ' GLU . . . . . . . . . . . . . 41.1 tt0 -169.15 108.65 0.45 Allowed 'General case' 0 N--CA 1.471 0.578 0 N-CA-C 109.907 -0.405 . . . . 0.0 109.907 -179.859 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 78.7 m-85 -84.61 140.59 31.26 Favored 'General case' 0 N--CA 1.475 0.798 0 O-C-N 122.031 -0.418 . . . . 0.0 109.895 179.347 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' F' F ' 5' ' ' ARG . . . . . . . . . . . . . 72.4 mtp180 -143.43 141.62 30.91 Favored 'General case' 0 N--CA 1.477 0.878 0 N-CA-C 109.38 -0.6 . . . . 0.0 109.38 179.895 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 76.8 m80 -150.12 117.87 6.21 Favored 'General case' 0 N--CA 1.473 0.714 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 179.207 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' F' F ' 7' ' ' ASP . . . . . . . . . . . . . 7.5 m-20 -66.5 150.42 48.98 Favored 'General case' 0 N--CA 1.461 0.106 0 O-C-N 123.468 0.48 . . . . 0.0 111.711 -179.447 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' F' F ' 8' ' ' SER . . . . . . . . . . . . . 7.8 t -167.53 172.9 9.09 Favored 'General case' 0 N--CA 1.476 0.847 0 CA-C-N 116.015 -0.539 . . . . 0.0 109.568 178.065 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 123.34 23.63 2.12 Favored Glycine 0 N--CA 1.481 1.637 0 N-CA-C 111.997 -0.441 . . . . 0.0 111.997 179.064 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 36.6 p90 -56.74 127.97 34.18 Favored 'General case' 0 CA--C 1.542 0.671 0 N-CA-C 112.599 0.592 . . . . 0.0 112.599 -179.217 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 57.2 mt-10 -84.41 156.37 21.84 Favored 'General case' 0 N--CA 1.475 0.813 0 N-CA-C 109.457 -0.571 . . . . 0.0 109.457 178.063 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -155.77 127.53 0.96 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.586 0 N-CA-C 108.189 -1.041 . . . . 0.0 108.189 178.637 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 50.3 m-70 -134.76 144.73 47.87 Favored 'General case' 0 N--CA 1.481 1.078 0 CA-C-O 120.748 0.309 . . . . 0.0 111.341 -177.819 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 6.3 t60 -164.11 98.13 0.83 Allowed 'General case' 0 N--CA 1.486 1.356 0 CA-C-N 116.707 -0.224 . . . . 0.0 111.169 179.674 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 35.2 mt-30 -106.09 -172.36 2.07 Favored 'General case' 0 CA--C 1.498 -1.05 0 N-CA-C 108.787 -0.82 . . . . 0.0 108.787 179.989 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -169.23 96.87 0.34 Allowed 'General case' 0 CA--C 1.54 0.584 0 CA-C-N 114.891 -1.05 . . . . 0.0 109.443 178.687 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' F' F ' 17' ' ' LEU . . . . . 0.565 HD12 ' N ' ' F' ' 17' ' ' LEU . 4.7 mp -106.27 164.1 12.29 Favored 'General case' 0 N--CA 1.489 1.48 0 N-CA-C 109.209 -0.663 . . . . 0.0 109.209 -179.842 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 41.3 t -141.69 118.74 7.6 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.457 0 C-N-CA 122.55 0.34 . . . . 0.0 110.473 179.098 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 53.2 m-85 -69.56 156.49 38.82 Favored 'General case' 0 C--N 1.358 0.949 0 N-CA-C 107.253 -1.388 . . . . 0.0 107.253 176.612 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 13.1 t80 -173.15 -55.48 0.02 OUTLIER 'General case' 0 N--CA 1.484 1.267 0 CA-C-O 121.735 0.778 . . . . 0.0 109.904 179.484 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.73 88.89 0.0 OUTLIER 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 114.428 -1.26 . . . . 0.0 112.95 -179.047 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 36.7 tt0 -65.16 158.2 26.65 Favored 'General case' 0 N--CA 1.47 0.567 0 CA-C-N 114.952 -1.022 . . . . 0.0 110.786 179.504 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 66.5 m-20 -140.84 137.32 33.18 Favored 'General case' 0 N--CA 1.478 0.949 0 C-N-CA 122.813 0.445 . . . . 0.0 110.58 179.994 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' F' F ' 24' ' ' VAL . . . . . . . . . . . . . 21.5 t -84.84 -115.98 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.09 0 N-CA-C 108.811 -0.811 . . . . 0.0 108.811 179.523 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -109.48 54.08 0.56 Allowed Glycine 0 N--CA 1.479 1.511 0 N-CA-C 111.24 -0.744 . . . . 0.0 111.24 -179.836 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 75.6 p -79.46 125.04 29.04 Favored 'General case' 0 N--CA 1.472 0.668 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 177.883 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 18.5 t-20 -66.19 99.71 0.55 Allowed 'General case' 0 N--CA 1.472 0.672 0 N-CA-C 108.125 -1.065 . . . . 0.0 108.125 178.457 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 66.1 mttm -96.78 119.29 34.98 Favored 'General case' 0 N--CA 1.484 1.269 0 N-CA-C 110.056 -0.35 . . . . 0.0 110.056 -178.711 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.19 -127.51 0.01 OUTLIER Glycine 0 CA--C 1.54 1.623 0 N-CA-C 111.093 -0.803 . . . . 0.0 111.093 178.796 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -126.35 133.14 51.43 Favored 'General case' 0 N--CA 1.482 1.161 0 N-CA-C 109.577 -0.527 . . . . 0.0 109.577 179.612 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 65.4 mt -82.73 138.07 19.98 Favored 'Isoleucine or valine' 0 C--O 1.236 0.345 0 N-CA-C 106.958 -1.497 . . . . 0.0 106.958 178.497 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 23.5 mt -129.22 129.61 67.59 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.811 0 N-CA-C 109.381 -0.6 . . . . 0.0 109.381 -179.365 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 60.51 80.17 0.1 Allowed Glycine 0 CA--C 1.522 0.518 0 CA-C-N 115.986 -0.552 . . . . 0.0 113.618 179.271 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' F' F ' 34' ' ' LEU . . . . . 0.407 HD23 ' N ' ' F' ' 35' ' ' MET . 2.0 tt -111.89 119.28 38.0 Favored 'General case' 0 N--CA 1.479 0.991 0 N-CA-C 106.971 -1.492 . . . . 0.0 106.971 177.472 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' F' F ' 35' ' ' MET . . . . . 0.407 ' N ' HD23 ' F' ' 34' ' ' LEU . 8.5 ttt -153.93 162.97 40.8 Favored 'General case' 0 C--O 1.209 -1.075 0 N-CA-C 108.81 -0.811 . . . . 0.0 108.81 179.212 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 81.2 t -159.61 150.64 6.4 Favored 'Isoleucine or valine' 0 C--O 1.237 0.412 0 N-CA-C 106.713 -1.588 . . . . 0.0 106.713 -179.651 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.34 75.0 0.26 Allowed Glycine 0 C--N 1.314 -0.644 0 CA-C-N 115.662 -0.699 . . . . 0.0 111.483 178.089 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 170.1 -147.89 11.19 Favored Glycine 0 C--O 1.221 -0.668 0 N-CA-C 111.226 -0.75 . . . . 0.0 111.226 -179.993 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 19.6 m -133.77 141.42 44.17 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.884 0 N-CA-C 109.203 -0.666 . . . . 0.0 109.203 179.442 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 19.3 t . . . . . 0 CA--C 1.533 0.313 0 CA-C-O 117.605 -1.188 . . . . 0.0 110.868 179.365 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' G' G ' 1' ' ' ASP . . . . . . . . . . . . . 8.7 m-20 . . . . . 0 N--CA 1.491 1.608 0 N-CA-C 109.624 -0.509 . . . . 0.0 109.624 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' G' G ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.71 129.47 40.68 Favored 'General case' 0 N--CA 1.468 0.471 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.445 179.661 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' G' G ' 3' ' ' GLU . . . . . . . . . . . . . 40.7 tt0 -168.87 108.14 0.46 Allowed 'General case' 0 N--CA 1.469 0.512 0 N-CA-C 110.233 -0.284 . . . . 0.0 110.233 179.709 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 78.6 m-85 -84.87 140.19 31.33 Favored 'General case' 0 N--CA 1.476 0.836 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 179.227 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' G' G ' 5' ' ' ARG . . . . . . . . . . . . . 72.7 mtp180 -143.93 141.16 30.09 Favored 'General case' 0 N--CA 1.483 1.191 0 N-CA-C 109.282 -0.636 . . . . 0.0 109.282 -179.657 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 76.9 m80 -149.49 119.36 7.1 Favored 'General case' 0 N--CA 1.473 0.715 0 N-CA-C 109.05 -0.722 . . . . 0.0 109.05 179.116 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 8.0 m-20 -68.74 145.96 53.36 Favored 'General case' 0 CA--C 1.536 0.411 0 O-C-N 123.472 0.482 . . . . 0.0 111.942 -179.327 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' G' G ' 8' ' ' SER . . . . . . . . . . . . . 7.1 t -163.83 174.2 11.83 Favored 'General case' 0 N--CA 1.47 0.55 0 N-CA-C 109.443 -0.577 . . . . 0.0 109.443 178.171 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 123.06 23.34 2.23 Favored Glycine 0 N--CA 1.48 1.606 0 N-CA-C 111.643 -0.583 . . . . 0.0 111.643 178.89 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 40.8 p90 -56.86 127.86 33.82 Favored 'General case' 0 N--CA 1.473 0.68 0 N-CA-C 112.418 0.525 . . . . 0.0 112.418 -178.89 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 57.6 mt-10 -84.94 154.74 22.0 Favored 'General case' 0 N--CA 1.473 0.717 0 CA-C-O 121.054 0.454 . . . . 0.0 109.981 178.795 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -155.26 127.67 1.04 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.97 0 N-CA-C 108.246 -1.02 . . . . 0.0 108.246 178.847 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 51.6 m-70 -133.77 146.13 50.44 Favored 'General case' 0 N--CA 1.476 0.844 0 CA-C-N 115.443 -0.799 . . . . 0.0 111.09 -178.159 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 6.4 t60 -165.57 97.74 0.68 Allowed 'General case' 0 N--CA 1.483 1.183 0 CA-C-N 116.511 -0.313 . . . . 0.0 110.656 179.123 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 35.8 mt-30 -105.7 -172.64 2.13 Favored 'General case' 0 CA--C 1.503 -0.862 0 N-CA-C 108.726 -0.842 . . . . 0.0 108.726 -179.849 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' G' G ' 16' ' ' LYS . . . . . 0.405 ' C ' HD12 ' G' ' 17' ' ' LEU . 88.5 tttt -169.2 97.07 0.35 Allowed 'General case' 0 CA--C 1.54 0.587 0 CA-C-N 115.0 -1.0 . . . . 0.0 109.444 178.629 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' G' G ' 17' ' ' LEU . . . . . 0.572 ' N ' HD12 ' G' ' 17' ' ' LEU . 5.4 mp -106.31 163.14 13.07 Favored 'General case' 0 N--CA 1.487 1.387 0 N-CA-C 109.427 -0.583 . . . . 0.0 109.427 -179.669 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 39.6 t -142.5 118.92 6.04 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.068 0 CA-C-O 120.886 0.374 . . . . 0.0 110.327 178.779 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 47.2 m-85 -69.79 150.32 47.0 Favored 'General case' 0 C--N 1.37 1.482 0 N-CA-C 107.357 -1.349 . . . . 0.0 107.357 176.737 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 10.7 t80 -170.73 -55.26 0.02 OUTLIER 'General case' 0 N--CA 1.486 1.359 0 CA-C-N 117.903 0.319 . . . . 0.0 110.356 -179.601 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.73 90.02 0.0 OUTLIER 'General case' 0 C--N 1.325 -0.477 0 C-N-CA 123.74 0.816 . . . . 0.0 112.574 -179.882 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 37.1 tt0 -65.54 159.3 24.87 Favored 'General case' 0 N--CA 1.468 0.462 0 CA-C-N 114.694 -1.139 . . . . 0.0 109.954 179.069 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 67.2 m-20 -141.23 137.35 32.51 Favored 'General case' 0 N--CA 1.476 0.873 0 C-N-CA 122.792 0.437 . . . . 0.0 109.993 179.962 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' G' G ' 24' ' ' VAL . . . . . . . . . . . . . 21.6 t -85.53 -115.41 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.99 0 N-CA-C 108.408 -0.96 . . . . 0.0 108.408 179.598 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -110.16 53.9 0.57 Allowed Glycine 0 N--CA 1.478 1.443 0 N-CA-C 111.612 -0.595 . . . . 0.0 111.612 -179.812 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 75.8 p -79.67 125.88 30.21 Favored 'General case' 0 N--CA 1.466 0.366 0 N-CA-C 109.119 -0.697 . . . . 0.0 109.119 178.026 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 19.2 t-20 -66.87 100.5 0.73 Allowed 'General case' 0 CA--C 1.54 0.569 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 178.424 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 67.0 mttm -96.7 119.93 36.09 Favored 'General case' 0 N--CA 1.482 1.139 0 N-CA-C 110.085 -0.339 . . . . 0.0 110.085 -179.087 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.76 -125.52 0.01 OUTLIER Glycine 0 CA--C 1.533 1.21 0 N-CA-C 110.571 -1.012 . . . . 0.0 110.571 178.828 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -127.81 133.09 49.41 Favored 'General case' 0 N--CA 1.47 0.555 0 N-CA-C 109.579 -0.526 . . . . 0.0 109.579 179.684 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 68.2 mt -81.93 140.19 16.84 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.646 0 N-CA-C 107.22 -1.4 . . . . 0.0 107.22 178.475 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 27.6 mt -131.1 130.84 63.9 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 CA-C-N 119.057 0.844 . . . . 0.0 109.274 179.912 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 60.46 79.81 0.11 Allowed Glycine 0 CA--C 1.527 0.813 0 CA-C-N 116.269 -0.423 . . . . 0.0 113.127 179.273 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' G' G ' 34' ' ' LEU . . . . . 0.419 HD23 ' N ' ' G' ' 35' ' ' MET . 1.9 tt -111.87 120.29 41.46 Favored 'General case' 0 N--CA 1.479 1.011 0 N-CA-C 106.909 -1.515 . . . . 0.0 106.909 177.394 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' G' G ' 35' ' ' MET . . . . . 0.419 ' N ' HD23 ' G' ' 34' ' ' LEU . 8.4 ttt -155.35 163.08 40.58 Favored 'General case' 0 C--O 1.211 -0.945 0 N-CA-C 108.03 -1.1 . . . . 0.0 108.03 179.466 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 99.6 t -159.44 150.19 6.7 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 N-CA-C 106.295 -1.742 . . . . 0.0 106.295 -179.72 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.41 75.2 0.26 Allowed Glycine 0 C--N 1.312 -0.755 0 C-N-CA 121.093 -0.575 . . . . 0.0 111.956 177.801 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 168.51 -146.24 10.24 Favored Glycine 0 N--CA 1.47 0.928 0 N-CA-C 110.688 -0.965 . . . . 0.0 110.688 179.209 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 22.2 m -134.43 141.61 43.03 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.914 0 CA-C-N 117.039 0.42 . . . . 0.0 109.994 179.873 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 19.3 t . . . . . 0 N--CA 1.471 0.595 0 CA-C-O 117.678 -1.153 . . . . 0.0 110.914 179.541 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' H' H ' 1' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 . . . . . 0 N--CA 1.49 1.561 0 N-CA-C 109.654 -0.499 . . . . 0.0 109.654 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' H' H ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.79 129.26 39.7 Favored 'General case' 0 N--CA 1.468 0.442 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.453 179.578 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' H' H ' 3' ' ' GLU . . . . . . . . . . . . . 40.7 tt0 -168.6 108.4 0.5 Allowed 'General case' 0 N--CA 1.47 0.53 0 N-CA-C 110.146 -0.316 . . . . 0.0 110.146 179.775 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 79.4 m-85 -84.93 140.33 31.17 Favored 'General case' 0 N--CA 1.474 0.757 0 N-CA-C 109.662 -0.496 . . . . 0.0 109.662 179.233 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' H' H ' 5' ' ' ARG . . . . . . . . . . . . . 72.6 mtp180 -144.1 140.95 29.75 Favored 'General case' 0 N--CA 1.482 1.149 0 N-CA-C 109.219 -0.66 . . . . 0.0 109.219 -179.608 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 76.9 m80 -149.35 119.21 7.09 Favored 'General case' 0 N--CA 1.473 0.721 0 N-CA-C 109.076 -0.712 . . . . 0.0 109.076 179.07 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -68.33 145.87 53.79 Favored 'General case' 0 N--CA 1.468 0.431 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.951 -179.413 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' H' H ' 8' ' ' SER . . . . . . . . . . . . . 8.2 t -163.84 173.85 12.25 Favored 'General case' 0 N--CA 1.469 0.508 0 N-CA-C 109.373 -0.602 . . . . 0.0 109.373 178.321 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.89 23.09 2.31 Favored Glycine 0 N--CA 1.48 1.632 0 N-CA-C 111.828 -0.509 . . . . 0.0 111.828 179.125 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 40.4 p90 -56.64 127.81 33.26 Favored 'General case' 0 N--CA 1.474 0.735 0 N-CA-C 112.402 0.519 . . . . 0.0 112.402 -178.996 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 57.7 mt-10 -84.74 155.28 21.95 Favored 'General case' 0 N--CA 1.475 0.806 0 CA-C-O 121.121 0.486 . . . . 0.0 109.917 178.791 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -155.78 127.62 0.97 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.971 0 N-CA-C 108.263 -1.014 . . . . 0.0 108.263 178.847 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 51.3 m-70 -133.79 146.08 50.37 Favored 'General case' 0 N--CA 1.476 0.847 0 CA-C-N 115.423 -0.808 . . . . 0.0 111.239 -178.197 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 6.4 t60 -165.55 97.75 0.68 Allowed 'General case' 0 N--CA 1.482 1.146 0 CA-C-N 116.582 -0.281 . . . . 0.0 110.673 179.159 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 35.3 mt-30 -105.68 -173.04 2.21 Favored 'General case' 0 CA--C 1.501 -0.934 0 N-CA-C 108.549 -0.908 . . . . 0.0 108.549 -179.848 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' H' H ' 16' ' ' LYS . . . . . 0.404 ' C ' HD12 ' H' ' 17' ' ' LEU . 88.5 tttt -169.08 96.74 0.35 Allowed 'General case' 0 CA--C 1.54 0.562 0 CA-C-N 114.941 -1.027 . . . . 0.0 109.276 178.775 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' H' H ' 17' ' ' LEU . . . . . 0.57 HD12 ' N ' ' H' ' 17' ' ' LEU . 5.4 mp -106.21 163.29 12.92 Favored 'General case' 0 N--CA 1.487 1.382 0 N-CA-C 109.349 -0.612 . . . . 0.0 109.349 -179.553 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 40.1 t -142.63 118.48 5.44 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.037 0 CA-C-O 120.929 0.395 . . . . 0.0 110.479 178.895 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 48.0 m-85 -69.57 150.72 46.8 Favored 'General case' 0 C--N 1.37 1.483 0 N-CA-C 107.386 -1.338 . . . . 0.0 107.386 176.686 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 11.6 t80 -171.99 -54.66 0.02 OUTLIER 'General case' 0 N--CA 1.485 1.293 0 CA-C-N 117.837 0.289 . . . . 0.0 110.32 -179.537 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.94 90.39 0.0 OUTLIER 'General case' 0 CA--C 1.535 0.371 0 C-N-CA 123.685 0.794 . . . . 0.0 112.299 -179.974 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 37.2 tt0 -65.86 159.07 26.26 Favored 'General case' 0 N--CA 1.469 0.506 0 CA-C-N 114.784 -1.098 . . . . 0.0 110.006 179.254 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 67.0 m-20 -140.99 137.46 33.03 Favored 'General case' 0 N--CA 1.477 0.877 0 C-N-CA 122.845 0.458 . . . . 0.0 110.098 179.884 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' H' H ' 24' ' ' VAL . . . . . . . . . . . . . 21.4 t -85.8 -115.59 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.991 0 N-CA-C 108.531 -0.915 . . . . 0.0 108.531 179.601 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . -109.57 53.88 0.57 Allowed Glycine 0 N--CA 1.481 1.651 0 N-CA-C 111.379 -0.688 . . . . 0.0 111.379 -179.813 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 75.8 p -79.75 125.75 30.07 Favored 'General case' 0 N--CA 1.467 0.386 0 N-CA-C 108.958 -0.756 . . . . 0.0 108.958 178.034 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 19.3 t-20 -66.95 100.59 0.75 Allowed 'General case' 0 N--CA 1.471 0.605 0 N-CA-C 108.352 -0.981 . . . . 0.0 108.352 178.51 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 66.6 mttm -96.79 119.6 35.57 Favored 'General case' 0 N--CA 1.483 1.189 0 N-CA-C 110.097 -0.334 . . . . 0.0 110.097 -179.076 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.41 -125.18 0.01 OUTLIER Glycine 0 CA--C 1.534 1.267 0 N-CA-C 110.738 -0.945 . . . . 0.0 110.738 178.71 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.11 132.81 48.95 Favored 'General case' 0 N--CA 1.47 0.569 0 N-CA-C 109.66 -0.496 . . . . 0.0 109.66 179.839 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 68.7 mt -81.95 139.96 17.18 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.587 0 N-CA-C 107.11 -1.441 . . . . 0.0 107.11 178.525 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 28.0 mt -130.98 130.75 64.17 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.417 0 CA-C-N 118.912 0.778 . . . . 0.0 109.273 -179.978 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 60.48 79.7 0.11 Allowed Glycine 0 CA--C 1.526 0.742 0 CA-C-N 116.301 -0.409 . . . . 0.0 113.126 179.231 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' H' H ' 34' ' ' LEU . . . . . 0.409 HD23 ' N ' ' H' ' 35' ' ' MET . 1.9 tt -111.84 120.05 40.64 Favored 'General case' 0 N--CA 1.479 1.018 0 N-CA-C 106.889 -1.523 . . . . 0.0 106.889 177.42 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' H' H ' 35' ' ' MET . . . . . 0.409 ' N ' HD23 ' H' ' 34' ' ' LEU . 8.5 ttt -154.97 163.18 40.67 Favored 'General case' 0 N--CA 1.479 0.982 0 N-CA-C 107.958 -1.127 . . . . 0.0 107.958 179.505 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 93.6 t -159.78 150.43 6.29 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.254 0 N-CA-C 106.275 -1.75 . . . . 0.0 106.275 -179.735 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.15 75.13 0.26 Allowed Glycine 0 C--N 1.313 -0.731 0 CA-C-N 115.942 -0.572 . . . . 0.0 111.922 177.959 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 168.42 -146.51 10.49 Favored Glycine 0 N--CA 1.471 0.992 0 N-CA-C 110.632 -0.987 . . . . 0.0 110.632 179.273 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 22.3 m -134.23 141.85 42.55 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.924 0 CA-C-N 116.977 0.389 . . . . 0.0 109.998 179.976 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 19.4 t . . . . . 0 N--CA 1.47 0.543 0 CA-C-O 117.768 -1.111 . . . . 0.0 110.918 179.489 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' I' I ' 1' ' ' ASP . . . . . . . . . . . . . 8.8 m-20 . . . . . 0 N--CA 1.491 1.606 0 N-CA-C 109.608 -0.516 . . . . 0.0 109.608 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' I' I ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.93 129.39 40.19 Favored 'General case' 0 N--CA 1.468 0.472 0 CA-C-N 115.903 -0.589 . . . . 0.0 110.381 179.669 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' I' I ' 3' ' ' GLU . . . . . . . . . . . . . 40.5 tt0 -168.76 107.98 0.47 Allowed 'General case' 0 N--CA 1.47 0.552 0 N-CA-C 110.221 -0.288 . . . . 0.0 110.221 179.765 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 78.3 m-85 -84.5 140.81 31.2 Favored 'General case' 0 N--CA 1.474 0.745 0 N-CA-C 109.651 -0.5 . . . . 0.0 109.651 179.253 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' I' I ' 5' ' ' ARG . . . . . . . . . . . . . 72.7 mtp180 -144.49 140.95 29.21 Favored 'General case' 0 N--CA 1.482 1.158 0 N-CA-C 109.232 -0.655 . . . . 0.0 109.232 -179.619 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 76.9 m80 -149.31 118.93 6.97 Favored 'General case' 0 N--CA 1.474 0.753 0 N-CA-C 109.11 -0.7 . . . . 0.0 109.11 179.095 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 8.0 m-20 -68.1 145.87 54.0 Favored 'General case' 0 N--CA 1.467 0.385 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.82 -179.361 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' I' I ' 8' ' ' SER . . . . . . . . . . . . . 8.3 t -163.91 173.7 12.36 Favored 'General case' 0 N--CA 1.47 0.555 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 178.34 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.97 23.32 2.25 Favored Glycine 0 N--CA 1.481 1.657 0 N-CA-C 111.845 -0.502 . . . . 0.0 111.845 179.156 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 41.0 p90 -56.81 128.03 34.61 Favored 'General case' 0 N--CA 1.473 0.683 0 N-CA-C 112.437 0.532 . . . . 0.0 112.437 -178.99 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 57.9 mt-10 -84.86 155.19 21.85 Favored 'General case' 0 N--CA 1.474 0.757 0 CA-C-O 121.074 0.464 . . . . 0.0 109.976 178.755 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -155.7 127.65 0.99 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.977 0 N-CA-C 108.236 -1.024 . . . . 0.0 108.236 178.777 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 51.2 m-70 -133.68 146.41 50.81 Favored 'General case' 0 N--CA 1.476 0.849 0 CA-C-N 115.372 -0.831 . . . . 0.0 111.119 -178.162 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 6.5 t60 -165.99 97.89 0.63 Allowed 'General case' 0 N--CA 1.482 1.164 0 CA-C-N 116.556 -0.293 . . . . 0.0 110.696 179.026 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 35.3 mt-30 -105.85 -172.75 2.15 Favored 'General case' 0 CA--C 1.5 -0.948 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 -179.825 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' I' I ' 16' ' ' LYS . . . . . 0.403 ' C ' HD12 ' I' ' 17' ' ' LEU . 88.6 tttt -169.18 96.82 0.34 Allowed 'General case' 0 CA--C 1.539 0.543 0 CA-C-N 114.901 -1.045 . . . . 0.0 109.355 178.769 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' I' I ' 17' ' ' LEU . . . . . 0.566 HD12 ' N ' ' I' ' 17' ' ' LEU . 5.4 mp -106.19 163.15 13.03 Favored 'General case' 0 N--CA 1.488 1.43 0 N-CA-C 109.301 -0.629 . . . . 0.0 109.301 -179.555 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 40.1 t -142.48 118.37 5.66 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.015 0 CA-C-O 120.901 0.382 . . . . 0.0 110.387 178.933 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 48.6 m-85 -69.43 151.02 46.61 Favored 'General case' 0 C--N 1.372 1.553 0 N-CA-C 107.414 -1.328 . . . . 0.0 107.414 176.654 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 11.7 t80 -172.19 -54.98 0.02 OUTLIER 'General case' 0 N--CA 1.483 1.225 0 CA-C-N 117.822 0.283 . . . . 0.0 110.346 -179.587 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.81 90.29 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.465 0 C-N-CA 123.712 0.805 . . . . 0.0 112.327 -179.984 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 37.3 tt0 -65.68 159.15 25.57 Favored 'General case' 0 N--CA 1.468 0.464 0 CA-C-N 114.686 -1.143 . . . . 0.0 110.023 179.304 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 66.6 m-20 -140.92 137.21 32.97 Favored 'General case' 0 N--CA 1.476 0.834 0 C-N-CA 122.906 0.482 . . . . 0.0 110.122 179.835 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' I' I ' 24' ' ' VAL . . . . . . . . . . . . . 21.5 t -85.47 -115.35 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.034 0 N-CA-C 108.479 -0.934 . . . . 0.0 108.479 179.58 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . -109.84 53.44 0.59 Allowed Glycine 0 N--CA 1.48 1.584 0 N-CA-C 111.495 -0.642 . . . . 0.0 111.495 -179.761 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 77.0 p -79.29 125.79 29.95 Favored 'General case' 0 N--CA 1.467 0.388 0 N-CA-C 109.131 -0.692 . . . . 0.0 109.131 177.992 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 19.5 t-20 -67.14 100.54 0.78 Allowed 'General case' 0 N--CA 1.471 0.625 0 N-CA-C 108.395 -0.965 . . . . 0.0 108.395 178.525 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 66.8 mttm -96.71 120.05 36.32 Favored 'General case' 0 N--CA 1.483 1.221 0 N-CA-C 110.129 -0.323 . . . . 0.0 110.129 -179.11 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.7 -125.36 0.01 OUTLIER Glycine 0 CA--C 1.535 1.319 0 N-CA-C 110.688 -0.965 . . . . 0.0 110.688 178.793 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -127.78 132.82 49.47 Favored 'General case' 0 N--CA 1.473 0.682 0 C-N-CA 123.023 0.529 . . . . 0.0 109.653 179.633 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 68.2 mt -81.92 139.91 17.24 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.582 0 N-CA-C 107.13 -1.433 . . . . 0.0 107.13 178.479 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 27.2 mt -130.99 130.87 64.22 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.373 0 CA-C-N 118.977 0.808 . . . . 0.0 109.282 -179.938 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 60.38 79.68 0.11 Allowed Glycine 0 CA--C 1.527 0.805 0 CA-C-N 116.285 -0.416 . . . . 0.0 113.079 179.261 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' I' I ' 34' ' ' LEU . . . . . 0.412 HD23 ' N ' ' I' ' 35' ' ' MET . 1.9 tt -111.9 120.07 40.67 Favored 'General case' 0 N--CA 1.48 1.038 0 N-CA-C 106.823 -1.547 . . . . 0.0 106.823 177.432 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' I' I ' 35' ' ' MET . . . . . 0.412 ' N ' HD23 ' I' ' 34' ' ' LEU . 8.5 ttt -154.9 163.28 40.51 Favored 'General case' 0 C--O 1.211 -0.958 0 N-CA-C 108.005 -1.109 . . . . 0.0 108.005 179.461 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 98.7 t -159.72 150.41 6.35 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.257 0 N-CA-C 106.273 -1.751 . . . . 0.0 106.273 -179.739 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.08 75.23 0.26 Allowed Glycine 0 C--N 1.315 -0.631 0 CA-C-N 115.893 -0.594 . . . . 0.0 111.951 177.907 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 168.46 -146.33 10.33 Favored Glycine 0 N--CA 1.469 0.886 0 N-CA-C 110.643 -0.983 . . . . 0.0 110.643 179.287 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 22.3 m -134.39 141.72 42.75 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.856 0 CA-C-N 116.985 0.392 . . . . 0.0 110.038 179.928 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 18.9 t . . . . . 0 N--CA 1.469 0.488 0 CA-C-O 117.765 -1.112 . . . . 0.0 110.92 179.434 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . 0.446 ' H1 ' ' CG ' ' D' ' 1' ' ' ASP . 65.9 m-20 . . . . . 0 N--CA 1.49 1.555 0 N-CA-C 108.808 -0.812 . . . . 0.0 108.808 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.31 133.2 50.9 Favored 'General case' 0 CA--C 1.539 0.537 0 CA-C-N 116.528 -0.306 . . . . 0.0 110.287 -179.743 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.403 ' CD ' HH21 ' A' ' 5' ' ' ARG . 43.2 tt0 -169.09 105.91 0.41 Allowed 'General case' 0 N--CA 1.472 0.646 0 N-CA-C 109.873 -0.417 . . . . 0.0 109.873 -179.197 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 55.1 m-85 -85.12 147.54 26.58 Favored 'General case' 0 N--CA 1.475 0.804 0 N-CA-C 110.241 -0.281 . . . . 0.0 110.241 179.573 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' ARG . . . . . 0.403 HH21 ' CD ' ' A' ' 3' ' ' GLU . 99.2 mtt180 -144.33 142.14 30.2 Favored 'General case' 0 N--CA 1.482 1.131 0 N-CA-C 110.01 -0.366 . . . . 0.0 110.01 179.713 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 41.7 t-80 -152.43 119.69 5.92 Favored 'General case' 0 N--CA 1.472 0.674 0 N-CA-C 109.23 -0.655 . . . . 0.0 109.23 179.098 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' ASP . . . . . 0.507 ' O ' ' OG ' ' D' ' 8' ' ' SER . 4.6 m-20 -69.02 148.68 49.73 Favored 'General case' 0 CA--C 1.535 0.383 0 CA-C-N 116.341 -0.39 . . . . 0.0 110.412 179.893 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 54.0 p -167.65 -173.58 2.21 Favored 'General case' 0 N--CA 1.481 1.084 0 CA-C-O 120.92 0.391 . . . . 0.0 110.698 179.217 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.26 47.45 1.32 Allowed Glycine 0 N--CA 1.482 1.742 0 CA-C-N 116.036 -0.529 . . . . 0.0 111.905 -179.941 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 49.7 p90 -66.03 133.03 49.93 Favored 'General case' 0 N--CA 1.473 0.695 0 CA-C-O 120.74 0.305 . . . . 0.0 111.618 179.814 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 84.2 mt-10 -91.82 152.19 20.24 Favored 'General case' 0 N--CA 1.477 0.91 0 N-CA-C 109.662 -0.496 . . . . 0.0 109.662 178.443 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -152.67 128.31 1.68 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.593 0 N-CA-C 107.884 -1.154 . . . . 0.0 107.884 178.074 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 43.7 m-70 -135.9 148.5 48.6 Favored 'General case' 0 N--CA 1.493 1.681 0 CA-C-N 119.025 0.829 . . . . 0.0 111.292 -178.986 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 6.6 t60 -164.82 98.47 0.76 Allowed 'General case' 0 N--CA 1.48 1.053 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.823 179.396 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -91.85 -177.38 4.72 Favored 'General case' 0 CA--C 1.514 -0.432 0 N-CA-C 108.851 -0.796 . . . . 0.0 108.851 -179.933 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -172.06 93.74 0.14 Allowed 'General case' 0 N--CA 1.469 0.489 0 CA-C-N 114.659 -1.155 . . . . 0.0 108.566 177.94 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 6.3 mp -124.77 155.98 38.46 Favored 'General case' 0 N--CA 1.497 1.896 0 CA-C-O 121.744 0.783 . . . . 0.0 110.989 -178.417 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 61.0 t -111.63 124.46 68.4 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.024 0 CA-C-O 117.825 -1.083 . . . . 0.0 108.469 177.77 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 29.4 m-85 -124.27 143.78 50.35 Favored 'General case' 0 N--CA 1.498 1.946 0 CA-C-N 120.177 1.353 . . . . 0.0 110.268 179.227 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 67.2 m-85 52.49 68.33 0.84 Allowed 'General case' 0 N--CA 1.472 0.637 0 CA-C-N 116.367 -0.378 . . . . 0.0 111.875 178.458 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -78.14 -84.62 0.08 Allowed 'General case' 0 C--N 1.361 1.097 0 CA-C-N 115.463 -0.79 . . . . 0.0 110.173 -179.829 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 41.2 tt0 -123.07 96.9 5.19 Favored 'General case' 0 C--N 1.323 -0.547 0 N-CA-C 108.089 -1.078 . . . . 0.0 108.089 179.7 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 4.1 p30 -158.97 143.67 15.78 Favored 'General case' 0 N--CA 1.484 1.261 0 O-C-N 122.313 -0.242 . . . . 0.0 111.102 179.092 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 61.6 t -61.38 162.66 1.36 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.784 0 N-CA-C 107.968 -1.123 . . . . 0.0 107.968 177.206 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.494 ' H ' ' HB ' ' D' ' 24' ' ' VAL . . . -117.71 48.96 0.89 Allowed Glycine 0 N--CA 1.476 1.328 0 N-CA-C 111.81 -0.516 . . . . 0.0 111.81 -179.377 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -61.84 -169.05 0.02 OUTLIER 'General case' 0 N--CA 1.469 0.522 0 O-C-N 123.722 0.307 . . . . 0.0 110.404 179.56 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 15.1 t30 -69.52 80.35 0.4 Allowed 'General case' 0 N--CA 1.464 0.271 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.132 179.717 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -79.8 154.71 28.28 Favored 'General case' 0 N--CA 1.473 0.677 0 N-CA-C 108.883 -0.784 . . . . 0.0 108.883 179.059 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.0 -144.07 0.02 OUTLIER Glycine 0 CA--C 1.526 0.748 0 N-CA-C 109.749 -1.34 . . . . 0.0 109.749 178.496 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -136.89 120.3 16.97 Favored 'General case' 0 N--CA 1.479 0.976 0 CA-C-N 117.247 0.523 . . . . 0.0 109.755 179.38 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 69.5 mt -80.39 124.73 38.67 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.528 0 N-CA-C 106.741 -1.577 . . . . 0.0 106.741 178.339 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . 0.413 ' C ' ' H ' ' A' ' 34' ' ' LEU . 41.5 pt -151.34 162.71 2.93 Favored 'Isoleucine or valine' 0 C--N 1.358 0.958 0 CA-C-N 115.741 -0.663 . . . . 0.0 111.552 -178.805 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 64.88 0.44 5.24 Favored Glycine 0 CA--C 1.524 0.603 0 N-CA-C 111.008 -0.837 . . . . 0.0 111.008 179.611 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.413 ' H ' ' C ' ' A' ' 32' ' ' ILE . 7.8 tt -79.7 148.46 31.55 Favored 'General case' 0 N--CA 1.466 0.346 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 -179.989 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 28.6 ttt -159.89 140.68 12.21 Favored 'General case' 0 N--CA 1.473 0.68 0 N-CA-C 108.816 -0.809 . . . . 0.0 108.816 178.993 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 27.6 m -156.22 162.57 1.64 Allowed 'Isoleucine or valine' 0 C--N 1.347 0.495 0 N-CA-C 108.259 -1.015 . . . . 0.0 108.259 -179.756 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.63 67.55 2.15 Favored Glycine 0 C--N 1.308 -1.026 0 CA-C-N 115.773 -0.649 . . . . 0.0 111.967 178.6 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.91 172.49 17.98 Favored Glycine 0 N--CA 1.475 1.242 0 N-CA-C 110.649 -0.98 . . . . 0.0 110.649 179.28 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.56 ' H ' HG12 ' D' ' 39' ' ' VAL . 34.9 m -125.16 164.42 24.18 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.943 0 C-N-CA 123.549 0.739 . . . . 0.0 110.803 -179.546 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 25.0 t . . . . . 0 C--O 1.221 -0.437 0 CA-C-O 118.382 -0.818 . . . . 0.0 110.766 179.333 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' B' B ' 1' ' ' ASP . . . . . . . . . . . . . 65.7 m-20 . . . . . 0 N--CA 1.488 1.469 0 N-CA-C 108.989 -0.745 . . . . 0.0 108.989 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' B' B ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.61 133.1 50.45 Favored 'General case' 0 CA--C 1.539 0.552 0 CA-C-N 116.513 -0.312 . . . . 0.0 110.178 -179.752 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 3' ' ' GLU . . . . . . . . . . . . . 42.6 tt0 -169.1 105.73 0.4 Allowed 'General case' 0 N--CA 1.472 0.671 0 N-CA-C 109.971 -0.381 . . . . 0.0 109.971 -179.188 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 55.6 m-85 -84.89 147.49 26.74 Favored 'General case' 0 N--CA 1.476 0.843 0 N-CA-C 110.272 -0.269 . . . . 0.0 110.272 179.439 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 -144.22 142.09 30.28 Favored 'General case' 0 N--CA 1.481 1.124 0 N-CA-C 109.989 -0.375 . . . . 0.0 109.989 179.687 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 41.1 t-80 -152.34 119.46 5.87 Favored 'General case' 0 N--CA 1.473 0.686 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 179.146 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 7' ' ' ASP . . . . . 0.467 ' O ' ' OG ' ' E' ' 8' ' ' SER . 4.4 m-20 -69.01 148.31 50.29 Favored 'General case' 0 CA--C 1.536 0.436 0 CA-C-N 116.435 -0.348 . . . . 0.0 110.465 179.914 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 8' ' ' SER . . . . . . . . . . . . . 54.0 p -167.26 -173.35 2.25 Favored 'General case' 0 N--CA 1.48 1.048 0 CA-C-O 120.873 0.368 . . . . 0.0 110.645 179.214 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.08 47.37 1.35 Allowed Glycine 0 N--CA 1.482 1.762 0 CA-C-N 115.982 -0.554 . . . . 0.0 111.927 179.896 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 49.3 p90 -65.93 133.73 51.49 Favored 'General case' 0 N--CA 1.473 0.679 0 CA-C-O 120.751 0.31 . . . . 0.0 111.714 179.699 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 83.5 mt-10 -92.39 152.51 19.7 Favored 'General case' 0 N--CA 1.476 0.839 0 N-CA-C 109.666 -0.494 . . . . 0.0 109.666 178.398 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -153.14 128.42 1.56 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.609 0 N-CA-C 107.776 -1.194 . . . . 0.0 107.776 178.261 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 43.6 m-70 -136.27 148.35 47.96 Favored 'General case' 0 N--CA 1.492 1.655 0 CA-C-N 118.864 0.756 . . . . 0.0 111.37 -179.033 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 6.7 t60 -164.67 98.06 0.77 Allowed 'General case' 0 N--CA 1.481 1.093 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.694 179.512 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 5.1 pt20 -91.14 -176.86 4.73 Favored 'General case' 0 CA--C 1.515 -0.386 0 N-CA-C 108.74 -0.837 . . . . 0.0 108.74 -179.984 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -172.7 93.77 0.12 Allowed 'General case' 0 N--CA 1.469 0.505 0 CA-C-N 114.711 -1.131 . . . . 0.0 108.405 177.807 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 6.3 mp -124.71 156.1 38.18 Favored 'General case' 0 N--CA 1.497 1.918 0 CA-C-O 121.77 0.795 . . . . 0.0 110.985 -178.465 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 62.0 t -111.85 125.14 69.13 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.007 0 N-CA-C 108.297 -1.001 . . . . 0.0 108.297 177.645 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 29.6 m-85 -124.87 143.76 50.67 Favored 'General case' 0 N--CA 1.495 1.803 0 CA-C-N 119.813 1.188 . . . . 0.0 110.161 179.433 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 68.2 m-85 51.45 68.41 0.8 Allowed 'General case' 0 N--CA 1.468 0.452 0 CA-C-O 121.199 0.524 . . . . 0.0 111.994 178.48 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -78.09 -84.28 0.08 Allowed 'General case' 0 C--N 1.356 0.875 0 CA-C-N 115.198 -0.91 . . . . 0.0 110.055 -179.847 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 41.2 tt0 -123.14 97.42 5.42 Favored 'General case' 0 C--N 1.323 -0.583 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 179.682 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 4.0 p30 -159.34 143.5 15.1 Favored 'General case' 0 N--CA 1.483 1.206 0 O-C-N 122.342 -0.224 . . . . 0.0 111.083 179.103 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 61.9 t -61.17 162.65 1.31 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.89 0 N-CA-C 107.983 -1.117 . . . . 0.0 107.983 177.136 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . 0.495 ' H ' ' HB ' ' E' ' 24' ' ' VAL . . . -117.62 49.03 0.89 Allowed Glycine 0 N--CA 1.475 1.294 0 N-CA-C 111.725 -0.55 . . . . 0.0 111.725 -179.281 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -62.2 -168.78 0.02 OUTLIER 'General case' 0 N--CA 1.469 0.514 0 O-C-N 123.616 0.245 . . . . 0.0 110.374 179.598 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 14.9 t30 -69.72 80.64 0.44 Allowed 'General case' 0 N--CA 1.465 0.312 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.043 179.773 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 97.9 mttt -80.2 154.41 27.96 Favored 'General case' 0 N--CA 1.472 0.633 0 N-CA-C 108.882 -0.784 . . . . 0.0 108.882 179.072 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.9 -144.5 0.02 OUTLIER Glycine 0 CA--C 1.526 0.738 0 N-CA-C 109.636 -1.386 . . . . 0.0 109.636 178.476 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -136.39 120.84 18.14 Favored 'General case' 0 N--CA 1.478 0.973 0 CA-C-N 117.142 0.471 . . . . 0.0 109.83 179.376 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 70.1 mt -80.65 124.98 39.12 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.524 0 N-CA-C 106.721 -1.585 . . . . 0.0 106.721 178.249 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . 0.408 ' C ' ' H ' ' B' ' 34' ' ' LEU . 41.3 pt -151.59 162.75 2.8 Favored 'Isoleucine or valine' 0 C--N 1.358 0.951 0 CA-C-N 115.836 -0.62 . . . . 0.0 111.491 -178.728 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 64.61 0.52 5.0 Favored Glycine 0 C--N 1.337 0.635 0 CA-C-N 115.507 -0.77 . . . . 0.0 111.177 179.716 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 34' ' ' LEU . . . . . 0.408 ' H ' ' C ' ' B' ' 32' ' ' ILE . 7.8 tt -79.85 148.15 31.47 Favored 'General case' 0 N--CA 1.465 0.292 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 -179.952 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 28.6 ttt -159.32 140.75 13.03 Favored 'General case' 0 N--CA 1.475 0.795 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 179.051 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 28.3 m -156.35 162.56 1.63 Allowed 'Isoleucine or valine' 0 C--N 1.346 0.422 0 N-CA-C 108.214 -1.032 . . . . 0.0 108.214 -179.796 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.67 67.45 2.2 Favored Glycine 0 C--N 1.306 -1.111 0 CA-C-N 115.756 -0.657 . . . . 0.0 111.932 178.558 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.86 172.8 18.27 Favored Glycine 0 N--CA 1.474 1.202 0 N-CA-C 110.678 -0.969 . . . . 0.0 110.678 179.208 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 39' ' ' VAL . . . . . 0.553 ' H ' HG12 ' E' ' 39' ' ' VAL . 35.2 m -125.3 164.29 24.67 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.082 0 C-N-CA 123.523 0.729 . . . . 0.0 110.819 -179.392 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 24.9 t . . . . . 0 N--CA 1.471 0.576 0 CA-C-O 118.237 -0.887 . . . . 0.0 110.636 179.164 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' C' C ' 1' ' ' ASP . . . . . 0.49 ' H1 ' ' CG ' ' F' ' 1' ' ' ASP . 66.2 m-20 . . . . . 0 N--CA 1.491 1.589 0 N-CA-C 108.86 -0.793 . . . . 0.0 108.86 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' C' C ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.4 133.13 50.68 Favored 'General case' 0 CA--C 1.54 0.562 0 CA-C-N 116.454 -0.339 . . . . 0.0 110.235 -179.782 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' C' C ' 3' ' ' GLU . . . . . . . . . . . . . 43.0 tt0 -169.19 105.71 0.4 Allowed 'General case' 0 N--CA 1.471 0.614 0 N-CA-C 109.884 -0.413 . . . . 0.0 109.884 -179.102 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 54.9 m-85 -84.98 147.41 26.71 Favored 'General case' 0 N--CA 1.477 0.922 0 N-CA-C 110.238 -0.282 . . . . 0.0 110.238 179.462 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 -144.22 142.12 30.31 Favored 'General case' 0 N--CA 1.482 1.15 0 N-CA-C 109.974 -0.38 . . . . 0.0 109.974 179.645 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 40.8 t-80 -152.37 119.98 6.05 Favored 'General case' 0 N--CA 1.473 0.708 0 N-CA-C 109.251 -0.648 . . . . 0.0 109.251 179.152 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' C' C ' 7' ' ' ASP . . . . . 0.477 ' O ' ' OG ' ' F' ' 8' ' ' SER . 4.4 m-20 -69.45 148.39 49.63 Favored 'General case' 0 CA--C 1.535 0.397 0 CA-C-N 116.352 -0.385 . . . . 0.0 110.518 179.908 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' C' C ' 8' ' ' SER . . . . . . . . . . . . . 55.4 p -167.32 -173.51 2.29 Favored 'General case' 0 N--CA 1.48 1.029 0 CA-C-O 120.839 0.352 . . . . 0.0 110.656 179.272 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.18 47.58 1.31 Allowed Glycine 0 N--CA 1.483 1.795 0 CA-C-N 116.006 -0.543 . . . . 0.0 111.903 179.961 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 49.5 p90 -66.15 133.3 50.41 Favored 'General case' 0 N--CA 1.472 0.665 0 CA-C-N 116.783 0.292 . . . . 0.0 111.681 179.697 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 83.2 mt-10 -92.15 152.08 20.08 Favored 'General case' 0 N--CA 1.476 0.851 0 N-CA-C 109.696 -0.483 . . . . 0.0 109.696 178.4 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -152.61 128.35 1.71 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.588 0 N-CA-C 107.791 -1.189 . . . . 0.0 107.791 178.146 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 42.4 m-70 -136.03 148.38 48.35 Favored 'General case' 0 N--CA 1.492 1.663 0 CA-C-N 118.937 0.79 . . . . 0.0 111.286 -179.102 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 6.7 t60 -164.69 98.55 0.78 Allowed 'General case' 0 N--CA 1.481 1.105 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.685 179.475 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -91.91 -176.99 4.6 Favored 'General case' 0 CA--C 1.512 -0.484 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 -179.937 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -172.49 93.84 0.13 Allowed 'General case' 0 N--CA 1.47 0.533 0 CA-C-N 114.707 -1.133 . . . . 0.0 108.451 177.959 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 6.1 mp -124.93 155.7 39.15 Favored 'General case' 0 N--CA 1.496 1.842 0 CA-C-O 121.768 0.794 . . . . 0.0 111.096 -178.381 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 61.6 t -111.54 125.52 68.86 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.996 0 N-CA-C 108.238 -1.023 . . . . 0.0 108.238 177.754 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 29.3 m-85 -125.31 143.31 51.03 Favored 'General case' 0 N--CA 1.495 1.822 0 CA-C-N 119.673 1.124 . . . . 0.0 110.083 179.369 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 67.5 m-85 51.93 68.46 0.81 Allowed 'General case' 0 N--CA 1.47 0.534 0 CA-C-O 121.215 0.531 . . . . 0.0 111.975 178.501 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -78.09 -84.41 0.08 Allowed 'General case' 0 C--N 1.356 0.873 0 CA-C-N 115.186 -0.915 . . . . 0.0 110.071 -179.851 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 40.9 tt0 -123.14 96.97 5.21 Favored 'General case' 0 C--N 1.323 -0.546 0 N-CA-C 108.08 -1.081 . . . . 0.0 108.08 179.746 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 4.1 p30 -158.8 143.71 16.02 Favored 'General case' 0 N--CA 1.484 1.263 0 CA-C-O 119.672 -0.204 . . . . 0.0 111.118 179.002 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 59.9 t -61.43 162.38 1.45 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.849 0 N-CA-C 107.96 -1.126 . . . . 0.0 107.96 177.129 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' C' C ' 25' ' ' GLY . . . . . 0.481 ' H ' ' HB ' ' F' ' 24' ' ' VAL . . . -117.5 49.49 0.86 Allowed Glycine 0 N--CA 1.477 1.414 0 N-CA-C 111.726 -0.55 . . . . 0.0 111.726 -179.286 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -62.65 -168.51 0.02 OUTLIER 'General case' 0 N--CA 1.468 0.44 0 O-C-N 123.666 0.274 . . . . 0.0 110.443 179.64 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 15.8 t30 -69.88 80.47 0.46 Allowed 'General case' 0 N--CA 1.465 0.322 0 N-CA-C 110.073 -0.343 . . . . 0.0 110.073 179.781 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -79.98 154.62 28.11 Favored 'General case' 0 N--CA 1.472 0.668 0 N-CA-C 108.915 -0.772 . . . . 0.0 108.915 179.111 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.89 -144.17 0.02 OUTLIER Glycine 0 CA--C 1.527 0.821 0 N-CA-C 109.769 -1.332 . . . . 0.0 109.769 178.488 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -136.78 120.47 17.28 Favored 'General case' 0 N--CA 1.481 1.083 0 CA-C-N 117.185 0.493 . . . . 0.0 109.719 179.258 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 70.0 mt -80.49 124.8 38.81 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.541 0 N-CA-C 106.762 -1.57 . . . . 0.0 106.762 178.254 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' C' C ' 32' ' ' ILE . . . . . 0.418 ' C ' ' H ' ' C' ' 34' ' ' LEU . 41.3 pt -151.39 162.53 2.97 Favored 'Isoleucine or valine' 0 C--N 1.359 0.991 0 CA-C-N 115.68 -0.691 . . . . 0.0 111.53 -178.634 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 64.89 0.68 5.5 Favored Glycine 0 N--CA 1.465 0.598 0 N-CA-C 110.973 -0.851 . . . . 0.0 110.973 179.606 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' C' C ' 34' ' ' LEU . . . . . 0.418 ' H ' ' C ' ' C' ' 32' ' ' ILE . 7.7 tt -79.87 148.12 31.45 Favored 'General case' 0 N--CA 1.465 0.302 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 179.955 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 28.6 ttt -159.29 140.85 13.16 Favored 'General case' 0 N--CA 1.474 0.742 0 N-CA-C 108.751 -0.833 . . . . 0.0 108.751 178.955 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 28.1 m -156.5 162.77 1.55 Allowed 'Isoleucine or valine' 0 C--N 1.348 0.511 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 -179.798 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.37 67.14 2.36 Favored Glycine 0 C--N 1.307 -1.07 0 CA-C-N 115.695 -0.684 . . . . 0.0 111.901 178.56 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 148.23 172.58 18.32 Favored Glycine 0 N--CA 1.474 1.218 0 N-CA-C 110.604 -0.998 . . . . 0.0 110.604 179.237 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' C' C ' 39' ' ' VAL . . . . . 0.55 ' H ' HG12 ' F' ' 39' ' ' VAL . 35.1 m -125.25 164.48 24.23 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.996 0 C-N-CA 123.518 0.727 . . . . 0.0 110.789 -179.415 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 25.4 t . . . . . 0 N--CA 1.469 0.484 0 CA-C-O 118.234 -0.889 . . . . 0.0 110.649 179.207 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' D' D ' 1' ' ' ASP . . . . . 0.446 ' CG ' ' H1 ' ' A' ' 1' ' ' ASP . 66.4 m-20 . . . . . 0 N--CA 1.49 1.551 0 N-CA-C 109.084 -0.71 . . . . 0.0 109.084 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' D' D ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.14 131.14 46.59 Favored 'General case' 0 CA--C 1.535 0.38 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.535 179.902 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' D' D ' 3' ' ' GLU . . . . . 0.4 ' CD ' HH21 ' D' ' 5' ' ' ARG . 41.8 tt0 -169.22 108.49 0.44 Allowed 'General case' 0 N--CA 1.47 0.573 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 179.852 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 61.4 m-85 -89.42 153.05 21.14 Favored 'General case' 0 C--N 1.36 1.055 0 C-N-CA 119.473 -0.891 . . . . 0.0 108.792 179.729 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' D' D ' 5' ' ' ARG . . . . . 0.4 HH21 ' CD ' ' D' ' 3' ' ' GLU . 99.2 mtt180 -146.43 140.49 26.33 Favored 'General case' 0 N--CA 1.476 0.85 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.236 -179.994 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 38.0 t-80 -149.82 124.02 9.5 Favored 'General case' 0 CA--C 1.545 0.781 0 N-CA-C 108.344 -0.984 . . . . 0.0 108.344 175.303 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' D' D ' 7' ' ' ASP . . . . . 0.57 ' O ' ' OG ' ' G' ' 8' ' ' SER . 3.3 m-20 -63.76 132.46 51.04 Favored 'General case' 0 C--N 1.322 -0.596 0 C-N-CA 126.885 2.074 . . . . 0.0 114.325 174.69 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' D' D ' 8' ' ' SER . . . . . 0.507 ' OG ' ' O ' ' A' ' 7' ' ' ASP . 54.2 p -154.63 -170.65 3.58 Favored 'General case' 0 N--CA 1.486 1.334 0 CA-C-N 119.77 1.168 . . . . 0.0 111.22 175.927 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.35 48.15 1.15 Allowed Glycine 0 N--CA 1.483 1.804 0 C-N-CA 124.562 1.077 . . . . 0.0 110.539 174.952 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 51.5 p90 -60.97 131.57 51.09 Favored 'General case' 0 N--CA 1.472 0.626 0 N-CA-C 112.908 0.707 . . . . 0.0 112.908 177.925 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 84.2 mt-10 -89.28 150.91 22.39 Favored 'General case' 0 N--CA 1.481 1.1 0 CA-C-N 117.974 0.352 . . . . 0.0 110.637 175.315 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.0 p -149.58 129.86 4.2 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.637 0 N-CA-C 107.416 -1.328 . . . . 0.0 107.416 173.066 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 38.3 m-70 -129.91 151.28 50.64 Favored 'General case' 0 N--CA 1.484 1.262 0 N-CA-C 112.329 0.492 . . . . 0.0 112.329 176.791 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 6.7 t60 -164.79 104.84 0.81 Allowed 'General case' 0 N--CA 1.482 1.145 0 N-CA-C 109.155 -0.683 . . . . 0.0 109.155 172.664 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' D' D ' 15' ' ' GLN . . . . . 0.401 ' OE1' ' N ' ' G' ' 37' ' ' GLY . 4.9 pt20 -94.96 -177.3 4.12 Favored 'General case' 0 CA--C 1.509 -0.631 0 N-CA-C 108.574 -0.898 . . . . 0.0 108.574 179.044 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -169.75 103.49 0.32 Allowed 'General case' 0 N--CA 1.465 0.308 0 N-CA-C 105.891 -1.892 . . . . 0.0 105.891 173.374 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 5.0 mp -132.19 153.44 50.57 Favored 'General case' 0 N--CA 1.498 1.97 0 CA-C-O 122.011 0.91 . . . . 0.0 110.214 178.912 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 35.8 t -101.12 129.01 52.79 Favored 'Isoleucine or valine' 0 C--O 1.266 1.943 0 CA-C-O 116.373 -1.775 . . . . 0.0 109.693 174.267 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 25.8 m-85 -126.63 149.25 49.59 Favored 'General case' 0 N--CA 1.49 1.562 0 CA-C-N 120.525 1.511 . . . . 0.0 109.472 172.329 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 66.7 m-85 55.14 63.64 2.05 Favored 'General case' 0 C--O 1.24 0.599 0 CA-C-O 118.518 -0.753 . . . . 0.0 111.555 175.097 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -79.99 -81.35 0.12 Allowed 'General case' 0 N--CA 1.474 0.741 0 CA-C-N 118.942 0.792 . . . . 0.0 109.967 -176.345 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 41.3 tt0 -124.91 101.81 7.24 Favored 'General case' 0 N--CA 1.479 0.999 0 N-CA-C 106.036 -1.838 . . . . 0.0 106.036 175.969 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 4.1 p30 -152.44 143.08 22.8 Favored 'General case' 0 N--CA 1.476 0.842 0 CA-C-O 116.792 -1.575 . . . . 0.0 113.624 177.592 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' D' D ' 24' ' ' VAL . . . . . 0.494 ' HB ' ' H ' ' A' ' 25' ' ' GLY . 67.1 t -63.58 165.26 1.29 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.366 0 CA-C-N 120.971 1.714 . . . . 0.0 107.824 174.538 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' D' D ' 25' ' ' GLY . . . . . 0.556 ' H ' ' HB ' ' G' ' 24' ' ' VAL . . . -116.84 51.3 0.74 Allowed Glycine 0 N--CA 1.48 1.613 0 CA-C-O 118.978 -0.901 . . . . 0.0 111.977 178.795 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -58.87 -171.23 0.01 OUTLIER 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 117.558 0.679 . . . . 0.0 111.533 176.88 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 15.7 t30 -71.92 86.66 1.0 Allowed 'General case' 0 CA--C 1.537 0.468 0 N-CA-C 108.432 -0.951 . . . . 0.0 108.432 178.516 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 97.4 mttt -85.34 156.37 20.93 Favored 'General case' 0 N--CA 1.475 0.779 0 N-CA-C 108.124 -1.065 . . . . 0.0 108.124 179.031 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.39 -144.27 0.02 OUTLIER Glycine 0 C--N 1.335 0.488 0 N-CA-C 110.33 -1.108 . . . . 0.0 110.33 179.387 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -136.41 123.74 21.93 Favored 'General case' 0 N--CA 1.474 0.733 0 N-CA-C 109.159 -0.682 . . . . 0.0 109.159 177.648 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 76.4 mt -83.9 134.53 26.74 Favored 'Isoleucine or valine' 0 C--N 1.355 0.819 0 N-CA-C 104.846 -2.279 . . . . 0.0 104.846 178.776 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 46.0 pt -159.07 162.47 1.35 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.02 0 CA-C-O 121.407 0.622 . . . . 0.0 110.397 -178.37 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 64.83 0.17 4.89 Favored Glycine 0 CA--C 1.525 0.685 0 CA-C-N 115.46 -0.791 . . . . 0.0 111.186 -178.563 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 7.6 tt -79.25 150.04 31.69 Favored 'General case' 0 C--N 1.343 0.325 0 N-CA-C 109.345 -0.613 . . . . 0.0 109.345 -179.49 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 27.7 ttt -155.78 151.44 27.26 Favored 'General case' 0 N--CA 1.474 0.728 0 N-CA-C 107.509 -1.293 . . . . 0.0 107.509 174.348 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 29.7 m -164.52 163.65 0.73 Allowed 'Isoleucine or valine' 0 CA--C 1.513 -0.445 0 N-CA-C 107.661 -1.237 . . . . 0.0 107.661 176.901 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 60.32 63.75 4.75 Favored Glycine 0 CA--C 1.528 0.885 0 C-N-CA 119.584 -1.293 . . . . 0.0 112.359 177.88 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.92 173.2 15.2 Favored Glycine 0 N--CA 1.479 1.519 0 CA-C-N 118.451 1.125 . . . . 0.0 111.567 -177.851 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' D' D ' 39' ' ' VAL . . . . . 0.575 ' H ' HG12 ' G' ' 39' ' ' VAL . 34.6 m -128.14 160.16 38.41 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.061 0 C-N-CA 122.895 0.478 . . . . 0.0 110.422 -175.953 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 24.2 t . . . . . 0 C--N 1.331 -0.213 0 CA-C-O 116.386 -1.769 . . . . 0.0 109.855 177.694 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' E' E ' 1' ' ' ASP . . . . . 0.415 ' H1 ' ' CG ' ' H' ' 1' ' ' ASP . 65.8 m-20 . . . . . 0 N--CA 1.489 1.485 0 N-CA-C 109.369 -0.604 . . . . 0.0 109.369 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' E' E ' 2' ' ' ALA . . . . . . . . . . . . . . . -63.76 131.06 46.69 Favored 'General case' 0 N--CA 1.468 0.449 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.414 179.966 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' E' E ' 3' ' ' GLU . . . . . . . . . . . . . 41.7 tt0 -168.71 105.78 0.44 Allowed 'General case' 0 C--O 1.215 -0.735 0 N-CA-C 110.477 -0.194 . . . . 0.0 110.477 -179.722 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 53.7 m-85 -85.94 146.94 26.47 Favored 'General case' 0 N--CA 1.475 0.81 0 N-CA-C 110.348 -0.241 . . . . 0.0 110.348 179.131 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' E' E ' 5' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 -143.5 142.62 31.23 Favored 'General case' 0 N--CA 1.479 0.99 0 CA-C-O 120.794 0.33 . . . . 0.0 110.201 179.565 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 41.2 t-80 -152.46 119.54 5.85 Favored 'General case' 0 N--CA 1.474 0.725 0 N-CA-C 109.247 -0.649 . . . . 0.0 109.247 178.985 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' E' E ' 7' ' ' ASP . . . . . 0.435 ' O ' ' OG ' ' H' ' 8' ' ' SER . 4.3 m-20 -69.58 148.27 49.61 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-N 116.491 -0.322 . . . . 0.0 110.671 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' E' E ' 8' ' ' SER . . . . . 0.467 ' OG ' ' O ' ' B' ' 7' ' ' ASP . 52.5 p -167.92 -172.49 1.84 Allowed 'General case' 0 N--CA 1.486 1.328 0 CA-C-O 121.013 0.435 . . . . 0.0 110.87 178.952 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.87 47.66 1.24 Allowed Glycine 0 N--CA 1.48 1.595 0 N-CA-C 111.781 -0.528 . . . . 0.0 111.781 179.684 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 47.8 p90 -65.45 133.36 51.14 Favored 'General case' 0 N--CA 1.473 0.683 0 N-CA-C 112.06 0.392 . . . . 0.0 112.06 -179.846 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 85.1 mt-10 -91.4 152.68 20.31 Favored 'General case' 0 N--CA 1.479 1.002 0 N-CA-C 109.617 -0.512 . . . . 0.0 109.617 177.996 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -154.67 127.28 1.07 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.619 0 N-CA-C 107.816 -1.179 . . . . 0.0 107.816 178.067 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 40.8 m-70 -136.18 146.72 47.17 Favored 'General case' 0 N--CA 1.482 1.157 0 CA-C-O 120.851 0.357 . . . . 0.0 111.639 -178.047 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 6.6 t60 -163.64 98.39 0.88 Allowed 'General case' 0 N--CA 1.485 1.293 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.735 179.553 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 4.8 pt20 -91.36 -176.87 4.68 Favored 'General case' 0 CA--C 1.514 -0.43 0 N-CA-C 109.028 -0.73 . . . . 0.0 109.028 -179.925 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -172.31 92.72 0.12 Allowed 'General case' 0 N--CA 1.47 0.557 0 CA-C-N 114.77 -1.104 . . . . 0.0 108.693 177.929 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 6.0 mp -123.35 155.77 36.67 Favored 'General case' 0 N--CA 1.496 1.864 0 CA-C-O 121.443 0.64 . . . . 0.0 111.433 -177.901 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 48.0 t -113.33 122.57 67.72 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.198 0 N-CA-C 108.333 -0.988 . . . . 0.0 108.333 177.37 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 32.4 m-85 -122.76 142.51 50.65 Favored 'General case' 0 N--CA 1.491 1.594 0 CA-C-O 120.974 0.416 . . . . 0.0 110.649 -179.928 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 67.8 m-85 52.73 67.71 0.95 Allowed 'General case' 0 C--N 1.346 0.42 0 CA-C-N 115.767 -0.651 . . . . 0.0 111.614 178.245 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.15 -83.66 0.07 Allowed 'General case' 0 CA--C 1.541 0.605 0 N-CA-C 109.981 -0.377 . . . . 0.0 109.981 -179.464 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 41.0 tt0 -123.28 97.14 5.28 Favored 'General case' 0 C--N 1.32 -0.686 0 N-CA-C 108.14 -1.059 . . . . 0.0 108.14 179.938 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 4.1 p30 -158.35 143.46 16.44 Favored 'General case' 0 N--CA 1.48 1.057 0 O-C-N 122.422 -0.174 . . . . 0.0 111.33 179.062 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' E' E ' 24' ' ' VAL . . . . . 0.495 ' HB ' ' H ' ' B' ' 25' ' ' GLY . 57.9 t -59.53 167.42 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.954 0 N-CA-C 107.412 -1.329 . . . . 0.0 107.412 176.991 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' E' E ' 25' ' ' GLY . . . . . 0.461 ' H ' ' HB ' ' H' ' 24' ' ' VAL . . . -122.61 49.66 0.88 Allowed Glycine 0 N--CA 1.475 1.266 0 N-CA-C 110.915 -0.874 . . . . 0.0 110.915 -179.386 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -63.24 -168.54 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.639 0 CA-C-O 120.689 0.281 . . . . 0.0 110.572 179.946 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 14.9 t30 -68.98 77.94 0.32 Allowed 'General case' 0 N--CA 1.465 0.281 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.261 179.946 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -78.12 155.28 30.59 Favored 'General case' 0 N--CA 1.475 0.779 0 N-CA-C 109.458 -0.571 . . . . 0.0 109.458 179.279 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.76 -144.74 0.02 OUTLIER Glycine 0 C--N 1.337 0.634 0 N-CA-C 110.34 -1.104 . . . . 0.0 110.34 178.022 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -137.12 117.25 13.42 Favored 'General case' 0 N--CA 1.476 0.831 0 CA-C-O 120.79 0.328 . . . . 0.0 110.286 179.723 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 67.0 mt -77.45 125.15 36.96 Favored 'Isoleucine or valine' 0 C--O 1.238 0.475 0 N-CA-C 107.011 -1.477 . . . . 0.0 107.011 178.411 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' E' E ' 32' ' ' ILE . . . . . 0.405 ' C ' ' H ' ' E' ' 34' ' ' LEU . 46.4 pt -150.96 164.47 2.64 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.085 0 CA-C-O 121.279 0.561 . . . . 0.0 111.019 -178.943 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.82 1.1 3.36 Favored Glycine 0 CA--C 1.529 0.911 0 CA-C-N 115.542 -0.753 . . . . 0.0 111.871 -179.643 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' E' E ' 34' ' ' LEU . . . . . 0.405 ' H ' ' C ' ' E' ' 32' ' ' ILE . 7.9 tt -79.31 148.18 32.2 Favored 'General case' 0 N--CA 1.468 0.462 0 C-N-CA 122.838 0.455 . . . . 0.0 109.832 -179.964 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 28.0 ttt -158.78 140.97 13.93 Favored 'General case' 0 N--CA 1.477 0.922 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 178.784 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 32.4 m -156.52 162.22 1.7 Allowed 'Isoleucine or valine' 0 C--N 1.344 0.368 0 N-CA-C 108.431 -0.951 . . . . 0.0 108.431 -179.598 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.5 67.36 2.25 Favored Glycine 0 C--N 1.308 -1.012 0 CA-C-N 115.975 -0.557 . . . . 0.0 111.894 178.494 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 148.33 173.06 18.87 Favored Glycine 0 N--CA 1.475 1.255 0 N-CA-C 110.875 -0.89 . . . . 0.0 110.875 179.222 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' E' E ' 39' ' ' VAL . . . . . 0.559 ' H ' HG12 ' H' ' 39' ' ' VAL . 32.9 m -126.18 163.08 28.71 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.909 0 C-N-CA 123.41 0.684 . . . . 0.0 111.016 -179.067 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 24.6 t . . . . . 0 N--CA 1.465 0.309 0 CA-C-O 118.253 -0.88 . . . . 0.0 110.466 178.972 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' F' F ' 1' ' ' ASP . . . . . 0.49 ' CG ' ' H1 ' ' C' ' 1' ' ' ASP . 66.1 m-20 . . . . . 0 N--CA 1.49 1.561 0 N-CA-C 109.218 -0.66 . . . . 0.0 109.218 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' F' F ' 2' ' ' ALA . . . . . . . . . . . . . . . -63.78 131.0 46.48 Favored 'General case' 0 N--CA 1.468 0.456 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.487 179.97 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' F' F ' 3' ' ' GLU . . . . . 0.413 ' CD ' HH21 ' F' ' 5' ' ' ARG . 41.6 tt0 -168.52 105.74 0.45 Allowed 'General case' 0 C--O 1.215 -0.733 0 N-CA-C 110.467 -0.197 . . . . 0.0 110.467 -179.765 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 53.7 m-85 -85.95 146.69 26.57 Favored 'General case' 0 N--CA 1.474 0.774 0 N-CA-C 110.234 -0.284 . . . . 0.0 110.234 179.25 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' F' F ' 5' ' ' ARG . . . . . 0.413 HH21 ' CD ' ' F' ' 3' ' ' GLU . 99.2 mtt180 -143.3 142.42 31.32 Favored 'General case' 0 N--CA 1.478 0.945 0 CA-C-O 120.803 0.335 . . . . 0.0 110.141 179.544 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 38.8 t-80 -152.42 119.3 5.77 Favored 'General case' 0 N--CA 1.472 0.674 0 N-CA-C 109.283 -0.636 . . . . 0.0 109.283 178.966 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' F' F ' 7' ' ' ASP . . . . . 0.465 ' O ' ' OG ' ' I' ' 8' ' ' SER . 4.2 m-20 -69.17 148.39 49.97 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-N 116.471 -0.331 . . . . 0.0 110.746 179.968 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' F' F ' 8' ' ' SER . . . . . 0.477 ' OG ' ' O ' ' C' ' 7' ' ' ASP . 52.6 p -168.01 -171.99 1.69 Allowed 'General case' 0 N--CA 1.486 1.335 0 CA-C-O 120.931 0.396 . . . . 0.0 111.012 178.74 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.35 47.32 1.32 Allowed Glycine 0 N--CA 1.48 1.591 0 N-CA-C 111.746 -0.542 . . . . 0.0 111.746 179.689 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 47.5 p90 -65.4 134.05 52.66 Favored 'General case' 0 N--CA 1.473 0.678 0 N-CA-C 111.981 0.363 . . . . 0.0 111.981 -179.856 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 85.7 mt-10 -91.8 152.88 19.93 Favored 'General case' 0 N--CA 1.479 0.987 0 N-CA-C 109.699 -0.482 . . . . 0.0 109.699 178.002 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -154.61 127.25 1.07 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.594 0 N-CA-C 107.823 -1.177 . . . . 0.0 107.823 178.029 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 42.2 m-70 -136.27 146.48 46.73 Favored 'General case' 0 N--CA 1.483 1.212 0 CA-C-O 120.833 0.349 . . . . 0.0 111.602 -177.948 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 6.5 t60 -163.51 98.74 0.9 Allowed 'General case' 0 N--CA 1.486 1.348 0 CA-C-N 116.343 -0.389 . . . . 0.0 110.736 179.609 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 4.8 pt20 -91.56 -176.95 4.66 Favored 'General case' 0 CA--C 1.51 -0.563 0 N-CA-C 109.109 -0.7 . . . . 0.0 109.109 179.934 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -172.3 92.38 0.12 Allowed 'General case' 0 C--O 1.219 -0.507 0 CA-C-N 114.777 -1.101 . . . . 0.0 108.591 177.961 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 6.0 mp -123.05 155.95 35.86 Favored 'General case' 0 N--CA 1.495 1.794 0 CA-C-O 121.581 0.705 . . . . 0.0 111.455 -177.983 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 48.2 t -113.52 122.5 67.77 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.141 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 177.362 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 32.6 m-85 -122.67 142.52 50.58 Favored 'General case' 0 N--CA 1.489 1.504 0 CA-C-O 120.955 0.407 . . . . 0.0 110.584 179.934 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 67.4 m-85 52.67 68.08 0.89 Allowed 'General case' 0 C--N 1.343 0.318 0 CA-C-N 115.866 -0.606 . . . . 0.0 111.918 178.474 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -77.42 -83.75 0.07 Allowed 'General case' 0 CA--C 1.54 0.57 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 -179.496 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 40.9 tt0 -123.22 97.68 5.53 Favored 'General case' 0 C--N 1.32 -0.689 0 N-CA-C 108.099 -1.074 . . . . 0.0 108.099 179.849 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 4.1 p30 -158.79 143.51 15.91 Favored 'General case' 0 N--CA 1.48 1.065 0 CA-C-O 119.692 -0.194 . . . . 0.0 111.277 179.059 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' F' F ' 24' ' ' VAL . . . . . 0.481 ' HB ' ' H ' ' C' ' 25' ' ' GLY . 58.0 t -59.95 166.82 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.96 0 N-CA-C 107.341 -1.355 . . . . 0.0 107.341 177.01 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' F' F ' 25' ' ' GLY . . . . . 0.443 ' H ' ' HB ' ' I' ' 24' ' ' VAL . . . -122.14 49.82 0.87 Allowed Glycine 0 N--CA 1.476 1.343 0 N-CA-C 111.039 -0.824 . . . . 0.0 111.039 -179.407 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -63.41 -168.43 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.526 0 CA-C-O 120.597 0.237 . . . . 0.0 110.505 179.938 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 14.4 t30 -68.93 78.11 0.32 Allowed 'General case' 0 CA--C 1.534 0.359 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.23 -180.0 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -78.26 155.12 30.42 Favored 'General case' 0 N--CA 1.475 0.794 0 N-CA-C 109.408 -0.589 . . . . 0.0 109.408 179.248 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.56 -144.77 0.02 OUTLIER Glycine 0 C--N 1.338 0.679 0 N-CA-C 110.384 -1.087 . . . . 0.0 110.384 178.005 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -136.8 117.35 13.82 Favored 'General case' 0 N--CA 1.476 0.829 0 CA-C-O 120.751 0.31 . . . . 0.0 110.165 179.752 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 68.3 mt -77.69 125.42 37.35 Favored 'Isoleucine or valine' 0 C--O 1.238 0.45 0 N-CA-C 106.948 -1.501 . . . . 0.0 106.948 178.373 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' F' F ' 32' ' ' ILE . . . . . 0.419 ' C ' ' H ' ' F' ' 34' ' ' LEU . 45.8 pt -151.25 164.63 2.46 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.994 0 CA-C-O 121.154 0.502 . . . . 0.0 111.043 -179.018 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.64 1.43 3.53 Favored Glycine 0 CA--C 1.529 0.911 0 CA-C-N 115.583 -0.735 . . . . 0.0 111.864 -179.67 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' F' F ' 34' ' ' LEU . . . . . 0.419 ' H ' ' C ' ' F' ' 32' ' ' ILE . 7.9 tt -79.6 148.16 31.8 Favored 'General case' 0 N--CA 1.468 0.464 0 C-N-CA 122.837 0.455 . . . . 0.0 109.775 179.95 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 28.0 ttt -158.68 140.97 14.07 Favored 'General case' 0 N--CA 1.477 0.914 0 N-CA-C 108.806 -0.812 . . . . 0.0 108.806 178.725 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 32.2 m -156.59 161.86 1.78 Allowed 'Isoleucine or valine' 0 C--N 1.344 0.358 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 -179.611 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.0 67.22 2.33 Favored Glycine 0 C--N 1.307 -1.047 0 CA-C-N 115.962 -0.563 . . . . 0.0 111.887 178.458 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 148.46 173.82 19.63 Favored Glycine 0 N--CA 1.475 1.26 0 N-CA-C 110.943 -0.863 . . . . 0.0 110.943 179.192 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' F' F ' 39' ' ' VAL . . . . . 0.575 ' H ' HG12 ' I' ' 39' ' ' VAL . 33.1 m -126.82 163.08 30.06 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.935 0 C-N-CA 123.416 0.686 . . . . 0.0 110.899 -179.058 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 24.7 t . . . . . 0 C--O 1.223 -0.304 0 CA-C-O 118.29 -0.862 . . . . 0.0 110.435 178.89 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' G' G ' 1' ' ' ASP . . . . . 0.429 ' CG ' ' H1 ' ' D' ' 1' ' ' ASP . 67.0 m-20 . . . . . 0 N--CA 1.491 1.62 0 N-CA-C 109.342 -0.614 . . . . 0.0 109.342 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' G' G ' 2' ' ' ALA . . . . . . . . . . . . . . . -61.79 129.21 39.92 Favored 'General case' 0 N--CA 1.468 0.46 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.632 179.687 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' G' G ' 3' ' ' GLU . . . . . . . . . . . . . 41.0 tt0 -168.62 106.78 0.46 Allowed 'General case' 0 N--CA 1.473 0.692 0 CA-C-O 120.398 0.142 . . . . 0.0 110.668 179.572 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 56.4 m-85 -87.62 146.45 25.73 Favored 'General case' 0 N--CA 1.474 0.756 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 179.215 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' G' G ' 5' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 -143.67 142.58 31.06 Favored 'General case' 0 N--CA 1.482 1.131 0 C-N-CA 122.585 0.354 . . . . 0.0 110.301 179.813 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 40.0 t-80 -152.53 120.34 6.12 Favored 'General case' 0 N--CA 1.473 0.712 0 N-CA-C 109.46 -0.57 . . . . 0.0 109.46 179.016 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -71.16 143.88 50.38 Favored 'General case' 0 N--CA 1.471 0.584 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.12 -179.936 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' G' G ' 8' ' ' SER . . . . . 0.57 ' OG ' ' O ' ' D' ' 7' ' ' ASP . 49.1 p -164.54 -170.1 1.94 Allowed 'General case' 0 N--CA 1.475 0.783 0 CA-C-O 120.923 0.392 . . . . 0.0 110.52 178.506 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.11 47.32 1.35 Allowed Glycine 0 N--CA 1.48 1.571 0 N-CA-C 111.37 -0.692 . . . . 0.0 111.37 179.529 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 50.1 p90 -65.62 133.31 50.88 Favored 'General case' 0 CA--C 1.543 0.683 0 N-CA-C 111.875 0.324 . . . . 0.0 111.875 -179.497 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 83.0 mt-10 -91.6 151.89 20.51 Favored 'General case' 0 N--CA 1.478 0.974 0 CA-C-O 120.991 0.424 . . . . 0.0 110.076 178.555 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -154.78 127.41 1.07 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.014 0 N-CA-C 107.864 -1.161 . . . . 0.0 107.864 178.17 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 42.4 m-70 -135.42 148.21 49.24 Favored 'General case' 0 N--CA 1.479 1.004 0 CA-C-N 115.505 -0.77 . . . . 0.0 111.409 -178.258 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 6.6 t60 -165.49 98.97 0.7 Allowed 'General case' 0 N--CA 1.484 1.263 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.307 179.012 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -92.09 -176.73 4.48 Favored 'General case' 0 CA--C 1.513 -0.477 0 N-CA-C 108.901 -0.777 . . . . 0.0 108.901 -179.847 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -172.85 92.28 0.1 Allowed 'General case' 0 N--CA 1.47 0.565 0 CA-C-N 114.86 -1.064 . . . . 0.0 108.37 178.123 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 6.0 mp -123.19 154.77 38.27 Favored 'General case' 0 N--CA 1.498 1.955 0 CA-C-O 121.302 0.572 . . . . 0.0 111.668 -177.995 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 42.4 t -112.83 123.08 68.14 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.99 0 CA-C-N 114.747 -1.115 . . . . 0.0 108.394 176.866 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 34.8 m-85 -123.53 142.05 51.4 Favored 'General case' 0 C--N 1.367 1.35 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.691 -179.807 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 66.9 m-85 53.64 66.25 1.28 Allowed 'General case' 0 C--O 1.237 0.422 0 CA-C-N 115.742 -0.663 . . . . 0.0 111.584 178.192 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -76.02 -83.62 0.06 Allowed 'General case' 0 N--CA 1.471 0.586 0 N-CA-C 110.003 -0.369 . . . . 0.0 110.003 -179.076 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 41.3 tt0 -123.0 97.25 5.35 Favored 'General case' 0 C--N 1.321 -0.673 0 N-CA-C 107.829 -1.174 . . . . 0.0 107.829 -179.976 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 4.1 p30 -158.59 144.2 16.62 Favored 'General case' 0 N--CA 1.479 1.008 0 CA-C-O 120.463 0.173 . . . . 0.0 111.279 178.891 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' G' G ' 24' ' ' VAL . . . . . 0.556 ' HB ' ' H ' ' D' ' 25' ' ' GLY . 61.0 t -60.96 165.62 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.685 0 N-CA-C 107.617 -1.253 . . . . 0.0 107.617 177.347 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' G' G ' 25' ' ' GLY . . . . . 0.404 ' N ' HG12 ' G' ' 24' ' ' VAL . . . -120.36 50.34 0.83 Allowed Glycine 0 N--CA 1.482 1.711 0 N-CA-C 110.567 -1.013 . . . . 0.0 110.567 -179.561 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -64.06 -168.04 0.03 OUTLIER 'General case' 0 N--CA 1.472 0.647 0 CA-C-N 117.002 0.401 . . . . 0.0 109.963 179.875 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 15.5 t30 -69.46 77.92 0.4 Allowed 'General case' 0 CA--C 1.537 0.459 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.444 179.954 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -77.2 155.22 32.37 Favored 'General case' 0 N--CA 1.475 0.788 0 N-CA-C 109.602 -0.518 . . . . 0.0 109.602 179.189 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.03 -142.53 0.02 OUTLIER Glycine 0 CA--C 1.527 0.792 0 N-CA-C 109.918 -1.273 . . . . 0.0 109.918 178.313 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -137.72 117.45 13.12 Favored 'General case' 0 N--CA 1.471 0.583 0 C-N-CA 122.624 0.37 . . . . 0.0 110.737 -179.915 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 71.7 mt -77.79 125.85 37.74 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.496 0 N-CA-C 107.007 -1.479 . . . . 0.0 107.007 178.382 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' G' G ' 32' ' ' ILE . . . . . 0.426 ' C ' ' H ' ' G' ' 34' ' ' LEU . 44.7 pt -152.31 164.95 1.96 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.755 0 CA-C-N 120.091 1.314 . . . . 0.0 110.032 -179.36 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.61 0.64 3.9 Favored Glycine 0 N--CA 1.468 0.779 0 N-CA-C 111.19 -0.764 . . . . 0.0 111.19 -179.912 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' G' G ' 34' ' ' LEU . . . . . 0.426 ' H ' ' C ' ' G' ' 32' ' ' ILE . 7.9 tt -79.71 148.34 31.58 Favored 'General case' 0 N--CA 1.465 0.303 0 C-N-CA 122.832 0.453 . . . . 0.0 109.841 179.855 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 27.1 ttt -159.14 141.98 14.27 Favored 'General case' 0 N--CA 1.476 0.837 0 N-CA-C 108.731 -0.84 . . . . 0.0 108.731 179.004 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 33.8 m -156.68 162.21 1.67 Allowed 'Isoleucine or valine' 0 C--N 1.345 0.412 0 N-CA-C 108.618 -0.882 . . . . 0.0 108.618 -179.492 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' G' G ' 37' ' ' GLY . . . . . 0.401 ' N ' ' OE1' ' D' ' 15' ' ' GLN . . . 54.95 67.86 1.98 Allowed Glycine 0 C--N 1.31 -0.879 0 CA-C-N 115.637 -0.71 . . . . 0.0 112.141 178.134 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 148.75 174.41 20.37 Favored Glycine 0 N--CA 1.475 1.296 0 N-CA-C 110.462 -1.055 . . . . 0.0 110.462 179.229 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' G' G ' 39' ' ' VAL . . . . . 0.575 HG12 ' H ' ' D' ' 39' ' ' VAL . 33.8 m -127.27 162.73 31.82 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.76 0 C-N-CA 123.1 0.56 . . . . 0.0 110.877 -179.308 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 28.1 t . . . . . 0 N--CA 1.469 0.493 0 CA-C-O 118.351 -0.833 . . . . 0.0 110.702 178.773 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' H' H ' 1' ' ' ASP . . . . . 0.415 ' CG ' ' H1 ' ' E' ' 1' ' ' ASP . 67.0 m-20 . . . . . 0 N--CA 1.49 1.561 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' H' H ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.36 129.14 39.33 Favored 'General case' 0 N--CA 1.467 0.416 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.601 179.693 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' H' H ' 3' ' ' GLU . . . . . 0.404 ' CD ' HH21 ' H' ' 5' ' ' ARG . 41.1 tt0 -168.48 106.86 0.48 Allowed 'General case' 0 N--CA 1.471 0.617 0 CA-C-O 120.425 0.155 . . . . 0.0 110.705 179.711 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 57.5 m-85 -87.56 146.63 25.68 Favored 'General case' 0 N--CA 1.473 0.705 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 179.129 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' H' H ' 5' ' ' ARG . . . . . 0.404 HH21 ' CD ' ' H' ' 3' ' ' GLU . 99.2 mtt180 -143.91 142.64 30.89 Favored 'General case' 0 N--CA 1.483 1.178 0 C-N-CA 122.551 0.341 . . . . 0.0 110.169 179.846 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 41.9 t-80 -152.55 120.38 6.13 Favored 'General case' 0 N--CA 1.474 0.737 0 N-CA-C 109.409 -0.589 . . . . 0.0 109.409 178.946 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -71.28 143.89 50.18 Favored 'General case' 0 N--CA 1.469 0.518 0 C-N-CA 122.699 0.399 . . . . 0.0 111.158 -179.913 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' H' H ' 8' ' ' SER . . . . . 0.435 ' OG ' ' O ' ' E' ' 7' ' ' ASP . 53.6 p -164.36 -170.42 2.06 Favored 'General case' 0 N--CA 1.474 0.759 0 CA-C-O 120.965 0.412 . . . . 0.0 110.422 178.766 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.95 47.97 1.3 Allowed Glycine 0 N--CA 1.48 1.586 0 N-CA-C 111.461 -0.655 . . . . 0.0 111.461 179.601 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 50.2 p90 -66.28 133.18 50.03 Favored 'General case' 0 N--CA 1.472 0.675 0 N-CA-C 112.046 0.387 . . . . 0.0 112.046 -179.605 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 83.4 mt-10 -91.42 151.66 20.72 Favored 'General case' 0 N--CA 1.478 0.957 0 CA-C-O 121.069 0.461 . . . . 0.0 110.195 178.576 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -154.73 127.41 1.08 Allowed 'Isoleucine or valine' 0 CA--C 1.553 1.059 0 N-CA-C 107.888 -1.153 . . . . 0.0 107.888 178.251 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 42.7 m-70 -135.46 148.2 49.17 Favored 'General case' 0 C--N 1.357 0.912 0 CA-C-N 115.461 -0.79 . . . . 0.0 111.444 -178.293 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 6.6 t60 -165.43 98.75 0.7 Allowed 'General case' 0 N--CA 1.482 1.136 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.427 178.996 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 4.9 pt20 -91.88 -177.02 4.61 Favored 'General case' 0 CA--C 1.513 -0.468 0 N-CA-C 108.799 -0.815 . . . . 0.0 108.799 -179.814 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -172.7 92.13 0.11 Allowed 'General case' 0 N--CA 1.472 0.663 0 CA-C-N 114.707 -1.133 . . . . 0.0 108.239 178.142 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 6.0 mp -122.93 154.72 37.99 Favored 'General case' 0 N--CA 1.499 1.991 0 CA-C-O 121.224 0.535 . . . . 0.0 111.784 -178.064 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 41.5 t -112.72 123.25 68.21 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.947 0 CA-C-N 114.841 -1.072 . . . . 0.0 108.368 176.742 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 34.2 m-85 -123.66 141.58 51.88 Favored 'General case' 0 C--N 1.369 1.425 0 CA-C-N 115.427 -0.806 . . . . 0.0 110.598 -179.65 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 66.9 m-85 53.02 67.44 1.0 Allowed 'General case' 0 C--O 1.237 0.419 0 CA-C-N 115.623 -0.717 . . . . 0.0 111.674 178.389 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -76.66 -83.15 0.07 Allowed 'General case' 0 N--CA 1.469 0.504 0 N-CA-C 110.025 -0.361 . . . . 0.0 110.025 -179.168 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 41.1 tt0 -123.25 96.93 5.19 Favored 'General case' 0 C--N 1.319 -0.726 0 N-CA-C 107.891 -1.151 . . . . 0.0 107.891 -179.969 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 4.2 p30 -158.16 143.98 17.06 Favored 'General case' 0 N--CA 1.478 0.968 0 CA-C-O 120.423 0.154 . . . . 0.0 111.264 179.021 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' H' H ' 24' ' ' VAL . . . . . 0.461 ' HB ' ' H ' ' E' ' 25' ' ' GLY . 58.3 t -60.77 165.9 0.77 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.599 0 N-CA-C 107.61 -1.256 . . . . 0.0 107.61 177.285 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' H' H ' 25' ' ' GLY . . . . . 0.408 ' N ' HG12 ' H' ' 24' ' ' VAL . . . -120.47 49.7 0.86 Allowed Glycine 0 N--CA 1.479 1.518 0 N-CA-C 110.665 -0.974 . . . . 0.0 110.665 -179.472 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -63.71 -168.16 0.02 OUTLIER 'General case' 0 N--CA 1.471 0.625 0 CA-C-N 117.022 0.411 . . . . 0.0 110.125 179.926 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 15.8 t30 -69.52 78.45 0.41 Allowed 'General case' 0 CA--C 1.536 0.413 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.41 179.987 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -77.86 155.44 30.98 Favored 'General case' 0 N--CA 1.474 0.768 0 N-CA-C 109.459 -0.571 . . . . 0.0 109.459 179.262 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.36 -142.76 0.02 OUTLIER Glycine 0 C--N 1.339 0.733 0 N-CA-C 109.798 -1.321 . . . . 0.0 109.798 178.386 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -137.67 117.38 13.09 Favored 'General case' 0 N--CA 1.469 0.522 0 C-N-CA 122.526 0.33 . . . . 0.0 110.758 -179.855 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 71.5 mt -77.49 125.73 37.42 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.506 0 N-CA-C 106.946 -1.502 . . . . 0.0 106.946 178.498 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' H' H ' 32' ' ' ILE . . . . . 0.418 ' C ' ' H ' ' H' ' 34' ' ' LEU . 44.7 pt -152.27 164.92 1.98 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 CA-C-N 120.094 1.316 . . . . 0.0 110.005 -179.452 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.91 0.3 3.97 Favored Glycine 0 CA--C 1.527 0.796 0 N-CA-C 111.202 -0.759 . . . . 0.0 111.202 -179.827 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' H' H ' 34' ' ' LEU . . . . . 0.418 ' H ' ' C ' ' H' ' 32' ' ' ILE . 7.9 tt -79.39 148.36 32.02 Favored 'General case' 0 N--CA 1.465 0.308 0 C-N-CA 122.84 0.456 . . . . 0.0 109.889 179.935 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 27.1 ttt -159.23 141.73 13.95 Favored 'General case' 0 N--CA 1.477 0.915 0 N-CA-C 108.709 -0.848 . . . . 0.0 108.709 178.999 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 35.9 m -156.69 162.13 1.7 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.416 0 N-CA-C 108.599 -0.889 . . . . 0.0 108.599 -179.39 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.04 67.79 2.02 Favored Glycine 0 C--N 1.31 -0.896 0 CA-C-N 115.638 -0.71 . . . . 0.0 112.086 178.239 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 149.01 174.89 20.98 Favored Glycine 0 N--CA 1.475 1.267 0 N-CA-C 110.571 -1.012 . . . . 0.0 110.571 179.19 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' H' H ' 39' ' ' VAL . . . . . 0.559 HG12 ' H ' ' E' ' 39' ' ' VAL . 33.9 m -127.65 162.53 33.09 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.799 0 C-N-CA 123.114 0.565 . . . . 0.0 110.923 -179.368 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 25.9 t . . . . . 0 N--CA 1.47 0.541 0 CA-C-O 118.402 -0.809 . . . . 0.0 110.707 178.74 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' I' I ' 1' ' ' ASP . . . . . . . . . . . . . 66.4 m-20 . . . . . 0 N--CA 1.492 1.629 0 N-CA-C 109.442 -0.577 . . . . 0.0 109.442 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' I' I ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.15 129.27 40.02 Favored 'General case' 0 N--CA 1.468 0.436 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.617 179.685 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' I' I ' 3' ' ' GLU . . . . . 0.408 ' CD ' HH21 ' I' ' 5' ' ' ARG . 40.6 tt0 -168.6 106.91 0.47 Allowed 'General case' 0 N--CA 1.471 0.616 0 CA-C-O 120.397 0.142 . . . . 0.0 110.644 179.693 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 56.3 m-85 -87.66 146.69 25.59 Favored 'General case' 0 N--CA 1.474 0.772 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 179.054 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' I' I ' 5' ' ' ARG . . . . . 0.408 HH21 ' CD ' ' I' ' 3' ' ' GLU . 99.2 mtt180 -143.93 142.37 30.72 Favored 'General case' 0 N--CA 1.483 1.199 0 C-N-CA 122.569 0.348 . . . . 0.0 110.108 179.827 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 40.7 t-80 -152.36 120.13 6.12 Favored 'General case' 0 N--CA 1.473 0.687 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 178.976 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -71.06 143.98 50.51 Favored 'General case' 0 N--CA 1.47 0.574 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.178 -179.856 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' I' I ' 8' ' ' SER . . . . . 0.465 ' OG ' ' O ' ' F' ' 7' ' ' ASP . 54.1 p -164.5 -170.43 2.04 Favored 'General case' 0 N--CA 1.475 0.781 0 CA-C-O 120.964 0.411 . . . . 0.0 110.456 178.707 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.19 47.24 1.35 Allowed Glycine 0 N--CA 1.48 1.611 0 N-CA-C 111.598 -0.601 . . . . 0.0 111.598 179.67 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 50.4 p90 -65.76 133.48 51.13 Favored 'General case' 0 N--CA 1.473 0.676 0 N-CA-C 112.0 0.37 . . . . 0.0 112.0 -179.566 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 82.6 mt-10 -91.81 151.71 20.47 Favored 'General case' 0 N--CA 1.476 0.871 0 CA-C-O 120.978 0.418 . . . . 0.0 110.184 178.639 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -154.67 127.48 1.1 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.033 0 N-CA-C 107.969 -1.123 . . . . 0.0 107.969 178.16 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 41.7 m-70 -135.5 148.1 49.07 Favored 'General case' 0 N--CA 1.477 0.922 0 CA-C-N 115.407 -0.815 . . . . 0.0 111.467 -178.248 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 6.6 t60 -165.3 99.01 0.72 Allowed 'General case' 0 N--CA 1.483 1.192 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.383 179.013 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -92.07 -176.92 4.54 Favored 'General case' 0 CA--C 1.511 -0.521 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 -179.848 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -172.83 92.08 0.1 Allowed 'General case' 0 N--CA 1.47 0.534 0 CA-C-N 114.74 -1.118 . . . . 0.0 108.291 178.199 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 6.0 mp -122.84 154.91 37.63 Favored 'General case' 0 N--CA 1.499 1.983 0 CA-C-O 121.223 0.535 . . . . 0.0 111.754 -178.054 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 41.3 t -113.09 123.42 68.72 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.927 0 CA-C-N 114.861 -1.063 . . . . 0.0 108.247 176.784 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 33.4 m-85 -123.96 141.18 52.27 Favored 'General case' 0 C--N 1.37 1.461 0 CA-C-N 115.413 -0.812 . . . . 0.0 110.636 -179.444 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 67.1 m-85 53.35 67.15 1.05 Allowed 'General case' 0 C--O 1.238 0.45 0 CA-C-N 115.69 -0.686 . . . . 0.0 111.537 178.41 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -76.32 -83.14 0.07 Allowed 'General case' 0 N--CA 1.47 0.541 0 N-CA-C 109.913 -0.402 . . . . 0.0 109.913 -179.148 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 41.3 tt0 -123.33 97.1 5.25 Favored 'General case' 0 C--N 1.32 -0.712 0 N-CA-C 107.868 -1.16 . . . . 0.0 107.868 -179.924 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 4.1 p30 -158.29 144.36 17.13 Favored 'General case' 0 N--CA 1.479 1.002 0 O-C-N 122.458 -0.151 . . . . 0.0 111.257 178.964 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' I' I ' 24' ' ' VAL . . . . . 0.443 ' HB ' ' H ' ' F' ' 25' ' ' GLY . 59.5 t -61.2 165.57 0.86 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.589 0 N-CA-C 107.63 -1.248 . . . . 0.0 107.63 177.345 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' I' I ' 25' ' ' GLY . . . . . 0.412 ' N ' HG12 ' I' ' 24' ' ' VAL . . . -120.24 49.95 0.85 Allowed Glycine 0 N--CA 1.481 1.661 0 N-CA-C 110.588 -1.005 . . . . 0.0 110.588 -179.383 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -63.8 -168.1 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.649 0 CA-C-N 116.991 0.395 . . . . 0.0 110.134 179.825 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 15.2 t30 -69.56 78.3 0.41 Allowed 'General case' 0 CA--C 1.536 0.421 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.364 179.924 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -77.77 155.34 31.22 Favored 'General case' 0 N--CA 1.475 0.78 0 N-CA-C 109.504 -0.554 . . . . 0.0 109.504 179.263 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.28 -143.0 0.02 OUTLIER Glycine 0 CA--C 1.527 0.842 0 N-CA-C 109.813 -1.315 . . . . 0.0 109.813 178.39 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -137.3 117.36 13.38 Favored 'General case' 0 N--CA 1.471 0.597 0 C-N-CA 122.627 0.371 . . . . 0.0 110.778 -179.863 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 71.7 mt -77.57 125.89 37.6 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.488 0 N-CA-C 106.986 -1.487 . . . . 0.0 106.986 178.389 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' I' I ' 32' ' ' ILE . . . . . 0.429 ' C ' ' H ' ' I' ' 34' ' ' LEU . 44.9 pt -152.34 164.95 1.94 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 CA-C-N 120.143 1.338 . . . . 0.0 110.06 -179.436 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.64 0.98 4.22 Favored Glycine 0 N--CA 1.469 0.844 0 N-CA-C 111.127 -0.789 . . . . 0.0 111.127 -179.909 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' I' I ' 34' ' ' LEU . . . . . 0.429 ' H ' ' C ' ' I' ' 32' ' ' ILE . 8.1 tt -80.1 148.02 31.17 Favored 'General case' 0 CA--C 1.533 0.313 0 C-N-CA 122.845 0.458 . . . . 0.0 109.792 179.895 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 26.9 ttt -158.69 141.68 14.63 Favored 'General case' 0 N--CA 1.476 0.85 0 N-CA-C 108.611 -0.885 . . . . 0.0 108.611 179.086 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 35.9 m -156.65 162.06 1.72 Allowed 'Isoleucine or valine' 0 C--N 1.346 0.442 0 N-CA-C 108.523 -0.917 . . . . 0.0 108.523 -179.562 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.22 67.78 2.03 Favored Glycine 0 C--N 1.312 -0.798 0 CA-C-N 115.638 -0.71 . . . . 0.0 112.107 178.185 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 148.68 174.73 20.59 Favored Glycine 0 N--CA 1.474 1.217 0 N-CA-C 110.461 -1.056 . . . . 0.0 110.461 179.244 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' I' I ' 39' ' ' VAL . . . . . 0.575 HG12 ' H ' ' F' ' 39' ' ' VAL . 33.9 m -127.66 162.76 32.64 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.786 0 C-N-CA 123.1 0.56 . . . . 0.0 110.923 -179.259 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 27.1 t . . . . . 0 N--CA 1.47 0.544 0 CA-C-O 118.377 -0.821 . . . . 0.0 110.56 178.75 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 9.4 m-20 . . . . . 0 N--CA 1.493 1.694 0 N-CA-C 109.835 -0.431 . . . . 0.0 109.835 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.35 129.74 42.1 Favored 'General case' 0 N--CA 1.47 0.529 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.228 179.473 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 38.6 tt0 -138.7 104.54 5.13 Favored 'General case' 0 N--CA 1.48 1.043 0 N-CA-C 109.555 -0.535 . . . . 0.0 109.555 179.427 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 26.6 m-85 -73.16 169.12 17.7 Favored 'General case' 0 CA--C 1.537 0.478 0 N-CA-C 109.142 -0.688 . . . . 0.0 109.142 179.512 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 38.2 mtp180 -68.41 147.02 52.67 Favored 'General case' 0 C--O 1.201 -1.452 0 CA-C-N 115.821 -0.627 . . . . 0.0 111.293 -177.505 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 39.2 m80 -109.55 119.1 38.39 Favored 'General case' 0 N--CA 1.482 1.165 0 N-CA-C 108.953 -0.758 . . . . 0.0 108.953 178.289 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' ASP . . . . . 0.459 ' OD1' ' NH2' ' G' ' 5' ' ' ARG . 7.3 m-20 -67.52 140.7 57.01 Favored 'General case' 0 N--CA 1.469 0.502 0 CA-C-O 121.135 0.493 . . . . 0.0 111.795 -178.758 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 39.0 t -158.65 -169.49 2.74 Favored 'General case' 0 N--CA 1.467 0.376 0 CA-C-N 115.848 -0.615 . . . . 0.0 109.662 179.092 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 119.83 32.39 1.2 Allowed Glycine 0 N--CA 1.485 1.922 0 N-CA-C 111.574 -0.61 . . . . 0.0 111.574 179.61 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 46.9 p90 -57.2 130.43 46.16 Favored 'General case' 0 N--CA 1.471 0.61 0 CA-C-N 116.736 0.268 . . . . 0.0 111.49 179.971 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.506 ' CG ' HD21 ' C' ' 27' ' ' ASN . 60.6 mt-10 -90.44 153.15 20.61 Favored 'General case' 0 N--CA 1.473 0.717 0 N-CA-C 109.329 -0.619 . . . . 0.0 109.329 178.69 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.6 p -153.48 126.55 1.15 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 N-CA-C 107.698 -1.223 . . . . 0.0 107.698 177.988 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 45.6 m-70 -136.91 162.06 34.3 Favored 'General case' 0 N--CA 1.49 1.537 0 CA-C-N 118.685 0.675 . . . . 0.0 110.879 -178.721 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 38.3 t60 -152.91 96.43 2.1 Favored 'General case' 0 N--CA 1.486 1.333 0 C-N-CA 122.634 0.374 . . . . 0.0 110.049 179.065 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . 0.725 HE22 ' H ' ' A' ' 38' ' ' GLY . 28.3 mt-30 -90.63 121.52 32.61 Favored 'General case' 0 N--CA 1.452 -0.371 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 -178.964 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -112.98 103.67 11.63 Favored 'General case' 0 N--CA 1.475 0.789 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 176.686 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 57.8 tp -133.34 150.43 51.85 Favored 'General case' 0 N--CA 1.486 1.347 0 N-CA-C 108.766 -0.827 . . . . 0.0 108.766 -179.391 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 84.5 t -145.42 123.13 4.65 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.969 0 CA-C-O 118.523 -0.751 . . . . 0.0 109.137 179.755 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 11.9 m-85 -70.74 158.67 35.89 Favored 'General case' 0 N--CA 1.485 1.324 0 N-CA-C 107.461 -1.311 . . . . 0.0 107.461 177.564 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 18.6 t80 -170.07 -58.44 0.02 OUTLIER 'General case' 0 N--CA 1.481 1.101 0 CA-C-O 122.425 1.107 . . . . 0.0 109.765 179.735 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -39.19 89.68 0.0 OUTLIER 'General case' 0 N--CA 1.456 -0.135 0 CA-C-N 113.807 -1.542 . . . . 0.0 112.844 -178.034 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 38.6 tt0 -64.49 159.59 21.2 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.175 -0.92 . . . . 0.0 110.552 179.245 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 9.6 m-20 -136.23 125.81 25.3 Favored 'General case' 0 N--CA 1.481 1.086 0 C-N-CA 123.297 0.639 . . . . 0.0 109.781 -179.897 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.861 HG12 ' H ' ' A' ' 25' ' ' GLY . 57.8 t -76.55 -170.44 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.591 0 N-CA-C 108.511 -0.922 . . . . 0.0 108.511 179.673 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.861 ' H ' HG12 ' A' ' 24' ' ' VAL . . . -69.11 48.86 0.52 Allowed Glycine 0 CA--C 1.53 1.003 0 CA-C-N 118.344 0.52 . . . . 0.0 112.313 -178.147 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 13.1 p -69.54 137.52 52.52 Favored 'General case' 0 C--O 1.217 -0.61 0 N-CA-C 109.596 -0.52 . . . . 0.0 109.596 178.66 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . 0.512 HD21 ' CG ' ' B' ' 11' ' ' GLU . 34.6 t30 -68.57 95.06 0.61 Allowed 'General case' 0 N--CA 1.47 0.553 0 N-CA-C 108.15 -1.055 . . . . 0.0 108.15 177.847 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 68.6 mttm -92.45 117.66 30.16 Favored 'General case' 0 N--CA 1.481 1.079 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 -179.221 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.33 -134.27 0.01 OUTLIER Glycine 0 CA--C 1.534 1.226 0 N-CA-C 110.771 -0.932 . . . . 0.0 110.771 179.044 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -115.65 127.16 54.98 Favored 'General case' 0 N--CA 1.477 0.897 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 179.12 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 66.1 mt -90.53 134.97 27.76 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.59 0 N-CA-C 107.673 -1.232 . . . . 0.0 107.673 179.012 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 30.3 mt -136.52 138.16 46.92 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.815 0 CA-C-N 115.982 -0.554 . . . . 0.0 109.606 -179.134 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.97 57.46 15.75 Favored Glycine 0 CA--C 1.527 0.842 0 CA-C-N 115.904 -0.589 . . . . 0.0 112.795 178.543 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 25.4 tp -106.11 132.77 51.79 Favored 'General case' 0 N--CA 1.488 1.474 0 N-CA-C 107.508 -1.293 . . . . 0.0 107.508 177.919 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 24.9 ttt -138.2 148.15 44.52 Favored 'General case' 0 N--CA 1.471 0.576 0 N-CA-C 107.769 -1.197 . . . . 0.0 107.769 179.136 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 60.4 t -156.64 160.45 2.25 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.587 0 N-CA-C 106.097 -1.816 . . . . 0.0 106.097 -178.855 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . 0.455 ' O ' ' NE2' ' D' ' 15' ' ' GLN . . . 53.55 74.48 0.3 Allowed Glycine 0 C--N 1.308 -0.993 0 C-N-CA 121.214 -0.517 . . . . 0.0 111.818 177.839 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . 0.725 ' H ' HE22 ' A' ' 15' ' ' GLN . . . 164.73 -168.51 39.02 Favored Glycine 0 N--CA 1.466 0.692 0 N-CA-C 111.042 -0.823 . . . . 0.0 111.042 179.352 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 24.5 m -126.67 148.9 31.38 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.855 0 C-N-CA 122.977 0.511 . . . . 0.0 109.847 179.665 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 9.7 t . . . . . 0 CA--C 1.535 0.385 0 CA-C-O 118.109 -0.948 . . . . 0.0 110.723 178.893 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' B' B ' 1' ' ' ASP . . . . . . . . . . . . . 9.5 m-20 . . . . . 0 N--CA 1.494 1.74 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' B' B ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.28 129.85 42.65 Favored 'General case' 0 N--CA 1.47 0.544 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.238 179.47 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 3' ' ' GLU . . . . . . . . . . . . . 38.6 tt0 -138.77 104.59 5.13 Favored 'General case' 0 N--CA 1.48 1.029 0 N-CA-C 109.515 -0.55 . . . . 0.0 109.515 179.333 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 27.8 m-85 -72.9 169.03 17.7 Favored 'General case' 0 N--CA 1.468 0.435 0 N-CA-C 109.154 -0.684 . . . . 0.0 109.154 179.428 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 39.3 mtp180 -68.48 146.74 52.88 Favored 'General case' 0 C--O 1.201 -1.478 0 CA-C-N 115.708 -0.678 . . . . 0.0 111.3 -177.653 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 39.4 m80 -109.35 119.36 39.24 Favored 'General case' 0 N--CA 1.484 1.247 0 N-CA-C 108.995 -0.742 . . . . 0.0 108.995 178.282 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 7' ' ' ASP . . . . . 0.46 ' OD1' ' NH2' ' H' ' 5' ' ' ARG . 7.1 m-20 -67.66 141.02 56.84 Favored 'General case' 0 N--CA 1.469 0.501 0 CA-C-O 121.043 0.449 . . . . 0.0 111.76 -178.745 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 8' ' ' SER . . . . . . . . . . . . . 39.1 t -158.8 -169.45 2.7 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-N 115.814 -0.63 . . . . 0.0 109.634 179.099 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 119.75 32.37 1.21 Allowed Glycine 0 N--CA 1.485 1.92 0 N-CA-C 111.552 -0.619 . . . . 0.0 111.552 179.578 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 46.8 p90 -57.36 130.54 46.71 Favored 'General case' 0 N--CA 1.472 0.651 0 CA-C-O 120.64 0.257 . . . . 0.0 111.514 -179.996 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 11' ' ' GLU . . . . . 0.512 ' CG ' HD21 ' A' ' 27' ' ' ASN . 60.4 mt-10 -90.52 153.16 20.57 Favored 'General case' 0 N--CA 1.472 0.664 0 N-CA-C 109.357 -0.609 . . . . 0.0 109.357 178.857 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.6 p -153.53 126.14 1.09 Allowed 'Isoleucine or valine' 0 C--O 1.234 0.281 0 N-CA-C 107.846 -1.168 . . . . 0.0 107.846 178.086 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 45.6 m-70 -136.63 162.07 34.15 Favored 'General case' 0 N--CA 1.49 1.533 0 CA-C-N 118.648 0.658 . . . . 0.0 110.936 -178.567 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 38.4 t60 -152.86 96.44 2.1 Favored 'General case' 0 N--CA 1.487 1.422 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.087 179.057 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . 0.721 HE22 ' H ' ' B' ' 38' ' ' GLY . 28.3 mt-30 -90.48 121.16 32.2 Favored 'General case' 0 CA--C 1.517 -0.309 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 -179.01 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -112.63 103.49 11.53 Favored 'General case' 0 N--CA 1.474 0.742 0 N-CA-C 107.988 -1.115 . . . . 0.0 107.988 176.619 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 57.8 tp -133.34 150.25 51.86 Favored 'General case' 0 N--CA 1.486 1.369 0 N-CA-C 108.755 -0.831 . . . . 0.0 108.755 -179.368 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 84.6 t -145.41 122.48 4.28 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.011 0 CA-C-O 118.629 -0.7 . . . . 0.0 109.333 179.707 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 12.4 m-85 -70.52 158.91 35.26 Favored 'General case' 0 N--CA 1.486 1.334 0 N-CA-C 107.287 -1.375 . . . . 0.0 107.287 177.572 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 19.9 t80 -170.99 -57.67 0.02 OUTLIER 'General case' 0 N--CA 1.478 0.934 0 CA-C-O 122.22 1.009 . . . . 0.0 109.705 179.651 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -39.4 90.12 0.0 OUTLIER 'General case' 0 C--O 1.231 0.124 0 CA-C-N 113.959 -1.473 . . . . 0.0 112.721 -178.16 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 38.6 tt0 -64.85 159.55 22.35 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 115.1 -0.955 . . . . 0.0 110.559 179.298 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 9.7 m-20 -136.26 125.9 25.4 Favored 'General case' 0 N--CA 1.481 1.118 0 C-N-CA 123.217 0.607 . . . . 0.0 109.765 -179.876 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . 0.848 HG12 ' H ' ' B' ' 25' ' ' GLY . 56.9 t -76.7 -170.39 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.661 0 N-CA-C 108.586 -0.894 . . . . 0.0 108.586 179.722 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . 0.848 ' H ' HG12 ' B' ' 24' ' ' VAL . . . -68.71 48.42 0.45 Allowed Glycine 0 CA--C 1.531 1.087 0 CA-C-N 118.321 0.509 . . . . 0.0 112.208 -178.126 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 13.3 p -69.72 137.41 52.02 Favored 'General case' 0 C--O 1.219 -0.548 0 N-CA-C 109.591 -0.522 . . . . 0.0 109.591 178.706 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 27' ' ' ASN . . . . . 0.507 HD21 ' CG ' ' C' ' 11' ' ' GLU . 34.8 t30 -68.72 95.07 0.64 Allowed 'General case' 0 N--CA 1.47 0.543 0 N-CA-C 108.159 -1.052 . . . . 0.0 108.159 177.847 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 68.6 mttm -92.34 117.62 30.08 Favored 'General case' 0 N--CA 1.48 1.028 0 N-CA-C 109.997 -0.371 . . . . 0.0 109.997 -179.227 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.3 -134.17 0.01 OUTLIER Glycine 0 CA--C 1.532 1.128 0 N-CA-C 110.769 -0.932 . . . . 0.0 110.769 179.014 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -115.88 127.28 54.89 Favored 'General case' 0 N--CA 1.478 0.955 0 N-CA-C 109.428 -0.582 . . . . 0.0 109.428 179.149 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 66.0 mt -90.55 135.0 27.69 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.536 0 N-CA-C 107.676 -1.231 . . . . 0.0 107.676 179.035 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 30.2 mt -136.45 138.35 46.8 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.714 0 CA-C-N 115.933 -0.576 . . . . 0.0 109.567 -179.115 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.65 57.72 15.16 Favored Glycine 0 CA--C 1.527 0.829 0 CA-C-N 115.876 -0.602 . . . . 0.0 112.82 178.604 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 25.8 tp -106.3 132.83 51.88 Favored 'General case' 0 N--CA 1.486 1.375 0 N-CA-C 107.502 -1.296 . . . . 0.0 107.502 177.897 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 25.0 ttt -138.18 147.83 44.22 Favored 'General case' 0 N--CA 1.473 0.683 0 N-CA-C 107.778 -1.193 . . . . 0.0 107.778 179.216 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 36' ' ' VAL . . . . . 0.404 HG12 ' N ' ' B' ' 37' ' ' GLY . 60.8 t -156.67 159.98 2.45 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.625 0 N-CA-C 106.178 -1.786 . . . . 0.0 106.178 -178.928 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . 0.464 ' O ' ' NE2' ' E' ' 15' ' ' GLN . . . 54.12 74.26 0.33 Allowed Glycine 0 C--N 1.308 -0.973 0 N-CA-C 111.739 -0.544 . . . . 0.0 111.739 177.963 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 38' ' ' GLY . . . . . 0.721 ' H ' HE22 ' B' ' 15' ' ' GLN . . . 164.85 -168.44 39.07 Favored Glycine 0 N--CA 1.465 0.58 0 N-CA-C 111.124 -0.791 . . . . 0.0 111.124 179.266 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 24.5 m -126.62 148.89 31.33 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.808 0 C-N-CA 122.992 0.517 . . . . 0.0 109.955 179.601 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 9.7 t . . . . . 0 CA--C 1.535 0.392 0 CA-C-O 118.095 -0.955 . . . . 0.0 110.872 179.001 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' C' C ' 1' ' ' ASP . . . . . . . . . . . . . 9.5 m-20 . . . . . 0 N--CA 1.494 1.727 0 N-CA-C 109.703 -0.48 . . . . 0.0 109.703 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' C' C ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.4 129.73 42.02 Favored 'General case' 0 N--CA 1.47 0.538 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.29 179.4 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' C' C ' 3' ' ' GLU . . . . . . . . . . . . . 38.6 tt0 -138.64 104.6 5.16 Favored 'General case' 0 N--CA 1.48 1.062 0 N-CA-C 109.635 -0.506 . . . . 0.0 109.635 179.33 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 27.7 m-85 -72.93 169.23 17.32 Favored 'General case' 0 N--CA 1.468 0.429 0 N-CA-C 109.265 -0.643 . . . . 0.0 109.265 179.448 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 39.2 mtp180 -68.67 146.37 53.05 Favored 'General case' 0 C--O 1.201 -1.489 0 CA-C-N 115.849 -0.614 . . . . 0.0 111.221 -177.564 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 39.2 m80 -109.11 119.22 38.9 Favored 'General case' 0 N--CA 1.484 1.232 0 N-CA-C 108.978 -0.749 . . . . 0.0 108.978 178.269 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' C' C ' 7' ' ' ASP . . . . . 0.473 ' OD1' ' NH2' ' I' ' 5' ' ' ARG . 7.3 m-20 -67.64 141.11 56.83 Favored 'General case' 0 N--CA 1.468 0.448 0 CA-C-O 121.049 0.452 . . . . 0.0 111.79 -178.721 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' C' C ' 8' ' ' SER . . . . . . . . . . . . . 39.2 t -158.89 -169.49 2.71 Favored 'General case' 0 N--CA 1.466 0.37 0 CA-C-N 115.837 -0.62 . . . . 0.0 109.604 179.149 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 119.8 32.34 1.21 Allowed Glycine 0 N--CA 1.485 1.94 0 N-CA-C 111.506 -0.638 . . . . 0.0 111.506 179.543 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 46.8 p90 -57.32 130.42 46.15 Favored 'General case' 0 N--CA 1.471 0.587 0 CA-C-O 120.676 0.274 . . . . 0.0 111.53 179.951 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' C' C ' 11' ' ' GLU . . . . . 0.507 ' CG ' HD21 ' B' ' 27' ' ' ASN . 60.5 mt-10 -90.39 153.12 20.65 Favored 'General case' 0 N--CA 1.473 0.722 0 N-CA-C 109.368 -0.605 . . . . 0.0 109.368 178.792 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.6 p -153.47 126.16 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 N-CA-C 107.858 -1.164 . . . . 0.0 107.858 178.017 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 45.8 m-70 -136.59 162.16 33.9 Favored 'General case' 0 N--CA 1.491 1.589 0 CA-C-N 118.604 0.638 . . . . 0.0 110.958 -178.658 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 38.6 t60 -153.01 96.61 2.1 Favored 'General case' 0 N--CA 1.487 1.413 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.1 179.086 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' C' C ' 15' ' ' GLN . . . . . 0.739 HE22 ' H ' ' C' ' 38' ' ' GLY . 28.3 mt-30 -90.72 121.5 32.67 Favored 'General case' 0 CA--C 1.515 -0.381 0 N-CA-C 109.843 -0.429 . . . . 0.0 109.843 -178.99 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -112.92 103.49 11.46 Favored 'General case' 0 N--CA 1.473 0.677 0 N-CA-C 107.898 -1.149 . . . . 0.0 107.898 176.665 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 57.8 tp -133.28 150.23 51.92 Favored 'General case' 0 N--CA 1.486 1.337 0 N-CA-C 108.769 -0.826 . . . . 0.0 108.769 -179.435 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 85.3 t -145.38 122.59 4.37 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.013 0 CA-C-O 118.694 -0.67 . . . . 0.0 109.289 179.714 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 12.4 m-85 -70.63 158.88 35.41 Favored 'General case' 0 N--CA 1.487 1.39 0 N-CA-C 107.345 -1.354 . . . . 0.0 107.345 177.516 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 19.9 t80 -170.9 -57.72 0.02 OUTLIER 'General case' 0 N--CA 1.476 0.86 0 CA-C-O 122.29 1.043 . . . . 0.0 109.731 179.641 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -39.31 90.01 0.0 OUTLIER 'General case' 0 N--CA 1.457 -0.088 0 CA-C-N 113.986 -1.461 . . . . 0.0 112.711 -178.157 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 38.6 tt0 -64.84 159.64 22.11 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 115.183 -0.917 . . . . 0.0 110.593 179.343 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 9.6 m-20 -136.28 125.77 25.15 Favored 'General case' 0 N--CA 1.48 1.048 0 C-N-CA 123.315 0.646 . . . . 0.0 109.798 -179.838 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' C' C ' 24' ' ' VAL . . . . . 0.845 HG12 ' H ' ' C' ' 25' ' ' GLY . 57.1 t -76.66 -170.4 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.578 0 N-CA-C 108.609 -0.885 . . . . 0.0 108.609 179.708 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' C' C ' 25' ' ' GLY . . . . . 0.845 ' H ' HG12 ' C' ' 24' ' ' VAL . . . -68.8 48.56 0.47 Allowed Glycine 0 CA--C 1.533 1.18 0 CA-C-N 118.409 0.549 . . . . 0.0 112.249 -178.066 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 13.3 p -69.73 137.47 52.04 Favored 'General case' 0 C--O 1.22 -0.459 0 N-CA-C 109.646 -0.501 . . . . 0.0 109.646 178.716 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' C' C ' 27' ' ' ASN . . . . . 0.506 HD21 ' CG ' ' A' ' 11' ' ' GLU . 34.8 t30 -68.7 95.04 0.63 Allowed 'General case' 0 N--CA 1.469 0.485 0 N-CA-C 108.179 -1.045 . . . . 0.0 108.179 177.851 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 68.6 mttm -92.36 117.66 30.14 Favored 'General case' 0 N--CA 1.48 1.053 0 N-CA-C 109.988 -0.375 . . . . 0.0 109.988 -179.233 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.32 -134.2 0.01 OUTLIER Glycine 0 CA--C 1.533 1.16 0 N-CA-C 110.784 -0.926 . . . . 0.0 110.784 179.02 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -115.7 127.12 54.91 Favored 'General case' 0 N--CA 1.48 1.067 0 N-CA-C 109.314 -0.625 . . . . 0.0 109.314 179.203 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 66.2 mt -90.57 134.9 28.0 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.574 0 N-CA-C 107.666 -1.235 . . . . 0.0 107.666 178.845 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 30.4 mt -136.51 138.37 46.7 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.77 0 CA-C-N 115.937 -0.574 . . . . 0.0 109.545 -179.099 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.72 57.55 15.76 Favored Glycine 0 CA--C 1.528 0.887 0 CA-C-N 115.866 -0.606 . . . . 0.0 112.791 178.663 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 25.6 tp -106.13 132.75 51.83 Favored 'General case' 0 N--CA 1.486 1.353 0 N-CA-C 107.471 -1.307 . . . . 0.0 107.471 177.832 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 25.1 ttt -138.09 147.96 44.54 Favored 'General case' 0 N--CA 1.47 0.568 0 N-CA-C 107.591 -1.262 . . . . 0.0 107.591 179.315 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' C' C ' 36' ' ' VAL . . . . . 0.401 HG12 ' N ' ' C' ' 37' ' ' GLY . 60.6 t -156.81 160.05 2.4 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.546 0 N-CA-C 106.076 -1.824 . . . . 0.0 106.076 -178.959 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' C' C ' 37' ' ' GLY . . . . . 0.46 ' O ' ' NE2' ' F' ' 15' ' ' GLN . . . 54.1 74.12 0.34 Allowed Glycine 0 C--N 1.309 -0.925 0 C-N-CA 121.116 -0.564 . . . . 0.0 111.788 177.848 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' C' C ' 38' ' ' GLY . . . . . 0.739 ' H ' HE22 ' C' ' 15' ' ' GLN . . . 164.9 -168.36 39.07 Favored Glycine 0 N--CA 1.466 0.65 0 N-CA-C 111.104 -0.799 . . . . 0.0 111.104 179.349 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 24.2 m -126.71 148.88 31.43 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.858 0 C-N-CA 122.934 0.494 . . . . 0.0 109.935 179.716 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 9.8 t . . . . . 0 CA--C 1.534 0.364 0 CA-C-O 118.187 -0.911 . . . . 0.0 110.7 178.884 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' D' D ' 1' ' ' ASP . . . . . . . . . . . . . 9.5 m-20 . . . . . 0 N--CA 1.492 1.633 0 N-CA-C 108.994 -0.743 . . . . 0.0 108.994 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' D' D ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.18 130.94 45.16 Favored 'General case' 0 N--CA 1.468 0.449 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.289 -179.9 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' D' D ' 3' ' ' GLU . . . . . . . . . . . . . 38.8 tt0 -136.81 108.62 7.06 Favored 'General case' 0 C--O 1.212 -0.886 0 C-N-CA 123.14 0.576 . . . . 0.0 109.492 179.463 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 28.7 m-85 -77.57 165.4 24.36 Favored 'General case' 0 C--N 1.306 -1.294 0 C-N-CA 125.804 1.642 . . . . 0.0 107.949 179.843 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' D' D ' 5' ' ' ARG . . . . . 0.772 HH12 HG13 ' C' ' 24' ' ' VAL 0.273 47.8 mtp180 -77.55 143.45 38.37 Favored 'General case' 0 C--O 1.207 -1.15 0 C-N-CA 123.595 0.758 . . . . 0.0 109.044 -169.708 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 40.5 m80 -107.79 124.44 50.05 Favored 'General case' 0 C--N 1.366 1.301 0 N-CA-C 106.87 -1.53 . . . . 0.0 106.87 -176.282 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' D' D ' 7' ' ' ASP . . . . . 0.468 ' OD2' HG11 ' I' ' 24' ' ' VAL . 7.9 m-20 -64.28 131.92 48.73 Favored 'General case' 0 CA--C 1.512 -0.485 0 CA-C-N 113.897 -1.501 . . . . 0.0 114.077 179.004 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' D' D ' 8' ' ' SER . . . . . . . . . . . . . 40.9 t -152.62 -167.8 2.86 Favored 'General case' 0 N--CA 1.482 1.152 0 C-N-CA 120.908 -0.317 . . . . 0.0 110.17 177.028 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 120.71 30.23 1.41 Allowed Glycine 0 N--CA 1.486 1.967 0 N-CA-C 111.35 -0.7 . . . . 0.0 111.35 177.862 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 44.9 p90 -54.46 131.13 41.87 Favored 'General case' 0 CA--C 1.545 0.785 0 CA-C-N 117.085 0.442 . . . . 0.0 111.591 -179.557 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' D' D ' 11' ' ' GLU . . . . . 0.435 ' CG ' HD21 ' F' ' 27' ' ' ASN . 60.3 mt-10 -89.7 151.2 21.98 Favored 'General case' 0 N--CA 1.475 0.808 0 N-CA-C 109.781 -0.451 . . . . 0.0 109.781 177.324 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -149.66 129.07 3.53 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.529 0 N-CA-C 107.339 -1.356 . . . . 0.0 107.339 172.59 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 36.0 m-70 -130.29 162.59 28.67 Favored 'General case' 0 N--CA 1.48 1.054 0 C-N-CA 123.678 0.791 . . . . 0.0 112.902 178.205 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 41.5 t60 -153.96 104.31 2.65 Favored 'General case' 0 N--CA 1.486 1.35 0 N-CA-C 108.418 -0.956 . . . . 0.0 108.418 171.54 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' D' D ' 15' ' ' GLN . . . . . 0.655 HE22 ' H ' ' D' ' 38' ' ' GLY . 28.1 mt-30 -93.84 116.03 28.46 Favored 'General case' 0 CA--C 1.505 -0.762 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.325 -179.625 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -108.37 111.82 23.93 Favored 'General case' 0 C--N 1.359 0.99 0 N-CA-C 106.059 -1.83 . . . . 0.0 106.059 174.383 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 52.7 tp -134.32 150.73 50.98 Favored 'General case' 0 N--CA 1.484 1.238 0 N-CA-C 108.973 -0.751 . . . . 0.0 108.973 176.074 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 71.0 t -142.39 126.05 15.1 Favored 'Isoleucine or valine' 0 C--O 1.242 0.674 0 N-CA-C 109.141 -0.689 . . . . 0.0 109.141 173.863 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 26.8 m-85 -62.12 151.54 35.42 Favored 'General case' 0 N--CA 1.473 0.699 0 C-N-CA 124.284 1.034 . . . . 0.0 110.325 169.712 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 14.0 t80 -170.13 -66.86 0.02 OUTLIER 'General case' 0 C--N 1.318 -0.766 0 N-CA-C 107.765 -1.198 . . . . 0.0 107.765 -179.703 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -38.17 95.54 0.01 OUTLIER 'General case' 0 N--CA 1.449 -0.502 0 CA-C-N 114.207 -1.361 . . . . 0.0 111.798 -175.017 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 39.2 tt0 -67.51 161.12 26.19 Favored 'General case' 0 N--CA 1.468 0.458 0 CA-C-N 113.628 -1.624 . . . . 0.0 110.139 178.805 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 9.9 m-20 -137.22 126.52 24.79 Favored 'General case' 0 N--CA 1.479 1.019 0 C-N-CA 123.472 0.709 . . . . 0.0 109.942 -179.068 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' D' D ' 24' ' ' VAL . . . . . 0.943 HG12 ' H ' ' D' ' 25' ' ' GLY . 92.3 t -81.13 -165.64 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.482 1.169 0 N-CA-C 107.566 -1.272 . . . . 0.0 107.566 -178.098 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' D' D ' 25' ' ' GLY . . . . . 0.943 ' H ' HG12 ' D' ' 24' ' ' VAL . . . -79.27 56.62 4.4 Favored Glycine 0 C--N 1.362 1.997 0 C-N-CA 117.855 -2.117 . . . . 0.0 110.628 -174.263 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 21.8 p -61.34 132.83 54.82 Favored 'General case' 0 C--N 1.346 0.426 0 CA-C-N 113.545 -1.328 . . . . 0.0 111.965 170.648 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' D' D ' 27' ' ' ASN . . . . . 0.447 HD21 ' CG ' ' E' ' 11' ' ' GLU . 40.6 t30 -65.53 95.06 0.2 Allowed 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 119.908 1.231 . . . . 0.0 108.751 172.971 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 68.3 mttm -93.89 120.97 34.87 Favored 'General case' 0 N--CA 1.484 1.26 0 C-N-CA 119.521 -0.871 . . . . 0.0 108.908 179.756 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -57.45 -135.01 0.01 OUTLIER Glycine 0 C--N 1.341 0.806 0 CA-C-N 115.858 -0.61 . . . . 0.0 113.067 175.974 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -114.22 131.76 56.36 Favored 'General case' 0 C--N 1.367 1.357 0 N-CA-C 109.101 -0.703 . . . . 0.0 109.101 174.572 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 68.6 mt -91.79 138.43 19.82 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.298 0 N-CA-C 107.182 -1.414 . . . . 0.0 107.182 176.845 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 35.2 mt -138.7 140.85 38.4 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.879 0 N-CA-C 108.639 -0.875 . . . . 0.0 108.639 178.518 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.54 55.04 27.62 Favored Glycine 0 CA--C 1.529 0.911 0 CA-C-O 119.381 -0.677 . . . . 0.0 112.588 178.313 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 19.2 tp -102.84 141.59 35.39 Favored 'General case' 0 C--N 1.364 1.207 0 N-CA-C 106.333 -1.728 . . . . 0.0 106.333 176.536 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 23.9 ttt -142.07 156.95 45.42 Favored 'General case' 0 N--CA 1.472 0.664 0 N-CA-C 105.952 -1.87 . . . . 0.0 105.952 175.085 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 73.7 t -164.34 161.89 0.93 Allowed 'Isoleucine or valine' 0 CA--C 1.503 -0.835 0 N-CA-C 105.349 -2.093 . . . . 0.0 105.349 179.19 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' D' D ' 37' ' ' GLY . . . . . 0.457 ' O ' ' NE2' ' G' ' 15' ' ' GLN . . . 60.21 64.44 4.15 Favored Glycine 0 N--CA 1.441 -1.004 0 C-N-CA 118.38 -1.867 . . . . 0.0 112.453 176.301 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' D' D ' 38' ' ' GLY . . . . . 0.655 ' H ' HE22 ' D' ' 15' ' ' GLN . . . 166.46 -163.86 37.23 Favored Glycine 0 C--O 1.215 -1.051 0 CA-C-N 119.308 1.554 . . . . 0.0 112.264 176.493 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 29.4 m -121.64 147.45 25.61 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.067 0 CA-C-O 118.041 -0.981 . . . . 0.0 112.259 179.35 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 7.5 t . . . . . 0 C--O 1.213 -0.864 0 N-CA-C 108.798 -0.815 . . . . 0.0 108.798 171.652 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' E' E ' 1' ' ' ASP . . . . . . . . . . . . . 9.5 m-20 . . . . . 0 N--CA 1.491 1.585 0 N-CA-C 108.965 -0.754 . . . . 0.0 108.965 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' E' E ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.65 132.01 48.53 Favored 'General case' 0 N--CA 1.467 0.407 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.21 179.693 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' E' E ' 3' ' ' GLU . . . . . . . . . . . . . 38.8 tt0 -139.08 103.12 4.69 Favored 'General case' 0 N--CA 1.48 1.059 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 -179.794 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 24.8 m-85 -70.29 169.23 14.21 Favored 'General case' 0 N--CA 1.471 0.579 0 N-CA-C 109.445 -0.576 . . . . 0.0 109.445 179.354 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' E' E ' 5' ' ' ARG . . . . . 0.756 HH12 HG13 ' A' ' 24' ' ' VAL . 34.9 mtp180 -68.13 148.15 51.31 Favored 'General case' 0 C--O 1.202 -1.419 0 CA-C-N 115.567 -0.742 . . . . 0.0 111.313 -178.012 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 39.2 m80 -109.9 118.97 37.89 Favored 'General case' 0 N--CA 1.483 1.181 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 177.889 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' E' E ' 7' ' ' ASP . . . . . 0.442 ' OD1' HG11 ' G' ' 24' ' ' VAL . 13.0 m-20 -66.31 140.28 58.1 Favored 'General case' 0 N--CA 1.466 0.37 0 CA-C-O 120.91 0.386 . . . . 0.0 112.02 -178.442 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' E' E ' 8' ' ' SER . . . . . . . . . . . . . 38.2 t -158.7 -169.87 2.86 Favored 'General case' 0 N--CA 1.487 1.378 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.194 178.924 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 120.33 32.84 1.09 Allowed Glycine 0 N--CA 1.484 1.867 0 N-CA-C 111.717 -0.553 . . . . 0.0 111.717 179.538 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 43.3 p90 -56.84 130.54 46.19 Favored 'General case' 0 CA--C 1.546 0.796 0 CA-C-N 116.948 0.374 . . . . 0.0 111.64 -179.963 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' E' E ' 11' ' ' GLU . . . . . 0.447 ' CG ' HD21 ' D' ' 27' ' ' ASN . 60.2 mt-10 -89.98 153.49 20.55 Favored 'General case' 0 N--CA 1.478 0.945 0 N-CA-C 109.404 -0.591 . . . . 0.0 109.404 178.606 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.8 p -155.15 124.78 0.74 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.575 0 N-CA-C 108.183 -1.043 . . . . 0.0 108.183 177.872 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 43.9 m-70 -136.04 160.95 37.07 Favored 'General case' 0 N--CA 1.481 1.113 0 CA-C-O 120.746 0.308 . . . . 0.0 111.115 -177.515 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 38.8 t60 -152.96 96.75 2.13 Favored 'General case' 0 N--CA 1.488 1.475 0 C-N-CA 122.687 0.395 . . . . 0.0 109.951 179.241 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' E' E ' 15' ' ' GLN . . . . . 0.648 HE22 ' H ' ' E' ' 38' ' ' GLY . 28.2 mt-30 -90.75 122.25 33.33 Favored 'General case' 0 C--N 1.329 -0.297 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 -179.064 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -113.78 103.5 11.27 Favored 'General case' 0 N--CA 1.474 0.726 0 N-CA-C 107.69 -1.226 . . . . 0.0 107.69 176.638 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 53.9 tp -132.19 149.1 52.47 Favored 'General case' 0 N--CA 1.486 1.343 0 C-N-CA 123.368 0.667 . . . . 0.0 109.269 -178.844 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 57.7 t -145.25 123.59 5.23 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.837 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 179.154 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 11.2 m-85 -71.4 156.35 39.58 Favored 'General case' 0 C--N 1.363 1.155 0 N-CA-C 106.911 -1.515 . . . . 0.0 106.911 176.937 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 17.8 t80 -172.13 -55.94 0.02 OUTLIER 'General case' 0 N--CA 1.481 1.084 0 CA-C-O 121.83 0.824 . . . . 0.0 110.238 179.733 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.99 88.26 0.0 OUTLIER 'General case' 0 C--N 1.319 -0.759 0 CA-C-N 114.107 -1.406 . . . . 0.0 112.87 -178.986 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 39.0 tt0 -63.26 159.72 17.24 Favored 'General case' 0 N--CA 1.471 0.625 0 CA-C-N 114.855 -1.066 . . . . 0.0 110.842 179.831 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 9.6 m-20 -136.56 125.52 24.29 Favored 'General case' 0 N--CA 1.482 1.162 0 C-N-CA 123.3 0.64 . . . . 0.0 110.23 -179.67 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' E' E ' 24' ' ' VAL . . . . . 0.873 HG12 ' H ' ' E' ' 25' ' ' GLY . 58.5 t -76.08 -170.35 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.484 1.252 0 N-CA-C 108.029 -1.1 . . . . 0.0 108.029 179.436 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' E' E ' 25' ' ' GLY . . . . . 0.873 ' H ' HG12 ' E' ' 24' ' ' VAL . . . -68.89 49.65 0.5 Allowed Glycine 0 CA--C 1.531 1.031 0 CA-C-N 118.079 0.4 . . . . 0.0 112.626 -178.132 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 8.1 p -69.16 136.79 52.65 Favored 'General case' 0 C--O 1.219 -0.514 0 N-CA-C 109.705 -0.48 . . . . 0.0 109.705 178.494 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' E' E ' 27' ' ' ASN . . . . . 0.445 HD21 ' CG ' ' F' ' 11' ' ' GLU . 36.2 t30 -68.3 95.5 0.6 Allowed 'General case' 0 N--CA 1.466 0.328 0 N-CA-C 107.481 -1.303 . . . . 0.0 107.481 177.388 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 68.1 mttm -93.33 117.09 29.66 Favored 'General case' 0 N--CA 1.482 1.136 0 N-CA-C 109.612 -0.514 . . . . 0.0 109.612 -178.858 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.16 -133.98 0.01 OUTLIER Glycine 0 CA--C 1.536 1.392 0 N-CA-C 111.308 -0.717 . . . . 0.0 111.308 178.877 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -115.66 126.42 54.13 Favored 'General case' 0 N--CA 1.481 1.081 0 N-CA-C 109.637 -0.505 . . . . 0.0 109.637 179.225 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 66.8 mt -89.35 135.02 27.02 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.213 0 N-CA-C 107.571 -1.27 . . . . 0.0 107.571 178.914 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 33.1 mt -136.21 137.83 47.85 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.867 0 N-CA-C 108.991 -0.744 . . . . 0.0 108.991 -179.768 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.37 59.68 8.54 Favored Glycine 0 CA--C 1.527 0.82 0 CA-C-N 116.047 -0.524 . . . . 0.0 112.947 178.835 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 22.0 tp -107.49 131.81 53.91 Favored 'General case' 0 N--CA 1.487 1.41 0 N-CA-C 107.454 -1.313 . . . . 0.0 107.454 177.741 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 23.6 ttt -137.26 147.82 45.99 Favored 'General case' 0 N--CA 1.472 0.66 0 N-CA-C 107.815 -1.18 . . . . 0.0 107.815 178.709 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' E' E ' 36' ' ' VAL . . . . . 0.407 HG12 ' N ' ' E' ' 37' ' ' GLY . 59.8 t -156.7 159.94 2.47 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.693 0 N-CA-C 106.457 -1.683 . . . . 0.0 106.457 -178.899 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' E' E ' 37' ' ' GLY . . . . . 0.425 ' O ' ' NE2' ' H' ' 15' ' ' GLN . . . 54.12 73.4 0.41 Allowed Glycine 0 C--N 1.31 -0.904 0 N-CA-C 111.801 -0.52 . . . . 0.0 111.801 177.787 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' E' E ' 38' ' ' GLY . . . . . 0.648 ' H ' HE22 ' E' ' 15' ' ' GLN . . . 165.83 -166.63 38.71 Favored Glycine 0 C--O 1.21 -1.395 0 N-CA-C 111.278 -0.729 . . . . 0.0 111.278 179.256 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 21.6 m -128.34 148.88 32.8 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.827 0 C-N-CA 122.833 0.453 . . . . 0.0 109.91 179.913 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 7.5 t . . . . . 0 CA--C 1.541 0.598 0 CA-C-O 118.202 -0.904 . . . . 0.0 110.473 178.85 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' F' F ' 1' ' ' ASP . . . . . . . . . . . . . 9.6 m-20 . . . . . 0 N--CA 1.492 1.633 0 N-CA-C 108.88 -0.785 . . . . 0.0 108.88 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' F' F ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.71 132.11 48.75 Favored 'General case' 0 N--CA 1.468 0.449 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.191 179.692 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' F' F ' 3' ' ' GLU . . . . . . . . . . . . . 38.7 tt0 -139.16 103.08 4.67 Favored 'General case' 0 N--CA 1.482 1.157 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 -179.833 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 25.7 m-85 -70.2 169.52 13.48 Favored 'General case' 0 N--CA 1.472 0.645 0 N-CA-C 109.572 -0.529 . . . . 0.0 109.572 179.393 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' F' F ' 5' ' ' ARG . . . . . 0.756 HH12 HG13 ' B' ' 24' ' ' VAL . 35.5 mtp180 -68.08 147.4 52.4 Favored 'General case' 0 C--O 1.201 -1.476 0 CA-C-N 115.499 -0.773 . . . . 0.0 111.468 -178.017 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 39.2 m80 -109.47 118.89 37.82 Favored 'General case' 0 N--CA 1.484 1.266 0 N-CA-C 109.094 -0.706 . . . . 0.0 109.094 177.815 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' F' F ' 7' ' ' ASP . . . . . 0.474 ' OD1' HG11 ' H' ' 24' ' ' VAL . 13.0 m-20 -66.32 140.27 58.09 Favored 'General case' 0 N--CA 1.466 0.341 0 N-CA-C 112.159 0.429 . . . . 0.0 112.159 -178.453 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' F' F ' 8' ' ' SER . . . . . . . . . . . . . 38.3 t -158.73 -169.81 2.84 Favored 'General case' 0 N--CA 1.486 1.365 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.18 178.9 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 120.33 32.84 1.09 Allowed Glycine 0 N--CA 1.483 1.808 0 N-CA-C 111.679 -0.568 . . . . 0.0 111.679 179.559 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 43.3 p90 -57.02 130.73 47.35 Favored 'General case' 0 CA--C 1.545 0.763 0 CA-C-N 116.945 0.372 . . . . 0.0 111.614 -179.952 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' F' F ' 11' ' ' GLU . . . . . 0.445 ' CG ' HD21 ' E' ' 27' ' ' ASN . 60.3 mt-10 -90.04 153.53 20.5 Favored 'General case' 0 N--CA 1.478 0.959 0 CA-C-O 121.306 0.574 . . . . 0.0 109.457 178.513 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.8 p -155.22 124.78 0.74 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.532 0 N-CA-C 108.071 -1.085 . . . . 0.0 108.071 177.942 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 44.4 m-70 -136.03 160.83 37.42 Favored 'General case' 0 N--CA 1.48 1.062 0 CA-C-O 120.668 0.271 . . . . 0.0 111.142 -177.645 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 39.0 t60 -152.93 97.13 2.17 Favored 'General case' 0 N--CA 1.487 1.406 0 C-N-CA 122.75 0.42 . . . . 0.0 110.06 179.278 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' F' F ' 15' ' ' GLN . . . . . 0.621 HE22 ' H ' ' F' ' 38' ' ' GLY . 28.2 mt-30 -91.21 122.87 34.21 Favored 'General case' 0 CA--C 1.513 -0.474 0 N-CA-C 110.174 -0.306 . . . . 0.0 110.174 -179.141 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -114.23 103.48 11.14 Favored 'General case' 0 N--CA 1.471 0.608 0 N-CA-C 107.808 -1.182 . . . . 0.0 107.808 176.694 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 54.2 tp -132.17 149.13 52.46 Favored 'General case' 0 N--CA 1.486 1.355 0 C-N-CA 123.388 0.675 . . . . 0.0 109.307 -179.041 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 58.7 t -145.24 123.69 5.32 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.805 0 N-CA-C 109.37 -0.604 . . . . 0.0 109.37 179.205 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 11.2 m-85 -71.5 156.14 39.77 Favored 'General case' 0 C--N 1.363 1.195 0 N-CA-C 106.795 -1.557 . . . . 0.0 106.795 176.92 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 18.5 t80 -171.87 -55.96 0.02 OUTLIER 'General case' 0 N--CA 1.481 1.105 0 CA-C-O 121.784 0.802 . . . . 0.0 109.873 179.799 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.02 88.24 0.0 OUTLIER 'General case' 0 C--N 1.319 -0.725 0 CA-C-N 114.235 -1.348 . . . . 0.0 112.968 -178.968 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 38.9 tt0 -63.22 159.91 16.74 Favored 'General case' 0 N--CA 1.472 0.638 0 CA-C-N 114.857 -1.065 . . . . 0.0 110.856 179.756 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 9.7 m-20 -136.82 125.77 24.27 Favored 'General case' 0 N--CA 1.481 1.122 0 C-N-CA 123.271 0.628 . . . . 0.0 110.252 -179.735 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' F' F ' 24' ' ' VAL . . . . . 0.848 HG12 ' H ' ' F' ' 25' ' ' GLY . 59.1 t -76.28 -170.1 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.484 1.267 0 N-CA-C 108.168 -1.049 . . . . 0.0 108.168 179.485 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' F' F ' 25' ' ' GLY . . . . . 0.848 ' H ' HG12 ' F' ' 24' ' ' VAL . . . -68.85 49.4 0.49 Allowed Glycine 0 CA--C 1.528 0.847 0 CA-C-N 118.264 0.484 . . . . 0.0 112.491 -178.305 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 8.1 p -68.96 136.66 52.85 Favored 'General case' 0 C--O 1.219 -0.535 0 N-CA-C 109.536 -0.542 . . . . 0.0 109.536 178.378 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' F' F ' 27' ' ' ASN . . . . . 0.435 HD21 ' CG ' ' D' ' 11' ' ' GLU . 35.4 t30 -68.38 95.73 0.63 Allowed 'General case' 0 CA--C 1.535 0.371 0 N-CA-C 107.35 -1.352 . . . . 0.0 107.35 177.464 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 68.1 mttm -93.41 116.96 29.5 Favored 'General case' 0 N--CA 1.48 1.073 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 -178.931 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.13 -134.15 0.01 OUTLIER Glycine 0 CA--C 1.537 1.444 0 N-CA-C 111.383 -0.687 . . . . 0.0 111.383 178.997 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -115.19 125.99 54.05 Favored 'General case' 0 N--CA 1.485 1.277 0 C-N-CA 123.064 0.546 . . . . 0.0 109.615 179.212 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 66.9 mt -89.3 134.88 27.37 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.236 0 N-CA-C 107.457 -1.312 . . . . 0.0 107.457 178.816 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 32.9 mt -136.25 137.87 47.73 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.805 0 N-CA-C 108.984 -0.747 . . . . 0.0 108.984 -179.723 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.24 59.81 8.44 Favored Glycine 0 CA--C 1.525 0.663 0 CA-C-N 116.01 -0.541 . . . . 0.0 112.884 178.878 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 21.8 tp -107.78 132.04 53.81 Favored 'General case' 0 N--CA 1.487 1.376 0 N-CA-C 107.585 -1.265 . . . . 0.0 107.585 177.668 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 23.4 ttt -137.53 147.99 45.61 Favored 'General case' 0 N--CA 1.468 0.434 0 N-CA-C 108.324 -0.991 . . . . 0.0 108.324 178.733 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' F' F ' 36' ' ' VAL . . . . . 0.401 HG12 ' N ' ' F' ' 37' ' ' GLY . 60.8 t -156.63 160.03 2.44 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.772 0 N-CA-C 106.579 -1.637 . . . . 0.0 106.579 -178.741 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' F' F ' 37' ' ' GLY . . . . . 0.42 ' O ' ' NE2' ' I' ' 15' ' ' GLN . . . 54.05 73.37 0.42 Allowed Glycine 0 C--N 1.309 -0.964 0 CA-C-N 116.075 -0.512 . . . . 0.0 111.937 177.709 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' F' F ' 38' ' ' GLY . . . . . 0.621 ' H ' HE22 ' F' ' 15' ' ' GLN . . . 165.83 -166.58 38.68 Favored Glycine 0 C--O 1.209 -1.459 0 N-CA-C 111.264 -0.735 . . . . 0.0 111.264 179.315 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 21.1 m -128.46 148.76 32.9 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.811 0 C-N-CA 122.729 0.412 . . . . 0.0 109.906 179.935 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 6.8 t . . . . . 0 CA--C 1.54 0.565 0 CA-C-O 118.207 -0.901 . . . . 0.0 110.423 178.911 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' G' G ' 1' ' ' ASP . . . . . . . . . . . . . 9.3 m-20 . . . . . 0 N--CA 1.487 1.404 0 N-CA-C 108.763 -0.829 . . . . 0.0 108.763 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' G' G ' 2' ' ' ALA . . . . . . . . . . . . . . . -66.63 133.82 51.06 Favored 'General case' 0 CA--C 1.538 0.486 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 -179.776 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' G' G ' 3' ' ' GLU . . . . . . . . . . . . . 38.9 tt0 -139.01 104.93 5.16 Favored 'General case' 0 N--CA 1.477 0.911 0 C-N-CA 123.097 0.559 . . . . 0.0 109.815 -178.969 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 35.4 m-85 -71.12 169.15 15.65 Favored 'General case' 0 N--CA 1.469 0.499 0 CA-C-O 121.173 0.511 . . . . 0.0 109.833 179.367 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' G' G ' 5' ' ' ARG . . . . . 0.736 HH12 HG13 ' F' ' 24' ' ' VAL . 33.8 mtp180 -68.69 144.92 54.28 Favored 'General case' 0 N--CA 1.469 0.524 0 CA-C-N 115.415 -0.811 . . . . 0.0 111.146 -178.325 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 38.6 m80 -107.98 118.78 37.64 Favored 'General case' 0 N--CA 1.478 0.961 0 N-CA-C 109.226 -0.657 . . . . 0.0 109.226 178.095 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 10.5 m-20 -66.84 139.47 57.77 Favored 'General case' 0 N--CA 1.469 0.49 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.948 -179.061 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' G' G ' 8' ' ' SER . . . . . . . . . . . . . 37.8 t -158.09 -170.23 3.07 Favored 'General case' 0 N--CA 1.471 0.603 0 N-CA-C 109.666 -0.494 . . . . 0.0 109.666 179.024 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 120.37 31.97 1.2 Allowed Glycine 0 N--CA 1.484 1.869 0 N-CA-C 111.539 -0.624 . . . . 0.0 111.539 179.497 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 47.1 p90 -57.11 130.71 47.32 Favored 'General case' 0 N--CA 1.472 0.629 0 CA-C-N 116.825 0.313 . . . . 0.0 111.716 -179.822 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 60.4 mt-10 -90.34 152.58 20.96 Favored 'General case' 0 N--CA 1.474 0.758 0 CA-C-O 121.138 0.494 . . . . 0.0 109.807 179.082 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 3.5 p -155.47 124.83 0.72 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.058 0 N-CA-C 108.175 -1.046 . . . . 0.0 108.175 178.19 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 43.6 m-70 -135.86 160.73 37.68 Favored 'General case' 0 N--CA 1.475 0.781 0 CA-C-N 114.722 -1.126 . . . . 0.0 110.973 -177.619 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 39.6 t60 -153.39 96.93 2.09 Favored 'General case' 0 N--CA 1.484 1.231 0 CA-C-N 115.858 -0.61 . . . . 0.0 109.659 178.855 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' G' G ' 15' ' ' GLN . . . . . 0.681 HE22 ' H ' ' G' ' 38' ' ' GLY . 28.5 mt-30 -90.75 121.52 32.71 Favored 'General case' 0 N--CA 1.451 -0.406 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 -178.896 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -113.03 103.77 11.71 Favored 'General case' 0 N--CA 1.476 0.831 0 N-CA-C 107.694 -1.224 . . . . 0.0 107.694 176.65 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 56.6 tp -132.17 147.33 52.42 Favored 'General case' 0 N--CA 1.486 1.343 0 C-N-CA 123.336 0.654 . . . . 0.0 109.56 -179.288 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 61.3 t -144.99 123.3 5.31 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.861 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 178.664 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 9.6 m-85 -70.39 150.37 46.33 Favored 'General case' 0 C--N 1.376 1.728 0 N-CA-C 106.91 -1.515 . . . . 0.0 106.91 176.699 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 15.6 t80 -169.94 -55.4 0.02 OUTLIER 'General case' 0 N--CA 1.483 1.22 0 N-CA-C 110.248 -0.278 . . . . 0.0 110.248 -179.729 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.0 90.02 0.0 OUTLIER 'General case' 0 C--N 1.323 -0.545 0 C-N-CA 123.72 0.808 . . . . 0.0 112.471 -179.964 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 39.3 tt0 -64.4 160.76 18.36 Favored 'General case' 0 N--CA 1.468 0.467 0 CA-C-N 114.834 -1.076 . . . . 0.0 110.023 179.273 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 9.6 m-20 -137.26 125.38 22.99 Favored 'General case' 0 N--CA 1.48 1.072 0 C-N-CA 123.154 0.582 . . . . 0.0 109.721 -179.701 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' G' G ' 24' ' ' VAL . . . . . 0.857 HG12 ' H ' ' G' ' 25' ' ' GLY . 61.9 t -76.75 -169.97 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.827 0 N-CA-C 108.156 -1.053 . . . . 0.0 108.156 179.608 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' G' G ' 25' ' ' GLY . . . . . 0.857 ' H ' HG12 ' G' ' 24' ' ' VAL . . . -68.89 49.98 0.5 Allowed Glycine 0 CA--C 1.53 0.973 0 CA-C-N 118.48 0.582 . . . . 0.0 112.726 -178.467 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 8.4 p -69.51 137.63 52.67 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 109.157 -0.682 . . . . 0.0 109.157 177.748 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 34.2 t30 -69.49 94.72 0.77 Allowed 'General case' 0 CA--C 1.532 0.265 0 N-CA-C 107.618 -1.253 . . . . 0.0 107.618 177.562 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -91.63 117.81 30.07 Favored 'General case' 0 N--CA 1.478 0.953 0 N-CA-C 109.713 -0.477 . . . . 0.0 109.713 -179.396 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -62.37 -133.3 0.01 OUTLIER Glycine 0 CA--C 1.532 1.099 0 N-CA-C 110.547 -1.021 . . . . 0.0 110.547 178.927 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -115.19 126.83 55.05 Favored 'General case' 0 N--CA 1.475 0.808 0 N-CA-C 109.615 -0.513 . . . . 0.0 109.615 179.186 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 69.6 mt -89.64 136.14 24.41 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.671 0 N-CA-C 107.598 -1.26 . . . . 0.0 107.598 178.743 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 38.2 mt -137.46 139.18 43.98 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.249 0 CA-C-N 118.782 0.719 . . . . 0.0 109.158 179.721 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.1 57.98 13.56 Favored Glycine 0 CA--C 1.53 0.977 0 CA-C-N 116.11 -0.496 . . . . 0.0 112.624 178.99 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 23.1 tp -105.81 132.23 52.18 Favored 'General case' 0 N--CA 1.484 1.256 0 N-CA-C 107.6 -1.259 . . . . 0.0 107.6 177.775 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 22.1 ttt -137.63 147.97 45.4 Favored 'General case' 0 N--CA 1.474 0.727 0 N-CA-C 108.211 -1.033 . . . . 0.0 108.211 178.788 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 61.2 t -156.77 158.4 3.24 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 106.613 -1.625 . . . . 0.0 106.613 -179.095 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.57 71.74 0.68 Allowed Glycine 0 C--N 1.308 -0.973 0 CA-C-N 115.951 -0.568 . . . . 0.0 112.384 177.549 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' G' G ' 38' ' ' GLY . . . . . 0.681 ' H ' HE22 ' G' ' 15' ' ' GLN . . . 167.75 -165.22 38.55 Favored Glycine 0 C--O 1.212 -1.268 0 N-CA-C 110.747 -0.941 . . . . 0.0 110.747 178.631 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 18.7 m -128.64 148.14 33.07 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.93 0 C-N-CA 122.789 0.435 . . . . 0.0 109.93 179.911 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 8.6 t . . . . . 0 CA--C 1.534 0.337 0 CA-C-O 118.156 -0.926 . . . . 0.0 110.888 178.815 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' H' H ' 1' ' ' ASP . . . . . . . . . . . . . 9.3 m-20 . . . . . 0 N--CA 1.488 1.43 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' H' H ' 2' ' ' ALA . . . . . . . . . . . . . . . -66.49 133.78 51.09 Favored 'General case' 0 CA--C 1.537 0.453 0 N-CA-C 109.886 -0.413 . . . . 0.0 109.886 -179.813 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' H' H ' 3' ' ' GLU . . . . . . . . . . . . . 38.9 tt0 -138.89 104.71 5.13 Favored 'General case' 0 N--CA 1.478 0.968 0 C-N-CA 123.064 0.546 . . . . 0.0 109.807 -178.855 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 35.0 m-85 -70.95 169.31 15.12 Favored 'General case' 0 N--CA 1.47 0.557 0 CA-C-O 121.234 0.54 . . . . 0.0 109.756 179.448 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' H' H ' 5' ' ' ARG . . . . . 0.757 HH12 HG13 ' D' ' 24' ' ' VAL . 33.8 mtp180 -69.04 145.12 53.78 Favored 'General case' 0 N--CA 1.466 0.373 0 CA-C-N 115.387 -0.824 . . . . 0.0 111.229 -178.312 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 38.5 m80 -108.05 118.77 37.63 Favored 'General case' 0 N--CA 1.478 0.958 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 178.265 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 10.5 m-20 -66.91 139.58 57.73 Favored 'General case' 0 N--CA 1.468 0.441 0 CA-C-N 116.275 -0.421 . . . . 0.0 111.889 -179.066 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' H' H ' 8' ' ' SER . . . . . . . . . . . . . 37.9 t -158.12 -170.08 3.01 Favored 'General case' 0 N--CA 1.471 0.595 0 N-CA-C 109.73 -0.47 . . . . 0.0 109.73 178.985 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 120.11 32.09 1.21 Allowed Glycine 0 N--CA 1.483 1.829 0 N-CA-C 111.641 -0.583 . . . . 0.0 111.641 179.549 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 46.9 p90 -57.17 130.79 47.72 Favored 'General case' 0 CA--C 1.542 0.64 0 CA-C-N 116.715 0.258 . . . . 0.0 111.607 -179.777 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 60.5 mt-10 -90.3 152.54 20.99 Favored 'General case' 0 N--CA 1.474 0.771 0 CA-C-O 121.116 0.484 . . . . 0.0 109.859 179.023 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 3.4 p -155.53 124.95 0.72 Allowed 'Isoleucine or valine' 0 CA--C 1.553 1.089 0 N-CA-C 108.161 -1.051 . . . . 0.0 108.161 178.074 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 43.6 m-70 -135.93 160.78 37.55 Favored 'General case' 0 C--N 1.353 0.751 0 CA-C-N 114.627 -1.169 . . . . 0.0 111.072 -177.527 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 39.3 t60 -153.51 96.86 2.07 Favored 'General case' 0 N--CA 1.484 1.268 0 CA-C-N 115.868 -0.606 . . . . 0.0 109.773 178.911 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' H' H ' 15' ' ' GLN . . . . . 0.676 HE22 ' H ' ' H' ' 38' ' ' GLY . 28.3 mt-30 -90.71 121.37 32.55 Favored 'General case' 0 CA--C 1.514 -0.406 0 N-CA-C 109.711 -0.477 . . . . 0.0 109.711 -178.946 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -112.84 103.66 11.65 Favored 'General case' 0 N--CA 1.474 0.726 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 176.672 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 56.3 tp -132.14 147.37 52.42 Favored 'General case' 0 N--CA 1.486 1.374 0 C-N-CA 123.273 0.629 . . . . 0.0 109.488 -179.196 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 61.4 t -144.93 123.21 5.36 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.89 0 N-CA-C 109.368 -0.604 . . . . 0.0 109.368 178.667 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 9.5 m-85 -70.67 150.96 45.45 Favored 'General case' 0 C--N 1.376 1.741 0 N-CA-C 106.951 -1.5 . . . . 0.0 106.951 176.658 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 16.6 t80 -171.19 -55.13 0.02 OUTLIER 'General case' 0 N--CA 1.48 1.061 0 N-CA-C 110.216 -0.291 . . . . 0.0 110.216 -179.696 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.05 89.92 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.472 0 O-C-N 123.971 0.795 . . . . 0.0 112.269 -179.96 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 39.4 tt0 -64.12 160.76 17.56 Favored 'General case' 0 N--CA 1.469 0.487 0 CA-C-N 114.777 -1.102 . . . . 0.0 110.063 179.482 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 9.7 m-20 -137.11 125.43 23.27 Favored 'General case' 0 N--CA 1.481 1.077 0 C-N-CA 123.098 0.559 . . . . 0.0 109.869 -179.791 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' H' H ' 24' ' ' VAL . . . . . 0.836 HG12 ' H ' ' H' ' 25' ' ' GLY . 57.4 t -76.69 -170.0 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.475 0.806 0 N-CA-C 108.408 -0.96 . . . . 0.0 108.408 179.612 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' H' H ' 25' ' ' GLY . . . . . 0.836 ' H ' HG12 ' H' ' 24' ' ' VAL . . . -68.64 49.56 0.46 Allowed Glycine 0 CA--C 1.53 1.009 0 CA-C-N 118.627 0.649 . . . . 0.0 112.43 -178.468 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 8.5 p -69.56 137.47 52.44 Favored 'General case' 0 C--N 1.33 -0.266 0 N-CA-C 109.152 -0.684 . . . . 0.0 109.152 177.823 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 34.7 t30 -69.57 94.82 0.8 Allowed 'General case' 0 N--CA 1.464 0.258 0 N-CA-C 107.638 -1.245 . . . . 0.0 107.638 177.635 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -91.76 117.88 30.17 Favored 'General case' 0 N--CA 1.477 0.91 0 N-CA-C 109.708 -0.479 . . . . 0.0 109.708 -179.408 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -62.48 -133.15 0.01 OUTLIER Glycine 0 CA--C 1.532 1.107 0 N-CA-C 110.582 -1.007 . . . . 0.0 110.582 178.977 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -115.25 126.89 55.07 Favored 'General case' 0 N--CA 1.474 0.745 0 C-N-CA 122.984 0.514 . . . . 0.0 109.634 179.192 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 69.6 mt -89.67 136.03 24.68 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.621 0 N-CA-C 107.535 -1.283 . . . . 0.0 107.535 178.707 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 37.7 mt -137.4 139.24 44.01 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.263 0 N-CA-C 109.142 -0.688 . . . . 0.0 109.142 179.611 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.23 58.1 12.92 Favored Glycine 0 CA--C 1.529 0.964 0 CA-C-N 116.067 -0.515 . . . . 0.0 112.593 178.967 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 23.5 tp -105.85 131.81 52.73 Favored 'General case' 0 N--CA 1.484 1.256 0 N-CA-C 107.688 -1.227 . . . . 0.0 107.688 177.893 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 22.0 ttt -137.16 147.36 45.89 Favored 'General case' 0 N--CA 1.475 0.808 0 N-CA-C 108.135 -1.061 . . . . 0.0 108.135 178.924 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 61.7 t -156.5 158.14 3.45 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.487 0 N-CA-C 106.634 -1.617 . . . . 0.0 106.634 -179.109 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.68 71.53 0.71 Allowed Glycine 0 C--N 1.308 -0.992 0 CA-C-N 115.901 -0.59 . . . . 0.0 112.352 177.526 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' H' H ' 38' ' ' GLY . . . . . 0.676 ' H ' HE22 ' H' ' 15' ' ' GLN . . . 167.75 -165.75 38.91 Favored Glycine 0 C--O 1.212 -1.277 0 N-CA-C 110.6 -1.0 . . . . 0.0 110.6 178.693 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 18.9 m -128.2 148.45 32.72 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.023 0 C-N-CA 122.777 0.431 . . . . 0.0 109.926 179.966 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 8.6 t . . . . . 0 CA--C 1.535 0.369 0 CA-C-O 118.196 -0.907 . . . . 0.0 110.811 178.764 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' I' I ' 1' ' ' ASP . . . . . . . . . . . . . 9.3 m-20 . . . . . 0 N--CA 1.487 1.414 0 N-CA-C 108.828 -0.804 . . . . 0.0 108.828 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' I' I ' 2' ' ' ALA . . . . . . . . . . . . . . . -66.56 133.91 51.29 Favored 'General case' 0 CA--C 1.538 0.499 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 -179.836 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' I' I ' 3' ' ' GLU . . . . . . . . . . . . . 38.9 tt0 -139.0 104.83 5.14 Favored 'General case' 0 N--CA 1.478 0.975 0 C-N-CA 123.062 0.545 . . . . 0.0 109.846 -178.909 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 34.6 m-85 -71.1 169.2 15.52 Favored 'General case' 0 N--CA 1.47 0.537 0 CA-C-O 121.136 0.493 . . . . 0.0 109.827 179.465 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' I' I ' 5' ' ' ARG . . . . . 0.747 HH12 HG13 ' E' ' 24' ' ' VAL . 32.8 mtp180 -68.94 144.87 54.04 Favored 'General case' 0 N--CA 1.468 0.475 0 CA-C-N 115.473 -0.785 . . . . 0.0 111.206 -178.343 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 38.6 m80 -107.88 118.59 37.13 Favored 'General case' 0 N--CA 1.477 0.925 0 N-CA-C 109.195 -0.669 . . . . 0.0 109.195 178.314 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 10.5 m-20 -66.77 139.61 57.81 Favored 'General case' 0 N--CA 1.469 0.485 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.916 -179.059 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' I' I ' 8' ' ' SER . . . . . . . . . . . . . 37.8 t -158.08 -170.15 3.05 Favored 'General case' 0 N--CA 1.47 0.557 0 N-CA-C 109.688 -0.486 . . . . 0.0 109.688 178.996 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 120.29 32.0 1.2 Allowed Glycine 0 N--CA 1.483 1.809 0 N-CA-C 111.584 -0.606 . . . . 0.0 111.584 179.413 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 47.1 p90 -57.12 130.75 47.52 Favored 'General case' 0 N--CA 1.473 0.705 0 O-C-N 122.671 -0.311 . . . . 0.0 111.665 -179.815 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 60.5 mt-10 -90.3 152.5 21.01 Favored 'General case' 0 N--CA 1.475 0.813 0 CA-C-O 121.152 0.501 . . . . 0.0 109.865 179.013 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 3.5 p -155.46 124.87 0.73 Allowed 'Isoleucine or valine' 0 CA--C 1.554 1.125 0 N-CA-C 108.194 -1.039 . . . . 0.0 108.194 178.103 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 44.1 m-70 -135.82 160.85 37.29 Favored 'General case' 0 C--N 1.354 0.761 0 CA-C-N 114.6 -1.182 . . . . 0.0 111.0 -177.556 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 39.6 t60 -153.6 97.05 2.08 Favored 'General case' 0 N--CA 1.484 1.262 0 CA-C-N 115.841 -0.618 . . . . 0.0 109.761 178.841 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' I' I ' 15' ' ' GLN . . . . . 0.658 HE22 ' H ' ' I' ' 38' ' ' GLY . 28.4 mt-30 -90.79 121.37 32.6 Favored 'General case' 0 CA--C 1.514 -0.416 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 -178.95 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -112.86 103.69 11.68 Favored 'General case' 0 N--CA 1.473 0.709 0 N-CA-C 107.677 -1.231 . . . . 0.0 107.677 176.6 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 56.5 tp -132.18 147.26 52.41 Favored 'General case' 0 N--CA 1.485 1.296 0 C-N-CA 123.329 0.652 . . . . 0.0 109.436 -179.153 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 61.7 t -144.88 123.12 5.4 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.9 0 N-CA-C 109.425 -0.583 . . . . 0.0 109.425 178.642 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 9.4 m-85 -70.66 150.89 45.53 Favored 'General case' 0 C--N 1.374 1.642 0 N-CA-C 106.853 -1.536 . . . . 0.0 106.853 176.701 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 16.7 t80 -171.14 -55.26 0.02 OUTLIER 'General case' 0 N--CA 1.48 1.073 0 N-CA-C 110.212 -0.292 . . . . 0.0 110.212 -179.561 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.07 90.01 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.45 0 O-C-N 123.998 0.811 . . . . 0.0 112.327 -179.986 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 39.4 tt0 -64.22 160.77 17.85 Favored 'General case' 0 N--CA 1.469 0.511 0 CA-C-N 114.743 -1.117 . . . . 0.0 110.011 179.557 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 9.6 m-20 -137.01 125.31 23.25 Favored 'General case' 0 N--CA 1.481 1.082 0 C-N-CA 123.259 0.624 . . . . 0.0 109.891 -179.771 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' I' I ' 24' ' ' VAL . . . . . 0.846 HG12 ' H ' ' I' ' 25' ' ' GLY . 57.3 t -76.58 -169.96 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.757 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 179.568 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' I' I ' 25' ' ' GLY . . . . . 0.846 ' H ' HG12 ' I' ' 24' ' ' VAL . . . -68.81 49.72 0.49 Allowed Glycine 0 CA--C 1.531 1.054 0 CA-C-N 118.541 0.61 . . . . 0.0 112.485 -178.457 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 8.5 p -69.63 137.67 52.42 Favored 'General case' 0 C--N 1.33 -0.254 0 N-CA-C 109.166 -0.679 . . . . 0.0 109.166 177.856 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 35.0 t30 -69.57 94.74 0.79 Allowed 'General case' 0 CA--C 1.531 0.234 0 N-CA-C 107.676 -1.231 . . . . 0.0 107.676 177.534 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -91.8 117.84 30.15 Favored 'General case' 0 N--CA 1.478 0.936 0 N-CA-C 109.722 -0.473 . . . . 0.0 109.722 -179.395 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -62.37 -133.19 0.01 OUTLIER Glycine 0 CA--C 1.532 1.14 0 N-CA-C 110.613 -0.995 . . . . 0.0 110.613 178.96 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -115.22 126.54 54.68 Favored 'General case' 0 N--CA 1.474 0.737 0 C-N-CA 123.031 0.532 . . . . 0.0 109.697 179.246 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 69.5 mt -89.46 135.94 24.81 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.657 0 N-CA-C 107.552 -1.277 . . . . 0.0 107.552 178.784 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 37.7 mt -137.44 139.21 43.98 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.28 0 N-CA-C 109.004 -0.739 . . . . 0.0 109.004 179.739 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.24 57.99 13.3 Favored Glycine 0 CA--C 1.529 0.959 0 CA-C-N 115.978 -0.555 . . . . 0.0 112.562 178.908 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 23.1 tp -105.71 131.95 52.44 Favored 'General case' 0 N--CA 1.485 1.298 0 N-CA-C 107.531 -1.285 . . . . 0.0 107.531 177.839 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 22.1 ttt -137.3 147.53 45.72 Favored 'General case' 0 N--CA 1.475 0.783 0 N-CA-C 107.997 -1.112 . . . . 0.0 107.997 178.877 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 61.3 t -156.66 158.2 3.38 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.466 0 N-CA-C 106.623 -1.621 . . . . 0.0 106.623 -179.094 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.63 71.57 0.7 Allowed Glycine 0 C--N 1.308 -1.011 0 CA-C-N 115.953 -0.567 . . . . 0.0 112.376 177.556 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' I' I ' 38' ' ' GLY . . . . . 0.658 ' H ' HE22 ' I' ' 15' ' ' GLN . . . 167.72 -165.68 38.85 Favored Glycine 0 C--O 1.211 -1.337 0 N-CA-C 110.603 -0.999 . . . . 0.0 110.603 178.697 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 18.9 m -128.26 148.4 32.77 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.003 0 C-N-CA 122.831 0.452 . . . . 0.0 109.949 179.965 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 8.9 t . . . . . 0 CA--C 1.535 0.387 0 CA-C-O 118.104 -0.95 . . . . 0.0 110.738 178.824 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 . . . . . 0 N--CA 1.49 1.537 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.55 132.44 48.89 Favored 'General case' 0 CA--C 1.54 0.58 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.215 -179.893 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 55.0 tt0 -169.45 108.16 0.42 Allowed 'General case' 0 N--CA 1.47 0.528 0 N-CA-C 109.621 -0.511 . . . . 0.0 109.621 -179.164 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 76.6 m-85 -83.51 141.22 31.8 Favored 'General case' 0 N--CA 1.474 0.74 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 179.516 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 72.4 mtp180 -144.29 141.82 30.04 Favored 'General case' 0 N--CA 1.483 1.207 0 N-CA-C 109.035 -0.728 . . . . 0.0 109.035 179.866 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 77.2 m80 -149.72 118.51 6.62 Favored 'General case' 0 N--CA 1.472 0.655 0 N-CA-C 108.763 -0.828 . . . . 0.0 108.763 179.037 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 12.2 m-20 -66.83 149.5 50.49 Favored 'General case' 0 CA--C 1.531 0.242 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.193 -179.395 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 7.9 t -167.53 170.08 11.52 Favored 'General case' 0 N--CA 1.473 0.682 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 178.613 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 123.47 24.44 1.95 Allowed Glycine 0 N--CA 1.487 2.051 0 N-CA-C 112.089 -0.405 . . . . 0.0 112.089 179.466 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 41.0 p90 -56.59 128.26 35.4 Favored 'General case' 0 N--CA 1.473 0.714 0 N-CA-C 112.136 0.421 . . . . 0.0 112.136 -179.868 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 46.1 mt-10 -84.61 154.49 22.54 Favored 'General case' 0 N--CA 1.468 0.465 0 N-CA-C 108.847 -0.797 . . . . 0.0 108.847 178.256 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -154.03 129.18 1.54 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 N-CA-C 108.091 -1.077 . . . . 0.0 108.091 178.855 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 51.5 m-70 -134.5 144.77 48.24 Favored 'General case' 0 N--CA 1.487 1.409 0 CA-C-N 118.567 0.621 . . . . 0.0 110.729 -178.951 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 6.2 t60 -164.5 98.38 0.8 Allowed 'General case' 0 N--CA 1.482 1.172 0 CA-C-N 116.744 -0.207 . . . . 0.0 111.204 179.581 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . 0.642 ' NE2' ' H ' ' A' ' 37' ' ' GLY . 75.8 mt-30 -103.03 -172.65 2.15 Favored 'General case' 0 CA--C 1.506 -0.745 0 N-CA-C 108.191 -1.04 . . . . 0.0 108.191 179.338 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -167.25 98.17 0.51 Allowed 'General case' 0 N--CA 1.47 0.531 0 CA-C-N 115.084 -0.962 . . . . 0.0 109.366 178.766 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.564 HD12 ' N ' ' A' ' 17' ' ' LEU . 4.9 mp -106.69 162.44 13.76 Favored 'General case' 0 N--CA 1.485 1.303 0 N-CA-C 108.364 -0.976 . . . . 0.0 108.364 179.808 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 55.3 t -142.42 118.63 5.98 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.275 0 CA-C-O 118.804 -0.617 . . . . 0.0 109.899 179.29 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 54.2 m-85 -70.41 158.7 35.53 Favored 'General case' 0 N--CA 1.479 1.006 0 N-CA-C 107.812 -1.181 . . . . 0.0 107.812 177.07 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 15.0 t80 -171.0 -58.75 0.02 OUTLIER 'General case' 0 N--CA 1.483 1.198 0 CA-C-O 122.435 1.112 . . . . 0.0 109.546 179.244 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.33 90.56 0.0 OUTLIER 'General case' 0 N--CA 1.458 -0.073 0 CA-C-N 113.845 -1.525 . . . . 0.0 112.818 -178.113 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 53.6 tt0 -62.88 155.34 27.39 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 115.238 -0.892 . . . . 0.0 110.463 178.952 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 18.1 m-20 -136.51 134.71 37.85 Favored 'General case' 0 N--CA 1.48 1.071 0 C-N-CA 122.967 0.507 . . . . 0.0 109.983 179.851 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 16.2 t -84.74 -117.05 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.763 0 N-CA-C 108.173 -1.047 . . . . 0.0 108.173 179.296 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -107.4 53.27 0.61 Allowed Glycine 0 N--CA 1.474 1.172 0 N-CA-C 111.178 -0.769 . . . . 0.0 111.178 179.867 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 88.7 p -77.04 126.55 31.15 Favored 'General case' 0 N--CA 1.465 0.311 0 N-CA-C 109.023 -0.732 . . . . 0.0 109.023 178.398 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 1.8 t-20 -67.18 100.03 0.74 Allowed 'General case' 0 N--CA 1.472 0.656 0 N-CA-C 108.615 -0.883 . . . . 0.0 108.615 178.664 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 67.3 mttm -94.01 128.26 40.25 Favored 'General case' 0 N--CA 1.479 1.012 0 N-CA-C 109.634 -0.506 . . . . 0.0 109.634 -179.451 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.28 -133.26 0.01 OUTLIER Glycine 0 CA--C 1.53 0.985 0 N-CA-C 110.398 -1.081 . . . . 0.0 110.398 179.11 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.34 127.78 43.32 Favored 'General case' 0 N--CA 1.484 1.243 0 CA-C-N 117.096 0.448 . . . . 0.0 110.178 179.356 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 30.3 mt -91.9 160.52 2.68 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.648 0 N-CA-C 106.824 -1.547 . . . . 0.0 106.824 178.157 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 38.0 mt -138.27 94.14 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.766 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 -179.065 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 53.5 104.82 0.01 OUTLIER Glycine 0 CA--C 1.531 1.085 0 CA-C-N 115.899 -0.592 . . . . 0.0 114.192 176.621 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 91.1 mt -72.22 155.2 40.48 Favored 'General case' 0 N--CA 1.469 0.512 0 N-CA-C 107.502 -1.295 . . . . 0.0 107.502 176.51 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 2.2 ttp -143.84 139.3 29.21 Favored 'General case' 0 N--CA 1.473 0.725 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 178.943 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 59.1 t -159.23 150.05 6.96 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.261 0 N-CA-C 106.714 -1.587 . . . . 0.0 106.714 -179.229 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . 0.642 ' H ' ' NE2' ' A' ' 15' ' ' GLN . . . 54.78 75.15 0.25 Allowed Glycine 0 C--N 1.314 -0.667 0 N-CA-C 111.823 -0.511 . . . . 0.0 111.823 177.909 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 174.14 -148.97 10.33 Favored Glycine 0 CA--C 1.52 0.36 0 N-CA-C 110.974 -0.85 . . . . 0.0 110.974 179.928 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 30.9 m -134.81 146.0 31.44 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.906 0 C-N-CA 122.599 0.36 . . . . 0.0 110.373 -179.72 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 19.6 t . . . . . 0 C--O 1.221 -0.428 0 CA-C-O 117.59 -1.195 . . . . 0.0 110.986 179.153 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' B' B ' 1' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 . . . . . 0 N--CA 1.489 1.497 0 N-CA-C 109.124 -0.695 . . . . 0.0 109.124 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' B' B ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.64 132.44 48.83 Favored 'General case' 0 CA--C 1.539 0.528 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.142 -179.877 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 3' ' ' GLU . . . . . . . . . . . . . 55.0 tt0 -169.45 108.21 0.42 Allowed 'General case' 0 N--CA 1.47 0.57 0 N-CA-C 109.608 -0.515 . . . . 0.0 109.608 -179.166 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 77.1 m-85 -83.53 141.22 31.78 Favored 'General case' 0 N--CA 1.473 0.712 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 179.531 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 72.0 mtp180 -144.33 141.61 29.87 Favored 'General case' 0 N--CA 1.48 1.071 0 N-CA-C 108.999 -0.741 . . . . 0.0 108.999 179.955 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 77.2 m80 -149.51 118.65 6.77 Favored 'General case' 0 N--CA 1.474 0.742 0 N-CA-C 108.903 -0.777 . . . . 0.0 108.903 179.04 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 7' ' ' ASP . . . . . . . . . . . . . 12.4 m-20 -66.87 149.03 51.17 Favored 'General case' 0 CA--C 1.532 0.261 0 CA-C-N 116.411 -0.359 . . . . 0.0 111.236 -179.399 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 8' ' ' SER . . . . . . . . . . . . . 7.9 t -167.21 170.21 11.91 Favored 'General case' 0 N--CA 1.471 0.613 0 N-CA-C 109.288 -0.634 . . . . 0.0 109.288 178.459 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 123.43 24.4 1.97 Allowed Glycine 0 N--CA 1.486 2.023 0 N-CA-C 111.982 -0.447 . . . . 0.0 111.982 179.416 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 40.6 p90 -56.63 128.37 36.01 Favored 'General case' 0 N--CA 1.471 0.581 0 N-CA-C 112.091 0.404 . . . . 0.0 112.091 -179.775 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 46.1 mt-10 -84.69 154.54 22.41 Favored 'General case' 0 N--CA 1.469 0.498 0 N-CA-C 108.911 -0.774 . . . . 0.0 108.911 178.327 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -154.01 129.04 1.5 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 N-CA-C 108.173 -1.047 . . . . 0.0 108.173 178.861 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 51.4 m-70 -134.35 144.94 48.54 Favored 'General case' 0 N--CA 1.488 1.429 0 CA-C-N 118.475 0.579 . . . . 0.0 110.777 -178.95 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 6.2 t60 -164.66 98.16 0.78 Allowed 'General case' 0 N--CA 1.484 1.243 0 CA-C-N 116.697 -0.229 . . . . 0.0 111.189 179.596 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . 0.62 ' NE2' ' H ' ' B' ' 37' ' ' GLY . 75.8 mt-30 -102.84 -172.95 2.21 Favored 'General case' 0 CA--C 1.506 -0.743 0 N-CA-C 108.135 -1.061 . . . . 0.0 108.135 179.415 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -167.08 97.94 0.52 Allowed 'General case' 0 N--CA 1.47 0.558 0 CA-C-N 115.034 -0.984 . . . . 0.0 109.309 178.898 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . 0.571 ' N ' HD12 ' B' ' 17' ' ' LEU . 4.9 mp -106.63 162.19 13.97 Favored 'General case' 0 N--CA 1.486 1.329 0 N-CA-C 108.373 -0.973 . . . . 0.0 108.373 179.819 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 56.8 t -142.31 118.35 5.98 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.243 0 CA-C-O 118.873 -0.584 . . . . 0.0 109.924 179.309 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 56.0 m-85 -70.69 158.81 35.6 Favored 'General case' 0 N--CA 1.478 0.93 0 N-CA-C 107.671 -1.233 . . . . 0.0 107.671 177.036 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 16.0 t80 -171.73 -57.98 0.02 OUTLIER 'General case' 0 N--CA 1.481 1.102 0 CA-C-O 122.254 1.026 . . . . 0.0 109.541 179.233 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.54 90.8 0.0 OUTLIER 'General case' 0 C--O 1.231 0.103 0 CA-C-N 114.1 -1.409 . . . . 0.0 112.67 -178.169 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 53.5 tt0 -63.11 155.34 28.23 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-N 115.274 -0.875 . . . . 0.0 110.495 179.035 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 18.0 m-20 -136.46 134.91 38.16 Favored 'General case' 0 N--CA 1.481 1.088 0 C-N-CA 122.991 0.516 . . . . 0.0 110.007 179.875 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 16.1 t -85.21 -117.13 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.475 0.795 0 N-CA-C 108.331 -0.988 . . . . 0.0 108.331 179.282 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -106.66 52.74 0.66 Allowed Glycine 0 N--CA 1.476 1.306 0 N-CA-C 111.14 -0.784 . . . . 0.0 111.14 179.915 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 89.5 p -77.02 126.22 30.61 Favored 'General case' 0 N--CA 1.466 0.352 0 N-CA-C 109.207 -0.664 . . . . 0.0 109.207 178.421 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 1.8 t-20 -67.15 100.17 0.75 Allowed 'General case' 0 N--CA 1.473 0.676 0 N-CA-C 108.588 -0.893 . . . . 0.0 108.588 178.674 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 67.4 mttm -94.03 128.22 40.26 Favored 'General case' 0 N--CA 1.479 1.01 0 N-CA-C 109.684 -0.487 . . . . 0.0 109.684 -179.469 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.16 -132.94 0.01 OUTLIER Glycine 0 CA--C 1.53 0.991 0 N-CA-C 110.493 -1.043 . . . . 0.0 110.493 179.067 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.63 127.83 42.99 Favored 'General case' 0 N--CA 1.485 1.286 0 CA-C-N 117.192 0.496 . . . . 0.0 110.09 179.355 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 29.8 mt -92.03 160.3 2.7 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.69 0 N-CA-C 106.896 -1.52 . . . . 0.0 106.896 178.093 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 37.5 mt -138.0 94.05 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.684 0 N-CA-C 109.908 -0.405 . . . . 0.0 109.908 -178.969 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 53.47 104.91 0.01 OUTLIER Glycine 0 CA--C 1.53 1.02 0 CA-C-N 115.899 -0.591 . . . . 0.0 114.229 176.648 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 90.9 mt -72.29 155.26 40.38 Favored 'General case' 0 N--CA 1.471 0.578 0 N-CA-C 107.481 -1.303 . . . . 0.0 107.481 176.524 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 2.2 ttp -143.73 139.02 29.25 Favored 'General case' 0 N--CA 1.476 0.859 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 178.954 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 59.0 t -159.05 149.96 7.17 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.274 0 N-CA-C 106.58 -1.637 . . . . 0.0 106.58 -179.23 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . 0.62 ' H ' ' NE2' ' B' ' 15' ' ' GLN . . . 54.83 75.12 0.25 Allowed Glycine 0 C--N 1.314 -0.647 0 N-CA-C 111.786 -0.526 . . . . 0.0 111.786 177.778 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 174.06 -148.89 10.31 Favored Glycine 0 CA--C 1.521 0.452 0 N-CA-C 110.989 -0.844 . . . . 0.0 110.989 179.869 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 31.5 m -134.83 145.99 31.44 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.942 0 C-N-CA 122.566 0.346 . . . . 0.0 110.35 -179.717 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 20.0 t . . . . . 0 C--O 1.22 -0.448 0 CA-C-O 117.636 -1.173 . . . . 0.0 110.985 179.136 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' C' C ' 1' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 . . . . . 0 N--CA 1.489 1.507 0 N-CA-C 109.013 -0.736 . . . . 0.0 109.013 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' C' C ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.51 132.41 48.83 Favored 'General case' 0 CA--C 1.539 0.535 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.202 -179.966 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 3' ' ' GLU . . . . . . . . . . . . . 55.0 tt0 -169.43 108.32 0.42 Allowed 'General case' 0 N--CA 1.471 0.62 0 N-CA-C 109.584 -0.524 . . . . 0.0 109.584 -179.247 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 76.5 m-85 -83.58 141.05 31.86 Favored 'General case' 0 N--CA 1.473 0.72 0 N-CA-C 109.9 -0.407 . . . . 0.0 109.9 179.472 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 72.4 mtp180 -144.19 141.56 29.99 Favored 'General case' 0 N--CA 1.483 1.221 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 179.946 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 77.1 m80 -149.49 118.59 6.75 Favored 'General case' 0 N--CA 1.473 0.705 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 179.053 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 7' ' ' ASP . . . . . . . . . . . . . 11.7 m-20 -66.88 149.08 51.1 Favored 'General case' 0 N--CA 1.464 0.251 0 CA-C-N 116.337 -0.392 . . . . 0.0 111.25 -179.416 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 8' ' ' SER . . . . . . . . . . . . . 7.9 t -167.18 170.18 11.99 Favored 'General case' 0 N--CA 1.472 0.642 0 N-CA-C 109.188 -0.671 . . . . 0.0 109.188 178.493 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 123.45 24.42 1.96 Allowed Glycine 0 N--CA 1.486 2.023 0 N-CA-C 111.944 -0.462 . . . . 0.0 111.944 179.37 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 40.7 p90 -56.57 128.21 35.13 Favored 'General case' 0 N--CA 1.472 0.628 0 N-CA-C 112.066 0.395 . . . . 0.0 112.066 -179.836 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 46.0 mt-10 -84.54 154.54 22.59 Favored 'General case' 0 N--CA 1.469 0.51 0 N-CA-C 108.881 -0.785 . . . . 0.0 108.881 178.252 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -154.07 129.02 1.48 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 178.826 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 51.3 m-70 -134.24 144.96 48.71 Favored 'General case' 0 N--CA 1.487 1.411 0 CA-C-N 118.428 0.558 . . . . 0.0 110.827 -178.954 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 6.2 t60 -164.75 98.35 0.77 Allowed 'General case' 0 N--CA 1.484 1.259 0 CA-C-N 116.823 -0.171 . . . . 0.0 111.254 179.6 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 15' ' ' GLN . . . . . 0.634 ' NE2' ' H ' ' C' ' 37' ' ' GLY . 75.8 mt-30 -103.09 -172.73 2.16 Favored 'General case' 0 CA--C 1.503 -0.851 0 N-CA-C 108.244 -1.021 . . . . 0.0 108.244 179.322 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -167.18 98.11 0.51 Allowed 'General case' 0 CA--C 1.538 0.502 0 CA-C-N 114.973 -1.012 . . . . 0.0 109.333 178.861 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 17' ' ' LEU . . . . . 0.563 HD12 ' N ' ' C' ' 17' ' ' LEU . 4.9 mp -106.72 162.19 13.99 Favored 'General case' 0 N--CA 1.486 1.344 0 N-CA-C 108.291 -1.003 . . . . 0.0 108.291 179.76 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 57.5 t -142.24 118.41 6.18 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.296 0 CA-C-O 118.934 -0.555 . . . . 0.0 109.944 179.285 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 55.7 m-85 -70.64 158.82 35.53 Favored 'General case' 0 N--CA 1.478 0.946 0 N-CA-C 107.754 -1.202 . . . . 0.0 107.754 176.981 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 16.0 t80 -171.71 -57.94 0.02 OUTLIER 'General case' 0 N--CA 1.479 0.977 0 CA-C-O 122.299 1.047 . . . . 0.0 109.573 179.176 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.6 90.82 0.0 OUTLIER 'General case' 0 C--N 1.338 0.087 0 CA-C-N 114.137 -1.392 . . . . 0.0 112.653 -178.171 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 53.6 tt0 -63.11 155.34 28.24 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 115.226 -0.897 . . . . 0.0 110.462 179.04 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 17.9 m-20 -136.43 134.94 38.25 Favored 'General case' 0 N--CA 1.48 1.069 0 C-N-CA 122.898 0.479 . . . . 0.0 110.002 179.83 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 16.1 t -85.08 -117.23 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.475 0.796 0 N-CA-C 108.344 -0.984 . . . . 0.0 108.344 179.273 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -106.54 52.68 0.66 Allowed Glycine 0 N--CA 1.476 1.327 0 N-CA-C 111.144 -0.782 . . . . 0.0 111.144 179.852 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 89.3 p -77.1 126.45 30.98 Favored 'General case' 0 N--CA 1.466 0.364 0 N-CA-C 109.151 -0.685 . . . . 0.0 109.151 178.494 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 1.8 t-20 -67.24 100.17 0.77 Allowed 'General case' 0 N--CA 1.471 0.615 0 N-CA-C 108.627 -0.879 . . . . 0.0 108.627 178.619 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 67.3 mttm -94.09 128.23 40.35 Favored 'General case' 0 N--CA 1.479 1.016 0 N-CA-C 109.656 -0.498 . . . . 0.0 109.656 -179.41 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.29 -133.09 0.01 OUTLIER Glycine 0 CA--C 1.531 1.039 0 N-CA-C 110.481 -1.047 . . . . 0.0 110.481 179.139 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.37 127.52 42.79 Favored 'General case' 0 N--CA 1.486 1.332 0 CA-C-N 117.195 0.498 . . . . 0.0 110.177 179.379 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 29.6 mt -91.78 160.25 2.71 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.642 0 N-CA-C 106.887 -1.523 . . . . 0.0 106.887 178.063 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 36.9 mt -138.0 94.0 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.696 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 -178.964 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 53.52 104.93 0.01 OUTLIER Glycine 0 CA--C 1.531 1.067 0 CA-C-N 115.885 -0.598 . . . . 0.0 114.118 176.608 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 90.9 mt -72.21 155.17 40.52 Favored 'General case' 0 N--CA 1.47 0.563 0 N-CA-C 107.477 -1.305 . . . . 0.0 107.477 176.463 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 2.2 ttp -143.54 139.09 29.59 Favored 'General case' 0 N--CA 1.473 0.722 0 N-CA-C 108.812 -0.81 . . . . 0.0 108.812 178.9 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 59.3 t -159.2 150.08 6.98 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.258 0 N-CA-C 106.659 -1.608 . . . . 0.0 106.659 -179.279 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 37' ' ' GLY . . . . . 0.634 ' H ' ' NE2' ' C' ' 15' ' ' GLN . . . 54.84 75.04 0.25 Allowed Glycine 0 N--CA 1.465 0.633 0 N-CA-C 111.775 -0.53 . . . . 0.0 111.775 177.837 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 174.04 -148.9 10.32 Favored Glycine 0 CA--C 1.521 0.411 0 N-CA-C 110.967 -0.853 . . . . 0.0 110.967 179.8 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 31.3 m -134.8 145.97 31.5 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.97 0 C-N-CA 122.535 0.334 . . . . 0.0 110.481 -179.739 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 20.1 t . . . . . 0 C--O 1.222 -0.392 0 CA-C-O 117.616 -1.183 . . . . 0.0 110.873 179.116 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' D' D ' 1' ' ' ASP . . . . . . . . . . . . . 8.6 m-20 . . . . . 0 N--CA 1.491 1.597 0 N-CA-C 109.075 -0.713 . . . . 0.0 109.075 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' D' D ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.29 131.1 46.33 Favored 'General case' 0 CA--C 1.536 0.427 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.431 179.769 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' D' D ' 3' ' ' GLU . . . . . . . . . . . . . 54.5 tt0 -169.36 110.52 0.47 Allowed 'General case' 0 N--CA 1.469 0.507 0 N-CA-C 109.333 -0.617 . . . . 0.0 109.333 179.51 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 84.5 m-85 -87.0 148.55 25.27 Favored 'General case' 0 C--N 1.361 1.103 0 C-N-CA 118.619 -1.232 . . . . 0.0 108.346 179.664 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' D' D ' 5' ' ' ARG . . . . . . . . . . . . . 71.9 mtp180 -147.73 141.4 25.58 Favored 'General case' 0 N--CA 1.472 0.625 0 N-CA-C 109.037 -0.727 . . . . 0.0 109.037 179.779 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 77.5 m80 -149.2 123.46 9.57 Favored 'General case' 0 CA--C 1.541 0.627 0 N-CA-C 107.705 -1.22 . . . . 0.0 107.705 175.53 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' D' D ' 7' ' ' ASP . . . . . . . . . . . . . 7.9 m-20 -63.33 133.5 54.22 Favored 'General case' 0 C--N 1.322 -0.591 0 C-N-CA 126.813 2.045 . . . . 0.0 114.543 176.425 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' D' D ' 8' ' ' SER . . . . . . . . . . . . . 7.0 t -154.22 173.1 16.58 Favored 'General case' 0 N--CA 1.478 0.943 0 CA-C-N 118.468 0.576 . . . . 0.0 110.05 176.977 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 124.48 20.51 2.38 Favored Glycine 0 N--CA 1.484 1.874 0 N-CA-C 112.185 -0.366 . . . . 0.0 112.185 176.649 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 36.2 p90 -55.55 130.46 42.96 Favored 'General case' 0 CA--C 1.546 0.803 0 CA-C-O 121.089 0.471 . . . . 0.0 112.026 -177.341 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 46.2 mt-10 -84.89 152.25 23.69 Favored 'General case' 0 N--CA 1.474 0.755 0 N-CA-C 109.422 -0.584 . . . . 0.0 109.422 177.628 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -149.53 130.09 4.42 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.411 0 N-CA-C 108.158 -1.053 . . . . 0.0 108.158 175.389 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 49.4 m-70 -129.49 148.52 51.4 Favored 'General case' 0 N--CA 1.48 1.062 0 CA-C-N 118.016 0.371 . . . . 0.0 111.021 176.687 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 6.3 t60 -165.0 104.78 0.78 Allowed 'General case' 0 N--CA 1.484 1.256 0 N-CA-C 109.716 -0.476 . . . . 0.0 109.716 173.618 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' D' D ' 15' ' ' GLN . . . . . 0.659 ' NE2' ' H ' ' D' ' 37' ' ' GLY . 75.9 mt-30 -106.3 -175.7 2.87 Favored 'General case' 0 CA--C 1.498 -1.056 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 178.602 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' D' D ' 16' ' ' LYS . . . . . 0.414 ' C ' HD12 ' D' ' 17' ' ' LEU . 88.6 tttt -163.54 106.28 0.98 Allowed 'General case' 0 CA--C 1.536 0.423 0 N-CA-C 107.493 -1.299 . . . . 0.0 107.493 175.514 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' D' D ' 17' ' ' LEU . . . . . 0.498 HD12 ' N ' ' D' ' 17' ' ' LEU . 5.9 mp -112.94 162.18 16.14 Favored 'General case' 0 N--CA 1.487 1.381 0 N-CA-C 107.503 -1.295 . . . . 0.0 107.503 179.01 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 48.7 t -141.24 123.44 14.59 Favored 'Isoleucine or valine' 0 C--N 1.362 1.134 0 N-CA-C 109.084 -0.71 . . . . 0.0 109.084 175.344 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 80.4 m-85 -62.85 151.37 39.23 Favored 'General case' 0 C--N 1.349 0.582 0 C-N-CA 124.435 1.094 . . . . 0.0 110.703 170.11 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 11.4 t80 -170.23 -66.84 0.02 OUTLIER 'General case' 0 C--N 1.319 -0.723 0 N-CA-C 107.72 -1.215 . . . . 0.0 107.72 179.31 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -38.37 95.52 0.01 OUTLIER 'General case' 0 N--CA 1.451 -0.38 0 CA-C-N 113.964 -1.471 . . . . 0.0 111.672 -175.501 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 53.6 tt0 -65.39 156.03 33.53 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 114.072 -1.422 . . . . 0.0 110.104 178.587 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 17.9 m-20 -136.49 138.89 41.88 Favored 'General case' 0 N--CA 1.477 0.898 0 N-CA-C 109.256 -0.646 . . . . 0.0 109.256 178.501 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' D' D ' 24' ' ' VAL . . . . . . . . . . . . . 17.3 t -88.5 -120.4 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.482 1.168 0 N-CA-C 107.602 -1.259 . . . . 0.0 107.602 179.607 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . -110.35 61.77 0.3 Allowed Glycine 0 C--N 1.373 2.585 0 C-N-CA 117.706 -2.188 . . . . 0.0 109.162 178.44 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 94.5 p -67.91 121.74 16.67 Favored 'General case' 0 C--O 1.243 0.763 0 CA-C-O 116.524 -1.703 . . . . 0.0 112.307 168.7 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 1.9 t-20 -62.73 101.75 0.28 Allowed 'General case' 0 N--CA 1.476 0.845 0 CA-C-N 121.519 1.963 . . . . 0.0 109.476 172.984 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 67.1 mttm -95.95 127.37 41.91 Favored 'General case' 0 N--CA 1.485 1.277 0 CA-C-N 119.243 0.928 . . . . 0.0 109.102 178.377 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -55.84 -135.05 0.0 OUTLIER Glycine 0 CA--C 1.527 0.803 0 C-N-CA 123.573 0.606 . . . . 0.0 112.443 174.696 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.45 130.94 48.31 Favored 'General case' 0 C--N 1.373 1.62 0 CA-C-N 114.968 -0.616 . . . . 0.0 110.283 175.995 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 35.9 mt -92.08 162.32 2.43 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.455 0 N-CA-C 106.475 -1.676 . . . . 0.0 106.475 177.673 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . 0.267 41.6 mt -140.6 105.49 1.84 Allowed 'Isoleucine or valine' 0 C--N 1.359 1.015 0 N-CA-C 106.728 -1.582 . . . . 0.0 106.728 173.053 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.49 96.24 0.01 OUTLIER Glycine 0 CA--C 1.533 1.171 0 CA-C-O 115.935 -2.592 . . . . 0.0 112.682 169.063 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 95.2 mt -69.65 158.56 35.1 Favored 'General case' 0 N--CA 1.481 1.086 0 CA-C-N 122.731 3.265 . . . . 0.0 107.441 176.507 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 2.9 ttp -143.82 149.53 37.14 Favored 'General case' 0 N--CA 1.481 1.089 0 N-CA-C 106.352 -1.722 . . . . 0.0 106.352 174.293 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 89.6 t -165.18 154.09 1.91 Allowed 'Isoleucine or valine' 0 C--O 1.249 1.032 0 N-CA-C 105.41 -2.07 . . . . 0.0 105.41 177.601 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' D' D ' 37' ' ' GLY . . . . . 0.659 ' H ' ' NE2' ' D' ' 15' ' ' GLN . . . 60.83 66.74 2.5 Favored Glycine 0 N--CA 1.442 -0.953 0 C-N-CA 117.326 -2.369 . . . . 0.0 113.981 174.565 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 168.41 -147.85 11.88 Favored Glycine 0 N--CA 1.466 0.674 0 CA-C-O 117.0 -2.0 . . . . 0.0 112.492 -178.698 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 31.1 m -131.19 145.42 35.39 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.271 0 CA-C-N 119.958 1.879 . . . . 0.0 110.588 -176.988 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 18.0 t . . . . . 0 C--O 1.208 -1.128 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 173.591 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' E' E ' 1' ' ' ASP . . . . . . . . . . . . . 8.6 m-20 . . . . . 0 N--CA 1.49 1.531 0 N-CA-C 109.196 -0.668 . . . . 0.0 109.196 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' E' E ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.3 131.14 46.44 Favored 'General case' 0 CA--C 1.536 0.416 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.373 179.866 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' E' E ' 3' ' ' GLU . . . . . . . . . . . . . 54.5 tt0 -169.14 108.32 0.44 Allowed 'General case' 0 N--CA 1.469 0.503 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 -179.784 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 77.1 m-85 -84.36 141.31 30.98 Favored 'General case' 0 N--CA 1.473 0.7 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 179.416 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' E' E ' 5' ' ' ARG . . . . . . . . . . . . . 71.8 mtp180 -144.27 142.32 30.38 Favored 'General case' 0 N--CA 1.476 0.826 0 N-CA-C 109.234 -0.654 . . . . 0.0 109.234 179.666 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 77.3 m80 -150.11 117.62 6.12 Favored 'General case' 0 N--CA 1.475 0.787 0 N-CA-C 109.049 -0.723 . . . . 0.0 109.049 179.073 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' E' E ' 7' ' ' ASP . . . . . . . . . . . . . 12.1 m-20 -65.85 149.19 50.58 Favored 'General case' 0 N--CA 1.463 0.205 0 O-C-N 123.276 0.36 . . . . 0.0 111.482 -179.409 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' E' E ' 8' ' ' SER . . . . . . . . . . . . . 7.2 t -167.6 171.34 10.34 Favored 'General case' 0 N--CA 1.476 0.836 0 N-CA-C 109.219 -0.66 . . . . 0.0 109.219 178.03 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 123.9 23.78 1.98 Allowed Glycine 0 N--CA 1.481 1.655 0 N-CA-C 111.876 -0.489 . . . . 0.0 111.876 179.024 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 37.1 p90 -55.82 127.53 30.64 Favored 'General case' 0 CA--C 1.543 0.694 0 N-CA-C 112.703 0.631 . . . . 0.0 112.703 -179.076 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 46.4 mt-10 -83.05 155.2 24.03 Favored 'General case' 0 N--CA 1.475 0.79 0 N-CA-C 109.234 -0.654 . . . . 0.0 109.234 177.774 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -155.69 127.88 1.02 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.498 0 N-CA-C 108.22 -1.03 . . . . 0.0 108.22 178.622 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 48.5 m-70 -134.29 143.1 47.54 Favored 'General case' 0 N--CA 1.478 0.97 0 C-N-CA 122.491 0.316 . . . . 0.0 111.099 -177.976 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 6.1 t60 -163.52 98.5 0.9 Allowed 'General case' 0 N--CA 1.486 1.359 0 CA-C-O 119.735 -0.174 . . . . 0.0 111.247 179.693 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' E' E ' 15' ' ' GLN . . . . . 0.611 ' NE2' ' H ' ' E' ' 37' ' ' GLY . 76.0 mt-30 -102.66 -172.7 2.17 Favored 'General case' 0 CA--C 1.506 -0.736 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 179.464 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -167.16 98.13 0.52 Allowed 'General case' 0 CA--C 1.54 0.59 0 CA-C-N 114.97 -1.014 . . . . 0.0 109.259 178.617 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' E' E ' 17' ' ' LEU . . . . . 0.537 ' N ' HD12 ' E' ' 17' ' ' LEU . 4.9 mp -106.43 161.44 14.58 Favored 'General case' 0 N--CA 1.487 1.411 0 N-CA-C 108.771 -0.826 . . . . 0.0 108.771 -179.95 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 42.0 t -142.4 117.82 5.39 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.379 0 C-N-CA 122.549 0.339 . . . . 0.0 110.463 178.896 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 54.9 m-85 -69.72 156.54 38.83 Favored 'General case' 0 C--N 1.356 0.891 0 N-CA-C 107.636 -1.246 . . . . 0.0 107.636 176.449 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 14.2 t80 -173.23 -56.16 0.02 OUTLIER 'General case' 0 N--CA 1.482 1.129 0 CA-C-O 121.731 0.777 . . . . 0.0 110.018 179.242 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.84 89.1 0.0 OUTLIER 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 114.364 -1.289 . . . . 0.0 112.689 -179.095 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 54.0 tt0 -61.69 155.08 23.55 Favored 'General case' 0 N--CA 1.47 0.55 0 CA-C-N 115.131 -0.94 . . . . 0.0 110.604 179.489 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 17.6 m-20 -136.46 134.54 37.77 Favored 'General case' 0 N--CA 1.479 0.978 0 C-N-CA 122.918 0.487 . . . . 0.0 110.301 -179.931 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 20.2 t -84.85 -116.64 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.873 0 N-CA-C 108.449 -0.945 . . . . 0.0 108.449 179.209 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . -106.84 52.98 0.64 Allowed Glycine 0 C--N 1.346 1.138 0 N-CA-C 111.255 -0.738 . . . . 0.0 111.255 -179.987 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 89.2 p -77.0 125.99 30.24 Favored 'General case' 0 N--CA 1.472 0.664 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 178.169 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 1.8 t-20 -66.66 100.22 0.67 Allowed 'General case' 0 N--CA 1.472 0.633 0 N-CA-C 108.108 -1.071 . . . . 0.0 108.108 178.528 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 66.6 mttm -94.31 127.15 40.01 Favored 'General case' 0 N--CA 1.481 1.101 0 N-CA-C 109.149 -0.685 . . . . 0.0 109.149 -179.463 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.84 -130.58 0.01 OUTLIER Glycine 0 CA--C 1.533 1.218 0 N-CA-C 110.454 -1.058 . . . . 0.0 110.454 179.31 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -129.25 127.56 41.49 Favored 'General case' 0 N--CA 1.484 1.265 0 CA-C-N 117.439 0.62 . . . . 0.0 111.324 -179.906 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 27.8 mt -90.91 161.01 2.65 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.499 0 N-CA-C 106.796 -1.557 . . . . 0.0 106.796 178.152 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 37.3 mt -138.75 94.5 0.89 Allowed 'Isoleucine or valine' 0 N--CA 1.479 0.979 0 N-CA-C 109.606 -0.516 . . . . 0.0 109.606 179.872 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 53.62 104.37 0.01 OUTLIER Glycine 0 CA--C 1.531 1.037 0 CA-C-N 116.101 -0.499 . . . . 0.0 114.204 176.791 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 93.8 mt -71.52 155.64 40.34 Favored 'General case' 0 N--CA 1.473 0.682 0 N-CA-C 107.49 -1.3 . . . . 0.0 107.49 176.516 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 2.4 ttp -143.81 139.99 29.62 Favored 'General case' 0 N--CA 1.479 1.019 0 N-CA-C 108.301 -1.0 . . . . 0.0 108.301 178.787 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 65.6 t -160.27 148.8 6.11 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.456 0 N-CA-C 106.618 -1.623 . . . . 0.0 106.618 -179.058 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' E' E ' 37' ' ' GLY . . . . . 0.611 ' H ' ' NE2' ' E' ' 15' ' ' GLN . . . 55.15 75.32 0.24 Allowed Glycine 0 N--CA 1.464 0.516 0 N-CA-C 111.815 -0.514 . . . . 0.0 111.815 178.118 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 174.77 -146.95 8.77 Favored Glycine 0 C--O 1.221 -0.663 0 N-CA-C 111.207 -0.757 . . . . 0.0 111.207 179.881 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 29.8 m -136.69 145.15 30.73 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.794 0 CA-C-N 117.104 0.452 . . . . 0.0 109.808 -179.647 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 19.0 t . . . . . 0 CA--C 1.537 0.449 0 CA-C-O 117.576 -1.202 . . . . 0.0 111.153 179.183 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' F' F ' 1' ' ' ASP . . . . . . . . . . . . . 8.6 m-20 . . . . . 0 N--CA 1.49 1.573 0 N-CA-C 109.177 -0.675 . . . . 0.0 109.177 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' F' F ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.31 131.16 46.49 Favored 'General case' 0 CA--C 1.536 0.441 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.382 179.832 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' F' F ' 3' ' ' GLU . . . . . . . . . . . . . 54.5 tt0 -169.19 108.34 0.44 Allowed 'General case' 0 N--CA 1.469 0.523 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 -179.824 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 77.0 m-85 -84.38 141.25 30.99 Favored 'General case' 0 N--CA 1.474 0.75 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 179.414 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' F' F ' 5' ' ' ARG . . . . . . . . . . . . . 72.0 mtp180 -144.11 142.15 30.43 Favored 'General case' 0 N--CA 1.478 0.954 0 N-CA-C 109.092 -0.707 . . . . 0.0 109.092 179.755 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 77.2 m80 -150.14 117.43 6.04 Favored 'General case' 0 N--CA 1.476 0.843 0 N-CA-C 108.983 -0.747 . . . . 0.0 108.983 179.093 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' F' F ' 7' ' ' ASP . . . . . . . . . . . . . 11.5 m-20 -65.74 149.07 50.73 Favored 'General case' 0 N--CA 1.464 0.247 0 O-C-N 123.327 0.392 . . . . 0.0 111.662 -179.433 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' F' F ' 8' ' ' SER . . . . . . . . . . . . . 7.1 t -167.38 171.43 10.58 Favored 'General case' 0 N--CA 1.476 0.87 0 N-CA-C 109.253 -0.647 . . . . 0.0 109.253 178.056 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 123.79 23.71 2.01 Favored Glycine 0 N--CA 1.482 1.746 0 N-CA-C 111.901 -0.48 . . . . 0.0 111.901 179.008 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 37.4 p90 -55.9 127.75 31.81 Favored 'General case' 0 CA--C 1.542 0.647 0 N-CA-C 112.717 0.636 . . . . 0.0 112.717 -179.113 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 46.4 mt-10 -83.21 155.25 23.81 Favored 'General case' 0 N--CA 1.475 0.779 0 N-CA-C 109.2 -0.667 . . . . 0.0 109.2 177.756 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -155.74 127.94 1.02 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.538 0 N-CA-C 108.218 -1.03 . . . . 0.0 108.218 178.551 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 49.0 m-70 -134.29 143.16 47.58 Favored 'General case' 0 N--CA 1.479 1.024 0 C-N-CA 122.419 0.288 . . . . 0.0 110.996 -177.871 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 6.1 t60 -163.81 99.12 0.88 Allowed 'General case' 0 N--CA 1.487 1.38 0 CA-C-N 116.85 -0.159 . . . . 0.0 111.252 179.677 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' F' F ' 15' ' ' GLN . . . . . 0.625 ' NE2' ' H ' ' F' ' 37' ' ' GLY . 76.0 mt-30 -103.58 -171.91 2.02 Favored 'General case' 0 CA--C 1.501 -0.921 0 N-CA-C 108.388 -0.967 . . . . 0.0 108.388 179.384 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -167.6 98.3 0.48 Allowed 'General case' 0 CA--C 1.54 0.59 0 CA-C-N 114.842 -1.072 . . . . 0.0 109.322 178.775 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' F' F ' 17' ' ' LEU . . . . . 0.529 HD12 ' N ' ' F' ' 17' ' ' LEU . 4.9 mp -106.45 161.45 14.58 Favored 'General case' 0 N--CA 1.487 1.415 0 N-CA-C 108.721 -0.844 . . . . 0.0 108.721 -179.967 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 41.6 t -142.32 117.96 5.64 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.378 0 C-N-CA 122.638 0.375 . . . . 0.0 110.478 178.921 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 55.2 m-85 -69.82 156.47 38.99 Favored 'General case' 0 C--N 1.357 0.906 0 N-CA-C 107.455 -1.313 . . . . 0.0 107.455 176.363 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 15.0 t80 -173.11 -56.09 0.02 OUTLIER 'General case' 0 N--CA 1.482 1.164 0 CA-C-O 121.743 0.783 . . . . 0.0 109.606 179.233 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.99 89.09 0.0 OUTLIER 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 114.46 -1.245 . . . . 0.0 112.76 -179.02 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 53.9 tt0 -61.6 155.19 22.95 Favored 'General case' 0 N--CA 1.472 0.659 0 CA-C-N 115.151 -0.931 . . . . 0.0 110.641 179.346 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 17.5 m-20 -136.66 134.73 37.59 Favored 'General case' 0 N--CA 1.479 1.006 0 C-N-CA 122.925 0.49 . . . . 0.0 110.345 -179.986 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' F' F ' 24' ' ' VAL . . . . . . . . . . . . . 19.3 t -85.08 -116.69 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.93 0 N-CA-C 108.525 -0.917 . . . . 0.0 108.525 179.241 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -106.6 52.61 0.67 Allowed Glycine 0 N--CA 1.477 1.42 0 N-CA-C 111.172 -0.771 . . . . 0.0 111.172 179.974 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 89.3 p -76.78 125.86 29.99 Favored 'General case' 0 N--CA 1.472 0.655 0 N-CA-C 109.271 -0.64 . . . . 0.0 109.271 178.176 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 1.9 t-20 -66.83 100.35 0.71 Allowed 'General case' 0 N--CA 1.471 0.603 0 N-CA-C 108.134 -1.061 . . . . 0.0 108.134 178.587 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 66.7 mttm -94.31 126.96 39.89 Favored 'General case' 0 N--CA 1.481 1.123 0 N-CA-C 109.169 -0.678 . . . . 0.0 109.169 -179.389 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.81 -130.96 0.01 OUTLIER Glycine 0 CA--C 1.532 1.155 0 N-CA-C 110.591 -1.004 . . . . 0.0 110.591 179.212 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.55 126.94 41.38 Favored 'General case' 0 N--CA 1.488 1.433 0 CA-C-N 117.4 0.6 . . . . 0.0 111.348 -179.765 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 28.1 mt -90.62 160.92 2.68 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.547 0 N-CA-C 106.694 -1.595 . . . . 0.0 106.694 178.033 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 36.8 mt -138.87 94.57 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.093 0 N-CA-C 109.613 -0.514 . . . . 0.0 109.613 179.822 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 53.69 104.3 0.01 OUTLIER Glycine 0 CA--C 1.531 1.075 0 CA-C-N 116.039 -0.528 . . . . 0.0 114.145 176.752 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 94.1 mt -71.47 155.93 40.03 Favored 'General case' 0 N--CA 1.471 0.62 0 N-CA-C 107.524 -1.287 . . . . 0.0 107.524 176.588 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 2.3 ttp -144.13 140.01 29.15 Favored 'General case' 0 N--CA 1.478 0.957 0 N-CA-C 108.691 -0.855 . . . . 0.0 108.691 178.708 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 65.0 t -160.3 148.95 6.08 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.447 0 N-CA-C 106.703 -1.591 . . . . 0.0 106.703 -178.973 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' F' F ' 37' ' ' GLY . . . . . 0.625 ' H ' ' NE2' ' F' ' 15' ' ' GLN . . . 55.16 75.25 0.25 Allowed Glycine 0 N--CA 1.464 0.551 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.812 178.038 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 174.77 -146.94 8.76 Favored Glycine 0 C--O 1.22 -0.738 0 N-CA-C 111.22 -0.752 . . . . 0.0 111.22 179.845 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 30.3 m -136.7 145.05 30.88 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.757 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 -179.644 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 18.7 t . . . . . 0 C--O 1.221 -0.418 0 CA-C-O 117.621 -1.18 . . . . 0.0 111.157 179.215 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' G' G ' 1' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 . . . . . 0 N--CA 1.492 1.643 0 N-CA-C 109.494 -0.558 . . . . 0.0 109.494 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' G' G ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.72 129.55 41.02 Favored 'General case' 0 N--CA 1.469 0.514 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.416 179.698 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' G' G ' 3' ' ' GLU . . . . . . . . . . . . . 53.7 tt0 -169.16 108.17 0.44 Allowed 'General case' 0 N--CA 1.47 0.53 0 N-CA-C 110.114 -0.328 . . . . 0.0 110.114 179.763 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 77.1 m-85 -84.88 140.85 30.83 Favored 'General case' 0 N--CA 1.472 0.668 0 N-CA-C 109.594 -0.521 . . . . 0.0 109.594 179.314 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' G' G ' 5' ' ' ARG . . . . . . . . . . . . . 72.4 mtp180 -144.56 141.94 29.83 Favored 'General case' 0 N--CA 1.48 1.053 0 N-CA-C 109.088 -0.708 . . . . 0.0 109.088 -179.799 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 77.1 m80 -149.85 118.75 6.66 Favored 'General case' 0 N--CA 1.475 0.797 0 N-CA-C 108.979 -0.749 . . . . 0.0 108.979 179.072 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 12.1 m-20 -68.1 144.85 54.87 Favored 'General case' 0 CA--C 1.537 0.467 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.878 -179.2 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' G' G ' 8' ' ' SER . . . . . . . . . . . . . 6.1 t -163.58 173.1 13.44 Favored 'General case' 0 N--CA 1.47 0.552 0 N-CA-C 109.068 -0.715 . . . . 0.0 109.068 178.089 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 123.4 23.12 2.19 Favored Glycine 0 N--CA 1.481 1.644 0 N-CA-C 111.712 -0.555 . . . . 0.0 111.712 178.936 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 40.5 p90 -56.18 127.68 31.87 Favored 'General case' 0 N--CA 1.473 0.718 0 N-CA-C 112.682 0.623 . . . . 0.0 112.682 -178.705 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 46.2 mt-10 -83.44 154.1 24.14 Favored 'General case' 0 N--CA 1.47 0.561 0 N-CA-C 109.632 -0.507 . . . . 0.0 109.632 178.307 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -155.68 128.07 1.05 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.933 0 N-CA-C 108.036 -1.098 . . . . 0.0 108.036 178.846 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 50.2 m-70 -133.66 144.15 49.01 Favored 'General case' 0 N--CA 1.475 0.801 0 CA-C-N 115.353 -0.84 . . . . 0.0 110.773 -178.238 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 6.2 t60 -164.82 98.83 0.77 Allowed 'General case' 0 N--CA 1.483 1.204 0 CA-C-N 116.635 -0.257 . . . . 0.0 110.786 179.033 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' G' G ' 15' ' ' GLN . . . . . 0.637 ' NE2' ' H ' ' G' ' 37' ' ' GLY . 76.1 mt-30 -103.18 -172.32 2.1 Favored 'General case' 0 CA--C 1.506 -0.737 0 N-CA-C 108.358 -0.979 . . . . 0.0 108.358 179.578 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -167.29 98.31 0.51 Allowed 'General case' 0 CA--C 1.539 0.546 0 CA-C-N 115.051 -0.977 . . . . 0.0 109.367 178.7 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' G' G ' 17' ' ' LEU . . . . . 0.55 ' N ' HD12 ' G' ' 17' ' ' LEU . 5.4 mp -106.2 160.81 15.05 Favored 'General case' 0 N--CA 1.486 1.335 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 -179.908 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 40.4 t -143.59 117.95 3.84 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.001 0 C-N-CA 122.573 0.349 . . . . 0.0 110.235 178.753 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 49.0 m-85 -69.7 150.84 46.53 Favored 'General case' 0 C--N 1.37 1.487 0 N-CA-C 107.404 -1.332 . . . . 0.0 107.404 176.477 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 12.4 t80 -171.03 -55.9 0.02 OUTLIER 'General case' 0 N--CA 1.485 1.29 0 N-CA-C 110.025 -0.361 . . . . 0.0 110.025 179.957 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.88 90.61 0.0 OUTLIER 'General case' 0 C--N 1.325 -0.481 0 O-C-N 123.938 0.774 . . . . 0.0 112.267 179.986 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 53.7 tt0 -62.81 155.84 25.68 Favored 'General case' 0 N--CA 1.469 0.475 0 CA-C-N 114.838 -1.074 . . . . 0.0 109.718 179.03 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 18.0 m-20 -136.71 134.71 37.48 Favored 'General case' 0 N--CA 1.478 0.96 0 C-N-CA 122.782 0.433 . . . . 0.0 109.87 -179.939 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' G' G ' 24' ' ' VAL . . . . . . . . . . . . . 19.6 t -85.5 -116.02 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.894 0 N-CA-C 108.293 -1.003 . . . . 0.0 108.293 179.289 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -107.28 53.06 0.63 Allowed Glycine 0 N--CA 1.476 1.311 0 N-CA-C 111.286 -0.726 . . . . 0.0 111.286 -179.947 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 89.3 p -77.48 126.2 30.53 Favored 'General case' 0 N--CA 1.466 0.37 0 N-CA-C 109.152 -0.684 . . . . 0.0 109.152 178.139 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 1.9 t-20 -67.16 99.82 0.72 Allowed 'General case' 0 N--CA 1.469 0.495 0 N-CA-C 108.604 -0.887 . . . . 0.0 108.604 178.81 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 67.3 mttm -93.51 127.09 39.01 Favored 'General case' 0 N--CA 1.481 1.081 0 N-CA-C 109.512 -0.551 . . . . 0.0 109.512 -179.662 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.87 -128.71 0.01 OUTLIER Glycine 0 CA--C 1.527 0.801 0 N-CA-C 110.576 -1.01 . . . . 0.0 110.576 179.27 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.84 126.09 35.36 Favored 'General case' 0 CA--C 1.54 0.567 0 C-N-CA 122.814 0.446 . . . . 0.0 110.933 -179.361 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 37.7 mt -90.53 162.26 2.49 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.842 0 N-CA-C 107.0 -1.482 . . . . 0.0 107.0 178.239 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 40.8 mt -139.04 95.96 0.96 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.437 0 CA-C-N 119.714 1.143 . . . . 0.0 110.068 178.173 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 53.64 103.92 0.01 OUTLIER Glycine 0 CA--C 1.53 1.019 0 CA-C-N 116.026 -0.534 . . . . 0.0 114.106 176.818 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 92.3 mt -71.34 154.96 41.19 Favored 'General case' 0 N--CA 1.47 0.57 0 N-CA-C 107.772 -1.196 . . . . 0.0 107.772 176.717 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 2.6 ttp -143.48 140.46 30.34 Favored 'General case' 0 N--CA 1.474 0.756 0 N-CA-C 108.555 -0.906 . . . . 0.0 108.555 178.897 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 69.2 t -160.36 149.11 5.98 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.256 0 N-CA-C 106.636 -1.616 . . . . 0.0 106.636 -179.329 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' G' G ' 37' ' ' GLY . . . . . 0.637 ' H ' ' NE2' ' G' ' 15' ' ' GLN . . . 55.5 75.12 0.26 Allowed Glycine 0 N--CA 1.466 0.637 0 C-N-CA 121.012 -0.613 . . . . 0.0 112.04 177.494 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 173.92 -146.17 8.59 Favored Glycine 0 C--O 1.221 -0.708 0 N-CA-C 110.581 -1.008 . . . . 0.0 110.581 179.339 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 32.9 m -136.76 145.9 29.42 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.923 0 CA-C-N 117.002 0.401 . . . . 0.0 110.185 -179.413 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 20.7 t . . . . . 0 C--O 1.22 -0.467 0 CA-C-O 117.603 -1.189 . . . . 0.0 111.417 179.091 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' H' H ' 1' ' ' ASP . . . . . . . . . . . . . 8.5 m-20 . . . . . 0 N--CA 1.491 1.577 0 N-CA-C 109.568 -0.53 . . . . 0.0 109.568 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' H' H ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.83 129.47 40.59 Favored 'General case' 0 N--CA 1.469 0.5 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.381 179.711 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' H' H ' 3' ' ' GLU . . . . . . . . . . . . . 53.8 tt0 -169.04 108.12 0.45 Allowed 'General case' 0 N--CA 1.469 0.505 0 N-CA-C 110.137 -0.32 . . . . 0.0 110.137 179.78 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 77.6 m-85 -84.64 141.04 30.92 Favored 'General case' 0 N--CA 1.472 0.666 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 179.387 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' H' H ' 5' ' ' ARG . . . . . . . . . . . . . 72.3 mtp180 -144.6 141.86 29.73 Favored 'General case' 0 N--CA 1.48 1.062 0 N-CA-C 109.13 -0.693 . . . . 0.0 109.13 -179.859 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 77.1 m80 -149.84 118.3 6.49 Favored 'General case' 0 N--CA 1.476 0.831 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 179.096 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 11.9 m-20 -67.54 144.89 55.4 Favored 'General case' 0 N--CA 1.468 0.453 0 O-C-N 123.426 0.453 . . . . 0.0 111.931 -179.29 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' H' H ' 8' ' ' SER . . . . . . . . . . . . . 7.5 t -163.74 172.36 14.29 Favored 'General case' 0 N--CA 1.47 0.532 0 N-CA-C 109.174 -0.676 . . . . 0.0 109.174 178.261 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 123.52 23.36 2.13 Favored Glycine 0 N--CA 1.482 1.714 0 N-CA-C 111.817 -0.513 . . . . 0.0 111.817 179.084 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 40.5 p90 -56.17 127.82 32.56 Favored 'General case' 0 N--CA 1.473 0.714 0 N-CA-C 112.575 0.583 . . . . 0.0 112.575 -178.82 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 46.2 mt-10 -83.53 154.23 23.96 Favored 'General case' 0 N--CA 1.473 0.708 0 N-CA-C 109.597 -0.52 . . . . 0.0 109.597 178.297 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -155.85 127.99 1.02 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.943 0 N-CA-C 108.07 -1.085 . . . . 0.0 108.07 178.8 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 51.4 m-70 -133.54 144.33 49.28 Favored 'General case' 0 N--CA 1.476 0.825 0 CA-C-N 115.274 -0.875 . . . . 0.0 110.81 -178.214 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 6.2 t60 -164.96 98.5 0.75 Allowed 'General case' 0 N--CA 1.483 1.197 0 CA-C-N 116.709 -0.223 . . . . 0.0 110.85 179.034 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' H' H ' 15' ' ' GLN . . . . . 0.62 ' NE2' ' H ' ' H' ' 37' ' ' GLY . 76.0 mt-30 -102.8 -172.8 2.18 Favored 'General case' 0 CA--C 1.505 -0.77 0 N-CA-C 108.26 -1.015 . . . . 0.0 108.26 179.642 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -167.11 98.24 0.52 Allowed 'General case' 0 CA--C 1.539 0.524 0 CA-C-N 114.997 -1.001 . . . . 0.0 109.251 178.719 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' H' H ' 17' ' ' LEU . . . . . 0.56 HD12 ' N ' ' H' ' 17' ' ' LEU . 5.4 mp -106.17 160.84 15.02 Favored 'General case' 0 N--CA 1.485 1.279 0 N-CA-C 109.103 -0.702 . . . . 0.0 109.103 -179.823 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 40.4 t -143.52 117.77 3.81 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.089 0 C-N-CA 122.547 0.339 . . . . 0.0 110.25 178.744 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 50.2 m-85 -69.75 151.29 45.97 Favored 'General case' 0 C--N 1.369 1.426 0 N-CA-C 107.527 -1.286 . . . . 0.0 107.527 176.33 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 13.1 t80 -172.25 -55.58 0.02 OUTLIER 'General case' 0 N--CA 1.483 1.177 0 N-CA-C 110.069 -0.345 . . . . 0.0 110.069 180.0 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.96 90.71 0.0 OUTLIER 'General case' 0 CA--C 1.535 0.367 0 C-N-CA 123.517 0.727 . . . . 0.0 112.097 179.924 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 53.7 tt0 -62.61 155.83 24.99 Favored 'General case' 0 N--CA 1.469 0.512 0 CA-C-N 114.849 -1.069 . . . . 0.0 109.919 179.115 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 17.9 m-20 -136.55 134.86 37.93 Favored 'General case' 0 N--CA 1.48 1.025 0 C-N-CA 122.835 0.454 . . . . 0.0 109.917 -179.957 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' H' H ' 24' ' ' VAL . . . . . . . . . . . . . 19.6 t -85.85 -116.13 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.846 0 N-CA-C 108.358 -0.979 . . . . 0.0 108.358 179.364 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . -106.91 52.89 0.64 Allowed Glycine 0 N--CA 1.478 1.483 0 N-CA-C 111.099 -0.8 . . . . 0.0 111.099 -179.969 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 89.0 p -77.45 126.16 30.47 Favored 'General case' 0 N--CA 1.467 0.383 0 N-CA-C 109.006 -0.738 . . . . 0.0 109.006 178.304 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 1.9 t-20 -67.06 100.49 0.76 Allowed 'General case' 0 N--CA 1.469 0.5 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 178.667 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 67.3 mttm -94.39 127.12 40.07 Favored 'General case' 0 N--CA 1.481 1.084 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 -179.598 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.11 -128.54 0.01 OUTLIER Glycine 0 CA--C 1.527 0.783 0 N-CA-C 110.643 -0.983 . . . . 0.0 110.643 179.385 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.97 126.04 34.99 Favored 'General case' 0 N--CA 1.471 0.582 0 C-N-CA 122.853 0.461 . . . . 0.0 111.033 -179.251 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 35.8 mt -90.66 161.81 2.55 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.845 0 N-CA-C 107.014 -1.476 . . . . 0.0 107.014 178.228 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 40.4 mt -138.73 95.93 1.01 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.435 0 CA-C-N 119.511 1.051 . . . . 0.0 109.981 178.38 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 53.58 104.32 0.01 OUTLIER Glycine 0 CA--C 1.53 1.029 0 CA-C-N 116.101 -0.5 . . . . 0.0 114.144 176.832 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 92.1 mt -71.67 154.76 41.16 Favored 'General case' 0 N--CA 1.47 0.57 0 N-CA-C 107.673 -1.232 . . . . 0.0 107.673 176.716 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 2.6 ttp -143.09 140.09 30.74 Favored 'General case' 0 N--CA 1.477 0.889 0 N-CA-C 108.503 -0.925 . . . . 0.0 108.503 178.802 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 69.1 t -159.96 149.34 6.38 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.278 0 N-CA-C 106.525 -1.657 . . . . 0.0 106.525 -179.388 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' H' H ' 37' ' ' GLY . . . . . 0.62 ' H ' ' NE2' ' H' ' 15' ' ' GLN . . . 55.28 74.91 0.27 Allowed Glycine 0 C--N 1.314 -0.643 0 C-N-CA 120.989 -0.624 . . . . 0.0 112.155 177.489 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 173.97 -146.32 8.66 Favored Glycine 0 C--O 1.221 -0.675 0 N-CA-C 110.631 -0.988 . . . . 0.0 110.631 179.393 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 32.7 m -136.68 145.87 29.55 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.87 0 CA-C-N 116.98 0.39 . . . . 0.0 110.327 -179.423 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 21.1 t . . . . . 0 C--O 1.221 -0.4 0 CA-C-O 117.64 -1.171 . . . . 0.0 111.326 179.163 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' I' I ' 1' ' ' ASP . . . . . . . . . . . . . 8.5 m-20 . . . . . 0 N--CA 1.492 1.634 0 N-CA-C 109.435 -0.58 . . . . 0.0 109.435 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' I' I ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.77 129.43 40.44 Favored 'General case' 0 N--CA 1.469 0.502 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.478 179.672 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' I' I ' 3' ' ' GLU . . . . . . . . . . . . . 53.8 tt0 -169.02 108.2 0.45 Allowed 'General case' 0 N--CA 1.468 0.452 0 N-CA-C 110.13 -0.322 . . . . 0.0 110.13 179.833 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 77.1 m-85 -84.75 141.18 30.72 Favored 'General case' 0 N--CA 1.473 0.704 0 N-CA-C 109.553 -0.536 . . . . 0.0 109.553 179.377 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' I' I ' 5' ' ' ARG . . . . . . . . . . . . . 72.3 mtp180 -144.78 141.9 29.56 Favored 'General case' 0 N--CA 1.481 1.094 0 N-CA-C 109.056 -0.72 . . . . 0.0 109.056 -179.834 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 77.1 m80 -149.83 118.34 6.51 Favored 'General case' 0 N--CA 1.476 0.838 0 N-CA-C 109.083 -0.71 . . . . 0.0 109.083 179.093 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 12.0 m-20 -67.62 144.76 55.39 Favored 'General case' 0 CA--C 1.535 0.396 0 CA-C-O 120.979 0.419 . . . . 0.0 111.927 -179.268 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' I' I ' 8' ' ' SER . . . . . . . . . . . . . 7.6 t -163.54 172.31 14.59 Favored 'General case' 0 N--CA 1.469 0.5 0 N-CA-C 109.152 -0.684 . . . . 0.0 109.152 178.276 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 123.7 23.26 2.1 Favored Glycine 0 N--CA 1.483 1.789 0 N-CA-C 111.747 -0.541 . . . . 0.0 111.747 179.027 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 40.3 p90 -56.08 127.82 32.43 Favored 'General case' 0 N--CA 1.474 0.75 0 N-CA-C 112.501 0.556 . . . . 0.0 112.501 -178.792 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 46.2 mt-10 -83.61 154.17 23.89 Favored 'General case' 0 N--CA 1.474 0.73 0 N-CA-C 109.644 -0.502 . . . . 0.0 109.644 178.203 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -155.74 128.01 1.03 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.927 0 N-CA-C 108.125 -1.065 . . . . 0.0 108.125 178.854 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 50.9 m-70 -133.58 144.33 49.24 Favored 'General case' 0 N--CA 1.476 0.832 0 CA-C-N 115.33 -0.85 . . . . 0.0 110.861 -178.236 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 6.2 t60 -165.05 98.61 0.74 Allowed 'General case' 0 N--CA 1.485 1.297 0 CA-C-N 116.687 -0.233 . . . . 0.0 110.914 179.131 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' I' I ' 15' ' ' GLN . . . . . 0.632 ' NE2' ' H ' ' I' ' 37' ' ' GLY . 76.0 mt-30 -103.11 -172.55 2.13 Favored 'General case' 0 CA--C 1.503 -0.852 0 N-CA-C 108.328 -0.99 . . . . 0.0 108.328 179.598 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -167.26 98.23 0.51 Allowed 'General case' 0 CA--C 1.538 0.517 0 CA-C-N 114.977 -1.011 . . . . 0.0 109.279 178.82 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' I' I ' 17' ' ' LEU . . . . . 0.553 HD12 ' N ' ' I' ' 17' ' ' LEU . 5.4 mp -106.18 160.77 15.08 Favored 'General case' 0 N--CA 1.484 1.259 0 N-CA-C 109.089 -0.708 . . . . 0.0 109.089 -179.854 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 40.5 t -143.4 117.83 3.95 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.016 0 C-N-CA 122.542 0.337 . . . . 0.0 110.306 178.753 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 49.7 m-85 -69.83 151.3 45.88 Favored 'General case' 0 C--N 1.369 1.431 0 N-CA-C 107.486 -1.302 . . . . 0.0 107.486 176.423 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 13.2 t80 -172.25 -55.55 0.02 OUTLIER 'General case' 0 N--CA 1.481 1.093 0 N-CA-C 110.065 -0.346 . . . . 0.0 110.065 -179.999 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.98 90.8 0.0 OUTLIER 'General case' 0 CA--C 1.535 0.387 0 C-N-CA 123.496 0.718 . . . . 0.0 112.046 179.877 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 53.7 tt0 -62.69 155.96 24.91 Favored 'General case' 0 N--CA 1.469 0.5 0 CA-C-N 114.862 -1.063 . . . . 0.0 109.866 179.141 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 17.9 m-20 -136.69 134.85 37.66 Favored 'General case' 0 N--CA 1.479 0.987 0 C-N-CA 122.804 0.442 . . . . 0.0 109.867 -179.954 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' I' I ' 24' ' ' VAL . . . . . . . . . . . . . 19.4 t -85.76 -116.09 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.878 0 N-CA-C 108.337 -0.986 . . . . 0.0 108.337 179.39 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . -106.98 52.9 0.64 Allowed Glycine 0 N--CA 1.477 1.402 0 N-CA-C 111.225 -0.75 . . . . 0.0 111.225 179.991 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 89.3 p -77.46 126.2 30.53 Favored 'General case' 0 N--CA 1.466 0.372 0 N-CA-C 109.066 -0.716 . . . . 0.0 109.066 178.313 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 1.9 t-20 -67.03 100.4 0.74 Allowed 'General case' 0 N--CA 1.47 0.538 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 178.623 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 67.4 mttm -94.27 127.03 39.88 Favored 'General case' 0 N--CA 1.481 1.111 0 N-CA-C 109.452 -0.573 . . . . 0.0 109.452 -179.659 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.97 -128.78 0.01 OUTLIER Glycine 0 CA--C 1.527 0.831 0 N-CA-C 110.695 -0.962 . . . . 0.0 110.695 179.339 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.69 125.74 34.72 Favored 'General case' 0 N--CA 1.471 0.612 0 C-N-CA 122.957 0.503 . . . . 0.0 111.057 -179.299 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 36.2 mt -90.56 161.85 2.55 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.781 0 N-CA-C 106.933 -1.506 . . . . 0.0 106.933 178.201 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 40.4 mt -138.85 95.79 0.98 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 CA-C-N 119.485 1.039 . . . . 0.0 109.99 178.475 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 53.7 104.23 0.01 OUTLIER Glycine 0 CA--C 1.531 1.039 0 CA-C-N 116.103 -0.499 . . . . 0.0 114.093 176.818 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 91.9 mt -71.56 154.63 41.32 Favored 'General case' 0 N--CA 1.471 0.576 0 N-CA-C 107.683 -1.228 . . . . 0.0 107.683 176.687 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 2.6 ttp -143.03 140.03 30.8 Favored 'General case' 0 N--CA 1.475 0.815 0 N-CA-C 108.497 -0.927 . . . . 0.0 108.497 178.871 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 68.6 t -159.95 149.37 6.39 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.228 0 N-CA-C 106.567 -1.642 . . . . 0.0 106.567 -179.371 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' I' I ' 37' ' ' GLY . . . . . 0.632 ' H ' ' NE2' ' I' ' 15' ' ' GLN . . . 55.2 74.99 0.26 Allowed Glycine 0 N--CA 1.465 0.617 0 C-N-CA 120.942 -0.647 . . . . 0.0 112.152 177.517 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 173.95 -146.24 8.63 Favored Glycine 0 N--CA 1.465 0.633 0 N-CA-C 110.662 -0.975 . . . . 0.0 110.662 179.354 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 32.8 m -136.73 145.91 29.43 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.93 0 CA-C-N 117.013 0.406 . . . . 0.0 110.172 -179.369 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 20.9 t . . . . . 0 C--O 1.221 -0.42 0 CA-C-O 117.648 -1.168 . . . . 0.0 111.381 179.145 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 8.6 m-20 . . . . . 0 N--CA 1.487 1.413 0 N-CA-C 109.04 -0.726 . . . . 0.0 109.04 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.49 132.45 48.95 Favored 'General case' 0 CA--C 1.539 0.528 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.18 -179.879 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 38.9 tt0 -169.44 108.27 0.42 Allowed 'General case' 0 N--CA 1.47 0.542 0 N-CA-C 109.558 -0.534 . . . . 0.0 109.558 -179.12 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 76.5 m-85 -83.59 140.78 32.02 Favored 'General case' 0 N--CA 1.475 0.791 0 N-CA-C 109.98 -0.378 . . . . 0.0 109.98 179.449 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 73.7 mtp180 -143.71 141.31 30.45 Favored 'General case' 0 N--CA 1.482 1.152 0 N-CA-C 109.045 -0.724 . . . . 0.0 109.045 -179.968 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 76.7 m80 -149.77 119.53 7.05 Favored 'General case' 0 N--CA 1.47 0.548 0 N-CA-C 108.781 -0.822 . . . . 0.0 108.781 179.137 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 -67.84 149.56 49.7 Favored 'General case' 0 N--CA 1.463 0.187 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.179 -179.62 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 7.0 t -167.22 171.28 10.94 Favored 'General case' 0 N--CA 1.473 0.698 0 N-CA-C 109.46 -0.57 . . . . 0.0 109.46 178.496 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.21 24.07 2.29 Favored Glycine 0 N--CA 1.487 2.065 0 N-CA-C 112.125 -0.39 . . . . 0.0 112.125 179.375 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 41.9 p90 -56.78 128.01 34.45 Favored 'General case' 0 N--CA 1.471 0.623 0 N-CA-C 112.106 0.41 . . . . 0.0 112.106 -179.889 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.45 ' CD ' HD21 ' C' ' 27' ' ' ASN . 46.1 mt-10 -84.86 156.09 21.44 Favored 'General case' 0 N--CA 1.468 0.443 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 178.544 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -154.86 124.48 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 N-CA-C 108.119 -1.067 . . . . 0.0 108.119 178.534 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 35.1 m80 -107.33 161.12 15.09 Favored 'General case' 0 N--CA 1.491 1.624 0 CA-C-N 118.455 0.57 . . . . 0.0 111.213 -178.767 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 57.1 t60 -164.66 99.14 0.79 Allowed 'General case' 0 N--CA 1.485 1.289 0 CA-C-N 116.766 -0.197 . . . . 0.0 111.06 179.63 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . 0.694 HE22 ' H ' ' A' ' 37' ' ' GLY . 68.3 mt-30 -125.67 -175.15 3.26 Favored 'General case' 0 CA--C 1.491 -1.301 0 N-CA-C 107.862 -1.162 . . . . 0.0 107.862 -179.99 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -169.7 103.28 0.33 Allowed 'General case' 0 CA--C 1.542 0.644 0 CA-C-N 115.011 -0.995 . . . . 0.0 109.395 179.026 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 9.3 mp -110.75 151.35 27.88 Favored 'General case' 0 N--CA 1.489 1.515 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 -179.932 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 61.6 t -143.98 119.06 4.0 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.245 0 CA-C-O 118.69 -0.671 . . . . 0.0 109.543 179.084 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 17.3 m-85 -70.19 157.2 38.08 Favored 'General case' 0 N--CA 1.477 0.923 0 N-CA-C 107.727 -1.212 . . . . 0.0 107.727 177.542 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 14.6 t80 -170.99 -60.0 0.02 OUTLIER 'General case' 0 N--CA 1.482 1.156 0 CA-C-O 122.315 1.055 . . . . 0.0 109.482 179.278 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.0 89.64 0.0 OUTLIER 'General case' 0 N--CA 1.456 -0.152 0 CA-C-N 113.891 -1.504 . . . . 0.0 112.875 -177.973 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 43.4 mt-10 -61.42 158.22 15.14 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 115.166 -0.924 . . . . 0.0 110.782 179.037 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 12.0 m-20 -139.98 135.26 32.55 Favored 'General case' 0 N--CA 1.483 1.21 0 C-N-CA 122.769 0.427 . . . . 0.0 110.399 -179.956 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 18.1 t -84.34 -115.98 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.475 0.802 0 N-CA-C 108.35 -0.981 . . . . 0.0 108.35 179.355 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -109.32 54.25 0.55 Allowed Glycine 0 N--CA 1.473 1.112 0 N-CA-C 111.254 -0.738 . . . . 0.0 111.254 -179.986 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 82.8 p -77.49 126.96 31.72 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 109.0 -0.741 . . . . 0.0 109.0 178.469 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . 0.462 HD21 ' CD ' ' B' ' 11' ' ' GLU . 47.5 t30 -66.7 100.92 0.74 Allowed 'General case' 0 N--CA 1.471 0.599 0 N-CA-C 108.611 -0.885 . . . . 0.0 108.611 178.593 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 67.2 mttm -95.3 128.88 42.51 Favored 'General case' 0 N--CA 1.481 1.089 0 N-CA-C 109.812 -0.44 . . . . 0.0 109.812 -179.155 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.71 -132.12 0.01 OUTLIER Glycine 0 CA--C 1.533 1.203 0 N-CA-C 110.775 -0.93 . . . . 0.0 110.775 178.907 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.77 126.91 37.6 Favored 'General case' 0 N--CA 1.484 1.237 0 CA-C-N 117.097 0.448 . . . . 0.0 110.016 179.345 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 33.0 mt -91.31 159.17 2.83 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.496 0 N-CA-C 106.631 -1.618 . . . . 0.0 106.631 178.416 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 42.9 mt -138.25 92.86 0.83 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.468 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 -178.972 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 54.05 106.23 0.01 OUTLIER Glycine 0 CA--C 1.53 1.002 0 CA-C-N 115.933 -0.576 . . . . 0.0 114.162 177.239 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 97.9 mt -72.26 153.5 41.52 Favored 'General case' 0 CA--C 1.539 0.536 0 N-CA-C 107.27 -1.382 . . . . 0.0 107.27 176.703 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 27.2 ttt -147.07 138.34 24.01 Favored 'General case' 0 N--CA 1.477 0.879 0 N-CA-C 108.761 -0.829 . . . . 0.0 108.761 179.147 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 61.9 t -159.69 153.51 5.02 Favored 'Isoleucine or valine' 0 C--N 1.342 0.262 0 N-CA-C 106.596 -1.631 . . . . 0.0 106.596 -179.279 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . 0.694 ' H ' HE22 ' A' ' 15' ' ' GLN . . . 55.98 73.56 0.42 Allowed Glycine 0 C--N 1.313 -0.697 0 N-CA-C 111.663 -0.575 . . . . 0.0 111.663 177.987 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 174.65 -161.58 31.34 Favored Glycine 0 C--N 1.335 0.483 0 N-CA-C 111.086 -0.806 . . . . 0.0 111.086 -179.828 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 23.5 m -124.29 139.63 50.04 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.951 0 C-N-CA 122.762 0.425 . . . . 0.0 110.084 179.744 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 26.1 t . . . . . 0 C--O 1.221 -0.447 0 CA-C-O 117.635 -1.174 . . . . 0.0 111.108 179.37 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' B' B ' 1' ' ' ASP . . . . . . . . . . . . . 8.7 m-20 . . . . . 0 N--CA 1.488 1.461 0 N-CA-C 109.144 -0.687 . . . . 0.0 109.144 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' B' B ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.3 132.35 48.82 Favored 'General case' 0 CA--C 1.538 0.507 0 CA-C-N 116.385 -0.371 . . . . 0.0 110.234 -179.852 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 3' ' ' GLU . . . . . . . . . . . . . 39.1 tt0 -169.29 108.36 0.43 Allowed 'General case' 0 N--CA 1.469 0.509 0 N-CA-C 109.569 -0.53 . . . . 0.0 109.569 -179.153 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 77.0 m-85 -83.6 140.88 31.94 Favored 'General case' 0 N--CA 1.474 0.76 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 179.44 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 73.5 mtp180 -143.69 141.32 30.47 Favored 'General case' 0 N--CA 1.48 1.055 0 N-CA-C 109.092 -0.707 . . . . 0.0 109.092 -179.972 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 76.7 m80 -149.83 119.49 7.01 Favored 'General case' 0 N--CA 1.472 0.627 0 N-CA-C 108.93 -0.767 . . . . 0.0 108.93 179.104 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 7' ' ' ASP . . . . . . . . . . . . . 9.6 m-20 -67.77 149.4 49.97 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.196 -179.609 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 8' ' ' SER . . . . . . . . . . . . . 7.0 t -167.15 171.4 10.93 Favored 'General case' 0 N--CA 1.473 0.676 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 178.451 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.11 24.06 2.32 Favored Glycine 0 N--CA 1.487 2.072 0 N-CA-C 112.05 -0.42 . . . . 0.0 112.05 179.38 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 41.4 p90 -56.75 128.15 35.11 Favored 'General case' 0 N--CA 1.472 0.669 0 N-CA-C 112.071 0.397 . . . . 0.0 112.071 -179.834 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 11' ' ' GLU . . . . . 0.462 ' CD ' HD21 ' A' ' 27' ' ' ASN . 45.7 mt-10 -84.99 155.63 21.49 Favored 'General case' 0 N--CA 1.47 0.557 0 N-CA-C 109.268 -0.642 . . . . 0.0 109.268 178.589 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -154.47 124.35 0.78 Allowed 'Isoleucine or valine' 0 C--O 1.234 0.249 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 178.538 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 34.2 m80 -107.27 161.2 15.0 Favored 'General case' 0 N--CA 1.491 1.585 0 CA-C-N 118.41 0.55 . . . . 0.0 111.155 -178.774 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 58.2 t60 -164.72 98.87 0.78 Allowed 'General case' 0 N--CA 1.485 1.301 0 CA-C-O 119.64 -0.219 . . . . 0.0 111.001 179.636 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . 0.717 HE22 ' H ' ' B' ' 37' ' ' GLY . 68.3 mt-30 -125.19 -175.48 3.32 Favored 'General case' 0 CA--C 1.492 -1.275 0 N-CA-C 107.832 -1.173 . . . . 0.0 107.832 179.995 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -169.62 103.13 0.33 Allowed 'General case' 0 CA--C 1.541 0.6 0 CA-C-N 114.944 -1.025 . . . . 0.0 109.334 179.023 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 9.4 mp -110.67 151.23 27.94 Favored 'General case' 0 N--CA 1.489 1.507 0 N-CA-C 108.695 -0.854 . . . . 0.0 108.695 -179.951 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 61.9 t -143.92 118.77 3.91 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.139 0 CA-C-O 118.748 -0.644 . . . . 0.0 109.561 179.07 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 16.6 m-85 -70.45 157.17 38.31 Favored 'General case' 0 N--CA 1.475 0.798 0 N-CA-C 107.638 -1.245 . . . . 0.0 107.638 177.413 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 15.8 t80 -171.66 -59.06 0.02 OUTLIER 'General case' 0 N--CA 1.479 1.007 0 CA-C-O 122.261 1.029 . . . . 0.0 109.619 179.23 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.21 89.88 0.0 OUTLIER 'General case' 0 C--O 1.231 0.112 0 CA-C-N 114.051 -1.431 . . . . 0.0 112.764 -178.108 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 43.8 mt-10 -61.53 158.38 15.13 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 115.276 -0.875 . . . . 0.0 110.828 179.095 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 12.2 m-20 -140.25 135.6 32.48 Favored 'General case' 0 N--CA 1.483 1.196 0 C-N-CA 122.793 0.437 . . . . 0.0 110.416 179.955 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 18.1 t -84.97 -116.1 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.906 0 N-CA-C 108.408 -0.96 . . . . 0.0 108.408 179.499 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -108.45 53.65 0.59 Allowed Glycine 0 N--CA 1.476 1.366 0 N-CA-C 111.083 -0.807 . . . . 0.0 111.083 -179.909 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 86.0 p -77.35 126.58 31.15 Favored 'General case' 0 C--N 1.329 -0.294 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 178.409 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 27' ' ' ASN . . . . . 0.459 HD21 ' CD ' ' C' ' 11' ' ' GLU . 47.5 t30 -66.74 100.98 0.75 Allowed 'General case' 0 N--CA 1.471 0.608 0 N-CA-C 108.593 -0.892 . . . . 0.0 108.593 178.672 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 67.1 mttm -95.3 128.91 42.52 Favored 'General case' 0 N--CA 1.481 1.121 0 N-CA-C 109.972 -0.381 . . . . 0.0 109.972 -179.226 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.77 -131.63 0.01 OUTLIER Glycine 0 CA--C 1.535 1.33 0 N-CA-C 110.746 -0.942 . . . . 0.0 110.746 178.904 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -131.18 127.12 37.31 Favored 'General case' 0 N--CA 1.485 1.304 0 C-N-CA 122.704 0.402 . . . . 0.0 110.081 179.431 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 32.8 mt -91.75 158.79 2.86 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.538 0 N-CA-C 106.602 -1.629 . . . . 0.0 106.602 178.516 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 43.1 mt -137.81 92.89 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.502 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 -178.816 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 53.85 106.17 0.01 OUTLIER Glycine 0 CA--C 1.53 0.993 0 CA-C-N 116.021 -0.536 . . . . 0.0 114.212 177.237 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 97.7 mt -72.12 153.4 41.69 Favored 'General case' 0 CA--C 1.539 0.53 0 N-CA-C 107.364 -1.346 . . . . 0.0 107.364 176.651 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 27.1 ttt -146.82 138.05 24.16 Favored 'General case' 0 N--CA 1.478 0.954 0 N-CA-C 108.701 -0.851 . . . . 0.0 108.701 179.21 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 62.3 t -159.54 153.47 5.14 Favored 'Isoleucine or valine' 0 C--N 1.344 0.356 0 N-CA-C 106.52 -1.659 . . . . 0.0 106.52 -179.273 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . 0.717 ' H ' HE22 ' B' ' 15' ' ' GLN . . . 56.03 73.23 0.45 Allowed Glycine 0 C--N 1.313 -0.696 0 N-CA-C 111.686 -0.566 . . . . 0.0 111.686 178.005 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 174.98 -161.5 30.92 Favored Glycine 0 C--N 1.334 0.43 0 N-CA-C 111.056 -0.818 . . . . 0.0 111.056 -179.865 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 24.1 m -124.4 139.6 50.21 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.929 0 C-N-CA 122.751 0.421 . . . . 0.0 110.072 179.695 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 26.5 t . . . . . 0 C--O 1.219 -0.52 0 CA-C-O 117.651 -1.166 . . . . 0.0 111.054 179.381 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' C' C ' 1' ' ' ASP . . . . . . . . . . . . . 9.0 m-20 . . . . . 0 N--CA 1.489 1.5 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' C' C ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.28 132.42 49.01 Favored 'General case' 0 CA--C 1.538 0.519 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.181 -179.791 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 3' ' ' GLU . . . . . . . . . . . . . 39.0 tt0 -169.42 108.42 0.42 Allowed 'General case' 0 N--CA 1.47 0.55 0 N-CA-C 109.657 -0.497 . . . . 0.0 109.657 -179.2 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 77.1 m-85 -83.77 140.88 31.8 Favored 'General case' 0 N--CA 1.474 0.75 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 179.495 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 73.7 mtp180 -143.72 141.24 30.4 Favored 'General case' 0 N--CA 1.482 1.141 0 N-CA-C 109.005 -0.739 . . . . 0.0 109.005 -179.858 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 76.8 m80 -149.9 119.39 6.92 Favored 'General case' 0 N--CA 1.471 0.594 0 N-CA-C 108.798 -0.816 . . . . 0.0 108.798 179.159 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 7' ' ' ASP . . . . . . . . . . . . . 9.0 m-20 -67.71 149.29 50.17 Favored 'General case' 0 N--CA 1.463 0.218 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.244 -179.562 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 8' ' ' SER . . . . . . . . . . . . . 6.7 t -167.12 171.15 11.21 Favored 'General case' 0 N--CA 1.472 0.652 0 N-CA-C 109.502 -0.555 . . . . 0.0 109.502 178.424 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.49 23.92 2.26 Favored Glycine 0 N--CA 1.487 2.034 0 N-CA-C 111.968 -0.453 . . . . 0.0 111.968 179.38 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 41.5 p90 -56.61 128.16 34.93 Favored 'General case' 0 N--CA 1.471 0.614 0 N-CA-C 112.07 0.396 . . . . 0.0 112.07 -179.85 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 11' ' ' GLU . . . . . 0.459 ' CD ' HD21 ' B' ' 27' ' ' ASN . 45.9 mt-10 -85.02 155.97 21.32 Favored 'General case' 0 N--CA 1.47 0.535 0 N-CA-C 109.24 -0.652 . . . . 0.0 109.24 178.592 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -154.76 124.54 0.76 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 N-CA-C 108.168 -1.049 . . . . 0.0 108.168 178.525 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 33.9 m80 -107.39 161.23 15.0 Favored 'General case' 0 N--CA 1.49 1.573 0 CA-C-N 118.397 0.544 . . . . 0.0 111.181 -178.717 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 57.3 t60 -164.83 99.22 0.77 Allowed 'General case' 0 N--CA 1.485 1.286 0 CA-C-N 116.77 -0.196 . . . . 0.0 111.094 179.651 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 15' ' ' GLN . . . . . 0.717 HE22 ' H ' ' C' ' 37' ' ' GLY . 68.1 mt-30 -125.79 -175.34 3.32 Favored 'General case' 0 CA--C 1.489 -1.373 0 N-CA-C 107.904 -1.147 . . . . 0.0 107.904 -179.957 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -169.64 103.19 0.33 Allowed 'General case' 0 CA--C 1.541 0.624 0 CA-C-N 114.888 -1.051 . . . . 0.0 109.331 179.062 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 9.4 mp -110.67 150.92 28.32 Favored 'General case' 0 N--CA 1.488 1.441 0 N-CA-C 108.712 -0.848 . . . . 0.0 108.712 179.968 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 61.1 t -143.66 118.97 4.29 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.175 0 CA-C-O 118.765 -0.636 . . . . 0.0 109.61 179.029 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 16.6 m-85 -70.49 157.28 38.14 Favored 'General case' 0 N--CA 1.475 0.802 0 N-CA-C 107.664 -1.236 . . . . 0.0 107.664 177.436 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 15.4 t80 -171.59 -59.31 0.02 OUTLIER 'General case' 0 N--CA 1.478 0.953 0 CA-C-O 122.259 1.028 . . . . 0.0 109.642 179.195 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.12 89.96 0.0 OUTLIER 'General case' 0 C--O 1.231 0.11 0 CA-C-N 114.041 -1.436 . . . . 0.0 112.753 -178.076 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 43.9 mt-10 -61.6 158.23 15.68 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-N 115.219 -0.9 . . . . 0.0 110.833 179.047 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 12.3 m-20 -139.92 135.9 33.32 Favored 'General case' 0 N--CA 1.483 1.199 0 C-N-CA 122.861 0.464 . . . . 0.0 110.343 -179.977 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 18.2 t -85.27 -116.01 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.902 0 N-CA-C 108.414 -0.958 . . . . 0.0 108.414 179.444 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -108.58 53.42 0.6 Allowed Glycine 0 N--CA 1.475 1.257 0 N-CA-C 111.107 -0.797 . . . . 0.0 111.107 -179.918 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 85.9 p -77.3 126.73 31.4 Favored 'General case' 0 C--N 1.329 -0.32 0 N-CA-C 109.122 -0.695 . . . . 0.0 109.122 178.508 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 27' ' ' ASN . . . . . 0.45 HD21 ' CD ' ' A' ' 11' ' ' GLU . 47.3 t30 -66.79 101.11 0.77 Allowed 'General case' 0 N--CA 1.471 0.582 0 N-CA-C 108.633 -0.877 . . . . 0.0 108.633 178.625 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 67.1 mttm -95.34 128.99 42.63 Favored 'General case' 0 N--CA 1.483 1.2 0 N-CA-C 109.886 -0.413 . . . . 0.0 109.886 -179.117 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.84 -131.85 0.01 OUTLIER Glycine 0 CA--C 1.535 1.293 0 N-CA-C 110.858 -0.897 . . . . 0.0 110.858 178.844 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.96 126.66 36.63 Favored 'General case' 0 N--CA 1.486 1.356 0 C-N-CA 122.822 0.449 . . . . 0.0 110.003 179.456 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 32.5 mt -91.33 158.81 2.86 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.525 0 N-CA-C 106.684 -1.599 . . . . 0.0 106.684 178.334 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 42.5 mt -137.99 92.89 0.86 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.505 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 -178.799 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 53.93 106.09 0.01 OUTLIER Glycine 0 CA--C 1.529 0.966 0 CA-C-N 115.921 -0.581 . . . . 0.0 114.257 177.229 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 97.6 mt -72.05 153.3 41.82 Favored 'General case' 0 CA--C 1.537 0.461 0 N-CA-C 107.328 -1.36 . . . . 0.0 107.328 176.655 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 27.3 ttt -146.63 138.09 24.42 Favored 'General case' 0 N--CA 1.477 0.891 0 N-CA-C 108.74 -0.837 . . . . 0.0 108.74 179.214 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 61.1 t -159.57 153.56 5.07 Favored 'Isoleucine or valine' 0 C--N 1.345 0.372 0 N-CA-C 106.566 -1.642 . . . . 0.0 106.566 -179.251 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 37' ' ' GLY . . . . . 0.717 ' H ' HE22 ' C' ' 15' ' ' GLN . . . 55.89 73.15 0.46 Allowed Glycine 0 C--N 1.314 -0.671 0 N-CA-C 111.626 -0.59 . . . . 0.0 111.626 177.951 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 175.03 -161.75 31.24 Favored Glycine 0 C--N 1.335 0.479 0 N-CA-C 111.054 -0.818 . . . . 0.0 111.054 -179.865 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 23.5 m -124.2 139.67 49.88 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.923 0 C-N-CA 122.785 0.434 . . . . 0.0 110.054 179.727 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 27.7 t . . . . . 0 C--O 1.221 -0.424 0 CA-C-O 117.655 -1.164 . . . . 0.0 110.98 179.336 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' D' D ' 1' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 . . . . . 0 N--CA 1.49 1.565 0 N-CA-C 109.196 -0.668 . . . . 0.0 109.196 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' D' D ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.29 130.96 45.9 Favored 'General case' 0 CA--C 1.535 0.4 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.369 179.931 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' D' D ' 3' ' ' GLU . . . . . . . . . . . . . 38.7 tt0 -169.3 110.97 0.48 Allowed 'General case' 0 N--CA 1.47 0.534 0 N-CA-C 109.196 -0.668 . . . . 0.0 109.196 179.524 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 85.9 m-85 -87.31 148.61 24.99 Favored 'General case' 0 C--N 1.366 1.285 0 C-N-CA 118.584 -1.246 . . . . 0.0 108.113 179.765 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' D' D ' 5' ' ' ARG . . . . . . . . . . . . . 73.9 mtp180 -147.52 141.05 25.45 Favored 'General case' 0 N--CA 1.473 0.7 0 N-CA-C 108.967 -0.753 . . . . 0.0 108.967 179.637 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 77.0 m80 -149.2 123.55 9.62 Favored 'General case' 0 CA--C 1.539 0.519 0 N-CA-C 107.926 -1.138 . . . . 0.0 107.926 175.967 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' D' D ' 7' ' ' ASP . . . . . . . . . . . . . 6.3 m-20 -63.42 133.41 53.94 Favored 'General case' 0 C--N 1.32 -0.688 0 C-N-CA 126.937 2.095 . . . . 0.0 114.798 176.152 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' D' D ' 8' ' ' SER . . . . . . . . . . . . . 5.9 t -154.04 173.52 15.91 Favored 'General case' 0 N--CA 1.477 0.925 0 CA-C-N 118.548 0.613 . . . . 0.0 110.443 176.799 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 124.23 20.38 2.47 Favored Glycine 0 N--CA 1.484 1.864 0 N-CA-C 111.99 -0.444 . . . . 0.0 111.99 176.203 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 37.2 p90 -55.67 130.32 42.67 Favored 'General case' 0 CA--C 1.545 0.753 0 CA-C-O 121.103 0.478 . . . . 0.0 111.914 -177.388 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' D' D ' 11' ' ' GLU . . . . . 0.487 ' CG ' HD21 ' F' ' 27' ' ' ASN . 46.0 mt-10 -84.87 153.77 22.69 Favored 'General case' 0 N--CA 1.472 0.64 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 177.886 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.0 p -150.91 129.01 2.57 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.594 0 N-CA-C 106.937 -1.505 . . . . 0.0 106.937 172.73 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 24.6 m80 -100.86 161.98 13.22 Favored 'General case' 0 N--CA 1.481 1.116 0 C-N-CA 123.911 0.884 . . . . 0.0 113.168 176.722 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 61.0 t60 -165.0 105.27 0.79 Allowed 'General case' 0 N--CA 1.486 1.354 0 N-CA-C 109.694 -0.484 . . . . 0.0 109.694 172.242 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' D' D ' 15' ' ' GLN . . . . . 0.716 HE22 ' H ' ' D' ' 37' ' ' GLY . 69.1 mt-30 -128.59 -176.33 3.8 Favored 'General case' 0 CA--C 1.485 -1.534 0 N-CA-C 107.255 -1.387 . . . . 0.0 107.255 178.892 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 88.8 tttt -166.87 109.51 0.7 Allowed 'General case' 0 C--O 1.238 0.487 0 N-CA-C 107.926 -1.139 . . . . 0.0 107.926 176.779 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 10.5 mp -115.69 153.16 31.85 Favored 'General case' 0 N--CA 1.489 1.502 0 N-CA-C 107.198 -1.408 . . . . 0.0 107.198 178.205 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 52.5 t -141.95 124.03 13.61 Favored 'Isoleucine or valine' 0 C--N 1.362 1.152 0 N-CA-C 108.668 -0.864 . . . . 0.0 108.668 174.283 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 16.0 m-85 -62.62 150.81 39.77 Favored 'General case' 0 C--N 1.348 0.513 0 C-N-CA 124.308 1.043 . . . . 0.0 110.719 169.695 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 11.3 t80 -170.51 -67.22 0.02 OUTLIER 'General case' 0 N--CA 1.475 0.788 0 N-CA-C 107.983 -1.117 . . . . 0.0 107.983 178.55 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -38.61 94.99 0.01 OUTLIER 'General case' 0 N--CA 1.451 -0.403 0 CA-C-N 113.855 -1.521 . . . . 0.0 111.586 -175.866 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 45.8 mt-10 -64.47 159.09 22.21 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 114.293 -1.321 . . . . 0.0 110.504 178.491 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 12.2 m-20 -139.87 139.47 36.27 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-O 121.253 0.549 . . . . 0.0 109.637 178.609 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' D' D ' 24' ' ' VAL . . . . . . . . . . . . . 19.4 t -88.17 -119.86 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.483 1.217 0 N-CA-C 107.597 -1.26 . . . . 0.0 107.597 179.58 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . -111.47 61.8 0.3 Allowed Glycine 0 C--N 1.368 2.359 0 C-N-CA 118.222 -1.942 . . . . 0.0 109.206 178.763 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 92.8 p -68.04 121.59 16.44 Favored 'General case' 0 C--O 1.24 0.595 0 CA-C-O 116.453 -1.737 . . . . 0.0 112.517 168.985 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' D' D ' 27' ' ' ASN . . . . . 0.444 HD21 ' CG ' ' E' ' 11' ' ' GLU . 53.8 t30 -62.52 101.79 0.27 Allowed 'General case' 0 N--CA 1.474 0.765 0 CA-C-N 121.603 2.001 . . . . 0.0 109.453 173.65 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 66.8 mttm -96.84 128.28 43.64 Favored 'General case' 0 N--CA 1.487 1.387 0 CA-C-N 118.842 0.746 . . . . 0.0 109.35 178.996 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -55.21 -134.81 0.0 OUTLIER Glycine 0 CA--C 1.532 1.135 0 C-N-CA 123.793 0.711 . . . . 0.0 112.343 174.925 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -129.42 130.96 46.62 Favored 'General case' 0 C--N 1.371 1.507 0 CA-C-N 115.022 -0.589 . . . . 0.0 110.121 176.231 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 38.8 mt -91.64 161.75 2.52 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.338 0 N-CA-C 106.148 -1.797 . . . . 0.0 106.148 177.499 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . 0.28 43.1 mt -141.01 105.06 1.57 Allowed 'Isoleucine or valine' 0 C--N 1.363 1.191 0 N-CA-C 106.231 -1.766 . . . . 0.0 106.231 172.511 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.6 98.11 0.01 OUTLIER Glycine 0 CA--C 1.533 1.21 0 CA-C-O 116.312 -2.382 . . . . 0.0 112.198 169.074 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 97.0 mt -70.0 157.61 37.17 Favored 'General case' 0 CA--C 1.539 0.55 0 CA-C-N 122.355 3.078 . . . . 0.0 107.217 176.055 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 26.1 ttt -147.18 148.92 32.02 Favored 'General case' 0 N--CA 1.482 1.161 0 N-CA-C 106.373 -1.714 . . . . 0.0 106.373 174.269 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 88.5 t -165.22 159.14 1.18 Allowed 'Isoleucine or valine' 0 C--O 1.248 1.004 0 N-CA-C 105.302 -2.11 . . . . 0.0 105.302 177.15 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' D' D ' 37' ' ' GLY . . . . . 0.716 ' H ' HE22 ' D' ' 15' ' ' GLN . . . 60.54 64.84 3.77 Favored Glycine 0 N--CA 1.442 -0.917 0 C-N-CA 117.24 -2.41 . . . . 0.0 113.756 174.581 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' D' D ' 38' ' ' GLY . . . . . 0.407 ' HA3' ' O ' ' G' ' 38' ' ' GLY . . . 169.8 -160.7 33.85 Favored Glycine 0 N--CA 1.47 0.956 0 CA-C-O 117.808 -1.551 . . . . 0.0 112.304 -178.987 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 23.2 m -120.37 139.31 48.06 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.256 0 CA-C-N 118.829 1.315 . . . . 0.0 110.348 -177.003 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 25.4 t . . . . . 0 C--O 1.203 -1.35 0 CA-C-N 118.211 0.46 . . . . 0.0 110.102 173.766 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' E' E ' 1' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 . . . . . 0 N--CA 1.488 1.454 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' E' E ' 2' ' ' ALA . . . . . . . . . . . . . . . -63.86 131.1 46.72 Favored 'General case' 0 N--CA 1.468 0.468 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.375 179.862 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' E' E ' 3' ' ' GLU . . . . . . . . . . . . . 38.6 tt0 -169.04 108.43 0.45 Allowed 'General case' 0 N--CA 1.47 0.54 0 N-CA-C 109.906 -0.405 . . . . 0.0 109.906 -179.811 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 77.8 m-85 -84.47 140.91 31.16 Favored 'General case' 0 N--CA 1.475 0.812 0 N-CA-C 109.904 -0.406 . . . . 0.0 109.904 179.451 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' E' E ' 5' ' ' ARG . . . . . . . . . . . . . 74.1 mtp180 -143.55 141.72 30.81 Favored 'General case' 0 N--CA 1.476 0.837 0 N-CA-C 109.388 -0.597 . . . . 0.0 109.388 179.875 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 76.7 m80 -150.31 118.57 6.38 Favored 'General case' 0 N--CA 1.471 0.62 0 N-CA-C 108.994 -0.743 . . . . 0.0 108.994 179.215 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' E' E ' 7' ' ' ASP . . . . . . . . . . . . . 8.6 m-20 -66.82 149.48 50.51 Favored 'General case' 0 N--CA 1.464 0.24 0 O-C-N 123.388 0.43 . . . . 0.0 111.608 -179.552 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' E' E ' 8' ' ' SER . . . . . . . . . . . . . 6.0 t -167.63 171.72 9.98 Favored 'General case' 0 N--CA 1.477 0.878 0 CA-C-N 115.938 -0.574 . . . . 0.0 109.606 178.077 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 123.22 23.91 2.09 Favored Glycine 0 N--CA 1.482 1.754 0 N-CA-C 111.843 -0.503 . . . . 0.0 111.843 179.078 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 37.4 p90 -56.29 127.33 30.36 Favored 'General case' 0 N--CA 1.472 0.674 0 N-CA-C 112.621 0.6 . . . . 0.0 112.621 -179.283 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' E' E ' 11' ' ' GLU . . . . . 0.444 ' CG ' HD21 ' D' ' 27' ' ' ASN . 46.0 mt-10 -83.36 156.77 22.83 Favored 'General case' 0 N--CA 1.476 0.856 0 N-CA-C 109.489 -0.56 . . . . 0.0 109.489 177.973 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -156.54 122.89 0.54 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.646 0 N-CA-C 108.324 -0.991 . . . . 0.0 108.324 178.257 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 36.5 m80 -106.88 160.24 15.66 Favored 'General case' 0 N--CA 1.482 1.135 0 C-N-CA 122.855 0.462 . . . . 0.0 111.238 -177.944 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 58.1 t60 -164.61 99.18 0.79 Allowed 'General case' 0 N--CA 1.487 1.38 0 CA-C-N 116.859 -0.155 . . . . 0.0 111.013 -179.842 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' E' E ' 15' ' ' GLN . . . . . 0.695 HE22 ' H ' ' E' ' 37' ' ' GLY . 69.3 mt-30 -125.42 -175.06 3.22 Favored 'General case' 0 CA--C 1.492 -1.263 0 N-CA-C 107.835 -1.172 . . . . 0.0 107.835 -179.98 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -169.54 103.85 0.34 Allowed 'General case' 0 CA--C 1.54 0.591 0 CA-C-N 114.9 -1.045 . . . . 0.0 109.109 179.015 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 9.6 mp -111.03 150.16 29.7 Favored 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 -179.639 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 46.1 t -144.04 118.17 3.52 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.22 0 CA-C-O 118.928 -0.558 . . . . 0.0 109.903 178.646 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 19.7 m-85 -69.32 155.27 40.7 Favored 'General case' 0 C--N 1.357 0.908 0 N-CA-C 107.569 -1.271 . . . . 0.0 107.569 176.798 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 14.0 t80 -173.41 -56.94 0.02 OUTLIER 'General case' 0 N--CA 1.48 1.072 0 CA-C-O 121.624 0.726 . . . . 0.0 110.136 179.163 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -42.74 88.48 0.0 OUTLIER 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 114.425 -1.261 . . . . 0.0 112.76 -179.051 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 44.4 mt-10 -60.11 158.37 11.36 Favored 'General case' 0 N--CA 1.471 0.619 0 CA-C-N 115.039 -0.982 . . . . 0.0 110.944 179.535 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 11.7 m-20 -140.34 135.02 31.75 Favored 'General case' 0 N--CA 1.483 1.183 0 C-N-CA 122.653 0.381 . . . . 0.0 110.687 -179.829 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 21.4 t -84.55 -115.51 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.939 0 N-CA-C 108.61 -0.885 . . . . 0.0 108.61 179.416 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . -108.65 53.65 0.58 Allowed Glycine 0 C--N 1.347 1.139 0 N-CA-C 111.317 -0.713 . . . . 0.0 111.317 -179.91 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 86.1 p -77.15 126.37 30.84 Favored 'General case' 0 N--CA 1.471 0.577 0 N-CA-C 109.336 -0.616 . . . . 0.0 109.336 178.259 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' E' E ' 27' ' ' ASN . . . . . 0.465 HD21 ' CG ' ' F' ' 11' ' ' GLU . 49.2 t30 -66.22 100.64 0.63 Allowed 'General case' 0 N--CA 1.471 0.612 0 N-CA-C 108.079 -1.082 . . . . 0.0 108.079 178.442 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 66.5 mttm -95.39 127.67 41.62 Favored 'General case' 0 N--CA 1.483 1.182 0 N-CA-C 109.305 -0.628 . . . . 0.0 109.305 -179.15 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.36 -128.93 0.01 OUTLIER Glycine 0 CA--C 1.537 1.462 0 N-CA-C 111.013 -0.835 . . . . 0.0 111.013 179.163 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -131.67 127.1 36.24 Favored 'General case' 0 N--CA 1.484 1.236 0 CA-C-N 117.307 0.554 . . . . 0.0 110.939 -179.62 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 31.2 mt -91.09 160.4 2.71 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.238 0 N-CA-C 106.338 -1.727 . . . . 0.0 106.338 178.306 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 41.6 mt -139.29 93.69 0.78 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.766 0 N-CA-C 109.653 -0.499 . . . . 0.0 109.653 179.879 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 53.54 105.96 0.01 OUTLIER Glycine 0 CA--C 1.531 1.053 0 CA-C-N 116.11 -0.495 . . . . 0.0 114.157 177.603 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 97.7 mt -72.03 153.72 41.58 Favored 'General case' 0 CA--C 1.542 0.636 0 N-CA-C 107.206 -1.405 . . . . 0.0 107.206 176.523 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 27.6 ttt -146.41 140.23 26.16 Favored 'General case' 0 N--CA 1.485 1.285 0 N-CA-C 108.005 -1.109 . . . . 0.0 108.005 178.841 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 80.2 t -161.18 152.86 4.31 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.389 0 N-CA-C 106.358 -1.719 . . . . 0.0 106.358 -179.208 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' E' E ' 37' ' ' GLY . . . . . 0.695 ' H ' HE22 ' E' ' 15' ' ' GLN . . . 55.56 73.81 0.39 Allowed Glycine 0 C--N 1.316 -0.54 0 N-CA-C 111.633 -0.587 . . . . 0.0 111.633 178.199 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 175.91 -159.34 26.79 Favored Glycine 0 C--O 1.213 -1.166 0 N-CA-C 111.313 -0.715 . . . . 0.0 111.313 -179.708 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 23.7 m -127.16 138.81 53.71 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.83 0 N-CA-C 109.332 -0.618 . . . . 0.0 109.332 179.776 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 27.6 t . . . . . 0 CA--C 1.537 0.453 0 CA-C-O 117.986 -1.007 . . . . 0.0 111.106 179.739 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' F' F ' 1' ' ' ASP . . . . . . . . . . . . . 9.3 m-20 . . . . . 0 N--CA 1.49 1.561 0 N-CA-C 109.106 -0.701 . . . . 0.0 109.106 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' F' F ' 2' ' ' ALA . . . . . . . . . . . . . . . -63.79 131.05 46.62 Favored 'General case' 0 N--CA 1.468 0.432 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.47 179.85 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' F' F ' 3' ' ' GLU . . . . . . . . . . . . . 38.7 tt0 -168.99 108.54 0.46 Allowed 'General case' 0 N--CA 1.469 0.513 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 -179.861 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 77.7 m-85 -84.53 140.85 31.15 Favored 'General case' 0 N--CA 1.476 0.831 0 N-CA-C 109.91 -0.404 . . . . 0.0 109.91 179.353 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' F' F ' 5' ' ' ARG . . . . . . . . . . . . . 74.2 mtp180 -143.54 141.39 30.68 Favored 'General case' 0 N--CA 1.479 1.023 0 N-CA-C 109.07 -0.715 . . . . 0.0 109.07 179.933 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 76.8 m80 -150.08 118.48 6.46 Favored 'General case' 0 N--CA 1.472 0.658 0 N-CA-C 108.957 -0.757 . . . . 0.0 108.957 179.139 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' F' F ' 7' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -66.97 149.79 50.14 Favored 'General case' 0 N--CA 1.463 0.21 0 O-C-N 123.434 0.459 . . . . 0.0 111.632 -179.366 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' F' F ' 8' ' ' SER . . . . . . . . . . . . . 6.1 t -167.73 172.27 9.37 Favored 'General case' 0 N--CA 1.476 0.869 0 CA-C-N 115.885 -0.598 . . . . 0.0 109.564 178.068 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.76 23.64 2.24 Favored Glycine 0 N--CA 1.483 1.789 0 N-CA-C 111.903 -0.479 . . . . 0.0 111.903 179.003 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 37.6 p90 -56.1 127.47 30.74 Favored 'General case' 0 N--CA 1.473 0.679 0 N-CA-C 112.615 0.598 . . . . 0.0 112.615 -179.296 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' F' F ' 11' ' ' GLU . . . . . 0.465 ' CG ' HD21 ' E' ' 27' ' ' ASN . 45.9 mt-10 -83.45 156.79 22.72 Favored 'General case' 0 N--CA 1.477 0.875 0 N-CA-C 109.514 -0.55 . . . . 0.0 109.514 177.994 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -156.45 122.75 0.54 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.696 0 N-CA-C 108.297 -1.001 . . . . 0.0 108.297 178.274 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 37.5 m80 -106.65 160.36 15.51 Favored 'General case' 0 N--CA 1.483 1.218 0 C-N-CA 122.8 0.44 . . . . 0.0 111.294 -177.997 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 58.7 t60 -164.86 99.65 0.77 Allowed 'General case' 0 N--CA 1.486 1.374 0 CA-C-N 116.865 -0.152 . . . . 0.0 111.131 -179.775 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' F' F ' 15' ' ' GLN . . . . . 0.703 HE22 ' H ' ' F' ' 37' ' ' GLY . 69.3 mt-30 -126.15 -174.68 3.16 Favored 'General case' 0 CA--C 1.488 -1.428 0 N-CA-C 108.02 -1.104 . . . . 0.0 108.02 -179.893 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -169.86 103.93 0.32 Allowed 'General case' 0 CA--C 1.541 0.61 0 CA-C-N 114.677 -1.147 . . . . 0.0 109.218 178.969 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 9.6 mp -110.93 149.92 29.96 Favored 'General case' 0 N--CA 1.489 1.518 0 N-CA-C 108.933 -0.766 . . . . 0.0 108.933 -179.704 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 46.3 t -143.85 118.32 3.77 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.223 0 CA-C-O 118.975 -0.536 . . . . 0.0 109.827 178.653 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 19.5 m-85 -69.4 155.15 40.92 Favored 'General case' 0 C--N 1.358 0.96 0 N-CA-C 107.506 -1.294 . . . . 0.0 107.506 176.721 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 14.9 t80 -173.13 -57.1 0.02 OUTLIER 'General case' 0 N--CA 1.483 1.198 0 CA-C-O 121.564 0.697 . . . . 0.0 109.613 179.245 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -42.52 88.47 0.0 OUTLIER 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 114.716 -1.129 . . . . 0.0 112.856 -179.015 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 44.1 mt-10 -60.28 158.2 12.1 Favored 'General case' 0 N--CA 1.472 0.643 0 CA-C-N 115.085 -0.961 . . . . 0.0 110.999 179.437 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 12.1 m-20 -140.2 134.97 31.9 Favored 'General case' 0 N--CA 1.482 1.132 0 C-N-CA 122.752 0.421 . . . . 0.0 110.784 -179.822 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' F' F ' 24' ' ' VAL . . . . . . . . . . . . . 21.3 t -84.51 -115.73 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.986 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 179.327 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -108.36 53.31 0.6 Allowed Glycine 0 N--CA 1.477 1.373 0 N-CA-C 111.154 -0.778 . . . . 0.0 111.154 -179.872 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 87.3 p -76.75 126.36 30.85 Favored 'General case' 0 N--CA 1.47 0.535 0 N-CA-C 109.313 -0.625 . . . . 0.0 109.313 178.141 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' F' F ' 27' ' ' ASN . . . . . 0.487 HD21 ' CG ' ' D' ' 11' ' ' GLU . 48.7 t30 -66.48 100.7 0.68 Allowed 'General case' 0 N--CA 1.471 0.609 0 N-CA-C 108.195 -1.039 . . . . 0.0 108.195 178.412 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 66.6 mttm -95.39 127.65 41.61 Favored 'General case' 0 N--CA 1.483 1.221 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 -179.082 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.53 -129.15 0.01 OUTLIER Glycine 0 CA--C 1.539 1.576 0 N-CA-C 111.139 -0.784 . . . . 0.0 111.139 179.161 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -131.17 126.67 36.23 Favored 'General case' 0 N--CA 1.488 1.451 0 CA-C-N 117.308 0.554 . . . . 0.0 111.058 -179.668 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 32.2 mt -90.95 160.14 2.74 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.237 0 N-CA-C 106.236 -1.764 . . . . 0.0 106.236 178.265 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 41.0 mt -139.09 93.65 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.763 0 N-CA-C 109.671 -0.492 . . . . 0.0 109.671 179.864 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 53.61 106.0 0.01 OUTLIER Glycine 0 CA--C 1.532 1.114 0 CA-C-N 116.099 -0.5 . . . . 0.0 114.121 177.607 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 97.8 mt -72.0 153.94 41.47 Favored 'General case' 0 CA--C 1.54 0.561 0 N-CA-C 107.295 -1.372 . . . . 0.0 107.295 176.589 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 27.5 ttt -146.75 140.21 25.7 Favored 'General case' 0 N--CA 1.481 1.087 0 N-CA-C 108.408 -0.96 . . . . 0.0 108.408 178.819 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 75.8 t -161.13 153.02 4.29 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.472 0 N-CA-C 106.452 -1.685 . . . . 0.0 106.452 -179.073 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' F' F ' 37' ' ' GLY . . . . . 0.703 ' H ' HE22 ' F' ' 15' ' ' GLN . . . 55.67 73.83 0.39 Allowed Glycine 0 C--N 1.316 -0.573 0 N-CA-C 111.543 -0.623 . . . . 0.0 111.543 178.049 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 175.5 -159.99 28.2 Favored Glycine 0 C--O 1.213 -1.195 0 N-CA-C 111.202 -0.759 . . . . 0.0 111.202 -179.723 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 23.3 m -126.36 139.01 52.89 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.824 0 N-CA-C 109.414 -0.588 . . . . 0.0 109.414 179.764 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 28.0 t . . . . . 0 CA--C 1.537 0.48 0 CA-C-O 117.957 -1.021 . . . . 0.0 111.181 179.703 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' G' G ' 1' ' ' ASP . . . . . . . . . . . . . 8.8 m-20 . . . . . 0 N--CA 1.491 1.588 0 N-CA-C 109.514 -0.55 . . . . 0.0 109.514 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' G' G ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.42 129.33 40.17 Favored 'General case' 0 N--CA 1.47 0.531 0 CA-C-N 115.89 -0.596 . . . . 0.0 110.511 179.69 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' G' G ' 3' ' ' GLU . . . . . . . . . . . . . 38.3 tt0 -168.92 108.1 0.46 Allowed 'General case' 0 N--CA 1.471 0.576 0 N-CA-C 110.158 -0.312 . . . . 0.0 110.158 179.631 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 77.4 m-85 -84.72 140.55 31.2 Favored 'General case' 0 N--CA 1.474 0.744 0 N-CA-C 109.583 -0.525 . . . . 0.0 109.583 179.287 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' G' G ' 5' ' ' ARG . . . . . . . . . . . . . 74.1 mtp180 -144.01 140.97 29.88 Favored 'General case' 0 N--CA 1.482 1.162 0 N-CA-C 109.178 -0.675 . . . . 0.0 109.178 -179.671 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 76.6 m80 -149.47 119.84 7.36 Favored 'General case' 0 N--CA 1.472 0.666 0 N-CA-C 109.04 -0.726 . . . . 0.0 109.04 179.016 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 8.7 m-20 -69.05 145.27 53.62 Favored 'General case' 0 CA--C 1.537 0.462 0 O-C-N 123.509 0.505 . . . . 0.0 112.062 -179.167 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' G' G ' 8' ' ' SER . . . . . . . . . . . . . 5.6 t -163.98 173.6 12.41 Favored 'General case' 0 N--CA 1.47 0.534 0 N-CA-C 109.474 -0.565 . . . . 0.0 109.474 178.2 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.47 23.33 2.37 Favored Glycine 0 N--CA 1.48 1.613 0 N-CA-C 111.731 -0.548 . . . . 0.0 111.731 178.942 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 41.7 p90 -56.55 127.68 32.46 Favored 'General case' 0 N--CA 1.475 0.8 0 N-CA-C 112.381 0.511 . . . . 0.0 112.381 -178.862 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' G' G ' 11' ' ' GLU . . . . . 0.427 ' CG ' HD21 ' I' ' 27' ' ' ASN . 46.1 mt-10 -84.02 155.74 22.59 Favored 'General case' 0 N--CA 1.472 0.638 0 CA-C-O 121.05 0.452 . . . . 0.0 109.935 178.595 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -156.4 123.28 0.57 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.05 0 N-CA-C 108.277 -1.009 . . . . 0.0 108.277 178.545 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 35.3 m80 -106.36 160.21 15.55 Favored 'General case' 0 N--CA 1.481 1.093 0 CA-C-N 115.213 -0.903 . . . . 0.0 110.845 -178.419 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 59.2 t60 -165.64 99.27 0.68 Allowed 'General case' 0 N--CA 1.484 1.238 0 CA-C-N 116.453 -0.339 . . . . 0.0 110.777 179.51 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' G' G ' 15' ' ' GLN . . . . . 0.693 HE22 ' H ' ' G' ' 37' ' ' GLY . 69.4 mt-30 -125.18 -175.0 3.19 Favored 'General case' 0 CA--C 1.493 -1.237 0 N-CA-C 108.031 -1.099 . . . . 0.0 108.031 -179.94 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -169.76 103.46 0.32 Allowed 'General case' 0 CA--C 1.541 0.624 0 CA-C-N 114.904 -1.043 . . . . 0.0 109.338 179.013 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 9.6 mp -109.89 149.5 29.79 Favored 'General case' 0 N--CA 1.49 1.533 0 N-CA-C 109.21 -0.663 . . . . 0.0 109.21 -179.793 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 43.9 t -145.24 117.64 2.31 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.841 0 N-CA-C 109.607 -0.516 . . . . 0.0 109.607 178.33 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 28.8 m-85 -68.11 149.45 49.6 Favored 'General case' 0 C--N 1.37 1.495 0 O-C-N 124.873 1.358 . . . . 0.0 107.842 176.653 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' G' G ' 20' ' ' PHE . . . . . 0.402 ' O ' ' N ' ' G' ' 22' ' ' GLU . 12.0 t80 -171.46 -56.15 0.02 OUTLIER 'General case' 0 N--CA 1.484 1.274 0 N-CA-C 110.205 -0.294 . . . . 0.0 110.205 179.943 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -42.99 90.01 0.0 OUTLIER 'General case' 0 C--N 1.325 -0.485 0 C-N-CA 123.521 0.729 . . . . 0.0 112.343 179.895 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' G' G ' 22' ' ' GLU . . . . . 0.402 ' N ' ' O ' ' G' ' 20' ' ' PHE . 46.1 mt-10 -61.44 158.65 14.28 Favored 'General case' 0 N--CA 1.468 0.43 0 CA-C-N 114.895 -1.048 . . . . 0.0 110.149 179.087 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 12.0 m-20 -140.11 135.49 32.59 Favored 'General case' 0 N--CA 1.481 1.103 0 C-N-CA 122.702 0.401 . . . . 0.0 110.3 -179.897 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' G' G ' 24' ' ' VAL . . . . . . . . . . . . . 21.4 t -85.63 -115.24 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.96 0 N-CA-C 108.331 -0.989 . . . . 0.0 108.331 179.356 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -108.8 53.87 0.57 Allowed Glycine 0 N--CA 1.477 1.43 0 N-CA-C 111.382 -0.687 . . . . 0.0 111.382 -179.883 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 86.8 p -77.32 126.6 31.19 Favored 'General case' 0 C--N 1.327 -0.413 0 N-CA-C 109.146 -0.686 . . . . 0.0 109.146 178.08 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' G' G ' 27' ' ' ASN . . . . . 0.449 HD21 ' CG ' ' H' ' 11' ' ' GLU . 48.1 t30 -66.38 100.31 0.63 Allowed 'General case' 0 N--CA 1.469 0.504 0 N-CA-C 108.531 -0.915 . . . . 0.0 108.531 178.542 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 67.1 mttm -94.65 127.56 40.7 Favored 'General case' 0 N--CA 1.484 1.259 0 N-CA-C 109.646 -0.501 . . . . 0.0 109.646 -179.452 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -62.95 -127.11 0.01 OUTLIER Glycine 0 CA--C 1.529 0.962 0 N-CA-C 111.166 -0.774 . . . . 0.0 111.166 179.227 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -132.81 125.73 30.71 Favored 'General case' 0 N--CA 1.47 0.532 0 C-N-CA 122.874 0.47 . . . . 0.0 110.563 -179.141 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 40.9 mt -90.23 162.15 2.52 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.667 0 N-CA-C 106.477 -1.675 . . . . 0.0 106.477 178.356 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 45.0 mt -140.11 95.01 0.78 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.312 0 CA-C-N 119.756 1.162 . . . . 0.0 109.834 178.212 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 53.98 105.26 0.01 OUTLIER Glycine 0 CA--C 1.532 1.115 0 N-CA-C 114.07 0.388 . . . . 0.0 114.07 177.53 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 98.8 mt -71.93 152.85 42.23 Favored 'General case' 0 CA--C 1.539 0.536 0 N-CA-C 107.366 -1.346 . . . . 0.0 107.366 176.729 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 27.5 ttt -146.27 141.13 27.03 Favored 'General case' 0 N--CA 1.477 0.913 0 N-CA-C 107.996 -1.113 . . . . 0.0 107.996 179.084 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 93.0 t -161.45 153.09 4.06 Favored 'Isoleucine or valine' 0 C--O 1.233 0.206 0 N-CA-C 106.553 -1.647 . . . . 0.0 106.553 -179.423 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' G' G ' 37' ' ' GLY . . . . . 0.693 ' H ' HE22 ' G' ' 15' ' ' GLN . . . 55.64 73.84 0.38 Allowed Glycine 0 C--N 1.313 -0.696 0 C-N-CA 121.035 -0.602 . . . . 0.0 111.951 177.701 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' G' G ' 38' ' ' GLY . . . . . 0.407 ' O ' ' HA3' ' D' ' 38' ' ' GLY . . . 174.75 -158.82 27.11 Favored Glycine 0 C--O 1.215 -1.067 0 N-CA-C 110.499 -1.04 . . . . 0.0 110.499 179.462 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 27.8 m -126.61 139.07 52.79 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.095 0 CA-C-N 117.249 0.525 . . . . 0.0 109.989 -179.824 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 36.3 t . . . . . 0 N--CA 1.469 0.503 0 CA-C-O 117.8 -1.095 . . . . 0.0 111.327 179.581 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' H' H ' 1' ' ' ASP . . . . . . . . . . . . . 9.5 m-20 . . . . . 0 N--CA 1.49 1.571 0 N-CA-C 109.625 -0.509 . . . . 0.0 109.625 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' H' H ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.2 129.35 40.37 Favored 'General case' 0 N--CA 1.468 0.448 0 CA-C-N 115.947 -0.57 . . . . 0.0 110.491 179.607 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' H' H ' 3' ' ' GLU . . . . . . . . . . . . . 38.8 tt0 -168.98 107.88 0.45 Allowed 'General case' 0 N--CA 1.47 0.546 0 N-CA-C 110.047 -0.353 . . . . 0.0 110.047 179.8 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 77.9 m-85 -84.52 140.86 31.15 Favored 'General case' 0 N--CA 1.474 0.765 0 N-CA-C 109.526 -0.546 . . . . 0.0 109.526 179.313 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' H' H ' 5' ' ' ARG . . . . . . . . . . . . . 74.2 mtp180 -144.22 140.87 29.54 Favored 'General case' 0 N--CA 1.481 1.103 0 N-CA-C 109.162 -0.681 . . . . 0.0 109.162 -179.65 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 76.9 m80 -149.46 119.79 7.34 Favored 'General case' 0 N--CA 1.475 0.79 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 179.07 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 8.8 m-20 -69.05 145.27 53.63 Favored 'General case' 0 N--CA 1.468 0.43 0 CA-C-N 116.203 -0.453 . . . . 0.0 112.092 -179.305 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' H' H ' 8' ' ' SER . . . . . . . . . . . . . 6.3 t -163.97 172.82 13.38 Favored 'General case' 0 N--CA 1.47 0.555 0 N-CA-C 109.458 -0.571 . . . . 0.0 109.458 178.555 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.69 23.5 2.29 Favored Glycine 0 N--CA 1.481 1.67 0 N-CA-C 111.77 -0.532 . . . . 0.0 111.77 179.008 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 40.8 p90 -56.49 127.58 31.9 Favored 'General case' 0 N--CA 1.472 0.674 0 N-CA-C 112.461 0.541 . . . . 0.0 112.461 -178.986 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' H' H ' 11' ' ' GLU . . . . . 0.449 ' CG ' HD21 ' G' ' 27' ' ' ASN . 46.1 mt-10 -83.94 155.85 22.63 Favored 'General case' 0 N--CA 1.473 0.687 0 CA-C-O 121.086 0.469 . . . . 0.0 109.906 178.706 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -156.63 122.92 0.53 Allowed 'Isoleucine or valine' 0 CA--C 1.554 1.126 0 N-CA-C 108.335 -0.987 . . . . 0.0 108.335 178.649 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 34.1 m80 -106.08 160.45 15.3 Favored 'General case' 0 N--CA 1.48 1.047 0 CA-C-N 115.167 -0.924 . . . . 0.0 110.943 -178.385 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 58.1 t60 -165.86 99.43 0.66 Allowed 'General case' 0 N--CA 1.483 1.204 0 CA-C-N 116.532 -0.303 . . . . 0.0 110.854 179.533 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' H' H ' 15' ' ' GLN . . . . . 0.721 HE22 ' H ' ' H' ' 37' ' ' GLY . 70.0 mt-30 -125.34 -175.33 3.29 Favored 'General case' 0 CA--C 1.49 -1.335 0 N-CA-C 107.834 -1.172 . . . . 0.0 107.834 -179.829 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -169.51 103.95 0.35 Allowed 'General case' 0 CA--C 1.541 0.623 0 CA-C-N 114.808 -1.087 . . . . 0.0 109.182 178.987 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 9.7 mp -110.34 149.15 30.64 Favored 'General case' 0 N--CA 1.489 1.502 0 N-CA-C 109.115 -0.698 . . . . 0.0 109.115 -179.746 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 43.7 t -144.99 117.51 2.38 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.818 0 N-CA-C 109.705 -0.48 . . . . 0.0 109.705 178.386 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 29.1 m-85 -68.64 149.74 48.78 Favored 'General case' 0 C--N 1.37 1.489 0 O-C-N 124.83 1.331 . . . . 0.0 107.855 176.741 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 12.5 t80 -172.45 -56.23 0.02 OUTLIER 'General case' 0 N--CA 1.482 1.162 0 N-CA-C 110.209 -0.293 . . . . 0.0 110.209 -179.882 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -42.88 90.2 0.0 OUTLIER 'General case' 0 CA--C 1.536 0.406 0 C-N-CA 123.429 0.692 . . . . 0.0 112.031 -179.971 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 46.0 mt-10 -61.34 158.95 13.34 Favored 'General case' 0 N--CA 1.469 0.522 0 CA-C-N 114.907 -1.042 . . . . 0.0 110.22 179.245 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 12.3 m-20 -140.14 135.74 32.79 Favored 'General case' 0 N--CA 1.482 1.148 0 C-N-CA 122.658 0.383 . . . . 0.0 110.301 -179.949 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' H' H ' 24' ' ' VAL . . . . . . . . . . . . . 21.3 t -85.81 -115.48 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.991 0 N-CA-C 108.467 -0.938 . . . . 0.0 108.467 179.366 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . -108.3 53.3 0.6 Allowed Glycine 0 N--CA 1.479 1.558 0 N-CA-C 111.138 -0.785 . . . . 0.0 111.138 -179.878 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 85.5 p -77.04 126.64 31.31 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 109.11 -0.7 . . . . 0.0 109.11 178.195 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' H' H ' 27' ' ' ASN . . . . . 0.444 HD21 ' CG ' ' I' ' 11' ' ' GLU . 47.7 t30 -66.7 100.81 0.73 Allowed 'General case' 0 N--CA 1.469 0.516 0 N-CA-C 108.479 -0.934 . . . . 0.0 108.479 178.589 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 67.1 mttm -95.21 127.62 41.4 Favored 'General case' 0 N--CA 1.485 1.299 0 N-CA-C 109.605 -0.517 . . . . 0.0 109.605 -179.408 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.01 -126.85 0.01 OUTLIER Glycine 0 CA--C 1.528 0.877 0 N-CA-C 111.137 -0.785 . . . . 0.0 111.137 179.26 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -133.16 125.82 30.31 Favored 'General case' 0 N--CA 1.47 0.563 0 C-N-CA 122.824 0.45 . . . . 0.0 110.718 -179.126 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 40.1 mt -90.4 161.83 2.56 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.67 0 N-CA-C 106.496 -1.668 . . . . 0.0 106.496 178.369 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 46.0 mt -139.97 94.84 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.324 0 CA-C-N 119.533 1.06 . . . . 0.0 109.789 178.343 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 53.99 105.93 0.01 OUTLIER Glycine 0 CA--C 1.532 1.135 0 CA-C-N 116.291 -0.413 . . . . 0.0 114.042 177.617 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 99.1 mt -72.42 152.64 41.87 Favored 'General case' 0 CA--C 1.54 0.579 0 N-CA-C 107.255 -1.387 . . . . 0.0 107.255 176.706 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 27.6 ttt -145.94 140.82 27.22 Favored 'General case' 0 N--CA 1.478 0.975 0 N-CA-C 107.941 -1.133 . . . . 0.0 107.941 179.062 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 90.1 t -161.24 153.22 4.15 Favored 'Isoleucine or valine' 0 C--O 1.233 0.216 0 N-CA-C 106.488 -1.671 . . . . 0.0 106.488 -179.39 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' H' H ' 37' ' ' GLY . . . . . 0.721 ' H ' HE22 ' H' ' 15' ' ' GLN . . . 55.42 73.78 0.39 Allowed Glycine 0 C--N 1.314 -0.679 0 C-N-CA 121.255 -0.498 . . . . 0.0 111.949 177.796 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 174.93 -158.63 26.59 Favored Glycine 0 C--O 1.215 -1.057 0 N-CA-C 110.527 -1.029 . . . . 0.0 110.527 179.469 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 27.0 m -126.81 138.97 53.16 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.161 0 CA-C-N 117.084 0.442 . . . . 0.0 109.964 -179.823 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 35.8 t . . . . . 0 N--CA 1.468 0.431 0 CA-C-O 117.801 -1.095 . . . . 0.0 111.436 179.61 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' I' I ' 1' ' ' ASP . . . . . . . . . . . . . 9.4 m-20 . . . . . 0 N--CA 1.492 1.641 0 N-CA-C 109.488 -0.56 . . . . 0.0 109.488 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' I' I ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.69 129.29 39.88 Favored 'General case' 0 N--CA 1.469 0.509 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.448 179.677 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' I' I ' 3' ' ' GLU . . . . . . . . . . . . . 38.4 tt0 -168.92 108.07 0.46 Allowed 'General case' 0 N--CA 1.471 0.612 0 N-CA-C 110.076 -0.342 . . . . 0.0 110.076 179.8 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 77.4 m-85 -84.68 141.01 30.9 Favored 'General case' 0 N--CA 1.475 0.825 0 N-CA-C 109.54 -0.541 . . . . 0.0 109.54 179.277 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' I' I ' 5' ' ' ARG . . . . . . . . . . . . . 74.0 mtp180 -144.39 141.02 29.4 Favored 'General case' 0 N--CA 1.482 1.169 0 N-CA-C 109.079 -0.712 . . . . 0.0 109.079 -179.687 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 76.8 m80 -149.62 119.41 7.06 Favored 'General case' 0 N--CA 1.472 0.636 0 N-CA-C 109.017 -0.734 . . . . 0.0 109.017 179.17 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 8.6 m-20 -68.67 145.42 53.89 Favored 'General case' 0 N--CA 1.467 0.406 0 O-C-N 123.455 0.472 . . . . 0.0 112.024 -179.244 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' I' I ' 8' ' ' SER . . . . . . . . . . . . . 6.6 t -164.17 172.9 13.06 Favored 'General case' 0 N--CA 1.469 0.502 0 N-CA-C 109.529 -0.545 . . . . 0.0 109.529 178.435 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.68 23.48 2.29 Favored Glycine 0 N--CA 1.48 1.626 0 N-CA-C 111.76 -0.536 . . . . 0.0 111.76 179.052 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 40.9 p90 -56.54 127.57 31.92 Favored 'General case' 0 N--CA 1.474 0.744 0 N-CA-C 112.398 0.518 . . . . 0.0 112.398 -178.995 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' I' I ' 11' ' ' GLU . . . . . 0.444 ' CG ' HD21 ' H' ' 27' ' ' ASN . 46.0 mt-10 -83.92 155.83 22.67 Favored 'General case' 0 N--CA 1.474 0.76 0 CA-C-O 121.096 0.474 . . . . 0.0 109.896 178.632 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -156.54 123.05 0.54 Allowed 'Isoleucine or valine' 0 CA--C 1.553 1.082 0 N-CA-C 108.299 -1.0 . . . . 0.0 108.299 178.586 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 35.0 m80 -106.04 160.08 15.57 Favored 'General case' 0 N--CA 1.481 1.081 0 CA-C-N 115.128 -0.942 . . . . 0.0 110.978 -178.336 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 58.4 t60 -165.65 99.38 0.68 Allowed 'General case' 0 N--CA 1.484 1.239 0 CA-C-N 116.563 -0.289 . . . . 0.0 110.943 179.459 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' I' I ' 15' ' ' GLN . . . . . 0.726 HE22 ' H ' ' I' ' 37' ' ' GLY . 70.0 mt-30 -125.38 -175.12 3.23 Favored 'General case' 0 CA--C 1.489 -1.403 0 N-CA-C 107.905 -1.146 . . . . 0.0 107.905 -179.865 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -169.65 104.12 0.34 Allowed 'General case' 0 CA--C 1.541 0.615 0 CA-C-N 114.8 -1.091 . . . . 0.0 109.255 179.047 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 9.7 mp -110.43 149.34 30.42 Favored 'General case' 0 N--CA 1.488 1.465 0 N-CA-C 109.16 -0.682 . . . . 0.0 109.16 -179.763 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 43.7 t -145.2 117.57 2.3 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.863 0 N-CA-C 109.649 -0.5 . . . . 0.0 109.649 178.391 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 28.8 m-85 -68.7 149.79 48.66 Favored 'General case' 0 C--N 1.371 1.536 0 O-C-N 124.773 1.296 . . . . 0.0 107.817 176.72 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' I' I ' 20' ' ' PHE . . . . . 0.403 ' O ' ' N ' ' I' ' 22' ' ' GLU . 12.6 t80 -172.54 -56.14 0.02 OUTLIER 'General case' 0 N--CA 1.481 1.115 0 N-CA-C 110.205 -0.294 . . . . 0.0 110.205 -179.855 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -43.0 90.2 0.0 OUTLIER 'General case' 0 CA--C 1.535 0.381 0 C-N-CA 123.378 0.671 . . . . 0.0 112.06 -179.98 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' I' I ' 22' ' ' GLU . . . . . 0.403 ' N ' ' O ' ' I' ' 20' ' ' PHE . 46.1 mt-10 -61.17 158.93 12.88 Favored 'General case' 0 N--CA 1.47 0.528 0 CA-C-N 114.893 -1.049 . . . . 0.0 110.267 179.241 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 12.2 m-20 -140.22 135.68 32.61 Favored 'General case' 0 N--CA 1.482 1.143 0 C-N-CA 122.597 0.359 . . . . 0.0 110.304 -179.992 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' I' I ' 24' ' ' VAL . . . . . . . . . . . . . 21.2 t -85.8 -115.51 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.96 0 N-CA-C 108.463 -0.94 . . . . 0.0 108.463 179.386 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . -108.31 53.29 0.6 Allowed Glycine 0 N--CA 1.478 1.469 0 N-CA-C 111.249 -0.74 . . . . 0.0 111.249 -179.909 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 85.9 p -77.01 126.73 31.46 Favored 'General case' 0 C--N 1.329 -0.289 0 N-CA-C 109.202 -0.666 . . . . 0.0 109.202 178.148 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' I' I ' 27' ' ' ASN . . . . . 0.427 HD21 ' CG ' ' G' ' 11' ' ' GLU . 47.9 t30 -66.67 100.97 0.74 Allowed 'General case' 0 N--CA 1.469 0.488 0 N-CA-C 108.474 -0.936 . . . . 0.0 108.474 178.56 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 67.2 mttm -95.38 127.52 41.5 Favored 'General case' 0 N--CA 1.483 1.224 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 -179.431 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -62.99 -127.4 0.01 OUTLIER Glycine 0 CA--C 1.53 0.969 0 N-CA-C 111.099 -0.8 . . . . 0.0 111.099 179.33 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -132.38 125.86 31.84 Favored 'General case' 0 N--CA 1.471 0.624 0 C-N-CA 122.906 0.482 . . . . 0.0 110.719 -179.109 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 39.8 mt -90.61 161.41 2.61 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.624 0 N-CA-C 106.458 -1.682 . . . . 0.0 106.458 178.233 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 47.0 mt -139.54 94.73 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.297 0 CA-C-N 119.586 1.085 . . . . 0.0 109.8 178.374 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 54.1 105.87 0.01 OUTLIER Glycine 0 CA--C 1.532 1.103 0 CA-C-N 116.32 -0.4 . . . . 0.0 114.011 177.568 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 98.7 mt -72.35 152.79 41.85 Favored 'General case' 0 CA--C 1.539 0.527 0 N-CA-C 107.295 -1.372 . . . . 0.0 107.295 176.721 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 27.6 ttt -146.02 140.77 27.06 Favored 'General case' 0 N--CA 1.478 0.956 0 N-CA-C 107.877 -1.157 . . . . 0.0 107.877 179.157 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 94.9 t -161.12 153.46 4.13 Favored 'Isoleucine or valine' 0 C--O 1.233 0.193 0 N-CA-C 106.382 -1.71 . . . . 0.0 106.382 -179.45 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' I' I ' 37' ' ' GLY . . . . . 0.726 ' H ' HE22 ' I' ' 15' ' ' GLN . . . 55.08 73.95 0.37 Allowed Glycine 0 C--N 1.313 -0.724 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.894 177.762 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 174.95 -158.67 26.65 Favored Glycine 0 C--O 1.216 -1.012 0 N-CA-C 110.547 -1.021 . . . . 0.0 110.547 179.43 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 27.3 m -126.88 138.82 53.65 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.097 0 CA-C-N 117.186 0.493 . . . . 0.0 109.86 -179.722 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 36.8 t . . . . . 0 N--CA 1.469 0.517 0 CA-C-O 117.849 -1.072 . . . . 0.0 111.329 179.525 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 9.8 m-20 . . . . . 0 N--CA 1.491 1.592 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.78 147.74 52.89 Favored 'General case' 0 N--CA 1.47 0.555 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.045 179.6 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 39.5 tt0 -162.18 104.77 1.14 Allowed 'General case' 0 N--CA 1.472 0.646 0 N-CA-C 110.075 -0.343 . . . . 0.0 110.075 179.669 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 16.5 m-85 -71.32 172.3 9.62 Favored 'General case' 0 N--CA 1.469 0.498 0 N-CA-C 109.369 -0.604 . . . . 0.0 109.369 179.681 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 54.0 mtp180 -68.03 129.7 40.71 Favored 'General case' 0 N--CA 1.467 0.383 0 CA-C-N 115.868 -0.606 . . . . 0.0 110.533 -177.798 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 45.2 m170 -96.1 125.59 40.74 Favored 'General case' 0 N--CA 1.473 0.691 0 N-CA-C 109.725 -0.472 . . . . 0.0 109.725 179.002 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' ASP . . . . . 0.495 ' OD1' HG11 ' F' ' 24' ' ' VAL . 10.0 m-20 -72.23 144.81 48.32 Favored 'General case' 0 CA--C 1.532 0.255 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.109 -179.81 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 23.0 t -160.72 179.47 8.51 Favored 'General case' 0 N--CA 1.471 0.615 0 N-CA-C 109.329 -0.619 . . . . 0.0 109.329 178.89 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 124.52 19.86 2.49 Favored Glycine 0 N--CA 1.487 2.064 0 N-CA-C 111.886 -0.486 . . . . 0.0 111.886 179.896 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 43.6 p90 -57.43 129.2 40.74 Favored 'General case' 0 N--CA 1.475 0.82 0 O-C-N 122.458 -0.436 . . . . 0.0 112.084 -179.707 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 46.7 mt-10 -85.54 154.7 21.57 Favored 'General case' 0 N--CA 1.469 0.512 0 N-CA-C 109.046 -0.724 . . . . 0.0 109.046 178.406 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -153.76 129.3 1.64 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 N-CA-C 108.046 -1.094 . . . . 0.0 108.046 178.895 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 51.3 m-70 -135.05 143.75 46.89 Favored 'General case' 0 N--CA 1.49 1.543 0 CA-C-N 118.803 0.729 . . . . 0.0 110.956 -179.218 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -165.98 98.21 0.64 Allowed 'General case' 0 N--CA 1.482 1.16 0 CA-C-N 116.688 -0.233 . . . . 0.0 111.099 179.673 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . 0.53 HE21 ' CA ' ' A' ' 37' ' ' GLY . 49.6 mt-30 -108.06 -171.98 1.97 Allowed 'General case' 0 CA--C 1.503 -0.851 0 N-CA-C 108.176 -1.046 . . . . 0.0 108.176 179.712 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -164.34 97.86 0.8 Allowed 'General case' 0 N--CA 1.472 0.651 0 CA-C-N 115.243 -0.889 . . . . 0.0 109.516 178.686 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.582 HD12 ' N ' ' A' ' 17' ' ' LEU . 4.8 mp -107.02 163.85 12.64 Favored 'General case' 0 N--CA 1.488 1.44 0 N-CA-C 108.59 -0.893 . . . . 0.0 108.59 179.916 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 56.3 t -141.28 119.05 8.84 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.31 0 CA-C-O 118.772 -0.632 . . . . 0.0 109.847 179.433 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 54.5 m-85 -70.13 158.55 35.55 Favored 'General case' 0 N--CA 1.479 1.021 0 N-CA-C 107.706 -1.22 . . . . 0.0 107.706 177.275 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 13.8 t80 -171.03 -58.46 0.02 OUTLIER 'General case' 0 N--CA 1.483 1.217 0 CA-C-O 122.424 1.107 . . . . 0.0 109.672 179.333 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.42 90.05 0.0 OUTLIER 'General case' 0 N--CA 1.457 -0.092 0 CA-C-N 113.927 -1.488 . . . . 0.0 112.852 -178.078 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 37.7 tt0 -62.13 156.51 21.42 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 115.166 -0.925 . . . . 0.0 110.618 178.891 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 12.2 m-20 -138.09 129.75 28.09 Favored 'General case' 0 N--CA 1.482 1.132 0 C-N-CA 122.93 0.492 . . . . 0.0 110.246 -179.659 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.953 HG12 ' H ' ' A' ' 25' ' ' GLY . 39.6 t -79.6 -164.37 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 1.024 0 N-CA-C 108.518 -0.919 . . . . 0.0 108.518 179.583 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.953 ' H ' HG12 ' A' ' 24' ' ' VAL . . . -71.42 51.43 1.08 Allowed Glycine 0 CA--C 1.527 0.827 0 CA-C-N 118.399 0.545 . . . . 0.0 112.038 -179.086 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 27.1 p -72.36 136.45 46.14 Favored 'General case' 0 C--O 1.22 -0.488 0 N-CA-C 109.564 -0.532 . . . . 0.0 109.564 178.877 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 2.0 t-20 -68.66 95.5 0.66 Allowed 'General case' 0 N--CA 1.468 0.463 0 N-CA-C 108.479 -0.934 . . . . 0.0 108.479 178.139 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 67.8 mttm -93.34 119.26 32.27 Favored 'General case' 0 N--CA 1.481 1.108 0 N-CA-C 110.295 -0.261 . . . . 0.0 110.295 -179.104 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.12 -126.12 0.01 OUTLIER Glycine 0 CA--C 1.533 1.166 0 N-CA-C 110.485 -1.046 . . . . 0.0 110.485 178.639 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.24 134.23 48.94 Favored 'General case' 0 N--CA 1.48 1.035 0 N-CA-C 109.078 -0.712 . . . . 0.0 109.078 179.111 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 65.4 mt -83.3 138.05 19.95 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.467 0 N-CA-C 107.3 -1.37 . . . . 0.0 107.3 178.657 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 31.3 mt -130.46 127.71 62.8 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.914 0 O-C-N 123.472 0.483 . . . . 0.0 110.044 -178.592 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.27 78.9 0.14 Allowed Glycine 0 CA--C 1.524 0.653 0 CA-C-N 115.885 -0.598 . . . . 0.0 112.869 178.7 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.438 HD23 ' N ' ' A' ' 35' ' ' MET . 1.7 tt -109.94 120.82 43.67 Favored 'General case' 0 N--CA 1.481 1.077 0 N-CA-C 107.175 -1.417 . . . . 0.0 107.175 177.653 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' MET . . . . . 0.438 ' N ' HD23 ' A' ' 34' ' ' LEU . 8.8 mtp -154.08 161.24 42.05 Favored 'General case' 0 N--CA 1.472 0.647 0 N-CA-C 108.662 -0.866 . . . . 0.0 108.662 179.736 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 78.1 t -158.07 144.76 8.81 Favored 'Isoleucine or valine' 0 C--O 1.234 0.261 0 N-CA-C 106.774 -1.565 . . . . 0.0 106.774 -179.789 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . 0.53 ' CA ' HE21 ' A' ' 15' ' ' GLN . . . 55.77 74.06 0.36 Allowed Glycine 0 C--N 1.315 -0.616 0 N-CA-C 111.511 -0.636 . . . . 0.0 111.511 178.675 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 169.99 -149.07 12.43 Favored Glycine 0 CA--C 1.519 0.324 0 N-CA-C 110.898 -0.881 . . . . 0.0 110.898 179.938 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 16.0 m -134.65 148.74 29.36 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.84 0 C-N-CA 122.675 0.39 . . . . 0.0 109.951 179.955 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 21.9 t . . . . . 0 C--O 1.22 -0.497 0 CA-C-O 117.81 -1.09 . . . . 0.0 111.043 178.931 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' B' B ' 1' ' ' ASP . . . . . . . . . . . . . 9.2 m-20 . . . . . 0 N--CA 1.491 1.61 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' B' B ' 2' ' ' ALA . . . . . . . . . . . . . . . -66.16 147.83 52.75 Favored 'General case' 0 N--CA 1.47 0.537 0 CA-C-N 116.204 -0.453 . . . . 0.0 109.98 179.636 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 3' ' ' GLU . . . . . . . . . . . . . 39.8 tt0 -162.31 104.66 1.12 Allowed 'General case' 0 N--CA 1.473 0.718 0 N-CA-C 110.072 -0.344 . . . . 0.0 110.072 179.64 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 17.3 m-85 -71.11 172.51 9.05 Favored 'General case' 0 N--CA 1.47 0.548 0 N-CA-C 109.404 -0.591 . . . . 0.0 109.404 179.625 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 54.3 mtp180 -68.36 129.61 40.45 Favored 'General case' 0 CA--C 1.534 0.349 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.525 -177.748 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 44.0 m170 -95.99 125.6 40.65 Favored 'General case' 0 N--CA 1.473 0.703 0 N-CA-C 109.797 -0.446 . . . . 0.0 109.797 179.048 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 7' ' ' ASP . . . . . 0.513 ' OD1' HG11 ' D' ' 24' ' ' VAL . 10.0 m-20 -72.18 144.98 48.34 Favored 'General case' 0 CA--C 1.532 0.269 0 CA-C-N 116.464 -0.334 . . . . 0.0 111.163 -179.863 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 8' ' ' SER . . . . . . . . . . . . . 23.1 t -160.82 179.49 8.47 Favored 'General case' 0 N--CA 1.47 0.539 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 178.851 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 124.37 19.88 2.52 Favored Glycine 0 N--CA 1.487 2.081 0 N-CA-C 111.8 -0.52 . . . . 0.0 111.8 179.854 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 43.3 p90 -57.36 129.24 40.92 Favored 'General case' 0 N--CA 1.474 0.736 0 O-C-N 122.489 -0.418 . . . . 0.0 112.073 -179.788 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 46.6 mt-10 -85.55 154.79 21.51 Favored 'General case' 0 N--CA 1.47 0.557 0 N-CA-C 109.15 -0.685 . . . . 0.0 109.15 178.389 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -153.8 129.09 1.56 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.328 0 N-CA-C 108.188 -1.041 . . . . 0.0 108.188 178.839 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 50.9 m-70 -134.8 143.87 47.33 Favored 'General case' 0 N--CA 1.49 1.566 0 CA-C-N 118.79 0.723 . . . . 0.0 110.91 -179.089 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -166.02 98.23 0.63 Allowed 'General case' 0 N--CA 1.483 1.203 0 CA-C-N 116.616 -0.266 . . . . 0.0 111.117 179.619 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . 0.521 HE21 ' CA ' ' B' ' 37' ' ' GLY . 49.7 mt-30 -108.09 -172.52 2.08 Favored 'General case' 0 CA--C 1.502 -0.896 0 N-CA-C 108.168 -1.049 . . . . 0.0 108.168 179.805 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 16' ' ' LYS . . . . . 0.401 ' C ' HD12 ' B' ' 17' ' ' LEU . 88.2 tttt -164.06 97.69 0.83 Allowed 'General case' 0 N--CA 1.473 0.698 0 CA-C-N 115.152 -0.931 . . . . 0.0 109.411 178.747 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . 0.584 ' N ' HD12 ' B' ' 17' ' ' LEU . 4.8 mp -106.97 163.91 12.58 Favored 'General case' 0 N--CA 1.488 1.427 0 N-CA-C 108.506 -0.924 . . . . 0.0 108.506 179.867 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 58.7 t -141.37 118.7 8.22 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.358 0 CA-C-O 118.957 -0.544 . . . . 0.0 109.821 179.512 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 56.0 m-85 -70.39 158.64 35.62 Favored 'General case' 0 N--CA 1.477 0.907 0 N-CA-C 107.614 -1.254 . . . . 0.0 107.614 177.25 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 14.5 t80 -171.64 -57.7 0.02 OUTLIER 'General case' 0 N--CA 1.482 1.164 0 CA-C-O 122.284 1.04 . . . . 0.0 109.764 179.288 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.56 90.49 0.0 OUTLIER 'General case' 0 C--O 1.232 0.156 0 CA-C-N 114.098 -1.41 . . . . 0.0 112.682 -178.126 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 37.6 tt0 -62.55 156.37 23.28 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 115.173 -0.921 . . . . 0.0 110.544 179.038 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 12.3 m-20 -138.0 130.16 28.88 Favored 'General case' 0 N--CA 1.483 1.196 0 C-N-CA 123.01 0.524 . . . . 0.0 110.193 -179.671 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . 0.983 HG12 ' H ' ' B' ' 25' ' ' GLY . 39.2 t -80.13 -163.89 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.037 0 N-CA-C 108.593 -0.891 . . . . 0.0 108.593 179.618 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . 0.983 ' H ' HG12 ' B' ' 24' ' ' VAL . . . -71.36 50.93 1.05 Allowed Glycine 0 C--N 1.342 0.897 0 CA-C-N 118.324 0.511 . . . . 0.0 112.045 -179.182 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 28.9 p -72.16 136.16 46.38 Favored 'General case' 0 C--O 1.22 -0.476 0 N-CA-C 109.644 -0.502 . . . . 0.0 109.644 178.798 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 2.0 t-20 -68.61 95.39 0.64 Allowed 'General case' 0 N--CA 1.469 0.5 0 N-CA-C 108.495 -0.928 . . . . 0.0 108.495 178.137 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 67.9 mttm -93.19 119.12 32.03 Favored 'General case' 0 N--CA 1.481 1.1 0 N-CA-C 110.358 -0.238 . . . . 0.0 110.358 -179.061 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.08 -125.67 0.01 OUTLIER Glycine 0 CA--C 1.534 1.28 0 N-CA-C 110.511 -1.036 . . . . 0.0 110.511 178.64 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.65 134.36 48.51 Favored 'General case' 0 N--CA 1.481 1.103 0 N-CA-C 109.159 -0.682 . . . . 0.0 109.159 179.141 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 65.6 mt -83.43 138.25 19.6 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.462 0 N-CA-C 107.288 -1.375 . . . . 0.0 107.288 178.626 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 29.9 mt -130.78 127.56 61.82 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.884 0 O-C-N 123.541 0.525 . . . . 0.0 110.012 -178.523 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.46 78.56 0.15 Allowed Glycine 0 CA--C 1.526 0.745 0 CA-C-N 115.898 -0.592 . . . . 0.0 112.888 178.642 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 34' ' ' LEU . . . . . 0.429 HD23 ' N ' ' B' ' 35' ' ' MET . 1.7 tt -109.6 120.65 43.14 Favored 'General case' 0 N--CA 1.48 1.061 0 N-CA-C 107.163 -1.421 . . . . 0.0 107.163 177.629 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 35' ' ' MET . . . . . 0.429 ' N ' HD23 ' B' ' 34' ' ' LEU . 8.9 mtp -153.81 161.07 42.37 Favored 'General case' 0 N--CA 1.473 0.682 0 N-CA-C 108.704 -0.85 . . . . 0.0 108.704 179.574 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 72.8 t -157.93 144.65 9.0 Favored 'Isoleucine or valine' 0 C--O 1.233 0.201 0 N-CA-C 106.786 -1.561 . . . . 0.0 106.786 -179.739 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . 0.521 ' CA ' HE21 ' B' ' 15' ' ' GLN . . . 55.71 74.08 0.36 Allowed Glycine 0 C--N 1.317 -0.526 0 N-CA-C 111.544 -0.622 . . . . 0.0 111.544 178.713 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 169.97 -148.9 12.23 Favored Glycine 0 CA--C 1.519 0.319 0 N-CA-C 110.796 -0.922 . . . . 0.0 110.796 179.886 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 16.1 m -134.69 148.73 29.32 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.823 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 -179.914 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 21.9 t . . . . . 0 N--CA 1.47 0.54 0 CA-C-O 117.717 -1.135 . . . . 0.0 110.959 178.801 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' C' C ' 1' ' ' ASP . . . . . . . . . . . . . 9.0 m-20 . . . . . 0 N--CA 1.49 1.551 0 N-CA-C 109.4 -0.593 . . . . 0.0 109.4 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' C' C ' 2' ' ' ALA . . . . . . . . . . . . . . . -66.0 147.69 52.96 Favored 'General case' 0 N--CA 1.469 0.491 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.128 179.562 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' C' C ' 3' ' ' GLU . . . . . . . . . . . . . 39.5 tt0 -162.14 104.83 1.15 Allowed 'General case' 0 N--CA 1.472 0.659 0 N-CA-C 110.145 -0.317 . . . . 0.0 110.145 179.69 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 17.4 m-85 -71.3 172.61 9.05 Favored 'General case' 0 N--CA 1.469 0.516 0 N-CA-C 109.473 -0.565 . . . . 0.0 109.473 179.677 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 54.4 mtp180 -68.37 129.25 39.36 Favored 'General case' 0 N--CA 1.468 0.469 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.481 -177.729 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 44.7 m170 -95.74 125.66 40.47 Favored 'General case' 0 N--CA 1.474 0.733 0 N-CA-C 109.714 -0.476 . . . . 0.0 109.714 178.978 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' C' C ' 7' ' ' ASP . . . . . 0.516 ' OD1' HG11 ' E' ' 24' ' ' VAL . 10.1 m-20 -72.33 145.18 47.97 Favored 'General case' 0 CA--C 1.53 0.208 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.198 -179.842 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' C' C ' 8' ' ' SER . . . . . . . . . . . . . 22.9 t -160.91 179.53 8.4 Favored 'General case' 0 N--CA 1.469 0.506 0 N-CA-C 109.343 -0.614 . . . . 0.0 109.343 178.835 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 124.46 19.83 2.51 Favored Glycine 0 N--CA 1.487 2.055 0 N-CA-C 111.772 -0.531 . . . . 0.0 111.772 179.822 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 43.9 p90 -57.24 128.96 39.64 Favored 'General case' 0 N--CA 1.473 0.705 0 O-C-N 122.403 -0.469 . . . . 0.0 112.127 -179.767 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 46.5 mt-10 -85.35 154.95 21.54 Favored 'General case' 0 N--CA 1.47 0.553 0 N-CA-C 109.049 -0.723 . . . . 0.0 109.049 178.426 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -154.08 129.05 1.49 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 N-CA-C 108.174 -1.047 . . . . 0.0 108.174 178.802 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 50.7 m-70 -134.68 144.2 47.66 Favored 'General case' 0 N--CA 1.491 1.624 0 CA-C-N 118.716 0.689 . . . . 0.0 110.974 -179.117 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -166.38 98.16 0.6 Allowed 'General case' 0 N--CA 1.482 1.174 0 CA-C-N 116.674 -0.239 . . . . 0.0 111.161 179.753 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' C' C ' 15' ' ' GLN . . . . . 0.528 HE21 ' CA ' ' C' ' 37' ' ' GLY . 49.7 mt-30 -108.31 -172.12 2.0 Allowed 'General case' 0 CA--C 1.501 -0.941 0 N-CA-C 108.177 -1.046 . . . . 0.0 108.177 179.796 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' C' C ' 16' ' ' LYS . . . . . 0.406 ' C ' HD12 ' C' ' 17' ' ' LEU . 88.2 tttt -164.29 97.84 0.81 Allowed 'General case' 0 N--CA 1.472 0.626 0 CA-C-N 115.143 -0.935 . . . . 0.0 109.443 178.761 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' C' C ' 17' ' ' LEU . . . . . 0.581 HD12 ' N ' ' C' ' 17' ' ' LEU . 4.8 mp -106.96 163.81 12.65 Favored 'General case' 0 N--CA 1.487 1.406 0 N-CA-C 108.559 -0.904 . . . . 0.0 108.559 179.89 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 58.0 t -141.28 118.81 8.54 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.293 0 CA-C-O 118.917 -0.563 . . . . 0.0 109.805 179.48 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 55.1 m-85 -70.49 158.73 35.55 Favored 'General case' 0 N--CA 1.478 0.926 0 N-CA-C 107.529 -1.285 . . . . 0.0 107.529 177.317 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 14.7 t80 -171.63 -57.67 0.02 OUTLIER 'General case' 0 N--CA 1.481 1.104 0 CA-C-O 122.246 1.022 . . . . 0.0 109.857 179.21 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -40.59 90.4 0.0 OUTLIER 'General case' 0 C--O 1.231 0.107 0 CA-C-N 114.181 -1.372 . . . . 0.0 112.79 -178.168 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 38.0 tt0 -62.32 156.45 22.25 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.223 -0.899 . . . . 0.0 110.577 179.09 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 12.2 m-20 -138.05 129.93 28.42 Favored 'General case' 0 N--CA 1.482 1.156 0 C-N-CA 123.026 0.531 . . . . 0.0 110.255 -179.689 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' C' C ' 24' ' ' VAL . . . . . 0.967 HG12 ' H ' ' C' ' 25' ' ' GLY . 40.4 t -79.99 -164.08 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.035 0 N-CA-C 108.523 -0.917 . . . . 0.0 108.523 179.639 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' C' C ' 25' ' ' GLY . . . . . 0.967 ' H ' HG12 ' C' ' 24' ' ' VAL . . . -71.34 50.96 1.04 Allowed Glycine 0 CA--C 1.527 0.812 0 CA-C-N 118.363 0.529 . . . . 0.0 112.042 -179.019 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 27.3 p -72.13 136.43 46.52 Favored 'General case' 0 C--O 1.221 -0.414 0 N-CA-C 109.526 -0.546 . . . . 0.0 109.526 178.902 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 2.0 t-20 -68.87 95.65 0.7 Allowed 'General case' 0 N--CA 1.468 0.472 0 N-CA-C 108.419 -0.956 . . . . 0.0 108.419 178.107 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 67.9 mttm -93.46 119.07 32.11 Favored 'General case' 0 N--CA 1.481 1.105 0 N-CA-C 110.354 -0.239 . . . . 0.0 110.354 -179.092 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.93 -126.03 0.01 OUTLIER Glycine 0 CA--C 1.534 1.281 0 N-CA-C 110.563 -1.015 . . . . 0.0 110.563 178.606 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.28 134.12 48.89 Favored 'General case' 0 N--CA 1.481 1.102 0 N-CA-C 109.105 -0.702 . . . . 0.0 109.105 179.135 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 65.3 mt -83.26 138.0 20.02 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.451 0 N-CA-C 107.311 -1.366 . . . . 0.0 107.311 178.538 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 30.7 mt -130.41 127.79 63.03 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.931 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.015 -178.537 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.14 78.57 0.15 Allowed Glycine 0 CA--C 1.525 0.68 0 CA-C-N 115.908 -0.587 . . . . 0.0 112.933 178.677 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' C' C ' 34' ' ' LEU . . . . . 0.432 HD23 ' N ' ' C' ' 35' ' ' MET . 1.7 tt -109.49 120.77 43.51 Favored 'General case' 0 N--CA 1.48 1.035 0 N-CA-C 107.202 -1.407 . . . . 0.0 107.202 177.606 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' C' C ' 35' ' ' MET . . . . . 0.432 ' N ' HD23 ' C' ' 34' ' ' LEU . 8.8 mtp -153.93 161.22 42.16 Favored 'General case' 0 N--CA 1.469 0.524 0 N-CA-C 108.664 -0.865 . . . . 0.0 108.664 179.665 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 79.2 t -158.05 144.86 8.89 Favored 'Isoleucine or valine' 0 C--O 1.233 0.232 0 N-CA-C 106.845 -1.539 . . . . 0.0 106.845 -179.832 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' C' C ' 37' ' ' GLY . . . . . 0.528 ' CA ' HE21 ' C' ' 15' ' ' GLN . . . 55.65 74.03 0.37 Allowed Glycine 0 C--N 1.316 -0.535 0 CA-C-N 115.812 -0.631 . . . . 0.0 111.537 178.687 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 169.95 -149.12 12.54 Favored Glycine 0 CA--C 1.518 0.275 0 N-CA-C 110.815 -0.914 . . . . 0.0 110.815 179.941 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 16.4 m -134.58 148.85 29.41 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.872 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 -179.964 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 22.0 t . . . . . 0 N--CA 1.469 0.507 0 CA-C-O 117.717 -1.135 . . . . 0.0 110.952 178.916 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' D' D ' 1' ' ' ASP . . . . . . . . . . . . . 9.2 m-20 . . . . . 0 N--CA 1.489 1.511 0 N-CA-C 109.0 -0.741 . . . . 0.0 109.0 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' D' D ' 2' ' ' ALA . . . . . . . . . . . . . . . -67.96 148.78 50.61 Favored 'General case' 0 N--CA 1.467 0.411 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.383 179.337 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' D' D ' 3' ' ' GLU . . . . . . . . . . . . . 40.0 tt0 -160.99 107.28 1.43 Allowed 'General case' 0 C--O 1.204 -1.291 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.005 -179.8 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 18.7 m-85 -77.12 167.66 21.4 Favored 'General case' 0 C--N 1.303 -1.428 0 C-N-CA 126.343 1.857 . . . . 0.0 107.9 -178.876 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' D' D ' 5' ' ' ARG . . . . . 0.852 HH21 HG13 ' C' ' 24' ' ' VAL 0.344 64.5 mtp180 -77.03 133.52 39.09 Favored 'General case' 0 C--N 1.355 0.821 0 CA-C-O 123.248 1.499 . . . . 0.0 107.088 -167.987 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 45.2 m170 -94.27 128.13 40.56 Favored 'General case' 0 C--N 1.365 1.273 0 CA-C-N 113.371 -1.741 . . . . 0.0 108.502 -177.669 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' D' D ' 7' ' ' ASP . . . . . 0.584 ' OD1' HG11 ' I' ' 24' ' ' VAL . 6.7 m-20 -66.35 130.48 43.37 Favored 'General case' 0 C--N 1.31 -1.134 0 C-N-CA 127.505 2.322 . . . . 0.0 115.117 175.029 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' D' D ' 8' ' ' SER . . . . . . . . . . . . . 22.9 t -152.11 -178.53 6.84 Favored 'General case' 0 N--CA 1.478 0.954 0 CA-C-N 119.168 0.895 . . . . 0.0 109.411 177.145 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 124.58 18.85 2.64 Favored Glycine 0 N--CA 1.485 1.914 0 N-CA-C 111.788 -0.525 . . . . 0.0 111.788 178.691 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 40.2 p90 -56.21 130.62 45.09 Favored 'General case' 0 CA--C 1.544 0.74 0 N-CA-C 112.134 0.42 . . . . 0.0 112.134 -179.209 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 46.7 mt-10 -85.6 152.5 23.08 Favored 'General case' 0 N--CA 1.475 0.78 0 N-CA-C 109.649 -0.5 . . . . 0.0 109.649 177.479 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -149.6 130.1 4.37 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.447 0 N-CA-C 108.1 -1.074 . . . . 0.0 108.1 175.357 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 48.5 m-70 -129.81 146.97 51.53 Favored 'General case' 0 N--CA 1.483 1.218 0 CA-C-N 117.867 0.303 . . . . 0.0 111.286 176.482 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -165.35 104.84 0.74 Allowed 'General case' 0 N--CA 1.483 1.209 0 N-CA-C 109.688 -0.486 . . . . 0.0 109.688 173.354 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' D' D ' 15' ' ' GLN . . . . . 0.538 HE21 ' CA ' ' D' ' 37' ' ' GLY . 49.1 mt-30 -111.62 -175.59 2.73 Favored 'General case' 0 CA--C 1.493 -1.249 0 N-CA-C 108.018 -1.104 . . . . 0.0 108.018 179.092 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' D' D ' 16' ' ' LYS . . . . . 0.451 ' C ' HD12 ' D' ' 17' ' ' LEU . 88.7 tttt -160.56 106.12 1.47 Allowed 'General case' 0 CA--C 1.538 0.5 0 N-CA-C 107.683 -1.228 . . . . 0.0 107.683 175.383 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' D' D ' 17' ' ' LEU . . . . . 0.528 HD12 ' N ' ' D' ' 17' ' ' LEU . 5.7 mp -113.38 163.03 15.38 Favored 'General case' 0 N--CA 1.488 1.456 0 N-CA-C 107.945 -1.132 . . . . 0.0 107.945 179.457 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 53.3 t -140.96 123.63 15.5 Favored 'Isoleucine or valine' 0 C--N 1.362 1.136 0 N-CA-C 108.753 -0.832 . . . . 0.0 108.753 175.964 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 79.1 m-85 -62.97 151.3 39.99 Favored 'General case' 0 C--N 1.355 0.82 0 C-N-CA 124.517 1.127 . . . . 0.0 110.515 170.967 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 9.9 t80 -170.11 -66.91 0.02 OUTLIER 'General case' 0 N--CA 1.475 0.789 0 N-CA-C 107.781 -1.192 . . . . 0.0 107.781 179.834 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -38.27 95.43 0.01 OUTLIER 'General case' 0 CA--C 1.535 0.39 0 CA-C-N 113.99 -1.459 . . . . 0.0 111.731 -175.293 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 38.3 tt0 -65.18 157.61 28.3 Favored 'General case' 0 N--CA 1.467 0.418 0 CA-C-N 113.919 -1.491 . . . . 0.0 110.122 178.469 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 12.0 m-20 -138.68 130.46 27.82 Favored 'General case' 0 N--CA 1.479 0.985 0 C-N-CA 123.181 0.592 . . . . 0.0 110.407 -178.969 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' D' D ' 24' ' ' VAL . . . . . 1.037 HG12 ' H ' ' D' ' 25' ' ' GLY . 48.7 t -84.42 -160.12 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.299 0 N-CA-C 107.742 -1.206 . . . . 0.0 107.742 -178.346 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' D' D ' 25' ' ' GLY . . . . . 1.037 ' H ' HG12 ' D' ' 24' ' ' VAL . . . -80.3 57.19 4.67 Favored Glycine 0 C--N 1.359 1.84 0 C-N-CA 118.198 -1.953 . . . . 0.0 110.695 -175.556 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 54.0 p -61.81 132.36 52.84 Favored 'General case' 0 C--N 1.346 0.431 0 CA-C-O 117.515 -1.231 . . . . 0.0 112.187 170.377 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 2.0 t-20 -65.53 95.32 0.21 Allowed 'General case' 0 C--O 1.242 0.666 0 CA-C-N 120.263 1.392 . . . . 0.0 109.044 172.049 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 67.6 mttm -95.0 122.17 37.37 Favored 'General case' 0 N--CA 1.483 1.219 0 C-N-CA 119.627 -0.829 . . . . 0.0 109.245 179.537 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -55.84 -130.18 0.01 OUTLIER Glycine 0 CA--C 1.528 0.893 0 C-N-CA 123.804 0.716 . . . . 0.0 112.045 174.717 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -125.33 139.97 53.23 Favored 'General case' 0 C--N 1.369 1.421 0 N-CA-C 108.669 -0.863 . . . . 0.0 108.669 174.602 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 65.2 mt -83.86 140.54 16.04 Favored 'Isoleucine or valine' 0 C--O 1.238 0.47 0 N-CA-C 107.374 -1.343 . . . . 0.0 107.374 176.342 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 42.1 mt -132.79 132.21 59.48 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.996 0 N-CA-C 108.329 -0.989 . . . . 0.0 108.329 178.079 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.22 76.96 0.22 Allowed Glycine 0 C--O 1.245 0.799 0 CA-C-O 118.552 -1.138 . . . . 0.0 112.519 178.351 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' D' D ' 34' ' ' LEU . . . . . 0.434 HD23 ' N ' ' D' ' 35' ' ' MET . 2.1 tt -109.32 132.17 54.38 Favored 'General case' 0 C--N 1.371 1.528 0 N-CA-C 104.73 -2.322 . . . . 0.0 104.73 175.275 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' D' D ' 35' ' ' MET . . . . . 0.434 ' N ' HD23 ' D' ' 34' ' ' LEU . 9.0 mtp -156.43 166.72 32.61 Favored 'General case' 0 N--CA 1.475 0.822 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 177.494 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 93.2 t -163.73 150.72 3.06 Favored 'Isoleucine or valine' 0 C--O 1.237 0.401 0 N-CA-C 104.989 -2.226 . . . . 0.0 104.989 173.986 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' D' D ' 37' ' ' GLY . . . . . 0.538 ' CA ' HE21 ' D' ' 15' ' ' GLN . . . 60.95 66.91 2.38 Favored Glycine 0 N--CA 1.444 -0.794 0 C-N-CA 118.509 -1.805 . . . . 0.0 112.129 177.13 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 166.8 -148.06 12.82 Favored Glycine 0 N--CA 1.468 0.767 0 CA-C-N 119.085 1.443 . . . . 0.0 112.296 -179.589 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 14.1 m -131.15 147.92 32.95 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.263 0 CA-C-N 119.009 1.405 . . . . 0.0 110.332 -178.908 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 21.2 t . . . . . 0 C--O 1.212 -0.897 0 N-CA-C 109.388 -0.597 . . . . 0.0 109.388 173.574 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' E' E ' 1' ' ' ASP . . . . . . . . . . . . . 9.7 m-20 . . . . . 0 N--CA 1.487 1.422 0 N-CA-C 109.204 -0.665 . . . . 0.0 109.204 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' E' E ' 2' ' ' ALA . . . . . . . . . . . . . . . -67.86 149.48 49.79 Favored 'General case' 0 N--CA 1.468 0.442 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.34 179.429 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' E' E ' 3' ' ' GLU . . . . . . . . . . . . . 39.9 tt0 -162.97 103.29 1.0 Allowed 'General case' 0 C--O 1.214 -0.801 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.182 -179.704 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 15.9 m-85 -68.41 172.84 5.5 Favored 'General case' 0 N--CA 1.472 0.631 0 CA-C-O 121.171 0.51 . . . . 0.0 109.864 179.479 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' E' E ' 5' ' ' ARG . . . . . 0.837 HH21 HG13 ' A' ' 24' ' ' VAL . 53.0 mtp180 -68.14 130.15 42.07 Favored 'General case' 0 CA--C 1.535 0.398 0 CA-C-N 115.579 -0.737 . . . . 0.0 110.585 -177.917 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 45.6 m170 -96.42 125.3 40.81 Favored 'General case' 0 N--CA 1.476 0.854 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 178.958 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' E' E ' 7' ' ' ASP . . . . . 0.569 ' OD1' HG11 ' G' ' 24' ' ' VAL . 11.6 m-20 -71.75 145.24 48.89 Favored 'General case' 0 N--CA 1.465 0.31 0 O-C-N 123.286 0.366 . . . . 0.0 111.301 -179.823 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' E' E ' 8' ' ' SER . . . . . . . . . . . . . 22.6 t -161.05 179.88 8.07 Favored 'General case' 0 N--CA 1.473 0.702 0 N-CA-C 109.263 -0.643 . . . . 0.0 109.263 178.521 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 125.16 20.12 2.28 Favored Glycine 0 N--CA 1.482 1.754 0 N-CA-C 111.757 -0.537 . . . . 0.0 111.757 179.612 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 40.3 p90 -57.17 128.49 37.24 Favored 'General case' 0 N--CA 1.473 0.682 0 N-CA-C 112.607 0.595 . . . . 0.0 112.607 -179.214 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 45.8 mt-10 -84.37 155.08 22.48 Favored 'General case' 0 N--CA 1.475 0.813 0 N-CA-C 109.228 -0.656 . . . . 0.0 109.228 178.111 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -155.29 127.76 1.05 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.543 0 N-CA-C 108.367 -0.975 . . . . 0.0 108.367 178.764 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 47.4 m-70 -134.63 142.12 46.79 Favored 'General case' 0 N--CA 1.482 1.139 0 CA-C-O 120.591 0.234 . . . . 0.0 111.337 -177.995 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -165.17 98.38 0.73 Allowed 'General case' 0 N--CA 1.486 1.37 0 CA-C-N 116.688 -0.233 . . . . 0.0 111.127 179.711 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' E' E ' 15' ' ' GLN . . . . . 0.537 HE21 ' CA ' ' E' ' 37' ' ' GLY . 49.2 mt-30 -107.73 -172.2 2.02 Favored 'General case' 0 CA--C 1.501 -0.925 0 N-CA-C 108.393 -0.965 . . . . 0.0 108.393 179.81 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -164.34 97.88 0.8 Allowed 'General case' 0 CA--C 1.542 0.635 0 CA-C-N 115.007 -0.997 . . . . 0.0 109.337 178.697 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' E' E ' 17' ' ' LEU . . . . . 0.571 ' N ' HD12 ' E' ' 17' ' ' LEU . 4.7 mp -106.85 163.34 13.03 Favored 'General case' 0 N--CA 1.49 1.538 0 N-CA-C 109.075 -0.713 . . . . 0.0 109.075 -179.876 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 41.6 t -141.66 118.05 6.93 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.319 0 C-N-CA 122.684 0.394 . . . . 0.0 110.442 178.952 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 54.7 m-85 -69.43 156.31 39.05 Favored 'General case' 0 C--N 1.358 0.969 0 N-CA-C 107.489 -1.3 . . . . 0.0 107.489 176.621 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 13.1 t80 -173.29 -55.33 0.02 OUTLIER 'General case' 0 N--CA 1.484 1.244 0 CA-C-O 121.724 0.773 . . . . 0.0 110.292 179.333 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -42.35 88.94 0.0 OUTLIER 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 114.502 -1.226 . . . . 0.0 112.654 -179.036 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 37.7 tt0 -61.1 156.42 18.14 Favored 'General case' 0 N--CA 1.47 0.554 0 CA-C-N 115.014 -0.994 . . . . 0.0 110.733 179.416 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 12.0 m-20 -138.16 129.39 27.43 Favored 'General case' 0 N--CA 1.481 1.101 0 C-N-CA 123.003 0.521 . . . . 0.0 110.551 -179.52 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' E' E ' 24' ' ' VAL . . . . . 0.975 HG12 ' H ' ' E' ' 25' ' ' GLY . 40.4 t -79.94 -164.25 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.484 1.238 0 N-CA-C 108.164 -1.05 . . . . 0.0 108.164 179.557 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' E' E ' 25' ' ' GLY . . . . . 0.975 ' H ' HG12 ' E' ' 24' ' ' VAL . . . -70.79 52.25 0.92 Allowed Glycine 0 CA--C 1.529 0.928 0 CA-C-N 118.422 0.556 . . . . 0.0 112.534 -178.807 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 18.1 p -72.68 135.32 45.39 Favored 'General case' 0 C--O 1.219 -0.512 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 178.645 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 2.0 t-20 -68.36 95.33 0.6 Allowed 'General case' 0 CA--C 1.536 0.421 0 N-CA-C 107.681 -1.229 . . . . 0.0 107.681 177.866 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 67.4 mttm -93.74 118.38 31.34 Favored 'General case' 0 N--CA 1.483 1.187 0 N-CA-C 109.94 -0.393 . . . . 0.0 109.94 -178.586 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.93 -124.97 0.01 OUTLIER Glycine 0 CA--C 1.539 1.587 0 N-CA-C 110.998 -0.841 . . . . 0.0 110.998 178.588 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -129.05 133.65 47.79 Favored 'General case' 0 N--CA 1.48 1.057 0 N-CA-C 109.511 -0.551 . . . . 0.0 109.511 179.493 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 65.3 mt -82.44 138.53 19.26 Favored 'Isoleucine or valine' 0 C--O 1.235 0.29 0 N-CA-C 107.158 -1.423 . . . . 0.0 107.158 178.617 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 36.2 mt -130.33 127.85 63.3 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.895 0 N-CA-C 109.437 -0.579 . . . . 0.0 109.437 -179.447 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.64 79.89 0.12 Allowed Glycine 0 CA--C 1.522 0.485 0 CA-C-N 115.914 -0.585 . . . . 0.0 113.299 179.021 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' E' E ' 34' ' ' LEU . . . . . 0.413 HD23 ' N ' ' E' ' 35' ' ' MET . 1.8 tt -110.56 120.26 41.83 Favored 'General case' 0 N--CA 1.48 1.044 0 N-CA-C 107.312 -1.366 . . . . 0.0 107.312 177.419 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' E' E ' 35' ' ' MET . . . . . 0.413 ' N ' HD23 ' E' ' 34' ' ' LEU . 8.7 mtp -152.4 163.23 39.92 Favored 'General case' 0 C--O 1.213 -0.864 0 N-CA-C 108.32 -0.992 . . . . 0.0 108.32 179.421 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 97.5 t -159.85 145.3 6.17 Favored 'Isoleucine or valine' 0 C--O 1.233 0.235 0 N-CA-C 106.693 -1.595 . . . . 0.0 106.693 179.919 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' E' E ' 37' ' ' GLY . . . . . 0.537 ' CA ' HE21 ' E' ' 15' ' ' GLN . . . 55.03 73.62 0.4 Allowed Glycine 0 C--N 1.316 -0.54 0 N-CA-C 111.202 -0.759 . . . . 0.0 111.202 178.769 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 171.03 -148.22 11.07 Favored Glycine 0 C--O 1.221 -0.688 0 C-N-CA 120.882 -0.675 . . . . 0.0 111.459 -179.807 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 14.0 m -136.04 147.89 27.97 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.918 0 N-CA-C 109.239 -0.652 . . . . 0.0 109.239 -179.833 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 21.5 t . . . . . 0 C--O 1.221 -0.395 0 CA-C-O 117.8 -1.095 . . . . 0.0 111.19 179.168 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' F' F ' 1' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 . . . . . 0 N--CA 1.488 1.471 0 N-CA-C 109.166 -0.679 . . . . 0.0 109.166 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' F' F ' 2' ' ' ALA . . . . . . . . . . . . . . . -67.95 149.69 49.44 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-N 116.501 -0.318 . . . . 0.0 110.285 179.519 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' F' F ' 3' ' ' GLU . . . . . . . . . . . . . 40.2 tt0 -163.11 103.23 0.98 Allowed 'General case' 0 C--O 1.212 -0.89 0 CA-C-N 116.428 -0.351 . . . . 0.0 110.054 -179.679 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 15.7 m-85 -68.3 173.17 5.04 Favored 'General case' 0 N--CA 1.473 0.691 0 CA-C-O 121.143 0.497 . . . . 0.0 110.015 179.419 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' F' F ' 5' ' ' ARG . . . . . 0.843 HH21 HG13 ' B' ' 24' ' ' VAL . 53.3 mtp180 -68.03 129.75 40.87 Favored 'General case' 0 CA--C 1.537 0.465 0 CA-C-N 115.422 -0.808 . . . . 0.0 110.602 -177.962 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 45.4 m170 -96.39 125.33 40.81 Favored 'General case' 0 N--CA 1.476 0.874 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 178.885 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' F' F ' 7' ' ' ASP . . . . . 0.577 ' OD1' HG11 ' H' ' 24' ' ' VAL . 11.7 m-20 -71.72 145.05 49.06 Favored 'General case' 0 N--CA 1.465 0.307 0 O-C-N 123.293 0.37 . . . . 0.0 111.423 -179.842 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' F' F ' 8' ' ' SER . . . . . . . . . . . . . 22.8 t -161.06 179.35 8.5 Favored 'General case' 0 N--CA 1.473 0.685 0 N-CA-C 109.277 -0.638 . . . . 0.0 109.277 178.448 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 125.78 19.84 2.19 Favored Glycine 0 N--CA 1.482 1.742 0 N-CA-C 111.752 -0.539 . . . . 0.0 111.752 179.634 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 40.4 p90 -57.07 128.87 39.18 Favored 'General case' 0 N--CA 1.474 0.756 0 N-CA-C 112.528 0.566 . . . . 0.0 112.528 -179.18 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 45.8 mt-10 -84.49 155.34 22.22 Favored 'General case' 0 N--CA 1.474 0.732 0 N-CA-C 109.318 -0.623 . . . . 0.0 109.318 177.986 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -155.49 127.81 1.03 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.53 0 N-CA-C 108.31 -0.996 . . . . 0.0 108.31 178.742 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 48.6 m-70 -134.74 141.97 46.62 Favored 'General case' 0 N--CA 1.482 1.128 0 CA-C-O 120.606 0.241 . . . . 0.0 111.387 -178.034 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -165.19 99.14 0.73 Allowed 'General case' 0 N--CA 1.485 1.3 0 CA-C-N 116.811 -0.177 . . . . 0.0 111.191 179.702 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' F' F ' 15' ' ' GLN . . . . . 0.538 HE21 ' CA ' ' F' ' 37' ' ' GLY . 49.1 mt-30 -108.84 -171.44 1.85 Allowed 'General case' 0 CA--C 1.499 -0.981 0 N-CA-C 108.525 -0.917 . . . . 0.0 108.525 179.817 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -164.6 98.08 0.78 Allowed 'General case' 0 CA--C 1.54 0.58 0 CA-C-N 114.883 -1.053 . . . . 0.0 109.537 178.657 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' F' F ' 17' ' ' LEU . . . . . 0.569 HD12 ' N ' ' F' ' 17' ' ' LEU . 4.8 mp -106.78 163.14 13.18 Favored 'General case' 0 N--CA 1.49 1.573 0 N-CA-C 109.029 -0.73 . . . . 0.0 109.029 -179.899 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 42.4 t -141.54 118.19 7.31 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.308 0 C-N-CA 122.584 0.354 . . . . 0.0 110.361 179.071 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 55.1 m-85 -69.51 156.06 39.48 Favored 'General case' 0 C--N 1.357 0.932 0 N-CA-C 107.329 -1.36 . . . . 0.0 107.329 176.602 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 13.6 t80 -172.92 -55.69 0.02 OUTLIER 'General case' 0 N--CA 1.483 1.22 0 CA-C-O 121.868 0.842 . . . . 0.0 109.799 179.456 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -42.24 88.8 0.0 OUTLIER 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 114.534 -1.212 . . . . 0.0 112.789 -178.992 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 38.0 tt0 -61.12 156.33 18.4 Favored 'General case' 0 N--CA 1.471 0.617 0 CA-C-N 114.943 -1.026 . . . . 0.0 110.802 179.268 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 12.0 m-20 -138.1 129.63 27.89 Favored 'General case' 0 N--CA 1.482 1.134 0 C-N-CA 122.96 0.504 . . . . 0.0 110.637 -179.638 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' F' F ' 24' ' ' VAL . . . . . 0.963 HG12 ' H ' ' F' ' 25' ' ' GLY . 40.0 t -80.1 -164.07 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.283 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 179.613 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' F' F ' 25' ' ' GLY . . . . . 0.963 ' H ' HG12 ' F' ' 24' ' ' VAL . . . -70.82 52.25 0.93 Allowed Glycine 0 C--N 1.342 0.888 0 CA-C-N 118.608 0.64 . . . . 0.0 112.378 -178.779 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 19.8 p -72.79 134.97 45.17 Favored 'General case' 0 C--O 1.218 -0.558 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 178.525 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 2.0 t-20 -68.21 95.16 0.56 Allowed 'General case' 0 CA--C 1.536 0.422 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 177.967 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 67.4 mttm -93.56 118.21 31.07 Favored 'General case' 0 N--CA 1.482 1.134 0 N-CA-C 110.066 -0.346 . . . . 0.0 110.066 -178.657 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.8 -125.33 0.01 OUTLIER Glycine 0 CA--C 1.539 1.565 0 N-CA-C 111.022 -0.831 . . . . 0.0 111.022 178.629 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.49 133.46 48.47 Favored 'General case' 0 N--CA 1.483 1.193 0 N-CA-C 109.533 -0.543 . . . . 0.0 109.533 179.479 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 65.7 mt -82.47 138.64 19.07 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.306 0 N-CA-C 107.051 -1.463 . . . . 0.0 107.051 178.587 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 35.0 mt -130.34 127.82 63.23 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.833 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 -179.437 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.56 80.05 0.11 Allowed Glycine 0 CA--C 1.525 0.67 0 CA-C-N 115.929 -0.578 . . . . 0.0 113.241 179.023 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' F' F ' 34' ' ' LEU . . . . . 0.443 HD23 ' N ' ' F' ' 35' ' ' MET . 1.8 tt -110.65 121.23 44.81 Favored 'General case' 0 N--CA 1.48 1.067 0 N-CA-C 107.298 -1.371 . . . . 0.0 107.298 177.59 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' F' F ' 35' ' ' MET . . . . . 0.443 ' N ' HD23 ' F' ' 34' ' ' LEU . 8.7 mtp -153.83 163.85 39.35 Favored 'General case' 0 C--O 1.212 -0.894 0 N-CA-C 108.97 -0.752 . . . . 0.0 108.97 179.314 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 98.3 t -160.19 145.48 5.79 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.27 0 N-CA-C 106.906 -1.516 . . . . 0.0 106.906 -179.857 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' F' F ' 37' ' ' GLY . . . . . 0.538 ' CA ' HE21 ' F' ' 15' ' ' GLN . . . 55.15 73.84 0.38 Allowed Glycine 0 C--N 1.317 -0.507 0 N-CA-C 111.188 -0.765 . . . . 0.0 111.188 178.624 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 170.73 -148.17 11.16 Favored Glycine 0 C--O 1.222 -0.635 0 C-N-CA 120.832 -0.699 . . . . 0.0 111.493 -179.728 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 14.1 m -136.22 147.99 27.7 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.981 0 N-CA-C 109.119 -0.697 . . . . 0.0 109.119 -179.793 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 21.6 t . . . . . 0 C--O 1.221 -0.405 0 CA-C-O 117.722 -1.132 . . . . 0.0 111.129 179.138 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' G' G ' 1' ' ' ASP . . . . . . . . . . . . . 8.0 m-20 . . . . . 0 N--CA 1.487 1.41 0 N-CA-C 109.338 -0.616 . . . . 0.0 109.338 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' G' G ' 2' ' ' ALA . . . . . . . . . . . . . . . -68.85 151.1 47.03 Favored 'General case' 0 CA--C 1.533 0.291 0 CA-C-O 120.855 0.359 . . . . 0.0 110.243 179.779 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' G' G ' 3' ' ' GLU . . . . . . . . . . . . . 40.4 tt0 -162.89 103.89 1.02 Allowed 'General case' 0 C--O 1.216 -0.706 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.088 -179.286 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 21.7 m-85 -67.93 171.49 6.66 Favored 'General case' 0 N--CA 1.475 0.778 0 CA-C-O 120.991 0.424 . . . . 0.0 110.149 179.422 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' G' G ' 5' ' ' ARG . . . . . 0.746 HH21 HG13 ' F' ' 24' ' ' VAL . 55.0 mtp180 -67.13 129.1 38.79 Favored 'General case' 0 N--CA 1.469 0.512 0 CA-C-N 115.65 -0.705 . . . . 0.0 110.287 -178.152 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 44.2 m170 -96.09 125.48 40.65 Favored 'General case' 0 N--CA 1.474 0.726 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 178.904 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 9.8 m-20 -72.37 141.5 48.74 Favored 'General case' 0 N--CA 1.468 0.437 0 O-C-N 123.742 0.652 . . . . 0.0 111.52 -179.698 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' G' G ' 8' ' ' SER . . . . . . . . . . . . . 23.2 t -158.58 -179.76 8.38 Favored 'General case' 0 N--CA 1.472 0.665 0 N-CA-C 109.196 -0.668 . . . . 0.0 109.196 178.408 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 125.02 20.16 2.31 Favored Glycine 0 N--CA 1.481 1.675 0 N-CA-C 111.617 -0.593 . . . . 0.0 111.617 179.477 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 43.1 p90 -57.75 128.7 38.41 Favored 'General case' 0 N--CA 1.474 0.727 0 N-CA-C 112.362 0.505 . . . . 0.0 112.362 -178.939 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 46.9 mt-10 -84.51 154.44 22.69 Favored 'General case' 0 N--CA 1.473 0.684 0 CA-C-O 121.055 0.455 . . . . 0.0 109.803 178.611 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 2.6 p -155.8 127.82 1.0 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.028 0 N-CA-C 108.353 -0.98 . . . . 0.0 108.353 178.926 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 50.2 m-70 -134.02 142.99 47.83 Favored 'General case' 0 N--CA 1.476 0.832 0 CA-C-N 115.154 -0.93 . . . . 0.0 111.077 -178.214 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -166.32 98.33 0.6 Allowed 'General case' 0 N--CA 1.484 1.227 0 CA-C-N 116.52 -0.309 . . . . 0.0 110.655 179.129 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' G' G ' 15' ' ' GLN . . . . . 0.548 HE21 ' CA ' ' G' ' 37' ' ' GLY . 49.5 mt-30 -107.92 -171.91 1.96 Allowed 'General case' 0 CA--C 1.5 -0.943 0 N-CA-C 108.544 -0.91 . . . . 0.0 108.544 179.959 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' G' G ' 16' ' ' LYS . . . . . 0.405 ' C ' HD12 ' G' ' 17' ' ' LEU . 88.1 tttt -164.35 98.18 0.81 Allowed 'General case' 0 N--CA 1.472 0.627 0 CA-C-N 115.083 -0.962 . . . . 0.0 109.441 178.567 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' G' G ' 17' ' ' LEU . . . . . 0.575 ' N ' HD12 ' G' ' 17' ' ' LEU . 5.3 mp -106.83 162.28 13.95 Favored 'General case' 0 N--CA 1.486 1.36 0 N-CA-C 109.33 -0.619 . . . . 0.0 109.33 -179.757 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 41.0 t -142.46 118.27 5.62 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.974 0 C-N-CA 122.601 0.361 . . . . 0.0 110.18 178.823 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 48.7 m-85 -69.33 150.49 47.29 Favored 'General case' 0 C--N 1.371 1.524 0 N-CA-C 107.454 -1.313 . . . . 0.0 107.454 176.709 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 11.4 t80 -171.09 -55.29 0.02 OUTLIER 'General case' 0 N--CA 1.486 1.351 0 CA-C-N 117.802 0.274 . . . . 0.0 110.263 -179.926 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.88 90.09 0.0 OUTLIER 'General case' 0 C--N 1.326 -0.446 0 C-N-CA 123.655 0.782 . . . . 0.0 112.339 179.925 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 38.4 tt0 -61.93 156.66 20.36 Favored 'General case' 0 N--CA 1.469 0.484 0 CA-C-N 114.855 -1.066 . . . . 0.0 110.029 178.886 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 12.1 m-20 -138.31 129.85 27.76 Favored 'General case' 0 N--CA 1.481 1.101 0 C-N-CA 122.958 0.503 . . . . 0.0 110.148 -179.557 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' G' G ' 24' ' ' VAL . . . . . 0.967 HG12 ' H ' ' G' ' 25' ' ' GLY . 39.5 t -81.03 -164.03 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.972 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 179.578 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' G' G ' 25' ' ' GLY . . . . . 0.967 ' H ' HG12 ' G' ' 24' ' ' VAL . . . -70.48 51.51 0.84 Allowed Glycine 0 CA--C 1.527 0.836 0 CA-C-N 118.383 0.538 . . . . 0.0 112.452 -179.016 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 18.0 p -72.34 135.9 46.03 Favored 'General case' 0 C--N 1.329 -0.294 0 N-CA-C 109.175 -0.676 . . . . 0.0 109.175 177.936 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 2.0 t-20 -69.1 94.5 0.67 Allowed 'General case' 0 CA--C 1.536 0.416 0 N-CA-C 107.902 -1.147 . . . . 0.0 107.902 177.814 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 68.0 mttm -92.14 118.94 31.32 Favored 'General case' 0 N--CA 1.482 1.134 0 N-CA-C 110.06 -0.348 . . . . 0.0 110.06 -179.2 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.45 -123.37 0.01 OUTLIER Glycine 0 CA--C 1.534 1.247 0 N-CA-C 110.517 -1.033 . . . . 0.0 110.517 178.608 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -129.91 133.54 46.92 Favored 'General case' 0 N--CA 1.47 0.547 0 N-CA-C 109.526 -0.546 . . . . 0.0 109.526 179.604 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 68.8 mt -81.9 140.23 16.78 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.664 0 N-CA-C 107.37 -1.344 . . . . 0.0 107.37 178.626 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 41.3 mt -131.81 129.27 60.94 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.402 0 CA-C-N 119.135 0.88 . . . . 0.0 109.375 179.698 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.47 79.41 0.13 Allowed Glycine 0 CA--C 1.527 0.816 0 CA-C-N 116.302 -0.408 . . . . 0.0 112.882 179.13 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' G' G ' 34' ' ' LEU . . . . . 0.441 HD23 ' N ' ' G' ' 35' ' ' MET . 1.7 tt -110.34 121.69 45.88 Favored 'General case' 0 N--CA 1.482 1.142 0 N-CA-C 107.146 -1.427 . . . . 0.0 107.146 177.616 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' G' G ' 35' ' ' MET . . . . . 0.441 ' N ' HD23 ' G' ' 34' ' ' LEU . 9.2 mtp -154.34 163.91 39.43 Favored 'General case' 0 N--CA 1.477 0.917 0 N-CA-C 107.94 -1.133 . . . . 0.0 107.94 179.583 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 91.6 t -160.03 145.22 5.92 Favored 'Isoleucine or valine' 0 C--O 1.232 0.167 0 N-CA-C 106.376 -1.713 . . . . 0.0 106.376 179.901 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' G' G ' 37' ' ' GLY . . . . . 0.548 ' CA ' HE21 ' G' ' 15' ' ' GLN . . . 55.75 73.88 0.38 Allowed Glycine 0 C--N 1.316 -0.561 0 N-CA-C 111.58 -0.608 . . . . 0.0 111.58 178.355 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 169.69 -146.96 10.46 Favored Glycine 0 N--CA 1.469 0.886 0 N-CA-C 110.834 -0.907 . . . . 0.0 110.834 179.583 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 15.3 m -136.33 148.31 27.41 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.932 0 CA-C-N 117.042 0.421 . . . . 0.0 109.995 -179.768 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 21.2 t . . . . . 0 N--CA 1.472 0.649 0 CA-C-O 117.881 -1.057 . . . . 0.0 111.232 179.257 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' H' H ' 1' ' ' ASP . . . . . . . . . . . . . 8.5 m-20 . . . . . 0 N--CA 1.488 1.468 0 N-CA-C 109.366 -0.605 . . . . 0.0 109.366 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' H' H ' 2' ' ' ALA . . . . . . . . . . . . . . . -68.85 150.96 47.2 Favored 'General case' 0 CA--C 1.532 0.286 0 CA-C-N 116.482 -0.326 . . . . 0.0 110.268 179.719 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' H' H ' 3' ' ' GLU . . . . . . . . . . . . . 39.9 tt0 -162.86 103.65 1.02 Allowed 'General case' 0 N--CA 1.472 0.673 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.16 -179.23 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 21.8 m-85 -67.82 171.56 6.43 Favored 'General case' 0 N--CA 1.473 0.7 0 CA-C-O 121.064 0.459 . . . . 0.0 110.105 179.489 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' H' H ' 5' ' ' ARG . . . . . 0.741 HH21 HG13 ' D' ' 24' ' ' VAL . 54.5 mtp180 -67.16 129.12 38.88 Favored 'General case' 0 N--CA 1.469 0.489 0 CA-C-N 115.591 -0.731 . . . . 0.0 110.382 -178.15 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 44.5 m170 -96.13 125.27 40.55 Favored 'General case' 0 N--CA 1.474 0.772 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 179.0 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 9.7 m-20 -72.34 141.29 48.79 Favored 'General case' 0 N--CA 1.468 0.458 0 O-C-N 123.453 0.47 . . . . 0.0 111.506 -179.643 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' H' H ' 8' ' ' SER . . . . . . . . . . . . . 22.7 t -158.25 -179.83 8.47 Favored 'General case' 0 N--CA 1.472 0.642 0 N-CA-C 109.192 -0.669 . . . . 0.0 109.192 178.626 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 124.74 20.23 2.36 Favored Glycine 0 N--CA 1.481 1.645 0 N-CA-C 111.67 -0.572 . . . . 0.0 111.67 179.573 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 42.5 p90 -57.77 128.81 38.94 Favored 'General case' 0 N--CA 1.473 0.708 0 N-CA-C 112.344 0.498 . . . . 0.0 112.344 -179.038 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 46.9 mt-10 -84.48 154.36 22.77 Favored 'General case' 0 N--CA 1.475 0.795 0 CA-C-O 121.074 0.464 . . . . 0.0 109.839 178.571 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.6 p -155.69 128.03 1.04 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.048 0 N-CA-C 108.373 -0.973 . . . . 0.0 108.373 178.867 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 50.2 m-70 -134.11 143.27 47.88 Favored 'General case' 0 N--CA 1.476 0.851 0 CA-C-N 115.158 -0.928 . . . . 0.0 111.151 -178.171 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -166.75 98.32 0.56 Allowed 'General case' 0 N--CA 1.482 1.168 0 CA-C-N 116.65 -0.25 . . . . 0.0 110.726 179.131 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' H' H ' 15' ' ' GLN . . . . . 0.537 HE21 ' CA ' ' H' ' 37' ' ' GLY . 49.0 mt-30 -108.0 -172.39 2.05 Favored 'General case' 0 CA--C 1.499 -1.001 0 N-CA-C 108.42 -0.956 . . . . 0.0 108.42 -179.964 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -164.1 97.94 0.83 Allowed 'General case' 0 N--CA 1.471 0.582 0 CA-C-N 115.083 -0.962 . . . . 0.0 109.277 178.748 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' H' H ' 17' ' ' LEU . . . . . 0.578 HD12 ' N ' ' H' ' 17' ' ' LEU . 5.3 mp -106.67 162.24 13.94 Favored 'General case' 0 N--CA 1.486 1.354 0 N-CA-C 109.259 -0.645 . . . . 0.0 109.259 -179.774 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 41.0 t -142.35 118.15 5.73 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.032 0 C-N-CA 122.613 0.365 . . . . 0.0 110.209 178.899 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 49.1 m-85 -69.65 150.88 46.55 Favored 'General case' 0 C--N 1.371 1.502 0 N-CA-C 107.517 -1.29 . . . . 0.0 107.517 176.631 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 12.1 t80 -172.31 -54.88 0.02 OUTLIER 'General case' 0 N--CA 1.482 1.163 0 N-CA-C 110.213 -0.292 . . . . 0.0 110.213 -179.752 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -42.14 90.55 0.0 OUTLIER 'General case' 0 CA--C 1.534 0.352 0 C-N-CA 123.543 0.737 . . . . 0.0 112.095 179.942 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 38.5 tt0 -62.09 156.64 20.95 Favored 'General case' 0 N--CA 1.469 0.493 0 CA-C-N 114.815 -1.084 . . . . 0.0 110.105 179.087 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 12.0 m-20 -138.16 129.98 28.27 Favored 'General case' 0 N--CA 1.48 1.066 0 C-N-CA 122.968 0.507 . . . . 0.0 110.215 -179.536 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' H' H ' 24' ' ' VAL . . . . . 0.951 HG12 ' H ' ' H' ' 25' ' ' GLY . 39.4 t -81.3 -164.1 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.992 0 N-CA-C 108.376 -0.972 . . . . 0.0 108.376 179.664 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' H' H ' 25' ' ' GLY . . . . . 0.951 ' H ' HG12 ' H' ' 24' ' ' VAL . . . -70.18 51.32 0.77 Allowed Glycine 0 CA--C 1.529 0.932 0 CA-C-N 118.483 0.583 . . . . 0.0 112.268 -179.095 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 17.9 p -72.44 135.96 45.89 Favored 'General case' 0 C--N 1.33 -0.254 0 N-CA-C 109.3 -0.63 . . . . 0.0 109.3 177.945 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 2.0 t-20 -69.2 94.58 0.69 Allowed 'General case' 0 CA--C 1.535 0.368 0 N-CA-C 107.968 -1.123 . . . . 0.0 107.968 177.944 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 68.0 mttm -92.27 118.86 31.31 Favored 'General case' 0 N--CA 1.48 1.066 0 N-CA-C 110.111 -0.329 . . . . 0.0 110.111 -179.21 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.47 -123.02 0.01 OUTLIER Glycine 0 CA--C 1.535 1.291 0 N-CA-C 110.477 -1.049 . . . . 0.0 110.477 178.601 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.04 133.77 46.94 Favored 'General case' 0 N--CA 1.471 0.616 0 C-N-CA 123.0 0.52 . . . . 0.0 109.61 179.715 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 68.5 mt -82.2 140.1 16.93 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.591 0 N-CA-C 107.315 -1.365 . . . . 0.0 107.315 178.57 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 41.6 mt -131.74 129.46 61.26 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.278 0 CA-C-N 119.092 0.86 . . . . 0.0 109.317 179.826 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.14 79.48 0.12 Allowed Glycine 0 CA--C 1.527 0.788 0 CA-C-N 116.239 -0.437 . . . . 0.0 112.933 179.155 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' H' H ' 34' ' ' LEU . . . . . 0.432 HD23 ' N ' ' H' ' 35' ' ' MET . 1.7 tt -110.44 121.76 46.09 Favored 'General case' 0 N--CA 1.481 1.099 0 N-CA-C 107.082 -1.451 . . . . 0.0 107.082 177.592 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' H' H ' 35' ' ' MET . . . . . 0.432 ' N ' HD23 ' H' ' 34' ' ' LEU . 9.3 mtp -154.3 163.71 39.73 Favored 'General case' 0 N--CA 1.476 0.85 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 179.679 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 89.9 t -160.05 145.2 5.89 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.163 0 N-CA-C 106.415 -1.698 . . . . 0.0 106.415 179.838 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' H' H ' 37' ' ' GLY . . . . . 0.537 ' CA ' HE21 ' H' ' 15' ' ' GLN . . . 55.75 73.77 0.39 Allowed Glycine 0 C--N 1.316 -0.537 0 N-CA-C 111.536 -0.625 . . . . 0.0 111.536 178.433 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 169.9 -147.19 10.6 Favored Glycine 0 N--CA 1.469 0.899 0 N-CA-C 110.779 -0.928 . . . . 0.0 110.779 179.641 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 15.1 m -136.25 148.18 27.57 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.918 0 CA-C-N 116.938 0.369 . . . . 0.0 110.033 -179.763 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 21.3 t . . . . . 0 N--CA 1.471 0.625 0 CA-C-O 117.864 -1.065 . . . . 0.0 111.138 179.227 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' I' I ' 1' ' ' ASP . . . . . . . . . . . . . 8.5 m-20 . . . . . 0 N--CA 1.488 1.442 0 N-CA-C 109.306 -0.627 . . . . 0.0 109.306 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' I' I ' 2' ' ' ALA . . . . . . . . . . . . . . . -69.19 151.29 46.51 Favored 'General case' 0 CA--C 1.533 0.298 0 CA-C-O 120.956 0.407 . . . . 0.0 110.171 179.789 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' I' I ' 3' ' ' GLU . . . . . . . . . . . . . 40.4 tt0 -163.1 103.96 0.99 Allowed 'General case' 0 N--CA 1.471 0.624 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.105 -179.266 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 21.8 m-85 -67.97 171.48 6.72 Favored 'General case' 0 N--CA 1.473 0.712 0 CA-C-O 120.981 0.42 . . . . 0.0 110.169 179.433 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' I' I ' 5' ' ' ARG . . . . . 0.725 HH21 HG13 ' E' ' 24' ' ' VAL . 54.6 mtp180 -67.18 128.89 38.07 Favored 'General case' 0 N--CA 1.468 0.455 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.378 -178.214 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 44.3 m170 -95.87 125.22 40.27 Favored 'General case' 0 N--CA 1.475 0.777 0 N-CA-C 109.736 -0.468 . . . . 0.0 109.736 178.99 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 9.8 m-20 -72.21 141.76 49.0 Favored 'General case' 0 N--CA 1.468 0.442 0 O-C-N 123.484 0.49 . . . . 0.0 111.397 -179.682 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' I' I ' 8' ' ' SER . . . . . . . . . . . . . 22.7 t -158.65 179.94 8.65 Favored 'General case' 0 N--CA 1.472 0.63 0 N-CA-C 109.201 -0.666 . . . . 0.0 109.201 178.636 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 124.87 20.29 2.32 Favored Glycine 0 N--CA 1.482 1.739 0 N-CA-C 111.646 -0.582 . . . . 0.0 111.646 179.487 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 42.8 p90 -57.71 128.75 38.62 Favored 'General case' 0 N--CA 1.474 0.765 0 N-CA-C 112.342 0.497 . . . . 0.0 112.342 -179.053 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 46.8 mt-10 -84.39 154.48 22.8 Favored 'General case' 0 N--CA 1.474 0.773 0 CA-C-O 121.043 0.449 . . . . 0.0 109.806 178.538 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 2.6 p -155.82 128.04 1.03 Allowed 'Isoleucine or valine' 0 CA--C 1.553 1.062 0 N-CA-C 108.332 -0.988 . . . . 0.0 108.332 178.843 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 50.4 m-70 -134.17 143.27 47.81 Favored 'General case' 0 N--CA 1.476 0.848 0 CA-C-N 115.094 -0.957 . . . . 0.0 111.094 -178.182 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -166.75 98.37 0.56 Allowed 'General case' 0 N--CA 1.483 1.198 0 CA-C-N 116.626 -0.261 . . . . 0.0 110.795 179.125 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' I' I ' 15' ' ' GLN . . . . . 0.548 HE21 ' CA ' ' I' ' 37' ' ' GLY . 48.9 mt-30 -108.12 -172.15 2.01 Favored 'General case' 0 CA--C 1.499 -0.99 0 N-CA-C 108.441 -0.948 . . . . 0.0 108.441 -179.981 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' I' I ' 16' ' ' LYS . . . . . 0.403 ' C ' HD12 ' I' ' 17' ' ' LEU . 88.1 tttt -164.21 98.03 0.82 Allowed 'General case' 0 N--CA 1.471 0.606 0 CA-C-N 114.992 -1.004 . . . . 0.0 109.333 178.691 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' I' I ' 17' ' ' LEU . . . . . 0.576 HD12 ' N ' ' I' ' 17' ' ' LEU . 5.3 mp -106.64 162.21 13.96 Favored 'General case' 0 N--CA 1.487 1.388 0 N-CA-C 109.278 -0.638 . . . . 0.0 109.278 -179.749 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 40.7 t -142.24 118.12 5.93 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.059 0 C-N-CA 122.632 0.373 . . . . 0.0 110.223 178.851 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 49.2 m-85 -69.61 150.81 46.66 Favored 'General case' 0 C--N 1.37 1.494 0 N-CA-C 107.49 -1.3 . . . . 0.0 107.49 176.599 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 12.2 t80 -172.2 -55.0 0.02 OUTLIER 'General case' 0 N--CA 1.483 1.201 0 N-CA-C 110.231 -0.285 . . . . 0.0 110.231 -179.826 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -42.08 90.45 0.0 OUTLIER 'General case' 0 CA--C 1.535 0.389 0 C-N-CA 123.657 0.783 . . . . 0.0 112.084 179.958 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 38.3 tt0 -62.02 156.68 20.65 Favored 'General case' 0 N--CA 1.469 0.519 0 CA-C-N 114.793 -1.094 . . . . 0.0 110.043 179.147 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 12.3 m-20 -138.17 129.83 28.04 Favored 'General case' 0 N--CA 1.481 1.097 0 C-N-CA 122.973 0.509 . . . . 0.0 110.217 -179.624 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' I' I ' 24' ' ' VAL . . . . . 0.944 HG12 ' H ' ' I' ' 25' ' ' GLY . 38.8 t -80.96 -163.87 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 1.005 0 N-CA-C 108.381 -0.97 . . . . 0.0 108.381 179.618 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' I' I ' 25' ' ' GLY . . . . . 0.944 ' H ' HG12 ' I' ' 24' ' ' VAL . . . -70.57 51.33 0.85 Allowed Glycine 0 CA--C 1.528 0.895 0 CA-C-N 118.364 0.529 . . . . 0.0 112.376 -179.074 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 17.7 p -72.34 136.04 46.07 Favored 'General case' 0 C--N 1.33 -0.252 0 N-CA-C 109.252 -0.647 . . . . 0.0 109.252 177.947 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 2.0 t-20 -69.23 94.58 0.7 Allowed 'General case' 0 CA--C 1.535 0.371 0 N-CA-C 107.953 -1.128 . . . . 0.0 107.953 177.888 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 68.1 mttm -92.32 118.96 31.43 Favored 'General case' 0 N--CA 1.48 1.068 0 N-CA-C 110.15 -0.315 . . . . 0.0 110.15 -179.15 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.52 -123.31 0.01 OUTLIER Glycine 0 CA--C 1.534 1.249 0 N-CA-C 110.632 -0.987 . . . . 0.0 110.632 178.648 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -129.77 133.21 46.86 Favored 'General case' 0 N--CA 1.472 0.665 0 C-N-CA 123.047 0.539 . . . . 0.0 109.594 179.715 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 68.5 mt -81.86 139.99 17.15 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.555 0 N-CA-C 107.266 -1.383 . . . . 0.0 107.266 178.605 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 41.1 mt -131.62 129.48 61.62 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.359 0 CA-C-N 119.023 0.829 . . . . 0.0 109.318 179.807 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.13 79.36 0.13 Allowed Glycine 0 CA--C 1.527 0.814 0 CA-C-N 116.289 -0.414 . . . . 0.0 112.936 179.085 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' I' I ' 34' ' ' LEU . . . . . 0.436 HD23 ' N ' ' I' ' 35' ' ' MET . 1.7 tt -110.28 121.73 45.97 Favored 'General case' 0 N--CA 1.481 1.087 0 N-CA-C 107.163 -1.421 . . . . 0.0 107.163 177.55 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' I' I ' 35' ' ' MET . . . . . 0.436 ' N ' HD23 ' I' ' 34' ' ' LEU . 9.4 mtp -154.26 163.7 39.72 Favored 'General case' 0 N--CA 1.475 0.786 0 N-CA-C 107.971 -1.122 . . . . 0.0 107.971 179.786 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 89.5 t -160.04 145.31 5.94 Favored 'Isoleucine or valine' 0 C--O 1.232 0.162 0 N-CA-C 106.423 -1.695 . . . . 0.0 106.423 179.801 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' I' I ' 37' ' ' GLY . . . . . 0.548 ' CA ' HE21 ' I' ' 15' ' ' GLN . . . 55.55 74.03 0.36 Allowed Glycine 0 C--N 1.315 -0.599 0 N-CA-C 111.573 -0.611 . . . . 0.0 111.573 178.484 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 169.68 -147.04 10.53 Favored Glycine 0 N--CA 1.469 0.877 0 N-CA-C 110.806 -0.918 . . . . 0.0 110.806 179.587 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 15.1 m -136.3 148.27 27.47 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.96 0 CA-C-N 116.979 0.389 . . . . 0.0 110.06 -179.79 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 21.4 t . . . . . 0 N--CA 1.471 0.61 0 CA-C-O 117.899 -1.048 . . . . 0.0 111.07 179.139 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 67.6 m-20 . . . . . 0 N--CA 1.49 1.573 0 N-CA-C 109.385 -0.598 . . . . 0.0 109.385 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -63.02 -170.59 0.03 OUTLIER 'General case' 0 N--CA 1.468 0.457 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.507 179.867 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 26.7 tt0 -153.21 165.98 33.97 Favored 'General case' 0 N--CA 1.475 0.798 0 N-CA-C 109.966 -0.383 . . . . 0.0 109.966 -179.904 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 21.1 p90 -67.45 137.44 55.87 Favored 'General case' 0 N--CA 1.471 0.578 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.384 -178.525 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 99.0 mtt180 -136.73 153.18 50.93 Favored 'General case' 0 N--CA 1.482 1.137 0 N-CA-C 109.527 -0.546 . . . . 0.0 109.527 178.523 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 58.5 t-80 -113.98 114.82 26.69 Favored 'General case' 0 N--CA 1.477 0.9 0 C-N-CA 123.094 0.557 . . . . 0.0 109.627 179.493 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' ASP . . . . . 0.424 ' O ' ' OG ' ' D' ' 8' ' ' SER . 8.9 m-20 -72.99 156.36 38.91 Favored 'General case' 0 N--CA 1.465 0.307 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.062 179.053 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 9.5 p -166.17 -177.08 3.97 Favored 'General case' 0 N--CA 1.483 1.181 0 CA-C-O 120.913 0.387 . . . . 0.0 110.528 178.736 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.9 43.94 1.58 Allowed Glycine 0 N--CA 1.482 1.708 0 CA-C-N 115.747 -0.661 . . . . 0.0 112.19 179.427 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 51.2 p90 -65.32 131.86 47.54 Favored 'General case' 0 N--CA 1.473 0.715 0 CA-C-N 116.83 0.315 . . . . 0.0 111.479 179.751 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 84.4 mt-10 -94.3 153.52 17.97 Favored 'General case' 0 N--CA 1.476 0.853 0 N-CA-C 109.655 -0.498 . . . . 0.0 109.655 178.587 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -153.28 128.52 1.55 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.583 0 N-CA-C 107.781 -1.192 . . . . 0.0 107.781 178.126 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 50.9 m-70 -135.13 144.88 47.34 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 119.144 0.884 . . . . 0.0 111.221 -179.143 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 6.3 t60 -165.83 99.0 0.66 Allowed 'General case' 0 N--CA 1.48 1.061 0 CA-C-N 116.394 -0.366 . . . . 0.0 110.588 179.465 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . 0.451 HE22 ' H ' ' A' ' 37' ' ' GLY . 22.2 pt20 -124.41 155.33 39.01 Favored 'General case' 0 CA--C 1.501 -0.927 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 -179.609 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -124.99 106.02 9.64 Favored 'General case' 0 N--CA 1.478 0.974 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 177.986 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 6.1 mp -121.16 148.88 43.62 Favored 'General case' 0 N--CA 1.497 1.908 0 CA-C-O 121.412 0.625 . . . . 0.0 110.797 -178.528 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 30.8 t -107.57 123.77 63.12 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.018 0 N-CA-C 108.077 -1.083 . . . . 0.0 108.077 177.612 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.506 ' O ' ' N ' ' A' ' 21' ' ' ALA . 25.7 m-85 -119.57 -160.89 0.83 Allowed 'General case' 0 N--CA 1.498 1.962 0 CA-C-N 120.232 1.378 . . . . 0.0 109.178 -179.966 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.555 ' O ' ' HA ' ' D' ' 20' ' ' PHE . 78.7 m-85 -50.94 76.8 0.0 OUTLIER 'General case' 0 C--O 1.2 -1.511 0 C-N-CA 123.772 0.829 . . . . 0.0 111.318 -179.164 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . 0.506 ' N ' ' O ' ' A' ' 19' ' ' PHE . . . -88.47 -75.61 0.42 Allowed 'General case' 0 N--CA 1.471 0.597 0 CA-C-N 115.691 -0.686 . . . . 0.0 110.158 -179.614 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 40.4 tt0 -96.12 98.65 10.51 Favored 'General case' 0 N--CA 1.463 0.205 0 N-CA-C 108.461 -0.94 . . . . 0.0 108.461 179.349 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 4.1 p30 -159.45 145.03 15.91 Favored 'General case' 0 N--CA 1.484 1.242 0 O-C-N 122.334 -0.229 . . . . 0.0 110.828 179.598 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.405 HG12 ' N ' ' A' ' 25' ' ' GLY . 88.6 t -63.04 163.91 1.46 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.799 0 N-CA-C 107.619 -1.252 . . . . 0.0 107.619 176.998 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.5 ' H ' ' HB ' ' D' ' 24' ' ' VAL . . . -117.8 45.62 1.25 Allowed Glycine 0 N--CA 1.474 1.183 0 CA-C-O 119.649 -0.529 . . . . 0.0 111.927 -179.409 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -60.32 -165.21 0.01 OUTLIER 'General case' 0 N--CA 1.471 0.622 0 O-C-N 123.805 0.356 . . . . 0.0 110.461 179.618 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 24.0 t-20 -70.23 80.77 0.52 Allowed 'General case' 0 N--CA 1.463 0.197 0 CA-C-N 116.378 -0.373 . . . . 0.0 110.384 179.654 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 96.9 mttt -79.73 138.23 37.25 Favored 'General case' 0 N--CA 1.472 0.635 0 N-CA-C 109.195 -0.668 . . . . 0.0 109.195 179.365 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.84 -166.13 0.9 Allowed Glycine 0 C--N 1.337 0.621 0 N-CA-C 109.68 -1.368 . . . . 0.0 109.68 178.189 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.73 113.99 26.83 Favored 'General case' 0 N--CA 1.474 0.772 0 N-CA-C 109.546 -0.538 . . . . 0.0 109.546 179.505 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 76.5 mt -99.58 135.39 35.2 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.601 0 N-CA-C 107.054 -1.462 . . . . 0.0 107.054 178.734 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . 0.405 ' C ' ' H ' ' A' ' 34' ' ' LEU . 26.7 pt -150.78 -172.1 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.353 0.743 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.326 -179.27 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.57 2.53 6.0 Favored Glycine 0 CA--C 1.525 0.711 0 N-CA-C 110.864 -0.894 . . . . 0.0 110.864 -179.905 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.418 HD23 ' N ' ' A' ' 35' ' ' MET . 1.1 tt -74.66 133.58 42.1 Favored 'General case' 0 CA--C 1.544 0.735 0 N-CA-C 109.247 -0.649 . . . . 0.0 109.247 -179.611 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' MET . . . . . 0.418 ' N ' HD23 ' A' ' 34' ' ' LEU . 26.6 ttt -159.44 151.4 20.68 Favored 'General case' 0 N--CA 1.47 0.527 0 N-CA-C 108.297 -1.001 . . . . 0.0 108.297 178.924 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.473 HG12 ' N ' ' A' ' 37' ' ' GLY . 63.3 t -154.49 162.89 1.81 Allowed 'Isoleucine or valine' 0 C--N 1.344 0.353 0 N-CA-C 107.774 -1.195 . . . . 0.0 107.774 -179.52 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . 0.473 ' N ' HG12 ' A' ' 36' ' ' VAL . . . 57.57 67.32 2.27 Favored Glycine 0 C--N 1.306 -1.091 0 CA-C-N 115.606 -0.725 . . . . 0.0 112.133 178.717 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.7 177.83 22.44 Favored Glycine 0 N--CA 1.476 1.325 0 N-CA-C 111.045 -0.822 . . . . 0.0 111.045 178.717 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 33.4 m -109.69 152.71 11.66 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.612 0 C-N-CA 123.419 0.687 . . . . 0.0 110.217 -179.58 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 21.9 t . . . . . 0 C--O 1.216 -0.678 0 CA-C-O 118.319 -0.848 . . . . 0.0 110.531 179.615 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' B' B ' 1' ' ' ASP . . . . . . . . . . . . . 67.0 m-20 . . . . . 0 N--CA 1.49 1.566 0 N-CA-C 109.403 -0.592 . . . . 0.0 109.403 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' B' B ' 2' ' ' ALA . . . . . . . . . . . . . . . -63.5 -170.34 0.03 OUTLIER 'General case' 0 N--CA 1.468 0.427 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.562 179.798 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 3' ' ' GLU . . . . . . . . . . . . . 26.7 tt0 -153.5 166.09 33.8 Favored 'General case' 0 N--CA 1.475 0.799 0 N-CA-C 110.005 -0.369 . . . . 0.0 110.005 -179.935 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 20.5 p90 -67.29 137.26 55.96 Favored 'General case' 0 N--CA 1.47 0.549 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.546 -178.564 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 99.0 mtt180 -136.56 152.98 51.08 Favored 'General case' 0 N--CA 1.481 1.094 0 N-CA-C 109.517 -0.549 . . . . 0.0 109.517 178.534 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 58.4 t-80 -113.91 114.85 26.8 Favored 'General case' 0 N--CA 1.477 0.918 0 C-N-CA 123.156 0.582 . . . . 0.0 109.691 179.522 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 7' ' ' ASP . . . . . 0.419 ' O ' ' OG ' ' E' ' 8' ' ' SER . 8.4 m-20 -73.13 155.95 39.15 Favored 'General case' 0 N--CA 1.467 0.41 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.124 179.151 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 8' ' ' SER . . . . . . . . . . . . . 9.6 p -165.94 -176.93 4.0 Favored 'General case' 0 N--CA 1.481 1.105 0 CA-C-O 120.942 0.401 . . . . 0.0 110.567 178.847 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.67 44.08 1.6 Allowed Glycine 0 N--CA 1.483 1.779 0 CA-C-N 115.701 -0.681 . . . . 0.0 112.232 179.528 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 51.0 p90 -65.66 132.02 47.78 Favored 'General case' 0 N--CA 1.472 0.649 0 CA-C-O 120.688 0.28 . . . . 0.0 111.492 179.823 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 84.2 mt-10 -94.28 153.71 17.89 Favored 'General case' 0 N--CA 1.477 0.876 0 N-CA-C 109.746 -0.464 . . . . 0.0 109.746 178.483 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -153.41 128.38 1.5 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.511 0 N-CA-C 107.738 -1.208 . . . . 0.0 107.738 178.119 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 49.9 m-70 -135.19 144.5 47.02 Favored 'General case' 0 N--CA 1.492 1.664 0 CA-C-N 119.042 0.837 . . . . 0.0 111.218 -179.091 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 6.3 t60 -165.45 98.71 0.7 Allowed 'General case' 0 N--CA 1.481 1.088 0 CA-C-N 116.461 -0.336 . . . . 0.0 110.482 179.573 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . 0.435 HE22 ' H ' ' B' ' 37' ' ' GLY . 22.2 pt20 -124.14 155.38 38.54 Favored 'General case' 0 CA--C 1.501 -0.909 0 N-CA-C 107.988 -1.116 . . . . 0.0 107.988 -179.694 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -124.99 106.13 9.73 Favored 'General case' 0 N--CA 1.479 1.016 0 N-CA-C 108.121 -1.066 . . . . 0.0 108.121 178.037 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 6.1 mp -121.25 148.82 43.77 Favored 'General case' 0 N--CA 1.497 1.901 0 CA-C-O 121.397 0.618 . . . . 0.0 110.809 -178.518 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 29.8 t -107.6 124.59 63.72 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.038 0 N-CA-C 107.949 -1.13 . . . . 0.0 107.949 177.502 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 19' ' ' PHE . . . . . 0.514 ' O ' ' N ' ' B' ' 21' ' ' ALA . 25.5 m-85 -120.65 -161.12 0.87 Allowed 'General case' 0 N--CA 1.496 1.842 0 CA-C-N 119.906 1.23 . . . . 0.0 109.09 -179.779 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . 0.512 ' O ' ' HA ' ' E' ' 20' ' ' PHE . 77.7 m-85 -51.1 76.56 0.0 OUTLIER 'General case' 0 C--O 1.202 -1.421 0 C-N-CA 123.684 0.794 . . . . 0.0 111.451 -179.129 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 21' ' ' ALA . . . . . 0.514 ' N ' ' O ' ' B' ' 19' ' ' PHE . . . -88.35 -75.9 0.41 Allowed 'General case' 0 N--CA 1.47 0.539 0 CA-C-N 115.628 -0.715 . . . . 0.0 110.1 -179.692 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 40.5 tt0 -95.9 98.95 10.8 Favored 'General case' 0 N--CA 1.464 0.231 0 N-CA-C 108.49 -0.929 . . . . 0.0 108.49 179.358 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 4.1 p30 -159.65 144.96 15.55 Favored 'General case' 0 N--CA 1.483 1.212 0 O-C-N 122.407 -0.183 . . . . 0.0 110.892 179.578 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . 0.402 HG12 ' N ' ' B' ' 25' ' ' GLY . 94.0 t -62.9 163.76 1.46 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.808 0 N-CA-C 107.609 -1.256 . . . . 0.0 107.609 177.088 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . 0.495 ' H ' ' HB ' ' E' ' 24' ' ' VAL . . . -117.54 45.67 1.24 Allowed Glycine 0 N--CA 1.474 1.231 0 N-CA-C 111.903 -0.479 . . . . 0.0 111.903 -179.371 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -60.67 -165.05 0.01 OUTLIER 'General case' 0 N--CA 1.472 0.643 0 O-C-N 123.62 0.247 . . . . 0.0 110.452 179.688 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 24.1 t-20 -70.4 80.93 0.55 Allowed 'General case' 0 N--CA 1.464 0.272 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.268 179.664 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 96.8 mttt -79.87 138.28 37.13 Favored 'General case' 0 N--CA 1.472 0.656 0 N-CA-C 109.187 -0.672 . . . . 0.0 109.187 179.373 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.82 -166.14 0.9 Allowed Glycine 0 C--N 1.337 0.602 0 N-CA-C 109.638 -1.385 . . . . 0.0 109.638 178.231 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.68 113.84 26.55 Favored 'General case' 0 N--CA 1.474 0.729 0 N-CA-C 109.639 -0.504 . . . . 0.0 109.639 179.475 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 76.0 mt -99.44 135.32 35.25 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.527 0 N-CA-C 107.054 -1.461 . . . . 0.0 107.054 178.733 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . 0.403 ' C ' ' H ' ' B' ' 34' ' ' LEU . 26.6 pt -150.73 -172.05 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.353 0.729 0 CA-C-O 121.185 0.517 . . . . 0.0 111.259 -179.278 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.67 2.35 5.94 Favored Glycine 0 CA--C 1.525 0.692 0 N-CA-C 110.776 -0.93 . . . . 0.0 110.776 -179.919 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 34' ' ' LEU . . . . . 0.403 ' H ' ' C ' ' B' ' 32' ' ' ILE . 1.1 tt -74.55 133.2 42.28 Favored 'General case' 0 CA--C 1.545 0.773 0 N-CA-C 109.209 -0.663 . . . . 0.0 109.209 -179.588 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 35' ' ' MET . . . . . 0.4 ' N ' HD23 ' B' ' 34' ' ' LEU . 26.6 ttt -159.04 150.76 20.68 Favored 'General case' 0 N--CA 1.47 0.562 0 N-CA-C 108.362 -0.977 . . . . 0.0 108.362 178.722 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 36' ' ' VAL . . . . . 0.472 HG12 ' N ' ' B' ' 37' ' ' GLY . 64.0 t -153.79 162.51 2.08 Favored 'Isoleucine or valine' 0 C--N 1.345 0.394 0 N-CA-C 107.838 -1.171 . . . . 0.0 107.838 -179.599 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . 0.472 ' N ' HG12 ' B' ' 36' ' ' VAL . . . 58.07 67.13 2.36 Favored Glycine 0 C--N 1.307 -1.043 0 CA-C-N 115.586 -0.734 . . . . 0.0 112.071 178.627 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.85 177.31 22.14 Favored Glycine 0 N--CA 1.475 1.298 0 N-CA-C 111.042 -0.823 . . . . 0.0 111.042 178.797 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 33.6 m -109.21 152.5 11.25 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.621 0 C-N-CA 123.37 0.668 . . . . 0.0 110.316 -179.599 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 22.0 t . . . . . 0 C--O 1.215 -0.758 0 CA-C-O 118.379 -0.82 . . . . 0.0 110.422 179.604 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' C' C ' 1' ' ' ASP . . . . . . . . . . . . . 66.9 m-20 . . . . . 0 N--CA 1.491 1.596 0 N-CA-C 109.422 -0.584 . . . . 0.0 109.422 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' C' C ' 2' ' ' ALA . . . . . . . . . . . . . . . -63.45 -170.53 0.03 OUTLIER 'General case' 0 N--CA 1.466 0.374 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.437 179.906 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' C' C ' 3' ' ' GLU . . . . . . . . . . . . . 26.2 tt0 -153.25 166.38 32.76 Favored 'General case' 0 N--CA 1.474 0.763 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 -179.877 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 20.4 p90 -67.69 137.34 55.45 Favored 'General case' 0 N--CA 1.47 0.542 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.566 -178.58 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 99.0 mtt180 -136.68 153.09 50.99 Favored 'General case' 0 N--CA 1.481 1.089 0 N-CA-C 109.546 -0.539 . . . . 0.0 109.546 178.528 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 58.3 t-80 -113.86 115.06 27.14 Favored 'General case' 0 N--CA 1.478 0.951 0 C-N-CA 123.052 0.541 . . . . 0.0 109.6 179.634 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' C' C ' 7' ' ' ASP . . . . . . . . . . . . . 8.6 m-20 -73.38 155.75 39.04 Favored 'General case' 0 N--CA 1.467 0.385 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.167 179.086 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' C' C ' 8' ' ' SER . . . . . . . . . . . . . 9.5 p -165.67 -176.98 4.13 Favored 'General case' 0 N--CA 1.482 1.167 0 CA-C-O 120.909 0.385 . . . . 0.0 110.567 178.748 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.87 44.01 1.58 Allowed Glycine 0 N--CA 1.483 1.781 0 CA-C-N 115.728 -0.669 . . . . 0.0 112.284 179.49 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 51.0 p90 -65.49 132.0 47.83 Favored 'General case' 0 N--CA 1.473 0.724 0 O-C-N 122.653 -0.322 . . . . 0.0 111.465 179.789 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 83.7 mt-10 -94.27 153.78 17.86 Favored 'General case' 0 N--CA 1.476 0.84 0 N-CA-C 109.634 -0.506 . . . . 0.0 109.634 178.507 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -153.43 128.52 1.52 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.61 0 N-CA-C 107.757 -1.201 . . . . 0.0 107.757 178.135 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 50.0 m-70 -135.33 144.57 46.78 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 119.084 0.856 . . . . 0.0 111.142 -179.104 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 6.3 t60 -165.65 98.71 0.68 Allowed 'General case' 0 N--CA 1.48 1.066 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.458 179.549 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' C' C ' 15' ' ' GLN . . . . . 0.425 HE22 ' H ' ' C' ' 37' ' ' GLY . 21.9 pt20 -124.24 155.47 38.53 Favored 'General case' 0 CA--C 1.503 -0.859 0 N-CA-C 107.865 -1.161 . . . . 0.0 107.865 -179.66 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -124.97 106.31 9.87 Favored 'General case' 0 N--CA 1.479 1.004 0 N-CA-C 108.208 -1.034 . . . . 0.0 108.208 177.969 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 6.1 mp -121.34 148.88 43.76 Favored 'General case' 0 N--CA 1.498 1.966 0 CA-C-O 121.474 0.654 . . . . 0.0 110.796 -178.433 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 29.0 t -107.74 124.53 63.88 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.088 0 N-CA-C 107.968 -1.123 . . . . 0.0 107.968 177.51 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' C' C ' 19' ' ' PHE . . . . . 0.517 ' O ' ' N ' ' C' ' 21' ' ' ALA . 25.5 m-85 -120.55 -161.05 0.86 Allowed 'General case' 0 N--CA 1.496 1.857 0 CA-C-N 119.936 1.244 . . . . 0.0 109.13 -179.674 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' C' C ' 20' ' ' PHE . . . . . 0.514 ' O ' ' HA ' ' F' ' 20' ' ' PHE . 77.8 m-85 -51.25 76.46 0.0 OUTLIER 'General case' 0 C--O 1.202 -1.414 0 C-N-CA 123.716 0.807 . . . . 0.0 111.404 -179.186 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' C' C ' 21' ' ' ALA . . . . . 0.517 ' N ' ' O ' ' C' ' 19' ' ' PHE . . . -88.26 -75.89 0.41 Allowed 'General case' 0 N--CA 1.47 0.533 0 CA-C-N 115.604 -0.725 . . . . 0.0 110.142 -179.7 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 40.8 tt0 -95.74 98.62 10.6 Favored 'General case' 0 N--CA 1.464 0.265 0 N-CA-C 108.482 -0.933 . . . . 0.0 108.482 179.326 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 4.1 p30 -159.51 144.77 15.66 Favored 'General case' 0 N--CA 1.482 1.172 0 O-C-N 122.287 -0.258 . . . . 0.0 110.985 179.616 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' C' C ' 24' ' ' VAL . . . . . 0.41 HG12 ' N ' ' C' ' 25' ' ' GLY . 89.7 t -62.76 163.8 1.43 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.765 0 N-CA-C 107.681 -1.229 . . . . 0.0 107.681 177.067 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' C' C ' 25' ' ' GLY . . . . . 0.516 ' H ' ' HB ' ' F' ' 24' ' ' VAL . . . -117.65 45.72 1.24 Allowed Glycine 0 N--CA 1.476 1.364 0 N-CA-C 111.724 -0.55 . . . . 0.0 111.724 -179.377 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -60.47 -165.1 0.01 OUTLIER 'General case' 0 N--CA 1.472 0.647 0 CA-C-O 120.61 0.243 . . . . 0.0 110.421 179.616 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 24.1 t-20 -70.52 80.62 0.57 Allowed 'General case' 0 N--CA 1.464 0.258 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.308 179.684 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -79.41 138.5 37.65 Favored 'General case' 0 N--CA 1.472 0.639 0 N-CA-C 109.222 -0.659 . . . . 0.0 109.222 179.333 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -63.96 -165.68 0.87 Allowed Glycine 0 CA--C 1.523 0.588 0 N-CA-C 109.614 -1.394 . . . . 0.0 109.614 178.322 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.88 113.81 26.6 Favored 'General case' 0 N--CA 1.474 0.745 0 N-CA-C 109.617 -0.512 . . . . 0.0 109.617 179.459 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 76.0 mt -99.67 135.12 36.5 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.591 0 N-CA-C 107.041 -1.466 . . . . 0.0 107.041 178.83 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' C' C ' 32' ' ' ILE . . . . . 0.409 ' C ' ' H ' ' C' ' 34' ' ' LEU . 26.8 pt -150.61 -171.91 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.353 0.741 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.296 -179.305 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.59 2.24 5.67 Favored Glycine 0 CA--C 1.524 0.615 0 N-CA-C 110.808 -0.917 . . . . 0.0 110.808 -179.893 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' C' C ' 34' ' ' LEU . . . . . 0.413 HD23 ' N ' ' C' ' 35' ' ' MET . 1.1 tt -74.43 133.28 42.42 Favored 'General case' 0 CA--C 1.544 0.725 0 N-CA-C 109.275 -0.639 . . . . 0.0 109.275 -179.59 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' C' C ' 35' ' ' MET . . . . . 0.413 ' N ' HD23 ' C' ' 34' ' ' LEU . 26.6 ttt -159.03 150.69 20.65 Favored 'General case' 0 N--CA 1.47 0.557 0 N-CA-C 108.477 -0.934 . . . . 0.0 108.477 178.786 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' C' C ' 36' ' ' VAL . . . . . 0.478 HG12 ' N ' ' C' ' 37' ' ' GLY . 62.7 t -153.64 162.82 2.01 Favored 'Isoleucine or valine' 0 C--N 1.344 0.336 0 N-CA-C 107.78 -1.193 . . . . 0.0 107.78 -179.695 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' C' C ' 37' ' ' GLY . . . . . 0.478 ' N ' HG12 ' C' ' 36' ' ' VAL . . . 57.85 67.37 2.24 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-N 115.488 -0.778 . . . . 0.0 112.043 178.549 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.65 177.41 22.06 Favored Glycine 0 N--CA 1.475 1.271 0 N-CA-C 111.027 -0.829 . . . . 0.0 111.027 178.736 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' C' C ' 39' ' ' VAL . . . . . 0.401 ' H ' HG12 ' F' ' 39' ' ' VAL . 33.6 m -109.16 152.67 11.15 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.647 0 C-N-CA 123.303 0.641 . . . . 0.0 110.19 -179.601 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 22.0 t . . . . . 0 C--O 1.216 -0.687 0 CA-C-O 118.273 -0.87 . . . . 0.0 110.581 179.608 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' D' D ' 1' ' ' ASP . . . . . . . . . . . . . 65.2 m-20 . . . . . 0 N--CA 1.491 1.587 0 N-CA-C 109.35 -0.611 . . . . 0.0 109.35 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' D' D ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.91 -170.31 0.08 Allowed 'General case' 0 CA--C 1.533 0.305 0 C-N-CA 123.252 0.621 . . . . 0.0 109.797 179.373 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' D' D ' 3' ' ' GLU . . . . . . . . . . . . . 23.6 tt0 -156.45 161.93 40.03 Favored 'General case' 0 N--CA 1.473 0.676 0 C-N-CA 123.522 0.729 . . . . 0.0 110.37 -172.856 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 34.1 p90 -75.12 135.42 41.14 Favored 'General case' 0 C--O 1.221 -0.423 0 N-CA-C 108.43 -0.952 . . . . 0.0 108.43 -172.236 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' D' D ' 5' ' ' ARG . . . . . . . . . . . . . 99.1 mtt180 -132.18 154.67 49.32 Favored 'General case' 0 N--CA 1.477 0.921 0 N-CA-C 109.163 -0.68 . . . . 0.0 109.163 -177.501 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 55.5 t-80 -115.78 121.65 43.06 Favored 'General case' 0 C--N 1.37 1.466 0 N-CA-C 107.827 -1.175 . . . . 0.0 107.827 176.283 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' D' D ' 7' ' ' ASP . . . . . 0.533 ' O ' ' OG ' ' G' ' 8' ' ' SER 0.279 5.0 m-20 -65.11 136.91 57.27 Favored 'General case' 0 C--N 1.313 -1.005 0 C-N-CA 129.589 3.155 . . . . 0.0 115.638 171.6 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' D' D ' 8' ' ' SER . . . . . 0.424 ' OG ' ' O ' ' A' ' 7' ' ' ASP . 7.0 p -153.4 -174.21 4.86 Favored 'General case' 0 N--CA 1.487 1.411 0 CA-C-N 120.825 1.648 . . . . 0.0 111.062 174.704 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 105.07 46.5 1.25 Allowed Glycine 0 N--CA 1.483 1.769 0 C-N-CA 125.071 1.319 . . . . 0.0 110.558 174.78 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 52.6 p90 -60.96 130.69 47.68 Favored 'General case' 0 N--CA 1.472 0.637 0 N-CA-C 112.543 0.572 . . . . 0.0 112.543 177.151 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 84.9 mt-10 -90.94 151.83 20.95 Favored 'General case' 0 N--CA 1.48 1.027 0 CA-C-N 118.029 0.377 . . . . 0.0 110.857 174.946 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -149.62 130.1 4.35 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.615 0 N-CA-C 107.355 -1.35 . . . . 0.0 107.355 172.829 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 47.0 m-70 -129.92 147.61 51.69 Favored 'General case' 0 N--CA 1.483 1.223 0 CA-C-N 118.102 0.41 . . . . 0.0 111.774 176.32 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 6.3 t60 -165.32 104.98 0.75 Allowed 'General case' 0 N--CA 1.485 1.303 0 N-CA-C 109.366 -0.605 . . . . 0.0 109.366 173.233 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' D' D ' 15' ' ' GLN . . . . . 0.461 HE22 ' H ' ' D' ' 37' ' ' GLY . 23.2 pt20 -128.59 148.38 50.78 Favored 'General case' 0 C--N 1.296 -1.726 0 C-N-CA 123.764 0.826 . . . . 0.0 108.879 -178.631 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -118.64 111.5 18.62 Favored 'General case' 0 N--CA 1.476 0.846 0 N-CA-C 107.486 -1.302 . . . . 0.0 107.486 177.054 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 5.0 mp -126.77 148.71 49.9 Favored 'General case' 0 N--CA 1.5 2.059 0 CA-C-O 122.068 0.937 . . . . 0.0 109.983 179.169 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 12.9 t -99.91 128.44 51.79 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.769 0 CA-C-O 116.37 -1.776 . . . . 0.0 109.691 174.939 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' D' D ' 19' ' ' PHE . . . . . 0.511 ' O ' ' N ' ' D' ' 21' ' ' ALA . 25.2 m-85 -127.43 -163.06 1.22 Allowed 'General case' 0 N--CA 1.499 1.977 0 CA-C-N 120.686 1.584 . . . . 0.0 107.681 -179.966 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' D' D ' 20' ' ' PHE . . . . . 0.555 ' HA ' ' O ' ' A' ' 20' ' ' PHE . 90.1 m-85 -53.22 70.73 0.0 OUTLIER 'General case' 0 C--O 1.198 -1.62 0 C-N-CA 126.344 1.857 . . . . 0.0 111.44 -174.517 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' D' D ' 21' ' ' ALA . . . . . 0.511 ' N ' ' O ' ' D' ' 19' ' ' PHE . . . -86.39 -74.18 0.43 Allowed 'General case' 0 C--N 1.362 1.117 0 CA-C-N 114.922 -1.036 . . . . 0.0 109.701 -175.945 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 41.1 tt0 -98.82 102.99 14.9 Favored 'General case' 0 N--CA 1.483 1.212 0 N-CA-C 106.577 -1.638 . . . . 0.0 106.577 178.108 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 4.2 p30 -152.4 143.92 23.43 Favored 'General case' 0 N--CA 1.476 0.872 0 CA-C-O 116.783 -1.58 . . . . 0.0 113.501 178.551 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' D' D ' 24' ' ' VAL . . . . . 0.5 ' HB ' ' H ' ' A' ' 25' ' ' GLY . 89.3 t -64.46 165.26 1.46 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.351 0 CA-C-N 120.952 1.705 . . . . 0.0 107.584 173.953 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' D' D ' 25' ' ' GLY . . . . . 0.581 ' H ' ' HB ' ' G' ' 24' ' ' VAL . . . -117.02 51.1 0.75 Allowed Glycine 0 N--CA 1.48 1.573 0 CA-C-O 118.885 -0.953 . . . . 0.0 111.575 177.849 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -57.87 -168.74 0.01 OUTLIER 'General case' 0 C--N 1.321 -0.655 0 C-N-CA 124.037 0.935 . . . . 0.0 111.491 175.509 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 25.7 t-20 -72.33 86.86 1.12 Allowed 'General case' 0 C--N 1.35 0.588 0 C-N-CA 119.003 -1.079 . . . . 0.0 108.598 178.455 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 96.4 mttt -83.47 141.19 31.84 Favored 'General case' 0 C--N 1.352 0.688 0 N-CA-C 108.181 -1.044 . . . . 0.0 108.181 178.596 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -62.47 -164.69 0.43 Allowed Glycine 0 C--N 1.333 0.394 0 N-CA-C 110.451 -1.06 . . . . 0.0 110.451 177.463 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -102.28 115.88 31.48 Favored 'General case' 0 N--CA 1.471 0.595 0 N-CA-C 108.727 -0.842 . . . . 0.0 108.727 178.735 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 82.9 mt -102.91 142.57 16.66 Favored 'Isoleucine or valine' 0 C--N 1.356 0.889 0 N-CA-C 104.949 -2.241 . . . . 0.0 104.949 179.215 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' D' D ' 32' ' ' ILE . . . . . 0.426 HG22 ' H ' ' G' ' 32' ' ' ILE . 27.4 pt -157.18 -172.41 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.109 0 CA-C-O 120.759 0.314 . . . . 0.0 110.219 -178.141 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 63.95 2.13 6.12 Favored Glycine 0 N--CA 1.465 0.615 0 N-CA-C 110.513 -1.035 . . . . 0.0 110.513 -178.706 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 1.3 tt -75.85 138.05 40.86 Favored 'General case' 0 C--N 1.354 0.777 0 N-CA-C 107.729 -1.211 . . . . 0.0 107.729 -178.311 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 25.3 ttt -156.5 160.73 39.8 Favored 'General case' 0 C--O 1.237 0.444 0 N-CA-C 107.877 -1.157 . . . . 0.0 107.877 175.009 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' D' D ' 36' ' ' VAL . . . . . 0.484 HG12 ' N ' ' D' ' 37' ' ' GLY . 97.0 t -163.2 163.83 0.8 Allowed 'Isoleucine or valine' 0 CA--C 1.517 -0.326 0 N-CA-C 107.021 -1.474 . . . . 0.0 107.021 177.03 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' D' D ' 37' ' ' GLY . . . . . 0.484 ' N ' HG12 ' D' ' 36' ' ' VAL . . . 60.61 63.55 4.89 Favored Glycine 0 CA--C 1.528 0.874 0 C-N-CA 120.075 -1.06 . . . . 0.0 112.888 179.869 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 146.24 178.63 21.81 Favored Glycine 0 N--CA 1.481 1.639 0 CA-C-N 117.801 0.8 . . . . 0.0 111.588 179.803 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 34.5 m -112.69 149.89 15.04 Favored 'Isoleucine or valine' 0 C--N 1.357 0.911 0 N-CA-C 109.432 -0.581 . . . . 0.0 109.432 -176.943 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 21.8 t . . . . . 0 CA--C 1.52 -0.179 0 CA-C-O 115.976 -1.964 . . . . 0.0 109.604 178.486 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' E' E ' 1' ' ' ASP . . . . . . . . . . . . . 66.4 m-20 . . . . . 0 N--CA 1.491 1.575 0 N-CA-C 109.362 -0.607 . . . . 0.0 109.362 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' E' E ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.13 -168.6 0.04 OUTLIER 'General case' 0 N--CA 1.467 0.379 0 CA-C-N 116.319 -0.401 . . . . 0.0 110.74 -179.967 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' E' E ' 3' ' ' GLU . . . . . . . . . . . . . 25.0 tt0 -153.82 166.8 31.77 Favored 'General case' 0 N--CA 1.473 0.692 0 CA-C-N 116.508 -0.314 . . . . 0.0 110.37 -179.574 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 21.7 p90 -67.02 137.59 56.58 Favored 'General case' 0 C--O 1.217 -0.626 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.662 -178.476 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' E' E ' 5' ' ' ARG . . . . . . . . . . . . . 99.0 mtt180 -136.89 154.11 50.56 Favored 'General case' 0 N--CA 1.479 0.992 0 N-CA-C 109.433 -0.58 . . . . 0.0 109.433 178.539 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 58.4 t-80 -114.31 114.5 26.02 Favored 'General case' 0 N--CA 1.48 1.032 0 N-CA-C 109.68 -0.489 . . . . 0.0 109.68 179.581 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' E' E ' 7' ' ' ASP . . . . . 0.42 ' O ' ' OG ' ' H' ' 8' ' ' SER . 7.9 m-20 -73.27 156.29 38.63 Favored 'General case' 0 N--CA 1.466 0.352 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.173 179.095 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' E' E ' 8' ' ' SER . . . . . 0.419 ' OG ' ' O ' ' B' ' 7' ' ' ASP . 5.4 p -166.72 -175.06 2.98 Favored 'General case' 0 N--CA 1.485 1.31 0 CA-C-O 121.17 0.509 . . . . 0.0 110.727 178.388 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.48 44.12 1.61 Allowed Glycine 0 N--CA 1.48 1.59 0 CA-C-N 115.577 -0.738 . . . . 0.0 112.169 179.294 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 49.7 p90 -64.9 131.93 48.02 Favored 'General case' 0 CA--C 1.542 0.672 0 N-CA-C 111.769 0.285 . . . . 0.0 111.769 -179.922 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 86.8 mt-10 -93.55 153.81 18.22 Favored 'General case' 0 N--CA 1.48 1.027 0 CA-C-O 121.163 0.506 . . . . 0.0 109.654 178.074 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -154.72 127.24 1.05 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.546 0 N-CA-C 107.782 -1.192 . . . . 0.0 107.782 177.917 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 48.7 m-70 -135.09 142.61 46.3 Favored 'General case' 0 N--CA 1.483 1.185 0 CA-C-O 120.739 0.304 . . . . 0.0 111.473 -178.009 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 6.2 t60 -164.46 98.83 0.81 Allowed 'General case' 0 N--CA 1.486 1.364 0 CA-C-N 116.448 -0.342 . . . . 0.0 110.327 179.594 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' E' E ' 15' ' ' GLN . . . . . 0.441 HE22 ' H ' ' E' ' 37' ' ' GLY . 22.1 pt20 -123.63 155.57 37.46 Favored 'General case' 0 CA--C 1.503 -0.83 0 N-CA-C 108.243 -1.021 . . . . 0.0 108.243 -179.588 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -125.14 105.88 9.49 Favored 'General case' 0 N--CA 1.484 1.269 0 N-CA-C 108.216 -1.031 . . . . 0.0 108.216 178.145 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 6.0 mp -120.58 148.42 43.9 Favored 'General case' 0 N--CA 1.494 1.74 0 CA-C-O 121.123 0.487 . . . . 0.0 111.293 -178.063 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 21.8 t -109.62 120.53 60.97 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.146 0 N-CA-C 108.126 -1.065 . . . . 0.0 108.126 177.313 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' E' E ' 19' ' ' PHE . . . . . 0.54 ' O ' ' N ' ' E' ' 21' ' ' ALA . 28.5 m-85 -117.11 -162.98 0.89 Allowed 'General case' 0 N--CA 1.495 1.8 0 C-N-CA 122.911 0.485 . . . . 0.0 109.749 -179.365 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' E' E ' 20' ' ' PHE . . . . . 0.512 ' HA ' ' O ' ' B' ' 20' ' ' PHE . 77.2 m-85 -47.76 75.3 0.0 OUTLIER 'General case' 0 C--O 1.206 -1.202 0 C-N-CA 124.288 1.035 . . . . 0.0 111.551 -179.887 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' E' E ' 21' ' ' ALA . . . . . 0.54 ' N ' ' O ' ' E' ' 19' ' ' PHE . . . -87.82 -75.46 0.41 Allowed 'General case' 0 N--CA 1.469 0.52 0 C-N-CA 122.536 0.335 . . . . 0.0 110.399 -179.162 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 41.2 tt0 -96.78 98.92 10.54 Favored 'General case' 0 N--CA 1.463 0.197 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 179.469 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 4.1 p30 -158.58 144.59 16.9 Favored 'General case' 0 N--CA 1.481 1.078 0 O-C-N 122.356 -0.215 . . . . 0.0 111.166 179.821 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' E' E ' 24' ' ' VAL . . . . . 0.495 ' HB ' ' H ' ' B' ' 25' ' ' GLY . 89.5 t -61.8 167.32 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.944 0 N-CA-C 106.925 -1.509 . . . . 0.0 106.925 176.86 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' E' E ' 25' ' ' GLY . . . . . 0.491 ' H ' ' HB ' ' H' ' 24' ' ' VAL . . . -121.48 46.76 1.08 Allowed Glycine 0 N--CA 1.472 1.069 0 N-CA-C 111.163 -0.775 . . . . 0.0 111.163 -179.195 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -61.81 -164.43 0.01 OUTLIER 'General case' 0 N--CA 1.471 0.58 0 CA-C-N 116.943 0.371 . . . . 0.0 110.541 -179.948 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 24.6 t-20 -70.07 77.23 0.5 Allowed 'General case' 0 CA--C 1.533 0.319 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.693 -179.785 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 97.1 mttt -76.14 139.0 41.1 Favored 'General case' 0 N--CA 1.474 0.754 0 N-CA-C 109.715 -0.476 . . . . 0.0 109.715 179.394 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.64 -165.62 1.06 Allowed Glycine 0 C--N 1.335 0.486 0 N-CA-C 109.909 -1.276 . . . . 0.0 109.909 178.011 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.68 113.09 25.32 Favored 'General case' 0 N--CA 1.473 0.711 0 N-CA-C 109.805 -0.442 . . . . 0.0 109.805 179.494 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 75.9 mt -99.07 135.24 34.98 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.447 0 N-CA-C 106.893 -1.521 . . . . 0.0 106.893 178.768 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' E' E ' 32' ' ' ILE . . . . . 0.428 HG22 ' H ' ' H' ' 32' ' ' ILE . 28.3 pt -150.58 -170.31 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.099 0 CA-C-O 120.949 0.404 . . . . 0.0 110.755 -179.471 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.9 2.49 3.72 Favored Glycine 0 CA--C 1.529 0.92 0 N-CA-C 111.476 -0.65 . . . . 0.0 111.476 -179.59 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' E' E ' 34' ' ' LEU . . . . . 0.409 ' H ' ' C ' ' E' ' 32' ' ' ILE . 1.1 tt -73.89 133.73 43.15 Favored 'General case' 0 CA--C 1.545 0.78 0 N-CA-C 109.095 -0.706 . . . . 0.0 109.095 -179.7 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 25.0 ttt -159.34 149.56 19.12 Favored 'General case' 0 N--CA 1.473 0.69 0 N-CA-C 108.567 -0.901 . . . . 0.0 108.567 178.751 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' E' E ' 36' ' ' VAL . . . . . 0.476 HG12 ' N ' ' E' ' 37' ' ' GLY . 61.6 t -152.68 162.78 2.3 Favored 'Isoleucine or valine' 0 C--N 1.345 0.384 0 N-CA-C 108.228 -1.027 . . . . 0.0 108.228 -179.681 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' E' E ' 37' ' ' GLY . . . . . 0.476 ' N ' HG12 ' E' ' 36' ' ' VAL . . . 57.1 67.44 2.22 Favored Glycine 0 C--N 1.309 -0.93 0 CA-C-N 115.473 -0.785 . . . . 0.0 112.012 178.694 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.29 174.94 19.73 Favored Glycine 0 N--CA 1.476 1.325 0 N-CA-C 111.285 -0.726 . . . . 0.0 111.285 178.825 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 31.2 m -107.16 152.55 8.65 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.638 0 C-N-CA 123.475 0.71 . . . . 0.0 110.372 -179.079 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 21.9 t . . . . . 0 C--O 1.214 -0.784 0 O-C-N 124.222 0.951 . . . . 0.0 110.519 179.922 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' F' F ' 1' ' ' ASP . . . . . . . . . . . . . 66.1 m-20 . . . . . 0 N--CA 1.492 1.637 0 N-CA-C 109.327 -0.62 . . . . 0.0 109.327 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' F' F ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.75 -168.24 0.03 OUTLIER 'General case' 0 N--CA 1.467 0.394 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.602 -179.943 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' F' F ' 3' ' ' GLU . . . . . . . . . . . . . 24.8 tt0 -154.02 166.86 31.69 Favored 'General case' 0 N--CA 1.474 0.733 0 CA-C-N 116.429 -0.35 . . . . 0.0 110.291 -179.523 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 22.5 p90 -67.26 137.57 56.23 Favored 'General case' 0 C--O 1.218 -0.587 0 CA-C-N 116.251 -0.432 . . . . 0.0 110.575 -178.497 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' F' F ' 5' ' ' ARG . . . . . . . . . . . . . 99.0 mtt180 -136.73 154.04 50.7 Favored 'General case' 0 N--CA 1.478 0.937 0 N-CA-C 109.409 -0.589 . . . . 0.0 109.409 178.49 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 58.1 t-80 -114.45 114.54 25.96 Favored 'General case' 0 N--CA 1.48 1.027 0 C-N-CA 122.909 0.483 . . . . 0.0 109.76 179.534 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' F' F ' 7' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -73.28 156.39 38.52 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.274 179.129 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' F' F ' 8' ' ' SER . . . . . 0.421 ' HA ' ' OG ' ' I' ' 8' ' ' SER . 5.4 p -166.87 -174.99 2.9 Favored 'General case' 0 N--CA 1.485 1.301 0 CA-C-O 121.023 0.439 . . . . 0.0 110.936 178.468 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.38 43.69 1.69 Allowed Glycine 0 N--CA 1.479 1.543 0 CA-C-N 115.757 -0.656 . . . . 0.0 112.149 179.199 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 49.9 p90 -64.4 132.31 49.69 Favored 'General case' 0 CA--C 1.544 0.724 0 O-C-N 122.632 -0.334 . . . . 0.0 111.813 -179.945 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 86.7 mt-10 -93.73 153.59 18.25 Favored 'General case' 0 N--CA 1.48 1.067 0 N-CA-C 109.636 -0.505 . . . . 0.0 109.636 178.085 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -154.57 127.18 1.07 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.545 0 N-CA-C 107.811 -1.181 . . . . 0.0 107.811 177.885 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 46.6 m-70 -135.06 142.77 46.4 Favored 'General case' 0 N--CA 1.483 1.215 0 CA-C-O 120.77 0.319 . . . . 0.0 111.515 -178.131 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 6.2 t60 -164.55 98.7 0.8 Allowed 'General case' 0 N--CA 1.485 1.302 0 CA-C-N 116.465 -0.334 . . . . 0.0 110.437 179.62 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' F' F ' 15' ' ' GLN . . . . . 0.426 HE22 ' H ' ' F' ' 37' ' ' GLY . 22.2 pt20 -123.52 155.61 37.23 Favored 'General case' 0 CA--C 1.501 -0.914 0 N-CA-C 108.225 -1.028 . . . . 0.0 108.225 -179.527 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -125.09 105.89 9.51 Favored 'General case' 0 N--CA 1.485 1.286 0 N-CA-C 108.245 -1.02 . . . . 0.0 108.245 178.104 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 6.0 mp -120.64 148.21 44.21 Favored 'General case' 0 N--CA 1.495 1.811 0 CA-C-O 121.168 0.509 . . . . 0.0 111.181 -178.009 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 21.7 t -109.45 120.3 60.42 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.167 0 N-CA-C 108.13 -1.063 . . . . 0.0 108.13 177.244 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' F' F ' 19' ' ' PHE . . . . . 0.539 ' O ' ' N ' ' F' ' 21' ' ' ALA . 28.4 m-85 -116.76 -162.7 0.87 Allowed 'General case' 0 N--CA 1.494 1.763 0 C-N-CA 122.919 0.487 . . . . 0.0 109.864 -179.436 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' F' F ' 20' ' ' PHE . . . . . 0.514 ' HA ' ' O ' ' C' ' 20' ' ' PHE . 78.3 m-85 -48.04 75.1 0.0 OUTLIER 'General case' 0 C--O 1.206 -1.229 0 C-N-CA 124.3 1.04 . . . . 0.0 111.466 -179.878 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' F' F ' 21' ' ' ALA . . . . . 0.539 ' N ' ' O ' ' F' ' 19' ' ' PHE . . . -87.38 -77.08 0.35 Allowed 'General case' 0 N--CA 1.466 0.369 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.044 -179.386 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 41.2 tt0 -95.21 99.29 11.27 Favored 'General case' 0 N--CA 1.462 0.173 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 179.49 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 4.1 p30 -158.8 144.8 16.73 Favored 'General case' 0 N--CA 1.481 1.097 0 CA-C-O 119.655 -0.212 . . . . 0.0 111.304 179.745 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' F' F ' 24' ' ' VAL . . . . . 0.516 ' HB ' ' H ' ' C' ' 25' ' ' GLY . 88.8 t -61.98 167.3 0.77 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.93 0 N-CA-C 106.933 -1.506 . . . . 0.0 106.933 176.894 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' F' F ' 25' ' ' GLY . . . . . 0.479 ' H ' ' HB ' ' I' ' 24' ' ' VAL . . . -121.67 46.88 1.07 Allowed Glycine 0 N--CA 1.478 1.44 0 N-CA-C 110.88 -0.888 . . . . 0.0 110.88 -179.239 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -61.89 -164.43 0.01 OUTLIER 'General case' 0 N--CA 1.471 0.612 0 CA-C-N 116.887 0.343 . . . . 0.0 110.436 -179.977 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 24.6 t-20 -69.88 77.11 0.47 Allowed 'General case' 0 CA--C 1.533 0.297 0 CA-C-N 116.319 -0.401 . . . . 0.0 110.752 -179.779 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -76.09 138.97 41.14 Favored 'General case' 0 N--CA 1.475 0.807 0 N-CA-C 109.638 -0.504 . . . . 0.0 109.638 179.451 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.47 -165.36 0.96 Allowed Glycine 0 C--N 1.335 0.484 0 N-CA-C 110.081 -1.207 . . . . 0.0 110.081 177.99 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.92 112.82 25.08 Favored 'General case' 0 N--CA 1.472 0.638 0 N-CA-C 109.695 -0.483 . . . . 0.0 109.695 179.511 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 76.1 mt -98.99 135.3 34.6 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.498 0 N-CA-C 106.882 -1.525 . . . . 0.0 106.882 178.84 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' F' F ' 32' ' ' ILE . . . . . 0.441 HG22 ' H ' ' I' ' 32' ' ' ILE . 28.2 pt -150.64 -170.19 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.128 0 CA-C-O 120.988 0.423 . . . . 0.0 110.777 -179.516 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.99 2.28 3.65 Favored Glycine 0 CA--C 1.53 1.006 0 N-CA-C 111.409 -0.676 . . . . 0.0 111.409 -179.673 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' F' F ' 34' ' ' LEU . . . . . 0.411 HD23 ' N ' ' F' ' 35' ' ' MET . 1.1 tt -73.91 133.72 43.13 Favored 'General case' 0 CA--C 1.546 0.798 0 N-CA-C 109.128 -0.693 . . . . 0.0 109.128 -179.654 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' F' F ' 35' ' ' MET . . . . . 0.411 ' N ' HD23 ' F' ' 34' ' ' LEU . 25.1 ttt -159.4 149.74 19.16 Favored 'General case' 0 N--CA 1.47 0.573 0 N-CA-C 108.563 -0.903 . . . . 0.0 108.563 178.832 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' F' F ' 36' ' ' VAL . . . . . 0.479 HG12 ' N ' ' F' ' 37' ' ' GLY . 62.2 t -152.83 162.84 2.21 Favored 'Isoleucine or valine' 0 C--N 1.345 0.37 0 N-CA-C 108.169 -1.049 . . . . 0.0 108.169 -179.667 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' F' F ' 37' ' ' GLY . . . . . 0.479 ' N ' HG12 ' F' ' 36' ' ' VAL . . . 57.1 67.44 2.22 Favored Glycine 0 C--N 1.308 -0.974 0 CA-C-N 115.433 -0.803 . . . . 0.0 112.004 178.626 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.34 175.04 19.85 Favored Glycine 0 N--CA 1.475 1.275 0 N-CA-C 111.248 -0.741 . . . . 0.0 111.248 178.848 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' F' F ' 39' ' ' VAL . . . . . 0.404 ' H ' HG12 ' I' ' 39' ' ' VAL . 31.4 m -107.27 152.41 8.85 Favored 'Isoleucine or valine' 0 C--N 1.35 0.597 0 C-N-CA 123.546 0.738 . . . . 0.0 110.361 -179.025 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 22.0 t . . . . . 0 C--O 1.213 -0.821 0 O-C-N 124.216 0.948 . . . . 0.0 110.385 179.804 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' G' G ' 1' ' ' ASP . . . . . . . . . . . . . 65.3 m-20 . . . . . 0 N--CA 1.49 1.558 0 N-CA-C 109.029 -0.73 . . . . 0.0 109.029 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' G' G ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.78 -165.98 0.03 OUTLIER 'General case' 0 N--CA 1.467 0.4 0 CA-C-N 116.591 -0.277 . . . . 0.0 110.758 -179.814 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' G' G ' 3' ' ' GLU . . . . . . . . . . . . . 24.8 tt0 -154.87 166.95 31.9 Favored 'General case' 0 N--CA 1.474 0.74 0 CA-C-O 120.709 0.29 . . . . 0.0 110.632 -179.056 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 20.1 p90 -66.71 137.3 56.58 Favored 'General case' 0 N--CA 1.472 0.625 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.339 -178.643 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' G' G ' 5' ' ' ARG . . . . . . . . . . . . . 99.1 mtt180 -136.54 154.04 50.83 Favored 'General case' 0 N--CA 1.482 1.13 0 N-CA-C 109.463 -0.569 . . . . 0.0 109.463 178.555 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 58.3 t-80 -114.1 115.54 27.7 Favored 'General case' 0 N--CA 1.483 1.207 0 C-N-CA 122.823 0.449 . . . . 0.0 109.891 179.649 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 -75.86 152.46 37.2 Favored 'General case' 0 N--CA 1.47 0.569 0 CA-C-N 116.0 -0.545 . . . . 0.0 110.772 179.279 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' G' G ' 8' ' ' SER . . . . . 0.533 ' OG ' ' O ' ' D' ' 7' ' ' ASP . 4.9 p -164.03 -172.39 2.78 Favored 'General case' 0 N--CA 1.475 0.775 0 CA-C-O 121.105 0.479 . . . . 0.0 110.596 178.621 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.12 43.6 1.87 Allowed Glycine 0 N--CA 1.479 1.563 0 CA-C-N 115.633 -0.712 . . . . 0.0 111.655 178.983 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 51.0 p90 -64.2 132.23 49.75 Favored 'General case' 0 CA--C 1.542 0.67 0 CA-C-O 120.648 0.261 . . . . 0.0 111.664 -179.772 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 84.1 mt-10 -94.01 152.88 18.49 Favored 'General case' 0 N--CA 1.479 1.008 0 CA-C-O 121.035 0.445 . . . . 0.0 110.057 178.644 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -155.21 127.55 1.03 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.016 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 178.179 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 49.9 m-70 -134.63 144.05 47.65 Favored 'General case' 0 N--CA 1.478 0.925 0 CA-C-N 115.416 -0.811 . . . . 0.0 111.405 -178.326 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 6.3 t60 -166.12 98.74 0.63 Allowed 'General case' 0 N--CA 1.481 1.12 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.122 178.977 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' G' G ' 15' ' ' GLN . . . . . 0.436 HE22 ' H ' ' G' ' 37' ' ' GLY . 22.3 pt20 -123.91 154.95 38.99 Favored 'General case' 0 CA--C 1.497 -1.07 0 N-CA-C 107.998 -1.112 . . . . 0.0 107.998 -179.287 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -124.8 106.19 9.85 Favored 'General case' 0 N--CA 1.483 1.192 0 N-CA-C 108.04 -1.096 . . . . 0.0 108.04 178.151 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 6.0 mp -120.22 148.76 43.27 Favored 'General case' 0 N--CA 1.496 1.85 0 CA-C-O 121.091 0.472 . . . . 0.0 111.625 -178.244 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 20.4 t -111.11 120.21 61.29 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.043 0 N-CA-C 107.775 -1.194 . . . . 0.0 107.775 176.909 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' G' G ' 19' ' ' PHE . . . . . 0.556 ' O ' ' N ' ' G' ' 21' ' ' ALA . 28.1 m-85 -117.17 -164.58 1.0 Allowed 'General case' 0 N--CA 1.494 1.728 0 C-N-CA 124.372 1.069 . . . . 0.0 110.225 -178.846 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' G' G ' 20' ' ' PHE . . . . . 0.507 ' HA ' ' O ' ' D' ' 20' ' ' PHE . 78.4 m-85 -47.13 73.02 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.03 0 C-N-CA 124.522 1.129 . . . . 0.0 111.664 -179.83 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' G' G ' 21' ' ' ALA . . . . . 0.556 ' N ' ' O ' ' G' ' 19' ' ' PHE . . . -85.37 -78.23 0.27 Allowed 'General case' 0 N--CA 1.466 0.364 0 C-N-CA 122.715 0.406 . . . . 0.0 110.246 -178.901 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 41.0 tt0 -94.6 99.8 11.87 Favored 'General case' 0 N--CA 1.465 0.284 0 N-CA-C 108.284 -1.006 . . . . 0.0 108.284 179.364 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 4.1 p30 -159.17 144.83 16.23 Favored 'General case' 0 N--CA 1.477 0.91 0 O-C-N 122.313 -0.242 . . . . 0.0 111.226 179.745 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' G' G ' 24' ' ' VAL . . . . . 0.581 ' HB ' ' H ' ' D' ' 25' ' ' GLY . 92.4 t -62.48 165.74 1.02 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.655 0 N-CA-C 107.283 -1.377 . . . . 0.0 107.283 177.231 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' G' G ' 25' ' ' GLY . . . . . 0.408 ' N ' HG12 ' G' ' 24' ' ' VAL . . . -119.86 48.85 0.91 Allowed Glycine 0 N--CA 1.482 1.734 0 N-CA-C 110.587 -1.005 . . . . 0.0 110.587 -179.66 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -64.11 -164.65 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.669 0 CA-C-N 117.194 0.497 . . . . 0.0 109.752 179.787 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 24.8 t-20 -69.97 76.81 0.48 Allowed 'General case' 0 N--CA 1.467 0.415 0 CA-C-N 116.428 -0.351 . . . . 0.0 110.775 -179.699 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -75.2 139.02 42.35 Favored 'General case' 0 N--CA 1.474 0.759 0 N-CA-C 109.724 -0.473 . . . . 0.0 109.724 179.319 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.75 -164.48 0.9 Allowed Glycine 0 C--N 1.337 0.63 0 N-CA-C 109.679 -1.369 . . . . 0.0 109.679 178.185 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.71 113.04 25.25 Favored 'General case' 0 N--CA 1.467 0.412 0 C-N-CA 122.681 0.392 . . . . 0.0 110.204 179.627 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 77.8 mt -99.7 135.42 35.27 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.825 0 N-CA-C 106.932 -1.506 . . . . 0.0 106.932 178.789 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' G' G ' 32' ' ' ILE . . . . . 0.426 ' H ' HG22 ' D' ' 32' ' ' ILE . 30.4 pt -151.09 -169.13 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.745 0 CA-C-N 119.448 1.022 . . . . 0.0 109.946 179.963 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.98 2.42 3.76 Favored Glycine 0 CA--C 1.528 0.861 0 N-CA-C 111.253 -0.739 . . . . 0.0 111.253 -179.749 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' G' G ' 34' ' ' LEU . . . . . 0.415 HD23 ' N ' ' G' ' 35' ' ' MET . 1.1 tt -74.57 133.28 42.25 Favored 'General case' 0 CA--C 1.543 0.687 0 N-CA-C 109.156 -0.683 . . . . 0.0 109.156 -179.586 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' G' G ' 35' ' ' MET . . . . . 0.415 ' N ' HD23 ' G' ' 34' ' ' LEU . 23.8 ttt -159.04 150.27 20.26 Favored 'General case' 0 N--CA 1.469 0.486 0 N-CA-C 108.59 -0.893 . . . . 0.0 108.59 179.126 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' G' G ' 36' ' ' VAL . . . . . 0.445 HG12 ' N ' ' G' ' 37' ' ' GLY . 62.5 t -153.8 161.35 2.44 Favored 'Isoleucine or valine' 0 C--N 1.346 0.426 0 N-CA-C 108.05 -1.093 . . . . 0.0 108.05 -179.5 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' G' G ' 37' ' ' GLY . . . . . 0.445 ' N ' HG12 ' G' ' 36' ' ' VAL . . . 58.43 67.45 2.19 Favored Glycine 0 C--N 1.309 -0.957 0 CA-C-N 115.331 -0.85 . . . . 0.0 111.91 178.566 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.44 174.37 19.36 Favored Glycine 0 N--CA 1.477 1.383 0 N-CA-C 110.641 -0.983 . . . . 0.0 110.641 178.872 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 32.9 m -107.02 152.16 8.62 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.912 0 C-N-CA 123.256 0.622 . . . . 0.0 110.487 -179.453 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 22.7 t . . . . . 0 C--O 1.217 -0.63 0 CA-C-O 118.373 -0.822 . . . . 0.0 110.688 179.867 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' H' H ' 1' ' ' ASP . . . . . . . . . . . . . 64.8 m-20 . . . . . 0 N--CA 1.49 1.57 0 N-CA-C 109.215 -0.661 . . . . 0.0 109.215 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' H' H ' 2' ' ' ALA . . . . . . . . . . . . . . . -66.07 -165.65 0.03 OUTLIER 'General case' 0 N--CA 1.466 0.339 0 CA-C-N 116.588 -0.278 . . . . 0.0 110.709 -179.758 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' H' H ' 3' ' ' GLU . . . . . . . . . . . . . 24.5 tt0 -155.22 166.91 32.09 Favored 'General case' 0 N--CA 1.473 0.694 0 CA-C-O 120.739 0.304 . . . . 0.0 110.588 -178.982 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 20.4 p90 -66.77 137.03 56.34 Favored 'General case' 0 N--CA 1.472 0.636 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.313 -178.592 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' H' H ' 5' ' ' ARG . . . . . . . . . . . . . 99.1 mtt180 -136.18 153.84 51.13 Favored 'General case' 0 N--CA 1.484 1.258 0 N-CA-C 109.398 -0.593 . . . . 0.0 109.398 178.571 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 58.4 t-80 -113.91 115.31 27.48 Favored 'General case' 0 N--CA 1.482 1.129 0 C-N-CA 122.829 0.452 . . . . 0.0 109.96 179.521 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -75.55 152.7 37.72 Favored 'General case' 0 N--CA 1.47 0.57 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.681 179.295 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' H' H ' 8' ' ' SER . . . . . 0.42 ' OG ' ' O ' ' E' ' 7' ' ' ASP . 6.9 p -164.17 -172.67 2.85 Favored 'General case' 0 N--CA 1.474 0.731 0 CA-C-O 121.113 0.482 . . . . 0.0 110.683 178.63 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.13 43.67 1.86 Allowed Glycine 0 N--CA 1.48 1.599 0 CA-C-N 115.79 -0.641 . . . . 0.0 111.765 179.157 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 51.0 p90 -64.44 132.28 49.56 Favored 'General case' 0 CA--C 1.541 0.61 0 O-C-N 122.68 -0.306 . . . . 0.0 111.709 -179.878 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 84.4 mt-10 -94.04 152.92 18.45 Favored 'General case' 0 N--CA 1.478 0.936 0 CA-C-O 121.095 0.474 . . . . 0.0 110.082 178.651 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -155.27 127.12 0.96 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.032 0 N-CA-C 108.03 -1.1 . . . . 0.0 108.03 178.176 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 48.9 m-70 -134.32 143.84 47.93 Favored 'General case' 0 N--CA 1.479 1.016 0 CA-C-N 115.415 -0.811 . . . . 0.0 111.348 -178.183 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 6.3 t60 -165.96 98.94 0.65 Allowed 'General case' 0 N--CA 1.484 1.227 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.012 178.958 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' H' H ' 15' ' ' GLN . . . . . 0.428 HE22 ' H ' ' H' ' 37' ' ' GLY . 22.5 pt20 -124.07 154.77 39.47 Favored 'General case' 0 CA--C 1.495 -1.135 0 N-CA-C 108.054 -1.091 . . . . 0.0 108.054 -179.339 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -124.52 106.06 9.87 Favored 'General case' 0 N--CA 1.483 1.204 0 N-CA-C 108.156 -1.054 . . . . 0.0 108.156 178.107 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 6.0 mp -120.17 148.58 43.46 Favored 'General case' 0 N--CA 1.496 1.868 0 CA-C-O 121.072 0.463 . . . . 0.0 111.567 -178.201 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 20.2 t -110.61 121.02 62.64 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.008 0 N-CA-C 107.777 -1.194 . . . . 0.0 107.777 176.776 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' H' H ' 19' ' ' PHE . . . . . 0.56 ' O ' ' N ' ' H' ' 21' ' ' ALA . 27.4 m-85 -117.95 -164.32 1.0 Allowed 'General case' 0 N--CA 1.492 1.675 0 C-N-CA 124.268 1.027 . . . . 0.0 110.127 -178.734 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' H' H ' 20' ' ' PHE . . . . . 0.485 ' HA ' ' O ' ' E' ' 20' ' ' PHE . 79.1 m-85 -47.53 73.03 0.0 OUTLIER 'General case' 0 N--CA 1.481 1.081 0 C-N-CA 124.425 1.09 . . . . 0.0 111.621 -179.78 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' H' H ' 21' ' ' ALA . . . . . 0.56 ' N ' ' O ' ' H' ' 19' ' ' PHE . . . -85.13 -77.8 0.27 Allowed 'General case' 0 N--CA 1.466 0.339 0 C-N-CA 122.744 0.417 . . . . 0.0 110.432 -179.018 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 41.1 tt0 -95.14 99.48 11.45 Favored 'General case' 0 N--CA 1.465 0.303 0 N-CA-C 108.313 -0.995 . . . . 0.0 108.313 179.439 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 4.2 p30 -158.76 145.06 16.97 Favored 'General case' 0 N--CA 1.478 0.938 0 O-C-N 122.475 -0.14 . . . . 0.0 111.188 179.874 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' H' H ' 24' ' ' VAL . . . . . 0.491 ' HB ' ' H ' ' E' ' 25' ' ' GLY . 88.8 t -62.65 165.45 1.09 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.594 0 N-CA-C 107.247 -1.39 . . . . 0.0 107.247 177.113 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' H' H ' 25' ' ' GLY . . . . . 0.41 ' N ' HG12 ' H' ' 24' ' ' VAL . . . -119.49 48.69 0.92 Allowed Glycine 0 N--CA 1.48 1.582 0 N-CA-C 110.625 -0.99 . . . . 0.0 110.625 -179.579 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -64.31 -164.83 0.02 OUTLIER 'General case' 0 N--CA 1.473 0.685 0 CA-C-N 117.233 0.517 . . . . 0.0 109.852 179.897 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 24.7 t-20 -69.68 76.95 0.44 Allowed 'General case' 0 N--CA 1.467 0.395 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.71 -179.733 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -75.57 139.29 42.02 Favored 'General case' 0 N--CA 1.472 0.672 0 N-CA-C 109.695 -0.483 . . . . 0.0 109.695 179.326 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -65.15 -164.65 1.07 Allowed Glycine 0 C--N 1.336 0.574 0 N-CA-C 109.651 -1.38 . . . . 0.0 109.651 178.27 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.56 112.92 25.07 Favored 'General case' 0 N--CA 1.468 0.443 0 C-N-CA 122.714 0.406 . . . . 0.0 110.22 179.761 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 76.6 mt -99.6 135.28 35.68 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.812 0 N-CA-C 106.986 -1.487 . . . . 0.0 106.986 178.774 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' H' H ' 32' ' ' ILE . . . . . 0.428 ' H ' HG22 ' E' ' 32' ' ' ILE . 30.5 pt -151.05 -169.16 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.707 0 CA-C-N 119.494 1.043 . . . . 0.0 109.836 -179.914 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.06 2.2 3.66 Favored Glycine 0 CA--C 1.528 0.852 0 N-CA-C 111.167 -0.773 . . . . 0.0 111.167 -179.834 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' H' H ' 34' ' ' LEU . . . . . 0.423 ' H ' ' C ' ' H' ' 32' ' ' ILE . 1.1 tt -74.28 133.13 42.61 Favored 'General case' 0 CA--C 1.544 0.733 0 N-CA-C 109.223 -0.658 . . . . 0.0 109.223 -179.58 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' H' H ' 35' ' ' MET . . . . . 0.404 ' N ' HD23 ' H' ' 34' ' ' LEU . 23.9 ttt -158.85 150.29 20.64 Favored 'General case' 0 N--CA 1.468 0.465 0 N-CA-C 108.644 -0.873 . . . . 0.0 108.644 179.066 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' H' H ' 36' ' ' VAL . . . . . 0.449 HG12 ' N ' ' H' ' 37' ' ' GLY . 59.9 t -153.83 161.38 2.43 Favored 'Isoleucine or valine' 0 C--N 1.346 0.425 0 N-CA-C 108.005 -1.109 . . . . 0.0 108.005 -179.438 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' H' H ' 37' ' ' GLY . . . . . 0.449 ' N ' HG12 ' H' ' 36' ' ' VAL . . . 58.35 67.35 2.24 Favored Glycine 0 C--N 1.309 -0.955 0 CA-C-N 115.349 -0.841 . . . . 0.0 111.902 178.52 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.29 173.8 18.75 Favored Glycine 0 N--CA 1.477 1.39 0 N-CA-C 110.708 -0.957 . . . . 0.0 110.708 178.907 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 32.7 m -106.35 152.08 8.12 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.914 0 C-N-CA 123.341 0.656 . . . . 0.0 110.554 -179.438 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 22.1 t . . . . . 0 C--O 1.218 -0.588 0 CA-C-O 118.321 -0.847 . . . . 0.0 110.644 179.843 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' I' I ' 1' ' ' ASP . . . . . . . . . . . . . 65.3 m-20 . . . . . 0 N--CA 1.49 1.552 0 N-CA-C 109.173 -0.677 . . . . 0.0 109.173 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' I' I ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.8 -166.05 0.03 OUTLIER 'General case' 0 N--CA 1.467 0.412 0 CA-C-N 116.577 -0.283 . . . . 0.0 110.77 -179.857 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' I' I ' 3' ' ' GLU . . . . . . . . . . . . . 24.3 tt0 -154.72 167.14 31.18 Favored 'General case' 0 N--CA 1.474 0.741 0 CA-C-O 120.704 0.287 . . . . 0.0 110.71 -179.058 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 20.4 p90 -66.97 137.0 56.19 Favored 'General case' 0 N--CA 1.471 0.615 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.325 -178.602 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' I' I ' 5' ' ' ARG . . . . . . . . . . . . . 99.1 mtt180 -136.11 153.92 51.15 Favored 'General case' 0 N--CA 1.483 1.213 0 N-CA-C 109.47 -0.566 . . . . 0.0 109.47 178.62 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 58.2 t-80 -114.12 115.53 27.68 Favored 'General case' 0 N--CA 1.482 1.153 0 C-N-CA 122.809 0.444 . . . . 0.0 109.863 179.545 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 8.0 m-20 -75.98 152.33 37.02 Favored 'General case' 0 N--CA 1.47 0.567 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.697 179.335 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' I' I ' 8' ' ' SER . . . . . 0.421 ' OG ' ' HA ' ' F' ' 8' ' ' SER . 6.7 p -163.89 -172.82 2.97 Favored 'General case' 0 N--CA 1.475 0.78 0 CA-C-O 121.124 0.487 . . . . 0.0 110.681 178.801 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.35 43.61 1.84 Allowed Glycine 0 N--CA 1.481 1.676 0 CA-C-N 115.773 -0.649 . . . . 0.0 111.71 179.105 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 51.1 p90 -64.32 132.38 50.03 Favored 'General case' 0 CA--C 1.541 0.622 0 O-C-N 122.681 -0.306 . . . . 0.0 111.722 -179.853 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 84.1 mt-10 -94.06 152.92 18.44 Favored 'General case' 0 N--CA 1.477 0.921 0 CA-C-O 121.11 0.481 . . . . 0.0 110.033 178.619 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -155.33 127.31 0.98 Allowed 'Isoleucine or valine' 0 CA--C 1.553 1.069 0 N-CA-C 107.978 -1.119 . . . . 0.0 107.978 178.098 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 50.3 m-70 -134.48 144.02 47.83 Favored 'General case' 0 N--CA 1.477 0.92 0 CA-C-N 115.387 -0.824 . . . . 0.0 111.391 -178.269 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 6.3 t60 -166.09 98.59 0.63 Allowed 'General case' 0 N--CA 1.483 1.183 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.06 179.094 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' I' I ' 15' ' ' GLN . . . . . 0.422 HE22 ' H ' ' I' ' 37' ' ' GLY . 22.6 pt20 -123.84 154.77 39.15 Favored 'General case' 0 CA--C 1.497 -1.082 0 N-CA-C 108.014 -1.106 . . . . 0.0 108.014 -179.323 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -124.54 106.07 9.87 Favored 'General case' 0 N--CA 1.483 1.199 0 N-CA-C 108.154 -1.054 . . . . 0.0 108.154 178.125 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 6.0 mp -120.25 148.61 43.47 Favored 'General case' 0 N--CA 1.495 1.819 0 CA-C-O 121.06 0.457 . . . . 0.0 111.593 -178.179 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 20.2 t -110.61 121.1 62.78 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.01 0 N-CA-C 107.799 -1.186 . . . . 0.0 107.799 176.87 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' I' I ' 19' ' ' PHE . . . . . 0.559 ' O ' ' N ' ' I' ' 21' ' ' ALA . 27.2 m-85 -118.11 -164.1 0.99 Allowed 'General case' 0 N--CA 1.495 1.776 0 C-N-CA 124.229 1.012 . . . . 0.0 110.095 -178.659 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' I' I ' 20' ' ' PHE . . . . . 0.485 ' HA ' ' O ' ' F' ' 20' ' ' PHE . 79.6 m-85 -47.61 72.97 0.0 OUTLIER 'General case' 0 N--CA 1.481 1.085 0 C-N-CA 124.54 1.136 . . . . 0.0 111.502 -179.771 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' I' I ' 21' ' ' ALA . . . . . 0.559 ' N ' ' O ' ' I' ' 19' ' ' PHE . . . -85.11 -78.82 0.24 Allowed 'General case' 0 N--CA 1.468 0.43 0 C-N-CA 122.76 0.424 . . . . 0.0 110.12 -178.935 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 41.3 tt0 -93.95 99.48 11.81 Favored 'General case' 0 N--CA 1.464 0.274 0 N-CA-C 108.469 -0.938 . . . . 0.0 108.469 179.247 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 4.2 p30 -158.87 145.26 16.94 Favored 'General case' 0 N--CA 1.478 0.928 0 O-C-N 122.388 -0.195 . . . . 0.0 111.214 179.616 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' I' I ' 24' ' ' VAL . . . . . 0.479 ' HB ' ' H ' ' F' ' 25' ' ' GLY . 92.1 t -62.78 165.71 1.07 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.606 0 N-CA-C 107.257 -1.386 . . . . 0.0 107.257 177.154 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' I' I ' 25' ' ' GLY . . . . . 0.419 ' N ' HG12 ' I' ' 24' ' ' VAL . . . -119.94 48.8 0.92 Allowed Glycine 0 N--CA 1.48 1.619 0 N-CA-C 110.546 -1.022 . . . . 0.0 110.546 -179.559 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -64.08 -164.37 0.02 OUTLIER 'General case' 0 N--CA 1.473 0.684 0 CA-C-N 117.168 0.484 . . . . 0.0 109.747 179.865 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 24.9 t-20 -70.27 77.2 0.53 Allowed 'General case' 0 CA--C 1.536 0.42 0 CA-C-N 116.394 -0.366 . . . . 0.0 110.63 -179.701 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 97.0 mttt -75.65 139.06 41.77 Favored 'General case' 0 N--CA 1.473 0.713 0 N-CA-C 109.62 -0.511 . . . . 0.0 109.62 179.367 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.83 -164.62 0.94 Allowed Glycine 0 C--N 1.337 0.59 0 N-CA-C 109.76 -1.336 . . . . 0.0 109.76 178.179 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.4 112.75 24.88 Favored 'General case' 0 CA--C 1.535 0.379 0 C-N-CA 122.723 0.409 . . . . 0.0 110.251 179.668 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 77.0 mt -99.52 135.21 35.84 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.852 0 N-CA-C 106.927 -1.508 . . . . 0.0 106.927 178.829 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' I' I ' 32' ' ' ILE . . . . . 0.441 ' H ' HG22 ' F' ' 32' ' ' ILE . 30.3 pt -151.05 -169.08 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 CA-C-N 119.487 1.039 . . . . 0.0 109.876 179.956 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.05 2.25 3.7 Favored Glycine 0 CA--C 1.527 0.827 0 N-CA-C 111.22 -0.752 . . . . 0.0 111.22 -179.751 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' I' I ' 34' ' ' LEU . . . . . 0.42 HD23 ' N ' ' I' ' 35' ' ' MET . 1.1 tt -74.27 133.2 42.62 Favored 'General case' 0 CA--C 1.545 0.761 0 N-CA-C 109.122 -0.696 . . . . 0.0 109.122 -179.598 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' I' I ' 35' ' ' MET . . . . . 0.42 ' N ' HD23 ' I' ' 34' ' ' LEU . 23.8 ttt -158.95 150.13 20.31 Favored 'General case' 0 N--CA 1.468 0.443 0 N-CA-C 108.612 -0.884 . . . . 0.0 108.612 179.04 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' I' I ' 36' ' ' VAL . . . . . 0.451 HG12 ' N ' ' I' ' 37' ' ' GLY . 60.4 t -153.79 161.24 2.48 Favored 'Isoleucine or valine' 0 C--N 1.345 0.396 0 N-CA-C 107.959 -1.126 . . . . 0.0 107.959 -179.46 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' I' I ' 37' ' ' GLY . . . . . 0.451 ' N ' HG12 ' I' ' 36' ' ' VAL . . . 58.45 67.41 2.21 Favored Glycine 0 C--N 1.311 -0.86 0 CA-C-N 115.275 -0.875 . . . . 0.0 111.935 178.564 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.28 173.92 18.84 Favored Glycine 0 N--CA 1.476 1.312 0 N-CA-C 110.674 -0.97 . . . . 0.0 110.674 178.841 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' I' I ' 39' ' ' VAL . . . . . 0.404 HG12 ' H ' ' F' ' 39' ' ' VAL . 32.8 m -106.51 151.98 8.28 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.923 0 C-N-CA 123.28 0.632 . . . . 0.0 110.643 -179.48 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 22.3 t . . . . . 0 C--O 1.217 -0.614 0 CA-C-O 118.413 -0.803 . . . . 0.0 110.752 179.908 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . 0.469 ' H2 ' ' HB2' ' D' ' 1' ' ' ASP . 9.0 m-20 . . . . . 0 N--CA 1.487 1.383 0 N-CA-C 109.126 -0.694 . . . . 0.0 109.126 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.15 132.27 48.7 Favored 'General case' 0 CA--C 1.539 0.526 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.108 -179.922 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 39.8 tt0 -169.4 108.84 0.43 Allowed 'General case' 0 N--CA 1.47 0.573 0 N-CA-C 109.556 -0.535 . . . . 0.0 109.556 -179.139 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 77.9 m-85 -83.75 141.38 31.47 Favored 'General case' 0 N--CA 1.473 0.694 0 N-CA-C 109.658 -0.497 . . . . 0.0 109.658 179.363 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 35.6 mtp180 -142.43 143.03 32.45 Favored 'General case' 0 N--CA 1.48 1.059 0 N-CA-C 109.285 -0.635 . . . . 0.0 109.285 -179.951 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 74.4 m80 -150.29 117.84 6.13 Favored 'General case' 0 N--CA 1.472 0.64 0 N-CA-C 108.991 -0.744 . . . . 0.0 108.991 178.749 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 10.1 m-20 -68.31 149.4 49.47 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.822 -179.848 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 4.3 t -168.42 176.34 5.87 Favored 'General case' 0 N--CA 1.473 0.695 0 N-CA-C 109.643 -0.503 . . . . 0.0 109.643 178.592 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 105.08 51.54 0.88 Allowed Glycine 0 N--CA 1.484 1.884 0 N-CA-C 112.065 -0.414 . . . . 0.0 112.065 179.276 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 45.9 p90 -64.8 131.85 47.92 Favored 'General case' 0 N--CA 1.471 0.617 0 CA-C-O 120.51 0.195 . . . . 0.0 111.524 179.652 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.424 ' OE2' ' ND2' ' F' ' 27' ' ' ASN . 43.2 mt-10 -82.78 150.49 26.61 Favored 'General case' 0 N--CA 1.472 0.669 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 177.756 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -154.17 128.98 1.45 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 N-CA-C 108.094 -1.076 . . . . 0.0 108.094 178.167 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 56.7 m-70 -133.39 145.22 50.12 Favored 'General case' 0 N--CA 1.488 1.451 0 CA-C-N 118.616 0.644 . . . . 0.0 110.806 -178.959 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 5.9 t60 -166.11 98.16 0.62 Allowed 'General case' 0 N--CA 1.482 1.141 0 N-CA-C 111.392 0.145 . . . . 0.0 111.392 179.476 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . 0.515 HE22 ' H ' ' A' ' 37' ' ' GLY . 49.8 mt-30 -107.44 -172.65 2.11 Favored 'General case' 0 CA--C 1.502 -0.886 0 N-CA-C 107.948 -1.13 . . . . 0.0 107.948 179.219 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -163.13 97.92 0.92 Allowed 'General case' 0 N--CA 1.471 0.576 0 CA-C-N 115.121 -0.945 . . . . 0.0 109.291 178.739 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.502 HD12 ' N ' ' A' ' 17' ' ' LEU . 6.2 mp -108.7 163.98 12.78 Favored 'General case' 0 N--CA 1.487 1.394 0 N-CA-C 108.05 -1.093 . . . . 0.0 108.05 179.792 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 55.3 t -141.84 120.25 9.18 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.395 0 CA-C-O 118.663 -0.684 . . . . 0.0 110.33 179.77 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 52.9 m-85 -72.97 158.07 36.19 Favored 'General case' 0 N--CA 1.482 1.172 0 N-CA-C 107.383 -1.34 . . . . 0.0 107.383 176.917 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 24.8 t80 -169.29 -58.22 0.02 OUTLIER 'General case' 0 N--CA 1.481 1.076 0 CA-C-O 122.553 1.168 . . . . 0.0 109.475 -179.82 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -39.76 91.12 0.0 OUTLIER 'General case' 0 N--CA 1.457 -0.092 0 CA-C-N 113.665 -1.607 . . . . 0.0 112.709 -178.115 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 36.4 tt0 -58.2 131.95 52.12 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-N 115.143 -0.935 . . . . 0.0 111.128 179.429 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 9.0 m-20 -80.45 162.89 24.18 Favored 'General case' 0 N--CA 1.478 0.961 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 179.772 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 98.3 t -161.2 -74.25 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.484 1.267 0 N-CA-C 107.609 -1.256 . . . . 0.0 107.609 -178.612 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -38.96 91.01 0.01 OUTLIER Glycine 0 N--CA 1.471 1.002 0 CA-C-N 115.385 -0.825 . . . . 0.0 111.981 -179.736 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 89.1 p -37.46 -99.91 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.917 0 C-N-CA 123.714 0.806 . . . . 0.0 112.9 -176.622 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 40.8 t30 -61.23 126.35 27.04 Favored 'General case' 0 CA--C 1.546 0.807 0 CA-C-N 119.495 1.043 . . . . 0.0 108.855 179.465 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 62.8 mttm -106.36 -178.95 3.8 Favored 'General case' 0 N--CA 1.484 1.259 0 N-CA-C 109.249 -0.648 . . . . 0.0 109.249 -179.728 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.83 -141.27 0.02 OUTLIER Glycine 0 CA--C 1.528 0.888 0 N-CA-C 109.39 -1.484 . . . . 0.0 109.39 177.967 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.79 119.42 22.25 Favored 'General case' 0 N--CA 1.477 0.922 0 N-CA-C 109.257 -0.645 . . . . 0.0 109.257 178.439 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 68.9 mt -100.76 146.3 9.61 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.876 0 N-CA-C 107.856 -1.164 . . . . 0.0 107.856 178.614 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 28.4 mt -146.07 124.59 4.87 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.745 0 N-CA-C 109.435 -0.579 . . . . 0.0 109.435 -177.877 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.55 83.91 0.07 OUTLIER Glycine 0 C--N 1.338 0.677 0 CA-C-N 116.138 -0.483 . . . . 0.0 112.93 178.08 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 14.6 tp -101.9 123.2 45.42 Favored 'General case' 0 N--CA 1.484 1.263 0 N-CA-C 107.112 -1.44 . . . . 0.0 107.112 177.394 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 13.5 ttt -158.37 158.06 33.55 Favored 'General case' 0 N--CA 1.468 0.452 0 N-CA-C 109.018 -0.734 . . . . 0.0 109.018 179.94 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 89.5 t -155.93 152.46 8.52 Favored 'Isoleucine or valine' 0 C--O 1.234 0.262 0 N-CA-C 107.37 -1.345 . . . . 0.0 107.37 -179.435 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . 0.515 ' H ' HE22 ' A' ' 15' ' ' GLN . . . 57.22 73.34 0.46 Allowed Glycine 0 C--N 1.31 -0.881 0 CA-C-N 115.569 -0.741 . . . . 0.0 111.834 178.398 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 169.84 -150.03 14.19 Favored Glycine 0 N--CA 1.462 0.394 0 N-CA-C 110.744 -0.942 . . . . 0.0 110.744 179.432 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 33.1 m -133.77 144.77 34.8 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.875 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 179.93 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 19.8 t . . . . . 0 C--O 1.222 -0.393 0 CA-C-O 117.787 -1.101 . . . . 0.0 110.924 179.753 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' B' B ' 1' ' ' ASP . . . . . 0.405 ' N ' ' CB ' ' E' ' 1' ' ' ASP . 9.1 m-20 . . . . . 0 N--CA 1.488 1.441 0 N-CA-C 109.113 -0.699 . . . . 0.0 109.113 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.18 132.2 48.5 Favored 'General case' 0 CA--C 1.538 0.487 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.16 -179.945 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 3' ' ' GLU . . . . . . . . . . . . . 39.9 tt0 -169.35 108.77 0.43 Allowed 'General case' 0 N--CA 1.47 0.548 0 N-CA-C 109.519 -0.548 . . . . 0.0 109.519 -179.077 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 78.1 m-85 -83.67 141.52 31.43 Favored 'General case' 0 N--CA 1.471 0.621 0 N-CA-C 109.656 -0.498 . . . . 0.0 109.656 179.33 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 35.7 mtp180 -142.58 143.15 32.31 Favored 'General case' 0 N--CA 1.479 1.015 0 N-CA-C 109.296 -0.631 . . . . 0.0 109.296 -179.93 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 74.5 m80 -150.38 118.04 6.16 Favored 'General case' 0 N--CA 1.473 0.701 0 N-CA-C 109.045 -0.724 . . . . 0.0 109.045 178.768 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 7' ' ' ASP . . . . . . . . . . . . . 10.0 m-20 -68.46 149.05 49.75 Favored 'General case' 0 N--CA 1.464 0.233 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.929 -179.884 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 8' ' ' SER . . . . . . . . . . . . . 4.3 t -168.14 176.44 6.04 Favored 'General case' 0 N--CA 1.472 0.666 0 N-CA-C 109.614 -0.513 . . . . 0.0 109.614 178.575 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 105.03 51.31 0.89 Allowed Glycine 0 N--CA 1.483 1.814 0 N-CA-C 112.042 -0.423 . . . . 0.0 112.042 179.296 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 46.7 p90 -64.49 131.9 48.43 Favored 'General case' 0 N--CA 1.471 0.618 0 CA-C-O 120.583 0.23 . . . . 0.0 111.538 179.596 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 11' ' ' GLU . . . . . 0.432 ' OE2' ' ND2' ' D' ' 27' ' ' ASN . 43.2 mt-10 -82.88 150.61 26.42 Favored 'General case' 0 N--CA 1.473 0.696 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 177.787 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -154.29 128.9 1.41 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 N-CA-C 108.214 -1.032 . . . . 0.0 108.214 178.162 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 56.8 m-70 -133.4 145.35 50.23 Favored 'General case' 0 N--CA 1.489 1.479 0 CA-C-N 118.458 0.572 . . . . 0.0 110.762 -178.84 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 5.9 t60 -166.25 97.91 0.61 Allowed 'General case' 0 N--CA 1.484 1.27 0 CA-C-O 119.694 -0.193 . . . . 0.0 111.236 179.554 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . 0.514 HE22 ' H ' ' B' ' 37' ' ' GLY . 49.7 mt-30 -107.21 -172.77 2.14 Favored 'General case' 0 CA--C 1.504 -0.803 0 N-CA-C 107.862 -1.162 . . . . 0.0 107.862 179.238 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -163.11 97.9 0.93 Allowed 'General case' 0 N--CA 1.471 0.625 0 CA-C-N 115.154 -0.93 . . . . 0.0 109.192 178.748 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . 0.502 ' N ' HD12 ' B' ' 17' ' ' LEU . 6.1 mp -108.77 163.96 12.81 Favored 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 108.075 -1.083 . . . . 0.0 108.075 179.784 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 57.6 t -141.98 119.92 8.39 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.31 0 CA-C-O 118.724 -0.655 . . . . 0.0 110.293 179.868 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 55.4 m-85 -73.14 158.29 35.58 Favored 'General case' 0 N--CA 1.48 1.036 0 N-CA-C 107.343 -1.355 . . . . 0.0 107.343 176.792 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 26.1 t80 -170.33 -57.25 0.02 OUTLIER 'General case' 0 N--CA 1.478 0.953 0 CA-C-O 122.354 1.073 . . . . 0.0 109.533 -179.962 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -39.87 91.07 0.0 OUTLIER 'General case' 0 C--N 1.34 0.161 0 CA-C-N 113.999 -1.455 . . . . 0.0 112.558 -178.314 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 36.1 tt0 -58.19 132.0 52.25 Favored 'General case' 0 C--N 1.317 -0.811 0 CA-C-N 115.142 -0.936 . . . . 0.0 111.219 179.545 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 -80.58 162.71 24.14 Favored 'General case' 0 N--CA 1.479 1.015 0 N-CA-C 109.491 -0.559 . . . . 0.0 109.491 179.776 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 98.5 t -160.99 -74.13 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.483 1.192 0 C-N-CA 124.76 1.224 . . . . 0.0 107.732 -178.526 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -39.38 91.04 0.01 OUTLIER Glycine 0 N--CA 1.473 1.154 0 CA-C-N 115.42 -0.809 . . . . 0.0 111.828 -179.709 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 92.4 p -37.08 -99.93 0.0 OUTLIER 'General case' 0 N--CA 1.481 1.107 0 C-N-CA 123.881 0.873 . . . . 0.0 112.615 -177.045 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 41.6 t30 -61.23 126.35 27.03 Favored 'General case' 0 CA--C 1.544 0.746 0 CA-C-N 119.547 1.067 . . . . 0.0 109.076 179.508 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 62.9 mttm -106.43 -179.03 3.82 Favored 'General case' 0 N--CA 1.483 1.178 0 N-CA-C 109.223 -0.658 . . . . 0.0 109.223 -179.703 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.85 -141.22 0.02 OUTLIER Glycine 0 CA--C 1.527 0.814 0 N-CA-C 109.411 -1.476 . . . . 0.0 109.411 177.924 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.77 119.36 22.18 Favored 'General case' 0 N--CA 1.478 0.962 0 N-CA-C 109.304 -0.628 . . . . 0.0 109.304 178.488 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 69.0 mt -100.84 146.03 10.13 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.901 0 N-CA-C 107.862 -1.162 . . . . 0.0 107.862 178.551 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 28.7 mt -145.9 124.59 5.1 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.755 0 N-CA-C 109.428 -0.582 . . . . 0.0 109.428 -177.817 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.87 83.87 0.07 OUTLIER Glycine 0 C--N 1.338 0.678 0 CA-C-N 116.119 -0.492 . . . . 0.0 112.872 178.005 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 15.0 tp -102.27 121.52 42.43 Favored 'General case' 0 N--CA 1.486 1.335 0 N-CA-C 107.386 -1.338 . . . . 0.0 107.386 177.441 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 13.3 ttt -156.75 158.18 36.41 Favored 'General case' 0 N--CA 1.466 0.327 0 N-CA-C 109.27 -0.641 . . . . 0.0 109.27 179.836 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 89.1 t -155.97 152.32 8.64 Favored 'Isoleucine or valine' 0 C--O 1.235 0.317 0 N-CA-C 107.256 -1.387 . . . . 0.0 107.256 -179.444 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . 0.514 ' H ' HE22 ' B' ' 15' ' ' GLN . . . 57.39 73.24 0.47 Allowed Glycine 0 C--N 1.312 -0.797 0 CA-C-N 115.525 -0.762 . . . . 0.0 111.789 178.332 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 169.79 -149.99 14.16 Favored Glycine 0 N--CA 1.462 0.412 0 N-CA-C 110.751 -0.94 . . . . 0.0 110.751 179.408 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 33.1 m -133.78 144.83 34.62 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.91 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 179.996 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 20.4 t . . . . . 0 C--O 1.221 -0.425 0 CA-C-O 117.766 -1.111 . . . . 0.0 110.877 179.708 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' C' C ' 1' ' ' ASP . . . . . 0.407 ' N ' ' CB ' ' F' ' 1' ' ' ASP . 9.2 m-20 . . . . . 0 N--CA 1.489 1.494 0 N-CA-C 109.011 -0.737 . . . . 0.0 109.011 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' C' C ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.29 132.23 48.53 Favored 'General case' 0 CA--C 1.539 0.535 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.214 -179.896 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' C' C ' 3' ' ' GLU . . . . . . . . . . . . . 39.8 tt0 -169.42 108.92 0.43 Allowed 'General case' 0 N--CA 1.47 0.537 0 N-CA-C 109.553 -0.536 . . . . 0.0 109.553 -179.054 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 78.2 m-85 -83.74 141.59 31.32 Favored 'General case' 0 N--CA 1.473 0.714 0 N-CA-C 109.605 -0.517 . . . . 0.0 109.605 179.297 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 35.7 mtp180 -142.66 143.11 32.2 Favored 'General case' 0 N--CA 1.48 1.057 0 N-CA-C 109.227 -0.657 . . . . 0.0 109.227 -179.93 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 74.6 m80 -150.44 118.08 6.15 Favored 'General case' 0 N--CA 1.472 0.641 0 N-CA-C 108.958 -0.756 . . . . 0.0 108.958 178.765 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' C' C ' 7' ' ' ASP . . . . . . . . . . . . . 10.0 m-20 -68.52 149.17 49.55 Favored 'General case' 0 N--CA 1.462 0.17 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.994 -179.92 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' C' C ' 8' ' ' SER . . . . . . . . . . . . . 4.3 t -168.22 176.49 5.95 Favored 'General case' 0 N--CA 1.472 0.655 0 N-CA-C 109.546 -0.539 . . . . 0.0 109.546 178.631 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 105.01 51.35 0.89 Allowed Glycine 0 N--CA 1.483 1.821 0 N-CA-C 112.006 -0.438 . . . . 0.0 112.006 179.275 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 46.1 p90 -64.64 131.82 48.02 Favored 'General case' 0 N--CA 1.471 0.602 0 CA-C-O 120.57 0.224 . . . . 0.0 111.509 179.648 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' C' C ' 11' ' ' GLU . . . . . 0.435 ' OE2' ' ND2' ' E' ' 27' ' ' ASN . 43.2 mt-10 -82.76 150.44 26.66 Favored 'General case' 0 N--CA 1.473 0.68 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 177.815 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -154.11 129.04 1.48 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 178.133 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 56.8 m-70 -133.44 145.41 50.22 Favored 'General case' 0 N--CA 1.489 1.507 0 CA-C-N 118.496 0.589 . . . . 0.0 110.81 -178.914 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 5.9 t60 -166.36 98.04 0.6 Allowed 'General case' 0 N--CA 1.483 1.204 0 CA-C-O 119.79 -0.148 . . . . 0.0 111.3 179.534 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' C' C ' 15' ' ' GLN . . . . . 0.494 HE22 ' H ' ' C' ' 37' ' ' GLY . 49.7 mt-30 -107.42 -172.69 2.12 Favored 'General case' 0 CA--C 1.5 -0.945 0 N-CA-C 107.999 -1.111 . . . . 0.0 107.999 179.246 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -163.15 97.86 0.92 Allowed 'General case' 0 N--CA 1.47 0.532 0 CA-C-N 115.181 -0.918 . . . . 0.0 109.308 178.782 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' C' C ' 17' ' ' LEU . . . . . 0.5 HD12 ' N ' ' C' ' 17' ' ' LEU . 6.1 mp -108.69 163.96 12.79 Favored 'General case' 0 N--CA 1.487 1.395 0 N-CA-C 108.037 -1.097 . . . . 0.0 108.037 179.879 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 57.3 t -141.93 119.97 8.59 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.365 0 CA-C-O 118.721 -0.657 . . . . 0.0 110.257 179.836 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 55.1 m-85 -73.14 158.28 35.61 Favored 'General case' 0 N--CA 1.479 1.016 0 N-CA-C 107.293 -1.373 . . . . 0.0 107.293 176.761 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 26.1 t80 -170.23 -57.21 0.02 OUTLIER 'General case' 0 N--CA 1.477 0.898 0 CA-C-O 122.358 1.075 . . . . 0.0 109.587 179.978 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -39.93 91.26 0.0 OUTLIER 'General case' 0 C--N 1.34 0.169 0 CA-C-N 114.028 -1.442 . . . . 0.0 112.549 -178.294 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 36.1 tt0 -58.3 131.88 51.96 Favored 'General case' 0 C--N 1.317 -0.847 0 CA-C-N 115.129 -0.941 . . . . 0.0 111.165 179.501 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 -80.45 162.76 24.25 Favored 'General case' 0 N--CA 1.479 0.994 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 179.722 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 98.2 t -161.07 -74.27 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.483 1.21 0 C-N-CA 124.753 1.221 . . . . 0.0 107.744 -178.556 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -39.46 91.09 0.01 OUTLIER Glycine 0 N--CA 1.473 1.105 0 CA-C-N 115.463 -0.79 . . . . 0.0 111.84 -179.68 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 91.1 p -37.03 -99.88 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.036 0 C-N-CA 123.831 0.852 . . . . 0.0 112.748 -177.0 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 41.6 t30 -61.17 126.37 27.12 Favored 'General case' 0 CA--C 1.545 0.752 0 CA-C-N 119.506 1.048 . . . . 0.0 109.061 179.484 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 62.9 mttm -106.46 -179.12 3.85 Favored 'General case' 0 N--CA 1.483 1.185 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 -179.713 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.79 -141.25 0.02 OUTLIER Glycine 0 CA--C 1.528 0.878 0 N-CA-C 109.362 -1.495 . . . . 0.0 109.362 177.996 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.73 119.34 22.21 Favored 'General case' 0 N--CA 1.477 0.882 0 N-CA-C 109.37 -0.604 . . . . 0.0 109.37 178.436 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 68.7 mt -100.81 146.01 10.15 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.945 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 178.598 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 28.6 mt -145.96 124.63 5.03 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.726 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 -177.793 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.74 83.78 0.07 OUTLIER Glycine 0 C--N 1.339 0.701 0 CA-C-N 116.127 -0.488 . . . . 0.0 112.92 178.05 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 15.2 tp -102.12 121.39 42.11 Favored 'General case' 0 N--CA 1.484 1.26 0 N-CA-C 107.485 -1.302 . . . . 0.0 107.485 177.349 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 13.4 ttt -156.62 158.23 36.67 Favored 'General case' 0 N--CA 1.465 0.32 0 N-CA-C 109.254 -0.647 . . . . 0.0 109.254 179.848 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 87.9 t -155.94 152.44 8.53 Favored 'Isoleucine or valine' 0 C--O 1.235 0.314 0 N-CA-C 107.331 -1.359 . . . . 0.0 107.331 -179.48 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' C' C ' 37' ' ' GLY . . . . . 0.494 ' H ' HE22 ' C' ' 15' ' ' GLN . . . 57.26 73.27 0.47 Allowed Glycine 0 C--N 1.311 -0.82 0 CA-C-N 115.535 -0.757 . . . . 0.0 111.812 178.384 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 169.78 -150.0 14.19 Favored Glycine 0 N--CA 1.462 0.433 0 N-CA-C 110.716 -0.954 . . . . 0.0 110.716 179.377 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 33.2 m -133.7 144.82 34.72 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.883 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 179.98 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 20.3 t . . . . . 0 N--CA 1.467 0.403 0 CA-C-O 117.747 -1.121 . . . . 0.0 110.864 179.667 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' D' D ' 1' ' ' ASP . . . . . 0.469 ' HB2' ' H2 ' ' A' ' 1' ' ' ASP . 9.4 m-20 . . . . . 0 N--CA 1.489 1.477 0 N-CA-C 109.269 -0.641 . . . . 0.0 109.269 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' D' D ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.45 131.11 46.21 Favored 'General case' 0 CA--C 1.536 0.409 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.229 179.956 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' D' D ' 3' ' ' GLU . . . . . . . . . . . . . 39.6 tt0 -169.32 110.59 0.47 Allowed 'General case' 0 N--CA 1.469 0.487 0 N-CA-C 109.29 -0.633 . . . . 0.0 109.29 179.975 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 85.5 m-85 -86.8 148.82 25.23 Favored 'General case' 0 C--N 1.362 1.11 0 C-N-CA 118.68 -1.208 . . . . 0.0 108.142 179.59 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' D' D ' 5' ' ' ARG . . . . . 0.417 HH21 HG22 ' F' ' 24' ' ' VAL . 36.8 mtp180 -145.95 141.99 28.27 Favored 'General case' 0 N--CA 1.474 0.76 0 N-CA-C 109.365 -0.606 . . . . 0.0 109.365 -179.834 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 75.5 m80 -149.13 123.39 9.57 Favored 'General case' 0 CA--C 1.543 0.684 0 N-CA-C 107.815 -1.18 . . . . 0.0 107.815 174.618 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' D' D ' 7' ' ' ASP . . . . . . . . . . . . . 6.7 m-20 -63.71 133.13 53.02 Favored 'General case' 0 C--N 1.322 -0.615 0 C-N-CA 126.968 2.107 . . . . 0.0 114.675 175.231 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' D' D ' 8' ' ' SER . . . . . . . . . . . . . 3.5 t -154.59 -179.74 8.27 Favored 'General case' 0 N--CA 1.475 0.823 0 CA-C-N 119.081 0.855 . . . . 0.0 110.214 175.99 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.36 49.92 1.02 Allowed Glycine 0 N--CA 1.482 1.743 0 N-CA-C 112.047 -0.421 . . . . 0.0 112.047 175.194 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 46.4 p90 -61.49 132.31 52.98 Favored 'General case' 0 CA--C 1.54 0.575 0 N-CA-C 112.116 0.413 . . . . 0.0 112.116 179.505 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' D' D ' 11' ' ' GLU . . . . . 0.401 ' CG ' ' ND2' ' F' ' 27' ' ' ASN . 42.7 mt-10 -83.23 148.97 27.1 Favored 'General case' 0 N--CA 1.48 1.065 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 176.661 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -149.84 130.15 4.19 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.341 0 N-CA-C 108.325 -0.991 . . . . 0.0 108.325 174.876 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 54.7 m-70 -129.42 148.05 51.29 Favored 'General case' 0 N--CA 1.482 1.137 0 CA-C-N 118.158 0.436 . . . . 0.0 110.897 176.801 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' D' D ' 14' ' ' HIS . . . . . 0.41 ' ND1' ' O ' ' G' ' 14' ' ' HIS . 6.0 t60 -165.34 104.64 0.74 Allowed 'General case' 0 N--CA 1.484 1.246 0 CA-C-O 119.016 -0.516 . . . . 0.0 109.667 173.637 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' D' D ' 15' ' ' GLN . . . . . 0.541 HE22 ' H ' ' D' ' 37' ' ' GLY . 49.7 mt-30 -110.63 -175.72 2.79 Favored 'General case' 0 CA--C 1.492 -1.268 0 N-CA-C 107.551 -1.277 . . . . 0.0 107.551 178.285 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -159.54 105.88 1.67 Allowed 'General case' 0 CA--C 1.536 0.431 0 N-CA-C 107.679 -1.23 . . . . 0.0 107.679 175.619 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' D' D ' 17' ' ' LEU . . . . . 0.442 HD12 ' N ' ' D' ' 17' ' ' LEU . 6.9 mp -114.87 162.65 16.63 Favored 'General case' 0 N--CA 1.487 1.419 0 N-CA-C 107.638 -1.245 . . . . 0.0 107.638 179.401 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 48.1 t -140.99 123.78 15.58 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.147 0 N-CA-C 109.483 -0.562 . . . . 0.0 109.483 176.319 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 82.7 m-85 -63.25 151.08 41.53 Favored 'General case' 0 C--N 1.357 0.923 0 C-N-CA 124.569 1.147 . . . . 0.0 110.634 169.586 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 19.0 t80 -169.68 -66.85 0.02 OUTLIER 'General case' 0 C--N 1.315 -0.916 0 N-CA-C 107.456 -1.312 . . . . 0.0 107.456 -179.877 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -37.98 95.82 0.01 OUTLIER 'General case' 0 CA--C 1.536 0.42 0 CA-C-N 114.162 -1.381 . . . . 0.0 111.683 -175.407 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 36.6 tt0 -60.38 134.34 56.97 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 113.709 -1.587 . . . . 0.0 111.018 179.297 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' D' D ' 23' ' ' ASP . . . . . 0.469 ' O ' HG23 ' D' ' 24' ' ' VAL . 9.5 m-20 -82.57 168.27 17.52 Favored 'General case' 0 C--O 1.205 -1.285 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 179.558 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' D' D ' 24' ' ' VAL . . . . . 0.469 HG23 ' O ' ' D' ' 23' ' ' ASP 0.288 46.3 t -168.93 -94.15 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.505 2.291 0 N-CA-C 103.507 -2.775 . . . . 0.0 103.507 -164.215 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . -26.35 77.14 0.0 OUTLIER Glycine 0 C--N 1.259 -3.721 0 C-N-CA 129.754 3.549 . . . . 0.0 116.908 -179.957 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' D' D ' 26' ' ' SER . . . . . 0.459 ' OG ' ' N ' ' D' ' 27' ' ' ASN 0.51 75.0 p -59.05 -93.05 0.0 OUTLIER 'General case' 0 C--O 1.28 2.692 1 CA-C-O 107.247 -6.12 . . . . 0.0 104.856 -155.503 . . . . . . . . 4 3 . 1 . 018 nuclear nobuild full ' D' D ' 27' ' ' ASN . . . . . 0.459 ' N ' ' OG ' ' D' ' 26' ' ' SER 0.293 32.8 t30 -62.98 135.82 57.5 Favored 'General case' 0 N--CA 1.491 1.581 1 CA-C-N 133.294 7.315 . . . . 0.0 108.193 -172.984 . . . . . . . . 4 3 . 1 . 018 nuclear nobuild full ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 60.0 mttm -102.76 178.58 4.53 Favored 'General case' 0 N--CA 1.475 0.82 0 C-N-CA 125.3 1.44 . . . . 0.0 111.632 177.889 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -60.02 -145.83 0.01 OUTLIER Glycine 0 CA--C 1.537 1.447 0 N-CA-C 111.267 -0.733 . . . . 0.0 111.267 171.401 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -126.9 122.02 33.44 Favored 'General case' 0 C--N 1.369 1.421 0 N-CA-C 108.779 -0.823 . . . . 0.0 108.779 174.689 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 68.4 mt -97.81 152.27 4.17 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.758 0 N-CA-C 107.829 -1.174 . . . . 0.0 107.829 175.492 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 34.7 mt -152.04 128.68 1.99 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.006 0 N-CA-C 107.884 -1.154 . . . . 0.0 107.884 177.226 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . 64.06 80.47 0.13 Allowed Glycine 0 C--N 1.35 1.344 0 CA-C-O 117.996 -1.447 . . . . 0.0 113.185 178.06 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 10.5 tp -101.42 131.98 47.24 Favored 'General case' 0 C--N 1.38 1.931 0 N-CA-C 104.792 -2.299 . . . . 0.0 104.792 176.402 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 12.5 ttt -157.3 165.69 35.15 Favored 'General case' 0 N--CA 1.467 0.395 0 N-CA-C 108.721 -0.844 . . . . 0.0 108.721 176.756 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 81.4 t -163.19 156.61 2.11 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.485 0 N-CA-C 106.145 -1.798 . . . . 0.0 106.145 175.089 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' D' D ' 37' ' ' GLY . . . . . 0.541 ' H ' HE22 ' D' ' 15' ' ' GLN . . . 61.25 66.17 2.83 Favored Glycine 0 N--CA 1.447 -0.633 0 C-N-CA 117.956 -2.068 . . . . 0.0 113.754 178.087 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 167.1 -148.95 13.88 Favored Glycine 0 N--CA 1.467 0.751 0 CA-C-O 118.011 -1.438 . . . . 0.0 112.105 179.982 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 33.0 m -130.67 144.47 37.81 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.225 0 CA-C-N 119.02 1.41 . . . . 0.0 109.956 -178.821 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 18.4 t . . . . . 0 C--O 1.214 -0.802 0 N-CA-C 109.2 -0.667 . . . . 0.0 109.2 174.99 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' E' E ' 1' ' ' ASP . . . . . 0.418 ' H2 ' ' HB2' ' H' ' 1' ' ' ASP . 9.3 m-20 . . . . . 0 N--CA 1.487 1.407 0 N-CA-C 109.323 -0.621 . . . . 0.0 109.323 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' E' E ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.12 130.98 46.11 Favored 'General case' 0 CA--C 1.536 0.405 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.27 179.83 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' E' E ' 3' ' ' GLU . . . . . . . . . . . . . 39.7 tt0 -169.11 108.62 0.45 Allowed 'General case' 0 N--CA 1.469 0.516 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 -179.665 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 77.6 m-85 -84.26 141.83 30.69 Favored 'General case' 0 N--CA 1.474 0.763 0 N-CA-C 109.703 -0.48 . . . . 0.0 109.703 179.235 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' E' E ' 5' ' ' ARG . . . . . 0.416 HH21 HG22 ' D' ' 24' ' ' VAL . 37.1 mtp180 -142.62 143.56 32.45 Favored 'General case' 0 N--CA 1.477 0.888 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 179.906 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 74.7 m80 -150.56 117.55 5.92 Favored 'General case' 0 N--CA 1.473 0.699 0 N-CA-C 109.136 -0.691 . . . . 0.0 109.136 178.653 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' E' E ' 7' ' ' ASP . . . . . . . . . . . . . 9.5 m-20 -68.06 149.18 49.98 Favored 'General case' 0 CA--C 1.529 0.171 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.043 -179.816 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' E' E ' 8' ' ' SER . . . . . . . . . . . . . 3.4 t -168.5 178.06 4.98 Favored 'General case' 0 N--CA 1.475 0.806 0 N-CA-C 109.574 -0.528 . . . . 0.0 109.574 178.224 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.85 50.9 0.92 Allowed Glycine 0 N--CA 1.477 1.385 0 N-CA-C 111.97 -0.452 . . . . 0.0 111.97 179.124 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 44.2 p90 -63.78 131.21 47.13 Favored 'General case' 0 CA--C 1.545 0.756 0 N-CA-C 111.895 0.332 . . . . 0.0 111.895 -179.861 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 41.4 mt-10 -81.78 151.42 27.43 Favored 'General case' 0 N--CA 1.479 1.008 0 N-CA-C 108.683 -0.858 . . . . 0.0 108.683 177.433 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.6 p -155.92 127.91 1.0 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.449 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 177.906 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 52.2 m-70 -133.5 143.51 48.82 Favored 'General case' 0 N--CA 1.48 1.034 0 O-C-N 122.259 -0.276 . . . . 0.0 111.073 -177.884 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 5.9 t60 -165.35 97.43 0.7 Allowed 'General case' 0 N--CA 1.488 1.437 0 CA-C-O 119.602 -0.237 . . . . 0.0 111.211 179.816 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' E' E ' 15' ' ' GLN . . . . . 0.497 HE22 ' H ' ' E' ' 37' ' ' GLY . 50.0 mt-30 -106.44 -172.29 2.06 Favored 'General case' 0 CA--C 1.505 -0.769 0 N-CA-C 107.969 -1.123 . . . . 0.0 107.969 179.228 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -163.23 98.0 0.92 Allowed 'General case' 0 N--CA 1.47 0.575 0 CA-C-N 115.135 -0.938 . . . . 0.0 109.241 178.634 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' E' E ' 17' ' ' LEU . . . . . 0.488 ' N ' HD12 ' E' ' 17' ' ' LEU . 6.2 mp -108.54 163.13 13.5 Favored 'General case' 0 N--CA 1.488 1.441 0 N-CA-C 108.636 -0.876 . . . . 0.0 108.636 -179.919 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 40.6 t -141.86 120.79 9.83 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.281 0 C-N-CA 122.465 0.306 . . . . 0.0 110.631 179.194 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 51.9 m-85 -73.64 155.6 38.87 Favored 'General case' 0 C--N 1.362 1.138 0 N-CA-C 106.823 -1.547 . . . . 0.0 106.823 176.349 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 23.6 t80 -171.78 -54.82 0.02 OUTLIER 'General case' 0 N--CA 1.479 1.01 0 CA-C-O 121.682 0.753 . . . . 0.0 110.161 -179.942 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.95 89.63 0.0 OUTLIER 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 114.426 -1.261 . . . . 0.0 112.634 -179.436 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 36.0 tt0 -56.2 133.47 52.4 Favored 'General case' 0 CA--C 1.539 0.536 0 CA-C-N 114.912 -1.04 . . . . 0.0 111.291 179.861 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 9.2 m-20 -81.72 162.25 23.05 Favored 'General case' 0 N--CA 1.475 0.779 0 N-CA-C 109.66 -0.496 . . . . 0.0 109.66 179.782 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' E' E ' 24' ' ' VAL . . . . . 0.429 HG22 HH21 ' F' ' 5' ' ' ARG . 95.0 t -160.7 -74.64 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.291 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 -179.003 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . -38.81 91.22 0.01 OUTLIER Glycine 0 CA--C 1.53 0.974 0 CA-C-N 115.263 -0.88 . . . . 0.0 112.403 -179.673 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 84.8 p -37.7 -101.33 0.0 OUTLIER 'General case' 0 N--CA 1.481 1.079 0 N-CA-C 113.725 1.009 . . . . 0.0 113.725 -177.429 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' E' E ' 27' ' ' ASN . . . . . 0.435 ' ND2' ' OE2' ' C' ' 11' ' ' GLU . 40.2 t30 -60.01 124.63 20.8 Favored 'General case' 0 CA--C 1.542 0.663 0 CA-C-N 119.482 1.037 . . . . 0.0 108.781 -179.89 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 62.8 mttm -105.38 -178.65 3.71 Favored 'General case' 0 N--CA 1.483 1.214 0 N-CA-C 108.889 -0.782 . . . . 0.0 108.889 -179.613 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -65.35 -141.45 0.03 OUTLIER Glycine 0 CA--C 1.532 1.102 0 N-CA-C 110.421 -1.072 . . . . 0.0 110.421 178.02 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.93 118.31 22.44 Favored 'General case' 0 C--N 1.349 0.582 0 C-N-CA 123.234 0.614 . . . . 0.0 109.46 178.471 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 71.6 mt -100.28 148.76 6.44 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.816 0 N-CA-C 106.88 -1.526 . . . . 0.0 106.88 178.103 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 34.1 mt -148.17 125.0 2.77 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.958 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 -179.434 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.76 85.49 0.05 OUTLIER Glycine 0 C--N 1.34 0.767 0 CA-C-N 115.966 -0.561 . . . . 0.0 112.827 178.493 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 13.2 tp -103.39 121.38 42.68 Favored 'General case' 0 N--CA 1.484 1.258 0 N-CA-C 106.97 -1.492 . . . . 0.0 106.97 177.371 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 12.6 ttt -156.08 158.93 38.6 Favored 'General case' 0 N--CA 1.476 0.859 0 N-CA-C 108.883 -0.784 . . . . 0.0 108.883 179.661 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 95.3 t -156.76 151.98 8.33 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.416 0 N-CA-C 107.493 -1.299 . . . . 0.0 107.493 -179.693 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' E' E ' 37' ' ' GLY . . . . . 0.497 ' H ' HE22 ' E' ' 15' ' ' GLN . . . 57.59 72.41 0.59 Allowed Glycine 0 C--N 1.313 -0.74 0 CA-C-N 115.397 -0.819 . . . . 0.0 111.481 178.168 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 171.62 -148.81 11.31 Favored Glycine 0 CA--C 1.524 0.624 0 N-CA-C 111.025 -0.83 . . . . 0.0 111.025 179.606 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 32.9 m -135.53 144.06 34.95 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.826 0 N-CA-C 109.095 -0.705 . . . . 0.0 109.095 179.906 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 19.5 t . . . . . 0 CA--C 1.537 0.471 0 CA-C-O 117.66 -1.162 . . . . 0.0 110.817 -179.988 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' F' F ' 1' ' ' ASP . . . . . 0.407 ' CB ' ' N ' ' C' ' 1' ' ' ASP . 9.4 m-20 . . . . . 0 N--CA 1.489 1.476 0 N-CA-C 109.286 -0.635 . . . . 0.0 109.286 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' F' F ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.13 131.05 46.34 Favored 'General case' 0 CA--C 1.536 0.421 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.322 179.804 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' F' F ' 3' ' ' GLU . . . . . . . . . . . . . 39.7 tt0 -169.1 108.56 0.45 Allowed 'General case' 0 N--CA 1.469 0.484 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 -179.632 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 77.6 m-85 -84.24 141.83 30.71 Favored 'General case' 0 N--CA 1.475 0.777 0 N-CA-C 109.625 -0.509 . . . . 0.0 109.625 179.228 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' F' F ' 5' ' ' ARG . . . . . 0.429 HH21 HG22 ' E' ' 24' ' ' VAL . 37.1 mtp180 -142.51 143.43 32.53 Favored 'General case' 0 N--CA 1.477 0.898 0 N-CA-C 109.396 -0.594 . . . . 0.0 109.396 179.979 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 74.8 m80 -150.59 117.65 5.94 Favored 'General case' 0 N--CA 1.474 0.744 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 178.626 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' F' F ' 7' ' ' ASP . . . . . . . . . . . . . 9.5 m-20 -68.05 149.11 50.08 Favored 'General case' 0 N--CA 1.463 0.21 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.057 -179.812 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' F' F ' 8' ' ' SER . . . . . . . . . . . . . 3.4 t -168.65 177.7 5.04 Favored 'General case' 0 N--CA 1.474 0.773 0 N-CA-C 109.521 -0.548 . . . . 0.0 109.521 178.153 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 105.13 50.95 0.9 Allowed Glycine 0 N--CA 1.478 1.496 0 N-CA-C 111.858 -0.497 . . . . 0.0 111.858 179.054 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 43.8 p90 -64.07 131.74 48.44 Favored 'General case' 0 CA--C 1.543 0.697 0 N-CA-C 112.0 0.37 . . . . 0.0 112.0 -179.867 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 41.5 mt-10 -82.01 151.56 27.07 Favored 'General case' 0 N--CA 1.479 0.994 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 177.448 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.6 p -156.0 127.88 0.98 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.46 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 177.921 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 52.3 m-70 -133.49 143.63 48.92 Favored 'General case' 0 N--CA 1.481 1.122 0 O-C-N 122.25 -0.281 . . . . 0.0 110.965 -177.856 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 5.9 t60 -165.44 97.73 0.69 Allowed 'General case' 0 N--CA 1.486 1.341 0 CA-C-O 119.604 -0.236 . . . . 0.0 111.386 179.777 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' F' F ' 15' ' ' GLN . . . . . 0.468 HE22 ' H ' ' F' ' 37' ' ' GLY . 50.0 mt-30 -106.75 -172.31 2.06 Favored 'General case' 0 CA--C 1.497 -1.064 0 N-CA-C 108.088 -1.078 . . . . 0.0 108.088 179.177 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -163.26 97.86 0.91 Allowed 'General case' 0 CA--C 1.539 0.551 0 CA-C-N 114.96 -1.018 . . . . 0.0 109.16 178.77 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' F' F ' 17' ' ' LEU . . . . . 0.483 HD12 ' N ' ' F' ' 17' ' ' LEU . 6.2 mp -108.46 163.14 13.48 Favored 'General case' 0 N--CA 1.489 1.488 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 -179.914 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 40.5 t -141.89 120.72 9.66 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.227 0 C-N-CA 122.549 0.339 . . . . 0.0 110.648 179.261 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 52.4 m-85 -73.59 155.43 39.11 Favored 'General case' 0 C--N 1.362 1.125 0 N-CA-C 106.765 -1.568 . . . . 0.0 106.765 176.219 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 24.3 t80 -171.48 -55.1 0.02 OUTLIER 'General case' 0 N--CA 1.481 1.084 0 CA-C-O 121.739 0.781 . . . . 0.0 109.75 -179.861 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -41.83 89.72 0.0 OUTLIER 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 114.49 -1.232 . . . . 0.0 112.693 -179.342 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 36.0 tt0 -56.4 133.4 52.99 Favored 'General case' 0 CA--C 1.54 0.586 0 CA-C-N 114.953 -1.021 . . . . 0.0 111.283 179.79 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 -81.7 162.39 23.01 Favored 'General case' 0 N--CA 1.475 0.793 0 N-CA-C 109.627 -0.508 . . . . 0.0 109.627 179.826 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' F' F ' 24' ' ' VAL . . . . . 0.417 HG22 HH21 ' D' ' 5' ' ' ARG . 95.8 t -160.7 -74.96 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.486 1.333 0 N-CA-C 107.095 -1.446 . . . . 0.0 107.095 -179.005 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -38.49 91.01 0.01 OUTLIER Glycine 0 CA--C 1.529 0.91 0 CA-C-N 115.305 -0.862 . . . . 0.0 112.451 -179.779 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 84.9 p -37.58 -100.97 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.067 0 N-CA-C 113.69 0.996 . . . . 0.0 113.69 -177.443 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' F' F ' 27' ' ' ASN . . . . . 0.424 ' ND2' ' OE2' ' A' ' 11' ' ' GLU . 39.9 t30 -60.18 124.91 21.7 Favored 'General case' 0 CA--C 1.542 0.642 0 CA-C-N 119.492 1.042 . . . . 0.0 108.769 -179.954 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 62.8 mttm -105.65 -178.6 3.7 Favored 'General case' 0 N--CA 1.483 1.197 0 N-CA-C 108.893 -0.78 . . . . 0.0 108.893 -179.737 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -65.29 -141.67 0.03 OUTLIER Glycine 0 CA--C 1.532 1.152 0 N-CA-C 110.463 -1.055 . . . . 0.0 110.463 178.008 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.65 117.79 21.8 Favored 'General case' 0 C--N 1.351 0.633 0 C-N-CA 123.351 0.66 . . . . 0.0 109.399 178.468 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 71.6 mt -99.81 148.86 6.15 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.871 0 N-CA-C 106.934 -1.506 . . . . 0.0 106.934 178.021 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 34.6 mt -148.15 124.99 2.78 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.912 0 N-CA-C 108.874 -0.787 . . . . 0.0 108.874 -179.399 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . 62.71 85.5 0.05 OUTLIER Glycine 0 C--N 1.339 0.741 0 CA-C-N 115.967 -0.561 . . . . 0.0 112.793 178.526 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 13.1 tp -103.44 121.43 42.8 Favored 'General case' 0 N--CA 1.483 1.208 0 N-CA-C 106.945 -1.502 . . . . 0.0 106.945 177.43 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 12.5 ttt -156.17 159.01 38.6 Favored 'General case' 0 N--CA 1.474 0.771 0 N-CA-C 109.058 -0.719 . . . . 0.0 109.058 179.639 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 93.3 t -156.76 151.96 8.35 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.437 0 N-CA-C 107.615 -1.254 . . . . 0.0 107.615 -179.663 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' F' F ' 37' ' ' GLY . . . . . 0.468 ' H ' HE22 ' F' ' 15' ' ' GLN . . . 57.73 72.38 0.6 Allowed Glycine 0 C--N 1.312 -0.759 0 CA-C-N 115.491 -0.777 . . . . 0.0 111.508 178.162 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 171.57 -148.92 11.42 Favored Glycine 0 CA--C 1.523 0.578 0 N-CA-C 111.035 -0.826 . . . . 0.0 111.035 179.686 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 32.9 m -135.42 144.04 35.16 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.837 0 N-CA-C 109.054 -0.721 . . . . 0.0 109.054 179.932 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 19.6 t . . . . . 0 CA--C 1.537 0.454 0 CA-C-O 117.658 -1.163 . . . . 0.0 110.853 179.996 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' G' G ' 1' ' ' ASP . . . . . 0.433 ' HB2' ' H2 ' ' D' ' 1' ' ' ASP . 9.6 m-20 . . . . . 0 N--CA 1.49 1.569 0 N-CA-C 109.556 -0.535 . . . . 0.0 109.556 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' G' G ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.66 129.52 40.91 Favored 'General case' 0 N--CA 1.469 0.512 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.445 179.587 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' G' G ' 3' ' ' GLU . . . . . . . . . . . . . 39.5 tt0 -168.99 108.33 0.46 Allowed 'General case' 0 N--CA 1.47 0.557 0 N-CA-C 110.013 -0.365 . . . . 0.0 110.013 179.854 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 78.3 m-85 -84.51 141.17 30.94 Favored 'General case' 0 N--CA 1.473 0.691 0 N-CA-C 109.413 -0.588 . . . . 0.0 109.413 179.174 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' G' G ' 5' ' ' ARG . . . . . 0.414 HH21 HG22 ' I' ' 24' ' ' VAL . 37.0 mtp180 -142.79 143.37 32.15 Favored 'General case' 0 N--CA 1.481 1.113 0 N-CA-C 109.422 -0.585 . . . . 0.0 109.422 -179.635 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 74.7 m80 -150.41 118.81 6.43 Favored 'General case' 0 N--CA 1.473 0.711 0 N-CA-C 109.173 -0.677 . . . . 0.0 109.173 178.69 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 9.7 m-20 -70.0 144.41 52.3 Favored 'General case' 0 CA--C 1.538 0.482 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.642 -179.717 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' G' G ' 8' ' ' SER . . . . . . . . . . . . . 2.9 t -164.46 179.74 6.53 Favored 'General case' 0 N--CA 1.471 0.595 0 N-CA-C 109.465 -0.568 . . . . 0.0 109.465 177.998 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.3 50.7 0.97 Allowed Glycine 0 N--CA 1.476 1.327 0 N-CA-C 111.919 -0.472 . . . . 0.0 111.919 179.049 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 46.9 p90 -64.78 131.86 47.96 Favored 'General case' 0 N--CA 1.474 0.753 0 N-CA-C 112.097 0.406 . . . . 0.0 112.097 -179.484 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 44.0 mt-10 -82.08 150.39 27.54 Favored 'General case' 0 N--CA 1.474 0.748 0 N-CA-C 109.141 -0.688 . . . . 0.0 109.141 177.969 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 3.0 p -156.26 127.82 0.94 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.976 0 N-CA-C 108.285 -1.005 . . . . 0.0 108.285 178.168 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 55.9 m-70 -132.89 144.03 49.9 Favored 'General case' 0 N--CA 1.476 0.827 0 CA-C-N 115.392 -0.822 . . . . 0.0 110.718 -177.935 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' G' G ' 14' ' ' HIS . . . . . 0.41 ' O ' ' ND1' ' D' ' 14' ' ' HIS . 6.0 t60 -165.94 98.29 0.64 Allowed 'General case' 0 N--CA 1.483 1.19 0 CA-C-O 119.599 -0.239 . . . . 0.0 110.765 179.129 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' G' G ' 15' ' ' GLN . . . . . 0.516 HE22 ' H ' ' G' ' 37' ' ' GLY . 50.0 mt-30 -107.42 -172.24 2.03 Favored 'General case' 0 CA--C 1.503 -0.85 0 N-CA-C 108.194 -1.039 . . . . 0.0 108.194 179.306 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -163.19 98.27 0.93 Allowed 'General case' 0 N--CA 1.472 0.653 0 CA-C-N 115.05 -0.977 . . . . 0.0 109.281 178.718 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' G' G ' 17' ' ' LEU . . . . . 0.481 ' N ' HD12 ' G' ' 17' ' ' LEU . 6.6 mp -108.47 162.18 14.36 Favored 'General case' 0 N--CA 1.486 1.367 0 N-CA-C 108.946 -0.761 . . . . 0.0 108.946 -179.751 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 36.5 t -142.99 120.48 6.38 Favored 'Isoleucine or valine' 0 CA--C 1.551 1.019 0 CA-C-O 121.223 0.535 . . . . 0.0 110.435 178.973 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 47.3 m-85 -72.73 149.83 43.4 Favored 'General case' 0 C--N 1.375 1.71 0 N-CA-C 106.8 -1.555 . . . . 0.0 106.8 176.166 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 20.0 t80 -169.84 -54.23 0.02 OUTLIER 'General case' 0 N--CA 1.484 1.252 0 N-CA-C 110.194 -0.298 . . . . 0.0 110.194 -179.349 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -42.34 91.43 0.0 OUTLIER 'General case' 0 C--N 1.323 -0.571 0 O-C-N 123.942 0.776 . . . . 0.0 112.129 179.69 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 36.9 tt0 -57.83 133.67 55.62 Favored 'General case' 0 CA--C 1.539 0.542 0 CA-C-N 114.795 -1.093 . . . . 0.0 110.741 179.426 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 -81.08 161.51 24.12 Favored 'General case' 0 N--CA 1.474 0.749 0 N-CA-C 109.714 -0.476 . . . . 0.0 109.714 179.992 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' G' G ' 24' ' ' VAL . . . . . 0.423 HG22 HH21 ' H' ' 5' ' ' ARG . 94.8 t -159.44 -76.96 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.957 0 N-CA-C 106.839 -1.541 . . . . 0.0 106.839 -179.027 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -35.35 90.18 0.01 OUTLIER Glycine 0 C--O 1.225 -0.46 0 CA-C-N 114.876 -1.056 . . . . 0.0 112.765 179.381 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 94.2 p -37.78 -99.1 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.899 0 C-N-CA 123.626 0.771 . . . . 0.0 112.708 -176.861 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' G' G ' 27' ' ' ASN . . . . . 0.415 ' ND2' ' CG ' ' H' ' 11' ' ' GLU . 40.8 t30 -61.84 126.54 27.72 Favored 'General case' 0 CA--C 1.545 0.773 0 CA-C-N 119.474 1.034 . . . . 0.0 109.161 179.064 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 63.3 mttm -107.03 -179.09 3.83 Favored 'General case' 0 N--CA 1.483 1.184 0 N-CA-C 109.307 -0.627 . . . . 0.0 109.307 -179.76 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.97 -141.27 0.02 OUTLIER Glycine 0 N--CA 1.464 0.523 0 N-CA-C 109.848 -1.301 . . . . 0.0 109.848 178.422 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.96 115.2 17.45 Favored 'General case' 0 C--O 1.218 -0.558 0 C-N-CA 123.213 0.605 . . . . 0.0 109.413 179.572 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 74.5 mt -97.45 150.96 4.39 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.046 0 N-CA-C 106.92 -1.511 . . . . 0.0 106.92 178.1 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 35.8 mt -149.53 126.91 2.53 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.345 0 N-CA-C 108.876 -0.787 . . . . 0.0 108.876 178.405 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.28 85.95 0.04 OUTLIER Glycine 0 C--N 1.341 0.835 0 CA-C-N 115.957 -0.565 . . . . 0.0 112.823 178.559 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 14.4 tp -103.17 123.66 47.12 Favored 'General case' 0 N--CA 1.484 1.264 0 N-CA-C 107.029 -1.471 . . . . 0.0 107.029 177.271 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 11.9 ttt -158.75 158.57 33.88 Favored 'General case' 0 N--CA 1.469 0.494 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 179.973 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 94.5 t -156.47 153.13 7.42 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.289 0 N-CA-C 106.897 -1.519 . . . . 0.0 106.897 -179.663 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' G' G ' 37' ' ' GLY . . . . . 0.516 ' H ' HE22 ' G' ' 15' ' ' GLN . . . 56.89 73.18 0.47 Allowed Glycine 0 C--N 1.311 -0.811 0 CA-C-N 115.761 -0.654 . . . . 0.0 111.978 178.292 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 169.98 -148.05 11.4 Favored Glycine 0 N--CA 1.469 0.846 0 N-CA-C 110.703 -0.959 . . . . 0.0 110.703 179.019 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 33.5 m -135.48 144.03 35.11 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.009 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 -179.803 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 20.2 t . . . . . 0 N--CA 1.468 0.426 0 CA-C-O 117.776 -1.106 . . . . 0.0 110.838 179.914 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' H' H ' 1' ' ' ASP . . . . . 0.418 ' HB2' ' H2 ' ' E' ' 1' ' ' ASP . 9.7 m-20 . . . . . 0 N--CA 1.491 1.603 0 N-CA-C 109.591 -0.522 . . . . 0.0 109.591 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' H' H ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.75 129.5 40.79 Favored 'General case' 0 N--CA 1.469 0.494 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.374 179.641 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' H' H ' 3' ' ' GLU . . . . . . . . . . . . . 39.5 tt0 -168.91 108.28 0.46 Allowed 'General case' 0 N--CA 1.47 0.541 0 N-CA-C 109.981 -0.377 . . . . 0.0 109.981 179.845 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 78.7 m-85 -84.25 141.56 30.89 Favored 'General case' 0 N--CA 1.473 0.714 0 N-CA-C 109.362 -0.607 . . . . 0.0 109.362 179.183 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' H' H ' 5' ' ' ARG . . . . . 0.423 HH21 HG22 ' G' ' 24' ' ' VAL . 37.2 mtp180 -142.99 143.28 31.85 Favored 'General case' 0 N--CA 1.482 1.157 0 N-CA-C 109.302 -0.629 . . . . 0.0 109.302 -179.638 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 74.6 m80 -150.43 118.7 6.38 Favored 'General case' 0 N--CA 1.473 0.68 0 N-CA-C 109.252 -0.648 . . . . 0.0 109.252 178.642 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 9.4 m-20 -69.86 144.35 52.55 Favored 'General case' 0 N--CA 1.468 0.44 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.579 -179.693 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' H' H ' 8' ' ' SER . . . . . . . . . . . . . 3.6 t -164.38 179.09 6.99 Favored 'General case' 0 N--CA 1.47 0.538 0 N-CA-C 109.517 -0.549 . . . . 0.0 109.517 178.091 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.56 50.9 0.94 Allowed Glycine 0 N--CA 1.478 1.442 0 N-CA-C 111.948 -0.461 . . . . 0.0 111.948 179.054 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 46.7 p90 -64.79 131.87 48.0 Favored 'General case' 0 N--CA 1.474 0.765 0 N-CA-C 112.015 0.376 . . . . 0.0 112.015 -179.546 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' H' H ' 11' ' ' GLU . . . . . 0.415 ' CG ' ' ND2' ' G' ' 27' ' ' ASN . 44.0 mt-10 -82.05 150.38 27.59 Favored 'General case' 0 N--CA 1.474 0.749 0 N-CA-C 109.186 -0.672 . . . . 0.0 109.186 177.929 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 3.0 p -156.4 127.82 0.92 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.044 0 N-CA-C 108.291 -1.003 . . . . 0.0 108.291 178.108 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 56.0 m-70 -132.74 144.14 50.07 Favored 'General case' 0 N--CA 1.475 0.804 0 CA-C-N 115.22 -0.9 . . . . 0.0 110.731 -177.906 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 6.0 t60 -166.12 97.74 0.62 Allowed 'General case' 0 N--CA 1.482 1.163 0 CA-C-O 119.554 -0.26 . . . . 0.0 110.775 179.105 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' H' H ' 15' ' ' GLN . . . . . 0.508 HE22 ' H ' ' H' ' 37' ' ' GLY . 49.9 mt-30 -106.87 -172.56 2.1 Favored 'General case' 0 CA--C 1.505 -0.768 0 N-CA-C 108.099 -1.074 . . . . 0.0 108.099 179.403 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -163.0 98.24 0.94 Allowed 'General case' 0 N--CA 1.472 0.643 0 CA-C-N 115.268 -0.878 . . . . 0.0 109.218 178.679 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' H' H ' 17' ' ' LEU . . . . . 0.486 HD12 ' N ' ' H' ' 17' ' ' LEU . 6.6 mp -108.48 162.24 14.31 Favored 'General case' 0 N--CA 1.485 1.312 0 N-CA-C 108.978 -0.749 . . . . 0.0 108.978 -179.769 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 37.0 t -142.99 120.15 6.08 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.037 0 CA-C-O 121.16 0.505 . . . . 0.0 110.553 178.994 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 48.2 m-85 -72.76 150.41 42.84 Favored 'General case' 0 C--N 1.373 1.629 0 N-CA-C 106.909 -1.515 . . . . 0.0 106.909 176.182 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 21.3 t80 -171.25 -53.95 0.02 OUTLIER 'General case' 0 N--CA 1.481 1.093 0 N-CA-C 110.202 -0.295 . . . . 0.0 110.202 -179.361 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -42.26 91.6 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.463 0 O-C-N 123.872 0.732 . . . . 0.0 111.896 179.613 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 37.0 tt0 -57.81 133.89 55.8 Favored 'General case' 0 CA--C 1.54 0.564 0 CA-C-N 114.777 -1.102 . . . . 0.0 110.694 179.793 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 9.0 m-20 -81.24 161.44 23.96 Favored 'General case' 0 N--CA 1.474 0.768 0 N-CA-C 109.69 -0.485 . . . . 0.0 109.69 -179.986 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' H' H ' 24' ' ' VAL . . . . . 0.42 HG22 HH21 ' I' ' 5' ' ' ARG . 95.0 t -159.77 -77.03 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.99 0 N-CA-C 106.983 -1.488 . . . . 0.0 106.983 -179.037 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . -35.43 89.96 0.01 OUTLIER Glycine 0 N--CA 1.47 0.924 0 CA-C-N 115.086 -0.961 . . . . 0.0 112.245 179.547 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 97.5 p -37.47 -98.79 0.0 OUTLIER 'General case' 0 N--CA 1.478 0.954 0 C-N-CA 123.693 0.797 . . . . 0.0 112.739 -176.711 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' H' H ' 27' ' ' ASN . . . . . 0.409 ' ND2' ' CG ' ' I' ' 11' ' ' GLU . 40.1 t30 -61.62 126.69 28.23 Favored 'General case' 0 CA--C 1.543 0.689 0 CA-C-N 119.368 0.985 . . . . 0.0 109.144 179.01 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 63.3 mttm -106.97 -178.9 3.78 Favored 'General case' 0 N--CA 1.484 1.241 0 N-CA-C 109.365 -0.606 . . . . 0.0 109.365 -179.797 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.92 -141.19 0.02 OUTLIER Glycine 0 CA--C 1.522 0.521 0 N-CA-C 109.935 -1.266 . . . . 0.0 109.935 178.207 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -129.0 115.51 17.9 Favored 'General case' 0 C--O 1.217 -0.643 0 C-N-CA 123.263 0.625 . . . . 0.0 109.437 179.499 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 74.6 mt -97.86 150.6 4.65 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.027 0 N-CA-C 106.908 -1.515 . . . . 0.0 106.908 178.13 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 35.4 mt -149.32 126.89 2.62 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.309 0 N-CA-C 108.912 -0.773 . . . . 0.0 108.912 178.579 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.3 85.65 0.05 OUTLIER Glycine 0 C--N 1.34 0.801 0 CA-C-N 115.946 -0.57 . . . . 0.0 112.994 178.586 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 14.5 tp -102.97 123.28 46.29 Favored 'General case' 0 N--CA 1.482 1.158 0 N-CA-C 107.04 -1.466 . . . . 0.0 107.04 177.332 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 11.8 ttt -158.38 158.48 34.34 Favored 'General case' 0 N--CA 1.469 0.516 0 N-CA-C 108.585 -0.895 . . . . 0.0 108.585 -179.958 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 96.9 t -156.51 152.4 8.12 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.357 0 N-CA-C 107.076 -1.453 . . . . 0.0 107.076 -179.782 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' H' H ' 37' ' ' GLY . . . . . 0.508 ' H ' HE22 ' H' ' 15' ' ' GLN . . . 57.46 73.03 0.5 Allowed Glycine 0 C--N 1.313 -0.698 0 CA-C-N 115.644 -0.707 . . . . 0.0 112.028 178.169 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 169.98 -148.17 11.52 Favored Glycine 0 N--CA 1.468 0.792 0 N-CA-C 110.566 -1.014 . . . . 0.0 110.566 179.068 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 33.4 m -135.36 144.01 35.31 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.995 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 -179.706 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 20.3 t . . . . . 0 C--O 1.222 -0.385 0 CA-C-O 117.852 -1.07 . . . . 0.0 110.916 179.99 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' I' I ' 1' ' ' ASP . . . . . . . . . . . . . 9.7 m-20 . . . . . 0 N--CA 1.491 1.603 0 N-CA-C 109.64 -0.504 . . . . 0.0 109.64 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' I' I ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.67 129.64 41.42 Favored 'General case' 0 N--CA 1.47 0.544 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.345 179.64 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' I' I ' 3' ' ' GLU . . . . . . . . . . . . . 39.4 tt0 -169.04 108.21 0.45 Allowed 'General case' 0 N--CA 1.47 0.527 0 N-CA-C 109.935 -0.394 . . . . 0.0 109.935 179.811 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 79.0 m-85 -84.27 141.63 30.82 Favored 'General case' 0 N--CA 1.474 0.764 0 N-CA-C 109.323 -0.621 . . . . 0.0 109.323 179.191 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' I' I ' 5' ' ' ARG . . . . . 0.42 HH21 HG22 ' H' ' 24' ' ' VAL . 37.1 mtp180 -143.15 143.36 31.78 Favored 'General case' 0 N--CA 1.482 1.17 0 N-CA-C 109.273 -0.64 . . . . 0.0 109.273 -179.687 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 74.6 m80 -150.51 118.55 6.29 Favored 'General case' 0 N--CA 1.474 0.729 0 N-CA-C 109.243 -0.651 . . . . 0.0 109.243 178.691 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 9.5 m-20 -69.72 144.21 52.85 Favored 'General case' 0 CA--C 1.537 0.444 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.681 -179.696 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' I' I ' 8' ' ' SER . . . . . . . . . . . . . 3.6 t -164.23 179.11 7.06 Favored 'General case' 0 N--CA 1.469 0.514 0 N-CA-C 109.492 -0.558 . . . . 0.0 109.492 178.182 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 104.58 50.9 0.94 Allowed Glycine 0 N--CA 1.477 1.426 0 N-CA-C 111.929 -0.469 . . . . 0.0 111.929 179.047 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 47.1 p90 -64.85 131.91 48.01 Favored 'General case' 0 N--CA 1.474 0.734 0 N-CA-C 112.104 0.409 . . . . 0.0 112.104 -179.573 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' I' I ' 11' ' ' GLU . . . . . 0.409 ' CG ' ' ND2' ' H' ' 27' ' ' ASN . 43.9 mt-10 -82.14 150.39 27.48 Favored 'General case' 0 N--CA 1.473 0.71 0 N-CA-C 109.249 -0.648 . . . . 0.0 109.249 177.934 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 3.1 p -156.38 127.7 0.91 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.971 0 N-CA-C 108.366 -0.976 . . . . 0.0 108.366 178.209 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 55.5 m-70 -132.8 144.13 50.02 Favored 'General case' 0 N--CA 1.475 0.779 0 CA-C-N 115.24 -0.891 . . . . 0.0 110.735 -177.839 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 6.0 t60 -166.21 97.98 0.61 Allowed 'General case' 0 N--CA 1.483 1.181 0 CA-C-N 116.664 -0.244 . . . . 0.0 110.818 179.228 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' I' I ' 15' ' ' GLN . . . . . 0.479 HE22 ' H ' ' I' ' 37' ' ' GLY . 49.8 mt-30 -107.11 -172.21 2.03 Favored 'General case' 0 CA--C 1.501 -0.918 0 N-CA-C 108.12 -1.067 . . . . 0.0 108.12 179.322 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -163.24 98.27 0.92 Allowed 'General case' 0 N--CA 1.47 0.563 0 CA-C-N 115.109 -0.95 . . . . 0.0 109.22 178.704 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' I' I ' 17' ' ' LEU . . . . . 0.48 HD12 ' N ' ' I' ' 17' ' ' LEU . 6.6 mp -108.45 162.12 14.41 Favored 'General case' 0 N--CA 1.485 1.323 0 N-CA-C 108.968 -0.753 . . . . 0.0 108.968 -179.751 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 37.7 t -142.9 120.18 6.35 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.048 0 CA-C-O 121.2 0.524 . . . . 0.0 110.483 178.987 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 47.7 m-85 -72.81 150.39 42.78 Favored 'General case' 0 C--N 1.374 1.645 0 N-CA-C 106.759 -1.571 . . . . 0.0 106.759 176.196 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 21.3 t80 -171.17 -54.15 0.02 OUTLIER 'General case' 0 N--CA 1.48 1.048 0 N-CA-C 110.217 -0.29 . . . . 0.0 110.217 -179.304 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -42.25 91.58 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.461 0 CA-C-O 121.632 0.729 . . . . 0.0 111.856 179.656 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 37.0 tt0 -57.75 133.82 55.7 Favored 'General case' 0 CA--C 1.539 0.558 0 CA-C-N 114.769 -1.105 . . . . 0.0 110.773 179.691 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 -81.09 161.38 24.16 Favored 'General case' 0 N--CA 1.473 0.716 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 179.936 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' I' I ' 24' ' ' VAL . . . . . 0.414 HG22 HH21 ' G' ' 5' ' ' ARG . 95.1 t -159.75 -77.11 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.04 0 N-CA-C 107.045 -1.465 . . . . 0.0 107.045 -179.095 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . -35.53 90.09 0.01 OUTLIER Glycine 0 C--N 1.34 0.804 0 CA-C-N 115.073 -0.967 . . . . 0.0 112.25 179.611 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 97.5 p -37.4 -98.95 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.875 0 C-N-CA 123.794 0.838 . . . . 0.0 112.82 -176.733 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 40.5 t30 -61.5 126.62 28.02 Favored 'General case' 0 CA--C 1.542 0.645 0 CA-C-N 119.431 1.014 . . . . 0.0 109.148 179.005 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 63.2 mttm -106.96 -178.95 3.79 Favored 'General case' 0 N--CA 1.484 1.275 0 N-CA-C 109.356 -0.609 . . . . 0.0 109.356 -179.791 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -64.92 -141.27 0.02 OUTLIER Glycine 0 CA--C 1.523 0.58 0 N-CA-C 109.906 -1.278 . . . . 0.0 109.906 178.254 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.86 115.46 17.93 Favored 'General case' 0 C--O 1.218 -0.584 0 C-N-CA 123.247 0.619 . . . . 0.0 109.434 179.537 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 74.6 mt -97.94 150.67 4.64 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.047 0 N-CA-C 106.878 -1.527 . . . . 0.0 106.878 178.186 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 35.7 mt -149.31 126.93 2.65 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.292 0 N-CA-C 108.863 -0.791 . . . . 0.0 108.863 178.646 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . 61.28 85.69 0.05 OUTLIER Glycine 0 C--N 1.339 0.71 0 CA-C-N 115.986 -0.552 . . . . 0.0 112.919 178.571 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 14.6 tp -102.91 123.25 46.19 Favored 'General case' 0 N--CA 1.482 1.151 0 N-CA-C 107.008 -1.479 . . . . 0.0 107.008 177.208 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 11.8 ttt -158.31 158.51 34.51 Favored 'General case' 0 N--CA 1.469 0.489 0 N-CA-C 108.56 -0.904 . . . . 0.0 108.56 179.97 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 96.6 t -156.57 152.39 8.09 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.297 0 N-CA-C 107.007 -1.479 . . . . 0.0 107.007 -179.776 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' I' I ' 37' ' ' GLY . . . . . 0.479 ' H ' HE22 ' I' ' 15' ' ' GLN . . . 57.44 73.2 0.48 Allowed Glycine 0 C--N 1.313 -0.734 0 CA-C-N 115.661 -0.7 . . . . 0.0 111.932 178.141 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 169.9 -148.29 11.66 Favored Glycine 0 N--CA 1.467 0.719 0 N-CA-C 110.651 -0.979 . . . . 0.0 110.651 179.094 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 33.4 m -135.21 144.01 35.49 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.947 0 C-N-CA 122.765 0.426 . . . . 0.0 109.904 -179.83 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 20.3 t . . . . . 0 C--O 1.222 -0.378 0 CA-C-O 117.803 -1.094 . . . . 0.0 110.932 179.996 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 8.8 m-20 . . . . . 0 N--CA 1.49 1.538 0 N-CA-C 108.49 -0.93 . . . . 0.0 108.49 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.82 132.54 49.76 Favored 'General case' 0 CA--C 1.541 0.614 0 CA-C-N 116.452 -0.34 . . . . 0.0 110.085 -179.943 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 54.6 tt0 -169.32 126.8 0.94 Allowed 'General case' 0 N--CA 1.472 0.653 0 N-CA-C 109.707 -0.479 . . . . 0.0 109.707 -179.133 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 29.1 m-85 -117.15 126.97 53.65 Favored 'General case' 0 N--CA 1.476 0.864 0 N-CA-C 108.637 -0.875 . . . . 0.0 108.637 179.578 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' ARG . . . . . 0.897 HH12 HG11 ' C' ' 24' ' ' VAL . 6.2 ptm180 -165.06 146.65 7.73 Favored 'General case' 0 N--CA 1.478 0.954 0 N-CA-C 112.349 0.5 . . . . 0.0 112.349 -179.738 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 21.2 p80 -151.89 107.79 3.38 Favored 'General case' 0 N--CA 1.475 0.788 0 CA-C-O 120.884 0.374 . . . . 0.0 110.552 177.93 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -78.13 151.69 33.2 Favored 'General case' 0 N--CA 1.475 0.805 0 CA-C-O 121.03 0.443 . . . . 0.0 109.827 178.961 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 99.8 p -155.2 173.67 16.29 Favored 'General case' 0 N--CA 1.475 0.794 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.595 -179.766 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 125.13 78.99 0.35 Allowed Glycine 0 N--CA 1.481 1.692 0 N-CA-C 111.441 -0.664 . . . . 0.0 111.441 -179.969 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 23.6 p90 -55.14 156.05 4.33 Favored 'General case' 0 N--CA 1.478 0.954 0 C-N-CA 122.528 0.331 . . . . 0.0 110.698 178.982 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 65.7 mt-10 -119.65 127.21 52.7 Favored 'General case' 0 N--CA 1.486 1.366 0 N-CA-C 109.708 -0.479 . . . . 0.0 109.708 179.281 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 40.2 t -101.69 139.83 21.85 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.705 0 N-CA-C 109.194 -0.669 . . . . 0.0 109.194 178.815 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 42.3 m80 -140.42 138.98 35.16 Favored 'General case' 0 N--CA 1.488 1.445 0 CA-C-N 118.762 0.71 . . . . 0.0 109.98 178.494 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 13.0 t60 -167.55 97.31 0.48 Allowed 'General case' 0 N--CA 1.481 1.119 0 CA-C-O 119.745 -0.169 . . . . 0.0 110.632 178.979 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 55.2 mt-30 -100.55 116.48 32.6 Favored 'General case' 0 CA--C 1.512 -0.493 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 -179.484 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 64.4 tttp -104.32 105.95 16.27 Favored 'General case' 0 N--CA 1.48 1.07 0 N-CA-C 108.648 -0.871 . . . . 0.0 108.648 178.148 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 10.0 mp -122.63 165.17 16.92 Favored 'General case' 0 N--CA 1.487 1.412 0 N-CA-C 108.712 -0.847 . . . . 0.0 108.712 -179.55 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 62.1 t -142.57 111.28 2.19 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.09 0 N-CA-C 108.499 -0.926 . . . . 0.0 108.499 177.757 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 59.7 m-85 -101.24 164.92 11.55 Favored 'General case' 0 N--CA 1.475 0.821 0 N-CA-C 109.29 -0.633 . . . . 0.0 109.29 178.244 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.453 ' O ' ' O ' ' D' ' 21' ' ' ALA . 77.7 t80 -165.53 -83.46 0.02 OUTLIER 'General case' 0 C--O 1.209 -1.052 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 177.205 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -88.29 94.08 9.72 Favored 'General case' 0 C--N 1.353 0.726 0 N-CA-C 108.249 -1.019 . . . . 0.0 108.249 177.567 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 11.2 mm-40 -73.85 -170.13 0.84 Allowed 'General case' 0 N--CA 1.482 1.153 0 C-N-CA 120.344 -0.542 . . . . 0.0 110.771 179.812 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 8.2 m-20 -73.17 153.35 40.75 Favored 'General case' 0 N--CA 1.473 0.712 0 CA-C-O 121.886 0.85 . . . . 0.0 112.995 -177.637 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.917 HG11 HH12 ' B' ' 5' ' ' ARG . 71.2 t -155.23 94.35 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.466 0.369 0 CA-C-N 114.551 -1.204 . . . . 0.0 108.244 177.005 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -121.56 60.3 0.55 Allowed Glycine 0 N--CA 1.481 1.638 0 N-CA-C 110.995 -0.842 . . . . 0.0 110.995 179.038 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 15.3 m 47.32 -143.34 0.38 Allowed 'General case' 0 N--CA 1.484 1.261 0 CA-C-N 118.164 0.982 . . . . 0.0 110.479 -179.633 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 3.9 m-80 -79.67 92.38 5.37 Favored 'General case' 0 N--CA 1.47 0.527 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 177.636 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 96.4 mttt -65.76 146.21 55.05 Favored 'General case' 0 CA--C 1.539 0.537 0 CA-C-O 121.264 0.554 . . . . 0.0 110.537 -178.559 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -70.17 -129.17 0.06 OUTLIER Glycine 0 CA--C 1.525 0.688 0 N-CA-C 109.445 -1.462 . . . . 0.0 109.445 178.533 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -85.01 131.35 34.48 Favored 'General case' 0 N--CA 1.465 0.3 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 179.69 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 18.3 tt -165.54 173.52 0.17 Allowed 'Isoleucine or valine' 0 C--O 1.215 -0.745 0 N-CA-C 108.815 -0.809 . . . . 0.0 108.815 -177.85 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 24.3 mt -140.27 145.21 26.41 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.487 0 N-CA-C 107.179 -1.415 . . . . 0.0 107.179 -179.288 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -52.0 168.17 0.71 Allowed Glycine 0 N--CA 1.473 1.14 0 C-N-CA 121.268 -0.491 . . . . 0.0 112.147 -179.328 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 2.7 pp -65.99 158.08 29.17 Favored 'General case' 0 N--CA 1.465 0.293 0 N-CA-C 109.671 -0.492 . . . . 0.0 109.671 179.741 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 21.3 ttt -142.57 154.76 44.72 Favored 'General case' 0 N--CA 1.473 0.676 0 N-CA-C 108.965 -0.754 . . . . 0.0 108.965 -179.919 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 41.3 t -149.49 139.33 16.03 Favored 'Isoleucine or valine' 0 C--O 1.235 0.318 0 N-CA-C 107.241 -1.392 . . . . 0.0 107.241 -179.695 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 60.54 67.44 2.14 Favored Glycine 0 C--N 1.318 -0.437 0 N-CA-C 109.006 -1.637 . . . . 0.0 109.006 -179.85 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -82.22 130.08 9.47 Favored Glycine 0 N--CA 1.468 0.788 0 N-CA-C 111.312 -0.715 . . . . 0.0 111.312 -178.818 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 1.9 t -146.71 113.43 1.05 Allowed 'Isoleucine or valine' 0 CA--C 1.561 1.373 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 179.257 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 19.1 t . . . . . 0 N--CA 1.497 1.899 0 CA-C-O 118.475 -0.774 . . . . 0.0 112.477 -177.877 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' B' B ' 1' ' ' ASP . . . . . . . . . . . . . 8.5 m-20 . . . . . 0 N--CA 1.488 1.447 0 N-CA-C 108.799 -0.815 . . . . 0.0 108.799 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' B' B ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.87 132.33 49.14 Favored 'General case' 0 CA--C 1.54 0.582 0 N-CA-C 110.019 -0.363 . . . . 0.0 110.019 -179.906 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 3' ' ' GLU . . . . . . . . . . . . . 54.6 tt0 -169.28 126.62 0.94 Allowed 'General case' 0 CA--C 1.541 0.606 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 -179.056 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 29.0 m-85 -117.03 127.3 54.03 Favored 'General case' 0 N--CA 1.476 0.847 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 179.481 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 5' ' ' ARG . . . . . 0.917 HH12 HG11 ' A' ' 24' ' ' VAL . 6.3 ptm180 -165.39 146.59 7.31 Favored 'General case' 0 N--CA 1.474 0.773 0 C-N-CA 120.569 -0.452 . . . . 0.0 112.165 -179.698 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 20.9 p80 -151.79 108.07 3.43 Favored 'General case' 0 N--CA 1.476 0.838 0 CA-C-O 120.831 0.348 . . . . 0.0 110.562 177.867 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 7' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -78.56 151.1 32.64 Favored 'General case' 0 N--CA 1.476 0.834 0 CA-C-O 121.088 0.471 . . . . 0.0 109.889 179.042 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 8' ' ' SER . . . . . . . . . . . . . 99.3 p -154.54 173.72 15.92 Favored 'General case' 0 N--CA 1.473 0.718 0 CA-C-N 115.784 -0.643 . . . . 0.0 110.731 -179.759 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 125.2 78.91 0.34 Allowed Glycine 0 N--CA 1.48 1.621 0 N-CA-C 111.433 -0.667 . . . . 0.0 111.433 -179.972 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 23.9 p90 -55.28 156.05 4.55 Favored 'General case' 0 N--CA 1.478 0.927 0 C-N-CA 122.401 0.28 . . . . 0.0 110.742 179.054 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 65.6 mt-10 -119.55 127.43 52.98 Favored 'General case' 0 N--CA 1.486 1.367 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 179.288 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 40.0 t -102.04 139.66 22.55 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.708 0 N-CA-C 109.194 -0.669 . . . . 0.0 109.194 178.85 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 41.9 m80 -140.41 139.09 35.2 Favored 'General case' 0 N--CA 1.484 1.272 0 CA-C-N 118.689 0.677 . . . . 0.0 110.011 178.729 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 13.2 t60 -167.87 97.37 0.45 Allowed 'General case' 0 N--CA 1.482 1.165 0 N-CA-C 110.507 -0.183 . . . . 0.0 110.507 179.017 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 55.4 mt-30 -100.67 116.86 33.56 Favored 'General case' 0 CA--C 1.511 -0.546 0 N-CA-C 108.604 -0.887 . . . . 0.0 108.604 -179.533 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 64.6 tttp -104.51 105.97 16.29 Favored 'General case' 0 N--CA 1.479 1.014 0 N-CA-C 108.674 -0.861 . . . . 0.0 108.674 178.106 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 10.0 mp -122.83 165.05 17.26 Favored 'General case' 0 N--CA 1.489 1.516 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 -179.51 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 61.6 t -142.45 110.24 2.04 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.117 0 N-CA-C 108.743 -0.836 . . . . 0.0 108.743 177.838 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 61.1 m-85 -100.11 164.32 12.03 Favored 'General case' 0 N--CA 1.474 0.746 0 CA-C-N 118.745 0.702 . . . . 0.0 109.456 178.275 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . 0.433 ' O ' ' O ' ' E' ' 21' ' ' ALA . 76.4 t80 -164.38 -83.59 0.03 OUTLIER 'General case' 0 C--O 1.212 -0.881 0 N-CA-C 109.277 -0.638 . . . . 0.0 109.277 177.238 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -88.73 94.3 9.86 Favored 'General case' 0 C--N 1.35 0.59 0 N-CA-C 108.171 -1.048 . . . . 0.0 108.171 177.599 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 11.4 mm-40 -73.73 -170.24 0.84 Allowed 'General case' 0 N--CA 1.481 1.124 0 C-N-CA 120.487 -0.485 . . . . 0.0 110.791 179.881 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 23' ' ' ASP . . . . . 0.422 ' HB3' ' HZ1' ' B' ' 28' ' ' LYS . 8.2 m-20 -73.24 153.45 40.63 Favored 'General case' 0 N--CA 1.473 0.709 0 CA-C-O 121.943 0.878 . . . . 0.0 112.971 -177.598 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . 0.925 HG11 HH12 ' C' ' 5' ' ' ARG . 65.5 t -155.22 94.3 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.391 0 CA-C-N 114.586 -1.188 . . . . 0.0 108.166 177.013 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -121.35 60.16 0.55 Allowed Glycine 0 N--CA 1.479 1.547 0 N-CA-C 111.138 -0.785 . . . . 0.0 111.138 178.874 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 15.3 m 47.4 -143.72 0.36 Allowed 'General case' 0 N--CA 1.485 1.281 0 CA-C-N 118.209 1.005 . . . . 0.0 110.317 -179.574 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 4.1 m-80 -79.43 92.45 5.23 Favored 'General case' 0 N--CA 1.469 0.497 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 177.661 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 28' ' ' LYS . . . . . 0.422 ' HZ1' ' HB3' ' B' ' 23' ' ' ASP . 96.4 mttt -65.87 146.47 54.71 Favored 'General case' 0 CA--C 1.54 0.569 0 CA-C-O 121.333 0.587 . . . . 0.0 110.42 -178.472 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -70.33 -129.11 0.06 OUTLIER Glycine 0 CA--C 1.526 0.745 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 178.523 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -85.0 131.32 34.48 Favored 'General case' 0 C--O 1.235 0.291 0 N-CA-C 109.413 -0.588 . . . . 0.0 109.413 179.628 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 18.3 tt -165.61 173.44 0.17 Allowed 'Isoleucine or valine' 0 C--O 1.215 -0.751 0 N-CA-C 108.753 -0.832 . . . . 0.0 108.753 -177.8 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 24.6 mt -140.25 145.14 26.53 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.475 0 N-CA-C 107.194 -1.41 . . . . 0.0 107.194 -179.24 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -51.94 168.25 0.68 Allowed Glycine 0 N--CA 1.472 1.078 0 C-N-CA 121.202 -0.523 . . . . 0.0 112.195 -179.372 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 2.7 pp -66.13 157.76 30.39 Favored 'General case' 0 N--CA 1.465 0.28 0 N-CA-C 109.646 -0.501 . . . . 0.0 109.646 179.79 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 21.3 ttt -142.25 154.93 45.16 Favored 'General case' 0 N--CA 1.473 0.677 0 N-CA-C 109.02 -0.733 . . . . 0.0 109.02 -179.975 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 41.0 t -149.46 139.51 16.21 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.313 0 N-CA-C 107.267 -1.382 . . . . 0.0 107.267 -179.638 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 60.1 67.41 2.17 Favored Glycine 0 C--N 1.318 -0.445 0 N-CA-C 109.152 -1.579 . . . . 0.0 109.152 -179.803 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . -82.16 129.98 9.41 Favored Glycine 0 CA--C 1.526 0.769 0 N-CA-C 111.284 -0.726 . . . . 0.0 111.284 -178.892 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 1.9 t -146.68 113.46 1.06 Allowed 'Isoleucine or valine' 0 CA--C 1.561 1.371 0 N-CA-C 108.459 -0.941 . . . . 0.0 108.459 179.192 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 19.8 t . . . . . 0 N--CA 1.498 1.937 0 CA-C-O 118.409 -0.805 . . . . 0.0 112.195 -177.997 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' C' C ' 1' ' ' ASP . . . . . . . . . . . . . 8.6 m-20 . . . . . 0 N--CA 1.488 1.436 0 N-CA-C 108.833 -0.802 . . . . 0.0 108.833 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' C' C ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.68 132.29 49.26 Favored 'General case' 0 CA--C 1.54 0.577 0 N-CA-C 110.109 -0.33 . . . . 0.0 110.109 -179.987 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' C' C ' 3' ' ' GLU . . . . . . . . . . . . . 54.5 tt0 -169.2 126.49 0.95 Allowed 'General case' 0 CA--C 1.541 0.596 0 N-CA-C 109.833 -0.432 . . . . 0.0 109.833 -179.059 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 28.6 m-85 -116.88 126.99 53.83 Favored 'General case' 0 N--CA 1.477 0.92 0 N-CA-C 108.653 -0.869 . . . . 0.0 108.653 179.432 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' C' C ' 5' ' ' ARG . . . . . 0.925 HH12 HG11 ' B' ' 24' ' ' VAL . 6.3 ptm180 -164.98 146.54 7.79 Favored 'General case' 0 N--CA 1.476 0.86 0 N-CA-C 112.231 0.456 . . . . 0.0 112.231 -179.706 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 21.2 p80 -151.78 107.92 3.42 Favored 'General case' 0 N--CA 1.476 0.868 0 CA-C-O 120.804 0.335 . . . . 0.0 110.554 177.883 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' C' C ' 7' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -78.51 150.91 32.81 Favored 'General case' 0 N--CA 1.476 0.862 0 CA-C-O 121.061 0.457 . . . . 0.0 109.861 179.038 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' C' C ' 8' ' ' SER . . . . . . . . . . . . . 99.3 p -154.38 173.86 15.64 Favored 'General case' 0 N--CA 1.475 0.796 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.711 -179.856 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 125.07 78.96 0.35 Allowed Glycine 0 N--CA 1.48 1.627 0 N-CA-C 111.447 -0.661 . . . . 0.0 111.447 179.984 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 24.3 p90 -55.24 156.01 4.53 Favored 'General case' 0 N--CA 1.478 0.925 0 C-N-CA 122.501 0.32 . . . . 0.0 110.757 178.959 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 65.5 mt-10 -119.49 127.33 52.94 Favored 'General case' 0 N--CA 1.485 1.325 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 179.326 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 39.9 t -101.87 139.59 22.61 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.717 0 N-CA-C 109.266 -0.642 . . . . 0.0 109.266 178.76 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 42.0 m80 -140.41 138.92 35.12 Favored 'General case' 0 N--CA 1.486 1.366 0 CA-C-N 118.635 0.652 . . . . 0.0 110.009 178.662 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 13.2 t60 -167.67 97.46 0.47 Allowed 'General case' 0 N--CA 1.481 1.109 0 N-CA-C 110.542 -0.17 . . . . 0.0 110.542 178.939 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 55.5 mt-30 -100.58 116.71 33.14 Favored 'General case' 0 CA--C 1.513 -0.474 0 N-CA-C 108.608 -0.886 . . . . 0.0 108.608 -179.491 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 64.6 tttp -104.39 106.07 16.43 Favored 'General case' 0 N--CA 1.481 1.111 0 N-CA-C 108.632 -0.877 . . . . 0.0 108.632 178.062 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 10.0 mp -122.91 164.88 17.63 Favored 'General case' 0 N--CA 1.488 1.452 0 N-CA-C 108.599 -0.889 . . . . 0.0 108.599 -179.567 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 60.8 t -142.21 110.31 2.19 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 N-CA-C 108.587 -0.894 . . . . 0.0 108.587 177.836 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 61.4 m-85 -100.09 164.3 12.04 Favored 'General case' 0 N--CA 1.476 0.839 0 CA-C-N 118.734 0.697 . . . . 0.0 109.426 178.202 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' C' C ' 20' ' ' PHE . . . . . 0.44 ' O ' ' O ' ' F' ' 21' ' ' ALA . 76.1 t80 -164.23 -83.66 0.03 OUTLIER 'General case' 0 C--O 1.211 -0.955 0 N-CA-C 109.441 -0.577 . . . . 0.0 109.441 177.132 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -88.61 94.27 9.83 Favored 'General case' 0 C--N 1.349 0.554 0 N-CA-C 108.124 -1.065 . . . . 0.0 108.124 177.633 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 11.3 mm-40 -73.81 -170.14 0.84 Allowed 'General case' 0 N--CA 1.48 1.074 0 C-N-CA 120.393 -0.523 . . . . 0.0 110.816 179.928 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 8.2 m-20 -73.2 153.41 40.69 Favored 'General case' 0 N--CA 1.474 0.76 0 CA-C-O 122.04 0.924 . . . . 0.0 112.864 -177.613 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' C' C ' 24' ' ' VAL . . . . . 0.897 HG11 HH12 ' A' ' 5' ' ' ARG . 65.5 t -155.31 94.43 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.39 0 CA-C-N 114.418 -1.264 . . . . 0.0 108.147 176.958 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -121.57 60.41 0.55 Allowed Glycine 0 N--CA 1.48 1.598 0 N-CA-C 110.984 -0.846 . . . . 0.0 110.984 178.96 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 15.4 m 47.23 -143.79 0.35 Allowed 'General case' 0 N--CA 1.484 1.265 0 CA-C-N 118.21 1.005 . . . . 0.0 110.456 -179.554 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 4.1 m-80 -79.33 92.44 5.17 Favored 'General case' 0 N--CA 1.469 0.512 0 N-CA-C 108.71 -0.848 . . . . 0.0 108.71 177.613 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 96.4 mttt -65.87 146.2 55.03 Favored 'General case' 0 CA--C 1.541 0.603 0 CA-C-O 121.292 0.567 . . . . 0.0 110.502 -178.458 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -70.13 -129.0 0.06 OUTLIER Glycine 0 C--N 1.339 0.708 0 N-CA-C 109.591 -1.404 . . . . 0.0 109.591 178.483 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -85.01 131.25 34.49 Favored 'General case' 0 C--O 1.234 0.277 0 N-CA-C 109.423 -0.584 . . . . 0.0 109.423 179.65 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 18.3 tt -165.5 173.53 0.17 Allowed 'Isoleucine or valine' 0 C--O 1.215 -0.749 0 N-CA-C 108.832 -0.803 . . . . 0.0 108.832 -177.954 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 24.4 mt -140.25 145.22 26.43 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.466 0 N-CA-C 107.123 -1.436 . . . . 0.0 107.123 -179.22 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -52.01 168.19 0.71 Allowed Glycine 0 N--CA 1.473 1.113 0 C-N-CA 121.253 -0.499 . . . . 0.0 112.213 -179.442 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 2.7 pp -66.0 157.85 29.8 Favored 'General case' 0 N--CA 1.464 0.274 0 N-CA-C 109.679 -0.489 . . . . 0.0 109.679 179.736 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 21.4 ttt -142.28 154.79 45.01 Favored 'General case' 0 N--CA 1.473 0.68 0 N-CA-C 108.966 -0.753 . . . . 0.0 108.966 -179.939 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 41.1 t -149.4 139.65 16.37 Favored 'Isoleucine or valine' 0 C--O 1.234 0.288 0 N-CA-C 107.165 -1.42 . . . . 0.0 107.165 -179.71 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 60.01 67.3 2.22 Favored Glycine 0 C--N 1.32 -0.331 0 N-CA-C 109.173 -1.571 . . . . 0.0 109.173 -179.868 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . -81.97 130.04 9.45 Favored Glycine 0 CA--C 1.526 0.754 0 N-CA-C 111.264 -0.735 . . . . 0.0 111.264 -178.91 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 1.9 t -146.67 113.48 1.06 Allowed 'Isoleucine or valine' 0 CA--C 1.558 1.284 0 N-CA-C 108.47 -0.937 . . . . 0.0 108.47 179.131 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 19.9 t . . . . . 0 N--CA 1.495 1.789 0 CA-C-O 118.467 -0.778 . . . . 0.0 112.399 -177.894 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' D' D ' 1' ' ' ASP . . . . . . . . . . . . . 8.6 m-20 . . . . . 0 N--CA 1.482 1.152 0 N-CA-C 109.707 -0.479 . . . . 0.0 109.707 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' D' D ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.13 131.36 47.26 Favored 'General case' 0 N--CA 1.472 0.625 0 CA-C-N 116.503 -0.317 . . . . 0.0 110.438 179.57 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' D' D ' 3' ' ' GLU . . . . . . . . . . . . . 53.6 tt0 -169.53 121.13 0.71 Allowed 'General case' 0 C--O 1.245 0.843 0 CA-C-O 119.124 -0.465 . . . . 0.0 111.062 -176.737 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' D' D ' 4' ' ' PHE . . . . . 0.41 ' N ' ' CD1' ' D' ' 4' ' ' PHE 0.289 35.2 m-85 -116.63 131.53 56.93 Favored 'General case' 0 C--N 1.379 1.88 0 N-CA-C 106.381 -1.711 . . . . 0.0 106.381 177.108 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' D' D ' 5' ' ' ARG . . . . . 0.916 HH12 HG11 ' F' ' 24' ' ' VAL . 6.0 ptm180 -154.59 150.01 27.26 Favored 'General case' 0 C--O 1.247 0.924 0 CA-C-O 116.565 -1.683 . . . . 0.0 113.175 176.423 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 15.4 p80 -150.75 117.98 5.99 Favored 'General case' 0 N--CA 1.481 1.102 0 CA-C-N 119.992 1.269 . . . . 0.0 107.882 163.217 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' D' D ' 7' ' ' ASP . . . . . . . . . . . . 0.367 0.7 OUTLIER -66.25 141.64 57.97 Favored 'General case' 0 C--N 1.324 -0.522 0 C-N-CA 128.565 2.746 . . . . 0.0 115.839 168.32 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' D' D ' 8' ' ' SER . . . . . . . . . . . . . 97.9 p -151.16 175.45 12.14 Favored 'General case' 0 N--CA 1.488 1.437 0 CA-C-N 119.452 1.024 . . . . 0.0 111.471 175.404 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 122.37 77.12 0.4 Allowed Glycine 0 N--CA 1.48 1.567 0 CA-C-N 116.056 -0.52 . . . . 0.0 112.762 179.594 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 25.9 p90 -50.98 152.25 2.26 Favored 'General case' 0 N--CA 1.48 1.053 0 C-N-CA 123.662 0.785 . . . . 0.0 111.967 177.768 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 64.9 mt-10 -117.39 131.13 56.83 Favored 'General case' 0 N--CA 1.49 1.568 0 C-N-CA 118.94 -1.104 . . . . 0.0 108.524 175.992 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 21.3 t -95.22 140.26 17.22 Favored 'Isoleucine or valine' 0 C--O 1.245 0.856 0 CA-C-O 117.678 -1.153 . . . . 0.0 111.083 173.673 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 39.6 m80 -138.64 140.62 38.95 Favored 'General case' 0 N--CA 1.483 1.185 0 CA-C-N 119.543 1.065 . . . . 0.0 110.236 172.544 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 14.0 t60 -165.5 104.47 0.73 Allowed 'General case' 0 N--CA 1.48 1.066 0 N-CA-C 108.922 -0.77 . . . . 0.0 108.922 173.611 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 55.8 mt-30 -104.19 114.95 29.55 Favored 'General case' 0 C--N 1.311 -1.067 0 N-CA-C 108.698 -0.853 . . . . 0.0 108.698 179.15 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 64.6 tttp -102.49 112.89 25.82 Favored 'General case' 0 C--N 1.358 0.964 0 N-CA-C 107.677 -1.231 . . . . 0.0 107.677 177.073 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 9.3 mp -126.69 162.26 26.2 Favored 'General case' 0 N--CA 1.488 1.439 0 N-CA-C 108.409 -0.96 . . . . 0.0 108.409 179.499 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . 0.365 89.7 t -140.62 119.65 11.34 Favored 'Isoleucine or valine' 0 C--N 1.372 1.563 0 N-CA-C 105.636 -1.987 . . . . 0.0 105.636 168.099 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' D' D ' 19' ' ' PHE . . . . . . . . . . . . 0.69 57.8 m-85 -67.33 150.34 49.12 Favored 'General case' 0 N--CA 1.423 -1.794 1 C-N-CA 135.005 5.322 . . . . 0.0 121.46 159.418 . . . . . . . . 3 2 . 1 . 019 nuclear nobuild full ' D' D ' 20' ' ' PHE . . . . . 0.403 ' O ' ' O ' ' G' ' 21' ' ' ALA 0.315 82.4 t80 -169.25 -67.79 0.02 OUTLIER 'General case' 0 N--CA 1.477 0.922 0 CA-C-O 114.713 -2.565 . . . . 0.0 113.794 152.691 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' D' D ' 21' ' ' ALA . . . . . 0.453 ' O ' ' O ' ' A' ' 20' ' ' PHE 0.354 . . -68.91 91.56 0.47 Allowed 'General case' 0 C--O 1.259 1.597 0 CA-C-O 113.016 -3.373 . . . . 0.0 113.057 160.959 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 11.8 mm-40 -76.88 -169.13 1.2 Allowed 'General case' 0 C--N 1.282 -2.34 1 CA-C-N 126.396 4.18 . . . . 0.0 111.316 177.061 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 9.7 m-20 -75.92 154.87 35.64 Favored 'General case' 0 C--O 1.241 0.625 0 CA-C-O 121.708 0.766 . . . . 0.0 111.233 -176.399 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' D' D ' 24' ' ' VAL . . . . . 0.927 HG11 HH12 ' E' ' 5' ' ' ARG 0.294 42.7 t -154.72 103.71 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.663 0 N-CA-C 104.002 -2.592 . . . . 0.0 104.002 170.27 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . -118.43 63.33 0.42 Allowed Glycine 0 C--N 1.361 1.929 0 CA-C-O 117.303 -1.831 . . . . 0.0 111.876 170.345 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 14.7 m 54.72 -143.15 0.76 Allowed 'General case' 0 N--CA 1.481 1.093 0 CA-C-N 121.411 2.606 . . . . 0.0 110.396 175.727 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 3.5 m-80 -82.36 92.49 7.0 Favored 'General case' 0 N--CA 1.471 0.624 0 C-N-CA 123.78 0.832 . . . . 0.0 109.012 173.051 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 94.5 mttt -71.64 149.54 45.47 Favored 'General case' 0 CA--C 1.548 0.879 0 CA-C-O 122.601 1.191 . . . . 0.0 108.66 -175.815 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -70.01 -132.7 0.08 OUTLIER Glycine 0 N--CA 1.466 0.658 0 N-CA-C 107.804 -2.118 . . . . 0.0 107.804 179.481 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -89.42 132.89 34.78 Favored 'General case' 0 C--N 1.353 0.749 0 N-CA-C 106.923 -1.51 . . . . 0.0 106.923 -176.754 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' D' D ' 31' ' ' ILE . . . . . 0.409 ' N ' ' O ' ' E' ' 40' ' ' VAL . 18.9 tt -165.32 173.05 0.18 Allowed 'Isoleucine or valine' 0 C--O 1.218 -0.567 0 CA-C-N 113.21 -1.814 . . . . 0.0 109.085 -175.245 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 26.9 mt -141.65 145.49 24.37 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.623 0 N-CA-C 107.095 -1.446 . . . . 0.0 107.095 -179.659 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -52.33 169.15 0.66 Allowed Glycine 0 N--CA 1.473 1.115 0 C-N-CA 121.312 -0.471 . . . . 0.0 112.111 -178.581 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 2.5 pp -68.33 158.58 33.17 Favored 'General case' 0 N--CA 1.464 0.273 0 N-CA-C 109.34 -0.615 . . . . 0.0 109.34 -178.813 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 22.7 ttt -140.41 161.03 38.67 Favored 'General case' 0 N--CA 1.474 0.769 0 N-CA-C 107.98 -1.119 . . . . 0.0 107.98 179.168 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' D' D ' 36' ' ' VAL . . . . . . . . . . . . 0.284 62.0 t -155.71 147.05 12.5 Favored 'Isoleucine or valine' 0 C--N 1.349 0.573 0 N-CA-C 104.971 -2.233 . . . . 0.0 104.971 174.25 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 61.55 66.46 2.63 Favored Glycine 0 CA--C 1.535 1.326 0 N-CA-C 106.468 -2.653 . . . . 0.0 106.468 179.549 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . -80.74 129.9 9.37 Favored Glycine 0 C--N 1.313 -0.723 0 CA-C-N 118.683 1.242 . . . . 0.0 111.987 -179.077 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 2.4 t -148.74 122.74 1.8 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.789 0 N-CA-C 105.114 -2.18 . . . . 0.0 105.114 173.546 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 12.7 t . . . . . 0 N--CA 1.485 1.315 0 CA-C-O 116.567 -1.682 . . . . 0.0 113.769 179.317 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' E' E ' 1' ' ' ASP . . . . . . . . . . . . . 8.9 m-20 . . . . . 0 N--CA 1.485 1.323 0 N-CA-C 109.579 -0.526 . . . . 0.0 109.579 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' E' E ' 2' ' ' ALA . . . . . . . . . . . . . . . -63.66 131.17 47.12 Favored 'General case' 0 N--CA 1.469 0.515 0 N-CA-C 110.119 -0.326 . . . . 0.0 110.119 179.681 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' E' E ' 3' ' ' GLU . . . . . . . . . . . . . 54.0 tt0 -169.38 127.31 0.96 Allowed 'General case' 0 N--CA 1.47 0.562 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 -179.457 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 27.3 m-85 -118.24 127.74 54.02 Favored 'General case' 0 N--CA 1.478 0.926 0 N-CA-C 108.379 -0.971 . . . . 0.0 108.379 179.367 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' E' E ' 5' ' ' ARG . . . . . 0.927 HH12 HG11 ' D' ' 24' ' ' VAL . 6.3 ptm180 -165.06 147.37 8.02 Favored 'General case' 0 C--O 1.217 -0.637 0 C-N-CA 120.365 -0.534 . . . . 0.0 112.166 -179.973 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 20.6 p80 -152.17 106.84 3.21 Favored 'General case' 0 N--CA 1.477 0.899 0 CA-C-O 120.839 0.352 . . . . 0.0 110.58 178.047 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' E' E ' 7' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -77.98 152.35 33.17 Favored 'General case' 0 N--CA 1.474 0.744 0 CA-C-O 121.556 0.693 . . . . 0.0 110.091 178.939 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' E' E ' 8' ' ' SER . . . . . . . . . . . . . 92.8 p -156.34 172.9 17.69 Favored 'General case' 0 N--CA 1.487 1.4 0 CA-C-N 115.07 -0.968 . . . . 0.0 111.377 -178.815 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 125.7 79.56 0.35 Allowed Glycine 0 N--CA 1.481 1.669 0 N-CA-C 111.441 -0.664 . . . . 0.0 111.441 179.543 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 18.4 p90 -53.48 157.65 2.03 Favored 'General case' 0 N--CA 1.479 0.986 0 C-N-CA 122.393 0.277 . . . . 0.0 111.125 179.298 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 65.6 mt-10 -120.11 126.96 52.03 Favored 'General case' 0 N--CA 1.49 1.551 0 N-CA-C 109.229 -0.656 . . . . 0.0 109.229 178.429 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 39.6 t -103.52 136.95 33.99 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.685 0 N-CA-C 109.014 -0.736 . . . . 0.0 109.014 178.255 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 35.9 m80 -138.64 138.63 38.0 Favored 'General case' 0 N--CA 1.481 1.102 0 C-N-CA 122.326 0.25 . . . . 0.0 110.585 179.748 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 13.2 t60 -167.96 97.45 0.45 Allowed 'General case' 0 N--CA 1.484 1.258 0 C-N-CA 122.239 0.215 . . . . 0.0 110.593 179.303 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 55.1 mt-30 -100.57 117.12 34.06 Favored 'General case' 0 CA--C 1.512 -0.509 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 -179.681 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 64.6 tttp -104.63 105.63 15.8 Favored 'General case' 0 N--CA 1.48 1.042 0 N-CA-C 108.657 -0.868 . . . . 0.0 108.657 178.225 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 9.9 mp -122.06 164.06 18.35 Favored 'General case' 0 N--CA 1.487 1.408 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 -179.239 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 54.8 t -142.58 113.22 2.75 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.848 0 N-CA-C 108.097 -1.075 . . . . 0.0 108.097 177.167 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 60.3 m-85 -102.86 163.46 12.2 Favored 'General case' 0 C--N 1.362 1.121 0 O-C-N 124.005 0.816 . . . . 0.0 109.459 178.12 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' E' E ' 20' ' ' PHE . . . . . 0.431 ' O ' ' O ' ' H' ' 21' ' ' ALA . 69.1 t80 -166.59 -84.41 0.02 OUTLIER 'General case' 0 C--O 1.215 -0.74 0 CA-C-N 115.907 -0.588 . . . . 0.0 109.726 177.335 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' E' E ' 21' ' ' ALA . . . . . 0.433 ' O ' ' O ' ' B' ' 20' ' ' PHE . . . -85.39 91.3 8.16 Favored 'General case' 0 N--CA 1.474 0.763 0 N-CA-C 108.28 -1.007 . . . . 0.0 108.28 178.498 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 11.2 mm-40 -70.89 -172.84 0.71 Allowed 'General case' 0 N--CA 1.481 1.086 0 C-N-CA 119.67 -0.812 . . . . 0.0 111.061 -179.932 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' E' E ' 23' ' ' ASP . . . . . 0.444 ' HB3' ' HZ1' ' E' ' 28' ' ' LYS . 8.5 m-20 -71.34 154.07 41.87 Favored 'General case' 0 N--CA 1.472 0.665 0 CA-C-O 121.749 0.785 . . . . 0.0 112.623 -177.405 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' E' E ' 24' ' ' VAL . . . . . 0.92 HG11 HH12 ' F' ' 5' ' ' ARG . 53.0 t -155.37 92.15 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.762 0 CA-C-N 114.733 -1.122 . . . . 0.0 108.072 177.274 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . -119.45 61.13 0.49 Allowed Glycine 0 N--CA 1.478 1.439 0 N-CA-C 110.87 -0.892 . . . . 0.0 110.87 178.798 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 15.8 m 45.95 -143.2 0.28 Allowed 'General case' 0 N--CA 1.485 1.294 0 CA-C-N 118.299 1.049 . . . . 0.0 110.701 -179.8 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' E' E ' 27' ' ' ASN . . . . . 0.4 HD22 ' H ' ' E' ' 27' ' ' ASN . 3.6 m-80 -79.9 92.44 5.52 Favored 'General case' 0 N--CA 1.472 0.631 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 177.474 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' E' E ' 28' ' ' LYS . . . . . 0.444 ' HZ1' ' HB3' ' E' ' 23' ' ' ASP . 96.4 mttt -65.97 146.53 54.6 Favored 'General case' 0 CA--C 1.543 0.675 0 CA-C-O 121.193 0.52 . . . . 0.0 110.635 -178.565 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -71.29 -129.27 0.08 OUTLIER Glycine 0 CA--C 1.538 1.486 0 N-CA-C 109.912 -1.275 . . . . 0.0 109.912 178.492 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -82.22 131.28 35.23 Favored 'General case' 0 N--CA 1.439 -1.005 0 CA-C-N 117.637 0.719 . . . . 0.0 109.391 178.743 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 18.4 tt -165.28 173.31 0.18 Allowed 'Isoleucine or valine' 0 C--O 1.219 -0.532 0 N-CA-C 108.587 -0.894 . . . . 0.0 108.587 -178.737 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 25.5 mt -141.31 145.6 24.62 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.438 0 N-CA-C 107.106 -1.442 . . . . 0.0 107.106 179.674 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -51.63 167.93 0.64 Allowed Glycine 0 N--CA 1.474 1.209 0 C-N-CA 121.383 -0.437 . . . . 0.0 112.662 -179.333 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 2.7 pp -65.71 157.28 30.56 Favored 'General case' 0 N--CA 1.466 0.362 0 N-CA-C 109.97 -0.381 . . . . 0.0 109.97 179.746 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 23.0 ttt -142.37 154.24 44.47 Favored 'General case' 0 N--CA 1.478 0.949 0 N-CA-C 108.996 -0.742 . . . . 0.0 108.996 -179.956 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 40.3 t -149.41 138.54 15.42 Favored 'Isoleucine or valine' 0 C--O 1.238 0.458 0 N-CA-C 107.543 -1.28 . . . . 0.0 107.543 -179.57 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 60.94 67.96 1.89 Allowed Glycine 0 C--N 1.32 -0.336 0 N-CA-C 108.724 -1.751 . . . . 0.0 108.724 -179.882 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . -82.86 131.02 10.07 Favored Glycine 0 C--N 1.334 0.467 0 N-CA-C 111.286 -0.726 . . . . 0.0 111.286 -178.434 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 1.9 t -147.49 113.52 0.92 Allowed 'Isoleucine or valine' 0 N--CA 1.5 2.045 0 N-CA-C 108.447 -0.946 . . . . 0.0 108.447 179.389 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' E' E ' 40' ' ' VAL . . . . . 0.409 ' O ' ' N ' ' D' ' 31' ' ' ILE . 19.3 t . . . . . 0 N--CA 1.495 1.8 0 CA-C-O 118.074 -0.965 . . . . 0.0 112.127 -177.664 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' F' F ' 1' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 . . . . . 0 N--CA 1.486 1.335 0 N-CA-C 109.434 -0.58 . . . . 0.0 109.434 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' F' F ' 2' ' ' ALA . . . . . . . . . . . . . . . -63.64 131.24 47.37 Favored 'General case' 0 N--CA 1.469 0.512 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.152 179.749 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' F' F ' 3' ' ' GLU . . . . . . . . . . . . . 53.8 tt0 -169.42 127.04 0.94 Allowed 'General case' 0 N--CA 1.469 0.52 0 N-CA-C 109.911 -0.403 . . . . 0.0 109.911 -179.474 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 27.0 m-85 -117.88 127.43 53.85 Favored 'General case' 0 N--CA 1.476 0.873 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 179.361 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' F' F ' 5' ' ' ARG . . . . . 0.92 HH12 HG11 ' E' ' 24' ' ' VAL . 6.3 ptm180 -164.45 146.94 8.81 Favored 'General case' 0 N--CA 1.473 0.701 0 C-N-CA 120.291 -0.564 . . . . 0.0 112.063 -179.894 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 20.9 p80 -152.0 106.56 3.21 Favored 'General case' 0 N--CA 1.477 0.883 0 CA-C-O 120.793 0.33 . . . . 0.0 110.605 178.039 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' F' F ' 7' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -77.98 152.43 33.12 Favored 'General case' 0 N--CA 1.474 0.748 0 CA-C-O 121.573 0.701 . . . . 0.0 110.004 179.047 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' F' F ' 8' ' ' SER . . . . . . . . . . . . . 93.5 p -156.24 173.76 16.39 Favored 'General case' 0 N--CA 1.487 1.376 0 CA-C-N 114.933 -1.031 . . . . 0.0 111.488 -178.88 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 124.59 79.49 0.39 Allowed Glycine 0 N--CA 1.481 1.66 0 N-CA-C 111.424 -0.67 . . . . 0.0 111.424 179.669 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 18.3 p90 -53.89 158.11 2.16 Favored 'General case' 0 N--CA 1.479 0.996 0 C-N-CA 122.418 0.287 . . . . 0.0 111.136 179.252 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 65.3 mt-10 -120.23 126.97 51.95 Favored 'General case' 0 N--CA 1.489 1.483 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 178.506 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 39.3 t -103.44 136.87 34.24 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.687 0 N-CA-C 109.022 -0.733 . . . . 0.0 109.022 178.188 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 35.8 m80 -138.52 138.52 38.11 Favored 'General case' 0 N--CA 1.481 1.075 0 C-N-CA 122.417 0.287 . . . . 0.0 110.591 179.757 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 13.1 t60 -167.89 97.31 0.45 Allowed 'General case' 0 N--CA 1.483 1.191 0 C-N-CA 122.249 0.219 . . . . 0.0 110.626 179.198 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 55.3 mt-30 -100.29 117.24 34.09 Favored 'General case' 0 CA--C 1.513 -0.448 0 N-CA-C 108.399 -0.963 . . . . 0.0 108.399 -179.56 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 64.7 tttp -104.76 105.7 15.88 Favored 'General case' 0 N--CA 1.481 1.121 0 N-CA-C 108.558 -0.905 . . . . 0.0 108.558 178.104 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 9.9 mp -122.06 164.05 18.36 Favored 'General case' 0 N--CA 1.488 1.436 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 -179.398 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 55.2 t -142.39 112.75 2.76 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.911 0 N-CA-C 108.008 -1.108 . . . . 0.0 108.008 177.102 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 60.7 m-85 -102.09 163.68 12.11 Favored 'General case' 0 C--N 1.359 1.007 0 O-C-N 124.028 0.83 . . . . 0.0 109.107 177.779 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' F' F ' 20' ' ' PHE . . . . . 0.409 ' O ' ' O ' ' I' ' 21' ' ' ALA . 72.8 t80 -166.54 -84.12 0.02 OUTLIER 'General case' 0 C--O 1.215 -0.73 0 N-CA-C 109.399 -0.593 . . . . 0.0 109.399 177.173 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' F' F ' 21' ' ' ALA . . . . . 0.44 ' O ' ' O ' ' C' ' 20' ' ' PHE . . . -85.83 91.7 8.41 Favored 'General case' 0 N--CA 1.478 0.931 0 N-CA-C 108.302 -0.999 . . . . 0.0 108.302 178.547 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 11.1 mm-40 -71.14 -172.79 0.75 Allowed 'General case' 0 N--CA 1.481 1.124 0 C-N-CA 119.668 -0.813 . . . . 0.0 111.25 -179.842 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 8.5 m-20 -71.46 153.98 41.85 Favored 'General case' 0 N--CA 1.473 0.722 0 CA-C-O 121.847 0.832 . . . . 0.0 112.597 -177.334 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' F' F ' 24' ' ' VAL . . . . . 0.916 HG11 HH12 ' D' ' 5' ' ' ARG . 54.9 t -155.25 91.97 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.473 0.702 0 CA-C-N 114.65 -1.159 . . . . 0.0 108.261 177.302 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -119.51 61.33 0.49 Allowed Glycine 0 N--CA 1.482 1.703 0 N-CA-C 110.929 -0.868 . . . . 0.0 110.929 178.792 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 15.9 m 45.91 -143.18 0.28 Allowed 'General case' 0 N--CA 1.484 1.247 0 CA-C-N 118.206 1.003 . . . . 0.0 110.688 -179.973 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' F' F ' 27' ' ' ASN . . . . . 0.413 ' H ' HD22 ' F' ' 27' ' ' ASN . 3.6 m-80 -79.86 92.5 5.5 Favored 'General case' 0 N--CA 1.472 0.637 0 N-CA-C 108.818 -0.808 . . . . 0.0 108.818 177.413 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 96.4 mttt -66.1 146.4 54.7 Favored 'General case' 0 CA--C 1.542 0.639 0 CA-C-O 121.229 0.538 . . . . 0.0 110.626 -178.582 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -71.26 -129.45 0.08 OUTLIER Glycine 0 CA--C 1.538 1.529 0 N-CA-C 109.874 -1.29 . . . . 0.0 109.874 178.578 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.97 131.31 35.25 Favored 'General case' 0 N--CA 1.436 -1.137 0 CA-C-N 117.528 0.664 . . . . 0.0 109.484 178.754 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 18.4 tt -165.22 173.65 0.17 Allowed 'Isoleucine or valine' 0 C--O 1.218 -0.553 0 N-CA-C 108.571 -0.9 . . . . 0.0 108.571 -178.756 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 25.9 mt -141.48 145.59 24.43 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.524 0 N-CA-C 107.016 -1.476 . . . . 0.0 107.016 179.665 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -51.78 167.9 0.69 Allowed Glycine 0 N--CA 1.476 1.354 0 C-N-CA 121.316 -0.469 . . . . 0.0 112.567 -179.38 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 2.6 pp -65.64 157.29 30.36 Favored 'General case' 0 N--CA 1.466 0.351 0 CA-C-O 120.834 0.35 . . . . 0.0 110.061 179.772 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 22.9 ttt -142.29 154.02 44.37 Favored 'General case' 0 N--CA 1.476 0.858 0 N-CA-C 109.111 -0.7 . . . . 0.0 109.111 -179.984 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 40.6 t -149.19 138.68 15.77 Favored 'Isoleucine or valine' 0 C--O 1.237 0.399 0 N-CA-C 107.559 -1.274 . . . . 0.0 107.559 -179.625 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 60.97 67.83 1.95 Allowed Glycine 0 C--N 1.321 -0.251 0 N-CA-C 108.721 -1.751 . . . . 0.0 108.721 -179.974 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -82.69 130.86 9.96 Favored Glycine 0 C--N 1.334 0.462 0 N-CA-C 111.335 -0.706 . . . . 0.0 111.335 -178.38 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 1.9 t -147.3 113.57 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.5 2.052 0 N-CA-C 108.494 -0.928 . . . . 0.0 108.494 179.324 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 19.4 t . . . . . 0 N--CA 1.492 1.653 0 CA-C-O 118.215 -0.898 . . . . 0.0 112.5 -177.474 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' G' G ' 1' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 . . . . . 0 N--CA 1.491 1.596 0 N-CA-C 109.54 -0.541 . . . . 0.0 109.54 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' G' G ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.81 130.36 44.53 Favored 'General case' 0 N--CA 1.472 0.647 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.305 179.53 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' G' G ' 3' ' ' GLU . . . . . . . . . . . . . 53.6 tt0 -169.73 125.85 0.85 Allowed 'General case' 0 N--CA 1.471 0.575 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 -179.986 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 31.9 m-85 -117.63 127.93 54.43 Favored 'General case' 0 N--CA 1.48 1.046 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 179.317 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' G' G ' 5' ' ' ARG . . . . . 0.9 HH12 HG11 ' I' ' 24' ' ' VAL . 6.1 ptm180 -165.07 148.81 8.58 Favored 'General case' 0 N--CA 1.47 0.555 0 C-N-CA 120.446 -0.502 . . . . 0.0 111.933 -179.907 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' G' G ' 6' ' ' HIS . . . . . 0.404 ' O ' ' ND1' ' G' ' 6' ' ' HIS . 21.8 p80 -153.81 106.71 2.89 Favored 'General case' 0 N--CA 1.474 0.767 0 CA-C-O 121.06 0.457 . . . . 0.0 110.719 178.224 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -77.39 152.11 34.52 Favored 'General case' 0 N--CA 1.474 0.727 0 CA-C-O 121.084 0.468 . . . . 0.0 110.276 179.008 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' G' G ' 8' ' ' SER . . . . . . . . . . . . . 99.2 p -155.7 174.5 15.2 Favored 'General case' 0 N--CA 1.474 0.75 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.846 179.996 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 124.61 78.87 0.37 Allowed Glycine 0 N--CA 1.478 1.466 0 N-CA-C 111.202 -0.759 . . . . 0.0 111.202 179.582 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 24.0 p90 -54.23 157.47 2.67 Favored 'General case' 0 N--CA 1.476 0.827 0 O-C-N 122.802 -0.234 . . . . 0.0 111.107 179.358 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 64.6 mt-10 -120.15 126.93 51.92 Favored 'General case' 0 N--CA 1.487 1.376 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 179.257 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 29.9 t -103.79 136.12 38.28 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.021 0 N-CA-C 109.158 -0.682 . . . . 0.0 109.158 178.658 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 38.6 m80 -137.92 138.4 38.96 Favored 'General case' 0 N--CA 1.481 1.092 0 C-N-CA 122.827 0.451 . . . . 0.0 110.634 179.926 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 13.1 t60 -168.26 97.4 0.42 Allowed 'General case' 0 N--CA 1.481 1.125 0 N-CA-C 110.355 -0.239 . . . . 0.0 110.355 178.727 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 55.3 mt-30 -100.4 117.53 34.77 Favored 'General case' 0 CA--C 1.512 -0.5 0 N-CA-C 108.476 -0.935 . . . . 0.0 108.476 -179.652 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 64.6 tttp -104.97 105.67 15.82 Favored 'General case' 0 N--CA 1.482 1.142 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 178.323 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 9.8 mp -121.71 161.97 21.62 Favored 'General case' 0 N--CA 1.486 1.345 0 C-N-CA 123.478 0.711 . . . . 0.0 109.413 -179.204 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 43.6 t -142.59 112.78 2.59 Favored 'Isoleucine or valine' 0 C--O 1.246 0.891 0 N-CA-C 108.269 -1.012 . . . . 0.0 108.269 176.734 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 61.4 m-85 -101.73 161.01 13.97 Favored 'General case' 0 C--N 1.371 1.539 0 O-C-N 125.566 1.791 . . . . 0.0 109.959 177.307 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 68.7 t80 -167.95 -82.5 0.02 OUTLIER 'General case' 0 CA--C 1.539 0.527 0 CA-C-N 115.7 -0.682 . . . . 0.0 109.36 177.389 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' G' G ' 21' ' ' ALA . . . . . 0.403 ' O ' ' O ' ' D' ' 20' ' ' PHE . . . -84.96 90.69 7.88 Favored 'General case' 0 N--CA 1.474 0.754 0 N-CA-C 108.302 -0.999 . . . . 0.0 108.302 179.184 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 11.6 mm-40 -70.36 -175.09 0.94 Allowed 'General case' 0 N--CA 1.483 1.177 0 C-N-CA 119.691 -0.803 . . . . 0.0 111.167 -179.935 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 8.9 m-20 -70.97 154.47 41.79 Favored 'General case' 0 N--CA 1.475 0.82 0 CA-C-O 121.3 0.571 . . . . 0.0 112.169 -177.218 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' G' G ' 24' ' ' VAL . . . . . 0.895 HG11 HH12 ' H' ' 5' ' ' ARG . 65.2 t -156.63 92.8 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.471 0.597 0 CA-C-N 114.951 -1.022 . . . . 0.0 108.323 177.085 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -119.34 61.38 0.48 Allowed Glycine 0 N--CA 1.477 1.43 0 N-CA-C 110.93 -0.868 . . . . 0.0 110.93 179.107 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 17.2 m 47.0 -139.02 0.62 Allowed 'General case' 0 N--CA 1.484 1.233 0 CA-C-N 118.23 1.015 . . . . 0.0 110.815 179.691 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 3.7 m-80 -84.31 91.72 7.83 Favored 'General case' 0 N--CA 1.473 0.697 0 N-CA-C 108.087 -1.079 . . . . 0.0 108.087 177.511 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 96.5 mttt -65.3 146.61 54.7 Favored 'General case' 0 CA--C 1.539 0.539 0 CA-C-O 121.249 0.547 . . . . 0.0 110.576 -178.176 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -72.22 -127.84 0.09 OUTLIER Glycine 0 CA--C 1.526 0.779 0 N-CA-C 109.417 -1.473 . . . . 0.0 109.417 178.541 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.95 128.4 34.03 Favored 'General case' 0 CA--C 1.528 0.104 0 C-N-CA 122.66 0.384 . . . . 0.0 110.179 179.718 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 18.8 tt -164.41 172.88 0.21 Allowed 'Isoleucine or valine' 0 CA--C 1.506 -0.736 0 N-CA-C 109.53 -0.544 . . . . 0.0 109.53 -178.836 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 32.1 mt -139.42 146.9 24.87 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.092 0 N-CA-C 107.117 -1.438 . . . . 0.0 107.117 177.975 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -52.05 167.72 0.79 Allowed Glycine 0 N--CA 1.474 1.188 0 C-N-CA 121.489 -0.386 . . . . 0.0 112.187 -179.463 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 2.6 pp -65.87 157.61 30.1 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-O 120.793 0.33 . . . . 0.0 110.208 -179.935 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 22.8 ttt -142.74 154.54 44.37 Favored 'General case' 0 N--CA 1.472 0.669 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 -179.934 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 39.0 t -149.28 139.13 16.1 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.258 0 N-CA-C 107.712 -1.218 . . . . 0.0 107.712 -179.709 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 60.32 68.26 1.76 Allowed Glycine 0 C--N 1.319 -0.375 0 N-CA-C 108.956 -1.658 . . . . 0.0 108.956 179.963 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . -83.27 131.0 10.06 Favored Glycine 0 N--CA 1.465 0.599 0 N-CA-C 111.335 -0.706 . . . . 0.0 111.335 -178.703 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 2.1 t -146.97 113.2 0.96 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.91 0 N-CA-C 108.515 -0.92 . . . . 0.0 108.515 179.604 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 21.4 t . . . . . 0 N--CA 1.492 1.648 0 CA-C-O 118.205 -0.902 . . . . 0.0 111.958 -178.304 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' H' H ' 1' ' ' ASP . . . . . . . . . . . . . 9.0 m-20 . . . . . 0 N--CA 1.491 1.576 0 N-CA-C 109.608 -0.516 . . . . 0.0 109.608 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' H' H ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.72 130.09 43.43 Favored 'General case' 0 N--CA 1.471 0.597 0 CA-C-N 116.284 -0.417 . . . . 0.0 110.315 179.455 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' H' H ' 3' ' ' GLU . . . . . . . . . . . . . 53.9 tt0 -169.61 125.7 0.86 Allowed 'General case' 0 N--CA 1.471 0.593 0 N-CA-C 110.009 -0.367 . . . . 0.0 110.009 179.948 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 32.4 m-85 -117.21 128.24 54.9 Favored 'General case' 0 N--CA 1.48 1.068 0 N-CA-C 108.486 -0.931 . . . . 0.0 108.486 179.22 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' H' H ' 5' ' ' ARG . . . . . 0.895 HH12 HG11 ' G' ' 24' ' ' VAL . 6.1 ptm180 -165.33 148.78 8.23 Favored 'General case' 0 N--CA 1.47 0.558 0 C-N-CA 120.533 -0.467 . . . . 0.0 112.031 -179.968 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' H' H ' 6' ' ' HIS . . . . . 0.403 ' O ' ' ND1' ' H' ' 6' ' ' HIS . 21.7 p80 -153.89 106.76 2.88 Favored 'General case' 0 N--CA 1.475 0.79 0 CA-C-O 120.993 0.425 . . . . 0.0 110.645 178.204 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -77.58 151.75 34.28 Favored 'General case' 0 N--CA 1.474 0.745 0 CA-C-O 121.039 0.447 . . . . 0.0 110.261 179.016 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' H' H ' 8' ' ' SER . . . . . . . . . . . . . 99.3 p -155.22 174.89 14.57 Favored 'General case' 0 N--CA 1.475 0.808 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.839 179.99 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 124.15 78.89 0.39 Allowed Glycine 0 N--CA 1.478 1.472 0 N-CA-C 111.305 -0.718 . . . . 0.0 111.305 179.714 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 24.2 p90 -54.36 157.73 2.65 Favored 'General case' 0 N--CA 1.475 0.789 0 O-C-N 122.747 -0.267 . . . . 0.0 111.137 179.29 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 64.8 mt-10 -120.31 126.93 51.77 Favored 'General case' 0 N--CA 1.485 1.3 0 C-N-CA 122.694 0.397 . . . . 0.0 109.931 179.347 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 28.1 t -103.97 135.94 39.36 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.998 0 N-CA-C 109.153 -0.684 . . . . 0.0 109.153 178.683 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 38.6 m80 -137.76 138.65 39.47 Favored 'General case' 0 N--CA 1.481 1.107 0 C-N-CA 122.981 0.512 . . . . 0.0 110.584 -179.949 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 13.2 t60 -168.56 97.48 0.4 Allowed 'General case' 0 N--CA 1.482 1.127 0 N-CA-C 110.31 -0.256 . . . . 0.0 110.31 178.66 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 55.5 mt-30 -100.56 116.97 33.73 Favored 'General case' 0 CA--C 1.512 -0.49 0 N-CA-C 108.72 -0.845 . . . . 0.0 108.72 -179.619 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 64.5 tttp -104.35 105.72 15.96 Favored 'General case' 0 N--CA 1.482 1.136 0 N-CA-C 108.62 -0.882 . . . . 0.0 108.62 178.282 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 9.8 mp -121.91 162.29 21.29 Favored 'General case' 0 N--CA 1.487 1.386 0 C-N-CA 123.494 0.718 . . . . 0.0 109.224 -179.262 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 45.8 t -142.35 111.96 2.55 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.601 0 N-CA-C 108.372 -0.974 . . . . 0.0 108.372 176.921 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 61.1 m-85 -100.6 161.37 13.65 Favored 'General case' 0 C--N 1.364 1.228 0 O-C-N 124.724 1.265 . . . . 0.0 109.944 177.404 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 67.2 t80 -167.26 -83.15 0.02 OUTLIER 'General case' 0 N--CA 1.469 0.48 0 CA-C-N 115.696 -0.684 . . . . 0.0 109.572 177.214 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' H' H ' 21' ' ' ALA . . . . . 0.431 ' O ' ' O ' ' E' ' 20' ' ' PHE . . . -84.91 90.33 7.78 Favored 'General case' 0 N--CA 1.473 0.715 0 N-CA-C 108.406 -0.961 . . . . 0.0 108.406 179.22 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 11.7 mm-40 -69.76 -175.02 0.81 Allowed 'General case' 0 N--CA 1.483 1.176 0 C-N-CA 119.694 -0.803 . . . . 0.0 111.171 -179.872 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' H' H ' 23' ' ' ASP . . . . . 0.463 ' HB3' ' HZ1' ' H' ' 28' ' ' LYS . 8.8 m-20 -71.2 154.36 41.74 Favored 'General case' 0 N--CA 1.473 0.691 0 CA-C-O 121.333 0.587 . . . . 0.0 112.245 -177.093 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' H' H ' 24' ' ' VAL . . . . . 0.919 HG11 HH12 ' I' ' 5' ' ' ARG . 65.7 t -156.36 92.8 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.471 0.619 0 CA-C-N 114.943 -1.026 . . . . 0.0 108.407 177.095 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . -119.45 61.46 0.49 Allowed Glycine 0 N--CA 1.48 1.615 0 N-CA-C 110.961 -0.856 . . . . 0.0 110.961 179.226 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 17.2 m 46.82 -138.83 0.61 Allowed 'General case' 0 N--CA 1.485 1.296 0 CA-C-N 118.082 0.941 . . . . 0.0 110.832 -179.979 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 3.4 m-80 -84.26 91.9 7.85 Favored 'General case' 0 N--CA 1.473 0.691 0 N-CA-C 108.027 -1.101 . . . . 0.0 108.027 177.417 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' H' H ' 28' ' ' LYS . . . . . 0.463 ' HZ1' ' HB3' ' H' ' 23' ' ' ASP . 96.4 mttt -65.47 146.75 54.48 Favored 'General case' 0 CA--C 1.539 0.549 0 CA-C-O 121.373 0.606 . . . . 0.0 110.487 -178.212 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -72.16 -127.87 0.09 OUTLIER Glycine 0 CA--C 1.528 0.856 0 N-CA-C 109.554 -1.419 . . . . 0.0 109.554 178.542 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.91 128.8 34.43 Favored 'General case' 0 C--O 1.231 0.086 0 N-CA-C 110.05 -0.352 . . . . 0.0 110.05 179.591 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 18.9 tt -164.73 172.57 0.21 Allowed 'Isoleucine or valine' 0 CA--C 1.505 -0.778 0 N-CA-C 109.578 -0.527 . . . . 0.0 109.578 -178.719 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 31.9 mt -139.34 147.01 24.78 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.038 0 N-CA-C 107.132 -1.433 . . . . 0.0 107.132 177.974 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -52.25 167.59 0.87 Allowed Glycine 0 N--CA 1.472 1.088 0 C-N-CA 121.505 -0.378 . . . . 0.0 112.267 -179.454 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 2.6 pp -65.5 157.84 28.52 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-O 120.937 0.399 . . . . 0.0 110.123 -179.95 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 22.8 ttt -142.97 154.48 44.08 Favored 'General case' 0 N--CA 1.473 0.712 0 N-CA-C 109.225 -0.657 . . . . 0.0 109.225 -179.859 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 39.2 t -149.54 139.11 15.82 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.216 0 N-CA-C 107.566 -1.272 . . . . 0.0 107.566 -179.578 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 60.19 67.88 1.94 Allowed Glycine 0 C--N 1.32 -0.335 0 N-CA-C 109.093 -1.603 . . . . 0.0 109.093 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . -83.02 131.17 10.17 Favored Glycine 0 N--CA 1.464 0.544 0 N-CA-C 111.45 -0.66 . . . . 0.0 111.45 -178.765 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 2.1 t -147.04 113.36 0.96 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.927 0 N-CA-C 108.324 -0.991 . . . . 0.0 108.324 179.539 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 21.7 t . . . . . 0 N--CA 1.491 1.589 0 CA-C-O 118.298 -0.858 . . . . 0.0 111.574 -178.358 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' I' I ' 1' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 . . . . . 0 N--CA 1.491 1.613 0 N-CA-C 109.532 -0.544 . . . . 0.0 109.532 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' I' I ' 2' ' ' ALA . . . . . . . . . . . . . . . -62.66 130.2 43.97 Favored 'General case' 0 N--CA 1.472 0.641 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.308 179.448 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' I' I ' 3' ' ' GLU . . . . . . . . . . . . . 53.7 tt0 -169.77 125.66 0.84 Allowed 'General case' 0 N--CA 1.47 0.559 0 N-CA-C 109.97 -0.382 . . . . 0.0 109.97 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 32.8 m-85 -117.32 128.15 54.77 Favored 'General case' 0 N--CA 1.48 1.041 0 N-CA-C 108.46 -0.941 . . . . 0.0 108.46 179.247 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' I' I ' 5' ' ' ARG . . . . . 0.919 HH12 HG11 ' H' ' 24' ' ' VAL . 6.1 ptm180 -165.24 148.48 8.23 Favored 'General case' 0 N--CA 1.47 0.545 0 C-N-CA 120.567 -0.453 . . . . 0.0 112.017 -179.881 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' I' I ' 6' ' ' HIS . . . . . 0.401 ' ND1' ' O ' ' I' ' 6' ' ' HIS . 21.6 p80 -153.66 106.83 2.94 Favored 'General case' 0 N--CA 1.475 0.793 0 CA-C-O 121.008 0.432 . . . . 0.0 110.61 178.198 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -77.59 151.83 34.23 Favored 'General case' 0 N--CA 1.474 0.775 0 CA-C-O 121.072 0.463 . . . . 0.0 110.249 178.958 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' I' I ' 8' ' ' SER . . . . . . . . . . . . . 98.2 p -155.23 174.88 14.58 Favored 'General case' 0 N--CA 1.476 0.849 0 CA-C-N 115.945 -0.57 . . . . 0.0 110.854 179.915 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 124.23 78.92 0.39 Allowed Glycine 0 N--CA 1.479 1.56 0 N-CA-C 111.256 -0.738 . . . . 0.0 111.256 179.663 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 24.0 p90 -54.58 157.63 2.86 Favored 'General case' 0 N--CA 1.477 0.891 0 O-C-N 122.803 -0.234 . . . . 0.0 111.045 179.308 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 64.5 mt-10 -120.23 126.92 51.81 Favored 'General case' 0 N--CA 1.484 1.266 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 179.391 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 27.2 t -103.9 135.86 39.66 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.937 0 N-CA-C 109.16 -0.681 . . . . 0.0 109.16 178.679 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 38.5 m80 -137.76 138.53 39.37 Favored 'General case' 0 N--CA 1.482 1.15 0 C-N-CA 122.966 0.506 . . . . 0.0 110.579 -179.943 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 13.2 t60 -168.47 97.27 0.4 Allowed 'General case' 0 N--CA 1.482 1.136 0 N-CA-C 110.278 -0.267 . . . . 0.0 110.278 178.736 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 55.8 mt-30 -100.38 116.93 33.5 Favored 'General case' 0 C--N 1.326 -0.436 0 N-CA-C 108.611 -0.885 . . . . 0.0 108.611 -179.585 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 64.6 tttp -104.35 105.7 15.92 Favored 'General case' 0 N--CA 1.482 1.143 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 178.236 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 9.8 mp -121.88 162.35 21.14 Favored 'General case' 0 N--CA 1.487 1.416 0 C-N-CA 123.475 0.71 . . . . 0.0 109.21 -179.244 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 45.7 t -142.35 111.99 2.57 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.579 0 N-CA-C 108.32 -0.993 . . . . 0.0 108.32 176.937 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 60.8 m-85 -100.75 161.41 13.62 Favored 'General case' 0 C--N 1.364 1.208 0 O-C-N 124.79 1.306 . . . . 0.0 109.949 177.434 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 66.9 t80 -167.28 -83.39 0.02 OUTLIER 'General case' 0 N--CA 1.468 0.446 0 CA-C-N 115.629 -0.714 . . . . 0.0 109.649 177.267 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' I' I ' 21' ' ' ALA . . . . . 0.409 ' O ' ' O ' ' F' ' 20' ' ' PHE . . . -84.7 90.62 7.75 Favored 'General case' 0 N--CA 1.471 0.62 0 N-CA-C 108.274 -1.01 . . . . 0.0 108.274 179.243 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 11.7 mm-40 -70.16 -175.01 0.88 Allowed 'General case' 0 N--CA 1.482 1.17 0 C-N-CA 119.725 -0.79 . . . . 0.0 111.114 -179.836 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 8.8 m-20 -71.21 154.17 41.89 Favored 'General case' 0 N--CA 1.473 0.701 0 CA-C-O 121.296 0.57 . . . . 0.0 112.292 -177.067 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' I' I ' 24' ' ' VAL . . . . . 0.9 HG11 HH12 ' G' ' 5' ' ' ARG . 65.6 t -156.22 92.75 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.47 0.528 0 CA-C-N 115.023 -0.99 . . . . 0.0 108.396 177.08 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . -119.17 61.36 0.48 Allowed Glycine 0 N--CA 1.48 1.628 0 N-CA-C 110.981 -0.848 . . . . 0.0 110.981 179.148 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 17.4 m 46.81 -138.84 0.61 Allowed 'General case' 0 N--CA 1.486 1.36 0 CA-C-N 118.214 1.007 . . . . 0.0 110.707 179.948 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 3.3 m-80 -84.29 91.97 7.88 Favored 'General case' 0 N--CA 1.472 0.665 0 N-CA-C 108.089 -1.078 . . . . 0.0 108.089 177.413 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 96.4 mttt -65.52 146.58 54.68 Favored 'General case' 0 CA--C 1.539 0.555 0 CA-C-O 121.378 0.608 . . . . 0.0 110.512 -178.195 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -71.92 -128.13 0.09 OUTLIER Glycine 0 CA--C 1.527 0.835 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 178.49 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.87 128.47 34.07 Favored 'General case' 0 CA--C 1.529 0.155 0 C-N-CA 122.709 0.404 . . . . 0.0 109.939 179.698 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 18.8 tt -164.38 172.64 0.22 Allowed 'Isoleucine or valine' 0 CA--C 1.506 -0.716 0 N-CA-C 109.553 -0.536 . . . . 0.0 109.553 -178.695 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 31.7 mt -139.31 146.99 24.85 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.101 0 N-CA-C 107.214 -1.402 . . . . 0.0 107.214 177.896 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -52.25 167.62 0.87 Allowed Glycine 0 N--CA 1.473 1.163 0 C-N-CA 121.528 -0.367 . . . . 0.0 112.234 -179.444 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 2.6 pp -65.59 157.59 29.41 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-O 120.892 0.377 . . . . 0.0 110.086 -179.956 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 22.9 ttt -142.73 154.17 44.03 Favored 'General case' 0 N--CA 1.472 0.655 0 N-CA-C 109.172 -0.677 . . . . 0.0 109.172 -179.827 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 39.6 t -149.26 139.27 16.23 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.252 0 N-CA-C 107.551 -1.277 . . . . 0.0 107.551 -179.719 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 60.09 67.93 1.92 Allowed Glycine 0 N--CA 1.461 0.344 0 N-CA-C 109.135 -1.586 . . . . 0.0 109.135 -179.921 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . -82.99 131.22 10.21 Favored Glycine 0 N--CA 1.464 0.564 0 N-CA-C 111.359 -0.697 . . . . 0.0 111.359 -178.702 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 2.1 t -147.16 113.39 0.95 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.908 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 179.527 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 21.6 t . . . . . 0 N--CA 1.489 1.521 0 CA-C-O 118.192 -0.909 . . . . 0.0 111.766 -178.315 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . 0.408 ' HB3' ' H2 ' ' D' ' 1' ' ' ASP . 3.9 p-10 . . . . . 0 N--CA 1.49 1.574 0 N-CA-C 109.165 -0.68 . . . . 0.0 109.165 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.62 130.32 43.19 Favored 'General case' 0 N--CA 1.47 0.535 0 CA-C-N 116.378 -0.374 . . . . 0.0 111.406 -179.593 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 13.4 pt-20 -170.69 108.84 0.33 Allowed 'General case' 0 CA--C 1.545 0.781 0 CA-C-O 121.275 0.56 . . . . 0.0 110.143 179.08 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 29.8 m-85 -87.47 156.97 19.31 Favored 'General case' 0 N--CA 1.472 0.659 0 N-CA-C 109.426 -0.583 . . . . 0.0 109.426 -179.813 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 77.1 mtt85 -139.85 145.58 38.26 Favored 'General case' 0 N--CA 1.478 0.925 0 CA-C-N 115.886 -0.597 . . . . 0.0 109.885 179.776 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' HIS . . . . . . . . . . . . . 57.6 t-80 -150.51 116.96 5.73 Favored 'General case' 0 N--CA 1.476 0.863 0 N-CA-C 109.631 -0.507 . . . . 0.0 109.631 179.164 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' ASP . . . . . . . . . . . . . 9.9 m-20 -66.94 144.6 56.13 Favored 'General case' 0 N--CA 1.474 0.75 0 C-N-CA 122.897 0.479 . . . . 0.0 111.83 -179.809 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 1.7 t -164.3 -176.89 4.64 Favored 'General case' 0 N--CA 1.471 0.597 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 177.986 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 85.54 70.46 1.33 Allowed Glycine 0 CA--C 1.53 1.029 0 CA-C-N 115.837 -0.62 . . . . 0.0 112.087 178.725 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 40.3 p90 -73.01 122.16 21.28 Favored 'General case' 0 N--CA 1.477 0.888 0 CA-C-N 117.255 0.527 . . . . 0.0 110.892 179.976 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 17.7 pt-20 -82.76 151.82 25.99 Favored 'General case' 0 N--CA 1.477 0.903 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 178.853 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 13.7 t -144.68 117.72 2.73 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.877 0 CA-C-O 121.578 0.704 . . . . 0.0 109.365 178.302 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 73.5 m80 -95.79 164.87 12.57 Favored 'General case' 0 C--N 1.358 0.941 0 CA-C-N 114.641 -1.163 . . . . 0.0 109.29 177.996 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . 0.449 ' NE2' ' NZ ' ' A' ' 16' ' ' LYS . 17.2 t60 -164.74 99.27 0.78 Allowed 'General case' 0 N--CA 1.476 0.855 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.12 179.223 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -91.66 111.58 23.15 Favored 'General case' 0 CA--C 1.517 -0.326 0 N-CA-C 108.386 -0.968 . . . . 0.0 108.386 179.668 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . 0.449 ' NZ ' ' NE2' ' A' ' 14' ' ' HIS . 8.5 ttmm -94.37 171.38 8.85 Favored 'General case' 0 N--CA 1.483 1.206 0 N-CA-C 108.893 -0.781 . . . . 0.0 108.893 179.926 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.422 HD12 ' N ' ' A' ' 17' ' ' LEU . 9.6 mp -55.09 157.9 3.16 Favored 'General case' 0 N--CA 1.476 0.837 0 N-CA-C 110.002 -0.37 . . . . 0.0 110.002 -178.408 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 71.2 t -140.81 150.22 20.69 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.714 0 C-N-CA 123.206 0.602 . . . . 0.0 109.76 -177.798 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.69 ' HB3' ' O ' ' D' ' 18' ' ' VAL . 43.9 p90 -40.44 162.34 0.01 OUTLIER 'General case' 0 CA--C 1.542 0.666 0 N-CA-C 120.228 3.418 . . . . 0.0 120.228 -178.729 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.409 ' O ' ' CD2' ' A' ' 20' ' ' PHE . 20.9 p90 -119.75 69.82 0.85 Allowed 'General case' 0 CA--C 1.56 1.352 0 CA-C-N 112.033 -2.349 . . . . 0.0 109.449 173.552 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . 0.411 ' H ' ' HD1' ' A' ' 19' ' ' PHE . . . -62.97 95.04 0.07 Allowed 'General case' 0 C--N 1.325 -0.493 0 N-CA-C 108.38 -0.97 . . . . 0.0 108.38 176.767 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 77.5 mt-10 -49.61 123.73 8.3 Favored 'General case' 0 N--CA 1.475 0.813 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.517 -179.954 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 16.6 t70 -76.73 169.37 18.43 Favored 'General case' 0 N--CA 1.471 0.624 0 CA-C-O 120.983 0.42 . . . . 0.0 110.648 -178.901 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.548 HG13 ' H ' ' A' ' 25' ' ' GLY . 0.7 OUTLIER 178.28 -79.05 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.542 0.636 0 N-CA-C 107.298 -1.371 . . . . 0.0 107.298 -179.865 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.548 ' H ' HG13 ' A' ' 24' ' ' VAL . . . -34.03 84.4 0.0 OUTLIER Glycine 0 N--CA 1.473 1.166 0 C-N-CA 124.425 1.012 . . . . 0.0 113.461 178.546 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . 0.438 ' N ' ' O ' ' A' ' 24' ' ' VAL . 87.9 p -41.25 -105.55 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.65 0 N-CA-C 113.676 0.991 . . . . 0.0 113.676 -177.401 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 16.8 p-10 -59.97 112.47 1.88 Allowed 'General case' 0 N--CA 1.469 0.488 0 CA-C-N 118.833 0.742 . . . . 0.0 110.417 -178.637 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 41.8 mttm -96.83 164.57 12.5 Favored 'General case' 0 N--CA 1.475 0.801 0 C-N-CA 123.31 0.644 . . . . 0.0 110.008 -179.564 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -72.95 -141.45 0.45 Allowed Glycine 0 N--CA 1.461 0.342 0 N-CA-C 107.876 -2.089 . . . . 0.0 107.876 176.548 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . 0.458 ' O ' ' O ' ' D' ' 31' ' ' ILE . . . -90.42 123.12 33.88 Favored 'General case' 0 C--O 1.208 -1.084 0 N-CA-C 106.836 -1.542 . . . . 0.0 106.836 176.524 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 16.7 tt -148.28 155.6 9.41 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.884 0 N-CA-C 107.996 -1.113 . . . . 0.0 107.996 179.192 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 20.5 pt -150.88 138.89 14.24 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 CA-C-N 119.042 0.837 . . . . 0.0 109.394 178.56 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -56.68 154.3 17.7 Favored Glycine 0 CA--C 1.533 1.167 0 CA-C-N 116.605 -0.27 . . . . 0.0 112.591 -178.537 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 2.5 pp -76.29 158.92 31.06 Favored 'General case' 0 N--CA 1.472 0.673 0 N-CA-C 109.68 -0.489 . . . . 0.0 109.68 179.242 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 11.9 ttp -102.84 151.59 22.25 Favored 'General case' 0 N--CA 1.481 1.08 0 N-CA-C 109.383 -0.599 . . . . 0.0 109.383 179.711 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 7.3 p -168.62 159.82 0.71 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.553 0 N-CA-C 108.044 -1.095 . . . . 0.0 108.044 179.772 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.41 69.86 1.14 Allowed Glycine 0 C--N 1.31 -0.862 0 N-CA-C 111.665 -0.574 . . . . 0.0 111.665 178.836 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 152.04 -177.49 29.84 Favored Glycine 0 N--CA 1.468 0.828 0 N-CA-C 110.214 -1.154 . . . . 0.0 110.214 179.659 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 4.6 t -124.99 139.14 51.99 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.758 0 N-CA-C 107.206 -1.405 . . . . 0.0 107.206 -179.502 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 72.7 t . . . . . 0 N--CA 1.481 1.081 0 CA-C-O 117.776 -1.107 . . . . 0.0 109.64 -177.501 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' B' B ' 1' ' ' ASP . . . . . . . . . . . . . 3.9 p-10 . . . . . 0 N--CA 1.489 1.493 0 N-CA-C 109.194 -0.669 . . . . 0.0 109.194 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' B' B ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.52 130.19 42.74 Favored 'General case' 0 N--CA 1.469 0.496 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.403 -179.671 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 3' ' ' GLU . . . . . . . . . . . . . 13.3 pt-20 -170.69 108.86 0.33 Allowed 'General case' 0 CA--C 1.546 0.818 0 CA-C-O 121.334 0.588 . . . . 0.0 110.111 179.01 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 4' ' ' PHE . . . . . . . . . . . . . 30.1 m-85 -87.29 157.16 19.36 Favored 'General case' 0 N--CA 1.473 0.72 0 N-CA-C 109.531 -0.544 . . . . 0.0 109.531 -179.808 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 5' ' ' ARG . . . . . . . . . . . . . 77.1 mtt85 -140.05 145.61 37.93 Favored 'General case' 0 N--CA 1.477 0.92 0 CA-C-N 115.941 -0.572 . . . . 0.0 109.991 179.724 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 6' ' ' HIS . . . . . . . . . . . . . 58.1 t-80 -150.43 117.29 5.87 Favored 'General case' 0 N--CA 1.475 0.814 0 N-CA-C 109.644 -0.502 . . . . 0.0 109.644 179.153 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 7' ' ' ASP . . . . . . . . . . . . . 9.8 m-20 -67.16 144.38 56.06 Favored 'General case' 0 N--CA 1.472 0.671 0 C-N-CA 122.863 0.465 . . . . 0.0 111.682 -179.713 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 8' ' ' SER . . . . . . . . . . . . . 2.2 t -163.96 -177.63 5.18 Favored 'General case' 0 N--CA 1.471 0.578 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 178.148 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . 85.88 70.5 1.32 Allowed Glycine 0 CA--C 1.532 1.154 0 CA-C-N 115.916 -0.584 . . . . 0.0 112.158 178.775 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 40.1 p90 -72.81 121.99 20.83 Favored 'General case' 0 N--CA 1.478 0.931 0 CA-C-N 117.295 0.548 . . . . 0.0 110.87 179.833 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 17.7 pt-20 -82.67 151.92 26.06 Favored 'General case' 0 N--CA 1.479 0.986 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 178.828 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 13.1 t -144.75 117.81 2.71 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.842 0 CA-C-O 121.598 0.713 . . . . 0.0 109.318 178.362 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 73.5 m80 -96.02 164.66 12.61 Favored 'General case' 0 C--N 1.357 0.932 0 CA-C-N 114.616 -1.175 . . . . 0.0 109.333 177.919 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 14' ' ' HIS . . . . . 0.448 ' NE2' ' NZ ' ' B' ' 16' ' ' LYS . 17.2 t60 -164.59 99.25 0.8 Allowed 'General case' 0 N--CA 1.476 0.839 0 CA-C-N 116.471 -0.331 . . . . 0.0 110.113 179.224 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -91.44 111.54 23.08 Favored 'General case' 0 CA--C 1.515 -0.381 0 N-CA-C 108.441 -0.948 . . . . 0.0 108.441 179.585 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 16' ' ' LYS . . . . . 0.448 ' NZ ' ' NE2' ' B' ' 14' ' ' HIS . 8.5 ttmm -94.33 171.49 8.79 Favored 'General case' 0 N--CA 1.483 1.197 0 N-CA-C 108.899 -0.778 . . . . 0.0 108.899 179.995 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . 0.412 ' N ' HD12 ' B' ' 17' ' ' LEU . 9.7 mp -55.25 157.83 3.38 Favored 'General case' 0 N--CA 1.476 0.836 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 -178.41 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 71.3 t -140.87 150.46 20.49 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.763 0 C-N-CA 123.113 0.565 . . . . 0.0 109.652 -177.767 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 19' ' ' PHE . . . . . 0.704 ' HB3' ' O ' ' E' ' 18' ' ' VAL . 44.4 p90 -40.58 162.07 0.01 OUTLIER 'General case' 0 CA--C 1.543 0.7 0 N-CA-C 120.055 3.354 . . . . 0.0 120.055 -178.738 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . 0.418 ' O ' ' CD2' ' B' ' 20' ' ' PHE . 21.1 p90 -119.61 69.68 0.84 Allowed 'General case' 0 CA--C 1.561 1.371 0 CA-C-N 111.946 -2.388 . . . . 0.0 109.257 173.545 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 21' ' ' ALA . . . . . 0.42 ' H ' ' HD1' ' B' ' 19' ' ' PHE . . . -62.75 95.11 0.07 Allowed 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 108.409 -0.959 . . . . 0.0 108.409 176.759 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 77.2 mt-10 -49.62 123.73 8.3 Favored 'General case' 0 N--CA 1.476 0.849 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.421 -179.892 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 16.7 t70 -76.74 169.27 18.61 Favored 'General case' 0 N--CA 1.471 0.609 0 CA-C-O 121.007 0.432 . . . . 0.0 110.702 -179.044 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . 0.515 HG13 ' H ' ' B' ' 25' ' ' GLY . 0.7 OUTLIER 178.2 -79.11 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.545 0.755 0 N-CA-C 107.333 -1.358 . . . . 0.0 107.333 -179.608 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . 0.515 ' H ' HG13 ' B' ' 24' ' ' VAL . . . -34.1 84.12 0.0 OUTLIER Glycine 0 N--CA 1.48 1.633 0 C-N-CA 124.334 0.969 . . . . 0.0 113.258 178.7 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 26' ' ' SER . . . . . 0.453 ' N ' ' O ' ' B' ' 24' ' ' VAL . 88.0 p -41.02 -105.38 0.0 OUTLIER 'General case' 0 N--CA 1.475 0.817 0 N-CA-C 113.602 0.964 . . . . 0.0 113.602 -177.411 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 27' ' ' ASN . . . . . . . . . . . . . 16.6 p-10 -60.02 112.27 1.81 Allowed 'General case' 0 N--CA 1.471 0.578 0 CA-C-N 118.83 0.741 . . . . 0.0 110.357 -178.631 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 41.6 mttm -96.53 164.43 12.62 Favored 'General case' 0 N--CA 1.474 0.773 0 C-N-CA 123.203 0.601 . . . . 0.0 110.195 -179.628 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -72.82 -141.03 0.42 Allowed Glycine 0 N--CA 1.461 0.365 0 N-CA-C 107.816 -2.114 . . . . 0.0 107.816 176.574 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 30' ' ' ALA . . . . . 0.491 ' O ' ' O ' ' E' ' 31' ' ' ILE . . . -91.05 123.4 34.48 Favored 'General case' 0 C--O 1.208 -1.128 0 N-CA-C 106.734 -1.58 . . . . 0.0 106.734 176.587 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 16.6 tt -148.35 155.6 9.33 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.829 0 N-CA-C 107.91 -1.144 . . . . 0.0 107.91 179.194 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 20.5 pt -150.79 138.92 14.37 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.469 0 CA-C-N 118.949 0.795 . . . . 0.0 109.246 178.664 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -56.81 154.29 18.32 Favored Glycine 0 CA--C 1.532 1.148 0 CA-C-N 116.598 -0.274 . . . . 0.0 112.63 -178.691 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 2.5 pp -76.18 158.81 31.3 Favored 'General case' 0 N--CA 1.472 0.635 0 C-N-CA 122.707 0.403 . . . . 0.0 109.971 179.161 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 11.8 ttp -102.73 151.21 22.66 Favored 'General case' 0 N--CA 1.481 1.078 0 N-CA-C 109.507 -0.553 . . . . 0.0 109.507 179.717 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 7.3 p -168.37 159.89 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.524 0 N-CA-C 108.035 -1.098 . . . . 0.0 108.035 179.826 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.42 69.6 1.22 Allowed Glycine 0 C--N 1.313 -0.746 0 N-CA-C 111.617 -0.593 . . . . 0.0 111.617 178.774 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 152.14 -177.75 29.77 Favored Glycine 0 N--CA 1.468 0.795 0 N-CA-C 110.217 -1.153 . . . . 0.0 110.217 179.696 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 4.4 t -124.69 139.05 52.05 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.717 0 N-CA-C 107.31 -1.367 . . . . 0.0 107.31 -179.515 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 74.2 t . . . . . 0 N--CA 1.481 1.115 0 CA-C-O 117.756 -1.116 . . . . 0.0 109.647 -177.522 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' C' C ' 1' ' ' ASP . . . . . 0.416 ' HB3' ' H2 ' ' F' ' 1' ' ' ASP . 3.9 p-10 . . . . . 0 N--CA 1.488 1.451 0 N-CA-C 109.317 -0.624 . . . . 0.0 109.317 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' C' C ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.22 130.46 43.98 Favored 'General case' 0 CA--C 1.538 0.493 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.368 -179.708 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' C' C ' 3' ' ' GLU . . . . . . . . . . . . . 13.4 pt-20 -171.01 108.87 0.3 Allowed 'General case' 0 CA--C 1.546 0.79 0 CA-C-O 121.267 0.555 . . . . 0.0 110.053 179.039 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' C' C ' 4' ' ' PHE . . . . . . . . . . . . . 29.9 m-85 -87.29 157.23 19.34 Favored 'General case' 0 N--CA 1.473 0.698 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 -179.846 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' C' C ' 5' ' ' ARG . . . . . . . . . . . . . 77.4 mtt85 -140.08 145.46 37.68 Favored 'General case' 0 N--CA 1.478 0.965 0 C-N-CA 122.999 0.52 . . . . 0.0 109.797 179.766 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' C' C ' 6' ' ' HIS . . . . . . . . . . . . . 57.9 t-80 -150.37 116.94 5.78 Favored 'General case' 0 N--CA 1.476 0.864 0 N-CA-C 109.655 -0.498 . . . . 0.0 109.655 179.087 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' C' C ' 7' ' ' ASP . . . . . . . . . . . . . 9.9 m-20 -66.89 144.39 56.28 Favored 'General case' 0 N--CA 1.472 0.643 0 O-C-N 123.444 0.465 . . . . 0.0 111.777 -179.728 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' C' C ' 8' ' ' SER . . . . . . . . . . . . . 2.3 t -163.92 -177.68 5.22 Favored 'General case' 0 N--CA 1.471 0.589 0 N-CA-C 109.873 -0.417 . . . . 0.0 109.873 178.247 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . 85.97 70.47 1.32 Allowed Glycine 0 CA--C 1.532 1.125 0 CA-C-N 115.904 -0.589 . . . . 0.0 112.165 178.736 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 40.4 p90 -72.92 122.17 21.22 Favored 'General case' 0 N--CA 1.477 0.882 0 CA-C-N 117.331 0.565 . . . . 0.0 110.882 179.886 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 17.7 pt-20 -82.8 151.9 25.9 Favored 'General case' 0 N--CA 1.478 0.962 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 178.859 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 13.0 t -144.69 117.87 2.78 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.889 0 CA-C-O 121.621 0.724 . . . . 0.0 109.361 178.343 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 73.6 m80 -96.07 164.76 12.56 Favored 'General case' 0 C--N 1.358 0.947 0 CA-C-N 114.623 -1.171 . . . . 0.0 109.263 177.96 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' C' C ' 14' ' ' HIS . . . . . 0.455 ' NE2' ' NZ ' ' C' ' 16' ' ' LYS . 17.1 t60 -164.68 99.38 0.79 Allowed 'General case' 0 N--CA 1.476 0.83 0 N-CA-C 110.038 -0.356 . . . . 0.0 110.038 179.221 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -91.74 111.72 23.36 Favored 'General case' 0 CA--C 1.516 -0.359 0 N-CA-C 108.381 -0.97 . . . . 0.0 108.381 179.574 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' C' C ' 16' ' ' LYS . . . . . 0.455 ' NZ ' ' NE2' ' C' ' 14' ' ' HIS . 8.5 ttmm -94.51 171.45 8.8 Favored 'General case' 0 N--CA 1.483 1.185 0 N-CA-C 108.831 -0.803 . . . . 0.0 108.831 -179.841 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' C' C ' 17' ' ' LEU . . . . . 0.413 HD12 ' N ' ' C' ' 17' ' ' LEU . 9.7 mp -55.11 157.75 3.25 Favored 'General case' 0 N--CA 1.475 0.809 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 -178.424 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 71.3 t -140.75 150.43 20.69 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 C-N-CA 123.188 0.595 . . . . 0.0 109.663 -177.769 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' C' C ' 19' ' ' PHE . . . . . 0.709 ' HB3' ' O ' ' F' ' 18' ' ' VAL . 44.5 p90 -40.67 162.2 0.01 OUTLIER 'General case' 0 CA--C 1.543 0.677 0 N-CA-C 120.081 3.363 . . . . 0.0 120.081 -178.675 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' C' C ' 20' ' ' PHE . . . . . 0.414 ' O ' ' CD2' ' C' ' 20' ' ' PHE . 20.8 p90 -119.65 69.65 0.84 Allowed 'General case' 0 CA--C 1.562 1.437 0 CA-C-N 112.048 -2.342 . . . . 0.0 109.299 173.568 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' C' C ' 21' ' ' ALA . . . . . 0.423 ' H ' ' HD1' ' C' ' 19' ' ' PHE . . . -62.85 95.19 0.07 Allowed 'General case' 0 C--N 1.326 -0.454 0 N-CA-C 108.42 -0.956 . . . . 0.0 108.42 176.824 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 77.3 mt-10 -49.7 123.76 8.45 Favored 'General case' 0 N--CA 1.475 0.814 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.495 -179.862 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 16.5 t70 -76.63 169.16 18.8 Favored 'General case' 0 N--CA 1.472 0.631 0 CA-C-O 121.002 0.43 . . . . 0.0 110.713 -179.009 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' C' C ' 24' ' ' VAL . . . . . 0.506 HG13 ' H ' ' C' ' 25' ' ' GLY . 0.7 OUTLIER 178.25 -79.28 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.544 0.729 0 N-CA-C 107.458 -1.312 . . . . 0.0 107.458 -179.658 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' C' C ' 25' ' ' GLY . . . . . 0.506 ' H ' HG13 ' C' ' 24' ' ' VAL . . . -34.09 84.25 0.0 OUTLIER Glycine 0 N--CA 1.48 1.62 0 C-N-CA 124.356 0.979 . . . . 0.0 113.254 178.591 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' C' C ' 26' ' ' SER . . . . . 0.451 ' N ' ' O ' ' C' ' 24' ' ' VAL . 88.7 p -41.15 -105.25 0.0 OUTLIER 'General case' 0 N--CA 1.473 0.702 0 N-CA-C 113.692 0.997 . . . . 0.0 113.692 -177.334 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 16.6 p-10 -59.98 112.21 1.78 Allowed 'General case' 0 N--CA 1.468 0.474 0 CA-C-N 118.874 0.761 . . . . 0.0 110.381 -178.632 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 41.7 mttm -96.55 164.51 12.58 Favored 'General case' 0 N--CA 1.475 0.78 0 C-N-CA 123.204 0.602 . . . . 0.0 110.113 -179.53 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -72.87 -141.31 0.44 Allowed Glycine 0 N--CA 1.462 0.398 0 N-CA-C 107.769 -2.132 . . . . 0.0 107.769 176.535 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' C' C ' 30' ' ' ALA . . . . . 0.489 ' O ' ' O ' ' F' ' 31' ' ' ILE . . . -90.68 123.16 34.07 Favored 'General case' 0 C--O 1.211 -0.968 0 N-CA-C 106.775 -1.565 . . . . 0.0 106.775 176.58 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 16.6 tt -148.08 155.59 9.7 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.889 0 N-CA-C 107.888 -1.153 . . . . 0.0 107.888 179.186 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 20.2 pt -150.79 138.85 14.28 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.469 0 CA-C-N 118.943 0.792 . . . . 0.0 109.266 178.674 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -56.78 154.3 18.17 Favored Glycine 0 CA--C 1.531 1.088 0 CA-C-N 116.606 -0.27 . . . . 0.0 112.56 -178.656 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 2.5 pp -76.32 158.76 31.19 Favored 'General case' 0 N--CA 1.472 0.644 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 179.232 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 11.6 ttp -102.58 151.47 22.3 Favored 'General case' 0 N--CA 1.481 1.091 0 N-CA-C 109.449 -0.574 . . . . 0.0 109.449 179.649 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 7.3 p -168.55 159.88 0.71 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.542 0 N-CA-C 108.038 -1.097 . . . . 0.0 108.038 179.764 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 55.45 69.69 1.19 Allowed Glycine 0 C--N 1.312 -0.774 0 N-CA-C 111.611 -0.596 . . . . 0.0 111.611 178.826 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 151.95 -177.82 29.57 Favored Glycine 0 N--CA 1.468 0.792 0 N-CA-C 110.25 -1.14 . . . . 0.0 110.25 179.669 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 4.4 t -124.57 138.8 52.81 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.722 0 N-CA-C 107.335 -1.358 . . . . 0.0 107.335 -179.445 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 74.3 t . . . . . 0 N--CA 1.48 1.032 0 CA-C-O 117.771 -1.109 . . . . 0.0 109.696 -177.589 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' D' D ' 1' ' ' ASP . . . . . 0.415 ' HB3' ' H2 ' ' G' ' 1' ' ' ASP . 3.9 p-10 . . . . . 0 N--CA 1.487 1.396 0 N-CA-C 109.013 -0.736 . . . . 0.0 109.013 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' D' D ' 2' ' ' ALA . . . . . . . . . . . . . . . -64.62 131.75 47.86 Favored 'General case' 0 N--CA 1.469 0.485 0 CA-C-N 116.501 -0.318 . . . . 0.0 111.441 -179.675 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' D' D ' 3' ' ' GLU . . . . . . . . . . . . . 13.2 pt-20 -169.65 108.24 0.4 Allowed 'General case' 0 CA--C 1.542 0.646 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.208 179.114 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' D' D ' 4' ' ' PHE . . . . . . . . . . . . . 30.0 m-85 -88.09 159.89 18.04 Favored 'General case' 0 N--CA 1.475 0.784 0 N-CA-C 109.117 -0.698 . . . . 0.0 109.117 -179.318 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' D' D ' 5' ' ' ARG . . . . . . . . . . . . . 76.7 mtt85 -140.11 141.91 36.09 Favored 'General case' 0 N--CA 1.474 0.761 0 C-N-CA 123.974 0.909 . . . . 0.0 110.559 -178.702 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' D' D ' 6' ' ' HIS . . . . . . . . . . . . . 54.3 t-80 -148.63 123.39 9.89 Favored 'General case' 0 CA--C 1.547 0.852 0 N-CA-C 107.86 -1.163 . . . . 0.0 107.86 174.848 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' D' D ' 7' ' ' ASP . . . . . . . . . . . . . 8.8 m-20 -63.47 133.17 53.45 Favored 'General case' 0 N--CA 1.469 0.496 0 C-N-CA 126.9 2.08 . . . . 0.0 114.15 176.313 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' D' D ' 8' ' ' SER . . . . . . . . . . . . . 2.4 t -154.35 -177.31 6.36 Favored 'General case' 0 N--CA 1.473 0.712 0 CA-C-N 118.895 0.771 . . . . 0.0 110.555 176.242 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . 88.11 69.45 1.28 Allowed Glycine 0 N--CA 1.475 1.279 0 N-CA-C 111.33 -0.708 . . . . 0.0 111.33 174.523 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 35.2 p90 -70.82 124.34 24.09 Favored 'General case' 0 N--CA 1.476 0.837 0 CA-C-N 118.134 0.967 . . . . 0.0 110.507 -179.907 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 17.6 pt-20 -81.0 154.04 27.12 Favored 'General case' 0 C--N 1.363 1.162 0 C-N-CA 119.982 -0.687 . . . . 0.0 109.948 175.935 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 21.8 t -141.29 124.07 15.21 Favored 'Isoleucine or valine' 0 C--N 1.357 0.925 0 N-CA-C 107.945 -1.131 . . . . 0.0 107.945 171.011 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 61.5 m80 -89.03 164.37 15.1 Favored 'General case' 0 N--CA 1.472 0.657 0 C-N-CA 125.229 1.412 . . . . 0.0 112.607 171.865 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' D' D ' 14' ' ' HIS . . . . . 0.45 ' NE2' ' NZ ' ' D' ' 16' ' ' LYS . 17.1 t60 -163.82 104.91 0.92 Allowed 'General case' 0 N--CA 1.478 0.949 0 N-CA-C 109.0 -0.741 . . . . 0.0 109.0 171.671 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -95.24 111.45 23.3 Favored 'General case' 0 C--O 1.218 -0.59 0 N-CA-C 107.913 -1.143 . . . . 0.0 107.913 178.885 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' D' D ' 16' ' ' LYS . . . . . 0.45 ' NZ ' ' NE2' ' D' ' 14' ' ' HIS . 8.6 ttmm -95.49 169.93 9.7 Favored 'General case' 0 N--CA 1.487 1.409 0 C-N-CA 125.749 1.619 . . . . 0.0 108.715 -178.385 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 10.7 mp -65.79 156.23 33.82 Favored 'General case' 0 C--O 1.21 -0.975 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 -172.779 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' D' D ' 18' ' ' VAL . . . . . 0.69 ' O ' ' HB3' ' A' ' 19' ' ' PHE . 88.5 t -139.74 146.72 24.79 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.143 0 C-N-CA 126.183 1.793 . . . . 0.0 109.015 -168.808 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' D' D ' 19' ' ' PHE . . . . . 0.757 ' HB3' ' O ' ' G' ' 18' ' ' VAL 0.485 37.4 p90 -57.67 162.4 3.09 Favored 'General case' 0 C--N 1.391 2.403 0 N-CA-C 118.552 2.797 . . . . 0.0 118.552 -169.325 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' D' D ' 20' ' ' PHE . . . . . 0.404 ' O ' ' CD2' ' D' ' 20' ' ' PHE . 21.5 p90 -114.48 66.24 0.68 Allowed 'General case' 0 C--N 1.375 1.684 0 CA-C-N 112.958 -1.928 . . . . 0.0 110.608 -178.781 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' D' D ' 21' ' ' ALA . . . . . 0.45 ' H ' ' HD1' ' D' ' 19' ' ' PHE . . . -50.2 92.47 0.01 OUTLIER 'General case' 0 N--CA 1.441 -0.91 0 CA-C-N 113.448 -1.705 . . . . 0.0 110.669 173.675 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 77.0 mt-10 -52.69 125.53 16.98 Favored 'General case' 0 CA--C 1.547 0.843 0 CA-C-N 118.881 0.764 . . . . 0.0 110.306 -179.652 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 14.6 t70 -78.04 168.75 19.39 Favored 'General case' 0 N--CA 1.475 0.802 0 C-N-CA 122.764 0.426 . . . . 0.0 110.163 -179.747 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' D' D ' 24' ' ' VAL . . . . . 0.468 HG13 ' H ' ' D' ' 25' ' ' GLY 0.624 2.7 p -179.4 -100.54 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.203 -1.395 0 CA-C-O 125.938 2.78 . . . . 0.0 106.256 -164.685 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' D' D ' 25' ' ' GLY . . . . . 0.468 ' H ' HG13 ' D' ' 24' ' ' VAL . . . -24.32 71.59 0.0 OUTLIER Glycine 0 C--N 1.3 -1.46 0 C-N-CA 129.459 3.409 . . . . 0.0 116.907 178.476 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' D' D ' 26' ' ' SER . . . . . 0.412 ' OG ' ' N ' ' D' ' 27' ' ' ASN 0.381 78.9 p -52.69 -100.46 0.0 OUTLIER 'General case' 0 C--O 1.273 2.318 1 CA-C-O 110.787 -4.435 . . . . 0.0 107.203 -162.704 . . . . . . . . 4 3 . 1 . 020 nuclear nobuild full ' D' D ' 27' ' ' ASN . . . . . 0.503 ' OD1' ' N ' ' D' ' 27' ' ' ASN 0.409 11.7 p-10 -70.38 121.87 18.53 Favored 'General case' 0 N--CA 1.481 1.109 1 CA-C-N 129.149 5.431 . . . . 0.0 108.818 -168.719 . . . . . . . . 4 3 . 1 . 020 nuclear nobuild full ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 31.7 mttm -86.24 161.18 18.92 Favored 'General case' 0 C--N 1.364 1.23 0 CA-C-N 110.65 -2.977 . . . . 0.0 113.104 177.762 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -66.89 -145.13 0.07 OUTLIER Glycine 0 CA--C 1.535 1.331 0 N-CA-C 108.997 -1.641 . . . . 0.0 108.997 167.354 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' D' D ' 30' ' ' ALA . . . . . 0.489 ' O ' ' O ' ' G' ' 31' ' ' ILE . . . -92.12 123.45 35.47 Favored 'General case' 0 C--N 1.358 0.945 0 N-CA-C 106.708 -1.59 . . . . 0.0 106.708 174.207 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' D' D ' 31' ' ' ILE . . . . . 0.458 ' O ' ' O ' ' A' ' 30' ' ' ALA . 17.3 tt -144.73 155.42 14.42 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.451 0 N-CA-C 109.107 -0.701 . . . . 0.0 109.107 178.959 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 23.4 pt -150.99 135.31 8.94 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.912 0 CA-C-N 118.402 0.546 . . . . 0.0 110.035 178.939 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -52.85 153.9 6.47 Favored Glycine 0 N--CA 1.476 1.317 0 CA-C-N 116.32 -0.4 . . . . 0.0 112.891 -179.492 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 2.5 pp -76.46 159.85 30.05 Favored 'General case' 0 N--CA 1.473 0.677 0 N-CA-C 110.0 -0.37 . . . . 0.0 110.0 178.433 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 8.2 ttp -103.38 155.14 18.7 Favored 'General case' 0 N--CA 1.48 1.06 0 N-CA-C 108.655 -0.868 . . . . 0.0 108.655 178.781 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 6.7 p -167.04 163.73 0.58 Allowed 'Isoleucine or valine' 0 CA--C 1.507 -0.708 0 N-CA-C 107.456 -1.313 . . . . 0.0 107.456 177.054 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 59.32 63.9 4.74 Favored Glycine 0 C--N 1.319 -0.364 0 C-N-CA 118.733 -1.699 . . . . 0.0 113.143 174.397 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 148.4 179.73 24.58 Favored Glycine 0 N--CA 1.471 1.026 0 CA-C-N 118.0 0.9 . . . . 0.0 111.225 -177.175 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 5.5 t -122.2 138.42 52.47 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.86 0 N-CA-C 106.412 -1.699 . . . . 0.0 106.412 -177.546 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 77.1 t . . . . . 0 C--O 1.212 -0.887 0 N-CA-C 108.224 -1.028 . . . . 0.0 108.224 178.886 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' E' E ' 1' ' ' ASP . . . . . . . . . . . . . 4.0 p-10 . . . . . 0 N--CA 1.485 1.321 0 N-CA-C 109.189 -0.671 . . . . 0.0 109.189 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' E' E ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.12 131.09 45.64 Favored 'General case' 0 CA--C 1.539 0.543 0 CA-C-O 120.835 0.35 . . . . 0.0 111.244 -179.265 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' E' E ' 3' ' ' GLU . . . . . . . . . . . . . 13.3 pt-20 -170.01 108.76 0.38 Allowed 'General case' 0 CA--C 1.543 0.709 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.059 179.397 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' E' E ' 4' ' ' PHE . . . . . . . . . . . . . 27.7 m-85 -86.74 156.67 19.85 Favored 'General case' 0 N--CA 1.474 0.727 0 O-C-N 121.935 -0.478 . . . . 0.0 109.822 -179.696 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' E' E ' 5' ' ' ARG . . . . . . . . . . . . . 76.9 mtt85 -139.71 145.75 38.74 Favored 'General case' 0 N--CA 1.477 0.917 0 CA-C-N 115.978 -0.556 . . . . 0.0 110.015 179.378 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' E' E ' 6' ' ' HIS . . . . . . . . . . . . . 57.9 t-80 -150.52 116.44 5.58 Favored 'General case' 0 N--CA 1.475 0.796 0 N-CA-C 109.472 -0.566 . . . . 0.0 109.472 179.239 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' E' E ' 7' ' ' ASP . . . . . . . . . . . . . 9.7 m-20 -66.11 148.64 51.51 Favored 'General case' 0 N--CA 1.47 0.549 0 O-C-N 123.259 0.349 . . . . 0.0 111.136 -179.825 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' E' E ' 8' ' ' SER . . . . . . . . . . . . . 2.2 t -167.45 -178.04 3.83 Favored 'General case' 0 N--CA 1.471 0.611 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 178.28 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . 86.11 70.21 1.32 Allowed Glycine 0 CA--C 1.533 1.168 0 CA-C-N 115.964 -0.562 . . . . 0.0 112.089 178.779 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 34.2 p90 -71.65 121.87 19.58 Favored 'General case' 0 N--CA 1.479 1.008 0 CA-C-N 117.52 0.66 . . . . 0.0 110.771 179.704 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 17.4 pt-20 -83.01 152.77 25.27 Favored 'General case' 0 N--CA 1.482 1.159 0 N-CA-C 109.405 -0.591 . . . . 0.0 109.405 178.136 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 19.2 t -144.83 117.03 2.35 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.667 0 N-CA-C 109.478 -0.564 . . . . 0.0 109.478 178.831 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 73.8 m80 -95.33 165.89 12.16 Favored 'General case' 0 N--CA 1.475 0.794 0 N-CA-C 109.701 -0.481 . . . . 0.0 109.701 178.588 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' E' E ' 14' ' ' HIS . . . . . 0.447 ' NE2' ' NZ ' ' E' ' 16' ' ' LYS . 16.5 t60 -164.71 99.12 0.78 Allowed 'General case' 0 N--CA 1.478 0.971 0 N-CA-C 110.095 -0.335 . . . . 0.0 110.095 179.327 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -92.06 110.96 22.33 Favored 'General case' 0 CA--C 1.511 -0.548 0 N-CA-C 108.442 -0.948 . . . . 0.0 108.442 179.721 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' E' E ' 16' ' ' LYS . . . . . 0.447 ' NZ ' ' NE2' ' E' ' 14' ' ' HIS . 9.5 ttmm -93.53 172.04 8.52 Favored 'General case' 0 N--CA 1.485 1.303 0 N-CA-C 109.279 -0.638 . . . . 0.0 109.279 179.999 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' E' E ' 17' ' ' LEU . . . . . 0.438 ' N ' HD12 ' E' ' 17' ' ' LEU . 9.2 mp -55.11 155.98 4.32 Favored 'General case' 0 C--O 1.216 -0.693 0 N-CA-C 109.981 -0.377 . . . . 0.0 109.981 -178.599 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' E' E ' 18' ' ' VAL . . . . . 0.704 ' O ' ' HB3' ' B' ' 19' ' ' PHE . 79.5 t -141.48 150.61 19.62 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.966 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 -178.475 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' E' E ' 19' ' ' PHE . . . . . 0.735 ' HB3' ' O ' ' H' ' 18' ' ' VAL . 38.9 p90 -43.69 153.95 0.11 Allowed 'General case' 0 C--N 1.385 2.139 0 N-CA-C 120.387 3.477 . . . . 0.0 120.387 -177.216 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' E' E ' 20' ' ' PHE . . . . . 0.403 ' CD2' ' O ' ' E' ' 20' ' ' PHE . 20.8 p90 -111.62 66.95 0.64 Allowed 'General case' 0 N--CA 1.484 1.243 0 CA-C-N 113.938 -1.483 . . . . 0.0 111.495 175.007 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' E' E ' 21' ' ' ALA . . . . . 0.409 ' H ' ' HD1' ' E' ' 19' ' ' PHE . . . -58.64 93.96 0.02 OUTLIER 'General case' 0 N--CA 1.441 -0.919 0 CA-C-N 114.133 -1.394 . . . . 0.0 109.212 177.919 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 76.1 mt-10 -50.0 122.16 6.33 Favored 'General case' 0 N--CA 1.474 0.749 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.25 -179.712 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 18.4 t70 -75.03 173.51 10.62 Favored 'General case' 0 N--CA 1.466 0.349 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 -178.823 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' E' E ' 24' ' ' VAL . . . . . 0.526 HG13 ' H ' ' E' ' 25' ' ' GLY . 0.9 OUTLIER 173.71 -77.9 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.472 0.656 0 N-CA-C 107.896 -1.15 . . . . 0.0 107.896 -179.925 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' E' E ' 25' ' ' GLY . . . . . 0.526 ' H ' HG13 ' E' ' 24' ' ' VAL . . . -36.51 84.47 0.0 OUTLIER Glycine 0 CA--C 1.538 1.523 0 C-N-CA 124.102 0.858 . . . . 0.0 113.396 179.132 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' E' E ' 26' ' ' SER . . . . . 0.451 ' N ' ' O ' ' E' ' 24' ' ' VAL . 95.2 p -40.81 -107.11 0.0 OUTLIER 'General case' 0 N--CA 1.482 1.133 0 N-CA-C 114.25 1.204 . . . . 0.0 114.25 -177.544 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 16.5 p-10 -58.36 111.57 1.27 Allowed 'General case' 0 N--CA 1.473 0.688 0 CA-C-N 118.858 0.754 . . . . 0.0 110.067 -178.664 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 39.1 mttm -95.15 167.82 11.13 Favored 'General case' 0 N--CA 1.476 0.851 0 O-C-N 123.786 0.679 . . . . 0.0 109.588 -179.592 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -76.14 -140.17 0.94 Allowed Glycine 0 CA--C 1.524 0.652 0 N-CA-C 106.996 -2.441 . . . . 0.0 106.996 176.396 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' E' E ' 30' ' ' ALA . . . . . 0.458 ' O ' ' O ' ' H' ' 31' ' ' ILE . . . -91.82 126.34 36.87 Favored 'General case' 0 C--O 1.215 -0.723 0 N-CA-C 106.507 -1.664 . . . . 0.0 106.507 175.682 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' E' E ' 31' ' ' ILE . . . . . 0.491 ' O ' ' O ' ' B' ' 30' ' ' ALA . 16.6 tt -149.87 155.62 7.81 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.604 0 N-CA-C 108.077 -1.083 . . . . 0.0 108.077 179.07 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 19.2 pt -152.61 138.14 11.21 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.628 0 N-CA-C 109.096 -0.705 . . . . 0.0 109.096 -179.509 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -57.56 154.65 20.98 Favored Glycine 0 N--CA 1.474 1.174 0 CA-C-N 115.407 -0.815 . . . . 0.0 112.66 -177.851 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 2.5 pp -75.98 160.32 29.97 Favored 'General case' 0 N--CA 1.469 0.505 0 N-CA-C 109.64 -0.504 . . . . 0.0 109.64 179.244 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 7.7 ttp -104.91 151.95 23.24 Favored 'General case' 0 N--CA 1.48 1.052 0 N-CA-C 109.259 -0.645 . . . . 0.0 109.259 179.454 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 7.5 p -168.13 159.93 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.446 -0.641 0 N-CA-C 107.844 -1.169 . . . . 0.0 107.844 179.744 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . 53.85 70.87 0.81 Allowed Glycine 0 C--N 1.313 -0.72 0 O-C-N 123.381 0.426 . . . . 0.0 112.328 179.365 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 153.06 -177.14 30.86 Favored Glycine 0 N--CA 1.461 0.367 0 N-CA-C 110.131 -1.188 . . . . 0.0 110.131 179.556 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 5.5 t -126.7 137.08 58.93 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.361 0 N-CA-C 106.259 -1.756 . . . . 0.0 106.259 -178.867 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 75.1 t . . . . . 0 N--CA 1.474 0.754 0 CA-C-O 117.649 -1.167 . . . . 0.0 109.504 -176.889 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' F' F ' 1' ' ' ASP . . . . . 0.416 ' H2 ' ' HB3' ' C' ' 1' ' ' ASP . 4.0 p-10 . . . . . 0 N--CA 1.487 1.398 0 N-CA-C 109.157 -0.682 . . . . 0.0 109.157 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' F' F ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.14 131.26 46.07 Favored 'General case' 0 CA--C 1.539 0.554 0 CA-C-O 120.808 0.337 . . . . 0.0 111.132 -179.206 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' F' F ' 3' ' ' GLU . . . . . . . . . . . . . 13.3 pt-20 -170.17 108.73 0.37 Allowed 'General case' 0 CA--C 1.545 0.767 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.002 179.436 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' F' F ' 4' ' ' PHE . . . . . . . . . . . . . 27.7 m-85 -86.76 156.66 19.84 Favored 'General case' 0 N--CA 1.472 0.672 0 N-CA-C 109.676 -0.49 . . . . 0.0 109.676 -179.673 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' F' F ' 5' ' ' ARG . . . . . . . . . . . . . 76.8 mtt85 -139.61 145.34 38.4 Favored 'General case' 0 N--CA 1.479 0.98 0 CA-C-N 115.861 -0.609 . . . . 0.0 109.96 179.427 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' F' F ' 6' ' ' HIS . . . . . . . . . . . . . 57.7 t-80 -150.33 116.31 5.61 Favored 'General case' 0 N--CA 1.475 0.776 0 N-CA-C 109.61 -0.515 . . . . 0.0 109.61 179.158 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' F' F ' 7' ' ' ASP . . . . . . . . . . . . . 9.8 m-20 -65.84 148.42 51.81 Favored 'General case' 0 N--CA 1.469 0.515 0 O-C-N 123.261 0.351 . . . . 0.0 111.301 -179.813 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' F' F ' 8' ' ' SER . . . . . . . . . . . . . 2.2 t -167.37 -178.0 3.85 Favored 'General case' 0 N--CA 1.471 0.59 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 178.214 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . 86.25 70.15 1.32 Allowed Glycine 0 CA--C 1.532 1.143 0 CA-C-N 115.972 -0.558 . . . . 0.0 112.113 178.734 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 34.6 p90 -71.7 121.71 19.34 Favored 'General case' 0 N--CA 1.476 0.858 0 CA-C-N 117.514 0.657 . . . . 0.0 110.95 179.739 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 17.4 pt-20 -82.79 152.69 25.57 Favored 'General case' 0 N--CA 1.481 1.116 0 N-CA-C 109.399 -0.593 . . . . 0.0 109.399 178.156 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 19.3 t -144.83 117.02 2.35 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.635 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 178.795 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 73.8 m80 -95.3 165.94 12.14 Favored 'General case' 0 N--CA 1.476 0.871 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 178.534 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' F' F ' 14' ' ' HIS . . . . . 0.456 ' NE2' ' NZ ' ' F' ' 16' ' ' LYS . 16.4 t60 -164.66 98.86 0.79 Allowed 'General case' 0 N--CA 1.478 0.969 0 N-CA-C 110.224 -0.287 . . . . 0.0 110.224 179.394 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -91.74 110.93 22.27 Favored 'General case' 0 CA--C 1.507 -0.693 0 N-CA-C 108.376 -0.972 . . . . 0.0 108.376 179.655 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' F' F ' 16' ' ' LYS . . . . . 0.456 ' NZ ' ' NE2' ' F' ' 14' ' ' HIS . 9.7 ttmm -93.59 171.75 8.7 Favored 'General case' 0 N--CA 1.484 1.258 0 N-CA-C 109.224 -0.658 . . . . 0.0 109.224 179.919 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' F' F ' 17' ' ' LEU . . . . . 0.433 HD12 ' N ' ' F' ' 17' ' ' LEU . 9.2 mp -54.8 155.84 4.05 Favored 'General case' 0 N--CA 1.472 0.671 0 N-CA-C 110.044 -0.354 . . . . 0.0 110.044 -178.625 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' F' F ' 18' ' ' VAL . . . . . 0.709 ' O ' ' HB3' ' C' ' 19' ' ' PHE . 79.0 t -141.43 150.49 19.75 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.955 0 N-CA-C 107.929 -1.138 . . . . 0.0 107.929 -178.409 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' F' F ' 19' ' ' PHE . . . . . 0.745 ' HB3' ' O ' ' I' ' 18' ' ' VAL . 38.6 p90 -43.48 153.63 0.11 Allowed 'General case' 0 C--N 1.384 2.101 0 N-CA-C 120.41 3.485 . . . . 0.0 120.41 -177.232 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' F' F ' 20' ' ' PHE . . . . . 0.415 ' O ' ' CD2' ' F' ' 20' ' ' PHE . 20.1 p90 -111.46 67.25 0.64 Allowed 'General case' 0 N--CA 1.48 1.053 0 CA-C-N 113.947 -1.479 . . . . 0.0 111.538 175.029 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' F' F ' 21' ' ' ALA . . . . . 0.402 ' H ' ' HD1' ' F' ' 19' ' ' PHE . . . -58.82 94.27 0.02 OUTLIER 'General case' 0 C--N 1.317 -0.843 0 CA-C-N 114.211 -1.359 . . . . 0.0 109.262 178.074 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 76.5 mt-10 -50.29 122.28 6.71 Favored 'General case' 0 N--CA 1.476 0.85 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.296 -179.743 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 18.2 t70 -75.06 173.54 10.6 Favored 'General case' 0 N--CA 1.468 0.429 0 N-CA-C 110.031 -0.359 . . . . 0.0 110.031 -178.852 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' F' F ' 24' ' ' VAL . . . . . 0.527 HG13 ' H ' ' F' ' 25' ' ' GLY . 0.9 OUTLIER 173.83 -78.35 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.728 0 N-CA-C 107.934 -1.136 . . . . 0.0 107.934 -179.828 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' F' F ' 25' ' ' GLY . . . . . 0.527 ' H ' HG13 ' F' ' 24' ' ' VAL . . . -36.7 84.95 0.01 OUTLIER Glycine 0 CA--C 1.536 1.382 0 C-N-CA 124.045 0.831 . . . . 0.0 113.354 179.294 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' F' F ' 26' ' ' SER . . . . . 0.45 ' N ' ' O ' ' F' ' 24' ' ' VAL . 96.0 p -40.82 -107.11 0.0 OUTLIER 'General case' 0 N--CA 1.479 0.989 0 N-CA-C 114.19 1.181 . . . . 0.0 114.19 -177.696 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 16.6 p-10 -58.42 111.55 1.27 Allowed 'General case' 0 N--CA 1.472 0.654 0 CA-C-N 118.804 0.729 . . . . 0.0 110.171 -178.69 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 38.9 mttm -95.08 167.71 11.21 Favored 'General case' 0 N--CA 1.477 0.918 0 C-N-CA 123.392 0.677 . . . . 0.0 109.597 -179.553 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -76.03 -139.98 0.9 Allowed Glycine 0 CA--C 1.525 0.702 0 N-CA-C 107.113 -2.395 . . . . 0.0 107.113 176.403 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' F' F ' 30' ' ' ALA . . . . . 0.456 ' O ' ' O ' ' I' ' 31' ' ' ILE . . . -91.97 126.37 37.03 Favored 'General case' 0 N--CA 1.472 0.635 0 N-CA-C 106.227 -1.768 . . . . 0.0 106.227 175.706 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' F' F ' 31' ' ' ILE . . . . . 0.489 ' O ' ' O ' ' C' ' 30' ' ' ALA . 16.6 tt -150.01 155.29 8.01 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.619 0 N-CA-C 108.078 -1.082 . . . . 0.0 108.078 179.221 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 19.3 pt -152.48 138.34 11.7 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.651 0 N-CA-C 109.157 -0.683 . . . . 0.0 109.157 -179.482 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -57.63 154.54 21.62 Favored Glycine 0 N--CA 1.474 1.18 0 CA-C-N 115.421 -0.808 . . . . 0.0 112.622 -177.74 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 2.5 pp -75.96 160.51 29.8 Favored 'General case' 0 N--CA 1.47 0.543 0 N-CA-C 109.58 -0.526 . . . . 0.0 109.58 179.14 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 7.6 ttp -105.15 152.08 23.24 Favored 'General case' 0 N--CA 1.479 0.986 0 N-CA-C 109.313 -0.625 . . . . 0.0 109.313 179.528 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 7.5 p -168.19 160.23 0.72 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.625 0 N-CA-C 107.837 -1.172 . . . . 0.0 107.837 179.631 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . 53.76 70.89 0.8 Allowed Glycine 0 C--N 1.313 -0.745 0 O-C-N 123.448 0.467 . . . . 0.0 112.425 179.4 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 152.97 -177.19 30.77 Favored Glycine 0 N--CA 1.461 0.364 0 N-CA-C 110.08 -1.208 . . . . 0.0 110.08 179.538 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 5.3 t -126.45 136.81 59.7 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.347 0 N-CA-C 106.242 -1.762 . . . . 0.0 106.242 -178.852 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 76.4 t . . . . . 0 N--CA 1.47 0.567 0 CA-C-O 117.597 -1.192 . . . . 0.0 109.692 -176.926 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' G' G ' 1' ' ' ASP . . . . . 0.415 ' H2 ' ' HB3' ' D' ' 1' ' ' ASP . 4.1 p-10 . . . . . 0 N--CA 1.486 1.337 0 N-CA-C 108.508 -0.923 . . . . 0.0 108.508 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' G' G ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.61 132.82 49.77 Favored 'General case' 0 CA--C 1.538 0.505 0 CA-C-O 120.828 0.347 . . . . 0.0 110.97 -178.906 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' G' G ' 3' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -170.2 108.74 0.37 Allowed 'General case' 0 CA--C 1.544 0.727 0 N-CA-C 109.636 -0.505 . . . . 0.0 109.636 179.63 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' G' G ' 4' ' ' PHE . . . . . . . . . . . . . 30.3 m-85 -85.87 156.94 20.33 Favored 'General case' 0 N--CA 1.474 0.748 0 O-C-N 122.015 -0.428 . . . . 0.0 109.849 -179.342 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' G' G ' 5' ' ' ARG . . . . . . . . . . . . . 77.0 mtt85 -140.01 145.14 37.41 Favored 'General case' 0 N--CA 1.481 1.095 0 N-CA-C 109.688 -0.486 . . . . 0.0 109.688 179.515 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' G' G ' 6' ' ' HIS . . . . . . . . . . . . . 58.7 t-80 -150.03 117.38 6.06 Favored 'General case' 0 N--CA 1.473 0.675 0 N-CA-C 109.209 -0.663 . . . . 0.0 109.209 179.217 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' G' G ' 7' ' ' ASP . . . . . . . . . . . . . 12.4 m-20 -66.89 148.39 52.0 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.961 -179.83 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' G' G ' 8' ' ' SER . . . . . . . . . . . . . 3.5 t -166.93 -179.38 4.67 Favored 'General case' 0 N--CA 1.472 0.674 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.095 178.342 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . 85.44 71.95 1.3 Allowed Glycine 0 N--CA 1.477 1.406 0 CA-C-N 116.144 -0.48 . . . . 0.0 112.247 179.015 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 38.5 p90 -72.84 122.03 20.92 Favored 'General case' 0 N--CA 1.477 0.887 0 CA-C-N 117.098 0.449 . . . . 0.0 110.76 179.353 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 17.7 pt-20 -83.28 153.16 24.8 Favored 'General case' 0 N--CA 1.478 0.932 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 178.263 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 22.0 t -143.76 117.64 3.53 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.006 0 CA-C-O 118.527 -0.749 . . . . 0.0 109.032 179.003 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 76.7 m80 -95.42 167.36 11.37 Favored 'General case' 0 N--CA 1.486 1.374 0 CA-C-N 119.569 1.077 . . . . 0.0 109.521 178.597 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' G' G ' 14' ' ' HIS . . . . . 0.442 ' NE2' ' NZ ' ' G' ' 16' ' ' LYS . 16.1 t60 -164.42 98.1 0.8 Allowed 'General case' 0 N--CA 1.479 1.014 0 N-CA-C 110.061 -0.348 . . . . 0.0 110.061 179.216 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -91.63 111.67 23.28 Favored 'General case' 0 CA--C 1.509 -0.6 0 N-CA-C 107.904 -1.146 . . . . 0.0 107.904 179.479 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' G' G ' 16' ' ' LYS . . . . . 0.442 ' NZ ' ' NE2' ' G' ' 14' ' ' HIS . 9.1 ttmm -93.61 171.97 8.56 Favored 'General case' 0 N--CA 1.485 1.315 0 N-CA-C 109.314 -0.624 . . . . 0.0 109.314 -179.86 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' G' G ' 17' ' ' LEU . . . . . 0.411 ' N ' HD12 ' G' ' 17' ' ' LEU . 9.5 mp -55.14 152.24 8.23 Favored 'General case' 0 N--CA 1.471 0.606 0 CA-C-O 121.147 0.498 . . . . 0.0 110.366 -178.829 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' G' G ' 18' ' ' VAL . . . . . 0.757 ' O ' ' HB3' ' D' ' 19' ' ' PHE . 87.0 t -138.13 150.9 24.77 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.622 0 N-CA-C 107.635 -1.246 . . . . 0.0 107.635 -179.166 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' G' G ' 19' ' ' PHE . . . . . 0.475 ' O ' ' CG ' ' D' ' 19' ' ' PHE . 29.3 p90 -44.26 149.22 0.38 Allowed 'General case' 0 C--N 1.406 3.034 0 O-C-N 128.483 3.615 . . . . 0.0 117.721 -175.283 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' G' G ' 20' ' ' PHE . . . . . 0.401 ' CD2' ' O ' ' G' ' 20' ' ' PHE . 23.0 p90 -109.77 62.54 0.6 Allowed 'General case' 0 N--CA 1.496 1.855 0 CA-C-O 122.787 1.28 . . . . 0.0 112.681 177.685 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -53.66 94.3 0.01 OUTLIER 'General case' 0 N--CA 1.445 -0.709 0 CA-C-N 113.928 -1.487 . . . . 0.0 110.303 179.933 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 74.5 mt-10 -51.3 120.3 4.9 Favored 'General case' 0 CA--C 1.541 0.612 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.274 179.912 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 19.2 t70 -73.47 173.66 9.31 Favored 'General case' 0 N--CA 1.468 0.443 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 -178.905 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' G' G ' 24' ' ' VAL . . . . . 0.526 HG13 ' H ' ' G' ' 25' ' ' GLY . 0.9 OUTLIER 174.18 -79.19 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.755 0 N-CA-C 108.221 -1.029 . . . . 0.0 108.221 -179.773 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' G' G ' 25' ' ' GLY . . . . . 0.526 ' H ' HG13 ' G' ' 24' ' ' VAL . . . -37.51 85.91 0.01 OUTLIER Glycine 0 N--CA 1.479 1.54 0 C-N-CA 123.698 0.666 . . . . 0.0 113.171 179.658 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' G' G ' 26' ' ' SER . . . . . 0.441 ' N ' ' O ' ' G' ' 24' ' ' VAL . 90.6 p -40.95 -105.81 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.882 0 N-CA-C 113.877 1.066 . . . . 0.0 113.877 -177.506 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 16.9 p-10 -59.46 110.38 1.1 Allowed 'General case' 0 N--CA 1.473 0.71 0 CA-C-N 118.908 0.776 . . . . 0.0 110.63 -178.795 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 41.7 mttm -93.27 167.82 11.49 Favored 'General case' 0 N--CA 1.47 0.542 0 CA-C-N 115.823 -0.626 . . . . 0.0 109.669 -179.728 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -75.76 -140.28 0.87 Allowed Glycine 0 CA--C 1.525 0.698 0 N-CA-C 106.209 -2.757 . . . . 0.0 106.209 176.236 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -93.64 125.95 38.54 Favored 'General case' 0 N--CA 1.469 0.489 0 N-CA-C 107.154 -1.425 . . . . 0.0 107.154 176.23 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' G' G ' 31' ' ' ILE . . . . . 0.489 ' O ' ' O ' ' D' ' 30' ' ' ALA . 16.4 tt -149.86 155.37 8.04 Favored 'Isoleucine or valine' 0 C--O 1.211 -0.936 0 N-CA-C 108.783 -0.821 . . . . 0.0 108.783 179.786 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 26.7 pt -151.42 136.33 10.21 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.434 0 N-CA-C 109.287 -0.634 . . . . 0.0 109.287 -177.588 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -56.58 154.3 17.24 Favored Glycine 0 CA--C 1.526 0.76 0 CA-C-N 116.147 -0.479 . . . . 0.0 112.179 -178.543 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 2.5 pp -75.63 160.7 29.82 Favored 'General case' 0 N--CA 1.466 0.369 0 N-CA-C 109.499 -0.556 . . . . 0.0 109.499 179.313 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 6.6 ttp -104.78 152.21 22.84 Favored 'General case' 0 N--CA 1.48 1.046 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 179.378 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 7.4 p -168.69 162.22 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 N-CA-C 107.343 -1.355 . . . . 0.0 107.343 179.632 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 54.08 68.93 1.4 Allowed Glycine 0 C--N 1.312 -0.774 0 N-CA-C 111.848 -0.501 . . . . 0.0 111.848 178.77 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 152.66 -178.31 29.88 Favored Glycine 0 N--CA 1.465 0.581 0 N-CA-C 110.473 -1.051 . . . . 0.0 110.473 179.7 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 4.3 t -124.67 138.59 53.55 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.844 0 N-CA-C 107.098 -1.445 . . . . 0.0 107.098 -180.0 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 74.1 t . . . . . 0 N--CA 1.482 1.135 0 CA-C-O 117.788 -1.101 . . . . 0.0 109.8 -177.213 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' H' H ' 1' ' ' ASP . . . . . . . . . . . . . 4.0 p-10 . . . . . 0 N--CA 1.487 1.421 0 N-CA-C 108.509 -0.923 . . . . 0.0 108.509 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' H' H ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.74 132.99 50.08 Favored 'General case' 0 N--CA 1.469 0.495 0 CA-C-O 120.904 0.383 . . . . 0.0 110.94 -179.035 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' H' H ' 3' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -170.24 108.77 0.36 Allowed 'General case' 0 CA--C 1.542 0.661 0 N-CA-C 109.552 -0.536 . . . . 0.0 109.552 179.662 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' H' H ' 4' ' ' PHE . . . . . . . . . . . . . 31.6 m-85 -85.98 157.21 20.17 Favored 'General case' 0 N--CA 1.473 0.712 0 N-CA-C 109.641 -0.503 . . . . 0.0 109.641 -179.325 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' H' H ' 5' ' ' ARG . . . . . . . . . . . . . 77.1 mtt85 -140.26 145.31 37.15 Favored 'General case' 0 N--CA 1.479 0.979 0 C-N-CA 122.86 0.464 . . . . 0.0 109.801 179.485 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' H' H ' 6' ' ' HIS . . . . . . . . . . . . . 58.7 t-80 -150.28 117.59 6.04 Favored 'General case' 0 N--CA 1.475 0.786 0 N-CA-C 109.423 -0.584 . . . . 0.0 109.423 179.216 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' H' H ' 7' ' ' ASP . . . . . . . . . . . . . 12.6 m-20 -67.02 148.17 52.29 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-N 116.386 -0.37 . . . . 0.0 111.078 -179.79 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' H' H ' 8' ' ' SER . . . . . . . . . . . . . 3.5 t -166.86 -179.29 4.66 Favored 'General case' 0 N--CA 1.471 0.598 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.151 178.326 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . 85.36 71.68 1.31 Allowed Glycine 0 N--CA 1.477 1.406 0 CA-C-N 116.166 -0.47 . . . . 0.0 112.211 179.098 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 38.3 p90 -72.62 122.2 21.0 Favored 'General case' 0 N--CA 1.474 0.762 0 O-C-N 122.437 -0.449 . . . . 0.0 110.712 179.468 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 17.7 pt-20 -83.39 153.03 24.75 Favored 'General case' 0 N--CA 1.48 1.042 0 N-CA-C 109.294 -0.632 . . . . 0.0 109.294 178.37 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 21.8 t -143.81 116.83 3.12 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.029 0 CA-C-O 118.546 -0.74 . . . . 0.0 109.292 178.952 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 76.5 m80 -94.66 167.26 11.57 Favored 'General case' 0 N--CA 1.484 1.272 0 CA-C-N 119.441 1.018 . . . . 0.0 109.603 178.556 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' H' H ' 14' ' ' HIS . . . . . 0.442 ' NE2' ' NZ ' ' H' ' 16' ' ' LYS . 16.1 t60 -164.41 98.12 0.8 Allowed 'General case' 0 N--CA 1.479 0.979 0 N-CA-C 110.019 -0.363 . . . . 0.0 110.019 179.184 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -91.5 111.76 23.4 Favored 'General case' 0 CA--C 1.511 -0.544 0 N-CA-C 107.891 -1.151 . . . . 0.0 107.891 179.459 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' H' H ' 16' ' ' LYS . . . . . 0.442 ' NZ ' ' NE2' ' H' ' 14' ' ' HIS . 9.1 ttmm -93.72 172.06 8.49 Favored 'General case' 0 N--CA 1.486 1.338 0 N-CA-C 109.344 -0.613 . . . . 0.0 109.344 -179.768 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' H' H ' 17' ' ' LEU . . . . . 0.41 HD12 ' N ' ' H' ' 17' ' ' LEU . 9.4 mp -55.16 152.29 8.2 Favored 'General case' 0 N--CA 1.472 0.656 0 CA-C-O 121.152 0.501 . . . . 0.0 110.382 -178.921 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' H' H ' 18' ' ' VAL . . . . . 0.735 ' O ' ' HB3' ' E' ' 19' ' ' PHE . 89.0 t -138.23 151.15 24.71 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.711 0 N-CA-C 107.783 -1.191 . . . . 0.0 107.783 -179.158 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' H' H ' 19' ' ' PHE . . . . . 0.47 ' O ' ' CG ' ' E' ' 19' ' ' PHE . 29.5 p90 -44.73 149.0 0.45 Allowed 'General case' 0 C--N 1.406 3.033 0 O-C-N 128.487 3.617 . . . . 0.0 117.613 -175.055 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 23.3 p90 -109.56 62.45 0.6 Allowed 'General case' 0 N--CA 1.498 1.953 0 CA-C-O 122.758 1.266 . . . . 0.0 112.533 177.805 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -53.64 94.37 0.01 OUTLIER 'General case' 0 N--CA 1.446 -0.652 0 CA-C-N 113.954 -1.475 . . . . 0.0 110.211 179.947 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 74.8 mt-10 -51.45 120.18 4.85 Favored 'General case' 0 CA--C 1.541 0.62 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.297 179.91 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 19.0 t70 -73.47 173.34 9.77 Favored 'General case' 0 N--CA 1.466 0.355 0 N-CA-C 109.943 -0.391 . . . . 0.0 109.943 -178.897 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' H' H ' 24' ' ' VAL . . . . . 0.509 HG13 ' H ' ' H' ' 25' ' ' GLY . 0.9 OUTLIER 174.52 -79.16 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.542 0.661 0 N-CA-C 108.149 -1.056 . . . . 0.0 108.149 -179.693 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' H' H ' 25' ' ' GLY . . . . . 0.509 ' H ' HG13 ' H' ' 24' ' ' VAL . . . -37.33 85.74 0.01 OUTLIER Glycine 0 N--CA 1.478 1.455 0 C-N-CA 123.732 0.682 . . . . 0.0 113.269 179.646 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' H' H ' 26' ' ' SER . . . . . 0.437 ' N ' ' O ' ' H' ' 24' ' ' VAL . 89.5 p -40.64 -106.07 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.885 0 N-CA-C 113.614 0.968 . . . . 0.0 113.614 -177.789 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 17.0 p-10 -59.35 110.36 1.07 Allowed 'General case' 0 N--CA 1.473 0.686 0 CA-C-N 118.941 0.791 . . . . 0.0 110.68 -178.771 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 41.7 mttm -93.46 167.42 11.72 Favored 'General case' 0 N--CA 1.468 0.461 0 CA-C-N 115.757 -0.656 . . . . 0.0 109.701 -179.896 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -75.43 -140.22 0.79 Allowed Glycine 0 CA--C 1.524 0.645 0 N-CA-C 106.262 -2.735 . . . . 0.0 106.262 176.218 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -93.7 125.92 38.58 Favored 'General case' 0 N--CA 1.47 0.529 0 N-CA-C 107.14 -1.43 . . . . 0.0 107.14 176.342 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' H' H ' 31' ' ' ILE . . . . . 0.458 ' O ' ' O ' ' E' ' 30' ' ' ALA . 16.4 tt -150.02 155.32 7.97 Favored 'Isoleucine or valine' 0 C--O 1.213 -0.846 0 N-CA-C 108.658 -0.867 . . . . 0.0 108.658 179.673 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 27.3 pt -151.38 136.27 10.16 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.399 0 N-CA-C 109.243 -0.651 . . . . 0.0 109.243 -177.526 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -56.69 154.49 17.26 Favored Glycine 0 CA--C 1.528 0.854 0 CA-C-N 116.166 -0.47 . . . . 0.0 112.193 -178.442 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 2.5 pp -75.59 160.78 29.76 Favored 'General case' 0 N--CA 1.467 0.418 0 N-CA-C 109.515 -0.55 . . . . 0.0 109.515 179.37 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 6.5 ttp -104.83 152.17 22.93 Favored 'General case' 0 N--CA 1.48 1.027 0 N-CA-C 109.102 -0.703 . . . . 0.0 109.102 179.343 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 7.4 p -168.81 162.29 0.56 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.487 0 N-CA-C 107.209 -1.404 . . . . 0.0 107.209 179.639 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 54.14 68.87 1.43 Allowed Glycine 0 C--N 1.311 -0.828 0 N-CA-C 111.853 -0.499 . . . . 0.0 111.853 178.721 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 152.41 -178.26 29.7 Favored Glycine 0 N--CA 1.466 0.697 0 N-CA-C 110.564 -1.014 . . . . 0.0 110.564 179.781 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 4.4 t -124.58 138.58 53.54 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.788 0 N-CA-C 107.077 -1.453 . . . . 0.0 107.077 -179.931 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 75.2 t . . . . . 0 N--CA 1.483 1.217 0 CA-C-O 117.755 -1.117 . . . . 0.0 109.813 -177.254 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' I' I ' 1' ' ' ASP . . . . . 0.408 ' H2 ' ' HB3' ' F' ' 1' ' ' ASP . 4.0 p-10 . . . . . 0 N--CA 1.487 1.414 0 N-CA-C 108.509 -0.923 . . . . 0.0 108.509 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' I' I ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.68 132.83 49.75 Favored 'General case' 0 CA--C 1.538 0.494 0 CA-C-O 120.916 0.388 . . . . 0.0 110.883 -178.955 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' I' I ' 3' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -170.16 108.61 0.37 Allowed 'General case' 0 CA--C 1.542 0.659 0 CA-C-N 116.068 -0.515 . . . . 0.0 109.613 179.684 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' I' I ' 4' ' ' PHE . . . . . . . . . . . . . 31.0 m-85 -85.84 157.24 20.26 Favored 'General case' 0 N--CA 1.474 0.763 0 O-C-N 121.9 -0.5 . . . . 0.0 109.7 -179.293 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' I' I ' 5' ' ' ARG . . . . . . . . . . . . . 77.0 mtt85 -140.3 145.26 37.02 Favored 'General case' 0 N--CA 1.48 1.038 0 C-N-CA 122.896 0.478 . . . . 0.0 109.798 179.514 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' I' I ' 6' ' ' HIS . . . . . . . . . . . . . 58.7 t-80 -150.25 117.4 5.98 Favored 'General case' 0 N--CA 1.474 0.746 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 179.226 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' I' I ' 7' ' ' ASP . . . . . . . . . . . . . 12.3 m-20 -66.76 148.15 52.31 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-N 116.379 -0.373 . . . . 0.0 111.014 -179.848 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' I' I ' 8' ' ' SER . . . . . . . . . . . . . 3.5 t -166.81 -179.31 4.7 Favored 'General case' 0 N--CA 1.472 0.67 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.082 178.3 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . 85.36 71.72 1.31 Allowed Glycine 0 N--CA 1.476 1.355 0 CA-C-N 116.14 -0.482 . . . . 0.0 112.232 179.086 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 38.0 p90 -72.48 121.95 20.46 Favored 'General case' 0 N--CA 1.476 0.837 0 O-C-N 122.356 -0.496 . . . . 0.0 110.745 179.38 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 17.7 pt-20 -83.2 153.02 24.96 Favored 'General case' 0 N--CA 1.478 0.959 0 N-CA-C 109.279 -0.638 . . . . 0.0 109.279 178.361 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 21.8 t -143.78 116.83 3.14 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.097 0 CA-C-O 118.584 -0.722 . . . . 0.0 109.326 178.928 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 76.5 m80 -94.69 167.24 11.58 Favored 'General case' 0 N--CA 1.485 1.317 0 CA-C-N 119.505 1.048 . . . . 0.0 109.574 178.603 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' I' I ' 14' ' ' HIS . . . . . 0.446 ' NE2' ' NZ ' ' I' ' 16' ' ' LYS . 15.9 t60 -164.41 98.01 0.8 Allowed 'General case' 0 N--CA 1.479 0.991 0 N-CA-C 110.181 -0.303 . . . . 0.0 110.181 179.149 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -91.43 111.63 23.21 Favored 'General case' 0 CA--C 1.509 -0.632 0 N-CA-C 107.94 -1.133 . . . . 0.0 107.94 179.49 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' I' I ' 16' ' ' LYS . . . . . 0.446 ' NZ ' ' NE2' ' I' ' 14' ' ' HIS . 9.1 ttmm -93.62 172.11 8.47 Favored 'General case' 0 N--CA 1.485 1.304 0 N-CA-C 109.362 -0.607 . . . . 0.0 109.362 -179.778 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' I' I ' 17' ' ' LEU . . . . . 0.405 HD12 ' N ' ' I' ' 17' ' ' LEU . 9.5 mp -55.17 152.29 8.24 Favored 'General case' 0 N--CA 1.472 0.652 0 CA-C-O 121.15 0.5 . . . . 0.0 110.3 -178.857 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' I' I ' 18' ' ' VAL . . . . . 0.745 ' O ' ' HB3' ' F' ' 19' ' ' PHE . 88.8 t -138.21 151.28 24.86 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.634 0 N-CA-C 107.683 -1.228 . . . . 0.0 107.683 -179.218 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' I' I ' 19' ' ' PHE . . . . . 0.466 ' O ' ' CG ' ' F' ' 19' ' ' PHE . 29.1 p90 -44.83 148.93 0.47 Allowed 'General case' 0 C--N 1.407 3.093 0 O-C-N 128.378 3.549 . . . . 0.0 117.57 -175.06 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 23.2 p90 -109.5 62.48 0.6 Allowed 'General case' 0 N--CA 1.497 1.904 0 CA-C-O 122.764 1.268 . . . . 0.0 112.522 177.763 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -53.65 94.42 0.01 OUTLIER 'General case' 0 N--CA 1.446 -0.673 0 CA-C-N 113.901 -1.499 . . . . 0.0 110.201 179.947 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 74.5 mt-10 -51.4 120.17 4.82 Favored 'General case' 0 CA--C 1.541 0.634 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.375 179.929 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 18.9 t70 -73.52 173.13 10.11 Favored 'General case' 0 N--CA 1.467 0.404 0 N-CA-C 109.98 -0.378 . . . . 0.0 109.98 -178.9 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' I' I ' 24' ' ' VAL . . . . . 0.511 HG13 ' H ' ' I' ' 25' ' ' GLY . 0.9 OUTLIER 174.61 -79.24 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.544 0.738 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 -179.745 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' I' I ' 25' ' ' GLY . . . . . 0.511 ' H ' HG13 ' I' ' 24' ' ' VAL . . . -37.29 85.87 0.01 OUTLIER Glycine 0 N--CA 1.48 1.63 0 C-N-CA 123.61 0.624 . . . . 0.0 113.229 179.636 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' I' I ' 26' ' ' SER . . . . . 0.44 ' N ' ' O ' ' I' ' 24' ' ' VAL . 87.7 p -40.77 -105.58 0.0 OUTLIER 'General case' 0 N--CA 1.478 0.949 0 N-CA-C 113.6 0.963 . . . . 0.0 113.6 -177.748 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 17.0 p-10 -59.68 110.4 1.13 Allowed 'General case' 0 N--CA 1.473 0.688 0 CA-C-N 118.993 0.815 . . . . 0.0 110.64 -178.754 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 41.6 mttm -93.53 167.53 11.63 Favored 'General case' 0 N--CA 1.469 0.517 0 CA-C-N 115.788 -0.642 . . . . 0.0 109.778 -179.912 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -75.39 -140.21 0.78 Allowed Glycine 0 CA--C 1.525 0.709 0 N-CA-C 106.361 -2.695 . . . . 0.0 106.361 176.289 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -93.65 125.82 38.47 Favored 'General case' 0 N--CA 1.469 0.508 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 176.242 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' I' I ' 31' ' ' ILE . . . . . 0.456 ' O ' ' O ' ' F' ' 30' ' ' ALA . 16.3 tt -149.91 155.24 8.12 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.806 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 179.688 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 27.5 pt -151.3 136.26 10.26 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.413 0 N-CA-C 109.311 -0.626 . . . . 0.0 109.311 -177.468 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -56.55 154.45 16.76 Favored Glycine 0 CA--C 1.526 0.762 0 CA-C-N 116.238 -0.437 . . . . 0.0 112.244 -178.468 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 2.5 pp -75.64 160.78 29.73 Favored 'General case' 0 N--CA 1.467 0.38 0 N-CA-C 109.448 -0.575 . . . . 0.0 109.448 179.338 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 6.5 ttp -104.78 152.32 22.7 Favored 'General case' 0 N--CA 1.48 1.045 0 N-CA-C 109.04 -0.726 . . . . 0.0 109.04 179.417 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 7.4 p -168.87 162.26 0.56 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.529 0 N-CA-C 107.324 -1.362 . . . . 0.0 107.324 179.582 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 54.04 68.95 1.39 Allowed Glycine 0 C--N 1.312 -0.795 0 N-CA-C 111.924 -0.471 . . . . 0.0 111.924 178.801 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 152.37 -178.25 29.67 Favored Glycine 0 N--CA 1.466 0.646 0 N-CA-C 110.525 -1.03 . . . . 0.0 110.525 179.716 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 4.2 t -124.49 138.34 54.29 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.803 0 N-CA-C 107.193 -1.41 . . . . 0.0 107.193 -179.967 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 74.0 t . . . . . 0 N--CA 1.481 1.125 0 CA-C-O 117.719 -1.134 . . . . 0.0 109.822 -177.304 . . . . . . . . 0 0 . 1 stop_ save_